id category subject predicate object publications sources primary_knowledge_source knowledge_level agent_type supporting_text original_object original_subject uuid:54c05911-a480-4014-a4a4-2225147100c0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8327 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:d894399a-5687-4414-94f7-8ebceca46916"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:86b93ce0-b6b5-4a40-a295-2e984c08f986"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Renese is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Renese has also been found useful in edema due to various forms of renal dysfunction as: Nephrotic syndrome; Acute glomerulonephritis; and Chronic renal failure. Renese is indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. uuid:c4b0b6ab-3a53-4e0c-b783-54c0f97a61b2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8327 biolink:treats MONDO:0005155 PMID:41385096 "[{""id"":""uuid:35d58c87-3b14-4016-b79a-a9541a60cddd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6f493b94-6651-4732-848b-99a4cc4d228f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Renese is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Renese has also been found useful in edema due to various forms of renal dysfunction as: Nephrotic syndrome; Acute glomerulonephritis; and Chronic renal failure. Renese is indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. uuid:af75f967-ce64-4fb8-a9c6-0b0afc754a05 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8327 biolink:treats MONDO:0005377 PMID:41385096 "[{""id"":""uuid:9b366e93-3031-40ee-915d-8a760494373d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9d7b6049-94ec-4fdd-9250-410da34c0d8e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Renese is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Renese has also been found useful in edema due to various forms of renal dysfunction as: Nephrotic syndrome; Acute glomerulonephritis; and Chronic renal failure. Renese is indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. uuid:bcb61c90-f235-455a-bd42-2acdb19f2f4d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8327 biolink:treats UMLS:C0156221 PMID:41385096 "[{""id"":""uuid:596476f9-e548-4f79-bab2-37ec9d5c045a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0e53a28a-adbc-4d4f-a57c-b8a8ce76a7b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Renese is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Renese has also been found useful in edema due to various forms of renal dysfunction as: Nephrotic syndrome; Acute glomerulonephritis; and Chronic renal failure. Renese is indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. uuid:aa3c321b-0864-47ae-b690-b3c76413c8af biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8327 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:47f8be29-dc07-49b0-82a5-ec48be114d78"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e1f5028d-5cd3-4e06-9254-4ba306635fba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Renese is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Renese has also been found useful in edema due to various forms of renal dysfunction as: Nephrotic syndrome; Acute glomerulonephritis; and Chronic renal failure. Renese is indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. uuid:be870e43-0a7f-4506-9312-37ba893fa955 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8327 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:b90e8a38-7cf8-4f07-b362-f022f7e5868a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ba24046b-81c1-4d67-a6bf-3d9d6a34b0fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Renese is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Renese has also been found useful in edema due to various forms of renal dysfunction as: Nephrotic syndrome; Acute glomerulonephritis; and Chronic renal failure. Renese is indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. uuid:727ffe94-cb64-45de-b2bd-3c269cef5bc6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64354 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:a3f2bc6a-79ca-48e6-81c7-fee4d8c0f0e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:53e06836-f9df-4439-aa1c-899dd05baaba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MYKROX Tablets are indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs of a different class. MYKROX TABLETS HAVE NOT BEEN EVALUATED FOR THE TREATMENT OF CONGESTIVE HEART FAILURE OR FLUID RETENTION DUE TO RENAL OR HEPATIC DISEASE AND THE CORRECT DOSAGE FOR THESE CONDITIONS AND OTHER EDEMA STATES HAS NOT BEEN ESTABLISHED. SINCE A SAFE AND EFFECTIVE DIURETIC DOSE HAS NOT BEEN ESTABLISHED, MYKROX TABLETS SHOULD NOT BE USED WHEN DIURESIS IS DESIRED. uuid:cc2f0016-0807-4621-8bb5-651f067cd08f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9613 biolink:treats MONDO:0011072 PMID:41385096 "[{""id"":""uuid:fada2f91-c6e4-47a7-9107-a9df909504f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4aa16a87-aac0-499f-8f8d-0839931fc83f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TOLINASE Tablets are indicated as an adjunct to diet to lower the blood glucose in patients with noninsulin dependent diabetes mellitus (Type II) whose hyperglycemia cannot be satisfactorily controlled by diet alone. In initiating treatment for noninsulin-dependent diabetes, diet should be emphasized as the primary form of treatment. Caloric restriction and weight loss are essential in the obese diabetic patient. Proper dietary management alone may be effective in controlling the blood glucose and symptoms of hyperglycemia. The importance of regular physical activity should also be stressed and cardiovascular risk factors should be identified and corrective measures taken where possible. If this treatment program fails to reduce symptoms and/or blood glucose, the use of an oral sulfonylurea or insulin should be considered. Use of TOLINASE must be viewed by both the physician and patient as a treatment in addition to diet and not as a substitute for diet or as a convenient mechanism for avoiding dietary restraint. Furthermore, loss of blood glucose control on diet alone may be transient thus requiring only short-term administration of TOLINASE. During maintenance programs, TOLINASE should be discontinued if satisfactory lowering of blood glucose is no longer achieved. Judgments should be based on regular clinical and laboratory evaluations. In considering the use of TOLINASE in asymptomatic patients, it should be recognized that controlling the blood glucose in noninsulin-dependent diabetes has not been definitely established to be effective in preventing the long-term cardiovascular or neural complications of diabetes. uuid:a5e7b1d3-1853-4c8d-8a2c-ed06383ff4bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9613 biolink:treats MONDO:0002909 PMID:41385096 "[{""id"":""uuid:a7fbaf1b-c3b4-402a-9670-6cc97b3d2d76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:78a307df-308c-48f3-a72c-1309f7e8c112"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TOLINASE Tablets are indicated as an adjunct to diet to lower the blood glucose in patients with noninsulin dependent diabetes mellitus (Type II) whose hyperglycemia cannot be satisfactorily controlled by diet alone. In initiating treatment for noninsulin-dependent diabetes, diet should be emphasized as the primary form of treatment. Caloric restriction and weight loss are essential in the obese diabetic patient. Proper dietary management alone may be effective in controlling the blood glucose and symptoms of hyperglycemia. The importance of regular physical activity should also be stressed and cardiovascular risk factors should be identified and corrective measures taken where possible. If this treatment program fails to reduce symptoms and/or blood glucose, the use of an oral sulfonylurea or insulin should be considered. Use of TOLINASE must be viewed by both the physician and patient as a treatment in addition to diet and not as a substitute for diet or as a convenient mechanism for avoiding dietary restraint. Furthermore, loss of blood glucose control on diet alone may be transient thus requiring only short-term administration of TOLINASE. During maintenance programs, TOLINASE should be discontinued if satisfactory lowering of blood glucose is no longer achieved. Judgments should be based on regular clinical and laboratory evaluations. In considering the use of TOLINASE in asymptomatic patients, it should be recognized that controlling the blood glucose in noninsulin-dependent diabetes has not been definitely established to be effective in preventing the long-term cardiovascular or neural complications of diabetes. uuid:f6a3e17a-f9d3-4555-8ece-898b2e31b381 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6754 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:9f322ef7-bbec-454a-ae0e-977da2780a3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1f095cb3-c274-4046-96eb-36a18171f0be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Meperidine is indicated for the relief of moderate to severe pain. uuid:be44a84c-07c4-4d01-85da-51d2e36a5cc9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5120 biolink:treats MONDO:0009420 PMID:41385096 "[{""id"":""uuid:3998a57c-ed34-41bb-bf3e-ffc75c36be2d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9652dd1f-f451-4d2d-8d83-48d428a53f46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In the male —HALOTESTIN Tablets are indicated for Replacement therapy in conditions associated with symptoms of deficiency or absence of endogenous testosterone. Primary hypogonadism (congenital or acquired) testicular failure due to cryptorchidism, bilateral torsion, orchitis , vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired)—idiopathic gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. Delayed puberty, provided it has been definitely established as such, and is not just a familial trait. In the female —HALOTESTIN Tablets are indicated for palliation of androgen-responsive recurrent mammary cancer in women who are more than one year but less than five years postmenopausal, or who have been proven to have a hormone- dependent tumor as shown by previous beneficial response to castration. uuid:2e5da4bc-29a8-4ef1-8163-10e8cf96249e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5120 biolink:treats MONDO:0023554 PMID:41385096 "[{""id"":""uuid:11bf4571-ac56-4b03-aeb9-5f63107a9254"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3fc10409-7c31-4169-8ea0-9f1d9c66ad64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In the male —HALOTESTIN Tablets are indicated for Replacement therapy in conditions associated with symptoms of deficiency or absence of endogenous testosterone. Primary hypogonadism (congenital or acquired) testicular failure due to cryptorchidism, bilateral torsion, orchitis , vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired)—idiopathic gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. Delayed puberty, provided it has been definitely established as such, and is not just a familial trait. In the female —HALOTESTIN Tablets are indicated for palliation of androgen-responsive recurrent mammary cancer in women who are more than one year but less than five years postmenopausal, or who have been proven to have a hormone- dependent tumor as shown by previous beneficial response to castration. uuid:9fef3b8e-80a8-4e76-b749-f7ef2e284a6a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5120 biolink:treats MONDO:0009047 PMID:41385096 "[{""id"":""uuid:81726a44-fc4c-4ff1-a05c-fa7972655412"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:42cf7bb8-331f-46eb-8d77-4bdd55aa656c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In the male —HALOTESTIN Tablets are indicated for Replacement therapy in conditions associated with symptoms of deficiency or absence of endogenous testosterone. Primary hypogonadism (congenital or acquired) testicular failure due to cryptorchidism, bilateral torsion, orchitis , vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired)—idiopathic gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. Delayed puberty, provided it has been definitely established as such, and is not just a familial trait. In the female —HALOTESTIN Tablets are indicated for palliation of androgen-responsive recurrent mammary cancer in women who are more than one year but less than five years postmenopausal, or who have been proven to have a hormone- dependent tumor as shown by previous beneficial response to castration. uuid:977d7478-92ad-4cb1-b470-2bdc4f32aa66 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5120 biolink:treats MONDO:0008573 PMID:41385096 "[{""id"":""uuid:ade2c2bf-8885-4731-ae5b-721d53efc46b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:099cdcda-ec50-4fac-bd79-73acef4b9bf0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In the male —HALOTESTIN Tablets are indicated for Replacement therapy in conditions associated with symptoms of deficiency or absence of endogenous testosterone. Primary hypogonadism (congenital or acquired) testicular failure due to cryptorchidism, bilateral torsion, orchitis , vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired)—idiopathic gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. Delayed puberty, provided it has been definitely established as such, and is not just a familial trait. In the female —HALOTESTIN Tablets are indicated for palliation of androgen-responsive recurrent mammary cancer in women who are more than one year but less than five years postmenopausal, or who have been proven to have a hormone- dependent tumor as shown by previous beneficial response to castration. uuid:f5314c3d-d10d-47a7-8ee8-abf5d17f4c97 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5120 biolink:treats MONDO:0006882 PMID:41385096 "[{""id"":""uuid:6ba8dcfd-3856-4d60-b5f9-7dc1c1f45a43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1edc62f1-f4f2-4d56-b671-8c27e7618d22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In the male —HALOTESTIN Tablets are indicated for Replacement therapy in conditions associated with symptoms of deficiency or absence of endogenous testosterone. Primary hypogonadism (congenital or acquired) testicular failure due to cryptorchidism, bilateral torsion, orchitis , vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired)—idiopathic gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. Delayed puberty, provided it has been definitely established as such, and is not just a familial trait. In the female —HALOTESTIN Tablets are indicated for palliation of androgen-responsive recurrent mammary cancer in women who are more than one year but less than five years postmenopausal, or who have been proven to have a hormone- dependent tumor as shown by previous beneficial response to castration. uuid:8d09ce56-0b1c-4dcd-9707-cce602259ceb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5120 biolink:treats MONDO:8000015 PMID:41385096 "[{""id"":""uuid:91fce425-e195-4a1b-a004-084b3315e202"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7f8bbe79-8120-4a29-a432-847bfea9e4c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In the male —HALOTESTIN Tablets are indicated for Replacement therapy in conditions associated with symptoms of deficiency or absence of endogenous testosterone. Primary hypogonadism (congenital or acquired) testicular failure due to cryptorchidism, bilateral torsion, orchitis , vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired)—idiopathic gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. Delayed puberty, provided it has been definitely established as such, and is not just a familial trait. In the female —HALOTESTIN Tablets are indicated for palliation of androgen-responsive recurrent mammary cancer in women who are more than one year but less than five years postmenopausal, or who have been proven to have a hormone- dependent tumor as shown by previous beneficial response to castration. uuid:ef9ad4d6-016c-4500-8250-dbcc63df8b05 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5120 biolink:treats MONDO:0018555 PMID:41385096 "[{""id"":""uuid:c8f84676-3272-4d75-b467-d56951caddab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a1327dc9-b905-4711-bd8b-b4da994a30a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In the male —HALOTESTIN Tablets are indicated for Replacement therapy in conditions associated with symptoms of deficiency or absence of endogenous testosterone. Primary hypogonadism (congenital or acquired) testicular failure due to cryptorchidism, bilateral torsion, orchitis , vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired)—idiopathic gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. Delayed puberty, provided it has been definitely established as such, and is not just a familial trait. In the female —HALOTESTIN Tablets are indicated for palliation of androgen-responsive recurrent mammary cancer in women who are more than one year but less than five years postmenopausal, or who have been proven to have a hormone- dependent tumor as shown by previous beneficial response to castration. uuid:fb881ead-c1c2-42cf-8b94-840df51f8197 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5120 biolink:treats MONDO:0013914 PMID:41385096 "[{""id"":""uuid:532d4bb7-2667-432b-a171-7fe0dec03bbf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:33e306c6-16c1-4f3d-b23d-9f70c36aaccb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In the male —HALOTESTIN Tablets are indicated for Replacement therapy in conditions associated with symptoms of deficiency or absence of endogenous testosterone. Primary hypogonadism (congenital or acquired) testicular failure due to cryptorchidism, bilateral torsion, orchitis , vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired)—idiopathic gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. Delayed puberty, provided it has been definitely established as such, and is not just a familial trait. In the female —HALOTESTIN Tablets are indicated for palliation of androgen-responsive recurrent mammary cancer in women who are more than one year but less than five years postmenopausal, or who have been proven to have a hormone- dependent tumor as shown by previous beneficial response to castration. uuid:38a989d1-e803-4713-9665-b9f1a588323f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5120 biolink:treats HP:0000823 PMID:41385096 "[{""id"":""uuid:36962ea1-88bd-4000-bb51-c3bf45aa65d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9f8fc9e7-5d27-4272-b944-351f04bbc58b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In the male —HALOTESTIN Tablets are indicated for Replacement therapy in conditions associated with symptoms of deficiency or absence of endogenous testosterone. Primary hypogonadism (congenital or acquired) testicular failure due to cryptorchidism, bilateral torsion, orchitis , vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired)—idiopathic gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. Delayed puberty, provided it has been definitely established as such, and is not just a familial trait. In the female —HALOTESTIN Tablets are indicated for palliation of androgen-responsive recurrent mammary cancer in women who are more than one year but less than five years postmenopausal, or who have been proven to have a hormone- dependent tumor as shown by previous beneficial response to castration. uuid:6d226216-5e7c-48de-aee4-b0911b76a6bd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5120 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:a5f797d1-b495-40e3-9b27-802461cdd5a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:73737969-ab42-42c9-b043-3d7f9294ec83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In the male —HALOTESTIN Tablets are indicated for Replacement therapy in conditions associated with symptoms of deficiency or absence of endogenous testosterone. Primary hypogonadism (congenital or acquired) testicular failure due to cryptorchidism, bilateral torsion, orchitis , vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired)—idiopathic gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. Delayed puberty, provided it has been definitely established as such, and is not just a familial trait. In the female —HALOTESTIN Tablets are indicated for palliation of androgen-responsive recurrent mammary cancer in women who are more than one year but less than five years postmenopausal, or who have been proven to have a hormone- dependent tumor as shown by previous beneficial response to castration. uuid:1302cdfb-bc82-4a6b-9bb9-e14516faa20d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4317 biolink:treats MONDO:0043797 PMID:41385096 "[{""id"":""uuid:628a42ae-753e-4050-8938-58715efb8359"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:51dcdfe1-afd5-40da-8497-e1ad6e74883d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In Chronic Spasticity: Dantrium is indicated in controlling the manifestations of clinical spasticity resulting from upper motor neuron disorders (e.g., spinal cord injury, stroke, cerebral palsy, or multiple sclerosis). It is of particular benefit to the patient whose functional rehabilitation has been retarded by the sequelae of spasticity. Such patients must have presumably reversible spasticity where relief of spasticity will aid in restoring residual function. Dantrium is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. If improvement occurs, it will ordinarily occur within the dosage titration (see DOSAGE AND ADMINISTRATION ), and will be manifested by a decrease in the severity of spasticity and the ability to resume a daily function not quite attainable without Dantrium. Occasionally, subtle but meaningful improvement in spasticity may occur with Dantrium therapy. In such instances, information regarding improvement should be solicited from the patient and those who are in constant daily contact and attendance with him. Brief withdrawal of Dantrium for a period of 2 to 4 days will frequently demonstrate exacerbation of the manifestations of spasticity and may serve to confirm a clinical impression. A decision to continue the administration of Dantrium on a long-term basis is justified if introduction of the drug into the patient's regimen: produces a significant reduction in painful and/or disabling spasticity such as clonus, or permits a significant reduction in the intensity and/or degree of nursing care required, or rids the patient of any annoying manifestation of spasticity considered important by the patient himself. uuid:e0e88aab-5a8b-45f0-b963-e3362760306c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4317 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:d49a9129-a949-49ca-b5a7-742fa1bb5936"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:073ca80a-db36-48d1-adaa-b63c5c138e08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In Chronic Spasticity: Dantrium is indicated in controlling the manifestations of clinical spasticity resulting from upper motor neuron disorders (e.g., spinal cord injury, stroke, cerebral palsy, or multiple sclerosis). It is of particular benefit to the patient whose functional rehabilitation has been retarded by the sequelae of spasticity. Such patients must have presumably reversible spasticity where relief of spasticity will aid in restoring residual function. Dantrium is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. If improvement occurs, it will ordinarily occur within the dosage titration (see DOSAGE AND ADMINISTRATION ), and will be manifested by a decrease in the severity of spasticity and the ability to resume a daily function not quite attainable without Dantrium. Occasionally, subtle but meaningful improvement in spasticity may occur with Dantrium therapy. In such instances, information regarding improvement should be solicited from the patient and those who are in constant daily contact and attendance with him. Brief withdrawal of Dantrium for a period of 2 to 4 days will frequently demonstrate exacerbation of the manifestations of spasticity and may serve to confirm a clinical impression. A decision to continue the administration of Dantrium on a long-term basis is justified if introduction of the drug into the patient's regimen: produces a significant reduction in painful and/or disabling spasticity such as clonus, or permits a significant reduction in the intensity and/or degree of nursing care required, or rids the patient of any annoying manifestation of spasticity considered important by the patient himself. uuid:d3f7576f-591f-4fd5-83b4-731a24390afd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4317 biolink:treats MONDO:0006497 PMID:41385096 "[{""id"":""uuid:4684451d-063e-4ab4-83fe-d07c1dfaaec9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:87b29df7-f095-4e8b-b1b5-3000ff244fdb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In Chronic Spasticity: Dantrium is indicated in controlling the manifestations of clinical spasticity resulting from upper motor neuron disorders (e.g., spinal cord injury, stroke, cerebral palsy, or multiple sclerosis). It is of particular benefit to the patient whose functional rehabilitation has been retarded by the sequelae of spasticity. Such patients must have presumably reversible spasticity where relief of spasticity will aid in restoring residual function. Dantrium is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. If improvement occurs, it will ordinarily occur within the dosage titration (see DOSAGE AND ADMINISTRATION ), and will be manifested by a decrease in the severity of spasticity and the ability to resume a daily function not quite attainable without Dantrium. Occasionally, subtle but meaningful improvement in spasticity may occur with Dantrium therapy. In such instances, information regarding improvement should be solicited from the patient and those who are in constant daily contact and attendance with him. Brief withdrawal of Dantrium for a period of 2 to 4 days will frequently demonstrate exacerbation of the manifestations of spasticity and may serve to confirm a clinical impression. A decision to continue the administration of Dantrium on a long-term basis is justified if introduction of the drug into the patient's regimen: produces a significant reduction in painful and/or disabling spasticity such as clonus, or permits a significant reduction in the intensity and/or degree of nursing care required, or rids the patient of any annoying manifestation of spasticity considered important by the patient himself. uuid:7e8f4451-8c5e-4914-92b8-aaac1d2e3a51 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4317 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:1200b8c8-dea6-49df-9ad7-ef78c05ea13a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c4937358-6560-42e5-904e-2820bd7a0d47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In Chronic Spasticity: Dantrium is indicated in controlling the manifestations of clinical spasticity resulting from upper motor neuron disorders (e.g., spinal cord injury, stroke, cerebral palsy, or multiple sclerosis). It is of particular benefit to the patient whose functional rehabilitation has been retarded by the sequelae of spasticity. Such patients must have presumably reversible spasticity where relief of spasticity will aid in restoring residual function. Dantrium is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. If improvement occurs, it will ordinarily occur within the dosage titration (see DOSAGE AND ADMINISTRATION ), and will be manifested by a decrease in the severity of spasticity and the ability to resume a daily function not quite attainable without Dantrium. Occasionally, subtle but meaningful improvement in spasticity may occur with Dantrium therapy. In such instances, information regarding improvement should be solicited from the patient and those who are in constant daily contact and attendance with him. Brief withdrawal of Dantrium for a period of 2 to 4 days will frequently demonstrate exacerbation of the manifestations of spasticity and may serve to confirm a clinical impression. A decision to continue the administration of Dantrium on a long-term basis is justified if introduction of the drug into the patient's regimen: produces a significant reduction in painful and/or disabling spasticity such as clonus, or permits a significant reduction in the intensity and/or degree of nursing care required, or rids the patient of any annoying manifestation of spasticity considered important by the patient himself. uuid:23b78276-a3c1-45e5-b271-92dff5773700 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6504 biolink:treats MONDO:0004985 PMID:41385096 "[{""id"":""uuid:a26ffdff-99f5-42a9-b7d0-8822561c0da6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:86f3d6b6-5f4b-471b-8a25-f2f6b18cb8fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lithium carbonate is indicated in the treatment of manic episodes of manic-depressive illness. Maintenance therapy prevents or diminishes the intensity of subsequent episodes in those manic-depressive patients with a history of mania. Typical symptoms of mania include pressure of speech, motor hyperactivity, reduced need for sleep, flight of ideas, grandiosity, elation, poor judgment, aggressiveness, and possibly hostility. When given to a patient experiencing a manic episode, lithium may produce a normalization of symptomatology within 1 to 3 weeks. uuid:cb79ee22-11a8-4c35-9b83-c90e7d25240e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6504 biolink:treats HP:0100754 PMID:41385096 "[{""id"":""uuid:4b689f3e-499e-4d43-a340-af812f8cf0b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7128a165-de74-4e1e-87a2-a38c864b1d72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lithium carbonate is indicated in the treatment of manic episodes of manic-depressive illness. Maintenance therapy prevents or diminishes the intensity of subsequent episodes in those manic-depressive patients with a history of mania. Typical symptoms of mania include pressure of speech, motor hyperactivity, reduced need for sleep, flight of ideas, grandiosity, elation, poor judgment, aggressiveness, and possibly hostility. When given to a patient experiencing a manic episode, lithium may produce a normalization of symptomatology within 1 to 3 weeks. uuid:a948ba2f-fd59-416c-b342-c89005e58586 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9763 biolink:treats UMLS:C0949083 PMID:41385096 "[{""id"":""uuid:996eec2f-fcbb-42d9-ba7c-324817c3fbef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:39681fe7-e3eb-4eca-927a-6cb2e3ceb7f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TROVAN is indicated for the treatment of patients initiating therapy in in-patient health care facilities (i.e., hospitals and long term nursing care facilities) with serious, life- or limb-threatening infections caused by susceptible strains of the designated microorganisms in the conditions listed below. (See DOSAGE AND ADMINISTRATION .) Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae , or Staphylococcus aureus . As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae . Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. NOTE : TROVAN has not been studied in the treatment of osteomyelitis. (See WARNINGS .) uuid:97ae9503-e13a-4369-942e-f59cabbec376 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9763 biolink:treats UMLS:C0694549 PMID:41385096 "[{""id"":""uuid:d2c9c93a-a32b-4f29-b6b3-915c918da247"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b5cb62ec-f8ec-4630-9732-e90b1d04b4be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TROVAN is indicated for the treatment of patients initiating therapy in in-patient health care facilities (i.e., hospitals and long term nursing care facilities) with serious, life- or limb-threatening infections caused by susceptible strains of the designated microorganisms in the conditions listed below. (See DOSAGE AND ADMINISTRATION .) Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae , or Staphylococcus aureus . As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae . Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. NOTE : TROVAN has not been studied in the treatment of osteomyelitis. (See WARNINGS .) uuid:e1c9fc57-6686-495b-8c01-0f0590b0e2a5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9763 biolink:treats MONDO:0000922 PMID:41385096 "[{""id"":""uuid:8d508fcf-e40f-4aa4-abe1-b1463a1542c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:050b012e-c928-42da-a36d-48a7533e21e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TROVAN is indicated for the treatment of patients initiating therapy in in-patient health care facilities (i.e., hospitals and long term nursing care facilities) with serious, life- or limb-threatening infections caused by susceptible strains of the designated microorganisms in the conditions listed below. (See DOSAGE AND ADMINISTRATION .) Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae , or Staphylococcus aureus . As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae . Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. NOTE : TROVAN has not been studied in the treatment of osteomyelitis. (See WARNINGS .) uuid:4689546c-3653-411c-9c9f-474b6a51767c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9763 biolink:treats MONDO:0042451 PMID:41385096 "[{""id"":""uuid:458febbc-e0da-4cec-a875-5af6bcfb0c63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3d2978e4-fa4e-4d91-b935-307019c65c4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TROVAN is indicated for the treatment of patients initiating therapy in in-patient health care facilities (i.e., hospitals and long term nursing care facilities) with serious, life- or limb-threatening infections caused by susceptible strains of the designated microorganisms in the conditions listed below. (See DOSAGE AND ADMINISTRATION .) Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae , or Staphylococcus aureus . As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae . Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. NOTE : TROVAN has not been studied in the treatment of osteomyelitis. (See WARNINGS .) uuid:7133a07c-94b1-47f4-b485-c6c58bfc6cae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9763 biolink:treats MONDO:0006887 PMID:41385096 "[{""id"":""uuid:66ff09fb-818a-4e73-8dd9-d1f8f204d5a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4cff4464-510d-483d-8ce3-4701b20a5131"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TROVAN is indicated for the treatment of patients initiating therapy in in-patient health care facilities (i.e., hospitals and long term nursing care facilities) with serious, life- or limb-threatening infections caused by susceptible strains of the designated microorganisms in the conditions listed below. (See DOSAGE AND ADMINISTRATION .) Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae , or Staphylococcus aureus . As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae . Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. NOTE : TROVAN has not been studied in the treatment of osteomyelitis. (See WARNINGS .) uuid:d253cfea-ff59-4ae5-95d2-dd09ec45a363 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9763 biolink:treats DOID:2910 PMID:41385096 "[{""id"":""uuid:d7cc03a4-ac37-44f7-a1bc-4f74d661a96e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:914ca9a7-c5e3-4498-8e30-a7c738812da5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TROVAN is indicated for the treatment of patients initiating therapy in in-patient health care facilities (i.e., hospitals and long term nursing care facilities) with serious, life- or limb-threatening infections caused by susceptible strains of the designated microorganisms in the conditions listed below. (See DOSAGE AND ADMINISTRATION .) Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae , or Staphylococcus aureus . As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae . Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. NOTE : TROVAN has not been studied in the treatment of osteomyelitis. (See WARNINGS .) uuid:2f7640f0-6267-4d7e-9bb7-302a221ce24c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9763 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:74c2f7ea-d9c4-416a-af58-56f1be0994e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ef8e3e32-c807-4495-9fa2-768de03c351d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TROVAN is indicated for the treatment of patients initiating therapy in in-patient health care facilities (i.e., hospitals and long term nursing care facilities) with serious, life- or limb-threatening infections caused by susceptible strains of the designated microorganisms in the conditions listed below. (See DOSAGE AND ADMINISTRATION .) Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae , or Staphylococcus aureus . As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae . Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. NOTE : TROVAN has not been studied in the treatment of osteomyelitis. (See WARNINGS .) uuid:a4d722b9-091a-403e-af1f-c28862aa3575 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9763 biolink:treats UMLS:C0744130 PMID:41385096 "[{""id"":""uuid:3c2cc8b2-dde9-4673-9266-8e093538fba7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cd441531-a5d5-4cf1-ac00-aa5a22de7b0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TROVAN is indicated for the treatment of patients initiating therapy in in-patient health care facilities (i.e., hospitals and long term nursing care facilities) with serious, life- or limb-threatening infections caused by susceptible strains of the designated microorganisms in the conditions listed below. (See DOSAGE AND ADMINISTRATION .) Nosocomial pneumonia caused by Escherichia coli, Pseudomonas aeruginosa, Haemophilus influenzae , or Staphylococcus aureus . As with other antimicrobials, where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with either an aminoglycoside or aztreonam may be clinically indicated. Community acquired pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae, Klebsiella pneumoniae, Staphylococcus aureus, Mycoplasma pneumoniae, Moraxella catarrhalis, Legionella pneumophila, or Chlamydia pneumoniae . Complicated intra-abdominal infections, including post-surgical infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae, Peptostreptococcus species, or Prevotella species. Gynecologic and pelvic infections including endomyometritis, parametritis, septic abortion and post-partum infections caused by Escherichia coli, Bacteroides fragilis, viridans group streptococci, Enterococcus faecalis, Streptococcus agalactiae, Peptostreptococcus species, Prevotella species, or Gardnerella vaginalis. Complicated skin and skin structure infections, including diabetic foot infections, caused by Staphylococcus aureus, Streptococcus agalactiae, Pseudomonas aeruginosa, Enterococcus faecalis, Escherichia coli, or Proteus mirabilis. NOTE : TROVAN has not been studied in the treatment of osteomyelitis. (See WARNINGS .) uuid:cc6f9af5-51a1-47b3-bb19-d886076c9dca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4317 biolink:treats MONDO:0018493 PMID:41385096 "[{""id"":""uuid:3fcd79b6-a0dc-4a54-a7d3-e8b3c13ee961"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:594b01ae-a2dd-4afd-a6ed-6b5f2d72b394"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dantrium Intravenous is indicated, along with appropriate supportive measures, for the management of the fulminant hypermetabolism of skeletal muscle characteristic of malignant hyperthermia crises in patients of all ages. Dantrium Intravenous should be administered by continuous rapid intravenous push as soon as the malignant hyperthermia reaction is recognized (i.e., tachycardia, tachypnea, central venous desaturation, hypercarbia, metabolic acidosis, skeletal muscle rigidity, increased utilization of anesthesia circuit carbon dioxide absorber, cyanosis and mottling of the skin, and, in many cases, fever). Dantrium Intravenous is also indicated preoperatively, and sometimes postoperatively, to prevent or attenuate the development of clinical and laboratory signs of malignant hyperthermia in individuals judged to be malignant hyperthermia susceptible. uuid:4f7500be-284e-4846-96df-0fe0b5608c11 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0019359 PMID:41385096 "[{""id"":""uuid:6a74d88d-b5f5-4aa8-8fa7-83c9ff57e641"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4de8f574-2b05-4de6-a9e4-cbf4b0b51377"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:2087ac43-eaf0-4587-923c-8221d4da7c10 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0001246 PMID:41385096 "[{""id"":""uuid:d51c5dd0-53a8-41d2-a5b9-840c899523a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a5540ed2-ea5c-491f-acba-445669f69365"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:ee5fedad-1d04-4932-9cf6-5396e16ea006 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0019186 PMID:41385096 "[{""id"":""uuid:31b09b11-f12d-4be2-8de0-1cfe609c3171"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ea874bce-2683-4dd1-9eb2-fce631807e1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:449401a5-90a0-4ef2-8701-a5f23c4fa3ea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0019360 PMID:41385096 "[{""id"":""uuid:d6e1b38e-6b22-47fc-b969-527de74b110f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:93c0b809-d36e-4241-a12a-74d647386ee7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:17ff3bf5-9cf8-4f1a-8ce5-86e396ad79b4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0025294 PMID:41385096 "[{""id"":""uuid:512cb80b-ac8f-49ad-bd94-e54bccec7240"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8abf758c-0eb6-47fe-b348-ac3196741880"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:96255f4b-20ff-4262-b730-428afdb8d81b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0005867 PMID:41385096 "[{""id"":""uuid:5fc164c8-db43-4354-ac24-51a99d22c901"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eddaa50a-d7e7-44a0-b8fc-381dc25d31ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:61da07be-a6cc-4a9c-b311-f6ff5631a8f6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0005888 PMID:41385096 "[{""id"":""uuid:e5bb881a-c286-489e-8526-f72fa07a992f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8d10de80-1258-4eb2-86fa-e0bdf30ec2c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:bfd0de15-cbbe-44b4-b666-1cbefab0c8bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0005834 PMID:41385096 "[{""id"":""uuid:589e7370-a587-40d3-ac08-58b7106d4851"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6ec2c62b-e280-4ca4-bc54-12a9d3bec6f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:c70f26eb-7cf1-4e17-85c9-a7af9b567720 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0005777 PMID:41385096 "[{""id"":""uuid:2b27d122-0c12-417c-89cb-cef00f392da3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ca06d76a-2d91-4f21-8f86-68ef44b71652"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:7d7b8894-94ca-4886-bf8e-1d7a7a8aa897 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0019633 PMID:41385096 "[{""id"":""uuid:74f43106-7cff-48fd-ad6b-45daa5556b37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4b585b55-3885-4511-86e3-763d055376d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:615eea94-b347-436f-9424-ec531c594d4d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0001797 PMID:41385096 "[{""id"":""uuid:dabdd9a1-463f-406d-b661-e8c7cc3a1ede"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:09e3ee7e-817b-4d26-b99f-5d8b581eb577"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:4a47f7ff-3c02-4f30-9d09-350fb66024b1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0019095 PMID:41385096 "[{""id"":""uuid:3fa6d411-d6fc-441b-a4a7-1736b6fa810a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4d69da35-3c88-4fa0-b2b0-8cd76e75f0f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:3f619bbb-e15e-4aee-9e74-0c044af79573 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0018077 PMID:41385096 "[{""id"":""uuid:61cab703-c273-4306-b34d-79fbd7bf344e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ebf62c9a-34de-4425-9694-e6f8ee91cf5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:91ac1fe2-c7a6-48b2-adfb-413451a54a07 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0020920 PMID:41385096 "[{""id"":""uuid:31611804-aa6d-4e9f-a825-0381c6c33655"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:01191509-8139-4140-9ab1-655b52a826da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:95c81a4c-3ed0-4454-9bdd-dc20734e9aa8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0019345 PMID:41385096 "[{""id"":""uuid:c362322a-8801-4291-a0f6-6d83a81fa1f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:727cade2-706a-4a33-b07a-cd37096839b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:f5ea2a87-6d76-4a46-a855-05ca655c18fe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0006635 PMID:41385096 "[{""id"":""uuid:429c17a0-90b6-44ea-9227-9dd4e3fcc19f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:767f13a0-6ea9-4b3a-8998-6ee25345e484"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:235ca861-4e5d-4426-977a-8eaf7773ef52 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0006926 PMID:41385096 "[{""id"":""uuid:4567651e-813a-4aff-b6be-4b219c0f5dd1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:75371e40-393a-412c-ac2c-6c81a23f3ba0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:5e717994-3167-42c9-a3fd-c82182ec6de9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0030602 PMID:41385096 "[{""id"":""uuid:dbdee24b-f8f9-47af-b108-d23706cdd717"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:627f59ea-a64d-46b4-b63d-a7f97fa59a05"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:f5c22d89-cddd-4888-bd38-4c18862bf758 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0030603 PMID:41385096 "[{""id"":""uuid:1951433a-b4a7-46b0-802c-35919b917a67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cb3f7cdf-47dd-49b5-b76a-42f32cb9dadb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:c55062b9-7791-4ac1-9e18-d7ddad250d73 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0021680 PMID:41385096 "[{""id"":""uuid:0af45c75-2d84-4d81-9b88-4cd47d8604ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:300efd97-5b75-4db3-b911-de620a943111"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:1e983aca-8545-4857-83e1-bd00b39a7b9f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0005114 PMID:41385096 "[{""id"":""uuid:8833ad18-4335-4382-a94b-b4dc68eb8028"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:28cb7693-dcbe-420b-8ee8-6b80927610b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:4762da76-b9d3-4713-b3df-b4060d9044d3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0005545 PMID:41385096 "[{""id"":""uuid:60644415-9871-484a-9742-06741843fb65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f1332879-2d18-41d1-87a7-f01898446bff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:e7ae1863-edc0-4373-a8d3-cf696dfad653 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:478de27d-131e-4fd3-81b0-4b1631835f4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:88a2b8ea-6f67-4f0a-80aa-c534f51cc88e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:b86f0534-939e-4887-a6da-ddfea1574834 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0004277 PMID:41385096 "[{""id"":""uuid:1c0a2056-68ba-42d5-8ad6-a6a1fc9938aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:781aeee9-fa9f-4ff4-85e0-74b0f079a276"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:09bb2876-50a1-47ef-90c9-4cb6b80abf55 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0005976 PMID:41385096 "[{""id"":""uuid:7baa1d7e-6662-43d5-a949-b83f55f6bf27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d9688da0-41dc-4117-9507-917d24f46d1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:07bccbda-a639-429e-a6f2-a263e338ae97 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0006019 PMID:41385096 "[{""id"":""uuid:32ebb13a-078d-498f-885b-12f67a59ea63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dae16ec0-246e-4daa-aeb3-f950dec3ea05"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:f9e6aadf-5497-4a76-bc1e-9fffb10f8bfd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0005828 PMID:41385096 "[{""id"":""uuid:a5414468-b00f-4cb0-89a4-3e2ba6fa181d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d972568d-0a97-4f8a-9215-9d28083da94b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:af3441ef-95ab-4b2e-9c5b-f6cbb2f9d694 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0024388 PMID:41385096 "[{""id"":""uuid:151f01dc-4331-4b41-87ac-919486cea0df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:39636573-d896-49c9-aff1-12f9623d33f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:de8f97c9-b26f-40bd-aa60-bd86abcbae7a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0005119 PMID:41385096 "[{""id"":""uuid:af887ef9-ee6a-4a22-83e6-07457f73846f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4515b98c-d5f2-411d-9456-0ebddb85f2f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:4a7c3ce5-6bbf-475a-952c-30036f1e9f72 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0005631 PMID:41385096 "[{""id"":""uuid:f6d8333f-33ea-41a2-b194-72935352b397"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eed7a6db-0ce0-428b-926f-f4ec727cd7d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:f7b04b32-1d11-4a00-82b6-9d3ba5d70a76 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0005644 PMID:41385096 "[{""id"":""uuid:9cc44266-2e9b-4e75-a298-482b8307201d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ccdc018c-bafd-4c8a-96c0-cf13c946e5ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:e52dbfe9-bc6e-411b-8949-93a8112df561 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:d9d7fb51-d3ae-4e72-98c2-58ca9b4b8553"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8b9de6e4-555c-4333-8a70-66916dbde685"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:5aceaff7-4916-4589-9611-a9e2eabb86a0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0001249 PMID:41385096 "[{""id"":""uuid:262713d3-cea4-4407-adad-cd4495c38f66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:67246b05-673b-4ae0-9775-c03b81ca274d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:a0318f5e-a52d-44e4-8eb1-09394ea1b387 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133011 biolink:treats MONDO:0005808 PMID:41385096 "[{""id"":""uuid:4d10537d-f4bd-497b-b02d-efde9d3f7d77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4535ebdb-cc52-486c-867e-10596cf9f793"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxytetracycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers), Mycoplasma pneumoniae (PPLO, Eaton Agent), Agents of psittacosis and ornithosis, Agents of lymphogranuloma venereum and granuloma inguinale, The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram negative microorganisms: Haemophilus ducreyi (chancroid), Pasteurella pestis , and Pasteurella tularensis , Bartonella bacilliformis , Bacteroides species, Vibrio comma and Vibrio fetus , Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Oxytetracycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli , Enterobacter aerogenes (formerly Aerobacter aerogenes ), Shigella species, Mima species and Herellea species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Oxytetracycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to Group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Diplococcus pneumoniae , Staphylococcus aureus , skin and soft-tissue infections. Oxytetracycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of infections due to: Neisseria gonorrhoeae , Treponema pallidum and Treponema pertenue (syphilis and yaws), Listeria monocytogenes , Clostridium species, Bacillus anthracis , Fusobacterium fusiforme (Vincent's infection), Actinomyces species. In acute intestinal amebiasis, the tetracyclines may be a useful adjunct to amebicides. In severe acne, the tetracyclines may be useful adjunctive therapy. Tetracyclines are indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral tetracyclines or with a combination of oral and topical agents. uuid:67c05c8c-1630-40f1-ac91-29afdf722797 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2904 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:c999eeff-b860-4708-bf38-1d314c327ca7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:691a7831-6751-4804-bfa3-f18cc8f4e5fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Atenolol tablets are indicated in the management of hypertension. They may be used alone or concomitantly with other antihypertensive agents, particularly with a thiazide-type diuretic. Angina Pectoris Due to Coronary Atherosclerosis Atenolol tablets are indicated for the long-term management of patients with angina pectoris. Acute Myocardial Infarction Atenolol tablets are indicated in the management of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality. Treatment can be initiated as soon as the patient’s clinical condition allows. (See DOSAGE AND ADMINISTRATION , CONTRAINDICATIONS , and WARNINGS .) In general, there is no basis for treating patients like those who were excluded from the ISIS-1 trial (blood pressure less than 100 mm Hg systolic, heart rate less than 50 bpm) or have other reasons to avoid beta blockade. As noted above, some subgroups (e.g., elderly patients with systolic blood pressure below 120 mm Hg) seemed less likely to benefit. uuid:a6c2b464-c3d0-47c6-bc35-3c3a6a8bee25 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2904 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:dbe396fe-6c23-4fff-9a51-4eb516f5c697"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6002ea44-4e6d-43ab-ad94-6f85e94bb654"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Atenolol tablets are indicated in the management of hypertension. They may be used alone or concomitantly with other antihypertensive agents, particularly with a thiazide-type diuretic. Angina Pectoris Due to Coronary Atherosclerosis Atenolol tablets are indicated for the long-term management of patients with angina pectoris. Acute Myocardial Infarction Atenolol tablets are indicated in the management of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality. Treatment can be initiated as soon as the patient’s clinical condition allows. (See DOSAGE AND ADMINISTRATION , CONTRAINDICATIONS , and WARNINGS .) In general, there is no basis for treating patients like those who were excluded from the ISIS-1 trial (blood pressure less than 100 mm Hg systolic, heart rate less than 50 bpm) or have other reasons to avoid beta blockade. As noted above, some subgroups (e.g., elderly patients with systolic blood pressure below 120 mm Hg) seemed less likely to benefit. uuid:abc46d8f-969a-43a8-ac48-6f163c7d6d76 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2904 biolink:treats MONDO:0004781 PMID:41385096 "[{""id"":""uuid:df465965-f1e2-4c52-9072-1dcf6d7080ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:562dcb58-892b-402f-877f-f2b05d919995"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Atenolol tablets are indicated in the management of hypertension. They may be used alone or concomitantly with other antihypertensive agents, particularly with a thiazide-type diuretic. Angina Pectoris Due to Coronary Atherosclerosis Atenolol tablets are indicated for the long-term management of patients with angina pectoris. Acute Myocardial Infarction Atenolol tablets are indicated in the management of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality. Treatment can be initiated as soon as the patient’s clinical condition allows. (See DOSAGE AND ADMINISTRATION , CONTRAINDICATIONS , and WARNINGS .) In general, there is no basis for treating patients like those who were excluded from the ISIS-1 trial (blood pressure less than 100 mm Hg systolic, heart rate less than 50 bpm) or have other reasons to avoid beta blockade. As noted above, some subgroups (e.g., elderly patients with systolic blood pressure below 120 mm Hg) seemed less likely to benefit. uuid:e4f16424-7b9e-4e71-bd05-bf2059709884 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:374687 biolink:treats MONDO:0006939 PMID:41385096 "[{""id"":""uuid:27118fbc-3594-4c1e-9600-8bac2fbc934c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ab5c236e-4afa-48df-b501-1a57a07c3288"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of this drug by the National Academy of Sciences-National Research Council and/or other information, FDA has classified the indications as follows: ""Lacking substantial evidence of effectiveness as a fixed combination"": Urobiotic-250 is indicated in the therapy of a number of genitourinary infections caused by susceptible organisms. These infections include the following: pyelonephritis, pyelitis, ureteritis, cystitis, prostatitis, and urethritis. Since both Terramycin and sulfamethizole provide effective levels in blood, tissue, and urine, Urobiotic-250 provides a multiple antimicrobial approach at the site of infection. Both antibacterial components are active against the most common urinary pathogens, including Escherichia coli, Pseudomonas aeruginosa, Aerobacter aerogenes, Streptococcus faecalis, Streptococcus hemolyticus , and Micrococcus pyogenes . Urobiotic-250 is particularly useful in the treatment of infections caused by bacteria more sensitive to the combination than to either component alone. The combination is also of value in those cases with mixed infections, and in those instances where the causative organism is unknown pending laboratory isolation. Final classification of the less than effective indications requires further investigation. Clinical studies to substantiate the efficacy of Urobiotic 250 are ongoing. Completion of these ongoing studies will provide data for final classification of these indications ." uuid:70171674-5a61-4369-8efb-1537b7b53a39 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:374687 biolink:treats MONDO:0006938 PMID:41385096 "[{""id"":""uuid:0d9e986d-2b5e-48a7-ad22-2a14c73c1603"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2e4cd741-cb74-447a-ab70-de0527eb6f34"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of this drug by the National Academy of Sciences-National Research Council and/or other information, FDA has classified the indications as follows: ""Lacking substantial evidence of effectiveness as a fixed combination"": Urobiotic-250 is indicated in the therapy of a number of genitourinary infections caused by susceptible organisms. These infections include the following: pyelonephritis, pyelitis, ureteritis, cystitis, prostatitis, and urethritis. Since both Terramycin and sulfamethizole provide effective levels in blood, tissue, and urine, Urobiotic-250 provides a multiple antimicrobial approach at the site of infection. Both antibacterial components are active against the most common urinary pathogens, including Escherichia coli, Pseudomonas aeruginosa, Aerobacter aerogenes, Streptococcus faecalis, Streptococcus hemolyticus , and Micrococcus pyogenes . Urobiotic-250 is particularly useful in the treatment of infections caused by bacteria more sensitive to the combination than to either component alone. The combination is also of value in those cases with mixed infections, and in those instances where the causative organism is unknown pending laboratory isolation. Final classification of the less than effective indications requires further investigation. Clinical studies to substantiate the efficacy of Urobiotic 250 are ongoing. Completion of these ongoing studies will provide data for final classification of these indications ." uuid:86871c96-a1ee-4d44-9c11-dfe040d94782 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:374687 biolink:treats MONDO:0021960 PMID:41385096 "[{""id"":""uuid:b06eae62-501e-4a3e-9c68-166081948ce9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:46712703-833d-42e3-9dbf-50c870828cd7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of this drug by the National Academy of Sciences-National Research Council and/or other information, FDA has classified the indications as follows: ""Lacking substantial evidence of effectiveness as a fixed combination"": Urobiotic-250 is indicated in the therapy of a number of genitourinary infections caused by susceptible organisms. These infections include the following: pyelonephritis, pyelitis, ureteritis, cystitis, prostatitis, and urethritis. Since both Terramycin and sulfamethizole provide effective levels in blood, tissue, and urine, Urobiotic-250 provides a multiple antimicrobial approach at the site of infection. Both antibacterial components are active against the most common urinary pathogens, including Escherichia coli, Pseudomonas aeruginosa, Aerobacter aerogenes, Streptococcus faecalis, Streptococcus hemolyticus , and Micrococcus pyogenes . Urobiotic-250 is particularly useful in the treatment of infections caused by bacteria more sensitive to the combination than to either component alone. The combination is also of value in those cases with mixed infections, and in those instances where the causative organism is unknown pending laboratory isolation. Final classification of the less than effective indications requires further investigation. Clinical studies to substantiate the efficacy of Urobiotic 250 are ongoing. Completion of these ongoing studies will provide data for final classification of these indications ." uuid:7accfd12-4738-413a-af19-69e6f0e912c3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:374687 biolink:treats MONDO:0006032 PMID:41385096 "[{""id"":""uuid:41ecbe51-4ade-4f7e-b494-1e5a69c7a9f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2aa3cd0b-9a4f-4e81-88f9-f35fabde629a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of this drug by the National Academy of Sciences-National Research Council and/or other information, FDA has classified the indications as follows: ""Lacking substantial evidence of effectiveness as a fixed combination"": Urobiotic-250 is indicated in the therapy of a number of genitourinary infections caused by susceptible organisms. These infections include the following: pyelonephritis, pyelitis, ureteritis, cystitis, prostatitis, and urethritis. Since both Terramycin and sulfamethizole provide effective levels in blood, tissue, and urine, Urobiotic-250 provides a multiple antimicrobial approach at the site of infection. Both antibacterial components are active against the most common urinary pathogens, including Escherichia coli, Pseudomonas aeruginosa, Aerobacter aerogenes, Streptococcus faecalis, Streptococcus hemolyticus , and Micrococcus pyogenes . Urobiotic-250 is particularly useful in the treatment of infections caused by bacteria more sensitive to the combination than to either component alone. The combination is also of value in those cases with mixed infections, and in those instances where the causative organism is unknown pending laboratory isolation. Final classification of the less than effective indications requires further investigation. Clinical studies to substantiate the efficacy of Urobiotic 250 are ongoing. Completion of these ongoing studies will provide data for final classification of these indications ." uuid:556e8053-b961-40b4-89e3-65d3e5dd3773 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:374687 biolink:treats MONDO:0005280 PMID:41385096 "[{""id"":""uuid:058daf71-c143-4f83-a161-da56b8291a1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2a19590c-6373-46bb-8185-14d8afd8b19b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of this drug by the National Academy of Sciences-National Research Council and/or other information, FDA has classified the indications as follows: ""Lacking substantial evidence of effectiveness as a fixed combination"": Urobiotic-250 is indicated in the therapy of a number of genitourinary infections caused by susceptible organisms. These infections include the following: pyelonephritis, pyelitis, ureteritis, cystitis, prostatitis, and urethritis. Since both Terramycin and sulfamethizole provide effective levels in blood, tissue, and urine, Urobiotic-250 provides a multiple antimicrobial approach at the site of infection. Both antibacterial components are active against the most common urinary pathogens, including Escherichia coli, Pseudomonas aeruginosa, Aerobacter aerogenes, Streptococcus faecalis, Streptococcus hemolyticus , and Micrococcus pyogenes . Urobiotic-250 is particularly useful in the treatment of infections caused by bacteria more sensitive to the combination than to either component alone. The combination is also of value in those cases with mixed infections, and in those instances where the causative organism is unknown pending laboratory isolation. Final classification of the less than effective indications requires further investigation. Clinical studies to substantiate the efficacy of Urobiotic 250 are ongoing. Completion of these ongoing studies will provide data for final classification of these indications ." uuid:b5a06f49-35e8-48cf-b267-7968ad4a494e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:374687 biolink:treats MONDO:0005297 PMID:41385096 "[{""id"":""uuid:5bd4b99c-2740-43c7-8847-f15d77c330c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:31942671-cd61-4104-a76f-3a804e091a51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of this drug by the National Academy of Sciences-National Research Council and/or other information, FDA has classified the indications as follows: ""Lacking substantial evidence of effectiveness as a fixed combination"": Urobiotic-250 is indicated in the therapy of a number of genitourinary infections caused by susceptible organisms. These infections include the following: pyelonephritis, pyelitis, ureteritis, cystitis, prostatitis, and urethritis. Since both Terramycin and sulfamethizole provide effective levels in blood, tissue, and urine, Urobiotic-250 provides a multiple antimicrobial approach at the site of infection. Both antibacterial components are active against the most common urinary pathogens, including Escherichia coli, Pseudomonas aeruginosa, Aerobacter aerogenes, Streptococcus faecalis, Streptococcus hemolyticus , and Micrococcus pyogenes . Urobiotic-250 is particularly useful in the treatment of infections caused by bacteria more sensitive to the combination than to either component alone. The combination is also of value in those cases with mixed infections, and in those instances where the causative organism is unknown pending laboratory isolation. Final classification of the less than effective indications requires further investigation. Clinical studies to substantiate the efficacy of Urobiotic 250 are ongoing. Completion of these ongoing studies will provide data for final classification of these indications ." uuid:e2cff749-cc65-4ed5-b0a3-b56922da0875 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:370642 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:9ca2b2dc-1a84-4178-a8f6-eaf93cc23650"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7b1c2357-5626-471d-b3bb-2cb3c4ae37c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydrocodone bitartrate and acetaminophen tablets are indicated for the relief of moderate to moderately severe pain. uuid:76c9a458-9b36-4b41-a9a0-0aeacc763ca0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:216913 biolink:treats MONDO:0009688 PMID:41385096 "[{""id"":""uuid:300b507c-bb88-4950-98eb-e7adcd54d520"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8fd2c74a-8309-4df4-83ba-cd4140db9d0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENLON-PLUS (edrophonium chloride, USP and atropine sulfate, USP) Injection is recommended as a reversal agent or antagonist of nondepolarizing neuromuscular blocking agents. It is not effective against depolarizing neuromuscular blocking agents. It is also useful if used adjunctively in the treatment of respiratory depression caused by curare overdosage. The appropriateness of the specific fixed ratio of edrophonium and atropine contained in ENLON-PLUS has not been evaluated in myasthenia gravis. Therefore, ENLON-PLUS is not recommended for use in the differential diagnosis of this condition. uuid:30ab60e3-a8cc-44e8-8fcf-b252d6da1bad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:216913 biolink:treats MONDO:0043775 PMID:41385096 "[{""id"":""uuid:7f90b20d-8304-4e7d-9726-c32a271c7ca6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c02d47ff-c99f-4bd7-b24a-038da7ba35a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENLON-PLUS (edrophonium chloride, USP and atropine sulfate, USP) Injection is recommended as a reversal agent or antagonist of nondepolarizing neuromuscular blocking agents. It is not effective against depolarizing neuromuscular blocking agents. It is also useful if used adjunctively in the treatment of respiratory depression caused by curare overdosage. The appropriateness of the specific fixed ratio of edrophonium and atropine contained in ENLON-PLUS has not been evaluated in myasthenia gravis. Therefore, ENLON-PLUS is not recommended for use in the differential diagnosis of this condition. uuid:f4684170-0fc6-4592-bebb-16da11c8b503 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3699 biolink:treats MONDO:0005412 PMID:41385096 "[{""id"":""uuid:43b1bd16-3695-4cad-8b87-65f4a342ed8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9db6e1ad-4483-4ed8-8e5d-17b7498667d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cimetidine hydrochloride injection is indicated in: (1) Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks and there is rarely reason to use cimetidine at full dosage for longer than 6 to 8 weeks (see DOSAGE AND ADMINISTRATION − Duodenal Ulcer). Concomitant antacids should be given as needed for relief of pain. However, simultaneous administration of oral cimetidine and antacids is not recommended, since antacids have been reported to interfere with the absorption of oral cimetidine. (2) Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of active ulcer. Patients have been maintained on continued treatment with cimetidine 400 mg h.s. for periods of up to five years. (3) Short-term treatment of active benign gastric ulcer. There is no information concerning usefulness of treatment periods of longer than 8 weeks. (4) Prevention of upper gastrointestinal bleeding in critically ill patients. (5) The treatment of pathological hypersecretory conditions (i.e., Zollinger-Ellison Syndrome, systemic mastocytosis, multiple endocrine adenomas). uuid:92bd06bd-54c6-4a29-8b17-7731db68dd62 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3699 biolink:treats MONDO:0001126 PMID:41385096 "[{""id"":""uuid:84483e01-523f-456f-bdb7-9c74a7d9afd9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d8d4179c-4fbb-4e3e-a7d9-42f7663bb76a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cimetidine hydrochloride injection is indicated in: (1) Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks and there is rarely reason to use cimetidine at full dosage for longer than 6 to 8 weeks (see DOSAGE AND ADMINISTRATION − Duodenal Ulcer). Concomitant antacids should be given as needed for relief of pain. However, simultaneous administration of oral cimetidine and antacids is not recommended, since antacids have been reported to interfere with the absorption of oral cimetidine. (2) Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of active ulcer. Patients have been maintained on continued treatment with cimetidine 400 mg h.s. for periods of up to five years. (3) Short-term treatment of active benign gastric ulcer. There is no information concerning usefulness of treatment periods of longer than 8 weeks. (4) Prevention of upper gastrointestinal bleeding in critically ill patients. (5) The treatment of pathological hypersecretory conditions (i.e., Zollinger-Ellison Syndrome, systemic mastocytosis, multiple endocrine adenomas). uuid:c3b94674-98dd-4d71-b87a-acbc7bc436b9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3699 biolink:treats MONDO:0016586 PMID:41385096 "[{""id"":""uuid:28007795-9079-4f26-9bfb-b9670b02e643"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:72027c64-493d-4f89-946e-2a4372fd83d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cimetidine hydrochloride injection is indicated in: (1) Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks and there is rarely reason to use cimetidine at full dosage for longer than 6 to 8 weeks (see DOSAGE AND ADMINISTRATION − Duodenal Ulcer). Concomitant antacids should be given as needed for relief of pain. However, simultaneous administration of oral cimetidine and antacids is not recommended, since antacids have been reported to interfere with the absorption of oral cimetidine. (2) Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of active ulcer. Patients have been maintained on continued treatment with cimetidine 400 mg h.s. for periods of up to five years. (3) Short-term treatment of active benign gastric ulcer. There is no information concerning usefulness of treatment periods of longer than 8 weeks. (4) Prevention of upper gastrointestinal bleeding in critically ill patients. (5) The treatment of pathological hypersecretory conditions (i.e., Zollinger-Ellison Syndrome, systemic mastocytosis, multiple endocrine adenomas). uuid:baf7cccf-9508-4f66-8691-19949e78395d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3699 biolink:treats MONDO:0017169 PMID:41385096 "[{""id"":""uuid:12748f55-a7e4-490b-9633-1aba9584ca32"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a0ff8b1d-27ff-42af-81b3-188f956748ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cimetidine hydrochloride injection is indicated in: (1) Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks and there is rarely reason to use cimetidine at full dosage for longer than 6 to 8 weeks (see DOSAGE AND ADMINISTRATION − Duodenal Ulcer). Concomitant antacids should be given as needed for relief of pain. However, simultaneous administration of oral cimetidine and antacids is not recommended, since antacids have been reported to interfere with the absorption of oral cimetidine. (2) Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of active ulcer. Patients have been maintained on continued treatment with cimetidine 400 mg h.s. for periods of up to five years. (3) Short-term treatment of active benign gastric ulcer. There is no information concerning usefulness of treatment periods of longer than 8 weeks. (4) Prevention of upper gastrointestinal bleeding in critically ill patients. (5) The treatment of pathological hypersecretory conditions (i.e., Zollinger-Ellison Syndrome, systemic mastocytosis, multiple endocrine adenomas). uuid:00503ac7-480e-4acc-beb7-fdfbe42b9cba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59773 biolink:treats MONDO:0007950 PMID:41385096 "[{""id"":""uuid:978a2dec-d820-456c-8eb8-8ba275e95da7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e19cee5f-2b75-462c-9add-af4ae7b98f85"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] GASTROCROM is indicated in the management of patients with mastocytosis. Use of this product has been associated with improvement in diarrhea, flushing, headaches, vomiting, urticaria, abdominal pain, nausea, and itching in some patients. uuid:c17ceb17-5d22-4a29-a556-1fd6072b675f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:54692993 biolink:treats MONDO:0006668 PMID:41385096 "[{""id"":""uuid:8c015d95-b852-429b-9c3d-d01936be9e57"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8181f4f9-c392-42de-8e95-b72112fd2196"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical radiation, thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus Streptococci , including Streptococcus pneumoniae Escherichia coli Neisseria species The product does not provide adequate coverage against: Haemophilus influenzae Klebsiella/Enterobacter species Pseudomonas aeruginosa Serratia marcescens uuid:5ecb7d15-7c9f-435e-adb6-393bea74501d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:54692993 biolink:treats UMLS:C0008690 PMID:41385096 "[{""id"":""uuid:b4e8d403-b6d3-4849-bf71-18044684642c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:43fafc97-9670-46e7-959f-61fce3b4b193"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical radiation, thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus Streptococci , including Streptococcus pneumoniae Escherichia coli Neisseria species The product does not provide adequate coverage against: Haemophilus influenzae Klebsiella/Enterobacter species Pseudomonas aeruginosa Serratia marcescens uuid:865bbddc-2804-4f56-a769-a7aaa499b803 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:54692993 biolink:treats UMLS:C0339289 PMID:41385096 "[{""id"":""uuid:7464e766-c833-45a9-ac87-b307d0a6c63f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:79ec3c43-5d47-4ac3-892c-6977f65eb4dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical radiation, thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus Streptococci , including Streptococcus pneumoniae Escherichia coli Neisseria species The product does not provide adequate coverage against: Haemophilus influenzae Klebsiella/Enterobacter species Pseudomonas aeruginosa Serratia marcescens uuid:89c8e602-15e9-48e0-9567-5da58593fbd7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77733 biolink:treats HP:0004763 PMID:41385096 "[{""id"":""uuid:973bc376-2be4-49a6-960d-12d8500bab3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:276aa2be-300f-4d82-86a8-0438fd894330"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f135afd0-2371-4d33-91eb-2e5151c8799e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous Verapamil HCI is indicated for the following: Rapid conversion to sinus rhythm of paroxysmal supraventricular tachycardias, including those associated with accessory bypass tracts (Wolff-Parkinson-White [W-P-W] and Lown-Ganong-Levine [L-G-L] syndromes). When clinically advisable, appropriate vagal maneuvers (e.g., Valsalva maneuver) should be attempted prior to verapamil hydrochloride administration. Temporary control of rapid ventricular rate in atrial flutter or atrial fibrillation except when the atrial flutter and/or atrial fibrillation are associated with accessory bypass tracts (Wolff-Parkinson-White [W-P-W] and Lown-Ganong-Levine [L-G-L] syndromes). In controlled studies in the United States, about 60% of patients with supraventricular tachycardia converted to normal sinus rhythm within 10 minutes after intravenous verapamil. Uncontrolled studies reported in the world literature describe a conversion rate of about 80%. About 70% of patients with atrial flutter and/or fibrillation with a fast ventricular rate respond with a decrease in ventricular rate of at least 20%. Conversion of atrial flutter or fibrillation to sinus rhythm is uncommon (about 10%) after verapamil and may reflect the spontaneous conversion rate, since the conversion rate after placebo was similar. Slowing of the ventricular rate in patients with atrial fibrillation/flutter lasts 30 to 60 minutes after a single injection. Because a small fraction (<1%) of patients treated with verapamil respond with life-threatening adverse responses (rapid ventricular rate In atrial flutter/fibrillation and an accessory bypass tract, marked hypotension, or extreme bradycardia/asystole - see Contraindications and Warnings ), the initial use of intravenous verapamil should, if possible, be in a treatment setting with monitoring and resuscitation facilities, including DC-cardioversion capability (see Suggested Treatment of Acute Cardiovascular Adverse Reactions ). As familiarity with the patient's response is gained, use in an office setting may be acceptable. Cardioversion has been used safely and effectively after intravenous verapamil.|[PMDA] A drug with a new additional dosage indicated for the treatment of tachyarrhythmia in pediatric patients (paroxysmal supraventricular tachycardia, paroxysmal atrial fibrillation, paroxysmal atrial flutter). [Public knowledge-based application after PAFSC's preliminary assessment] uuid:76890399-6d39-497c-ba66-8f59f7509d91 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77733 biolink:treats MONDO:0008685 PMID:41385096 "[{""id"":""uuid:475e005f-d235-459e-a43c-ee50197b73d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9d499dd9-a921-43d6-81f7-864d3ffb06b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous Verapamil HCI is indicated for the following: Rapid conversion to sinus rhythm of paroxysmal supraventricular tachycardias, including those associated with accessory bypass tracts (Wolff-Parkinson-White [W-P-W] and Lown-Ganong-Levine [L-G-L] syndromes). When clinically advisable, appropriate vagal maneuvers (e.g., Valsalva maneuver) should be attempted prior to verapamil hydrochloride administration. Temporary control of rapid ventricular rate in atrial flutter or atrial fibrillation except when the atrial flutter and/or atrial fibrillation are associated with accessory bypass tracts (Wolff-Parkinson-White [W-P-W] and Lown-Ganong-Levine [L-G-L] syndromes). In controlled studies in the United States, about 60% of patients with supraventricular tachycardia converted to normal sinus rhythm within 10 minutes after intravenous verapamil. Uncontrolled studies reported in the world literature describe a conversion rate of about 80%. About 70% of patients with atrial flutter and/or fibrillation with a fast ventricular rate respond with a decrease in ventricular rate of at least 20%. Conversion of atrial flutter or fibrillation to sinus rhythm is uncommon (about 10%) after verapamil and may reflect the spontaneous conversion rate, since the conversion rate after placebo was similar. Slowing of the ventricular rate in patients with atrial fibrillation/flutter lasts 30 to 60 minutes after a single injection. Because a small fraction (<1%) of patients treated with verapamil respond with life-threatening adverse responses (rapid ventricular rate In atrial flutter/fibrillation and an accessory bypass tract, marked hypotension, or extreme bradycardia/asystole - see Contraindications and Warnings ), the initial use of intravenous verapamil should, if possible, be in a treatment setting with monitoring and resuscitation facilities, including DC-cardioversion capability (see Suggested Treatment of Acute Cardiovascular Adverse Reactions ). As familiarity with the patient's response is gained, use in an office setting may be acceptable. Cardioversion has been used safely and effectively after intravenous verapamil. uuid:aa966392-6b88-4aab-be2d-fea661753555 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77733 biolink:treats MONDO:0005310 PMID:41385096 "[{""id"":""uuid:f4051ac8-b0ad-4979-a88f-78cf1cbd3f01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cf34b962-f6cc-406a-8368-8b6ff1a0101e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b12340e0-0ed7-4785-b27c-ac13d9e89ab3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous Verapamil HCI is indicated for the following: Rapid conversion to sinus rhythm of paroxysmal supraventricular tachycardias, including those associated with accessory bypass tracts (Wolff-Parkinson-White [W-P-W] and Lown-Ganong-Levine [L-G-L] syndromes). When clinically advisable, appropriate vagal maneuvers (e.g., Valsalva maneuver) should be attempted prior to verapamil hydrochloride administration. Temporary control of rapid ventricular rate in atrial flutter or atrial fibrillation except when the atrial flutter and/or atrial fibrillation are associated with accessory bypass tracts (Wolff-Parkinson-White [W-P-W] and Lown-Ganong-Levine [L-G-L] syndromes). In controlled studies in the United States, about 60% of patients with supraventricular tachycardia converted to normal sinus rhythm within 10 minutes after intravenous verapamil. Uncontrolled studies reported in the world literature describe a conversion rate of about 80%. About 70% of patients with atrial flutter and/or fibrillation with a fast ventricular rate respond with a decrease in ventricular rate of at least 20%. Conversion of atrial flutter or fibrillation to sinus rhythm is uncommon (about 10%) after verapamil and may reflect the spontaneous conversion rate, since the conversion rate after placebo was similar. Slowing of the ventricular rate in patients with atrial fibrillation/flutter lasts 30 to 60 minutes after a single injection. Because a small fraction (<1%) of patients treated with verapamil respond with life-threatening adverse responses (rapid ventricular rate In atrial flutter/fibrillation and an accessory bypass tract, marked hypotension, or extreme bradycardia/asystole - see Contraindications and Warnings ), the initial use of intravenous verapamil should, if possible, be in a treatment setting with monitoring and resuscitation facilities, including DC-cardioversion capability (see Suggested Treatment of Acute Cardiovascular Adverse Reactions ). As familiarity with the patient's response is gained, use in an office setting may be acceptable. Cardioversion has been used safely and effectively after intravenous verapamil.|[PMDA] A drug with a new additional indication and a new dosage for the treatment of tachyarrhythmia in pediatric patients (atrial fibrillation, atrial flutter, paroxysmal supraventricular tachycardia). [Public knowledge-based application after PAFSC's preliminary assessment] uuid:f771b3aa-3c68-4741-bb85-1803c986555a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77733 biolink:treats MONDO:0004981 PMID:41385096 "[{""id"":""uuid:ecb1eb4b-dd1e-4d47-906d-46f14a841f87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5a7a7ea6-7664-4e34-82a6-9ff064101048"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:8d838887-b039-4919-9411-8a35af474534"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous Verapamil HCI is indicated for the following: Rapid conversion to sinus rhythm of paroxysmal supraventricular tachycardias, including those associated with accessory bypass tracts (Wolff-Parkinson-White [W-P-W] and Lown-Ganong-Levine [L-G-L] syndromes). When clinically advisable, appropriate vagal maneuvers (e.g., Valsalva maneuver) should be attempted prior to verapamil hydrochloride administration. Temporary control of rapid ventricular rate in atrial flutter or atrial fibrillation except when the atrial flutter and/or atrial fibrillation are associated with accessory bypass tracts (Wolff-Parkinson-White [W-P-W] and Lown-Ganong-Levine [L-G-L] syndromes). In controlled studies in the United States, about 60% of patients with supraventricular tachycardia converted to normal sinus rhythm within 10 minutes after intravenous verapamil. Uncontrolled studies reported in the world literature describe a conversion rate of about 80%. About 70% of patients with atrial flutter and/or fibrillation with a fast ventricular rate respond with a decrease in ventricular rate of at least 20%. Conversion of atrial flutter or fibrillation to sinus rhythm is uncommon (about 10%) after verapamil and may reflect the spontaneous conversion rate, since the conversion rate after placebo was similar. Slowing of the ventricular rate in patients with atrial fibrillation/flutter lasts 30 to 60 minutes after a single injection. Because a small fraction (<1%) of patients treated with verapamil respond with life-threatening adverse responses (rapid ventricular rate In atrial flutter/fibrillation and an accessory bypass tract, marked hypotension, or extreme bradycardia/asystole - see Contraindications and Warnings ), the initial use of intravenous verapamil should, if possible, be in a treatment setting with monitoring and resuscitation facilities, including DC-cardioversion capability (see Suggested Treatment of Acute Cardiovascular Adverse Reactions ). As familiarity with the patient's response is gained, use in an office setting may be acceptable. Cardioversion has been used safely and effectively after intravenous verapamil.|[PMDA] A drug with a new additional indication and a new dosage for the treatment of tachyarrhythmia in pediatric patients (atrial fibrillation, atrial flutter, paroxysmal supraventricular tachycardia). [Public knowledge-based application after PAFSC's preliminary assessment] uuid:69f12f20-4a8c-49a7-bfe6-3da4c0dd96c0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6709 biolink:treats HP:0002018 PMID:41385096 "[{""id"":""uuid:da2460bc-0b88-4949-b03c-1481cadce4b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d2c362f5-0b0a-496f-9186-42f31f139caf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prophylactic treatment and management of nausea and vomiting, and dizziness associated with motion sickness. uuid:84fd866d-4e7e-4fb8-bf76-d63f39cb67d7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6709 biolink:treats HP:0002013 PMID:41385096 "[{""id"":""uuid:58630234-0a14-4fdd-b535-5cfc078cecea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3882b907-a952-44e0-8b3a-7b15691efe1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prophylactic treatment and management of nausea and vomiting, and dizziness associated with motion sickness. uuid:79454336-a975-43bf-8030-4711eef1e0b9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6709 biolink:treats MONDO:0002317 PMID:41385096 "[{""id"":""uuid:83d16e62-eebc-43af-9b04-2e4f36f0bd42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8b26f695-c5ca-4b72-8e12-e7c6e28ddb12"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prophylactic treatment and management of nausea and vomiting, and dizziness associated with motion sickness. uuid:3ef6f7c9-8cfd-4483-aede-366c00d91184 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6904 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:7122952d-c824-459a-8a51-58cae91e35d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ae166f79-6c6b-444c-92ec-901dfef110f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Myocardial Infarction Metoprolol tartrate injection and tablets are indicated in the treatment of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality. Treatment with intravenous metoprolol tartrate can be initiated as soon as the patient’s clinical condition allows (see DOSAGE AND ADMINISTRATION , CONTRAINDICATIONS , and WARNINGS ). Alternatively, treatment can begin within 3 to 10 days of the acute event (see DOSAGE AND ADMINISTRATION ). uuid:eefb3b2e-cd0d-48f0-8551-26ccce7e174e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6904 biolink:treats MONDO:0004781 PMID:41385096 "[{""id"":""uuid:d279d49f-6622-457c-9681-1f0e999ca745"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:748452fd-5172-4352-a193-e03c4187d337"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Myocardial Infarction Metoprolol tartrate injection and tablets are indicated in the treatment of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality. Treatment with intravenous metoprolol tartrate can be initiated as soon as the patient’s clinical condition allows (see DOSAGE AND ADMINISTRATION , CONTRAINDICATIONS , and WARNINGS ). Alternatively, treatment can begin within 3 to 10 days of the acute event (see DOSAGE AND ADMINISTRATION ). uuid:45bd1b29-84af-4b4a-bce4-c4ddbcd7a1df biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6539 biolink:treats MONDO:0002125 PMID:41385096 "[{""id"":""uuid:16877d3a-39d9-491f-bb42-eedb666e89c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8c2f9966-04ab-4af9-8d7a-40dce736deec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ce3ffb51-b8cf-49d9-b893-286926964a2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Status Epilepticus Lorazepam injection is indicated for the treatment of status epilepticus. Preanesthetic Lorazepam injection is indicated in adult patients for preanesthetic medication, producing sedation (sleepiness or drowsiness), relief of anxiety, and a decreased ability to recall events related to the day of surgery. It is most useful in those patients who are anxious about their surgical procedure and who would prefer to have diminished recall of the events of the day of surgery (see PRECAUTIONS, Information for Patients ).|[PMDA] A drug with a new route of administration indicated for the treatment of status epilepticus. uuid:f5b1e20e-61a9-48da-ad8a-641aa62f083d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6539 biolink:treats MONDO:0011918 PMID:41385096 "[{""id"":""uuid:4eb6a18c-193d-4a15-8cec-77133a0cd1b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7540a07c-8836-4095-bd1d-4a7a3b282ce4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Status Epilepticus Lorazepam injection is indicated for the treatment of status epilepticus. Preanesthetic Lorazepam injection is indicated in adult patients for preanesthetic medication, producing sedation (sleepiness or drowsiness), relief of anxiety, and a decreased ability to recall events related to the day of surgery. It is most useful in those patients who are anxious about their surgical procedure and who would prefer to have diminished recall of the events of the day of surgery (see PRECAUTIONS, Information for Patients ). uuid:09a5a106-8bc2-4df8-9201-f80b70a90320 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31625 biolink:treats MONDO:0003799 PMID:41385096 "[{""id"":""uuid:a1ab71bb-a268-49dd-81a9-801d2b77dcc3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c588ef85-7c64-49ec-a55d-8136c778a5dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FLUOR-OP is indicated for the treatment of corticosteroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe. uuid:941814dd-322b-461c-a1e9-fe8bd99f3fd7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31625 biolink:treats MONDO:0003085 PMID:41385096 "[{""id"":""uuid:ffb44edb-79a0-41ae-a2c1-544ba7bab921"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a5b901cc-12d5-4201-bd4c-17d388f4e1a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FLUOR-OP is indicated for the treatment of corticosteroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe. uuid:2d24a6aa-34d8-46ae-aabb-d0cfaa9695f4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3611 biolink:treats MONDO:0005618 PMID:41385096 "[{""id"":""uuid:5eb3de55-f9b0-408e-9623-c04231d43449"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:25d69e04-34e1-4abc-b9cd-10696dbb7e77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chlordiazepoxide HCI Capsules are indicated for the management of anxiety disorders or for the short-term relief of symptoms of anxiety, withdrawal symptoms of acute alcoholism, and preoperative apprehension and anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The effectiveness of chlordiazepoxide in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. uuid:6b754b02-eb30-4417-96cd-0509ae133753 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3611 biolink:treats MONDO:0011918 PMID:41385096 "[{""id"":""uuid:24d7ef04-4254-4dfc-99de-7df4d7d71149"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aba1e60c-0cbb-4070-b39c-eeac81c66ba8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chlordiazepoxide HCI Capsules are indicated for the management of anxiety disorders or for the short-term relief of symptoms of anxiety, withdrawal symptoms of acute alcoholism, and preoperative apprehension and anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The effectiveness of chlordiazepoxide in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. uuid:51bf31bf-b952-4928-a4c1-7ac6c83e8296 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3611 biolink:treats MONDO:0005433 PMID:41385096 "[{""id"":""uuid:c2b76662-f909-4e2e-9212-9a751707d140"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1ce81768-7ebb-49c1-ba68-79f51094af39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chlordiazepoxide HCI Capsules are indicated for the management of anxiety disorders or for the short-term relief of symptoms of anxiety, withdrawal symptoms of acute alcoholism, and preoperative apprehension and anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The effectiveness of chlordiazepoxide in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. uuid:250d94fe-7605-4f65-9dd7-a9ab55bae08a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135679 biolink:treats UMLS:C0339164 PMID:41385096 "[{""id"":""uuid:b4c3cc27-8e76-4372-aac4-4680aa95fe81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f2a16936-c02d-4366-a839-f302aeb3bc3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LIVOSTIN™ 0.05% (levocabastine hydrochloride ophthalmic suspension) is indicated for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis. uuid:b100cb70-67c0-432f-8326-3f57d118ac34 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:34829 biolink:treats MONDO:0002313 PMID:41385096 "[{""id"":""uuid:e68ab827-5431-437e-9a6e-7dfe625b1043"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:418d94bd-e2df-4d21-9909-be8d98b338e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] HMS ® (medrysone ophthalmic suspension) is indicated for the treatment of allergic conjunctivitis, vernal conjunctivitis, episcleritis, and epinephrine sensitivity. uuid:846b26f9-8dca-43ca-b164-a79205dc182f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:34829 biolink:treats MONDO:0001439 PMID:41385096 "[{""id"":""uuid:1294171b-393b-4773-b303-aea438ae7801"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:542a924e-3897-49ff-a003-2bfcb419018d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] HMS ® (medrysone ophthalmic suspension) is indicated for the treatment of allergic conjunctivitis, vernal conjunctivitis, episcleritis, and epinephrine sensitivity. uuid:a05d249e-5809-4096-8099-4437320a8941 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0002154 PMID:41385096 "[{""id"":""uuid:d3db22a0-05f2-499b-a558-26b31759c269"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e30b9d5b-aa11-48a9-8365-f74813cf6a7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metronidazole is indicated for the treatment of symptomatic trichomoniasis in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). uuid:b6db015b-2a39-481b-8349-0a98dc2bfb06 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8461 biolink:treats MONDO:0100053 PMID:41385096 "[{""id"":""uuid:b961ac9c-b75a-419a-a0b2-ab76d0d1aae3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:760169e0-e809-422a-81b5-7993b3a9c575"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Promethazine HCl Injection is indicated for the following conditions: Amelioration of allergic reactions to blood or plasma. In anaphylaxis as an adjunct to epinephrine and other standard measures after the acute symptoms have been controlled. For other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated. For sedation and relief of apprehension and to produce light sleep from which the patient can be easily aroused. Active treatment of motion sickness. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. As an adjunct to analgesics for the control of postoperative pain. Preoperative, postoperative, and obstetric (during labor) sedation. Intravenously in special surgical situations, such as repeated bronchoscopy, ophthalmic surgery, and poor-risk patients, with reduced amounts of meperidine or other narcotic analgesic as an adjunct to anesthesia and analgesia. uuid:13b2acf9-5280-491a-9d14-70d2a048c227 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8461 biolink:treats MONDO:0008015 PMID:41385096 "[{""id"":""uuid:44a1e16f-c55b-4ef1-a17d-8cd6fde57310"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:351940e1-79bf-4ab3-9256-3f107d84fe51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Promethazine HCl Injection is indicated for the following conditions: Amelioration of allergic reactions to blood or plasma. In anaphylaxis as an adjunct to epinephrine and other standard measures after the acute symptoms have been controlled. For other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated. For sedation and relief of apprehension and to produce light sleep from which the patient can be easily aroused. Active treatment of motion sickness. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. As an adjunct to analgesics for the control of postoperative pain. Preoperative, postoperative, and obstetric (during labor) sedation. Intravenously in special surgical situations, such as repeated bronchoscopy, ophthalmic surgery, and poor-risk patients, with reduced amounts of meperidine or other narcotic analgesic as an adjunct to anesthesia and analgesia. uuid:9ee95785-d525-4114-b4d0-88d901b003de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8461 biolink:treats HP:0002018 PMID:41385096 "[{""id"":""uuid:6792daab-bbad-4339-9363-5a6fcc37c2ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5459404a-1ef3-4e94-b224-21485ab8fe69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Promethazine HCl Injection is indicated for the following conditions: Amelioration of allergic reactions to blood or plasma. In anaphylaxis as an adjunct to epinephrine and other standard measures after the acute symptoms have been controlled. For other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated. For sedation and relief of apprehension and to produce light sleep from which the patient can be easily aroused. Active treatment of motion sickness. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. As an adjunct to analgesics for the control of postoperative pain. Preoperative, postoperative, and obstetric (during labor) sedation. Intravenously in special surgical situations, such as repeated bronchoscopy, ophthalmic surgery, and poor-risk patients, with reduced amounts of meperidine or other narcotic analgesic as an adjunct to anesthesia and analgesia. uuid:d2b54862-3d6d-4a40-a0a4-38f58421148f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8461 biolink:treats HP:0002013 PMID:41385096 "[{""id"":""uuid:3d4356b9-1a91-4329-9f62-d1be8668e800"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3f64a9c2-8f9e-4055-943c-b2ca26b065a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Promethazine HCl Injection is indicated for the following conditions: Amelioration of allergic reactions to blood or plasma. In anaphylaxis as an adjunct to epinephrine and other standard measures after the acute symptoms have been controlled. For other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated. For sedation and relief of apprehension and to produce light sleep from which the patient can be easily aroused. Active treatment of motion sickness. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. As an adjunct to analgesics for the control of postoperative pain. Preoperative, postoperative, and obstetric (during labor) sedation. Intravenously in special surgical situations, such as repeated bronchoscopy, ophthalmic surgery, and poor-risk patients, with reduced amounts of meperidine or other narcotic analgesic as an adjunct to anesthesia and analgesia. uuid:9c990b9d-b632-4ecb-9b4d-96dd26a7ffad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8461 biolink:treats NCIT:C34887 PMID:41385096 "[{""id"":""uuid:e904d429-9d8c-49b9-8010-953e59e91bb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d7e8ccf6-86e4-4dd6-9152-d711ecfbc10e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Promethazine HCl Injection is indicated for the following conditions: Amelioration of allergic reactions to blood or plasma. In anaphylaxis as an adjunct to epinephrine and other standard measures after the acute symptoms have been controlled. For other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated. For sedation and relief of apprehension and to produce light sleep from which the patient can be easily aroused. Active treatment of motion sickness. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. As an adjunct to analgesics for the control of postoperative pain. Preoperative, postoperative, and obstetric (during labor) sedation. Intravenously in special surgical situations, such as repeated bronchoscopy, ophthalmic surgery, and poor-risk patients, with reduced amounts of meperidine or other narcotic analgesic as an adjunct to anesthesia and analgesia. uuid:0da4cd8b-9791-40a9-a906-24a04675a77a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:553473 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:57c6806d-32a8-4762-b311-29457e18594c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:61bc8a46-51eb-472e-a740-13506e326e76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefizox (ceftizoxime for injection, USP) is indicated in the treatment of infections due to susceptible strains of the microorganisms listed below. Lower Respiratory Tract Infections caused by Klebsiella spp.; Proteus mirabilis ; Escherichia coli; Haemophilus influenzae including ampicillin‐resistant strains; Staphylococcus aureus (penicillinase­ and nonpenicillinase‐producing); Serratia spp.; Enterobacter spp.; Bacteroides spp.; and Streptococcus spp. including S. pneumoniae , but excluding enterococci. Urinary Tract Infections caused by Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Escherichia coli ; Pseudomonas spp. including P. aeruginosa ; Proteus mirabilis ; P. vulgaris ; Providencia rettgeri (formerly Proteus rettgeri ) and Morganella morganii (formerly Proteus morganii ); Klebsiella spp.; Serratia spp. including S. marcescens ; and Enterobacter spp. Gonorrhea including uncomplicated cervical and urethral gonorrhea caused by Neisseria gonorrhoeae . Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae, Escherichia coli or Streptococcus agalactiae . NOTE: Ceftizoxime, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti­chlamydial coverage should be added. Intra‐Abdominal Infections caused by Escherichia coli; Staphylococcus epidermidis; Streptococcus spp. (excluding enterococci); Enterobacter spp.; Klebsiella spp.; Bacteroides spp. including B. fragilis ; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Septicemia caused by Streptococcus spp. including S. pneumoniae (but excluding enterococci); Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Escherichia coli; Bacteroides spp. including B. fragilis ; Klebsiella spp.; and Serratia spp. Skin and Skin Structure Infections caused by Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Staphylococcus epidermidis ; Escherichia coli; Klebsiella spp.; Streptococcus spp. including Streptococcus pyogenes (but excluding enterococci); Proteus mirabilis ; Serratia spp.; Enterobacter spp.; Bacteroides spp. including B. fragilis ; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Bone and Joint Infections caused by Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Streptococcus spp. (excluding enterococci); Proteus mirabilis ; Bacteroides spp.; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Meningitis caused by Haemophilus influenzae . Cefizox has also been used successfully in the treatment of a limited number of pediatric and adult cases of meningitis caused by Streptococcus pneumoniae . Cefizox has been effective in the treatment of seriously ill, compromised patients, including those who were debilitated, immunosuppressed, or neutropenic. Infections caused by aerobic gram‐negative and by mixtures of organisms resistant to other cephalosporins, aminoglycosides, or penicillins have responded to treatment with Cefizox. Because of the serious nature of some urinary tract infections due to P. aeruginosa and because many strains of Pseudomonas species are only moderately susceptible to Cefizox, higher dosage is recommended. Other therapy should be instituted if the response is not prompt. Susceptibility studies on specimens obtained prior to therapy should be used to determine the response of causative organisms to Cefizox. Therapy with Cefizox may be initiated pending results of the studies; however, treatment should be adjusted according to study findings. In serious infections, Cefizox has been used concomitantly with aminoglycosides (see PRECAUTIONS ). Before using Cefizox concomitantly with other antibiotics, the prescribing information for those agents should be reviewed for contraindications, warnings, precautions, and adverse reactions. Renal function should be carefully monitored. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefizox and other antibacterial drugs, Cefizox should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:1de198e2-ebad-4dea-97a0-f704bc03520b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:553473 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:d3799391-3736-4ace-bd23-ba25b22a2966"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:06808be5-6184-4eba-bbde-8720f8bbf7f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefizox (ceftizoxime for injection, USP) is indicated in the treatment of infections due to susceptible strains of the microorganisms listed below. Lower Respiratory Tract Infections caused by Klebsiella spp.; Proteus mirabilis ; Escherichia coli; Haemophilus influenzae including ampicillin‐resistant strains; Staphylococcus aureus (penicillinase­ and nonpenicillinase‐producing); Serratia spp.; Enterobacter spp.; Bacteroides spp.; and Streptococcus spp. including S. pneumoniae , but excluding enterococci. Urinary Tract Infections caused by Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Escherichia coli ; Pseudomonas spp. including P. aeruginosa ; Proteus mirabilis ; P. vulgaris ; Providencia rettgeri (formerly Proteus rettgeri ) and Morganella morganii (formerly Proteus morganii ); Klebsiella spp.; Serratia spp. including S. marcescens ; and Enterobacter spp. Gonorrhea including uncomplicated cervical and urethral gonorrhea caused by Neisseria gonorrhoeae . Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae, Escherichia coli or Streptococcus agalactiae . NOTE: Ceftizoxime, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti­chlamydial coverage should be added. Intra‐Abdominal Infections caused by Escherichia coli; Staphylococcus epidermidis; Streptococcus spp. (excluding enterococci); Enterobacter spp.; Klebsiella spp.; Bacteroides spp. including B. fragilis ; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Septicemia caused by Streptococcus spp. including S. pneumoniae (but excluding enterococci); Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Escherichia coli; Bacteroides spp. including B. fragilis ; Klebsiella spp.; and Serratia spp. Skin and Skin Structure Infections caused by Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Staphylococcus epidermidis ; Escherichia coli; Klebsiella spp.; Streptococcus spp. including Streptococcus pyogenes (but excluding enterococci); Proteus mirabilis ; Serratia spp.; Enterobacter spp.; Bacteroides spp. including B. fragilis ; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Bone and Joint Infections caused by Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Streptococcus spp. (excluding enterococci); Proteus mirabilis ; Bacteroides spp.; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Meningitis caused by Haemophilus influenzae . Cefizox has also been used successfully in the treatment of a limited number of pediatric and adult cases of meningitis caused by Streptococcus pneumoniae . Cefizox has been effective in the treatment of seriously ill, compromised patients, including those who were debilitated, immunosuppressed, or neutropenic. Infections caused by aerobic gram‐negative and by mixtures of organisms resistant to other cephalosporins, aminoglycosides, or penicillins have responded to treatment with Cefizox. Because of the serious nature of some urinary tract infections due to P. aeruginosa and because many strains of Pseudomonas species are only moderately susceptible to Cefizox, higher dosage is recommended. Other therapy should be instituted if the response is not prompt. Susceptibility studies on specimens obtained prior to therapy should be used to determine the response of causative organisms to Cefizox. Therapy with Cefizox may be initiated pending results of the studies; however, treatment should be adjusted according to study findings. In serious infections, Cefizox has been used concomitantly with aminoglycosides (see PRECAUTIONS ). Before using Cefizox concomitantly with other antibiotics, the prescribing information for those agents should be reviewed for contraindications, warnings, precautions, and adverse reactions. Renal function should be carefully monitored. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefizox and other antibacterial drugs, Cefizox should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:4fb10838-3af6-4de5-92c3-f1c9fa716f8e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:553473 biolink:treats MONDO:0004277 PMID:41385096 "[{""id"":""uuid:77f62fe3-3e3f-4ed9-a939-b3d3cda27d82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c4d0d86e-14bf-4deb-8766-f0071ecc017a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefizox (ceftizoxime for injection, USP) is indicated in the treatment of infections due to susceptible strains of the microorganisms listed below. Lower Respiratory Tract Infections caused by Klebsiella spp.; Proteus mirabilis ; Escherichia coli; Haemophilus influenzae including ampicillin‐resistant strains; Staphylococcus aureus (penicillinase­ and nonpenicillinase‐producing); Serratia spp.; Enterobacter spp.; Bacteroides spp.; and Streptococcus spp. including S. pneumoniae , but excluding enterococci. Urinary Tract Infections caused by Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Escherichia coli ; Pseudomonas spp. including P. aeruginosa ; Proteus mirabilis ; P. vulgaris ; Providencia rettgeri (formerly Proteus rettgeri ) and Morganella morganii (formerly Proteus morganii ); Klebsiella spp.; Serratia spp. including S. marcescens ; and Enterobacter spp. Gonorrhea including uncomplicated cervical and urethral gonorrhea caused by Neisseria gonorrhoeae . Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae, Escherichia coli or Streptococcus agalactiae . NOTE: Ceftizoxime, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti­chlamydial coverage should be added. Intra‐Abdominal Infections caused by Escherichia coli; Staphylococcus epidermidis; Streptococcus spp. (excluding enterococci); Enterobacter spp.; Klebsiella spp.; Bacteroides spp. including B. fragilis ; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Septicemia caused by Streptococcus spp. including S. pneumoniae (but excluding enterococci); Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Escherichia coli; Bacteroides spp. including B. fragilis ; Klebsiella spp.; and Serratia spp. Skin and Skin Structure Infections caused by Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Staphylococcus epidermidis ; Escherichia coli; Klebsiella spp.; Streptococcus spp. including Streptococcus pyogenes (but excluding enterococci); Proteus mirabilis ; Serratia spp.; Enterobacter spp.; Bacteroides spp. including B. fragilis ; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Bone and Joint Infections caused by Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Streptococcus spp. (excluding enterococci); Proteus mirabilis ; Bacteroides spp.; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Meningitis caused by Haemophilus influenzae . Cefizox has also been used successfully in the treatment of a limited number of pediatric and adult cases of meningitis caused by Streptococcus pneumoniae . Cefizox has been effective in the treatment of seriously ill, compromised patients, including those who were debilitated, immunosuppressed, or neutropenic. Infections caused by aerobic gram‐negative and by mixtures of organisms resistant to other cephalosporins, aminoglycosides, or penicillins have responded to treatment with Cefizox. Because of the serious nature of some urinary tract infections due to P. aeruginosa and because many strains of Pseudomonas species are only moderately susceptible to Cefizox, higher dosage is recommended. Other therapy should be instituted if the response is not prompt. Susceptibility studies on specimens obtained prior to therapy should be used to determine the response of causative organisms to Cefizox. Therapy with Cefizox may be initiated pending results of the studies; however, treatment should be adjusted according to study findings. In serious infections, Cefizox has been used concomitantly with aminoglycosides (see PRECAUTIONS ). Before using Cefizox concomitantly with other antibiotics, the prescribing information for those agents should be reviewed for contraindications, warnings, precautions, and adverse reactions. Renal function should be carefully monitored. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefizox and other antibacterial drugs, Cefizox should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:9794b5c1-e9b7-42ea-83a8-32b88aad75ad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:553473 biolink:treats MONDO:0000922 PMID:41385096 "[{""id"":""uuid:ae19a29b-a0a7-4db4-94cd-8c41b39ad645"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eb1febe7-4443-44ab-976e-03997f7cde50"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefizox (ceftizoxime for injection, USP) is indicated in the treatment of infections due to susceptible strains of the microorganisms listed below. Lower Respiratory Tract Infections caused by Klebsiella spp.; Proteus mirabilis ; Escherichia coli; Haemophilus influenzae including ampicillin‐resistant strains; Staphylococcus aureus (penicillinase­ and nonpenicillinase‐producing); Serratia spp.; Enterobacter spp.; Bacteroides spp.; and Streptococcus spp. including S. pneumoniae , but excluding enterococci. Urinary Tract Infections caused by Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Escherichia coli ; Pseudomonas spp. including P. aeruginosa ; Proteus mirabilis ; P. vulgaris ; Providencia rettgeri (formerly Proteus rettgeri ) and Morganella morganii (formerly Proteus morganii ); Klebsiella spp.; Serratia spp. including S. marcescens ; and Enterobacter spp. Gonorrhea including uncomplicated cervical and urethral gonorrhea caused by Neisseria gonorrhoeae . Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae, Escherichia coli or Streptococcus agalactiae . NOTE: Ceftizoxime, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti­chlamydial coverage should be added. Intra‐Abdominal Infections caused by Escherichia coli; Staphylococcus epidermidis; Streptococcus spp. (excluding enterococci); Enterobacter spp.; Klebsiella spp.; Bacteroides spp. including B. fragilis ; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Septicemia caused by Streptococcus spp. including S. pneumoniae (but excluding enterococci); Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Escherichia coli; Bacteroides spp. including B. fragilis ; Klebsiella spp.; and Serratia spp. Skin and Skin Structure Infections caused by Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Staphylococcus epidermidis ; Escherichia coli; Klebsiella spp.; Streptococcus spp. including Streptococcus pyogenes (but excluding enterococci); Proteus mirabilis ; Serratia spp.; Enterobacter spp.; Bacteroides spp. including B. fragilis ; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Bone and Joint Infections caused by Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Streptococcus spp. (excluding enterococci); Proteus mirabilis ; Bacteroides spp.; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Meningitis caused by Haemophilus influenzae . Cefizox has also been used successfully in the treatment of a limited number of pediatric and adult cases of meningitis caused by Streptococcus pneumoniae . Cefizox has been effective in the treatment of seriously ill, compromised patients, including those who were debilitated, immunosuppressed, or neutropenic. Infections caused by aerobic gram‐negative and by mixtures of organisms resistant to other cephalosporins, aminoglycosides, or penicillins have responded to treatment with Cefizox. Because of the serious nature of some urinary tract infections due to P. aeruginosa and because many strains of Pseudomonas species are only moderately susceptible to Cefizox, higher dosage is recommended. Other therapy should be instituted if the response is not prompt. Susceptibility studies on specimens obtained prior to therapy should be used to determine the response of causative organisms to Cefizox. Therapy with Cefizox may be initiated pending results of the studies; however, treatment should be adjusted according to study findings. In serious infections, Cefizox has been used concomitantly with aminoglycosides (see PRECAUTIONS ). Before using Cefizox concomitantly with other antibiotics, the prescribing information for those agents should be reviewed for contraindications, warnings, precautions, and adverse reactions. Renal function should be carefully monitored. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefizox and other antibacterial drugs, Cefizox should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:e6de2b26-5a59-419f-baa7-4d8a829943b9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:553473 biolink:treats UMLS:C1112209 PMID:41385096 "[{""id"":""uuid:1cf94239-5ee6-4616-ae50-bea184af6fcb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9a298843-1806-439b-be2c-c27f7a2c5755"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefizox (ceftizoxime for injection, USP) is indicated in the treatment of infections due to susceptible strains of the microorganisms listed below. Lower Respiratory Tract Infections caused by Klebsiella spp.; Proteus mirabilis ; Escherichia coli; Haemophilus influenzae including ampicillin‐resistant strains; Staphylococcus aureus (penicillinase­ and nonpenicillinase‐producing); Serratia spp.; Enterobacter spp.; Bacteroides spp.; and Streptococcus spp. including S. pneumoniae , but excluding enterococci. Urinary Tract Infections caused by Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Escherichia coli ; Pseudomonas spp. including P. aeruginosa ; Proteus mirabilis ; P. vulgaris ; Providencia rettgeri (formerly Proteus rettgeri ) and Morganella morganii (formerly Proteus morganii ); Klebsiella spp.; Serratia spp. including S. marcescens ; and Enterobacter spp. Gonorrhea including uncomplicated cervical and urethral gonorrhea caused by Neisseria gonorrhoeae . Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae, Escherichia coli or Streptococcus agalactiae . NOTE: Ceftizoxime, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti­chlamydial coverage should be added. Intra‐Abdominal Infections caused by Escherichia coli; Staphylococcus epidermidis; Streptococcus spp. (excluding enterococci); Enterobacter spp.; Klebsiella spp.; Bacteroides spp. including B. fragilis ; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Septicemia caused by Streptococcus spp. including S. pneumoniae (but excluding enterococci); Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Escherichia coli; Bacteroides spp. including B. fragilis ; Klebsiella spp.; and Serratia spp. Skin and Skin Structure Infections caused by Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Staphylococcus epidermidis ; Escherichia coli; Klebsiella spp.; Streptococcus spp. including Streptococcus pyogenes (but excluding enterococci); Proteus mirabilis ; Serratia spp.; Enterobacter spp.; Bacteroides spp. including B. fragilis ; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Bone and Joint Infections caused by Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Streptococcus spp. (excluding enterococci); Proteus mirabilis ; Bacteroides spp.; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Meningitis caused by Haemophilus influenzae . Cefizox has also been used successfully in the treatment of a limited number of pediatric and adult cases of meningitis caused by Streptococcus pneumoniae . Cefizox has been effective in the treatment of seriously ill, compromised patients, including those who were debilitated, immunosuppressed, or neutropenic. Infections caused by aerobic gram‐negative and by mixtures of organisms resistant to other cephalosporins, aminoglycosides, or penicillins have responded to treatment with Cefizox. Because of the serious nature of some urinary tract infections due to P. aeruginosa and because many strains of Pseudomonas species are only moderately susceptible to Cefizox, higher dosage is recommended. Other therapy should be instituted if the response is not prompt. Susceptibility studies on specimens obtained prior to therapy should be used to determine the response of causative organisms to Cefizox. Therapy with Cefizox may be initiated pending results of the studies; however, treatment should be adjusted according to study findings. In serious infections, Cefizox has been used concomitantly with aminoglycosides (see PRECAUTIONS ). Before using Cefizox concomitantly with other antibiotics, the prescribing information for those agents should be reviewed for contraindications, warnings, precautions, and adverse reactions. Renal function should be carefully monitored. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefizox and other antibacterial drugs, Cefizox should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:5b541465-fd9e-449b-8e02-0b120a210ec1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:553473 biolink:treats MONDO:0700217 PMID:41385096 "[{""id"":""uuid:24791315-1ae3-47d2-b925-297d39fee2a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1d4f7477-476b-4215-bd56-51e767f6c35a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefizox (ceftizoxime for injection, USP) is indicated in the treatment of infections due to susceptible strains of the microorganisms listed below. Lower Respiratory Tract Infections caused by Klebsiella spp.; Proteus mirabilis ; Escherichia coli; Haemophilus influenzae including ampicillin‐resistant strains; Staphylococcus aureus (penicillinase­ and nonpenicillinase‐producing); Serratia spp.; Enterobacter spp.; Bacteroides spp.; and Streptococcus spp. including S. pneumoniae , but excluding enterococci. Urinary Tract Infections caused by Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Escherichia coli ; Pseudomonas spp. including P. aeruginosa ; Proteus mirabilis ; P. vulgaris ; Providencia rettgeri (formerly Proteus rettgeri ) and Morganella morganii (formerly Proteus morganii ); Klebsiella spp.; Serratia spp. including S. marcescens ; and Enterobacter spp. Gonorrhea including uncomplicated cervical and urethral gonorrhea caused by Neisseria gonorrhoeae . Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae, Escherichia coli or Streptococcus agalactiae . NOTE: Ceftizoxime, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti­chlamydial coverage should be added. Intra‐Abdominal Infections caused by Escherichia coli; Staphylococcus epidermidis; Streptococcus spp. (excluding enterococci); Enterobacter spp.; Klebsiella spp.; Bacteroides spp. including B. fragilis ; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Septicemia caused by Streptococcus spp. including S. pneumoniae (but excluding enterococci); Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Escherichia coli; Bacteroides spp. including B. fragilis ; Klebsiella spp.; and Serratia spp. Skin and Skin Structure Infections caused by Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Staphylococcus epidermidis ; Escherichia coli; Klebsiella spp.; Streptococcus spp. including Streptococcus pyogenes (but excluding enterococci); Proteus mirabilis ; Serratia spp.; Enterobacter spp.; Bacteroides spp. including B. fragilis ; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Bone and Joint Infections caused by Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Streptococcus spp. (excluding enterococci); Proteus mirabilis ; Bacteroides spp.; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Meningitis caused by Haemophilus influenzae . Cefizox has also been used successfully in the treatment of a limited number of pediatric and adult cases of meningitis caused by Streptococcus pneumoniae . Cefizox has been effective in the treatment of seriously ill, compromised patients, including those who were debilitated, immunosuppressed, or neutropenic. Infections caused by aerobic gram‐negative and by mixtures of organisms resistant to other cephalosporins, aminoglycosides, or penicillins have responded to treatment with Cefizox. Because of the serious nature of some urinary tract infections due to P. aeruginosa and because many strains of Pseudomonas species are only moderately susceptible to Cefizox, higher dosage is recommended. Other therapy should be instituted if the response is not prompt. Susceptibility studies on specimens obtained prior to therapy should be used to determine the response of causative organisms to Cefizox. Therapy with Cefizox may be initiated pending results of the studies; however, treatment should be adjusted according to study findings. In serious infections, Cefizox has been used concomitantly with aminoglycosides (see PRECAUTIONS ). Before using Cefizox concomitantly with other antibiotics, the prescribing information for those agents should be reviewed for contraindications, warnings, precautions, and adverse reactions. Renal function should be carefully monitored. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefizox and other antibacterial drugs, Cefizox should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:74543081-3df0-4711-8980-c78e7b84767f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:553473 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:e181d58d-4e11-4192-b487-d6601e3e727b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:77383f2b-efd7-4d8b-993a-cdbf07cd076a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefizox (ceftizoxime for injection, USP) is indicated in the treatment of infections due to susceptible strains of the microorganisms listed below. Lower Respiratory Tract Infections caused by Klebsiella spp.; Proteus mirabilis ; Escherichia coli; Haemophilus influenzae including ampicillin‐resistant strains; Staphylococcus aureus (penicillinase­ and nonpenicillinase‐producing); Serratia spp.; Enterobacter spp.; Bacteroides spp.; and Streptococcus spp. including S. pneumoniae , but excluding enterococci. Urinary Tract Infections caused by Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Escherichia coli ; Pseudomonas spp. including P. aeruginosa ; Proteus mirabilis ; P. vulgaris ; Providencia rettgeri (formerly Proteus rettgeri ) and Morganella morganii (formerly Proteus morganii ); Klebsiella spp.; Serratia spp. including S. marcescens ; and Enterobacter spp. Gonorrhea including uncomplicated cervical and urethral gonorrhea caused by Neisseria gonorrhoeae . Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae, Escherichia coli or Streptococcus agalactiae . NOTE: Ceftizoxime, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti­chlamydial coverage should be added. Intra‐Abdominal Infections caused by Escherichia coli; Staphylococcus epidermidis; Streptococcus spp. (excluding enterococci); Enterobacter spp.; Klebsiella spp.; Bacteroides spp. including B. fragilis ; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Septicemia caused by Streptococcus spp. including S. pneumoniae (but excluding enterococci); Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Escherichia coli; Bacteroides spp. including B. fragilis ; Klebsiella spp.; and Serratia spp. Skin and Skin Structure Infections caused by Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Staphylococcus epidermidis ; Escherichia coli; Klebsiella spp.; Streptococcus spp. including Streptococcus pyogenes (but excluding enterococci); Proteus mirabilis ; Serratia spp.; Enterobacter spp.; Bacteroides spp. including B. fragilis ; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Bone and Joint Infections caused by Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Streptococcus spp. (excluding enterococci); Proteus mirabilis ; Bacteroides spp.; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Meningitis caused by Haemophilus influenzae . Cefizox has also been used successfully in the treatment of a limited number of pediatric and adult cases of meningitis caused by Streptococcus pneumoniae . Cefizox has been effective in the treatment of seriously ill, compromised patients, including those who were debilitated, immunosuppressed, or neutropenic. Infections caused by aerobic gram‐negative and by mixtures of organisms resistant to other cephalosporins, aminoglycosides, or penicillins have responded to treatment with Cefizox. Because of the serious nature of some urinary tract infections due to P. aeruginosa and because many strains of Pseudomonas species are only moderately susceptible to Cefizox, higher dosage is recommended. Other therapy should be instituted if the response is not prompt. Susceptibility studies on specimens obtained prior to therapy should be used to determine the response of causative organisms to Cefizox. Therapy with Cefizox may be initiated pending results of the studies; however, treatment should be adjusted according to study findings. In serious infections, Cefizox has been used concomitantly with aminoglycosides (see PRECAUTIONS ). Before using Cefizox concomitantly with other antibiotics, the prescribing information for those agents should be reviewed for contraindications, warnings, precautions, and adverse reactions. Renal function should be carefully monitored. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefizox and other antibacterial drugs, Cefizox should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:63214061-6d49-444b-a0f5-43682711742a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:553473 biolink:treats UMLS:C0851989 PMID:41385096 "[{""id"":""uuid:a09c2c87-e5da-4168-bd53-7cc8fca70386"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b5c799ed-27d0-4552-b264-e820d892cee0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefizox (ceftizoxime for injection, USP) is indicated in the treatment of infections due to susceptible strains of the microorganisms listed below. Lower Respiratory Tract Infections caused by Klebsiella spp.; Proteus mirabilis ; Escherichia coli; Haemophilus influenzae including ampicillin‐resistant strains; Staphylococcus aureus (penicillinase­ and nonpenicillinase‐producing); Serratia spp.; Enterobacter spp.; Bacteroides spp.; and Streptococcus spp. including S. pneumoniae , but excluding enterococci. Urinary Tract Infections caused by Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Escherichia coli ; Pseudomonas spp. including P. aeruginosa ; Proteus mirabilis ; P. vulgaris ; Providencia rettgeri (formerly Proteus rettgeri ) and Morganella morganii (formerly Proteus morganii ); Klebsiella spp.; Serratia spp. including S. marcescens ; and Enterobacter spp. Gonorrhea including uncomplicated cervical and urethral gonorrhea caused by Neisseria gonorrhoeae . Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae, Escherichia coli or Streptococcus agalactiae . NOTE: Ceftizoxime, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti­chlamydial coverage should be added. Intra‐Abdominal Infections caused by Escherichia coli; Staphylococcus epidermidis; Streptococcus spp. (excluding enterococci); Enterobacter spp.; Klebsiella spp.; Bacteroides spp. including B. fragilis ; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Septicemia caused by Streptococcus spp. including S. pneumoniae (but excluding enterococci); Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Escherichia coli; Bacteroides spp. including B. fragilis ; Klebsiella spp.; and Serratia spp. Skin and Skin Structure Infections caused by Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Staphylococcus epidermidis ; Escherichia coli; Klebsiella spp.; Streptococcus spp. including Streptococcus pyogenes (but excluding enterococci); Proteus mirabilis ; Serratia spp.; Enterobacter spp.; Bacteroides spp. including B. fragilis ; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Bone and Joint Infections caused by Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Streptococcus spp. (excluding enterococci); Proteus mirabilis ; Bacteroides spp.; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Meningitis caused by Haemophilus influenzae . Cefizox has also been used successfully in the treatment of a limited number of pediatric and adult cases of meningitis caused by Streptococcus pneumoniae . Cefizox has been effective in the treatment of seriously ill, compromised patients, including those who were debilitated, immunosuppressed, or neutropenic. Infections caused by aerobic gram‐negative and by mixtures of organisms resistant to other cephalosporins, aminoglycosides, or penicillins have responded to treatment with Cefizox. Because of the serious nature of some urinary tract infections due to P. aeruginosa and because many strains of Pseudomonas species are only moderately susceptible to Cefizox, higher dosage is recommended. Other therapy should be instituted if the response is not prompt. Susceptibility studies on specimens obtained prior to therapy should be used to determine the response of causative organisms to Cefizox. Therapy with Cefizox may be initiated pending results of the studies; however, treatment should be adjusted according to study findings. In serious infections, Cefizox has been used concomitantly with aminoglycosides (see PRECAUTIONS ). Before using Cefizox concomitantly with other antibiotics, the prescribing information for those agents should be reviewed for contraindications, warnings, precautions, and adverse reactions. Renal function should be carefully monitored. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefizox and other antibacterial drugs, Cefizox should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:21960150-ea06-4f28-b358-135a317c7677 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:553473 biolink:treats MONDO:0021108 PMID:41385096 "[{""id"":""uuid:cfa8f6d9-dcd6-40a3-9f05-08f3c7c83f73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ffa02cc9-4290-44b6-bf52-5a927695b82c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefizox (ceftizoxime for injection, USP) is indicated in the treatment of infections due to susceptible strains of the microorganisms listed below. Lower Respiratory Tract Infections caused by Klebsiella spp.; Proteus mirabilis ; Escherichia coli; Haemophilus influenzae including ampicillin‐resistant strains; Staphylococcus aureus (penicillinase­ and nonpenicillinase‐producing); Serratia spp.; Enterobacter spp.; Bacteroides spp.; and Streptococcus spp. including S. pneumoniae , but excluding enterococci. Urinary Tract Infections caused by Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Escherichia coli ; Pseudomonas spp. including P. aeruginosa ; Proteus mirabilis ; P. vulgaris ; Providencia rettgeri (formerly Proteus rettgeri ) and Morganella morganii (formerly Proteus morganii ); Klebsiella spp.; Serratia spp. including S. marcescens ; and Enterobacter spp. Gonorrhea including uncomplicated cervical and urethral gonorrhea caused by Neisseria gonorrhoeae . Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae, Escherichia coli or Streptococcus agalactiae . NOTE: Ceftizoxime, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti­chlamydial coverage should be added. Intra‐Abdominal Infections caused by Escherichia coli; Staphylococcus epidermidis; Streptococcus spp. (excluding enterococci); Enterobacter spp.; Klebsiella spp.; Bacteroides spp. including B. fragilis ; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Septicemia caused by Streptococcus spp. including S. pneumoniae (but excluding enterococci); Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Escherichia coli; Bacteroides spp. including B. fragilis ; Klebsiella spp.; and Serratia spp. Skin and Skin Structure Infections caused by Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Staphylococcus epidermidis ; Escherichia coli; Klebsiella spp.; Streptococcus spp. including Streptococcus pyogenes (but excluding enterococci); Proteus mirabilis ; Serratia spp.; Enterobacter spp.; Bacteroides spp. including B. fragilis ; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Bone and Joint Infections caused by Staphylococcus aureus (penicillinase‐ and nonpenicillinase‐producing); Streptococcus spp. (excluding enterococci); Proteus mirabilis ; Bacteroides spp.; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Meningitis caused by Haemophilus influenzae . Cefizox has also been used successfully in the treatment of a limited number of pediatric and adult cases of meningitis caused by Streptococcus pneumoniae . Cefizox has been effective in the treatment of seriously ill, compromised patients, including those who were debilitated, immunosuppressed, or neutropenic. Infections caused by aerobic gram‐negative and by mixtures of organisms resistant to other cephalosporins, aminoglycosides, or penicillins have responded to treatment with Cefizox. Because of the serious nature of some urinary tract infections due to P. aeruginosa and because many strains of Pseudomonas species are only moderately susceptible to Cefizox, higher dosage is recommended. Other therapy should be instituted if the response is not prompt. Susceptibility studies on specimens obtained prior to therapy should be used to determine the response of causative organisms to Cefizox. Therapy with Cefizox may be initiated pending results of the studies; however, treatment should be adjusted according to study findings. In serious infections, Cefizox has been used concomitantly with aminoglycosides (see PRECAUTIONS ). Before using Cefizox concomitantly with other antibiotics, the prescribing information for those agents should be reviewed for contraindications, warnings, precautions, and adverse reactions. Renal function should be carefully monitored. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefizox and other antibacterial drugs, Cefizox should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:d003bfff-38bc-4f33-810c-75fe98b1da27 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:553473 biolink:treats MONDO:0100128 PMID:41385096 "[{""id"":""uuid:1fc9003f-964a-42d5-9573-b47f81104b15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2f36f6d4-876a-46d4-a9c0-b77df7e4ae9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefizox (ceftizoxime injection) is indicated in the treatment of infections due to susceptible strains of the microorganisms listed below. Lower Respiratory Tract Infections caused by Klebsiella spp.; Proteus mirabilis ; Escherichia coli; Haemophilus influenzae including ampicillin­resistant strains; Staphylococcus aureus (penicillinase­ and nonpenicillinase­producing); Serratia spp.; Enterobacter spp.; Bacteroides spp.; and Streptococcus spp. including S. pneumoniae , but excluding enterococci. Urinary Tract Infections caused by Staphylococcus aureus (penicillinase­ and nonpenicillinase­producing); Escherichia coli ; Pseudomonas spp. including P. aeruginosa ; Proteus mirabilis ; P. vulgaris ; Providencia rettgeri (formerly Proteus rettgeri ) and Morganella morganii (formerly Proteus morganii ); Klebsiella spp.; Serratia spp. including S. marcescens ; and Enterobacter spp. Gonorrhea including uncomplicated cervical and urethral gonorrhea caused by Neisseria gonorrhoeae . Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae, Escherichia coli or Streptococcus agalactiae . NOTE: Ceftizoxime, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti­chlamydial coverage should be added. Intra­Abdominal Infections caused by Escherichia coli; Staphylococcus epidermidis; Streptococcus spp. (excluding enterococci); Enterobacter spp.; Klebsiella spp.; Bacteroides spp. including B. fragilis ; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Septicemia caused by Streptococcus spp. including S. pneumoniae (but excluding enterococci); Staphylococcus aureus (penicillinase­ and nonpenicillinase­producing); Escherichia coli; Bacteroides spp. including B. fragilis ; Klebsiella spp.; and Serratia spp. Skin and Skin Structure Infections caused by Staphylococcus aureus (penicillinase­ and nonpenicillinase­producing); Staphylococcus epidermidis ; Escherichia coli; Klebsiella spp.; Streptococcus spp. including Streptococcus pyogenes (but excluding enterococci); Proteus mirabilis ; Serratia spp.; Enterobacter spp.; Bacteroides spp. including B. fragilis ; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Bone and Joint Infections caused by Staphylococcus aureus (penicillinase­ and nonpenicillinase­producing); Streptococcus spp. (excluding enterococci); Proteus mirabilis ; Bacteroides spp.; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Meningitis caused by Haemophilus influenzae . Cefizox has also been used successfully in the treatment of a limited number of pediatric and adult cases of meningitis caused by Streptococcus pneumoniae . Cefizox has been effective in the treatment of seriously ill, compromised patients, including those who were debilitated, immunosuppressed, or neutropenic. Infections caused by aerobic gram­negative and by mixtures of organisms resistant to other cephalosporins, aminoglycosides, or penicillins have responded to treatment with Cefizox. Because of the serious nature of some urinary tract infections due to P. aeruginosa and because many strains of Pseudomonas species are only moderately susceptible to Cefizox, higher dosage is recommended. Other therapy should be instituted if the response is not prompt. Susceptibility studies on specimens obtained prior to therapy should be used to determine the response of causative organisms to Cefizox. Therapy with Cefizox may be initiated pending results of the studies; however, treatment should be adjusted according to study findings. In serious infections, Cefizox has been used concomitantly with aminoglycosides (see PRECAUTIONS ). Before using Cefizox concomitantly with other antibiotics, the prescribing information for those agents should be reviewed for contraindications, warnings, precautions, and adverse reactions. Renal function should be carefully monitored. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefizox and other antibacterial drugs, Cefizox should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:21df64a0-d868-41f5-b3cf-8e4112582537 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:553473 biolink:treats MONDO:0005113 PMID:41385096 "[{""id"":""uuid:4a1aa4f0-f432-4114-8690-b10804fa2675"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:25832b5c-e685-4696-a726-a7260324d09b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefizox (ceftizoxime injection) is indicated in the treatment of infections due to susceptible strains of the microorganisms listed below. Lower Respiratory Tract Infections caused by Klebsiella spp.; Proteus mirabilis ; Escherichia coli; Haemophilus influenzae including ampicillin­resistant strains; Staphylococcus aureus (penicillinase­ and nonpenicillinase­producing); Serratia spp.; Enterobacter spp.; Bacteroides spp.; and Streptococcus spp. including S. pneumoniae , but excluding enterococci. Urinary Tract Infections caused by Staphylococcus aureus (penicillinase­ and nonpenicillinase­producing); Escherichia coli ; Pseudomonas spp. including P. aeruginosa ; Proteus mirabilis ; P. vulgaris ; Providencia rettgeri (formerly Proteus rettgeri ) and Morganella morganii (formerly Proteus morganii ); Klebsiella spp.; Serratia spp. including S. marcescens ; and Enterobacter spp. Gonorrhea including uncomplicated cervical and urethral gonorrhea caused by Neisseria gonorrhoeae . Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae, Escherichia coli or Streptococcus agalactiae . NOTE: Ceftizoxime, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti­chlamydial coverage should be added. Intra­Abdominal Infections caused by Escherichia coli; Staphylococcus epidermidis; Streptococcus spp. (excluding enterococci); Enterobacter spp.; Klebsiella spp.; Bacteroides spp. including B. fragilis ; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Septicemia caused by Streptococcus spp. including S. pneumoniae (but excluding enterococci); Staphylococcus aureus (penicillinase­ and nonpenicillinase­producing); Escherichia coli; Bacteroides spp. including B. fragilis ; Klebsiella spp.; and Serratia spp. Skin and Skin Structure Infections caused by Staphylococcus aureus (penicillinase­ and nonpenicillinase­producing); Staphylococcus epidermidis ; Escherichia coli; Klebsiella spp.; Streptococcus spp. including Streptococcus pyogenes (but excluding enterococci); Proteus mirabilis ; Serratia spp.; Enterobacter spp.; Bacteroides spp. including B. fragilis ; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Bone and Joint Infections caused by Staphylococcus aureus (penicillinase­ and nonpenicillinase­producing); Streptococcus spp. (excluding enterococci); Proteus mirabilis ; Bacteroides spp.; and anaerobic cocci, including Peptococcus spp. and Peptostreptococcus spp. Meningitis caused by Haemophilus influenzae . Cefizox has also been used successfully in the treatment of a limited number of pediatric and adult cases of meningitis caused by Streptococcus pneumoniae . Cefizox has been effective in the treatment of seriously ill, compromised patients, including those who were debilitated, immunosuppressed, or neutropenic. Infections caused by aerobic gram­negative and by mixtures of organisms resistant to other cephalosporins, aminoglycosides, or penicillins have responded to treatment with Cefizox. Because of the serious nature of some urinary tract infections due to P. aeruginosa and because many strains of Pseudomonas species are only moderately susceptible to Cefizox, higher dosage is recommended. Other therapy should be instituted if the response is not prompt. Susceptibility studies on specimens obtained prior to therapy should be used to determine the response of causative organisms to Cefizox. Therapy with Cefizox may be initiated pending results of the studies; however, treatment should be adjusted according to study findings. In serious infections, Cefizox has been used concomitantly with aminoglycosides (see PRECAUTIONS ). Before using Cefizox concomitantly with other antibiotics, the prescribing information for those agents should be reviewed for contraindications, warnings, precautions, and adverse reactions. Renal function should be carefully monitored. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefizox and other antibacterial drugs, Cefizox should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:e8d2b548-ec88-4ac6-9de4-679bb16120ce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17303 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:fac1b7ce-0a42-46f7-a861-96254a4700bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5afbe414-5fbf-4840-9f8d-e0f589694b1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0c5bded2-a002-4762-98a6-324a8a28b8e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Morphine sulfate extended-release tablets are a controlled release oral morphine formulation indicated for the relief of moderate to severe pain. They are intended for use in patients who require repeated dosing with potent opioid analgesics over periods of more than a few days.|[PMDA] Drugs with a new formulation, a sustained-release preparation containing morphine hydrochloride given once a day uuid:dea8634f-2a33-4e89-8491-14c772385275 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6801 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:818b3afa-0d93-4f57-89ab-d724c480b399"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5c30732b-0637-4372-8926-d08a621746b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3adbd984-9ab8-4648-8e89-3b0c04832fcb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metformin hydrochloride tablets, as monotherapy, are indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. Metformin is indicated in patients 10 years of age and older. Metformin may be used concomitantly with a sulfonylurea or insulin to improve glycemic control in adults (17 years of age and older).|[PMDA] A drug with a new dosage exceeding the maximum dosage (750 mg/day) of the conventional formulation indicated for the treatment of type 2 diabetes mellitus (for use only in patients who have not responded sufficiently to either [1] diet and exercise therapies alone or [2] sulfonylurea along with diet and exercise therapies). uuid:88d65ad8-af03-4770-8d6a-5ed19a6897f5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6129 biolink:treats NCIT:C27003 PMID:41385096 "[{""id"":""uuid:31d3bf0a-3de5-4c25-88ab-9057ffde8149"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:76294875-8964-48a3-ac8a-0941d1798e36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ketorolac tromethamine is indicated for the short-term (≤5 days) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting. Therapy should always be initiated with Ketorolac Tromethamine Injection and ketorolac tromethamine tablets are to be used only as continuation treatment, if necessary. Combined use of Ketorolac Tromethamine Injection and ketorolac tromethamine tablets is not to exceed 5 days of use because of the potential of increasing the frequency and severity of adverse reactions associated with the recommended doses (see WARNINGS , PRECAUTIONS , DOSAGE AND ADMINISTRATION and ADVERSE REACTIONS ). Patients should be switched to alternative analgesics as soon as possible, but ketorolac tromethamine therapy is not to exceed 5 days. Ketorolac Tromethamine Injection has been used concomitantly with morphine and meperidine and has shown an opioid-sparing effect. For breakthrough pain, it is recommended to supplement the lower end of the Ketorolac Tromethamine Injection dosage range with low doses of narcotics prn, unless otherwise contraindicated. Ketorolac Tromethamine Injection and narcotics should not be administered in the same syringe (see DOSAGE AND ADMINISTRATION - Pharmaceutical Information for Ketorolac Tromethamine Injection ). uuid:b7033d07-8dde-4398-b8dd-ee5d1952f17a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5784 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:6e16175c-08a8-4f85-b4df-ee83595ffd87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6c890e44-62ad-4c87-8666-8179f4b0b5f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Saluron® is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis and corticosteroid and estrogen therapy. Saluron® has also been found useful in edema due to various forms of renal dysfunction, such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Saluron® is indicated in the management of hypertension, either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. uuid:785d42a9-5059-41d5-8fba-b6b88fe91895 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5784 biolink:treats MONDO:0005155 PMID:41385096 "[{""id"":""uuid:60cd4025-4cdb-4040-ab1e-f49d684c2edf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:886292cb-6586-45c1-bc5b-4666a52feb95"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Saluron® is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis and corticosteroid and estrogen therapy. Saluron® has also been found useful in edema due to various forms of renal dysfunction, such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Saluron® is indicated in the management of hypertension, either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. uuid:aee0bad9-6e00-43d3-871a-29babe5b1ad1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5784 biolink:treats MONDO:0005377 PMID:41385096 "[{""id"":""uuid:9ae6ef85-d4fd-4df1-bfb6-012e08c9fdf5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:35a16616-cfdd-4dc5-8836-3187fe174881"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Saluron® is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis and corticosteroid and estrogen therapy. Saluron® has also been found useful in edema due to various forms of renal dysfunction, such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Saluron® is indicated in the management of hypertension, either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. uuid:63ba80a3-23a2-435b-bcad-9d0c7763fbd5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5784 biolink:treats UMLS:C0156221 PMID:41385096 "[{""id"":""uuid:a80f0274-1b07-479a-9ff2-39802ae9510f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:91a0af8e-bdd8-4212-b88a-609bfe43905a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Saluron® is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis and corticosteroid and estrogen therapy. Saluron® has also been found useful in edema due to various forms of renal dysfunction, such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Saluron® is indicated in the management of hypertension, either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. uuid:9e75ec47-80ed-4c38-88bf-96daa95bf207 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5784 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:c014121c-53e5-49e4-994d-cf5c25dba174"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f5eb51c4-8233-4bf9-9ea8-918feea50549"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Saluron® is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis and corticosteroid and estrogen therapy. Saluron® has also been found useful in edema due to various forms of renal dysfunction, such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Saluron® is indicated in the management of hypertension, either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. uuid:1ac2da45-431a-4a41-b969-564591025d37 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5784 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:1dd006ab-7361-4398-a713-00ce5611af7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:249be8fe-9518-4f25-9460-cf952ed4e735"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Saluron® is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis and corticosteroid and estrogen therapy. Saluron® has also been found useful in edema due to various forms of renal dysfunction, such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Saluron® is indicated in the management of hypertension, either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. uuid:045c804d-dafd-4c09-9b44-72c36b2632e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7470 biolink:treats MONDO:0005552 PMID:41385096 "[{""id"":""uuid:726d8cbe-3343-4e09-8d84-2251531b29b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4fc8a293-03fa-4d06-9739-0076cc48e6a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VA SO CON REGULAR is indicated for use as a topical ocular vasoconstrictor. uuid:270a97b7-d845-4a94-8a7c-4f131f82f90d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9327 biolink:treats MONDO:0003799 PMID:41385096 "[{""id"":""uuid:f184a9ca-932c-4624-a65a-6bd2ae1f6f25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0344a0ac-c90f-4dc2-a9a8-ed3713477131"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of conjunctivitis and other superficial ocular infections due to susceptible microorganisms and as an adjunctive in systemic sulfonamide therapy of trachoma: Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus (viridans group), Haemophilus influenzae, Klebsiella species , and Enterobacter species. Topically applied sulfonamides do not provide adequate coverage against Neisseria species, Serratia marcescens and Pseudomonas aeruginosa. A significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. uuid:f501c728-9bb6-47b9-aba4-4bd517799144 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9327 biolink:treats MONDO:0001249 PMID:41385096 "[{""id"":""uuid:dd5150af-b230-4837-ba53-f9b1f53e166d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c567ea26-f770-4150-ab3b-65fbc1dd5dc0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of conjunctivitis and other superficial ocular infections due to susceptible microorganisms and as an adjunctive in systemic sulfonamide therapy of trachoma: Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus (viridans group), Haemophilus influenzae, Klebsiella species , and Enterobacter species. Topically applied sulfonamides do not provide adequate coverage against Neisseria species, Serratia marcescens and Pseudomonas aeruginosa. A significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. uuid:e55c63fa-2513-4201-b08f-6022962dab7a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4653 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:80c26485-48dd-43e4-83c8-6db1e1f307e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dafdba43-f58b-481d-bc62-885f016eff5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dipyridamole injection is indicated as an alternative to exercise in thallium myocardial perfusion imaging for the evaluation of coronary artery disease in patients who cannot exercise adequately. In a study of about 1100 patients who underwent coronary arteriography and dipyridamole injection assisted thallium imaging, the results of both tests were interpreted blindly and the sensitivity and specificity of the dipyridamole thallium study in predicting the angiographic outcome were calculated. The sensitivity of the dipyridamole test (true positive dipyridamole divided by the total number of patients with positive angiography) was about 85%. The specificity (true negative divided by the number of patients with negative angiograms) was about 50%. In a subset of patients who had exercise thallium imaging as well as dipyridamole thallium imaging, sensitivity and specificity of the two tests was almost identical. uuid:d36557b7-355a-4f02-9aba-44ce2d61274d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9737 biolink:treats MONDO:0019121 PMID:41385096 "[{""id"":""uuid:4e165df3-a2d8-44c0-9aba-19937a8bcea0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aafce2fa-3fbf-4c65-bf32-3e869f45d5bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Neutrexin (trimetrexate glucuronate for injection) with concurrent leucovorin administration (leucovorin protection) is indicated as an alternative therapy for the treatment of moderate-to-severe Pneumocystis carinii pneumonia (PCP) in immunocompromised patients, including patients with the acquired immunodeficiency syndrome (AIDS), who are intolerant of, or are refractory to, trimethoprim-sulfamethoxazole therapy or for whom trimethoprim-sulfamethoxazole is contraindicated. uuid:cca1a3c8-a302-4f92-9136-34d0de8ea3c6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9737 biolink:treats MONDO:0012268 PMID:41385096 "[{""id"":""uuid:2efd6754-8142-4636-b6a7-2bb04613d0a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:99f29e6a-ff9a-4350-ab30-b1c16de216b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Neutrexin (trimetrexate glucuronate for injection) with concurrent leucovorin administration (leucovorin protection) is indicated as an alternative therapy for the treatment of moderate-to-severe Pneumocystis carinii pneumonia (PCP) in immunocompromised patients, including patients with the acquired immunodeficiency syndrome (AIDS), who are intolerant of, or are refractory to, trimethoprim-sulfamethoxazole therapy or for whom trimethoprim-sulfamethoxazole is contraindicated. uuid:85dbd968-be73-447b-8cbb-eeec273ae929 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5818 biolink:treats MONDO:0011918 PMID:41385096 "[{""id"":""uuid:bbd33277-cb7d-4d62-b353-48ba0ca65daa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7dd172a8-4548-465e-b646-fdaedbaacc3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested. Useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses, and in histamine-mediated pruritus. As a sedative when used as premedication and following general anesthesia, Hydroxyzine may potentiate meperidine (Demerol®) and barbiturates , so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis. Atropine and other belladonna alkaloids are not affected by the drug. Hydroxyzine is not known to interfere with the action of digitalis in any way and it may be used concurrently with this agent. The effectiveness of hydroxyzine as an antianxiety agent for long term use, that is more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient. uuid:fca9fa2a-c13e-440d-89f6-052fa1073b2f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5818 biolink:treats UMLS:C0233494 PMID:41385096 "[{""id"":""uuid:d013b4ca-4faf-400a-a7fb-fcb55187d045"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:99672d58-5ad3-4434-842e-e5fa931c8313"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested. Useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses, and in histamine-mediated pruritus. As a sedative when used as premedication and following general anesthesia, Hydroxyzine may potentiate meperidine (Demerol®) and barbiturates , so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis. Atropine and other belladonna alkaloids are not affected by the drug. Hydroxyzine is not known to interfere with the action of digitalis in any way and it may be used concurrently with this agent. The effectiveness of hydroxyzine as an antianxiety agent for long term use, that is more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient. uuid:acf0e6c1-8ac6-4146-b582-b3b14d932c7b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5818 biolink:treats HP:0000989 PMID:41385096 "[{""id"":""uuid:5424f083-a1bd-4830-bb6f-b2f56514e076"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ad67e958-5b84-41b0-b35e-08be4e34357a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested. Useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses, and in histamine-mediated pruritus. As a sedative when used as premedication and following general anesthesia, Hydroxyzine may potentiate meperidine (Demerol®) and barbiturates , so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis. Atropine and other belladonna alkaloids are not affected by the drug. Hydroxyzine is not known to interfere with the action of digitalis in any way and it may be used concurrently with this agent. The effectiveness of hydroxyzine as an antianxiety agent for long term use, that is more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient. uuid:ab170f0b-5b51-4d4f-9e0a-c74495314cba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5818 biolink:treats MONDO:0850230 PMID:41385096 "[{""id"":""uuid:8b647013-6dd6-458f-9be0-926f4461a14a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:519b5cc3-85a8-4cff-8c90-c3e2953360aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested. Useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses, and in histamine-mediated pruritus. As a sedative when used as premedication and following general anesthesia, Hydroxyzine may potentiate meperidine (Demerol®) and barbiturates , so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis. Atropine and other belladonna alkaloids are not affected by the drug. Hydroxyzine is not known to interfere with the action of digitalis in any way and it may be used concurrently with this agent. The effectiveness of hydroxyzine as an antianxiety agent for long term use, that is more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient. uuid:2088053f-447a-4f9c-922f-63578a538cb5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5818 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:d4aade4d-4366-40ac-9b82-b249ad74fa82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f33ae8a8-dcf7-4f16-b5a6-61cb458ca260"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested. Useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses, and in histamine-mediated pruritus. As a sedative when used as premedication and following general anesthesia, Hydroxyzine may potentiate meperidine (Demerol®) and barbiturates , so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis. Atropine and other belladonna alkaloids are not affected by the drug. Hydroxyzine is not known to interfere with the action of digitalis in any way and it may be used concurrently with this agent. The effectiveness of hydroxyzine as an antianxiety agent for long term use, that is more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient. uuid:854eb30f-5dda-47bd-9eaa-ebc1911c99e4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5818 biolink:treats MONDO:0005480 PMID:41385096 "[{""id"":""uuid:26a2d1c7-e5f0-4cac-b40e-5ce469e5dcf7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:97facff4-e939-4ee5-b9a7-d6db6bd9b429"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested. Useful in the management of pruritus due to allergic conditions such as chronic urticaria and atopic and contact dermatoses, and in histamine-mediated pruritus. As a sedative when used as premedication and following general anesthesia, Hydroxyzine may potentiate meperidine (Demerol®) and barbiturates , so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis. Atropine and other belladonna alkaloids are not affected by the drug. Hydroxyzine is not known to interfere with the action of digitalis in any way and it may be used concurrently with this agent. The effectiveness of hydroxyzine as an antianxiety agent for long term use, that is more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient. uuid:cb042a18-a057-410e-af36-e091e847daea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:187893 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:ee208182-61c4-4d3d-aa07-20af574f2990"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:49199835-3711-4343-a6a1-9c8f6a228c2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEMSTRO™ is useful for the alleviation of signs and symptoms of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. Patients should have reversible spasticity so that treatment with KEMSTRO™ will aid in restoring residual function. KEMSTRO™ may also be of some value in patients with spinal cord injuries and other spinal cord diseases. KEMSTRO™ is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. The efficacy of KEMSTRO™ in stroke, cerebral palsy, and Parkinson's disease has not been established and, therefore, it is not recommended for these conditions. uuid:014323e9-c0e5-4315-b972-12116f8d15e2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:187893 biolink:treats MONDO:0043797 PMID:41385096 "[{""id"":""uuid:ffe34f03-ec17-4470-b6a5-802363399f00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:06eba312-2e3c-4fe5-8f67-6e1bb0ad10ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEMSTRO™ is useful for the alleviation of signs and symptoms of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. Patients should have reversible spasticity so that treatment with KEMSTRO™ will aid in restoring residual function. KEMSTRO™ may also be of some value in patients with spinal cord injuries and other spinal cord diseases. KEMSTRO™ is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. The efficacy of KEMSTRO™ in stroke, cerebral palsy, and Parkinson's disease has not been established and, therefore, it is not recommended for these conditions. uuid:84c0f113-d1ea-498f-84bf-11e5ec505c0c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:187893 biolink:treats MONDO:0002545 PMID:41385096 "[{""id"":""uuid:aadb9d61-2ee6-406f-af26-89cc0eaad6e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:49716495-e7be-42d9-8dfa-ccc6424ccadb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEMSTRO™ is useful for the alleviation of signs and symptoms of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. Patients should have reversible spasticity so that treatment with KEMSTRO™ will aid in restoring residual function. KEMSTRO™ may also be of some value in patients with spinal cord injuries and other spinal cord diseases. KEMSTRO™ is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. The efficacy of KEMSTRO™ in stroke, cerebral palsy, and Parkinson's disease has not been established and, therefore, it is not recommended for these conditions. uuid:ad83103d-59de-4ec2-9493-a6f5bd865a29 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4530 biolink:treats NCIT:C120380 PMID:41385096 "[{""id"":""uuid:d8951171-1c31-41f9-8909-fd66612ad641"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d314d1d3-e42c-4c91-9f80-b1f224f8785a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diethylpropion hydrochloride tablets are indicated in the management of exogenous obesity as a short-term adjunct (a few weeks) in a regiment of weight reduction based on caloric restriction. The usefulness of agents of this class should be measured against possible risk factors inherent in their use such as those described (see CLINICAL PHARMACOLOGY ). uuid:a79f4ff2-792b-405e-8efa-eaf18134e1e1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3437 biolink:treats MONDO:0005338 PMID:41385096 "[{""id"":""uuid:30bea155-2e2d-4420-8bd6-0cdedca578a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7f880a13-374b-4b66-aa67-7e17ca599a19"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ocupress Ophthalmic Solution, 1%, has been shown to be effective in lowering intraocular pressure and may be used in patients with chronic open-angle glaucoma and intraocular hypertension. It may be used alone or in combination with other intraocular pressure lowering medications. uuid:f21baae0-7596-43e6-8fd5-4271e58d4634 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3437 biolink:treats MONDO:0006875 PMID:41385096 "[{""id"":""uuid:fb4ded98-0a26-4a72-8299-58691762d459"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:26069422-bd13-4fa2-a46a-739fbbbc3de4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ocupress Ophthalmic Solution, 1%, has been shown to be effective in lowering intraocular pressure and may be used in patients with chronic open-angle glaucoma and intraocular hypertension. It may be used alone or in combination with other intraocular pressure lowering medications. uuid:de2807b4-a1fb-43ca-9e35-d5376b1a4f15 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6887 biolink:treats MONDO:0007743 PMID:41385096 "[{""id"":""uuid:8f3792a9-1d3e-4824-a4b0-14dd1606a27f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:48f9fd69-ca71-415a-851e-b356974fad02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Attention Deficit Disorders (previously known as Minimal Brain Dysfunction in Children). Other terms being used to describe the behavioral syndrome below include: Hyperkinetic Child Syndrome, Minimal Brain Damage, Minimal Cerebral Dysfunction, Minor Cerebral Dysfunction. Methylphenidate hydrochloride is indicated as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted. uuid:f84c5134-f98a-4669-92c9-eb5b477be593 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6887 biolink:treats MONDO:0043510 PMID:41385096 "[{""id"":""uuid:dff01a5d-01dc-405e-84ed-70aedd82e02b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a6cabc84-1075-4a50-95f9-275196107bef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Attention Deficit Disorders (previously known as Minimal Brain Dysfunction in Children). Other terms being used to describe the behavioral syndrome below include: Hyperkinetic Child Syndrome, Minimal Brain Damage, Minimal Cerebral Dysfunction, Minor Cerebral Dysfunction. Methylphenidate hydrochloride is indicated as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted. uuid:694a34e2-7977-403d-b333-e6abeadadfd2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6887 biolink:treats MONDO:0004681 PMID:41385096 "[{""id"":""uuid:876c4087-97ba-4f16-a5d1-98c138ad951f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fd534cf9-0d75-45e8-a866-04c7248b557e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Attention Deficit Disorders (previously known as Minimal Brain Dysfunction in Children). Other terms being used to describe the behavioral syndrome below include: Hyperkinetic Child Syndrome, Minimal Brain Damage, Minimal Cerebral Dysfunction, Minor Cerebral Dysfunction. Methylphenidate hydrochloride is indicated as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted. uuid:b4dbf44f-c904-4931-94d5-f897bc734bbf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75722 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:147755e9-6783-4e23-819c-9f667b6c6974"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:af1fa91c-a145-4a5f-ae2c-1a7213345fee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tramadol hydrochloride tablets are indicated for the management of moderate to moderately severe pain in adults. uuid:6d8e7e03-1d16-44c0-8fd9-d48ae42c420b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:21659 biolink:treats MONDO:0006668 PMID:41385096 "[{""id"":""uuid:507ce513-9651-4879-ba9f-dfef758d8e10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8f39792b-0d3d-4a02-acef-85b1ecf4140c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Neomycin and polymyxin B sulfates and bacitracin zinc with hydrocortisone acetate ophthalmic ointment is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye (see CLINICAL PHARMACOLOGY: Microbiology ). The particular anti-infective drugs in this product are active against the following common bacterial eye pathogens: Staphylococcus aureus, streptococci, including Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, and Pseudomonas aeruginosa. The product does not provide adequate coverage against Serratia marcescens. uuid:99acb23f-a4d0-4d16-85d7-cbedcd49a137 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:21659 biolink:treats UMLS:C0008690 PMID:41385096 "[{""id"":""uuid:4e6802f8-dbc3-4e3b-b7e6-c4e64732407e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:920fd718-68cd-4cc8-8a5d-82d3d702da56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Neomycin and polymyxin B sulfates and bacitracin zinc with hydrocortisone acetate ophthalmic ointment is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye (see CLINICAL PHARMACOLOGY: Microbiology ). The particular anti-infective drugs in this product are active against the following common bacterial eye pathogens: Staphylococcus aureus, streptococci, including Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, and Pseudomonas aeruginosa. The product does not provide adequate coverage against Serratia marcescens. uuid:0556c383-ca1a-419a-8714-c3bb93c4b127 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:21659 biolink:treats UMLS:C0339289 PMID:41385096 "[{""id"":""uuid:80a4ce92-b6b1-4ef0-a207-60ddf32f39fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:457f1cee-cdbe-40c4-bcbd-876bb4e3c5d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Neomycin and polymyxin B sulfates and bacitracin zinc with hydrocortisone acetate ophthalmic ointment is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye (see CLINICAL PHARMACOLOGY: Microbiology ). The particular anti-infective drugs in this product are active against the following common bacterial eye pathogens: Staphylococcus aureus, streptococci, including Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, and Pseudomonas aeruginosa. The product does not provide adequate coverage against Serratia marcescens. uuid:61c4cd50-e03f-4830-9cae-13d6edb858e1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50648 biolink:treats MONDO:0005055 PMID:41385096 "[{""id"":""uuid:5e46c539-00db-4abc-b318-c968facf8b3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b4637bd7-e614-46dd-a4b4-6d2182646961"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Panretin® gel is indicated for topical treatment of cutaneous lesions in patients with AIDS-related Kaposi’s sarcoma. Panretin® gel is not indicated when systemic anti-KS therapy is required (e.g., more than 10 new KS lesions in the prior month, symptomatic lymphedema, symptomatic pulmonary KS, or symptomatic visceral involvement). There is no experience to date using Panretin® gel with systemic anti-KS treatment. uuid:66fe130b-1f09-4ddc-af06-3eb2a25b450e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50648 biolink:treats MONDO:0019297 PMID:41385096 "[{""id"":""uuid:ce4bc198-516e-4e25-a3d3-ac437b20fde8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2b3b87a5-1704-4353-b8b2-69e8aa268941"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Panretin® gel is indicated for topical treatment of cutaneous lesions in patients with AIDS-related Kaposi’s sarcoma. Panretin® gel is not indicated when systemic anti-KS therapy is required (e.g., more than 10 new KS lesions in the prior month, symptomatic lymphedema, symptomatic pulmonary KS, or symptomatic visceral involvement). There is no experience to date using Panretin® gel with systemic anti-KS treatment. uuid:a190fcfe-7b8d-4c61-b07e-409c2c5125e1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17698 biolink:treats MONDO:0043885 PMID:41385096 "[{""id"":""uuid:29b506e8-8947-47ad-8d52-8b466b78f0a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d4b0a62e-8d51-40d8-bf94-1f9377813c2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chloramphenicol should be used only in those serious infections for which less potentially dangerous drugs are ineffective or contraindicated. Bacteriological studies should be performed to determine the causative organisms and their sensitivity to chloramphenicol (see Boxed Warning ). Chloromycetin Ophthalmic Ointment, 1% (Chloramphenicol Ophthalmic Ointment, USP) is indicated for the treatment of surface ocular infections involving the conjunctiva and/or cornea caused by chloramphenicol-susceptible organisms. The particular antiinfective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus Streptococcus , including Streptococcus pneumoniae Escherichia coli Haemophilus influenzae Klebsiella/Enterobacter species Moraxella lucunata (Morax-Axenfeld bacillus) Neisseria species This product does not provide adequate coverage against: Pseudomonas aeruginosa Serratia marcescens uuid:cc30f829-115e-48b6-bcce-b6eff70f5529 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17698 biolink:treats MONDO:0003799 PMID:41385096 "[{""id"":""uuid:ecc4add6-8bcf-4156-8f9e-61df0c14f704"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d8ed1e7e-fc13-4851-bc23-7b2e4c0fb476"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chloramphenicol should be used only in those serious infections for which less potentially dangerous drugs are ineffective or contraindicated. Bacteriological studies should be performed to determine the causative organisms and their sensitivity to chloramphenicol (see Boxed Warning ). Chloromycetin Ophthalmic Ointment, 1% (Chloramphenicol Ophthalmic Ointment, USP) is indicated for the treatment of surface ocular infections involving the conjunctiva and/or cornea caused by chloramphenicol-susceptible organisms. The particular antiinfective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus Streptococcus , including Streptococcus pneumoniae Escherichia coli Haemophilus influenzae Klebsiella/Enterobacter species Moraxella lucunata (Morax-Axenfeld bacillus) Neisseria species This product does not provide adequate coverage against: Pseudomonas aeruginosa Serratia marcescens uuid:7016823c-9d3a-4ba4-a90e-424e7f05614b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17698 biolink:treats MONDO:0023865 PMID:41385096 "[{""id"":""uuid:36e0f61f-68df-474a-a65c-4d91d26c5b6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e256db14-b121-4d99-85cf-b4daca952687"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chloramphenicol should be used only in those serious infections for which less potentially dangerous drugs are ineffective or contraindicated. Bacteriological studies should be performed to determine the causative organisms and their sensitivity to chloramphenicol (see Boxed Warning ). Chloromycetin Ophthalmic Ointment, 1% (Chloramphenicol Ophthalmic Ointment, USP) is indicated for the treatment of surface ocular infections involving the conjunctiva and/or cornea caused by chloramphenicol-susceptible organisms. The particular antiinfective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus Streptococcus , including Streptococcus pneumoniae Escherichia coli Haemophilus influenzae Klebsiella/Enterobacter species Moraxella lucunata (Morax-Axenfeld bacillus) Neisseria species This product does not provide adequate coverage against: Pseudomonas aeruginosa Serratia marcescens uuid:f843ed34-80a4-4462-821a-5df903c43fb2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:376030 biolink:treats MONDO:0003799 PMID:41385096 "[{""id"":""uuid:88e13a12-cd78-4017-9257-4a4e23c45bb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5467bd8a-5a90-45b7-913e-382a19906c17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NEOSPORIN Ophthalmic Ointment is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. Such infections encompass conjunctivitis, keratitis and keratoconjunctivitis, blepharitis and blepharoconjunctivitis. uuid:613474d6-b20f-472e-a01f-30e6e21ca2da biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:376030 biolink:treats MONDO:0003085 PMID:41385096 "[{""id"":""uuid:b05fa038-bcc2-4fb2-a950-21d70cd037bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:21d4e41f-90fd-447c-9465-1133de946328"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NEOSPORIN Ophthalmic Ointment is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. Such infections encompass conjunctivitis, keratitis and keratoconjunctivitis, blepharitis and blepharoconjunctivitis. uuid:531dddf6-ea7a-4745-8a29-71d74b3f3067 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:376030 biolink:treats MONDO:0004768 PMID:41385096 "[{""id"":""uuid:3ab163b8-8c5d-46a9-bfe9-a9669939f865"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e0310d8c-b137-4a4f-a815-caee96a09ba8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NEOSPORIN Ophthalmic Ointment is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. Such infections encompass conjunctivitis, keratitis and keratoconjunctivitis, blepharitis and blepharoconjunctivitis. uuid:b0fed0ca-c0e0-44a0-a4ef-e447e386e155 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:376030 biolink:treats MONDO:0004785 PMID:41385096 "[{""id"":""uuid:0926c048-4f68-435c-8fe4-6fd79ca6e12a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:69e0f40f-8f08-4d50-8f76-2e197f65e6d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NEOSPORIN Ophthalmic Ointment is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. Such infections encompass conjunctivitis, keratitis and keratoconjunctivitis, blepharitis and blepharoconjunctivitis. uuid:d9d165c8-bd3f-4848-ba3a-ffc2bcc8876c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:376030 biolink:treats MONDO:0002307 PMID:41385096 "[{""id"":""uuid:427d6167-1ce5-46f9-ae22-375d36885160"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:de763b63-789f-457d-9c29-2898ae9cf02d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NEOSPORIN Ophthalmic Ointment is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. Such infections encompass conjunctivitis, keratitis and keratoconjunctivitis, blepharitis and blepharoconjunctivitis. uuid:3a751863-bf15-4f30-a046-7efdaba6b426 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8776 biolink:treats MONDO:0005412 PMID:41385096 "[{""id"":""uuid:0a115452-7c62-4835-be79-a2f98ce77579"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4ac31344-8254-4c2c-b968-29c0072ec0bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ranitidine tablets are indicated in: 1.Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than eight weeks. 2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo-controlled comparative studies have been carried out for periods of longer than 1 year. 3. The treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and systemic mastocytosis). 4. Short-term treatment of active, benign gastric ulcer. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. Studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. 5. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled studies have been carried out for 1 year. 6. Treatment of GERD: Symptomatic relief commonly occurs within 24 hours after starting therapy with ranitidine 150 mg b.i.d. 7. Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with ranitidine 150 mg q.i.d. 8.Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks. Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis. uuid:73dc79ff-b626-45c1-b662-18c1498ca23e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8776 biolink:treats MONDO:0016586 PMID:41385096 "[{""id"":""uuid:74c0274f-7ed1-4599-90ae-8d637819f246"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:205f36f8-2148-4c27-b942-1ee54262b83e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ranitidine tablets are indicated in: 1.Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than eight weeks. 2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo-controlled comparative studies have been carried out for periods of longer than 1 year. 3. The treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and systemic mastocytosis). 4. Short-term treatment of active, benign gastric ulcer. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. Studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. 5. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled studies have been carried out for 1 year. 6. Treatment of GERD: Symptomatic relief commonly occurs within 24 hours after starting therapy with ranitidine 150 mg b.i.d. 7. Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with ranitidine 150 mg q.i.d. 8.Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks. Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis. uuid:10298c4e-5567-4c40-978b-2b61aacf3ebd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8776 biolink:treats MONDO:0001126 PMID:41385096 "[{""id"":""uuid:d2acf8c6-4607-4e87-9809-48ec893eb046"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8f06ad56-b717-47de-b99f-f899516968e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ranitidine tablets are indicated in: 1.Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than eight weeks. 2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo-controlled comparative studies have been carried out for periods of longer than 1 year. 3. The treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and systemic mastocytosis). 4. Short-term treatment of active, benign gastric ulcer. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. Studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. 5. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled studies have been carried out for 1 year. 6. Treatment of GERD: Symptomatic relief commonly occurs within 24 hours after starting therapy with ranitidine 150 mg b.i.d. 7. Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with ranitidine 150 mg q.i.d. 8.Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks. Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis. uuid:29b6a349-045e-4904-9554-b00576bc5a5c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8776 biolink:treats UMLS:C0267055 PMID:41385096 "[{""id"":""uuid:6e45f6d0-f378-48bd-ba2d-f224c5412f17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cc5db0d0-bd9c-4729-b5f0-8255937bc0bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ranitidine tablets are indicated in: 1.Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than eight weeks. 2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo-controlled comparative studies have been carried out for periods of longer than 1 year. 3. The treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and systemic mastocytosis). 4. Short-term treatment of active, benign gastric ulcer. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. Studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. 5. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled studies have been carried out for 1 year. 6. Treatment of GERD: Symptomatic relief commonly occurs within 24 hours after starting therapy with ranitidine 150 mg b.i.d. 7. Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with ranitidine 150 mg q.i.d. 8.Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks. Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis. uuid:9613f33a-453c-453d-bae0-9a7e2a39df07 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4975 biolink:treats MONDO:0005412 PMID:41385096 "[{""id"":""uuid:f44d56e6-d775-4533-a3ab-6c9c9e79282f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ffd6dff1-f11c-40d2-b82b-57bb07de0819"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FLUXID™ is indicated in: 1. Short term treatment of active duodenal ulcer. Most adult patients heal within 4 weeks; there is rarely reason to use famotidine at full dosage for longer than 6 to 8 weeks. Studies have not assessed the safety of famotidine in uncomplicated active duodenal ulcer for periods of more than eight weeks. 2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer. Controlled studies in adults have not extended beyond one year. 3. Short term treatment of active benign gastric ulcer. Most adult patients heal within 6 weeks. Studies have not assessed the safety or efficacy of famotidine in uncomplicated active benign gastric ulcer for periods of more than 8 weeks. 4. Short term treatment of gastroesophageal reflux disease (GERD) . FLUXID™ is indicated for short term treatment of patients with symptoms of GERD (see CLINICAL PHARMACOLOGY IN ADULTS, Clinical Studies ). FLUXID™ is also indicated for the short term treatment of esophagitis due to GERD including erosive or ulcerative disease diagnosed by endoscopy (see CLINICAL PHARMACOLOGY IN ADULTS, Clinical Studies ). 5. Treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison Syndrome, multiple endocrine adenomas) (see CLINICAL PHARMACOLOGY IN ADULTS, Clinical Studies ). uuid:6a160e8b-55c2-4d9c-b115-680e933980d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4975 biolink:treats MONDO:0001126 PMID:41385096 "[{""id"":""uuid:c6588ddf-0c4a-486b-a1ee-b3baec9172c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c2fc2527-41a5-4978-9ff9-855102d52c1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FLUXID™ is indicated in: 1. Short term treatment of active duodenal ulcer. Most adult patients heal within 4 weeks; there is rarely reason to use famotidine at full dosage for longer than 6 to 8 weeks. Studies have not assessed the safety of famotidine in uncomplicated active duodenal ulcer for periods of more than eight weeks. 2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer. Controlled studies in adults have not extended beyond one year. 3. Short term treatment of active benign gastric ulcer. Most adult patients heal within 6 weeks. Studies have not assessed the safety or efficacy of famotidine in uncomplicated active benign gastric ulcer for periods of more than 8 weeks. 4. Short term treatment of gastroesophageal reflux disease (GERD) . FLUXID™ is indicated for short term treatment of patients with symptoms of GERD (see CLINICAL PHARMACOLOGY IN ADULTS, Clinical Studies ). FLUXID™ is also indicated for the short term treatment of esophagitis due to GERD including erosive or ulcerative disease diagnosed by endoscopy (see CLINICAL PHARMACOLOGY IN ADULTS, Clinical Studies ). 5. Treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison Syndrome, multiple endocrine adenomas) (see CLINICAL PHARMACOLOGY IN ADULTS, Clinical Studies ). uuid:d1d86723-a6b3-439d-ae27-f1eb9151544d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4975 biolink:treats MONDO:0006896 PMID:41385096 "[{""id"":""uuid:673845c5-1c25-4566-8a10-386431cb034d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:198da2b5-d273-42d0-bef5-0fb8704b75e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FLUXID™ is indicated in: 1. Short term treatment of active duodenal ulcer. Most adult patients heal within 4 weeks; there is rarely reason to use famotidine at full dosage for longer than 6 to 8 weeks. Studies have not assessed the safety of famotidine in uncomplicated active duodenal ulcer for periods of more than eight weeks. 2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer. Controlled studies in adults have not extended beyond one year. 3. Short term treatment of active benign gastric ulcer. Most adult patients heal within 6 weeks. Studies have not assessed the safety or efficacy of famotidine in uncomplicated active benign gastric ulcer for periods of more than 8 weeks. 4. Short term treatment of gastroesophageal reflux disease (GERD) . FLUXID™ is indicated for short term treatment of patients with symptoms of GERD (see CLINICAL PHARMACOLOGY IN ADULTS, Clinical Studies ). FLUXID™ is also indicated for the short term treatment of esophagitis due to GERD including erosive or ulcerative disease diagnosed by endoscopy (see CLINICAL PHARMACOLOGY IN ADULTS, Clinical Studies ). 5. Treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison Syndrome, multiple endocrine adenomas) (see CLINICAL PHARMACOLOGY IN ADULTS, Clinical Studies ). uuid:ff996146-f4f4-4b70-bf85-b94fb4239111 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4975 biolink:treats MONDO:0017169 PMID:41385096 "[{""id"":""uuid:9e88f35b-7869-42d8-91ab-0f086cfa7284"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:da5c684a-356c-49e4-af66-de5463c2cc64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FLUXID™ is indicated in: 1. Short term treatment of active duodenal ulcer. Most adult patients heal within 4 weeks; there is rarely reason to use famotidine at full dosage for longer than 6 to 8 weeks. Studies have not assessed the safety of famotidine in uncomplicated active duodenal ulcer for periods of more than eight weeks. 2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer. Controlled studies in adults have not extended beyond one year. 3. Short term treatment of active benign gastric ulcer. Most adult patients heal within 6 weeks. Studies have not assessed the safety or efficacy of famotidine in uncomplicated active benign gastric ulcer for periods of more than 8 weeks. 4. Short term treatment of gastroesophageal reflux disease (GERD) . FLUXID™ is indicated for short term treatment of patients with symptoms of GERD (see CLINICAL PHARMACOLOGY IN ADULTS, Clinical Studies ). FLUXID™ is also indicated for the short term treatment of esophagitis due to GERD including erosive or ulcerative disease diagnosed by endoscopy (see CLINICAL PHARMACOLOGY IN ADULTS, Clinical Studies ). 5. Treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison Syndrome, multiple endocrine adenomas) (see CLINICAL PHARMACOLOGY IN ADULTS, Clinical Studies ). uuid:e13e1e4c-9682-4f97-a27d-fe8977d447c7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6067 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:a767e21e-2004-4e01-9764-9d412a7dacae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ca51f608-20fc-4ac7-a049-738cac9de15b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sotret is indicated for the treatment of severe recalcitrant nodular acne. Nodules are inflammatory lesions with a diameter of 5 mm or greater. The nodules may become suppurative or hemorrhagic. “Severe,” by definition, 2 means “many” as opposed to “few or several” nodules. Because of significant adverse effects associated with its use, Sotret should be reserved for patients with severe nodular acne who are unresponsive to conventional therapy, including systemic antibiotics. In addition, Sotret is indicated only for those female patients who are not pregnant, because Sotret can cause severe birth defects (see Boxed CONTRAINDICATIONS AND WARNINGS ). A single course of therapy for 15 to 20 weeks has been shown to result in complete and prolonged remission of disease in many patients. 1,3,4 If a second course of therapy is needed, it should not be initiated until at least 8 weeks after completion of the first course, because experience has shown that patients may continue to improve while off isotretinoin capsules. The optimal interval before retreatment has not been defined for patients who have not completed skeletal growth (see WARNINGS: Skeletal: Bone Mineral Density, Hyperostosis , and Premature Epiphyseal Closure ). uuid:dd8788c5-ec44-44c8-a04e-8293b03ec315 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:370748 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:f3444fb5-61e7-4b0a-8478-06cb57e0316f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:04db7068-5fc4-41ab-bb0f-7676a6719dcf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acetaminophen and codeine phosphate tablets are indicated for the relief of mild to moderately severe pain. uuid:bf09c09e-b220-4e35-80e0-fe53714a7fd4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63622 biolink:treats HP:0004308 PMID:41385096 "[{""id"":""uuid:c09b6858-f297-4b8b-9849-2baeec251714"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:48fdf5a1-3255-47d4-a36c-e51e4fed220c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sotalol is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgment of the physician are life-threatening. Because of the proarrhythmic effects of sotalol (See WARNINGS ), including a 1.5 to 2% rate of torsade de pointes or new VT/VF in patients with either NSVT or supraventricular arrhythmias, its use in patients with less severe arrhythmias, even if the patients are symptomatic, is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of sotalol treatment or increasing doses, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. The response to treatment should then be evaluated by a suitable method (e.g., PES or Holter monitoring) prior to continuing the patient on chronic therapy. Various approaches have been used to determine the response to antiarrhythmic therapy, including sotalol. In the ESVEM Trial, response by Holter monitoring was tentatively defined as 100% suppression of ventricular tachycardia, 90% suppression of non-sustained VT, 80% suppression of paired VPCs, and 75% suppression of total VPCs in patients who had at least 10 VPCs/hour at baseline; this tentative response was confirmed if VT lasting 5 or more beats was not observed during treadmill exercise testing using a standard Bruce protocol. The PES protocol utilized a maximum of three extrastimuli at three pacing cycle lengths and two right ventricular pacing sites. Response to PES was defined as prevention of induction of the following: 1) monomorphic VT lasting over 15 seconds; 2) non-sustained polymorphic VT containing more than 15 beats of monomorphic VT in patients with a history of monomorphic VT; 3) polymorphic VT or VF greater than 15 beats in patients with VF or a history of aborted sudden death without monomorphic VT; and 4) two episodes of polymorphic VT or VF of greater than 15 beats in a patient presenting with monomorphic VT. Sustained VT or NSVT producing hypotension during the final treadmill test was considered a drug failure. In a multicenter open-label long-term study of sotalol in patients with life-threatening ventricular arrhythmias which had proved refractory to other antiarrhythmic medications, response by Holter monitoring was defined as in ESVEM. Response by PES was defined as non-inducibility of sustained VT by at least double extrastimuli delivered at a pacing cycle length of 400 msec. Overall survival and arrhythmia recurrence rates in this study were similar to those seen in ESVEM, although there was no comparative group to allow a definitive assessment of outcome. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. Sotalol is also indicated for the maintenance of normal sinus rhythm [delay in time to recurrence of atrial fibrillation/atrial flutter (AFIB/AFL)] in patients with symptomatic AFIB/AFL who are currently in sinus rhythm and is marketed under the brand name BETAPACE AF™. Sotalol is not approved for the AFIB/AFL indication and should not be substituted for BETAPACE AF™ because only BETAPACE AF is distributed with a patient package insert that is appropriate for patients with AFIB/AFL. uuid:917babc7-6288-49d9-a27b-ba4fbef50f8f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63622 biolink:treats UMLS:C0750197 PMID:41385096 "[{""id"":""uuid:5d9c3fa1-1353-4bc9-9679-8daccc584ceb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:90f92ec6-e4e3-4df0-8f95-8d77b44c910a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sotalol is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgment of the physician are life-threatening. Because of the proarrhythmic effects of sotalol (See WARNINGS ), including a 1.5 to 2% rate of torsade de pointes or new VT/VF in patients with either NSVT or supraventricular arrhythmias, its use in patients with less severe arrhythmias, even if the patients are symptomatic, is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of sotalol treatment or increasing doses, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. The response to treatment should then be evaluated by a suitable method (e.g., PES or Holter monitoring) prior to continuing the patient on chronic therapy. Various approaches have been used to determine the response to antiarrhythmic therapy, including sotalol. In the ESVEM Trial, response by Holter monitoring was tentatively defined as 100% suppression of ventricular tachycardia, 90% suppression of non-sustained VT, 80% suppression of paired VPCs, and 75% suppression of total VPCs in patients who had at least 10 VPCs/hour at baseline; this tentative response was confirmed if VT lasting 5 or more beats was not observed during treadmill exercise testing using a standard Bruce protocol. The PES protocol utilized a maximum of three extrastimuli at three pacing cycle lengths and two right ventricular pacing sites. Response to PES was defined as prevention of induction of the following: 1) monomorphic VT lasting over 15 seconds; 2) non-sustained polymorphic VT containing more than 15 beats of monomorphic VT in patients with a history of monomorphic VT; 3) polymorphic VT or VF greater than 15 beats in patients with VF or a history of aborted sudden death without monomorphic VT; and 4) two episodes of polymorphic VT or VF of greater than 15 beats in a patient presenting with monomorphic VT. Sustained VT or NSVT producing hypotension during the final treadmill test was considered a drug failure. In a multicenter open-label long-term study of sotalol in patients with life-threatening ventricular arrhythmias which had proved refractory to other antiarrhythmic medications, response by Holter monitoring was defined as in ESVEM. Response by PES was defined as non-inducibility of sustained VT by at least double extrastimuli delivered at a pacing cycle length of 400 msec. Overall survival and arrhythmia recurrence rates in this study were similar to those seen in ESVEM, although there was no comparative group to allow a definitive assessment of outcome. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. Sotalol is also indicated for the maintenance of normal sinus rhythm [delay in time to recurrence of atrial fibrillation/atrial flutter (AFIB/AFL)] in patients with symptomatic AFIB/AFL who are currently in sinus rhythm and is marketed under the brand name BETAPACE AF™. Sotalol is not approved for the AFIB/AFL indication and should not be substituted for BETAPACE AF™ because only BETAPACE AF is distributed with a patient package insert that is appropriate for patients with AFIB/AFL. uuid:9f1f9057-e8f3-4583-89f5-6476402889f1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63622 biolink:treats MONDO:0013317 PMID:41385096 "[{""id"":""uuid:e90ab969-620f-4e39-9dbe-78b437a53c98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:13113d7f-0072-461f-9fdf-1446c1eb2428"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sotalol is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgment of the physician are life-threatening. Because of the proarrhythmic effects of sotalol (See WARNINGS ), including a 1.5 to 2% rate of torsade de pointes or new VT/VF in patients with either NSVT or supraventricular arrhythmias, its use in patients with less severe arrhythmias, even if the patients are symptomatic, is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of sotalol treatment or increasing doses, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. The response to treatment should then be evaluated by a suitable method (e.g., PES or Holter monitoring) prior to continuing the patient on chronic therapy. Various approaches have been used to determine the response to antiarrhythmic therapy, including sotalol. In the ESVEM Trial, response by Holter monitoring was tentatively defined as 100% suppression of ventricular tachycardia, 90% suppression of non-sustained VT, 80% suppression of paired VPCs, and 75% suppression of total VPCs in patients who had at least 10 VPCs/hour at baseline; this tentative response was confirmed if VT lasting 5 or more beats was not observed during treadmill exercise testing using a standard Bruce protocol. The PES protocol utilized a maximum of three extrastimuli at three pacing cycle lengths and two right ventricular pacing sites. Response to PES was defined as prevention of induction of the following: 1) monomorphic VT lasting over 15 seconds; 2) non-sustained polymorphic VT containing more than 15 beats of monomorphic VT in patients with a history of monomorphic VT; 3) polymorphic VT or VF greater than 15 beats in patients with VF or a history of aborted sudden death without monomorphic VT; and 4) two episodes of polymorphic VT or VF of greater than 15 beats in a patient presenting with monomorphic VT. Sustained VT or NSVT producing hypotension during the final treadmill test was considered a drug failure. In a multicenter open-label long-term study of sotalol in patients with life-threatening ventricular arrhythmias which had proved refractory to other antiarrhythmic medications, response by Holter monitoring was defined as in ESVEM. Response by PES was defined as non-inducibility of sustained VT by at least double extrastimuli delivered at a pacing cycle length of 400 msec. Overall survival and arrhythmia recurrence rates in this study were similar to those seen in ESVEM, although there was no comparative group to allow a definitive assessment of outcome. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. Sotalol is also indicated for the maintenance of normal sinus rhythm [delay in time to recurrence of atrial fibrillation/atrial flutter (AFIB/AFL)] in patients with symptomatic AFIB/AFL who are currently in sinus rhythm and is marketed under the brand name BETAPACE AF™. Sotalol is not approved for the AFIB/AFL indication and should not be substituted for BETAPACE AF™ because only BETAPACE AF is distributed with a patient package insert that is appropriate for patients with AFIB/AFL. uuid:ae7787d6-bea4-448d-ad2d-4b02db0415a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63622 biolink:treats MONDO:0004981 PMID:41385096 "[{""id"":""uuid:dbdbef32-d53f-4f88-a677-2416ef6fc547"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:82d74da9-e051-4cc4-9b17-7b442712d0a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sotalol is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgment of the physician are life-threatening. Because of the proarrhythmic effects of sotalol (See WARNINGS ), including a 1.5 to 2% rate of torsade de pointes or new VT/VF in patients with either NSVT or supraventricular arrhythmias, its use in patients with less severe arrhythmias, even if the patients are symptomatic, is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of sotalol treatment or increasing doses, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. The response to treatment should then be evaluated by a suitable method (e.g., PES or Holter monitoring) prior to continuing the patient on chronic therapy. Various approaches have been used to determine the response to antiarrhythmic therapy, including sotalol. In the ESVEM Trial, response by Holter monitoring was tentatively defined as 100% suppression of ventricular tachycardia, 90% suppression of non-sustained VT, 80% suppression of paired VPCs, and 75% suppression of total VPCs in patients who had at least 10 VPCs/hour at baseline; this tentative response was confirmed if VT lasting 5 or more beats was not observed during treadmill exercise testing using a standard Bruce protocol. The PES protocol utilized a maximum of three extrastimuli at three pacing cycle lengths and two right ventricular pacing sites. Response to PES was defined as prevention of induction of the following: 1) monomorphic VT lasting over 15 seconds; 2) non-sustained polymorphic VT containing more than 15 beats of monomorphic VT in patients with a history of monomorphic VT; 3) polymorphic VT or VF greater than 15 beats in patients with VF or a history of aborted sudden death without monomorphic VT; and 4) two episodes of polymorphic VT or VF of greater than 15 beats in a patient presenting with monomorphic VT. Sustained VT or NSVT producing hypotension during the final treadmill test was considered a drug failure. In a multicenter open-label long-term study of sotalol in patients with life-threatening ventricular arrhythmias which had proved refractory to other antiarrhythmic medications, response by Holter monitoring was defined as in ESVEM. Response by PES was defined as non-inducibility of sustained VT by at least double extrastimuli delivered at a pacing cycle length of 400 msec. Overall survival and arrhythmia recurrence rates in this study were similar to those seen in ESVEM, although there was no comparative group to allow a definitive assessment of outcome. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. Sotalol is also indicated for the maintenance of normal sinus rhythm [delay in time to recurrence of atrial fibrillation/atrial flutter (AFIB/AFL)] in patients with symptomatic AFIB/AFL who are currently in sinus rhythm and is marketed under the brand name BETAPACE AF™. Sotalol is not approved for the AFIB/AFL indication and should not be substituted for BETAPACE AF™ because only BETAPACE AF is distributed with a patient package insert that is appropriate for patients with AFIB/AFL. uuid:be8ba394-5150-4c79-a83a-052aa49acde4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63622 biolink:treats MONDO:0005310 PMID:41385096 "[{""id"":""uuid:ddfb81bd-bcc5-4893-a3f3-4c554b0a3b8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0857e8ea-137a-4b6c-a62f-ddfcc1a6b218"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sotalol is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgment of the physician are life-threatening. Because of the proarrhythmic effects of sotalol (See WARNINGS ), including a 1.5 to 2% rate of torsade de pointes or new VT/VF in patients with either NSVT or supraventricular arrhythmias, its use in patients with less severe arrhythmias, even if the patients are symptomatic, is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of sotalol treatment or increasing doses, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. The response to treatment should then be evaluated by a suitable method (e.g., PES or Holter monitoring) prior to continuing the patient on chronic therapy. Various approaches have been used to determine the response to antiarrhythmic therapy, including sotalol. In the ESVEM Trial, response by Holter monitoring was tentatively defined as 100% suppression of ventricular tachycardia, 90% suppression of non-sustained VT, 80% suppression of paired VPCs, and 75% suppression of total VPCs in patients who had at least 10 VPCs/hour at baseline; this tentative response was confirmed if VT lasting 5 or more beats was not observed during treadmill exercise testing using a standard Bruce protocol. The PES protocol utilized a maximum of three extrastimuli at three pacing cycle lengths and two right ventricular pacing sites. Response to PES was defined as prevention of induction of the following: 1) monomorphic VT lasting over 15 seconds; 2) non-sustained polymorphic VT containing more than 15 beats of monomorphic VT in patients with a history of monomorphic VT; 3) polymorphic VT or VF greater than 15 beats in patients with VF or a history of aborted sudden death without monomorphic VT; and 4) two episodes of polymorphic VT or VF of greater than 15 beats in a patient presenting with monomorphic VT. Sustained VT or NSVT producing hypotension during the final treadmill test was considered a drug failure. In a multicenter open-label long-term study of sotalol in patients with life-threatening ventricular arrhythmias which had proved refractory to other antiarrhythmic medications, response by Holter monitoring was defined as in ESVEM. Response by PES was defined as non-inducibility of sustained VT by at least double extrastimuli delivered at a pacing cycle length of 400 msec. Overall survival and arrhythmia recurrence rates in this study were similar to those seen in ESVEM, although there was no comparative group to allow a definitive assessment of outcome. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. Sotalol is also indicated for the maintenance of normal sinus rhythm [delay in time to recurrence of atrial fibrillation/atrial flutter (AFIB/AFL)] in patients with symptomatic AFIB/AFL who are currently in sinus rhythm and is marketed under the brand name BETAPACE AF™. Sotalol is not approved for the AFIB/AFL indication and should not be substituted for BETAPACE AF™ because only BETAPACE AF is distributed with a patient package insert that is appropriate for patients with AFIB/AFL. uuid:711f80a2-0e42-4d3b-af62-6f1252f62d57 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:251408 biolink:treats MONDO:0009688 PMID:41385096 "[{""id"":""uuid:69a90d62-9f10-44a3-97c7-6328dca83cf2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7b04af05-7712-499e-8bc3-78aa5318e316"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENLON is recommended for the differential diagnosis of myasthenia gravis and as an adjunct in the evaluation of treatment requirements in this disease. It may also be used for evaluating emergency treatment in myasthenic crises. Because of its brief duration of action, it is not recommended for maintenance therapy in myasthenia gravis. ENLON is also useful whenever a curare antagonist is needed to reverse the neuromuscular block produced by curare, tubocurarine, gallamine triethiodide or dimethyl-tubocurarine. It is not effective against decamethonium bromide and succinylcholine chloride. It may be used adjunctively in the treatment of respiratory depression caused by curare overdosage. uuid:7a5da1ec-5d2a-4b55-b655-006aefe5bd89 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:251408 biolink:treats MONDO:0021113 PMID:41385096 "[{""id"":""uuid:327d3ee0-1d44-4a96-99c4-68532992fc5d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a92db409-de8e-4173-a87c-a501f13a533b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENLON is recommended for the differential diagnosis of myasthenia gravis and as an adjunct in the evaluation of treatment requirements in this disease. It may also be used for evaluating emergency treatment in myasthenic crises. Because of its brief duration of action, it is not recommended for maintenance therapy in myasthenia gravis. ENLON is also useful whenever a curare antagonist is needed to reverse the neuromuscular block produced by curare, tubocurarine, gallamine triethiodide or dimethyl-tubocurarine. It is not effective against decamethonium bromide and succinylcholine chloride. It may be used adjunctively in the treatment of respiratory depression caused by curare overdosage. uuid:45a6351c-60a5-42c6-ad09-76a7f8c9d5b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28177 biolink:treats MONDO:0850282 PMID:41385096 "[{""id"":""uuid:35cd188d-08f8-45d9-a16d-ba9d15dc3fb9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5115b9b9-cbbd-4d13-833d-332c36b8acb0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Theophylline is indicated for the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis. uuid:c9d0477e-19cb-4248-a17e-74fa9a6e9522 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28177 biolink:treats MONDO:0004849 PMID:41385096 "[{""id"":""uuid:315963bd-eff2-4ae9-a581-7d00f31ab4b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:66f41f91-246a-432f-bbb9-1f3f59fc6727"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Theophylline is indicated for the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis. uuid:f8dcce47-d388-4995-b3a1-e04bf87617e6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28177 biolink:treats MONDO:0005607 PMID:41385096 "[{""id"":""uuid:3ec65aa5-b19f-4605-bf63-004d3e85c3e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:20759431-db5d-49b5-9c3b-315e8a0e2653"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Theophylline is indicated for the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis. uuid:081910d4-e7de-477b-9939-21b81c999fb7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6741 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:eee958f6-3bb6-4c7d-92ad-1da45a32c7d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0c617a9d-5109-47e0-8c7a-9eefcb434f1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of meloxicam tablets and other treatment options before deciding to use meloxicam tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Meloxicam tablets are indicated for relief of the signs and symptoms of osteoarthritis. uuid:e0d01744-ceaf-4bcb-96fd-67d3e9140470 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1154705 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:715ce125-472e-4247-9189-700903d09273"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ff432710-0668-4d87-b99f-1e9f8c8e46c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bisoprolol and hydrochlorothiazide is indicated in the management of hypertension. uuid:d9534e5d-2d2e-446c-8979-f77dc489ce4b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6923 biolink:treats MONDO:0006014 PMID:41385096 "[{""id"":""uuid:4889cf40-2902-451d-a3a6-c2d73f95ad8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:234b5b91-bb6a-480d-80ea-2a86f5acbd80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MONISTAT 3 Vaginal Suppositories are indicated for the local treatment of vulvovaginal candidiasis (moniliasis). Effectiveness in pregnancy and in diabetic patients has not been established. As MONISTAT is effective only for candidal vulvovaginitis, the diagnosis should be confirmed by KOH smear and/or cultures. Other pathogens commonly associated with vulvovaginitis ( Trichomonas and Haemophilus vaginalis [Gardnerella] ) should be ruled out by appropriate laboratory methods. uuid:fbf9d78d-968b-455e-a719-119d40bcff85 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6923 biolink:treats UMLS:C0343886 PMID:41385096 "[{""id"":""uuid:62916f81-6fd9-43ea-bf2a-5885e13a1d4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:46aff044-5871-4a25-ab56-b372f9d430bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MONISTAT 3 Vaginal Suppositories are indicated for the local treatment of vulvovaginal candidiasis (moniliasis). Effectiveness in pregnancy and in diabetic patients has not been established. As MONISTAT is effective only for candidal vulvovaginitis, the diagnosis should be confirmed by KOH smear and/or cultures. Other pathogens commonly associated with vulvovaginitis ( Trichomonas and Haemophilus vaginalis [Gardnerella] ) should be ruled out by appropriate laboratory methods. uuid:6c257e03-67bf-40c0-8fc8-ebd28bc4d271 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5296 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:340dbf25-6aaf-4ca4-b9c6-8b1a39029708"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ae1c168a-4359-4a44-b431-421c401ccf72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gemfibrozil tablets are indicated as adjunctive therapy to diet for: Treatment of adult patients with very high elevations of serum triglyceride levels (Types IV and V hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Patients who present such risk typically have serum triglycerides over 2000 mg/dL and have elevations of VLDL-cholesterol as well as fasting chylomicrons (Type V hyperlipidemia). Subjects who consistently have total serum or plasma triglycerides below 1000 mg/dL are unlikely to present a risk of pancreatitis. Gemfibrozil therapy may be considered for those subjects with triglyceride elevations between 1000 and 2000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. It is recognized that some Type IV patients with triglycerides under 1000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of gemfibrozil therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia (ref. 5). Reducing the risk of developing coronary heart disease only in Type IIb patients without history of or symptoms of existing coronary heart disease who have had an inadequate response to weight loss, dietary therapy, exercise, and other pharmacologic agents (such as bile acid sequestrants and nicotinic acid, known to reduce LDL- and raise HDL-cholesterol) and who have the following triad of lipid abnormalities: low HDL-cholesterol levels in addition to elevated LDL-cholesterol and elevated triglycerides (see WARNINGS , PRECAUTIONS , and CLINICAL PHARMACOLOGY ). The National Cholesterol Education Program has defined a serum HDL-cholesterol value that is consistently below 35 mg/dL as constituting an independent risk factor for coronary heart disease (ref. 6). Patients with significantly elevated triglycerides should be closely observed when treated with gemfibrozil. In some patients with high triglyceride levels, treatment with gemfibrozil is associated with a significant increase in LDL-cholesterol. BECAUSE OF POTENTIAL TOXICITY SUCH AS MALIGNANCY, GALLBLADDER DISEASE, ABDOMINAL PAIN LEADING TO APPENDECTOMY AND OTHER ABDOMINAL SURGERIES, AN INCREASED INCIDENCE IN NONCORONARY MORTALITY, AND THE 44% RELATIVE INCREASE DURING THE TRIAL PERIOD IN AGE-ADJUSTED ALL-CAUSE MORTALITY SEEN WITH THE CHEMICALLY AND PHARMACOLOGICALLY RELATED DRUG, CLOFIBRATE, THE POTENTIAL BENEFIT OF GEMFIBROZIL IN TREATING TYPE IIA PATIENTS WITH ELEVATIONS OF LDL-CHOLESTEROL ONLY IS NOT LIKELY TO OUTWEIGH THE RISKS. GEMFIBROZIL IS ALSO NOT INDICATED FOR THE TREATMENT OF PATIENTS WITH LOW HDL- CHOLESTEROL AS THEIR ONLY LIPID ABNORMALITY. In a subgroup analysis of patients in the Helsinki Heart Study with above-median HDL-cholesterol values at baseline (greater than 46.4 mg/dL), the incidence of serious coronary events was similar for gemfibrozil and placebo subgroups (see Table I ). The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcohol intake may be important factors in hypertriglyceridemia and should be managed prior to any drug therapy. Physical exercise can be an important ancillary measure, and has been associated with rises in HDL-cholesterol. Diseases contributory to hyperlipidemia such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy is sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of estrogen therapy may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with nondrug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet. uuid:c95b05b9-ea06-495f-b39e-cc5fe5bcae1c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5296 biolink:treats MONDO:0007788 PMID:41385096 "[{""id"":""uuid:dd9e81d4-f88e-48f3-849c-0f357c658a49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:34efd3bc-807e-4c32-938b-8da4fa8dc1de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gemfibrozil tablets are indicated as adjunctive therapy to diet for: Treatment of adult patients with very high elevations of serum triglyceride levels (Types IV and V hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Patients who present such risk typically have serum triglycerides over 2000 mg/dL and have elevations of VLDL-cholesterol as well as fasting chylomicrons (Type V hyperlipidemia). Subjects who consistently have total serum or plasma triglycerides below 1000 mg/dL are unlikely to present a risk of pancreatitis. Gemfibrozil therapy may be considered for those subjects with triglyceride elevations between 1000 and 2000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. It is recognized that some Type IV patients with triglycerides under 1000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of gemfibrozil therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia (ref. 5). Reducing the risk of developing coronary heart disease only in Type IIb patients without history of or symptoms of existing coronary heart disease who have had an inadequate response to weight loss, dietary therapy, exercise, and other pharmacologic agents (such as bile acid sequestrants and nicotinic acid, known to reduce LDL- and raise HDL-cholesterol) and who have the following triad of lipid abnormalities: low HDL-cholesterol levels in addition to elevated LDL-cholesterol and elevated triglycerides (see WARNINGS , PRECAUTIONS , and CLINICAL PHARMACOLOGY ). The National Cholesterol Education Program has defined a serum HDL-cholesterol value that is consistently below 35 mg/dL as constituting an independent risk factor for coronary heart disease (ref. 6). Patients with significantly elevated triglycerides should be closely observed when treated with gemfibrozil. In some patients with high triglyceride levels, treatment with gemfibrozil is associated with a significant increase in LDL-cholesterol. BECAUSE OF POTENTIAL TOXICITY SUCH AS MALIGNANCY, GALLBLADDER DISEASE, ABDOMINAL PAIN LEADING TO APPENDECTOMY AND OTHER ABDOMINAL SURGERIES, AN INCREASED INCIDENCE IN NONCORONARY MORTALITY, AND THE 44% RELATIVE INCREASE DURING THE TRIAL PERIOD IN AGE-ADJUSTED ALL-CAUSE MORTALITY SEEN WITH THE CHEMICALLY AND PHARMACOLOGICALLY RELATED DRUG, CLOFIBRATE, THE POTENTIAL BENEFIT OF GEMFIBROZIL IN TREATING TYPE IIA PATIENTS WITH ELEVATIONS OF LDL-CHOLESTEROL ONLY IS NOT LIKELY TO OUTWEIGH THE RISKS. GEMFIBROZIL IS ALSO NOT INDICATED FOR THE TREATMENT OF PATIENTS WITH LOW HDL- CHOLESTEROL AS THEIR ONLY LIPID ABNORMALITY. In a subgroup analysis of patients in the Helsinki Heart Study with above-median HDL-cholesterol values at baseline (greater than 46.4 mg/dL), the incidence of serious coronary events was similar for gemfibrozil and placebo subgroups (see Table I ). The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcohol intake may be important factors in hypertriglyceridemia and should be managed prior to any drug therapy. Physical exercise can be an important ancillary measure, and has been associated with rises in HDL-cholesterol. Diseases contributory to hyperlipidemia such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy is sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of estrogen therapy may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with nondrug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet. uuid:327fd83f-5fa6-43ea-b3d3-678f9bf17c80 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5296 biolink:treats MONDO:0007762 PMID:41385096 "[{""id"":""uuid:26b62b8b-d492-4dd8-bfaf-9e3e617ca24f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3869571e-f6f4-4146-ae8f-f45897923563"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gemfibrozil tablets are indicated as adjunctive therapy to diet for: Treatment of adult patients with very high elevations of serum triglyceride levels (Types IV and V hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Patients who present such risk typically have serum triglycerides over 2000 mg/dL and have elevations of VLDL-cholesterol as well as fasting chylomicrons (Type V hyperlipidemia). Subjects who consistently have total serum or plasma triglycerides below 1000 mg/dL are unlikely to present a risk of pancreatitis. Gemfibrozil therapy may be considered for those subjects with triglyceride elevations between 1000 and 2000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. It is recognized that some Type IV patients with triglycerides under 1000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of gemfibrozil therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia (ref. 5). Reducing the risk of developing coronary heart disease only in Type IIb patients without history of or symptoms of existing coronary heart disease who have had an inadequate response to weight loss, dietary therapy, exercise, and other pharmacologic agents (such as bile acid sequestrants and nicotinic acid, known to reduce LDL- and raise HDL-cholesterol) and who have the following triad of lipid abnormalities: low HDL-cholesterol levels in addition to elevated LDL-cholesterol and elevated triglycerides (see WARNINGS , PRECAUTIONS , and CLINICAL PHARMACOLOGY ). The National Cholesterol Education Program has defined a serum HDL-cholesterol value that is consistently below 35 mg/dL as constituting an independent risk factor for coronary heart disease (ref. 6). Patients with significantly elevated triglycerides should be closely observed when treated with gemfibrozil. In some patients with high triglyceride levels, treatment with gemfibrozil is associated with a significant increase in LDL-cholesterol. BECAUSE OF POTENTIAL TOXICITY SUCH AS MALIGNANCY, GALLBLADDER DISEASE, ABDOMINAL PAIN LEADING TO APPENDECTOMY AND OTHER ABDOMINAL SURGERIES, AN INCREASED INCIDENCE IN NONCORONARY MORTALITY, AND THE 44% RELATIVE INCREASE DURING THE TRIAL PERIOD IN AGE-ADJUSTED ALL-CAUSE MORTALITY SEEN WITH THE CHEMICALLY AND PHARMACOLOGICALLY RELATED DRUG, CLOFIBRATE, THE POTENTIAL BENEFIT OF GEMFIBROZIL IN TREATING TYPE IIA PATIENTS WITH ELEVATIONS OF LDL-CHOLESTEROL ONLY IS NOT LIKELY TO OUTWEIGH THE RISKS. GEMFIBROZIL IS ALSO NOT INDICATED FOR THE TREATMENT OF PATIENTS WITH LOW HDL- CHOLESTEROL AS THEIR ONLY LIPID ABNORMALITY. In a subgroup analysis of patients in the Helsinki Heart Study with above-median HDL-cholesterol values at baseline (greater than 46.4 mg/dL), the incidence of serious coronary events was similar for gemfibrozil and placebo subgroups (see Table I ). The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcohol intake may be important factors in hypertriglyceridemia and should be managed prior to any drug therapy. Physical exercise can be an important ancillary measure, and has been associated with rises in HDL-cholesterol. Diseases contributory to hyperlipidemia such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy is sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of estrogen therapy may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with nondrug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet. uuid:9022f0bb-fa57-4029-acb6-52638331362c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5296 biolink:treats MONDO:0004982 PMID:41385096 "[{""id"":""uuid:1e95ee7e-c2fe-45f8-af5f-b4e6be5cfeaf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:98193182-70ee-4e0f-959b-6064737383b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gemfibrozil tablets are indicated as adjunctive therapy to diet for: Treatment of adult patients with very high elevations of serum triglyceride levels (Types IV and V hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Patients who present such risk typically have serum triglycerides over 2000 mg/dL and have elevations of VLDL-cholesterol as well as fasting chylomicrons (Type V hyperlipidemia). Subjects who consistently have total serum or plasma triglycerides below 1000 mg/dL are unlikely to present a risk of pancreatitis. Gemfibrozil therapy may be considered for those subjects with triglyceride elevations between 1000 and 2000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. It is recognized that some Type IV patients with triglycerides under 1000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of gemfibrozil therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia (ref. 5). Reducing the risk of developing coronary heart disease only in Type IIb patients without history of or symptoms of existing coronary heart disease who have had an inadequate response to weight loss, dietary therapy, exercise, and other pharmacologic agents (such as bile acid sequestrants and nicotinic acid, known to reduce LDL- and raise HDL-cholesterol) and who have the following triad of lipid abnormalities: low HDL-cholesterol levels in addition to elevated LDL-cholesterol and elevated triglycerides (see WARNINGS , PRECAUTIONS , and CLINICAL PHARMACOLOGY ). The National Cholesterol Education Program has defined a serum HDL-cholesterol value that is consistently below 35 mg/dL as constituting an independent risk factor for coronary heart disease (ref. 6). Patients with significantly elevated triglycerides should be closely observed when treated with gemfibrozil. In some patients with high triglyceride levels, treatment with gemfibrozil is associated with a significant increase in LDL-cholesterol. BECAUSE OF POTENTIAL TOXICITY SUCH AS MALIGNANCY, GALLBLADDER DISEASE, ABDOMINAL PAIN LEADING TO APPENDECTOMY AND OTHER ABDOMINAL SURGERIES, AN INCREASED INCIDENCE IN NONCORONARY MORTALITY, AND THE 44% RELATIVE INCREASE DURING THE TRIAL PERIOD IN AGE-ADJUSTED ALL-CAUSE MORTALITY SEEN WITH THE CHEMICALLY AND PHARMACOLOGICALLY RELATED DRUG, CLOFIBRATE, THE POTENTIAL BENEFIT OF GEMFIBROZIL IN TREATING TYPE IIA PATIENTS WITH ELEVATIONS OF LDL-CHOLESTEROL ONLY IS NOT LIKELY TO OUTWEIGH THE RISKS. GEMFIBROZIL IS ALSO NOT INDICATED FOR THE TREATMENT OF PATIENTS WITH LOW HDL- CHOLESTEROL AS THEIR ONLY LIPID ABNORMALITY. In a subgroup analysis of patients in the Helsinki Heart Study with above-median HDL-cholesterol values at baseline (greater than 46.4 mg/dL), the incidence of serious coronary events was similar for gemfibrozil and placebo subgroups (see Table I ). The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcohol intake may be important factors in hypertriglyceridemia and should be managed prior to any drug therapy. Physical exercise can be an important ancillary measure, and has been associated with rises in HDL-cholesterol. Diseases contributory to hyperlipidemia such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy is sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of estrogen therapy may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with nondrug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet. uuid:bdc8ab42-17ad-479f-b862-f64cbe3c2d95 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5296 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:4eb3ad92-31a9-44c5-8ced-f0fa15a770e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7cf5276f-1044-4f97-9fa6-3cd82331b0a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gemfibrozil tablets are indicated as adjunctive therapy to diet for: Treatment of adult patients with very high elevations of serum triglyceride levels (Types IV and V hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Patients who present such risk typically have serum triglycerides over 2000 mg/dL and have elevations of VLDL-cholesterol as well as fasting chylomicrons (Type V hyperlipidemia). Subjects who consistently have total serum or plasma triglycerides below 1000 mg/dL are unlikely to present a risk of pancreatitis. Gemfibrozil therapy may be considered for those subjects with triglyceride elevations between 1000 and 2000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. It is recognized that some Type IV patients with triglycerides under 1000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of gemfibrozil therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia (ref. 5). Reducing the risk of developing coronary heart disease only in Type IIb patients without history of or symptoms of existing coronary heart disease who have had an inadequate response to weight loss, dietary therapy, exercise, and other pharmacologic agents (such as bile acid sequestrants and nicotinic acid, known to reduce LDL- and raise HDL-cholesterol) and who have the following triad of lipid abnormalities: low HDL-cholesterol levels in addition to elevated LDL-cholesterol and elevated triglycerides (see WARNINGS , PRECAUTIONS , and CLINICAL PHARMACOLOGY ). The National Cholesterol Education Program has defined a serum HDL-cholesterol value that is consistently below 35 mg/dL as constituting an independent risk factor for coronary heart disease (ref. 6). Patients with significantly elevated triglycerides should be closely observed when treated with gemfibrozil. In some patients with high triglyceride levels, treatment with gemfibrozil is associated with a significant increase in LDL-cholesterol. BECAUSE OF POTENTIAL TOXICITY SUCH AS MALIGNANCY, GALLBLADDER DISEASE, ABDOMINAL PAIN LEADING TO APPENDECTOMY AND OTHER ABDOMINAL SURGERIES, AN INCREASED INCIDENCE IN NONCORONARY MORTALITY, AND THE 44% RELATIVE INCREASE DURING THE TRIAL PERIOD IN AGE-ADJUSTED ALL-CAUSE MORTALITY SEEN WITH THE CHEMICALLY AND PHARMACOLOGICALLY RELATED DRUG, CLOFIBRATE, THE POTENTIAL BENEFIT OF GEMFIBROZIL IN TREATING TYPE IIA PATIENTS WITH ELEVATIONS OF LDL-CHOLESTEROL ONLY IS NOT LIKELY TO OUTWEIGH THE RISKS. GEMFIBROZIL IS ALSO NOT INDICATED FOR THE TREATMENT OF PATIENTS WITH LOW HDL- CHOLESTEROL AS THEIR ONLY LIPID ABNORMALITY. In a subgroup analysis of patients in the Helsinki Heart Study with above-median HDL-cholesterol values at baseline (greater than 46.4 mg/dL), the incidence of serious coronary events was similar for gemfibrozil and placebo subgroups (see Table I ). The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcohol intake may be important factors in hypertriglyceridemia and should be managed prior to any drug therapy. Physical exercise can be an important ancillary measure, and has been associated with rises in HDL-cholesterol. Diseases contributory to hyperlipidemia such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy is sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of estrogen therapy may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with nondrug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet. uuid:c8b90dfd-ab8d-4438-b861-193c97d44044 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5296 biolink:treats MONDO:0007759 PMID:41385096 "[{""id"":""uuid:6bc352b4-fae7-402a-96d2-28a69331cdc4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2072b74d-da53-4bd8-b7eb-905e1cf5b745"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gemfibrozil tablets are indicated as adjunctive therapy to diet for: Treatment of adult patients with very high elevations of serum triglyceride levels (Types IV and V hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Patients who present such risk typically have serum triglycerides over 2000 mg/dL and have elevations of VLDL-cholesterol as well as fasting chylomicrons (Type V hyperlipidemia). Subjects who consistently have total serum or plasma triglycerides below 1000 mg/dL are unlikely to present a risk of pancreatitis. Gemfibrozil therapy may be considered for those subjects with triglyceride elevations between 1000 and 2000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. It is recognized that some Type IV patients with triglycerides under 1000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of gemfibrozil therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia (ref. 5). Reducing the risk of developing coronary heart disease only in Type IIb patients without history of or symptoms of existing coronary heart disease who have had an inadequate response to weight loss, dietary therapy, exercise, and other pharmacologic agents (such as bile acid sequestrants and nicotinic acid, known to reduce LDL- and raise HDL-cholesterol) and who have the following triad of lipid abnormalities: low HDL-cholesterol levels in addition to elevated LDL-cholesterol and elevated triglycerides (see WARNINGS , PRECAUTIONS , and CLINICAL PHARMACOLOGY ). The National Cholesterol Education Program has defined a serum HDL-cholesterol value that is consistently below 35 mg/dL as constituting an independent risk factor for coronary heart disease (ref. 6). Patients with significantly elevated triglycerides should be closely observed when treated with gemfibrozil. In some patients with high triglyceride levels, treatment with gemfibrozil is associated with a significant increase in LDL-cholesterol. BECAUSE OF POTENTIAL TOXICITY SUCH AS MALIGNANCY, GALLBLADDER DISEASE, ABDOMINAL PAIN LEADING TO APPENDECTOMY AND OTHER ABDOMINAL SURGERIES, AN INCREASED INCIDENCE IN NONCORONARY MORTALITY, AND THE 44% RELATIVE INCREASE DURING THE TRIAL PERIOD IN AGE-ADJUSTED ALL-CAUSE MORTALITY SEEN WITH THE CHEMICALLY AND PHARMACOLOGICALLY RELATED DRUG, CLOFIBRATE, THE POTENTIAL BENEFIT OF GEMFIBROZIL IN TREATING TYPE IIA PATIENTS WITH ELEVATIONS OF LDL-CHOLESTEROL ONLY IS NOT LIKELY TO OUTWEIGH THE RISKS. GEMFIBROZIL IS ALSO NOT INDICATED FOR THE TREATMENT OF PATIENTS WITH LOW HDL- CHOLESTEROL AS THEIR ONLY LIPID ABNORMALITY. In a subgroup analysis of patients in the Helsinki Heart Study with above-median HDL-cholesterol values at baseline (greater than 46.4 mg/dL), the incidence of serious coronary events was similar for gemfibrozil and placebo subgroups (see Table I ). The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcohol intake may be important factors in hypertriglyceridemia and should be managed prior to any drug therapy. Physical exercise can be an important ancillary measure, and has been associated with rises in HDL-cholesterol. Diseases contributory to hyperlipidemia such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy is sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of estrogen therapy may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with nondrug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet. uuid:65f05643-1a19-4805-a1b9-b5ee586fd877 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5296 biolink:treats MONDO:0009387 PMID:41385096 "[{""id"":""uuid:51abf7e4-afea-40fb-b10e-fdb57588723e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9fb30ee9-b5e1-46a6-ba32-de277bc0ea7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gemfibrozil tablets are indicated as adjunctive therapy to diet for: Treatment of adult patients with very high elevations of serum triglyceride levels (Types IV and V hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Patients who present such risk typically have serum triglycerides over 2000 mg/dL and have elevations of VLDL-cholesterol as well as fasting chylomicrons (Type V hyperlipidemia). Subjects who consistently have total serum or plasma triglycerides below 1000 mg/dL are unlikely to present a risk of pancreatitis. Gemfibrozil therapy may be considered for those subjects with triglyceride elevations between 1000 and 2000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. It is recognized that some Type IV patients with triglycerides under 1000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of gemfibrozil therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia (ref. 5). Reducing the risk of developing coronary heart disease only in Type IIb patients without history of or symptoms of existing coronary heart disease who have had an inadequate response to weight loss, dietary therapy, exercise, and other pharmacologic agents (such as bile acid sequestrants and nicotinic acid, known to reduce LDL- and raise HDL-cholesterol) and who have the following triad of lipid abnormalities: low HDL-cholesterol levels in addition to elevated LDL-cholesterol and elevated triglycerides (see WARNINGS , PRECAUTIONS , and CLINICAL PHARMACOLOGY ). The National Cholesterol Education Program has defined a serum HDL-cholesterol value that is consistently below 35 mg/dL as constituting an independent risk factor for coronary heart disease (ref. 6). Patients with significantly elevated triglycerides should be closely observed when treated with gemfibrozil. In some patients with high triglyceride levels, treatment with gemfibrozil is associated with a significant increase in LDL-cholesterol. BECAUSE OF POTENTIAL TOXICITY SUCH AS MALIGNANCY, GALLBLADDER DISEASE, ABDOMINAL PAIN LEADING TO APPENDECTOMY AND OTHER ABDOMINAL SURGERIES, AN INCREASED INCIDENCE IN NONCORONARY MORTALITY, AND THE 44% RELATIVE INCREASE DURING THE TRIAL PERIOD IN AGE-ADJUSTED ALL-CAUSE MORTALITY SEEN WITH THE CHEMICALLY AND PHARMACOLOGICALLY RELATED DRUG, CLOFIBRATE, THE POTENTIAL BENEFIT OF GEMFIBROZIL IN TREATING TYPE IIA PATIENTS WITH ELEVATIONS OF LDL-CHOLESTEROL ONLY IS NOT LIKELY TO OUTWEIGH THE RISKS. GEMFIBROZIL IS ALSO NOT INDICATED FOR THE TREATMENT OF PATIENTS WITH LOW HDL- CHOLESTEROL AS THEIR ONLY LIPID ABNORMALITY. In a subgroup analysis of patients in the Helsinki Heart Study with above-median HDL-cholesterol values at baseline (greater than 46.4 mg/dL), the incidence of serious coronary events was similar for gemfibrozil and placebo subgroups (see Table I ). The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcohol intake may be important factors in hypertriglyceridemia and should be managed prior to any drug therapy. Physical exercise can be an important ancillary measure, and has been associated with rises in HDL-cholesterol. Diseases contributory to hyperlipidemia such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy is sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of estrogen therapy may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with nondrug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet. uuid:a7c59820-5f9d-4524-ae00-e47f8860fa1d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5296 biolink:treats MONDO:0005420 PMID:41385096 "[{""id"":""uuid:9f8ce306-8d46-4ca7-9566-b5381b36e852"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:90490384-9604-48da-9d3b-3ef519af4552"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gemfibrozil tablets are indicated as adjunctive therapy to diet for: Treatment of adult patients with very high elevations of serum triglyceride levels (Types IV and V hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Patients who present such risk typically have serum triglycerides over 2000 mg/dL and have elevations of VLDL-cholesterol as well as fasting chylomicrons (Type V hyperlipidemia). Subjects who consistently have total serum or plasma triglycerides below 1000 mg/dL are unlikely to present a risk of pancreatitis. Gemfibrozil therapy may be considered for those subjects with triglyceride elevations between 1000 and 2000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. It is recognized that some Type IV patients with triglycerides under 1000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of gemfibrozil therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia (ref. 5). Reducing the risk of developing coronary heart disease only in Type IIb patients without history of or symptoms of existing coronary heart disease who have had an inadequate response to weight loss, dietary therapy, exercise, and other pharmacologic agents (such as bile acid sequestrants and nicotinic acid, known to reduce LDL- and raise HDL-cholesterol) and who have the following triad of lipid abnormalities: low HDL-cholesterol levels in addition to elevated LDL-cholesterol and elevated triglycerides (see WARNINGS , PRECAUTIONS , and CLINICAL PHARMACOLOGY ). The National Cholesterol Education Program has defined a serum HDL-cholesterol value that is consistently below 35 mg/dL as constituting an independent risk factor for coronary heart disease (ref. 6). Patients with significantly elevated triglycerides should be closely observed when treated with gemfibrozil. In some patients with high triglyceride levels, treatment with gemfibrozil is associated with a significant increase in LDL-cholesterol. BECAUSE OF POTENTIAL TOXICITY SUCH AS MALIGNANCY, GALLBLADDER DISEASE, ABDOMINAL PAIN LEADING TO APPENDECTOMY AND OTHER ABDOMINAL SURGERIES, AN INCREASED INCIDENCE IN NONCORONARY MORTALITY, AND THE 44% RELATIVE INCREASE DURING THE TRIAL PERIOD IN AGE-ADJUSTED ALL-CAUSE MORTALITY SEEN WITH THE CHEMICALLY AND PHARMACOLOGICALLY RELATED DRUG, CLOFIBRATE, THE POTENTIAL BENEFIT OF GEMFIBROZIL IN TREATING TYPE IIA PATIENTS WITH ELEVATIONS OF LDL-CHOLESTEROL ONLY IS NOT LIKELY TO OUTWEIGH THE RISKS. GEMFIBROZIL IS ALSO NOT INDICATED FOR THE TREATMENT OF PATIENTS WITH LOW HDL- CHOLESTEROL AS THEIR ONLY LIPID ABNORMALITY. In a subgroup analysis of patients in the Helsinki Heart Study with above-median HDL-cholesterol values at baseline (greater than 46.4 mg/dL), the incidence of serious coronary events was similar for gemfibrozil and placebo subgroups (see Table I ). The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcohol intake may be important factors in hypertriglyceridemia and should be managed prior to any drug therapy. Physical exercise can be an important ancillary measure, and has been associated with rises in HDL-cholesterol. Diseases contributory to hyperlipidemia such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy is sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of estrogen therapy may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with nondrug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet. uuid:57389cc7-be1d-4807-a5ed-3bd7a0275493 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5296 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:1971fa69-e1b7-4172-9d31-68f396d92490"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b68e22c5-ab59-4d54-b8e6-bddcc7c76ce7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gemfibrozil tablets are indicated as adjunctive therapy to diet for: Treatment of adult patients with very high elevations of serum triglyceride levels (Types IV and V hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Patients who present such risk typically have serum triglycerides over 2000 mg/dL and have elevations of VLDL-cholesterol as well as fasting chylomicrons (Type V hyperlipidemia). Subjects who consistently have total serum or plasma triglycerides below 1000 mg/dL are unlikely to present a risk of pancreatitis. Gemfibrozil therapy may be considered for those subjects with triglyceride elevations between 1000 and 2000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. It is recognized that some Type IV patients with triglycerides under 1000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of gemfibrozil therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia (ref. 5). Reducing the risk of developing coronary heart disease only in Type IIb patients without history of or symptoms of existing coronary heart disease who have had an inadequate response to weight loss, dietary therapy, exercise, and other pharmacologic agents (such as bile acid sequestrants and nicotinic acid, known to reduce LDL- and raise HDL-cholesterol) and who have the following triad of lipid abnormalities: low HDL-cholesterol levels in addition to elevated LDL-cholesterol and elevated triglycerides (see WARNINGS , PRECAUTIONS , and CLINICAL PHARMACOLOGY ). The National Cholesterol Education Program has defined a serum HDL-cholesterol value that is consistently below 35 mg/dL as constituting an independent risk factor for coronary heart disease (ref. 6). Patients with significantly elevated triglycerides should be closely observed when treated with gemfibrozil. In some patients with high triglyceride levels, treatment with gemfibrozil is associated with a significant increase in LDL-cholesterol. BECAUSE OF POTENTIAL TOXICITY SUCH AS MALIGNANCY, GALLBLADDER DISEASE, ABDOMINAL PAIN LEADING TO APPENDECTOMY AND OTHER ABDOMINAL SURGERIES, AN INCREASED INCIDENCE IN NONCORONARY MORTALITY, AND THE 44% RELATIVE INCREASE DURING THE TRIAL PERIOD IN AGE-ADJUSTED ALL-CAUSE MORTALITY SEEN WITH THE CHEMICALLY AND PHARMACOLOGICALLY RELATED DRUG, CLOFIBRATE, THE POTENTIAL BENEFIT OF GEMFIBROZIL IN TREATING TYPE IIA PATIENTS WITH ELEVATIONS OF LDL-CHOLESTEROL ONLY IS NOT LIKELY TO OUTWEIGH THE RISKS. GEMFIBROZIL IS ALSO NOT INDICATED FOR THE TREATMENT OF PATIENTS WITH LOW HDL- CHOLESTEROL AS THEIR ONLY LIPID ABNORMALITY. In a subgroup analysis of patients in the Helsinki Heart Study with above-median HDL-cholesterol values at baseline (greater than 46.4 mg/dL), the incidence of serious coronary events was similar for gemfibrozil and placebo subgroups (see Table I ). The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcohol intake may be important factors in hypertriglyceridemia and should be managed prior to any drug therapy. Physical exercise can be an important ancillary measure, and has been associated with rises in HDL-cholesterol. Diseases contributory to hyperlipidemia such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy is sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of estrogen therapy may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with nondrug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet. uuid:34e50110-5ad6-4277-815e-1d1b3807bb87 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5296 biolink:treats MONDO:0005347 PMID:41385096 "[{""id"":""uuid:efd0b77c-3fc3-4147-9103-692a42248a53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3364696a-38fb-4d3e-a2eb-25f1f0bc227a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gemfibrozil tablets are indicated as adjunctive therapy to diet for: Treatment of adult patients with very high elevations of serum triglyceride levels (Types IV and V hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Patients who present such risk typically have serum triglycerides over 2000 mg/dL and have elevations of VLDL-cholesterol as well as fasting chylomicrons (Type V hyperlipidemia). Subjects who consistently have total serum or plasma triglycerides below 1000 mg/dL are unlikely to present a risk of pancreatitis. Gemfibrozil therapy may be considered for those subjects with triglyceride elevations between 1000 and 2000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. It is recognized that some Type IV patients with triglycerides under 1000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of gemfibrozil therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia (ref. 5). Reducing the risk of developing coronary heart disease only in Type IIb patients without history of or symptoms of existing coronary heart disease who have had an inadequate response to weight loss, dietary therapy, exercise, and other pharmacologic agents (such as bile acid sequestrants and nicotinic acid, known to reduce LDL- and raise HDL-cholesterol) and who have the following triad of lipid abnormalities: low HDL-cholesterol levels in addition to elevated LDL-cholesterol and elevated triglycerides (see WARNINGS , PRECAUTIONS , and CLINICAL PHARMACOLOGY ). The National Cholesterol Education Program has defined a serum HDL-cholesterol value that is consistently below 35 mg/dL as constituting an independent risk factor for coronary heart disease (ref. 6). Patients with significantly elevated triglycerides should be closely observed when treated with gemfibrozil. In some patients with high triglyceride levels, treatment with gemfibrozil is associated with a significant increase in LDL-cholesterol. BECAUSE OF POTENTIAL TOXICITY SUCH AS MALIGNANCY, GALLBLADDER DISEASE, ABDOMINAL PAIN LEADING TO APPENDECTOMY AND OTHER ABDOMINAL SURGERIES, AN INCREASED INCIDENCE IN NONCORONARY MORTALITY, AND THE 44% RELATIVE INCREASE DURING THE TRIAL PERIOD IN AGE-ADJUSTED ALL-CAUSE MORTALITY SEEN WITH THE CHEMICALLY AND PHARMACOLOGICALLY RELATED DRUG, CLOFIBRATE, THE POTENTIAL BENEFIT OF GEMFIBROZIL IN TREATING TYPE IIA PATIENTS WITH ELEVATIONS OF LDL-CHOLESTEROL ONLY IS NOT LIKELY TO OUTWEIGH THE RISKS. GEMFIBROZIL IS ALSO NOT INDICATED FOR THE TREATMENT OF PATIENTS WITH LOW HDL- CHOLESTEROL AS THEIR ONLY LIPID ABNORMALITY. In a subgroup analysis of patients in the Helsinki Heart Study with above-median HDL-cholesterol values at baseline (greater than 46.4 mg/dL), the incidence of serious coronary events was similar for gemfibrozil and placebo subgroups (see Table I ). The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcohol intake may be important factors in hypertriglyceridemia and should be managed prior to any drug therapy. Physical exercise can be an important ancillary measure, and has been associated with rises in HDL-cholesterol. Diseases contributory to hyperlipidemia such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy is sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of estrogen therapy may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with nondrug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet. uuid:88bf34bb-2b98-413b-9704-828897dc0d11 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5296 biolink:treats HP:0003119 PMID:41385096 "[{""id"":""uuid:61769538-0fdd-4bc1-b33a-4ca5182b4b08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:85495350-7ee9-47a1-98b3-730004507a73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gemfibrozil tablets are indicated as adjunctive therapy to diet for: Treatment of adult patients with very high elevations of serum triglyceride levels (Types IV and V hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Patients who present such risk typically have serum triglycerides over 2000 mg/dL and have elevations of VLDL-cholesterol as well as fasting chylomicrons (Type V hyperlipidemia). Subjects who consistently have total serum or plasma triglycerides below 1000 mg/dL are unlikely to present a risk of pancreatitis. Gemfibrozil therapy may be considered for those subjects with triglyceride elevations between 1000 and 2000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. It is recognized that some Type IV patients with triglycerides under 1000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of gemfibrozil therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia (ref. 5). Reducing the risk of developing coronary heart disease only in Type IIb patients without history of or symptoms of existing coronary heart disease who have had an inadequate response to weight loss, dietary therapy, exercise, and other pharmacologic agents (such as bile acid sequestrants and nicotinic acid, known to reduce LDL- and raise HDL-cholesterol) and who have the following triad of lipid abnormalities: low HDL-cholesterol levels in addition to elevated LDL-cholesterol and elevated triglycerides (see WARNINGS , PRECAUTIONS , and CLINICAL PHARMACOLOGY ). The National Cholesterol Education Program has defined a serum HDL-cholesterol value that is consistently below 35 mg/dL as constituting an independent risk factor for coronary heart disease (ref. 6). Patients with significantly elevated triglycerides should be closely observed when treated with gemfibrozil. In some patients with high triglyceride levels, treatment with gemfibrozil is associated with a significant increase in LDL-cholesterol. BECAUSE OF POTENTIAL TOXICITY SUCH AS MALIGNANCY, GALLBLADDER DISEASE, ABDOMINAL PAIN LEADING TO APPENDECTOMY AND OTHER ABDOMINAL SURGERIES, AN INCREASED INCIDENCE IN NONCORONARY MORTALITY, AND THE 44% RELATIVE INCREASE DURING THE TRIAL PERIOD IN AGE-ADJUSTED ALL-CAUSE MORTALITY SEEN WITH THE CHEMICALLY AND PHARMACOLOGICALLY RELATED DRUG, CLOFIBRATE, THE POTENTIAL BENEFIT OF GEMFIBROZIL IN TREATING TYPE IIA PATIENTS WITH ELEVATIONS OF LDL-CHOLESTEROL ONLY IS NOT LIKELY TO OUTWEIGH THE RISKS. GEMFIBROZIL IS ALSO NOT INDICATED FOR THE TREATMENT OF PATIENTS WITH LOW HDL- CHOLESTEROL AS THEIR ONLY LIPID ABNORMALITY. In a subgroup analysis of patients in the Helsinki Heart Study with above-median HDL-cholesterol values at baseline (greater than 46.4 mg/dL), the incidence of serious coronary events was similar for gemfibrozil and placebo subgroups (see Table I ). The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcohol intake may be important factors in hypertriglyceridemia and should be managed prior to any drug therapy. Physical exercise can be an important ancillary measure, and has been associated with rises in HDL-cholesterol. Diseases contributory to hyperlipidemia such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy is sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of estrogen therapy may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with nondrug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet. uuid:fd496811-c2da-491b-a893-5f18638f45fb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6344 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:d112d80a-c814-4571-a1d7-5eddb8545227"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9189a4da-84f2-4457-8913-bcaae0f5b71d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Labetalol hydrochloride tablets are indicated in the management of hypertension. Labetalol tablets may be used alone or in combination with other antihypertensive agents, especially thiazide and loop diuretics. uuid:10eea5f2-3d8c-41be-be07-c010e7ef659b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3310 biolink:treats MONDO:0000328 PMID:41385096 "[{""id"":""uuid:099d05d7-339e-4be2-9b26-bc6cb380722f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:911fe31d-3ede-41f1-afad-907039b42fd9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PhosLo is indicated for the control of hyperphosphatemia in end stage renal failure and does not promote aluminum absorption. uuid:22270541-21e1-4661-a8c3-217a20dc2003 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3310 biolink:treats MONDO:0004375 PMID:41385096 "[{""id"":""uuid:2a26df56-7f2f-4eb4-9328-a0f98f045656"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:542d6b98-ddaf-4ba9-8f26-e3b4d6e6298d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PhosLo is indicated for the control of hyperphosphatemia in end stage renal failure and does not promote aluminum absorption. uuid:eef65d62-1dc0-464f-a807-25cf73c7ffa5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6060 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:3f596a2b-dac2-40de-a856-884e891282dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:335cfd72-c7be-4c35-a454-606f46d08c31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] dilatrate®-SR sustained release capsules are indicated for the prevention of angina pectoris due to coronary artery disease. The onset of action of controlled-release oral isosorbide dinitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episode. uuid:c6b67f91-5b66-49c1-819a-fa842d74ffc0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6060 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:9336704b-131e-4b25-8710-8e167c3bec47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a10e4385-3bcf-4b41-a667-100c600bb780"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] dilatrate®-SR sustained release capsules are indicated for the prevention of angina pectoris due to coronary artery disease. The onset of action of controlled-release oral isosorbide dinitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episode. uuid:b369ae9d-123c-4ef8-b0a4-5ac96d4fc413 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27470 biolink:treats MONDO:0001700 PMID:41385096 "[{""id"":""uuid:ef4c8898-dd21-4eff-a7c0-afc2a81d7028"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0762ee19-75f9-4600-98ff-9c1fe75326da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Folic acid is effective in the treatment of megaloblastic anemias due to a deficiency of folic acid (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, pregnancy, infancy, or childhood. uuid:8a64b1ea-706c-4779-b565-270a4f2720f0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27470 biolink:treats MONDO:0001078 PMID:41385096 "[{""id"":""uuid:3374983d-e25b-43b6-84d5-6a939229e0af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6881e155-cdca-4725-9630-9fb0912e4dc3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Folic acid is effective in the treatment of megaloblastic anemias due to a deficiency of folic acid (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, pregnancy, infancy, or childhood. uuid:fecef476-a323-4d7b-ab2f-cf7bbd004622 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27470 biolink:treats MONDO:0005130 PMID:41385096 "[{""id"":""uuid:bbd09085-3501-4949-9c18-5b5d33acc6c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ecd4d3f4-4f73-498d-afb9-24a48a8f13fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Folic acid is effective in the treatment of megaloblastic anemias due to a deficiency of folic acid (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, pregnancy, infancy, or childhood. uuid:381ad2b9-f8d8-4528-9a8b-230d69e968a8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27470 biolink:treats UMLS:C0271903 PMID:41385096 "[{""id"":""uuid:f023d29a-c754-419b-a0dd-e75f9ce0776d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5012ec16-b548-4fe3-a37b-be2cfd03ee16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Folic acid is effective in the treatment of megaloblastic anemias due to a deficiency of folic acid (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, pregnancy, infancy, or childhood. uuid:bc5576c0-ac73-4474-850b-54ab24153cf6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0005093 PMID:41385096 "[{""id"":""uuid:4eb27370-30e4-4d74-a95e-400ae4720aed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d5314b6f-e7f0-4cf0-b50f-d071dd6d34f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Augmented Betamethasone Dipropionate Ointment is indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. uuid:12961bb2-3aa3-4d74-8d98-74a74f290434 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2549 biolink:treats MONDO:0001358 PMID:41385096 "[{""id"":""uuid:4ba97140-cc58-4843-9ef7-5f3527ea2727"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f77cc644-6f65-4e34-8828-df1a102d456a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Albuterol Inhalation Aerosol is indicated in patients 12 years of age and older, for the prevention and relief of bronchospasm in patients with reversible obstructive airway disease, and for the prevention of exercise-induced bronchospasm. uuid:0a7c9e5d-154e-4315-9b8c-4bc1392898b7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2549 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:ad8421e5-0257-4fa2-8b8d-4b279ede5554"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:119a009d-484e-4263-94c2-bfba32bacda7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Albuterol Inhalation Aerosol is indicated in patients 12 years of age and older, for the prevention and relief of bronchospasm in patients with reversible obstructive airway disease, and for the prevention of exercise-induced bronchospasm. uuid:b7627f94-6a88-4595-acbb-6481ed32f633 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2549 biolink:treats MONDO:0850286 PMID:41385096 "[{""id"":""uuid:c58232ef-9d25-4253-9e07-328016a0a94e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:834393b6-fade-44cb-b65a-03a85ccf8f5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Albuterol Inhalation Aerosol is indicated in patients 12 years of age and older, for the prevention and relief of bronchospasm in patients with reversible obstructive airway disease, and for the prevention of exercise-induced bronchospasm. UMLS:C0015263 uuid:81197c93-b680-4472-b14d-0c02acc4d7dd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:187893 biolink:treats HP:0002169 PMID:41385096 "[{""id"":""uuid:9feec04d-e08e-403b-8023-bd6ed0673a8e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:62c27b86-b930-48d1-b179-12b10c79f5cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Baclofen is useful for the alleviation of signs and symptoms of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. Patients should have reversible spasticity so that baclofen treatment will aid in restoring residual function. Baclofen may also be of some value in patients with spinal cord injuries and other spinal cord diseases. Baclofen is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. The efficacy of baclofen in stroke, cerebral palsy, and Parkinson’s disease has not been established and, therefore, it is not recommended for these conditions. uuid:e45974c1-ab12-4977-8320-dc9f04c1bcc7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:187893 biolink:treats HP:0002063 PMID:41385096 "[{""id"":""uuid:281511b9-e9fd-4716-947b-19732e3a243d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:17616706-2d76-4512-b53c-3130b353b7a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Baclofen is useful for the alleviation of signs and symptoms of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. Patients should have reversible spasticity so that baclofen treatment will aid in restoring residual function. Baclofen may also be of some value in patients with spinal cord injuries and other spinal cord diseases. Baclofen is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. The efficacy of baclofen in stroke, cerebral palsy, and Parkinson’s disease has not been established and, therefore, it is not recommended for these conditions. uuid:284b9a86-fb7f-4a13-88f2-38c4819ff000 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:187893 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:4b88c96f-9ad1-496a-814b-ec88e458ceac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d825393f-806a-4a6a-a22e-a4fb518488e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Baclofen is useful for the alleviation of signs and symptoms of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. Patients should have reversible spasticity so that baclofen treatment will aid in restoring residual function. Baclofen may also be of some value in patients with spinal cord injuries and other spinal cord diseases. Baclofen is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. The efficacy of baclofen in stroke, cerebral palsy, and Parkinson’s disease has not been established and, therefore, it is not recommended for these conditions. uuid:2ec78cb5-41fc-4c2b-bed3-305237d037de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:187893 biolink:treats MONDO:0006497 PMID:41385096 "[{""id"":""uuid:b542532e-7885-4059-b050-e3935a6601f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ca12819f-c61c-45e4-8488-e675bacef315"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Baclofen is useful for the alleviation of signs and symptoms of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. Patients should have reversible spasticity so that baclofen treatment will aid in restoring residual function. Baclofen may also be of some value in patients with spinal cord injuries and other spinal cord diseases. Baclofen is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. The efficacy of baclofen in stroke, cerebral palsy, and Parkinson’s disease has not been established and, therefore, it is not recommended for these conditions. uuid:5c99e08d-0fa0-4f39-b9fd-87478d1df3a1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:187893 biolink:treats MONDO:0005180 PMID:41385096 "[{""id"":""uuid:7abd1e2c-4032-417c-8f14-33367be66bc3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c118ef2d-87a3-4a09-b3a1-84552a1714f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Baclofen is useful for the alleviation of signs and symptoms of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. Patients should have reversible spasticity so that baclofen treatment will aid in restoring residual function. Baclofen may also be of some value in patients with spinal cord injuries and other spinal cord diseases. Baclofen is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. The efficacy of baclofen in stroke, cerebral palsy, and Parkinson’s disease has not been established and, therefore, it is not recommended for these conditions. uuid:bfeafa10-c3ca-4174-b2c7-ee6f979322e3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42797 biolink:treats MONDO:0041052 PMID:41385096 "[{""id"":""uuid:9c8b795d-c41b-4833-bc3f-d556c5ff1a6c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0d0ad1cb-76c4-459c-819a-c7d0ddef3e2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gabapentin is indicated for the management of postherpetic neuralgia in adults. uuid:669e78b2-0706-40e6-b60b-90de4e10e644 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5141 biolink:treats MONDO:0017861 PMID:41385096 "[{""id"":""uuid:dc35873f-5288-4f05-9b52-faca60fe0528"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e7432a20-d7f8-47d0-879b-beb06da8781f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:14adaf2f-01db-43a5-a84a-0c32488f93ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Antizol is indicated as an antidote for ethylene glycol (such as antifreeze) or methanol poisoning, or for use in suspected ethylene glycol or methanol ingestion, either alone or in combination with hemodialysis (see DOSAGE AND ADMINISTRATION ).|[PMDA] A drug with a new active ingredient indicated for the treatment of ethylene glycol and methanol poisonings. uuid:1bde638f-b1c5-411c-a8f2-388754f9a487 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5141 biolink:treats MONDO:0017860 PMID:41385096 "[{""id"":""uuid:a3da7f49-4956-4d01-9b30-4914fd1fd5c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6236bdc0-27d5-478e-b2cd-8be4c0431026"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:5d69f3cf-62a0-48aa-96ed-4645e0a7c234"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Antizol is indicated as an antidote for ethylene glycol (such as antifreeze) or methanol poisoning, or for use in suspected ethylene glycol or methanol ingestion, either alone or in combination with hemodialysis (see DOSAGE AND ADMINISTRATION ).|[PMDA] A drug with a new active ingredient indicated for the treatment of ethylene glycol and methanol poisonings. uuid:190aa270-a62d-4ea0-a7c2-d8239c4a1da2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7466 biolink:treats MONDO:0002280 PMID:41385096 "[{""id"":""uuid:93390588-bb8d-4ff5-818c-9dede66f44b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6239b9b0-b108-4f96-9928-62954e80203d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nandrolone decanoate is indicated for the management of the anemia of renal insufficiency and has been shown to increase hemoglobin and red cell mass. Surgically induced anephric patients have been reported to be less responsive. uuid:76beb6bc-b8a4-41a5-9ddc-6fc8faf15b64 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9637 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:e827636c-5ef7-4393-acd3-7add7be47887"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e0d65ffa-738b-4a80-91bf-01166e6902cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DEMADEX is indicated for the treatment of edema associated with congestive heart failure, renal disease, or hepatic disease. Use of torsemide has been found to be effective for the treatment of edema associated with chronic renal failure. Chronic use of any diuretic in hepatic disease has not been studied in adequate and well-controlled trials. DEMADEX intravenous injection is indicated when a rapid onset of diuresis is desired or when oral administration is impractical. DEMADEX is indicated for the treatment of hypertension alone or in combination with other antihypertensive agents. uuid:ac017bb5-b24e-4920-b023-d4050ccf9214 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9637 biolink:treats MONDO:0005240 PMID:41385096 "[{""id"":""uuid:4863f53b-68af-49f6-834a-984471a61f9d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a3567f68-b9e0-4707-acf7-d31b8eea34c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DEMADEX is indicated for the treatment of edema associated with congestive heart failure, renal disease, or hepatic disease. Use of torsemide has been found to be effective for the treatment of edema associated with chronic renal failure. Chronic use of any diuretic in hepatic disease has not been studied in adequate and well-controlled trials. DEMADEX intravenous injection is indicated when a rapid onset of diuresis is desired or when oral administration is impractical. DEMADEX is indicated for the treatment of hypertension alone or in combination with other antihypertensive agents. uuid:4be23ad3-317c-4cef-95d6-ca3931270f30 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9637 biolink:treats MONDO:0005154 PMID:41385096 "[{""id"":""uuid:9fc7e2c1-01ad-432e-8775-702977ec40c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:05db53ec-5eb5-4105-8435-87c8c6286721"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DEMADEX is indicated for the treatment of edema associated with congestive heart failure, renal disease, or hepatic disease. Use of torsemide has been found to be effective for the treatment of edema associated with chronic renal failure. Chronic use of any diuretic in hepatic disease has not been studied in adequate and well-controlled trials. DEMADEX intravenous injection is indicated when a rapid onset of diuresis is desired or when oral administration is impractical. DEMADEX is indicated for the treatment of hypertension alone or in combination with other antihypertensive agents. uuid:6cb1ad09-4e50-414d-80ff-00c1f1e6d5dd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9637 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:b55a6bd3-b286-4b7c-b1b8-9dcb1d910b6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:89510b46-1b8f-4876-b7d8-0397c4e7697d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DEMADEX is indicated for the treatment of edema associated with congestive heart failure, renal disease, or hepatic disease. Use of torsemide has been found to be effective for the treatment of edema associated with chronic renal failure. Chronic use of any diuretic in hepatic disease has not been studied in adequate and well-controlled trials. DEMADEX intravenous injection is indicated when a rapid onset of diuresis is desired or when oral administration is impractical. DEMADEX is indicated for the treatment of hypertension alone or in combination with other antihypertensive agents. uuid:67a54c70-ea9e-4893-aab7-1743f4d06725 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9637 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:0f2e5146-9a55-41c1-bc91-256af1bd53e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c4217bc4-9669-4363-b319-e0d9f90f0afe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DEMADEX is indicated for the treatment of edema associated with congestive heart failure, renal disease, or hepatic disease. Use of torsemide has been found to be effective for the treatment of edema associated with chronic renal failure. Chronic use of any diuretic in hepatic disease has not been studied in adequate and well-controlled trials. DEMADEX intravenous injection is indicated when a rapid onset of diuresis is desired or when oral administration is impractical. DEMADEX is indicated for the treatment of hypertension alone or in combination with other antihypertensive agents. uuid:d3391eec-73cf-48bf-bd1c-6bfdac62fe19 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7025 biolink:treats MONDO:0004592 PMID:41385096 "[{""id"":""uuid:a2422c36-c8bc-4d75-909d-c53ea4fcf253"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:825dbcff-d417-457c-8879-5c76b477214b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Centany (mupirocin ointment),2% is indicated for the topical treatment of impetigo due to: Staphylococcus aureus and Streptococcus pyogenes . uuid:1273f466-435c-4a56-9fb6-8ee9987e753d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7025 biolink:treats MONDO:0005545 PMID:41385096 "[{""id"":""uuid:dda2b5d7-04a3-46af-917e-9ff26bebdcfb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:664057e6-e633-4082-8de7-9e9fb02f2837"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Centany (mupirocin ointment),2% is indicated for the topical treatment of impetigo due to: Staphylococcus aureus and Streptococcus pyogenes . uuid:97e35ed6-2f19-44e1-a328-7fa74022bf6f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7025 biolink:treats UMLS:C0554628 PMID:41385096 "[{""id"":""uuid:df7f9099-ee0c-4fc3-82df-fcb956f9a52e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fbaf18cf-2d6e-4b5e-83bd-a07afdad0741"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Centany (mupirocin ointment),2% is indicated for the topical treatment of impetigo due to: Staphylococcus aureus and Streptococcus pyogenes . uuid:aab188f9-7731-43ba-9afb-a9c487f899c6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841838 biolink:treats MONDO:0006668 PMID:41385096 "[{""id"":""uuid:0665345c-3313-46d7-bc39-4c57b4893ad5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2fe6abaf-ac69-4d59-b92a-57ffb4f2d3dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FML-S® ophthalmic suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe, where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The anti-infective drug in this product, sulfacetamide, is active against the following common bacterial eye pathogens: Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus (viridans group), Haemophilus influenzae, Klebsiella species, and Enterobacter species. This product does not provide adequate coverage against Neisseria species and Serratia marcescens. A significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. uuid:b0079bbe-b43f-4062-a4f9-769217c09322 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841838 biolink:treats UMLS:C0008690 PMID:41385096 "[{""id"":""uuid:c98d5c64-d010-4c48-8f72-659be5165cb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3683de45-35c5-4f12-87e1-618caeb65e02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FML-S® ophthalmic suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe, where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The anti-infective drug in this product, sulfacetamide, is active against the following common bacterial eye pathogens: Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus (viridans group), Haemophilus influenzae, Klebsiella species, and Enterobacter species. This product does not provide adequate coverage against Neisseria species and Serratia marcescens. A significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. uuid:ba3a7217-9d95-4f35-b44e-6f53533bb0b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841838 biolink:treats UMLS:C0339289 PMID:41385096 "[{""id"":""uuid:c0eca5bf-dfd3-4a25-85e9-ee88d1ee9415"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f980b52a-9dd9-46bc-81b4-1ecf1805d10d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FML-S® ophthalmic suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe, where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The anti-infective drug in this product, sulfacetamide, is active against the following common bacterial eye pathogens: Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus (viridans group), Haemophilus influenzae, Klebsiella species, and Enterobacter species. This product does not provide adequate coverage against Neisseria species and Serratia marcescens. A significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. uuid:fed7b048-1bcb-425f-b629-38a934613b29 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841838 biolink:treats MONDO:0020920 PMID:41385096 "[{""id"":""uuid:0314aeae-47b8-49bf-b1e5-d3d31c4af7a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0bc98e1a-e5b4-4840-9c40-381f06521ae8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FML-S® ophthalmic suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe, where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The anti-infective drug in this product, sulfacetamide, is active against the following common bacterial eye pathogens: Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus (viridans group), Haemophilus influenzae, Klebsiella species, and Enterobacter species. This product does not provide adequate coverage against Neisseria species and Serratia marcescens. A significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. uuid:09462c8d-aaaa-46b0-856c-b5207db50bee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841838 biolink:treats MONDO:0005545 PMID:41385096 "[{""id"":""uuid:452c55ae-e850-4e3a-8844-1b77475a0930"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:df1a10b7-e22a-4cd8-96f1-ae04e48a4fc9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FML-S® ophthalmic suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe, where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The anti-infective drug in this product, sulfacetamide, is active against the following common bacterial eye pathogens: Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus (viridans group), Haemophilus influenzae, Klebsiella species, and Enterobacter species. This product does not provide adequate coverage against Neisseria species and Serratia marcescens. A significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. uuid:a01ad4bd-8313-49a9-831f-2c5bf2e43a85 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841838 biolink:treats MONDO:0005114 PMID:41385096 "[{""id"":""uuid:cbab660b-95c8-407c-a973-4a2e584283d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:69d9489b-2379-4790-b654-e7c215fc000f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FML-S® ophthalmic suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe, where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The anti-infective drug in this product, sulfacetamide, is active against the following common bacterial eye pathogens: Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus (viridans group), Haemophilus influenzae, Klebsiella species, and Enterobacter species. This product does not provide adequate coverage against Neisseria species and Serratia marcescens. A significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. uuid:3d4c4c10-aec4-425b-be63-4ba241117edf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841838 biolink:treats UMLS:C1096266 PMID:41385096 "[{""id"":""uuid:d2ccf262-46dc-4ef4-89d4-a9c354c4340a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7b4dfa84-51c3-4457-aa17-cf5259fc774e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FML-S® ophthalmic suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe, where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The anti-infective drug in this product, sulfacetamide, is active against the following common bacterial eye pathogens: Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus (viridans group), Haemophilus influenzae, Klebsiella species, and Enterobacter species. This product does not provide adequate coverage against Neisseria species and Serratia marcescens. A significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. uuid:a0ab974a-9f45-4c29-864d-d343a87e3731 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841838 biolink:treats UMLS:C0348321 PMID:41385096 "[{""id"":""uuid:c979d4e2-4fb8-4f95-839f-50a948371044"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:04c0154e-778f-4e0f-9282-bf39e188de86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FML-S® ophthalmic suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe, where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The anti-infective drug in this product, sulfacetamide, is active against the following common bacterial eye pathogens: Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus (viridans group), Haemophilus influenzae, Klebsiella species, and Enterobacter species. This product does not provide adequate coverage against Neisseria species and Serratia marcescens. A significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. uuid:c1021d92-9bbd-482a-9b29-27d39a3ca608 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841838 biolink:treats MONDO:0030603 PMID:41385096 "[{""id"":""uuid:b3b03ba8-a7ed-4371-ad53-dad459fe671e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f51de2a1-bbe4-419d-8d69-666fa7791a08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FML-S® ophthalmic suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe, where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The anti-infective drug in this product, sulfacetamide, is active against the following common bacterial eye pathogens: Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus (viridans group), Haemophilus influenzae, Klebsiella species, and Enterobacter species. This product does not provide adequate coverage against Neisseria species and Serratia marcescens. A significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. uuid:13df1520-712e-4d0a-93a1-a4f2d33a8e8c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:373644 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:51a9bf5f-1bf4-4e7c-845b-244ba7758271"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eb8d7e14-0447-4998-a1e5-32fcaacf71b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Propoxyphene hydrochloride and acetaminophen tablets are indicated for the relief of mild-to-moderate pain, either when pain is present alone or when it is accompanied by fever. uuid:88b6f89f-df1a-4cec-a5e2-32627fe932be biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:373644 biolink:treats HP:0001945 PMID:41385096 "[{""id"":""uuid:3f64f986-32e8-4452-8272-249e6c76b53a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7bac5b00-c70f-4213-82fb-ac1329f6604e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Propoxyphene hydrochloride and acetaminophen tablets are indicated for the relief of mild-to-moderate pain, either when pain is present alone or when it is accompanied by fever. uuid:804a1930-f1f0-4df0-8daa-8a12fc32ae3e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4735 biolink:treats MONDO:0001566 PMID:41385096 "[{""id"":""uuid:e833306c-f0fe-4589-b649-b2ddf3ff6d4c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7e48eb4e-6829-4033-b0c7-7d49a18dff56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endrate (Edetate Disodium Injection, USP) is indicated in selected patients for the emergency treatment of hypercalcemia and for the control of ventricular arrhythmias associated with digitalis toxicity. uuid:52334768-b3e0-4409-af6b-71a4363a70ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0019359 PMID:41385096 "[{""id"":""uuid:efb70f36-13d3-4b5f-81e0-15a60fc04cd6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:94647306-a5d2-462f-9dc8-3b71b7d21c91"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:93e7ef9f-094a-4a80-91f7-6fa48dbb94aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0001246 PMID:41385096 "[{""id"":""uuid:47197f2e-e798-4782-8436-e90e769a351c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6ca76227-23c1-47a8-a5bf-6592d36efb58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:3b54894e-4ae6-44a8-8440-bdf212b441f0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0019186 PMID:41385096 "[{""id"":""uuid:9a0b538f-7983-4295-b0a9-2da23bf38840"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:123f799f-14de-444d-a84d-494ee564869a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:3fcfa1a3-f1b6-4ed4-b5a0-0b4f16fab874 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0019360 PMID:41385096 "[{""id"":""uuid:64ad199d-6805-4b52-b17d-a96adcd9a206"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b00b875c-ebab-4bb2-8155-320c8bd44422"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:6e3b1ba5-fc45-4c0d-984f-2a02041e221f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0025294 PMID:41385096 "[{""id"":""uuid:e7b0e74e-df11-4a6f-8c93-5a63c07017b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0e1b7b23-4135-455e-9ea6-d55ddf295024"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:97479525-845b-4f09-9144-27635378277a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:660d06e3-98de-40af-9931-4ddb4f8ca383"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bd899d80-2088-4402-a95f-946d15a03e0c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:54b87faf-7b6a-4750-88eb-0a81ebf095f1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0005834 PMID:41385096 "[{""id"":""uuid:b4f86b6d-15e9-4f4f-83c5-a463d13b990e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2110b8d5-2f83-4099-9bf0-71b6736eb081"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:dcdd47f5-0067-4ff4-afc4-a05afbcec257 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0005888 PMID:41385096 "[{""id"":""uuid:e6d80f2a-b85e-499d-acfb-22701c6d3ca6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a29f8a4f-529e-4ee0-9e34-4110afed5b3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:383bc726-fa52-459b-b8fa-b92bba65aee2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0001249 PMID:41385096 "[{""id"":""uuid:54ef435f-5271-4ad8-a069-7289e71311c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f0fbd85d-c4e4-4d73-88f8-82deba348988"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:e7cd1747-25fb-41c4-a6f2-3a94ffc2d1f4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0005808 PMID:41385096 "[{""id"":""uuid:093899c6-41cd-4aef-86cf-e2bb5640b0f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:15e281e5-6a16-4af9-9036-28151bd51476"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:14bd88f6-46c2-4a38-801d-a675ba7fbdd0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0021697 PMID:41385096 "[{""id"":""uuid:68ef80a0-3e2a-478d-b8b2-18b684c0a06b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:709599e0-2448-4d20-9a33-bec9315b8082"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:9fc953d9-cdfe-4a3b-8aa0-036995da7fe3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0005297 PMID:41385096 "[{""id"":""uuid:a163d3b1-e472-47c0-b817-b8d814c46c1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c84f3a59-ad13-497d-bc81-ece513574c31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:369c0219-9b27-4ad8-b929-5d48a19330bc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0019633 PMID:41385096 "[{""id"":""uuid:577b31c2-e448-4985-97a7-e7c3e3cb46b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ba7464f6-2ce2-48a1-b285-219dda524896"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:8d1db58c-a026-4adb-a723-7be81c7edd21 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0001797 PMID:41385096 "[{""id"":""uuid:100a62c4-ed82-4e95-be41-224dbae77eae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:893012e8-3393-490e-ba1e-98ffe22d11c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:d135a12b-e7c2-456e-a16c-d1d160030739 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0019095 PMID:41385096 "[{""id"":""uuid:ab967955-3d89-490a-8a16-2b904135efad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8e6ecdd7-a927-4b69-b4b2-ad099fb6d9f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:fb20c5cb-f381-41ac-9131-516b903f856c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0018077 PMID:41385096 "[{""id"":""uuid:0c6b2c9b-e551-450c-abc3-b35c6a178696"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4c2c6269-5b21-45f2-bb68-45d6036bd32c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:a774225b-70d2-4395-a7a8-7a14c86eb715 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0015766 PMID:41385096 "[{""id"":""uuid:b1de45f7-bbd7-4600-81ec-adb504962fbd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4b6f2a4e-f4fc-4100-a184-34e48d60e0af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:0f01ec0c-9172-4bdf-9373-1ada6ee1a80e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0040728 PMID:41385096 "[{""id"":""uuid:f62e4054-7944-4e41-9df5-296efb339a14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f9768102-d9b0-4a35-863c-dd17c83e4864"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:39f87f64-a723-494f-b25e-2c255d61d76c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0005683 PMID:41385096 "[{""id"":""uuid:965c9624-7612-4328-be83-876c10d155e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e2ab3ac9-8faf-40d8-aaca-eb6d110fc0f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:b562eec7-fda0-4364-bdcb-28ceed0705ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0005664 PMID:41385096 "[{""id"":""uuid:cf5067bb-2e57-4334-8bde-784553df0a46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4e5dfc9b-381a-49e4-8722-317053729b62"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:328740fb-a55a-4fc1-9727-9e697ba10c1f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0005777 PMID:41385096 "[{""id"":""uuid:00750095-bf17-4202-8aa4-2088faa22186"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aad5f7d2-ee9c-4b15-ac12-e4889cce78be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:f2102dcb-65f9-4deb-9cc1-220ffbc315c5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0020920 PMID:41385096 "[{""id"":""uuid:df2c273b-e765-414c-bd13-38673899fcc6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a01769e7-eaa2-480f-b673-53d76b60bcd5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:04a14c5f-d632-480c-8f97-2d9184c96117 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0019345 PMID:41385096 "[{""id"":""uuid:d5839560-352b-4ddf-8ac6-235a7535b868"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a36a560c-1f02-4c69-9737-75ae12e0b786"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:d3a71a94-cdb7-4d77-8182-5569cea8cb77 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0006635 PMID:41385096 "[{""id"":""uuid:81bfaa45-cf14-468c-9b30-c2e18853bbc2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:326b2888-0f28-4bc2-9f4f-5b0066efa1ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:b5f8e1a8-c97a-4cb3-9498-069db8559471 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats HP:0005376 PMID:41385096 "[{""id"":""uuid:3538bd64-8ec7-4d92-8d11-06220d6291e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cb3997dc-33dc-4511-a0d3-24b20f2f4ce6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:73160bfc-6161-4e70-8d6c-2879f78703d1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0030603 PMID:41385096 "[{""id"":""uuid:e48a22dc-d6b5-45e8-8e4a-fca4f40091a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:62d0f46f-463b-4793-87c5-f8d854046a9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:bd460df4-0487-478a-9c10-97f099f5ebf6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats UMLS:C0041912 PMID:41385096 "[{""id"":""uuid:a584ba94-5fdd-434b-9b17-d13d26c689cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d7a2871c-b8cc-4fb2-8cb8-a5827b811fdf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:7223f610-8ad0-464e-adfa-bf47cefe1346 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:38f6ffa0-9e1f-438e-a26a-8076dcdd7f6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9e6fe936-29cf-4399-9eb2-7a5f387423c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:9d409aab-e715-45c7-82c0-f82bd8e94b52 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0005119 PMID:41385096 "[{""id"":""uuid:4f02cc78-cff2-4914-86c8-70aa75f56f0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b5bd76ba-3f9b-4c2e-876b-d7b88ce8c4fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:acbaf4b2-49c1-4f2c-a2f4-96e74a812bbd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0004277 PMID:41385096 "[{""id"":""uuid:631f3c23-6aec-4d2a-99f4-56935a3fecb2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e75a1e4a-ed8c-4ba5-8f7e-3976bfa0cf4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:72f16cb3-fc86-4f06-821f-aad0508c5bde biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0005976 PMID:41385096 "[{""id"":""uuid:c331d9f5-c7a8-4b6d-8e0b-e8f477e771ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:591d500f-7dd3-4785-8458-44102251995f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:6620114d-2f67-468d-afaf-07beb99f3c77 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0006019 PMID:41385096 "[{""id"":""uuid:a8ffe16b-cd07-4139-a1f2-e6c919d2be8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8332e854-314a-4578-99ce-164ce0d5d617"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:0e92188a-4e7f-4033-a99e-dcbd011842d1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0005828 PMID:41385096 "[{""id"":""uuid:56f35073-780f-4bfa-80bc-7b1a8bafff62"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2a002357-218b-4f5b-8ebc-f57120a282c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:48b15a45-8d93-4810-91cb-b1969012126c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0005631 PMID:41385096 "[{""id"":""uuid:142b4256-7eab-4ce7-afde-23fd7e20246e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9e253160-d088-4232-a7e2-4cb4947f141f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:efcdd552-98c5-4428-a1f5-412e3a2f2c61 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0024388 PMID:41385096 "[{""id"":""uuid:e94d8395-dd2e-445b-a420-f261f0cfbac9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:befe2e77-428e-4383-9c9b-b4b15668e325"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:0b1fb767-871c-4e10-bad4-4d5b7fb12b0e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0005644 PMID:41385096 "[{""id"":""uuid:6aa5337e-265e-40f6-9b60-4c37f7c5ce49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c4c55aec-69c1-4c92-a9dc-05440d3cc59b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:3cd9d340-4e80-48aa-a33b-4ca45727805a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:5f85e3c6-ac55-4994-8d6c-232b00e48a29"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:22548f6b-3234-4b5b-a306-25bd96bb5cae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (omithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes (formerly Aerobacter aerogenes ) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following grampositive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus p neumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure); to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:795cc478-3203-46c2-96c3-8829f4a9bc12 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats UMLS:C5779507 PMID:41385096 "[{""id"":""uuid:9d632bf7-6505-4b42-9f26-8663827b4728"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:99fa43fb-a261-4226-810f-b8508ba1fcfe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cortifoam® is indicated as adjunctive therapy in the topical treatment of ulcerative proctitis of the distal portion of the rectum in patients who cannot retain hydrocortisone or other corticosteroid enemas. uuid:5c287358-ffcd-4f8d-a9bc-5eb18bcdf4ed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5855 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:4502b5e5-4f49-4779-be15-89d9f339df03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:15a0b5ed-4153-491a-a1c8-2af389af664d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of ibuprofen tablets and other treatment options before deciding to use ibuprofen. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Ibuprofen tablets are indicated for relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Ibuprofen tablets are indicated for relief of mild to moderate pain. Ibuprofen tablets are also indicated for the treatment of primary dysmenorrhea. Controlled clinical trials to establish the safety and effectiveness of ibuprofen tablets in children have not been conducted. uuid:0812cc7a-e9ab-4e3a-b90f-120a10aa6bae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5855 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:cb901b4d-664c-4888-90b2-6b0b1d9481f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:002722d8-6159-41ec-b24f-1212e3613ba8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of ibuprofen tablets and other treatment options before deciding to use ibuprofen. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Ibuprofen tablets are indicated for relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Ibuprofen tablets are indicated for relief of mild to moderate pain. Ibuprofen tablets are also indicated for the treatment of primary dysmenorrhea. Controlled clinical trials to establish the safety and effectiveness of ibuprofen tablets in children have not been conducted. uuid:6d3fea31-94b8-41cf-8d62-2395498e82bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5855 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:e29cb4e9-21c5-438a-9fa3-426e50089096"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e9ac5b08-d19d-4f19-aa43-8bf9c43c52d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of ibuprofen tablets and other treatment options before deciding to use ibuprofen. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Ibuprofen tablets are indicated for relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Ibuprofen tablets are indicated for relief of mild to moderate pain. Ibuprofen tablets are also indicated for the treatment of primary dysmenorrhea. Controlled clinical trials to establish the safety and effectiveness of ibuprofen tablets in children have not been conducted. uuid:3ae002a7-a3ef-48cd-929a-478f667971c8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5855 biolink:treats MONDO:1060206 PMID:41385096 "[{""id"":""uuid:3caceaa4-e2bc-472e-93ae-d13b2aa5cdae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:404f1ddf-2396-4006-8ac7-7576ea1fef73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of ibuprofen tablets and other treatment options before deciding to use ibuprofen. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Ibuprofen tablets are indicated for relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Ibuprofen tablets are indicated for relief of mild to moderate pain. Ibuprofen tablets are also indicated for the treatment of primary dysmenorrhea. Controlled clinical trials to establish the safety and effectiveness of ibuprofen tablets in children have not been conducted. UMLS:C0149875 uuid:6877e3df-da1b-4299-a571-d2e3dbde9010 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1157483 biolink:treats MONDO:0005412 PMID:41385096 "[{""id"":""uuid:eb3fa17d-0e82-4892-86d2-10bd9dc10e59"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a378c609-c291-4fb3-a964-55941d5aff7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZEGERID with Magnesium Hydroxide is indicated for short-term treatment of active duodenal ulcer. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy. uuid:11db3a71-27ef-490f-9577-20ade1feaa6c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28787 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:99d6071c-7732-4dc4-903e-3f527ddadd4c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f567fa38-1c40-4158-9536-c13ab0809ed8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nitrolingual ® Pumpspray is indicated for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease. uuid:f947e391-928e-4000-93fc-402e64067ebd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28787 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:4dfe295e-8fa1-4d8b-87cf-5b48700e4bdc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4151bb16-37c4-4732-9bb2-9ca25d0a0233"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nitrolingual ® Pumpspray is indicated for acute relief of an attack or prophylaxis of angina pectoris due to coronary artery disease. uuid:42787676-b442-4fd8-af6a-0227e2d2d9e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0000004 PMID:41385096 "[{""id"":""uuid:8c16f6a5-8037-49c3-85cf-25c8aa0b26a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:198a3019-9935-4124-99cf-f2968a86a6c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:97fc7fc7-cbc3-4a6d-ab28-71d124d19fd4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0018479 PMID:41385096 "[{""id"":""uuid:982455f3-d07b-429c-b452-67248ff09b72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:345cf684-899f-46df-9f86-53a970ce52a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:be54bd7b-0746-4e56-9060-caaa68f11506 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0006982 PMID:41385096 "[{""id"":""uuid:029d690f-69e8-4f90-96d6-90580e437265"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9b128d0a-3215-4b55-a240-2f62594bffd7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:d349f0b5-2223-4e99-a67d-3950136c7fe5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0043455 PMID:41385096 "[{""id"":""uuid:07a38278-22b0-40c1-b197-7781282576c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:10e6595e-28ec-47b8-8e53-40f66bf4a1ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:6c2d4d81-3154-4ab3-a039-724c1dc90884 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:bd53d83e-c5e1-42d1-bd7d-f081de32e83e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6c33b220-c959-4172-8ba3-353ccede0d4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:8e7f7511-c4af-4322-8fd8-7d35d8b4b1bc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:dd4fab98-fdb7-462e-ab10-9564dda96a6c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e0907bf8-65f7-4ce5-94f1-c797c0787025"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:c43ac07d-523a-418c-a43c-bcc9cb42669a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0011429 PMID:41385096 "[{""id"":""uuid:6d1d20ac-c0ce-44c4-86c6-b78d52710810"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bd5b2309-9db2-41b7-9cd8-c961273dc977"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:2b61d9c9-c07a-4a33-b24e-210511e9b991 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:1dab26a8-4c3f-44da-93a1-7643300a9a01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5f94e4f1-80e7-4150-ac07-38bdcd2603fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:ce168cd2-2a9c-4ca4-a458-500d63ab126b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats UMLS:C1290158 PMID:41385096 "[{""id"":""uuid:c52ee706-b354-4a1b-93f1-d29fef00dbce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:62097911-ae66-4ff2-9b0b-daf8c2b63d29"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:18ddb403-d4fb-48c6-8d12-ff02e50c67ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0040698 PMID:41385096 "[{""id"":""uuid:6c214613-041a-46e8-94dc-defb10ff57d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f4d282f9-8614-47a0-9c8b-2c7e3851793d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:3b8780c0-0a1c-4a98-94b7-e6652b350e59 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0004855 PMID:41385096 "[{""id"":""uuid:1dc88e20-6d6c-4cc4-b084-c721cd2d1cee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2bbffbb5-6f89-4d57-be7c-bc5cab37e4a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:1f2973a5-2649-4f3c-8e64-8625e5445cd5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats UMLS:C0149896 PMID:41385096 "[{""id"":""uuid:34477be6-ddca-4197-9199-e16f34bdecc2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:acf050ae-4688-40b5-9d0c-9cf294a96284"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:0fd5a199-3a37-4542-bf24-a7fef6f16b50 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:33f15341-0d84-4277-8680-478668bbb14d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:35fc4fba-8637-4d24-83dc-9692d785cee6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:e0b2a194-3fc2-4dd1-9dd0-0e5ba40bf88b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0001875 PMID:41385096 "[{""id"":""uuid:f8686672-44d0-42b0-9e71-e5abb3e85703"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ddedebce-d93a-4103-b244-853d1a45e32a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:e5faaab6-978e-4100-9459-09ecadd228fc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats UMLS:C5441648 PMID:41385096 "[{""id"":""uuid:15cfe4c0-a509-4120-ae10-162f995403e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:03eae9c9-c57e-490a-b0c0-ddd04523b087"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:533396a2-0d46-4950-960e-71db7ac2b886 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0016367 PMID:41385096 "[{""id"":""uuid:fd6ff9be-5053-41c6-ad54-da0a2322f565"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:95adbac2-dfa3-474e-9efb-ec9ebe0f192b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:b2c4bedc-158f-4fe5-aea6-bda5bfbbaf39 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0019127 PMID:41385096 "[{""id"":""uuid:343ce285-6f31-4271-9c0d-3ec176a1080e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3044d8c0-3731-4283-811d-8c6c99b6395a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:1794bcf0-1144-4b5e-ad8a-0fa25f2bc82c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0006594 PMID:41385096 "[{""id"":""uuid:a0f86f4a-9b7b-43a1-b7f0-88c82b1a1087"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9356cee1-8baf-4410-8c1b-fdd3070b9bbf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:04bebce1-77af-4ff4-9f75-da0f92bd7509 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0015614 PMID:41385096 "[{""id"":""uuid:f7528365-beec-4e34-8824-a46492e5b62d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:47b6543a-e1c9-475f-90eb-a018c9afbb7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:66b30554-7e0a-4bba-8d6c-691540c25a62 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0006545 PMID:41385096 "[{""id"":""uuid:ffb31188-7d0c-4a5e-8805-2a70879a0270"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dad990e9-d848-45db-9c8e-c46382060dde"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:2ae00a8a-3da3-4860-8d4a-fd9a12e3db71 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0018229 PMID:41385096 "[{""id"":""uuid:e86cb1fd-5298-4b85-85c0-9b7b31a0cb5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e6ecb85e-190f-4509-b9ef-bc4d429d5d08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:769fd2c3-3028-40f4-b767-cf111c9a9790 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0043233 PMID:41385096 "[{""id"":""uuid:6708d820-1168-4262-9e89-03ceadcd1e29"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:45944e52-29b9-43fd-b230-95279e80bbcd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:ba585786-6508-4c9f-b468-0ecf9a739cb6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0009691 PMID:41385096 "[{""id"":""uuid:202c2d10-3d87-432d-ac77-f57dd311bdb6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:122c696a-e280-42a5-be4d-74213b1bca4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:92d47a23-e7eb-47c8-8667-371cf60eb205 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:e3a526c6-1011-468c-a11f-42a8636b92e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:969cbd4c-d695-4878-880f-38a32397e5cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:7de39822-4861-49ee-a622-cd5e3b8b2d5b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0006608 PMID:41385096 "[{""id"":""uuid:c1d391a5-7b15-44fb-909a-a76d168d736b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d2969154-4e10-419a-8222-63fcf6816cc6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:e3c13377-eaa5-4c32-9244-6af76442fcc5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:e8987853-68f4-4f3e-9b07-58feef5e8706"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:401d8839-65bc-4241-bc3a-d8455be086c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:797acf1a-6698-4b04-90fa-addc96d72672 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0024332 PMID:41385096 "[{""id"":""uuid:200ef7cb-4406-4a0a-9fa6-da956f1110b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8327886a-1ffa-4610-982e-bf4223abeba4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:3b127dc3-fd65-4b8c-b3a8-7cbb7dabe621 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0043789 PMID:41385096 "[{""id"":""uuid:cd59cc76-ad77-4e0d-9e2a-63bb458eb114"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2818966b-6742-46f9-bc18-c6427e97d6fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:e5e546b3-8720-4cc0-9f5d-bd842180d4bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:205a9a0f-7396-4f54-85fe-17d10279fbe1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d1370704-8a32-4d1a-9ca7-3b50fe1d85db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:5fd585bc-d009-41ab-ae34-16ea02c668d9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0005480 PMID:41385096 "[{""id"":""uuid:df2f8532-d171-4566-8cba-10f4efd1a88a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6fb0a7ab-183c-4248-bf67-0e1d4c9698c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:0f8e1cfc-a39a-4aca-8b54-73220589e28b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:4183acc2-dc2e-4ae3-93cb-b62a7aa1d92e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4b3b6808-5150-4519-b01b-89b832c4d654"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:4fa577d1-53f8-45d0-8a34-13d2740afedb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0000775 PMID:41385096 "[{""id"":""uuid:5cbd6f9e-bb77-45d3-a4a5-9e1005b1b284"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d94da8f5-9c64-4854-88de-b16557ed164f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:b9afe9b0-7170-4d84-999d-734300b921c0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0003085 PMID:41385096 "[{""id"":""uuid:0072a643-9816-4e73-a4e7-6dc75640ffec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8c7b2357-d111-4d4a-b041-dfc14f232b36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:537dd1e4-b618-4196-ba03-39eabf6406f3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0001034 PMID:41385096 "[{""id"":""uuid:176fdbd4-448d-4fcc-8462-b6c29b1f50a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:641e8c2f-369b-4ef9-947b-41c04d0ef8a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:9dce82fa-292c-4a19-9fa0-dc9cbda6984a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0005883 PMID:41385096 "[{""id"":""uuid:dafe33dd-87e9-49da-9a0d-be003fc3e550"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0608f617-f8c1-4cf0-8a4d-fc5ca93976b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:4dc91ca3-968d-4197-aad6-3e1659d6aa9e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0006814 PMID:41385096 "[{""id"":""uuid:c9427c73-0c38-43ef-a0d2-9ecc8d231941"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c37497f3-97cd-4eec-bba5-c47e9bae8a48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:7123b0ab-b5e8-4474-89e7-2ce306d194b7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0004773 PMID:41385096 "[{""id"":""uuid:b21b4ec4-ee65-4535-8ff1-fb0591824bfc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bf8b6c16-8bdf-4f44-9ac6-68cc0bcb8476"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:c50d019c-94f9-45c6-9e8e-cb2d54d7f1d9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0004674 PMID:41385096 "[{""id"":""uuid:48bbc356-76f7-4b78-9787-dc5528b36cb7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:96684a18-9bda-4430-964e-dc6c58b849be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:34a8c710-3dfa-48c5-9ba5-0ce05feb4304 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0006651 PMID:41385096 "[{""id"":""uuid:c64afcd1-0a8b-4bc2-b256-89b3a860db45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bfab0824-b008-491c-ac22-c76ea4de6ce4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:f3fd40c1-5b9d-43a2-999c-03d58055b480 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0006918 PMID:41385096 "[{""id"":""uuid:3dbbaddb-a25c-4154-b1cc-1e772d6aa0cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bffacc24-d60a-41c5-a01b-105224821518"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:71eaf41d-08f4-4ea7-a0c8-afe85886ea43 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0001280 PMID:41385096 "[{""id"":""uuid:0196066a-d91f-416c-b07c-bb50d24bb9ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0aaa9249-1d1f-4911-8281-4c95297adba3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:b535cfe4-6f11-4ab9-a014-d25aa9256bf0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0005885 PMID:41385096 "[{""id"":""uuid:5a24c397-c199-49b2-badc-0ed9c7aae0ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4e068841-a051-4684-a855-872f7605b5f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:a5f771cc-7745-4c99-8f00-1f343b02621e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0019198 PMID:41385096 "[{""id"":""uuid:e3d7e301-4887-4d3a-afed-988e9f3944f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3173b82a-91fd-4298-9c20-7bf2e50d7f91"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:38c187ee-8d5a-4a8e-8d53-7c1ac6293f21 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0019338 PMID:41385096 "[{""id"":""uuid:e17a15f3-5171-4c28-87a7-d1e0d34cfeba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:12e747d8-516d-4f38-8f80-9cabf92eef07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:a90cf76e-c674-428f-bda3-6479de461ca0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0015274 PMID:41385096 "[{""id"":""uuid:151ed43e-da7e-4698-9043-33c6c88b8aa7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0d5b549a-b1ff-459b-b839-e172160988da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:05f6e149-027a-428a-adfc-0b598881eaad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0006052 PMID:41385096 "[{""id"":""uuid:2f91b6f1-9f8b-4dc7-8340-c387a64ef566"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9763859b-12c2-4d23-82e6-809c9226298f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:a049b643-e0c1-40fd-b9ae-6aee3076dbf4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0005848 PMID:41385096 "[{""id"":""uuid:cff15598-52c6-4c08-8633-9df6e27d9320"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:35ca79ff-871d-43ae-b67e-7b9faa82bdc9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:55a7a313-3253-49dc-a988-e92696f7ff89 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0002572 PMID:41385096 "[{""id"":""uuid:1eb1026b-cb7f-4dad-b80f-79b00da6146b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:433cb476-f30a-453a-845c-57c765b52365"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:8d83d6e1-e704-4428-be66-63f069965770 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0019098 PMID:41385096 "[{""id"":""uuid:8b97eeaf-e019-4857-96dc-3e594193125c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:72ffc4e1-0665-4b43-a4e0-aea46102fc04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:3bd53e16-92df-44cb-a80b-689d41b11902 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0001198 PMID:41385096 "[{""id"":""uuid:06232e6f-fc98-4ab9-b6f4-b768d2ee0f1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:873f96f1-fb85-4c09-b804-8ddd799ebb7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:564baf19-6c38-4388-ac50-9e0bbfc77890 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats UMLS:C0002879 PMID:41385096 "[{""id"":""uuid:b6435276-4975-4298-b470-cf72f8b23c11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b42cc201-f71a-413e-a16f-02d993b286fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:40ec89e3-0d15-49f9-b08a-00e3de7c9ea0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0020108 PMID:41385096 "[{""id"":""uuid:422f2d37-4905-4b4b-9699-06c8593c4f69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ab0bc2d4-dce6-46e9-b63c-81d125581995"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:904abc98-4b78-4f39-8b37-5c7b6ae3499f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0002280 PMID:41385096 "[{""id"":""uuid:77a27be7-287b-4e40-b5d1-3357cdf837d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cd0a086a-7a58-44b9-ab16-f2c927e11431"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:791c6f65-95b7-4b8f-84b3-0f333e8594ce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0015253 PMID:41385096 "[{""id"":""uuid:824127a5-3a1d-4b32-ab21-2f5b0c1c025c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cf0b9804-b6fa-4898-a6e0-c609ac73844b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:4e662b3b-a650-4560-9799-b491947c1a6d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats HP:0001908 PMID:41385096 "[{""id"":""uuid:8e8b47eb-1e67-4b9f-ac81-14c3d57a0231"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:90c807f3-6511-441b-830f-ffda9acdf407"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:729837ec-5ac2-4828-aac5-4d704d32a5b0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0005059 PMID:41385096 "[{""id"":""uuid:5e45d445-b0c3-414e-8459-1bed71bf0472"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:137f19fb-5c20-4c98-b948-797bf6cf7a31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:c2c01d66-0817-496f-a1d9-d713f9381a63 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0004095 PMID:41385096 "[{""id"":""uuid:0251ba0c-8d87-4f6f-8e02-aff2717c6e91"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bc7d37b1-4e92-45b8-83e8-ebc74aac14f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:0f8652a9-2dd1-4b89-82af-918b336c442e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0004355 PMID:41385096 "[{""id"":""uuid:c6d688ad-8e1c-4168-ac9b-bef8ca435ddb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c740a039-165f-4f93-8513-48e809606b26"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:cc654012-0b24-4a1b-9b28-0696316690df biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats UMLS:C0268732 PMID:41385096 "[{""id"":""uuid:c67d6fcb-6cd7-4133-9226-0434e7261713"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:92612d14-8221-42f4-8280-32e7811062ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:b6fc7d50-31be-4fcb-9670-71d1059b6b08 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:ca9079dc-0dd5-4c7b-b793-b0d50fb50f80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:867171e4-9379-4b66-8bed-27257f519462"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:9a774fad-1ddc-40b8-82bb-eaf4606a471e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats UMLS:C0678202 PMID:41385096 "[{""id"":""uuid:e6b7a2ae-35cc-4c10-93c5-acfa94718ec4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7f94a7c3-9211-483c-9d1e-b55e5038e992"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:5ecaf5b1-6499-4156-8fc2-2f5c00239bf6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:04884fe5-5c2a-4c45-828b-9dd3907116a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:91f72b5e-54c6-4964-9358-bd545aebbb11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:e1cf1d61-a9c1-41e2-b9b6-c5d572e059ae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0006042 PMID:41385096 "[{""id"":""uuid:a95f6c62-1a8e-4dd0-9c2f-011d8a7ca9f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9f8c7db7-d57d-4e96-a629-2123da59a5e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:9e78df53-29a3-49e0-a135-d4931333b5a9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0019444 PMID:41385096 "[{""id"":""uuid:ff434e3c-05a1-4c40-ae06-5bb818e50ec8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7dadaa2e-cbf6-4035-be04-121f62d8d260"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis; including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous states. To induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous system. Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with sub-arachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:2bc985a7-99f8-4fb1-90b4-70a3bde20df1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17549 biolink:treats MONDO:0005173 PMID:41385096 "[{""id"":""uuid:94aa8786-5682-45e5-9b1c-7b80e8c247cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9acd9230-307b-465b-a359-a0bfaa69cfda"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:8b88381c-25a7-461d-a576-e726a4128ac6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/gliolan""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] The LEVULAN KERASTICK for Topical Solution plus blue light illumination using the BLU-U Blue Light Photodynamic Therapy Illuminator is indicated for the treatment of minimally to moderately thick actinic keratoses (Grade 1 or 2, see table 2 for definition) of the face or scalp.|[EMA] Treatment of actinic keratosis of mild to moderate severity on the face and scalp (Olsen grade 1 to 2; see section 5.1) and of field cancerization in adults.Treatment of superficial and/or nodular basal cell carcinoma unsuitable for surgical treatment due to possible treatment-related morbidity and/or poor cosmetic outcome in adults. uuid:20745bbc-2809-4acd-9cfe-f114f068fe25 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0000004 PMID:41385096 "[{""id"":""uuid:8c01e444-76e3-4f8f-a694-0cfd97c4e771"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9ade75de-9220-4bb1-ac0f-ca5cca638a5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:dc4b8cac-1e13-4fe4-a88b-b8b8d88e396e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0018479 PMID:41385096 "[{""id"":""uuid:4a23f884-ec6c-49bf-8fb7-ececddfac373"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8714d46d-438f-4058-b92b-452dff9e768f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:0a809930-88af-4d72-9108-5b0006db6b78 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0043455 PMID:41385096 "[{""id"":""uuid:740918ac-dc65-49be-93ed-a18882e1a9f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f73aeddc-cd83-45b3-bf56-fec7c3bec21a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:de72d653-6044-4514-a50b-f58e16046841 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0006982 PMID:41385096 "[{""id"":""uuid:3e436fe2-91bf-44f3-ac57-744591980a26"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a9721163-b70b-4df3-9ee8-f3be3fbbe9fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:e867a020-450a-4d88-ad56-a48829e2046c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:606cd5d7-95d1-4bf2-96a2-a91b75c3dd3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1485879c-af70-43eb-8b03-7bd26c1b0aac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:0300d95b-d2c5-4047-a2a1-b350c813c845 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:e2380864-10c2-4abd-8ee1-f0f9b826d928"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1a24627d-0e54-408b-ba74-c2bb18d6025a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:cdc6b4a7-923f-4c94-a37f-35591ccb473a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0011429 PMID:41385096 "[{""id"":""uuid:27f63e65-f67f-4f82-b856-77e7dedb0e8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bf208c9b-ca06-4105-973a-fe3adc559a1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:deac8098-61a1-40ec-8d2d-66ad55f1b220 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:4e6de3b1-3518-4eb7-b21d-59a3d3cb6e13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ad5dbdc5-4872-4f62-a50e-9586212522b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:48643f16-97d9-4ff0-9c9b-cd15f305cd6b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats UMLS:C1290158 PMID:41385096 "[{""id"":""uuid:e8fd54a0-b408-4150-964d-e806caaf1556"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2dca7731-585c-4357-b0d2-578dcb5d295e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:8ca03916-daee-45cb-b4cb-8718c38e5bd5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0040698 PMID:41385096 "[{""id"":""uuid:dbc9da4b-5b3c-4c0f-873b-4093bfbfdc8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7beea924-0b9b-4096-8873-ec28c43579a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:fba1a225-63a8-4ade-9260-d81ae33769a3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0004855 PMID:41385096 "[{""id"":""uuid:a25f27fb-381f-4b38-b80a-036dc59e4514"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:df3d2a81-6afc-42de-aa12-67d4ab64b99c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:6664954c-8ba5-4da6-ad2c-a528ad002298 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats UMLS:C0149896 PMID:41385096 "[{""id"":""uuid:79c5cc3f-76c2-4748-9420-d178f5e46635"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fc9d0634-4561-4b85-b890-2c0cbc61041b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:bd7f21ad-0c50-4e06-b8ba-f441c9f56865 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:35818b9f-8e58-4b0e-9840-a59ab9c853a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b3919648-1326-44d6-a08d-cef5a9c0daf2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:d2baf297-5edf-42b0-b1a6-d710c07f527d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0001875 PMID:41385096 "[{""id"":""uuid:b5def87f-09e9-42ff-a9e2-4e8e57a573da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5f2a40f5-3b2a-4a9f-b22f-a57d88cfebef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:ba51685e-3111-44c3-b51a-df974989f4f7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0016367 PMID:41385096 "[{""id"":""uuid:2cffae66-5ab2-4899-ad78-fc0def967ab4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bb81840a-be60-444d-a02b-a90d640ec474"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:4e98e907-8c35-4b67-ad11-fb20f8a1ad8e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0019127 PMID:41385096 "[{""id"":""uuid:a915de8c-84b7-4dd5-b597-318c8df35e0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:da20383d-e737-4ac9-8f34-374db33ecce1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:218290cd-ac33-40f2-93e4-afbe41cd08b1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats UMLS:C5441648 PMID:41385096 "[{""id"":""uuid:92e08409-3374-4140-9e8a-f25d8b5c0f26"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:580d18b2-0c06-40be-b6c3-ccef2cabb331"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:0b4fca59-8b22-42c9-b296-2048ad5366b4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0006594 PMID:41385096 "[{""id"":""uuid:03bf14d0-27eb-4e3d-9afb-c61f71962c26"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d0c578f5-0cd0-4526-891f-5a259f4d272e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:eb3bbbfc-8ec5-4dc4-ad3c-94d6ba408868 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0015614 PMID:41385096 "[{""id"":""uuid:fa257570-093d-4e23-8205-ca3fb797baef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ebd0cdad-772f-44a1-95ce-be6439894e4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:053171e5-bc4e-41ce-a0b4-b89e2f48e911 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0006545 PMID:41385096 "[{""id"":""uuid:80b95b48-0ef9-49e7-985d-097faeac5d31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7a77e679-aa07-47be-b3c5-3244bb0c1d58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:0aadc88e-b621-40e5-9451-945653644235 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0018229 PMID:41385096 "[{""id"":""uuid:5436ffcf-e6df-47ff-8a7f-3a511937bf6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f1ca00e1-e322-4df1-9484-97ba9f383e06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:fd39bad7-65bb-4761-b0af-b1286a9fb9f7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0043233 PMID:41385096 "[{""id"":""uuid:fed4def0-38f8-4ccb-b86d-2a8ab709e183"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e693216e-1724-4230-a3b1-2415c0d0a7e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:df541e3a-3061-49c2-9b67-ab093a0cdbfe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0009691 PMID:41385096 "[{""id"":""uuid:295172be-844e-4863-ae14-70e857dc107a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5c1f1b07-d062-43b2-8e14-4436c3bfb1d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:fcbb309e-64d7-4f2f-9cc6-cd2a4f1e7b49 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:b081075f-2118-4d63-a1b3-6dbbcc3de9f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5631390c-0b44-4b5e-8b4d-8db66bc192c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:8ddf450c-70f8-4c2d-80cd-fb32ab183120 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0006608 PMID:41385096 "[{""id"":""uuid:5b0672ba-9485-4998-9655-048c0ffd9bec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1517a947-7225-4db6-af39-6929f797fd01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:cf9dbe9f-24b3-40bd-a4a3-5fd1ce0edcfb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:9017fe86-c5be-4ff8-8b96-11fe799e4330"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ed75e7f5-f300-4a41-9e99-48671948fab0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:4fa9d65f-8634-468f-aa1f-667d50d454de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0024332 PMID:41385096 "[{""id"":""uuid:7f0c4f6a-39e7-43e0-a1fb-e5573df33a1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a884e34d-0a53-45d9-b39e-35f7bf5a822c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:915de50a-1bec-4e17-972d-611d1d4fb9a3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:06f31c6a-6e6c-49ab-9e8f-13e26fc04096"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2236202c-a596-4ea1-abdb-f09ca20fe86c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:40ad9ff3-0b99-489a-9860-64cd6d7e984e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0005480 PMID:41385096 "[{""id"":""uuid:aa2326bc-2ee2-4973-abf9-78d116c1684c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4c22ae3f-79a9-4de8-940c-e7a222ffa2ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:bafe3490-c77c-41c5-bd73-2c3ec895aca3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:092c47ac-9db2-4a66-a94e-bf6c22d9c3d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0c535210-562e-44df-9d9c-685302d3c55f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:72c01b58-3a4b-448e-8e8c-3bc87e713596 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0043789 PMID:41385096 "[{""id"":""uuid:ffdce2b4-3f06-4c25-9b4c-6a3e058121bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c6a3c694-ce4f-4994-8e0b-e25139c48ed8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:cb8d07aa-0a18-4b97-bc9d-d62f4c3a88b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0000775 PMID:41385096 "[{""id"":""uuid:cc9d2dc8-25a1-4aec-a7df-9659a7c124b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ead69bda-1da1-41f5-8f3a-70968ea6ce72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:163384e0-c6bd-406d-88a5-7b6aa1e9de4b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0001034 PMID:41385096 "[{""id"":""uuid:d9f5dfe3-4380-4a8e-82c7-17b5ab8f8fa6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eb624013-ab6e-4756-a597-aa79ccf7708c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:d6787c8f-7308-4e03-bfc9-05a1750d1ddf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0005883 PMID:41385096 "[{""id"":""uuid:79f72912-222b-4ef3-ac74-31533129976c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:260953c7-6831-408c-9e56-943d4c178f33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:2a23b3fe-b96c-46c1-b276-26e179c0b070 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0006651 PMID:41385096 "[{""id"":""uuid:3d8c2c52-e700-44ea-870f-f760e139ee59"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:72681db6-7134-4367-9d3f-678059e0839e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:4d3cbc78-14a3-4a73-a690-79696709e5ff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0006918 PMID:41385096 "[{""id"":""uuid:83c08d9f-0448-432a-8cf0-acaa8aac4239"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:98480733-d046-4ecf-965e-e4e888618707"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:cfc58b07-f301-4b13-9ae5-1ec85122d0f5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0001280 PMID:41385096 "[{""id"":""uuid:c30057ab-3d1d-489a-8a4d-3cdc383ff54f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a4f45b6f-6f0e-4cd3-9056-aca386bf8314"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:a0a130c2-5fd5-4ad5-a334-3cf284876568 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0019198 PMID:41385096 "[{""id"":""uuid:fe4e453e-73a7-4006-8e97-f455fe762ed6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e23c406e-99a8-4d3b-bafb-515855460960"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:d16f8fa3-01af-49c7-a576-ba8e397a8055 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0003085 PMID:41385096 "[{""id"":""uuid:e6c4fbcc-2945-416a-b310-b37f4cfcb7a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c73e5615-c96c-4dd6-9a2d-7589e6427677"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:75fd0fc4-4754-41e3-aac1-4667bd92cee0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0004674 PMID:41385096 "[{""id"":""uuid:6e8ad4e5-3131-4371-8027-e8fe830387ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ff5d322f-f779-4bda-9537-7462164c5a83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:9bc02ac4-d66a-4d24-b7d0-1a9e881e7130 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0005885 PMID:41385096 "[{""id"":""uuid:a73e708c-ebbb-4189-9dbe-134255f42e40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e9a25348-bcf4-4510-ac60-bd4cdebabb6a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:8b858fec-7e65-4dad-878f-052cdd67d0d2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0006814 PMID:41385096 "[{""id"":""uuid:7a15e071-1bed-4d97-acb3-844b6dd372a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8ba93c3e-f16d-4166-a79a-482f9a529b46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:3228c338-ee79-4ffe-a409-08fd9820966d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0004773 PMID:41385096 "[{""id"":""uuid:4e5dbae9-53cc-459d-8b7d-678e1afd9007"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8e1bdde0-896a-4eea-b143-afa0d752665a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:6cdf2cd2-bba2-49cd-8567-da44299cd177 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0019338 PMID:41385096 "[{""id"":""uuid:506ba805-580a-4ccb-9321-ae9b1a5f569e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a11f4b26-8c09-45b8-b0dd-7f19c9f3698f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:775cce57-35d5-47cf-9b42-17d25fe1e931 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0015274 PMID:41385096 "[{""id"":""uuid:39d4e821-73ef-443e-9766-c15bf21834c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e97197ce-b7d3-48b5-99d7-32ee9be5a363"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:22ed8b8a-6f9f-4ebe-9e54-58a974a08ca6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0006052 PMID:41385096 "[{""id"":""uuid:6c9c271f-2e00-4047-985c-3fb19af36d29"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1009f0c2-8350-4761-b06d-670f4ac85d1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:cc23d5c2-1755-4da8-abc3-cd995dda1180 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0005848 PMID:41385096 "[{""id"":""uuid:0506a998-78c9-4e99-b796-2baa54c778a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eca2cd96-f454-40dd-8c94-fff908963394"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:81fdcc69-d9aa-42ae-820c-480bcb253909 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0002572 PMID:41385096 "[{""id"":""uuid:61623eb5-fac8-4ba2-8495-00efd4e1181d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3bbe2d9f-ce79-4a57-a62d-d1c0ef5d5906"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:4f4a8e85-af4f-4451-b2b1-0f7514864a32 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0019098 PMID:41385096 "[{""id"":""uuid:1303cb83-07d3-4f8f-9172-bbc00f595786"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a48e560b-7220-437f-ae09-503e8088ea07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:f086ebd8-b593-4656-b6b0-0658821465e2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0001198 PMID:41385096 "[{""id"":""uuid:dffc9829-7de8-42a7-a3da-88bf12aae0d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5fe36330-6b8f-4766-a3f2-431e335f9f20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:d28e9b6f-fdad-4dd7-ac79-5abda5e3ebee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats UMLS:C0002879 PMID:41385096 "[{""id"":""uuid:5322d0b8-0999-4909-8d71-5aea31a6c2cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e7525fad-d547-4807-8ca6-2a20f8711cd8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:bb99f971-980a-4cde-8eb3-4eb582dbbb63 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0020108 PMID:41385096 "[{""id"":""uuid:300c2559-5833-4268-a5d3-e8f00a5daf3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4d0c06b2-d6da-48d5-bfa2-157ffe90fbc2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:407653a3-b508-4436-9b9a-749858eef8da biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0002280 PMID:41385096 "[{""id"":""uuid:90d60e2a-a6f0-46f9-a331-ad7394a512ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2661c9cd-666c-4c3a-bd97-a58f4e1620a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:f2711dd7-26d6-46ac-adb9-93ea81f3521d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0015253 PMID:41385096 "[{""id"":""uuid:64f05a97-de4a-447a-a9be-c62dd98c08f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cda01d5d-55a2-4c45-b1ee-bdb7bf833895"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:4b844b75-0a76-437e-85c9-426dca33ba6b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats HP:0001908 PMID:41385096 "[{""id"":""uuid:870e6801-291e-4820-85d3-af11e5f80dc1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:edad9162-f3fb-44b2-a9e0-902e8269f79e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:45841483-d861-4562-bebf-9b1fce074934 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0005059 PMID:41385096 "[{""id"":""uuid:060e820f-d719-4706-a286-756b5cdcf83f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8e391670-fd6b-4e22-aa13-00091d285876"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:f47b113a-2d9b-4b2b-a968-0441acdde8d7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0004095 PMID:41385096 "[{""id"":""uuid:16fb3146-e102-4005-b7ca-bd4e10697986"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dc0ba074-d83a-4e1e-aacd-929b3f7e2d27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:0ec3f2fe-faf3-40f0-b4dd-eb7239e70309 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0004355 PMID:41385096 "[{""id"":""uuid:2017991c-13f3-4e9b-bb87-6c964739e328"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:34707ac0-d193-4421-b040-2e230f18601d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:95973853-0b13-43fb-88e9-5eada133ab73 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0005377 PMID:41385096 "[{""id"":""uuid:6b45279d-0481-47e4-a550-56f1dad7b26f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cbb74507-7590-4aea-8262-c4c00c897593"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:d7240f15-8611-4415-9820-de3bb4bd78da biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:3125affb-0829-4b2b-b349-37f35817ce3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7821c4b6-4930-4ada-b21c-26b57119d1be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:c894cbad-6fa0-42fd-975e-46e0c3ce36ce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats UMLS:C0678202 PMID:41385096 "[{""id"":""uuid:3cf8f939-a0ed-4fb1-bda9-c8097e075d32"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:03cd85d9-59a0-4ce7-aae3-5589db1dfeec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:e5333d98-7677-43aa-a32a-7aea4741c222 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:f995c753-ef92-44d7-8f8a-16f007bc6b1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e9471e8a-ac3d-4286-a90a-25b7f2d2df8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:196a5d3b-a7b9-486a-b986-15c36d3101b1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0006042 PMID:41385096 "[{""id"":""uuid:572c2259-4277-47df-b8e5-99dba3cc99c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:319da56e-c809-47b2-88f2-419753874bf5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:60df7e0f-2094-48eb-bc70-fe79053350d4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0019444 PMID:41385096 "[{""id"":""uuid:761201e7-aefa-4b69-911e-346d9334b659"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:12925f77-c16d-4569-8a46-3da6a4859a68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELTASONE Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:d665cf53-d210-4da3-8c30-280e4f92c3d7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41774 biolink:treats UMLS:C0278488 PMID:41385096 "[{""id"":""uuid:368f20ed-41ea-47a1-bf47-ca1c17499061"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:33c97701-33b7-4642-9bf8-903631f983ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metastatic Breast Cancer: Tamoxifen citrate tablets are effective in the treatment of metastatic breast cancer in women and men. In premenopausal women with metastatic breast cancer, tamoxifen is an alternative to oophorectomy or ovarian irradiation. Available evidence indicates that patients whose tumors are estrogen receptor positive are more likely to benefit from tamoxifen therapy. uuid:219517b5-3b4f-47be-9ae3-cf621945c3d3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47426 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:2e95afd9-c366-4f92-bb8c-da476d775948"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ce4a8352-3ae9-476d-bc2d-387074ae945d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Furosemide is indicated in adults and pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. Furosemide is particularly useful when an agent with greater diuretic potential is desired. uuid:4773d2e5-69ed-4b1a-b24b-3cdb9b6164d0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47426 biolink:treats MONDO:0005155 PMID:41385096 "[{""id"":""uuid:059dade7-f089-468e-84e3-ab4eaa70a0d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c3d435c3-268d-4e47-ab3a-15c27cacc1fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Furosemide is indicated in adults and pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. Furosemide is particularly useful when an agent with greater diuretic potential is desired. uuid:7015ea70-2a9f-4d1b-bd7e-cb6c62a6dddd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47426 biolink:treats MONDO:0005240 PMID:41385096 "[{""id"":""uuid:bf325c46-1fb3-45d5-8f27-abf08dae09e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:295576fc-83b9-44dc-80e9-eaf4913bec53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Furosemide is indicated in adults and pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. Furosemide is particularly useful when an agent with greater diuretic potential is desired. uuid:6a574047-6e2a-446c-b28d-aa7b263ac040 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47426 biolink:treats MONDO:0005377 PMID:41385096 "[{""id"":""uuid:a92f547a-bb33-4aa1-8a6a-595c9aada9a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:29d487b9-537c-4d15-96f0-d23cb535385d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Furosemide is indicated in adults and pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. Furosemide is particularly useful when an agent with greater diuretic potential is desired. uuid:cd9baf78-fb9e-4aa5-b48c-1e8da5252655 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17750 biolink:treats MONDO:0004737 PMID:41385096 "[{""id"":""uuid:42e02f83-e122-46a5-aff6-0633ae2ac178"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:45272867-e3b4-473f-a3d4-17bdab0a2752"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:5546e8b7-fd67-49bb-b863-51ef1c203d4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a4c71520-a40c-4459-818a-1f970261b767"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cystadane (betaine anhydrous for oral solution) is indicated for the treatment of homocystinuria to decrease elevated homocysteine blood levels. Included within the category of homocystinuria are deficiencies or defects in: cystathionine beta-synthase (CBS), 5,10-methylenetetrahydrofolate reductase (MTHFR), cobalamin cofactor metabolism ( cbl ). Patient response to Cystadane can be monitored by homocysteine plasma levels (see DOSAGE AND ADMINISTRATION ). Response usually occurs within a week and steady state within a month. Cystadane has been administered concomitantly with vitamin B 6 (pyridoxine), vitamin B 12 (cobalamin), and folate.|[EMA] Amversio is indicated as adjunctive treatment of homocystinuria, involving deficiencies or defects in:• cystathionine beta-synthase (CBS),• 5,10 methylene tetrahydrofolate reductase (MTHFR),• cobalamin cofactor metabolism (cbl).|[PMDA] A drug with a new active ingredient indicated for the treatment of homocystinuria. [Orphan drug] uuid:ae44241f-7dbc-4d98-9b16-7b38d59a16c4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17750 biolink:treats MONDO:0009352 PMID:41385096 "[{""id"":""uuid:67845cb1-30ff-4123-a767-00f2b7493c9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:68e095f5-da3a-486b-b9fd-848a55934f2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cystadane (betaine anhydrous for oral solution) is indicated for the treatment of homocystinuria to decrease elevated homocysteine blood levels. Included within the category of homocystinuria are deficiencies or defects in: cystathionine beta-synthase (CBS), 5,10-methylenetetrahydrofolate reductase (MTHFR), cobalamin cofactor metabolism ( cbl ). Patient response to Cystadane can be monitored by homocysteine plasma levels (see DOSAGE AND ADMINISTRATION ). Response usually occurs within a week and steady state within a month. Cystadane has been administered concomitantly with vitamin B 6 (pyridoxine), vitamin B 12 (cobalamin), and folate. uuid:5dfc67d9-3ca6-47e7-8367-af54c3c76c09 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17750 biolink:treats MONDO:0009353 PMID:41385096 "[{""id"":""uuid:0a8d1a2d-8dee-4058-ad47-fd94d0acef3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fa6a6388-0455-4c49-98d0-027ab1b338c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cystadane (betaine anhydrous for oral solution) is indicated for the treatment of homocystinuria to decrease elevated homocysteine blood levels. Included within the category of homocystinuria are deficiencies or defects in: cystathionine beta-synthase (CBS), 5,10-methylenetetrahydrofolate reductase (MTHFR), cobalamin cofactor metabolism ( cbl ). Patient response to Cystadane can be monitored by homocysteine plasma levels (see DOSAGE AND ADMINISTRATION ). Response usually occurs within a week and steady state within a month. Cystadane has been administered concomitantly with vitamin B 6 (pyridoxine), vitamin B 12 (cobalamin), and folate. uuid:32fb0894-f7fe-4c52-b18e-3bdeb7a324be biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17750 biolink:treats MONDO:0019220 PMID:41385096 "[{""id"":""uuid:970aac35-48c1-4fe5-bf6c-ee95e7605e27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c3d90668-ab21-4b16-9915-3dec10b0f8b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cystadane (betaine anhydrous for oral solution) is indicated for the treatment of homocystinuria to decrease elevated homocysteine blood levels. Included within the category of homocystinuria are deficiencies or defects in: cystathionine beta-synthase (CBS), 5,10-methylenetetrahydrofolate reductase (MTHFR), cobalamin cofactor metabolism ( cbl ). Patient response to Cystadane can be monitored by homocysteine plasma levels (see DOSAGE AND ADMINISTRATION ). Response usually occurs within a week and steady state within a month. Cystadane has been administered concomitantly with vitamin B 6 (pyridoxine), vitamin B 12 (cobalamin), and folate. uuid:88c3f20b-ae29-46e5-a0a0-0fab188c1db7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:204734 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:e18ab1fb-6e11-40ca-9d4f-521a25781788"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:81e71d57-202b-4ee5-bd86-8cdc88d2024a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Desonate Gel is indicated for the treatment of mild to moderate atopic dermatitis in patients 3 months of age and older. Patients should be instructed to use Desonate Gel for the minimum amount of time as necessary to achieve the desired results because of the potential for Desonate Gel to suppress the hypothalamic-pituitary-adrenal (HPA) axis (see PRECAUTIONS ). Treatment should not exceed 4 consecutive weeks. uuid:01c555b9-7ee6-4138-9261-51645278eaa0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:607 biolink:treats MONDO:0005302 PMID:41385096 "[{""id"":""uuid:62602bdb-df45-4ee2-972e-36558fd03915"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:098d0ac7-0f6b-48b0-af6c-01193eaf707f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate tablets are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy. MESH:C090411 uuid:663f7ce0-a731-42d9-bb5c-aa6b0cb5d3fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:607 biolink:treats MONDO:0021107 PMID:41385096 "[{""id"":""uuid:adf10bc6-4504-49b3-bcf3-409b3ecb097a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:136a4984-4e57-46b0-8987-538b147e7be8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate tablets are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy. MESH:C090411 uuid:34cb74e5-d401-4dfd-a93d-3927f8e8fd9b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7820 biolink:treats MONDO:0005298 PMID:41385096 "[{""id"":""uuid:3fab9df1-1f53-48d7-a788-59ef5a845043"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8708e4f5-a672-4c85-90b7-4a82d3904f8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxandrin is indicated as adjunctive therapy to promote weight gain after weight loss following extensive surgery, chronic infections, or severe trauma, and in some patients who without definite pathophysiologic reasons fail to gain or to maintain normal weight, to offset the protein catabolism associated with prolonged administration of corticosteroids, and for the relief of the bone pain frequently accompanying osteoporosis (See DOSAGE AND ADMINISTRATION ). uuid:8579b208-995c-4730-ad17-4920a759fbc6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8232 biolink:treats UMLS:C1112209 PMID:41385096 "[{""id"":""uuid:82ff32f9-919c-444a-b384-d7d6663bd4d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4ee15661-6e11-4954-b063-5cc726f2ba64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapeutic: PIPRACIL is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Intra-Abdominal Infections including hepatobiliary and surgical infections caused by E. coli , Pseudomonas aeruginosa , enterococci, Clostridium spp., anaerobic cocci, or Bacteroides spp., including B. fragilis. Urinary Tract Infections caused by E. coli , Klebsiella spp., P. aeruginosa , Proteus spp., including P. mirabilis , or enterococci. Gynecologic Infections including endometritis, pelvic inflammatory disease, pelvic cellulitis caused by Bacteroides spp., including B. fragilis , anaerobic cocci, Neisseria gonorrhoeae , or enterococci ( E. faecalis ). Septicemia including bacteremia caused by E. coli , Klebsiella spp., Enterobacter spp., Serratia spp., P. mirabilis , S. pneumoniae , enterococci, P. aeruginosa , Bacteroides spp., or anaerobic cocci. Lower RespiratoryTract Infections caused by E. coli , Klebsiella spp., Enterobacter spp., P . aeruginosa , Serratia spp., H. influenzae , Bacteroides spp., or anaerobic cocci. Although improvement has been noted in patients with cystic fibrosis, lasting bacterial eradication may not necessarily be achieved. Skin and Skin Structure Infections caused by E. coli , Klebsiella spp., Serratia spp., Acinetobacter spp., Enterobacter spp., P. aeruginosa , Morganella morganii , Providencia rettgeri , Proteus vulgaris , P. mirabilis , Bacteroides spp., including B. fragilis , anaerobic cocci, or enterococci. Bone and Joint Infections caused by P. aeruginosa , enterococci, Bacteroides spp., or anaerobic cocci. Uncomplicated Gonococcal Urethritis caused by N. gonorrhoeae. PIPRACIL has also been shown to be clinically effective for the treatment of infections at various sites caused by Streptococcus species including S. pyogenes and S. pneumoniae ; however, infections caused by these organisms are ordinarily treated with more narrow spectrum penicillins. Because of its broad spectrum of bactericidal activity against gram-positive and gram-negative aerobic and anaerobic bacteria, PIPRACIL is particularly useful for the treatment of mixed infections and presumptive therapy prior to the identification of the causative organisms. Also, PIPRACIL may be administered as single drug therapy in some situations where normally two antibiotics might be employed. Piperacillin has been successfully used with aminoglycosides, especially in patients with impaired host defenses. Both drugs should be used in full therapeutic doses. Appropriate cultures should be made for susceptibility testing before initiating therapy and therapy adjusted, if appropriate, once the results are known. Prophylaxis: PIPRACIL is indicated for prophylactic use in surgery including intra-abdominal (gastrointestinal and biliary) procedures, vaginal hysterectomy, abdominal hysterectomy, and cesarean section. Effective prophylactic use depends on the time of administration; PIPRACIL should be given one-half to one hour before the operation so that effective levels can be achieved in the site prior to the procedure. The prophylactic use of piperacillin should be stopped within 24 hours, since continuing administration of any antibiotic increases the possibility of adverse reactions, but in the majority of surgical procedures, does not reduce the incidence of subsequent infections. If there are signs of infection, specimens for culture and susceptibility testing should be obtained for identification of the causative microorganism so that appropriate therapy can be instituted. To reduce the development of drug-resistant bacteria and maintain the effectiveness of PIPRACIL and other antibacterial drugs, PIPRACILshould only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:e2149f3a-3fa3-4cad-af60-f907fc7072ed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8232 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:958a077a-853c-47ef-be1b-704c043185cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a0ad726b-53a5-428e-b014-4d200c45ba9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapeutic: PIPRACIL is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Intra-Abdominal Infections including hepatobiliary and surgical infections caused by E. coli , Pseudomonas aeruginosa , enterococci, Clostridium spp., anaerobic cocci, or Bacteroides spp., including B. fragilis. Urinary Tract Infections caused by E. coli , Klebsiella spp., P. aeruginosa , Proteus spp., including P. mirabilis , or enterococci. Gynecologic Infections including endometritis, pelvic inflammatory disease, pelvic cellulitis caused by Bacteroides spp., including B. fragilis , anaerobic cocci, Neisseria gonorrhoeae , or enterococci ( E. faecalis ). Septicemia including bacteremia caused by E. coli , Klebsiella spp., Enterobacter spp., Serratia spp., P. mirabilis , S. pneumoniae , enterococci, P. aeruginosa , Bacteroides spp., or anaerobic cocci. Lower RespiratoryTract Infections caused by E. coli , Klebsiella spp., Enterobacter spp., P . aeruginosa , Serratia spp., H. influenzae , Bacteroides spp., or anaerobic cocci. Although improvement has been noted in patients with cystic fibrosis, lasting bacterial eradication may not necessarily be achieved. Skin and Skin Structure Infections caused by E. coli , Klebsiella spp., Serratia spp., Acinetobacter spp., Enterobacter spp., P. aeruginosa , Morganella morganii , Providencia rettgeri , Proteus vulgaris , P. mirabilis , Bacteroides spp., including B. fragilis , anaerobic cocci, or enterococci. Bone and Joint Infections caused by P. aeruginosa , enterococci, Bacteroides spp., or anaerobic cocci. Uncomplicated Gonococcal Urethritis caused by N. gonorrhoeae. PIPRACIL has also been shown to be clinically effective for the treatment of infections at various sites caused by Streptococcus species including S. pyogenes and S. pneumoniae ; however, infections caused by these organisms are ordinarily treated with more narrow spectrum penicillins. Because of its broad spectrum of bactericidal activity against gram-positive and gram-negative aerobic and anaerobic bacteria, PIPRACIL is particularly useful for the treatment of mixed infections and presumptive therapy prior to the identification of the causative organisms. Also, PIPRACIL may be administered as single drug therapy in some situations where normally two antibiotics might be employed. Piperacillin has been successfully used with aminoglycosides, especially in patients with impaired host defenses. Both drugs should be used in full therapeutic doses. Appropriate cultures should be made for susceptibility testing before initiating therapy and therapy adjusted, if appropriate, once the results are known. Prophylaxis: PIPRACIL is indicated for prophylactic use in surgery including intra-abdominal (gastrointestinal and biliary) procedures, vaginal hysterectomy, abdominal hysterectomy, and cesarean section. Effective prophylactic use depends on the time of administration; PIPRACIL should be given one-half to one hour before the operation so that effective levels can be achieved in the site prior to the procedure. The prophylactic use of piperacillin should be stopped within 24 hours, since continuing administration of any antibiotic increases the possibility of adverse reactions, but in the majority of surgical procedures, does not reduce the incidence of subsequent infections. If there are signs of infection, specimens for culture and susceptibility testing should be obtained for identification of the causative microorganism so that appropriate therapy can be instituted. To reduce the development of drug-resistant bacteria and maintain the effectiveness of PIPRACIL and other antibacterial drugs, PIPRACILshould only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:61ecdf24-45f0-407a-9da9-de250c10af31 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8232 biolink:treats MONDO:0000918 PMID:41385096 "[{""id"":""uuid:90291bcc-27a6-4891-86e1-1d07d2b30ca9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c2e1d673-868f-4481-b1aa-9522cfb520ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapeutic: PIPRACIL is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Intra-Abdominal Infections including hepatobiliary and surgical infections caused by E. coli , Pseudomonas aeruginosa , enterococci, Clostridium spp., anaerobic cocci, or Bacteroides spp., including B. fragilis. Urinary Tract Infections caused by E. coli , Klebsiella spp., P. aeruginosa , Proteus spp., including P. mirabilis , or enterococci. Gynecologic Infections including endometritis, pelvic inflammatory disease, pelvic cellulitis caused by Bacteroides spp., including B. fragilis , anaerobic cocci, Neisseria gonorrhoeae , or enterococci ( E. faecalis ). Septicemia including bacteremia caused by E. coli , Klebsiella spp., Enterobacter spp., Serratia spp., P. mirabilis , S. pneumoniae , enterococci, P. aeruginosa , Bacteroides spp., or anaerobic cocci. Lower RespiratoryTract Infections caused by E. coli , Klebsiella spp., Enterobacter spp., P . aeruginosa , Serratia spp., H. influenzae , Bacteroides spp., or anaerobic cocci. Although improvement has been noted in patients with cystic fibrosis, lasting bacterial eradication may not necessarily be achieved. Skin and Skin Structure Infections caused by E. coli , Klebsiella spp., Serratia spp., Acinetobacter spp., Enterobacter spp., P. aeruginosa , Morganella morganii , Providencia rettgeri , Proteus vulgaris , P. mirabilis , Bacteroides spp., including B. fragilis , anaerobic cocci, or enterococci. Bone and Joint Infections caused by P. aeruginosa , enterococci, Bacteroides spp., or anaerobic cocci. Uncomplicated Gonococcal Urethritis caused by N. gonorrhoeae. PIPRACIL has also been shown to be clinically effective for the treatment of infections at various sites caused by Streptococcus species including S. pyogenes and S. pneumoniae ; however, infections caused by these organisms are ordinarily treated with more narrow spectrum penicillins. Because of its broad spectrum of bactericidal activity against gram-positive and gram-negative aerobic and anaerobic bacteria, PIPRACIL is particularly useful for the treatment of mixed infections and presumptive therapy prior to the identification of the causative organisms. Also, PIPRACIL may be administered as single drug therapy in some situations where normally two antibiotics might be employed. Piperacillin has been successfully used with aminoglycosides, especially in patients with impaired host defenses. Both drugs should be used in full therapeutic doses. Appropriate cultures should be made for susceptibility testing before initiating therapy and therapy adjusted, if appropriate, once the results are known. Prophylaxis: PIPRACIL is indicated for prophylactic use in surgery including intra-abdominal (gastrointestinal and biliary) procedures, vaginal hysterectomy, abdominal hysterectomy, and cesarean section. Effective prophylactic use depends on the time of administration; PIPRACIL should be given one-half to one hour before the operation so that effective levels can be achieved in the site prior to the procedure. The prophylactic use of piperacillin should be stopped within 24 hours, since continuing administration of any antibiotic increases the possibility of adverse reactions, but in the majority of surgical procedures, does not reduce the incidence of subsequent infections. If there are signs of infection, specimens for culture and susceptibility testing should be obtained for identification of the causative microorganism so that appropriate therapy can be instituted. To reduce the development of drug-resistant bacteria and maintain the effectiveness of PIPRACIL and other antibacterial drugs, PIPRACILshould only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:25038aa8-ad2a-4b0c-9853-a02d00eccd0f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8232 biolink:treats MONDO:0000922 PMID:41385096 "[{""id"":""uuid:f6d161b2-c660-4876-9d91-21775beca8e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:191a7254-b210-473f-ac09-52241ec6c8b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapeutic: PIPRACIL is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Intra-Abdominal Infections including hepatobiliary and surgical infections caused by E. coli , Pseudomonas aeruginosa , enterococci, Clostridium spp., anaerobic cocci, or Bacteroides spp., including B. fragilis. Urinary Tract Infections caused by E. coli , Klebsiella spp., P. aeruginosa , Proteus spp., including P. mirabilis , or enterococci. Gynecologic Infections including endometritis, pelvic inflammatory disease, pelvic cellulitis caused by Bacteroides spp., including B. fragilis , anaerobic cocci, Neisseria gonorrhoeae , or enterococci ( E. faecalis ). Septicemia including bacteremia caused by E. coli , Klebsiella spp., Enterobacter spp., Serratia spp., P. mirabilis , S. pneumoniae , enterococci, P. aeruginosa , Bacteroides spp., or anaerobic cocci. Lower RespiratoryTract Infections caused by E. coli , Klebsiella spp., Enterobacter spp., P . aeruginosa , Serratia spp., H. influenzae , Bacteroides spp., or anaerobic cocci. Although improvement has been noted in patients with cystic fibrosis, lasting bacterial eradication may not necessarily be achieved. Skin and Skin Structure Infections caused by E. coli , Klebsiella spp., Serratia spp., Acinetobacter spp., Enterobacter spp., P. aeruginosa , Morganella morganii , Providencia rettgeri , Proteus vulgaris , P. mirabilis , Bacteroides spp., including B. fragilis , anaerobic cocci, or enterococci. Bone and Joint Infections caused by P. aeruginosa , enterococci, Bacteroides spp., or anaerobic cocci. Uncomplicated Gonococcal Urethritis caused by N. gonorrhoeae. PIPRACIL has also been shown to be clinically effective for the treatment of infections at various sites caused by Streptococcus species including S. pyogenes and S. pneumoniae ; however, infections caused by these organisms are ordinarily treated with more narrow spectrum penicillins. Because of its broad spectrum of bactericidal activity against gram-positive and gram-negative aerobic and anaerobic bacteria, PIPRACIL is particularly useful for the treatment of mixed infections and presumptive therapy prior to the identification of the causative organisms. Also, PIPRACIL may be administered as single drug therapy in some situations where normally two antibiotics might be employed. Piperacillin has been successfully used with aminoglycosides, especially in patients with impaired host defenses. Both drugs should be used in full therapeutic doses. Appropriate cultures should be made for susceptibility testing before initiating therapy and therapy adjusted, if appropriate, once the results are known. Prophylaxis: PIPRACIL is indicated for prophylactic use in surgery including intra-abdominal (gastrointestinal and biliary) procedures, vaginal hysterectomy, abdominal hysterectomy, and cesarean section. Effective prophylactic use depends on the time of administration; PIPRACIL should be given one-half to one hour before the operation so that effective levels can be achieved in the site prior to the procedure. The prophylactic use of piperacillin should be stopped within 24 hours, since continuing administration of any antibiotic increases the possibility of adverse reactions, but in the majority of surgical procedures, does not reduce the incidence of subsequent infections. If there are signs of infection, specimens for culture and susceptibility testing should be obtained for identification of the causative microorganism so that appropriate therapy can be instituted. To reduce the development of drug-resistant bacteria and maintain the effectiveness of PIPRACIL and other antibacterial drugs, PIPRACILshould only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:852506d2-ac9d-419c-8948-c68442121c83 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8232 biolink:treats MONDO:0006887 PMID:41385096 "[{""id"":""uuid:8e6b2bc5-d304-4681-9091-85c502415955"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3a81e083-60ed-4b09-9b9c-bba83ed42ad9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:81857608-93df-4fcd-a482-8d85772c130d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapeutic: PIPRACIL is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Intra-Abdominal Infections including hepatobiliary and surgical infections caused by E. coli , Pseudomonas aeruginosa , enterococci, Clostridium spp., anaerobic cocci, or Bacteroides spp., including B. fragilis. Urinary Tract Infections caused by E. coli , Klebsiella spp., P. aeruginosa , Proteus spp., including P. mirabilis , or enterococci. Gynecologic Infections including endometritis, pelvic inflammatory disease, pelvic cellulitis caused by Bacteroides spp., including B. fragilis , anaerobic cocci, Neisseria gonorrhoeae , or enterococci ( E. faecalis ). Septicemia including bacteremia caused by E. coli , Klebsiella spp., Enterobacter spp., Serratia spp., P. mirabilis , S. pneumoniae , enterococci, P. aeruginosa , Bacteroides spp., or anaerobic cocci. Lower RespiratoryTract Infections caused by E. coli , Klebsiella spp., Enterobacter spp., P . aeruginosa , Serratia spp., H. influenzae , Bacteroides spp., or anaerobic cocci. Although improvement has been noted in patients with cystic fibrosis, lasting bacterial eradication may not necessarily be achieved. Skin and Skin Structure Infections caused by E. coli , Klebsiella spp., Serratia spp., Acinetobacter spp., Enterobacter spp., P. aeruginosa , Morganella morganii , Providencia rettgeri , Proteus vulgaris , P. mirabilis , Bacteroides spp., including B. fragilis , anaerobic cocci, or enterococci. Bone and Joint Infections caused by P. aeruginosa , enterococci, Bacteroides spp., or anaerobic cocci. Uncomplicated Gonococcal Urethritis caused by N. gonorrhoeae. PIPRACIL has also been shown to be clinically effective for the treatment of infections at various sites caused by Streptococcus species including S. pyogenes and S. pneumoniae ; however, infections caused by these organisms are ordinarily treated with more narrow spectrum penicillins. Because of its broad spectrum of bactericidal activity against gram-positive and gram-negative aerobic and anaerobic bacteria, PIPRACIL is particularly useful for the treatment of mixed infections and presumptive therapy prior to the identification of the causative organisms. Also, PIPRACIL may be administered as single drug therapy in some situations where normally two antibiotics might be employed. Piperacillin has been successfully used with aminoglycosides, especially in patients with impaired host defenses. Both drugs should be used in full therapeutic doses. Appropriate cultures should be made for susceptibility testing before initiating therapy and therapy adjusted, if appropriate, once the results are known. Prophylaxis: PIPRACIL is indicated for prophylactic use in surgery including intra-abdominal (gastrointestinal and biliary) procedures, vaginal hysterectomy, abdominal hysterectomy, and cesarean section. Effective prophylactic use depends on the time of administration; PIPRACIL should be given one-half to one hour before the operation so that effective levels can be achieved in the site prior to the procedure. The prophylactic use of piperacillin should be stopped within 24 hours, since continuing administration of any antibiotic increases the possibility of adverse reactions, but in the majority of surgical procedures, does not reduce the incidence of subsequent infections. If there are signs of infection, specimens for culture and susceptibility testing should be obtained for identification of the causative microorganism so that appropriate therapy can be instituted. To reduce the development of drug-resistant bacteria and maintain the effectiveness of PIPRACIL and other antibacterial drugs, PIPRACILshould only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.|[PMDA] Drugs with a new dosage indicated for the treatment of sepsis, acute bronchitis, pneumonia, lung abscess, thoracic empyema, secondary infection of chronic respiratory disease, cystitis, pyelonephritis, cholecystitis, choledochitis, bartholinitis, intrauterine infection, uterine adnexitis, parametritis, and purulent meningitis. uuid:454a7f42-81d9-4a37-aeee-be8a0eddbb63 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8232 biolink:treats MONDO:0700217 PMID:41385096 "[{""id"":""uuid:bc0c12e3-88e3-4d07-8699-034f0f830044"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6d7ec644-f8bf-429e-afc4-a83a9fd7e6ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapeutic: PIPRACIL is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Intra-Abdominal Infections including hepatobiliary and surgical infections caused by E. coli , Pseudomonas aeruginosa , enterococci, Clostridium spp., anaerobic cocci, or Bacteroides spp., including B. fragilis. Urinary Tract Infections caused by E. coli , Klebsiella spp., P. aeruginosa , Proteus spp., including P. mirabilis , or enterococci. Gynecologic Infections including endometritis, pelvic inflammatory disease, pelvic cellulitis caused by Bacteroides spp., including B. fragilis , anaerobic cocci, Neisseria gonorrhoeae , or enterococci ( E. faecalis ). Septicemia including bacteremia caused by E. coli , Klebsiella spp., Enterobacter spp., Serratia spp., P. mirabilis , S. pneumoniae , enterococci, P. aeruginosa , Bacteroides spp., or anaerobic cocci. Lower RespiratoryTract Infections caused by E. coli , Klebsiella spp., Enterobacter spp., P . aeruginosa , Serratia spp., H. influenzae , Bacteroides spp., or anaerobic cocci. Although improvement has been noted in patients with cystic fibrosis, lasting bacterial eradication may not necessarily be achieved. Skin and Skin Structure Infections caused by E. coli , Klebsiella spp., Serratia spp., Acinetobacter spp., Enterobacter spp., P. aeruginosa , Morganella morganii , Providencia rettgeri , Proteus vulgaris , P. mirabilis , Bacteroides spp., including B. fragilis , anaerobic cocci, or enterococci. Bone and Joint Infections caused by P. aeruginosa , enterococci, Bacteroides spp., or anaerobic cocci. Uncomplicated Gonococcal Urethritis caused by N. gonorrhoeae. PIPRACIL has also been shown to be clinically effective for the treatment of infections at various sites caused by Streptococcus species including S. pyogenes and S. pneumoniae ; however, infections caused by these organisms are ordinarily treated with more narrow spectrum penicillins. Because of its broad spectrum of bactericidal activity against gram-positive and gram-negative aerobic and anaerobic bacteria, PIPRACIL is particularly useful for the treatment of mixed infections and presumptive therapy prior to the identification of the causative organisms. Also, PIPRACIL may be administered as single drug therapy in some situations where normally two antibiotics might be employed. Piperacillin has been successfully used with aminoglycosides, especially in patients with impaired host defenses. Both drugs should be used in full therapeutic doses. Appropriate cultures should be made for susceptibility testing before initiating therapy and therapy adjusted, if appropriate, once the results are known. Prophylaxis: PIPRACIL is indicated for prophylactic use in surgery including intra-abdominal (gastrointestinal and biliary) procedures, vaginal hysterectomy, abdominal hysterectomy, and cesarean section. Effective prophylactic use depends on the time of administration; PIPRACIL should be given one-half to one hour before the operation so that effective levels can be achieved in the site prior to the procedure. The prophylactic use of piperacillin should be stopped within 24 hours, since continuing administration of any antibiotic increases the possibility of adverse reactions, but in the majority of surgical procedures, does not reduce the incidence of subsequent infections. If there are signs of infection, specimens for culture and susceptibility testing should be obtained for identification of the causative microorganism so that appropriate therapy can be instituted. To reduce the development of drug-resistant bacteria and maintain the effectiveness of PIPRACIL and other antibacterial drugs, PIPRACILshould only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:c240cb1e-f141-41db-b310-c0dd507823e1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8232 biolink:treats MONDO:0005229 PMID:41385096 "[{""id"":""uuid:81fd1141-21bd-4daa-af9d-10366280d3cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cac188ae-198f-411a-8b4e-506cd456ac02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapeutic: PIPRACIL is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Intra-Abdominal Infections including hepatobiliary and surgical infections caused by E. coli , Pseudomonas aeruginosa , enterococci, Clostridium spp., anaerobic cocci, or Bacteroides spp., including B. fragilis. Urinary Tract Infections caused by E. coli , Klebsiella spp., P. aeruginosa , Proteus spp., including P. mirabilis , or enterococci. Gynecologic Infections including endometritis, pelvic inflammatory disease, pelvic cellulitis caused by Bacteroides spp., including B. fragilis , anaerobic cocci, Neisseria gonorrhoeae , or enterococci ( E. faecalis ). Septicemia including bacteremia caused by E. coli , Klebsiella spp., Enterobacter spp., Serratia spp., P. mirabilis , S. pneumoniae , enterococci, P. aeruginosa , Bacteroides spp., or anaerobic cocci. Lower RespiratoryTract Infections caused by E. coli , Klebsiella spp., Enterobacter spp., P . aeruginosa , Serratia spp., H. influenzae , Bacteroides spp., or anaerobic cocci. Although improvement has been noted in patients with cystic fibrosis, lasting bacterial eradication may not necessarily be achieved. Skin and Skin Structure Infections caused by E. coli , Klebsiella spp., Serratia spp., Acinetobacter spp., Enterobacter spp., P. aeruginosa , Morganella morganii , Providencia rettgeri , Proteus vulgaris , P. mirabilis , Bacteroides spp., including B. fragilis , anaerobic cocci, or enterococci. Bone and Joint Infections caused by P. aeruginosa , enterococci, Bacteroides spp., or anaerobic cocci. Uncomplicated Gonococcal Urethritis caused by N. gonorrhoeae. PIPRACIL has also been shown to be clinically effective for the treatment of infections at various sites caused by Streptococcus species including S. pyogenes and S. pneumoniae ; however, infections caused by these organisms are ordinarily treated with more narrow spectrum penicillins. Because of its broad spectrum of bactericidal activity against gram-positive and gram-negative aerobic and anaerobic bacteria, PIPRACIL is particularly useful for the treatment of mixed infections and presumptive therapy prior to the identification of the causative organisms. Also, PIPRACIL may be administered as single drug therapy in some situations where normally two antibiotics might be employed. Piperacillin has been successfully used with aminoglycosides, especially in patients with impaired host defenses. Both drugs should be used in full therapeutic doses. Appropriate cultures should be made for susceptibility testing before initiating therapy and therapy adjusted, if appropriate, once the results are known. Prophylaxis: PIPRACIL is indicated for prophylactic use in surgery including intra-abdominal (gastrointestinal and biliary) procedures, vaginal hysterectomy, abdominal hysterectomy, and cesarean section. Effective prophylactic use depends on the time of administration; PIPRACIL should be given one-half to one hour before the operation so that effective levels can be achieved in the site prior to the procedure. The prophylactic use of piperacillin should be stopped within 24 hours, since continuing administration of any antibiotic increases the possibility of adverse reactions, but in the majority of surgical procedures, does not reduce the incidence of subsequent infections. If there are signs of infection, specimens for culture and susceptibility testing should be obtained for identification of the causative microorganism so that appropriate therapy can be instituted. To reduce the development of drug-resistant bacteria and maintain the effectiveness of PIPRACIL and other antibacterial drugs, PIPRACILshould only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:d4350205-38ed-43c5-97ee-0900beab5904 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8232 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:8ec009fa-0844-4ec1-8b7c-ebf1a42c5f9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:767c6a0e-6536-4e41-85d9-89a9a652bff9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapeutic: PIPRACIL is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Intra-Abdominal Infections including hepatobiliary and surgical infections caused by E. coli , Pseudomonas aeruginosa , enterococci, Clostridium spp., anaerobic cocci, or Bacteroides spp., including B. fragilis. Urinary Tract Infections caused by E. coli , Klebsiella spp., P. aeruginosa , Proteus spp., including P. mirabilis , or enterococci. Gynecologic Infections including endometritis, pelvic inflammatory disease, pelvic cellulitis caused by Bacteroides spp., including B. fragilis , anaerobic cocci, Neisseria gonorrhoeae , or enterococci ( E. faecalis ). Septicemia including bacteremia caused by E. coli , Klebsiella spp., Enterobacter spp., Serratia spp., P. mirabilis , S. pneumoniae , enterococci, P. aeruginosa , Bacteroides spp., or anaerobic cocci. Lower RespiratoryTract Infections caused by E. coli , Klebsiella spp., Enterobacter spp., P . aeruginosa , Serratia spp., H. influenzae , Bacteroides spp., or anaerobic cocci. Although improvement has been noted in patients with cystic fibrosis, lasting bacterial eradication may not necessarily be achieved. Skin and Skin Structure Infections caused by E. coli , Klebsiella spp., Serratia spp., Acinetobacter spp., Enterobacter spp., P. aeruginosa , Morganella morganii , Providencia rettgeri , Proteus vulgaris , P. mirabilis , Bacteroides spp., including B. fragilis , anaerobic cocci, or enterococci. Bone and Joint Infections caused by P. aeruginosa , enterococci, Bacteroides spp., or anaerobic cocci. Uncomplicated Gonococcal Urethritis caused by N. gonorrhoeae. PIPRACIL has also been shown to be clinically effective for the treatment of infections at various sites caused by Streptococcus species including S. pyogenes and S. pneumoniae ; however, infections caused by these organisms are ordinarily treated with more narrow spectrum penicillins. Because of its broad spectrum of bactericidal activity against gram-positive and gram-negative aerobic and anaerobic bacteria, PIPRACIL is particularly useful for the treatment of mixed infections and presumptive therapy prior to the identification of the causative organisms. Also, PIPRACIL may be administered as single drug therapy in some situations where normally two antibiotics might be employed. Piperacillin has been successfully used with aminoglycosides, especially in patients with impaired host defenses. Both drugs should be used in full therapeutic doses. Appropriate cultures should be made for susceptibility testing before initiating therapy and therapy adjusted, if appropriate, once the results are known. Prophylaxis: PIPRACIL is indicated for prophylactic use in surgery including intra-abdominal (gastrointestinal and biliary) procedures, vaginal hysterectomy, abdominal hysterectomy, and cesarean section. Effective prophylactic use depends on the time of administration; PIPRACIL should be given one-half to one hour before the operation so that effective levels can be achieved in the site prior to the procedure. The prophylactic use of piperacillin should be stopped within 24 hours, since continuing administration of any antibiotic increases the possibility of adverse reactions, but in the majority of surgical procedures, does not reduce the incidence of subsequent infections. If there are signs of infection, specimens for culture and susceptibility testing should be obtained for identification of the causative microorganism so that appropriate therapy can be instituted. To reduce the development of drug-resistant bacteria and maintain the effectiveness of PIPRACIL and other antibacterial drugs, PIPRACILshould only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:167dd930-d4d6-460a-886c-7dc4d7a52993 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8232 biolink:treats MONDO:0009061 PMID:41385096 "[{""id"":""uuid:64eecdea-0355-436e-b18c-2717524d6e92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3787c3bc-24fc-4339-89a8-9b45c43cdf8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapeutic: PIPRACIL is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Intra-Abdominal Infections including hepatobiliary and surgical infections caused by E. coli , Pseudomonas aeruginosa , enterococci, Clostridium spp., anaerobic cocci, or Bacteroides spp., including B. fragilis. Urinary Tract Infections caused by E. coli , Klebsiella spp., P. aeruginosa , Proteus spp., including P. mirabilis , or enterococci. Gynecologic Infections including endometritis, pelvic inflammatory disease, pelvic cellulitis caused by Bacteroides spp., including B. fragilis , anaerobic cocci, Neisseria gonorrhoeae , or enterococci ( E. faecalis ). Septicemia including bacteremia caused by E. coli , Klebsiella spp., Enterobacter spp., Serratia spp., P. mirabilis , S. pneumoniae , enterococci, P. aeruginosa , Bacteroides spp., or anaerobic cocci. Lower RespiratoryTract Infections caused by E. coli , Klebsiella spp., Enterobacter spp., P . aeruginosa , Serratia spp., H. influenzae , Bacteroides spp., or anaerobic cocci. Although improvement has been noted in patients with cystic fibrosis, lasting bacterial eradication may not necessarily be achieved. Skin and Skin Structure Infections caused by E. coli , Klebsiella spp., Serratia spp., Acinetobacter spp., Enterobacter spp., P. aeruginosa , Morganella morganii , Providencia rettgeri , Proteus vulgaris , P. mirabilis , Bacteroides spp., including B. fragilis , anaerobic cocci, or enterococci. Bone and Joint Infections caused by P. aeruginosa , enterococci, Bacteroides spp., or anaerobic cocci. Uncomplicated Gonococcal Urethritis caused by N. gonorrhoeae. PIPRACIL has also been shown to be clinically effective for the treatment of infections at various sites caused by Streptococcus species including S. pyogenes and S. pneumoniae ; however, infections caused by these organisms are ordinarily treated with more narrow spectrum penicillins. Because of its broad spectrum of bactericidal activity against gram-positive and gram-negative aerobic and anaerobic bacteria, PIPRACIL is particularly useful for the treatment of mixed infections and presumptive therapy prior to the identification of the causative organisms. Also, PIPRACIL may be administered as single drug therapy in some situations where normally two antibiotics might be employed. Piperacillin has been successfully used with aminoglycosides, especially in patients with impaired host defenses. Both drugs should be used in full therapeutic doses. Appropriate cultures should be made for susceptibility testing before initiating therapy and therapy adjusted, if appropriate, once the results are known. Prophylaxis: PIPRACIL is indicated for prophylactic use in surgery including intra-abdominal (gastrointestinal and biliary) procedures, vaginal hysterectomy, abdominal hysterectomy, and cesarean section. Effective prophylactic use depends on the time of administration; PIPRACIL should be given one-half to one hour before the operation so that effective levels can be achieved in the site prior to the procedure. The prophylactic use of piperacillin should be stopped within 24 hours, since continuing administration of any antibiotic increases the possibility of adverse reactions, but in the majority of surgical procedures, does not reduce the incidence of subsequent infections. If there are signs of infection, specimens for culture and susceptibility testing should be obtained for identification of the causative microorganism so that appropriate therapy can be instituted. To reduce the development of drug-resistant bacteria and maintain the effectiveness of PIPRACIL and other antibacterial drugs, PIPRACILshould only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:da053704-86c6-4d58-94b3-8eb4bc751968 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8232 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:8ebeb58d-e341-4142-b698-4c75c99c20fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5acb8d61-124d-41b6-b787-894e41e77442"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapeutic: PIPRACIL is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Intra-Abdominal Infections including hepatobiliary and surgical infections caused by E. coli , Pseudomonas aeruginosa , enterococci, Clostridium spp., anaerobic cocci, or Bacteroides spp., including B. fragilis. Urinary Tract Infections caused by E. coli , Klebsiella spp., P. aeruginosa , Proteus spp., including P. mirabilis , or enterococci. Gynecologic Infections including endometritis, pelvic inflammatory disease, pelvic cellulitis caused by Bacteroides spp., including B. fragilis , anaerobic cocci, Neisseria gonorrhoeae , or enterococci ( E. faecalis ). Septicemia including bacteremia caused by E. coli , Klebsiella spp., Enterobacter spp., Serratia spp., P. mirabilis , S. pneumoniae , enterococci, P. aeruginosa , Bacteroides spp., or anaerobic cocci. Lower RespiratoryTract Infections caused by E. coli , Klebsiella spp., Enterobacter spp., P . aeruginosa , Serratia spp., H. influenzae , Bacteroides spp., or anaerobic cocci. Although improvement has been noted in patients with cystic fibrosis, lasting bacterial eradication may not necessarily be achieved. Skin and Skin Structure Infections caused by E. coli , Klebsiella spp., Serratia spp., Acinetobacter spp., Enterobacter spp., P. aeruginosa , Morganella morganii , Providencia rettgeri , Proteus vulgaris , P. mirabilis , Bacteroides spp., including B. fragilis , anaerobic cocci, or enterococci. Bone and Joint Infections caused by P. aeruginosa , enterococci, Bacteroides spp., or anaerobic cocci. Uncomplicated Gonococcal Urethritis caused by N. gonorrhoeae. PIPRACIL has also been shown to be clinically effective for the treatment of infections at various sites caused by Streptococcus species including S. pyogenes and S. pneumoniae ; however, infections caused by these organisms are ordinarily treated with more narrow spectrum penicillins. Because of its broad spectrum of bactericidal activity against gram-positive and gram-negative aerobic and anaerobic bacteria, PIPRACIL is particularly useful for the treatment of mixed infections and presumptive therapy prior to the identification of the causative organisms. Also, PIPRACIL may be administered as single drug therapy in some situations where normally two antibiotics might be employed. Piperacillin has been successfully used with aminoglycosides, especially in patients with impaired host defenses. Both drugs should be used in full therapeutic doses. Appropriate cultures should be made for susceptibility testing before initiating therapy and therapy adjusted, if appropriate, once the results are known. Prophylaxis: PIPRACIL is indicated for prophylactic use in surgery including intra-abdominal (gastrointestinal and biliary) procedures, vaginal hysterectomy, abdominal hysterectomy, and cesarean section. Effective prophylactic use depends on the time of administration; PIPRACIL should be given one-half to one hour before the operation so that effective levels can be achieved in the site prior to the procedure. The prophylactic use of piperacillin should be stopped within 24 hours, since continuing administration of any antibiotic increases the possibility of adverse reactions, but in the majority of surgical procedures, does not reduce the incidence of subsequent infections. If there are signs of infection, specimens for culture and susceptibility testing should be obtained for identification of the causative microorganism so that appropriate therapy can be instituted. To reduce the development of drug-resistant bacteria and maintain the effectiveness of PIPRACIL and other antibacterial drugs, PIPRACILshould only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:c73fc4bc-7b1a-4d47-b052-86c173962634 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8232 biolink:treats UMLS:C0851989 PMID:41385096 "[{""id"":""uuid:2fc1e793-7f68-4478-82ef-9e060e733e0f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:976e95fc-8162-4a01-ad13-9d2aaab81be0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapeutic: PIPRACIL is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Intra-Abdominal Infections including hepatobiliary and surgical infections caused by E. coli , Pseudomonas aeruginosa , enterococci, Clostridium spp., anaerobic cocci, or Bacteroides spp., including B. fragilis. Urinary Tract Infections caused by E. coli , Klebsiella spp., P. aeruginosa , Proteus spp., including P. mirabilis , or enterococci. Gynecologic Infections including endometritis, pelvic inflammatory disease, pelvic cellulitis caused by Bacteroides spp., including B. fragilis , anaerobic cocci, Neisseria gonorrhoeae , or enterococci ( E. faecalis ). Septicemia including bacteremia caused by E. coli , Klebsiella spp., Enterobacter spp., Serratia spp., P. mirabilis , S. pneumoniae , enterococci, P. aeruginosa , Bacteroides spp., or anaerobic cocci. Lower RespiratoryTract Infections caused by E. coli , Klebsiella spp., Enterobacter spp., P . aeruginosa , Serratia spp., H. influenzae , Bacteroides spp., or anaerobic cocci. Although improvement has been noted in patients with cystic fibrosis, lasting bacterial eradication may not necessarily be achieved. Skin and Skin Structure Infections caused by E. coli , Klebsiella spp., Serratia spp., Acinetobacter spp., Enterobacter spp., P. aeruginosa , Morganella morganii , Providencia rettgeri , Proteus vulgaris , P. mirabilis , Bacteroides spp., including B. fragilis , anaerobic cocci, or enterococci. Bone and Joint Infections caused by P. aeruginosa , enterococci, Bacteroides spp., or anaerobic cocci. Uncomplicated Gonococcal Urethritis caused by N. gonorrhoeae. PIPRACIL has also been shown to be clinically effective for the treatment of infections at various sites caused by Streptococcus species including S. pyogenes and S. pneumoniae ; however, infections caused by these organisms are ordinarily treated with more narrow spectrum penicillins. Because of its broad spectrum of bactericidal activity against gram-positive and gram-negative aerobic and anaerobic bacteria, PIPRACIL is particularly useful for the treatment of mixed infections and presumptive therapy prior to the identification of the causative organisms. Also, PIPRACIL may be administered as single drug therapy in some situations where normally two antibiotics might be employed. Piperacillin has been successfully used with aminoglycosides, especially in patients with impaired host defenses. Both drugs should be used in full therapeutic doses. Appropriate cultures should be made for susceptibility testing before initiating therapy and therapy adjusted, if appropriate, once the results are known. Prophylaxis: PIPRACIL is indicated for prophylactic use in surgery including intra-abdominal (gastrointestinal and biliary) procedures, vaginal hysterectomy, abdominal hysterectomy, and cesarean section. Effective prophylactic use depends on the time of administration; PIPRACIL should be given one-half to one hour before the operation so that effective levels can be achieved in the site prior to the procedure. The prophylactic use of piperacillin should be stopped within 24 hours, since continuing administration of any antibiotic increases the possibility of adverse reactions, but in the majority of surgical procedures, does not reduce the incidence of subsequent infections. If there are signs of infection, specimens for culture and susceptibility testing should be obtained for identification of the causative microorganism so that appropriate therapy can be instituted. To reduce the development of drug-resistant bacteria and maintain the effectiveness of PIPRACIL and other antibacterial drugs, PIPRACILshould only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:4eb0e13d-dfa7-466a-a6c1-3b9755de8d72 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8232 biolink:treats MONDO:0020971 PMID:41385096 "[{""id"":""uuid:26f9e027-6a6d-4d35-ae3c-8eee752b44ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:54fb1587-e6eb-48e0-8b6a-24ee3644bc16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapeutic: PIPRACIL is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Intra-Abdominal Infections including hepatobiliary and surgical infections caused by E. coli , Pseudomonas aeruginosa , enterococci, Clostridium spp., anaerobic cocci, or Bacteroides spp., including B. fragilis. Urinary Tract Infections caused by E. coli , Klebsiella spp., P. aeruginosa , Proteus spp., including P. mirabilis , or enterococci. Gynecologic Infections including endometritis, pelvic inflammatory disease, pelvic cellulitis caused by Bacteroides spp., including B. fragilis , anaerobic cocci, Neisseria gonorrhoeae , or enterococci ( E. faecalis ). Septicemia including bacteremia caused by E. coli , Klebsiella spp., Enterobacter spp., Serratia spp., P. mirabilis , S. pneumoniae , enterococci, P. aeruginosa , Bacteroides spp., or anaerobic cocci. Lower RespiratoryTract Infections caused by E. coli , Klebsiella spp., Enterobacter spp., P . aeruginosa , Serratia spp., H. influenzae , Bacteroides spp., or anaerobic cocci. Although improvement has been noted in patients with cystic fibrosis, lasting bacterial eradication may not necessarily be achieved. Skin and Skin Structure Infections caused by E. coli , Klebsiella spp., Serratia spp., Acinetobacter spp., Enterobacter spp., P. aeruginosa , Morganella morganii , Providencia rettgeri , Proteus vulgaris , P. mirabilis , Bacteroides spp., including B. fragilis , anaerobic cocci, or enterococci. Bone and Joint Infections caused by P. aeruginosa , enterococci, Bacteroides spp., or anaerobic cocci. Uncomplicated Gonococcal Urethritis caused by N. gonorrhoeae. PIPRACIL has also been shown to be clinically effective for the treatment of infections at various sites caused by Streptococcus species including S. pyogenes and S. pneumoniae ; however, infections caused by these organisms are ordinarily treated with more narrow spectrum penicillins. Because of its broad spectrum of bactericidal activity against gram-positive and gram-negative aerobic and anaerobic bacteria, PIPRACIL is particularly useful for the treatment of mixed infections and presumptive therapy prior to the identification of the causative organisms. Also, PIPRACIL may be administered as single drug therapy in some situations where normally two antibiotics might be employed. Piperacillin has been successfully used with aminoglycosides, especially in patients with impaired host defenses. Both drugs should be used in full therapeutic doses. Appropriate cultures should be made for susceptibility testing before initiating therapy and therapy adjusted, if appropriate, once the results are known. Prophylaxis: PIPRACIL is indicated for prophylactic use in surgery including intra-abdominal (gastrointestinal and biliary) procedures, vaginal hysterectomy, abdominal hysterectomy, and cesarean section. Effective prophylactic use depends on the time of administration; PIPRACIL should be given one-half to one hour before the operation so that effective levels can be achieved in the site prior to the procedure. The prophylactic use of piperacillin should be stopped within 24 hours, since continuing administration of any antibiotic increases the possibility of adverse reactions, but in the majority of surgical procedures, does not reduce the incidence of subsequent infections. If there are signs of infection, specimens for culture and susceptibility testing should be obtained for identification of the causative microorganism so that appropriate therapy can be instituted. To reduce the development of drug-resistant bacteria and maintain the effectiveness of PIPRACIL and other antibacterial drugs, PIPRACILshould only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:cd5e7b96-6484-482c-be87-0e5dece76846 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10125 biolink:treats MONDO:0013600 PMID:41385096 "[{""id"":""uuid:52a6f5cc-fc72-495f-8d2b-695115ecd86b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0e8b468d-6515-4868-a840-dd384dc4e957"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Zolpidem tartrate tablets are indicated for the short-term treatment of insomnia characterized by difficulties with sleep initiation. Zolpidem tartrate tablets have been shown to decrease sleep latency for up to 35 days in controlled clinical studies [see Clinical Studies (14) ] . The clinical trials performed in support of efficacy were 4-5 weeks in duration with the final formal assessments of sleep latency performed at the end of treatment. uuid:836ffe06-22ee-44fd-abeb-fc7107c1f330 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17439 biolink:treats MONDO:0008228 PMID:41385096 "[{""id"":""uuid:b4e2136e-4bf7-41d5-9f95-bcaeb389d043"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:be2f9e37-d97d-450a-850e-2ce4e03e8e5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nascobal Nasal Spray is indicated for the maintenance of normal hematologic status in pernicious anemia patients who are in remission following intramuscular vitamin B 12 therapy and who have no nervous system involvement. Nascobal Nasal Spray is also indicated as a supplement for other vitamin B 12 deficiencies, including: I. Dietary deficiency of vitamin B 12 occurring in strict vegetarians (Isolated vitamin B 12 deficiency is very rare). II. Malabsorption of vitamin B 12 resulting from structural or functional damage to the stomach, where intrinsic factor is secreted, or to the ileum, where intrinsic factor facilitates vitamin B 12 absorption. These conditions include HIV infection, AIDS, Crohn's disease, tropical sprue, and nontropical sprue (idiopathic steatorrhea, gluten-induced enteropathy). Folate deficiency in these patients is usually more severe than vitamin B 12 deficiency. III. Inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric atrophy (such as multiple sclerosis, HIV infection, AIDS, certain endocrine disorders, iron deficiency, and subtotal gastrectomy). Total gastrectomy always produces vitamin B 12 deficiency. Structural lesions leading to vitamin B 12 deficiency include regional ileitis, ileal resections, malignancies, etc. IV. Competition for vitamin B 12 by intestinal parasites or bacteria. The fish tapeworm (Diphyllobothrium latum) absorbs huge quantities of vitamin B 12 and infested patients often have associated gastric atrophy. The blind loop syndrome may produce deficiency of vitamin B 12 or folate. V. Inadequate utilization of vitamin B 12 . This may occur if antimetabolites for the vitamin are employed in the treatment of neoplasia. It may be possible to treat the underlying disease by surgical correction of anatomic lesions leading to small bowel bacterial overgrowth, expulsion of fish tapeworm, discontinuation of drugs leading to vitamin malabsorption (see Drug/Laboratory Test Interactions ), use of a gluten free diet in nontropical sprue, or administration of antibiotics in tropical sprue. Such measures remove the need for long-term administration of vitamin B 12 . Requirements of vitamin B 12 in excess of normal (due to pregnancy, thyrotoxicosis, hemolytic anemia, hemorrhage, malignancy, hepatic and renal disease) can usually be met with intranasal or oral supplementation. Nascobal Nasal Spray is not suitable for vitamin B 12 absorption test (Schilling Test). uuid:0d4b1a76-71a6-4ad2-935c-8ed7be01726d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17439 biolink:treats MONDO:0020696 PMID:41385096 "[{""id"":""uuid:7337f67a-fdf4-4c92-9ca8-2fc8ad8c0025"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c2381887-9caa-401c-924b-a9b539767d1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nascobal Nasal Spray is indicated for the maintenance of normal hematologic status in pernicious anemia patients who are in remission following intramuscular vitamin B 12 therapy and who have no nervous system involvement. Nascobal Nasal Spray is also indicated as a supplement for other vitamin B 12 deficiencies, including: I. Dietary deficiency of vitamin B 12 occurring in strict vegetarians (Isolated vitamin B 12 deficiency is very rare). II. Malabsorption of vitamin B 12 resulting from structural or functional damage to the stomach, where intrinsic factor is secreted, or to the ileum, where intrinsic factor facilitates vitamin B 12 absorption. These conditions include HIV infection, AIDS, Crohn's disease, tropical sprue, and nontropical sprue (idiopathic steatorrhea, gluten-induced enteropathy). Folate deficiency in these patients is usually more severe than vitamin B 12 deficiency. III. Inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric atrophy (such as multiple sclerosis, HIV infection, AIDS, certain endocrine disorders, iron deficiency, and subtotal gastrectomy). Total gastrectomy always produces vitamin B 12 deficiency. Structural lesions leading to vitamin B 12 deficiency include regional ileitis, ileal resections, malignancies, etc. IV. Competition for vitamin B 12 by intestinal parasites or bacteria. The fish tapeworm (Diphyllobothrium latum) absorbs huge quantities of vitamin B 12 and infested patients often have associated gastric atrophy. The blind loop syndrome may produce deficiency of vitamin B 12 or folate. V. Inadequate utilization of vitamin B 12 . This may occur if antimetabolites for the vitamin are employed in the treatment of neoplasia. It may be possible to treat the underlying disease by surgical correction of anatomic lesions leading to small bowel bacterial overgrowth, expulsion of fish tapeworm, discontinuation of drugs leading to vitamin malabsorption (see Drug/Laboratory Test Interactions ), use of a gluten free diet in nontropical sprue, or administration of antibiotics in tropical sprue. Such measures remove the need for long-term administration of vitamin B 12 . Requirements of vitamin B 12 in excess of normal (due to pregnancy, thyrotoxicosis, hemolytic anemia, hemorrhage, malignancy, hepatic and renal disease) can usually be met with intranasal or oral supplementation. Nascobal Nasal Spray is not suitable for vitamin B 12 absorption test (Schilling Test). uuid:07b9313c-fafd-4c58-bfc7-2b15d5d074aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17439 biolink:treats MONDO:0005011 PMID:41385096 "[{""id"":""uuid:6078a203-7a7c-4d1c-ac94-a6fe6f74d4c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7a1d4007-3524-4dab-960d-0592dc2f2d49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nascobal Nasal Spray is indicated for the maintenance of normal hematologic status in pernicious anemia patients who are in remission following intramuscular vitamin B 12 therapy and who have no nervous system involvement. Nascobal Nasal Spray is also indicated as a supplement for other vitamin B 12 deficiencies, including: I. Dietary deficiency of vitamin B 12 occurring in strict vegetarians (Isolated vitamin B 12 deficiency is very rare). II. Malabsorption of vitamin B 12 resulting from structural or functional damage to the stomach, where intrinsic factor is secreted, or to the ileum, where intrinsic factor facilitates vitamin B 12 absorption. These conditions include HIV infection, AIDS, Crohn's disease, tropical sprue, and nontropical sprue (idiopathic steatorrhea, gluten-induced enteropathy). Folate deficiency in these patients is usually more severe than vitamin B 12 deficiency. III. Inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric atrophy (such as multiple sclerosis, HIV infection, AIDS, certain endocrine disorders, iron deficiency, and subtotal gastrectomy). Total gastrectomy always produces vitamin B 12 deficiency. Structural lesions leading to vitamin B 12 deficiency include regional ileitis, ileal resections, malignancies, etc. IV. Competition for vitamin B 12 by intestinal parasites or bacteria. The fish tapeworm (Diphyllobothrium latum) absorbs huge quantities of vitamin B 12 and infested patients often have associated gastric atrophy. The blind loop syndrome may produce deficiency of vitamin B 12 or folate. V. Inadequate utilization of vitamin B 12 . This may occur if antimetabolites for the vitamin are employed in the treatment of neoplasia. It may be possible to treat the underlying disease by surgical correction of anatomic lesions leading to small bowel bacterial overgrowth, expulsion of fish tapeworm, discontinuation of drugs leading to vitamin malabsorption (see Drug/Laboratory Test Interactions ), use of a gluten free diet in nontropical sprue, or administration of antibiotics in tropical sprue. Such measures remove the need for long-term administration of vitamin B 12 . Requirements of vitamin B 12 in excess of normal (due to pregnancy, thyrotoxicosis, hemolytic anemia, hemorrhage, malignancy, hepatic and renal disease) can usually be met with intranasal or oral supplementation. Nascobal Nasal Spray is not suitable for vitamin B 12 absorption test (Schilling Test). uuid:fb715efa-06f4-4d7e-867d-6f91b00665f4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17439 biolink:treats MONDO:0001078 PMID:41385096 "[{""id"":""uuid:90ece25c-478a-44f2-b7bb-9870ceecf1ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a98ba94e-6940-4867-bc84-26f38ed14081"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nascobal Nasal Spray is indicated for the maintenance of normal hematologic status in pernicious anemia patients who are in remission following intramuscular vitamin B 12 therapy and who have no nervous system involvement. Nascobal Nasal Spray is also indicated as a supplement for other vitamin B 12 deficiencies, including: I. Dietary deficiency of vitamin B 12 occurring in strict vegetarians (Isolated vitamin B 12 deficiency is very rare). II. Malabsorption of vitamin B 12 resulting from structural or functional damage to the stomach, where intrinsic factor is secreted, or to the ileum, where intrinsic factor facilitates vitamin B 12 absorption. These conditions include HIV infection, AIDS, Crohn's disease, tropical sprue, and nontropical sprue (idiopathic steatorrhea, gluten-induced enteropathy). Folate deficiency in these patients is usually more severe than vitamin B 12 deficiency. III. Inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric atrophy (such as multiple sclerosis, HIV infection, AIDS, certain endocrine disorders, iron deficiency, and subtotal gastrectomy). Total gastrectomy always produces vitamin B 12 deficiency. Structural lesions leading to vitamin B 12 deficiency include regional ileitis, ileal resections, malignancies, etc. IV. Competition for vitamin B 12 by intestinal parasites or bacteria. The fish tapeworm (Diphyllobothrium latum) absorbs huge quantities of vitamin B 12 and infested patients often have associated gastric atrophy. The blind loop syndrome may produce deficiency of vitamin B 12 or folate. V. Inadequate utilization of vitamin B 12 . This may occur if antimetabolites for the vitamin are employed in the treatment of neoplasia. It may be possible to treat the underlying disease by surgical correction of anatomic lesions leading to small bowel bacterial overgrowth, expulsion of fish tapeworm, discontinuation of drugs leading to vitamin malabsorption (see Drug/Laboratory Test Interactions ), use of a gluten free diet in nontropical sprue, or administration of antibiotics in tropical sprue. Such measures remove the need for long-term administration of vitamin B 12 . Requirements of vitamin B 12 in excess of normal (due to pregnancy, thyrotoxicosis, hemolytic anemia, hemorrhage, malignancy, hepatic and renal disease) can usually be met with intranasal or oral supplementation. Nascobal Nasal Spray is not suitable for vitamin B 12 absorption test (Schilling Test). uuid:0d96d7da-85d2-4443-a7b8-f66637210642 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17439 biolink:treats MONDO:0005130 PMID:41385096 "[{""id"":""uuid:ec63d980-76dc-479f-99fc-d29449be91f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:995c3586-d42f-43dc-9e80-362089966f16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nascobal Nasal Spray is indicated for the maintenance of normal hematologic status in pernicious anemia patients who are in remission following intramuscular vitamin B 12 therapy and who have no nervous system involvement. Nascobal Nasal Spray is also indicated as a supplement for other vitamin B 12 deficiencies, including: I. Dietary deficiency of vitamin B 12 occurring in strict vegetarians (Isolated vitamin B 12 deficiency is very rare). II. Malabsorption of vitamin B 12 resulting from structural or functional damage to the stomach, where intrinsic factor is secreted, or to the ileum, where intrinsic factor facilitates vitamin B 12 absorption. These conditions include HIV infection, AIDS, Crohn's disease, tropical sprue, and nontropical sprue (idiopathic steatorrhea, gluten-induced enteropathy). Folate deficiency in these patients is usually more severe than vitamin B 12 deficiency. III. Inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric atrophy (such as multiple sclerosis, HIV infection, AIDS, certain endocrine disorders, iron deficiency, and subtotal gastrectomy). Total gastrectomy always produces vitamin B 12 deficiency. Structural lesions leading to vitamin B 12 deficiency include regional ileitis, ileal resections, malignancies, etc. IV. Competition for vitamin B 12 by intestinal parasites or bacteria. The fish tapeworm (Diphyllobothrium latum) absorbs huge quantities of vitamin B 12 and infested patients often have associated gastric atrophy. The blind loop syndrome may produce deficiency of vitamin B 12 or folate. V. Inadequate utilization of vitamin B 12 . This may occur if antimetabolites for the vitamin are employed in the treatment of neoplasia. It may be possible to treat the underlying disease by surgical correction of anatomic lesions leading to small bowel bacterial overgrowth, expulsion of fish tapeworm, discontinuation of drugs leading to vitamin malabsorption (see Drug/Laboratory Test Interactions ), use of a gluten free diet in nontropical sprue, or administration of antibiotics in tropical sprue. Such measures remove the need for long-term administration of vitamin B 12 . Requirements of vitamin B 12 in excess of normal (due to pregnancy, thyrotoxicosis, hemolytic anemia, hemorrhage, malignancy, hepatic and renal disease) can usually be met with intranasal or oral supplementation. Nascobal Nasal Spray is not suitable for vitamin B 12 absorption test (Schilling Test). uuid:1b6500a9-811d-4a92-ad53-9864ade2bbf0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17439 biolink:treats MONDO:0001075 PMID:41385096 "[{""id"":""uuid:5e4ae4cf-d834-491c-a4d6-f838cafb3c4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0d3d5aed-dfc4-46a8-8de0-5e2d6d1211b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nascobal Nasal Spray is indicated for the maintenance of normal hematologic status in pernicious anemia patients who are in remission following intramuscular vitamin B 12 therapy and who have no nervous system involvement. Nascobal Nasal Spray is also indicated as a supplement for other vitamin B 12 deficiencies, including: I. Dietary deficiency of vitamin B 12 occurring in strict vegetarians (Isolated vitamin B 12 deficiency is very rare). II. Malabsorption of vitamin B 12 resulting from structural or functional damage to the stomach, where intrinsic factor is secreted, or to the ileum, where intrinsic factor facilitates vitamin B 12 absorption. These conditions include HIV infection, AIDS, Crohn's disease, tropical sprue, and nontropical sprue (idiopathic steatorrhea, gluten-induced enteropathy). Folate deficiency in these patients is usually more severe than vitamin B 12 deficiency. III. Inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric atrophy (such as multiple sclerosis, HIV infection, AIDS, certain endocrine disorders, iron deficiency, and subtotal gastrectomy). Total gastrectomy always produces vitamin B 12 deficiency. Structural lesions leading to vitamin B 12 deficiency include regional ileitis, ileal resections, malignancies, etc. IV. Competition for vitamin B 12 by intestinal parasites or bacteria. The fish tapeworm (Diphyllobothrium latum) absorbs huge quantities of vitamin B 12 and infested patients often have associated gastric atrophy. The blind loop syndrome may produce deficiency of vitamin B 12 or folate. V. Inadequate utilization of vitamin B 12 . This may occur if antimetabolites for the vitamin are employed in the treatment of neoplasia. It may be possible to treat the underlying disease by surgical correction of anatomic lesions leading to small bowel bacterial overgrowth, expulsion of fish tapeworm, discontinuation of drugs leading to vitamin malabsorption (see Drug/Laboratory Test Interactions ), use of a gluten free diet in nontropical sprue, or administration of antibiotics in tropical sprue. Such measures remove the need for long-term administration of vitamin B 12 . Requirements of vitamin B 12 in excess of normal (due to pregnancy, thyrotoxicosis, hemolytic anemia, hemorrhage, malignancy, hepatic and renal disease) can usually be met with intranasal or oral supplementation. Nascobal Nasal Spray is not suitable for vitamin B 12 absorption test (Schilling Test). uuid:464edef5-9fcd-4a82-8737-00db67f8a30a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17439 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:0b6e07f0-739c-469a-a35c-e8e0f9a69ceb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c92b12f3-0706-486d-822c-6f329c52afcc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nascobal Nasal Spray is indicated for the maintenance of normal hematologic status in pernicious anemia patients who are in remission following intramuscular vitamin B 12 therapy and who have no nervous system involvement. Nascobal Nasal Spray is also indicated as a supplement for other vitamin B 12 deficiencies, including: I. Dietary deficiency of vitamin B 12 occurring in strict vegetarians (Isolated vitamin B 12 deficiency is very rare). II. Malabsorption of vitamin B 12 resulting from structural or functional damage to the stomach, where intrinsic factor is secreted, or to the ileum, where intrinsic factor facilitates vitamin B 12 absorption. These conditions include HIV infection, AIDS, Crohn's disease, tropical sprue, and nontropical sprue (idiopathic steatorrhea, gluten-induced enteropathy). Folate deficiency in these patients is usually more severe than vitamin B 12 deficiency. III. Inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric atrophy (such as multiple sclerosis, HIV infection, AIDS, certain endocrine disorders, iron deficiency, and subtotal gastrectomy). Total gastrectomy always produces vitamin B 12 deficiency. Structural lesions leading to vitamin B 12 deficiency include regional ileitis, ileal resections, malignancies, etc. IV. Competition for vitamin B 12 by intestinal parasites or bacteria. The fish tapeworm (Diphyllobothrium latum) absorbs huge quantities of vitamin B 12 and infested patients often have associated gastric atrophy. The blind loop syndrome may produce deficiency of vitamin B 12 or folate. V. Inadequate utilization of vitamin B 12 . This may occur if antimetabolites for the vitamin are employed in the treatment of neoplasia. It may be possible to treat the underlying disease by surgical correction of anatomic lesions leading to small bowel bacterial overgrowth, expulsion of fish tapeworm, discontinuation of drugs leading to vitamin malabsorption (see Drug/Laboratory Test Interactions ), use of a gluten free diet in nontropical sprue, or administration of antibiotics in tropical sprue. Such measures remove the need for long-term administration of vitamin B 12 . Requirements of vitamin B 12 in excess of normal (due to pregnancy, thyrotoxicosis, hemolytic anemia, hemorrhage, malignancy, hepatic and renal disease) can usually be met with intranasal or oral supplementation. Nascobal Nasal Spray is not suitable for vitamin B 12 absorption test (Schilling Test). uuid:de76e522-15ef-44ac-bd84-74a12e565495 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17439 biolink:treats UMLS:C0240066 PMID:41385096 "[{""id"":""uuid:253103e3-dbd6-4c6c-a985-75279a266052"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1871fd99-18af-4d2d-ba27-58a38a6e4a1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nascobal Nasal Spray is indicated for the maintenance of normal hematologic status in pernicious anemia patients who are in remission following intramuscular vitamin B 12 therapy and who have no nervous system involvement. Nascobal Nasal Spray is also indicated as a supplement for other vitamin B 12 deficiencies, including: I. Dietary deficiency of vitamin B 12 occurring in strict vegetarians (Isolated vitamin B 12 deficiency is very rare). II. Malabsorption of vitamin B 12 resulting from structural or functional damage to the stomach, where intrinsic factor is secreted, or to the ileum, where intrinsic factor facilitates vitamin B 12 absorption. These conditions include HIV infection, AIDS, Crohn's disease, tropical sprue, and nontropical sprue (idiopathic steatorrhea, gluten-induced enteropathy). Folate deficiency in these patients is usually more severe than vitamin B 12 deficiency. III. Inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric atrophy (such as multiple sclerosis, HIV infection, AIDS, certain endocrine disorders, iron deficiency, and subtotal gastrectomy). Total gastrectomy always produces vitamin B 12 deficiency. Structural lesions leading to vitamin B 12 deficiency include regional ileitis, ileal resections, malignancies, etc. IV. Competition for vitamin B 12 by intestinal parasites or bacteria. The fish tapeworm (Diphyllobothrium latum) absorbs huge quantities of vitamin B 12 and infested patients often have associated gastric atrophy. The blind loop syndrome may produce deficiency of vitamin B 12 or folate. V. Inadequate utilization of vitamin B 12 . This may occur if antimetabolites for the vitamin are employed in the treatment of neoplasia. It may be possible to treat the underlying disease by surgical correction of anatomic lesions leading to small bowel bacterial overgrowth, expulsion of fish tapeworm, discontinuation of drugs leading to vitamin malabsorption (see Drug/Laboratory Test Interactions ), use of a gluten free diet in nontropical sprue, or administration of antibiotics in tropical sprue. Such measures remove the need for long-term administration of vitamin B 12 . Requirements of vitamin B 12 in excess of normal (due to pregnancy, thyrotoxicosis, hemolytic anemia, hemorrhage, malignancy, hepatic and renal disease) can usually be met with intranasal or oral supplementation. Nascobal Nasal Spray is not suitable for vitamin B 12 absorption test (Schilling Test). uuid:6df0b0b2-1b19-44a6-ba77-03863f3436d7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17439 biolink:treats MONDO:0000709 PMID:41385096 "[{""id"":""uuid:c934e867-9c96-462f-9812-d951468170d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9aff4967-4f0c-47b9-9b64-c29c10077bcd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nascobal Nasal Spray is indicated for the maintenance of normal hematologic status in pernicious anemia patients who are in remission following intramuscular vitamin B 12 therapy and who have no nervous system involvement. Nascobal Nasal Spray is also indicated as a supplement for other vitamin B 12 deficiencies, including: I. Dietary deficiency of vitamin B 12 occurring in strict vegetarians (Isolated vitamin B 12 deficiency is very rare). II. Malabsorption of vitamin B 12 resulting from structural or functional damage to the stomach, where intrinsic factor is secreted, or to the ileum, where intrinsic factor facilitates vitamin B 12 absorption. These conditions include HIV infection, AIDS, Crohn's disease, tropical sprue, and nontropical sprue (idiopathic steatorrhea, gluten-induced enteropathy). Folate deficiency in these patients is usually more severe than vitamin B 12 deficiency. III. Inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric atrophy (such as multiple sclerosis, HIV infection, AIDS, certain endocrine disorders, iron deficiency, and subtotal gastrectomy). Total gastrectomy always produces vitamin B 12 deficiency. Structural lesions leading to vitamin B 12 deficiency include regional ileitis, ileal resections, malignancies, etc. IV. Competition for vitamin B 12 by intestinal parasites or bacteria. The fish tapeworm (Diphyllobothrium latum) absorbs huge quantities of vitamin B 12 and infested patients often have associated gastric atrophy. The blind loop syndrome may produce deficiency of vitamin B 12 or folate. V. Inadequate utilization of vitamin B 12 . This may occur if antimetabolites for the vitamin are employed in the treatment of neoplasia. It may be possible to treat the underlying disease by surgical correction of anatomic lesions leading to small bowel bacterial overgrowth, expulsion of fish tapeworm, discontinuation of drugs leading to vitamin malabsorption (see Drug/Laboratory Test Interactions ), use of a gluten free diet in nontropical sprue, or administration of antibiotics in tropical sprue. Such measures remove the need for long-term administration of vitamin B 12 . Requirements of vitamin B 12 in excess of normal (due to pregnancy, thyrotoxicosis, hemolytic anemia, hemorrhage, malignancy, hepatic and renal disease) can usually be met with intranasal or oral supplementation. Nascobal Nasal Spray is not suitable for vitamin B 12 absorption test (Schilling Test). uuid:d6a10aa3-2dfb-4eab-a305-a84e45f3cd87 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17439 biolink:treats MONDO:0005673 PMID:41385096 "[{""id"":""uuid:8ee8daee-b895-448f-9f32-3378edd1d842"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5f6b3562-4779-412a-b61b-9bae5e9838fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nascobal Nasal Spray is indicated for the maintenance of normal hematologic status in pernicious anemia patients who are in remission following intramuscular vitamin B 12 therapy and who have no nervous system involvement. Nascobal Nasal Spray is also indicated as a supplement for other vitamin B 12 deficiencies, including: I. Dietary deficiency of vitamin B 12 occurring in strict vegetarians (Isolated vitamin B 12 deficiency is very rare). II. Malabsorption of vitamin B 12 resulting from structural or functional damage to the stomach, where intrinsic factor is secreted, or to the ileum, where intrinsic factor facilitates vitamin B 12 absorption. These conditions include HIV infection, AIDS, Crohn's disease, tropical sprue, and nontropical sprue (idiopathic steatorrhea, gluten-induced enteropathy). Folate deficiency in these patients is usually more severe than vitamin B 12 deficiency. III. Inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric atrophy (such as multiple sclerosis, HIV infection, AIDS, certain endocrine disorders, iron deficiency, and subtotal gastrectomy). Total gastrectomy always produces vitamin B 12 deficiency. Structural lesions leading to vitamin B 12 deficiency include regional ileitis, ileal resections, malignancies, etc. IV. Competition for vitamin B 12 by intestinal parasites or bacteria. The fish tapeworm (Diphyllobothrium latum) absorbs huge quantities of vitamin B 12 and infested patients often have associated gastric atrophy. The blind loop syndrome may produce deficiency of vitamin B 12 or folate. V. Inadequate utilization of vitamin B 12 . This may occur if antimetabolites for the vitamin are employed in the treatment of neoplasia. It may be possible to treat the underlying disease by surgical correction of anatomic lesions leading to small bowel bacterial overgrowth, expulsion of fish tapeworm, discontinuation of drugs leading to vitamin malabsorption (see Drug/Laboratory Test Interactions ), use of a gluten free diet in nontropical sprue, or administration of antibiotics in tropical sprue. Such measures remove the need for long-term administration of vitamin B 12 . Requirements of vitamin B 12 in excess of normal (due to pregnancy, thyrotoxicosis, hemolytic anemia, hemorrhage, malignancy, hepatic and renal disease) can usually be met with intranasal or oral supplementation. Nascobal Nasal Spray is not suitable for vitamin B 12 absorption test (Schilling Test). uuid:d3a997a0-b8ab-426a-a9d1-1e2d4d157929 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17439 biolink:treats MONDO:0010138 PMID:41385096 "[{""id"":""uuid:ec568c6f-fb0c-4817-843a-c964c96fb0c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3ff5169a-fa62-4fc3-9154-c4c21557cfd4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nascobal Nasal Spray is indicated for the maintenance of normal hematologic status in pernicious anemia patients who are in remission following intramuscular vitamin B 12 therapy and who have no nervous system involvement. Nascobal Nasal Spray is also indicated as a supplement for other vitamin B 12 deficiencies, including: I. Dietary deficiency of vitamin B 12 occurring in strict vegetarians (Isolated vitamin B 12 deficiency is very rare). II. Malabsorption of vitamin B 12 resulting from structural or functional damage to the stomach, where intrinsic factor is secreted, or to the ileum, where intrinsic factor facilitates vitamin B 12 absorption. These conditions include HIV infection, AIDS, Crohn's disease, tropical sprue, and nontropical sprue (idiopathic steatorrhea, gluten-induced enteropathy). Folate deficiency in these patients is usually more severe than vitamin B 12 deficiency. III. Inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric atrophy (such as multiple sclerosis, HIV infection, AIDS, certain endocrine disorders, iron deficiency, and subtotal gastrectomy). Total gastrectomy always produces vitamin B 12 deficiency. Structural lesions leading to vitamin B 12 deficiency include regional ileitis, ileal resections, malignancies, etc. IV. Competition for vitamin B 12 by intestinal parasites or bacteria. The fish tapeworm (Diphyllobothrium latum) absorbs huge quantities of vitamin B 12 and infested patients often have associated gastric atrophy. The blind loop syndrome may produce deficiency of vitamin B 12 or folate. V. Inadequate utilization of vitamin B 12 . This may occur if antimetabolites for the vitamin are employed in the treatment of neoplasia. It may be possible to treat the underlying disease by surgical correction of anatomic lesions leading to small bowel bacterial overgrowth, expulsion of fish tapeworm, discontinuation of drugs leading to vitamin malabsorption (see Drug/Laboratory Test Interactions ), use of a gluten free diet in nontropical sprue, or administration of antibiotics in tropical sprue. Such measures remove the need for long-term administration of vitamin B 12 . Requirements of vitamin B 12 in excess of normal (due to pregnancy, thyrotoxicosis, hemolytic anemia, hemorrhage, malignancy, hepatic and renal disease) can usually be met with intranasal or oral supplementation. Nascobal Nasal Spray is not suitable for vitamin B 12 absorption test (Schilling Test). uuid:92d4a0ac-d89e-470e-8e21-e7555c7f3116 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17439 biolink:treats MONDO:0003664 PMID:41385096 "[{""id"":""uuid:2b11cb03-5415-4e0b-8653-f6ad2fd4e598"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c7bf1daa-7b27-46a5-bbd5-88ddb5599124"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nascobal Nasal Spray is indicated for the maintenance of normal hematologic status in pernicious anemia patients who are in remission following intramuscular vitamin B 12 therapy and who have no nervous system involvement. Nascobal Nasal Spray is also indicated as a supplement for other vitamin B 12 deficiencies, including: I. Dietary deficiency of vitamin B 12 occurring in strict vegetarians (Isolated vitamin B 12 deficiency is very rare). II. Malabsorption of vitamin B 12 resulting from structural or functional damage to the stomach, where intrinsic factor is secreted, or to the ileum, where intrinsic factor facilitates vitamin B 12 absorption. These conditions include HIV infection, AIDS, Crohn's disease, tropical sprue, and nontropical sprue (idiopathic steatorrhea, gluten-induced enteropathy). Folate deficiency in these patients is usually more severe than vitamin B 12 deficiency. III. Inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric atrophy (such as multiple sclerosis, HIV infection, AIDS, certain endocrine disorders, iron deficiency, and subtotal gastrectomy). Total gastrectomy always produces vitamin B 12 deficiency. Structural lesions leading to vitamin B 12 deficiency include regional ileitis, ileal resections, malignancies, etc. IV. Competition for vitamin B 12 by intestinal parasites or bacteria. The fish tapeworm (Diphyllobothrium latum) absorbs huge quantities of vitamin B 12 and infested patients often have associated gastric atrophy. The blind loop syndrome may produce deficiency of vitamin B 12 or folate. V. Inadequate utilization of vitamin B 12 . This may occur if antimetabolites for the vitamin are employed in the treatment of neoplasia. It may be possible to treat the underlying disease by surgical correction of anatomic lesions leading to small bowel bacterial overgrowth, expulsion of fish tapeworm, discontinuation of drugs leading to vitamin malabsorption (see Drug/Laboratory Test Interactions ), use of a gluten free diet in nontropical sprue, or administration of antibiotics in tropical sprue. Such measures remove the need for long-term administration of vitamin B 12 . Requirements of vitamin B 12 in excess of normal (due to pregnancy, thyrotoxicosis, hemolytic anemia, hemorrhage, malignancy, hepatic and renal disease) can usually be met with intranasal or oral supplementation. Nascobal Nasal Spray is not suitable for vitamin B 12 absorption test (Schilling Test). uuid:9ca96e2d-1c9a-461b-af74-f8351927b10b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17439 biolink:treats MONDO:0005154 PMID:41385096 "[{""id"":""uuid:5c86cebd-0a34-4d80-ad02-484032cad3a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4ff7d654-f489-4f29-a15d-db8c90ebe407"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nascobal Nasal Spray is indicated for the maintenance of normal hematologic status in pernicious anemia patients who are in remission following intramuscular vitamin B 12 therapy and who have no nervous system involvement. Nascobal Nasal Spray is also indicated as a supplement for other vitamin B 12 deficiencies, including: I. Dietary deficiency of vitamin B 12 occurring in strict vegetarians (Isolated vitamin B 12 deficiency is very rare). II. Malabsorption of vitamin B 12 resulting from structural or functional damage to the stomach, where intrinsic factor is secreted, or to the ileum, where intrinsic factor facilitates vitamin B 12 absorption. These conditions include HIV infection, AIDS, Crohn's disease, tropical sprue, and nontropical sprue (idiopathic steatorrhea, gluten-induced enteropathy). Folate deficiency in these patients is usually more severe than vitamin B 12 deficiency. III. Inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric atrophy (such as multiple sclerosis, HIV infection, AIDS, certain endocrine disorders, iron deficiency, and subtotal gastrectomy). Total gastrectomy always produces vitamin B 12 deficiency. Structural lesions leading to vitamin B 12 deficiency include regional ileitis, ileal resections, malignancies, etc. IV. Competition for vitamin B 12 by intestinal parasites or bacteria. The fish tapeworm (Diphyllobothrium latum) absorbs huge quantities of vitamin B 12 and infested patients often have associated gastric atrophy. The blind loop syndrome may produce deficiency of vitamin B 12 or folate. V. Inadequate utilization of vitamin B 12 . This may occur if antimetabolites for the vitamin are employed in the treatment of neoplasia. It may be possible to treat the underlying disease by surgical correction of anatomic lesions leading to small bowel bacterial overgrowth, expulsion of fish tapeworm, discontinuation of drugs leading to vitamin malabsorption (see Drug/Laboratory Test Interactions ), use of a gluten free diet in nontropical sprue, or administration of antibiotics in tropical sprue. Such measures remove the need for long-term administration of vitamin B 12 . Requirements of vitamin B 12 in excess of normal (due to pregnancy, thyrotoxicosis, hemolytic anemia, hemorrhage, malignancy, hepatic and renal disease) can usually be met with intranasal or oral supplementation. Nascobal Nasal Spray is not suitable for vitamin B 12 absorption test (Schilling Test). uuid:589b1086-cce3-4d37-bb89-14b1a320bf05 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17439 biolink:treats MONDO:0005240 PMID:41385096 "[{""id"":""uuid:d68094a7-54d7-4082-a915-5d37aba77b34"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:69a041f5-3db9-4dd8-977e-4bb6bc0bf770"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nascobal Nasal Spray is indicated for the maintenance of normal hematologic status in pernicious anemia patients who are in remission following intramuscular vitamin B 12 therapy and who have no nervous system involvement. Nascobal Nasal Spray is also indicated as a supplement for other vitamin B 12 deficiencies, including: I. Dietary deficiency of vitamin B 12 occurring in strict vegetarians (Isolated vitamin B 12 deficiency is very rare). II. Malabsorption of vitamin B 12 resulting from structural or functional damage to the stomach, where intrinsic factor is secreted, or to the ileum, where intrinsic factor facilitates vitamin B 12 absorption. These conditions include HIV infection, AIDS, Crohn's disease, tropical sprue, and nontropical sprue (idiopathic steatorrhea, gluten-induced enteropathy). Folate deficiency in these patients is usually more severe than vitamin B 12 deficiency. III. Inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric atrophy (such as multiple sclerosis, HIV infection, AIDS, certain endocrine disorders, iron deficiency, and subtotal gastrectomy). Total gastrectomy always produces vitamin B 12 deficiency. Structural lesions leading to vitamin B 12 deficiency include regional ileitis, ileal resections, malignancies, etc. IV. Competition for vitamin B 12 by intestinal parasites or bacteria. The fish tapeworm (Diphyllobothrium latum) absorbs huge quantities of vitamin B 12 and infested patients often have associated gastric atrophy. The blind loop syndrome may produce deficiency of vitamin B 12 or folate. V. Inadequate utilization of vitamin B 12 . This may occur if antimetabolites for the vitamin are employed in the treatment of neoplasia. It may be possible to treat the underlying disease by surgical correction of anatomic lesions leading to small bowel bacterial overgrowth, expulsion of fish tapeworm, discontinuation of drugs leading to vitamin malabsorption (see Drug/Laboratory Test Interactions ), use of a gluten free diet in nontropical sprue, or administration of antibiotics in tropical sprue. Such measures remove the need for long-term administration of vitamin B 12 . Requirements of vitamin B 12 in excess of normal (due to pregnancy, thyrotoxicosis, hemolytic anemia, hemorrhage, malignancy, hepatic and renal disease) can usually be met with intranasal or oral supplementation. Nascobal Nasal Spray is not suitable for vitamin B 12 absorption test (Schilling Test). uuid:81da7ead-bcd0-4856-8fbc-0bda157e131f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:145499 biolink:treats MONDO:0004975 PMID:41385096 "[{""id"":""uuid:8e66664b-cb92-4329-9e4f-96c196fd5ca7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:adc4ef6d-692c-4e1b-bc03-46f9e8d3f4f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2ac365b7-9976-4a85-b713-1542a68fe76d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ARICEPT® is indicated for the treatment of dementia of the Alzheimer's type. Efficacy has been demonstrated in patients with mild to moderate Alzheimer's Disease, as well as in patients with severe Alzheimer's Disease.|[PMDA] Drugs with a new active ingredient indicated for inhibiting progression of symptoms of dementia in patients with Alzheimer's disease. uuid:62b06e4c-cc1e-4604-9781-feae1f52e634 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47426 biolink:treats HP:0000969 PMID:41385096 "[{""id"":""uuid:72877665-5d57-4e5c-88ef-2296a81c3802"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:82c7e966-db1b-4067-9b08-74a8f47eb4f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Edema: Furosemide is indicated in adults and pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephritic syndrome. Furosemide is particularly useful when an agent with greater diuretic potential is desired. Hypertension: Oral furosemide may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents. Hypertensive patients who cannot be adequately controlled with thiazides will probably also not be adequately controlled with furosemide alone. uuid:1c21442b-b17f-44a4-ad5d-8d45ff5173fa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47426 biolink:treats UMLS:C0268732 PMID:41385096 "[{""id"":""uuid:9d1ced6d-4385-4f08-a7a3-5b7c85cfeff7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7d0533ba-2747-4e44-b55c-8b574c20ef35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Edema: Furosemide is indicated in adults and pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephritic syndrome. Furosemide is particularly useful when an agent with greater diuretic potential is desired. Hypertension: Oral furosemide may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents. Hypertensive patients who cannot be adequately controlled with thiazides will probably also not be adequately controlled with furosemide alone. uuid:126c4a0c-721f-4fe0-9c48-d2403499533a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47426 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:c29f319c-4a4a-4652-80aa-7fc0726d7f3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8dd4a18a-afa3-4806-b4e7-87c0677922b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Edema: Furosemide is indicated in adults and pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephritic syndrome. Furosemide is particularly useful when an agent with greater diuretic potential is desired. Hypertension: Oral furosemide may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents. Hypertensive patients who cannot be adequately controlled with thiazides will probably also not be adequately controlled with furosemide alone. uuid:0737113c-7b0c-4219-ae16-71d276d7e5dc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6923 biolink:treats MONDO:0005984 PMID:41385096 "[{""id"":""uuid:d94f8239-27c6-4abf-89b2-5fbb8fb639f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:88896621-cb14-4728-ab6f-c51a46f79002"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For topical application in the treatment of tinea pedis (athlete's foot), tinea cruris, and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum, in the treatment of cutaneous candidiasis (moniliasis), and in the treatment of tinea versicolor. uuid:7d367a45-4207-482b-931c-e9b34a1987ae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6923 biolink:treats MONDO:0001405 PMID:41385096 "[{""id"":""uuid:bf785f34-7c1d-46d8-94e9-c4623a099e77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d84cd504-96e5-433f-a8fe-a0e50f190a1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For topical application in the treatment of tinea pedis (athlete's foot), tinea cruris, and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum, in the treatment of cutaneous candidiasis (moniliasis), and in the treatment of tinea versicolor. uuid:b9dd72df-2381-4e18-ad95-cce22971accc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6923 biolink:treats MONDO:0001461 PMID:41385096 "[{""id"":""uuid:5ed47b41-a686-402b-abaa-5a7c39d24cc1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9de1357d-fbf1-4c71-9c95-e9162f3f3907"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For topical application in the treatment of tinea pedis (athlete's foot), tinea cruris, and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum, in the treatment of cutaneous candidiasis (moniliasis), and in the treatment of tinea versicolor. uuid:bbc65c33-f943-4a60-af8b-fe3ee5a18dfe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6923 biolink:treats MONDO:0000879 PMID:41385096 "[{""id"":""uuid:d5cd9fb2-8c2b-44ce-bcf0-2cc444bf972c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:712aee06-6e5e-401f-a456-8ca86190e454"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For topical application in the treatment of tinea pedis (athlete's foot), tinea cruris, and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum, in the treatment of cutaneous candidiasis (moniliasis), and in the treatment of tinea versicolor. uuid:4eb53fb9-f1d7-45f6-adfd-d1cdd4b4b177 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6923 biolink:treats MONDO:0005915 PMID:41385096 "[{""id"":""uuid:27cfabae-c0d4-473a-ace5-92c39137de0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fea3b703-835a-42f2-b86f-a8c052dd4a85"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For topical application in the treatment of tinea pedis (athlete's foot), tinea cruris, and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum, in the treatment of cutaneous candidiasis (moniliasis), and in the treatment of tinea versicolor. uuid:0d194510-24e7-4aef-89f2-e937048f3a7b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27470 biolink:treats MONDO:0009197 PMID:41385096 "[{""id"":""uuid:f3dd282a-8979-48eb-b823-b40b33b51215"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bb9b8a1c-a09c-45b7-9378-093b03745ce3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Folic acid is effective in the treatment of megaloblastic anemias due to deficiency of folic acid (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, pregnancy, infancy, or childhood. uuid:cf15908b-f5f4-42f4-ba29-857c0d7be5c4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8776 biolink:treats MONDO:0007186 PMID:41385096 "[{""id"":""uuid:7d852064-d70a-4239-afed-047247e2144f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:100b576e-5c6d-4458-a577-91c544c52f3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ranitidine is indicated in: Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo-controlled comparative studies have been carried out for periods of longer than 1 year. The treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and systemic mastocytosis). Short-term treatment of active, benign gastric ulcer. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. Studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled studies have been carried out for 1 year. Treatment of GERD. Symptomatic relief commonly occurs within 24 hours after starting therapy with ranitidine 150 mg b.i.d. Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with ranitidine 150 mg q.i.d. Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks. Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis. uuid:81c1c94e-2b5a-42e5-973e-0e89c8758d88 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:101278 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:5fceb031-d1bd-4e27-ac4b-3506e39c2848"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:66bdf553-3ab0-416e-8326-b7b3d7739c76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diltiazem Hydrochloride Extended Release Tablets are indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive medications. Diltiazem Hydrochloride Extended Release Tablets are indicated for the management of chronic stable angina. uuid:8a67a2bd-82d7-4452-b9e0-ab30640a3da2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:70691422 biolink:treats MONDO:0005240 PMID:41385096 "[{""id"":""uuid:1d8979e3-dd7e-47b0-a5d4-cf4a86d31e8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d071aa84-ae60-4acb-98f9-1d1c444d5b00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] GLOFIL ® -125 (Sodium Iothalamate I-125 Injection) is indicated for evaluation of glomerular filtration in the diagnosis or monitoring of patients with renal disease. uuid:2dd2e9a2-c0da-4f72-8139-07708634b6f6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24847961 biolink:treats HP:0012228 PMID:41385096 "[{""id"":""uuid:6a39f526-eaf5-4ed1-a48a-330a7a2ff2b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:89ed8c92-f7a8-4596-8815-69544ae6aea6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Butalbital aspirin, and caffeine capsules are indicated for the relief of the symptom complex of tension (or muscle contraction) headache. Evidence supporting the efficacy and safety of butalbital, aspirin, and caffeine capsules in the treatment of multiple recurrent headaches is unavailable. Caution in this regard is required because butalbital is habit-forming and potentially abusable. uuid:42f7ef75-4d34-4245-b2ed-030ce0236a27 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24847961 biolink:treats UMLS:C0393736 PMID:41385096 "[{""id"":""uuid:a2f9185b-5fdc-435f-abdf-f388ed97cb6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9948cf71-9bc8-4ad8-8bb1-96fd3a9b7599"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Butalbital aspirin, and caffeine capsules are indicated for the relief of the symptom complex of tension (or muscle contraction) headache. Evidence supporting the efficacy and safety of butalbital, aspirin, and caffeine capsules in the treatment of multiple recurrent headaches is unavailable. Caution in this regard is required because butalbital is habit-forming and potentially abusable. uuid:a7876227-1553-4203-a376-7cf91176e7a1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5778 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:adcab669-cd08-4b44-89e9-86f7a10b1d60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:73e2dbcc-4efa-4de5-8b89-88127adeabf1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydrochlorothiazide Tablet, USP is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Hydrochlorothiazide Tablet, USP has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Hydrochlorothiazide Tablet, USP is indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. uuid:0b60f560-9e76-4329-838d-1d09988ab1cc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5778 biolink:treats MONDO:0005155 PMID:41385096 "[{""id"":""uuid:c0b35f73-8733-4cc3-b067-85a6e8bc412c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:425f3e31-9d5e-4861-82d9-3d40c51f82e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydrochlorothiazide Tablet, USP is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Hydrochlorothiazide Tablet, USP has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Hydrochlorothiazide Tablet, USP is indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. uuid:1ae89d1d-3e58-4967-a4c8-46b73d0aef65 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5778 biolink:treats MONDO:0005377 PMID:41385096 "[{""id"":""uuid:6a2b0fba-ed7d-4c59-9f07-91a5c787bde1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d61a7cf7-b5ee-4d56-876a-09eca9f1e872"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydrochlorothiazide Tablet, USP is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Hydrochlorothiazide Tablet, USP has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Hydrochlorothiazide Tablet, USP is indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. uuid:ecd08b77-b15f-4c95-8098-eaa30cb87162 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5778 biolink:treats UMLS:C0156221 PMID:41385096 "[{""id"":""uuid:b4faa57b-335c-412e-92ad-77833035f43a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4b097032-073f-4bac-a732-cb6ed6f402c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydrochlorothiazide Tablet, USP is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Hydrochlorothiazide Tablet, USP has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Hydrochlorothiazide Tablet, USP is indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. uuid:ef47cd01-b705-4514-9146-c8a2a7c95fd6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5778 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:364d7b7e-4ce0-4585-bee6-f90fd619e88d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2d1ee0e1-1e8f-42c6-adad-653b8e991dfb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydrochlorothiazide Tablet, USP is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Hydrochlorothiazide Tablet, USP has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Hydrochlorothiazide Tablet, USP is indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. uuid:3e7e1198-4720-463f-a61c-f6395e85952e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5778 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:30d9ab5f-b049-4c09-b664-1039b3425c05"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f2842d42-80e5-4562-ae62-01dd4b269e54"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydrochlorothiazide Tablet, USP is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Hydrochlorothiazide Tablet, USP has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Hydrochlorothiazide Tablet, USP is indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. uuid:f531ce72-9bc0-4c62-965a-46faed8403c1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C106429 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:acd1b5f5-005a-41ae-a36b-fe72b060699b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1dc9a057-7dd2-462a-ada3-c229b0fbd11b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acetaminophen, Caffeine and Dihydrocodeine Bitartrate Tablets are indicated for the relief of moderate to moderately severe pain. uuid:65a3ba04-bb6d-4476-b31d-65b66d9c5a05 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7476 biolink:treats MONDO:0011429 PMID:41385096 "[{""id"":""uuid:c2c80af0-8a3e-446e-88f8-6c3edf6129ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3f7036e0-0165-4876-8bfd-adbccb1698f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of naproxen and other treatment options before deciding to use naproxen. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Naproxen tablets are indicated: For relief of mild to moderate pain For relief of signs and symptoms of juvenile arthritis For relief of the signs and symptoms of rheumatoid arthritis For relief of the signs and symptoms of osteoarthritis For treatment of primary dysmenorrhea For acute or long-term use in the relief of signs and symptoms of the following: Ankylosing spondylitis Acute painful shoulder (Acute subacromial bursitis/supraspinatus tendinitis) Acute gouty arthritis uuid:0728d138-12d3-4eb9-9b9f-d5b718cda947 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7476 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:bb1fc1b4-cbb0-4712-9d7f-992558b829e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5d0d96ef-24bb-4213-a705-3e6f8321ed5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of naproxen and other treatment options before deciding to use naproxen. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Naproxen tablets are indicated: For relief of mild to moderate pain For relief of signs and symptoms of juvenile arthritis For relief of the signs and symptoms of rheumatoid arthritis For relief of the signs and symptoms of osteoarthritis For treatment of primary dysmenorrhea For acute or long-term use in the relief of signs and symptoms of the following: Ankylosing spondylitis Acute painful shoulder (Acute subacromial bursitis/supraspinatus tendinitis) Acute gouty arthritis uuid:8cb9806d-1371-437c-955a-48692e584ce5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7476 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:41056970-cf6b-45df-9856-5ba2accdedc6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:43b85978-c317-4d5c-842e-f8ecd42e8745"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of naproxen and other treatment options before deciding to use naproxen. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Naproxen tablets are indicated: For relief of mild to moderate pain For relief of signs and symptoms of juvenile arthritis For relief of the signs and symptoms of rheumatoid arthritis For relief of the signs and symptoms of osteoarthritis For treatment of primary dysmenorrhea For acute or long-term use in the relief of signs and symptoms of the following: Ankylosing spondylitis Acute painful shoulder (Acute subacromial bursitis/supraspinatus tendinitis) Acute gouty arthritis uuid:4368604c-98c6-4d45-b5e3-211107b5cb15 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7476 biolink:treats MONDO:1060206 PMID:41385096 "[{""id"":""uuid:19f4678e-322e-41ac-bd36-42cbef84940b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e44d1289-745b-46d1-8325-d27ef6cd04b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of naproxen and other treatment options before deciding to use naproxen. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Naproxen tablets are indicated: For relief of mild to moderate pain For relief of signs and symptoms of juvenile arthritis For relief of the signs and symptoms of rheumatoid arthritis For relief of the signs and symptoms of osteoarthritis For treatment of primary dysmenorrhea For acute or long-term use in the relief of signs and symptoms of the following: Ankylosing spondylitis Acute painful shoulder (Acute subacromial bursitis/supraspinatus tendinitis) Acute gouty arthritis UMLS:C0149875 uuid:91165972-d363-4eba-b3aa-2bc4971c5990 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7476 biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:2d7503f4-94fd-45c7-b6d6-f9600e6ef170"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c85a84cb-edd7-4c7a-a0d5-6d6c6c85f718"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of naproxen and other treatment options before deciding to use naproxen. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Naproxen tablets are indicated: For relief of mild to moderate pain For relief of signs and symptoms of juvenile arthritis For relief of the signs and symptoms of rheumatoid arthritis For relief of the signs and symptoms of osteoarthritis For treatment of primary dysmenorrhea For acute or long-term use in the relief of signs and symptoms of the following: Ankylosing spondylitis Acute painful shoulder (Acute subacromial bursitis/supraspinatus tendinitis) Acute gouty arthritis uuid:a1e8461d-9618-4571-bdcc-d4c15e30c4d4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7476 biolink:treats UMLS:C0149896 PMID:41385096 "[{""id"":""uuid:7522ffff-7c33-41ef-a016-bac911f146fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0b69c518-7c61-44c6-909c-7f004d5723c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of naproxen and other treatment options before deciding to use naproxen. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Naproxen tablets are indicated: For relief of mild to moderate pain For relief of signs and symptoms of juvenile arthritis For relief of the signs and symptoms of rheumatoid arthritis For relief of the signs and symptoms of osteoarthritis For treatment of primary dysmenorrhea For acute or long-term use in the relief of signs and symptoms of the following: Ankylosing spondylitis Acute painful shoulder (Acute subacromial bursitis/supraspinatus tendinitis) Acute gouty arthritis uuid:2f82aa35-0252-440a-b773-f6f00eaccf9a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6061 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:6c8ec5d4-8cb7-439a-bac1-ef553358e855"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:917f8895-9226-4baa-b344-f78c8e01a350"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isosorbide Dinitrate Extended-release Tablets are indicated for the prevention of angina pectoris due to coronary artery disease. The onset of action of controlled-release oral isosorbide dinitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episode. uuid:5064c5ca-c7da-4e53-b62f-cf2389acf1ae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6061 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:121bf40e-f4b5-4edd-846c-d2d560f0c524"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3b455987-24de-4701-8aec-925a28ec54fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isosorbide Dinitrate Extended-release Tablets are indicated for the prevention of angina pectoris due to coronary artery disease. The onset of action of controlled-release oral isosorbide dinitrate is not sufficiently rapid for this product to be useful in aborting an acute anginal episode. uuid:11605761-1bff-46a2-bac1-115c85027d00 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0019359 PMID:41385096 "[{""id"":""uuid:9e2952d5-5aab-46ca-a276-60bf547ee3fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bbb3a8a5-0d02-4326-b494-48def6dc152f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:69da5cf6-de94-4ef1-bf86-43187fb33357 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0001246 PMID:41385096 "[{""id"":""uuid:5bb203ae-c649-4b7d-8911-2d2e6676a137"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7ce690e0-402f-40b8-9df0-c49fe300dd15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:410f18b2-49c2-4c17-94ee-cd6d938325e6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0019186 PMID:41385096 "[{""id"":""uuid:84f2bf3c-a3a2-43c6-80f1-4641aea5843e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e61d5197-556a-41da-a221-2179777aad8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:12a396a7-a22f-42aa-a609-ba7421091eb7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0019360 PMID:41385096 "[{""id"":""uuid:1ad41ad6-8103-496b-8a16-06959d191945"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:af994444-b684-4057-ad78-3f286b669689"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:4bc90b76-0b23-41d4-ade2-20a9f41401ad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0025294 PMID:41385096 "[{""id"":""uuid:ec76d423-067f-4e19-93a9-56079d337938"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7617ad7f-76fa-405e-b93b-370e8f037b10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:0c421fa4-90e5-45d4-8fbd-a3776f9a5e8b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:03c9cd5b-4d69-4f29-89ed-905aba0dcf65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7cfc6265-87b8-4a89-aa31-3ba2ddbf34dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:b5eef971-3c0f-4a92-9416-9664a456b762 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0005834 PMID:41385096 "[{""id"":""uuid:c2db07de-9eb7-4243-a321-ab8ee41d270c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:238b36ca-6861-45e8-aaa8-2f4fba3951b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:fa7d0d9c-b7af-4c4e-a42b-837ce64b4640 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0005888 PMID:41385096 "[{""id"":""uuid:81987052-843a-4c82-a221-ec417940c320"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0530d584-b835-4969-a56d-ce3b14222750"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:43039d2d-539b-491d-bdf0-6c17be2f00a0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0001249 PMID:41385096 "[{""id"":""uuid:dc9892d4-d891-439f-86e5-a67b02938df8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:16945a02-400f-443e-8ae7-f2126abc1ba8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:77ed9214-238c-4e76-be1e-9e82670ac26d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0005808 PMID:41385096 "[{""id"":""uuid:a4d18f19-d5fe-4941-a964-ef9d1e5a7b47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:98dee879-9411-40d5-8926-ce0deae01f1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:82dc999d-0a74-47cc-b6e3-93e028dd1f83 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0005297 PMID:41385096 "[{""id"":""uuid:73606eea-d138-4808-9dc7-810236e33a44"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:500c0da8-6509-48f4-a6f8-1b579d9b8ac6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:528392b4-9e69-4ffa-8b63-2fa4960d37db biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0019633 PMID:41385096 "[{""id"":""uuid:c2ffe3bc-8c49-455b-be16-a147efaa9efa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f975a942-9740-4ce5-82c3-09261ebd98c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:54324729-5011-4a51-9f3e-2ddcc7b395b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0001797 PMID:41385096 "[{""id"":""uuid:1a061571-e474-4542-829b-73f85ae4a795"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8257673c-aaa7-47e7-8552-91036ddd83f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:b1a44348-fa3e-403d-9707-0cffde01bcbd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0019095 PMID:41385096 "[{""id"":""uuid:ed040741-faf5-4249-9feb-450daadf5009"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cd52db1e-d0ee-4528-9644-c1ae15ca2d30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:9d22fb65-e1ad-481f-9f9b-f396c31cccfa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0018077 PMID:41385096 "[{""id"":""uuid:683b159a-1d5c-4603-ac23-a891a658b922"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:72c2c28a-5f9e-44f3-a325-0661daf45982"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:ef37074d-7e29-4b98-9bf1-6b471825940e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0015766 PMID:41385096 "[{""id"":""uuid:4a13d9e7-8ed6-49dc-898c-8ca2f0307075"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f195f7cb-80ab-496f-82a5-02a7008b84cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:37104b9a-761d-4053-a29a-8917f15d263e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0040728 PMID:41385096 "[{""id"":""uuid:b7717dd9-4243-42f1-9b33-c3a93eba97a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:47334e16-17fa-4fd5-892c-19fcc946fccc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:2735b2f2-9cad-4c76-a668-70c32255bef7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0005683 PMID:41385096 "[{""id"":""uuid:6460705b-f65f-48d0-aa72-e74b02612d6a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e377db08-9932-40d0-b606-2d177ed90355"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:58d8d11b-12b8-40ba-86fc-c291540ecdbd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0005777 PMID:41385096 "[{""id"":""uuid:2b9f7947-35f1-401a-aa4e-4b5c49d63847"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2ba23059-768c-495f-8f2a-7f6f204437b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:1e5decc2-b8b4-42b7-8d39-7a71b2bd66ed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0020920 PMID:41385096 "[{""id"":""uuid:2e3aad3f-4781-4082-a945-0f5c98e4fa54"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:72f1379a-1ad0-4340-bb62-dec9d7a68d98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:67909347-cc15-41cd-b957-567e3cd92ce4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0019345 PMID:41385096 "[{""id"":""uuid:dc58fff9-af4a-41a0-9c35-5ec90a109163"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a6c62275-a65e-43ee-b369-bd5b5ee8fa68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:cb77f26a-afe5-41df-bedb-3dfa8652ab72 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0006635 PMID:41385096 "[{""id"":""uuid:fc6a870c-7536-4e11-80fe-f036d80946b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:64c509eb-7cf7-4fb4-af8b-8abb722c9544"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:0c387869-03f3-44dc-8ab9-90e75d598428 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats HP:0005376 PMID:41385096 "[{""id"":""uuid:d57cf758-8fe4-4666-a40a-b0f542e100f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7c6e57c1-5504-423a-8046-4433d900747f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:2d939f80-2ddb-44e7-a590-d6c06d75bf85 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0030603 PMID:41385096 "[{""id"":""uuid:638d998b-f9e2-4930-aa1c-835815ad9a31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7aa7a095-d30a-4d57-a64f-6d2fc6042537"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:d6bb1877-182a-4c83-b751-0458cb19bd68 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:a3710987-b7cc-4717-8022-5cd45cb59009"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:57613b0a-f164-417f-bc03-719a4ba92015"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:4a935d07-13f7-4051-9ee1-356baf0f2715 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0004277 PMID:41385096 "[{""id"":""uuid:3b237d4b-cc90-44cb-bbb7-8e13ed0b35e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:78404bef-ffc4-46f4-85a5-63152a7ca068"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:1694424b-0b70-4d4d-b888-3b9527ac0d6f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0005976 PMID:41385096 "[{""id"":""uuid:b282e527-0684-4dac-8e13-14f60cfb8528"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ba4447c6-edeb-47da-ba44-c589fcbc7504"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:a6a4a6de-6f89-44ba-b65d-fd7c3772c013 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0006019 PMID:41385096 "[{""id"":""uuid:e8921fd0-0515-4cb5-94be-9b0dbfe84581"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:69f9c3d3-1108-4a76-b126-be3138ff6cce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:4fca13ca-aac1-4419-b613-991aa86ce84a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0005828 PMID:41385096 "[{""id"":""uuid:90058279-d8d3-402e-b727-53df3fc329b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ecb9666e-be64-492a-991a-3e9dba58c779"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:2d996243-be6e-4323-a6d6-8fcbaadea4c8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0005119 PMID:41385096 "[{""id"":""uuid:ab3455ac-25d2-4d75-b9ed-956b2890f675"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:802cfeff-bd32-45dc-83e0-964efe215178"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:301debae-1f5c-4280-9e9f-3b56047fa07d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0005631 PMID:41385096 "[{""id"":""uuid:d9ced695-2b7d-4ce2-a48d-7e316ae6ce4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2ca68374-f7e5-4cc3-b0e4-d85e9d9b261d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:45f73c11-6265-4e12-ac28-99ae0965a67a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0024388 PMID:41385096 "[{""id"":""uuid:eff31a86-77a0-42b0-824e-bc39071260b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:66e986b7-67d3-4d44-a4bc-57ff5ff40453"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:27fd84a6-0dcc-4bef-9288-5b7b7eb393ff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0005644 PMID:41385096 "[{""id"":""uuid:2d8b2f26-c51f-4e96-9e9a-de76c13df8bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ba256001-a3d1-4cfa-aa5f-2ee0d13e1506"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:12812803-6d9e-4446-9f9c-0af21907baf3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:06b3d708-6bda-47cb-ba24-9219a7c2ea60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:790e184e-f57c-4b54-9293-aa8771514525"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:3d706ced-8073-4b0a-b773-ba9ec06e1223 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0043314 PMID:41385096 "[{""id"":""uuid:20af3899-731b-4475-a95c-a19136b19154"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:05e3c795-e2a1-480d-8b29-c9911a4fed76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline Hydrochloride Capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae Respiratory tract infections caused by Mycoplasma pneumoniae Lymphogranuloma venereum caused by Chlamydia trachomatis Psittacosis (Ornithosis) due to Chlamydia psittaci Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence Inclusion conjunctivitis caused by Chlamydia trachomatis Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis Relapsing fever due to Borrelia recurrentis Chancroid caused by Haemophilus ducreyi Plague due to Yersinia pestis Tularemia due to Francisella tularensis Cholera caused by Vibrio cholerae Campylobacter fetus infections caused by Campylobacter fetus Brucellosis due to Brucella species (in conjunction with streptomycin) Brucellosis due to Bartonella bacilliformis Granuloma inguinale caused by Calymmatobacterium granulomatis Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae Respiratory tract and urinary tract infections caused by Klebsiella species Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae Skin and skin structure infections caused by Straphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections when penicillin is contraindicated. Infections in women caused by Neisseria gonorrhoeae Syphilis caused by Treponema pallidum subspecies pallidum Yaws caused by Treponema pallidum subspecies pertenue Listeriosis due to Listeria monocytogenes Anthrax due to Bacillus anthracis Vincent's infection caused by Fusobacteruim fusiforme Actinomycosis caused by Actinomyces israelii Infections caused by Clostridium species In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:6c46bb76-e608-4776-bf0d-7aa0cfa1a0fe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7457 biolink:treats UMLS:C0572061 PMID:41385096 "[{""id"":""uuid:2e85c4d9-5698-40a8-b1fc-6886ba8c2ac8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cd8340df-cee7-4a57-95d6-396c1d55a230"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] REVEX is indicated for the complete or partial reversal of opioid drug effects, including respiratory depression, induced by either natural or synthetic opioids. REVEX is indicated in the management of known or suspected opioid overdose. uuid:2260e991-dc76-4fda-9403-fde8565df9dc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7457 biolink:treats MONDO:0043775 PMID:41385096 "[{""id"":""uuid:c8e4bacf-ef00-4b8f-bf6b-6e35d1287dfc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1f64b06e-bea2-454d-820f-ca8dc72cae9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] REVEX is indicated for the complete or partial reversal of opioid drug effects, including respiratory depression, induced by either natural or synthetic opioids. REVEX is indicated in the management of known or suspected opioid overdose. uuid:139d453b-9fe6-4bcd-980d-ebbe0644c537 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50673 biolink:treats MONDO:0004425 PMID:41385096 "[{""id"":""uuid:b1b4b3b1-a0b3-49ef-a229-71853ff18aea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8cd13756-47c4-4300-b9c5-6bae2fdfbf41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methimazole is indicated in the medical treatment of hyperthyroidism. Long-term therapy may lead to remission of the disease. Methimazole may be used to ameliorate hyperthyroidism in preparation for subtotal thyroidectomy or radioactive iodine therapy. Methimazole is also used when thyroidectomy is contraindicated or not advisable. uuid:ec172112-f020-4d9c-b741-4a3286d18d75 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64198 biolink:treats UMLS:C0311375 PMID:41385096 "[{""id"":""uuid:2c1fa45f-f5af-40e1-abd1-0b6c1ae008ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:26075398-52ed-470a-b7b1-0f8049384e67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BAL in Oil (Dimercaprol Injection USP) is indicated in the treatment of arsenic, gold and mercury poisoning. It is indicated in acute lead poisoning when used concomitantly with Edetate Calcium Disodium Injection USP. Dimercaprol Injection USP is effective for use in acute poisoning by mercury salts if therapy is begun within one or two hours following ingestion. It is not very effective for chronic mercury poisoning. Dimercaprol Injection USP is of questionable value in poisoning caused by other heavy metals such as antimony and bismuth. It should not be used in iron, cadmium, or selenium poisoning because the resulting dimercaprol-metal complexes are more toxic than the metal alone, especially to the kidneys. uuid:535d35f4-3a98-4dd9-a631-91baf7bca516 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64198 biolink:treats UMLS:C0274944 PMID:41385096 "[{""id"":""uuid:aeffd5f2-fad0-409c-b369-b6ee8eaf310f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9f03adb7-9e65-4deb-ba27-a171f5b6b227"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BAL in Oil (Dimercaprol Injection USP) is indicated in the treatment of arsenic, gold and mercury poisoning. It is indicated in acute lead poisoning when used concomitantly with Edetate Calcium Disodium Injection USP. Dimercaprol Injection USP is effective for use in acute poisoning by mercury salts if therapy is begun within one or two hours following ingestion. It is not very effective for chronic mercury poisoning. Dimercaprol Injection USP is of questionable value in poisoning caused by other heavy metals such as antimony and bismuth. It should not be used in iron, cadmium, or selenium poisoning because the resulting dimercaprol-metal complexes are more toxic than the metal alone, especially to the kidneys. uuid:7bf62241-923b-4322-8954-7062937f7b0d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64198 biolink:treats MONDO:0018020 PMID:41385096 "[{""id"":""uuid:cb9f9ed0-9051-4ffc-b3f4-5dba8624bc83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:556f2bfa-319e-42ab-920b-6e1772eda56a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BAL in Oil (Dimercaprol Injection USP) is indicated in the treatment of arsenic, gold and mercury poisoning. It is indicated in acute lead poisoning when used concomitantly with Edetate Calcium Disodium Injection USP. Dimercaprol Injection USP is effective for use in acute poisoning by mercury salts if therapy is begun within one or two hours following ingestion. It is not very effective for chronic mercury poisoning. Dimercaprol Injection USP is of questionable value in poisoning caused by other heavy metals such as antimony and bismuth. It should not be used in iron, cadmium, or selenium poisoning because the resulting dimercaprol-metal complexes are more toxic than the metal alone, especially to the kidneys. uuid:bd0c7abc-3330-4663-934c-62214e2e5709 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64198 biolink:treats MONDO:0018019 PMID:41385096 "[{""id"":""uuid:2d69870a-6e2c-4f5a-bdbf-f01b529b1692"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f2f9ed4c-f4d5-4f60-922c-c0ca07374651"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BAL in Oil (Dimercaprol Injection USP) is indicated in the treatment of arsenic, gold and mercury poisoning. It is indicated in acute lead poisoning when used concomitantly with Edetate Calcium Disodium Injection USP. Dimercaprol Injection USP is effective for use in acute poisoning by mercury salts if therapy is begun within one or two hours following ingestion. It is not very effective for chronic mercury poisoning. Dimercaprol Injection USP is of questionable value in poisoning caused by other heavy metals such as antimony and bismuth. It should not be used in iron, cadmium, or selenium poisoning because the resulting dimercaprol-metal complexes are more toxic than the metal alone, especially to the kidneys. uuid:82100716-2447-434e-8d53-90486807be80 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64198 biolink:treats UMLS:C0553526 PMID:41385096 "[{""id"":""uuid:0c8cb769-f559-4366-98fc-160f9974aa4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0b5a3a09-a033-4275-a251-351d39f363a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BAL in Oil (Dimercaprol Injection USP) is indicated in the treatment of arsenic, gold and mercury poisoning. It is indicated in acute lead poisoning when used concomitantly with Edetate Calcium Disodium Injection USP. Dimercaprol Injection USP is effective for use in acute poisoning by mercury salts if therapy is begun within one or two hours following ingestion. It is not very effective for chronic mercury poisoning. Dimercaprol Injection USP is of questionable value in poisoning caused by other heavy metals such as antimony and bismuth. It should not be used in iron, cadmium, or selenium poisoning because the resulting dimercaprol-metal complexes are more toxic than the metal alone, especially to the kidneys. uuid:75e71e0a-0702-4d25-9e77-dd2c8cb7a7c0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64198 biolink:treats UMLS:C0274920 PMID:41385096 "[{""id"":""uuid:019c1d0f-e6e0-4493-9ad1-b2bcfd7617c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a6646b71-c1f8-4072-9545-1b50d26be0f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BAL in Oil (Dimercaprol Injection USP) is indicated in the treatment of arsenic, gold and mercury poisoning. It is indicated in acute lead poisoning when used concomitantly with Edetate Calcium Disodium Injection USP. Dimercaprol Injection USP is effective for use in acute poisoning by mercury salts if therapy is begun within one or two hours following ingestion. It is not very effective for chronic mercury poisoning. Dimercaprol Injection USP is of questionable value in poisoning caused by other heavy metals such as antimony and bismuth. It should not be used in iron, cadmium, or selenium poisoning because the resulting dimercaprol-metal complexes are more toxic than the metal alone, especially to the kidneys. uuid:8483ceb1-cbb8-44e6-a940-fff9720a95e2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64198 biolink:treats MONDO:0043523 PMID:41385096 "[{""id"":""uuid:bae2e6d6-9d10-431a-9aa7-067f7f57d737"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:982eba5f-41c9-403a-a92e-a256a431eb2d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BAL in Oil (Dimercaprol Injection USP) is indicated in the treatment of arsenic, gold and mercury poisoning. It is indicated in acute lead poisoning when used concomitantly with Edetate Calcium Disodium Injection USP. Dimercaprol Injection USP is effective for use in acute poisoning by mercury salts if therapy is begun within one or two hours following ingestion. It is not very effective for chronic mercury poisoning. Dimercaprol Injection USP is of questionable value in poisoning caused by other heavy metals such as antimony and bismuth. It should not be used in iron, cadmium, or selenium poisoning because the resulting dimercaprol-metal complexes are more toxic than the metal alone, especially to the kidneys. uuid:0acc36fd-d515-4d77-84cc-c72889bbac2d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64198 biolink:treats UMLS:C0274973 PMID:41385096 "[{""id"":""uuid:7866ed11-cc29-4552-ace6-e4b8be592edd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9ef51b65-2426-47ab-aa0e-1fea7ba8f350"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BAL in Oil (Dimercaprol Injection USP) is indicated in the treatment of arsenic, gold and mercury poisoning. It is indicated in acute lead poisoning when used concomitantly with Edetate Calcium Disodium Injection USP. Dimercaprol Injection USP is effective for use in acute poisoning by mercury salts if therapy is begun within one or two hours following ingestion. It is not very effective for chronic mercury poisoning. Dimercaprol Injection USP is of questionable value in poisoning caused by other heavy metals such as antimony and bismuth. It should not be used in iron, cadmium, or selenium poisoning because the resulting dimercaprol-metal complexes are more toxic than the metal alone, especially to the kidneys. uuid:b0113b85-256e-4a98-af09-370efe48d88b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5130 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:96017104-8810-49a0-9ff8-53406071a9ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8922f7c6-1033-40e8-9d19-3e4c6fa72290"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of Flurbiprofen tablet, USP and other treatment options before deciding to use Flurbiprofen tablet, USP. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Flurbiprofen tablet, USP is indicated: For relief of the signs and symptoms of rheumatoid arthritis. For relief of the signs and symptoms of osteoarthritis. uuid:0c1acab9-b364-4848-9775-df0c4297a397 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5130 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:ef794cda-2070-49b5-8f5c-54a263c8e420"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c24c75ce-101e-42da-855b-66457e827409"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of Flurbiprofen tablet, USP and other treatment options before deciding to use Flurbiprofen tablet, USP. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Flurbiprofen tablet, USP is indicated: For relief of the signs and symptoms of rheumatoid arthritis. For relief of the signs and symptoms of osteoarthritis. uuid:dbb605ce-9560-422b-b74d-1d94ef4171d8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9123 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:5fec787d-01f3-4e24-9963-376daa6dfcca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3c0f3129-ddbe-4ab9-a0a1-12b0710d693f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sertraline hydrochloride tablets are indicated for the treatment of major depressive disorder in adults. The efficacy of sertraline in the treatment of a major depressive episode was established in six to eight week controlled trials of adult outpatients whose diagnoses corresponded most closely to the DSM-III category of major depressive disorder (see Clinical Trials under CLINICAL PHARMACOLOGY ). A major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. The antidepressant action of sertraline in hospitalized depressed patients has not been adequately studied. The efficacy of sertraline in maintaining an antidepressant response for up to 44 weeks following 8 weeks of open-label acute treatment (52 weeks total) was demonstrated in a placebo-controlled trial. The usefulness of the drug in patients receiving sertraline for extended periods should be reevaluated periodically (see Clinical Trials under CLINICAL PHARMACOLOGY ). uuid:d7c63307-594a-4bfa-97ab-a0a83000254d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63617 biolink:treats MONDO:0005180 PMID:41385096 "[{""id"":""uuid:646adb89-3b05-4137-bcab-335128a4599a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:095e3cf7-b1af-4947-ba9b-bf06911cf0f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Permax is indicated as adjunctive treatment to levodopa/carbidopa in the management of the signs and symptoms of Parkinson's disease. Evidence to support the efficacy of pergolide as an antiparkinsonian adjunct was obtained in a multicenter study enrolling 376 patients with mild to moderate Parkinson's disease who were intolerant to l -dopa/carbidopa as manifested by moderate to severe dyskinesia and/or on-off phenomena. On average, the patients evaluated had been on l -dopa/carbidopa for 3.9 years (range, 2 days to 16.8 years). The administration of pergolide permitted a 5% to 30% reduction in the daily dose of l -dopa. On average, these patients treated with pergolide maintained an equivalent or better clinical status than they exhibited at baseline. uuid:90bb7a93-367e-43fd-ab40-69193f796a22 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63617 biolink:treats HP:0100660 PMID:41385096 "[{""id"":""uuid:385d7276-ff64-4bd4-8795-056cdabd03ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a9e41f91-00cb-4d58-ac62-d4eaf546f5fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Permax is indicated as adjunctive treatment to levodopa/carbidopa in the management of the signs and symptoms of Parkinson's disease. Evidence to support the efficacy of pergolide as an antiparkinsonian adjunct was obtained in a multicenter study enrolling 376 patients with mild to moderate Parkinson's disease who were intolerant to l -dopa/carbidopa as manifested by moderate to severe dyskinesia and/or on-off phenomena. On average, the patients evaluated had been on l -dopa/carbidopa for 3.9 years (range, 2 days to 16.8 years). The administration of pergolide permitted a 5% to 30% reduction in the daily dose of l -dopa. On average, these patients treated with pergolide maintained an equivalent or better clinical status than they exhibited at baseline. uuid:87e4376b-04b2-4ace-b430-0a3c6c042ef7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9073 biolink:treats MONDO:0013600 PMID:41385096 "[{""id"":""uuid:344b3ec5-1104-4118-87f6-5510b6a667bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:820eb1a6-38c3-4460-b6db-708ea2d74aa9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A. Hypnotic, for the short-term treatment of insomnia, since it appears to lose its effectiveness for sleep induction and sleep maintenance after 2 weeks (see Clinical Pharmacology). B. Preanesthetic uuid:58712ac6-a3e6-4f37-9ef8-a56b112c384b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2668 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:ce5542e1-3951-426e-aab1-630f8b0e41c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e2afbb4e-437b-4fd2-be3d-de68a3c9d080"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c5dffdea-7584-4707-b436-681935924fe1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Hypertension Amlodipine besylate is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents. 2. Chronic Stable Angina Amlodipine besylate is indicated for the treatment of chronic stable angina. Amlodipine besylate may be used alone or in combination with other antianginal agents. 3. Vasospastic Angina (Prinzmetal's or Variant Angina) Amlodipine besylate is indicated for the treatment of confirmed or suspected vasospastic angina. Amlodipine besylate may be used as monotherapy or in combination with other antianginal drugs.|[PMDA] Drugs with a new additional pediatric dosages. These drugs are indicated for the treatment of hypertension. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:75211e0d-4ec1-4d3c-8f0a-75a5b640e89a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2668 biolink:treats MONDO:0006021 PMID:41385096 "[{""id"":""uuid:e746d10c-be0d-4591-bcc5-e9bc8bfce9f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:34e9988f-aa84-4d06-b21a-edd9cdb5d740"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Hypertension Amlodipine besylate is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents. 2. Chronic Stable Angina Amlodipine besylate is indicated for the treatment of chronic stable angina. Amlodipine besylate may be used alone or in combination with other antianginal agents. 3. Vasospastic Angina (Prinzmetal's or Variant Angina) Amlodipine besylate is indicated for the treatment of confirmed or suspected vasospastic angina. Amlodipine besylate may be used as monotherapy or in combination with other antianginal drugs. uuid:0c1edb05-62e6-4eae-9cde-ba9d915accf3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7660 biolink:treats MONDO:0002040 PMID:41385096 "[{""id"":""uuid:b939e12d-a022-43f3-9e89-2b3e3be5df74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7e3ac836-f937-47a2-a774-68ff0efb7d9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nystatin topical powder is indicated in the treatment of cutaneous or mucocutaneous mycotic infections caused by Candida albicans and other susceptible Candida species. This topical powder is not indicated for systemic, oral, intravaginal or ophthalmic use. uuid:851c25ea-77a9-4453-a183-e3786405afa9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7660 biolink:treats MONDO:0002041 PMID:41385096 "[{""id"":""uuid:887fd7e2-1508-460e-a6ce-f9c896eb9c25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:32622050-e2e3-4e47-a048-824af03d83d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nystatin topical powder is indicated in the treatment of cutaneous or mucocutaneous mycotic infections caused by Candida albicans and other susceptible Candida species. This topical powder is not indicated for systemic, oral, intravaginal or ophthalmic use. uuid:3d43c341-5924-4e84-aa34-70bbe875150f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:85783 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:dc804cc6-d7ed-41f8-bc04-6b6501d8e404"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dbf84cc9-cdad-413a-8898-8c3f4d078b7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lisinopril and hydrochlorothiazide tablets are indicated for the treatment of hypertension. These fixed-dose combinations are not indicated for initial therapy (see DOSAGE AND ADMINISTRATION ). In using lisinopril and hydrochlorothiazide, consideration should be given to the fact that an angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that lisinopril does not have a similar risk. (See WARNINGS .) In considering use of lisinopril and hydrochlorothiazide, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks. (See WARNINGS, Angioedema .) uuid:56e3fd6a-ad32-44e3-b570-f2e076564557 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:85783 biolink:treats MONDO:0001609 PMID:41385096 "[{""id"":""uuid:6c1a06ac-f75f-4e57-8b11-2ff164beb0f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fd69d71f-75e7-4b72-b7a8-7450db7cda4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lisinopril and hydrochlorothiazide tablets are indicated for the treatment of hypertension. These fixed-dose combinations are not indicated for initial therapy (see DOSAGE AND ADMINISTRATION ). In using lisinopril and hydrochlorothiazide, consideration should be given to the fact that an angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that lisinopril does not have a similar risk. (See WARNINGS .) In considering use of lisinopril and hydrochlorothiazide, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks. (See WARNINGS, Angioedema .) uuid:a104b9ee-af2e-4b09-aae2-a1d3be885405 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:85783 biolink:treats MONDO:0001343 PMID:41385096 "[{""id"":""uuid:b78a8c35-47ec-4023-a960-d8be5593f20b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:66c06f5d-0e7b-490b-9829-0cfd3ca778e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lisinopril and hydrochlorothiazide tablets are indicated for the treatment of hypertension. These fixed-dose combinations are not indicated for initial therapy (see DOSAGE AND ADMINISTRATION ). In using lisinopril and hydrochlorothiazide, consideration should be given to the fact that an angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that lisinopril does not have a similar risk. (See WARNINGS .) In considering use of lisinopril and hydrochlorothiazide, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks. (See WARNINGS, Angioedema .) uuid:fec96025-8fc4-4556-8b54-c50d049673c7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:85783 biolink:treats MONDO:0010481 PMID:41385096 "[{""id"":""uuid:cc54c602-075c-4317-8ad6-44f4ac37c53a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a2a63d2e-9428-4a60-bdd4-88b2d3690c8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lisinopril and hydrochlorothiazide tablets are indicated for the treatment of hypertension. These fixed-dose combinations are not indicated for initial therapy (see DOSAGE AND ADMINISTRATION ). In using lisinopril and hydrochlorothiazide, consideration should be given to the fact that an angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that lisinopril does not have a similar risk. (See WARNINGS .) In considering use of lisinopril and hydrochlorothiazide, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks. (See WARNINGS, Angioedema .) uuid:9aae02f5-9b1d-47a3-a5f7-69afea8ecb97 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:167309 biolink:treats MONDO:0005530 PMID:41385096 "[{""id"":""uuid:2e17f79c-12f0-4a30-afd8-3c20f3a39746"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9d61d236-ffdb-416e-b251-f9e2b14e093d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Detoxification treatment of opioid addiction (heroin or other morphine-like drugs). Maintenance treatment of opioid addiction (heroin or other morphine-like drugs), in conjunction with appropriate social and medical services. uuid:04a15656-68ee-423f-839a-3d500c301565 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:167309 biolink:treats MONDO:0005367 PMID:41385096 "[{""id"":""uuid:e2f20829-bda5-4908-9c83-45eead342114"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:be655db2-a0b3-431c-a09b-93fab371b80b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Detoxification treatment of opioid addiction (heroin or other morphine-like drugs). Maintenance treatment of opioid addiction (heroin or other morphine-like drugs), in conjunction with appropriate social and medical services. uuid:31464404-9cf9-43b3-bd82-887018f6b15d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:167309 biolink:treats MONDO:0005303 PMID:41385096 "[{""id"":""uuid:5b66c1d0-ee19-48ab-a2a2-9eb6fae0cfc1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:85d2774a-412e-4ba5-88f2-1d1f7625507d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Detoxification treatment of opioid addiction (heroin or other morphine-like drugs). Maintenance treatment of opioid addiction (heroin or other morphine-like drugs), in conjunction with appropriate social and medical services. uuid:431ab246-ba0f-423a-823b-f4b19b1b55b5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5138 biolink:treats UMLS:C0233697 PMID:41385096 "[{""id"":""uuid:c57a8878-83ca-4660-a754-c493b6533e6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:723ebd16-6e51-42df-b372-57f61a7de3c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluvoxamine Maleate Tablets are indicated for the treatment of obsessions and compulsions in patients with Obsessive Compulsive Disorder (OCD), as defined in the DSM-III-R. The obsessions or compulsions cause marked distress, are time-consuming, or significantly interfere with social or occupational functioning. The efficacy of Fluvoxamine Maleate Tablets was established in three 10-week trials with obsessive compulsive outpatients with the diagnosis of Obsessive Compulsive Disorder as defined in DSM-III-R. (See Clinical Trials under CLINICAL PHARMACOLOGY .) Obsessive Compulsive Disorder is characterized by recurrent and persistent ideas, thoughts, impulses or images (obsessions) that are ego- dystonic and/or repetitive, purposeful, and intentional behaviors (compulsions) that are recognized by the person as excessive or unreasonable. The effectiveness of Fluvoxamine Maleate Tablets for long-term use, i.e., for more than 10 weeks, has not been systematically evaluated in placebo-controlled trials. Therefore, the physician who elects to use Fluvoxamine Maleate Tablets for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient. (See DOSAGE AND ADMINISTRATION .) uuid:4090aea9-6642-42d2-b34a-bc20c928e2eb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5138 biolink:treats MONDO:0008114 PMID:41385096 "[{""id"":""uuid:0fcbcc36-9620-4de7-94e4-163f20a63d40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:30480edb-c51e-44ca-9266-4a510574ad66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluvoxamine Maleate Tablets are indicated for the treatment of obsessions and compulsions in patients with Obsessive Compulsive Disorder (OCD), as defined in the DSM-III-R. The obsessions or compulsions cause marked distress, are time-consuming, or significantly interfere with social or occupational functioning. The efficacy of Fluvoxamine Maleate Tablets was established in three 10-week trials with obsessive compulsive outpatients with the diagnosis of Obsessive Compulsive Disorder as defined in DSM-III-R. (See Clinical Trials under CLINICAL PHARMACOLOGY .) Obsessive Compulsive Disorder is characterized by recurrent and persistent ideas, thoughts, impulses or images (obsessions) that are ego- dystonic and/or repetitive, purposeful, and intentional behaviors (compulsions) that are recognized by the person as excessive or unreasonable. The effectiveness of Fluvoxamine Maleate Tablets for long-term use, i.e., for more than 10 weeks, has not been systematically evaluated in placebo-controlled trials. Therefore, the physician who elects to use Fluvoxamine Maleate Tablets for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient. (See DOSAGE AND ADMINISTRATION .) uuid:7beffdd9-5a75-42b5-b063-8a4f38ddb7d3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29103 biolink:treats MONDO:0003019 PMID:41385096 "[{""id"":""uuid:32dd4a50-ff18-40e2-ba33-395d3a7703fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e5a38e82-2ec9-4ef1-8b14-884c41e5d966"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BECAUSE OF REPORTS OF INTESTINAL AND GASTRIC ULCERATION AND BLEEDING WITH CONTROLLED-RELEASE POTASSIUM CHLORIDE PREPARATIONS, THESE DRUGS SHOULD BE RESERVED FOR THOSE PATIENTS WHO CANNOT TOLERATE OR REFUSE TO TAKE LIQUID OR EFFERVESCENT POTASSIUM PREPARATIONS OR FOR PATIENTS IN WHOM THERE IS A PROBLEM OF COMPLIANCE WITH THESE PREPARATIONS. For the treatment of patients with hypokalemia, with or without metabolic alkalosis, in digitalis intoxications, and in patients with hypokalemic familial periodic paralysis. If hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. For the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias, hepatic cirrhosis with ascites, states of aldosterone excess with normal renal function, potassium-losing nephropathy, and certain diarrheal states. The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern and when low doses of the diuretic are used. Serum potassium should be checked periodically, however, and if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases, and if dose adjustment of the diuretic is ineffective or unwarranted, supplementation with potassium salts may be indicated. uuid:f4c0b936-ed8a-4145-b3c8-d112589ac207 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29103 biolink:treats HP:0200114 PMID:41385096 "[{""id"":""uuid:998388ff-ef82-4cfd-8fc7-457cbdd5760d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a5650758-dd47-43b2-b123-eed3e1e5feba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BECAUSE OF REPORTS OF INTESTINAL AND GASTRIC ULCERATION AND BLEEDING WITH CONTROLLED-RELEASE POTASSIUM CHLORIDE PREPARATIONS, THESE DRUGS SHOULD BE RESERVED FOR THOSE PATIENTS WHO CANNOT TOLERATE OR REFUSE TO TAKE LIQUID OR EFFERVESCENT POTASSIUM PREPARATIONS OR FOR PATIENTS IN WHOM THERE IS A PROBLEM OF COMPLIANCE WITH THESE PREPARATIONS. For the treatment of patients with hypokalemia, with or without metabolic alkalosis, in digitalis intoxications, and in patients with hypokalemic familial periodic paralysis. If hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. For the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias, hepatic cirrhosis with ascites, states of aldosterone excess with normal renal function, potassium-losing nephropathy, and certain diarrheal states. The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern and when low doses of the diuretic are used. Serum potassium should be checked periodically, however, and if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases, and if dose adjustment of the diuretic is ineffective or unwarranted, supplementation with potassium salts may be indicated. uuid:f3e3f84c-da41-4e65-abe3-00f22bab7baa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29103 biolink:treats MONDO:0017863 PMID:41385096 "[{""id"":""uuid:b78d4298-18a4-40b2-b028-1d26c2bf859d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fe6ce868-77b5-4264-a54b-ccc32aaf89df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BECAUSE OF REPORTS OF INTESTINAL AND GASTRIC ULCERATION AND BLEEDING WITH CONTROLLED-RELEASE POTASSIUM CHLORIDE PREPARATIONS, THESE DRUGS SHOULD BE RESERVED FOR THOSE PATIENTS WHO CANNOT TOLERATE OR REFUSE TO TAKE LIQUID OR EFFERVESCENT POTASSIUM PREPARATIONS OR FOR PATIENTS IN WHOM THERE IS A PROBLEM OF COMPLIANCE WITH THESE PREPARATIONS. For the treatment of patients with hypokalemia, with or without metabolic alkalosis, in digitalis intoxications, and in patients with hypokalemic familial periodic paralysis. If hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. For the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias, hepatic cirrhosis with ascites, states of aldosterone excess with normal renal function, potassium-losing nephropathy, and certain diarrheal states. The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern and when low doses of the diuretic are used. Serum potassium should be checked periodically, however, and if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases, and if dose adjustment of the diuretic is ineffective or unwarranted, supplementation with potassium salts may be indicated. uuid:a107a3a0-b0a3-4742-a49b-4b4c854779f1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29103 biolink:treats MONDO:0008223 PMID:41385096 "[{""id"":""uuid:01cd6ee4-7672-4ed4-bf0f-4dd78dd4c013"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1e2eda3b-fa78-4bd4-919e-913ac070fd52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BECAUSE OF REPORTS OF INTESTINAL AND GASTRIC ULCERATION AND BLEEDING WITH CONTROLLED-RELEASE POTASSIUM CHLORIDE PREPARATIONS, THESE DRUGS SHOULD BE RESERVED FOR THOSE PATIENTS WHO CANNOT TOLERATE OR REFUSE TO TAKE LIQUID OR EFFERVESCENT POTASSIUM PREPARATIONS OR FOR PATIENTS IN WHOM THERE IS A PROBLEM OF COMPLIANCE WITH THESE PREPARATIONS. For the treatment of patients with hypokalemia, with or without metabolic alkalosis, in digitalis intoxications, and in patients with hypokalemic familial periodic paralysis. If hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. For the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias, hepatic cirrhosis with ascites, states of aldosterone excess with normal renal function, potassium-losing nephropathy, and certain diarrheal states. The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern and when low doses of the diuretic are used. Serum potassium should be checked periodically, however, and if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases, and if dose adjustment of the diuretic is ineffective or unwarranted, supplementation with potassium salts may be indicated. uuid:189882d7-3702-4759-8ded-9dd5234de7cd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29103 biolink:treats MONDO:0007263 PMID:41385096 "[{""id"":""uuid:6a39f17c-75b6-4fdd-b5c7-90f1ac9dff09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4b5e8ec0-44c7-4c63-9d72-2989edb1a763"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BECAUSE OF REPORTS OF INTESTINAL AND GASTRIC ULCERATION AND BLEEDING WITH CONTROLLED-RELEASE POTASSIUM CHLORIDE PREPARATIONS, THESE DRUGS SHOULD BE RESERVED FOR THOSE PATIENTS WHO CANNOT TOLERATE OR REFUSE TO TAKE LIQUID OR EFFERVESCENT POTASSIUM PREPARATIONS OR FOR PATIENTS IN WHOM THERE IS A PROBLEM OF COMPLIANCE WITH THESE PREPARATIONS. For the treatment of patients with hypokalemia, with or without metabolic alkalosis, in digitalis intoxications, and in patients with hypokalemic familial periodic paralysis. If hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. For the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias, hepatic cirrhosis with ascites, states of aldosterone excess with normal renal function, potassium-losing nephropathy, and certain diarrheal states. The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern and when low doses of the diuretic are used. Serum potassium should be checked periodically, however, and if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases, and if dose adjustment of the diuretic is ineffective or unwarranted, supplementation with potassium salts may be indicated. uuid:9916b81d-4190-4a22-a95c-f5b34f60512f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29103 biolink:treats MONDO:0005155 PMID:41385096 "[{""id"":""uuid:18a7e5ed-6c37-4873-a24f-f7d06b7fd8e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2311c3ce-6e49-45dc-95fa-744a1d8fb3d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BECAUSE OF REPORTS OF INTESTINAL AND GASTRIC ULCERATION AND BLEEDING WITH CONTROLLED-RELEASE POTASSIUM CHLORIDE PREPARATIONS, THESE DRUGS SHOULD BE RESERVED FOR THOSE PATIENTS WHO CANNOT TOLERATE OR REFUSE TO TAKE LIQUID OR EFFERVESCENT POTASSIUM PREPARATIONS OR FOR PATIENTS IN WHOM THERE IS A PROBLEM OF COMPLIANCE WITH THESE PREPARATIONS. For the treatment of patients with hypokalemia, with or without metabolic alkalosis, in digitalis intoxications, and in patients with hypokalemic familial periodic paralysis. If hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. For the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias, hepatic cirrhosis with ascites, states of aldosterone excess with normal renal function, potassium-losing nephropathy, and certain diarrheal states. The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern and when low doses of the diuretic are used. Serum potassium should be checked periodically, however, and if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases, and if dose adjustment of the diuretic is ineffective or unwarranted, supplementation with potassium salts may be indicated. uuid:7f2f7a01-cec3-441f-bb32-4e9cdcd34888 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29103 biolink:treats MONDO:0001673 PMID:41385096 "[{""id"":""uuid:536fab64-dac5-4864-8002-5e378cafa295"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3c84c1e3-99af-465c-b50a-d99dfb9b781b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BECAUSE OF REPORTS OF INTESTINAL AND GASTRIC ULCERATION AND BLEEDING WITH CONTROLLED-RELEASE POTASSIUM CHLORIDE PREPARATIONS, THESE DRUGS SHOULD BE RESERVED FOR THOSE PATIENTS WHO CANNOT TOLERATE OR REFUSE TO TAKE LIQUID OR EFFERVESCENT POTASSIUM PREPARATIONS OR FOR PATIENTS IN WHOM THERE IS A PROBLEM OF COMPLIANCE WITH THESE PREPARATIONS. For the treatment of patients with hypokalemia, with or without metabolic alkalosis, in digitalis intoxications, and in patients with hypokalemic familial periodic paralysis. If hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. For the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias, hepatic cirrhosis with ascites, states of aldosterone excess with normal renal function, potassium-losing nephropathy, and certain diarrheal states. The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern and when low doses of the diuretic are used. Serum potassium should be checked periodically, however, and if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases, and if dose adjustment of the diuretic is ineffective or unwarranted, supplementation with potassium salts may be indicated. uuid:d9c1a21c-4ed0-4e43-a389-1f007323031e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29103 biolink:treats MONDO:0001134 PMID:41385096 "[{""id"":""uuid:adbca2eb-e213-4eaf-8daa-c5db41b3934b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:06de3691-7d5a-4ecb-8976-58d630946e6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BECAUSE OF REPORTS OF INTESTINAL AND GASTRIC ULCERATION AND BLEEDING WITH CONTROLLED-RELEASE POTASSIUM CHLORIDE PREPARATIONS, THESE DRUGS SHOULD BE RESERVED FOR THOSE PATIENTS WHO CANNOT TOLERATE OR REFUSE TO TAKE LIQUID OR EFFERVESCENT POTASSIUM PREPARATIONS OR FOR PATIENTS IN WHOM THERE IS A PROBLEM OF COMPLIANCE WITH THESE PREPARATIONS. For the treatment of patients with hypokalemia, with or without metabolic alkalosis, in digitalis intoxications, and in patients with hypokalemic familial periodic paralysis. If hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. For the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias, hepatic cirrhosis with ascites, states of aldosterone excess with normal renal function, potassium-losing nephropathy, and certain diarrheal states. The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern and when low doses of the diuretic are used. Serum potassium should be checked periodically, however, and if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases, and if dose adjustment of the diuretic is ineffective or unwarranted, supplementation with potassium salts may be indicated. uuid:09fbc3da-56c2-4558-ac04-5eae926f7b88 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:91495 biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:d33dfada-c7a7-4fb9-be4d-7ef2a824cfc4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9c4fbf87-56fc-4d1c-ba43-810fc67fe131"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ipratropium Bromide Inhalation Solution administered either alone or with other bronchodilators, especially beta adrenergics, is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. uuid:044dc1a3-b3b7-4986-bd4a-d172d2929213 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:91495 biolink:treats MONDO:0005607 PMID:41385096 "[{""id"":""uuid:535e4111-28c1-4f79-adb6-cef4771ab471"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9f4b2d0b-281d-41e7-8e88-bfef684d5f04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ipratropium Bromide Inhalation Solution administered either alone or with other bronchodilators, especially beta adrenergics, is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. uuid:d3bd4236-7a10-442e-8fe8-ac8f7ae2cff4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:91495 biolink:treats MONDO:0004849 PMID:41385096 "[{""id"":""uuid:23e16449-911d-4d76-8b39-edabf8ae2041"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:928575a6-27ec-46bf-91e9-cd03ac1d38b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ipratropium Bromide Inhalation Solution administered either alone or with other bronchodilators, especially beta adrenergics, is indicated as a bronchodilator for maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema. uuid:8b00474e-e59d-438d-8f70-84114ab0ab5a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42355 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:7e209ea4-ae05-4321-a4cc-a4abbb0bc279"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:83a4b0d9-86ce-47f6-87df-07ac25c654b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Erythromycin pledgets, USP are indicated for the topical treatment of acne vulgaris. uuid:3cb3297d-9848-41cc-9d15-673d791f354c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0008315 PMID:41385096 "[{""id"":""uuid:03aaa6ba-6cf3-40ff-b575-b773f731749d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f6fa296f-7425-49ff-96a4-c35fbd83346f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Viadur ® is indicated in the palliative treatment of advanced prostate cancer. uuid:a1e1cee5-ffbb-4c0c-b930-2ae0a2efbded biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3441 biolink:treats HP:0025169 PMID:41385096 "[{""id"":""uuid:ad760de1-6889-4457-ad57-b9db59adcdf2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:29ccdbbb-57c0-476b-a3be-5db36d3124fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carvedilol is an alpha/beta-adrenergic blocking agent indicated for the treatment of: Left ventricular dysfunction following myocardial infarction in clinically stable patients (1.1) Hypertension (1.2) uuid:89120b74-5d7c-498b-b3f0-bb1a9b3b1551 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3441 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:36439518-98e8-4d2e-b6cd-ee51ff5c4002"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6045861e-283f-48ce-9d71-a8271206e1c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carvedilol is an alpha/beta-adrenergic blocking agent indicated for the treatment of: Left ventricular dysfunction following myocardial infarction in clinically stable patients (1.1) Hypertension (1.2) uuid:89325180-6bad-42e4-846f-72c12409d33f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:167309 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:da13200f-880c-4160-9ea3-469d9deae0af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:69fd1c94-3809-4628-beab-1ebaa902733e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of moderate to severe pain not responsive to non-narcotic analgesics. For use in temporary treatment of opioid dependence in patients unable to take oral medication. Outpatient maintenance and outpatient detoxification treatment may be provided only by opioid treatment programs (OTPs) certified by the Federal Substance Abuse and Mental Health Services Administration (SAMHSA) and registered by the Drug Enforcement Administration (DEA). This does not preclude the maintenance treatment of a patient with concurrent opioid addiction who is hospitalized for conditions other than opioid addiction and who requires temporary maintenance during the critical period of hospitalization, or of a patient whose enrollment has been verified in a program which has been certified for maintenance treatment with methadone. uuid:8e1b69ce-8faa-4c40-9940-dd85ff5b2c40 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:d49f84d5-7030-48ad-bfe8-a82f260d3e3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2926935b-0411-497d-bab9-1e6734255fdb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. uuid:80acbfd9-9767-4ce5-ad38-c59d20f88feb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:f842525e-8243-44f2-b27e-902b1b6b5244"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:62510aa7-048b-4504-a896-af30c05b8262"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. uuid:08b34494-5466-4cf2-946a-83453b02606d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0005480 PMID:41385096 "[{""id"":""uuid:c994de2d-bdb9-423e-bd26-d2f5f534397f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4839099c-3e86-45b9-b5d3-2fdfeae376e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. uuid:f05ed1c3-69e6-4abe-a93c-3810f2a8bf04 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0000775 PMID:41385096 "[{""id"":""uuid:407c0222-437d-4675-8b18-ec0af593e6df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:84182e19-48dc-4cac-a5f3-75b03793342a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. uuid:372c7f6f-3aca-4463-90d2-d2dc9711b264 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0024332 PMID:41385096 "[{""id"":""uuid:0e3cfde2-6dc3-42b3-b2b2-e65373a7b3a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5453e2ef-c493-4197-b052-93b6fd8bf784"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. uuid:ffdea7cf-37ed-41b2-bf12-7d4c5b3e792a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:7a74857d-88c6-4c9e-a0de-00dad8d8e2e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fb83ab36-b972-454e-af7d-8837b52ec50d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. uuid:13f8ff3f-c24f-4e92-8cfa-795fe5f6b564 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0043789 PMID:41385096 "[{""id"":""uuid:d1db3307-1e48-4614-aeee-cf544884644f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2af4bf51-a984-4084-a326-d8656d405906"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. uuid:258cae98-2b43-4537-b913-19382dbd8999 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:474053 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:15317ef4-93f7-4d73-8795-e3685d02aa90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:74d352d5-afe5-4cdf-8574-333814d16703"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefazolin for injection is indicated in the treatment of the following serious infections due to susceptible organisms: Respiratory Tract Infections due to S. pneumoniae, Klebsiella species, H. influenzae, S. aureus (penicillin-sensitive and penicillin-resistant), and group A beta-hemolytic streptococci. Injectable benzathine penicillin is considered to be the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefazolin for injection is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of Cefazolin for injection in the subsequent prevention of rheumatic fever are not available at present. Urinary Tract Infections due to E. coli, P. mirabilis, Klebsiella species, and some strains of enterobacter and enterococci. Skin and Skin Structure Infections due to S. aureus (penicillin-sensitive and penicillin-resistant), group A beta-hemolytic streptococci, and other strains of streptococci. Biliary Tract Infections due to E. coli, various strains of streptococci, P. mirabilis, Klebsiella species, and S. aureus. Bone and Joint Infections due to S. aureus. Genital Infections (i.e., prostatitis, epididymitis) due to E. coli, P. mirabilis, Klebsiella species, and some strains of enterococci. Septicemia due to S. pneumoniae, S. aureus (penicillin-sensitive and penicillin-resistant), P. mirabilis, E. coli , and Klebsiella species. Endocarditis due to S. aureus (penicillin-sensitive and penicillin-resistant) and group A beta-hemolytic streptococci. Perioperative Prophylaxis the prophylactic administration of Cefazolin for injection preoperatively, intraoperatively, and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high-risk patients such as those older than 70 years, with acute cholecystitis, obstructive jaundice, or common duct bile stones). The perioperative use of Cefazolin for injection may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g., during open-heart surgery and prosthetic arthroplasty). The prophylactic administration of Cefazolin for injection should usually be discontinued within a 24 hour period after the surgical procedure. In surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of Cefazolin for injection may be continued for 3 to 5 days following the completion of surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism so that appropriate therapy may be instituted.(See DOSAGE AND ADMINISTRATION .) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for injection and other antibacterial drugs, Cefazolin for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:b33300bf-6bd8-438c-9f2d-2230cede6e05 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:474053 biolink:treats MONDO:0021680 PMID:41385096 "[{""id"":""uuid:b6da4e76-9ad5-4317-84ff-8a907430f27c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:715bed27-3492-4a78-a6bd-c4c43e85c570"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefazolin for injection is indicated in the treatment of the following serious infections due to susceptible organisms: Respiratory Tract Infections due to S. pneumoniae, Klebsiella species, H. influenzae, S. aureus (penicillin-sensitive and penicillin-resistant), and group A beta-hemolytic streptococci. Injectable benzathine penicillin is considered to be the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefazolin for injection is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of Cefazolin for injection in the subsequent prevention of rheumatic fever are not available at present. Urinary Tract Infections due to E. coli, P. mirabilis, Klebsiella species, and some strains of enterobacter and enterococci. Skin and Skin Structure Infections due to S. aureus (penicillin-sensitive and penicillin-resistant), group A beta-hemolytic streptococci, and other strains of streptococci. Biliary Tract Infections due to E. coli, various strains of streptococci, P. mirabilis, Klebsiella species, and S. aureus. Bone and Joint Infections due to S. aureus. Genital Infections (i.e., prostatitis, epididymitis) due to E. coli, P. mirabilis, Klebsiella species, and some strains of enterococci. Septicemia due to S. pneumoniae, S. aureus (penicillin-sensitive and penicillin-resistant), P. mirabilis, E. coli , and Klebsiella species. Endocarditis due to S. aureus (penicillin-sensitive and penicillin-resistant) and group A beta-hemolytic streptococci. Perioperative Prophylaxis the prophylactic administration of Cefazolin for injection preoperatively, intraoperatively, and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high-risk patients such as those older than 70 years, with acute cholecystitis, obstructive jaundice, or common duct bile stones). The perioperative use of Cefazolin for injection may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g., during open-heart surgery and prosthetic arthroplasty). The prophylactic administration of Cefazolin for injection should usually be discontinued within a 24 hour period after the surgical procedure. In surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of Cefazolin for injection may be continued for 3 to 5 days following the completion of surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism so that appropriate therapy may be instituted.(See DOSAGE AND ADMINISTRATION .) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for injection and other antibacterial drugs, Cefazolin for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:a8b7848c-5597-4647-8bd9-4b5061871f00 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:474053 biolink:treats MONDO:0017767 PMID:41385096 "[{""id"":""uuid:451a50b3-e1ff-47b1-a72b-8ed9ec42dd4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:61066adf-3b6a-4414-8212-d8f65e52ace3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefazolin for injection is indicated in the treatment of the following serious infections due to susceptible organisms: Respiratory Tract Infections due to S. pneumoniae, Klebsiella species, H. influenzae, S. aureus (penicillin-sensitive and penicillin-resistant), and group A beta-hemolytic streptococci. Injectable benzathine penicillin is considered to be the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefazolin for injection is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of Cefazolin for injection in the subsequent prevention of rheumatic fever are not available at present. Urinary Tract Infections due to E. coli, P. mirabilis, Klebsiella species, and some strains of enterobacter and enterococci. Skin and Skin Structure Infections due to S. aureus (penicillin-sensitive and penicillin-resistant), group A beta-hemolytic streptococci, and other strains of streptococci. Biliary Tract Infections due to E. coli, various strains of streptococci, P. mirabilis, Klebsiella species, and S. aureus. Bone and Joint Infections due to S. aureus. Genital Infections (i.e., prostatitis, epididymitis) due to E. coli, P. mirabilis, Klebsiella species, and some strains of enterococci. Septicemia due to S. pneumoniae, S. aureus (penicillin-sensitive and penicillin-resistant), P. mirabilis, E. coli , and Klebsiella species. Endocarditis due to S. aureus (penicillin-sensitive and penicillin-resistant) and group A beta-hemolytic streptococci. Perioperative Prophylaxis the prophylactic administration of Cefazolin for injection preoperatively, intraoperatively, and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high-risk patients such as those older than 70 years, with acute cholecystitis, obstructive jaundice, or common duct bile stones). The perioperative use of Cefazolin for injection may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g., during open-heart surgery and prosthetic arthroplasty). The prophylactic administration of Cefazolin for injection should usually be discontinued within a 24 hour period after the surgical procedure. In surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of Cefazolin for injection may be continued for 3 to 5 days following the completion of surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism so that appropriate therapy may be instituted.(See DOSAGE AND ADMINISTRATION .) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for injection and other antibacterial drugs, Cefazolin for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:4484591b-e9df-4770-b218-4653d5c09ddc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:474053 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:9b3920f2-f101-4c97-b5e7-ca5d4f928a39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2aced3a9-4b95-49e2-8b0b-c5e860e90cab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefazolin for injection is indicated in the treatment of the following serious infections due to susceptible organisms: Respiratory Tract Infections due to S. pneumoniae, Klebsiella species, H. influenzae, S. aureus (penicillin-sensitive and penicillin-resistant), and group A beta-hemolytic streptococci. Injectable benzathine penicillin is considered to be the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefazolin for injection is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of Cefazolin for injection in the subsequent prevention of rheumatic fever are not available at present. Urinary Tract Infections due to E. coli, P. mirabilis, Klebsiella species, and some strains of enterobacter and enterococci. Skin and Skin Structure Infections due to S. aureus (penicillin-sensitive and penicillin-resistant), group A beta-hemolytic streptococci, and other strains of streptococci. Biliary Tract Infections due to E. coli, various strains of streptococci, P. mirabilis, Klebsiella species, and S. aureus. Bone and Joint Infections due to S. aureus. Genital Infections (i.e., prostatitis, epididymitis) due to E. coli, P. mirabilis, Klebsiella species, and some strains of enterococci. Septicemia due to S. pneumoniae, S. aureus (penicillin-sensitive and penicillin-resistant), P. mirabilis, E. coli , and Klebsiella species. Endocarditis due to S. aureus (penicillin-sensitive and penicillin-resistant) and group A beta-hemolytic streptococci. Perioperative Prophylaxis the prophylactic administration of Cefazolin for injection preoperatively, intraoperatively, and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high-risk patients such as those older than 70 years, with acute cholecystitis, obstructive jaundice, or common duct bile stones). The perioperative use of Cefazolin for injection may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g., during open-heart surgery and prosthetic arthroplasty). The prophylactic administration of Cefazolin for injection should usually be discontinued within a 24 hour period after the surgical procedure. In surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of Cefazolin for injection may be continued for 3 to 5 days following the completion of surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism so that appropriate therapy may be instituted.(See DOSAGE AND ADMINISTRATION .) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for injection and other antibacterial drugs, Cefazolin for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:d8172819-30fa-430d-9c11-332133164fa7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:474053 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:918bc9c2-0912-4d97-bf03-9f990996b634"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a8a19fc4-e04b-4ca4-8cda-54cf36450540"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefazolin for injection is indicated in the treatment of the following serious infections due to susceptible organisms: Respiratory Tract Infections due to S. pneumoniae, Klebsiella species, H. influenzae, S. aureus (penicillin-sensitive and penicillin-resistant), and group A beta-hemolytic streptococci. Injectable benzathine penicillin is considered to be the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefazolin for injection is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of Cefazolin for injection in the subsequent prevention of rheumatic fever are not available at present. Urinary Tract Infections due to E. coli, P. mirabilis, Klebsiella species, and some strains of enterobacter and enterococci. Skin and Skin Structure Infections due to S. aureus (penicillin-sensitive and penicillin-resistant), group A beta-hemolytic streptococci, and other strains of streptococci. Biliary Tract Infections due to E. coli, various strains of streptococci, P. mirabilis, Klebsiella species, and S. aureus. Bone and Joint Infections due to S. aureus. Genital Infections (i.e., prostatitis, epididymitis) due to E. coli, P. mirabilis, Klebsiella species, and some strains of enterococci. Septicemia due to S. pneumoniae, S. aureus (penicillin-sensitive and penicillin-resistant), P. mirabilis, E. coli , and Klebsiella species. Endocarditis due to S. aureus (penicillin-sensitive and penicillin-resistant) and group A beta-hemolytic streptococci. Perioperative Prophylaxis the prophylactic administration of Cefazolin for injection preoperatively, intraoperatively, and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high-risk patients such as those older than 70 years, with acute cholecystitis, obstructive jaundice, or common duct bile stones). The perioperative use of Cefazolin for injection may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g., during open-heart surgery and prosthetic arthroplasty). The prophylactic administration of Cefazolin for injection should usually be discontinued within a 24 hour period after the surgical procedure. In surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of Cefazolin for injection may be continued for 3 to 5 days following the completion of surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism so that appropriate therapy may be instituted.(See DOSAGE AND ADMINISTRATION .) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for injection and other antibacterial drugs, Cefazolin for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:19bdfa49-721f-4805-bc05-97dcbb226063 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:474053 biolink:treats UMLS:C0851989 PMID:41385096 "[{""id"":""uuid:d59f56f3-89bd-4f22-a923-a7a7be23b915"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9423fe3c-d9fb-4e92-a70d-779057be3497"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefazolin for injection is indicated in the treatment of the following serious infections due to susceptible organisms: Respiratory Tract Infections due to S. pneumoniae, Klebsiella species, H. influenzae, S. aureus (penicillin-sensitive and penicillin-resistant), and group A beta-hemolytic streptococci. Injectable benzathine penicillin is considered to be the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefazolin for injection is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of Cefazolin for injection in the subsequent prevention of rheumatic fever are not available at present. Urinary Tract Infections due to E. coli, P. mirabilis, Klebsiella species, and some strains of enterobacter and enterococci. Skin and Skin Structure Infections due to S. aureus (penicillin-sensitive and penicillin-resistant), group A beta-hemolytic streptococci, and other strains of streptococci. Biliary Tract Infections due to E. coli, various strains of streptococci, P. mirabilis, Klebsiella species, and S. aureus. Bone and Joint Infections due to S. aureus. Genital Infections (i.e., prostatitis, epididymitis) due to E. coli, P. mirabilis, Klebsiella species, and some strains of enterococci. Septicemia due to S. pneumoniae, S. aureus (penicillin-sensitive and penicillin-resistant), P. mirabilis, E. coli , and Klebsiella species. Endocarditis due to S. aureus (penicillin-sensitive and penicillin-resistant) and group A beta-hemolytic streptococci. Perioperative Prophylaxis the prophylactic administration of Cefazolin for injection preoperatively, intraoperatively, and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high-risk patients such as those older than 70 years, with acute cholecystitis, obstructive jaundice, or common duct bile stones). The perioperative use of Cefazolin for injection may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g., during open-heart surgery and prosthetic arthroplasty). The prophylactic administration of Cefazolin for injection should usually be discontinued within a 24 hour period after the surgical procedure. In surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of Cefazolin for injection may be continued for 3 to 5 days following the completion of surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism so that appropriate therapy may be instituted.(See DOSAGE AND ADMINISTRATION .) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for injection and other antibacterial drugs, Cefazolin for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:44c4519b-49ae-4631-9e98-99b1bd291669 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:474053 biolink:treats MONDO:0005280 PMID:41385096 "[{""id"":""uuid:3bb2afef-679a-4d93-9a2f-c1d9849237c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:914eb2b3-434d-424c-946b-67a7219a218e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefazolin for injection is indicated in the treatment of the following serious infections due to susceptible organisms: Respiratory Tract Infections due to S. pneumoniae, Klebsiella species, H. influenzae, S. aureus (penicillin-sensitive and penicillin-resistant), and group A beta-hemolytic streptococci. Injectable benzathine penicillin is considered to be the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefazolin for injection is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of Cefazolin for injection in the subsequent prevention of rheumatic fever are not available at present. Urinary Tract Infections due to E. coli, P. mirabilis, Klebsiella species, and some strains of enterobacter and enterococci. Skin and Skin Structure Infections due to S. aureus (penicillin-sensitive and penicillin-resistant), group A beta-hemolytic streptococci, and other strains of streptococci. Biliary Tract Infections due to E. coli, various strains of streptococci, P. mirabilis, Klebsiella species, and S. aureus. Bone and Joint Infections due to S. aureus. Genital Infections (i.e., prostatitis, epididymitis) due to E. coli, P. mirabilis, Klebsiella species, and some strains of enterococci. Septicemia due to S. pneumoniae, S. aureus (penicillin-sensitive and penicillin-resistant), P. mirabilis, E. coli , and Klebsiella species. Endocarditis due to S. aureus (penicillin-sensitive and penicillin-resistant) and group A beta-hemolytic streptococci. Perioperative Prophylaxis the prophylactic administration of Cefazolin for injection preoperatively, intraoperatively, and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high-risk patients such as those older than 70 years, with acute cholecystitis, obstructive jaundice, or common duct bile stones). The perioperative use of Cefazolin for injection may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g., during open-heart surgery and prosthetic arthroplasty). The prophylactic administration of Cefazolin for injection should usually be discontinued within a 24 hour period after the surgical procedure. In surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of Cefazolin for injection may be continued for 3 to 5 days following the completion of surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism so that appropriate therapy may be instituted.(See DOSAGE AND ADMINISTRATION .) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for injection and other antibacterial drugs, Cefazolin for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:f6db4f1b-79e3-4449-bcf9-3b9b7b8a6fad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:474053 biolink:treats MONDO:0004779 PMID:41385096 "[{""id"":""uuid:128c4f24-6f1f-4681-9af0-cd5d28378766"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:557b23b6-179c-4b4c-930b-78ea4d23b614"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefazolin for injection is indicated in the treatment of the following serious infections due to susceptible organisms: Respiratory Tract Infections due to S. pneumoniae, Klebsiella species, H. influenzae, S. aureus (penicillin-sensitive and penicillin-resistant), and group A beta-hemolytic streptococci. Injectable benzathine penicillin is considered to be the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefazolin for injection is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of Cefazolin for injection in the subsequent prevention of rheumatic fever are not available at present. Urinary Tract Infections due to E. coli, P. mirabilis, Klebsiella species, and some strains of enterobacter and enterococci. Skin and Skin Structure Infections due to S. aureus (penicillin-sensitive and penicillin-resistant), group A beta-hemolytic streptococci, and other strains of streptococci. Biliary Tract Infections due to E. coli, various strains of streptococci, P. mirabilis, Klebsiella species, and S. aureus. Bone and Joint Infections due to S. aureus. Genital Infections (i.e., prostatitis, epididymitis) due to E. coli, P. mirabilis, Klebsiella species, and some strains of enterococci. Septicemia due to S. pneumoniae, S. aureus (penicillin-sensitive and penicillin-resistant), P. mirabilis, E. coli , and Klebsiella species. Endocarditis due to S. aureus (penicillin-sensitive and penicillin-resistant) and group A beta-hemolytic streptococci. Perioperative Prophylaxis the prophylactic administration of Cefazolin for injection preoperatively, intraoperatively, and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high-risk patients such as those older than 70 years, with acute cholecystitis, obstructive jaundice, or common duct bile stones). The perioperative use of Cefazolin for injection may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g., during open-heart surgery and prosthetic arthroplasty). The prophylactic administration of Cefazolin for injection should usually be discontinued within a 24 hour period after the surgical procedure. In surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of Cefazolin for injection may be continued for 3 to 5 days following the completion of surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism so that appropriate therapy may be instituted.(See DOSAGE AND ADMINISTRATION .) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for injection and other antibacterial drugs, Cefazolin for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:e52ac609-3cca-4c6e-9383-20ecde0ebeba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:474053 biolink:treats MONDO:0700217 PMID:41385096 "[{""id"":""uuid:ccee5356-8639-441e-af71-8eb29529a976"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7c783b74-e1f9-4029-806f-a8bf0419c31c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefazolin for injection is indicated in the treatment of the following serious infections due to susceptible organisms: Respiratory Tract Infections due to S. pneumoniae, Klebsiella species, H. influenzae, S. aureus (penicillin-sensitive and penicillin-resistant), and group A beta-hemolytic streptococci. Injectable benzathine penicillin is considered to be the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefazolin for injection is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of Cefazolin for injection in the subsequent prevention of rheumatic fever are not available at present. Urinary Tract Infections due to E. coli, P. mirabilis, Klebsiella species, and some strains of enterobacter and enterococci. Skin and Skin Structure Infections due to S. aureus (penicillin-sensitive and penicillin-resistant), group A beta-hemolytic streptococci, and other strains of streptococci. Biliary Tract Infections due to E. coli, various strains of streptococci, P. mirabilis, Klebsiella species, and S. aureus. Bone and Joint Infections due to S. aureus. Genital Infections (i.e., prostatitis, epididymitis) due to E. coli, P. mirabilis, Klebsiella species, and some strains of enterococci. Septicemia due to S. pneumoniae, S. aureus (penicillin-sensitive and penicillin-resistant), P. mirabilis, E. coli , and Klebsiella species. Endocarditis due to S. aureus (penicillin-sensitive and penicillin-resistant) and group A beta-hemolytic streptococci. Perioperative Prophylaxis the prophylactic administration of Cefazolin for injection preoperatively, intraoperatively, and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high-risk patients such as those older than 70 years, with acute cholecystitis, obstructive jaundice, or common duct bile stones). The perioperative use of Cefazolin for injection may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g., during open-heart surgery and prosthetic arthroplasty). The prophylactic administration of Cefazolin for injection should usually be discontinued within a 24 hour period after the surgical procedure. In surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of Cefazolin for injection may be continued for 3 to 5 days following the completion of surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism so that appropriate therapy may be instituted.(See DOSAGE AND ADMINISTRATION .) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for injection and other antibacterial drugs, Cefazolin for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:ee860d5c-3bee-476c-bc36-73b640dc4da5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:474053 biolink:treats MONDO:0005025 PMID:41385096 "[{""id"":""uuid:fe791df5-aa07-42e7-9df7-107e3d348ae2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b4dbea2a-8ed5-4d77-96fe-3bfb99f94a1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefazolin for injection is indicated in the treatment of the following serious infections due to susceptible organisms: Respiratory Tract Infections due to S. pneumoniae, Klebsiella species, H. influenzae, S. aureus (penicillin-sensitive and penicillin-resistant), and group A beta-hemolytic streptococci. Injectable benzathine penicillin is considered to be the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefazolin for injection is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of Cefazolin for injection in the subsequent prevention of rheumatic fever are not available at present. Urinary Tract Infections due to E. coli, P. mirabilis, Klebsiella species, and some strains of enterobacter and enterococci. Skin and Skin Structure Infections due to S. aureus (penicillin-sensitive and penicillin-resistant), group A beta-hemolytic streptococci, and other strains of streptococci. Biliary Tract Infections due to E. coli, various strains of streptococci, P. mirabilis, Klebsiella species, and S. aureus. Bone and Joint Infections due to S. aureus. Genital Infections (i.e., prostatitis, epididymitis) due to E. coli, P. mirabilis, Klebsiella species, and some strains of enterococci. Septicemia due to S. pneumoniae, S. aureus (penicillin-sensitive and penicillin-resistant), P. mirabilis, E. coli , and Klebsiella species. Endocarditis due to S. aureus (penicillin-sensitive and penicillin-resistant) and group A beta-hemolytic streptococci. Perioperative Prophylaxis the prophylactic administration of Cefazolin for injection preoperatively, intraoperatively, and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high-risk patients such as those older than 70 years, with acute cholecystitis, obstructive jaundice, or common duct bile stones). The perioperative use of Cefazolin for injection may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g., during open-heart surgery and prosthetic arthroplasty). The prophylactic administration of Cefazolin for injection should usually be discontinued within a 24 hour period after the surgical procedure. In surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of Cefazolin for injection may be continued for 3 to 5 days following the completion of surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism so that appropriate therapy may be instituted.(See DOSAGE AND ADMINISTRATION .) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for injection and other antibacterial drugs, Cefazolin for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:b2b92daf-5917-4d43-b3ab-8a8b0b5afb30 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:474053 biolink:treats MONDO:0043994 PMID:41385096 "[{""id"":""uuid:eabb9d75-088e-49f5-b656-ecccbb32fe88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f53cbc14-3b65-4be7-a6d2-23fb42505d77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefazolin for injection is indicated in the treatment of the following serious infections due to susceptible organisms: Respiratory Tract Infections due to S. pneumoniae, Klebsiella species, H. influenzae, S. aureus (penicillin-sensitive and penicillin-resistant), and group A beta-hemolytic streptococci. Injectable benzathine penicillin is considered to be the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefazolin for injection is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of Cefazolin for injection in the subsequent prevention of rheumatic fever are not available at present. Urinary Tract Infections due to E. coli, P. mirabilis, Klebsiella species, and some strains of enterobacter and enterococci. Skin and Skin Structure Infections due to S. aureus (penicillin-sensitive and penicillin-resistant), group A beta-hemolytic streptococci, and other strains of streptococci. Biliary Tract Infections due to E. coli, various strains of streptococci, P. mirabilis, Klebsiella species, and S. aureus. Bone and Joint Infections due to S. aureus. Genital Infections (i.e., prostatitis, epididymitis) due to E. coli, P. mirabilis, Klebsiella species, and some strains of enterococci. Septicemia due to S. pneumoniae, S. aureus (penicillin-sensitive and penicillin-resistant), P. mirabilis, E. coli , and Klebsiella species. Endocarditis due to S. aureus (penicillin-sensitive and penicillin-resistant) and group A beta-hemolytic streptococci. Perioperative Prophylaxis the prophylactic administration of Cefazolin for injection preoperatively, intraoperatively, and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high-risk patients such as those older than 70 years, with acute cholecystitis, obstructive jaundice, or common duct bile stones). The perioperative use of Cefazolin for injection may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g., during open-heart surgery and prosthetic arthroplasty). The prophylactic administration of Cefazolin for injection should usually be discontinued within a 24 hour period after the surgical procedure. In surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of Cefazolin for injection may be continued for 3 to 5 days following the completion of surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism so that appropriate therapy may be instituted.(See DOSAGE AND ADMINISTRATION .) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for injection and other antibacterial drugs, Cefazolin for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:cc2ca373-2a32-4c87-890b-8f4bd9b3d786 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:474053 biolink:treats MONDO:0006874 PMID:41385096 "[{""id"":""uuid:670b422c-03e6-48f8-8e62-91868d6eebde"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ebfd863f-5fbf-4070-b0ed-72f5b4f18706"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefazolin for injection is indicated in the treatment of the following serious infections due to susceptible organisms: Respiratory Tract Infections due to S. pneumoniae, Klebsiella species, H. influenzae, S. aureus (penicillin-sensitive and penicillin-resistant), and group A beta-hemolytic streptococci. Injectable benzathine penicillin is considered to be the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefazolin for injection is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of Cefazolin for injection in the subsequent prevention of rheumatic fever are not available at present. Urinary Tract Infections due to E. coli, P. mirabilis, Klebsiella species, and some strains of enterobacter and enterococci. Skin and Skin Structure Infections due to S. aureus (penicillin-sensitive and penicillin-resistant), group A beta-hemolytic streptococci, and other strains of streptococci. Biliary Tract Infections due to E. coli, various strains of streptococci, P. mirabilis, Klebsiella species, and S. aureus. Bone and Joint Infections due to S. aureus. Genital Infections (i.e., prostatitis, epididymitis) due to E. coli, P. mirabilis, Klebsiella species, and some strains of enterococci. Septicemia due to S. pneumoniae, S. aureus (penicillin-sensitive and penicillin-resistant), P. mirabilis, E. coli , and Klebsiella species. Endocarditis due to S. aureus (penicillin-sensitive and penicillin-resistant) and group A beta-hemolytic streptococci. Perioperative Prophylaxis the prophylactic administration of Cefazolin for injection preoperatively, intraoperatively, and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high-risk patients such as those older than 70 years, with acute cholecystitis, obstructive jaundice, or common duct bile stones). The perioperative use of Cefazolin for injection may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g., during open-heart surgery and prosthetic arthroplasty). The prophylactic administration of Cefazolin for injection should usually be discontinued within a 24 hour period after the surgical procedure. In surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of Cefazolin for injection may be continued for 3 to 5 days following the completion of surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism so that appropriate therapy may be instituted.(See DOSAGE AND ADMINISTRATION .) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefazolin for injection and other antibacterial drugs, Cefazolin for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:9d414051-1413-4f6f-a24a-7e5b6a9d4196 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9654 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:24b19eb1-e937-43b3-ae15-fbe67dae5c73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ac339a54-dfc5-4c79-ba6f-982da176e5ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Trazodone hydrochloride is indicated for the treatment of depression. The efficacy of trazodone has been demonstrated in both inpatient and out-patient settings and for depressed patients with and without prominent anxiety. The depressive illness of patients studied corresponds to the Major Depressive Episode criteria of the American Psychiatric Association’s Diagnostic and Statistical Manual, III. a Major Depressive Episode implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least four of the following eight symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigability, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and suicidal ideation or attempts. uuid:9a385179-3071-4626-9c41-82f5c4b03ca7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1154057 biolink:treats HP:0012228 PMID:41385096 "[{""id"":""uuid:30eb08ad-8b7b-4134-933e-2fb75ca8f618"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:236e5313-62ca-4726-822b-5f66189cc325"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Butalbital, Aspirin, Caffeine and Codeine Phosphate Capsules are indicated for the relief of the symptom complex of tension (or muscle contraction) headache. Evidence supporting the efficacy of butalbital, aspirin, caffeine and codeine phosphate capsules is derived from 2 multi-clinic trials that compared patients with tension headache randomly assigned to 4 parallel treatments: 1) butalbital, aspirin, caffeine and codeine; 2) codeine; 3) butalbital, aspirin and caffeine; 4) placebo. Response was assessed over the course of the first 4 hours of each of 2 distinct headaches, separated by at least 24 hours. The combination product of butalbital, aspirin, caffeine and codeine proved statistically significantly superior to each of its components and to placebo on measures of pain relief. Evidence supporting the efficacy and safety of butalbital, aspirin, caffeine and codeine in the treatment of multiple recurrent headaches is unavailable. Caution in this regard is required because codeine and butalbital are habit-forming and potentially abusable. uuid:72510eb8-4ddb-47a6-9430-a5e2d19b9b90 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4710 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:5a8d413a-95f2-4fc6-bfee-6010c5159e26"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:55c61a88-fb9a-4772-a334-c440a69ef52e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxepin hydrochloride capsules are recommended for the treatment of: Psychoneurotic patients with depression and/or anxiety. Depression and/or anxiety associated with alcoholism (not to be taken concomitantly with alcohol). Depression and/or anxiety associated with organic disease (the possibility of drug interaction should be considered if the patient is receiving other drugs concomitantly). Psychotic depressive disorders with associated anxiety including involutional depression and manic-depressive disorders. The target symptoms of psychoneurosis that respond particularly well to doxepin hydrochloride capsules include anxiety, tension, depression, somatic symptoms and concerns, sleep disturbances, guilt, lack of energy, fear, apprehension and worry. Clinical experience has shown that doxepin hydrochloride capsules are safe and well tolerated even in the elderly patient. Owing to lack of clinical experience in the pediatric population, doxepin hydrochloride capsules are not recommended for use in children under 12 years of age. uuid:f232255b-94ca-4d48-8df6-b8882f220f78 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4710 biolink:treats MONDO:0011918 PMID:41385096 "[{""id"":""uuid:ef1f8485-a231-49a4-af1e-7bad8a144624"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2fc68870-ea45-4e48-8b84-e6f885856eca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxepin hydrochloride capsules are recommended for the treatment of: Psychoneurotic patients with depression and/or anxiety. Depression and/or anxiety associated with alcoholism (not to be taken concomitantly with alcohol). Depression and/or anxiety associated with organic disease (the possibility of drug interaction should be considered if the patient is receiving other drugs concomitantly). Psychotic depressive disorders with associated anxiety including involutional depression and manic-depressive disorders. The target symptoms of psychoneurosis that respond particularly well to doxepin hydrochloride capsules include anxiety, tension, depression, somatic symptoms and concerns, sleep disturbances, guilt, lack of energy, fear, apprehension and worry. Clinical experience has shown that doxepin hydrochloride capsules are safe and well tolerated even in the elderly patient. Owing to lack of clinical experience in the pediatric population, doxepin hydrochloride capsules are not recommended for use in children under 12 years of age. uuid:d1517d0a-07f6-426b-963c-f2a2571f9c64 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4710 biolink:treats MONDO:0007079 PMID:41385096 "[{""id"":""uuid:0dd633c1-0948-40d4-aa59-825a75ccab7d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5fed2f26-ec34-41b4-bdd1-17acab0b3c43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxepin hydrochloride capsules are recommended for the treatment of: Psychoneurotic patients with depression and/or anxiety. Depression and/or anxiety associated with alcoholism (not to be taken concomitantly with alcohol). Depression and/or anxiety associated with organic disease (the possibility of drug interaction should be considered if the patient is receiving other drugs concomitantly). Psychotic depressive disorders with associated anxiety including involutional depression and manic-depressive disorders. The target symptoms of psychoneurosis that respond particularly well to doxepin hydrochloride capsules include anxiety, tension, depression, somatic symptoms and concerns, sleep disturbances, guilt, lack of energy, fear, apprehension and worry. Clinical experience has shown that doxepin hydrochloride capsules are safe and well tolerated even in the elderly patient. Owing to lack of clinical experience in the pediatric population, doxepin hydrochloride capsules are not recommended for use in children under 12 years of age. uuid:b98cc378-9929-4126-afce-4bf44caea7ab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4710 biolink:treats UMLS:C0277542 PMID:41385096 "[{""id"":""uuid:819b8d38-cbc2-4eb0-beda-6b82b83bc053"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2461961c-23c7-4e4e-ae24-5ffb7c988e6a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxepin hydrochloride capsules are recommended for the treatment of: Psychoneurotic patients with depression and/or anxiety. Depression and/or anxiety associated with alcoholism (not to be taken concomitantly with alcohol). Depression and/or anxiety associated with organic disease (the possibility of drug interaction should be considered if the patient is receiving other drugs concomitantly). Psychotic depressive disorders with associated anxiety including involutional depression and manic-depressive disorders. The target symptoms of psychoneurosis that respond particularly well to doxepin hydrochloride capsules include anxiety, tension, depression, somatic symptoms and concerns, sleep disturbances, guilt, lack of energy, fear, apprehension and worry. Clinical experience has shown that doxepin hydrochloride capsules are safe and well tolerated even in the elderly patient. Owing to lack of clinical experience in the pediatric population, doxepin hydrochloride capsules are not recommended for use in children under 12 years of age. uuid:06351a04-c31c-41a1-a6c5-09cd7a01d386 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4710 biolink:treats UMLS:C0011574 PMID:41385096 "[{""id"":""uuid:c3c11c78-7958-4502-b113-c112291d3976"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:63c06f4d-314a-4cc5-bb05-e62dc84ff838"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxepin hydrochloride capsules are recommended for the treatment of: Psychoneurotic patients with depression and/or anxiety. Depression and/or anxiety associated with alcoholism (not to be taken concomitantly with alcohol). Depression and/or anxiety associated with organic disease (the possibility of drug interaction should be considered if the patient is receiving other drugs concomitantly). Psychotic depressive disorders with associated anxiety including involutional depression and manic-depressive disorders. The target symptoms of psychoneurosis that respond particularly well to doxepin hydrochloride capsules include anxiety, tension, depression, somatic symptoms and concerns, sleep disturbances, guilt, lack of energy, fear, apprehension and worry. Clinical experience has shown that doxepin hydrochloride capsules are safe and well tolerated even in the elderly patient. Owing to lack of clinical experience in the pediatric population, doxepin hydrochloride capsules are not recommended for use in children under 12 years of age. uuid:c8087895-4742-44d9-8e98-33f12f1f0cac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4710 biolink:treats MONDO:0005371 PMID:41385096 "[{""id"":""uuid:8e8ea66f-367d-4727-8815-d54111c49620"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7a747f41-d943-4b22-86d3-48eead4b0bbf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxepin hydrochloride capsules are recommended for the treatment of: Psychoneurotic patients with depression and/or anxiety. Depression and/or anxiety associated with alcoholism (not to be taken concomitantly with alcohol). Depression and/or anxiety associated with organic disease (the possibility of drug interaction should be considered if the patient is receiving other drugs concomitantly). Psychotic depressive disorders with associated anxiety including involutional depression and manic-depressive disorders. The target symptoms of psychoneurosis that respond particularly well to doxepin hydrochloride capsules include anxiety, tension, depression, somatic symptoms and concerns, sleep disturbances, guilt, lack of energy, fear, apprehension and worry. Clinical experience has shown that doxepin hydrochloride capsules are safe and well tolerated even in the elderly patient. Owing to lack of clinical experience in the pediatric population, doxepin hydrochloride capsules are not recommended for use in children under 12 years of age. uuid:42b0bb8d-bdea-48c4-a2a8-dc6841532d7b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4710 biolink:treats MONDO:0005379 PMID:41385096 "[{""id"":""uuid:326f141f-a851-4f82-9155-0b8bbe26abab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9e5445cb-21e9-45a0-9adc-257527a41c6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxepin hydrochloride capsules are recommended for the treatment of: Psychoneurotic patients with depression and/or anxiety. Depression and/or anxiety associated with alcoholism (not to be taken concomitantly with alcohol). Depression and/or anxiety associated with organic disease (the possibility of drug interaction should be considered if the patient is receiving other drugs concomitantly). Psychotic depressive disorders with associated anxiety including involutional depression and manic-depressive disorders. The target symptoms of psychoneurosis that respond particularly well to doxepin hydrochloride capsules include anxiety, tension, depression, somatic symptoms and concerns, sleep disturbances, guilt, lack of energy, fear, apprehension and worry. Clinical experience has shown that doxepin hydrochloride capsules are safe and well tolerated even in the elderly patient. Owing to lack of clinical experience in the pediatric population, doxepin hydrochloride capsules are not recommended for use in children under 12 years of age. uuid:4f9989f5-a3f5-4a0d-8927-2f1cbc6e4522 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:36572 biolink:treats MONDO:0005180 PMID:41385096 "[{""id"":""uuid:db9ea1b7-711c-4468-bc84-6f4c40fb177b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:771c56d3-e2c5-48bc-9f37-f10f1f21f284"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9c15cf0a-cd32-4be5-9859-fbbddad850d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/stalevo""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] PARCOPA ® is indicated in the treatment of the symptoms of idiopathic Parkinson’s disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication. PARCOPA ® is indicated in these conditions to permit the administration of lower doses of levodopa with reduced nausea and vomiting, with more rapid dosage titration, with a somewhat smoother response, and with supplemental pyridoxine (vitamin B 6 ). In some patients, a somewhat smoother antiparkinsonian effect results from therapy with carbidopa-levodopa than with levodopa. However, patients with markedly irregular (“on-off”) responses to levodopa have not been shown to benefit from carbidopa-levodopa therapy. Although the administration of carbidopa permits control of parkinsonism and Parkinson’s disease with much lower doses of levodopa, there is no conclusive evidence at present that this is beneficial other than in reducing nausea and vomiting, permitting more rapid titration, and providing a somewhat smoother response to levodopa. Certain patients who responded poorly to levodopa have improved when carbidopa-levodopa was substituted. This is most likely due to decreased peripheral decarboxylation of levodopa which results from administration of carbidopa rather than to a primary effect of carbidopa on the nervous system. Carbidopa has not been shown to enhance the intrinsic efficacy of levodopa in parkinsonian syndromes. In considering whether to give PARCOPA ® to patients already on levodopa who have nausea and/or vomiting, the practitioner should be aware that, while many patients may be expected to improve, some do not. Since one cannot predict which patients are likely to improve, this can only be determined by a trial of therapy. It should be further noted that in controlled trials comparing carbidopa-levodopa with levodopa, about half of the patients with nausea and/or vomiting on levodopa improved spontaneously despite being retained on the same dose of levodopa during the controlled portion of the trial.|[EMA] Stalevo is indicated for the treatment of adult patients with Parkinson's disease and end-of-dose motor fluctuations not stabilised on levodopa / dopa-decarboxylase (DDC)-inhibitor treatment. uuid:d0737e41-b73f-4094-8f65-c3f3829a6369 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:36572 biolink:treats MONDO:0008193 PMID:41385096 "[{""id"":""uuid:68823d68-0f0d-4409-89b0-b77accc5acbb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6aa2192d-6d42-423b-823b-97da86e4f2f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PARCOPA ® is indicated in the treatment of the symptoms of idiopathic Parkinson’s disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication. PARCOPA ® is indicated in these conditions to permit the administration of lower doses of levodopa with reduced nausea and vomiting, with more rapid dosage titration, with a somewhat smoother response, and with supplemental pyridoxine (vitamin B 6 ). In some patients, a somewhat smoother antiparkinsonian effect results from therapy with carbidopa-levodopa than with levodopa. However, patients with markedly irregular (“on-off”) responses to levodopa have not been shown to benefit from carbidopa-levodopa therapy. Although the administration of carbidopa permits control of parkinsonism and Parkinson’s disease with much lower doses of levodopa, there is no conclusive evidence at present that this is beneficial other than in reducing nausea and vomiting, permitting more rapid titration, and providing a somewhat smoother response to levodopa. Certain patients who responded poorly to levodopa have improved when carbidopa-levodopa was substituted. This is most likely due to decreased peripheral decarboxylation of levodopa which results from administration of carbidopa rather than to a primary effect of carbidopa on the nervous system. Carbidopa has not been shown to enhance the intrinsic efficacy of levodopa in parkinsonian syndromes. In considering whether to give PARCOPA ® to patients already on levodopa who have nausea and/or vomiting, the practitioner should be aware that, while many patients may be expected to improve, some do not. Since one cannot predict which patients are likely to improve, this can only be determined by a trial of therapy. It should be further noted that in controlled trials comparing carbidopa-levodopa with levodopa, about half of the patients with nausea and/or vomiting on levodopa improved spontaneously despite being retained on the same dose of levodopa during the controlled portion of the trial. uuid:55697ce4-9def-47c8-b41c-0a4172c22be3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:36572 biolink:treats MONDO:0001945 PMID:41385096 "[{""id"":""uuid:3efd202d-9797-48dd-9b0b-cc5f78c1e36e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7273a38f-fa02-4e40-b59c-098833abbae4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PARCOPA ® is indicated in the treatment of the symptoms of idiopathic Parkinson’s disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication. PARCOPA ® is indicated in these conditions to permit the administration of lower doses of levodopa with reduced nausea and vomiting, with more rapid dosage titration, with a somewhat smoother response, and with supplemental pyridoxine (vitamin B 6 ). In some patients, a somewhat smoother antiparkinsonian effect results from therapy with carbidopa-levodopa than with levodopa. However, patients with markedly irregular (“on-off”) responses to levodopa have not been shown to benefit from carbidopa-levodopa therapy. Although the administration of carbidopa permits control of parkinsonism and Parkinson’s disease with much lower doses of levodopa, there is no conclusive evidence at present that this is beneficial other than in reducing nausea and vomiting, permitting more rapid titration, and providing a somewhat smoother response to levodopa. Certain patients who responded poorly to levodopa have improved when carbidopa-levodopa was substituted. This is most likely due to decreased peripheral decarboxylation of levodopa which results from administration of carbidopa rather than to a primary effect of carbidopa on the nervous system. Carbidopa has not been shown to enhance the intrinsic efficacy of levodopa in parkinsonian syndromes. In considering whether to give PARCOPA ® to patients already on levodopa who have nausea and/or vomiting, the practitioner should be aware that, while many patients may be expected to improve, some do not. Since one cannot predict which patients are likely to improve, this can only be determined by a trial of therapy. It should be further noted that in controlled trials comparing carbidopa-levodopa with levodopa, about half of the patients with nausea and/or vomiting on levodopa improved spontaneously despite being retained on the same dose of levodopa during the controlled portion of the trial. uuid:493207bc-0096-4ec6-932e-e40643413206 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:36572 biolink:treats MONDO:0021095 PMID:41385096 "[{""id"":""uuid:605bda9c-8211-446c-af2b-f27bfd81088b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2046875d-f2b2-41b8-851e-07b282041ac0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PARCOPA ® is indicated in the treatment of the symptoms of idiopathic Parkinson’s disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication. PARCOPA ® is indicated in these conditions to permit the administration of lower doses of levodopa with reduced nausea and vomiting, with more rapid dosage titration, with a somewhat smoother response, and with supplemental pyridoxine (vitamin B 6 ). In some patients, a somewhat smoother antiparkinsonian effect results from therapy with carbidopa-levodopa than with levodopa. However, patients with markedly irregular (“on-off”) responses to levodopa have not been shown to benefit from carbidopa-levodopa therapy. Although the administration of carbidopa permits control of parkinsonism and Parkinson’s disease with much lower doses of levodopa, there is no conclusive evidence at present that this is beneficial other than in reducing nausea and vomiting, permitting more rapid titration, and providing a somewhat smoother response to levodopa. Certain patients who responded poorly to levodopa have improved when carbidopa-levodopa was substituted. This is most likely due to decreased peripheral decarboxylation of levodopa which results from administration of carbidopa rather than to a primary effect of carbidopa on the nervous system. Carbidopa has not been shown to enhance the intrinsic efficacy of levodopa in parkinsonian syndromes. In considering whether to give PARCOPA ® to patients already on levodopa who have nausea and/or vomiting, the practitioner should be aware that, while many patients may be expected to improve, some do not. Since one cannot predict which patients are likely to improve, this can only be determined by a trial of therapy. It should be further noted that in controlled trials comparing carbidopa-levodopa with levodopa, about half of the patients with nausea and/or vomiting on levodopa improved spontaneously despite being retained on the same dose of levodopa during the controlled portion of the trial. uuid:15051762-36fc-46c0-b1cf-fb303066e126 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47898 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:fc3deadc-8129-4860-bda9-9234fcaa15c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d5408682-e6ed-4800-85d2-469e4b399ede"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ffaaf90d-db97-4d0d-a44d-00b34d5e3be6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Epirubicin Hydrochloride Injection is indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.|[PMDA] A new indication and a new dosage regimen in combination with other anti-cancer agents for the treatment of breast cancer [Combination chemotherapy with anti-cancer drgs] uuid:cb845f1e-a383-47df-b750-8194af4e3819 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28304 biolink:treats HP:0002625 PMID:41385096 "[{""id"":""uuid:4aaffac4-82b0-4359-b801-989baba819ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3eabf888-f4f4-4cfd-b1ed-a0bce7d4e9f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Heparin Sodium Injection is indicated for: Anticoagulant therapy in prophylaxis and treatment of venous thrombosis and its extension; (In a low-dose regimen) for prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdomino-thoracic surgery or who for other reasons are at risk of developing thromboembolic disease (see DOSAGE AND ADMINISTRATION ); Prophylaxis and treatment of pulmonary embolism; Atrial fibrillation with embolization; Diagnosis and treatment of acute and chronic consumption coagulopathies (disseminated intravascular coagulation); Prevention of clotting in arterial and heart surgery; Prophylaxis and treatment of peripheral arterial embolism; As an anticoagulant in blood transfusions, extracorporeal circulation, and dialysis procedures and in blood samples for laboratory purposes. uuid:494b67e3-2c37-45cc-8b38-d868483390ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28304 biolink:treats MONDO:0005279 PMID:41385096 "[{""id"":""uuid:f5a36be7-a4c2-44a2-bfa6-0af02eb94eea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9a5793e9-ba3e-40d3-9c0d-e8bef1025d1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Heparin Sodium Injection is indicated for: Anticoagulant therapy in prophylaxis and treatment of venous thrombosis and its extension; (In a low-dose regimen) for prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdomino-thoracic surgery or who for other reasons are at risk of developing thromboembolic disease (see DOSAGE AND ADMINISTRATION ); Prophylaxis and treatment of pulmonary embolism; Atrial fibrillation with embolization; Diagnosis and treatment of acute and chronic consumption coagulopathies (disseminated intravascular coagulation); Prevention of clotting in arterial and heart surgery; Prophylaxis and treatment of peripheral arterial embolism; As an anticoagulant in blood transfusions, extracorporeal circulation, and dialysis procedures and in blood samples for laboratory purposes. uuid:8fa0e9ff-24b3-49fa-8bdb-352bd86bb086 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28304 biolink:treats HP:0001907 PMID:41385096 "[{""id"":""uuid:91cef8d9-8767-4d89-8024-7b568db20545"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ac12cad8-e3b8-4d7d-9e1e-45f4a4a9f811"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Heparin Sodium Injection is indicated for: Anticoagulant therapy in prophylaxis and treatment of venous thrombosis and its extension; (In a low-dose regimen) for prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdomino-thoracic surgery or who for other reasons are at risk of developing thromboembolic disease (see DOSAGE AND ADMINISTRATION ); Prophylaxis and treatment of pulmonary embolism; Atrial fibrillation with embolization; Diagnosis and treatment of acute and chronic consumption coagulopathies (disseminated intravascular coagulation); Prevention of clotting in arterial and heart surgery; Prophylaxis and treatment of peripheral arterial embolism; As an anticoagulant in blood transfusions, extracorporeal circulation, and dialysis procedures and in blood samples for laboratory purposes. uuid:7805ebf9-a0a5-4f08-a9c6-03f5cd15a45c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28304 biolink:treats MONDO:0001243 PMID:41385096 "[{""id"":""uuid:30e0c035-da1e-44a0-8538-332c3814e274"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7c8a7e12-7fa6-45ef-a7d5-b0b3e618aef0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Heparin Sodium Injection is indicated for: Anticoagulant therapy in prophylaxis and treatment of venous thrombosis and its extension; (In a low-dose regimen) for prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdomino-thoracic surgery or who for other reasons are at risk of developing thromboembolic disease (see DOSAGE AND ADMINISTRATION ); Prophylaxis and treatment of pulmonary embolism; Atrial fibrillation with embolization; Diagnosis and treatment of acute and chronic consumption coagulopathies (disseminated intravascular coagulation); Prevention of clotting in arterial and heart surgery; Prophylaxis and treatment of peripheral arterial embolism; As an anticoagulant in blood transfusions, extracorporeal circulation, and dialysis procedures and in blood samples for laboratory purposes. uuid:c0e44032-3889-410a-aace-a81c0dc16d31 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28304 biolink:treats UMLS:C0564750 PMID:41385096 "[{""id"":""uuid:2e75b268-fca7-4f2f-acd8-f2ba0b69df94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3bffd9b6-067d-45b9-8727-bd9936ca7bf9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Heparin Sodium Injection is indicated for: Anticoagulant therapy in prophylaxis and treatment of venous thrombosis and its extension; (In a low-dose regimen) for prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdomino-thoracic surgery or who for other reasons are at risk of developing thromboembolic disease (see DOSAGE AND ADMINISTRATION ); Prophylaxis and treatment of pulmonary embolism; Atrial fibrillation with embolization; Diagnosis and treatment of acute and chronic consumption coagulopathies (disseminated intravascular coagulation); Prevention of clotting in arterial and heart surgery; Prophylaxis and treatment of peripheral arterial embolism; As an anticoagulant in blood transfusions, extracorporeal circulation, and dialysis procedures and in blood samples for laboratory purposes. uuid:c0aea33f-b8f3-4093-a241-ab8de412c5e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7640 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:03250024-2fe7-4277-a26d-213148042df6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:78036469-6477-4ff2-b9d2-249f6d910748"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nortriptyline hydrochloride is indicated for the relief of symptoms of depression. Endogenous depressions are more likely to be alleviated than are other depressive states. uuid:807180df-8fc9-40a5-9ed4-874ffdcc6824 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7640 biolink:treats MONDO:0012048 PMID:41385096 "[{""id"":""uuid:01b5be29-c31a-4f2c-85c9-97f69e6a8f25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a33ff6aa-0064-4c6f-91bd-de2c6cd009f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nortriptyline hydrochloride is indicated for the relief of symptoms of depression. Endogenous depressions are more likely to be alleviated than are other depressive states. uuid:9fc03c57-587d-4abe-95dc-52ed69dad58b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3723 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:bd744d7a-8ae2-4220-84f1-9f4e5ce259e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:70005303-2d0d-4759-be80-8baeca6e7462"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Citalopram HBr is indicated for the treatment of depression. The efficacy of citalopram HBr in the treatment of depression was established in 4-6 week controlled trials of outpatients whose diagnosis corresponded most closely to the DSM-III and DSM-III-R category of major depressive disorder (see CLINICAL PHARMACOLOGY ). A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. The antidepressant action of citalopram in hospitalized depressed patients has not been adequately studied. The efficacy of citalopram in maintaining an antidepressant response for up to 24 weeks following 6 to 8 weeks of acute treatment was demonstrated in two placebo-controlled trials (see CLINICAL PHARMACOLOGY ). Nevertheless, the physician who elects to use citalopram for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient. uuid:6d201c72-ddfd-4c17-af30-fe8c4cfd2153 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9150 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:47b85633-0e6b-42c1-9cd8-defa434731c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4e757abd-4686-420b-b515-22fdcc686554"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol (see National Cholesterol Education Program [NCEP] Treatment Guidelines , below). In patients with CHD or at high risk of CHD, Simvastatin Orally Disintegrating Tablets can be started simultaneously with diet. uuid:3cd4488b-f591-4c72-8c26-7401d1284772 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:78320 biolink:treats HP:0000958 PMID:41385096 "[{""id"":""uuid:907d36a9-6af9-420d-9949-c2878fd6da78"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bf9a1b02-f8cd-43ac-9d21-3ca01057158b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lac-Hydrin Cream is indicated for the treatment of dry, scaly skin (xerosis) and ichthyosis vulgaris and for temporary relief of itching associated with these conditions. uuid:e9a763dc-88d2-451c-b806-27354952662c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:78320 biolink:treats MONDO:0024304 PMID:41385096 "[{""id"":""uuid:18d85d0c-cd0a-49a2-8534-35e7f682d924"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:521e4841-cce0-429d-b149-7c27ff78395d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lac-Hydrin Cream is indicated for the treatment of dry, scaly skin (xerosis) and ichthyosis vulgaris and for temporary relief of itching associated with these conditions. uuid:fc4a8c4d-d9d1-4be5-a7e3-a58e497e040f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3479 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:a04d630c-11c9-45e7-b64e-e30b1c94677a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:85576513-8bb8-4793-abc2-970ac0bed210"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefadroxil monohydrate is indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases: Urinary tract infections caused by E. coli , P. mirabilis , and Klebsiella species. Skin and skin structure infections caused by staphylococci and/or streptococci. Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes (Group A beta-hemolytic streptococci). Note : Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefadroxil monohydrate is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefadroxil monohydrate for the prophylaxis of subsequent rheumatic fever are not available. Note : Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefadroxil monohydrate and other antibacterial drugs, cefadroxil monohydrate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:fabb9876-c93f-4999-b461-af7d3b88e29b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3479 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:b9bbe9cd-6db0-4112-a49e-ac6cc94dbaa0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7e9789b3-121d-4b4b-96a0-fe34e0da40f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefadroxil monohydrate is indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases: Urinary tract infections caused by E. coli , P. mirabilis , and Klebsiella species. Skin and skin structure infections caused by staphylococci and/or streptococci. Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes (Group A beta-hemolytic streptococci). Note : Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefadroxil monohydrate is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefadroxil monohydrate for the prophylaxis of subsequent rheumatic fever are not available. Note : Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefadroxil monohydrate and other antibacterial drugs, cefadroxil monohydrate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:f11e3336-4c6a-4438-a7c0-ce191023ef9e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3479 biolink:treats MONDO:0002258 PMID:41385096 "[{""id"":""uuid:e0327fd8-77c3-4edb-a343-5f4e9881ce2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3fc23379-1c55-471a-a4ac-347db3fbcc71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefadroxil monohydrate is indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases: Urinary tract infections caused by E. coli , P. mirabilis , and Klebsiella species. Skin and skin structure infections caused by staphylococci and/or streptococci. Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes (Group A beta-hemolytic streptococci). Note : Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefadroxil monohydrate is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefadroxil monohydrate for the prophylaxis of subsequent rheumatic fever are not available. Note : Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefadroxil monohydrate and other antibacterial drugs, cefadroxil monohydrate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:6072e69f-c550-43e4-a577-b83c359ac22d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3479 biolink:treats MONDO:0001039 PMID:41385096 "[{""id"":""uuid:95a42727-b8d4-48fb-b566-d04e39a1a9d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f7456b1c-57ed-4706-8ea2-2025ffb5b698"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefadroxil monohydrate is indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases: Urinary tract infections caused by E. coli , P. mirabilis , and Klebsiella species. Skin and skin structure infections caused by staphylococci and/or streptococci. Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes (Group A beta-hemolytic streptococci). Note : Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefadroxil monohydrate is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefadroxil monohydrate for the prophylaxis of subsequent rheumatic fever are not available. Note : Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefadroxil monohydrate and other antibacterial drugs, cefadroxil monohydrate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:02fa45f5-076a-41df-b967-d8ad11f0fb5d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3479 biolink:treats MONDO:0017767 PMID:41385096 "[{""id"":""uuid:68bbbc33-546e-431e-8378-57fef7c04c59"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ba86df17-6b71-402f-abd5-d51a38fc95bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefadroxil monohydrate is indicated for the treatment of patients with infection caused by susceptible strains of the designated organisms in the following diseases: Urinary tract infections caused by E. coli , P. mirabilis , and Klebsiella species. Skin and skin structure infections caused by staphylococci and/or streptococci. Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes (Group A beta-hemolytic streptococci). Note : Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefadroxil monohydrate is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefadroxil monohydrate for the prophylaxis of subsequent rheumatic fever are not available. Note : Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefadroxil monohydrate and other antibacterial drugs, cefadroxil monohydrate should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:6566b183-79a4-46f6-9b4c-acae912d4177 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats HP:0004755 PMID:41385096 "[{""id"":""uuid:c84ccec0-8996-4459-85ff-3b54704f7377"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2a812854-50c1-4999-9e71-92d2d516003d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous administration is usually reserved for life-threatening arrhythmias or those occurring under anesthesia. Supraventricular arrhythmiasIntravenous propranolol is indicated for the short-term treatment of supraventricular tachycardia, including Wolff-Parkinson-White syndrome and thyrotoxicosis, to decrease ventricular rate. Use in patients with atrial flutter or atrial fibrillation should be reserved for arrythmias unresponsive to standard therapy or when more prolonged control is required. Reversion to normal sinus rhythm has occasionally been observed, predominantly in patients with sinus or atrial tachycardia. Ventricular tachycardias With the exception of those induced by catecholamines or digitalis, propranolol is not the drug of first choice. In critical situations when cardioversion techniques or other drugs are not indicated or are not effective, propranolol may be considered. If, after consideration of the risks involved, propranolol is used, it should be given intravenously in low dosage and very slowly, as the failing heart requires some sympathetic drive for maintenance of myocardial tone. (See ). Some patients may respond with complete reversion to normal sinus rhythm, but reduction in ventricular rate is more likely. Ventricular arrhythmias do not respond to propranolol as predictably as do the supraventricular arrhythmias. Intravenous propranolol is indicated for the treatment of persistent premature ventricular extrasystoles that impair the well-being of the patient and do not respond to conventional measures. Tachyarrhythmias of digitalis intoxicationIntravenous propranolol is indicated to control ventricular rate in life-threatening digitalis-induced arrhythmias. Severe bradycardia may occur. (See ). Resistant tachyarrhythmias due to excessive catecholamine action during anesthesia Intravenous propranolol is indicated to abolish tachyarrhythmias due to excessive catecholamine action during anesthesia when other measures fail. These arrhythmias may arise because of release of endogenous catecholamines or administration of catecholamines. All general inhalation anesthetics produce some degree of myocardial depression. Therefore, when propranolol is used to treat arrhythmias during anesthesia, it should be used with extreme caution, usually with constant monitoring of the ECG and central venous pressure. (See ). uuid:bd389f60-7183-4307-892a-5c901116d2db biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats MONDO:0008685 PMID:41385096 "[{""id"":""uuid:1f27f998-32eb-4962-b272-19fe8e3707cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cf02fa39-4249-4ece-9b75-c03dd9226ab0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous administration is usually reserved for life-threatening arrhythmias or those occurring under anesthesia. Supraventricular arrhythmiasIntravenous propranolol is indicated for the short-term treatment of supraventricular tachycardia, including Wolff-Parkinson-White syndrome and thyrotoxicosis, to decrease ventricular rate. Use in patients with atrial flutter or atrial fibrillation should be reserved for arrythmias unresponsive to standard therapy or when more prolonged control is required. Reversion to normal sinus rhythm has occasionally been observed, predominantly in patients with sinus or atrial tachycardia. Ventricular tachycardias With the exception of those induced by catecholamines or digitalis, propranolol is not the drug of first choice. In critical situations when cardioversion techniques or other drugs are not indicated or are not effective, propranolol may be considered. If, after consideration of the risks involved, propranolol is used, it should be given intravenously in low dosage and very slowly, as the failing heart requires some sympathetic drive for maintenance of myocardial tone. (See ). Some patients may respond with complete reversion to normal sinus rhythm, but reduction in ventricular rate is more likely. Ventricular arrhythmias do not respond to propranolol as predictably as do the supraventricular arrhythmias. Intravenous propranolol is indicated for the treatment of persistent premature ventricular extrasystoles that impair the well-being of the patient and do not respond to conventional measures. Tachyarrhythmias of digitalis intoxicationIntravenous propranolol is indicated to control ventricular rate in life-threatening digitalis-induced arrhythmias. Severe bradycardia may occur. (See ). Resistant tachyarrhythmias due to excessive catecholamine action during anesthesia Intravenous propranolol is indicated to abolish tachyarrhythmias due to excessive catecholamine action during anesthesia when other measures fail. These arrhythmias may arise because of release of endogenous catecholamines or administration of catecholamines. All general inhalation anesthetics produce some degree of myocardial depression. Therefore, when propranolol is used to treat arrhythmias during anesthesia, it should be used with extreme caution, usually with constant monitoring of the ECG and central venous pressure. (See ). uuid:136fa7d0-3c01-45ff-b503-19ae106dab9b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats MONDO:0010138 PMID:41385096 "[{""id"":""uuid:115f6575-f280-45d1-83f8-f85e31daf742"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f99240f4-e01f-4d88-8533-fe851fa25f8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous administration is usually reserved for life-threatening arrhythmias or those occurring under anesthesia. Supraventricular arrhythmiasIntravenous propranolol is indicated for the short-term treatment of supraventricular tachycardia, including Wolff-Parkinson-White syndrome and thyrotoxicosis, to decrease ventricular rate. Use in patients with atrial flutter or atrial fibrillation should be reserved for arrythmias unresponsive to standard therapy or when more prolonged control is required. Reversion to normal sinus rhythm has occasionally been observed, predominantly in patients with sinus or atrial tachycardia. Ventricular tachycardias With the exception of those induced by catecholamines or digitalis, propranolol is not the drug of first choice. In critical situations when cardioversion techniques or other drugs are not indicated or are not effective, propranolol may be considered. If, after consideration of the risks involved, propranolol is used, it should be given intravenously in low dosage and very slowly, as the failing heart requires some sympathetic drive for maintenance of myocardial tone. (See ). Some patients may respond with complete reversion to normal sinus rhythm, but reduction in ventricular rate is more likely. Ventricular arrhythmias do not respond to propranolol as predictably as do the supraventricular arrhythmias. Intravenous propranolol is indicated for the treatment of persistent premature ventricular extrasystoles that impair the well-being of the patient and do not respond to conventional measures. Tachyarrhythmias of digitalis intoxicationIntravenous propranolol is indicated to control ventricular rate in life-threatening digitalis-induced arrhythmias. Severe bradycardia may occur. (See ). Resistant tachyarrhythmias due to excessive catecholamine action during anesthesia Intravenous propranolol is indicated to abolish tachyarrhythmias due to excessive catecholamine action during anesthesia when other measures fail. These arrhythmias may arise because of release of endogenous catecholamines or administration of catecholamines. All general inhalation anesthetics produce some degree of myocardial depression. Therefore, when propranolol is used to treat arrhythmias during anesthesia, it should be used with extreme caution, usually with constant monitoring of the ECG and central venous pressure. (See ). uuid:d05db81f-73a5-4804-bc5c-82bd55169992 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats MONDO:0005310 PMID:41385096 "[{""id"":""uuid:ea69d64d-b2a6-4482-a103-08c13929774b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b35e0e1d-f741-47ad-b33e-78dea03a18c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous administration is usually reserved for life-threatening arrhythmias or those occurring under anesthesia. Supraventricular arrhythmiasIntravenous propranolol is indicated for the short-term treatment of supraventricular tachycardia, including Wolff-Parkinson-White syndrome and thyrotoxicosis, to decrease ventricular rate. Use in patients with atrial flutter or atrial fibrillation should be reserved for arrythmias unresponsive to standard therapy or when more prolonged control is required. Reversion to normal sinus rhythm has occasionally been observed, predominantly in patients with sinus or atrial tachycardia. Ventricular tachycardias With the exception of those induced by catecholamines or digitalis, propranolol is not the drug of first choice. In critical situations when cardioversion techniques or other drugs are not indicated or are not effective, propranolol may be considered. If, after consideration of the risks involved, propranolol is used, it should be given intravenously in low dosage and very slowly, as the failing heart requires some sympathetic drive for maintenance of myocardial tone. (See ). Some patients may respond with complete reversion to normal sinus rhythm, but reduction in ventricular rate is more likely. Ventricular arrhythmias do not respond to propranolol as predictably as do the supraventricular arrhythmias. Intravenous propranolol is indicated for the treatment of persistent premature ventricular extrasystoles that impair the well-being of the patient and do not respond to conventional measures. Tachyarrhythmias of digitalis intoxicationIntravenous propranolol is indicated to control ventricular rate in life-threatening digitalis-induced arrhythmias. Severe bradycardia may occur. (See ). Resistant tachyarrhythmias due to excessive catecholamine action during anesthesia Intravenous propranolol is indicated to abolish tachyarrhythmias due to excessive catecholamine action during anesthesia when other measures fail. These arrhythmias may arise because of release of endogenous catecholamines or administration of catecholamines. All general inhalation anesthetics produce some degree of myocardial depression. Therefore, when propranolol is used to treat arrhythmias during anesthesia, it should be used with extreme caution, usually with constant monitoring of the ECG and central venous pressure. (See ). uuid:294283e2-9b49-4e93-a4e2-d20aa0b7cac4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats MONDO:0004981 PMID:41385096 "[{""id"":""uuid:79a93af3-88d2-40da-bfc2-eaa5c6722d1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:641b2699-2ff3-4a70-bdfa-2e543d6baed8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:573c3feb-e91b-49bd-b153-eedcda5e6b0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous administration is usually reserved for life-threatening arrhythmias or those occurring under anesthesia. Supraventricular arrhythmiasIntravenous propranolol is indicated for the short-term treatment of supraventricular tachycardia, including Wolff-Parkinson-White syndrome and thyrotoxicosis, to decrease ventricular rate. Use in patients with atrial flutter or atrial fibrillation should be reserved for arrythmias unresponsive to standard therapy or when more prolonged control is required. Reversion to normal sinus rhythm has occasionally been observed, predominantly in patients with sinus or atrial tachycardia. Ventricular tachycardias With the exception of those induced by catecholamines or digitalis, propranolol is not the drug of first choice. In critical situations when cardioversion techniques or other drugs are not indicated or are not effective, propranolol may be considered. If, after consideration of the risks involved, propranolol is used, it should be given intravenously in low dosage and very slowly, as the failing heart requires some sympathetic drive for maintenance of myocardial tone. (See ). Some patients may respond with complete reversion to normal sinus rhythm, but reduction in ventricular rate is more likely. Ventricular arrhythmias do not respond to propranolol as predictably as do the supraventricular arrhythmias. Intravenous propranolol is indicated for the treatment of persistent premature ventricular extrasystoles that impair the well-being of the patient and do not respond to conventional measures. Tachyarrhythmias of digitalis intoxicationIntravenous propranolol is indicated to control ventricular rate in life-threatening digitalis-induced arrhythmias. Severe bradycardia may occur. (See ). Resistant tachyarrhythmias due to excessive catecholamine action during anesthesia Intravenous propranolol is indicated to abolish tachyarrhythmias due to excessive catecholamine action during anesthesia when other measures fail. These arrhythmias may arise because of release of endogenous catecholamines or administration of catecholamines. All general inhalation anesthetics produce some degree of myocardial depression. Therefore, when propranolol is used to treat arrhythmias during anesthesia, it should be used with extreme caution, usually with constant monitoring of the ECG and central venous pressure. (See ).|[PMDA] Drugs with new additional pediatric dosages for extrasystole (supraventricular/ventricular), the prevention of paroxysmal tachycardia, atrial fibrillation with rapid ventricular response (bradycardiac effect), sinus tachycardia, atrial fibrillation, and the prevention of paroxysmal atrial fibrillation. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:4a081e85-2a62-4775-8410-3be0593a4288 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats HP:0011703 PMID:41385096 "[{""id"":""uuid:9b45f485-46b3-4d9a-acd7-3447c880a0c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:69c22ae6-807e-4ff6-a77d-afff13fe4d98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2b108779-2452-43bc-9cbb-1a3b19aa70d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous administration is usually reserved for life-threatening arrhythmias or those occurring under anesthesia. Supraventricular arrhythmiasIntravenous propranolol is indicated for the short-term treatment of supraventricular tachycardia, including Wolff-Parkinson-White syndrome and thyrotoxicosis, to decrease ventricular rate. Use in patients with atrial flutter or atrial fibrillation should be reserved for arrythmias unresponsive to standard therapy or when more prolonged control is required. Reversion to normal sinus rhythm has occasionally been observed, predominantly in patients with sinus or atrial tachycardia. Ventricular tachycardias With the exception of those induced by catecholamines or digitalis, propranolol is not the drug of first choice. In critical situations when cardioversion techniques or other drugs are not indicated or are not effective, propranolol may be considered. If, after consideration of the risks involved, propranolol is used, it should be given intravenously in low dosage and very slowly, as the failing heart requires some sympathetic drive for maintenance of myocardial tone. (See ). Some patients may respond with complete reversion to normal sinus rhythm, but reduction in ventricular rate is more likely. Ventricular arrhythmias do not respond to propranolol as predictably as do the supraventricular arrhythmias. Intravenous propranolol is indicated for the treatment of persistent premature ventricular extrasystoles that impair the well-being of the patient and do not respond to conventional measures. Tachyarrhythmias of digitalis intoxicationIntravenous propranolol is indicated to control ventricular rate in life-threatening digitalis-induced arrhythmias. Severe bradycardia may occur. (See ). Resistant tachyarrhythmias due to excessive catecholamine action during anesthesia Intravenous propranolol is indicated to abolish tachyarrhythmias due to excessive catecholamine action during anesthesia when other measures fail. These arrhythmias may arise because of release of endogenous catecholamines or administration of catecholamines. All general inhalation anesthetics produce some degree of myocardial depression. Therefore, when propranolol is used to treat arrhythmias during anesthesia, it should be used with extreme caution, usually with constant monitoring of the ECG and central venous pressure. (See ).|[PMDA] Drugs with new additional pediatric dosages for extrasystole (supraventricular/ventricular), the prevention of paroxysmal tachycardia, atrial fibrillation with rapid ventricular response (bradycardiac effect), sinus tachycardia, atrial fibrillation, and the prevention of paroxysmal atrial fibrillation. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:cf3a1260-91e5-4254-8107-74f41b509883 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats MONDO:0005479 PMID:41385096 "[{""id"":""uuid:abe9820a-a78e-4d87-a947-dfbb5ae32dec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:83409a47-2304-4e4e-aaa0-b05266567262"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous administration is usually reserved for life-threatening arrhythmias or those occurring under anesthesia. Supraventricular arrhythmiasIntravenous propranolol is indicated for the short-term treatment of supraventricular tachycardia, including Wolff-Parkinson-White syndrome and thyrotoxicosis, to decrease ventricular rate. Use in patients with atrial flutter or atrial fibrillation should be reserved for arrythmias unresponsive to standard therapy or when more prolonged control is required. Reversion to normal sinus rhythm has occasionally been observed, predominantly in patients with sinus or atrial tachycardia. Ventricular tachycardias With the exception of those induced by catecholamines or digitalis, propranolol is not the drug of first choice. In critical situations when cardioversion techniques or other drugs are not indicated or are not effective, propranolol may be considered. If, after consideration of the risks involved, propranolol is used, it should be given intravenously in low dosage and very slowly, as the failing heart requires some sympathetic drive for maintenance of myocardial tone. (See ). Some patients may respond with complete reversion to normal sinus rhythm, but reduction in ventricular rate is more likely. Ventricular arrhythmias do not respond to propranolol as predictably as do the supraventricular arrhythmias. Intravenous propranolol is indicated for the treatment of persistent premature ventricular extrasystoles that impair the well-being of the patient and do not respond to conventional measures. Tachyarrhythmias of digitalis intoxicationIntravenous propranolol is indicated to control ventricular rate in life-threatening digitalis-induced arrhythmias. Severe bradycardia may occur. (See ). Resistant tachyarrhythmias due to excessive catecholamine action during anesthesia Intravenous propranolol is indicated to abolish tachyarrhythmias due to excessive catecholamine action during anesthesia when other measures fail. These arrhythmias may arise because of release of endogenous catecholamines or administration of catecholamines. All general inhalation anesthetics produce some degree of myocardial depression. Therefore, when propranolol is used to treat arrhythmias during anesthesia, it should be used with extreme caution, usually with constant monitoring of the ECG and central venous pressure. (See ). uuid:dfbdaa6b-b39a-4165-b2a4-f0d3a7ed3675 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats HP:0006682 PMID:41385096 "[{""id"":""uuid:57f88835-7245-43d9-a95e-993ef986be55"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cb0f06e6-7634-4f7c-a70a-5466289dff8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous administration is usually reserved for life-threatening arrhythmias or those occurring under anesthesia. Supraventricular arrhythmiasIntravenous propranolol is indicated for the short-term treatment of supraventricular tachycardia, including Wolff-Parkinson-White syndrome and thyrotoxicosis, to decrease ventricular rate. Use in patients with atrial flutter or atrial fibrillation should be reserved for arrythmias unresponsive to standard therapy or when more prolonged control is required. Reversion to normal sinus rhythm has occasionally been observed, predominantly in patients with sinus or atrial tachycardia. Ventricular tachycardias With the exception of those induced by catecholamines or digitalis, propranolol is not the drug of first choice. In critical situations when cardioversion techniques or other drugs are not indicated or are not effective, propranolol may be considered. If, after consideration of the risks involved, propranolol is used, it should be given intravenously in low dosage and very slowly, as the failing heart requires some sympathetic drive for maintenance of myocardial tone. (See ). Some patients may respond with complete reversion to normal sinus rhythm, but reduction in ventricular rate is more likely. Ventricular arrhythmias do not respond to propranolol as predictably as do the supraventricular arrhythmias. Intravenous propranolol is indicated for the treatment of persistent premature ventricular extrasystoles that impair the well-being of the patient and do not respond to conventional measures. Tachyarrhythmias of digitalis intoxicationIntravenous propranolol is indicated to control ventricular rate in life-threatening digitalis-induced arrhythmias. Severe bradycardia may occur. (See ). Resistant tachyarrhythmias due to excessive catecholamine action during anesthesia Intravenous propranolol is indicated to abolish tachyarrhythmias due to excessive catecholamine action during anesthesia when other measures fail. These arrhythmias may arise because of release of endogenous catecholamines or administration of catecholamines. All general inhalation anesthetics produce some degree of myocardial depression. Therefore, when propranolol is used to treat arrhythmias during anesthesia, it should be used with extreme caution, usually with constant monitoring of the ECG and central venous pressure. (See ). uuid:5be574cb-891f-4271-acf1-88cd04ea17ad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats MONDO:0007263 PMID:41385096 "[{""id"":""uuid:ffedacfb-68c8-4704-9a36-39246d7a264c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:11bd58b1-aba0-4f5a-a49f-c7057945292c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous administration is usually reserved for life-threatening arrhythmias or those occurring under anesthesia. Supraventricular arrhythmiasIntravenous propranolol is indicated for the short-term treatment of supraventricular tachycardia, including Wolff-Parkinson-White syndrome and thyrotoxicosis, to decrease ventricular rate. Use in patients with atrial flutter or atrial fibrillation should be reserved for arrythmias unresponsive to standard therapy or when more prolonged control is required. Reversion to normal sinus rhythm has occasionally been observed, predominantly in patients with sinus or atrial tachycardia. Ventricular tachycardias With the exception of those induced by catecholamines or digitalis, propranolol is not the drug of first choice. In critical situations when cardioversion techniques or other drugs are not indicated or are not effective, propranolol may be considered. If, after consideration of the risks involved, propranolol is used, it should be given intravenously in low dosage and very slowly, as the failing heart requires some sympathetic drive for maintenance of myocardial tone. (See ). Some patients may respond with complete reversion to normal sinus rhythm, but reduction in ventricular rate is more likely. Ventricular arrhythmias do not respond to propranolol as predictably as do the supraventricular arrhythmias. Intravenous propranolol is indicated for the treatment of persistent premature ventricular extrasystoles that impair the well-being of the patient and do not respond to conventional measures. Tachyarrhythmias of digitalis intoxicationIntravenous propranolol is indicated to control ventricular rate in life-threatening digitalis-induced arrhythmias. Severe bradycardia may occur. (See ). Resistant tachyarrhythmias due to excessive catecholamine action during anesthesia Intravenous propranolol is indicated to abolish tachyarrhythmias due to excessive catecholamine action during anesthesia when other measures fail. These arrhythmias may arise because of release of endogenous catecholamines or administration of catecholamines. All general inhalation anesthetics produce some degree of myocardial depression. Therefore, when propranolol is used to treat arrhythmias during anesthesia, it should be used with extreme caution, usually with constant monitoring of the ECG and central venous pressure. (See ). uuid:103ae44f-f847-4205-a4f5-679a5402e269 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0005664 PMID:41385096 "[{""id"":""uuid:f472dfcc-ad05-4978-bf59-aac864291bcd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:122e4a76-a486-4cbf-9311-34abe789ef8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline hydrochloride tablets are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunoflourescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Minocycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes. Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride tablets are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections. Infections in women caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum subspecies pallidum . Yaws caused by Treponema pallidum subspecies pertenue . Listeriosis due to Listeria monocytogenes . Anthrax due to Bacillus anthracis . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis , minocycline may be useful adjunct to amebicides. In severe acne, minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitides to eliminate the meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carrier, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum . To reduce the development of drug-resistant bacteria and maintain the effectiveness of, minocycline hydrochloride tablets and other antibacterial drugs, minocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antimicrobial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:7bcf8c18-4157-4a3a-ab10-85f660197a49 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5001 biolink:treats UMLS:C0342879 PMID:41385096 "[{""id"":""uuid:bf39cdcf-699b-49bc-9bf5-ac89588b4554"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6df17509-2e7c-4daf-a15f-51bff2f4fccf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Antara is indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C, Triglycerides, and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types II a and II b). Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate (see National Cholesterol Education Program [NCEP] Treatment Guidelines, below ). uuid:dee2ad89-ddea-48fb-810c-6886ad000747 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5001 biolink:treats HP:0003119 PMID:41385096 "[{""id"":""uuid:05a19009-dec1-420f-82d4-0a870de621fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:78405e54-b7a1-4e46-831d-768291ac5f9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Antara is indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C, Triglycerides, and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types II a and II b). Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate (see National Cholesterol Education Program [NCEP] Treatment Guidelines, below ). uuid:0548494f-6e45-4e82-9816-527d9b3ac829 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3534 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:cc90910e-630b-4bc8-8e5c-ae209a32c7f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:93e5ac5f-c299-47dd-a9a4-9c5e1b74f5cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Keflex is indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Respiratory tract infections caused by Streptococcus pneumoniae and Streptococcus pyogenes (Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Keflex is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of Keflex in the subsequent prevention of rheumatic fever are not available at present.) Otitis media due to Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Streptococcus pyogenes , and Moraxella catarrhalis Skin and skin structure infections caused by Staphylococcus aureus and/or Streptococcus pyogenes Bone infections caused by Staphylococcus aureus and/or Proteus mirabilis Genitourinary tract infections, including acute prostatitis, caused by Escherichia coli, Proteus mirabilis, and Klebsiella pneumoniae Note — Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Keflex and other antibacterial drugs, Keflex should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:e37a0a1b-3384-4bd8-b6b5-fc6d59eb2472 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3534 biolink:treats MONDO:0021680 PMID:41385096 "[{""id"":""uuid:0f58f689-345b-4a8f-aa31-1acbeb1f9d4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:794f8b13-a02c-4066-8f71-4897960b31f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Keflex is indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Respiratory tract infections caused by Streptococcus pneumoniae and Streptococcus pyogenes (Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Keflex is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of Keflex in the subsequent prevention of rheumatic fever are not available at present.) Otitis media due to Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Streptococcus pyogenes , and Moraxella catarrhalis Skin and skin structure infections caused by Staphylococcus aureus and/or Streptococcus pyogenes Bone infections caused by Staphylococcus aureus and/or Proteus mirabilis Genitourinary tract infections, including acute prostatitis, caused by Escherichia coli, Proteus mirabilis, and Klebsiella pneumoniae Note — Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Keflex and other antibacterial drugs, Keflex should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:84611004-dce4-4a45-8b5d-e120fc37fa44 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3534 biolink:treats MONDO:0017767 PMID:41385096 "[{""id"":""uuid:5a054d14-8b81-459f-88fa-6532b72541bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cd8fbc63-3adf-4682-aea4-c14f852a5913"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Keflex is indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Respiratory tract infections caused by Streptococcus pneumoniae and Streptococcus pyogenes (Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Keflex is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of Keflex in the subsequent prevention of rheumatic fever are not available at present.) Otitis media due to Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Streptococcus pyogenes , and Moraxella catarrhalis Skin and skin structure infections caused by Staphylococcus aureus and/or Streptococcus pyogenes Bone infections caused by Staphylococcus aureus and/or Proteus mirabilis Genitourinary tract infections, including acute prostatitis, caused by Escherichia coli, Proteus mirabilis, and Klebsiella pneumoniae Note — Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Keflex and other antibacterial drugs, Keflex should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:e8d9dc1b-af5c-42fa-8a35-af5572a82ef5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3534 biolink:treats MONDO:0005441 PMID:41385096 "[{""id"":""uuid:c559ed1b-680a-4483-b8ea-e692c8579229"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a5cb33fb-f59a-47b0-be7a-5c947b2a33f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Keflex is indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Respiratory tract infections caused by Streptococcus pneumoniae and Streptococcus pyogenes (Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Keflex is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of Keflex in the subsequent prevention of rheumatic fever are not available at present.) Otitis media due to Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Streptococcus pyogenes , and Moraxella catarrhalis Skin and skin structure infections caused by Staphylococcus aureus and/or Streptococcus pyogenes Bone infections caused by Staphylococcus aureus and/or Proteus mirabilis Genitourinary tract infections, including acute prostatitis, caused by Escherichia coli, Proteus mirabilis, and Klebsiella pneumoniae Note — Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Keflex and other antibacterial drugs, Keflex should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:76a5daa6-4820-45ab-bf22-4c27514a3bbb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3534 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:5b445adb-1510-46aa-a83c-58a090043b4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9d272737-886c-45c6-9915-f8de16af5a25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Keflex is indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Respiratory tract infections caused by Streptococcus pneumoniae and Streptococcus pyogenes (Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Keflex is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of Keflex in the subsequent prevention of rheumatic fever are not available at present.) Otitis media due to Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Streptococcus pyogenes , and Moraxella catarrhalis Skin and skin structure infections caused by Staphylococcus aureus and/or Streptococcus pyogenes Bone infections caused by Staphylococcus aureus and/or Proteus mirabilis Genitourinary tract infections, including acute prostatitis, caused by Escherichia coli, Proteus mirabilis, and Klebsiella pneumoniae Note — Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Keflex and other antibacterial drugs, Keflex should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:a236128a-0ab7-49e0-a9ee-9e3e8239c8b1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3534 biolink:treats MONDO:0005246 PMID:41385096 "[{""id"":""uuid:0a859b6f-9f2b-47b9-ae7b-419d0eb390c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9aeacda2-69ea-4968-b477-ade315a34175"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Keflex is indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Respiratory tract infections caused by Streptococcus pneumoniae and Streptococcus pyogenes (Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Keflex is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of Keflex in the subsequent prevention of rheumatic fever are not available at present.) Otitis media due to Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Streptococcus pyogenes , and Moraxella catarrhalis Skin and skin structure infections caused by Staphylococcus aureus and/or Streptococcus pyogenes Bone infections caused by Staphylococcus aureus and/or Proteus mirabilis Genitourinary tract infections, including acute prostatitis, caused by Escherichia coli, Proteus mirabilis, and Klebsiella pneumoniae Note — Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Keflex and other antibacterial drugs, Keflex should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:0a4186d1-8922-4adf-8dbe-becb52ae7dfc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3534 biolink:treats UMLS:C0852158 PMID:41385096 "[{""id"":""uuid:ac50a893-9e4a-4686-9f92-ef26d09c831f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a3ad20f6-8c60-4171-ab83-b9a81905a09e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Keflex is indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Respiratory tract infections caused by Streptococcus pneumoniae and Streptococcus pyogenes (Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Keflex is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of Keflex in the subsequent prevention of rheumatic fever are not available at present.) Otitis media due to Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Streptococcus pyogenes , and Moraxella catarrhalis Skin and skin structure infections caused by Staphylococcus aureus and/or Streptococcus pyogenes Bone infections caused by Staphylococcus aureus and/or Proteus mirabilis Genitourinary tract infections, including acute prostatitis, caused by Escherichia coli, Proteus mirabilis, and Klebsiella pneumoniae Note — Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Keflex and other antibacterial drugs, Keflex should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:c5c733b8-c321-40af-8118-2bfdc13af03b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3534 biolink:treats UMLS:C0149524 PMID:41385096 "[{""id"":""uuid:55e6a68b-c209-49a2-84fe-a86843ea7268"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ac65c78d-d0a9-4d15-ac54-384f9ed6c9ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Keflex is indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Respiratory tract infections caused by Streptococcus pneumoniae and Streptococcus pyogenes (Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Keflex is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of Keflex in the subsequent prevention of rheumatic fever are not available at present.) Otitis media due to Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Streptococcus pyogenes , and Moraxella catarrhalis Skin and skin structure infections caused by Staphylococcus aureus and/or Streptococcus pyogenes Bone infections caused by Staphylococcus aureus and/or Proteus mirabilis Genitourinary tract infections, including acute prostatitis, caused by Escherichia coli, Proteus mirabilis, and Klebsiella pneumoniae Note — Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Keflex and other antibacterial drugs, Keflex should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:1c3afc2c-d4f1-4848-97b1-887c90e51f4b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3387 biolink:treats MONDO:0006710 PMID:41385096 "[{""id"":""uuid:8040f5e5-bb8f-4627-8651-b8546fd2d54e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:64982c4f-5e0c-41d4-a1fd-494fabec569c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carbamazepine is indicated for use as an anticonvulsant drug. Evidence supporting efficacy of carbamazepine as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types: Partial seizures with complex symptomatology (psychomotor, temporal lobe). Patients with these seizures appear to show greater improvement than those with other types. Generalized tonic-clonic seizures (grand mal). Mixed seizure patterns which include the above, or other partial or generalized seizures. Absence seizures (petitmal) do not appear to be controlled by carbamazepine (see PRECAUTIONS, General ). uuid:4055aa15-89d7-4476-adaa-da833b68ca32 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3387 biolink:treats MONDO:0005754 PMID:41385096 "[{""id"":""uuid:70e5f924-41d5-4681-83b7-b47e8dbbb1d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9b7b4277-7b1d-4ffc-ac27-e157aaa23a5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carbamazepine is indicated for use as an anticonvulsant drug. Evidence supporting efficacy of carbamazepine as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types: Partial seizures with complex symptomatology (psychomotor, temporal lobe). Patients with these seizures appear to show greater improvement than those with other types. Generalized tonic-clonic seizures (grand mal). Mixed seizure patterns which include the above, or other partial or generalized seizures. Absence seizures (petitmal) do not appear to be controlled by carbamazepine (see PRECAUTIONS, General ). uuid:d713f94b-ed87-480c-8d44-6d60192ec234 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3387 biolink:treats MONDO:0005027 PMID:41385096 "[{""id"":""uuid:47d94322-2bc6-442b-a790-ffc32da6796f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b669643f-95b4-4762-a7de-d77aad67c917"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carbamazepine is indicated for use as an anticonvulsant drug. Evidence supporting efficacy of carbamazepine as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types: Partial seizures with complex symptomatology (psychomotor, temporal lobe). Patients with these seizures appear to show greater improvement than those with other types. Generalized tonic-clonic seizures (grand mal). Mixed seizure patterns which include the above, or other partial or generalized seizures. Absence seizures (petitmal) do not appear to be controlled by carbamazepine (see PRECAUTIONS, General ). uuid:a7953c25-e277-4742-92e3-92bf6589244d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:23742 biolink:treats HP:0000969 PMID:41385096 "[{""id"":""uuid:b20ab410-cb99-45f3-b185-aee32a8302e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a87d176a-79fd-4865-920b-4e3a14f40ec4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] This fixed combination drug is not indicated for the initial therapy of edema or hypertension except in individuals in whom the development of hypokalemia cannot be risked. Triamterene and Hydrochlorothiazide Tablets are indicated for the treatment of hypertension or edema in patients who develop hypokalemia on hydrochlorothiazide alone. Triamterene and hydrochlorothiazide is also indicated for those patients who require a thiazide diuretic and in whom the development of hypokalemia cannot be risked (e.g., patients on concomitant digitalis preparations, or with a history of cardiac arrhythmias, etc.). Triamterene and hydrochlorothiazide may be used alone or in combination with other antihypertensive drugs such as beta-blockers. Since triamterene and hydrochlorothiazide may enhance the actions of these drugs, dosage adjustments may be necessary. uuid:e93a8f7c-7139-4a37-8472-42dd128517e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:23742 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:77cff7d9-119b-49ce-b138-6f5db639245a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:39d6a2f6-01b3-4800-8cd2-e0b4531f27bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] This fixed combination drug is not indicated for the initial therapy of edema or hypertension except in individuals in whom the development of hypokalemia cannot be risked. Triamterene and Hydrochlorothiazide Tablets are indicated for the treatment of hypertension or edema in patients who develop hypokalemia on hydrochlorothiazide alone. Triamterene and hydrochlorothiazide is also indicated for those patients who require a thiazide diuretic and in whom the development of hypokalemia cannot be risked (e.g., patients on concomitant digitalis preparations, or with a history of cardiac arrhythmias, etc.). Triamterene and hydrochlorothiazide may be used alone or in combination with other antihypertensive drugs such as beta-blockers. Since triamterene and hydrochlorothiazide may enhance the actions of these drugs, dosage adjustments may be necessary. uuid:f10f1f49-8a20-470e-9248-457c31de07e1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:23742 biolink:treats MONDO:0003019 PMID:41385096 "[{""id"":""uuid:81ef892f-42fa-4c57-a8e3-2ba74a47053e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eabb62af-c44b-4b34-82c9-3334002e742c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] This fixed combination drug is not indicated for the initial therapy of edema or hypertension except in individuals in whom the development of hypokalemia cannot be risked. Triamterene and Hydrochlorothiazide Tablets are indicated for the treatment of hypertension or edema in patients who develop hypokalemia on hydrochlorothiazide alone. Triamterene and hydrochlorothiazide is also indicated for those patients who require a thiazide diuretic and in whom the development of hypokalemia cannot be risked (e.g., patients on concomitant digitalis preparations, or with a history of cardiac arrhythmias, etc.). Triamterene and hydrochlorothiazide may be used alone or in combination with other antihypertensive drugs such as beta-blockers. Since triamterene and hydrochlorothiazide may enhance the actions of these drugs, dosage adjustments may be necessary. uuid:ec69f1ee-b52e-4f4e-9d96-aef6bc2e083f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:23742 biolink:treats MONDO:0007263 PMID:41385096 "[{""id"":""uuid:19733869-f996-4151-bb21-7763182d8a1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4a4c793b-72e3-4df4-8fdc-404585aab508"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] This fixed combination drug is not indicated for the initial therapy of edema or hypertension except in individuals in whom the development of hypokalemia cannot be risked. Triamterene and Hydrochlorothiazide Tablets are indicated for the treatment of hypertension or edema in patients who develop hypokalemia on hydrochlorothiazide alone. Triamterene and hydrochlorothiazide is also indicated for those patients who require a thiazide diuretic and in whom the development of hypokalemia cannot be risked (e.g., patients on concomitant digitalis preparations, or with a history of cardiac arrhythmias, etc.). Triamterene and hydrochlorothiazide may be used alone or in combination with other antihypertensive drugs such as beta-blockers. Since triamterene and hydrochlorothiazide may enhance the actions of these drugs, dosage adjustments may be necessary. uuid:cbefe027-0bb6-45bc-b873-ac076b44e05b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6532 biolink:treats MONDO:0000257 PMID:41385096 "[{""id"":""uuid:58b34f1b-efe3-4641-99f2-7c6989842de3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:efbc0e78-d72a-46d8-83ac-2b7bf030e76e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IMODIUM® (loperamide hydrochloride) is indicated for the control and symptomatic relief of acute nonspecific diarrhea and of chronic diarrhea associated with inflammatory bowel disease. IMODIUM® is also indicated for reducing the volume of discharge from ileostomies. uuid:8adadf5f-5666-4857-9c82-913a0a7a1375 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6532 biolink:treats MONDO:0005265 PMID:41385096 "[{""id"":""uuid:80eeec64-57aa-4b9b-80af-9e59b4e6af47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ca4e56a4-4013-493f-a07b-6e8dae62044a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IMODIUM® (loperamide hydrochloride) is indicated for the control and symptomatic relief of acute nonspecific diarrhea and of chronic diarrhea associated with inflammatory bowel disease. IMODIUM® is also indicated for reducing the volume of discharge from ileostomies. uuid:5ecc0ec1-fbca-4f5d-940c-a9ae37517f53 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28901 biolink:treats MONDO:0011996 PMID:41385096 "[{""id"":""uuid:4d06418e-5866-47c0-998e-854692325809"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4324b401-1b05-42f1-aa94-7f445e70dbe7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BUSULFEX ® (busulfan) Injection is indicated for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia. uuid:6fad9c6f-a854-498c-9dbb-0871d55c3ead biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats MONDO:0005129 PMID:41385096 "[{""id"":""uuid:0fee42de-4062-4028-acfb-6b212648f859"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7bb92048-944b-4c4d-acf6-38e9912703b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diclofenac Sodium Ophthalmic Solution, 0.1% is indicated for the treatment of postoperative inflammation in patients who have undergone cataract extraction. uuid:19f0f3ae-fc45-47a1-8456-9a1dfecdee6f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4708 biolink:treats MONDO:0010811 PMID:41385096 "[{""id"":""uuid:1453d35c-755f-4ef4-9d68-f5c77b361bae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:80cc5b62-ecb8-485d-8ab0-052f9e2c503e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A. Benign Prostatic Hyperplasia (BPH) Doxazosin mesylate tablets are indicated for the treatment of both the urinary outflow obstruction and obstructive and irritative symptoms associated with BPH: obstructive symptoms (hesitation, intermittency, dribbling, weak urinary stream, incomplete emptying of the bladder) and irritative symptoms (nocturia, daytime frequency, urgency, burning). Doxazosin mesylate tablets may be used in all BPH patients whether hypertensive or normotensive. In patients with hypertension and BPH, both conditions were effectively treated with doxazosin mesylate tablet monotherapy. Doxazosin mesylate tablets provides rapid improvement in symptoms and urinary flow rate in 66-71% of patients. Sustained improvements with doxazosin mesylate tablets were seen in patients treated for up to 14 weeks in double-blind studies and up to 2 years in open-label studies. B. Hypertension Doxazosin mesylate tablets are also indicated for the treatment of hypertension. Doxazosin mesylate tablets may be used alone or in combination with diuretics, beta-adrenergic blocking agents, calcium channel blockers or angiotensin-converting enzyme inhibitors. uuid:80e2c5ec-8c37-47cc-ab51-75d63ff94944 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4708 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:dacfb716-2ada-4562-9b99-5fcba579b0d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cc3a9bd1-4ee0-4d08-b398-94189768036f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A. Benign Prostatic Hyperplasia (BPH) Doxazosin mesylate tablets are indicated for the treatment of both the urinary outflow obstruction and obstructive and irritative symptoms associated with BPH: obstructive symptoms (hesitation, intermittency, dribbling, weak urinary stream, incomplete emptying of the bladder) and irritative symptoms (nocturia, daytime frequency, urgency, burning). Doxazosin mesylate tablets may be used in all BPH patients whether hypertensive or normotensive. In patients with hypertension and BPH, both conditions were effectively treated with doxazosin mesylate tablet monotherapy. Doxazosin mesylate tablets provides rapid improvement in symptoms and urinary flow rate in 66-71% of patients. Sustained improvements with doxazosin mesylate tablets were seen in patients treated for up to 14 weeks in double-blind studies and up to 2 years in open-label studies. B. Hypertension Doxazosin mesylate tablets are also indicated for the treatment of hypertension. Doxazosin mesylate tablets may be used alone or in combination with diuretics, beta-adrenergic blocking agents, calcium channel blockers or angiotensin-converting enzyme inhibitors. uuid:6d1ff102-da8e-4e3f-8837-9b0335a3dc75 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3223 biolink:treats MONDO:0005618 PMID:41385096 "[{""id"":""uuid:23816be8-3967-47b1-bcca-d85df9337b30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:27269527-4296-40f9-82fe-2b95518f5eb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The efficacy of buspirone has been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to Generalized Anxiety Disorder (GAD). Many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone relieved anxiety in the presence of these coexisting depressive symptoms. The patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. Generalized Anxiety Disorder (300.02) is described in the American Psychiatric Association’s Diagnostic and Statistical Manual, III 1 as follows: Generalized, persistent anxiety (of at least 1 month continual duration), manifested by symptoms from three of the four following categories: Motor tension: shakiness, jitteriness, jumpiness, trembling, tension, muscle aches, fatigability, inability to relax, eyelid twitch, furrowed brow, strained face, fidgeting, restlessness, easy startle. Autonomic hyperactivity: sweating, heart pounding or racing, cold, clammy hands, dry mouth, dizziness, lightheadedness, paresthesias (tingling in hands or feet), upset stomach, hot or cold spells, frequent urination, diarrhea, discomfort in the pit of the stomach, lump in the throat, flushing, pallor, high resting pulse and respiration rate. Apprehensive expectation: anxiety, worry, fear, rumination, and anticipation of misfortune to self or others. Vigilance and scanning: hyperattentiveness resulting in distractibility, difficulty in concentrating, insomnia, feeling ""on edge"", irritability, impatience. The above symptoms would not be due to another mental disorder, such as a depressive disorder or schizophrenia. However, mild depressive symptoms are common in GAD. The effectiveness of buspirone in long-term use, that is, for more than 3 to 4 weeks, has not been demonstrated in controlled trials. There is no body of evidence available that systematically addresses the appropriate duration of treatment for GAD. However, in a study of long-term use, 264 patients were treated with buspirone for 1 year without ill effect. Therefore, the physician who elects to use buspirone for extended periods should periodically reassess the usefulness of the drug for the individual patient." uuid:328ac67b-372f-4451-9d77-968acb4533a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3223 biolink:treats MONDO:0011918 PMID:41385096 "[{""id"":""uuid:dbfe2992-6dc2-4961-a258-209dd2eb9cb7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0e9bb859-3572-4c87-a9cb-e79965b3d0fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The efficacy of buspirone has been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to Generalized Anxiety Disorder (GAD). Many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone relieved anxiety in the presence of these coexisting depressive symptoms. The patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. Generalized Anxiety Disorder (300.02) is described in the American Psychiatric Association’s Diagnostic and Statistical Manual, III 1 as follows: Generalized, persistent anxiety (of at least 1 month continual duration), manifested by symptoms from three of the four following categories: Motor tension: shakiness, jitteriness, jumpiness, trembling, tension, muscle aches, fatigability, inability to relax, eyelid twitch, furrowed brow, strained face, fidgeting, restlessness, easy startle. Autonomic hyperactivity: sweating, heart pounding or racing, cold, clammy hands, dry mouth, dizziness, lightheadedness, paresthesias (tingling in hands or feet), upset stomach, hot or cold spells, frequent urination, diarrhea, discomfort in the pit of the stomach, lump in the throat, flushing, pallor, high resting pulse and respiration rate. Apprehensive expectation: anxiety, worry, fear, rumination, and anticipation of misfortune to self or others. Vigilance and scanning: hyperattentiveness resulting in distractibility, difficulty in concentrating, insomnia, feeling ""on edge"", irritability, impatience. The above symptoms would not be due to another mental disorder, such as a depressive disorder or schizophrenia. However, mild depressive symptoms are common in GAD. The effectiveness of buspirone in long-term use, that is, for more than 3 to 4 weeks, has not been demonstrated in controlled trials. There is no body of evidence available that systematically addresses the appropriate duration of treatment for GAD. However, in a study of long-term use, 264 patients were treated with buspirone for 1 year without ill effect. Therefore, the physician who elects to use buspirone for extended periods should periodically reassess the usefulness of the drug for the individual patient." uuid:0697bda3-d1ce-4ba4-9166-4484ce6e4399 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3223 biolink:treats MONDO:0001942 PMID:41385096 "[{""id"":""uuid:37d4d8ee-9b31-4102-a747-4d8e7a859644"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0c8f5f06-e126-4115-8bbe-9da6bd8151dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The efficacy of buspirone has been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to Generalized Anxiety Disorder (GAD). Many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone relieved anxiety in the presence of these coexisting depressive symptoms. The patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. Generalized Anxiety Disorder (300.02) is described in the American Psychiatric Association’s Diagnostic and Statistical Manual, III 1 as follows: Generalized, persistent anxiety (of at least 1 month continual duration), manifested by symptoms from three of the four following categories: Motor tension: shakiness, jitteriness, jumpiness, trembling, tension, muscle aches, fatigability, inability to relax, eyelid twitch, furrowed brow, strained face, fidgeting, restlessness, easy startle. Autonomic hyperactivity: sweating, heart pounding or racing, cold, clammy hands, dry mouth, dizziness, lightheadedness, paresthesias (tingling in hands or feet), upset stomach, hot or cold spells, frequent urination, diarrhea, discomfort in the pit of the stomach, lump in the throat, flushing, pallor, high resting pulse and respiration rate. Apprehensive expectation: anxiety, worry, fear, rumination, and anticipation of misfortune to self or others. Vigilance and scanning: hyperattentiveness resulting in distractibility, difficulty in concentrating, insomnia, feeling ""on edge"", irritability, impatience. The above symptoms would not be due to another mental disorder, such as a depressive disorder or schizophrenia. However, mild depressive symptoms are common in GAD. The effectiveness of buspirone in long-term use, that is, for more than 3 to 4 weeks, has not been demonstrated in controlled trials. There is no body of evidence available that systematically addresses the appropriate duration of treatment for GAD. However, in a study of long-term use, 264 patients were treated with buspirone for 1 year without ill effect. Therefore, the physician who elects to use buspirone for extended periods should periodically reassess the usefulness of the drug for the individual patient." uuid:99afb479-6d21-4810-bbdc-10109a3db118 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0006604 PMID:41385096 "[{""id"":""uuid:cbfb38ea-24d3-4c85-b21e-be7b906faff8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1215f495-b75e-4e88-bbd0-ed09bf23e375"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. uuid:aa105eeb-1f60-4ff7-ba3a-f49213490bc3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0033816 PMID:41385096 "[{""id"":""uuid:f8a6f4b2-e809-49a8-b025-ec0c55022e66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:94dd5028-c610-4d2c-87c9-1ad15705be14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. uuid:a06107ff-164f-4d46-87a8-d40081920611 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats UMLS:C1275687 PMID:41385096 "[{""id"":""uuid:51b69599-4cc4-4ebd-af68-b3a851d9e23c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b61fda58-453a-408b-bbf7-e8affb695dc8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. uuid:dcde7f06-cb74-4bbc-80aa-9fe6fb120fbb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats UMLS:C0010543 PMID:41385096 "[{""id"":""uuid:c2999506-fb36-4829-ad16-85698b04b35f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:47e89f61-b3c3-49e9-8832-d4311f6d26b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. uuid:80cd6060-abc1-4568-87ea-4595a625e39a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0006668 PMID:41385096 "[{""id"":""uuid:41dd75c5-b68c-4d5b-9f17-8ed55654af6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e5d3c32c-1094-48b9-bf0a-fd9ea8d2875a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. uuid:1f062a83-57b3-4bb2-85ac-b9f9a8eb027b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats UMLS:C0339289 PMID:41385096 "[{""id"":""uuid:e7a9a5ba-5579-4a6e-83ee-5b49f67c4efa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ddac4e37-15d5-4dad-b5ad-4c8691fc4d93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. uuid:72790534-f9a3-4973-a9c0-3881438e6586 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3082 biolink:treats MONDO:0006875 PMID:41385096 "[{""id"":""uuid:a427c3cc-3c02-419b-ac2e-e8839a33b8b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d725e703-4f33-45f9-9864-f739a6f1858e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BETOPTIC Ophthalmic Solution has been shown to be effective in lowering intraocular pressure and is indicated in the treatment of ocular hypertension and chronic open-angle glaucoma. It may be used alone or in combination with other anti-glaucoma drugs. In clinical studies BETOPTIC was safely used to lower intraocular pressure in 47 patients with both glaucoma and reactive airway disease who were followed for a mean period of 15 months. However, caution should be used in treating patients with severe reactive airway disease or a history of asthma. uuid:ae6e90d8-f4c7-4ea3-9c73-2a909d6467d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3082 biolink:treats MONDO:0005338 PMID:41385096 "[{""id"":""uuid:10bd19e0-64d4-4ea9-8c94-6331db1d0194"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4b7765a8-f7d2-4ca1-9226-33f18bc98334"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BETOPTIC Ophthalmic Solution has been shown to be effective in lowering intraocular pressure and is indicated in the treatment of ocular hypertension and chronic open-angle glaucoma. It may be used alone or in combination with other anti-glaucoma drugs. In clinical studies BETOPTIC was safely used to lower intraocular pressure in 47 patients with both glaucoma and reactive airway disease who were followed for a mean period of 15 months. However, caution should be used in treating patients with severe reactive airway disease or a history of asthma. uuid:2851b66b-cec6-4a07-8561-ef22a20b39fb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3082 biolink:treats MONDO:0005041 PMID:41385096 "[{""id"":""uuid:0f613a19-112f-4fc0-88fb-6250e5a61c19"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:84c53735-5de6-4e5e-a833-88339d6d812d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BETOPTIC Ophthalmic Solution has been shown to be effective in lowering intraocular pressure and is indicated in the treatment of ocular hypertension and chronic open-angle glaucoma. It may be used alone or in combination with other anti-glaucoma drugs. In clinical studies BETOPTIC was safely used to lower intraocular pressure in 47 patients with both glaucoma and reactive airway disease who were followed for a mean period of 15 months. However, caution should be used in treating patients with severe reactive airway disease or a history of asthma. uuid:c8416ea0-625a-4ce0-a082-704142218042 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3082 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:14289ff5-b55b-4c09-9542-587d77ab23b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3741c692-25e1-4f51-8144-e3e133d72113"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BETOPTIC Ophthalmic Solution has been shown to be effective in lowering intraocular pressure and is indicated in the treatment of ocular hypertension and chronic open-angle glaucoma. It may be used alone or in combination with other anti-glaucoma drugs. In clinical studies BETOPTIC was safely used to lower intraocular pressure in 47 patients with both glaucoma and reactive airway disease who were followed for a mean period of 15 months. However, caution should be used in treating patients with severe reactive airway disease or a history of asthma. uuid:93947e1b-06ce-4521-b4fe-d328329dd1dd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63619 biolink:treats MONDO:1030011 PMID:41385096 "[{""id"":""uuid:a9b82e38-535f-47f7-b054-69d6ff216d4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:83291b1c-bbd9-4012-909c-337b8f353972"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In patients without structural heart disease, propafenone HCl is indicated to prolong the time to recurrence of - paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms. - paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms. As with other agents, some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional AV refractory period is recommended. The use of propafenone in patients with chronic atrial fibrillation has not been evaluated. Propafenone should not be used to control ventricular rate during atrial fibrillation. Propafenone is also indicated for the treatment of - documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. Because of the proarrhythmic effects of propafenone, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits out-weigh the risks. Initiation of propafenone treatment, as with other antiarrhythmics used to treat life-threatening ventricular arrhythmias, should be carried out in the hospital. Propafenone, like other antiarrhythmic drugs, has not been shown to enhance survival in patients with ventricular or atrial arrhythmias. uuid:1eac044c-a1b8-4e25-97f0-3d9d0c3947c3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63619 biolink:treats UMLS:C0741292 PMID:41385096 "[{""id"":""uuid:ac54b608-3fa7-4847-9591-a73ca5dbcc98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:afb7b61c-c1fb-49ed-9456-30a04e715330"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In patients without structural heart disease, propafenone HCl is indicated to prolong the time to recurrence of - paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms. - paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms. As with other agents, some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional AV refractory period is recommended. The use of propafenone in patients with chronic atrial fibrillation has not been evaluated. Propafenone should not be used to control ventricular rate during atrial fibrillation. Propafenone is also indicated for the treatment of - documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. Because of the proarrhythmic effects of propafenone, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits out-weigh the risks. Initiation of propafenone treatment, as with other antiarrhythmics used to treat life-threatening ventricular arrhythmias, should be carried out in the hospital. Propafenone, like other antiarrhythmic drugs, has not been shown to enhance survival in patients with ventricular or atrial arrhythmias. uuid:168e6988-41dc-400a-ab71-fe850af7c18e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63619 biolink:treats HP:0004763 PMID:41385096 "[{""id"":""uuid:b40a554e-d1dc-41bb-a0d9-7700c526d23c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1419a1d6-c4e3-4df0-b2f7-24c0fa9962aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In patients without structural heart disease, propafenone HCl is indicated to prolong the time to recurrence of - paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms. - paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms. As with other agents, some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional AV refractory period is recommended. The use of propafenone in patients with chronic atrial fibrillation has not been evaluated. Propafenone should not be used to control ventricular rate during atrial fibrillation. Propafenone is also indicated for the treatment of - documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. Because of the proarrhythmic effects of propafenone, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits out-weigh the risks. Initiation of propafenone treatment, as with other antiarrhythmics used to treat life-threatening ventricular arrhythmias, should be carried out in the hospital. Propafenone, like other antiarrhythmic drugs, has not been shown to enhance survival in patients with ventricular or atrial arrhythmias. uuid:a0ed424b-bec9-4319-8d2d-a3fa96834c6d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63619 biolink:treats HP:0004308 PMID:41385096 "[{""id"":""uuid:7ce847d0-f4ee-468e-865d-50b02b229fb7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:03f43b63-4887-40cb-89d0-f40f1b6b86af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In patients without structural heart disease, propafenone HCl is indicated to prolong the time to recurrence of - paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms. - paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms. As with other agents, some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional AV refractory period is recommended. The use of propafenone in patients with chronic atrial fibrillation has not been evaluated. Propafenone should not be used to control ventricular rate during atrial fibrillation. Propafenone is also indicated for the treatment of - documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. Because of the proarrhythmic effects of propafenone, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits out-weigh the risks. Initiation of propafenone treatment, as with other antiarrhythmics used to treat life-threatening ventricular arrhythmias, should be carried out in the hospital. Propafenone, like other antiarrhythmic drugs, has not been shown to enhance survival in patients with ventricular or atrial arrhythmias. uuid:ffac8b8c-e6f3-45ae-b2c5-00f3b91abb5a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63619 biolink:treats UMLS:C0750197 PMID:41385096 "[{""id"":""uuid:c9a0de95-a130-4d9e-95d0-872e84e02ff4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:db2b7f06-6d90-44b3-bf1f-cebb5597fbfb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In patients without structural heart disease, propafenone HCl is indicated to prolong the time to recurrence of - paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms. - paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms. As with other agents, some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional AV refractory period is recommended. The use of propafenone in patients with chronic atrial fibrillation has not been evaluated. Propafenone should not be used to control ventricular rate during atrial fibrillation. Propafenone is also indicated for the treatment of - documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. Because of the proarrhythmic effects of propafenone, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits out-weigh the risks. Initiation of propafenone treatment, as with other antiarrhythmics used to treat life-threatening ventricular arrhythmias, should be carried out in the hospital. Propafenone, like other antiarrhythmic drugs, has not been shown to enhance survival in patients with ventricular or atrial arrhythmias. uuid:9e326b9b-59e3-4bd5-b85f-ce9382b67dc5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63619 biolink:treats MONDO:0004981 PMID:41385096 "[{""id"":""uuid:d637bc55-787e-423a-9ee1-433551ba1e3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c7c4a1e6-690b-4a53-9b7e-a20d4549cc91"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In patients without structural heart disease, propafenone HCl is indicated to prolong the time to recurrence of - paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms. - paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms. As with other agents, some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional AV refractory period is recommended. The use of propafenone in patients with chronic atrial fibrillation has not been evaluated. Propafenone should not be used to control ventricular rate during atrial fibrillation. Propafenone is also indicated for the treatment of - documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. Because of the proarrhythmic effects of propafenone, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits out-weigh the risks. Initiation of propafenone treatment, as with other antiarrhythmics used to treat life-threatening ventricular arrhythmias, should be carried out in the hospital. Propafenone, like other antiarrhythmic drugs, has not been shown to enhance survival in patients with ventricular or atrial arrhythmias. uuid:6c45a92a-e75b-4c00-a560-a292ad432d7f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63619 biolink:treats MONDO:0005310 PMID:41385096 "[{""id"":""uuid:387bd96d-098f-4a5e-a945-a656eab43049"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:42e7128c-68f8-479a-8dc7-2a7efd6fdaf8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In patients without structural heart disease, propafenone HCl is indicated to prolong the time to recurrence of - paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms. - paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms. As with other agents, some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional AV refractory period is recommended. The use of propafenone in patients with chronic atrial fibrillation has not been evaluated. Propafenone should not be used to control ventricular rate during atrial fibrillation. Propafenone is also indicated for the treatment of - documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. Because of the proarrhythmic effects of propafenone, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits out-weigh the risks. Initiation of propafenone treatment, as with other antiarrhythmics used to treat life-threatening ventricular arrhythmias, should be carried out in the hospital. Propafenone, like other antiarrhythmic drugs, has not been shown to enhance survival in patients with ventricular or atrial arrhythmias. uuid:5c436f23-ab7c-4516-bed5-38f85a949a17 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4657 biolink:treats UMLS:C0750197 PMID:41385096 "[{""id"":""uuid:0d6dfb9e-027e-4704-a23a-22ba3b898fc4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f6a33de5-f977-437e-8bed-122bcf9eb2b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Disopyramide Phosphate Extended-release Capsules, USP are indicated for the treatment of documented ventricular arrhythmias such as sustained ventricular tachycardia, that in the judgement of the physician, are life-threatening. Because of the proarrhythmic effects of disopyramide, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of disopyramide treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. The extended-release capsules should not be used initially if rapid establishment of disopyramide plasma levels is desired. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. uuid:fdd64116-7e73-4fb1-b489-12491a46984a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4657 biolink:treats HP:0004308 PMID:41385096 "[{""id"":""uuid:9d020f94-2fef-48c0-bd12-1d788b43b6ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:38b3aebf-e778-487d-9ff6-c4251a584267"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Disopyramide Phosphate Extended-release Capsules, USP are indicated for the treatment of documented ventricular arrhythmias such as sustained ventricular tachycardia, that in the judgement of the physician, are life-threatening. Because of the proarrhythmic effects of disopyramide, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of disopyramide treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. The extended-release capsules should not be used initially if rapid establishment of disopyramide plasma levels is desired. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. uuid:1e707847-f91d-43bf-a3e6-0afd9c0f15ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4657 biolink:treats HP:0006682 PMID:41385096 "[{""id"":""uuid:8ab0d5ce-9198-4c19-9df4-288dbac24194"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:386d9277-435e-4188-afc9-8261a56d226d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Disopyramide Phosphate Extended-release Capsules, USP are indicated for the treatment of documented ventricular arrhythmias such as sustained ventricular tachycardia, that in the judgement of the physician, are life-threatening. Because of the proarrhythmic effects of disopyramide, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of disopyramide treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. The extended-release capsules should not be used initially if rapid establishment of disopyramide plasma levels is desired. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. uuid:3e89a9da-cf5e-4447-be17-87cdfa16bb79 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0005377 PMID:41385096 "[{""id"":""uuid:f1a74d24-c767-4ddd-b4c2-4fd409ced3e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eb46d58c-5246-4f98-82af-ca8e275b854e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PrednisoLONE Syrup (PrednisoLONE Oral Solution USP) is indicated in the following conditions: Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice: synthetic analogs may be used in conjunction with mineralocorticoids where applicable: in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and Iridocyclitis Respiratory Disorders Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate chemotherapy Aspiration pneumonitis Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. In addition to the above indications, PrednisoLONE Syrup (PrednisoLONE Oral Solution USP) is indicated for systemic dermatomyositis (polymyositis). uuid:3470f278-2ae6-473a-aaa6-3395a8b741aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2645731 biolink:treats MONDO:0005338 PMID:41385096 "[{""id"":""uuid:9942725d-b950-48d6-b125-fe3051e6092c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5061c674-784c-4046-b112-557706e1a4c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Betoptic ® Pilo Ophthalmic Suspension is indicated for the reduction of elevated intraocular pressure in patients with primary open-angle glaucoma and ocular hypertension who are insufficiently responsive to Betoptic ® -S (failed to achieve target IOP determined after multiple measurements over time). It is not known whether Betoptic ® Pilo is equivalent in IOP lowering efficacy to the administration of Betoptic ® -S 0.25% and pilocarpine 1.75% dosed separately. It is not known whether Betoptic ® Pilo is equivalent to other beta-blockers given in combination with pilocarpine. uuid:86faa95a-a2df-447d-9f86-68acfe278aa9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2645731 biolink:treats MONDO:0006875 PMID:41385096 "[{""id"":""uuid:f469e8d4-8ae6-44ac-b24b-b097c94c477a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8988243e-4d96-445b-90d9-323a62cb090e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Betoptic ® Pilo Ophthalmic Suspension is indicated for the reduction of elevated intraocular pressure in patients with primary open-angle glaucoma and ocular hypertension who are insufficiently responsive to Betoptic ® -S (failed to achieve target IOP determined after multiple measurements over time). It is not known whether Betoptic ® Pilo is equivalent in IOP lowering efficacy to the administration of Betoptic ® -S 0.25% and pilocarpine 1.75% dosed separately. It is not known whether Betoptic ® Pilo is equivalent to other beta-blockers given in combination with pilocarpine. uuid:7fdeeca1-efd7-4670-b353-5afeabce95fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3011 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:c5a4a9c4-c153-4a57-8a69-374d22212605"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:df1c86c8-1137-49a5-aa79-3154f6cb47ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Benazepril hydrochloride tablets are indicated for the treatment of hypertension. Benazepril hydrochloride tablets may be used alone or in combination with thiazide diuretics. In using benazepril hydrochloride tablets, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that benazepril hydrochloride tablets do not have a similar risk (see WARNINGS ). Black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to nonblacks. It should also be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in nonblacks. uuid:35c4b5da-c764-450f-8224-f8f5362250ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3011 biolink:treats MONDO:0001609 PMID:41385096 "[{""id"":""uuid:0147ad0a-f0a1-445f-9123-7a4b3246736f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:07b0979f-7ad8-4c4b-af48-9dd2a25f8f9a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Benazepril hydrochloride tablets are indicated for the treatment of hypertension. Benazepril hydrochloride tablets may be used alone or in combination with thiazide diuretics. In using benazepril hydrochloride tablets, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that benazepril hydrochloride tablets do not have a similar risk (see WARNINGS ). Black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to nonblacks. It should also be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in nonblacks. uuid:250da054-de39-422e-80c1-6ea8407972a7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3011 biolink:treats MONDO:0001343 PMID:41385096 "[{""id"":""uuid:2cf1e624-3fe1-4858-969a-f488d1414012"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5eaf4560-41b0-481a-bdfd-606f1fee69e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Benazepril hydrochloride tablets are indicated for the treatment of hypertension. Benazepril hydrochloride tablets may be used alone or in combination with thiazide diuretics. In using benazepril hydrochloride tablets, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that benazepril hydrochloride tablets do not have a similar risk (see WARNINGS ). Black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to nonblacks. It should also be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in nonblacks. uuid:4b962afc-2076-4927-9073-42606a8d2787 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3011 biolink:treats MONDO:0010481 PMID:41385096 "[{""id"":""uuid:7d1adaac-d1ff-4d6f-a7ee-23fc892efe64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4934fc55-3807-41f9-a62e-737ea09efe6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Benazepril hydrochloride tablets are indicated for the treatment of hypertension. Benazepril hydrochloride tablets may be used alone or in combination with thiazide diuretics. In using benazepril hydrochloride tablets, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that benazepril hydrochloride tablets do not have a similar risk (see WARNINGS ). Black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to nonblacks. It should also be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in nonblacks. uuid:cfbc423d-be08-41fe-a0b3-390f588d29c5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5790 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:d4dc6763-1225-4b6a-adc7-807b11978823"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:43e7b3b3-3d24-4c1d-93db-fdf09c9abc77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydromorphone hydrochloride tablets are indicated for the management of pain in patients where an opioid analgesic is appropriate. uuid:fa068cf3-f6b7-423e-aa5c-4caf3e8a759f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68638 biolink:treats MONDO:0006604 PMID:41385096 "[{""id"":""uuid:9469729e-d9c1-476e-82b8-dcb33c450a94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5324117c-ca41-42b5-8d4a-a6f0731966f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe. These include allergic conjunctivitis, acne rosacea, superficial punctate keratits, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivities when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical or thermal burns, or penetration of foreign bodies. uuid:476e2bce-887d-4079-9f2f-3315a59cf751 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68638 biolink:treats MONDO:0033816 PMID:41385096 "[{""id"":""uuid:f7ff5154-86eb-4cc0-a603-f39f79b48f6c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f40324be-5a1e-4ff0-aa67-aa77f354c7cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe. These include allergic conjunctivitis, acne rosacea, superficial punctate keratits, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivities when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical or thermal burns, or penetration of foreign bodies. uuid:9597bd69-3b4c-4cfb-91fc-03b1a87b3c90 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68638 biolink:treats UMLS:C1275687 PMID:41385096 "[{""id"":""uuid:52280c10-04fb-450d-9067-a21ba6a629b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dd146ef6-b230-4a0a-9224-0a7a51ddc6fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe. These include allergic conjunctivitis, acne rosacea, superficial punctate keratits, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivities when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical or thermal burns, or penetration of foreign bodies. uuid:8feca607-a39d-4cff-8190-5fae86a0e59a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68638 biolink:treats MONDO:0006814 PMID:41385096 "[{""id"":""uuid:385aaa8d-70b7-45a2-bedc-b2d280750150"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8f64ec2f-1e2b-4416-9171-cee938b0f666"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe. These include allergic conjunctivitis, acne rosacea, superficial punctate keratits, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivities when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical or thermal burns, or penetration of foreign bodies. uuid:0d63dc8e-b301-47de-a6f3-2011ab877a16 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68638 biolink:treats UMLS:C0010543 PMID:41385096 "[{""id"":""uuid:d33845e5-d6a3-460c-92b8-decc74eb7c4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:132e4d5d-d958-43fe-a103-69b65ae7b74f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe. These include allergic conjunctivitis, acne rosacea, superficial punctate keratits, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivities when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical or thermal burns, or penetration of foreign bodies. uuid:433eadb2-224c-4687-8463-705640cc1c43 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68638 biolink:treats UMLS:C0497209 PMID:41385096 "[{""id"":""uuid:d2534fcb-eda8-4fe8-913a-39dc93657d06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fd4754be-2a09-4be3-b6cb-4ee23b070094"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe. These include allergic conjunctivitis, acne rosacea, superficial punctate keratits, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivities when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical or thermal burns, or penetration of foreign bodies. uuid:eb43baa0-1019-4567-83e2-6abc6e47b5da biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68638 biolink:treats UMLS:C0339289 PMID:41385096 "[{""id"":""uuid:0b73ffc2-6402-4642-8275-f776719ecc00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0e7d5f50-c87f-467d-b6b9-a354577a98f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe. These include allergic conjunctivitis, acne rosacea, superficial punctate keratits, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivities when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical or thermal burns, or penetration of foreign bodies. uuid:b95083b6-b9ad-4ef3-a6cc-a4cc0221800c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4786 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:49cb2af9-7859-44cd-843c-8ecc3a702955"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e58db77c-f5fc-47f3-bfa7-ba8b62d8387a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Enalaprilat injection is indicated for the treatment of hypertension when oral therapy is not practical. Enalaprilat injection has been studied with only one other antihypertensive agent, furosemide, which showed approximately additive effects on blood pressure. Enalapril, the pro-drug of enalaprilat, has been used extensively with a variety of other antihypertensive agents, without apparent difficulty except for occasional hypotension. In using enalaprilat injection, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalaprilat injection does not have a similar risk (See WARNINGS ). In considering use of enalaprilat injection, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (See WARNINGS , Angioedema ). uuid:5305da68-b5b5-4be1-8b72-17047fd644a9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4786 biolink:treats MONDO:0001609 PMID:41385096 "[{""id"":""uuid:cdd98d33-2eb2-4b54-86ff-edbccc88654f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:19f67685-62f2-437a-b1ee-75543c70eccd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Enalaprilat injection is indicated for the treatment of hypertension when oral therapy is not practical. Enalaprilat injection has been studied with only one other antihypertensive agent, furosemide, which showed approximately additive effects on blood pressure. Enalapril, the pro-drug of enalaprilat, has been used extensively with a variety of other antihypertensive agents, without apparent difficulty except for occasional hypotension. In using enalaprilat injection, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalaprilat injection does not have a similar risk (See WARNINGS ). In considering use of enalaprilat injection, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (See WARNINGS , Angioedema ). uuid:28665683-0749-4474-9022-f6c6ec5c91c5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4786 biolink:treats MONDO:0001343 PMID:41385096 "[{""id"":""uuid:2a66010a-d628-4d69-8459-2ea80cca1fdd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3f1d249a-86bf-4a4d-b075-2f3f801a41c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Enalaprilat injection is indicated for the treatment of hypertension when oral therapy is not practical. Enalaprilat injection has been studied with only one other antihypertensive agent, furosemide, which showed approximately additive effects on blood pressure. Enalapril, the pro-drug of enalaprilat, has been used extensively with a variety of other antihypertensive agents, without apparent difficulty except for occasional hypotension. In using enalaprilat injection, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalaprilat injection does not have a similar risk (See WARNINGS ). In considering use of enalaprilat injection, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (See WARNINGS , Angioedema ). uuid:f7ca3cba-4586-4570-bb23-e0978671ba54 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4786 biolink:treats MONDO:0010481 PMID:41385096 "[{""id"":""uuid:a6c52ccb-a746-4299-bf5d-1042101e1736"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3e9a3310-8abb-4f8f-b26d-5604aa9e9304"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Enalaprilat injection is indicated for the treatment of hypertension when oral therapy is not practical. Enalaprilat injection has been studied with only one other antihypertensive agent, furosemide, which showed approximately additive effects on blood pressure. Enalapril, the pro-drug of enalaprilat, has been used extensively with a variety of other antihypertensive agents, without apparent difficulty except for occasional hypotension. In using enalaprilat injection, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalaprilat injection does not have a similar risk (See WARNINGS ). In considering use of enalaprilat injection, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (See WARNINGS , Angioedema ). uuid:6bb39c74-8809-4e35-847c-0f4ad73b1d16 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9362 biolink:treats HP:0000616 PMID:41385096 "[{""id"":""uuid:f0783c34-e173-4afa-9436-58778d32c28d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:acdc084e-3b7d-4bbf-844e-f1b106ef067f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROFENAL Ophthalmic Solution is indicated for inhibition of intraoperative miosis. uuid:8f7279aa-022f-4bff-b9f6-36e62b1e63e3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2682 biolink:treats MONDO:0000240 PMID:41385096 "[{""id"":""uuid:2d9e3420-daa5-4b7d-8bd2-b9b09a6e2f7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:611d8776-886f-4c53-9a60-768679e64607"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AMPHOTEC is indicated for the treatment of invasive aspergillosis in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B deoxycholate in effective doses, and in patients with invasive aspergillosis where prior amphotericin B deoxycholate therapy has failed. uuid:c3441901-c685-4809-918b-159c20670e53 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0006604 PMID:41385096 "[{""id"":""uuid:aed6fc00-6554-4138-9754-3425f566f495"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a3e5e351-c2f3-4ac8-b8e8-4e7719ba2e61"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctuate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. uuid:5717021d-e75d-4dbc-8fd9-a3b37d4ca8a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0001465 PMID:41385096 "[{""id"":""uuid:f096c395-b6d9-4f1f-be4c-26f12c1467fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8317adfa-24f8-468f-9125-f9cd60afa70d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctuate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. uuid:84e5bcc7-1d82-4ca9-aadf-138a1810cf00 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats UMLS:C1275687 PMID:41385096 "[{""id"":""uuid:68d6bdb7-6f30-46fc-8282-aeb529d976a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:105ac46c-fcac-4c3f-9458-61c5627fae5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctuate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. uuid:b6c3e5b9-45e0-4754-bd7a-1e8ef6ad8352 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0006814 PMID:41385096 "[{""id"":""uuid:e7823e22-e091-4b21-b073-af36ffe9e31a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e302ae3f-d321-4764-a3c7-a2887c224bd9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctuate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. uuid:81c34e9b-cf95-4188-89d9-6662a93a44fb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats UMLS:C0010543 PMID:41385096 "[{""id"":""uuid:bba14004-235a-41a5-9670-9de76356afb6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dcc91ec5-0c28-484a-b07c-f3df443faa2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctuate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. uuid:dde9bd7e-132c-470a-a132-6e258339e72b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0006668 PMID:41385096 "[{""id"":""uuid:7ec051c0-6e66-46d0-96eb-b6cb3a59817b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f222e83b-45d6-428b-9113-47a9cd304b72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctuate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. uuid:5537fe20-18b0-49d8-9bc6-040ded93c1f4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats UMLS:C0339289 PMID:41385096 "[{""id"":""uuid:5f4e424f-4441-4fe7-ac7f-ff677a533f9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bff6d99b-5ee3-4609-a896-22da7261de12"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctuate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. uuid:7b84a12b-9906-48db-bc7a-8e04ffcedcfc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:724125 biolink:treats MONDO:0005173 PMID:41385096 "[{""id"":""uuid:7628f9e6-4548-45a4-89ef-391f527d24cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:675b4d1e-e0c9-4e79-bb99-99d251977515"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metvixia Cream in combination with 570 to 670 nm wavelength red light illumination using the CureLight BroadBand Model CureLight 01 lamp is indicated for treatment of non-hyperkeratotic actinic keratoses of the face and scalp in immunocompetent patients when used in conjunction with lesion preparation (debridement using a sharp dermal curette) in the physician’s office when other therapies are unacceptable or considered medically less appropriate. uuid:f0b2bf17-9b21-459d-96f0-46db3219ddcf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0011786 PMID:41385096 "[{""id"":""uuid:b36bb758-d1c4-44e9-a263-e267b34cd5cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:42f00851-d3ed-4bc8-8215-d17ac4060bec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisolone syrup is indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice: synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia ( RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. In addition to the above indications prednisolone syrup is indicated for systemic dermatomyositis (polymyositis). uuid:6ea997fa-001a-4e6b-bcb5-0db7b5cdbf9e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0009197 PMID:41385096 "[{""id"":""uuid:4586aedf-303b-4074-a759-d527c1d9af04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4c0aef47-7dbd-42bf-a7ac-8563e32e7bb9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisolone syrup is indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice: synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia ( RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. In addition to the above indications prednisolone syrup is indicated for systemic dermatomyositis (polymyositis). uuid:c660eaec-d5c2-4ff4-a226-21934337208a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6060 biolink:treats MONDO:0005041 PMID:41385096 "[{""id"":""uuid:48a87719-071a-4bae-a2f2-a6f7193279ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9c0d81a4-1283-4b5a-bde7-2d8aedb26754"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the short-term reduction of intraocular pressure. May be used prior to and after intraocular surgery. May be used to interrupt an acute attack of glaucoma. uuid:911f606d-054f-486d-bcad-a8bda912f371 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9613 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:b84e1abb-efb0-4b34-a3ea-354809097c92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6ceab387-90c4-41ba-9067-4ceb05b544b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tolazamide tablets are indicated as an adjunct to diet to lower the blood glucose in patients with noninsulin-dependent diabetes mellitus (Type II) whose hyperglycemia cannot be satisfactorily controlled by diet alone. In initiating treatment for noninsulin-dependent diabetes, diet should be emphasized as the primary form of treatment. Caloric restriction and weight loss are essential in the obese diabetic patient. Proper dietary management alone may be effective in controlling the blood glucose and symptoms of hyperglycemia. The importance of regular physical activity should also be stressed and cardiovascular risk factors should be identified and corrective measures taken where possible. If this treatment program fails to reduce symptoms and/or blood glucose, the use of an oral sulfonylurea or insulin should be considered. Use of tolazamide must be viewed by both the physician and patient as a treatment in addition to diet and not as a substitute for diet or as a convenient mechanism for avoiding dietary restraint. Furthermore, loss of blood glucose control on diet alone may be transient thus requiring only short-term administration of tolazamide. During maintenance programs, tolazamide should be discontinued if satisfactory lowering of blood glucose is no longer achieved. Judgments should be based on regular clinical and laboratory evaluations. In considering the use of tolazamide in asymptomatic patients, it should be recognized that controlling the blood glucose in noninsulin-dependent diabetes has not been definitely established to be effective in preventing the long-term cardiovascular or neural complications of diabetes. uuid:d6a1efd7-330e-4413-a363-5b1498c75723 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4717 biolink:treats HP:0002018 PMID:41385096 "[{""id"":""uuid:7491fadc-b153-472b-97e7-4288f03da539"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fdc9b8e2-5f8a-47f6-b63d-075a2fe83539"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INAPSINE (droperidol) is indicated to reduce the incidence of nausea and vomiting associated with surgical and diagnostic procedures. uuid:827d9712-6991-4ceb-b62d-75d7dfcf8aa4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4717 biolink:treats HP:0002013 PMID:41385096 "[{""id"":""uuid:48a608c4-4878-440a-8e4e-31dcba7081b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8c718942-c5fb-4fd9-82ce-aad2b6039dc2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INAPSINE (droperidol) is indicated to reduce the incidence of nausea and vomiting associated with surgical and diagnostic procedures. uuid:232e0d71-479c-410f-8541-16c84e827fa0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6427 biolink:treats MONDO:0004956 PMID:41385096 "[{""id"":""uuid:106ad5c6-c61b-4039-a025-517348ceb56f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d7b3ff5e-0eb6-4731-b709-77466a4d9039"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LUPRON INJECTION (leuprolide acetate) is indicated in the palliative treatment of advanced prostatic cancer. uuid:11291042-6cee-4ed5-a686-4d7d12a3daf3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28864 biolink:treats MONDO:0700217 PMID:41385096 "[{""id"":""uuid:275c71a7-59ad-41c8-83a9-7b68c5bc8c5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6a6b19e1-311a-4ee1-b559-8b66aa72a5c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Tobramycin Injection USP and other antibacterial drugs, Tobramycin Injection USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tobramycin is indicated for the treatment of serious bacterial infections caused by susceptible strains of the designated microorganisms in the diseases listed below: Septicemia in the pediatric patient and adult caused by P. aeruginosa, E. coli., and Klebsiella spp Lower respiratory tract infections caused by P. aeruginosa, Klebsiella spp, Enterobacter spp, Serratia spp, E. coli, and S. aureus (penicillinase and non-penicillinase-producing strains) Serious central nervous system infections (meningitis) caused by susceptible organisms. Intra-abdominal infections, including peritonitis, caused by E. coli, Klebsiella spp, and Enterobacter spp Skin, bone, and skin-structure infections caused by P. aeruginosa, Proteus spp, E. coli, Klebsiella spp, Enterobacter spp, and S. aureus Complicated and recurrent urinary tract infections caused by P. aeruginosa, Proteus spp (indole-positive and indole-negative), E. coli, Klebsiella spp, Enterobacter spp, Serratia spp, S. aureus, Providencia, and Citrobacter spp Aminoglycosides, including tobramycin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Tobramycin may be considered in serious staphylococcal infections when penicillin or other potentially less toxic drugs are contraindicated and when bacterial susceptibility testing and clinical judgment indicate its use. Bacterial cultures should be obtained prior to and during treatment to isolate and identify etiologic organisms and to test their susceptibility to tobramycin. If susceptibility tests show that the causative organisms are resistant to tobramycin, other appropriate therapy should be instituted. In patients in whom a serious life-threatening gram-negative infection is suspected, including those in whom concurrent therapy with penicillin or cephalosporin and an aminoglycoside may be indicated, treatment with tobramycin may be initiated before the results of susceptibility studies are obtained. The decision to continue therapy with tobramycin should be based on the results of susceptibility studies, the severity of the infection, and the important additional concepts discussed in the WARNINGS box above. uuid:53a53190-2cc7-4c67-88c2-6a234b45ebd7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28864 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:0ab3d150-6cbf-4e6f-a7ab-8ba2ef1c6d4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2255e8eb-adac-44ef-9c8e-56661846f39f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a4b19955-3941-4f04-8753-7b4cbbecfcd0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Tobramycin Injection USP and other antibacterial drugs, Tobramycin Injection USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tobramycin is indicated for the treatment of serious bacterial infections caused by susceptible strains of the designated microorganisms in the diseases listed below: Septicemia in the pediatric patient and adult caused by P. aeruginosa, E. coli., and Klebsiella spp Lower respiratory tract infections caused by P. aeruginosa, Klebsiella spp, Enterobacter spp, Serratia spp, E. coli, and S. aureus (penicillinase and non-penicillinase-producing strains) Serious central nervous system infections (meningitis) caused by susceptible organisms. Intra-abdominal infections, including peritonitis, caused by E. coli, Klebsiella spp, and Enterobacter spp Skin, bone, and skin-structure infections caused by P. aeruginosa, Proteus spp, E. coli, Klebsiella spp, Enterobacter spp, and S. aureus Complicated and recurrent urinary tract infections caused by P. aeruginosa, Proteus spp (indole-positive and indole-negative), E. coli, Klebsiella spp, Enterobacter spp, Serratia spp, S. aureus, Providencia, and Citrobacter spp Aminoglycosides, including tobramycin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Tobramycin may be considered in serious staphylococcal infections when penicillin or other potentially less toxic drugs are contraindicated and when bacterial susceptibility testing and clinical judgment indicate its use. Bacterial cultures should be obtained prior to and during treatment to isolate and identify etiologic organisms and to test their susceptibility to tobramycin. If susceptibility tests show that the causative organisms are resistant to tobramycin, other appropriate therapy should be instituted. In patients in whom a serious life-threatening gram-negative infection is suspected, including those in whom concurrent therapy with penicillin or cephalosporin and an aminoglycoside may be indicated, treatment with tobramycin may be initiated before the results of susceptibility studies are obtained. The decision to continue therapy with tobramycin should be based on the results of susceptibility studies, the severity of the infection, and the important additional concepts discussed in the WARNINGS box above.|[PMDA] A drug with a new route of administration indicated for the improvement of symptoms associated with respiratory infection caused by Pseudomonas aeruginosa in cystic fibrosis patients. uuid:b77d5482-e155-416d-bbeb-a157ebd6381e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28864 biolink:treats MONDO:0021108 PMID:41385096 "[{""id"":""uuid:1c8122b9-0817-482d-951c-191209867dae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d68b16ae-6652-40e9-9ffb-91bdaf0a439d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Tobramycin Injection USP and other antibacterial drugs, Tobramycin Injection USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tobramycin is indicated for the treatment of serious bacterial infections caused by susceptible strains of the designated microorganisms in the diseases listed below: Septicemia in the pediatric patient and adult caused by P. aeruginosa, E. coli., and Klebsiella spp Lower respiratory tract infections caused by P. aeruginosa, Klebsiella spp, Enterobacter spp, Serratia spp, E. coli, and S. aureus (penicillinase and non-penicillinase-producing strains) Serious central nervous system infections (meningitis) caused by susceptible organisms. Intra-abdominal infections, including peritonitis, caused by E. coli, Klebsiella spp, and Enterobacter spp Skin, bone, and skin-structure infections caused by P. aeruginosa, Proteus spp, E. coli, Klebsiella spp, Enterobacter spp, and S. aureus Complicated and recurrent urinary tract infections caused by P. aeruginosa, Proteus spp (indole-positive and indole-negative), E. coli, Klebsiella spp, Enterobacter spp, Serratia spp, S. aureus, Providencia, and Citrobacter spp Aminoglycosides, including tobramycin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Tobramycin may be considered in serious staphylococcal infections when penicillin or other potentially less toxic drugs are contraindicated and when bacterial susceptibility testing and clinical judgment indicate its use. Bacterial cultures should be obtained prior to and during treatment to isolate and identify etiologic organisms and to test their susceptibility to tobramycin. If susceptibility tests show that the causative organisms are resistant to tobramycin, other appropriate therapy should be instituted. In patients in whom a serious life-threatening gram-negative infection is suspected, including those in whom concurrent therapy with penicillin or cephalosporin and an aminoglycoside may be indicated, treatment with tobramycin may be initiated before the results of susceptibility studies are obtained. The decision to continue therapy with tobramycin should be based on the results of susceptibility studies, the severity of the infection, and the important additional concepts discussed in the WARNINGS box above. uuid:90ee9fe9-96ed-422c-839a-b408e2a13ed7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28864 biolink:treats UMLS:C1112209 PMID:41385096 "[{""id"":""uuid:59a22021-5484-4429-9054-dc423b588493"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d7761d19-ca83-4bf7-b53a-a16f57fa63ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Tobramycin Injection USP and other antibacterial drugs, Tobramycin Injection USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tobramycin is indicated for the treatment of serious bacterial infections caused by susceptible strains of the designated microorganisms in the diseases listed below: Septicemia in the pediatric patient and adult caused by P. aeruginosa, E. coli., and Klebsiella spp Lower respiratory tract infections caused by P. aeruginosa, Klebsiella spp, Enterobacter spp, Serratia spp, E. coli, and S. aureus (penicillinase and non-penicillinase-producing strains) Serious central nervous system infections (meningitis) caused by susceptible organisms. Intra-abdominal infections, including peritonitis, caused by E. coli, Klebsiella spp, and Enterobacter spp Skin, bone, and skin-structure infections caused by P. aeruginosa, Proteus spp, E. coli, Klebsiella spp, Enterobacter spp, and S. aureus Complicated and recurrent urinary tract infections caused by P. aeruginosa, Proteus spp (indole-positive and indole-negative), E. coli, Klebsiella spp, Enterobacter spp, Serratia spp, S. aureus, Providencia, and Citrobacter spp Aminoglycosides, including tobramycin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Tobramycin may be considered in serious staphylococcal infections when penicillin or other potentially less toxic drugs are contraindicated and when bacterial susceptibility testing and clinical judgment indicate its use. Bacterial cultures should be obtained prior to and during treatment to isolate and identify etiologic organisms and to test their susceptibility to tobramycin. If susceptibility tests show that the causative organisms are resistant to tobramycin, other appropriate therapy should be instituted. In patients in whom a serious life-threatening gram-negative infection is suspected, including those in whom concurrent therapy with penicillin or cephalosporin and an aminoglycoside may be indicated, treatment with tobramycin may be initiated before the results of susceptibility studies are obtained. The decision to continue therapy with tobramycin should be based on the results of susceptibility studies, the severity of the infection, and the important additional concepts discussed in the WARNINGS box above. uuid:8c703ccc-f488-4181-b445-ed87000fe8cc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28864 biolink:treats MONDO:0004522 PMID:41385096 "[{""id"":""uuid:57bb2a3c-23dc-4c6e-bcda-25f24ba3b29c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cc0b9991-9eb6-46ee-ace1-82fcc2975daa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Tobramycin Injection USP and other antibacterial drugs, Tobramycin Injection USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tobramycin is indicated for the treatment of serious bacterial infections caused by susceptible strains of the designated microorganisms in the diseases listed below: Septicemia in the pediatric patient and adult caused by P. aeruginosa, E. coli., and Klebsiella spp Lower respiratory tract infections caused by P. aeruginosa, Klebsiella spp, Enterobacter spp, Serratia spp, E. coli, and S. aureus (penicillinase and non-penicillinase-producing strains) Serious central nervous system infections (meningitis) caused by susceptible organisms. Intra-abdominal infections, including peritonitis, caused by E. coli, Klebsiella spp, and Enterobacter spp Skin, bone, and skin-structure infections caused by P. aeruginosa, Proteus spp, E. coli, Klebsiella spp, Enterobacter spp, and S. aureus Complicated and recurrent urinary tract infections caused by P. aeruginosa, Proteus spp (indole-positive and indole-negative), E. coli, Klebsiella spp, Enterobacter spp, Serratia spp, S. aureus, Providencia, and Citrobacter spp Aminoglycosides, including tobramycin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Tobramycin may be considered in serious staphylococcal infections when penicillin or other potentially less toxic drugs are contraindicated and when bacterial susceptibility testing and clinical judgment indicate its use. Bacterial cultures should be obtained prior to and during treatment to isolate and identify etiologic organisms and to test their susceptibility to tobramycin. If susceptibility tests show that the causative organisms are resistant to tobramycin, other appropriate therapy should be instituted. In patients in whom a serious life-threatening gram-negative infection is suspected, including those in whom concurrent therapy with penicillin or cephalosporin and an aminoglycoside may be indicated, treatment with tobramycin may be initiated before the results of susceptibility studies are obtained. The decision to continue therapy with tobramycin should be based on the results of susceptibility studies, the severity of the infection, and the important additional concepts discussed in the WARNINGS box above. uuid:4cdb799f-0fd5-4382-9690-ff08fa0e9dde biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28864 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:d9ea33aa-f0a4-4c35-96e0-6ddc263372f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:40ad0122-5bd7-4d3d-8fc8-070e71657a88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Tobramycin Injection USP and other antibacterial drugs, Tobramycin Injection USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tobramycin is indicated for the treatment of serious bacterial infections caused by susceptible strains of the designated microorganisms in the diseases listed below: Septicemia in the pediatric patient and adult caused by P. aeruginosa, E. coli., and Klebsiella spp Lower respiratory tract infections caused by P. aeruginosa, Klebsiella spp, Enterobacter spp, Serratia spp, E. coli, and S. aureus (penicillinase and non-penicillinase-producing strains) Serious central nervous system infections (meningitis) caused by susceptible organisms. Intra-abdominal infections, including peritonitis, caused by E. coli, Klebsiella spp, and Enterobacter spp Skin, bone, and skin-structure infections caused by P. aeruginosa, Proteus spp, E. coli, Klebsiella spp, Enterobacter spp, and S. aureus Complicated and recurrent urinary tract infections caused by P. aeruginosa, Proteus spp (indole-positive and indole-negative), E. coli, Klebsiella spp, Enterobacter spp, Serratia spp, S. aureus, Providencia, and Citrobacter spp Aminoglycosides, including tobramycin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Tobramycin may be considered in serious staphylococcal infections when penicillin or other potentially less toxic drugs are contraindicated and when bacterial susceptibility testing and clinical judgment indicate its use. Bacterial cultures should be obtained prior to and during treatment to isolate and identify etiologic organisms and to test their susceptibility to tobramycin. If susceptibility tests show that the causative organisms are resistant to tobramycin, other appropriate therapy should be instituted. In patients in whom a serious life-threatening gram-negative infection is suspected, including those in whom concurrent therapy with penicillin or cephalosporin and an aminoglycoside may be indicated, treatment with tobramycin may be initiated before the results of susceptibility studies are obtained. The decision to continue therapy with tobramycin should be based on the results of susceptibility studies, the severity of the infection, and the important additional concepts discussed in the WARNINGS box above. uuid:aa64c1cd-5833-4078-9e49-46cf9d810826 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28864 biolink:treats MONDO:0005246 PMID:41385096 "[{""id"":""uuid:3d4fe91f-059c-4ed4-8901-a2d26dddfc0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:297ddced-4e69-4a91-8cb5-d850cbf2015c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Tobramycin Injection USP and other antibacterial drugs, Tobramycin Injection USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tobramycin is indicated for the treatment of serious bacterial infections caused by susceptible strains of the designated microorganisms in the diseases listed below: Septicemia in the pediatric patient and adult caused by P. aeruginosa, E. coli., and Klebsiella spp Lower respiratory tract infections caused by P. aeruginosa, Klebsiella spp, Enterobacter spp, Serratia spp, E. coli, and S. aureus (penicillinase and non-penicillinase-producing strains) Serious central nervous system infections (meningitis) caused by susceptible organisms. Intra-abdominal infections, including peritonitis, caused by E. coli, Klebsiella spp, and Enterobacter spp Skin, bone, and skin-structure infections caused by P. aeruginosa, Proteus spp, E. coli, Klebsiella spp, Enterobacter spp, and S. aureus Complicated and recurrent urinary tract infections caused by P. aeruginosa, Proteus spp (indole-positive and indole-negative), E. coli, Klebsiella spp, Enterobacter spp, Serratia spp, S. aureus, Providencia, and Citrobacter spp Aminoglycosides, including tobramycin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Tobramycin may be considered in serious staphylococcal infections when penicillin or other potentially less toxic drugs are contraindicated and when bacterial susceptibility testing and clinical judgment indicate its use. Bacterial cultures should be obtained prior to and during treatment to isolate and identify etiologic organisms and to test their susceptibility to tobramycin. If susceptibility tests show that the causative organisms are resistant to tobramycin, other appropriate therapy should be instituted. In patients in whom a serious life-threatening gram-negative infection is suspected, including those in whom concurrent therapy with penicillin or cephalosporin and an aminoglycoside may be indicated, treatment with tobramycin may be initiated before the results of susceptibility studies are obtained. The decision to continue therapy with tobramycin should be based on the results of susceptibility studies, the severity of the infection, and the important additional concepts discussed in the WARNINGS box above. uuid:3f2c6386-9430-4782-8af7-b95456f4ca66 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28864 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:4e2c0ef8-6bc7-4689-a3a1-7fd3d6549b6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:076ce1b1-e39b-49e9-b494-73b36b657535"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Tobramycin Injection USP and other antibacterial drugs, Tobramycin Injection USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tobramycin is indicated for the treatment of serious bacterial infections caused by susceptible strains of the designated microorganisms in the diseases listed below: Septicemia in the pediatric patient and adult caused by P. aeruginosa, E. coli., and Klebsiella spp Lower respiratory tract infections caused by P. aeruginosa, Klebsiella spp, Enterobacter spp, Serratia spp, E. coli, and S. aureus (penicillinase and non-penicillinase-producing strains) Serious central nervous system infections (meningitis) caused by susceptible organisms. Intra-abdominal infections, including peritonitis, caused by E. coli, Klebsiella spp, and Enterobacter spp Skin, bone, and skin-structure infections caused by P. aeruginosa, Proteus spp, E. coli, Klebsiella spp, Enterobacter spp, and S. aureus Complicated and recurrent urinary tract infections caused by P. aeruginosa, Proteus spp (indole-positive and indole-negative), E. coli, Klebsiella spp, Enterobacter spp, Serratia spp, S. aureus, Providencia, and Citrobacter spp Aminoglycosides, including tobramycin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Tobramycin may be considered in serious staphylococcal infections when penicillin or other potentially less toxic drugs are contraindicated and when bacterial susceptibility testing and clinical judgment indicate its use. Bacterial cultures should be obtained prior to and during treatment to isolate and identify etiologic organisms and to test their susceptibility to tobramycin. If susceptibility tests show that the causative organisms are resistant to tobramycin, other appropriate therapy should be instituted. In patients in whom a serious life-threatening gram-negative infection is suspected, including those in whom concurrent therapy with penicillin or cephalosporin and an aminoglycoside may be indicated, treatment with tobramycin may be initiated before the results of susceptibility studies are obtained. The decision to continue therapy with tobramycin should be based on the results of susceptibility studies, the severity of the infection, and the important additional concepts discussed in the WARNINGS box above. uuid:54f375d9-af2d-4e23-80c8-c28158e58971 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28864 biolink:treats HP:0000010 PMID:41385096 "[{""id"":""uuid:7bf50d2a-c5da-4699-8e8b-e4bd56a6fbad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:547038d3-8b31-4cd3-b1be-164800058139"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Tobramycin Injection USP and other antibacterial drugs, Tobramycin Injection USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tobramycin is indicated for the treatment of serious bacterial infections caused by susceptible strains of the designated microorganisms in the diseases listed below: Septicemia in the pediatric patient and adult caused by P. aeruginosa, E. coli., and Klebsiella spp Lower respiratory tract infections caused by P. aeruginosa, Klebsiella spp, Enterobacter spp, Serratia spp, E. coli, and S. aureus (penicillinase and non-penicillinase-producing strains) Serious central nervous system infections (meningitis) caused by susceptible organisms. Intra-abdominal infections, including peritonitis, caused by E. coli, Klebsiella spp, and Enterobacter spp Skin, bone, and skin-structure infections caused by P. aeruginosa, Proteus spp, E. coli, Klebsiella spp, Enterobacter spp, and S. aureus Complicated and recurrent urinary tract infections caused by P. aeruginosa, Proteus spp (indole-positive and indole-negative), E. coli, Klebsiella spp, Enterobacter spp, Serratia spp, S. aureus, Providencia, and Citrobacter spp Aminoglycosides, including tobramycin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Tobramycin may be considered in serious staphylococcal infections when penicillin or other potentially less toxic drugs are contraindicated and when bacterial susceptibility testing and clinical judgment indicate its use. Bacterial cultures should be obtained prior to and during treatment to isolate and identify etiologic organisms and to test their susceptibility to tobramycin. If susceptibility tests show that the causative organisms are resistant to tobramycin, other appropriate therapy should be instituted. In patients in whom a serious life-threatening gram-negative infection is suspected, including those in whom concurrent therapy with penicillin or cephalosporin and an aminoglycoside may be indicated, treatment with tobramycin may be initiated before the results of susceptibility studies are obtained. The decision to continue therapy with tobramycin should be based on the results of susceptibility studies, the severity of the infection, and the important additional concepts discussed in the WARNINGS box above. uuid:c005da8f-0f3a-4ff6-af61-2ba0e74df782 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28864 biolink:treats MONDO:0024313 PMID:41385096 "[{""id"":""uuid:5bf9f840-cd57-4b77-939f-2003cfb45b08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:80415660-528f-468c-924a-4e7fb3af4bb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Tobramycin Injection USP and other antibacterial drugs, Tobramycin Injection USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tobramycin is indicated for the treatment of serious bacterial infections caused by susceptible strains of the designated microorganisms in the diseases listed below: Septicemia in the pediatric patient and adult caused by P. aeruginosa, E. coli., and Klebsiella spp Lower respiratory tract infections caused by P. aeruginosa, Klebsiella spp, Enterobacter spp, Serratia spp, E. coli, and S. aureus (penicillinase and non-penicillinase-producing strains) Serious central nervous system infections (meningitis) caused by susceptible organisms. Intra-abdominal infections, including peritonitis, caused by E. coli, Klebsiella spp, and Enterobacter spp Skin, bone, and skin-structure infections caused by P. aeruginosa, Proteus spp, E. coli, Klebsiella spp, Enterobacter spp, and S. aureus Complicated and recurrent urinary tract infections caused by P. aeruginosa, Proteus spp (indole-positive and indole-negative), E. coli, Klebsiella spp, Enterobacter spp, Serratia spp, S. aureus, Providencia, and Citrobacter spp Aminoglycosides, including tobramycin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Tobramycin may be considered in serious staphylococcal infections when penicillin or other potentially less toxic drugs are contraindicated and when bacterial susceptibility testing and clinical judgment indicate its use. Bacterial cultures should be obtained prior to and during treatment to isolate and identify etiologic organisms and to test their susceptibility to tobramycin. If susceptibility tests show that the causative organisms are resistant to tobramycin, other appropriate therapy should be instituted. In patients in whom a serious life-threatening gram-negative infection is suspected, including those in whom concurrent therapy with penicillin or cephalosporin and an aminoglycoside may be indicated, treatment with tobramycin may be initiated before the results of susceptibility studies are obtained. The decision to continue therapy with tobramycin should be based on the results of susceptibility studies, the severity of the infection, and the important additional concepts discussed in the WARNINGS box above. uuid:d33c3f30-82e7-41a1-aead-4c5ec15055dc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4784 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:0643e4e3-4ceb-42cd-a43a-7a6e0af7dfea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:73abdfeb-25e6-485d-9ba9-3a14a8d0f597"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7934529b-b238-40aa-8214-3779efc3ec0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Enalapril maleate is indicated for the treatment of hypertension. Enalapril maleate is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of enalapril maleate and thiazides are approximately additive. Heart Failure Enalapril maleate is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. In these patients enalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization (see CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials). Asymptomatic Left Ventricular Dysfunction In clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction <35 percent), enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure. (See CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials.) In using enalapril maleate consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril maleate does not have a similar risk. (See WARNINGS. ) In considering use of enalapril maleate, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks. (See WARNINGS, Angioedema. )|[PMDA] Drugs with a new additional pediatric dosage. These drugs are indicated for the treatment of hypertension. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:8ee518c6-81fd-4658-bd6b-76078686d6f4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4784 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:ed560f5b-46a0-46f9-a6ea-e1f387627ee8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e0c67c62-01d9-4c27-9818-46ba75be14e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Enalapril maleate is indicated for the treatment of hypertension. Enalapril maleate is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of enalapril maleate and thiazides are approximately additive. Heart Failure Enalapril maleate is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. In these patients enalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization (see CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials). Asymptomatic Left Ventricular Dysfunction In clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction <35 percent), enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure. (See CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials.) In using enalapril maleate consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril maleate does not have a similar risk. (See WARNINGS. ) In considering use of enalapril maleate, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks. (See WARNINGS, Angioedema. ) uuid:85541157-e4c5-4cbd-a08a-a8338f9b6015 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4784 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:a155c481-2970-45a7-9dfd-fe235a6274a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:09eb38c2-d820-4aaf-a6e2-98a3d13d89c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2b1e6379-3b4c-4070-a99a-852c66df8f8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Enalapril maleate is indicated for the treatment of hypertension. Enalapril maleate is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of enalapril maleate and thiazides are approximately additive. Heart Failure Enalapril maleate is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. In these patients enalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization (see CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials). Asymptomatic Left Ventricular Dysfunction In clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction <35 percent), enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure. (See CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials.) In using enalapril maleate consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril maleate does not have a similar risk. (See WARNINGS. ) In considering use of enalapril maleate, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks. (See WARNINGS, Angioedema. )|[EMA] Treatment of heart failure. uuid:3e950995-9350-4ec1-a3cd-419d23d0a6b7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4469 biolink:treats MONDO:0021107 PMID:41385096 "[{""id"":""uuid:1e456e21-a613-48e7-af7e-bc8874a8d69e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e9765bf0-c10f-4481-965e-d96457329cd2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dextroamphetamine sulfate tablets are indicated in: 1. Narcolepsy . 2. Attention Deficit Disorder with Hyperactivity : As an integral part of a total treatment program that typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in pediatric patients (ages 3 years to 16 years) with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted. uuid:e3488bbd-6bf6-46f4-8361-784469f4272e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4469 biolink:treats MONDO:0007743 PMID:41385096 "[{""id"":""uuid:a03233a5-ba31-4703-ab9a-5503dfc67d0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:322082fa-8443-4f8d-b03f-70c95cf06b0f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dextroamphetamine sulfate tablets are indicated in: 1. Narcolepsy . 2. Attention Deficit Disorder with Hyperactivity : As an integral part of a total treatment program that typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in pediatric patients (ages 3 years to 16 years) with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted. uuid:85e0fa8a-e2cc-4568-b2c6-a936b8891b41 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5931 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:350710e3-5c4f-4bdc-adbc-14ecd5112d9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:707fee45-24b6-4fb5-9400-ff8921820925"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:849c898c-ca96-4b06-85fe-322a6f9734ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/semglee""]},{""id"":""uuid:33540c9c-5999-4754-86d0-22d58c47d0e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EXUBERA is indicated for the treatment of adult patients with diabetes mellitus for the control of hyperglycemia. EXUBERA has an onset of action similar to rapid-acting insulin analogs and has a duration of glucose-lowering activity comparable to subcutaneously administered regular human insulin. In patients with type 1 diabetes, EXUBERA should be used in regimens that include a longer-acting insulin. In patients with type 2 diabetes, EXUBERA can be used as monotherapy or in combination with oral agents or longer-acting insulins.|[EMA] Treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above.|[PMDA] A drug in a new dosage form indicated for the treatment of diabetes mellitus in cases where insulin therapy is indicated. uuid:a84a8202-eab8-453b-9883-20d408027dae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5931 biolink:treats MONDO:0002909 PMID:41385096 "[{""id"":""uuid:3b8d480b-1dc3-4ae7-a7cc-3e82dd5f8786"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:99d31c4a-7838-4896-858b-c6a228807d52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EXUBERA is indicated for the treatment of adult patients with diabetes mellitus for the control of hyperglycemia. EXUBERA has an onset of action similar to rapid-acting insulin analogs and has a duration of glucose-lowering activity comparable to subcutaneously administered regular human insulin. In patients with type 1 diabetes, EXUBERA should be used in regimens that include a longer-acting insulin. In patients with type 2 diabetes, EXUBERA can be used as monotherapy or in combination with oral agents or longer-acting insulins. uuid:f43bff19-d8c4-4fac-861b-b943e9edde14 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5931 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:4b4305f8-9946-4eb3-ae41-aa82701aa98f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:881d9a55-8960-466a-8b7d-89e9c29fbb85"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EXUBERA is indicated for the treatment of adult patients with diabetes mellitus for the control of hyperglycemia. EXUBERA has an onset of action similar to rapid-acting insulin analogs and has a duration of glucose-lowering activity comparable to subcutaneously administered regular human insulin. In patients with type 1 diabetes, EXUBERA should be used in regimens that include a longer-acting insulin. In patients with type 2 diabetes, EXUBERA can be used as monotherapy or in combination with oral agents or longer-acting insulins. uuid:7ee9237f-5ace-4ca6-b287-4613fabd86f0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5931 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:e7fd62df-8398-416c-bfea-b382d6b0e51c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:df20f7a1-3486-4402-8140-708ba61202e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EXUBERA is indicated for the treatment of adult patients with diabetes mellitus for the control of hyperglycemia. EXUBERA has an onset of action similar to rapid-acting insulin analogs and has a duration of glucose-lowering activity comparable to subcutaneously administered regular human insulin. In patients with type 1 diabetes, EXUBERA should be used in regimens that include a longer-acting insulin. In patients with type 2 diabetes, EXUBERA can be used as monotherapy or in combination with oral agents or longer-acting insulins. uuid:39f6c275-f52f-4bb9-ac2f-12febd1e7832 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2676 biolink:treats MONDO:0021666 PMID:41385096 "[{""id"":""uuid:cca46083-b49a-4794-85eb-ad823f603c5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:db675f22-ba24-4ecd-9b98-503852f56932"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and other antibacterial drugs, amoxicillin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Amoxicillin is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) strains of the designated microorganisms in the conditions listed below: Infections of the ear, nose, and throat –due to Streptococcus spp. (α- and β-hemolytic strains only), Streptococcus pneumoniae, Staphylococcus spp., or H. influenzae. Infections of the genitourinary tract – due to E. coli, P. mirabilis, or E. faecalis. Infections of the skin and skin structure – due to Streptococcus spp. (α- and β-hemolytic strains only), Staphylococcus spp., or E. coli. Infections of the lower respiratory tract due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Gonorrhea, acute uncomplicated (ano-genital and urethral infections) due to N. gonorrhoeae (males and females). H. pylori eradication to reduce the risk of duodenal ulcer recurrence Triple therapy: Amoxicillin /clarithromycin/lansoprazole Amoxicillin, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION . ) Dual therapy: Amoxicillin/lansoprazole Amoxicillin, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION . ) Indicated surgical procedures should be performed. uuid:08dcd5a2-d677-4500-ac91-532d88b2a0c3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2676 biolink:treats MONDO:0002436 PMID:41385096 "[{""id"":""uuid:df8a628b-3395-4424-b0be-238f32846b83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4aafa823-d780-4541-9cda-5136c919f6a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and other antibacterial drugs, amoxicillin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Amoxicillin is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) strains of the designated microorganisms in the conditions listed below: Infections of the ear, nose, and throat –due to Streptococcus spp. (α- and β-hemolytic strains only), Streptococcus pneumoniae, Staphylococcus spp., or H. influenzae. Infections of the genitourinary tract – due to E. coli, P. mirabilis, or E. faecalis. Infections of the skin and skin structure – due to Streptococcus spp. (α- and β-hemolytic strains only), Staphylococcus spp., or E. coli. Infections of the lower respiratory tract due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Gonorrhea, acute uncomplicated (ano-genital and urethral infections) due to N. gonorrhoeae (males and females). H. pylori eradication to reduce the risk of duodenal ulcer recurrence Triple therapy: Amoxicillin /clarithromycin/lansoprazole Amoxicillin, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION . ) Dual therapy: Amoxicillin/lansoprazole Amoxicillin, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION . ) Indicated surgical procedures should be performed. uuid:33d49f27-b761-42be-8a48-edc389a86499 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2676 biolink:treats MONDO:0002258 PMID:41385096 "[{""id"":""uuid:758b0efe-7828-4c5c-ad56-ae0d5f275b03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f58d37f9-f68d-49c1-97d0-a210be67fafe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and other antibacterial drugs, amoxicillin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Amoxicillin is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) strains of the designated microorganisms in the conditions listed below: Infections of the ear, nose, and throat –due to Streptococcus spp. (α- and β-hemolytic strains only), Streptococcus pneumoniae, Staphylococcus spp., or H. influenzae. Infections of the genitourinary tract – due to E. coli, P. mirabilis, or E. faecalis. Infections of the skin and skin structure – due to Streptococcus spp. (α- and β-hemolytic strains only), Staphylococcus spp., or E. coli. Infections of the lower respiratory tract due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Gonorrhea, acute uncomplicated (ano-genital and urethral infections) due to N. gonorrhoeae (males and females). H. pylori eradication to reduce the risk of duodenal ulcer recurrence Triple therapy: Amoxicillin /clarithromycin/lansoprazole Amoxicillin, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION . ) Dual therapy: Amoxicillin/lansoprazole Amoxicillin, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION . ) Indicated surgical procedures should be performed. uuid:f1d3456b-3f2d-4966-9e6a-9a9d7b3bbfe5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2676 biolink:treats MONDO:0006002 PMID:41385096 "[{""id"":""uuid:e14fe83d-53eb-49b1-9735-d2772878cfa2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fce7ec39-a82a-4045-b66e-e6c80640dee3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and other antibacterial drugs, amoxicillin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Amoxicillin is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) strains of the designated microorganisms in the conditions listed below: Infections of the ear, nose, and throat –due to Streptococcus spp. (α- and β-hemolytic strains only), Streptococcus pneumoniae, Staphylococcus spp., or H. influenzae. Infections of the genitourinary tract – due to E. coli, P. mirabilis, or E. faecalis. Infections of the skin and skin structure – due to Streptococcus spp. (α- and β-hemolytic strains only), Staphylococcus spp., or E. coli. Infections of the lower respiratory tract due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Gonorrhea, acute uncomplicated (ano-genital and urethral infections) due to N. gonorrhoeae (males and females). H. pylori eradication to reduce the risk of duodenal ulcer recurrence Triple therapy: Amoxicillin /clarithromycin/lansoprazole Amoxicillin, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION . ) Dual therapy: Amoxicillin/lansoprazole Amoxicillin, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION . ) Indicated surgical procedures should be performed. uuid:80723329-80dc-4160-922f-fdd3d520bd47 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2676 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:43237f39-f7dd-487d-86d6-2f2af71cc145"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bf96e8be-deb1-4eb8-94d0-d7990effc930"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and other antibacterial drugs, amoxicillin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Amoxicillin is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) strains of the designated microorganisms in the conditions listed below: Infections of the ear, nose, and throat –due to Streptococcus spp. (α- and β-hemolytic strains only), Streptococcus pneumoniae, Staphylococcus spp., or H. influenzae. Infections of the genitourinary tract – due to E. coli, P. mirabilis, or E. faecalis. Infections of the skin and skin structure – due to Streptococcus spp. (α- and β-hemolytic strains only), Staphylococcus spp., or E. coli. Infections of the lower respiratory tract due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Gonorrhea, acute uncomplicated (ano-genital and urethral infections) due to N. gonorrhoeae (males and females). H. pylori eradication to reduce the risk of duodenal ulcer recurrence Triple therapy: Amoxicillin /clarithromycin/lansoprazole Amoxicillin, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION . ) Dual therapy: Amoxicillin/lansoprazole Amoxicillin, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION . ) Indicated surgical procedures should be performed. uuid:e1866689-27b6-4ad2-8829-d6281ce7c1df biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2676 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:6758241c-3b2d-40fa-8a87-25a466f1a8d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:20334a4b-7ff6-4ace-a873-2272116bb5ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and other antibacterial drugs, amoxicillin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Amoxicillin is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) strains of the designated microorganisms in the conditions listed below: Infections of the ear, nose, and throat –due to Streptococcus spp. (α- and β-hemolytic strains only), Streptococcus pneumoniae, Staphylococcus spp., or H. influenzae. Infections of the genitourinary tract – due to E. coli, P. mirabilis, or E. faecalis. Infections of the skin and skin structure – due to Streptococcus spp. (α- and β-hemolytic strains only), Staphylococcus spp., or E. coli. Infections of the lower respiratory tract due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Gonorrhea, acute uncomplicated (ano-genital and urethral infections) due to N. gonorrhoeae (males and females). H. pylori eradication to reduce the risk of duodenal ulcer recurrence Triple therapy: Amoxicillin /clarithromycin/lansoprazole Amoxicillin, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION . ) Dual therapy: Amoxicillin/lansoprazole Amoxicillin, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION . ) Indicated surgical procedures should be performed. uuid:ea110e69-b2f9-41bc-a8cd-f37bf5aad470 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2676 biolink:treats MONDO:0004277 PMID:41385096 "[{""id"":""uuid:41eb4be8-312c-4237-8142-7d200f66f8e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e7a2a3dd-98ae-49c3-ab3f-04ddaa36559c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and other antibacterial drugs, amoxicillin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Amoxicillin is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) strains of the designated microorganisms in the conditions listed below: Infections of the ear, nose, and throat –due to Streptococcus spp. (α- and β-hemolytic strains only), Streptococcus pneumoniae, Staphylococcus spp., or H. influenzae. Infections of the genitourinary tract – due to E. coli, P. mirabilis, or E. faecalis. Infections of the skin and skin structure – due to Streptococcus spp. (α- and β-hemolytic strains only), Staphylococcus spp., or E. coli. Infections of the lower respiratory tract due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Gonorrhea, acute uncomplicated (ano-genital and urethral infections) due to N. gonorrhoeae (males and females). H. pylori eradication to reduce the risk of duodenal ulcer recurrence Triple therapy: Amoxicillin /clarithromycin/lansoprazole Amoxicillin, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION . ) Dual therapy: Amoxicillin/lansoprazole Amoxicillin, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION . ) Indicated surgical procedures should be performed. uuid:7c23ec51-3876-4a8a-bedb-78a11700ddcd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2676 biolink:treats HP:0005202 PMID:41385096 "[{""id"":""uuid:651bff80-bcb9-4a59-a481-d71472118b51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0f54a6ca-23e6-4de5-b38e-33ca0c369242"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and other antibacterial drugs, amoxicillin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Amoxicillin is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) strains of the designated microorganisms in the conditions listed below: Infections of the ear, nose, and throat –due to Streptococcus spp. (α- and β-hemolytic strains only), Streptococcus pneumoniae, Staphylococcus spp., or H. influenzae. Infections of the genitourinary tract – due to E. coli, P. mirabilis, or E. faecalis. Infections of the skin and skin structure – due to Streptococcus spp. (α- and β-hemolytic strains only), Staphylococcus spp., or E. coli. Infections of the lower respiratory tract due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Gonorrhea, acute uncomplicated (ano-genital and urethral infections) due to N. gonorrhoeae (males and females). H. pylori eradication to reduce the risk of duodenal ulcer recurrence Triple therapy: Amoxicillin /clarithromycin/lansoprazole Amoxicillin, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION . ) Dual therapy: Amoxicillin/lansoprazole Amoxicillin, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION . ) Indicated surgical procedures should be performed. uuid:88504d9a-4c5b-4ca8-bba0-4c4c2d476c7a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2676 biolink:treats MONDO:0005412 PMID:41385096 "[{""id"":""uuid:332e36ff-8a99-4473-aed8-c5f7c3c2d68a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:759f6377-535c-4ed2-b8fe-1a99ce939d6c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and other antibacterial drugs, amoxicillin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Amoxicillin is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) strains of the designated microorganisms in the conditions listed below: Infections of the ear, nose, and throat –due to Streptococcus spp. (α- and β-hemolytic strains only), Streptococcus pneumoniae, Staphylococcus spp., or H. influenzae. Infections of the genitourinary tract – due to E. coli, P. mirabilis, or E. faecalis. Infections of the skin and skin structure – due to Streptococcus spp. (α- and β-hemolytic strains only), Staphylococcus spp., or E. coli. Infections of the lower respiratory tract due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae. Gonorrhea, acute uncomplicated (ano-genital and urethral infections) due to N. gonorrhoeae (males and females). H. pylori eradication to reduce the risk of duodenal ulcer recurrence Triple therapy: Amoxicillin /clarithromycin/lansoprazole Amoxicillin, in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION . ) Dual therapy: Amoxicillin/lansoprazole Amoxicillin, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. (See CLINICAL STUDIES and DOSAGE AND ADMINISTRATION . ) Indicated surgical procedures should be performed. uuid:2fb5afc5-d182-47ad-b4ec-eb367a4ebc60 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7UQ7X4Y489 biolink:treats HP:0002625 PMID:41385096 "[{""id"":""uuid:a79ec4a9-e5c2-4121-91a2-fdee895c4b58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:debf0dd4-225c-4a98-b471-a03295698e97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INNOHEP® is indicated for the treatment of acute symptomatic deep vein thrombosis with or without pulmonary embolism when administered in conjunction with warfarin sodium. The safety and effectiveness of INNOHEP® were established in hospitalized patients. uuid:f15adace-ea71-4f16-be16-9e8144ebfeda biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7UQ7X4Y489 biolink:treats MONDO:0005279 PMID:41385096 "[{""id"":""uuid:3a7523df-80ed-45ca-a7b9-3a20df451fa0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c79dd39a-1e1c-4ca3-be4f-8392a79e58e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INNOHEP® is indicated for the treatment of acute symptomatic deep vein thrombosis with or without pulmonary embolism when administered in conjunction with warfarin sodium. The safety and effectiveness of INNOHEP® were established in hospitalized patients. uuid:8ab5c0bd-647c-449a-91ea-214780459650 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5103 biolink:treats UMLS:C0572933 PMID:41385096 "[{""id"":""uuid:5430c45b-b225-4eea-a481-424820c4ba71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3ca2335d-25a3-4d2a-9086-70da4f947617"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Flumazenil injection, USP is indicated for the complete or partial reversal of the sedative effects of benzodiazepines in cases where general anesthesia has been induced and/or maintained with benzodiazepines, where sedation has been produced with benzodiazepines for diagnostic and therapeutic procedures, and for the management of benzodiazepine overdose. uuid:8a966bfa-5ff9-4c42-b6e6-41f46a83e59e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77733 biolink:treats MONDO:0001134 PMID:41385096 "[{""id"":""uuid:95117304-f678-4922-a31c-923e74dd24d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3dfb99c1-63fd-463c-9253-08585993af5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ISOPTIN SR (verapamil HCI) is indicated for the management of essential hypertension. uuid:8d6b18fa-aa69-4273-b94b-dcce9507c29b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6916 biolink:treats UMLS:C0750197 PMID:41385096 "[{""id"":""uuid:e502ea1f-cb70-4e0e-ba9e-c4cdf1599b6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7e237004-faa3-49a4-96bb-fe83633eb132"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mexiletine Hydrochloride Capsules are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgement of the physician, are life-threatening. Because of the proarrhythmic effects of mexiletine, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of mexiletine treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. uuid:086f6fa1-ad3a-4dc7-9f9e-0aa3cefbbff8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6916 biolink:treats HP:0004308 PMID:41385096 "[{""id"":""uuid:1bff4d2b-79d9-4b2f-8fb1-414501e9f4b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fabf6f2c-849d-46cc-8c60-ba9c260c1660"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mexiletine Hydrochloride Capsules are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgement of the physician, are life-threatening. Because of the proarrhythmic effects of mexiletine, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of mexiletine treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. uuid:8c688656-97c7-4ba1-b105-08ed67af2c32 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6916 biolink:treats HP:0006682 PMID:41385096 "[{""id"":""uuid:5984deb5-581a-4669-9b0a-4630784b110f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5b3eebcb-1eef-436b-8a3c-7bc8a36287ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mexiletine Hydrochloride Capsules are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgement of the physician, are life-threatening. Because of the proarrhythmic effects of mexiletine, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of mexiletine treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. uuid:d01a5414-16e3-4aec-99b2-b4e062f3b7a0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3756 biolink:treats UMLS:C0347869 PMID:41385096 "[{""id"":""uuid:c81ff3e5-41d4-4a13-9365-1cea6414e18c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:55d5bb0c-f259-41dd-b8c1-aa271dda479b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Seizure Disorders: Clonazepam is useful alone or as an adjunct in the treatment of the Lennox-Gastaut syndrome (petit mal variant), akinetic and myoclonic seizures. In patients with absence seizures (petit mal) who have failed to respond to succinimides, clonazepam may be useful. In some studies, up to 30% of patients have shown a loss of anticonvulsant activity, often within three months of administration. In some cases, dosage adjustment may re-establish efficacy. Panic Disorder: Clonazepam is indicated for the treatment of panic disorder, with or without agoraphobia, as defined in DSM-IV. Panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. The efficacy of clonazepam was established in two 6- to 9-week trials in panic disorder patients whose diagnoses corresponded to the DSM-lllR category of panic disorder (see CLINICAL PHARMACOLOGY: Clinical Trials ). Panic disorder (DSM-IV) is characterized by recurrent unexpected panic attacks, i.e., a discrete period of intense fear or discomfort in which four (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) palpitations, pounding heart or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes. The effectiveness of clonazepam in long-term use, that is, for more than 9 weeks, has not been systematically studied in controlled clinical trials. The physician who elects to use clonazepam for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). uuid:3593b433-2789-458c-9d22-16e3f917ae97 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3756 biolink:treats HP:0032794 PMID:41385096 "[{""id"":""uuid:4961db81-5ae6-4f3a-86ba-f3f07ad46422"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:41b4efe3-c27f-4c33-9d33-3d1cb717fa61"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Seizure Disorders: Clonazepam is useful alone or as an adjunct in the treatment of the Lennox-Gastaut syndrome (petit mal variant), akinetic and myoclonic seizures. In patients with absence seizures (petit mal) who have failed to respond to succinimides, clonazepam may be useful. In some studies, up to 30% of patients have shown a loss of anticonvulsant activity, often within three months of administration. In some cases, dosage adjustment may re-establish efficacy. Panic Disorder: Clonazepam is indicated for the treatment of panic disorder, with or without agoraphobia, as defined in DSM-IV. Panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. The efficacy of clonazepam was established in two 6- to 9-week trials in panic disorder patients whose diagnoses corresponded to the DSM-lllR category of panic disorder (see CLINICAL PHARMACOLOGY: Clinical Trials ). Panic disorder (DSM-IV) is characterized by recurrent unexpected panic attacks, i.e., a discrete period of intense fear or discomfort in which four (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) palpitations, pounding heart or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes. The effectiveness of clonazepam in long-term use, that is, for more than 9 weeks, has not been systematically studied in controlled clinical trials. The physician who elects to use clonazepam for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). uuid:25136196-b2ad-4ea1-a062-9ded10ded4f7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3756 biolink:treats MONDO:0005383 PMID:41385096 "[{""id"":""uuid:a8b1ebca-a1c2-42fb-826b-21ac5aae06af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d2b947b0-e092-4036-aeea-b199e1f1a76a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Seizure Disorders: Clonazepam is useful alone or as an adjunct in the treatment of the Lennox-Gastaut syndrome (petit mal variant), akinetic and myoclonic seizures. In patients with absence seizures (petit mal) who have failed to respond to succinimides, clonazepam may be useful. In some studies, up to 30% of patients have shown a loss of anticonvulsant activity, often within three months of administration. In some cases, dosage adjustment may re-establish efficacy. Panic Disorder: Clonazepam is indicated for the treatment of panic disorder, with or without agoraphobia, as defined in DSM-IV. Panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. The efficacy of clonazepam was established in two 6- to 9-week trials in panic disorder patients whose diagnoses corresponded to the DSM-lllR category of panic disorder (see CLINICAL PHARMACOLOGY: Clinical Trials ). Panic disorder (DSM-IV) is characterized by recurrent unexpected panic attacks, i.e., a discrete period of intense fear or discomfort in which four (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) palpitations, pounding heart or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes. The effectiveness of clonazepam in long-term use, that is, for more than 9 weeks, has not been systematically studied in controlled clinical trials. The physician who elects to use clonazepam for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). uuid:9f216018-f944-4d98-b1a8-d2f2cab2f568 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151392 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:0a593ebe-a7d9-41a0-9ca6-e27bbe117f27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4208bf1a-4f6c-4cc9-9f39-7b6f3644f523"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower Respiratory Tract Infections - caused by β-lactamase-producing strains of H. influenzae and M. catarrhalis . Otitis Media - caused by β-lactamase-producing strains of H. influenzae and M. catarrhalis . Sinusitis - caused by β-lactamase-producing strains of H. influenzae and M. catarrhalis . Skin and Skin Structure Infections - caused by β-lactamase-producing strains of S. aureus , E. coli , and Klebsiella spp. Urinary Tract Infections - caused by β-lactamase-producing strains of E. coli , Klebsiella spp. and Enterobacter spp. While amoxicillin and clavulanate potassium is indicated only for the conditions listed above, infections caused by ampicillin-susceptible organisms are also amenable to treatment with amoxicillin and clavulanate potassium due to its amoxicillin content. Therefore, mixed infections caused by ampicillin-susceptible organisms and β-lactamase-producing organisms susceptible to amoxicillin and clavulanate potassium should not require the addition of another antibiotic. Because amoxicillin has greater in vitro activity against S. pneumoniae than does ampicillin or penicillin, the majority of S. pneumoniae strains with intermediate susceptibility to ampicillin or penicillin are fully susceptible to amoxicillin and amoxicillin and clavulanate potassium. (See Microbiology .) To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) and other antibacterial drugs, amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Bacteriological studies, to determine the causative organisms and their susceptibility to amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) should be performed together with any indicated surgical procedures. uuid:9f091efc-23e6-400b-b025-948619f3bc47 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151392 biolink:treats MONDO:0005441 PMID:41385096 "[{""id"":""uuid:906fa31e-edf8-4172-8fab-00f6a6ea0593"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:83f410a6-2313-4bd5-a175-7d8afdfae77d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower Respiratory Tract Infections - caused by β-lactamase-producing strains of H. influenzae and M. catarrhalis . Otitis Media - caused by β-lactamase-producing strains of H. influenzae and M. catarrhalis . Sinusitis - caused by β-lactamase-producing strains of H. influenzae and M. catarrhalis . Skin and Skin Structure Infections - caused by β-lactamase-producing strains of S. aureus , E. coli , and Klebsiella spp. Urinary Tract Infections - caused by β-lactamase-producing strains of E. coli , Klebsiella spp. and Enterobacter spp. While amoxicillin and clavulanate potassium is indicated only for the conditions listed above, infections caused by ampicillin-susceptible organisms are also amenable to treatment with amoxicillin and clavulanate potassium due to its amoxicillin content. Therefore, mixed infections caused by ampicillin-susceptible organisms and β-lactamase-producing organisms susceptible to amoxicillin and clavulanate potassium should not require the addition of another antibiotic. Because amoxicillin has greater in vitro activity against S. pneumoniae than does ampicillin or penicillin, the majority of S. pneumoniae strains with intermediate susceptibility to ampicillin or penicillin are fully susceptible to amoxicillin and amoxicillin and clavulanate potassium. (See Microbiology .) To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) and other antibacterial drugs, amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Bacteriological studies, to determine the causative organisms and their susceptibility to amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) should be performed together with any indicated surgical procedures. uuid:316f7ee3-db34-490b-a02c-3714107cc8ed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151392 biolink:treats MONDO:0005961 PMID:41385096 "[{""id"":""uuid:2a77b192-685f-4d7d-8479-7087ce690f16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8bacc2f6-72b3-4eab-b94c-3bc9ebb4c3cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:55946ddb-bbe8-463c-a5dc-3b06312dbea9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower Respiratory Tract Infections - caused by β-lactamase-producing strains of H. influenzae and M. catarrhalis . Otitis Media - caused by β-lactamase-producing strains of H. influenzae and M. catarrhalis . Sinusitis - caused by β-lactamase-producing strains of H. influenzae and M. catarrhalis . Skin and Skin Structure Infections - caused by β-lactamase-producing strains of S. aureus , E. coli , and Klebsiella spp. Urinary Tract Infections - caused by β-lactamase-producing strains of E. coli , Klebsiella spp. and Enterobacter spp. While amoxicillin and clavulanate potassium is indicated only for the conditions listed above, infections caused by ampicillin-susceptible organisms are also amenable to treatment with amoxicillin and clavulanate potassium due to its amoxicillin content. Therefore, mixed infections caused by ampicillin-susceptible organisms and β-lactamase-producing organisms susceptible to amoxicillin and clavulanate potassium should not require the addition of another antibiotic. Because amoxicillin has greater in vitro activity against S. pneumoniae than does ampicillin or penicillin, the majority of S. pneumoniae strains with intermediate susceptibility to ampicillin or penicillin are fully susceptible to amoxicillin and amoxicillin and clavulanate potassium. (See Microbiology .) To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) and other antibacterial drugs, amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Bacteriological studies, to determine the causative organisms and their susceptibility to amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) should be performed together with any indicated surgical procedures.|[PMDA] A drug with a new additional indication for the treatment of sinusitis. uuid:ef8f9056-b9b3-4d71-9eb0-02736390685e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151392 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:4e8a8c33-7da2-452e-af1c-e697fef86e17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4f7c275a-63e5-4467-8ddd-19ece1082e2b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:52e2706a-c2e9-4872-8641-8f3612cbdeec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower Respiratory Tract Infections - caused by β-lactamase-producing strains of H. influenzae and M. catarrhalis . Otitis Media - caused by β-lactamase-producing strains of H. influenzae and M. catarrhalis . Sinusitis - caused by β-lactamase-producing strains of H. influenzae and M. catarrhalis . Skin and Skin Structure Infections - caused by β-lactamase-producing strains of S. aureus , E. coli , and Klebsiella spp. Urinary Tract Infections - caused by β-lactamase-producing strains of E. coli , Klebsiella spp. and Enterobacter spp. While amoxicillin and clavulanate potassium is indicated only for the conditions listed above, infections caused by ampicillin-susceptible organisms are also amenable to treatment with amoxicillin and clavulanate potassium due to its amoxicillin content. Therefore, mixed infections caused by ampicillin-susceptible organisms and β-lactamase-producing organisms susceptible to amoxicillin and clavulanate potassium should not require the addition of another antibiotic. Because amoxicillin has greater in vitro activity against S. pneumoniae than does ampicillin or penicillin, the majority of S. pneumoniae strains with intermediate susceptibility to ampicillin or penicillin are fully susceptible to amoxicillin and amoxicillin and clavulanate potassium. (See Microbiology .) To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) and other antibacterial drugs, amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Bacteriological studies, to determine the causative organisms and their susceptibility to amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) should be performed together with any indicated surgical procedures.|[PMDA] A drug with a new indication for the treatment of superficial skin infections, deep skin infections, lymphangitis and lymphadenitis, chronic pyoderma, laryngopharyngitis, tonsillitis, acute bronchitis, cystitis, and pyelonephritis. uuid:c274931b-201a-4706-83fd-980c6a854e56 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151392 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:2f959b2e-438b-4eb8-8ac4-6eb884b3d4c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fab8c3ee-b947-4c0d-b5a4-99372a6d6b55"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower Respiratory Tract Infections - caused by β-lactamase-producing strains of H. influenzae and M. catarrhalis . Otitis Media - caused by β-lactamase-producing strains of H. influenzae and M. catarrhalis . Sinusitis - caused by β-lactamase-producing strains of H. influenzae and M. catarrhalis . Skin and Skin Structure Infections - caused by β-lactamase-producing strains of S. aureus , E. coli , and Klebsiella spp. Urinary Tract Infections - caused by β-lactamase-producing strains of E. coli , Klebsiella spp. and Enterobacter spp. While amoxicillin and clavulanate potassium is indicated only for the conditions listed above, infections caused by ampicillin-susceptible organisms are also amenable to treatment with amoxicillin and clavulanate potassium due to its amoxicillin content. Therefore, mixed infections caused by ampicillin-susceptible organisms and β-lactamase-producing organisms susceptible to amoxicillin and clavulanate potassium should not require the addition of another antibiotic. Because amoxicillin has greater in vitro activity against S. pneumoniae than does ampicillin or penicillin, the majority of S. pneumoniae strains with intermediate susceptibility to ampicillin or penicillin are fully susceptible to amoxicillin and amoxicillin and clavulanate potassium. (See Microbiology .) To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) and other antibacterial drugs, amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Bacteriological studies, to determine the causative organisms and their susceptibility to amoxicillin and clavulanate potassium for oral suspension, and amoxicillin and clavulanate potassium tablets (chewable) should be performed together with any indicated surgical procedures. uuid:9bf7b47a-4ec3-4090-b1f9-060b0f44d48b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6706 biolink:treats MONDO:0001134 PMID:41385096 "[{""id"":""uuid:618e7915-0929-4278-b95f-3e66a0711bc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:43c61321-2fc4-4e64-8b27-6ee6d503f9be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the management of moderately severe to severe essential hypertension and in uncomplicated cases of malignant hypertension. uuid:13e5f373-7dfc-4341-82b6-858a5c377f70 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6706 biolink:treats MONDO:0006846 PMID:41385096 "[{""id"":""uuid:46c5a5f6-fd53-48a7-a58b-28bafa4941e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c6a785ff-0876-4412-a08f-1cf287bfee21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the management of moderately severe to severe essential hypertension and in uncomplicated cases of malignant hypertension. uuid:afc2aaef-0e1d-42a2-b1a7-dc982bc85a7f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:370778 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:5a1f7bf2-e123-4547-a7da-6c7fad82ec4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:45bbeec8-ade2-4da0-b3fe-03c9ad182029"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SEMPREX-D Capsules are indicated for relief of symptoms associated with seasonal allergic rhinitis such as sneezing, rhinorrhea, pruritus, lacrimation, and nasal congestion. SEMPREX-D Capsules should be administered when both the antihistaminic activity of acrivastine and the nasal decongestant activity of pseudoephedrine are desired (see CLINICAL PHARMACOLOGY ). The efficacy of SEMPREX-D Capsules beyond 14 days of continuous treatment in patients with seasonal allergic rhinitis has not been adequately investigated in clinical trials. SEMPREX-D Capsules have not been adequately studied for effectiveness in relieving the symptoms of the common cold. uuid:bb846782-15ec-4def-9b4d-2721a46c9abb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:370778 biolink:treats MONDO:0005709 PMID:41385096 "[{""id"":""uuid:430f2a1e-a0d6-4118-83d5-9ecb624dd894"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e5438684-9636-4367-a9be-264749a7031a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SEMPREX-D Capsules are indicated for relief of symptoms associated with seasonal allergic rhinitis such as sneezing, rhinorrhea, pruritus, lacrimation, and nasal congestion. SEMPREX-D Capsules should be administered when both the antihistaminic activity of acrivastine and the nasal decongestant activity of pseudoephedrine are desired (see CLINICAL PHARMACOLOGY ). The efficacy of SEMPREX-D Capsules beyond 14 days of continuous treatment in patients with seasonal allergic rhinitis has not been adequately investigated in clinical trials. SEMPREX-D Capsules have not been adequately studied for effectiveness in relieving the symptoms of the common cold. uuid:bf3e49d0-b9c1-42b8-b9be-df97c0555a40 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9943 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:529e5715-445b-44c1-b4bd-eb14feb83b2d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b673ebe1-996f-4dd6-8525-395238c66925"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Venlafaxine Extended Release Tablets are a selective serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for: Major Depressive Disorder (MDD) ( 1.1 ) Social Anxiety Disorder (SAD) ( 1.2 ) uuid:ab030c95-ccc9-4757-8fb2-da7a8b200558 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9943 biolink:treats MONDO:0001247 PMID:41385096 "[{""id"":""uuid:8cf54418-d73b-46e9-8736-de348d16645f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8fc783ac-df74-452e-ad3a-4c620c405f47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Venlafaxine Extended Release Tablets are a selective serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for: Major Depressive Disorder (MDD) ( 1.1 ) Social Anxiety Disorder (SAD) ( 1.2 ) uuid:10a841ab-283a-47dc-81e0-bc40e11e56f0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7D96IR0PPM biolink:treats MONDO:0004967 PMID:41385096 "[{""id"":""uuid:7917b1e2-a2bc-4e49-ae59-ff010368d6bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:65b21466-b067-4246-b777-dc5662188c9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:bd2bcaf0-b5f9-4477-b084-1626578d21d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/oncaspar""]},{""id"":""uuid:42ee6324-07ad-4887-b44b-c3d60329d1b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oncaspar ® is indicated as a component of a multi-agent chemotherapeutic regimen for treatment of patients with: First line acute lymphoblastic leukemia (1.1) Acute lymphoblastic leukemia and hypersensitivity to asparaginase (1.2)|[EMA] Oncaspar is indicated as a component of antineoplastic combination therapy in acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years, and adult patients.|[PMDA] A drug with a new active ingredient indicated for the treatment of acute lymphocytic leukemia and malignant lymphoma. uuid:b37e3775-8267-4e79-88f4-c914ba20ff10 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:83G67E21XI biolink:treats MONDO:0005279 PMID:41385096 "[{""id"":""uuid:892fe00b-3969-4590-9b8c-15634fc52f66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:485ea878-bca5-404e-b36e-fbd2b0db2bf2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Kinlytic™ is indicated in adults: For the lysis of acute massive pulmonary emboli, defined as obstruction of blood flow to a lobe or multiple segments. For the lysis of pulmonary emboli accompanied by unstable hemodynamics, i.e., failure to maintain blood pressure without supportive measures. The diagnosis should be confirmed by objective means, such as pulmonary angiography or non-invasive procedures such as lung scanning. uuid:62de45e9-3f51-4185-99da-8ae853afa950 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8774 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:ab1cd987-f5a0-4e29-bef8-1f0fe2543278"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:199a0fde-b214-4804-81c7-7ce7f473435b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ramipril is indicated for the treatment of hypertension. It may be used alone or in combination with thiazide diuretics. In using ramipril, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that ramipril does not have a similar risk. (See WARNINGS . ) In considering use of ramipril, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients. (see WARNINGS , Angioedema . ) uuid:bac965dc-e7dc-466a-a3da-2c09c0871c0f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8774 biolink:treats MONDO:0001609 PMID:41385096 "[{""id"":""uuid:c135d101-3ad1-4432-bbb7-5be64aab3d42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c9c5fb19-b373-4a63-a3e3-59ae8344a0cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ramipril is indicated for the treatment of hypertension. It may be used alone or in combination with thiazide diuretics. In using ramipril, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that ramipril does not have a similar risk. (See WARNINGS . ) In considering use of ramipril, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients. (see WARNINGS , Angioedema . ) uuid:d68cd24d-3de1-472a-86cd-4b6efbc31522 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8774 biolink:treats MONDO:0001343 PMID:41385096 "[{""id"":""uuid:1dd15d35-cc5a-4f71-8389-d69ca2837ca8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:15d7eba1-7cbc-43bf-adad-f2a1447f9ab9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ramipril is indicated for the treatment of hypertension. It may be used alone or in combination with thiazide diuretics. In using ramipril, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that ramipril does not have a similar risk. (See WARNINGS . ) In considering use of ramipril, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients. (see WARNINGS , Angioedema . ) uuid:f79d715f-98f3-48de-aa25-faaa1810b635 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8774 biolink:treats MONDO:0010481 PMID:41385096 "[{""id"":""uuid:1dff58a3-c922-469e-b2dc-4193de833232"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5c6c02f9-5f1b-4193-aaa6-482fdab82272"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ramipril is indicated for the treatment of hypertension. It may be used alone or in combination with thiazide diuretics. In using ramipril, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that ramipril does not have a similar risk. (See WARNINGS . ) In considering use of ramipril, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients. (see WARNINGS , Angioedema . ) uuid:f033b1e2-098e-4225-a2f5-85aafca769bd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8461 biolink:treats MONDO:0024332 PMID:41385096 "[{""id"":""uuid:1cbe5a7d-331c-41ed-b0e6-91a8bbe2252e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d1033990-35d0-4c43-a746-6031e35b4f7c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Promethazine is useful for: Perennial and seasonal allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients. uuid:92e24b37-0a43-45bc-97b2-3c406016c16a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8461 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:30662f51-b4df-4759-8f50-9a91e79320b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:66563a35-28d5-4aad-8731-365e103d1c2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Promethazine is useful for: Perennial and seasonal allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients. uuid:1e583882-98cd-46da-98d8-cc1ecf999a83 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8461 biolink:treats MONDO:0006004 PMID:41385096 "[{""id"":""uuid:ea94656a-cd66-4ede-8e73-1d4a4dc10ec7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:20126370-5f7b-46ed-8310-cbcc47410471"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Promethazine is useful for: Perennial and seasonal allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients. uuid:ad7c91ff-1709-437b-bb21-12fb623e8555 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8461 biolink:treats MONDO:0005492 PMID:41385096 "[{""id"":""uuid:4122e512-113b-4c79-9ca1-a62e68037e1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2a867e54-1ffd-4520-a98f-0730fec8710b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Promethazine is useful for: Perennial and seasonal allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients. uuid:aabcaa64-c6ef-4641-a002-b332fc060fdc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8461 biolink:treats MONDO:0010481 PMID:41385096 "[{""id"":""uuid:1a2881bc-9f55-496a-bfdb-40f7a2fafb01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:86d9fb51-3290-4d81-bca0-1486bf6ce343"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Promethazine is useful for: Perennial and seasonal allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients. uuid:75666273-b47b-4c77-b531-f499db20bff4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8461 biolink:treats MONDO:0007448 PMID:41385096 "[{""id"":""uuid:69861c37-834f-4671-8049-0563d972c5b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e56bc720-6121-4a72-bb34-d9e4c22d3f85"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Promethazine is useful for: Perennial and seasonal allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma. Dermographism. Anaphylactic reactions, as adjunctive therapy to epinephrine and other standard measures, after the acute manifestations have been controlled. Preoperative, postoperative, or obstetric sedation. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. Therapy adjunctive to meperidine or other analgesics for control of post-operative pain. Sedation in both children and adults, as well as relief of apprehension and production of light sleep from which the patient can be easily aroused. Active and prophylactic treatment of motion sickness. Antiemetic therapy in postoperative patients. uuid:cc587ed5-d803-4bea-bfe7-4da372ecd0f0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3515 biolink:treats MONDO:0002258 PMID:41385096 "[{""id"":""uuid:dfe47a66-a7cb-48ce-849a-f1b648ca07da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0ec78838-56d0-4b33-9a52-b6547cedc708"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NOTE: CEFUROXIME AXETIL TABLETS AND CEFUROXIME AXETIL FOR ORAL SUSPENSION ARE NOT BIOEQUIVALENT AND ARE NOT SUBSTITUTABLE ON A MILLIGRAM-PER-MILLIGRAM BASIS (SEE CLINICAL PHARMACOLOGY ). Cefuroxime Axetil Tablets: Cefuroxime axetil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: 1. Pharyngitis/Tonsillitis caused by Streptococcus pyogenes. NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefuroxime axetil tablets are generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefuroxime in the subsequent prevention of rheumatic fever are not available. Please also note that in all clinical trials, all isolates had to be sensitive to both penicillin and cefuroxime. There are no data from adequate and well-controlled trials to demonstrate the effectiveness of cefuroxime in the treatment of penicillin-resistant strains of Streptococcus pyogenes. 2. Acute Bacterial Otitis Media caused by Streptococcus pneumoniae , Haemophilus influenzae (including beta-lactamase–producing strains), Moraxella catarrhalis (including beta-lactamase–producing strains), or Streptococcus pyogenes. 3. Acute Bacterial Maxillary Sinusitis caused by Streptococcus pneumoniae or Haemophilus influenzae (non-beta-lactamase–producing strains only). (See CLINICAL STUDIES section.) NOTE: In view of the insufficient numbers of isolates of beta-lactamase–producing strains of Haemophilus influenzae and Moraxella catarrhalis that were obtained from clinical trials with cefuroxime axetil tablets for patients with acute bacterial maxillary sinusitis, it was not possible to adequately evaluate the effectiveness of cefuroxime axetil tablets for sinus infections known, suspected, or considered potentially to be caused by beta-lactamase–producing Haemophilus influenzae or Moraxella catarrhalis. 4. Acute Bacterial Exacerbations of Chronic Bronchitis and Secondary Bacterial Infections of Acute Bronchitis caused by Streptococcus pneumoniae , Haemophilus influenzae (beta-lactamase negative strains), or Haemophilus parainfluenzae (beta-lactamase negative strains). (See DOSAGE AND ADMINISTRATION section and CLINICAL STUDIES section.) 5. Uncomplicated Skin and Skin-Structure Infections caused by Staphylococcus aureus (including beta-lactamase–producing strains) or Streptococcus pyogenes. 6. Uncomplicated Urinary Tract Infections caused by Escherichia coli or Klebsiella pneumoniae . 7. Uncomplicated Gonorrhea, urethral and endocervical, caused by penicillinase-producing and non-penicillinase–producing strains of Neisseria gonorrhoeae and uncomplicated gonorrhea, rectal, in females, caused by non-penicillinase–producing strains of Neisseria gonorrhoeae . 8. Early Lyme Disease (erythema migrans) caused by Borrelia burgdorferi . To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefuroxime axetil tablets and other antibacterial drugs, cefuroxime axetil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:99836f3b-f4d8-45db-81e6-0ea6b0ebc58d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3515 biolink:treats MONDO:0001039 PMID:41385096 "[{""id"":""uuid:2cbeabd9-8387-496b-9f65-14adcdeec17b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:53f53cef-89a8-4060-9c61-db81f039a7fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NOTE: CEFUROXIME AXETIL TABLETS AND CEFUROXIME AXETIL FOR ORAL SUSPENSION ARE NOT BIOEQUIVALENT AND ARE NOT SUBSTITUTABLE ON A MILLIGRAM-PER-MILLIGRAM BASIS (SEE CLINICAL PHARMACOLOGY ). Cefuroxime Axetil Tablets: Cefuroxime axetil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: 1. Pharyngitis/Tonsillitis caused by Streptococcus pyogenes. NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefuroxime axetil tablets are generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefuroxime in the subsequent prevention of rheumatic fever are not available. Please also note that in all clinical trials, all isolates had to be sensitive to both penicillin and cefuroxime. There are no data from adequate and well-controlled trials to demonstrate the effectiveness of cefuroxime in the treatment of penicillin-resistant strains of Streptococcus pyogenes. 2. Acute Bacterial Otitis Media caused by Streptococcus pneumoniae , Haemophilus influenzae (including beta-lactamase–producing strains), Moraxella catarrhalis (including beta-lactamase–producing strains), or Streptococcus pyogenes. 3. Acute Bacterial Maxillary Sinusitis caused by Streptococcus pneumoniae or Haemophilus influenzae (non-beta-lactamase–producing strains only). (See CLINICAL STUDIES section.) NOTE: In view of the insufficient numbers of isolates of beta-lactamase–producing strains of Haemophilus influenzae and Moraxella catarrhalis that were obtained from clinical trials with cefuroxime axetil tablets for patients with acute bacterial maxillary sinusitis, it was not possible to adequately evaluate the effectiveness of cefuroxime axetil tablets for sinus infections known, suspected, or considered potentially to be caused by beta-lactamase–producing Haemophilus influenzae or Moraxella catarrhalis. 4. Acute Bacterial Exacerbations of Chronic Bronchitis and Secondary Bacterial Infections of Acute Bronchitis caused by Streptococcus pneumoniae , Haemophilus influenzae (beta-lactamase negative strains), or Haemophilus parainfluenzae (beta-lactamase negative strains). (See DOSAGE AND ADMINISTRATION section and CLINICAL STUDIES section.) 5. Uncomplicated Skin and Skin-Structure Infections caused by Staphylococcus aureus (including beta-lactamase–producing strains) or Streptococcus pyogenes. 6. Uncomplicated Urinary Tract Infections caused by Escherichia coli or Klebsiella pneumoniae . 7. Uncomplicated Gonorrhea, urethral and endocervical, caused by penicillinase-producing and non-penicillinase–producing strains of Neisseria gonorrhoeae and uncomplicated gonorrhea, rectal, in females, caused by non-penicillinase–producing strains of Neisseria gonorrhoeae . 8. Early Lyme Disease (erythema migrans) caused by Borrelia burgdorferi . To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefuroxime axetil tablets and other antibacterial drugs, cefuroxime axetil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:f71fcc87-642a-4b09-ab44-629cd2abf58a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3515 biolink:treats MONDO:0001031 PMID:41385096 "[{""id"":""uuid:7650ec24-1daa-4834-902e-fdcb6f9b342a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8d9e877c-f51e-4ab2-b675-86a8b5b840f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NOTE: CEFUROXIME AXETIL TABLETS AND CEFUROXIME AXETIL FOR ORAL SUSPENSION ARE NOT BIOEQUIVALENT AND ARE NOT SUBSTITUTABLE ON A MILLIGRAM-PER-MILLIGRAM BASIS (SEE CLINICAL PHARMACOLOGY ). Cefuroxime Axetil Tablets: Cefuroxime axetil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: 1. Pharyngitis/Tonsillitis caused by Streptococcus pyogenes. NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefuroxime axetil tablets are generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefuroxime in the subsequent prevention of rheumatic fever are not available. Please also note that in all clinical trials, all isolates had to be sensitive to both penicillin and cefuroxime. There are no data from adequate and well-controlled trials to demonstrate the effectiveness of cefuroxime in the treatment of penicillin-resistant strains of Streptococcus pyogenes. 2. Acute Bacterial Otitis Media caused by Streptococcus pneumoniae , Haemophilus influenzae (including beta-lactamase–producing strains), Moraxella catarrhalis (including beta-lactamase–producing strains), or Streptococcus pyogenes. 3. Acute Bacterial Maxillary Sinusitis caused by Streptococcus pneumoniae or Haemophilus influenzae (non-beta-lactamase–producing strains only). (See CLINICAL STUDIES section.) NOTE: In view of the insufficient numbers of isolates of beta-lactamase–producing strains of Haemophilus influenzae and Moraxella catarrhalis that were obtained from clinical trials with cefuroxime axetil tablets for patients with acute bacterial maxillary sinusitis, it was not possible to adequately evaluate the effectiveness of cefuroxime axetil tablets for sinus infections known, suspected, or considered potentially to be caused by beta-lactamase–producing Haemophilus influenzae or Moraxella catarrhalis. 4. Acute Bacterial Exacerbations of Chronic Bronchitis and Secondary Bacterial Infections of Acute Bronchitis caused by Streptococcus pneumoniae , Haemophilus influenzae (beta-lactamase negative strains), or Haemophilus parainfluenzae (beta-lactamase negative strains). (See DOSAGE AND ADMINISTRATION section and CLINICAL STUDIES section.) 5. Uncomplicated Skin and Skin-Structure Infections caused by Staphylococcus aureus (including beta-lactamase–producing strains) or Streptococcus pyogenes. 6. Uncomplicated Urinary Tract Infections caused by Escherichia coli or Klebsiella pneumoniae . 7. Uncomplicated Gonorrhea, urethral and endocervical, caused by penicillinase-producing and non-penicillinase–producing strains of Neisseria gonorrhoeae and uncomplicated gonorrhea, rectal, in females, caused by non-penicillinase–producing strains of Neisseria gonorrhoeae . 8. Early Lyme Disease (erythema migrans) caused by Borrelia burgdorferi . To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefuroxime axetil tablets and other antibacterial drugs, cefuroxime axetil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:9607ec93-ee6f-4b18-9423-8a6ba5e8ed34 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3515 biolink:treats MONDO:0002186 PMID:41385096 "[{""id"":""uuid:4af85823-cc9e-43bf-b9c9-ed03992c6f67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:22840737-1eca-4ca8-9e97-ebd1ca42a520"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NOTE: CEFUROXIME AXETIL TABLETS AND CEFUROXIME AXETIL FOR ORAL SUSPENSION ARE NOT BIOEQUIVALENT AND ARE NOT SUBSTITUTABLE ON A MILLIGRAM-PER-MILLIGRAM BASIS (SEE CLINICAL PHARMACOLOGY ). Cefuroxime Axetil Tablets: Cefuroxime axetil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: 1. Pharyngitis/Tonsillitis caused by Streptococcus pyogenes. NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefuroxime axetil tablets are generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefuroxime in the subsequent prevention of rheumatic fever are not available. Please also note that in all clinical trials, all isolates had to be sensitive to both penicillin and cefuroxime. There are no data from adequate and well-controlled trials to demonstrate the effectiveness of cefuroxime in the treatment of penicillin-resistant strains of Streptococcus pyogenes. 2. Acute Bacterial Otitis Media caused by Streptococcus pneumoniae , Haemophilus influenzae (including beta-lactamase–producing strains), Moraxella catarrhalis (including beta-lactamase–producing strains), or Streptococcus pyogenes. 3. Acute Bacterial Maxillary Sinusitis caused by Streptococcus pneumoniae or Haemophilus influenzae (non-beta-lactamase–producing strains only). (See CLINICAL STUDIES section.) NOTE: In view of the insufficient numbers of isolates of beta-lactamase–producing strains of Haemophilus influenzae and Moraxella catarrhalis that were obtained from clinical trials with cefuroxime axetil tablets for patients with acute bacterial maxillary sinusitis, it was not possible to adequately evaluate the effectiveness of cefuroxime axetil tablets for sinus infections known, suspected, or considered potentially to be caused by beta-lactamase–producing Haemophilus influenzae or Moraxella catarrhalis. 4. Acute Bacterial Exacerbations of Chronic Bronchitis and Secondary Bacterial Infections of Acute Bronchitis caused by Streptococcus pneumoniae , Haemophilus influenzae (beta-lactamase negative strains), or Haemophilus parainfluenzae (beta-lactamase negative strains). (See DOSAGE AND ADMINISTRATION section and CLINICAL STUDIES section.) 5. Uncomplicated Skin and Skin-Structure Infections caused by Staphylococcus aureus (including beta-lactamase–producing strains) or Streptococcus pyogenes. 6. Uncomplicated Urinary Tract Infections caused by Escherichia coli or Klebsiella pneumoniae . 7. Uncomplicated Gonorrhea, urethral and endocervical, caused by penicillinase-producing and non-penicillinase–producing strains of Neisseria gonorrhoeae and uncomplicated gonorrhea, rectal, in females, caused by non-penicillinase–producing strains of Neisseria gonorrhoeae . 8. Early Lyme Disease (erythema migrans) caused by Borrelia burgdorferi . To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefuroxime axetil tablets and other antibacterial drugs, cefuroxime axetil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:bb49a613-a969-4b73-aa58-33cc13f03419 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3515 biolink:treats UMLS:C0853854 PMID:41385096 "[{""id"":""uuid:aaa9cb60-3a51-4498-92af-68f2fe8d8b27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:59a3b55d-b73a-4ae6-b8d4-0d6521bac438"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NOTE: CEFUROXIME AXETIL TABLETS AND CEFUROXIME AXETIL FOR ORAL SUSPENSION ARE NOT BIOEQUIVALENT AND ARE NOT SUBSTITUTABLE ON A MILLIGRAM-PER-MILLIGRAM BASIS (SEE CLINICAL PHARMACOLOGY ). Cefuroxime Axetil Tablets: Cefuroxime axetil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: 1. Pharyngitis/Tonsillitis caused by Streptococcus pyogenes. NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefuroxime axetil tablets are generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefuroxime in the subsequent prevention of rheumatic fever are not available. Please also note that in all clinical trials, all isolates had to be sensitive to both penicillin and cefuroxime. There are no data from adequate and well-controlled trials to demonstrate the effectiveness of cefuroxime in the treatment of penicillin-resistant strains of Streptococcus pyogenes. 2. Acute Bacterial Otitis Media caused by Streptococcus pneumoniae , Haemophilus influenzae (including beta-lactamase–producing strains), Moraxella catarrhalis (including beta-lactamase–producing strains), or Streptococcus pyogenes. 3. Acute Bacterial Maxillary Sinusitis caused by Streptococcus pneumoniae or Haemophilus influenzae (non-beta-lactamase–producing strains only). (See CLINICAL STUDIES section.) NOTE: In view of the insufficient numbers of isolates of beta-lactamase–producing strains of Haemophilus influenzae and Moraxella catarrhalis that were obtained from clinical trials with cefuroxime axetil tablets for patients with acute bacterial maxillary sinusitis, it was not possible to adequately evaluate the effectiveness of cefuroxime axetil tablets for sinus infections known, suspected, or considered potentially to be caused by beta-lactamase–producing Haemophilus influenzae or Moraxella catarrhalis. 4. Acute Bacterial Exacerbations of Chronic Bronchitis and Secondary Bacterial Infections of Acute Bronchitis caused by Streptococcus pneumoniae , Haemophilus influenzae (beta-lactamase negative strains), or Haemophilus parainfluenzae (beta-lactamase negative strains). (See DOSAGE AND ADMINISTRATION section and CLINICAL STUDIES section.) 5. Uncomplicated Skin and Skin-Structure Infections caused by Staphylococcus aureus (including beta-lactamase–producing strains) or Streptococcus pyogenes. 6. Uncomplicated Urinary Tract Infections caused by Escherichia coli or Klebsiella pneumoniae . 7. Uncomplicated Gonorrhea, urethral and endocervical, caused by penicillinase-producing and non-penicillinase–producing strains of Neisseria gonorrhoeae and uncomplicated gonorrhea, rectal, in females, caused by non-penicillinase–producing strains of Neisseria gonorrhoeae . 8. Early Lyme Disease (erythema migrans) caused by Borrelia burgdorferi . To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefuroxime axetil tablets and other antibacterial drugs, cefuroxime axetil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:305c9a73-0ce7-4361-a993-4636a87f134e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3515 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:d23de61c-c29b-42bc-9ff0-f131f03d47ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:709e7a2b-c994-42dd-be8e-5b19e335fcf2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NOTE: CEFUROXIME AXETIL TABLETS AND CEFUROXIME AXETIL FOR ORAL SUSPENSION ARE NOT BIOEQUIVALENT AND ARE NOT SUBSTITUTABLE ON A MILLIGRAM-PER-MILLIGRAM BASIS (SEE CLINICAL PHARMACOLOGY ). Cefuroxime Axetil Tablets: Cefuroxime axetil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: 1. Pharyngitis/Tonsillitis caused by Streptococcus pyogenes. NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefuroxime axetil tablets are generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefuroxime in the subsequent prevention of rheumatic fever are not available. Please also note that in all clinical trials, all isolates had to be sensitive to both penicillin and cefuroxime. There are no data from adequate and well-controlled trials to demonstrate the effectiveness of cefuroxime in the treatment of penicillin-resistant strains of Streptococcus pyogenes. 2. Acute Bacterial Otitis Media caused by Streptococcus pneumoniae , Haemophilus influenzae (including beta-lactamase–producing strains), Moraxella catarrhalis (including beta-lactamase–producing strains), or Streptococcus pyogenes. 3. Acute Bacterial Maxillary Sinusitis caused by Streptococcus pneumoniae or Haemophilus influenzae (non-beta-lactamase–producing strains only). (See CLINICAL STUDIES section.) NOTE: In view of the insufficient numbers of isolates of beta-lactamase–producing strains of Haemophilus influenzae and Moraxella catarrhalis that were obtained from clinical trials with cefuroxime axetil tablets for patients with acute bacterial maxillary sinusitis, it was not possible to adequately evaluate the effectiveness of cefuroxime axetil tablets for sinus infections known, suspected, or considered potentially to be caused by beta-lactamase–producing Haemophilus influenzae or Moraxella catarrhalis. 4. Acute Bacterial Exacerbations of Chronic Bronchitis and Secondary Bacterial Infections of Acute Bronchitis caused by Streptococcus pneumoniae , Haemophilus influenzae (beta-lactamase negative strains), or Haemophilus parainfluenzae (beta-lactamase negative strains). (See DOSAGE AND ADMINISTRATION section and CLINICAL STUDIES section.) 5. Uncomplicated Skin and Skin-Structure Infections caused by Staphylococcus aureus (including beta-lactamase–producing strains) or Streptococcus pyogenes. 6. Uncomplicated Urinary Tract Infections caused by Escherichia coli or Klebsiella pneumoniae . 7. Uncomplicated Gonorrhea, urethral and endocervical, caused by penicillinase-producing and non-penicillinase–producing strains of Neisseria gonorrhoeae and uncomplicated gonorrhea, rectal, in females, caused by non-penicillinase–producing strains of Neisseria gonorrhoeae . 8. Early Lyme Disease (erythema migrans) caused by Borrelia burgdorferi . To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefuroxime axetil tablets and other antibacterial drugs, cefuroxime axetil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:b1038e1c-5974-4f2b-9064-1f5132dc4424 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3515 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:f0028ff8-dac5-43aa-93a4-a5148bc8bff3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c2acfbeb-29a9-4551-8cfc-333e66c9d098"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NOTE: CEFUROXIME AXETIL TABLETS AND CEFUROXIME AXETIL FOR ORAL SUSPENSION ARE NOT BIOEQUIVALENT AND ARE NOT SUBSTITUTABLE ON A MILLIGRAM-PER-MILLIGRAM BASIS (SEE CLINICAL PHARMACOLOGY ). Cefuroxime Axetil Tablets: Cefuroxime axetil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: 1. Pharyngitis/Tonsillitis caused by Streptococcus pyogenes. NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefuroxime axetil tablets are generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefuroxime in the subsequent prevention of rheumatic fever are not available. Please also note that in all clinical trials, all isolates had to be sensitive to both penicillin and cefuroxime. There are no data from adequate and well-controlled trials to demonstrate the effectiveness of cefuroxime in the treatment of penicillin-resistant strains of Streptococcus pyogenes. 2. Acute Bacterial Otitis Media caused by Streptococcus pneumoniae , Haemophilus influenzae (including beta-lactamase–producing strains), Moraxella catarrhalis (including beta-lactamase–producing strains), or Streptococcus pyogenes. 3. Acute Bacterial Maxillary Sinusitis caused by Streptococcus pneumoniae or Haemophilus influenzae (non-beta-lactamase–producing strains only). (See CLINICAL STUDIES section.) NOTE: In view of the insufficient numbers of isolates of beta-lactamase–producing strains of Haemophilus influenzae and Moraxella catarrhalis that were obtained from clinical trials with cefuroxime axetil tablets for patients with acute bacterial maxillary sinusitis, it was not possible to adequately evaluate the effectiveness of cefuroxime axetil tablets for sinus infections known, suspected, or considered potentially to be caused by beta-lactamase–producing Haemophilus influenzae or Moraxella catarrhalis. 4. Acute Bacterial Exacerbations of Chronic Bronchitis and Secondary Bacterial Infections of Acute Bronchitis caused by Streptococcus pneumoniae , Haemophilus influenzae (beta-lactamase negative strains), or Haemophilus parainfluenzae (beta-lactamase negative strains). (See DOSAGE AND ADMINISTRATION section and CLINICAL STUDIES section.) 5. Uncomplicated Skin and Skin-Structure Infections caused by Staphylococcus aureus (including beta-lactamase–producing strains) or Streptococcus pyogenes. 6. Uncomplicated Urinary Tract Infections caused by Escherichia coli or Klebsiella pneumoniae . 7. Uncomplicated Gonorrhea, urethral and endocervical, caused by penicillinase-producing and non-penicillinase–producing strains of Neisseria gonorrhoeae and uncomplicated gonorrhea, rectal, in females, caused by non-penicillinase–producing strains of Neisseria gonorrhoeae . 8. Early Lyme Disease (erythema migrans) caused by Borrelia burgdorferi . To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefuroxime axetil tablets and other antibacterial drugs, cefuroxime axetil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:863c045d-3694-46cc-ae45-483501f10027 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3515 biolink:treats MONDO:0004277 PMID:41385096 "[{""id"":""uuid:0248764f-4695-4e2f-98e2-eae5b3ef60c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e65d0ebd-5cca-425b-8e7c-f55d1d0c82fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NOTE: CEFUROXIME AXETIL TABLETS AND CEFUROXIME AXETIL FOR ORAL SUSPENSION ARE NOT BIOEQUIVALENT AND ARE NOT SUBSTITUTABLE ON A MILLIGRAM-PER-MILLIGRAM BASIS (SEE CLINICAL PHARMACOLOGY ). Cefuroxime Axetil Tablets: Cefuroxime axetil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: 1. Pharyngitis/Tonsillitis caused by Streptococcus pyogenes. NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefuroxime axetil tablets are generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefuroxime in the subsequent prevention of rheumatic fever are not available. Please also note that in all clinical trials, all isolates had to be sensitive to both penicillin and cefuroxime. There are no data from adequate and well-controlled trials to demonstrate the effectiveness of cefuroxime in the treatment of penicillin-resistant strains of Streptococcus pyogenes. 2. Acute Bacterial Otitis Media caused by Streptococcus pneumoniae , Haemophilus influenzae (including beta-lactamase–producing strains), Moraxella catarrhalis (including beta-lactamase–producing strains), or Streptococcus pyogenes. 3. Acute Bacterial Maxillary Sinusitis caused by Streptococcus pneumoniae or Haemophilus influenzae (non-beta-lactamase–producing strains only). (See CLINICAL STUDIES section.) NOTE: In view of the insufficient numbers of isolates of beta-lactamase–producing strains of Haemophilus influenzae and Moraxella catarrhalis that were obtained from clinical trials with cefuroxime axetil tablets for patients with acute bacterial maxillary sinusitis, it was not possible to adequately evaluate the effectiveness of cefuroxime axetil tablets for sinus infections known, suspected, or considered potentially to be caused by beta-lactamase–producing Haemophilus influenzae or Moraxella catarrhalis. 4. Acute Bacterial Exacerbations of Chronic Bronchitis and Secondary Bacterial Infections of Acute Bronchitis caused by Streptococcus pneumoniae , Haemophilus influenzae (beta-lactamase negative strains), or Haemophilus parainfluenzae (beta-lactamase negative strains). (See DOSAGE AND ADMINISTRATION section and CLINICAL STUDIES section.) 5. Uncomplicated Skin and Skin-Structure Infections caused by Staphylococcus aureus (including beta-lactamase–producing strains) or Streptococcus pyogenes. 6. Uncomplicated Urinary Tract Infections caused by Escherichia coli or Klebsiella pneumoniae . 7. Uncomplicated Gonorrhea, urethral and endocervical, caused by penicillinase-producing and non-penicillinase–producing strains of Neisseria gonorrhoeae and uncomplicated gonorrhea, rectal, in females, caused by non-penicillinase–producing strains of Neisseria gonorrhoeae . 8. Early Lyme Disease (erythema migrans) caused by Borrelia burgdorferi . To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefuroxime axetil tablets and other antibacterial drugs, cefuroxime axetil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:5a378e6a-2f4f-4982-9642-e16c00d34c3d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3515 biolink:treats MONDO:0019632 PMID:41385096 "[{""id"":""uuid:a628d4f6-6423-4278-a4db-4aa4f74b1d8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c91cc529-4493-4f48-8e6b-36e01d8d737e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NOTE: CEFUROXIME AXETIL TABLETS AND CEFUROXIME AXETIL FOR ORAL SUSPENSION ARE NOT BIOEQUIVALENT AND ARE NOT SUBSTITUTABLE ON A MILLIGRAM-PER-MILLIGRAM BASIS (SEE CLINICAL PHARMACOLOGY ). Cefuroxime Axetil Tablets: Cefuroxime axetil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: 1. Pharyngitis/Tonsillitis caused by Streptococcus pyogenes. NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefuroxime axetil tablets are generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefuroxime in the subsequent prevention of rheumatic fever are not available. Please also note that in all clinical trials, all isolates had to be sensitive to both penicillin and cefuroxime. There are no data from adequate and well-controlled trials to demonstrate the effectiveness of cefuroxime in the treatment of penicillin-resistant strains of Streptococcus pyogenes. 2. Acute Bacterial Otitis Media caused by Streptococcus pneumoniae , Haemophilus influenzae (including beta-lactamase–producing strains), Moraxella catarrhalis (including beta-lactamase–producing strains), or Streptococcus pyogenes. 3. Acute Bacterial Maxillary Sinusitis caused by Streptococcus pneumoniae or Haemophilus influenzae (non-beta-lactamase–producing strains only). (See CLINICAL STUDIES section.) NOTE: In view of the insufficient numbers of isolates of beta-lactamase–producing strains of Haemophilus influenzae and Moraxella catarrhalis that were obtained from clinical trials with cefuroxime axetil tablets for patients with acute bacterial maxillary sinusitis, it was not possible to adequately evaluate the effectiveness of cefuroxime axetil tablets for sinus infections known, suspected, or considered potentially to be caused by beta-lactamase–producing Haemophilus influenzae or Moraxella catarrhalis. 4. Acute Bacterial Exacerbations of Chronic Bronchitis and Secondary Bacterial Infections of Acute Bronchitis caused by Streptococcus pneumoniae , Haemophilus influenzae (beta-lactamase negative strains), or Haemophilus parainfluenzae (beta-lactamase negative strains). (See DOSAGE AND ADMINISTRATION section and CLINICAL STUDIES section.) 5. Uncomplicated Skin and Skin-Structure Infections caused by Staphylococcus aureus (including beta-lactamase–producing strains) or Streptococcus pyogenes. 6. Uncomplicated Urinary Tract Infections caused by Escherichia coli or Klebsiella pneumoniae . 7. Uncomplicated Gonorrhea, urethral and endocervical, caused by penicillinase-producing and non-penicillinase–producing strains of Neisseria gonorrhoeae and uncomplicated gonorrhea, rectal, in females, caused by non-penicillinase–producing strains of Neisseria gonorrhoeae . 8. Early Lyme Disease (erythema migrans) caused by Borrelia burgdorferi . To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefuroxime axetil tablets and other antibacterial drugs, cefuroxime axetil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:2cb48dab-8ddb-46cc-b93a-c5b4121ed7f7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3515 biolink:treats HP:0031180 PMID:41385096 "[{""id"":""uuid:cf4e472b-7889-4da5-90dc-c918cb9e28bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ed168dbe-961f-40eb-93b7-d358310eb9eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NOTE: CEFUROXIME AXETIL TABLETS AND CEFUROXIME AXETIL FOR ORAL SUSPENSION ARE NOT BIOEQUIVALENT AND ARE NOT SUBSTITUTABLE ON A MILLIGRAM-PER-MILLIGRAM BASIS (SEE CLINICAL PHARMACOLOGY ). Cefuroxime Axetil Tablets: Cefuroxime axetil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: 1. Pharyngitis/Tonsillitis caused by Streptococcus pyogenes. NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefuroxime axetil tablets are generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefuroxime in the subsequent prevention of rheumatic fever are not available. Please also note that in all clinical trials, all isolates had to be sensitive to both penicillin and cefuroxime. There are no data from adequate and well-controlled trials to demonstrate the effectiveness of cefuroxime in the treatment of penicillin-resistant strains of Streptococcus pyogenes. 2. Acute Bacterial Otitis Media caused by Streptococcus pneumoniae , Haemophilus influenzae (including beta-lactamase–producing strains), Moraxella catarrhalis (including beta-lactamase–producing strains), or Streptococcus pyogenes. 3. Acute Bacterial Maxillary Sinusitis caused by Streptococcus pneumoniae or Haemophilus influenzae (non-beta-lactamase–producing strains only). (See CLINICAL STUDIES section.) NOTE: In view of the insufficient numbers of isolates of beta-lactamase–producing strains of Haemophilus influenzae and Moraxella catarrhalis that were obtained from clinical trials with cefuroxime axetil tablets for patients with acute bacterial maxillary sinusitis, it was not possible to adequately evaluate the effectiveness of cefuroxime axetil tablets for sinus infections known, suspected, or considered potentially to be caused by beta-lactamase–producing Haemophilus influenzae or Moraxella catarrhalis. 4. Acute Bacterial Exacerbations of Chronic Bronchitis and Secondary Bacterial Infections of Acute Bronchitis caused by Streptococcus pneumoniae , Haemophilus influenzae (beta-lactamase negative strains), or Haemophilus parainfluenzae (beta-lactamase negative strains). (See DOSAGE AND ADMINISTRATION section and CLINICAL STUDIES section.) 5. Uncomplicated Skin and Skin-Structure Infections caused by Staphylococcus aureus (including beta-lactamase–producing strains) or Streptococcus pyogenes. 6. Uncomplicated Urinary Tract Infections caused by Escherichia coli or Klebsiella pneumoniae . 7. Uncomplicated Gonorrhea, urethral and endocervical, caused by penicillinase-producing and non-penicillinase–producing strains of Neisseria gonorrhoeae and uncomplicated gonorrhea, rectal, in females, caused by non-penicillinase–producing strains of Neisseria gonorrhoeae . 8. Early Lyme Disease (erythema migrans) caused by Borrelia burgdorferi . To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefuroxime axetil tablets and other antibacterial drugs, cefuroxime axetil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:a9721bd6-c4b4-4c8f-badd-ccd2c595bc42 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5775 biolink:treats MONDO:0001134 PMID:41385096 "[{""id"":""uuid:bcd9d139-33de-4d66-b53c-cb28f7fa0085"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2d5b6095-0c7a-497a-ab82-2c46876e2b0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Essential hypertension, alone or as an adjunct. uuid:a15d2ac8-727f-4457-97c1-0eb3c75faff0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2611 biolink:treats MONDO:0005383 PMID:41385096 "[{""id"":""uuid:1da6d919-1b33-4489-8158-31962d682ff3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d57ecd4e-083e-4376-951b-bc5badac31fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Alprazolam extended-release tablets are indicated for the treatment of panic disorder, with or without agoraphobia. This claim is supported on the basis of two positive studies with alprazolam extended-release tablets conducted in patients whose diagnoses corresponded closely to the DSM-III-R/IV criteria for panic disorder (see CLINICAL STUDIES ). Panic disorder (DSM-IV) is characterized by recurrent unexpected panic attacks, i.e., a discrete period of intense fear or discomfort in which four (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) palpitations, pounding heart, or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded, or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes. The longer-term efficacy of alprazolam extended-release tablets has not been systematically evaluated. Thus, the physician who elects to use this drug for periods longer than 8 weeks should periodically reassess the usefulness of the drug for the individual patient. uuid:518b148c-8e11-431a-ac03-1a29f03ec720 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2611 biolink:treats MONDO:0003709 PMID:41385096 "[{""id"":""uuid:3f8ef47c-d8a8-47be-9774-edd89cfca1d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4fc09ba3-37a8-45b3-a053-fc5e10ab8af8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Alprazolam extended-release tablets are indicated for the treatment of panic disorder, with or without agoraphobia. This claim is supported on the basis of two positive studies with alprazolam extended-release tablets conducted in patients whose diagnoses corresponded closely to the DSM-III-R/IV criteria for panic disorder (see CLINICAL STUDIES ). Panic disorder (DSM-IV) is characterized by recurrent unexpected panic attacks, i.e., a discrete period of intense fear or discomfort in which four (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) palpitations, pounding heart, or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded, or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes. The longer-term efficacy of alprazolam extended-release tablets has not been systematically evaluated. Thus, the physician who elects to use this drug for periods longer than 8 weeks should periodically reassess the usefulness of the drug for the individual patient. uuid:36a13640-2347-4db7-bebe-c768d772f08c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8665 biolink:treats MONDO:0029000 PMID:41385096 "[{""id"":""uuid:ab6db989-25be-418e-80f1-65876439ccd4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:976ff3cc-08e2-4948-97dc-e14bc6201aae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pyridostigmine bromide is indicated for pretreatment against the lethal effects of Soman nerve agent poisoning. Pyridostigmine is intended for use in conjunction with protective garments, including a mask. At the first sign of nerve agent poisoning, pyridostigmine should be stopped, and atropine and pralidoxime therapy started immediately. The evidence for the effectiveness of pyridostigmine as pretreatment against Soman-induced toxicity was derived from animal studies alone [see Nonclinical Toxicology (13.2) ]. FOR MILITARY MEDICAL USE ONLY uuid:954f23b3-29a4-48f0-b525-e2349cbf34dc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:101853 biolink:treats UMLS:C1735365 PMID:41385096 "[{""id"":""uuid:32c813d1-1996-44d4-92aa-89a171ad1632"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3453fa41-3f50-4537-9cd9-2d99a484406b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FACTIVE is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below. (See DOSAGE AND ADMINISTRATION and CLINICAL STUDIES . ) Acute bacterial exacerbation of chronic bronchitis caused by Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis . Community-acquired pneumonia (of mild to moderate severity) caused by Streptococcus pneumoniae (including multi-drug resistant strains [MDRSP])*, Haemophilus influenzae, Moraxella catarrhalis, Mycoplasma pneumoniae, Chlamydia pneumoniae, or Klebsiella pneumoniae . *MDRSP: multi-drug resistant Streptococcus pneumoniae , includes isolates previously known as PRSP (penicillin-resistant Streptococcus pneumoniae ), and are strains resistant to two or more of the following antibiotics: penicillin (MIC ≥2 μg/mL), 2nd generation cephalosporins (e.g., cefuroxime), macrolides, tetracyclines and trimethoprim/sulfamethoxazole. To reduce the development of drug-resistant bacteria and maintain the effectiveness of FACTIVE and other antibacterial drugs, FACTIVE should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:9dc7fe8f-8573-464c-93ee-1f6b28dfa1b6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:101853 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:5439b1b7-4236-4662-9b50-130685805b33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a3f1661b-4ae9-42ae-9b6f-1e8ec969afe5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FACTIVE is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below. (See DOSAGE AND ADMINISTRATION and CLINICAL STUDIES . ) Acute bacterial exacerbation of chronic bronchitis caused by Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis . Community-acquired pneumonia (of mild to moderate severity) caused by Streptococcus pneumoniae (including multi-drug resistant strains [MDRSP])*, Haemophilus influenzae, Moraxella catarrhalis, Mycoplasma pneumoniae, Chlamydia pneumoniae, or Klebsiella pneumoniae . *MDRSP: multi-drug resistant Streptococcus pneumoniae , includes isolates previously known as PRSP (penicillin-resistant Streptococcus pneumoniae ), and are strains resistant to two or more of the following antibiotics: penicillin (MIC ≥2 μg/mL), 2nd generation cephalosporins (e.g., cefuroxime), macrolides, tetracyclines and trimethoprim/sulfamethoxazole. To reduce the development of drug-resistant bacteria and maintain the effectiveness of FACTIVE and other antibacterial drugs, FACTIVE should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:fcdcfac3-2120-4086-ad13-ffd422f3fd5c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63618 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:c6ab736c-81fe-4de3-9c7b-a7efc6de7402"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:09afa148-6a6a-4e3b-b189-001860f2252f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with Pravastatin Sodium Tablets should be considered in those individuals at increased risk for atherosclerosis-related clinical events as a function of cholesterol level, the presence or absence of coronary heart disease, and other risk factors. uuid:99d57f75-6e69-43c1-a0ca-5d1854d47331 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6741 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:d4daedfb-c115-4311-b89e-d8ffbe17e236"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ae4b1c08-2d47-4258-ab4b-65f3ef7a0fa8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of meloxicam tablets and other treatment options before deciding to use meloxicam tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Meloxicam tablets are indicated for relief of the signs and symptoms of osteoarthritis and rheumatoid arthritis. uuid:6d4e40eb-7334-4d42-bf47-cb39dae82e9b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3764 biolink:treats UMLS:C0919659 PMID:41385096 "[{""id"":""uuid:432f1322-689c-4d73-89a2-e05748d3cd51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:82ec400c-24fc-4935-aa96-cce54af52da9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clotrimazole Troches (clotrimazole lozenges) are indicated for the local treatment of oropharyngeal candidiasis. The diagnosis should be confirmed by a KOH smear and/or culture prior to treatment. Clotrimazole Troches (clotrimazole lozenges) are also indicated prophylactically to reduce the incidence of oropharyngeal candidiasis in patients immunocompromised by conditions that include chemotherapy, radiotherapy, or steroid therapy utilized in the treatment of leukemia, solid tumors, or renal transplantation. There are no data from adequate and well-controlled trials to establish the safety and efficacy of this product for prophylactic use in patients immunocompromised by etiologies other than those listed in the previous sentence. (See DOSAGE AND ADMINISTRATION .) uuid:af96464c-c937-458a-a1de-6c80d127815d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3764 biolink:treats MONDO:0005059 PMID:41385096 "[{""id"":""uuid:ac7a3cdf-947b-4f24-8a75-c61acaef9e72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ec74edb7-0781-4737-a6fc-e4cbaddeedd7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clotrimazole Troches (clotrimazole lozenges) are indicated for the local treatment of oropharyngeal candidiasis. The diagnosis should be confirmed by a KOH smear and/or culture prior to treatment. Clotrimazole Troches (clotrimazole lozenges) are also indicated prophylactically to reduce the incidence of oropharyngeal candidiasis in patients immunocompromised by conditions that include chemotherapy, radiotherapy, or steroid therapy utilized in the treatment of leukemia, solid tumors, or renal transplantation. There are no data from adequate and well-controlled trials to establish the safety and efficacy of this product for prophylactic use in patients immunocompromised by etiologies other than those listed in the previous sentence. (See DOSAGE AND ADMINISTRATION .) uuid:b392b277-875b-46f5-a400-c6a67d76df2f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3764 biolink:treats UMLS:C0280100 PMID:41385096 "[{""id"":""uuid:db425a48-f411-4b08-ab67-52923b2262a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:41711e3a-11ac-4da5-a58f-48c0896eb556"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clotrimazole Troches (clotrimazole lozenges) are indicated for the local treatment of oropharyngeal candidiasis. The diagnosis should be confirmed by a KOH smear and/or culture prior to treatment. Clotrimazole Troches (clotrimazole lozenges) are also indicated prophylactically to reduce the incidence of oropharyngeal candidiasis in patients immunocompromised by conditions that include chemotherapy, radiotherapy, or steroid therapy utilized in the treatment of leukemia, solid tumors, or renal transplantation. There are no data from adequate and well-controlled trials to establish the safety and efficacy of this product for prophylactic use in patients immunocompromised by etiologies other than those listed in the previous sentence. (See DOSAGE AND ADMINISTRATION .) uuid:4fd78c81-f31b-4354-bef3-23be6bcc74f0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7903 biolink:treats MONDO:0043455 PMID:41385096 "[{""id"":""uuid:c7b7b107-c6ce-42e6-ab9b-b7b039eeea43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0cc153d6-a7ec-4c53-9f62-65d37ab6fe6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pamidronate disodium, in conjunction with adequate hydration, is indicated for the treatment of moderate or severe hypercalcemia associated with malignancy, with or without bone metastases. Patients who have either epidermoid or non-epidermoid tumors respond to treatment with pamidronate disodium. Vigorous saline hydration, an integral part of hypercalcemia therapy, should be initiated promptly and an attempt should be made to restore the urine output to about 2 L/day throughout treatment. Mild or asymptomatic hypercalcemia may be treated with conservative measures (i.e., saline hydration, with or without loop diuretics). Patients should be hydrated adequately throughout the treatment, but overhydration, especially in those patients who have cardiac failure, must be avoided. Diuretic therapy should not be employed prior to correction of hypovolemia. The safety and efficacy of pamidronate disodium in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions has not been established. uuid:b2f145df-9abf-4725-a386-53b62d3a2edf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0000004 PMID:41385096 "[{""id"":""uuid:4d1423db-63cb-47a5-a63e-ff7224228a9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cdbfb33f-44dc-4eab-98a7-dc2556039c8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:7dc6d099-a71a-48a4-a6d2-94089e577dff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0018479 PMID:41385096 "[{""id"":""uuid:e136e4e6-e8e2-4769-88f6-1c018682aa84"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a540533f-3577-42a6-8036-7f3ce7a5369e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:e695dc6e-630a-425b-beac-44bc8e13c5d3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0006982 PMID:41385096 "[{""id"":""uuid:6d9fe9b0-0c84-4a84-9957-b74b55b72edd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0d08eefd-06bb-4805-ac9d-5ad14ab5427c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:781c9b32-5619-41d8-a686-064c803fe5c9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0043455 PMID:41385096 "[{""id"":""uuid:07aa8942-f36c-41e3-94a4-c9fbc71b2d43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:545996cd-ce9b-40f4-bb06-358fa292da8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:5df806a8-c242-4384-b699-1dfc36b58242 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:8888f4dc-2604-4479-9583-9db656766247"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3e864380-dc7f-4095-b84d-6059a497bc0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:a3bedc38-270d-4783-a1b6-a558307b312d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:0faa4f24-96de-4132-bc75-71870296f1b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:87762a94-ca62-4ece-9130-13b80e93641b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:2535d052-91ba-4e4a-941a-4d46464c1c75 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0011429 PMID:41385096 "[{""id"":""uuid:50c8dda4-a862-4ada-a616-0524545fb39e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a430c9b2-3922-43c7-9c87-a4ecbc02cd35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:c818915f-f477-436a-9043-78f1ff1fca40 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:732dc598-50b7-46dd-904d-28dbb1c4b714"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:69898c1e-8b49-45bd-9e9d-d1ed256bf72c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:df1a5f9d-90ea-463c-9c64-3c475e238bdd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats UMLS:C1290158 PMID:41385096 "[{""id"":""uuid:2b6f2abb-1d9e-4bc3-97aa-f5e721f40cdb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:881340df-21bf-4606-ae91-f81b2cfe4dda"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:a705879f-2118-4894-b53e-1a75398f411b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0040698 PMID:41385096 "[{""id"":""uuid:a56c4583-775b-4387-b646-4517910ac733"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:81e422d2-0942-4f8d-97b6-c2c138f98d58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:c4614a4c-9518-4ddc-b392-04f8995b1bdc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0004855 PMID:41385096 "[{""id"":""uuid:a3c89eea-a668-4bf3-a228-36a77ca00f2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:645b4ce3-814a-43dc-b764-7d0e7c8768fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:42479658-9860-464f-b53a-b0de95c7eafb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats UMLS:C0149896 PMID:41385096 "[{""id"":""uuid:e9d903d3-7a53-45c9-88a9-879076ea37bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d1c1126b-8b1b-4bc9-9a30-6ecd23fe26c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:26a03be7-62cb-4eb1-839e-b854895c02ea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0002400 PMID:41385096 "[{""id"":""uuid:4c28e23f-e3b0-4be2-b5fc-bb9f3f8add18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:855160c7-d226-4cf2-a683-356fd9edf231"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:83d7c7aa-01b9-4a02-a954-2a855ab2bb20 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:28bf6e2f-2659-4539-9b46-ba07173cfe1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:53260e78-26ba-46e5-a680-0160f2a966da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:99ba14d5-7657-4b3b-aa4f-c36bc2992a4e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0001875 PMID:41385096 "[{""id"":""uuid:17cb6815-fb67-4568-9238-433231654b17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:17711292-7b9d-4bf7-86f8-bb9969bf7f1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:32e1208c-aa4a-4a06-a723-b4b3d952fa8c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats UMLS:C5441648 PMID:41385096 "[{""id"":""uuid:f13e7889-a58e-4237-94f8-e729fdaf2e7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b9572a03-39f7-448a-8a88-dd40d6696f8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:19195404-b174-42e8-8b80-da93dcb197bd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0016367 PMID:41385096 "[{""id"":""uuid:ac42087c-25d8-4f1e-afae-e418b0e429e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7f8c08bf-b38a-44f0-9d68-de3673fbf22c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:d9549c6e-59d3-4fb3-90a7-d28b12e04f30 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0019127 PMID:41385096 "[{""id"":""uuid:caa7bf25-2822-47c0-9209-02b86512f244"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8a9026c4-ef04-4430-b0a8-8f24d99aaa6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:24134f6d-f53b-4ce6-8cf4-7b9c56ceddcb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0006594 PMID:41385096 "[{""id"":""uuid:0895a483-9266-4aa8-8af1-8f1ecfc5d689"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cfa1f9a7-8d60-4008-9b60-8e8d4c52d193"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:bd50d8f4-08ca-41b5-8155-d54df122e16f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0015614 PMID:41385096 "[{""id"":""uuid:8da31639-d579-4821-b0d2-b249bdcae574"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:15e85fa1-c3f5-4465-9423-b4e040027031"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:42103b8e-4aa4-480e-b1f5-7a8e9bb8bef8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0006545 PMID:41385096 "[{""id"":""uuid:e8499a46-212c-4382-ae1c-f551ace59a71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a87bef8a-3349-4f66-9435-72bcff706dcf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:6203b418-abd8-49e9-820d-921b2beb2412 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0018229 PMID:41385096 "[{""id"":""uuid:e18577e6-6c11-43df-9627-1528d6482baf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8e0e2db7-50cb-461d-97d5-095d64b84432"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:93a14893-be17-43cc-850f-5ba4825eeba8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0043233 PMID:41385096 "[{""id"":""uuid:8c10fd64-cef3-4ff5-b5e5-38d339324b4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1a28ce65-cd61-4aa1-b207-2b1785db8223"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:80ac6d0b-8d62-4a10-9cef-29fba8c17473 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0009691 PMID:41385096 "[{""id"":""uuid:936743d3-e6a6-4f2d-9566-4d45376cfded"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9da142d3-261c-4d12-9c09-d612302ed447"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:686ef76a-836e-4277-b476-19a6834355ef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:c995fa0a-890d-4a32-a103-5ae5ddd72e0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:98b4da75-d7db-426a-9f6a-2f2b3757dc47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:18c30e29-f4b8-4b14-9d4d-dc23d6a01be5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0006608 PMID:41385096 "[{""id"":""uuid:9ce4b353-4f30-4866-b1ae-6fc9ff198a6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ed3bcd37-0ebb-4d67-a240-1796bac4087a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:5bfd3730-d3f1-4208-9627-611afa5180a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:bfc7343e-b80d-4377-8a5e-4e6792775b00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a7ae3d39-2c29-454b-a3e1-36242c45a3e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:d077a58f-96a8-4722-ae4a-176c4859c7ab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0024332 PMID:41385096 "[{""id"":""uuid:3bd03e1d-4bd3-4e28-9384-235bcb85753a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c268be63-dafd-4f0d-9f0b-21dcea1a3438"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:8d71d7e2-8871-4761-b907-626f677c1740 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:9e48911d-32e5-44b2-b0fe-9edafc615820"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f30b0a85-d51a-4873-bb52-52c0b48aa56d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:dd793e18-647b-46f1-b47d-7f0edee9acfc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0005480 PMID:41385096 "[{""id"":""uuid:927d2d3b-bc0c-4c23-aa0c-f395a376ddda"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7d6a97c9-8078-41dc-9c7e-87c8941fd570"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:62e437b2-d9f6-4be9-9cab-d71c7dfac1ca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:ebcd2d56-9c9f-4f7c-aa43-bc7f1a7ff025"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4b10bd35-5407-4205-987a-e7c182932a5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:46dde75e-00c5-41f1-9633-d561a5cfbebd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0043789 PMID:41385096 "[{""id"":""uuid:774f12da-17b6-4108-bb4e-1180af88fdc3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:781477df-b769-46f0-87c5-0bfa9ad99d1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:c15da950-cd2a-48d7-b4d2-749ba05515d1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0000775 PMID:41385096 "[{""id"":""uuid:0c9a318e-b99a-458b-b5e5-0a5861bc66be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7d3c8fdf-b60f-43f0-bd63-58ca62eb1cc6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:e23bce56-d7bb-4266-9f94-11ac889b27a3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0003085 PMID:41385096 "[{""id"":""uuid:ce30022c-20d8-4429-8b30-4176f05a1d51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:737d2421-2ad0-4d4b-9a6d-6df0ed482624"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:048d871c-d95d-4adf-935f-fe252d0fb423 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0001034 PMID:41385096 "[{""id"":""uuid:549b7eb2-6837-4cf1-9791-b6364a8f59b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:170d7a1a-0b55-43ce-ab32-a731146fe44f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:f25d091a-9e5e-4087-a7a9-fd07ffc32c7c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0005883 PMID:41385096 "[{""id"":""uuid:3cdf32e3-e7a6-471d-a103-de6dcfa30197"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:59ca2488-6644-4d39-ac6a-7e8c242a2def"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:2e648c2e-c7b1-46e5-867a-14ef2ad521cb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0006814 PMID:41385096 "[{""id"":""uuid:44f667f6-c3db-4016-9aeb-b88e8b83da46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0df5749b-91cf-4d89-b42d-5e49df445668"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:4a21b1a2-9b16-49bf-809f-2feac964adaf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0004773 PMID:41385096 "[{""id"":""uuid:91c2c7e9-994f-4341-a84f-22a9d58a12e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ebb1b9a6-fd86-4dd7-867c-8100c647fe27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:78f3bd30-1060-413a-9bc5-9f576e992063 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0004674 PMID:41385096 "[{""id"":""uuid:ed9521db-9900-410e-82e2-ec55aec868d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2aac68d4-e92c-4181-a1a2-8f1e2cdf5cd6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:fc199608-9dbf-41ed-8110-7a0b72642b16 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0006651 PMID:41385096 "[{""id"":""uuid:c7a2daf4-230a-4fea-97b2-f1b46d781a84"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7bffe333-f9bc-4f96-9ca9-b09045d78fea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:c2e91665-2e86-4414-b9d7-a187ade7f48e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0006918 PMID:41385096 "[{""id"":""uuid:f7dae415-b8d9-4b21-b76a-382b1d86d36c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:82efbcab-2dad-4b53-a28f-b606864106d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:ad9bfbab-b625-4af9-a1d7-4a69ace57f7b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0001280 PMID:41385096 "[{""id"":""uuid:7c163ef7-6eaa-463a-b959-333f9c694d96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2ef9a450-dda4-48ee-9888-cd166bf6258d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:ee3fac72-9b1e-4521-8343-18ab765cb902 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0005885 PMID:41385096 "[{""id"":""uuid:e94b213c-f488-41a1-a359-5434e904e5ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8c1b2a89-a0bb-4f7a-83a4-5121b96fb94c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:9f4bf9ca-cb25-40c0-bc7b-ce986008e626 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0019198 PMID:41385096 "[{""id"":""uuid:6263f372-9961-4ca7-b494-1a025d784c72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2ec6ddfe-ea7d-4b0d-a7ad-38366a4e6ef0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:5d147b9e-8425-4c7f-a9b1-9c2e8e5e69e7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0019338 PMID:41385096 "[{""id"":""uuid:e152f7c0-7949-4e9c-8910-a48c811465e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7522ecf9-2406-4c9e-8e83-d2c94c1cf4c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:348865f3-6ac7-434a-a2e5-b7cf9c0085f3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0015274 PMID:41385096 "[{""id"":""uuid:e2a3fbcf-deec-4624-b08b-9c6c3fe26da5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:578b7297-501d-4d93-ab94-d2003abd1b9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:3466f277-5196-41b1-958e-3deb13c3e277 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0006052 PMID:41385096 "[{""id"":""uuid:61ffadbe-7afa-457c-beee-1ff4c2259c21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:367070ba-4746-4425-981f-926635f602db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:6709c624-f278-4cd9-8769-0a53e9eacb00 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0005848 PMID:41385096 "[{""id"":""uuid:75835f5e-445a-4c30-8be6-81afaab818f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dfc4996d-6754-4adb-bb33-949f7cc7dfd7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:4b3139d0-ee2b-4b24-a3ec-b0c9900c3fad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0002572 PMID:41385096 "[{""id"":""uuid:358fa424-b950-46f6-a161-cf1a09cde7ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:840eab05-04f1-42e5-b141-5b834bad2ae6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:a030190a-fc9e-456c-a025-a84b7f30c60a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0019098 PMID:41385096 "[{""id"":""uuid:1bbfade7-7b55-4024-b3df-38ca39f31507"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:38db3728-c7a5-4faa-95cc-f154c7a761fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:3f4d8906-630a-41a1-985b-147a1fc7a84b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0001198 PMID:41385096 "[{""id"":""uuid:d7215efd-5160-451b-b16b-a612937b0843"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6bc085a5-1754-45e7-95c1-89d986c044d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:5ef691e3-cbe9-4da4-b727-2360f4b4f97f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats UMLS:C0002879 PMID:41385096 "[{""id"":""uuid:1ec880a7-c5af-4c4e-b551-078e6ba7652b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d7f7ef1c-b24f-4622-9db8-5bd536c94bea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:304c64aa-bbcd-4f1e-a420-575d3b9082eb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0020108 PMID:41385096 "[{""id"":""uuid:e48cc30c-dfc1-40e3-a62f-944d31093086"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6c2f7bcc-0e70-46ae-8332-72da6cea2d31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:53146d6a-7f43-4aa6-856c-299959cd607a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0002280 PMID:41385096 "[{""id"":""uuid:2e6180d3-047a-425f-b4bc-bdc41f6243a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1c5cb487-ecf8-499a-9e69-f65b10c972f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:1156da91-71c7-4607-bc2d-adfa1f55a975 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0015253 PMID:41385096 "[{""id"":""uuid:37a75167-4c37-4714-8693-e9bc32f7a227"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fd9f828c-5a2e-4788-9513-799fd2cfea72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:0c23a6ee-175e-47c4-b74a-515a59c485d0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats HP:0001908 PMID:41385096 "[{""id"":""uuid:5a9056d3-0bd2-417b-adfe-bd57530bc077"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:91c050d3-b5b6-4707-99f7-7b1e5051a200"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:de2d5b18-18f2-4fbb-a366-7053c1b35f7a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0005059 PMID:41385096 "[{""id"":""uuid:6359d1f9-fe6e-47ab-afab-f999a779fedf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:42afdf71-4895-45f3-b26b-96b6b67cd251"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:14438c14-9b62-47c0-97f2-e900217a2459 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0004095 PMID:41385096 "[{""id"":""uuid:962a16c9-39f9-4b47-829b-e66d259b76f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a6b913cf-b0cd-4a66-a1a7-7f20c0fb41a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:d2b20719-eb01-4d54-a869-700c9487cc31 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0004355 PMID:41385096 "[{""id"":""uuid:337e94f8-8bed-4f91-a5bf-c5b78626b6bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a38018a3-7d28-48d2-8af3-b2d0620e4b59"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:f2bf798e-30a9-484e-b572-a8ffc1d0ac5a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0005377 PMID:41385096 "[{""id"":""uuid:222aebce-e947-4743-ab0f-af810c6ad9a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a19252fb-07b1-460e-a9a3-10c338f6a7e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:5b95e8f2-a258-41a6-85ea-753b43dff39b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0007008 PMID:41385096 "[{""id"":""uuid:a9b131fa-8c3f-467d-be12-4bac66fdafc8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5227eebf-3c77-4946-9519-fee10cfb9879"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:4e6d0b14-1a1b-4db7-82f2-afc1a3a845f7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:ceeb3817-d124-4a7f-8dd0-8e927a97e0f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e9bfb754-a435-489e-9d1f-f992575db718"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:d4b48ce5-3284-44f7-8119-2a9d666c7b74 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats UMLS:C0678202 PMID:41385096 "[{""id"":""uuid:9382b3f4-d906-4851-ac4b-eb976273a4f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7f9d5738-31e7-4e70-a4b2-d08c8fc02a9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:f866e931-299f-465f-a527-45c7c4861200 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0006042 PMID:41385096 "[{""id"":""uuid:43606b05-2ef3-4ad9-815e-a4fd35171f93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8cd3a082-cbdf-49ad-b33a-d088b1f0898a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:c57cdf17-bdc6-4b58-85a1-1691e6c736f3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0019444 PMID:41385096 "[{""id"":""uuid:ff2eec43-1feb-4df1-9565-21eb5f401a28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c8658580-cf92-40a1-b25c-f5287dcda856"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy): Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis or osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Disease Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis Hematologic Disorder Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Disease For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:04a714f7-9594-4182-8977-55d9b96bc6f6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:39867 biolink:treats MONDO:0004985 PMID:41385096 "[{""id"":""uuid:04b5fbd4-f896-4506-9bc3-74a9b744e6e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5474ef16-a1ec-421a-94b8-ec78dcd95a3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Divalproex sodium is indicated for the treatment of the manic episodes associated with bipolar disorder. A manic episode is a distinct period of abnormally and persistently elevated, expansive, or irritable mood. Typical symptoms of mania include pressure of speech, motor hyperactivity, reduced need for sleep, flight of ideas, grandiosity, poor judgement, aggressiveness, and possible hostility. The efficacy of divalproex sodium was established in 3 week trials with patients meeting DSM-III-R criteria for bipolar disorder who were hospitalized for acute mania (See Clinical Trials under CLINICAL PHARMACOLOGY ). The safety and effectiveness of divalproex sodium for long-term use in mania, i.e., more than 3 weeks, has not been systematically evaluated in controlled clinical trials. Therefore, physicians who elect to use divalproex sodium for extended periods should continually reevaluate the long-term usefulness of the drug for the individual patient. uuid:28094953-c835-481b-ba88-193527ef9029 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:39867 biolink:treats UMLS:C0235165 PMID:41385096 "[{""id"":""uuid:836ca90f-cae3-42fd-b99a-df42f03f41bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dea6bec5-8757-4971-9b65-ed3bc0cf6e26"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Divalproex sodium is indicated for the treatment of the manic episodes associated with bipolar disorder. A manic episode is a distinct period of abnormally and persistently elevated, expansive, or irritable mood. Typical symptoms of mania include pressure of speech, motor hyperactivity, reduced need for sleep, flight of ideas, grandiosity, poor judgement, aggressiveness, and possible hostility. The efficacy of divalproex sodium was established in 3 week trials with patients meeting DSM-III-R criteria for bipolar disorder who were hospitalized for acute mania (See Clinical Trials under CLINICAL PHARMACOLOGY ). The safety and effectiveness of divalproex sodium for long-term use in mania, i.e., more than 3 weeks, has not been systematically evaluated in controlled clinical trials. Therefore, physicians who elect to use divalproex sodium for extended periods should continually reevaluate the long-term usefulness of the drug for the individual patient. uuid:387c93d5-42f7-4ee6-b3d7-39fa57d8f1e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2676 biolink:treats MONDO:0001039 PMID:41385096 "[{""id"":""uuid:9a499389-5e26-4e0d-aece-8871b2d5ae5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6dabf261-b017-4303-af63-5038b18d8b14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MOXATAG is a penicillin-class antibacterial indicated for the treatment of tonsillitis and/or pharyngitis secondary to Streptococcus pyogenes in adults and pediatric patients 12 years or older. ( 1 ) uuid:7e0cbacc-19e9-43f7-9f81-e2a59d614d73 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3032 biolink:treats HP:0012735 PMID:41385096 "[{""id"":""uuid:a0b61ad7-651f-493e-8e1a-1b5d815f010a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c0a8c868-533c-4fc9-b14c-cfaca641b263"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Benzonatate capsules, USP are indicated for the symptomatic relief of cough. uuid:5765aa79-7c74-4a7e-bbf4-724d57624f18 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:XM33Q67UVH biolink:treats UMLS:C1306762 PMID:41385096 "[{""id"":""uuid:88590065-5be4-482a-8e7d-fe0ef10d9c60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ee9ce580-be41-4354-985d-eb6952cfdb06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VASOVIST is indicated for use as a contrast agent in magnetic resonance angiography (MRA) to evaluate aortoiliac occlusive disease (AIOD) in adults with known or suspected peripheral vascular disease [ see Clinical Studies (14) ] . uuid:87a4d8df-a0e1-4cbb-a2f5-e1e261ca4572 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:XM33Q67UVH biolink:treats MONDO:0005294 PMID:41385096 "[{""id"":""uuid:2860384e-00da-4115-972c-402c4caac80a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:89a586b0-fe13-4bcd-b1c7-1b7433742ad0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VASOVIST is indicated for use as a contrast agent in magnetic resonance angiography (MRA) to evaluate aortoiliac occlusive disease (AIOD) in adults with known or suspected peripheral vascular disease [ see Clinical Studies (14) ] . uuid:86775d40-f09f-42f9-b0e9-efa36eaa4888 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0007008 PMID:41385096 "[{""id"":""uuid:f80d6020-be4e-49e9-9253-4ad00786399d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cd788c37-ea6a-42b0-89d4-ac0d448a0f4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisone tablets are indicated in the following conditions: Endocrine disorders: primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. Rheumatic disorders: as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy), ankylosing spondylitis, acute and subacute bursitis, acute nonspecific tenosynovitis, acute gouty arthritis, post-traumatic osteoarthritis, synovitis of osteoarthritis, epicondylitis. Collagen diseases: during an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematosus, systemic dermatomyositis (polymyositis), acute rheumatic carditis. Dermatologic diseases: pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative dermatitis; mycosis fungoides; severe psoriasis; severe seborrheic dermatitis. Allergic states: control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: seasonal or perennial allergic rhinitis; bronchial asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. Ophthalmic diseases: severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: allergic corneal marginal ulcers, herpes zoster ophthalmicus, anterior segment inflammation, diffuse posterior uveitis and choroiditis, sympathetic ophthalmia, allergic conjunctivitis, keratitis, chorioretinitis, optic neuritis, iritis and iridocyclitis. Respiratory diseases: symptomatic sarcoidosis; Loeffler’s syndrome not manageable by other means; berylliosis; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; aspiration pneumonitis. Hematologic disorders: idiopathic thrombocytopenic purpura in adults; secondary thrombocytopenia in adults; acquired (autoimmune) hemolytic anemia; erythroblastopenia (RBC anemia); congenital (erythroid) hypoplastic anemia. Neoplastic diseases: for palliative management of: leukemias and lymphomas in adults, acute leukemia of childhood. Edematous states: to induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. Gastrointestinal diseases: to tide the patient over a critical period of the disease in: ulcerative colitis, regional enteritis. Nervous system: acute exacerbations of multiple sclerosis. Miscellaneous: tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy; trichinosis with neurologic or myocardial involvement. uuid:374869dd-043f-4091-b35f-37eccee2e51c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1162674 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:01050a7d-e2db-4a61-b818-79e7ab4facae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7bb5f55f-32d3-4af0-aac0-6905d8dc8a4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fosinopril sodium and hydrochlorothiazide tablets are indicated for the treatment of hypertension. These fixed dose combinations are not indicated for initial therapy. (See DOSAGE AND ADMINISTRATION .) In using fosinopril sodium-hydrochlorothiazide tablets, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that fosinopril does not have a similar risk (see WARNINGS: Neutropenia/Agranulocytosis ). ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see WARNINGS: Head and Neck Angioedema and Intestinal Angiodema .) uuid:4b1eb344-ae75-4553-a491-e9085053337c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1162674 biolink:treats MONDO:0001609 PMID:41385096 "[{""id"":""uuid:1e5f3ccd-178b-401b-9419-27b8b111ddd7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4ab324d5-5d8c-43cb-8e6f-fb0a706dde40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fosinopril sodium and hydrochlorothiazide tablets are indicated for the treatment of hypertension. These fixed dose combinations are not indicated for initial therapy. (See DOSAGE AND ADMINISTRATION .) In using fosinopril sodium-hydrochlorothiazide tablets, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that fosinopril does not have a similar risk (see WARNINGS: Neutropenia/Agranulocytosis ). ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see WARNINGS: Head and Neck Angioedema and Intestinal Angiodema .) uuid:14eb09b7-a499-40cd-934c-83a34fbeff7e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1162674 biolink:treats MONDO:0001343 PMID:41385096 "[{""id"":""uuid:d0ac479b-e75a-4c6f-a135-6f32ed5e8c93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:060df3ad-3435-4f91-8a0c-60873a2d53a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fosinopril sodium and hydrochlorothiazide tablets are indicated for the treatment of hypertension. These fixed dose combinations are not indicated for initial therapy. (See DOSAGE AND ADMINISTRATION .) In using fosinopril sodium-hydrochlorothiazide tablets, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that fosinopril does not have a similar risk (see WARNINGS: Neutropenia/Agranulocytosis ). ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see WARNINGS: Head and Neck Angioedema and Intestinal Angiodema .) uuid:1571162e-1fe1-48d1-8012-132f2463cd08 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1162674 biolink:treats MONDO:0010481 PMID:41385096 "[{""id"":""uuid:a7ae0aec-e97f-4562-bf6d-fa36cd9407ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f4aa1e63-3373-43d7-87ed-980fab5fdf5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fosinopril sodium and hydrochlorothiazide tablets are indicated for the treatment of hypertension. These fixed dose combinations are not indicated for initial therapy. (See DOSAGE AND ADMINISTRATION .) In using fosinopril sodium-hydrochlorothiazide tablets, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that fosinopril does not have a similar risk (see WARNINGS: Neutropenia/Agranulocytosis ). ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see WARNINGS: Head and Neck Angioedema and Intestinal Angiodema .) uuid:90158d13-3df9-4c8c-abee-884af4aada05 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59750 biolink:treats MONDO:0005093 PMID:41385096 "[{""id"":""uuid:fc4b2cc3-80ed-4e53-ace3-100200224317"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c1689e92-0395-4318-a53f-2840319ecffe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] psorcon (diflorasone diacetate cream), 0.05% is a high potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. uuid:c3576c1a-cef3-4a10-86d7-bd323e4a17ff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17823 biolink:treats HP:0002901 PMID:41385096 "[{""id"":""uuid:cc91d0d9-67fb-4554-89b7-b988e7a35c10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cbae2c5b-d326-4b8a-a0ed-7f745d70895c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Calcitriol Injection is indicated in the management of hypocalcemia in patients undergoing chronic renal dialysis. It has been shown to significantly reduce elevated parathyroid hormone levels. Reduction of PTH has been shown to result in an improvement in renal osteodystrophy. uuid:cd81e184-ecfc-45f1-84aa-403b7b315fda biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17823 biolink:treats MONDO:0006946 PMID:41385096 "[{""id"":""uuid:95931fd5-14a6-4550-af4b-ff1c9f96bbf0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:901d9632-c1fe-487e-b3c7-f817f08ba22e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Calcitriol Injection is indicated in the management of hypocalcemia in patients undergoing chronic renal dialysis. It has been shown to significantly reduce elevated parathyroid hormone levels. Reduction of PTH has been shown to result in an improvement in renal osteodystrophy. uuid:556313ee-13c9-4091-bd21-e63352b2dc8c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49713 biolink:treats MONDO:0004985 PMID:41385096 "[{""id"":""uuid:ae81e9b5-423b-44bd-b28c-75b1db290834"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a027b2a5-6467-4557-8931-1b63c09c3fa6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lithium is indicated in the treatment of manic episodes of Bipolar Disorder. Bipolar Disorder, Manic (DSM-III) is equivalent to Manic Depressive illness, Manic, in the older DSM-II terminology. Lithium is also indicated as a maintenance treatment for individuals with a diagnosis of Bipolar Disorder. Maintenance therapy reduces the frequency of manic episodes and diminishes the intensity of those episodes which may occur. Typical symptoms of mania include pressure of speech, motor hyperactivity, reduced need for sleep, flight of ideas, grandiosity, elation, poor judgment, aggressiveness, and possibly hostility. When given to a patient experiencing a manic episode, lithium may produce a normalization of symptomatology within 1 to 3 weeks. uuid:8e5c94f3-018f-4a03-a775-1057787f7ee9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63599 biolink:treats MONDO:0004948 PMID:41385096 "[{""id"":""uuid:f281a40e-8e62-48d9-918d-691c20a31c6a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d2371a1e-5ea5-4917-94cd-af720c01070a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:219fc1f0-a348-4f4e-89aa-23f696c3851d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fludarabine phosphate is indicated as a single agent for the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) whose disease has not responded to or has progressed during or after treatment with at least one standard alkylating-agent containing regimen. Studies demonstrating clinical benefit such as prolongation of survival or relief of symptoms have not been performed. Studies providing a direct comparison of the clinical efficacy and safety of orally administered fludarabine phosphate relative to intravenously administered fludarabine phosphate have not been performed.|[PMDA] A drug with a new additional indication for the treatment of chronic lymphocytic leukemia with anemia or thrombocytopenia. uuid:d198a771-3e68-4e93-8f08-123b5b26c33b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63599 biolink:treats UMLS:C0861880 PMID:41385096 "[{""id"":""uuid:30ccbeb4-2211-4a2b-bdcf-4ed03959ee1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3d4a5d1b-d28f-426e-97e0-02e5380b4c86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fludarabine phosphate is indicated as a single agent for the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) whose disease has not responded to or has progressed during or after treatment with at least one standard alkylating-agent containing regimen. Studies demonstrating clinical benefit such as prolongation of survival or relief of symptoms have not been performed. Studies providing a direct comparison of the clinical efficacy and safety of orally administered fludarabine phosphate relative to intravenously administered fludarabine phosphate have not been performed. uuid:c8118db7-cd0a-4659-ba96-2e4c28c650a1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7494 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:3dad79c1-c184-4c1d-8eb1-dc7b51bcf445"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a3818cff-6de3-47b9-b56b-6de40eedeac9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nefazodone hydrochloride tablets, USP is indicated for the treatment of depression. When deciding among the alternative treatments available for this condition, the prescriber should consider the risk of hepatic failure associated with nefazodone hydrochloride tablets, USP treatment (see WARNINGS ). In many cases, this would lead to the conclusion that other drugs should be tried first. The efficacy of nefazodone in the treatment of depression was established in 6 to 8 week controlled trials of outpatients and in a 6-week controlled trial of depressed inpatients whose diagnoses corresponded most closely to the DSM-III or DSM-IIIR category of major depressive disorder (see CLINICAL PHARMACOLOGY ). A major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks). It must include either depressed mood or loss of interest or pleasure and at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. The efficacy of nefazodone in reducing relapse in patients with major depression who were judged to have had a satisfactory clinical response to 16 weeks of open-label nefazodone treatment for an acute depressive episode has been demonstrated in a randomized placebo-controlled trial (see CLINICAL PHARMACOLOGY ). Although remitted patients were followed for as long as 36 weeks in the study cited (i.e., 52 weeks total), the physician who elects to use nefazodone for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual patient. uuid:c3742884-7286-4ab3-ba48-da22af14bc55 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2647566 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:0d070c47-a318-41ab-b963-656fab5418b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:06277519-41ce-488c-be83-09fcd9fc22d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pseudodine™ C Cough Syrup is indicated for temporary relief of coughs and upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold. uuid:10eb32af-4761-46ad-a1fa-7df07278f1ed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2647566 biolink:treats MONDO:0005709 PMID:41385096 "[{""id"":""uuid:52145ebb-3efa-4adc-88ce-d234f0109121"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aaca8ef9-ee5f-4441-9f0b-2a5ef9f39bac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pseudodine™ C Cough Syrup is indicated for temporary relief of coughs and upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold. uuid:d50ff80c-cd61-4233-ad68-e6639e1cf26d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7903 biolink:treats MONDO:0001741 PMID:41385096 "[{""id"":""uuid:9090bfec-365d-4959-aad5-f76fbf4fd52a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6083a7da-58ad-49aa-8e32-7029bb3bcb25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pamidronate disodium in conjunction with adequate hydration, is indicated for the treatment of moderate or severe hypercalcemia associated with malignancy, with or without bone metastases. Patients who have either epidermoid or non-epidermoid tumors respond to treatment with pamidronate disodium. Vigorous saline hydration, an integral part of hypercalcemia therapy, should be initiated promptly and an attempt should be made to restore the urine output to about 2 L/day throughout treatment. Mild or asymptomatic hypercalcemia may be treated with conservative measures (i.e., saline hydration, with or without loop diuretics). Patients should be hydrated adequately throughout the treatment, but overhydration, especially in those patients who have cardiac failure, must be avoided. Diuretic therapy should not be employed prior to correction of hypovolemia. The safety and efficacy of pamidronate disodium in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions has not been established. uuid:d89aebe6-a3b8-40d6-b21d-33a0a6e96b9b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71415 biolink:treats MONDO:0005247 PMID:41385096 "[{""id"":""uuid:2faa01bb-6d10-4b0c-9510-2886c1bee89d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5cf654bd-738a-4d11-aa64-2900e2205e49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Macrobid is indicated only for the treatment of acute uncomplicated urinary tract infections (acute cystitis) caused by susceptible strains of Escherichia coli or Staphylococcus saprophyticus. Nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Macrobid and other antibacterial drugs, Macrobid should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Nitrofurantoins lack the broader tissue distribution of other therapeutic agents approved for urinary tract infections. Consequently, many patients who are treated with Macrobid are predisposed to persistence or reappearance of bacteriuria. (See CLINICAL STUDIES .) Urine specimens for culture and susceptibility testing should be obtained before and after completion of therapy. If persistence or reappearance of bacteriuria occurs after treatment with Macrobid , other therapeutic agents with broader tissue distribution should be selected. In considering the use of Macrobid , lower eradication rates should be balanced against the increased potential for systemic toxicity and for the development of antimicrobial resistance when agents with broader tissue distribution are utilized. uuid:14e15386-30b0-4bc7-bf44-c4a92a5a8347 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71415 biolink:treats MONDO:0001650 PMID:41385096 "[{""id"":""uuid:09b6e2ed-b838-46ef-bac5-bb2c537aecc4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:005c7cca-11fd-46a9-ac88-d19123c0198e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Macrobid is indicated only for the treatment of acute uncomplicated urinary tract infections (acute cystitis) caused by susceptible strains of Escherichia coli or Staphylococcus saprophyticus. Nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Macrobid and other antibacterial drugs, Macrobid should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Nitrofurantoins lack the broader tissue distribution of other therapeutic agents approved for urinary tract infections. Consequently, many patients who are treated with Macrobid are predisposed to persistence or reappearance of bacteriuria. (See CLINICAL STUDIES .) Urine specimens for culture and susceptibility testing should be obtained before and after completion of therapy. If persistence or reappearance of bacteriuria occurs after treatment with Macrobid , other therapeutic agents with broader tissue distribution should be selected. In considering the use of Macrobid , lower eradication rates should be balanced against the increased potential for systemic toxicity and for the development of antimicrobial resistance when agents with broader tissue distribution are utilized. uuid:2fc3a80b-cbb1-45b6-b5c5-82193727601f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71415 biolink:treats MONDO:0006939 PMID:41385096 "[{""id"":""uuid:ebd61a97-40e7-477a-a7d5-a45ed0469fce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fb7a7911-927c-4690-9c2a-fae359b1ae70"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Macrobid is indicated only for the treatment of acute uncomplicated urinary tract infections (acute cystitis) caused by susceptible strains of Escherichia coli or Staphylococcus saprophyticus. Nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Macrobid and other antibacterial drugs, Macrobid should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Nitrofurantoins lack the broader tissue distribution of other therapeutic agents approved for urinary tract infections. Consequently, many patients who are treated with Macrobid are predisposed to persistence or reappearance of bacteriuria. (See CLINICAL STUDIES .) Urine specimens for culture and susceptibility testing should be obtained before and after completion of therapy. If persistence or reappearance of bacteriuria occurs after treatment with Macrobid , other therapeutic agents with broader tissue distribution should be selected. In considering the use of Macrobid , lower eradication rates should be balanced against the increased potential for systemic toxicity and for the development of antimicrobial resistance when agents with broader tissue distribution are utilized. uuid:baeef84a-dafd-4fbc-b123-82c88bd0c746 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71415 biolink:treats HP:0032619 PMID:41385096 "[{""id"":""uuid:96982745-b477-4294-8fb3-927514978856"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:93a8d044-7f1c-4c9c-a686-48c2c2f0aae2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Macrobid is indicated only for the treatment of acute uncomplicated urinary tract infections (acute cystitis) caused by susceptible strains of Escherichia coli or Staphylococcus saprophyticus. Nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Macrobid and other antibacterial drugs, Macrobid should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Nitrofurantoins lack the broader tissue distribution of other therapeutic agents approved for urinary tract infections. Consequently, many patients who are treated with Macrobid are predisposed to persistence or reappearance of bacteriuria. (See CLINICAL STUDIES .) Urine specimens for culture and susceptibility testing should be obtained before and after completion of therapy. If persistence or reappearance of bacteriuria occurs after treatment with Macrobid , other therapeutic agents with broader tissue distribution should be selected. In considering the use of Macrobid , lower eradication rates should be balanced against the increased potential for systemic toxicity and for the development of antimicrobial resistance when agents with broader tissue distribution are utilized. uuid:49596581-2804-4693-9e8b-5ed916e8b760 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71415 biolink:treats MONDO:0001882 PMID:41385096 "[{""id"":""uuid:c28bff1a-1869-4bbb-88e6-d307044adb1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2d37d1af-5695-40d2-ba64-a196058cdcbc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Macrobid is indicated only for the treatment of acute uncomplicated urinary tract infections (acute cystitis) caused by susceptible strains of Escherichia coli or Staphylococcus saprophyticus. Nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Macrobid and other antibacterial drugs, Macrobid should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Nitrofurantoins lack the broader tissue distribution of other therapeutic agents approved for urinary tract infections. Consequently, many patients who are treated with Macrobid are predisposed to persistence or reappearance of bacteriuria. (See CLINICAL STUDIES .) Urine specimens for culture and susceptibility testing should be obtained before and after completion of therapy. If persistence or reappearance of bacteriuria occurs after treatment with Macrobid , other therapeutic agents with broader tissue distribution should be selected. In considering the use of Macrobid , lower eradication rates should be balanced against the increased potential for systemic toxicity and for the development of antimicrobial resistance when agents with broader tissue distribution are utilized. uuid:0d3feeb1-8f5e-4223-a475-174a2ff0dc15 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71415 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:2a68d67a-d229-4c02-88e5-32b1f557007b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c0dc4937-d3e0-420a-af7c-4f32b656801c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Macrodantin is specifically indicated for the treatment of urinary tract infections when due to susceptible strains of Escherichia coli, enterococci , Staphylococcus aureus , and certain susceptible strains of Klebsiella and Enterobacter species. Nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Macrodantin and other antibacterial drugs, Macrodantin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Nitrofurantoins lack the broader tissue distribution of other therapeutic agents approved for urinary tract infections. Consequently, many patients who are treated with Macrodantin are predisposed to persistence or reappearance of bacteriuria. Urine specimens for culture and susceptibility testing should be obtained before and after completion of therapy. If persistence or reappearance of bacteriuria occurs after treatment with Macrodantin , other therapeutic agents with broader tissue distribution should be selected. In considering the use of Macrodantin , lower eradication rates should be balanced against the increased potential for systemic toxicity and for the development of antimicrobial resistance when agents with broader tissue distribution are utilized. uuid:194a4b48-385f-4ed1-aa22-f9ab096284e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32888 biolink:treats MONDO:0004525 PMID:41385096 "[{""id"":""uuid:007b2c46-4b6a-4fbf-8353-44c2e07df90e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6a303105-0615-435d-8969-6b9ebb16fe8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lindane Lotion is indicated for the treatment of scabies (infestations of Sarcoptes scabei ) only in patients who: cannot tolerate other approved therapies, or have failed treatment with other approved therapies. Lindane Lotion should be used in the context of an overall scabies management program that includes: Microscopic evaluation of skin scrapings to confirm the diagnosis. Evaluation and treatment of sexual contacts simultaneously. Sexual contacts should be prescribed Lindane Lotion only if they either have failed to respond to adequate doses of other approved therapies or are intolerant of other approved therapies. Washing of all recently worn clothing, underwear, pajamas, used sheets, pillowcases, and towels in very hot water or dry-cleaned. Caregivers applying this product to patients should wear gloves less permeable to Lindane, such as nitrile, latex with neoprene, or sheer vinyl, and thoroughly clean hands after application. Natural latex gloves should be avoided because they are more permeable to Lindane. Lindane Lotion does not prevent infestation or reinfestation and should not be used to ward off a possible infestation. uuid:43c73418-5432-48b4-b4a4-c54f90c9fab5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32888 biolink:treats MONDO:0003471 PMID:41385096 "[{""id"":""uuid:79bd829d-7088-4f44-9fe3-c412d0087b62"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:32d32258-142f-4a5c-bda7-be25261a9961"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Lindane Shampoo is indicated for the treatment of head lice (infestations of Pediculosis humanis capitis ), crab lice (infestations of Pthirus pubis ), and their ova only in patients who cannot tolerate other approved therapies, or have failed treatment with other approved therapies. Lindane Shampoo should be used in the context of an overall lice management program that includes: Visual inspection to ensure that the patient is currently infested with live lice (empty egg casings or ""nits"" can remain on hair shaft long after true infestation). Manual removal of nits using a comb designed for this purpose and/or individual removal with tweezers followed by close examination of the hair and scalp. Evaluation and treatment of sexual contacts simultaneously. Sexual contacts should be prescribed Lindane Shampoo only if they either have failed to respond to adequate doses of other approved therapies or are intolerant of other approved therapies. All recently worn clothing, underwear, pajamas, used sheets, pillowcases, and towels should be washed in very hot water or dry-cleaned. Caregivers applying this product to patients should wear gloves less permeable to Lindane such as nitrile, latex with neoprene or sheer vinyl, and thoroughly clean hands after application. Natural latex gloves should be avoided because they are more permeable to Lindane. Lindane Shampoo does not prevent infestation or reinfestation and should not be used to ward off a possible infestation." uuid:a824348b-e6bb-4c66-8afc-f2a65c8f3047 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32888 biolink:treats MONDO:0001794 PMID:41385096 "[{""id"":""uuid:bf51c488-e01c-4ca0-8621-1a7870eeff96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:710684bc-24ed-48b6-b73d-291be758542e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Lindane Shampoo is indicated for the treatment of head lice (infestations of Pediculosis humanis capitis ), crab lice (infestations of Pthirus pubis ), and their ova only in patients who cannot tolerate other approved therapies, or have failed treatment with other approved therapies. Lindane Shampoo should be used in the context of an overall lice management program that includes: Visual inspection to ensure that the patient is currently infested with live lice (empty egg casings or ""nits"" can remain on hair shaft long after true infestation). Manual removal of nits using a comb designed for this purpose and/or individual removal with tweezers followed by close examination of the hair and scalp. Evaluation and treatment of sexual contacts simultaneously. Sexual contacts should be prescribed Lindane Shampoo only if they either have failed to respond to adequate doses of other approved therapies or are intolerant of other approved therapies. All recently worn clothing, underwear, pajamas, used sheets, pillowcases, and towels should be washed in very hot water or dry-cleaned. Caregivers applying this product to patients should wear gloves less permeable to Lindane such as nitrile, latex with neoprene or sheer vinyl, and thoroughly clean hands after application. Natural latex gloves should be avoided because they are more permeable to Lindane. Lindane Shampoo does not prevent infestation or reinfestation and should not be used to ward off a possible infestation." uuid:ad15494e-0b13-4dc8-aa46-60dd2d5423c7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3614 biolink:treats MONDO:0002508 PMID:41385096 "[{""id"":""uuid:a56a7996-963e-4ae2-ae6a-ddc4412779c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c5a04817-4118-4613-99a0-84c37cbffe0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chlorhexidine Gluconate Oral Rinse is indicated for use between dental visits as part of a professional program for the treatment of gingivitis as characterized by redness and swelling of the gingivae, including gingival bleeding upon probing. Chlorhexidine gluconate has not been tested among patients with acute necrotizing ulcerative gingivitis (ANUG). For patients having coexisting gingivitis and periodontitis, see PRECAUTIONS . uuid:62397e9e-6777-41ed-a727-75f78aa7dab7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3614 biolink:treats MONDO:0006865 PMID:41385096 "[{""id"":""uuid:47fa2031-5a39-4b91-a52e-fd389b47d676"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ac4bcdf3-598d-4759-ab5a-bc0690979aab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chlorhexidine Gluconate Oral Rinse is indicated for use between dental visits as part of a professional program for the treatment of gingivitis as characterized by redness and swelling of the gingivae, including gingival bleeding upon probing. Chlorhexidine gluconate has not been tested among patients with acute necrotizing ulcerative gingivitis (ANUG). For patients having coexisting gingivitis and periodontitis, see PRECAUTIONS . uuid:77a28b29-fddb-4a06-9e14-cbb213aacba7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1156197 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:ea609164-d316-43c3-bc2d-26ebb5082aff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:399600c5-c9fa-4ac2-b5f0-740ea14abba8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Glyburide and Metformin Hydrochloride Tablets is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. uuid:d4fb7c27-b14b-4817-9a4a-49e77df995b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0015129 PMID:41385096 "[{""id"":""uuid:ffbcd758-1447-4a52-bb2e-7225a4109081"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:75ea3a96-7a68-42eb-9de9-2d0bd34a1829"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer uuid:f59dc2e7-66fb-46dc-ab48-480ebfe980dd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0043370 PMID:41385096 "[{""id"":""uuid:01f4cb11-bbfc-4b34-836f-2296a20b2b76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c7273eec-edb0-44dc-a909-e028c0d0f0cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer uuid:dbb58a65-095b-4ad5-bf67-71627363facd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0018479 PMID:41385096 "[{""id"":""uuid:eda4426a-5beb-4ad2-823d-6c2ae03fd52b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:550f2c12-befc-4310-afbd-2f5998e9da16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer uuid:2fb3a3be-04f8-4782-9087-912b8f6b6a3f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0006982 PMID:41385096 "[{""id"":""uuid:fa2f637a-2f96-4be0-a7e4-23dc64af6261"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b3e3eabc-2b17-41ef-8fb7-22f78f4d2638"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer uuid:b72038e2-f78d-4c67-94cb-ad34c8adc170 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0043455 PMID:41385096 "[{""id"":""uuid:a0f3c9f1-8843-4f08-847c-482769813707"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0adac1c8-25a2-46f2-bff9-c45548fa6563"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer uuid:fceeef11-e4e1-4f77-acb4-b3b1292404c0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:144093 biolink:treats MONDO:0004956 PMID:41385096 "[{""id"":""uuid:50fc344b-4c29-4624-aec9-52783932842f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2b5829e3-b480-426a-9c97-a6423963a1f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bicalutamide Tablets, USP 50 mg daily are indicated for use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analog for the treatment of Stage D 2 metastatic carcinoma of the prostate. Bicalutamide Tablets, USP 150 mg daily are not approved for use alone or with other treatments [see Clinical Studies (14.2) ]. uuid:d54d0f68-90d1-4592-a114-d07c8e3b18c1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10385 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:f5e565ff-1fa1-4726-ad0a-a7a77698828a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3f761113-7526-4f52-8528-dd1c504fdb15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Allergenic extract is indicated for diagnostic testing and treatment (immunotherapy) of patients whose histories indicate allergic symptoms upon natural exposure to short ragweed pollen. Confirmation is determined by skin testing. uuid:2bee0673-3ee6-447e-9754-6a4872281b34 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10499 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:c772efb6-8883-4e97-827d-02c2dab8fa28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fa77d8ba-ffe7-4fd9-a66a-8423a3eabe0c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Allergenic extract is indicated for diagnostic testing and for the treatment (immunotherapy) of patients whose histories indicate that upon natural exposure to cat allergen, they experience allergic symptoms. Confirmation is determined by skin testing. An orderly approach to the diagnostic use of allergenic extracts usually begins with direct skin testing. uuid:e7f9e86d-93db-4ddc-bb17-f6e990d9b155 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10499 biolink:treats UMLS:C0339805 PMID:41385096 "[{""id"":""uuid:ee637bf7-024d-4d58-8f06-276a01b27869"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8a166146-702b-416c-a029-0a41ffb62cce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Allergenic extract is indicated for diagnostic testing and for the treatment (immunotherapy) of patients whose histories indicate that upon natural exposure to cat allergen, they experience allergic symptoms. Confirmation is determined by skin testing. An orderly approach to the diagnostic use of allergenic extracts usually begins with direct skin testing. uuid:b7daea25-29ab-4764-a6f0-5c91357662ea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15367 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:f51bcc57-dd76-48cc-81bb-ca71ede06aec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:70f1e531-7f6d-46b0-ad4f-965c2c0fe21b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tretinoin gel and cream are indicated for topical application in the treatment of acne vulgaris. The safety and efficacy of the long-term use of this product in the treatment of other disorders have not been established. uuid:995bab43-6e64-4f97-8b96-6ef14bfb6ae1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7577 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:a7f61aba-c91f-48da-b56d-04f0cdbb0fe4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7fc5a69f-5f5d-4cb7-bb19-be4e352e8874"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nisoldipine is indicated for the treatment of hypertension. It maybe used alone or in combination with other antihypertensive agents. uuid:fdd8c54f-3661-40b9-9f1f-20e3757536e7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6761 biolink:treats MONDO:0005618 PMID:41385096 "[{""id"":""uuid:3ef50044-f473-49d4-8321-17d3a78058a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b34222c6-598f-4052-b5d1-619aadcd4c10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Meprobamate tablets are indicated for the management of anxietydisorders or for the short-term relief of the symptoms of anxiety.Anxiety or tension associated with the stress of everyday life usuallydo not require treatment with an anxiolytic. The effectiveness of meprobamate tablets in long-term use, that is,more than 4 months, has not been assessed by systematic clinicalstudies. The physician should periodically reassess the usefulness ofthe drug for the individual patient. uuid:5091c951-52c1-481f-83cb-e7e6e553ef3a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6761 biolink:treats MONDO:0011918 PMID:41385096 "[{""id"":""uuid:9b6329e3-7d78-4d1e-a317-04c38a84eb16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d5dbd79c-7673-44d7-a001-accef3e9a65f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Meprobamate tablets are indicated for the management of anxietydisorders or for the short-term relief of the symptoms of anxiety.Anxiety or tension associated with the stress of everyday life usuallydo not require treatment with an anxiolytic. The effectiveness of meprobamate tablets in long-term use, that is,more than 4 months, has not been assessed by systematic clinicalstudies. The physician should periodically reassess the usefulness ofthe drug for the individual patient. uuid:7650b96e-475e-412d-91f4-5b71286aa1b5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:585948 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:5088dde5-3dba-48a8-b3dd-d4bfdea205bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e0aff2a5-74df-47f5-88fc-a36aff9312ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Felodipine extended-release tablets are indicated for the treatment of hypertension. Felodipine extended-release tablets may be used alone or concomitantly with other antihypertensive agents. uuid:8a9481a8-45ea-45c8-a59c-7a08fab26a73 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10394 biolink:treats UMLS:C1387134 PMID:41385096 "[{""id"":""uuid:69bedd17-d2fa-43b9-954c-4a5ad8fc04f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a04b3dd4-7c20-4533-986c-410f2de5a36e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Allergenic extract is indicated for diagnostic testing and treatment (immunotherapy) of patients whose histories indicate allergic symptoms upon natural exposure to grass allergens. Confirmation is determined by skin testing. 10,000 BAU/ml extracts are intended for percutaneous testing. If negative, 100,000 BAU/ml products can be used for percutaneous test. Dilutions made from 10,000 BAU/ml products are indicated for immunotherapy of previously untreated patients. If 10,000 BAU/ml product is tolerated and symptoms persist, dilutions made from 100,000 BAU/ml can be administered. Standardized Grass Pollen extracts labeled in Bioequivalent Allergy Units (BAU/ml) are not interchangeable with grass pollen extracts labeled In Allergy Units (AU/ml) or with non-standardized grass pollen extracts. uuid:14759ddd-1a49-48eb-8f44-6f1d824e1b50 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10394 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:36e48f3d-d702-46af-8a15-149b14c486f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5cd7fb51-b5df-4e65-8a47-145279a21f36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Allergenic extract is indicated for diagnostic testing and treatment (immunotherapy) of patients whose histories indicate allergic symptoms upon natural exposure to grass allergens. Confirmation is determined by skin testing. 10,000 BAU/ml extracts are intended for percutaneous testing. If negative, 100,000 BAU/ml products can be used for percutaneous test. Dilutions made from 10,000 BAU/ml products are indicated for immunotherapy of previously untreated patients. If 10,000 BAU/ml product is tolerated and symptoms persist, dilutions made from 100,000 BAU/ml can be administered. Standardized Grass Pollen extracts labeled in Bioequivalent Allergy Units (BAU/ml) are not interchangeable with grass pollen extracts labeled In Allergy Units (AU/ml) or with non-standardized grass pollen extracts. uuid:bc74abad-e05b-4566-b676-d41f1656ca52 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:54955 biolink:treats MONDO:0003799 PMID:41385096 "[{""id"":""uuid:e5d9b5f0-b47e-458d-9033-29df9158a0b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7a273ad7-233c-4369-a7f5-1c3e0a1c133b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bacitracin Zinc and Polymyxin B Sulfate Ophthalmic Ointment is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. Such infections encompass conjunctivitis, keratitis and keratoconjunctivitis, blepharitis and blepharoconjunctivitis. uuid:bc8e0276-cf0f-4351-a399-e6e6a0e8e527 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:54955 biolink:treats MONDO:0003085 PMID:41385096 "[{""id"":""uuid:093d9e4e-ecf8-42e1-9158-33dc539ed8e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:76547001-ab5e-4a84-9876-56213916d044"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bacitracin Zinc and Polymyxin B Sulfate Ophthalmic Ointment is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. Such infections encompass conjunctivitis, keratitis and keratoconjunctivitis, blepharitis and blepharoconjunctivitis. uuid:300f5664-4956-4b94-b745-70920949b38f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:54955 biolink:treats MONDO:0004768 PMID:41385096 "[{""id"":""uuid:6b943e33-5a04-439f-b577-a500a89dae79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:48822efe-44cb-46d7-b661-a0d10556d753"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bacitracin Zinc and Polymyxin B Sulfate Ophthalmic Ointment is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. Such infections encompass conjunctivitis, keratitis and keratoconjunctivitis, blepharitis and blepharoconjunctivitis. uuid:9b17e28a-174c-4c13-b7a9-2de051176ce0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:54955 biolink:treats MONDO:0004785 PMID:41385096 "[{""id"":""uuid:6389edbf-f6f7-4574-b1ef-e9fd9b74b47a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aaa0d194-1bf8-427d-b08e-5b86b25756d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bacitracin Zinc and Polymyxin B Sulfate Ophthalmic Ointment is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. Such infections encompass conjunctivitis, keratitis and keratoconjunctivitis, blepharitis and blepharoconjunctivitis. uuid:7f41a68d-73c0-4aa7-8ec8-d1f15f862728 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:54955 biolink:treats MONDO:0002307 PMID:41385096 "[{""id"":""uuid:79117149-9505-4084-b938-b7e16162ece1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:48d065c6-0fe3-4961-81ac-194765e3dd10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bacitracin Zinc and Polymyxin B Sulfate Ophthalmic Ointment is indicated for the topical treatment of superficial infections of the external eye and its adnexa caused by susceptible bacteria. Such infections encompass conjunctivitis, keratitis and keratoconjunctivitis, blepharitis and blepharoconjunctivitis. uuid:7ddbd6fc-b134-4585-afbd-7a81281c6ca6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3757 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:d25ab0ad-d59f-4afa-ba4a-f20b952d8139"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0eace2af-355c-444a-aa56-d5f9ab65fdd0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clonidine hydrochloride is indicated in the treatment of hypertension. Clonidine hydrochloride may be employed alone or concomitantly with other antihypertensive agents. uuid:61c03d5c-1923-479e-bcbb-2c20206f7a39 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27732 biolink:treats MONDO:0020567 PMID:41385096 "[{""id"":""uuid:e77e248a-5f5e-4403-bd52-0de26af1046e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:838ce2ad-5ebe-4b41-9852-8fdf89706f05"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a23f3f75-5fef-42d0-a257-94dbd90c84ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f0102c39-8c5c-44b7-8fd5-dc2c1fa116f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Caffeine citrate injection and caffeine citrate oral solution are indicated for the short term treatment of apnea of prematurity in infants between 28 and <33 weeks gestational age.|[EMA] Treatment of primary apnoea of premature newborns.|[PMDA] A drug with a new route of administration indicated for the treatment of primary apnea (apnea of prematurity) in immature or low birth weight infants. [Orphan drug] uuid:0f0e7e5a-89ee-4e50-8e50-84cb3fb1284d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3757 biolink:treats MONDO:0004992 PMID:41385096 "[{""id"":""uuid:e44fe3e6-d21a-4cdd-9dd6-9bab1df3fc93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:77e7194d-6885-4136-86b5-de9ef83183b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clonidine hydrochloride is indicated in combination with opiates for the treatment of severe pain in cancer patients that is not adequately relieved by opioid analgesics alone. Epidural clonidine is more likely to be effective in patients with neuropathic pain than somatic or visceral pain (see CLINICAL PHARMACOLOGY, Clinical Trials ). The safety of this drug product has only been established in a highly selected group of cancer patients, and only after an adequate trial of opioid analgesia. Other use is of unproven safety and is not recommended. In a rare patient, the potential benefits may outweigh the known risks (see WARNINGS ). uuid:40cf5238-e1a9-4717-998f-d71893f9788b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3757 biolink:treats UMLS:C0234245 PMID:41385096 "[{""id"":""uuid:d98b8b48-2740-47bc-86ab-50903b2ec716"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:19b68d9b-0bc3-4886-89a7-3f104e4cfc4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clonidine hydrochloride is indicated in combination with opiates for the treatment of severe pain in cancer patients that is not adequately relieved by opioid analgesics alone. Epidural clonidine is more likely to be effective in patients with neuropathic pain than somatic or visceral pain (see CLINICAL PHARMACOLOGY, Clinical Trials ). The safety of this drug product has only been established in a highly selected group of cancer patients, and only after an adequate trial of opioid analgesia. Other use is of unproven safety and is not recommended. In a rare patient, the potential benefits may outweigh the known risks (see WARNINGS ). uuid:6f486a09-8f80-4e04-92c4-1565341883de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16714 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:b5e6ef26-cda0-443a-a351-78347e8f9ece"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:19429460-85a3-411a-8702-e1b125577c22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Codeine sulfate is an opioid analgesic indicated for the relief of mild to moderately severe pain where the use of an opioid analgesic is appropriate. uuid:c0db626d-1485-4dd8-92d7-8133a219bcc5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:371909 biolink:treats MONDO:0001673 PMID:41385096 "[{""id"":""uuid:cb0d301f-9386-47bd-ba4e-7f367c81b10c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:39d4d291-99e1-4a35-ad73-20c0866e6c10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lomotil is effective as adjunctive therapy in the management of diarrhea. uuid:ff281435-7bed-4124-83d7-c6a10856a6a7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7551 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:82960014-a4e1-4321-970a-f432dbe38581"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4952550f-4ed5-441d-8946-5f69eae691e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nicardipine hydrochloride injection is indicated for the short-term treatment of hypertension when oral therapy is not feasible or not desirable. For prolonged control of blood pressure, patients should be transferred to oral medication as soon as their clinical condition permits (see DOSAGE AND ADMINISTRATION ). uuid:fe0716ee-fc23-4bf8-8f2c-e8b6f982d1c7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28876 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:80a53477-f47d-4895-bb2a-bfcb5cc493d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9b836515-eac9-47a5-8e5a-d6da61e1d345"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d6e046cd-9d18-4157-961d-03f2ab56a37c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Melphalan Hydrochloride for Injection is indicated for the palliative treatment of patients with multiple myeloma for whom oral therapy is not appropriate.|[EMA] High-dose of Phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (Hodgkin, non-Hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma.Phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (RIC) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-HSCT) in malignant haematological diseases in adults.Phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:Myeloablative conditioning (MAC) treatment in case of malignant haematological diseasesRIC treatment in case of non-malignant haematological diseases. uuid:694cc1f6-c0f0-4656-b767-a9040b064f8e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1151145 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:a25291b8-c28c-4944-82c3-0c64d451df53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0a38e556-8d1e-449f-a64f-11a99a15caa3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of ARTHROTEC and other treatment options before deciding to use ARTHROTEC. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). ARTHROTEC is indicated for treatment of the signs and symptoms of osteoarthritis or rheumatoid arthritis in patients at high risk of developing NSAID-induced gastric and duodenal ulcers and their complications. See WARNINGS, Gastrointestinal Effects - Risk of Ulceration, Bleeding and Perforation for a list of factors that may increase the risk of NSAID-induced gastric and duodenal ulcers and their complications. uuid:f7e20601-5e9f-4f19-92c4-7e25fbe9ecfb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1151145 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:d97155ab-12f3-4f20-8958-42233d74b917"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b56d774f-8f1c-4ad5-ace5-5644a992b25b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of ARTHROTEC and other treatment options before deciding to use ARTHROTEC. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). ARTHROTEC is indicated for treatment of the signs and symptoms of osteoarthritis or rheumatoid arthritis in patients at high risk of developing NSAID-induced gastric and duodenal ulcers and their complications. See WARNINGS, Gastrointestinal Effects - Risk of Ulceration, Bleeding and Perforation for a list of factors that may increase the risk of NSAID-induced gastric and duodenal ulcers and their complications. uuid:789bcdcc-971a-405a-b4e0-beff9b005846 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1151145 biolink:treats MONDO:0001126 PMID:41385096 "[{""id"":""uuid:4beb3e97-8930-49a5-886e-d5533dd26b19"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:50d10cfb-56c8-4209-beae-08d6657dee55"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of ARTHROTEC and other treatment options before deciding to use ARTHROTEC. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). ARTHROTEC is indicated for treatment of the signs and symptoms of osteoarthritis or rheumatoid arthritis in patients at high risk of developing NSAID-induced gastric and duodenal ulcers and their complications. See WARNINGS, Gastrointestinal Effects - Risk of Ulceration, Bleeding and Perforation for a list of factors that may increase the risk of NSAID-induced gastric and duodenal ulcers and their complications. uuid:46f22134-4c3f-4e21-97b3-d7a172af5691 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1151145 biolink:treats MONDO:0005412 PMID:41385096 "[{""id"":""uuid:a5b98be5-3e55-40c5-bec5-211c4e44efa0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b3a883d3-5b72-4e51-a8d4-09b1387cb3e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of ARTHROTEC and other treatment options before deciding to use ARTHROTEC. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). ARTHROTEC is indicated for treatment of the signs and symptoms of osteoarthritis or rheumatoid arthritis in patients at high risk of developing NSAID-induced gastric and duodenal ulcers and their complications. See WARNINGS, Gastrointestinal Effects - Risk of Ulceration, Bleeding and Perforation for a list of factors that may increase the risk of NSAID-induced gastric and duodenal ulcers and their complications. uuid:fc6743ee-15c6-49cf-a761-1bed9f8105ac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6904 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:d17af23a-1783-4dde-bbb7-88332d42cb6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:22ad59eb-5566-42d1-81ca-472067ea07b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metoprolol succinate extended-release tablets are indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents. uuid:6a28b211-b9c4-43b6-9172-6d8ff84dec5a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3561 biolink:treats MONDO:0024332 PMID:41385096 "[{""id"":""uuid:d787d30c-b613-4c58-920e-9ef804d59829"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9478955d-d87a-482d-971d-0860cfbca3e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cetirizine hydrochloride syrup is indicated for the relief of symptoms associated with perennial allergic rhinitis due to allergens such as dust mites, animal dander and molds in children 6 to 23 months of age. Symptoms treated effectively include sneezing, rhinorrhea, postnasal discharge, nasal pruritus, ocular pruritus, and tearing. uuid:4644dfb0-e391-4987-a482-4e8f7fad4983 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4551 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:1283ed07-272c-4c30-957d-d9bd87bca058"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fe75aec1-3951-48ac-8f4d-b587896dcfe2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE: Heart Failure: Digoxin is indicated for the treatment of mild to moderate heart failure. Digoxin increases left ventricular ejection fraction and improves heart failure symptoms as evidenced by exercise capacity and heart failure-related hospitalizations and emergency care, while having no effect on mortality. Where possible, digoxin should be used with a diuretic and an angiotensinconverting enzyme inhibitor, but an optimal order for starting these three drugs cannot be specified. Atrial Fibrillation: Digoxin is indicated for the control of ventricular response rate in patients with chronic atrial fibrillation uuid:95abccda-9340-4afe-b869-fc67bfa0d140 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4551 biolink:treats MONDO:0004981 PMID:41385096 "[{""id"":""uuid:60d7002d-4445-4e3f-be70-dd0a9bc3ec99"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f059344b-e984-4c37-a2fa-17dbb7f1b448"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE: Heart Failure: Digoxin is indicated for the treatment of mild to moderate heart failure. Digoxin increases left ventricular ejection fraction and improves heart failure symptoms as evidenced by exercise capacity and heart failure-related hospitalizations and emergency care, while having no effect on mortality. Where possible, digoxin should be used with a diuretic and an angiotensinconverting enzyme inhibitor, but an optimal order for starting these three drugs cannot be specified. Atrial Fibrillation: Digoxin is indicated for the control of ventricular response rate in patients with chronic atrial fibrillation uuid:e8addc7c-409d-4d92-94c5-0a5fc3c9a7de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82866 biolink:treats MONDO:0005984 PMID:41385096 "[{""id"":""uuid:81b6f171-9220-4618-a797-19142ea75bb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1907a92b-233c-45a9-bd3e-c5243870df25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ERTACZO ® (sertaconazole nitrate) Cream, 2%, is indicated for the topical treatment of interdigital tinea pedis in immunocompetent patients 12 years of age and older, caused by: Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum (see CLINICAL STUDIES Section). uuid:1e7b8a5c-c20b-48d1-a9cf-bf47f292fda7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17026 biolink:treats MONDO:0005047 PMID:41385096 "[{""id"":""uuid:c13b6d69-f2f3-4e7c-ba0c-b10e278ec898"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:01f0b9c6-1299-4cfe-bcbf-9c57d5dc719c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f7740e54-679b-4f97-b4dd-6a30bca2c21a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Crinone ® 8% is indicated for progesterone supplementation or replacement as part of an Assisted Reproductive Technology (""ART"") treatment for infertile women with progesterone deficiency.|[PMDA] A drug with a new route of administration indicated for luteal support as part of assisted reproductive technology for infertile women." uuid:cde82e61-4199-4b61-b73f-94fc6b266d82 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17026 biolink:treats UMLS:C5848632 PMID:41385096 "[{""id"":""uuid:d68f70ed-09f0-42c9-b39e-ebbf3d69b7f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:010ef872-b2e0-476c-82c2-f76d1e463063"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Crinone ® 8% is indicated for progesterone supplementation or replacement as part of an Assisted Reproductive Technology (""ART"") treatment for infertile women with progesterone deficiency." uuid:f81fa361-94a6-4669-ac0b-b3dcdedca8ee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17347 biolink:treats MONDO:0009420 PMID:41385096 "[{""id"":""uuid:0ecc9d55-e6b8-4466-8d23-17e3b9022cd6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:74fa6a7f-c513-404f-8183-1f92e9831c91"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Striant ® is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) - testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchidectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone levels and gonadotropins (FSH, LH) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired) -- idiopathic gonadotropin or LHRH deficiency, or pituitary hypothalamic injury from tumors, trauma, or radiation. These patients have low serum testosterone levels but have gonadotropins in the normal or low range. uuid:631db471-e8e9-406e-87cf-e520f7960432 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17347 biolink:treats MONDO:0023554 PMID:41385096 "[{""id"":""uuid:fc8a2405-4aee-4612-944d-008eb98fc61c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0419ec33-cbf7-493c-850c-0e585b98df41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Striant ® is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) - testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchidectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone levels and gonadotropins (FSH, LH) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired) -- idiopathic gonadotropin or LHRH deficiency, or pituitary hypothalamic injury from tumors, trauma, or radiation. These patients have low serum testosterone levels but have gonadotropins in the normal or low range. uuid:dcf1d6a5-6c48-4067-b86d-209124f41845 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17347 biolink:treats MONDO:8000015 PMID:41385096 "[{""id"":""uuid:02462ac6-c859-42d5-9a45-1ca6d2bd81da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f926f6cb-4972-405c-8efe-0f1478e8be73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Striant ® is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) - testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchidectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone levels and gonadotropins (FSH, LH) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired) -- idiopathic gonadotropin or LHRH deficiency, or pituitary hypothalamic injury from tumors, trauma, or radiation. These patients have low serum testosterone levels but have gonadotropins in the normal or low range. uuid:65ef73d2-5568-4f5c-be0e-89c0a717985c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17347 biolink:treats MONDO:0018555 PMID:41385096 "[{""id"":""uuid:9fa14566-87b5-41ec-aea1-6cff951d6977"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c3e4e6a3-b1c7-4865-8623-69ee62bc8dd7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Striant ® is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) - testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchidectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone levels and gonadotropins (FSH, LH) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired) -- idiopathic gonadotropin or LHRH deficiency, or pituitary hypothalamic injury from tumors, trauma, or radiation. These patients have low serum testosterone levels but have gonadotropins in the normal or low range. uuid:92e4369d-d66a-47ee-bd5c-ed8ca7d1ef75 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17347 biolink:treats MONDO:0013914 PMID:41385096 "[{""id"":""uuid:a5911c10-8910-4a34-8be5-9ee9b81dfe10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2615bd9f-0dc9-4280-99d2-10f7b272cb05"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Striant ® is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) - testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchidectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone levels and gonadotropins (FSH, LH) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired) -- idiopathic gonadotropin or LHRH deficiency, or pituitary hypothalamic injury from tumors, trauma, or radiation. These patients have low serum testosterone levels but have gonadotropins in the normal or low range. uuid:7a931fad-15f0-4dd5-8051-2fdc41b20107 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17347 biolink:treats MONDO:0043459 PMID:41385096 "[{""id"":""uuid:550af41c-3041-4619-b663-94a8c7d6e5f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9261a77e-c188-4796-8f8a-e44c698bafd6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Striant ® is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) - testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchidectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone levels and gonadotropins (FSH, LH) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired) -- idiopathic gonadotropin or LHRH deficiency, or pituitary hypothalamic injury from tumors, trauma, or radiation. These patients have low serum testosterone levels but have gonadotropins in the normal or low range. uuid:2d7bd0a6-a27a-467d-849c-d31fb2e5ddb7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40279 biolink:treats MONDO:0005393 PMID:41385096 "[{""id"":""uuid:b9b5612e-50e4-4b43-a542-2cdfd1ad23cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:520e647d-86df-46da-8c3b-7a84cb6412bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] THIS IS NOT AN INNOCUOUS DRUG. IT IS NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA. ZYLOPRIM reduces serum and urinary uric acid concentrations. Its use should be individualized for each patient and requires an understanding of its mode of action and pharmacokinetics (see CLINICAL PHARMACOLOGY , CONTRAINDICATIONS , WARNINGS , and PRECAUTIONS ). ZYLOPRIM is indicated in: the management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy). the management of patients with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment with ZYLOPRIM should be discontinued when the potential for overproduction of uric acid is no longer present. the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients. Therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks. uuid:a8e0b130-4e16-4c01-90e2-789b89bfeb68 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40279 biolink:treats MONDO:0008629 PMID:41385096 "[{""id"":""uuid:4f0f0c5e-7ad2-4dfa-aa06-a4243cd15ba2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1f631d04-a2c1-46cd-8c1c-68c079a20754"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] THIS IS NOT AN INNOCUOUS DRUG. IT IS NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA. ZYLOPRIM reduces serum and urinary uric acid concentrations. Its use should be individualized for each patient and requires an understanding of its mode of action and pharmacokinetics (see CLINICAL PHARMACOLOGY , CONTRAINDICATIONS , WARNINGS , and PRECAUTIONS ). ZYLOPRIM is indicated in: the management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy). the management of patients with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment with ZYLOPRIM should be discontinued when the potential for overproduction of uric acid is no longer present. the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients. Therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks. uuid:d80cc154-96ac-4723-bbb6-32ca52c1116d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40279 biolink:treats MONDO:0005059 PMID:41385096 "[{""id"":""uuid:5f1e3ac0-932c-45c0-855c-8824f3f0f53d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1e577016-77f2-4def-9230-94af3c4299bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] THIS IS NOT AN INNOCUOUS DRUG. IT IS NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA. ZYLOPRIM reduces serum and urinary uric acid concentrations. Its use should be individualized for each patient and requires an understanding of its mode of action and pharmacokinetics (see CLINICAL PHARMACOLOGY , CONTRAINDICATIONS , WARNINGS , and PRECAUTIONS ). ZYLOPRIM is indicated in: the management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy). the management of patients with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment with ZYLOPRIM should be discontinued when the potential for overproduction of uric acid is no longer present. the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients. Therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks. uuid:969ca619-461a-4d85-a513-58601fb690a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40279 biolink:treats MONDO:0005062 PMID:41385096 "[{""id"":""uuid:db10d276-cc2b-42bf-b889-84d7d294c6ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f94a7388-2412-4bed-9b4e-980166123b72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] THIS IS NOT AN INNOCUOUS DRUG. IT IS NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA. ZYLOPRIM reduces serum and urinary uric acid concentrations. Its use should be individualized for each patient and requires an understanding of its mode of action and pharmacokinetics (see CLINICAL PHARMACOLOGY , CONTRAINDICATIONS , WARNINGS , and PRECAUTIONS ). ZYLOPRIM is indicated in: the management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy). the management of patients with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment with ZYLOPRIM should be discontinued when the potential for overproduction of uric acid is no longer present. the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients. Therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks. uuid:371f6dc7-deac-48cb-a67d-ae4bdd840f6f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40279 biolink:treats MONDO:0004992 PMID:41385096 "[{""id"":""uuid:0875d23a-0dee-470e-8643-e2d6b9f05062"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b15eb742-75d4-4f53-9f40-ee7ae3197fb9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] THIS IS NOT AN INNOCUOUS DRUG. IT IS NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA. ZYLOPRIM reduces serum and urinary uric acid concentrations. Its use should be individualized for each patient and requires an understanding of its mode of action and pharmacokinetics (see CLINICAL PHARMACOLOGY , CONTRAINDICATIONS , WARNINGS , and PRECAUTIONS ). ZYLOPRIM is indicated in: the management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy). the management of patients with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment with ZYLOPRIM should be discontinued when the potential for overproduction of uric acid is no longer present. the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients. Therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks. uuid:99bb18f6-62ac-468a-9221-1e7e246498f2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40279 biolink:treats MONDO:0957318 PMID:41385096 "[{""id"":""uuid:02d2b962-ac43-4653-abaf-73ca16721cb6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:71d89b16-3433-40c9-aa8a-523a1af04a9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] THIS IS NOT AN INNOCUOUS DRUG. IT IS NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA. ZYLOPRIM reduces serum and urinary uric acid concentrations. Its use should be individualized for each patient and requires an understanding of its mode of action and pharmacokinetics (see CLINICAL PHARMACOLOGY , CONTRAINDICATIONS , WARNINGS , and PRECAUTIONS ). ZYLOPRIM is indicated in: the management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy). the management of patients with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment with ZYLOPRIM should be discontinued when the potential for overproduction of uric acid is no longer present. the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients. Therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks. uuid:e66ea7d0-b3b8-4bb4-88df-6a3931f76a03 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1162650 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:4d533bf1-5099-4a8b-87d8-5930e69730df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4f43a864-3325-45b8-8e08-908c14935b61"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Enalapril maleate and hydrochlorothiazide tablets are indicated for the treatment of hypertension. These fixed dose combinations are not indicated for initial treatment (see DOSAGE AND ADMINISTRATION ). In using enalapril maleate and hydrochlorothiazide tablets, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril does not have a similar risk (see WARNINGS ). In considering use of enalapril maleate and hydrochlorothiazide tablets, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see WARNINGS: Angioedema ). uuid:daed25f2-a0f5-4465-bef0-7fdcbee759f2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1162650 biolink:treats MONDO:0001609 PMID:41385096 "[{""id"":""uuid:3c37eade-6bf8-4d48-8629-1e7436b8018c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:50bdba75-ec20-438f-bb56-63979e78bb98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Enalapril maleate and hydrochlorothiazide tablets are indicated for the treatment of hypertension. These fixed dose combinations are not indicated for initial treatment (see DOSAGE AND ADMINISTRATION ). In using enalapril maleate and hydrochlorothiazide tablets, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril does not have a similar risk (see WARNINGS ). In considering use of enalapril maleate and hydrochlorothiazide tablets, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see WARNINGS: Angioedema ). uuid:7a2f8433-9818-4f32-b930-18506107bbc5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1162650 biolink:treats MONDO:0001343 PMID:41385096 "[{""id"":""uuid:616d57d5-9bb6-4f41-a571-56d35f33a232"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a6fef815-2dac-4098-85e1-89116b783b7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Enalapril maleate and hydrochlorothiazide tablets are indicated for the treatment of hypertension. These fixed dose combinations are not indicated for initial treatment (see DOSAGE AND ADMINISTRATION ). In using enalapril maleate and hydrochlorothiazide tablets, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril does not have a similar risk (see WARNINGS ). In considering use of enalapril maleate and hydrochlorothiazide tablets, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see WARNINGS: Angioedema ). uuid:89bfa1a4-6458-4677-8e6e-7e2792b9f8c3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1162650 biolink:treats MONDO:0010481 PMID:41385096 "[{""id"":""uuid:b16b77fc-33c9-45d4-af2e-faa9af8429c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e919448d-94ad-42fc-b32f-43c40abf5139"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Enalapril maleate and hydrochlorothiazide tablets are indicated for the treatment of hypertension. These fixed dose combinations are not indicated for initial treatment (see DOSAGE AND ADMINISTRATION ). In using enalapril maleate and hydrochlorothiazide tablets, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril does not have a similar risk (see WARNINGS ). In considering use of enalapril maleate and hydrochlorothiazide tablets, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see WARNINGS: Angioedema ). uuid:cf42e236-9f07-4e38-b82a-9ce23a2d9e65 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:453011 biolink:treats MONDO:0001628 PMID:41385096 "[{""id"":""uuid:129f6097-8371-4268-9a36-9a96a72498d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9e0ea414-15de-45aa-acf0-a1a5907d31d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] (To understand fully the indication for this product, please read the entire INDICATIONS AND USAGE section of the labeling.) Ciclopirox Topical Solution, 8% (Nail Lacquer) as a component of a comprehensive management program, is indicated as topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to Tricho-phyto rubrum . The comprehensive management program includes removal of the unattached, infected nails as frequently as monthly, by a health care professional who has special competence in the diagnosis and treatment of nail disorders, including minor nail procedures. No studies have been conducted to determine whether ciclopirox might reduce the effectiveness of systemic antifungal agents for onychomycosis. Therefore, the concomitant use of 8% ciclopirox topical solution and systemic antifungal agents for onychomycosis, is not recommended. Ciclopirox Topical Solution, 8% (Nail Lacquer) should be used only under medical supervision as described above. The effectiveness and safety of Ciclopirox Topical Solution, 8% (Nail Lacquer) in the following populations has not been studied.The clinical trials with use of Ciclopirox Topical Solution, 8% (Nail Lacquer) excluded patients who: were pregnant or nursing, planned to become pregnant, had a history of immunosuppression (e.g., extensive, persistent, or unusual distribution of dermatomycoses, extensive seborrheic dermatitis, recent or recurring herpes zoster, or persistent herpes simplex), were HIV seropositive, received organ transplant, required medication to control epilepsy, were insulin dependent diabetics or had diabetic neuropathy. Patients with severe plantar (moccasin) tinea pedis were also excluded. The safety and efficacy of using Ciclopirox Topical Solution, 8% (Nail Lacquer) daily for greater than 48 weeks have not been established. uuid:b69c42f2-cb25-440e-a1cb-93187f765309 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:453011 biolink:treats UMLS:C1274470 PMID:41385096 "[{""id"":""uuid:93854831-dce3-46dd-ba4a-5e1aa991e1ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:024c2e8d-7b6b-4e1c-854f-4983cdd95d6c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] (To understand fully the indication for this product, please read the entire INDICATIONS AND USAGE section of the labeling.) Ciclopirox Topical Solution, 8% (Nail Lacquer) as a component of a comprehensive management program, is indicated as topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to Tricho-phyto rubrum . The comprehensive management program includes removal of the unattached, infected nails as frequently as monthly, by a health care professional who has special competence in the diagnosis and treatment of nail disorders, including minor nail procedures. No studies have been conducted to determine whether ciclopirox might reduce the effectiveness of systemic antifungal agents for onychomycosis. Therefore, the concomitant use of 8% ciclopirox topical solution and systemic antifungal agents for onychomycosis, is not recommended. Ciclopirox Topical Solution, 8% (Nail Lacquer) should be used only under medical supervision as described above. The effectiveness and safety of Ciclopirox Topical Solution, 8% (Nail Lacquer) in the following populations has not been studied.The clinical trials with use of Ciclopirox Topical Solution, 8% (Nail Lacquer) excluded patients who: were pregnant or nursing, planned to become pregnant, had a history of immunosuppression (e.g., extensive, persistent, or unusual distribution of dermatomycoses, extensive seborrheic dermatitis, recent or recurring herpes zoster, or persistent herpes simplex), were HIV seropositive, received organ transplant, required medication to control epilepsy, were insulin dependent diabetics or had diabetic neuropathy. Patients with severe plantar (moccasin) tinea pedis were also excluded. The safety and efficacy of using Ciclopirox Topical Solution, 8% (Nail Lacquer) daily for greater than 48 weeks have not been established. uuid:b8890fed-e49a-42c0-9c48-d94d1c8c883b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:453011 biolink:treats MONDO:0002040 PMID:41385096 "[{""id"":""uuid:51e32ee7-f22a-4a49-b85e-483f394be994"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:126e1a7a-d4ab-46aa-8586-a8ac186db44f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] (To understand fully the indication for this product, please read the entire INDICATIONS AND USAGE section of the labeling.) Ciclopirox Topical Solution, 8% (Nail Lacquer) as a component of a comprehensive management program, is indicated as topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to Tricho-phyto rubrum . The comprehensive management program includes removal of the unattached, infected nails as frequently as monthly, by a health care professional who has special competence in the diagnosis and treatment of nail disorders, including minor nail procedures. No studies have been conducted to determine whether ciclopirox might reduce the effectiveness of systemic antifungal agents for onychomycosis. Therefore, the concomitant use of 8% ciclopirox topical solution and systemic antifungal agents for onychomycosis, is not recommended. Ciclopirox Topical Solution, 8% (Nail Lacquer) should be used only under medical supervision as described above. The effectiveness and safety of Ciclopirox Topical Solution, 8% (Nail Lacquer) in the following populations has not been studied.The clinical trials with use of Ciclopirox Topical Solution, 8% (Nail Lacquer) excluded patients who: were pregnant or nursing, planned to become pregnant, had a history of immunosuppression (e.g., extensive, persistent, or unusual distribution of dermatomycoses, extensive seborrheic dermatitis, recent or recurring herpes zoster, or persistent herpes simplex), were HIV seropositive, received organ transplant, required medication to control epilepsy, were insulin dependent diabetics or had diabetic neuropathy. Patients with severe plantar (moccasin) tinea pedis were also excluded. The safety and efficacy of using Ciclopirox Topical Solution, 8% (Nail Lacquer) daily for greater than 48 weeks have not been established. uuid:c9e70b1f-a70b-4c8b-a1f4-2528d7be7d50 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:453011 biolink:treats MONDO:0006608 PMID:41385096 "[{""id"":""uuid:58920712-5167-4197-9f10-558d922c44e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1e70b581-e585-4e45-b160-99b02352112d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] (To understand fully the indication for this product, please read the entire INDICATIONS AND USAGE section of the labeling.) Ciclopirox Topical Solution, 8% (Nail Lacquer) as a component of a comprehensive management program, is indicated as topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to Tricho-phyto rubrum . The comprehensive management program includes removal of the unattached, infected nails as frequently as monthly, by a health care professional who has special competence in the diagnosis and treatment of nail disorders, including minor nail procedures. No studies have been conducted to determine whether ciclopirox might reduce the effectiveness of systemic antifungal agents for onychomycosis. Therefore, the concomitant use of 8% ciclopirox topical solution and systemic antifungal agents for onychomycosis, is not recommended. Ciclopirox Topical Solution, 8% (Nail Lacquer) should be used only under medical supervision as described above. The effectiveness and safety of Ciclopirox Topical Solution, 8% (Nail Lacquer) in the following populations has not been studied.The clinical trials with use of Ciclopirox Topical Solution, 8% (Nail Lacquer) excluded patients who: were pregnant or nursing, planned to become pregnant, had a history of immunosuppression (e.g., extensive, persistent, or unusual distribution of dermatomycoses, extensive seborrheic dermatitis, recent or recurring herpes zoster, or persistent herpes simplex), were HIV seropositive, received organ transplant, required medication to control epilepsy, were insulin dependent diabetics or had diabetic neuropathy. Patients with severe plantar (moccasin) tinea pedis were also excluded. The safety and efficacy of using Ciclopirox Topical Solution, 8% (Nail Lacquer) daily for greater than 48 weeks have not been established. uuid:54dbc3ad-a643-4ff9-9a74-3a23ad095c8a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:453011 biolink:treats MONDO:0005609 PMID:41385096 "[{""id"":""uuid:8f3e25d1-9dd8-443e-b89e-7a2b9796535b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c8822e04-dcfc-4995-9cee-ba7f8fee3659"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] (To understand fully the indication for this product, please read the entire INDICATIONS AND USAGE section of the labeling.) Ciclopirox Topical Solution, 8% (Nail Lacquer) as a component of a comprehensive management program, is indicated as topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to Tricho-phyto rubrum . The comprehensive management program includes removal of the unattached, infected nails as frequently as monthly, by a health care professional who has special competence in the diagnosis and treatment of nail disorders, including minor nail procedures. No studies have been conducted to determine whether ciclopirox might reduce the effectiveness of systemic antifungal agents for onychomycosis. Therefore, the concomitant use of 8% ciclopirox topical solution and systemic antifungal agents for onychomycosis, is not recommended. Ciclopirox Topical Solution, 8% (Nail Lacquer) should be used only under medical supervision as described above. The effectiveness and safety of Ciclopirox Topical Solution, 8% (Nail Lacquer) in the following populations has not been studied.The clinical trials with use of Ciclopirox Topical Solution, 8% (Nail Lacquer) excluded patients who: were pregnant or nursing, planned to become pregnant, had a history of immunosuppression (e.g., extensive, persistent, or unusual distribution of dermatomycoses, extensive seborrheic dermatitis, recent or recurring herpes zoster, or persistent herpes simplex), were HIV seropositive, received organ transplant, required medication to control epilepsy, were insulin dependent diabetics or had diabetic neuropathy. Patients with severe plantar (moccasin) tinea pedis were also excluded. The safety and efficacy of using Ciclopirox Topical Solution, 8% (Nail Lacquer) daily for greater than 48 weeks have not been established. uuid:165b6cfc-5064-42ce-be7c-a995a4a66b41 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:453011 biolink:treats MONDO:0004609 PMID:41385096 "[{""id"":""uuid:22bc2e3a-79b5-47c6-924b-c97e7796bb66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:349ec451-a287-42d3-b327-c581d73d3851"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] (To understand fully the indication for this product, please read the entire INDICATIONS AND USAGE section of the labeling.) Ciclopirox Topical Solution, 8% (Nail Lacquer) as a component of a comprehensive management program, is indicated as topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to Tricho-phyto rubrum . The comprehensive management program includes removal of the unattached, infected nails as frequently as monthly, by a health care professional who has special competence in the diagnosis and treatment of nail disorders, including minor nail procedures. No studies have been conducted to determine whether ciclopirox might reduce the effectiveness of systemic antifungal agents for onychomycosis. Therefore, the concomitant use of 8% ciclopirox topical solution and systemic antifungal agents for onychomycosis, is not recommended. Ciclopirox Topical Solution, 8% (Nail Lacquer) should be used only under medical supervision as described above. The effectiveness and safety of Ciclopirox Topical Solution, 8% (Nail Lacquer) in the following populations has not been studied.The clinical trials with use of Ciclopirox Topical Solution, 8% (Nail Lacquer) excluded patients who: were pregnant or nursing, planned to become pregnant, had a history of immunosuppression (e.g., extensive, persistent, or unusual distribution of dermatomycoses, extensive seborrheic dermatitis, recent or recurring herpes zoster, or persistent herpes simplex), were HIV seropositive, received organ transplant, required medication to control epilepsy, were insulin dependent diabetics or had diabetic neuropathy. Patients with severe plantar (moccasin) tinea pedis were also excluded. The safety and efficacy of using Ciclopirox Topical Solution, 8% (Nail Lacquer) daily for greater than 48 weeks have not been established. uuid:bba392b1-666f-48ad-84cf-f2afacb285dc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:453011 biolink:treats MONDO:0005984 PMID:41385096 "[{""id"":""uuid:781c8ad6-224e-4feb-beb8-d727e0e88c3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2e986441-0032-43de-b600-ac76322e153b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] (To understand fully the indication for this product, please read the entire INDICATIONS AND USAGE section of the labeling.) Ciclopirox Topical Solution, 8% (Nail Lacquer) as a component of a comprehensive management program, is indicated as topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to Tricho-phyto rubrum . The comprehensive management program includes removal of the unattached, infected nails as frequently as monthly, by a health care professional who has special competence in the diagnosis and treatment of nail disorders, including minor nail procedures. No studies have been conducted to determine whether ciclopirox might reduce the effectiveness of systemic antifungal agents for onychomycosis. Therefore, the concomitant use of 8% ciclopirox topical solution and systemic antifungal agents for onychomycosis, is not recommended. Ciclopirox Topical Solution, 8% (Nail Lacquer) should be used only under medical supervision as described above. The effectiveness and safety of Ciclopirox Topical Solution, 8% (Nail Lacquer) in the following populations has not been studied.The clinical trials with use of Ciclopirox Topical Solution, 8% (Nail Lacquer) excluded patients who: were pregnant or nursing, planned to become pregnant, had a history of immunosuppression (e.g., extensive, persistent, or unusual distribution of dermatomycoses, extensive seborrheic dermatitis, recent or recurring herpes zoster, or persistent herpes simplex), were HIV seropositive, received organ transplant, required medication to control epilepsy, were insulin dependent diabetics or had diabetic neuropathy. Patients with severe plantar (moccasin) tinea pedis were also excluded. The safety and efficacy of using Ciclopirox Topical Solution, 8% (Nail Lacquer) daily for greater than 48 weeks have not been established. uuid:258380eb-a95a-43b1-838d-35cea3c4364c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10385 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:50aafe0c-da77-40bb-ab3a-0dd16886add3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e36f84a7-c856-40da-8c69-155857afcdd8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. Allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. The use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. Allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. Allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. uuid:6495fcb7-e850-4491-9d6e-b7825f548652 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10400 biolink:treats HP:0410324 PMID:41385096 "[{""id"":""uuid:bfd98f6e-a2d9-475e-9a58-d93c79b1d83c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4b554ed6-8242-4c8f-8ec3-0aea0dd32660"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Standardized mite allergenic extracts are intended for use in the diagnosis and therapy of D.farinae and D.pteronyssinus mite allergy, as established by allergy history and skin test reactivity (6,10) . Standardized Mite extracts are not interchangeable with non standardized mite extracts. To select patients for a confirmation of allergic disease diagnosis and/or treatment with allergen extracts, screening tests should be done using in vivo identification testing methods (i.e. scratch or intradermal testing). (13) Standardized mite extract containing equal parts of D.farinae and D.pteronyssinus is intended for therapy only. The use of standardized mites extract is indicated for hypersensitization treatment and may be used as part of the over-all management of the allergic patient. This treatment is particularly to be recommended when a patient's sensitivity to mite has been determined initially by scratch or intradermal skin tests. uuid:3620bae6-0c05-45f6-bf48-a10ff8d6c7a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10535 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:0572938c-cbba-4ef9-a0df-8dccb85de314"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4f42cb5b-8290-4964-9ba0-528c40cc8dfa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. Allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. The use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. Allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. Allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. uuid:df11e160-d04f-4073-bc42-eedb09f0d4c7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10394 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:40c3ceb8-f790-49b6-8d72-a564f478ace4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9323a10c-91f1-498f-a1d3-36ef6cc7b824"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Standardized Pollen Extract is intended for use in the diagnosis and therapy of pollen allergic patients as established by allergy history and skin test reactivity. Standardized Grass Pollen extracts labeled in BAU/mL are not interchangeable with Grass Pollen extracts labeled in AU/mL or with non-standardized Grass Pollen extracts. The 10,000 BAU/mL dose form is indicated for percutaneous testing. If negative, 100,000 BAU/mL dose form can be used for percutaneous testing. For immunotherapy, availability of 10,000 and 100,000 BAU/mL dosages facilitates safe switching. (See Dosage & Administration) The use of standardized grass pollen extracts is indicated for hyposensitization treatment and may be used as part of the over-all management of the allergic patient. Treatment of grass sensitive patients consists of using specific standardized grass products of up to and including doses of 100,000 BAU/mL (up to 10,000 BAU/mL for Bermuda grass) or stock mixtures of standardized grass products. Stock mixtures of standardized grass extracts are particularly useful in hyposensitization treatment when multiple allergies to grasses are diagnosed. For previously untreated patients, the 10,000 BAU/mL concentrates can be used to formulate dosages. If tolerated, the concentrates can be inceased to 100,000 BAU/mL dose formulation. uuid:f8ef2fa3-89ca-48f5-9146-b5b7bbf977d2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10388 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:bc565cdf-839e-40fb-9bf7-8a09a576dc84"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ff2dca31-571d-44aa-8c75-5a816f567641"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. Allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. The use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. Allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. Allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. uuid:8579fdac-4b50-4765-81da-aee0cb5a0c2f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10410 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:f94caf30-e107-482f-8c1a-65489bbd8722"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e5d4f079-f676-44f2-bf3b-5609bace7d89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. Allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. The use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. Allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. Allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. uuid:f219f86c-8199-4f3c-8fd9-03f25b35c335 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10620 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:fce4d45a-004a-4fb9-8e53-414918b00bf3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:224aa962-3b7c-4f72-b4c6-2cf93d9a3294"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. Allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. The use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. Allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. Allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. uuid:a49da8a0-6f2c-40cf-81be-599e99ebb937 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10349 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:d3b1804a-0361-4af0-924d-19239394193a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0ec87604-fe4d-4e71-8f8f-32018450f6e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. Allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. The use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. Allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. Allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. uuid:975e42bd-59bb-407c-9a39-0875b93dce5f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10411 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:baf19e65-d640-4384-baf7-eb1b38c05cd1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b8e8af6d-5a24-43ef-8b13-73be1c7797a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. Allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. The use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. Allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. Allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. uuid:718bc2da-fce5-405a-8412-38778006129d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10419 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:eae33cad-a5b5-4bc9-9170-e2b4c39eff83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:173fc431-8f76-496c-b5f7-3ecc874a29a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. Allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. The use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. Allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. Allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. uuid:efc949d0-a083-4714-a14d-57aee12ee9cd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10464 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:06c40bef-26c3-453a-865b-11b90d9f081f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:79310a57-4ad9-4ee7-9cae-1ad01db06b5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. Allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. The use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. Allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. Allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. uuid:e816f321-8077-4cef-b29c-a7461e560494 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10426 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:2b319178-8bf8-484f-96fe-6ff7d16e9fdf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3b2e7303-9c85-4ad0-8b1c-5d5f8ac62a4c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. Allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. The use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. Allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. Allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. uuid:ff8f3d76-1a05-4434-94a4-4dd5a6663967 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10708 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:97b716b7-14b6-4674-b8eb-27dff463a2e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0ee3e5c6-c397-4d62-90ed-f1a98428a8a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. Allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. The use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. Allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. Allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. uuid:69ed4c2b-a102-4c2a-998e-e23d22d9f3a9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10543 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:b81a020a-695e-48a6-8d11-efc26f778bb3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0fc453b7-92b4-4cde-a113-edee5f6dc4da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. Allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. The use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. Allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. Allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. uuid:3febc2d9-7aca-45d0-a888-1d937e536c77 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7825 biolink:treats MONDO:0005984 PMID:41385096 "[{""id"":""uuid:0e954766-78d3-4e3e-a226-4894d1a33336"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:165c4cce-0e6a-408e-9a9a-c7d00eaf5621"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OXISTAT ® Cream and Lotion are indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, or Epidermophyton floccosum. OXISTAT ® Cream is indicated for the topical treatment of tinea (pityriasis) versicolor due to Malassezia furfur (see DOSAGE AND ADMINISTRATION and CLINICAL STUDIES ). OXISTAT ® Cream may be used in pediatric patients for tinea corporis, tinea cruris, tinea pedis, and tinea (pityriasis) versicolor; however, these indications for which OXISTAT ® Cream has been shown to be effective rarely occur in children below the age of 12. uuid:3dca5c2b-7b52-462c-b1ce-149fea47a7cc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7825 biolink:treats MONDO:0001405 PMID:41385096 "[{""id"":""uuid:c5c4c166-edca-4f61-a375-a836609902f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ec8b6767-9cf3-458e-89d9-baa5422afda0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OXISTAT ® Cream and Lotion are indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, or Epidermophyton floccosum. OXISTAT ® Cream is indicated for the topical treatment of tinea (pityriasis) versicolor due to Malassezia furfur (see DOSAGE AND ADMINISTRATION and CLINICAL STUDIES ). OXISTAT ® Cream may be used in pediatric patients for tinea corporis, tinea cruris, tinea pedis, and tinea (pityriasis) versicolor; however, these indications for which OXISTAT ® Cream has been shown to be effective rarely occur in children below the age of 12. uuid:76e20f4a-9980-4f2b-96ad-db71099ebfb9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7825 biolink:treats MONDO:0001461 PMID:41385096 "[{""id"":""uuid:e8404a90-18c4-4936-87fb-2d06dc192f6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b289a79e-b665-4eb3-8f38-bb4a85232f05"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OXISTAT ® Cream and Lotion are indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, or Epidermophyton floccosum. OXISTAT ® Cream is indicated for the topical treatment of tinea (pityriasis) versicolor due to Malassezia furfur (see DOSAGE AND ADMINISTRATION and CLINICAL STUDIES ). OXISTAT ® Cream may be used in pediatric patients for tinea corporis, tinea cruris, tinea pedis, and tinea (pityriasis) versicolor; however, these indications for which OXISTAT ® Cream has been shown to be effective rarely occur in children below the age of 12. uuid:92249dd2-75a2-480a-8841-986ddfc98c38 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7825 biolink:treats MONDO:0005915 PMID:41385096 "[{""id"":""uuid:326a2074-b19c-447e-9612-2994c71a88e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f5801e13-fc52-4ef1-b7c8-9101f1b33b62"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OXISTAT ® Cream and Lotion are indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, or Epidermophyton floccosum. OXISTAT ® Cream is indicated for the topical treatment of tinea (pityriasis) versicolor due to Malassezia furfur (see DOSAGE AND ADMINISTRATION and CLINICAL STUDIES ). OXISTAT ® Cream may be used in pediatric patients for tinea corporis, tinea cruris, tinea pedis, and tinea (pityriasis) versicolor; however, these indications for which OXISTAT ® Cream has been shown to be effective rarely occur in children below the age of 12. uuid:9fd0bf25-4385-4510-8a0a-8973d716f905 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10666 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:16fb1df6-b0cf-49ba-9535-4bc805f14ede"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a24b7627-c316-47a8-88f1-1d400f176812"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. Allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. The use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. Allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. Allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. uuid:77e7d1bd-34b7-4437-bbbe-8568ebb717b6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10611 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:1738cc7b-165b-4e13-880f-8b540600b896"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:40dc2aff-9fd3-4b82-85bf-da6a93c769fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. Allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. The use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. Allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. Allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. uuid:2c221d5e-a550-49a4-9de7-69fa2d8cfa6a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:144551 biolink:treats UMLS:C0392115 PMID:41385096 "[{""id"":""uuid:2f95b037-4d85-44b1-83c7-0b267b5ace48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:15914528-cbaf-4641-8488-de828b596059"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxybutynin chloride tablets are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria). uuid:d8cb7a15-1dc2-4d48-ab29-ed05a11de42f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:144551 biolink:treats HP:0000011 PMID:41385096 "[{""id"":""uuid:eb9c380c-befc-41ab-a347-a296d49608bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6a2b493b-d55a-49ba-b89c-ce192be5fb6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxybutynin chloride tablets are indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria). uuid:c84aa299-765f-4bba-8107-98a96006018d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10102 biolink:treats MONDO:0013600 PMID:41385096 "[{""id"":""uuid:189f9889-7f72-4a1f-b6fd-f1b09137c06a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:55da7e40-764c-4e4d-a6e4-97966ce385fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Zaleplon is indicated for the short-term treatment of insomnia. Zaleplon has been shown to decrease the time to sleep onset for up to 30 days in controlled clinical studies (see Clinical Trials under CLINICAL PHARMACOLOGY ). It has not been shown to increase total sleep time or decrease the number of awakenings. The clinical trials performed in support of efficacy ranged from a single night to 5 weeks in duration. The final formal assessments of sleep latency were performed at the end of treatment. uuid:118d4d48-d784-4346-8bb1-ae209823688c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10686 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:f52ba3a4-cc64-4df4-954c-9096248412e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:72b72806-fed4-4449-beef-d55ac28cc4c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. Allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. The use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. Allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. Allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. uuid:b425b2bd-1120-4aa6-9fd4-7dd6a5e78153 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6359 biolink:treats MONDO:0002203 PMID:41385096 "[{""id"":""uuid:5cfc136c-15ec-4f98-8602-18df8cf4a20e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aebdeb43-750c-40b3-83a4-a053677ef381"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of constipation. In patients with a history of chronic constipation, lactulose solution therapy increases the number of bowel movements per day and the number of days on which bowel movements occur. uuid:5e975d65-ce9f-4b80-9045-142d34601edc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6359 biolink:treats HP:0012450 PMID:41385096 "[{""id"":""uuid:c49422a5-547d-41b6-8023-15dc68402ea8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1561506e-ff0b-433d-abe7-43f58e490378"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:aeead15d-3a72-4d9b-a0f2-8f9dcf534984"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of constipation. In patients with a history of chronic constipation, lactulose solution therapy increases the number of bowel movements per day and the number of days on which bowel movements occur.|[PMDA] A drug with a new additional indication and a new dosage in an additional dosage form indicated for the treatment of chronic constipation (excluding constipation due to organic diseases). uuid:766b1b53-e53a-4d9d-8304-77e6ed835cdf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4514 biolink:treats MONDO:0005052 PMID:41385096 "[{""id"":""uuid:7c8e8630-54b6-4510-b865-4f48ead1cd2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:104929e0-74ca-452d-be8e-46e9b297ed96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of functional bowel/irritable bowel syndrome. uuid:1e321efb-620d-4a14-b77c-5e39db74c9e5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27796 biolink:treats EFO:0004888 PMID:41385096 "[{""id"":""uuid:d197efab-54ba-4bcf-8a1f-87237aa90186"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cbc986c6-b238-4f30-9585-dcc58e4c2378"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Trimethobenzamide hydrochloride capsules are indicated for the treatment of postoperative nausea and vomiting and for nausea associated with gastroenteritis. uuid:1f5bdce5-f536-4474-baf0-2b2577897c61 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27796 biolink:treats MONDO:0002269 PMID:41385096 "[{""id"":""uuid:d4655a35-5583-416f-8274-69a391067c73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:edd13eb3-a307-4595-9387-a65cfa7b2a65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Trimethobenzamide hydrochloride capsules are indicated for the treatment of postoperative nausea and vomiting and for nausea associated with gastroenteritis. uuid:e47392a0-703b-4d43-ad31-37b6f02f1489 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10581 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:d9ec100f-5b8f-4ebb-9b69-7cd3069b464f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a46e9381-fe57-418b-9e79-d28c64268665"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. Allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. The use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. Allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. Allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. uuid:bd536a57-9ba1-421f-8bfc-c999766dd905 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10634 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:f6905f9c-4e34-4012-a5cf-643a19c1e1e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fb0689da-b5d4-4f73-99bd-8b66d205c531"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. Allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. The use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. Allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. Allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. uuid:5ba6a3b2-acbe-4ea9-8d9e-62993f79480d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10761 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:1d49fbbc-c6bd-4ff5-b735-614c251308c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:71fe7080-7947-462a-9c5d-6bbc5f7cc8dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. Allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. The use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. Allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. Allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. uuid:b6677a12-bfa4-4532-90fc-e776c1dec106 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10716 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:d8d808d5-09f1-4718-8ec3-c5da285fed31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c9ca7bef-78cd-49e9-b878-def28b59e7a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. Allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. The use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. Allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. Allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. uuid:87812dcb-01f9-4588-8077-a9d1e833109f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16755 biolink:treats MONDO:0024647 PMID:41385096 "[{""id"":""uuid:0ed30263-2f0b-4947-8355-92064baaac05"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7509625a-734a-4e83-b4b4-32f2de0abcbc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chenodal (chenodiol tablets) is indicated for patients with radiolucent stones in well-opacifying gallbladders, in whom selective surgery would be undertaken except for the presence of increased surgical risk due to systemic disease or age. The likelihood of successful dissolution is far greater if the stones are floatable or small. For patients with nonfloatable stones, dissolution is less likely and added weight should be given to the risk that more emergent surgery might result form a delay due to unsuccessful treatment. Safety of use beyond 24 months is not established. Chenodiol will not dissolve calcified (radiopaque) or radiolucent bile pigment stones. uuid:e028f67a-0205-47f6-a198-0ad566b4282a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16755 biolink:treats MONDO:0012672 PMID:41385096 "[{""id"":""uuid:32534185-1c55-46e1-bedb-2e8cbc9a40ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5d92c8e2-ea1d-4c00-9d75-682ed8207d09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chenodal (chenodiol tablets) is indicated for patients with radiolucent stones in well-opacifying gallbladders, in whom selective surgery would be undertaken except for the presence of increased surgical risk due to systemic disease or age. The likelihood of successful dissolution is far greater if the stones are floatable or small. For patients with nonfloatable stones, dissolution is less likely and added weight should be given to the risk that more emergent surgery might result form a delay due to unsuccessful treatment. Safety of use beyond 24 months is not established. Chenodiol will not dissolve calcified (radiopaque) or radiolucent bile pigment stones. uuid:6f7fd207-9bef-4c98-bd03-db6fa2a4308e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5134 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:0b658bc1-15ce-42e3-9ecf-674cac8818a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9b1a52e1-34e3-41a3-a199-b1483624bd1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluticasone Propionate Nasal Spray is indicated for the management of the nasal symptoms of seasonal and perennial allergic and nonallergic rhinitis in adults and pediatric patients 4 years of age and older. Safety and effectiveness of Fluticasone Propionate Nasal Spray in children below 4 years of age have not been adequately established. uuid:790fbd80-715b-4231-9d00-d09e2daac354 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5134 biolink:treats MONDO:0024332 PMID:41385096 "[{""id"":""uuid:67d182e9-e0d3-43a1-8f19-561642d30663"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:59879f7b-4889-44b6-8561-04dd0b7f8038"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluticasone Propionate Nasal Spray is indicated for the management of the nasal symptoms of seasonal and perennial allergic and nonallergic rhinitis in adults and pediatric patients 4 years of age and older. Safety and effectiveness of Fluticasone Propionate Nasal Spray in children below 4 years of age have not been adequately established. uuid:9855e55c-fd24-4648-a27c-c08bca1eba4f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5134 biolink:treats MONDO:0006004 PMID:41385096 "[{""id"":""uuid:e77b8657-fff9-4c23-ba9f-b4d64c196449"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:143df0b4-a0f8-4b56-b124-03c516118e90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluticasone Propionate Nasal Spray is indicated for the management of the nasal symptoms of seasonal and perennial allergic and nonallergic rhinitis in adults and pediatric patients 4 years of age and older. Safety and effectiveness of Fluticasone Propionate Nasal Spray in children below 4 years of age have not been adequately established. uuid:9acfee12-e4d1-4167-a880-d40895387b5b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats UMLS:C0343734 PMID:41385096 "[{""id"":""uuid:6f79d9ff-c2a7-4e96-b098-b3447f4122c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:09c8dd49-6848-44fb-97d5-d06ca9f1a3d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Symptomatic Trichomoniasis: Metronidazole is indicated for the treatment of symptomatic trichomoniasis in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis: Metronidazole is indicated in the treatment of asymptomatic females when the organism is associated with endocervicitis, cervicitis, or cervical erosion.Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. Treatment of Asymptomatic Consorts: T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her consort is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the consort should be treated with metronidazole in cases of reinfection. Amebiasis: Metronidazole is indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. In amebic liver abscess, metronidazole therapy does not obviate the need for aspiration or drainage of pus. Anaerobic Bacterial Infections: Metronidazole is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with metronidazole therapy. In a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole. In the treatment of most serious anaerobic infections, the intravenous form of metronidazole is usually administered initially. This may be followed by oral therapy with metronidazole at the discretion of the physician. Intra-Abdominal Infections, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species, including the B. fragilis group, ( B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus ), Clostridium species, Eubacterium species, Peptococcus niger, and Peptostreptococcus species. Skin and Skin Structure Infections caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger, Peptostreptococcus species, and Fusobacterium species. Gynecologic Infections , including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger and Peptostreptococcus species. Bacterial Septicemia caused by Bacteroides species including the B. fragilis group and Clostridium species. Bone and Joint Infections, as adjunctive therapy, caused by Bacteroides species, including the B. fragilis group. Central Nervous System (CNS) Infection , including meningitis and brain abscess, caused by Bacteroides species, including the B. fragilis group. Lower Respiratory Tract Infections , including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group. Endocarditis caused by Bacteroides species including the B. fragilis group. uuid:94ae83ff-b0bb-4ce9-a2fc-422df3032082 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0003632 PMID:41385096 "[{""id"":""uuid:bdf582a8-cbd7-4852-8f8d-878f59278878"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e0d43e23-7283-43bf-897b-fc5eb4ff2cd9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Symptomatic Trichomoniasis: Metronidazole is indicated for the treatment of symptomatic trichomoniasis in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis: Metronidazole is indicated in the treatment of asymptomatic females when the organism is associated with endocervicitis, cervicitis, or cervical erosion.Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. Treatment of Asymptomatic Consorts: T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her consort is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the consort should be treated with metronidazole in cases of reinfection. Amebiasis: Metronidazole is indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. In amebic liver abscess, metronidazole therapy does not obviate the need for aspiration or drainage of pus. Anaerobic Bacterial Infections: Metronidazole is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with metronidazole therapy. In a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole. In the treatment of most serious anaerobic infections, the intravenous form of metronidazole is usually administered initially. This may be followed by oral therapy with metronidazole at the discretion of the physician. Intra-Abdominal Infections, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species, including the B. fragilis group, ( B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus ), Clostridium species, Eubacterium species, Peptococcus niger, and Peptostreptococcus species. Skin and Skin Structure Infections caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger, Peptostreptococcus species, and Fusobacterium species. Gynecologic Infections , including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger and Peptostreptococcus species. Bacterial Septicemia caused by Bacteroides species including the B. fragilis group and Clostridium species. Bone and Joint Infections, as adjunctive therapy, caused by Bacteroides species, including the B. fragilis group. Central Nervous System (CNS) Infection , including meningitis and brain abscess, caused by Bacteroides species, including the B. fragilis group. Lower Respiratory Tract Infections , including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group. Endocarditis caused by Bacteroides species including the B. fragilis group. uuid:3105bc25-ffd4-4953-a15c-6bf244370eed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0002345 PMID:41385096 "[{""id"":""uuid:a852f96b-3b21-4ad7-b22b-b1927a5c628d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7e1294f6-61c1-48d1-92b5-eb8a8ddda0cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Symptomatic Trichomoniasis: Metronidazole is indicated for the treatment of symptomatic trichomoniasis in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis: Metronidazole is indicated in the treatment of asymptomatic females when the organism is associated with endocervicitis, cervicitis, or cervical erosion.Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. Treatment of Asymptomatic Consorts: T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her consort is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the consort should be treated with metronidazole in cases of reinfection. Amebiasis: Metronidazole is indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. In amebic liver abscess, metronidazole therapy does not obviate the need for aspiration or drainage of pus. Anaerobic Bacterial Infections: Metronidazole is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with metronidazole therapy. In a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole. In the treatment of most serious anaerobic infections, the intravenous form of metronidazole is usually administered initially. This may be followed by oral therapy with metronidazole at the discretion of the physician. Intra-Abdominal Infections, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species, including the B. fragilis group, ( B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus ), Clostridium species, Eubacterium species, Peptococcus niger, and Peptostreptococcus species. Skin and Skin Structure Infections caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger, Peptostreptococcus species, and Fusobacterium species. Gynecologic Infections , including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger and Peptostreptococcus species. Bacterial Septicemia caused by Bacteroides species including the B. fragilis group and Clostridium species. Bone and Joint Infections, as adjunctive therapy, caused by Bacteroides species, including the B. fragilis group. Central Nervous System (CNS) Infection , including meningitis and brain abscess, caused by Bacteroides species, including the B. fragilis group. Lower Respiratory Tract Infections , including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group. Endocarditis caused by Bacteroides species including the B. fragilis group. uuid:b82bd228-3933-4568-9b21-7def6f0b9a04 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0006696 PMID:41385096 "[{""id"":""uuid:b62a86ea-3718-49c1-b7bb-e458bd80fc65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c2582746-1411-49f0-bf1f-70a6b6664b72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Symptomatic Trichomoniasis: Metronidazole is indicated for the treatment of symptomatic trichomoniasis in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis: Metronidazole is indicated in the treatment of asymptomatic females when the organism is associated with endocervicitis, cervicitis, or cervical erosion.Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. Treatment of Asymptomatic Consorts: T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her consort is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the consort should be treated with metronidazole in cases of reinfection. Amebiasis: Metronidazole is indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. In amebic liver abscess, metronidazole therapy does not obviate the need for aspiration or drainage of pus. Anaerobic Bacterial Infections: Metronidazole is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with metronidazole therapy. In a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole. In the treatment of most serious anaerobic infections, the intravenous form of metronidazole is usually administered initially. This may be followed by oral therapy with metronidazole at the discretion of the physician. Intra-Abdominal Infections, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species, including the B. fragilis group, ( B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus ), Clostridium species, Eubacterium species, Peptococcus niger, and Peptostreptococcus species. Skin and Skin Structure Infections caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger, Peptostreptococcus species, and Fusobacterium species. Gynecologic Infections , including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger and Peptostreptococcus species. Bacterial Septicemia caused by Bacteroides species including the B. fragilis group and Clostridium species. Bone and Joint Infections, as adjunctive therapy, caused by Bacteroides species, including the B. fragilis group. Central Nervous System (CNS) Infection , including meningitis and brain abscess, caused by Bacteroides species, including the B. fragilis group. Lower Respiratory Tract Infections , including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group. Endocarditis caused by Bacteroides species including the B. fragilis group. uuid:c0f5707a-f39b-4805-9e0b-7e6aabff1d0c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0005644 PMID:41385096 "[{""id"":""uuid:94c7ee5b-3e53-44c3-90ab-123ad0215f05"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:69fa31ce-93bb-45a7-88fc-614ffa0d1cf3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Symptomatic Trichomoniasis: Metronidazole is indicated for the treatment of symptomatic trichomoniasis in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis: Metronidazole is indicated in the treatment of asymptomatic females when the organism is associated with endocervicitis, cervicitis, or cervical erosion.Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. Treatment of Asymptomatic Consorts: T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her consort is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the consort should be treated with metronidazole in cases of reinfection. Amebiasis: Metronidazole is indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. In amebic liver abscess, metronidazole therapy does not obviate the need for aspiration or drainage of pus. Anaerobic Bacterial Infections: Metronidazole is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with metronidazole therapy. In a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole. In the treatment of most serious anaerobic infections, the intravenous form of metronidazole is usually administered initially. This may be followed by oral therapy with metronidazole at the discretion of the physician. Intra-Abdominal Infections, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species, including the B. fragilis group, ( B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus ), Clostridium species, Eubacterium species, Peptococcus niger, and Peptostreptococcus species. Skin and Skin Structure Infections caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger, Peptostreptococcus species, and Fusobacterium species. Gynecologic Infections , including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger and Peptostreptococcus species. Bacterial Septicemia caused by Bacteroides species including the B. fragilis group and Clostridium species. Bone and Joint Infections, as adjunctive therapy, caused by Bacteroides species, including the B. fragilis group. Central Nervous System (CNS) Infection , including meningitis and brain abscess, caused by Bacteroides species, including the B. fragilis group. Lower Respiratory Tract Infections , including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group. Endocarditis caused by Bacteroides species including the B. fragilis group. uuid:a18ba1ef-1573-4a10-ae1f-4abccdab5422 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0024275 PMID:41385096 "[{""id"":""uuid:37024146-72b9-44ba-a33a-0e6b4acbcb50"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a1742fb9-0a3f-44d2-9c24-6f9094e846ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0d292815-a105-4312-ab94-0bff3632d79d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Symptomatic Trichomoniasis: Metronidazole is indicated for the treatment of symptomatic trichomoniasis in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis: Metronidazole is indicated in the treatment of asymptomatic females when the organism is associated with endocervicitis, cervicitis, or cervical erosion.Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. Treatment of Asymptomatic Consorts: T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her consort is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the consort should be treated with metronidazole in cases of reinfection. Amebiasis: Metronidazole is indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. In amebic liver abscess, metronidazole therapy does not obviate the need for aspiration or drainage of pus. Anaerobic Bacterial Infections: Metronidazole is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with metronidazole therapy. In a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole. In the treatment of most serious anaerobic infections, the intravenous form of metronidazole is usually administered initially. This may be followed by oral therapy with metronidazole at the discretion of the physician. Intra-Abdominal Infections, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species, including the B. fragilis group, ( B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus ), Clostridium species, Eubacterium species, Peptococcus niger, and Peptostreptococcus species. Skin and Skin Structure Infections caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger, Peptostreptococcus species, and Fusobacterium species. Gynecologic Infections , including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger and Peptostreptococcus species. Bacterial Septicemia caused by Bacteroides species including the B. fragilis group and Clostridium species. Bone and Joint Infections, as adjunctive therapy, caused by Bacteroides species, including the B. fragilis group. Central Nervous System (CNS) Infection , including meningitis and brain abscess, caused by Bacteroides species, including the B. fragilis group. Lower Respiratory Tract Infections , including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group. Endocarditis caused by Bacteroides species including the B. fragilis group.|[PMDA] A drug with a new route of administration indicated for the treatment of different kinds of anaerobic bacterial infections, infectious enteritis, and amebic dysentery. uuid:fa0712b0-cdf3-485a-824f-082559a6f80f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats UMLS:C0023886 PMID:41385096 "[{""id"":""uuid:7543cfce-fb59-400e-9f11-ca6c6941d6f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bd8b14c4-e66a-471b-84c4-b52b7e7b0c73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Symptomatic Trichomoniasis: Metronidazole is indicated for the treatment of symptomatic trichomoniasis in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis: Metronidazole is indicated in the treatment of asymptomatic females when the organism is associated with endocervicitis, cervicitis, or cervical erosion.Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. Treatment of Asymptomatic Consorts: T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her consort is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the consort should be treated with metronidazole in cases of reinfection. Amebiasis: Metronidazole is indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. In amebic liver abscess, metronidazole therapy does not obviate the need for aspiration or drainage of pus. Anaerobic Bacterial Infections: Metronidazole is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with metronidazole therapy. In a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole. In the treatment of most serious anaerobic infections, the intravenous form of metronidazole is usually administered initially. This may be followed by oral therapy with metronidazole at the discretion of the physician. Intra-Abdominal Infections, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species, including the B. fragilis group, ( B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus ), Clostridium species, Eubacterium species, Peptococcus niger, and Peptostreptococcus species. Skin and Skin Structure Infections caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger, Peptostreptococcus species, and Fusobacterium species. Gynecologic Infections , including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger and Peptostreptococcus species. Bacterial Septicemia caused by Bacteroides species including the B. fragilis group and Clostridium species. Bone and Joint Infections, as adjunctive therapy, caused by Bacteroides species, including the B. fragilis group. Central Nervous System (CNS) Infection , including meningitis and brain abscess, caused by Bacteroides species, including the B. fragilis group. Lower Respiratory Tract Infections , including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group. Endocarditis caused by Bacteroides species including the B. fragilis group. uuid:68f59935-0ac5-47e8-92a8-d12418476015 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0004522 PMID:41385096 "[{""id"":""uuid:6168ae8b-f05b-46dd-8f2e-c92020c0479f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b53c62eb-3868-4b81-9475-cac9745bf000"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Symptomatic Trichomoniasis: Metronidazole is indicated for the treatment of symptomatic trichomoniasis in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis: Metronidazole is indicated in the treatment of asymptomatic females when the organism is associated with endocervicitis, cervicitis, or cervical erosion.Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. Treatment of Asymptomatic Consorts: T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her consort is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the consort should be treated with metronidazole in cases of reinfection. Amebiasis: Metronidazole is indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. In amebic liver abscess, metronidazole therapy does not obviate the need for aspiration or drainage of pus. Anaerobic Bacterial Infections: Metronidazole is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with metronidazole therapy. In a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole. In the treatment of most serious anaerobic infections, the intravenous form of metronidazole is usually administered initially. This may be followed by oral therapy with metronidazole at the discretion of the physician. Intra-Abdominal Infections, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species, including the B. fragilis group, ( B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus ), Clostridium species, Eubacterium species, Peptococcus niger, and Peptostreptococcus species. Skin and Skin Structure Infections caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger, Peptostreptococcus species, and Fusobacterium species. Gynecologic Infections , including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger and Peptostreptococcus species. Bacterial Septicemia caused by Bacteroides species including the B. fragilis group and Clostridium species. Bone and Joint Infections, as adjunctive therapy, caused by Bacteroides species, including the B. fragilis group. Central Nervous System (CNS) Infection , including meningitis and brain abscess, caused by Bacteroides species, including the B. fragilis group. Lower Respiratory Tract Infections , including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group. Endocarditis caused by Bacteroides species including the B. fragilis group. uuid:3d02cfec-c334-415c-8796-aa2caf65fb8e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0700051 PMID:41385096 "[{""id"":""uuid:560d4b60-5c75-4844-b223-17dba24221d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:00d88eac-5e6c-45b3-9c02-3d2c0ec89d6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Symptomatic Trichomoniasis: Metronidazole is indicated for the treatment of symptomatic trichomoniasis in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis: Metronidazole is indicated in the treatment of asymptomatic females when the organism is associated with endocervicitis, cervicitis, or cervical erosion.Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. Treatment of Asymptomatic Consorts: T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her consort is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the consort should be treated with metronidazole in cases of reinfection. Amebiasis: Metronidazole is indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. In amebic liver abscess, metronidazole therapy does not obviate the need for aspiration or drainage of pus. Anaerobic Bacterial Infections: Metronidazole is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with metronidazole therapy. In a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole. In the treatment of most serious anaerobic infections, the intravenous form of metronidazole is usually administered initially. This may be followed by oral therapy with metronidazole at the discretion of the physician. Intra-Abdominal Infections, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species, including the B. fragilis group, ( B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus ), Clostridium species, Eubacterium species, Peptococcus niger, and Peptostreptococcus species. Skin and Skin Structure Infections caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger, Peptostreptococcus species, and Fusobacterium species. Gynecologic Infections , including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger and Peptostreptococcus species. Bacterial Septicemia caused by Bacteroides species including the B. fragilis group and Clostridium species. Bone and Joint Infections, as adjunctive therapy, caused by Bacteroides species, including the B. fragilis group. Central Nervous System (CNS) Infection , including meningitis and brain abscess, caused by Bacteroides species, including the B. fragilis group. Lower Respiratory Tract Infections , including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group. Endocarditis caused by Bacteroides species including the B. fragilis group. uuid:b4e5b074-d7eb-4569-90ee-17013f51e420 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0000918 PMID:41385096 "[{""id"":""uuid:ced8e421-8c43-497e-a8ac-721034686cab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4c77010d-bb6c-4d99-906d-ae7c9aa47672"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Symptomatic Trichomoniasis: Metronidazole is indicated for the treatment of symptomatic trichomoniasis in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis: Metronidazole is indicated in the treatment of asymptomatic females when the organism is associated with endocervicitis, cervicitis, or cervical erosion.Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. Treatment of Asymptomatic Consorts: T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her consort is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the consort should be treated with metronidazole in cases of reinfection. Amebiasis: Metronidazole is indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. In amebic liver abscess, metronidazole therapy does not obviate the need for aspiration or drainage of pus. Anaerobic Bacterial Infections: Metronidazole is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with metronidazole therapy. In a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole. In the treatment of most serious anaerobic infections, the intravenous form of metronidazole is usually administered initially. This may be followed by oral therapy with metronidazole at the discretion of the physician. Intra-Abdominal Infections, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species, including the B. fragilis group, ( B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus ), Clostridium species, Eubacterium species, Peptococcus niger, and Peptostreptococcus species. Skin and Skin Structure Infections caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger, Peptostreptococcus species, and Fusobacterium species. Gynecologic Infections , including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger and Peptostreptococcus species. Bacterial Septicemia caused by Bacteroides species including the B. fragilis group and Clostridium species. Bone and Joint Infections, as adjunctive therapy, caused by Bacteroides species, including the B. fragilis group. Central Nervous System (CNS) Infection , including meningitis and brain abscess, caused by Bacteroides species, including the B. fragilis group. Lower Respiratory Tract Infections , including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group. Endocarditis caused by Bacteroides species including the B. fragilis group. uuid:7e2b90f9-968b-4098-88bf-37c83e2dde2a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0042451 PMID:41385096 "[{""id"":""uuid:a22045a4-8165-4d3c-a19e-27cfffb6a290"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:11d2f2c7-90f6-4fbe-b02b-3fe9acd511c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Symptomatic Trichomoniasis: Metronidazole is indicated for the treatment of symptomatic trichomoniasis in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis: Metronidazole is indicated in the treatment of asymptomatic females when the organism is associated with endocervicitis, cervicitis, or cervical erosion.Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. Treatment of Asymptomatic Consorts: T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her consort is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the consort should be treated with metronidazole in cases of reinfection. Amebiasis: Metronidazole is indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. In amebic liver abscess, metronidazole therapy does not obviate the need for aspiration or drainage of pus. Anaerobic Bacterial Infections: Metronidazole is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with metronidazole therapy. In a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole. In the treatment of most serious anaerobic infections, the intravenous form of metronidazole is usually administered initially. This may be followed by oral therapy with metronidazole at the discretion of the physician. Intra-Abdominal Infections, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species, including the B. fragilis group, ( B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus ), Clostridium species, Eubacterium species, Peptococcus niger, and Peptostreptococcus species. Skin and Skin Structure Infections caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger, Peptostreptococcus species, and Fusobacterium species. Gynecologic Infections , including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger and Peptostreptococcus species. Bacterial Septicemia caused by Bacteroides species including the B. fragilis group and Clostridium species. Bone and Joint Infections, as adjunctive therapy, caused by Bacteroides species, including the B. fragilis group. Central Nervous System (CNS) Infection , including meningitis and brain abscess, caused by Bacteroides species, including the B. fragilis group. Lower Respiratory Tract Infections , including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group. Endocarditis caused by Bacteroides species including the B. fragilis group. uuid:b8377ed8-1f64-4e7a-8aea-2c831f1bd1c4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats HP:0034493 PMID:41385096 "[{""id"":""uuid:63baa523-13c9-4aa5-809a-381fff1b1ace"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7bbfaf7d-8e2d-4bfa-b85a-31aa5ac27622"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Symptomatic Trichomoniasis: Metronidazole is indicated for the treatment of symptomatic trichomoniasis in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis: Metronidazole is indicated in the treatment of asymptomatic females when the organism is associated with endocervicitis, cervicitis, or cervical erosion.Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. Treatment of Asymptomatic Consorts: T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her consort is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the consort should be treated with metronidazole in cases of reinfection. Amebiasis: Metronidazole is indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. In amebic liver abscess, metronidazole therapy does not obviate the need for aspiration or drainage of pus. Anaerobic Bacterial Infections: Metronidazole is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with metronidazole therapy. In a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole. In the treatment of most serious anaerobic infections, the intravenous form of metronidazole is usually administered initially. This may be followed by oral therapy with metronidazole at the discretion of the physician. Intra-Abdominal Infections, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species, including the B. fragilis group, ( B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus ), Clostridium species, Eubacterium species, Peptococcus niger, and Peptostreptococcus species. Skin and Skin Structure Infections caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger, Peptostreptococcus species, and Fusobacterium species. Gynecologic Infections , including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger and Peptostreptococcus species. Bacterial Septicemia caused by Bacteroides species including the B. fragilis group and Clostridium species. Bone and Joint Infections, as adjunctive therapy, caused by Bacteroides species, including the B. fragilis group. Central Nervous System (CNS) Infection , including meningitis and brain abscess, caused by Bacteroides species, including the B. fragilis group. Lower Respiratory Tract Infections , including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group. Endocarditis caused by Bacteroides species including the B. fragilis group. uuid:59fd1130-6b8d-4e9e-b82d-aa42073b17ad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats UMLS:C0684256 PMID:41385096 "[{""id"":""uuid:50b0b980-eb00-47ac-aa86-5639ef3eb5ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:93f73f41-c617-458a-8d02-893ae64378ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Symptomatic Trichomoniasis: Metronidazole is indicated for the treatment of symptomatic trichomoniasis in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis: Metronidazole is indicated in the treatment of asymptomatic females when the organism is associated with endocervicitis, cervicitis, or cervical erosion.Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. Treatment of Asymptomatic Consorts: T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her consort is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the consort should be treated with metronidazole in cases of reinfection. Amebiasis: Metronidazole is indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. In amebic liver abscess, metronidazole therapy does not obviate the need for aspiration or drainage of pus. Anaerobic Bacterial Infections: Metronidazole is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with metronidazole therapy. In a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole. In the treatment of most serious anaerobic infections, the intravenous form of metronidazole is usually administered initially. This may be followed by oral therapy with metronidazole at the discretion of the physician. Intra-Abdominal Infections, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species, including the B. fragilis group, ( B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus ), Clostridium species, Eubacterium species, Peptococcus niger, and Peptostreptococcus species. Skin and Skin Structure Infections caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger, Peptostreptococcus species, and Fusobacterium species. Gynecologic Infections , including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger and Peptostreptococcus species. Bacterial Septicemia caused by Bacteroides species including the B. fragilis group and Clostridium species. Bone and Joint Infections, as adjunctive therapy, caused by Bacteroides species, including the B. fragilis group. Central Nervous System (CNS) Infection , including meningitis and brain abscess, caused by Bacteroides species, including the B. fragilis group. Lower Respiratory Tract Infections , including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group. Endocarditis caused by Bacteroides species including the B. fragilis group. uuid:d3eb75b1-a6e9-4940-8056-c2c06cda6107 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0021108 PMID:41385096 "[{""id"":""uuid:9de19147-2383-488a-b0ed-219be2c905b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cdf72c9a-5e64-4988-bc7b-d1bcbf357a0c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Symptomatic Trichomoniasis: Metronidazole is indicated for the treatment of symptomatic trichomoniasis in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis: Metronidazole is indicated in the treatment of asymptomatic females when the organism is associated with endocervicitis, cervicitis, or cervical erosion.Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. Treatment of Asymptomatic Consorts: T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her consort is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the consort should be treated with metronidazole in cases of reinfection. Amebiasis: Metronidazole is indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. In amebic liver abscess, metronidazole therapy does not obviate the need for aspiration or drainage of pus. Anaerobic Bacterial Infections: Metronidazole is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with metronidazole therapy. In a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole. In the treatment of most serious anaerobic infections, the intravenous form of metronidazole is usually administered initially. This may be followed by oral therapy with metronidazole at the discretion of the physician. Intra-Abdominal Infections, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species, including the B. fragilis group, ( B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus ), Clostridium species, Eubacterium species, Peptococcus niger, and Peptostreptococcus species. Skin and Skin Structure Infections caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger, Peptostreptococcus species, and Fusobacterium species. Gynecologic Infections , including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger and Peptostreptococcus species. Bacterial Septicemia caused by Bacteroides species including the B. fragilis group and Clostridium species. Bone and Joint Infections, as adjunctive therapy, caused by Bacteroides species, including the B. fragilis group. Central Nervous System (CNS) Infection , including meningitis and brain abscess, caused by Bacteroides species, including the B. fragilis group. Lower Respiratory Tract Infections , including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group. Endocarditis caused by Bacteroides species including the B. fragilis group. uuid:284134ca-6682-4ecb-a965-6d23dafcf8e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats HP:0030049 PMID:41385096 "[{""id"":""uuid:6facd1a1-4c50-4900-8036-dbe405f97485"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c2c9d9cd-179e-43b9-a239-9ec57c50b72f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Symptomatic Trichomoniasis: Metronidazole is indicated for the treatment of symptomatic trichomoniasis in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis: Metronidazole is indicated in the treatment of asymptomatic females when the organism is associated with endocervicitis, cervicitis, or cervical erosion.Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. Treatment of Asymptomatic Consorts: T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her consort is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the consort should be treated with metronidazole in cases of reinfection. Amebiasis: Metronidazole is indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. In amebic liver abscess, metronidazole therapy does not obviate the need for aspiration or drainage of pus. Anaerobic Bacterial Infections: Metronidazole is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with metronidazole therapy. In a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole. In the treatment of most serious anaerobic infections, the intravenous form of metronidazole is usually administered initially. This may be followed by oral therapy with metronidazole at the discretion of the physician. Intra-Abdominal Infections, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species, including the B. fragilis group, ( B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus ), Clostridium species, Eubacterium species, Peptococcus niger, and Peptostreptococcus species. Skin and Skin Structure Infections caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger, Peptostreptococcus species, and Fusobacterium species. Gynecologic Infections , including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger and Peptostreptococcus species. Bacterial Septicemia caused by Bacteroides species including the B. fragilis group and Clostridium species. Bone and Joint Infections, as adjunctive therapy, caused by Bacteroides species, including the B. fragilis group. Central Nervous System (CNS) Infection , including meningitis and brain abscess, caused by Bacteroides species, including the B. fragilis group. Lower Respiratory Tract Infections , including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group. Endocarditis caused by Bacteroides species including the B. fragilis group. uuid:fe466ecf-7fbc-49c7-9767-a67f6cc42e49 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:f4a0a0c5-d8a9-4a43-a020-63837ec82057"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b55338aa-8f22-4ae1-937a-195e5fa22b84"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Symptomatic Trichomoniasis: Metronidazole is indicated for the treatment of symptomatic trichomoniasis in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis: Metronidazole is indicated in the treatment of asymptomatic females when the organism is associated with endocervicitis, cervicitis, or cervical erosion.Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. Treatment of Asymptomatic Consorts: T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her consort is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the consort should be treated with metronidazole in cases of reinfection. Amebiasis: Metronidazole is indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. In amebic liver abscess, metronidazole therapy does not obviate the need for aspiration or drainage of pus. Anaerobic Bacterial Infections: Metronidazole is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with metronidazole therapy. In a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole. In the treatment of most serious anaerobic infections, the intravenous form of metronidazole is usually administered initially. This may be followed by oral therapy with metronidazole at the discretion of the physician. Intra-Abdominal Infections, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species, including the B. fragilis group, ( B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus ), Clostridium species, Eubacterium species, Peptococcus niger, and Peptostreptococcus species. Skin and Skin Structure Infections caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger, Peptostreptococcus species, and Fusobacterium species. Gynecologic Infections , including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger and Peptostreptococcus species. Bacterial Septicemia caused by Bacteroides species including the B. fragilis group and Clostridium species. Bone and Joint Infections, as adjunctive therapy, caused by Bacteroides species, including the B. fragilis group. Central Nervous System (CNS) Infection , including meningitis and brain abscess, caused by Bacteroides species, including the B. fragilis group. Lower Respiratory Tract Infections , including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group. Endocarditis caused by Bacteroides species including the B. fragilis group. uuid:32fd000c-76ae-45b7-b4e3-b36d391cd478 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0005242 PMID:41385096 "[{""id"":""uuid:6d26b7b0-e778-4752-9325-1d8c3086f20d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6f01a45d-72e9-45f6-85e8-a4604acd9fc2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Symptomatic Trichomoniasis: Metronidazole is indicated for the treatment of symptomatic trichomoniasis in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis: Metronidazole is indicated in the treatment of asymptomatic females when the organism is associated with endocervicitis, cervicitis, or cervical erosion.Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. Treatment of Asymptomatic Consorts: T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her consort is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the consort should be treated with metronidazole in cases of reinfection. Amebiasis: Metronidazole is indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. In amebic liver abscess, metronidazole therapy does not obviate the need for aspiration or drainage of pus. Anaerobic Bacterial Infections: Metronidazole is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with metronidazole therapy. In a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole. In the treatment of most serious anaerobic infections, the intravenous form of metronidazole is usually administered initially. This may be followed by oral therapy with metronidazole at the discretion of the physician. Intra-Abdominal Infections, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species, including the B. fragilis group, ( B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus ), Clostridium species, Eubacterium species, Peptococcus niger, and Peptostreptococcus species. Skin and Skin Structure Infections caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger, Peptostreptococcus species, and Fusobacterium species. Gynecologic Infections , including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger and Peptostreptococcus species. Bacterial Septicemia caused by Bacteroides species including the B. fragilis group and Clostridium species. Bone and Joint Infections, as adjunctive therapy, caused by Bacteroides species, including the B. fragilis group. Central Nervous System (CNS) Infection , including meningitis and brain abscess, caused by Bacteroides species, including the B. fragilis group. Lower Respiratory Tract Infections , including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group. Endocarditis caused by Bacteroides species including the B. fragilis group. uuid:49836bb2-7607-4eb1-9cc4-5e9460cd065e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0000744 PMID:41385096 "[{""id"":""uuid:043fd96d-f972-404a-b11d-c93c9519be14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:37e31638-11ef-4068-bf91-903d4ad23950"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Symptomatic Trichomoniasis: Metronidazole is indicated for the treatment of symptomatic trichomoniasis in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis: Metronidazole is indicated in the treatment of asymptomatic females when the organism is associated with endocervicitis, cervicitis, or cervical erosion.Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. Treatment of Asymptomatic Consorts: T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her consort is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the consort should be treated with metronidazole in cases of reinfection. Amebiasis: Metronidazole is indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. In amebic liver abscess, metronidazole therapy does not obviate the need for aspiration or drainage of pus. Anaerobic Bacterial Infections: Metronidazole is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with metronidazole therapy. In a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole. In the treatment of most serious anaerobic infections, the intravenous form of metronidazole is usually administered initially. This may be followed by oral therapy with metronidazole at the discretion of the physician. Intra-Abdominal Infections, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species, including the B. fragilis group, ( B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus ), Clostridium species, Eubacterium species, Peptococcus niger, and Peptostreptococcus species. Skin and Skin Structure Infections caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger, Peptostreptococcus species, and Fusobacterium species. Gynecologic Infections , including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger and Peptostreptococcus species. Bacterial Septicemia caused by Bacteroides species including the B. fragilis group and Clostridium species. Bone and Joint Infections, as adjunctive therapy, caused by Bacteroides species, including the B. fragilis group. Central Nervous System (CNS) Infection , including meningitis and brain abscess, caused by Bacteroides species, including the B. fragilis group. Lower Respiratory Tract Infections , including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group. Endocarditis caused by Bacteroides species including the B. fragilis group. uuid:30e20c8f-8941-47be-b63c-9f3fe74818e3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0005025 PMID:41385096 "[{""id"":""uuid:38f851f7-be71-4465-8a5f-29f20d9c6049"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:af583210-2ceb-490f-8705-d97f0b025ad6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Symptomatic Trichomoniasis: Metronidazole is indicated for the treatment of symptomatic trichomoniasis in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis: Metronidazole is indicated in the treatment of asymptomatic females when the organism is associated with endocervicitis, cervicitis, or cervical erosion.Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. Treatment of Asymptomatic Consorts: T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her consort is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the consort should be treated with metronidazole in cases of reinfection. Amebiasis: Metronidazole is indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. In amebic liver abscess, metronidazole therapy does not obviate the need for aspiration or drainage of pus. Anaerobic Bacterial Infections: Metronidazole is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with metronidazole therapy. In a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole. In the treatment of most serious anaerobic infections, the intravenous form of metronidazole is usually administered initially. This may be followed by oral therapy with metronidazole at the discretion of the physician. Intra-Abdominal Infections, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species, including the B. fragilis group, ( B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus ), Clostridium species, Eubacterium species, Peptococcus niger, and Peptostreptococcus species. Skin and Skin Structure Infections caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger, Peptostreptococcus species, and Fusobacterium species. Gynecologic Infections , including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus niger and Peptostreptococcus species. Bacterial Septicemia caused by Bacteroides species including the B. fragilis group and Clostridium species. Bone and Joint Infections, as adjunctive therapy, caused by Bacteroides species, including the B. fragilis group. Central Nervous System (CNS) Infection , including meningitis and brain abscess, caused by Bacteroides species, including the B. fragilis group. Lower Respiratory Tract Infections , including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group. Endocarditis caused by Bacteroides species including the B. fragilis group. uuid:480c74dc-c1e3-44bd-a0fd-873c1d964ab6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51173 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:d3ba1361-66c8-4ab4-8985-48318ceeaaa9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3a176210-b58e-40bc-9962-a50e72a87c14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATION Propoxyphene hydrochloride capsules are indicated for the relief of mild to moderate pain. uuid:c4980343-f249-44e5-896e-2ad1d579fdde biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63681 biolink:treats MONDO:0005136 PMID:41385096 "[{""id"":""uuid:b0dc731e-2a20-436d-8447-8b5ceb760ab2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aeece90e-344e-425d-be4a-71354826fb23"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment of Acute Malaria Infections Mefloquine hydrochloride tablets are indicated for the treatment of mild to moderate acute malaria caused by mefloquine-susceptible strains of P. falciparum (both chloroquine-susceptible and resistant strains) or by Plasmodium vivax . There are insufficient clinical data to document the effect of mefloquine in malaria caused by P. ovale or P. malariae . Note: Patients with acute P. vivax malaria, treated with mefloquine, are at high risk of relapse because mefloquine does not eliminate exoerythrocytic (hepatic phase) parasites. To avoid relapse, after initial treatment of the acute infection with mefloquine, patients should subsequently be treated with an 8-aminoquinoline derivative (e.g., primaquine). Prevention of Malaria Mefloquine hydrochloride tablets are indicated for the prophylaxis of P. falciparum and P. vivax malaria infections, including prophylaxis of chloroquine-resistant strains of P. falciparum . uuid:750d2f20-3489-402c-8b86-073e6ea70ed7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63681 biolink:treats MONDO:0005920 PMID:41385096 "[{""id"":""uuid:4568db1b-461d-4c1b-b0a4-61823bab7fff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d81b8759-71f1-466d-9ea9-f950c7dca034"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment of Acute Malaria Infections Mefloquine hydrochloride tablets are indicated for the treatment of mild to moderate acute malaria caused by mefloquine-susceptible strains of P. falciparum (both chloroquine-susceptible and resistant strains) or by Plasmodium vivax . There are insufficient clinical data to document the effect of mefloquine in malaria caused by P. ovale or P. malariae . Note: Patients with acute P. vivax malaria, treated with mefloquine, are at high risk of relapse because mefloquine does not eliminate exoerythrocytic (hepatic phase) parasites. To avoid relapse, after initial treatment of the acute infection with mefloquine, patients should subsequently be treated with an 8-aminoquinoline derivative (e.g., primaquine). Prevention of Malaria Mefloquine hydrochloride tablets are indicated for the prophylaxis of P. falciparum and P. vivax malaria infections, including prophylaxis of chloroquine-resistant strains of P. falciparum . uuid:5185abef-4550-4fd3-a1e0-af92b7516e56 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63681 biolink:treats MONDO:0005921 PMID:41385096 "[{""id"":""uuid:06224ef4-ba08-47a6-8d43-fba0f6efcba1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e1fd8c7a-d917-4eab-bba1-1e3eeb9f64c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment of Acute Malaria Infections Mefloquine hydrochloride tablets are indicated for the treatment of mild to moderate acute malaria caused by mefloquine-susceptible strains of P. falciparum (both chloroquine-susceptible and resistant strains) or by Plasmodium vivax . There are insufficient clinical data to document the effect of mefloquine in malaria caused by P. ovale or P. malariae . Note: Patients with acute P. vivax malaria, treated with mefloquine, are at high risk of relapse because mefloquine does not eliminate exoerythrocytic (hepatic phase) parasites. To avoid relapse, after initial treatment of the acute infection with mefloquine, patients should subsequently be treated with an 8-aminoquinoline derivative (e.g., primaquine). Prevention of Malaria Mefloquine hydrochloride tablets are indicated for the prophylaxis of P. falciparum and P. vivax malaria infections, including prophylaxis of chloroquine-resistant strains of P. falciparum . uuid:4b9fcd6c-f302-49b6-bd6e-5cbfccd07614 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63681 biolink:treats MONDO:0001601 PMID:41385096 "[{""id"":""uuid:3c771381-5f3c-46b7-80be-cb7887cb61f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:54b07a18-3ecc-443f-b621-90725b2d2c9d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment of Acute Malaria Infections Mefloquine hydrochloride tablets are indicated for the treatment of mild to moderate acute malaria caused by mefloquine-susceptible strains of P. falciparum (both chloroquine-susceptible and resistant strains) or by Plasmodium vivax . There are insufficient clinical data to document the effect of mefloquine in malaria caused by P. ovale or P. malariae . Note: Patients with acute P. vivax malaria, treated with mefloquine, are at high risk of relapse because mefloquine does not eliminate exoerythrocytic (hepatic phase) parasites. To avoid relapse, after initial treatment of the acute infection with mefloquine, patients should subsequently be treated with an 8-aminoquinoline derivative (e.g., primaquine). Prevention of Malaria Mefloquine hydrochloride tablets are indicated for the prophylaxis of P. falciparum and P. vivax malaria infections, including prophylaxis of chloroquine-resistant strains of P. falciparum . uuid:66c7bd8d-f816-42a3-bf55-7318942aa26c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63681 biolink:treats MONDO:0001943 PMID:41385096 "[{""id"":""uuid:2306bd03-d6d1-4764-96d2-aab6abacfd5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f0f260e2-33be-467e-8c40-ff019c72c530"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment of Acute Malaria Infections Mefloquine hydrochloride tablets are indicated for the treatment of mild to moderate acute malaria caused by mefloquine-susceptible strains of P. falciparum (both chloroquine-susceptible and resistant strains) or by Plasmodium vivax . There are insufficient clinical data to document the effect of mefloquine in malaria caused by P. ovale or P. malariae . Note: Patients with acute P. vivax malaria, treated with mefloquine, are at high risk of relapse because mefloquine does not eliminate exoerythrocytic (hepatic phase) parasites. To avoid relapse, after initial treatment of the acute infection with mefloquine, patients should subsequently be treated with an 8-aminoquinoline derivative (e.g., primaquine). Prevention of Malaria Mefloquine hydrochloride tablets are indicated for the prophylaxis of P. falciparum and P. vivax malaria infections, including prophylaxis of chloroquine-resistant strains of P. falciparum . uuid:52cdcb29-a3ab-4010-b8dc-d10b556e2308 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7852 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:21897059-d22c-4a7d-bf19-42a44cb7c6f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c4787677-5664-48e1-9f26-8efcb6e5c665"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxycodone hydrochloride tablets, USP, are an immediate-release oral formulation of oxycodone hydrochloride indicated for the management of moderate to severe pain where the use of an opioid analgesic is appropriate. uuid:b2c951a9-d642-4813-a5ab-912128f5e63a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:166679 biolink:treats MONDO:0004592 PMID:41385096 "[{""id"":""uuid:1e0810b3-fd84-4dd8-9dbc-e07a5e6c8c65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:107ecef0-955c-45b6-b5e6-10429c74cd1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ALTABAX is indicated for use in adults and pediatric patients aged 9 months and older for the topical treatment of impetigo (up to 100 cm 2 in total area in adults or 2% total body surface area in pediatric patients aged 9 months or older) due to Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes [see Clinical Studies (14)] . To reduce the development of drug-resistant bacteria and maintain the effectiveness of ALTABAX and other antibacterial drugs, ALTABAX should uuid:4a84d38f-b877-4f42-a7a9-1ded5368518a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3510 biolink:treats UMLS:C0853854 PMID:41385096 "[{""id"":""uuid:e955163b-0c40-4611-b42d-bd70390ee4f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4af6cb0f-e744-424d-b7d0-1af44773ce56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CEDAX (ceftibuten) is indicated for the treatment of individuals with mild-to-moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below (see DOSAGE AND ADMINISTRATION and CLINICAL STUDIES sections). Acute Bacterial Exacerbations of Chronic Bronchitis due to Haemophilus influenzae (including β-lactamase-producing strains), Moraxella catarrhalis (including β-lactamase-producing strains), or Streptococcus pneumoniae (penicillin-susceptible strains only). uuid:ec792a3e-2c13-4587-b688-05d6c9f43631 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7565 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:73010f9f-3011-4361-a7df-9f550b76a69c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c28211be-5b72-4034-a8d2-162a7b1848df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0952574b-1d9e-46a1-80a7-4cd32fe6caa7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ADALAT CC is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents|[PMDA] Drugs with a new dosage indicated for the treatment of hypertension. uuid:da153c73-4a6e-4095-95ea-cad3dfcb143f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:109549 biolink:treats MONDO:0013600 PMID:41385096 "[{""id"":""uuid:d8609843-548a-41aa-9743-bfc8f8418d52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5779b6e2-3586-49bc-ac2e-38aaf1b0eb31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1ae730dd-6369-475f-bfd3-e61bf7a22107"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ROZEREM is indicated for the treatment of insomnia characterized by difficulty with sleep onset. The clinical trials performed in support of efficacy were up to 6 months in duration. The final formal assessments of sleep latency were performed after 2 days of treatment during the crossover study (elderly only), at 5 weeks in the 6-week studies (adults and elderly), and at the end of the 6-month study (adults and elderly) [see Clinical Studies (14) ] .|[PMDA] A drug with a new active ingredient indicated for the improvement of difficulty with sleep onset in insomnia. uuid:23e85009-01ef-426e-9e31-df5cdd0f01be biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7601 biolink:treats MONDO:0005412 PMID:41385096 "[{""id"":""uuid:750f3719-92dc-4702-b022-3d677b6a1637"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b52753f9-9fc8-4e73-8b67-8d13fcc7b232"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Nizatidine is indicated for up to 8 weeks for the treatment of active duodenal ulcer. In most patients, the ulcer will heal within 4 weeks. Nizatidine is indicated for maintenance therapy for duodenal ulcer patients, at a reduced dosage of 150 mg h.s. after healing of an active duodenal ulcer. The consequences of continuous therapy with nizatidine for longer than 1 year are not known. Nizatidine is indicated for up to 12 weeks for the treatment of endoscopically diagnosed esophagitis, including erosive and ulcerative esophagitis, and associated heartburn due to GERD. Nizatidine is indicated for up to 8 weeks for the treatment of active benign gastric ulcer. Before initiating therapy, care should be taken to exclude the possibility of malignant gastric ulceration. uuid:59659c3c-34ec-446e-b9ac-4cee47e245e4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7601 biolink:treats MONDO:0001409 PMID:41385096 "[{""id"":""uuid:fd86154e-66ba-4de4-8320-4f8a995522b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bbcb9534-a796-41ac-95b1-904fdf1120ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Nizatidine is indicated for up to 8 weeks for the treatment of active duodenal ulcer. In most patients, the ulcer will heal within 4 weeks. Nizatidine is indicated for maintenance therapy for duodenal ulcer patients, at a reduced dosage of 150 mg h.s. after healing of an active duodenal ulcer. The consequences of continuous therapy with nizatidine for longer than 1 year are not known. Nizatidine is indicated for up to 12 weeks for the treatment of endoscopically diagnosed esophagitis, including erosive and ulcerative esophagitis, and associated heartburn due to GERD. Nizatidine is indicated for up to 8 weeks for the treatment of active benign gastric ulcer. Before initiating therapy, care should be taken to exclude the possibility of malignant gastric ulceration. uuid:75cb7f06-7dec-4d6f-b7b6-20757ddffa42 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7601 biolink:treats UMLS:C0267055 PMID:41385096 "[{""id"":""uuid:5b8f7999-8b8d-4078-9240-270e109b0ad5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ff3e6ded-9987-4a64-af8f-9c0fa6703c1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Nizatidine is indicated for up to 8 weeks for the treatment of active duodenal ulcer. In most patients, the ulcer will heal within 4 weeks. Nizatidine is indicated for maintenance therapy for duodenal ulcer patients, at a reduced dosage of 150 mg h.s. after healing of an active duodenal ulcer. The consequences of continuous therapy with nizatidine for longer than 1 year are not known. Nizatidine is indicated for up to 12 weeks for the treatment of endoscopically diagnosed esophagitis, including erosive and ulcerative esophagitis, and associated heartburn due to GERD. Nizatidine is indicated for up to 8 weeks for the treatment of active benign gastric ulcer. Before initiating therapy, care should be taken to exclude the possibility of malignant gastric ulceration. uuid:68804c4d-76b7-439a-8cde-96429deb72a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7601 biolink:treats UMLS:C2586050 PMID:41385096 "[{""id"":""uuid:609f1e7b-65a2-46ad-b0d0-89ff05abf480"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:88419e0b-fb8e-48ef-bd45-12adc4e712e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Nizatidine is indicated for up to 8 weeks for the treatment of active duodenal ulcer. In most patients, the ulcer will heal within 4 weeks. Nizatidine is indicated for maintenance therapy for duodenal ulcer patients, at a reduced dosage of 150 mg h.s. after healing of an active duodenal ulcer. The consequences of continuous therapy with nizatidine for longer than 1 year are not known. Nizatidine is indicated for up to 12 weeks for the treatment of endoscopically diagnosed esophagitis, including erosive and ulcerative esophagitis, and associated heartburn due to GERD. Nizatidine is indicated for up to 8 weeks for the treatment of active benign gastric ulcer. Before initiating therapy, care should be taken to exclude the possibility of malignant gastric ulceration. uuid:95727b2c-7dab-4518-878b-1f92b3786853 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7601 biolink:treats MONDO:0007186 PMID:41385096 "[{""id"":""uuid:a42a576f-68c5-4e5f-b9a1-721377769264"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9362ba88-c456-46bb-bbb5-e4a3463a6b08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Nizatidine is indicated for up to 8 weeks for the treatment of active duodenal ulcer. In most patients, the ulcer will heal within 4 weeks. Nizatidine is indicated for maintenance therapy for duodenal ulcer patients, at a reduced dosage of 150 mg h.s. after healing of an active duodenal ulcer. The consequences of continuous therapy with nizatidine for longer than 1 year are not known. Nizatidine is indicated for up to 12 weeks for the treatment of endoscopically diagnosed esophagitis, including erosive and ulcerative esophagitis, and associated heartburn due to GERD. Nizatidine is indicated for up to 8 weeks for the treatment of active benign gastric ulcer. Before initiating therapy, care should be taken to exclude the possibility of malignant gastric ulceration. uuid:a7bc87e9-707f-4c29-9dc2-903a17c6dd71 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7601 biolink:treats MONDO:0001126 PMID:41385096 "[{""id"":""uuid:323e89fc-f72f-49d2-bc7b-e578b754e645"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bc4f842e-f9ca-48c9-a739-5c87592fd7e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Nizatidine is indicated for up to 8 weeks for the treatment of active duodenal ulcer. In most patients, the ulcer will heal within 4 weeks. Nizatidine is indicated for maintenance therapy for duodenal ulcer patients, at a reduced dosage of 150 mg h.s. after healing of an active duodenal ulcer. The consequences of continuous therapy with nizatidine for longer than 1 year are not known. Nizatidine is indicated for up to 12 weeks for the treatment of endoscopically diagnosed esophagitis, including erosive and ulcerative esophagitis, and associated heartburn due to GERD. Nizatidine is indicated for up to 8 weeks for the treatment of active benign gastric ulcer. Before initiating therapy, care should be taken to exclude the possibility of malignant gastric ulceration. uuid:e479c917-c5d3-4075-a771-645277b3e8c6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:144551 biolink:treats EFO:0006865 PMID:41385096 "[{""id"":""uuid:7cf363c6-9ad5-492a-8c41-e00accfa7623"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9dc66185-0008-407b-9757-471f26f2d39e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9296fbcf-d994-4bdb-9a57-010ba4181616"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxybutynin chloride extended-release tablets are once daily controlled-release tablets indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. Pediatric use information for the treatment of patients aged 6 years and older with symptoms of detrusor overactivity associated with a neurological condition (e.g., spina bifida) is approved for Alza Corporation’s oxybutynin extended-release tablets. However, due to Alza Corporation’s marketing exclusivity rights, this drug product is not labeled for pediatric use.|[PMDA] A drug with a new route of administration and new indications for the treatment of urinary urgency, urinary frequency, and urge urinary incontinence associated with overactive bladder. uuid:2919617a-6eef-4bb8-8e36-d8daa9c1904f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:144551 biolink:treats UMLS:C0341736 PMID:41385096 "[{""id"":""uuid:c1c5ff5f-238c-4778-aac6-235cf47a284a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:76c19643-4d2c-465f-b35c-1b53d0931b09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxybutynin chloride extended-release tablets are once daily controlled-release tablets indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. Pediatric use information for the treatment of patients aged 6 years and older with symptoms of detrusor overactivity associated with a neurological condition (e.g., spina bifida) is approved for Alza Corporation’s oxybutynin extended-release tablets. However, due to Alza Corporation’s marketing exclusivity rights, this drug product is not labeled for pediatric use. uuid:d6fd0167-1cbb-48f6-94d2-d5cd78cf3c7d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:144551 biolink:treats MONDO:0008449 PMID:41385096 "[{""id"":""uuid:22523544-f89d-4053-820f-3c3a95f09945"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e89debcb-8c5a-4032-be0d-d64bb083079d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxybutynin chloride extended-release tablets are once daily controlled-release tablets indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. Pediatric use information for the treatment of patients aged 6 years and older with symptoms of detrusor overactivity associated with a neurological condition (e.g., spina bifida) is approved for Alza Corporation’s oxybutynin extended-release tablets. However, due to Alza Corporation’s marketing exclusivity rights, this drug product is not labeled for pediatric use. uuid:e66915de-71b7-4f04-88cb-5fc21ff59c21 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1165009 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:95d06858-b5d9-42aa-a604-287c36d3462f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4bf1456c-769f-4da4-a763-5fea7fd73518"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended-Release Tablets are indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 12 years of age and older. Symptoms treated effectively include sneezing, rhinorrhea, itchy nose/palate/ and/or throat, itchy/watery/red eyes, and nasal congestion. Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended-Release Tablets should be administered when both the antihistaminic properties of fexofenadine hydrochloride and the nasal decongestant properties of pseudoephedrine hydrochloride are desired (see CLINICAL PHARMACOLOGY ). uuid:5c1122b3-7f8e-4a0f-bb6e-138ef71699e4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:393371 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:1a28f88a-0501-4b85-b36e-1b684e5eb4e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7730eb2d-de33-40a9-9291-9d0205fd84c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Promethazine hydrochloride and dextromethorphan hydrobromide syrup is indicated for the temporary relief of coughs and upper respiratory symptoms associated with allergy or the common cold. uuid:4a42dda9-7986-4f0a-8a7b-220ae61d524f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:393371 biolink:treats MONDO:0005709 PMID:41385096 "[{""id"":""uuid:dee438b0-6e07-4830-802b-56311eb8b6c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:95663087-7663-407a-a267-d61fb7cfea2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Promethazine hydrochloride and dextromethorphan hydrobromide syrup is indicated for the temporary relief of coughs and upper respiratory symptoms associated with allergy or the common cold. uuid:855208c3-ec7b-4373-afc1-b8b192fc68ad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:216653 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:7875e5fb-fcdf-4729-b1c6-593aa9b9ba00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9f3b9c7f-8134-429f-902f-a180d9e1f784"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Diovan HCT (valsartan and hydrochlorothiazide, USP) is indicated for the treatment of hypertension. Diovan HCT may be used in patients whose blood pressure is not adequately controlled on monotherapy. Diovan HCT may be used as initial therapy in patients who are likely to need multiple drugs to achieve blood pressure goals. The choice of Diovan HCT as initial therapy for hypertension should be based on an assessment of potential benefits and risks. Patients with stage 2 hypertension are at a relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from the high dose multifactorial trial [See Clinical Studies (14.1)] provides estimates of the probability of reaching a target blood pressure with Diovan HCT compared to valsartan or hydrochlorothiazide monotherapy. The figures below provide estimates of the likelihood of achieving systolic or diastolic blood pressure control with Diovan HCT 320/25 mg, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling. The estimated likelihood at the right tail of each curve is less reliable due to small numbers of subjects with high baseline blood pressures. For example, a patient with a baseline blood pressure of 160/100 mmHg has about a 41% likelihood of achieving a goal of less than 140 mmHg (systolic) and 60% likelihood of achieving less than 90 mmHg (diastolic) on valsartan alone and the likelihood of achieving these goals on HCTZ alone is about 50% (systolic) or 57% (diastolic). The likelihood of achieving these goals on Diovan HCT rises to about 84% (systolic) or 80% (diastolic). The likelihood of achieving these goals on placebo is about 23% (systolic) or 36% (diastolic). uuid:b04ba1ac-75bd-4887-a0c7-259d63ac0fc6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:216653 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:256ea5fa-d4be-4124-bd57-610ab48daa57"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e046455e-cfd1-4924-b9f2-9b202f1b5674"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Diovan HCT (valsartan and hydrochlorothiazide, USP) is indicated for the treatment of hypertension. Diovan HCT may be used in patients whose blood pressure is not adequately controlled on monotherapy. Diovan HCT may be used as initial therapy in patients who are likely to need multiple drugs to achieve blood pressure goals. The choice of Diovan HCT as initial therapy for hypertension should be based on an assessment of potential benefits and risks. Patients with stage 2 hypertension are at a relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from the high dose multifactorial trial [See Clinical Studies (14.1)] provides estimates of the probability of reaching a target blood pressure with Diovan HCT compared to valsartan or hydrochlorothiazide monotherapy. The figures below provide estimates of the likelihood of achieving systolic or diastolic blood pressure control with Diovan HCT 320/25 mg, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling. The estimated likelihood at the right tail of each curve is less reliable due to small numbers of subjects with high baseline blood pressures. For example, a patient with a baseline blood pressure of 160/100 mmHg has about a 41% likelihood of achieving a goal of less than 140 mmHg (systolic) and 60% likelihood of achieving less than 90 mmHg (diastolic) on valsartan alone and the likelihood of achieving these goals on HCTZ alone is about 50% (systolic) or 57% (diastolic). The likelihood of achieving these goals on Diovan HCT rises to about 84% (systolic) or 80% (diastolic). The likelihood of achieving these goals on placebo is about 23% (systolic) or 36% (diastolic). uuid:2a766bdd-ddb1-48ed-8568-02eb73a1f673 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:216653 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:7bf5b1cb-895c-41fc-a1de-5746cf49fe87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:36919946-22ea-43b5-9b0a-32377439a0eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Diovan HCT (valsartan and hydrochlorothiazide, USP) is indicated for the treatment of hypertension. Diovan HCT may be used in patients whose blood pressure is not adequately controlled on monotherapy. Diovan HCT may be used as initial therapy in patients who are likely to need multiple drugs to achieve blood pressure goals. The choice of Diovan HCT as initial therapy for hypertension should be based on an assessment of potential benefits and risks. Patients with stage 2 hypertension are at a relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from the high dose multifactorial trial [See Clinical Studies (14.1)] provides estimates of the probability of reaching a target blood pressure with Diovan HCT compared to valsartan or hydrochlorothiazide monotherapy. The figures below provide estimates of the likelihood of achieving systolic or diastolic blood pressure control with Diovan HCT 320/25 mg, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling. The estimated likelihood at the right tail of each curve is less reliable due to small numbers of subjects with high baseline blood pressures. For example, a patient with a baseline blood pressure of 160/100 mmHg has about a 41% likelihood of achieving a goal of less than 140 mmHg (systolic) and 60% likelihood of achieving less than 90 mmHg (diastolic) on valsartan alone and the likelihood of achieving these goals on HCTZ alone is about 50% (systolic) or 57% (diastolic). The likelihood of achieving these goals on Diovan HCT rises to about 84% (systolic) or 80% (diastolic). The likelihood of achieving these goals on placebo is about 23% (systolic) or 36% (diastolic). uuid:971972f9-9fb3-4288-a0e1-dbad604fefbf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:216653 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:8a6f16cf-1ea9-47fc-b16a-9cda1303ee65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f5f998ed-dbfe-4f83-8270-dbc529d33534"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Diovan HCT (valsartan and hydrochlorothiazide, USP) is indicated for the treatment of hypertension. Diovan HCT may be used in patients whose blood pressure is not adequately controlled on monotherapy. Diovan HCT may be used as initial therapy in patients who are likely to need multiple drugs to achieve blood pressure goals. The choice of Diovan HCT as initial therapy for hypertension should be based on an assessment of potential benefits and risks. Patients with stage 2 hypertension are at a relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from the high dose multifactorial trial [See Clinical Studies (14.1)] provides estimates of the probability of reaching a target blood pressure with Diovan HCT compared to valsartan or hydrochlorothiazide monotherapy. The figures below provide estimates of the likelihood of achieving systolic or diastolic blood pressure control with Diovan HCT 320/25 mg, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling. The estimated likelihood at the right tail of each curve is less reliable due to small numbers of subjects with high baseline blood pressures. For example, a patient with a baseline blood pressure of 160/100 mmHg has about a 41% likelihood of achieving a goal of less than 140 mmHg (systolic) and 60% likelihood of achieving less than 90 mmHg (diastolic) on valsartan alone and the likelihood of achieving these goals on HCTZ alone is about 50% (systolic) or 57% (diastolic). The likelihood of achieving these goals on Diovan HCT rises to about 84% (systolic) or 80% (diastolic). The likelihood of achieving these goals on placebo is about 23% (systolic) or 36% (diastolic). uuid:53c1dcc1-5636-41a2-a79b-b880e2fb7f0b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:216653 biolink:treats MONDO:0001106 PMID:41385096 "[{""id"":""uuid:bbdd3802-c2a2-436d-962e-8949818d5cdf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:52eaebed-b231-4128-a66b-b454d2765fab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Diovan HCT (valsartan and hydrochlorothiazide, USP) is indicated for the treatment of hypertension. Diovan HCT may be used in patients whose blood pressure is not adequately controlled on monotherapy. Diovan HCT may be used as initial therapy in patients who are likely to need multiple drugs to achieve blood pressure goals. The choice of Diovan HCT as initial therapy for hypertension should be based on an assessment of potential benefits and risks. Patients with stage 2 hypertension are at a relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from the high dose multifactorial trial [See Clinical Studies (14.1)] provides estimates of the probability of reaching a target blood pressure with Diovan HCT compared to valsartan or hydrochlorothiazide monotherapy. The figures below provide estimates of the likelihood of achieving systolic or diastolic blood pressure control with Diovan HCT 320/25 mg, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling. The estimated likelihood at the right tail of each curve is less reliable due to small numbers of subjects with high baseline blood pressures. For example, a patient with a baseline blood pressure of 160/100 mmHg has about a 41% likelihood of achieving a goal of less than 140 mmHg (systolic) and 60% likelihood of achieving less than 90 mmHg (diastolic) on valsartan alone and the likelihood of achieving these goals on HCTZ alone is about 50% (systolic) or 57% (diastolic). The likelihood of achieving these goals on Diovan HCT rises to about 84% (systolic) or 80% (diastolic). The likelihood of achieving these goals on placebo is about 23% (systolic) or 36% (diastolic). uuid:75214ce1-5ef1-465a-acbd-be862dede813 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:02ca812c-72a1-4c82-bb5f-41ece285131b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b99a3d67-5e8e-437d-81bf-d257bf81f6df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of diclofenac sodium extended-release and other treatment options before deciding to use diclofenac sodium extended-release. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Diclofenac sodium extended-release tablets are indicated: • For relief of signs and symptoms of osteoarthritis • For relief of signs and symptoms of rheumatoid arthritis uuid:f44c85cd-d998-4da4-af71-5d2c58925c37 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:75db74a5-ae73-4cbf-b594-fd6a4e42e656"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:82d6f83f-f3e7-4b8d-99df-7edb7a5f2023"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c62bef24-8bfe-4c30-a3f7-f10da216c793"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Carefully consider the potential benefits and risks of diclofenac sodium extended-release and other treatment options before deciding to use diclofenac sodium extended-release. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Diclofenac sodium extended-release tablets are indicated: • For relief of signs and symptoms of osteoarthritis • For relief of signs and symptoms of rheumatoid arthritis|[PMDA] A new indication for the treatment of “toothache”, the format of the indication for ""rheumatoid arthritis"" was coordinated. [Notification of off label use]" uuid:036e069c-f3d4-44fd-9d5b-6a13a839a157 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8080 biolink:treats NCIT:C120380 PMID:41385096 "[{""id"":""uuid:0e64a8de-bbd0-4a89-9af4-0024197963d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:994ddd8b-603a-4f0a-8097-f4e529fb9aa1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Phentermine hydrochloride is indicated as a short-term (a few weeks) adjunct in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity for patients with an initial body mass index ≥30 kg/m 2 , or ≥27 kg/m 2 in the presence of other risk factors (e. g., hypertension, diabetes, hyperlipidemia). Below is a chart of Body Mass Index (BMI) based on various heights and weights. BMI is calculated by taking the patient's weight, in kilograms (kg), divided by the patient's height, in meters (m), squared. Metric conversions are as follows; pounds ÷ 2.2 = kg; inches × 0.0254 = meters. BODY MASS INDEX (BMI), kg/m 2 Height (feet, inches) Weight (pounds) 5'0"" 5'3"" 5'6"" 5'9"" 6'0"" 6'3"" 140 27 25 23 21 19 18 150 29 27 24 22 20 19 160 31 28 26 24 22 20 170 33 30 28 25 23 21 180 35 32 29 27 25 23 190 37 34 31 28 26 24 200 39 36 32 30 27 25 210 41 37 34 31 29 26 220 43 39 36 33 30 28 230 45 41 37 34 31 29 240 47 43 39 36 33 30 250 49 44 40 37 34 31 The limited usefulness of agents of this class (see CLINICAL PHARMACOLOGY ) should be measured against possible risk factors inherent in their use such as those described below." uuid:6430830e-cfdb-4778-83b1-851bac20631f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8080 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:1d56e95f-bcb7-49bd-ae7e-e340169195ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:97e626f1-d9ec-4013-a395-685ea5ddece4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Phentermine hydrochloride is indicated as a short-term (a few weeks) adjunct in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity for patients with an initial body mass index ≥30 kg/m 2 , or ≥27 kg/m 2 in the presence of other risk factors (e. g., hypertension, diabetes, hyperlipidemia). Below is a chart of Body Mass Index (BMI) based on various heights and weights. BMI is calculated by taking the patient's weight, in kilograms (kg), divided by the patient's height, in meters (m), squared. Metric conversions are as follows; pounds ÷ 2.2 = kg; inches × 0.0254 = meters. BODY MASS INDEX (BMI), kg/m 2 Height (feet, inches) Weight (pounds) 5'0"" 5'3"" 5'6"" 5'9"" 6'0"" 6'3"" 140 27 25 23 21 19 18 150 29 27 24 22 20 19 160 31 28 26 24 22 20 170 33 30 28 25 23 21 180 35 32 29 27 25 23 190 37 34 31 28 26 24 200 39 36 32 30 27 25 210 41 37 34 31 29 26 220 43 39 36 33 30 28 230 45 41 37 34 31 29 240 47 43 39 36 33 30 250 49 44 40 37 34 31 The limited usefulness of agents of this class (see CLINICAL PHARMACOLOGY ) should be measured against possible risk factors inherent in their use such as those described below." uuid:f962a755-bc4d-4ad5-b8b3-6f6e9fc749a5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8080 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:7adaa24a-4f3b-4f47-9c77-17087887b968"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ad50062c-c9d9-4985-9555-8f1cc5435af6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Phentermine hydrochloride is indicated as a short-term (a few weeks) adjunct in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity for patients with an initial body mass index ≥30 kg/m 2 , or ≥27 kg/m 2 in the presence of other risk factors (e. g., hypertension, diabetes, hyperlipidemia). Below is a chart of Body Mass Index (BMI) based on various heights and weights. BMI is calculated by taking the patient's weight, in kilograms (kg), divided by the patient's height, in meters (m), squared. Metric conversions are as follows; pounds ÷ 2.2 = kg; inches × 0.0254 = meters. BODY MASS INDEX (BMI), kg/m 2 Height (feet, inches) Weight (pounds) 5'0"" 5'3"" 5'6"" 5'9"" 6'0"" 6'3"" 140 27 25 23 21 19 18 150 29 27 24 22 20 19 160 31 28 26 24 22 20 170 33 30 28 25 23 21 180 35 32 29 27 25 23 190 37 34 31 28 26 24 200 39 36 32 30 27 25 210 41 37 34 31 29 26 220 43 39 36 33 30 28 230 45 41 37 34 31 29 240 47 43 39 36 33 30 250 49 44 40 37 34 31 The limited usefulness of agents of this class (see CLINICAL PHARMACOLOGY ) should be measured against possible risk factors inherent in their use such as those described below." uuid:e0064ba3-4ac1-4913-aee9-2ea2e92b474e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8080 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:c2a5b844-2e4e-47e7-8757-6755accd1fa1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a325f6d9-33f1-4c79-98c6-fac691afa064"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Phentermine hydrochloride is indicated as a short-term (a few weeks) adjunct in a regimen of weight reduction based on exercise, behavioral modification and caloric restriction in the management of exogenous obesity for patients with an initial body mass index ≥30 kg/m 2 , or ≥27 kg/m 2 in the presence of other risk factors (e. g., hypertension, diabetes, hyperlipidemia). Below is a chart of Body Mass Index (BMI) based on various heights and weights. BMI is calculated by taking the patient's weight, in kilograms (kg), divided by the patient's height, in meters (m), squared. Metric conversions are as follows; pounds ÷ 2.2 = kg; inches × 0.0254 = meters. BODY MASS INDEX (BMI), kg/m 2 Height (feet, inches) Weight (pounds) 5'0"" 5'3"" 5'6"" 5'9"" 6'0"" 6'3"" 140 27 25 23 21 19 18 150 29 27 24 22 20 19 160 31 28 26 24 22 20 170 33 30 28 25 23 21 180 35 32 29 27 25 23 190 37 34 31 28 26 24 200 39 36 32 30 27 25 210 41 37 34 31 29 26 220 43 39 36 33 30 28 230 45 41 37 34 31 29 240 47 43 39 36 33 30 250 49 44 40 37 34 31 The limited usefulness of agents of this class (see CLINICAL PHARMACOLOGY ) should be measured against possible risk factors inherent in their use such as those described below." uuid:4519ef0f-7e1a-4c09-8277-3ff0330ba3eb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7852 biolink:treats NCIT:C34887 PMID:41385096 "[{""id"":""uuid:edee5219-74d8-4ab3-8f56-5ddba645042e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7261c1aa-885b-43ce-ab15-2c4a4cc87a85"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxycodone HCl Controlled-Release Tablets are a controlled-release oral formulation of oxycodone hydrochloride indicated for the management of moderate to severe pain when a continuous, around-the-clock analgesic is needed for an extended period of time. Oxycodone HCl Controlled-Release Tablets are NOT intended for use as a prn analgesic. Physicians should individualize treatment in every case, initiating therapy at the appropriate point along a progression from non-opioid analgesics, such as non-steroidal anti-inflammatory drugs and acetaminophen to opioids in a plan of pain management such as outlined by the World Health Organization, the Agency for Healthcare Research and Quality (formerly known as the Agency for Health Care Policy and Research), the Federation of State Medical Boards Model Guidelines, or the American Pain Society. Oxycodone HCl Controlled-Release Tablets are not indicated for pain in the immediate postoperative period (the first 12-24 hours following surgery), or if the pain is mild, or not expected to persist for an extended period of time. Oxycodone HCl Controlled-Release Tablets are only indicated for postoperative use if the patient is already receiving the drug prior to surgery or if the postoperative pain is expected to be moderate to severe and persist for an extended period of time. Physicians should individualize treatment, moving from parenteral to oral analgesics as appropriate. (See American Pain Society guidelines.) uuid:68c782fe-c44a-4729-b428-2c14eedc613b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10650 biolink:treats MONDO:0005475 PMID:41385096 "[{""id"":""uuid:952c9a8e-5966-4a42-b049-81de014ade87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bc55c411-ec55-48d7-9205-e0b55bcc7a44"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Sumatriptan Succinate Tablets are indicated for the acute treatment of migraine attacks with or without aura in adults. Sumatriptan Succinate Tablets are not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS). Safety and effectiveness of Sumatriptan Succinate Tablets have not been established for cluster headache, which is present in an older, predominantly male population. uuid:2152e462-204d-4d78-b968-5a4f1c7d52cc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10650 biolink:treats MONDO:0100431 PMID:41385096 "[{""id"":""uuid:ac8c777b-b6f4-4a62-80c6-84cd8c5c2f9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:da3a108b-5744-4227-b977-c8b767b0d3d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Sumatriptan Succinate Tablets are indicated for the acute treatment of migraine attacks with or without aura in adults. Sumatriptan Succinate Tablets are not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS). Safety and effectiveness of Sumatriptan Succinate Tablets have not been established for cluster headache, which is present in an older, predominantly male population. uuid:deb2f9ec-997c-4ba7-8ccc-5436ce3b95df biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10650 biolink:treats MONDO:0018925 PMID:41385096 "[{""id"":""uuid:13acf916-8416-44de-9ed9-e7365136dd22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:944c4f31-1bbb-4a61-96d1-c77cdf307641"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Sumatriptan Succinate Tablets are indicated for the acute treatment of migraine attacks with or without aura in adults. Sumatriptan Succinate Tablets are not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS). Safety and effectiveness of Sumatriptan Succinate Tablets have not been established for cluster headache, which is present in an older, predominantly male population. uuid:5e48afce-34d7-4bf5-bc32-58fd826465d0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10650 biolink:treats MONDO:0043219 PMID:41385096 "[{""id"":""uuid:2037e5dd-276f-486d-be0f-fb7d74195b1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:80d71ea4-d817-429b-896e-bcc898e42b13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Sumatriptan Succinate Tablets are indicated for the acute treatment of migraine attacks with or without aura in adults. Sumatriptan Succinate Tablets are not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS). Safety and effectiveness of Sumatriptan Succinate Tablets have not been established for cluster headache, which is present in an older, predominantly male population. uuid:994c9163-4ebd-46e8-a43e-60cfe71e13f4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10650 biolink:treats MONDO:0043537 PMID:41385096 "[{""id"":""uuid:8ea87ef6-8c06-4df3-898c-6cf4aea652e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:458ca7ee-499e-4231-92d6-8e8edafe5429"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Sumatriptan Succinate Tablets are indicated for the acute treatment of migraine attacks with or without aura in adults. Sumatriptan Succinate Tablets are not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS). Safety and effectiveness of Sumatriptan Succinate Tablets have not been established for cluster headache, which is present in an older, predominantly male population. uuid:f5ea55d5-d9cd-417b-90e6-3065c0af6c60 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2676 biolink:treats UMLS:C0852158 PMID:41385096 "[{""id"":""uuid:2b65780e-a8ff-4002-afda-fd8a98f34696"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9ed3d82f-ebeb-404a-a01c-1148fa7b6eb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amoxicillin is indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) strains of the designated microorganisms in the conditions listed below: Infections of the ear, nose, and throat – due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae , Staphylococcus spp., or H. influenzae . Infections of the genitourinary tract – due to E. coli, P. mirabilis , or E. faecalis . Infections of the skin and skin structure – due to Streptococcus spp. (α- and β-hemolytic strains only), Staphylococcus spp., or E. coli . Infections of the lower respiratory tract – due to Streptococcus spp. (α- and β-hemolytic strains only), S. pneumoniae, Staphylococcus spp., or H. influenzae . Gonorrhea, acute uncomplicated (ano-genital and urethral infections) – due to N. gonorrhoeae (males and females). uuid:6b40cce2-223e-4a9e-a5cf-bfd7d12c7888 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7773 biolink:treats HP:0002018 PMID:41385096 "[{""id"":""uuid:3227c6e2-2692-4306-8269-a0f63a978711"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:483194a1-087a-40f0-a353-134394622103"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ab8fec34-0f13-4d36-a518-8a643fc3b94d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin. Efficacy of the 32-mg single dose beyond 24 hours in these patients has not been established.|[PMDA] A drug with a new indication and a new dosage for the treatment of digestive symptoms (nausea and vomiting) after surgery. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:08b7a67e-3da4-48ed-82a6-fecd2da0dda3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7773 biolink:treats HP:0002013 PMID:41385096 "[{""id"":""uuid:cae9a446-e38e-43dc-a4a4-35d5877fcf0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:557a51a6-977b-4a06-bbb1-44c05cefbfdf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3fec5af8-0d60-4b37-8ae2-0b4e585bb2fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin. Efficacy of the 32-mg single dose beyond 24 hours in these patients has not been established.|[PMDA] A drug with a new indication and a new dosage for the treatment of digestive symptoms (nausea and vomiting) after surgery. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:e19ee42e-7c1f-44d1-8f08-121505bd3c29 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:a1fa4d54-8906-47b2-8a06-5455473a0fcf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d0b21327-609b-419e-8274-f9537fe81db2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metronidazole Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with Metronidazole Injection, USP therapy. In a mixed aerobic and anaerobic infection, antibiotics appropriate for the treatment of the aerobic infection should be used in addition to Metronidazole Injection, USP. Metronidazole Injection, USP is effective in Bacteroides fragilis infections resistant to clindamycin, chloramphenicol and penicillin. Intra-Abdominal Infections , including peritonitis, intra-abdominal abscess and liver abscess, caused by Bacteroides species including the B. fragilis group ( B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus ), Clostridium species, Eubacterium species, Peptococcus species and Peptostreptococcus species. Skin and Skin Structure Infections caused by Bacteroides species including the B. fragilis group, Clostridium species , Peptococcus species, Peptostreptococcus species and Fusobacterium species. Gynecologic Infections , including endometritis, endomyometritis, tubo-ovarian abscess and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptostreptococcus species and Fusobacterium species. Bacterial Septicemia caused by Bacteroides species including the B. fragilis group and Clostridium species. Bone and Joint Infections , as adjunctive therapy, caused by Bacteroides species including the B. fragilis group. Central Nervous System (CNS) Infections , including meningitis and brain abscess, caused by Bacteroides species including the B. fragilis group. Lower Respiratory Tract Infections , including pneumonia, empyema and lung abscess, caused by Bacteroides species including the B. fragilis group. Endocarditis caused by Bacteroides species including the B. fragilis group. uuid:b688468a-164c-485b-9bae-f2d66058f737 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats UMLS:C0851989 PMID:41385096 "[{""id"":""uuid:e725f438-2f2b-4c7f-af2f-4d7f3d4769e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8096b1c2-fa5e-4a0b-8b8d-bfa8baa5a1f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metronidazole Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with Metronidazole Injection, USP therapy. In a mixed aerobic and anaerobic infection, antibiotics appropriate for the treatment of the aerobic infection should be used in addition to Metronidazole Injection, USP. Metronidazole Injection, USP is effective in Bacteroides fragilis infections resistant to clindamycin, chloramphenicol and penicillin. Intra-Abdominal Infections , including peritonitis, intra-abdominal abscess and liver abscess, caused by Bacteroides species including the B. fragilis group ( B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus ), Clostridium species, Eubacterium species, Peptococcus species and Peptostreptococcus species. Skin and Skin Structure Infections caused by Bacteroides species including the B. fragilis group, Clostridium species , Peptococcus species, Peptostreptococcus species and Fusobacterium species. Gynecologic Infections , including endometritis, endomyometritis, tubo-ovarian abscess and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptostreptococcus species and Fusobacterium species. Bacterial Septicemia caused by Bacteroides species including the B. fragilis group and Clostridium species. Bone and Joint Infections , as adjunctive therapy, caused by Bacteroides species including the B. fragilis group. Central Nervous System (CNS) Infections , including meningitis and brain abscess, caused by Bacteroides species including the B. fragilis group. Lower Respiratory Tract Infections , including pneumonia, empyema and lung abscess, caused by Bacteroides species including the B. fragilis group. Endocarditis caused by Bacteroides species including the B. fragilis group. uuid:a492a9f7-590b-4bf6-bdab-8ad9d6583a80 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:308714 biolink:treats MONDO:0005984 PMID:41385096 "[{""id"":""uuid:752ee8cc-0ca1-4273-8a06-c82b5c9aea5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c7df9c76-599d-47ce-84d2-bfc8dd49d70a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Clotrimazole and betamethasone dipropionate cream is indicated in patients 17 years and older for the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris and tinea corporis due to Epidermophyton floccosum , Trichophyton mentagrophytes , and Trichophyton rubrum . Effective treatment without the risks associated with topical corticosteroid use may be obtained using a topical antifungal agent that does not contain a corticosteroid, especially for noninflammatory tinea infections. The efficacy of clotrimazole and betamethasone dipropionate cream for the treatment of infections caused by zoophilic dermatophytes (e.g., Microsporum canis ) has not been established. Several cases of treatment failure of clotrimazole and betamethasone dipropionate cream in the treatment of infections caused by Microsporum canis have been reported. uuid:f9e9c966-4f2e-4264-bba6-948d205b0cbc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:308714 biolink:treats MONDO:0001405 PMID:41385096 "[{""id"":""uuid:4e89bee4-5192-40e9-af0f-23d0973d5883"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:54596b58-54ad-4db7-8ca4-bb9da337dda3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Clotrimazole and betamethasone dipropionate cream is indicated in patients 17 years and older for the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris and tinea corporis due to Epidermophyton floccosum , Trichophyton mentagrophytes , and Trichophyton rubrum . Effective treatment without the risks associated with topical corticosteroid use may be obtained using a topical antifungal agent that does not contain a corticosteroid, especially for noninflammatory tinea infections. The efficacy of clotrimazole and betamethasone dipropionate cream for the treatment of infections caused by zoophilic dermatophytes (e.g., Microsporum canis ) has not been established. Several cases of treatment failure of clotrimazole and betamethasone dipropionate cream in the treatment of infections caused by Microsporum canis have been reported. uuid:658428b2-df53-4144-848d-f25833db344b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:308714 biolink:treats MONDO:0001461 PMID:41385096 "[{""id"":""uuid:bae6216b-fad3-4764-9d36-7ca39be5f818"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:208aa2b7-7bd0-4a0e-8f0f-120eaa2bec51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Clotrimazole and betamethasone dipropionate cream is indicated in patients 17 years and older for the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris and tinea corporis due to Epidermophyton floccosum , Trichophyton mentagrophytes , and Trichophyton rubrum . Effective treatment without the risks associated with topical corticosteroid use may be obtained using a topical antifungal agent that does not contain a corticosteroid, especially for noninflammatory tinea infections. The efficacy of clotrimazole and betamethasone dipropionate cream for the treatment of infections caused by zoophilic dermatophytes (e.g., Microsporum canis ) has not been established. Several cases of treatment failure of clotrimazole and betamethasone dipropionate cream in the treatment of infections caused by Microsporum canis have been reported. uuid:b0e8d940-bd0c-4b35-ab23-411f4de6917e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0041052 PMID:41385096 "[{""id"":""uuid:834017ef-0576-4005-8367-fc2e33e73aa4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:824ac612-d671-4344-be8e-eed2eae019d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LIDODERM is indicated for relief of pain associated with post-herpetic neuralgia. It should be applied only to intact skin . uuid:f934c00d-1720-4bde-94bd-4f49019eb63b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3746 biolink:treats MONDO:0005242 PMID:41385096 "[{""id"":""uuid:273c1177-a41e-40c2-89c0-2324b4ea7705"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:403aedf6-4969-49cb-950a-4b25b23aec5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride capsules and other antibacterial drugs, clindamycin hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. uuid:8833909f-d64b-47bd-be85-359012260f3b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3746 biolink:treats MONDO:0004649 PMID:41385096 "[{""id"":""uuid:f567894a-c32c-4c78-8f7a-b0ebcf8e982d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:71e4eff5-37d9-43ab-b4a2-ff6cc67c5bda"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride capsules and other antibacterial drugs, clindamycin hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. uuid:be0299a4-1ad9-4b2a-b138-97ada9cbb885 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3746 biolink:treats MONDO:0000744 PMID:41385096 "[{""id"":""uuid:3c401940-c0bf-4f1a-8e88-61ac907082c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5e0bc381-d185-4f75-9176-fd2f0ed97ff0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride capsules and other antibacterial drugs, clindamycin hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. uuid:1a75395a-2746-456c-ba41-4ec387da346b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3746 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:e9093d9c-ac1f-4a67-9c59-3734d72767cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:705e7a3b-c0b8-43a2-8ce2-221f65b3a261"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride capsules and other antibacterial drugs, clindamycin hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. uuid:12eb7d8b-7b9e-4723-b325-15bafaeadf0d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3746 biolink:treats MONDO:0700217 PMID:41385096 "[{""id"":""uuid:883458db-d9a2-429f-93d3-bbb4c01c837a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fdd77159-4a59-4387-8d41-9249b36f4ca6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride capsules and other antibacterial drugs, clindamycin hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. uuid:abd6633e-1236-4349-977f-f4a7c13eafbd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3746 biolink:treats MONDO:0004522 PMID:41385096 "[{""id"":""uuid:16b0e05e-8ce9-4015-89c8-6a7fff572828"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:94b3ef3e-1445-4615-a662-bc20d645ada5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride capsules and other antibacterial drugs, clindamycin hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. uuid:68c3ec63-0af0-42e8-b2d2-099890f7c62d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3746 biolink:treats MONDO:0000918 PMID:41385096 "[{""id"":""uuid:d317caea-7925-4b22-a007-4d85f10d3c99"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:05a8d83f-0068-41b2-b14c-5b3b9cb9e650"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride capsules and other antibacterial drugs, clindamycin hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. uuid:9c275db9-7236-4e7d-9fb2-1e4f9a31c80f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3746 biolink:treats HP:0034493 PMID:41385096 "[{""id"":""uuid:addc58f7-3d37-428e-90ea-038339e5bc07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cb98dbcb-dc8f-4ad1-831e-91d92e38eb79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride capsules and other antibacterial drugs, clindamycin hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. uuid:9056e265-118b-4e22-9e94-b4bcb56d2b51 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3746 biolink:treats MONDO:0006887 PMID:41385096 "[{""id"":""uuid:ba1d808f-a6f1-445e-b52e-7766c9292a74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:359f197c-9361-40ce-a712-f274be3df845"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride capsules and other antibacterial drugs, clindamycin hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. uuid:3bef2109-f5bf-4cac-a05c-45a097c2fc9f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3746 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:610a4a04-e95d-412d-bb09-2586f8854d27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:08661e97-8b4f-4d51-9969-a236a42b1158"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride capsules and other antibacterial drugs, clindamycin hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. uuid:609ebb3b-41af-4ead-9240-d7ddf828cef0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0006604 PMID:41385096 "[{""id"":""uuid:650fd30b-25d1-4e05-9bac-813ebb6ee2c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fe4ae1a7-31d6-4434-b21a-13468309ed00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ORACEA is indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. No meaningful effect was demonstrated for generalized erythema (redness) of rosacea. ORACEA has not been evaluated for the treatment of the erythematous, telangiectatic, or ocular components of rosacea. Efficacy of ORACEA beyond 16 weeks and safety beyond 9 months have not been established. This formulation of doxycycline has not been evaluated in the treatment or prevention of infections. ORACEA should not be used for treating bacterial infections, providing antibacterial prophylaxis, or reducing the numbers or eliminating microorganisms associated with any bacterial disease. To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, ORACEA should be used only as indicated. uuid:2321ee82-711f-420f-896a-91655f06debd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0005113 PMID:41385096 "[{""id"":""uuid:d576aeaf-d6a2-4012-a327-e14c4a221ed1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8c80bb50-f2e7-465b-a4d7-d127695a87f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ORACEA is indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. No meaningful effect was demonstrated for generalized erythema (redness) of rosacea. ORACEA has not been evaluated for the treatment of the erythematous, telangiectatic, or ocular components of rosacea. Efficacy of ORACEA beyond 16 weeks and safety beyond 9 months have not been established. This formulation of doxycycline has not been evaluated in the treatment or prevention of infections. ORACEA should not be used for treating bacterial infections, providing antibacterial prophylaxis, or reducing the numbers or eliminating microorganisms associated with any bacterial disease. To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, ORACEA should be used only as indicated. uuid:785c1d73-b67d-45de-a7be-3eeb49618ab7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:19ea0b4b-af9c-4da3-863e-97c563167ed1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:418de62e-1835-4b0b-ae4f-c9b7c5114996"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:04615f97-f296-4ec8-ad9d-6f10a5c2663f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azithromycin tablets are indicated for the treatment of patients with mild to moderate infections (pneumonia: see WARNINGS ) caused by susceptible strains of the designated microorganisms in the specific conditions listed below. As recommended dosages, durations of therapy and applicable patient populations vary among these infections, please see DOSAGE AND ADMINISTRATION for specific dosing recommendations.|[PMDA] A drug with a new route of administration indicated for the treatment of pneumonia. uuid:661a538a-1f6c-4e54-9431-4f6ddb035831 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8249 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:302832b2-3b64-466f-be4a-8711f069795e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8d059f82-81de-431c-a121-dc5535c363fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of piroxicam capsules and other treatment options before deciding to use piroxicam capsules. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Piroxicam capsules are indicated: For relief of the signs and symptoms of osteoarthritis. For relief of the signs and symptoms of rheumatoid arthritis. uuid:a3dcfb18-9e12-48c5-9c17-3bfa6a50a713 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8249 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:035065a6-a57c-47a1-97e5-fab21d440dc2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9dc5cdd6-59c3-4141-8000-bab420fb89ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of piroxicam capsules and other treatment options before deciding to use piroxicam capsules. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Piroxicam capsules are indicated: For relief of the signs and symptoms of osteoarthritis. For relief of the signs and symptoms of rheumatoid arthritis. uuid:563a3999-b58c-4b04-9aa9-a085c567d98c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18258 biolink:treats MONDO:0005420 PMID:41385096 "[{""id"":""uuid:13eec5f3-d684-4884-a071-5486bdf70bf3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ceafb357-e1eb-401a-97eb-415a918134d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Thyroid hormone drugs are indicated: As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema and ordinary hypothyroidism in patients of any age (pediatric patients, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary) or tertiary (hypothalamic) hypothyroidism (see WARNINGS ). As pituitary thyroid-stimulating hormone (TSH) suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto's) and multinodular goiter. As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy. Liothyronine Sodium Tablets, USP can be used in patients allergic to desiccated thyroid or thyroid extract derived from pork or beef. uuid:2d35af62-157e-4898-abd8-fa8f618b6812 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18258 biolink:treats MONDO:0018612 PMID:41385096 "[{""id"":""uuid:780fb265-0a18-43a9-a918-a5a350d84ba5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c664ab1c-ea8e-4e9d-ada8-606e95df34ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Thyroid hormone drugs are indicated: As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema and ordinary hypothyroidism in patients of any age (pediatric patients, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary) or tertiary (hypothalamic) hypothyroidism (see WARNINGS ). As pituitary thyroid-stimulating hormone (TSH) suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto's) and multinodular goiter. As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy. Liothyronine Sodium Tablets, USP can be used in patients allergic to desiccated thyroid or thyroid extract derived from pork or beef. uuid:489e9c69-f4d0-4f7b-bf8f-a48e71b4502b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18258 biolink:treats MONDO:0009718 PMID:41385096 "[{""id"":""uuid:2ec2ffaf-5dbf-4f71-a8f7-629e800c9dc4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:94f8e70e-5d57-45f8-a8df-4bf9fa6319b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Thyroid hormone drugs are indicated: As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema and ordinary hypothyroidism in patients of any age (pediatric patients, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary) or tertiary (hypothalamic) hypothyroidism (see WARNINGS ). As pituitary thyroid-stimulating hormone (TSH) suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto's) and multinodular goiter. As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy. Liothyronine Sodium Tablets, USP can be used in patients allergic to desiccated thyroid or thyroid extract derived from pork or beef. uuid:6dd37198-2716-4751-8e83-3a8f2dc6db19 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18258 biolink:treats MONDO:0001658 PMID:41385096 "[{""id"":""uuid:b2843d01-d76d-4031-bad2-29c321a72e35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:911676f6-5216-4e20-9860-c7fa928a70ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Thyroid hormone drugs are indicated: As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema and ordinary hypothyroidism in patients of any age (pediatric patients, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary) or tertiary (hypothalamic) hypothyroidism (see WARNINGS ). As pituitary thyroid-stimulating hormone (TSH) suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto's) and multinodular goiter. As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy. Liothyronine Sodium Tablets, USP can be used in patients allergic to desiccated thyroid or thyroid extract derived from pork or beef. uuid:d43a5227-16f2-43ae-bf0d-62a20b93b27c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18258 biolink:treats HP:0025388 PMID:41385096 "[{""id"":""uuid:1bfe3fc3-52c1-4571-b27a-58bec28aa91b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:df5aeed6-10f4-45d9-bad6-e7f536b13f0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Thyroid hormone drugs are indicated: As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema and ordinary hypothyroidism in patients of any age (pediatric patients, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary) or tertiary (hypothalamic) hypothyroidism (see WARNINGS ). As pituitary thyroid-stimulating hormone (TSH) suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto's) and multinodular goiter. As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy. Liothyronine Sodium Tablets, USP can be used in patients allergic to desiccated thyroid or thyroid extract derived from pork or beef. uuid:a188357d-727f-406b-8ca0-6e163fdae4d9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18258 biolink:treats MONDO:0007699 PMID:41385096 "[{""id"":""uuid:08eb84c8-8923-4baa-a3d4-7413ab142a14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9ebb2881-82d6-4c4e-bb61-8763330dcc6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Thyroid hormone drugs are indicated: As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema and ordinary hypothyroidism in patients of any age (pediatric patients, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary) or tertiary (hypothalamic) hypothyroidism (see WARNINGS ). As pituitary thyroid-stimulating hormone (TSH) suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto's) and multinodular goiter. As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy. Liothyronine Sodium Tablets, USP can be used in patients allergic to desiccated thyroid or thyroid extract derived from pork or beef. uuid:b9597b40-2d59-4311-a73f-3127db3a7a0b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18258 biolink:treats MONDO:0000334 PMID:41385096 "[{""id"":""uuid:83f05e46-a937-4a4a-9ce7-e2234c82e4b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d1c35c52-0d73-4de1-83e7-2cec108f07f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Thyroid hormone drugs are indicated: As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema and ordinary hypothyroidism in patients of any age (pediatric patients, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary) or tertiary (hypothalamic) hypothyroidism (see WARNINGS ). As pituitary thyroid-stimulating hormone (TSH) suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto's) and multinodular goiter. As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy. Liothyronine Sodium Tablets, USP can be used in patients allergic to desiccated thyroid or thyroid extract derived from pork or beef. uuid:7e7ccff9-99dd-4e4c-a06b-8ddb5cf5640c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18258 biolink:treats MONDO:0004425 PMID:41385096 "[{""id"":""uuid:2413c03d-39ed-4382-a3ca-8d8092a2b0d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:64401f7f-4d8b-4c6b-815d-b5b420dd25f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Thyroid hormone drugs are indicated: As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema and ordinary hypothyroidism in patients of any age (pediatric patients, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary) or tertiary (hypothalamic) hypothyroidism (see WARNINGS ). As pituitary thyroid-stimulating hormone (TSH) suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto's) and multinodular goiter. As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy. Liothyronine Sodium Tablets, USP can be used in patients allergic to desiccated thyroid or thyroid extract derived from pork or beef. uuid:2b56c905-2ea3-4454-a2dd-8d56598d417e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:192254 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:d112efe1-450f-43b4-9a52-0df143686796"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8804f3ce-2b56-45cf-8709-2b6716a0f4c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1 INDICATIONS AND USAGE COMBIVIR, a combination of two nucleoside analogues, is indicated in combination with other antiretrovirals for the treatment of HIV-1 infection. uuid:21b47864-31ec-4146-9efe-5f76b602bf29 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0010643 PMID:41385096 "[{""id"":""uuid:c5d2a24f-4876-43fc-a873-4749b0bf0bc8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:87d1ea80-188f-47bf-b41e-17ff413e92b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Prednisolone Oral Solution is indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice: synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. In addition to the above indications Prednisolone Oral Solution is indicated for systemic dermatomyositis (polymyositis). uuid:7b2c8aed-ec23-4e4e-9f84-1228ecf4fa13 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0033816 PMID:41385096 "[{""id"":""uuid:ea30701e-813b-4178-b8d6-e7322834fdf6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0a1330ae-8f2b-4a4d-ab6d-26cefd891cd2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE For the treatment of the following conditions: Ophthalmic Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe, such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitis when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical or thermal burns, or penetration of foreign bodies. Otic Steroid responsive inflammatory conditions of the external auditory meatus, such as allergic otitis externa, selected purulent and nonpurulent infective otitis externa when the hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. uuid:951a1a3f-2167-4176-8486-0052d012761f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats UMLS:C0497209 PMID:41385096 "[{""id"":""uuid:85a4fc0c-edde-4f2a-a71c-43364002681d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8e74b28d-581e-4430-a93e-99c873aa8533"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE For the treatment of the following conditions: Ophthalmic Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe, such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitis when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical or thermal burns, or penetration of foreign bodies. Otic Steroid responsive inflammatory conditions of the external auditory meatus, such as allergic otitis externa, selected purulent and nonpurulent infective otitis externa when the hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. uuid:db2f682c-f748-4cf5-901a-15935cbd122c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats UMLS:C1320547 PMID:41385096 "[{""id"":""uuid:807df6bd-258b-46aa-b371-62f375956c10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d053dfde-ad2c-40ea-b194-71c69dec0b4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE For the treatment of the following conditions: Ophthalmic Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe, such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitis when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical or thermal burns, or penetration of foreign bodies. Otic Steroid responsive inflammatory conditions of the external auditory meatus, such as allergic otitis externa, selected purulent and nonpurulent infective otitis externa when the hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. uuid:e61d5ec6-b31e-48de-80d1-4f2220cb92a8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0004795 PMID:41385096 "[{""id"":""uuid:d5a9dce2-2374-481e-84ba-512b3aef1541"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7babd99b-e037-4294-b642-0515be67c6cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE For the treatment of the following conditions: Ophthalmic Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe, such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitis when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical or thermal burns, or penetration of foreign bodies. Otic Steroid responsive inflammatory conditions of the external auditory meatus, such as allergic otitis externa, selected purulent and nonpurulent infective otitis externa when the hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. uuid:d0919e04-9c72-4920-9c41-1a399f9abac8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75722 biolink:treats HP:0012532 PMID:41385096 "[{""id"":""uuid:ad03fe71-9d5e-4ad7-a122-94ce6cc7e5e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:dbc15872-467d-4067-a0eb-6f1571d46269"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:657420b2-2ef2-41d1-b2bc-4b69294b3c51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Tramadol hydrochloride ER tablets are indicated for the management of moderate to moderately severe chronic pain in adults who require around-the-clock treatment of their pain for an extended period of time|[PMDA] A drug in a new dosage form indicated for analgesia in patients with cancers-associated pain or chronic pain, which cannot be managed by treatments with non-opioid analgesics. uuid:17cbd86b-d7d6-4d09-b2f8-fe97bb1b2c46 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75722 biolink:treats MONDO:0024317 PMID:41385096 "[{""id"":""uuid:96db1bd1-3b49-4abe-bcce-f242e9e8536f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7b32be2c-553f-4546-a033-5672e99a7643"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Tramadol hydrochloride ER tablets are indicated for the management of moderate to moderately severe chronic pain in adults who require around-the-clock treatment of their pain for an extended period of time uuid:0ac0eb8e-43fa-4859-a481-2dfee613f541 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7822 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:9afd215f-a5e4-4915-8b72-a1162c6d1e8e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:10a7e933-9965-4b89-80ef-705b1b30d2cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of oxaprozin tablet, USP and other treatment options before deciding to use oxaprozin tablet, USP. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Oxaprozin Tablet, USP is indicated: For relief of the signs and symptoms of osteoarthritis For relief of the signs and symptoms of rheumatoid arthritis For relief of the signs and symptoms of juvenile rheumatoid arthritis uuid:77161b68-2250-4d93-82ca-17b9551e48ca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7822 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:6557ea61-434c-4c2e-a6f7-78b104fa2785"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:02086468-c3e3-45cb-8866-b229306c8844"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of oxaprozin tablet, USP and other treatment options before deciding to use oxaprozin tablet, USP. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Oxaprozin Tablet, USP is indicated: For relief of the signs and symptoms of osteoarthritis For relief of the signs and symptoms of rheumatoid arthritis For relief of the signs and symptoms of juvenile rheumatoid arthritis uuid:852d63e4-dfb6-45b0-9838-315856a6f96d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7822 biolink:treats MONDO:0011429 PMID:41385096 "[{""id"":""uuid:ba47a46f-ce76-4dbb-a738-360f63e9f19e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:71d62d1f-56ff-4dba-bc50-8d6cf855769d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of oxaprozin tablet, USP and other treatment options before deciding to use oxaprozin tablet, USP. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Oxaprozin Tablet, USP is indicated: For relief of the signs and symptoms of osteoarthritis For relief of the signs and symptoms of rheumatoid arthritis For relief of the signs and symptoms of juvenile rheumatoid arthritis uuid:a423fd0f-8df2-4ae2-adca-4c0de5d3a0cd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16469 biolink:treats UMLS:C5442256 PMID:41385096 "[{""id"":""uuid:c4bb49b8-b21e-4569-bca0-c14607e9e9b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2a2ebd97-8bc8-44fe-a958-e9ba493a4ead"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE: Estradiol Tablets, USP are indicated in the: Treatment of moderate to severe vasomotor symptoms associated with the menopause. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. Treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. Treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). Prevention of osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate. (See CLINICAL PHARMACOLOGY , Clinical Studies .) The mainstays for decreasing the risk of postmenopausal osteoporosis are weight bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400-800 IU/day may also be required to ensure adequate daily intake in postmenopausal women. uuid:c4628c70-3050-4055-b1fc-8e1fcdb4640a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16469 biolink:treats MONDO:0001932 PMID:41385096 "[{""id"":""uuid:b8cd0c87-39f0-44a0-bc32-28f1821fa188"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:88dd1064-ea84-4dc3-a8c0-480e42bdca46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE: Estradiol Tablets, USP are indicated in the: Treatment of moderate to severe vasomotor symptoms associated with the menopause. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. Treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. Treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). Prevention of osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate. (See CLINICAL PHARMACOLOGY , Clinical Studies .) The mainstays for decreasing the risk of postmenopausal osteoporosis are weight bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400-800 IU/day may also be required to ensure adequate daily intake in postmenopausal women. DOID:14275 uuid:a8c58b62-ab88-48c7-884f-428444a23aaa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16469 biolink:treats MONDO:0018555 PMID:41385096 "[{""id"":""uuid:8cbe50d3-e632-445f-bacf-039958666c53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:47a7253e-6355-4ce9-beda-8eb779df63b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE: Estradiol Tablets, USP are indicated in the: Treatment of moderate to severe vasomotor symptoms associated with the menopause. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. Treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. Treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). Prevention of osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate. (See CLINICAL PHARMACOLOGY , Clinical Studies .) The mainstays for decreasing the risk of postmenopausal osteoporosis are weight bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400-800 IU/day may also be required to ensure adequate daily intake in postmenopausal women. uuid:f0cca9d7-9aac-4e69-ba11-55f29e3abc2c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16469 biolink:treats MONDO:0005387 PMID:41385096 "[{""id"":""uuid:493f7ad8-294e-48c6-8879-e212b7c2fdf7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1cd868c6-f874-4450-98c6-950b2b6adc93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:00208bda-86e3-4fd0-a09c-a31451e40bd6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE: Estradiol Tablets, USP are indicated in the: Treatment of moderate to severe vasomotor symptoms associated with the menopause. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. Treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. Treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). Prevention of osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate. (See CLINICAL PHARMACOLOGY , Clinical Studies .) The mainstays for decreasing the risk of postmenopausal osteoporosis are weight bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400-800 IU/day may also be required to ensure adequate daily intake in postmenopausal women.|[PMDA] A drug with a new route of administration indicated for the treatment of vasomotor symptoms (hot flushes and sweating) and vaginal atrophy symptoms associated with climacteric disturbance and ovarian deficiency symptoms. uuid:9c74c086-baaa-495f-89fd-c034933306c5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16469 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:144b9b95-70f6-48e9-b4c4-9728416b9351"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8e13e2b4-fb08-4f56-80a1-ca2575402854"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE: Estradiol Tablets, USP are indicated in the: Treatment of moderate to severe vasomotor symptoms associated with the menopause. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. Treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. Treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). Prevention of osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate. (See CLINICAL PHARMACOLOGY , Clinical Studies .) The mainstays for decreasing the risk of postmenopausal osteoporosis are weight bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400-800 IU/day may also be required to ensure adequate daily intake in postmenopausal women. uuid:5c8f6a61-873d-4082-9fc2-008e2b5affe4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16469 biolink:treats MONDO:0850353 PMID:41385096 "[{""id"":""uuid:fc269e8b-42d0-4eaa-b3c3-a67bbda6d3d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:37c434b4-2101-4cb2-947b-72d0b46bc12c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE: Estradiol Tablets, USP are indicated in the: Treatment of moderate to severe vasomotor symptoms associated with the menopause. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. Treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. Treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). Prevention of osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate. (See CLINICAL PHARMACOLOGY , Clinical Studies .) The mainstays for decreasing the risk of postmenopausal osteoporosis are weight bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400-800 IU/day may also be required to ensure adequate daily intake in postmenopausal women. uuid:3f3719a0-972e-4366-bde5-fbc0432fa182 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16469 biolink:treats MONDO:0005298 PMID:41385096 "[{""id"":""uuid:dd80d4e1-2538-4213-80e7-f44d2557a4da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:30f97a67-2b17-4333-adda-be8eb5054ad2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE: Estradiol Tablets, USP are indicated in the: Treatment of moderate to severe vasomotor symptoms associated with the menopause. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. Treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. Treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). Prevention of osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate. (See CLINICAL PHARMACOLOGY , Clinical Studies .) The mainstays for decreasing the risk of postmenopausal osteoporosis are weight bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400-800 IU/day may also be required to ensure adequate daily intake in postmenopausal women. uuid:21c294fa-dab8-4aac-86ae-7737c9081cc5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7823 biolink:treats MONDO:0005618 PMID:41385096 "[{""id"":""uuid:ca0b1975-01d5-48fc-9f48-61038270b6f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ae9d0620-24f9-45e6-bdba-79074f90dcf9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Oxazepam is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. Anxiety associated with depression is also responsive to Oxazepam therapy. This product has been found particularly useful in the management of anxiety, tension, agitation, and irritability in older patients. Alcoholics with acute tremulousness, inebriation, or with anxiety, associated with alcohol withdrawal are responsive to therapy. The effectiveness of Oxazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. uuid:75ee1dd6-fcdc-4d27-a699-7cc0b64ef06a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7823 biolink:treats MONDO:0011918 PMID:41385096 "[{""id"":""uuid:9b35d2a3-9a6f-4034-9ca1-6b4f5e3cc7b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7d112553-a1a4-42c0-942f-5a4c26821693"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Oxazepam is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. Anxiety associated with depression is also responsive to Oxazepam therapy. This product has been found particularly useful in the management of anxiety, tension, agitation, and irritability in older patients. Alcoholics with acute tremulousness, inebriation, or with anxiety, associated with alcohol withdrawal are responsive to therapy. The effectiveness of Oxazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. uuid:c7709530-3ba5-4688-8329-30c62de8206c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7823 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:898662b1-205a-4dcb-8220-1275187061aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eea1bb11-8546-4cdb-bf2d-8e1e279eedb5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Oxazepam is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. Anxiety associated with depression is also responsive to Oxazepam therapy. This product has been found particularly useful in the management of anxiety, tension, agitation, and irritability in older patients. Alcoholics with acute tremulousness, inebriation, or with anxiety, associated with alcohol withdrawal are responsive to therapy. The effectiveness of Oxazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. uuid:155a735b-e06f-4758-9156-007271822f65 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7823 biolink:treats UMLS:C0001969 PMID:41385096 "[{""id"":""uuid:5efd9efd-c9e5-4773-8d1f-6100a445d89f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0c7b9096-62b8-4fae-9e1a-788ef5e446fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Oxazepam is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. Anxiety associated with depression is also responsive to Oxazepam therapy. This product has been found particularly useful in the management of anxiety, tension, agitation, and irritability in older patients. Alcoholics with acute tremulousness, inebriation, or with anxiety, associated with alcohol withdrawal are responsive to therapy. The effectiveness of Oxazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. uuid:5512f8fc-3b6c-4e6d-9d2a-9efc2b95d6fe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7823 biolink:treats MONDO:0005433 PMID:41385096 "[{""id"":""uuid:58df5964-2ecc-4d78-8b55-c83704c333b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9f2ef414-0428-44b5-86e1-9c89e3adafe9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Oxazepam is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. Anxiety associated with depression is also responsive to Oxazepam therapy. This product has been found particularly useful in the management of anxiety, tension, agitation, and irritability in older patients. Alcoholics with acute tremulousness, inebriation, or with anxiety, associated with alcohol withdrawal are responsive to therapy. The effectiveness of Oxazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. uuid:39999c6e-5452-4793-b55f-215aaaf47868 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5050 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:151d30c7-2269-45c8-acb4-7996aa55ba8e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6ea6fd8d-c23f-4c87-8ac9-3fbf765cfe5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Seasonal Allergic Rhinitis Fexofenadine Hydrochloride Tablets are indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older. Symptoms treated effectively were sneezing, rhinorrhea, itchy nose/palate/throat, itchy/watery/red eyes. Chronic Idiopathic Urticaria Fexofenadine Hydrochloride Tablets are indicated for treatment of uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 years of age and older. It significantly reduces pruritus and the number of wheals. uuid:f0ba0558-7f94-43cd-8ec7-8f2aabacc7e7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5050 biolink:treats MONDO:0044212 PMID:41385096 "[{""id"":""uuid:2bf30392-13b9-4a04-80fe-6c1dcdc939ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:43a1ae3e-a999-40bc-8f80-1644f4b468da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Seasonal Allergic Rhinitis Fexofenadine Hydrochloride Tablets are indicated for the relief of symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older. Symptoms treated effectively were sneezing, rhinorrhea, itchy nose/palate/throat, itchy/watery/red eyes. Chronic Idiopathic Urticaria Fexofenadine Hydrochloride Tablets are indicated for treatment of uncomplicated skin manifestations of chronic idiopathic urticaria in adults and children 6 years of age and older. It significantly reduces pruritus and the number of wheals. uuid:fb78860e-5f53-4332-b8f9-4bebdd9ccc49 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3996 biolink:treats HP:0003394 PMID:41385096 "[{""id"":""uuid:175c1b33-b060-4b00-8f0c-69b2b06c8366"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f084a784-fdd9-4c1d-9194-6d02b412ff65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclobenzaprine hydrochloride is indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride has not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy. uuid:53401819-783a-4aaa-bf62-26407046122c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3996 biolink:treats MONDO:0006497 PMID:41385096 "[{""id"":""uuid:514c9ca7-2809-45bc-ab7c-96ba908908ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c6957443-7fa5-43e8-82d7-2387b27dc2bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclobenzaprine hydrochloride is indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride has not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy. uuid:327d6813-71c0-419b-b5a2-36221e5a153d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3996 biolink:treats MONDO:0002545 PMID:41385096 "[{""id"":""uuid:f39bd577-9f61-4c68-abc1-f76f2ae98bd8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9a947fe8-b020-4114-ab5b-e6195cc6a753"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclobenzaprine hydrochloride is indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride has not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy. uuid:3cd39656-a352-4642-9403-f9c72adcae0c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2666 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:8b491c5e-9bb0-45d1-a648-4a7f1e1bfbb5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2b8924b0-7e07-40ee-925c-8a545bdc8458"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the relief of symptoms of depression. Endogenous depression is more likely to be alleviated than are other depressive states. uuid:1f681ddf-a458-46ec-b2f5-dead4939b5fb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2666 biolink:treats MONDO:0012048 PMID:41385096 "[{""id"":""uuid:4adf5fae-dc78-42ee-802f-34b6f5677265"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3d931011-29e9-41d8-b47a-f300b01348d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the relief of symptoms of depression. Endogenous depression is more likely to be alleviated than are other depressive states. uuid:63b4d721-2efe-4004-9bbf-de5d5d1fc494 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5118 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:dd6f14be-5ff4-4a32-ac1b-d7240cee0886"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fee36a47-ca6d-434f-bc7d-cfa1969d8a18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Major Depressive Disorder Prozac is indicated for the treatment of major depressive disorder. Adult — The efficacy of Prozac was established in 5– and 6–week trials with depressed adult and geriatric outpatients (≥18 years of age) whose diagnoses corresponded most closely to the DSM–III (currently DSM–IV) category of major depressive disorder ( see CLINICAL TRIALS ). A major depressive episode (DSM–IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least 5 of the following 9 symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. The effects of Prozac in hospitalized depressed patients have not been adequately studied. The efficacy of Prozac 20 mg once daily in maintaining a response in major depressive disorder for up to 38 weeks following 12 weeks of open–label acute treatment (50 weeks total) was demonstrated in a placebo–controlled trial. The efficacy of Prozac Weekly once weekly in maintaining a response in major depressive disorder has been demonstrated in a placebo–controlled trial for up to 25 weeks following open–label acute treatment of 13 weeks with Prozac 20 mg daily for a total treatment of 38 weeks. However, it is unknown whether or not Prozac Weekly given on a once–weekly basis provides the same level of protection from relapse as that provided by Prozac 20 mg daily ( see CLINICAL TRIALS ). Pediatric (children and adolescents) — The efficacy of Prozac in children and adolescents was established in two 8– to 9–week placebo–controlled clinical trials in depressed outpatients whose diagnoses corresponded most closely to the DSM–III–R or DSM–IV category of major depressive disorder ( see CLINICAL TRIALS ). The usefulness of the drug in adult and pediatric patients receiving fluoxetine for extended periods should be reevaluated periodically. Obsessive Compulsive Disorder Adult — Prozac is indicated for the treatment of obsessions and compulsions in patients with obsessive compulsive disorder (OCD), as defined in the DSM–III–R; i.e., the obsessions or compulsions cause marked distress, are time–consuming, or significantly interfere with social or occupational functioning. The efficacy of Prozac was established in 13–week trials with obsessive compulsive outpatients whose diagnoses corresponded most closely to the DSM–III–R category of OCD ( see CLINICAL TRIALS ). OCD is characterized by recurrent and persistent ideas, thoughts, impulses, or images (obsessions) that are ego–dystonic and/or repetitive, purposeful, and intentional behaviors (compulsions) that are recognized by the person as excessive or unreasonable. The effectiveness of Prozac in long–term use, i.e., for more than 13 weeks, has not been systematically evaluated in placebo–controlled trials. Therefore, the physician who elects to use Prozac for extended periods should periodically reevaluate the long–term usefulness of the drug for the individual patient ( see DOSAGE AND ADMINISTRATION ). Pediatric (children and adolescents) — The efficacy of Prozac in children and adolescents was established in a 13–week, dose titration, clinical trial in patients with OCD, as defined in DSM–IV ( see CLINICAL TRIALS ). Bulimia Nervosa Prozac is indicated for the treatment of binge–eating and vomiting behaviors in patients with moderate to severe bulimia nervosa. The efficacy of Prozac was established in 8– to 16–week trials for adult outpatients with moderate to severe bulimia nervosa, i.e., at least 3 bulimic episodes per week for 6 months ( see CLINICAL TRIALS ). The efficacy of Prozac 60 mg/day in maintaining a response, in patients with bulimia who responded during an 8–week acute treatment phase while taking Prozac 60 mg/day and were then observed for relapse during a period of up to 52 weeks, was demonstrated in a placebo–controlled trial ( see CLINICAL TRIALS ). Nevertheless, the physician who elects to use Prozac for extended periods should periodically reevaluate the long–term usefulness of the drug for the individual patient ( see DOSAGE AND ADMINISTRATION ). Panic Disorder Prozac is indicated for the treatment of panic disorder, with or without agoraphobia, as defined in DSM–IV. Panic disorder is characterized by the occurrence of unexpected panic attacks, and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. The efficacy of Prozac was established in two 12–week clinical trials in patients whose diagnoses corresponded to the DSM–IV category of panic disorder ( see CLINICAL TRIALS ). Panic disorder (DSM–IV) is characterized by recurrent, unexpected panic attacks, i.e., a discrete period of intense fear or discomfort in which 4 or more of the following symptoms develop abruptly and reach a peak within 10 minutes: 1) palpitations, pounding heart, or accelerated heart rate; 2) sweating; 3) trembling or shaking; 4) sensations of shortness of breath or smothering; 5) feeling of choking; 6) chest pain or discomfort; 7) nausea or abdominal distress; 8) feeling dizzy, unsteady, lightheaded, or faint; 9) fear of losing control; 10) fear of dying; 11) paresthesias (numbness or tingling sensations); 12) chills or hot flashes. The effectiveness of Prozac in long–term use, i.e., for more than 12 weeks, has not been established in placebo–controlled trials. Therefore, the physician who elects to use Prozac for extended periods should periodically reevaluate the long–term usefulness of the drug for the individual patient ( see DOSAGE AND ADMINISTRATION ). uuid:48ad144e-f324-4ada-a3e4-24af022fb0ae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5118 biolink:treats MONDO:0005452 PMID:41385096 "[{""id"":""uuid:0e639444-e812-4f6a-8bd7-a670e6c04299"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a5c2dc5e-a3ff-4c71-9452-691648458194"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Major Depressive Disorder Prozac is indicated for the treatment of major depressive disorder. Adult — The efficacy of Prozac was established in 5– and 6–week trials with depressed adult and geriatric outpatients (≥18 years of age) whose diagnoses corresponded most closely to the DSM–III (currently DSM–IV) category of major depressive disorder ( see CLINICAL TRIALS ). A major depressive episode (DSM–IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least 5 of the following 9 symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. The effects of Prozac in hospitalized depressed patients have not been adequately studied. The efficacy of Prozac 20 mg once daily in maintaining a response in major depressive disorder for up to 38 weeks following 12 weeks of open–label acute treatment (50 weeks total) was demonstrated in a placebo–controlled trial. The efficacy of Prozac Weekly once weekly in maintaining a response in major depressive disorder has been demonstrated in a placebo–controlled trial for up to 25 weeks following open–label acute treatment of 13 weeks with Prozac 20 mg daily for a total treatment of 38 weeks. However, it is unknown whether or not Prozac Weekly given on a once–weekly basis provides the same level of protection from relapse as that provided by Prozac 20 mg daily ( see CLINICAL TRIALS ). Pediatric (children and adolescents) — The efficacy of Prozac in children and adolescents was established in two 8– to 9–week placebo–controlled clinical trials in depressed outpatients whose diagnoses corresponded most closely to the DSM–III–R or DSM–IV category of major depressive disorder ( see CLINICAL TRIALS ). The usefulness of the drug in adult and pediatric patients receiving fluoxetine for extended periods should be reevaluated periodically. Obsessive Compulsive Disorder Adult — Prozac is indicated for the treatment of obsessions and compulsions in patients with obsessive compulsive disorder (OCD), as defined in the DSM–III–R; i.e., the obsessions or compulsions cause marked distress, are time–consuming, or significantly interfere with social or occupational functioning. The efficacy of Prozac was established in 13–week trials with obsessive compulsive outpatients whose diagnoses corresponded most closely to the DSM–III–R category of OCD ( see CLINICAL TRIALS ). OCD is characterized by recurrent and persistent ideas, thoughts, impulses, or images (obsessions) that are ego–dystonic and/or repetitive, purposeful, and intentional behaviors (compulsions) that are recognized by the person as excessive or unreasonable. The effectiveness of Prozac in long–term use, i.e., for more than 13 weeks, has not been systematically evaluated in placebo–controlled trials. Therefore, the physician who elects to use Prozac for extended periods should periodically reevaluate the long–term usefulness of the drug for the individual patient ( see DOSAGE AND ADMINISTRATION ). Pediatric (children and adolescents) — The efficacy of Prozac in children and adolescents was established in a 13–week, dose titration, clinical trial in patients with OCD, as defined in DSM–IV ( see CLINICAL TRIALS ). Bulimia Nervosa Prozac is indicated for the treatment of binge–eating and vomiting behaviors in patients with moderate to severe bulimia nervosa. The efficacy of Prozac was established in 8– to 16–week trials for adult outpatients with moderate to severe bulimia nervosa, i.e., at least 3 bulimic episodes per week for 6 months ( see CLINICAL TRIALS ). The efficacy of Prozac 60 mg/day in maintaining a response, in patients with bulimia who responded during an 8–week acute treatment phase while taking Prozac 60 mg/day and were then observed for relapse during a period of up to 52 weeks, was demonstrated in a placebo–controlled trial ( see CLINICAL TRIALS ). Nevertheless, the physician who elects to use Prozac for extended periods should periodically reevaluate the long–term usefulness of the drug for the individual patient ( see DOSAGE AND ADMINISTRATION ). Panic Disorder Prozac is indicated for the treatment of panic disorder, with or without agoraphobia, as defined in DSM–IV. Panic disorder is characterized by the occurrence of unexpected panic attacks, and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. The efficacy of Prozac was established in two 12–week clinical trials in patients whose diagnoses corresponded to the DSM–IV category of panic disorder ( see CLINICAL TRIALS ). Panic disorder (DSM–IV) is characterized by recurrent, unexpected panic attacks, i.e., a discrete period of intense fear or discomfort in which 4 or more of the following symptoms develop abruptly and reach a peak within 10 minutes: 1) palpitations, pounding heart, or accelerated heart rate; 2) sweating; 3) trembling or shaking; 4) sensations of shortness of breath or smothering; 5) feeling of choking; 6) chest pain or discomfort; 7) nausea or abdominal distress; 8) feeling dizzy, unsteady, lightheaded, or faint; 9) fear of losing control; 10) fear of dying; 11) paresthesias (numbness or tingling sensations); 12) chills or hot flashes. The effectiveness of Prozac in long–term use, i.e., for more than 12 weeks, has not been established in placebo–controlled trials. Therefore, the physician who elects to use Prozac for extended periods should periodically reevaluate the long–term usefulness of the drug for the individual patient ( see DOSAGE AND ADMINISTRATION ). uuid:bd41c352-7b16-45a7-bfd8-eea2b42aabfc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5118 biolink:treats MONDO:0005383 PMID:41385096 "[{""id"":""uuid:035c97fd-d3cb-4d47-bfdb-691e66a8fb8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b5182606-3e53-49eb-8738-8f97baad9256"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Major Depressive Disorder Prozac is indicated for the treatment of major depressive disorder. Adult — The efficacy of Prozac was established in 5– and 6–week trials with depressed adult and geriatric outpatients (≥18 years of age) whose diagnoses corresponded most closely to the DSM–III (currently DSM–IV) category of major depressive disorder ( see CLINICAL TRIALS ). A major depressive episode (DSM–IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least 5 of the following 9 symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. The effects of Prozac in hospitalized depressed patients have not been adequately studied. The efficacy of Prozac 20 mg once daily in maintaining a response in major depressive disorder for up to 38 weeks following 12 weeks of open–label acute treatment (50 weeks total) was demonstrated in a placebo–controlled trial. The efficacy of Prozac Weekly once weekly in maintaining a response in major depressive disorder has been demonstrated in a placebo–controlled trial for up to 25 weeks following open–label acute treatment of 13 weeks with Prozac 20 mg daily for a total treatment of 38 weeks. However, it is unknown whether or not Prozac Weekly given on a once–weekly basis provides the same level of protection from relapse as that provided by Prozac 20 mg daily ( see CLINICAL TRIALS ). Pediatric (children and adolescents) — The efficacy of Prozac in children and adolescents was established in two 8– to 9–week placebo–controlled clinical trials in depressed outpatients whose diagnoses corresponded most closely to the DSM–III–R or DSM–IV category of major depressive disorder ( see CLINICAL TRIALS ). The usefulness of the drug in adult and pediatric patients receiving fluoxetine for extended periods should be reevaluated periodically. Obsessive Compulsive Disorder Adult — Prozac is indicated for the treatment of obsessions and compulsions in patients with obsessive compulsive disorder (OCD), as defined in the DSM–III–R; i.e., the obsessions or compulsions cause marked distress, are time–consuming, or significantly interfere with social or occupational functioning. The efficacy of Prozac was established in 13–week trials with obsessive compulsive outpatients whose diagnoses corresponded most closely to the DSM–III–R category of OCD ( see CLINICAL TRIALS ). OCD is characterized by recurrent and persistent ideas, thoughts, impulses, or images (obsessions) that are ego–dystonic and/or repetitive, purposeful, and intentional behaviors (compulsions) that are recognized by the person as excessive or unreasonable. The effectiveness of Prozac in long–term use, i.e., for more than 13 weeks, has not been systematically evaluated in placebo–controlled trials. Therefore, the physician who elects to use Prozac for extended periods should periodically reevaluate the long–term usefulness of the drug for the individual patient ( see DOSAGE AND ADMINISTRATION ). Pediatric (children and adolescents) — The efficacy of Prozac in children and adolescents was established in a 13–week, dose titration, clinical trial in patients with OCD, as defined in DSM–IV ( see CLINICAL TRIALS ). Bulimia Nervosa Prozac is indicated for the treatment of binge–eating and vomiting behaviors in patients with moderate to severe bulimia nervosa. The efficacy of Prozac was established in 8– to 16–week trials for adult outpatients with moderate to severe bulimia nervosa, i.e., at least 3 bulimic episodes per week for 6 months ( see CLINICAL TRIALS ). The efficacy of Prozac 60 mg/day in maintaining a response, in patients with bulimia who responded during an 8–week acute treatment phase while taking Prozac 60 mg/day and were then observed for relapse during a period of up to 52 weeks, was demonstrated in a placebo–controlled trial ( see CLINICAL TRIALS ). Nevertheless, the physician who elects to use Prozac for extended periods should periodically reevaluate the long–term usefulness of the drug for the individual patient ( see DOSAGE AND ADMINISTRATION ). Panic Disorder Prozac is indicated for the treatment of panic disorder, with or without agoraphobia, as defined in DSM–IV. Panic disorder is characterized by the occurrence of unexpected panic attacks, and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. The efficacy of Prozac was established in two 12–week clinical trials in patients whose diagnoses corresponded to the DSM–IV category of panic disorder ( see CLINICAL TRIALS ). Panic disorder (DSM–IV) is characterized by recurrent, unexpected panic attacks, i.e., a discrete period of intense fear or discomfort in which 4 or more of the following symptoms develop abruptly and reach a peak within 10 minutes: 1) palpitations, pounding heart, or accelerated heart rate; 2) sweating; 3) trembling or shaking; 4) sensations of shortness of breath or smothering; 5) feeling of choking; 6) chest pain or discomfort; 7) nausea or abdominal distress; 8) feeling dizzy, unsteady, lightheaded, or faint; 9) fear of losing control; 10) fear of dying; 11) paresthesias (numbness or tingling sensations); 12) chills or hot flashes. The effectiveness of Prozac in long–term use, i.e., for more than 12 weeks, has not been established in placebo–controlled trials. Therefore, the physician who elects to use Prozac for extended periods should periodically reevaluate the long–term usefulness of the drug for the individual patient ( see DOSAGE AND ADMINISTRATION ). uuid:bafb8006-76c9-469a-bff9-460a52283f4c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:43755 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:f77fc2cc-9c19-42c0-aab4-71483553578a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4d863b98-7f12-4948-bf20-37dbeba65779"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:8748998a-aa15-4922-a0aa-c141164def37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lisinopril tablets, USP is indicated for the treatment of hypertension. It may be used alone as initial therapy or concomitantly with other classes of antihypertensive agents.|[PMDA] Drugs with a new additional pediatric dosage. These drugs are indicated for the treatment of hypertension. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:b91a667e-6e16-48c3-9929-1293b0ea91fc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0001051 PMID:41385096 "[{""id"":""uuid:15f2f55d-6537-4f8e-b3f5-79da286d9ed4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b030b0d4-7586-4567-bef3-21d01520986c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE CIPRO ® HC OTIC is indicated for the treatment of acute otitis externa in adult and pediatric patients, one year and older, due to susceptible strains of Pseudomonas aeruginosa, Staphylococcus aureus, and Proteus mirabilis. uuid:135edd2f-dee2-4f1a-bf95-e156e8c1519d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2567 biolink:treats MONDO:0005298 PMID:41385096 "[{""id"":""uuid:30f829cf-8935-44ec-93e8-33f44988ff0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9f657fde-b629-41e7-b7fc-bbebdeb1cae6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:8f097a9e-65d2-49a6-a838-c9ad202bb6e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Alendronate sodium tablets, USP are indicated for: Treatment and prevention of osteoporosis in postmenopausal women For the treatment of osteoporosis, alendronate sodium tablets, USP increase bone mass and reduce the incidence of fractures, including those of the hip and spine (vertebral compression fractures). Osteoporosis may be confirmed by the finding of low bone mass (for example, at least 2 standard deviations below the premenopausal mean) or by the presence or history of osteoporotic fracture. (See CLINICAL PHARMACOLOGY, Pharmacodynamics .) For the prevention of osteoporosis, alendronate sodium tablets, USP may be considered in postmenopausal women who are at risk of developing osteoporosis and for whom the desired clinical outcome is to maintain bone mass and to reduce the risk of future fracture. Bone loss is particularly rapid in postmenopausal women younger than age 60. Risk factors often associated with the development of postmenopausal osteoporosis include early menopause; moderately low bone mass (for example, at least 1 standard deviation below the mean for healthy young adult women); thin body build; Caucasian or Asian race; and family history of osteoporosis. The presence of such risk factors may be important when considering the use of alendronate sodium tablets, USP for prevention of osteoporosis. Treatment to increase bone mass in men with osteoporosis. Treatment of glucocorticoid-induced osteoporosis in men and women receiving glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who have low bone mineral density (see PRECAUTIONS, Glucocorticoid-induced osteoporosis ). Patients treated with glucocorticoids should receive adequate amounts of calcium and vitamin D. Treatment of Paget's disease of bone in men and women Treatment is indicated in patients with Paget's disease of bone having alkaline phosphatase at least two times the upper limit of normal, or those who are symptomatic, or those at risk for future complications from their disease.|[PMDA] A drug with a new dosage in a new additional dosage form indicated for the treatment of osteoporosis (not in the reexamination period). uuid:5c45856b-30f9-4e1f-8396-be13b23aa052 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2567 biolink:treats UMLS:C0521170 PMID:41385096 "[{""id"":""uuid:03efd2ca-d00c-44af-b70f-6eaf1eac36b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8fdeb21e-b596-4f48-b0f6-9cd3488ebd8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Alendronate sodium tablets, USP are indicated for: Treatment and prevention of osteoporosis in postmenopausal women For the treatment of osteoporosis, alendronate sodium tablets, USP increase bone mass and reduce the incidence of fractures, including those of the hip and spine (vertebral compression fractures). Osteoporosis may be confirmed by the finding of low bone mass (for example, at least 2 standard deviations below the premenopausal mean) or by the presence or history of osteoporotic fracture. (See CLINICAL PHARMACOLOGY, Pharmacodynamics .) For the prevention of osteoporosis, alendronate sodium tablets, USP may be considered in postmenopausal women who are at risk of developing osteoporosis and for whom the desired clinical outcome is to maintain bone mass and to reduce the risk of future fracture. Bone loss is particularly rapid in postmenopausal women younger than age 60. Risk factors often associated with the development of postmenopausal osteoporosis include early menopause; moderately low bone mass (for example, at least 1 standard deviation below the mean for healthy young adult women); thin body build; Caucasian or Asian race; and family history of osteoporosis. The presence of such risk factors may be important when considering the use of alendronate sodium tablets, USP for prevention of osteoporosis. Treatment to increase bone mass in men with osteoporosis. Treatment of glucocorticoid-induced osteoporosis in men and women receiving glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who have low bone mineral density (see PRECAUTIONS, Glucocorticoid-induced osteoporosis ). Patients treated with glucocorticoids should receive adequate amounts of calcium and vitamin D. Treatment of Paget's disease of bone in men and women Treatment is indicated in patients with Paget's disease of bone having alkaline phosphatase at least two times the upper limit of normal, or those who are symptomatic, or those at risk for future complications from their disease. uuid:23b05b8b-ea5f-4c6f-8ccc-8eacf31f0a88 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2567 biolink:treats MONDO:0024651 PMID:41385096 "[{""id"":""uuid:9c936716-7b97-4324-9180-7198ab9fc286"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d3e3b7a8-0689-415b-92ff-a004dead7314"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Alendronate sodium tablets, USP are indicated for: Treatment and prevention of osteoporosis in postmenopausal women For the treatment of osteoporosis, alendronate sodium tablets, USP increase bone mass and reduce the incidence of fractures, including those of the hip and spine (vertebral compression fractures). Osteoporosis may be confirmed by the finding of low bone mass (for example, at least 2 standard deviations below the premenopausal mean) or by the presence or history of osteoporotic fracture. (See CLINICAL PHARMACOLOGY, Pharmacodynamics .) For the prevention of osteoporosis, alendronate sodium tablets, USP may be considered in postmenopausal women who are at risk of developing osteoporosis and for whom the desired clinical outcome is to maintain bone mass and to reduce the risk of future fracture. Bone loss is particularly rapid in postmenopausal women younger than age 60. Risk factors often associated with the development of postmenopausal osteoporosis include early menopause; moderately low bone mass (for example, at least 1 standard deviation below the mean for healthy young adult women); thin body build; Caucasian or Asian race; and family history of osteoporosis. The presence of such risk factors may be important when considering the use of alendronate sodium tablets, USP for prevention of osteoporosis. Treatment to increase bone mass in men with osteoporosis. Treatment of glucocorticoid-induced osteoporosis in men and women receiving glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who have low bone mineral density (see PRECAUTIONS, Glucocorticoid-induced osteoporosis ). Patients treated with glucocorticoids should receive adequate amounts of calcium and vitamin D. Treatment of Paget's disease of bone in men and women Treatment is indicated in patients with Paget's disease of bone having alkaline phosphatase at least two times the upper limit of normal, or those who are symptomatic, or those at risk for future complications from their disease. uuid:4de529c5-710f-43c3-a915-35f3c0d9e4f5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2567 biolink:treats MONDO:0005382 PMID:41385096 "[{""id"":""uuid:b8f53635-482f-47d4-aa0a-119a13262dea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9b5153ff-7a95-4277-bd90-8fb947e0b9d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Alendronate sodium tablets, USP are indicated for: Treatment and prevention of osteoporosis in postmenopausal women For the treatment of osteoporosis, alendronate sodium tablets, USP increase bone mass and reduce the incidence of fractures, including those of the hip and spine (vertebral compression fractures). Osteoporosis may be confirmed by the finding of low bone mass (for example, at least 2 standard deviations below the premenopausal mean) or by the presence or history of osteoporotic fracture. (See CLINICAL PHARMACOLOGY, Pharmacodynamics .) For the prevention of osteoporosis, alendronate sodium tablets, USP may be considered in postmenopausal women who are at risk of developing osteoporosis and for whom the desired clinical outcome is to maintain bone mass and to reduce the risk of future fracture. Bone loss is particularly rapid in postmenopausal women younger than age 60. Risk factors often associated with the development of postmenopausal osteoporosis include early menopause; moderately low bone mass (for example, at least 1 standard deviation below the mean for healthy young adult women); thin body build; Caucasian or Asian race; and family history of osteoporosis. The presence of such risk factors may be important when considering the use of alendronate sodium tablets, USP for prevention of osteoporosis. Treatment to increase bone mass in men with osteoporosis. Treatment of glucocorticoid-induced osteoporosis in men and women receiving glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who have low bone mineral density (see PRECAUTIONS, Glucocorticoid-induced osteoporosis ). Patients treated with glucocorticoids should receive adequate amounts of calcium and vitamin D. Treatment of Paget's disease of bone in men and women Treatment is indicated in patients with Paget's disease of bone having alkaline phosphatase at least two times the upper limit of normal, or those who are symptomatic, or those at risk for future complications from their disease. uuid:d58adb63-0250-46f3-82dc-a41bc4ddeae2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6874 biolink:treats UMLS:C5906822 PMID:41385096 "[{""id"":""uuid:30ef9b98-300c-4616-b1a1-74d781399f7d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e16c3981-03ca-49e9-b0c6-6f37f3cebd3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For routine management after delivery of the placenta; postpartum atony and hemorrhage; subinvolution. Under full obstetric supervision, it may be given in the second stage of labor following delivery of the anterior shoulder. uuid:0f9ff544-ab7f-4e15-a1fb-22633a969456 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6874 biolink:treats NCIT:C26791 PMID:41385096 "[{""id"":""uuid:d4ac1b7b-6654-47c4-b3b1-b27f7889a6d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ee4bd737-4ac5-47b4-8b59-87013401c282"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For routine management after delivery of the placenta; postpartum atony and hemorrhage; subinvolution. Under full obstetric supervision, it may be given in the second stage of labor following delivery of the anterior shoulder. uuid:448fda35-5145-4779-ab40-85ae58a25a6c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6874 biolink:treats MONDO:0001808 PMID:41385096 "[{""id"":""uuid:e5ce06f8-91c1-4c37-90b9-d5601b91f0fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dfdc6183-2326-4c1f-ad68-585bd383b43d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For routine management after delivery of the placenta; postpartum atony and hemorrhage; subinvolution. Under full obstetric supervision, it may be given in the second stage of labor following delivery of the anterior shoulder. uuid:cc1492cb-d15d-4217-b827-12038ca372d3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50122 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:dd1552c8-e958-48ea-acef-f7cbd6bcba93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:53c8b2b0-41ad-409f-8303-27471d988979"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Monotherapy and Combination Therapy AVANDIA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. 1.2 Important Limitations of Use Due to its mechanism of action, AVANDIA is active only in the presence of endogenous insulin. Therefore, AVANDIA should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. The coadministration of AVANDIA and insulin is not recommended. The use of AVANDIA with nitrates is not recommended. uuid:e6e7b683-226a-4a22-97f2-1c090c826823 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50122 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:64217f38-362c-4bc1-a6cc-547255f15f1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:22b43d59-a7e3-4496-beac-2ed5f676cf2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Monotherapy and Combination Therapy AVANDIA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. 1.2 Important Limitations of Use Due to its mechanism of action, AVANDIA is active only in the presence of endogenous insulin. Therefore, AVANDIA should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. The coadministration of AVANDIA and insulin is not recommended. The use of AVANDIA with nitrates is not recommended. uuid:28573b04-01b6-4032-af6b-7b11c6d9b37a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50122 biolink:treats MONDO:0012819 PMID:41385096 "[{""id"":""uuid:fad4b63b-bc17-449b-b439-8c3ece24a743"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8a17e931-92f8-4a31-a00a-1426c52766c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Monotherapy and Combination Therapy AVANDIA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. 1.2 Important Limitations of Use Due to its mechanism of action, AVANDIA is active only in the presence of endogenous insulin. Therefore, AVANDIA should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. The coadministration of AVANDIA and insulin is not recommended. The use of AVANDIA with nitrates is not recommended. uuid:700ff595-17f5-4f41-8744-282dbdb5c9e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4953 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:28e33606-6cd1-4130-b056-c14217475249"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f61f6d9d-704c-4e76-b3e6-22ef584de8c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AROMASIN is indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to AROMASIN for completion of a total of five consecutive years of adjuvant hormonal therapy. AROMASIN is indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy. uuid:b49f0ef8-129d-4211-b950-9c752e84accc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4953 biolink:treats UMLS:C3495917 PMID:41385096 "[{""id"":""uuid:0c998f02-db39-409d-b810-4d2afd4851ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:58a1a1f6-da3e-44d5-a2bb-813f532fba46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AROMASIN is indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received two to three years of tamoxifen and are switched to AROMASIN for completion of a total of five consecutive years of adjuvant hormonal therapy. AROMASIN is indicated for the treatment of advanced breast cancer in postmenopausal women whose disease has progressed following tamoxifen therapy. uuid:5bf89c90-38eb-4ad0-8a39-2a306479e40b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3647 biolink:treats MONDO:0005485 PMID:41385096 "[{""id"":""uuid:c39d5c77-7528-4140-8184-71d9ce4a8d1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5072500c-343a-46f2-bcd8-14f6e0d7405b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the management of manifestations of psychotic disorders. For the treatment of schizophrenia. To control nausea and vomiting. For relief of restlessness and apprehension before surgery. For acute intermittent porphyria. As an adjunct in the treatment of tetanus. To control the manifestations of the manic type of manic-depressive illness. For relief of intractable hiccups. For the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability and poor frustration tolerance. uuid:765c0607-035f-4404-9db4-6c572171a598 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3647 biolink:treats MONDO:0005090 PMID:41385096 "[{""id"":""uuid:57f96e30-91ff-45e2-bdd9-200cca552dd2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2569aa4b-9774-4367-a523-7a3abf74c327"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the management of manifestations of psychotic disorders. For the treatment of schizophrenia. To control nausea and vomiting. For relief of restlessness and apprehension before surgery. For acute intermittent porphyria. As an adjunct in the treatment of tetanus. To control the manifestations of the manic type of manic-depressive illness. For relief of intractable hiccups. For the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability and poor frustration tolerance. uuid:b83544f0-c2b4-4b23-8cf9-99b2cf792c2d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3647 biolink:treats MONDO:0008294 PMID:41385096 "[{""id"":""uuid:73cbce6d-c97a-4552-8661-3337d3361802"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:044d3801-266e-48b0-8ea5-046aaae0f3bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the management of manifestations of psychotic disorders. For the treatment of schizophrenia. To control nausea and vomiting. For relief of restlessness and apprehension before surgery. For acute intermittent porphyria. As an adjunct in the treatment of tetanus. To control the manifestations of the manic type of manic-depressive illness. For relief of intractable hiccups. For the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability and poor frustration tolerance. uuid:d7dcacde-e35c-4215-8997-f5bc7f136fb1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3647 biolink:treats MONDO:0005526 PMID:41385096 "[{""id"":""uuid:dbf6fd90-a975-4aff-8271-9efb6dd542d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7aceb5d0-72bf-4726-9e38-db8b62bb0e45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the management of manifestations of psychotic disorders. For the treatment of schizophrenia. To control nausea and vomiting. For relief of restlessness and apprehension before surgery. For acute intermittent porphyria. As an adjunct in the treatment of tetanus. To control the manifestations of the manic type of manic-depressive illness. For relief of intractable hiccups. For the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability and poor frustration tolerance. uuid:f833c6e2-ec14-40e0-9ee1-fdbf81d29f5a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3647 biolink:treats MONDO:0004985 PMID:41385096 "[{""id"":""uuid:1b4239ce-92c1-40f6-a1f3-5fa3ad15bec0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5338b61c-1f44-42fa-b7f8-0cb6c12973b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the management of manifestations of psychotic disorders. For the treatment of schizophrenia. To control nausea and vomiting. For relief of restlessness and apprehension before surgery. For acute intermittent porphyria. As an adjunct in the treatment of tetanus. To control the manifestations of the manic type of manic-depressive illness. For relief of intractable hiccups. For the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability and poor frustration tolerance. uuid:71f2b68e-8961-4b6d-8c27-17c4731cc4fc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3647 biolink:treats MONDO:0035133 PMID:41385096 "[{""id"":""uuid:003ac011-6f67-4447-8b8d-ad4e39661ee0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3f18e7c2-eec2-43af-9be2-e22663366e4c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the management of manifestations of psychotic disorders. For the treatment of schizophrenia. To control nausea and vomiting. For relief of restlessness and apprehension before surgery. For acute intermittent porphyria. As an adjunct in the treatment of tetanus. To control the manifestations of the manic type of manic-depressive illness. For relief of intractable hiccups. For the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability and poor frustration tolerance. uuid:e067b854-2b6b-4cb3-bf81-f242f11b2d11 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3647 biolink:treats MONDO:0005352 PMID:41385096 "[{""id"":""uuid:87bf0c3d-b407-4185-a7f8-cf64e3c8e180"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:15bb63d7-57ac-45ca-b11b-899c033269c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the management of manifestations of psychotic disorders. For the treatment of schizophrenia. To control nausea and vomiting. For relief of restlessness and apprehension before surgery. For acute intermittent porphyria. As an adjunct in the treatment of tetanus. To control the manifestations of the manic type of manic-depressive illness. For relief of intractable hiccups. For the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability and poor frustration tolerance. uuid:35d55424-2ca6-4a3e-9a5b-4da58f9ff4d8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8435 biolink:treats HP:0002017 PMID:41385096 "[{""id"":""uuid:0b2c6a3d-c091-4b84-b1cf-aeb47b3b2026"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9ce35df3-10fd-4f90-a88a-612d28a65bbc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE For control of severe nausea and vomiting. For the treatment of schizophrenia. Prochlorperazine is effective for the short-term treatment of generalized non-psychotic anxiety. However, prochlorperazine is not the first drug to be used in therapy for most patients with non-psychotic anxiety, because certain risks associated with its use are not shared by common alternative treatments (e.g., benzodiazepines). When used in the treatment of non-psychotic anxiety, prochlorperazine should not be administered at doses of more than 20 mg per day or for longer than 12 weeks, because the use of prochlorperazine at higher doses or for longer intervals may cause persistent tardive dyskinesia that may prove irreversible (see WARNINGS ). The effectiveness of prochlorperazine as treatment for non-psychotic anxiety was established in 4 week clinical studies of outpatients with generalized anxiety disorder. This evidence does not predict that prochlorperazine will be useful in patients with other non-psychotic conditions in which anxiety, or signs that mimic anxiety, are found (e.g., physical illness, organic mental conditions, agitated depression, character pathologies, etc.). Prochlorperazine has not been shown effective in the management of behavioral complications in patients with mental retardation. uuid:a13bf62d-7d0a-40fc-bc7f-36280f1c5d68 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8435 biolink:treats MONDO:0005090 PMID:41385096 "[{""id"":""uuid:063542de-c22f-4e9a-bc56-8efbe77b3aef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:68228423-13ef-4120-a192-d91bce817632"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE For control of severe nausea and vomiting. For the treatment of schizophrenia. Prochlorperazine is effective for the short-term treatment of generalized non-psychotic anxiety. However, prochlorperazine is not the first drug to be used in therapy for most patients with non-psychotic anxiety, because certain risks associated with its use are not shared by common alternative treatments (e.g., benzodiazepines). When used in the treatment of non-psychotic anxiety, prochlorperazine should not be administered at doses of more than 20 mg per day or for longer than 12 weeks, because the use of prochlorperazine at higher doses or for longer intervals may cause persistent tardive dyskinesia that may prove irreversible (see WARNINGS ). The effectiveness of prochlorperazine as treatment for non-psychotic anxiety was established in 4 week clinical studies of outpatients with generalized anxiety disorder. This evidence does not predict that prochlorperazine will be useful in patients with other non-psychotic conditions in which anxiety, or signs that mimic anxiety, are found (e.g., physical illness, organic mental conditions, agitated depression, character pathologies, etc.). Prochlorperazine has not been shown effective in the management of behavioral complications in patients with mental retardation. uuid:40e22ee2-d41d-4242-ae0d-27ea05579403 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8435 biolink:treats MONDO:0001942 PMID:41385096 "[{""id"":""uuid:41dce448-9523-4c4a-b855-1d6281952fc3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2f574ba5-dec1-44db-9626-cd95e6d6ed1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE For control of severe nausea and vomiting. For the treatment of schizophrenia. Prochlorperazine is effective for the short-term treatment of generalized non-psychotic anxiety. However, prochlorperazine is not the first drug to be used in therapy for most patients with non-psychotic anxiety, because certain risks associated with its use are not shared by common alternative treatments (e.g., benzodiazepines). When used in the treatment of non-psychotic anxiety, prochlorperazine should not be administered at doses of more than 20 mg per day or for longer than 12 weeks, because the use of prochlorperazine at higher doses or for longer intervals may cause persistent tardive dyskinesia that may prove irreversible (see WARNINGS ). The effectiveness of prochlorperazine as treatment for non-psychotic anxiety was established in 4 week clinical studies of outpatients with generalized anxiety disorder. This evidence does not predict that prochlorperazine will be useful in patients with other non-psychotic conditions in which anxiety, or signs that mimic anxiety, are found (e.g., physical illness, organic mental conditions, agitated depression, character pathologies, etc.). Prochlorperazine has not been shown effective in the management of behavioral complications in patients with mental retardation. uuid:6927e539-79f1-4bb9-992d-78d511726c39 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8435 biolink:treats MONDO:0010096 PMID:41385096 "[{""id"":""uuid:c71a1655-d42f-4563-be99-5113ff35d8f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5657a315-f7d5-46a3-b76b-61a81a8025f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE For control of severe nausea and vomiting. For the treatment of schizophrenia. Prochlorperazine is effective for the short-term treatment of generalized non-psychotic anxiety. However, prochlorperazine is not the first drug to be used in therapy for most patients with non-psychotic anxiety, because certain risks associated with its use are not shared by common alternative treatments (e.g., benzodiazepines). When used in the treatment of non-psychotic anxiety, prochlorperazine should not be administered at doses of more than 20 mg per day or for longer than 12 weeks, because the use of prochlorperazine at higher doses or for longer intervals may cause persistent tardive dyskinesia that may prove irreversible (see WARNINGS ). The effectiveness of prochlorperazine as treatment for non-psychotic anxiety was established in 4 week clinical studies of outpatients with generalized anxiety disorder. This evidence does not predict that prochlorperazine will be useful in patients with other non-psychotic conditions in which anxiety, or signs that mimic anxiety, are found (e.g., physical illness, organic mental conditions, agitated depression, character pathologies, etc.). Prochlorperazine has not been shown effective in the management of behavioral complications in patients with mental retardation. uuid:01ec8250-c7da-4d73-943b-d9f45333f063 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63611 biolink:treats UMLS:C0275556 PMID:41385096 "[{""id"":""uuid:7f841445-8ea0-4e6a-a8b7-cb094bc6ffa5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7f7e047f-1084-41df-8fab-1f74309d6aef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE AVELOX Tablets and I.V. are indicated for the treatment of adults (≥ 18 years of age) with infections caused by susceptible strains of the designated microorganisms in the conditions listed below. (See DOSAGE AND ADMINISTRATION for specific recommendations. In addition, for I.V. use, see PRECAUTIONS, Geriatric Use .) Acute Bacterial Sinusitis caused by Streptococcus pneumoniae, Haemophilus influenzae , or Moraxella catarrhalis . Acute Bacterial Exacerbation of Chronic Bronchitis caused by Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, methicillin-susceptible Staphylococcus aureus, or Moraxella catarrhalis. Community Acquired Pneumonia caused by Streptococcus pneumoniae (including multi-drug resistant strains*), Haemophilus influenzae, Moraxella catarrhalis, methicillin-susceptible Staphylococcus aureus, Klebsiella pneumoniae, Mycoplasma pneumoniae, or Chlamydia pneumoniae . * MDRSP, Multi-drug resistant Streptococcus pneumoniae includes isolates previously known as PRSP (Penicillin-resistant S. pneumoniae ), and are strains resistant to two or more of the following antibiotics: penicillin (MIC ≥ 2 µg/mL), 2 nd generation cephalosporins (e.g., cefuroxime), macrolides, tetracyclines, and trimethoprim/sulfamethoxazole. Uncomplicated Skin and Skin Structure Infections caused by methicillin-susceptible Staphylococcus aureus or Streptococcus pyogenes . Complicated Intra-Abdominal Infections including polymicrobial infections such as abscess caused by Escherichia coli, Bacteroides fragilis, Streptococcus anginosus, Streptococcus constellatus, Enterococcus faecalis, Proteus mirabilis, Clostridium perfringens, Bacteroides thetaiotaomicron, or Peptostreptococcus species . Complicated Skin and Skin Structure Infections caused by methicillin-susceptible Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, or Enterobacter cloacae (See Clinical Studies ). Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. Therapy with AVELOX may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. To reduce the development of drug-resistant bacteria and maintain the effectiveness of AVELOX and other antibacterial drugs, AVELOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:405961f8-cf13-4829-b1d3-ad3e4998d69e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63611 biolink:treats UMLS:C1735365 PMID:41385096 "[{""id"":""uuid:797dfd9b-9a58-435c-b01b-f9bc67f5bdb8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:31c0ef96-6d6e-4f30-a9b9-f83787d883b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE AVELOX Tablets and I.V. are indicated for the treatment of adults (≥ 18 years of age) with infections caused by susceptible strains of the designated microorganisms in the conditions listed below. (See DOSAGE AND ADMINISTRATION for specific recommendations. In addition, for I.V. use, see PRECAUTIONS, Geriatric Use .) Acute Bacterial Sinusitis caused by Streptococcus pneumoniae, Haemophilus influenzae , or Moraxella catarrhalis . Acute Bacterial Exacerbation of Chronic Bronchitis caused by Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, methicillin-susceptible Staphylococcus aureus, or Moraxella catarrhalis. Community Acquired Pneumonia caused by Streptococcus pneumoniae (including multi-drug resistant strains*), Haemophilus influenzae, Moraxella catarrhalis, methicillin-susceptible Staphylococcus aureus, Klebsiella pneumoniae, Mycoplasma pneumoniae, or Chlamydia pneumoniae . * MDRSP, Multi-drug resistant Streptococcus pneumoniae includes isolates previously known as PRSP (Penicillin-resistant S. pneumoniae ), and are strains resistant to two or more of the following antibiotics: penicillin (MIC ≥ 2 µg/mL), 2 nd generation cephalosporins (e.g., cefuroxime), macrolides, tetracyclines, and trimethoprim/sulfamethoxazole. Uncomplicated Skin and Skin Structure Infections caused by methicillin-susceptible Staphylococcus aureus or Streptococcus pyogenes . Complicated Intra-Abdominal Infections including polymicrobial infections such as abscess caused by Escherichia coli, Bacteroides fragilis, Streptococcus anginosus, Streptococcus constellatus, Enterococcus faecalis, Proteus mirabilis, Clostridium perfringens, Bacteroides thetaiotaomicron, or Peptostreptococcus species . Complicated Skin and Skin Structure Infections caused by methicillin-susceptible Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, or Enterobacter cloacae (See Clinical Studies ). Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. Therapy with AVELOX may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. To reduce the development of drug-resistant bacteria and maintain the effectiveness of AVELOX and other antibacterial drugs, AVELOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:cfa60e18-b5b3-4acc-b465-d6da1d668f1b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63611 biolink:treats UMLS:C0694549 PMID:41385096 "[{""id"":""uuid:6bf55ac5-8e22-434d-9a3a-233e04d68105"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7401fcce-f1b2-4311-806f-9bf537f88469"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE AVELOX Tablets and I.V. are indicated for the treatment of adults (≥ 18 years of age) with infections caused by susceptible strains of the designated microorganisms in the conditions listed below. (See DOSAGE AND ADMINISTRATION for specific recommendations. In addition, for I.V. use, see PRECAUTIONS, Geriatric Use .) Acute Bacterial Sinusitis caused by Streptococcus pneumoniae, Haemophilus influenzae , or Moraxella catarrhalis . Acute Bacterial Exacerbation of Chronic Bronchitis caused by Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, methicillin-susceptible Staphylococcus aureus, or Moraxella catarrhalis. Community Acquired Pneumonia caused by Streptococcus pneumoniae (including multi-drug resistant strains*), Haemophilus influenzae, Moraxella catarrhalis, methicillin-susceptible Staphylococcus aureus, Klebsiella pneumoniae, Mycoplasma pneumoniae, or Chlamydia pneumoniae . * MDRSP, Multi-drug resistant Streptococcus pneumoniae includes isolates previously known as PRSP (Penicillin-resistant S. pneumoniae ), and are strains resistant to two or more of the following antibiotics: penicillin (MIC ≥ 2 µg/mL), 2 nd generation cephalosporins (e.g., cefuroxime), macrolides, tetracyclines, and trimethoprim/sulfamethoxazole. Uncomplicated Skin and Skin Structure Infections caused by methicillin-susceptible Staphylococcus aureus or Streptococcus pyogenes . Complicated Intra-Abdominal Infections including polymicrobial infections such as abscess caused by Escherichia coli, Bacteroides fragilis, Streptococcus anginosus, Streptococcus constellatus, Enterococcus faecalis, Proteus mirabilis, Clostridium perfringens, Bacteroides thetaiotaomicron, or Peptostreptococcus species . Complicated Skin and Skin Structure Infections caused by methicillin-susceptible Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, or Enterobacter cloacae (See Clinical Studies ). Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. Therapy with AVELOX may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. To reduce the development of drug-resistant bacteria and maintain the effectiveness of AVELOX and other antibacterial drugs, AVELOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:c63ef80c-cf78-4676-83ed-f2c8fe2b7ee9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63611 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:6c2269d6-472b-491b-a7bc-36224ef72e6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9db7c67e-5000-4390-8fb4-3507c5af1e3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE AVELOX Tablets and I.V. are indicated for the treatment of adults (≥ 18 years of age) with infections caused by susceptible strains of the designated microorganisms in the conditions listed below. (See DOSAGE AND ADMINISTRATION for specific recommendations. In addition, for I.V. use, see PRECAUTIONS, Geriatric Use .) Acute Bacterial Sinusitis caused by Streptococcus pneumoniae, Haemophilus influenzae , or Moraxella catarrhalis . Acute Bacterial Exacerbation of Chronic Bronchitis caused by Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, methicillin-susceptible Staphylococcus aureus, or Moraxella catarrhalis. Community Acquired Pneumonia caused by Streptococcus pneumoniae (including multi-drug resistant strains*), Haemophilus influenzae, Moraxella catarrhalis, methicillin-susceptible Staphylococcus aureus, Klebsiella pneumoniae, Mycoplasma pneumoniae, or Chlamydia pneumoniae . * MDRSP, Multi-drug resistant Streptococcus pneumoniae includes isolates previously known as PRSP (Penicillin-resistant S. pneumoniae ), and are strains resistant to two or more of the following antibiotics: penicillin (MIC ≥ 2 µg/mL), 2 nd generation cephalosporins (e.g., cefuroxime), macrolides, tetracyclines, and trimethoprim/sulfamethoxazole. Uncomplicated Skin and Skin Structure Infections caused by methicillin-susceptible Staphylococcus aureus or Streptococcus pyogenes . Complicated Intra-Abdominal Infections including polymicrobial infections such as abscess caused by Escherichia coli, Bacteroides fragilis, Streptococcus anginosus, Streptococcus constellatus, Enterococcus faecalis, Proteus mirabilis, Clostridium perfringens, Bacteroides thetaiotaomicron, or Peptostreptococcus species . Complicated Skin and Skin Structure Infections caused by methicillin-susceptible Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, or Enterobacter cloacae (See Clinical Studies ). Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. Therapy with AVELOX may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. To reduce the development of drug-resistant bacteria and maintain the effectiveness of AVELOX and other antibacterial drugs, AVELOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:c329d00f-3cec-49f4-8266-c3fe9255b468 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3219 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:9968a9cc-f98d-4fe6-aa30-8635167176d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a69cc335-45c8-4cd8-9da1-4af64b0b4622"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bupropion hydrochloride tablets are indicated for the treatment of major depressive disorder. A physician considering bupropion for the management of a patient’s first episode of depression should be aware that the drug may cause generalized seizures in a dose dependent manner with an approximate incidence of 0.4% (4/1,000). This incidence of seizures may exceed that of other marketed antidepressants by as much as 4-fold. This relative risk is only an approximate estimate because no direct comparative studies have been conducted (see WARNINGS ). The efficacy of bupropion has been established in three placebo-controlled trials, including two of approximately 3 weeks’ duration in depressed inpatients and one of approximately 6 weeks’ duration in depressed outpatients. The depressive disorder of the patients studied corresponds most closely to the Major Depression category of the APA Diagnostic and Statistical Manual III. Major depression implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least four of the following eight symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigability, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and suicidal ideation or attempts. Effectiveness of bupropion in long-term use, that is, for more than 6 weeks, has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use bupropion for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual patient. uuid:11663d5a-0923-4dea-a296-d02d6bd6b96d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3175 biolink:treats MONDO:0005338 PMID:41385096 "[{""id"":""uuid:b4196900-309b-4621-82ff-955683c74190"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2fd5db80-58a1-4e7c-95da-e08177bb3ac2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Brimonidine Tartrate Ophthalmic Solution, 0.15% is indicated for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. uuid:67a27013-c37a-4195-9e22-6702643098d0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3175 biolink:treats MONDO:0006875 PMID:41385096 "[{""id"":""uuid:67944e78-d886-41a8-a094-6bd89230400c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eb39dc96-1f2d-402a-b7e4-954022b11ccd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Brimonidine Tartrate Ophthalmic Solution, 0.15% is indicated for the lowering of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. uuid:58e6d276-3d0e-4a0a-8747-24c49ab94e29 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9622 biolink:treats EFO:0006865 PMID:41385096 "[{""id"":""uuid:33e7b185-884f-4eb8-b087-6611a7235866"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:39788a03-ebf6-491a-97f3-0ba908906b60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:31ee1dd4-726a-4f45-9711-fa4404f60dca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1 INDICATIONS AND USAGE DETROL LA Capsules is indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency [see CLINICAL STUDIES (14) ].|[PMDA] Drugs with a new active ingredient indicated for treatment of urinary urgency, urinary frequency, and urge urinary incontinence associated with overactive bladder. uuid:f8b659a4-f918-43ea-8c92-ea46b14f7dc0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37941 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:dcb609cf-4011-4e6d-a684-25ad4da2738a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:42ffac1c-ed07-4027-952b-3a15116979f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE PLAVIX (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as follows: Recent MI, Recent Stroke or Established Peripheral Arterial Disease For patients with a history of recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease, PLAVIX has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death. Acute Coronary Syndrome - For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/non-Q-wave MI) including patients who are to be managed medically and those who are to be managed with percutaneous coronary intervention (with or without stent) or CABG, PLAVIX has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia. - For patients with ST-segment elevation acute myocardial infarction, PLAVIX has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke. This benefit is not known to pertain to patients who receive primary angioplasty uuid:03adc36b-68d7-4c63-9352-8a2efc387427 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37941 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:d6f2491f-f4c1-4a10-a5f3-24f179627ab2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dabd718c-feff-4700-af98-4f6e1b59d2b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE PLAVIX (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as follows: Recent MI, Recent Stroke or Established Peripheral Arterial Disease For patients with a history of recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease, PLAVIX has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death. Acute Coronary Syndrome - For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/non-Q-wave MI) including patients who are to be managed medically and those who are to be managed with percutaneous coronary intervention (with or without stent) or CABG, PLAVIX has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia. - For patients with ST-segment elevation acute myocardial infarction, PLAVIX has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke. This benefit is not known to pertain to patients who receive primary angioplasty uuid:5d950295-6aa0-4d26-b7c7-2d000f163acb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37941 biolink:treats MONDO:0005386 PMID:41385096 "[{""id"":""uuid:175f7640-df65-41e9-a794-5d8e052fc920"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:670ed4e8-b45e-43d2-a8ac-5adf015d0b27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE PLAVIX (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as follows: Recent MI, Recent Stroke or Established Peripheral Arterial Disease For patients with a history of recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease, PLAVIX has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death. Acute Coronary Syndrome - For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/non-Q-wave MI) including patients who are to be managed medically and those who are to be managed with percutaneous coronary intervention (with or without stent) or CABG, PLAVIX has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia. - For patients with ST-segment elevation acute myocardial infarction, PLAVIX has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke. This benefit is not known to pertain to patients who receive primary angioplasty uuid:540b3da9-125f-4e5d-baa6-61f5dc57ccba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37941 biolink:treats MONDO:0006805 PMID:41385096 "[{""id"":""uuid:c6f3123f-aacb-4e00-94c7-95b994faef4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:233ba00d-2ede-4bd1-a28b-389725831fe7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f9b559b3-4cf0-455f-bb40-f67ecb860ad9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE PLAVIX (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as follows: Recent MI, Recent Stroke or Established Peripheral Arterial Disease For patients with a history of recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease, PLAVIX has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death. Acute Coronary Syndrome - For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/non-Q-wave MI) including patients who are to be managed medically and those who are to be managed with percutaneous coronary intervention (with or without stent) or CABG, PLAVIX has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia. - For patients with ST-segment elevation acute myocardial infarction, PLAVIX has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke. This benefit is not known to pertain to patients who receive primary angioplasty|[PMDA] A new combination drug indicated for the treatment of ischemic heart diseases (acute coronary syndrome [unstable angina, non-ST-segment elevation myocardial infarction, ST-segment elevation myocardial infarction], stable angina, old myocardial infarction) to which percutaneous coronary intervention (PCI) is applicable. uuid:7f585dc3-bc2e-43fa-9f07-221036c98958 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37941 biolink:treats MONDO:0041656 PMID:41385096 "[{""id"":""uuid:add61d7e-8b8e-4f4b-ba02-734977c859c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b0dfd359-2efb-49c7-bc6a-a70c571298af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:aea334c2-dfe7-48b0-aaf3-3facb2b7886a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE PLAVIX (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as follows: Recent MI, Recent Stroke or Established Peripheral Arterial Disease For patients with a history of recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease, PLAVIX has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death. Acute Coronary Syndrome - For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/non-Q-wave MI) including patients who are to be managed medically and those who are to be managed with percutaneous coronary intervention (with or without stent) or CABG, PLAVIX has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia. - For patients with ST-segment elevation acute myocardial infarction, PLAVIX has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke. This benefit is not known to pertain to patients who receive primary angioplasty|[PMDA] A new combination drug indicated for the treatment of ischemic heart diseases (acute coronary syndrome [unstable angina, non-ST-segment elevation myocardial infarction, ST-segment elevation myocardial infarction], stable angina, old myocardial infarction) to which percutaneous coronary intervention (PCI) is applicable. uuid:8775afd7-f7d8-4e78-a7d3-325912e04c55 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37941 biolink:treats UMLS:C1112767 PMID:41385096 "[{""id"":""uuid:238e8506-218b-43f0-a037-1a27aef3f2ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aec9b512-0748-4b3e-90e6-1fb320450600"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE PLAVIX (clopidogrel bisulfate) is indicated for the reduction of atherothrombotic events as follows: Recent MI, Recent Stroke or Established Peripheral Arterial Disease For patients with a history of recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease, PLAVIX has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death. Acute Coronary Syndrome - For patients with non-ST-segment elevation acute coronary syndrome (unstable angina/non-Q-wave MI) including patients who are to be managed medically and those who are to be managed with percutaneous coronary intervention (with or without stent) or CABG, PLAVIX has been shown to decrease the rate of a combined endpoint of cardiovascular death, MI, or stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia. - For patients with ST-segment elevation acute myocardial infarction, PLAVIX has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction or stroke. This benefit is not known to pertain to patients who receive primary angioplasty uuid:c61c7b9e-45c2-4e7b-bec0-a5f6746200a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7915 biolink:treats UMLS:C0267055 PMID:41385096 "[{""id"":""uuid:9df56c78-f13a-42ba-ac7f-b3612fa1f4b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:139a80a7-ae81-4e74-bc47-ee77d4371008"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pantoprazole sodium delayed-release tablets are indicated for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis. For those patients who have not healed after 8 weeks of treatment, an additional 8-week course of pantoprazole sodium may be considered. uuid:b3e76b3c-945f-46e5-9b11-0067d08c070b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50730 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:b366fd1d-f197-47df-ad13-9761a6a80db3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6f3af04d-92e1-4eca-bec4-85f0144e69bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f829e3e7-00a6-4e99-afc1-aa68e9295fcb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SINGULAIR is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 12 months of age and older. SINGULAIR is indicated for prevention of exercise-induced bronchoconstriction in patients 15 years of age and older. SINGULAIR is indicated for the relief of symptoms of allergic rhinitis (seasonal allergic rhinitis in adults and pediatric patients 2 years of age and older, and perennial allergic rhinitis in adults and pediatric patients 6 months of age and older).|[PMDA] Drugs with a new dosage and in a new dosage form, or fine granules, indicated for the treatment of asthma in children aged 1 or more and less than 6 years. uuid:cb1c91aa-b3e6-401c-8ec4-ae0d62cf1a76 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50730 biolink:treats MONDO:0850286 PMID:41385096 "[{""id"":""uuid:89645cc9-0840-4f1e-88e5-17048b82e0d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ea2a3a55-f59f-4bdb-890b-f5a70549d9a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SINGULAIR is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 12 months of age and older. SINGULAIR is indicated for prevention of exercise-induced bronchoconstriction in patients 15 years of age and older. SINGULAIR is indicated for the relief of symptoms of allergic rhinitis (seasonal allergic rhinitis in adults and pediatric patients 2 years of age and older, and perennial allergic rhinitis in adults and pediatric patients 6 months of age and older). uuid:abfdfbe9-40f2-497b-8353-17ff6cac1956 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50730 biolink:treats MONDO:0011786 PMID:41385096 "[{""id"":""uuid:30dedd0e-5401-42fb-b5f0-21c80fd67f54"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2c058609-7a2d-42e9-ac59-6ce2db75b09f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f4c14c74-404e-47f5-8e55-e803da1a9466"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SINGULAIR is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 12 months of age and older. SINGULAIR is indicated for prevention of exercise-induced bronchoconstriction in patients 15 years of age and older. SINGULAIR is indicated for the relief of symptoms of allergic rhinitis (seasonal allergic rhinitis in adults and pediatric patients 2 years of age and older, and perennial allergic rhinitis in adults and pediatric patients 6 months of age and older).|[PMDA] Drugs with a new indication and dosage and in a new dosge form for the treatment of allergic rhinitis. uuid:396ec65f-b4aa-41c4-8594-14b4eeac3966 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50730 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:74272816-b5d6-45a6-9d32-5eb5128facee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ceb0fad2-7de8-4adc-87a0-b3a99cdd865f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SINGULAIR is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 12 months of age and older. SINGULAIR is indicated for prevention of exercise-induced bronchoconstriction in patients 15 years of age and older. SINGULAIR is indicated for the relief of symptoms of allergic rhinitis (seasonal allergic rhinitis in adults and pediatric patients 2 years of age and older, and perennial allergic rhinitis in adults and pediatric patients 6 months of age and older). uuid:7bbc60ee-b5f6-4044-b8cd-2311b732fea6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50730 biolink:treats MONDO:0024332 PMID:41385096 "[{""id"":""uuid:89903211-d219-40af-8b49-9918ac10b07e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5a0ec708-5675-429a-a8d7-cd2a89ac0570"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SINGULAIR is indicated for the prophylaxis and chronic treatment of asthma in adults and pediatric patients 12 months of age and older. SINGULAIR is indicated for prevention of exercise-induced bronchoconstriction in patients 15 years of age and older. SINGULAIR is indicated for the relief of symptoms of allergic rhinitis (seasonal allergic rhinitis in adults and pediatric patients 2 years of age and older, and perennial allergic rhinitis in adults and pediatric patients 6 months of age and older). uuid:ec1f927c-8431-4f75-b343-e97e55aec3ee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50663 biolink:treats MONDO:0005812 PMID:41385096 "[{""id"":""uuid:3dc3d8e3-40e2-4402-90de-bfbd83bc0be3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:eed05643-bdaa-4120-bd1a-97941c8e9909"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f7848548-c96b-444f-99c2-991f8c61f28a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/dectova""]},{""id"":""uuid:44aedd20-b278-44f8-ad0b-4cea9704e69d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RELENZA, an influenza neuraminidase inhibitor, is indicated for: Treatment of influenza in patients 7 years of age and older who have been symptomatic for no more than 2 days. (1.1) Prophylaxis of influenza in patients 5 years of age and older. (1.2) Important Limitations on Use of RELENZA: Not recommended for treatment or prophylaxis of influenza in: Individuals with underlying airways disease. (5.1) Not proven effective for: Treatment in individuals with underlying airways disease. (1.3) Prophylaxis in nursing home residents. (1.3) Not a substitute for annual influenza vaccination. (1.3) Consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use RELENZA. (1.3)|[EMA] Dectova is indicated for the treatment of complicated and potentially life-threatening influenza A or B virus infection in adult and paediatric patients (aged ≥6 months) when:The patient’s influenza virus is known or suspected to be resistant to anti-influenza medicinal products other than zanamivir, and/orOther anti-viral medicinal products for treatment of influenza, including inhaled zanamivir, are not suitable for the individual patient.Dectova should be used in accordance with official guidance.|[PMDA] Addition of a new indication for prophylaxis of influenza typeA or typeB infections. [Expedited Review] uuid:99819750-ad27-4ef0-937f-3ca0b038926e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8461 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:15343e2a-c77d-46dd-bb30-2fbe1f3566ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:523a9116-627c-4a0f-93e9-cfa36a8de384"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Promethazine hydrochloride injection is indicated for the following conditions: Amelioration of allergic reactions to blood or plasma. In anaphylaxis as an adjunct to epinephrine and other standard measures after the acute symptoms have been controlled. For other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated. For sedation and relief of apprehension and to produce light sleep from which the patient can be easily aroused. Active treatment of motion sickness. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. As an adjunct to analgesics for the control of postoperative pain. Preoperative, postoperative, and obstetric (during labor) sedation. Intravenously in special surgical situations, such as repeated bronchoscopy, ophthalmic surgery, and poor-risk patients, with reduced amounts of meperidine or other narcotic analgesic as an adjunct to anesthesia and analgesia. uuid:54e32ba2-74aa-41d0-a5d3-21df3184cbd3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8461 biolink:treats UMLS:C0851444 PMID:41385096 "[{""id"":""uuid:854a1864-a892-4381-bb2a-56928c09913d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:689586a4-0ac3-48e3-939f-f9f9ffe8efd2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Promethazine hydrochloride injection is indicated for the following conditions: Amelioration of allergic reactions to blood or plasma. In anaphylaxis as an adjunct to epinephrine and other standard measures after the acute symptoms have been controlled. For other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated. For sedation and relief of apprehension and to produce light sleep from which the patient can be easily aroused. Active treatment of motion sickness. Prevention and control of nausea and vomiting associated with certain types of anesthesia and surgery. As an adjunct to analgesics for the control of postoperative pain. Preoperative, postoperative, and obstetric (during labor) sedation. Intravenously in special surgical situations, such as repeated bronchoscopy, ophthalmic surgery, and poor-risk patients, with reduced amounts of meperidine or other narcotic analgesic as an adjunct to anesthesia and analgesia. uuid:e5a6e3b0-c7cb-4922-9c51-a828894d183e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C075654 biolink:treats MONDO:0005344 PMID:41385096 "[{""id"":""uuid:d7a6699c-acf5-48f1-b812-11c64cdb1637"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ae3972b6-4cbc-46b5-bf93-91b02e1ac302"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e522008d-3099-48ae-bc17-f26ac8e18014"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/prehevbri""]},{""id"":""uuid:67bf2e9a-3b56-44a9-8032-b5a4bbd79d4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENGERIX-B is indicated for immunization against infection caused by all known subtypes of hepatitis B virus. As hepatitis D (caused by the delta virus) does not occur in the absence of hepatitis B infection, it can be expected that hepatitis D will also be prevented by ENGERIX-B vaccination. ENGERIX-B will not prevent hepatitis caused by other agents, such as hepatitis A, C, and E viruses, or other pathogens known to infect the liver. Immunization is recommended in persons of all ages, especially those who are, or will be, at increased risk of exposure to hepatitis B virus, 1 for example: Infants, Including Those Born of HBsAg-Positive Mothers (See DOSAGE AND ADMINISTRATION.) Adolescents (See CLINICAL PHARMACOLOGY.) Healthcare Personnel: Dentists and oral surgeons. Dental, medical, and nursing students. Physicians, surgeons, and podiatrists. Nurses. Paramedical and ambulance personnel and custodial staff who may be exposed to the virus via blood or other patient specimens. Dental hygienists and dental nurses. Laboratory and blood bank personnel handling blood, blood products, and other patient specimens. Hospital cleaning staff who handle waste. Selected Patients and Patient Contacts: Patients and staff in hemodialysis units and hematology/oncology units. Patients requiring frequent and/or large volume blood transfusions or clotting factor concentrates (e.g., persons with hemophilia, thalassemia, sickle cell anemia, cirrhosis). Clients (residents) and staff of institutions for the mentally handicapped. Classroom contacts of deinstitutionalized mentally handicapped persons who have persistent hepatitis B surface antigenemia and who show aggressive behavior. Household and other intimate contacts of persons with persistent hepatitis B surface antigenemia. Subpopulations With a Known High Incidence of the Disease, such as: Alaskan Eskimos. Pacific Islanders. Indochinese immigrants. Haitian immigrants. Refugees from other HBV-endemic areas. All infants of women born in areas where the infection is highly endemic. Individuals With Chronic Hepatitis C: Risk factors for hepatitis C are similar to those for hepatitis B. Consequently, immunization with hepatitis B vaccine is recommended for individuals with chronic hepatitis C. Persons Who May Be Exposed to the Hepatitis B Virus by Travel to High-Risk Areas (See ACIP Guidelines, 1990.) Military Personnel Identified as Being at Increased Risk Morticians and Embalmers Persons at Increased Risk of the Disease Due to Their Sexual Practices, 1,16 such as: Persons with more than 1 sexual partner in a 6-month period. Persons who have contracted a sexually transmitted disease. Homosexually active males. Female prostitutes. Prisoners Users of Illicit Injectable Drugs Others: Police and fire department personnel who render first aid or medical assistance, and any others who, through their work or personal life-style, may be exposed to the hepatitis B virus. Adoptees from countries of high HBV endemicity.|[EMA] PreHevbri is indicated for active immunisation against infection caused by all known subtypes of the hepatitis B virus in adults., , It can be expected that hepatitis D will also be prevented by immunisation with PreHevbri as hepatitis D (caused by the delta agent) does not occur in the absence of hepatitis B infection., , The use of PreHevbri should be in accordance with official recommendations.,|[PMDA] Drugs with a revised dosage indicated for the prevention of perinatal hepatitis B virus infection (concomitant use with anti-Hepatitis B surface [HBs] human immunoglobulin). [Public knowledge-based application after PAFSC's preliminary assessment] uuid:2ab9cec4-9629-4262-a335-2a52e9a344f1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C075654 biolink:treats MONDO:0005789 PMID:41385096 "[{""id"":""uuid:8107c7bc-78e3-40bc-ab89-59897f202049"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f094dd54-d2ed-49f7-81c8-fa4fbdee5096"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a64a59b9-0d16-4eb8-921b-b2ac50546224"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/prehevbri""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENGERIX-B is indicated for immunization against infection caused by all known subtypes of hepatitis B virus. As hepatitis D (caused by the delta virus) does not occur in the absence of hepatitis B infection, it can be expected that hepatitis D will also be prevented by ENGERIX-B vaccination. ENGERIX-B will not prevent hepatitis caused by other agents, such as hepatitis A, C, and E viruses, or other pathogens known to infect the liver. Immunization is recommended in persons of all ages, especially those who are, or will be, at increased risk of exposure to hepatitis B virus, 1 for example: Infants, Including Those Born of HBsAg-Positive Mothers (See DOSAGE AND ADMINISTRATION.) Adolescents (See CLINICAL PHARMACOLOGY.) Healthcare Personnel: Dentists and oral surgeons. Dental, medical, and nursing students. Physicians, surgeons, and podiatrists. Nurses. Paramedical and ambulance personnel and custodial staff who may be exposed to the virus via blood or other patient specimens. Dental hygienists and dental nurses. Laboratory and blood bank personnel handling blood, blood products, and other patient specimens. Hospital cleaning staff who handle waste. Selected Patients and Patient Contacts: Patients and staff in hemodialysis units and hematology/oncology units. Patients requiring frequent and/or large volume blood transfusions or clotting factor concentrates (e.g., persons with hemophilia, thalassemia, sickle cell anemia, cirrhosis). Clients (residents) and staff of institutions for the mentally handicapped. Classroom contacts of deinstitutionalized mentally handicapped persons who have persistent hepatitis B surface antigenemia and who show aggressive behavior. Household and other intimate contacts of persons with persistent hepatitis B surface antigenemia. Subpopulations With a Known High Incidence of the Disease, such as: Alaskan Eskimos. Pacific Islanders. Indochinese immigrants. Haitian immigrants. Refugees from other HBV-endemic areas. All infants of women born in areas where the infection is highly endemic. Individuals With Chronic Hepatitis C: Risk factors for hepatitis C are similar to those for hepatitis B. Consequently, immunization with hepatitis B vaccine is recommended for individuals with chronic hepatitis C. Persons Who May Be Exposed to the Hepatitis B Virus by Travel to High-Risk Areas (See ACIP Guidelines, 1990.) Military Personnel Identified as Being at Increased Risk Morticians and Embalmers Persons at Increased Risk of the Disease Due to Their Sexual Practices, 1,16 such as: Persons with more than 1 sexual partner in a 6-month period. Persons who have contracted a sexually transmitted disease. Homosexually active males. Female prostitutes. Prisoners Users of Illicit Injectable Drugs Others: Police and fire department personnel who render first aid or medical assistance, and any others who, through their work or personal life-style, may be exposed to the hepatitis B virus. Adoptees from countries of high HBV endemicity.|[EMA] PreHevbri is indicated for active immunisation against infection caused by all known subtypes of the hepatitis B virus in adults., , It can be expected that hepatitis D will also be prevented by immunisation with PreHevbri as hepatitis D (caused by the delta agent) does not occur in the absence of hepatitis B infection., , The use of PreHevbri should be in accordance with official recommendations., uuid:5eca34b9-8a02-41c1-8d89-afdd96fdc13e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C075654 biolink:treats MONDO:0018660 PMID:41385096 "[{""id"":""uuid:583deadf-6828-45ff-b98e-f872b7bac3be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5211377a-7ea5-4b2a-bb09-ae348a854fe8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENGERIX-B is indicated for immunization against infection caused by all known subtypes of hepatitis B virus. As hepatitis D (caused by the delta virus) does not occur in the absence of hepatitis B infection, it can be expected that hepatitis D will also be prevented by ENGERIX-B vaccination. ENGERIX-B will not prevent hepatitis caused by other agents, such as hepatitis A, C, and E viruses, or other pathogens known to infect the liver. Immunization is recommended in persons of all ages, especially those who are, or will be, at increased risk of exposure to hepatitis B virus, 1 for example: Infants, Including Those Born of HBsAg-Positive Mothers (See DOSAGE AND ADMINISTRATION.) Adolescents (See CLINICAL PHARMACOLOGY.) Healthcare Personnel: Dentists and oral surgeons. Dental, medical, and nursing students. Physicians, surgeons, and podiatrists. Nurses. Paramedical and ambulance personnel and custodial staff who may be exposed to the virus via blood or other patient specimens. Dental hygienists and dental nurses. Laboratory and blood bank personnel handling blood, blood products, and other patient specimens. Hospital cleaning staff who handle waste. Selected Patients and Patient Contacts: Patients and staff in hemodialysis units and hematology/oncology units. Patients requiring frequent and/or large volume blood transfusions or clotting factor concentrates (e.g., persons with hemophilia, thalassemia, sickle cell anemia, cirrhosis). Clients (residents) and staff of institutions for the mentally handicapped. Classroom contacts of deinstitutionalized mentally handicapped persons who have persistent hepatitis B surface antigenemia and who show aggressive behavior. Household and other intimate contacts of persons with persistent hepatitis B surface antigenemia. Subpopulations With a Known High Incidence of the Disease, such as: Alaskan Eskimos. Pacific Islanders. Indochinese immigrants. Haitian immigrants. Refugees from other HBV-endemic areas. All infants of women born in areas where the infection is highly endemic. Individuals With Chronic Hepatitis C: Risk factors for hepatitis C are similar to those for hepatitis B. Consequently, immunization with hepatitis B vaccine is recommended for individuals with chronic hepatitis C. Persons Who May Be Exposed to the Hepatitis B Virus by Travel to High-Risk Areas (See ACIP Guidelines, 1990.) Military Personnel Identified as Being at Increased Risk Morticians and Embalmers Persons at Increased Risk of the Disease Due to Their Sexual Practices, 1,16 such as: Persons with more than 1 sexual partner in a 6-month period. Persons who have contracted a sexually transmitted disease. Homosexually active males. Female prostitutes. Prisoners Users of Illicit Injectable Drugs Others: Police and fire department personnel who render first aid or medical assistance, and any others who, through their work or personal life-style, may be exposed to the hepatitis B virus. Adoptees from countries of high HBV endemicity. uuid:59a3a61e-13f7-4b00-8496-488b0faa69d2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C075654 biolink:treats MONDO:0000984 PMID:41385096 "[{""id"":""uuid:541c2b98-9872-433d-83e1-9e349459ec25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9d827958-e8fb-4e81-a80f-f3c46b37c2e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENGERIX-B is indicated for immunization against infection caused by all known subtypes of hepatitis B virus. As hepatitis D (caused by the delta virus) does not occur in the absence of hepatitis B infection, it can be expected that hepatitis D will also be prevented by ENGERIX-B vaccination. ENGERIX-B will not prevent hepatitis caused by other agents, such as hepatitis A, C, and E viruses, or other pathogens known to infect the liver. Immunization is recommended in persons of all ages, especially those who are, or will be, at increased risk of exposure to hepatitis B virus, 1 for example: Infants, Including Those Born of HBsAg-Positive Mothers (See DOSAGE AND ADMINISTRATION.) Adolescents (See CLINICAL PHARMACOLOGY.) Healthcare Personnel: Dentists and oral surgeons. Dental, medical, and nursing students. Physicians, surgeons, and podiatrists. Nurses. Paramedical and ambulance personnel and custodial staff who may be exposed to the virus via blood or other patient specimens. Dental hygienists and dental nurses. Laboratory and blood bank personnel handling blood, blood products, and other patient specimens. Hospital cleaning staff who handle waste. Selected Patients and Patient Contacts: Patients and staff in hemodialysis units and hematology/oncology units. Patients requiring frequent and/or large volume blood transfusions or clotting factor concentrates (e.g., persons with hemophilia, thalassemia, sickle cell anemia, cirrhosis). Clients (residents) and staff of institutions for the mentally handicapped. Classroom contacts of deinstitutionalized mentally handicapped persons who have persistent hepatitis B surface antigenemia and who show aggressive behavior. Household and other intimate contacts of persons with persistent hepatitis B surface antigenemia. Subpopulations With a Known High Incidence of the Disease, such as: Alaskan Eskimos. Pacific Islanders. Indochinese immigrants. Haitian immigrants. Refugees from other HBV-endemic areas. All infants of women born in areas where the infection is highly endemic. Individuals With Chronic Hepatitis C: Risk factors for hepatitis C are similar to those for hepatitis B. Consequently, immunization with hepatitis B vaccine is recommended for individuals with chronic hepatitis C. Persons Who May Be Exposed to the Hepatitis B Virus by Travel to High-Risk Areas (See ACIP Guidelines, 1990.) Military Personnel Identified as Being at Increased Risk Morticians and Embalmers Persons at Increased Risk of the Disease Due to Their Sexual Practices, 1,16 such as: Persons with more than 1 sexual partner in a 6-month period. Persons who have contracted a sexually transmitted disease. Homosexually active males. Female prostitutes. Prisoners Users of Illicit Injectable Drugs Others: Police and fire department personnel who render first aid or medical assistance, and any others who, through their work or personal life-style, may be exposed to the hepatitis B virus. Adoptees from countries of high HBV endemicity. uuid:de35a5cd-4f98-4739-ae9b-ddc4af3a9ab6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C075654 biolink:treats MONDO:0011382 PMID:41385096 "[{""id"":""uuid:159e5720-69cf-49f6-af87-ccd731633eea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:18eadc79-341d-4b29-af0a-3e7caccdbaef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENGERIX-B is indicated for immunization against infection caused by all known subtypes of hepatitis B virus. As hepatitis D (caused by the delta virus) does not occur in the absence of hepatitis B infection, it can be expected that hepatitis D will also be prevented by ENGERIX-B vaccination. ENGERIX-B will not prevent hepatitis caused by other agents, such as hepatitis A, C, and E viruses, or other pathogens known to infect the liver. Immunization is recommended in persons of all ages, especially those who are, or will be, at increased risk of exposure to hepatitis B virus, 1 for example: Infants, Including Those Born of HBsAg-Positive Mothers (See DOSAGE AND ADMINISTRATION.) Adolescents (See CLINICAL PHARMACOLOGY.) Healthcare Personnel: Dentists and oral surgeons. Dental, medical, and nursing students. Physicians, surgeons, and podiatrists. Nurses. Paramedical and ambulance personnel and custodial staff who may be exposed to the virus via blood or other patient specimens. Dental hygienists and dental nurses. Laboratory and blood bank personnel handling blood, blood products, and other patient specimens. Hospital cleaning staff who handle waste. Selected Patients and Patient Contacts: Patients and staff in hemodialysis units and hematology/oncology units. Patients requiring frequent and/or large volume blood transfusions or clotting factor concentrates (e.g., persons with hemophilia, thalassemia, sickle cell anemia, cirrhosis). Clients (residents) and staff of institutions for the mentally handicapped. Classroom contacts of deinstitutionalized mentally handicapped persons who have persistent hepatitis B surface antigenemia and who show aggressive behavior. Household and other intimate contacts of persons with persistent hepatitis B surface antigenemia. Subpopulations With a Known High Incidence of the Disease, such as: Alaskan Eskimos. Pacific Islanders. Indochinese immigrants. Haitian immigrants. Refugees from other HBV-endemic areas. All infants of women born in areas where the infection is highly endemic. Individuals With Chronic Hepatitis C: Risk factors for hepatitis C are similar to those for hepatitis B. Consequently, immunization with hepatitis B vaccine is recommended for individuals with chronic hepatitis C. Persons Who May Be Exposed to the Hepatitis B Virus by Travel to High-Risk Areas (See ACIP Guidelines, 1990.) Military Personnel Identified as Being at Increased Risk Morticians and Embalmers Persons at Increased Risk of the Disease Due to Their Sexual Practices, 1,16 such as: Persons with more than 1 sexual partner in a 6-month period. Persons who have contracted a sexually transmitted disease. Homosexually active males. Female prostitutes. Prisoners Users of Illicit Injectable Drugs Others: Police and fire department personnel who render first aid or medical assistance, and any others who, through their work or personal life-style, may be exposed to the hepatitis B virus. Adoptees from countries of high HBV endemicity. uuid:2dfb6bf9-7cde-4479-8265-00baea7af402 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C075654 biolink:treats MONDO:0005155 PMID:41385096 "[{""id"":""uuid:9c3ba131-a90b-4140-b43e-3b0a3f35a0dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:88c7b0a3-330a-4b09-8e48-03d9713f297b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENGERIX-B is indicated for immunization against infection caused by all known subtypes of hepatitis B virus. As hepatitis D (caused by the delta virus) does not occur in the absence of hepatitis B infection, it can be expected that hepatitis D will also be prevented by ENGERIX-B vaccination. ENGERIX-B will not prevent hepatitis caused by other agents, such as hepatitis A, C, and E viruses, or other pathogens known to infect the liver. Immunization is recommended in persons of all ages, especially those who are, or will be, at increased risk of exposure to hepatitis B virus, 1 for example: Infants, Including Those Born of HBsAg-Positive Mothers (See DOSAGE AND ADMINISTRATION.) Adolescents (See CLINICAL PHARMACOLOGY.) Healthcare Personnel: Dentists and oral surgeons. Dental, medical, and nursing students. Physicians, surgeons, and podiatrists. Nurses. Paramedical and ambulance personnel and custodial staff who may be exposed to the virus via blood or other patient specimens. Dental hygienists and dental nurses. Laboratory and blood bank personnel handling blood, blood products, and other patient specimens. Hospital cleaning staff who handle waste. Selected Patients and Patient Contacts: Patients and staff in hemodialysis units and hematology/oncology units. Patients requiring frequent and/or large volume blood transfusions or clotting factor concentrates (e.g., persons with hemophilia, thalassemia, sickle cell anemia, cirrhosis). Clients (residents) and staff of institutions for the mentally handicapped. Classroom contacts of deinstitutionalized mentally handicapped persons who have persistent hepatitis B surface antigenemia and who show aggressive behavior. Household and other intimate contacts of persons with persistent hepatitis B surface antigenemia. Subpopulations With a Known High Incidence of the Disease, such as: Alaskan Eskimos. Pacific Islanders. Indochinese immigrants. Haitian immigrants. Refugees from other HBV-endemic areas. All infants of women born in areas where the infection is highly endemic. Individuals With Chronic Hepatitis C: Risk factors for hepatitis C are similar to those for hepatitis B. Consequently, immunization with hepatitis B vaccine is recommended for individuals with chronic hepatitis C. Persons Who May Be Exposed to the Hepatitis B Virus by Travel to High-Risk Areas (See ACIP Guidelines, 1990.) Military Personnel Identified as Being at Increased Risk Morticians and Embalmers Persons at Increased Risk of the Disease Due to Their Sexual Practices, 1,16 such as: Persons with more than 1 sexual partner in a 6-month period. Persons who have contracted a sexually transmitted disease. Homosexually active males. Female prostitutes. Prisoners Users of Illicit Injectable Drugs Others: Police and fire department personnel who render first aid or medical assistance, and any others who, through their work or personal life-style, may be exposed to the hepatitis B virus. Adoptees from countries of high HBV endemicity. uuid:4d5d873e-4122-4e67-940e-5faa1e9adfb1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C075654 biolink:treats MONDO:0005354 PMID:41385096 "[{""id"":""uuid:e2107057-5ea0-4f47-86ea-2b07add3e4b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dc399af1-300f-4f0d-9c57-c802b0f5a15b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENGERIX-B is indicated for immunization against infection caused by all known subtypes of hepatitis B virus. As hepatitis D (caused by the delta virus) does not occur in the absence of hepatitis B infection, it can be expected that hepatitis D will also be prevented by ENGERIX-B vaccination. ENGERIX-B will not prevent hepatitis caused by other agents, such as hepatitis A, C, and E viruses, or other pathogens known to infect the liver. Immunization is recommended in persons of all ages, especially those who are, or will be, at increased risk of exposure to hepatitis B virus, 1 for example: Infants, Including Those Born of HBsAg-Positive Mothers (See DOSAGE AND ADMINISTRATION.) Adolescents (See CLINICAL PHARMACOLOGY.) Healthcare Personnel: Dentists and oral surgeons. Dental, medical, and nursing students. Physicians, surgeons, and podiatrists. Nurses. Paramedical and ambulance personnel and custodial staff who may be exposed to the virus via blood or other patient specimens. Dental hygienists and dental nurses. Laboratory and blood bank personnel handling blood, blood products, and other patient specimens. Hospital cleaning staff who handle waste. Selected Patients and Patient Contacts: Patients and staff in hemodialysis units and hematology/oncology units. Patients requiring frequent and/or large volume blood transfusions or clotting factor concentrates (e.g., persons with hemophilia, thalassemia, sickle cell anemia, cirrhosis). Clients (residents) and staff of institutions for the mentally handicapped. Classroom contacts of deinstitutionalized mentally handicapped persons who have persistent hepatitis B surface antigenemia and who show aggressive behavior. Household and other intimate contacts of persons with persistent hepatitis B surface antigenemia. Subpopulations With a Known High Incidence of the Disease, such as: Alaskan Eskimos. Pacific Islanders. Indochinese immigrants. Haitian immigrants. Refugees from other HBV-endemic areas. All infants of women born in areas where the infection is highly endemic. Individuals With Chronic Hepatitis C: Risk factors for hepatitis C are similar to those for hepatitis B. Consequently, immunization with hepatitis B vaccine is recommended for individuals with chronic hepatitis C. Persons Who May Be Exposed to the Hepatitis B Virus by Travel to High-Risk Areas (See ACIP Guidelines, 1990.) Military Personnel Identified as Being at Increased Risk Morticians and Embalmers Persons at Increased Risk of the Disease Due to Their Sexual Practices, 1,16 such as: Persons with more than 1 sexual partner in a 6-month period. Persons who have contracted a sexually transmitted disease. Homosexually active males. Female prostitutes. Prisoners Users of Illicit Injectable Drugs Others: Police and fire department personnel who render first aid or medical assistance, and any others who, through their work or personal life-style, may be exposed to the hepatitis B virus. Adoptees from countries of high HBV endemicity. uuid:05a3a991-f258-45e8-9957-0324d1f3e6c6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46081 biolink:treats UMLS:C0006852 PMID:41385096 "[{""id"":""uuid:b3358e2c-49fb-4dad-8f51-db1894a7936c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fbec539e-9e79-4766-b871-7f7ee208a209"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluconazole is indicated for the treatment of: Vaginal candidiasis (vaginal yeast infections due to Candida ). Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole was also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia. Cryptococcal meningitis. Before prescribing fluconazole for AIDS patients with cryptococcal meningitis, please see CLINICAL STUDIES section. Studies comparing fluconazole to amphotericin B in non-HIV infected patients have not been conducted. Prophylaxis. Fluconazole is also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly. uuid:f23d94de-1a5d-44d5-8ae8-b778af5960e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46081 biolink:treats UMLS:C0919659 PMID:41385096 "[{""id"":""uuid:62cb44c7-3f12-489e-9e77-6f7e54709251"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:de000a67-e239-4010-8dfe-bde92f2c3129"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluconazole is indicated for the treatment of: Vaginal candidiasis (vaginal yeast infections due to Candida ). Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole was also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia. Cryptococcal meningitis. Before prescribing fluconazole for AIDS patients with cryptococcal meningitis, please see CLINICAL STUDIES section. Studies comparing fluconazole to amphotericin B in non-HIV infected patients have not been conducted. Prophylaxis. Fluconazole is also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly. uuid:b87b4a10-9eec-4951-af85-809b94e6f503 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46081 biolink:treats MONDO:0001648 PMID:41385096 "[{""id"":""uuid:83161028-4d57-4f1b-821f-a052962dc895"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9469862a-5ca6-4466-8b89-75bef3a35111"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluconazole is indicated for the treatment of: Vaginal candidiasis (vaginal yeast infections due to Candida ). Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole was also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia. Cryptococcal meningitis. Before prescribing fluconazole for AIDS patients with cryptococcal meningitis, please see CLINICAL STUDIES section. Studies comparing fluconazole to amphotericin B in non-HIV infected patients have not been conducted. Prophylaxis. Fluconazole is also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly. uuid:1621be0b-4412-4b45-b2c4-1b3bf6701604 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46081 biolink:treats MONDO:0002026 PMID:41385096 "[{""id"":""uuid:7a4caa79-0e85-4f47-9e5d-2c1a374071a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ee51309d-c73f-4d67-b6d2-f6f3d138e2f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluconazole is indicated for the treatment of: Vaginal candidiasis (vaginal yeast infections due to Candida ). Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole was also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia. Cryptococcal meningitis. Before prescribing fluconazole for AIDS patients with cryptococcal meningitis, please see CLINICAL STUDIES section. Studies comparing fluconazole to amphotericin B in non-HIV infected patients have not been conducted. Prophylaxis. Fluconazole is also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly. uuid:6ae3ac65-77d6-4999-94d2-2d7100ae6e22 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46081 biolink:treats MONDO:0004522 PMID:41385096 "[{""id"":""uuid:572e6319-b0ce-4d1d-81d4-8768af86b171"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:651334a0-6a46-40bd-bfc2-5dddbdfd9399"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluconazole is indicated for the treatment of: Vaginal candidiasis (vaginal yeast infections due to Candida ). Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole was also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia. Cryptococcal meningitis. Before prescribing fluconazole for AIDS patients with cryptococcal meningitis, please see CLINICAL STUDIES section. Studies comparing fluconazole to amphotericin B in non-HIV infected patients have not been conducted. Prophylaxis. Fluconazole is also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly. uuid:da0d9d1b-e3f0-49d0-b71e-a45fd64ae4d1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46081 biolink:treats MONDO:0042233 PMID:41385096 "[{""id"":""uuid:9dd0585e-0b46-46e4-a43a-3d72760f1faa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:88611ca2-7b5e-4fa3-a348-893d8491e8e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluconazole is indicated for the treatment of: Vaginal candidiasis (vaginal yeast infections due to Candida ). Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole was also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia. Cryptococcal meningitis. Before prescribing fluconazole for AIDS patients with cryptococcal meningitis, please see CLINICAL STUDIES section. Studies comparing fluconazole to amphotericin B in non-HIV infected patients have not been conducted. Prophylaxis. Fluconazole is also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly. uuid:8840104c-33bf-45a0-93ce-bd713a498a2b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46081 biolink:treats MONDO:0044070 PMID:41385096 "[{""id"":""uuid:8a0709f3-a87b-495f-abb9-d8c354f47df9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ef281ece-f4ee-4748-bb2a-68a70cdfadc3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluconazole is indicated for the treatment of: Vaginal candidiasis (vaginal yeast infections due to Candida ). Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole was also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia. Cryptococcal meningitis. Before prescribing fluconazole for AIDS patients with cryptococcal meningitis, please see CLINICAL STUDIES section. Studies comparing fluconazole to amphotericin B in non-HIV infected patients have not been conducted. Prophylaxis. Fluconazole is also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly. uuid:d0bb72a7-3bd7-434f-9790-da33e421603d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46081 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:54845727-f6fa-48e3-8c40-a4b7e04e4e8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:52242111-7cc5-4f90-a4f4-662541a534c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluconazole is indicated for the treatment of: Vaginal candidiasis (vaginal yeast infections due to Candida ). Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole was also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia. Cryptococcal meningitis. Before prescribing fluconazole for AIDS patients with cryptococcal meningitis, please see CLINICAL STUDIES section. Studies comparing fluconazole to amphotericin B in non-HIV infected patients have not been conducted. Prophylaxis. Fluconazole is also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly. uuid:97ed1b73-c1ce-4f69-9697-64340789f3c9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46081 biolink:treats MONDO:0005723 PMID:41385096 "[{""id"":""uuid:c3d41579-6978-4844-a306-f13a2d2e599a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:748224ec-f4ce-4453-be1a-91fa79af4653"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluconazole is indicated for the treatment of: Vaginal candidiasis (vaginal yeast infections due to Candida ). Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole was also effective for the treatment of Candida urinary tract infections, peritonitis, and systemic Candida infections including candidemia, disseminated candidiasis, and pneumonia. Cryptococcal meningitis. Before prescribing fluconazole for AIDS patients with cryptococcal meningitis, please see CLINICAL STUDIES section. Studies comparing fluconazole to amphotericin B in non-HIV infected patients have not been conducted. Prophylaxis. Fluconazole is also indicated to decrease the incidence of candidiasis in patients undergoing bone marrow transplantation who receive cytotoxic chemotherapy and/or radiation therapy. Specimens for fungal culture and other relevant laboratory studies (serology, histopathology) should be obtained prior to therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, anti-infective therapy should be adjusted accordingly. uuid:7130ec2d-e242-48d6-8a76-4b32af50f015 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0000004 PMID:41385096 "[{""id"":""uuid:c6db6d19-ef27-4ff4-8ae9-69ba37272e76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f3da3946-040c-4c0d-b1c5-b04e7e14ac5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:13d986b6-a4db-4e47-b484-a813a76a73d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0018479 PMID:41385096 "[{""id"":""uuid:722a5a64-14be-44c8-b438-3c1654411a06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d29984b5-17b9-48c1-9ea1-43452594486b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:d4b87292-4896-437b-ac4f-60cabb69cfd9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0006982 PMID:41385096 "[{""id"":""uuid:f4213b70-1558-4c5e-9c49-6e50b2db26f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:741c9975-09aa-41bc-b2db-9f06f20cc854"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:57d9be20-99f6-41c3-850e-b0170d19d491 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0043455 PMID:41385096 "[{""id"":""uuid:c11fa6be-cadb-473f-beca-debfdf3866b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bfc93a82-893b-4e6b-8e69-bf07c2badb5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:c255c6f0-2edb-4426-92ef-066d19df54b5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:e7879835-cc77-4c31-b4cc-8c6f31469241"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9a23856f-97e9-4cfa-8277-46c94582c9ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:1f639599-a954-49cf-832f-012f2285c4a2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0011429 PMID:41385096 "[{""id"":""uuid:a2a0b1ae-3863-4fdc-9f39-e0cbe92860f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2c029146-42eb-48d0-90e5-e3460ae8760c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:01475f59-eb25-4da5-8d37-73498e0dde66 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:773cdbad-a1d9-4c5b-8293-12b926b2ef3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e46dc8e7-07fa-42d4-8af5-157f1a665db9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:694ead09-7e70-4f3c-9f16-a533c99e32ac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats UMLS:C1290158 PMID:41385096 "[{""id"":""uuid:68fb2a35-babe-425e-b72a-bf142c61641d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:502e6421-d81d-4309-b737-66b57cda0870"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:c5116380-4bf5-4f30-92c8-b138bf5cc767 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0040698 PMID:41385096 "[{""id"":""uuid:f8ebf1ea-9ed0-4f75-94c2-c7de0d3d23ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:237f6318-0082-4a73-82c9-d3d1be6da893"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:ecc84225-58f2-44fb-ade1-80df7cfe92a3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:2aadbd3f-471d-4e9a-be69-26dad88fb150"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3c319911-e0ad-46ab-971e-d255fccba00a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:76745c55-d017-4852-b522-02326cb9f753 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0004855 PMID:41385096 "[{""id"":""uuid:1684921a-e1a0-4c0e-ba04-79bef614d047"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c21534d3-6571-4769-911b-76f73439dd1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:1bccdd4d-4351-44a4-80d0-5f257231ce53 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:b8392bfa-1e92-4205-9f46-d60725b7d05d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fa62914f-d0aa-47fa-83f1-23b9c82e7a40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:da40fdd2-3cd4-4bb3-9498-a560c9897e75 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0001875 PMID:41385096 "[{""id"":""uuid:566b8827-5883-438d-b428-8f6f07e5df20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b093d612-475e-4036-a3af-404b5bd8267e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:33328817-3fcc-4ee4-a685-0a13d414a3cf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats UMLS:C0149896 PMID:41385096 "[{""id"":""uuid:405c5368-6c52-415d-99f0-d869b57c3857"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f2fbac6b-ce5e-4a5f-b830-3b6ec0b6220a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:e80f64d6-232a-4614-b8e3-b19191bce5bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0016367 PMID:41385096 "[{""id"":""uuid:46a05285-d0ba-4004-b12d-5d8890cabd90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bd133905-2172-4ea6-bc7b-9682b18406ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3c693daa-a6e7-482b-a521-e525bebef046"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement.|[PMDA] Drugs with new additional indications and a new dosage for the treatment of the following treatment- resistant rheumatic diseases: systemic vasculitis (including microscopic polyangiitis, Wegener's granulomatosis, polyarteritis nodosa, Churg- Strauss syndrome, aortitis syndrome), systemic lupus erythematosus, polymyositis, dermatomyositis, scleroderma, mixed connective tissue disease, and refractory rheumatic disease. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:005030a4-d3ea-4fb2-a66f-2e5ade8e975e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0019127 PMID:41385096 "[{""id"":""uuid:d2d59cd5-19e4-4344-8b7b-fcb22ccd3909"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7f751266-bcbb-4f1d-ac8b-d20b8831da7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:63ed4bd5-464b-4f9a-9c8f-b03f02daae3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement.|[PMDA] Drugs with new additional indications and a new dosage for the treatment of the following treatment- resistant rheumatic diseases: systemic vasculitis (including microscopic polyangiitis, Wegener's granulomatosis, polyarteritis nodosa, Churg- Strauss syndrome, aortitis syndrome), systemic lupus erythematosus, polymyositis, dermatomyositis, scleroderma, mixed connective tissue disease, and refractory rheumatic disease. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:529a977f-b1d5-41e6-bef3-0d19c5a34a4d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats UMLS:C5441648 PMID:41385096 "[{""id"":""uuid:b5b0ff62-a88d-4336-999c-2ecde564375d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6e96fbba-394c-4707-9c24-8e794ef4cfea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:18bc5942-67ea-4246-8c84-b37b999b7a9a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0015614 PMID:41385096 "[{""id"":""uuid:79119811-9f14-48c1-8904-4280293f5ad5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ca7ee7c5-0b94-4cc8-97bb-759f320457c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:ad30c2d0-37ed-4951-93d9-d28269bd82d1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0006545 PMID:41385096 "[{""id"":""uuid:6f511051-c301-47e7-b1cd-bd90f7d48e38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aa6e7cd1-de42-45a1-bc4a-aac30d2828e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:11d519e7-7dc7-44cb-986c-7f4325b817a3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0018229 PMID:41385096 "[{""id"":""uuid:3b337ce7-a5f2-4203-802f-11b729505764"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c7a41651-b575-402c-b921-90ec3afd74ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:062f67b0-8e1c-42ca-8b2d-7123d4aaaba2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0006608 PMID:41385096 "[{""id"":""uuid:457aa68b-fbc3-46d2-a922-a38206581679"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:56c5dac3-6ea6-4996-b8b4-ed7ba7895682"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:81bdb5f8-3908-4ed7-968e-35124c8d52a5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0043233 PMID:41385096 "[{""id"":""uuid:8d589489-436e-4bcc-a224-9eaaa2824c80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:07fe2124-1854-4779-ad6c-612b5ccfc8ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:a039a213-7103-417f-8a18-b9fcd8b87676 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0009691 PMID:41385096 "[{""id"":""uuid:98658e77-5093-4822-b394-c06e29758acc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6f1d2640-bda9-4f8c-bee8-c4ec85aae5ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:46485dc1-82e5-4611-9409-1cc5c6997cf9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0006594 PMID:41385096 "[{""id"":""uuid:958f1a7d-c907-4c4d-9b6f-f74a40d1d50a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:803561ff-9e68-48b0-b03e-7255ccf7ed52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:bd5cf871-9ee3-4b83-aeb6-1a00408d88d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:8924c9ba-ba65-4173-899a-c15d8936d09c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:13d506ad-006d-4b5d-a53b-baa6f9b759d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:23de2d48-fee8-4279-8a9d-26fe3b490a68 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:629edc90-b487-42a7-872f-23cbb8a77b6c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6f7fcff4-ed10-4185-b759-6bc692a9f350"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:fe8d71e9-0ba9-4c69-88d9-8ed40e8c5c56 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0024332 PMID:41385096 "[{""id"":""uuid:76faf779-c304-4d63-a50c-251e4003bf01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ebe181ab-e5bc-43e9-9bcb-22631c2d25b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:663b2fb6-dc34-4a18-8857-7ceaf15de64c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0000775 PMID:41385096 "[{""id"":""uuid:7892f0b7-8283-4aba-b1df-8c812131098e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0294d558-0db8-4e59-986f-2148ca66b06c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:4623da4d-84db-46d7-a0ff-ef881bc516b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0043789 PMID:41385096 "[{""id"":""uuid:b1b1bb75-0d35-4b68-b521-7419cd0324d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:037f08de-762b-4fb8-9899-d75c70beac81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:0200b2af-8b33-4d92-a497-fc6795c74ca9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0005480 PMID:41385096 "[{""id"":""uuid:c2e97146-5494-47c4-80d8-5b63be6bf0bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:27b4a0f5-2488-4e8e-8577-5c3c48951e8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:7ca0320a-19ef-4229-9408-c20ac15b9fe3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:8ca6193c-dcf9-4ab6-9032-124320b7db4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a13fb1a7-059f-4089-8076-527da06d3bbc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:c0ad282d-8364-4746-a208-6df1f988b30b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:6e340907-4679-4a33-a18e-01aaa358bbbc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dd568402-1446-4633-89c7-7b01fe60494b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:bc021941-ee89-4e23-8cd1-c80fd0c9b6ee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0001034 PMID:41385096 "[{""id"":""uuid:2221a046-09d8-456a-a4d1-91dafa7c6630"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0c5312fd-4864-4bf7-8776-fec69e23dab7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:b5357340-59e1-4359-b867-b884c4c02919 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0005883 PMID:41385096 "[{""id"":""uuid:889b1150-3187-4e98-86fe-09415a81499f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ef43b954-0186-45bf-b2bd-7a35a53cdcfc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:26d4b6cb-cf24-45b4-8cbf-26d9d216ee45 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0006651 PMID:41385096 "[{""id"":""uuid:edc8a3c7-2c9e-4057-81e7-fe97aa654802"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a0ba651c-350a-4e13-8efa-84d7e4e411a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:cb25d029-6e70-4614-8c17-35ea93cea4f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0006918 PMID:41385096 "[{""id"":""uuid:7b993229-37ae-4f3a-82bc-800f1ff92669"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:050c4404-e723-4dce-8414-81acfcbe9b17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:85302307-a9ea-45d1-8162-0db9f74f0f55 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0001280 PMID:41385096 "[{""id"":""uuid:b733f4bc-d7e1-4a84-b32a-078bdf4a7e0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:735aaa9b-3bfe-4e8a-a7f8-79372c4515e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:546e01e5-2224-49f2-9cd2-98b2928e979b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0019198 PMID:41385096 "[{""id"":""uuid:f15eeb23-6358-4fd5-ad63-4148b7a53fb6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bdc96526-db34-4937-8d2c-97494e0e6db7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:eba8af98-5f54-40c3-9912-2f4c4072175e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0003085 PMID:41385096 "[{""id"":""uuid:cbfac958-d65e-4324-8dcb-77d6882f59fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:138e88c7-6495-4d3c-afa1-f833d57bc0fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:1baa8284-28cc-4611-bc2d-88ad6f85ee0d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0005885 PMID:41385096 "[{""id"":""uuid:bf361900-3ee4-4973-9299-ca153518cef1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4559ca33-ebdf-4e17-9d58-e383133cc64b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:7635c1e3-3e89-4a44-8787-659336df022a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0004674 PMID:41385096 "[{""id"":""uuid:dd3ff1fd-56b9-4776-8292-0a0c1ef60052"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8b740117-fa58-4f0a-a7bb-7ae2e318f438"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:b878f96b-d87f-4643-958c-1f31f37595d1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0006814 PMID:41385096 "[{""id"":""uuid:10215c19-ed40-4bb1-972f-0d6e036d5f14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4309ef35-e762-4db6-946f-e32e994741a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:efb1ca09-53d9-4042-883a-f0f1a6fafc4d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0004773 PMID:41385096 "[{""id"":""uuid:4de77e9f-99b2-4485-8534-a5c71763266d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2a73450e-b528-48f8-b862-5324258759c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:328190ea-28f0-4912-b077-292a836b7acc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0019338 PMID:41385096 "[{""id"":""uuid:9c6328c6-a311-4b88-8e95-256d7ca363e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7bdcc6e6-51e5-453f-9e1d-338694605d85"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:0bdd54f1-91c2-4b87-ab53-feb923c26999 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0015274 PMID:41385096 "[{""id"":""uuid:ec6e081f-af12-456a-8619-a976fdcdd2cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6bec54e1-180d-4813-8b14-f3f8a4ad2b5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:4e92af91-8db3-4f62-8c6d-2c0769da9caf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0006052 PMID:41385096 "[{""id"":""uuid:513bc0bb-844f-420a-a712-e37de0117c5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f6ecb86a-2d45-4b82-a2d1-ca7bb6ca17d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:3b326812-dfa4-4fb4-93c6-3d044d2b0f51 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0005848 PMID:41385096 "[{""id"":""uuid:e5d10f73-3d91-41db-aef7-9bb4c1e00621"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:560154bf-9f3a-4639-bad9-39f74b181455"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:16b043a1-2a1f-4fea-880d-5318c0fbb740 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0002572 PMID:41385096 "[{""id"":""uuid:223c1e6a-9eed-4de3-841a-2d109944cf60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e1bb8e22-d383-4e26-a9c9-27931d28c163"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:817e954d-0bc6-4b67-9115-ad587939dc1e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0019098 PMID:41385096 "[{""id"":""uuid:69383b21-f930-43b5-9c52-5dc912f834b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7e98a3c6-d676-4d7d-9e9a-bdd53b603488"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:b56d7a80-97fc-40f6-9d5c-2aa6738c34e5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0001198 PMID:41385096 "[{""id"":""uuid:66b091df-d9d7-43f2-a5f6-1d3428bf993d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:18d42902-8d15-40b6-a416-512c1a6a5e50"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:3d1e59ce-0973-4c0f-887e-7cc808fc0503 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats UMLS:C0002879 PMID:41385096 "[{""id"":""uuid:1067e5f6-db5e-4b93-bc96-f09b400ace60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:49e482d4-32d2-43cc-a5ad-5d5d43585643"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:3e6adcb3-5a5b-45ac-abf3-29923136d7ab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0020108 PMID:41385096 "[{""id"":""uuid:facf84b0-6513-4804-8c96-c09906bf9d27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0cb75470-6f95-4780-9035-12f539e7d4d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:f38f0a80-2d48-42ac-9a87-6832efc9e6e7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0002280 PMID:41385096 "[{""id"":""uuid:4e74e6dd-c9fb-48b1-a6fd-48bd37c970b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:47e9d1f4-5b6d-43b4-9521-912fdf76c74b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:50e4f415-d079-4666-a5b1-6c51fd3721be biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0015253 PMID:41385096 "[{""id"":""uuid:586cc8f8-0d62-42dd-89bd-ef6d41693ffc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:98d322da-dcda-4eea-b6fb-3c1f9dc6b271"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:60c37a88-8912-4f36-90fb-de988f081aef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats HP:0001908 PMID:41385096 "[{""id"":""uuid:13be072e-7e03-4d9b-a927-b60d4151e4a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1f3a7764-1987-41f3-9bb8-5336a75ff668"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:4e802094-db3c-4d1d-aeed-a462740d9866 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0005059 PMID:41385096 "[{""id"":""uuid:78641d66-3e02-4525-a5d0-532d94a92582"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:223022f1-89fb-4921-9418-1463355a1f14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:9b29d908-2563-4721-81d7-1f1a55e663cb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0004095 PMID:41385096 "[{""id"":""uuid:1d4362f1-4497-46f9-a0c7-5a67fdccb2bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2be5f91b-8924-4087-b3b3-abb043bc3fb8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:c22ab5ac-d7d8-420f-910e-31414105d011 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0004355 PMID:41385096 "[{""id"":""uuid:f65305d6-cfee-4646-9841-a61757ea8f3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1432312a-2efd-4c5e-803a-f71b04fa80dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:8c14e2be-4df8-40cd-aed2-e34938bf2da3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0005377 PMID:41385096 "[{""id"":""uuid:c04e2c1f-6ba5-42b0-8bcf-7832ae8bb1fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:033f3760-41c8-48d3-97df-d3ed34560c89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:6434659c-df88-4ef0-86a4-e7677a995686"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement.|[PMDA] Drugs with a new additional indication and a new dosage for the treatment of nephrotic syndrome. [Public knowledge-based application after preliminary assessment by the Pharmaceutical Affairs and Food Sanitation Council (PAFSC)] uuid:6ba90803-e655-46a8-be5a-8e3c18bfbddf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:bea95498-dfb0-4239-bec5-987bac2c7eeb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6768839f-709a-4ecc-ae8d-cff53585add2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:1dc3954b-750b-4a51-9ee2-dad9a8a79a70 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats UMLS:C0678202 PMID:41385096 "[{""id"":""uuid:6053591d-e0ed-4027-97a2-4dc0c04201df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6616124d-97d8-423f-916a-0b67f1f17cf7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:b8137083-b44b-49d5-9e82-ca5cbaa93d22 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:558a15ed-ed05-43b2-9f88-9b728b71ebbf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9f5318dc-3e1d-4238-bbea-fa86b149de7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:baa3aec7-16e0-45a9-a9a9-e81a3a25865f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement.|[PMDA] Drugs with a new additional indication and a new dosage for the treatment of acute exacerbation of multiple sclerosis. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:0656aa53-f11b-4a26-8221-4c165db020dc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0006042 PMID:41385096 "[{""id"":""uuid:8522347f-eba5-4c6f-82d0-16c667438fde"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:48347331-7ab6-496d-9f0e-600cf45ee941"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:24a19d48-4693-4ac5-941a-53b135c8bdfc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0019444 PMID:41385096 "[{""id"":""uuid:9bb4214a-1fbc-4875-9130-b3730c658fa3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3b7fbd3e-d9d0-4124-89fa-28afff8ce73d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1.Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2.Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode orexacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3.Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4.Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5.Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6.Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7.Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9.Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10.Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12.Nervous System Acute exacerbations of multiple sclerosis 13.Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:99de8497-0740-4c98-b165-d269a8d7a8f6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51209 biolink:treats MONDO:0005709 PMID:41385096 "[{""id"":""uuid:dae05044-d061-4457-8814-e5871b6d2bc2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c6297c57-21ef-4241-82ea-55e0bba43b23"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive temporarily relieves nasal congestion due to: common cold hay fever upper respiratory allergies temporarily restores freer breathing through the nose promotes nasal and/or sinus drainage temporarily relieves sinus congestion and pressure uuid:07a2019c-7821-4f7b-b3d5-1712fb642d95 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51209 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:7a5d5447-73f8-445d-a96e-093686addd3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c468eb29-e799-42d2-97a3-aef1c569230c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive temporarily relieves nasal congestion due to: common cold hay fever upper respiratory allergies temporarily restores freer breathing through the nose promotes nasal and/or sinus drainage temporarily relieves sinus congestion and pressure uuid:c54f72cc-6dab-45a0-9c33-14a339731127 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51209 biolink:treats MONDO:0004867 PMID:41385096 "[{""id"":""uuid:258314ad-149b-42c3-88cc-f9a11ac0b3b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b216f008-8fb6-4d43-b7e4-e0439a606d0f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive temporarily relieves nasal congestion due to: common cold hay fever upper respiratory allergies temporarily restores freer breathing through the nose promotes nasal and/or sinus drainage temporarily relieves sinus congestion and pressure uuid:82e3e74e-dffc-4e7c-8c0f-8a1930388fb3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51209 biolink:treats UMLS:C0152029 PMID:41385096 "[{""id"":""uuid:c75d5964-9a9c-4362-8ded-3d04d42045d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:075108a4-9f94-4d28-a52e-47194e2ad2de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive temporarily relieves nasal congestion due to: common cold hay fever upper respiratory allergies temporarily restores freer breathing through the nose promotes nasal and/or sinus drainage temporarily relieves sinus congestion and pressure uuid:29cbbb85-184e-4d75-a178-ebdba117aa22 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1165654 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:443522cb-3f05-44a4-833a-3c7b056879d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c9d8a176-3625-4ec8-9ece-805b7d208925"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:65bcb20f-24bd-4820-98e1-783027d79869"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/bropair-spiromax""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ADVAIR DISKUS is a combination product containing a corticosteroid and a long-acting beta 2 -adrenergic agonist indicated for: Maintenance treatment of asthma in patients aged 4 years and older. (1.1) Maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD). (1.2) Important limitations: Not indicated for patients whose asthma can be managed by inhaled corticosteroids with occasional use of inhaled short-acting beta 2 -agonists. (1.1) Not indicated for the relief of acute bronchospasm. (1.1, 1.2)|[EMA] BroPair Spiromax is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β₂ agonists. uuid:cdfc7661-9828-4efe-a06a-b745167310ee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1165654 biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:67f4c53a-b817-47ca-9bff-d62954bbedcf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6932b24d-b252-4790-b3b9-4f286669cae2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ADVAIR DISKUS is a combination product containing a corticosteroid and a long-acting beta 2 -adrenergic agonist indicated for: Maintenance treatment of asthma in patients aged 4 years and older. (1.1) Maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD). (1.2) Important limitations: Not indicated for patients whose asthma can be managed by inhaled corticosteroids with occasional use of inhaled short-acting beta 2 -agonists. (1.1) Not indicated for the relief of acute bronchospasm. (1.1, 1.2) uuid:dbff2fd5-df33-429b-a120-32df116ff78f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9609 biolink:treats HP:0001257 PMID:41385096 "[{""id"":""uuid:775c92d4-0f97-49bb-9840-e4ffe9226eda"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:10878c48-e86f-4587-ac36-bbe95acd8b0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tizanidine is a short-acting drug for the management of spasticity. Because of the short duration of effect, treatment with tizanidine should be reserved for those daily activities and times when relief of spasticity is most important (see DOSAGE AND ADMINISTRATION ). uuid:4e404973-425b-446c-afc8-5c839c19108a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841598 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:28d998cc-965c-40a3-820d-da2ea0b860df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7d49220e-ba4b-4c33-871d-42f0652df0b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1 INDICATIONS AND USAGE EMBEDA is an extended-release oral formulation of morphine sulfate and naltrexone hydrochloride indicated for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. EMBEDA is NOT intended for use as a prn analgesic. EMBEDA is not indicated for acute/postoperative pain or if the pain is mild or not expected to persist for an extended period of time. EMBEDA is only indicated for postoperative use if the patient is already receiving chronic opioid therapy prior to surgery or if the postoperative pain is expected to be moderate to severe and persist for an extended period of time. Physicians should individualize treatment, moving from parenteral to oral analgesics as appropriate uuid:6ab248f6-1127-4b72-8ff5-23a488a80806 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42797 biolink:treats MONDO:0005027 PMID:41385096 "[{""id"":""uuid:9d917f04-c444-4686-9b21-096620483499"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:eaf16425-981e-4a3b-a78b-9f17012e4aa2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:17415edb-595c-4f5c-8938-2d89786ba028"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Postherpetic Neuralgia Gabapentin is indicated for the management of postherpetic neuralgia in adults. Epilepsy Gabapentin is indicated as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in patients over 12 years of age with epilepsy. Gabapentin is also indicated as adjunctive therapy in the treatment of partial seizures in pediatric patients age 3 – 12 years.|[PMDA] Drugs containing a new active ingredient indicated for use as adjunctive therapy with other antiepileptic drugs to treat partial seizures (including secondarily generalized seizure) in patients with epilepsy, to whom other antiepileptic therapies are not sufficiently effective. uuid:59fd73a0-dd5a-4d0d-b0db-7cb3bf90bd11 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42797 biolink:treats HP:0007359 PMID:41385096 "[{""id"":""uuid:9261d6c2-6f4d-47a6-ace2-14078f07b097"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c6afb3b2-f339-4452-8e2b-c02d889b7389"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ef8ce212-1372-452d-bcbf-449c7baac176"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Postherpetic Neuralgia Gabapentin is indicated for the management of postherpetic neuralgia in adults. Epilepsy Gabapentin is indicated as adjunctive therapy in the treatment of partial seizures with and without secondary generalization in patients over 12 years of age with epilepsy. Gabapentin is also indicated as adjunctive therapy in the treatment of partial seizures in pediatric patients age 3 – 12 years.|[PMDA] Drugs containing a new active ingredient indicated for use as adjunctive therapy with other antiepileptic drugs to treat partial seizures (including secondarily generalized seizure) in patients with epilepsy, to whom other antiepileptic therapies are not sufficiently effective. uuid:30ad0d03-780d-4900-97a9-e80077323c3c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats UMLS:C0275556 PMID:41385096 "[{""id"":""uuid:bae90c2b-2e8e-44f8-a46e-5b223d941b89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0c1e1434-bfcd-4484-b6e1-488c7956f55a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azithromycin is indicated for the treatment of patients with mild to moderate infections (pneumonia: see WARNINGS ) caused by susceptible strains of the designated microorganisms in the specific conditions listed below. As recommended dosages, durations of therapy and applicable patient populations vary among these infections, please see DOSAGE AND ADMINISTRATION for specific dosing recommendations . Adults Acute bacterial exacerbations of chronic obstructive pulmonary disease due to Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae . Acute bacterial sinusitis due to Haemophilus influenzae , Moraxella catarrhalis or Streptococcus pneumoniae . Community -acquired pneumonia due to Chlamydia pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae or Streptococcus pneumoniae in patients appropriate for oral therapy. NOTE: Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomially acquired infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of Streptococcus pyogenes infection and the prophylaxis of rheumatic fever. Azithromycin is often effective in the eradication of susceptible strains of Streptococcus pyogenes from the nasopharynx. Because some strains are resistant to azithromycin, susceptibility tests should be performed when patients are treated with azithromycin. Data establishing efficacy of azithromycin in subsequent prevention of rheumatic fever are not available. Uncomplicated skin and skin structure infections due to Staphylococcus aureus , Streptococcus pyogenes , or Streptococcus agalactiae . Abscesses usually require surgical drainage. Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae . Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. Azithromycin, at the recommended dose, should not be relied upon to treat syphilis. Antimicrobial agents used in high doses for short periods of time to treat non-gonococcal urethritis may mask or delay the symptoms of incubating syphilis. All patients with sexually-transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate cultures for gonorrhea performed at the time of diagnosis. Appropriate antimicrobial therapy and follow-up tests for these diseases should be initiated if infection is confirmed. Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin. Therapy with azithromycin may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly. To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Pediatric Patients (See PRECAUTIONS—Pediatric Use and CLINICAL STUDIES IN PEDIATRIC PATIENTS .) Acute otitis media caused by Haemophilus influenzae , Moraxella catarrhalis or Streptococcus pneumoniae . (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) Community-acquired pneumonia due to Chlamydia pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae or Streptococcus pneumoniae in patients appropriate for oral therapy. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) NOTE: Azithromycin should not be used in pediatric patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomially acquired infections, patients with known or suspected bacteremia, patients requiring hospitalization, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of Streptococcus pyogenes infection and the prophylaxis of rheumatic fever. Azithromycin is often effective in the eradication of susceptible strains of Streptococcus pyogenes from the nasopharynx. Because some strains are resistant to azithromycin, susceptibility tests should be performed when patients are treated with azithromycin. Data establishing efficacy of azithromycin in subsequent prevention of rheumatic fever are not available. Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin. Therapy with azithromycin may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly. uuid:ca23d6ff-e0cf-4042-b6c3-9fda05f78fd1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats MONDO:0002258 PMID:41385096 "[{""id"":""uuid:b14bfec1-e638-43c3-bbc1-a89e52e30462"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:11232324-bc20-416a-a3cf-56bfce4a9c38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azithromycin is indicated for the treatment of patients with mild to moderate infections (pneumonia: see WARNINGS ) caused by susceptible strains of the designated microorganisms in the specific conditions listed below. As recommended dosages, durations of therapy and applicable patient populations vary among these infections, please see DOSAGE AND ADMINISTRATION for specific dosing recommendations . Adults Acute bacterial exacerbations of chronic obstructive pulmonary disease due to Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae . Acute bacterial sinusitis due to Haemophilus influenzae , Moraxella catarrhalis or Streptococcus pneumoniae . Community -acquired pneumonia due to Chlamydia pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae or Streptococcus pneumoniae in patients appropriate for oral therapy. NOTE: Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomially acquired infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of Streptococcus pyogenes infection and the prophylaxis of rheumatic fever. Azithromycin is often effective in the eradication of susceptible strains of Streptococcus pyogenes from the nasopharynx. Because some strains are resistant to azithromycin, susceptibility tests should be performed when patients are treated with azithromycin. Data establishing efficacy of azithromycin in subsequent prevention of rheumatic fever are not available. Uncomplicated skin and skin structure infections due to Staphylococcus aureus , Streptococcus pyogenes , or Streptococcus agalactiae . Abscesses usually require surgical drainage. Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae . Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. Azithromycin, at the recommended dose, should not be relied upon to treat syphilis. Antimicrobial agents used in high doses for short periods of time to treat non-gonococcal urethritis may mask or delay the symptoms of incubating syphilis. All patients with sexually-transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate cultures for gonorrhea performed at the time of diagnosis. Appropriate antimicrobial therapy and follow-up tests for these diseases should be initiated if infection is confirmed. Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin. Therapy with azithromycin may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly. To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Pediatric Patients (See PRECAUTIONS—Pediatric Use and CLINICAL STUDIES IN PEDIATRIC PATIENTS .) Acute otitis media caused by Haemophilus influenzae , Moraxella catarrhalis or Streptococcus pneumoniae . (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) Community-acquired pneumonia due to Chlamydia pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae or Streptococcus pneumoniae in patients appropriate for oral therapy. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) NOTE: Azithromycin should not be used in pediatric patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomially acquired infections, patients with known or suspected bacteremia, patients requiring hospitalization, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of Streptococcus pyogenes infection and the prophylaxis of rheumatic fever. Azithromycin is often effective in the eradication of susceptible strains of Streptococcus pyogenes from the nasopharynx. Because some strains are resistant to azithromycin, susceptibility tests should be performed when patients are treated with azithromycin. Data establishing efficacy of azithromycin in subsequent prevention of rheumatic fever are not available. Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin. Therapy with azithromycin may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly. uuid:0e08ae5b-62eb-4d59-bfa7-1e5a61b2bc17 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats MONDO:0001039 PMID:41385096 "[{""id"":""uuid:b640d9c7-d2d0-493e-bd2a-23f0b176e412"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f59a2beb-5620-4a40-bb8f-f714ef9dc3ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azithromycin is indicated for the treatment of patients with mild to moderate infections (pneumonia: see WARNINGS ) caused by susceptible strains of the designated microorganisms in the specific conditions listed below. As recommended dosages, durations of therapy and applicable patient populations vary among these infections, please see DOSAGE AND ADMINISTRATION for specific dosing recommendations . Adults Acute bacterial exacerbations of chronic obstructive pulmonary disease due to Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae . Acute bacterial sinusitis due to Haemophilus influenzae , Moraxella catarrhalis or Streptococcus pneumoniae . Community -acquired pneumonia due to Chlamydia pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae or Streptococcus pneumoniae in patients appropriate for oral therapy. NOTE: Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomially acquired infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of Streptococcus pyogenes infection and the prophylaxis of rheumatic fever. Azithromycin is often effective in the eradication of susceptible strains of Streptococcus pyogenes from the nasopharynx. Because some strains are resistant to azithromycin, susceptibility tests should be performed when patients are treated with azithromycin. Data establishing efficacy of azithromycin in subsequent prevention of rheumatic fever are not available. Uncomplicated skin and skin structure infections due to Staphylococcus aureus , Streptococcus pyogenes , or Streptococcus agalactiae . Abscesses usually require surgical drainage. Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae . Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. Azithromycin, at the recommended dose, should not be relied upon to treat syphilis. Antimicrobial agents used in high doses for short periods of time to treat non-gonococcal urethritis may mask or delay the symptoms of incubating syphilis. All patients with sexually-transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate cultures for gonorrhea performed at the time of diagnosis. Appropriate antimicrobial therapy and follow-up tests for these diseases should be initiated if infection is confirmed. Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin. Therapy with azithromycin may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly. To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Pediatric Patients (See PRECAUTIONS—Pediatric Use and CLINICAL STUDIES IN PEDIATRIC PATIENTS .) Acute otitis media caused by Haemophilus influenzae , Moraxella catarrhalis or Streptococcus pneumoniae . (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) Community-acquired pneumonia due to Chlamydia pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae or Streptococcus pneumoniae in patients appropriate for oral therapy. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) NOTE: Azithromycin should not be used in pediatric patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomially acquired infections, patients with known or suspected bacteremia, patients requiring hospitalization, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of Streptococcus pyogenes infection and the prophylaxis of rheumatic fever. Azithromycin is often effective in the eradication of susceptible strains of Streptococcus pyogenes from the nasopharynx. Because some strains are resistant to azithromycin, susceptibility tests should be performed when patients are treated with azithromycin. Data establishing efficacy of azithromycin in subsequent prevention of rheumatic fever are not available. Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin. Therapy with azithromycin may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly. uuid:6c9b96e2-cf87-44d4-868a-b0013d837abf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:afc91959-98ec-4f9c-9237-da40f07a4b8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d54e3977-269f-43d9-8a87-104c67e71ede"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azithromycin is indicated for the treatment of patients with mild to moderate infections (pneumonia: see WARNINGS ) caused by susceptible strains of the designated microorganisms in the specific conditions listed below. As recommended dosages, durations of therapy and applicable patient populations vary among these infections, please see DOSAGE AND ADMINISTRATION for specific dosing recommendations . Adults Acute bacterial exacerbations of chronic obstructive pulmonary disease due to Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae . Acute bacterial sinusitis due to Haemophilus influenzae , Moraxella catarrhalis or Streptococcus pneumoniae . Community -acquired pneumonia due to Chlamydia pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae or Streptococcus pneumoniae in patients appropriate for oral therapy. NOTE: Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomially acquired infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of Streptococcus pyogenes infection and the prophylaxis of rheumatic fever. Azithromycin is often effective in the eradication of susceptible strains of Streptococcus pyogenes from the nasopharynx. Because some strains are resistant to azithromycin, susceptibility tests should be performed when patients are treated with azithromycin. Data establishing efficacy of azithromycin in subsequent prevention of rheumatic fever are not available. Uncomplicated skin and skin structure infections due to Staphylococcus aureus , Streptococcus pyogenes , or Streptococcus agalactiae . Abscesses usually require surgical drainage. Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae . Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. Azithromycin, at the recommended dose, should not be relied upon to treat syphilis. Antimicrobial agents used in high doses for short periods of time to treat non-gonococcal urethritis may mask or delay the symptoms of incubating syphilis. All patients with sexually-transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate cultures for gonorrhea performed at the time of diagnosis. Appropriate antimicrobial therapy and follow-up tests for these diseases should be initiated if infection is confirmed. Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin. Therapy with azithromycin may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly. To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Pediatric Patients (See PRECAUTIONS—Pediatric Use and CLINICAL STUDIES IN PEDIATRIC PATIENTS .) Acute otitis media caused by Haemophilus influenzae , Moraxella catarrhalis or Streptococcus pneumoniae . (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) Community-acquired pneumonia due to Chlamydia pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae or Streptococcus pneumoniae in patients appropriate for oral therapy. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) NOTE: Azithromycin should not be used in pediatric patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomially acquired infections, patients with known or suspected bacteremia, patients requiring hospitalization, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of Streptococcus pyogenes infection and the prophylaxis of rheumatic fever. Azithromycin is often effective in the eradication of susceptible strains of Streptococcus pyogenes from the nasopharynx. Because some strains are resistant to azithromycin, susceptibility tests should be performed when patients are treated with azithromycin. Data establishing efficacy of azithromycin in subsequent prevention of rheumatic fever are not available. Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin. Therapy with azithromycin may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly. uuid:57e77e59-d3bc-47bc-bb0c-fd8d2a2e3fc6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats MONDO:0005297 PMID:41385096 "[{""id"":""uuid:1c621fe0-6e71-4656-86b3-0e4f005e374f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:14401aac-b894-49d0-bad7-8945a6c89349"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9e63da4e-7b39-4799-a1a6-4175e90ad39b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azithromycin is indicated for the treatment of patients with mild to moderate infections (pneumonia: see WARNINGS ) caused by susceptible strains of the designated microorganisms in the specific conditions listed below. As recommended dosages, durations of therapy and applicable patient populations vary among these infections, please see DOSAGE AND ADMINISTRATION for specific dosing recommendations . Adults Acute bacterial exacerbations of chronic obstructive pulmonary disease due to Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae . Acute bacterial sinusitis due to Haemophilus influenzae , Moraxella catarrhalis or Streptococcus pneumoniae . Community -acquired pneumonia due to Chlamydia pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae or Streptococcus pneumoniae in patients appropriate for oral therapy. NOTE: Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomially acquired infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of Streptococcus pyogenes infection and the prophylaxis of rheumatic fever. Azithromycin is often effective in the eradication of susceptible strains of Streptococcus pyogenes from the nasopharynx. Because some strains are resistant to azithromycin, susceptibility tests should be performed when patients are treated with azithromycin. Data establishing efficacy of azithromycin in subsequent prevention of rheumatic fever are not available. Uncomplicated skin and skin structure infections due to Staphylococcus aureus , Streptococcus pyogenes , or Streptococcus agalactiae . Abscesses usually require surgical drainage. Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae . Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. Azithromycin, at the recommended dose, should not be relied upon to treat syphilis. Antimicrobial agents used in high doses for short periods of time to treat non-gonococcal urethritis may mask or delay the symptoms of incubating syphilis. All patients with sexually-transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate cultures for gonorrhea performed at the time of diagnosis. Appropriate antimicrobial therapy and follow-up tests for these diseases should be initiated if infection is confirmed. Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin. Therapy with azithromycin may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly. To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Pediatric Patients (See PRECAUTIONS—Pediatric Use and CLINICAL STUDIES IN PEDIATRIC PATIENTS .) Acute otitis media caused by Haemophilus influenzae , Moraxella catarrhalis or Streptococcus pneumoniae . (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) Community-acquired pneumonia due to Chlamydia pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae or Streptococcus pneumoniae in patients appropriate for oral therapy. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) NOTE: Azithromycin should not be used in pediatric patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomially acquired infections, patients with known or suspected bacteremia, patients requiring hospitalization, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of Streptococcus pyogenes infection and the prophylaxis of rheumatic fever. Azithromycin is often effective in the eradication of susceptible strains of Streptococcus pyogenes from the nasopharynx. Because some strains are resistant to azithromycin, susceptibility tests should be performed when patients are treated with azithromycin. Data establishing efficacy of azithromycin in subsequent prevention of rheumatic fever are not available. Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin. Therapy with azithromycin may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly.|[PMDA] Addition of indications for Chlamydia trachomatis, urethritis and uterine cervicitis and to dosage regimen. uuid:e95b75e2-efff-41e8-92d6-6e8acf3b9a47 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats MONDO:0002345 PMID:41385096 "[{""id"":""uuid:53222da6-7ab0-4d74-b7ba-92ce10cdc057"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f2a67edc-29a5-4c5c-94e3-eb7b6d7d02cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:67f1a630-954e-464e-999b-bb9861da0057"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azithromycin is indicated for the treatment of patients with mild to moderate infections (pneumonia: see WARNINGS ) caused by susceptible strains of the designated microorganisms in the specific conditions listed below. As recommended dosages, durations of therapy and applicable patient populations vary among these infections, please see DOSAGE AND ADMINISTRATION for specific dosing recommendations . Adults Acute bacterial exacerbations of chronic obstructive pulmonary disease due to Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae . Acute bacterial sinusitis due to Haemophilus influenzae , Moraxella catarrhalis or Streptococcus pneumoniae . Community -acquired pneumonia due to Chlamydia pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae or Streptococcus pneumoniae in patients appropriate for oral therapy. NOTE: Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomially acquired infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of Streptococcus pyogenes infection and the prophylaxis of rheumatic fever. Azithromycin is often effective in the eradication of susceptible strains of Streptococcus pyogenes from the nasopharynx. Because some strains are resistant to azithromycin, susceptibility tests should be performed when patients are treated with azithromycin. Data establishing efficacy of azithromycin in subsequent prevention of rheumatic fever are not available. Uncomplicated skin and skin structure infections due to Staphylococcus aureus , Streptococcus pyogenes , or Streptococcus agalactiae . Abscesses usually require surgical drainage. Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae . Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. Azithromycin, at the recommended dose, should not be relied upon to treat syphilis. Antimicrobial agents used in high doses for short periods of time to treat non-gonococcal urethritis may mask or delay the symptoms of incubating syphilis. All patients with sexually-transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate cultures for gonorrhea performed at the time of diagnosis. Appropriate antimicrobial therapy and follow-up tests for these diseases should be initiated if infection is confirmed. Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin. Therapy with azithromycin may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly. To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Pediatric Patients (See PRECAUTIONS—Pediatric Use and CLINICAL STUDIES IN PEDIATRIC PATIENTS .) Acute otitis media caused by Haemophilus influenzae , Moraxella catarrhalis or Streptococcus pneumoniae . (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) Community-acquired pneumonia due to Chlamydia pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae or Streptococcus pneumoniae in patients appropriate for oral therapy. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) NOTE: Azithromycin should not be used in pediatric patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomially acquired infections, patients with known or suspected bacteremia, patients requiring hospitalization, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of Streptococcus pyogenes infection and the prophylaxis of rheumatic fever. Azithromycin is often effective in the eradication of susceptible strains of Streptococcus pyogenes from the nasopharynx. Because some strains are resistant to azithromycin, susceptibility tests should be performed when patients are treated with azithromycin. Data establishing efficacy of azithromycin in subsequent prevention of rheumatic fever are not available. Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin. Therapy with azithromycin may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly.|[PMDA] Addition of indications for Chlamydia trachomatis, urethritis and uterine cervicitis and to dosage regimen. uuid:ad0b767a-e243-451c-a71e-650525a03a55 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats MONDO:0001797 PMID:41385096 "[{""id"":""uuid:3bf07cc4-fb0a-4f10-bd9d-36c7f4c484df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9c463446-0585-41ee-afe4-01062e9ffdb9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azithromycin is indicated for the treatment of patients with mild to moderate infections (pneumonia: see WARNINGS ) caused by susceptible strains of the designated microorganisms in the specific conditions listed below. As recommended dosages, durations of therapy and applicable patient populations vary among these infections, please see DOSAGE AND ADMINISTRATION for specific dosing recommendations . Adults Acute bacterial exacerbations of chronic obstructive pulmonary disease due to Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae . Acute bacterial sinusitis due to Haemophilus influenzae , Moraxella catarrhalis or Streptococcus pneumoniae . Community -acquired pneumonia due to Chlamydia pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae or Streptococcus pneumoniae in patients appropriate for oral therapy. NOTE: Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomially acquired infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of Streptococcus pyogenes infection and the prophylaxis of rheumatic fever. Azithromycin is often effective in the eradication of susceptible strains of Streptococcus pyogenes from the nasopharynx. Because some strains are resistant to azithromycin, susceptibility tests should be performed when patients are treated with azithromycin. Data establishing efficacy of azithromycin in subsequent prevention of rheumatic fever are not available. Uncomplicated skin and skin structure infections due to Staphylococcus aureus , Streptococcus pyogenes , or Streptococcus agalactiae . Abscesses usually require surgical drainage. Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae . Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. Azithromycin, at the recommended dose, should not be relied upon to treat syphilis. Antimicrobial agents used in high doses for short periods of time to treat non-gonococcal urethritis may mask or delay the symptoms of incubating syphilis. All patients with sexually-transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate cultures for gonorrhea performed at the time of diagnosis. Appropriate antimicrobial therapy and follow-up tests for these diseases should be initiated if infection is confirmed. Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin. Therapy with azithromycin may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly. To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Pediatric Patients (See PRECAUTIONS—Pediatric Use and CLINICAL STUDIES IN PEDIATRIC PATIENTS .) Acute otitis media caused by Haemophilus influenzae , Moraxella catarrhalis or Streptococcus pneumoniae . (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) Community-acquired pneumonia due to Chlamydia pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae or Streptococcus pneumoniae in patients appropriate for oral therapy. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) NOTE: Azithromycin should not be used in pediatric patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomially acquired infections, patients with known or suspected bacteremia, patients requiring hospitalization, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of Streptococcus pyogenes infection and the prophylaxis of rheumatic fever. Azithromycin is often effective in the eradication of susceptible strains of Streptococcus pyogenes from the nasopharynx. Because some strains are resistant to azithromycin, susceptibility tests should be performed when patients are treated with azithromycin. Data establishing efficacy of azithromycin in subsequent prevention of rheumatic fever are not available. Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin. Therapy with azithromycin may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly. uuid:4dee4623-6903-4511-abb9-a844c57e57ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats HP:0000371 PMID:41385096 "[{""id"":""uuid:a6b790c2-0453-4ae1-bb33-3d58cf3fd028"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5a98fd89-c73e-4801-9e28-66a19feb5501"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azithromycin is indicated for the treatment of patients with mild to moderate infections (pneumonia: see WARNINGS ) caused by susceptible strains of the designated microorganisms in the specific conditions listed below. As recommended dosages, durations of therapy and applicable patient populations vary among these infections, please see DOSAGE AND ADMINISTRATION for specific dosing recommendations . Adults Acute bacterial exacerbations of chronic obstructive pulmonary disease due to Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae . Acute bacterial sinusitis due to Haemophilus influenzae , Moraxella catarrhalis or Streptococcus pneumoniae . Community -acquired pneumonia due to Chlamydia pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae or Streptococcus pneumoniae in patients appropriate for oral therapy. NOTE: Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomially acquired infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of Streptococcus pyogenes infection and the prophylaxis of rheumatic fever. Azithromycin is often effective in the eradication of susceptible strains of Streptococcus pyogenes from the nasopharynx. Because some strains are resistant to azithromycin, susceptibility tests should be performed when patients are treated with azithromycin. Data establishing efficacy of azithromycin in subsequent prevention of rheumatic fever are not available. Uncomplicated skin and skin structure infections due to Staphylococcus aureus , Streptococcus pyogenes , or Streptococcus agalactiae . Abscesses usually require surgical drainage. Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae . Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. Azithromycin, at the recommended dose, should not be relied upon to treat syphilis. Antimicrobial agents used in high doses for short periods of time to treat non-gonococcal urethritis may mask or delay the symptoms of incubating syphilis. All patients with sexually-transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate cultures for gonorrhea performed at the time of diagnosis. Appropriate antimicrobial therapy and follow-up tests for these diseases should be initiated if infection is confirmed. Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin. Therapy with azithromycin may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly. To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Pediatric Patients (See PRECAUTIONS—Pediatric Use and CLINICAL STUDIES IN PEDIATRIC PATIENTS .) Acute otitis media caused by Haemophilus influenzae , Moraxella catarrhalis or Streptococcus pneumoniae . (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) Community-acquired pneumonia due to Chlamydia pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae or Streptococcus pneumoniae in patients appropriate for oral therapy. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) NOTE: Azithromycin should not be used in pediatric patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomially acquired infections, patients with known or suspected bacteremia, patients requiring hospitalization, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of Streptococcus pyogenes infection and the prophylaxis of rheumatic fever. Azithromycin is often effective in the eradication of susceptible strains of Streptococcus pyogenes from the nasopharynx. Because some strains are resistant to azithromycin, susceptibility tests should be performed when patients are treated with azithromycin. Data establishing efficacy of azithromycin in subsequent prevention of rheumatic fever are not available. Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin. Therapy with azithromycin may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly. uuid:00bb1888-ca11-4e49-80db-712cdc807d09 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:101278 biolink:treats MONDO:0005356 PMID:41385096 "[{""id"":""uuid:f723876c-a026-4c0d-8531-d795d80bcded"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3d547b5b-2946-4bc1-93c6-f988fca610c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diltiazem hydrochloride extended-release capsules are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive medications. Diltiazem hydrochloride extended-release capsules are indicated for the management of chronic stable angina and angina due to coronary artery spasm. uuid:fc147aae-32ce-4d87-b939-a27fff344186 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17823 biolink:treats MONDO:0006964 PMID:41385096 "[{""id"":""uuid:c7dab730-404d-4678-b5a8-2ecad974d9f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0ada97cb-fb72-4d6c-b743-bb182e9d2e82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Predialysis Patients Calcitriol is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (C cr 15 to 55 mL/min) not yet on dialysis. In children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. A serum iPTH level of ≥ 100 pg/mL is strongly suggestive of secondary hyperparathyroidism. Dialysis Patients Calcitriol is indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. In these patients, calcitriol administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. Hypoparathydroidism Patients Calcitriol is also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparathyroidism. uuid:4984e0d8-6d67-4485-afeb-5a54e1546edd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17823 biolink:treats MONDO:0800486 PMID:41385096 "[{""id"":""uuid:b5b24d8a-5a47-47da-bbb8-9606b41f9e08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:397c35fb-c471-4abe-9a51-344a8442635d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Predialysis Patients Calcitriol is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (C cr 15 to 55 mL/min) not yet on dialysis. In children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. A serum iPTH level of ≥ 100 pg/mL is strongly suggestive of secondary hyperparathyroidism. Dialysis Patients Calcitriol is indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. In these patients, calcitriol administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. Hypoparathydroidism Patients Calcitriol is also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparathyroidism. uuid:ee191c27-2a20-4830-8b14-a12dad0c3156 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17823 biolink:treats UMLS:C0342342 PMID:41385096 "[{""id"":""uuid:67a5dcac-fa8f-411c-814f-e5d057823035"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f5f38bc3-a2a1-49ba-8ef0-257d20526ea7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Predialysis Patients Calcitriol is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (C cr 15 to 55 mL/min) not yet on dialysis. In children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. A serum iPTH level of ≥ 100 pg/mL is strongly suggestive of secondary hyperparathyroidism. Dialysis Patients Calcitriol is indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. In these patients, calcitriol administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. Hypoparathydroidism Patients Calcitriol is also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparathyroidism. uuid:220375c3-ed2f-4c2b-a26c-00b3322cbb11 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17823 biolink:treats MONDO:0019992 PMID:41385096 "[{""id"":""uuid:7c5d00c5-5388-4692-a7c0-756bdce47230"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:26d8dfa3-dc03-4012-9077-1bed08cb5ae5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Predialysis Patients Calcitriol is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (C cr 15 to 55 mL/min) not yet on dialysis. In children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. A serum iPTH level of ≥ 100 pg/mL is strongly suggestive of secondary hyperparathyroidism. Dialysis Patients Calcitriol is indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. In these patients, calcitriol administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. Hypoparathydroidism Patients Calcitriol is also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparathyroidism. uuid:ca3535bb-b825-4614-b291-852da18adfa7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2567 biolink:treats HP:0002953 PMID:41385096 "[{""id"":""uuid:86cb699b-6915-4b39-9596-3238f423f992"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:74e497e7-ad55-4fa5-99f3-96af79fd76ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FOSAMAX is indicated for: Treatment and prevention of osteoporosis in postmenopausal women For the treatment of osteoporosis, FOSAMAX increases bone mass and reduces the incidence of fractures, including those of the hip and spine (vertebral compression fractures). Osteoporosis may be confirmed by the finding of low bone mass (for example, at least 2 standard deviations below the premenopausal mean) or by the presence or history of osteoporotic fracture. (See CLINICAL PHARMACOLOGY, Pharmacodynamics .) For the prevention of osteoporosis, FOSAMAX may be considered in postmenopausal women who are at risk of developing osteoporosis and for whom the desired clinical outcome is to maintain bone mass and to reduce the risk of future fracture. Bone loss is particularly rapid in postmenopausal women younger than age 60. Risk factors often associated with the development of postmenopausal osteoporosis include early menopause; moderately low bone mass (for example, at least 1 standard deviation below the mean for healthy young adult women); thin body build; Caucasian or Asian race; and family history of osteoporosis. The presence of such risk factors may be important when considering the use of FOSAMAX for prevention of osteoporosis. Treatment to increase bone mass in men with osteoporosis Treatment of glucocorticoid-induced osteoporosis in men and women receiving glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who have low bone mineral density (see PRECAUTIONS, Glucocorticoid-induced osteoporosis ). Patients treated with glucocorticoids should receive adequate amounts of calcium and vitamin D. Treatment of Paget's disease of bone in men and women Treatment is indicated in patients with Paget's disease of bone having alkaline phosphatase at least two times the upper limit of normal, or those who are symptomatic, or those at risk for future complications from their disease. uuid:1a9cd67f-0739-48fa-b4cc-b1b11912d204 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8746 biolink:treats MONDO:0001358 PMID:41385096 "[{""id"":""uuid:061b7bb4-fb58-4b7f-ab8b-6511dc7218df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0206534f-a962-4e32-8686-62ad227ba809"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Xopenex (levalbuterol HCl) Inhalation Solution is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. uuid:7511fc21-bbe3-42c9-85da-977159717726 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8746 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:65aafa78-8d73-455c-abe4-5f717ce0369f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b1398246-fccb-4798-965f-5629ff4276ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Xopenex (levalbuterol HCl) Inhalation Solution is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. uuid:789ffc7b-0872-4d4e-9614-18263c34219b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50749 biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:e82b4ed9-354c-487a-838e-5afa340bd335"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0c5c1823-761f-49fc-b2cc-ea4d7a7db194"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dovonex ® (calcipotriene solution) Scalp Solution, 0.005%, is indicated for the topical treatment of chronic, moderately severe psoriasis of the scalp. The safety and effectiveness of topical calcipotriene in dermatoses other than psoriasis have not been established. uuid:12b3293d-0b03-4ed4-97d3-de4481ba16d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2948 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:db0768c5-417b-422c-93f4-9f42cad90837"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5cb12867-a68a-47e1-b8ca-af24847f946e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:de4d7131-e576-4baa-94d7-1f78547ed2cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/jayempi""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azathioprine tablets are indicated as an adjunct for the prevention of rejection in renal homotransplantation. It is also indicated for the management of active rheumatoid arthritis to reduce signs and symptoms.|[EMA] Jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. Azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression).Jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response.Jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – DMARDs)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidBehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm IgG antibodieschronic refractory idiopathic thrombocytopenic purpuraJayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (IBD) (Crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice.It is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3Jayempi is indicated for the treatment of generalised myasthenia gravis. Depending on the severity of the disease, Jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment. uuid:163ab1dc-dae1-4be0-a43a-56a65a29a480 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:119915 biolink:treats HP:0012532 PMID:41385096 "[{""id"":""uuid:36b2cd3f-1381-4a23-b429-0226595a7630"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e601554a-4e21-49a0-94c0-fce8f95261ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a38a4916-b56a-4fa0-8b73-86c3d4a7c9a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fentanyl transdermal system is indicated for management of persistent, moderate to severe chronic pain that: requires continuous, around-the-clock opioid administration for an extended period of time, and cannot be managed by other means such as non-steroidal analgesics, opioid combination products, or immediate-release opioids Fentanyl transdermal system should ONLY be used in patients who are already receiving opioid therapy, who have demonstrated opioid tolerance, and who require a total daily dose at least equivalent to fentanyl transdermal system 25 mcg/hr (see DOSAGE AND ADMINISTRATION ). Patients who are considered opioid-tolerant are those who have been taking, for a week or longer, at least 60 mg of morphine daily, or at least 30 mg of oral oxycodone daily, or at least 8 mg of oral hydromorphone daily, or an equianalgesic dose of another opioid. Because serious or life-threatening hypoventilation could result, fentanyl transdermal system is contraindicated for use on an as needed basis (i.e., prn), for the management of post-operative or acute pain, or in patients who are not opioid-tolerant or who require opioid analgesia for a short period of time (see BOX WARNING and CONTRAINDICATIONS ). An evaluation of the appropriateness and adequacy of treating with immediate-release opioids is advisable prior to initiating therapy with any modified-release opioid. Prescribers should individualize treatment in every case, initiating therapy at the appropriate point along a progression from non-opioid analgesics, such as non-steroidal anti-inflammatory drugs and acetaminophen, to opioids, in a plan of pain management such as outlined by the World Health Organization, the Agency for Health Research and Quality, the Federation of State Medical Boards Model Policy, or the American Pain Society. Patients should be assessed for their clinical risks for opioid abuse or addiction prior to being prescribed opioids. Patients receiving opioids should be routinely monitored for signs of misuse, abuse, and addiction. Persons at increased risk for opioid abuse include those with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression). Patients at increased risk may still be appropriately treated with modified-release opioid formulations; however these patients will require intensive monitoring for signs of misuse, abuse, or addiction.|[PMDA] Drugs with a new dosage and in additional dosage form indicated for: (1) analgesia in various types of cancer with moderate to severe pain that cannot be managed with non-opioid analgesics or weak opioid analgesics (for use only in patients who switch from other opioid analgesics); or (2) analgesia in moderate to severe chronic pain (for use only in patients who switch from other opioid analgesics). uuid:926a5b1d-182f-4740-9d8a-6d6f6a4c07d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51141 biolink:treats MONDO:0010811 PMID:41385096 "[{""id"":""uuid:a0dbef3e-131c-4b37-bc04-58245c0b3273"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2e9b7ba9-ef75-4760-bf03-59fe71167d52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1 INDICATIONS AND USAGE UROXATRAL is indicated for the treatment of signs and symptoms of benign prostatic hyperplasia. UROXATRAL is not indicated for the treatment of hypertension. 2 DOSAGE AND ADMINISTRATION The recommended dosage is one 10 mg UROXATRAL (alfuzosin HCl) extended-release tablet once daily. The extent of absorption of Uroxatral is 50% lower under fasting conditions. Therefore, Uroxatral should be taken immediately after the same meal each day. The tablets should not be chewed or crushed. 3 DOSAGE FORMS AND STRENGTHS UROXATRAL (alfuzosin HCl) extended-release tablet 10 mg is available as a round, three-layer tablet: one white layer between two yellow layers, debossed with X10. 4 CONTRAINDICATIONS UROXATRAL is contraindicated for use in patients with moderate or severe hepatic impairment (Childs-Pugh categories B and C), since alfuzosin blood levels are increased in these patients. [see Clinical Pharmacology (12.3) ]. UROXATRAL is contraindicated for use with potent CYP3A4 inhibitors such as ketoconazole, itraconazole, and ritonavir, since alfuzosin blood levels are increased. [see Clinical Pharmacology (12.3) ] . UROXATRAL is contraindicated in patients known to be hypersensitive to alfuzosin hydrochloride or any component of UROXATRAL tablets. uuid:6bc63394-31a0-4323-9ba3-b78853cfcb89 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51141 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:1b9b99f7-f438-4b89-936a-0655e8b272e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c6477680-6957-4eec-b7a1-220dd7ed6a88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1 INDICATIONS AND USAGE UROXATRAL is indicated for the treatment of signs and symptoms of benign prostatic hyperplasia. UROXATRAL is not indicated for the treatment of hypertension. 2 DOSAGE AND ADMINISTRATION The recommended dosage is one 10 mg UROXATRAL (alfuzosin HCl) extended-release tablet once daily. The extent of absorption of Uroxatral is 50% lower under fasting conditions. Therefore, Uroxatral should be taken immediately after the same meal each day. The tablets should not be chewed or crushed. 3 DOSAGE FORMS AND STRENGTHS UROXATRAL (alfuzosin HCl) extended-release tablet 10 mg is available as a round, three-layer tablet: one white layer between two yellow layers, debossed with X10. 4 CONTRAINDICATIONS UROXATRAL is contraindicated for use in patients with moderate or severe hepatic impairment (Childs-Pugh categories B and C), since alfuzosin blood levels are increased in these patients. [see Clinical Pharmacology (12.3) ]. UROXATRAL is contraindicated for use with potent CYP3A4 inhibitors such as ketoconazole, itraconazole, and ritonavir, since alfuzosin blood levels are increased. [see Clinical Pharmacology (12.3) ] . UROXATRAL is contraindicated in patients known to be hypersensitive to alfuzosin hydrochloride or any component of UROXATRAL tablets. uuid:796e7b67-90db-4f8d-84b0-02aa394baf15 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51141 biolink:treats UMLS:C0948807 PMID:41385096 "[{""id"":""uuid:50022b07-d091-47c8-a283-d464e1d806f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:20dbff10-5676-4688-9bf8-25cd61ec860d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1 INDICATIONS AND USAGE UROXATRAL is indicated for the treatment of signs and symptoms of benign prostatic hyperplasia. UROXATRAL is not indicated for the treatment of hypertension. 2 DOSAGE AND ADMINISTRATION The recommended dosage is one 10 mg UROXATRAL (alfuzosin HCl) extended-release tablet once daily. The extent of absorption of Uroxatral is 50% lower under fasting conditions. Therefore, Uroxatral should be taken immediately after the same meal each day. The tablets should not be chewed or crushed. 3 DOSAGE FORMS AND STRENGTHS UROXATRAL (alfuzosin HCl) extended-release tablet 10 mg is available as a round, three-layer tablet: one white layer between two yellow layers, debossed with X10. 4 CONTRAINDICATIONS UROXATRAL is contraindicated for use in patients with moderate or severe hepatic impairment (Childs-Pugh categories B and C), since alfuzosin blood levels are increased in these patients. [see Clinical Pharmacology (12.3) ]. UROXATRAL is contraindicated for use with potent CYP3A4 inhibitors such as ketoconazole, itraconazole, and ritonavir, since alfuzosin blood levels are increased. [see Clinical Pharmacology (12.3) ] . UROXATRAL is contraindicated in patients known to be hypersensitive to alfuzosin hydrochloride or any component of UROXATRAL tablets. uuid:07c799a6-5ab4-4bad-a253-272112941a73 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0003634 PMID:41385096 "[{""id"":""uuid:a3a70930-35cb-4d34-b698-66df09657601"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3a8774ea-5185-41f9-a8c1-7f954bb03e98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PredniSONE Tablets are indicated in the following conditions: Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Aspiration pneumonitis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Nervous System Acute exacerbations of multiple sclerosis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:76f74ced-8e66-452d-8b1b-01c678e856cb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0005314 PMID:41385096 "[{""id"":""uuid:a9cc01b4-6d00-4b52-a5c6-5b441aa7084d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:88eb5be1-b128-4c78-a425-c8086de72e07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PredniSONE Tablets are indicated in the following conditions: Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Aspiration pneumonitis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Nervous System Acute exacerbations of multiple sclerosis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:d248618b-891b-4815-9015-9d604f8dbfd3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63631 biolink:treats HP:0007359 PMID:41385096 "[{""id"":""uuid:c4ee3dad-4fb6-4d58-8072-84bf26ffc102"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1c05bfe4-3a7e-4d24-a5d6-1aeb49f14ee4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:8870d176-d0f8-4b0a-98e0-30891d008962"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Topiramate tablets are indicated as initial monotherapy in patients 10 years of age and older with partial onset or primary generalized tonic-clonic seizures. Effectiveness was demonstrated in a controlled trial in patients with epilepsy who had no more than 2 seizures in the 3 months prior to enrollment. Safety and effectiveness in patients who were converted to monotherapy from a previous regimen of other anticonvulsant drugs have not been established in controlled trials.|[PMDA] A drug with a new additional pediatric dosage in an additional dosage form. The drug is indicated for use as an adjunctive therapy with other antiepileptic drugs to treat partial seizures (including secondary generalized seizures) in patients with epilepsy who have not responded sufficiently to other antiepileptic drugs. uuid:3f27a3ae-4524-4019-bf0f-53877b2a022c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63631 biolink:treats MONDO:0005754 PMID:41385096 "[{""id"":""uuid:7292ab34-81f2-4ccc-b5e7-9af1521e9fe7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fec91939-82d3-4947-bd0a-e763c8e50a7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Topiramate tablets are indicated as initial monotherapy in patients 10 years of age and older with partial onset or primary generalized tonic-clonic seizures. Effectiveness was demonstrated in a controlled trial in patients with epilepsy who had no more than 2 seizures in the 3 months prior to enrollment. Safety and effectiveness in patients who were converted to monotherapy from a previous regimen of other anticonvulsant drugs have not been established in controlled trials. uuid:86d661c3-60c4-4b06-bb12-793110a335b1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63631 biolink:treats MONDO:0005027 PMID:41385096 "[{""id"":""uuid:2b36aee5-f1df-4d8c-abbf-4f6313bb9e72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2d8765f7-3b0e-4b58-bf17-089473759fc4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d63ddac8-a443-4ac7-974c-d077d5004d31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Topiramate tablets are indicated as initial monotherapy in patients 10 years of age and older with partial onset or primary generalized tonic-clonic seizures. Effectiveness was demonstrated in a controlled trial in patients with epilepsy who had no more than 2 seizures in the 3 months prior to enrollment. Safety and effectiveness in patients who were converted to monotherapy from a previous regimen of other anticonvulsant drugs have not been established in controlled trials.|[PMDA] A drug with a new additional pediatric dosage in an additional dosage form. The drug is indicated for use as an adjunctive therapy with other antiepileptic drugs to treat partial seizures (including secondary generalized seizures) in patients with epilepsy who have not responded sufficiently to other antiepileptic drugs. uuid:8db641e5-019f-4573-85fd-ea821ff6902f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49575 biolink:treats MONDO:0005618 PMID:41385096 "[{""id"":""uuid:0362d935-4d21-4698-a4e8-f019844e3103"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eba559c0-10e1-4110-8ea5-06b967c824a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diazepam Tablets USP are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. In acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. Diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma), spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia), athetosis, and stiff-man syndrome. Oral diazepam may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy. The effectiveness of diazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. uuid:92125c5f-d88c-4835-8b32-86c3f640c7e2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49575 biolink:treats HP:0000713 PMID:41385096 "[{""id"":""uuid:1def94bc-4a5d-4ee2-958a-b28d6ac74f02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9c9b94fd-4865-4d63-8bd8-cef0fac2fff5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diazepam Tablets USP are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. In acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. Diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma), spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia), athetosis, and stiff-man syndrome. Oral diazepam may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy. The effectiveness of diazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. uuid:1ee969fb-8e93-4c93-b6ea-7af89c7d9717 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49575 biolink:treats HP:0001337 PMID:41385096 "[{""id"":""uuid:76169271-b666-4fd2-965a-bb9dcd5004a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bbc95da5-bc63-464d-b4ce-9af252197953"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diazepam Tablets USP are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. In acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. Diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma), spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia), athetosis, and stiff-man syndrome. Oral diazepam may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy. The effectiveness of diazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. uuid:d0822cb6-3a49-4c3b-bb5f-ee357e440ed6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49575 biolink:treats MONDO:0006642 PMID:41385096 "[{""id"":""uuid:a9ea7ac7-25f6-4d7b-92a5-24cddf77d59e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8ca1c617-ded3-498e-b072-115bbbc3a758"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diazepam Tablets USP are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. In acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. Diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma), spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia), athetosis, and stiff-man syndrome. Oral diazepam may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy. The effectiveness of diazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. uuid:c665d82a-b225-49ba-b8b6-41a090b70c7d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49575 biolink:treats UMLS:C0233777 PMID:41385096 "[{""id"":""uuid:9d2eef58-0e6e-4f74-ae91-b66a827d7a5d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d62041af-05a1-443f-b61f-55604603296d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diazepam Tablets USP are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. In acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. Diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma), spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia), athetosis, and stiff-man syndrome. Oral diazepam may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy. The effectiveness of diazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. uuid:cf96d1ba-c6c5-4cab-8309-327cd16f235d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49575 biolink:treats HP:0003394 PMID:41385096 "[{""id"":""uuid:404ba453-e05c-4d82-a243-0f389c0e9ffd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:33587115-7c72-4e69-a590-5c6f3a6e11f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diazepam Tablets USP are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. In acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. Diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma), spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia), athetosis, and stiff-man syndrome. Oral diazepam may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy. The effectiveness of diazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. uuid:5ef93848-d6af-4b39-bda0-960bbeb66623 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49575 biolink:treats MONDO:0005578 PMID:41385096 "[{""id"":""uuid:346d7a09-9c7c-4013-aaa1-ad4a23e4d9ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0869635a-a7cd-45a1-acde-ee4e8e87343c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diazepam Tablets USP are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. In acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. Diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma), spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia), athetosis, and stiff-man syndrome. Oral diazepam may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy. The effectiveness of diazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. uuid:2dd1a7ba-9aae-440a-9695-1db51f410154 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49575 biolink:treats MONDO:0006497 PMID:41385096 "[{""id"":""uuid:38865936-dcfc-4efc-bb98-2bbfc7a74272"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c4fa1251-b303-4ceb-9b2f-ba87d3764ea1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diazepam Tablets USP are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. In acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. Diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma), spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia), athetosis, and stiff-man syndrome. Oral diazepam may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy. The effectiveness of diazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. uuid:dd3e5521-235d-4dc7-9495-51d05e7f430a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49575 biolink:treats MONDO:0003757 PMID:41385096 "[{""id"":""uuid:317aa76a-4329-43c2-92dc-20f4006d7c84"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:caf2d545-1b86-4f4d-8c6a-7bdf447ecc27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diazepam Tablets USP are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. In acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. Diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma), spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia), athetosis, and stiff-man syndrome. Oral diazepam may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy. The effectiveness of diazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. uuid:e8db03ba-04be-4d35-a701-b423833ead1f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49575 biolink:treats HP:0002305 PMID:41385096 "[{""id"":""uuid:0b2e99a8-0699-409b-be43-8373b2d66e93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0e92249d-6a9c-4d92-ab1e-f9d35606a8c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diazepam Tablets USP are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. In acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. Diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma), spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia), athetosis, and stiff-man syndrome. Oral diazepam may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy. The effectiveness of diazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. uuid:6408bc64-58f4-48b5-b23d-0ef6e8222b46 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49575 biolink:treats MONDO:0008491 PMID:41385096 "[{""id"":""uuid:d73c7128-e3e8-426c-9ff6-36498b742b07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:76484116-d31b-4024-8fb0-7d0860c0c677"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diazepam Tablets USP are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. In acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. Diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma), spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia), athetosis, and stiff-man syndrome. Oral diazepam may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy. The effectiveness of diazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. uuid:28de5665-7a6a-4a6b-b3be-49a6bc92b585 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49575 biolink:treats UMLS:C0234972 PMID:41385096 "[{""id"":""uuid:4897bc5c-f352-4745-b42e-4b19b88a4b55"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:727b43f0-ec88-4792-9b39-99321de97b34"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diazepam Tablets USP are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. In acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. Diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma), spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia), athetosis, and stiff-man syndrome. Oral diazepam may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy. The effectiveness of diazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. uuid:a187f8df-3a48-42af-9428-043e4fdb7e32 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9943 biolink:treats MONDO:0001942 PMID:41385096 "[{""id"":""uuid:07cc7e1d-9a6f-4c63-9a06-179daf1d4c92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:54be0818-4a8f-4100-ac77-98ad83ec6ab5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Major Depressive Disorder Effexor XR (venlafaxine hydrochloride) extended-release capsules is indicated for the treatment of major depressive disorder. The efficacy of Effexor XR in the treatment of major depressive disorder was established in 8- and 12-week controlled trials of adult outpatients whose diagnoses corresponded most closely to the DSM-III-R or DSM-IV category of major depressive disorder (see Clinical Trials ). A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed mood or the loss of interest or pleasure in nearly all activities, representing a change from previous functioning, and includes the presence of at least five of the following nine symptoms during the same two-week period: depressed mood, markedly diminished interest or pleasure in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. The efficacy of Effexor (immediate release) in the treatment of major depressive disorder in adult inpatients meeting diagnostic criteria for major depressive disorder with melancholia was established in a 4-week controlled trial (see Clinical Trials ). The safety and efficacy of Effexor XR in hospitalized depressed patients have not been adequately studied. The efficacy of Effexor XR in maintaining a response in major depressive disorder for up to 26 weeks following 8 weeks of acute treatment was demonstrated in a placebo-controlled trial. The efficacy of Effexor (immediate release) in maintaining a response in patients with recurrent major depressive disorder who had responded and continued to be improved during an initial 26 weeks of treatment and were then followed for a period of up to 52 weeks was demonstrated in a second placebo-controlled trial (see Clinical Trials ). Nevertheless, the physician who elects to use Effexor/Effexor XR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Generalized Anxiety Disorder Effexor XR is indicated for the treatment of Generalized Anxiety Disorder (GAD) as defined in DSM-IV. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The efficacy of Effexor XR in the treatment of GAD was established in 8-week and 6-month placebo-controlled trials in adult outpatients diagnosed with GAD according to DSM-IV criteria (see Clinical Trials ). Generalized Anxiety Disorder (DSM-IV) is characterized by excessive anxiety and worry (apprehensive expectation) that is persistent for at least 6 months and which the person finds difficult to control. It must be associated with at least 3 of the following 6 symptoms: restlessness or feeling keyed up or on edge, being easily fatigued, difficulty concentrating or mind going blank, irritability, muscle tension, sleep disturbance. Although the effectiveness of Effexor XR has been demonstrated in 6-month clinical trials in patients with GAD, the physician who elects to use Effexor XR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Social Anxiety Disorder Effexor XR is indicated for the treatment of Social Anxiety Disorder, also known as Social Phobia, as defined in DSM-IV (300.23). Social Anxiety Disorder (DSM-IV) is characterized by a marked and persistent fear of 1 or more social or performance situations in which the person is exposed to unfamiliar people or to possible scrutiny by others. Exposure to the feared situation almost invariably provokes anxiety, which may approach the intensity of a panic attack. The feared situations are avoided or endured with intense anxiety or distress. The avoidance, anxious anticipation, or distress in the feared situation(s) interferes significantly with the person's normal routine, occupational or academic functioning, or social activities or relationships, or there is a marked distress about having the phobias. Lesser degrees of performance anxiety or shyness generally do not require psychopharmacological treatment. The efficacy of Effexor XR in the treatment of Social Anxiety Disorder was established in four 12-week and one 6-month placebo-controlled trials in adult outpatients with Social Anxiety Disorder (DSM-IV) (see Clinical Trials ). Although the effectiveness of Effexor XR has been demonstrated in a 6-month clinical trial in patients with Social Anxiety Disorder, the physician who elects to use Effexor XR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Panic Disorder Effexor XR is indicated for the treatment of panic disorder, with or without agoraphobia, as defined in DSM-IV. Panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. Panic disorder (DSM-IV) is characterized by recurrent, unexpected panic attacks, ie, a discrete period of intense fear or discomfort, in which four (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: 1) palpitations, pounding heart, or accelerated heart rate; 2) sweating; 3) trembling or shaking; 4) sensations of shortness of breath or smothering; 5) feeling of choking; 6) chest pain or discomfort; 7) nausea or abdominal distress; 8) feeling dizzy, unsteady, lightheaded, or faint; 9) derealization (feelings of unreality) or depersonalization (being detached from oneself); 10) fear of losing control; 11) fear of dying; 12) paresthesias (numbness or tingling sensations); 13) chills or hot flushes. The efficacy of Effexor XR in the treatment of panic disorder was established in two 12-week placebo-controlled trials in adult outpatients with panic disorder (DSM-IV). The efficacy of Effexor XR in prolonging time to relapse in panic disorder among responders following 12 weeks of open-label acute treatment was demonstrated in a placebo-controlled study (see CLINICAL PHARMACOLOGY, Clinical Trials ). Nevertheless, the physician who elects to use Effexor XR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). uuid:fb0033ac-caff-4a1e-9f4e-5177fc7c4f57 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9943 biolink:treats MONDO:0005383 PMID:41385096 "[{""id"":""uuid:410eb699-f40e-455c-bb7a-258ed12b68ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:92398341-cae1-44f3-a541-3576e18acece"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Major Depressive Disorder Effexor XR (venlafaxine hydrochloride) extended-release capsules is indicated for the treatment of major depressive disorder. The efficacy of Effexor XR in the treatment of major depressive disorder was established in 8- and 12-week controlled trials of adult outpatients whose diagnoses corresponded most closely to the DSM-III-R or DSM-IV category of major depressive disorder (see Clinical Trials ). A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed mood or the loss of interest or pleasure in nearly all activities, representing a change from previous functioning, and includes the presence of at least five of the following nine symptoms during the same two-week period: depressed mood, markedly diminished interest or pleasure in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. The efficacy of Effexor (immediate release) in the treatment of major depressive disorder in adult inpatients meeting diagnostic criteria for major depressive disorder with melancholia was established in a 4-week controlled trial (see Clinical Trials ). The safety and efficacy of Effexor XR in hospitalized depressed patients have not been adequately studied. The efficacy of Effexor XR in maintaining a response in major depressive disorder for up to 26 weeks following 8 weeks of acute treatment was demonstrated in a placebo-controlled trial. The efficacy of Effexor (immediate release) in maintaining a response in patients with recurrent major depressive disorder who had responded and continued to be improved during an initial 26 weeks of treatment and were then followed for a period of up to 52 weeks was demonstrated in a second placebo-controlled trial (see Clinical Trials ). Nevertheless, the physician who elects to use Effexor/Effexor XR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Generalized Anxiety Disorder Effexor XR is indicated for the treatment of Generalized Anxiety Disorder (GAD) as defined in DSM-IV. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The efficacy of Effexor XR in the treatment of GAD was established in 8-week and 6-month placebo-controlled trials in adult outpatients diagnosed with GAD according to DSM-IV criteria (see Clinical Trials ). Generalized Anxiety Disorder (DSM-IV) is characterized by excessive anxiety and worry (apprehensive expectation) that is persistent for at least 6 months and which the person finds difficult to control. It must be associated with at least 3 of the following 6 symptoms: restlessness or feeling keyed up or on edge, being easily fatigued, difficulty concentrating or mind going blank, irritability, muscle tension, sleep disturbance. Although the effectiveness of Effexor XR has been demonstrated in 6-month clinical trials in patients with GAD, the physician who elects to use Effexor XR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Social Anxiety Disorder Effexor XR is indicated for the treatment of Social Anxiety Disorder, also known as Social Phobia, as defined in DSM-IV (300.23). Social Anxiety Disorder (DSM-IV) is characterized by a marked and persistent fear of 1 or more social or performance situations in which the person is exposed to unfamiliar people or to possible scrutiny by others. Exposure to the feared situation almost invariably provokes anxiety, which may approach the intensity of a panic attack. The feared situations are avoided or endured with intense anxiety or distress. The avoidance, anxious anticipation, or distress in the feared situation(s) interferes significantly with the person's normal routine, occupational or academic functioning, or social activities or relationships, or there is a marked distress about having the phobias. Lesser degrees of performance anxiety or shyness generally do not require psychopharmacological treatment. The efficacy of Effexor XR in the treatment of Social Anxiety Disorder was established in four 12-week and one 6-month placebo-controlled trials in adult outpatients with Social Anxiety Disorder (DSM-IV) (see Clinical Trials ). Although the effectiveness of Effexor XR has been demonstrated in a 6-month clinical trial in patients with Social Anxiety Disorder, the physician who elects to use Effexor XR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Panic Disorder Effexor XR is indicated for the treatment of panic disorder, with or without agoraphobia, as defined in DSM-IV. Panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. Panic disorder (DSM-IV) is characterized by recurrent, unexpected panic attacks, ie, a discrete period of intense fear or discomfort, in which four (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: 1) palpitations, pounding heart, or accelerated heart rate; 2) sweating; 3) trembling or shaking; 4) sensations of shortness of breath or smothering; 5) feeling of choking; 6) chest pain or discomfort; 7) nausea or abdominal distress; 8) feeling dizzy, unsteady, lightheaded, or faint; 9) derealization (feelings of unreality) or depersonalization (being detached from oneself); 10) fear of losing control; 11) fear of dying; 12) paresthesias (numbness or tingling sensations); 13) chills or hot flushes. The efficacy of Effexor XR in the treatment of panic disorder was established in two 12-week placebo-controlled trials in adult outpatients with panic disorder (DSM-IV). The efficacy of Effexor XR in prolonging time to relapse in panic disorder among responders following 12 weeks of open-label acute treatment was demonstrated in a placebo-controlled study (see CLINICAL PHARMACOLOGY, Clinical Trials ). Nevertheless, the physician who elects to use Effexor XR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). uuid:086f9c1b-ec2d-4548-a7de-3d3b4c0b1eba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9943 biolink:treats MONDO:0044144 PMID:41385096 "[{""id"":""uuid:8f68a2c4-e7a7-4632-a1e4-fbdf5b96519f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fad0610b-7167-4bdc-bb10-d618760d4141"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Major Depressive Disorder Effexor XR (venlafaxine hydrochloride) extended-release capsules is indicated for the treatment of major depressive disorder. The efficacy of Effexor XR in the treatment of major depressive disorder was established in 8- and 12-week controlled trials of adult outpatients whose diagnoses corresponded most closely to the DSM-III-R or DSM-IV category of major depressive disorder (see Clinical Trials ). A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed mood or the loss of interest or pleasure in nearly all activities, representing a change from previous functioning, and includes the presence of at least five of the following nine symptoms during the same two-week period: depressed mood, markedly diminished interest or pleasure in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. The efficacy of Effexor (immediate release) in the treatment of major depressive disorder in adult inpatients meeting diagnostic criteria for major depressive disorder with melancholia was established in a 4-week controlled trial (see Clinical Trials ). The safety and efficacy of Effexor XR in hospitalized depressed patients have not been adequately studied. The efficacy of Effexor XR in maintaining a response in major depressive disorder for up to 26 weeks following 8 weeks of acute treatment was demonstrated in a placebo-controlled trial. The efficacy of Effexor (immediate release) in maintaining a response in patients with recurrent major depressive disorder who had responded and continued to be improved during an initial 26 weeks of treatment and were then followed for a period of up to 52 weeks was demonstrated in a second placebo-controlled trial (see Clinical Trials ). Nevertheless, the physician who elects to use Effexor/Effexor XR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Generalized Anxiety Disorder Effexor XR is indicated for the treatment of Generalized Anxiety Disorder (GAD) as defined in DSM-IV. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The efficacy of Effexor XR in the treatment of GAD was established in 8-week and 6-month placebo-controlled trials in adult outpatients diagnosed with GAD according to DSM-IV criteria (see Clinical Trials ). Generalized Anxiety Disorder (DSM-IV) is characterized by excessive anxiety and worry (apprehensive expectation) that is persistent for at least 6 months and which the person finds difficult to control. It must be associated with at least 3 of the following 6 symptoms: restlessness or feeling keyed up or on edge, being easily fatigued, difficulty concentrating or mind going blank, irritability, muscle tension, sleep disturbance. Although the effectiveness of Effexor XR has been demonstrated in 6-month clinical trials in patients with GAD, the physician who elects to use Effexor XR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Social Anxiety Disorder Effexor XR is indicated for the treatment of Social Anxiety Disorder, also known as Social Phobia, as defined in DSM-IV (300.23). Social Anxiety Disorder (DSM-IV) is characterized by a marked and persistent fear of 1 or more social or performance situations in which the person is exposed to unfamiliar people or to possible scrutiny by others. Exposure to the feared situation almost invariably provokes anxiety, which may approach the intensity of a panic attack. The feared situations are avoided or endured with intense anxiety or distress. The avoidance, anxious anticipation, or distress in the feared situation(s) interferes significantly with the person's normal routine, occupational or academic functioning, or social activities or relationships, or there is a marked distress about having the phobias. Lesser degrees of performance anxiety or shyness generally do not require psychopharmacological treatment. The efficacy of Effexor XR in the treatment of Social Anxiety Disorder was established in four 12-week and one 6-month placebo-controlled trials in adult outpatients with Social Anxiety Disorder (DSM-IV) (see Clinical Trials ). Although the effectiveness of Effexor XR has been demonstrated in a 6-month clinical trial in patients with Social Anxiety Disorder, the physician who elects to use Effexor XR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Panic Disorder Effexor XR is indicated for the treatment of panic disorder, with or without agoraphobia, as defined in DSM-IV. Panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. Panic disorder (DSM-IV) is characterized by recurrent, unexpected panic attacks, ie, a discrete period of intense fear or discomfort, in which four (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: 1) palpitations, pounding heart, or accelerated heart rate; 2) sweating; 3) trembling or shaking; 4) sensations of shortness of breath or smothering; 5) feeling of choking; 6) chest pain or discomfort; 7) nausea or abdominal distress; 8) feeling dizzy, unsteady, lightheaded, or faint; 9) derealization (feelings of unreality) or depersonalization (being detached from oneself); 10) fear of losing control; 11) fear of dying; 12) paresthesias (numbness or tingling sensations); 13) chills or hot flushes. The efficacy of Effexor XR in the treatment of panic disorder was established in two 12-week placebo-controlled trials in adult outpatients with panic disorder (DSM-IV). The efficacy of Effexor XR in prolonging time to relapse in panic disorder among responders following 12 weeks of open-label acute treatment was demonstrated in a placebo-controlled study (see CLINICAL PHARMACOLOGY, Clinical Trials ). Nevertheless, the physician who elects to use Effexor XR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). uuid:dcb0fab7-1326-47c0-aeb8-d4f7a4056059 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8024 biolink:treats MONDO:0021661 PMID:41385096 "[{""id"":""uuid:dfed24e0-4339-4a43-aac0-5ebf2bc3c0da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cd39b366-6364-4a5e-a9f2-f146a6a6a7de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Stable Coronary Artery Disease Perindopril erbumine tablets are indicated in patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or non-fatal myocardial infarction. Perindopril erbumine tablets can be used with conventional treatment for management of coronary artery disease, such as antiplatelet, antihypertensive or lipid-lowering therapy. Hypertension Perindopril erbumine tablets are indicated for the treatment of patients with essential hypertension. Perindopril erbumine tablets may be used alone or given with other classes of antihypertensives, especially thiazide diuretics. When using perindopril erbumine tablets, consideration should be given to the fact that another angiotensin converting enzyme inhibitor (captopril) has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease. Available data are insufficient to determine whether perindopril erbumine tablets has a similar potential. (See WARNINGS .) In considering use of perindopril erbumine tablets, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in nonblacks. In addition, it should be noted that black patients receiving ACE inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to nonblacks. (See WARNINGS : Head and Neck Angioedema .) uuid:fb9e96af-ecfe-445b-afc7-1f709d0bad0e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8024 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:6370c0c4-9f20-4c9d-9f1b-78b1b8346cc2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a17323ef-3e3e-4606-8003-3842da9254a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Stable Coronary Artery Disease Perindopril erbumine tablets are indicated in patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or non-fatal myocardial infarction. Perindopril erbumine tablets can be used with conventional treatment for management of coronary artery disease, such as antiplatelet, antihypertensive or lipid-lowering therapy. Hypertension Perindopril erbumine tablets are indicated for the treatment of patients with essential hypertension. Perindopril erbumine tablets may be used alone or given with other classes of antihypertensives, especially thiazide diuretics. When using perindopril erbumine tablets, consideration should be given to the fact that another angiotensin converting enzyme inhibitor (captopril) has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease. Available data are insufficient to determine whether perindopril erbumine tablets has a similar potential. (See WARNINGS .) In considering use of perindopril erbumine tablets, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in nonblacks. In addition, it should be noted that black patients receiving ACE inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to nonblacks. (See WARNINGS : Head and Neck Angioedema .) uuid:d4d08d04-aa8c-44c7-9fb6-2b4feb07f9ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8024 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:00d917f6-a016-41bb-bc11-ed308d609797"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:06efcd42-13bb-4685-a5e3-89b2f0768b0f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Stable Coronary Artery Disease Perindopril erbumine tablets are indicated in patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or non-fatal myocardial infarction. Perindopril erbumine tablets can be used with conventional treatment for management of coronary artery disease, such as antiplatelet, antihypertensive or lipid-lowering therapy. Hypertension Perindopril erbumine tablets are indicated for the treatment of patients with essential hypertension. Perindopril erbumine tablets may be used alone or given with other classes of antihypertensives, especially thiazide diuretics. When using perindopril erbumine tablets, consideration should be given to the fact that another angiotensin converting enzyme inhibitor (captopril) has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease. Available data are insufficient to determine whether perindopril erbumine tablets has a similar potential. (See WARNINGS .) In considering use of perindopril erbumine tablets, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in nonblacks. In addition, it should be noted that black patients receiving ACE inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to nonblacks. (See WARNINGS : Head and Neck Angioedema .) uuid:535ceae7-4e4c-4b41-b94f-800b0aa26e31 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8024 biolink:treats MONDO:0001134 PMID:41385096 "[{""id"":""uuid:71cb6002-45f2-48ad-8434-3e39f417300e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:922cc6a1-e4f3-4e29-8af5-36151c355e27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Stable Coronary Artery Disease Perindopril erbumine tablets are indicated in patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or non-fatal myocardial infarction. Perindopril erbumine tablets can be used with conventional treatment for management of coronary artery disease, such as antiplatelet, antihypertensive or lipid-lowering therapy. Hypertension Perindopril erbumine tablets are indicated for the treatment of patients with essential hypertension. Perindopril erbumine tablets may be used alone or given with other classes of antihypertensives, especially thiazide diuretics. When using perindopril erbumine tablets, consideration should be given to the fact that another angiotensin converting enzyme inhibitor (captopril) has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease. Available data are insufficient to determine whether perindopril erbumine tablets has a similar potential. (See WARNINGS .) In considering use of perindopril erbumine tablets, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in nonblacks. In addition, it should be noted that black patients receiving ACE inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to nonblacks. (See WARNINGS : Head and Neck Angioedema .) uuid:3fb627b9-3858-4cfe-b9ee-9c346c725379 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8024 biolink:treats MONDO:0001609 PMID:41385096 "[{""id"":""uuid:b839a812-b4bd-4a3e-9de8-8d5977e1392c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eb654d67-8a39-4a65-acf7-2657de526cc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Stable Coronary Artery Disease Perindopril erbumine tablets are indicated in patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or non-fatal myocardial infarction. Perindopril erbumine tablets can be used with conventional treatment for management of coronary artery disease, such as antiplatelet, antihypertensive or lipid-lowering therapy. Hypertension Perindopril erbumine tablets are indicated for the treatment of patients with essential hypertension. Perindopril erbumine tablets may be used alone or given with other classes of antihypertensives, especially thiazide diuretics. When using perindopril erbumine tablets, consideration should be given to the fact that another angiotensin converting enzyme inhibitor (captopril) has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease. Available data are insufficient to determine whether perindopril erbumine tablets has a similar potential. (See WARNINGS .) In considering use of perindopril erbumine tablets, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in nonblacks. In addition, it should be noted that black patients receiving ACE inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to nonblacks. (See WARNINGS : Head and Neck Angioedema .) uuid:4596852f-8987-4bcf-83ca-ded76e255234 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8024 biolink:treats MONDO:0001343 PMID:41385096 "[{""id"":""uuid:62f905ab-ba35-4768-a568-884eac596f5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d2f4e3b8-2e3c-4e28-9403-6bcb2acf5350"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Stable Coronary Artery Disease Perindopril erbumine tablets are indicated in patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or non-fatal myocardial infarction. Perindopril erbumine tablets can be used with conventional treatment for management of coronary artery disease, such as antiplatelet, antihypertensive or lipid-lowering therapy. Hypertension Perindopril erbumine tablets are indicated for the treatment of patients with essential hypertension. Perindopril erbumine tablets may be used alone or given with other classes of antihypertensives, especially thiazide diuretics. When using perindopril erbumine tablets, consideration should be given to the fact that another angiotensin converting enzyme inhibitor (captopril) has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease. Available data are insufficient to determine whether perindopril erbumine tablets has a similar potential. (See WARNINGS .) In considering use of perindopril erbumine tablets, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in nonblacks. In addition, it should be noted that black patients receiving ACE inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to nonblacks. (See WARNINGS : Head and Neck Angioedema .) uuid:d7086c7f-2379-4a91-b190-725f62d8356d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8024 biolink:treats MONDO:0010481 PMID:41385096 "[{""id"":""uuid:ac2f3709-71e8-4fe0-b822-5c790dcf535f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c8361b3a-9ca1-4481-b252-e37b97f5c8e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Stable Coronary Artery Disease Perindopril erbumine tablets are indicated in patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or non-fatal myocardial infarction. Perindopril erbumine tablets can be used with conventional treatment for management of coronary artery disease, such as antiplatelet, antihypertensive or lipid-lowering therapy. Hypertension Perindopril erbumine tablets are indicated for the treatment of patients with essential hypertension. Perindopril erbumine tablets may be used alone or given with other classes of antihypertensives, especially thiazide diuretics. When using perindopril erbumine tablets, consideration should be given to the fact that another angiotensin converting enzyme inhibitor (captopril) has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease. Available data are insufficient to determine whether perindopril erbumine tablets has a similar potential. (See WARNINGS .) In considering use of perindopril erbumine tablets, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in nonblacks. In addition, it should be noted that black patients receiving ACE inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to nonblacks. (See WARNINGS : Head and Neck Angioedema .) uuid:c5c1a042-b41c-40a3-9c34-c46482699ad7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17347 biolink:treats MONDO:0009047 PMID:41385096 "[{""id"":""uuid:5e5a635d-1522-4fa4-ad73-d3c1a0781bd2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fda9318c-780c-42bb-9bf6-ff9863914280"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Testim ® is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired): testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone levels and gonadotropins (FSH, LH) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired): idiopathic gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum levels but have gonadotropins in the normal or low range. Testim ® has not been clinically evaluated in males under 18 years of age. uuid:1a33b158-ed1c-4b29-a7cf-ac760763513d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17347 biolink:treats MONDO:0008573 PMID:41385096 "[{""id"":""uuid:1e4fc792-6d92-4a42-b194-f3f701c53529"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:56e5e397-f4fb-4cb7-b68a-47e696c2eb97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Testim ® is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired): testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone levels and gonadotropins (FSH, LH) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired): idiopathic gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum levels but have gonadotropins in the normal or low range. Testim ® has not been clinically evaluated in males under 18 years of age. uuid:8a0aefab-9fdc-48e7-a676-6e2d95513d6f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17347 biolink:treats MONDO:0006882 PMID:41385096 "[{""id"":""uuid:e5769102-e3fd-4b07-880d-11fa2e4339b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f27afa11-5599-43a4-bf2e-76bed33e91a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Testim ® is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired): testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone levels and gonadotropins (FSH, LH) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired): idiopathic gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum levels but have gonadotropins in the normal or low range. Testim ® has not been clinically evaluated in males under 18 years of age. uuid:544549e0-811a-497d-8587-1499e9efdc34 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats MONDO:1060206 PMID:41385096 "[{""id"":""uuid:cfb6c264-6448-4e2c-a825-99f0ee2faba9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a9ee3f81-2076-4c6e-b9d0-4d5853e76b6d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Carefully consider the potential benefits and risks of diclofenac potassium immediate-release tablets and other treatment options before deciding to use diclofenac potassium immediate-release tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS). Diclofenac potassium immediate-release tablets are indicated: For treatment of primary dysmenorrhea For relief of mild to moderate pain For relief of the signs and symptoms of osteoarthritis For relief of the signs and symptoms of rheumatoid arthritis UMLS:C0149875 uuid:740f23ff-90d4-4de7-b912-e54cde162e2d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:af9e9736-d30f-466b-8302-8cf88f3f61e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1108fbe4-6fd0-41df-a661-d4aae1fde176"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Carefully consider the potential benefits and risks of diclofenac potassium immediate-release tablets and other treatment options before deciding to use diclofenac potassium immediate-release tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS). Diclofenac potassium immediate-release tablets are indicated: For treatment of primary dysmenorrhea For relief of mild to moderate pain For relief of the signs and symptoms of osteoarthritis For relief of the signs and symptoms of rheumatoid arthritis uuid:de2e0374-8598-478a-8e6a-cc54a651a125 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:5378c126-e8ae-4eb8-a90c-1af09f052701"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b5548377-3609-440e-8c87-cb1195bb5b80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Carefully consider the potential benefits and risks of diclofenac sodium delayed-release tablets and other treatment options before deciding to use diclofenac sodium delayed-release tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Diclofenac sodium delayed-release tablets, are indicated: For relief of signs and symptoms of osteoarthritis For relief of signs and symptoms of rheumatoid arthritis For acute or long-term use in the relief of signs and symptoms of ankylosing spondylitis uuid:2a39d302-d9f1-45eb-8b77-a6a3334d9044 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:36791 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:d5ac1dea-f139-4634-950a-1c757e667b1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:95e52e03-da75-4ba7-867d-22f4790f39a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Major Depressive Disorder Lexapro (escitalopram) is indicated for the acute and maintenance treatment of major depressive disorder in adults and in adolescents 12 to 17 years of age [ see Clinical Studies ( 14.1 ) ]. A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. 1.2 Generalized Anxiety Disorder Lexapro is indicated for the acute treatment of Generalized Anxiety Disorder (GAD) in adults [ see Clinical Studies ( 14.2 ) ]. Generalized Anxiety Disorder (DSM-IV) is characterized by excessive anxiety and worry (apprehensive expectation) that is persistent for at least 6 months and which the person finds difficult to control. It must be associated with at least 3 of the following symptoms: restlessness or feeling keyed up or on edge, being easily fatigued, difficulty concentrating or mind going blank, irritability, muscle tension, and sleep disturbance. uuid:4023d6b7-496d-455b-be0f-ee0a1f5ca016 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:36791 biolink:treats MONDO:0001942 PMID:41385096 "[{""id"":""uuid:a395b22f-d0f7-4ff0-a34e-151055606dda"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c9feaeb3-dc42-4bb5-97e9-276d3892cef8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Major Depressive Disorder Lexapro (escitalopram) is indicated for the acute and maintenance treatment of major depressive disorder in adults and in adolescents 12 to 17 years of age [ see Clinical Studies ( 14.1 ) ]. A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. 1.2 Generalized Anxiety Disorder Lexapro is indicated for the acute treatment of Generalized Anxiety Disorder (GAD) in adults [ see Clinical Studies ( 14.2 ) ]. Generalized Anxiety Disorder (DSM-IV) is characterized by excessive anxiety and worry (apprehensive expectation) that is persistent for at least 6 months and which the person finds difficult to control. It must be associated with at least 3 of the following symptoms: restlessness or feeling keyed up or on edge, being easily fatigued, difficulty concentrating or mind going blank, irritability, muscle tension, and sleep disturbance. uuid:5a26bae4-a256-450c-99e3-ea6716cdad15 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:3081207 biolink:treats HP:0012228 PMID:41385096 "[{""id"":""uuid:88f86673-ebd3-44b4-8448-f3a6a1bd64d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f087262c-1b46-428f-845d-e8b5acd09a31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules is indicated for the relief of the symptom complex of tension (or muscle contraction) headache. Evidence supporting the efficacy and safety of Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules in the treatment of multiple recurrent headaches is unavailable. Caution in this regard is required because codeine and butalbital are habit-forming and potentially abusable. uuid:f3c083d6-6d00-423d-9fa8-35677f418e2b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63618 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:13bcc267-413c-41f1-a5b8-77163aacff64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3295accf-08f9-47ca-a51b-e8f595e27e8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with pravastatin sodium tablets should be considered in those individuals at increased risk for atherosclerosis-related clinical events as a function of cholesterol level, the presence or absence of coronary heart disease, and other risk factors. Primary Prevention of Coronary Events In hypercholesterolemic patients without clinically evident coronary heart disease, pravastatin sodium tablets are indicated to: - Reduce the risk of myocardial infarction - Reduce the risk of undergoing myocardial revascularization procedures - Reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes Hyperlipidemia Pravastatin sodium tablets are indicated as an adjunct to diet to reduce elevated Total-C, LDL-C, ApoB, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Type IIa and IIb). 6 Pravastatin sodium tablets are indicated as adjunctive therapy to diet for the treatment of patients with elevated serum triglyceride levels (Fredrickson Type IV). Pravastatin sodium tablets are indicated for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet. Pravastatin sodium tablets are indicated as an adjunct to diet and lifestyle modification for treatment of HeFH in children and adolescent patients ages 8 years and older if after an adequate trial of diet the following findings are present: LDL-C remains greater than or equal to 190 mg/dL or LDL-C remains greater than or equal to 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the patient. Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate (see NCEP Treatment Guidelines below). Prior to initiating therapy with pravastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure Total-C, HDL-C, and TG. For patients with triglycerides (TG) less than 400 mg/dL (less than 4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total-C - HDL-C - 1/5 TG For TG levels greater than 400 mg/dL (greater than 4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In many hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases, HMG-CoA reductase inhibitors are not indicated. Lipid determinations should be performed at intervals of no less than four weeks and dosage adjusted according to the patient’s response to therapy. The National Cholesterol Education Program’s Treatment Guidelines are summarized below: Table 5: NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD a or CHD risk equivalents (10 year risk greater than 20%) less than 100 greater than or equal to 100 greater than or equal to 130 (100 to 129: drug optional) b 2+ Risk factors (10 year risk less than or equal to 20%) less than 130 greater than or equal to 130 10 year risk 10% to 20%: greater than 130 10 year risk less than 10%: greater than or equal to 160 0 to 1 Risk factor c less than 160 greater than or equal to 160 greater than or equal to 190 (160 to 189: LDL- lowering drug optional) a CHD, coronary heart disease. b Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of less than 100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgement also may call for deferring drug therapy in this subcategory. c Almost all people with 0 to 1 risk factor have 10 year risk less than 10%; thus, 10 year risk assessment in people with 0 to 1 risk factor is not necessary. After the LDL-C goal has been achieved, if the TG is still greater than or equal to 200 mg/dL, non-HDL-C (Total-C minus HDL-C) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is greater than or equal to 130 mg/dL (see NCEP Treatment Guidelines , above). Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the Total-C be used to monitor therapy. As with other lipid-lowering therapy, pravastatin sodium tablets are not indicated when hypercholesterolemia is due to hyperalphalipoproteinemia (elevated HDL-C). The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable less than 170 less than 110 Borderline 170 to 199 110 to 129 High greater than or equal to200 greater than or equal to 130 uuid:592ef86b-bdec-4287-a234-f1c28c55e1a5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63618 biolink:treats HP:0003124 PMID:41385096 "[{""id"":""uuid:35c790bd-5636-4f4f-a341-b5f8baa9c457"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:55983fde-0bbd-4b26-a50e-61562fff06d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with pravastatin sodium tablets should be considered in those individuals at increased risk for atherosclerosis-related clinical events as a function of cholesterol level, the presence or absence of coronary heart disease, and other risk factors. Primary Prevention of Coronary Events In hypercholesterolemic patients without clinically evident coronary heart disease, pravastatin sodium tablets are indicated to: - Reduce the risk of myocardial infarction - Reduce the risk of undergoing myocardial revascularization procedures - Reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes Hyperlipidemia Pravastatin sodium tablets are indicated as an adjunct to diet to reduce elevated Total-C, LDL-C, ApoB, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Type IIa and IIb). 6 Pravastatin sodium tablets are indicated as adjunctive therapy to diet for the treatment of patients with elevated serum triglyceride levels (Fredrickson Type IV). Pravastatin sodium tablets are indicated for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet. Pravastatin sodium tablets are indicated as an adjunct to diet and lifestyle modification for treatment of HeFH in children and adolescent patients ages 8 years and older if after an adequate trial of diet the following findings are present: LDL-C remains greater than or equal to 190 mg/dL or LDL-C remains greater than or equal to 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the patient. Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate (see NCEP Treatment Guidelines below). Prior to initiating therapy with pravastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure Total-C, HDL-C, and TG. For patients with triglycerides (TG) less than 400 mg/dL (less than 4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total-C - HDL-C - 1/5 TG For TG levels greater than 400 mg/dL (greater than 4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In many hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases, HMG-CoA reductase inhibitors are not indicated. Lipid determinations should be performed at intervals of no less than four weeks and dosage adjusted according to the patient’s response to therapy. The National Cholesterol Education Program’s Treatment Guidelines are summarized below: Table 5: NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD a or CHD risk equivalents (10 year risk greater than 20%) less than 100 greater than or equal to 100 greater than or equal to 130 (100 to 129: drug optional) b 2+ Risk factors (10 year risk less than or equal to 20%) less than 130 greater than or equal to 130 10 year risk 10% to 20%: greater than 130 10 year risk less than 10%: greater than or equal to 160 0 to 1 Risk factor c less than 160 greater than or equal to 160 greater than or equal to 190 (160 to 189: LDL- lowering drug optional) a CHD, coronary heart disease. b Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of less than 100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgement also may call for deferring drug therapy in this subcategory. c Almost all people with 0 to 1 risk factor have 10 year risk less than 10%; thus, 10 year risk assessment in people with 0 to 1 risk factor is not necessary. After the LDL-C goal has been achieved, if the TG is still greater than or equal to 200 mg/dL, non-HDL-C (Total-C minus HDL-C) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is greater than or equal to 130 mg/dL (see NCEP Treatment Guidelines , above). Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the Total-C be used to monitor therapy. As with other lipid-lowering therapy, pravastatin sodium tablets are not indicated when hypercholesterolemia is due to hyperalphalipoproteinemia (elevated HDL-C). The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable less than 170 less than 110 Borderline 170 to 199 110 to 129 High greater than or equal to200 greater than or equal to 130 uuid:8ae6ceb0-493b-423e-ae22-be11272af3c6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63618 biolink:treats HP:0003119 PMID:41385096 "[{""id"":""uuid:4047d48c-3cd9-4ae2-b48c-0c06db0f44f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d6dbf948-f393-4cfe-8c7e-f65ceb87a3fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with pravastatin sodium tablets should be considered in those individuals at increased risk for atherosclerosis-related clinical events as a function of cholesterol level, the presence or absence of coronary heart disease, and other risk factors. Primary Prevention of Coronary Events In hypercholesterolemic patients without clinically evident coronary heart disease, pravastatin sodium tablets are indicated to: - Reduce the risk of myocardial infarction - Reduce the risk of undergoing myocardial revascularization procedures - Reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes Hyperlipidemia Pravastatin sodium tablets are indicated as an adjunct to diet to reduce elevated Total-C, LDL-C, ApoB, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Type IIa and IIb). 6 Pravastatin sodium tablets are indicated as adjunctive therapy to diet for the treatment of patients with elevated serum triglyceride levels (Fredrickson Type IV). Pravastatin sodium tablets are indicated for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet. Pravastatin sodium tablets are indicated as an adjunct to diet and lifestyle modification for treatment of HeFH in children and adolescent patients ages 8 years and older if after an adequate trial of diet the following findings are present: LDL-C remains greater than or equal to 190 mg/dL or LDL-C remains greater than or equal to 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the patient. Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate (see NCEP Treatment Guidelines below). Prior to initiating therapy with pravastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure Total-C, HDL-C, and TG. For patients with triglycerides (TG) less than 400 mg/dL (less than 4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total-C - HDL-C - 1/5 TG For TG levels greater than 400 mg/dL (greater than 4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In many hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases, HMG-CoA reductase inhibitors are not indicated. Lipid determinations should be performed at intervals of no less than four weeks and dosage adjusted according to the patient’s response to therapy. The National Cholesterol Education Program’s Treatment Guidelines are summarized below: Table 5: NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD a or CHD risk equivalents (10 year risk greater than 20%) less than 100 greater than or equal to 100 greater than or equal to 130 (100 to 129: drug optional) b 2+ Risk factors (10 year risk less than or equal to 20%) less than 130 greater than or equal to 130 10 year risk 10% to 20%: greater than 130 10 year risk less than 10%: greater than or equal to 160 0 to 1 Risk factor c less than 160 greater than or equal to 160 greater than or equal to 190 (160 to 189: LDL- lowering drug optional) a CHD, coronary heart disease. b Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of less than 100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgement also may call for deferring drug therapy in this subcategory. c Almost all people with 0 to 1 risk factor have 10 year risk less than 10%; thus, 10 year risk assessment in people with 0 to 1 risk factor is not necessary. After the LDL-C goal has been achieved, if the TG is still greater than or equal to 200 mg/dL, non-HDL-C (Total-C minus HDL-C) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is greater than or equal to 130 mg/dL (see NCEP Treatment Guidelines , above). Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the Total-C be used to monitor therapy. As with other lipid-lowering therapy, pravastatin sodium tablets are not indicated when hypercholesterolemia is due to hyperalphalipoproteinemia (elevated HDL-C). The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable less than 170 less than 110 Borderline 170 to 199 110 to 129 High greater than or equal to200 greater than or equal to 130 uuid:8629a378-aba7-4f0e-b517-88aefc725cd9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63618 biolink:treats UMLS:C0342879 PMID:41385096 "[{""id"":""uuid:a452d869-a39d-4dba-a225-418cb59a2e26"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c35bb837-6985-4277-87f2-220e71fd4f7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with pravastatin sodium tablets should be considered in those individuals at increased risk for atherosclerosis-related clinical events as a function of cholesterol level, the presence or absence of coronary heart disease, and other risk factors. Primary Prevention of Coronary Events In hypercholesterolemic patients without clinically evident coronary heart disease, pravastatin sodium tablets are indicated to: - Reduce the risk of myocardial infarction - Reduce the risk of undergoing myocardial revascularization procedures - Reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes Hyperlipidemia Pravastatin sodium tablets are indicated as an adjunct to diet to reduce elevated Total-C, LDL-C, ApoB, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Type IIa and IIb). 6 Pravastatin sodium tablets are indicated as adjunctive therapy to diet for the treatment of patients with elevated serum triglyceride levels (Fredrickson Type IV). Pravastatin sodium tablets are indicated for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet. Pravastatin sodium tablets are indicated as an adjunct to diet and lifestyle modification for treatment of HeFH in children and adolescent patients ages 8 years and older if after an adequate trial of diet the following findings are present: LDL-C remains greater than or equal to 190 mg/dL or LDL-C remains greater than or equal to 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the patient. Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate (see NCEP Treatment Guidelines below). Prior to initiating therapy with pravastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure Total-C, HDL-C, and TG. For patients with triglycerides (TG) less than 400 mg/dL (less than 4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total-C - HDL-C - 1/5 TG For TG levels greater than 400 mg/dL (greater than 4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In many hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases, HMG-CoA reductase inhibitors are not indicated. Lipid determinations should be performed at intervals of no less than four weeks and dosage adjusted according to the patient’s response to therapy. The National Cholesterol Education Program’s Treatment Guidelines are summarized below: Table 5: NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD a or CHD risk equivalents (10 year risk greater than 20%) less than 100 greater than or equal to 100 greater than or equal to 130 (100 to 129: drug optional) b 2+ Risk factors (10 year risk less than or equal to 20%) less than 130 greater than or equal to 130 10 year risk 10% to 20%: greater than 130 10 year risk less than 10%: greater than or equal to 160 0 to 1 Risk factor c less than 160 greater than or equal to 160 greater than or equal to 190 (160 to 189: LDL- lowering drug optional) a CHD, coronary heart disease. b Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of less than 100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgement also may call for deferring drug therapy in this subcategory. c Almost all people with 0 to 1 risk factor have 10 year risk less than 10%; thus, 10 year risk assessment in people with 0 to 1 risk factor is not necessary. After the LDL-C goal has been achieved, if the TG is still greater than or equal to 200 mg/dL, non-HDL-C (Total-C minus HDL-C) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is greater than or equal to 130 mg/dL (see NCEP Treatment Guidelines , above). Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the Total-C be used to monitor therapy. As with other lipid-lowering therapy, pravastatin sodium tablets are not indicated when hypercholesterolemia is due to hyperalphalipoproteinemia (elevated HDL-C). The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable less than 170 less than 110 Borderline 170 to 199 110 to 129 High greater than or equal to200 greater than or equal to 130 uuid:b7b93cf9-bfc0-4286-b9ed-cc11f9f395a5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63618 biolink:treats MONDO:0018473 PMID:41385096 "[{""id"":""uuid:62550c0b-aebd-4983-acb8-de45e31ef030"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:467983fc-089f-46ff-8eae-023c2814f636"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with pravastatin sodium tablets should be considered in those individuals at increased risk for atherosclerosis-related clinical events as a function of cholesterol level, the presence or absence of coronary heart disease, and other risk factors. Primary Prevention of Coronary Events In hypercholesterolemic patients without clinically evident coronary heart disease, pravastatin sodium tablets are indicated to: - Reduce the risk of myocardial infarction - Reduce the risk of undergoing myocardial revascularization procedures - Reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes Hyperlipidemia Pravastatin sodium tablets are indicated as an adjunct to diet to reduce elevated Total-C, LDL-C, ApoB, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Type IIa and IIb). 6 Pravastatin sodium tablets are indicated as adjunctive therapy to diet for the treatment of patients with elevated serum triglyceride levels (Fredrickson Type IV). Pravastatin sodium tablets are indicated for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet. Pravastatin sodium tablets are indicated as an adjunct to diet and lifestyle modification for treatment of HeFH in children and adolescent patients ages 8 years and older if after an adequate trial of diet the following findings are present: LDL-C remains greater than or equal to 190 mg/dL or LDL-C remains greater than or equal to 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the patient. Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate (see NCEP Treatment Guidelines below). Prior to initiating therapy with pravastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure Total-C, HDL-C, and TG. For patients with triglycerides (TG) less than 400 mg/dL (less than 4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total-C - HDL-C - 1/5 TG For TG levels greater than 400 mg/dL (greater than 4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In many hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases, HMG-CoA reductase inhibitors are not indicated. Lipid determinations should be performed at intervals of no less than four weeks and dosage adjusted according to the patient’s response to therapy. The National Cholesterol Education Program’s Treatment Guidelines are summarized below: Table 5: NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD a or CHD risk equivalents (10 year risk greater than 20%) less than 100 greater than or equal to 100 greater than or equal to 130 (100 to 129: drug optional) b 2+ Risk factors (10 year risk less than or equal to 20%) less than 130 greater than or equal to 130 10 year risk 10% to 20%: greater than 130 10 year risk less than 10%: greater than or equal to 160 0 to 1 Risk factor c less than 160 greater than or equal to 160 greater than or equal to 190 (160 to 189: LDL- lowering drug optional) a CHD, coronary heart disease. b Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of less than 100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgement also may call for deferring drug therapy in this subcategory. c Almost all people with 0 to 1 risk factor have 10 year risk less than 10%; thus, 10 year risk assessment in people with 0 to 1 risk factor is not necessary. After the LDL-C goal has been achieved, if the TG is still greater than or equal to 200 mg/dL, non-HDL-C (Total-C minus HDL-C) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is greater than or equal to 130 mg/dL (see NCEP Treatment Guidelines , above). Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the Total-C be used to monitor therapy. As with other lipid-lowering therapy, pravastatin sodium tablets are not indicated when hypercholesterolemia is due to hyperalphalipoproteinemia (elevated HDL-C). The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable less than 170 less than 110 Borderline 170 to 199 110 to 129 High greater than or equal to200 greater than or equal to 130 uuid:0c525b7f-2a58-40a3-b367-92641c4a6df4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63618 biolink:treats MONDO:0005420 PMID:41385096 "[{""id"":""uuid:88c95864-7078-48cf-8a57-631876225b45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:02d7f466-27e8-4225-b99f-6aa31fd93d93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with pravastatin sodium tablets should be considered in those individuals at increased risk for atherosclerosis-related clinical events as a function of cholesterol level, the presence or absence of coronary heart disease, and other risk factors. Primary Prevention of Coronary Events In hypercholesterolemic patients without clinically evident coronary heart disease, pravastatin sodium tablets are indicated to: - Reduce the risk of myocardial infarction - Reduce the risk of undergoing myocardial revascularization procedures - Reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes Hyperlipidemia Pravastatin sodium tablets are indicated as an adjunct to diet to reduce elevated Total-C, LDL-C, ApoB, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Type IIa and IIb). 6 Pravastatin sodium tablets are indicated as adjunctive therapy to diet for the treatment of patients with elevated serum triglyceride levels (Fredrickson Type IV). Pravastatin sodium tablets are indicated for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet. Pravastatin sodium tablets are indicated as an adjunct to diet and lifestyle modification for treatment of HeFH in children and adolescent patients ages 8 years and older if after an adequate trial of diet the following findings are present: LDL-C remains greater than or equal to 190 mg/dL or LDL-C remains greater than or equal to 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the patient. Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate (see NCEP Treatment Guidelines below). Prior to initiating therapy with pravastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure Total-C, HDL-C, and TG. For patients with triglycerides (TG) less than 400 mg/dL (less than 4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total-C - HDL-C - 1/5 TG For TG levels greater than 400 mg/dL (greater than 4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In many hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases, HMG-CoA reductase inhibitors are not indicated. Lipid determinations should be performed at intervals of no less than four weeks and dosage adjusted according to the patient’s response to therapy. The National Cholesterol Education Program’s Treatment Guidelines are summarized below: Table 5: NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD a or CHD risk equivalents (10 year risk greater than 20%) less than 100 greater than or equal to 100 greater than or equal to 130 (100 to 129: drug optional) b 2+ Risk factors (10 year risk less than or equal to 20%) less than 130 greater than or equal to 130 10 year risk 10% to 20%: greater than 130 10 year risk less than 10%: greater than or equal to 160 0 to 1 Risk factor c less than 160 greater than or equal to 160 greater than or equal to 190 (160 to 189: LDL- lowering drug optional) a CHD, coronary heart disease. b Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of less than 100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgement also may call for deferring drug therapy in this subcategory. c Almost all people with 0 to 1 risk factor have 10 year risk less than 10%; thus, 10 year risk assessment in people with 0 to 1 risk factor is not necessary. After the LDL-C goal has been achieved, if the TG is still greater than or equal to 200 mg/dL, non-HDL-C (Total-C minus HDL-C) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is greater than or equal to 130 mg/dL (see NCEP Treatment Guidelines , above). Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the Total-C be used to monitor therapy. As with other lipid-lowering therapy, pravastatin sodium tablets are not indicated when hypercholesterolemia is due to hyperalphalipoproteinemia (elevated HDL-C). The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable less than 170 less than 110 Borderline 170 to 199 110 to 129 High greater than or equal to200 greater than or equal to 130 uuid:e45773be-5ad4-4c83-8e81-f4469bbd919c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63618 biolink:treats MONDO:0005377 PMID:41385096 "[{""id"":""uuid:95a7873e-b2d9-41f6-a7bb-2388c3b70caa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:df6fffc1-c81c-4401-b62c-713670fa3e95"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with pravastatin sodium tablets should be considered in those individuals at increased risk for atherosclerosis-related clinical events as a function of cholesterol level, the presence or absence of coronary heart disease, and other risk factors. Primary Prevention of Coronary Events In hypercholesterolemic patients without clinically evident coronary heart disease, pravastatin sodium tablets are indicated to: - Reduce the risk of myocardial infarction - Reduce the risk of undergoing myocardial revascularization procedures - Reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes Hyperlipidemia Pravastatin sodium tablets are indicated as an adjunct to diet to reduce elevated Total-C, LDL-C, ApoB, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Type IIa and IIb). 6 Pravastatin sodium tablets are indicated as adjunctive therapy to diet for the treatment of patients with elevated serum triglyceride levels (Fredrickson Type IV). Pravastatin sodium tablets are indicated for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet. Pravastatin sodium tablets are indicated as an adjunct to diet and lifestyle modification for treatment of HeFH in children and adolescent patients ages 8 years and older if after an adequate trial of diet the following findings are present: LDL-C remains greater than or equal to 190 mg/dL or LDL-C remains greater than or equal to 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the patient. Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate (see NCEP Treatment Guidelines below). Prior to initiating therapy with pravastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure Total-C, HDL-C, and TG. For patients with triglycerides (TG) less than 400 mg/dL (less than 4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total-C - HDL-C - 1/5 TG For TG levels greater than 400 mg/dL (greater than 4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In many hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases, HMG-CoA reductase inhibitors are not indicated. Lipid determinations should be performed at intervals of no less than four weeks and dosage adjusted according to the patient’s response to therapy. The National Cholesterol Education Program’s Treatment Guidelines are summarized below: Table 5: NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD a or CHD risk equivalents (10 year risk greater than 20%) less than 100 greater than or equal to 100 greater than or equal to 130 (100 to 129: drug optional) b 2+ Risk factors (10 year risk less than or equal to 20%) less than 130 greater than or equal to 130 10 year risk 10% to 20%: greater than 130 10 year risk less than 10%: greater than or equal to 160 0 to 1 Risk factor c less than 160 greater than or equal to 160 greater than or equal to 190 (160 to 189: LDL- lowering drug optional) a CHD, coronary heart disease. b Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of less than 100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgement also may call for deferring drug therapy in this subcategory. c Almost all people with 0 to 1 risk factor have 10 year risk less than 10%; thus, 10 year risk assessment in people with 0 to 1 risk factor is not necessary. After the LDL-C goal has been achieved, if the TG is still greater than or equal to 200 mg/dL, non-HDL-C (Total-C minus HDL-C) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is greater than or equal to 130 mg/dL (see NCEP Treatment Guidelines , above). Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the Total-C be used to monitor therapy. As with other lipid-lowering therapy, pravastatin sodium tablets are not indicated when hypercholesterolemia is due to hyperalphalipoproteinemia (elevated HDL-C). The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable less than 170 less than 110 Borderline 170 to 199 110 to 129 High greater than or equal to200 greater than or equal to 130 uuid:f0d7099d-9692-4ee0-93f9-c9d0f30d3922 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63618 biolink:treats UMLS:C0259744 PMID:41385096 "[{""id"":""uuid:cc5e8ba3-396b-4821-86ea-58e48768ddd5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8f40fa74-f848-4057-93d7-f5170cc0474c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with pravastatin sodium tablets should be considered in those individuals at increased risk for atherosclerosis-related clinical events as a function of cholesterol level, the presence or absence of coronary heart disease, and other risk factors. Primary Prevention of Coronary Events In hypercholesterolemic patients without clinically evident coronary heart disease, pravastatin sodium tablets are indicated to: - Reduce the risk of myocardial infarction - Reduce the risk of undergoing myocardial revascularization procedures - Reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes Hyperlipidemia Pravastatin sodium tablets are indicated as an adjunct to diet to reduce elevated Total-C, LDL-C, ApoB, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Type IIa and IIb). 6 Pravastatin sodium tablets are indicated as adjunctive therapy to diet for the treatment of patients with elevated serum triglyceride levels (Fredrickson Type IV). Pravastatin sodium tablets are indicated for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet. Pravastatin sodium tablets are indicated as an adjunct to diet and lifestyle modification for treatment of HeFH in children and adolescent patients ages 8 years and older if after an adequate trial of diet the following findings are present: LDL-C remains greater than or equal to 190 mg/dL or LDL-C remains greater than or equal to 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the patient. Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate (see NCEP Treatment Guidelines below). Prior to initiating therapy with pravastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure Total-C, HDL-C, and TG. For patients with triglycerides (TG) less than 400 mg/dL (less than 4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total-C - HDL-C - 1/5 TG For TG levels greater than 400 mg/dL (greater than 4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In many hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases, HMG-CoA reductase inhibitors are not indicated. Lipid determinations should be performed at intervals of no less than four weeks and dosage adjusted according to the patient’s response to therapy. The National Cholesterol Education Program’s Treatment Guidelines are summarized below: Table 5: NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD a or CHD risk equivalents (10 year risk greater than 20%) less than 100 greater than or equal to 100 greater than or equal to 130 (100 to 129: drug optional) b 2+ Risk factors (10 year risk less than or equal to 20%) less than 130 greater than or equal to 130 10 year risk 10% to 20%: greater than 130 10 year risk less than 10%: greater than or equal to 160 0 to 1 Risk factor c less than 160 greater than or equal to 160 greater than or equal to 190 (160 to 189: LDL- lowering drug optional) a CHD, coronary heart disease. b Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of less than 100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgement also may call for deferring drug therapy in this subcategory. c Almost all people with 0 to 1 risk factor have 10 year risk less than 10%; thus, 10 year risk assessment in people with 0 to 1 risk factor is not necessary. After the LDL-C goal has been achieved, if the TG is still greater than or equal to 200 mg/dL, non-HDL-C (Total-C minus HDL-C) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is greater than or equal to 130 mg/dL (see NCEP Treatment Guidelines , above). Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the Total-C be used to monitor therapy. As with other lipid-lowering therapy, pravastatin sodium tablets are not indicated when hypercholesterolemia is due to hyperalphalipoproteinemia (elevated HDL-C). The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable less than 170 less than 110 Borderline 170 to 199 110 to 129 High greater than or equal to200 greater than or equal to 130 uuid:b1b8f896-80f0-4fce-9087-d676d91719cb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63618 biolink:treats MONDO:0006874 PMID:41385096 "[{""id"":""uuid:05366d95-5767-4a76-b684-116b73547a26"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8ab5b203-6a79-4a04-a558-d59fc3fcbbf1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with pravastatin sodium tablets should be considered in those individuals at increased risk for atherosclerosis-related clinical events as a function of cholesterol level, the presence or absence of coronary heart disease, and other risk factors. Primary Prevention of Coronary Events In hypercholesterolemic patients without clinically evident coronary heart disease, pravastatin sodium tablets are indicated to: - Reduce the risk of myocardial infarction - Reduce the risk of undergoing myocardial revascularization procedures - Reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes Hyperlipidemia Pravastatin sodium tablets are indicated as an adjunct to diet to reduce elevated Total-C, LDL-C, ApoB, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Type IIa and IIb). 6 Pravastatin sodium tablets are indicated as adjunctive therapy to diet for the treatment of patients with elevated serum triglyceride levels (Fredrickson Type IV). Pravastatin sodium tablets are indicated for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet. Pravastatin sodium tablets are indicated as an adjunct to diet and lifestyle modification for treatment of HeFH in children and adolescent patients ages 8 years and older if after an adequate trial of diet the following findings are present: LDL-C remains greater than or equal to 190 mg/dL or LDL-C remains greater than or equal to 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the patient. Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate (see NCEP Treatment Guidelines below). Prior to initiating therapy with pravastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure Total-C, HDL-C, and TG. For patients with triglycerides (TG) less than 400 mg/dL (less than 4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total-C - HDL-C - 1/5 TG For TG levels greater than 400 mg/dL (greater than 4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In many hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases, HMG-CoA reductase inhibitors are not indicated. Lipid determinations should be performed at intervals of no less than four weeks and dosage adjusted according to the patient’s response to therapy. The National Cholesterol Education Program’s Treatment Guidelines are summarized below: Table 5: NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD a or CHD risk equivalents (10 year risk greater than 20%) less than 100 greater than or equal to 100 greater than or equal to 130 (100 to 129: drug optional) b 2+ Risk factors (10 year risk less than or equal to 20%) less than 130 greater than or equal to 130 10 year risk 10% to 20%: greater than 130 10 year risk less than 10%: greater than or equal to 160 0 to 1 Risk factor c less than 160 greater than or equal to 160 greater than or equal to 190 (160 to 189: LDL- lowering drug optional) a CHD, coronary heart disease. b Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of less than 100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgement also may call for deferring drug therapy in this subcategory. c Almost all people with 0 to 1 risk factor have 10 year risk less than 10%; thus, 10 year risk assessment in people with 0 to 1 risk factor is not necessary. After the LDL-C goal has been achieved, if the TG is still greater than or equal to 200 mg/dL, non-HDL-C (Total-C minus HDL-C) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is greater than or equal to 130 mg/dL (see NCEP Treatment Guidelines , above). Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the Total-C be used to monitor therapy. As with other lipid-lowering therapy, pravastatin sodium tablets are not indicated when hypercholesterolemia is due to hyperalphalipoproteinemia (elevated HDL-C). The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable less than 170 less than 110 Borderline 170 to 199 110 to 129 High greater than or equal to200 greater than or equal to 130 uuid:6ed0f289-6f92-49c6-9ce8-2d553c89d3dd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63618 biolink:treats MONDO:0005347 PMID:41385096 "[{""id"":""uuid:44116f0d-adc0-44a7-b9c9-82fc1a688357"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a2cdccb1-0b9a-498f-b36b-167f687a87f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with pravastatin sodium tablets should be considered in those individuals at increased risk for atherosclerosis-related clinical events as a function of cholesterol level, the presence or absence of coronary heart disease, and other risk factors. Primary Prevention of Coronary Events In hypercholesterolemic patients without clinically evident coronary heart disease, pravastatin sodium tablets are indicated to: - Reduce the risk of myocardial infarction - Reduce the risk of undergoing myocardial revascularization procedures - Reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes Hyperlipidemia Pravastatin sodium tablets are indicated as an adjunct to diet to reduce elevated Total-C, LDL-C, ApoB, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Type IIa and IIb). 6 Pravastatin sodium tablets are indicated as adjunctive therapy to diet for the treatment of patients with elevated serum triglyceride levels (Fredrickson Type IV). Pravastatin sodium tablets are indicated for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet. Pravastatin sodium tablets are indicated as an adjunct to diet and lifestyle modification for treatment of HeFH in children and adolescent patients ages 8 years and older if after an adequate trial of diet the following findings are present: LDL-C remains greater than or equal to 190 mg/dL or LDL-C remains greater than or equal to 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the patient. Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate (see NCEP Treatment Guidelines below). Prior to initiating therapy with pravastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure Total-C, HDL-C, and TG. For patients with triglycerides (TG) less than 400 mg/dL (less than 4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total-C - HDL-C - 1/5 TG For TG levels greater than 400 mg/dL (greater than 4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In many hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases, HMG-CoA reductase inhibitors are not indicated. Lipid determinations should be performed at intervals of no less than four weeks and dosage adjusted according to the patient’s response to therapy. The National Cholesterol Education Program’s Treatment Guidelines are summarized below: Table 5: NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD a or CHD risk equivalents (10 year risk greater than 20%) less than 100 greater than or equal to 100 greater than or equal to 130 (100 to 129: drug optional) b 2+ Risk factors (10 year risk less than or equal to 20%) less than 130 greater than or equal to 130 10 year risk 10% to 20%: greater than 130 10 year risk less than 10%: greater than or equal to 160 0 to 1 Risk factor c less than 160 greater than or equal to 160 greater than or equal to 190 (160 to 189: LDL- lowering drug optional) a CHD, coronary heart disease. b Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of less than 100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgement also may call for deferring drug therapy in this subcategory. c Almost all people with 0 to 1 risk factor have 10 year risk less than 10%; thus, 10 year risk assessment in people with 0 to 1 risk factor is not necessary. After the LDL-C goal has been achieved, if the TG is still greater than or equal to 200 mg/dL, non-HDL-C (Total-C minus HDL-C) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is greater than or equal to 130 mg/dL (see NCEP Treatment Guidelines , above). Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the Total-C be used to monitor therapy. As with other lipid-lowering therapy, pravastatin sodium tablets are not indicated when hypercholesterolemia is due to hyperalphalipoproteinemia (elevated HDL-C). The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable less than 170 less than 110 Borderline 170 to 199 110 to 129 High greater than or equal to200 greater than or equal to 130 uuid:b21370a4-6f3d-4f14-8502-254b917eced8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63618 biolink:treats MONDO:0015903 PMID:41385096 "[{""id"":""uuid:cceccb61-a28d-4f5b-a13b-4234d041677d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1fc0a3cc-bb66-4359-a98c-813d15e9d770"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with pravastatin sodium tablets should be considered in those individuals at increased risk for atherosclerosis-related clinical events as a function of cholesterol level, the presence or absence of coronary heart disease, and other risk factors. Primary Prevention of Coronary Events In hypercholesterolemic patients without clinically evident coronary heart disease, pravastatin sodium tablets are indicated to: - Reduce the risk of myocardial infarction - Reduce the risk of undergoing myocardial revascularization procedures - Reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes Hyperlipidemia Pravastatin sodium tablets are indicated as an adjunct to diet to reduce elevated Total-C, LDL-C, ApoB, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Type IIa and IIb). 6 Pravastatin sodium tablets are indicated as adjunctive therapy to diet for the treatment of patients with elevated serum triglyceride levels (Fredrickson Type IV). Pravastatin sodium tablets are indicated for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet. Pravastatin sodium tablets are indicated as an adjunct to diet and lifestyle modification for treatment of HeFH in children and adolescent patients ages 8 years and older if after an adequate trial of diet the following findings are present: LDL-C remains greater than or equal to 190 mg/dL or LDL-C remains greater than or equal to 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the patient. Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate (see NCEP Treatment Guidelines below). Prior to initiating therapy with pravastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure Total-C, HDL-C, and TG. For patients with triglycerides (TG) less than 400 mg/dL (less than 4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total-C - HDL-C - 1/5 TG For TG levels greater than 400 mg/dL (greater than 4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In many hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases, HMG-CoA reductase inhibitors are not indicated. Lipid determinations should be performed at intervals of no less than four weeks and dosage adjusted according to the patient’s response to therapy. The National Cholesterol Education Program’s Treatment Guidelines are summarized below: Table 5: NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD a or CHD risk equivalents (10 year risk greater than 20%) less than 100 greater than or equal to 100 greater than or equal to 130 (100 to 129: drug optional) b 2+ Risk factors (10 year risk less than or equal to 20%) less than 130 greater than or equal to 130 10 year risk 10% to 20%: greater than 130 10 year risk less than 10%: greater than or equal to 160 0 to 1 Risk factor c less than 160 greater than or equal to 160 greater than or equal to 190 (160 to 189: LDL- lowering drug optional) a CHD, coronary heart disease. b Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of less than 100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgement also may call for deferring drug therapy in this subcategory. c Almost all people with 0 to 1 risk factor have 10 year risk less than 10%; thus, 10 year risk assessment in people with 0 to 1 risk factor is not necessary. After the LDL-C goal has been achieved, if the TG is still greater than or equal to 200 mg/dL, non-HDL-C (Total-C minus HDL-C) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is greater than or equal to 130 mg/dL (see NCEP Treatment Guidelines , above). Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the Total-C be used to monitor therapy. As with other lipid-lowering therapy, pravastatin sodium tablets are not indicated when hypercholesterolemia is due to hyperalphalipoproteinemia (elevated HDL-C). The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable less than 170 less than 110 Borderline 170 to 199 110 to 129 High greater than or equal to200 greater than or equal to 130 uuid:367d50f6-e664-4154-8cac-922bc2c59c51 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135931 biolink:treats UMLS:C0267055 PMID:41385096 "[{""id"":""uuid:c5979899-8484-4080-bdb2-da4f7eefbb5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:126fd81b-003d-40ad-8f51-101e5f07eef2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Healing of Erosive Esophagitis KAPIDEX is indicated for healing of all grades of erosive esophagitis (EE) for up to 8 weeks. 1.2 Maintenance of Healed Erosive Esophagitis KAPIDEX is indicated to maintain healing of EE for up to 6 months. 1.3 Symptomatic Non-Erosive Gastroesophageal Reflux Disease KAPIDEX is indicated for the treatment of heartburn associated with non-erosive gastroesophageal reflux disease (GERD) for 4 weeks. uuid:25b7cf61-f31c-4136-aafc-a0f3cd561b20 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:63785457-7a9b-4cff-9cd8-9321303d3ab1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6014426c-1200-45cb-b1dc-b84e87344fe1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp.) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis or ornithosis caused by Chlamydia Psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Calymmatobacterium granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes, Shigella sp., Acinetobacter sp., Klebsiella sp., and Bacteroides sp. In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , infections caused by Neisseria gonorrhoeae , anthrax caused by Bacillus anthracis , infections due to Listeria monocytogenes , actinomycosis caused by Actinomyces species, infections due to Clostridium species. uuid:ae9efc57-ae11-4c6e-a528-166c70cb27b0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:6d44c987-7a28-4ce1-805a-2ec07abbd05f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:134a0e1b-ed04-4489-bda5-c87dd1fae8a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp.) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis or ornithosis caused by Chlamydia Psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Calymmatobacterium granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes, Shigella sp., Acinetobacter sp., Klebsiella sp., and Bacteroides sp. In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , infections caused by Neisseria gonorrhoeae , anthrax caused by Bacillus anthracis , infections due to Listeria monocytogenes , actinomycosis caused by Actinomyces species, infections due to Clostridium species. uuid:4ff34e86-12ac-40da-a59f-b2802830c770 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0019359 PMID:41385096 "[{""id"":""uuid:d999a41a-b68d-408b-8032-a217f3962aae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e6fb5b24-b3ea-47f0-87d4-a455e4790ec6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp.) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis or ornithosis caused by Chlamydia Psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Calymmatobacterium granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes, Shigella sp., Acinetobacter sp., Klebsiella sp., and Bacteroides sp. In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , infections caused by Neisseria gonorrhoeae , anthrax caused by Bacillus anthracis , infections due to Listeria monocytogenes , actinomycosis caused by Actinomyces species, infections due to Clostridium species. uuid:afd7a592-f1d6-4f3b-b062-df3a961522b8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0001246 PMID:41385096 "[{""id"":""uuid:b88c2d95-b751-417f-a6e6-3403408c60b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d075023e-8dea-4b1a-acc1-0e874396e4c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp.) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis or ornithosis caused by Chlamydia Psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Calymmatobacterium granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes, Shigella sp., Acinetobacter sp., Klebsiella sp., and Bacteroides sp. In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , infections caused by Neisseria gonorrhoeae , anthrax caused by Bacillus anthracis , infections due to Listeria monocytogenes , actinomycosis caused by Actinomyces species, infections due to Clostridium species. uuid:5b6f64f6-8495-4eec-9ac0-3d1d200b1083 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0019186 PMID:41385096 "[{""id"":""uuid:431192be-2963-4acf-acf1-fda535d2940c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e92b9d05-4cc9-4992-aade-274e2671f8ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp.) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis or ornithosis caused by Chlamydia Psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Calymmatobacterium granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes, Shigella sp., Acinetobacter sp., Klebsiella sp., and Bacteroides sp. In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , infections caused by Neisseria gonorrhoeae , anthrax caused by Bacillus anthracis , infections due to Listeria monocytogenes , actinomycosis caused by Actinomyces species, infections due to Clostridium species. uuid:c42414a9-088c-4742-8c7a-d39324b98f09 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0019360 PMID:41385096 "[{""id"":""uuid:23c2ff07-19ee-4144-bb57-237e63574e3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4c3567af-0945-4c3c-9cf9-ef5367772b2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp.) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis or ornithosis caused by Chlamydia Psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Calymmatobacterium granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes, Shigella sp., Acinetobacter sp., Klebsiella sp., and Bacteroides sp. In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , infections caused by Neisseria gonorrhoeae , anthrax caused by Bacillus anthracis , infections due to Listeria monocytogenes , actinomycosis caused by Actinomyces species, infections due to Clostridium species. uuid:724f40c0-603c-43ed-b4ef-9b73ef7028d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0005888 PMID:41385096 "[{""id"":""uuid:3ec0d20c-0785-4052-bbd1-38727c818492"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:726c6a00-4b53-46e9-b0fd-faf3f374d40d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp.) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis or ornithosis caused by Chlamydia Psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Calymmatobacterium granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes, Shigella sp., Acinetobacter sp., Klebsiella sp., and Bacteroides sp. In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , infections caused by Neisseria gonorrhoeae , anthrax caused by Bacillus anthracis , infections due to Listeria monocytogenes , actinomycosis caused by Actinomyces species, infections due to Clostridium species. uuid:4583ff61-35f7-4e56-9214-22d4978d4e04 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0005808 PMID:41385096 "[{""id"":""uuid:cb681b23-b624-4fc3-bcb5-6a3aa8257318"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2e071aab-271b-4793-a5df-3ac390cdbccb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp.) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis or ornithosis caused by Chlamydia Psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Calymmatobacterium granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes, Shigella sp., Acinetobacter sp., Klebsiella sp., and Bacteroides sp. In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , infections caused by Neisseria gonorrhoeae , anthrax caused by Bacillus anthracis , infections due to Listeria monocytogenes , actinomycosis caused by Actinomyces species, infections due to Clostridium species. uuid:12090978-ccf1-4fc8-8e5d-7b071c122aab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0001249 PMID:41385096 "[{""id"":""uuid:e2dd24c6-60bf-4f47-8c95-d440cbe91ae3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:22c1b48f-840f-4d0d-a6b3-eb51d6b8269d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp.) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis or ornithosis caused by Chlamydia Psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Calymmatobacterium granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes, Shigella sp., Acinetobacter sp., Klebsiella sp., and Bacteroides sp. In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , infections caused by Neisseria gonorrhoeae , anthrax caused by Bacillus anthracis , infections due to Listeria monocytogenes , actinomycosis caused by Actinomyces species, infections due to Clostridium species. uuid:fd7f3ee9-63cc-4216-ba54-3a03bfe5b6d3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0005834 PMID:41385096 "[{""id"":""uuid:c98b1b65-a46b-4cdf-b875-6338f010c3b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bb60da43-d3db-4b57-aba7-989dd4d81df9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp.) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis or ornithosis caused by Chlamydia Psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Calymmatobacterium granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes, Shigella sp., Acinetobacter sp., Klebsiella sp., and Bacteroides sp. In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , infections caused by Neisseria gonorrhoeae , anthrax caused by Bacillus anthracis , infections due to Listeria monocytogenes , actinomycosis caused by Actinomyces species, infections due to Clostridium species. uuid:d89516f2-007b-48b2-8d1d-3af750749a09 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0005777 PMID:41385096 "[{""id"":""uuid:b36c7ff8-57af-4b87-b937-85832455f773"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:022e8f3d-ea87-4cda-be93-470c37498a76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp.) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis or ornithosis caused by Chlamydia Psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Calymmatobacterium granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes, Shigella sp., Acinetobacter sp., Klebsiella sp., and Bacteroides sp. In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , infections caused by Neisseria gonorrhoeae , anthrax caused by Bacillus anthracis , infections due to Listeria monocytogenes , actinomycosis caused by Actinomyces species, infections due to Clostridium species. uuid:b7ab0eca-2bc1-4588-9d75-9803ee4675ad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0019633 PMID:41385096 "[{""id"":""uuid:6433ef8d-f328-456b-9761-11eb9b46a461"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:185a0311-cdfe-4c38-aad5-2f5cbf655e58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp.) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis or ornithosis caused by Chlamydia Psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Calymmatobacterium granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes, Shigella sp., Acinetobacter sp., Klebsiella sp., and Bacteroides sp. In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , infections caused by Neisseria gonorrhoeae , anthrax caused by Bacillus anthracis , infections due to Listeria monocytogenes , actinomycosis caused by Actinomyces species, infections due to Clostridium species. uuid:9c859773-2faa-45d7-814a-8054bdf43f66 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0005664 PMID:41385096 "[{""id"":""uuid:d90e30f0-10c2-496b-aeca-c533f0b1c025"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0df2e518-376c-4074-ac5e-55fe681fe893"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp.) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis or ornithosis caused by Chlamydia Psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Calymmatobacterium granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes, Shigella sp., Acinetobacter sp., Klebsiella sp., and Bacteroides sp. In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , infections caused by Neisseria gonorrhoeae , anthrax caused by Bacillus anthracis , infections due to Listeria monocytogenes , actinomycosis caused by Actinomyces species, infections due to Clostridium species. uuid:50352a31-84e1-4880-9b7f-5bccdf508df4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0001797 PMID:41385096 "[{""id"":""uuid:856622f5-4b24-421b-98a6-3027af5ad467"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:54d3bd69-012a-4cc4-a4dc-021aa13f273d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp.) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis or ornithosis caused by Chlamydia Psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Calymmatobacterium granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes, Shigella sp., Acinetobacter sp., Klebsiella sp., and Bacteroides sp. In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , infections caused by Neisseria gonorrhoeae , anthrax caused by Bacillus anthracis , infections due to Listeria monocytogenes , actinomycosis caused by Actinomyces species, infections due to Clostridium species. uuid:60cb8f16-9272-49f0-89a0-3b21ec6797d4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0018077 PMID:41385096 "[{""id"":""uuid:fb940bfc-2cba-4463-9967-67929827beb4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:19195002-98d8-4c20-b82e-d248731c4e11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp.) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis or ornithosis caused by Chlamydia Psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Calymmatobacterium granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes, Shigella sp., Acinetobacter sp., Klebsiella sp., and Bacteroides sp. In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , infections caused by Neisseria gonorrhoeae , anthrax caused by Bacillus anthracis , infections due to Listeria monocytogenes , actinomycosis caused by Actinomyces species, infections due to Clostridium species. uuid:9fdadacd-06cb-4a7c-80c9-18fff4aa62f9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0015766 PMID:41385096 "[{""id"":""uuid:16cc6589-1e28-431f-9fa7-7541698f62bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d8a20e6d-1d7d-4d3b-8ad3-3b1c040ae25a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp.) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis or ornithosis caused by Chlamydia Psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Calymmatobacterium granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes, Shigella sp., Acinetobacter sp., Klebsiella sp., and Bacteroides sp. In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , infections caused by Neisseria gonorrhoeae , anthrax caused by Bacillus anthracis , infections due to Listeria monocytogenes , actinomycosis caused by Actinomyces species, infections due to Clostridium species. uuid:59ce7a42-0baf-4dc9-9bdf-08783d2176c2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0005683 PMID:41385096 "[{""id"":""uuid:6222ce8e-6eb8-4640-9e1d-89480d00cb84"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:62911088-3451-40c2-aa4e-e7b642fd5d2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp.) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis or ornithosis caused by Chlamydia Psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Calymmatobacterium granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes, Shigella sp., Acinetobacter sp., Klebsiella sp., and Bacteroides sp. In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , infections caused by Neisseria gonorrhoeae , anthrax caused by Bacillus anthracis , infections due to Listeria monocytogenes , actinomycosis caused by Actinomyces species, infections due to Clostridium species. uuid:cd3d1b7d-6535-4f86-8abd-34e0da9fd631 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0005644 PMID:41385096 "[{""id"":""uuid:01211c21-78b1-4248-b9f3-9d023b9a0f13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f34464c7-d579-4d6d-afc4-58ec7f19d933"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp.) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis or ornithosis caused by Chlamydia Psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Calymmatobacterium granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes, Shigella sp., Acinetobacter sp., Klebsiella sp., and Bacteroides sp. In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , infections caused by Neisseria gonorrhoeae , anthrax caused by Bacillus anthracis , infections due to Listeria monocytogenes , actinomycosis caused by Actinomyces species, infections due to Clostridium species. uuid:241c3473-03d5-4ad6-a9e6-a390481742d9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:1872d1de-221c-48aa-8857-a01f3413664c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e266789a-a10a-41e8-af0d-22cb2ad089a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp.) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis or ornithosis caused by Chlamydia Psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Calymmatobacterium granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes, Shigella sp., Acinetobacter sp., Klebsiella sp., and Bacteroides sp. In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , infections caused by Neisseria gonorrhoeae , anthrax caused by Bacillus anthracis , infections due to Listeria monocytogenes , actinomycosis caused by Actinomyces species, infections due to Clostridium species. uuid:6bd3cd70-559c-4936-9b93-7113c228a472 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:d894d737-8483-4fc1-8701-0c755c0cc0cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:82945865-54f3-4383-9c5b-b4fbbfa25f23"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp.) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis or ornithosis caused by Chlamydia Psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Calymmatobacterium granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes, Shigella sp., Acinetobacter sp., Klebsiella sp., and Bacteroides sp. In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , infections caused by Neisseria gonorrhoeae , anthrax caused by Bacillus anthracis , infections due to Listeria monocytogenes , actinomycosis caused by Actinomyces species, infections due to Clostridium species. uuid:1f426e5d-bc29-4378-870d-0340e4fc2da5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0005976 PMID:41385096 "[{""id"":""uuid:f35e8114-5350-440e-9419-a87e1fb6b1d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0d8c9724-ef73-41f0-99f1-0c83f849bf41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp.) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis or ornithosis caused by Chlamydia Psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Calymmatobacterium granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes, Shigella sp., Acinetobacter sp., Klebsiella sp., and Bacteroides sp. In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , infections caused by Neisseria gonorrhoeae , anthrax caused by Bacillus anthracis , infections due to Listeria monocytogenes , actinomycosis caused by Actinomyces species, infections due to Clostridium species. uuid:deeb34a8-ea5b-4da4-9863-714c9931e14a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0006019 PMID:41385096 "[{""id"":""uuid:5ebe18f2-5ae3-4da2-af51-d03fd28dc092"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3e750494-583e-49f1-a4fb-c34a110f11af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp.) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis or ornithosis caused by Chlamydia Psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Calymmatobacterium granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes, Shigella sp., Acinetobacter sp., Klebsiella sp., and Bacteroides sp. In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , infections caused by Neisseria gonorrhoeae , anthrax caused by Bacillus anthracis , infections due to Listeria monocytogenes , actinomycosis caused by Actinomyces species, infections due to Clostridium species. uuid:a85598cf-801e-47a7-801f-7b6e70136700 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0005119 PMID:41385096 "[{""id"":""uuid:c65efe48-cc2e-40f1-98f3-54dc1f8526ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:57c5f4d4-a11f-4d10-9778-9fff2135109e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp.) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis or ornithosis caused by Chlamydia Psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Calymmatobacterium granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes, Shigella sp., Acinetobacter sp., Klebsiella sp., and Bacteroides sp. In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , infections caused by Neisseria gonorrhoeae , anthrax caused by Bacillus anthracis , infections due to Listeria monocytogenes , actinomycosis caused by Actinomyces species, infections due to Clostridium species. uuid:81a50563-5d2c-444b-b941-bf3e1fd580bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0005631 PMID:41385096 "[{""id"":""uuid:1406d312-ece7-445b-be1a-cd442ccc5dd8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9aee20d6-ddc3-44ca-8527-a30d652a1e04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp.) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis or ornithosis caused by Chlamydia Psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Calymmatobacterium granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes, Shigella sp., Acinetobacter sp., Klebsiella sp., and Bacteroides sp. In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , infections caused by Neisseria gonorrhoeae , anthrax caused by Bacillus anthracis , infections due to Listeria monocytogenes , actinomycosis caused by Actinomyces species, infections due to Clostridium species. uuid:822376cd-b924-4d8d-a711-1c1925ae8893 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7476 biolink:treats MONDO:0004857 PMID:41385096 "[{""id"":""uuid:b23c643c-f66b-47a5-8e36-710afc60dd7c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a4ef5a7c-5682-4a00-a684-e67a2fb9cd6d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of naproxen, naproxen sodium and other treatment options before deciding to use naproxen and naproxen sodium tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Naproxen as naproxen or naproxen sodium tablets are indicated: For the relief of the signs and symptoms of rheumatoid arthritis For the relief of the signs and symptoms of osteoarthritis For the relief of the signs and symptoms of ankylosing spondylitis For the relief of the signs and symptoms of juvenile arthritis Naproxen as naproxen suspension is recommended for juvenile rheumatoid arthritis in order to obtain the maximum dosage flexibility based on the patient’s weight. Naproxen as naproxen and naproxen sodium tablets are also indicated: For relief of the signs and symptoms of tendonitis For relief of the signs and symptoms of bursitis For relief of the signs and symptoms of acute gout For the management of pain For the management of primary dysmenorrhea uuid:73148cc5-e338-48e4-81de-78c939e8e520 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7476 biolink:treats MONDO:0002471 PMID:41385096 "[{""id"":""uuid:f67caf70-e44d-43d3-877a-7269e5fba768"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1deea39b-493c-431a-a09a-46e564385bab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of naproxen, naproxen sodium and other treatment options before deciding to use naproxen and naproxen sodium tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Naproxen as naproxen or naproxen sodium tablets are indicated: For the relief of the signs and symptoms of rheumatoid arthritis For the relief of the signs and symptoms of osteoarthritis For the relief of the signs and symptoms of ankylosing spondylitis For the relief of the signs and symptoms of juvenile arthritis Naproxen as naproxen suspension is recommended for juvenile rheumatoid arthritis in order to obtain the maximum dosage flexibility based on the patient’s weight. Naproxen as naproxen and naproxen sodium tablets are also indicated: For relief of the signs and symptoms of tendonitis For relief of the signs and symptoms of bursitis For relief of the signs and symptoms of acute gout For the management of pain For the management of primary dysmenorrhea uuid:6194ecc4-ed4c-4fc5-a329-f31bb14e83ad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7476 biolink:treats MONDO:0005393 PMID:41385096 "[{""id"":""uuid:4c97700a-fb72-4d8d-a8c7-fda2486f41f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e676e8b0-dfaf-4bc4-9ba5-8de039e290fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of naproxen, naproxen sodium and other treatment options before deciding to use naproxen and naproxen sodium tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Naproxen as naproxen or naproxen sodium tablets are indicated: For the relief of the signs and symptoms of rheumatoid arthritis For the relief of the signs and symptoms of osteoarthritis For the relief of the signs and symptoms of ankylosing spondylitis For the relief of the signs and symptoms of juvenile arthritis Naproxen as naproxen suspension is recommended for juvenile rheumatoid arthritis in order to obtain the maximum dosage flexibility based on the patient’s weight. Naproxen as naproxen and naproxen sodium tablets are also indicated: For relief of the signs and symptoms of tendonitis For relief of the signs and symptoms of bursitis For relief of the signs and symptoms of acute gout For the management of pain For the management of primary dysmenorrhea uuid:8f7b8c07-3435-4402-afe5-0bf889d6ffdb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PVI5M0M1GW biolink:treats MONDO:0004992 PMID:41385096 "[{""id"":""uuid:255b19b9-479f-400b-905d-f09bf4f09633"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6ac87f47-ff3b-4f04-a8c8-fe403ee66b8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:de61410a-e41b-47c5-83e8-61fdfd719b63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/filgrastim-hexal""]},{""id"":""uuid:642e44ff-e861-4965-b950-5cb6866ed1b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cancer Patients Receiving Myelosuppressive Chemotherapy NEUPOGEN ® is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever (see CLINICAL EXPERIENCE ). A complete blood count (CBC) and platelet count should be obtained prior to chemotherapy‚ and twice per week (see LABORATORY MONITORING ) during NEUPOGEN ® therapy to avoid leukocytosis and to monitor the neutrophil count. In phase 3 clinical studies‚ NEUPOGEN ® therapy was discontinued when the ANC was ≥ 10‚000/mm 3 after the expected chemotherapy-induced nadir. Patients With Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy NEUPOGEN ® is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of adults with AML. Cancer Patients Receiving Bone Marrow Transplant NEUPOGEN ® is indicated to reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ eg‚ febrile neutropenia‚ in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by marrow transplantation (see CLINICAL EXPERIENCE ). It is recommended that CBCs and platelet counts be obtained at a minimum of 3 times per week (see LABORATORY MONITORING ) following marrow infusion to monitor the recovery of marrow reconstitution. Patients Undergoing Peripheral Blood Progenitor Cell Collection and Therapy NEUPOGEN ® is indicated for the mobilization of hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis. Mobilization allows for the collection of increased numbers of progenitor cells capable of engraftment compared with collection by leukapheresis without mobilization or bone marrow harvest. After myeloablative chemotherapy‚ the transplantation of an increased number of progenitor cells can lead to more rapid engraftment‚ which may result in a decreased need for supportive care (see CLINICAL EXPERIENCE ). Patients With Severe Chronic Neutropenia NEUPOGEN ® is indicated for chronic administration to reduce the incidence and duration of sequelae of neutropenia (eg‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia (see CLINICAL EXPERIENCE ). It is essential that serial CBCs with differential and platelet counts‚ and an evaluation of bone marrow morphology and karyotype be performed prior to initiation of NEUPOGEN ® therapy (see WARNINGS ). The use of NEUPOGEN ® prior to confirmation of SCN may impair diagnostic efforts and may thus impair or delay evaluation and treatment of an underlying condition‚ other than SCN‚ causing the neutropenia.|[EMA] Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone-marrow transplantation considered to be at increased risk of prolonged severe neutropenia.The safety and efficacy of filgrastim are similar in adults and children receiving cytotoxic chemotherapy.Mobilisation of peripheral blood progenitor cells (PBPCs).In children and adults with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of of ≤ 0.5 x 109/l, and a history of severe or recurrent infections, long-term administration of filgrastim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.Treatment of persistent neutropenia (ANC ≤ 0.5 x 109/l), and a history of severe or recurrent infections, long-term administration of filgrastim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other therapeutic options are inappropriate.|[PMDA] Follow-on biologics indicated for mobilization of hematopoietic stem cell to peripheral blood, promotion of increase in neutrophil count at the time of hematopoietic stem cell transplantation, and the treatment of neutropenia caused by cancer chemotherapy, neutropenia which affects the treatment of human immunodeficiency virus (HIV) infection, neutropenia associated with myelodysplastic syndrome, neutropenia associated with aplastic anemia and congenital/idiopathic neutropenia. uuid:e11044ef-a3b2-4c9f-ba16-adecd352f182 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PVI5M0M1GW biolink:treats MONDO:0018874 PMID:41385096 "[{""id"":""uuid:64201c71-bb31-4c62-993e-34170e0ebe72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:16a2df5a-635a-490d-b4b9-1f6f12aba7aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ccd99628-9b58-4b80-ba71-b7e6752bb209"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cancer Patients Receiving Myelosuppressive Chemotherapy NEUPOGEN ® is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever (see CLINICAL EXPERIENCE ). A complete blood count (CBC) and platelet count should be obtained prior to chemotherapy‚ and twice per week (see LABORATORY MONITORING ) during NEUPOGEN ® therapy to avoid leukocytosis and to monitor the neutrophil count. In phase 3 clinical studies‚ NEUPOGEN ® therapy was discontinued when the ANC was ≥ 10‚000/mm 3 after the expected chemotherapy-induced nadir. Patients With Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy NEUPOGEN ® is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of adults with AML. Cancer Patients Receiving Bone Marrow Transplant NEUPOGEN ® is indicated to reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ eg‚ febrile neutropenia‚ in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by marrow transplantation (see CLINICAL EXPERIENCE ). It is recommended that CBCs and platelet counts be obtained at a minimum of 3 times per week (see LABORATORY MONITORING ) following marrow infusion to monitor the recovery of marrow reconstitution. Patients Undergoing Peripheral Blood Progenitor Cell Collection and Therapy NEUPOGEN ® is indicated for the mobilization of hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis. Mobilization allows for the collection of increased numbers of progenitor cells capable of engraftment compared with collection by leukapheresis without mobilization or bone marrow harvest. After myeloablative chemotherapy‚ the transplantation of an increased number of progenitor cells can lead to more rapid engraftment‚ which may result in a decreased need for supportive care (see CLINICAL EXPERIENCE ). Patients With Severe Chronic Neutropenia NEUPOGEN ® is indicated for chronic administration to reduce the incidence and duration of sequelae of neutropenia (eg‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia (see CLINICAL EXPERIENCE ). It is essential that serial CBCs with differential and platelet counts‚ and an evaluation of bone marrow morphology and karyotype be performed prior to initiation of NEUPOGEN ® therapy (see WARNINGS ). The use of NEUPOGEN ® prior to confirmation of SCN may impair diagnostic efforts and may thus impair or delay evaluation and treatment of an underlying condition‚ other than SCN‚ causing the neutropenia.|[PMDA] Drugs with a new indication and a new dosage for use as an adjunctive therapy with antineoplastic agents for the treatment of relapsed or refractory acute myeloid leukemia. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:bfaa5de3-cf2b-4608-b194-df33a36420cb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PVI5M0M1GW biolink:treats MONDO:0018542 PMID:41385096 "[{""id"":""uuid:30e021a0-95b2-4c94-89a9-b81507247779"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:1ab4b382-7b26-4b5c-a251-53314d7b3101"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4bb02735-6197-4710-bdb1-c3880da76752"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/filgrastim-hexal""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cancer Patients Receiving Myelosuppressive Chemotherapy NEUPOGEN ® is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever (see CLINICAL EXPERIENCE ). A complete blood count (CBC) and platelet count should be obtained prior to chemotherapy‚ and twice per week (see LABORATORY MONITORING ) during NEUPOGEN ® therapy to avoid leukocytosis and to monitor the neutrophil count. In phase 3 clinical studies‚ NEUPOGEN ® therapy was discontinued when the ANC was ≥ 10‚000/mm 3 after the expected chemotherapy-induced nadir. Patients With Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy NEUPOGEN ® is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of adults with AML. Cancer Patients Receiving Bone Marrow Transplant NEUPOGEN ® is indicated to reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ eg‚ febrile neutropenia‚ in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by marrow transplantation (see CLINICAL EXPERIENCE ). It is recommended that CBCs and platelet counts be obtained at a minimum of 3 times per week (see LABORATORY MONITORING ) following marrow infusion to monitor the recovery of marrow reconstitution. Patients Undergoing Peripheral Blood Progenitor Cell Collection and Therapy NEUPOGEN ® is indicated for the mobilization of hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis. Mobilization allows for the collection of increased numbers of progenitor cells capable of engraftment compared with collection by leukapheresis without mobilization or bone marrow harvest. After myeloablative chemotherapy‚ the transplantation of an increased number of progenitor cells can lead to more rapid engraftment‚ which may result in a decreased need for supportive care (see CLINICAL EXPERIENCE ). Patients With Severe Chronic Neutropenia NEUPOGEN ® is indicated for chronic administration to reduce the incidence and duration of sequelae of neutropenia (eg‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia (see CLINICAL EXPERIENCE ). It is essential that serial CBCs with differential and platelet counts‚ and an evaluation of bone marrow morphology and karyotype be performed prior to initiation of NEUPOGEN ® therapy (see WARNINGS ). The use of NEUPOGEN ® prior to confirmation of SCN may impair diagnostic efforts and may thus impair or delay evaluation and treatment of an underlying condition‚ other than SCN‚ causing the neutropenia.|[EMA] Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone-marrow transplantation considered to be at increased risk of prolonged severe neutropenia.The safety and efficacy of filgrastim are similar in adults and children receiving cytotoxic chemotherapy.Mobilisation of peripheral blood progenitor cells (PBPCs).In children and adults with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of of ≤ 0.5 x 109/l, and a history of severe or recurrent infections, long-term administration of filgrastim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.Treatment of persistent neutropenia (ANC ≤ 0.5 x 109/l), and a history of severe or recurrent infections, long-term administration of filgrastim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other therapeutic options are inappropriate. uuid:e27723a5-296f-4283-babd-716b94091148 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PVI5M0M1GW biolink:treats MONDO:0008090 PMID:41385096 "[{""id"":""uuid:7678ddc4-c17f-4b65-b7a8-b10c475bc016"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:707c08d5-0ccf-40f8-98c5-5aad9ccae550"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:075546df-35e0-4e5c-bf2c-b8252cce5801"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/filgrastim-hexal""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cancer Patients Receiving Myelosuppressive Chemotherapy NEUPOGEN ® is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever (see CLINICAL EXPERIENCE ). A complete blood count (CBC) and platelet count should be obtained prior to chemotherapy‚ and twice per week (see LABORATORY MONITORING ) during NEUPOGEN ® therapy to avoid leukocytosis and to monitor the neutrophil count. In phase 3 clinical studies‚ NEUPOGEN ® therapy was discontinued when the ANC was ≥ 10‚000/mm 3 after the expected chemotherapy-induced nadir. Patients With Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy NEUPOGEN ® is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of adults with AML. Cancer Patients Receiving Bone Marrow Transplant NEUPOGEN ® is indicated to reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ eg‚ febrile neutropenia‚ in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by marrow transplantation (see CLINICAL EXPERIENCE ). It is recommended that CBCs and platelet counts be obtained at a minimum of 3 times per week (see LABORATORY MONITORING ) following marrow infusion to monitor the recovery of marrow reconstitution. Patients Undergoing Peripheral Blood Progenitor Cell Collection and Therapy NEUPOGEN ® is indicated for the mobilization of hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis. Mobilization allows for the collection of increased numbers of progenitor cells capable of engraftment compared with collection by leukapheresis without mobilization or bone marrow harvest. After myeloablative chemotherapy‚ the transplantation of an increased number of progenitor cells can lead to more rapid engraftment‚ which may result in a decreased need for supportive care (see CLINICAL EXPERIENCE ). Patients With Severe Chronic Neutropenia NEUPOGEN ® is indicated for chronic administration to reduce the incidence and duration of sequelae of neutropenia (eg‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia (see CLINICAL EXPERIENCE ). It is essential that serial CBCs with differential and platelet counts‚ and an evaluation of bone marrow morphology and karyotype be performed prior to initiation of NEUPOGEN ® therapy (see WARNINGS ). The use of NEUPOGEN ® prior to confirmation of SCN may impair diagnostic efforts and may thus impair or delay evaluation and treatment of an underlying condition‚ other than SCN‚ causing the neutropenia.|[EMA] Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone-marrow transplantation considered to be at increased risk of prolonged severe neutropenia.The safety and efficacy of filgrastim are similar in adults and children receiving cytotoxic chemotherapy.Mobilisation of peripheral blood progenitor cells (PBPCs).In children and adults with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of of ≤ 0.5 x 109/l, and a history of severe or recurrent infections, long-term administration of filgrastim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.Treatment of persistent neutropenia (ANC ≤ 0.5 x 109/l), and a history of severe or recurrent infections, long-term administration of filgrastim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other therapeutic options are inappropriate. uuid:2d74f2ba-78eb-4c00-a8d0-99bd0ab54dd4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PVI5M0M1GW biolink:treats UMLS:C0948109 PMID:41385096 "[{""id"":""uuid:c5c8c782-e4af-404c-a79c-a11290358f3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cc637204-8a59-4d82-8b3e-e87ac9613012"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cancer Patients Receiving Myelosuppressive Chemotherapy NEUPOGEN ® is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a significant incidence of severe neutropenia with fever (see CLINICAL EXPERIENCE ). A complete blood count (CBC) and platelet count should be obtained prior to chemotherapy‚ and twice per week (see LABORATORY MONITORING ) during NEUPOGEN ® therapy to avoid leukocytosis and to monitor the neutrophil count. In phase 3 clinical studies‚ NEUPOGEN ® therapy was discontinued when the ANC was ≥ 10‚000/mm 3 after the expected chemotherapy-induced nadir. Patients With Acute Myeloid Leukemia Receiving Induction or Consolidation Chemotherapy NEUPOGEN ® is indicated for reducing the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of adults with AML. Cancer Patients Receiving Bone Marrow Transplant NEUPOGEN ® is indicated to reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ eg‚ febrile neutropenia‚ in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by marrow transplantation (see CLINICAL EXPERIENCE ). It is recommended that CBCs and platelet counts be obtained at a minimum of 3 times per week (see LABORATORY MONITORING ) following marrow infusion to monitor the recovery of marrow reconstitution. Patients Undergoing Peripheral Blood Progenitor Cell Collection and Therapy NEUPOGEN ® is indicated for the mobilization of hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis. Mobilization allows for the collection of increased numbers of progenitor cells capable of engraftment compared with collection by leukapheresis without mobilization or bone marrow harvest. After myeloablative chemotherapy‚ the transplantation of an increased number of progenitor cells can lead to more rapid engraftment‚ which may result in a decreased need for supportive care (see CLINICAL EXPERIENCE ). Patients With Severe Chronic Neutropenia NEUPOGEN ® is indicated for chronic administration to reduce the incidence and duration of sequelae of neutropenia (eg‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia (see CLINICAL EXPERIENCE ). It is essential that serial CBCs with differential and platelet counts‚ and an evaluation of bone marrow morphology and karyotype be performed prior to initiation of NEUPOGEN ® therapy (see WARNINGS ). The use of NEUPOGEN ® prior to confirmation of SCN may impair diagnostic efforts and may thus impair or delay evaluation and treatment of an underlying condition‚ other than SCN‚ causing the neutropenia. uuid:d7654e65-16b1-4ec3-9cec-c19fe4ab68e1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7936 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:9e2a7c08-907e-4d61-9b55-dbb9fc4c79f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9dba0bcc-1dbd-4586-9196-460af2f26a6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Major Depressive Disorder PAXIL CR is indicated for the treatment of major depressive disorder. The efficacy of PAXIL CR in the treatment of a major depressive episode was established in two 12-week controlled trials of outpatients whose diagnoses corresponded to the DSM-IV category of major depressive disorder (see CLINICAL PHARMACOLOGY—Clinical Trials). A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed mood or loss of interest or pleasure in nearly all activities, representing a change from previous functioning, and includes the presence of at least 5 of the following 9 symptoms during the same 2-week period: Depressed mood, markedly diminished interest or pleasure in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt, or suicidal ideation. The antidepressant action of paroxetine in hospitalized depressed patients has not been adequately studied. PAXIL CR has not been systematically evaluated beyond 12 weeks in controlled clinical trials; however, the effectiveness of immediate-release paroxetine hydrochloride in maintaining a response in major depressive disorder for up to 1 year has been demonstrated in a placebo-controlled trial (see CLINICAL PHARMACOLOGY—Clinical Trials). The physician who elects to use PAXIL CR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient. Panic Disorder PAXIL CR is indicated for the treatment of panic disorder, with or without agoraphobia, as defined in DSM-IV. Panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. The efficacy of PAXIL CR controlled-release tablets was established in two 10-week trials in panic disorder patients whose diagnoses corresponded to the DSM-IV category of panic disorder (see CLINICAL PHARMACOLOGY—Clinical Trials). Panic disorder (DSM-IV) is characterized by recurrent unexpected panic attacks, i.e., a discrete period of intense fear or discomfort in which 4 (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) palpitations, pounding heart, or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded, or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes. Long-term maintenance of efficacy with the immediate-release formulation of paroxetine was demonstrated in a 3-month relapse prevention trial. In this trial, patients with panic disorder assigned to immediate-release paroxetine demonstrated a lower relapse rate compared to patients on placebo (see CLINICAL PHARMACOLOGY—Clinical Trials). Nevertheless, the physician who prescribes PAXIL CR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient. Social Anxiety Disorder PAXIL CR is indicated for the treatment of social anxiety disorder, also known as social phobia, as defined in DSM-IV (300.23). Social anxiety disorder is characterized by a marked and persistent fear of 1 or more social or performance situations in which the person is exposed to unfamiliar people or to possible scrutiny by others. Exposure to the feared situation almost invariably provokes anxiety, which may approach the intensity of a panic attack. The feared situations are avoided or endured with intense anxiety or distress. The avoidance, anxious anticipation, or distress in the feared situation(s) interferes significantly with the person's normal routine, occupational or academic functioning, or social activities or relationships, or there is marked distress about having the phobias. Lesser degrees of performance anxiety or shyness generally do not require psychopharmacological treatment. The efficacy of PAXIL CR as a treatment for social anxiety disorder has been established, in part, on the basis of extrapolation from the established effectiveness of the immediate-release formulation of paroxetine. In addition, the efficacy of PAXIL CR was established in a 12-week trial, in adult outpatients with social anxiety disorder (DSM-IV). PAXIL CR has not been studied in children or adolescents with social phobia (see CLINICAL PHARMACOLOGY—Clinical Trials). The effectiveness of PAXIL CR in long-term treatment of social anxiety disorder, i.e., for more than 12 weeks, has not been systematically evaluated in adequate and well-controlled trials. Therefore, the physician who elects to prescribe PAXIL CR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION). Premenstrual Dysphoric Disorder PAXIL CR is indicated for the treatment of PMDD. The efficacy of PAXIL CR in the treatment of PMDD has been established in 3 placebo-controlled trials (see CLINICAL PHARMACOLOGY—Clinical Trials). The essential features of PMDD, according to DSM-IV, include markedly depressed mood, anxiety or tension, affective lability, and persistent anger or irritability. Other features include decreased interest in usual activities, difficulty concentrating, lack of energy, change in appetite or sleep, and feeling out of control. Physical symptoms associated with PMDD include breast tenderness, headache, joint and muscle pain, bloating, and weight gain. These symptoms occur regularly during the luteal phase and remit within a few days following the onset of menses; the disturbance markedly interferes with work or school or with usual social activities and relationships with others. In making the diagnosis, care should be taken to rule out other cyclical mood disorders that may be exacerbated by treatment with an antidepressant. The effectiveness of PAXIL CR in long-term use, that is, for more than 3 menstrual cycles, has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use PAXIL CR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient. uuid:26cdef9e-4f1e-40cb-8f95-45a5eb525348 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7936 biolink:treats MONDO:0005383 PMID:41385096 "[{""id"":""uuid:ce4a7fa8-7ad1-4090-98bc-a141f2673bcc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f3be961b-fe06-4268-8b07-ebfb68473b6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Major Depressive Disorder PAXIL CR is indicated for the treatment of major depressive disorder. The efficacy of PAXIL CR in the treatment of a major depressive episode was established in two 12-week controlled trials of outpatients whose diagnoses corresponded to the DSM-IV category of major depressive disorder (see CLINICAL PHARMACOLOGY—Clinical Trials). A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed mood or loss of interest or pleasure in nearly all activities, representing a change from previous functioning, and includes the presence of at least 5 of the following 9 symptoms during the same 2-week period: Depressed mood, markedly diminished interest or pleasure in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt, or suicidal ideation. The antidepressant action of paroxetine in hospitalized depressed patients has not been adequately studied. PAXIL CR has not been systematically evaluated beyond 12 weeks in controlled clinical trials; however, the effectiveness of immediate-release paroxetine hydrochloride in maintaining a response in major depressive disorder for up to 1 year has been demonstrated in a placebo-controlled trial (see CLINICAL PHARMACOLOGY—Clinical Trials). The physician who elects to use PAXIL CR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient. Panic Disorder PAXIL CR is indicated for the treatment of panic disorder, with or without agoraphobia, as defined in DSM-IV. Panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. The efficacy of PAXIL CR controlled-release tablets was established in two 10-week trials in panic disorder patients whose diagnoses corresponded to the DSM-IV category of panic disorder (see CLINICAL PHARMACOLOGY—Clinical Trials). Panic disorder (DSM-IV) is characterized by recurrent unexpected panic attacks, i.e., a discrete period of intense fear or discomfort in which 4 (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) palpitations, pounding heart, or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded, or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes. Long-term maintenance of efficacy with the immediate-release formulation of paroxetine was demonstrated in a 3-month relapse prevention trial. In this trial, patients with panic disorder assigned to immediate-release paroxetine demonstrated a lower relapse rate compared to patients on placebo (see CLINICAL PHARMACOLOGY—Clinical Trials). Nevertheless, the physician who prescribes PAXIL CR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient. Social Anxiety Disorder PAXIL CR is indicated for the treatment of social anxiety disorder, also known as social phobia, as defined in DSM-IV (300.23). Social anxiety disorder is characterized by a marked and persistent fear of 1 or more social or performance situations in which the person is exposed to unfamiliar people or to possible scrutiny by others. Exposure to the feared situation almost invariably provokes anxiety, which may approach the intensity of a panic attack. The feared situations are avoided or endured with intense anxiety or distress. The avoidance, anxious anticipation, or distress in the feared situation(s) interferes significantly with the person's normal routine, occupational or academic functioning, or social activities or relationships, or there is marked distress about having the phobias. Lesser degrees of performance anxiety or shyness generally do not require psychopharmacological treatment. The efficacy of PAXIL CR as a treatment for social anxiety disorder has been established, in part, on the basis of extrapolation from the established effectiveness of the immediate-release formulation of paroxetine. In addition, the efficacy of PAXIL CR was established in a 12-week trial, in adult outpatients with social anxiety disorder (DSM-IV). PAXIL CR has not been studied in children or adolescents with social phobia (see CLINICAL PHARMACOLOGY—Clinical Trials). The effectiveness of PAXIL CR in long-term treatment of social anxiety disorder, i.e., for more than 12 weeks, has not been systematically evaluated in adequate and well-controlled trials. Therefore, the physician who elects to prescribe PAXIL CR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION). Premenstrual Dysphoric Disorder PAXIL CR is indicated for the treatment of PMDD. The efficacy of PAXIL CR in the treatment of PMDD has been established in 3 placebo-controlled trials (see CLINICAL PHARMACOLOGY—Clinical Trials). The essential features of PMDD, according to DSM-IV, include markedly depressed mood, anxiety or tension, affective lability, and persistent anger or irritability. Other features include decreased interest in usual activities, difficulty concentrating, lack of energy, change in appetite or sleep, and feeling out of control. Physical symptoms associated with PMDD include breast tenderness, headache, joint and muscle pain, bloating, and weight gain. These symptoms occur regularly during the luteal phase and remit within a few days following the onset of menses; the disturbance markedly interferes with work or school or with usual social activities and relationships with others. In making the diagnosis, care should be taken to rule out other cyclical mood disorders that may be exacerbated by treatment with an antidepressant. The effectiveness of PAXIL CR in long-term use, that is, for more than 3 menstrual cycles, has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use PAXIL CR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient. uuid:6e5f0f7b-acc7-44de-878f-baabcb76e383 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7936 biolink:treats MONDO:0003709 PMID:41385096 "[{""id"":""uuid:72dbb1c1-caf7-4538-a51a-d7312ecc0072"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3779e94a-788e-431a-9bf9-c75c796c6b44"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Major Depressive Disorder PAXIL CR is indicated for the treatment of major depressive disorder. The efficacy of PAXIL CR in the treatment of a major depressive episode was established in two 12-week controlled trials of outpatients whose diagnoses corresponded to the DSM-IV category of major depressive disorder (see CLINICAL PHARMACOLOGY—Clinical Trials). A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed mood or loss of interest or pleasure in nearly all activities, representing a change from previous functioning, and includes the presence of at least 5 of the following 9 symptoms during the same 2-week period: Depressed mood, markedly diminished interest or pleasure in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt, or suicidal ideation. The antidepressant action of paroxetine in hospitalized depressed patients has not been adequately studied. PAXIL CR has not been systematically evaluated beyond 12 weeks in controlled clinical trials; however, the effectiveness of immediate-release paroxetine hydrochloride in maintaining a response in major depressive disorder for up to 1 year has been demonstrated in a placebo-controlled trial (see CLINICAL PHARMACOLOGY—Clinical Trials). The physician who elects to use PAXIL CR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient. Panic Disorder PAXIL CR is indicated for the treatment of panic disorder, with or without agoraphobia, as defined in DSM-IV. Panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. The efficacy of PAXIL CR controlled-release tablets was established in two 10-week trials in panic disorder patients whose diagnoses corresponded to the DSM-IV category of panic disorder (see CLINICAL PHARMACOLOGY—Clinical Trials). Panic disorder (DSM-IV) is characterized by recurrent unexpected panic attacks, i.e., a discrete period of intense fear or discomfort in which 4 (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) palpitations, pounding heart, or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded, or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes. Long-term maintenance of efficacy with the immediate-release formulation of paroxetine was demonstrated in a 3-month relapse prevention trial. In this trial, patients with panic disorder assigned to immediate-release paroxetine demonstrated a lower relapse rate compared to patients on placebo (see CLINICAL PHARMACOLOGY—Clinical Trials). Nevertheless, the physician who prescribes PAXIL CR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient. Social Anxiety Disorder PAXIL CR is indicated for the treatment of social anxiety disorder, also known as social phobia, as defined in DSM-IV (300.23). Social anxiety disorder is characterized by a marked and persistent fear of 1 or more social or performance situations in which the person is exposed to unfamiliar people or to possible scrutiny by others. Exposure to the feared situation almost invariably provokes anxiety, which may approach the intensity of a panic attack. The feared situations are avoided or endured with intense anxiety or distress. The avoidance, anxious anticipation, or distress in the feared situation(s) interferes significantly with the person's normal routine, occupational or academic functioning, or social activities or relationships, or there is marked distress about having the phobias. Lesser degrees of performance anxiety or shyness generally do not require psychopharmacological treatment. The efficacy of PAXIL CR as a treatment for social anxiety disorder has been established, in part, on the basis of extrapolation from the established effectiveness of the immediate-release formulation of paroxetine. In addition, the efficacy of PAXIL CR was established in a 12-week trial, in adult outpatients with social anxiety disorder (DSM-IV). PAXIL CR has not been studied in children or adolescents with social phobia (see CLINICAL PHARMACOLOGY—Clinical Trials). The effectiveness of PAXIL CR in long-term treatment of social anxiety disorder, i.e., for more than 12 weeks, has not been systematically evaluated in adequate and well-controlled trials. Therefore, the physician who elects to prescribe PAXIL CR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION). Premenstrual Dysphoric Disorder PAXIL CR is indicated for the treatment of PMDD. The efficacy of PAXIL CR in the treatment of PMDD has been established in 3 placebo-controlled trials (see CLINICAL PHARMACOLOGY—Clinical Trials). The essential features of PMDD, according to DSM-IV, include markedly depressed mood, anxiety or tension, affective lability, and persistent anger or irritability. Other features include decreased interest in usual activities, difficulty concentrating, lack of energy, change in appetite or sleep, and feeling out of control. Physical symptoms associated with PMDD include breast tenderness, headache, joint and muscle pain, bloating, and weight gain. These symptoms occur regularly during the luteal phase and remit within a few days following the onset of menses; the disturbance markedly interferes with work or school or with usual social activities and relationships with others. In making the diagnosis, care should be taken to rule out other cyclical mood disorders that may be exacerbated by treatment with an antidepressant. The effectiveness of PAXIL CR in long-term use, that is, for more than 3 menstrual cycles, has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use PAXIL CR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient. uuid:16fa6988-5ed4-448a-a9ba-f4319da8fa6b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7936 biolink:treats MONDO:0001247 PMID:41385096 "[{""id"":""uuid:372586e7-caa5-4ddc-9145-8d6ad7571eaf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5c78f8bd-ee2f-41ff-a9ec-0dee1d6f0032"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9ebf5b6d-7a2d-43b5-a32f-d72dde135c3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Major Depressive Disorder PAXIL CR is indicated for the treatment of major depressive disorder. The efficacy of PAXIL CR in the treatment of a major depressive episode was established in two 12-week controlled trials of outpatients whose diagnoses corresponded to the DSM-IV category of major depressive disorder (see CLINICAL PHARMACOLOGY—Clinical Trials). A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed mood or loss of interest or pleasure in nearly all activities, representing a change from previous functioning, and includes the presence of at least 5 of the following 9 symptoms during the same 2-week period: Depressed mood, markedly diminished interest or pleasure in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt, or suicidal ideation. The antidepressant action of paroxetine in hospitalized depressed patients has not been adequately studied. PAXIL CR has not been systematically evaluated beyond 12 weeks in controlled clinical trials; however, the effectiveness of immediate-release paroxetine hydrochloride in maintaining a response in major depressive disorder for up to 1 year has been demonstrated in a placebo-controlled trial (see CLINICAL PHARMACOLOGY—Clinical Trials). The physician who elects to use PAXIL CR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient. Panic Disorder PAXIL CR is indicated for the treatment of panic disorder, with or without agoraphobia, as defined in DSM-IV. Panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. The efficacy of PAXIL CR controlled-release tablets was established in two 10-week trials in panic disorder patients whose diagnoses corresponded to the DSM-IV category of panic disorder (see CLINICAL PHARMACOLOGY—Clinical Trials). Panic disorder (DSM-IV) is characterized by recurrent unexpected panic attacks, i.e., a discrete period of intense fear or discomfort in which 4 (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) palpitations, pounding heart, or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded, or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes. Long-term maintenance of efficacy with the immediate-release formulation of paroxetine was demonstrated in a 3-month relapse prevention trial. In this trial, patients with panic disorder assigned to immediate-release paroxetine demonstrated a lower relapse rate compared to patients on placebo (see CLINICAL PHARMACOLOGY—Clinical Trials). Nevertheless, the physician who prescribes PAXIL CR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient. Social Anxiety Disorder PAXIL CR is indicated for the treatment of social anxiety disorder, also known as social phobia, as defined in DSM-IV (300.23). Social anxiety disorder is characterized by a marked and persistent fear of 1 or more social or performance situations in which the person is exposed to unfamiliar people or to possible scrutiny by others. Exposure to the feared situation almost invariably provokes anxiety, which may approach the intensity of a panic attack. The feared situations are avoided or endured with intense anxiety or distress. The avoidance, anxious anticipation, or distress in the feared situation(s) interferes significantly with the person's normal routine, occupational or academic functioning, or social activities or relationships, or there is marked distress about having the phobias. Lesser degrees of performance anxiety or shyness generally do not require psychopharmacological treatment. The efficacy of PAXIL CR as a treatment for social anxiety disorder has been established, in part, on the basis of extrapolation from the established effectiveness of the immediate-release formulation of paroxetine. In addition, the efficacy of PAXIL CR was established in a 12-week trial, in adult outpatients with social anxiety disorder (DSM-IV). PAXIL CR has not been studied in children or adolescents with social phobia (see CLINICAL PHARMACOLOGY—Clinical Trials). The effectiveness of PAXIL CR in long-term treatment of social anxiety disorder, i.e., for more than 12 weeks, has not been systematically evaluated in adequate and well-controlled trials. Therefore, the physician who elects to prescribe PAXIL CR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION). Premenstrual Dysphoric Disorder PAXIL CR is indicated for the treatment of PMDD. The efficacy of PAXIL CR in the treatment of PMDD has been established in 3 placebo-controlled trials (see CLINICAL PHARMACOLOGY—Clinical Trials). The essential features of PMDD, according to DSM-IV, include markedly depressed mood, anxiety or tension, affective lability, and persistent anger or irritability. Other features include decreased interest in usual activities, difficulty concentrating, lack of energy, change in appetite or sleep, and feeling out of control. Physical symptoms associated with PMDD include breast tenderness, headache, joint and muscle pain, bloating, and weight gain. These symptoms occur regularly during the luteal phase and remit within a few days following the onset of menses; the disturbance markedly interferes with work or school or with usual social activities and relationships with others. In making the diagnosis, care should be taken to rule out other cyclical mood disorders that may be exacerbated by treatment with an antidepressant. The effectiveness of PAXIL CR in long-term use, that is, for more than 3 menstrual cycles, has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use PAXIL CR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.|[PMDA] Drugs with a new additional indication and a new dosage for the treatment of social anxiety disorder. uuid:4ac63f79-3631-4232-ae1f-2e9e0748232a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7936 biolink:treats MONDO:1010182 PMID:41385096 "[{""id"":""uuid:07988aa8-c988-4e40-943c-6d69c1db84ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ec51d69d-a650-441c-bfda-940d2531e782"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Major Depressive Disorder PAXIL CR is indicated for the treatment of major depressive disorder. The efficacy of PAXIL CR in the treatment of a major depressive episode was established in two 12-week controlled trials of outpatients whose diagnoses corresponded to the DSM-IV category of major depressive disorder (see CLINICAL PHARMACOLOGY—Clinical Trials). A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed mood or loss of interest or pleasure in nearly all activities, representing a change from previous functioning, and includes the presence of at least 5 of the following 9 symptoms during the same 2-week period: Depressed mood, markedly diminished interest or pleasure in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt, or suicidal ideation. The antidepressant action of paroxetine in hospitalized depressed patients has not been adequately studied. PAXIL CR has not been systematically evaluated beyond 12 weeks in controlled clinical trials; however, the effectiveness of immediate-release paroxetine hydrochloride in maintaining a response in major depressive disorder for up to 1 year has been demonstrated in a placebo-controlled trial (see CLINICAL PHARMACOLOGY—Clinical Trials). The physician who elects to use PAXIL CR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient. Panic Disorder PAXIL CR is indicated for the treatment of panic disorder, with or without agoraphobia, as defined in DSM-IV. Panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. The efficacy of PAXIL CR controlled-release tablets was established in two 10-week trials in panic disorder patients whose diagnoses corresponded to the DSM-IV category of panic disorder (see CLINICAL PHARMACOLOGY—Clinical Trials). Panic disorder (DSM-IV) is characterized by recurrent unexpected panic attacks, i.e., a discrete period of intense fear or discomfort in which 4 (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) palpitations, pounding heart, or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded, or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes. Long-term maintenance of efficacy with the immediate-release formulation of paroxetine was demonstrated in a 3-month relapse prevention trial. In this trial, patients with panic disorder assigned to immediate-release paroxetine demonstrated a lower relapse rate compared to patients on placebo (see CLINICAL PHARMACOLOGY—Clinical Trials). Nevertheless, the physician who prescribes PAXIL CR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient. Social Anxiety Disorder PAXIL CR is indicated for the treatment of social anxiety disorder, also known as social phobia, as defined in DSM-IV (300.23). Social anxiety disorder is characterized by a marked and persistent fear of 1 or more social or performance situations in which the person is exposed to unfamiliar people or to possible scrutiny by others. Exposure to the feared situation almost invariably provokes anxiety, which may approach the intensity of a panic attack. The feared situations are avoided or endured with intense anxiety or distress. The avoidance, anxious anticipation, or distress in the feared situation(s) interferes significantly with the person's normal routine, occupational or academic functioning, or social activities or relationships, or there is marked distress about having the phobias. Lesser degrees of performance anxiety or shyness generally do not require psychopharmacological treatment. The efficacy of PAXIL CR as a treatment for social anxiety disorder has been established, in part, on the basis of extrapolation from the established effectiveness of the immediate-release formulation of paroxetine. In addition, the efficacy of PAXIL CR was established in a 12-week trial, in adult outpatients with social anxiety disorder (DSM-IV). PAXIL CR has not been studied in children or adolescents with social phobia (see CLINICAL PHARMACOLOGY—Clinical Trials). The effectiveness of PAXIL CR in long-term treatment of social anxiety disorder, i.e., for more than 12 weeks, has not been systematically evaluated in adequate and well-controlled trials. Therefore, the physician who elects to prescribe PAXIL CR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION). Premenstrual Dysphoric Disorder PAXIL CR is indicated for the treatment of PMDD. The efficacy of PAXIL CR in the treatment of PMDD has been established in 3 placebo-controlled trials (see CLINICAL PHARMACOLOGY—Clinical Trials). The essential features of PMDD, according to DSM-IV, include markedly depressed mood, anxiety or tension, affective lability, and persistent anger or irritability. Other features include decreased interest in usual activities, difficulty concentrating, lack of energy, change in appetite or sleep, and feeling out of control. Physical symptoms associated with PMDD include breast tenderness, headache, joint and muscle pain, bloating, and weight gain. These symptoms occur regularly during the luteal phase and remit within a few days following the onset of menses; the disturbance markedly interferes with work or school or with usual social activities and relationships with others. In making the diagnosis, care should be taken to rule out other cyclical mood disorders that may be exacerbated by treatment with an antidepressant. The effectiveness of PAXIL CR in long-term use, that is, for more than 3 menstrual cycles, has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use PAXIL CR for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient. UMLS:C0520676 uuid:0ab6535c-a055-4f4d-927e-95efc3bd1819 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64312 biolink:treats MONDO:0004975 PMID:41385096 "[{""id"":""uuid:7c60e1e5-f743-4323-ad2a-00fc070522f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:397ae377-7579-47a3-98f4-686b96e453a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c294299f-1cf0-4848-b8c3-2a208b4d687c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/nemdatine""]},{""id"":""uuid:7561515a-a539-44d6-8b37-25f6ed424b8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Namenda (memantine hydrochloride) is indicated for the treatment of moderate to severe dementia of the Alzheimer's type.|[EMA] Treatment of patients with moderate to severe Alzheimer’s disease.|[PMDA] Drugs with a new active ingredient indicated for inhibition of progression of symptoms of dementia in moderate and severe Alzheimer's dementia. uuid:b44b0761-fb5e-407f-b691-4018ff94599c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:43755 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:a7475fca-791c-4826-9d96-f9ba5ef3e1ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:63a539e0-e5bb-4af7-85e1-95353a5906d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension: Lisinopril tablets are indicated for the treatment of hypertension. It may be used alone as initial therapy or concomitantly with other classes of antihypertensive agents. Heart Failure: Lisinopril tablets are indicated as adjunctive therapy in the management of heart failure in patients who are not responding adequately to diuretics and digitalis. Acute Myocardial Infarction: Lisinopril tablets are indicated for the treatment of hemodynamically stable patients within 24 hours of acute myocardial infarction, to improve survival. Patients should receive, as appropriate, the standard recommended treatments such as thrombolytics, aspirin and beta blockers. In using lisinopril tablets, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that lisinopril does not have a similar risk. (See WARNINGS .) In considering the use of lisinopril tablets, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in Black patients than in non-Blacks. In addition, ACE inhibitors have been associated with a higher rate of angioedema in Black than in non-Black patients (see WARNINGS, Anaphylactoid and Possibly Related Reactions ). uuid:c104c8c6-af14-4928-ae12-8d4df7743412 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:43755 biolink:treats MONDO:0004781 PMID:41385096 "[{""id"":""uuid:d2ea01c0-6637-4291-9506-439ef20e1fbb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b7b0c6b8-b8dc-4d0f-936e-a4d9c1b79521"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension: Lisinopril tablets are indicated for the treatment of hypertension. It may be used alone as initial therapy or concomitantly with other classes of antihypertensive agents. Heart Failure: Lisinopril tablets are indicated as adjunctive therapy in the management of heart failure in patients who are not responding adequately to diuretics and digitalis. Acute Myocardial Infarction: Lisinopril tablets are indicated for the treatment of hemodynamically stable patients within 24 hours of acute myocardial infarction, to improve survival. Patients should receive, as appropriate, the standard recommended treatments such as thrombolytics, aspirin and beta blockers. In using lisinopril tablets, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that lisinopril does not have a similar risk. (See WARNINGS .) In considering the use of lisinopril tablets, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in Black patients than in non-Blacks. In addition, ACE inhibitors have been associated with a higher rate of angioedema in Black than in non-Black patients (see WARNINGS, Anaphylactoid and Possibly Related Reactions ). uuid:9f64db59-a141-4195-bb79-c77be9442947 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6775 biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:d044881c-5575-4806-babe-83402aad1c0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8af15ea8-9fff-4fa6-b81a-139e0aa41413"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:32d4bdc5-ec0c-40bf-bc14-aef9f0967dbd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Asacol tablets are indicated for the treatment of mildly to moderately active ulcerative colitis and for the maintenance of remission of ulcerative colitis.|[PMDA] A drug in a new dosage form indicated for the treatment of ulcerative colitis (excluding severe cases). uuid:d301e937-35cc-4a06-b032-6ab0d37c602b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3614 biolink:treats MONDO:0009850 PMID:41385096 "[{""id"":""uuid:c98ba839-4678-42be-9e17-1716adbd7538"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ca2337f3-ae95-44ac-a95a-242f566b1eae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PerioChip is indicated as an adjunct to scaling and root planing procedures for reduction of pocket depth in patients with adult periodontitis. PerioChip may be used as a part of a periodontal maintenance program, which includes good oral hygiene and scaling and root planing. uuid:4669ebaa-fc45-4751-b8ab-e64b1abcb19d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3048 biolink:treats MONDO:0021095 PMID:41385096 "[{""id"":""uuid:8a62a149-4cb1-4857-8b9a-16bc53d33ba7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:705dd732-5edf-4b1c-8d0a-2af640c7c479"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For use as an adjunct in the therapy of all forms of parkinsonism. Useful also in the control of extrapyramidal disorders (except tardive dyskinesia - see PRECAUTIONS ) due to neuroleptic drugs (e.g., phenothiazines). uuid:6393fbfb-d407-4aa7-aca8-f114f2aee16a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3048 biolink:treats HP:0002071 PMID:41385096 "[{""id"":""uuid:190734c3-a200-4f89-9078-4a041ee71dbd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ca1bd3a9-3a03-4dd6-8680-4b19a2ab8060"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For use as an adjunct in the therapy of all forms of parkinsonism. Useful also in the control of extrapyramidal disorders (except tardive dyskinesia - see PRECAUTIONS ) due to neuroleptic drugs (e.g., phenothiazines). uuid:3a695890-ae71-44f6-9f76-730e83c128c0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3048 biolink:treats MONDO:0010096 PMID:41385096 "[{""id"":""uuid:b2899318-d98b-49b5-8ad8-7be5f7b00492"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f5f003f0-d0c4-4f2a-8fb8-779c718e88db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For use as an adjunct in the therapy of all forms of parkinsonism. Useful also in the control of extrapyramidal disorders (except tardive dyskinesia - see PRECAUTIONS ) due to neuroleptic drugs (e.g., phenothiazines). uuid:f97c864e-f1c8-4280-9d35-f6692f345c13 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8874 biolink:treats MONDO:0004975 PMID:41385096 "[{""id"":""uuid:16241ce9-8d03-4299-8acb-f5a7863de61a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b892151c-1c8e-400a-ad99-98afb75bc017"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a61ccf4d-61b9-4e48-b7d7-e9fa4340f656"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/prometax""]},{""id"":""uuid:73fc258d-95c1-4066-a745-4f0132b764f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Alzheimer’s Disease Exelon Patch (rivastigmine transdermal system) is indicated for the treatment of mild to moderate dementia of the Alzheimer’s type. 1.2 Parkinson’s Disease Dementia Exelon Patch (rivastigmine transdermal system) is indicated for the treatment of mild to moderate dementia associated with Parkinson’s disease. The dementia of Parkinson’s disease is purportedly characterized by impairments in executive function, memory retrieval, and attention in patients with an established diagnosis of Parkinson’s disease. The diagnosis of dementia of Parkinson’s disease can be made reliably in patients in whom a progressive dementia syndrome occurs (without the necessity to document the specific deficits described above) at least 2 years after a diagnosis of Parkinson’s disease has been made, and in whom other causes of dementia have been ruled out.|[EMA] Symptomatic treatment of mild to moderately severe Alzheimer's dementia.Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease.|[PMDA] Drugs with a new active ingredient indicated for inhibition of progression of symptoms of dementia in mild and moderate Alzheimer's dementia. uuid:df6f99e2-0f9d-4edd-a5fe-50df076bc55e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8874 biolink:treats UMLS:C0236960 PMID:41385096 "[{""id"":""uuid:839662f2-0c4a-4288-aa11-ceb849d45c00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:12e5be53-2572-45cd-a352-326481817cad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Alzheimer’s Disease Exelon Patch (rivastigmine transdermal system) is indicated for the treatment of mild to moderate dementia of the Alzheimer’s type. 1.2 Parkinson’s Disease Dementia Exelon Patch (rivastigmine transdermal system) is indicated for the treatment of mild to moderate dementia associated with Parkinson’s disease. The dementia of Parkinson’s disease is purportedly characterized by impairments in executive function, memory retrieval, and attention in patients with an established diagnosis of Parkinson’s disease. The diagnosis of dementia of Parkinson’s disease can be made reliably in patients in whom a progressive dementia syndrome occurs (without the necessity to document the specific deficits described above) at least 2 years after a diagnosis of Parkinson’s disease has been made, and in whom other causes of dementia have been ruled out. uuid:2bd4b9b1-3b95-4897-8466-280880a0183b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5109 biolink:treats MONDO:0005093 PMID:41385096 "[{""id"":""uuid:5d83f616-2dc5-40b3-bcff-5807291d41e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:de1a0bef-b73f-49f6-b5b4-1d1d496ca82f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluocinonide Cream is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. uuid:94dc51c3-e7bc-45a8-a2a3-982529a28700 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1162789 biolink:treats NCIT:C27003 PMID:41385096 "[{""id"":""uuid:dbb71e0f-9925-41bc-90bd-a47fedc98842"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:102fb471-9a86-4f3b-a45e-34461c3de492"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of hydrocodone bitartrate and ibuprofen tablets and other treatment options before deciding to use hydrocodone bitartrate and ibuprofen tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Hydrocodone bitartrate and ibuprofen tablets are indicated for the short-term (generally less than 10 days) management of acute pain. Hydrocodone bitartrate and ibuprofen tablets are not indicated for the treatment of such conditions as osteoarthritis or rheumatoid arthritis. uuid:f757b031-4a83-419a-bef9-36608075b986 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1162789 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:114e6f34-c7a5-48fe-8f95-a31f746b54b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2d2f6098-0eeb-4b3f-889f-2328eafef816"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of hydrocodone bitartrate and ibuprofen tablets and other treatment options before deciding to use hydrocodone bitartrate and ibuprofen tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Hydrocodone bitartrate and ibuprofen tablets are indicated for the short-term (generally less than 10 days) management of acute pain. Hydrocodone bitartrate and ibuprofen tablets are not indicated for the treatment of such conditions as osteoarthritis or rheumatoid arthritis. uuid:6a552230-e750-45d4-b519-aab079d19e27 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1162789 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:10c94819-af0e-41ed-903a-a48f96f32a4c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fb23bb19-b5d4-4249-b7e9-fdd1b2ef295f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of hydrocodone bitartrate and ibuprofen tablets and other treatment options before deciding to use hydrocodone bitartrate and ibuprofen tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Hydrocodone bitartrate and ibuprofen tablets are indicated for the short-term (generally less than 10 days) management of acute pain. Hydrocodone bitartrate and ibuprofen tablets are not indicated for the treatment of such conditions as osteoarthritis or rheumatoid arthritis. uuid:1f5db3da-edf7-4afe-adc5-6aa233435319 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6722 biolink:treats MONDO:0012268 PMID:41385096 "[{""id"":""uuid:d70f98ce-7e79-4513-b2fa-02a3ed06b839"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:08979ce8-ed6f-43d1-ae98-e9391b443700"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Megace ® ES (megestrol acetate) oral suspension is indicated for the treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS). uuid:a5ef52ed-543a-4844-9103-ec858f12e611 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6722 biolink:treats MONDO:0005351 PMID:41385096 "[{""id"":""uuid:e2e9839f-1012-4e8a-a01f-da9996a1ac73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a26c24b0-04b0-4d35-8e85-8d6a893dee7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Megace ® ES (megestrol acetate) oral suspension is indicated for the treatment of anorexia, cachexia, or an unexplained, significant weight loss in patients with a diagnosis of acquired immunodeficiency syndrome (AIDS). uuid:0d6a76ce-78fe-42c8-ba15-1fa05e5b1f10 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16469 biolink:treats MONDO:0008159 PMID:41385096 "[{""id"":""uuid:8e424283-3bb3-426c-87ed-2c2039dec4a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2be89e6d-235b-4716-93c4-dbff2e36d7f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9ea26bfe-356b-451f-8465-58e5a0dce750"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Estradiol Transdermal System Continuous Delivery (Once-Weekly), USP is indicated in the: Treatment of moderate to severe vasomotor symptoms associated with the menopause. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. Prevention of postmenopausal osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and non-estrogen medications should be carefully considered. The mainstays for decreasing the risk of postmenopausal osteoporosis are weight bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 1500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400 IU/day to 800 IU/day may also be required to ensure adequate daily intake in postmenopausal women.|[PMDA] A new combination drug and 2) a drug with a new indication and a new dosage for the treatment of postmenopausal osteoporosis. uuid:818bd76a-1c5c-4ca1-9040-686fd89baa65 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40279 biolink:treats HP:0033073 PMID:41385096 "[{""id"":""uuid:5841f877-327d-40fb-bc03-6a67b9e6d1f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0c63d7ca-80e8-4194-bc3b-d010f8e046a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] THIS IS NOT AN INNOCUOUS DRUG. IT IS NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA. Allopurinol reduces serum and urinary uric acid concentrations. Its use should be individualized for each patient and requires an understanding of its mode of action and pharmacokinetics (see CLINICAL PHARMACOLOGY , CONTRAINDICATIONS , WARNINGS and PRECAUTIONS ). Allopurinol is indicated in: the management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy). the management of patients with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Allopurinol treatment should be discontinued when the potential for overproduction of uric acid is no longer present. the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients. Therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks. uuid:f769318c-68ac-45b6-a04e-efd5ad5a4540 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40279 biolink:treats UMLS:C0541875 PMID:41385096 "[{""id"":""uuid:7c6fbec9-6690-4868-8b95-48707ed9c8af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cdd05497-d4db-41ff-9774-e4c26073e970"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] THIS IS NOT AN INNOCUOUS DRUG. IT IS NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA. Allopurinol reduces serum and urinary uric acid concentrations. Its use should be individualized for each patient and requires an understanding of its mode of action and pharmacokinetics (see CLINICAL PHARMACOLOGY , CONTRAINDICATIONS , WARNINGS and PRECAUTIONS ). Allopurinol is indicated in: the management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy). the management of patients with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Allopurinol treatment should be discontinued when the potential for overproduction of uric acid is no longer present. the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients. Therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks. uuid:b5f168e7-d3b3-40b4-a67a-233d584b9d02 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71940 biolink:treats NCIT:C55615 PMID:41385096 "[{""id"":""uuid:616e9100-a277-4a43-a948-eccdc6a3a181"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d9d581b9-ed63-49a3-a85c-500df60a60c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1f3c4f67-566e-4297-bc5f-962e22dcfa67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CIALIS ® is a phosphodiesterase 5 (PDE5) inhibitor indicated for erectile dysfunction (ED) ( 1.1 ).|[PMDA] Drugs containing a new active ingredient indicated for the treatment of erectile dysfunction (patients unable to obtain or maintain erections sufficient for satisfactory sexual activity). uuid:bf230cce-f56f-4a06-a691-0cea7dd4c9fa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71940 biolink:treats MONDO:0020740 PMID:41385096 "[{""id"":""uuid:b866eb90-ae59-439d-9fea-063b292bd3ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:32a5dd70-0bba-418d-89bf-a82e24f49175"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CIALIS ® is a phosphodiesterase 5 (PDE5) inhibitor indicated for erectile dysfunction (ED) ( 1.1 ). uuid:d395a861-04ad-423f-8508-6e988c9b6744 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:404914 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:433c122f-3200-412c-8fe1-c60416752e37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c9854810-1a74-4a70-9cd6-f2d71f0dc875"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:07351cfc-404a-4c08-989d-13c71c9ebdae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CADUET (amlodipine and atorvastatin) is indicated in patients for whom treatment with both amlodipine and atorvastatin is appropriate. Amlodipine1. Hypertension : Amlodipine is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents; 2. Coronary Artery Disease (CAD) Chronic Stable Angina: Amlodipine is indicated for the treatment of chronic stable angina. Amlodipine may be used alone or in combination with other antianginal or antihypertensive agents; Vasospastic Angina (Prinzmetal's or Variant Angina): Amlodipine is indicated for the treatment of confirmed or suspected vasospastic angina. Amlodipine may be used as monotherapy or in combination with other antianginal drugs. Angiographically Documented CAD: In patients with recently documented CAD by angiography and without heart failure or an ejection fraction less than 40%, amlodipine is indicated to reduce the risk of hospitalization due to angina and to reduce the risk of a coronary revascularization procedure. AND Atorvastatin Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, the atorvastatin component of CADUET can be started simultaneously with diet restriction. 1. Prevention of Cardiovascular Disease: In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, LIPITOR is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke; In patients with clinically evident coronary heart disease, LIPITOR is indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 2. Heterozygous Familial and Nonfamilial Hyperlipidemia : Atorvastatin is indicated as an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia ( Fredrickson Types IIa and IIb); 3. Elevated Serum TG Levels : Atorvastatin is indicated as an adjunct to diet for the treatment of patients with elevated serum TG levels ( Fredrickson Type IV); 4. Primary Dysbetalipoproteinemia : Atorvastatin is indicated for the treatment of patients with primary dysbetalipoproteinemia ( Fredrickson Type III) who do not respond adequately to diet; 5. Homozygous Familial Hypercholesterolemia : Atorvastatin is indicated to reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; 6. Pediatric Patients : Atorvastatin is indicated as an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C remains greater than or equal to 190 mg/dL or LDL-C remains greater than or equal to 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patients. The antidyslipidemic component of CADUET has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons ( Fredrickson Types I and V).|[PMDA] A drug with a new dosage in an additional dosage form for the treatment of hypertension. uuid:93554c8b-882b-4c85-8d2e-5b38997e6472 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:404914 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:50297e70-2fd3-49de-92f4-225512d1dc41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9bbdb7e8-e1ae-45c1-b6aa-ddf6cf1a824b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CADUET (amlodipine and atorvastatin) is indicated in patients for whom treatment with both amlodipine and atorvastatin is appropriate. Amlodipine1. Hypertension : Amlodipine is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents; 2. Coronary Artery Disease (CAD) Chronic Stable Angina: Amlodipine is indicated for the treatment of chronic stable angina. Amlodipine may be used alone or in combination with other antianginal or antihypertensive agents; Vasospastic Angina (Prinzmetal's or Variant Angina): Amlodipine is indicated for the treatment of confirmed or suspected vasospastic angina. Amlodipine may be used as monotherapy or in combination with other antianginal drugs. Angiographically Documented CAD: In patients with recently documented CAD by angiography and without heart failure or an ejection fraction less than 40%, amlodipine is indicated to reduce the risk of hospitalization due to angina and to reduce the risk of a coronary revascularization procedure. AND Atorvastatin Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, the atorvastatin component of CADUET can be started simultaneously with diet restriction. 1. Prevention of Cardiovascular Disease: In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, LIPITOR is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke; In patients with clinically evident coronary heart disease, LIPITOR is indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 2. Heterozygous Familial and Nonfamilial Hyperlipidemia : Atorvastatin is indicated as an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia ( Fredrickson Types IIa and IIb); 3. Elevated Serum TG Levels : Atorvastatin is indicated as an adjunct to diet for the treatment of patients with elevated serum TG levels ( Fredrickson Type IV); 4. Primary Dysbetalipoproteinemia : Atorvastatin is indicated for the treatment of patients with primary dysbetalipoproteinemia ( Fredrickson Type III) who do not respond adequately to diet; 5. Homozygous Familial Hypercholesterolemia : Atorvastatin is indicated to reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; 6. Pediatric Patients : Atorvastatin is indicated as an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C remains greater than or equal to 190 mg/dL or LDL-C remains greater than or equal to 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patients. The antidyslipidemic component of CADUET has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons ( Fredrickson Types I and V). uuid:52e3bb36-73b1-450c-bce2-69ce7c1ea2ac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:404914 biolink:treats MONDO:0006021 PMID:41385096 "[{""id"":""uuid:8b29e436-bb04-4215-805e-4f40cb90dc09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5c953993-bd7d-447d-b0cf-da1466014e4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CADUET (amlodipine and atorvastatin) is indicated in patients for whom treatment with both amlodipine and atorvastatin is appropriate. Amlodipine1. Hypertension : Amlodipine is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents; 2. Coronary Artery Disease (CAD) Chronic Stable Angina: Amlodipine is indicated for the treatment of chronic stable angina. Amlodipine may be used alone or in combination with other antianginal or antihypertensive agents; Vasospastic Angina (Prinzmetal's or Variant Angina): Amlodipine is indicated for the treatment of confirmed or suspected vasospastic angina. Amlodipine may be used as monotherapy or in combination with other antianginal drugs. Angiographically Documented CAD: In patients with recently documented CAD by angiography and without heart failure or an ejection fraction less than 40%, amlodipine is indicated to reduce the risk of hospitalization due to angina and to reduce the risk of a coronary revascularization procedure. AND Atorvastatin Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, the atorvastatin component of CADUET can be started simultaneously with diet restriction. 1. Prevention of Cardiovascular Disease: In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, LIPITOR is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke; In patients with clinically evident coronary heart disease, LIPITOR is indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 2. Heterozygous Familial and Nonfamilial Hyperlipidemia : Atorvastatin is indicated as an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia ( Fredrickson Types IIa and IIb); 3. Elevated Serum TG Levels : Atorvastatin is indicated as an adjunct to diet for the treatment of patients with elevated serum TG levels ( Fredrickson Type IV); 4. Primary Dysbetalipoproteinemia : Atorvastatin is indicated for the treatment of patients with primary dysbetalipoproteinemia ( Fredrickson Type III) who do not respond adequately to diet; 5. Homozygous Familial Hypercholesterolemia : Atorvastatin is indicated to reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; 6. Pediatric Patients : Atorvastatin is indicated as an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C remains greater than or equal to 190 mg/dL or LDL-C remains greater than or equal to 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patients. The antidyslipidemic component of CADUET has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons ( Fredrickson Types I and V). uuid:4af526bc-e41f-434c-9eab-9368e87c495b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:404914 biolink:treats HP:0003124 PMID:41385096 "[{""id"":""uuid:c25e0a74-4515-4559-920b-8cdd22a670d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:31474b1e-8f1d-4fe6-8383-913f2fb43865"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:245b78c9-20cd-42dc-83bf-f8c7696f6cbd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CADUET (amlodipine and atorvastatin) is indicated in patients for whom treatment with both amlodipine and atorvastatin is appropriate. Amlodipine1. Hypertension : Amlodipine is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents; 2. Coronary Artery Disease (CAD) Chronic Stable Angina: Amlodipine is indicated for the treatment of chronic stable angina. Amlodipine may be used alone or in combination with other antianginal or antihypertensive agents; Vasospastic Angina (Prinzmetal's or Variant Angina): Amlodipine is indicated for the treatment of confirmed or suspected vasospastic angina. Amlodipine may be used as monotherapy or in combination with other antianginal drugs. Angiographically Documented CAD: In patients with recently documented CAD by angiography and without heart failure or an ejection fraction less than 40%, amlodipine is indicated to reduce the risk of hospitalization due to angina and to reduce the risk of a coronary revascularization procedure. AND Atorvastatin Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, the atorvastatin component of CADUET can be started simultaneously with diet restriction. 1. Prevention of Cardiovascular Disease: In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, LIPITOR is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke; In patients with clinically evident coronary heart disease, LIPITOR is indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 2. Heterozygous Familial and Nonfamilial Hyperlipidemia : Atorvastatin is indicated as an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia ( Fredrickson Types IIa and IIb); 3. Elevated Serum TG Levels : Atorvastatin is indicated as an adjunct to diet for the treatment of patients with elevated serum TG levels ( Fredrickson Type IV); 4. Primary Dysbetalipoproteinemia : Atorvastatin is indicated for the treatment of patients with primary dysbetalipoproteinemia ( Fredrickson Type III) who do not respond adequately to diet; 5. Homozygous Familial Hypercholesterolemia : Atorvastatin is indicated to reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; 6. Pediatric Patients : Atorvastatin is indicated as an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C remains greater than or equal to 190 mg/dL or LDL-C remains greater than or equal to 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patients. The antidyslipidemic component of CADUET has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons ( Fredrickson Types I and V).|[PMDA] New combination drugs indicated for the treatment of comorbidity of hypertension or angina pectoris and hypercholesterolemia or familial hypercholesterolemia. uuid:0277e9b0-cebe-49ba-bb5c-383daa9d5a56 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:404914 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:3856bfbc-57ff-488f-ba6a-a89ffcd96540"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0c75966a-5ae5-4a61-b8be-55bde0b3f300"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CADUET (amlodipine and atorvastatin) is indicated in patients for whom treatment with both amlodipine and atorvastatin is appropriate. Amlodipine1. Hypertension : Amlodipine is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents; 2. Coronary Artery Disease (CAD) Chronic Stable Angina: Amlodipine is indicated for the treatment of chronic stable angina. Amlodipine may be used alone or in combination with other antianginal or antihypertensive agents; Vasospastic Angina (Prinzmetal's or Variant Angina): Amlodipine is indicated for the treatment of confirmed or suspected vasospastic angina. Amlodipine may be used as monotherapy or in combination with other antianginal drugs. Angiographically Documented CAD: In patients with recently documented CAD by angiography and without heart failure or an ejection fraction less than 40%, amlodipine is indicated to reduce the risk of hospitalization due to angina and to reduce the risk of a coronary revascularization procedure. AND Atorvastatin Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, the atorvastatin component of CADUET can be started simultaneously with diet restriction. 1. Prevention of Cardiovascular Disease: In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, LIPITOR is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke; In patients with clinically evident coronary heart disease, LIPITOR is indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 2. Heterozygous Familial and Nonfamilial Hyperlipidemia : Atorvastatin is indicated as an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia ( Fredrickson Types IIa and IIb); 3. Elevated Serum TG Levels : Atorvastatin is indicated as an adjunct to diet for the treatment of patients with elevated serum TG levels ( Fredrickson Type IV); 4. Primary Dysbetalipoproteinemia : Atorvastatin is indicated for the treatment of patients with primary dysbetalipoproteinemia ( Fredrickson Type III) who do not respond adequately to diet; 5. Homozygous Familial Hypercholesterolemia : Atorvastatin is indicated to reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; 6. Pediatric Patients : Atorvastatin is indicated as an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C remains greater than or equal to 190 mg/dL or LDL-C remains greater than or equal to 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patients. The antidyslipidemic component of CADUET has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons ( Fredrickson Types I and V). uuid:dc50e5e8-8c47-45ba-8f67-c03c7f97be62 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:404914 biolink:treats HP:0012592 PMID:41385096 "[{""id"":""uuid:182088fe-f3c7-4f61-bd3d-5d8268d89295"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:61ce4fbc-31c7-4727-901e-0cd98589ab13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CADUET (amlodipine and atorvastatin) is indicated in patients for whom treatment with both amlodipine and atorvastatin is appropriate. Amlodipine1. Hypertension : Amlodipine is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents; 2. Coronary Artery Disease (CAD) Chronic Stable Angina: Amlodipine is indicated for the treatment of chronic stable angina. Amlodipine may be used alone or in combination with other antianginal or antihypertensive agents; Vasospastic Angina (Prinzmetal's or Variant Angina): Amlodipine is indicated for the treatment of confirmed or suspected vasospastic angina. Amlodipine may be used as monotherapy or in combination with other antianginal drugs. Angiographically Documented CAD: In patients with recently documented CAD by angiography and without heart failure or an ejection fraction less than 40%, amlodipine is indicated to reduce the risk of hospitalization due to angina and to reduce the risk of a coronary revascularization procedure. AND Atorvastatin Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, the atorvastatin component of CADUET can be started simultaneously with diet restriction. 1. Prevention of Cardiovascular Disease: In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, LIPITOR is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke; In patients with clinically evident coronary heart disease, LIPITOR is indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 2. Heterozygous Familial and Nonfamilial Hyperlipidemia : Atorvastatin is indicated as an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia ( Fredrickson Types IIa and IIb); 3. Elevated Serum TG Levels : Atorvastatin is indicated as an adjunct to diet for the treatment of patients with elevated serum TG levels ( Fredrickson Type IV); 4. Primary Dysbetalipoproteinemia : Atorvastatin is indicated for the treatment of patients with primary dysbetalipoproteinemia ( Fredrickson Type III) who do not respond adequately to diet; 5. Homozygous Familial Hypercholesterolemia : Atorvastatin is indicated to reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; 6. Pediatric Patients : Atorvastatin is indicated as an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C remains greater than or equal to 190 mg/dL or LDL-C remains greater than or equal to 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patients. The antidyslipidemic component of CADUET has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons ( Fredrickson Types I and V). uuid:2edcfde9-9c22-4147-b7c8-26d08495200b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:404914 biolink:treats MONDO:0001336 PMID:41385096 "[{""id"":""uuid:d14a203c-eb58-4cda-a2d8-2ce84061bb3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6fa7a15e-551f-497f-8d95-e157148f6e3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CADUET (amlodipine and atorvastatin) is indicated in patients for whom treatment with both amlodipine and atorvastatin is appropriate. Amlodipine1. Hypertension : Amlodipine is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents; 2. Coronary Artery Disease (CAD) Chronic Stable Angina: Amlodipine is indicated for the treatment of chronic stable angina. Amlodipine may be used alone or in combination with other antianginal or antihypertensive agents; Vasospastic Angina (Prinzmetal's or Variant Angina): Amlodipine is indicated for the treatment of confirmed or suspected vasospastic angina. Amlodipine may be used as monotherapy or in combination with other antianginal drugs. Angiographically Documented CAD: In patients with recently documented CAD by angiography and without heart failure or an ejection fraction less than 40%, amlodipine is indicated to reduce the risk of hospitalization due to angina and to reduce the risk of a coronary revascularization procedure. AND Atorvastatin Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, the atorvastatin component of CADUET can be started simultaneously with diet restriction. 1. Prevention of Cardiovascular Disease: In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, LIPITOR is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke; In patients with clinically evident coronary heart disease, LIPITOR is indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 2. Heterozygous Familial and Nonfamilial Hyperlipidemia : Atorvastatin is indicated as an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia ( Fredrickson Types IIa and IIb); 3. Elevated Serum TG Levels : Atorvastatin is indicated as an adjunct to diet for the treatment of patients with elevated serum TG levels ( Fredrickson Type IV); 4. Primary Dysbetalipoproteinemia : Atorvastatin is indicated for the treatment of patients with primary dysbetalipoproteinemia ( Fredrickson Type III) who do not respond adequately to diet; 5. Homozygous Familial Hypercholesterolemia : Atorvastatin is indicated to reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; 6. Pediatric Patients : Atorvastatin is indicated as an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C remains greater than or equal to 190 mg/dL or LDL-C remains greater than or equal to 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patients. The antidyslipidemic component of CADUET has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons ( Fredrickson Types I and V). uuid:067dae98-4f49-42a9-ab57-2a1502be79a9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:404914 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:5b700b91-a486-40a8-a105-eb4ce359e8de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:93f2b771-133e-4d62-9973-7a6574eacb2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CADUET (amlodipine and atorvastatin) is indicated in patients for whom treatment with both amlodipine and atorvastatin is appropriate. Amlodipine1. Hypertension : Amlodipine is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents; 2. Coronary Artery Disease (CAD) Chronic Stable Angina: Amlodipine is indicated for the treatment of chronic stable angina. Amlodipine may be used alone or in combination with other antianginal or antihypertensive agents; Vasospastic Angina (Prinzmetal's or Variant Angina): Amlodipine is indicated for the treatment of confirmed or suspected vasospastic angina. Amlodipine may be used as monotherapy or in combination with other antianginal drugs. Angiographically Documented CAD: In patients with recently documented CAD by angiography and without heart failure or an ejection fraction less than 40%, amlodipine is indicated to reduce the risk of hospitalization due to angina and to reduce the risk of a coronary revascularization procedure. AND Atorvastatin Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, the atorvastatin component of CADUET can be started simultaneously with diet restriction. 1. Prevention of Cardiovascular Disease: In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, LIPITOR is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke; In patients with clinically evident coronary heart disease, LIPITOR is indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 2. Heterozygous Familial and Nonfamilial Hyperlipidemia : Atorvastatin is indicated as an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia ( Fredrickson Types IIa and IIb); 3. Elevated Serum TG Levels : Atorvastatin is indicated as an adjunct to diet for the treatment of patients with elevated serum TG levels ( Fredrickson Type IV); 4. Primary Dysbetalipoproteinemia : Atorvastatin is indicated for the treatment of patients with primary dysbetalipoproteinemia ( Fredrickson Type III) who do not respond adequately to diet; 5. Homozygous Familial Hypercholesterolemia : Atorvastatin is indicated to reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; 6. Pediatric Patients : Atorvastatin is indicated as an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C remains greater than or equal to 190 mg/dL or LDL-C remains greater than or equal to 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patients. The antidyslipidemic component of CADUET has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons ( Fredrickson Types I and V). uuid:76359b8f-9689-4f63-87e1-2b9fe6e48195 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:404914 biolink:treats HP:0003119 PMID:41385096 "[{""id"":""uuid:59b1713c-37f5-49e4-9d2d-b648a77d0476"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:628e4afa-61e5-4921-928a-0da8dcc8070c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CADUET (amlodipine and atorvastatin) is indicated in patients for whom treatment with both amlodipine and atorvastatin is appropriate. Amlodipine1. Hypertension : Amlodipine is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents; 2. Coronary Artery Disease (CAD) Chronic Stable Angina: Amlodipine is indicated for the treatment of chronic stable angina. Amlodipine may be used alone or in combination with other antianginal or antihypertensive agents; Vasospastic Angina (Prinzmetal's or Variant Angina): Amlodipine is indicated for the treatment of confirmed or suspected vasospastic angina. Amlodipine may be used as monotherapy or in combination with other antianginal drugs. Angiographically Documented CAD: In patients with recently documented CAD by angiography and without heart failure or an ejection fraction less than 40%, amlodipine is indicated to reduce the risk of hospitalization due to angina and to reduce the risk of a coronary revascularization procedure. AND Atorvastatin Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, the atorvastatin component of CADUET can be started simultaneously with diet restriction. 1. Prevention of Cardiovascular Disease: In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, LIPITOR is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke; In patients with clinically evident coronary heart disease, LIPITOR is indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 2. Heterozygous Familial and Nonfamilial Hyperlipidemia : Atorvastatin is indicated as an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia ( Fredrickson Types IIa and IIb); 3. Elevated Serum TG Levels : Atorvastatin is indicated as an adjunct to diet for the treatment of patients with elevated serum TG levels ( Fredrickson Type IV); 4. Primary Dysbetalipoproteinemia : Atorvastatin is indicated for the treatment of patients with primary dysbetalipoproteinemia ( Fredrickson Type III) who do not respond adequately to diet; 5. Homozygous Familial Hypercholesterolemia : Atorvastatin is indicated to reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; 6. Pediatric Patients : Atorvastatin is indicated as an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C remains greater than or equal to 190 mg/dL or LDL-C remains greater than or equal to 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patients. The antidyslipidemic component of CADUET has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons ( Fredrickson Types I and V). uuid:2291485d-30f1-4000-8f52-e2e0ebc224c0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:404914 biolink:treats MONDO:0005347 PMID:41385096 "[{""id"":""uuid:5efc1e15-c7f0-4247-9ec4-897c2fe9d86d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:69009ecf-0381-4631-8147-f23f6305f2a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CADUET (amlodipine and atorvastatin) is indicated in patients for whom treatment with both amlodipine and atorvastatin is appropriate. Amlodipine1. Hypertension : Amlodipine is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents; 2. Coronary Artery Disease (CAD) Chronic Stable Angina: Amlodipine is indicated for the treatment of chronic stable angina. Amlodipine may be used alone or in combination with other antianginal or antihypertensive agents; Vasospastic Angina (Prinzmetal's or Variant Angina): Amlodipine is indicated for the treatment of confirmed or suspected vasospastic angina. Amlodipine may be used as monotherapy or in combination with other antianginal drugs. Angiographically Documented CAD: In patients with recently documented CAD by angiography and without heart failure or an ejection fraction less than 40%, amlodipine is indicated to reduce the risk of hospitalization due to angina and to reduce the risk of a coronary revascularization procedure. AND Atorvastatin Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, the atorvastatin component of CADUET can be started simultaneously with diet restriction. 1. Prevention of Cardiovascular Disease: In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, LIPITOR is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke; In patients with clinically evident coronary heart disease, LIPITOR is indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 2. Heterozygous Familial and Nonfamilial Hyperlipidemia : Atorvastatin is indicated as an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia ( Fredrickson Types IIa and IIb); 3. Elevated Serum TG Levels : Atorvastatin is indicated as an adjunct to diet for the treatment of patients with elevated serum TG levels ( Fredrickson Type IV); 4. Primary Dysbetalipoproteinemia : Atorvastatin is indicated for the treatment of patients with primary dysbetalipoproteinemia ( Fredrickson Type III) who do not respond adequately to diet; 5. Homozygous Familial Hypercholesterolemia : Atorvastatin is indicated to reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; 6. Pediatric Patients : Atorvastatin is indicated as an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C remains greater than or equal to 190 mg/dL or LDL-C remains greater than or equal to 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patients. The antidyslipidemic component of CADUET has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons ( Fredrickson Types I and V). uuid:14db9154-86b2-499a-bbdc-d7a2ba70a588 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:404914 biolink:treats MONDO:0018473 PMID:41385096 "[{""id"":""uuid:ad1f7a00-2cdc-439f-ba0c-a0c69674abc4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7ac68f97-b1f9-4b97-ba19-3dec8b99c3aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CADUET (amlodipine and atorvastatin) is indicated in patients for whom treatment with both amlodipine and atorvastatin is appropriate. Amlodipine1. Hypertension : Amlodipine is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents; 2. Coronary Artery Disease (CAD) Chronic Stable Angina: Amlodipine is indicated for the treatment of chronic stable angina. Amlodipine may be used alone or in combination with other antianginal or antihypertensive agents; Vasospastic Angina (Prinzmetal's or Variant Angina): Amlodipine is indicated for the treatment of confirmed or suspected vasospastic angina. Amlodipine may be used as monotherapy or in combination with other antianginal drugs. Angiographically Documented CAD: In patients with recently documented CAD by angiography and without heart failure or an ejection fraction less than 40%, amlodipine is indicated to reduce the risk of hospitalization due to angina and to reduce the risk of a coronary revascularization procedure. AND Atorvastatin Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, the atorvastatin component of CADUET can be started simultaneously with diet restriction. 1. Prevention of Cardiovascular Disease: In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, LIPITOR is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke; In patients with clinically evident coronary heart disease, LIPITOR is indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 2. Heterozygous Familial and Nonfamilial Hyperlipidemia : Atorvastatin is indicated as an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia ( Fredrickson Types IIa and IIb); 3. Elevated Serum TG Levels : Atorvastatin is indicated as an adjunct to diet for the treatment of patients with elevated serum TG levels ( Fredrickson Type IV); 4. Primary Dysbetalipoproteinemia : Atorvastatin is indicated for the treatment of patients with primary dysbetalipoproteinemia ( Fredrickson Type III) who do not respond adequately to diet; 5. Homozygous Familial Hypercholesterolemia : Atorvastatin is indicated to reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; 6. Pediatric Patients : Atorvastatin is indicated as an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C remains greater than or equal to 190 mg/dL or LDL-C remains greater than or equal to 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patients. The antidyslipidemic component of CADUET has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons ( Fredrickson Types I and V). uuid:04a93a10-43bf-4bcc-9752-f84ed42fef45 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:404914 biolink:treats MONDO:0018328 PMID:41385096 "[{""id"":""uuid:11be39f4-1b5b-4c88-8f5d-439f2e871718"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7e05c07a-6f65-41b3-8380-39a9956972e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CADUET (amlodipine and atorvastatin) is indicated in patients for whom treatment with both amlodipine and atorvastatin is appropriate. Amlodipine1. Hypertension : Amlodipine is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents; 2. Coronary Artery Disease (CAD) Chronic Stable Angina: Amlodipine is indicated for the treatment of chronic stable angina. Amlodipine may be used alone or in combination with other antianginal or antihypertensive agents; Vasospastic Angina (Prinzmetal's or Variant Angina): Amlodipine is indicated for the treatment of confirmed or suspected vasospastic angina. Amlodipine may be used as monotherapy or in combination with other antianginal drugs. Angiographically Documented CAD: In patients with recently documented CAD by angiography and without heart failure or an ejection fraction less than 40%, amlodipine is indicated to reduce the risk of hospitalization due to angina and to reduce the risk of a coronary revascularization procedure. AND Atorvastatin Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, the atorvastatin component of CADUET can be started simultaneously with diet restriction. 1. Prevention of Cardiovascular Disease: In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, LIPITOR is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke; In patients with clinically evident coronary heart disease, LIPITOR is indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 2. Heterozygous Familial and Nonfamilial Hyperlipidemia : Atorvastatin is indicated as an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia ( Fredrickson Types IIa and IIb); 3. Elevated Serum TG Levels : Atorvastatin is indicated as an adjunct to diet for the treatment of patients with elevated serum TG levels ( Fredrickson Type IV); 4. Primary Dysbetalipoproteinemia : Atorvastatin is indicated for the treatment of patients with primary dysbetalipoproteinemia ( Fredrickson Type III) who do not respond adequately to diet; 5. Homozygous Familial Hypercholesterolemia : Atorvastatin is indicated to reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; 6. Pediatric Patients : Atorvastatin is indicated as an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C remains greater than or equal to 190 mg/dL or LDL-C remains greater than or equal to 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patients. The antidyslipidemic component of CADUET has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons ( Fredrickson Types I and V). uuid:bcd95bd2-9246-4b86-ac32-03785ab8a427 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2611 biolink:treats MONDO:0005618 PMID:41385096 "[{""id"":""uuid:f75d905d-5a81-4f6a-8b0f-9de209ce5d6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:980a9efc-714d-429f-acb3-aeed1e76bbb9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Alprazolam tablets are indicated for the management of anxiety disorder (a condition corresponding most closely to the APA Diagnostic and Statistical Manual [DSM-III-R] diagnosis of generalized anxiety disorder) or the short-term relief of symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. Generalized anxiety disorder is characterized by unrealistic or excessive anxiety and worry (apprehensive expectation) about two or more life circumstances, for a period of six months or longer, during which the person has been bothered more days than not by these concerns. At least 6 of the following 18 symptoms are often present in these patients: Motor Tension (trembling, twitching, or feeling shaky; muscle tension, aches, or soreness; restlessness; easy fatigability); Autonomic Hyperactivity (shortness of breath or smothering sensations; palpitations or accelerated heart rate; sweating, or cold clammy hands; dry mouth; dizziness or light-headedness; nausea, diarrhea, or other abdominal distress; flushes or chills; frequent urination; trouble swallowing or ‘lump in throat’); Vigilance and Scanning (feeling keyed up or on edge; exaggerated startle response; difficulty concentrating or ‘mind going blank’ because of anxiety; trouble falling or staying asleep; irritability). These symptoms must not be secondary to another psychiatric disorder or caused by some organic factor. Anxiety associated with depression is responsive to alprazolam. uuid:629d2043-9d18-4380-b8e3-7681db2f27a0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2611 biolink:treats MONDO:0001942 PMID:41385096 "[{""id"":""uuid:74b37e9c-7f22-438a-9d5e-a9cdd5d9e0ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:938efb2a-b4f8-401b-bc70-39f46658a2ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Alprazolam tablets are indicated for the management of anxiety disorder (a condition corresponding most closely to the APA Diagnostic and Statistical Manual [DSM-III-R] diagnosis of generalized anxiety disorder) or the short-term relief of symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. Generalized anxiety disorder is characterized by unrealistic or excessive anxiety and worry (apprehensive expectation) about two or more life circumstances, for a period of six months or longer, during which the person has been bothered more days than not by these concerns. At least 6 of the following 18 symptoms are often present in these patients: Motor Tension (trembling, twitching, or feeling shaky; muscle tension, aches, or soreness; restlessness; easy fatigability); Autonomic Hyperactivity (shortness of breath or smothering sensations; palpitations or accelerated heart rate; sweating, or cold clammy hands; dry mouth; dizziness or light-headedness; nausea, diarrhea, or other abdominal distress; flushes or chills; frequent urination; trouble swallowing or ‘lump in throat’); Vigilance and Scanning (feeling keyed up or on edge; exaggerated startle response; difficulty concentrating or ‘mind going blank’ because of anxiety; trouble falling or staying asleep; irritability). These symptoms must not be secondary to another psychiatric disorder or caused by some organic factor. Anxiety associated with depression is responsive to alprazolam. uuid:953c75cb-1bd1-4c7e-8799-9310ddb7ba96 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2611 biolink:treats MONDO:0011918 PMID:41385096 "[{""id"":""uuid:61437737-b172-4fe5-9e6d-77f59de29a44"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a4fef95f-d501-45e7-b1dd-6c236bd98bed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Alprazolam tablets are indicated for the management of anxiety disorder (a condition corresponding most closely to the APA Diagnostic and Statistical Manual [DSM-III-R] diagnosis of generalized anxiety disorder) or the short-term relief of symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. Generalized anxiety disorder is characterized by unrealistic or excessive anxiety and worry (apprehensive expectation) about two or more life circumstances, for a period of six months or longer, during which the person has been bothered more days than not by these concerns. At least 6 of the following 18 symptoms are often present in these patients: Motor Tension (trembling, twitching, or feeling shaky; muscle tension, aches, or soreness; restlessness; easy fatigability); Autonomic Hyperactivity (shortness of breath or smothering sensations; palpitations or accelerated heart rate; sweating, or cold clammy hands; dry mouth; dizziness or light-headedness; nausea, diarrhea, or other abdominal distress; flushes or chills; frequent urination; trouble swallowing or ‘lump in throat’); Vigilance and Scanning (feeling keyed up or on edge; exaggerated startle response; difficulty concentrating or ‘mind going blank’ because of anxiety; trouble falling or staying asleep; irritability). These symptoms must not be secondary to another psychiatric disorder or caused by some organic factor. Anxiety associated with depression is responsive to alprazolam. uuid:cdcda89b-17ee-4505-81c7-bc2933c2f378 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2611 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:1f97aa19-075f-4b6c-a106-fd67fecee9d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:144a00b7-972e-4a95-bb0f-81237b961b11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Alprazolam tablets are indicated for the management of anxiety disorder (a condition corresponding most closely to the APA Diagnostic and Statistical Manual [DSM-III-R] diagnosis of generalized anxiety disorder) or the short-term relief of symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. Generalized anxiety disorder is characterized by unrealistic or excessive anxiety and worry (apprehensive expectation) about two or more life circumstances, for a period of six months or longer, during which the person has been bothered more days than not by these concerns. At least 6 of the following 18 symptoms are often present in these patients: Motor Tension (trembling, twitching, or feeling shaky; muscle tension, aches, or soreness; restlessness; easy fatigability); Autonomic Hyperactivity (shortness of breath or smothering sensations; palpitations or accelerated heart rate; sweating, or cold clammy hands; dry mouth; dizziness or light-headedness; nausea, diarrhea, or other abdominal distress; flushes or chills; frequent urination; trouble swallowing or ‘lump in throat’); Vigilance and Scanning (feeling keyed up or on edge; exaggerated startle response; difficulty concentrating or ‘mind going blank’ because of anxiety; trouble falling or staying asleep; irritability). These symptoms must not be secondary to another psychiatric disorder or caused by some organic factor. Anxiety associated with depression is responsive to alprazolam. uuid:24c7f733-97bb-4423-bf9f-97ff7b7b9cb6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2668 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:5ce7ab49-ee23-4ac7-a354-ecc1f63379cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c457e2b6-73e5-4371-ae38-ae6e95ecfd42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Amlodipine is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents. Coronary Artery Disease (CAD) Chronic Stable Angina Amlodipine is indicated for the symptomatic treatment of chronic stable angina. Amlodipine may be used alone or in combination with other antianginal agents. Vasospastic Angina (Prinzmetal's or Variant Angina) Amlodipine is indicated for the treatment of confirmed or suspected vasospastic angina. Amlodipine may be used as monotherapy or in combination with other antianginal drugs. Angiographically Documented CAD In patients with recently documented CAD by angiography and without heart failure or an ejection fraction <40%, amlodipine besylate tablets are indicated to reduce the risk of hospitalization due to angina and to reduce the risk of a coronary revascularization procedure. uuid:c1c8d507-277f-438d-a3c4-1d09fd92c849 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135935 biolink:treats NCIT:C27003 PMID:41385096 "[{""id"":""uuid:4317adf5-c271-4001-b677-f10ea6c98b8e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d1beeaf3-c362-4c51-b39f-12bcbe5b8b04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NUCYNTA™ (tapentadol) is indicated for the relief of moderate to severe acute pain in patients 18 years of age or older. uuid:6d9ad2aa-633d-472b-9463-cc73c7fe51a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63610 biolink:treats UMLS:C0341178 PMID:41385096 "[{""id"":""uuid:410635e2-65dd-43f3-9f03-a625b5a3306d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:20769042-3a9b-4b9b-b210-a6b233da1970"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Misoprostol tablets are indicated for reducing the risk of NSAID (nonsteroidal anti-inflammatory drugs, including aspirin)–induced gastric ulcers in patients at high risk of complications from gastric ulcer, e.g., the elderly and patients with concomitant debilitating disease, as well as patients at high risk of developing gastric ulceration, such as patients with a history of ulcer. Misoprostol has not been shown to reduce the risk of duodenal ulcers in patients taking NSAIDs. Misoprostol should be taken for the duration of NSAID therapy. Misoprostol has been shown to reduce the risk of gastric ulcers in controlled studies of 3 months’ duration. It had no effect, compared to placebo, on gastrointestinal pain or discomfort associated with NSAID use. uuid:1f994fec-6ff0-422c-b35e-642a1b04245a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63610 biolink:treats MONDO:0005412 PMID:41385096 "[{""id"":""uuid:db9c2bd1-ae35-47a7-9cce-65156b58cf56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ed78849f-bdc4-4b94-a479-dcb60f98e213"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Misoprostol tablets are indicated for reducing the risk of NSAID (nonsteroidal anti-inflammatory drugs, including aspirin)–induced gastric ulcers in patients at high risk of complications from gastric ulcer, e.g., the elderly and patients with concomitant debilitating disease, as well as patients at high risk of developing gastric ulceration, such as patients with a history of ulcer. Misoprostol has not been shown to reduce the risk of duodenal ulcers in patients taking NSAIDs. Misoprostol should be taken for the duration of NSAID therapy. Misoprostol has been shown to reduce the risk of gastric ulcers in controlled studies of 3 months’ duration. It had no effect, compared to placebo, on gastrointestinal pain or discomfort associated with NSAID use. uuid:1701d7e0-667f-4475-80b1-1cde276f469f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3223 biolink:treats UMLS:C0086132 PMID:41385096 "[{""id"":""uuid:7b6aa92a-53f8-4be7-9502-a80d33b22e96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5f027a4e-3bc0-44cb-bdf8-3903156c6cab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The efficacy of buspirone has been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to Generalized Anxiety Disorder (GAD). Many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone relieved anxiety in the presence of these coexisting depressive symptoms. The patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months. Generalized Anxiety Disorder (300.02) is described in the American Psychiatric Association’s Diagnostic and Statistical Manual, III 1 as follows: Generalized, persistent anxiety (of at least 1 month continual duration), manifested by symptoms from three of the four following categories: Motor tension: shakiness, jitteriness, jumpiness, trembling, tension, muscle aches, fatigability, inability to relax, eyelid twitch, furrowed brow, strained face, fidgeting, restlessness, easy startle. Autonomic hyperactivity: sweating, heart pounding or racing, cold, clammy hands, dry mouth, dizziness, lightheadedness, paresthesias (tingling in hands or feet), upset stomach, hot or cold spells, frequent urination, diarrhea, discomfort in the pit of the stomach, lump in the throat, flushing, pallor, high resting pulse, and respiration rate. Apprehensive expectation: anxiety, worry, fear, rumination, and anticipation of misfortune to self or others. Vigilance and scanning: hyperattentiveness resulting in distractibility, difficulty in concentrating, insomnia, feeling “on edge,” irritability, impatience. The above symptoms would not be due to another mental disorder, such as a depressive disorder or schizophrenia. However, mild depressive symptoms are common in GAD. The effectiveness of buspirone in long-term use, that is, for more than 3 to 4 weeks, has not been demonstrated in controlled trials. There is no body of evidence available that systematically addresses the appropriate duration of treatment for GAD. However, in a study of long-term use, 264 patients were treated with buspirone for 1 year without ill effect. Therefore, the physician who elects to use buspirone for extended periods should periodically reassess the usefulness of the drug for the individual patient. uuid:4e12120c-4120-47f8-a515-5550704ede37 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:39867 biolink:treats MONDO:0006710 PMID:41385096 "[{""id"":""uuid:3f4d87ba-79d7-4eda-b22e-6e2bb7084a54"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:18b80a7a-9a31-4783-94da-f4ef0e12a3cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Valproic Acid is indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. Valproic Acid is indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures. Simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs. Complex absence is the term used when other signs are also present. SEE WARNINGS FOR STATEMENT REGARDING FATAL HEPATIC DYSFUNCTION. uuid:85ab1aae-38ff-44e0-ac66-3865b0dfa0ce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:39867 biolink:treats MONDO:0010826 PMID:41385096 "[{""id"":""uuid:f33ce4ab-533e-440c-81cd-1ede30f24101"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e485f74c-ee99-4049-8be9-eec58419b5d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Valproic Acid is indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. Valproic Acid is indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures. Simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs. Complex absence is the term used when other signs are also present. SEE WARNINGS FOR STATEMENT REGARDING FATAL HEPATIC DYSFUNCTION. uuid:88196e7b-5307-4de3-b467-91a9408ddd89 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:39867 biolink:treats MONDO:0005027 PMID:41385096 "[{""id"":""uuid:1502c6c7-caca-4a3e-844d-7e77d348441c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3e910a3a-63a6-46a0-b0a7-2b8b6a849a80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Valproic Acid is indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. Valproic Acid is indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures. Simple absence is defined as very brief clouding of the sensorium or loss of consciousness accompanied by certain generalized epileptic discharges without other detectable clinical signs. Complex absence is the term used when other signs are also present. SEE WARNINGS FOR STATEMENT REGARDING FATAL HEPATIC DYSFUNCTION. uuid:1a68a291-2712-4d83-84af-4ed4b4750842 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5384 biolink:treats MONDO:0002909 PMID:41385096 "[{""id"":""uuid:6d879a2b-bc2e-4f9c-9ffc-18eaffb65af8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5bddb761-1e66-431e-af06-aa725fd6a068"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Glipizide tablets are indicated as an adjunct to diet for the control of hyperglycemia and its associated symptomatology in patients with non-insulin-dependent diabetes mellitus (NIDDM; type II), formerly known as maturity-onset diabetes, after an adequate trial of dietary therapy has proved unsatisfactory. In initiating treatment for non-insulin-dependent diabetes, diet should be emphasized as the primary form of treatment. Caloric restriction and weight loss are essential in the obese diabetic patient. Proper dietary management alone may be effective in controlling the blood glucose and symptoms of hyperglycemia. The importance of regular physical activity should also be stressed, and cardiovascular risk factors should be identified, and corrective measures taken where possible. If this treatment program fails to reduce symptoms and/or blood glucose, the use of an oral sulfonylurea or insulin should be considered. Use of glipizide must be viewed by both the physician and patient as a treatment in addition to diet, and not as a substitute for diet or as a convenient mechanism for avoiding dietary restraint. Furthermore, loss of blood glucose control on diet alone also may be transient, thus requiring only short-term administration of glipizide. During maintenance programs, glipizide should be discontinued if satisfactory lowering of blood glucose is no longer achieved. Judgements should be based on regular clinical and laboratory evaluations. In considering the use of glipizide in asymptomatic patients, it should be recognized that controlling the blood glucose in non-insulin-dependent diabetes has not been definitely established to be effective in preventing the long-term cardiovascular or neural complications of diabetes. uuid:485e9f05-b7d3-4386-8f5f-a90831ff992c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5384 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:c1763d52-8e96-464e-ae67-602502f7ed53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:93766e74-6bad-4239-9589-4209510a230a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Glipizide tablets are indicated as an adjunct to diet for the control of hyperglycemia and its associated symptomatology in patients with non-insulin-dependent diabetes mellitus (NIDDM; type II), formerly known as maturity-onset diabetes, after an adequate trial of dietary therapy has proved unsatisfactory. In initiating treatment for non-insulin-dependent diabetes, diet should be emphasized as the primary form of treatment. Caloric restriction and weight loss are essential in the obese diabetic patient. Proper dietary management alone may be effective in controlling the blood glucose and symptoms of hyperglycemia. The importance of regular physical activity should also be stressed, and cardiovascular risk factors should be identified, and corrective measures taken where possible. If this treatment program fails to reduce symptoms and/or blood glucose, the use of an oral sulfonylurea or insulin should be considered. Use of glipizide must be viewed by both the physician and patient as a treatment in addition to diet, and not as a substitute for diet or as a convenient mechanism for avoiding dietary restraint. Furthermore, loss of blood glucose control on diet alone also may be transient, thus requiring only short-term administration of glipizide. During maintenance programs, glipizide should be discontinued if satisfactory lowering of blood glucose is no longer achieved. Judgements should be based on regular clinical and laboratory evaluations. In considering the use of glipizide in asymptomatic patients, it should be recognized that controlling the blood glucose in non-insulin-dependent diabetes has not been definitely established to be effective in preventing the long-term cardiovascular or neural complications of diabetes. uuid:0619a126-0d0d-4c0f-9a45-71120cdc8334 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8107 biolink:treats MONDO:0005754 PMID:41385096 "[{""id"":""uuid:744994a9-cec4-4e9b-bf80-192d69443e6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e7173981-e89d-40c9-aa20-d494147023f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Extended Phenytoin Sodium Capsules USP, 100 mg are indicated for the control of generalized tonic-clonic (grand mal) and complex partial (psychomotor, temporal lobe) seizures and prevention and treatment of seizures occurring during or following neurosurgery. Phenytoin serum level determinations may be necessary for optimal dosage adjustments (see DOSAGE AND ADMINISTRATION and CLINICAL PHARMACOLOGY ). uuid:618f2727-7c3f-4e44-a39f-5fc4f0c5d77f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8107 biolink:treats MONDO:0015638 PMID:41385096 "[{""id"":""uuid:42063ba4-edcf-42cf-8ea1-dc9ca6981a95"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f6a92831-44f2-48f5-9601-0b5166feb24e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Extended Phenytoin Sodium Capsules USP, 100 mg are indicated for the control of generalized tonic-clonic (grand mal) and complex partial (psychomotor, temporal lobe) seizures and prevention and treatment of seizures occurring during or following neurosurgery. Phenytoin serum level determinations may be necessary for optimal dosage adjustments (see DOSAGE AND ADMINISTRATION and CLINICAL PHARMACOLOGY ). uuid:00b446ae-12df-4318-bc2b-6937b4e9711e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8028 biolink:treats MONDO:0005090 PMID:41385096 "[{""id"":""uuid:c06b38db-b649-45ee-8448-9576e32968a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1e50662a-fd3c-45bc-b904-ce6bde98688d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Perphenazine is indicated for use in the treatment of schizophrenia and for the control of severe nausea and vomiting in adults. Perphenazine has not been shown effective for the management of behavioral complications in patients with mental retardation. uuid:6276b6a1-77af-4b37-8acb-37e60552a319 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8028 biolink:treats HP:0002017 PMID:41385096 "[{""id"":""uuid:cda90fcf-f31c-40fc-bcfa-795330904a76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e5b4f617-a46f-4d7a-8d87-cd8037ba545f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Perphenazine is indicated for use in the treatment of schizophrenia and for the control of severe nausea and vomiting in adults. Perphenazine has not been shown effective for the management of behavioral complications in patients with mental retardation. uuid:bd2b78de-9457-47f9-82f3-22d3460bf4a3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7565 biolink:treats MONDO:0006021 PMID:41385096 "[{""id"":""uuid:aa043497-d8ac-4cc1-b589-a93e09d2810b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8e56a847-fb81-44d7-ac31-61bf5447f6dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nifedipine extended-release tablets are indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. In those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. Nifedipine extended-release may also be used where the clinical presentation suggests a possible vasospastic component but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion or in unstable angina where electrocardiographic findings are compatible with intermittent vasospasm, or when angina is refractory to nitrates and/or adequate doses of beta blockers. uuid:2f63a91f-1930-4688-9785-249efa9d1ec5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7565 biolink:treats MONDO:0006805 PMID:41385096 "[{""id"":""uuid:c8e587fb-0021-4eee-95b5-7242f0579fdb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b30af97c-c990-4757-883e-0a8ec8531c81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nifedipine extended-release tablets are indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. In those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. Nifedipine extended-release may also be used where the clinical presentation suggests a possible vasospastic component but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion or in unstable angina where electrocardiographic findings are compatible with intermittent vasospasm, or when angina is refractory to nitrates and/or adequate doses of beta blockers. uuid:9e4c7c56-cb2c-46e5-b119-05d2e9ff8c1c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7565 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:3cebe1cd-6e04-4efe-8c9a-b088a37a42ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:46f75ad2-8a0a-40b6-8913-16ecbdae7344"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nifedipine extended-release tablets are indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. In those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. Nifedipine extended-release may also be used where the clinical presentation suggests a possible vasospastic component but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion or in unstable angina where electrocardiographic findings are compatible with intermittent vasospasm, or when angina is refractory to nitrates and/or adequate doses of beta blockers. uuid:bc78b85e-0629-4638-9aa6-35b1692378a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5441 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:2daec229-5558-43d2-aa2d-da98bd670c8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:af7f67a9-0acb-45ec-a678-9a08e7323765"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Glyburide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. uuid:0958560f-36ff-4295-9bf9-f493d9fde960 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29103 biolink:treats UMLS:C0151595 PMID:41385096 "[{""id"":""uuid:cce42d99-0479-474a-89dc-94260ef28d63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7efaa13e-dd63-42f9-830d-133be8bfa0bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BECAUSE OF REPORTS OF INTESTINAL AND GASTRIC ULCERATION AND BLEEDING WITH EXTENDED-RELEASE POTASSIUM CHLORIDE PREPARATIONS, THESE DRUGS SHOULD BE RESERVED FOR THOSE PATIENTS WHO CANNOT TOLERATE OR REFUSE TO TAKE LIQUID OR EFFERVESCENT POTASSIUM PREPARATIONS OR FOR PATIENTS IN WHOM THERE IS A PROBLEM OF COMPLIANCE WITH THESE PREPARATIONS. For the therapeutic use of patients with hypokalemia, with or without metabolic alkalosis; in digitalis intoxication; and in patients with hypokalemic familial periodic paralysis. If hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. For the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias. The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern and when low doses of the diuretic are used. Serum potassium should be checked periodically, however, and if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases, and if dose adjustment of the diuretic is ineffective or unwarranted, supplementation with potassium salts may be indicated. uuid:829344eb-9f61-4523-8c95-c36022d2a339 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49040 biolink:treats MONDO:0005311 PMID:41385096 "[{""id"":""uuid:619795d1-6f64-4ff0-a437-e2cb7cab07e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5d066def-d2d7-4a5e-85e4-58431a104a26"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.1 Primary Hyperlipidemia Monotherapy ZETIA 1 , administered alone, is indicated as adjunctive therapy to diet for the reduction of elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), and apolipoprotein B (Apo B) in patients with primary (heterozygous familial and non-familial) hyperlipidemia. 1 COPYRIGHT © 2001, 2002, 2005, 2007, 2008 Merck/Schering-Plough Pharmaceuticals. All rights reserved. Combination Therapy with HMG-CoA Reductase Inhibitors (Statins) ZETIA, administered in combination with a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor (statin), is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, and Apo B in patients with primary (heterozygous familial and non-familial) hyperlipidemia. Combination Therapy with Fenofibrate ZETIA, administered in combination with fenofibrate, is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, Apo B, and non-high-density lipoprotein cholesterol (non-HDL-C) in adult patients with mixed hyperlipidemia. 1.2 Homozygous Familial Hypercholesterolemia (HoFH) The combination of ZETIA and atorvastatin or simvastatin is indicated for the reduction of elevated total-C and LDL-C levels in patients with HoFH, as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable. 1.3 Homozygous Sitosterolemia ZETIA is indicated as adjunctive therapy to diet for the reduction of elevated sitosterol and campesterol levels in patients with homozygous familial sitosterolemia. 1.4 Limitations of Use The effect of ZETIA on cardiovascular morbidity and mortality has not been determined. ZETIA has not been studied in Fredrickson Type I, III, IV, and V dyslipidemias. uuid:fb105804-b1ec-471f-8158-fac738e27e27 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49040 biolink:treats HP:0003124 PMID:41385096 "[{""id"":""uuid:f39dbbdc-c536-4437-8841-ec22ee9703bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b973cf99-31b2-4314-887d-2484966e2bda"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a63a3879-1ab9-416a-a6df-f2f8a9f3013e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.1 Primary Hyperlipidemia Monotherapy ZETIA 1 , administered alone, is indicated as adjunctive therapy to diet for the reduction of elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), and apolipoprotein B (Apo B) in patients with primary (heterozygous familial and non-familial) hyperlipidemia. 1 COPYRIGHT © 2001, 2002, 2005, 2007, 2008 Merck/Schering-Plough Pharmaceuticals. All rights reserved. Combination Therapy with HMG-CoA Reductase Inhibitors (Statins) ZETIA, administered in combination with a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor (statin), is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, and Apo B in patients with primary (heterozygous familial and non-familial) hyperlipidemia. Combination Therapy with Fenofibrate ZETIA, administered in combination with fenofibrate, is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, Apo B, and non-high-density lipoprotein cholesterol (non-HDL-C) in adult patients with mixed hyperlipidemia. 1.2 Homozygous Familial Hypercholesterolemia (HoFH) The combination of ZETIA and atorvastatin or simvastatin is indicated for the reduction of elevated total-C and LDL-C levels in patients with HoFH, as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable. 1.3 Homozygous Sitosterolemia ZETIA is indicated as adjunctive therapy to diet for the reduction of elevated sitosterol and campesterol levels in patients with homozygous familial sitosterolemia. 1.4 Limitations of Use The effect of ZETIA on cardiovascular morbidity and mortality has not been determined. ZETIA has not been studied in Fredrickson Type I, III, IV, and V dyslipidemias.|[PMDA] A drug containing a new active ingredient indicated for the inhibition of cholesterol absorption. uuid:a01113e0-49e8-43bb-b1d5-708dc36aaf45 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49040 biolink:treats MONDO:0001336 PMID:41385096 "[{""id"":""uuid:65957d19-3835-419d-bcce-4409f55b0f64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:867307ef-d96f-403a-8008-ba1c05776713"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.1 Primary Hyperlipidemia Monotherapy ZETIA 1 , administered alone, is indicated as adjunctive therapy to diet for the reduction of elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), and apolipoprotein B (Apo B) in patients with primary (heterozygous familial and non-familial) hyperlipidemia. 1 COPYRIGHT © 2001, 2002, 2005, 2007, 2008 Merck/Schering-Plough Pharmaceuticals. All rights reserved. Combination Therapy with HMG-CoA Reductase Inhibitors (Statins) ZETIA, administered in combination with a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor (statin), is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, and Apo B in patients with primary (heterozygous familial and non-familial) hyperlipidemia. Combination Therapy with Fenofibrate ZETIA, administered in combination with fenofibrate, is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, Apo B, and non-high-density lipoprotein cholesterol (non-HDL-C) in adult patients with mixed hyperlipidemia. 1.2 Homozygous Familial Hypercholesterolemia (HoFH) The combination of ZETIA and atorvastatin or simvastatin is indicated for the reduction of elevated total-C and LDL-C levels in patients with HoFH, as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable. 1.3 Homozygous Sitosterolemia ZETIA is indicated as adjunctive therapy to diet for the reduction of elevated sitosterol and campesterol levels in patients with homozygous familial sitosterolemia. 1.4 Limitations of Use The effect of ZETIA on cardiovascular morbidity and mortality has not been determined. ZETIA has not been studied in Fredrickson Type I, III, IV, and V dyslipidemias. uuid:256706d7-7d35-4613-97fd-7f93e03d08e9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49040 biolink:treats NCIT:C34821 PMID:41385096 "[{""id"":""uuid:71d0a969-a4d3-41e1-b306-355fc16a328a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1df9f2b1-f3ce-4693-b5f9-4f8ce8584aa1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.1 Primary Hyperlipidemia Monotherapy ZETIA 1 , administered alone, is indicated as adjunctive therapy to diet for the reduction of elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), and apolipoprotein B (Apo B) in patients with primary (heterozygous familial and non-familial) hyperlipidemia. 1 COPYRIGHT © 2001, 2002, 2005, 2007, 2008 Merck/Schering-Plough Pharmaceuticals. All rights reserved. Combination Therapy with HMG-CoA Reductase Inhibitors (Statins) ZETIA, administered in combination with a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor (statin), is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, and Apo B in patients with primary (heterozygous familial and non-familial) hyperlipidemia. Combination Therapy with Fenofibrate ZETIA, administered in combination with fenofibrate, is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, Apo B, and non-high-density lipoprotein cholesterol (non-HDL-C) in adult patients with mixed hyperlipidemia. 1.2 Homozygous Familial Hypercholesterolemia (HoFH) The combination of ZETIA and atorvastatin or simvastatin is indicated for the reduction of elevated total-C and LDL-C levels in patients with HoFH, as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable. 1.3 Homozygous Sitosterolemia ZETIA is indicated as adjunctive therapy to diet for the reduction of elevated sitosterol and campesterol levels in patients with homozygous familial sitosterolemia. 1.4 Limitations of Use The effect of ZETIA on cardiovascular morbidity and mortality has not been determined. ZETIA has not been studied in Fredrickson Type I, III, IV, and V dyslipidemias. uuid:d7a50425-b0bb-4601-bdae-e38db1e9ecca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49040 biolink:treats MONDO:0018328 PMID:41385096 "[{""id"":""uuid:af6af948-b9ef-44f4-8316-3ad22d935f49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dfa40797-a328-4a5e-8fc2-c051e7855d09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.1 Primary Hyperlipidemia Monotherapy ZETIA 1 , administered alone, is indicated as adjunctive therapy to diet for the reduction of elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), and apolipoprotein B (Apo B) in patients with primary (heterozygous familial and non-familial) hyperlipidemia. 1 COPYRIGHT © 2001, 2002, 2005, 2007, 2008 Merck/Schering-Plough Pharmaceuticals. All rights reserved. Combination Therapy with HMG-CoA Reductase Inhibitors (Statins) ZETIA, administered in combination with a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor (statin), is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, and Apo B in patients with primary (heterozygous familial and non-familial) hyperlipidemia. Combination Therapy with Fenofibrate ZETIA, administered in combination with fenofibrate, is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, Apo B, and non-high-density lipoprotein cholesterol (non-HDL-C) in adult patients with mixed hyperlipidemia. 1.2 Homozygous Familial Hypercholesterolemia (HoFH) The combination of ZETIA and atorvastatin or simvastatin is indicated for the reduction of elevated total-C and LDL-C levels in patients with HoFH, as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable. 1.3 Homozygous Sitosterolemia ZETIA is indicated as adjunctive therapy to diet for the reduction of elevated sitosterol and campesterol levels in patients with homozygous familial sitosterolemia. 1.4 Limitations of Use The effect of ZETIA on cardiovascular morbidity and mortality has not been determined. ZETIA has not been studied in Fredrickson Type I, III, IV, and V dyslipidemias. uuid:231b1854-83f8-4ce4-95ff-3f04460935c2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49040 biolink:treats MONDO:0008863 PMID:41385096 "[{""id"":""uuid:e58cc5dd-6844-4d87-91b6-1f184865b3a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7bc7fb58-7d34-4e8e-94ee-e6c2bc86501a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.1 Primary Hyperlipidemia Monotherapy ZETIA 1 , administered alone, is indicated as adjunctive therapy to diet for the reduction of elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), and apolipoprotein B (Apo B) in patients with primary (heterozygous familial and non-familial) hyperlipidemia. 1 COPYRIGHT © 2001, 2002, 2005, 2007, 2008 Merck/Schering-Plough Pharmaceuticals. All rights reserved. Combination Therapy with HMG-CoA Reductase Inhibitors (Statins) ZETIA, administered in combination with a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor (statin), is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, and Apo B in patients with primary (heterozygous familial and non-familial) hyperlipidemia. Combination Therapy with Fenofibrate ZETIA, administered in combination with fenofibrate, is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, Apo B, and non-high-density lipoprotein cholesterol (non-HDL-C) in adult patients with mixed hyperlipidemia. 1.2 Homozygous Familial Hypercholesterolemia (HoFH) The combination of ZETIA and atorvastatin or simvastatin is indicated for the reduction of elevated total-C and LDL-C levels in patients with HoFH, as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable. 1.3 Homozygous Sitosterolemia ZETIA is indicated as adjunctive therapy to diet for the reduction of elevated sitosterol and campesterol levels in patients with homozygous familial sitosterolemia. 1.4 Limitations of Use The effect of ZETIA on cardiovascular morbidity and mortality has not been determined. ZETIA has not been studied in Fredrickson Type I, III, IV, and V dyslipidemias. uuid:0761bfa7-778c-49fa-91bb-fbe167083d1b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49040 biolink:treats MONDO:0007788 PMID:41385096 "[{""id"":""uuid:3a5ea43d-31df-46ad-88a7-cdce3e9a1e97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7001f14e-e725-4850-907b-313609941c72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.1 Primary Hyperlipidemia Monotherapy ZETIA 1 , administered alone, is indicated as adjunctive therapy to diet for the reduction of elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), and apolipoprotein B (Apo B) in patients with primary (heterozygous familial and non-familial) hyperlipidemia. 1 COPYRIGHT © 2001, 2002, 2005, 2007, 2008 Merck/Schering-Plough Pharmaceuticals. All rights reserved. Combination Therapy with HMG-CoA Reductase Inhibitors (Statins) ZETIA, administered in combination with a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor (statin), is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, and Apo B in patients with primary (heterozygous familial and non-familial) hyperlipidemia. Combination Therapy with Fenofibrate ZETIA, administered in combination with fenofibrate, is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, Apo B, and non-high-density lipoprotein cholesterol (non-HDL-C) in adult patients with mixed hyperlipidemia. 1.2 Homozygous Familial Hypercholesterolemia (HoFH) The combination of ZETIA and atorvastatin or simvastatin is indicated for the reduction of elevated total-C and LDL-C levels in patients with HoFH, as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable. 1.3 Homozygous Sitosterolemia ZETIA is indicated as adjunctive therapy to diet for the reduction of elevated sitosterol and campesterol levels in patients with homozygous familial sitosterolemia. 1.4 Limitations of Use The effect of ZETIA on cardiovascular morbidity and mortality has not been determined. ZETIA has not been studied in Fredrickson Type I, III, IV, and V dyslipidemias. uuid:ac40c1ad-86f5-4f46-ab8b-ca7e35d97a3e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49040 biolink:treats MONDO:0018473 PMID:41385096 "[{""id"":""uuid:c3e80cc3-a813-4d47-a715-f6867052247d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b2378e8f-52de-40b1-a07f-26ee831ac4fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.1 Primary Hyperlipidemia Monotherapy ZETIA 1 , administered alone, is indicated as adjunctive therapy to diet for the reduction of elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), and apolipoprotein B (Apo B) in patients with primary (heterozygous familial and non-familial) hyperlipidemia. 1 COPYRIGHT © 2001, 2002, 2005, 2007, 2008 Merck/Schering-Plough Pharmaceuticals. All rights reserved. Combination Therapy with HMG-CoA Reductase Inhibitors (Statins) ZETIA, administered in combination with a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor (statin), is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, and Apo B in patients with primary (heterozygous familial and non-familial) hyperlipidemia. Combination Therapy with Fenofibrate ZETIA, administered in combination with fenofibrate, is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, Apo B, and non-high-density lipoprotein cholesterol (non-HDL-C) in adult patients with mixed hyperlipidemia. 1.2 Homozygous Familial Hypercholesterolemia (HoFH) The combination of ZETIA and atorvastatin or simvastatin is indicated for the reduction of elevated total-C and LDL-C levels in patients with HoFH, as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable. 1.3 Homozygous Sitosterolemia ZETIA is indicated as adjunctive therapy to diet for the reduction of elevated sitosterol and campesterol levels in patients with homozygous familial sitosterolemia. 1.4 Limitations of Use The effect of ZETIA on cardiovascular morbidity and mortality has not been determined. ZETIA has not been studied in Fredrickson Type I, III, IV, and V dyslipidemias. uuid:a0de240e-81b1-42ce-9a3f-d76e94586401 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49040 biolink:treats MONDO:0007762 PMID:41385096 "[{""id"":""uuid:efafb14d-a316-42c2-8b7f-5ce0233c8178"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:608ead9e-f601-4bc2-82cd-efadf3d489dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.1 Primary Hyperlipidemia Monotherapy ZETIA 1 , administered alone, is indicated as adjunctive therapy to diet for the reduction of elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), and apolipoprotein B (Apo B) in patients with primary (heterozygous familial and non-familial) hyperlipidemia. 1 COPYRIGHT © 2001, 2002, 2005, 2007, 2008 Merck/Schering-Plough Pharmaceuticals. All rights reserved. Combination Therapy with HMG-CoA Reductase Inhibitors (Statins) ZETIA, administered in combination with a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor (statin), is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, and Apo B in patients with primary (heterozygous familial and non-familial) hyperlipidemia. Combination Therapy with Fenofibrate ZETIA, administered in combination with fenofibrate, is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, Apo B, and non-high-density lipoprotein cholesterol (non-HDL-C) in adult patients with mixed hyperlipidemia. 1.2 Homozygous Familial Hypercholesterolemia (HoFH) The combination of ZETIA and atorvastatin or simvastatin is indicated for the reduction of elevated total-C and LDL-C levels in patients with HoFH, as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable. 1.3 Homozygous Sitosterolemia ZETIA is indicated as adjunctive therapy to diet for the reduction of elevated sitosterol and campesterol levels in patients with homozygous familial sitosterolemia. 1.4 Limitations of Use The effect of ZETIA on cardiovascular morbidity and mortality has not been determined. ZETIA has not been studied in Fredrickson Type I, III, IV, and V dyslipidemias. uuid:e6b5bbfd-b80f-42bc-b912-68d216723dc2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7496 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:a9afc69e-5b8f-4b37-b541-cebbde25f8fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:07cb8704-3a44-419b-894c-986235df4d48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VIRACEPT in combination with other antiretroviral agents is indicated for the treatment of HIV infection. uuid:068cc746-abd8-4aa5-a1a3-49259e52ec57 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:11954236 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:f84ce110-14d9-4b9e-ae3c-b891fb807024"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d7d01f3d-5206-447c-b972-4c8a2b2e75d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRUVADA ® , a combination of EMTRIVA ® and VIREAD ® , is indicated in combination with other antiretroviral agents (such as non-nucleoside reverse transcriptase inhibitors or protease inhibitors) for the treatment of HIV-1 infection in adults. The following points should be considered when initiating therapy with TRUVADA for the treatment of HIV-1 infection: It is not recommended that TRUVADA be used as a component of a triple nucleoside regimen. TRUVADA should not be coadministered with ATRIPLA ® , EMTRIVA, VIREAD or lamivudine-containing products [See Warnings and Precautions (5.4) ] . In treatment experienced patients, the use of TRUVADA should be guided by laboratory testing and treatment history [See Clinical Pharmacology (12.4) ] . uuid:5ceb53d8-6ec0-4f20-8206-49e9d13f600b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9352 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:1ebb8272-b1f4-4ba6-ad8c-6afd889fd645"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6f0661a5-d175-4db5-90ed-02db3d90266d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of sulindac and other treatment options before deciding to use sulindac. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Sulindac tablets are indicated for acute long-term use in the relief of signs and symptoms of the following: Osteoarthritis Rheumatoid arthritis * Ankylosing spondylitis Acute painful shoulder (Acute subacromial bursitis/supraspinatus tendinitis) Acute gouty arthritis uuid:7d7687b5-a171-48ef-92ce-2a5480935402 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9352 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:3c32a32b-f38f-4d30-bd00-e73629de1180"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:600a9e26-c0ba-4876-a49a-9debcb8c2005"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of sulindac and other treatment options before deciding to use sulindac. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Sulindac tablets are indicated for acute long-term use in the relief of signs and symptoms of the following: Osteoarthritis Rheumatoid arthritis * Ankylosing spondylitis Acute painful shoulder (Acute subacromial bursitis/supraspinatus tendinitis) Acute gouty arthritis uuid:a1fe0e19-fe0d-48b3-b9bf-221b217a34b6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9352 biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:418aa29d-ed23-47d7-8bbd-59c2492d81e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8c2eb8d6-2ccb-4581-98f1-93f99eb75f9d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of sulindac and other treatment options before deciding to use sulindac. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Sulindac tablets are indicated for acute long-term use in the relief of signs and symptoms of the following: Osteoarthritis Rheumatoid arthritis * Ankylosing spondylitis Acute painful shoulder (Acute subacromial bursitis/supraspinatus tendinitis) Acute gouty arthritis uuid:4597944a-e8dd-4579-8a0d-e674f33b7d44 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9352 biolink:treats UMLS:C0149896 PMID:41385096 "[{""id"":""uuid:78ff049c-fdcb-44dc-9633-2819de721682"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0776e281-3b73-4ab0-9330-9e3726ac82fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of sulindac and other treatment options before deciding to use sulindac. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Sulindac tablets are indicated for acute long-term use in the relief of signs and symptoms of the following: Osteoarthritis Rheumatoid arthritis * Ankylosing spondylitis Acute painful shoulder (Acute subacromial bursitis/supraspinatus tendinitis) Acute gouty arthritis uuid:08181735-616b-4455-927c-d9a426707383 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63625 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:a6728867-c223-4336-8451-6c6a11cb6077"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:77c0738d-39e8-4da7-8696-03db56dae9ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VIREAD is a nucleotide analog HIV-1 reverse transcriptase and HBV polymerase inhibitor. Viread is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults. ( 1 ) Viread is indicated for the treatment of chronic hepatitis B in adults. ( 1 ) uuid:314eb055-6b4b-4d13-ab8c-361f190fd4c8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63625 biolink:treats MONDO:0005366 PMID:41385096 "[{""id"":""uuid:18597016-6373-4c3a-b0c5-5c92ee2a2e38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b2eae5b7-8ef5-4da3-a545-11716f7d3925"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VIREAD is a nucleotide analog HIV-1 reverse transcriptase and HBV polymerase inhibitor. Viread is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults. ( 1 ) Viread is indicated for the treatment of chronic hepatitis B in adults. ( 1 ) uuid:613006c2-ca70-4677-8f5e-7913920dce98 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9398 biolink:treats MONDO:0010811 PMID:41385096 "[{""id"":""uuid:b146d0c0-c818-4f11-b77b-579a7a1ef1db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a0297087-04bf-4920-953f-735a7a87d9bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Flomax ® (tamsulosin hydrochloride) capsules are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) [ see Clinical Studies (14) ]. FLOMAX capsules are not indicated for the treatment of hypertension. uuid:7715978b-a34a-4dd1-80b4-84c28e6d31b6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9398 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:5d64673d-9ac4-4c6d-bce0-19eee7e1219e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9fd94dc8-f119-4e9a-ace4-01c5dea351d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Flomax ® (tamsulosin hydrochloride) capsules are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) [ see Clinical Studies (14) ]. FLOMAX capsules are not indicated for the treatment of hypertension. uuid:70cbfd54-906f-4ad6-a7c4-577e7cf72391 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31401 biolink:treats MONDO:0005295 PMID:41385096 "[{""id"":""uuid:eb7fbd0d-10dc-46c1-a997-56074ec610d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:021139bc-6091-469f-90c7-4a8857870596"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cilostazol tablets are indicated for the reduction of symptoms of intermittent claudication, as indicated by an increased walking distance. uuid:c603ef53-e810-44b2-a090-3ba5d2e56a5e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49662 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:6a4cb9af-acd4-474b-8c43-ebbd1bdf5c69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ed6732b4-c6ab-4cbd-b423-b976447f4242"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of indomethacin capsules and other treatment options before deciding to use indomethacin. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS) Indomethacin has been found effective in active stages of the following: Moderate to severe rheumatoid arthritis including acute flares of chronic disease. Moderate to severe ankylosing spondylitis. Moderate to severe osteoarthritis. Acute painful shoulder (bursitis and/or tendinitis). Acute gouty arthritis. uuid:78e20e81-7fe1-4f04-b08a-3c29394c66c4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49662 biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:5ce444f3-6ee2-4d56-bede-62a1c2dd1348"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:213537cc-91a1-4870-9b25-85ef033e0454"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of indomethacin capsules and other treatment options before deciding to use indomethacin. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS) Indomethacin has been found effective in active stages of the following: Moderate to severe rheumatoid arthritis including acute flares of chronic disease. Moderate to severe ankylosing spondylitis. Moderate to severe osteoarthritis. Acute painful shoulder (bursitis and/or tendinitis). Acute gouty arthritis. uuid:7da9ac90-70ab-402e-9ce7-fb3c403da6e2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49662 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:79005d0b-f902-4270-b3cf-115571812778"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c87ab4c5-47fa-43ae-9427-ed88f6e092fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of indomethacin capsules and other treatment options before deciding to use indomethacin. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS) Indomethacin has been found effective in active stages of the following: Moderate to severe rheumatoid arthritis including acute flares of chronic disease. Moderate to severe ankylosing spondylitis. Moderate to severe osteoarthritis. Acute painful shoulder (bursitis and/or tendinitis). Acute gouty arthritis. uuid:da437a2a-38ec-4314-844e-69c31b0b5adb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49662 biolink:treats MONDO:0002471 PMID:41385096 "[{""id"":""uuid:0698b7d6-ebeb-405f-b2e0-c7ccafed9310"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e6c344b0-d6c2-4fe5-b1fa-9a61c1751078"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of indomethacin capsules and other treatment options before deciding to use indomethacin. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS) Indomethacin has been found effective in active stages of the following: Moderate to severe rheumatoid arthritis including acute flares of chronic disease. Moderate to severe ankylosing spondylitis. Moderate to severe osteoarthritis. Acute painful shoulder (bursitis and/or tendinitis). Acute gouty arthritis. uuid:46d61eb7-118a-4589-b558-7b27a02dcd5e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49662 biolink:treats MONDO:0004857 PMID:41385096 "[{""id"":""uuid:def8a6fa-d2c8-4dd4-93c3-f447379bb894"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:afabb113-1aab-4696-a375-5ab2d8d3832d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of indomethacin capsules and other treatment options before deciding to use indomethacin. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS) Indomethacin has been found effective in active stages of the following: Moderate to severe rheumatoid arthritis including acute flares of chronic disease. Moderate to severe ankylosing spondylitis. Moderate to severe osteoarthritis. Acute painful shoulder (bursitis and/or tendinitis). Acute gouty arthritis. uuid:5d3ddb1e-a269-4fba-9675-e99101c86837 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49662 biolink:treats MONDO:0005393 PMID:41385096 "[{""id"":""uuid:55c6374b-0830-4ecd-881b-26f076936ce6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ce45ff75-bae2-4867-9ee4-3a0025118fe0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of indomethacin capsules and other treatment options before deciding to use indomethacin. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS) Indomethacin has been found effective in active stages of the following: Moderate to severe rheumatoid arthritis including acute flares of chronic disease. Moderate to severe ankylosing spondylitis. Moderate to severe osteoarthritis. Acute painful shoulder (bursitis and/or tendinitis). Acute gouty arthritis. uuid:e05d5638-64f8-41e3-b25e-633cd381565f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6030 biolink:treats MONDO:0018076 PMID:41385096 "[{""id"":""uuid:40b28c29-b171-4ffd-bfd5-1129fdb10b66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aebf6b17-66e2-49fe-ac57-4fe63dd3db37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isoniazid is recommended for all forms of tuberculosis in which organisms are susceptible. However, active tuberculosis must be treated with multiple concomitant antituberculosis medications to prevent the emergence of drug resistance. Single-drug treatment of active tuberculosis with isoniazid, or any other medication, is inadequate therapy. Isoniazid is recommended as preventive therapy for the following groups, regardless of age. (Note: the criterion for a positive reaction to a skin test (in millimeters of induration) for each group is given in parenthesis): Persons with human immunodeficiency virus (HIV) infection (≥ 5 mm) and persons with risk factors for HIV infection whose HIV infection status is unknown but who are suspected of having HIV infection. Preventive therapy may be considered for HIV infected persons who are tuberculin-negative but belong to groups in which the prevalence of tuberculosis infection is high. Candidates for preventive therapy who have HIV infection should have a minimum of 12 months of therapy. Close contacts of persons with newly diagnosed infectious tuberculosis (≥ 5 mm). In addition, tuberculin-negative (< 5 mm) children and adolescents who have been close contacts of infectious persons within the past 3 months are candidates for preventive therapy until a repeat tuberculin skin test is done 12 weeks after contact with the infectious source. If the repeat skin test is positive (> 5 mm), therapy should be continued. Recent converters, as indicated by a tuberculin skin test (≥ 10 mm increase within a 2-year period for those < 35 years old; ≥ 15 mm increase for those ≥ 35 years of age). All infants and children younger than 4 years of age with a > 10 mm skin test are included in this category. Persons with abnormal chest radiographs that show fibrotic lesions likely to represent old healed tuberculosis (≥ 5 mm). Candidates for preventive therapy who have fibrotic pulmonary lesions consistent with healed tuberculosis or who have pulmonary silicosis should have 12 months of isoniazid or 4 months of isoniazid and rifampin, concomitantly. Intravenous drug users known to be HIV-seronegative (> 10 mm). Persons with the following medical conditions that have been reported to increase the risk of tuberculosis (≥ 10 mm): silicosis; diabetes mellitus; prolonged therapy with adrenocorticosteroids; immunosuppressive therapy; some hematologic and reticuloendothelial diseases, such as leukemia or Hodgkin's disease; end-stage renal disease; clinical situations associated with substantial rapid weight loss or chronic undernutrition (including: intestinal bypass surgery for obesity, the postgastrectomy state (with or without weight loss), chronic peptic ulcer disease, chronic malabsorption syndromes, and carcinomas of the oropharynx and upper gastrointestinal tract that prevent adequate nutritional intake). Candidates for preventive therapy who have fibrotic pulmonary lesions consistent with healed tuberculosis or who have pulmonary silicosis should have 12 months of isoniazid or 4 months of isoniazid and rifampin, concomitantly. Additionally, in the absence of any of the above risk factors, persons under the age of 35 with a tuberculin skin test reaction of 10 mm or more are also appropriate candidates for preventive therapy if they are a member of any of the following high-incidence groups: Foreign-born persons from high-prevalence countries who never received BCG vaccine. Medically underserved low-income populations, including high-risk racial or ethnic minority populations, especially blacks, Hispanics, and Native Americans. Residents of facilities for long-term care (e.g., correctional institutions, nursing homes, and mental institutions). Children who are less than 4 years old are candidates for isoniazid preventive therapy if they have >10 mm induration from a PPD Mantoux tuberculin skin test. Finally, persons under the age of 35 who a) have none of the above risk factors (1-6); b) belong to none of the high-incidence groups; and c) have a tuberculin skin test reaction of 15 mm or more, are appropriate candidates for preventive therapy. The risk of hepatitis must be weighed against the risk of tuberculosis in positive tuberculin reactors over the age of 35. However, the use of isoniazid is recommended for those with the additional risk factors listed above (1-6) and on an individual basis in situations where there is likelihood of serious consequences to contacts who may become infected. uuid:c1086a78-98d0-4404-9c3f-22c77d2086c8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6030 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:c468f65b-00c5-435e-9023-51b677127605"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:803bf623-4f60-426f-8575-4fbc7dbd60b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isoniazid is recommended for all forms of tuberculosis in which organisms are susceptible. However, active tuberculosis must be treated with multiple concomitant antituberculosis medications to prevent the emergence of drug resistance. Single-drug treatment of active tuberculosis with isoniazid, or any other medication, is inadequate therapy. Isoniazid is recommended as preventive therapy for the following groups, regardless of age. (Note: the criterion for a positive reaction to a skin test (in millimeters of induration) for each group is given in parenthesis): Persons with human immunodeficiency virus (HIV) infection (≥ 5 mm) and persons with risk factors for HIV infection whose HIV infection status is unknown but who are suspected of having HIV infection. Preventive therapy may be considered for HIV infected persons who are tuberculin-negative but belong to groups in which the prevalence of tuberculosis infection is high. Candidates for preventive therapy who have HIV infection should have a minimum of 12 months of therapy. Close contacts of persons with newly diagnosed infectious tuberculosis (≥ 5 mm). In addition, tuberculin-negative (< 5 mm) children and adolescents who have been close contacts of infectious persons within the past 3 months are candidates for preventive therapy until a repeat tuberculin skin test is done 12 weeks after contact with the infectious source. If the repeat skin test is positive (> 5 mm), therapy should be continued. Recent converters, as indicated by a tuberculin skin test (≥ 10 mm increase within a 2-year period for those < 35 years old; ≥ 15 mm increase for those ≥ 35 years of age). All infants and children younger than 4 years of age with a > 10 mm skin test are included in this category. Persons with abnormal chest radiographs that show fibrotic lesions likely to represent old healed tuberculosis (≥ 5 mm). Candidates for preventive therapy who have fibrotic pulmonary lesions consistent with healed tuberculosis or who have pulmonary silicosis should have 12 months of isoniazid or 4 months of isoniazid and rifampin, concomitantly. Intravenous drug users known to be HIV-seronegative (> 10 mm). Persons with the following medical conditions that have been reported to increase the risk of tuberculosis (≥ 10 mm): silicosis; diabetes mellitus; prolonged therapy with adrenocorticosteroids; immunosuppressive therapy; some hematologic and reticuloendothelial diseases, such as leukemia or Hodgkin's disease; end-stage renal disease; clinical situations associated with substantial rapid weight loss or chronic undernutrition (including: intestinal bypass surgery for obesity, the postgastrectomy state (with or without weight loss), chronic peptic ulcer disease, chronic malabsorption syndromes, and carcinomas of the oropharynx and upper gastrointestinal tract that prevent adequate nutritional intake). Candidates for preventive therapy who have fibrotic pulmonary lesions consistent with healed tuberculosis or who have pulmonary silicosis should have 12 months of isoniazid or 4 months of isoniazid and rifampin, concomitantly. Additionally, in the absence of any of the above risk factors, persons under the age of 35 with a tuberculin skin test reaction of 10 mm or more are also appropriate candidates for preventive therapy if they are a member of any of the following high-incidence groups: Foreign-born persons from high-prevalence countries who never received BCG vaccine. Medically underserved low-income populations, including high-risk racial or ethnic minority populations, especially blacks, Hispanics, and Native Americans. Residents of facilities for long-term care (e.g., correctional institutions, nursing homes, and mental institutions). Children who are less than 4 years old are candidates for isoniazid preventive therapy if they have >10 mm induration from a PPD Mantoux tuberculin skin test. Finally, persons under the age of 35 who a) have none of the above risk factors (1-6); b) belong to none of the high-incidence groups; and c) have a tuberculin skin test reaction of 15 mm or more, are appropriate candidates for preventive therapy. The risk of hepatitis must be weighed against the risk of tuberculosis in positive tuberculin reactors over the age of 35. However, the use of isoniazid is recommended for those with the additional risk factors listed above (1-6) and on an individual basis in situations where there is likelihood of serious consequences to contacts who may become infected. uuid:644fed94-0f82-46c1-b866-bb08a5ba6610 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6030 biolink:treats MONDO:0005960 PMID:41385096 "[{""id"":""uuid:09719064-dde9-4ef3-bc97-ddca2d87791a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:97abf3e9-41c2-40a0-8e43-4550da0cb6ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isoniazid is recommended for all forms of tuberculosis in which organisms are susceptible. However, active tuberculosis must be treated with multiple concomitant antituberculosis medications to prevent the emergence of drug resistance. Single-drug treatment of active tuberculosis with isoniazid, or any other medication, is inadequate therapy. Isoniazid is recommended as preventive therapy for the following groups, regardless of age. (Note: the criterion for a positive reaction to a skin test (in millimeters of induration) for each group is given in parenthesis): Persons with human immunodeficiency virus (HIV) infection (≥ 5 mm) and persons with risk factors for HIV infection whose HIV infection status is unknown but who are suspected of having HIV infection. Preventive therapy may be considered for HIV infected persons who are tuberculin-negative but belong to groups in which the prevalence of tuberculosis infection is high. Candidates for preventive therapy who have HIV infection should have a minimum of 12 months of therapy. Close contacts of persons with newly diagnosed infectious tuberculosis (≥ 5 mm). In addition, tuberculin-negative (< 5 mm) children and adolescents who have been close contacts of infectious persons within the past 3 months are candidates for preventive therapy until a repeat tuberculin skin test is done 12 weeks after contact with the infectious source. If the repeat skin test is positive (> 5 mm), therapy should be continued. Recent converters, as indicated by a tuberculin skin test (≥ 10 mm increase within a 2-year period for those < 35 years old; ≥ 15 mm increase for those ≥ 35 years of age). All infants and children younger than 4 years of age with a > 10 mm skin test are included in this category. Persons with abnormal chest radiographs that show fibrotic lesions likely to represent old healed tuberculosis (≥ 5 mm). Candidates for preventive therapy who have fibrotic pulmonary lesions consistent with healed tuberculosis or who have pulmonary silicosis should have 12 months of isoniazid or 4 months of isoniazid and rifampin, concomitantly. Intravenous drug users known to be HIV-seronegative (> 10 mm). Persons with the following medical conditions that have been reported to increase the risk of tuberculosis (≥ 10 mm): silicosis; diabetes mellitus; prolonged therapy with adrenocorticosteroids; immunosuppressive therapy; some hematologic and reticuloendothelial diseases, such as leukemia or Hodgkin's disease; end-stage renal disease; clinical situations associated with substantial rapid weight loss or chronic undernutrition (including: intestinal bypass surgery for obesity, the postgastrectomy state (with or without weight loss), chronic peptic ulcer disease, chronic malabsorption syndromes, and carcinomas of the oropharynx and upper gastrointestinal tract that prevent adequate nutritional intake). Candidates for preventive therapy who have fibrotic pulmonary lesions consistent with healed tuberculosis or who have pulmonary silicosis should have 12 months of isoniazid or 4 months of isoniazid and rifampin, concomitantly. Additionally, in the absence of any of the above risk factors, persons under the age of 35 with a tuberculin skin test reaction of 10 mm or more are also appropriate candidates for preventive therapy if they are a member of any of the following high-incidence groups: Foreign-born persons from high-prevalence countries who never received BCG vaccine. Medically underserved low-income populations, including high-risk racial or ethnic minority populations, especially blacks, Hispanics, and Native Americans. Residents of facilities for long-term care (e.g., correctional institutions, nursing homes, and mental institutions). Children who are less than 4 years old are candidates for isoniazid preventive therapy if they have >10 mm induration from a PPD Mantoux tuberculin skin test. Finally, persons under the age of 35 who a) have none of the above risk factors (1-6); b) belong to none of the high-incidence groups; and c) have a tuberculin skin test reaction of 15 mm or more, are appropriate candidates for preventive therapy. The risk of hepatitis must be weighed against the risk of tuberculosis in positive tuberculin reactors over the age of 35. However, the use of isoniazid is recommended for those with the additional risk factors listed above (1-6) and on an individual basis in situations where there is likelihood of serious consequences to contacts who may become infected. uuid:2813463f-b0a7-4d43-93a6-6213a4b86beb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6030 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:b72f7479-8d3c-4827-b53e-ea2f6270484c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:240d33b6-c824-401e-ae8f-68813af657ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isoniazid is recommended for all forms of tuberculosis in which organisms are susceptible. However, active tuberculosis must be treated with multiple concomitant antituberculosis medications to prevent the emergence of drug resistance. Single-drug treatment of active tuberculosis with isoniazid, or any other medication, is inadequate therapy. Isoniazid is recommended as preventive therapy for the following groups, regardless of age. (Note: the criterion for a positive reaction to a skin test (in millimeters of induration) for each group is given in parenthesis): Persons with human immunodeficiency virus (HIV) infection (≥ 5 mm) and persons with risk factors for HIV infection whose HIV infection status is unknown but who are suspected of having HIV infection. Preventive therapy may be considered for HIV infected persons who are tuberculin-negative but belong to groups in which the prevalence of tuberculosis infection is high. Candidates for preventive therapy who have HIV infection should have a minimum of 12 months of therapy. Close contacts of persons with newly diagnosed infectious tuberculosis (≥ 5 mm). In addition, tuberculin-negative (< 5 mm) children and adolescents who have been close contacts of infectious persons within the past 3 months are candidates for preventive therapy until a repeat tuberculin skin test is done 12 weeks after contact with the infectious source. If the repeat skin test is positive (> 5 mm), therapy should be continued. Recent converters, as indicated by a tuberculin skin test (≥ 10 mm increase within a 2-year period for those < 35 years old; ≥ 15 mm increase for those ≥ 35 years of age). All infants and children younger than 4 years of age with a > 10 mm skin test are included in this category. Persons with abnormal chest radiographs that show fibrotic lesions likely to represent old healed tuberculosis (≥ 5 mm). Candidates for preventive therapy who have fibrotic pulmonary lesions consistent with healed tuberculosis or who have pulmonary silicosis should have 12 months of isoniazid or 4 months of isoniazid and rifampin, concomitantly. Intravenous drug users known to be HIV-seronegative (> 10 mm). Persons with the following medical conditions that have been reported to increase the risk of tuberculosis (≥ 10 mm): silicosis; diabetes mellitus; prolonged therapy with adrenocorticosteroids; immunosuppressive therapy; some hematologic and reticuloendothelial diseases, such as leukemia or Hodgkin's disease; end-stage renal disease; clinical situations associated with substantial rapid weight loss or chronic undernutrition (including: intestinal bypass surgery for obesity, the postgastrectomy state (with or without weight loss), chronic peptic ulcer disease, chronic malabsorption syndromes, and carcinomas of the oropharynx and upper gastrointestinal tract that prevent adequate nutritional intake). Candidates for preventive therapy who have fibrotic pulmonary lesions consistent with healed tuberculosis or who have pulmonary silicosis should have 12 months of isoniazid or 4 months of isoniazid and rifampin, concomitantly. Additionally, in the absence of any of the above risk factors, persons under the age of 35 with a tuberculin skin test reaction of 10 mm or more are also appropriate candidates for preventive therapy if they are a member of any of the following high-incidence groups: Foreign-born persons from high-prevalence countries who never received BCG vaccine. Medically underserved low-income populations, including high-risk racial or ethnic minority populations, especially blacks, Hispanics, and Native Americans. Residents of facilities for long-term care (e.g., correctional institutions, nursing homes, and mental institutions). Children who are less than 4 years old are candidates for isoniazid preventive therapy if they have >10 mm induration from a PPD Mantoux tuberculin skin test. Finally, persons under the age of 35 who a) have none of the above risk factors (1-6); b) belong to none of the high-incidence groups; and c) have a tuberculin skin test reaction of 15 mm or more, are appropriate candidates for preventive therapy. The risk of hepatitis must be weighed against the risk of tuberculosis in positive tuberculin reactors over the age of 35. However, the use of isoniazid is recommended for those with the additional risk factors listed above (1-6) and on an individual basis in situations where there is likelihood of serious consequences to contacts who may become infected. uuid:d9b6c8d6-ea3e-42b6-a7eb-67509ac18ac3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6030 biolink:treats MONDO:0005059 PMID:41385096 "[{""id"":""uuid:b8a81bb6-f567-4a7e-95b6-70b5d708cff0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5fc8ffa6-133c-4999-bdef-3920297c6455"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isoniazid is recommended for all forms of tuberculosis in which organisms are susceptible. However, active tuberculosis must be treated with multiple concomitant antituberculosis medications to prevent the emergence of drug resistance. Single-drug treatment of active tuberculosis with isoniazid, or any other medication, is inadequate therapy. Isoniazid is recommended as preventive therapy for the following groups, regardless of age. (Note: the criterion for a positive reaction to a skin test (in millimeters of induration) for each group is given in parenthesis): Persons with human immunodeficiency virus (HIV) infection (≥ 5 mm) and persons with risk factors for HIV infection whose HIV infection status is unknown but who are suspected of having HIV infection. Preventive therapy may be considered for HIV infected persons who are tuberculin-negative but belong to groups in which the prevalence of tuberculosis infection is high. Candidates for preventive therapy who have HIV infection should have a minimum of 12 months of therapy. Close contacts of persons with newly diagnosed infectious tuberculosis (≥ 5 mm). In addition, tuberculin-negative (< 5 mm) children and adolescents who have been close contacts of infectious persons within the past 3 months are candidates for preventive therapy until a repeat tuberculin skin test is done 12 weeks after contact with the infectious source. If the repeat skin test is positive (> 5 mm), therapy should be continued. Recent converters, as indicated by a tuberculin skin test (≥ 10 mm increase within a 2-year period for those < 35 years old; ≥ 15 mm increase for those ≥ 35 years of age). All infants and children younger than 4 years of age with a > 10 mm skin test are included in this category. Persons with abnormal chest radiographs that show fibrotic lesions likely to represent old healed tuberculosis (≥ 5 mm). Candidates for preventive therapy who have fibrotic pulmonary lesions consistent with healed tuberculosis or who have pulmonary silicosis should have 12 months of isoniazid or 4 months of isoniazid and rifampin, concomitantly. Intravenous drug users known to be HIV-seronegative (> 10 mm). Persons with the following medical conditions that have been reported to increase the risk of tuberculosis (≥ 10 mm): silicosis; diabetes mellitus; prolonged therapy with adrenocorticosteroids; immunosuppressive therapy; some hematologic and reticuloendothelial diseases, such as leukemia or Hodgkin's disease; end-stage renal disease; clinical situations associated with substantial rapid weight loss or chronic undernutrition (including: intestinal bypass surgery for obesity, the postgastrectomy state (with or without weight loss), chronic peptic ulcer disease, chronic malabsorption syndromes, and carcinomas of the oropharynx and upper gastrointestinal tract that prevent adequate nutritional intake). Candidates for preventive therapy who have fibrotic pulmonary lesions consistent with healed tuberculosis or who have pulmonary silicosis should have 12 months of isoniazid or 4 months of isoniazid and rifampin, concomitantly. Additionally, in the absence of any of the above risk factors, persons under the age of 35 with a tuberculin skin test reaction of 10 mm or more are also appropriate candidates for preventive therapy if they are a member of any of the following high-incidence groups: Foreign-born persons from high-prevalence countries who never received BCG vaccine. Medically underserved low-income populations, including high-risk racial or ethnic minority populations, especially blacks, Hispanics, and Native Americans. Residents of facilities for long-term care (e.g., correctional institutions, nursing homes, and mental institutions). Children who are less than 4 years old are candidates for isoniazid preventive therapy if they have >10 mm induration from a PPD Mantoux tuberculin skin test. Finally, persons under the age of 35 who a) have none of the above risk factors (1-6); b) belong to none of the high-incidence groups; and c) have a tuberculin skin test reaction of 15 mm or more, are appropriate candidates for preventive therapy. The risk of hepatitis must be weighed against the risk of tuberculosis in positive tuberculin reactors over the age of 35. However, the use of isoniazid is recommended for those with the additional risk factors listed above (1-6) and on an individual basis in situations where there is likelihood of serious consequences to contacts who may become infected. uuid:f9fc0a12-c0aa-4072-b787-f27dae9fe397 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6030 biolink:treats MONDO:0009348 PMID:41385096 "[{""id"":""uuid:f10aba9d-eb39-486d-90e2-38ab2d4ed944"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3d74e49a-4347-412f-8127-875918b3ac47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isoniazid is recommended for all forms of tuberculosis in which organisms are susceptible. However, active tuberculosis must be treated with multiple concomitant antituberculosis medications to prevent the emergence of drug resistance. Single-drug treatment of active tuberculosis with isoniazid, or any other medication, is inadequate therapy. Isoniazid is recommended as preventive therapy for the following groups, regardless of age. (Note: the criterion for a positive reaction to a skin test (in millimeters of induration) for each group is given in parenthesis): Persons with human immunodeficiency virus (HIV) infection (≥ 5 mm) and persons with risk factors for HIV infection whose HIV infection status is unknown but who are suspected of having HIV infection. Preventive therapy may be considered for HIV infected persons who are tuberculin-negative but belong to groups in which the prevalence of tuberculosis infection is high. Candidates for preventive therapy who have HIV infection should have a minimum of 12 months of therapy. Close contacts of persons with newly diagnosed infectious tuberculosis (≥ 5 mm). In addition, tuberculin-negative (< 5 mm) children and adolescents who have been close contacts of infectious persons within the past 3 months are candidates for preventive therapy until a repeat tuberculin skin test is done 12 weeks after contact with the infectious source. If the repeat skin test is positive (> 5 mm), therapy should be continued. Recent converters, as indicated by a tuberculin skin test (≥ 10 mm increase within a 2-year period for those < 35 years old; ≥ 15 mm increase for those ≥ 35 years of age). All infants and children younger than 4 years of age with a > 10 mm skin test are included in this category. Persons with abnormal chest radiographs that show fibrotic lesions likely to represent old healed tuberculosis (≥ 5 mm). Candidates for preventive therapy who have fibrotic pulmonary lesions consistent with healed tuberculosis or who have pulmonary silicosis should have 12 months of isoniazid or 4 months of isoniazid and rifampin, concomitantly. Intravenous drug users known to be HIV-seronegative (> 10 mm). Persons with the following medical conditions that have been reported to increase the risk of tuberculosis (≥ 10 mm): silicosis; diabetes mellitus; prolonged therapy with adrenocorticosteroids; immunosuppressive therapy; some hematologic and reticuloendothelial diseases, such as leukemia or Hodgkin's disease; end-stage renal disease; clinical situations associated with substantial rapid weight loss or chronic undernutrition (including: intestinal bypass surgery for obesity, the postgastrectomy state (with or without weight loss), chronic peptic ulcer disease, chronic malabsorption syndromes, and carcinomas of the oropharynx and upper gastrointestinal tract that prevent adequate nutritional intake). Candidates for preventive therapy who have fibrotic pulmonary lesions consistent with healed tuberculosis or who have pulmonary silicosis should have 12 months of isoniazid or 4 months of isoniazid and rifampin, concomitantly. Additionally, in the absence of any of the above risk factors, persons under the age of 35 with a tuberculin skin test reaction of 10 mm or more are also appropriate candidates for preventive therapy if they are a member of any of the following high-incidence groups: Foreign-born persons from high-prevalence countries who never received BCG vaccine. Medically underserved low-income populations, including high-risk racial or ethnic minority populations, especially blacks, Hispanics, and Native Americans. Residents of facilities for long-term care (e.g., correctional institutions, nursing homes, and mental institutions). Children who are less than 4 years old are candidates for isoniazid preventive therapy if they have >10 mm induration from a PPD Mantoux tuberculin skin test. Finally, persons under the age of 35 who a) have none of the above risk factors (1-6); b) belong to none of the high-incidence groups; and c) have a tuberculin skin test reaction of 15 mm or more, are appropriate candidates for preventive therapy. The risk of hepatitis must be weighed against the risk of tuberculosis in positive tuberculin reactors over the age of 35. However, the use of isoniazid is recommended for those with the additional risk factors listed above (1-6) and on an individual basis in situations where there is likelihood of serious consequences to contacts who may become infected. uuid:2f8d8aa5-cd93-4eaf-8698-56a7159d35da biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6030 biolink:treats MONDO:0004375 PMID:41385096 "[{""id"":""uuid:1089744e-3311-424c-b1a1-a5c3a0612e0f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b8a5efe8-0eef-4e37-89d3-d69ea0a4df52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isoniazid is recommended for all forms of tuberculosis in which organisms are susceptible. However, active tuberculosis must be treated with multiple concomitant antituberculosis medications to prevent the emergence of drug resistance. Single-drug treatment of active tuberculosis with isoniazid, or any other medication, is inadequate therapy. Isoniazid is recommended as preventive therapy for the following groups, regardless of age. (Note: the criterion for a positive reaction to a skin test (in millimeters of induration) for each group is given in parenthesis): Persons with human immunodeficiency virus (HIV) infection (≥ 5 mm) and persons with risk factors for HIV infection whose HIV infection status is unknown but who are suspected of having HIV infection. Preventive therapy may be considered for HIV infected persons who are tuberculin-negative but belong to groups in which the prevalence of tuberculosis infection is high. Candidates for preventive therapy who have HIV infection should have a minimum of 12 months of therapy. Close contacts of persons with newly diagnosed infectious tuberculosis (≥ 5 mm). In addition, tuberculin-negative (< 5 mm) children and adolescents who have been close contacts of infectious persons within the past 3 months are candidates for preventive therapy until a repeat tuberculin skin test is done 12 weeks after contact with the infectious source. If the repeat skin test is positive (> 5 mm), therapy should be continued. Recent converters, as indicated by a tuberculin skin test (≥ 10 mm increase within a 2-year period for those < 35 years old; ≥ 15 mm increase for those ≥ 35 years of age). All infants and children younger than 4 years of age with a > 10 mm skin test are included in this category. Persons with abnormal chest radiographs that show fibrotic lesions likely to represent old healed tuberculosis (≥ 5 mm). Candidates for preventive therapy who have fibrotic pulmonary lesions consistent with healed tuberculosis or who have pulmonary silicosis should have 12 months of isoniazid or 4 months of isoniazid and rifampin, concomitantly. Intravenous drug users known to be HIV-seronegative (> 10 mm). Persons with the following medical conditions that have been reported to increase the risk of tuberculosis (≥ 10 mm): silicosis; diabetes mellitus; prolonged therapy with adrenocorticosteroids; immunosuppressive therapy; some hematologic and reticuloendothelial diseases, such as leukemia or Hodgkin's disease; end-stage renal disease; clinical situations associated with substantial rapid weight loss or chronic undernutrition (including: intestinal bypass surgery for obesity, the postgastrectomy state (with or without weight loss), chronic peptic ulcer disease, chronic malabsorption syndromes, and carcinomas of the oropharynx and upper gastrointestinal tract that prevent adequate nutritional intake). Candidates for preventive therapy who have fibrotic pulmonary lesions consistent with healed tuberculosis or who have pulmonary silicosis should have 12 months of isoniazid or 4 months of isoniazid and rifampin, concomitantly. Additionally, in the absence of any of the above risk factors, persons under the age of 35 with a tuberculin skin test reaction of 10 mm or more are also appropriate candidates for preventive therapy if they are a member of any of the following high-incidence groups: Foreign-born persons from high-prevalence countries who never received BCG vaccine. Medically underserved low-income populations, including high-risk racial or ethnic minority populations, especially blacks, Hispanics, and Native Americans. Residents of facilities for long-term care (e.g., correctional institutions, nursing homes, and mental institutions). Children who are less than 4 years old are candidates for isoniazid preventive therapy if they have >10 mm induration from a PPD Mantoux tuberculin skin test. Finally, persons under the age of 35 who a) have none of the above risk factors (1-6); b) belong to none of the high-incidence groups; and c) have a tuberculin skin test reaction of 15 mm or more, are appropriate candidates for preventive therapy. The risk of hepatitis must be weighed against the risk of tuberculosis in positive tuberculin reactors over the age of 35. However, the use of isoniazid is recommended for those with the additional risk factors listed above (1-6) and on an individual basis in situations where there is likelihood of serious consequences to contacts who may become infected. uuid:8cb41a5d-3a2b-4faf-909e-575db598d58f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6030 biolink:treats MONDO:0004608 PMID:41385096 "[{""id"":""uuid:ecdf4858-01fc-4740-8f07-0dc3d984903e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2a2390c9-4397-4091-b890-38d60d414cd7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isoniazid is recommended for all forms of tuberculosis in which organisms are susceptible. However, active tuberculosis must be treated with multiple concomitant antituberculosis medications to prevent the emergence of drug resistance. Single-drug treatment of active tuberculosis with isoniazid, or any other medication, is inadequate therapy. Isoniazid is recommended as preventive therapy for the following groups, regardless of age. (Note: the criterion for a positive reaction to a skin test (in millimeters of induration) for each group is given in parenthesis): Persons with human immunodeficiency virus (HIV) infection (≥ 5 mm) and persons with risk factors for HIV infection whose HIV infection status is unknown but who are suspected of having HIV infection. Preventive therapy may be considered for HIV infected persons who are tuberculin-negative but belong to groups in which the prevalence of tuberculosis infection is high. Candidates for preventive therapy who have HIV infection should have a minimum of 12 months of therapy. Close contacts of persons with newly diagnosed infectious tuberculosis (≥ 5 mm). In addition, tuberculin-negative (< 5 mm) children and adolescents who have been close contacts of infectious persons within the past 3 months are candidates for preventive therapy until a repeat tuberculin skin test is done 12 weeks after contact with the infectious source. If the repeat skin test is positive (> 5 mm), therapy should be continued. Recent converters, as indicated by a tuberculin skin test (≥ 10 mm increase within a 2-year period for those < 35 years old; ≥ 15 mm increase for those ≥ 35 years of age). All infants and children younger than 4 years of age with a > 10 mm skin test are included in this category. Persons with abnormal chest radiographs that show fibrotic lesions likely to represent old healed tuberculosis (≥ 5 mm). Candidates for preventive therapy who have fibrotic pulmonary lesions consistent with healed tuberculosis or who have pulmonary silicosis should have 12 months of isoniazid or 4 months of isoniazid and rifampin, concomitantly. Intravenous drug users known to be HIV-seronegative (> 10 mm). Persons with the following medical conditions that have been reported to increase the risk of tuberculosis (≥ 10 mm): silicosis; diabetes mellitus; prolonged therapy with adrenocorticosteroids; immunosuppressive therapy; some hematologic and reticuloendothelial diseases, such as leukemia or Hodgkin's disease; end-stage renal disease; clinical situations associated with substantial rapid weight loss or chronic undernutrition (including: intestinal bypass surgery for obesity, the postgastrectomy state (with or without weight loss), chronic peptic ulcer disease, chronic malabsorption syndromes, and carcinomas of the oropharynx and upper gastrointestinal tract that prevent adequate nutritional intake). Candidates for preventive therapy who have fibrotic pulmonary lesions consistent with healed tuberculosis or who have pulmonary silicosis should have 12 months of isoniazid or 4 months of isoniazid and rifampin, concomitantly. Additionally, in the absence of any of the above risk factors, persons under the age of 35 with a tuberculin skin test reaction of 10 mm or more are also appropriate candidates for preventive therapy if they are a member of any of the following high-incidence groups: Foreign-born persons from high-prevalence countries who never received BCG vaccine. Medically underserved low-income populations, including high-risk racial or ethnic minority populations, especially blacks, Hispanics, and Native Americans. Residents of facilities for long-term care (e.g., correctional institutions, nursing homes, and mental institutions). Children who are less than 4 years old are candidates for isoniazid preventive therapy if they have >10 mm induration from a PPD Mantoux tuberculin skin test. Finally, persons under the age of 35 who a) have none of the above risk factors (1-6); b) belong to none of the high-incidence groups; and c) have a tuberculin skin test reaction of 15 mm or more, are appropriate candidates for preventive therapy. The risk of hepatitis must be weighed against the risk of tuberculosis in positive tuberculin reactors over the age of 35. However, the use of isoniazid is recommended for those with the additional risk factors listed above (1-6) and on an individual basis in situations where there is likelihood of serious consequences to contacts who may become infected. uuid:5344a5dc-a8fc-490c-be55-027bb63ba205 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6030 biolink:treats MONDO:0006181 PMID:41385096 "[{""id"":""uuid:5162d63b-7617-4c7d-8fea-2265ae1fe614"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:80daeb86-2e6b-4fbc-beb8-2c44709d12ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isoniazid is recommended for all forms of tuberculosis in which organisms are susceptible. However, active tuberculosis must be treated with multiple concomitant antituberculosis medications to prevent the emergence of drug resistance. Single-drug treatment of active tuberculosis with isoniazid, or any other medication, is inadequate therapy. Isoniazid is recommended as preventive therapy for the following groups, regardless of age. (Note: the criterion for a positive reaction to a skin test (in millimeters of induration) for each group is given in parenthesis): Persons with human immunodeficiency virus (HIV) infection (≥ 5 mm) and persons with risk factors for HIV infection whose HIV infection status is unknown but who are suspected of having HIV infection. Preventive therapy may be considered for HIV infected persons who are tuberculin-negative but belong to groups in which the prevalence of tuberculosis infection is high. Candidates for preventive therapy who have HIV infection should have a minimum of 12 months of therapy. Close contacts of persons with newly diagnosed infectious tuberculosis (≥ 5 mm). In addition, tuberculin-negative (< 5 mm) children and adolescents who have been close contacts of infectious persons within the past 3 months are candidates for preventive therapy until a repeat tuberculin skin test is done 12 weeks after contact with the infectious source. If the repeat skin test is positive (> 5 mm), therapy should be continued. Recent converters, as indicated by a tuberculin skin test (≥ 10 mm increase within a 2-year period for those < 35 years old; ≥ 15 mm increase for those ≥ 35 years of age). All infants and children younger than 4 years of age with a > 10 mm skin test are included in this category. Persons with abnormal chest radiographs that show fibrotic lesions likely to represent old healed tuberculosis (≥ 5 mm). Candidates for preventive therapy who have fibrotic pulmonary lesions consistent with healed tuberculosis or who have pulmonary silicosis should have 12 months of isoniazid or 4 months of isoniazid and rifampin, concomitantly. Intravenous drug users known to be HIV-seronegative (> 10 mm). Persons with the following medical conditions that have been reported to increase the risk of tuberculosis (≥ 10 mm): silicosis; diabetes mellitus; prolonged therapy with adrenocorticosteroids; immunosuppressive therapy; some hematologic and reticuloendothelial diseases, such as leukemia or Hodgkin's disease; end-stage renal disease; clinical situations associated with substantial rapid weight loss or chronic undernutrition (including: intestinal bypass surgery for obesity, the postgastrectomy state (with or without weight loss), chronic peptic ulcer disease, chronic malabsorption syndromes, and carcinomas of the oropharynx and upper gastrointestinal tract that prevent adequate nutritional intake). Candidates for preventive therapy who have fibrotic pulmonary lesions consistent with healed tuberculosis or who have pulmonary silicosis should have 12 months of isoniazid or 4 months of isoniazid and rifampin, concomitantly. Additionally, in the absence of any of the above risk factors, persons under the age of 35 with a tuberculin skin test reaction of 10 mm or more are also appropriate candidates for preventive therapy if they are a member of any of the following high-incidence groups: Foreign-born persons from high-prevalence countries who never received BCG vaccine. Medically underserved low-income populations, including high-risk racial or ethnic minority populations, especially blacks, Hispanics, and Native Americans. Residents of facilities for long-term care (e.g., correctional institutions, nursing homes, and mental institutions). Children who are less than 4 years old are candidates for isoniazid preventive therapy if they have >10 mm induration from a PPD Mantoux tuberculin skin test. Finally, persons under the age of 35 who a) have none of the above risk factors (1-6); b) belong to none of the high-incidence groups; and c) have a tuberculin skin test reaction of 15 mm or more, are appropriate candidates for preventive therapy. The risk of hepatitis must be weighed against the risk of tuberculosis in positive tuberculin reactors over the age of 35. However, the use of isoniazid is recommended for those with the additional risk factors listed above (1-6) and on an individual basis in situations where there is likelihood of serious consequences to contacts who may become infected. uuid:bdbfa2da-f82e-454a-b909-3254df5c96d4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7443 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:e5b0e180-ecba-49a4-82ff-99432ef608a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3a2f0c76-29f4-4f4b-a974-1ca4f4e16506"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of nabumetone and other treatment options before deciding to use nabumetone. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Nabumetone tablets are indicated for relief of signs and symptoms of osteoarthritis and rheumatoid arthritis. uuid:07a15149-74f1-4cef-8747-8d880b8192a5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7443 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:fe9af51c-d75a-45d9-a06b-30157317853b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ef01d94e-cff1-4c4c-9095-bab5fdfffefc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of nabumetone and other treatment options before deciding to use nabumetone. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Nabumetone tablets are indicated for relief of signs and symptoms of osteoarthritis and rheumatoid arthritis. uuid:ab90de52-eaaf-4ebd-8b92-00f9de93b7c3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:39867 biolink:treats HP:0100754 PMID:41385096 "[{""id"":""uuid:3e941127-ccb3-453d-8579-243e522dd551"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:71a1fa28-7569-44ba-b336-bf918d92c9d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Divalproex sodium delayed-release tablets (divalproex sodium) are indicated for the treatment of the manic episodes associated with bipolar disorder. A manic episode is a distinct period of abnormally and persistently elevated, expansive, or irritable mood. Typical symptoms of mania include pressure of speech, motor hyperactivity, reduced need for sleep, flight of ideas, grandiosity, poor judgement, aggressiveness, and possible hostility. The efficacy of divalproex sodium delayed-release tablets was established in 3 week trials with patients meeting DSM-III-R criteria for bipolar disorder who were hospitalized for acute mania (see Clinical Trials under CLINICAL PHARMACOLOGY ). The safety and effectiveness of divalproex sodium delayed-release tablets for long-term use in mania, i.e., more than 3 weeks, has not been systematically evaluated in controlled clinical trials. Therefore, healthcare providers who elect to use divalproex sodium delayed-release tablets for extended periods should continually reevaluate the long-term usefulness of the drug for the individual patient. uuid:ad098c70-3ad7-48c7-8df0-1dd37b9a9538 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:36795 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:4ee14a27-b96f-4569-ac83-45f17e08372d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2aadf68f-d785-4a26-a292-22878ab9b400"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:cc441508-c69f-4803-8104-7570089aba23"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/duloxetine-mylan""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Major Depressive Disorder Cymbalta is indicated for the treatment of major depressive disorder (MDD). The efficacy of Cymbalta was established in four short term and one maintenance trial in adults [see Clinical Studies ( 14.1 )] . A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least 5 of the following 9 symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, or a suicide attempt or suicidal ideation. 1.2 Generalized Anxiety Disorder Cymbalta is indicated for the treatment of generalized anxiety disorder (GAD). The efficacy of Cymbalta was established in three short-term trials and one maintenance trial in adults [see Clinical Studies ( 14.2 )] . Generalized anxiety disorder is defined by the DSM-IV as excessive anxiety and worry, present more days than not, for at least 6 months. The excessive anxiety and worry must be difficult to control and must cause significant distress or impairment in normal functioning. It must be associated with at least 3 of the following 6 symptoms: restlessness or feeling keyed up or on edge, being easily fatigued, difficulty concentrating or mind going blank, irritability, muscle tension, and/or sleep disturbance. 1.3 Diabetic Peripheral Neuropathic Pain Cymbalta is indicated for the management of neuropathic pain (DPNP) associated with diabetic peripheral neuropathy [see Clinical Studies ( 14.3 )] . 1.4 Fibromyalgia Cymbalta is indicated for the management of fibromyalgia (FM) [see Clinical Studies ( 14.4 )] .|[EMA] Treatment of major depressive disorder;Treatment of diabetic peripheral neuropathic pain;Treatment of generalised anxiety disorder;Duloxetine Mylan is indicated in adults. uuid:1ce26246-43ea-416c-86a7-01d137e5045e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:36795 biolink:treats MONDO:0001942 PMID:41385096 "[{""id"":""uuid:99889bc1-97f4-40c3-a3cb-6dd4d89b1857"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f4709eff-1865-4a0b-b3cd-792c513c7edf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:03c9e29d-4bef-4be0-a944-424749adfaf9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/duloxetine-mylan""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Major Depressive Disorder Cymbalta is indicated for the treatment of major depressive disorder (MDD). The efficacy of Cymbalta was established in four short term and one maintenance trial in adults [see Clinical Studies ( 14.1 )] . A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least 5 of the following 9 symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, or a suicide attempt or suicidal ideation. 1.2 Generalized Anxiety Disorder Cymbalta is indicated for the treatment of generalized anxiety disorder (GAD). The efficacy of Cymbalta was established in three short-term trials and one maintenance trial in adults [see Clinical Studies ( 14.2 )] . Generalized anxiety disorder is defined by the DSM-IV as excessive anxiety and worry, present more days than not, for at least 6 months. The excessive anxiety and worry must be difficult to control and must cause significant distress or impairment in normal functioning. It must be associated with at least 3 of the following 6 symptoms: restlessness or feeling keyed up or on edge, being easily fatigued, difficulty concentrating or mind going blank, irritability, muscle tension, and/or sleep disturbance. 1.3 Diabetic Peripheral Neuropathic Pain Cymbalta is indicated for the management of neuropathic pain (DPNP) associated with diabetic peripheral neuropathy [see Clinical Studies ( 14.3 )] . 1.4 Fibromyalgia Cymbalta is indicated for the management of fibromyalgia (FM) [see Clinical Studies ( 14.4 )] .|[EMA] Treatment of major depressive disorder;Treatment of diabetic peripheral neuropathic pain;Treatment of generalised anxiety disorder;Duloxetine Mylan is indicated in adults. uuid:4adc73a3-fe0b-4643-abf9-244863713321 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:36795 biolink:treats MONDO:0001583 PMID:41385096 "[{""id"":""uuid:8cbc0973-ff02-4def-bb29-af263836ed04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:516cd77d-5ce7-4106-b38a-346cc21b9cdd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Major Depressive Disorder Cymbalta is indicated for the treatment of major depressive disorder (MDD). The efficacy of Cymbalta was established in four short term and one maintenance trial in adults [see Clinical Studies ( 14.1 )] . A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least 5 of the following 9 symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, or a suicide attempt or suicidal ideation. 1.2 Generalized Anxiety Disorder Cymbalta is indicated for the treatment of generalized anxiety disorder (GAD). The efficacy of Cymbalta was established in three short-term trials and one maintenance trial in adults [see Clinical Studies ( 14.2 )] . Generalized anxiety disorder is defined by the DSM-IV as excessive anxiety and worry, present more days than not, for at least 6 months. The excessive anxiety and worry must be difficult to control and must cause significant distress or impairment in normal functioning. It must be associated with at least 3 of the following 6 symptoms: restlessness or feeling keyed up or on edge, being easily fatigued, difficulty concentrating or mind going blank, irritability, muscle tension, and/or sleep disturbance. 1.3 Diabetic Peripheral Neuropathic Pain Cymbalta is indicated for the management of neuropathic pain (DPNP) associated with diabetic peripheral neuropathy [see Clinical Studies ( 14.3 )] . 1.4 Fibromyalgia Cymbalta is indicated for the management of fibromyalgia (FM) [see Clinical Studies ( 14.4 )] . uuid:b38f9d76-c807-4fe6-a4f1-a9770817c458 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:36795 biolink:treats MONDO:0005546 PMID:41385096 "[{""id"":""uuid:c8833fc0-11f6-435f-93c1-167277a05db6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:78167417-4f58-46c2-bfa3-a43c755730c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:48827e5c-57f4-42c4-84a4-c6cd9fdf85ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Major Depressive Disorder Cymbalta is indicated for the treatment of major depressive disorder (MDD). The efficacy of Cymbalta was established in four short term and one maintenance trial in adults [see Clinical Studies ( 14.1 )] . A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least 5 of the following 9 symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, or a suicide attempt or suicidal ideation. 1.2 Generalized Anxiety Disorder Cymbalta is indicated for the treatment of generalized anxiety disorder (GAD). The efficacy of Cymbalta was established in three short-term trials and one maintenance trial in adults [see Clinical Studies ( 14.2 )] . Generalized anxiety disorder is defined by the DSM-IV as excessive anxiety and worry, present more days than not, for at least 6 months. The excessive anxiety and worry must be difficult to control and must cause significant distress or impairment in normal functioning. It must be associated with at least 3 of the following 6 symptoms: restlessness or feeling keyed up or on edge, being easily fatigued, difficulty concentrating or mind going blank, irritability, muscle tension, and/or sleep disturbance. 1.3 Diabetic Peripheral Neuropathic Pain Cymbalta is indicated for the management of neuropathic pain (DPNP) associated with diabetic peripheral neuropathy [see Clinical Studies ( 14.3 )] . 1.4 Fibromyalgia Cymbalta is indicated for the management of fibromyalgia (FM) [see Clinical Studies ( 14.4 )] .|[PMDA] Drugs with a new additional indication and a new dosage for the treatment of pain associated with fibromyalgia. uuid:4f70029d-9117-40a0-b980-9d8dc242aee4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:175184 biolink:treats HP:0012228 PMID:41385096 "[{""id"":""uuid:350eacb6-6ea0-4a2d-8230-d2662132be7d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cdd64ec5-88a5-4e75-9b25-001802f94328"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ORBIVAN™ Butalbital, Acetaminophen and Caffeine capsules are indicated for the relief of the symptom complex of tension (or muscle contraction) headache. Evidence supporting the efficacy and safety of this combination product in the treatment of multiple recurrent headaches is unavailable. Caution in this regard is required because butalbital is habit-forming and potentially abusable. uuid:c48cc745-6ed7-4980-abb8-9f27de1f97ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:175184 biolink:treats UMLS:C0393736 PMID:41385096 "[{""id"":""uuid:f2d6cc61-6fe3-41de-92b7-e41f9b77ff3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:086db9c5-cbd5-48b0-b8c2-f1b5eb12d2f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ORBIVAN™ Butalbital, Acetaminophen and Caffeine capsules are indicated for the relief of the symptom complex of tension (or muscle contraction) headache. Evidence supporting the efficacy and safety of this combination product in the treatment of multiple recurrent headaches is unavailable. Caution in this regard is required because butalbital is habit-forming and potentially abusable. uuid:40e885ca-493a-464b-a864-672260d81f2d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28971 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:92849dd4-519f-4bdc-a6f0-901b52a6f8ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:40f29daa-44ca-44a8-8fbe-d380c8bea12a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory tract Infections caused by S. pneumoniae (formerly D. pneumoniae ). Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae, and Group A beta-hemolytic Streptococci. Bacterial Meningitis caused by E. coli, Group B Streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus sp., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella sp. respond to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptoccoccal endocarditis. Urinary Tract Infections caused by sensitve strains of E. coli and Proteus mirabilis. Gastrointestinal Infections caused by Salmonella typhosa (typhoid fever), other Salmonella sp., and Shigella sp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ampicillin for Injection, USP and other antibacterial drugs, Ampicillin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Indicated surgical procedures should be performed. uuid:00b95b8e-0d11-4612-8812-8647c6f0cab6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28971 biolink:treats MONDO:0006670 PMID:41385096 "[{""id"":""uuid:2e0daa57-c9ce-4d15-a3e2-0dbd5c8112d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:db588a18-f331-4e02-a350-73dada1b369b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory tract Infections caused by S. pneumoniae (formerly D. pneumoniae ). Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae, and Group A beta-hemolytic Streptococci. Bacterial Meningitis caused by E. coli, Group B Streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus sp., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella sp. respond to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptoccoccal endocarditis. Urinary Tract Infections caused by sensitve strains of E. coli and Proteus mirabilis. Gastrointestinal Infections caused by Salmonella typhosa (typhoid fever), other Salmonella sp., and Shigella sp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ampicillin for Injection, USP and other antibacterial drugs, Ampicillin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Indicated surgical procedures should be performed. uuid:7a914325-d7db-4f58-9147-5b6ab440fa6b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28971 biolink:treats MONDO:0700217 PMID:41385096 "[{""id"":""uuid:dd03433a-4684-49f8-9092-3d87c131fb0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8ad63832-bb0c-4382-960a-47f9c4b1db17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory tract Infections caused by S. pneumoniae (formerly D. pneumoniae ). Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae, and Group A beta-hemolytic Streptococci. Bacterial Meningitis caused by E. coli, Group B Streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus sp., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella sp. respond to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptoccoccal endocarditis. Urinary Tract Infections caused by sensitve strains of E. coli and Proteus mirabilis. Gastrointestinal Infections caused by Salmonella typhosa (typhoid fever), other Salmonella sp., and Shigella sp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ampicillin for Injection, USP and other antibacterial drugs, Ampicillin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Indicated surgical procedures should be performed. uuid:a2e57da3-f285-47cd-a55e-fbe3d73f29c7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28971 biolink:treats MONDO:0005025 PMID:41385096 "[{""id"":""uuid:41cbbe9a-0ac0-4ce2-b9df-a6143844cda4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:24bb8a60-0169-475f-8234-332fc00891a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory tract Infections caused by S. pneumoniae (formerly D. pneumoniae ). Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae, and Group A beta-hemolytic Streptococci. Bacterial Meningitis caused by E. coli, Group B Streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus sp., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella sp. respond to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptoccoccal endocarditis. Urinary Tract Infections caused by sensitve strains of E. coli and Proteus mirabilis. Gastrointestinal Infections caused by Salmonella typhosa (typhoid fever), other Salmonella sp., and Shigella sp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ampicillin for Injection, USP and other antibacterial drugs, Ampicillin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Indicated surgical procedures should be performed. uuid:a2ebaee5-6687-4523-9f41-c62e5ff63110 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28971 biolink:treats UMLS:C0036685 PMID:41385096 "[{""id"":""uuid:a37e8df0-0f49-42de-9f26-a79f301c7d92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0cd38243-0834-4391-879b-e8008811489a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory tract Infections caused by S. pneumoniae (formerly D. pneumoniae ). Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae, and Group A beta-hemolytic Streptococci. Bacterial Meningitis caused by E. coli, Group B Streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus sp., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella sp. respond to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptoccoccal endocarditis. Urinary Tract Infections caused by sensitve strains of E. coli and Proteus mirabilis. Gastrointestinal Infections caused by Salmonella typhosa (typhoid fever), other Salmonella sp., and Shigella sp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ampicillin for Injection, USP and other antibacterial drugs, Ampicillin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Indicated surgical procedures should be performed. uuid:12748ab0-d911-4752-b9a2-bb4be1df75ac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28971 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:fb6629fc-c049-4d68-ac6f-db95793531d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ea3fc824-22c2-4c63-b988-22a0a4f8f004"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory tract Infections caused by S. pneumoniae (formerly D. pneumoniae ). Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae, and Group A beta-hemolytic Streptococci. Bacterial Meningitis caused by E. coli, Group B Streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus sp., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella sp. respond to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptoccoccal endocarditis. Urinary Tract Infections caused by sensitve strains of E. coli and Proteus mirabilis. Gastrointestinal Infections caused by Salmonella typhosa (typhoid fever), other Salmonella sp., and Shigella sp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ampicillin for Injection, USP and other antibacterial drugs, Ampicillin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Indicated surgical procedures should be performed. uuid:390993dd-042c-46c3-952c-9e2662d2512d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28971 biolink:treats MONDO:0043424 PMID:41385096 "[{""id"":""uuid:f1bc6741-0b30-47dc-b77b-a6f74d573f2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d6796983-3744-4ea3-aa56-c0a27459a705"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory tract Infections caused by S. pneumoniae (formerly D. pneumoniae ). Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae, and Group A beta-hemolytic Streptococci. Bacterial Meningitis caused by E. coli, Group B Streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus sp., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella sp. respond to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptoccoccal endocarditis. Urinary Tract Infections caused by sensitve strains of E. coli and Proteus mirabilis. Gastrointestinal Infections caused by Salmonella typhosa (typhoid fever), other Salmonella sp., and Shigella sp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ampicillin for Injection, USP and other antibacterial drugs, Ampicillin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Indicated surgical procedures should be performed. uuid:8ba0617e-00c8-4025-a067-34c326ca53ab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28971 biolink:treats MONDO:0005619 PMID:41385096 "[{""id"":""uuid:b6e35f86-9d3e-4e05-a8dc-bbbffcb4e312"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3809ca8e-8ffa-45c5-a6a3-1636cae9dd73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory tract Infections caused by S. pneumoniae (formerly D. pneumoniae ). Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae, and Group A beta-hemolytic Streptococci. Bacterial Meningitis caused by E. coli, Group B Streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus sp., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella sp. respond to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptoccoccal endocarditis. Urinary Tract Infections caused by sensitve strains of E. coli and Proteus mirabilis. Gastrointestinal Infections caused by Salmonella typhosa (typhoid fever), other Salmonella sp., and Shigella sp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ampicillin for Injection, USP and other antibacterial drugs, Ampicillin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Indicated surgical procedures should be performed. uuid:5d76f8b8-56aa-457e-8085-b4797d22c20e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28971 biolink:treats MONDO:0001517 PMID:41385096 "[{""id"":""uuid:8b746d3b-7add-48a9-ba0e-c5aa26312b2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7b3a1251-f270-42aa-bff7-443e77196798"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ampicillin for Injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the following conditions: Respiratory tract Infections caused by S. pneumoniae (formerly D. pneumoniae ). Staphylococcus aureus (penicillinase and nonpenicillinase-producing), H. influenzae, and Group A beta-hemolytic Streptococci. Bacterial Meningitis caused by E. coli, Group B Streptococci, and other Gram-negative bacteria ( Listeria monocytogenes, N. meningitidis ). The addition of an aminoglycoside with ampicillin may increase its effectiveness against Gram-negative bacteria. Septicemia and Endocarditis caused by susceptible Gram-positive organisms including Streptococcus sp., penicillin G-susceptible staphylococci, and enterococci. Gram-negative sepsis caused by E. coli, Proteus mirabilis and Salmonella sp. respond to ampicillin. Endocarditis due to enterococcal strains usually respond to intravenous therapy. The addition of an aminoglycoside may enhance the effectiveness of ampicillin when treating streptoccoccal endocarditis. Urinary Tract Infections caused by sensitve strains of E. coli and Proteus mirabilis. Gastrointestinal Infections caused by Salmonella typhosa (typhoid fever), other Salmonella sp., and Shigella sp. (dysentery) usually respond to oral or intravenous therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to obtaining results of susceptibility testing. It is advisable to reserve the parenteral form of this drug for moderately severe and severe infections and for patients who are unable to take the oral forms. A change to oral ampicillin may be made as soon as appropriate. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ampicillin for Injection, USP and other antibacterial drugs, Ampicillin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Indicated surgical procedures should be performed. uuid:a7b22143-848d-456e-949e-79370454855d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3996 biolink:treats MONDO:0014115 PMID:41385096 "[{""id"":""uuid:2facb27c-cb3c-41ee-a3a3-805208c89d23"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8e65ec20-87d4-4e85-a5e2-de4ba4b705ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclobenzaprine HCl tablets are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine HCl tablets should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine HCl tablets have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy. uuid:0cb3fc27-f326-4de5-a971-f1a708acecb6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:194135 biolink:treats MONDO:0003799 PMID:41385096 "[{""id"":""uuid:0b1937bb-ae9a-4388-b0a4-9277f10b055f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a74d99db-3e1d-49af-81e2-ea7351732fb0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: CONJUNCTIVITIS: Gram-positive bacteria: Gram-negative bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Enterobacter cloacae Haemophilus influenzae Proteus mirabilis Pseudomonas aeruginosa CORNEAL ULCERS: Gram-positive bacteria: Gram-negative bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Pseudomonas aeruginosa Serratia marcescens* Anaerobic species: Propionibacterium acnes *Efficacy for this organism was studied in fewer than 10 infections uuid:964bb06f-e4d2-4e2e-9838-b4ea865ce610 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:194135 biolink:treats MONDO:0004577 PMID:41385096 "[{""id"":""uuid:b30c5e2e-e939-4f42-a61a-4f891af519cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2f02a9d1-2804-4491-be6a-0245ce45d90f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: CONJUNCTIVITIS: Gram-positive bacteria: Gram-negative bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Enterobacter cloacae Haemophilus influenzae Proteus mirabilis Pseudomonas aeruginosa CORNEAL ULCERS: Gram-positive bacteria: Gram-negative bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Pseudomonas aeruginosa Serratia marcescens* Anaerobic species: Propionibacterium acnes *Efficacy for this organism was studied in fewer than 10 infections uuid:9b5f3611-df7b-42ec-b173-ee81135cd4a9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75722 biolink:treats UMLS:C0278139 PMID:41385096 "[{""id"":""uuid:910e1a6b-1a61-4ffc-ad4a-22a3aa27e4a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:369d41df-e568-413d-bdee-941c6ae31451"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tramadol hydrochloride is indicated for the management of moderate to moderately severe pain in adults. uuid:53cd0195-d330-467d-a057-fffa864b93e4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151399 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:bebfd0ca-f44c-44e7-b298-d84fac19d010"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6533daf7-f2b2-4e63-a98e-f8c1d1864f70"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Sulfamethoxazole and Trimethoprim Oral Suspension and other antibacterial drugs, Sulfamethoxazole and Trimethoprim Oral Suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Urinary Tract Infections: For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli , Klebsiella species, Enterobacter species, Morganella morganii , Proteus mirabilis and Proteus vulgaris . It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media: For the treatment of acute otitis media in children due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician this combination offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim in children under two years of age. This product is not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations Of Chronic Bronchitis In Adults: For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician, this combination offers some advantage over the use of a single antimicrobial agent. Shigellosis: For the treatment of enteritis caused by susceptible strains of Shigella flexneri and Shigella sonnei when antibacterial therapy is indicated. Pneumocystis Carinii Pneumonia: For the treatment of documented Pneumocystis carinii pneumonia. For prophylaxis against Pneumocystis carinii pneumonia in individuals who are immunosuppressed and considered to be at an increased risk of developing Pneumocystis carinii pneumonia. Travelers’ Diarrhea In Adults: For the treatment of travelers’ diarrhea due to susceptible strains of enterotoxigenic E. coli. uuid:2100a014-aaae-4a0d-9f18-a17ef266be81 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151399 biolink:treats HP:0000371 PMID:41385096 "[{""id"":""uuid:6aadbe2d-4680-4b61-b1c1-0573caed534d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3dacf464-6581-458c-ad58-a0294b957275"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Sulfamethoxazole and Trimethoprim Oral Suspension and other antibacterial drugs, Sulfamethoxazole and Trimethoprim Oral Suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Urinary Tract Infections: For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli , Klebsiella species, Enterobacter species, Morganella morganii , Proteus mirabilis and Proteus vulgaris . It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media: For the treatment of acute otitis media in children due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician this combination offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim in children under two years of age. This product is not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations Of Chronic Bronchitis In Adults: For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician, this combination offers some advantage over the use of a single antimicrobial agent. Shigellosis: For the treatment of enteritis caused by susceptible strains of Shigella flexneri and Shigella sonnei when antibacterial therapy is indicated. Pneumocystis Carinii Pneumonia: For the treatment of documented Pneumocystis carinii pneumonia. For prophylaxis against Pneumocystis carinii pneumonia in individuals who are immunosuppressed and considered to be at an increased risk of developing Pneumocystis carinii pneumonia. Travelers’ Diarrhea In Adults: For the treatment of travelers’ diarrhea due to susceptible strains of enterotoxigenic E. coli. uuid:21395f80-ecb3-478f-b1da-ff0d57e42a1b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151399 biolink:treats UMLS:C0853854 PMID:41385096 "[{""id"":""uuid:adb4b94c-9d2e-448f-9c2d-f5a8f974238b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:becc6991-5d95-4cec-988f-3ff39d5c2631"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Sulfamethoxazole and Trimethoprim Oral Suspension and other antibacterial drugs, Sulfamethoxazole and Trimethoprim Oral Suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Urinary Tract Infections: For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli , Klebsiella species, Enterobacter species, Morganella morganii , Proteus mirabilis and Proteus vulgaris . It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media: For the treatment of acute otitis media in children due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician this combination offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim in children under two years of age. This product is not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations Of Chronic Bronchitis In Adults: For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician, this combination offers some advantage over the use of a single antimicrobial agent. Shigellosis: For the treatment of enteritis caused by susceptible strains of Shigella flexneri and Shigella sonnei when antibacterial therapy is indicated. Pneumocystis Carinii Pneumonia: For the treatment of documented Pneumocystis carinii pneumonia. For prophylaxis against Pneumocystis carinii pneumonia in individuals who are immunosuppressed and considered to be at an increased risk of developing Pneumocystis carinii pneumonia. Travelers’ Diarrhea In Adults: For the treatment of travelers’ diarrhea due to susceptible strains of enterotoxigenic E. coli. uuid:ebb8fa66-f1ca-4640-9a93-29746553b033 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151399 biolink:treats MONDO:0019345 PMID:41385096 "[{""id"":""uuid:ec72f526-dd56-46f8-b31c-11c4ba279e59"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:84e0db05-4512-415d-bf91-214ff7408b3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Sulfamethoxazole and Trimethoprim Oral Suspension and other antibacterial drugs, Sulfamethoxazole and Trimethoprim Oral Suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Urinary Tract Infections: For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli , Klebsiella species, Enterobacter species, Morganella morganii , Proteus mirabilis and Proteus vulgaris . It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media: For the treatment of acute otitis media in children due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician this combination offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim in children under two years of age. This product is not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations Of Chronic Bronchitis In Adults: For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician, this combination offers some advantage over the use of a single antimicrobial agent. Shigellosis: For the treatment of enteritis caused by susceptible strains of Shigella flexneri and Shigella sonnei when antibacterial therapy is indicated. Pneumocystis Carinii Pneumonia: For the treatment of documented Pneumocystis carinii pneumonia. For prophylaxis against Pneumocystis carinii pneumonia in individuals who are immunosuppressed and considered to be at an increased risk of developing Pneumocystis carinii pneumonia. Travelers’ Diarrhea In Adults: For the treatment of travelers’ diarrhea due to susceptible strains of enterotoxigenic E. coli. uuid:8865303f-d83f-4849-bf76-83684892186d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151399 biolink:treats MONDO:0019121 PMID:41385096 "[{""id"":""uuid:b987defe-054d-4b02-96a0-a01c1a0b2a45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:af687e83-aa1a-4840-913b-acfa32cbbf91"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7d899847-5a39-4271-bddc-25d7fac4715e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Sulfamethoxazole and Trimethoprim Oral Suspension and other antibacterial drugs, Sulfamethoxazole and Trimethoprim Oral Suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Urinary Tract Infections: For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli , Klebsiella species, Enterobacter species, Morganella morganii , Proteus mirabilis and Proteus vulgaris . It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media: For the treatment of acute otitis media in children due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician this combination offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim in children under two years of age. This product is not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations Of Chronic Bronchitis In Adults: For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician, this combination offers some advantage over the use of a single antimicrobial agent. Shigellosis: For the treatment of enteritis caused by susceptible strains of Shigella flexneri and Shigella sonnei when antibacterial therapy is indicated. Pneumocystis Carinii Pneumonia: For the treatment of documented Pneumocystis carinii pneumonia. For prophylaxis against Pneumocystis carinii pneumonia in individuals who are immunosuppressed and considered to be at an increased risk of developing Pneumocystis carinii pneumonia. Travelers’ Diarrhea In Adults: For the treatment of travelers’ diarrhea due to susceptible strains of enterotoxigenic E. coli.|[PMDA] Drugs with a new additional indication and a new dosage for the treatment and prevention of Pneumocystis pneumonia. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:e505c570-4d54-4e6b-baf4-f79f2b03f4fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151399 biolink:treats UMLS:C0277528 PMID:41385096 "[{""id"":""uuid:7631ae45-0f75-414b-94ce-d9fc2cceef5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3bd9d5bb-1e0d-47d6-81e7-95e8c5dc8ca4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Sulfamethoxazole and Trimethoprim Oral Suspension and other antibacterial drugs, Sulfamethoxazole and Trimethoprim Oral Suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Urinary Tract Infections: For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli , Klebsiella species, Enterobacter species, Morganella morganii , Proteus mirabilis and Proteus vulgaris . It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media: For the treatment of acute otitis media in children due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician this combination offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim in children under two years of age. This product is not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations Of Chronic Bronchitis In Adults: For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician, this combination offers some advantage over the use of a single antimicrobial agent. Shigellosis: For the treatment of enteritis caused by susceptible strains of Shigella flexneri and Shigella sonnei when antibacterial therapy is indicated. Pneumocystis Carinii Pneumonia: For the treatment of documented Pneumocystis carinii pneumonia. For prophylaxis against Pneumocystis carinii pneumonia in individuals who are immunosuppressed and considered to be at an increased risk of developing Pneumocystis carinii pneumonia. Travelers’ Diarrhea In Adults: For the treatment of travelers’ diarrhea due to susceptible strains of enterotoxigenic E. coli. uuid:15b21f58-17cc-466f-a36d-bbf478f75dba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9599 biolink:treats MONDO:0006875 PMID:41385096 "[{""id"":""uuid:f90f1026-8144-4984-92de-9d352f6ee6c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c8dcd61a-ec11-48aa-a4bc-85d5f0d67aea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Betimol ® is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. uuid:65a82124-bb6b-412b-a224-2f05796949b8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9599 biolink:treats MONDO:0005338 PMID:41385096 "[{""id"":""uuid:9d775585-1712-429f-9475-bf05f7d59fdc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:58f9a6ba-0c78-41b5-a121-2905c0828ac2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Betimol ® is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. uuid:0e813601-79bf-4996-a991-2676d1f0d066 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:87681 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:79385d6b-3ab2-401e-b6bf-bb72337f9ffc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:47054adc-1298-4b76-ab4d-5049dede9e71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ranexa is indicated for the treatment of chronic angina. Ranexa may be used with beta-blockers, nitrates, calcium channel blockers, anti-platelet therapy, lipid-lowering therapy, ACE inhibitors, and angiotensin receptor blockers. uuid:a9c06584-cccb-4f4a-9c91-8fe620349b90 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4B33BGI082 biolink:treats UMLS:C0342879 PMID:41385096 "[{""id"":""uuid:0612fda0-995d-43db-b32f-96c5a3bce5f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d248afa4-91de-4d7b-b528-3c7526f201ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1) Cholestyramine for Oral Suspension USP is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Cholestyramine may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. Excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. Prior to initiating therapy with Cholestyramine, secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism), should be excluded, and a lipid profile performed to assess Total cholesterol, HDL-C, and triglycerides (TG). For individuals with TG less than 400 mg/dL (less than 4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total cholesterol – [(TG/5) + HDL-C] For TG levels >400 mg/dL, this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases Cholestyramine may not be indicated. Serum cholesterol and triglyceride levels should be determined periodically based on NCEP guidelines to confirm initial and adequate long-term response. A favorable trend in cholesterol reduction should occur during the first month of Cholestyramine therapy. The therapy should be continued to sustain cholesterol reduction. If adequate cholesterol reduction is not attained, increasing the dosage of Cholestyramine or adding other lipid-lowering agents in combination with Cholestyramine should be considered. Since the goal of treatment is to lower LDL-C, the NCEP 4 recommends that LDL-C levels be used to initiate and assess treatment response. If LDL-C levels are not available then Total-C alone may be used to monitor long-term therapy. A lipoprotein analysis (including LDL-C determination) should be carried out once a year. The NCEP treatment guidelines are summarized below. LDL-Cholesterol mg/dL (mmol/L) Definite Atherosclerotic Disease* Two or More Other Risk Factors** Initiation Level Goal NO NO Greater Than or Equal to 190 (Greater Than or Equal To 4.9) Less Than 160 (Less Than 4.1) NO YES Greater Than or Equal To 160 (Greater Than or Equal To 4.1) Less Than 130 (Less Than 3.4) YES YES or NO Greater Than or Equal To 130 (Greater Than or Equal To 3.4) Less Than or Equal To 100 (Less Than or Equal To 2.6) * Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). ** Other risk factors for coronary heart disease (CHD) include: age (males greater than or equal to 45 years; females greater than or equal to 55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C less than 35 mg/dL (less than 0.91 mmol/L); and diabetes mellitus. Subtract one risk factor if HDL-C is greater than or equal to 60 mg/dL (greater than or equal to 1.6 mmol/L). Cholestyramine monotherapy has been demonstrated to retard the rate of progression 2,3 and increase the rate of regression 3 of coronary atherosclerosis. 2) Cholestyramine for oral suspension is indicated for the relief of pruritus associated with partial biliary obstruction. Cholestyramine for oral suspension has been shown to have a variable effect on serum cholesterol in these patients. Patients with primary biliary cirrhosis may exhibit an elevated cholesterol as part of their disease. uuid:5ee55249-d836-411f-8c10-dde756bdf198 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4B33BGI082 biolink:treats MONDO:0005347 PMID:41385096 "[{""id"":""uuid:463a53bf-d503-4b41-ae85-266422e1daf9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d1db7b70-2d2f-4b03-872d-82a49e1de37d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1) Cholestyramine for Oral Suspension USP is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Cholestyramine may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. Excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. Prior to initiating therapy with Cholestyramine, secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism), should be excluded, and a lipid profile performed to assess Total cholesterol, HDL-C, and triglycerides (TG). For individuals with TG less than 400 mg/dL (less than 4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total cholesterol – [(TG/5) + HDL-C] For TG levels >400 mg/dL, this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases Cholestyramine may not be indicated. Serum cholesterol and triglyceride levels should be determined periodically based on NCEP guidelines to confirm initial and adequate long-term response. A favorable trend in cholesterol reduction should occur during the first month of Cholestyramine therapy. The therapy should be continued to sustain cholesterol reduction. If adequate cholesterol reduction is not attained, increasing the dosage of Cholestyramine or adding other lipid-lowering agents in combination with Cholestyramine should be considered. Since the goal of treatment is to lower LDL-C, the NCEP 4 recommends that LDL-C levels be used to initiate and assess treatment response. If LDL-C levels are not available then Total-C alone may be used to monitor long-term therapy. A lipoprotein analysis (including LDL-C determination) should be carried out once a year. The NCEP treatment guidelines are summarized below. LDL-Cholesterol mg/dL (mmol/L) Definite Atherosclerotic Disease* Two or More Other Risk Factors** Initiation Level Goal NO NO Greater Than or Equal to 190 (Greater Than or Equal To 4.9) Less Than 160 (Less Than 4.1) NO YES Greater Than or Equal To 160 (Greater Than or Equal To 4.1) Less Than 130 (Less Than 3.4) YES YES or NO Greater Than or Equal To 130 (Greater Than or Equal To 3.4) Less Than or Equal To 100 (Less Than or Equal To 2.6) * Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). ** Other risk factors for coronary heart disease (CHD) include: age (males greater than or equal to 45 years; females greater than or equal to 55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C less than 35 mg/dL (less than 0.91 mmol/L); and diabetes mellitus. Subtract one risk factor if HDL-C is greater than or equal to 60 mg/dL (greater than or equal to 1.6 mmol/L). Cholestyramine monotherapy has been demonstrated to retard the rate of progression 2,3 and increase the rate of regression 3 of coronary atherosclerosis. 2) Cholestyramine for oral suspension is indicated for the relief of pruritus associated with partial biliary obstruction. Cholestyramine for oral suspension has been shown to have a variable effect on serum cholesterol in these patients. Patients with primary biliary cirrhosis may exhibit an elevated cholesterol as part of their disease. uuid:99d5f92b-454c-46de-8892-9e6a9c9803df biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4B33BGI082 biolink:treats MONDO:0005311 PMID:41385096 "[{""id"":""uuid:97d4b543-e47c-4674-a501-8d6123f77496"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:29b58985-2f64-45c2-a176-eb64aab70c3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1) Cholestyramine for Oral Suspension USP is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Cholestyramine may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. Excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. Prior to initiating therapy with Cholestyramine, secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism), should be excluded, and a lipid profile performed to assess Total cholesterol, HDL-C, and triglycerides (TG). For individuals with TG less than 400 mg/dL (less than 4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total cholesterol – [(TG/5) + HDL-C] For TG levels >400 mg/dL, this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases Cholestyramine may not be indicated. Serum cholesterol and triglyceride levels should be determined periodically based on NCEP guidelines to confirm initial and adequate long-term response. A favorable trend in cholesterol reduction should occur during the first month of Cholestyramine therapy. The therapy should be continued to sustain cholesterol reduction. If adequate cholesterol reduction is not attained, increasing the dosage of Cholestyramine or adding other lipid-lowering agents in combination with Cholestyramine should be considered. Since the goal of treatment is to lower LDL-C, the NCEP 4 recommends that LDL-C levels be used to initiate and assess treatment response. If LDL-C levels are not available then Total-C alone may be used to monitor long-term therapy. A lipoprotein analysis (including LDL-C determination) should be carried out once a year. The NCEP treatment guidelines are summarized below. LDL-Cholesterol mg/dL (mmol/L) Definite Atherosclerotic Disease* Two or More Other Risk Factors** Initiation Level Goal NO NO Greater Than or Equal to 190 (Greater Than or Equal To 4.9) Less Than 160 (Less Than 4.1) NO YES Greater Than or Equal To 160 (Greater Than or Equal To 4.1) Less Than 130 (Less Than 3.4) YES YES or NO Greater Than or Equal To 130 (Greater Than or Equal To 3.4) Less Than or Equal To 100 (Less Than or Equal To 2.6) * Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). ** Other risk factors for coronary heart disease (CHD) include: age (males greater than or equal to 45 years; females greater than or equal to 55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C less than 35 mg/dL (less than 0.91 mmol/L); and diabetes mellitus. Subtract one risk factor if HDL-C is greater than or equal to 60 mg/dL (greater than or equal to 1.6 mmol/L). Cholestyramine monotherapy has been demonstrated to retard the rate of progression 2,3 and increase the rate of regression 3 of coronary atherosclerosis. 2) Cholestyramine for oral suspension is indicated for the relief of pruritus associated with partial biliary obstruction. Cholestyramine for oral suspension has been shown to have a variable effect on serum cholesterol in these patients. Patients with primary biliary cirrhosis may exhibit an elevated cholesterol as part of their disease. uuid:4bb53a03-0768-43d8-b4a6-2d289b460985 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4B33BGI082 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:486f6223-f43a-4ba2-a001-384bebd1f000"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:25be5c30-79ad-4ecc-8517-6d0dcf67e558"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1) Cholestyramine for Oral Suspension USP is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Cholestyramine may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. Excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. Prior to initiating therapy with Cholestyramine, secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism), should be excluded, and a lipid profile performed to assess Total cholesterol, HDL-C, and triglycerides (TG). For individuals with TG less than 400 mg/dL (less than 4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total cholesterol – [(TG/5) + HDL-C] For TG levels >400 mg/dL, this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases Cholestyramine may not be indicated. Serum cholesterol and triglyceride levels should be determined periodically based on NCEP guidelines to confirm initial and adequate long-term response. A favorable trend in cholesterol reduction should occur during the first month of Cholestyramine therapy. The therapy should be continued to sustain cholesterol reduction. If adequate cholesterol reduction is not attained, increasing the dosage of Cholestyramine or adding other lipid-lowering agents in combination with Cholestyramine should be considered. Since the goal of treatment is to lower LDL-C, the NCEP 4 recommends that LDL-C levels be used to initiate and assess treatment response. If LDL-C levels are not available then Total-C alone may be used to monitor long-term therapy. A lipoprotein analysis (including LDL-C determination) should be carried out once a year. The NCEP treatment guidelines are summarized below. LDL-Cholesterol mg/dL (mmol/L) Definite Atherosclerotic Disease* Two or More Other Risk Factors** Initiation Level Goal NO NO Greater Than or Equal to 190 (Greater Than or Equal To 4.9) Less Than 160 (Less Than 4.1) NO YES Greater Than or Equal To 160 (Greater Than or Equal To 4.1) Less Than 130 (Less Than 3.4) YES YES or NO Greater Than or Equal To 130 (Greater Than or Equal To 3.4) Less Than or Equal To 100 (Less Than or Equal To 2.6) * Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). ** Other risk factors for coronary heart disease (CHD) include: age (males greater than or equal to 45 years; females greater than or equal to 55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C less than 35 mg/dL (less than 0.91 mmol/L); and diabetes mellitus. Subtract one risk factor if HDL-C is greater than or equal to 60 mg/dL (greater than or equal to 1.6 mmol/L). Cholestyramine monotherapy has been demonstrated to retard the rate of progression 2,3 and increase the rate of regression 3 of coronary atherosclerosis. 2) Cholestyramine for oral suspension is indicated for the relief of pruritus associated with partial biliary obstruction. Cholestyramine for oral suspension has been shown to have a variable effect on serum cholesterol in these patients. Patients with primary biliary cirrhosis may exhibit an elevated cholesterol as part of their disease. uuid:ef4e66e8-d88b-4f6e-9919-56f6f5ec9260 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4B33BGI082 biolink:treats MONDO:0005420 PMID:41385096 "[{""id"":""uuid:e85002de-46f1-4c4e-aa9e-3a378e377249"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e93df821-733a-45cc-86cc-35c922979598"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1) Cholestyramine for Oral Suspension USP is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Cholestyramine may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. Excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. Prior to initiating therapy with Cholestyramine, secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism), should be excluded, and a lipid profile performed to assess Total cholesterol, HDL-C, and triglycerides (TG). For individuals with TG less than 400 mg/dL (less than 4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total cholesterol – [(TG/5) + HDL-C] For TG levels >400 mg/dL, this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases Cholestyramine may not be indicated. Serum cholesterol and triglyceride levels should be determined periodically based on NCEP guidelines to confirm initial and adequate long-term response. A favorable trend in cholesterol reduction should occur during the first month of Cholestyramine therapy. The therapy should be continued to sustain cholesterol reduction. If adequate cholesterol reduction is not attained, increasing the dosage of Cholestyramine or adding other lipid-lowering agents in combination with Cholestyramine should be considered. Since the goal of treatment is to lower LDL-C, the NCEP 4 recommends that LDL-C levels be used to initiate and assess treatment response. If LDL-C levels are not available then Total-C alone may be used to monitor long-term therapy. A lipoprotein analysis (including LDL-C determination) should be carried out once a year. The NCEP treatment guidelines are summarized below. LDL-Cholesterol mg/dL (mmol/L) Definite Atherosclerotic Disease* Two or More Other Risk Factors** Initiation Level Goal NO NO Greater Than or Equal to 190 (Greater Than or Equal To 4.9) Less Than 160 (Less Than 4.1) NO YES Greater Than or Equal To 160 (Greater Than or Equal To 4.1) Less Than 130 (Less Than 3.4) YES YES or NO Greater Than or Equal To 130 (Greater Than or Equal To 3.4) Less Than or Equal To 100 (Less Than or Equal To 2.6) * Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). ** Other risk factors for coronary heart disease (CHD) include: age (males greater than or equal to 45 years; females greater than or equal to 55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C less than 35 mg/dL (less than 0.91 mmol/L); and diabetes mellitus. Subtract one risk factor if HDL-C is greater than or equal to 60 mg/dL (greater than or equal to 1.6 mmol/L). Cholestyramine monotherapy has been demonstrated to retard the rate of progression 2,3 and increase the rate of regression 3 of coronary atherosclerosis. 2) Cholestyramine for oral suspension is indicated for the relief of pruritus associated with partial biliary obstruction. Cholestyramine for oral suspension has been shown to have a variable effect on serum cholesterol in these patients. Patients with primary biliary cirrhosis may exhibit an elevated cholesterol as part of their disease. uuid:e5324a26-390d-4ccf-bfee-5aac62e7ca96 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4B33BGI082 biolink:treats MONDO:0005377 PMID:41385096 "[{""id"":""uuid:c7661c8d-8d8f-473d-9a5f-b1b51f29afa6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2d021459-4780-49e5-8118-b2663a1aacda"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1) Cholestyramine for Oral Suspension USP is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Cholestyramine may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. Excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. Prior to initiating therapy with Cholestyramine, secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism), should be excluded, and a lipid profile performed to assess Total cholesterol, HDL-C, and triglycerides (TG). For individuals with TG less than 400 mg/dL (less than 4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total cholesterol – [(TG/5) + HDL-C] For TG levels >400 mg/dL, this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases Cholestyramine may not be indicated. Serum cholesterol and triglyceride levels should be determined periodically based on NCEP guidelines to confirm initial and adequate long-term response. A favorable trend in cholesterol reduction should occur during the first month of Cholestyramine therapy. The therapy should be continued to sustain cholesterol reduction. If adequate cholesterol reduction is not attained, increasing the dosage of Cholestyramine or adding other lipid-lowering agents in combination with Cholestyramine should be considered. Since the goal of treatment is to lower LDL-C, the NCEP 4 recommends that LDL-C levels be used to initiate and assess treatment response. If LDL-C levels are not available then Total-C alone may be used to monitor long-term therapy. A lipoprotein analysis (including LDL-C determination) should be carried out once a year. The NCEP treatment guidelines are summarized below. LDL-Cholesterol mg/dL (mmol/L) Definite Atherosclerotic Disease* Two or More Other Risk Factors** Initiation Level Goal NO NO Greater Than or Equal to 190 (Greater Than or Equal To 4.9) Less Than 160 (Less Than 4.1) NO YES Greater Than or Equal To 160 (Greater Than or Equal To 4.1) Less Than 130 (Less Than 3.4) YES YES or NO Greater Than or Equal To 130 (Greater Than or Equal To 3.4) Less Than or Equal To 100 (Less Than or Equal To 2.6) * Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). ** Other risk factors for coronary heart disease (CHD) include: age (males greater than or equal to 45 years; females greater than or equal to 55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C less than 35 mg/dL (less than 0.91 mmol/L); and diabetes mellitus. Subtract one risk factor if HDL-C is greater than or equal to 60 mg/dL (greater than or equal to 1.6 mmol/L). Cholestyramine monotherapy has been demonstrated to retard the rate of progression 2,3 and increase the rate of regression 3 of coronary atherosclerosis. 2) Cholestyramine for oral suspension is indicated for the relief of pruritus associated with partial biliary obstruction. Cholestyramine for oral suspension has been shown to have a variable effect on serum cholesterol in these patients. Patients with primary biliary cirrhosis may exhibit an elevated cholesterol as part of their disease. uuid:e209eb4d-0495-4b4c-866c-9c66ffa7b57e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4B33BGI082 biolink:treats UMLS:C0259744 PMID:41385096 "[{""id"":""uuid:b56ca649-91e4-4b9c-9021-831334c14189"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f167c0c1-5528-4c54-93c3-1d402c781cf4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1) Cholestyramine for Oral Suspension USP is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Cholestyramine may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. Excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. Prior to initiating therapy with Cholestyramine, secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism), should be excluded, and a lipid profile performed to assess Total cholesterol, HDL-C, and triglycerides (TG). For individuals with TG less than 400 mg/dL (less than 4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total cholesterol – [(TG/5) + HDL-C] For TG levels >400 mg/dL, this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases Cholestyramine may not be indicated. Serum cholesterol and triglyceride levels should be determined periodically based on NCEP guidelines to confirm initial and adequate long-term response. A favorable trend in cholesterol reduction should occur during the first month of Cholestyramine therapy. The therapy should be continued to sustain cholesterol reduction. If adequate cholesterol reduction is not attained, increasing the dosage of Cholestyramine or adding other lipid-lowering agents in combination with Cholestyramine should be considered. Since the goal of treatment is to lower LDL-C, the NCEP 4 recommends that LDL-C levels be used to initiate and assess treatment response. If LDL-C levels are not available then Total-C alone may be used to monitor long-term therapy. A lipoprotein analysis (including LDL-C determination) should be carried out once a year. The NCEP treatment guidelines are summarized below. LDL-Cholesterol mg/dL (mmol/L) Definite Atherosclerotic Disease* Two or More Other Risk Factors** Initiation Level Goal NO NO Greater Than or Equal to 190 (Greater Than or Equal To 4.9) Less Than 160 (Less Than 4.1) NO YES Greater Than or Equal To 160 (Greater Than or Equal To 4.1) Less Than 130 (Less Than 3.4) YES YES or NO Greater Than or Equal To 130 (Greater Than or Equal To 3.4) Less Than or Equal To 100 (Less Than or Equal To 2.6) * Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). ** Other risk factors for coronary heart disease (CHD) include: age (males greater than or equal to 45 years; females greater than or equal to 55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C less than 35 mg/dL (less than 0.91 mmol/L); and diabetes mellitus. Subtract one risk factor if HDL-C is greater than or equal to 60 mg/dL (greater than or equal to 1.6 mmol/L). Cholestyramine monotherapy has been demonstrated to retard the rate of progression 2,3 and increase the rate of regression 3 of coronary atherosclerosis. 2) Cholestyramine for oral suspension is indicated for the relief of pruritus associated with partial biliary obstruction. Cholestyramine for oral suspension has been shown to have a variable effect on serum cholesterol in these patients. Patients with primary biliary cirrhosis may exhibit an elevated cholesterol as part of their disease. uuid:92af82b7-bde3-446b-998d-8a334c02732e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4B33BGI082 biolink:treats MONDO:0006874 PMID:41385096 "[{""id"":""uuid:c5f37bee-3bfb-41a6-8a13-0c141c002a73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e8c7b70b-95c4-4018-8e17-15a83acfe86b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1) Cholestyramine for Oral Suspension USP is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Cholestyramine may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. Excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. Prior to initiating therapy with Cholestyramine, secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism), should be excluded, and a lipid profile performed to assess Total cholesterol, HDL-C, and triglycerides (TG). For individuals with TG less than 400 mg/dL (less than 4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total cholesterol – [(TG/5) + HDL-C] For TG levels >400 mg/dL, this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases Cholestyramine may not be indicated. Serum cholesterol and triglyceride levels should be determined periodically based on NCEP guidelines to confirm initial and adequate long-term response. A favorable trend in cholesterol reduction should occur during the first month of Cholestyramine therapy. The therapy should be continued to sustain cholesterol reduction. If adequate cholesterol reduction is not attained, increasing the dosage of Cholestyramine or adding other lipid-lowering agents in combination with Cholestyramine should be considered. Since the goal of treatment is to lower LDL-C, the NCEP 4 recommends that LDL-C levels be used to initiate and assess treatment response. If LDL-C levels are not available then Total-C alone may be used to monitor long-term therapy. A lipoprotein analysis (including LDL-C determination) should be carried out once a year. The NCEP treatment guidelines are summarized below. LDL-Cholesterol mg/dL (mmol/L) Definite Atherosclerotic Disease* Two or More Other Risk Factors** Initiation Level Goal NO NO Greater Than or Equal to 190 (Greater Than or Equal To 4.9) Less Than 160 (Less Than 4.1) NO YES Greater Than or Equal To 160 (Greater Than or Equal To 4.1) Less Than 130 (Less Than 3.4) YES YES or NO Greater Than or Equal To 130 (Greater Than or Equal To 3.4) Less Than or Equal To 100 (Less Than or Equal To 2.6) * Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). ** Other risk factors for coronary heart disease (CHD) include: age (males greater than or equal to 45 years; females greater than or equal to 55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C less than 35 mg/dL (less than 0.91 mmol/L); and diabetes mellitus. Subtract one risk factor if HDL-C is greater than or equal to 60 mg/dL (greater than or equal to 1.6 mmol/L). Cholestyramine monotherapy has been demonstrated to retard the rate of progression 2,3 and increase the rate of regression 3 of coronary atherosclerosis. 2) Cholestyramine for oral suspension is indicated for the relief of pruritus associated with partial biliary obstruction. Cholestyramine for oral suspension has been shown to have a variable effect on serum cholesterol in these patients. Patients with primary biliary cirrhosis may exhibit an elevated cholesterol as part of their disease. uuid:041ca2be-3429-46a7-851a-ca66920ddb39 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4B33BGI082 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:d0f19afb-51b8-4afa-a1fa-fbb592fb3358"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a48ab8ea-e44b-4913-9d9c-c3be20238c40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1) Cholestyramine for Oral Suspension USP is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Cholestyramine may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. Excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. Prior to initiating therapy with Cholestyramine, secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism), should be excluded, and a lipid profile performed to assess Total cholesterol, HDL-C, and triglycerides (TG). For individuals with TG less than 400 mg/dL (less than 4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total cholesterol – [(TG/5) + HDL-C] For TG levels >400 mg/dL, this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases Cholestyramine may not be indicated. Serum cholesterol and triglyceride levels should be determined periodically based on NCEP guidelines to confirm initial and adequate long-term response. A favorable trend in cholesterol reduction should occur during the first month of Cholestyramine therapy. The therapy should be continued to sustain cholesterol reduction. If adequate cholesterol reduction is not attained, increasing the dosage of Cholestyramine or adding other lipid-lowering agents in combination with Cholestyramine should be considered. Since the goal of treatment is to lower LDL-C, the NCEP 4 recommends that LDL-C levels be used to initiate and assess treatment response. If LDL-C levels are not available then Total-C alone may be used to monitor long-term therapy. A lipoprotein analysis (including LDL-C determination) should be carried out once a year. The NCEP treatment guidelines are summarized below. LDL-Cholesterol mg/dL (mmol/L) Definite Atherosclerotic Disease* Two or More Other Risk Factors** Initiation Level Goal NO NO Greater Than or Equal to 190 (Greater Than or Equal To 4.9) Less Than 160 (Less Than 4.1) NO YES Greater Than or Equal To 160 (Greater Than or Equal To 4.1) Less Than 130 (Less Than 3.4) YES YES or NO Greater Than or Equal To 130 (Greater Than or Equal To 3.4) Less Than or Equal To 100 (Less Than or Equal To 2.6) * Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). ** Other risk factors for coronary heart disease (CHD) include: age (males greater than or equal to 45 years; females greater than or equal to 55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C less than 35 mg/dL (less than 0.91 mmol/L); and diabetes mellitus. Subtract one risk factor if HDL-C is greater than or equal to 60 mg/dL (greater than or equal to 1.6 mmol/L). Cholestyramine monotherapy has been demonstrated to retard the rate of progression 2,3 and increase the rate of regression 3 of coronary atherosclerosis. 2) Cholestyramine for oral suspension is indicated for the relief of pruritus associated with partial biliary obstruction. Cholestyramine for oral suspension has been shown to have a variable effect on serum cholesterol in these patients. Patients with primary biliary cirrhosis may exhibit an elevated cholesterol as part of their disease. uuid:98688f67-087f-4f07-933d-117442e38469 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4B33BGI082 biolink:treats MONDO:0005294 PMID:41385096 "[{""id"":""uuid:1cef4963-7686-41ad-a166-845fa1e3e8da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d14ff1bf-d83c-4d4a-9e4f-a5961a3c7743"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1) Cholestyramine for Oral Suspension USP is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Cholestyramine may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. Excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. Prior to initiating therapy with Cholestyramine, secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism), should be excluded, and a lipid profile performed to assess Total cholesterol, HDL-C, and triglycerides (TG). For individuals with TG less than 400 mg/dL (less than 4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total cholesterol – [(TG/5) + HDL-C] For TG levels >400 mg/dL, this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases Cholestyramine may not be indicated. Serum cholesterol and triglyceride levels should be determined periodically based on NCEP guidelines to confirm initial and adequate long-term response. A favorable trend in cholesterol reduction should occur during the first month of Cholestyramine therapy. The therapy should be continued to sustain cholesterol reduction. If adequate cholesterol reduction is not attained, increasing the dosage of Cholestyramine or adding other lipid-lowering agents in combination with Cholestyramine should be considered. Since the goal of treatment is to lower LDL-C, the NCEP 4 recommends that LDL-C levels be used to initiate and assess treatment response. If LDL-C levels are not available then Total-C alone may be used to monitor long-term therapy. A lipoprotein analysis (including LDL-C determination) should be carried out once a year. The NCEP treatment guidelines are summarized below. LDL-Cholesterol mg/dL (mmol/L) Definite Atherosclerotic Disease* Two or More Other Risk Factors** Initiation Level Goal NO NO Greater Than or Equal to 190 (Greater Than or Equal To 4.9) Less Than 160 (Less Than 4.1) NO YES Greater Than or Equal To 160 (Greater Than or Equal To 4.1) Less Than 130 (Less Than 3.4) YES YES or NO Greater Than or Equal To 130 (Greater Than or Equal To 3.4) Less Than or Equal To 100 (Less Than or Equal To 2.6) * Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). ** Other risk factors for coronary heart disease (CHD) include: age (males greater than or equal to 45 years; females greater than or equal to 55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C less than 35 mg/dL (less than 0.91 mmol/L); and diabetes mellitus. Subtract one risk factor if HDL-C is greater than or equal to 60 mg/dL (greater than or equal to 1.6 mmol/L). Cholestyramine monotherapy has been demonstrated to retard the rate of progression 2,3 and increase the rate of regression 3 of coronary atherosclerosis. 2) Cholestyramine for oral suspension is indicated for the relief of pruritus associated with partial biliary obstruction. Cholestyramine for oral suspension has been shown to have a variable effect on serum cholesterol in these patients. Patients with primary biliary cirrhosis may exhibit an elevated cholesterol as part of their disease. uuid:48bd2ab0-636c-409b-8fcc-02666c30b5ae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4B33BGI082 biolink:treats MONDO:0005269 PMID:41385096 "[{""id"":""uuid:485237c2-0a43-474d-986f-70586b1462b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c7dcc367-f0d6-41c4-aee7-2de06de38848"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1) Cholestyramine for Oral Suspension USP is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Cholestyramine may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. Excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. Prior to initiating therapy with Cholestyramine, secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism), should be excluded, and a lipid profile performed to assess Total cholesterol, HDL-C, and triglycerides (TG). For individuals with TG less than 400 mg/dL (less than 4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total cholesterol – [(TG/5) + HDL-C] For TG levels >400 mg/dL, this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases Cholestyramine may not be indicated. Serum cholesterol and triglyceride levels should be determined periodically based on NCEP guidelines to confirm initial and adequate long-term response. A favorable trend in cholesterol reduction should occur during the first month of Cholestyramine therapy. The therapy should be continued to sustain cholesterol reduction. If adequate cholesterol reduction is not attained, increasing the dosage of Cholestyramine or adding other lipid-lowering agents in combination with Cholestyramine should be considered. Since the goal of treatment is to lower LDL-C, the NCEP 4 recommends that LDL-C levels be used to initiate and assess treatment response. If LDL-C levels are not available then Total-C alone may be used to monitor long-term therapy. A lipoprotein analysis (including LDL-C determination) should be carried out once a year. The NCEP treatment guidelines are summarized below. LDL-Cholesterol mg/dL (mmol/L) Definite Atherosclerotic Disease* Two or More Other Risk Factors** Initiation Level Goal NO NO Greater Than or Equal to 190 (Greater Than or Equal To 4.9) Less Than 160 (Less Than 4.1) NO YES Greater Than or Equal To 160 (Greater Than or Equal To 4.1) Less Than 130 (Less Than 3.4) YES YES or NO Greater Than or Equal To 130 (Greater Than or Equal To 3.4) Less Than or Equal To 100 (Less Than or Equal To 2.6) * Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). ** Other risk factors for coronary heart disease (CHD) include: age (males greater than or equal to 45 years; females greater than or equal to 55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C less than 35 mg/dL (less than 0.91 mmol/L); and diabetes mellitus. Subtract one risk factor if HDL-C is greater than or equal to 60 mg/dL (greater than or equal to 1.6 mmol/L). Cholestyramine monotherapy has been demonstrated to retard the rate of progression 2,3 and increase the rate of regression 3 of coronary atherosclerosis. 2) Cholestyramine for oral suspension is indicated for the relief of pruritus associated with partial biliary obstruction. Cholestyramine for oral suspension has been shown to have a variable effect on serum cholesterol in these patients. Patients with primary biliary cirrhosis may exhibit an elevated cholesterol as part of their disease. uuid:90cc70c4-8870-41f5-8572-ff5240b1d17b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4B33BGI082 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:c23a78b6-bf2f-4d62-856a-39430978ef02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:176ca300-f17f-4cbf-ba9e-eaecd99d5cd0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1) Cholestyramine for Oral Suspension USP is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Cholestyramine may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. Excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. Prior to initiating therapy with Cholestyramine, secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism), should be excluded, and a lipid profile performed to assess Total cholesterol, HDL-C, and triglycerides (TG). For individuals with TG less than 400 mg/dL (less than 4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total cholesterol – [(TG/5) + HDL-C] For TG levels >400 mg/dL, this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases Cholestyramine may not be indicated. Serum cholesterol and triglyceride levels should be determined periodically based on NCEP guidelines to confirm initial and adequate long-term response. A favorable trend in cholesterol reduction should occur during the first month of Cholestyramine therapy. The therapy should be continued to sustain cholesterol reduction. If adequate cholesterol reduction is not attained, increasing the dosage of Cholestyramine or adding other lipid-lowering agents in combination with Cholestyramine should be considered. Since the goal of treatment is to lower LDL-C, the NCEP 4 recommends that LDL-C levels be used to initiate and assess treatment response. If LDL-C levels are not available then Total-C alone may be used to monitor long-term therapy. A lipoprotein analysis (including LDL-C determination) should be carried out once a year. The NCEP treatment guidelines are summarized below. LDL-Cholesterol mg/dL (mmol/L) Definite Atherosclerotic Disease* Two or More Other Risk Factors** Initiation Level Goal NO NO Greater Than or Equal to 190 (Greater Than or Equal To 4.9) Less Than 160 (Less Than 4.1) NO YES Greater Than or Equal To 160 (Greater Than or Equal To 4.1) Less Than 130 (Less Than 3.4) YES YES or NO Greater Than or Equal To 130 (Greater Than or Equal To 3.4) Less Than or Equal To 100 (Less Than or Equal To 2.6) * Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). ** Other risk factors for coronary heart disease (CHD) include: age (males greater than or equal to 45 years; females greater than or equal to 55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C less than 35 mg/dL (less than 0.91 mmol/L); and diabetes mellitus. Subtract one risk factor if HDL-C is greater than or equal to 60 mg/dL (greater than or equal to 1.6 mmol/L). Cholestyramine monotherapy has been demonstrated to retard the rate of progression 2,3 and increase the rate of regression 3 of coronary atherosclerosis. 2) Cholestyramine for oral suspension is indicated for the relief of pruritus associated with partial biliary obstruction. Cholestyramine for oral suspension has been shown to have a variable effect on serum cholesterol in these patients. Patients with primary biliary cirrhosis may exhibit an elevated cholesterol as part of their disease. uuid:44210715-2be7-43c8-8ad3-8a00eddbaeec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4B33BGI082 biolink:treats MONDO:0005388 PMID:41385096 "[{""id"":""uuid:b192ef4e-2a8d-407a-98d5-ededcdb6e422"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:040e25fd-bfc6-413a-bf44-e633317fbb1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1) Cholestyramine for Oral Suspension USP is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Cholestyramine may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. Excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. Prior to initiating therapy with Cholestyramine, secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism), should be excluded, and a lipid profile performed to assess Total cholesterol, HDL-C, and triglycerides (TG). For individuals with TG less than 400 mg/dL (less than 4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total cholesterol – [(TG/5) + HDL-C] For TG levels >400 mg/dL, this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases Cholestyramine may not be indicated. Serum cholesterol and triglyceride levels should be determined periodically based on NCEP guidelines to confirm initial and adequate long-term response. A favorable trend in cholesterol reduction should occur during the first month of Cholestyramine therapy. The therapy should be continued to sustain cholesterol reduction. If adequate cholesterol reduction is not attained, increasing the dosage of Cholestyramine or adding other lipid-lowering agents in combination with Cholestyramine should be considered. Since the goal of treatment is to lower LDL-C, the NCEP 4 recommends that LDL-C levels be used to initiate and assess treatment response. If LDL-C levels are not available then Total-C alone may be used to monitor long-term therapy. A lipoprotein analysis (including LDL-C determination) should be carried out once a year. The NCEP treatment guidelines are summarized below. LDL-Cholesterol mg/dL (mmol/L) Definite Atherosclerotic Disease* Two or More Other Risk Factors** Initiation Level Goal NO NO Greater Than or Equal to 190 (Greater Than or Equal To 4.9) Less Than 160 (Less Than 4.1) NO YES Greater Than or Equal To 160 (Greater Than or Equal To 4.1) Less Than 130 (Less Than 3.4) YES YES or NO Greater Than or Equal To 130 (Greater Than or Equal To 3.4) Less Than or Equal To 100 (Less Than or Equal To 2.6) * Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). ** Other risk factors for coronary heart disease (CHD) include: age (males greater than or equal to 45 years; females greater than or equal to 55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C less than 35 mg/dL (less than 0.91 mmol/L); and diabetes mellitus. Subtract one risk factor if HDL-C is greater than or equal to 60 mg/dL (greater than or equal to 1.6 mmol/L). Cholestyramine monotherapy has been demonstrated to retard the rate of progression 2,3 and increase the rate of regression 3 of coronary atherosclerosis. 2) Cholestyramine for oral suspension is indicated for the relief of pruritus associated with partial biliary obstruction. Cholestyramine for oral suspension has been shown to have a variable effect on serum cholesterol in these patients. Patients with primary biliary cirrhosis may exhibit an elevated cholesterol as part of their disease. uuid:5c145dcc-5d2a-47a0-9e20-8a90ccdf579c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4B33BGI082 biolink:treats MONDO:0006757 PMID:41385096 "[{""id"":""uuid:c928b247-a8b5-4718-9086-ec39d774a9f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0e97a76c-8fc2-4355-bf2c-7318bf5fad92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1) Cholestyramine for Oral Suspension USP is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Cholestyramine may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. Excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. Prior to initiating therapy with Cholestyramine, secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism), should be excluded, and a lipid profile performed to assess Total cholesterol, HDL-C, and triglycerides (TG). For individuals with TG less than 400 mg/dL (less than 4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total cholesterol – [(TG/5) + HDL-C] For TG levels >400 mg/dL, this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases Cholestyramine may not be indicated. Serum cholesterol and triglyceride levels should be determined periodically based on NCEP guidelines to confirm initial and adequate long-term response. A favorable trend in cholesterol reduction should occur during the first month of Cholestyramine therapy. The therapy should be continued to sustain cholesterol reduction. If adequate cholesterol reduction is not attained, increasing the dosage of Cholestyramine or adding other lipid-lowering agents in combination with Cholestyramine should be considered. Since the goal of treatment is to lower LDL-C, the NCEP 4 recommends that LDL-C levels be used to initiate and assess treatment response. If LDL-C levels are not available then Total-C alone may be used to monitor long-term therapy. A lipoprotein analysis (including LDL-C determination) should be carried out once a year. The NCEP treatment guidelines are summarized below. LDL-Cholesterol mg/dL (mmol/L) Definite Atherosclerotic Disease* Two or More Other Risk Factors** Initiation Level Goal NO NO Greater Than or Equal to 190 (Greater Than or Equal To 4.9) Less Than 160 (Less Than 4.1) NO YES Greater Than or Equal To 160 (Greater Than or Equal To 4.1) Less Than 130 (Less Than 3.4) YES YES or NO Greater Than or Equal To 130 (Greater Than or Equal To 3.4) Less Than or Equal To 100 (Less Than or Equal To 2.6) * Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). ** Other risk factors for coronary heart disease (CHD) include: age (males greater than or equal to 45 years; females greater than or equal to 55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C less than 35 mg/dL (less than 0.91 mmol/L); and diabetes mellitus. Subtract one risk factor if HDL-C is greater than or equal to 60 mg/dL (greater than or equal to 1.6 mmol/L). Cholestyramine monotherapy has been demonstrated to retard the rate of progression 2,3 and increase the rate of regression 3 of coronary atherosclerosis. 2) Cholestyramine for oral suspension is indicated for the relief of pruritus associated with partial biliary obstruction. Cholestyramine for oral suspension has been shown to have a variable effect on serum cholesterol in these patients. Patients with primary biliary cirrhosis may exhibit an elevated cholesterol as part of their disease. uuid:1f831942-9f6a-4c70-8d5d-1a433476f66c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0015614 PMID:41385096 "[{""id"":""uuid:5b2a997b-ae09-4150-b041-4f088f61a72a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c88eb8e4-8816-47c0-8110-26f0a1ad7901"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:ed711557-df92-48e9-9193-802d654532d9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0043233 PMID:41385096 "[{""id"":""uuid:39911624-f901-40f6-a3f8-34359e973f48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7f9543df-45f4-40d7-adb7-4340dc0256cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:bf52582b-bb99-4570-98a2-04f5375bbd72 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0009691 PMID:41385096 "[{""id"":""uuid:e804c3f8-f029-4a21-8e30-85d4ef5c7ba3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f53c25d7-1947-4e0f-8119-c266e97c4b68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:1a3c2e4e-a3d7-465a-9827-7b43c46f400c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0006594 PMID:41385096 "[{""id"":""uuid:a85f6511-c7ee-4e7e-89d8-2ed51d24743e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:03688076-76ff-48fe-b16d-922ffd847acc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:fcb242ab-8d09-4ba8-84a1-0885980ac853 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0018229 PMID:41385096 "[{""id"":""uuid:ec31ceb9-3885-4007-9707-b53153d09df2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:47777395-2fe7-48e9-b7b2-c7f99432028d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:ca406e23-f985-4a42-86f6-675f7696de4d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0000004 PMID:41385096 "[{""id"":""uuid:1f2a9988-37ae-4793-ad7f-71160b1cf6d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:288cfd42-fac6-4315-bf51-694a8f312a60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:3e329939-f8b2-4bf1-a8f3-1eca060e4f1b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats UMLS:C0678202 PMID:41385096 "[{""id"":""uuid:1c7b5caf-4d19-423e-81d8-361cbe24123f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1403d5cb-2170-42d9-8a71-ec6059b9df06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:828bd2ae-f890-483b-a505-7735416ec1c2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:6645a447-e133-460b-95c8-44a6c324e475"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6127d0bf-e679-4bed-bcc8-573585567dfa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:2bb26bb9-0d1d-4a0a-8f04-a0b0c41bab4a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0020108 PMID:41385096 "[{""id"":""uuid:22dcbbf2-f1da-4f25-a5e5-245534dfd7dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b87ac776-e2c4-4c0b-b3fe-4f3565d04125"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:8d1c463c-cc67-4f8c-b90d-ca22538e3e0d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0001713 PMID:41385096 "[{""id"":""uuid:2cbd3a6f-783d-4e4f-9263-1b850a18beae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b74fd927-b3da-41bc-b131-a96cab27ef76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:20f5b453-6b73-45b3-b7a0-ba872a6c3b44 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0019098 PMID:41385096 "[{""id"":""uuid:88463e21-e9cb-4799-a366-c08bf50664ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:807558e0-099d-4dd3-8777-84a6bc26c361"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:2225564f-513c-428f-922a-a547fe87c79d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0001705 PMID:41385096 "[{""id"":""uuid:658cbd1b-fedb-4330-b786-729465510a12"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1753a232-c80f-482b-8f84-3050b7416ab8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:b7cb5ddf-abb9-4b70-9aa6-eddbddf9b09a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0001198 PMID:41385096 "[{""id"":""uuid:6873c492-f668-49df-986d-c4a80a38c4be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8f3bf5cf-6171-4ff4-9053-4470f2fc9937"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:8364c7c6-b055-4dec-bc6b-dc71d6b4f1a9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0019444 PMID:41385096 "[{""id"":""uuid:158ace59-351d-4387-b6c9-79267c282f9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d1f08037-ac9f-44b1-ad6c-be211fb83bf9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:40507940-ae5e-47f5-b85f-b00a5f974432 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0006042 PMID:41385096 "[{""id"":""uuid:047135b3-ae01-4c18-b3a0-e4f296b02928"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:373fb1a3-80c8-42ba-94a8-12e71c399613"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:c70750b3-85b1-4944-b403-5a0ce0291a83 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0005059 PMID:41385096 "[{""id"":""uuid:3988c17e-d5c9-4a54-9a74-3a1d7ea576bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ca753f63-ae14-42b3-9fa0-477b63b6304b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:5e95d7fd-91e6-43c0-9502-d4d3ff08d7f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0004095 PMID:41385096 "[{""id"":""uuid:7ae7e800-4d8d-4036-bd70-a244b37c56b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b388e691-b887-46a8-9b9c-a5732db91eb5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:e4cfed3d-ad07-434b-91c7-66311bff94a7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:e736127b-4938-4d7b-92a9-853c3540d5b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:579a6882-7343-4b22-8163-b1d48b1d2300"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:be4caf33-2a40-467b-ba20-c9d200556557 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0006684 PMID:41385096 "[{""id"":""uuid:bfec8f25-87e0-4873-a6ec-2729187cf641"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:85e2bfc7-5fb1-40e6-93b7-bf657b7f0b21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:18e71d83-d3f8-438c-8604-d7706580ffa7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0021211 PMID:41385096 "[{""id"":""uuid:950f7fea-bb87-4f13-b04a-ac026e68c749"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:58ff6349-6758-4f25-912d-3709ee125bfc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:a3e57e7f-eda8-4089-a38e-bfa82543240b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0019198 PMID:41385096 "[{""id"":""uuid:9966b6da-00fc-4cd3-aaeb-ee1fe30a049c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:374a8e5c-a81b-4b0e-9ccb-11255a27661e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:a1f12597-3015-4267-8da1-adbdb89e549c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0008538 PMID:41385096 "[{""id"":""uuid:91cbae40-c8ef-437c-b52a-1490a2233321"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:94f9a209-1490-4f59-b626-ee3d7c3e514f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:7a30f290-3b5a-4246-8a21-b7e74d086737 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0020283 PMID:41385096 "[{""id"":""uuid:b1fad2cc-92f3-4feb-830c-62158b1d82b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ec9db90d-54cf-4a1e-a712-e32c3f1e5f4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:6c78f5ba-8d9e-4d43-b211-5c44fbb2fa74 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0018170 PMID:41385096 "[{""id"":""uuid:8d1daef7-c12b-4694-b91d-8028ee10b0ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ff053b64-2247-4d0d-b070-b2e0c38efe3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:fd9953c6-768d-4095-b1e2-f3c1a2fd7474 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0004670 PMID:41385096 "[{""id"":""uuid:fd53fc33-f198-44f8-b74f-60222f000136"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:525e1ad4-258b-46a5-8c38-3a55b5197525"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:281f6c5b-f334-4006-b842-d366b804e776 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0015274 PMID:41385096 "[{""id"":""uuid:e4b9e7a2-93f5-4b94-bc68-b60582656e58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ac7be933-581a-46c9-8ce6-8f82b8b0e754"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:b204a46a-ba76-4bcd-bfbc-82d9d935222c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0006052 PMID:41385096 "[{""id"":""uuid:d3910755-3a16-470d-bbda-d26c3bd17da1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:93257911-12ff-49bd-8535-2922b28828aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:fe1d60af-59af-4095-8061-5f2b877a8331 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0015927 PMID:41385096 "[{""id"":""uuid:3fb1815b-70d9-4b70-b6cc-a4853acda0ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5ff6ed24-07e3-4891-bcd6-715985110f21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:1ad5155d-713b-4a98-baa6-c2d7aae8647f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0019338 PMID:41385096 "[{""id"":""uuid:f378b263-3f78-47d7-8865-c7a7ecae95a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6a56f0e4-da11-434c-a07a-ea38c382538f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:f060c6d5-5335-4ada-9967-d05d12122d16 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats UMLS:C0149896 PMID:41385096 "[{""id"":""uuid:6cce9d44-2903-4245-9ecd-7cd6e071f054"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:be4825aa-3cbf-4403-a3ff-204378ff804f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:f94f7591-bf55-46ad-82e4-5f12560322bb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats UMLS:C5441648 PMID:41385096 "[{""id"":""uuid:5cdafec6-44f8-4831-bdea-9bcdb5f5fc89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cefad18b-2c64-42f9-b99b-ac797a4ecf7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:f94e1dd8-4304-430c-ac51-c1b24daf20ff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:8cdf9bc1-c666-4e23-a472-a3959765c5dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1c3038d8-679b-4907-86d6-62ea5bcec190"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:c385a767-3392-4f7f-b75f-54f7aeb1cae9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:fd236eaf-a6ca-4ed6-8e0c-65f507d3d960"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:12c05990-d10c-4fd2-8e61-d25edbac5d27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:cc710836-e294-496e-aaa4-ae1ed76a858e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:2b4cf918-39ea-45ab-b75f-9bb831fd183e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:047bb905-19fe-4dea-b308-910e31b2a043"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:a3ffc7bd-a0f9-4e20-8b67-f3e43967609e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0011429 PMID:41385096 "[{""id"":""uuid:c84af3d2-3516-4e82-afec-5d92be3776fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7fcdcce3-d246-4771-ba06-6cbe37bf08fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:f481789e-3714-4d3d-a8df-b161b0bc66fb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0016367 PMID:41385096 "[{""id"":""uuid:35bb66dc-0feb-4fb3-af5d-bb08b30e3c68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0824649d-b60c-4e3c-b9ff-a5748d48c641"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:3c63a80a-c1ce-4ff5-b7e2-f153efacc111 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0019127 PMID:41385096 "[{""id"":""uuid:c4a8cf34-9005-49f6-9344-f3fdb1c1b712"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dbc04871-ed25-4871-ad6f-d2f44805130d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:8dadd944-2b3b-4371-887b-7dd841ab5e32 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5778 biolink:treats MONDO:0045048 PMID:41385096 "[{""id"":""uuid:ffa6ef6f-1e81-478e-86f6-14013f83f179"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:79336098-71b1-4b24-a608-cf3cb59c1b3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydrochlorothiazide tablets are indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Hydrochlorothiazide tablets have also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Hydrochlorothiazide tablets are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. Use in Pregnancy Routine use of diuretics during normal pregnancy is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy and there is no satisfactory evidence that they are useful in the treatment of toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Thiazides are indicated in pregnancy when edema is due to pathologic causes, just as they are in the absence of pregnancy ( see PRECAUTIONS, Pregnancy). Dependent edema in pregnancy, resulting from restriction of venous return by the gravid uterus, is properly treated through elevation of the lower extremities and use of support stockings. Use of diuretics to lower intravascular volume in this instance is illogical and unnecessary. During normal pregnancy there is hypervolemia which is not harmful to the fetus or the mother in the absence of cardiovascular disease. However, it may be associated with edema, rarely generalized edema. If such edema causes discomfort, increased recumbency will often provide relief. Rarely this edema may cause extreme discomfort which is not relieved by rest. In these instances, a short course of diuretic therapy may provide relief and be appropriate. uuid:b055f3ab-9c52-4385-86a3-5003203d285e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5778 biolink:treats HP:0007430 PMID:41385096 "[{""id"":""uuid:f0e442a5-afb9-4e1b-826a-ead548cccdc9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2cf1fbb4-d845-4b4b-81c7-1b4a434ea53b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydrochlorothiazide tablets are indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Hydrochlorothiazide tablets have also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Hydrochlorothiazide tablets are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. Use in Pregnancy Routine use of diuretics during normal pregnancy is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy and there is no satisfactory evidence that they are useful in the treatment of toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Thiazides are indicated in pregnancy when edema is due to pathologic causes, just as they are in the absence of pregnancy ( see PRECAUTIONS, Pregnancy). Dependent edema in pregnancy, resulting from restriction of venous return by the gravid uterus, is properly treated through elevation of the lower extremities and use of support stockings. Use of diuretics to lower intravascular volume in this instance is illogical and unnecessary. During normal pregnancy there is hypervolemia which is not harmful to the fetus or the mother in the absence of cardiovascular disease. However, it may be associated with edema, rarely generalized edema. If such edema causes discomfort, increased recumbency will often provide relief. Rarely this edema may cause extreme discomfort which is not relieved by rest. In these instances, a short course of diuretic therapy may provide relief and be appropriate. uuid:353711a9-0bff-45f7-8ec3-cd989e5148a5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:91495 biolink:treats MONDO:0005709 PMID:41385096 "[{""id"":""uuid:9a20768f-98b7-403d-b05e-73f6ba59f062"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6237cbb5-6b81-48e6-b913-d4cdd222df0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ipratropium bromide nasal solution 0.06% (Nasal Spray) is indicated for the symptomatic relief of rhinorrhea associated with the common cold for adults and children age 5 years and older. Ipratropium bromide nasal solution 0.06% (Nasal Spray) does not relieve nasal congestion or sneezing associated with the common cold or seasonal allergic rhinitis. The safety and effectiveness of the use of ipratropium bromide nasal solution 0.06% (Nasal Spray) beyond four days in patients with the common cold or beyond three weeks in patients with seasonal allergic rhinitis has not been established. uuid:68029d7c-7d90-4d51-9c6a-b746fc54c33d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:91495 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:7ce9ef79-c16b-4e69-a2e8-6cb4cf3bb2a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:82e6d2e9-487d-4cf6-94b2-ec9ead276b3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ipratropium bromide nasal solution 0.06% (Nasal Spray) is indicated for the symptomatic relief of rhinorrhea associated with the common cold for adults and children age 5 years and older. Ipratropium bromide nasal solution 0.06% (Nasal Spray) does not relieve nasal congestion or sneezing associated with the common cold or seasonal allergic rhinitis. The safety and effectiveness of the use of ipratropium bromide nasal solution 0.06% (Nasal Spray) beyond four days in patients with the common cold or beyond three weeks in patients with seasonal allergic rhinitis has not been established. uuid:437d0296-e31a-4764-9008-afec0e0dd592 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151293 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:9724d698-0172-49fd-91e1-d7e5ca77ae1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:02978528-54af-4040-9fd4-2f007941a794"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Quinapril hydrochloride and hydrochlorothiazide tablets are indicated for the treatment of hypertension. This fixed combination is not indicated for the initial therapy of hypertension (see DOSAGE AND ADMINISTRATION ). In using quinapril hydrochloride and hydrochlorothiazide, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that quinapril does not have a similar risk (see WARNINGS: Neutropenia/Agranulocytosis ). Angioedema in Black Patients: Black patients receiving ACE inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to non-blacks. It should also be noted that in controlled clinical trials, ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. uuid:3d77fdf2-85ff-472f-bbe8-dd90276eb30e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151293 biolink:treats MONDO:0001609 PMID:41385096 "[{""id"":""uuid:55c70d4c-70da-4809-b1cb-937e5fe3dfc9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:48d056ab-567b-44e4-a3d4-4aee02a36bae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Quinapril hydrochloride and hydrochlorothiazide tablets are indicated for the treatment of hypertension. This fixed combination is not indicated for the initial therapy of hypertension (see DOSAGE AND ADMINISTRATION ). In using quinapril hydrochloride and hydrochlorothiazide, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that quinapril does not have a similar risk (see WARNINGS: Neutropenia/Agranulocytosis ). Angioedema in Black Patients: Black patients receiving ACE inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to non-blacks. It should also be noted that in controlled clinical trials, ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. uuid:0515db06-c4e4-4626-b50d-555c5a544f66 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151293 biolink:treats MONDO:0001343 PMID:41385096 "[{""id"":""uuid:45e1f4e5-6516-4a62-9092-0dbc87e09fdd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3e0e7e54-4e23-4432-969b-ee599cb71e46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Quinapril hydrochloride and hydrochlorothiazide tablets are indicated for the treatment of hypertension. This fixed combination is not indicated for the initial therapy of hypertension (see DOSAGE AND ADMINISTRATION ). In using quinapril hydrochloride and hydrochlorothiazide, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that quinapril does not have a similar risk (see WARNINGS: Neutropenia/Agranulocytosis ). Angioedema in Black Patients: Black patients receiving ACE inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to non-blacks. It should also be noted that in controlled clinical trials, ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. uuid:fd0266cd-ad88-4ec5-a616-dd54fa7177da biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151293 biolink:treats MONDO:0010481 PMID:41385096 "[{""id"":""uuid:8f7a5593-faf2-42ca-bac4-5d0deec8c566"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5fee8233-ef1a-4b60-a330-e2ab24473ef5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Quinapril hydrochloride and hydrochlorothiazide tablets are indicated for the treatment of hypertension. This fixed combination is not indicated for the initial therapy of hypertension (see DOSAGE AND ADMINISTRATION ). In using quinapril hydrochloride and hydrochlorothiazide, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that quinapril does not have a similar risk (see WARNINGS: Neutropenia/Agranulocytosis ). Angioedema in Black Patients: Black patients receiving ACE inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to non-blacks. It should also be noted that in controlled clinical trials, ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. uuid:e5771ec9-ac2c-4082-91cd-79e1f3003b86 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1152239 biolink:treats NCIT:C27003 PMID:41385096 "[{""id"":""uuid:9972b684-c52a-4605-9b17-5f19ca60c944"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6c018aa7-1c09-45f2-a5dd-34af900869cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tramadol hydrochloride and acetaminophen tablets, 37.5 mg/325 mg, are indicated for the short-term (five days or less) management of acute pain. uuid:08b87885-61e8-432e-8aad-f304ecb74c31 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63610 biolink:treats MONDO:0001126 PMID:41385096 "[{""id"":""uuid:0c7963dd-d621-4bbe-92b0-aaac8b853c2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e80d02e4-c083-4ebf-b87e-551ec69034e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cytotec (misoprostol) is indicated for reducing the risk of NSAID (nonsteroidal anti-inflammatory drugs, including aspirin)–induced gastric ulcers in patients at high risk of complications from gastric ulcer, e.g., the elderly and patients with concomitant debilitating disease, as well as patients at high risk of developing gastric ulceration, such as patients with a history of ulcer. Cytotec has not been shown to reduce the risk of duodenal ulcers in patients taking NSAIDs. Cytotec should be taken for the duration of NSAID therapy. Cytotec has been shown to reduce the risk of gastric ulcers in controlled studies of 3 months' duration. It had no effect, compared to placebo, on gastrointestinal pain or discomfort associated with NSAID use. uuid:66bb8678-0a1b-4506-9d0c-1a886511b138 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:91495 biolink:treats MONDO:0011786 PMID:41385096 "[{""id"":""uuid:514cc610-870c-441f-be0e-53d66f86e950"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3bdc5eeb-d6b5-46d2-8075-364db391b8fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ipratropium bromide nasal solution 0.03% (Nasal Spray) is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis in adults and children age 6 years and older. Ipratropium bromide nasal solution 0.03% (Nasal Spray) does not relieve nasal congestion, sneezing, or postnasal drip associated with allergic or nonallergic perennial rhinitis. uuid:62bc6e50-39ab-4185-8e66-83ba840467f2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:91495 biolink:treats MONDO:0006004 PMID:41385096 "[{""id"":""uuid:1f89e935-a979-4dd1-9867-6c7d561c49b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1a4b4439-b76f-4b73-b4c3-6c2ab07c82b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ipratropium bromide nasal solution 0.03% (Nasal Spray) is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis in adults and children age 6 years and older. Ipratropium bromide nasal solution 0.03% (Nasal Spray) does not relieve nasal congestion, sneezing, or postnasal drip associated with allergic or nonallergic perennial rhinitis. uuid:c96a3182-0865-418b-8f82-652545aea3be biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3387 biolink:treats MONDO:0008599 PMID:41385096 "[{""id"":""uuid:d7fa7a8b-1509-4aef-99ef-9a841bc0f8af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2d2a3911-46cc-49fa-b2d2-885d1cfa15e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Epilepsy Carbamazepine is indicated for use as an anticonvulsant drug. Evidence supporting efficacy of carbamazepine as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types: Partial seizures with complex symptomatology (psychomotor, temporal lobe). Patients with these seizures appear to show greater improvement than those with other types. Generalized tonic-clonic seizures (grand mal). Mixed seizure patterns which include the above, or other partial or generalized seizures. Absence seizures (petit mal) do not appear to be controlled by carbamazepine (see PRECAUTIONS, General). Trigeminal Neuralgia Carbamazepine is indicated in the treatment of the pain associated with true trigeminal neuralgia. Beneficial results have also been reported in glossopharyngeal neuralgia. This drug is not a simple analgesic and should not be used for the relief of trivial aches or pains. uuid:71ddf18f-6c98-40a5-87db-ba2b04055ec1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3387 biolink:treats MONDO:0016372 PMID:41385096 "[{""id"":""uuid:4e04cd9d-b7ed-40c9-a1ac-06b6e128767d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0bc53858-042c-4daa-854d-2ccef9e6bead"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Epilepsy Carbamazepine is indicated for use as an anticonvulsant drug. Evidence supporting efficacy of carbamazepine as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types: Partial seizures with complex symptomatology (psychomotor, temporal lobe). Patients with these seizures appear to show greater improvement than those with other types. Generalized tonic-clonic seizures (grand mal). Mixed seizure patterns which include the above, or other partial or generalized seizures. Absence seizures (petit mal) do not appear to be controlled by carbamazepine (see PRECAUTIONS, General). Trigeminal Neuralgia Carbamazepine is indicated in the treatment of the pain associated with true trigeminal neuralgia. Beneficial results have also been reported in glossopharyngeal neuralgia. This drug is not a simple analgesic and should not be used for the relief of trivial aches or pains. uuid:a8ba3142-887d-4ba2-be65-d0b3cab8141e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17303 biolink:treats NCIT:C34887 PMID:41385096 "[{""id"":""uuid:b2ca5546-f121-48c0-9f30-22153cb86fdd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:65c38994-28b9-4aa8-a5af-52f372c129e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Morphine sulfate extended-release tablets are a controlled-release oral formulation of morphine sulfate indicated for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. Morphine sulfate extended-release tablets are NOT intended for use as a prn analgesic. Morphine sulfate extended-release 100 mg and 200 mg tablet strengths are high dose, controlled-release, oral morphine formulations indicated for the relief of pain in opioid-tolerant patients only. Morphine sulfate extended-release tablets are not indicated for pain in the immediate postoperative period (the first 12 to 24 hours following surgery) for patients not previously taking the drug, because its safety in this setting has not been established. Morphine sulfate extended-release tablets are not indicated for pain in the postoperative period if the pain is mild, or not expected to persist for an extended period of time. Morphine sulfate extended-release tablets are only indicated for postoperative use if the patient is already receiving the drug prior to surgery or if the postoperative pain is expected to be moderate to severe and persist for an extended period of time. Physicians should individualize treatment, moving from parenteral to oral analgesics as appropriate (see American Pain Society guidelines). uuid:ae1549fe-56ea-49c9-baca-3ca51b812dab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:61049 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:6ca64ad1-a366-4df2-914f-78f48a22cd38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:1e4fefaa-f0f6-4a4d-b09e-1bc9ff5c7e03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0709d195-e3b9-4ca4-9798-7e547b2b0fdb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/advagraf""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROTOPIC Ointment, both 0.03% and 0.1% for adults, and only 0.03% for children aged 2 to 15 years, is indicated as second-line therapy for the short-term and non-continuous chronic treatment of moderate to severe atopic dermatitis in non-immunocompromised adults and children who have failed to respond adequately to other topical prescription treatments for atopic dermatitis, or when those treatments are not advisable. PROTOPIC Ointment is not indicated for children younger than 2 years of age (see boxed WARNING, WARNINGS and PRECAUTIONS : Pediatric Use ).|[EMA] Flare treatmentAdults and adolescents (16 years of age and above)Treatment of moderate to severe atopic dermatitis in adults who are not adequately responsive to or are intolerant of conventional therapies such as topical corticosteroids.Children (two years of age and above)Treatment of moderate to severe atopic dermatitis in children (two years of age and above) who failed to respond adequately to conventional therapies such as topical corticosteroids.Maintenance treatmentMaintenance treatment of moderate to severe atopic dermatitis for the prevention of flares and the prolongation of flare-free intervals in patients experiencing a high frequency of disease exacerbations (i.e. occurring four or more times per year) who have had an initial response to a maximum of six weeks treatment of twice daily tacrolimus ointment (lesions cleared, almost cleared or mildly affected). uuid:52f80bf0-1875-4c19-800e-7a6033e28b6e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31397 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:aef23ab7-622b-4fda-b0c2-cf05c34d5a25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bb08cd17-46d9-4348-9525-fd9f9478f066"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Seasonal Allergic Rhinitis OMNARIS Nasal Spray is indicated for the treatment of nasal symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older. Perennial Allergic Rhinitis OMNARIS Nasal Spray is indicated for the treatment of nasal symptoms associated with perennial allergic rhinitis in adults and adolescents 12 years of age and older. uuid:29583afc-e41e-4082-b0bf-ce05a1ef6ee7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31397 biolink:treats MONDO:0024332 PMID:41385096 "[{""id"":""uuid:631dd0ba-f89e-4665-b387-15e1e28543e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2f93958e-75b5-4330-86a0-0cb771af3d05"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Seasonal Allergic Rhinitis OMNARIS Nasal Spray is indicated for the treatment of nasal symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older. Perennial Allergic Rhinitis OMNARIS Nasal Spray is indicated for the treatment of nasal symptoms associated with perennial allergic rhinitis in adults and adolescents 12 years of age and older. uuid:0fbad33d-2d03-4f5e-ba3c-6c9bfafa6b50 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40050 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:9d787d37-05f4-4d56-b582-618602b7ab53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:06dfb978-b862-4be6-9c05-471a63b2d64d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LEXIVA ® is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection. The following points should be considered when initiating therapy with LEXIVA plus ritonavir in protease inhibitor-experienced patients: The protease inhibitor-experienced patient study was not large enough to reach a definitive conclusion that LEXIVA plus ritonavir and lopinavir plus ritonavir are clinically equivalent [see Clinical Studies (14.2)] . Once-daily administration of LEXIVA plus ritonavir is not recommended for adult protease inhibitor-experienced patients or any pediatric patients. uuid:3120491b-ab29-4467-8b7d-05b0bdecdceb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63577 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:f3f9ac52-bdcf-47b7-b3cf-a58812046894"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4e18e55a-7a17-404e-9e37-c77e2f0dab9a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EPIVIR is a nucleoside analogue indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection. Limitation of use: The dosage of this product is for HIV-1 and not for HBV. uuid:af1371fb-858d-4ce6-bef5-0fefba82bbeb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9150 biolink:treats HP:0003124 PMID:41385096 "[{""id"":""uuid:7a19c7a2-ffbd-4cdd-8974-4097415d2350"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:967d2a40-1140-4372-8fc2-62c78e7475b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with coronary heart disease (CHD) or at high risk of CHD, simvastatin tablets can be started simultaneously with diet. uuid:e7d0162f-489b-4ab2-98dd-72f934af31cc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134751 biolink:treats MONDO:0005326 PMID:41385096 "[{""id"":""uuid:caf1cb39-c0fe-4ecc-a989-9cb01b881553"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:feea9cdb-6495-4083-881f-7b9a064abc21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Uses -helps prevent sunburn -for skin that burns easily -provides moderate protection against sunburn -higher SPF gives more sunburn protection Directions -for external use only -when using this product keep out of eyes -rinse with water to remove -stop use and ask doctor if rash or irritation develops and lasts -keep out of reach of children -do not use on infants under 6 months of age uuid:42756222-d613-48f2-be85-9347a97965b2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134751 biolink:treats MONDO:0006547 PMID:41385096 "[{""id"":""uuid:158e7bb5-2f75-4362-9634-43cfb5cac394"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9466cec9-29fd-491e-8de3-e61b13958d5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Uses -helps prevent sunburn -for skin that burns easily -provides moderate protection against sunburn -higher SPF gives more sunburn protection Directions -for external use only -when using this product keep out of eyes -rinse with water to remove -stop use and ask doctor if rash or irritation develops and lasts -keep out of reach of children -do not use on infants under 6 months of age uuid:7aae810e-e2bf-4298-8151-fcbdcd183922 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134751 biolink:treats NCIT:C50624 PMID:41385096 "[{""id"":""uuid:fc3fd122-3a9b-460c-9796-ac4668c05568"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2994db86-f4ea-44dc-993f-7d76e18005ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Uses -helps prevent sunburn -for skin that burns easily -provides moderate protection against sunburn -higher SPF gives more sunburn protection Directions -for external use only -when using this product keep out of eyes -rinse with water to remove -stop use and ask doctor if rash or irritation develops and lasts -keep out of reach of children -do not use on infants under 6 months of age uuid:bc6b1d1c-928a-49fc-8f21-916793962b95 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:421707 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:2a80932b-1362-42bf-9054-5e626a117fd0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:37275b6e-2816-468c-8a69-a03e16b3e9fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d747b0a7-dc92-499d-abbf-280239c180d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ziagen""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZIAGEN Tablets and Oral Solution, in combination with other antiretroviral agents, are indicated for the treatment of human immunodeficiency virus (HIV-1) infection. Additional important information on the use of ZIAGEN for treatment of HIV-1 infection: ZIAGEN is one of multiple products containing abacavir. Before starting ZIAGEN, review medical history for prior exposure to any abacavir-containing product in order to avoid reintroduction in a patient with a history of hypersensitivity to abacavir.|[EMA] Ziagen is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection in adults, adolescents and children.The demonstration of the benefit of Ziagen is mainly based on results of studies performed with a twice daily regimen, in treatment-naïve adult patients on combination therapy.Before initiating treatment with abacavir, screening for carriage of the HLA-B*5701 allele should be performed in any HIV-infected patient, irrespective of racial origin. Abacavir should not be used in patients known to carry the HLA-B*5701 allele. uuid:d08f93b1-5a7b-43aa-bc4a-a6358e73b5f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15854 biolink:treats MONDO:0005920 PMID:41385096 "[{""id"":""uuid:1b2a7b03-50a6-45c2-a0ac-d4d990eb7e61"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e3d8ec88-84c7-4498-9596-b16fb7c3b2e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] QUALAQUIN (quinine sulfate) is an antimalarial drug indicated only for treatment of uncomplicated Plasmodium falciparum malaria. Quinine sulfate has been shown to be effective in geographical regions where resistance to chloroquine has been documented [ see Clinical Studies (14) ]. QUALAQUIN oral capsules are not approved for: Treatment of severe or complicated P. falciparum malaria. Prevention of malaria. Treatment or prevention of nocturnal leg cramps [ see Warnings and Precautions (5.1) ]. uuid:06bafc2b-1b6c-47d5-a038-b8797a8acecf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15854 biolink:treats UMLS:C0860058 PMID:41385096 "[{""id"":""uuid:67aa31f5-d05b-48ff-8835-629841a3ef81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d828c467-89d0-4035-a4e3-4963a71525d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] QUALAQUIN (quinine sulfate) is an antimalarial drug indicated only for treatment of uncomplicated Plasmodium falciparum malaria. Quinine sulfate has been shown to be effective in geographical regions where resistance to chloroquine has been documented [ see Clinical Studies (14) ]. QUALAQUIN oral capsules are not approved for: Treatment of severe or complicated P. falciparum malaria. Prevention of malaria. Treatment or prevention of nocturnal leg cramps [ see Warnings and Precautions (5.1) ]. uuid:9e799d92-1150-4fcd-b416-8e53f1bf0863 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29103 biolink:treats MONDO:0006919 PMID:41385096 "[{""id"":""uuid:2550ef00-335a-48fe-a3fb-c50666d7c33a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dad65621-1eb6-4aa0-8f43-7f92b304f42b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Potassium Chloride for Injection Concentrate, USP is indicated in the treatment of potassium deficiency states when oral replacement is not feasible. uuid:b207a0e8-b141-4884-9a0e-5cdbfa4bf4a8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6933 biolink:treats MONDO:0005469 PMID:41385096 "[{""id"":""uuid:f360a362-2656-44d5-87c2-8b95e87c9738"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a0cd3939-40cb-41b4-af77-9337cf2e75f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ProAmatine ® is indicated for the treatment of symptomatic orthostatic hypotension (OH). Because ProAmatine ® can cause marked elevation of supine blood pressure (BP>200 mmHg systolic), it should be used in patients whose lives are considerably impaired despite standard clinical care, including non-pharmacologic treatment (such as support stockings), fluid expansion, and lifestyle alterations. The indication is based on ProAmatine ® 's effect on increases in 1-minute standing systolic blood pressure, a surrogate marker considered likely to correspond to a clinical benefit. At present, however, clinical benefits of ProAmatine ® , principally improved ability to perform life activities, have not been established. Further clinical trials are underway to verify and describe the clinical benefits of ProAmatine ® . After initiation of treatment, ProAmatine ® should be continued only for patients who report significant symptomatic improvement. uuid:b2bf9e70-e350-483d-981b-a715a4dbe352 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats HP:0005115 PMID:41385096 "[{""id"":""uuid:21c94fc2-1fe1-4cc1-b3f1-f135f865385e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bdc4ef15-db28-4542-a639-08cd307e5e65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cardiac Arrhythmias Intravenous administration is usually reserved for life-threatening arrhythmias or those occurring under anesthesia. Supraventricular arrhythmias Intravenous propranolol is indicated for the short-term treatment of supraventricular tachycardia, including Wolff-Parkinson-White syndrome and thyrotoxicosis, to decrease ventricular rate. Use in patients with atrial flutter or atrial fibrillation should be reserved for arrythmias unresponsive to standard therapy or when more prolonged control is required. Reversion to normal sinus rhythm has occasionally been observed, predominantly in patients with sinus or atrial tachycardia. Ventricular tachycardias With the exception of those induced by catecholamines or digitalis, propranolol is not the drug of first choice. In critical situations when cardioversion techniques or other drugs are not indicated or are not effective, propranolol may be considered. If, after consideration of the risks involved, propranolol is used, it should be given intravenously in low dosage and very slowly, as the failing heart requires some sympathetic drive for maintenance of myocardial tone. (See DOSAGE AND ADMINISTRATION ). Some patients may respond with complete reversion to normal sinus rhythm, but reduction in ventricular rate is more likely. Ventricular arrhythmias do not respond to propranolol as predictably as do the supraventricular arrhythmias. Intravenous propranolol is indicated for the treatment of persistent premature ventricular extrasystoles that impair the well-being of the patient and do not respond to conventional measures. Tachyarrhythmias of digitalis intoxication Intravenous propranolol is indicated to control ventricular rate in life-threatening digitalis-induced arrhythmias. Severe bradycardia may occur. (See OVERDOSAGE ). Resistant tachyarrhythmias due to excessive catecholamine action during anesthesia Intravenous propranolol is indicated to abolish tachyarrhythmias due to excessive catecholamine action during anesthesia when other measures fail. These arrhythmias may arise because of release of endogenous catecholamines or administration of catecholamines. All general inhalation anesthetics produce some degree of myocardial depression. Therefore, when propranolol is used to treat arrhythmias during anesthesia, it should be used with extreme caution, usually with constant monitoring of the ECG and central venous pressure. (See WARNINGS ). uuid:ea35e54d-49da-466d-a75b-dd93fb99ecde biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats MONDO:0005477 PMID:41385096 "[{""id"":""uuid:c9f7de6e-244f-4fc2-b2c8-ef50aaf6d067"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2e1ea6d9-730b-4be4-9ef3-a04b71f7c43c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cardiac Arrhythmias Intravenous administration is usually reserved for life-threatening arrhythmias or those occurring under anesthesia. Supraventricular arrhythmias Intravenous propranolol is indicated for the short-term treatment of supraventricular tachycardia, including Wolff-Parkinson-White syndrome and thyrotoxicosis, to decrease ventricular rate. Use in patients with atrial flutter or atrial fibrillation should be reserved for arrythmias unresponsive to standard therapy or when more prolonged control is required. Reversion to normal sinus rhythm has occasionally been observed, predominantly in patients with sinus or atrial tachycardia. Ventricular tachycardias With the exception of those induced by catecholamines or digitalis, propranolol is not the drug of first choice. In critical situations when cardioversion techniques or other drugs are not indicated or are not effective, propranolol may be considered. If, after consideration of the risks involved, propranolol is used, it should be given intravenously in low dosage and very slowly, as the failing heart requires some sympathetic drive for maintenance of myocardial tone. (See DOSAGE AND ADMINISTRATION ). Some patients may respond with complete reversion to normal sinus rhythm, but reduction in ventricular rate is more likely. Ventricular arrhythmias do not respond to propranolol as predictably as do the supraventricular arrhythmias. Intravenous propranolol is indicated for the treatment of persistent premature ventricular extrasystoles that impair the well-being of the patient and do not respond to conventional measures. Tachyarrhythmias of digitalis intoxication Intravenous propranolol is indicated to control ventricular rate in life-threatening digitalis-induced arrhythmias. Severe bradycardia may occur. (See OVERDOSAGE ). Resistant tachyarrhythmias due to excessive catecholamine action during anesthesia Intravenous propranolol is indicated to abolish tachyarrhythmias due to excessive catecholamine action during anesthesia when other measures fail. These arrhythmias may arise because of release of endogenous catecholamines or administration of catecholamines. All general inhalation anesthetics produce some degree of myocardial depression. Therefore, when propranolol is used to treat arrhythmias during anesthesia, it should be used with extreme caution, usually with constant monitoring of the ECG and central venous pressure. (See WARNINGS ). uuid:c6719f71-3f7f-4ea6-b93f-27d1f0127dbd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats MONDO:0017863 PMID:41385096 "[{""id"":""uuid:0b52dd61-f325-49e7-8271-6460944f08f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:edbb4927-f526-4967-aa27-38e7cb42a68b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cardiac Arrhythmias Intravenous administration is usually reserved for life-threatening arrhythmias or those occurring under anesthesia. Supraventricular arrhythmias Intravenous propranolol is indicated for the short-term treatment of supraventricular tachycardia, including Wolff-Parkinson-White syndrome and thyrotoxicosis, to decrease ventricular rate. Use in patients with atrial flutter or atrial fibrillation should be reserved for arrythmias unresponsive to standard therapy or when more prolonged control is required. Reversion to normal sinus rhythm has occasionally been observed, predominantly in patients with sinus or atrial tachycardia. Ventricular tachycardias With the exception of those induced by catecholamines or digitalis, propranolol is not the drug of first choice. In critical situations when cardioversion techniques or other drugs are not indicated or are not effective, propranolol may be considered. If, after consideration of the risks involved, propranolol is used, it should be given intravenously in low dosage and very slowly, as the failing heart requires some sympathetic drive for maintenance of myocardial tone. (See DOSAGE AND ADMINISTRATION ). Some patients may respond with complete reversion to normal sinus rhythm, but reduction in ventricular rate is more likely. Ventricular arrhythmias do not respond to propranolol as predictably as do the supraventricular arrhythmias. Intravenous propranolol is indicated for the treatment of persistent premature ventricular extrasystoles that impair the well-being of the patient and do not respond to conventional measures. Tachyarrhythmias of digitalis intoxication Intravenous propranolol is indicated to control ventricular rate in life-threatening digitalis-induced arrhythmias. Severe bradycardia may occur. (See OVERDOSAGE ). Resistant tachyarrhythmias due to excessive catecholamine action during anesthesia Intravenous propranolol is indicated to abolish tachyarrhythmias due to excessive catecholamine action during anesthesia when other measures fail. These arrhythmias may arise because of release of endogenous catecholamines or administration of catecholamines. All general inhalation anesthetics produce some degree of myocardial depression. Therefore, when propranolol is used to treat arrhythmias during anesthesia, it should be used with extreme caution, usually with constant monitoring of the ECG and central venous pressure. (See WARNINGS ). uuid:f24789fe-2f0a-4d9e-809c-a5eca4d65611 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats MONDO:0018493 PMID:41385096 "[{""id"":""uuid:da0c4c5f-8e11-4094-be21-4d1e84398db2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d94b5baa-643a-43c3-91ad-6d96e942dca9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cardiac Arrhythmias Intravenous administration is usually reserved for life-threatening arrhythmias or those occurring under anesthesia. Supraventricular arrhythmias Intravenous propranolol is indicated for the short-term treatment of supraventricular tachycardia, including Wolff-Parkinson-White syndrome and thyrotoxicosis, to decrease ventricular rate. Use in patients with atrial flutter or atrial fibrillation should be reserved for arrythmias unresponsive to standard therapy or when more prolonged control is required. Reversion to normal sinus rhythm has occasionally been observed, predominantly in patients with sinus or atrial tachycardia. Ventricular tachycardias With the exception of those induced by catecholamines or digitalis, propranolol is not the drug of first choice. In critical situations when cardioversion techniques or other drugs are not indicated or are not effective, propranolol may be considered. If, after consideration of the risks involved, propranolol is used, it should be given intravenously in low dosage and very slowly, as the failing heart requires some sympathetic drive for maintenance of myocardial tone. (See DOSAGE AND ADMINISTRATION ). Some patients may respond with complete reversion to normal sinus rhythm, but reduction in ventricular rate is more likely. Ventricular arrhythmias do not respond to propranolol as predictably as do the supraventricular arrhythmias. Intravenous propranolol is indicated for the treatment of persistent premature ventricular extrasystoles that impair the well-being of the patient and do not respond to conventional measures. Tachyarrhythmias of digitalis intoxication Intravenous propranolol is indicated to control ventricular rate in life-threatening digitalis-induced arrhythmias. Severe bradycardia may occur. (See OVERDOSAGE ). Resistant tachyarrhythmias due to excessive catecholamine action during anesthesia Intravenous propranolol is indicated to abolish tachyarrhythmias due to excessive catecholamine action during anesthesia when other measures fail. These arrhythmias may arise because of release of endogenous catecholamines or administration of catecholamines. All general inhalation anesthetics produce some degree of myocardial depression. Therefore, when propranolol is used to treat arrhythmias during anesthesia, it should be used with extreme caution, usually with constant monitoring of the ECG and central venous pressure. (See WARNINGS ). uuid:77b674d8-0f76-49f5-8cf7-928d6ff6fd80 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:3a2245f7-e77c-4782-a6ed-e82e4c66974c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e901e907-0958-4428-8038-87bf19b5ea16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Propranolol hydrochloride tablets are indicated in the management of hypertension. They may be used alone or used in combination with other antihypertensive agents, particularly a thiazide diuretic. Propranolol hydrochloride tablets are not indicated in the management of hypertensive emergencies. Angina Pectoris Due to Coronary Atherosclerosis Propranolol hydrochloride tablets are indicated to decrease angina frequency and increase exercise tolerance in patients with angina pectoris. Atrial Fibrillation Propranolol hydrochloride tablets are indicated to control ventricular rate in patients with atrial fibrillation and a rapid ventricular response. Myocardial Infarction Propranolol hydrochloride tablets are indicated to reduce cardiovascular mortality in patients who have survived the acute phase of myocardial infarction and are clinically stable. Migraine Propranolol hydrochloride tablets are indicated for the prophylaxis of common migraine headache. The efficacy of propranolol in the treatment of a migraine attack that has started has not been established, and propranolol is not indicated for such use. Essential Tremor Propranolol hydrochloride tablets are indicated in the management of familial or hereditary essential tremor. Familial or essential tremor consists of involuntary, rhythmic, oscillatory movements, usually limited to the upper limbs. It is absent at rest, but occurs when the limb is held in a fixed posture or position against gravity and during active movement. Propranolol hydrochloride tablets, USP causes a reduction in the tremor amplitude but not in the tremor frequency. Propranolol hydrochloride tablets are not indicated for the treatment of tremor associated with Parkinsonism. Hypertrophic Subaortic Stenosis Propranolol hydrochloride tablets improve NYHA functional class in symptomatic patients with hypertrophic subaortic stenosis. Pheochromocytoma Propranolol hydrochloride tablets are indicated as an adjunct to alpha-adrenergic blockade to control blood pressure and reduce symptoms of catecholamine-secreting tumors. uuid:9abca9e9-61d4-4def-b1f4-e401e70dc17b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:0b01dae6-6af5-4ad9-bd35-81479a937374"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4e436029-6482-4de3-9f60-5a9fee9ef182"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Propranolol hydrochloride tablets are indicated in the management of hypertension. They may be used alone or used in combination with other antihypertensive agents, particularly a thiazide diuretic. Propranolol hydrochloride tablets are not indicated in the management of hypertensive emergencies. Angina Pectoris Due to Coronary Atherosclerosis Propranolol hydrochloride tablets are indicated to decrease angina frequency and increase exercise tolerance in patients with angina pectoris. Atrial Fibrillation Propranolol hydrochloride tablets are indicated to control ventricular rate in patients with atrial fibrillation and a rapid ventricular response. Myocardial Infarction Propranolol hydrochloride tablets are indicated to reduce cardiovascular mortality in patients who have survived the acute phase of myocardial infarction and are clinically stable. Migraine Propranolol hydrochloride tablets are indicated for the prophylaxis of common migraine headache. The efficacy of propranolol in the treatment of a migraine attack that has started has not been established, and propranolol is not indicated for such use. Essential Tremor Propranolol hydrochloride tablets are indicated in the management of familial or hereditary essential tremor. Familial or essential tremor consists of involuntary, rhythmic, oscillatory movements, usually limited to the upper limbs. It is absent at rest, but occurs when the limb is held in a fixed posture or position against gravity and during active movement. Propranolol hydrochloride tablets, USP causes a reduction in the tremor amplitude but not in the tremor frequency. Propranolol hydrochloride tablets are not indicated for the treatment of tremor associated with Parkinsonism. Hypertrophic Subaortic Stenosis Propranolol hydrochloride tablets improve NYHA functional class in symptomatic patients with hypertrophic subaortic stenosis. Pheochromocytoma Propranolol hydrochloride tablets are indicated as an adjunct to alpha-adrenergic blockade to control blood pressure and reduce symptoms of catecholamine-secreting tumors. uuid:04bdbabf-c538-441d-a9d4-bdad8034aff8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:a4ef12b7-4756-4c9b-a91d-6aeb45ec38d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:682e96df-31f1-41fd-9457-f91c9837d84e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Propranolol hydrochloride tablets are indicated in the management of hypertension. They may be used alone or used in combination with other antihypertensive agents, particularly a thiazide diuretic. Propranolol hydrochloride tablets are not indicated in the management of hypertensive emergencies. Angina Pectoris Due to Coronary Atherosclerosis Propranolol hydrochloride tablets are indicated to decrease angina frequency and increase exercise tolerance in patients with angina pectoris. Atrial Fibrillation Propranolol hydrochloride tablets are indicated to control ventricular rate in patients with atrial fibrillation and a rapid ventricular response. Myocardial Infarction Propranolol hydrochloride tablets are indicated to reduce cardiovascular mortality in patients who have survived the acute phase of myocardial infarction and are clinically stable. Migraine Propranolol hydrochloride tablets are indicated for the prophylaxis of common migraine headache. The efficacy of propranolol in the treatment of a migraine attack that has started has not been established, and propranolol is not indicated for such use. Essential Tremor Propranolol hydrochloride tablets are indicated in the management of familial or hereditary essential tremor. Familial or essential tremor consists of involuntary, rhythmic, oscillatory movements, usually limited to the upper limbs. It is absent at rest, but occurs when the limb is held in a fixed posture or position against gravity and during active movement. Propranolol hydrochloride tablets, USP causes a reduction in the tremor amplitude but not in the tremor frequency. Propranolol hydrochloride tablets are not indicated for the treatment of tremor associated with Parkinsonism. Hypertrophic Subaortic Stenosis Propranolol hydrochloride tablets improve NYHA functional class in symptomatic patients with hypertrophic subaortic stenosis. Pheochromocytoma Propranolol hydrochloride tablets are indicated as an adjunct to alpha-adrenergic blockade to control blood pressure and reduce symptoms of catecholamine-secreting tumors. uuid:484344c9-0c8e-46c2-9913-c1d19ab23fd7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats MONDO:0005277 PMID:41385096 "[{""id"":""uuid:2378dcf6-5023-477d-af90-5ce21e2d767b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:326f9f9e-3bd3-41a3-8167-415becca8a00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:16b07693-9b3c-4a47-9d28-2664cef3a7a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Propranolol hydrochloride tablets are indicated in the management of hypertension. They may be used alone or used in combination with other antihypertensive agents, particularly a thiazide diuretic. Propranolol hydrochloride tablets are not indicated in the management of hypertensive emergencies. Angina Pectoris Due to Coronary Atherosclerosis Propranolol hydrochloride tablets are indicated to decrease angina frequency and increase exercise tolerance in patients with angina pectoris. Atrial Fibrillation Propranolol hydrochloride tablets are indicated to control ventricular rate in patients with atrial fibrillation and a rapid ventricular response. Myocardial Infarction Propranolol hydrochloride tablets are indicated to reduce cardiovascular mortality in patients who have survived the acute phase of myocardial infarction and are clinically stable. Migraine Propranolol hydrochloride tablets are indicated for the prophylaxis of common migraine headache. The efficacy of propranolol in the treatment of a migraine attack that has started has not been established, and propranolol is not indicated for such use. Essential Tremor Propranolol hydrochloride tablets are indicated in the management of familial or hereditary essential tremor. Familial or essential tremor consists of involuntary, rhythmic, oscillatory movements, usually limited to the upper limbs. It is absent at rest, but occurs when the limb is held in a fixed posture or position against gravity and during active movement. Propranolol hydrochloride tablets, USP causes a reduction in the tremor amplitude but not in the tremor frequency. Propranolol hydrochloride tablets are not indicated for the treatment of tremor associated with Parkinsonism. Hypertrophic Subaortic Stenosis Propranolol hydrochloride tablets improve NYHA functional class in symptomatic patients with hypertrophic subaortic stenosis. Pheochromocytoma Propranolol hydrochloride tablets are indicated as an adjunct to alpha-adrenergic blockade to control blood pressure and reduce symptoms of catecholamine-secreting tumors.|[PMDA] Drugs with a new additional indication and a new dosage for the prevention of migraine attack. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:70a33ddd-ff1d-4c22-b19f-3b54aaca7286 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats MONDO:0008590 PMID:41385096 "[{""id"":""uuid:759ee05c-ba9e-4664-b3d8-c168b63a7c2d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3383828f-3c12-49e9-8f7c-846d874946b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Propranolol hydrochloride tablets are indicated in the management of hypertension. They may be used alone or used in combination with other antihypertensive agents, particularly a thiazide diuretic. Propranolol hydrochloride tablets are not indicated in the management of hypertensive emergencies. Angina Pectoris Due to Coronary Atherosclerosis Propranolol hydrochloride tablets are indicated to decrease angina frequency and increase exercise tolerance in patients with angina pectoris. Atrial Fibrillation Propranolol hydrochloride tablets are indicated to control ventricular rate in patients with atrial fibrillation and a rapid ventricular response. Myocardial Infarction Propranolol hydrochloride tablets are indicated to reduce cardiovascular mortality in patients who have survived the acute phase of myocardial infarction and are clinically stable. Migraine Propranolol hydrochloride tablets are indicated for the prophylaxis of common migraine headache. The efficacy of propranolol in the treatment of a migraine attack that has started has not been established, and propranolol is not indicated for such use. Essential Tremor Propranolol hydrochloride tablets are indicated in the management of familial or hereditary essential tremor. Familial or essential tremor consists of involuntary, rhythmic, oscillatory movements, usually limited to the upper limbs. It is absent at rest, but occurs when the limb is held in a fixed posture or position against gravity and during active movement. Propranolol hydrochloride tablets, USP causes a reduction in the tremor amplitude but not in the tremor frequency. Propranolol hydrochloride tablets are not indicated for the treatment of tremor associated with Parkinsonism. Hypertrophic Subaortic Stenosis Propranolol hydrochloride tablets improve NYHA functional class in symptomatic patients with hypertrophic subaortic stenosis. Pheochromocytoma Propranolol hydrochloride tablets are indicated as an adjunct to alpha-adrenergic blockade to control blood pressure and reduce symptoms of catecholamine-secreting tumors. uuid:b1dd3627-b1c6-499a-b349-980c67517e0e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats MONDO:0008647 PMID:41385096 "[{""id"":""uuid:850f251d-7954-44bd-9a2a-6bc7a260533d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d66cb013-0bea-41bf-907b-4f6f3067bd85"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Propranolol hydrochloride tablets are indicated in the management of hypertension. They may be used alone or used in combination with other antihypertensive agents, particularly a thiazide diuretic. Propranolol hydrochloride tablets are not indicated in the management of hypertensive emergencies. Angina Pectoris Due to Coronary Atherosclerosis Propranolol hydrochloride tablets are indicated to decrease angina frequency and increase exercise tolerance in patients with angina pectoris. Atrial Fibrillation Propranolol hydrochloride tablets are indicated to control ventricular rate in patients with atrial fibrillation and a rapid ventricular response. Myocardial Infarction Propranolol hydrochloride tablets are indicated to reduce cardiovascular mortality in patients who have survived the acute phase of myocardial infarction and are clinically stable. Migraine Propranolol hydrochloride tablets are indicated for the prophylaxis of common migraine headache. The efficacy of propranolol in the treatment of a migraine attack that has started has not been established, and propranolol is not indicated for such use. Essential Tremor Propranolol hydrochloride tablets are indicated in the management of familial or hereditary essential tremor. Familial or essential tremor consists of involuntary, rhythmic, oscillatory movements, usually limited to the upper limbs. It is absent at rest, but occurs when the limb is held in a fixed posture or position against gravity and during active movement. Propranolol hydrochloride tablets, USP causes a reduction in the tremor amplitude but not in the tremor frequency. Propranolol hydrochloride tablets are not indicated for the treatment of tremor associated with Parkinsonism. Hypertrophic Subaortic Stenosis Propranolol hydrochloride tablets improve NYHA functional class in symptomatic patients with hypertrophic subaortic stenosis. Pheochromocytoma Propranolol hydrochloride tablets are indicated as an adjunct to alpha-adrenergic blockade to control blood pressure and reduce symptoms of catecholamine-secreting tumors. uuid:83aca0c6-ea67-4d92-86d0-246198c36ea5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats MONDO:0008233 PMID:41385096 "[{""id"":""uuid:2b779cae-7815-4378-ae34-45ed60b2fff7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:173b25db-1eaf-4570-b9f0-f18a3f106e7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Propranolol hydrochloride tablets are indicated in the management of hypertension. They may be used alone or used in combination with other antihypertensive agents, particularly a thiazide diuretic. Propranolol hydrochloride tablets are not indicated in the management of hypertensive emergencies. Angina Pectoris Due to Coronary Atherosclerosis Propranolol hydrochloride tablets are indicated to decrease angina frequency and increase exercise tolerance in patients with angina pectoris. Atrial Fibrillation Propranolol hydrochloride tablets are indicated to control ventricular rate in patients with atrial fibrillation and a rapid ventricular response. Myocardial Infarction Propranolol hydrochloride tablets are indicated to reduce cardiovascular mortality in patients who have survived the acute phase of myocardial infarction and are clinically stable. Migraine Propranolol hydrochloride tablets are indicated for the prophylaxis of common migraine headache. The efficacy of propranolol in the treatment of a migraine attack that has started has not been established, and propranolol is not indicated for such use. Essential Tremor Propranolol hydrochloride tablets are indicated in the management of familial or hereditary essential tremor. Familial or essential tremor consists of involuntary, rhythmic, oscillatory movements, usually limited to the upper limbs. It is absent at rest, but occurs when the limb is held in a fixed posture or position against gravity and during active movement. Propranolol hydrochloride tablets, USP causes a reduction in the tremor amplitude but not in the tremor frequency. Propranolol hydrochloride tablets are not indicated for the treatment of tremor associated with Parkinsonism. Hypertrophic Subaortic Stenosis Propranolol hydrochloride tablets improve NYHA functional class in symptomatic patients with hypertrophic subaortic stenosis. Pheochromocytoma Propranolol hydrochloride tablets are indicated as an adjunct to alpha-adrenergic blockade to control blood pressure and reduce symptoms of catecholamine-secreting tumors. uuid:94f626c8-4ded-4416-90ae-b5db47e1a531 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:17276 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:619c7b50-17a1-4626-8179-d5c32d3c7e1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:32fe63cf-9f76-4117-a319-ba9fca95a18d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone has been shown to be a tumorigen in chronic toxicity studies in rats (see PRECAUTIONS section). Spironolactone and hydrochlorothiazide tablets should be used only in those conditions described below. Unnecessary use of this drug should be avoided. Spironolactone and Hydrochlorothiazide Tablets are Indicated for: Edematous Conditions for Patients with: Congestive Heart Failure For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. The treatment of diuretic-induced hypokalemia in patients with congestive heart failure when other measures are considered inappropriate. The treatment of patients with congestive heart failure taking digitalis when other therapies are considered inadequate or inappropriate. Cirrhosis of the Liver Accompanied by Edema and/or Ascites Aldosterone levels may be exceptionally high in this condition. Spironolactone and hydrochlorothiazide tablets are indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. The Nephrotic Syndrome For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response. Essential Hypertension For patients with essential hypertension in whom other measures are considered inadequate or inappropriate. In hypertensive patients for the treatment of a diuretic-induced hypokalemia when other measures are considered inappropriate. Usage in Pregnancy The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developing toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Spironolactone and hydrochlorothiazide tablets are indicated in pregnancy when edema is due to pathologic causes just as it is in the absence of pregnancy (however, see PRECAUTIONS: Pregnancy ). Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is unsupported and unnecessary. There is hypervolemia during normal pregnancy which is not harmful to either the fetus or the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort which is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate. uuid:654c9757-4fa2-47ed-974d-0cdbe1d5f4ff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:17276 biolink:treats MONDO:0005155 PMID:41385096 "[{""id"":""uuid:90613199-81ec-4516-bcbc-443839d573f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3b0e5d01-f3b8-4c7c-88bb-148bfb85c48d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone has been shown to be a tumorigen in chronic toxicity studies in rats (see PRECAUTIONS section). Spironolactone and hydrochlorothiazide tablets should be used only in those conditions described below. Unnecessary use of this drug should be avoided. Spironolactone and Hydrochlorothiazide Tablets are Indicated for: Edematous Conditions for Patients with: Congestive Heart Failure For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. The treatment of diuretic-induced hypokalemia in patients with congestive heart failure when other measures are considered inappropriate. The treatment of patients with congestive heart failure taking digitalis when other therapies are considered inadequate or inappropriate. Cirrhosis of the Liver Accompanied by Edema and/or Ascites Aldosterone levels may be exceptionally high in this condition. Spironolactone and hydrochlorothiazide tablets are indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. The Nephrotic Syndrome For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response. Essential Hypertension For patients with essential hypertension in whom other measures are considered inadequate or inappropriate. In hypertensive patients for the treatment of a diuretic-induced hypokalemia when other measures are considered inappropriate. Usage in Pregnancy The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developing toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Spironolactone and hydrochlorothiazide tablets are indicated in pregnancy when edema is due to pathologic causes just as it is in the absence of pregnancy (however, see PRECAUTIONS: Pregnancy ). Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is unsupported and unnecessary. There is hypervolemia during normal pregnancy which is not harmful to either the fetus or the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort which is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate. uuid:e17686ae-81be-41ff-b5b9-d77283aea198 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:17276 biolink:treats MONDO:0005377 PMID:41385096 "[{""id"":""uuid:ae9b23bc-3205-43c9-a090-578e2f399e25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2d558bb3-5072-4501-8197-f81d0c024a59"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone has been shown to be a tumorigen in chronic toxicity studies in rats (see PRECAUTIONS section). Spironolactone and hydrochlorothiazide tablets should be used only in those conditions described below. Unnecessary use of this drug should be avoided. Spironolactone and Hydrochlorothiazide Tablets are Indicated for: Edematous Conditions for Patients with: Congestive Heart Failure For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. The treatment of diuretic-induced hypokalemia in patients with congestive heart failure when other measures are considered inappropriate. The treatment of patients with congestive heart failure taking digitalis when other therapies are considered inadequate or inappropriate. Cirrhosis of the Liver Accompanied by Edema and/or Ascites Aldosterone levels may be exceptionally high in this condition. Spironolactone and hydrochlorothiazide tablets are indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. The Nephrotic Syndrome For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response. Essential Hypertension For patients with essential hypertension in whom other measures are considered inadequate or inappropriate. In hypertensive patients for the treatment of a diuretic-induced hypokalemia when other measures are considered inappropriate. Usage in Pregnancy The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developing toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Spironolactone and hydrochlorothiazide tablets are indicated in pregnancy when edema is due to pathologic causes just as it is in the absence of pregnancy (however, see PRECAUTIONS: Pregnancy ). Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is unsupported and unnecessary. There is hypervolemia during normal pregnancy which is not harmful to either the fetus or the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort which is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate. uuid:fe24cd27-495f-4dcf-883d-838a0bc398b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:17276 biolink:treats MONDO:0001134 PMID:41385096 "[{""id"":""uuid:7757dc1c-2af5-4be5-a737-8d01997b1e82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d3f8fc24-7926-4745-ad77-7866c01c9184"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone has been shown to be a tumorigen in chronic toxicity studies in rats (see PRECAUTIONS section). Spironolactone and hydrochlorothiazide tablets should be used only in those conditions described below. Unnecessary use of this drug should be avoided. Spironolactone and Hydrochlorothiazide Tablets are Indicated for: Edematous Conditions for Patients with: Congestive Heart Failure For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. The treatment of diuretic-induced hypokalemia in patients with congestive heart failure when other measures are considered inappropriate. The treatment of patients with congestive heart failure taking digitalis when other therapies are considered inadequate or inappropriate. Cirrhosis of the Liver Accompanied by Edema and/or Ascites Aldosterone levels may be exceptionally high in this condition. Spironolactone and hydrochlorothiazide tablets are indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. The Nephrotic Syndrome For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response. Essential Hypertension For patients with essential hypertension in whom other measures are considered inadequate or inappropriate. In hypertensive patients for the treatment of a diuretic-induced hypokalemia when other measures are considered inappropriate. Usage in Pregnancy The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developing toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Spironolactone and hydrochlorothiazide tablets are indicated in pregnancy when edema is due to pathologic causes just as it is in the absence of pregnancy (however, see PRECAUTIONS: Pregnancy ). Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is unsupported and unnecessary. There is hypervolemia during normal pregnancy which is not harmful to either the fetus or the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort which is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate. uuid:20058f8a-c3bb-45b4-8bef-336957673515 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:17276 biolink:treats MONDO:0045048 PMID:41385096 "[{""id"":""uuid:7912a54e-8124-4759-bd56-c2662240c24d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:314c6ba6-b1f3-4e79-a02d-efb06f5fe5d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone has been shown to be a tumorigen in chronic toxicity studies in rats (see PRECAUTIONS section). Spironolactone and hydrochlorothiazide tablets should be used only in those conditions described below. Unnecessary use of this drug should be avoided. Spironolactone and Hydrochlorothiazide Tablets are Indicated for: Edematous Conditions for Patients with: Congestive Heart Failure For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. The treatment of diuretic-induced hypokalemia in patients with congestive heart failure when other measures are considered inappropriate. The treatment of patients with congestive heart failure taking digitalis when other therapies are considered inadequate or inappropriate. Cirrhosis of the Liver Accompanied by Edema and/or Ascites Aldosterone levels may be exceptionally high in this condition. Spironolactone and hydrochlorothiazide tablets are indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. The Nephrotic Syndrome For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response. Essential Hypertension For patients with essential hypertension in whom other measures are considered inadequate or inappropriate. In hypertensive patients for the treatment of a diuretic-induced hypokalemia when other measures are considered inappropriate. Usage in Pregnancy The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developing toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Spironolactone and hydrochlorothiazide tablets are indicated in pregnancy when edema is due to pathologic causes just as it is in the absence of pregnancy (however, see PRECAUTIONS: Pregnancy ). Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is unsupported and unnecessary. There is hypervolemia during normal pregnancy which is not harmful to either the fetus or the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort which is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate. uuid:1bb2d28e-989a-484d-a487-e846c26af7bc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats UMLS:C0038045 PMID:41385096 "[{""id"":""uuid:89b21e9a-3ccc-438c-ba2d-b7ab0c50bc3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:444659bc-8875-40ed-9765-1ddd63e7774f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of Flector® Patch and other treatment options before deciding to use Flector® Patch. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Flector® Patch is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions. uuid:09637cc7-57ad-43ed-8c3a-d5dae39432b6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats UMLS:C0009938 PMID:41385096 "[{""id"":""uuid:06f8c6dc-3aa6-489e-889f-c3cdd4c8f1ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a50f39ea-e85b-4c12-a826-c19d74a1bf9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of Flector® Patch and other treatment options before deciding to use Flector® Patch. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Flector® Patch is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions. uuid:119b80c0-043b-4d6d-af85-a82a7b966186 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:453011 biolink:treats MONDO:0006626 PMID:41385096 "[{""id"":""uuid:4fa1cb0d-d8e6-43bf-acd5-fd919f847bdf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e42d7e93-5a40-438f-a170-9462316683f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] (To understand fully the indication for this product, please read the entire INDICATIONS AND USAGE section of the labeling.) Ciclopirox topical solution, 8% (nail lacquer), as a component of a comprehensive management program, is indicated as topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to Trichophyton rubrum . The comprehensive management program includes removal of the unattached, infected nails as frequently as monthly, by a health care professional who has special competence in the diagnosis and treatment of nail disorders, including minor nail procedures. No studies have been conducted to determine whether ciclopirox might reduce the effectiveness of systemic antifungal agents for onychomycosis. Therefore, the concomitant use of 8% ciclopirox topical solution and systemic antifungal agents for onychomycosis, is not recommended. Ciclopirox topical solution, 8% (nail lacquer), should be used only under medical supervision as described above. The effectiveness and safety of ciclopirox topical solution, 8% (nail lacquer), in the following populations has not been studied. The clinical trials with use of ciclopirox topical solution, 8% (nail lacquer), excluded patients who: were pregnant or nursing, planned to become pregnant, had a history of immunosuppression (e.g., extensive, persistent, or unusual distribution of dermatomycoses, extensive seborrheic dermatitis, recent or recurring herpes zoster, or persistent herpes simplex), were HIV seropositive, received organ transplant, required medication to control epilepsy, were insulin dependent diabetics or had diabetic neuropathy. Patients with severe plantar (moccasin) tinea pedis were also excluded. The safety and efficacy of using ciclopirox topical solution, 8% (nail lacquer), daily for greater than 48 weeks have not been established. Clinical Trials Data The results of use of ciclopirox topical solution, 8% (nail lacquer), in treatment of onychomycosis of the toenail without lunula involvement were obtained from two double-blind, placebo-controlled studies conducted in the US. In these studies, patients with onychomycosis of the great toenails without lunula involvement were treated with ciclopirox topical solution, 8% (nail lacquer) in conjunction with monthly removal of the unattached, infected toenail by the investigator. Ciclopirox topical solution, 8% (nail lacquer), was applied for 48 weeks. At baseline, patients had 20 to 65% involvement of the target great toenail plate. Statistical significance was demonstrated in one of two studies for the endpoint “complete cure” (clear nail and negative mycology), and in two studies for the endpoint “almost clear” (≤ 10% nail involvement and negative mycology) at the end of study. These results are presented below. At Week 48 (plus Last Observation Carried Forward) for the Intent-to-Treat (ITT) Population Study 312 Study 313 Active Vehicle Active Vehicle CompleteCure* 6/110 (5.5%) 1/109 (0.9%) 10/118 (8.5%) 0/117 (0%) AlmostClear** 7/107 (6.5%) 1/108 (0.9%) 14/116 (12%) 1/115 (0.9%) Negative MycologyAlone*** 30/105 (29%) 12/106 (11%) 41/115 (36%) 10/114 (9%) * Clear nail and negative mycology ** ≤ 10% nail involvement and negative mycology *** Negative KOH and negative culture The summary of reported patient outcomes for the ITT population at 12 weeks following the end of treatment are presented below. Note that post-treatment efficacy assessments were scheduled only for patients who achieved a complete cure. Post-Treatment Week 12 Data for Patients Who Achieved Complete Cure at Week 48 Study 312 Study 313 Active Vehicle Active Vehicle Number of Treated Patients 112 111 119 118 Complete Cure at Week 48 6 1 10 0 Post-Treatment Week 12 Outcomes: Patients Missing All Week 12 Assessments 2 0 2 0 Patients with Week 12 Assessments 4 1 8 0 Complete Cure 3 1 4 0 Almost Clear 2* 1 1* 0 Negative Mycology 3 1 5 0 * Four patients (from studies 312 and 313) who were completely cured did not have post-treatment Week 12 planimetry data. uuid:1abbf546-6288-4ef6-bd18-b2d5c2b55a59 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:453011 biolink:treats MONDO:0005027 PMID:41385096 "[{""id"":""uuid:7e0a8582-0ddb-47fe-a681-5f77798686e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:39efca09-9268-489a-a97c-7957b513268e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] (To understand fully the indication for this product, please read the entire INDICATIONS AND USAGE section of the labeling.) Ciclopirox topical solution, 8% (nail lacquer), as a component of a comprehensive management program, is indicated as topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to Trichophyton rubrum . The comprehensive management program includes removal of the unattached, infected nails as frequently as monthly, by a health care professional who has special competence in the diagnosis and treatment of nail disorders, including minor nail procedures. No studies have been conducted to determine whether ciclopirox might reduce the effectiveness of systemic antifungal agents for onychomycosis. Therefore, the concomitant use of 8% ciclopirox topical solution and systemic antifungal agents for onychomycosis, is not recommended. Ciclopirox topical solution, 8% (nail lacquer), should be used only under medical supervision as described above. The effectiveness and safety of ciclopirox topical solution, 8% (nail lacquer), in the following populations has not been studied. The clinical trials with use of ciclopirox topical solution, 8% (nail lacquer), excluded patients who: were pregnant or nursing, planned to become pregnant, had a history of immunosuppression (e.g., extensive, persistent, or unusual distribution of dermatomycoses, extensive seborrheic dermatitis, recent or recurring herpes zoster, or persistent herpes simplex), were HIV seropositive, received organ transplant, required medication to control epilepsy, were insulin dependent diabetics or had diabetic neuropathy. Patients with severe plantar (moccasin) tinea pedis were also excluded. The safety and efficacy of using ciclopirox topical solution, 8% (nail lacquer), daily for greater than 48 weeks have not been established. Clinical Trials Data The results of use of ciclopirox topical solution, 8% (nail lacquer), in treatment of onychomycosis of the toenail without lunula involvement were obtained from two double-blind, placebo-controlled studies conducted in the US. In these studies, patients with onychomycosis of the great toenails without lunula involvement were treated with ciclopirox topical solution, 8% (nail lacquer) in conjunction with monthly removal of the unattached, infected toenail by the investigator. Ciclopirox topical solution, 8% (nail lacquer), was applied for 48 weeks. At baseline, patients had 20 to 65% involvement of the target great toenail plate. Statistical significance was demonstrated in one of two studies for the endpoint “complete cure” (clear nail and negative mycology), and in two studies for the endpoint “almost clear” (≤ 10% nail involvement and negative mycology) at the end of study. These results are presented below. At Week 48 (plus Last Observation Carried Forward) for the Intent-to-Treat (ITT) Population Study 312 Study 313 Active Vehicle Active Vehicle CompleteCure* 6/110 (5.5%) 1/109 (0.9%) 10/118 (8.5%) 0/117 (0%) AlmostClear** 7/107 (6.5%) 1/108 (0.9%) 14/116 (12%) 1/115 (0.9%) Negative MycologyAlone*** 30/105 (29%) 12/106 (11%) 41/115 (36%) 10/114 (9%) * Clear nail and negative mycology ** ≤ 10% nail involvement and negative mycology *** Negative KOH and negative culture The summary of reported patient outcomes for the ITT population at 12 weeks following the end of treatment are presented below. Note that post-treatment efficacy assessments were scheduled only for patients who achieved a complete cure. Post-Treatment Week 12 Data for Patients Who Achieved Complete Cure at Week 48 Study 312 Study 313 Active Vehicle Active Vehicle Number of Treated Patients 112 111 119 118 Complete Cure at Week 48 6 1 10 0 Post-Treatment Week 12 Outcomes: Patients Missing All Week 12 Assessments 2 0 2 0 Patients with Week 12 Assessments 4 1 8 0 Complete Cure 3 1 4 0 Almost Clear 2* 1 1* 0 Negative Mycology 3 1 5 0 * Four patients (from studies 312 and 313) who were completely cured did not have post-treatment Week 12 planimetry data. uuid:226ef511-99d0-4d26-b152-837a65a6adac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9649 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:9b81daa8-ed51-407e-9ed3-be83731a6706"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f5833958-d24d-482e-9631-273c025ab650"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension: Trandolapril tablets are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive medication such as hydrochlorothiazide. In considering the use of trandolapril tablets, it should be noted that in controlled trials ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients. (See Warnings: Angioedema .) When using trandolapril tablets, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that trandolapril tablets do not have a similar risk. (See WARNINGS .) uuid:fcf8124b-8ca1-4d3d-addd-59c79c86b4e6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9649 biolink:treats MONDO:0010481 PMID:41385096 "[{""id"":""uuid:e8c6b95d-8dd4-4e29-b2f5-a55616956113"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8e793ee1-4e30-45ee-8680-a56b1c10a851"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension: Trandolapril tablets are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive medication such as hydrochlorothiazide. In considering the use of trandolapril tablets, it should be noted that in controlled trials ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients. (See Warnings: Angioedema .) When using trandolapril tablets, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that trandolapril tablets do not have a similar risk. (See WARNINGS .) uuid:21c08a03-f484-4dca-bb89-c5753d2798bc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9649 biolink:treats MONDO:0001609 PMID:41385096 "[{""id"":""uuid:dcd6f095-50ce-4e88-88c3-2e213e51079f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6d60bdf9-3958-4dfd-b999-219ec67b6fc2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension: Trandolapril tablets are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive medication such as hydrochlorothiazide. In considering the use of trandolapril tablets, it should be noted that in controlled trials ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients. (See Warnings: Angioedema .) When using trandolapril tablets, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that trandolapril tablets do not have a similar risk. (See WARNINGS .) uuid:b01a707c-c928-4360-9ff2-a9e97861cee2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9649 biolink:treats MONDO:0001343 PMID:41385096 "[{""id"":""uuid:84d2fd01-79c9-4749-b3fc-1d84ebde6bc8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f10fe8bc-1de2-4054-b032-8571627d7de4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension: Trandolapril tablets are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive medication such as hydrochlorothiazide. In considering the use of trandolapril tablets, it should be noted that in controlled trials ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients. (See Warnings: Angioedema .) When using trandolapril tablets, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that trandolapril tablets do not have a similar risk. (See WARNINGS .) uuid:eb2a2f1a-b94b-4461-8301-061d2279d012 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0003799 PMID:41385096 "[{""id"":""uuid:2e9b2e43-b900-4080-9616-ad6739b9af40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ae88ee34-203c-48de-ae8a-113a399a10bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gentamicin Sulfate Ophthalmic Ointment is indicated in the topical treatment of ocular bacterial infections, including conjunctivitis, keratitis, keratoconjunctivitis, corneal ulcers, blepharitis, blepharoconjunctivitis, acute meibomianitis, and dacryocystitis caused by susceptible strains of the following microorganisms: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, Enterobacter aerogenes, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Neisseria gonorrhoeae, Pseudomonas aeruginosa, and Serratia marcescens. uuid:eecc94d9-e97e-40eb-8fc7-60d48928efd8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0003085 PMID:41385096 "[{""id"":""uuid:3a873f95-d8a0-47b6-a399-6960946550cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:01aa3e6c-b1ad-4765-b575-5c64b838dda3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gentamicin Sulfate Ophthalmic Ointment is indicated in the topical treatment of ocular bacterial infections, including conjunctivitis, keratitis, keratoconjunctivitis, corneal ulcers, blepharitis, blepharoconjunctivitis, acute meibomianitis, and dacryocystitis caused by susceptible strains of the following microorganisms: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, Enterobacter aerogenes, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Neisseria gonorrhoeae, Pseudomonas aeruginosa, and Serratia marcescens. uuid:7abcde9b-9e7d-4b28-afce-45c2993f3006 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0004768 PMID:41385096 "[{""id"":""uuid:0d322cdd-3242-4510-b1d6-ffa1047bdd37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:62dd4ac6-d5b2-4d4c-9392-5d828532faa6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gentamicin Sulfate Ophthalmic Ointment is indicated in the topical treatment of ocular bacterial infections, including conjunctivitis, keratitis, keratoconjunctivitis, corneal ulcers, blepharitis, blepharoconjunctivitis, acute meibomianitis, and dacryocystitis caused by susceptible strains of the following microorganisms: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, Enterobacter aerogenes, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Neisseria gonorrhoeae, Pseudomonas aeruginosa, and Serratia marcescens. uuid:f9dcc09f-b027-4436-b103-59b1b0365d5a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0004577 PMID:41385096 "[{""id"":""uuid:8c12f554-e1e3-4043-958c-e1f5f8d41e85"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:66870db2-505b-4152-8d04-b03109ab2721"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gentamicin Sulfate Ophthalmic Ointment is indicated in the topical treatment of ocular bacterial infections, including conjunctivitis, keratitis, keratoconjunctivitis, corneal ulcers, blepharitis, blepharoconjunctivitis, acute meibomianitis, and dacryocystitis caused by susceptible strains of the following microorganisms: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, Enterobacter aerogenes, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Neisseria gonorrhoeae, Pseudomonas aeruginosa, and Serratia marcescens. uuid:e7cc9b00-c428-42a7-ba32-cb0da1ea627d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0004785 PMID:41385096 "[{""id"":""uuid:02db30fa-ea51-4f76-bcc0-48e25067cba3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:397f7474-7b29-495a-93aa-33ee2fa58c8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gentamicin Sulfate Ophthalmic Ointment is indicated in the topical treatment of ocular bacterial infections, including conjunctivitis, keratitis, keratoconjunctivitis, corneal ulcers, blepharitis, blepharoconjunctivitis, acute meibomianitis, and dacryocystitis caused by susceptible strains of the following microorganisms: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, Enterobacter aerogenes, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Neisseria gonorrhoeae, Pseudomonas aeruginosa, and Serratia marcescens. uuid:c6a4d17e-97e2-412f-b00e-ca8562d71807 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0002307 PMID:41385096 "[{""id"":""uuid:6fbe092e-de00-4bba-95bf-d481850f8418"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c9d3705c-f6c9-4839-88d9-0861a3472371"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gentamicin Sulfate Ophthalmic Ointment is indicated in the topical treatment of ocular bacterial infections, including conjunctivitis, keratitis, keratoconjunctivitis, corneal ulcers, blepharitis, blepharoconjunctivitis, acute meibomianitis, and dacryocystitis caused by susceptible strains of the following microorganisms: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, Enterobacter aerogenes, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Neisseria gonorrhoeae, Pseudomonas aeruginosa, and Serratia marcescens. uuid:f3d0bf81-162c-43cf-bdef-a3b25e4f8b7c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0004926 PMID:41385096 "[{""id"":""uuid:9dcc4279-32c9-4a9f-b84b-b35c0c5e580b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:92aeea6a-556f-407c-bfc8-fe115524e57a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gentamicin Sulfate Ophthalmic Ointment is indicated in the topical treatment of ocular bacterial infections, including conjunctivitis, keratitis, keratoconjunctivitis, corneal ulcers, blepharitis, blepharoconjunctivitis, acute meibomianitis, and dacryocystitis caused by susceptible strains of the following microorganisms: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Streptococcus pneumoniae, Enterobacter aerogenes, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Neisseria gonorrhoeae, Pseudomonas aeruginosa, and Serratia marcescens. uuid:c283558e-1479-4c08-a06e-bd54a7f7e77b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8874 biolink:treats MONDO:0019977 PMID:41385096 "[{""id"":""uuid:023dcded-5278-4200-bbb8-7a0c48c3ff6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e28d1c76-05e4-4e81-95e5-6ac5ba861ffd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Exelon ® (rivastigmine tartrate) is indicated for the treatment of mild to moderate dementia of the Alzheimer's type. Exelon ® (rivastigmine tartrate) is indicated for the treatment of mild to moderate dementia associated with Parkinson’s disease. The dementia of Parkinson’s disease is purportedly characterized by impairments in executive function, memory retrieval, and attention in patients with an established diagnosis of Parkinson’s disease. The diagnosis of the dementia of Parkinson’s disease, however, can reliably be made in patients in whom a progressive dementia syndrome occurs (without the necessity to document the specific deficits described above) at least 2 years after a diagnosis of Parkinson’s disease has been made, and in whom other causes of dementia have been ruled out (see CLINICAL PHARMACOLOGY, Clinical Trial Data). uuid:05fa9832-a21b-48c3-aa49-18f03b901e62 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8874 biolink:treats MONDO:0005180 PMID:41385096 "[{""id"":""uuid:bc7b8fed-a77f-4e6b-9417-f940f6326b41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:7b676e1e-7b52-4c23-8252-1bc3c8d6c361"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:5018ddcf-fa99-4435-811b-54ead8d963e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/prometax""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Exelon ® (rivastigmine tartrate) is indicated for the treatment of mild to moderate dementia of the Alzheimer's type. Exelon ® (rivastigmine tartrate) is indicated for the treatment of mild to moderate dementia associated with Parkinson’s disease. The dementia of Parkinson’s disease is purportedly characterized by impairments in executive function, memory retrieval, and attention in patients with an established diagnosis of Parkinson’s disease. The diagnosis of the dementia of Parkinson’s disease, however, can reliably be made in patients in whom a progressive dementia syndrome occurs (without the necessity to document the specific deficits described above) at least 2 years after a diagnosis of Parkinson’s disease has been made, and in whom other causes of dementia have been ruled out (see CLINICAL PHARMACOLOGY, Clinical Trial Data).|[EMA] Symptomatic treatment of mild to moderately severe Alzheimer's dementia.Symptomatic treatment of mild to moderately severe dementia in patients with idiopathic Parkinson's disease. uuid:912b5465-d96e-471e-ad41-93e9cce1d5e1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37941 biolink:treats MONDO:0000990 PMID:41385096 "[{""id"":""uuid:853d6bd3-09c3-4ad9-9bbd-78568b5eb433"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9b3dd73e-4f9e-40da-8fb6-ba51f082b2ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a19fb82c-9b00-46b8-af0b-c6a519a39ee6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Plavix is a P2Y 12 platelet inhibitor indicated for: Acute coronary syndrome - For patients with non-ST-segment elevation ACS [unstable angina (UA)/non-ST-elevation myocardial infarction (NSTEMI)] including patients who are to be managed medically and those who are to be managed with coronary revascularization, Plavix has been shown to decrease the rate of a combined endpoint of cardiovascular death, myocardial infarction (MI), or stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia. ( 1.1 ) - For patients with ST-elevation myocardial infarction (STEMI), Plavix has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction, or stroke. The benefit for patients who undergo primary PCI is unknown. ( 1.1 ) Recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease. Plavix has been shown to reduce the combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death. ( 1.2 )|[PMDA] A new combination drug indicated for the treatment of ischemic heart diseases (acute coronary syndrome [unstable angina, non-ST-segment elevation myocardial infarction, ST-segment elevation myocardial infarction], stable angina, old myocardial infarction) to which percutaneous coronary intervention (PCI) is applicable. uuid:e5a4b950-f605-4b60-993b-ab695b54ffb1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37941 biolink:treats UMLS:C1998297 PMID:41385096 "[{""id"":""uuid:baa19310-4087-4e92-86eb-fae5faad85c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cdee0ebd-84d8-4e4c-83b9-aae9fb60b078"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Plavix is a P2Y 12 platelet inhibitor indicated for: Acute coronary syndrome - For patients with non-ST-segment elevation ACS [unstable angina (UA)/non-ST-elevation myocardial infarction (NSTEMI)] including patients who are to be managed medically and those who are to be managed with coronary revascularization, Plavix has been shown to decrease the rate of a combined endpoint of cardiovascular death, myocardial infarction (MI), or stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia. ( 1.1 ) - For patients with ST-elevation myocardial infarction (STEMI), Plavix has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction, or stroke. The benefit for patients who undergo primary PCI is unknown. ( 1.1 ) Recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease. Plavix has been shown to reduce the combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death. ( 1.2 ) uuid:c74b8d80-938e-4f34-80be-e57ec95ac71c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37941 biolink:treats HP:0002140 PMID:41385096 "[{""id"":""uuid:6d6b1067-1a53-4882-b09c-e74d35511ac0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:70764cda-4947-497c-a7b1-79c8652c7a41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Plavix is a P2Y 12 platelet inhibitor indicated for: Acute coronary syndrome - For patients with non-ST-segment elevation ACS [unstable angina (UA)/non-ST-elevation myocardial infarction (NSTEMI)] including patients who are to be managed medically and those who are to be managed with coronary revascularization, Plavix has been shown to decrease the rate of a combined endpoint of cardiovascular death, myocardial infarction (MI), or stroke as well as the rate of a combined endpoint of cardiovascular death, MI, stroke, or refractory ischemia. ( 1.1 ) - For patients with ST-elevation myocardial infarction (STEMI), Plavix has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re-infarction, or stroke. The benefit for patients who undergo primary PCI is unknown. ( 1.1 ) Recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease. Plavix has been shown to reduce the combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death. ( 1.2 ) uuid:a40ccf11-05df-46f1-b722-7beb8b51e2b7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8389 biolink:treats MONDO:0018555 PMID:41385096 "[{""id"":""uuid:18ddf7c2-e1cb-4a97-be5c-10980872e2dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:44637ba8-ab8b-4429-89d4-b16ecba8da7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PREMARIN therapy is indicated in the: Treatment of moderate to severe vasomotor symptoms due to menopause. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. Treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. Treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). Prevention of postmenopausal osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate. (See CLINICAL STUDIES .) The mainstays for decreasing the risk of postmenopausal osteoporosis are weight-bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 1500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400-800 IU/day may also be required to ensure adequate daily intake in postmenopausal women. uuid:0e520112-566f-4b3d-aa16-ba06dbbbf565 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8389 biolink:treats MONDO:0005387 PMID:41385096 "[{""id"":""uuid:2b9f6a5f-3324-4f78-b9a3-88717bc72aa5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f2e70731-aef8-474b-8322-e7bac714112c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PREMARIN therapy is indicated in the: Treatment of moderate to severe vasomotor symptoms due to menopause. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. Treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. Treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). Prevention of postmenopausal osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate. (See CLINICAL STUDIES .) The mainstays for decreasing the risk of postmenopausal osteoporosis are weight-bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 1500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400-800 IU/day may also be required to ensure adequate daily intake in postmenopausal women. uuid:375aea97-0e40-4258-99e8-f78c793e96d3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8389 biolink:treats UMLS:C0278488 PMID:41385096 "[{""id"":""uuid:c58efdfd-b8c1-49e1-a750-d9d8c1a5591e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:35c7e836-083c-40a8-b1a4-258abafd2035"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PREMARIN therapy is indicated in the: Treatment of moderate to severe vasomotor symptoms due to menopause. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. Treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. Treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). Prevention of postmenopausal osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate. (See CLINICAL STUDIES .) The mainstays for decreasing the risk of postmenopausal osteoporosis are weight-bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 1500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400-800 IU/day may also be required to ensure adequate daily intake in postmenopausal women. uuid:2d93429f-89ef-4854-8bbb-8be41db84432 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8389 biolink:treats MONDO:0850353 PMID:41385096 "[{""id"":""uuid:6c97b899-7b50-44b1-9cc5-71e5d04e45ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f0a0f868-5e68-4414-b5d8-d43e6bf9b443"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PREMARIN therapy is indicated in the: Treatment of moderate to severe vasomotor symptoms due to menopause. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. Treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. Treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). Prevention of postmenopausal osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate. (See CLINICAL STUDIES .) The mainstays for decreasing the risk of postmenopausal osteoporosis are weight-bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 1500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400-800 IU/day may also be required to ensure adequate daily intake in postmenopausal women. uuid:70fd574c-ef69-465e-ad6a-2db7b1d7b7b8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8389 biolink:treats MONDO:0008159 PMID:41385096 "[{""id"":""uuid:99d4140e-47ea-4b79-8ae6-74617e8d0614"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b56505fc-97e7-473c-b5ef-f8ab877891cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PREMARIN therapy is indicated in the: Treatment of moderate to severe vasomotor symptoms due to menopause. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. Treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. Treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). Prevention of postmenopausal osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate. (See CLINICAL STUDIES .) The mainstays for decreasing the risk of postmenopausal osteoporosis are weight-bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 1500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400-800 IU/day may also be required to ensure adequate daily intake in postmenopausal women. uuid:9463fe77-3c0c-4ec8-954e-393180b03ed2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:9717e171-1ef5-41d0-89ed-9b5adb4a40cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:43ba5bb5-833a-4594-82d7-bca3c1af64c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Uses: -For the treatment of acne -Helps prevent new acne blemishes Directions -Cleanse skin thoroughly before applying -Apply to cotton pad and wipe over skin, avoiding eye area. uuid:a6d6b544-3889-4207-ba2c-6286dc66dc18 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9449 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:f8145079-94ac-457c-b540-bb957bd1944e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c25bc1c0-3795-494a-837d-43a2afc177ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Terbutaline sulfate is indicated for the prevention and reversal of bronchospasm in patients 12 years of age and older with asthma and reversible bronchospasm associated with bronchitis and emphysema. uuid:708cf5b8-3a23-408d-9aa5-b39ec5c97397 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9449 biolink:treats MONDO:0003781 PMID:41385096 "[{""id"":""uuid:aa47e644-3f6b-4049-b76a-c77f837ef835"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b4c232ea-3a12-4bd9-8aba-78dff7630bfe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Terbutaline sulfate is indicated for the prevention and reversal of bronchospasm in patients 12 years of age and older with asthma and reversible bronchospasm associated with bronchitis and emphysema. uuid:ca8c6609-37c8-4bda-bd2e-9a73410d7811 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9449 biolink:treats MONDO:0004849 PMID:41385096 "[{""id"":""uuid:4641c822-3c61-435f-bbe5-93ed630d5049"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:53b6740e-0225-41d4-aea9-d88dba8187de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Terbutaline sulfate is indicated for the prevention and reversal of bronchospasm in patients 12 years of age and older with asthma and reversible bronchospasm associated with bronchitis and emphysema. uuid:aa7b5787-2f2b-4311-9686-f8d90edf6d8c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4046 biolink:treats MONDO:0024332 PMID:41385096 "[{""id"":""uuid:467f062f-6212-473d-8432-f2410c79fdac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2d127c9c-b930-4d59-bf14-953d5a149d9a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma Cold urticaria Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. uuid:18dd5bbe-d0b4-4be2-aa4a-ee2e8de5917e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4046 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:d4730d6e-f660-4c17-9908-43e99bc60d44"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:249ca13d-8c48-4b24-816e-10428bd2b0a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma Cold urticaria Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. uuid:5e82bb5a-38bc-4683-ba22-14309c10f031 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4046 biolink:treats MONDO:0006004 PMID:41385096 "[{""id"":""uuid:001bcd74-2644-4ee0-9ab6-21d3f6ee5e1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e3ec8491-31c3-4877-a32e-f54505a1322f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma Cold urticaria Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. uuid:ffc388d7-c8cd-4ac8-a993-bf861a008be2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4046 biolink:treats MONDO:0005492 PMID:41385096 "[{""id"":""uuid:befe81b9-a9a9-48cd-9003-176e830fb896"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:55d92d6a-8ade-4a3e-90a9-47087c5b3183"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma Cold urticaria Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. uuid:123e07e1-d3e9-4a52-9e65-1572cbdee606 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4046 biolink:treats MONDO:0010481 PMID:41385096 "[{""id"":""uuid:c2e8eea3-2746-4a8f-b2f3-06986921b5d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:779899bc-6087-46e6-bd46-3c252b7dac07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma Cold urticaria Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. uuid:480242f0-7a0a-493c-ba4a-d30d8e725471 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4046 biolink:treats MONDO:0022799 PMID:41385096 "[{""id"":""uuid:335fcb00-7708-47b9-b357-ec5cb5b5f92c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:93914093-87e5-4c93-bc50-02716ab495f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma Cold urticaria Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. uuid:0e67d072-5ffe-4ccd-b18f-8f887ef6420c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4046 biolink:treats MONDO:0007448 PMID:41385096 "[{""id"":""uuid:23290a87-f7d5-4c76-8562-1c71ba002158"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2f81b799-8c3d-40a2-a55d-396b6f3f8977"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma Cold urticaria Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. uuid:00c45fe6-fa2d-4d6b-83a2-03de6b1673dd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4046 biolink:treats MONDO:0100053 PMID:41385096 "[{""id"":""uuid:e270e57b-7b2c-42cf-ac1e-b648dad686ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c26cd176-ab14-4f14-90ef-f209ac901cfc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Amelioration of allergic reactions to blood or plasma Cold urticaria Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. uuid:f19c937f-5e04-41f4-8a2a-708f00ff2ce9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63613 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:404730ab-22e0-4b57-a392-6ed03907263b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f31467c5-2239-41a4-8f28-82eeca39b029"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VIRAMUNE is indicated for use in combination with other antiretroviral agents for the treatment of HIV-1 infection. This indication is based on one principal clinical trial (BI 1090) that demonstrated prolonged suppression of HIV-1 RNA and two smaller supportive studies, one of which (BI 1046) is described below. Additional important information regarding the use of VIRAMUNE for the treatment of HIV-1 infection: Based on serious and life-threatening hepatotoxicity observed in controlled and uncontrolled studies, VIRAMUNE should not be initiated in adult females with CD4 + cell counts greater than 250 cells/mm 3 or in adult males with CD4 + cell counts greater than 400 cells/mm 3 unless the benefit outweighs the risk [ see Boxed Warning and Warnings and Precautions (5.1) ]. The 14-day lead-in period with VIRAMUNE 200 mg daily dosing has been demonstrated to reduce the frequency of rash [ see Dosage and Administration (2.4) and Warnings and Precautions (5.2) ]. If rash persists beyond the 14-day lead-in period, do not dose escalate to 200 mg twice daily. The 200 mg once-daily dosing regimen should not be continued beyond 28 days, at which point an alternative regimen should be sought. uuid:9d93add7-4ec6-4fff-a58b-df809de315c9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6437 biolink:treats MONDO:0005027 PMID:41385096 "[{""id"":""uuid:515ab04c-2323-4964-9e6b-637185b2fda9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2dcd50e5-b0b9-4ac4-8b1c-167eb7ff263d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:826a31f0-e327-4f0c-95d6-fd536b0382f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/levetiracetam-sun""]},{""id"":""uuid:3c0da83a-a2e5-4c61-bf3d-0ce4b415698b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levetiracetam is indicated as adjunctive therapy in the treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy.|[EMA] Levetiracetam Sun is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.Levetiracetam Sun is indicated as adjunctive therapy:in the treatment of partial-onset seizures with or without secondary generalisation in adults and children from four years of age with epilepsy;in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.Levetiracetam Sun concentrate is an alternative for patients when oral administration is temporarily not feasible.|[PMDA] A drug with a new route of administration indicated for use as an adjunctive therapy with other antiepileptic drugs to treat partial seizure (including secondary generalized seizure) in patients with epilepsy who have not responded sufficiently to other antiepileptic drugs. It is used as an alternative therapy for levetiracetam oral formulation in patients who are temporarily unable to be administered orally. uuid:2e647bd1-8a9f-4321-8933-27173bbf42e3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6437 biolink:treats HP:0007359 PMID:41385096 "[{""id"":""uuid:3aa01d0d-e08a-4a14-97cb-5f3e480bff7d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d159f9d9-311d-4f7c-8296-32ca4cec0e86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:8942a0f1-3ac6-40f2-9105-6455edcad1c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/levetiracetam-sun""]},{""id"":""uuid:e402ce5d-5327-4ad3-b91d-618144850d58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levetiracetam is indicated as adjunctive therapy in the treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy.|[EMA] Levetiracetam Sun is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.Levetiracetam Sun is indicated as adjunctive therapy:in the treatment of partial-onset seizures with or without secondary generalisation in adults and children from four years of age with epilepsy;in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.Levetiracetam Sun concentrate is an alternative for patients when oral administration is temporarily not feasible.|[PMDA] A drug with a new additional pediatric dosage in an additional dosage form indicated for use as an adjunctive therapy with other antiepileptic drugs to treat partial seizures (including secondary generalized seizures) in patients with epilepsy who have not responded sufficiently to other antiepileptic drugs. uuid:a5893422-c114-41d4-8f15-1e6ac0373d09 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0004592 PMID:41385096 "[{""id"":""uuid:cbf124e6-13fb-4e6f-9ead-98a7fad2212e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:045e8590-6cf3-470e-b87b-843d2a07f949"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Primary skin infections: Impetigo contagiosa, superficial folliculitis, ecthyma, furunculosis, sycosis barbae, and pyoderma gangrenosum. Secondary skin infections: Infectious eczematoid dermatitis, pustular acne, pustular psoriasis, infected seborrheic dermatitis, infected contact dermatitis (including poison ivy), infected excoriations, and bacterial super-infections of fungal or viral infections. Please Note: Gentamicin sulfate is a bactericidal agent that is not effective against viruses or fungi in skin infections. Gentamicin sulfate is useful in the treatment of infected skin cysts and certain other skin abscesses when preceded by incision and drainage to permit adequate contact between the antibiotic and the infecting bacteria. Good results have been obtained in the treatment of infected stasis and other skin ulcers , infected superficial burns, paronychia, infected insect bites and stings, infected lacerations and abrasions, and wounds from minor surgery. Patients sensitive to neomycin can be treated with gentamicin sulfate, although regular observation of patients sensitive to topical antibiotics is advisable when such patients are treated with any topical antibiotic. Gentamicin Sulfate Ointment helps retain moisture and has been useful in infection on dry eczematous or psoriatic skin. Gentamicin Sulfate Ointment may be used in children over one year of age as well as in adults. uuid:6883547d-7018-4a42-8efc-902e895ad5b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats UMLS:C0302160 PMID:41385096 "[{""id"":""uuid:d9a62c29-a199-40b2-a02e-964626a64ba2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:27acdca7-70d4-4ad9-929a-dfa37e68b434"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Primary skin infections: Impetigo contagiosa, superficial folliculitis, ecthyma, furunculosis, sycosis barbae, and pyoderma gangrenosum. Secondary skin infections: Infectious eczematoid dermatitis, pustular acne, pustular psoriasis, infected seborrheic dermatitis, infected contact dermatitis (including poison ivy), infected excoriations, and bacterial super-infections of fungal or viral infections. Please Note: Gentamicin sulfate is a bactericidal agent that is not effective against viruses or fungi in skin infections. Gentamicin sulfate is useful in the treatment of infected skin cysts and certain other skin abscesses when preceded by incision and drainage to permit adequate contact between the antibiotic and the infecting bacteria. Good results have been obtained in the treatment of infected stasis and other skin ulcers , infected superficial burns, paronychia, infected insect bites and stings, infected lacerations and abrasions, and wounds from minor surgery. Patients sensitive to neomycin can be treated with gentamicin sulfate, although regular observation of patients sensitive to topical antibiotics is advisable when such patients are treated with any topical antibiotic. Gentamicin Sulfate Ointment helps retain moisture and has been useful in infection on dry eczematous or psoriatic skin. Gentamicin Sulfate Ointment may be used in children over one year of age as well as in adults. uuid:ebb1f814-559a-4177-a1d5-7c0c574c3a54 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0001404 PMID:41385096 "[{""id"":""uuid:a3e1fd73-c273-4e5b-82e0-75851bd4e66c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ef9e2581-122d-4aa9-b623-f7f0bff4f5aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Primary skin infections: Impetigo contagiosa, superficial folliculitis, ecthyma, furunculosis, sycosis barbae, and pyoderma gangrenosum. Secondary skin infections: Infectious eczematoid dermatitis, pustular acne, pustular psoriasis, infected seborrheic dermatitis, infected contact dermatitis (including poison ivy), infected excoriations, and bacterial super-infections of fungal or viral infections. Please Note: Gentamicin sulfate is a bactericidal agent that is not effective against viruses or fungi in skin infections. Gentamicin sulfate is useful in the treatment of infected skin cysts and certain other skin abscesses when preceded by incision and drainage to permit adequate contact between the antibiotic and the infecting bacteria. Good results have been obtained in the treatment of infected stasis and other skin ulcers , infected superficial burns, paronychia, infected insect bites and stings, infected lacerations and abrasions, and wounds from minor surgery. Patients sensitive to neomycin can be treated with gentamicin sulfate, although regular observation of patients sensitive to topical antibiotics is advisable when such patients are treated with any topical antibiotic. Gentamicin Sulfate Ointment helps retain moisture and has been useful in infection on dry eczematous or psoriatic skin. Gentamicin Sulfate Ointment may be used in children over one year of age as well as in adults. uuid:7556642e-45c0-4173-b157-c5d00d53b72d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0100595 PMID:41385096 "[{""id"":""uuid:f691c66d-ee54-45ee-92a4-fcadbca1648a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f82da591-eda7-407a-b21d-aaae035e908e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Primary skin infections: Impetigo contagiosa, superficial folliculitis, ecthyma, furunculosis, sycosis barbae, and pyoderma gangrenosum. Secondary skin infections: Infectious eczematoid dermatitis, pustular acne, pustular psoriasis, infected seborrheic dermatitis, infected contact dermatitis (including poison ivy), infected excoriations, and bacterial super-infections of fungal or viral infections. Please Note: Gentamicin sulfate is a bactericidal agent that is not effective against viruses or fungi in skin infections. Gentamicin sulfate is useful in the treatment of infected skin cysts and certain other skin abscesses when preceded by incision and drainage to permit adequate contact between the antibiotic and the infecting bacteria. Good results have been obtained in the treatment of infected stasis and other skin ulcers , infected superficial burns, paronychia, infected insect bites and stings, infected lacerations and abrasions, and wounds from minor surgery. Patients sensitive to neomycin can be treated with gentamicin sulfate, although regular observation of patients sensitive to topical antibiotics is advisable when such patients are treated with any topical antibiotic. Gentamicin Sulfate Ointment helps retain moisture and has been useful in infection on dry eczematous or psoriatic skin. Gentamicin Sulfate Ointment may be used in children over one year of age as well as in adults. uuid:531be0e2-cffd-414f-ade7-117faa77d047 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:1050000 PMID:41385096 "[{""id"":""uuid:c689da24-78e3-44b6-8c35-3446258d5296"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:26775e20-51c7-4c24-aa31-637c3c870001"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Primary skin infections: Impetigo contagiosa, superficial folliculitis, ecthyma, furunculosis, sycosis barbae, and pyoderma gangrenosum. Secondary skin infections: Infectious eczematoid dermatitis, pustular acne, pustular psoriasis, infected seborrheic dermatitis, infected contact dermatitis (including poison ivy), infected excoriations, and bacterial super-infections of fungal or viral infections. Please Note: Gentamicin sulfate is a bactericidal agent that is not effective against viruses or fungi in skin infections. Gentamicin sulfate is useful in the treatment of infected skin cysts and certain other skin abscesses when preceded by incision and drainage to permit adequate contact between the antibiotic and the infecting bacteria. Good results have been obtained in the treatment of infected stasis and other skin ulcers , infected superficial burns, paronychia, infected insect bites and stings, infected lacerations and abrasions, and wounds from minor surgery. Patients sensitive to neomycin can be treated with gentamicin sulfate, although regular observation of patients sensitive to topical antibiotics is advisable when such patients are treated with any topical antibiotic. Gentamicin Sulfate Ointment helps retain moisture and has been useful in infection on dry eczematous or psoriatic skin. Gentamicin Sulfate Ointment may be used in children over one year of age as well as in adults. uuid:b66b6f00-ed54-4808-a2ea-99939b09471f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0018824 PMID:41385096 "[{""id"":""uuid:11d111a9-9301-4491-8ef8-a1805e00fd7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f5658199-fcb5-4870-9f72-ee3b2f311978"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Primary skin infections: Impetigo contagiosa, superficial folliculitis, ecthyma, furunculosis, sycosis barbae, and pyoderma gangrenosum. Secondary skin infections: Infectious eczematoid dermatitis, pustular acne, pustular psoriasis, infected seborrheic dermatitis, infected contact dermatitis (including poison ivy), infected excoriations, and bacterial super-infections of fungal or viral infections. Please Note: Gentamicin sulfate is a bactericidal agent that is not effective against viruses or fungi in skin infections. Gentamicin sulfate is useful in the treatment of infected skin cysts and certain other skin abscesses when preceded by incision and drainage to permit adequate contact between the antibiotic and the infecting bacteria. Good results have been obtained in the treatment of infected stasis and other skin ulcers , infected superficial burns, paronychia, infected insect bites and stings, infected lacerations and abrasions, and wounds from minor surgery. Patients sensitive to neomycin can be treated with gentamicin sulfate, although regular observation of patients sensitive to topical antibiotics is advisable when such patients are treated with any topical antibiotic. Gentamicin Sulfate Ointment helps retain moisture and has been useful in infection on dry eczematous or psoriatic skin. Gentamicin Sulfate Ointment may be used in children over one year of age as well as in adults. uuid:ef5835b1-da9b-4928-9a5c-758bea417b60 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats UMLS:C0263443 PMID:41385096 "[{""id"":""uuid:9ba4c00c-1ac9-4bf7-9132-d70caf3a24b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b697d90c-699b-44bb-bf4c-b224600863e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Primary skin infections: Impetigo contagiosa, superficial folliculitis, ecthyma, furunculosis, sycosis barbae, and pyoderma gangrenosum. Secondary skin infections: Infectious eczematoid dermatitis, pustular acne, pustular psoriasis, infected seborrheic dermatitis, infected contact dermatitis (including poison ivy), infected excoriations, and bacterial super-infections of fungal or viral infections. Please Note: Gentamicin sulfate is a bactericidal agent that is not effective against viruses or fungi in skin infections. Gentamicin sulfate is useful in the treatment of infected skin cysts and certain other skin abscesses when preceded by incision and drainage to permit adequate contact between the antibiotic and the infecting bacteria. Good results have been obtained in the treatment of infected stasis and other skin ulcers , infected superficial burns, paronychia, infected insect bites and stings, infected lacerations and abrasions, and wounds from minor surgery. Patients sensitive to neomycin can be treated with gentamicin sulfate, although regular observation of patients sensitive to topical antibiotics is advisable when such patients are treated with any topical antibiotic. Gentamicin Sulfate Ointment helps retain moisture and has been useful in infection on dry eczematous or psoriatic skin. Gentamicin Sulfate Ointment may be used in children over one year of age as well as in adults. uuid:e580cbba-d478-4b65-9f8d-c4f9e5fc3c70 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0022205 PMID:41385096 "[{""id"":""uuid:5fb64329-dd8d-4149-a123-0d61282ffe7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1c68e9c3-b4d3-4e31-b6a3-99245b712732"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Primary skin infections: Impetigo contagiosa, superficial folliculitis, ecthyma, furunculosis, sycosis barbae, and pyoderma gangrenosum. Secondary skin infections: Infectious eczematoid dermatitis, pustular acne, pustular psoriasis, infected seborrheic dermatitis, infected contact dermatitis (including poison ivy), infected excoriations, and bacterial super-infections of fungal or viral infections. Please Note: Gentamicin sulfate is a bactericidal agent that is not effective against viruses or fungi in skin infections. Gentamicin sulfate is useful in the treatment of infected skin cysts and certain other skin abscesses when preceded by incision and drainage to permit adequate contact between the antibiotic and the infecting bacteria. Good results have been obtained in the treatment of infected stasis and other skin ulcers , infected superficial burns, paronychia, infected insect bites and stings, infected lacerations and abrasions, and wounds from minor surgery. Patients sensitive to neomycin can be treated with gentamicin sulfate, although regular observation of patients sensitive to topical antibiotics is advisable when such patients are treated with any topical antibiotic. Gentamicin Sulfate Ointment helps retain moisture and has been useful in infection on dry eczematous or psoriatic skin. Gentamicin Sulfate Ointment may be used in children over one year of age as well as in adults. uuid:ac9ed212-4a1c-4996-ba41-25f4922044c1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0006608 PMID:41385096 "[{""id"":""uuid:a2bb08f1-80c9-40c1-b02e-8649e6d9869f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d575c1cc-f6d9-4ca8-9e32-7610644332e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Primary skin infections: Impetigo contagiosa, superficial folliculitis, ecthyma, furunculosis, sycosis barbae, and pyoderma gangrenosum. Secondary skin infections: Infectious eczematoid dermatitis, pustular acne, pustular psoriasis, infected seborrheic dermatitis, infected contact dermatitis (including poison ivy), infected excoriations, and bacterial super-infections of fungal or viral infections. Please Note: Gentamicin sulfate is a bactericidal agent that is not effective against viruses or fungi in skin infections. Gentamicin sulfate is useful in the treatment of infected skin cysts and certain other skin abscesses when preceded by incision and drainage to permit adequate contact between the antibiotic and the infecting bacteria. Good results have been obtained in the treatment of infected stasis and other skin ulcers , infected superficial burns, paronychia, infected insect bites and stings, infected lacerations and abrasions, and wounds from minor surgery. Patients sensitive to neomycin can be treated with gentamicin sulfate, although regular observation of patients sensitive to topical antibiotics is advisable when such patients are treated with any topical antibiotic. Gentamicin Sulfate Ointment helps retain moisture and has been useful in infection on dry eczematous or psoriatic skin. Gentamicin Sulfate Ointment may be used in children over one year of age as well as in adults. uuid:ded92e4d-8093-49f0-82b6-f957c891c268 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats UMLS:C0162451 PMID:41385096 "[{""id"":""uuid:0c1b8a5c-4d40-4957-b8e3-ba4418adddbc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3ce4d70c-31ea-4eb6-9d25-d39938f41894"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Primary skin infections: Impetigo contagiosa, superficial folliculitis, ecthyma, furunculosis, sycosis barbae, and pyoderma gangrenosum. Secondary skin infections: Infectious eczematoid dermatitis, pustular acne, pustular psoriasis, infected seborrheic dermatitis, infected contact dermatitis (including poison ivy), infected excoriations, and bacterial super-infections of fungal or viral infections. Please Note: Gentamicin sulfate is a bactericidal agent that is not effective against viruses or fungi in skin infections. Gentamicin sulfate is useful in the treatment of infected skin cysts and certain other skin abscesses when preceded by incision and drainage to permit adequate contact between the antibiotic and the infecting bacteria. Good results have been obtained in the treatment of infected stasis and other skin ulcers , infected superficial burns, paronychia, infected insect bites and stings, infected lacerations and abrasions, and wounds from minor surgery. Patients sensitive to neomycin can be treated with gentamicin sulfate, although regular observation of patients sensitive to topical antibiotics is advisable when such patients are treated with any topical antibiotic. Gentamicin Sulfate Ointment helps retain moisture and has been useful in infection on dry eczematous or psoriatic skin. Gentamicin Sulfate Ointment may be used in children over one year of age as well as in adults. uuid:583bf9be-169c-4fa5-8fb6-5c32b8207264 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats HP:0031292 PMID:41385096 "[{""id"":""uuid:2c702430-feb9-4f82-9d45-f0fe12771cdb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:af1a69e3-33c2-4286-b6f5-26de94b5d1ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Primary skin infections: Impetigo contagiosa, superficial folliculitis, ecthyma, furunculosis, sycosis barbae, and pyoderma gangrenosum. Secondary skin infections: Infectious eczematoid dermatitis, pustular acne, pustular psoriasis, infected seborrheic dermatitis, infected contact dermatitis (including poison ivy), infected excoriations, and bacterial super-infections of fungal or viral infections. Please Note: Gentamicin sulfate is a bactericidal agent that is not effective against viruses or fungi in skin infections. Gentamicin sulfate is useful in the treatment of infected skin cysts and certain other skin abscesses when preceded by incision and drainage to permit adequate contact between the antibiotic and the infecting bacteria. Good results have been obtained in the treatment of infected stasis and other skin ulcers , infected superficial burns, paronychia, infected insect bites and stings, infected lacerations and abrasions, and wounds from minor surgery. Patients sensitive to neomycin can be treated with gentamicin sulfate, although regular observation of patients sensitive to topical antibiotics is advisable when such patients are treated with any topical antibiotic. Gentamicin Sulfate Ointment helps retain moisture and has been useful in infection on dry eczematous or psoriatic skin. Gentamicin Sulfate Ointment may be used in children over one year of age as well as in adults. uuid:0ffcdc90-1dce-40aa-a291-f0112289ebc9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats HP:0200042 PMID:41385096 "[{""id"":""uuid:76040372-1201-4836-9124-0a62438e1e08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:61ce1f67-28e6-43bc-b33f-59c7da4f325f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Primary skin infections: Impetigo contagiosa, superficial folliculitis, ecthyma, furunculosis, sycosis barbae, and pyoderma gangrenosum. Secondary skin infections: Infectious eczematoid dermatitis, pustular acne, pustular psoriasis, infected seborrheic dermatitis, infected contact dermatitis (including poison ivy), infected excoriations, and bacterial super-infections of fungal or viral infections. Please Note: Gentamicin sulfate is a bactericidal agent that is not effective against viruses or fungi in skin infections. Gentamicin sulfate is useful in the treatment of infected skin cysts and certain other skin abscesses when preceded by incision and drainage to permit adequate contact between the antibiotic and the infecting bacteria. Good results have been obtained in the treatment of infected stasis and other skin ulcers , infected superficial burns, paronychia, infected insect bites and stings, infected lacerations and abrasions, and wounds from minor surgery. Patients sensitive to neomycin can be treated with gentamicin sulfate, although regular observation of patients sensitive to topical antibiotics is advisable when such patients are treated with any topical antibiotic. Gentamicin Sulfate Ointment helps retain moisture and has been useful in infection on dry eczematous or psoriatic skin. Gentamicin Sulfate Ointment may be used in children over one year of age as well as in adults. uuid:1d9e7f9f-de97-4433-b09c-eb489808ddbd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0005898 PMID:41385096 "[{""id"":""uuid:eafe6451-d045-4cd6-bf22-54c64d3d1df1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5bf3365d-3b6a-4969-8dd4-93d62a98256d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Primary skin infections: Impetigo contagiosa, superficial folliculitis, ecthyma, furunculosis, sycosis barbae, and pyoderma gangrenosum. Secondary skin infections: Infectious eczematoid dermatitis, pustular acne, pustular psoriasis, infected seborrheic dermatitis, infected contact dermatitis (including poison ivy), infected excoriations, and bacterial super-infections of fungal or viral infections. Please Note: Gentamicin sulfate is a bactericidal agent that is not effective against viruses or fungi in skin infections. Gentamicin sulfate is useful in the treatment of infected skin cysts and certain other skin abscesses when preceded by incision and drainage to permit adequate contact between the antibiotic and the infecting bacteria. Good results have been obtained in the treatment of infected stasis and other skin ulcers , infected superficial burns, paronychia, infected insect bites and stings, infected lacerations and abrasions, and wounds from minor surgery. Patients sensitive to neomycin can be treated with gentamicin sulfate, although regular observation of patients sensitive to topical antibiotics is advisable when such patients are treated with any topical antibiotic. Gentamicin Sulfate Ointment helps retain moisture and has been useful in infection on dry eczematous or psoriatic skin. Gentamicin Sulfate Ointment may be used in children over one year of age as well as in adults. uuid:1ec9e484-e81c-46f4-81d5-f0d1f2db364d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:36135651-9b13-4a77-b4f3-dbbabbc33ed2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d963569e-5aa4-47e9-8dfd-a40b3cdbdfc3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Primary skin infections: Impetigo contagiosa, superficial folliculitis, ecthyma, furunculosis, sycosis barbae, and pyoderma gangrenosum. Secondary skin infections: Infectious eczematoid dermatitis, pustular acne, pustular psoriasis, infected seborrheic dermatitis, infected contact dermatitis (including poison ivy), infected excoriations, and bacterial super-infections of fungal or viral infections. Please Note: Gentamicin sulfate is a bactericidal agent that is not effective against viruses or fungi in skin infections. Gentamicin sulfate is useful in the treatment of infected skin cysts and certain other skin abscesses when preceded by incision and drainage to permit adequate contact between the antibiotic and the infecting bacteria. Good results have been obtained in the treatment of infected stasis and other skin ulcers , infected superficial burns, paronychia, infected insect bites and stings, infected lacerations and abrasions, and wounds from minor surgery. Patients sensitive to neomycin can be treated with gentamicin sulfate, although regular observation of patients sensitive to topical antibiotics is advisable when such patients are treated with any topical antibiotic. Gentamicin Sulfate Ointment helps retain moisture and has been useful in infection on dry eczematous or psoriatic skin. Gentamicin Sulfate Ointment may be used in children over one year of age as well as in adults. uuid:9f44100f-d23d-4c9a-9602-30455be5164c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10033 biolink:treats MONDO:0005279 PMID:41385096 "[{""id"":""uuid:c7ea9747-d28b-4495-8fef-f34b8156fe6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:66afcda0-4cc4-4ee4-a380-88290b30e51c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:311f0cba-e896-412b-9ab9-32c6003f0952"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Warfarin sodium tablets, USP are indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonary embolism. Warfarin sodium tablets, USP are indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. Warfarin sodium tablets, USP are indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction.|[PMDA] Drugs with new additional pediatric dosages. These drugs are indicated for the treatment and prophylaxis of thromboembolism (e.g., phlebothrombosis, myocardial infarction, pulmonary embolism, brain embolism, slowly- progressive cerebral thrombosis). [Public knowledge-based application after PAFSC's preliminary assessment] uuid:9d10b08c-e2bb-44e4-9eb6-ca0cb7ed1286 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10033 biolink:treats MONDO:0004981 PMID:41385096 "[{""id"":""uuid:d75512ae-bd24-40ff-83ca-f473ea56ff66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5bb51d5b-09aa-4ebe-956c-71a30897d6a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Warfarin sodium tablets, USP are indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonary embolism. Warfarin sodium tablets, USP are indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. Warfarin sodium tablets, USP are indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction. uuid:096f3ea3-4033-40b3-b5d4-1e5dbcd57bc4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10033 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:5fa141d0-4ba2-4115-8a0b-18d4c6f2d52a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0ede4749-dde5-49d3-88ed-96b676252fc9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Warfarin sodium tablets, USP are indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonary embolism. Warfarin sodium tablets, USP are indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. Warfarin sodium tablets, USP are indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction. uuid:95bf033b-beb9-4a23-baa3-96325aa39486 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10033 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:593cfcb7-df5c-4832-82c9-e74425bc4fc6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6a0093f6-e1f5-463b-9c99-23bf16b3a9fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7902a132-f6b2-4d18-80c3-1b761f0045ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Warfarin sodium tablets, USP are indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, and pulmonary embolism. Warfarin sodium tablets, USP are indicated for the prophylaxis and/or treatment of the thromboembolic complications associated with atrial fibrillation and/or cardiac valve replacement. Warfarin sodium tablets, USP are indicated to reduce the risk of death, recurrent myocardial infarction, and thromboembolic events such as stroke or systemic embolization after myocardial infarction.|[PMDA] Drugs with new additional pediatric dosages. These drugs are indicated for the treatment and prophylaxis of thromboembolism (e.g., phlebothrombosis, myocardial infarction, pulmonary embolism, brain embolism, slowly- progressive cerebral thrombosis). [Public knowledge-based application after PAFSC's preliminary assessment] uuid:b554ef5e-2e2a-4c75-aa18-1e692b603129 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:107736 biolink:treats UMLS:C0341117 PMID:41385096 "[{""id"":""uuid:15035e15-501a-4d61-a6f5-9d71b249701d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3ae3ae72-f343-4201-93ee-84ec1863fa70"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Symptomatic Gastroesophageal Reflux: Metoclopramide tablets are indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy. The principal effect of metoclopramide is on symptoms of postprandial and daytime heartburn with less observed effect on nocturnal symptoms. If symptoms are confined to particular situations, such as following the evening meal, use of metoclopramide as single doses prior to the provocative situation should be considered, rather than using the drug throughout the day. Healing of esophageal ulcers and erosions has been endoscopically demonstrated at the end of a 12-week trial using doses of 15 mg q.i.d. As there is no documented correlation between symptoms and healing of esophageal lesions, patients with documented lesions should be monitored endoscopically. Diabetic Gastroparesis (Diabetic Gastric Stasis): Metoclopramide is indicated for the relief of symptoms associated with acute and recurrent diabetic gastric stasis. The usual manifestations of delayed gastric emptying (e.g., nausea, vomiting, heartburn, persistent fullness after meals, and anorexia) appear to respond to metoclopramide within different time intervals. Significant relief of nausea occurs early and continues to improve over a three week period. Relief of vomiting and anorexia may precede the relief of abdominal fullness by one week or more. uuid:ff536aab-d669-4882-9ce1-e1d59cf91437 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:107736 biolink:treats UMLS:C0267176 PMID:41385096 "[{""id"":""uuid:f6a6aca9-59a4-49e3-8ccf-1644a2cf6f77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:618c5ec7-2855-4567-9696-f1984c393d3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Symptomatic Gastroesophageal Reflux: Metoclopramide tablets are indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy. The principal effect of metoclopramide is on symptoms of postprandial and daytime heartburn with less observed effect on nocturnal symptoms. If symptoms are confined to particular situations, such as following the evening meal, use of metoclopramide as single doses prior to the provocative situation should be considered, rather than using the drug throughout the day. Healing of esophageal ulcers and erosions has been endoscopically demonstrated at the end of a 12-week trial using doses of 15 mg q.i.d. As there is no documented correlation between symptoms and healing of esophageal lesions, patients with documented lesions should be monitored endoscopically. Diabetic Gastroparesis (Diabetic Gastric Stasis): Metoclopramide is indicated for the relief of symptoms associated with acute and recurrent diabetic gastric stasis. The usual manifestations of delayed gastric emptying (e.g., nausea, vomiting, heartburn, persistent fullness after meals, and anorexia) appear to respond to metoclopramide within different time intervals. Significant relief of nausea occurs early and continues to improve over a three week period. Relief of vomiting and anorexia may precede the relief of abdominal fullness by one week or more. uuid:4213ddd7-aa5a-4eb3-b7e8-2863f2969c1a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:107736 biolink:treats MONDO:0006769 PMID:41385096 "[{""id"":""uuid:4b828be6-5813-4304-acc6-4603ec3e6f3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e57905e9-56d6-4f80-aac1-1f0739c3ce59"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Symptomatic Gastroesophageal Reflux: Metoclopramide tablets are indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy. The principal effect of metoclopramide is on symptoms of postprandial and daytime heartburn with less observed effect on nocturnal symptoms. If symptoms are confined to particular situations, such as following the evening meal, use of metoclopramide as single doses prior to the provocative situation should be considered, rather than using the drug throughout the day. Healing of esophageal ulcers and erosions has been endoscopically demonstrated at the end of a 12-week trial using doses of 15 mg q.i.d. As there is no documented correlation between symptoms and healing of esophageal lesions, patients with documented lesions should be monitored endoscopically. Diabetic Gastroparesis (Diabetic Gastric Stasis): Metoclopramide is indicated for the relief of symptoms associated with acute and recurrent diabetic gastric stasis. The usual manifestations of delayed gastric emptying (e.g., nausea, vomiting, heartburn, persistent fullness after meals, and anorexia) appear to respond to metoclopramide within different time intervals. Significant relief of nausea occurs early and continues to improve over a three week period. Relief of vomiting and anorexia may precede the relief of abdominal fullness by one week or more. uuid:379dcb93-cfae-4cc2-b9fc-7b9126ad6003 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9352 biolink:treats UMLS:C0410022 PMID:41385096 "[{""id"":""uuid:23c3d95b-2347-4abc-a0ec-224183df734e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a62b908b-80c8-4fe9-974d-6262aa95840b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of sulindac tablets and other treatment options before deciding to use sulindac tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Sulindac tablets are indicated for acute or long-term use in the relief of signs and symptoms of the following: Osteoarthritis Rheumatoid arthritis The safety and effectiveness of sulindac tablets have not been established in rheumatoid arthritis patients who are designated in the American Rheumatism Association classification as Functional Class IV (incapacitated, largely or wholly bedridden, or confined to wheelchair; little or no self-care). Ankylosing spondylitis Acute painful shoulder (Acute subacromial bursitis/supraspinatus tendinitis) Acute gouty arthritis uuid:e2af5126-db51-4cd5-b430-3094737a6fbf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:48390 biolink:treats MONDO:0006964 PMID:41385096 "[{""id"":""uuid:c474aaa8-fe45-4817-9e23-6ddd60f795ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9cc28763-cba0-4f90-9d88-5129ac72e68d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:df5544ba-1c65-4f65-9740-e1d2482ccf29"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4cffe86f-a8bf-4da6-9593-55bb741a769b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sensipar ® is indicated for the treatment of secondary hyperparathyroidism in patients with Chronic Kidney Disease on dialysis. Sensipar ® is indicated for the treatment of hypercalcemia in patients with parathyroid carcinoma.|[EMA] Secondary hyperparathyroidismAdultsTreatment of secondary hyperparathyroidism (HPT) in adult patients with end-stage renal disease (ESRD) on maintenance dialysis therapy.Paediatric populationTreatment of secondary hyperparathyroidism (HPT) in children aged 3 years and older with end-stage renal disease (ESRD) on maintenance dialysis therapy in whom secondary HPT is not adequately controlled with standard of care therapy (see section 4.4).Cinacalcet Accordpharma may be used as part of a therapeutic regimen including phosphate binders and/or Vitamin D sterols, as appropriate (see section 5.1).Parathyroid carcinoma and primary hyperparathyroidism in adultsReduction of hypercalcaemia in adult patients with:parathyroid carcinoma.primary HPT for whom parathyroidectomy would be indicated on the basis of serum calcium levels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is contraindicated.|[PMDA] A drug containing a new active ingredient indicated for the treatment of secondary hyperparathyroidism in patients on maintenance dialysis. uuid:ef53bd83-d569-4cbb-8b35-a0450d8029aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:48390 biolink:treats MONDO:0001566 PMID:41385096 "[{""id"":""uuid:4e7db3cb-e3ed-4df8-b39e-021f684de1da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:69bb6587-d5bf-4bcd-ab73-329317bce184"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f4897050-8553-4afc-816e-c6a265e0c8a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:79ff1735-c34d-407b-a6a0-1a41bf8bfb43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sensipar ® is indicated for the treatment of secondary hyperparathyroidism in patients with Chronic Kidney Disease on dialysis. Sensipar ® is indicated for the treatment of hypercalcemia in patients with parathyroid carcinoma.|[EMA] Treatment of secondary hyperparathyroidism (HPT) in patients with end-stage renal disease (ESRD) on maintenance dialysis therapy.Cinacalcet Mylan may be used as part of a therapeutic regimen including phosphate binders and/or vitamin D sterols, as appropriate.Reduction of hypercalcaemia in patients with:parathyroid carcinomaprimary HPT for whom parathyroidectomywould be indicated on the basis of serum calcium levels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is contraindicated.|[PMDA] Drugs with a new additional indication and a new dosage for the treatment of hypercalcemia in patients with parathyroid carcinoma, and hypercalcemia in patients with primary hyperparathyroidism (HPT) who are unable to undergo parathyroidectomy or who experience recurrent primary HPT after the surgery. [Orphan drug] uuid:36264044-3b31-40a0-8cf2-feb0765321f0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6722 biolink:treats MONDO:0006256 PMID:41385096 "[{""id"":""uuid:5ebc0faf-2e49-4c27-ab43-868ee4f607c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d80e6aaa-a125-4e0c-9d05-15052fbd394b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Megestrol acetate tablets are indicated for the palliative treatment of advanced carcinoma of the breast or endometrium (i.e., recurrent, inoperable, or metastatic disease). It should not be used in lieu of currently accepted procedures such as surgery, radiation, or chemotherapy. uuid:3203c995-989e-417b-a357-b8e359495d9c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6722 biolink:treats MONDO:0002447 PMID:41385096 "[{""id"":""uuid:32cedfed-a22f-44e6-9051-7b901ecb5ab7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cc4e9f82-2c7f-4b2e-98c4-4bb54c8ce78a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Megestrol acetate tablets are indicated for the palliative treatment of advanced carcinoma of the breast or endometrium (i.e., recurrent, inoperable, or metastatic disease). It should not be used in lieu of currently accepted procedures such as surgery, radiation, or chemotherapy. uuid:fbb2a0d3-97d3-427b-9e89-5538b24aba60 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27779 biolink:treats MONDO:0001461 PMID:41385096 "[{""id"":""uuid:71610056-3e16-46a2-b12c-78befe601423"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2538b495-bcf5-4703-8f81-4f5f71b448c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gris-PEG ® (griseofulvin ultramicrosize) is indicated for the treatment of the following ringworm infections; tinea corporis (ringworm of the body), tinea pedis (athlete's foot), tinea cruris (ringworm of the groin and thigh), tinea barbae (barber's itch), tinea capitis (ringworm of the scalp), and tinea unguium (onychomycosis, ringworm of the nails), when caused by one or more of the following genera of fungi: Trichophyton rubrum, Trichophyton tonsurans, Trichophyton mentagrophytes, Trichophyton interdigitalis,Trichophyton verrucosum, Trichophyton megnini, Trichophyton gallinae, Trichophyton crateriform, Trichophyton sulphureum, Trichophyton schoenleini, Microsporum audouini, Microsporum canis, Microsporum gypseum and Epidermophyton floccosum . NOTE: Prior to therapy, the type of fungi responsible for the infection should be identified. The use of the drug is not justified in minor or trivial infections which will respond to topical agents alone. Griseofulvin is not effective in the following: bacterial infections, candidiasis (moniliasis), histoplasmosis, actinomycosis, sporotrichosis, chromoblastomycosis, coccidioidomycosis, North American blastomycosis, cryptococcosis (torulosis), tinea versicolor and nocardiosis. uuid:f5876aee-43db-48eb-b30d-87c50faca194 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27779 biolink:treats MONDO:0005984 PMID:41385096 "[{""id"":""uuid:2f577712-4b4b-4cfd-835e-139d5523b66b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1273cb31-bc00-47e7-b45e-ee9b157b5444"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gris-PEG ® (griseofulvin ultramicrosize) is indicated for the treatment of the following ringworm infections; tinea corporis (ringworm of the body), tinea pedis (athlete's foot), tinea cruris (ringworm of the groin and thigh), tinea barbae (barber's itch), tinea capitis (ringworm of the scalp), and tinea unguium (onychomycosis, ringworm of the nails), when caused by one or more of the following genera of fungi: Trichophyton rubrum, Trichophyton tonsurans, Trichophyton mentagrophytes, Trichophyton interdigitalis,Trichophyton verrucosum, Trichophyton megnini, Trichophyton gallinae, Trichophyton crateriform, Trichophyton sulphureum, Trichophyton schoenleini, Microsporum audouini, Microsporum canis, Microsporum gypseum and Epidermophyton floccosum . NOTE: Prior to therapy, the type of fungi responsible for the infection should be identified. The use of the drug is not justified in minor or trivial infections which will respond to topical agents alone. Griseofulvin is not effective in the following: bacterial infections, candidiasis (moniliasis), histoplasmosis, actinomycosis, sporotrichosis, chromoblastomycosis, coccidioidomycosis, North American blastomycosis, cryptococcosis (torulosis), tinea versicolor and nocardiosis. uuid:0cb5e5b1-daa0-40f0-a3c2-faf834b9ece5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27779 biolink:treats MONDO:0001405 PMID:41385096 "[{""id"":""uuid:86dc1534-dd9e-49ca-a39a-b4070602b044"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:22c31a67-f73c-43b6-a694-d686b7f51b0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gris-PEG ® (griseofulvin ultramicrosize) is indicated for the treatment of the following ringworm infections; tinea corporis (ringworm of the body), tinea pedis (athlete's foot), tinea cruris (ringworm of the groin and thigh), tinea barbae (barber's itch), tinea capitis (ringworm of the scalp), and tinea unguium (onychomycosis, ringworm of the nails), when caused by one or more of the following genera of fungi: Trichophyton rubrum, Trichophyton tonsurans, Trichophyton mentagrophytes, Trichophyton interdigitalis,Trichophyton verrucosum, Trichophyton megnini, Trichophyton gallinae, Trichophyton crateriform, Trichophyton sulphureum, Trichophyton schoenleini, Microsporum audouini, Microsporum canis, Microsporum gypseum and Epidermophyton floccosum . NOTE: Prior to therapy, the type of fungi responsible for the infection should be identified. The use of the drug is not justified in minor or trivial infections which will respond to topical agents alone. Griseofulvin is not effective in the following: bacterial infections, candidiasis (moniliasis), histoplasmosis, actinomycosis, sporotrichosis, chromoblastomycosis, coccidioidomycosis, North American blastomycosis, cryptococcosis (torulosis), tinea versicolor and nocardiosis. uuid:1cd82deb-f9c2-4c5d-961e-e3f375cba3de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27779 biolink:treats MONDO:0000242 PMID:41385096 "[{""id"":""uuid:392d5853-28a9-4c8d-95e7-e9b3b08ea70e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a453bc69-9252-4177-b596-72c407857ec1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gris-PEG ® (griseofulvin ultramicrosize) is indicated for the treatment of the following ringworm infections; tinea corporis (ringworm of the body), tinea pedis (athlete's foot), tinea cruris (ringworm of the groin and thigh), tinea barbae (barber's itch), tinea capitis (ringworm of the scalp), and tinea unguium (onychomycosis, ringworm of the nails), when caused by one or more of the following genera of fungi: Trichophyton rubrum, Trichophyton tonsurans, Trichophyton mentagrophytes, Trichophyton interdigitalis,Trichophyton verrucosum, Trichophyton megnini, Trichophyton gallinae, Trichophyton crateriform, Trichophyton sulphureum, Trichophyton schoenleini, Microsporum audouini, Microsporum canis, Microsporum gypseum and Epidermophyton floccosum . NOTE: Prior to therapy, the type of fungi responsible for the infection should be identified. The use of the drug is not justified in minor or trivial infections which will respond to topical agents alone. Griseofulvin is not effective in the following: bacterial infections, candidiasis (moniliasis), histoplasmosis, actinomycosis, sporotrichosis, chromoblastomycosis, coccidioidomycosis, North American blastomycosis, cryptococcosis (torulosis), tinea versicolor and nocardiosis. uuid:0a081ed1-dcc0-4dae-a7b0-6c351fb62805 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27779 biolink:treats MONDO:0002967 PMID:41385096 "[{""id"":""uuid:ec7ceb02-f237-4f8c-9ff3-7816b20d5a3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6dd694ab-982b-4563-a0d2-fe615e684584"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gris-PEG ® (griseofulvin ultramicrosize) is indicated for the treatment of the following ringworm infections; tinea corporis (ringworm of the body), tinea pedis (athlete's foot), tinea cruris (ringworm of the groin and thigh), tinea barbae (barber's itch), tinea capitis (ringworm of the scalp), and tinea unguium (onychomycosis, ringworm of the nails), when caused by one or more of the following genera of fungi: Trichophyton rubrum, Trichophyton tonsurans, Trichophyton mentagrophytes, Trichophyton interdigitalis,Trichophyton verrucosum, Trichophyton megnini, Trichophyton gallinae, Trichophyton crateriform, Trichophyton sulphureum, Trichophyton schoenleini, Microsporum audouini, Microsporum canis, Microsporum gypseum and Epidermophyton floccosum . NOTE: Prior to therapy, the type of fungi responsible for the infection should be identified. The use of the drug is not justified in minor or trivial infections which will respond to topical agents alone. Griseofulvin is not effective in the following: bacterial infections, candidiasis (moniliasis), histoplasmosis, actinomycosis, sporotrichosis, chromoblastomycosis, coccidioidomycosis, North American blastomycosis, cryptococcosis (torulosis), tinea versicolor and nocardiosis. uuid:dbf43801-1434-4087-8caf-c34d0c455777 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27779 biolink:treats MONDO:0001628 PMID:41385096 "[{""id"":""uuid:1296b8d6-f0c7-46cd-b3fb-ca4c74d83fd3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c0701d39-0df1-4e65-91d2-adb5b9dd7531"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gris-PEG ® (griseofulvin ultramicrosize) is indicated for the treatment of the following ringworm infections; tinea corporis (ringworm of the body), tinea pedis (athlete's foot), tinea cruris (ringworm of the groin and thigh), tinea barbae (barber's itch), tinea capitis (ringworm of the scalp), and tinea unguium (onychomycosis, ringworm of the nails), when caused by one or more of the following genera of fungi: Trichophyton rubrum, Trichophyton tonsurans, Trichophyton mentagrophytes, Trichophyton interdigitalis,Trichophyton verrucosum, Trichophyton megnini, Trichophyton gallinae, Trichophyton crateriform, Trichophyton sulphureum, Trichophyton schoenleini, Microsporum audouini, Microsporum canis, Microsporum gypseum and Epidermophyton floccosum . NOTE: Prior to therapy, the type of fungi responsible for the infection should be identified. The use of the drug is not justified in minor or trivial infections which will respond to topical agents alone. Griseofulvin is not effective in the following: bacterial infections, candidiasis (moniliasis), histoplasmosis, actinomycosis, sporotrichosis, chromoblastomycosis, coccidioidomycosis, North American blastomycosis, cryptococcosis (torulosis), tinea versicolor and nocardiosis. uuid:f90f9191-f038-43de-ad3c-03755216e770 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27779 biolink:treats MONDO:0005113 PMID:41385096 "[{""id"":""uuid:0f4ee9b7-d799-4dc8-a119-e73f2bc8b0c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:edaa0c36-7581-4bbc-8403-963fe9c4a0c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gris-PEG ® (griseofulvin ultramicrosize) is indicated for the treatment of the following ringworm infections; tinea corporis (ringworm of the body), tinea pedis (athlete's foot), tinea cruris (ringworm of the groin and thigh), tinea barbae (barber's itch), tinea capitis (ringworm of the scalp), and tinea unguium (onychomycosis, ringworm of the nails), when caused by one or more of the following genera of fungi: Trichophyton rubrum, Trichophyton tonsurans, Trichophyton mentagrophytes, Trichophyton interdigitalis,Trichophyton verrucosum, Trichophyton megnini, Trichophyton gallinae, Trichophyton crateriform, Trichophyton sulphureum, Trichophyton schoenleini, Microsporum audouini, Microsporum canis, Microsporum gypseum and Epidermophyton floccosum . NOTE: Prior to therapy, the type of fungi responsible for the infection should be identified. The use of the drug is not justified in minor or trivial infections which will respond to topical agents alone. Griseofulvin is not effective in the following: bacterial infections, candidiasis (moniliasis), histoplasmosis, actinomycosis, sporotrichosis, chromoblastomycosis, coccidioidomycosis, North American blastomycosis, cryptococcosis (torulosis), tinea versicolor and nocardiosis. uuid:e4752861-d3e9-4878-b61f-c244640d0cc9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27779 biolink:treats MONDO:0002026 PMID:41385096 "[{""id"":""uuid:a057a887-7093-4cd6-a54d-dd7b3cd29ecb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b5311c2e-ace5-418a-94fe-14dc10e65613"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gris-PEG ® (griseofulvin ultramicrosize) is indicated for the treatment of the following ringworm infections; tinea corporis (ringworm of the body), tinea pedis (athlete's foot), tinea cruris (ringworm of the groin and thigh), tinea barbae (barber's itch), tinea capitis (ringworm of the scalp), and tinea unguium (onychomycosis, ringworm of the nails), when caused by one or more of the following genera of fungi: Trichophyton rubrum, Trichophyton tonsurans, Trichophyton mentagrophytes, Trichophyton interdigitalis,Trichophyton verrucosum, Trichophyton megnini, Trichophyton gallinae, Trichophyton crateriform, Trichophyton sulphureum, Trichophyton schoenleini, Microsporum audouini, Microsporum canis, Microsporum gypseum and Epidermophyton floccosum . NOTE: Prior to therapy, the type of fungi responsible for the infection should be identified. The use of the drug is not justified in minor or trivial infections which will respond to topical agents alone. Griseofulvin is not effective in the following: bacterial infections, candidiasis (moniliasis), histoplasmosis, actinomycosis, sporotrichosis, chromoblastomycosis, coccidioidomycosis, North American blastomycosis, cryptococcosis (torulosis), tinea versicolor and nocardiosis. uuid:1736439e-1150-4085-94e4-f1928bdb7689 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27779 biolink:treats UMLS:C0343886 PMID:41385096 "[{""id"":""uuid:442d76fd-97db-400e-8ed0-31b057d5ee0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e7893908-a3de-4396-ab61-8e54518152b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gris-PEG ® (griseofulvin ultramicrosize) is indicated for the treatment of the following ringworm infections; tinea corporis (ringworm of the body), tinea pedis (athlete's foot), tinea cruris (ringworm of the groin and thigh), tinea barbae (barber's itch), tinea capitis (ringworm of the scalp), and tinea unguium (onychomycosis, ringworm of the nails), when caused by one or more of the following genera of fungi: Trichophyton rubrum, Trichophyton tonsurans, Trichophyton mentagrophytes, Trichophyton interdigitalis,Trichophyton verrucosum, Trichophyton megnini, Trichophyton gallinae, Trichophyton crateriform, Trichophyton sulphureum, Trichophyton schoenleini, Microsporum audouini, Microsporum canis, Microsporum gypseum and Epidermophyton floccosum . NOTE: Prior to therapy, the type of fungi responsible for the infection should be identified. The use of the drug is not justified in minor or trivial infections which will respond to topical agents alone. Griseofulvin is not effective in the following: bacterial infections, candidiasis (moniliasis), histoplasmosis, actinomycosis, sporotrichosis, chromoblastomycosis, coccidioidomycosis, North American blastomycosis, cryptococcosis (torulosis), tinea versicolor and nocardiosis. uuid:2b91df6f-6a75-4e24-8534-77383df5b820 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27779 biolink:treats MONDO:0018312 PMID:41385096 "[{""id"":""uuid:1325d51c-e35d-4e48-b5d1-57e01142c2d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a8b8df71-e6bf-4304-95bb-5f6782f1ea96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gris-PEG ® (griseofulvin ultramicrosize) is indicated for the treatment of the following ringworm infections; tinea corporis (ringworm of the body), tinea pedis (athlete's foot), tinea cruris (ringworm of the groin and thigh), tinea barbae (barber's itch), tinea capitis (ringworm of the scalp), and tinea unguium (onychomycosis, ringworm of the nails), when caused by one or more of the following genera of fungi: Trichophyton rubrum, Trichophyton tonsurans, Trichophyton mentagrophytes, Trichophyton interdigitalis,Trichophyton verrucosum, Trichophyton megnini, Trichophyton gallinae, Trichophyton crateriform, Trichophyton sulphureum, Trichophyton schoenleini, Microsporum audouini, Microsporum canis, Microsporum gypseum and Epidermophyton floccosum . NOTE: Prior to therapy, the type of fungi responsible for the infection should be identified. The use of the drug is not justified in minor or trivial infections which will respond to topical agents alone. Griseofulvin is not effective in the following: bacterial infections, candidiasis (moniliasis), histoplasmosis, actinomycosis, sporotrichosis, chromoblastomycosis, coccidioidomycosis, North American blastomycosis, cryptococcosis (torulosis), tinea versicolor and nocardiosis. uuid:8fbd95e5-bc8a-41aa-8de9-6fc3de682e17 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27779 biolink:treats MONDO:0005631 PMID:41385096 "[{""id"":""uuid:85fca1d7-af12-4c6f-ab3d-68e86e726330"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0728f375-c431-45fc-85f1-47a4aa0d4c7c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gris-PEG ® (griseofulvin ultramicrosize) is indicated for the treatment of the following ringworm infections; tinea corporis (ringworm of the body), tinea pedis (athlete's foot), tinea cruris (ringworm of the groin and thigh), tinea barbae (barber's itch), tinea capitis (ringworm of the scalp), and tinea unguium (onychomycosis, ringworm of the nails), when caused by one or more of the following genera of fungi: Trichophyton rubrum, Trichophyton tonsurans, Trichophyton mentagrophytes, Trichophyton interdigitalis,Trichophyton verrucosum, Trichophyton megnini, Trichophyton gallinae, Trichophyton crateriform, Trichophyton sulphureum, Trichophyton schoenleini, Microsporum audouini, Microsporum canis, Microsporum gypseum and Epidermophyton floccosum . NOTE: Prior to therapy, the type of fungi responsible for the infection should be identified. The use of the drug is not justified in minor or trivial infections which will respond to topical agents alone. Griseofulvin is not effective in the following: bacterial infections, candidiasis (moniliasis), histoplasmosis, actinomycosis, sporotrichosis, chromoblastomycosis, coccidioidomycosis, North American blastomycosis, cryptococcosis (torulosis), tinea versicolor and nocardiosis. uuid:463038d9-c9de-4e77-8505-2ec2663172bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27779 biolink:treats MONDO:0005968 PMID:41385096 "[{""id"":""uuid:15b1dbcf-6906-4e54-90c8-3d8e66aec5ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:66c48a07-74f1-4fba-baaf-4b490ca7df09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gris-PEG ® (griseofulvin ultramicrosize) is indicated for the treatment of the following ringworm infections; tinea corporis (ringworm of the body), tinea pedis (athlete's foot), tinea cruris (ringworm of the groin and thigh), tinea barbae (barber's itch), tinea capitis (ringworm of the scalp), and tinea unguium (onychomycosis, ringworm of the nails), when caused by one or more of the following genera of fungi: Trichophyton rubrum, Trichophyton tonsurans, Trichophyton mentagrophytes, Trichophyton interdigitalis,Trichophyton verrucosum, Trichophyton megnini, Trichophyton gallinae, Trichophyton crateriform, Trichophyton sulphureum, Trichophyton schoenleini, Microsporum audouini, Microsporum canis, Microsporum gypseum and Epidermophyton floccosum . NOTE: Prior to therapy, the type of fungi responsible for the infection should be identified. The use of the drug is not justified in minor or trivial infections which will respond to topical agents alone. Griseofulvin is not effective in the following: bacterial infections, candidiasis (moniliasis), histoplasmosis, actinomycosis, sporotrichosis, chromoblastomycosis, coccidioidomycosis, North American blastomycosis, cryptococcosis (torulosis), tinea versicolor and nocardiosis. uuid:2901596b-c5c3-4eec-bf14-965857012fc1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27779 biolink:treats MONDO:0015908 PMID:41385096 "[{""id"":""uuid:c85dcbfe-7edd-492c-86a5-ad1c2cfabb1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c428165f-9ddf-48df-a217-fb6fc6610674"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gris-PEG ® (griseofulvin ultramicrosize) is indicated for the treatment of the following ringworm infections; tinea corporis (ringworm of the body), tinea pedis (athlete's foot), tinea cruris (ringworm of the groin and thigh), tinea barbae (barber's itch), tinea capitis (ringworm of the scalp), and tinea unguium (onychomycosis, ringworm of the nails), when caused by one or more of the following genera of fungi: Trichophyton rubrum, Trichophyton tonsurans, Trichophyton mentagrophytes, Trichophyton interdigitalis,Trichophyton verrucosum, Trichophyton megnini, Trichophyton gallinae, Trichophyton crateriform, Trichophyton sulphureum, Trichophyton schoenleini, Microsporum audouini, Microsporum canis, Microsporum gypseum and Epidermophyton floccosum . NOTE: Prior to therapy, the type of fungi responsible for the infection should be identified. The use of the drug is not justified in minor or trivial infections which will respond to topical agents alone. Griseofulvin is not effective in the following: bacterial infections, candidiasis (moniliasis), histoplasmosis, actinomycosis, sporotrichosis, chromoblastomycosis, coccidioidomycosis, North American blastomycosis, cryptococcosis (torulosis), tinea versicolor and nocardiosis. uuid:d8ddfb86-f770-4da2-a8e4-9f215f45e5c9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27779 biolink:treats MONDO:0005706 PMID:41385096 "[{""id"":""uuid:ebbd4e2d-2957-4520-b606-75b146a6ce91"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bd1a8251-efc2-4616-a6aa-dbbe021600af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gris-PEG ® (griseofulvin ultramicrosize) is indicated for the treatment of the following ringworm infections; tinea corporis (ringworm of the body), tinea pedis (athlete's foot), tinea cruris (ringworm of the groin and thigh), tinea barbae (barber's itch), tinea capitis (ringworm of the scalp), and tinea unguium (onychomycosis, ringworm of the nails), when caused by one or more of the following genera of fungi: Trichophyton rubrum, Trichophyton tonsurans, Trichophyton mentagrophytes, Trichophyton interdigitalis,Trichophyton verrucosum, Trichophyton megnini, Trichophyton gallinae, Trichophyton crateriform, Trichophyton sulphureum, Trichophyton schoenleini, Microsporum audouini, Microsporum canis, Microsporum gypseum and Epidermophyton floccosum . NOTE: Prior to therapy, the type of fungi responsible for the infection should be identified. The use of the drug is not justified in minor or trivial infections which will respond to topical agents alone. Griseofulvin is not effective in the following: bacterial infections, candidiasis (moniliasis), histoplasmosis, actinomycosis, sporotrichosis, chromoblastomycosis, coccidioidomycosis, North American blastomycosis, cryptococcosis (torulosis), tinea versicolor and nocardiosis. uuid:dd4d6ae1-681a-449b-92a4-bc06fc57cef5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27779 biolink:treats MONDO:0005672 PMID:41385096 "[{""id"":""uuid:12a779dc-d31d-4ed1-b9e6-15bfcc11eb65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:425ee646-eb82-4c95-8a21-cd9de8bf7630"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gris-PEG ® (griseofulvin ultramicrosize) is indicated for the treatment of the following ringworm infections; tinea corporis (ringworm of the body), tinea pedis (athlete's foot), tinea cruris (ringworm of the groin and thigh), tinea barbae (barber's itch), tinea capitis (ringworm of the scalp), and tinea unguium (onychomycosis, ringworm of the nails), when caused by one or more of the following genera of fungi: Trichophyton rubrum, Trichophyton tonsurans, Trichophyton mentagrophytes, Trichophyton interdigitalis,Trichophyton verrucosum, Trichophyton megnini, Trichophyton gallinae, Trichophyton crateriform, Trichophyton sulphureum, Trichophyton schoenleini, Microsporum audouini, Microsporum canis, Microsporum gypseum and Epidermophyton floccosum . NOTE: Prior to therapy, the type of fungi responsible for the infection should be identified. The use of the drug is not justified in minor or trivial infections which will respond to topical agents alone. Griseofulvin is not effective in the following: bacterial infections, candidiasis (moniliasis), histoplasmosis, actinomycosis, sporotrichosis, chromoblastomycosis, coccidioidomycosis, North American blastomycosis, cryptococcosis (torulosis), tinea versicolor and nocardiosis. uuid:1beb7b65-f628-4b15-9439-4e5fc1e91f80 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27779 biolink:treats MONDO:0005724 PMID:41385096 "[{""id"":""uuid:1b4eaf52-c166-41ed-8975-42d77af4919f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f378899f-8948-452f-84b5-1986e663d7a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gris-PEG ® (griseofulvin ultramicrosize) is indicated for the treatment of the following ringworm infections; tinea corporis (ringworm of the body), tinea pedis (athlete's foot), tinea cruris (ringworm of the groin and thigh), tinea barbae (barber's itch), tinea capitis (ringworm of the scalp), and tinea unguium (onychomycosis, ringworm of the nails), when caused by one or more of the following genera of fungi: Trichophyton rubrum, Trichophyton tonsurans, Trichophyton mentagrophytes, Trichophyton interdigitalis,Trichophyton verrucosum, Trichophyton megnini, Trichophyton gallinae, Trichophyton crateriform, Trichophyton sulphureum, Trichophyton schoenleini, Microsporum audouini, Microsporum canis, Microsporum gypseum and Epidermophyton floccosum . NOTE: Prior to therapy, the type of fungi responsible for the infection should be identified. The use of the drug is not justified in minor or trivial infections which will respond to topical agents alone. Griseofulvin is not effective in the following: bacterial infections, candidiasis (moniliasis), histoplasmosis, actinomycosis, sporotrichosis, chromoblastomycosis, coccidioidomycosis, North American blastomycosis, cryptococcosis (torulosis), tinea versicolor and nocardiosis. uuid:a056f5bd-20b9-45a6-80d5-430efc3c3135 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27779 biolink:treats MONDO:0005915 PMID:41385096 "[{""id"":""uuid:e1522e9b-2642-475d-b373-3b000bee3bfa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:db4bdf9e-9da4-41f1-be14-829c5f8249be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gris-PEG ® (griseofulvin ultramicrosize) is indicated for the treatment of the following ringworm infections; tinea corporis (ringworm of the body), tinea pedis (athlete's foot), tinea cruris (ringworm of the groin and thigh), tinea barbae (barber's itch), tinea capitis (ringworm of the scalp), and tinea unguium (onychomycosis, ringworm of the nails), when caused by one or more of the following genera of fungi: Trichophyton rubrum, Trichophyton tonsurans, Trichophyton mentagrophytes, Trichophyton interdigitalis,Trichophyton verrucosum, Trichophyton megnini, Trichophyton gallinae, Trichophyton crateriform, Trichophyton sulphureum, Trichophyton schoenleini, Microsporum audouini, Microsporum canis, Microsporum gypseum and Epidermophyton floccosum . NOTE: Prior to therapy, the type of fungi responsible for the infection should be identified. The use of the drug is not justified in minor or trivial infections which will respond to topical agents alone. Griseofulvin is not effective in the following: bacterial infections, candidiasis (moniliasis), histoplasmosis, actinomycosis, sporotrichosis, chromoblastomycosis, coccidioidomycosis, North American blastomycosis, cryptococcosis (torulosis), tinea versicolor and nocardiosis. uuid:aabc8340-6443-4253-b263-b28eb2e8af10 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27779 biolink:treats MONDO:0017776 PMID:41385096 "[{""id"":""uuid:01ffb43f-b645-4e27-8900-dde4e1bbf150"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3121bd36-ec86-4a28-bb39-3fd472a66f97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gris-PEG ® (griseofulvin ultramicrosize) is indicated for the treatment of the following ringworm infections; tinea corporis (ringworm of the body), tinea pedis (athlete's foot), tinea cruris (ringworm of the groin and thigh), tinea barbae (barber's itch), tinea capitis (ringworm of the scalp), and tinea unguium (onychomycosis, ringworm of the nails), when caused by one or more of the following genera of fungi: Trichophyton rubrum, Trichophyton tonsurans, Trichophyton mentagrophytes, Trichophyton interdigitalis,Trichophyton verrucosum, Trichophyton megnini, Trichophyton gallinae, Trichophyton crateriform, Trichophyton sulphureum, Trichophyton schoenleini, Microsporum audouini, Microsporum canis, Microsporum gypseum and Epidermophyton floccosum . NOTE: Prior to therapy, the type of fungi responsible for the infection should be identified. The use of the drug is not justified in minor or trivial infections which will respond to topical agents alone. Griseofulvin is not effective in the following: bacterial infections, candidiasis (moniliasis), histoplasmosis, actinomycosis, sporotrichosis, chromoblastomycosis, coccidioidomycosis, North American blastomycosis, cryptococcosis (torulosis), tinea versicolor and nocardiosis. uuid:88fabb35-e913-447f-a48d-f1b11b79b672 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31348 biolink:treats UMLS:C0278480 PMID:41385096 "[{""id"":""uuid:32d5ee63-f95b-4f99-b1ff-d197d82498c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:00b9a92b-2c0c-4fa5-9c18-6d6ac3afa120"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XELODA is indicated as a single agent for adjuvant treatment in patients with Dukes' C colon cancer who have undergone complete resection of the primary tumor when treatment with fluoropyrimidine therapy alone is preferred. XELODA was non-inferior to 5-fluorouracil and leucovorin (5-FU/LV) for disease-free survival (DFS). Although neither XELODA nor combination chemotherapy prolongs overall survival (OS), combination chemotherapy has been demonstrated to improve disease-free survival compared to 5-FU/LV. Physicians should consider these results when prescribing single-agent XELODA in the adjuvant treatment of Dukes' C colon cancer. XELODA is indicated as first-line treatment of patients with metastatic colorectal carcinoma when treatment with fluoropyrimidine therapy alone is preferred. Combination chemotherapy has shown a survival benefit compared to 5-FU/LV alone. A survival benefit over 5-FU/LV has not been demonstrated with XELODA monotherapy. Use of XELODA instead of 5-FU/LV in combinations has not been adequately studied to assure safety or preservation of the survival advantage. uuid:70b0356f-1af5-45f1-80af-7b33de97286f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31348 biolink:treats UMLS:C4744564 PMID:41385096 "[{""id"":""uuid:6129d2fd-c63c-4d4c-b015-750c175b87e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6c880604-050f-40e9-934e-7b97c2e17613"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XELODA is indicated as a single agent for adjuvant treatment in patients with Dukes' C colon cancer who have undergone complete resection of the primary tumor when treatment with fluoropyrimidine therapy alone is preferred. XELODA was non-inferior to 5-fluorouracil and leucovorin (5-FU/LV) for disease-free survival (DFS). Although neither XELODA nor combination chemotherapy prolongs overall survival (OS), combination chemotherapy has been demonstrated to improve disease-free survival compared to 5-FU/LV. Physicians should consider these results when prescribing single-agent XELODA in the adjuvant treatment of Dukes' C colon cancer. XELODA is indicated as first-line treatment of patients with metastatic colorectal carcinoma when treatment with fluoropyrimidine therapy alone is preferred. Combination chemotherapy has shown a survival benefit compared to 5-FU/LV alone. A survival benefit over 5-FU/LV has not been demonstrated with XELODA monotherapy. Use of XELODA instead of 5-FU/LV in combinations has not been adequately studied to assure safety or preservation of the survival advantage. uuid:5341b9d7-ca88-46ee-ad2f-9e620a4c12fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9674 biolink:treats MONDO:0013600 PMID:41385096 "[{""id"":""uuid:72a72c5d-459f-4bc2-ba50-97375084631a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dcdafa9b-a8ed-48c1-a4cf-1d292e76eac9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Triazolam is indicated for the short-term treatment of insomnia (generally 7–10 days). Use for more than 2–3 weeks requires complete reevaluation of the patient (see WARNINGS ). Prescriptions for triazolam should be written for short-term use (7–10 days) and it should not be prescribed in quantities exceeding a 1-month supply. uuid:9cc540bb-e391-4b8c-9f54-50a83cc48d63 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28077 biolink:treats MONDO:0018076 PMID:41385096 "[{""id"":""uuid:43c70588-be85-42f4-b2c0-6c73a86698bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:befa5fa8-1d25-4d3e-aee5-13f61ee68bb8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In the treatment of both tuberculosis and the meningococcal carrier state, the small number of resistant cells present within large populations of susceptible cells can rapidly become the predominant type. Bacteriologic cultures should be obtained before the start of therapy to confirm the susceptibility of the organism to rifampin and they should be repeated throughout therapy to monitor the response to treatment. Since resistance can emerge rapidly, susceptibility tests should be performed in the event of persistent positive cultures during the course of treatment. If test results show resistance to rifampin and the patient is not responding to therapy, the drug regimen should be modified. uuid:7eb6ffd4-796b-43fd-a3ad-ca778e7edfe6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9313 biolink:treats MONDO:0005412 PMID:41385096 "[{""id"":""uuid:4e8cdea5-2014-478a-bcd0-e11f99425b83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1bfef8c4-080b-4754-89d5-9c5c9c7daeec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sucralfate is indicated in: Short-term treatment (up to 8 weeks) of active duodenal ulcer. While healing with sucralfate may occur during the first week or two, treatment should be continued for 4 to 8 weeks unless healing has been demonstrated by x-ray or endoscopic examination. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. UNII:XX73205DH5 uuid:d3dc7ac5-a28e-46ef-9ed7-4d9157c13cdc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63581 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:5e15b6b6-349a-482d-9c6b-943274878830"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:627a519c-00cb-4a66-a769-68c9ea11dce7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Stavudine capsules , in combination with other antiretroviral agents, is indicated for the treatment of HIV-1 infection (see Clinical Studies ). uuid:3c339803-dad4-4aa7-936f-21d501c8959f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5384 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:f1666560-c899-4ba4-b0cb-b64e55eabdcf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ff5c46ca-a6bd-4e44-a04a-2ade70c8e7c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Glipizide Tablets USP are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. uuid:82f135e0-f9f6-4453-b235-7d2cc2fed5a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4877 biolink:treats MONDO:0006052 PMID:41385096 "[{""id"":""uuid:66026d57-2a31-4841-9d75-6d04f973b8f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b6dc174b-03db-47cf-a7ad-f4afba7cc60f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ethambutol Hydrochloride Tablets are indicated for the treatment of pulmonary tuberculosis. It should not be used as the sole antituberculous drug, but should be used in conjunction with at least one other antituberculous drug. Selection of the companion drug should be based on clinical experience, considerations of comparative safety and appropriate in vitro susceptibility studies. In patients who have not received previous antituberculous therapy, i.e., initial treatment, the most frequently used regimens have been the following: Ethambutol plus isoniazid Ethambutol plus isoniazid plus streptomycin. In patients who have received previous antituberculous therapy, mycobacterial resistance to other drugs used in initial therapy is frequent. Consequently, in such retreatment patients, ethambutol should be combined with at least one of the second line drugs not previously administered to the patient and to which bacterial susceptibility has been indicated by appropriate in vitro studies. Antituberculous drugs used with ethambutol have included cycloserine, ethionamide, pyrazinamide, viomycin, and other drugs. Isoniazid, aminosalicylic acid, and streptomycin have also been used in multiple drug regimens. Alternating drug regimens have also been utilized. uuid:0d4c87fc-3502-45c6-a333-0ba27807febe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6950 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:7dd89c91-970c-4305-9ec8-0b88c00cf1d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e4e30d19-5a4e-4bda-b493-9c5e055b2f0c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mirtazapine tablets, USP are indicated for the treatment of major depressive disorder. The efficacy of mirtazapine tablets, USP in the treatment of major depressive disorder was established in six week controlled trials of outpatients whose diagnoses corresponded most closely to the Diagnostic and Statistical Manual of Mental Disorders - 3rd edition (DSM-lll) category of major depressive disorder (see CLINICAL PHARMACOLOGY ). A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. The effectiveness of mirtazapine in hospitalized depressed patients has not been adequately studied. The efficacy of mirtazapine, USP in maintaining a response in patients with major depressive disorder for up to 40 weeks following 8–12 weeks of initial open-label treatment was demonstrated in a placebo-controlled trial. Nevertheless, the physician who elects to use mirtazapine, USP for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see CLINICAL PHARMACOLOGY ). uuid:146c36e2-afab-479a-b563-94ac41abbafc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats MONDO:0005416 PMID:41385096 "[{""id"":""uuid:21d97578-62ce-4004-8c63-65bc0d7e63fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6047a614-1f90-41a4-913d-082f141fb3fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Voltaren® Gel is indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment, such as the knees and those of the hands. Voltaren® Gel has not been evaluated for use on the spine, hip, or shoulder. uuid:076f83a4-200d-4ac1-b331-7e2259276a8b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats MONDO:0006632 PMID:41385096 "[{""id"":""uuid:2d739582-c0a6-4372-8fe1-af71725d2658"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4f365e9f-8c99-4f70-a0a9-b2bd7fd2ba35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Voltaren® Gel is indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment, such as the knees and those of the hands. Voltaren® Gel has not been evaluated for use on the spine, hip, or shoulder. uuid:ad6a0088-bec5-4687-89b1-ae4193b66cad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8871 biolink:treats MONDO:0005090 PMID:41385096 "[{""id"":""uuid:8ab51821-1072-4776-8641-170d22a964a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ce77ab0a-59fa-45da-b903-76129815aa28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0d5a845d-506e-40c8-b558-d02898aed6ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/okedi""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Risperidone is an atypical antipsychotic agent indicated for: Treatment of schizophrenia in adults ( 1.1 ) Alone, or in combination with lithium or valproate, for the short-term treatment of acute manic or mixed episodes associated with Bipolar I Disorder in adults ( 1.2 ) Treatment of irritability associated with autistic disorder in children and adolescents aged 5 to 16 years ( 1.3 )|[EMA] Treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone. uuid:531c389d-1391-43cb-8fa4-b7dc6a88a967 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8871 biolink:treats MONDO:0001866 PMID:41385096 "[{""id"":""uuid:4d48e1f1-91bb-455e-97ab-3221a1552661"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5b13f568-a821-44b3-b096-be1c4d9ee316"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Risperidone is an atypical antipsychotic agent indicated for: Treatment of schizophrenia in adults ( 1.1 ) Alone, or in combination with lithium or valproate, for the short-term treatment of acute manic or mixed episodes associated with Bipolar I Disorder in adults ( 1.2 ) Treatment of irritability associated with autistic disorder in children and adolescents aged 5 to 16 years ( 1.3 ) uuid:54fdb624-c337-49d9-825e-126b4b4944e1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8871 biolink:treats MONDO:0005258 PMID:41385096 "[{""id"":""uuid:d7f119f4-51b4-4e91-a90f-002fa4d50650"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:12f7c72e-aab1-4e61-b843-20f7773244de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Risperidone is an atypical antipsychotic agent indicated for: Treatment of schizophrenia in adults ( 1.1 ) Alone, or in combination with lithium or valproate, for the short-term treatment of acute manic or mixed episodes associated with Bipolar I Disorder in adults ( 1.2 ) Treatment of irritability associated with autistic disorder in children and adolescents aged 5 to 16 years ( 1.3 ) uuid:1e371635-c840-40d2-8f8d-c295b6234a0f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats HP:0100735 PMID:41385096 "[{""id"":""uuid:98d9df12-f9e3-446f-aaf8-05a0f82dd2d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c4bc2718-e008-4c43-845c-ea7e9e807049"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Propranolol hydrochloride tablets are indicated in the management of hypertension. They may be used alone or used in combination with other antihypertensive agents, particularly a thiazide diuretic. Propranolol hydrochloride tablets are not indicated in the management of hypertensive emergencies. uuid:c9cfc10c-382c-4605-a5f9-2ba8f2034782 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1163424 biolink:treats MONDO:0006668 PMID:41385096 "[{""id"":""uuid:4106623e-8c59-47e6-be70-63dd7f322a4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0c6380eb-7a7f-4905-a33e-19302e539020"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Neomycin and Polymyxin B Sulfates and Hydrocortisone Ophthalmic Suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye (See CLINICAL PHARMACOLOGY: Microbiology ). The particular anti-infective drugs in this product are active against the following common bacterial eye pathogens: Staphylococcus aureus , Escherichia coli , Haemophilus influenzae , Klebsiella/Enterobacter species, Neisseria species, and Pseudomonas aeruginosa . The product does not provide adequate coverage against Serratia marcescens and streptococci, including Streptococcus pneumoniae . uuid:501b342c-ec62-45cd-88c0-b0e1bfe34e4e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1163424 biolink:treats UMLS:C0008690 PMID:41385096 "[{""id"":""uuid:b3dd73af-7aef-4d00-b83b-71ddb03c8af3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9c0d5154-7ab9-4085-8b4d-201b8f9428db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Neomycin and Polymyxin B Sulfates and Hydrocortisone Ophthalmic Suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye (See CLINICAL PHARMACOLOGY: Microbiology ). The particular anti-infective drugs in this product are active against the following common bacterial eye pathogens: Staphylococcus aureus , Escherichia coli , Haemophilus influenzae , Klebsiella/Enterobacter species, Neisseria species, and Pseudomonas aeruginosa . The product does not provide adequate coverage against Serratia marcescens and streptococci, including Streptococcus pneumoniae . uuid:ebaea54b-5222-48f5-8f44-88be7be85d44 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1163424 biolink:treats UMLS:C0339289 PMID:41385096 "[{""id"":""uuid:42a50d95-c8f9-47d7-b3a0-ca8bd19cb207"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d0ce2d26-0a99-4f7d-a785-7fabe2c66bab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Neomycin and Polymyxin B Sulfates and Hydrocortisone Ophthalmic Suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye (See CLINICAL PHARMACOLOGY: Microbiology ). The particular anti-infective drugs in this product are active against the following common bacterial eye pathogens: Staphylococcus aureus , Escherichia coli , Haemophilus influenzae , Klebsiella/Enterobacter species, Neisseria species, and Pseudomonas aeruginosa . The product does not provide adequate coverage against Serratia marcescens and streptococci, including Streptococcus pneumoniae . uuid:4963dcae-be15-4878-aee4-67788e1efaa6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7986 biolink:treats MONDO:0005295 PMID:41385096 "[{""id"":""uuid:2cd17f2f-5ffa-4717-9bf1-df4a0f467377"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e89b424c-655b-40b8-bd58-a2ca22a80fe9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pentoxifylline extended-release Tablet is indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. Pentoxifylline extended-release Tablet can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease. uuid:c40685e9-6945-4e05-a3e0-ca99aac8106a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7986 biolink:treats MONDO:0005294 PMID:41385096 "[{""id"":""uuid:f998dd27-80f4-41ee-ab98-38d588401fd4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:01c18554-2ed7-4c75-9930-b82d43cd681f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pentoxifylline extended-release Tablet is indicated for the treatment of patients with intermittent claudication on the basis of chronic occlusive arterial disease of the limbs. Pentoxifylline extended-release Tablet can improve function and symptoms but is not intended to replace more definitive therapy, such as surgical bypass, or removal of arterial obstructions when treating peripheral vascular disease. uuid:89cdb011-8720-4e04-b9a6-a4bad03f2667 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5613 biolink:treats MONDO:0005485 PMID:41385096 "[{""id"":""uuid:b7b4e5da-be10-4960-85e2-a607a901e131"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8b2a96a1-4ca7-4f8a-b0e7-08f1a4ff6ecd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Haloperidol is indicated for use in the management of manifestations of psychotic disorders. Haloperidol is indicated for the control of tics and vocal utterances of Tourette’s Disorder in children and adults. Haloperidol is effective for the treatment of severe behavior problems in children of combative, explosive hyperexcitability (which cannot be accounted for by immediate provocation). Haloperidol is also effective in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance. Haloperidol should be reserved for these two groups of children only after failure to respond to psychotherapy or medications other than antipsychotics. uuid:5c69b979-c3e1-4884-b5ec-de85a9932678 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5613 biolink:treats MONDO:0007661 PMID:41385096 "[{""id"":""uuid:4d976b4d-684c-421c-82da-d776032fd36f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9efe1117-9ea8-47f4-92e9-3f36ab51a879"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Haloperidol is indicated for use in the management of manifestations of psychotic disorders. Haloperidol is indicated for the control of tics and vocal utterances of Tourette’s Disorder in children and adults. Haloperidol is effective for the treatment of severe behavior problems in children of combative, explosive hyperexcitability (which cannot be accounted for by immediate provocation). Haloperidol is also effective in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance. Haloperidol should be reserved for these two groups of children only after failure to respond to psychotherapy or medications other than antipsychotics. uuid:ca25e34e-398d-4030-8fc8-b5226c18ed40 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5613 biolink:treats HP:0000718 PMID:41385096 "[{""id"":""uuid:3a49d167-d366-4f94-89bb-2eff5d430ba3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:981fdc7f-9a5d-415f-ad7c-45c723e0b7af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Haloperidol is indicated for use in the management of manifestations of psychotic disorders. Haloperidol is indicated for the control of tics and vocal utterances of Tourette’s Disorder in children and adults. Haloperidol is effective for the treatment of severe behavior problems in children of combative, explosive hyperexcitability (which cannot be accounted for by immediate provocation). Haloperidol is also effective in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance. Haloperidol should be reserved for these two groups of children only after failure to respond to psychotherapy or medications other than antipsychotics. uuid:1b24efaa-6252-4cf1-86e3-8ba947722c9a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5613 biolink:treats MONDO:0005352 PMID:41385096 "[{""id"":""uuid:99aac2de-629e-403f-81d3-8e75c846f83a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a63b0bc0-2d69-47ed-9f3a-decb43b440ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Haloperidol is indicated for use in the management of manifestations of psychotic disorders. Haloperidol is indicated for the control of tics and vocal utterances of Tourette’s Disorder in children and adults. Haloperidol is effective for the treatment of severe behavior problems in children of combative, explosive hyperexcitability (which cannot be accounted for by immediate provocation). Haloperidol is also effective in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance. Haloperidol should be reserved for these two groups of children only after failure to respond to psychotherapy or medications other than antipsychotics. uuid:ebf69d44-4787-4e6a-b765-ec6843b5f1c9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7735 biolink:treats MONDO:0005090 PMID:41385096 "[{""id"":""uuid:107fe6a9-62d4-4894-8649-78a54520c140"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4ca14adb-1340-4cbd-9587-0bb7ca8b0210"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:881e8a00-2786-408b-932d-bd29a6dca6b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/olanzapine-teva""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Schizophrenia Oral ZYPREXA is indicated for acute and maintenance treatment of Schizophrenia in adults. 1.2 Bipolar I Disorder (Manic or Mixed Episodes) Monotherapy — Oral ZYPREXA is indicated for acute treatment of manic or mixed episodes associated with Bipolar I Disorder (monotherapy and in combination with lithium or valproate) and maintenance treatment of Bipolar I Disorder (monotherapy) in adults. Combination Therapy — The combination of oral ZYPREXA with lithium or valproate is indicated for the short-term treatment of acute manic or mixed episodes associated with Bipolar I Disorder in adults [see Clinical Studies ( 14.2 )] . 1.3 ZYPREXA IntraMuscular: Agitation Associated with Schizophrenia and Bipolar I Mania ZYPREXA IntraMuscular is indicated for the treatment of acute agitation associated with Schizophrenia and Bipolar I Mania. “Psychomotor agitation” is defined in DSM-IV as “excessive motor activity associated with a feeling of inner tension.” Patients experiencing agitation often manifest behaviors that interfere with their diagnosis and care, e.g., threatening behaviors, escalating or urgently distressing behavior, or self-exhausting behavior, leading clinicians to the use of intramuscular antipsychotic medications to achieve immediate control of the agitation [see Clinical Studies ( 14.3 )] . 1.4 ZYPREXA and Fluoxetine in Combination: Depressive Episodes Associated with Bipolar I Disorder When using ZYPREXA and fluoxetine in combination, also refer to the Clinical Studies section of the package insert for Symbyax. Oral ZYPREXA and fluoxetine in combination is indicated for the acute treatment of depressive episodes associated with Bipolar I Disorder in adult patients. ZYPREXA monotherapy is not indicated for the treatment of depressive episodes associated with Bipolar I Disorder. 1.5 ZYPREXA and Fluoxetine in Combination: Treatment Resistant Depression When using ZYPREXA and fluoxetine in combination, also refer to the Indications and Usage section of the package insert for Symbyax. Oral ZYPREXA and fluoxetine in combination is indicated for the acute treatment of treatment resistant depression (Major Depressive Disorder in adult patients who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode). ZYPREXA monotherapy is not indicated for the treatment of treatment resistant depression.|[EMA] AdultsOlanzapine is indicated for the treatment of schizophrenia.Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Olanzapine is indicated for the treatment of moderate to severe manic episode.In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder. uuid:71c0fcba-5fb9-479c-be32-fc494121aed8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7735 biolink:treats MONDO:0001866 PMID:41385096 "[{""id"":""uuid:5de4cb42-0f5d-4c1b-822d-0a030fbfcb9d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bd85a85c-c79b-4e87-8924-fcf6b152ffac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Schizophrenia Oral ZYPREXA is indicated for acute and maintenance treatment of Schizophrenia in adults. 1.2 Bipolar I Disorder (Manic or Mixed Episodes) Monotherapy — Oral ZYPREXA is indicated for acute treatment of manic or mixed episodes associated with Bipolar I Disorder (monotherapy and in combination with lithium or valproate) and maintenance treatment of Bipolar I Disorder (monotherapy) in adults. Combination Therapy — The combination of oral ZYPREXA with lithium or valproate is indicated for the short-term treatment of acute manic or mixed episodes associated with Bipolar I Disorder in adults [see Clinical Studies ( 14.2 )] . 1.3 ZYPREXA IntraMuscular: Agitation Associated with Schizophrenia and Bipolar I Mania ZYPREXA IntraMuscular is indicated for the treatment of acute agitation associated with Schizophrenia and Bipolar I Mania. “Psychomotor agitation” is defined in DSM-IV as “excessive motor activity associated with a feeling of inner tension.” Patients experiencing agitation often manifest behaviors that interfere with their diagnosis and care, e.g., threatening behaviors, escalating or urgently distressing behavior, or self-exhausting behavior, leading clinicians to the use of intramuscular antipsychotic medications to achieve immediate control of the agitation [see Clinical Studies ( 14.3 )] . 1.4 ZYPREXA and Fluoxetine in Combination: Depressive Episodes Associated with Bipolar I Disorder When using ZYPREXA and fluoxetine in combination, also refer to the Clinical Studies section of the package insert for Symbyax. Oral ZYPREXA and fluoxetine in combination is indicated for the acute treatment of depressive episodes associated with Bipolar I Disorder in adult patients. ZYPREXA monotherapy is not indicated for the treatment of depressive episodes associated with Bipolar I Disorder. 1.5 ZYPREXA and Fluoxetine in Combination: Treatment Resistant Depression When using ZYPREXA and fluoxetine in combination, also refer to the Indications and Usage section of the package insert for Symbyax. Oral ZYPREXA and fluoxetine in combination is indicated for the acute treatment of treatment resistant depression (Major Depressive Disorder in adult patients who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode). ZYPREXA monotherapy is not indicated for the treatment of treatment resistant depression. uuid:50ba6373-2a33-4f2f-b2e4-4dcb783c607a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7735 biolink:treats HP:0100754 PMID:41385096 "[{""id"":""uuid:f7e4eadd-61de-4d23-9ee6-623f1940f38d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:cc95f76c-09bb-4350-abf1-8736ac6403a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1dc64e26-6d21-4445-8389-3554c9b9f664"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/olanzapine-teva""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Schizophrenia Oral ZYPREXA is indicated for acute and maintenance treatment of Schizophrenia in adults. 1.2 Bipolar I Disorder (Manic or Mixed Episodes) Monotherapy — Oral ZYPREXA is indicated for acute treatment of manic or mixed episodes associated with Bipolar I Disorder (monotherapy and in combination with lithium or valproate) and maintenance treatment of Bipolar I Disorder (monotherapy) in adults. Combination Therapy — The combination of oral ZYPREXA with lithium or valproate is indicated for the short-term treatment of acute manic or mixed episodes associated with Bipolar I Disorder in adults [see Clinical Studies ( 14.2 )] . 1.3 ZYPREXA IntraMuscular: Agitation Associated with Schizophrenia and Bipolar I Mania ZYPREXA IntraMuscular is indicated for the treatment of acute agitation associated with Schizophrenia and Bipolar I Mania. “Psychomotor agitation” is defined in DSM-IV as “excessive motor activity associated with a feeling of inner tension.” Patients experiencing agitation often manifest behaviors that interfere with their diagnosis and care, e.g., threatening behaviors, escalating or urgently distressing behavior, or self-exhausting behavior, leading clinicians to the use of intramuscular antipsychotic medications to achieve immediate control of the agitation [see Clinical Studies ( 14.3 )] . 1.4 ZYPREXA and Fluoxetine in Combination: Depressive Episodes Associated with Bipolar I Disorder When using ZYPREXA and fluoxetine in combination, also refer to the Clinical Studies section of the package insert for Symbyax. Oral ZYPREXA and fluoxetine in combination is indicated for the acute treatment of depressive episodes associated with Bipolar I Disorder in adult patients. ZYPREXA monotherapy is not indicated for the treatment of depressive episodes associated with Bipolar I Disorder. 1.5 ZYPREXA and Fluoxetine in Combination: Treatment Resistant Depression When using ZYPREXA and fluoxetine in combination, also refer to the Indications and Usage section of the package insert for Symbyax. Oral ZYPREXA and fluoxetine in combination is indicated for the acute treatment of treatment resistant depression (Major Depressive Disorder in adult patients who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode). ZYPREXA monotherapy is not indicated for the treatment of treatment resistant depression.|[EMA] AdultsOlanzapine is indicated for the treatment of schizophrenia.Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Olanzapine is indicated for the treatment of moderate to severe manic episode.In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder. uuid:9b06ad15-9237-444e-a892-9c746ab68bd3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7735 biolink:treats UMLS:C2063866 PMID:41385096 "[{""id"":""uuid:a0408ef9-327d-4e37-b4eb-d44798e77ee2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:893c3c04-b8da-4a93-b6e6-95466e41ba2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Schizophrenia Oral ZYPREXA is indicated for acute and maintenance treatment of Schizophrenia in adults. 1.2 Bipolar I Disorder (Manic or Mixed Episodes) Monotherapy — Oral ZYPREXA is indicated for acute treatment of manic or mixed episodes associated with Bipolar I Disorder (monotherapy and in combination with lithium or valproate) and maintenance treatment of Bipolar I Disorder (monotherapy) in adults. Combination Therapy — The combination of oral ZYPREXA with lithium or valproate is indicated for the short-term treatment of acute manic or mixed episodes associated with Bipolar I Disorder in adults [see Clinical Studies ( 14.2 )] . 1.3 ZYPREXA IntraMuscular: Agitation Associated with Schizophrenia and Bipolar I Mania ZYPREXA IntraMuscular is indicated for the treatment of acute agitation associated with Schizophrenia and Bipolar I Mania. “Psychomotor agitation” is defined in DSM-IV as “excessive motor activity associated with a feeling of inner tension.” Patients experiencing agitation often manifest behaviors that interfere with their diagnosis and care, e.g., threatening behaviors, escalating or urgently distressing behavior, or self-exhausting behavior, leading clinicians to the use of intramuscular antipsychotic medications to achieve immediate control of the agitation [see Clinical Studies ( 14.3 )] . 1.4 ZYPREXA and Fluoxetine in Combination: Depressive Episodes Associated with Bipolar I Disorder When using ZYPREXA and fluoxetine in combination, also refer to the Clinical Studies section of the package insert for Symbyax. Oral ZYPREXA and fluoxetine in combination is indicated for the acute treatment of depressive episodes associated with Bipolar I Disorder in adult patients. ZYPREXA monotherapy is not indicated for the treatment of depressive episodes associated with Bipolar I Disorder. 1.5 ZYPREXA and Fluoxetine in Combination: Treatment Resistant Depression When using ZYPREXA and fluoxetine in combination, also refer to the Indications and Usage section of the package insert for Symbyax. Oral ZYPREXA and fluoxetine in combination is indicated for the acute treatment of treatment resistant depression (Major Depressive Disorder in adult patients who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode). ZYPREXA monotherapy is not indicated for the treatment of treatment resistant depression. uuid:eb900f64-5af5-4def-beb6-eaa2d76a0610 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7735 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:2fc9d75c-f90e-4c6a-ac51-bc79eb61f221"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9f191589-7288-49ca-82b0-7dc15b011e28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Schizophrenia Oral ZYPREXA is indicated for acute and maintenance treatment of Schizophrenia in adults. 1.2 Bipolar I Disorder (Manic or Mixed Episodes) Monotherapy — Oral ZYPREXA is indicated for acute treatment of manic or mixed episodes associated with Bipolar I Disorder (monotherapy and in combination with lithium or valproate) and maintenance treatment of Bipolar I Disorder (monotherapy) in adults. Combination Therapy — The combination of oral ZYPREXA with lithium or valproate is indicated for the short-term treatment of acute manic or mixed episodes associated with Bipolar I Disorder in adults [see Clinical Studies ( 14.2 )] . 1.3 ZYPREXA IntraMuscular: Agitation Associated with Schizophrenia and Bipolar I Mania ZYPREXA IntraMuscular is indicated for the treatment of acute agitation associated with Schizophrenia and Bipolar I Mania. “Psychomotor agitation” is defined in DSM-IV as “excessive motor activity associated with a feeling of inner tension.” Patients experiencing agitation often manifest behaviors that interfere with their diagnosis and care, e.g., threatening behaviors, escalating or urgently distressing behavior, or self-exhausting behavior, leading clinicians to the use of intramuscular antipsychotic medications to achieve immediate control of the agitation [see Clinical Studies ( 14.3 )] . 1.4 ZYPREXA and Fluoxetine in Combination: Depressive Episodes Associated with Bipolar I Disorder When using ZYPREXA and fluoxetine in combination, also refer to the Clinical Studies section of the package insert for Symbyax. Oral ZYPREXA and fluoxetine in combination is indicated for the acute treatment of depressive episodes associated with Bipolar I Disorder in adult patients. ZYPREXA monotherapy is not indicated for the treatment of depressive episodes associated with Bipolar I Disorder. 1.5 ZYPREXA and Fluoxetine in Combination: Treatment Resistant Depression When using ZYPREXA and fluoxetine in combination, also refer to the Indications and Usage section of the package insert for Symbyax. Oral ZYPREXA and fluoxetine in combination is indicated for the acute treatment of treatment resistant depression (Major Depressive Disorder in adult patients who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode). ZYPREXA monotherapy is not indicated for the treatment of treatment resistant depression. uuid:80d55c34-25db-4288-ade0-4e8987778f93 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2469 biolink:treats MONDO:0005366 PMID:41385096 "[{""id"":""uuid:77a50e8c-88e7-48b4-bbbf-57400ea7e4fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ee52e5e4-2263-4320-8677-473814ece640"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] HEPSERA is indicated for the treatment of chronic hepatitis B in patients 12 years of age and older with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. This indication is based on histological, virological, biochemical, and serological responses in adult patients with HBeAg+ and HBeAg- chronic hepatitis B with compensated liver function, and with clinical evidence of lamivudine-resistant hepatitis B virus with either compensated or decompensated liver function. For patients 12 to <18 years of age, the indication is based on virological and biochemical responses in patients with HBeAg+ chronic hepatitis B virus infection with compensated liver function. uuid:fe49a068-889f-40a5-867f-b6b5a99fe424 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:36795 biolink:treats UMLS:C1963916 PMID:41385096 "[{""id"":""uuid:c49de58b-3e72-4fa1-ad7b-3707207808f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:933836c4-73ea-405a-85fa-dbe6e1bceca1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cymbalta ® is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for: Major Depressive Disorder (MDD) ( 1.1 ) Efficacy was established in 4 short-term and one maintenance trial in adults ( 14.1 ). Generalized Anxiety Disorder (GAD) ( 1.2 ) Efficacy was established in 3 short-term and one maintenance trial in adults ( 14.2 ). Diabetic Peripheral Neuropathic Pain (DPNP) ( 1.3 ) Fibromyalgia (FM) ( 1.4 ) uuid:817d43d5-1453-47b5-b755-270667aae69c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134991 biolink:treats MONDO:0005475 PMID:41385096 "[{""id"":""uuid:23b5ad5f-57d0-47e9-867c-018d3dc34e7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ca55e082-ac8b-4aa8-a3ad-63fbd06c71ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FROVA is indicated for the acute treatment of migraine attacks with or without aura in adults. FROVA is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS ). The safety and effectiveness of FROVA have not been established for cluster headache, which is present in an older, predominately male, population. uuid:d130d20f-e93d-439b-8f65-dc4f33258ee4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134991 biolink:treats MONDO:0100431 PMID:41385096 "[{""id"":""uuid:41a189cc-d264-4f53-b33a-54146f588beb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e9c9bf83-bbdf-4eec-9721-38eba4a78311"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FROVA is indicated for the acute treatment of migraine attacks with or without aura in adults. FROVA is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS ). The safety and effectiveness of FROVA have not been established for cluster headache, which is present in an older, predominately male, population. uuid:70ff6e4e-2726-40c1-a598-1fb05c5b358f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134991 biolink:treats MONDO:0018925 PMID:41385096 "[{""id"":""uuid:dc8a5821-ba7d-42fd-8a85-57a0c6028bfc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3cc432a3-a165-4e76-a957-6d37ac9f852b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FROVA is indicated for the acute treatment of migraine attacks with or without aura in adults. FROVA is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS ). The safety and effectiveness of FROVA have not been established for cluster headache, which is present in an older, predominately male, population. uuid:288eff62-5bf1-45fd-9bfc-9e6ec1710430 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134991 biolink:treats MONDO:0043219 PMID:41385096 "[{""id"":""uuid:ae609eac-4c32-4551-803b-d9d57b892925"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:477486d7-5f51-4443-aeb7-469775d72d4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FROVA is indicated for the acute treatment of migraine attacks with or without aura in adults. FROVA is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS ). The safety and effectiveness of FROVA have not been established for cluster headache, which is present in an older, predominately male, population. uuid:60f2d0af-e085-4680-980b-d26d07f2f121 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134991 biolink:treats MONDO:0043537 PMID:41385096 "[{""id"":""uuid:2362454c-5009-4e41-a535-37aa32607897"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f93e7d73-5d6d-41e1-bde0-b01eab397a24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FROVA is indicated for the acute treatment of migraine attacks with or without aura in adults. FROVA is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS ). The safety and effectiveness of FROVA have not been established for cluster headache, which is present in an older, predominately male, population. uuid:c7306844-77c1-4ffd-8bf0-45f3e5811a70 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31859 biolink:treats MONDO:0021107 PMID:41385096 "[{""id"":""uuid:ec6a0280-56dd-4595-90b0-20176a2baad7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:087d4026-2187-46c5-967d-20e6cad23134"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f094c090-ea08-4b58-b98e-51c7c875c96a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROVIGIL is indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome, and shift work sleep disorder. In OSAHS, PROVIGIL is indicated as an adjunct to standard treatment(s) for the underlying obstruction. If continuous positive airway pressure (CPAP) is the treatment of choice for a patient, a maximal effort to treat with CPAP for an adequate period of time should be made prior to initiating PROVIGIL. If PROVIGIL is used adjunctively with CPAP, the encouragement of and periodic assessment of CPAP compliance is necessary. In all cases, careful attention to the diagnosis and treatment of the underlying sleep disorder(s) is of utmost importance. Prescribers should be aware that some patients may have more than one sleep disorder contributing to their excessive sleepiness. The effectiveness of modafinil in long-term use (greater than 9 weeks in Narcolepsy clinical trials and 12 weeks in OSAHS and SWSD clinical trials) has not been systematically evaluated in placebo-controlled trials. The physician who elects to prescribe PROVIGIL for an extended time in patients with Narcolepsy, OSAHS, or SWSD should periodically reevaluate long-term usefulness for the individual patient.|[PMDA] Drugs containing a new active ingredient indicated for treatment of excessive daytime sleepiness associated with narcolepsy. [Orphan Drug] uuid:8ee28683-6ec3-403c-970c-64fa429e1fc5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31859 biolink:treats MONDO:0007147 PMID:41385096 "[{""id"":""uuid:b208069a-b8ec-40fb-9ac1-7b45419657ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7b532c68-23ec-46c8-9d4d-c5fb69ee6db8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:18efa83e-d02a-4e34-adb0-ed48778da9d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROVIGIL is indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome, and shift work sleep disorder. In OSAHS, PROVIGIL is indicated as an adjunct to standard treatment(s) for the underlying obstruction. If continuous positive airway pressure (CPAP) is the treatment of choice for a patient, a maximal effort to treat with CPAP for an adequate period of time should be made prior to initiating PROVIGIL. If PROVIGIL is used adjunctively with CPAP, the encouragement of and periodic assessment of CPAP compliance is necessary. In all cases, careful attention to the diagnosis and treatment of the underlying sleep disorder(s) is of utmost importance. Prescribers should be aware that some patients may have more than one sleep disorder contributing to their excessive sleepiness. The effectiveness of modafinil in long-term use (greater than 9 weeks in Narcolepsy clinical trials and 12 weeks in OSAHS and SWSD clinical trials) has not been systematically evaluated in placebo-controlled trials. The physician who elects to prescribe PROVIGIL for an extended time in patients with Narcolepsy, OSAHS, or SWSD should periodically reevaluate long-term usefulness for the individual patient.|[PMDA] A drug with a new additional indication for the treatment of excessive daytime sleepiness in patients with obstructive sleep apnea syndrome who receive treatment of airway obstruction with continuous positive airway pressure (CPAP) therapy, etc. uuid:ba0ab83e-38dc-47f8-9c6e-c76cec00ee69 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31859 biolink:treats MONDO:0024382 PMID:41385096 "[{""id"":""uuid:26e139f1-40ec-4a4b-8178-0cb30c73f069"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3fcd7bc0-c487-4052-a641-14fd926ee174"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROVIGIL is indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea/hypopnea syndrome, and shift work sleep disorder. In OSAHS, PROVIGIL is indicated as an adjunct to standard treatment(s) for the underlying obstruction. If continuous positive airway pressure (CPAP) is the treatment of choice for a patient, a maximal effort to treat with CPAP for an adequate period of time should be made prior to initiating PROVIGIL. If PROVIGIL is used adjunctively with CPAP, the encouragement of and periodic assessment of CPAP compliance is necessary. In all cases, careful attention to the diagnosis and treatment of the underlying sleep disorder(s) is of utmost importance. Prescribers should be aware that some patients may have more than one sleep disorder contributing to their excessive sleepiness. The effectiveness of modafinil in long-term use (greater than 9 weeks in Narcolepsy clinical trials and 12 weeks in OSAHS and SWSD clinical trials) has not been systematically evaluated in placebo-controlled trials. The physician who elects to prescribe PROVIGIL for an extended time in patients with Narcolepsy, OSAHS, or SWSD should periodically reevaluate long-term usefulness for the individual patient. uuid:d087e521-7521-454f-99f1-cec71177c297 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29103 biolink:treats MONDO:0001909 PMID:41385096 "[{""id"":""uuid:1c87da5d-4daa-46b0-9118-1195503d9f00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:318462d4-56a2-4df0-ac21-4e63d72616e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Potassium citrate extended-release tablets are indicated for the management of renal tubular acidosis (RTA) with calcium stones, hypocitraturic calcium oxalate nephrolithiasis of any etiology, and uric acid lithiasis with or without calcium stones. uuid:16d33616-484b-41ed-b56e-59a64bda11ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29103 biolink:treats MONDO:0957318 PMID:41385096 "[{""id"":""uuid:c0febb32-1757-418c-9ace-1a77ce485304"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ddfbef97-5e5a-4fea-b5dd-de836186cdbb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Potassium citrate extended-release tablets are indicated for the management of renal tubular acidosis (RTA) with calcium stones, hypocitraturic calcium oxalate nephrolithiasis of any etiology, and uric acid lithiasis with or without calcium stones. uuid:304d3a77-82f7-4c81-8fd6-252dc129b117 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29103 biolink:treats MONDO:0008629 PMID:41385096 "[{""id"":""uuid:3f44da25-da67-4f52-a99c-0010765f00b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bbff3924-a16e-4394-bbbc-c75bb2313103"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Potassium citrate extended-release tablets are indicated for the management of renal tubular acidosis (RTA) with calcium stones, hypocitraturic calcium oxalate nephrolithiasis of any etiology, and uric acid lithiasis with or without calcium stones. uuid:09310f33-90f7-4396-870b-db4576044caa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31536 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:81fa800c-018e-4f25-8bc4-fec8eee12173"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0ed32c86-97a4-4a18-9168-290184f989e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EMTRIVA ® is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. Additional important information regarding the use of EMTRIVA for the treatment of HIV-1 Infection: EMTRIVA should not be coadministered with ATRIPLA ® , TRUVADA ® , or lamivudine-containing products [See Warnings and Precautions (5.3) ] . In treatment-experienced patients, the use of EMTRIVA should be guided by laboratory testing and treatment history [See Clinical Pharmacology (12.4) ] . uuid:938ad5c7-4a7a-4ae4-8bce-37c179abce27 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8059 biolink:treats NCIT:C120380 PMID:41385096 "[{""id"":""uuid:9be8557f-7014-4370-90c6-97ec0c7c0b72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6ce701c8-a69d-4c29-8d45-f8a0e6310965"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Phendimetrazine tartrate tablets are indicated in the management of exogenous obesity as a short term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction. The limited usefulness of agents of this class (see CLINICAL PHARMACOLOGY ) should be measured against possible risk factors inherent in their use such as those described below. uuid:2d33472a-6128-4c3f-9c1d-9bcb46630983 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6539 biolink:treats MONDO:0005618 PMID:41385096 "[{""id"":""uuid:9de2ef55-d298-4646-b824-57292004131c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:211ea74c-5619-4228-824c-485ec9f2f3ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lorazepam is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The effectiveness of lorazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. uuid:da7faa0a-3403-4d83-b2da-3d9d5b74d5fc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6539 biolink:treats MONDO:0041086 PMID:41385096 "[{""id"":""uuid:5d4356c8-bb1c-4f57-b33c-b25226758971"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bf3ec54f-a0ee-4194-b723-d935bdb6560f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lorazepam is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The effectiveness of lorazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. uuid:be2fc389-759b-4f42-bf91-7f95a9ec4d5a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9907 biolink:treats MONDO:0006698 PMID:41385096 "[{""id"":""uuid:62e9a140-fd2c-4777-8fbf-33b498d52d71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6aa5b175-bfb5-4479-bbc4-8c32bcc17127"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ursodiol is indicated for patients with radiolucent, noncalcified gallbladder stones < 20 mm in greatest diameter in whom elective cholecystectomy would be undertaken except for the presence of increased surgical risk due to systemic disease, advanced age, idiosyncratic reaction to general anesthesia, or for those patients who refuse surgery. Safety of use of ursodiol beyond 24 months is not established. Ursodiol is indicated for the prevention of gallstone formation in obese patients experiencing rapid weight loss. uuid:f24afecb-7849-4181-bccc-a997b390fbdc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9907 biolink:treats MONDO:0012672 PMID:41385096 "[{""id"":""uuid:cb4ed1bb-3636-4e22-aacf-280b2ce24f04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:52c42bf7-e836-4685-9091-0f3ba3e953d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ursodiol is indicated for patients with radiolucent, noncalcified gallbladder stones < 20 mm in greatest diameter in whom elective cholecystectomy would be undertaken except for the presence of increased surgical risk due to systemic disease, advanced age, idiosyncratic reaction to general anesthesia, or for those patients who refuse surgery. Safety of use of ursodiol beyond 24 months is not established. Ursodiol is indicated for the prevention of gallstone formation in obese patients experiencing rapid weight loss. uuid:d487ce60-56de-4aeb-b1f8-417c9a3a46f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7451 biolink:treats MONDO:0005984 PMID:41385096 "[{""id"":""uuid:51ee04f2-7176-4832-99f3-384398d6a689"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6f4153b1-1b8f-405f-9339-d21111edc385"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Naftin ® Cream, 1% is indicated for the topical treatment of tinea pedis, tinea cruris and tinea corporis caused by the organisms Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum. uuid:2bf341ed-b9b8-4e32-b70b-58119c02a063 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7451 biolink:treats MONDO:0001405 PMID:41385096 "[{""id"":""uuid:ff72eaa4-f3f1-421c-b01e-9befa7b57a4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7da57826-8d55-4529-8131-2f593f82ad2d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Naftin ® Cream, 1% is indicated for the topical treatment of tinea pedis, tinea cruris and tinea corporis caused by the organisms Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum. uuid:fcc01d52-3a53-4ce2-bec9-7fe9b59ec7c4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7451 biolink:treats MONDO:0001461 PMID:41385096 "[{""id"":""uuid:5a0bb283-01c3-428b-8860-7b1baecba656"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c9ff9977-15c4-4d3c-bbb3-68462718eff5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Naftin ® Cream, 1% is indicated for the topical treatment of tinea pedis, tinea cruris and tinea corporis caused by the organisms Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum. uuid:654e346c-fd2c-4716-bacb-c3ce4021ca04 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17439 biolink:treats MONDO:0400000 PMID:41385096 "[{""id"":""uuid:b29d394b-7031-49ec-88cf-bb137495fa7d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3a4de241-5fe4-4691-bfb9-7d8d374b803c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyanocobalamin is indicated for vitamin B 12 deficiencies due to malabsorption which may be associated with the following conditions: Addisonian (pernicious) anemia Gastrointestinal pathology, dysfunction, or surgery, including gluten enteropathy or sprue, small bowel bacteria overgrowth, total or partial gastrectomy Fish tapeworm infestation Malignancy of pancreas or bowel Folic acid deficiency It may be possible to treat the underlying disease by surgical correction of anatomic lesions leading to small bowel bacterial overgrowth, expulsion of fish tapeworm, discontinuation of drugs leading to vitamin malabsorption (see Drug Interactions ), use of a gluten-free diet in nontropical sprue, or administration of antibiotics in tropical sprue. Such measures remove the need for long-term administration of cyanocobalamin. Requirements of vitamin B 12 in excess of normal (due to pregnancy, thyrotoxicosis, hemolytic anemia, hemorrhage, malignancy, hepatic and renal disease) can usually be met with oral supplementation. Cyanocobalamin Injection, USP is also suitable for the vitamin B 12 absorption test ( Schilling test ). uuid:63b40591-dfca-4b03-9692-31af22bc5530 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17439 biolink:treats MONDO:0015260 PMID:41385096 "[{""id"":""uuid:aa82fcad-fe38-478c-8a4a-cffa3810c9ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7b4fbb27-2397-464b-a0ad-3d37280c7a1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyanocobalamin is indicated for vitamin B 12 deficiencies due to malabsorption which may be associated with the following conditions: Addisonian (pernicious) anemia Gastrointestinal pathology, dysfunction, or surgery, including gluten enteropathy or sprue, small bowel bacteria overgrowth, total or partial gastrectomy Fish tapeworm infestation Malignancy of pancreas or bowel Folic acid deficiency It may be possible to treat the underlying disease by surgical correction of anatomic lesions leading to small bowel bacterial overgrowth, expulsion of fish tapeworm, discontinuation of drugs leading to vitamin malabsorption (see Drug Interactions ), use of a gluten-free diet in nontropical sprue, or administration of antibiotics in tropical sprue. Such measures remove the need for long-term administration of cyanocobalamin. Requirements of vitamin B 12 in excess of normal (due to pregnancy, thyrotoxicosis, hemolytic anemia, hemorrhage, malignancy, hepatic and renal disease) can usually be met with oral supplementation. Cyanocobalamin Injection, USP is also suitable for the vitamin B 12 absorption test ( Schilling test ). uuid:d963317b-03be-428a-b387-c53701bb73e1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17439 biolink:treats MONDO:0009831 PMID:41385096 "[{""id"":""uuid:64d25863-5ef2-4776-aec5-4c59c5f9d92d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6ec0d30e-e26d-4b85-b676-ab25f2ddd142"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyanocobalamin is indicated for vitamin B 12 deficiencies due to malabsorption which may be associated with the following conditions: Addisonian (pernicious) anemia Gastrointestinal pathology, dysfunction, or surgery, including gluten enteropathy or sprue, small bowel bacteria overgrowth, total or partial gastrectomy Fish tapeworm infestation Malignancy of pancreas or bowel Folic acid deficiency It may be possible to treat the underlying disease by surgical correction of anatomic lesions leading to small bowel bacterial overgrowth, expulsion of fish tapeworm, discontinuation of drugs leading to vitamin malabsorption (see Drug Interactions ), use of a gluten-free diet in nontropical sprue, or administration of antibiotics in tropical sprue. Such measures remove the need for long-term administration of cyanocobalamin. Requirements of vitamin B 12 in excess of normal (due to pregnancy, thyrotoxicosis, hemolytic anemia, hemorrhage, malignancy, hepatic and renal disease) can usually be met with oral supplementation. Cyanocobalamin Injection, USP is also suitable for the vitamin B 12 absorption test ( Schilling test ). uuid:6444b28b-11ac-43ee-bb82-3e6af566f0e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17439 biolink:treats MONDO:0005008 PMID:41385096 "[{""id"":""uuid:3b4444dc-405d-40a3-a7d0-13db3602ae3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:40821558-7f10-4c8c-aa0c-06a9042d7135"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyanocobalamin is indicated for vitamin B 12 deficiencies due to malabsorption which may be associated with the following conditions: Addisonian (pernicious) anemia Gastrointestinal pathology, dysfunction, or surgery, including gluten enteropathy or sprue, small bowel bacteria overgrowth, total or partial gastrectomy Fish tapeworm infestation Malignancy of pancreas or bowel Folic acid deficiency It may be possible to treat the underlying disease by surgical correction of anatomic lesions leading to small bowel bacterial overgrowth, expulsion of fish tapeworm, discontinuation of drugs leading to vitamin malabsorption (see Drug Interactions ), use of a gluten-free diet in nontropical sprue, or administration of antibiotics in tropical sprue. Such measures remove the need for long-term administration of cyanocobalamin. Requirements of vitamin B 12 in excess of normal (due to pregnancy, thyrotoxicosis, hemolytic anemia, hemorrhage, malignancy, hepatic and renal disease) can usually be met with oral supplementation. Cyanocobalamin Injection, USP is also suitable for the vitamin B 12 absorption test ( Schilling test ). uuid:f961b505-0301-4f0e-8ba7-58a2c87f30fb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17439 biolink:treats MONDO:0001860 PMID:41385096 "[{""id"":""uuid:dcd45610-4a38-4334-9a5e-d37101611fe1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7f0e12a2-d794-4896-9365-510f8843340d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyanocobalamin is indicated for vitamin B 12 deficiencies due to malabsorption which may be associated with the following conditions: Addisonian (pernicious) anemia Gastrointestinal pathology, dysfunction, or surgery, including gluten enteropathy or sprue, small bowel bacteria overgrowth, total or partial gastrectomy Fish tapeworm infestation Malignancy of pancreas or bowel Folic acid deficiency It may be possible to treat the underlying disease by surgical correction of anatomic lesions leading to small bowel bacterial overgrowth, expulsion of fish tapeworm, discontinuation of drugs leading to vitamin malabsorption (see Drug Interactions ), use of a gluten-free diet in nontropical sprue, or administration of antibiotics in tropical sprue. Such measures remove the need for long-term administration of cyanocobalamin. Requirements of vitamin B 12 in excess of normal (due to pregnancy, thyrotoxicosis, hemolytic anemia, hemorrhage, malignancy, hepatic and renal disease) can usually be met with oral supplementation. Cyanocobalamin Injection, USP is also suitable for the vitamin B 12 absorption test ( Schilling test ). uuid:8620e1ef-4f2e-4d96-9d63-1ac2704e1471 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32234 biolink:treats MONDO:0005326 PMID:41385096 "[{""id"":""uuid:795acc19-b81f-4ba7-91e4-f049fd9ca100"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9de42b34-09a6-4c55-9ce3-b122cc8bf6b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] USES Helps prevent sunburns Higher SPF gives more sunburn protection Apply liberally as needed 15 to 20 minutes before sun exposure Reapply as needed or after swimming, perspiring or towel drying Children under 6 months of age: ask doctor uuid:29e71f95-44af-4409-a5fe-306e6060369b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90959 biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:0d4b2fc0-3c52-4040-99d7-f379d9dc5b57"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:77d05c16-5251-43f0-a635-93fd6d4d9bd5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SPIRIVA HandiHaler (tiotropium bromide inhalation powder) is indicated for the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. SPIRIVA HandiHaler is indicated to reduce exacerbations in COPD patients. uuid:70504545-5e4a-47ea-b7e9-8e9f3042935d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90959 biolink:treats MONDO:0005607 PMID:41385096 "[{""id"":""uuid:be439819-5a49-448e-8404-6f116980a3af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:38c97050-b81f-4267-bebb-19d9734451f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SPIRIVA HandiHaler (tiotropium bromide inhalation powder) is indicated for the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. SPIRIVA HandiHaler is indicated to reduce exacerbations in COPD patients. uuid:43d3cac4-b69e-40cd-a399-a23e77604aab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90959 biolink:treats MONDO:0004849 PMID:41385096 "[{""id"":""uuid:2bb2b575-e843-4a0e-bda1-179241ee6cbc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:771270aa-d040-4017-a478-943e47d63fef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SPIRIVA HandiHaler (tiotropium bromide inhalation powder) is indicated for the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. SPIRIVA HandiHaler is indicated to reduce exacerbations in COPD patients. uuid:c5e3ce02-11bd-4da0-91a6-2fe48b665ce2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3219 biolink:treats MONDO:0000694 PMID:41385096 "[{""id"":""uuid:28d25193-1c87-4ac9-bcd0-f45963af3182"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:76da9c6b-eae4-486e-b871-474d5afd25ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Major Depressive Disorder: Bupropion hydrochloride extended-release tablets (XL) are indicated for the treatment of major depressive disorder. The efficacy of bupropion in the treatment of a major depressive episode was established in two 4-week controlled trials of inpatients and in one 6-week controlled trial of outpatients whose diagnoses corresponded most closely to the Major Depression category of the APA Diagnostic and Statistical Manual (DSM) (see CLINICAL TRIALS ). A major depressive episode (DSM-IV) implies the presence of 1) depressed mood or 2) loss of interest or pleasure; in addition, at least 5 of the following symptoms have been present during the same 2-week period and represent a change from previous functioning: depressed mood, markedly diminished interest or pleasure in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt, or suicidal ideation. The efficacy of bupropion in maintaining an antidepressant response for up to 44 weeks following 8 weeks of acute treatment was demonstrated in a placebo-controlled trial with the sustained-release formulation of bupropion (see CLINICAL TRIALS ). Nevertheless, the physician who elects to use bupropion hydrochloride extended-release tablets (XL) for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual patient. Seasonal Affective Disorder: Bupropion hydrochloride extended-release tablets (XL) are indicated for the prevention of seasonal major depressive episodes in patients with a diagnosis of seasonal affective disorder. The efficacy of bupropion hydrochloride extended-release tablets (XL) for the prevention of seasonal major depressive episodes was established in 3 controlled trials of adult outpatients with a history of major depressive disorder with an autumn-winter seasonal pattern as defined by Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) criteria (see CLINICAL TRIALS ). Seasonal affective disorder is characterized by recurrent major depressive episodes, most commonly occurring during the autumn and/or winter months. Episodes may last up to 6 months in duration, typically beginning in the autumn and remitting in the springtime. Although patients with seasonal affective disorder may have depressive episodes during other times of the year, the diagnosis of seasonal affective disorder requires that the number of seasonal episodes substantially outnumber the number of non-seasonal episodes during the individual's lifetime. uuid:c1636071-9eea-4629-919d-4f469c76297e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:378730 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:da384061-8524-470b-826c-860a37cc0559"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:80f675e9-b571-4037-b471-3eea7bdd4271"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Glipizide and metformin hydrochloride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. uuid:e005674c-91f2-4762-b2e1-052cf8fd31bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2453 biolink:treats MONDO:0005609 PMID:41385096 "[{""id"":""uuid:d494cf4d-8566-457e-82a5-7734657d212f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:10ab8ec5-8469-40ac-a0ad-ac46e4fd4b70"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:de53baf5-809e-414d-8b5b-76c68a004849"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Herpes Zoster Infections: Acyclovir oral suspension, USP is indicated for the acute treatment of herpes zoster (shingles). Genital Herpes: Acyclovir oral suspension, USP is indicated for the treatment of initial episodes and the management of recurrent episodes of genital herpes. Chickenpox: Acyclovir oral suspension, USP is indicated for the treatment of chickenpox (varicella).|[PMDA] Drugs with new additional indications and a new additional dosage for herpes simplex, prevention of herpes simplex virus infection in hematopoietic stem cell transplantation, herpes zoster, and prevention of recurrence of genital herpes (oral dosage form), and neonatal herpes simplex virus infection (injectable dosage form) based on the discussion of the Investigational Committee on Pediatric Drug Therapies. uuid:f6190206-012e-498a-a2fe-c42a9a9f910f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2453 biolink:treats MONDO:0005770 PMID:41385096 "[{""id"":""uuid:896d6b6c-52bd-42a6-b338-a5787de837e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:db4e74fc-f94b-471c-badc-2d8724e99a9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:aca0229b-ff09-4c0e-aa32-58c4456dd0ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Herpes Zoster Infections: Acyclovir oral suspension, USP is indicated for the acute treatment of herpes zoster (shingles). Genital Herpes: Acyclovir oral suspension, USP is indicated for the treatment of initial episodes and the management of recurrent episodes of genital herpes. Chickenpox: Acyclovir oral suspension, USP is indicated for the treatment of chickenpox (varicella).|[PMDA] Drugs with new additional indications and a new additional dosage for herpes simplex, prevention of herpes simplex virus infection in hematopoietic stem cell transplantation, herpes zoster, and prevention of recurrence of genital herpes (oral dosage form), and neonatal herpes simplex virus infection (injectable dosage form) based on the discussion of the Investigational Committee on Pediatric Drug Therapies. uuid:9b9fdf53-13db-4167-9ed8-3f62c83c22a7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2453 biolink:treats MONDO:0005700 PMID:41385096 "[{""id"":""uuid:ece17d58-199f-4dd5-95c8-901ab53281c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d1c167bf-432f-4bf8-9268-0ad295cfe481"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Herpes Zoster Infections: Acyclovir oral suspension, USP is indicated for the acute treatment of herpes zoster (shingles). Genital Herpes: Acyclovir oral suspension, USP is indicated for the treatment of initial episodes and the management of recurrent episodes of genital herpes. Chickenpox: Acyclovir oral suspension, USP is indicated for the treatment of chickenpox (varicella). uuid:971a433f-72fb-404d-9735-99a3bc57b898 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5950 biolink:treats MONDO:0005480 PMID:41385096 "[{""id"":""uuid:235945df-c57c-4711-9442-b06a33c21ade"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ab9f24bc-1eeb-48d1-9c2c-e46b86bc3d5d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:3da35d4f-fa9c-408b-a73c-66e8bb185e16 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5950 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:54f5ae9d-5628-44a0-9baa-9b1ef8982767"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:00cc898c-ae09-4b31-ad99-0c5e1c461a9a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:6c9a66d3-1f3a-4038-8a81-15bcc4d98067 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5950 biolink:treats MONDO:0002406 PMID:41385096 "[{""id"":""uuid:d76f38a8-9968-49b2-aac2-67be3e5662bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b1a13dae-29ab-4956-8432-246ffa7c6a78"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:e58dfd7b-a319-4080-a1f4-461815dd597b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5950 biolink:treats HP:0033120 PMID:41385096 "[{""id"":""uuid:dd83bc09-9690-4124-ad90-d76f582ffa1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8fecc3ed-6d3a-4f6b-b594-38f7d9f49ba3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:ade2f996-0dfa-4a4c-bf48-825386305cf0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5950 biolink:treats HP:0033564 PMID:41385096 "[{""id"":""uuid:9f691f24-6475-4e6b-8159-d8123631a706"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:91cca907-f708-42fd-9f7b-0a974e661f95"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:9fcf2bbf-8baa-4a55-bfcb-5a43bd905ef9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5950 biolink:treats MONDO:0002922 PMID:41385096 "[{""id"":""uuid:5995c9b2-83f9-4364-a77d-35d6985f8756"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:63beecd5-4e1b-4667-8378-11eb5a2ede51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:556aad25-5b4a-4bb8-888b-539b89e870e9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5950 biolink:treats MONDO:0004795 PMID:41385096 "[{""id"":""uuid:8faa9cfa-1f9c-4c9d-b841-49df3bcf7e06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:88488570-5761-47e3-80fe-adaac622a74d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:5e8a3d81-98cd-40e2-89ed-94a3e0083a33 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5950 biolink:treats UMLS:C0406297 PMID:41385096 "[{""id"":""uuid:224dd32c-3bed-4c3e-86c9-cbb0f8d412d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a3536d8c-c3ee-4b51-8ab5-99152c937061"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:473b5033-fa2b-4ca0-ac7c-d64336ca7451 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5950 biolink:treats MONDO:0006585 PMID:41385096 "[{""id"":""uuid:9e282fa1-497c-40a3-ad77-3beb5202b866"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9761f5d9-3149-4435-bd2a-fa509bbfe3f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:302ada9c-9ffb-4376-8cea-9b653b15218b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5950 biolink:treats UMLS:C0149922 PMID:41385096 "[{""id"":""uuid:7e045a97-f1c2-4400-9a18-baaa9d71c4e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5d01793a-bbb3-428b-85b6-328ddc295251"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:250f9bc4-686f-4d93-ae83-dc6bdadb6ff4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5950 biolink:treats UMLS:C0003107 PMID:41385096 "[{""id"":""uuid:d3459ba6-34d7-4bd7-b986-f8da8ceeae7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:666bdaaf-e2b0-46e8-b30a-1998a81eebba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:cc3ebcf3-0fcf-45ec-bb4b-2ce7a4bd11bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5950 biolink:treats HP:0032004 PMID:41385096 "[{""id"":""uuid:20ce8a91-3dd6-495c-bc5e-31b07f753827"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:93361259-cb62-45b9-83c2-3922d836e1b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:f5160973-fe47-4d8b-9184-b09da8309565 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5950 biolink:treats UMLS:C0451941 PMID:41385096 "[{""id"":""uuid:d1178c23-5946-42cb-9e0d-b4fe0ee089fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9321daec-924e-43ff-95d2-6c4e2f893a92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:d69d5baa-506f-439c-8f10-4af6b6dc426b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5950 biolink:treats UMLS:C0033775 PMID:41385096 "[{""id"":""uuid:67133c8d-a8bd-4f78-87f4-ca6cdc5c0d4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6c91c032-b36a-43ca-83a5-3ddc1a42225b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:f7023e41-5f67-4aa9-a404-2ad597f71770 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5950 biolink:treats MONDO:0006552 PMID:41385096 "[{""id"":""uuid:4af6c518-1678-4461-8842-967e56d9819a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f0b19814-7454-4a8f-a329-4e0ae3af5109"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:1bb050b5-4bc0-4e8c-bfee-1d1c6db190ab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5950 biolink:treats MONDO:0002967 PMID:41385096 "[{""id"":""uuid:9dc0d84f-0452-4c62-a6eb-660cebb89b88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f5fa7eb1-2ad7-4984-87f5-8cf41478de86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:78c1f243-6c69-4ee7-b400-4b3a0f002026 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5950 biolink:treats MONDO:0001405 PMID:41385096 "[{""id"":""uuid:2d9fbc95-b5c2-495c-88df-de3672f43f7d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1a016d31-b5b3-40a7-b866-262c664cc788"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:5c6595aa-e467-4f05-bb55-cc0d1f0d506b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5950 biolink:treats MONDO:0001461 PMID:41385096 "[{""id"":""uuid:02546924-43ca-4ece-bfc5-4719edd76e2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:44adcb79-12fa-44e5-8724-338ab3f1f35b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:d14e10c5-a995-4884-8dcd-51d90ec3487f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5950 biolink:treats MONDO:0005984 PMID:41385096 "[{""id"":""uuid:8019a9fe-a145-4140-a3dc-29c63b201239"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2b09be5a-4d3e-4240-8ad4-501a82154352"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:ddbc3f27-86fd-45a1-8591-3fe90f8bbd0e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5950 biolink:treats MONDO:0021340 PMID:41385096 "[{""id"":""uuid:7c56949e-d20f-4cf7-b49a-5b7e59959d96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a2a01cdf-a267-4f17-abb1-9a494be198be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:a806ce1d-a635-43e7-ac62-63cbe9198064 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17051 biolink:treats MONDO:0005276 PMID:41385096 "[{""id"":""uuid:b3dad46e-36ad-441e-8daa-6441dc7bf414"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f35c8aaa-2059-426c-a41d-169a44b23ae8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATION AND USE: A topically-applied foaming solution to aid in the prevention of dental caries. uuid:cd77ca2f-b704-40d2-8598-c061afb0239e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82405 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:60a1e2ad-cabb-4ae3-a1b7-07f85cb6b23f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9866e077-7ed0-4215-9b8e-b1b4e30209ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3cde509c-a1ad-42d4-b71f-3e9f0a0ee7e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NeoBenz® Micro, NeoBenz® Micro SD and NeoBenz® Micro Wash are indicated for use in the topical treatment of mild to moderated acne vulgaris.|[PMDA] A drug with a new active ingredient indicated for the treatment of acne vulgaris. uuid:83c860f9-2a2b-439b-9ebf-880a83252380 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0002406 PMID:41385096 "[{""id"":""uuid:0882f47f-757c-4ace-8e08-d6ce4890f05f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0eb6069c-11f3-40e8-b32b-5fcd75a69747"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:23ffd8fb-6118-420a-bf32-92a540f2891d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats HP:0033120 PMID:41385096 "[{""id"":""uuid:6b42c63e-5502-43f3-9486-a6cbb44d73d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ba0bed8a-8ba5-4cb4-8903-21dcc6dc6f6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:d405d2df-7db3-4a6f-9a0b-0f1a310c3399 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats HP:0033564 PMID:41385096 "[{""id"":""uuid:99ac67d0-c071-425b-b832-d856765de3f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4ebe40d0-5fe2-43dc-ab68-b2205c55fbd9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:f30877aa-9157-4e3a-91b3-03f78f575128 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0002922 PMID:41385096 "[{""id"":""uuid:36c1ba07-956f-4540-982f-eef50db8a16a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9110bb30-9bbb-42a8-b59d-319ff1e7fed7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:2729210e-76ff-4e66-b321-e24d93068d90 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0004795 PMID:41385096 "[{""id"":""uuid:a2f4380b-2d1d-4b33-8a08-ede89ada94b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9a872432-fd16-4920-80eb-b14fa07096ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:af86e02c-33ac-4939-b30b-bf2e1733a310 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats UMLS:C0406297 PMID:41385096 "[{""id"":""uuid:c74f98ba-6493-4725-891c-ab91f3c5ebdf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a845964c-556a-4bb8-b5dc-63b546a2df13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:4b162160-e412-4964-a7a0-1928d5099a12 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0006585 PMID:41385096 "[{""id"":""uuid:462454cb-1787-4562-9192-34e740f14680"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5b7243a4-20eb-4fb5-912b-73a90bceda89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:caaa13cf-8369-4c19-b50a-658aba5a5dae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats UMLS:C0149922 PMID:41385096 "[{""id"":""uuid:0806ef66-81d7-4d37-98e9-84b64df9c664"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c84048ce-0580-4c12-8aec-58399708ac82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:8c1ca235-16c7-428a-9394-0919292bb98d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats UMLS:C0003107 PMID:41385096 "[{""id"":""uuid:7e4aa8e0-a91a-411e-8094-a7e1cf1eae5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7ff3a638-83c8-4156-adcf-30544a85fc18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:04ada024-623f-4b34-9d9e-582602caf069 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats HP:0032004 PMID:41385096 "[{""id"":""uuid:235d0f74-1f31-41f7-90c7-af5777eb661c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:41eb0970-fbc3-479e-90ed-ac8a57a57d0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:bd438c64-a138-433a-9c41-07a45898d6ed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats UMLS:C0451941 PMID:41385096 "[{""id"":""uuid:3f386710-b56e-4c44-9f0b-edc268147d39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b0e1d49a-6b21-439d-85fc-1bd45e539ea1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:7d84532b-1a4f-46d9-adfa-a6933dbd14b8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats UMLS:C0033775 PMID:41385096 "[{""id"":""uuid:858f5ed6-ea1d-4a50-bda5-19a2af4dc235"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bc38d2bf-5b57-4ed1-b2d9-5316ac7386df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:2ff85fb2-0eb3-4035-8b45-2a17fb84426c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0006552 PMID:41385096 "[{""id"":""uuid:6ee22f34-d91e-4cc6-8d6b-60a0b3caca31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eac19bf0-f89a-4430-9cb4-f650ba33e953"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:68d82e8c-ca76-4579-8a5e-8942c8ac98cc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0002967 PMID:41385096 "[{""id"":""uuid:919c8230-aa1f-45a5-8346-debf10288c35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0d8108a0-4ff7-432d-bae2-e4ac1cec7f99"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:054f997a-1870-4d71-b2b5-3c1d0313ec2c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0001405 PMID:41385096 "[{""id"":""uuid:9ae973f1-ef1b-47d9-a8bf-13707990142a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:27a6e1d9-736b-4bab-92a6-68352dc4530a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:7b557e92-4954-4d72-b9fa-7561bf629bfd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0001461 PMID:41385096 "[{""id"":""uuid:c9575b91-6bed-47f8-8fcb-5b9652ee865a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:607928e3-98fe-4033-b19c-109ab8fad799"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:2f2f7993-a3f3-482b-9f13-df1a563e8348 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0005984 PMID:41385096 "[{""id"":""uuid:b799c87d-e435-4856-8069-3f5a2731fa24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1866c586-7901-48b5-bb7c-42da1a755271"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:0fc87052-e9e8-4a84-9034-34d9ec710286 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0021340 PMID:41385096 "[{""id"":""uuid:44e27f1c-5df4-4511-b6ab-021d53c7652b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f3640a36-4bad-4746-9774-b604d32f8ce0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:0012eacb-33f6-4526-9f83-4530020652b0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37510 biolink:treats UMLS:C0406317 PMID:41385096 "[{""id"":""uuid:4c9e7e0b-b1b1-465d-a006-efedaf7f341f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:68d2d789-c05a-4c67-aa90-1041c1c74dad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the topical treatment of patients with stable plaque psoriasis. uuid:c61a5ea3-3b8b-4bc1-bd44-abeaba7827b0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1152833 biolink:treats MONDO:0021146 PMID:41385096 "[{""id"":""uuid:debde62e-6ba9-400c-9380-a057a37fed9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:64e8d531-a9b8-4a84-b3bd-306065d720e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the temporary relief of minor aches and pains associated with headaches, backache, muscular aches, the menstrual and premenstrual periods, colds, the flu, toothaches, as well as for minor pain from arthritis, and to reduce fever. uuid:b2d61e22-d00a-40fd-9c62-dfecd58999ac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1152833 biolink:treats HP:0003418 PMID:41385096 "[{""id"":""uuid:087a9241-1e6c-46c2-9dc0-3ac074f8340d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4e87678b-6f13-43c4-9ab5-b0ae5c9cf5af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the temporary relief of minor aches and pains associated with headaches, backache, muscular aches, the menstrual and premenstrual periods, colds, the flu, toothaches, as well as for minor pain from arthritis, and to reduce fever. uuid:f51a921a-cfb6-470e-b455-b565631a42fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1152833 biolink:treats HP:0003326 PMID:41385096 "[{""id"":""uuid:3b974721-91c0-49dd-91c0-27edfc18c891"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:090d8424-3472-45e6-be07-3de1ca1e20fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the temporary relief of minor aches and pains associated with headaches, backache, muscular aches, the menstrual and premenstrual periods, colds, the flu, toothaches, as well as for minor pain from arthritis, and to reduce fever. uuid:d503f128-faf3-4b7d-8a5c-27d69f0b3cff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1152833 biolink:treats MONDO:0005709 PMID:41385096 "[{""id"":""uuid:38d6a75b-f7ba-4410-bb09-ae2c4da06efc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:82c12410-50fb-44c5-89cc-9c39e3a36e22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the temporary relief of minor aches and pains associated with headaches, backache, muscular aches, the menstrual and premenstrual periods, colds, the flu, toothaches, as well as for minor pain from arthritis, and to reduce fever. uuid:0557cd08-bdd6-4ea3-8053-a323c8dab15c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1152833 biolink:treats MONDO:0005812 PMID:41385096 "[{""id"":""uuid:57bb045e-9d84-4d79-bf47-56ff37f4fb85"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:26a8bd12-4be6-4074-a526-2378516a97f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the temporary relief of minor aches and pains associated with headaches, backache, muscular aches, the menstrual and premenstrual periods, colds, the flu, toothaches, as well as for minor pain from arthritis, and to reduce fever. uuid:9a4471be-795f-495f-98b4-9e296ced755a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1152833 biolink:treats EFO:0010072 PMID:41385096 "[{""id"":""uuid:e8402799-c4e6-4cbf-a37f-a8ef60d90170"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:12748cb3-e434-4fc1-a08b-f7ce9075abcd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the temporary relief of minor aches and pains associated with headaches, backache, muscular aches, the menstrual and premenstrual periods, colds, the flu, toothaches, as well as for minor pain from arthritis, and to reduce fever. uuid:57f423f4-7a8b-43ec-b66a-e2ae3eb8a498 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1152833 biolink:treats MONDO:0005578 PMID:41385096 "[{""id"":""uuid:33615b59-a038-4ee1-9062-b56c6cd4bae6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5f077464-5638-4a2f-8bad-1f6792a2678c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the temporary relief of minor aches and pains associated with headaches, backache, muscular aches, the menstrual and premenstrual periods, colds, the flu, toothaches, as well as for minor pain from arthritis, and to reduce fever. uuid:dd00df3f-0539-4638-93f8-45696e831987 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9327 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:e80d80f6-0ef0-4b54-94ea-ac8cfc6eddc1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:754a4685-0588-4717-b06b-31d1c21cb1d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Sulfacetamide Medicated Pads are indicated in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis. uuid:d7947f3e-781f-484f-b550-1f662ea73a43 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9327 biolink:treats MONDO:0006604 PMID:41385096 "[{""id"":""uuid:9366d6c6-c002-487f-952a-c153c24d6a36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:192816c9-8103-49e2-b2ad-b468e7d712d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Sulfacetamide Medicated Pads are indicated in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis. uuid:bfe06ab9-57cf-46df-bcd9-e62292b2671e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9327 biolink:treats MONDO:0006608 PMID:41385096 "[{""id"":""uuid:02c66515-83ca-41cf-8010-2be6141e07e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:da09185f-933a-4543-b529-b9800d8bcc2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Sulfacetamide Medicated Pads are indicated in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis. uuid:ba799d94-7217-441c-b7aa-48beed2a0bd7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9014 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:3ec8abf4-6763-4f25-b628-2b5c2d0a7d55"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0b8a5271-dbbf-49e4-94f7-c66324d5ddd9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of Salsalate tablets, USP and other treatment options before deciding to use Salsalate tablets, USP. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Salsalate is indicated for relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis and related rheumatic disorder. uuid:d8ddc563-50b7-49cf-9de8-3001b108ae53 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9014 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:6fab6da9-14ab-4732-b872-96e4fcd59621"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a27be6a5-e766-47db-88e9-c61b0a0bbd4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of Salsalate tablets, USP and other treatment options before deciding to use Salsalate tablets, USP. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Salsalate is indicated for relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis and related rheumatic disorder. uuid:27369bca-585f-4b4e-9b22-eb7feb79ec3b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9014 biolink:treats MONDO:0005554 PMID:41385096 "[{""id"":""uuid:309fdce8-3f82-40ab-9cb9-42b1fc08b848"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b4cc621a-4ffb-4324-b77d-cacd3404f242"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of Salsalate tablets, USP and other treatment options before deciding to use Salsalate tablets, USP. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Salsalate is indicated for relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis and related rheumatic disorder. uuid:992b5071-aeb3-4022-b5b3-1fb1ba16b8a2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0981911 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:351f913b-c498-4e2b-91a9-19303ca2818e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f3397616-4689-47c5-9a0d-6821cc57f8d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergenic extracts are indicated for use in diagnostic testing and as part of a treatment regime for allergic disease, as established by allergy history and skin test reactivity. Allergenic extracts are indicated for the treatment of allergen specific allergic disease for use as hyposensitization or immunotherapy when avoidance of specific allergens can not be attained. The use of allergenic extracts for therapeutic purpose has been established by well-controlled clinical studies. Allergenic extracts may be used as adjunctive therapy along with pharmacotherapy which includes antihistamines, corticosteroids, and cromoglycate, and avoidance measures. Allergenic extracts for therapeutic use should be given using only the allergen selection to which the patient is allergic, has a history of exposure and are likely to be exposed to again. DRUGBANK:DB10345 uuid:93f28d8d-a1cc-44f2-b46e-0fbd43c56bfa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1154173 biolink:treats MONDO:0005961 PMID:41385096 "[{""id"":""uuid:2504c05d-530a-4423-bc08-535b7592b8a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:697d8444-d94b-44f1-b84e-4617aebf1f07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atuss® DS Tannate Suspension is indicated for temporary relief of nasal congestion and cough associated with respiratory tract infections and related conditions such as sinusitis, pharyngitis, bronchitis and asthma when these conditions are complicated by tenacious mucus and/or mucous plugs and congestion. Atuss® DS Tannate Suspension is effective in a productive as well as a nonproductive cough, but is of particular value in a dry nonproductive cough which tends to injure the mucous membrane of the air passages. uuid:a52b0846-99a6-4c71-8550-23f27acd83f2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1154173 biolink:treats MONDO:0002258 PMID:41385096 "[{""id"":""uuid:36c6cd67-78d8-4d5c-9b68-3faa7328689e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:381ac8b5-bf45-466f-951e-29d93b2d3661"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atuss® DS Tannate Suspension is indicated for temporary relief of nasal congestion and cough associated with respiratory tract infections and related conditions such as sinusitis, pharyngitis, bronchitis and asthma when these conditions are complicated by tenacious mucus and/or mucous plugs and congestion. Atuss® DS Tannate Suspension is effective in a productive as well as a nonproductive cough, but is of particular value in a dry nonproductive cough which tends to injure the mucous membrane of the air passages. uuid:e3bfc384-0659-49a2-a960-25f15984541a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1154173 biolink:treats MONDO:0003781 PMID:41385096 "[{""id"":""uuid:e764cd2d-8339-4cc3-8980-823f7e836be2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:42e567e2-a52a-4499-a65f-6474a9a80a49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atuss® DS Tannate Suspension is indicated for temporary relief of nasal congestion and cough associated with respiratory tract infections and related conditions such as sinusitis, pharyngitis, bronchitis and asthma when these conditions are complicated by tenacious mucus and/or mucous plugs and congestion. Atuss® DS Tannate Suspension is effective in a productive as well as a nonproductive cough, but is of particular value in a dry nonproductive cough which tends to injure the mucous membrane of the air passages. uuid:30059350-0759-4156-906c-979c95efe5d1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1154173 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:f55ff877-8054-414e-9be0-007ebff44d10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:68fa62b3-2d2d-489a-bed6-effba83bb2ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atuss® DS Tannate Suspension is indicated for temporary relief of nasal congestion and cough associated with respiratory tract infections and related conditions such as sinusitis, pharyngitis, bronchitis and asthma when these conditions are complicated by tenacious mucus and/or mucous plugs and congestion. Atuss® DS Tannate Suspension is effective in a productive as well as a nonproductive cough, but is of particular value in a dry nonproductive cough which tends to injure the mucous membrane of the air passages. uuid:449beedc-aa02-4b9a-b95d-133604612041 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1156977 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:a1bdd028-0b3c-4ff7-a1d5-3e719a1777c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:51b47c4a-e2d0-4aea-8971-b9010dc9901f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Pentazocine and naloxone hydrochlorides tablets are intended for oral use only. Severe, potentially lethal, reactions may result from misuse of pentazocine and naloxone hydrochlorides tablets by injection either alone or in combination with other substances. (See DRUG ABUSE AND DEPENDENCE section.) Pentazocine and naloxone hydrochlorides tablets are indicated for the relief of moderate to severe pain. Pentazocine and naloxone hydrochlorides tablets are indicated for oral use only. uuid:b0d07523-91ac-4da1-9705-2b1726ee72af biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:37789 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:20e38f70-ea44-48ad-afe4-f1745bda398d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:054fc34d-b6ce-46db-9c9b-e8e0059a023b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atenolol and chlorthalidone tablets are indicated in the treatment of hypertension. This fixed dose combination drug is not indicated for initial therapy of hypertension. If the fixed dose combination represents the dose appropriate to the individual patient’s needs, it may be more convenient than the separate components. uuid:5a0f2774-323d-4925-8d16-783be2487a62 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31174 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:4189e5b2-6a79-4a0a-b7e9-2aee63b220f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0f38d96e-1f6a-4e6a-9469-22a88dccf846"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:5154a486-64e2-4b66-8891-79d5ee9f68df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Adapalene Gel is indicated for the topical treatment of acne vulgaris.|[PMDA] A drug containing a new active ingredient indicated for the treatment of acne vulgaris. uuid:6d898456-6de7-4b4f-ac46-3f9ed140faa1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:39867 biolink:treats MONDO:0005277 PMID:41385096 "[{""id"":""uuid:99357585-188f-4079-b4e1-e650d4e602be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:24ff4cd1-1551-46eb-942b-ff8da81fbb80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Divalproex sodium extended-release tablets are indicated for: Acute treatment of manic or mixed episodes associated with bipolar disorder, with or without psychotic features (1.1) Monotherapy and adjunctive therapy of complex partial seizures and simple and complex absence seizures; adjunctive therapy in patients with multiple seizure types that include absence seizures (1.2) Prophylaxis of migraine headaches (1.3) uuid:e56d27a5-3b1a-48fe-b05f-c27bcb3188d8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:352990 biolink:treats MONDO:0005530 PMID:41385096 "[{""id"":""uuid:13b31062-46eb-4df3-8e4c-5936bbbdaf5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f158d244-56d2-44e1-bdd1-4e5509187e7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ea8c341c-475e-4486-ae82-704fa27af42c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/suboxone""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] SUBOXONE and SUBUTEX are indicated for the treatment of opioid dependence.|[EMA] Substitution treatment for opioid-drug dependence, within a framework of medical, social and psychological treatment. The intention of the naloxone component is to deter intravenous misuse. Treatment is intended for use in adults and adolescents over 15 years of age who have agreed to be treated for addiction. uuid:f246bd90-0143-4704-8ed1-827900c56f13 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8NZ41MIK1O biolink:treats HP:0002625 PMID:41385096 "[{""id"":""uuid:6eb0504f-3beb-48af-a2f9-6b1b6c6833d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:138430c8-964a-4f01-ad0e-41ba5c6a7682"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f8edc2dc-e546-4891-8cbc-8b017cffc4f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/inhixa""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lovenox is a low molecular weight heparin [LMWH] indicated for: Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery, knee replacement surgery, or medical patients with severely restricted mobility during acute illness ( 1.1 ) Inpatient treatment of acute DVT with or without pulmonary embolism ( 1.2 ) Outpatient treatment of acute DVT without pulmonary embolism. ( 1.2 ) Prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction [MI] ( 1.3 ) Treatment of acute ST-segment elevation myocardial infarction [STEMI] managed medically or with subsequent percutaneous coronary intervention [PCI] ( 1.4 )|[EMA] Inhixa is indicated for adults for:Prophylaxis of venous thromboembolism, particularly in patients undergoing orthopaedic, general or oncological surgery.Prophylaxis of venous thromboembolism in patients bedridden due to acute illnesses including acute heart failure, acute respiratory failure, severe infections, as well as exacerbation of rheumatic diseases causing immobilisation of the patient (applies to strengths of 40 mg/0.4 mL).Treatment of deep vein thrombosis (DVT), complicated or uncomplicated by pulmonary embolism.Treatment of unstable angina and non Q wave myocardial infarction, in combination with acetylsalicylic acid (ASA).Treatment of acute ST segment elevation myocardial infarction (STEMI) including patients who will be treated conservatively or who will later undergo percutaneous coronary angioplasty (applies to strengths of 60 mg/0.6 mL, 80 mg/0.8 mL, and 100 mg/1 mL).Blood clot prevention in the extracorporeal circulation during haemodialysis. uuid:be89217e-422d-4b43-8dde-234666e98555 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8NZ41MIK1O biolink:treats MONDO:0005279 PMID:41385096 "[{""id"":""uuid:b8f3ffcc-90a9-4865-926e-95509ce08ff3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:7ba46926-1919-4958-b3b3-ca2dc1792d26"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1708a19e-2ecc-4bad-980a-88c84b7d7a62"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/inhixa""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lovenox is a low molecular weight heparin [LMWH] indicated for: Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery, knee replacement surgery, or medical patients with severely restricted mobility during acute illness ( 1.1 ) Inpatient treatment of acute DVT with or without pulmonary embolism ( 1.2 ) Outpatient treatment of acute DVT without pulmonary embolism. ( 1.2 ) Prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction [MI] ( 1.3 ) Treatment of acute ST-segment elevation myocardial infarction [STEMI] managed medically or with subsequent percutaneous coronary intervention [PCI] ( 1.4 )|[EMA] Inhixa is indicated for adults for:Prophylaxis of venous thromboembolism, particularly in patients undergoing orthopaedic, general or oncological surgery.Prophylaxis of venous thromboembolism in patients bedridden due to acute illnesses including acute heart failure, acute respiratory failure, severe infections, as well as exacerbation of rheumatic diseases causing immobilisation of the patient (applies to strengths of 40 mg/0.4 mL).Treatment of deep vein thrombosis (DVT), complicated or uncomplicated by pulmonary embolism.Treatment of unstable angina and non Q wave myocardial infarction, in combination with acetylsalicylic acid (ASA).Treatment of acute ST segment elevation myocardial infarction (STEMI) including patients who will be treated conservatively or who will later undergo percutaneous coronary angioplasty (applies to strengths of 60 mg/0.6 mL, 80 mg/0.8 mL, and 100 mg/1 mL).Blood clot prevention in the extracorporeal circulation during haemodialysis. uuid:c52c67fc-4d2e-452b-be7a-34b06f8a7645 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8NZ41MIK1O biolink:treats MONDO:0006805 PMID:41385096 "[{""id"":""uuid:9c2a7aa5-698c-4f3c-9d69-7e3f93798f82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a2c3d799-c76b-4847-bfcb-7165f47683aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:82adcaa6-8b9f-4830-9246-e9ea8e1905bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/inhixa""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lovenox is a low molecular weight heparin [LMWH] indicated for: Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery, knee replacement surgery, or medical patients with severely restricted mobility during acute illness ( 1.1 ) Inpatient treatment of acute DVT with or without pulmonary embolism ( 1.2 ) Outpatient treatment of acute DVT without pulmonary embolism. ( 1.2 ) Prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction [MI] ( 1.3 ) Treatment of acute ST-segment elevation myocardial infarction [STEMI] managed medically or with subsequent percutaneous coronary intervention [PCI] ( 1.4 )|[EMA] Inhixa is indicated for adults for:Prophylaxis of venous thromboembolism, particularly in patients undergoing orthopaedic, general or oncological surgery.Prophylaxis of venous thromboembolism in patients bedridden due to acute illnesses including acute heart failure, acute respiratory failure, severe infections, as well as exacerbation of rheumatic diseases causing immobilisation of the patient (applies to strengths of 40 mg/0.4 mL).Treatment of deep vein thrombosis (DVT), complicated or uncomplicated by pulmonary embolism.Treatment of unstable angina and non Q wave myocardial infarction, in combination with acetylsalicylic acid (ASA).Treatment of acute ST segment elevation myocardial infarction (STEMI) including patients who will be treated conservatively or who will later undergo percutaneous coronary angioplasty (applies to strengths of 60 mg/0.6 mL, 80 mg/0.8 mL, and 100 mg/1 mL).Blood clot prevention in the extracorporeal circulation during haemodialysis. uuid:33584d3a-0061-426c-8bc1-dd4bd58d7a83 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8NZ41MIK1O biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:78db5adb-d4e8-44ab-a5c7-a8241f0104a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b690eeb8-500f-4fb7-b2be-a29aafd2c445"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lovenox is a low molecular weight heparin [LMWH] indicated for: Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery, knee replacement surgery, or medical patients with severely restricted mobility during acute illness ( 1.1 ) Inpatient treatment of acute DVT with or without pulmonary embolism ( 1.2 ) Outpatient treatment of acute DVT without pulmonary embolism. ( 1.2 ) Prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction [MI] ( 1.3 ) Treatment of acute ST-segment elevation myocardial infarction [STEMI] managed medically or with subsequent percutaneous coronary intervention [PCI] ( 1.4 ) uuid:3142f6a8-8553-4ffd-914f-7e44965e1130 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8NZ41MIK1O biolink:treats MONDO:0041656 PMID:41385096 "[{""id"":""uuid:25898bf8-c4a8-4c3b-af6f-cf75f4ad5016"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f899ae4e-2506-4d70-a5dd-e1aaacb0b37b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:518fe5b5-c91d-4b1d-b9c3-c1c7584886c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/inhixa""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lovenox is a low molecular weight heparin [LMWH] indicated for: Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery, knee replacement surgery, or medical patients with severely restricted mobility during acute illness ( 1.1 ) Inpatient treatment of acute DVT with or without pulmonary embolism ( 1.2 ) Outpatient treatment of acute DVT without pulmonary embolism. ( 1.2 ) Prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction [MI] ( 1.3 ) Treatment of acute ST-segment elevation myocardial infarction [STEMI] managed medically or with subsequent percutaneous coronary intervention [PCI] ( 1.4 )|[EMA] Inhixa is indicated for adults for:Prophylaxis of venous thromboembolism, particularly in patients undergoing orthopaedic, general or oncological surgery.Prophylaxis of venous thromboembolism in patients bedridden due to acute illnesses including acute heart failure, acute respiratory failure, severe infections, as well as exacerbation of rheumatic diseases causing immobilisation of the patient (applies to strengths of 40 mg/0.4 mL).Treatment of deep vein thrombosis (DVT), complicated or uncomplicated by pulmonary embolism.Treatment of unstable angina and non Q wave myocardial infarction, in combination with acetylsalicylic acid (ASA).Treatment of acute ST segment elevation myocardial infarction (STEMI) including patients who will be treated conservatively or who will later undergo percutaneous coronary angioplasty (applies to strengths of 60 mg/0.6 mL, 80 mg/0.8 mL, and 100 mg/1 mL).Blood clot prevention in the extracorporeal circulation during haemodialysis. uuid:b3cdf6b4-ac85-46ea-a290-77e0cb4de042 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5118 biolink:treats MONDO:0001866 PMID:41385096 "[{""id"":""uuid:51a59f01-c268-4b1e-8240-949c008fcf5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0b83b3c0-4936-44a4-8657-dabced0b6f39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluoxetine is a selective serotonin reuptake inhibitor indicated for: Acute and maintenance treatment of Major Depressive Disorder (MDD) in adult and pediatric patients aged 8 to 18 years ( 1.1 ) Acute and maintenance treatment of Obsessive Compulsive Disorder (OCD) in adult and pediatric patients aged 7 to 17 years ( 1.2 ) Acute and maintenance treatment of Bulimia Nervosa in adult patients ( 1.3 ) Acute treatment of Panic Disorder, with or without agoraphobia, in adult patients ( 1.4 ) Fluoxetine and olanzapine in combination for: Acute treatment of Depressive Episodes Associated with Bipolar I Disorder in adults ( 1.5 ) uuid:c4bdd724-7607-42bf-9893-eae2e0ddc511 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63580 biolink:treats MONDO:0005354 PMID:41385096 "[{""id"":""uuid:999764b4-7483-4f2d-b1c1-4e96bfaa9784"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f8f94dde-04ff-4842-b940-bf4310139531"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:6c257c08-52f8-4dc7-b8c1-8e0d51bdeaab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ribavirin tablets in combination with peginterferon alfa-2a are indicated for the treatment of adults with chronic hepatitis C virus infection who have compensated liver disease and have not been previously treated with interferon alpha. Patients in whom efficacy was demonstrated included patients with compensated liver disease and histological evidence of cirrhosis (Child-Pugh class A) and patients with HIV disease that is clinically stable (e.g., antiretroviral therapy not required or receiving stable antiretroviral therapy).|[PMDA] New drug application for Copegus to treat the following conditions, and additional indications and dosages for Pegasys. Ribavirin In combination with peginterferon alfa-2a , Ribavirin is indicated for the treatment of either of the following viremia in chronic hepatitis C. Patients with a high viral RNA load of HCV serogroup 1 (genotype I (1a) or II (1b)). Patients who are not responding to or relapsing after interferon monotherapy. PEG-IFNα-2a In combination with Ribavirin, peginterferon alfa-2a is indicated for the treatment of either of the following viremia in chronic hepatitis C. Patients with a high viral RNA load of HCV serogroup 1 (genotype I (1a) or II (1b)). Patients who are not responding to or relapsing after interferon monotherapy. (the above is the added part of labeling) uuid:da1d76d8-6095-43e6-8c84-909da5db3c02 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63580 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:b510aa1e-e4b9-44b8-8f5f-8e56de5b1ee0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0f25e677-168a-489d-9926-42f19a635673"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ribavirin tablets in combination with peginterferon alfa-2a are indicated for the treatment of adults with chronic hepatitis C virus infection who have compensated liver disease and have not been previously treated with interferon alpha. Patients in whom efficacy was demonstrated included patients with compensated liver disease and histological evidence of cirrhosis (Child-Pugh class A) and patients with HIV disease that is clinically stable (e.g., antiretroviral therapy not required or receiving stable antiretroviral therapy). uuid:a0a1e3f1-30e5-4b71-9f0e-1e29d087f17e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9445 biolink:treats MONDO:0010811 PMID:41385096 "[{""id"":""uuid:8a348110-fddd-457b-9575-4c9511f4af96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3b5b0aa1-6577-4b7a-b902-927b0a32e67b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Terazosin hydrochloride is indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH). There is a rapid response, with approximately 70% of patients experiencing an increase in urinary flow and improvement in symptoms of BPH when treated with terazosin hydrochloride. The long-term effects of terazosin hydrochloride on the incidence of surgery, acute urinary obstruction or other complications of BPH are yet to be determined. Terazosin hydrochloride is also indicated for the treatment of hypertension. It can be used alone or in combination with other antihypertensive agents such as diuretics or beta-adrenergic blocking agents. uuid:99ef220c-a844-4f75-8bf7-7468f5603d7c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9445 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:88152aa2-e9bf-4503-ac55-51bbbd3d796d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:408ab30e-32f7-4a3d-9fbe-bf57d1626b3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Terazosin hydrochloride is indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH). There is a rapid response, with approximately 70% of patients experiencing an increase in urinary flow and improvement in symptoms of BPH when treated with terazosin hydrochloride. The long-term effects of terazosin hydrochloride on the incidence of surgery, acute urinary obstruction or other complications of BPH are yet to be determined. Terazosin hydrochloride is also indicated for the treatment of hypertension. It can be used alone or in combination with other antihypertensive agents such as diuretics or beta-adrenergic blocking agents. uuid:09cc50f0-7adb-4181-a29d-c19d2957e7d7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:39867 biolink:treats MONDO:0001866 PMID:41385096 "[{""id"":""uuid:7c60daec-3001-4b8c-aee9-3569c66c9661"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:623af071-8d9b-47cf-b863-7cb51d62fb4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Divalproex sodium delayed-release tablets are indicated for the treatment of the manic episodes associated with bipolar disorder. A manic episode is a distinct period of abnormally and persistently elevated, expansive, or irritable mood. Typical symptoms of mania include pressure of speech, motor hyperactivity, reduced need for sleep, flight of ideas, grandiosity, poor judgement, aggressiveness, and possible hostility. The efficacy of divalproex sodium delayed-release tablets was established in 3-week trials with patients meeting DSMIII-R criteria for bipolar disorder who were hospitalized for acute mania (see Clinical Trials under CLINICAL PHARMACOLOGY ). The safety and effectiveness of divalproex sodium delayed-release tablets for long-term use in mania, i.e., more than 3 weeks, has not been systematically evaluated in controlled clinical trials. Therefore, healthcare providers who elect to use divalproex sodium delayed-release tablets for extended periods should continually reevaluate the long-term usefulness of the drug for the individual patient. uuid:31f17f3f-ec2f-4638-aaff-54ac5b01fac1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3380 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:1d724bbd-5a2b-4f8c-985a-5d6958cde26f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ee7e6c78-40b4-465f-81a4-780b511a3df2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Captopril tablets are indicated for the treatment of hypertension. In using captopril, consideration should be given to the risk of neutropenia/agranulocytosis (see WARNINGS ). Captopril may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. Captopril is effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of captopril and thiazides are approximately additive. uuid:5c484f26-94b0-4eef-b146-44a6789f7bb2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10100 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:c03d07a5-0e43-4b2a-b581-45be05e551f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6d697164-c4a7-4876-b758-965b93e5669c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ACCOLATE is indicated for the prophylaxis and chronic treatment of asthma in adults and children 5 years of age and older. uuid:97622cae-be19-4d7d-b6f3-e07b16cba781 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3387 biolink:treats MONDO:0005115 PMID:41385096 "[{""id"":""uuid:ffd2f288-bf71-4622-be05-f365d9bd7fa3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c2bd6054-f766-44e6-aec5-b4b7c4eeefd2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Epilepsy: Carbamazepine tablets are indicated for use as an anticonvulsant drug. Evidence supporting efficacy of carbamazepine as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types: 1. Partial seizures with complex symptomatology (psychomotor, temporal lobe). Patients with these seizures appear to show greater improvement than those with other types. 2. Generalized tonic-clonic seizures (grand mal). 3. Mixed seizure patterns which include the above, or other partial or generalized seizures. Absence seizures (petit mal) do not appear to be controlled by carbamazepine (see PRECAUTIONS, General ). Trigeminal Neuralgia: Carbamazepine tablets are indicated in the treatment of the pain associated with true trigeminal neuralgia. Beneficial results have also been reported in glossopharyngeal neuralgia. This drug is not a simple analgesic and should not be used for the relief of trivial aches or pains. uuid:ac05c2b4-27e4-4494-b4db-2fe532df3040 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3387 biolink:treats HP:0002069 PMID:41385096 "[{""id"":""uuid:86e99a0f-64b7-4836-bb86-9d8477308ba2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fa55c76f-2b8e-48c5-8650-3499d238bc00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Epilepsy: Carbamazepine tablets are indicated for use as an anticonvulsant drug. Evidence supporting efficacy of carbamazepine as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types: 1. Partial seizures with complex symptomatology (psychomotor, temporal lobe). Patients with these seizures appear to show greater improvement than those with other types. 2. Generalized tonic-clonic seizures (grand mal). 3. Mixed seizure patterns which include the above, or other partial or generalized seizures. Absence seizures (petit mal) do not appear to be controlled by carbamazepine (see PRECAUTIONS, General ). Trigeminal Neuralgia: Carbamazepine tablets are indicated in the treatment of the pain associated with true trigeminal neuralgia. Beneficial results have also been reported in glossopharyngeal neuralgia. This drug is not a simple analgesic and should not be used for the relief of trivial aches or pains. uuid:b412995b-0e5b-4e64-af37-92fb5d9456fe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3441 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:bbdf9695-3af8-40ef-9d02-4f84faaf0714"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:00f2b719-48b9-4531-ae26-673857cbd7a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carvedilol is an alpha/beta-adrenergic blocking agent indicated for the treatment of: Mild to severe chronic heart failure (1.1) Left ventricular dysfunction following myocardial infarction in clinically stable patients (1.2) Hypertension (1.3) uuid:ef62cb59-96d8-48c3-8651-25b7138a270a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3441 biolink:treats HP:0005162 PMID:41385096 "[{""id"":""uuid:71ad4c0a-3d9a-40d0-bac7-88a309ed60c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7b1b4693-ab0e-422f-8346-384fe73fa9da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carvedilol is an alpha/beta-adrenergic blocking agent indicated for the treatment of: Mild to severe chronic heart failure (1.1) Left ventricular dysfunction following myocardial infarction in clinically stable patients (1.2) Hypertension (1.3) uuid:6edcf610-9a3b-4bbf-9efa-d923aa1fd6a3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63589 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:6b5c22f8-012b-4967-9068-79eb9c9cbea5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:272c8fd6-4ec6-4df4-b835-142ce371480f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INTELENCE ® Registered trademark of Tibotec Pharmaceuticals , in combination with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-experienced adult patients, who have evidence of viral replication and HIV-1 strains resistant to a non-nucleoside reverse transcriptase inhibitor (NNRTI) and other antiretroviral agents. This indication is based on Week 48 analyses from 2 randomized, double-blind, placebo-controlled trials of INTELENCE ® . Both studies were conducted in clinically advanced, 3-class antiretroviral (NNRTI, N[t]RTI, PI) treatment-experienced adults. The following points should be considered when initiating therapy with INTELENCE ® : Treatment history and, when available, resistance testing, should guide the use of INTELENCE ® . The use of other active antiretroviral agents with INTELENCE ® is associated with an increased likelihood of treatment response. In patients who have experienced virologic failure on an NNRTI-containing regimen, do not use INTELENCE ® in combination with only N[t]RTIs [ see Clinical Studies (14) ]. The risks and benefits of INTELENCE ® have not been established in pediatric patients or in treatment-naïve adult patients. uuid:78b90c27-9492-47af-a8c1-45fe5c9e8ff8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42355 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:25d7d625-9a56-45b0-8c11-ac7368faa84a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e2af6f6b-d0e8-4370-80b6-3f4973e93b5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate tablets and other antibacterial drugs, erythromycin ethylsuccinate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin ethylsuccinate tablets are indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes , Streptococcus pneumoniae , or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum . Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N. gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. Syphilis Caused by Treponema Pallidum : Erythromycin is an alternate choice of treatment for primary syphilis in penicillin-allergic patients. In primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: Conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis . When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum . Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Prophylaxis Prevention of Initial Attacks of Rheumatic Fever Penicillin is considered by the American Heart Association to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of Streptococcus pyogenes infections of the upper respiratory tract, e.g., tonsillitis or pharyngitis). Erythromycin is indicated for the treatment of penicillin-allergic patients. 3 The therapeutic dose should be administered for 10 days. Prevention of Recurrent Attacks of Rheumatic Fever Penicillin or sulfonamides are considered by the American Heart Association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. In patients who are allergic to penicillin and sulfonamides, oral erythromycin is recommended by the American Heart Association in the long-term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever). 3 uuid:d6369492-aebd-4d77-9f44-77bf189eaf61 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42355 biolink:treats MONDO:0005828 PMID:41385096 "[{""id"":""uuid:4734afe8-f2ba-42aa-8bd3-1f307f035c2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1af81398-2a4d-453b-9dcd-02109b7405f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate tablets and other antibacterial drugs, erythromycin ethylsuccinate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin ethylsuccinate tablets are indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes , Streptococcus pneumoniae , or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum . Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N. gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. Syphilis Caused by Treponema Pallidum : Erythromycin is an alternate choice of treatment for primary syphilis in penicillin-allergic patients. In primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: Conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis . When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum . Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Prophylaxis Prevention of Initial Attacks of Rheumatic Fever Penicillin is considered by the American Heart Association to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of Streptococcus pyogenes infections of the upper respiratory tract, e.g., tonsillitis or pharyngitis). Erythromycin is indicated for the treatment of penicillin-allergic patients. 3 The therapeutic dose should be administered for 10 days. Prevention of Recurrent Attacks of Rheumatic Fever Penicillin or sulfonamides are considered by the American Heart Association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. In patients who are allergic to penicillin and sulfonamides, oral erythromycin is recommended by the American Heart Association in the long-term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever). 3 uuid:e51660e3-9636-4c91-8250-167759fe0cac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42355 biolink:treats MONDO:0005077 PMID:41385096 "[{""id"":""uuid:b2ad5a80-ea05-4f36-82db-2db558c37f89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fc4dc4de-f4e2-48d9-9727-bbe075adeb13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate tablets and other antibacterial drugs, erythromycin ethylsuccinate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin ethylsuccinate tablets are indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes , Streptococcus pneumoniae , or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum . Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N. gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. Syphilis Caused by Treponema Pallidum : Erythromycin is an alternate choice of treatment for primary syphilis in penicillin-allergic patients. In primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: Conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis . When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum . Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Prophylaxis Prevention of Initial Attacks of Rheumatic Fever Penicillin is considered by the American Heart Association to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of Streptococcus pyogenes infections of the upper respiratory tract, e.g., tonsillitis or pharyngitis). Erythromycin is indicated for the treatment of penicillin-allergic patients. 3 The therapeutic dose should be administered for 10 days. Prevention of Recurrent Attacks of Rheumatic Fever Penicillin or sulfonamides are considered by the American Heart Association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. In patients who are allergic to penicillin and sulfonamides, oral erythromycin is recommended by the American Heart Association in the long-term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever). 3 uuid:d324840e-8a79-409d-8aa5-29519db984a1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42355 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:690093f4-35c8-484b-9a32-652989c6f741"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8e8f2c66-ab77-43fc-8d21-8000f2718838"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate tablets and other antibacterial drugs, erythromycin ethylsuccinate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin ethylsuccinate tablets are indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes , Streptococcus pneumoniae , or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum . Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N. gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. Syphilis Caused by Treponema Pallidum : Erythromycin is an alternate choice of treatment for primary syphilis in penicillin-allergic patients. In primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: Conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis . When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum . Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Prophylaxis Prevention of Initial Attacks of Rheumatic Fever Penicillin is considered by the American Heart Association to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of Streptococcus pyogenes infections of the upper respiratory tract, e.g., tonsillitis or pharyngitis). Erythromycin is indicated for the treatment of penicillin-allergic patients. 3 The therapeutic dose should be administered for 10 days. Prevention of Recurrent Attacks of Rheumatic Fever Penicillin or sulfonamides are considered by the American Heart Association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. In patients who are allergic to penicillin and sulfonamides, oral erythromycin is recommended by the American Heart Association in the long-term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever). 3 uuid:46f56ef7-a0eb-48da-9939-87d8c77d67ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42355 biolink:treats MONDO:0005504 PMID:41385096 "[{""id"":""uuid:99c31670-aee2-4c6e-9305-cf0a38919ecc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6c95bb68-7889-41a3-bacd-eac62006352a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate tablets and other antibacterial drugs, erythromycin ethylsuccinate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin ethylsuccinate tablets are indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes , Streptococcus pneumoniae , or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum . Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N. gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. Syphilis Caused by Treponema Pallidum : Erythromycin is an alternate choice of treatment for primary syphilis in penicillin-allergic patients. In primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: Conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis . When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum . Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Prophylaxis Prevention of Initial Attacks of Rheumatic Fever Penicillin is considered by the American Heart Association to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of Streptococcus pyogenes infections of the upper respiratory tract, e.g., tonsillitis or pharyngitis). Erythromycin is indicated for the treatment of penicillin-allergic patients. 3 The therapeutic dose should be administered for 10 days. Prevention of Recurrent Attacks of Rheumatic Fever Penicillin or sulfonamides are considered by the American Heart Association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. In patients who are allergic to penicillin and sulfonamides, oral erythromycin is recommended by the American Heart Association in the long-term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever). 3 uuid:68c6af0e-be22-427d-8a18-d7d137fea487 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42355 biolink:treats MONDO:0002885 PMID:41385096 "[{""id"":""uuid:79d347d7-ed2b-4540-b044-095bcd333357"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:498e50ee-9e69-4f4b-a413-07106395c66b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate tablets and other antibacterial drugs, erythromycin ethylsuccinate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin ethylsuccinate tablets are indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes , Streptococcus pneumoniae , or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum . Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N. gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. Syphilis Caused by Treponema Pallidum : Erythromycin is an alternate choice of treatment for primary syphilis in penicillin-allergic patients. In primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: Conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis . When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum . Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Prophylaxis Prevention of Initial Attacks of Rheumatic Fever Penicillin is considered by the American Heart Association to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of Streptococcus pyogenes infections of the upper respiratory tract, e.g., tonsillitis or pharyngitis). Erythromycin is indicated for the treatment of penicillin-allergic patients. 3 The therapeutic dose should be administered for 10 days. Prevention of Recurrent Attacks of Rheumatic Fever Penicillin or sulfonamides are considered by the American Heart Association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. In patients who are allergic to penicillin and sulfonamides, oral erythromycin is recommended by the American Heart Association in the long-term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever). 3 uuid:fa99690c-e6a6-4dea-8134-162f0f956b6c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42355 biolink:treats MONDO:0005644 PMID:41385096 "[{""id"":""uuid:923b3b8e-a020-4308-8bbb-f18a0bce3889"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a0d196f3-a1a7-4912-9148-ad609ab62a96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate tablets and other antibacterial drugs, erythromycin ethylsuccinate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin ethylsuccinate tablets are indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes , Streptococcus pneumoniae , or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum . Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N. gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. Syphilis Caused by Treponema Pallidum : Erythromycin is an alternate choice of treatment for primary syphilis in penicillin-allergic patients. In primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: Conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis . When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum . Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Prophylaxis Prevention of Initial Attacks of Rheumatic Fever Penicillin is considered by the American Heart Association to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of Streptococcus pyogenes infections of the upper respiratory tract, e.g., tonsillitis or pharyngitis). Erythromycin is indicated for the treatment of penicillin-allergic patients. 3 The therapeutic dose should be administered for 10 days. Prevention of Recurrent Attacks of Rheumatic Fever Penicillin or sulfonamides are considered by the American Heart Association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. In patients who are allergic to penicillin and sulfonamides, oral erythromycin is recommended by the American Heart Association in the long-term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever). 3 uuid:7b9d2cf7-35a8-4ef9-b2af-1fb90e544373 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42355 biolink:treats UMLS:C0149959 PMID:41385096 "[{""id"":""uuid:b13a5234-d928-4f9d-b05c-d49c83eea9f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cb617e95-d61f-4435-a75d-a8893fad32e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate tablets and other antibacterial drugs, erythromycin ethylsuccinate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin ethylsuccinate tablets are indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes , Streptococcus pneumoniae , or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum . Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N. gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. Syphilis Caused by Treponema Pallidum : Erythromycin is an alternate choice of treatment for primary syphilis in penicillin-allergic patients. In primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: Conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis . When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum . Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Prophylaxis Prevention of Initial Attacks of Rheumatic Fever Penicillin is considered by the American Heart Association to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of Streptococcus pyogenes infections of the upper respiratory tract, e.g., tonsillitis or pharyngitis). Erythromycin is indicated for the treatment of penicillin-allergic patients. 3 The therapeutic dose should be administered for 10 days. Prevention of Recurrent Attacks of Rheumatic Fever Penicillin or sulfonamides are considered by the American Heart Association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. In patients who are allergic to penicillin and sulfonamides, oral erythromycin is recommended by the American Heart Association in the long-term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever). 3 uuid:2925e92a-2965-45a9-8dcf-f295f05c6b04 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42355 biolink:treats MONDO:0005976 PMID:41385096 "[{""id"":""uuid:555cd645-ee95-460d-96ea-c7804db38c84"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cbae68e0-eaaa-4bc0-829d-d9cb17bc7091"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate tablets and other antibacterial drugs, erythromycin ethylsuccinate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin ethylsuccinate tablets are indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes , Streptococcus pneumoniae , or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum . Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N. gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. Syphilis Caused by Treponema Pallidum : Erythromycin is an alternate choice of treatment for primary syphilis in penicillin-allergic patients. In primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: Conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis . When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum . Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Prophylaxis Prevention of Initial Attacks of Rheumatic Fever Penicillin is considered by the American Heart Association to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of Streptococcus pyogenes infections of the upper respiratory tract, e.g., tonsillitis or pharyngitis). Erythromycin is indicated for the treatment of penicillin-allergic patients. 3 The therapeutic dose should be administered for 10 days. Prevention of Recurrent Attacks of Rheumatic Fever Penicillin or sulfonamides are considered by the American Heart Association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. In patients who are allergic to penicillin and sulfonamides, oral erythromycin is recommended by the American Heart Association in the long-term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever). 3 uuid:d095710a-d7c0-46dc-98e6-c64748e68384 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42355 biolink:treats MONDO:0004854 PMID:41385096 "[{""id"":""uuid:6976661b-e96c-4cd3-80f5-a6347ff24296"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bc33b7eb-fedc-4790-b7c9-7640e490ecec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate tablets and other antibacterial drugs, erythromycin ethylsuccinate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin ethylsuccinate tablets are indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes , Streptococcus pneumoniae , or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum . Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N. gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. Syphilis Caused by Treponema Pallidum : Erythromycin is an alternate choice of treatment for primary syphilis in penicillin-allergic patients. In primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: Conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis . When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum . Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Prophylaxis Prevention of Initial Attacks of Rheumatic Fever Penicillin is considered by the American Heart Association to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of Streptococcus pyogenes infections of the upper respiratory tract, e.g., tonsillitis or pharyngitis). Erythromycin is indicated for the treatment of penicillin-allergic patients. 3 The therapeutic dose should be administered for 10 days. Prevention of Recurrent Attacks of Rheumatic Fever Penicillin or sulfonamides are considered by the American Heart Association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. In patients who are allergic to penicillin and sulfonamides, oral erythromycin is recommended by the American Heart Association in the long-term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever). 3 uuid:9624d6c9-58de-4142-b2f5-c8401df05ccf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42355 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:fa4a32d9-0f1e-4805-b3ce-a4251077c65c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fd163182-6e32-4dc0-a942-276daee308f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate tablets and other antibacterial drugs, erythromycin ethylsuccinate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin ethylsuccinate tablets are indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes , Streptococcus pneumoniae , or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum . Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N. gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. Syphilis Caused by Treponema Pallidum : Erythromycin is an alternate choice of treatment for primary syphilis in penicillin-allergic patients. In primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: Conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis . When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum . Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Prophylaxis Prevention of Initial Attacks of Rheumatic Fever Penicillin is considered by the American Heart Association to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of Streptococcus pyogenes infections of the upper respiratory tract, e.g., tonsillitis or pharyngitis). Erythromycin is indicated for the treatment of penicillin-allergic patients. 3 The therapeutic dose should be administered for 10 days. Prevention of Recurrent Attacks of Rheumatic Fever Penicillin or sulfonamides are considered by the American Heart Association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. In patients who are allergic to penicillin and sulfonamides, oral erythromycin is recommended by the American Heart Association in the long-term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever). 3 uuid:866a0126-fb43-4cb9-8101-d691c80ed672 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42355 biolink:treats MONDO:0005297 PMID:41385096 "[{""id"":""uuid:9068920d-b4aa-4e27-a315-f5763b4a4b56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4b50a93b-04f5-4b51-a75b-2c70f3fad55f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate tablets and other antibacterial drugs, erythromycin ethylsuccinate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin ethylsuccinate tablets are indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes , Streptococcus pneumoniae , or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum . Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N. gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. Syphilis Caused by Treponema Pallidum : Erythromycin is an alternate choice of treatment for primary syphilis in penicillin-allergic patients. In primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: Conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis . When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum . Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Prophylaxis Prevention of Initial Attacks of Rheumatic Fever Penicillin is considered by the American Heart Association to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of Streptococcus pyogenes infections of the upper respiratory tract, e.g., tonsillitis or pharyngitis). Erythromycin is indicated for the treatment of penicillin-allergic patients. 3 The therapeutic dose should be administered for 10 days. Prevention of Recurrent Attacks of Rheumatic Fever Penicillin or sulfonamides are considered by the American Heart Association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. In patients who are allergic to penicillin and sulfonamides, oral erythromycin is recommended by the American Heart Association in the long-term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever). 3 uuid:40d7fb05-0de4-4c1a-84a5-0f8f4be575a5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42355 biolink:treats MONDO:0005824 PMID:41385096 "[{""id"":""uuid:323fc505-66c6-4c96-bce2-08849fa9826f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b24b0da8-766b-4ab6-9e7b-c1cd48edcdf2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate tablets and other antibacterial drugs, erythromycin ethylsuccinate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin ethylsuccinate tablets are indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes , Streptococcus pneumoniae , or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum . Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N. gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. Syphilis Caused by Treponema Pallidum : Erythromycin is an alternate choice of treatment for primary syphilis in penicillin-allergic patients. In primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: Conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis . When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum . Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Prophylaxis Prevention of Initial Attacks of Rheumatic Fever Penicillin is considered by the American Heart Association to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of Streptococcus pyogenes infections of the upper respiratory tract, e.g., tonsillitis or pharyngitis). Erythromycin is indicated for the treatment of penicillin-allergic patients. 3 The therapeutic dose should be administered for 10 days. Prevention of Recurrent Attacks of Rheumatic Fever Penicillin or sulfonamides are considered by the American Heart Association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. In patients who are allergic to penicillin and sulfonamides, oral erythromycin is recommended by the American Heart Association in the long-term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever). 3 uuid:f4b1a258-4ee5-4337-9102-896ce22efb10 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42355 biolink:treats MONDO:0017767 PMID:41385096 "[{""id"":""uuid:548348dc-18fa-499a-972d-f14c4ac1e408"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:111b7d67-3fbb-48c6-bc16-fe9dabb35daa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate tablets and other antibacterial drugs, erythromycin ethylsuccinate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin ethylsuccinate tablets are indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes , Streptococcus pneumoniae , or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum . Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N. gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. Syphilis Caused by Treponema Pallidum : Erythromycin is an alternate choice of treatment for primary syphilis in penicillin-allergic patients. In primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: Conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis . When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum . Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Prophylaxis Prevention of Initial Attacks of Rheumatic Fever Penicillin is considered by the American Heart Association to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of Streptococcus pyogenes infections of the upper respiratory tract, e.g., tonsillitis or pharyngitis). Erythromycin is indicated for the treatment of penicillin-allergic patients. 3 The therapeutic dose should be administered for 10 days. Prevention of Recurrent Attacks of Rheumatic Fever Penicillin or sulfonamides are considered by the American Heart Association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. In patients who are allergic to penicillin and sulfonamides, oral erythromycin is recommended by the American Heart Association in the long-term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever). 3 uuid:e389426a-ab08-4020-ae56-34742e21bbbd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42355 biolink:treats MONDO:0001039 PMID:41385096 "[{""id"":""uuid:e63f785b-31db-4e68-8097-be1671cae622"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:211136ad-2b40-4a4d-a4b3-67c0405f49cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate tablets and other antibacterial drugs, erythromycin ethylsuccinate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin ethylsuccinate tablets are indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes , Streptococcus pneumoniae , or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum . Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N. gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. Syphilis Caused by Treponema Pallidum : Erythromycin is an alternate choice of treatment for primary syphilis in penicillin-allergic patients. In primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: Conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis . When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum . Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Prophylaxis Prevention of Initial Attacks of Rheumatic Fever Penicillin is considered by the American Heart Association to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of Streptococcus pyogenes infections of the upper respiratory tract, e.g., tonsillitis or pharyngitis). Erythromycin is indicated for the treatment of penicillin-allergic patients. 3 The therapeutic dose should be administered for 10 days. Prevention of Recurrent Attacks of Rheumatic Fever Penicillin or sulfonamides are considered by the American Heart Association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. In patients who are allergic to penicillin and sulfonamides, oral erythromycin is recommended by the American Heart Association in the long-term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever). 3 uuid:4c25f56b-7b00-4f09-b995-f200630e71a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42355 biolink:treats MONDO:0002258 PMID:41385096 "[{""id"":""uuid:b396be05-39f8-4c5d-92dd-f36372537a4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9de17cbd-2c0f-4d05-8618-f3222b902923"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate tablets and other antibacterial drugs, erythromycin ethylsuccinate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin ethylsuccinate tablets are indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes , Streptococcus pneumoniae , or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum . Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N. gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. Syphilis Caused by Treponema Pallidum : Erythromycin is an alternate choice of treatment for primary syphilis in penicillin-allergic patients. In primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: Conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis . When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum . Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Prophylaxis Prevention of Initial Attacks of Rheumatic Fever Penicillin is considered by the American Heart Association to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of Streptococcus pyogenes infections of the upper respiratory tract, e.g., tonsillitis or pharyngitis). Erythromycin is indicated for the treatment of penicillin-allergic patients. 3 The therapeutic dose should be administered for 10 days. Prevention of Recurrent Attacks of Rheumatic Fever Penicillin or sulfonamides are considered by the American Heart Association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. In patients who are allergic to penicillin and sulfonamides, oral erythromycin is recommended by the American Heart Association in the long-term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever). 3 uuid:55e25692-6c00-44a6-91ae-794af81dfae3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42355 biolink:treats MONDO:0021783 PMID:41385096 "[{""id"":""uuid:62a71fc3-da2a-468f-9648-7b0b4ec78b15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5e5c7d7b-fcc5-49c6-9f80-ae846a0ee311"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin ethylsuccinate tablets and other antibacterial drugs, erythromycin ethylsuccinate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin ethylsuccinate tablets are indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes , Streptococcus pneumoniae , or Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower-respiratory tract infections of mild to moderate severity caused by Streptococcus pneumoniae or Streptococcus pyogenes . Listeriosis caused by Listeria monocytogenes . Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum . Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae: As an alternative drug in treatment of acute pelvic inflammatory disease caused by N. gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. Syphilis Caused by Treponema Pallidum : Erythromycin is an alternate choice of treatment for primary syphilis in penicillin-allergic patients. In primary syphilis, spinal fluid examinations should be done before treatment and as part of follow-up after therapy. Erythromycins are indicated for the treatment of the following infections caused by Chlamydia trachomatis: Conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis . When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum . Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Prophylaxis Prevention of Initial Attacks of Rheumatic Fever Penicillin is considered by the American Heart Association to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of Streptococcus pyogenes infections of the upper respiratory tract, e.g., tonsillitis or pharyngitis). Erythromycin is indicated for the treatment of penicillin-allergic patients. 3 The therapeutic dose should be administered for 10 days. Prevention of Recurrent Attacks of Rheumatic Fever Penicillin or sulfonamides are considered by the American Heart Association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. In patients who are allergic to penicillin and sulfonamides, oral erythromycin is recommended by the American Heart Association in the long-term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever). 3 uuid:a58d3f95-cb9a-4b3c-bb40-72b112ec21cc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:391960 biolink:treats EFO:0006865 PMID:41385096 "[{""id"":""uuid:df991bf8-6f2c-41e3-a774-92aae78ea166"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7b2c8220-724f-459c-a266-879fe82ab0b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENABLEX ® (darifenacin) extended-release tablets are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency. uuid:b687f7b6-39b5-45a8-9e06-3c59f777e556 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42355 biolink:treats MONDO:0043885 PMID:41385096 "[{""id"":""uuid:6a1f28ff-3fb4-4d97-ae42-90a933722430"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:68fb2294-d19c-4d1f-a6d0-c6ad8305c164"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by organisms susceptible to erythromycin. For prophylaxis of ophthalmia neonatorum due to N. gonorrhoeae or C. trachomatis . The effectiveness of erythromycin in the prevention of ophthalmia caused by penicillinase-producing N. gonorrhoeae is not established. For infants born to mothers with clinically apparent gonorrhea, intravenous or intramuscular injections of aqueous crystalline penicillin G should be given; a single dose of 50,000 units for term infants or 20,000 units for infants of low birth weight. Topical prophylaxis alone is inadequate for these infants. uuid:ec8bdc16-33b5-44dc-b335-96bc1974c8b0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42355 biolink:treats MONDO:0004277 PMID:41385096 "[{""id"":""uuid:47b0f201-6c12-4157-a555-7b37aea59058"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2c376a72-d574-4f60-af19-c30d7577e7a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by organisms susceptible to erythromycin. For prophylaxis of ophthalmia neonatorum due to N. gonorrhoeae or C. trachomatis . The effectiveness of erythromycin in the prevention of ophthalmia caused by penicillinase-producing N. gonorrhoeae is not established. For infants born to mothers with clinically apparent gonorrhea, intravenous or intramuscular injections of aqueous crystalline penicillin G should be given; a single dose of 50,000 units for term infants or 20,000 units for infants of low birth weight. Topical prophylaxis alone is inadequate for these infants. uuid:65dc10d0-2142-4dfd-981d-88a92e626e1b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:602393 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:7ef668c8-8604-4bc0-a62f-dacfb623310b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ccfff647-9d9f-4739-955c-d820ed317b17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EPZICOM Tablets, in combination with other antiretroviral agents, are indicated for the treatment of HIV-1 infection. Additional important information on the use of EPZICOM for treatment of HIV-1 infection: EPZICOM is one of multiple products containing abacavir. Before starting EPZICOM, review medical history for prior exposure to any abacavir-containing product in order to avoid reintroduction in a patient with a history of hypersensitivity to abacavir. In one controlled study (CNA30021), more patients taking ZIAGEN 600 mg once daily had severe hypersensitivity reactions compared with patients taking ZIAGEN 300 mg twice daily. As part of a triple-drug regimen, EPZICOM Tablets are recommended for use with antiretroviral agents from different pharmacological classes and not with other nucleoside/nucleotide reverse transcriptase inhibitors. See WARNINGS, ADVERSE REACTIONS, and Description of Clinical Studies. uuid:fd407a25-77ae-42f3-bebc-98c969afacfc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2647689 biolink:treats HP:0000371 PMID:41385096 "[{""id"":""uuid:f7b78c56-b0fe-433a-a902-b725e4f1ad1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:df9edb1b-9f5f-459f-9361-d1c7fa3564f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For treatment of ACUTE OTITIS MEDIA in children that is caused by susceptible strains of Haemophilus influenzae . uuid:87e76464-90fb-4426-a058-26abfcb0884d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3746 biolink:treats MONDO:0018602 PMID:41385096 "[{""id"":""uuid:ade73db7-f8a0-4430-854a-f525a5884d49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d8a898f2-b272-4d82-9b89-cdc426ef53b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin hydrochloride and other antibacterial drugs, clindamycin hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:de10616f-080b-487b-96d6-db31a6c3984f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:187893 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:dc929506-581d-45d9-8191-bc67e0599697"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7c8174d9-388b-4cf5-a18c-fdca04d324b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS Baclofen is useful for the alleviation of signs and symptoms of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. Patients should have reversible spasticity so that baclofen treatment will aid in restoring residual function. Baclofen may also be of some value in patients with spinal cord injuries and other spinal cord diseases. Baclofen is not indicated in the treatment of skeletal muscle spasm resulting from rheumatic disorders. The efficacy of baclofen in stroke, cerebral palsy, and Parkinson’s disease has not been established and, therefore, it is not recommended for these conditions. uuid:52f59b89-8dd8-4c51-88fe-d7d019b17a74 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:490877 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:71d8ec93-5c37-4a81-86d3-cf2d7ef50ace"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b120edb6-47e0-492a-936e-c0b996dd8b09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Didanosine delayed-release capsules, also known as ddI, in combination with other antiretroviral agents is indicated for the treatment of human immunodeficiency virus (HIV)-1 infection [ see Clinical Studies ( 14 ) ]. uuid:16ed426b-efb4-4809-9432-7df483b456f9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82960 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:59f7c542-acdc-450f-becb-9bff5dbf5e49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a5cc65bf-87c4-4029-942b-03fd03659a53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:efbef147-e856-40ff-b313-418fccb40960"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/isentress""]},{""id"":""uuid:a867d14e-8b3e-4af0-a95d-17fbfbebf15f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ISENTRESS Registered trademark of MERCK & CO., Inc. COPYRIGHT © 2007, 2009 MERCK & CO., Inc. All rights reserved is indicated in combination with other anti-retroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection in adult patients. This indication is based on analyses of plasma HIV-1 RNA levels up through 48 weeks in three double-blind controlled studies of ISENTRESS. Two of these studies were conducted in clinically advanced, 3-class antiretroviral (NNRTI, NRTI, PI) treatment-experienced adults and one was conducted in treatment-naïve adults. The use of other active agents with ISENTRESS is associated with a greater likelihood of treatment response [see Clinical Studies (14) ] . The safety and efficacy of ISENTRESS have not been established in pediatric patients.|[EMA] Isentress is indicated in combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (HIV 1) infection.|[PMDA] A drug with a new dosage and in an additional dosage form indicated for the treatment of HIV infection. [Orphan drug] uuid:688307ae-73d9-408f-a6b0-13fc35e14b62 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8107 biolink:treats MONDO:0006710 PMID:41385096 "[{""id"":""uuid:d557797b-0471-4e4f-9c2d-6350f79f425c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4afa2518-282c-4f8b-9c28-121ca60c68d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Extended phenytoin sodium capsules are indicated for the control of generalized tonic-clonic (grand mal) and complex partial (psychomotor, temporal lobe) seizures and prevention and treatment of seizures occurring during or following neurosurgery. Phenytoin serum level determinations may be necessary for optimal dosage adjustments (see DOSAGE AND ADMINISTRATION and CLINICAL PHARMACOLOGY ). uuid:22d3283b-07b0-47a2-a618-0465463c86af biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10119 biolink:treats MONDO:0005090 PMID:41385096 "[{""id"":""uuid:1b87d109-b6e5-48a6-b103-6c9d09303979"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:60816c61-e072-440b-813a-4abe856fe197"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] GEODON is indicated for the treatment of schizophrenia, as monotherapy for the acute treatment of bipolar manic or mixed episodes, and as an adjunct to lithium or valproate for the maintenance treatment of bipolar disorder. GEODON intramuscular is indicated for acute agitation in schizophrenic patients. When deciding among the alternative treatments available for the condition needing treatment, the prescriber should consider the finding of ziprasidone's greater capacity to prolong the QT/QTc interval compared to several other antipsychotic drugs [ see Warnings and Precautions (5.2) ]. Prolongation of the QTc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia, and sudden death. In many cases this would lead to the conclusion that other drugs should be tried first. Whether ziprasidone will cause torsade de pointes or increase the rate of sudden death is not yet known [see Warnings and Precautions (5.2) ] uuid:363e05cb-78d1-42de-917e-105196b8e425 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10119 biolink:treats MONDO:0024612 PMID:41385096 "[{""id"":""uuid:55f41acf-7996-4996-90f0-a234c7b73fc1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cabcf41a-5861-4310-8835-4d4ad82f6a89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] GEODON is indicated for the treatment of schizophrenia, as monotherapy for the acute treatment of bipolar manic or mixed episodes, and as an adjunct to lithium or valproate for the maintenance treatment of bipolar disorder. GEODON intramuscular is indicated for acute agitation in schizophrenic patients. When deciding among the alternative treatments available for the condition needing treatment, the prescriber should consider the finding of ziprasidone's greater capacity to prolong the QT/QTc interval compared to several other antipsychotic drugs [ see Warnings and Precautions (5.2) ]. Prolongation of the QTc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia, and sudden death. In many cases this would lead to the conclusion that other drugs should be tried first. Whether ziprasidone will cause torsade de pointes or increase the rate of sudden death is not yet known [see Warnings and Precautions (5.2) ] uuid:d95e86f0-ec54-4ec6-95dd-78eeaf7b54e6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10119 biolink:treats MONDO:0004985 PMID:41385096 "[{""id"":""uuid:6e101150-4af0-4f5c-8fb8-89f86e5987ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3c67c3ad-d599-452b-8145-6970ef067e66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] GEODON is indicated for the treatment of schizophrenia, as monotherapy for the acute treatment of bipolar manic or mixed episodes, and as an adjunct to lithium or valproate for the maintenance treatment of bipolar disorder. GEODON intramuscular is indicated for acute agitation in schizophrenic patients. When deciding among the alternative treatments available for the condition needing treatment, the prescriber should consider the finding of ziprasidone's greater capacity to prolong the QT/QTc interval compared to several other antipsychotic drugs [ see Warnings and Precautions (5.2) ]. Prolongation of the QTc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia, and sudden death. In many cases this would lead to the conclusion that other drugs should be tried first. Whether ziprasidone will cause torsade de pointes or increase the rate of sudden death is not yet known [see Warnings and Precautions (5.2) ] uuid:ad4f406f-1460-4304-803c-b59f031a7aec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7662KG2R6K biolink:treats UMLS:C0267509 PMID:41385096 "[{""id"":""uuid:3434490f-2170-4e0d-bb48-02e184a5eee1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9f249869-76f0-41f6-aa3d-9ef3b54e5b2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amitiza is a chloride channel activator indicated for: Treatment of chronic idiopathic constipation in adults (1.1) Treatment of irritable bowel syndrome with constipation in women ≥ 18 years old (1.2) uuid:37372be2-337c-457f-8f73-2e92dde9a404 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7662KG2R6K biolink:treats MONDO:0005052 PMID:41385096 "[{""id"":""uuid:8fde5fa5-63c0-400d-b11f-4c443d3820cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e35c45bc-0422-425d-b3c0-2aa2734b432a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amitiza is a chloride channel activator indicated for: Treatment of chronic idiopathic constipation in adults (1.1) Treatment of irritable bowel syndrome with constipation in women ≥ 18 years old (1.2) uuid:258576e4-105a-4647-8fb3-75a3ef368f6d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:375719 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:4e56554c-2493-445d-a3b0-3405686df651"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a1609402-51b4-41f7-b506-0f6feb3f541d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Promethazine with codeine syrup is indicated for the temporary relief of coughs and upper respiratory symptoms associated with allergy or the common cold. uuid:b8184b0e-8970-4470-845c-bcb40f2a811b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:375719 biolink:treats MONDO:0005709 PMID:41385096 "[{""id"":""uuid:61c06cc6-a6ab-4091-a021-d88e3d3ece78"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:718748a7-fa73-4c01-a5a6-cf65d79a8d77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Promethazine with codeine syrup is indicated for the temporary relief of coughs and upper respiratory symptoms associated with allergy or the common cold. uuid:936484f1-8da7-42fb-b1dc-702128539032 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8435 biolink:treats HP:0002018 PMID:41385096 "[{""id"":""uuid:e16610c4-1c47-41cc-91a3-4a199e2e41ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9f863ef9-bee8-48a6-b7c0-4172c8badfeb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prochlorperazine 25 mg suppositories are indicated in the control of severe nausea and vomiting in adults. uuid:ed0dbbba-fc63-4487-80b9-e6cff80503ca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8435 biolink:treats HP:0002013 PMID:41385096 "[{""id"":""uuid:f1c8f959-3e3c-4b63-87a4-c440139422c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6c92dbe0-46a9-463a-8ea0-30840d405f37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prochlorperazine 25 mg suppositories are indicated in the control of severe nausea and vomiting in adults. uuid:985ff919-e56c-4a19-a450-fb3d8117b893 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:NQX9KB6PCL biolink:treats MONDO:0018997 PMID:41385096 "[{""id"":""uuid:904cfd24-ff6c-4567-a211-4a1c1e18ffd1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:76601801-b239-4393-85b4-12a47aded202"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ce8e8aaa-1193-4878-9030-3f0d36ef5ff3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Norditropin is a recombinant human growth hormone indicated for: Pediatric : Treatment of children with growth failure due to growth hormone deficiency (GHD), short stature associated with Noonan syndrome, short stature associated with Turner syndrome and short stature born SGA with no catch-up growth by age 2-4 years ( 1.1 ) Adult : Treatment of adults with either adult onset or childhood onset GHD ( 1.2 )|[PMDA] Drugs with a new additional indication for the treatment of short stature associated with Noonan syndrome with no epiphyseal closure. uuid:13676a3a-1352-4c41-bdab-d8693e348526 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:92050aa7-274e-4c9d-85aa-f3f9e4e26384"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c86a61dc-fc81-4555-9b4a-3145b662282a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Proquin XR is indicated only for the treatment of uncomplicated urinary tract infections (acute cystitis) caused by susceptible strains of the designated microorganisms listed below. Proquin XR is not interchangeable with other ciprofloxacin extended-release or immediate release oral formulations. See DOSAGE AND ADMINISTRATION for specific recommendations. Uncomplicated urinary tract infections (acute cystitis) caused by Escherichia coli and Klebsiella pneumoniae . THE SAFETY AND EFFICACY OF PROQUIN XR IN TREATING PYELONEPHRITIS, COMPLICATED URINARY TRACT INFECTIONS, AND INFECTIONS OTHER THAN UNCOMPLICATED URINARY TRACT INFECTIONS HAVE NOT BEEN DEMONSTRATED. Alternative therapy should be considered for patients who remain symptomatic or develop fever and back pain while on treatment with Proquin XR. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Proquin XR and other antibacterial drugs, Proquin XR should only be used to treat uncomplicated urinary tract infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and sensitivity information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:3a0163b7-916d-49a5-a306-5cb6af35947b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats MONDO:0001650 PMID:41385096 "[{""id"":""uuid:274148d1-4623-413f-88cc-338fa66fa229"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3e6798e9-506f-46a1-a95a-1db9c30cbeb4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Proquin XR is indicated only for the treatment of uncomplicated urinary tract infections (acute cystitis) caused by susceptible strains of the designated microorganisms listed below. Proquin XR is not interchangeable with other ciprofloxacin extended-release or immediate release oral formulations. See DOSAGE AND ADMINISTRATION for specific recommendations. Uncomplicated urinary tract infections (acute cystitis) caused by Escherichia coli and Klebsiella pneumoniae . THE SAFETY AND EFFICACY OF PROQUIN XR IN TREATING PYELONEPHRITIS, COMPLICATED URINARY TRACT INFECTIONS, AND INFECTIONS OTHER THAN UNCOMPLICATED URINARY TRACT INFECTIONS HAVE NOT BEEN DEMONSTRATED. Alternative therapy should be considered for patients who remain symptomatic or develop fever and back pain while on treatment with Proquin XR. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Proquin XR and other antibacterial drugs, Proquin XR should only be used to treat uncomplicated urinary tract infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and sensitivity information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:96cf4caf-6383-4e14-97a0-17710cb6fc82 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47781 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:72d15b3f-9a16-42af-86b3-953b64b1cd71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:13e15318-041c-4a01-b183-25dc79dbc229"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Desipramine hydrochloride is indicated for the treatment of depression. uuid:95e2019d-5aeb-4ac2-b189-99785dc5a99a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:261454 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:97c8086b-6093-4dbd-862b-cf52237ce26e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:faa41d3c-6718-4678-bed8-379fa9bf88d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:de365351-cfe8-4055-a1a0-6c0cd501a440"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AVALIDE ® (irbesartan-hydrochlorothiazide) Tablets is indicated for the treatment of hypertension. AVALIDE may be used in patients whose blood pressure is not adequately controlled on monotherapy. AVALIDE may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. The choice of AVALIDE as initial therapy for hypertension should be based on an assessment of potential benefits and risks. Patients with stage 2 (moderate or severe) hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and may be shaped by considerations such as the baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared with monotherapy. Data from Studies V and VI [see Clinical Studies (14.2) ] provide estimates of the probability of reaching a blood pressure goal with AVALIDE compared to irbesartan or HCTZ monotherapy. The relationship between baseline blood pressure and achievement of a SeSBP less than 140 or less than 130 mmHg or SeDBP less than 90 or less than 80 mmHg in patients treated with AVALIDE compared to patients treated with irbesartan or HCTZ monotherapy are shown in Figures 1a through 2b. Figure 1a: Probability of Achieving SBP less than 140 mmHg in Patients from Initial Therapy Studies V (Week 8) and VI (Week 7)* Figure 1b: Probability of Achieving SBP less than 130 mmHg in Patients from Initial Therapy Studies V (Week 8) and VI (Week 7)* Figure 2a: Probability of Achieving DBP less than 90 mmHg in Patients from Initial Therapy Studies V (Week 8) and VI (Week 7)* Figure 2b: Probability of Achieving DBP less than 80 mmHg in Patients from Initial Therapy Studies V (Week 8) and VI (Week 7)* *For all probability curves, patients without blood pressure measurements at Week 7 (Study VI) and Week 8 (Study V) were counted as not reaching goal (intent-to-treat analysis). The above graphs provide a rough approximation of the likelihood of reaching a targeted blood pressure goal (eg, Week 8 sitting systolic blood pressure less than or equal to 140 mmHg) for the treatment groups. The curve of each treatment group in each study was estimated by logistic regression modeling from all available data of that treatment group. The estimated likelihood at the right tail of each curve is less reliable due to small numbers of subjects with high baseline blood pressures. For example, a patient with a blood pressure of 180/105 mmHg has about a 25% likelihood of achieving a goal of less than 140 mmHg (systolic) and 50% likelihood of achieving less than 90 mmHg (diastolic) on irbesartan alone (and lower still likelihoods on HCTZ alone). The likelihood of achieving these goals on AVALIDE rises to about 40% (systolic) or 70% (diastolic).|[PMDA] New combination drugs indicated for the treatment of hypertension. uuid:d60d2bdf-2b95-4f6c-8680-b9edbbe7af87 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:261454 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:f23dd4e7-1c0d-471c-abfa-41044cb3ad93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e8e2208d-bc93-4602-8b7b-6cae4605e200"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AVALIDE ® (irbesartan-hydrochlorothiazide) Tablets is indicated for the treatment of hypertension. AVALIDE may be used in patients whose blood pressure is not adequately controlled on monotherapy. AVALIDE may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. The choice of AVALIDE as initial therapy for hypertension should be based on an assessment of potential benefits and risks. Patients with stage 2 (moderate or severe) hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and may be shaped by considerations such as the baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared with monotherapy. Data from Studies V and VI [see Clinical Studies (14.2) ] provide estimates of the probability of reaching a blood pressure goal with AVALIDE compared to irbesartan or HCTZ monotherapy. The relationship between baseline blood pressure and achievement of a SeSBP less than 140 or less than 130 mmHg or SeDBP less than 90 or less than 80 mmHg in patients treated with AVALIDE compared to patients treated with irbesartan or HCTZ monotherapy are shown in Figures 1a through 2b. Figure 1a: Probability of Achieving SBP less than 140 mmHg in Patients from Initial Therapy Studies V (Week 8) and VI (Week 7)* Figure 1b: Probability of Achieving SBP less than 130 mmHg in Patients from Initial Therapy Studies V (Week 8) and VI (Week 7)* Figure 2a: Probability of Achieving DBP less than 90 mmHg in Patients from Initial Therapy Studies V (Week 8) and VI (Week 7)* Figure 2b: Probability of Achieving DBP less than 80 mmHg in Patients from Initial Therapy Studies V (Week 8) and VI (Week 7)* *For all probability curves, patients without blood pressure measurements at Week 7 (Study VI) and Week 8 (Study V) were counted as not reaching goal (intent-to-treat analysis). The above graphs provide a rough approximation of the likelihood of reaching a targeted blood pressure goal (eg, Week 8 sitting systolic blood pressure less than or equal to 140 mmHg) for the treatment groups. The curve of each treatment group in each study was estimated by logistic regression modeling from all available data of that treatment group. The estimated likelihood at the right tail of each curve is less reliable due to small numbers of subjects with high baseline blood pressures. For example, a patient with a blood pressure of 180/105 mmHg has about a 25% likelihood of achieving a goal of less than 140 mmHg (systolic) and 50% likelihood of achieving less than 90 mmHg (diastolic) on irbesartan alone (and lower still likelihoods on HCTZ alone). The likelihood of achieving these goals on AVALIDE rises to about 40% (systolic) or 70% (diastolic). uuid:5851b661-66ca-40d8-8952-8a25ab906dd8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:261454 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:4281a435-1f38-4999-9171-a66d8c43e54c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4ebaa710-e437-4647-a843-cd93ee487c64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AVALIDE ® (irbesartan-hydrochlorothiazide) Tablets is indicated for the treatment of hypertension. AVALIDE may be used in patients whose blood pressure is not adequately controlled on monotherapy. AVALIDE may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. The choice of AVALIDE as initial therapy for hypertension should be based on an assessment of potential benefits and risks. Patients with stage 2 (moderate or severe) hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and may be shaped by considerations such as the baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared with monotherapy. Data from Studies V and VI [see Clinical Studies (14.2) ] provide estimates of the probability of reaching a blood pressure goal with AVALIDE compared to irbesartan or HCTZ monotherapy. The relationship between baseline blood pressure and achievement of a SeSBP less than 140 or less than 130 mmHg or SeDBP less than 90 or less than 80 mmHg in patients treated with AVALIDE compared to patients treated with irbesartan or HCTZ monotherapy are shown in Figures 1a through 2b. Figure 1a: Probability of Achieving SBP less than 140 mmHg in Patients from Initial Therapy Studies V (Week 8) and VI (Week 7)* Figure 1b: Probability of Achieving SBP less than 130 mmHg in Patients from Initial Therapy Studies V (Week 8) and VI (Week 7)* Figure 2a: Probability of Achieving DBP less than 90 mmHg in Patients from Initial Therapy Studies V (Week 8) and VI (Week 7)* Figure 2b: Probability of Achieving DBP less than 80 mmHg in Patients from Initial Therapy Studies V (Week 8) and VI (Week 7)* *For all probability curves, patients without blood pressure measurements at Week 7 (Study VI) and Week 8 (Study V) were counted as not reaching goal (intent-to-treat analysis). The above graphs provide a rough approximation of the likelihood of reaching a targeted blood pressure goal (eg, Week 8 sitting systolic blood pressure less than or equal to 140 mmHg) for the treatment groups. The curve of each treatment group in each study was estimated by logistic regression modeling from all available data of that treatment group. The estimated likelihood at the right tail of each curve is less reliable due to small numbers of subjects with high baseline blood pressures. For example, a patient with a blood pressure of 180/105 mmHg has about a 25% likelihood of achieving a goal of less than 140 mmHg (systolic) and 50% likelihood of achieving less than 90 mmHg (diastolic) on irbesartan alone (and lower still likelihoods on HCTZ alone). The likelihood of achieving these goals on AVALIDE rises to about 40% (systolic) or 70% (diastolic). uuid:75263c52-195b-47a6-9596-aedd35bb668c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:261454 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:a10e7dcb-d057-4b71-a7a4-1741c45a8c7c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:522226aa-73c4-4170-b47c-7f160fe35da7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AVALIDE ® (irbesartan-hydrochlorothiazide) Tablets is indicated for the treatment of hypertension. AVALIDE may be used in patients whose blood pressure is not adequately controlled on monotherapy. AVALIDE may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. The choice of AVALIDE as initial therapy for hypertension should be based on an assessment of potential benefits and risks. Patients with stage 2 (moderate or severe) hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and may be shaped by considerations such as the baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared with monotherapy. Data from Studies V and VI [see Clinical Studies (14.2) ] provide estimates of the probability of reaching a blood pressure goal with AVALIDE compared to irbesartan or HCTZ monotherapy. The relationship between baseline blood pressure and achievement of a SeSBP less than 140 or less than 130 mmHg or SeDBP less than 90 or less than 80 mmHg in patients treated with AVALIDE compared to patients treated with irbesartan or HCTZ monotherapy are shown in Figures 1a through 2b. Figure 1a: Probability of Achieving SBP less than 140 mmHg in Patients from Initial Therapy Studies V (Week 8) and VI (Week 7)* Figure 1b: Probability of Achieving SBP less than 130 mmHg in Patients from Initial Therapy Studies V (Week 8) and VI (Week 7)* Figure 2a: Probability of Achieving DBP less than 90 mmHg in Patients from Initial Therapy Studies V (Week 8) and VI (Week 7)* Figure 2b: Probability of Achieving DBP less than 80 mmHg in Patients from Initial Therapy Studies V (Week 8) and VI (Week 7)* *For all probability curves, patients without blood pressure measurements at Week 7 (Study VI) and Week 8 (Study V) were counted as not reaching goal (intent-to-treat analysis). The above graphs provide a rough approximation of the likelihood of reaching a targeted blood pressure goal (eg, Week 8 sitting systolic blood pressure less than or equal to 140 mmHg) for the treatment groups. The curve of each treatment group in each study was estimated by logistic regression modeling from all available data of that treatment group. The estimated likelihood at the right tail of each curve is less reliable due to small numbers of subjects with high baseline blood pressures. For example, a patient with a blood pressure of 180/105 mmHg has about a 25% likelihood of achieving a goal of less than 140 mmHg (systolic) and 50% likelihood of achieving less than 90 mmHg (diastolic) on irbesartan alone (and lower still likelihoods on HCTZ alone). The likelihood of achieving these goals on AVALIDE rises to about 40% (systolic) or 70% (diastolic). uuid:37890496-2a22-4c05-92b8-c4369e91c4b4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:261454 biolink:treats MONDO:0001106 PMID:41385096 "[{""id"":""uuid:b3f51d80-6607-4466-8ffd-773209b8d6a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8f143782-49b1-4ff0-96f6-1bd5a071af2b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AVALIDE ® (irbesartan-hydrochlorothiazide) Tablets is indicated for the treatment of hypertension. AVALIDE may be used in patients whose blood pressure is not adequately controlled on monotherapy. AVALIDE may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. The choice of AVALIDE as initial therapy for hypertension should be based on an assessment of potential benefits and risks. Patients with stage 2 (moderate or severe) hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and may be shaped by considerations such as the baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared with monotherapy. Data from Studies V and VI [see Clinical Studies (14.2) ] provide estimates of the probability of reaching a blood pressure goal with AVALIDE compared to irbesartan or HCTZ monotherapy. The relationship between baseline blood pressure and achievement of a SeSBP less than 140 or less than 130 mmHg or SeDBP less than 90 or less than 80 mmHg in patients treated with AVALIDE compared to patients treated with irbesartan or HCTZ monotherapy are shown in Figures 1a through 2b. Figure 1a: Probability of Achieving SBP less than 140 mmHg in Patients from Initial Therapy Studies V (Week 8) and VI (Week 7)* Figure 1b: Probability of Achieving SBP less than 130 mmHg in Patients from Initial Therapy Studies V (Week 8) and VI (Week 7)* Figure 2a: Probability of Achieving DBP less than 90 mmHg in Patients from Initial Therapy Studies V (Week 8) and VI (Week 7)* Figure 2b: Probability of Achieving DBP less than 80 mmHg in Patients from Initial Therapy Studies V (Week 8) and VI (Week 7)* *For all probability curves, patients without blood pressure measurements at Week 7 (Study VI) and Week 8 (Study V) were counted as not reaching goal (intent-to-treat analysis). The above graphs provide a rough approximation of the likelihood of reaching a targeted blood pressure goal (eg, Week 8 sitting systolic blood pressure less than or equal to 140 mmHg) for the treatment groups. The curve of each treatment group in each study was estimated by logistic regression modeling from all available data of that treatment group. The estimated likelihood at the right tail of each curve is less reliable due to small numbers of subjects with high baseline blood pressures. For example, a patient with a blood pressure of 180/105 mmHg has about a 25% likelihood of achieving a goal of less than 140 mmHg (systolic) and 50% likelihood of achieving less than 90 mmHg (diastolic) on irbesartan alone (and lower still likelihoods on HCTZ alone). The likelihood of achieving these goals on AVALIDE rises to about 40% (systolic) or 70% (diastolic). uuid:102c2e52-fc4d-43e8-b51c-fcec52615bba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44032 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:e54dbc17-4595-4e6e-ad6e-ede4af9d1aec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f9386b15-5925-41d0-8149-fd78cbb00614"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CRIXIVAN in combination with antiretroviral agents is indicated for the treatment of HIV infection. This indication is based on two clinical trials of approximately 1 year duration that demonstrated: 1) a reduction in the risk of AIDS-defining illnesses or death; 2) a prolonged suppression of HIV RNA. uuid:399e5fff-360e-418a-929a-37594bc0bdc8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44032 biolink:treats UMLS:C0740842 PMID:41385096 "[{""id"":""uuid:b7c34ad9-ab28-4193-a5e8-f3b3d2dd2451"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ebd67f0e-8574-47ed-80e6-270781c60f7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CRIXIVAN in combination with antiretroviral agents is indicated for the treatment of HIV infection. This indication is based on two clinical trials of approximately 1 year duration that demonstrated: 1) a reduction in the risk of AIDS-defining illnesses or death; 2) a prolonged suppression of HIV RNA. uuid:5fb1830a-231c-4255-aa88-9328f85b6c06 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:578771 biolink:treats MONDO:0005093 PMID:41385096 "[{""id"":""uuid:6e502a06-940f-4cc2-8751-8b400a3e7503"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:de232b87-5af2-4bd1-92cd-1cafe9f088da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of cortico-steroid-responsive dermatoses. uuid:138f4744-7426-4bc1-834a-05393539dbb9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46345 biolink:treats MONDO:0005173 PMID:41385096 "[{""id"":""uuid:bdc6d52a-68b9-4908-b13f-36403bf23e5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e7564e3f-3542-4788-be3c-19cb10e7133c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluorouracil is recommended for the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Safety and efficacy in other indications have not been established. The diagnosis should be established prior to treatment, since this method has not been proven effective in other types of basal cell carcinomas. With isolated, easily accessible basal cell carcinomas, surgery is preferred since success with such lesions is almost 100%. The success rate with Fluorouracil Cream and Solution is approximately 93%, based on 113 lesions in 54 patients. Twenty-five lesions treated with the solution produced 1 failure and 88 lesions treated with the cream produced 7 failures. uuid:eecc6063-9d7e-4aa5-949f-25c11a10d2f0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46345 biolink:treats UMLS:C1274598 PMID:41385096 "[{""id"":""uuid:fe170b75-1693-49e7-9d24-1d01fab33e46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2111fcc3-e1ac-4bfa-9ab7-0afb1daa9ce4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluorouracil is recommended for the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Safety and efficacy in other indications have not been established. The diagnosis should be established prior to treatment, since this method has not been proven effective in other types of basal cell carcinomas. With isolated, easily accessible basal cell carcinomas, surgery is preferred since success with such lesions is almost 100%. The success rate with Fluorouracil Cream and Solution is approximately 93%, based on 113 lesions in 54 patients. Twenty-five lesions treated with the solution produced 1 failure and 88 lesions treated with the cream produced 7 failures. uuid:6283cf92-b1fd-45cb-9520-35d7a3ff6323 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46345 biolink:treats MONDO:0002954 PMID:41385096 "[{""id"":""uuid:49185140-9801-4292-b57f-21ed93d64578"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c7b4a170-bf9f-425e-8374-bbc4b3945664"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluorouracil is recommended for the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Safety and efficacy in other indications have not been established. The diagnosis should be established prior to treatment, since this method has not been proven effective in other types of basal cell carcinomas. With isolated, easily accessible basal cell carcinomas, surgery is preferred since success with such lesions is almost 100%. The success rate with Fluorouracil Cream and Solution is approximately 93%, based on 113 lesions in 54 patients. Twenty-five lesions treated with the solution produced 1 failure and 88 lesions treated with the cream produced 7 failures. uuid:62c83e71-4b40-418f-9510-5a1af718b805 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46345 biolink:treats MONDO:0005341 PMID:41385096 "[{""id"":""uuid:528bc96f-8c35-4574-bbae-297ce8ab072d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1f3cb088-9ad8-4e51-baeb-4c5d62e09e76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluorouracil is recommended for the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Safety and efficacy in other indications have not been established. The diagnosis should be established prior to treatment, since this method has not been proven effective in other types of basal cell carcinomas. With isolated, easily accessible basal cell carcinomas, surgery is preferred since success with such lesions is almost 100%. The success rate with Fluorouracil Cream and Solution is approximately 93%, based on 113 lesions in 54 patients. Twenty-five lesions treated with the solution produced 1 failure and 88 lesions treated with the cream produced 7 failures. uuid:d9fbdca9-c496-4019-bbb7-fd386edb7998 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0006604 PMID:41385096 "[{""id"":""uuid:afad87a3-40d4-4573-9ed1-a1dc9fd2cdfa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7726b968-47a0-44e1-864e-ef30402ec64a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:18afc5f0-bc06-4737-8a37-212ddfec3a6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metronidazole Topical Cream is indicated for topical application in the treatment of inflammatory papules and pustules of rosacea.|[PMDA] A drug with a new indication and a new dosage for the treatment of rosacea. uuid:68c80e68-7168-4953-a204-82b1983de5e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:367163 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:dee73bb2-1733-4dfc-95b9-c1a4b216ad6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fd85d7f4-d842-4bf0-a4ba-5526963439ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:46040b79-5ffc-4f75-a109-82f5276ef7f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/darunavir-mylan""]},{""id"":""uuid:44053613-0ce9-470d-b7ea-49e681aa2acd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PREZISTA is a human immunodeficiency virus (HIV-1) protease inhibitor indicated for the treatment of HIV infection in adult patients. PREZISTA is also indicated for the treatment of HIV infection in pediatric patients 6 years of age and older. PREZISTA must be co-administered with ritonavir (PREZISTA/ritonavir) and with other antiretroviral agents. ( 1 )|[EMA] Darunavir, co-administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (HIV-1) infection (see section 4.2).Darunavir Mylan 75 mg, 150 mg, 300 mg and 600 mg tablets may be used to provide suitable dose regimens (see section 4.2):For the treatment of HIV-1 infection in antiretroviral treatment (ART)-experienced adult patients, including those that have been highly pre-treated.For the treatment of HIV-1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight.In deciding to initiate treatment with darunavir co-administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. Genotypic or phenotypic testing (when available) and treatment history should guide the use of darunavir (see sections 4.2, 4.4 and 5.1).Darunavir co-administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (HIV-1) infection. Darunavir co-administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg) (see section 4.2). Darunavir Mylan 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of HIV-1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are: antiretroviral therapy (ART)-naïve (see section 4.2). ART-experienced with no darunavir resistance associated mutations (DRV-RAMs) and who have plasma HIV-1 RNA < 100,000 copies/ml and CD4+ cell count ≥ 100 cells x 10⁶/L. In deciding to initiate treatment with darunavir in such ART-experienced patients, genotypic testing should guide the use of darunavir (see sections 4.2, 4.3, 4.4 and 5.1).|[PMDA] A drug with a new dosage indicated for the treatment of HIV infection. [Orphan drug] uuid:cb0295d9-3e8f-43db-8e1c-b616ca5d87b4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6775 biolink:treats UMLS:C5779507 PMID:41385096 "[{""id"":""uuid:83177a19-5814-4b3e-a352-2d5446e35f82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ea397c84-167a-4404-a9e5-d59a17aa6fe4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CANASA ® 1000 mg Suppositories are indicated for the treatment of active ulcerative proctitis. uuid:ffde09ba-9b8a-4cd6-9ff7-ae444834730f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8871 biolink:treats HP:0100754 PMID:41385096 "[{""id"":""uuid:1a1cb6eb-83b9-40b1-bf09-7a2016319505"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:749a2e61-6016-4bf9-9abf-ea72f07469b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RISPERIDONE is an atypical antipsychotic agent indicated for: Treatment of schizophrenia in adults ( 1.1 ) Alone, or in combination with lithium or valproate, for the short-term treatment of acute manic or mixed episodes associated with Bipolar I Disorder in adults ( 1.2 ) Due to Janssen Pharmaceuticals Corporation's marketing exclusivity rights, this drug product is not labeled for use in pediatric patients with schizophrenia, bipolar mania or autistic disorder. ( 1.1 , 1.2 , 1.3 ) uuid:a4a071cd-5f4e-4dfe-9598-823cce33d16a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:375581 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:606c7ff9-e806-4b02-a434-8a6457c1bc19"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:29134beb-f886-4b74-ac6d-fecec46cc566"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxycodone and acetaminophen tablets USP are indicated for the relief of moderate to moderately severe pain. uuid:e3b6e1d6-1038-4208-b5d5-b71dc271a206 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37941 biolink:treats MONDO:0005542 PMID:41385096 "[{""id"":""uuid:c8bf0707-fb37-4df7-a0a2-dd40b4d8f648"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7c6cef4c-c834-4cd2-a1ba-ef543d3e5b22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Plavix is a P2Y 12 platelet inhibitor indicated for: Acute coronary syndrome Recent myocardial infarction (MI), recent stroke, or established peripheral arterial disease. Plavix has been shown to reduce the combined endpoint of new ischemic stroke (fatal or not), new MI (fatal or not), and other vascular death. ( 1.2 ) uuid:0d747f21-2146-4274-af2e-72fae14794b2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5778 biolink:treats HP:0000969 PMID:41385096 "[{""id"":""uuid:66cc7606-c23d-4d0e-8dbc-dba2dda32ac4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1d078b01-a358-48df-9fbd-bdc895b31a1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydrochlorothiazide is indicated in the management of hypertension either as the sole therapeutic agent, or in combination with other antihypertensives. Unlike potassium sparing combination diuretic products, hydrochlorothiazide may be used in those patients in whom the development of hyperkalemia cannot be risked, including patients taking ACE inhibitors. Usage in Pregnancy: The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. Edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. Diuretics are indicated in pregnancy when edema is due to pathologic causes, just as they are in the absence of pregnancy. Dependent edema in pregnancy resulting from restriction of venous return by the expanded uterus is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances this edema may cause extreme discomfort which is not relieved by rest. In these cases a short course of diuretics may provide relief and may be appropriate. uuid:ce4b6b14-1e81-467b-85a2-b6940bb75d27 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1157355 biolink:treats UMLS:C5442256 PMID:41385096 "[{""id"":""uuid:609d7818-e4d2-4d97-a61c-244fa36e39fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:83b6f1fa-3493-4f08-ac97-11fc8a4dfaeb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] femhrt is indicated in women with an intact uterus for the: Treatment of moderate to severe vasomotor symptoms associated with the menopause. Prevention of postmenopausal osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis. Non-estrogen medications should be carefully considered. The mainstays for decreasing the risk of postmenopausal osteoporosis are weight-bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 1500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400-800 IU/day may also be required to ensure adequate daily intake in postmenopausal women. Risk factors for osteoporosis include low bone mineral density, low estrogen levels, family history of osteoporosis, previous fracture, small frame (low BMI), light skin color, smoking, and alcohol intake. Response to therapy can be predicted by pre-treatment serum estradiol, and can be assessed during treatment by measuring biochemical markers of bone formation/resorption, and/or bone mineral density. Estrogen therapy reduces bone resorption and retards or halts postmenopausal bone loss. Studies have shown a risk ratio of about 0.4 for hip and wrist fractures in women whose estrogen therapy was begun within a few years of menopause, compared to women taking calcium and vitamin D alone. Studies also suggest that estrogen reduces the rate of vertebral fractures. Even when started as late as 6 years after menopause, estrogen reduces further loss of bone mass for as long as treatment is continued. When estrogen therapy is discontinued, bone mass declines at a rate comparable to the immediate postmenopausal period. Data from the Women's Health Initiative study showed that use of estrogen-plus-progestin (dose equivalent to 0.625 mg CE and 2.5 mg MPA) resulted in about 5 less hip fractures per 10,000 women-years, compared to use of placebo (risk ratio about 0.66). uuid:06874729-9abd-4df6-bcd3-59e830e9f91b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1157355 biolink:treats MONDO:0008159 PMID:41385096 "[{""id"":""uuid:d610e25f-3db0-42ff-97d5-bc16702a4487"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8e64e732-93f6-4621-99e1-93f9e921b35a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] femhrt is indicated in women with an intact uterus for the: Treatment of moderate to severe vasomotor symptoms associated with the menopause. Prevention of postmenopausal osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis. Non-estrogen medications should be carefully considered. The mainstays for decreasing the risk of postmenopausal osteoporosis are weight-bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 1500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400-800 IU/day may also be required to ensure adequate daily intake in postmenopausal women. Risk factors for osteoporosis include low bone mineral density, low estrogen levels, family history of osteoporosis, previous fracture, small frame (low BMI), light skin color, smoking, and alcohol intake. Response to therapy can be predicted by pre-treatment serum estradiol, and can be assessed during treatment by measuring biochemical markers of bone formation/resorption, and/or bone mineral density. Estrogen therapy reduces bone resorption and retards or halts postmenopausal bone loss. Studies have shown a risk ratio of about 0.4 for hip and wrist fractures in women whose estrogen therapy was begun within a few years of menopause, compared to women taking calcium and vitamin D alone. Studies also suggest that estrogen reduces the rate of vertebral fractures. Even when started as late as 6 years after menopause, estrogen reduces further loss of bone mass for as long as treatment is continued. When estrogen therapy is discontinued, bone mass declines at a rate comparable to the immediate postmenopausal period. Data from the Women's Health Initiative study showed that use of estrogen-plus-progestin (dose equivalent to 0.625 mg CE and 2.5 mg MPA) resulted in about 5 less hip fractures per 10,000 women-years, compared to use of placebo (risk ratio about 0.66). uuid:bbe6b361-43e5-4b33-8841-4ee725412399 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1157355 biolink:treats HP:6000655 PMID:41385096 "[{""id"":""uuid:786cf8f8-ab4d-4ced-855e-757f5008aac0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bed842bf-0536-4c6b-b3e2-936c16e5296d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] femhrt is indicated in women with an intact uterus for the: Treatment of moderate to severe vasomotor symptoms associated with the menopause. Prevention of postmenopausal osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis. Non-estrogen medications should be carefully considered. The mainstays for decreasing the risk of postmenopausal osteoporosis are weight-bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 1500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400-800 IU/day may also be required to ensure adequate daily intake in postmenopausal women. Risk factors for osteoporosis include low bone mineral density, low estrogen levels, family history of osteoporosis, previous fracture, small frame (low BMI), light skin color, smoking, and alcohol intake. Response to therapy can be predicted by pre-treatment serum estradiol, and can be assessed during treatment by measuring biochemical markers of bone formation/resorption, and/or bone mineral density. Estrogen therapy reduces bone resorption and retards or halts postmenopausal bone loss. Studies have shown a risk ratio of about 0.4 for hip and wrist fractures in women whose estrogen therapy was begun within a few years of menopause, compared to women taking calcium and vitamin D alone. Studies also suggest that estrogen reduces the rate of vertebral fractures. Even when started as late as 6 years after menopause, estrogen reduces further loss of bone mass for as long as treatment is continued. When estrogen therapy is discontinued, bone mass declines at a rate comparable to the immediate postmenopausal period. Data from the Women's Health Initiative study showed that use of estrogen-plus-progestin (dose equivalent to 0.625 mg CE and 2.5 mg MPA) resulted in about 5 less hip fractures per 10,000 women-years, compared to use of placebo (risk ratio about 0.66). uuid:04bca282-299b-45f4-9dce-e25446880a10 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1157355 biolink:treats EFO:0009515 PMID:41385096 "[{""id"":""uuid:2eb8a65d-54f9-4985-aff1-06213c8d5438"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7132c2a8-a257-4853-8209-9b49b63f7c81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] femhrt is indicated in women with an intact uterus for the: Treatment of moderate to severe vasomotor symptoms associated with the menopause. Prevention of postmenopausal osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis. Non-estrogen medications should be carefully considered. The mainstays for decreasing the risk of postmenopausal osteoporosis are weight-bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 1500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400-800 IU/day may also be required to ensure adequate daily intake in postmenopausal women. Risk factors for osteoporosis include low bone mineral density, low estrogen levels, family history of osteoporosis, previous fracture, small frame (low BMI), light skin color, smoking, and alcohol intake. Response to therapy can be predicted by pre-treatment serum estradiol, and can be assessed during treatment by measuring biochemical markers of bone formation/resorption, and/or bone mineral density. Estrogen therapy reduces bone resorption and retards or halts postmenopausal bone loss. Studies have shown a risk ratio of about 0.4 for hip and wrist fractures in women whose estrogen therapy was begun within a few years of menopause, compared to women taking calcium and vitamin D alone. Studies also suggest that estrogen reduces the rate of vertebral fractures. Even when started as late as 6 years after menopause, estrogen reduces further loss of bone mass for as long as treatment is continued. When estrogen therapy is discontinued, bone mass declines at a rate comparable to the immediate postmenopausal period. Data from the Women's Health Initiative study showed that use of estrogen-plus-progestin (dose equivalent to 0.625 mg CE and 2.5 mg MPA) resulted in about 5 less hip fractures per 10,000 women-years, compared to use of placebo (risk ratio about 0.66). uuid:43ba148e-d846-40d5-a19d-dbef6d94b959 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1157355 biolink:treats HP:0041166 PMID:41385096 "[{""id"":""uuid:62bacdb0-8924-48e0-99aa-62aa96cd6073"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d54aab09-0631-4bbc-9c84-84e203643b1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] femhrt is indicated in women with an intact uterus for the: Treatment of moderate to severe vasomotor symptoms associated with the menopause. Prevention of postmenopausal osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis. Non-estrogen medications should be carefully considered. The mainstays for decreasing the risk of postmenopausal osteoporosis are weight-bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 1500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400-800 IU/day may also be required to ensure adequate daily intake in postmenopausal women. Risk factors for osteoporosis include low bone mineral density, low estrogen levels, family history of osteoporosis, previous fracture, small frame (low BMI), light skin color, smoking, and alcohol intake. Response to therapy can be predicted by pre-treatment serum estradiol, and can be assessed during treatment by measuring biochemical markers of bone formation/resorption, and/or bone mineral density. Estrogen therapy reduces bone resorption and retards or halts postmenopausal bone loss. Studies have shown a risk ratio of about 0.4 for hip and wrist fractures in women whose estrogen therapy was begun within a few years of menopause, compared to women taking calcium and vitamin D alone. Studies also suggest that estrogen reduces the rate of vertebral fractures. Even when started as late as 6 years after menopause, estrogen reduces further loss of bone mass for as long as treatment is continued. When estrogen therapy is discontinued, bone mass declines at a rate comparable to the immediate postmenopausal period. Data from the Women's Health Initiative study showed that use of estrogen-plus-progestin (dose equivalent to 0.625 mg CE and 2.5 mg MPA) resulted in about 5 less hip fractures per 10,000 women-years, compared to use of placebo (risk ratio about 0.66). uuid:70b86c79-4eb9-4957-aa0b-2516cf0a70cc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16469 biolink:treats NCIT:C50476 PMID:41385096 "[{""id"":""uuid:dcdd0c82-23a2-4edf-8f0c-29b809242e5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:36c33d88-c817-43ba-b926-50d48a8d6b41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ESTRING (estradiol vaginal ring) is an estrogen indicated for the treatment of moderate to severe urogenital symptoms due to postmenopausal atrophy of the vagina (such as dryness, burning, pruritus and dyspareunia) and/or the lower urinary tract (urinary urgency and dysuria). uuid:c1dabb90-227d-4bcc-ad9a-c19d27b8c033 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16469 biolink:treats HP:0000989 PMID:41385096 "[{""id"":""uuid:9963c91b-87b7-4b7c-8e4f-2fe94422b94d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:93ad9eff-89ab-40f5-92f0-fafa2c00a76d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ESTRING (estradiol vaginal ring) is an estrogen indicated for the treatment of moderate to severe urogenital symptoms due to postmenopausal atrophy of the vagina (such as dryness, burning, pruritus and dyspareunia) and/or the lower urinary tract (urinary urgency and dysuria). uuid:23be6005-e568-4986-baa7-3c06dac0ec67 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16469 biolink:treats UMLS:C0423747 PMID:41385096 "[{""id"":""uuid:a391e8c6-5a89-43e2-b275-d08ad3486b3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:42fbd480-4b10-4765-a6bb-66eec051d7b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ESTRING (estradiol vaginal ring) is an estrogen indicated for the treatment of moderate to severe urogenital symptoms due to postmenopausal atrophy of the vagina (such as dryness, burning, pruritus and dyspareunia) and/or the lower urinary tract (urinary urgency and dysuria). uuid:16a0676a-3456-4cff-a680-7047e0bd2837 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16469 biolink:treats MONDO:0006624 PMID:41385096 "[{""id"":""uuid:368c172b-0b6c-483f-801b-2b503e2b13bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a08500f5-a0c5-498e-b701-34c4738ba333"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ESTRING (estradiol vaginal ring) is an estrogen indicated for the treatment of moderate to severe urogenital symptoms due to postmenopausal atrophy of the vagina (such as dryness, burning, pruritus and dyspareunia) and/or the lower urinary tract (urinary urgency and dysuria). uuid:aa4d4ccd-996b-4c05-862e-3fde844a7e25 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16469 biolink:treats HP:0100518 PMID:41385096 "[{""id"":""uuid:57800859-eda2-410d-a569-b968add4d0a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:48214b63-a0de-4078-98a0-289e0ff68c26"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ESTRING (estradiol vaginal ring) is an estrogen indicated for the treatment of moderate to severe urogenital symptoms due to postmenopausal atrophy of the vagina (such as dryness, burning, pruritus and dyspareunia) and/or the lower urinary tract (urinary urgency and dysuria). uuid:f88e0a1f-85c3-4fa0-8aa0-d234eef08c44 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82980 biolink:treats MONDO:0006014 PMID:41385096 "[{""id"":""uuid:551ebed2-d7af-4eb7-b2c1-86c93065e036"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:267f68a2-c4b9-4baf-9e85-06b22a1d8808"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Terconazole vaginal cream 0.4% is indicated for the local treatment of vulvovaginal candidiasis (moniliasis). As terconazole vaginal cream 0.4% is effective only for vulvovaginitis caused by the genus Candida, the diagnosis should be confirmed by KOH smears and/or cultures. uuid:7d38d457-6f0e-46b0-b9f3-3b910da11633 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82980 biolink:treats UMLS:C0343886 PMID:41385096 "[{""id"":""uuid:02d13c28-1b36-479c-9dba-c90ca31ebcce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:18c50765-da49-4f71-bf25-9cd8645d1aac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Terconazole vaginal cream 0.4% is indicated for the local treatment of vulvovaginal candidiasis (moniliasis). As terconazole vaginal cream 0.4% is effective only for vulvovaginitis caused by the genus Candida, the diagnosis should be confirmed by KOH smears and/or cultures. uuid:3ceebc5a-8efc-46e7-afda-c8b40b365d66 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82980 biolink:treats MONDO:0007019 PMID:41385096 "[{""id"":""uuid:32268d41-4e40-41a6-9ce0-8653b80628e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:96e36799-611e-408d-9a56-751578059105"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Terconazole vaginal cream 0.4% is indicated for the local treatment of vulvovaginal candidiasis (moniliasis). As terconazole vaginal cream 0.4% is effective only for vulvovaginitis caused by the genus Candida, the diagnosis should be confirmed by KOH smears and/or cultures. uuid:13d226f6-8eb3-4f4a-aa7d-a35c3bdd67a9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:48131 biolink:treats MONDO:0006604 PMID:41385096 "[{""id"":""uuid:e2c9ea13-0cb9-4ab3-8de1-242b96abcb2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:576203f1-c4d9-422d-836b-df43c1ece0dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FINACEA Gel, 15%, is indicated for topical treatment of inflammatory papules and pustules of mild to moderate rosacea. Although some reduction of erythema which was present in patients with papules and pustules of rosacea occurred in clinical studies, efficacy for treatment of erythema in rosacea in the absence of papules and pustules has not been evaluated. Patients should be instructed to avoid spicy foods, thermally hot foods and drinks, alcoholic beverages and to use only very mild soaps or soapless cleansing lotion for facial cleansing. uuid:4ffdf20e-da4c-4c94-9c1b-331366e156cd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135888 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:41d493e5-1f3d-4e6a-b558-75974c25c839"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f2c1e18d-b80d-4732-b4d8-6ea8836c133f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ELIDEL ® (pimecrolimus) Cream 1% is indicated as second-line therapy for the short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adults and children 2 years of age and older, who have failed to respond adequately to other topical prescription treatments, or when those treatments are not advisable. ELIDEL Cream is not indicated for use in children less than 2 years of age (see WARNINGS, boxed WARNING, and PRECAUTIONS, Pediatric Use). uuid:c4822903-8fa5-4cbf-8aef-5eb87caa4960 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17026 biolink:treats MONDO:0006193 PMID:41385096 "[{""id"":""uuid:bda6c2f2-8624-4cc2-bb85-19adc02bd9fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:acb4b7b0-09b7-44fa-a5f9-85c81834f008"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROMETRIUM Capsules are indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving conjugated estrogens tablets. They are also indicated for use in secondary amenorrhea. uuid:522e9bdf-5d03-4a5f-bad6-91b3288c2503 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17026 biolink:treats HP:0000869 PMID:41385096 "[{""id"":""uuid:6b918b80-2302-429b-b4bb-d1f9342ff00b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:95902765-1b10-4fa6-a58c-a670854f65e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROMETRIUM Capsules are indicated for use in the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women who are receiving conjugated estrogens tablets. They are also indicated for use in secondary amenorrhea. uuid:d861f778-5d99-470f-add1-95cd46a345a1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31236 biolink:treats MONDO:0005090 PMID:41385096 "[{""id"":""uuid:a6bf0f83-4381-4928-884b-acaace4b3cfa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f0c123f8-4108-4ed7-ac5f-9de56a759546"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:da43c506-55ee-4f21-b414-cd2fc1264ddf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/aripiprazole-mylan-pharma""]},{""id"":""uuid:3dcc8153-fd4b-4318-91e9-1dad63b95057"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ABILIFY is an atypical antipsychotic indicated as oral formulations for the: Treatment of schizophrenia (1.1) Adults: Efficacy was established in four 4-6 week trials and one maintenance trial in patients with schizophrenia (14.1) Adolescents (ages 13-17): Efficacy was established in one 6-week trial in patients with schizophrenia (14.1) Acute treatment of manic or mixed episodes associated with bipolar I disorder as monotherapy and as an adjunct to lithium or valproate (1.2) Adults: Efficacy was established in four 3-week monotherapy trials and one 6-week adjunctive trial in patients with manic or mixed episodes (14.2) Pediatric Patients (ages 10-17): Efficacy was established in one 4-week monotherapy trial in patients with manic or mixed episodes (14.2) Maintenance treatment of bipolar I disorder (1.2) Adults: Efficacy was established in one maintenance trial (14.2) Adjunctive treatment of major depressive disorder (MDD) (1.3) Adults: Efficacy was established in two 6-week trials in patients with MDD who had an inadequate response to antidepressant therapy during the current episode (14.3) Treatment of irritability associated with autistic disorder (1.4) Pediatric Patients (ages 6-17 years): Efficacy was established in two 8-week trials in patients with autistic disorder (14.4) as an injection for the: Acute treatment of agitation associated with schizophrenia or bipolar I disorder (1.5) Adults: Efficacy was established in three 24-hour trials in agitated patients with schizophrenia or manic/mixed episodes of bipolar I disorder (14.5)|[EMA] Aripiprazole Mylan Pharma is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older.Aripiprazole Mylan Pharma is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment.Aripiprazole Mylan Pharma is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older.|[PMDA] Drugs with a new route of administration indicated for the treatment of schizophrenia. uuid:0a17d498-2d12-415c-a7b0-87b4967a1435 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31236 biolink:treats MONDO:0024612 PMID:41385096 "[{""id"":""uuid:cbffdd64-161c-4a54-9f59-2a5e21fd09ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:91f6fa4e-88ea-4835-b989-7fb0adce601e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:01ef798d-ff41-470e-bf16-8ff9d603c37c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/aripiprazole-mylan-pharma""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ABILIFY is an atypical antipsychotic indicated as oral formulations for the: Treatment of schizophrenia (1.1) Adults: Efficacy was established in four 4-6 week trials and one maintenance trial in patients with schizophrenia (14.1) Adolescents (ages 13-17): Efficacy was established in one 6-week trial in patients with schizophrenia (14.1) Acute treatment of manic or mixed episodes associated with bipolar I disorder as monotherapy and as an adjunct to lithium or valproate (1.2) Adults: Efficacy was established in four 3-week monotherapy trials and one 6-week adjunctive trial in patients with manic or mixed episodes (14.2) Pediatric Patients (ages 10-17): Efficacy was established in one 4-week monotherapy trial in patients with manic or mixed episodes (14.2) Maintenance treatment of bipolar I disorder (1.2) Adults: Efficacy was established in one maintenance trial (14.2) Adjunctive treatment of major depressive disorder (MDD) (1.3) Adults: Efficacy was established in two 6-week trials in patients with MDD who had an inadequate response to antidepressant therapy during the current episode (14.3) Treatment of irritability associated with autistic disorder (1.4) Pediatric Patients (ages 6-17 years): Efficacy was established in two 8-week trials in patients with autistic disorder (14.4) as an injection for the: Acute treatment of agitation associated with schizophrenia or bipolar I disorder (1.5) Adults: Efficacy was established in three 24-hour trials in agitated patients with schizophrenia or manic/mixed episodes of bipolar I disorder (14.5)|[EMA] Aripiprazole Mylan Pharma is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older.Aripiprazole Mylan Pharma is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment.Aripiprazole Mylan Pharma is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older. uuid:b37f5e31-5e7c-4ddf-837b-0fa2dd0fafbd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31236 biolink:treats MONDO:0001866 PMID:41385096 "[{""id"":""uuid:9994d603-c574-450a-8c43-3fa0bc43fc42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:96f6f47b-1dcd-49ee-8b5b-90131a70a6bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:20454d33-5271-467c-8bc6-1735ee2cfafb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/aripiprazole-mylan-pharma""]},{""id"":""uuid:5ef1da77-123c-4927-8d46-60a74e0ba156"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ABILIFY is an atypical antipsychotic indicated as oral formulations for the: Treatment of schizophrenia (1.1) Adults: Efficacy was established in four 4-6 week trials and one maintenance trial in patients with schizophrenia (14.1) Adolescents (ages 13-17): Efficacy was established in one 6-week trial in patients with schizophrenia (14.1) Acute treatment of manic or mixed episodes associated with bipolar I disorder as monotherapy and as an adjunct to lithium or valproate (1.2) Adults: Efficacy was established in four 3-week monotherapy trials and one 6-week adjunctive trial in patients with manic or mixed episodes (14.2) Pediatric Patients (ages 10-17): Efficacy was established in one 4-week monotherapy trial in patients with manic or mixed episodes (14.2) Maintenance treatment of bipolar I disorder (1.2) Adults: Efficacy was established in one maintenance trial (14.2) Adjunctive treatment of major depressive disorder (MDD) (1.3) Adults: Efficacy was established in two 6-week trials in patients with MDD who had an inadequate response to antidepressant therapy during the current episode (14.3) Treatment of irritability associated with autistic disorder (1.4) Pediatric Patients (ages 6-17 years): Efficacy was established in two 8-week trials in patients with autistic disorder (14.4) as an injection for the: Acute treatment of agitation associated with schizophrenia or bipolar I disorder (1.5) Adults: Efficacy was established in three 24-hour trials in agitated patients with schizophrenia or manic/mixed episodes of bipolar I disorder (14.5)|[EMA] Aripiprazole Mylan Pharma is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older.Aripiprazole Mylan Pharma is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment.Aripiprazole Mylan Pharma is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older.|[PMDA] Drugs with a new indication for the prevention of recurrence/relapse of mood episodes in patients with bipolar I disorder. uuid:d0b8f229-ec23-486e-b9ea-a170de2a37be biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31236 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:80d56756-9197-4900-9939-e90d7d3a90a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:560ff7d7-9a34-49b0-a83e-4acfe0c74923"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ABILIFY is an atypical antipsychotic indicated as oral formulations for the: Treatment of schizophrenia (1.1) Adults: Efficacy was established in four 4-6 week trials and one maintenance trial in patients with schizophrenia (14.1) Adolescents (ages 13-17): Efficacy was established in one 6-week trial in patients with schizophrenia (14.1) Acute treatment of manic or mixed episodes associated with bipolar I disorder as monotherapy and as an adjunct to lithium or valproate (1.2) Adults: Efficacy was established in four 3-week monotherapy trials and one 6-week adjunctive trial in patients with manic or mixed episodes (14.2) Pediatric Patients (ages 10-17): Efficacy was established in one 4-week monotherapy trial in patients with manic or mixed episodes (14.2) Maintenance treatment of bipolar I disorder (1.2) Adults: Efficacy was established in one maintenance trial (14.2) Adjunctive treatment of major depressive disorder (MDD) (1.3) Adults: Efficacy was established in two 6-week trials in patients with MDD who had an inadequate response to antidepressant therapy during the current episode (14.3) Treatment of irritability associated with autistic disorder (1.4) Pediatric Patients (ages 6-17 years): Efficacy was established in two 8-week trials in patients with autistic disorder (14.4) as an injection for the: Acute treatment of agitation associated with schizophrenia or bipolar I disorder (1.5) Adults: Efficacy was established in three 24-hour trials in agitated patients with schizophrenia or manic/mixed episodes of bipolar I disorder (14.5) uuid:2895fa9e-11b7-4842-a2ac-59834bd3f468 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31236 biolink:treats MONDO:0005258 PMID:41385096 "[{""id"":""uuid:21c0cc1d-191c-4563-8505-a74aa5047c48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fcced8dc-4e3c-447b-be29-0a9f62b90f5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ABILIFY is an atypical antipsychotic indicated as oral formulations for the: Treatment of schizophrenia (1.1) Adults: Efficacy was established in four 4-6 week trials and one maintenance trial in patients with schizophrenia (14.1) Adolescents (ages 13-17): Efficacy was established in one 6-week trial in patients with schizophrenia (14.1) Acute treatment of manic or mixed episodes associated with bipolar I disorder as monotherapy and as an adjunct to lithium or valproate (1.2) Adults: Efficacy was established in four 3-week monotherapy trials and one 6-week adjunctive trial in patients with manic or mixed episodes (14.2) Pediatric Patients (ages 10-17): Efficacy was established in one 4-week monotherapy trial in patients with manic or mixed episodes (14.2) Maintenance treatment of bipolar I disorder (1.2) Adults: Efficacy was established in one maintenance trial (14.2) Adjunctive treatment of major depressive disorder (MDD) (1.3) Adults: Efficacy was established in two 6-week trials in patients with MDD who had an inadequate response to antidepressant therapy during the current episode (14.3) Treatment of irritability associated with autistic disorder (1.4) Pediatric Patients (ages 6-17 years): Efficacy was established in two 8-week trials in patients with autistic disorder (14.4) as an injection for the: Acute treatment of agitation associated with schizophrenia or bipolar I disorder (1.5) Adults: Efficacy was established in three 24-hour trials in agitated patients with schizophrenia or manic/mixed episodes of bipolar I disorder (14.5) uuid:7156f57e-9fa7-4656-a3b2-215c0456d7fa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31236 biolink:treats HP:0000713 PMID:41385096 "[{""id"":""uuid:db191f15-58e5-411d-a1af-d5c892395f86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e4cb2605-447e-4187-9fc9-d47f662b5feb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ABILIFY is an atypical antipsychotic indicated as oral formulations for the: Treatment of schizophrenia (1.1) Adults: Efficacy was established in four 4-6 week trials and one maintenance trial in patients with schizophrenia (14.1) Adolescents (ages 13-17): Efficacy was established in one 6-week trial in patients with schizophrenia (14.1) Acute treatment of manic or mixed episodes associated with bipolar I disorder as monotherapy and as an adjunct to lithium or valproate (1.2) Adults: Efficacy was established in four 3-week monotherapy trials and one 6-week adjunctive trial in patients with manic or mixed episodes (14.2) Pediatric Patients (ages 10-17): Efficacy was established in one 4-week monotherapy trial in patients with manic or mixed episodes (14.2) Maintenance treatment of bipolar I disorder (1.2) Adults: Efficacy was established in one maintenance trial (14.2) Adjunctive treatment of major depressive disorder (MDD) (1.3) Adults: Efficacy was established in two 6-week trials in patients with MDD who had an inadequate response to antidepressant therapy during the current episode (14.3) Treatment of irritability associated with autistic disorder (1.4) Pediatric Patients (ages 6-17 years): Efficacy was established in two 8-week trials in patients with autistic disorder (14.4) as an injection for the: Acute treatment of agitation associated with schizophrenia or bipolar I disorder (1.5) Adults: Efficacy was established in three 24-hour trials in agitated patients with schizophrenia or manic/mixed episodes of bipolar I disorder (14.5) uuid:2bdce892-15a1-4cc6-9ffc-4df0848beff9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:137329 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:4ff5959f-e241-452b-b8b7-b977d62dd39a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:19eb4ec2-aff6-4f35-b4ac-714e8ab5fcf1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AGGRENOX is indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis. uuid:329f032d-df8c-4025-8be3-dd0eb8b0efab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:137329 biolink:treats MONDO:0005299 PMID:41385096 "[{""id"":""uuid:f618d42b-e554-4c7b-964f-be0438b1fcb6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2f1f0f5d-9547-4b48-bbb1-2f568996aac1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AGGRENOX is indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis. uuid:0f9e6582-64d2-4f96-82cf-e99ff8b3c376 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6129 biolink:treats UMLS:C0339164 PMID:41385096 "[{""id"":""uuid:07cc7f42-47a9-44d1-8c2a-1f426728b7a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:72f0c867-fc18-44f1-941f-553dd905a899"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE ACULAR ® ophthalmic solution is indicated for the temporary relief of ocular itching due to seasonal allergic conjunctivitis. ACULAR ® ophthalmic solution is also indicated for the treatment of postoperative inflammation in patients who have undergone cataract extraction. uuid:92e19c31-a3a0-4be6-84ff-b87fbc9f45f4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8228 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:44c4e870-328c-4a3c-b3b4-561db7741f6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:56056190-3317-4f9e-88ff-66a81ab417aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b8094b47-c54b-439b-a641-12d396f92792"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:78a59086-13ca-4ac6-9a09-8e52e4109a76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ACTOS is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.|[EMA] Pioglitazone is indicated in the treatment of type-2 diabetes mellitus:as monotherapy:in patients (particularly overweight patients) inadequately controlled by diet and exercise for whom metformin is inappropriate because of contraindications or intolerance;as dual oral therapy in combination with:metformin, in patients (particularly overweight patients) with insufficient glycaemic control despite maximal tolerated dose of monotherapy with metformin;a sulphonylurea, only in patients who show intolerance to metformin or for whom metformin is contraindicated, with insufficient glycaemic control despite maximal tolerated dose of monotherapy with a sulphonylurea;as triple oral therapy in combination with:metformin and a sulphonylurea, in patients (particularly overweight patients) with insufficient glycaemic control despite dual oral therapy.Pioglitazone is also indicated for combination with insulin in type-2 diabetes mellitus patients with insufficient glycaemic control on insulin for whom metformin is inappropriate because of contraindications or intolerance.|[PMDA] Drugs with a new additional indication for the treatment of Type 2 diabetes mellitus (for use only in patients in whom treatment with biguanides in conjunction with dietary and exercise regimens is not sufficiently effective, and insulin resistance is suspected). uuid:a458094a-ab0e-42f7-b32e-e5b06db61b25 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50885 biolink:treats MONDO:0015129 PMID:41385096 "[{""id"":""uuid:46604325-5052-4eae-85ef-ec138756797b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e9a05a8a-884b-48d4-bbed-2d59bc622940"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fludrocortisone acetate tablets USP, 0.1 mg are indicated as partial replacement therapy for primary and secondary adrenocortical insufficiency in Addison's disease and for the treatment of salt-losing adrenogenital syndrome. uuid:d251e4a3-344a-4da4-b018-9ec21b7bef03 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50885 biolink:treats MONDO:0018479 PMID:41385096 "[{""id"":""uuid:f4931364-5ba2-4bc8-9fbc-39425d3bc2fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cff7dc0a-5e8c-44e2-8842-d12f501652d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fludrocortisone acetate tablets USP, 0.1 mg are indicated as partial replacement therapy for primary and secondary adrenocortical insufficiency in Addison's disease and for the treatment of salt-losing adrenogenital syndrome. uuid:1e36d969-c9a1-48fe-bb03-94fcb414c6a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:129011819 biolink:treats MONDO:0008159 PMID:41385096 "[{""id"":""uuid:70fa1013-6a3a-439e-b6b5-1f334043cf3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:abeb509f-ad7a-4d3f-815b-758d9acab040"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FORTICAL ® calcitonin-salmon (rDNA origin) Nasal Spray is indicated for the treatment of postmenopausal osteoporosis in women greater than 5 years postmenopause with low bone mass relative to healthy premenopausal women. Use of FORTICAL ® calcitonin-salmon (rDNA origin) Nasal Spray is recommended in conjunction with an adequate calcium (at least 1000 mg elemental calcium per day) and Vitamin D (400 International Units per day) intake to retard the progressive loss of bone mass. The evidence of efficacy for calcitonin-salmon is based on increases in spinal bone mineral density (BMD) observed in clinical trials. Two randomized, placebo-controlled trials were conducted in 325 postmenopausal women (227 treated with calcitonin-salmon nasal spray and 98 treated with placebo) with spinal, forearm or femoral BMD at least one standard deviation below the normal value for healthy premenopausal women. These studies conducted over two years demonstrated that 200 International Units daily of calcitonin-salmon nasal spray increases lumbar vertebral BMD relative to baseline and relative to placebo in osteoporotic women who were greater than 5 years postmenopause. Calcitonin-salmon nasal spray produced statistically significant increases in lumbar vertebral BMD compared to placebo as early as 6 months after initiation of therapy with persistence of this level for up to 2 years of observation. No effects of calcitonin-salmon nasal spray on cortical bone of the forearm or hip were demonstrated. However, in one study, BMD of the hip showed a statistically significant increase compared with placebo in a region composed of predominantly trabecular bone after 1 year of treatment changing to a trend at 2 years that was no longer statistically significant. uuid:bd80b7c3-843d-44dc-a6d0-6f14f4b88769 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3001 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:489c8c8a-ccf3-4eb3-831e-3e0d5dec1aec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:73208dd4-4733-4d9d-af1d-2feb70867fe5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE BECONASE AQ Nasal Spray is indicated for the relief of the symptoms of seasonal or perennial allergic and nonallergic (vasomotor) rhinitis. Results from 2 clinical trials have shown that significant symptomatic relief was obtained within 3 days. However, symptomatic relief may not occur in some patients for as long as 2 weeks. BECONASE AQ Nasal Spray should not be continued beyond 3 weeks in the absence of significant symptomatic improvement. BECONASE AQ Nasal Spray should not be used in the presence of untreated localized infection involving the nasal mucosa. BECONASE AQ Nasal Spray is also indicated for the prevention of recurrence of nasal polyps following surgical removal. Clinical studies have shown that treatment of the symptoms associated with nasal polyps may have to be continued for several weeks or more before a therapeutic result can be fully assessed. Recurrence of symptoms due to polyps can occur after stopping treatment, depending on the severity of the disease. uuid:d54b0c39-e0b6-4b7a-a9ea-f6fa6b61854c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3001 biolink:treats MONDO:0024332 PMID:41385096 "[{""id"":""uuid:86ecbc33-3d02-4dda-b111-76301f4dc88e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:09e30aa0-b6bd-49e9-8e0d-8111f6de6bd8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE BECONASE AQ Nasal Spray is indicated for the relief of the symptoms of seasonal or perennial allergic and nonallergic (vasomotor) rhinitis. Results from 2 clinical trials have shown that significant symptomatic relief was obtained within 3 days. However, symptomatic relief may not occur in some patients for as long as 2 weeks. BECONASE AQ Nasal Spray should not be continued beyond 3 weeks in the absence of significant symptomatic improvement. BECONASE AQ Nasal Spray should not be used in the presence of untreated localized infection involving the nasal mucosa. BECONASE AQ Nasal Spray is also indicated for the prevention of recurrence of nasal polyps following surgical removal. Clinical studies have shown that treatment of the symptoms associated with nasal polyps may have to be continued for several weeks or more before a therapeutic result can be fully assessed. Recurrence of symptoms due to polyps can occur after stopping treatment, depending on the severity of the disease. uuid:f75456db-4a5c-4eef-90f2-4397138b662b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3001 biolink:treats MONDO:0006004 PMID:41385096 "[{""id"":""uuid:29b82b26-be56-4cdb-ac97-d660bb61940a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bd0c13c2-b51c-49c8-abc8-fa0974fec909"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE BECONASE AQ Nasal Spray is indicated for the relief of the symptoms of seasonal or perennial allergic and nonallergic (vasomotor) rhinitis. Results from 2 clinical trials have shown that significant symptomatic relief was obtained within 3 days. However, symptomatic relief may not occur in some patients for as long as 2 weeks. BECONASE AQ Nasal Spray should not be continued beyond 3 weeks in the absence of significant symptomatic improvement. BECONASE AQ Nasal Spray should not be used in the presence of untreated localized infection involving the nasal mucosa. BECONASE AQ Nasal Spray is also indicated for the prevention of recurrence of nasal polyps following surgical removal. Clinical studies have shown that treatment of the symptoms associated with nasal polyps may have to be continued for several weeks or more before a therapeutic result can be fully assessed. Recurrence of symptoms due to polyps can occur after stopping treatment, depending on the severity of the disease. uuid:1a36efef-0145-4c36-81be-575d71065c0b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3001 biolink:treats MONDO:0006314 PMID:41385096 "[{""id"":""uuid:bf4f7e60-052b-4d16-9eb3-6673c636df29"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9b809489-a57c-4143-9149-f078b212cf97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE BECONASE AQ Nasal Spray is indicated for the relief of the symptoms of seasonal or perennial allergic and nonallergic (vasomotor) rhinitis. Results from 2 clinical trials have shown that significant symptomatic relief was obtained within 3 days. However, symptomatic relief may not occur in some patients for as long as 2 weeks. BECONASE AQ Nasal Spray should not be continued beyond 3 weeks in the absence of significant symptomatic improvement. BECONASE AQ Nasal Spray should not be used in the presence of untreated localized infection involving the nasal mucosa. BECONASE AQ Nasal Spray is also indicated for the prevention of recurrence of nasal polyps following surgical removal. Clinical studies have shown that treatment of the symptoms associated with nasal polyps may have to be continued for several weeks or more before a therapeutic result can be fully assessed. Recurrence of symptoms due to polyps can occur after stopping treatment, depending on the severity of the disease. uuid:ac6e2b53-eb8a-49b3-9293-43113503c6f7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:119915 biolink:treats NCIT:C34887 PMID:41385096 "[{""id"":""uuid:3ce12442-8642-4fea-b08c-5cf23b34d195"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:88f21bf9-f8f2-4886-aee7-6d7798346e01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fentanyl transdermal system is indicated for management of persistent , moderate to severe chronic pain that: requires continuous, around-the-clock opioid administration for an extended period of time, and cannot be managed by other means such as non-steroidal analgesics, opioid combination products, or immediate-release opioids Fentanyl transdermal system should ONLY be used in patients who are already receiving opioid therapy, who have demonstrated opioid tolerance, and who require a total daily dose at least equivalent to fentanyl transdermal system 25 mcg/hr (see DOSAGE AND ADMINISTRATION ). Patients who are considered opioid-tolerant are those who have been taking, for a week or longer, at least 60 mg of morphine daily, or at least 30 mg of oral oxycodone daily, or at least 8 mg of oral hydromorphone daily, or an equianalgesic dose of another opioid. Because serious or life-threatening hypoventilation could result, fentanyl transdermal system is contraindicated for use on an as needed basis (i.e., prn), for the management of postoperative or acute pain, or in patients who are not opioid-tolerant or who require opioid analgesia for a short period of time (see BOX WARNING and CONTRAINDICATIONS ). An evaluation of the appropriateness and adequacy of treating with immediate-release opioids is advisable prior to initiating therapy with any modified-release opioid. Prescribers should individualize treatment in every case, initiating therapy at the appropriate point along a progression from non-opioid analgesics, such as non-steroidal anti-inflammatory drugs and acetaminophen, to opioids, in a plan of pain management such as outlined by the World Health Organization, the Agency for Health Research and Quality, the Federation of State Medical Boards Model Policy, or the American Pain Society. Patients should be assessed for their clinical risks for opioid abuse or addiction prior to being prescribed opioids. Patients receiving opioids should be routinely monitored for signs of misuse, abuse, and addiction. Persons at increased risk for opioid abuse include those with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression). Patients at increased risk may still be appropriately treated with modified-release opioid formulations; however these patients will require intensive monitoring for signs of misuse, abuse, or addiction. uuid:7eae78c1-7966-4988-838b-f2013042da94 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:119915 biolink:treats NCIT:C27003 PMID:41385096 "[{""id"":""uuid:2b0ed9bb-79db-4213-bc57-7d60f06e407f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2cf6dd24-5aac-4558-9ec6-1dacd18bbeee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fentanyl transdermal system is indicated for management of persistent , moderate to severe chronic pain that: requires continuous, around-the-clock opioid administration for an extended period of time, and cannot be managed by other means such as non-steroidal analgesics, opioid combination products, or immediate-release opioids Fentanyl transdermal system should ONLY be used in patients who are already receiving opioid therapy, who have demonstrated opioid tolerance, and who require a total daily dose at least equivalent to fentanyl transdermal system 25 mcg/hr (see DOSAGE AND ADMINISTRATION ). Patients who are considered opioid-tolerant are those who have been taking, for a week or longer, at least 60 mg of morphine daily, or at least 30 mg of oral oxycodone daily, or at least 8 mg of oral hydromorphone daily, or an equianalgesic dose of another opioid. Because serious or life-threatening hypoventilation could result, fentanyl transdermal system is contraindicated for use on an as needed basis (i.e., prn), for the management of postoperative or acute pain, or in patients who are not opioid-tolerant or who require opioid analgesia for a short period of time (see BOX WARNING and CONTRAINDICATIONS ). An evaluation of the appropriateness and adequacy of treating with immediate-release opioids is advisable prior to initiating therapy with any modified-release opioid. Prescribers should individualize treatment in every case, initiating therapy at the appropriate point along a progression from non-opioid analgesics, such as non-steroidal anti-inflammatory drugs and acetaminophen, to opioids, in a plan of pain management such as outlined by the World Health Organization, the Agency for Health Research and Quality, the Federation of State Medical Boards Model Policy, or the American Pain Society. Patients should be assessed for their clinical risks for opioid abuse or addiction prior to being prescribed opioids. Patients receiving opioids should be routinely monitored for signs of misuse, abuse, and addiction. Persons at increased risk for opioid abuse include those with a personal or family history of substance abuse (including drug or alcohol abuse or addiction) or mental illness (e.g., major depression). Patients at increased risk may still be appropriately treated with modified-release opioid formulations; however these patients will require intensive monitoring for signs of misuse, abuse, or addiction. uuid:0e366fc6-21b4-43f0-916c-e5eafba7a967 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6887 biolink:treats MONDO:0021107 PMID:41385096 "[{""id"":""uuid:90560175-1f0b-4577-8954-725e6de7bdd2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6e43c556-cb76-469c-8f9a-237be7b8d710"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Attention Deficit Disorders, Narcolepsy Attention Deficit Disorders (previously known as Minimal Brain Dysfunction in Children). Other terms being used to describe the behavioral syndrome below include: Hyperkinetic Child Syndrome, Minimal Brain Damage, Minimal Cerebral Dysfunction, Minor Cerebral Dysfunction. Methylphenidate hydrochloride is indicated as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate-to-severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted. Special Diagnostic Considerations Specific etiology of this syndrome is unknown, and there is no single diagnostic test. Adequate diagnosis requires the use not only of medical but of special psychological, educational, and social resources. Characteristics commonly reported include: chronic history of short attention span, distractibility, emotional lability, impulsivity, and moderate-to-severe hyperactivity; minor neurological signs and abnormal EEG. Learning may or may not be impaired. The diagnosis must be based upon a complete history and evaluation of the child and not solely on the presence of one or more of these characteristics. Drug treatment is not indicated for all children with this syndrome. Stimulants are not intended for use in the child who exhibits symptoms secondary to environmental factors and/or primary psychiatric disorders, including psychosis. Appropriate educational placement is essential and psychosocial intervention is generally necessary. When remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physician’s assessment of the chronicity and severity of the child’s symptoms. uuid:c45d6ec9-7758-4f56-ac50-1cc972e882c0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63621 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:db7f741f-b75f-4ce0-9561-0e10adeb89c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:af8bc1ea-1aaf-4176-a82f-793fc229a17c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e8b9d700-30f7-4d25-8291-2028c3a5a4c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INVIRASE in combination with ritonavir and other antiretroviral agents is indicated for the treatment of HIV infection. The twice daily administration of INVIRASE in combination with ritonavir is supported by safety data from the MaxCmin 1 study (see Table 6 ) and pharmacokinetic data (see Table 1 ). The efficacy of INVIRASE with ritonavir has not been compared against the efficacy of antiretroviral regimens currently considered standard of care.|[PMDA] Addition of a new dosage and dosage form of 500mg tablets, indicated for treatment of HIV infection. [Orphan Drug] uuid:3e6bead6-9914-4c43-b61f-754b687a10a5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats UMLS:C0268732 PMID:41385096 "[{""id"":""uuid:725d1761-e803-4542-af51-65f141ee97cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ea4a9dd9-b3b5-4d5e-99ee-04cca4b75d7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisone tablets are indicated in the following conditions: Endocrine disorders: primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, nonsuppurative thyroiditis, hypercalcemia associated with cancer. Rheumatic disorders: as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; post-traumatic osteoarthritis; synovitis of osteoarthritis; epicondylitis. Collagen diseases: during an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematosus, systemic dermatomyositis (polymyositis), acute rheumatic carditis. Dermatologic diseases: pemphigus, bullous dermatitis herpetiformis, severe erythema multiforme (Stevens-Johnson syndrome), exfoliative dermatitis, mycosis fungoides, severe psoriasis, severe seborrheic dermatitis. Allergic states: control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: seasonal or perennial allergic rhinitis, serum sickness, bronchial asthma, contact dermatitis, atopic dermatitis, drug hypersensitivity reactions. Ophthalmic diseases: severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: allergic conjunctivitis, keratitis, allergic corneal marginal ulcers, herpes zoster ophthalmicus, iritis and iridocyclitis, chorioretinitis, anterior segment inflammation, diffuse posterior uveitis and choroiditis, optic neuritis, sympathetic ophthalmia. Respiratory diseases: symptomatic sarcoidosis, Loeffler’s syndrome not manageable by other means, berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, aspiration pneumonitis. Hematologic disorders: Idiopathic thrombocytopenic purpura in adults, secondary thrombocytopenia in adults, acquired (autoimmune) hemolytic anemia, eythroblastopenia (RBC anemia), congenital (erythroid) hypoplastic anemia. Neoplastic diseases: for palliative management of: leukemias and lymphomas in adults, acute leukemia of childhood. Edematous states: to induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. Gastrointestinal diseases: to tide the patient over a critical period of the disease in: ulcerative colitis, regional enteritis. Miscellaneous: tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy, trichinosis with neurologic or myocardial involvement. uuid:d6e8e043-2b20-4937-9f0e-cc67490ea8eb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0004670 PMID:41385096 "[{""id"":""uuid:09d0ba17-33f3-448b-913e-e73675cd8acb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3858dbf1-f60f-4593-b00e-8cb0a7d4546d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisone tablets are indicated in the following conditions: Endocrine disorders: primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, nonsuppurative thyroiditis, hypercalcemia associated with cancer. Rheumatic disorders: as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; post-traumatic osteoarthritis; synovitis of osteoarthritis; epicondylitis. Collagen diseases: during an exacerbation or as maintenance therapy in selected cases of: systemic lupus erythematosus, systemic dermatomyositis (polymyositis), acute rheumatic carditis. Dermatologic diseases: pemphigus, bullous dermatitis herpetiformis, severe erythema multiforme (Stevens-Johnson syndrome), exfoliative dermatitis, mycosis fungoides, severe psoriasis, severe seborrheic dermatitis. Allergic states: control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: seasonal or perennial allergic rhinitis, serum sickness, bronchial asthma, contact dermatitis, atopic dermatitis, drug hypersensitivity reactions. Ophthalmic diseases: severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: allergic conjunctivitis, keratitis, allergic corneal marginal ulcers, herpes zoster ophthalmicus, iritis and iridocyclitis, chorioretinitis, anterior segment inflammation, diffuse posterior uveitis and choroiditis, optic neuritis, sympathetic ophthalmia. Respiratory diseases: symptomatic sarcoidosis, Loeffler’s syndrome not manageable by other means, berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, aspiration pneumonitis. Hematologic disorders: Idiopathic thrombocytopenic purpura in adults, secondary thrombocytopenia in adults, acquired (autoimmune) hemolytic anemia, eythroblastopenia (RBC anemia), congenital (erythroid) hypoplastic anemia. Neoplastic diseases: for palliative management of: leukemias and lymphomas in adults, acute leukemia of childhood. Edematous states: to induce a diuresis or remission of proteinuria in the nephritic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. Gastrointestinal diseases: to tide the patient over a critical period of the disease in: ulcerative colitis, regional enteritis. Miscellaneous: tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy, trichinosis with neurologic or myocardial involvement. uuid:6e4a4b91-3ac5-4885-9dd1-1f9215d37cb1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3764 biolink:treats MONDO:0002026 PMID:41385096 "[{""id"":""uuid:00a708a3-4618-4162-8ccf-89f05436d351"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dc8ac896-b39b-4f63-9450-1aa07c2b323d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clotrimazole Cream is indicated for the topical treatment of candidiasis due to Candida albicans and tinea versicolor due to Malassezia furfur . Clotrimazole is also available as a nonprescription item which is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum , Trichophyton mentagrophytes , Epidermophyton floccosum , and Microsporum canis . uuid:334df252-8c50-4f18-902a-0f12c08061e4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3764 biolink:treats MONDO:0005915 PMID:41385096 "[{""id"":""uuid:601dd177-8c06-49a8-a800-6647fb98ec86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8c3cce7b-d88c-47e8-b517-1b87613174f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clotrimazole Cream is indicated for the topical treatment of candidiasis due to Candida albicans and tinea versicolor due to Malassezia furfur . Clotrimazole is also available as a nonprescription item which is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum , Trichophyton mentagrophytes , Epidermophyton floccosum , and Microsporum canis . uuid:3c1e24f8-7845-450a-acb4-cac0b24a5810 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3764 biolink:treats MONDO:0005984 PMID:41385096 "[{""id"":""uuid:089f78c0-92d0-43e5-8c96-abb79ff111a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ed214e37-7245-4b6a-8ff8-34a059b28228"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clotrimazole Cream is indicated for the topical treatment of candidiasis due to Candida albicans and tinea versicolor due to Malassezia furfur . Clotrimazole is also available as a nonprescription item which is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum , Trichophyton mentagrophytes , Epidermophyton floccosum , and Microsporum canis . uuid:e7a5832a-b5ad-48ea-9ce7-c1f559f3543b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3764 biolink:treats MONDO:0001405 PMID:41385096 "[{""id"":""uuid:a68bcef9-602e-4dba-8e67-a1f5177d6aa7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bbc96626-78c4-4016-8af4-181671013f7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clotrimazole Cream is indicated for the topical treatment of candidiasis due to Candida albicans and tinea versicolor due to Malassezia furfur . Clotrimazole is also available as a nonprescription item which is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum , Trichophyton mentagrophytes , Epidermophyton floccosum , and Microsporum canis . uuid:4951cb60-a7fc-418d-b5b9-d575af9cfb1f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3764 biolink:treats MONDO:0001461 PMID:41385096 "[{""id"":""uuid:4ed9e3cb-ae9b-4d01-b911-46995e81cc45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:916f72e5-f413-4406-ba57-bc473ece137a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clotrimazole Cream is indicated for the topical treatment of candidiasis due to Candida albicans and tinea versicolor due to Malassezia furfur . Clotrimazole is also available as a nonprescription item which is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum , Trichophyton mentagrophytes , Epidermophyton floccosum , and Microsporum canis . uuid:e791ab1b-ab88-4c58-889d-616a2211cec1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8L6LAK9BTR biolink:treats UMLS:C5442256 PMID:41385096 "[{""id"":""uuid:cda5f976-cd5f-4e76-a71f-cb82fa9af4f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6c6b1d7c-33e0-4ef5-bbe6-62ebfc2eb279"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENJUVIA tablets are indicated in the: Treatment of moderate to severe vasomotor symptoms associated with menopause. Treatment of moderate to severe vaginal dryness and pain with intercourse, symptoms of vulvar and vaginal atrophy, associated with menopause. When prescribing solely for the treatment of moderate to severe vaginal dryness and pain with intercourse, topical vaginal products should be considered. uuid:25e082de-4ea2-41fd-a6c4-b053ff323262 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8L6LAK9BTR biolink:treats HP:0031088 PMID:41385096 "[{""id"":""uuid:fce7f394-1325-41bd-8af9-332280497174"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bd7f6270-c7a4-4e02-a763-c2dc921d0d90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENJUVIA tablets are indicated in the: Treatment of moderate to severe vasomotor symptoms associated with menopause. Treatment of moderate to severe vaginal dryness and pain with intercourse, symptoms of vulvar and vaginal atrophy, associated with menopause. When prescribing solely for the treatment of moderate to severe vaginal dryness and pain with intercourse, topical vaginal products should be considered. uuid:6cd8f79a-ed14-4cf8-8164-7610597794a5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8L6LAK9BTR biolink:treats MONDO:0001932 PMID:41385096 "[{""id"":""uuid:73e32a06-a711-4ae8-9068-42e191206fa1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:98cbf70e-3297-4ea4-b92a-c5f38c1e281c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENJUVIA tablets are indicated in the: Treatment of moderate to severe vasomotor symptoms associated with menopause. Treatment of moderate to severe vaginal dryness and pain with intercourse, symptoms of vulvar and vaginal atrophy, associated with menopause. When prescribing solely for the treatment of moderate to severe vaginal dryness and pain with intercourse, topical vaginal products should be considered. DOID:14275 uuid:fffc280c-1275-41db-a8ce-e950a433276a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15640 biolink:treats MONDO:0034212 PMID:41385096 "[{""id"":""uuid:b178b6b4-48bd-4e7e-ad0f-89798d7d1bcc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dc2884d3-ca26-415c-860c-dd3a41d57942"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Leucovorin Calcium Tablets USP are indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists. uuid:c5ca47be-780c-4721-aa6c-e46ac0d17048 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6402 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:6982eda9-ce6f-4630-8790-cc526fd2a465"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0607e1ad-a5ae-4a92-b4ed-94b9b2178116"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b8c7e07a-f55a-40a4-91ce-b4254cfdc721"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/leflunomide-medac""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Leflunomide is indicated in adults for the treatment of active rheumatoid arthritis (RA): to reduce signs and symptoms to inhibit structural damage as evidenced by X-ray erosions and joint space narrowing to improve physical function (see CLINICAL STUDIES ). Aspirin, nonsteroidal anti-inflammatory agents and/or low dose corticosteroids may be continued during treatment with leflunomide (see PRECAUTIONS: Drug Interactions: NSAIDs ). The combined use of leflunomide with antimalarials, intramuscular or oral gold, D penicillamine, azathioprine, or methotrexate has not been adequately studied (see WARNINGS: Immunosuppression Potential/Bone Marrow Suppression ).|[EMA] Leflunomide is indicated for the treatment of adult patients with:active rheumatoid arthritis as a 'disease-modifying antirheumatic drug' (DMARD).Recent or concurrent treatment with hepatotoxic or haematotoxic DMARDs (e.g. methotrexate) may result in an increased risk of serious adverse reactions, therefore, the initiation of leflunomide treatment has to be carefully considered regarding these benefit / risk aspects.Moreover, switching from leflunomide to another DMARD without following the washout procedure may also increase the risk of serious adverse reactions even for a long time after the switching. uuid:e08b1720-5caf-4949-8204-fc9f8e9801f7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:184555 biolink:treats MONDO:0018301 PMID:41385096 "[{""id"":""uuid:0f64d981-1939-4c3b-82fe-e96aaad60fe6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:72a54ca6-a7a5-49f0-b404-df9a680ffb20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:479bd967-eda2-4e0f-86c6-92e7b621db10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/elmiron""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ELMIRON ® (pentosan polysulfate sodium) is indicated for the relief of bladder pain or discomfort associated with interstitial cystitis.|[EMA] Elmiron is indicated for the treatment of bladder pain syndrome characterized by either glomerulations or Hunner’s lesions in adults with moderate to severe pain, urgency and frequency of micturition., uuid:526325fc-26c0-4741-acc4-a7981397b8c8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:36704 biolink:treats MONDO:0005173 PMID:41385096 "[{""id"":""uuid:a3b3fe10-d81c-4156-94ee-4ba7b98cb63b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:271370db-dab1-4151-a729-3de17171bb98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d5a90d13-4abd-4e46-bada-4138b44d233d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zyclara""]},{""id"":""uuid:4b8af96e-e0fd-4842-ba71-73720f93b5f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Imiquimod Cream is indicated for the topical treatment of: Clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses (AK) on the face or scalp in immunocompetent adults ( 1.1 ) External genital and perianal warts/condyloma acuminata in patients 12 years old or older ( 1.3 ) Limitations of Use: Efficacy was not demonstrated for molluscum contagiosum in children aged 2-12 ( 1.4 , 8.4 )|[EMA] Zyclara is indicated for the topical treatment of clinically typical, non-hyperkeratotic, non-hypertrophic, visible or palpable actinic keratosis of the full face or balding scalp in immunocompetent adults when other topical treatment options are contraindicated or less appropriate.|[PMDA] A drug with a new additional indication and a new dosage for the treatment of actinic keratosis (limited to the face or baldness). uuid:f200eeb8-5529-4762-8e98-5346c8c2798a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:36704 biolink:treats MONDO:0005647 PMID:41385096 "[{""id"":""uuid:85e8b48b-d710-4e64-835c-ea895bef9bea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:38c65bb7-5b0d-47c5-bbef-49782c32c252"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7f23b3bb-afb3-4e65-b0af-12028533e9c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zyclara""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Imiquimod Cream is indicated for the topical treatment of: Clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses (AK) on the face or scalp in immunocompetent adults ( 1.1 ) External genital and perianal warts/condyloma acuminata in patients 12 years old or older ( 1.3 ) Limitations of Use: Efficacy was not demonstrated for molluscum contagiosum in children aged 2-12 ( 1.4 , 8.4 )|[EMA] Imiquimod cream is indicated for the topical treatment of :External genital and perianal warts (condylomata acuminata) in adults.Small superficial basal cell carcinomas (sBCCs) in adults.Clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses (AKs) on the face or scalp in immunocompetent adult patients when size or number of lesions limit the efficacy and/or acceptability of cryotherapy and other topical treatment options are contraindicated or less appropriate. uuid:924754a4-1e18-4d90-be71-cb5d77865229 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:36704 biolink:treats MONDO:0005855 PMID:41385096 "[{""id"":""uuid:5addacbf-3780-48b0-92fc-bd6d66dfe3c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:efe7c857-0256-4ca8-a3af-dc8742f0b0da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Imiquimod Cream is indicated for the topical treatment of: Clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses (AK) on the face or scalp in immunocompetent adults ( 1.1 ) External genital and perianal warts/condyloma acuminata in patients 12 years old or older ( 1.3 ) Limitations of Use: Efficacy was not demonstrated for molluscum contagiosum in children aged 2-12 ( 1.4 , 8.4 ) uuid:6558adab-71e8-4006-ae20-2228207c2d89 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1158109 biolink:treats HP:0003124 PMID:41385096 "[{""id"":""uuid:b60e7bad-2a46-40a2-9191-3eca98be69f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:59e61122-5906-4132-818a-7fe1bb2a50e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. uuid:8c42bec7-3bc2-4d9f-8ecd-f4367cb9dc33 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1158109 biolink:treats MONDO:0005311 PMID:41385096 "[{""id"":""uuid:3e1c06a6-ce59-432e-8a52-0b9a3c85d223"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f14ba689-b2e1-430a-beb5-22fe7c929924"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. uuid:689060f6-6528-4ab9-931d-db761f8a9766 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:116962 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:a5bdbe2c-dde3-4043-8729-99a33b852727"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:237e4300-045d-46b4-af11-2bd42fe89560"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fosinopril sodium and hydrochlorothiazide tablets are indicated for the treatment of hypertension. These fixed dose combinations are not indicated for initial therapy. (See DOSAGE AND ADMINISTRATION .) In using fosinopril sodium and hydrochlorothiazide tablets, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that fosinopril does not have a similar risk (see WARNINGS: Neutropenia/Agranulocytosis ). ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see WARNINGS: Head and Neck Angioedema and Intestinal Angioedema: ). uuid:331a4b34-d492-429b-b512-5407e6ed4ea5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:116962 biolink:treats MONDO:0001609 PMID:41385096 "[{""id"":""uuid:4cd10396-2429-4265-a548-071999809911"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0bdcb58a-b289-447a-ae8d-5815b4030231"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fosinopril sodium and hydrochlorothiazide tablets are indicated for the treatment of hypertension. These fixed dose combinations are not indicated for initial therapy. (See DOSAGE AND ADMINISTRATION .) In using fosinopril sodium and hydrochlorothiazide tablets, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that fosinopril does not have a similar risk (see WARNINGS: Neutropenia/Agranulocytosis ). ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see WARNINGS: Head and Neck Angioedema and Intestinal Angioedema: ). uuid:a237566f-fe36-40e5-a220-04a42b39ff6e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:116962 biolink:treats MONDO:0001343 PMID:41385096 "[{""id"":""uuid:d70b0eeb-af86-4a00-b3b9-f1c73e84d325"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c9e25890-fbab-4de5-a385-bf20ab081018"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fosinopril sodium and hydrochlorothiazide tablets are indicated for the treatment of hypertension. These fixed dose combinations are not indicated for initial therapy. (See DOSAGE AND ADMINISTRATION .) In using fosinopril sodium and hydrochlorothiazide tablets, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that fosinopril does not have a similar risk (see WARNINGS: Neutropenia/Agranulocytosis ). ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see WARNINGS: Head and Neck Angioedema and Intestinal Angioedema: ). uuid:6a193a5e-b020-4c40-a4a0-f777d67c1f4f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:116962 biolink:treats MONDO:0010481 PMID:41385096 "[{""id"":""uuid:9e412a29-aa9e-42fe-a783-b138e359b721"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7b77e2b5-1029-4f12-82aa-b42fa05df579"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fosinopril sodium and hydrochlorothiazide tablets are indicated for the treatment of hypertension. These fixed dose combinations are not indicated for initial therapy. (See DOSAGE AND ADMINISTRATION .) In using fosinopril sodium and hydrochlorothiazide tablets, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that fosinopril does not have a similar risk (see WARNINGS: Neutropenia/Agranulocytosis ). ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see WARNINGS: Head and Neck Angioedema and Intestinal Angioedema: ). uuid:e2b1c80f-d0b1-4d70-bdc3-b397dabf8988 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9327 biolink:treats MONDO:0043885 PMID:41385096 "[{""id"":""uuid:07ecd112-ff5d-49eb-a922-b4a257b003ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:36228f26-05d2-4a3f-b8c7-812f1975a0b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sulfacetamide Sodium Ophthalmic Solution USP, 10% is indicated for the treatment of conjunctivitis and other superficial ocular infections due to susceptible microorganisms, and as an adjunctive in systemic sulfonamide therapy of trachoma: Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus (viridans group), Haemophilus influenzae, Klebsiella species, and Enterobacter species. Topically applied sulfonamides do not provide adequate coverage against Neisseria species, Serratia marcescens and Pseudomonas aeruginosa. A significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. uuid:51df2444-c673-4923-89ae-04488f2947c5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3699 biolink:treats MONDO:0006896 PMID:41385096 "[{""id"":""uuid:ba217208-03da-426b-8f58-0e75fdc6ace3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6baa9ce7-fcb5-4bd0-923d-511b12318c05"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cimetidine tablets are indicated in: 1) Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks and there is rarely reason to use cimetidine at full dosage for longer than 6 to 8 weeks (see DOSAGE AND ADMINISTRATION , Duodenal Ulcer ). Concomitant antacids should be given as needed for relief of pain. However, simultaneous administration of oral cimetidine and antacids is not recommended, since antacids have been reported to interfere with the absorption of oral cimetidine. 2) Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of active ulcer. Patients have been maintained on continued treatment with cimetidine 400 mg at bedtime for periods of up to five years. 3) Short-term treatment of active benign gastric ulcer. There is no information concerning usefulness of treatment periods of longer than eight weeks. 4) Erosive gastroesophageal reflux disease (GERD). Erosive esophagitis diagnosed by endoscopy. Treatment is indicated for twelve weeks for healing of lesions and control of symptoms. The use of cimetidine beyond twelve weeks has not been established (see DOSAGE AND ADMINISTRATION , GERD ). 5) The treatment of pathological hypersecretory conditions (i.e., Zollinger-Ellison Syndrome, systemic mastocytosis, multiple endocrine adenomas). uuid:a404d27e-c4f1-408e-ae68-8dc6895ea2a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3699 biolink:treats UMLS:C0267055 PMID:41385096 "[{""id"":""uuid:938160d6-4616-48e3-9bc0-aa2827a2d713"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3950606e-4346-4c25-bb93-b8d2475e8910"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cimetidine tablets are indicated in: 1) Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks and there is rarely reason to use cimetidine at full dosage for longer than 6 to 8 weeks (see DOSAGE AND ADMINISTRATION , Duodenal Ulcer ). Concomitant antacids should be given as needed for relief of pain. However, simultaneous administration of oral cimetidine and antacids is not recommended, since antacids have been reported to interfere with the absorption of oral cimetidine. 2) Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of active ulcer. Patients have been maintained on continued treatment with cimetidine 400 mg at bedtime for periods of up to five years. 3) Short-term treatment of active benign gastric ulcer. There is no information concerning usefulness of treatment periods of longer than eight weeks. 4) Erosive gastroesophageal reflux disease (GERD). Erosive esophagitis diagnosed by endoscopy. Treatment is indicated for twelve weeks for healing of lesions and control of symptoms. The use of cimetidine beyond twelve weeks has not been established (see DOSAGE AND ADMINISTRATION , GERD ). 5) The treatment of pathological hypersecretory conditions (i.e., Zollinger-Ellison Syndrome, systemic mastocytosis, multiple endocrine adenomas). uuid:435bdc8d-4779-4aea-b864-c0dcf7201e96 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4754 biolink:treats MONDO:0005984 PMID:41385096 "[{""id"":""uuid:85ce0f2c-bc7b-4e99-9b53-1fbac4b51ec6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:03574df6-fdc0-421f-8bf2-62520d1eb2ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Econazole Nitrate Cream, 1% is indicated for topical application in the treatment of tinea pedis, tinea cruris, and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans, Microsporum canis, Microsporum audouini, Microsporum gypseum, and Epidermophyton floccosum, in the treatment of cutaneous candidiasis, and in the treatment of tinea versicolor. uuid:0f77bc48-8634-455f-a999-d55fcdb60118 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4754 biolink:treats MONDO:0001405 PMID:41385096 "[{""id"":""uuid:7593b5fd-0d72-4478-a3e6-35f2cb5594a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:53c6d05a-f1ef-4ca1-978c-be2d8d59495c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Econazole Nitrate Cream, 1% is indicated for topical application in the treatment of tinea pedis, tinea cruris, and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans, Microsporum canis, Microsporum audouini, Microsporum gypseum, and Epidermophyton floccosum, in the treatment of cutaneous candidiasis, and in the treatment of tinea versicolor. uuid:bdf36756-8013-456f-a9fb-43daefe0c197 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4754 biolink:treats MONDO:0001461 PMID:41385096 "[{""id"":""uuid:44e96c62-1b19-40af-90fc-7d98f8ec0451"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:97e8444f-bade-4251-9e98-9b987d578e7c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Econazole Nitrate Cream, 1% is indicated for topical application in the treatment of tinea pedis, tinea cruris, and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans, Microsporum canis, Microsporum audouini, Microsporum gypseum, and Epidermophyton floccosum, in the treatment of cutaneous candidiasis, and in the treatment of tinea versicolor. uuid:7d38cf51-11d6-4e71-bd0a-d107040e78fa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4754 biolink:treats MONDO:0000879 PMID:41385096 "[{""id"":""uuid:6e23cfc3-0624-4920-83b9-66602ae5a5ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7d354c11-b8ce-49c4-8a9a-f82330799644"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Econazole Nitrate Cream, 1% is indicated for topical application in the treatment of tinea pedis, tinea cruris, and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans, Microsporum canis, Microsporum audouini, Microsporum gypseum, and Epidermophyton floccosum, in the treatment of cutaneous candidiasis, and in the treatment of tinea versicolor. uuid:640edf59-dd4f-4aec-aea3-48bc14f84ea2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4754 biolink:treats MONDO:0005915 PMID:41385096 "[{""id"":""uuid:661e2e9f-841d-47c3-982b-b0e9507326bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:13a86595-5598-48a9-ab5c-e367ae0e8653"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Econazole Nitrate Cream, 1% is indicated for topical application in the treatment of tinea pedis, tinea cruris, and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans, Microsporum canis, Microsporum audouini, Microsporum gypseum, and Epidermophyton floccosum, in the treatment of cutaneous candidiasis, and in the treatment of tinea versicolor. uuid:791f4dcf-a369-4aa3-b2b6-acc5d518ad2f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:375581 biolink:treats UMLS:C0278139 PMID:41385096 "[{""id"":""uuid:97122fef-2fdd-4696-97c5-d4dd119d3b83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1d8ce434-886a-4146-97ce-e354b275a573"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxycodone and Acetaminophen Tablets, USP are indicated for the relief of moderate to moderately severe pain. uuid:983b227b-2cdc-45f2-a9cc-a5e6cc7f0568 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5551 biolink:treats MONDO:0005607 PMID:41385096 "[{""id"":""uuid:8d45e5cd-054a-4bde-b093-5642814e0ed0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:70ef9360-ffde-430e-a3fc-2399c675bb81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Helps loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus, drain bronchial tubes and make coughs more productive. Helps loosen phlegm and thin bronchial secretions in patients with stable chronic bronchitis. uuid:f1cd96d7-5e84-4cf5-844d-118f63af804b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9874151 biolink:treats MONDO:0001932 PMID:41385096 "[{""id"":""uuid:0b962e08-f641-4b1d-b530-9a673585bb37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7f17e6f8-a0fb-442f-85a5-bf694dd966c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ANGELIQ is indicated in women who have a uterus for the: 1. Treatment of moderate to severe vasomotor symptoms associated with the menopause. 2. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. DOID:14275 uuid:973e7601-d172-460a-bc45-9be9882620df biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46295 biolink:treats NCIT:C55615 PMID:41385096 "[{""id"":""uuid:1a5c02e1-3741-4396-9747-ddb22a326b62"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bb3b7c6a-e772-420e-8e3f-5150c8948991"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:19288904-51f3-4809-98b5-ff4603d9cf8e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LEVITRA is indicated for the treatment of erectile dysfunction.|[PMDA] A drugs containing a new active ingredient with indications for phosphodiesterase-5 inhibitor in erectile dysfunction. uuid:38a180ae-55da-4f1e-b53c-8aa920ea5619 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42355 biolink:treats MONDO:0002896 PMID:41385096 "[{""id"":""uuid:ca55f16e-14f3-4087-b2b0-8fe2f5969a1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:accea87c-b8a6-4eb4-89aa-9fa04dd6f1ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Erythromycin Base Filmtab tablets and other antibacterial drugs, Erythromycin Base Filmtab tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin Base Filmtab tablets are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes ; Streptococcus pneumoniae ; Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower respiratory tract infections of mild to moderate severity caused by Streptococcus pyogenes or Streptococcus pneumoniae . Listeriosis caused by Listeria monocytogenes . Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals, rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma - In the treatment of infections due to Corynebacterium minutissimum . Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae : Erythrocin ® Lactobionate-I.V. (erythromycin lactobionate for injection, USP) followed by erythromycin base orally, as an alternative drug in treatment of acute pelvic inflammatory disease caused by N. gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. Erythromycins are indicated for treatment of the following infections caused by Chlamydia trachomatis : conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis . 3 When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum . 3 Primary syphilis caused by Treponema pallidum . Erythromycin (oral forms only) is an alternative choice of treatment for primary syphilis in patients allergic to the penicillins. In treatment of primary syphilis, spinal fluid should be examined before treatment and as part of the follow-up after therapy. Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Prophylaxis Prevention of Initial Attacks of Rheumatic Fever Penicillin is considered by the American Heart Association to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of Streptococcus pyogenes infections of the upper respiratory tract e.g., tonsillitis, or pharyngitis). 3 Erythromycin is indicated for the treatment of penicillin-allergic patients. The therapeutic dose should be administered for ten days. Prevention of Recurrent Attacks of Rheumatic Fever Penicillin or sulfonamides are considered by the American Heart Association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. In patients who are allergic to penicillin and sulfonamides, oral erythromycin is recommended by the American Heart Association in the long-term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever). 3 uuid:f4253f1a-57f2-4c13-bfab-c453f01dacc4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3746 biolink:treats MONDO:0005316 PMID:41385096 "[{""id"":""uuid:6ea5255a-5a86-4b78-90be-e24777d02008"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c633a066-ede8-467f-ae52-14afa9fbcd73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Clindamycin phosphate vaginal cream 2%, is indicated in the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, Gardnerella vaginitis, nonspecific vaginitis, Corynebacterium vaginitis, or anaerobic vaginosis). Clindamycin phosphate vaginal cream 2%, can be used to treat non-pregnant women and pregnant women during the second and third trimester. (See CLINICAL STUDIES. ) NOTE: For purposes of this indication, a clinical diagnosis of bacterial vaginosis is usually defined by the presence of a homogeneous vaginal discharge that (a) has a pH of greater than 4.5, (b) emits a ""fishy"" amine odor when mixed with a 10% KOH solution, and (c) contains clue cells on microscopic examination. Gram's stain results consistent with a diagnosis of bacterial vaginosis include (a) markedly reduced or absent Lactobacillus morphology, (b) predominance of Gardnerella morphotype, and (c) absent or few white blood cells. Other pathogens commonly associated with vulvovaginitis, e.g., Trichomonas vaginalis , Chlamydia trachomatis, N. gonorrhoeae, Candida albicans , and Herpes simplex virus should be ruled out." uuid:26be895a-e280-4186-8c92-e5567c8c2ac9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3746 biolink:treats UMLS:C1622505 PMID:41385096 "[{""id"":""uuid:8e35c824-e06c-46fb-abeb-569f4a49d37f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3ce69018-2502-4158-b7c0-47bf61099af6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Clindamycin phosphate vaginal cream 2%, is indicated in the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, Gardnerella vaginitis, nonspecific vaginitis, Corynebacterium vaginitis, or anaerobic vaginosis). Clindamycin phosphate vaginal cream 2%, can be used to treat non-pregnant women and pregnant women during the second and third trimester. (See CLINICAL STUDIES. ) NOTE: For purposes of this indication, a clinical diagnosis of bacterial vaginosis is usually defined by the presence of a homogeneous vaginal discharge that (a) has a pH of greater than 4.5, (b) emits a ""fishy"" amine odor when mixed with a 10% KOH solution, and (c) contains clue cells on microscopic examination. Gram's stain results consistent with a diagnosis of bacterial vaginosis include (a) markedly reduced or absent Lactobacillus morphology, (b) predominance of Gardnerella morphotype, and (c) absent or few white blood cells. Other pathogens commonly associated with vulvovaginitis, e.g., Trichomonas vaginalis , Chlamydia trachomatis, N. gonorrhoeae, Candida albicans , and Herpes simplex virus should be ruled out." uuid:fd02eecc-33bf-4828-a020-c6e4fe56ca81 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3746 biolink:treats MONDO:0023557 PMID:41385096 "[{""id"":""uuid:f2f906a4-5343-4a6f-a90e-265a1cba2806"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aefdbcd7-b54b-4d3a-a6f4-225f2e338eb9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Clindamycin phosphate vaginal cream 2%, is indicated in the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, Gardnerella vaginitis, nonspecific vaginitis, Corynebacterium vaginitis, or anaerobic vaginosis). Clindamycin phosphate vaginal cream 2%, can be used to treat non-pregnant women and pregnant women during the second and third trimester. (See CLINICAL STUDIES. ) NOTE: For purposes of this indication, a clinical diagnosis of bacterial vaginosis is usually defined by the presence of a homogeneous vaginal discharge that (a) has a pH of greater than 4.5, (b) emits a ""fishy"" amine odor when mixed with a 10% KOH solution, and (c) contains clue cells on microscopic examination. Gram's stain results consistent with a diagnosis of bacterial vaginosis include (a) markedly reduced or absent Lactobacillus morphology, (b) predominance of Gardnerella morphotype, and (c) absent or few white blood cells. Other pathogens commonly associated with vulvovaginitis, e.g., Trichomonas vaginalis , Chlamydia trachomatis, N. gonorrhoeae, Candida albicans , and Herpes simplex virus should be ruled out." uuid:10b81e39-741d-454a-a4a9-a5241ed7d980 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DrugCentral:3875 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:79dff271-d68d-40cb-ae61-a403dc289f7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:91f6ff0a-2f9d-4a87-b56b-16c5033a79d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Erythromycin-Benzoyl Peroxide Topical Gel is indicated for the topical treatment of acne vulgaris. uuid:8799790d-449c-41b4-ab4e-4e96fe048543 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3814 biolink:treats UMLS:C0342879 PMID:41385096 "[{""id"":""uuid:386ed970-3200-4534-92f1-8c2b23624afc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7847dbb1-47de-4106-9ae8-f2263056e69c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Since no drug is innocuous, strict attention should be paid to the indications and contraindications, particularly when selecting drugs for chronic long-term use. Micronized colestipol hydrochloride tablets are indicated as adjunctive therapy to diet for the reduction of elevated serum total and LDL-C in patients with primary hypercholesterolemia (elevated LDL-C) who do not respond adequately to diet. Generally, micronized colestipol hydrochloride tablets have no clinically significant effect on serum triglycerides, but with their use, triglyceride levels may be raised in some patients. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy (see NCEP guidelines ). A minimum of six months of intensive dietary therapy and counseling should be carried out prior to initiation of drug therapy. Shorter periods may be considered in patients with severe elevations of LDL-C or with definite CHD. According to the NCEP guidelines, the goal of treatment is to lower LDL-C, and LDL-C is to be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the Total-C be used to monitor therapy. The NCEP treatment guidelines are shown below. LDL-Cholesterol mg/dL (mmol/L) Definite Atherosclerotic Disease Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). Two or More Other Risk Factors Other risk factors for coronary heart disease (CHD) include: age (males: ≥45 years; female: ≥55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C <35 mg/dL (0.91 mmol/L); and diabetes mellitus. Subtract one risk factor if HDL-C is ≥60 mg/dL (1.6 mmol/L). Initiation Level Goal No No ≥190 (≥4.9) <160 (<4.1) No Yes ≥160 (≥4.1) <130 (<3.4) Yes Yes or No ≥130 (≥3.4) ≤100 (≤2.6) uuid:e55ef273-ced8-48bc-b14d-058872f72e76 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3814 biolink:treats MONDO:0005311 PMID:41385096 "[{""id"":""uuid:fa33909c-4ff6-40a0-8987-2519f5df0d79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:391a8d90-fb31-477d-a88c-1797d8aa6377"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Since no drug is innocuous, strict attention should be paid to the indications and contraindications, particularly when selecting drugs for chronic long-term use. Micronized colestipol hydrochloride tablets are indicated as adjunctive therapy to diet for the reduction of elevated serum total and LDL-C in patients with primary hypercholesterolemia (elevated LDL-C) who do not respond adequately to diet. Generally, micronized colestipol hydrochloride tablets have no clinically significant effect on serum triglycerides, but with their use, triglyceride levels may be raised in some patients. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy (see NCEP guidelines ). A minimum of six months of intensive dietary therapy and counseling should be carried out prior to initiation of drug therapy. Shorter periods may be considered in patients with severe elevations of LDL-C or with definite CHD. According to the NCEP guidelines, the goal of treatment is to lower LDL-C, and LDL-C is to be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the Total-C be used to monitor therapy. The NCEP treatment guidelines are shown below. LDL-Cholesterol mg/dL (mmol/L) Definite Atherosclerotic Disease Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). Two or More Other Risk Factors Other risk factors for coronary heart disease (CHD) include: age (males: ≥45 years; female: ≥55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C <35 mg/dL (0.91 mmol/L); and diabetes mellitus. Subtract one risk factor if HDL-C is ≥60 mg/dL (1.6 mmol/L). Initiation Level Goal No No ≥190 (≥4.9) <160 (<4.1) No Yes ≥160 (≥4.1) <130 (<3.4) Yes Yes or No ≥130 (≥3.4) ≤100 (≤2.6) uuid:ee357183-a6e1-4181-969f-f4a0afd53803 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3814 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:596e6c53-1325-40b3-8dbb-9b2e579f80ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:98775b35-9a44-453f-b576-82b394eebbac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Since no drug is innocuous, strict attention should be paid to the indications and contraindications, particularly when selecting drugs for chronic long-term use. Micronized colestipol hydrochloride tablets are indicated as adjunctive therapy to diet for the reduction of elevated serum total and LDL-C in patients with primary hypercholesterolemia (elevated LDL-C) who do not respond adequately to diet. Generally, micronized colestipol hydrochloride tablets have no clinically significant effect on serum triglycerides, but with their use, triglyceride levels may be raised in some patients. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy (see NCEP guidelines ). A minimum of six months of intensive dietary therapy and counseling should be carried out prior to initiation of drug therapy. Shorter periods may be considered in patients with severe elevations of LDL-C or with definite CHD. According to the NCEP guidelines, the goal of treatment is to lower LDL-C, and LDL-C is to be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the Total-C be used to monitor therapy. The NCEP treatment guidelines are shown below. LDL-Cholesterol mg/dL (mmol/L) Definite Atherosclerotic Disease Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). Two or More Other Risk Factors Other risk factors for coronary heart disease (CHD) include: age (males: ≥45 years; female: ≥55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C <35 mg/dL (0.91 mmol/L); and diabetes mellitus. Subtract one risk factor if HDL-C is ≥60 mg/dL (1.6 mmol/L). Initiation Level Goal No No ≥190 (≥4.9) <160 (<4.1) No Yes ≥160 (≥4.1) <130 (<3.4) Yes Yes or No ≥130 (≥3.4) ≤100 (≤2.6) uuid:7f61f235-6521-4425-a884-5327f9adf634 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3814 biolink:treats MONDO:0005294 PMID:41385096 "[{""id"":""uuid:41d29a72-c5aa-460d-bbde-5e0b25806315"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4e78ee0b-32ae-4416-af6c-1de110b22660"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Since no drug is innocuous, strict attention should be paid to the indications and contraindications, particularly when selecting drugs for chronic long-term use. Micronized colestipol hydrochloride tablets are indicated as adjunctive therapy to diet for the reduction of elevated serum total and LDL-C in patients with primary hypercholesterolemia (elevated LDL-C) who do not respond adequately to diet. Generally, micronized colestipol hydrochloride tablets have no clinically significant effect on serum triglycerides, but with their use, triglyceride levels may be raised in some patients. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy (see NCEP guidelines ). A minimum of six months of intensive dietary therapy and counseling should be carried out prior to initiation of drug therapy. Shorter periods may be considered in patients with severe elevations of LDL-C or with definite CHD. According to the NCEP guidelines, the goal of treatment is to lower LDL-C, and LDL-C is to be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the Total-C be used to monitor therapy. The NCEP treatment guidelines are shown below. LDL-Cholesterol mg/dL (mmol/L) Definite Atherosclerotic Disease Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). Two or More Other Risk Factors Other risk factors for coronary heart disease (CHD) include: age (males: ≥45 years; female: ≥55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C <35 mg/dL (0.91 mmol/L); and diabetes mellitus. Subtract one risk factor if HDL-C is ≥60 mg/dL (1.6 mmol/L). Initiation Level Goal No No ≥190 (≥4.9) <160 (<4.1) No Yes ≥160 (≥4.1) <130 (<3.4) Yes Yes or No ≥130 (≥3.4) ≤100 (≤2.6) uuid:a91d727e-cc01-4856-b8e9-7ba1b3e241cb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3814 biolink:treats MONDO:0005269 PMID:41385096 "[{""id"":""uuid:70f79c84-dc01-4551-9ed3-59fde0c9af4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:207836f3-41d6-4f78-98cb-f493412506a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Since no drug is innocuous, strict attention should be paid to the indications and contraindications, particularly when selecting drugs for chronic long-term use. Micronized colestipol hydrochloride tablets are indicated as adjunctive therapy to diet for the reduction of elevated serum total and LDL-C in patients with primary hypercholesterolemia (elevated LDL-C) who do not respond adequately to diet. Generally, micronized colestipol hydrochloride tablets have no clinically significant effect on serum triglycerides, but with their use, triglyceride levels may be raised in some patients. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy (see NCEP guidelines ). A minimum of six months of intensive dietary therapy and counseling should be carried out prior to initiation of drug therapy. Shorter periods may be considered in patients with severe elevations of LDL-C or with definite CHD. According to the NCEP guidelines, the goal of treatment is to lower LDL-C, and LDL-C is to be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the Total-C be used to monitor therapy. The NCEP treatment guidelines are shown below. LDL-Cholesterol mg/dL (mmol/L) Definite Atherosclerotic Disease Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). Two or More Other Risk Factors Other risk factors for coronary heart disease (CHD) include: age (males: ≥45 years; female: ≥55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C <35 mg/dL (0.91 mmol/L); and diabetes mellitus. Subtract one risk factor if HDL-C is ≥60 mg/dL (1.6 mmol/L). Initiation Level Goal No No ≥190 (≥4.9) <160 (<4.1) No Yes ≥160 (≥4.1) <130 (<3.4) Yes Yes or No ≥130 (≥3.4) ≤100 (≤2.6) uuid:0b0f8667-4c49-4346-8262-93f97e93dfb4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3814 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:17817f7b-0c09-4922-9927-33004ef5f584"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:86c5fcaf-302a-4900-8ad9-695fa1b85d1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Since no drug is innocuous, strict attention should be paid to the indications and contraindications, particularly when selecting drugs for chronic long-term use. Micronized colestipol hydrochloride tablets are indicated as adjunctive therapy to diet for the reduction of elevated serum total and LDL-C in patients with primary hypercholesterolemia (elevated LDL-C) who do not respond adequately to diet. Generally, micronized colestipol hydrochloride tablets have no clinically significant effect on serum triglycerides, but with their use, triglyceride levels may be raised in some patients. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy (see NCEP guidelines ). A minimum of six months of intensive dietary therapy and counseling should be carried out prior to initiation of drug therapy. Shorter periods may be considered in patients with severe elevations of LDL-C or with definite CHD. According to the NCEP guidelines, the goal of treatment is to lower LDL-C, and LDL-C is to be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the Total-C be used to monitor therapy. The NCEP treatment guidelines are shown below. LDL-Cholesterol mg/dL (mmol/L) Definite Atherosclerotic Disease Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). Two or More Other Risk Factors Other risk factors for coronary heart disease (CHD) include: age (males: ≥45 years; female: ≥55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C <35 mg/dL (0.91 mmol/L); and diabetes mellitus. Subtract one risk factor if HDL-C is ≥60 mg/dL (1.6 mmol/L). Initiation Level Goal No No ≥190 (≥4.9) <160 (<4.1) No Yes ≥160 (≥4.1) <130 (<3.4) Yes Yes or No ≥130 (≥3.4) ≤100 (≤2.6) uuid:79a4b0ce-ee06-4652-98ee-1d50441438d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3814 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:2a52f673-9971-42c0-801a-f623d100cd28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8984d8c3-6821-4b3a-96bd-386dd75459d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Since no drug is innocuous, strict attention should be paid to the indications and contraindications, particularly when selecting drugs for chronic long-term use. Micronized colestipol hydrochloride tablets are indicated as adjunctive therapy to diet for the reduction of elevated serum total and LDL-C in patients with primary hypercholesterolemia (elevated LDL-C) who do not respond adequately to diet. Generally, micronized colestipol hydrochloride tablets have no clinically significant effect on serum triglycerides, but with their use, triglyceride levels may be raised in some patients. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy (see NCEP guidelines ). A minimum of six months of intensive dietary therapy and counseling should be carried out prior to initiation of drug therapy. Shorter periods may be considered in patients with severe elevations of LDL-C or with definite CHD. According to the NCEP guidelines, the goal of treatment is to lower LDL-C, and LDL-C is to be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the Total-C be used to monitor therapy. The NCEP treatment guidelines are shown below. LDL-Cholesterol mg/dL (mmol/L) Definite Atherosclerotic Disease Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). Two or More Other Risk Factors Other risk factors for coronary heart disease (CHD) include: age (males: ≥45 years; female: ≥55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C <35 mg/dL (0.91 mmol/L); and diabetes mellitus. Subtract one risk factor if HDL-C is ≥60 mg/dL (1.6 mmol/L). Initiation Level Goal No No ≥190 (≥4.9) <160 (<4.1) No Yes ≥160 (≥4.1) <130 (<3.4) Yes Yes or No ≥130 (≥3.4) ≤100 (≤2.6) uuid:f0aba128-f836-410d-b0aa-e73596d5f570 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3746 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:a4608d05-c58f-442f-8560-98855b8a5c77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:197c7a21-6ad5-441a-8171-0ec7a9289b82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clindamycin Phosphate Topical Solution, Clindamycin Phosphate Gel, and Clindamycin Phosphate Lotion are indicated in the treatment of acne vulgaris. In view of the potential for diarrhea, bloody diarrhea and pseudomembranous colitis, the physician should consider whether other agents are more appropriate. (See CONTRAINDICATIONS , WARNINGS and ADVERSE REACTIONS. ) uuid:1ee4f636-077e-48e1-bb0f-5c02c6e90774 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3746 biolink:treats MONDO:0001673 PMID:41385096 "[{""id"":""uuid:866cb05a-d9cd-469a-8870-70f2603e112b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:22d5e5b2-96d1-4771-950c-7295c8239aae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clindamycin Phosphate Topical Solution, Clindamycin Phosphate Gel, and Clindamycin Phosphate Lotion are indicated in the treatment of acne vulgaris. In view of the potential for diarrhea, bloody diarrhea and pseudomembranous colitis, the physician should consider whether other agents are more appropriate. (See CONTRAINDICATIONS , WARNINGS and ADVERSE REACTIONS. ) uuid:e7ff28c4-5a10-4114-9cda-b99fbc929916 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3746 biolink:treats HP:0025085 PMID:41385096 "[{""id"":""uuid:85640a3a-6037-4d53-834f-714fedf29b0c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:29b08032-4f60-4672-8e06-102776201b73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clindamycin Phosphate Topical Solution, Clindamycin Phosphate Gel, and Clindamycin Phosphate Lotion are indicated in the treatment of acne vulgaris. In view of the potential for diarrhea, bloody diarrhea and pseudomembranous colitis, the physician should consider whether other agents are more appropriate. (See CONTRAINDICATIONS , WARNINGS and ADVERSE REACTIONS. ) uuid:eb3d1c66-3862-4c6a-8f3a-4da508e15e75 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3746 biolink:treats MONDO:0000705 PMID:41385096 "[{""id"":""uuid:3401d774-1c57-40ec-a8f3-7ad9cd4c8511"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:802611b1-cca6-4373-8a95-285207eedbdf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clindamycin Phosphate Topical Solution, Clindamycin Phosphate Gel, and Clindamycin Phosphate Lotion are indicated in the treatment of acne vulgaris. In view of the potential for diarrhea, bloody diarrhea and pseudomembranous colitis, the physician should consider whether other agents are more appropriate. (See CONTRAINDICATIONS , WARNINGS and ADVERSE REACTIONS. ) uuid:9bfc4e1c-2e5e-4f51-bdfd-bc04720bcbef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31854 biolink:treats MONDO:0005546 PMID:41385096 "[{""id"":""uuid:d3c4caa0-0ee4-42f4-92a4-8ad63521137f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:acbc9337-c8c1-4520-aeb6-4a148ca21958"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Savella is indicated for the management of fibromyalgia. Savella is not approved for use in pediatric patients [ see Use in Specific Populations ( 8.4 ) ]. uuid:f4f30573-a4e0-48f5-812e-2cb5a3d8ff57 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32184 biolink:treats UMLS:C1304119 PMID:41385096 "[{""id"":""uuid:03a49f13-a614-4fbe-9fc0-d74e9a232cf6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a2ffbd03-20ac-4c7e-9c9c-9a8ff665b8c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TAZORAC ® (tazarotene) Gel 0.05% and 0.1% are indicated for the topical treatment of patients with stable plaque psoriasis of up to 20% body surface area involvement. TAZORAC ® (tazarotene) Gel 0.1% is also indicated for the topical treatment of patients with facial acne vulgaris of mild to moderate severity. The efficacy of TAZORAC ® Gel in the treatment of acne previously treated with other retinoids or resistant to oral antibiotics has not been established. uuid:250eccc2-1f7d-481e-b5c1-151df507f573 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32184 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:44a7ca08-033b-4a6b-a928-5faf7a9f0b88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5a5b3ee4-1025-4bf1-8fbe-0eafe959ae2d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TAZORAC ® (tazarotene) Gel 0.05% and 0.1% are indicated for the topical treatment of patients with stable plaque psoriasis of up to 20% body surface area involvement. TAZORAC ® (tazarotene) Gel 0.1% is also indicated for the topical treatment of patients with facial acne vulgaris of mild to moderate severity. The efficacy of TAZORAC ® Gel in the treatment of acne previously treated with other retinoids or resistant to oral antibiotics has not been established. uuid:25cef3d6-6ff4-47f5-8477-e8b595ec9ece biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5558 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:03346a3e-5907-44a5-8212-ff1026b6f496"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:681ad662-e139-4ff9-81ed-ecdc96c07b6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Guanfacine tablets are indicated in the management of hypertension. Guanfacine may be given alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. uuid:316c02f2-8329-448f-8a73-7f02f846ccab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8356 biolink:treats MONDO:0005180 PMID:41385096 "[{""id"":""uuid:b27603d0-6fd5-4373-a091-129cada21a88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:57681d7b-f337-4b60-a8e1-004b76a2064e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:6a2a3f6b-810f-4e6d-8421-fe60c2944233"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:19f4da7b-a79e-4591-8083-1f8275fd680c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Pramipexole dihydrochloride tablets are indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease. The effectiveness of pramipexole dihydrochloride tablets was demonstrated in randomized, controlled trials in patients with early Parkinson's disease who were not receiving concomitant levodopa therapy as well as in patients with advanced disease on concomitant levodopa (see CLINICAL STUDIES ).|[EMA] Oprymea is indicated for treatment of the signs and symptoms of idiopathic Parkinson's disease, alone (without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or ""on off"" fluctuations).Oprymea is indicated in adults for symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome in doses up to 0.54 mg of base (0.75 mg of salt) (see section 4.2).|[PMDA] Drugs in new dosage forms and with new dosages indicated for the treatment of Parkinson's disease." uuid:9d870ec1-2b41-4d4e-aa96-ae379dfed421 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7025 biolink:treats MONDO:0021680 PMID:41385096 "[{""id"":""uuid:c1e152a2-3e75-49b1-b9b1-52ff51d06473"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ce7510b2-cfac-4150-8bd2-fe08cf8f5963"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Mupirocin Ointment USP, 2% is indicated for the topical treatment of impetigo due to: Staphylococcus aureus and Streptococcus pyogenes . uuid:de22f7ac-65a6-4b86-830e-7d853dd09f05 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841899 biolink:treats MONDO:0006668 PMID:41385096 "[{""id"":""uuid:82c865cc-44c9-4b7e-be62-b37d1a1a6f03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:04ad0a45-89fa-4edc-add3-bc17c1e399e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroids use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns; or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, and Pseudomonas aeruginosa. This product does not provide adequate coverage against: Serratia marcescens and streptococci, including Streptococcus pneumoniae. uuid:a3f3cb12-55c9-41e4-a3d8-1db6ab11dab6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841899 biolink:treats UMLS:C0008690 PMID:41385096 "[{""id"":""uuid:e6da1348-4d00-403f-8a52-36eb148ca72b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c2f564e4-c450-4842-879f-5ab48c91ede4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroids use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns; or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, and Pseudomonas aeruginosa. This product does not provide adequate coverage against: Serratia marcescens and streptococci, including Streptococcus pneumoniae. uuid:88c36038-a4e5-423d-8ea4-d4772497f9ef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841899 biolink:treats UMLS:C0339289 PMID:41385096 "[{""id"":""uuid:1f24658d-8864-450c-95ff-18802bb51e1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:716ba10b-f3cf-4453-9fe2-2ca25819f428"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroids use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns; or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, and Pseudomonas aeruginosa. This product does not provide adequate coverage against: Serratia marcescens and streptococci, including Streptococcus pneumoniae. uuid:29d790fe-51bf-4fb0-99a6-5ddda14c8a01 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5296 biolink:treats MONDO:0037748 PMID:41385096 "[{""id"":""uuid:ab805aa9-e5f8-4638-8aad-aba47b860ab3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:52661a51-3090-480c-9302-00cd81ebed41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gemfibrozil Tablets, USP are indicated as adjunctive therapy to diet for: 1. Treatment of adult patients with very high elevations of serum triglyceride levels (Types IV and V hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Patients who present such risk typically have serum triglycerides over 2000 mg/dL and have elevations of VLDL-cholesterol as well as fasting chylomicrons (Type V hyperlipidemia). Subjects who consistently have total serum or plasma triglycerides below 1000 mg/dL are unlikely to present a risk of pancreatitis. Gemfibrozil tablets, USP therapy may be considered for those subjects with triglyceride elevations between 1000 and 2000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. It is recognized that some Type IV patients with triglycerides under 1000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of gemfibrozil tablets, USP therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia. 2. Reducing the risk of developing coronary heart disease only in Type IIb patients without history of or symptoms of existing coronary heart disease who have had an inadequate response to weight loss, dietary therapy, exercise, and other pharmacologic agents (such as bile acid sequestrants and nicotinic acid, known to reduce LDL- and raise HDL-cholesterol) and who have the following triad of lipid abnormalities: low HDL-cholesterol levels in addition to elevated LDL-cholesterol and elevated triglycerides (see WARNINGS , PRECAUTIONS , and CLINICAL PHARMACOLOGY ). The National Cholesterol Education Program has defined a serum HDL-cholesterol value that is consistently below 35 mg/dL as constituting an independent risk factor for coronary heart disease. Patients with significantly elevated triglycerides should be closely observed when treated with gemfibrozil. In some patients with high triglyceride levels, treatment with gemfibrozil is associated with a significant increase in LDL-cholesterol. BECAUSE OF POTENTIAL TOXICITY SUCH AS MALIGNANCY, GALLBLADDER DISEASE, ABDOMINAL PAIN LEADING TO APPENDECTOMY AND OTHER ABDOMINAL SURGERIES, AN INCREASED INCIDENCE IN NON-CORONARY MORTALITY, AND THE 44% RELATIVE INCREASE DURING THE TRIAL PERIOD IN AGE-ADJUSTED ALL-CAUSE MORTALITY SEEN WITH THE CHEMICALLY AND PHARMACOLOGICALLY RELATED DRUG, CLOFIBRATE, THE POTENTIAL BENEFIT OF GEMFIBROZIL IN TREATING TYPE IIA PATIENTS WITH ELEVATIONS OF LDL-CHOLESTEROL ONLY IS NOT LIKELY TO OUTWEIGH THE RISKS. GEMFIBROZIL TABLETS, USP ARE ALSO NOT INDICATED FOR THE TREATMENT OF PATIENTS WITH LOW HDL-CHOLESTEROL AS THEIR ONLY LIPID ABNORMALITY. In a subgroup analysis of patients in the Helsinki Heart Study with above-median HDL-cholesterol values at baseline (greater than 46.4 mg/dL), the incidence of serious coronary events was similar for gemfibrozil and placebo subgroups (see Table I). The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcohol intake may be important factors in hypertriglyceridemia and should be managed prior to any drug therapy. Physical exercise can be an important ancillary measure, and has been associated with rises in HDL-cholesterol. Diseases contributory to hyperlipidemia such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy is sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of estrogen therapy may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with nondrug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet. uuid:06a25820-d54c-4134-8a0e-a630907115f5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:129316490 biolink:treats MONDO:0000879 PMID:41385096 "[{""id"":""uuid:356400a9-9c43-4c1e-88de-17089d96d17d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:420811d1-a402-42ee-92e7-e4ad0f432af4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Nystatin and Triamcinolone Acetonide Cream and Ointment are indicated for the treatment of cutaneous candidiasis; it has been demonstrated that the nystatin-steroid combination provides greater benefit than the nystatin component alone during the first few days of treatment. uuid:ebb806bc-8715-4d65-9cdc-d11ff3c3d7c7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1154771 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:ae1683e5-d476-4550-a9a3-42aca2dc25c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d11d28f9-8f40-49ce-a4dc-dbbec226f648"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydrocodone polistirex and chlorpheniramine polistirex ER oral suspension is indicated for relief of cough and upper respiratory symptoms associated with allergy or a cold in adults and children 6 years of age and older. uuid:a74e4900-ec06-4099-a7aa-8c6fe10c282e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1154771 biolink:treats MONDO:0005709 PMID:41385096 "[{""id"":""uuid:25ebad23-7664-4d3d-a40c-a9f07e8d2334"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:698880e3-4eab-4d62-8c1b-47f16f7112a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydrocodone polistirex and chlorpheniramine polistirex ER oral suspension is indicated for relief of cough and upper respiratory symptoms associated with allergy or a cold in adults and children 6 years of age and older. uuid:f6f01ba4-6e94-41ca-9d30-45cc2fab4d6a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841573 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:89e1fc84-c1a5-4e44-8352-2a3f2b8d1167"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:52e16ff2-dc5b-41bb-aedd-53309cd5305a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tekturna HCT is indicated for the treatment of hypertension. Add-On Therapy A patient whose blood pressure is not adequately controlled with aliskiren alone or hydrochlorothiazide alone may be switched to combination therapy with Tekturna HCT. A patient whose blood pressure is controlled with hydrochlorothiazide alone but who experiences hypokalemia may be switched to combination therapy with Tekturna HCT. A patient who experiences dose-limiting adverse reactions on either component alone may be switched to Tekturna HCT containing a lower dose of that component in combination with the other to achieve similar blood pressure reductions. Replacement Therapy Tekturna HCT may be substituted for the titrated components. Initial Therapy Tekturna HCT may be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. The choice of Tekturna HCT as initial therapy should be based on an assessment of potential benefits and risks. Patients with Stage 2 hypertension are at a relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from the high-dose multifactorial study [ see Clinical Studies (14) ] provides estimates of the probability of reaching a target blood pressure with Tekturna HCT compared to aliskiren or hydrochlorothiazide monotherapy. The figures below provide estimates of the likelihood of achieving systolic or diastolic blood pressure control with Tekturna HCT 300/25 mg, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling. The estimated likelihood at the right tail of each curve is less reliable because of small numbers of subjects with high baseline blood pressures. Figure 1: Probability of Achieving Systolic Blood Pressure (SBP) <140 mmHg Figure 2: Probability of Achieving Systolic Blood Pressure (SBP) <130 mmHg Figure 3: Probability of Achieving Diastolic Blood Pressure (DBP) <90 mmHg Figure 4: Probability of Achieving Diastolic Blood Pressure (DBP) <80 mmHg At all levels of baseline blood pressure, the probability of achieving any given diastolic or systolic goal is greater with the combination than for either monotherapy. For example, the mean baseline msSBP/msDBP for patients participating in this multifactorial study was 154/99 mmHg. A patient with a baseline blood pressure of 154/99 mmHg has about a 62% chance of achieving a goal of <140 mmHg (systolic) and 61% chance of achieving <90 mmHg (diastolic) on aliskiren alone, and the chance of achieving these goals on hydrochlorothiazide alone is about 54% (systolic) and 49% (diastolic). The chance of achieving these goals on Tekturna HCT rises to about 77% (systolic) and 74% (diastolic). The chance of achieving these goals on placebo is about 34% (systolic) and 37% (diastolic). [See Dosage and Administration (2) and Clinical Studies (14) . ] uuid:d50ab1f1-8181-43f9-b1c3-e10b4c229807 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841573 biolink:treats MONDO:0003019 PMID:41385096 "[{""id"":""uuid:0477d049-344b-4dff-ab28-b199b66a4660"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fc4b2d51-0594-444f-8d3b-47730404685b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tekturna HCT is indicated for the treatment of hypertension. Add-On Therapy A patient whose blood pressure is not adequately controlled with aliskiren alone or hydrochlorothiazide alone may be switched to combination therapy with Tekturna HCT. A patient whose blood pressure is controlled with hydrochlorothiazide alone but who experiences hypokalemia may be switched to combination therapy with Tekturna HCT. A patient who experiences dose-limiting adverse reactions on either component alone may be switched to Tekturna HCT containing a lower dose of that component in combination with the other to achieve similar blood pressure reductions. Replacement Therapy Tekturna HCT may be substituted for the titrated components. Initial Therapy Tekturna HCT may be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. The choice of Tekturna HCT as initial therapy should be based on an assessment of potential benefits and risks. Patients with Stage 2 hypertension are at a relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from the high-dose multifactorial study [ see Clinical Studies (14) ] provides estimates of the probability of reaching a target blood pressure with Tekturna HCT compared to aliskiren or hydrochlorothiazide monotherapy. The figures below provide estimates of the likelihood of achieving systolic or diastolic blood pressure control with Tekturna HCT 300/25 mg, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling. The estimated likelihood at the right tail of each curve is less reliable because of small numbers of subjects with high baseline blood pressures. Figure 1: Probability of Achieving Systolic Blood Pressure (SBP) <140 mmHg Figure 2: Probability of Achieving Systolic Blood Pressure (SBP) <130 mmHg Figure 3: Probability of Achieving Diastolic Blood Pressure (DBP) <90 mmHg Figure 4: Probability of Achieving Diastolic Blood Pressure (DBP) <80 mmHg At all levels of baseline blood pressure, the probability of achieving any given diastolic or systolic goal is greater with the combination than for either monotherapy. For example, the mean baseline msSBP/msDBP for patients participating in this multifactorial study was 154/99 mmHg. A patient with a baseline blood pressure of 154/99 mmHg has about a 62% chance of achieving a goal of <140 mmHg (systolic) and 61% chance of achieving <90 mmHg (diastolic) on aliskiren alone, and the chance of achieving these goals on hydrochlorothiazide alone is about 54% (systolic) and 49% (diastolic). The chance of achieving these goals on Tekturna HCT rises to about 77% (systolic) and 74% (diastolic). The chance of achieving these goals on placebo is about 34% (systolic) and 37% (diastolic). [See Dosage and Administration (2) and Clinical Studies (14) . ] uuid:07e9d18e-ed72-42e2-a470-682941e84a4a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841573 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:2ae6e44c-3370-44c4-9873-7cf2eb7c2fe4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:101b8177-b15a-4bc0-a7c0-cfa8296ae3be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tekturna HCT is indicated for the treatment of hypertension. Add-On Therapy A patient whose blood pressure is not adequately controlled with aliskiren alone or hydrochlorothiazide alone may be switched to combination therapy with Tekturna HCT. A patient whose blood pressure is controlled with hydrochlorothiazide alone but who experiences hypokalemia may be switched to combination therapy with Tekturna HCT. A patient who experiences dose-limiting adverse reactions on either component alone may be switched to Tekturna HCT containing a lower dose of that component in combination with the other to achieve similar blood pressure reductions. Replacement Therapy Tekturna HCT may be substituted for the titrated components. Initial Therapy Tekturna HCT may be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. The choice of Tekturna HCT as initial therapy should be based on an assessment of potential benefits and risks. Patients with Stage 2 hypertension are at a relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from the high-dose multifactorial study [ see Clinical Studies (14) ] provides estimates of the probability of reaching a target blood pressure with Tekturna HCT compared to aliskiren or hydrochlorothiazide monotherapy. The figures below provide estimates of the likelihood of achieving systolic or diastolic blood pressure control with Tekturna HCT 300/25 mg, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling. The estimated likelihood at the right tail of each curve is less reliable because of small numbers of subjects with high baseline blood pressures. Figure 1: Probability of Achieving Systolic Blood Pressure (SBP) <140 mmHg Figure 2: Probability of Achieving Systolic Blood Pressure (SBP) <130 mmHg Figure 3: Probability of Achieving Diastolic Blood Pressure (DBP) <90 mmHg Figure 4: Probability of Achieving Diastolic Blood Pressure (DBP) <80 mmHg At all levels of baseline blood pressure, the probability of achieving any given diastolic or systolic goal is greater with the combination than for either monotherapy. For example, the mean baseline msSBP/msDBP for patients participating in this multifactorial study was 154/99 mmHg. A patient with a baseline blood pressure of 154/99 mmHg has about a 62% chance of achieving a goal of <140 mmHg (systolic) and 61% chance of achieving <90 mmHg (diastolic) on aliskiren alone, and the chance of achieving these goals on hydrochlorothiazide alone is about 54% (systolic) and 49% (diastolic). The chance of achieving these goals on Tekturna HCT rises to about 77% (systolic) and 74% (diastolic). The chance of achieving these goals on placebo is about 34% (systolic) and 37% (diastolic). [See Dosage and Administration (2) and Clinical Studies (14) . ] uuid:44d0f474-1fcf-4e7d-a609-efd7d0f10326 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841573 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:8a359a38-f2ba-4930-a604-7c4d17282422"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:126803bc-fd3e-4ab5-acae-9c2bf3387358"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tekturna HCT is indicated for the treatment of hypertension. Add-On Therapy A patient whose blood pressure is not adequately controlled with aliskiren alone or hydrochlorothiazide alone may be switched to combination therapy with Tekturna HCT. A patient whose blood pressure is controlled with hydrochlorothiazide alone but who experiences hypokalemia may be switched to combination therapy with Tekturna HCT. A patient who experiences dose-limiting adverse reactions on either component alone may be switched to Tekturna HCT containing a lower dose of that component in combination with the other to achieve similar blood pressure reductions. Replacement Therapy Tekturna HCT may be substituted for the titrated components. Initial Therapy Tekturna HCT may be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. The choice of Tekturna HCT as initial therapy should be based on an assessment of potential benefits and risks. Patients with Stage 2 hypertension are at a relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from the high-dose multifactorial study [ see Clinical Studies (14) ] provides estimates of the probability of reaching a target blood pressure with Tekturna HCT compared to aliskiren or hydrochlorothiazide monotherapy. The figures below provide estimates of the likelihood of achieving systolic or diastolic blood pressure control with Tekturna HCT 300/25 mg, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling. The estimated likelihood at the right tail of each curve is less reliable because of small numbers of subjects with high baseline blood pressures. Figure 1: Probability of Achieving Systolic Blood Pressure (SBP) <140 mmHg Figure 2: Probability of Achieving Systolic Blood Pressure (SBP) <130 mmHg Figure 3: Probability of Achieving Diastolic Blood Pressure (DBP) <90 mmHg Figure 4: Probability of Achieving Diastolic Blood Pressure (DBP) <80 mmHg At all levels of baseline blood pressure, the probability of achieving any given diastolic or systolic goal is greater with the combination than for either monotherapy. For example, the mean baseline msSBP/msDBP for patients participating in this multifactorial study was 154/99 mmHg. A patient with a baseline blood pressure of 154/99 mmHg has about a 62% chance of achieving a goal of <140 mmHg (systolic) and 61% chance of achieving <90 mmHg (diastolic) on aliskiren alone, and the chance of achieving these goals on hydrochlorothiazide alone is about 54% (systolic) and 49% (diastolic). The chance of achieving these goals on Tekturna HCT rises to about 77% (systolic) and 74% (diastolic). The chance of achieving these goals on placebo is about 34% (systolic) and 37% (diastolic). [See Dosage and Administration (2) and Clinical Studies (14) . ] uuid:f173fba3-e97f-4f73-b933-7ad3b45299ae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841573 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:1d96353f-541a-49d3-8abd-c43f2ae772a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6592199b-7522-4d38-8416-c5b9381ec6a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tekturna HCT is indicated for the treatment of hypertension. Add-On Therapy A patient whose blood pressure is not adequately controlled with aliskiren alone or hydrochlorothiazide alone may be switched to combination therapy with Tekturna HCT. A patient whose blood pressure is controlled with hydrochlorothiazide alone but who experiences hypokalemia may be switched to combination therapy with Tekturna HCT. A patient who experiences dose-limiting adverse reactions on either component alone may be switched to Tekturna HCT containing a lower dose of that component in combination with the other to achieve similar blood pressure reductions. Replacement Therapy Tekturna HCT may be substituted for the titrated components. Initial Therapy Tekturna HCT may be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. The choice of Tekturna HCT as initial therapy should be based on an assessment of potential benefits and risks. Patients with Stage 2 hypertension are at a relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from the high-dose multifactorial study [ see Clinical Studies (14) ] provides estimates of the probability of reaching a target blood pressure with Tekturna HCT compared to aliskiren or hydrochlorothiazide monotherapy. The figures below provide estimates of the likelihood of achieving systolic or diastolic blood pressure control with Tekturna HCT 300/25 mg, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling. The estimated likelihood at the right tail of each curve is less reliable because of small numbers of subjects with high baseline blood pressures. Figure 1: Probability of Achieving Systolic Blood Pressure (SBP) <140 mmHg Figure 2: Probability of Achieving Systolic Blood Pressure (SBP) <130 mmHg Figure 3: Probability of Achieving Diastolic Blood Pressure (DBP) <90 mmHg Figure 4: Probability of Achieving Diastolic Blood Pressure (DBP) <80 mmHg At all levels of baseline blood pressure, the probability of achieving any given diastolic or systolic goal is greater with the combination than for either monotherapy. For example, the mean baseline msSBP/msDBP for patients participating in this multifactorial study was 154/99 mmHg. A patient with a baseline blood pressure of 154/99 mmHg has about a 62% chance of achieving a goal of <140 mmHg (systolic) and 61% chance of achieving <90 mmHg (diastolic) on aliskiren alone, and the chance of achieving these goals on hydrochlorothiazide alone is about 54% (systolic) and 49% (diastolic). The chance of achieving these goals on Tekturna HCT rises to about 77% (systolic) and 74% (diastolic). The chance of achieving these goals on placebo is about 34% (systolic) and 37% (diastolic). [See Dosage and Administration (2) and Clinical Studies (14) . ] uuid:8550c651-9d9c-4276-a66a-aabd815ba725 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841573 biolink:treats MONDO:0001106 PMID:41385096 "[{""id"":""uuid:1cd1ddcf-f1a8-42d8-a7d0-ba41271af1b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b8941f0a-14ee-4656-b296-4b2f5d19de07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tekturna HCT is indicated for the treatment of hypertension. Add-On Therapy A patient whose blood pressure is not adequately controlled with aliskiren alone or hydrochlorothiazide alone may be switched to combination therapy with Tekturna HCT. A patient whose blood pressure is controlled with hydrochlorothiazide alone but who experiences hypokalemia may be switched to combination therapy with Tekturna HCT. A patient who experiences dose-limiting adverse reactions on either component alone may be switched to Tekturna HCT containing a lower dose of that component in combination with the other to achieve similar blood pressure reductions. Replacement Therapy Tekturna HCT may be substituted for the titrated components. Initial Therapy Tekturna HCT may be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. The choice of Tekturna HCT as initial therapy should be based on an assessment of potential benefits and risks. Patients with Stage 2 hypertension are at a relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from the high-dose multifactorial study [ see Clinical Studies (14) ] provides estimates of the probability of reaching a target blood pressure with Tekturna HCT compared to aliskiren or hydrochlorothiazide monotherapy. The figures below provide estimates of the likelihood of achieving systolic or diastolic blood pressure control with Tekturna HCT 300/25 mg, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling. The estimated likelihood at the right tail of each curve is less reliable because of small numbers of subjects with high baseline blood pressures. Figure 1: Probability of Achieving Systolic Blood Pressure (SBP) <140 mmHg Figure 2: Probability of Achieving Systolic Blood Pressure (SBP) <130 mmHg Figure 3: Probability of Achieving Diastolic Blood Pressure (DBP) <90 mmHg Figure 4: Probability of Achieving Diastolic Blood Pressure (DBP) <80 mmHg At all levels of baseline blood pressure, the probability of achieving any given diastolic or systolic goal is greater with the combination than for either monotherapy. For example, the mean baseline msSBP/msDBP for patients participating in this multifactorial study was 154/99 mmHg. A patient with a baseline blood pressure of 154/99 mmHg has about a 62% chance of achieving a goal of <140 mmHg (systolic) and 61% chance of achieving <90 mmHg (diastolic) on aliskiren alone, and the chance of achieving these goals on hydrochlorothiazide alone is about 54% (systolic) and 49% (diastolic). The chance of achieving these goals on Tekturna HCT rises to about 77% (systolic) and 74% (diastolic). The chance of achieving these goals on placebo is about 34% (systolic) and 37% (diastolic). [See Dosage and Administration (2) and Clinical Studies (14) . ] uuid:00393ba8-8a64-4ba2-a54c-ea9781e624d8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10125 biolink:treats HP:0031354 PMID:41385096 "[{""id"":""uuid:47ccfce6-ea7b-4c5c-a77a-c3c928396d1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4b4b4f15-826a-49f2-84ac-3d618328e007"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Zolpidem tartrate extended-release tablets are indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance (as measured by wake time after sleep onset). The clinical trials performed in support of efficacy were up to 3 weeks (using polysomnography measurement up to 2 weeks in both adult and elderly patients) and 24 weeks (using patient-reported assessment in adult patients only) in duration [see Clinical Studies (14) ]. uuid:467ecf2c-a0ed-4878-8b20-914672e58010 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10125 biolink:treats HP:0031355 PMID:41385096 "[{""id"":""uuid:9ab30035-7a6f-4b9c-b2ae-23b6a857fbea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e5afc116-f46b-4bb3-a03e-81f7c993e96a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Zolpidem tartrate extended-release tablets are indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance (as measured by wake time after sleep onset). The clinical trials performed in support of efficacy were up to 3 weeks (using polysomnography measurement up to 2 weeks in both adult and elderly patients) and 24 weeks (using patient-reported assessment in adult patients only) in duration [see Clinical Studies (14) ]. uuid:730d4e87-a476-4b6d-a103-93f3ec34a8ac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2376 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:c7f6a957-bab2-4863-bde3-1ff4eccaac62"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:57980a6a-82e7-4efc-9b9e-89e87801c259"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acarbose Tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. uuid:30c5caef-8890-4ba3-8746-2d7c5bdb5b23 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151539 biolink:treats MONDO:0011751 PMID:41385096 "[{""id"":""uuid:35914b88-19a6-4964-8e42-4c008b0a5c1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b5e4c6d6-1b0f-4dd1-8381-145f827bbba0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ipratropium Bromide and Albuterol Sulfate is indicated for the treatment of bronchospasm associated with COPD in patients requiring more than one bronchodilator. uuid:03374aea-2859-4fb3-a58c-6ba0f04fd07a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151539 biolink:treats MONDO:0001358 PMID:41385096 "[{""id"":""uuid:68b69147-1730-4a77-b3f8-cce67b1ccb56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:98c09752-e7ad-494d-99fd-b42a1884b7ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ipratropium Bromide and Albuterol Sulfate is indicated for the treatment of bronchospasm associated with COPD in patients requiring more than one bronchodilator. uuid:b4299ebd-b287-4abb-bc5b-c10389af30dc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16335 biolink:treats HP:0004763 PMID:41385096 "[{""id"":""uuid:1c3bfd4c-1133-4b7f-8a86-00eaaf93a5ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:66dfde7a-0c52-4621-bdc8-df49f2dbc644"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Adenosine injection is indicated for the following. Conversion to sinus rhythm of paroxysmal supraventricular tachycardia (PSVT), including that associated with accessory bypass tracts (Wolff-Parkinson-White Syndrome). When clinically advisable, appropriate vagal maneuvers (e.g., Valsalva maneuver), should be attempted prior to adenosine administration. It is important to be sure the adenosine solution actually reaches the systemic circulation (see DOSAGE AND ADMINISTRATION ). Adenosine does not convert atrial flutter, atrial fibrillation, or ventricular tachycardia to normal sinus rhythm. In the presence of atrial flutter or atrial fibrillation, a transient modest slowing of ventricular response may occur immediately following adenosine administration. uuid:c10aa7ee-4066-4ec4-92c6-1d4e0b84204c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16335 biolink:treats MONDO:0008685 PMID:41385096 "[{""id"":""uuid:c0d21c9a-15f0-4ef3-9cf5-71ba2269faf0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bb2b007e-dd74-44a9-9a06-f27086c0b031"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Adenosine injection is indicated for the following. Conversion to sinus rhythm of paroxysmal supraventricular tachycardia (PSVT), including that associated with accessory bypass tracts (Wolff-Parkinson-White Syndrome). When clinically advisable, appropriate vagal maneuvers (e.g., Valsalva maneuver), should be attempted prior to adenosine administration. It is important to be sure the adenosine solution actually reaches the systemic circulation (see DOSAGE AND ADMINISTRATION ). Adenosine does not convert atrial flutter, atrial fibrillation, or ventricular tachycardia to normal sinus rhythm. In the presence of atrial flutter or atrial fibrillation, a transient modest slowing of ventricular response may occur immediately following adenosine administration. uuid:b79b0a6d-3ed4-45ab-ad9e-b2317c218bf9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16335 biolink:treats MONDO:0005310 PMID:41385096 "[{""id"":""uuid:52044027-6736-4838-98fb-1580977a2e99"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8b4ecfb2-ebd5-4805-8f10-90e4a3f87d1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Adenosine injection is indicated for the following. Conversion to sinus rhythm of paroxysmal supraventricular tachycardia (PSVT), including that associated with accessory bypass tracts (Wolff-Parkinson-White Syndrome). When clinically advisable, appropriate vagal maneuvers (e.g., Valsalva maneuver), should be attempted prior to adenosine administration. It is important to be sure the adenosine solution actually reaches the systemic circulation (see DOSAGE AND ADMINISTRATION ). Adenosine does not convert atrial flutter, atrial fibrillation, or ventricular tachycardia to normal sinus rhythm. In the presence of atrial flutter or atrial fibrillation, a transient modest slowing of ventricular response may occur immediately following adenosine administration. uuid:d1767f3f-616a-463a-9bee-e728233018f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16335 biolink:treats MONDO:0004981 PMID:41385096 "[{""id"":""uuid:954b9558-a06e-4736-86b7-c146039f980f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ad52d572-7566-4a60-8cd2-61702cdf9b93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Adenosine injection is indicated for the following. Conversion to sinus rhythm of paroxysmal supraventricular tachycardia (PSVT), including that associated with accessory bypass tracts (Wolff-Parkinson-White Syndrome). When clinically advisable, appropriate vagal maneuvers (e.g., Valsalva maneuver), should be attempted prior to adenosine administration. It is important to be sure the adenosine solution actually reaches the systemic circulation (see DOSAGE AND ADMINISTRATION ). Adenosine does not convert atrial flutter, atrial fibrillation, or ventricular tachycardia to normal sinus rhythm. In the presence of atrial flutter or atrial fibrillation, a transient modest slowing of ventricular response may occur immediately following adenosine administration. uuid:0fbb8f1b-b696-4979-909c-e397fee42f6f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16335 biolink:treats MONDO:0005477 PMID:41385096 "[{""id"":""uuid:e18020fa-2330-4265-9471-03d0c8773302"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e6b7da78-b15f-435a-8f5d-b169806778b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Adenosine injection is indicated for the following. Conversion to sinus rhythm of paroxysmal supraventricular tachycardia (PSVT), including that associated with accessory bypass tracts (Wolff-Parkinson-White Syndrome). When clinically advisable, appropriate vagal maneuvers (e.g., Valsalva maneuver), should be attempted prior to adenosine administration. It is important to be sure the adenosine solution actually reaches the systemic circulation (see DOSAGE AND ADMINISTRATION ). Adenosine does not convert atrial flutter, atrial fibrillation, or ventricular tachycardia to normal sinus rhythm. In the presence of atrial flutter or atrial fibrillation, a transient modest slowing of ventricular response may occur immediately following adenosine administration. uuid:16b0d173-a26f-4376-81c7-427d7ad223af biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2663 biolink:treats UMLS:C1739149 PMID:41385096 "[{""id"":""uuid:31cb5e80-a708-4a93-af47-83434ae7447b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:277b3006-7861-492a-9ffc-26f5c43ed9de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Because of its life-threatening side effects and the substantial management difficulties associated with its use (see WARNINGS below), amiodarone is indicated only for the treatment of the following documented, life-threatening recurrent ventricular arrhythmias when these have not responded to documented adequate doses of other available antiarrhythmics or when alternative agents could not be tolerated. Recurrent ventricular fibrillation. Recurrent hemodynamically unstable ventricular tachycardia. As is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of amiodarone hydrochloride tablets favorably affects survival. Amiodarone should be used only by physicians familiar with and with access to (directly or through referral) the use of all available modalities for treating recurrent life-threatening ventricular arrhythmias, and who have access to appropriate monitoring facilities, including in-hospital and ambulatory continuous electrocardiographic monitoring and electrophysiologic techniques. Because of the life-threatening nature of the arrhythmias treated, potential interactions with prior therapy, and potential exacerbation of the arrhythmia, initiation of therapy with amiodarone should be carried out in the hospital. uuid:196a71f4-cdd5-4315-b09e-9f73eb946d67 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2663 biolink:treats MONDO:0005477 PMID:41385096 "[{""id"":""uuid:50cdb764-d5fe-43fe-9fef-f47ca0dbaece"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:abfe4876-145f-4b0a-82f4-ef79628d0a4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:8d640ae5-8dda-4bab-b65c-c92f985228bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Because of its life-threatening side effects and the substantial management difficulties associated with its use (see WARNINGS below), amiodarone is indicated only for the treatment of the following documented, life-threatening recurrent ventricular arrhythmias when these have not responded to documented adequate doses of other available antiarrhythmics or when alternative agents could not be tolerated. Recurrent ventricular fibrillation. Recurrent hemodynamically unstable ventricular tachycardia. As is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of amiodarone hydrochloride tablets favorably affects survival. Amiodarone should be used only by physicians familiar with and with access to (directly or through referral) the use of all available modalities for treating recurrent life-threatening ventricular arrhythmias, and who have access to appropriate monitoring facilities, including in-hospital and ambulatory continuous electrocardiographic monitoring and electrophysiologic techniques. Because of the life-threatening nature of the arrhythmias treated, potential interactions with prior therapy, and potential exacerbation of the arrhythmia, initiation of therapy with amiodarone should be carried out in the hospital.|[PMDA] Drug with a new route of administration, used for emergency treatment of refractory arrhythmias (ventricular fibrillation and hemodynamically unstable ventricular tachycardia). [Orphan Drug] uuid:a039e1a3-3e52-47ed-9059-9eca82959c9f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2618 biolink:treats UMLS:C0858004 PMID:41385096 "[{""id"":""uuid:c3acae18-b327-4406-ac7e-fdc61cb71ec5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ae12b849-39cf-40e3-a623-12dd1c46e704"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amantadine hydrochloride syrup (amantadine hydrochloride oral solution, USP) is indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine hydrochloride is also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions. Influenza A Prophylaxis Amantadine hydrochloride is indicated for chemoprophylaxis against signs and symptoms of influenza A virus infection when early vaccination is not feasible or when the vaccine is contraindicated or not available. In the prophylaxis of influenza, early vaccination on an annual basis as recommended by the Centers for Disease Control's Immunization Practices Advisory Committee is the method of choice. Because amantadine does not completely prevent the host immune response to influenza A infection, individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically related viruses. Following vaccination during an influenza A outbreak, amantadine prophylaxis should be considered for the 2-to 4-week time period required to develop an antibody response. Influenza A Treatment Amantadine hydrochloride is also indicated in the treatment of uncomplicated respiratory tract illness caused by influenza A virus strains especially when administered early in the course of illness. There are no well-controlled clinical studies demonstrating that treatment with amantadine will avoid the development of influenza A virus pneumonitis or other complications in high risk patients. There is no clinical evidence indicating that amantadine is effective in the prophylaxis or treatment of viral respiratory tract illnesses other than those caused by influenza A virus strains. Parkinson's Disease/Syndrome Amantadine is indicated in the treatment of idiopathic Parkinson's disease (Paralysis Agitans), postencephalitic parkinsonism, and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication. It is indicated in those elderly patients believed to develop parkinsonism in association with cerebral arteriosclerosis. In the treatment of Parkinson's disease, amantadine is less effective than levodopa, (-)-3-(3,4-dihydroxyphenyl)-L-alanine, and its efficacy in comparison with the anticholinergic antiparkinson drugs has not yet been established. Drug-Induced Extrapyramidal Reactions Amantadine hydrochloride is indicated in the treatment of drug-induced extrapyramidal reactions. Although anticholinergic-type side effects have been noted with amantadine when used in patients with drug-induced extrapyramidal reactions, there is a lower incidence of these side effects than that observed with the anticholinergic antiparkinson drugs. uuid:270ca77e-8074-46fc-9d7a-0584b29d3347 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2618 biolink:treats MONDO:0021095 PMID:41385096 "[{""id"":""uuid:2a6b4a50-a97b-4b64-98f8-7560489ec694"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e47ceb42-1447-4166-ab4b-2ae6f90d1f42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amantadine hydrochloride syrup (amantadine hydrochloride oral solution, USP) is indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine hydrochloride is also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions. Influenza A Prophylaxis Amantadine hydrochloride is indicated for chemoprophylaxis against signs and symptoms of influenza A virus infection when early vaccination is not feasible or when the vaccine is contraindicated or not available. In the prophylaxis of influenza, early vaccination on an annual basis as recommended by the Centers for Disease Control's Immunization Practices Advisory Committee is the method of choice. Because amantadine does not completely prevent the host immune response to influenza A infection, individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically related viruses. Following vaccination during an influenza A outbreak, amantadine prophylaxis should be considered for the 2-to 4-week time period required to develop an antibody response. Influenza A Treatment Amantadine hydrochloride is also indicated in the treatment of uncomplicated respiratory tract illness caused by influenza A virus strains especially when administered early in the course of illness. There are no well-controlled clinical studies demonstrating that treatment with amantadine will avoid the development of influenza A virus pneumonitis or other complications in high risk patients. There is no clinical evidence indicating that amantadine is effective in the prophylaxis or treatment of viral respiratory tract illnesses other than those caused by influenza A virus strains. Parkinson's Disease/Syndrome Amantadine is indicated in the treatment of idiopathic Parkinson's disease (Paralysis Agitans), postencephalitic parkinsonism, and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication. It is indicated in those elderly patients believed to develop parkinsonism in association with cerebral arteriosclerosis. In the treatment of Parkinson's disease, amantadine is less effective than levodopa, (-)-3-(3,4-dihydroxyphenyl)-L-alanine, and its efficacy in comparison with the anticholinergic antiparkinson drugs has not yet been established. Drug-Induced Extrapyramidal Reactions Amantadine hydrochloride is indicated in the treatment of drug-induced extrapyramidal reactions. Although anticholinergic-type side effects have been noted with amantadine when used in patients with drug-induced extrapyramidal reactions, there is a lower incidence of these side effects than that observed with the anticholinergic antiparkinson drugs. uuid:8399eb3f-ba1c-4c09-a24d-897e339019dc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2618 biolink:treats MONDO:0001815 PMID:41385096 "[{""id"":""uuid:d4eda0fb-2a6c-47fd-973b-4018c0fd7a2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5ad668f9-f027-4fe9-aedc-f0cae9593aa2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amantadine hydrochloride syrup (amantadine hydrochloride oral solution, USP) is indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine hydrochloride is also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions. Influenza A Prophylaxis Amantadine hydrochloride is indicated for chemoprophylaxis against signs and symptoms of influenza A virus infection when early vaccination is not feasible or when the vaccine is contraindicated or not available. In the prophylaxis of influenza, early vaccination on an annual basis as recommended by the Centers for Disease Control's Immunization Practices Advisory Committee is the method of choice. Because amantadine does not completely prevent the host immune response to influenza A infection, individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically related viruses. Following vaccination during an influenza A outbreak, amantadine prophylaxis should be considered for the 2-to 4-week time period required to develop an antibody response. Influenza A Treatment Amantadine hydrochloride is also indicated in the treatment of uncomplicated respiratory tract illness caused by influenza A virus strains especially when administered early in the course of illness. There are no well-controlled clinical studies demonstrating that treatment with amantadine will avoid the development of influenza A virus pneumonitis or other complications in high risk patients. There is no clinical evidence indicating that amantadine is effective in the prophylaxis or treatment of viral respiratory tract illnesses other than those caused by influenza A virus strains. Parkinson's Disease/Syndrome Amantadine is indicated in the treatment of idiopathic Parkinson's disease (Paralysis Agitans), postencephalitic parkinsonism, and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication. It is indicated in those elderly patients believed to develop parkinsonism in association with cerebral arteriosclerosis. In the treatment of Parkinson's disease, amantadine is less effective than levodopa, (-)-3-(3,4-dihydroxyphenyl)-L-alanine, and its efficacy in comparison with the anticholinergic antiparkinson drugs has not yet been established. Drug-Induced Extrapyramidal Reactions Amantadine hydrochloride is indicated in the treatment of drug-induced extrapyramidal reactions. Although anticholinergic-type side effects have been noted with amantadine when used in patients with drug-induced extrapyramidal reactions, there is a lower incidence of these side effects than that observed with the anticholinergic antiparkinson drugs. uuid:5451264c-d0cd-4b3a-b9ca-6c81f00aa3fb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2618 biolink:treats MONDO:0005180 PMID:41385096 "[{""id"":""uuid:e47f19d1-f6ff-40c0-b359-1cfe65569b42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1cb24774-fbba-4e4c-8281-df3523203332"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amantadine hydrochloride syrup (amantadine hydrochloride oral solution, USP) is indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine hydrochloride is also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions. Influenza A Prophylaxis Amantadine hydrochloride is indicated for chemoprophylaxis against signs and symptoms of influenza A virus infection when early vaccination is not feasible or when the vaccine is contraindicated or not available. In the prophylaxis of influenza, early vaccination on an annual basis as recommended by the Centers for Disease Control's Immunization Practices Advisory Committee is the method of choice. Because amantadine does not completely prevent the host immune response to influenza A infection, individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically related viruses. Following vaccination during an influenza A outbreak, amantadine prophylaxis should be considered for the 2-to 4-week time period required to develop an antibody response. Influenza A Treatment Amantadine hydrochloride is also indicated in the treatment of uncomplicated respiratory tract illness caused by influenza A virus strains especially when administered early in the course of illness. There are no well-controlled clinical studies demonstrating that treatment with amantadine will avoid the development of influenza A virus pneumonitis or other complications in high risk patients. There is no clinical evidence indicating that amantadine is effective in the prophylaxis or treatment of viral respiratory tract illnesses other than those caused by influenza A virus strains. Parkinson's Disease/Syndrome Amantadine is indicated in the treatment of idiopathic Parkinson's disease (Paralysis Agitans), postencephalitic parkinsonism, and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication. It is indicated in those elderly patients believed to develop parkinsonism in association with cerebral arteriosclerosis. In the treatment of Parkinson's disease, amantadine is less effective than levodopa, (-)-3-(3,4-dihydroxyphenyl)-L-alanine, and its efficacy in comparison with the anticholinergic antiparkinson drugs has not yet been established. Drug-Induced Extrapyramidal Reactions Amantadine hydrochloride is indicated in the treatment of drug-induced extrapyramidal reactions. Although anticholinergic-type side effects have been noted with amantadine when used in patients with drug-induced extrapyramidal reactions, there is a lower incidence of these side effects than that observed with the anticholinergic antiparkinson drugs. uuid:3ea19f2d-5f94-44e6-abe8-57f2651115d2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2618 biolink:treats MONDO:0008193 PMID:41385096 "[{""id"":""uuid:eb4a3efb-84bb-49f0-b359-3e880d442678"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e6b9c21c-b87a-4c01-a9c9-72292a3ff2c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amantadine hydrochloride syrup (amantadine hydrochloride oral solution, USP) is indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine hydrochloride is also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions. Influenza A Prophylaxis Amantadine hydrochloride is indicated for chemoprophylaxis against signs and symptoms of influenza A virus infection when early vaccination is not feasible or when the vaccine is contraindicated or not available. In the prophylaxis of influenza, early vaccination on an annual basis as recommended by the Centers for Disease Control's Immunization Practices Advisory Committee is the method of choice. Because amantadine does not completely prevent the host immune response to influenza A infection, individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically related viruses. Following vaccination during an influenza A outbreak, amantadine prophylaxis should be considered for the 2-to 4-week time period required to develop an antibody response. Influenza A Treatment Amantadine hydrochloride is also indicated in the treatment of uncomplicated respiratory tract illness caused by influenza A virus strains especially when administered early in the course of illness. There are no well-controlled clinical studies demonstrating that treatment with amantadine will avoid the development of influenza A virus pneumonitis or other complications in high risk patients. There is no clinical evidence indicating that amantadine is effective in the prophylaxis or treatment of viral respiratory tract illnesses other than those caused by influenza A virus strains. Parkinson's Disease/Syndrome Amantadine is indicated in the treatment of idiopathic Parkinson's disease (Paralysis Agitans), postencephalitic parkinsonism, and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication. It is indicated in those elderly patients believed to develop parkinsonism in association with cerebral arteriosclerosis. In the treatment of Parkinson's disease, amantadine is less effective than levodopa, (-)-3-(3,4-dihydroxyphenyl)-L-alanine, and its efficacy in comparison with the anticholinergic antiparkinson drugs has not yet been established. Drug-Induced Extrapyramidal Reactions Amantadine hydrochloride is indicated in the treatment of drug-induced extrapyramidal reactions. Although anticholinergic-type side effects have been noted with amantadine when used in patients with drug-induced extrapyramidal reactions, there is a lower incidence of these side effects than that observed with the anticholinergic antiparkinson drugs. uuid:a04a1f11-d39c-43fd-97ad-0cc1e6ebe853 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2618 biolink:treats MONDO:0001945 PMID:41385096 "[{""id"":""uuid:6e047d7c-3117-4da7-847f-8f891a4d8a27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d9190bfc-693c-403b-bf81-afedf2cdc556"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amantadine hydrochloride syrup (amantadine hydrochloride oral solution, USP) is indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine hydrochloride is also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions. Influenza A Prophylaxis Amantadine hydrochloride is indicated for chemoprophylaxis against signs and symptoms of influenza A virus infection when early vaccination is not feasible or when the vaccine is contraindicated or not available. In the prophylaxis of influenza, early vaccination on an annual basis as recommended by the Centers for Disease Control's Immunization Practices Advisory Committee is the method of choice. Because amantadine does not completely prevent the host immune response to influenza A infection, individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically related viruses. Following vaccination during an influenza A outbreak, amantadine prophylaxis should be considered for the 2-to 4-week time period required to develop an antibody response. Influenza A Treatment Amantadine hydrochloride is also indicated in the treatment of uncomplicated respiratory tract illness caused by influenza A virus strains especially when administered early in the course of illness. There are no well-controlled clinical studies demonstrating that treatment with amantadine will avoid the development of influenza A virus pneumonitis or other complications in high risk patients. There is no clinical evidence indicating that amantadine is effective in the prophylaxis or treatment of viral respiratory tract illnesses other than those caused by influenza A virus strains. Parkinson's Disease/Syndrome Amantadine is indicated in the treatment of idiopathic Parkinson's disease (Paralysis Agitans), postencephalitic parkinsonism, and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication. It is indicated in those elderly patients believed to develop parkinsonism in association with cerebral arteriosclerosis. In the treatment of Parkinson's disease, amantadine is less effective than levodopa, (-)-3-(3,4-dihydroxyphenyl)-L-alanine, and its efficacy in comparison with the anticholinergic antiparkinson drugs has not yet been established. Drug-Induced Extrapyramidal Reactions Amantadine hydrochloride is indicated in the treatment of drug-induced extrapyramidal reactions. Although anticholinergic-type side effects have been noted with amantadine when used in patients with drug-induced extrapyramidal reactions, there is a lower incidence of these side effects than that observed with the anticholinergic antiparkinson drugs. uuid:9d0ec9cd-1fb6-4118-8dd7-d60a5dfd3fba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2618 biolink:treats UMLS:C0007020 PMID:41385096 "[{""id"":""uuid:bfd9c648-c1d6-4b35-a949-35b61269a0b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:51a68930-e722-4746-83b0-049e6826cc7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amantadine hydrochloride syrup (amantadine hydrochloride oral solution, USP) is indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine hydrochloride is also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions. Influenza A Prophylaxis Amantadine hydrochloride is indicated for chemoprophylaxis against signs and symptoms of influenza A virus infection when early vaccination is not feasible or when the vaccine is contraindicated or not available. In the prophylaxis of influenza, early vaccination on an annual basis as recommended by the Centers for Disease Control's Immunization Practices Advisory Committee is the method of choice. Because amantadine does not completely prevent the host immune response to influenza A infection, individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically related viruses. Following vaccination during an influenza A outbreak, amantadine prophylaxis should be considered for the 2-to 4-week time period required to develop an antibody response. Influenza A Treatment Amantadine hydrochloride is also indicated in the treatment of uncomplicated respiratory tract illness caused by influenza A virus strains especially when administered early in the course of illness. There are no well-controlled clinical studies demonstrating that treatment with amantadine will avoid the development of influenza A virus pneumonitis or other complications in high risk patients. There is no clinical evidence indicating that amantadine is effective in the prophylaxis or treatment of viral respiratory tract illnesses other than those caused by influenza A virus strains. Parkinson's Disease/Syndrome Amantadine is indicated in the treatment of idiopathic Parkinson's disease (Paralysis Agitans), postencephalitic parkinsonism, and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication. It is indicated in those elderly patients believed to develop parkinsonism in association with cerebral arteriosclerosis. In the treatment of Parkinson's disease, amantadine is less effective than levodopa, (-)-3-(3,4-dihydroxyphenyl)-L-alanine, and its efficacy in comparison with the anticholinergic antiparkinson drugs has not yet been established. Drug-Induced Extrapyramidal Reactions Amantadine hydrochloride is indicated in the treatment of drug-induced extrapyramidal reactions. Although anticholinergic-type side effects have been noted with amantadine when used in patients with drug-induced extrapyramidal reactions, there is a lower incidence of these side effects than that observed with the anticholinergic antiparkinson drugs. uuid:9f14f6e9-17e9-4bf9-9c8d-6118fd2b26ff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5130 biolink:treats HP:0000616 PMID:41385096 "[{""id"":""uuid:a9e29e0d-c986-4723-a44d-5ca110654730"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8c0d88cc-0e48-4349-a4fc-582eb87a33dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Flurbiprofen sodium ophthalmic solution is indicated for the inhibition of intraoperative miosis. uuid:ffe15e94-fdb7-4e1f-b6fd-9ccb97ca2cbf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:194135 biolink:treats MONDO:0005545 PMID:41385096 "[{""id"":""uuid:0c0b5235-c143-400f-9623-b61066cff670"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bef25abc-65a9-4d4e-955e-5f6408c2b521"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: CONJUNCTIVITIS: Gram-positive bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Gram-negative bacteria: Enterobacter cloacae Haemophilus influenzae Proteus mirabilis Pseudomonas aeruginosa CORNEAL ULCERS: Gram-positive bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Gram-negative bacteria: Pseudomonas aeruginosa Serratia marcescens* Anaerobic species: Propionibacterium acnes *Efficacy for this organism was studied in fewer than 10 infections uuid:3eaa794c-6664-4d9a-b6ea-d19ee76b5a42 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:194135 biolink:treats UMLS:C1096572 PMID:41385096 "[{""id"":""uuid:f560371f-79fb-4b15-b1b0-602d9b7d7145"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b15af892-7e41-4aff-a2b7-b4c955705862"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: CONJUNCTIVITIS: Gram-positive bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Gram-negative bacteria: Enterobacter cloacae Haemophilus influenzae Proteus mirabilis Pseudomonas aeruginosa CORNEAL ULCERS: Gram-positive bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Gram-negative bacteria: Pseudomonas aeruginosa Serratia marcescens* Anaerobic species: Propionibacterium acnes *Efficacy for this organism was studied in fewer than 10 infections uuid:86eb2f81-64a9-4dfa-817d-03009abdecd0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:194135 biolink:treats MONDO:0005114 PMID:41385096 "[{""id"":""uuid:c36669c2-2587-4915-b4a6-5937f9f8d6a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2cfb6890-fc63-493d-be25-ce564f8e9546"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: CONJUNCTIVITIS: Gram-positive bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Gram-negative bacteria: Enterobacter cloacae Haemophilus influenzae Proteus mirabilis Pseudomonas aeruginosa CORNEAL ULCERS: Gram-positive bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Gram-negative bacteria: Pseudomonas aeruginosa Serratia marcescens* Anaerobic species: Propionibacterium acnes *Efficacy for this organism was studied in fewer than 10 infections uuid:0f5d035d-d131-485f-a789-c6b7a5c95025 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:194135 biolink:treats UMLS:C1096729 PMID:41385096 "[{""id"":""uuid:c0aa69cc-2a97-4a06-bf9c-825729baf280"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:221488c2-21fe-4210-a77b-1d3386b4edb0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: CONJUNCTIVITIS: Gram-positive bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Gram-negative bacteria: Enterobacter cloacae Haemophilus influenzae Proteus mirabilis Pseudomonas aeruginosa CORNEAL ULCERS: Gram-positive bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Gram-negative bacteria: Pseudomonas aeruginosa Serratia marcescens* Anaerobic species: Propionibacterium acnes *Efficacy for this organism was studied in fewer than 10 infections uuid:51879b6e-52a2-406d-b401-8f0395a68151 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:194135 biolink:treats UMLS:C0348321 PMID:41385096 "[{""id"":""uuid:99c0817e-4d2f-4f2b-900e-b0125b393815"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1e5441fb-5fda-4d4c-b3fd-f283782d6481"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: CONJUNCTIVITIS: Gram-positive bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Gram-negative bacteria: Enterobacter cloacae Haemophilus influenzae Proteus mirabilis Pseudomonas aeruginosa CORNEAL ULCERS: Gram-positive bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Gram-negative bacteria: Pseudomonas aeruginosa Serratia marcescens* Anaerobic species: Propionibacterium acnes *Efficacy for this organism was studied in fewer than 10 infections uuid:8af2a7e6-9c98-4d64-a984-8ba85d6d5978 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:194135 biolink:treats UMLS:C0276078 PMID:41385096 "[{""id"":""uuid:ac4cbc37-3fb6-4375-a187-5fe557a59e10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:887a8870-a192-47bc-80ab-c88d5ea67453"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: CONJUNCTIVITIS: Gram-positive bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Gram-negative bacteria: Enterobacter cloacae Haemophilus influenzae Proteus mirabilis Pseudomonas aeruginosa CORNEAL ULCERS: Gram-positive bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Gram-negative bacteria: Pseudomonas aeruginosa Serratia marcescens* Anaerobic species: Propionibacterium acnes *Efficacy for this organism was studied in fewer than 10 infections uuid:3e7b8374-90b4-4529-acc1-56705629440f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:194135 biolink:treats UMLS:C0854135 PMID:41385096 "[{""id"":""uuid:a9c79eed-eb5b-4b0d-81fa-63843d5d251c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d9710093-e84a-4757-a8fc-f5fad40bde2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: CONJUNCTIVITIS: Gram-positive bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Gram-negative bacteria: Enterobacter cloacae Haemophilus influenzae Proteus mirabilis Pseudomonas aeruginosa CORNEAL ULCERS: Gram-positive bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Gram-negative bacteria: Pseudomonas aeruginosa Serratia marcescens* Anaerobic species: Propionibacterium acnes *Efficacy for this organism was studied in fewer than 10 infections uuid:6c17a89f-5500-4242-850d-491d0b4a30ae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:194135 biolink:treats UMLS:C1096571 PMID:41385096 "[{""id"":""uuid:d75b9035-f4a7-4038-9e74-b22dfd10c5c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0053d19e-8c53-4066-a8f9-ed0bcd93252e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ofloxacin ophthalmic solution is indicated for the treatment of infections caused by susceptible strains of the following bacteria in the conditions listed below: CONJUNCTIVITIS: Gram-positive bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Gram-negative bacteria: Enterobacter cloacae Haemophilus influenzae Proteus mirabilis Pseudomonas aeruginosa CORNEAL ULCERS: Gram-positive bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Gram-negative bacteria: Pseudomonas aeruginosa Serratia marcescens* Anaerobic species: Propionibacterium acnes *Efficacy for this organism was studied in fewer than 10 infections uuid:6798adec-3c6f-4c6d-aeb9-82ab2ca9aa1a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6129 biolink:treats HP:0200026 PMID:41385096 "[{""id"":""uuid:3e1ae681-46fa-466d-a28f-80ca7bb66414"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:54d12139-9b11-4353-af2c-3ef04b8096e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ketorolac Tromethamine Ophthalmic Solution, 0.4% is indicated for the reduction of ocular pain and burning/stinging following corneal refractive surgery. uuid:54d499bd-60aa-4185-9346-3063b881ec12 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:34911 biolink:treats MONDO:0004525 PMID:41385096 "[{""id"":""uuid:d92a6dc6-9a5a-4dfd-8f80-7d9ae79684e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9a32c9a8-8c38-4047-b1d8-ccc03c6ddff1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Permethrin cream, 5% is indicated for the treatment of infestation with Sarcoptes scabiei (scabies). uuid:c94f409f-028d-450e-b786-3a52d7a6717c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4909 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:6ccdbe3f-e667-4ae8-83f6-9efea40b6a54"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0e6347ae-86ee-40c4-9056-761b6d7c41db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of etodolac capsules and tablets, USP, and other treatment options before deciding to use etodolac capsules and tablets, USP. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Etodolac Capsules and Tablets, USP are indicated: For acute and long-term use in the management of signs and symptoms of the following: Osteoarthritis Rheumatoid arthritis For the management of acute pain uuid:c36df784-2c1f-440e-8ea1-0184c22efd26 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4909 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:6820751a-e53f-49f2-9abd-6530a0f7d805"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7054ffee-548e-4e0b-ac3a-97fcf08e2d6a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of etodolac capsules and tablets, USP, and other treatment options before deciding to use etodolac capsules and tablets, USP. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Etodolac Capsules and Tablets, USP are indicated: For acute and long-term use in the management of signs and symptoms of the following: Osteoarthritis Rheumatoid arthritis For the management of acute pain uuid:c95b68d7-5e6a-45fa-8727-d739504b6202 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4909 biolink:treats NCIT:C27003 PMID:41385096 "[{""id"":""uuid:020706d9-8e3b-4fb8-b931-2476430598fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:852c3d1c-a8f1-461e-989d-e054653831a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of etodolac capsules and tablets, USP, and other treatment options before deciding to use etodolac capsules and tablets, USP. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Etodolac Capsules and Tablets, USP are indicated: For acute and long-term use in the management of signs and symptoms of the following: Osteoarthritis Rheumatoid arthritis For the management of acute pain uuid:3266d792-bc37-47df-974b-89a4355eda91 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31397 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:6d55900c-810e-4db7-82fa-28e73a3a5384"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4140efa5-eedc-455e-9e5e-2ce765b5496e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3ee95be7-62b6-4aad-9ded-ebd9fbb3ea1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ALVESCO is an inhaled corticosteroid indicated for: Maintenance treatment of asthma as prophylactic therapy in adult and adolescent patients 12 years of age and older. ( 1 ) ALVESCO is NOT indicated for the relief of acute bronchospasm. ( 1 )|[PMDA] Drugs containing a new active ingredient indicated for the treatment of asthma. uuid:676513de-617f-4c08-8ef4-30456b81f65b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47519 biolink:treats MONDO:0002026 PMID:41385096 "[{""id"":""uuid:ae240459-6acf-4612-8ca9-c5946e6252b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5d894304-d58f-45c8-a596-844731e796b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ketoconazole tablets are indicated for the treatment of the following systemic fungal infections: candidiasis, chronic mucocutaneous candidiasis, oral thrush, candiduria, blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis. Ketoconazole tablets should not be used for fungal meningitis because it penetrates poorly into the cerebral-spinal fluid. Ketoconazole tablets are also indicated for the treatment of patients with severe recalcitrant cutaneous dermatophyte infections who have not responded to topical therapy or oral griseofulvin, or who are unable to take griseofulvin. uuid:7d51ff3c-ec07-4e2d-bafe-01b495e01b5b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47519 biolink:treats MONDO:0015279 PMID:41385096 "[{""id"":""uuid:d5bbfaff-096b-423d-8e66-a8c4034769ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2cf08cc7-83ba-4377-88b5-fd76a63023f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ketoconazole tablets are indicated for the treatment of the following systemic fungal infections: candidiasis, chronic mucocutaneous candidiasis, oral thrush, candiduria, blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis. Ketoconazole tablets should not be used for fungal meningitis because it penetrates poorly into the cerebral-spinal fluid. Ketoconazole tablets are also indicated for the treatment of patients with severe recalcitrant cutaneous dermatophyte infections who have not responded to topical therapy or oral griseofulvin, or who are unable to take griseofulvin. uuid:b8f3fb8b-8cac-4bac-ae41-6341e9767b9b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47519 biolink:treats MONDO:0005886 PMID:41385096 "[{""id"":""uuid:7ec471ef-8e2a-4924-9aac-fa001835c4fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3de6ae2c-f66e-4a44-b2b8-3cad044ec68c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ketoconazole tablets are indicated for the treatment of the following systemic fungal infections: candidiasis, chronic mucocutaneous candidiasis, oral thrush, candiduria, blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis. Ketoconazole tablets should not be used for fungal meningitis because it penetrates poorly into the cerebral-spinal fluid. Ketoconazole tablets are also indicated for the treatment of patients with severe recalcitrant cutaneous dermatophyte infections who have not responded to topical therapy or oral griseofulvin, or who are unable to take griseofulvin. uuid:b756e9b1-b316-4687-a2e5-88ff38536b22 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47519 biolink:treats UMLS:C0403723 PMID:41385096 "[{""id"":""uuid:2ba76b5d-42a3-4e88-b96a-41ee1c346727"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dc8fe170-277c-4a18-95fc-79199f3e9624"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ketoconazole tablets are indicated for the treatment of the following systemic fungal infections: candidiasis, chronic mucocutaneous candidiasis, oral thrush, candiduria, blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis. Ketoconazole tablets should not be used for fungal meningitis because it penetrates poorly into the cerebral-spinal fluid. Ketoconazole tablets are also indicated for the treatment of patients with severe recalcitrant cutaneous dermatophyte infections who have not responded to topical therapy or oral griseofulvin, or who are unable to take griseofulvin. uuid:43463a4a-a66f-471e-bbb4-3851f9eb0a5b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47519 biolink:treats MONDO:0005672 PMID:41385096 "[{""id"":""uuid:545da8ea-e681-44e0-acb2-564a2ded565d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fe1c5d44-0b81-4b40-913b-e3a8fe5e601c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ketoconazole tablets are indicated for the treatment of the following systemic fungal infections: candidiasis, chronic mucocutaneous candidiasis, oral thrush, candiduria, blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis. Ketoconazole tablets should not be used for fungal meningitis because it penetrates poorly into the cerebral-spinal fluid. Ketoconazole tablets are also indicated for the treatment of patients with severe recalcitrant cutaneous dermatophyte infections who have not responded to topical therapy or oral griseofulvin, or who are unable to take griseofulvin. uuid:140872e4-0364-4d1b-bf2f-800e54937b19 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47519 biolink:treats MONDO:0005706 PMID:41385096 "[{""id"":""uuid:c4c375c2-d3c7-413f-a3d5-20584b0d86c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e12cebe3-1ebd-4b2c-aa8d-fa2ec4c47bc1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ketoconazole tablets are indicated for the treatment of the following systemic fungal infections: candidiasis, chronic mucocutaneous candidiasis, oral thrush, candiduria, blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis. Ketoconazole tablets should not be used for fungal meningitis because it penetrates poorly into the cerebral-spinal fluid. Ketoconazole tablets are also indicated for the treatment of patients with severe recalcitrant cutaneous dermatophyte infections who have not responded to topical therapy or oral griseofulvin, or who are unable to take griseofulvin. uuid:50d9a019-9861-410d-a134-f2655699ee35 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47519 biolink:treats MONDO:0018312 PMID:41385096 "[{""id"":""uuid:4b360952-ad4f-4f99-acfb-c941e113ff01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0bef805b-9dc9-4211-bc56-44844295e083"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ketoconazole tablets are indicated for the treatment of the following systemic fungal infections: candidiasis, chronic mucocutaneous candidiasis, oral thrush, candiduria, blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis. Ketoconazole tablets should not be used for fungal meningitis because it penetrates poorly into the cerebral-spinal fluid. Ketoconazole tablets are also indicated for the treatment of patients with severe recalcitrant cutaneous dermatophyte infections who have not responded to topical therapy or oral griseofulvin, or who are unable to take griseofulvin. uuid:8439ad1d-e7b5-4263-b788-4ecf83f4b2fa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47519 biolink:treats MONDO:0015908 PMID:41385096 "[{""id"":""uuid:f39a7ad4-c9fb-456f-b2a8-5b0aea05648a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:af49d1bf-22ba-48eb-b12d-7aa09434fff3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ketoconazole tablets are indicated for the treatment of the following systemic fungal infections: candidiasis, chronic mucocutaneous candidiasis, oral thrush, candiduria, blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis. Ketoconazole tablets should not be used for fungal meningitis because it penetrates poorly into the cerebral-spinal fluid. Ketoconazole tablets are also indicated for the treatment of patients with severe recalcitrant cutaneous dermatophyte infections who have not responded to topical therapy or oral griseofulvin, or who are unable to take griseofulvin. uuid:2ad7e7fa-76c9-43d8-8fc9-cea3a7312398 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47519 biolink:treats MONDO:0005894 PMID:41385096 "[{""id"":""uuid:ece7649f-89fb-4090-bd37-6357e13a755e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f7a41d08-399a-48df-90c9-ec8770de3ff0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ketoconazole tablets are indicated for the treatment of the following systemic fungal infections: candidiasis, chronic mucocutaneous candidiasis, oral thrush, candiduria, blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis. Ketoconazole tablets should not be used for fungal meningitis because it penetrates poorly into the cerebral-spinal fluid. Ketoconazole tablets are also indicated for the treatment of patients with severe recalcitrant cutaneous dermatophyte infections who have not responded to topical therapy or oral griseofulvin, or who are unable to take griseofulvin. uuid:63e1c30e-7948-4ea1-8e21-499a3edf793d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8207 biolink:treats MONDO:0010030 PMID:41385096 "[{""id"":""uuid:297fe37b-23bb-40d9-aa34-b899bd1587c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f23f1c80-e1b2-4b1b-a3ec-514c6d99d86f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d3aa5cce-7401-44ce-b8ec-0ff8d8aa8ae9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pilocarpine HCl Tablets are indicated for 1) the treatment of symptoms of dry mouth from salivary gland hypofunction caused by radiotherapy for cancer of the head and neck; and 2) the treatment of symptoms of dry mouth in patients with Sjogren's syndrome.|[PMDA] A drug with a new indication for the treatment of oral dryness in patients with Sjögren’s syndrome. uuid:d15d1b34-cca2-48ad-a446-4f79f9d388ef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8207 biolink:treats MONDO:0005627 PMID:41385096 "[{""id"":""uuid:3e852ba8-83a0-4628-aab8-637fbb997108"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:052c42e7-4789-4e5d-a633-89fc5b370cbe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2993d1b9-1fe0-4169-99f2-c45076fe1b86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pilocarpine HCl Tablets are indicated for 1) the treatment of symptoms of dry mouth from salivary gland hypofunction caused by radiotherapy for cancer of the head and neck; and 2) the treatment of symptoms of dry mouth in patients with Sjogren's syndrome.|[PMDA] Drug with a new route of oral administration indicated for the treatment of symptoms of dry mouth caused by radiotherapy for head and neck cancer uuid:8bd4a6e1-89e7-4fa3-8384-38f70d7a3d2e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50305 biolink:treats MONDO:0005647 PMID:41385096 "[{""id"":""uuid:25c561d2-7ef9-4497-88ad-38840a360ec7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e96851fd-908b-4f58-8e0b-9ffeeff53d5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Podofilox 0.5% Solution is indicated for the topical treatment of external genital warts (Condyloma acuminatum). This product is not indicated in the treatment of perianal or mucous membrane warts (see PRECAUTIONS ). uuid:d0fc4840-7ada-4e1d-9e80-978cbb502484 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:370638 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:5b070e9c-9a2d-4c70-8710-583a5558f102"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:20888620-00fe-477f-b2c6-f2539fdbd4a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amiloride hydrochloride and hydrochlorothiazide tablets are indicated in those patients with hypertension or with congestive heart failure who develop hypokalemia when thiazides or other kaliuretic diuretics are used alone, or in whom maintenance of normal serum potassium levels is considered to be clinically important, e.g., digitalized patients, or patients with significant cardiac arrhythmias. The use of potassium-conserving agents is often unnecessary in patients receiving diuretics for uncomplicated essential hypertension when such patients have a normal diet. Amiloride hydrochloride and hydrochlorothiazide tablets may be used alone or as an adjunct to other antihypertensive drugs, such as methyldopa or beta blockers. Since amiloride hydrochloride and hydrochlorothiazide enhances the action of these agents, dosage adjustments may be necessary to avoid an excessive fall in blood pressure and other unwanted side effects. This fixed combination drug is not indicated for the initial therapy of edema or hypertension except in individuals in whom the development of hypokalemia cannot be risked. uuid:4a47a6ec-aaf1-4988-991d-a476acbc1e06 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:370638 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:68be2abd-6fcb-436f-9c8c-1450901462b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:99bbc18b-ca8b-4bc9-9176-170a0ad825ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amiloride hydrochloride and hydrochlorothiazide tablets are indicated in those patients with hypertension or with congestive heart failure who develop hypokalemia when thiazides or other kaliuretic diuretics are used alone, or in whom maintenance of normal serum potassium levels is considered to be clinically important, e.g., digitalized patients, or patients with significant cardiac arrhythmias. The use of potassium-conserving agents is often unnecessary in patients receiving diuretics for uncomplicated essential hypertension when such patients have a normal diet. Amiloride hydrochloride and hydrochlorothiazide tablets may be used alone or as an adjunct to other antihypertensive drugs, such as methyldopa or beta blockers. Since amiloride hydrochloride and hydrochlorothiazide enhances the action of these agents, dosage adjustments may be necessary to avoid an excessive fall in blood pressure and other unwanted side effects. This fixed combination drug is not indicated for the initial therapy of edema or hypertension except in individuals in whom the development of hypokalemia cannot be risked. uuid:4842402a-a6f9-45be-9419-8657c4834342 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:370638 biolink:treats MONDO:0003019 PMID:41385096 "[{""id"":""uuid:a17af414-bc6d-4feb-91dc-9bdf946eeffc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a8a053de-83c2-4282-8312-3be1e8c3be9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amiloride hydrochloride and hydrochlorothiazide tablets are indicated in those patients with hypertension or with congestive heart failure who develop hypokalemia when thiazides or other kaliuretic diuretics are used alone, or in whom maintenance of normal serum potassium levels is considered to be clinically important, e.g., digitalized patients, or patients with significant cardiac arrhythmias. The use of potassium-conserving agents is often unnecessary in patients receiving diuretics for uncomplicated essential hypertension when such patients have a normal diet. Amiloride hydrochloride and hydrochlorothiazide tablets may be used alone or as an adjunct to other antihypertensive drugs, such as methyldopa or beta blockers. Since amiloride hydrochloride and hydrochlorothiazide enhances the action of these agents, dosage adjustments may be necessary to avoid an excessive fall in blood pressure and other unwanted side effects. This fixed combination drug is not indicated for the initial therapy of edema or hypertension except in individuals in whom the development of hypokalemia cannot be risked. uuid:8cd58a9b-b6e2-4f9c-9b9f-24ff765db637 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:370638 biolink:treats MONDO:0007263 PMID:41385096 "[{""id"":""uuid:e6ffc8fc-17f6-437d-b02e-80ae6c820190"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4cf63c15-afc2-4023-96d1-34a7f5de408a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amiloride hydrochloride and hydrochlorothiazide tablets are indicated in those patients with hypertension or with congestive heart failure who develop hypokalemia when thiazides or other kaliuretic diuretics are used alone, or in whom maintenance of normal serum potassium levels is considered to be clinically important, e.g., digitalized patients, or patients with significant cardiac arrhythmias. The use of potassium-conserving agents is often unnecessary in patients receiving diuretics for uncomplicated essential hypertension when such patients have a normal diet. Amiloride hydrochloride and hydrochlorothiazide tablets may be used alone or as an adjunct to other antihypertensive drugs, such as methyldopa or beta blockers. Since amiloride hydrochloride and hydrochlorothiazide enhances the action of these agents, dosage adjustments may be necessary to avoid an excessive fall in blood pressure and other unwanted side effects. This fixed combination drug is not indicated for the initial therapy of edema or hypertension except in individuals in whom the development of hypokalemia cannot be risked. uuid:b296a052-eba9-44b7-a75e-a985ba26bd4c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:370638 biolink:treats HP:0000969 PMID:41385096 "[{""id"":""uuid:7aa07b19-b7d0-40c0-8d54-af551b4cbed9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8094033a-4f69-4909-9572-7fcf12a0a8f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amiloride hydrochloride and hydrochlorothiazide tablets are indicated in those patients with hypertension or with congestive heart failure who develop hypokalemia when thiazides or other kaliuretic diuretics are used alone, or in whom maintenance of normal serum potassium levels is considered to be clinically important, e.g., digitalized patients, or patients with significant cardiac arrhythmias. The use of potassium-conserving agents is often unnecessary in patients receiving diuretics for uncomplicated essential hypertension when such patients have a normal diet. Amiloride hydrochloride and hydrochlorothiazide tablets may be used alone or as an adjunct to other antihypertensive drugs, such as methyldopa or beta blockers. Since amiloride hydrochloride and hydrochlorothiazide enhances the action of these agents, dosage adjustments may be necessary to avoid an excessive fall in blood pressure and other unwanted side effects. This fixed combination drug is not indicated for the initial therapy of edema or hypertension except in individuals in whom the development of hypokalemia cannot be risked. uuid:1b850470-d5da-4b5e-ae96-6386526845b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:370638 biolink:treats MONDO:0001134 PMID:41385096 "[{""id"":""uuid:11e5af6e-8cbe-44b8-b1e7-a77c632cba92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e896c5a4-4988-49cf-affb-407858083682"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amiloride hydrochloride and hydrochlorothiazide tablets are indicated in those patients with hypertension or with congestive heart failure who develop hypokalemia when thiazides or other kaliuretic diuretics are used alone, or in whom maintenance of normal serum potassium levels is considered to be clinically important, e.g., digitalized patients, or patients with significant cardiac arrhythmias. The use of potassium-conserving agents is often unnecessary in patients receiving diuretics for uncomplicated essential hypertension when such patients have a normal diet. Amiloride hydrochloride and hydrochlorothiazide tablets may be used alone or as an adjunct to other antihypertensive drugs, such as methyldopa or beta blockers. Since amiloride hydrochloride and hydrochlorothiazide enhances the action of these agents, dosage adjustments may be necessary to avoid an excessive fall in blood pressure and other unwanted side effects. This fixed combination drug is not indicated for the initial therapy of edema or hypertension except in individuals in whom the development of hypokalemia cannot be risked. uuid:87b8cba6-f2a9-4e07-b222-c81d739584de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151392 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:d64edc3d-aa59-4195-9305-dbda2d538cce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e1f39a7c-4a48-4b26-8a72-f98c27918827"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AUGMENTIN XR Extended Release Tablets are indicated for the treatment of patients with community-acquired pneumonia or acute bacterial sinusitis due to confirmed, or suspected β-lactamase−producing pathogens (i.e., H. influenzae , M. catarrhalis , H. parainfluenzae , K. pneumoniae , or methicillin-susceptible S. aureus ) and S. pneumoniae with reduced susceptibility to penicillin (i.e., penicillin MICs = 2 mcg/mL). AUGMENTIN XR is not indicated for the treatment of infections due to S. pneumoniae with penicillin MICs ≥ 4 mcg/mL. Data are limited with regard to infections due to S. pneumoniae with penicillin MICs ≥ 4 mcg/mL (see CLINICAL STUDIES). Of the common epidemiological risk factors for patients with resistant pneumococcal infections, only age > 65 years was studied. Patients with other common risk factors for resistant pneumococcal infections (e.g., alcoholism, immune-suppressive illness, and presence of multiple co-morbid conditions) were not studied. In patients with community-acquired pneumonia in whom penicillin-resistant S. pneumoniae is suspected, bacteriological studies should be performed to determine the causative organisms and their susceptibility when AUGMENTIN XR is prescribed. Acute bacterial sinusitis or community-acquired pneumonia due to a penicillin-susceptible strain of S. pneumoniae plus a β-lactamase−producing pathogen can be treated with another AUGMENTIN ® (amoxicillin/clavulanate potassium) product containing lower daily doses of amoxicillin (i.e., 500 mg every 8 hours or 875 mg every 12 hours). Acute bacterial sinusitis or community-acquired pneumonia due to S. pneumoniae alone can be treated with amoxicillin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of AUGMENTIN XR and other antibacterial drugs, AUGMENTIN XR should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:b7837f5b-5eae-46b2-891b-f3dd626ce2d4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151392 biolink:treats UMLS:C0275556 PMID:41385096 "[{""id"":""uuid:eaff3819-1fd8-4773-8e2c-ed2b6c757ae1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:35e9fb24-b5b7-4d38-bd9b-b22d205fc0e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AUGMENTIN XR Extended Release Tablets are indicated for the treatment of patients with community-acquired pneumonia or acute bacterial sinusitis due to confirmed, or suspected β-lactamase−producing pathogens (i.e., H. influenzae , M. catarrhalis , H. parainfluenzae , K. pneumoniae , or methicillin-susceptible S. aureus ) and S. pneumoniae with reduced susceptibility to penicillin (i.e., penicillin MICs = 2 mcg/mL). AUGMENTIN XR is not indicated for the treatment of infections due to S. pneumoniae with penicillin MICs ≥ 4 mcg/mL. Data are limited with regard to infections due to S. pneumoniae with penicillin MICs ≥ 4 mcg/mL (see CLINICAL STUDIES). Of the common epidemiological risk factors for patients with resistant pneumococcal infections, only age > 65 years was studied. Patients with other common risk factors for resistant pneumococcal infections (e.g., alcoholism, immune-suppressive illness, and presence of multiple co-morbid conditions) were not studied. In patients with community-acquired pneumonia in whom penicillin-resistant S. pneumoniae is suspected, bacteriological studies should be performed to determine the causative organisms and their susceptibility when AUGMENTIN XR is prescribed. Acute bacterial sinusitis or community-acquired pneumonia due to a penicillin-susceptible strain of S. pneumoniae plus a β-lactamase−producing pathogen can be treated with another AUGMENTIN ® (amoxicillin/clavulanate potassium) product containing lower daily doses of amoxicillin (i.e., 500 mg every 8 hours or 875 mg every 12 hours). Acute bacterial sinusitis or community-acquired pneumonia due to S. pneumoniae alone can be treated with amoxicillin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of AUGMENTIN XR and other antibacterial drugs, AUGMENTIN XR should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:a3480bb5-8818-4e9b-8915-e1a518152aaa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats MONDO:0004577 PMID:41385096 "[{""id"":""uuid:252d9cca-b21f-43b3-bcec-89e867f1b5c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a3c780a6-03d2-4702-95a7-3582a557bf98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciprofloxacin Hydrochloride Ophthalmic Solution is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Corneal Ulcers: Pseudomonas aeruginosa Serratia marcescens* Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Streptococcus (Viridans Group)* Conjunctivitis: Haemophilus influenzae Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae *Efficacy for this organism was studied in fewer than 10 infections. uuid:3a696409-c36d-4eec-9e13-41b878148492 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats MONDO:0003799 PMID:41385096 "[{""id"":""uuid:7bfb9746-f0ad-47e9-9024-a2e2a88a397f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1fb7cbb2-7f1c-44cd-bf76-5bb501b4715c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciprofloxacin Hydrochloride Ophthalmic Solution is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Corneal Ulcers: Pseudomonas aeruginosa Serratia marcescens* Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Streptococcus (Viridans Group)* Conjunctivitis: Haemophilus influenzae Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae *Efficacy for this organism was studied in fewer than 10 infections. uuid:a38422a0-97c1-4a36-b0a1-989a393c12d9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3752 biolink:treats HP:0000869 PMID:41385096 "[{""id"":""uuid:f0d24955-20b6-4a3f-9847-0cad7e9f61d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e8a98b20-df5e-4d47-9a34-21a7ca35e5ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clomiphene citrate is indicated for the treatment of ovulatory dysfunction in women desiring pregnancy. Impediments to achieving pregnancy must be excluded or adequately treated before beginning clomiphene citrate therapy. Those patients most likely to achieve success with clomiphene therapy include patients with polycystic ovary syndrome (see WARNINGS : Ovarian Hyperstimulation Syndrome ), amenorrhea-galactorrhea syndrome, psychogenic amenorrhea, post-oral-contraceptive amenorrhea, and certain cases of secondary amenorrhea of undetermined etiology. Properly timed coitus in relationship to ovulation is important. A basal body temperature graph or other appropriate tests may help the patient and her physician determine if ovulation occurred. Once ovulation has been established, each course of clomiphene citrate should be started on or about the 5th day of the cycle. Long-term cyclic therapy is not recommended beyond a total of about six cycles (including three ovulatory cycles). (See DOSAGE AND ADMINISTRATION and PRECAUTIONS .) Clomiphene citrate is indicated only in patients with demonstrated ovulatory dysfunction who meet the conditions described below (see CONTRAINDICATIONS ): Patients who are not pregnant. Patients without ovarian cysts. Clomiphene citrate should not be used in patients with ovarian enlargement except those with polycystic ovary syndrome. Pelvic examination is necessary prior to the first and each subsequent course of clomiphene citrate treatment. Patients without abnormal vaginal bleeding. If abnormal vaginal bleeding is present, the patient should be carefully evaluated to ensure that neoplastic lesions are not present. Patients with normal liver function. In addition, patients selected for clomiphene citrate therapy should be evaluated in regard to the following: Estrogen Levels. Patients should have adequate levels of endogenous estrogen (as estimated from vaginal smears, endometrial biopsy, assay of urinary estrogen, or from bleeding in response to progesterone). Reduced estrogen levels, while less favorable, do not preclude successful therapy. Primary Pituitary or Ovarian Failure. Clomiphene citrate therapy cannot be expected to substitute for specific treatment of other causes of ovulatory failure. Endometriosis and Endometrial Carcinoma. The incidence of endometriosis and endometrial carcinoma increases with age as does the incidence of ovulatory disorders. Endometrial biopsy should always be performed prior to clomiphene citrate therapy in this population. Other Impediments to Pregnancy. Impediments to pregnancy can include thyroid disorders, adrenal disorders, hyperprolactinemia, and male factor infertility. Uterine Fibroids. Caution should be exercised when using clomiphene citrate in patients with uterine fibroids due to the potential for further enlargement of the fibroids. There are no adequate or well-controlled studies that demonstrate the effectiveness of clomiphene citrate in the treatment of male infertility. In addition, testicular tumors and gynecomastia have been reported in males using clomiphene. The cause and effect relationship between reports of testicular tumors and the administration of clomiphene citrate is not known. Although the medical literature suggests various methods, there is no universally accepted standard regimen for combined therapy (i.e., clomiphene citrate in conjunction with other ovulation-inducing drugs). Similarly, there is no standard clomiphene citrate regimen for ovulation induction in vitro fertilization programs to produce ova for fertilization and reintroduction. Therefore, clomiphene citrate is not recommended for these uses. uuid:b5538bc0-c2c7-4b4c-a612-846a78f08e97 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3752 biolink:treats MONDO:0005133 PMID:41385096 "[{""id"":""uuid:f405191a-beb4-4bb6-a2b1-5851ebdc278e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:89c2b06a-3e80-42a6-aef5-c9879f7fa7e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clomiphene citrate is indicated for the treatment of ovulatory dysfunction in women desiring pregnancy. Impediments to achieving pregnancy must be excluded or adequately treated before beginning clomiphene citrate therapy. Those patients most likely to achieve success with clomiphene therapy include patients with polycystic ovary syndrome (see WARNINGS : Ovarian Hyperstimulation Syndrome ), amenorrhea-galactorrhea syndrome, psychogenic amenorrhea, post-oral-contraceptive amenorrhea, and certain cases of secondary amenorrhea of undetermined etiology. Properly timed coitus in relationship to ovulation is important. A basal body temperature graph or other appropriate tests may help the patient and her physician determine if ovulation occurred. Once ovulation has been established, each course of clomiphene citrate should be started on or about the 5th day of the cycle. Long-term cyclic therapy is not recommended beyond a total of about six cycles (including three ovulatory cycles). (See DOSAGE AND ADMINISTRATION and PRECAUTIONS .) Clomiphene citrate is indicated only in patients with demonstrated ovulatory dysfunction who meet the conditions described below (see CONTRAINDICATIONS ): Patients who are not pregnant. Patients without ovarian cysts. Clomiphene citrate should not be used in patients with ovarian enlargement except those with polycystic ovary syndrome. Pelvic examination is necessary prior to the first and each subsequent course of clomiphene citrate treatment. Patients without abnormal vaginal bleeding. If abnormal vaginal bleeding is present, the patient should be carefully evaluated to ensure that neoplastic lesions are not present. Patients with normal liver function. In addition, patients selected for clomiphene citrate therapy should be evaluated in regard to the following: Estrogen Levels. Patients should have adequate levels of endogenous estrogen (as estimated from vaginal smears, endometrial biopsy, assay of urinary estrogen, or from bleeding in response to progesterone). Reduced estrogen levels, while less favorable, do not preclude successful therapy. Primary Pituitary or Ovarian Failure. Clomiphene citrate therapy cannot be expected to substitute for specific treatment of other causes of ovulatory failure. Endometriosis and Endometrial Carcinoma. The incidence of endometriosis and endometrial carcinoma increases with age as does the incidence of ovulatory disorders. Endometrial biopsy should always be performed prior to clomiphene citrate therapy in this population. Other Impediments to Pregnancy. Impediments to pregnancy can include thyroid disorders, adrenal disorders, hyperprolactinemia, and male factor infertility. Uterine Fibroids. Caution should be exercised when using clomiphene citrate in patients with uterine fibroids due to the potential for further enlargement of the fibroids. There are no adequate or well-controlled studies that demonstrate the effectiveness of clomiphene citrate in the treatment of male infertility. In addition, testicular tumors and gynecomastia have been reported in males using clomiphene. The cause and effect relationship between reports of testicular tumors and the administration of clomiphene citrate is not known. Although the medical literature suggests various methods, there is no universally accepted standard regimen for combined therapy (i.e., clomiphene citrate in conjunction with other ovulation-inducing drugs). Similarly, there is no standard clomiphene citrate regimen for ovulation induction in vitro fertilization programs to produce ova for fertilization and reintroduction. Therefore, clomiphene citrate is not recommended for these uses. uuid:ff6c6138-5ec7-4f6e-8cb7-e7d73a292968 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3752 biolink:treats MONDO:0002447 PMID:41385096 "[{""id"":""uuid:2f24a04a-104f-44fa-a3c7-8bb89b3f9a16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5b2dea1a-6c59-46c0-a552-dabc5acada67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clomiphene citrate is indicated for the treatment of ovulatory dysfunction in women desiring pregnancy. Impediments to achieving pregnancy must be excluded or adequately treated before beginning clomiphene citrate therapy. Those patients most likely to achieve success with clomiphene therapy include patients with polycystic ovary syndrome (see WARNINGS : Ovarian Hyperstimulation Syndrome ), amenorrhea-galactorrhea syndrome, psychogenic amenorrhea, post-oral-contraceptive amenorrhea, and certain cases of secondary amenorrhea of undetermined etiology. Properly timed coitus in relationship to ovulation is important. A basal body temperature graph or other appropriate tests may help the patient and her physician determine if ovulation occurred. Once ovulation has been established, each course of clomiphene citrate should be started on or about the 5th day of the cycle. Long-term cyclic therapy is not recommended beyond a total of about six cycles (including three ovulatory cycles). (See DOSAGE AND ADMINISTRATION and PRECAUTIONS .) Clomiphene citrate is indicated only in patients with demonstrated ovulatory dysfunction who meet the conditions described below (see CONTRAINDICATIONS ): Patients who are not pregnant. Patients without ovarian cysts. Clomiphene citrate should not be used in patients with ovarian enlargement except those with polycystic ovary syndrome. Pelvic examination is necessary prior to the first and each subsequent course of clomiphene citrate treatment. Patients without abnormal vaginal bleeding. If abnormal vaginal bleeding is present, the patient should be carefully evaluated to ensure that neoplastic lesions are not present. Patients with normal liver function. In addition, patients selected for clomiphene citrate therapy should be evaluated in regard to the following: Estrogen Levels. Patients should have adequate levels of endogenous estrogen (as estimated from vaginal smears, endometrial biopsy, assay of urinary estrogen, or from bleeding in response to progesterone). Reduced estrogen levels, while less favorable, do not preclude successful therapy. Primary Pituitary or Ovarian Failure. Clomiphene citrate therapy cannot be expected to substitute for specific treatment of other causes of ovulatory failure. Endometriosis and Endometrial Carcinoma. The incidence of endometriosis and endometrial carcinoma increases with age as does the incidence of ovulatory disorders. Endometrial biopsy should always be performed prior to clomiphene citrate therapy in this population. Other Impediments to Pregnancy. Impediments to pregnancy can include thyroid disorders, adrenal disorders, hyperprolactinemia, and male factor infertility. Uterine Fibroids. Caution should be exercised when using clomiphene citrate in patients with uterine fibroids due to the potential for further enlargement of the fibroids. There are no adequate or well-controlled studies that demonstrate the effectiveness of clomiphene citrate in the treatment of male infertility. In addition, testicular tumors and gynecomastia have been reported in males using clomiphene. The cause and effect relationship between reports of testicular tumors and the administration of clomiphene citrate is not known. Although the medical literature suggests various methods, there is no universally accepted standard regimen for combined therapy (i.e., clomiphene citrate in conjunction with other ovulation-inducing drugs). Similarly, there is no standard clomiphene citrate regimen for ovulation induction in vitro fertilization programs to produce ova for fertilization and reintroduction. Therefore, clomiphene citrate is not recommended for these uses. uuid:8d36ed62-c9e6-4dfc-b597-86f05fb4ea45 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3752 biolink:treats MONDO:0003240 PMID:41385096 "[{""id"":""uuid:8edb50fc-91c1-4e09-983b-267f3ea7b1da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:71ce4f45-3170-4917-85a4-965a1979e722"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clomiphene citrate is indicated for the treatment of ovulatory dysfunction in women desiring pregnancy. Impediments to achieving pregnancy must be excluded or adequately treated before beginning clomiphene citrate therapy. Those patients most likely to achieve success with clomiphene therapy include patients with polycystic ovary syndrome (see WARNINGS : Ovarian Hyperstimulation Syndrome ), amenorrhea-galactorrhea syndrome, psychogenic amenorrhea, post-oral-contraceptive amenorrhea, and certain cases of secondary amenorrhea of undetermined etiology. Properly timed coitus in relationship to ovulation is important. A basal body temperature graph or other appropriate tests may help the patient and her physician determine if ovulation occurred. Once ovulation has been established, each course of clomiphene citrate should be started on or about the 5th day of the cycle. Long-term cyclic therapy is not recommended beyond a total of about six cycles (including three ovulatory cycles). (See DOSAGE AND ADMINISTRATION and PRECAUTIONS .) Clomiphene citrate is indicated only in patients with demonstrated ovulatory dysfunction who meet the conditions described below (see CONTRAINDICATIONS ): Patients who are not pregnant. Patients without ovarian cysts. Clomiphene citrate should not be used in patients with ovarian enlargement except those with polycystic ovary syndrome. Pelvic examination is necessary prior to the first and each subsequent course of clomiphene citrate treatment. Patients without abnormal vaginal bleeding. If abnormal vaginal bleeding is present, the patient should be carefully evaluated to ensure that neoplastic lesions are not present. Patients with normal liver function. In addition, patients selected for clomiphene citrate therapy should be evaluated in regard to the following: Estrogen Levels. Patients should have adequate levels of endogenous estrogen (as estimated from vaginal smears, endometrial biopsy, assay of urinary estrogen, or from bleeding in response to progesterone). Reduced estrogen levels, while less favorable, do not preclude successful therapy. Primary Pituitary or Ovarian Failure. Clomiphene citrate therapy cannot be expected to substitute for specific treatment of other causes of ovulatory failure. Endometriosis and Endometrial Carcinoma. The incidence of endometriosis and endometrial carcinoma increases with age as does the incidence of ovulatory disorders. Endometrial biopsy should always be performed prior to clomiphene citrate therapy in this population. Other Impediments to Pregnancy. Impediments to pregnancy can include thyroid disorders, adrenal disorders, hyperprolactinemia, and male factor infertility. Uterine Fibroids. Caution should be exercised when using clomiphene citrate in patients with uterine fibroids due to the potential for further enlargement of the fibroids. There are no adequate or well-controlled studies that demonstrate the effectiveness of clomiphene citrate in the treatment of male infertility. In addition, testicular tumors and gynecomastia have been reported in males using clomiphene. The cause and effect relationship between reports of testicular tumors and the administration of clomiphene citrate is not known. Although the medical literature suggests various methods, there is no universally accepted standard regimen for combined therapy (i.e., clomiphene citrate in conjunction with other ovulation-inducing drugs). Similarly, there is no standard clomiphene citrate regimen for ovulation induction in vitro fertilization programs to produce ova for fertilization and reintroduction. Therefore, clomiphene citrate is not recommended for these uses. uuid:b35d5263-fbca-43cf-a6c4-640fb6c5fb27 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3752 biolink:treats MONDO:0005495 PMID:41385096 "[{""id"":""uuid:36b0b812-f5cc-4c74-9a89-b5ea8a9271b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:74f89dce-ca0a-4c52-918a-a0fceb8c4cf0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clomiphene citrate is indicated for the treatment of ovulatory dysfunction in women desiring pregnancy. Impediments to achieving pregnancy must be excluded or adequately treated before beginning clomiphene citrate therapy. Those patients most likely to achieve success with clomiphene therapy include patients with polycystic ovary syndrome (see WARNINGS : Ovarian Hyperstimulation Syndrome ), amenorrhea-galactorrhea syndrome, psychogenic amenorrhea, post-oral-contraceptive amenorrhea, and certain cases of secondary amenorrhea of undetermined etiology. Properly timed coitus in relationship to ovulation is important. A basal body temperature graph or other appropriate tests may help the patient and her physician determine if ovulation occurred. Once ovulation has been established, each course of clomiphene citrate should be started on or about the 5th day of the cycle. Long-term cyclic therapy is not recommended beyond a total of about six cycles (including three ovulatory cycles). (See DOSAGE AND ADMINISTRATION and PRECAUTIONS .) Clomiphene citrate is indicated only in patients with demonstrated ovulatory dysfunction who meet the conditions described below (see CONTRAINDICATIONS ): Patients who are not pregnant. Patients without ovarian cysts. Clomiphene citrate should not be used in patients with ovarian enlargement except those with polycystic ovary syndrome. Pelvic examination is necessary prior to the first and each subsequent course of clomiphene citrate treatment. Patients without abnormal vaginal bleeding. If abnormal vaginal bleeding is present, the patient should be carefully evaluated to ensure that neoplastic lesions are not present. Patients with normal liver function. In addition, patients selected for clomiphene citrate therapy should be evaluated in regard to the following: Estrogen Levels. Patients should have adequate levels of endogenous estrogen (as estimated from vaginal smears, endometrial biopsy, assay of urinary estrogen, or from bleeding in response to progesterone). Reduced estrogen levels, while less favorable, do not preclude successful therapy. Primary Pituitary or Ovarian Failure. Clomiphene citrate therapy cannot be expected to substitute for specific treatment of other causes of ovulatory failure. Endometriosis and Endometrial Carcinoma. The incidence of endometriosis and endometrial carcinoma increases with age as does the incidence of ovulatory disorders. Endometrial biopsy should always be performed prior to clomiphene citrate therapy in this population. Other Impediments to Pregnancy. Impediments to pregnancy can include thyroid disorders, adrenal disorders, hyperprolactinemia, and male factor infertility. Uterine Fibroids. Caution should be exercised when using clomiphene citrate in patients with uterine fibroids due to the potential for further enlargement of the fibroids. There are no adequate or well-controlled studies that demonstrate the effectiveness of clomiphene citrate in the treatment of male infertility. In addition, testicular tumors and gynecomastia have been reported in males using clomiphene. The cause and effect relationship between reports of testicular tumors and the administration of clomiphene citrate is not known. Although the medical literature suggests various methods, there is no universally accepted standard regimen for combined therapy (i.e., clomiphene citrate in conjunction with other ovulation-inducing drugs). Similarly, there is no standard clomiphene citrate regimen for ovulation induction in vitro fertilization programs to produce ova for fertilization and reintroduction. Therefore, clomiphene citrate is not recommended for these uses. uuid:a8271230-cf01-4266-a2ab-d137fc1c641b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3752 biolink:treats MONDO:0005804 PMID:41385096 "[{""id"":""uuid:1d688277-75bf-4e05-9e3c-a94501631d24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:98a19dbc-899b-4c00-b7ef-80ab17662a05"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clomiphene citrate is indicated for the treatment of ovulatory dysfunction in women desiring pregnancy. Impediments to achieving pregnancy must be excluded or adequately treated before beginning clomiphene citrate therapy. Those patients most likely to achieve success with clomiphene therapy include patients with polycystic ovary syndrome (see WARNINGS : Ovarian Hyperstimulation Syndrome ), amenorrhea-galactorrhea syndrome, psychogenic amenorrhea, post-oral-contraceptive amenorrhea, and certain cases of secondary amenorrhea of undetermined etiology. Properly timed coitus in relationship to ovulation is important. A basal body temperature graph or other appropriate tests may help the patient and her physician determine if ovulation occurred. Once ovulation has been established, each course of clomiphene citrate should be started on or about the 5th day of the cycle. Long-term cyclic therapy is not recommended beyond a total of about six cycles (including three ovulatory cycles). (See DOSAGE AND ADMINISTRATION and PRECAUTIONS .) Clomiphene citrate is indicated only in patients with demonstrated ovulatory dysfunction who meet the conditions described below (see CONTRAINDICATIONS ): Patients who are not pregnant. Patients without ovarian cysts. Clomiphene citrate should not be used in patients with ovarian enlargement except those with polycystic ovary syndrome. Pelvic examination is necessary prior to the first and each subsequent course of clomiphene citrate treatment. Patients without abnormal vaginal bleeding. If abnormal vaginal bleeding is present, the patient should be carefully evaluated to ensure that neoplastic lesions are not present. Patients with normal liver function. In addition, patients selected for clomiphene citrate therapy should be evaluated in regard to the following: Estrogen Levels. Patients should have adequate levels of endogenous estrogen (as estimated from vaginal smears, endometrial biopsy, assay of urinary estrogen, or from bleeding in response to progesterone). Reduced estrogen levels, while less favorable, do not preclude successful therapy. Primary Pituitary or Ovarian Failure. Clomiphene citrate therapy cannot be expected to substitute for specific treatment of other causes of ovulatory failure. Endometriosis and Endometrial Carcinoma. The incidence of endometriosis and endometrial carcinoma increases with age as does the incidence of ovulatory disorders. Endometrial biopsy should always be performed prior to clomiphene citrate therapy in this population. Other Impediments to Pregnancy. Impediments to pregnancy can include thyroid disorders, adrenal disorders, hyperprolactinemia, and male factor infertility. Uterine Fibroids. Caution should be exercised when using clomiphene citrate in patients with uterine fibroids due to the potential for further enlargement of the fibroids. There are no adequate or well-controlled studies that demonstrate the effectiveness of clomiphene citrate in the treatment of male infertility. In addition, testicular tumors and gynecomastia have been reported in males using clomiphene. The cause and effect relationship between reports of testicular tumors and the administration of clomiphene citrate is not known. Although the medical literature suggests various methods, there is no universally accepted standard regimen for combined therapy (i.e., clomiphene citrate in conjunction with other ovulation-inducing drugs). Similarly, there is no standard clomiphene citrate regimen for ovulation induction in vitro fertilization programs to produce ova for fertilization and reintroduction. Therefore, clomiphene citrate is not recommended for these uses. uuid:dac514df-7e04-4f39-8970-537b309304aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3752 biolink:treats MONDO:0005372 PMID:41385096 "[{""id"":""uuid:584fbd4b-1dc7-4a08-bfb5-bd2aec4afde0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:283ade2b-e9db-422a-9bdf-fc1c6c54e55c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clomiphene citrate is indicated for the treatment of ovulatory dysfunction in women desiring pregnancy. Impediments to achieving pregnancy must be excluded or adequately treated before beginning clomiphene citrate therapy. Those patients most likely to achieve success with clomiphene therapy include patients with polycystic ovary syndrome (see WARNINGS : Ovarian Hyperstimulation Syndrome ), amenorrhea-galactorrhea syndrome, psychogenic amenorrhea, post-oral-contraceptive amenorrhea, and certain cases of secondary amenorrhea of undetermined etiology. Properly timed coitus in relationship to ovulation is important. A basal body temperature graph or other appropriate tests may help the patient and her physician determine if ovulation occurred. Once ovulation has been established, each course of clomiphene citrate should be started on or about the 5th day of the cycle. Long-term cyclic therapy is not recommended beyond a total of about six cycles (including three ovulatory cycles). (See DOSAGE AND ADMINISTRATION and PRECAUTIONS .) Clomiphene citrate is indicated only in patients with demonstrated ovulatory dysfunction who meet the conditions described below (see CONTRAINDICATIONS ): Patients who are not pregnant. Patients without ovarian cysts. Clomiphene citrate should not be used in patients with ovarian enlargement except those with polycystic ovary syndrome. Pelvic examination is necessary prior to the first and each subsequent course of clomiphene citrate treatment. Patients without abnormal vaginal bleeding. If abnormal vaginal bleeding is present, the patient should be carefully evaluated to ensure that neoplastic lesions are not present. Patients with normal liver function. In addition, patients selected for clomiphene citrate therapy should be evaluated in regard to the following: Estrogen Levels. Patients should have adequate levels of endogenous estrogen (as estimated from vaginal smears, endometrial biopsy, assay of urinary estrogen, or from bleeding in response to progesterone). Reduced estrogen levels, while less favorable, do not preclude successful therapy. Primary Pituitary or Ovarian Failure. Clomiphene citrate therapy cannot be expected to substitute for specific treatment of other causes of ovulatory failure. Endometriosis and Endometrial Carcinoma. The incidence of endometriosis and endometrial carcinoma increases with age as does the incidence of ovulatory disorders. Endometrial biopsy should always be performed prior to clomiphene citrate therapy in this population. Other Impediments to Pregnancy. Impediments to pregnancy can include thyroid disorders, adrenal disorders, hyperprolactinemia, and male factor infertility. Uterine Fibroids. Caution should be exercised when using clomiphene citrate in patients with uterine fibroids due to the potential for further enlargement of the fibroids. There are no adequate or well-controlled studies that demonstrate the effectiveness of clomiphene citrate in the treatment of male infertility. In addition, testicular tumors and gynecomastia have been reported in males using clomiphene. The cause and effect relationship between reports of testicular tumors and the administration of clomiphene citrate is not known. Although the medical literature suggests various methods, there is no universally accepted standard regimen for combined therapy (i.e., clomiphene citrate in conjunction with other ovulation-inducing drugs). Similarly, there is no standard clomiphene citrate regimen for ovulation induction in vitro fertilization programs to produce ova for fertilization and reintroduction. Therefore, clomiphene citrate is not recommended for these uses. uuid:4f38ecbb-223e-474f-9dd0-aac1290a04fa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1163424 biolink:treats MONDO:0004795 PMID:41385096 "[{""id"":""uuid:97d404b8-0c42-46f1-9478-2e242e255449"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1075dd8e-f60d-4127-9865-2a320bebd3f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of superficial bacterial infections of the external auditory canal caused by organisms susceptible to the action of the antibiotics, and for the treatment of infections of mastoidectomy and fenestration cavities caused by organisms susceptible to the antibiotics. uuid:0026f281-4c09-4dc2-a26c-a23ff7ab0f0c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1163424 biolink:treats MONDO:0021666 PMID:41385096 "[{""id"":""uuid:c60aba78-9e6a-4353-93a9-e71826c8077f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a59afa56-042e-4ab2-86d2-0b5b73b393f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of superficial bacterial infections of the external auditory canal caused by organisms susceptible to the action of the antibiotics, and for the treatment of infections of mastoidectomy and fenestration cavities caused by organisms susceptible to the antibiotics. uuid:5e792c0e-e853-4740-baec-3d988d258cd6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats HP:0000613 PMID:41385096 "[{""id"":""uuid:b7b5e924-b8c2-4afa-976e-31d3eadf5c95"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:169727c0-7eab-4f10-98e8-508856867517"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diclofenac Sodium Ophthalmic is indicated for the treatment of postoperative inflammation in patients who have undergone cataract extraction and for the temporary relief of pain and photophobia in patients undergoing corneal refractive surgery. uuid:b0e77c03-698b-449d-9c7d-960ed3a37018 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151392 biolink:treats HP:0000371 PMID:41385096 "[{""id"":""uuid:eaff8b25-f1c7-4ee1-88a2-a74f4a027424"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:03771382-3f18-42fa-9ea1-49f6dc9371c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amoxicillin and Clavulanate Potassium for Oral Suspension USP, 600 mg/5 mL is indicated for the treatment of pediatric patients with recurrent or persistent acute otitis media due to S. pneumoniae (penicillin MICs ≤ 2 mcg/mL), H. influenzae (including β-lactamase-producing strains), or M. catarrhalis (including β-lactamase-producing strains) characterized by the following risk factors: • antibiotic exposure for acute otitis media within the preceding 3 months, and either of the following: - age ≤ 2 years - daycare attendance [See CLINICAL PHARMACOLOGY , Microbiology .] NOTE: Acute otitis media due to S. pneumoniae alone can be treated with amoxicillin. Amoxicillin and Clavulanate Potassium for Oral Suspension is not indicated for the treatment of acute otitis media due to S. pneumoniae with penicillin MIC ≥ 4 mcg /mL. Therapy may be instituted prior to obtaining the results from bacteriological studies when there is reason to believe the infection may involve both S. pneumoniae (penicillin MIC ≤ 2 mcg/mL) and the β-lactamase-producing organisms listed above. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Amoxicillin and Clavulanate Potassium for Oral Suspension 600 mg/42.9 mg per 5 mL and other antibacterial drugs, Amoxicillin and Clavulanate Potassium for Oral Suspension 600 mg/42.9 mg per 5 mL should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:a539db29-b807-40ba-918c-cd4ad70387b6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:308714 biolink:treats UMLS:C0276733 PMID:41385096 "[{""id"":""uuid:a8a0b385-873c-4d64-8cc8-61149fec34a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eab52626-2a39-4e10-9f30-f3e2fcddea22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clotrimazole and Betamethasone Dipropionate Cream and Lotion are indicated in patients 17 years and older for the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris, and tinea corporis due to Epidermophyton floccosum, Trichophyton mentagrophytes and Trichophyton rubrum. Effective treatment without the risks associated with topical corticosteroid use may be obtained using a topical antifungal agent that does not contain a corticosteroid, especially for noninflammatory tinea infections. The efficacy of Clotrimazole and Betamethasone Dipropionate Cream or Lotion for the treatment of infections caused by zoophilic dermatophytes (e.g. Microsporum canis ) has not been established. Several cases of treatment failure of Clotrimazole and Betamethasone Dipropionate Cream, USP in the treatment of infections caused by Microsporum canis have been reported. uuid:251d42b8-f70c-4686-8096-30d155914eb6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6970 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:0139078b-7c3a-4813-84e1-d214abdb2c85"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e89497c4-8e7a-4906-a00a-1ca72ba64d5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ASMANEX TWISTHALER is a corticosteroid indicated for: Maintenance treatment of asthma as prophylactic therapy in patients 4 years of age and older. ( 1.1 ) ASMANEX TWISTHALER is NOT indicated for the relief of acute bronchospasm ( 1.1 , 5.2 ) or in children less than 4 years of age ( 1.1 , 8.4 ). uuid:8430b8ae-2e46-454a-9450-5aae19c2be8c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:84500 biolink:treats MONDO:0008575 PMID:41385096 "[{""id"":""uuid:16ec51db-9a5a-42f0-8f64-8cb4fbd18448"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b557cb04-3076-4e37-a569-5902192071b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a5201efc-8a4d-4d17-bb79-d4013d10279b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CHANTIX is indicated for use as an aid to smoking cessation treatment.|[PMDA] Drugs containing a new active ingredient indicated as a smoking-cessation aid for nicotine-dependent smokers. Expedited review. uuid:49ccbe07-c828-4659-9fbb-009e2396a700 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5855 biolink:treats HP:0001945 PMID:41385096 "[{""id"":""uuid:3f801778-6fcc-4d7d-8729-70b434bdaea2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b6b13fba-e310-4cab-ad78-51de8d01d877"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of ibuprofen suspension and other treatment options before deciding to use ibuprofen suspension. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). In Pediatric Patients , ibuprofen suspension is indicated: For reduction of fever in patients aged 6 months up to 2 years of age. For relief of mild to moderate pain in patients aged 6 months up to 2 years of age. For relief of signs and symptoms of juvenile arthritis. In Adults , ibuprofen is indicated: For treatment of primary dysmenorrhea. For relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Since there have been no controlled trials to demonstrate whether there is any beneficial effect or harmful interaction with the use of ibuprofen in conjunction with aspirin, the combination cannot be recommended. (See PRECAUTIONS - Drug Interactions ). uuid:a9db4cb2-a4d6-4586-a8ec-47df7b404b6b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5855 biolink:treats MONDO:0011429 PMID:41385096 "[{""id"":""uuid:58c19684-a9dd-484e-b98f-5c2149489bc1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7b782fa3-1059-465b-8064-9ed8f5d5aee1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of ibuprofen suspension and other treatment options before deciding to use ibuprofen suspension. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). In Pediatric Patients , ibuprofen suspension is indicated: For reduction of fever in patients aged 6 months up to 2 years of age. For relief of mild to moderate pain in patients aged 6 months up to 2 years of age. For relief of signs and symptoms of juvenile arthritis. In Adults , ibuprofen is indicated: For treatment of primary dysmenorrhea. For relief of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Since there have been no controlled trials to demonstrate whether there is any beneficial effect or harmful interaction with the use of ibuprofen in conjunction with aspirin, the combination cannot be recommended. (See PRECAUTIONS - Drug Interactions ). uuid:a3e5b0a3-b00c-4997-94ef-6a3841cc049b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats MONDO:0005866 PMID:41385096 "[{""id"":""uuid:1854eec4-f936-4723-a983-e15cdbe7964e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7ba97b0b-2cf3-4629-a41c-3a2ceadf2298"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azithromycin tablets are indicated for the treatment of patients with mild to moderate infections (pneumonia: see WARNINGS) caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Mycobacterial Infections Prophylaxis of Disseminated M ycobacterium avium complex (MAC) Disease Azithromycin tablet, taken alone or in combination with rifabutin at its approved dose, is indicated for the prevention of disseminated Mycobacterium avium complex (MAC) disease in persons with advanced HIV infection. (See DOSAGE AND ADMINISTRATION, CLINICAL STUDIES) Treatment of Disseminated Mycobacterium avium complex (MAC) Disease Azithromycin tablet, taken in combination with ethambutol, is indicated for the treatment of disseminated MAC infections in persons with advanced HIV infection. (See DOSAGE AND ADMINISTRATION, CLINICAL STUDIES) uuid:081fac1c-cb7f-420a-83f5-d6de8aa0076c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8774 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:ee1efd3a-47ef-4d5b-95be-62203da14d83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ae9cdb0c-cb14-4654-8ba1-248f665fec12"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ramipril capsules are indicated in patients 55 years or older at high risk of developing a major cardiovascular event because of a history of coronary artery disease, stroke, peripheral vascular disease, or diabetes that is accompanied by at least one other cardiovascular risk factor (hypertension, elevated total cholesterol levels, low HDL levels, cigarette smoking, or documented microalbuminuria), to reduce the risk of myocardial infarction, stroke, or death from cardiovascular causes. Ramipril capsules can be used in addition to other needed treatment (such as antihypertensive, antiplatelet or lipid-lowering therapy). uuid:e10923c8-6743-47bd-8319-9176a8d7cf7c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8774 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:a36fb1f0-bf78-4f3b-8e2b-719a48840b8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a6289fa1-c25f-4a90-98a7-02c10e98b2dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ramipril capsules are indicated in patients 55 years or older at high risk of developing a major cardiovascular event because of a history of coronary artery disease, stroke, peripheral vascular disease, or diabetes that is accompanied by at least one other cardiovascular risk factor (hypertension, elevated total cholesterol levels, low HDL levels, cigarette smoking, or documented microalbuminuria), to reduce the risk of myocardial infarction, stroke, or death from cardiovascular causes. Ramipril capsules can be used in addition to other needed treatment (such as antihypertensive, antiplatelet or lipid-lowering therapy). uuid:a097784d-ae45-4a66-866b-44a665ccc2f9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8774 biolink:treats MONDO:0005294 PMID:41385096 "[{""id"":""uuid:f9fafc36-d7c0-4e51-9046-efedc1fc86e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8ebd28d3-03cd-4515-b386-aae4f544ac34"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ramipril capsules are indicated in patients 55 years or older at high risk of developing a major cardiovascular event because of a history of coronary artery disease, stroke, peripheral vascular disease, or diabetes that is accompanied by at least one other cardiovascular risk factor (hypertension, elevated total cholesterol levels, low HDL levels, cigarette smoking, or documented microalbuminuria), to reduce the risk of myocardial infarction, stroke, or death from cardiovascular causes. Ramipril capsules can be used in addition to other needed treatment (such as antihypertensive, antiplatelet or lipid-lowering therapy). uuid:f46bd9d6-92a8-4a9f-909a-4ee879b6c9aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8774 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:6f6e258a-6e4d-4d2f-8bc1-710c1dcee106"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:34005f4a-69ea-495d-8c08-8d7bb1ec4e83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ramipril capsules are indicated in patients 55 years or older at high risk of developing a major cardiovascular event because of a history of coronary artery disease, stroke, peripheral vascular disease, or diabetes that is accompanied by at least one other cardiovascular risk factor (hypertension, elevated total cholesterol levels, low HDL levels, cigarette smoking, or documented microalbuminuria), to reduce the risk of myocardial infarction, stroke, or death from cardiovascular causes. Ramipril capsules can be used in addition to other needed treatment (such as antihypertensive, antiplatelet or lipid-lowering therapy). uuid:c4801900-4c00-4feb-8204-825ffeecceca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8774 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:e8da266b-32fb-42ab-b015-89ce9d17e20d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9bbaa1d9-69a2-4aaa-9b65-7143843f80e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ramipril capsules are indicated in patients 55 years or older at high risk of developing a major cardiovascular event because of a history of coronary artery disease, stroke, peripheral vascular disease, or diabetes that is accompanied by at least one other cardiovascular risk factor (hypertension, elevated total cholesterol levels, low HDL levels, cigarette smoking, or documented microalbuminuria), to reduce the risk of myocardial infarction, stroke, or death from cardiovascular causes. Ramipril capsules can be used in addition to other needed treatment (such as antihypertensive, antiplatelet or lipid-lowering therapy). uuid:fd00e729-21c6-4d0d-a319-157da24bcc46 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8888 biolink:treats MONDO:0005180 PMID:41385096 "[{""id"":""uuid:1cac7903-0871-4c51-ad26-04c8c288ddec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3baf250d-2e2b-4f9c-8de1-889042cfb4e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:bd8a4c0c-eab4-4893-8763-3ece32538adf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Parkinson's Disease: Ropinirole hydrochloride tablets are indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease. The effectiveness of ropinirole hydrochloride tablets was demonstrated in randomized, controlled trials in patients with early Parkinson's disease who were not receiving concomitant L-dopa therapy as well as in patients with advanced disease on concomitant L-dopa (see CLINICAL PHARMACOLOGY, Clinical Trials ).|[PMDA] Drugs in new dosage forms and with a new dosage. These drugs are indicated for the treatment of Parkinson's disease. uuid:69afa592-50dd-47de-85f2-4ad86b5daca4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:53760 biolink:treats MONDO:0013600 PMID:41385096 "[{""id"":""uuid:6609bf0c-62e0-43d9-9f35-bdf815c4ee45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b6c95c98-a651-4290-b321-6896eb4cbb18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:8d9c8363-2301-45c9-96b4-762dbb41b7c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LUNESTA is indicated for the treatment of insomnia. In controlled outpatient and sleep laboratory studies, LUNESTA administered at bedtime decreased sleep latency and improved sleep maintenance. The clinical trials performed in support of efficacy were up to 6 months in duration. The final formal assessments of sleep latency and maintenance were performed at 4 weeks in the 6-week study (adults only), at the end of both 2-week studies (elderly only) and at the end of the 6-month study (adults only).|[PMDA] Drugs with a new active ingredient indicated for the treatment of insomnia. uuid:1c7a5ae9-5167-4d0f-9b69-7267eaf12784 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0007008 PMID:41385096 "[{""id"":""uuid:3711fabd-2e54-4d59-ae69-70d8a0d7797f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8d956a3f-8926-4fa5-8276-2cf8c112db31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisolone Oral Solution is indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice: synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. In addition to the above indications Prednisolone Oral Solution is indicated for systemic dermatomyositis (polymyositis). uuid:361ce278-c9d3-4009-9762-730754083d95 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27446 biolink:treats MONDO:0021680 PMID:41385096 "[{""id"":""uuid:3b2fa25d-68d7-482c-a325-adcf6e3c0f76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7fd70b50-3dfb-4b62-8555-df12b2146fdb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium tablets, penicillin V potassium for oral solution, and other antibacterial drugs, penicillin V potassium tablets and penicillin V potassium for oral solution should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V potassium tablets and penicillin V potassium for oral solution are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. Streptococcal infections (without bacteremia). Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. Pneumococcal infections. Mild to moderately severe infections of the respiratory tract. Staphylococcal infections —penicillin G-sensitive. Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent's gingivitis and pharyngitis)— Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involving the gum tissue. Medical conditions in which oral penicillin therapy is indicated as prophylaxis: For the prevention of recurrence following rheumatic fever and/or chorea: Prophylaxis with oral penicillin on a continuing basis has proven effective in preventing recurrence of these conditions. Although no controlled clinical efficacy studies have been conducted, penicillin V has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients who have congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract. 1 Oral penicillin should not be used in those patients at particularly high risk for endocarditis (e.g., those with prosthetic heart valves or surgically constructed systemic pulmonary shunts). Penicillin V should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower-intestinal-tract surgery, sigmoidoscopy, and childbirth. Since it may happen that alpha hemolytic streptococci relatively resistant to penicillin may be found when patients are receiving continuous oral penicillin for secondary prevention of rheumatic fever, prophylactic agents other than penicillin may be chosen for these patients and prescribed in addition to their continuous rheumatic fever prophylactic regimen. NOTE: When selecting antibiotics for the prevention of bacterial endocarditis, the physician or dentist should read the full joint statement of the American Heart Association and the American Dental Association. 1 uuid:a225be67-8adc-467a-9a3f-b565584532a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27446 biolink:treats MONDO:0005952 PMID:41385096 "[{""id"":""uuid:af9097a0-97b2-4116-9eb5-bea7f6a5c862"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:842ba0e6-57c0-4459-a92d-7a7cd74536e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium tablets, penicillin V potassium for oral solution, and other antibacterial drugs, penicillin V potassium tablets and penicillin V potassium for oral solution should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V potassium tablets and penicillin V potassium for oral solution are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. Streptococcal infections (without bacteremia). Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. Pneumococcal infections. Mild to moderately severe infections of the respiratory tract. Staphylococcal infections —penicillin G-sensitive. Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent's gingivitis and pharyngitis)— Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involving the gum tissue. Medical conditions in which oral penicillin therapy is indicated as prophylaxis: For the prevention of recurrence following rheumatic fever and/or chorea: Prophylaxis with oral penicillin on a continuing basis has proven effective in preventing recurrence of these conditions. Although no controlled clinical efficacy studies have been conducted, penicillin V has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients who have congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract. 1 Oral penicillin should not be used in those patients at particularly high risk for endocarditis (e.g., those with prosthetic heart valves or surgically constructed systemic pulmonary shunts). Penicillin V should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower-intestinal-tract surgery, sigmoidoscopy, and childbirth. Since it may happen that alpha hemolytic streptococci relatively resistant to penicillin may be found when patients are receiving continuous oral penicillin for secondary prevention of rheumatic fever, prophylactic agents other than penicillin may be chosen for these patients and prescribed in addition to their continuous rheumatic fever prophylactic regimen. NOTE: When selecting antibiotics for the prevention of bacterial endocarditis, the physician or dentist should read the full joint statement of the American Heart Association and the American Dental Association. 1 uuid:ef0ee5a1-1554-4717-a7e0-be7b44603043 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27446 biolink:treats MONDO:0001266 PMID:41385096 "[{""id"":""uuid:5ede8640-218b-4abf-84a4-1bd473ab9a2d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e0b52a85-df5b-4d3c-9542-2177eec0f366"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium tablets, penicillin V potassium for oral solution, and other antibacterial drugs, penicillin V potassium tablets and penicillin V potassium for oral solution should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V potassium tablets and penicillin V potassium for oral solution are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. Streptococcal infections (without bacteremia). Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. Pneumococcal infections. Mild to moderately severe infections of the respiratory tract. Staphylococcal infections —penicillin G-sensitive. Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent's gingivitis and pharyngitis)— Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involving the gum tissue. Medical conditions in which oral penicillin therapy is indicated as prophylaxis: For the prevention of recurrence following rheumatic fever and/or chorea: Prophylaxis with oral penicillin on a continuing basis has proven effective in preventing recurrence of these conditions. Although no controlled clinical efficacy studies have been conducted, penicillin V has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients who have congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract. 1 Oral penicillin should not be used in those patients at particularly high risk for endocarditis (e.g., those with prosthetic heart valves or surgically constructed systemic pulmonary shunts). Penicillin V should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower-intestinal-tract surgery, sigmoidoscopy, and childbirth. Since it may happen that alpha hemolytic streptococci relatively resistant to penicillin may be found when patients are receiving continuous oral penicillin for secondary prevention of rheumatic fever, prophylactic agents other than penicillin may be chosen for these patients and prescribed in addition to their continuous rheumatic fever prophylactic regimen. NOTE: When selecting antibiotics for the prevention of bacterial endocarditis, the physician or dentist should read the full joint statement of the American Heart Association and the American Dental Association. 1 uuid:8b754e87-5afe-453a-ac3d-1f1cb495b9b7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27446 biolink:treats MONDO:0005114 PMID:41385096 "[{""id"":""uuid:f48e55bc-cb41-441a-abbe-0899ff86a703"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:33fb8d62-2be8-44f1-9a8e-15413c98ac5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium tablets, penicillin V potassium for oral solution, and other antibacterial drugs, penicillin V potassium tablets and penicillin V potassium for oral solution should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V potassium tablets and penicillin V potassium for oral solution are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. Streptococcal infections (without bacteremia). Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. Pneumococcal infections. Mild to moderately severe infections of the respiratory tract. Staphylococcal infections —penicillin G-sensitive. Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent's gingivitis and pharyngitis)— Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involving the gum tissue. Medical conditions in which oral penicillin therapy is indicated as prophylaxis: For the prevention of recurrence following rheumatic fever and/or chorea: Prophylaxis with oral penicillin on a continuing basis has proven effective in preventing recurrence of these conditions. Although no controlled clinical efficacy studies have been conducted, penicillin V has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients who have congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract. 1 Oral penicillin should not be used in those patients at particularly high risk for endocarditis (e.g., those with prosthetic heart valves or surgically constructed systemic pulmonary shunts). Penicillin V should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower-intestinal-tract surgery, sigmoidoscopy, and childbirth. Since it may happen that alpha hemolytic streptococci relatively resistant to penicillin may be found when patients are receiving continuous oral penicillin for secondary prevention of rheumatic fever, prophylactic agents other than penicillin may be chosen for these patients and prescribed in addition to their continuous rheumatic fever prophylactic regimen. NOTE: When selecting antibiotics for the prevention of bacterial endocarditis, the physician or dentist should read the full joint statement of the American Heart Association and the American Dental Association. 1 uuid:48876995-f8c6-4ba4-b8cd-3ddb3367678d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27446 biolink:treats MONDO:0024313 PMID:41385096 "[{""id"":""uuid:8f25cf4a-02c3-42e0-b22b-1c98a74523b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5b563b26-e21f-48c2-88be-1c4be08a0c6d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium tablets, penicillin V potassium for oral solution, and other antibacterial drugs, penicillin V potassium tablets and penicillin V potassium for oral solution should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V potassium tablets and penicillin V potassium for oral solution are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. Streptococcal infections (without bacteremia). Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. Pneumococcal infections. Mild to moderately severe infections of the respiratory tract. Staphylococcal infections —penicillin G-sensitive. Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent's gingivitis and pharyngitis)— Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involving the gum tissue. Medical conditions in which oral penicillin therapy is indicated as prophylaxis: For the prevention of recurrence following rheumatic fever and/or chorea: Prophylaxis with oral penicillin on a continuing basis has proven effective in preventing recurrence of these conditions. Although no controlled clinical efficacy studies have been conducted, penicillin V has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients who have congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract. 1 Oral penicillin should not be used in those patients at particularly high risk for endocarditis (e.g., those with prosthetic heart valves or surgically constructed systemic pulmonary shunts). Penicillin V should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower-intestinal-tract surgery, sigmoidoscopy, and childbirth. Since it may happen that alpha hemolytic streptococci relatively resistant to penicillin may be found when patients are receiving continuous oral penicillin for secondary prevention of rheumatic fever, prophylactic agents other than penicillin may be chosen for these patients and prescribed in addition to their continuous rheumatic fever prophylactic regimen. NOTE: When selecting antibiotics for the prevention of bacterial endocarditis, the physician or dentist should read the full joint statement of the American Heart Association and the American Dental Association. 1 uuid:6ed92d8e-1127-4f4f-8f1c-c8a0c3ad0cbc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27446 biolink:treats MONDO:0006865 PMID:41385096 "[{""id"":""uuid:6e9b8ba2-afc5-4b54-9da8-0743e2bfcc27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b50c0b01-1b1f-46b7-b719-00f63d87cdc1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium tablets, penicillin V potassium for oral solution, and other antibacterial drugs, penicillin V potassium tablets and penicillin V potassium for oral solution should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V potassium tablets and penicillin V potassium for oral solution are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. Streptococcal infections (without bacteremia). Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. Pneumococcal infections. Mild to moderately severe infections of the respiratory tract. Staphylococcal infections —penicillin G-sensitive. Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent's gingivitis and pharyngitis)— Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involving the gum tissue. Medical conditions in which oral penicillin therapy is indicated as prophylaxis: For the prevention of recurrence following rheumatic fever and/or chorea: Prophylaxis with oral penicillin on a continuing basis has proven effective in preventing recurrence of these conditions. Although no controlled clinical efficacy studies have been conducted, penicillin V has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients who have congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract. 1 Oral penicillin should not be used in those patients at particularly high risk for endocarditis (e.g., those with prosthetic heart valves or surgically constructed systemic pulmonary shunts). Penicillin V should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower-intestinal-tract surgery, sigmoidoscopy, and childbirth. Since it may happen that alpha hemolytic streptococci relatively resistant to penicillin may be found when patients are receiving continuous oral penicillin for secondary prevention of rheumatic fever, prophylactic agents other than penicillin may be chosen for these patients and prescribed in addition to their continuous rheumatic fever prophylactic regimen. NOTE: When selecting antibiotics for the prevention of bacterial endocarditis, the physician or dentist should read the full joint statement of the American Heart Association and the American Dental Association. 1 uuid:ba747701-2b17-419a-ad8f-114b15a8e018 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27446 biolink:treats MONDO:0002258 PMID:41385096 "[{""id"":""uuid:a555c572-5774-4836-a8d5-c0faef1034e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7dfdd86b-e639-4063-9e8d-8f579a8ecc72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium tablets, penicillin V potassium for oral solution, and other antibacterial drugs, penicillin V potassium tablets and penicillin V potassium for oral solution should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V potassium tablets and penicillin V potassium for oral solution are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. Streptococcal infections (without bacteremia). Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. Pneumococcal infections. Mild to moderately severe infections of the respiratory tract. Staphylococcal infections —penicillin G-sensitive. Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent's gingivitis and pharyngitis)— Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involving the gum tissue. Medical conditions in which oral penicillin therapy is indicated as prophylaxis: For the prevention of recurrence following rheumatic fever and/or chorea: Prophylaxis with oral penicillin on a continuing basis has proven effective in preventing recurrence of these conditions. Although no controlled clinical efficacy studies have been conducted, penicillin V has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients who have congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract. 1 Oral penicillin should not be used in those patients at particularly high risk for endocarditis (e.g., those with prosthetic heart valves or surgically constructed systemic pulmonary shunts). Penicillin V should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower-intestinal-tract surgery, sigmoidoscopy, and childbirth. Since it may happen that alpha hemolytic streptococci relatively resistant to penicillin may be found when patients are receiving continuous oral penicillin for secondary prevention of rheumatic fever, prophylactic agents other than penicillin may be chosen for these patients and prescribed in addition to their continuous rheumatic fever prophylactic regimen. NOTE: When selecting antibiotics for the prevention of bacterial endocarditis, the physician or dentist should read the full joint statement of the American Heart Association and the American Dental Association. 1 uuid:426f080e-3852-4905-aaa7-0d843bd50aec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27446 biolink:treats MONDO:0017767 PMID:41385096 "[{""id"":""uuid:4bc86e12-93ad-44e9-a6ab-b1c1f818ed83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1fe1b693-43a6-44c7-afb9-26a51b251cb2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium tablets, penicillin V potassium for oral solution, and other antibacterial drugs, penicillin V potassium tablets and penicillin V potassium for oral solution should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V potassium tablets and penicillin V potassium for oral solution are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. Streptococcal infections (without bacteremia). Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. Pneumococcal infections. Mild to moderately severe infections of the respiratory tract. Staphylococcal infections —penicillin G-sensitive. Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent's gingivitis and pharyngitis)— Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involving the gum tissue. Medical conditions in which oral penicillin therapy is indicated as prophylaxis: For the prevention of recurrence following rheumatic fever and/or chorea: Prophylaxis with oral penicillin on a continuing basis has proven effective in preventing recurrence of these conditions. Although no controlled clinical efficacy studies have been conducted, penicillin V has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients who have congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract. 1 Oral penicillin should not be used in those patients at particularly high risk for endocarditis (e.g., those with prosthetic heart valves or surgically constructed systemic pulmonary shunts). Penicillin V should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower-intestinal-tract surgery, sigmoidoscopy, and childbirth. Since it may happen that alpha hemolytic streptococci relatively resistant to penicillin may be found when patients are receiving continuous oral penicillin for secondary prevention of rheumatic fever, prophylactic agents other than penicillin may be chosen for these patients and prescribed in addition to their continuous rheumatic fever prophylactic regimen. NOTE: When selecting antibiotics for the prevention of bacterial endocarditis, the physician or dentist should read the full joint statement of the American Heart Association and the American Dental Association. 1 uuid:3e565b40-b53f-4748-8c19-622224523381 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27446 biolink:treats MONDO:0001595 PMID:41385096 "[{""id"":""uuid:e56ab2d0-b232-4381-bd7e-4d71097a52a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4936b2dd-c4ba-45e2-8863-9aeab9fadb0c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium tablets, penicillin V potassium for oral solution, and other antibacterial drugs, penicillin V potassium tablets and penicillin V potassium for oral solution should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V potassium tablets and penicillin V potassium for oral solution are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. Streptococcal infections (without bacteremia). Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. Pneumococcal infections. Mild to moderately severe infections of the respiratory tract. Staphylococcal infections —penicillin G-sensitive. Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent's gingivitis and pharyngitis)— Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involving the gum tissue. Medical conditions in which oral penicillin therapy is indicated as prophylaxis: For the prevention of recurrence following rheumatic fever and/or chorea: Prophylaxis with oral penicillin on a continuing basis has proven effective in preventing recurrence of these conditions. Although no controlled clinical efficacy studies have been conducted, penicillin V has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients who have congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract. 1 Oral penicillin should not be used in those patients at particularly high risk for endocarditis (e.g., those with prosthetic heart valves or surgically constructed systemic pulmonary shunts). Penicillin V should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower-intestinal-tract surgery, sigmoidoscopy, and childbirth. Since it may happen that alpha hemolytic streptococci relatively resistant to penicillin may be found when patients are receiving continuous oral penicillin for secondary prevention of rheumatic fever, prophylactic agents other than penicillin may be chosen for these patients and prescribed in addition to their continuous rheumatic fever prophylactic regimen. NOTE: When selecting antibiotics for the prevention of bacterial endocarditis, the physician or dentist should read the full joint statement of the American Heart Association and the American Dental Association. 1 uuid:32fd5768-0e3e-4b70-b587-19138ca20e36 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27446 biolink:treats MONDO:0006669 PMID:41385096 "[{""id"":""uuid:89cb3e81-6925-4a7a-9913-c0bef726fd98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d46982bb-2b4c-45f4-a5e1-843d686a5334"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium tablets, penicillin V potassium for oral solution, and other antibacterial drugs, penicillin V potassium tablets and penicillin V potassium for oral solution should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V potassium tablets and penicillin V potassium for oral solution are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. Streptococcal infections (without bacteremia). Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. Pneumococcal infections. Mild to moderately severe infections of the respiratory tract. Staphylococcal infections —penicillin G-sensitive. Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent's gingivitis and pharyngitis)— Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involving the gum tissue. Medical conditions in which oral penicillin therapy is indicated as prophylaxis: For the prevention of recurrence following rheumatic fever and/or chorea: Prophylaxis with oral penicillin on a continuing basis has proven effective in preventing recurrence of these conditions. Although no controlled clinical efficacy studies have been conducted, penicillin V has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients who have congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract. 1 Oral penicillin should not be used in those patients at particularly high risk for endocarditis (e.g., those with prosthetic heart valves or surgically constructed systemic pulmonary shunts). Penicillin V should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower-intestinal-tract surgery, sigmoidoscopy, and childbirth. Since it may happen that alpha hemolytic streptococci relatively resistant to penicillin may be found when patients are receiving continuous oral penicillin for secondary prevention of rheumatic fever, prophylactic agents other than penicillin may be chosen for these patients and prescribed in addition to their continuous rheumatic fever prophylactic regimen. NOTE: When selecting antibiotics for the prevention of bacterial endocarditis, the physician or dentist should read the full joint statement of the American Heart Association and the American Dental Association. 1 uuid:e61bd84e-943f-486f-bfcf-1c241fdffd9c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27446 biolink:treats MONDO:0005453 PMID:41385096 "[{""id"":""uuid:1eaa279b-5d91-4a2c-b7a8-8676fe69f151"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bde66245-0eb1-4bcb-8835-b0161c81d51b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium tablets, penicillin V potassium for oral solution, and other antibacterial drugs, penicillin V potassium tablets and penicillin V potassium for oral solution should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V potassium tablets and penicillin V potassium for oral solution are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. Streptococcal infections (without bacteremia). Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. Pneumococcal infections. Mild to moderately severe infections of the respiratory tract. Staphylococcal infections —penicillin G-sensitive. Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent's gingivitis and pharyngitis)— Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involving the gum tissue. Medical conditions in which oral penicillin therapy is indicated as prophylaxis: For the prevention of recurrence following rheumatic fever and/or chorea: Prophylaxis with oral penicillin on a continuing basis has proven effective in preventing recurrence of these conditions. Although no controlled clinical efficacy studies have been conducted, penicillin V has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients who have congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract. 1 Oral penicillin should not be used in those patients at particularly high risk for endocarditis (e.g., those with prosthetic heart valves or surgically constructed systemic pulmonary shunts). Penicillin V should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower-intestinal-tract surgery, sigmoidoscopy, and childbirth. Since it may happen that alpha hemolytic streptococci relatively resistant to penicillin may be found when patients are receiving continuous oral penicillin for secondary prevention of rheumatic fever, prophylactic agents other than penicillin may be chosen for these patients and prescribed in addition to their continuous rheumatic fever prophylactic regimen. NOTE: When selecting antibiotics for the prevention of bacterial endocarditis, the physician or dentist should read the full joint statement of the American Heart Association and the American Dental Association. 1 uuid:ca232661-c1e0-4af8-9a45-43550fe68a24 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27446 biolink:treats MONDO:0006955 PMID:41385096 "[{""id"":""uuid:83a689b9-968d-4f70-997b-3f6116e0da42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4fe72e21-1360-45bc-a320-fdecfe4b2951"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium tablets, penicillin V potassium for oral solution, and other antibacterial drugs, penicillin V potassium tablets and penicillin V potassium for oral solution should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V potassium tablets and penicillin V potassium for oral solution are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. Streptococcal infections (without bacteremia). Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. Pneumococcal infections. Mild to moderately severe infections of the respiratory tract. Staphylococcal infections —penicillin G-sensitive. Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent's gingivitis and pharyngitis)— Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involving the gum tissue. Medical conditions in which oral penicillin therapy is indicated as prophylaxis: For the prevention of recurrence following rheumatic fever and/or chorea: Prophylaxis with oral penicillin on a continuing basis has proven effective in preventing recurrence of these conditions. Although no controlled clinical efficacy studies have been conducted, penicillin V has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients who have congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract. 1 Oral penicillin should not be used in those patients at particularly high risk for endocarditis (e.g., those with prosthetic heart valves or surgically constructed systemic pulmonary shunts). Penicillin V should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower-intestinal-tract surgery, sigmoidoscopy, and childbirth. Since it may happen that alpha hemolytic streptococci relatively resistant to penicillin may be found when patients are receiving continuous oral penicillin for secondary prevention of rheumatic fever, prophylactic agents other than penicillin may be chosen for these patients and prescribed in addition to their continuous rheumatic fever prophylactic regimen. NOTE: When selecting antibiotics for the prevention of bacterial endocarditis, the physician or dentist should read the full joint statement of the American Heart Association and the American Dental Association. 1 uuid:b47e24fb-efc6-4464-b67d-a10f085a500e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27446 biolink:treats MONDO:0002869 PMID:41385096 "[{""id"":""uuid:5b088def-8773-46d6-ab42-01bd641b6bd4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2694811a-8d47-4532-9438-d986784e85eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin V potassium tablets, penicillin V potassium for oral solution, and other antibacterial drugs, penicillin V potassium tablets and penicillin V potassium for oral solution should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V potassium tablets and penicillin V potassium for oral solution are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. Streptococcal infections (without bacteremia). Mild-to-moderate infections of the upper respiratory tract, scarlet fever, and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus), are resistant. Pneumococcal infections. Mild to moderately severe infections of the respiratory tract. Staphylococcal infections —penicillin G-sensitive. Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent's gingivitis and pharyngitis)— Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involving the gum tissue. Medical conditions in which oral penicillin therapy is indicated as prophylaxis: For the prevention of recurrence following rheumatic fever and/or chorea: Prophylaxis with oral penicillin on a continuing basis has proven effective in preventing recurrence of these conditions. Although no controlled clinical efficacy studies have been conducted, penicillin V has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients who have congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract. 1 Oral penicillin should not be used in those patients at particularly high risk for endocarditis (e.g., those with prosthetic heart valves or surgically constructed systemic pulmonary shunts). Penicillin V should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower-intestinal-tract surgery, sigmoidoscopy, and childbirth. Since it may happen that alpha hemolytic streptococci relatively resistant to penicillin may be found when patients are receiving continuous oral penicillin for secondary prevention of rheumatic fever, prophylactic agents other than penicillin may be chosen for these patients and prescribed in addition to their continuous rheumatic fever prophylactic regimen. NOTE: When selecting antibiotics for the prevention of bacterial endocarditis, the physician or dentist should read the full joint statement of the American Heart Association and the American Dental Association. 1 uuid:490f224c-3a21-46f6-8269-f1bf7ffa8fa5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:122707137 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:afaf36b6-7fce-4401-81bb-28d61d2626b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b8128708-c330-4cbb-992e-74315b3e729b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pentazocine hydrochloride and acetaminophen tablets are indicated for the relief of mild to moderate pain. uuid:d225c36a-e835-4fa3-8a02-45ce4ccc98ab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841899 biolink:treats UMLS:C0497209 PMID:41385096 "[{""id"":""uuid:fca26620-e3dd-4049-8b71-aa0a7858130e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a900f145-7f15-4ef8-8301-2cd3a415a6f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitis is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella/Enterobacter species, Neisseria species, Pseudomonas aeruginosa . This product does not provide adequate coverage against Serratia marcescens , and Streptococci, including Streptococcus pneumoniae . uuid:896a2dc5-6949-478d-99bb-235e382b2c27 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:54955 biolink:treats MONDO:0043885 PMID:41385096 "[{""id"":""uuid:07ed671a-e75a-4dac-a1cb-2139a2ea81e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b17ba3e0-3b05-43e5-8cdf-3e5a0dac2799"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by organisms susceptible to bacitracin zinc and polymyxin B sulfate. uuid:80617098-c530-4611-ac66-eb4bc9688ed3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:54955 biolink:treats MONDO:0023865 PMID:41385096 "[{""id"":""uuid:bd7e54bb-89c8-47a5-af49-a4bd9e617644"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0a1504cb-4279-4fa0-90d5-66b4acd4cdc1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by organisms susceptible to bacitracin zinc and polymyxin B sulfate. uuid:8e6d5f8a-4b36-4383-9243-14fee37e239c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:184381 biolink:treats MONDO:0043885 PMID:41385096 "[{""id"":""uuid:40fa07ee-2b88-4ef8-a70d-4151db7a8553"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:111c2e9d-8834-4a4b-97ef-35e5989402c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by Bacitracin susceptible organisms. CHEBI:28669 uuid:76a63e6f-f712-40c7-b8e1-b0d32ad0da31 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:184381 biolink:treats MONDO:0003799 PMID:41385096 "[{""id"":""uuid:f7d39a14-4370-4901-8a57-bd100f47c07f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7b4e04c5-ecbd-4b5f-bfaf-59ec0e4e0d74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by Bacitracin susceptible organisms. CHEBI:28669 uuid:2fa7ba49-3d4f-45b2-984f-f2b792d131fb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:184381 biolink:treats MONDO:0023865 PMID:41385096 "[{""id"":""uuid:1d7c4f90-8732-47b3-bc88-216bc059d947"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:629a7705-0e78-45a2-bff3-5db2cba549b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by Bacitracin susceptible organisms. CHEBI:28669 uuid:1d862a5c-7831-4edf-8cff-19ae678f001f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats UMLS:C0497209 PMID:41385096 "[{""id"":""uuid:f93f9202-ca60-4106-8cb1-44356bb08a18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7fa05206-8642-4a61-b53c-d06a73ca9352"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisolone Sodium Phosphate Ophthalmic Solution 1% or 1/8% is for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe, such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitis when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation, corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. Prednisolone Sodium Phosphate Ophthalmic Solution, 1%, is recommended for moderate to severe inflammations, particularly when unusually rapid control is desired. In stubborn cases of anterior segment eye disease, systemic adrenocortical hormone therapy may be required. When deeper ocular structures are involved, systemic therapy is necessary. uuid:70ee20d4-c1a0-4e9a-9855-ef712a633dfe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2950 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:3d59cefc-ded9-425e-b581-2fa8d7a34e6c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c2d11b12-bed1-45b3-9e3a-981152f0bcbd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Astelin ® Nasal Spray is indicated for the treatment of the symptoms of seasonal allergic rhinitis such as rhinorrhea, sneezing, and nasal pruritus in adults and children 5 years and older, and for the treatment of the symptoms of vasomotor rhinitis, such as rhinorrhea, nasal congestion and postnasal drip in adults and children 12 years and older. uuid:d8cbe87e-8d4e-4d3c-9f22-278fff92c61c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2950 biolink:treats MONDO:0006004 PMID:41385096 "[{""id"":""uuid:c476cf5e-6160-4a3a-8322-9c581964b129"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:33e3c152-8d41-48f0-9a39-d8675e8faf39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Astelin ® Nasal Spray is indicated for the treatment of the symptoms of seasonal allergic rhinitis such as rhinorrhea, sneezing, and nasal pruritus in adults and children 5 years and older, and for the treatment of the symptoms of vasomotor rhinitis, such as rhinorrhea, nasal congestion and postnasal drip in adults and children 12 years and older. uuid:c13ec849-ecc3-45ee-b6ae-49dd3b0eb70b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31932 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:4a380339-b330-4eaa-adce-fb8d421354e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c6cfc7a7-1093-46b6-a56b-bf35463b74c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Benicar is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents. uuid:209d3b47-cf5a-407b-83ca-4a13c4685619 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9435 biolink:treats MONDO:0013600 PMID:41385096 "[{""id"":""uuid:d085e491-c14d-4d68-af87-285f5591b217"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:57f1c4bf-29ee-4061-8ab4-faf46cd697ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Temazepam Capsules, USP are indicated for the short-term treatment of insomnia (generally 7 to 10 days). For patients with short-term insomnia, instructions in the prescription should indicate that Temazepam Capsules should be used for short periods of time (7 to 10 days). The clinical trials performed in support of efficacy were 2 weeks in duration with the final formal assessment of sleep latency performed at the end of treatment. uuid:20abc6a8-e642-4aea-9771-d7edadc9f459 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9435 biolink:treats UMLS:C0393759 PMID:41385096 "[{""id"":""uuid:029f2b37-b6c4-417c-bce0-622b37c8a3ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:07baef84-6c77-4184-a64e-109de9a4638f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Temazepam Capsules, USP are indicated for the short-term treatment of insomnia (generally 7 to 10 days). For patients with short-term insomnia, instructions in the prescription should indicate that Temazepam Capsules should be used for short periods of time (7 to 10 days). The clinical trials performed in support of efficacy were 2 weeks in duration with the final formal assessment of sleep latency performed at the end of treatment. uuid:e3c90956-9754-4375-9238-e6c3b5b18987 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49575 biolink:treats HP:0001257 PMID:41385096 "[{""id"":""uuid:2a0336e2-4a4c-4024-88f9-f38de98ddd19"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:119a99f9-0520-499c-a398-baf1ff1bbafe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diazepam Tablets USP are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. In acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. Diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma); spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia); athetosis; and stiff-man syndrome. Oral diazepam may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy. The effectiveness of diazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. uuid:5db069ce-bf9b-453d-8ea8-5ea98488969a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28864 biolink:treats MONDO:0043885 PMID:41385096 "[{""id"":""uuid:a3438244-2a6c-43ac-898a-b0342ccc5814"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:912c6ee5-4496-44cf-91b7-1fd4d3e167c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TOBREX (tobramycin ophthalmic ointment) 0.3 % is a topical antibiotic indicated in the treatment of external infections of the eye and its adnexa caused by susceptible bacteria. Appropriate monitoring of bacterial response to topical antibiotic therapy should accompany the use of TOBREX (tobramycin ophthalmic ointment) 0.3%. Clinical studies have shown tobramycin to be safe and effective for use in children. uuid:08c93707-d75f-4ba3-98cc-b12dbfbbf35f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63622 biolink:treats UMLS:C2919575 PMID:41385096 "[{""id"":""uuid:33513c40-693b-491a-a248-476105e41eca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:07c3b60f-4f2c-4343-bd6d-6eb94cb72752"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sotalol hydrochloride tablets USP are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgment of the physician are life-threatening. Because of the proarrhythmic effects of sotalol hydrochloride tablets (see WARNINGS ), including a 1.5% to 2% rate of torsade de pointes or new VT/VF in patients with either NSVT or supraventricular arrhythmias, its use in patients with less severe arrhythmias, even if the patients are symptomatic, is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of sotalol hydrochloride tablet USP treatment or increasing doses, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. The response to treatment should then be evaluated by a suitable method (e.g., PES or Holter monitoring) prior to continuing the patient on chronic therapy. Various approaches have been used to determine the response to antiarrhythmic therapy, including sotalol hydrochloride tablets USP. In the ESVEM Trial, response by Holter monitoring was tentatively defined as 100% suppression of ventricular tachycardia, 90% suppression of non-sustained VT, 80% suppression of paired VPCs and 75% suppression of total VPCs in patients who had at least 10 VPCs/hour at baseline; this tentative response was confirmed if VT lasting 5 or more beats was not observed during treadmill exercise testing using a standard Bruce protocol. The PES protocol utilized a maximum of three extrastimuli at three pacing cycle lengths and two right ventricular pacing sites. Response to PES was defined as prevention of induction of the following: 1) monomorphic VT lasting over 15 seconds; 2) non-sustained polymorphic VT containing more than 15 beats of monomorphic VT in patients with a history of monomorphic VT; 3) polymorphic VT or VF greater than 15 beats in patients with VF or a history of aborted sudden death without monomorphic VT; and 4) two episodes of polymorphic VT or VF of greater than 15 beats in a patient presenting with monomorphic VT. Sustained VT or NSVT producing hypotension during the final treadmill test was considered a drug failure. In a multicenter open-label long-term study of sotalol hydrochloride tablets USP in patients with life-threatening ventricular arrhythmias which had proven refractory to other antiarrhythmic medications, response by Holter monitoring was defined as in ESVEM. Response by PES was defined as non-inducibility of sustained VT by at least double extrastimuli delivered at a pacing cycle length of 400 msec. Overall survival and arrhythmia recurrence rates in this study were similar to those seen in ESVEM, although there was no comparative group to allow a definitive assessment of outcome. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. Sotalol is also indicated for the maintenance of normal sinus rhythm [delay in time to recurrence of atrial fibrillation/atrial flutter (AFIB/AFL)] in patients with symptomatic AFIB/AFL who are currently in sinus rhythm and is marketed under the brand name BETAPACE AF TM . Sotalol hydrochloride tablets USP are not approved for the AFIB/AFL indication and should not be substituted for BETAPACE AF TM because only BETAPACE AF TM is distributed with a patient package insert that is appropriate for patients with AFIB/AFL. uuid:406480b0-dd92-4554-9b2d-dc4a1fe95fa1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63622 biolink:treats HP:0005115 PMID:41385096 "[{""id"":""uuid:0ac63859-54b9-4102-9958-6c6debcd742c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2d1d329e-7381-4f48-acc9-6bfbc7c2f47b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sotalol hydrochloride tablets USP are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgment of the physician are life-threatening. Because of the proarrhythmic effects of sotalol hydrochloride tablets (see WARNINGS ), including a 1.5% to 2% rate of torsade de pointes or new VT/VF in patients with either NSVT or supraventricular arrhythmias, its use in patients with less severe arrhythmias, even if the patients are symptomatic, is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of sotalol hydrochloride tablet USP treatment or increasing doses, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. The response to treatment should then be evaluated by a suitable method (e.g., PES or Holter monitoring) prior to continuing the patient on chronic therapy. Various approaches have been used to determine the response to antiarrhythmic therapy, including sotalol hydrochloride tablets USP. In the ESVEM Trial, response by Holter monitoring was tentatively defined as 100% suppression of ventricular tachycardia, 90% suppression of non-sustained VT, 80% suppression of paired VPCs and 75% suppression of total VPCs in patients who had at least 10 VPCs/hour at baseline; this tentative response was confirmed if VT lasting 5 or more beats was not observed during treadmill exercise testing using a standard Bruce protocol. The PES protocol utilized a maximum of three extrastimuli at three pacing cycle lengths and two right ventricular pacing sites. Response to PES was defined as prevention of induction of the following: 1) monomorphic VT lasting over 15 seconds; 2) non-sustained polymorphic VT containing more than 15 beats of monomorphic VT in patients with a history of monomorphic VT; 3) polymorphic VT or VF greater than 15 beats in patients with VF or a history of aborted sudden death without monomorphic VT; and 4) two episodes of polymorphic VT or VF of greater than 15 beats in a patient presenting with monomorphic VT. Sustained VT or NSVT producing hypotension during the final treadmill test was considered a drug failure. In a multicenter open-label long-term study of sotalol hydrochloride tablets USP in patients with life-threatening ventricular arrhythmias which had proven refractory to other antiarrhythmic medications, response by Holter monitoring was defined as in ESVEM. Response by PES was defined as non-inducibility of sustained VT by at least double extrastimuli delivered at a pacing cycle length of 400 msec. Overall survival and arrhythmia recurrence rates in this study were similar to those seen in ESVEM, although there was no comparative group to allow a definitive assessment of outcome. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. Sotalol is also indicated for the maintenance of normal sinus rhythm [delay in time to recurrence of atrial fibrillation/atrial flutter (AFIB/AFL)] in patients with symptomatic AFIB/AFL who are currently in sinus rhythm and is marketed under the brand name BETAPACE AF TM . Sotalol hydrochloride tablets USP are not approved for the AFIB/AFL indication and should not be substituted for BETAPACE AF TM because only BETAPACE AF TM is distributed with a patient package insert that is appropriate for patients with AFIB/AFL. uuid:44bdc591-609f-41a9-989a-c3636d22a600 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63622 biolink:treats HP:0006682 PMID:41385096 "[{""id"":""uuid:bdece8dd-5bff-4935-adbc-2752c35a14a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bc8de319-2083-4e60-877d-696090513000"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sotalol hydrochloride tablets USP are indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgment of the physician are life-threatening. Because of the proarrhythmic effects of sotalol hydrochloride tablets (see WARNINGS ), including a 1.5% to 2% rate of torsade de pointes or new VT/VF in patients with either NSVT or supraventricular arrhythmias, its use in patients with less severe arrhythmias, even if the patients are symptomatic, is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of sotalol hydrochloride tablet USP treatment or increasing doses, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. The response to treatment should then be evaluated by a suitable method (e.g., PES or Holter monitoring) prior to continuing the patient on chronic therapy. Various approaches have been used to determine the response to antiarrhythmic therapy, including sotalol hydrochloride tablets USP. In the ESVEM Trial, response by Holter monitoring was tentatively defined as 100% suppression of ventricular tachycardia, 90% suppression of non-sustained VT, 80% suppression of paired VPCs and 75% suppression of total VPCs in patients who had at least 10 VPCs/hour at baseline; this tentative response was confirmed if VT lasting 5 or more beats was not observed during treadmill exercise testing using a standard Bruce protocol. The PES protocol utilized a maximum of three extrastimuli at three pacing cycle lengths and two right ventricular pacing sites. Response to PES was defined as prevention of induction of the following: 1) monomorphic VT lasting over 15 seconds; 2) non-sustained polymorphic VT containing more than 15 beats of monomorphic VT in patients with a history of monomorphic VT; 3) polymorphic VT or VF greater than 15 beats in patients with VF or a history of aborted sudden death without monomorphic VT; and 4) two episodes of polymorphic VT or VF of greater than 15 beats in a patient presenting with monomorphic VT. Sustained VT or NSVT producing hypotension during the final treadmill test was considered a drug failure. In a multicenter open-label long-term study of sotalol hydrochloride tablets USP in patients with life-threatening ventricular arrhythmias which had proven refractory to other antiarrhythmic medications, response by Holter monitoring was defined as in ESVEM. Response by PES was defined as non-inducibility of sustained VT by at least double extrastimuli delivered at a pacing cycle length of 400 msec. Overall survival and arrhythmia recurrence rates in this study were similar to those seen in ESVEM, although there was no comparative group to allow a definitive assessment of outcome. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. Sotalol is also indicated for the maintenance of normal sinus rhythm [delay in time to recurrence of atrial fibrillation/atrial flutter (AFIB/AFL)] in patients with symptomatic AFIB/AFL who are currently in sinus rhythm and is marketed under the brand name BETAPACE AF TM . Sotalol hydrochloride tablets USP are not approved for the AFIB/AFL indication and should not be substituted for BETAPACE AF TM because only BETAPACE AF TM is distributed with a patient package insert that is appropriate for patients with AFIB/AFL. uuid:1c580453-dfe8-4eab-b7f4-82e6aec2dcda biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:476348 biolink:treats HP:0003124 PMID:41385096 "[{""id"":""uuid:f6d97428-29c6-463e-9b44-c000aa0e2fb6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4cbe57a2-5a6e-428c-b08b-4b7686be52c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. uuid:0922f10c-de40-476a-bd1d-bdb0e86c8d80 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:476348 biolink:treats MONDO:0005311 PMID:41385096 "[{""id"":""uuid:1f8f966b-acaf-4724-9cd4-90d4771bb923"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:08ab8414-533a-4cbe-be6d-be91331e0711"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. uuid:7a0e9605-bcb6-44a3-bb59-05b306c62475 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9241 biolink:treats MONDO:0001422 PMID:41385096 "[{""id"":""uuid:cf44ec1b-1e8e-4be4-9882-6f7b2614ba3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:eb0469c2-f171-4c3e-b3fc-80742e7ac761"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c49b20ef-fb1d-489d-adf4-0e20a98f6dc4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/qaialdo""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone is indicated in the management of: Primary hyperaldosteronism for: Establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. Short-term preoperative treatment of patients with primary hyperaldosteronism. Long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. Long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). Edematous conditions for patients with: Congestive heart failure: For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. Spironolactone is also indicated for patients with congestive heart failure taking digitalis when other therapies are considered inappropriate. Cirrhosis of the liver accompanied by edema and/or ascites: Aldosterone levels may be exceptionally high in this condition. Spironolactone is indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. The nephrotic syndrome: For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response.|[EMA] In the management of refractory oedema associated with congestive cardiac failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, diagnosis and treatment of primary aldosteronism, essential hypertension.Neonates, children and adolescents should only be treated under guidance of a paediatric specialist (see sections 5.1 and 5.2). uuid:379f4166-5cfa-4937-b5b9-1ac41eae2e07 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9241 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:43fa75ee-3a0e-4172-b099-e337ab6cc4ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ae4d5b96-c2e2-4504-8ce9-8d1ca5a1b028"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:8d686f95-7b56-48f8-8916-9a8698495227"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/qaialdo""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone is indicated in the management of: Primary hyperaldosteronism for: Establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. Short-term preoperative treatment of patients with primary hyperaldosteronism. Long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. Long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). Edematous conditions for patients with: Congestive heart failure: For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. Spironolactone is also indicated for patients with congestive heart failure taking digitalis when other therapies are considered inappropriate. Cirrhosis of the liver accompanied by edema and/or ascites: Aldosterone levels may be exceptionally high in this condition. Spironolactone is indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. The nephrotic syndrome: For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response.|[EMA] In the management of refractory oedema associated with congestive cardiac failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, diagnosis and treatment of primary aldosteronism, essential hypertension.Neonates, children and adolescents should only be treated under guidance of a paediatric specialist (see sections 5.1 and 5.2). uuid:ff09549a-10a9-4795-b6c7-eca610bb3535 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9241 biolink:treats MONDO:0005155 PMID:41385096 "[{""id"":""uuid:cf0d4ba6-68b0-4de8-8b03-f8dcd02559ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e363b2cc-ee20-4dda-996a-7c59e7181d90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f3ee3d29-39b4-472d-84b4-1134ae1787da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/qaialdo""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone is indicated in the management of: Primary hyperaldosteronism for: Establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. Short-term preoperative treatment of patients with primary hyperaldosteronism. Long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. Long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). Edematous conditions for patients with: Congestive heart failure: For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. Spironolactone is also indicated for patients with congestive heart failure taking digitalis when other therapies are considered inappropriate. Cirrhosis of the liver accompanied by edema and/or ascites: Aldosterone levels may be exceptionally high in this condition. Spironolactone is indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. The nephrotic syndrome: For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response.|[EMA] In the management of refractory oedema associated with congestive cardiac failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, diagnosis and treatment of primary aldosteronism, essential hypertension.Neonates, children and adolescents should only be treated under guidance of a paediatric specialist (see sections 5.1 and 5.2). uuid:40a61667-54fa-4652-befb-986635ed90ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9241 biolink:treats MONDO:0005377 PMID:41385096 "[{""id"":""uuid:70018293-6fc1-4a16-84a5-6081e6717e56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e7936f77-df44-4b7b-95c2-33b5249c6b7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:921b961e-dcb1-40ae-ad29-abc734543d1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/qaialdo""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone is indicated in the management of: Primary hyperaldosteronism for: Establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. Short-term preoperative treatment of patients with primary hyperaldosteronism. Long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. Long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). Edematous conditions for patients with: Congestive heart failure: For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. Spironolactone is also indicated for patients with congestive heart failure taking digitalis when other therapies are considered inappropriate. Cirrhosis of the liver accompanied by edema and/or ascites: Aldosterone levels may be exceptionally high in this condition. Spironolactone is indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. The nephrotic syndrome: For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response.|[EMA] In the management of refractory oedema associated with congestive cardiac failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, diagnosis and treatment of primary aldosteronism, essential hypertension.Neonates, children and adolescents should only be treated under guidance of a paediatric specialist (see sections 5.1 and 5.2). uuid:231bf446-8c3f-428b-a8cf-c37127b645d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77733 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:8b929f9e-d690-4d3e-b376-06200bb3a495"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:638f395f-37e3-4c57-9ff9-2610301e5513"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Verapamil Hydrochloride Tablets are indicated for the treatment of the following: Angina 1. Angina at rest including: – Vasospastic (Prinzmetal’s variant) angina – Unstable (crescendo, pre-infarction) angina 2. Chronic stable angina (classic effort-associated angina) Arrhythmias 1. In association with digitalis for the control of ventricular rate at rest and during stress in patients with chronic atrial flutter and/or atrial fibrillation (see WARNINGS; Accessory Bypass Tract) 2. Prophylaxis of repetitive paroxysmal supraventricular tachycardia Essential Hypertension uuid:15718fcc-b94c-4a30-8425-a1c2dae34303 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77733 biolink:treats MONDO:0006021 PMID:41385096 "[{""id"":""uuid:c4cb9c1c-d98c-4339-8156-a2ffea9d94fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:08ab1a77-2b27-4841-8d9f-7deac0a672a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Verapamil Hydrochloride Tablets are indicated for the treatment of the following: Angina 1. Angina at rest including: – Vasospastic (Prinzmetal’s variant) angina – Unstable (crescendo, pre-infarction) angina 2. Chronic stable angina (classic effort-associated angina) Arrhythmias 1. In association with digitalis for the control of ventricular rate at rest and during stress in patients with chronic atrial flutter and/or atrial fibrillation (see WARNINGS; Accessory Bypass Tract) 2. Prophylaxis of repetitive paroxysmal supraventricular tachycardia Essential Hypertension uuid:c517a2cd-0fa2-45ac-8053-2a61852843d1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77733 biolink:treats MONDO:0006805 PMID:41385096 "[{""id"":""uuid:e59791a9-2099-4126-b547-3c2ffb3930b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a09865db-ea05-4aa9-a976-0f46b35fc25d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Verapamil Hydrochloride Tablets are indicated for the treatment of the following: Angina 1. Angina at rest including: – Vasospastic (Prinzmetal’s variant) angina – Unstable (crescendo, pre-infarction) angina 2. Chronic stable angina (classic effort-associated angina) Arrhythmias 1. In association with digitalis for the control of ventricular rate at rest and during stress in patients with chronic atrial flutter and/or atrial fibrillation (see WARNINGS; Accessory Bypass Tract) 2. Prophylaxis of repetitive paroxysmal supraventricular tachycardia Essential Hypertension uuid:03fd09d3-2c27-4348-af2f-990e14943ef3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15940 biolink:treats MONDO:0005311 PMID:41385096 "[{""id"":""uuid:a6ca877e-3af2-47e5-a7b3-988dfaac593b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:68d87a10-9bbb-4e6c-b6c9-5f341c5ebcc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. Niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. NIASPAN is indicated to reduce elevated TC, LDL-C, Apo B and TG levels, and to increase HDL-C in patients with primary hyperlipidemia and mixed dyslipidemia. NIASPAN in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with NIASPAN, simvastatin, or lovastatin monotherapy is considered inadequate. In patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. In patients with a history of coronary artery disease (CAD) and hyperlipidemia, niacin, in combination with a bile acid binding resin, is indicated to slow progression or promote regression of atherosclerotic disease. NIASPAN in combination with a bile acid binding resin is indicated to reduce elevated TC and LDL-C levels in adult patients with primary hyperlipidemia. Niacin is also indicated as adjunctive therapy for treatment of adult patients with severe hypertriglyceridemia who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Limitations of Use No incremental benefit of NIASPAN coadministered with simvastatin or lovastatin on cardiovascular morbidity and mortality over and above that demonstrated for niacin, simvastatin, or lovastatin monotherapy has been established. uuid:4169d31a-484a-45a7-a01c-28827bfb06ea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15940 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:7156da10-48a8-4c4f-97a9-e19d629a150f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d68c1cb4-34a5-426d-b610-82e54d207cd7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. Niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. NIASPAN is indicated to reduce elevated TC, LDL-C, Apo B and TG levels, and to increase HDL-C in patients with primary hyperlipidemia and mixed dyslipidemia. NIASPAN in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with NIASPAN, simvastatin, or lovastatin monotherapy is considered inadequate. In patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. In patients with a history of coronary artery disease (CAD) and hyperlipidemia, niacin, in combination with a bile acid binding resin, is indicated to slow progression or promote regression of atherosclerotic disease. NIASPAN in combination with a bile acid binding resin is indicated to reduce elevated TC and LDL-C levels in adult patients with primary hyperlipidemia. Niacin is also indicated as adjunctive therapy for treatment of adult patients with severe hypertriglyceridemia who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Limitations of Use No incremental benefit of NIASPAN coadministered with simvastatin or lovastatin on cardiovascular morbidity and mortality over and above that demonstrated for niacin, simvastatin, or lovastatin monotherapy has been established. uuid:d48449f7-f329-4edf-ae7d-e0ef6d616faa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15940 biolink:treats HP:0003119 PMID:41385096 "[{""id"":""uuid:f02b1cc3-e73c-4ee5-9f63-7e564d17be44"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e1290d67-a0ec-46d3-ba2d-ea397f6dbf77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. Niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. NIASPAN is indicated to reduce elevated TC, LDL-C, Apo B and TG levels, and to increase HDL-C in patients with primary hyperlipidemia and mixed dyslipidemia. NIASPAN in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with NIASPAN, simvastatin, or lovastatin monotherapy is considered inadequate. In patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. In patients with a history of coronary artery disease (CAD) and hyperlipidemia, niacin, in combination with a bile acid binding resin, is indicated to slow progression or promote regression of atherosclerotic disease. NIASPAN in combination with a bile acid binding resin is indicated to reduce elevated TC and LDL-C levels in adult patients with primary hyperlipidemia. Niacin is also indicated as adjunctive therapy for treatment of adult patients with severe hypertriglyceridemia who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Limitations of Use No incremental benefit of NIASPAN coadministered with simvastatin or lovastatin on cardiovascular morbidity and mortality over and above that demonstrated for niacin, simvastatin, or lovastatin monotherapy has been established. uuid:53220d8c-8626-4af4-ac5a-5fab62c566c2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15940 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:a20930e9-9418-468c-8878-701a8b87cca7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:df26474d-eda2-43ee-ab42-9a4411e6aa8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. Niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. NIASPAN is indicated to reduce elevated TC, LDL-C, Apo B and TG levels, and to increase HDL-C in patients with primary hyperlipidemia and mixed dyslipidemia. NIASPAN in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with NIASPAN, simvastatin, or lovastatin monotherapy is considered inadequate. In patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. In patients with a history of coronary artery disease (CAD) and hyperlipidemia, niacin, in combination with a bile acid binding resin, is indicated to slow progression or promote regression of atherosclerotic disease. NIASPAN in combination with a bile acid binding resin is indicated to reduce elevated TC and LDL-C levels in adult patients with primary hyperlipidemia. Niacin is also indicated as adjunctive therapy for treatment of adult patients with severe hypertriglyceridemia who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Limitations of Use No incremental benefit of NIASPAN coadministered with simvastatin or lovastatin on cardiovascular morbidity and mortality over and above that demonstrated for niacin, simvastatin, or lovastatin monotherapy has been established. uuid:de2b3d61-6c44-4b39-a817-e63a817e8eb3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15940 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:835c41e4-64b6-4ad2-9648-14a95ca28293"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:adb46591-0ca5-451e-a199-9723207388b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. Niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. NIASPAN is indicated to reduce elevated TC, LDL-C, Apo B and TG levels, and to increase HDL-C in patients with primary hyperlipidemia and mixed dyslipidemia. NIASPAN in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with NIASPAN, simvastatin, or lovastatin monotherapy is considered inadequate. In patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. In patients with a history of coronary artery disease (CAD) and hyperlipidemia, niacin, in combination with a bile acid binding resin, is indicated to slow progression or promote regression of atherosclerotic disease. NIASPAN in combination with a bile acid binding resin is indicated to reduce elevated TC and LDL-C levels in adult patients with primary hyperlipidemia. Niacin is also indicated as adjunctive therapy for treatment of adult patients with severe hypertriglyceridemia who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Limitations of Use No incremental benefit of NIASPAN coadministered with simvastatin or lovastatin on cardiovascular morbidity and mortality over and above that demonstrated for niacin, simvastatin, or lovastatin monotherapy has been established. uuid:ca495595-c0cf-4eeb-a8b4-c388939e418f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15940 biolink:treats MONDO:0005347 PMID:41385096 "[{""id"":""uuid:34593a81-6d65-48e7-b490-53342c0bfb33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e1edf2d0-43b8-4f75-a15f-dd69bdeb55b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. Niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. NIASPAN is indicated to reduce elevated TC, LDL-C, Apo B and TG levels, and to increase HDL-C in patients with primary hyperlipidemia and mixed dyslipidemia. NIASPAN in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with NIASPAN, simvastatin, or lovastatin monotherapy is considered inadequate. In patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. In patients with a history of coronary artery disease (CAD) and hyperlipidemia, niacin, in combination with a bile acid binding resin, is indicated to slow progression or promote regression of atherosclerotic disease. NIASPAN in combination with a bile acid binding resin is indicated to reduce elevated TC and LDL-C levels in adult patients with primary hyperlipidemia. Niacin is also indicated as adjunctive therapy for treatment of adult patients with severe hypertriglyceridemia who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Limitations of Use No incremental benefit of NIASPAN coadministered with simvastatin or lovastatin on cardiovascular morbidity and mortality over and above that demonstrated for niacin, simvastatin, or lovastatin monotherapy has been established. uuid:eda5186b-9d4f-428a-99f1-239cefae2735 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1155751 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:0ec1fdf4-dfb2-47ce-abe4-e90880ed7b4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:146fc634-77ee-4641-a6d6-9e0267edd1fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Captopril and Hydrochlorothiazide tablets are indicated for the treatment of hypertension. The blood pressure lowering effects of captopril and thiazides are approximately additive. This fixed combination drug may be used as initial therapy or substituted for previously titrated doses of the individual components. When captopril and hydrochlorothiazide are given together it may not be necessary to administer captopril in divided doses to attain blood pressure control at trough (before the next dose). Also, with such a combination, a daily dose of 15 mg of hydrochlorothiazide may be adequate. Treatment may, therefore, be initiated with Captopril and Hydrochlorothiazide tablets 25 mg/15 mg once daily. Subsequent titration should be with additional doses of the components (captopril, hydrochlorothiazide) as single agents or as Captopril and Hydrochlorothiazide tablets 50 mg/15 mg, 25 mg/25 mg, or 50 mg/25 mg (see DOSAGE AND ADMINISTRATION ). In using Captopril and Hydrochlorothiazide, consideration should be given to the risk of neutropenia/agranulocytosis (see WARNINGS ). Captopril and Hydrochlorothiazide may be used for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, Captopril and Hydrochlorothiazide should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to other drug combinations. ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see WARNINGS: Captopril: Head and Neck Angioedema and Intestinal Angioedema ). uuid:2213bd2c-8af7-48a6-acce-dc4595398a2c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3478 biolink:treats MONDO:0005441 PMID:41385096 "[{""id"":""uuid:f4cbecb5-3cfe-4fa5-abc1-4ba28d42d85f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:118213bf-1acb-42da-a9b0-61ee243c0a9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Otitis media caused by Streptococcus pneumoniae, Haemophilus influenzae , staphylococci, and Streptococcus pyogenes Note: β-lactamase-negative, ampicillin-resistant (BLNAR) strains of Haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some BLNAR strains. Lower respiratory tract infections , including pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae , and Streptococcus. Note: β-lactamase-negative, ampicillin-resistant (BLNAR) strains of Haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some BLNAR strains. Pharyngitis and Tonsillitis , caused by Streptococcus pyogenes Note : Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefaclor is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefaclor in the subsequent prevention of rheumatic fever are not available at present. Urinary tract infections , including pyelonephritis and cystitis, caused by Escherichia coli, Proteus mirabilis, Klebsiella spp., and coagulase-negative staphylococci Skin and skin structure infections caused by Staphylococcus aureus and Streptococcus pyogenes Appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefaclor. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefaclor Capsules and Cefaclor for Oral Suspension and other antibacterial drugs, Cefaclor Capsules and Cefaclor for Oral Suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:3b3fe074-a053-4ff3-b6db-6dec232ee29a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3478 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:7e8dd954-79ca-4004-ae58-cc3437495ea4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:09ab2b7d-01af-48b1-8acc-dffc641a227c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Otitis media caused by Streptococcus pneumoniae, Haemophilus influenzae , staphylococci, and Streptococcus pyogenes Note: β-lactamase-negative, ampicillin-resistant (BLNAR) strains of Haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some BLNAR strains. Lower respiratory tract infections , including pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae , and Streptococcus. Note: β-lactamase-negative, ampicillin-resistant (BLNAR) strains of Haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some BLNAR strains. Pharyngitis and Tonsillitis , caused by Streptococcus pyogenes Note : Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefaclor is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefaclor in the subsequent prevention of rheumatic fever are not available at present. Urinary tract infections , including pyelonephritis and cystitis, caused by Escherichia coli, Proteus mirabilis, Klebsiella spp., and coagulase-negative staphylococci Skin and skin structure infections caused by Staphylococcus aureus and Streptococcus pyogenes Appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefaclor. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefaclor Capsules and Cefaclor for Oral Suspension and other antibacterial drugs, Cefaclor Capsules and Cefaclor for Oral Suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:88a00e3c-6e61-4c71-bf13-e567e1b4c024 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3478 biolink:treats MONDO:0002258 PMID:41385096 "[{""id"":""uuid:7cd4754b-52c5-4be6-a38e-93500b6ff34e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b3949066-b1e0-4e27-994f-0ec7e2f3818b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Otitis media caused by Streptococcus pneumoniae, Haemophilus influenzae , staphylococci, and Streptococcus pyogenes Note: β-lactamase-negative, ampicillin-resistant (BLNAR) strains of Haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some BLNAR strains. Lower respiratory tract infections , including pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae , and Streptococcus. Note: β-lactamase-negative, ampicillin-resistant (BLNAR) strains of Haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some BLNAR strains. Pharyngitis and Tonsillitis , caused by Streptococcus pyogenes Note : Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefaclor is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefaclor in the subsequent prevention of rheumatic fever are not available at present. Urinary tract infections , including pyelonephritis and cystitis, caused by Escherichia coli, Proteus mirabilis, Klebsiella spp., and coagulase-negative staphylococci Skin and skin structure infections caused by Staphylococcus aureus and Streptococcus pyogenes Appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefaclor. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefaclor Capsules and Cefaclor for Oral Suspension and other antibacterial drugs, Cefaclor Capsules and Cefaclor for Oral Suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:962f0cbd-5b34-423a-ab0e-1318a9027b25 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3478 biolink:treats MONDO:0001039 PMID:41385096 "[{""id"":""uuid:c9278ce0-da18-432f-a5fe-cf220a57e051"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:83e0bad6-747c-49c5-96d9-e2b88fd28d22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Otitis media caused by Streptococcus pneumoniae, Haemophilus influenzae , staphylococci, and Streptococcus pyogenes Note: β-lactamase-negative, ampicillin-resistant (BLNAR) strains of Haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some BLNAR strains. Lower respiratory tract infections , including pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae , and Streptococcus. Note: β-lactamase-negative, ampicillin-resistant (BLNAR) strains of Haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some BLNAR strains. Pharyngitis and Tonsillitis , caused by Streptococcus pyogenes Note : Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefaclor is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefaclor in the subsequent prevention of rheumatic fever are not available at present. Urinary tract infections , including pyelonephritis and cystitis, caused by Escherichia coli, Proteus mirabilis, Klebsiella spp., and coagulase-negative staphylococci Skin and skin structure infections caused by Staphylococcus aureus and Streptococcus pyogenes Appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefaclor. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefaclor Capsules and Cefaclor for Oral Suspension and other antibacterial drugs, Cefaclor Capsules and Cefaclor for Oral Suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:c77f1ae6-e7bd-47ab-85d5-4bfe13824538 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3478 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:bbbfd21e-e0ce-4ef1-b985-d22970579fc8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8e8cf2fe-f32b-4dd5-8102-344b3601ecac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Otitis media caused by Streptococcus pneumoniae, Haemophilus influenzae , staphylococci, and Streptococcus pyogenes Note: β-lactamase-negative, ampicillin-resistant (BLNAR) strains of Haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some BLNAR strains. Lower respiratory tract infections , including pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae , and Streptococcus. Note: β-lactamase-negative, ampicillin-resistant (BLNAR) strains of Haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some BLNAR strains. Pharyngitis and Tonsillitis , caused by Streptococcus pyogenes Note : Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefaclor is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefaclor in the subsequent prevention of rheumatic fever are not available at present. Urinary tract infections , including pyelonephritis and cystitis, caused by Escherichia coli, Proteus mirabilis, Klebsiella spp., and coagulase-negative staphylococci Skin and skin structure infections caused by Staphylococcus aureus and Streptococcus pyogenes Appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefaclor. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefaclor Capsules and Cefaclor for Oral Suspension and other antibacterial drugs, Cefaclor Capsules and Cefaclor for Oral Suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:531acc4c-72c2-4849-8282-f06302f65a9d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3478 biolink:treats MONDO:0006939 PMID:41385096 "[{""id"":""uuid:dd5fde3b-98a3-4b96-8cf2-7b7e793c8f12"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:15264f9c-6022-426c-8b84-a46771ebe0ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Otitis media caused by Streptococcus pneumoniae, Haemophilus influenzae , staphylococci, and Streptococcus pyogenes Note: β-lactamase-negative, ampicillin-resistant (BLNAR) strains of Haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some BLNAR strains. Lower respiratory tract infections , including pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae , and Streptococcus. Note: β-lactamase-negative, ampicillin-resistant (BLNAR) strains of Haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some BLNAR strains. Pharyngitis and Tonsillitis , caused by Streptococcus pyogenes Note : Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefaclor is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefaclor in the subsequent prevention of rheumatic fever are not available at present. Urinary tract infections , including pyelonephritis and cystitis, caused by Escherichia coli, Proteus mirabilis, Klebsiella spp., and coagulase-negative staphylococci Skin and skin structure infections caused by Staphylococcus aureus and Streptococcus pyogenes Appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefaclor. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefaclor Capsules and Cefaclor for Oral Suspension and other antibacterial drugs, Cefaclor Capsules and Cefaclor for Oral Suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:bfe514f1-4a17-4212-9923-ced397b9b23a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3478 biolink:treats MONDO:0006032 PMID:41385096 "[{""id"":""uuid:e0944101-df7e-4a90-bcf5-25ce0778ca4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:64e404bc-5c27-41bc-8915-e8c750f3624c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Otitis media caused by Streptococcus pneumoniae, Haemophilus influenzae , staphylococci, and Streptococcus pyogenes Note: β-lactamase-negative, ampicillin-resistant (BLNAR) strains of Haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some BLNAR strains. Lower respiratory tract infections , including pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae , and Streptococcus. Note: β-lactamase-negative, ampicillin-resistant (BLNAR) strains of Haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some BLNAR strains. Pharyngitis and Tonsillitis , caused by Streptococcus pyogenes Note : Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefaclor is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefaclor in the subsequent prevention of rheumatic fever are not available at present. Urinary tract infections , including pyelonephritis and cystitis, caused by Escherichia coli, Proteus mirabilis, Klebsiella spp., and coagulase-negative staphylococci Skin and skin structure infections caused by Staphylococcus aureus and Streptococcus pyogenes Appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefaclor. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefaclor Capsules and Cefaclor for Oral Suspension and other antibacterial drugs, Cefaclor Capsules and Cefaclor for Oral Suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:b0c23043-d1d8-4324-b9bb-2798b0de8042 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3478 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:ca360b08-17aa-455c-a7dd-d666307abaaf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:45d49215-dffd-4108-ae1c-c0c313fc51de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefaclor is indicated in the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Otitis media caused by Streptococcus pneumoniae, Haemophilus influenzae , staphylococci, and Streptococcus pyogenes Note: β-lactamase-negative, ampicillin-resistant (BLNAR) strains of Haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some BLNAR strains. Lower respiratory tract infections , including pneumonia caused by Streptococcus pneumoniae, Haemophilus influenzae , and Streptococcus. Note: β-lactamase-negative, ampicillin-resistant (BLNAR) strains of Haemophilus influenzae should be considered resistant to cefaclor despite apparent in vitro susceptibility of some BLNAR strains. Pharyngitis and Tonsillitis , caused by Streptococcus pyogenes Note : Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefaclor is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefaclor in the subsequent prevention of rheumatic fever are not available at present. Urinary tract infections , including pyelonephritis and cystitis, caused by Escherichia coli, Proteus mirabilis, Klebsiella spp., and coagulase-negative staphylococci Skin and skin structure infections caused by Staphylococcus aureus and Streptococcus pyogenes Appropriate culture and susceptibility studies should be performed to determine susceptibility of the causative organism to cefaclor. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefaclor Capsules and Cefaclor for Oral Suspension and other antibacterial drugs, Cefaclor Capsules and Cefaclor for Oral Suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:df743811-6aba-4944-8335-6d2415519f16 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29103 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:e18fbe1f-1b3f-4474-abc1-f7c8fdc5c66e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:97d520e9-eeea-45d1-8cd5-2b61dca3164e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AN USAGE: 1. For therapeutic use in patients with hypokalemia with or without metabolic alkalosis; in digitalis intoxication and in patients with hypokalemic familial periodic paralysis. 2. For prevention of potassium depletion when the dietary intake of potassium is inadequate in the following conditions; patients receiving digitalis and diuretics for congestive heart failure; hepatic cirrhosis with ascites; states of aldosterone excess with normal renal function; potassium-losing nephropathy, and certain diarrheal states. 3. The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern. Serum potassium should be checked periodically, however, and, if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases supplementation with potassium salts may be indicated. uuid:ff1e880a-67cc-4642-92f4-ad79a137639a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29103 biolink:treats MONDO:0003009 PMID:41385096 "[{""id"":""uuid:901f1e79-97e4-4d80-b894-baeaf112d3ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:28257e75-68a9-4042-b655-7247eb04046c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AN USAGE: 1. For therapeutic use in patients with hypokalemia with or without metabolic alkalosis; in digitalis intoxication and in patients with hypokalemic familial periodic paralysis. 2. For prevention of potassium depletion when the dietary intake of potassium is inadequate in the following conditions; patients receiving digitalis and diuretics for congestive heart failure; hepatic cirrhosis with ascites; states of aldosterone excess with normal renal function; potassium-losing nephropathy, and certain diarrheal states. 3. The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern. Serum potassium should be checked periodically, however, and, if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases supplementation with potassium salts may be indicated. uuid:9c8bb8f5-8deb-41e4-b353-51e4d17022c0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50690 biolink:treats MONDO:0005311 PMID:41385096 "[{""id"":""uuid:7a71bd6f-e219-4b89-8414-8260548a4323"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:44dfb979-a49c-43c0-9637-7e36627e004a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, LIPITOR can be started simultaneously with diet. uuid:0a2f5cc7-02c5-4188-bfda-788baad13a55 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50690 biolink:treats HP:0003124 PMID:41385096 "[{""id"":""uuid:de277ef0-3f30-43f3-9e46-fb2cbec9c4e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fa52cf40-d8dc-43ea-b838-f7e3051aca8e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, LIPITOR can be started simultaneously with diet. uuid:f2f0f43c-ee7b-4762-b671-c1444c3b9f28 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50690 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:7152f2a6-f90c-4186-9081-e6495a75dd80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9e156d6d-271c-4678-b69a-591b67374764"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, LIPITOR can be started simultaneously with diet. uuid:f3f9fb35-5f93-4d62-b969-cd67aa57bddc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:JM2621P2LS biolink:treats UMLS:C5442256 PMID:41385096 "[{""id"":""uuid:505a0258-14ed-496d-895a-176a28de4a8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6614254e-6766-47ee-9a7c-c91c169ab813"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cenestin therapy is indicated for the: 1. Treatment of moderate-to-severe vasomotor symptoms associated with the menopause. 0.45 mg Cenestin 0.625 mg Cenestin 0.9 mg Cenestin 1.25 mg Cenestin 2. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. 0.3 mg Cenestin uuid:a4862560-a5fa-48f5-9f49-50e033f0cca4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:JM2621P2LS biolink:treats MONDO:0001932 PMID:41385096 "[{""id"":""uuid:c59e84f3-0975-47f9-b82c-3d457fee72a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2bb583c8-9788-47e5-99a7-6d5e2a8bdc4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cenestin therapy is indicated for the: 1. Treatment of moderate-to-severe vasomotor symptoms associated with the menopause. 0.45 mg Cenestin 0.625 mg Cenestin 0.9 mg Cenestin 1.25 mg Cenestin 2. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. 0.3 mg Cenestin DOID:14275 uuid:ef497674-4e04-4273-8bc8-2b6a1dc8c55c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:404930 biolink:treats HP:0000371 PMID:41385096 "[{""id"":""uuid:640d89f6-dcf2-4b44-b66e-de83ab062369"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0134d196-aaf7-4541-8513-c9be293354b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CIPRODEX® Otic is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the specific conditions listed below: Acute Otitis Media in pediatric patients (age 6 months and older) with tympanostomy tubes due to Staphylococcus aureus , Streptococcus pneumoniae , Haemophilus influenzae , Moraxella catarrhalis , and Pseudomonas aeruginosa . Acute Otitis Externa in pediatric (age 6 months and older), adult and elderly patients due to Staphylococcus aureus and Pseudomonas aeruginosa . uuid:d287483f-7868-4c26-809a-96b4e2dded01 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:404930 biolink:treats MONDO:0001051 PMID:41385096 "[{""id"":""uuid:34f572a7-529c-4927-8ba7-ca754083f2da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2bcbf21c-29de-470d-bce6-d4f4902a6cb9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CIPRODEX® Otic is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the specific conditions listed below: Acute Otitis Media in pediatric patients (age 6 months and older) with tympanostomy tubes due to Staphylococcus aureus , Streptococcus pneumoniae , Haemophilus influenzae , Moraxella catarrhalis , and Pseudomonas aeruginosa . Acute Otitis Externa in pediatric (age 6 months and older), adult and elderly patients due to Staphylococcus aureus and Pseudomonas aeruginosa . uuid:5360aaed-c3aa-465a-b8aa-1b9badd2fbfe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:291342 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:f2925848-964e-4a25-b1ea-1852a2f6d047"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0f165664-83b4-4f32-800f-c5aaa211e773"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Seasonal Allergic Rhinitis CLARINEX is indicated for the relief of the nasal and non-nasal symptoms of seasonal allergic rhinitis in patients 2 years of age and older. Perennial Allergic Rhinitis CLARINEX is indicated for the relief of the nasal and non-nasal symptoms of perennial allergic rhinitis in patients 6 months of age and older. Chronic Idiopathic Urticaria CLARINEX is indicated for the symptomatic relief of pruritus, reduction in the number of hives, and size of hives, in patients with chronic idiopathic urticaria 6 months of age and older. uuid:74a6e243-a97b-474c-8a6e-c4886518c74c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:291342 biolink:treats MONDO:0024332 PMID:41385096 "[{""id"":""uuid:209a24ab-d2c6-41ca-997f-cd89ea12d049"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:032d0af7-60c4-4dcf-8757-ed6934df4a26"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Seasonal Allergic Rhinitis CLARINEX is indicated for the relief of the nasal and non-nasal symptoms of seasonal allergic rhinitis in patients 2 years of age and older. Perennial Allergic Rhinitis CLARINEX is indicated for the relief of the nasal and non-nasal symptoms of perennial allergic rhinitis in patients 6 months of age and older. Chronic Idiopathic Urticaria CLARINEX is indicated for the symptomatic relief of pruritus, reduction in the number of hives, and size of hives, in patients with chronic idiopathic urticaria 6 months of age and older. uuid:24ffee9a-68e5-4b97-b398-cd07cfbecaa8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:291342 biolink:treats MONDO:0044212 PMID:41385096 "[{""id"":""uuid:ba68b05c-1318-45d6-8d8c-ec2c2906ad73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ace2e434-465b-4d6d-bba0-9bd735cbc99e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:8677472e-7ce4-4d21-87b6-c82af20a955c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/neoclarityn""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Seasonal Allergic Rhinitis CLARINEX is indicated for the relief of the nasal and non-nasal symptoms of seasonal allergic rhinitis in patients 2 years of age and older. Perennial Allergic Rhinitis CLARINEX is indicated for the relief of the nasal and non-nasal symptoms of perennial allergic rhinitis in patients 6 months of age and older. Chronic Idiopathic Urticaria CLARINEX is indicated for the symptomatic relief of pruritus, reduction in the number of hives, and size of hives, in patients with chronic idiopathic urticaria 6 months of age and older.|[EMA] Desloratadine ratiopharm is indicated in adults for the relief of symptoms associated with:allergic rhinitischronic idiopathic urticaria as initially diagnosed by a physician uuid:6e9be898-5642-43ad-a7e1-4e8616c2a177 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3216 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:d22456c8-ca3f-4a43-95c2-bd3925eb5f30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c139dfde-4f23-4f82-aa1d-6819a72c5626"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Buprenorphine hydrochloride injection is indicated for the relief of moderate to severe pain. uuid:df957788-ebb0-49a0-ba4f-e1fe29b7077a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75984 biolink:treats HP:0004763 PMID:41385096 "[{""id"":""uuid:5a645603-a0df-4199-94d3-066ff3ad5883"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:52f71782-7582-479f-a529-d55e17b9eb04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:36d7063f-4eb4-46e1-b490-58941aa8b6b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In patients without structural heart disease, Flecainide Acetate Tablets, USP are indicated for the prevention of: •paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms •paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms Flecainide Acetate Tablets, USP are also indicated for the prevention of: •documented ventricular arrhythmias, such as sustained ventricular tachycardia ( sustained VT), that in the judgment of the physician are life-threatening. Use of Flecainide Acetate Tablets, USP for the treatment of sustained VT, like other antiarrhythmics, should be initiated in the hospital. The use of flecainide acetate is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. Because of the proarrhythmic effects of Flecainide Acetate Tablets, USP, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks. Flecainide Acetate Tablets, USP should not be used in patients with recent myocardial infarction. (See Boxed WARNINGS .) Use of Flecainide Acetate Tablets, USP in chronic atrial fibrillation has not been adequately studied and is not recommended. (See Boxed WARNINGS .) As is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of flecainide acetate favorably affects survival or the incidence of sudden death.|[PMDA] Drugs with a new additional indication and a new dosage for the treatment of tachyarrhythmia (paroxysmal atrial fibrillation/flutter, paroxysmal supraventricular tachycardia, ventricular tachycardia) in children. [Expedited review] uuid:b8271746-d6f0-4843-aa06-de67b86bd67d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75984 biolink:treats UMLS:C0039232 PMID:41385096 "[{""id"":""uuid:59a36d3a-b643-4826-bf2f-52acd5040f70"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1ff74d74-b021-4573-9dfa-d9d622174cd7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In patients without structural heart disease, Flecainide Acetate Tablets, USP are indicated for the prevention of: •paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms •paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms Flecainide Acetate Tablets, USP are also indicated for the prevention of: •documented ventricular arrhythmias, such as sustained ventricular tachycardia ( sustained VT), that in the judgment of the physician are life-threatening. Use of Flecainide Acetate Tablets, USP for the treatment of sustained VT, like other antiarrhythmics, should be initiated in the hospital. The use of flecainide acetate is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. Because of the proarrhythmic effects of Flecainide Acetate Tablets, USP, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks. Flecainide Acetate Tablets, USP should not be used in patients with recent myocardial infarction. (See Boxed WARNINGS .) Use of Flecainide Acetate Tablets, USP in chronic atrial fibrillation has not been adequately studied and is not recommended. (See Boxed WARNINGS .) As is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of flecainide acetate favorably affects survival or the incidence of sudden death. uuid:a2daa405-5571-41c3-93db-929d7f084d54 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75984 biolink:treats HP:0011717 PMID:41385096 "[{""id"":""uuid:060a73d3-cb39-480a-8ea5-a21b0d9ac8be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:83006020-93c9-417f-b284-6c2725e88674"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In patients without structural heart disease, Flecainide Acetate Tablets, USP are indicated for the prevention of: •paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms •paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms Flecainide Acetate Tablets, USP are also indicated for the prevention of: •documented ventricular arrhythmias, such as sustained ventricular tachycardia ( sustained VT), that in the judgment of the physician are life-threatening. Use of Flecainide Acetate Tablets, USP for the treatment of sustained VT, like other antiarrhythmics, should be initiated in the hospital. The use of flecainide acetate is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. Because of the proarrhythmic effects of Flecainide Acetate Tablets, USP, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks. Flecainide Acetate Tablets, USP should not be used in patients with recent myocardial infarction. (See Boxed WARNINGS .) Use of Flecainide Acetate Tablets, USP in chronic atrial fibrillation has not been adequately studied and is not recommended. (See Boxed WARNINGS .) As is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of flecainide acetate favorably affects survival or the incidence of sudden death. uuid:94b7ae77-37be-479f-83c7-661645627ab3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75984 biolink:treats HP:0004755 PMID:41385096 "[{""id"":""uuid:00030f26-5fab-4e6f-ad4f-1481c4758c97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:72f1792a-1146-4378-a2bc-d19c888cffeb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In patients without structural heart disease, Flecainide Acetate Tablets, USP are indicated for the prevention of: •paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms •paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms Flecainide Acetate Tablets, USP are also indicated for the prevention of: •documented ventricular arrhythmias, such as sustained ventricular tachycardia ( sustained VT), that in the judgment of the physician are life-threatening. Use of Flecainide Acetate Tablets, USP for the treatment of sustained VT, like other antiarrhythmics, should be initiated in the hospital. The use of flecainide acetate is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. Because of the proarrhythmic effects of Flecainide Acetate Tablets, USP, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks. Flecainide Acetate Tablets, USP should not be used in patients with recent myocardial infarction. (See Boxed WARNINGS .) Use of Flecainide Acetate Tablets, USP in chronic atrial fibrillation has not been adequately studied and is not recommended. (See Boxed WARNINGS .) As is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of flecainide acetate favorably affects survival or the incidence of sudden death. uuid:c3e0146a-444b-4cda-ac1e-290b0f88978a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75984 biolink:treats MONDO:1030011 PMID:41385096 "[{""id"":""uuid:b042377c-d764-48fa-a35e-e904f01dbdb6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cb1d3b6d-1c48-4bca-802b-11d8c13cb89e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4ddc1aa3-974b-474a-ad0c-9c8592bd7214"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In patients without structural heart disease, Flecainide Acetate Tablets, USP are indicated for the prevention of: •paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms •paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms Flecainide Acetate Tablets, USP are also indicated for the prevention of: •documented ventricular arrhythmias, such as sustained ventricular tachycardia ( sustained VT), that in the judgment of the physician are life-threatening. Use of Flecainide Acetate Tablets, USP for the treatment of sustained VT, like other antiarrhythmics, should be initiated in the hospital. The use of flecainide acetate is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. Because of the proarrhythmic effects of Flecainide Acetate Tablets, USP, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks. Flecainide Acetate Tablets, USP should not be used in patients with recent myocardial infarction. (See Boxed WARNINGS .) Use of Flecainide Acetate Tablets, USP in chronic atrial fibrillation has not been adequately studied and is not recommended. (See Boxed WARNINGS .) As is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of flecainide acetate favorably affects survival or the incidence of sudden death.|[PMDA] Drugs with a new additional indication and a new dosage for the treatment of tachyarrhythmia (paroxysmal atrial fibrillation/flutter, paroxysmal supraventricular tachycardia, ventricular tachycardia) in children. [Expedited review] uuid:15442f71-f410-45c8-956c-83895e86f724 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75984 biolink:treats UMLS:C0741292 PMID:41385096 "[{""id"":""uuid:b5167049-dbb0-4f89-9399-0667f747726f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5152c7da-d980-4dee-8a46-08ec92e617ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In patients without structural heart disease, Flecainide Acetate Tablets, USP are indicated for the prevention of: •paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms •paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms Flecainide Acetate Tablets, USP are also indicated for the prevention of: •documented ventricular arrhythmias, such as sustained ventricular tachycardia ( sustained VT), that in the judgment of the physician are life-threatening. Use of Flecainide Acetate Tablets, USP for the treatment of sustained VT, like other antiarrhythmics, should be initiated in the hospital. The use of flecainide acetate is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. Because of the proarrhythmic effects of Flecainide Acetate Tablets, USP, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks. Flecainide Acetate Tablets, USP should not be used in patients with recent myocardial infarction. (See Boxed WARNINGS .) Use of Flecainide Acetate Tablets, USP in chronic atrial fibrillation has not been adequately studied and is not recommended. (See Boxed WARNINGS .) As is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of flecainide acetate favorably affects survival or the incidence of sudden death. uuid:4673cba6-ffa5-4b68-bd1a-4e649e35c777 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75984 biolink:treats HP:0004308 PMID:41385096 "[{""id"":""uuid:1a0a341f-a273-426a-be82-a1a3a4e7feeb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d23620d5-bd2b-4014-85b3-7e6347686c5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In patients without structural heart disease, Flecainide Acetate Tablets, USP are indicated for the prevention of: •paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms •paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms Flecainide Acetate Tablets, USP are also indicated for the prevention of: •documented ventricular arrhythmias, such as sustained ventricular tachycardia ( sustained VT), that in the judgment of the physician are life-threatening. Use of Flecainide Acetate Tablets, USP for the treatment of sustained VT, like other antiarrhythmics, should be initiated in the hospital. The use of flecainide acetate is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. Because of the proarrhythmic effects of Flecainide Acetate Tablets, USP, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks. Flecainide Acetate Tablets, USP should not be used in patients with recent myocardial infarction. (See Boxed WARNINGS .) Use of Flecainide Acetate Tablets, USP in chronic atrial fibrillation has not been adequately studied and is not recommended. (See Boxed WARNINGS .) As is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of flecainide acetate favorably affects survival or the incidence of sudden death. uuid:c218dca6-2a67-428b-bf01-0c71ed44eddd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75984 biolink:treats UMLS:C0750197 PMID:41385096 "[{""id"":""uuid:1af68316-bbc5-486d-8d1b-192963432499"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:be988d94-1777-4bec-b33b-0d4aab3375a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In patients without structural heart disease, Flecainide Acetate Tablets, USP are indicated for the prevention of: •paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms •paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms Flecainide Acetate Tablets, USP are also indicated for the prevention of: •documented ventricular arrhythmias, such as sustained ventricular tachycardia ( sustained VT), that in the judgment of the physician are life-threatening. Use of Flecainide Acetate Tablets, USP for the treatment of sustained VT, like other antiarrhythmics, should be initiated in the hospital. The use of flecainide acetate is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. Because of the proarrhythmic effects of Flecainide Acetate Tablets, USP, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks. Flecainide Acetate Tablets, USP should not be used in patients with recent myocardial infarction. (See Boxed WARNINGS .) Use of Flecainide Acetate Tablets, USP in chronic atrial fibrillation has not been adequately studied and is not recommended. (See Boxed WARNINGS .) As is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of flecainide acetate favorably affects survival or the incidence of sudden death. uuid:e99cce25-0811-4991-8d6e-cf84b72a570c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3761 biolink:treats MONDO:0005618 PMID:41385096 "[{""id"":""uuid:d4d076a7-f933-47d9-a0e3-21298d4562b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:881c2908-f1e9-422f-83b1-9bcba846f8dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clorazepate dipotassium is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. Clorazepate dipotassium tablets are indicated as adjunctive therapy in the management of partial seizures. The effectiveness of clorazepate dipotassium tablets in long-term management of anxiety, that is, more than 4 months, has not been assessed by systematic clinical studies. Long-term studies in epileptic patients, however, have shown continued therapeutic activity. The physician should reassess periodically the usefulness of the drug for the individual patient. Clorazepate dipotassium tablets are indicated for the symptomatic relief of acute alcohol withdrawal. uuid:3d4208d7-c7c4-4577-ae9e-1ac2e8586ce8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3761 biolink:treats HP:0007359 PMID:41385096 "[{""id"":""uuid:802cce81-0bd9-4821-b475-e3f380fcffa1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dfbd40c8-26ce-4e04-a861-5a386a1d2044"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clorazepate dipotassium is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. Clorazepate dipotassium tablets are indicated as adjunctive therapy in the management of partial seizures. The effectiveness of clorazepate dipotassium tablets in long-term management of anxiety, that is, more than 4 months, has not been assessed by systematic clinical studies. Long-term studies in epileptic patients, however, have shown continued therapeutic activity. The physician should reassess periodically the usefulness of the drug for the individual patient. Clorazepate dipotassium tablets are indicated for the symptomatic relief of acute alcohol withdrawal. uuid:277682fe-d0c8-4e29-adb3-37bbb70ddf9a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3761 biolink:treats MONDO:0005433 PMID:41385096 "[{""id"":""uuid:2c81839b-ecdd-4c0d-9de5-caafc39afe8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4c99b87d-f0f4-4039-8e84-2bbbb6261893"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clorazepate dipotassium is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. Clorazepate dipotassium tablets are indicated as adjunctive therapy in the management of partial seizures. The effectiveness of clorazepate dipotassium tablets in long-term management of anxiety, that is, more than 4 months, has not been assessed by systematic clinical studies. Long-term studies in epileptic patients, however, have shown continued therapeutic activity. The physician should reassess periodically the usefulness of the drug for the individual patient. Clorazepate dipotassium tablets are indicated for the symptomatic relief of acute alcohol withdrawal. uuid:6e96fc4f-3f2f-4cf7-a8f3-7f30beaf7c24 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3654 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:c9db44e6-1c8b-4ab1-bc96-5fa75fcc6d71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d45f13eb-0c81-40f5-8d93-1cc1281daf3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diuretics such as chlorthalidone are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension. Chlorthalidone is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Chlorthalidone has also been found useful in edema due to various forms of renal dysfunction, such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. uuid:2467ea57-b000-4d0e-8d87-5b6f335413cd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3654 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:39861f71-2dd4-44b7-9213-f8b1d16c5f4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e751b738-6ec5-483b-ad7e-66e4192a8b34"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diuretics such as chlorthalidone are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension. Chlorthalidone is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Chlorthalidone has also been found useful in edema due to various forms of renal dysfunction, such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. uuid:f864e6ea-a95b-42bb-911b-7bbbdc842d63 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3654 biolink:treats MONDO:0005155 PMID:41385096 "[{""id"":""uuid:4c0804d7-2190-4e5a-9c88-c95c53717977"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0f4d11e3-1c87-48e3-a557-e7118527dcdb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diuretics such as chlorthalidone are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension. Chlorthalidone is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Chlorthalidone has also been found useful in edema due to various forms of renal dysfunction, such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. uuid:c8567b56-200d-4668-b576-49d72723b6ad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3654 biolink:treats MONDO:0005377 PMID:41385096 "[{""id"":""uuid:c79ba216-5171-417b-90d9-f98c81d05deb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bac51ab3-b0f1-40a8-a524-6f2b3a25533a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diuretics such as chlorthalidone are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension. Chlorthalidone is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Chlorthalidone has also been found useful in edema due to various forms of renal dysfunction, such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. uuid:1411421c-9be3-467b-b254-6645069bacce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3654 biolink:treats UMLS:C0156221 PMID:41385096 "[{""id"":""uuid:93279fab-10c8-4002-aeca-4781148f4a08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1b8b6eb2-eee3-4ef2-9b36-c24f2224ac72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diuretics such as chlorthalidone are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension. Chlorthalidone is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Chlorthalidone has also been found useful in edema due to various forms of renal dysfunction, such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. uuid:b3a8918d-e34a-4601-baed-af9527f074e7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3654 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:f4c034ce-c546-4601-8327-715711c93602"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:88115a34-14ac-47ba-90b0-789e0182d0d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diuretics such as chlorthalidone are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension. Chlorthalidone is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Chlorthalidone has also been found useful in edema due to various forms of renal dysfunction, such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. uuid:a1d7d8d1-d63c-4c85-9069-afd422f86f9b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3506 biolink:treats MONDO:0002258 PMID:41385096 "[{""id"":""uuid:aecacd48-7b63-48a8-8f32-be0e36bcc5f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:16c5d1f3-6d3b-44fb-8977-5702ed62bfa4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefprozil for oral suspension is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Upper Respiratory Tract: Pharyngitis/Tonsillitis: Caused by Streptococcus pyogenes . NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefprozil is generally effective in the eradication of Streptococcus pyogenes from the nasopharynx; however, substantial data establishing the efficacy of cefprozil in the subsequent prevention of rheumatic fever are not available at present. Otitis Media: Caused by Streptococcus pneumoniae, Haemophilus influenzae (including ß-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). (See CLINICAL STUDIES .) NOTE: In the treatment of otitis media due to ß-lactamase producing organisms, cefprozil had bacteriologic eradication rates somewhat lower than those observed with a product containing a specific ß-lactamase inhibitor. In considering the use of cefprozil, lower overall eradication rates should be balanced against the susceptibility patterns of the common microbes in a given geographic area and the increased potential for toxicity with products containing ß-lactamase inhibitors. Acute Sinusitis: Caused by Streptococcus pneumoniae, Haemophilus influenzae (including ß-lactamase producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). Lower Respiratory Tract: Secondary Bacterial Infection of Acute Bronchitis and Acute Bacterial Exacerbation of Chronic Bronchitis: Caused by Streptococcus pneumoniae , Haemophilus influenzae (including ß-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). Skin And Skin Structure: Uncomplicated Skin and Skin-Structure Infections: Caused by Staphylococcus aureus (including penicillinase producing strains) and Streptococcus pyogenes . Abscesses usually require surgical drainage. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefprozil for oral suspension and other antibacterial drugs, cefprozil for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:40661358-626f-49be-831f-e1f2b9fa5562 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3506 biolink:treats MONDO:0001039 PMID:41385096 "[{""id"":""uuid:b0d9c8d7-c59a-4273-b613-cc38a7bed57c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:42a79d07-99ec-4bf9-b19e-33eee0d4ece7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefprozil for oral suspension is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Upper Respiratory Tract: Pharyngitis/Tonsillitis: Caused by Streptococcus pyogenes . NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefprozil is generally effective in the eradication of Streptococcus pyogenes from the nasopharynx; however, substantial data establishing the efficacy of cefprozil in the subsequent prevention of rheumatic fever are not available at present. Otitis Media: Caused by Streptococcus pneumoniae, Haemophilus influenzae (including ß-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). (See CLINICAL STUDIES .) NOTE: In the treatment of otitis media due to ß-lactamase producing organisms, cefprozil had bacteriologic eradication rates somewhat lower than those observed with a product containing a specific ß-lactamase inhibitor. In considering the use of cefprozil, lower overall eradication rates should be balanced against the susceptibility patterns of the common microbes in a given geographic area and the increased potential for toxicity with products containing ß-lactamase inhibitors. Acute Sinusitis: Caused by Streptococcus pneumoniae, Haemophilus influenzae (including ß-lactamase producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). Lower Respiratory Tract: Secondary Bacterial Infection of Acute Bronchitis and Acute Bacterial Exacerbation of Chronic Bronchitis: Caused by Streptococcus pneumoniae , Haemophilus influenzae (including ß-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). Skin And Skin Structure: Uncomplicated Skin and Skin-Structure Infections: Caused by Staphylococcus aureus (including penicillinase producing strains) and Streptococcus pyogenes . Abscesses usually require surgical drainage. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefprozil for oral suspension and other antibacterial drugs, cefprozil for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:2f411343-fdfb-42e2-bcaf-9ff4aa7f9f5b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3506 biolink:treats MONDO:0005441 PMID:41385096 "[{""id"":""uuid:d064ffad-1398-4bc9-a5e8-15c9f72b7933"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:52304d13-bc5e-45df-a507-0c01649703be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefprozil for oral suspension is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Upper Respiratory Tract: Pharyngitis/Tonsillitis: Caused by Streptococcus pyogenes . NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefprozil is generally effective in the eradication of Streptococcus pyogenes from the nasopharynx; however, substantial data establishing the efficacy of cefprozil in the subsequent prevention of rheumatic fever are not available at present. Otitis Media: Caused by Streptococcus pneumoniae, Haemophilus influenzae (including ß-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). (See CLINICAL STUDIES .) NOTE: In the treatment of otitis media due to ß-lactamase producing organisms, cefprozil had bacteriologic eradication rates somewhat lower than those observed with a product containing a specific ß-lactamase inhibitor. In considering the use of cefprozil, lower overall eradication rates should be balanced against the susceptibility patterns of the common microbes in a given geographic area and the increased potential for toxicity with products containing ß-lactamase inhibitors. Acute Sinusitis: Caused by Streptococcus pneumoniae, Haemophilus influenzae (including ß-lactamase producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). Lower Respiratory Tract: Secondary Bacterial Infection of Acute Bronchitis and Acute Bacterial Exacerbation of Chronic Bronchitis: Caused by Streptococcus pneumoniae , Haemophilus influenzae (including ß-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). Skin And Skin Structure: Uncomplicated Skin and Skin-Structure Infections: Caused by Staphylococcus aureus (including penicillinase producing strains) and Streptococcus pyogenes . Abscesses usually require surgical drainage. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefprozil for oral suspension and other antibacterial drugs, cefprozil for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:94a0835a-a3e7-4b7c-889c-21a39a455dbb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3506 biolink:treats HP:0000255 PMID:41385096 "[{""id"":""uuid:5156e8a2-f929-495e-815c-fc111a526fbc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bc87747e-2f41-4e7f-bd97-82401ed4d503"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefprozil for oral suspension is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Upper Respiratory Tract: Pharyngitis/Tonsillitis: Caused by Streptococcus pyogenes . NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefprozil is generally effective in the eradication of Streptococcus pyogenes from the nasopharynx; however, substantial data establishing the efficacy of cefprozil in the subsequent prevention of rheumatic fever are not available at present. Otitis Media: Caused by Streptococcus pneumoniae, Haemophilus influenzae (including ß-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). (See CLINICAL STUDIES .) NOTE: In the treatment of otitis media due to ß-lactamase producing organisms, cefprozil had bacteriologic eradication rates somewhat lower than those observed with a product containing a specific ß-lactamase inhibitor. In considering the use of cefprozil, lower overall eradication rates should be balanced against the susceptibility patterns of the common microbes in a given geographic area and the increased potential for toxicity with products containing ß-lactamase inhibitors. Acute Sinusitis: Caused by Streptococcus pneumoniae, Haemophilus influenzae (including ß-lactamase producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). Lower Respiratory Tract: Secondary Bacterial Infection of Acute Bronchitis and Acute Bacterial Exacerbation of Chronic Bronchitis: Caused by Streptococcus pneumoniae , Haemophilus influenzae (including ß-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). Skin And Skin Structure: Uncomplicated Skin and Skin-Structure Infections: Caused by Staphylococcus aureus (including penicillinase producing strains) and Streptococcus pyogenes . Abscesses usually require surgical drainage. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefprozil for oral suspension and other antibacterial drugs, cefprozil for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:6f0eac2b-d76a-4e61-ba24-617895923fd0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3506 biolink:treats UMLS:C1735365 PMID:41385096 "[{""id"":""uuid:1343ab50-2a11-480a-94a7-bc85009d684a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6d2a82aa-10f0-414b-8ab8-f0de9f61498e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefprozil for oral suspension is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Upper Respiratory Tract: Pharyngitis/Tonsillitis: Caused by Streptococcus pyogenes . NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefprozil is generally effective in the eradication of Streptococcus pyogenes from the nasopharynx; however, substantial data establishing the efficacy of cefprozil in the subsequent prevention of rheumatic fever are not available at present. Otitis Media: Caused by Streptococcus pneumoniae, Haemophilus influenzae (including ß-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). (See CLINICAL STUDIES .) NOTE: In the treatment of otitis media due to ß-lactamase producing organisms, cefprozil had bacteriologic eradication rates somewhat lower than those observed with a product containing a specific ß-lactamase inhibitor. In considering the use of cefprozil, lower overall eradication rates should be balanced against the susceptibility patterns of the common microbes in a given geographic area and the increased potential for toxicity with products containing ß-lactamase inhibitors. Acute Sinusitis: Caused by Streptococcus pneumoniae, Haemophilus influenzae (including ß-lactamase producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). Lower Respiratory Tract: Secondary Bacterial Infection of Acute Bronchitis and Acute Bacterial Exacerbation of Chronic Bronchitis: Caused by Streptococcus pneumoniae , Haemophilus influenzae (including ß-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). Skin And Skin Structure: Uncomplicated Skin and Skin-Structure Infections: Caused by Staphylococcus aureus (including penicillinase producing strains) and Streptococcus pyogenes . Abscesses usually require surgical drainage. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefprozil for oral suspension and other antibacterial drugs, cefprozil for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:edc28d93-367f-40e1-b2cf-1e6e2842a8a3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3506 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:28801f43-be06-4aee-aba5-f112d1d3025c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4474de9b-0d3e-48c0-83bb-4d065365884b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefprozil for oral suspension is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Upper Respiratory Tract: Pharyngitis/Tonsillitis: Caused by Streptococcus pyogenes . NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefprozil is generally effective in the eradication of Streptococcus pyogenes from the nasopharynx; however, substantial data establishing the efficacy of cefprozil in the subsequent prevention of rheumatic fever are not available at present. Otitis Media: Caused by Streptococcus pneumoniae, Haemophilus influenzae (including ß-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). (See CLINICAL STUDIES .) NOTE: In the treatment of otitis media due to ß-lactamase producing organisms, cefprozil had bacteriologic eradication rates somewhat lower than those observed with a product containing a specific ß-lactamase inhibitor. In considering the use of cefprozil, lower overall eradication rates should be balanced against the susceptibility patterns of the common microbes in a given geographic area and the increased potential for toxicity with products containing ß-lactamase inhibitors. Acute Sinusitis: Caused by Streptococcus pneumoniae, Haemophilus influenzae (including ß-lactamase producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). Lower Respiratory Tract: Secondary Bacterial Infection of Acute Bronchitis and Acute Bacterial Exacerbation of Chronic Bronchitis: Caused by Streptococcus pneumoniae , Haemophilus influenzae (including ß-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). Skin And Skin Structure: Uncomplicated Skin and Skin-Structure Infections: Caused by Staphylococcus aureus (including penicillinase producing strains) and Streptococcus pyogenes . Abscesses usually require surgical drainage. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefprozil for oral suspension and other antibacterial drugs, cefprozil for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:bb416f33-2ec7-48b4-a072-6747a9a6bbb9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1162777 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:948cc672-f065-49c4-8584-f5ff2c9d3209"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d55378ee-b3ae-4478-aef2-59aa9ca73fb4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BENICAR HCT ® is indicated for the treatment of hypertension. This fixed dose combination is not indicated for initial therapy (see DOSAGE AND ADMINISTRATION ). uuid:70a09501-793a-448b-8999-141ad77c6cb7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63620 biolink:treats MONDO:0005180 PMID:41385096 "[{""id"":""uuid:91011c1f-f5a2-49a3-b595-600b00e52d7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:82da83f8-8258-491a-9361-7273b722ce75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3e7d46c9-e39e-4279-9522-6b7ce302a6b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/azilect""]},{""id"":""uuid:eb64039b-e358-4e25-b83a-2cf062dd717d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AZILECT (rasagiline tablets) is indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease as initial monotherapy and as adjunct therapy to levodopa. The effectiveness of AZILECT was demonstrated in patients with early Parkinson's disease who were receiving AZILECT as monotherapy and who were not receiving any concomitant dopaminergic therapy. The effectiveness of AZILECT as adjunct therapy was demonstrated in patients with Parkinson's disease who were treated with levodopa.|[EMA] Azilect is indicated for the treatment of idiopathic Parkinson's disease (PD) as monotherapy (without levodopa) or as adjunct therapy (with levodopa) in patients with end-of-dose fluctuations.|[PMDA] Drugs with a new active ingredient indicated for the treatment of Parkinson’s disease. uuid:10e10391-c1b7-47e5-9699-1a3ac043ef10 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8713 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:56725e7e-7442-4251-9500-7bee979d204c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ae0b6e90-b852-44a3-8ff0-66bfbe75af93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Quinapril hydrochloride tablets are indicated for the treatment of hypertension. It may be used alone or in combination with thiazide diuretics. In using quinapril hydrochloride tablets, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease. Available data are insufficient to show that quinapril hydrochloride tablets do not have a similar risk (see WARNINGS ). Angioedema in Black Patients Black patients receiving ACE inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to non-blacks. It should also be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. uuid:b092cfd7-e1c8-48f6-b3a9-8539e1391de1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8713 biolink:treats MONDO:0001609 PMID:41385096 "[{""id"":""uuid:fbd1a08e-3f03-4aa2-b9e5-678d2b1b90db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:35293e43-6228-4642-8e83-cf583a7c90f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Quinapril hydrochloride tablets are indicated for the treatment of hypertension. It may be used alone or in combination with thiazide diuretics. In using quinapril hydrochloride tablets, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease. Available data are insufficient to show that quinapril hydrochloride tablets do not have a similar risk (see WARNINGS ). Angioedema in Black Patients Black patients receiving ACE inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to non-blacks. It should also be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. uuid:8189763e-1a00-42a9-92f2-8f5ae67503ad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8713 biolink:treats MONDO:0001343 PMID:41385096 "[{""id"":""uuid:6ab98dc7-0ad7-4020-a77e-503f70ccd562"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:491cecb8-82d9-4e0d-a97d-e72ec8f1d424"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Quinapril hydrochloride tablets are indicated for the treatment of hypertension. It may be used alone or in combination with thiazide diuretics. In using quinapril hydrochloride tablets, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease. Available data are insufficient to show that quinapril hydrochloride tablets do not have a similar risk (see WARNINGS ). Angioedema in Black Patients Black patients receiving ACE inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to non-blacks. It should also be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. uuid:15d613d5-3c11-461c-9857-73053c2b14ac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8713 biolink:treats MONDO:0010481 PMID:41385096 "[{""id"":""uuid:35160b5e-b880-409b-b5d5-d8e8604f7d9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e5d21473-89a8-417f-96ee-cae2d443116e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Quinapril hydrochloride tablets are indicated for the treatment of hypertension. It may be used alone or in combination with thiazide diuretics. In using quinapril hydrochloride tablets, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease. Available data are insufficient to show that quinapril hydrochloride tablets do not have a similar risk (see WARNINGS ). Angioedema in Black Patients Black patients receiving ACE inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to non-blacks. It should also be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. uuid:f2acc629-1494-4357-ad53-7e2dceb838b4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5128 biolink:treats MONDO:0013600 PMID:41385096 "[{""id"":""uuid:9d42455f-6ffd-44f0-8adb-7920ddf71a10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6dd90731-cdb0-49bb-99d3-1ee55d11a4d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Flurazepam Hydrochloride Capsules are a hypnotic agent useful for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakening. Flurazepam Hydrochloride Capsules can be used effectively in patients with recurring insomnia or poor sleeping habits, and in acute or chronic medical situations requiring restful sleep. Sleep laboratory studies have objectively determined that Flurazepam Hydrochloride Capsules are effective for at least 28 consecutive nights of drug administration. Since insomnia is often transient and intermittent short-term use is usually sufficient. Prolonged use of hypnotics is usually not indicated and should only be undertaken concomitantly with appropriate evaluation of the patient. uuid:c3bcaeb9-8bcf-4921-82a5-2b5f1e2dae64 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:52017 biolink:treats MONDO:0024313 PMID:41385096 "[{""id"":""uuid:610efe5f-6e4b-4536-ac9f-fc81c2f383b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:71f8bf45-d535-428b-ad4f-b67feebd19c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The penicillinase-resistant penicillins are indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drugs. Cultures and susceptibility tests should be performed initially to determine the causative organism and their sensitivity to the drug (see CLINICAL PHARMACOLOGY – Susceptibility Testing ). The penicillinase-resistant penicillins may be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of laboratory test results. The penicillinase-resistant penicillins should not be used in infections caused by organisms susceptible to penicillin G. If the susceptibility tests indicate that the infection is due to an organism other than a resistant staphylococcus, therapy should not be continued with a penicillinase-resistant penicillin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of dicloxacillin sodium capsules and other antibacterial drugs, dicloxacillin sodium capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:94a713a0-4dd8-4e14-b4ab-2c1b8e3c6027 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:52017 biolink:treats MONDO:0100073 PMID:41385096 "[{""id"":""uuid:eebbbd55-e177-48db-acaf-b40324d9ced0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4a31ce3c-f1cc-4729-ac23-a591db2ac42e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The penicillinase-resistant penicillins are indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drugs. Cultures and susceptibility tests should be performed initially to determine the causative organism and their sensitivity to the drug (see CLINICAL PHARMACOLOGY – Susceptibility Testing ). The penicillinase-resistant penicillins may be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of laboratory test results. The penicillinase-resistant penicillins should not be used in infections caused by organisms susceptible to penicillin G. If the susceptibility tests indicate that the infection is due to an organism other than a resistant staphylococcus, therapy should not be continued with a penicillinase-resistant penicillin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of dicloxacillin sodium capsules and other antibacterial drugs, dicloxacillin sodium capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:5116878d-7338-4e18-9b0e-143a594eb752 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49575 biolink:treats MONDO:0005526 PMID:41385096 "[{""id"":""uuid:a617bc36-c6eb-45e3-b18f-2f27fa7d86f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0ec8dcaf-26ce-4153-a0dc-587e0ebf2c3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diazepam is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. In acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. As an adjunct prior to endoscopic procedures if apprehension, anxiety or acute stress reactions are present, and to diminish the patient’s recall of the procedures. (See WARNINGS.) Diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma); spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia); athetosis; stiff-man syndrome; and tetanus. Diazepam is a useful adjunct in status epilepticus and severe recurrent convulsive seizures. Diazepam is a useful premedication (the I.M. route is preferred) for relief of anxiety and tension in patients who are to undergo surgical procedures. Intravenously, prior to cardioversion for the relief of anxiety and tension and to diminish the patient’s recall of the procedure. uuid:c38b5a94-839d-465e-8899-339aae3dd50d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49575 biolink:treats MONDO:0002125 PMID:41385096 "[{""id"":""uuid:66a76463-2a57-434b-823d-3e3357b9349a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c2e17234-6901-477e-9192-0a7c109bae3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diazepam is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. In acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. As an adjunct prior to endoscopic procedures if apprehension, anxiety or acute stress reactions are present, and to diminish the patient’s recall of the procedures. (See WARNINGS.) Diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma); spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia); athetosis; stiff-man syndrome; and tetanus. Diazepam is a useful adjunct in status epilepticus and severe recurrent convulsive seizures. Diazepam is a useful premedication (the I.M. route is preferred) for relief of anxiety and tension in patients who are to undergo surgical procedures. Intravenously, prior to cardioversion for the relief of anxiety and tension and to diminish the patient’s recall of the procedure. uuid:faabff71-322b-431b-90b6-e0dde8d14f9c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49575 biolink:treats MONDO:0005754 PMID:41385096 "[{""id"":""uuid:c2cbe3d5-8b83-4eb0-a119-6a6a8b9ead98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b382161f-489b-495d-8175-aa73d274a448"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diazepam is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. In acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. As an adjunct prior to endoscopic procedures if apprehension, anxiety or acute stress reactions are present, and to diminish the patient’s recall of the procedures. (See WARNINGS.) Diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma); spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia); athetosis; stiff-man syndrome; and tetanus. Diazepam is a useful adjunct in status epilepticus and severe recurrent convulsive seizures. Diazepam is a useful premedication (the I.M. route is preferred) for relief of anxiety and tension in patients who are to undergo surgical procedures. Intravenously, prior to cardioversion for the relief of anxiety and tension and to diminish the patient’s recall of the procedure. uuid:35347005-0d75-4440-b2ef-e94e2176189f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49575 biolink:treats MONDO:0005433 PMID:41385096 "[{""id"":""uuid:cc8bd30d-f956-4f04-89de-0d52bfc31aec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:60f6303e-0ea9-4a22-8e98-a05b56dccb80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diazepam is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. In acute alcohol withdrawal, diazepam may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. As an adjunct prior to endoscopic procedures if apprehension, anxiety or acute stress reactions are present, and to diminish the patient’s recall of the procedures. (See WARNINGS.) Diazepam is a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma); spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia); athetosis; stiff-man syndrome; and tetanus. Diazepam is a useful adjunct in status epilepticus and severe recurrent convulsive seizures. Diazepam is a useful premedication (the I.M. route is preferred) for relief of anxiety and tension in patients who are to undergo surgical procedures. Intravenously, prior to cardioversion for the relief of anxiety and tension and to diminish the patient’s recall of the procedure. uuid:76347c11-5c00-4948-8d91-8166a94c196e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6367 biolink:treats HP:0007359 PMID:41385096 "[{""id"":""uuid:7f52b36c-ad90-4f60-b75e-d801f686770b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8b6bb647-0dff-4d24-97d0-406325f65d94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2e62261e-96c8-439d-b0e3-2bf90760fc7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LAMICTAL is an antiepileptic drug (AED) indicated for: Epilepsy—adjunctive therapy in patients ≥2 years of age: (1.1) partial seizures. primary generalized tonic-clonic seizures. generalized seizures of Lennox-Gastaut syndrome. Epilepsy—monotherapy in patients ≥16 years of age: conversion to monotherapy in patients with partial seizures who are receiving treatment with carbamazepine, phenobarbital, phenytoin, primidone, or valproate as the single AED. (1.1) Bipolar Disorder in patients ≥18 years of age: maintenance treatment of Bipolar I Disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard therapy. (1.2)|[PMDA] Drugs containing a new active ingredient indicated for use as adjunctive treatment with other antiepileptic drugs for partial seizures (including secondary generalized seizures), tonic-clonic seizures, and generalized seizures associated with Lennox-Gastaut syndrome in patients with epilepsy for whom other antiepileptic drugs are not sufficiently effective. uuid:a083d883-eae4-4eb5-b653-4de7de005540 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6367 biolink:treats MONDO:0005754 PMID:41385096 "[{""id"":""uuid:7da377e8-b153-467f-948f-562cb1de0211"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:764c7770-2e61-425b-9ecc-5f1de737177c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f01366dc-ebeb-41d7-8981-f349c72635d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LAMICTAL is an antiepileptic drug (AED) indicated for: Epilepsy—adjunctive therapy in patients ≥2 years of age: (1.1) partial seizures. primary generalized tonic-clonic seizures. generalized seizures of Lennox-Gastaut syndrome. Epilepsy—monotherapy in patients ≥16 years of age: conversion to monotherapy in patients with partial seizures who are receiving treatment with carbamazepine, phenobarbital, phenytoin, primidone, or valproate as the single AED. (1.1) Bipolar Disorder in patients ≥18 years of age: maintenance treatment of Bipolar I Disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard therapy. (1.2)|[PMDA] Drugs containing a new active ingredient indicated for use as adjunctive treatment with other antiepileptic drugs for partial seizures (including secondary generalized seizures), tonic-clonic seizures, and generalized seizures associated with Lennox-Gastaut syndrome in patients with epilepsy for whom other antiepileptic drugs are not sufficiently effective. uuid:dc50c823-3e7b-4fc5-89a4-40d40fa288ed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6367 biolink:treats MONDO:0001866 PMID:41385096 "[{""id"":""uuid:5cfa3e20-c78f-4f50-8c6c-4f2fcc236b3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:89d3b9c8-0808-4648-a83d-e7d46e65c6cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LAMICTAL is an antiepileptic drug (AED) indicated for: Epilepsy—adjunctive therapy in patients ≥2 years of age: (1.1) partial seizures. primary generalized tonic-clonic seizures. generalized seizures of Lennox-Gastaut syndrome. Epilepsy—monotherapy in patients ≥16 years of age: conversion to monotherapy in patients with partial seizures who are receiving treatment with carbamazepine, phenobarbital, phenytoin, primidone, or valproate as the single AED. (1.1) Bipolar Disorder in patients ≥18 years of age: maintenance treatment of Bipolar I Disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard therapy. (1.2) uuid:737d2b39-93c9-4a01-98a6-c01d687c5d5f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9571 biolink:treats MONDO:0005090 PMID:41385096 "[{""id"":""uuid:e0c73cab-859e-4135-9e11-88c7acc8e25e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ac9d2a69-2352-4f0c-8b16-66ef48d949c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thiothixene is effective in the management of schizophrenia. Thiothixene has not been evaluated in the management of behavioral complications in patients with mental retardation. uuid:eb8c3d8f-d26b-4ffc-bad0-b3ca80853287 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63631 biolink:treats MONDO:0005277 PMID:41385096 "[{""id"":""uuid:ee5dcc71-2247-43e7-804e-e869a8f4da8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:04c44d37-2488-4444-b3b0-4a62c8e49516"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TOPAMAX ® is an antiepileptic (AED) agent indicated for: Monotherapy epilepsy: Initial monotherapy in patients ≥10 years of age with partial onset or primary generalized tonic-clonic seizures ( 1.1 ). Adjunctive therapy epilepsy: Adjunctive therapy for adults and pediatric patients (2 to 16 years of age) with partial onset seizures or primary generalized tonic-clonic seizures, and in patients ≥2 years of age with seizures associated with Lennox-Gastaut syndrome (LGS) ( 1.2 ). Migraine: Treatment for adults for prophylaxis of migraine headache ( 1.3 ). uuid:370902f6-beef-4390-849f-3dd8f1e5cc1b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:284756 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:f5d0f1a2-95bc-4c21-8358-2797a2f717e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:54174f00-9983-4d71-984d-0f229312c6ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KALETRA is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. The following points should be considered when initiating therapy with KALETRA: The use of other active agents with KALETRA is associated with a greater likelihood of treatment response [see Clinical Pharmacology ( 12.4 ) and Clinical Studies ( 14 )] . Genotypic or phenotypic testing and/or treatment history should guide the use of KALETRA [see Clinical Pharmacology ( 12.4 )] . The number of baseline lopinavir resistance-associated substitutions affects the virologic response to KALETRA [see Clinical Pharmacology ( 12.4 )] . Once daily administration of KALETRA is not recommended for any pediatric patients. uuid:3f94d7ae-e3a9-48da-a530-47da1b658ba5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:11949636 biolink:treats MONDO:0006668 PMID:41385096 "[{""id"":""uuid:519b799f-fc21-42c5-ba88-7a1cf0f98e47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:23f4779b-a5fa-4ef5-96c3-71923b0f0a71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TOBRADEX Ophthalmic Suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococci, including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin-resistant strains. Streptococci, including some of the Group A-beta-hemolytic species, some nonhemolytic species, and some Streptococcus pneumoniae. Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii, most Proteus vulgaris strains, Haemophilus influenzae and H. aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus and some Neisseria species. uuid:2463b2cf-1463-4763-bd5d-afe451430f8e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:11949636 biolink:treats UMLS:C0008690 PMID:41385096 "[{""id"":""uuid:b905dec1-4214-4973-a54c-1185117ab6e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:64e6f9d9-49e8-4c76-aacb-ae4ef9ae2197"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TOBRADEX Ophthalmic Suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococci, including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin-resistant strains. Streptococci, including some of the Group A-beta-hemolytic species, some nonhemolytic species, and some Streptococcus pneumoniae. Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii, most Proteus vulgaris strains, Haemophilus influenzae and H. aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus and some Neisseria species. uuid:a7b5d665-96a8-4b21-bd39-0e9f90669919 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:11949636 biolink:treats UMLS:C0339289 PMID:41385096 "[{""id"":""uuid:f8ec56f7-20b8-43f4-9b28-1ce8dc2ce19d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bc9c572f-d709-480b-8775-4ed719a3e5f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TOBRADEX Ophthalmic Suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococci, including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin-resistant strains. Streptococci, including some of the Group A-beta-hemolytic species, some nonhemolytic species, and some Streptococcus pneumoniae. Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii, most Proteus vulgaris strains, Haemophilus influenzae and H. aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus and some Neisseria species. uuid:f4f84181-78a7-46ba-9f71-8ea51e51481e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18067 biolink:treats MONDO:0016990 PMID:41385096 "[{""id"":""uuid:b63081d3-1e93-47a8-8128-8526411e5bf4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6447f1a3-c6d6-4ba2-820b-e7323d4833ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MEPHYTON is indicated in the following coagulation disorders which are due to faulty formation of factors II, VII, IX and X when caused by vitamin K deficiency or interference with vitamin K activity. MEPHYTON tablets are indicated in: anticoagulant-induced prothrombin deficiency caused by coumarin or indanedione derivatives; hypoprothrombinemia secondary to antibacterial therapy; hypoprothrombinemia secondary to administration of salicylates; hypoprothrombinemia secondary to obstructive jaundice or biliary fistulas but only if bile salts are administered concurrently, since otherwise the oral vitamin K will not be absorbed. uuid:5185c978-4751-4f2f-b0f1-4be3599f5edd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9139 biolink:treats NCIT:C55615 PMID:41385096 "[{""id"":""uuid:124fc0dc-f272-45cc-bb4d-9e1f3a3be351"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e1fd925c-1f3a-4047-8955-0aea4db86062"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VIAGRA is indicated for the treatment of erectile dysfunction. uuid:2ae5f461-1b0e-4f90-b78f-ef881edfbe07 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50922 biolink:treats MONDO:0005475 PMID:41385096 "[{""id"":""uuid:5378f141-3fe9-4c3a-8ac8-8ccf1423a9e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d3a33e5a-3ed8-4f09-a140-083c2a5d2ccb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RELPAX is indicated for the acute treatment of migraine with or without aura in adults. RELPAX is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS ). Safety and effectiveness of RELPAX Tablets have not been established for cluster headache, which is present in an older, predominantly male population. uuid:c11c1225-b8c5-4220-9eae-b2e07815327e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50922 biolink:treats MONDO:0100431 PMID:41385096 "[{""id"":""uuid:d13dd6f6-25ed-45e2-97b5-83da904220f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bc0f44dd-d8f2-4c26-b23b-2dcadf2b47ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RELPAX is indicated for the acute treatment of migraine with or without aura in adults. RELPAX is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS ). Safety and effectiveness of RELPAX Tablets have not been established for cluster headache, which is present in an older, predominantly male population. uuid:cad454fe-af0f-4a30-b1af-b7e464804708 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50922 biolink:treats MONDO:0018925 PMID:41385096 "[{""id"":""uuid:134dd5d4-7661-45fd-aaf9-9d926268b3d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:60d788bc-616f-4dec-935d-6a0fde8748db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RELPAX is indicated for the acute treatment of migraine with or without aura in adults. RELPAX is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS ). Safety and effectiveness of RELPAX Tablets have not been established for cluster headache, which is present in an older, predominantly male population. uuid:c9903736-9c54-4cdb-b8e1-f373c62d31a9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50922 biolink:treats MONDO:0043219 PMID:41385096 "[{""id"":""uuid:a8443705-c33c-4667-a805-eb8a8051cd68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f4c48b0e-f526-4f95-98ea-ee70b2d2b93f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RELPAX is indicated for the acute treatment of migraine with or without aura in adults. RELPAX is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS ). Safety and effectiveness of RELPAX Tablets have not been established for cluster headache, which is present in an older, predominantly male population. uuid:c59e24dd-18a3-4bc9-9c2a-7055bebfd56a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50922 biolink:treats MONDO:0043537 PMID:41385096 "[{""id"":""uuid:87bec492-00fb-45ab-b9d3-91bcce5f4946"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c2480308-3cfa-4e10-bee9-d3ff9f9eaf9a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RELPAX is indicated for the acute treatment of migraine with or without aura in adults. RELPAX is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS ). Safety and effectiveness of RELPAX Tablets have not been established for cluster headache, which is present in an older, predominantly male population. uuid:94c343a1-4d20-4c41-8945-7d91a07b6d80 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:83804 biolink:treats MONDO:0005090 PMID:41385096 "[{""id"":""uuid:7d2e050d-9be6-4181-987d-653c62c8baa4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:25d9aa64-687a-4443-a9f0-585dfcf6aae7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4354e9e0-e2d5-41d4-86da-fc28784a6d20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d410dc70-afda-4a3f-a1c1-a25225b0fc04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INVEGA ® is an atypical antipsychotic agent indicated for the acute and maintenance treatment of schizophrenia ( 1.1 ) acute treatment of schizoaffective disorder as monotherapy ( 1.2 ) acute treatment of schizoaffective disorder as an adjunct to mood stabilizers and/or antidepressants ( 1.2 )|[EMA] Xeplion is indicated for maintenance treatment of schizophrenia in adult patients stabilised with paliperidone or risperidone.In selected adult patients with schizophrenia and previous responsiveness to oral paliperidone or risperidone, Xeplion may be used without prior stabilisation with oral treatment if psychotic symptoms are mild to moderate and a long-acting injectable treatment is needed.|[PMDA] Drugs with a new active ingredient indicated for the treatment of schizophrenia. uuid:1ab545d2-a0ad-4d66-bd2c-08349fd451ae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:83804 biolink:treats MONDO:0005487 PMID:41385096 "[{""id"":""uuid:940c1cea-59e0-4a68-a80e-45b93be5dc32"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:715eb755-b83b-4732-8e78-5cdda74b1174"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e47bd665-1211-4bae-8e76-b88e29987127"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INVEGA ® is an atypical antipsychotic agent indicated for the acute and maintenance treatment of schizophrenia ( 1.1 ) acute treatment of schizoaffective disorder as monotherapy ( 1.2 ) acute treatment of schizoaffective disorder as an adjunct to mood stabilizers and/or antidepressants ( 1.2 )|[EMA] Invega is indicated for the treatment of schizophrenia in adults and in adolescents 15 years and older.Invega is indicated for the treatment of schizoaffective disorder in adults. uuid:fd77da1b-695b-4675-9e6a-f526046d7e32 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5893 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:df5b6547-5a01-4161-a165-03ba74737a88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1521c47e-9380-4392-af18-10dd7be6ff1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Indapamide tablets are indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs. Indapamide tablets are also indicated for the treatment of salt and fluid retention associated with congestive heart failure. uuid:8bbc012c-17b1-4b37-9bd1-2c6fe55baa15 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5893 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:9eee7f00-2e77-40ac-9fff-7e5ad50ea8d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2a2c0f3e-91c7-4979-a37d-67a1990fb725"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Indapamide tablets are indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs. Indapamide tablets are also indicated for the treatment of salt and fluid retention associated with congestive heart failure. uuid:e2f7c9a7-fdfd-457d-ba29-2a80b32a37a0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6128 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:e620ead0-904b-44a4-980c-ca43e1a7b073"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:407b2fc0-a923-402c-8ab8-30b2c2f93096"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:eaeba635-baf2-4754-be5a-3ce7c9fab834"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of ketoprofen immediate-release capsules and ketoprofen extended-release capsules before deciding to use ketoprofen immediate-release capsules and ketoprofen extended-release capsules. Use of the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Ketoprofen immediate-release capsules and ketoprofen extended-release capsules are indicated for the management of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Ketoprofen extended-release capsules are not recommended for treatment of acute pain because of its extended-release characteristics (see CLINICAL PHARMACOLOGY: Pharmacokinetics ). Ketoprofen immediate-release capsules are indicated for the management of pain. Ketoprofen immediate-release capsules are also indicated for treatment of primary dysmenorrhea.|[PMDA] Drugs with a new additional indication for relief of local pain associated with rheumatoid arthritis. uuid:277638bc-51c4-4e7d-b9a7-a20fa6dbbde9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6128 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:e8689a52-979e-4c4d-8641-58ea69d1e254"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:48dcb2ae-6f80-4144-9099-b184324683c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of ketoprofen immediate-release capsules and ketoprofen extended-release capsules before deciding to use ketoprofen immediate-release capsules and ketoprofen extended-release capsules. Use of the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Ketoprofen immediate-release capsules and ketoprofen extended-release capsules are indicated for the management of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Ketoprofen extended-release capsules are not recommended for treatment of acute pain because of its extended-release characteristics (see CLINICAL PHARMACOLOGY: Pharmacokinetics ). Ketoprofen immediate-release capsules are indicated for the management of pain. Ketoprofen immediate-release capsules are also indicated for treatment of primary dysmenorrhea. uuid:9a86875e-5014-4865-9d8c-18690e81ad05 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6128 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:aafda614-33a2-433c-adf8-43c1ba2906d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9adc9a2d-0ddc-485f-b450-56d221a5d446"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of ketoprofen immediate-release capsules and ketoprofen extended-release capsules before deciding to use ketoprofen immediate-release capsules and ketoprofen extended-release capsules. Use of the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Ketoprofen immediate-release capsules and ketoprofen extended-release capsules are indicated for the management of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Ketoprofen extended-release capsules are not recommended for treatment of acute pain because of its extended-release characteristics (see CLINICAL PHARMACOLOGY: Pharmacokinetics ). Ketoprofen immediate-release capsules are indicated for the management of pain. Ketoprofen immediate-release capsules are also indicated for treatment of primary dysmenorrhea. uuid:285e65f3-8256-4a8a-9502-901cfa60a37c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6128 biolink:treats MONDO:1060206 PMID:41385096 "[{""id"":""uuid:ff71ffd5-9e8b-4bb7-8427-8f36cda46675"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b01e9e96-e768-4ace-9f05-c475e23a3744"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of ketoprofen immediate-release capsules and ketoprofen extended-release capsules before deciding to use ketoprofen immediate-release capsules and ketoprofen extended-release capsules. Use of the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Ketoprofen immediate-release capsules and ketoprofen extended-release capsules are indicated for the management of the signs and symptoms of rheumatoid arthritis and osteoarthritis. Ketoprofen extended-release capsules are not recommended for treatment of acute pain because of its extended-release characteristics (see CLINICAL PHARMACOLOGY: Pharmacokinetics ). Ketoprofen immediate-release capsules are indicated for the management of pain. Ketoprofen immediate-release capsules are also indicated for treatment of primary dysmenorrhea. UMLS:C0149875 uuid:4c76067d-2331-4441-9fe8-a2996d8258d1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7444 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:be957a32-86c8-4025-9732-662c570e4cd8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f0ef984b-c0e6-4fd0-91f5-75287b01531d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nadolol tablets are indicated for the long-term management of patients with angina pectoris. uuid:ea9e7bc3-593b-497c-baa1-e1f852055a38 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31596 biolink:treats MONDO:0005393 PMID:41385096 "[{""id"":""uuid:f6b7bbfc-989d-4b86-9df0-d4380e96d78d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7bfc3ba5-710f-4f22-858d-13d20e0fc417"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c73b78cd-e939-45d3-bf8c-6a753083172a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/febuxostat-mylan""]},{""id"":""uuid:50148266-ef57-4b76-8296-88a2da9014c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ULORIC ® is a xanthine oxidase (XO) inhibitor indicated for the chronic management of hyperuricemia in patients with gout. ULORIC is not recommended for the treatment of asymptomatic hyperuricemia.|[EMA] Febuxostat Mylan is indicated for the prevention and treatment of hyperuricaemia in adult patients undergoing chemotherapy for haematologic malignancies at intermediate to high risk of Tumor Lysis Syndrome (TLS).Febuxostat Mylan is indicated for the treatment of chronic hyperuricaemia in conditions where urate deposition has already occurred (including a history, or presence of, tophus and/or gouty arthritis).Febuxostat Mylan is indicated in adults.|[PMDA] Drugs with a new active ingredient indicated for the treatment of gout and hyperuricemia. uuid:c8896698-b973-418d-9f59-cd228e9eab4b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31596 biolink:treats HP:0002149 PMID:41385096 "[{""id"":""uuid:c48b86a6-6b04-4dc3-83fd-607ed624cfe9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:934c6b32-ef60-41fc-add2-29482dab758a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:64dd7902-ba46-4129-96dd-dfd3bd14376a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ULORIC ® is a xanthine oxidase (XO) inhibitor indicated for the chronic management of hyperuricemia in patients with gout. ULORIC is not recommended for the treatment of asymptomatic hyperuricemia.|[PMDA] Drugs with a new active ingredient indicated for the treatment of gout and hyperuricemia. uuid:e1c36ca8-aa04-4c27-8342-2db8f5cf6c89 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31547 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:dedd173d-7b4a-4c83-8368-ab27d29e79fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2af433db-426d-450c-90c9-fa0b6610b635"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b560fcfa-1863-42bd-a26f-1088c7fcb32c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INSPRA is an aldosterone antagonist indicated for: Improving survival of stable patients with LV systolic dysfunction (LVEF ≤40%) and CHF after an acute myocardial infarction. ( 1.2 ) Hypertension, alone or combined with other agents. ( 1.3 )|[PMDA] Drugs with a new additional indication and a new dosage for the treatment of chronic heart failure in patients receiving basic treatment with angiotensin converting enzyme inhibitors or angiotensin II receptor antagonists, β-blockers, diuretics, etc. uuid:2b9adb73-905e-4c28-b204-c5de73352f78 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31547 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:dcc667e6-09d1-4f1b-a5f1-97ada377ce35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6271a1ef-2346-44c6-a7f1-98ed0824945b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ca7e5dad-5b78-4756-a877-141c020f89a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INSPRA is an aldosterone antagonist indicated for: Improving survival of stable patients with LV systolic dysfunction (LVEF ≤40%) and CHF after an acute myocardial infarction. ( 1.2 ) Hypertension, alone or combined with other agents. ( 1.3 )|[PMDA] Drugs containing a new active ingredient indicated for the treatment of hypertension. uuid:3cbec66f-151e-48a2-9719-1057f7899c9c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6437 biolink:treats HP:0032794 PMID:41385096 "[{""id"":""uuid:40cb3b79-6a88-4f62-877a-f225a6fe8121"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ca038475-d639-44d7-ade9-7e45209d3ec9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:acd9f7fd-d55d-4c85-8772-6b6e3df2a53b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/levetiracetam-sun""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEPPRA is indicated as adjunctive therapy in the treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy. KEPPRA is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy. KEPPRA is indicated as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in adults and children 6 years of age and older with idiopathic generalized epilepsy.|[EMA] Levetiracetam Sun is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.Levetiracetam Sun is indicated as adjunctive therapy:in the treatment of partial-onset seizures with or without secondary generalisation in adults and children from four years of age with epilepsy;in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.Levetiracetam Sun concentrate is an alternative for patients when oral administration is temporarily not feasible. uuid:26ffbd01-be7d-45f1-9b47-28ba3d44ef3a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6437 biolink:treats MONDO:0009696 PMID:41385096 "[{""id"":""uuid:e71fd7b3-3d6c-47f3-a1a6-e6fe23ba7b40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:7e244685-1bc0-4b1c-9e52-1afcc92ad818"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:51e64f1a-1691-40f8-acfb-f22777e853aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/levetiracetam-sun""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEPPRA is indicated as adjunctive therapy in the treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy. KEPPRA is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy. KEPPRA is indicated as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in adults and children 6 years of age and older with idiopathic generalized epilepsy.|[EMA] Levetiracetam Sun is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.Levetiracetam Sun is indicated as adjunctive therapy:in the treatment of partial-onset seizures with or without secondary generalisation in adults and children from four years of age with epilepsy;in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.Levetiracetam Sun concentrate is an alternative for patients when oral administration is temporarily not feasible. uuid:31bfb0a1-dd5e-41f4-b69b-21d301f563f0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6437 biolink:treats MONDO:0005754 PMID:41385096 "[{""id"":""uuid:1690a412-04cf-4711-8d4b-e4e2a307e5f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a4fd1f58-d762-4ae3-93a7-bbb591569f2d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f2222a47-1775-4e5c-94d7-023f53c82ad2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/levetiracetam-sun""]},{""id"":""uuid:4ff631db-e605-4bb2-91cf-cc068bbba011"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEPPRA is indicated as adjunctive therapy in the treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy. KEPPRA is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy. KEPPRA is indicated as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in adults and children 6 years of age and older with idiopathic generalized epilepsy.|[EMA] Levetiracetam Sun is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.Levetiracetam Sun is indicated as adjunctive therapy:in the treatment of partial-onset seizures with or without secondary generalisation in adults and children from four years of age with epilepsy;in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.Levetiracetam Sun concentrate is an alternative for patients when oral administration is temporarily not feasible.|[PMDA] Drugs with a new additional indication for use as an adjunctive therapy with other antiepileptic drugs to treat tonic-clonic seizures in patients with epilepsy who have not responded sufficiently to other antiepileptic drugs. uuid:4f1162d7-2393-4271-952a-03321887353a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6437 biolink:treats MONDO:0005579 PMID:41385096 "[{""id"":""uuid:abc4fdaa-43cd-4617-96c7-142f49e0fb79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:7bf9f2cb-5547-499e-9ae1-0aaf168b339f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:702bd2eb-8561-491b-b9b1-29a45c48ed7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/levetiracetam-sun""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEPPRA is indicated as adjunctive therapy in the treatment of partial onset seizures in adults and children 4 years of age and older with epilepsy. KEPPRA is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy. KEPPRA is indicated as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in adults and children 6 years of age and older with idiopathic generalized epilepsy.|[EMA] Levetiracetam Sun is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.Levetiracetam Sun is indicated as adjunctive therapy:in the treatment of partial-onset seizures with or without secondary generalisation in adults and children from four years of age with epilepsy;in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy;in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.Levetiracetam Sun concentrate is an alternative for patients when oral administration is temporarily not feasible. uuid:b2c68252-742b-485b-8bf4-e89a7c023d9b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:61049 biolink:treats UMLS:C0345468 PMID:41385096 "[{""id"":""uuid:3e82c0d8-0bee-43fb-93d7-24af3e21f2c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b5d5c297-6a59-42d0-9a56-fcc7f45da1ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:462c35ce-d377-4dd1-91cd-21011425002d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/advagraf""]},{""id"":""uuid:aa40a6b1-b609-49fd-8c1e-098ca9032d09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prograf is indicated for the prophylaxis of organ rejection in patients receiving allogeneic liver, kidney, or heart transplants. It is recommended that Prograf be used concomitantly with adrenal corticosteroids. Because of the risk of anaphylaxis, Prograf injection should be reserved for patients unable to take Prograf capsules orally. In heart and kidney transplant recipients, it is recommended that Prograf be used in conjunction with azathioprine or mycophenolate mofetil (MMF). The safety and efficacy of the use of Prograf with sirolimus has not been established (see CLINICAL STUDIES ).|[EMA] Prophylaxis of transplant rejection in adult kidney or liver allograft recipients.Treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult patients.|[PMDA] Drugs in a new dosage form indicated for suppression of organ rejection in renal, liver, heart, lung, and pancreatic transplantation, as well as for suppression of graft rejection and graft versus host disease (GVHD) in bone marrow transplantation. uuid:93051d92-69d3-47e9-b2be-e12412d6473e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:61049 biolink:treats UMLS:C0400968 PMID:41385096 "[{""id"":""uuid:e09e91b6-ee73-418b-b576-974118dbab90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:65cad69f-b0bd-415e-abe6-cacfec1ac0e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prograf is indicated for the prophylaxis of organ rejection in patients receiving allogeneic liver, kidney, or heart transplants. It is recommended that Prograf be used concomitantly with adrenal corticosteroids. Because of the risk of anaphylaxis, Prograf injection should be reserved for patients unable to take Prograf capsules orally. In heart and kidney transplant recipients, it is recommended that Prograf be used in conjunction with azathioprine or mycophenolate mofetil (MMF). The safety and efficacy of the use of Prograf with sirolimus has not been established (see CLINICAL STUDIES ). uuid:0fca8dac-8790-420d-ba93-ff2d9576cf92 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:61049 biolink:treats UMLS:C0238217 PMID:41385096 "[{""id"":""uuid:8a7bae87-3203-4318-b2a7-489e488528fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2913558d-abde-4cb6-ba4d-eb836edd9466"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:22e7a56e-00e6-429c-9c9d-b7ef010915d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prograf is indicated for the prophylaxis of organ rejection in patients receiving allogeneic liver, kidney, or heart transplants. It is recommended that Prograf be used concomitantly with adrenal corticosteroids. Because of the risk of anaphylaxis, Prograf injection should be reserved for patients unable to take Prograf capsules orally. In heart and kidney transplant recipients, it is recommended that Prograf be used in conjunction with azathioprine or mycophenolate mofetil (MMF). The safety and efficacy of the use of Prograf with sirolimus has not been established (see CLINICAL STUDIES ).|[PMDA] Drugs with a new dosage indicated for the suppression of rejection reaction associated with kidney transplantation. [Orphan drug] uuid:d5513b12-d248-49af-a995-f15d291846e9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:61049 biolink:treats UMLS:C0340530 PMID:41385096 "[{""id"":""uuid:983f5873-2287-4927-a98f-22f446b7b9e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:16429031-4e58-4e92-a407-9ccb109e6e5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prograf is indicated for the prophylaxis of organ rejection in patients receiving allogeneic liver, kidney, or heart transplants. It is recommended that Prograf be used concomitantly with adrenal corticosteroids. Because of the risk of anaphylaxis, Prograf injection should be reserved for patients unable to take Prograf capsules orally. In heart and kidney transplant recipients, it is recommended that Prograf be used in conjunction with azathioprine or mycophenolate mofetil (MMF). The safety and efficacy of the use of Prograf with sirolimus has not been established (see CLINICAL STUDIES ). uuid:6983badf-22fd-4c83-ba7b-372addb71e3b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB09381 biolink:treats HP:0000134 PMID:41385096 "[{""id"":""uuid:7c8bf8c2-6910-4fa8-8bb1-b18923714739"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:94e1e4bf-6042-4959-ae81-f261dd110caf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Menest is indicated in the: Treatment of moderate to severe vasomotor symptoms associated with the menopause. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Female hypogonadism. Female castration. Primary ovarian failure. Breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. Prostatic carcinoma - palliative therapy of advanced disease. uuid:81c3191b-84aa-4afe-9900-dca2ee460b16 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB09381 biolink:treats MONDO:0005387 PMID:41385096 "[{""id"":""uuid:e369f576-4e21-41bd-9832-d92e3a704cba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e9ccf958-4338-4284-8bd6-d3e1b96157de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Menest is indicated in the: Treatment of moderate to severe vasomotor symptoms associated with the menopause. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Female hypogonadism. Female castration. Primary ovarian failure. Breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. Prostatic carcinoma - palliative therapy of advanced disease. uuid:8276f596-1072-4b99-81b3-aa38473db5e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB09381 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:4666f1be-3590-4dc6-9eae-2aa624af4689"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3afbbf14-1be5-4084-820a-aa566a95b09a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Menest is indicated in the: Treatment of moderate to severe vasomotor symptoms associated with the menopause. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Female hypogonadism. Female castration. Primary ovarian failure. Breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. Prostatic carcinoma - palliative therapy of advanced disease. uuid:5e503859-377c-478d-9a3e-623a9c7a8a8d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB09381 biolink:treats MONDO:0005159 PMID:41385096 "[{""id"":""uuid:b7e49926-a7dc-4e66-b34b-563a5f1926bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:67bd0d24-dd63-4588-a900-8d93f12aa12e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Menest is indicated in the: Treatment of moderate to severe vasomotor symptoms associated with the menopause. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Female hypogonadism. Female castration. Primary ovarian failure. Breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. Prostatic carcinoma - palliative therapy of advanced disease. uuid:adc53ebb-4fee-47d7-89b1-b99c59bc2f5d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:216244 biolink:treats MONDO:0004795 PMID:41385096 "[{""id"":""uuid:f72dec95-9f5e-419b-8e15-f67ec5f9ac6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6b52c737-28b5-4978-8bfa-fb68e8d3309f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cortisporin ® -TC Otic Suspension is indicated for the treatment of superficial bacterial infections of the external auditory canal, caused by organisms susceptible to the action of the antibiotics; and for the treatment of infections of mastoidectomy and fenestration cavities, caused by organisms susceptible to the antibiotics. uuid:b8d97d63-50b7-41c2-a6f1-040f049af03c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:216244 biolink:treats MONDO:0021666 PMID:41385096 "[{""id"":""uuid:0a32d65f-06ce-452e-ad14-26987a874b6d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:df146427-2869-484d-b72e-246c9f9e25fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cortisporin ® -TC Otic Suspension is indicated for the treatment of superficial bacterial infections of the external auditory canal, caused by organisms susceptible to the action of the antibiotics; and for the treatment of infections of mastoidectomy and fenestration cavities, caused by organisms susceptible to the antibiotics. uuid:82da0b21-987e-412d-adcc-b71000bf0dbe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:205919 biolink:treats MONDO:0006605 PMID:41385096 "[{""id"":""uuid:b34e5de7-dbe8-4442-8093-49000225968b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:80d16d66-704e-48e3-a101-99e04682918e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9674c47e-a3b1-4d21-b542-5bfb585f8ef7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clobetasol propionate topical solution is indicated for shortterm topical treatment of inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp. Treatment beyond 2 consecutive weeks is not recommended, and the total dosage should not exceed 50 mL/week because of the potential for the drug to suppress the HPA axis. This product is not recommended for use in pediatric patients under 12 years of age.|[PMDA] A drug with a new indication for the treatment of eczema/dermatitis of the scalp. uuid:9cfc4611-02e9-44f6-82cc-5ef1c1b6b4a3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7956 biolink:treats MONDO:0043653 PMID:41385096 "[{""id"":""uuid:5e37ecf3-a247-4672-b772-4abe26e00bad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f1f62ce9-29bd-4378-bd06-8de137d13f8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Denavir (penciclovir cream) is indicated for the treatment of recurrent herpes labialis (cold sores) in adults and children 12 years of age and older. uuid:4af39b01-32d2-4c9c-a3bc-bb1606db7454 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:3263 biolink:treats MONDO:0018555 PMID:41385096 "[{""id"":""uuid:f1a9396e-f0e1-4f43-ab32-a10f7d9bc4fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:728935fc-8ea8-4e3d-a1c1-36d77528aa87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DEPO-Estradiol Injection is indicated in the treatment of: Moderate to severe vasomotor symptoms associated with the menopause. Hypoestrogenism due to hypogonadism. uuid:03c7f4aa-1643-4685-ad36-fc1c0f54f3ad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841571 biolink:treats MONDO:0005338 PMID:41385096 "[{""id"":""uuid:92e8a848-d774-434d-86ff-c3572802e3d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:42226efa-48d8-4ae9-8fda-74eded0c5c7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] COSOPT is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers (failed to achieve target IOP determined after multiple measurements over time). The IOP-lowering of COSOPT b.i.d. was slightly less than that seen with the concomitant administration of 0.5% timolol b.i.d. and 2.0% dorzolamide t.i.d. (see CLINICAL PHARMACOLOGY, Clinical Studies ). uuid:1b5102e1-c103-4efe-8812-df94d12bb9b9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841571 biolink:treats MONDO:0006875 PMID:41385096 "[{""id"":""uuid:db088530-373b-42e0-833c-4a279908019b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0fbdbbe9-c767-4275-9b27-9d2b0fdf09d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] COSOPT is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to beta-blockers (failed to achieve target IOP determined after multiple measurements over time). The IOP-lowering of COSOPT b.i.d. was slightly less than that seen with the concomitant administration of 0.5% timolol b.i.d. and 2.0% dorzolamide t.i.d. (see CLINICAL PHARMACOLOGY, Clinical Studies ). uuid:ef43215a-b505-4872-b87d-3ce94d0d565d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:127342 biolink:treats MONDO:0005302 PMID:41385096 "[{""id"":""uuid:1df567a9-83bc-4517-9bea-f87e0fff7d2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d3d6fa06-7884-405e-a0ce-2829fb62fe04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ad51ee06-816d-425f-a839-33b0458d171f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atomoxetine hydrochloride is a selective norepinephrine reuptake inhibitor indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD). (1.1)|[PMDA] Drugs with a new active ingredient indicated for the treatment of attention-deficit/hyperactivity disorder (AD/HD) in children. [Expedited review] uuid:c0deef6d-87a3-4ce3-9f35-96b8d412a560 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45367 biolink:treats MONDO:0005866 PMID:41385096 "[{""id"":""uuid:794f4f26-8f28-4fd0-9e2d-a114d90dcb4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:08d4c8c9-dfe0-4f8c-bb4c-3a317c19043c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3e2a56ac-f0a9-4068-a147-cfba9ab0766a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MYCOBUTIN Capsules are indicated for the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection.|[PMDA] A drug containing a new active ingredient indicated for the treatment of 1) tuberculosis, 2) non-tuberculous mycobacteriosis including mycobacterium avium complex (MAC) infections, and 3) prophylaxis of disseminated MAC infections in patients with HIV disease. uuid:4b03e361-5d63-4c1f-b380-6fa764281c46 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5062 biolink:treats MONDO:0010811 PMID:41385096 "[{""id"":""uuid:d5c60944-1cdb-492b-a772-4e58b32e1200"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:25e3fe4d-fdfd-4a4e-867c-4b1f88e1eed3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Finasteride tablets USP are indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to: -Improve symptoms -Reduce the risk of the need for surgery including transurethral resection of the prostate (TURP) and prostatectomy. uuid:6728c71e-fcfc-4f0a-a9c1-be12513a0b6c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18258 biolink:treats MONDO:0006982 PMID:41385096 "[{""id"":""uuid:61922fce-24ab-4d4e-b014-b99e455459c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:01780112-f5b2-4954-946a-90f78388d0c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thyroid hormone drugs are indicated: As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema and ordinary hypothyroidism in patients of any age (pediatric patients, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary) or tertiary (hypothalamic) hypothyroidism (see WARNINGS ). As pituitary thyroid-stimulating hormone (TSH) suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto’s) and multinodular goiter. As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy. Cytomel (liothyronine sodium) Tablets can be used in patients allergic to desiccated thyroid or thyroid extract derived from pork or beef. uuid:60bd635b-52ec-4860-88e5-24c7216bead6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1163424 biolink:treats UMLS:C0442886 PMID:41385096 "[{""id"":""uuid:6c62d8ad-12fa-4d8b-b55a-88538b120859"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:232de488-4bbf-4f5a-94b2-488b383fcd59"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of corticosteroid-responsive dermatoses with secondary infection. It has not been demonstrated that this steroid-antibiotic combination provides greater benefit than the steroid component alone after 7 days of treatment (see WARNINGS ). uuid:87a65d6e-27eb-4b97-a3b8-45a25af46f8c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6887 biolink:treats MONDO:0005302 PMID:41385096 "[{""id"":""uuid:686734b9-4624-484b-9ab2-3c802ff3acef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a662df08-7cd5-4cd5-b6fc-51485453c6df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:48d2a0e9-3d5c-4361-9cf8-0b07daa8372f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] CONCERTA ® is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children 6 years of age and older, adolescents, and adults up to the age of 65 [see Clinical Studies (14) ] . A diagnosis of Attention Deficit Hyperactivity Disorder (ADHD; DSM-IV) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. The symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in two or more settings, e.g., school (or work) and at home. The symptoms must not be better accounted for by another mental disorder. For the Inattentive Type, at least six of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effort; loses things; easily distracted; forgetful. For the Hyperactive-Impulsive Type, at least six of the following symptoms must have persisted for at least 6 months: fidgeting/squirming; leaving seat; inappropriate running/climbing; difficulty with quiet activities; ""on the go;"" excessive talking; blurting answers; can't wait turn; intrusive. The Combined Type requires both inattentive and hyperactive-impulsive criteria to be met.|[PMDA] A drug with a new indication and a new dosage in an additional dosage form indicated for the treatment of attention deficit/hyperactivity disorder (AD/HD) in adults." uuid:4b49a78c-cbcc-4483-b23b-791cd762ffd2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4325 biolink:treats MONDO:0015614 PMID:41385096 "[{""id"":""uuid:a9eb4a89-2f4a-467d-9140-6bb21ea2dd9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c6a26690-ef41-49ed-b918-1c6e90c44eac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dermatitis herpetiformis: (D.H.) Leprosy: All forms of leprosy except for cases of proven Dapsone resistance. uuid:d061ab77-acf0-42e7-bfa6-03f927841b56 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4325 biolink:treats MONDO:0005124 PMID:41385096 "[{""id"":""uuid:020e2f3b-f57f-4d11-89e1-f569dfcfd776"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4aafee9c-9798-42e9-bd9e-8994d597b10a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dermatitis herpetiformis: (D.H.) Leprosy: All forms of leprosy except for cases of proven Dapsone resistance. uuid:6977a649-b3d9-4447-aa27-ebd65a0dfa9b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1162127 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:5735d828-0906-451b-ba9e-4b553560bb1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5759cea9-d884-4061-b2be-e8e050af24eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] HYZAAR is indicated for the treatment of hypertension. This fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients (see CLINICAL PHARMACOLOGY, Pharmacodynamics and Clinical Effects , and DOSAGE AND ADMINISTRATION ). uuid:9f67269a-37f9-4c6d-8187-0b6b35f9a395 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1152284 biolink:treats NCIT:C50995 PMID:41385096 "[{""id"":""uuid:04fe9cab-a546-4378-81bf-7f6e04cdaa33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9130313d-2be8-4bbd-8210-7bbc93b3fba6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] {template} uuid:f49a0867-eee5-4922-b27f-fb07c0b61a26 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7660 biolink:treats MONDO:0002026 PMID:41385096 "[{""id"":""uuid:183fca3b-7350-41bc-9b36-02aaacbadbc8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d961c596-e030-4abd-abf5-e66479af1722"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nystatin Oral Suspension is indicated for the treatment of candidiasis in the oral cavity. uuid:bad65bad-16fa-4357-8af3-d7d0fdee8c7c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7660 biolink:treats MONDO:0005886 PMID:41385096 "[{""id"":""uuid:ea6be383-931f-4586-a54a-e2a0f41ddbdd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:939db682-0ad0-447f-a66b-b41f8cd316ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nystatin Oral Suspension is indicated for the treatment of candidiasis in the oral cavity. uuid:b041960e-47e4-444d-bf48-7efc49301a04 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6541 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:686de6b3-2dc5-45c2-8337-c4b594eb59e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2730a770-e141-4fb2-b897-5abceba06b1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Losartan potassium tablets are indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents, including diuretics. uuid:a544c141-d514-4eda-a5fb-50db847594a0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40303 biolink:treats HP:0003119 PMID:41385096 "[{""id"":""uuid:e0f9ff29-59cd-4043-8b97-ae825dc011db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1a40d7b2-71f6-4e01-a0f7-9bc8560e2410"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lovastatin tablets should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C, lovastatin tablets are indicated to reduce the risk of: - Myocardial infarction - Unstable angina - Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies .) Coronary Heart Disease Lovastatin tablets are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb***), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. *** Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein Type Lipoproteins elevated Lipid Elevations major minor I Chylomicrons TG ↑ →C IIa LDL C — IIb LDL, VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑ →C V (rare) Chylomicrons, VLDL TG ↑ →C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets are indicated as an adjunct to diet to reduce total-C, LDL-C and apolipoprotein B levels in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with heFH if after an adequate trial of diet therapy the following findings are present: LDL-C remains >189 mg/dL or LDL-C remains >160 mg/dL and: • there is a positive family history of premature cardiovascular disease or • two or more other CVD risk factors are present in the adolescent patient General Recommendations Prior to initiating therapy with lovastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total-C, HDL-C, and TG. For patients with TG less than 400 mg / dL (<4.5 mmol / L), LDL-C can be estimated using the following equation: LDL-C = total-C – [0.2 x (TG) + HDL-C] For TG levels >400 mg/dL (>4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated total-C. In such cases, lovastatin tablets are not indicated. The National Cholesterol Education Program (NCEP) Treatment Guidelines are summarized below: NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD CHD, coronary heart disease or CHD risk equivalence (10-year risk >20%) <100 ≥100 ≥130 (100-129: drug optional) Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of <100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgment also may call for deferring drug therapy in this subcategory. 2+ Risk factors (10-year risk ≤20%) <130 ≥130 10-year risk 10-20%: ≥130 10-year risk<10%: ≥160 0-1 Risk factor Almost all people with 0-1 risk factor have a 10-year risk <10%; thus, 10-year risk assessment in people with 0-1 risk factor is not necessary. <160 ≥160 ≥190 (160-189: LDL-lowering drug optional) After the LDL-C goal has been achieved, if the TG is still ≥200 mg/dL, non-HDL-C (total-C minus HDLC) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is ≥130 mg/dL (see NCEP Guidelines above). Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the total-C be used to monitor therapy. Although lovastatin tablets may be useful to reduce elevated LDL-C levels in patients with combined hypercholesterolemia and hypertriglyceridemia where hypercholesterolemia is the major abnormality (Type IIb hyperlipoproteinemia), it has not been studied in conditions where the major abnormality is elevation of chylomicrons, VLDL or IDL (i.e., hyperlipoproteinemia types I, III, IV, or V).*** The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable <170 <110 Borderline 170-199 110-129 High ≥200 ≥130 Children treated with lovastatin in adolescence should be re-evaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult goals for LDL-C. uuid:a438dbf2-01ba-4053-8cea-71f58e625dd0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40303 biolink:treats MONDO:0005311 PMID:41385096 "[{""id"":""uuid:b855090f-adab-4f45-9da2-416e7ef252b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8be642e5-b8f7-4b49-80a7-c4211263b241"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lovastatin tablets should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C, lovastatin tablets are indicated to reduce the risk of: - Myocardial infarction - Unstable angina - Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies .) Coronary Heart Disease Lovastatin tablets are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb***), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. *** Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein Type Lipoproteins elevated Lipid Elevations major minor I Chylomicrons TG ↑ →C IIa LDL C — IIb LDL, VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑ →C V (rare) Chylomicrons, VLDL TG ↑ →C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets are indicated as an adjunct to diet to reduce total-C, LDL-C and apolipoprotein B levels in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with heFH if after an adequate trial of diet therapy the following findings are present: LDL-C remains >189 mg/dL or LDL-C remains >160 mg/dL and: • there is a positive family history of premature cardiovascular disease or • two or more other CVD risk factors are present in the adolescent patient General Recommendations Prior to initiating therapy with lovastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total-C, HDL-C, and TG. For patients with TG less than 400 mg / dL (<4.5 mmol / L), LDL-C can be estimated using the following equation: LDL-C = total-C – [0.2 x (TG) + HDL-C] For TG levels >400 mg/dL (>4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated total-C. In such cases, lovastatin tablets are not indicated. The National Cholesterol Education Program (NCEP) Treatment Guidelines are summarized below: NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD CHD, coronary heart disease or CHD risk equivalence (10-year risk >20%) <100 ≥100 ≥130 (100-129: drug optional) Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of <100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgment also may call for deferring drug therapy in this subcategory. 2+ Risk factors (10-year risk ≤20%) <130 ≥130 10-year risk 10-20%: ≥130 10-year risk<10%: ≥160 0-1 Risk factor Almost all people with 0-1 risk factor have a 10-year risk <10%; thus, 10-year risk assessment in people with 0-1 risk factor is not necessary. <160 ≥160 ≥190 (160-189: LDL-lowering drug optional) After the LDL-C goal has been achieved, if the TG is still ≥200 mg/dL, non-HDL-C (total-C minus HDLC) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is ≥130 mg/dL (see NCEP Guidelines above). Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the total-C be used to monitor therapy. Although lovastatin tablets may be useful to reduce elevated LDL-C levels in patients with combined hypercholesterolemia and hypertriglyceridemia where hypercholesterolemia is the major abnormality (Type IIb hyperlipoproteinemia), it has not been studied in conditions where the major abnormality is elevation of chylomicrons, VLDL or IDL (i.e., hyperlipoproteinemia types I, III, IV, or V).*** The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable <170 <110 Borderline 170-199 110-129 High ≥200 ≥130 Children treated with lovastatin in adolescence should be re-evaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult goals for LDL-C. uuid:53106de7-5cd9-4003-ae47-ff43d7d92f72 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40303 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:47355ea1-5df0-42ad-82d1-6d0a01189488"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9cc516fe-ae62-445f-b662-b62b73449f1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lovastatin tablets should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C, lovastatin tablets are indicated to reduce the risk of: - Myocardial infarction - Unstable angina - Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies .) Coronary Heart Disease Lovastatin tablets are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb***), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. *** Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein Type Lipoproteins elevated Lipid Elevations major minor I Chylomicrons TG ↑ →C IIa LDL C — IIb LDL, VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑ →C V (rare) Chylomicrons, VLDL TG ↑ →C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets are indicated as an adjunct to diet to reduce total-C, LDL-C and apolipoprotein B levels in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with heFH if after an adequate trial of diet therapy the following findings are present: LDL-C remains >189 mg/dL or LDL-C remains >160 mg/dL and: • there is a positive family history of premature cardiovascular disease or • two or more other CVD risk factors are present in the adolescent patient General Recommendations Prior to initiating therapy with lovastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total-C, HDL-C, and TG. For patients with TG less than 400 mg / dL (<4.5 mmol / L), LDL-C can be estimated using the following equation: LDL-C = total-C – [0.2 x (TG) + HDL-C] For TG levels >400 mg/dL (>4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated total-C. In such cases, lovastatin tablets are not indicated. The National Cholesterol Education Program (NCEP) Treatment Guidelines are summarized below: NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD CHD, coronary heart disease or CHD risk equivalence (10-year risk >20%) <100 ≥100 ≥130 (100-129: drug optional) Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of <100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgment also may call for deferring drug therapy in this subcategory. 2+ Risk factors (10-year risk ≤20%) <130 ≥130 10-year risk 10-20%: ≥130 10-year risk<10%: ≥160 0-1 Risk factor Almost all people with 0-1 risk factor have a 10-year risk <10%; thus, 10-year risk assessment in people with 0-1 risk factor is not necessary. <160 ≥160 ≥190 (160-189: LDL-lowering drug optional) After the LDL-C goal has been achieved, if the TG is still ≥200 mg/dL, non-HDL-C (total-C minus HDLC) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is ≥130 mg/dL (see NCEP Guidelines above). Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the total-C be used to monitor therapy. Although lovastatin tablets may be useful to reduce elevated LDL-C levels in patients with combined hypercholesterolemia and hypertriglyceridemia where hypercholesterolemia is the major abnormality (Type IIb hyperlipoproteinemia), it has not been studied in conditions where the major abnormality is elevation of chylomicrons, VLDL or IDL (i.e., hyperlipoproteinemia types I, III, IV, or V).*** The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable <170 <110 Borderline 170-199 110-129 High ≥200 ≥130 Children treated with lovastatin in adolescence should be re-evaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult goals for LDL-C. uuid:c571caae-d61b-43f4-a4e5-913e7a4f5e4d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40303 biolink:treats MONDO:0021661 PMID:41385096 "[{""id"":""uuid:9420ac78-eca1-4ba0-861f-59049576966f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:45f821eb-4c96-4dde-b43d-befbc8971425"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lovastatin tablets should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C, lovastatin tablets are indicated to reduce the risk of: - Myocardial infarction - Unstable angina - Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies .) Coronary Heart Disease Lovastatin tablets are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb***), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. *** Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein Type Lipoproteins elevated Lipid Elevations major minor I Chylomicrons TG ↑ →C IIa LDL C — IIb LDL, VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑ →C V (rare) Chylomicrons, VLDL TG ↑ →C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets are indicated as an adjunct to diet to reduce total-C, LDL-C and apolipoprotein B levels in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with heFH if after an adequate trial of diet therapy the following findings are present: LDL-C remains >189 mg/dL or LDL-C remains >160 mg/dL and: • there is a positive family history of premature cardiovascular disease or • two or more other CVD risk factors are present in the adolescent patient General Recommendations Prior to initiating therapy with lovastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total-C, HDL-C, and TG. For patients with TG less than 400 mg / dL (<4.5 mmol / L), LDL-C can be estimated using the following equation: LDL-C = total-C – [0.2 x (TG) + HDL-C] For TG levels >400 mg/dL (>4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated total-C. In such cases, lovastatin tablets are not indicated. The National Cholesterol Education Program (NCEP) Treatment Guidelines are summarized below: NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD CHD, coronary heart disease or CHD risk equivalence (10-year risk >20%) <100 ≥100 ≥130 (100-129: drug optional) Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of <100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgment also may call for deferring drug therapy in this subcategory. 2+ Risk factors (10-year risk ≤20%) <130 ≥130 10-year risk 10-20%: ≥130 10-year risk<10%: ≥160 0-1 Risk factor Almost all people with 0-1 risk factor have a 10-year risk <10%; thus, 10-year risk assessment in people with 0-1 risk factor is not necessary. <160 ≥160 ≥190 (160-189: LDL-lowering drug optional) After the LDL-C goal has been achieved, if the TG is still ≥200 mg/dL, non-HDL-C (total-C minus HDLC) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is ≥130 mg/dL (see NCEP Guidelines above). Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the total-C be used to monitor therapy. Although lovastatin tablets may be useful to reduce elevated LDL-C levels in patients with combined hypercholesterolemia and hypertriglyceridemia where hypercholesterolemia is the major abnormality (Type IIb hyperlipoproteinemia), it has not been studied in conditions where the major abnormality is elevation of chylomicrons, VLDL or IDL (i.e., hyperlipoproteinemia types I, III, IV, or V).*** The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable <170 <110 Borderline 170-199 110-129 High ≥200 ≥130 Children treated with lovastatin in adolescence should be re-evaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult goals for LDL-C. uuid:027888a8-bb92-4c57-9993-7c19436391c0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40303 biolink:treats HP:0003124 PMID:41385096 "[{""id"":""uuid:ca8c5be4-aa70-4410-8562-a5de7ded41eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bf9e1eb5-e6dc-46ef-a841-1e909b7c7338"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lovastatin tablets should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C, lovastatin tablets are indicated to reduce the risk of: - Myocardial infarction - Unstable angina - Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies .) Coronary Heart Disease Lovastatin tablets are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb***), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. *** Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein Type Lipoproteins elevated Lipid Elevations major minor I Chylomicrons TG ↑ →C IIa LDL C — IIb LDL, VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑ →C V (rare) Chylomicrons, VLDL TG ↑ →C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets are indicated as an adjunct to diet to reduce total-C, LDL-C and apolipoprotein B levels in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with heFH if after an adequate trial of diet therapy the following findings are present: LDL-C remains >189 mg/dL or LDL-C remains >160 mg/dL and: • there is a positive family history of premature cardiovascular disease or • two or more other CVD risk factors are present in the adolescent patient General Recommendations Prior to initiating therapy with lovastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total-C, HDL-C, and TG. For patients with TG less than 400 mg / dL (<4.5 mmol / L), LDL-C can be estimated using the following equation: LDL-C = total-C – [0.2 x (TG) + HDL-C] For TG levels >400 mg/dL (>4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated total-C. In such cases, lovastatin tablets are not indicated. The National Cholesterol Education Program (NCEP) Treatment Guidelines are summarized below: NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD CHD, coronary heart disease or CHD risk equivalence (10-year risk >20%) <100 ≥100 ≥130 (100-129: drug optional) Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of <100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgment also may call for deferring drug therapy in this subcategory. 2+ Risk factors (10-year risk ≤20%) <130 ≥130 10-year risk 10-20%: ≥130 10-year risk<10%: ≥160 0-1 Risk factor Almost all people with 0-1 risk factor have a 10-year risk <10%; thus, 10-year risk assessment in people with 0-1 risk factor is not necessary. <160 ≥160 ≥190 (160-189: LDL-lowering drug optional) After the LDL-C goal has been achieved, if the TG is still ≥200 mg/dL, non-HDL-C (total-C minus HDLC) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is ≥130 mg/dL (see NCEP Guidelines above). Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the total-C be used to monitor therapy. Although lovastatin tablets may be useful to reduce elevated LDL-C levels in patients with combined hypercholesterolemia and hypertriglyceridemia where hypercholesterolemia is the major abnormality (Type IIb hyperlipoproteinemia), it has not been studied in conditions where the major abnormality is elevation of chylomicrons, VLDL or IDL (i.e., hyperlipoproteinemia types I, III, IV, or V).*** The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable <170 <110 Borderline 170-199 110-129 High ≥200 ≥130 Children treated with lovastatin in adolescence should be re-evaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult goals for LDL-C. uuid:9d1e176a-0b0f-4896-a3f5-9473375343ac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40303 biolink:treats UMLS:C0342879 PMID:41385096 "[{""id"":""uuid:1c9bde9b-ee40-4850-891f-1e752ffe33ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5cc595ef-eed0-443c-b10b-454cbcd88ff8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lovastatin tablets should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C, lovastatin tablets are indicated to reduce the risk of: - Myocardial infarction - Unstable angina - Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies .) Coronary Heart Disease Lovastatin tablets are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb***), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. *** Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein Type Lipoproteins elevated Lipid Elevations major minor I Chylomicrons TG ↑ →C IIa LDL C — IIb LDL, VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑ →C V (rare) Chylomicrons, VLDL TG ↑ →C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets are indicated as an adjunct to diet to reduce total-C, LDL-C and apolipoprotein B levels in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with heFH if after an adequate trial of diet therapy the following findings are present: LDL-C remains >189 mg/dL or LDL-C remains >160 mg/dL and: • there is a positive family history of premature cardiovascular disease or • two or more other CVD risk factors are present in the adolescent patient General Recommendations Prior to initiating therapy with lovastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total-C, HDL-C, and TG. For patients with TG less than 400 mg / dL (<4.5 mmol / L), LDL-C can be estimated using the following equation: LDL-C = total-C – [0.2 x (TG) + HDL-C] For TG levels >400 mg/dL (>4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated total-C. In such cases, lovastatin tablets are not indicated. The National Cholesterol Education Program (NCEP) Treatment Guidelines are summarized below: NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD CHD, coronary heart disease or CHD risk equivalence (10-year risk >20%) <100 ≥100 ≥130 (100-129: drug optional) Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of <100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgment also may call for deferring drug therapy in this subcategory. 2+ Risk factors (10-year risk ≤20%) <130 ≥130 10-year risk 10-20%: ≥130 10-year risk<10%: ≥160 0-1 Risk factor Almost all people with 0-1 risk factor have a 10-year risk <10%; thus, 10-year risk assessment in people with 0-1 risk factor is not necessary. <160 ≥160 ≥190 (160-189: LDL-lowering drug optional) After the LDL-C goal has been achieved, if the TG is still ≥200 mg/dL, non-HDL-C (total-C minus HDLC) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is ≥130 mg/dL (see NCEP Guidelines above). Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the total-C be used to monitor therapy. Although lovastatin tablets may be useful to reduce elevated LDL-C levels in patients with combined hypercholesterolemia and hypertriglyceridemia where hypercholesterolemia is the major abnormality (Type IIb hyperlipoproteinemia), it has not been studied in conditions where the major abnormality is elevation of chylomicrons, VLDL or IDL (i.e., hyperlipoproteinemia types I, III, IV, or V).*** The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable <170 <110 Borderline 170-199 110-129 High ≥200 ≥130 Children treated with lovastatin in adolescence should be re-evaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult goals for LDL-C. uuid:25543314-e977-4571-91ad-1d47b5802a53 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40303 biolink:treats UMLS:C0342882 PMID:41385096 "[{""id"":""uuid:86eb6fd9-4155-4b8a-b342-c86bd4affc71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e3dcf412-37eb-4a56-86a6-c5e2b6803a9d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lovastatin tablets should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C, lovastatin tablets are indicated to reduce the risk of: - Myocardial infarction - Unstable angina - Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies .) Coronary Heart Disease Lovastatin tablets are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb***), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. *** Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein Type Lipoproteins elevated Lipid Elevations major minor I Chylomicrons TG ↑ →C IIa LDL C — IIb LDL, VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑ →C V (rare) Chylomicrons, VLDL TG ↑ →C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets are indicated as an adjunct to diet to reduce total-C, LDL-C and apolipoprotein B levels in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with heFH if after an adequate trial of diet therapy the following findings are present: LDL-C remains >189 mg/dL or LDL-C remains >160 mg/dL and: • there is a positive family history of premature cardiovascular disease or • two or more other CVD risk factors are present in the adolescent patient General Recommendations Prior to initiating therapy with lovastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total-C, HDL-C, and TG. For patients with TG less than 400 mg / dL (<4.5 mmol / L), LDL-C can be estimated using the following equation: LDL-C = total-C – [0.2 x (TG) + HDL-C] For TG levels >400 mg/dL (>4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated total-C. In such cases, lovastatin tablets are not indicated. The National Cholesterol Education Program (NCEP) Treatment Guidelines are summarized below: NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD CHD, coronary heart disease or CHD risk equivalence (10-year risk >20%) <100 ≥100 ≥130 (100-129: drug optional) Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of <100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgment also may call for deferring drug therapy in this subcategory. 2+ Risk factors (10-year risk ≤20%) <130 ≥130 10-year risk 10-20%: ≥130 10-year risk<10%: ≥160 0-1 Risk factor Almost all people with 0-1 risk factor have a 10-year risk <10%; thus, 10-year risk assessment in people with 0-1 risk factor is not necessary. <160 ≥160 ≥190 (160-189: LDL-lowering drug optional) After the LDL-C goal has been achieved, if the TG is still ≥200 mg/dL, non-HDL-C (total-C minus HDLC) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is ≥130 mg/dL (see NCEP Guidelines above). Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the total-C be used to monitor therapy. Although lovastatin tablets may be useful to reduce elevated LDL-C levels in patients with combined hypercholesterolemia and hypertriglyceridemia where hypercholesterolemia is the major abnormality (Type IIb hyperlipoproteinemia), it has not been studied in conditions where the major abnormality is elevation of chylomicrons, VLDL or IDL (i.e., hyperlipoproteinemia types I, III, IV, or V).*** The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable <170 <110 Borderline 170-199 110-129 High ≥200 ≥130 Children treated with lovastatin in adolescence should be re-evaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult goals for LDL-C. uuid:83800cc0-ce5d-4524-ad8c-a4b2f44d2064 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40303 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:d30d24d7-1e77-47eb-b78f-ab0b34919ec0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1b6f78ca-138c-41d8-a376-0ddee4a44f69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lovastatin tablets should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C, lovastatin tablets are indicated to reduce the risk of: - Myocardial infarction - Unstable angina - Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies .) Coronary Heart Disease Lovastatin tablets are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb***), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. *** Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein Type Lipoproteins elevated Lipid Elevations major minor I Chylomicrons TG ↑ →C IIa LDL C — IIb LDL, VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑ →C V (rare) Chylomicrons, VLDL TG ↑ →C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets are indicated as an adjunct to diet to reduce total-C, LDL-C and apolipoprotein B levels in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with heFH if after an adequate trial of diet therapy the following findings are present: LDL-C remains >189 mg/dL or LDL-C remains >160 mg/dL and: • there is a positive family history of premature cardiovascular disease or • two or more other CVD risk factors are present in the adolescent patient General Recommendations Prior to initiating therapy with lovastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total-C, HDL-C, and TG. For patients with TG less than 400 mg / dL (<4.5 mmol / L), LDL-C can be estimated using the following equation: LDL-C = total-C – [0.2 x (TG) + HDL-C] For TG levels >400 mg/dL (>4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated total-C. In such cases, lovastatin tablets are not indicated. The National Cholesterol Education Program (NCEP) Treatment Guidelines are summarized below: NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD CHD, coronary heart disease or CHD risk equivalence (10-year risk >20%) <100 ≥100 ≥130 (100-129: drug optional) Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of <100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgment also may call for deferring drug therapy in this subcategory. 2+ Risk factors (10-year risk ≤20%) <130 ≥130 10-year risk 10-20%: ≥130 10-year risk<10%: ≥160 0-1 Risk factor Almost all people with 0-1 risk factor have a 10-year risk <10%; thus, 10-year risk assessment in people with 0-1 risk factor is not necessary. <160 ≥160 ≥190 (160-189: LDL-lowering drug optional) After the LDL-C goal has been achieved, if the TG is still ≥200 mg/dL, non-HDL-C (total-C minus HDLC) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is ≥130 mg/dL (see NCEP Guidelines above). Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the total-C be used to monitor therapy. Although lovastatin tablets may be useful to reduce elevated LDL-C levels in patients with combined hypercholesterolemia and hypertriglyceridemia where hypercholesterolemia is the major abnormality (Type IIb hyperlipoproteinemia), it has not been studied in conditions where the major abnormality is elevation of chylomicrons, VLDL or IDL (i.e., hyperlipoproteinemia types I, III, IV, or V).*** The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable <170 <110 Borderline 170-199 110-129 High ≥200 ≥130 Children treated with lovastatin in adolescence should be re-evaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult goals for LDL-C. uuid:a01968cf-5342-40fa-aa43-272e9e1e2939 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40303 biolink:treats MONDO:0005420 PMID:41385096 "[{""id"":""uuid:a7491bee-1629-4981-b3d2-299c6c4cf2e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cd41c6e8-d459-421d-b0ad-24338b532426"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lovastatin tablets should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C, lovastatin tablets are indicated to reduce the risk of: - Myocardial infarction - Unstable angina - Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies .) Coronary Heart Disease Lovastatin tablets are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb***), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. *** Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein Type Lipoproteins elevated Lipid Elevations major minor I Chylomicrons TG ↑ →C IIa LDL C — IIb LDL, VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑ →C V (rare) Chylomicrons, VLDL TG ↑ →C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets are indicated as an adjunct to diet to reduce total-C, LDL-C and apolipoprotein B levels in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with heFH if after an adequate trial of diet therapy the following findings are present: LDL-C remains >189 mg/dL or LDL-C remains >160 mg/dL and: • there is a positive family history of premature cardiovascular disease or • two or more other CVD risk factors are present in the adolescent patient General Recommendations Prior to initiating therapy with lovastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total-C, HDL-C, and TG. For patients with TG less than 400 mg / dL (<4.5 mmol / L), LDL-C can be estimated using the following equation: LDL-C = total-C – [0.2 x (TG) + HDL-C] For TG levels >400 mg/dL (>4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated total-C. In such cases, lovastatin tablets are not indicated. The National Cholesterol Education Program (NCEP) Treatment Guidelines are summarized below: NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD CHD, coronary heart disease or CHD risk equivalence (10-year risk >20%) <100 ≥100 ≥130 (100-129: drug optional) Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of <100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgment also may call for deferring drug therapy in this subcategory. 2+ Risk factors (10-year risk ≤20%) <130 ≥130 10-year risk 10-20%: ≥130 10-year risk<10%: ≥160 0-1 Risk factor Almost all people with 0-1 risk factor have a 10-year risk <10%; thus, 10-year risk assessment in people with 0-1 risk factor is not necessary. <160 ≥160 ≥190 (160-189: LDL-lowering drug optional) After the LDL-C goal has been achieved, if the TG is still ≥200 mg/dL, non-HDL-C (total-C minus HDLC) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is ≥130 mg/dL (see NCEP Guidelines above). Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the total-C be used to monitor therapy. Although lovastatin tablets may be useful to reduce elevated LDL-C levels in patients with combined hypercholesterolemia and hypertriglyceridemia where hypercholesterolemia is the major abnormality (Type IIb hyperlipoproteinemia), it has not been studied in conditions where the major abnormality is elevation of chylomicrons, VLDL or IDL (i.e., hyperlipoproteinemia types I, III, IV, or V).*** The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable <170 <110 Borderline 170-199 110-129 High ≥200 ≥130 Children treated with lovastatin in adolescence should be re-evaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult goals for LDL-C. uuid:dda504ef-7bfc-4dd6-8952-53e2cff9f107 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40303 biolink:treats MONDO:0005377 PMID:41385096 "[{""id"":""uuid:a56814b1-5ffe-4d95-a4f5-1f12d21850be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e7c573e9-6f74-4deb-af2b-f1f34a829820"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lovastatin tablets should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C, lovastatin tablets are indicated to reduce the risk of: - Myocardial infarction - Unstable angina - Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies .) Coronary Heart Disease Lovastatin tablets are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb***), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. *** Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein Type Lipoproteins elevated Lipid Elevations major minor I Chylomicrons TG ↑ →C IIa LDL C — IIb LDL, VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑ →C V (rare) Chylomicrons, VLDL TG ↑ →C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets are indicated as an adjunct to diet to reduce total-C, LDL-C and apolipoprotein B levels in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with heFH if after an adequate trial of diet therapy the following findings are present: LDL-C remains >189 mg/dL or LDL-C remains >160 mg/dL and: • there is a positive family history of premature cardiovascular disease or • two or more other CVD risk factors are present in the adolescent patient General Recommendations Prior to initiating therapy with lovastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total-C, HDL-C, and TG. For patients with TG less than 400 mg / dL (<4.5 mmol / L), LDL-C can be estimated using the following equation: LDL-C = total-C – [0.2 x (TG) + HDL-C] For TG levels >400 mg/dL (>4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated total-C. In such cases, lovastatin tablets are not indicated. The National Cholesterol Education Program (NCEP) Treatment Guidelines are summarized below: NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD CHD, coronary heart disease or CHD risk equivalence (10-year risk >20%) <100 ≥100 ≥130 (100-129: drug optional) Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of <100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgment also may call for deferring drug therapy in this subcategory. 2+ Risk factors (10-year risk ≤20%) <130 ≥130 10-year risk 10-20%: ≥130 10-year risk<10%: ≥160 0-1 Risk factor Almost all people with 0-1 risk factor have a 10-year risk <10%; thus, 10-year risk assessment in people with 0-1 risk factor is not necessary. <160 ≥160 ≥190 (160-189: LDL-lowering drug optional) After the LDL-C goal has been achieved, if the TG is still ≥200 mg/dL, non-HDL-C (total-C minus HDLC) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is ≥130 mg/dL (see NCEP Guidelines above). Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the total-C be used to monitor therapy. Although lovastatin tablets may be useful to reduce elevated LDL-C levels in patients with combined hypercholesterolemia and hypertriglyceridemia where hypercholesterolemia is the major abnormality (Type IIb hyperlipoproteinemia), it has not been studied in conditions where the major abnormality is elevation of chylomicrons, VLDL or IDL (i.e., hyperlipoproteinemia types I, III, IV, or V).*** The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable <170 <110 Borderline 170-199 110-129 High ≥200 ≥130 Children treated with lovastatin in adolescence should be re-evaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult goals for LDL-C. uuid:27652551-c0ce-4f41-8823-f6188485286a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40303 biolink:treats UMLS:C0259744 PMID:41385096 "[{""id"":""uuid:12213a65-36ad-431d-b963-47d904f7aa65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b2640791-08af-42f5-ad9a-d18cd345e23c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lovastatin tablets should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C, lovastatin tablets are indicated to reduce the risk of: - Myocardial infarction - Unstable angina - Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies .) Coronary Heart Disease Lovastatin tablets are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb***), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. *** Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein Type Lipoproteins elevated Lipid Elevations major minor I Chylomicrons TG ↑ →C IIa LDL C — IIb LDL, VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑ →C V (rare) Chylomicrons, VLDL TG ↑ →C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets are indicated as an adjunct to diet to reduce total-C, LDL-C and apolipoprotein B levels in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with heFH if after an adequate trial of diet therapy the following findings are present: LDL-C remains >189 mg/dL or LDL-C remains >160 mg/dL and: • there is a positive family history of premature cardiovascular disease or • two or more other CVD risk factors are present in the adolescent patient General Recommendations Prior to initiating therapy with lovastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total-C, HDL-C, and TG. For patients with TG less than 400 mg / dL (<4.5 mmol / L), LDL-C can be estimated using the following equation: LDL-C = total-C – [0.2 x (TG) + HDL-C] For TG levels >400 mg/dL (>4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated total-C. In such cases, lovastatin tablets are not indicated. The National Cholesterol Education Program (NCEP) Treatment Guidelines are summarized below: NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD CHD, coronary heart disease or CHD risk equivalence (10-year risk >20%) <100 ≥100 ≥130 (100-129: drug optional) Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of <100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgment also may call for deferring drug therapy in this subcategory. 2+ Risk factors (10-year risk ≤20%) <130 ≥130 10-year risk 10-20%: ≥130 10-year risk<10%: ≥160 0-1 Risk factor Almost all people with 0-1 risk factor have a 10-year risk <10%; thus, 10-year risk assessment in people with 0-1 risk factor is not necessary. <160 ≥160 ≥190 (160-189: LDL-lowering drug optional) After the LDL-C goal has been achieved, if the TG is still ≥200 mg/dL, non-HDL-C (total-C minus HDLC) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is ≥130 mg/dL (see NCEP Guidelines above). Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the total-C be used to monitor therapy. Although lovastatin tablets may be useful to reduce elevated LDL-C levels in patients with combined hypercholesterolemia and hypertriglyceridemia where hypercholesterolemia is the major abnormality (Type IIb hyperlipoproteinemia), it has not been studied in conditions where the major abnormality is elevation of chylomicrons, VLDL or IDL (i.e., hyperlipoproteinemia types I, III, IV, or V).*** The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable <170 <110 Borderline 170-199 110-129 High ≥200 ≥130 Children treated with lovastatin in adolescence should be re-evaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult goals for LDL-C. uuid:3298b133-0e4e-44c2-9178-671f5755c091 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40303 biolink:treats MONDO:0006874 PMID:41385096 "[{""id"":""uuid:80f78725-e644-4e90-8178-27bd216e921a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:07e14cc3-3c1d-433d-8ab5-bc98fb711041"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lovastatin tablets should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C, lovastatin tablets are indicated to reduce the risk of: - Myocardial infarction - Unstable angina - Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies .) Coronary Heart Disease Lovastatin tablets are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb***), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. *** Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein Type Lipoproteins elevated Lipid Elevations major minor I Chylomicrons TG ↑ →C IIa LDL C — IIb LDL, VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑ →C V (rare) Chylomicrons, VLDL TG ↑ →C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets are indicated as an adjunct to diet to reduce total-C, LDL-C and apolipoprotein B levels in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with heFH if after an adequate trial of diet therapy the following findings are present: LDL-C remains >189 mg/dL or LDL-C remains >160 mg/dL and: • there is a positive family history of premature cardiovascular disease or • two or more other CVD risk factors are present in the adolescent patient General Recommendations Prior to initiating therapy with lovastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total-C, HDL-C, and TG. For patients with TG less than 400 mg / dL (<4.5 mmol / L), LDL-C can be estimated using the following equation: LDL-C = total-C – [0.2 x (TG) + HDL-C] For TG levels >400 mg/dL (>4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated total-C. In such cases, lovastatin tablets are not indicated. The National Cholesterol Education Program (NCEP) Treatment Guidelines are summarized below: NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD CHD, coronary heart disease or CHD risk equivalence (10-year risk >20%) <100 ≥100 ≥130 (100-129: drug optional) Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of <100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgment also may call for deferring drug therapy in this subcategory. 2+ Risk factors (10-year risk ≤20%) <130 ≥130 10-year risk 10-20%: ≥130 10-year risk<10%: ≥160 0-1 Risk factor Almost all people with 0-1 risk factor have a 10-year risk <10%; thus, 10-year risk assessment in people with 0-1 risk factor is not necessary. <160 ≥160 ≥190 (160-189: LDL-lowering drug optional) After the LDL-C goal has been achieved, if the TG is still ≥200 mg/dL, non-HDL-C (total-C minus HDLC) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is ≥130 mg/dL (see NCEP Guidelines above). Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the total-C be used to monitor therapy. Although lovastatin tablets may be useful to reduce elevated LDL-C levels in patients with combined hypercholesterolemia and hypertriglyceridemia where hypercholesterolemia is the major abnormality (Type IIb hyperlipoproteinemia), it has not been studied in conditions where the major abnormality is elevation of chylomicrons, VLDL or IDL (i.e., hyperlipoproteinemia types I, III, IV, or V).*** The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable <170 <110 Borderline 170-199 110-129 High ≥200 ≥130 Children treated with lovastatin in adolescence should be re-evaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult goals for LDL-C. uuid:7fae9594-b239-465b-9334-b71a7b5268e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40303 biolink:treats MONDO:0005347 PMID:41385096 "[{""id"":""uuid:26c2f343-5044-4791-8288-ca2524b2464f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fcfb4b74-5685-468e-a550-ac9f9879f5ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lovastatin tablets should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C, lovastatin tablets are indicated to reduce the risk of: - Myocardial infarction - Unstable angina - Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies .) Coronary Heart Disease Lovastatin tablets are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb***), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. *** Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein Type Lipoproteins elevated Lipid Elevations major minor I Chylomicrons TG ↑ →C IIa LDL C — IIb LDL, VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑ →C V (rare) Chylomicrons, VLDL TG ↑ →C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets are indicated as an adjunct to diet to reduce total-C, LDL-C and apolipoprotein B levels in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with heFH if after an adequate trial of diet therapy the following findings are present: LDL-C remains >189 mg/dL or LDL-C remains >160 mg/dL and: • there is a positive family history of premature cardiovascular disease or • two or more other CVD risk factors are present in the adolescent patient General Recommendations Prior to initiating therapy with lovastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total-C, HDL-C, and TG. For patients with TG less than 400 mg / dL (<4.5 mmol / L), LDL-C can be estimated using the following equation: LDL-C = total-C – [0.2 x (TG) + HDL-C] For TG levels >400 mg/dL (>4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated total-C. In such cases, lovastatin tablets are not indicated. The National Cholesterol Education Program (NCEP) Treatment Guidelines are summarized below: NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD CHD, coronary heart disease or CHD risk equivalence (10-year risk >20%) <100 ≥100 ≥130 (100-129: drug optional) Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of <100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgment also may call for deferring drug therapy in this subcategory. 2+ Risk factors (10-year risk ≤20%) <130 ≥130 10-year risk 10-20%: ≥130 10-year risk<10%: ≥160 0-1 Risk factor Almost all people with 0-1 risk factor have a 10-year risk <10%; thus, 10-year risk assessment in people with 0-1 risk factor is not necessary. <160 ≥160 ≥190 (160-189: LDL-lowering drug optional) After the LDL-C goal has been achieved, if the TG is still ≥200 mg/dL, non-HDL-C (total-C minus HDLC) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is ≥130 mg/dL (see NCEP Guidelines above). Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the total-C be used to monitor therapy. Although lovastatin tablets may be useful to reduce elevated LDL-C levels in patients with combined hypercholesterolemia and hypertriglyceridemia where hypercholesterolemia is the major abnormality (Type IIb hyperlipoproteinemia), it has not been studied in conditions where the major abnormality is elevation of chylomicrons, VLDL or IDL (i.e., hyperlipoproteinemia types I, III, IV, or V).*** The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable <170 <110 Borderline 170-199 110-129 High ≥200 ≥130 Children treated with lovastatin in adolescence should be re-evaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult goals for LDL-C. uuid:28d9f417-58c3-4ca1-a8d9-629c41b56d07 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40303 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:3450fe2c-f247-4c4f-afd3-8654aaaf9e46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3ffcd0a1-dbd5-4fb4-9d21-d8209354601c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lovastatin tablets should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C, lovastatin tablets are indicated to reduce the risk of: - Myocardial infarction - Unstable angina - Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies .) Coronary Heart Disease Lovastatin tablets are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb***), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. *** Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein Type Lipoproteins elevated Lipid Elevations major minor I Chylomicrons TG ↑ →C IIa LDL C — IIb LDL, VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑ →C V (rare) Chylomicrons, VLDL TG ↑ →C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets are indicated as an adjunct to diet to reduce total-C, LDL-C and apolipoprotein B levels in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with heFH if after an adequate trial of diet therapy the following findings are present: LDL-C remains >189 mg/dL or LDL-C remains >160 mg/dL and: • there is a positive family history of premature cardiovascular disease or • two or more other CVD risk factors are present in the adolescent patient General Recommendations Prior to initiating therapy with lovastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total-C, HDL-C, and TG. For patients with TG less than 400 mg / dL (<4.5 mmol / L), LDL-C can be estimated using the following equation: LDL-C = total-C – [0.2 x (TG) + HDL-C] For TG levels >400 mg/dL (>4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated total-C. In such cases, lovastatin tablets are not indicated. The National Cholesterol Education Program (NCEP) Treatment Guidelines are summarized below: NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD CHD, coronary heart disease or CHD risk equivalence (10-year risk >20%) <100 ≥100 ≥130 (100-129: drug optional) Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of <100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgment also may call for deferring drug therapy in this subcategory. 2+ Risk factors (10-year risk ≤20%) <130 ≥130 10-year risk 10-20%: ≥130 10-year risk<10%: ≥160 0-1 Risk factor Almost all people with 0-1 risk factor have a 10-year risk <10%; thus, 10-year risk assessment in people with 0-1 risk factor is not necessary. <160 ≥160 ≥190 (160-189: LDL-lowering drug optional) After the LDL-C goal has been achieved, if the TG is still ≥200 mg/dL, non-HDL-C (total-C minus HDLC) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is ≥130 mg/dL (see NCEP Guidelines above). Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the total-C be used to monitor therapy. Although lovastatin tablets may be useful to reduce elevated LDL-C levels in patients with combined hypercholesterolemia and hypertriglyceridemia where hypercholesterolemia is the major abnormality (Type IIb hyperlipoproteinemia), it has not been studied in conditions where the major abnormality is elevation of chylomicrons, VLDL or IDL (i.e., hyperlipoproteinemia types I, III, IV, or V).*** The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable <170 <110 Borderline 170-199 110-129 High ≥200 ≥130 Children treated with lovastatin in adolescence should be re-evaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult goals for LDL-C. uuid:263f67c3-29bf-42c4-bfc3-e776ff970d97 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40303 biolink:treats MONDO:0006805 PMID:41385096 "[{""id"":""uuid:9c47a01d-77f7-4276-a6b7-45689648167f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:85c03e91-ba0a-4372-85d0-ce2fe85e38bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lovastatin tablets should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C, lovastatin tablets are indicated to reduce the risk of: - Myocardial infarction - Unstable angina - Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies .) Coronary Heart Disease Lovastatin tablets are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb***), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. *** Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein Type Lipoproteins elevated Lipid Elevations major minor I Chylomicrons TG ↑ →C IIa LDL C — IIb LDL, VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑ →C V (rare) Chylomicrons, VLDL TG ↑ →C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets are indicated as an adjunct to diet to reduce total-C, LDL-C and apolipoprotein B levels in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with heFH if after an adequate trial of diet therapy the following findings are present: LDL-C remains >189 mg/dL or LDL-C remains >160 mg/dL and: • there is a positive family history of premature cardiovascular disease or • two or more other CVD risk factors are present in the adolescent patient General Recommendations Prior to initiating therapy with lovastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total-C, HDL-C, and TG. For patients with TG less than 400 mg / dL (<4.5 mmol / L), LDL-C can be estimated using the following equation: LDL-C = total-C – [0.2 x (TG) + HDL-C] For TG levels >400 mg/dL (>4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated total-C. In such cases, lovastatin tablets are not indicated. The National Cholesterol Education Program (NCEP) Treatment Guidelines are summarized below: NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD CHD, coronary heart disease or CHD risk equivalence (10-year risk >20%) <100 ≥100 ≥130 (100-129: drug optional) Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of <100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgment also may call for deferring drug therapy in this subcategory. 2+ Risk factors (10-year risk ≤20%) <130 ≥130 10-year risk 10-20%: ≥130 10-year risk<10%: ≥160 0-1 Risk factor Almost all people with 0-1 risk factor have a 10-year risk <10%; thus, 10-year risk assessment in people with 0-1 risk factor is not necessary. <160 ≥160 ≥190 (160-189: LDL-lowering drug optional) After the LDL-C goal has been achieved, if the TG is still ≥200 mg/dL, non-HDL-C (total-C minus HDLC) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is ≥130 mg/dL (see NCEP Guidelines above). Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the total-C be used to monitor therapy. Although lovastatin tablets may be useful to reduce elevated LDL-C levels in patients with combined hypercholesterolemia and hypertriglyceridemia where hypercholesterolemia is the major abnormality (Type IIb hyperlipoproteinemia), it has not been studied in conditions where the major abnormality is elevation of chylomicrons, VLDL or IDL (i.e., hyperlipoproteinemia types I, III, IV, or V).*** The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable <170 <110 Borderline 170-199 110-129 High ≥200 ≥130 Children treated with lovastatin in adolescence should be re-evaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult goals for LDL-C. uuid:5388d1eb-e7d5-4172-b159-b78b1268f7c2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2704 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:2dfa27a6-449a-439a-b0a9-ac4783a3a513"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:88b07fbe-c8a6-418d-a17c-01c9db3d0777"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Anastrozole tablets are an aromatase inhibitor indicated for: • Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1) • First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2) • Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets ( 1.3) uuid:34352fc3-2feb-44b5-a5ea-f070ac7f5ada biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2704 biolink:treats UMLS:C3495949 PMID:41385096 "[{""id"":""uuid:5acc94ac-8c45-423e-b2ad-a3933e559118"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c8e6dcfa-a8c3-41e4-a793-9f58462bf9f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Anastrozole tablets are an aromatase inhibitor indicated for: • Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1) • First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2) • Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets ( 1.3) uuid:11707523-8619-451d-8675-1deef16c8af9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2704 biolink:treats UMLS:C0278488 PMID:41385096 "[{""id"":""uuid:8af5b63f-6e95-48f3-a804-db98d2d97c5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d9f01668-99ea-4e85-8655-928fdd9c8bad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Anastrozole tablets are an aromatase inhibitor indicated for: • Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1) • First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2) • Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets ( 1.3) uuid:058e4e9f-569c-4b9b-a207-17125dc73538 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2704 biolink:treats UMLS:C3495917 PMID:41385096 "[{""id"":""uuid:93b3580f-a56c-4439-b36f-07f342ecdfd5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b43be324-f136-4f51-9c58-81d5bdec04f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Anastrozole tablets are an aromatase inhibitor indicated for: • Adjuvant treatment of postmenopausal women with hormone receptor-positive early breast cancer ( 1.1) • First-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer ( 1.2) • Treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy. Patients with ER-negative disease and patients who did not respond to previous tamoxifen therapy rarely responded to anastrozole tablets ( 1.3) uuid:48261943-ac9b-43b1-870c-a5b8ad5ce040 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:D87YGH4Z0Q biolink:treats MONDO:0005347 PMID:41385096 "[{""id"":""uuid:03dd56ae-588a-4645-99bf-17e6832bfa62"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bde62a23-eb18-4cbf-ad63-95afa6a68177"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LOVAZA ® (omega-3-acid ethyl esters) is indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia. Usage Considerations: Patients should be placed on an appropriate lipid-lowering diet before receiving LOVAZA and should continue this diet during treatment with LOVAZA. Laboratory studies should be done to ascertain that the lipid levels are consistently abnormal before instituting LOVAZA therapy. Every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that are contributing to the lipid abnormalities. Medications known to exacerbate hypertriglyceridemia (such as beta blockers, thiazides, estrogens) should be discontinued or changed if possible prior to consideration of triglyceride-lowering drug therapy. Limitations of Use: The effect of LOVAZA on cardiovascular mortality and morbidity in patients with elevated triglycerides has not been determined. uuid:d293e515-c39a-4f30-b7b9-8796625ea9e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:D87YGH4Z0Q biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:b251a523-89a5-4bf0-bba9-a6ca798c189c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:908ab513-5a52-42b1-9a9e-88871e809783"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LOVAZA ® (omega-3-acid ethyl esters) is indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia. Usage Considerations: Patients should be placed on an appropriate lipid-lowering diet before receiving LOVAZA and should continue this diet during treatment with LOVAZA. Laboratory studies should be done to ascertain that the lipid levels are consistently abnormal before instituting LOVAZA therapy. Every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that are contributing to the lipid abnormalities. Medications known to exacerbate hypertriglyceridemia (such as beta blockers, thiazides, estrogens) should be discontinued or changed if possible prior to consideration of triglyceride-lowering drug therapy. Limitations of Use: The effect of LOVAZA on cardiovascular mortality and morbidity in patients with elevated triglycerides has not been determined. uuid:2cb10957-1d6a-4467-b2d1-1dc551982d0b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:D87YGH4Z0Q biolink:treats MONDO:0005420 PMID:41385096 "[{""id"":""uuid:761a3cfc-67ae-4989-996e-f794f29e0f78"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c2a0cb14-8e52-4b70-ae6d-71e09de25e8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LOVAZA ® (omega-3-acid ethyl esters) is indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia. Usage Considerations: Patients should be placed on an appropriate lipid-lowering diet before receiving LOVAZA and should continue this diet during treatment with LOVAZA. Laboratory studies should be done to ascertain that the lipid levels are consistently abnormal before instituting LOVAZA therapy. Every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that are contributing to the lipid abnormalities. Medications known to exacerbate hypertriglyceridemia (such as beta blockers, thiazides, estrogens) should be discontinued or changed if possible prior to consideration of triglyceride-lowering drug therapy. Limitations of Use: The effect of LOVAZA on cardiovascular mortality and morbidity in patients with elevated triglycerides has not been determined. uuid:f81e08e8-14bc-4eb1-bc80-d941d6d6fa8a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3746 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:0ecd5ba1-8671-4504-a8a0-3eb8c0d39410"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1ff2268e-48b3-4ed0-a2b5-7f88a5f05ef0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae , other streptococci (except E. faecalis ), and Staphylococcus aureus . Skin and skin structure infections caused by Streptococcus pyogenes , Staphylococcus aureus , and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus , streptococci (except Enterococcus faecalis ), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:59c580a9-bfc0-4671-addc-a7742dd0b9a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3746 biolink:treats UMLS:C1112209 PMID:41385096 "[{""id"":""uuid:e2f53a02-d47a-4162-9850-d0c259dbffb3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:01de86ff-ce2d-4c06-963a-9e20fa36cde1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae , other streptococci (except E. faecalis ), and Staphylococcus aureus . Skin and skin structure infections caused by Streptococcus pyogenes , Staphylococcus aureus , and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus , streptococci (except Enterococcus faecalis ), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:c444a048-1a6c-4bb6-9b07-717efd408fed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3746 biolink:treats UMLS:C0851989 PMID:41385096 "[{""id"":""uuid:8391a6fc-43a3-4d5f-b88e-a193c4832d74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1ea168e4-6ec5-4a40-925a-e3a5fb9fc65d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae , other streptococci (except E. faecalis ), and Staphylococcus aureus . Skin and skin structure infections caused by Streptococcus pyogenes , Staphylococcus aureus , and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus , streptococci (except Enterococcus faecalis ), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:d088c0fc-7518-4b60-9fa5-fe68e0524525 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3746 biolink:treats UMLS:C0600123 PMID:41385096 "[{""id"":""uuid:9f1c4206-e860-4ada-a2dc-8f230aeea294"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:203e6984-657c-46fa-85a1-f557b842640a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae , other streptococci (except E. faecalis ), and Staphylococcus aureus . Skin and skin structure infections caused by Streptococcus pyogenes , Staphylococcus aureus , and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus , streptococci (except Enterococcus faecalis ), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:35081fc3-9fcc-4651-838b-86e801ec0b0b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3746 biolink:treats MONDO:0005246 PMID:41385096 "[{""id"":""uuid:422cbcab-ff9d-4efa-adde-8491ef3f4e1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:507c0c71-efbd-44b8-a3df-43b17fc05d4c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the WARNING box, before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae , other streptococci (except E. faecalis ), and Staphylococcus aureus . Skin and skin structure infections caused by Streptococcus pyogenes , Staphylococcus aureus , and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus , streptococci (except Enterococcus faecalis ), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:b98f970e-726c-4865-b84e-484e1cbdf99d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4450 biolink:treats MONDO:0015790 PMID:41385096 "[{""id"":""uuid:807d293e-8ada-451a-8398-a462c650bd5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:66eca514-58cf-4df8-9cb5-c05c91b7f0fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Central Diabetes Insipidus Desmopressin acetate tablets are indicated as antidiuretic replacement therapy in the management of central diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. Desmopressin acetate is ineffective for the treatment of nephrogenic diabetes insipidus. Patients were selected for therapy based on the diagnosis by means of the water deprivation test, the hypertonic saline infusion test, and/or response to antidiuretic hormone. Continued response to desmopressin acetate can be monitored by measuring urine volume and osmolality. Primary Nocturnal Enuresis Desmopressin acetate tablets are indicated for the management of primary nocturnal enuresis. Desmopressin acetate may be used alone or as an adjunct to behavioral conditioning or other non-pharmacologic intervention. uuid:ba604579-e746-40f5-bf87-9b907283b46f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4450 biolink:treats HP:0000103 PMID:41385096 "[{""id"":""uuid:cb8069bb-8648-48f6-85d4-efc49ba42746"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:559d4eac-fe00-459a-ad30-7c16588d44cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Central Diabetes Insipidus Desmopressin acetate tablets are indicated as antidiuretic replacement therapy in the management of central diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. Desmopressin acetate is ineffective for the treatment of nephrogenic diabetes insipidus. Patients were selected for therapy based on the diagnosis by means of the water deprivation test, the hypertonic saline infusion test, and/or response to antidiuretic hormone. Continued response to desmopressin acetate can be monitored by measuring urine volume and osmolality. Primary Nocturnal Enuresis Desmopressin acetate tablets are indicated for the management of primary nocturnal enuresis. Desmopressin acetate may be used alone or as an adjunct to behavioral conditioning or other non-pharmacologic intervention. uuid:82358cfa-f794-49a4-93f9-2dc5322b9efe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4450 biolink:treats MONDO:0040871 PMID:41385096 "[{""id"":""uuid:a9f2b8f1-df20-4aed-8e89-45bc5bd96bdd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:565ecddb-6cba-4d46-9032-068cdb3deb51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Central Diabetes Insipidus Desmopressin acetate tablets are indicated as antidiuretic replacement therapy in the management of central diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. Desmopressin acetate is ineffective for the treatment of nephrogenic diabetes insipidus. Patients were selected for therapy based on the diagnosis by means of the water deprivation test, the hypertonic saline infusion test, and/or response to antidiuretic hormone. Continued response to desmopressin acetate can be monitored by measuring urine volume and osmolality. Primary Nocturnal Enuresis Desmopressin acetate tablets are indicated for the management of primary nocturnal enuresis. Desmopressin acetate may be used alone or as an adjunct to behavioral conditioning or other non-pharmacologic intervention. uuid:d25167c9-5d96-4fcf-80cd-faca6b9dc093 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4450 biolink:treats UMLS:C2228139 PMID:41385096 "[{""id"":""uuid:38106a4c-dabf-47c0-b77c-034cfe8009b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eae43614-f638-4f5b-b1a9-98f21051ce81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Central Diabetes Insipidus Desmopressin acetate tablets are indicated as antidiuretic replacement therapy in the management of central diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. Desmopressin acetate is ineffective for the treatment of nephrogenic diabetes insipidus. Patients were selected for therapy based on the diagnosis by means of the water deprivation test, the hypertonic saline infusion test, and/or response to antidiuretic hormone. Continued response to desmopressin acetate can be monitored by measuring urine volume and osmolality. Primary Nocturnal Enuresis Desmopressin acetate tablets are indicated for the management of primary nocturnal enuresis. Desmopressin acetate may be used alone or as an adjunct to behavioral conditioning or other non-pharmacologic intervention. uuid:1fd4639b-1b2f-4711-8b31-788cf16682d4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6715 biolink:treats MONDO:0002447 PMID:41385096 "[{""id"":""uuid:a6525d4c-eae9-4aa8-92de-0461a26c9870"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f99cf1c8-8535-43e7-a947-98e4c0828a87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Adjunctive therapy and palliative treatment of inoperable, recurrent, and metastatic endometrial or renal carcinoma. uuid:ec888ec0-097c-44c3-a98e-3be26708ae26 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6715 biolink:treats MONDO:0005206 PMID:41385096 "[{""id"":""uuid:fdc07e8f-7fff-4539-aba3-7f65327306e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:885c6306-0ee5-40ec-b072-ab6d6646ea70"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Adjunctive therapy and palliative treatment of inoperable, recurrent, and metastatic endometrial or renal carcinoma. uuid:1ef0e363-bb1c-46f1-9bac-7c165467621c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17234 biolink:treats UMLS:C0858734 PMID:41385096 "[{""id"":""uuid:02337663-5167-48d2-9dd1-d3e95680d0da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:997ed211-99a3-4bb1-b17f-963e9771b92a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 50% Dextrose Injection is indicated in the treatment of insulin hypoglycemia (hyperinsulinemia or insulin shock) to restore blood glucose levels. The solution is also indicated, after dilution, for intravenous infusion as a source of carbohydrate calories in patients whose oral intake is restricted or inadequate to maintain nutritional requirements. Slow infusion of hypertonic solutions is essential to insure proper utilization of dextrose and avoid production of hyperglycemia. uuid:16fc116c-1f63-42c7-9fbe-cb88487187f9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17234 biolink:treats NCIT:C113104 PMID:41385096 "[{""id"":""uuid:d2d66b6a-68b4-42df-80ed-f186ccf0c963"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fe6f085b-a7c5-4951-a0b6-4f47cc152701"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 50% Dextrose Injection is indicated in the treatment of insulin hypoglycemia (hyperinsulinemia or insulin shock) to restore blood glucose levels. The solution is also indicated, after dilution, for intravenous infusion as a source of carbohydrate calories in patients whose oral intake is restricted or inadequate to maintain nutritional requirements. Slow infusion of hypertonic solutions is essential to insure proper utilization of dextrose and avoid production of hyperglycemia. uuid:ae452386-5768-42bb-b897-2b6320fe0351 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17234 biolink:treats UMLS:C1527401 PMID:41385096 "[{""id"":""uuid:5e3fd964-3cf2-4e77-ae51-c42e37814aa5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3215532d-a621-496a-952f-54e2b39ce256"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 50% Dextrose Injection is indicated in the treatment of insulin hypoglycemia (hyperinsulinemia or insulin shock) to restore blood glucose levels. The solution is also indicated, after dilution, for intravenous infusion as a source of carbohydrate calories in patients whose oral intake is restricted or inadequate to maintain nutritional requirements. Slow infusion of hypertonic solutions is essential to insure proper utilization of dextrose and avoid production of hyperglycemia. uuid:3e8cb3fb-5910-4161-bfa7-f3fdf8382868 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17234 biolink:treats MONDO:0002909 PMID:41385096 "[{""id"":""uuid:16fdef43-b5cf-42d5-9e3c-07db4eda199b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:98d3f201-2121-4c91-a76b-84d08fec66ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 50% Dextrose Injection is indicated in the treatment of insulin hypoglycemia (hyperinsulinemia or insulin shock) to restore blood glucose levels. The solution is also indicated, after dilution, for intravenous infusion as a source of carbohydrate calories in patients whose oral intake is restricted or inadequate to maintain nutritional requirements. Slow infusion of hypertonic solutions is essential to insure proper utilization of dextrose and avoid production of hyperglycemia. uuid:8595c567-9ba4-4c3a-b1e3-24aba0f437cf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47519 biolink:treats MONDO:0001461 PMID:41385096 "[{""id"":""uuid:07b744af-663a-48af-bf4b-7f599e95301e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:be1fcf97-f5a5-4d86-ae61-892054cfa640"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ketoconazole cream, 2% is indicated for the topical treatment of tinea corporis, tinea cruris and tinea pedis caused by Trichophyton rubrum, T. mentagrophytes and Epidermophyton floccosum; in the treatment of tinea (pityriasis) versicolor caused by Malassezia furfur (Pityrosporum orbiculare); in the treatment of cutaneous candidiasis caused by Candida spp. and in the treatment of seborrheic dermatitis. uuid:1bb49d65-977f-429b-abe5-880339b5a24e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47519 biolink:treats MONDO:0001405 PMID:41385096 "[{""id"":""uuid:8bdae1bf-895c-435e-ae65-50426da0a682"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b73be53e-5ba9-4bb3-84e7-569624ef15e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ketoconazole cream, 2% is indicated for the topical treatment of tinea corporis, tinea cruris and tinea pedis caused by Trichophyton rubrum, T. mentagrophytes and Epidermophyton floccosum; in the treatment of tinea (pityriasis) versicolor caused by Malassezia furfur (Pityrosporum orbiculare); in the treatment of cutaneous candidiasis caused by Candida spp. and in the treatment of seborrheic dermatitis. uuid:aae151b3-9990-42e7-a82e-32cc101ff289 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47519 biolink:treats MONDO:0005984 PMID:41385096 "[{""id"":""uuid:a2f17acb-caaa-46df-b6f6-554d4c32cbfb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:71261ebf-879c-4224-9cdc-b73e6883d6ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ketoconazole cream, 2% is indicated for the topical treatment of tinea corporis, tinea cruris and tinea pedis caused by Trichophyton rubrum, T. mentagrophytes and Epidermophyton floccosum; in the treatment of tinea (pityriasis) versicolor caused by Malassezia furfur (Pityrosporum orbiculare); in the treatment of cutaneous candidiasis caused by Candida spp. and in the treatment of seborrheic dermatitis. uuid:166dfac9-7b3e-47eb-a669-029b01b9b541 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47519 biolink:treats MONDO:0005915 PMID:41385096 "[{""id"":""uuid:ff114944-2300-42e4-bec6-9610a18be0d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:777c250e-2e81-4477-a486-4c83614bed16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ketoconazole cream, 2% is indicated for the topical treatment of tinea corporis, tinea cruris and tinea pedis caused by Trichophyton rubrum, T. mentagrophytes and Epidermophyton floccosum; in the treatment of tinea (pityriasis) versicolor caused by Malassezia furfur (Pityrosporum orbiculare); in the treatment of cutaneous candidiasis caused by Candida spp. and in the treatment of seborrheic dermatitis. uuid:c807e7a8-60e2-41b4-8538-3f6929a0ea2a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47519 biolink:treats MONDO:0000879 PMID:41385096 "[{""id"":""uuid:ddb31066-826d-45e6-8cdc-f6557b95325f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f3b405bd-1874-46a3-ae58-f2d426e2bd58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ketoconazole cream, 2% is indicated for the topical treatment of tinea corporis, tinea cruris and tinea pedis caused by Trichophyton rubrum, T. mentagrophytes and Epidermophyton floccosum; in the treatment of tinea (pityriasis) versicolor caused by Malassezia furfur (Pityrosporum orbiculare); in the treatment of cutaneous candidiasis caused by Candida spp. and in the treatment of seborrheic dermatitis. uuid:a8f5ae49-3dbd-4d8e-be7a-0a573ad2b071 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47519 biolink:treats MONDO:0006608 PMID:41385096 "[{""id"":""uuid:6a7d12c7-0bac-4855-8e05-51c2a1515aa9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9c745b82-4157-4547-9972-4b6429a54c45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ketoconazole cream, 2% is indicated for the topical treatment of tinea corporis, tinea cruris and tinea pedis caused by Trichophyton rubrum, T. mentagrophytes and Epidermophyton floccosum; in the treatment of tinea (pityriasis) versicolor caused by Malassezia furfur (Pityrosporum orbiculare); in the treatment of cutaneous candidiasis caused by Candida spp. and in the treatment of seborrheic dermatitis. uuid:71914e08-14ff-45f9-8d82-605be9e66cc0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17347 biolink:treats MONDO:0043510 PMID:41385096 "[{""id"":""uuid:990227e8-ae7f-4b65-9ecd-79ca1e5a5d87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:211db30d-20c6-461c-97ae-a6cf53c1f5e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DEPO-Testosterone Injection is indicated for replacement therapy in the male in conditions associated with symptoms of deficiency or absence of endogenous testosterone. 1. Primary hypogonadism (congenital or acquired)-testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome; or orchidectomy. 2. Hypogonadotropic hypogonadism (congenital or acquired)-idiopathic gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. uuid:3a971004-d08a-4b92-93aa-fcf0f0d8ad38 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:205919 biolink:treats UMLS:C0406317 PMID:41385096 "[{""id"":""uuid:da3261c6-b172-483f-a4a5-f3a2d5d3461e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:38f90a5f-2ea8-4a9e-b223-f9d8fadb54d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CLOBEX ® (clobetasol propionate) Spray, 0.05% is a super-high potent topical corticosteroid formulation indicated for the treatment of moderate to severe plaque psoriasis affecting up to 20% body surface area (BSA) in patients 18 years of age or older (see PRECAUTIONS ). Treatment should be limited to 4 consecutive weeks. The total dosage should not exceed 50 g (59 mL or 2 fl. oz.) per week. Before prescribing for more than 2 weeks, any additional benefits of extending treatment to 4 weeks should be weighed against the risk of HPA axis suppression. Patients should be instructed to use CLOBEX ® (clobetasol propionate) Spray, 0.05% for the minimum amount of time necessary to achieve the desired results (see PRECAUTIONS ). Use in patients under 18 years of age is not recommended because safety has not been established and because numerically high rates of HPA axis suppression were seen with other clobetasol propionate topical formulations (see PRECAUTIONS: Pediatric Use ). uuid:d5006ee8-7fc1-42c4-872f-5994b6969239 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27300 biolink:treats MONDO:0001220 PMID:41385096 "[{""id"":""uuid:c13ef699-2e70-4fab-81d1-a3e0ff5afa92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c67ca681-69a6-4b47-8342-47afa8af76f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ergocalciferol Capsules, USP are indicated for use in the treatment of hypoparathyroidism, refractory rickets, also known as vitamin D resistant rickets, and familial hypophosphatemia. CHEBI:28934 uuid:1a60b312-a7f5-483d-8f1b-186fa5042d75 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27300 biolink:treats MONDO:0024300 PMID:41385096 "[{""id"":""uuid:4f826d82-24f3-4585-afac-619ca9c5b4be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:243f63c3-75e5-4b8d-9f44-5276d14767ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ergocalciferol Capsules, USP are indicated for use in the treatment of hypoparathyroidism, refractory rickets, also known as vitamin D resistant rickets, and familial hypophosphatemia. CHEBI:28934 uuid:1b4fa734-8cb6-4918-93d8-ba4825744ff6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27300 biolink:treats MONDO:0010619 PMID:41385096 "[{""id"":""uuid:b6dfaed6-a79e-490f-bee6-6c3d5c4c812e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9ff57d92-df12-42fe-93a0-b4d69373b260"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ergocalciferol Capsules, USP are indicated for use in the treatment of hypoparathyroidism, refractory rickets, also known as vitamin D resistant rickets, and familial hypophosphatemia. CHEBI:28934 uuid:330456d8-819b-470a-b8a0-f2286bc08119 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27300 biolink:treats UMLS:C0020631 PMID:41385096 "[{""id"":""uuid:5e3d81e6-a0ef-4f65-b859-920565234636"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e511eb18-d740-4028-8659-1227c186be11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ergocalciferol Capsules, USP are indicated for use in the treatment of hypoparathyroidism, refractory rickets, also known as vitamin D resistant rickets, and familial hypophosphatemia. CHEBI:28934 uuid:cc687c54-2104-4fc4-808d-d5e8912bece3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63607 biolink:treats MONDO:0021679 PMID:41385096 "[{""id"":""uuid:4f3cf6a6-9f07-4c12-827e-a9efa4c7f312"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7b9f83db-5450-492c-804a-8fa8272b30ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZYVOX formulations are indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms (see PRECAUTIONS, Pediatric Use and DOSAGE AND ADMINISTRATION and CLINICAL STUDIES ). Linezolid is not indicated for the treatment of Gram-negative infections. It is critical that specific Gram-negative therapy be initiated immediately if a concomitant Gram-negative pathogen is documented or suspected (see WARNINGS ). Vancomycin-Resistant Enterococcus faecium infections, including cases with concurrent bacteremia. (see CLINICAL STUDIES ) Nosocomial pneumonia caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains), or Streptococcus pneumoniae (including multi-drug resistant strains [MDRSP]). Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis , caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains), Streptococcus pyogenes, or Streptococcus agalactiae . ZYVOX has not been studied in the treatment of decubitus ulcers. Uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible only) or Streptococcus pyogenes . Community-acquired pneumonia caused by Streptococcus pneumoniae (including multi-drug resistant strains [MDRSP] MDRSP refers to isolates resistant to two or more of the following antibiotics: penicillin, second-generation cephalosporins, macrolides, tetracycline, and trimethoprim/sulfamethoxazole. ), including cases with concurrent bacteremia, or Staphylococcus aureus (methicillin-susceptible strains only). To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZYVOX and other antibacterial drugs, ZYVOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:a36e9528-54c8-49a1-b721-c6b7034286c8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63607 biolink:treats MONDO:0005229 PMID:41385096 "[{""id"":""uuid:43c3bdff-ce60-4352-86c4-0bbae701d3af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4233b2b6-e8e6-4790-9740-db913db2f6dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZYVOX formulations are indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms (see PRECAUTIONS, Pediatric Use and DOSAGE AND ADMINISTRATION and CLINICAL STUDIES ). Linezolid is not indicated for the treatment of Gram-negative infections. It is critical that specific Gram-negative therapy be initiated immediately if a concomitant Gram-negative pathogen is documented or suspected (see WARNINGS ). Vancomycin-Resistant Enterococcus faecium infections, including cases with concurrent bacteremia. (see CLINICAL STUDIES ) Nosocomial pneumonia caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains), or Streptococcus pneumoniae (including multi-drug resistant strains [MDRSP]). Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis , caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains), Streptococcus pyogenes, or Streptococcus agalactiae . ZYVOX has not been studied in the treatment of decubitus ulcers. Uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible only) or Streptococcus pyogenes . Community-acquired pneumonia caused by Streptococcus pneumoniae (including multi-drug resistant strains [MDRSP] MDRSP refers to isolates resistant to two or more of the following antibiotics: penicillin, second-generation cephalosporins, macrolides, tetracycline, and trimethoprim/sulfamethoxazole. ), including cases with concurrent bacteremia, or Staphylococcus aureus (methicillin-susceptible strains only). To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZYVOX and other antibacterial drugs, ZYVOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:369575ca-02a1-4c14-9b9c-f6b9156788d7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63607 biolink:treats UMLS:C0949083 PMID:41385096 "[{""id"":""uuid:79b9c430-01ba-4f7d-99f9-a8888341e14f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c01580a2-d4d6-441a-9df2-86d8d028f85e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZYVOX formulations are indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms (see PRECAUTIONS, Pediatric Use and DOSAGE AND ADMINISTRATION and CLINICAL STUDIES ). Linezolid is not indicated for the treatment of Gram-negative infections. It is critical that specific Gram-negative therapy be initiated immediately if a concomitant Gram-negative pathogen is documented or suspected (see WARNINGS ). Vancomycin-Resistant Enterococcus faecium infections, including cases with concurrent bacteremia. (see CLINICAL STUDIES ) Nosocomial pneumonia caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains), or Streptococcus pneumoniae (including multi-drug resistant strains [MDRSP]). Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis , caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains), Streptococcus pyogenes, or Streptococcus agalactiae . ZYVOX has not been studied in the treatment of decubitus ulcers. Uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible only) or Streptococcus pyogenes . Community-acquired pneumonia caused by Streptococcus pneumoniae (including multi-drug resistant strains [MDRSP] MDRSP refers to isolates resistant to two or more of the following antibiotics: penicillin, second-generation cephalosporins, macrolides, tetracycline, and trimethoprim/sulfamethoxazole. ), including cases with concurrent bacteremia, or Staphylococcus aureus (methicillin-susceptible strains only). To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZYVOX and other antibacterial drugs, ZYVOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:3dfc9d99-b937-45ce-afef-f5e9b0e57469 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63607 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:d579d6d7-2e29-432e-959f-e022d3d21309"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:99fe4798-2286-4dc8-b412-cc0952d49c45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:81e9962b-6687-4aa7-b5bc-8268c75ff3e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZYVOX formulations are indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms (see PRECAUTIONS, Pediatric Use and DOSAGE AND ADMINISTRATION and CLINICAL STUDIES ). Linezolid is not indicated for the treatment of Gram-negative infections. It is critical that specific Gram-negative therapy be initiated immediately if a concomitant Gram-negative pathogen is documented or suspected (see WARNINGS ). Vancomycin-Resistant Enterococcus faecium infections, including cases with concurrent bacteremia. (see CLINICAL STUDIES ) Nosocomial pneumonia caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains), or Streptococcus pneumoniae (including multi-drug resistant strains [MDRSP]). Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis , caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains), Streptococcus pyogenes, or Streptococcus agalactiae . ZYVOX has not been studied in the treatment of decubitus ulcers. Uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible only) or Streptococcus pyogenes . Community-acquired pneumonia caused by Streptococcus pneumoniae (including multi-drug resistant strains [MDRSP] MDRSP refers to isolates resistant to two or more of the following antibiotics: penicillin, second-generation cephalosporins, macrolides, tetracycline, and trimethoprim/sulfamethoxazole. ), including cases with concurrent bacteremia, or Staphylococcus aureus (methicillin-susceptible strains only). To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZYVOX and other antibacterial drugs, ZYVOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.|[PMDA] Drugs with a new additional pediatric dosage. These drugs are indicated for sepsis, deep skin infection, chronic pyoderma, secondary infection of trauma, burn, and surgical wounds, and pneumonia. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:2e7519e9-c532-41af-a486-8ac0b7f5510a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63607 biolink:treats UMLS:C0744130 PMID:41385096 "[{""id"":""uuid:34829f8f-f7a1-4311-9c4c-8ac774ee54b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:be78024d-74e3-400c-84cd-36de73c938ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZYVOX formulations are indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms (see PRECAUTIONS, Pediatric Use and DOSAGE AND ADMINISTRATION and CLINICAL STUDIES ). Linezolid is not indicated for the treatment of Gram-negative infections. It is critical that specific Gram-negative therapy be initiated immediately if a concomitant Gram-negative pathogen is documented or suspected (see WARNINGS ). Vancomycin-Resistant Enterococcus faecium infections, including cases with concurrent bacteremia. (see CLINICAL STUDIES ) Nosocomial pneumonia caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains), or Streptococcus pneumoniae (including multi-drug resistant strains [MDRSP]). Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis , caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains), Streptococcus pyogenes, or Streptococcus agalactiae . ZYVOX has not been studied in the treatment of decubitus ulcers. Uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible only) or Streptococcus pyogenes . Community-acquired pneumonia caused by Streptococcus pneumoniae (including multi-drug resistant strains [MDRSP] MDRSP refers to isolates resistant to two or more of the following antibiotics: penicillin, second-generation cephalosporins, macrolides, tetracycline, and trimethoprim/sulfamethoxazole. ), including cases with concurrent bacteremia, or Staphylococcus aureus (methicillin-susceptible strains only). To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZYVOX and other antibacterial drugs, ZYVOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:99dd8bf9-70ab-4bc6-b384-348e95b6d96f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63607 biolink:treats MONDO:0005246 PMID:41385096 "[{""id"":""uuid:34c5d198-794f-4cbf-9973-9ef5839780e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0c2c0f26-8676-4343-96cf-937cc91c1b9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZYVOX formulations are indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms (see PRECAUTIONS, Pediatric Use and DOSAGE AND ADMINISTRATION and CLINICAL STUDIES ). Linezolid is not indicated for the treatment of Gram-negative infections. It is critical that specific Gram-negative therapy be initiated immediately if a concomitant Gram-negative pathogen is documented or suspected (see WARNINGS ). Vancomycin-Resistant Enterococcus faecium infections, including cases with concurrent bacteremia. (see CLINICAL STUDIES ) Nosocomial pneumonia caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains), or Streptococcus pneumoniae (including multi-drug resistant strains [MDRSP]). Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis , caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains), Streptococcus pyogenes, or Streptococcus agalactiae . ZYVOX has not been studied in the treatment of decubitus ulcers. Uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible only) or Streptococcus pyogenes . Community-acquired pneumonia caused by Streptococcus pneumoniae (including multi-drug resistant strains [MDRSP] MDRSP refers to isolates resistant to two or more of the following antibiotics: penicillin, second-generation cephalosporins, macrolides, tetracycline, and trimethoprim/sulfamethoxazole. ), including cases with concurrent bacteremia, or Staphylococcus aureus (methicillin-susceptible strains only). To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZYVOX and other antibacterial drugs, ZYVOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:fe6a1d0f-658d-45ed-8f0f-2069e26942e1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63607 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:5967882a-b75f-4cdd-a54e-3ec0d5301f97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c2500e83-4621-4111-ac43-31e80dd7894e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a8902fac-0a00-401b-a018-639085e4a98f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZYVOX formulations are indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms (see PRECAUTIONS, Pediatric Use and DOSAGE AND ADMINISTRATION and CLINICAL STUDIES ). Linezolid is not indicated for the treatment of Gram-negative infections. It is critical that specific Gram-negative therapy be initiated immediately if a concomitant Gram-negative pathogen is documented or suspected (see WARNINGS ). Vancomycin-Resistant Enterococcus faecium infections, including cases with concurrent bacteremia. (see CLINICAL STUDIES ) Nosocomial pneumonia caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains), or Streptococcus pneumoniae (including multi-drug resistant strains [MDRSP]). Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis , caused by Staphylococcus aureus (methicillin-susceptible and -resistant strains), Streptococcus pyogenes, or Streptococcus agalactiae . ZYVOX has not been studied in the treatment of decubitus ulcers. Uncomplicated skin and skin structure infections caused by Staphylococcus aureus (methicillin-susceptible only) or Streptococcus pyogenes . Community-acquired pneumonia caused by Streptococcus pneumoniae (including multi-drug resistant strains [MDRSP] MDRSP refers to isolates resistant to two or more of the following antibiotics: penicillin, second-generation cephalosporins, macrolides, tetracycline, and trimethoprim/sulfamethoxazole. ), including cases with concurrent bacteremia, or Staphylococcus aureus (methicillin-susceptible strains only). To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZYVOX and other antibacterial drugs, ZYVOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.|[PMDA] Drugs with a new additional pediatric dosage. These drugs are indicated for sepsis, deep skin infection, chronic pyoderma, secondary infection of trauma, burn, and surgical wounds, and pneumonia. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:10e31ff5-b869-4988-af83-00560d6d41a0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59594 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:f3bdcc45-eab6-44ee-879b-eb9e833a5d74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7b1da6cf-a0de-418e-af6e-39e9874488e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] WELCHOL is a bile acid sequestrant indicated as an adjunct to diet and exercise to reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia as monotherapy or in combination with an hydroxymethyl-glutaryl-coenzyme A (HMG CoA) reductase inhibitor (statin) (1.1) . reduce LDL-C levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia as monotherapy or in combination with a statin after failing an adequate trial of diet therapy improve glycemic control in adults with type 2 diabetes mellitus (1.2) . Important Limitations of Use (1.3) : Do not use for glycemic control in type 1 diabetes or for treating diabetic ketoacidosis. WELCHOL has not been studied in type 2 diabetes as monotherapy or in combination with a dipeptidyl peptidase 4 inhibitor and has not been extensively studied in combination with thiazolidinediones. WELCHOL has not been studied in Fredrickson Type I, III, IV, and V dyslipidemias. WELCHOL has not been studied in children younger than 10 years of age or in pre-menarchal girls. uuid:4f49f78e-bd9a-4b39-87a3-8807e39f4e92 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59594 biolink:treats UMLS:C0342882 PMID:41385096 "[{""id"":""uuid:691e6b02-b6d1-4b67-b631-7e2a406c0c54"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:29d835db-17b4-4f91-82e2-a2aa159b6e80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] WELCHOL is a bile acid sequestrant indicated as an adjunct to diet and exercise to reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia as monotherapy or in combination with an hydroxymethyl-glutaryl-coenzyme A (HMG CoA) reductase inhibitor (statin) (1.1) . reduce LDL-C levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia as monotherapy or in combination with a statin after failing an adequate trial of diet therapy improve glycemic control in adults with type 2 diabetes mellitus (1.2) . Important Limitations of Use (1.3) : Do not use for glycemic control in type 1 diabetes or for treating diabetic ketoacidosis. WELCHOL has not been studied in type 2 diabetes as monotherapy or in combination with a dipeptidyl peptidase 4 inhibitor and has not been extensively studied in combination with thiazolidinediones. WELCHOL has not been studied in Fredrickson Type I, III, IV, and V dyslipidemias. WELCHOL has not been studied in children younger than 10 years of age or in pre-menarchal girls. uuid:0daa3fee-e47d-478e-b4a4-54c9cf9c2ade biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59594 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:35fe8814-1ea2-44c4-af41-7a3b0bd53226"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:12f8bff5-701d-439c-aabf-d32674bbdd03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] WELCHOL is a bile acid sequestrant indicated as an adjunct to diet and exercise to reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia as monotherapy or in combination with an hydroxymethyl-glutaryl-coenzyme A (HMG CoA) reductase inhibitor (statin) (1.1) . reduce LDL-C levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia as monotherapy or in combination with a statin after failing an adequate trial of diet therapy improve glycemic control in adults with type 2 diabetes mellitus (1.2) . Important Limitations of Use (1.3) : Do not use for glycemic control in type 1 diabetes or for treating diabetic ketoacidosis. WELCHOL has not been studied in type 2 diabetes as monotherapy or in combination with a dipeptidyl peptidase 4 inhibitor and has not been extensively studied in combination with thiazolidinediones. WELCHOL has not been studied in Fredrickson Type I, III, IV, and V dyslipidemias. WELCHOL has not been studied in children younger than 10 years of age or in pre-menarchal girls. uuid:f6a42bd2-cda0-4ada-bd1d-822f7157beb7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59594 biolink:treats MONDO:0012819 PMID:41385096 "[{""id"":""uuid:aca0be6f-66c7-4ca4-9fef-a11e96220280"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:82f685b6-d59c-45c5-8438-278e2f51fb41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] WELCHOL is a bile acid sequestrant indicated as an adjunct to diet and exercise to reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia as monotherapy or in combination with an hydroxymethyl-glutaryl-coenzyme A (HMG CoA) reductase inhibitor (statin) (1.1) . reduce LDL-C levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia as monotherapy or in combination with a statin after failing an adequate trial of diet therapy improve glycemic control in adults with type 2 diabetes mellitus (1.2) . Important Limitations of Use (1.3) : Do not use for glycemic control in type 1 diabetes or for treating diabetic ketoacidosis. WELCHOL has not been studied in type 2 diabetes as monotherapy or in combination with a dipeptidyl peptidase 4 inhibitor and has not been extensively studied in combination with thiazolidinediones. WELCHOL has not been studied in Fredrickson Type I, III, IV, and V dyslipidemias. WELCHOL has not been studied in children younger than 10 years of age or in pre-menarchal girls. uuid:68c93737-1394-47ca-84a3-b77037555b59 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59594 biolink:treats MONDO:0007788 PMID:41385096 "[{""id"":""uuid:c347ac14-c7b0-4037-8831-31a602e6fcf0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7471d615-d632-487d-9fd0-6f0d5abffb9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] WELCHOL is a bile acid sequestrant indicated as an adjunct to diet and exercise to reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia as monotherapy or in combination with an hydroxymethyl-glutaryl-coenzyme A (HMG CoA) reductase inhibitor (statin) (1.1) . reduce LDL-C levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia as monotherapy or in combination with a statin after failing an adequate trial of diet therapy improve glycemic control in adults with type 2 diabetes mellitus (1.2) . Important Limitations of Use (1.3) : Do not use for glycemic control in type 1 diabetes or for treating diabetic ketoacidosis. WELCHOL has not been studied in type 2 diabetes as monotherapy or in combination with a dipeptidyl peptidase 4 inhibitor and has not been extensively studied in combination with thiazolidinediones. WELCHOL has not been studied in Fredrickson Type I, III, IV, and V dyslipidemias. WELCHOL has not been studied in children younger than 10 years of age or in pre-menarchal girls. uuid:5aae0a72-63a9-435f-a620-1f51c7c45d70 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59594 biolink:treats MONDO:0018473 PMID:41385096 "[{""id"":""uuid:27373d2b-a1a4-4f32-95f7-0397dfbb069b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:929e98d9-2bd6-43a6-acda-6c6fdb9a10bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] WELCHOL is a bile acid sequestrant indicated as an adjunct to diet and exercise to reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia as monotherapy or in combination with an hydroxymethyl-glutaryl-coenzyme A (HMG CoA) reductase inhibitor (statin) (1.1) . reduce LDL-C levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia as monotherapy or in combination with a statin after failing an adequate trial of diet therapy improve glycemic control in adults with type 2 diabetes mellitus (1.2) . Important Limitations of Use (1.3) : Do not use for glycemic control in type 1 diabetes or for treating diabetic ketoacidosis. WELCHOL has not been studied in type 2 diabetes as monotherapy or in combination with a dipeptidyl peptidase 4 inhibitor and has not been extensively studied in combination with thiazolidinediones. WELCHOL has not been studied in Fredrickson Type I, III, IV, and V dyslipidemias. WELCHOL has not been studied in children younger than 10 years of age or in pre-menarchal girls. uuid:a4d58955-1ef5-4c4a-bb01-048381e2c138 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59594 biolink:treats MONDO:0007762 PMID:41385096 "[{""id"":""uuid:5c6af3a6-c990-40e0-91ca-b6a6fe969610"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:656f9426-ff8d-400d-945f-3548a871d214"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] WELCHOL is a bile acid sequestrant indicated as an adjunct to diet and exercise to reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia as monotherapy or in combination with an hydroxymethyl-glutaryl-coenzyme A (HMG CoA) reductase inhibitor (statin) (1.1) . reduce LDL-C levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia as monotherapy or in combination with a statin after failing an adequate trial of diet therapy improve glycemic control in adults with type 2 diabetes mellitus (1.2) . Important Limitations of Use (1.3) : Do not use for glycemic control in type 1 diabetes or for treating diabetic ketoacidosis. WELCHOL has not been studied in type 2 diabetes as monotherapy or in combination with a dipeptidyl peptidase 4 inhibitor and has not been extensively studied in combination with thiazolidinediones. WELCHOL has not been studied in Fredrickson Type I, III, IV, and V dyslipidemias. WELCHOL has not been studied in children younger than 10 years of age or in pre-menarchal girls. uuid:a165236e-8d45-45f0-a131-fb09f738be94 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0005093 PMID:41385096 "[{""id"":""uuid:b6ebf299-e3b7-4380-b35e-73c75da02c0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:86909348-436f-4137-be71-2c1137e9b638"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Triamcinolone acetonide cream is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. uuid:0ab1917e-046f-4995-8330-2a2197653dba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10110 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:26efb10a-ed6b-4a2e-8087-aa19cf05247d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4e29ef82-3b84-4143-997e-181fedf12b7c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Zidovudine tablets are a nucleoside analogue reverse transcriptase inhibitor indicated for: Treatment of Human Immunodeficiency Virus (HIV-1) infection in combination with other antiretroviral agents. (1.1) Prevention of maternal-fetal HIV-1 transmission. (1.2) uuid:a7548aab-ee49-47ee-b0ef-a93715e9d9ac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10110 biolink:treats UMLS:C0242648 PMID:41385096 "[{""id"":""uuid:a6888917-79df-4bea-a154-ef57d9b91caf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9e60e23f-edd0-4365-b8f4-21409d659bc8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Zidovudine tablets are a nucleoside analogue reverse transcriptase inhibitor indicated for: Treatment of Human Immunodeficiency Virus (HIV-1) infection in combination with other antiretroviral agents. (1.1) Prevention of maternal-fetal HIV-1 transmission. (1.2) uuid:27e263f6-ecc3-47a1-9f4b-b5f51b2ef446 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C069202 biolink:treats MONDO:0005052 PMID:41385096 "[{""id"":""uuid:72774f29-1a41-4d03-80fc-67a4ea9cb431"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b9958daf-e024-43d5-8f21-7d36a4c41453"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FDA has classified the following indications as “possibly” effective: For use as adjunctive therapy in the treatment of irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis. May also be useful as adjunctive therapy in the treatment of duodenal ulcer. IT HAS NOT BEEN SHOWN CONCLUSIVELY WHETHER ANTICHOLINERGIC/ ANTISPASMODIC DRUGS AID IN THE HEALING OF A DUODENAL ULCER, DECREASE THE RATE OF RECURRENCES OR PREVENT COMPLICATIONS. uuid:fd625926-1ada-4075-90ef-1b2ff3bc1ba7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C069202 biolink:treats UMLS:C0856217 PMID:41385096 "[{""id"":""uuid:43e9656f-5ad9-454f-9b92-dbd31d54fe4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fb5fc04d-c473-405a-bcf0-f93d00d04661"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FDA has classified the following indications as “possibly” effective: For use as adjunctive therapy in the treatment of irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis. May also be useful as adjunctive therapy in the treatment of duodenal ulcer. IT HAS NOT BEEN SHOWN CONCLUSIVELY WHETHER ANTICHOLINERGIC/ ANTISPASMODIC DRUGS AID IN THE HEALING OF A DUODENAL ULCER, DECREASE THE RATE OF RECURRENCES OR PREVENT COMPLICATIONS. uuid:b1248ff4-b229-4734-9432-0b3f65806423 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C069202 biolink:treats UMLS:C3203466 PMID:41385096 "[{""id"":""uuid:85ab6790-2eec-4145-b2c4-51a28b4fdbaf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e9a60569-50aa-488c-b029-2d53b8585074"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FDA has classified the following indications as “possibly” effective: For use as adjunctive therapy in the treatment of irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis. May also be useful as adjunctive therapy in the treatment of duodenal ulcer. IT HAS NOT BEEN SHOWN CONCLUSIVELY WHETHER ANTICHOLINERGIC/ ANTISPASMODIC DRUGS AID IN THE HEALING OF A DUODENAL ULCER, DECREASE THE RATE OF RECURRENCES OR PREVENT COMPLICATIONS. uuid:0caed875-b693-450c-94da-5f04f7ca9963 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C069202 biolink:treats MONDO:0005412 PMID:41385096 "[{""id"":""uuid:16cf1d68-34eb-4517-b370-95ef96eb599d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b06e0994-02df-4c70-a35c-c7720262caa3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FDA has classified the following indications as “possibly” effective: For use as adjunctive therapy in the treatment of irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis. May also be useful as adjunctive therapy in the treatment of duodenal ulcer. IT HAS NOT BEEN SHOWN CONCLUSIVELY WHETHER ANTICHOLINERGIC/ ANTISPASMODIC DRUGS AID IN THE HEALING OF A DUODENAL ULCER, DECREASE THE RATE OF RECURRENCES OR PREVENT COMPLICATIONS. uuid:07a73e79-2677-473f-bcc3-4cf9253d9ecc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:11949636 biolink:treats UMLS:C0015404 PMID:41385096 "[{""id"":""uuid:9edabbcd-937c-4d1f-8248-2da8807356cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1c3b58f1-2ac0-4511-a415-9fb000545123"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tobramycin and dexamethasone ophthalmic suspension is indicated for steroid responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococci, including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin-resistant strains. Streptococci, including some of the Group A-beta-hemolytic species, some nonhemolytic species, and some Streptococcus pneumoniae . Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii, most Proteus vulgaris strains , Haemophilus influenzae and H. aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus and some Neisseria species. uuid:864efb64-ad68-4850-a96c-75bb1803e8b6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:f3ae39f8-4103-417e-87fe-9d86ad223cc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3902e8ad-dc2e-4191-b218-12cee18d91b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AllerNaze is indicated for the treatment of the nasal symptoms of seasonal and perennial allergic rhinitis in adults and children 12 years of age or older. uuid:ebe782b5-2982-4a6a-a68d-110603484a26 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0024332 PMID:41385096 "[{""id"":""uuid:d33105a7-42aa-4b25-9da4-94a9f6153573"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c08fc724-1e26-4720-82c1-b7038343240a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AllerNaze is indicated for the treatment of the nasal symptoms of seasonal and perennial allergic rhinitis in adults and children 12 years of age or older. uuid:d05b6de7-ae71-4e1b-a069-accc80eeee1f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:215703 biolink:treats MONDO:0006668 PMID:41385096 "[{""id"":""uuid:87ec2a9c-1a8f-4c4e-ba68-3d967da36e66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:600fa346-8114-4a85-8716-c1bbc214d99e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sulfacetamide sodium and prednisolone sodium phosphate ophthalmic solution is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where a superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular antibacterial drug in this product is active against the following common bacterial eye pathogens: Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus (viridans group), Haemophilus influenzae, Klebsiella species, and Enterobacter species. The product does not provide adequate coverage against: Neisseria species, Pseudomonas species, Serratia marcescens . A significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. uuid:a2de9a2a-25d8-4a9b-b87b-dbb4861c8762 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:215703 biolink:treats UMLS:C0008690 PMID:41385096 "[{""id"":""uuid:630b6ffd-f9d0-456b-9600-5a5370209a4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c360ce73-e964-4252-8d2a-a73353a45cf6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sulfacetamide sodium and prednisolone sodium phosphate ophthalmic solution is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where a superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular antibacterial drug in this product is active against the following common bacterial eye pathogens: Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus (viridans group), Haemophilus influenzae, Klebsiella species, and Enterobacter species. The product does not provide adequate coverage against: Neisseria species, Pseudomonas species, Serratia marcescens . A significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. uuid:3542e1ce-1a05-4aad-93d4-759eb92017d2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:215703 biolink:treats UMLS:C0339289 PMID:41385096 "[{""id"":""uuid:cf24fda1-565f-440a-ad47-ab828fd153d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:687df208-17fe-450b-b056-ae0f398a3e3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sulfacetamide sodium and prednisolone sodium phosphate ophthalmic solution is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where a superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular antibacterial drug in this product is active against the following common bacterial eye pathogens: Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus (viridans group), Haemophilus influenzae, Klebsiella species, and Enterobacter species. The product does not provide adequate coverage against: Neisseria species, Pseudomonas species, Serratia marcescens . A significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. uuid:270ca3a4-ab5d-4758-a7a3-1bf2f32d8856 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40237 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:250a7dd5-fa16-473c-9b2d-fe01f11c6155"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:688c95b6-6904-449f-9ebd-7dbc40a96442"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e2e47833-9a94-4645-b059-22da7f0c5074"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/xelevia""]},{""id"":""uuid:b2012ee8-22b7-45e0-bbdb-97c3e4e3f4c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] JANUVIA is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1.1 ) Important Limitations of Use: JANUVIA should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. ( 1.2 ) JANUVIA has not been studied in patients with a history of pancreatitis. ( 1.2 , 5.1 )|[EMA] For adult patients with type-2 diabetes mellitus, Xelevia is indicated to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy in combination with:metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control;a sulphonylurea when diet and exercise plus maximal tolerated dose of a sulphonylurea alone do not provide adequate glycaemic control and when metformin is inappropriate due to contraindications or intolerance;a peroxisome proliferator-activated receptor gamma (PPARγ) agonist (i.e. a thiazolidinedione) when use of a PPARγ agonist is appropriate and when diet and exercise plus the PPARγ agonist alone do not provide adequate glycaemic control;as triple oral therapy in combination with:a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control;a PPARγ agonist and metformin when use of a PPARγ agonist is appropriate and when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.Xelevia is also indicated as add-on to insulin (with or without metformin) when diet and exercise plus stable dose of insulin do not provide adequate glycaemic control.|[PMDA] Drugs with a new active ingredient indicated for the treatment of type 2 diabetes mellitus (for use only in patients who do not sufficiently respond to any one of the following treatments): Dietary therapy and/or exercise therapy only Use of sulfonylureas in addition to dietary therapy and/or exercise therapy Use of thiazolidinediones in addition to dietary therapy and/or exercise therapy Use of biguanides in addition to dietary therapy and/or exercise therapy uuid:3a963f97-001d-40c2-ba47-6583e9352188 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40237 biolink:treats MONDO:0012819 PMID:41385096 "[{""id"":""uuid:4ae8000b-f10c-4080-b08d-40cbe6edf311"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:21766755-1e33-4f29-b253-5255c190f001"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] JANUVIA is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1.1 ) Important Limitations of Use: JANUVIA should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. ( 1.2 ) JANUVIA has not been studied in patients with a history of pancreatitis. ( 1.2 , 5.1 ) uuid:4f9fad22-51ce-4b29-a807-9fc4bd010afb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40237 biolink:treats MONDO:0004982 PMID:41385096 "[{""id"":""uuid:a557065f-f90b-415b-93de-c036555eea70"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2a96bbfe-dc50-49ca-9728-6c8d3af573b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] JANUVIA is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1.1 ) Important Limitations of Use: JANUVIA should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. ( 1.2 ) JANUVIA has not been studied in patients with a history of pancreatitis. ( 1.2 , 5.1 ) uuid:ab1d86ab-6dfa-469a-b702-b5d1cfcf1162 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50749 biolink:treats UMLS:C0406317 PMID:41385096 "[{""id"":""uuid:8f346541-c3e2-4342-b899-e612782969d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:75652897-6798-49ce-8183-844d35c13e67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dovonex ® (calcipotriene cream) Cream, 0.005%, is indicated for the treatment of plaque psoriasis. The safety and effectiveness of topical calcipotriene in dermatoses other than psoriasis have not been established. uuid:17a05411-6e49-46db-83b6-f51b8b89c416 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4670 biolink:treats UMLS:C1740826 PMID:41385096 "[{""id"":""uuid:afb9e340-ded9-477b-b06d-59a4704d41d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a44620d9-3fa5-4a6c-89c3-ea0e0b54bdcc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dobutamine injection is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of adults with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. In patients who have atrial fibrillation with rapid ventricular response, a digitalis preparation should be used prior to institution of therapy with dobutamine hydrochloride. uuid:ba46c3dd-bab5-4993-98a4-766ca24b540c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4670 biolink:treats MONDO:0005267 PMID:41385096 "[{""id"":""uuid:e8727851-95bd-4666-91f3-e7d0920b3a27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f247e7ee-19f4-4a25-bcfa-d8839f5cdbea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dobutamine injection is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of adults with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. In patients who have atrial fibrillation with rapid ventricular response, a digitalis preparation should be used prior to institution of therapy with dobutamine hydrochloride. uuid:bef56608-5415-4ff9-a473-764f076ca1a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4670 biolink:treats MONDO:0004981 PMID:41385096 "[{""id"":""uuid:30ab265b-40fc-4a86-aca8-fede5b88e3b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:89080293-3bdc-469e-a5e2-2d11cd4b26d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dobutamine injection is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of adults with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. In patients who have atrial fibrillation with rapid ventricular response, a digitalis preparation should be used prior to institution of therapy with dobutamine hydrochloride. uuid:597cd545-0d09-4e1f-b5ca-354b786a14d2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4670 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:e461d15d-039b-4dff-82e5-ef667f214a40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:833db3ae-b542-4538-ba30-53be1b4c0c6a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dobutamine in 5% Dextrose Injection, USP is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. Experience with intravenous dobutamine in controlled trials does not extend beyond 48 hours of repeated boluses and/or continuous infusions. Whether given orally, continuously intravenously, or intermittently intravenously, neither dobutamine nor any other cyclic-AMP-dependent inotrope has been shown in controlled trials to be safe or effective in the long-term treatment of congestive heart failure. In controlled trials of chronic oral therapy with various such agents, symptoms were not consistently alleviated, and the cyclic-AMP-dependent inotropes were consistently associated with increased risks of hospitalization and death. Patients with NYHA Class IV symptoms appeared to be at particular risk. uuid:b2cf1016-1674-4e16-8854-aad15500a7bb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9448 biolink:treats MONDO:0001628 PMID:41385096 "[{""id"":""uuid:4c2413e3-9461-40ea-ac34-af64beca2f27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5929479d-cbb7-4a60-a697-610e19b1cbc6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Terbinafine hydrochloride tablets are indicated for the treatment of onychomycosis of the toenail or fingernail due to dermatophytes (tinea unguium) (see DOSAGE AND ADMINISTRATION and CLINICAL STUDIES ). Prior to initiating treatment, appropriate nail specimens for laboratory testing (KOH preparation, fungal culture, or nail biopsy) should be obtained to confirm the diagnosis of onychomycosis. uuid:221893db-9aa3-4db5-af46-4c3c7042ef70 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3219 biolink:treats MONDO:0002050 PMID:41385096 "[{""id"":""uuid:0435a09b-0224-41d1-b986-fb84bbba561a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a25454a7-c514-413f-877c-3431681f64d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Aplenzin™ (bupropion hydrobromide extended-release tablets) is indicated for the treatment of major depressive disorder. The efficacy of bupropion in the treatment of a major depressive episode was established in two 4-week controlled trials of inpatients and in one 6-week controlled trial of outpatients whose diagnoses corresponded most closely to the Major Depression category of the APA Diagnostic and Statistical Manual (DSM) [see CLINICAL STUDIES (14) ] . A major depressive episode (DSM-IV) implies the presence of 1) depressed mood or 2) loss of interest or pleasure; in addition, at least 5 of the following symptoms have been present during the same 2-week period and represent a change from previous functioning: depressed mood, markedly diminished interest or pleasure in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt, or suicidal ideation. The efficacy of bupropion in maintaining an antidepressant response for up to 44 weeks following 8 weeks of acute treatment was demonstrated in a placebo-controlled trial with the sustained-release formulation of bupropion [see CLINICAL STUDIES (14) ] . Nevertheless, the physician who elects to use Aplenzin for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual patient. uuid:640b43e2-91fa-4766-9477-78dc2420814a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3219 biolink:treats MONDO:0013600 PMID:41385096 "[{""id"":""uuid:83cce2d1-63de-4888-b49c-32d00c5287b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7ac97e97-3b59-42ee-ac3d-2b518c440695"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Aplenzin™ (bupropion hydrobromide extended-release tablets) is indicated for the treatment of major depressive disorder. The efficacy of bupropion in the treatment of a major depressive episode was established in two 4-week controlled trials of inpatients and in one 6-week controlled trial of outpatients whose diagnoses corresponded most closely to the Major Depression category of the APA Diagnostic and Statistical Manual (DSM) [see CLINICAL STUDIES (14) ] . A major depressive episode (DSM-IV) implies the presence of 1) depressed mood or 2) loss of interest or pleasure; in addition, at least 5 of the following symptoms have been present during the same 2-week period and represent a change from previous functioning: depressed mood, markedly diminished interest or pleasure in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt, or suicidal ideation. The efficacy of bupropion in maintaining an antidepressant response for up to 44 weeks following 8 weeks of acute treatment was demonstrated in a placebo-controlled trial with the sustained-release formulation of bupropion [see CLINICAL STUDIES (14) ] . Nevertheless, the physician who elects to use Aplenzin for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual patient. uuid:48ff3053-c2b4-45a7-b14b-162774f2fc55 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3219 biolink:treats MONDO:0005466 PMID:41385096 "[{""id"":""uuid:838201f5-1557-4876-a8e7-017368857ae7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:98b5ebea-06c3-4612-b1cf-0547d4a8bcf1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Aplenzin™ (bupropion hydrobromide extended-release tablets) is indicated for the treatment of major depressive disorder. The efficacy of bupropion in the treatment of a major depressive episode was established in two 4-week controlled trials of inpatients and in one 6-week controlled trial of outpatients whose diagnoses corresponded most closely to the Major Depression category of the APA Diagnostic and Statistical Manual (DSM) [see CLINICAL STUDIES (14) ] . A major depressive episode (DSM-IV) implies the presence of 1) depressed mood or 2) loss of interest or pleasure; in addition, at least 5 of the following symptoms have been present during the same 2-week period and represent a change from previous functioning: depressed mood, markedly diminished interest or pleasure in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt, or suicidal ideation. The efficacy of bupropion in maintaining an antidepressant response for up to 44 weeks following 8 weeks of acute treatment was demonstrated in a placebo-controlled trial with the sustained-release formulation of bupropion [see CLINICAL STUDIES (14) ] . Nevertheless, the physician who elects to use Aplenzin for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual patient. uuid:c12eb389-5d7e-466e-a40a-8513c6afbdfe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71253 biolink:treats MONDO:0005090 PMID:41385096 "[{""id"":""uuid:60870255-f910-4744-9510-d528305169e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:21a06910-f53e-4e9c-b0af-1e39ef6d815f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:12d70461-b561-4f90-a97e-3f7418b3dec8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SAPHRIS is an atypical antipsychotic indicated for: Treatment of schizophrenia. ( 1.1 ) Efficacy was established in two 6-week clinical trials and one maintenance trial in patients with schizophrenia in adults. ( 14.1 ) Acute treatment, as monotherapy or adjunctive therapy, of manic or mixed episodes associated with bipolar I disorder. ( 1.2 ) Efficacy was established in two 3-week monotherapy trials and in one 3-week adjunctive trial in patients with manic or mixed episodes associated with bipolar I disorder in adults. ( 14.2 )|[PMDA] Drugs with a new active ingredient indicated for the treatment of schizophrenia. uuid:bf7cb8f5-e0b3-4437-abfa-40c0161a355b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71253 biolink:treats MONDO:0001866 PMID:41385096 "[{""id"":""uuid:203b5d13-8343-4a3d-9a8d-6b3ee02420fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f7e1df27-3a95-4fd2-8379-6e61caeaa8d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SAPHRIS is an atypical antipsychotic indicated for: Treatment of schizophrenia. ( 1.1 ) Efficacy was established in two 6-week clinical trials and one maintenance trial in patients with schizophrenia in adults. ( 14.1 ) Acute treatment, as monotherapy or adjunctive therapy, of manic or mixed episodes associated with bipolar I disorder. ( 1.2 ) Efficacy was established in two 3-week monotherapy trials and in one 3-week adjunctive trial in patients with manic or mixed episodes associated with bipolar I disorder in adults. ( 14.2 ) uuid:25d9e1d4-11e6-4758-9328-ae9dbe02a079 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C4277251 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:d3d4b891-fcc8-44dc-9a3c-06707a5aa3d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ff15cc63-0785-448b-9c31-dd5465d2c257"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LANTUS is indicated to improve glycemic control in adults and children with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. Important Limitations of Use: LANTUS is not recommended for the treatment of diabetic ketoacidosis. Intravenous short-acting insulin is the preferred treatment for this condition. MESH:C000606659 uuid:3cab6664-ab33-40af-9a9b-e24ca2c5f25a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C4277251 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:2278eded-46c6-411e-95a7-19580f5a2502"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:36cc2da4-73bf-4dad-b50b-326f79ba7ddd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LANTUS is indicated to improve glycemic control in adults and children with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. Important Limitations of Use: LANTUS is not recommended for the treatment of diabetic ketoacidosis. Intravenous short-acting insulin is the preferred treatment for this condition. MESH:C000606659 uuid:31b8bad3-09b2-423c-a9d7-9fc4ae3d87a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C4277251 biolink:treats MONDO:0012819 PMID:41385096 "[{""id"":""uuid:a926c190-53f6-438c-81c8-1c73e45b67be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e872e64c-5fe3-48b1-b859-40e14701339b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LANTUS is indicated to improve glycemic control in adults and children with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. Important Limitations of Use: LANTUS is not recommended for the treatment of diabetic ketoacidosis. Intravenous short-acting insulin is the preferred treatment for this condition. MESH:C000606659 uuid:039835f8-1923-4b8d-a6d1-dfcaacecda59 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42944 biolink:treats MONDO:0004975 PMID:41385096 "[{""id"":""uuid:67ffe4b6-2769-4057-894c-d5305ea40831"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:af3ebb58-30d8-4e17-84dc-e9781b1fac29"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0f02fcd8-708f-40f5-9b68-c0f6d1afd85c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RAZADYNE ® ER/RAZADYNE ® (galantamine hydrobromide) is indicated for the treatment of mild to moderate dementia of the Alzheimer's type.|[PMDA] Drugs with a new active ingredient indicated for inhibition of progression of symptoms of dementia in mild and moderate Alzheimer's dementia. uuid:52ed2b05-cb77-48b6-bad0-7aa794f35451 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841818 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:25dc7f39-981d-44c4-9df7-356634e1fcab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c4870c33-ae49-4896-9a96-3fd5970117d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acetaminophen, caffeine, and dihydrocodeine bitartrate tablets are indicated for the relief of moderate to moderately severe pain. uuid:5d5bfad3-c21b-40d9-a7c1-befde55040cb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10127 biolink:treats MONDO:0005027 PMID:41385096 "[{""id"":""uuid:9547770d-083a-4e63-9661-2b1c8cd59fa3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:12e2ca6f-fd7e-456d-8040-80680a755694"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:479b71e0-03a7-4a1b-8aec-532911bf1fb2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zonisamide-mylan""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Zonisamide capsules are indicated as adjunctive therapy in the treatment of partial seizures in adults with epilepsy.|[EMA] Monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy;adjunctive therapy in the treatment of partial seizures, with or without secondary generalisation, in adults, adolescents, and children aged 6 years and above. uuid:03c64942-6146-4a35-b5a8-67b60c0891eb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10127 biolink:treats HP:0007359 PMID:41385096 "[{""id"":""uuid:791c91f8-2d31-4934-94dd-8d97fdd14eb3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6f41cba1-98e0-4c92-9ebf-8a2402a2a8c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e4011d6f-c55a-411b-9baa-7f58fedc43a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zonisamide-mylan""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Zonisamide capsules are indicated as adjunctive therapy in the treatment of partial seizures in adults with epilepsy.|[EMA] Monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy;adjunctive therapy in the treatment of partial seizures, with or without secondary generalisation, in adults, adolescents, and children aged 6 years and above. uuid:f75dd46d-0fad-459e-a7be-465237203a0d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29108 biolink:treats MONDO:0000328 PMID:41385096 "[{""id"":""uuid:3bf2bc4b-f5d4-4c59-b119-35a45ee6985e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a90fdd69-2777-4ae1-888a-b0ac35a76348"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PhosLo is indicated for the control of hyperphosphatemia in end stage renal failure and does not promote aluminum absorption. uuid:6212ebf6-06e5-4ba0-ae3e-07c6e007ea86 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29108 biolink:treats MONDO:0004375 PMID:41385096 "[{""id"":""uuid:168f24e7-4a35-412b-9e89-be971817aaf8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9c701779-167c-4b64-be5d-f415f5380246"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PhosLo is indicated for the control of hyperphosphatemia in end stage renal failure and does not promote aluminum absorption. uuid:caf3c103-04d1-4943-a254-f4db71814817 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats UMLS:C0433042 PMID:41385096 "[{""id"":""uuid:340cfcc4-3000-46e4-8c61-2f6692d931a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dfb09fde-3ec6-4ee0-b54e-0e1b1ed099b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Primary skin infections: Impetigo contagiosa, superficial folliculitis, ecthyma, furunculosis, sycosis barbae, and pyoderma gangrenosum. Secondary skin infections: Infectious eczematoid dermatitis, pustular acne, pustular psoriasis, infected seborrheic dermatitis, infected contact dermatitis (including poison ivy), infected excoriations, and bacterial superinfections of fungal or viral infections. NOTE: Gentamicin is a bactericidal agent that is not effective against viruses or fungi in skin infections. It is useful in the treatment of infected skin cysts and certain other skin abscesses when preceded by incision and drainage to permit adequate contact between the antibiotic and the infecting bacteria. Good results have been obtained in the treatment of infected stasis and other skin ulcers, infected superficial burns, paronychia, infected insect bites and stings, infected lacerations and abrasions and wounds from minor surgery. Patients sensitive to neomycin can be treated with GENTAMICIN, although regular observation of patients sensitive to topical antibiotics is advisable when such patients are treated with any topical antibiotic. GENTAMICIN CREAM is recommended for wet, oozing primary infections, and greasy, secondary infections, such as pustular acne or infected seborrheic dermatitis, and where a water washable cream preparation is desired. GENTAMICIN OINTMENT helps retain moisture and has been useful in infection on dry eczematous or psoriatic skin. GENTAMICIN CREAM and OINTMENT have been used successfully in infants over one year of age as well as in adults and children. uuid:5c99fb70-5e6d-4ce4-b8d3-e0adf3a0aaff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats UMLS:C0043241 PMID:41385096 "[{""id"":""uuid:3a45081c-7f13-4d25-b3b0-74c5ddebfc37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9edc362c-f2ac-43cf-b321-e6447baa27d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Primary skin infections: Impetigo contagiosa, superficial folliculitis, ecthyma, furunculosis, sycosis barbae, and pyoderma gangrenosum. Secondary skin infections: Infectious eczematoid dermatitis, pustular acne, pustular psoriasis, infected seborrheic dermatitis, infected contact dermatitis (including poison ivy), infected excoriations, and bacterial superinfections of fungal or viral infections. NOTE: Gentamicin is a bactericidal agent that is not effective against viruses or fungi in skin infections. It is useful in the treatment of infected skin cysts and certain other skin abscesses when preceded by incision and drainage to permit adequate contact between the antibiotic and the infecting bacteria. Good results have been obtained in the treatment of infected stasis and other skin ulcers, infected superficial burns, paronychia, infected insect bites and stings, infected lacerations and abrasions and wounds from minor surgery. Patients sensitive to neomycin can be treated with GENTAMICIN, although regular observation of patients sensitive to topical antibiotics is advisable when such patients are treated with any topical antibiotic. GENTAMICIN CREAM is recommended for wet, oozing primary infections, and greasy, secondary infections, such as pustular acne or infected seborrheic dermatitis, and where a water washable cream preparation is desired. GENTAMICIN OINTMENT helps retain moisture and has been useful in infection on dry eczematous or psoriatic skin. GENTAMICIN CREAM and OINTMENT have been used successfully in infants over one year of age as well as in adults and children. uuid:55002f0d-3112-40ae-b6f5-ee25b120201f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1162127 biolink:treats MONDO:0001302 PMID:41385096 "[{""id"":""uuid:9d4b12ae-155f-4094-a757-c1c3c15dce3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:643cc63c-4d00-417e-866f-a51fa346f183"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Losartan potassium and hydrochlorothiazide tablets are indicated for the treatment of hypertension. This fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients (see CLINICAL PHARMACOLOGY , Pharmacodynamics and Clinical Effects and DOSAGE AND ADMINISTRATION ). Hypertensive Patients with Left Ventricular Hypertrophy Losartan potassium and hydrochlorothiazide tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients (see PRECAUTIONS , Race ; CLINICAL PHARMACOLOGY , Pharmacodynamics and Clinical Effects , Losartan Potassium , Reduction in the risk of stroke , Race ; and DOSAGE AND ADMINISTRATION ). uuid:b18f0e01-2768-4ddf-b945-de0882106e54 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1162127 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:25703b89-7f8d-4363-ace5-0207d4d94164"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b855260e-c15f-4d01-a9d4-7e483562ac0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Losartan potassium and hydrochlorothiazide tablets are indicated for the treatment of hypertension. This fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients (see CLINICAL PHARMACOLOGY , Pharmacodynamics and Clinical Effects and DOSAGE AND ADMINISTRATION ). Hypertensive Patients with Left Ventricular Hypertrophy Losartan potassium and hydrochlorothiazide tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients (see PRECAUTIONS , Race ; CLINICAL PHARMACOLOGY , Pharmacodynamics and Clinical Effects , Losartan Potassium , Reduction in the risk of stroke , Race ; and DOSAGE AND ADMINISTRATION ). uuid:5c39a281-9c80-4213-9dad-5757efd9af38 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:1678OK0E08 biolink:treats MONDO:0007743 PMID:41385096 "[{""id"":""uuid:19a82347-2f82-4a39-a676-f6e5bbdc2203"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d097e08d-7e62-4243-a527-244734d5d572"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Focalin XR is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 years and older. The effectiveness of Focalin XR in the treatment of ADHD in patients aged 6 years and older was established in two placebo-controlled studies in patients meeting DSM-IV criteria for ADHD [ see Clinical Studies (14) ]. A diagnosis of Attention Deficit Hyperactivity Disorder (ADHD; DSM-IV) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. The symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in two or more settings, e.g., school (or work) and at home. The symptoms must not be better accounted for by another mental disorder. For the Inattentive Type, at least six of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effort; loses things; easily distracted; forgetful. For the Hyperactive-Impulsive Type, at least six of the following symptoms must have persisted for at least 6 months: fidgeting/squirming; leaving seat; inappropriate running/climbing; difficulty with quiet activities; “on the go”; excessive talking; blurting answers; can’t wait turn; intrusive. The Combined Types requires both inattentive and hyperactive-impulsive criteria to be met. Special Diagnostic Considerations Specific etiology of this syndrome is unknown, and there is no single diagnostic test. Adequate diagnosis requires the use not only of medical but of special psychological, educational, and social resources. Learning may or may not be impaired. The diagnosis must be based upon a complete history and evaluation of the child and not solely on the presence of the required number of DSM-IV characteristics. Need for Comprehensive Treatment Program Focalin XR is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, social) for patients with this syndrome. Drug treatment may not be indicated for all children with this syndrome. Stimulants are not intended for use in the child who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis. Appropriate educational placement is essential and psychosocial intervention is often helpful. When remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physician’s assessment of the chronicity and severity of the child’s symptoms. Long-Term Use The effectiveness of Focalin XR for long-term use, i.e., for more than 7 weeks, has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use Focalin XR for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual patient [ see Dosage a nd Administration (2.3) ]. CHEMBL.COMPOUND:CHEMBL904 uuid:4ef08562-622e-4f5f-87bc-5ad3f8429394 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9150 biolink:treats MONDO:0005311 PMID:41385096 "[{""id"":""uuid:9c118164-e7c7-4db7-8b9f-0ed9c90c5b85"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5c192540-23a4-42c5-aaeb-9618d5955c92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with coronary heart disease (CHD) or at high risk of CHD, simvastatin can be started simultaneously with diet. 1.1 Reductions in Risk of CHD Mortality and Cardiovascular Events In patients at high risk of coronary events because of existing coronary heart disease, diabetes, peripheral vessel disease, history of stroke or other cerebrovascular disease, simvastatin tablets, USP are indicated to: Reduce the risk of total mortality by reducing CHD deaths. Reduce the risk of non-fatal myocardial infarction and stroke. Reduce the need for coronary and non-coronary revascularization procedures. 1.2 Hyperlipidemia Simvastatin tablets, USP are indicated to: Reduce elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), and triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hyperlipidemia (Fredrickson type IIa, heterozygous familial and nonfamilial) or mixed dyslipidemia (Fredrickson type IIb). Reduce elevated TG in patients with hypertriglyceridemia (Fredrickson type lV hyperlipidemia). Reduce elevated TG and VLDL-C in patients with primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia). Reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable. 1.3 Adolescent Patients with Heterozygous Familial Hypercholesterolemia (HeFH) Simvastatin tablets, USP are indicated as an adjunct to diet to reduce total-C, LDL-C, and Apo B levels in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with HeFH, if after an adequate trial of diet therapy the following findings are present: LDL cholesterol remains greater than or equal to 190 mg/dL; or LDL cholesterol remains greater than or equal to 160 mg/dL and There is a positive family history of premature cardiovascular disease (CVD) or Two or more other CVD risk factors are present in the adolescent patient. The minimum goal of treatment in pediatric and adolescent patients is to achieve a mean LDL-C less than 130 mg/dL. The optimal age at which to initiate lipid-lowering therapy to decrease the risk of symptomatic adulthood CAD has not been determined. 1.4 Limitations of Use Simvastatin tablets, USP have not been studied in conditions where the major abnormality is elevation of chylomicrons (i.e., hyperlipidemia Fredrickson types I and V). uuid:3589d843-37cc-4838-8eeb-c601565486aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9150 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:45ccf706-293d-41c3-a2b1-97b939700058"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8384fa1c-0d7b-476f-a272-e504db3d9c26"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with coronary heart disease (CHD) or at high risk of CHD, simvastatin can be started simultaneously with diet. 1.1 Reductions in Risk of CHD Mortality and Cardiovascular Events In patients at high risk of coronary events because of existing coronary heart disease, diabetes, peripheral vessel disease, history of stroke or other cerebrovascular disease, simvastatin tablets, USP are indicated to: Reduce the risk of total mortality by reducing CHD deaths. Reduce the risk of non-fatal myocardial infarction and stroke. Reduce the need for coronary and non-coronary revascularization procedures. 1.2 Hyperlipidemia Simvastatin tablets, USP are indicated to: Reduce elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), and triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hyperlipidemia (Fredrickson type IIa, heterozygous familial and nonfamilial) or mixed dyslipidemia (Fredrickson type IIb). Reduce elevated TG in patients with hypertriglyceridemia (Fredrickson type lV hyperlipidemia). Reduce elevated TG and VLDL-C in patients with primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia). Reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable. 1.3 Adolescent Patients with Heterozygous Familial Hypercholesterolemia (HeFH) Simvastatin tablets, USP are indicated as an adjunct to diet to reduce total-C, LDL-C, and Apo B levels in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with HeFH, if after an adequate trial of diet therapy the following findings are present: LDL cholesterol remains greater than or equal to 190 mg/dL; or LDL cholesterol remains greater than or equal to 160 mg/dL and There is a positive family history of premature cardiovascular disease (CVD) or Two or more other CVD risk factors are present in the adolescent patient. The minimum goal of treatment in pediatric and adolescent patients is to achieve a mean LDL-C less than 130 mg/dL. The optimal age at which to initiate lipid-lowering therapy to decrease the risk of symptomatic adulthood CAD has not been determined. 1.4 Limitations of Use Simvastatin tablets, USP have not been studied in conditions where the major abnormality is elevation of chylomicrons (i.e., hyperlipidemia Fredrickson types I and V). uuid:28eaade8-95bc-47d9-a75e-6892b231a47d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9150 biolink:treats MONDO:0005294 PMID:41385096 "[{""id"":""uuid:615c6017-0fd6-4f09-ab24-a1dc6b78296c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6fe2fb1f-25a9-4b36-9a91-fb6d8a2533d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with coronary heart disease (CHD) or at high risk of CHD, simvastatin can be started simultaneously with diet. 1.1 Reductions in Risk of CHD Mortality and Cardiovascular Events In patients at high risk of coronary events because of existing coronary heart disease, diabetes, peripheral vessel disease, history of stroke or other cerebrovascular disease, simvastatin tablets, USP are indicated to: Reduce the risk of total mortality by reducing CHD deaths. Reduce the risk of non-fatal myocardial infarction and stroke. Reduce the need for coronary and non-coronary revascularization procedures. 1.2 Hyperlipidemia Simvastatin tablets, USP are indicated to: Reduce elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), and triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hyperlipidemia (Fredrickson type IIa, heterozygous familial and nonfamilial) or mixed dyslipidemia (Fredrickson type IIb). Reduce elevated TG in patients with hypertriglyceridemia (Fredrickson type lV hyperlipidemia). Reduce elevated TG and VLDL-C in patients with primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia). Reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable. 1.3 Adolescent Patients with Heterozygous Familial Hypercholesterolemia (HeFH) Simvastatin tablets, USP are indicated as an adjunct to diet to reduce total-C, LDL-C, and Apo B levels in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with HeFH, if after an adequate trial of diet therapy the following findings are present: LDL cholesterol remains greater than or equal to 190 mg/dL; or LDL cholesterol remains greater than or equal to 160 mg/dL and There is a positive family history of premature cardiovascular disease (CVD) or Two or more other CVD risk factors are present in the adolescent patient. The minimum goal of treatment in pediatric and adolescent patients is to achieve a mean LDL-C less than 130 mg/dL. The optimal age at which to initiate lipid-lowering therapy to decrease the risk of symptomatic adulthood CAD has not been determined. 1.4 Limitations of Use Simvastatin tablets, USP have not been studied in conditions where the major abnormality is elevation of chylomicrons (i.e., hyperlipidemia Fredrickson types I and V). uuid:4eb29cfa-408a-4620-9702-b6dda974209f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9150 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:c85e033d-1098-4d20-bf3b-25bcd86a9699"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:10701b00-f563-48c0-9a93-3fbab809f38c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with coronary heart disease (CHD) or at high risk of CHD, simvastatin can be started simultaneously with diet. 1.1 Reductions in Risk of CHD Mortality and Cardiovascular Events In patients at high risk of coronary events because of existing coronary heart disease, diabetes, peripheral vessel disease, history of stroke or other cerebrovascular disease, simvastatin tablets, USP are indicated to: Reduce the risk of total mortality by reducing CHD deaths. Reduce the risk of non-fatal myocardial infarction and stroke. Reduce the need for coronary and non-coronary revascularization procedures. 1.2 Hyperlipidemia Simvastatin tablets, USP are indicated to: Reduce elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), and triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hyperlipidemia (Fredrickson type IIa, heterozygous familial and nonfamilial) or mixed dyslipidemia (Fredrickson type IIb). Reduce elevated TG in patients with hypertriglyceridemia (Fredrickson type lV hyperlipidemia). Reduce elevated TG and VLDL-C in patients with primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia). Reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable. 1.3 Adolescent Patients with Heterozygous Familial Hypercholesterolemia (HeFH) Simvastatin tablets, USP are indicated as an adjunct to diet to reduce total-C, LDL-C, and Apo B levels in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with HeFH, if after an adequate trial of diet therapy the following findings are present: LDL cholesterol remains greater than or equal to 190 mg/dL; or LDL cholesterol remains greater than or equal to 160 mg/dL and There is a positive family history of premature cardiovascular disease (CVD) or Two or more other CVD risk factors are present in the adolescent patient. The minimum goal of treatment in pediatric and adolescent patients is to achieve a mean LDL-C less than 130 mg/dL. The optimal age at which to initiate lipid-lowering therapy to decrease the risk of symptomatic adulthood CAD has not been determined. 1.4 Limitations of Use Simvastatin tablets, USP have not been studied in conditions where the major abnormality is elevation of chylomicrons (i.e., hyperlipidemia Fredrickson types I and V). uuid:cbc65f48-a56d-4652-b96f-0a411d160041 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9150 biolink:treats MONDO:0011057 PMID:41385096 "[{""id"":""uuid:37a5e5c0-51ae-4e6a-ae74-56695422059e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d79618d9-ba48-4bc9-b5fe-9e6dc39c5644"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with coronary heart disease (CHD) or at high risk of CHD, simvastatin can be started simultaneously with diet. 1.1 Reductions in Risk of CHD Mortality and Cardiovascular Events In patients at high risk of coronary events because of existing coronary heart disease, diabetes, peripheral vessel disease, history of stroke or other cerebrovascular disease, simvastatin tablets, USP are indicated to: Reduce the risk of total mortality by reducing CHD deaths. Reduce the risk of non-fatal myocardial infarction and stroke. Reduce the need for coronary and non-coronary revascularization procedures. 1.2 Hyperlipidemia Simvastatin tablets, USP are indicated to: Reduce elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), and triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hyperlipidemia (Fredrickson type IIa, heterozygous familial and nonfamilial) or mixed dyslipidemia (Fredrickson type IIb). Reduce elevated TG in patients with hypertriglyceridemia (Fredrickson type lV hyperlipidemia). Reduce elevated TG and VLDL-C in patients with primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia). Reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable. 1.3 Adolescent Patients with Heterozygous Familial Hypercholesterolemia (HeFH) Simvastatin tablets, USP are indicated as an adjunct to diet to reduce total-C, LDL-C, and Apo B levels in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with HeFH, if after an adequate trial of diet therapy the following findings are present: LDL cholesterol remains greater than or equal to 190 mg/dL; or LDL cholesterol remains greater than or equal to 160 mg/dL and There is a positive family history of premature cardiovascular disease (CVD) or Two or more other CVD risk factors are present in the adolescent patient. The minimum goal of treatment in pediatric and adolescent patients is to achieve a mean LDL-C less than 130 mg/dL. The optimal age at which to initiate lipid-lowering therapy to decrease the risk of symptomatic adulthood CAD has not been determined. 1.4 Limitations of Use Simvastatin tablets, USP have not been studied in conditions where the major abnormality is elevation of chylomicrons (i.e., hyperlipidemia Fredrickson types I and V). uuid:96ac6e14-2d81-4d47-86a6-461bb09e1c76 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9150 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:03a6a5d7-21e4-480b-b608-6598d3551f94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c71b6e0d-5712-4e0c-a14b-d0f1d470390a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with coronary heart disease (CHD) or at high risk of CHD, simvastatin can be started simultaneously with diet. 1.1 Reductions in Risk of CHD Mortality and Cardiovascular Events In patients at high risk of coronary events because of existing coronary heart disease, diabetes, peripheral vessel disease, history of stroke or other cerebrovascular disease, simvastatin tablets, USP are indicated to: Reduce the risk of total mortality by reducing CHD deaths. Reduce the risk of non-fatal myocardial infarction and stroke. Reduce the need for coronary and non-coronary revascularization procedures. 1.2 Hyperlipidemia Simvastatin tablets, USP are indicated to: Reduce elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), and triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hyperlipidemia (Fredrickson type IIa, heterozygous familial and nonfamilial) or mixed dyslipidemia (Fredrickson type IIb). Reduce elevated TG in patients with hypertriglyceridemia (Fredrickson type lV hyperlipidemia). Reduce elevated TG and VLDL-C in patients with primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia). Reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable. 1.3 Adolescent Patients with Heterozygous Familial Hypercholesterolemia (HeFH) Simvastatin tablets, USP are indicated as an adjunct to diet to reduce total-C, LDL-C, and Apo B levels in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with HeFH, if after an adequate trial of diet therapy the following findings are present: LDL cholesterol remains greater than or equal to 190 mg/dL; or LDL cholesterol remains greater than or equal to 160 mg/dL and There is a positive family history of premature cardiovascular disease (CVD) or Two or more other CVD risk factors are present in the adolescent patient. The minimum goal of treatment in pediatric and adolescent patients is to achieve a mean LDL-C less than 130 mg/dL. The optimal age at which to initiate lipid-lowering therapy to decrease the risk of symptomatic adulthood CAD has not been determined. 1.4 Limitations of Use Simvastatin tablets, USP have not been studied in conditions where the major abnormality is elevation of chylomicrons (i.e., hyperlipidemia Fredrickson types I and V). uuid:f0eb6a22-0eca-4828-94be-e8f06a44041a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9150 biolink:treats HP:0003119 PMID:41385096 "[{""id"":""uuid:f8cff258-df9d-4ea6-a6a9-78baed480163"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cee33dfb-ade5-4e3e-8441-157fe7159b8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with coronary heart disease (CHD) or at high risk of CHD, simvastatin can be started simultaneously with diet. 1.1 Reductions in Risk of CHD Mortality and Cardiovascular Events In patients at high risk of coronary events because of existing coronary heart disease, diabetes, peripheral vessel disease, history of stroke or other cerebrovascular disease, simvastatin tablets, USP are indicated to: Reduce the risk of total mortality by reducing CHD deaths. Reduce the risk of non-fatal myocardial infarction and stroke. Reduce the need for coronary and non-coronary revascularization procedures. 1.2 Hyperlipidemia Simvastatin tablets, USP are indicated to: Reduce elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), and triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hyperlipidemia (Fredrickson type IIa, heterozygous familial and nonfamilial) or mixed dyslipidemia (Fredrickson type IIb). Reduce elevated TG in patients with hypertriglyceridemia (Fredrickson type lV hyperlipidemia). Reduce elevated TG and VLDL-C in patients with primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia). Reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable. 1.3 Adolescent Patients with Heterozygous Familial Hypercholesterolemia (HeFH) Simvastatin tablets, USP are indicated as an adjunct to diet to reduce total-C, LDL-C, and Apo B levels in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with HeFH, if after an adequate trial of diet therapy the following findings are present: LDL cholesterol remains greater than or equal to 190 mg/dL; or LDL cholesterol remains greater than or equal to 160 mg/dL and There is a positive family history of premature cardiovascular disease (CVD) or Two or more other CVD risk factors are present in the adolescent patient. The minimum goal of treatment in pediatric and adolescent patients is to achieve a mean LDL-C less than 130 mg/dL. The optimal age at which to initiate lipid-lowering therapy to decrease the risk of symptomatic adulthood CAD has not been determined. 1.4 Limitations of Use Simvastatin tablets, USP have not been studied in conditions where the major abnormality is elevation of chylomicrons (i.e., hyperlipidemia Fredrickson types I and V). uuid:6d08c0fd-1a6d-4d27-9279-0b149ce8dae4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9150 biolink:treats MONDO:0005347 PMID:41385096 "[{""id"":""uuid:36bf77a8-1652-4525-9963-c2405da3fceb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d421edab-1790-4c80-97a9-0515ca6270e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with coronary heart disease (CHD) or at high risk of CHD, simvastatin can be started simultaneously with diet. 1.1 Reductions in Risk of CHD Mortality and Cardiovascular Events In patients at high risk of coronary events because of existing coronary heart disease, diabetes, peripheral vessel disease, history of stroke or other cerebrovascular disease, simvastatin tablets, USP are indicated to: Reduce the risk of total mortality by reducing CHD deaths. Reduce the risk of non-fatal myocardial infarction and stroke. Reduce the need for coronary and non-coronary revascularization procedures. 1.2 Hyperlipidemia Simvastatin tablets, USP are indicated to: Reduce elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), and triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hyperlipidemia (Fredrickson type IIa, heterozygous familial and nonfamilial) or mixed dyslipidemia (Fredrickson type IIb). Reduce elevated TG in patients with hypertriglyceridemia (Fredrickson type lV hyperlipidemia). Reduce elevated TG and VLDL-C in patients with primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia). Reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable. 1.3 Adolescent Patients with Heterozygous Familial Hypercholesterolemia (HeFH) Simvastatin tablets, USP are indicated as an adjunct to diet to reduce total-C, LDL-C, and Apo B levels in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with HeFH, if after an adequate trial of diet therapy the following findings are present: LDL cholesterol remains greater than or equal to 190 mg/dL; or LDL cholesterol remains greater than or equal to 160 mg/dL and There is a positive family history of premature cardiovascular disease (CVD) or Two or more other CVD risk factors are present in the adolescent patient. The minimum goal of treatment in pediatric and adolescent patients is to achieve a mean LDL-C less than 130 mg/dL. The optimal age at which to initiate lipid-lowering therapy to decrease the risk of symptomatic adulthood CAD has not been determined. 1.4 Limitations of Use Simvastatin tablets, USP have not been studied in conditions where the major abnormality is elevation of chylomicrons (i.e., hyperlipidemia Fredrickson types I and V). uuid:cb8189c2-8b2f-4f2b-87e4-6892135aa327 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9150 biolink:treats MONDO:0018473 PMID:41385096 "[{""id"":""uuid:24f71d3a-d448-47bf-87d5-d43db1a60737"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:45358d65-5c50-4d83-8c60-da43d56eb35c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with coronary heart disease (CHD) or at high risk of CHD, simvastatin can be started simultaneously with diet. 1.1 Reductions in Risk of CHD Mortality and Cardiovascular Events In patients at high risk of coronary events because of existing coronary heart disease, diabetes, peripheral vessel disease, history of stroke or other cerebrovascular disease, simvastatin tablets, USP are indicated to: Reduce the risk of total mortality by reducing CHD deaths. Reduce the risk of non-fatal myocardial infarction and stroke. Reduce the need for coronary and non-coronary revascularization procedures. 1.2 Hyperlipidemia Simvastatin tablets, USP are indicated to: Reduce elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), and triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hyperlipidemia (Fredrickson type IIa, heterozygous familial and nonfamilial) or mixed dyslipidemia (Fredrickson type IIb). Reduce elevated TG in patients with hypertriglyceridemia (Fredrickson type lV hyperlipidemia). Reduce elevated TG and VLDL-C in patients with primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia). Reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable. 1.3 Adolescent Patients with Heterozygous Familial Hypercholesterolemia (HeFH) Simvastatin tablets, USP are indicated as an adjunct to diet to reduce total-C, LDL-C, and Apo B levels in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with HeFH, if after an adequate trial of diet therapy the following findings are present: LDL cholesterol remains greater than or equal to 190 mg/dL; or LDL cholesterol remains greater than or equal to 160 mg/dL and There is a positive family history of premature cardiovascular disease (CVD) or Two or more other CVD risk factors are present in the adolescent patient. The minimum goal of treatment in pediatric and adolescent patients is to achieve a mean LDL-C less than 130 mg/dL. The optimal age at which to initiate lipid-lowering therapy to decrease the risk of symptomatic adulthood CAD has not been determined. 1.4 Limitations of Use Simvastatin tablets, USP have not been studied in conditions where the major abnormality is elevation of chylomicrons (i.e., hyperlipidemia Fredrickson types I and V). uuid:50e3b505-8687-49b9-834c-d1bd3cd1e7be biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9150 biolink:treats MONDO:0018328 PMID:41385096 "[{""id"":""uuid:7fee948b-0c4b-47cf-8252-1e57ad9b5b4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:915c0527-8e3c-4370-b446-1dad80df126c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with coronary heart disease (CHD) or at high risk of CHD, simvastatin can be started simultaneously with diet. 1.1 Reductions in Risk of CHD Mortality and Cardiovascular Events In patients at high risk of coronary events because of existing coronary heart disease, diabetes, peripheral vessel disease, history of stroke or other cerebrovascular disease, simvastatin tablets, USP are indicated to: Reduce the risk of total mortality by reducing CHD deaths. Reduce the risk of non-fatal myocardial infarction and stroke. Reduce the need for coronary and non-coronary revascularization procedures. 1.2 Hyperlipidemia Simvastatin tablets, USP are indicated to: Reduce elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), and triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hyperlipidemia (Fredrickson type IIa, heterozygous familial and nonfamilial) or mixed dyslipidemia (Fredrickson type IIb). Reduce elevated TG in patients with hypertriglyceridemia (Fredrickson type lV hyperlipidemia). Reduce elevated TG and VLDL-C in patients with primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia). Reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable. 1.3 Adolescent Patients with Heterozygous Familial Hypercholesterolemia (HeFH) Simvastatin tablets, USP are indicated as an adjunct to diet to reduce total-C, LDL-C, and Apo B levels in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with HeFH, if after an adequate trial of diet therapy the following findings are present: LDL cholesterol remains greater than or equal to 190 mg/dL; or LDL cholesterol remains greater than or equal to 160 mg/dL and There is a positive family history of premature cardiovascular disease (CVD) or Two or more other CVD risk factors are present in the adolescent patient. The minimum goal of treatment in pediatric and adolescent patients is to achieve a mean LDL-C less than 130 mg/dL. The optimal age at which to initiate lipid-lowering therapy to decrease the risk of symptomatic adulthood CAD has not been determined. 1.4 Limitations of Use Simvastatin tablets, USP have not been studied in conditions where the major abnormality is elevation of chylomicrons (i.e., hyperlipidemia Fredrickson types I and V). uuid:59f17110-325e-4db3-a3b2-987bf84f138d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9150 biolink:treats UMLS:C0342882 PMID:41385096 "[{""id"":""uuid:905a1986-e9fa-47a9-959f-a716fca6f462"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:db7a20e9-442c-42bf-afad-854a1ebe7fc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with coronary heart disease (CHD) or at high risk of CHD, simvastatin can be started simultaneously with diet. 1.1 Reductions in Risk of CHD Mortality and Cardiovascular Events In patients at high risk of coronary events because of existing coronary heart disease, diabetes, peripheral vessel disease, history of stroke or other cerebrovascular disease, simvastatin tablets, USP are indicated to: Reduce the risk of total mortality by reducing CHD deaths. Reduce the risk of non-fatal myocardial infarction and stroke. Reduce the need for coronary and non-coronary revascularization procedures. 1.2 Hyperlipidemia Simvastatin tablets, USP are indicated to: Reduce elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), and triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hyperlipidemia (Fredrickson type IIa, heterozygous familial and nonfamilial) or mixed dyslipidemia (Fredrickson type IIb). Reduce elevated TG in patients with hypertriglyceridemia (Fredrickson type lV hyperlipidemia). Reduce elevated TG and VLDL-C in patients with primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia). Reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable. 1.3 Adolescent Patients with Heterozygous Familial Hypercholesterolemia (HeFH) Simvastatin tablets, USP are indicated as an adjunct to diet to reduce total-C, LDL-C, and Apo B levels in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with HeFH, if after an adequate trial of diet therapy the following findings are present: LDL cholesterol remains greater than or equal to 190 mg/dL; or LDL cholesterol remains greater than or equal to 160 mg/dL and There is a positive family history of premature cardiovascular disease (CVD) or Two or more other CVD risk factors are present in the adolescent patient. The minimum goal of treatment in pediatric and adolescent patients is to achieve a mean LDL-C less than 130 mg/dL. The optimal age at which to initiate lipid-lowering therapy to decrease the risk of symptomatic adulthood CAD has not been determined. 1.4 Limitations of Use Simvastatin tablets, USP have not been studied in conditions where the major abnormality is elevation of chylomicrons (i.e., hyperlipidemia Fredrickson types I and V). uuid:edf8ebc8-aff3-46cb-980c-fa6768f008ff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats UMLS:C0149896 PMID:41385096 "[{""id"":""uuid:3191e9d2-c4d7-4d7a-843d-6cf96a8c9e21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6b6b625d-4929-4038-9545-96d3f3ca59aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The intra-articular or soft tissue administration of Kenalog-10 Injection (triamcinolone acetonide injectable suspension, USP) is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis, or osteoarthritis. uuid:156126ca-1a91-493d-8207-79621003798a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0040698 PMID:41385096 "[{""id"":""uuid:ae29021f-cafa-49cd-94da-a7052bfd827e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:32f31047-b914-4a18-be12-a285cccc8f75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The intra-articular or soft tissue administration of Kenalog-10 Injection (triamcinolone acetonide injectable suspension, USP) is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis, or osteoarthritis. uuid:283134d0-a5c4-4648-b170-48980b50c7bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0004855 PMID:41385096 "[{""id"":""uuid:628ea9e0-5155-47e4-a347-5d6d29c59820"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:308dfd34-0ce2-4f26-849c-1ede4095c311"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The intra-articular or soft tissue administration of Kenalog-10 Injection (triamcinolone acetonide injectable suspension, USP) is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis, or osteoarthritis. uuid:8adc2cbe-84ec-4583-ab2e-aefb0c1d168c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0001875 PMID:41385096 "[{""id"":""uuid:b90a04c4-a77e-4b22-a4a2-d884bc039774"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:13743dba-cb56-4fdf-80ea-5783d1b2e9cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The intra-articular or soft tissue administration of Kenalog-10 Injection (triamcinolone acetonide injectable suspension, USP) is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis, or osteoarthritis. uuid:8057d44d-dc51-489b-9e53-68aae409f2d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:e4e866b2-5ca6-49dd-b377-c6b4204f067a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:22c6696c-ddd6-40d3-bee5-70dce5383744"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The intra-articular or soft tissue administration of Kenalog-10 Injection (triamcinolone acetonide injectable suspension, USP) is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis, or osteoarthritis. uuid:fbb976d1-a9b7-4a09-a6b9-3e10f70b06e5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0002400 PMID:41385096 "[{""id"":""uuid:2e8fba19-3ae3-4f50-9a96-fbf97107ecf8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bc73f52b-aac9-4dbe-b298-1f9fa93d91db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The intra-articular or soft tissue administration of Kenalog-10 Injection (triamcinolone acetonide injectable suspension, USP) is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis, or osteoarthritis. uuid:b2ba6ad3-367a-4623-b366-634f7e98047e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:de8ccaf0-da55-4ae5-a7ae-58228aa962a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2015d232-9a4b-4a02-b389-ca764b4618c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The intra-articular or soft tissue administration of Kenalog-10 Injection (triamcinolone acetonide injectable suspension, USP) is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis, or osteoarthritis. uuid:69cf3fe4-5a0d-4e7c-91d4-54f357994623 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151875 biolink:treats HP:0012735 PMID:41385096 "[{""id"":""uuid:7b5cff0d-2616-49e3-bf95-14d870ec51d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3c720b8f-05a2-46f4-81e4-7cf8f97633e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydrocodone bitartrate and homatropine methylbromide syrup is indicated for the symptomatic relief of cough. uuid:3aa3d29f-1e5c-4e69-8c06-609066bf7bcb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8207 biolink:treats MONDO:0005041 PMID:41385096 "[{""id"":""uuid:f95084aa-118d-467a-8bb6-866bc64671a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dc402451-8142-4168-87b6-ba6ce6ae5f05"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pilocarpine hydrochloride can be used in the medical management of glaucoma, especially open-angle glaucoma, in those cases in which the intraocular pressure can be controlled adequately by the topical administration of pilocarpine. In acute (closed-angle) glaucoma, pilocarpine hydrochloride may be used alone, or in combination with other cholinergic agents or carbonic anhydrase inhibitors, to relieve tension prior to emergency surgery. Patients may be maintained on pilocarpine hydrochloride as long as intraocular pressure is controlled and there is no deterioration in the visual fields. The choice of concentration should be determined by the severity of the condition and the response of the patient. Pilocarpine hydrochloride is also indicated to counter the effects of cycloplegics and mydriatics following surgery or ophthalmoscopic examination. uuid:620db93c-1a2c-4d76-b125-19416fb38ffa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8207 biolink:treats MONDO:0005338 PMID:41385096 "[{""id"":""uuid:8a1a9b9d-79fa-45a4-b860-e1810f7a8df9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c7ae7aac-5f93-482c-b2e4-eff163b6e38e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pilocarpine hydrochloride can be used in the medical management of glaucoma, especially open-angle glaucoma, in those cases in which the intraocular pressure can be controlled adequately by the topical administration of pilocarpine. In acute (closed-angle) glaucoma, pilocarpine hydrochloride may be used alone, or in combination with other cholinergic agents or carbonic anhydrase inhibitors, to relieve tension prior to emergency surgery. Patients may be maintained on pilocarpine hydrochloride as long as intraocular pressure is controlled and there is no deterioration in the visual fields. The choice of concentration should be determined by the severity of the condition and the response of the patient. Pilocarpine hydrochloride is also indicated to counter the effects of cycloplegics and mydriatics following surgery or ophthalmoscopic examination. uuid:07fc119f-e5ae-4320-8f1b-2adaae82e179 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8207 biolink:treats MONDO:0001817 PMID:41385096 "[{""id"":""uuid:25561e77-7ac0-45f7-90c5-a49136f45305"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a832f495-4cb5-41af-9904-bf0a466c5511"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pilocarpine hydrochloride can be used in the medical management of glaucoma, especially open-angle glaucoma, in those cases in which the intraocular pressure can be controlled adequately by the topical administration of pilocarpine. In acute (closed-angle) glaucoma, pilocarpine hydrochloride may be used alone, or in combination with other cholinergic agents or carbonic anhydrase inhibitors, to relieve tension prior to emergency surgery. Patients may be maintained on pilocarpine hydrochloride as long as intraocular pressure is controlled and there is no deterioration in the visual fields. The choice of concentration should be determined by the severity of the condition and the response of the patient. Pilocarpine hydrochloride is also indicated to counter the effects of cycloplegics and mydriatics following surgery or ophthalmoscopic examination. uuid:37652ced-3e1b-4b2a-8c44-d03f072eaf08 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:87715 biolink:treats MONDO:0006805 PMID:41385096 "[{""id"":""uuid:8095a2d6-d8b8-4e5a-9e5a-5be760f7f0ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:740b5de1-9205-4b46-8558-f884c42a7dee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:226c4d16-f9a3-4b93-8ac2-68755050fb46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/efient""]},{""id"":""uuid:96bd59a9-aec6-4f84-b615-9111c0777c32"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Effient is a P2Y 12 platelet inhibitor indicated for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome who are to be managed with PCI as follows: Patients with unstable angina or, non-ST-elevation myocardial infarction (NSTEMI) ( 1.1 ). Patients with ST-elevation myocardial infarction (STEMI) when managed with either primary or delayed PCI ( 1.1 ).|[EMA] Efient, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in patients with acute coronary syndrome (i.e. unstable angina, non-ST-segment-elevation myocardial infarction [UA / NSTEMI] or ST-segment-elevation myocardial infarction [STEMI]) undergoing primary or delayed percutaneous coronary intervention (PCI).|[PMDA] Drugs with a new active ingredient indicated for the treatment of the following ischemic heart diseases managed with percutaneous coronary intervention (PCI): acute coronary syndrome (unstable angina, non ST-segment elevation myocardial infarction, ST- segment elevation myocardial infarction), stable angina, old myocardial infarction. uuid:f4323725-12a4-4645-93b2-d10304d7db7a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:87715 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:0caee78e-d3b5-4762-8389-80577f5b5c52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:93937147-c2eb-4f66-a4a3-49a7f4cd1951"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:bb0c14dc-d55e-4ed4-9647-b23197a228c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Effient is a P2Y 12 platelet inhibitor indicated for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome who are to be managed with PCI as follows: Patients with unstable angina or, non-ST-elevation myocardial infarction (NSTEMI) ( 1.1 ). Patients with ST-elevation myocardial infarction (STEMI) when managed with either primary or delayed PCI ( 1.1 ).|[PMDA] Drugs with a new active ingredient indicated for the treatment of the following ischemic heart diseases managed with percutaneous coronary intervention (PCI): acute coronary syndrome (unstable angina, non ST-segment elevation myocardial infarction, ST- segment elevation myocardial infarction), stable angina, old myocardial infarction. uuid:fb0c8317-460f-4018-9d8a-120c95be0ddb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:87715 biolink:treats UMLS:C3897493 PMID:41385096 "[{""id"":""uuid:5930e3d1-0ddb-487c-a581-fdd555ef3ff3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e42e4fda-6d9e-4d67-86a8-ba05fb961fe1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Effient is a P2Y 12 platelet inhibitor indicated for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome who are to be managed with PCI as follows: Patients with unstable angina or, non-ST-elevation myocardial infarction (NSTEMI) ( 1.1 ). Patients with ST-elevation myocardial infarction (STEMI) when managed with either primary or delayed PCI ( 1.1 ). uuid:51d4e6ec-cf82-492d-a23e-285e4161e873 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:15873fb2-f0bd-46ec-acf9-56da94387c6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6a49d755-992d-4580-be9a-072242bafc8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:dd1a64d2-72a0-4513-9b01-6b7ab8aae76c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:3fc0d144-a642-4d87-a12f-22c5d11cf80e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:612ade4e-401c-4780-89b8-5580e1c44bd3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:7513ae76-0ee9-4e75-86b6-b54ed1d7623b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0005480 PMID:41385096 "[{""id"":""uuid:9f60c454-f701-4a06-a3db-7a213ef182c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f5488ccc-0238-49a9-90d4-5835e7d528e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:fcc46a6b-cd6e-4efb-aac2-85c30bd8a281 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0000775 PMID:41385096 "[{""id"":""uuid:a3d71013-19ff-48fe-ae06-ed713cac3880"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e0cc26a8-e027-4b58-9461-fa7b1d38d21c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:9c6bb4e4-40ab-44e2-b09f-3369454ae266 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0043789 PMID:41385096 "[{""id"":""uuid:89e22c16-4076-4db0-95bc-b17f8509eb81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d9bb0278-c551-4c7f-8769-6b4e1ecea703"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:c6be3764-652d-4905-9358-19d8e1dd1c9b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats UMLS:C0274435 PMID:41385096 "[{""id"":""uuid:3eaf04b9-5661-4cde-bfea-36e7e169e78c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a8c71d92-3a1b-4c73-b654-f6a2b8239e00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:797b5816-c345-4703-b28a-28d457395e4a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0015614 PMID:41385096 "[{""id"":""uuid:7f285e35-334a-4117-ba39-8daf6c2bb966"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d53ea798-9fed-4520-9329-256c18039b52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:c012ba19-81d8-4eff-ba46-6e62b7cb5edc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0043233 PMID:41385096 "[{""id"":""uuid:36364ef4-39cb-49c9-a70a-e5118ab8a995"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:90e2168b-2eb4-4586-884c-f53a25ff99fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:d0147765-7f0a-4965-a843-de7b8979cace biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0009691 PMID:41385096 "[{""id"":""uuid:75a58cfb-3eb7-4512-967c-c5464f169f56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1fe677d7-9132-425d-9e1d-eefa2cca0a82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:8820c4dd-db79-49db-9487-f2655f9f8632 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0006594 PMID:41385096 "[{""id"":""uuid:24bbbaf8-186b-4672-b9da-1aa4b79a317c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:720a21d3-2fc1-4727-b646-1e1dd556bdd9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:93c70da9-18c4-49cf-b683-3232757f204d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0018229 PMID:41385096 "[{""id"":""uuid:41b3819a-d353-4103-8c77-52643b8eda0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cabb3e5d-b0bc-4c06-9a8e-353ddb948880"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:bd04a51b-d101-40af-a14e-beed9c20f902 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0015129 PMID:41385096 "[{""id"":""uuid:4d3c4d2f-03ba-4d25-9a6b-4b4c7aeb2b8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:146a1a50-e85c-4494-97d1-ccac33383c0c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:a5cc3ee0-b8cd-4635-994d-50931c16faf2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0043370 PMID:41385096 "[{""id"":""uuid:a6a31510-631e-45d1-8e4a-9832f1dc446a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:37bd4af6-7b35-4fb1-b2f0-be85b1156daa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:35fb244a-ea0e-4825-8c3f-af5c84bae917 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0018479 PMID:41385096 "[{""id"":""uuid:7780bd34-b6d8-42cc-9df7-676087bb7e33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f4ac90ad-cb7a-489a-b575-143005b2e165"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:9e87a3bc-74f4-4a85-b8d1-536c1a6b20f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0043455 PMID:41385096 "[{""id"":""uuid:2167b18a-c191-4ac0-beb8-499a992da9e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:91c7dfdf-ff44-42e4-adec-4802d8e99f8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:3ef7e37e-6414-4eae-9098-83a8396ae3e3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0006982 PMID:41385096 "[{""id"":""uuid:bafef613-013d-42c1-be28-b8c6766b3330"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3a9cb5c3-1f98-46ec-ac03-1d25c5edd417"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:6f2f27b2-1890-4ae4-8f2d-462af80f8cbf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats UMLS:C0678202 PMID:41385096 "[{""id"":""uuid:2dbcedd0-5821-4096-b7b8-cb6e54041553"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a81b3a7d-e9df-4044-a4e2-767e4bd0f9fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:485354b1-f95b-45fa-a9a8-e82b090df078 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:8ded0d6d-abb6-4214-a1c2-969455a11101"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:20457392-ecba-4cc6-a22f-db312d2b0a3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:f7dd136b-1619-4a6c-b928-ec1fcea362b8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0020108 PMID:41385096 "[{""id"":""uuid:6c8b1b7b-d8b1-4f57-a515-d03555b79879"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e50a16ba-4010-4e21-b382-d5960abeef22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:05136f90-c34e-4130-a960-6c5de4cbc802 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0015253 PMID:41385096 "[{""id"":""uuid:bee0b69b-2f81-47a4-84c1-f1290748bda8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fe324571-ec92-4aeb-abbb-ab79beeac22d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:382c4bc9-c195-492e-915a-034a9a7e718f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0001705 PMID:41385096 "[{""id"":""uuid:9c1c3bf5-48c1-4015-8d1c-29cca912dc23"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:40cb6025-b8a1-486c-8818-387f8f392b3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:4d18b53a-6447-46f7-8d06-01e912c3dd59 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0001198 PMID:41385096 "[{""id"":""uuid:2fb95176-b542-4acd-9367-4f1506d1a48e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:650709f9-e333-4a4f-9834-b5a21165b62e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:8e391525-8ed5-4d78-9963-222d218663cb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0019444 PMID:41385096 "[{""id"":""uuid:b54b43ad-f27c-4467-85fa-30fbe345343d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ebc7edcf-ce47-4c4a-991b-f4f0607a6a49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:687bfa3f-f02f-4f6f-a86c-8bc14a07e332 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0006042 PMID:41385096 "[{""id"":""uuid:d21d94d4-cb8f-47b0-afd8-aade7ba1c61f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9d1394b2-b05f-4a31-847c-da5db871a968"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:ede4da6f-d21b-4ddb-9d5f-dad4fdf13b6c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0005059 PMID:41385096 "[{""id"":""uuid:203fb72d-1d50-419e-bd84-f3fa557ce8f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fc150729-a8a9-42ab-8d8f-296b1a5cd823"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:aeb7caf3-0c5f-415d-aa39-598801c58848 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0004095 PMID:41385096 "[{""id"":""uuid:6010d258-5d1e-47a1-93e9-3e36a8625a50"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:882dbd40-0732-470c-b778-25beebba4ffc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:9bcca2c8-d20e-426a-9951-cb03799cf00c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:6c7d4f8a-b7ee-4fd5-a903-116f8d636ec7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ffc53c86-5b9c-4ff5-aa5a-f9e7adb85bac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:5074c9b6-8091-4c94-a393-7c925d1c4d74 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0006684 PMID:41385096 "[{""id"":""uuid:f039dfa3-c017-405e-a547-40fce3750691"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9f8c53ea-9d6b-46bd-9621-7ffe4c4acbb0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:933e8191-7403-43b6-ad0d-215371a362c8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0021211 PMID:41385096 "[{""id"":""uuid:64c3e51f-7e72-40ff-8197-a636805f2826"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7d479963-78fc-4e93-8bc8-df40ddd325fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:9b3b9f51-a62e-450f-a7d3-d4b57d2c193f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0019198 PMID:41385096 "[{""id"":""uuid:7fb936a1-2147-4c56-985c-1d2530ac4c2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2b7a2809-d415-4011-a290-d19a8a049e11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:e801052a-28ce-475b-8b8c-6c3788c0de42 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0008538 PMID:41385096 "[{""id"":""uuid:09c73a2b-17b8-4ba7-83d7-36e3f5e0bc60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2e1771b5-50cb-4ea7-bfa9-50e62c155a17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:57236ff6-9168-42c1-98c2-ef800dc3bffc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0020283 PMID:41385096 "[{""id"":""uuid:655ea0de-0ca2-4485-aa17-2158be77cc2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:80527c78-f2f8-42fb-be54-7ee7d745f580"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:4c32d1bb-b724-42f1-9d7f-185f606d9929 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0008109 PMID:41385096 "[{""id"":""uuid:eb5a3eb2-a86e-48e0-ab26-9d8d6074c166"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a17be914-28fd-429d-8228-3e2affb1035b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:90997e5d-9e62-4543-a5a2-90c6f7c3650b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0018170 PMID:41385096 "[{""id"":""uuid:12d8eaa7-5c90-4db3-aadd-27667423452d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0e941101-865b-48b7-be74-e7bc84e3770a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:ab599080-794f-4df3-9798-eac628d295b6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0004670 PMID:41385096 "[{""id"":""uuid:9f0f2c31-a3d5-4d2e-bb96-fa626ee1620b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9b23e17a-8a78-4619-a2c8-4d4ca5ac3a9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:8f422568-9864-4e78-8d21-334ee7109bf9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0015274 PMID:41385096 "[{""id"":""uuid:e68a5b32-870a-4db5-93c2-7b01ed76e77b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d2841ca4-07f0-407f-b965-7a243790ef97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:0c62feae-8dcb-4bdf-9785-898df2d2a4ae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0006052 PMID:41385096 "[{""id"":""uuid:a1f379db-62a9-49d2-a5fa-86ae1d5cca3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2d553006-4ebc-4e59-a8fd-d04ac907de3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:86159e62-43af-4e15-8966-d9a3f2232465 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0005848 PMID:41385096 "[{""id"":""uuid:a021ff3d-0cff-4eb5-8318-cb446e89ba11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4718a8a8-66ae-4e98-8c85-2cdf95499cf4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:e86de735-87eb-4410-85ef-88bd271c24c3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0015927 PMID:41385096 "[{""id"":""uuid:3a1f2f09-8074-4d4c-b1c2-e06f5bf9baa1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3430d6dd-760f-435d-a8d6-14e30a9e342b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:9bb90cd1-a852-4cea-9b1f-b9e9c5dcffd9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0019338 PMID:41385096 "[{""id"":""uuid:b0646563-3077-452c-8e6c-218b2a43acd1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:51d59a76-e14c-435e-bed6-d2bb7b3a1759"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:aeb06df4-26e0-4e69-a2c4-8610d94a9798 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats UMLS:C5441648 PMID:41385096 "[{""id"":""uuid:21432e30-100e-40aa-a0c4-b9a451e1c810"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0b61c0c2-b2fe-4886-82a6-fafe4bd9eff2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:304befcf-4bc0-4234-8c44-7278d321d9ad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:95c946c5-0200-4138-9e30-d30caf9d83e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:96369aad-0164-481d-b246-c108e1631572"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:b11ec726-a0dd-4146-aea7-aed44ebfca11 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:857287da-41dd-4aff-a5a8-c7ad40109b9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2d18d59f-41af-4beb-be11-c2acb1951e4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:083d4e2c-ce88-4788-ac0f-5b753d4e9052 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0011429 PMID:41385096 "[{""id"":""uuid:1c127af2-8579-491a-b20b-b3533600ed36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bc08e582-3885-4e7f-9cea-6cb771dacd83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:a3714ae7-debf-4faf-a834-440a06473097 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0016367 PMID:41385096 "[{""id"":""uuid:83b73513-5cd6-4beb-9577-d1b619ee9c2d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:170bdc35-d010-45b1-80a3-ad98cfe7c589"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:368e8cfa-50d3-4380-a4e5-1bf016302202 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0019127 PMID:41385096 "[{""id"":""uuid:4d794ceb-90ba-467e-9cdf-3eb0d9ad3792"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b6d6f437-02d8-4a61-aee9-796a3468a743"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:b09737e6-dd04-4f37-a980-311d5b0c6868 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59164 biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:0dd9c1d5-b389-49cf-8a5b-fbe6230d1efb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:196fb935-a654-4d03-be56-197a3c31a1ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Balsalazide Disodium Capsules are indicated for the treatment of mildly to moderately active ulcerative colitis in adults. Safety and effectiveness of Balsalazide Disodium Capsules beyond 12 weeks in adults have not been established. uuid:3fc15ca1-3aa2-44d5-8c44-ff83fc927482 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4450 biolink:treats MONDO:0016383 PMID:41385096 "[{""id"":""uuid:fb38e366-50b2-4931-ad8d-dfbbc0337272"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e065fd25-f053-4183-9cda-be32141c508f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Desmopressin acetate nasal solution is indicated as antidiuretic replacement therapy in the management of central cranial diabetes insipidus and for management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. It is ineffective for the treatment of nephrogenic diabetes insipidus. The use of desmopressin acetate nasal solution in patients with an established diagnosis will result in a reduction in urinary output with increase in urine osmolality and a decrease in plasma osmolality. This will allow the resumption of a more normal life-style with a decrease in urinary frequency and nocturia. There are reports of an occasional change in response with time, usually greater than 6 months. Some patients may show a decreased responsiveness, others a shortened duration of effect. There is no evidence this effect is due to the development of binding antibodies but may be due to a local inactivation of the peptide. Patients are selected for therapy by establishing the diagnosis by means of the water deprivation test, the hypertonic saline infusion test, and/or the response to antidiuretic hormone. Continued response to intranasal desmopressin acetate can be monitored by urine volume and osmolality. Desmopressin acetate nasal solution is also available as a solution for injection when the intranasal route may be compromised. These situations include nasal congestion and blockage, nasal discharge, atrophy of nasal mucosa, and severe atrophic rhinitis. Intranasal delivery may also be inappropriate where there is an impaired level of consciousness. In addition, cranial surgical procedures, such as transsphenoidal hypophysectomy create situations where an alternative route of administration is needed as in cases of nasal packing or recovery from surgery. uuid:e82a7b6b-6ae3-41f3-a0e8-f073dfa2fb6e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4450 biolink:treats MONDO:0005659 PMID:41385096 "[{""id"":""uuid:b71f276c-ec0b-434b-a361-9639fb05e89e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ab32eb93-dc69-4fd0-bf2b-a41b1ad533dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Desmopressin acetate nasal solution is indicated as antidiuretic replacement therapy in the management of central cranial diabetes insipidus and for management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. It is ineffective for the treatment of nephrogenic diabetes insipidus. The use of desmopressin acetate nasal solution in patients with an established diagnosis will result in a reduction in urinary output with increase in urine osmolality and a decrease in plasma osmolality. This will allow the resumption of a more normal life-style with a decrease in urinary frequency and nocturia. There are reports of an occasional change in response with time, usually greater than 6 months. Some patients may show a decreased responsiveness, others a shortened duration of effect. There is no evidence this effect is due to the development of binding antibodies but may be due to a local inactivation of the peptide. Patients are selected for therapy by establishing the diagnosis by means of the water deprivation test, the hypertonic saline infusion test, and/or the response to antidiuretic hormone. Continued response to intranasal desmopressin acetate can be monitored by urine volume and osmolality. Desmopressin acetate nasal solution is also available as a solution for injection when the intranasal route may be compromised. These situations include nasal congestion and blockage, nasal discharge, atrophy of nasal mucosa, and severe atrophic rhinitis. Intranasal delivery may also be inappropriate where there is an impaired level of consciousness. In addition, cranial surgical procedures, such as transsphenoidal hypophysectomy create situations where an alternative route of administration is needed as in cases of nasal packing or recovery from surgery. uuid:68db1032-0e60-4fa9-801b-80d92996440a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:691037 biolink:treats MONDO:0005093 PMID:41385096 "[{""id"":""uuid:340777b1-7055-4b46-9daf-15c11ecbcd3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a539b403-4ce1-4339-bf05-f9b010d4dcb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Desoximetasone ointment USP, 0.25% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. uuid:7e3747eb-2a96-4d47-97d8-f46fc42dfd96 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats HP:0025245 PMID:41385096 "[{""id"":""uuid:649cfdd7-6eed-48b9-a04a-7333343743fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:267847f0-ce83-41ee-acf9-dd00f21ba38b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Primary skin infections: Impetigo contagiosa, superficial folliculitis, ecthyma, furunculosis, sycosis barbae, and pyoderma gangrenosum. Secondary skin infections: Infectious eczematoid dermatitis, pustular acne, pustular psoriasis, infected seborrheic dermatitis, infected contact dermatitis (including poison ivy), infected excoriations, and bacterial super-infections of fungal or viral infections. Please Note: Gentamicin sulfate is a bactericidal agent that is not effective against viruses or fungi in skin infections. Gentamicin sulfate is useful in the treatment of infected skin cysts and certain other skin abscesses when preceded by incision and drainage to permit adequate contact between the antibiotic and the infecting bacteria. Good results have been obtained in the treatment of infected stasis and other skin ulcers , infected superficial burns, paronychia, infected insect bites and stings, infected lacerations and abrasions, and wounds from minor surgery. Patients sensitive to neomycin can be treated with gentamicin sulfate, although regular observation of patients sensitive to topical antibiotics is advisable when such patients are treated with any topical antibiotic. Gentamicin sulfate cream is recommended for wet, oozing primary infections, and greasy, secondary infections, such as pustular acne or infected seborrheic dermatitis. If a water-washable preparation is desired, the cream is preferable. Gentamicin sulfate cream has been used successfully in infants over one year of age, as well as in adults and children. uuid:1f4a724e-400a-4a22-ab29-1963b964ca9f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5537 biolink:treats HP:0002017 PMID:41385096 "[{""id"":""uuid:a8be89af-745d-45e2-ae6e-fcf6e12483a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:523be93e-dd16-4952-84d5-75f8d5e4f272"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Granisetron HCl is indicated for the prevention of : Nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. Nausea and vomiting associated with radiation, including total body irradiation and fractionated abdominal radiation. uuid:09ed8a77-bd43-48ea-a459-e0aa8a01b10a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5537 biolink:treats EFO:0006911 PMID:41385096 "[{""id"":""uuid:355fd44a-2836-4363-aca1-609d5a5adaf1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:10d7b3fd-3f74-4825-85ff-8868374c9989"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Granisetron HCl is indicated for the prevention of : Nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. Nausea and vomiting associated with radiation, including total body irradiation and fractionated abdominal radiation. uuid:51f303ab-9672-47f7-ab8e-f875c1c28a1b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5537 biolink:treats EFO:0006912 PMID:41385096 "[{""id"":""uuid:36114c01-8de6-467b-b096-fc044b06dd01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9ed34bf8-4f67-444b-bb69-28cd89e58a7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Granisetron HCl is indicated for the prevention of : Nausea and vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. Nausea and vomiting associated with radiation, including total body irradiation and fractionated abdominal radiation. uuid:de18c56a-4eb2-4837-9737-463d3aae9493 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:119915 biolink:treats UMLS:C2721580 PMID:41385096 "[{""id"":""uuid:2529218d-2e4b-46e9-afb5-3d2332d8cd7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d24ac262-a810-448c-85a0-5d20aa0eae81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oral Transmucosal Fentanyl Citrate (OTFC) is indicated only for the management of breakthrough cancer pain in patients 16 and older with malignancies who are already receiving and who are tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain . Patients considered opioid tolerant are those who are taking around-the-clock medicine consisting of at least 60 mg of oral morphine daily, at least 25 mcg of transdermal fentanyl/hour, at least 30 mg of oral oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid daily for a week or longer. Patients must remain on around-the-clock opioids when taking OTFC. This product must not be used in opioid non-tolerant patients because life-threatening respiratory depression and death could occur at any dose in patients not on a chronic regimen of opioids. For this reason, OTFC is contraindicated in the management of acute or postoperative pain. OTFC is intended to be used only in the care of cancer patients and only by oncologists and pain specialists who are knowledgeable of and skilled in the use of Schedule II opioids to treat cancer pain. uuid:1fcae396-d104-4925-941f-fa521d199420 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:119915 biolink:treats EFO:0801084 PMID:41385096 "[{""id"":""uuid:1c7dca1f-232d-434b-b134-04d612433e35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7675124c-bb57-4807-a021-1942600d6b52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:cc1a9848-e932-47b0-b77a-4d3cc0853c79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oral Transmucosal Fentanyl Citrate (OTFC) is indicated only for the management of breakthrough cancer pain in patients 16 and older with malignancies who are already receiving and who are tolerant to around-the-clock opioid therapy for their underlying persistent cancer pain . Patients considered opioid tolerant are those who are taking around-the-clock medicine consisting of at least 60 mg of oral morphine daily, at least 25 mcg of transdermal fentanyl/hour, at least 30 mg of oral oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid daily for a week or longer. Patients must remain on around-the-clock opioids when taking OTFC. This product must not be used in opioid non-tolerant patients because life-threatening respiratory depression and death could occur at any dose in patients not on a chronic regimen of opioids. For this reason, OTFC is contraindicated in the management of acute or postoperative pain. OTFC is intended to be used only in the care of cancer patients and only by oncologists and pain specialists who are knowledgeable of and skilled in the use of Schedule II opioids to treat cancer pain.|[PMDA] Drugs with a new dosage in a new dosage form indicated for analgesia of breakthrough pain in patients with cancer receiving a potent opioid analgesic at fixed time. uuid:8393122d-1d27-4c79-97d1-8e01aa13102b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:61058 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:f09f6056-011e-4a24-ad1d-6e8897c96a02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b909845f-6ed6-4848-b9e4-4b008a266c27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension. uuid:e593c06b-84cd-4c26-8f47-f7c53a17f6ef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:13422922 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:df526a1a-da16-42f1-8424-aa177e9256c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cb75e389-3b49-447d-8874-a415806f02d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] QVAR is indicated in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older. QVAR is also indicated for asthma patients who require systemic corticosteroid administration, where adding QVAR may reduce or eliminate the need for the systemic corticosteroids. Beclomethasone dipropionate is NOT indicated for the relief of acute bronchospasm. uuid:23abc4bb-0a4b-4796-8e4f-24d7c230dcf7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7773 biolink:treats UMLS:C0520904 PMID:41385096 "[{""id"":""uuid:a47e4e4b-6cb9-470b-bf79-e1c7b35e0277"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f3d7d3e0-e78a-4ca3-b7ab-df88c15f881f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin ≥ 50 mg/m 2 . 2. Prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. 3. Prevention of nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. 4. Prevention of postoperative nausea and/or vomiting. As with other antiemetics, routine prophylaxis is not recommended for patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and/or vomiting must be avoided postoperatively, ondansetron hydrochloride tablets, ondansetron orally disintegrating tablets, and ondansetron hydrochloride oral solution are recommended even where the incidence of postoperative nausea and/or vomiting is low. uuid:c1d8a079-ce37-423a-a274-26afbe36366a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7773 biolink:treats UMLS:C0520905 PMID:41385096 "[{""id"":""uuid:70808030-25e7-45bd-a2d1-f696daf87434"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0857d560-bfc6-4235-8012-f27596835656"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy, including cisplatin ≥ 50 mg/m 2 . 2. Prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy. 3. Prevention of nausea and vomiting associated with radiotherapy in patients receiving either total body irradiation, single high-dose fraction to the abdomen, or daily fractions to the abdomen. 4. Prevention of postoperative nausea and/or vomiting. As with other antiemetics, routine prophylaxis is not recommended for patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and/or vomiting must be avoided postoperatively, ondansetron hydrochloride tablets, ondansetron orally disintegrating tablets, and ondansetron hydrochloride oral solution are recommended even where the incidence of postoperative nausea and/or vomiting is low. uuid:a73e598c-3cc6-48aa-bfdc-0c5948b62d16 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45951 biolink:treats MONDO:0005090 PMID:41385096 "[{""id"":""uuid:326fc84e-a4f3-4507-9e0d-7b4235c4dab8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:487ba952-da07-4483-9012-9b6078ef5792"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the management of schizophrenia. Trifluoperazine HCl is effective for the short-term treatment of generalized non-psychotic anxiety. However, trifluoperazine HCl is not the first drug to be used in therapy for most patients with non-psychotic anxiety because certain risks associated with its use are not shared by common alternative treatments (i.e., benzodiazepines). When used in the treatment of non-psychotic anxiety, trifluoperazine HCl should not be administered at doses of more than 6 mg per day or for longer than 12 weeks because the use of trifluoperazine HCl at higher doses or for longer intervals may cause persistent tardive dyskinesia that may prove irreversible (see WARNINGS ). The effectiveness of trifluoperazine HCl as a treatment for non-psychotic anxiety was established in a four-week clinical multicenter study of outpatients with generalized anxiety disorder (DSM-III). This evidence does not predict that trifluoperazine HCl will be useful in patients with other non-psychotic conditions in which anxiety, or signs that mimic anxiety, are found (i.e., physical illness, organic mental conditions, agitated depression, character pathologies, etc.). Trifluoperazine HCl has not been shown effective in the management of behavioral complications in patients with mental retardation. uuid:20fa3635-308b-42ac-a8cd-8eacd5bf3487 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45951 biolink:treats MONDO:0001942 PMID:41385096 "[{""id"":""uuid:e9133e1f-ed80-4481-8bc8-be2c036f4259"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c0088086-e223-4f4a-b14a-dcc1dd672ac5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the management of schizophrenia. Trifluoperazine HCl is effective for the short-term treatment of generalized non-psychotic anxiety. However, trifluoperazine HCl is not the first drug to be used in therapy for most patients with non-psychotic anxiety because certain risks associated with its use are not shared by common alternative treatments (i.e., benzodiazepines). When used in the treatment of non-psychotic anxiety, trifluoperazine HCl should not be administered at doses of more than 6 mg per day or for longer than 12 weeks because the use of trifluoperazine HCl at higher doses or for longer intervals may cause persistent tardive dyskinesia that may prove irreversible (see WARNINGS ). The effectiveness of trifluoperazine HCl as a treatment for non-psychotic anxiety was established in a four-week clinical multicenter study of outpatients with generalized anxiety disorder (DSM-III). This evidence does not predict that trifluoperazine HCl will be useful in patients with other non-psychotic conditions in which anxiety, or signs that mimic anxiety, are found (i.e., physical illness, organic mental conditions, agitated depression, character pathologies, etc.). Trifluoperazine HCl has not been shown effective in the management of behavioral complications in patients with mental retardation. uuid:944d5ce3-8a70-43b8-bf44-908a92397fb4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0006605 PMID:41385096 "[{""id"":""uuid:5ad54c85-8d50-4b41-9c69-a593c7c96759"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fd09e6fa-7f48-43c3-90fa-91e910419e51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Luxíq is a medium potency topical corticosteroid indicated for relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp. uuid:ca52e6b5-6c32-43f7-a050-ec3950a127d4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6715 biolink:treats HP:0000869 PMID:41385096 "[{""id"":""uuid:20d0c964-75b8-447a-98dd-0d1312632b50"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:00b6f4bd-f492-4550-ba75-4f9053785a4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Medroxyprogesterone acetate tablets contain a progestin indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. Medroxyprogesterone acetate is also indicated to reduce the incidence of endometrial hyperplasia in nonhysterectomized postmenopausal women receiving daily oral conjugated estrogens 0.625 mg tablets. uuid:9c288d76-9147-4c83-a5af-0c9bae2ef421 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6715 biolink:treats UMLS:C3650625 PMID:41385096 "[{""id"":""uuid:6c29546f-ae5a-4de8-8dc8-7521636b887e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:600d6f12-cfe5-4aea-8b0c-b43475df56e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Medroxyprogesterone acetate tablets contain a progestin indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. Medroxyprogesterone acetate is also indicated to reduce the incidence of endometrial hyperplasia in nonhysterectomized postmenopausal women receiving daily oral conjugated estrogens 0.625 mg tablets. uuid:52242ad5-79b7-4271-8002-cc32e228e254 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6715 biolink:treats MONDO:0006193 PMID:41385096 "[{""id"":""uuid:0672d4c9-9e02-492a-8f0b-9b0f622a80ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0e656703-33a6-4a20-9e13-0eefd7ec12a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Medroxyprogesterone acetate tablets contain a progestin indicated for the treatment of secondary amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as fibroids or uterine cancer. Medroxyprogesterone acetate is also indicated to reduce the incidence of endometrial hyperplasia in nonhysterectomized postmenopausal women receiving daily oral conjugated estrogens 0.625 mg tablets. uuid:17a3ae7c-aedf-4eaa-b68a-5f6dae2f12d8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40303 biolink:treats MONDO:0037748 PMID:41385096 "[{""id"":""uuid:efee6fc2-c0f6-4640-94e4-813013354b70"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0a212325-d336-428e-8b4f-2c00c68da3b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lovastatin tablets should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C, lovastatin tablets are indicated to reduce the risk of: - Myocardial infarction - Unstable angina - Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies .) Coronary Heart Disease Lovastatin tablets are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb***), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. *** Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein Type Lipoproteins elevated Lipid Elevations major minor I Chylomicrons TG ↑ →C IIa LDL C — IIb LDL, VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑ →C V (rare) Chylomicrons, VLDL TG ↑ →C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets are indicated as an adjunct to diet to reduce total-C, LDL-C and apolipoprotein B levels in adolescent boys and girls who are at least one year post-menarche, 10-17 years of age, with heFH if after an adequate trial of diet therapy the following findings are present: LDL-C remains >189 mg/dL or LDL-C remains >160 mg/dL and: • there is a positive family history of premature cardiovascular disease or • two or more other CVD risk factors are present in the adolescent patient General Recommendations Prior to initiating therapy with lovastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total-C, HDL-C, and TG. For patients with TG less than 400 mg / dL (<4.5 mmol / L), LDL-C can be estimated using the following equation: LDL-C = total-C – [0.2 x (TG) + HDL-C] For TG levels >400 mg/dL (>4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated total-C. In such cases, lovastatin tablets are not indicated. The National Cholesterol Education Program (NCEP) Treatment Guidelines are summarized below: NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD or CHD risk equivalence (10-year risk >20%) <100 ≥100 ≥130 (100-129: drug optional) 2+ Risk factors (10-year risk ≤20%) <130 ≥130 10-year risk 10-20%: ≥130 10-year risk<10%: ≥160 0-1 Risk factor <160 ≥160 ≥190 (160-189: LDL-lowering drug optional) After the LDL-C goal has been achieved, if the TG is still ≥200 mg/dL, non-HDL-C (total-C minus HDLC) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is ≥130 mg/dL (see NCEP Guidelines above). Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the total-C be used to monitor therapy. Although lovastatin tablets may be useful to reduce elevated LDL-C levels in patients with combined hypercholesterolemia and hypertriglyceridemia where hypercholesterolemia is the major abnormality (Type IIb hyperlipoproteinemia), it has not been studied in conditions where the major abnormality is elevation of chylomicrons, VLDL or IDL (i.e., hyperlipoproteinemia types I, III, IV, or V).*** The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable <170 <110 Borderline 170-199 110-129 High ≥200 ≥130 Children treated with lovastatin in adolescence should be re-evaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult goals for LDL-C. uuid:085aebe6-6d99-4b6a-9a4a-170718ad2c8b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6704 biolink:treats MONDO:0005746 PMID:41385096 "[{""id"":""uuid:6ea84445-1a0f-4152-8ac9-9473c7d62633"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0e575063-20fb-4461-864b-3a1ea842ade7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mebendazole tablets are indicated for the treatment of Enterobius vermicularis (pinworm), Trichuris trichiura (whipworm), Ascaris lumbricoides (common roundworm), Ancylostoma duodenale (common hookworm), Necator americanus (American hookworm) in single or mixed infections. Efficacy varies as a function of such factors as preexisting diarrhea and gastrointestinal transit time, degree of infection, and helminth strains. Efficacy rates derived from various studies are shown in the table below: Pinworm (enterobiasis) Whipworm (trichuriasis) Common Roundworm (ascariasis) Hookworm Cure rates mean 95% 68% 98% 96% Egg reduction mean — 93% 99% 99% uuid:7126296b-d6a1-4594-ac14-371a3dc2e373 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6704 biolink:treats MONDO:0005996 PMID:41385096 "[{""id"":""uuid:4c5d7e6b-44f0-496c-84ec-a69e0e16b351"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:947856ee-2240-4ae6-bcc0-d7e8684deedb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mebendazole tablets are indicated for the treatment of Enterobius vermicularis (pinworm), Trichuris trichiura (whipworm), Ascaris lumbricoides (common roundworm), Ancylostoma duodenale (common hookworm), Necator americanus (American hookworm) in single or mixed infections. Efficacy varies as a function of such factors as preexisting diarrhea and gastrointestinal transit time, degree of infection, and helminth strains. Efficacy rates derived from various studies are shown in the table below: Pinworm (enterobiasis) Whipworm (trichuriasis) Common Roundworm (ascariasis) Hookworm Cure rates mean 95% 68% 98% 96% Egg reduction mean — 93% 99% 99% uuid:d5466770-f29b-4d44-a5c4-a29161e95b28 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6704 biolink:treats MONDO:0011427 PMID:41385096 "[{""id"":""uuid:c78f3ef9-c98f-40e6-aae0-15e7d90dce89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7ec53143-2861-4fbd-8faf-84362189c01b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mebendazole tablets are indicated for the treatment of Enterobius vermicularis (pinworm), Trichuris trichiura (whipworm), Ascaris lumbricoides (common roundworm), Ancylostoma duodenale (common hookworm), Necator americanus (American hookworm) in single or mixed infections. Efficacy varies as a function of such factors as preexisting diarrhea and gastrointestinal transit time, degree of infection, and helminth strains. Efficacy rates derived from various studies are shown in the table below: Pinworm (enterobiasis) Whipworm (trichuriasis) Common Roundworm (ascariasis) Hookworm Cure rates mean 95% 68% 98% 96% Egg reduction mean — 93% 99% 99% uuid:a22b030f-1c36-4469-98f5-0d7dd51c1565 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6704 biolink:treats MONDO:0005654 PMID:41385096 "[{""id"":""uuid:fa9fc5a4-8bd4-4156-8894-138797ea78c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bf1ebb7e-8a96-4a2d-9104-86019f9f219a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mebendazole tablets are indicated for the treatment of Enterobius vermicularis (pinworm), Trichuris trichiura (whipworm), Ascaris lumbricoides (common roundworm), Ancylostoma duodenale (common hookworm), Necator americanus (American hookworm) in single or mixed infections. Efficacy varies as a function of such factors as preexisting diarrhea and gastrointestinal transit time, degree of infection, and helminth strains. Efficacy rates derived from various studies are shown in the table below: Pinworm (enterobiasis) Whipworm (trichuriasis) Common Roundworm (ascariasis) Hookworm Cure rates mean 95% 68% 98% 96% Egg reduction mean — 93% 99% 99% uuid:dde9a981-083c-4607-bd28-bd8ed2dc6238 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6704 biolink:treats MONDO:0005645 PMID:41385096 "[{""id"":""uuid:249d60e0-1df9-4d89-a1ab-c2796304a2d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:98c4dae0-c4ec-4763-acb1-9c4e1ec4dcf9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mebendazole tablets are indicated for the treatment of Enterobius vermicularis (pinworm), Trichuris trichiura (whipworm), Ascaris lumbricoides (common roundworm), Ancylostoma duodenale (common hookworm), Necator americanus (American hookworm) in single or mixed infections. Efficacy varies as a function of such factors as preexisting diarrhea and gastrointestinal transit time, degree of infection, and helminth strains. Efficacy rates derived from various studies are shown in the table below: Pinworm (enterobiasis) Whipworm (trichuriasis) Common Roundworm (ascariasis) Hookworm Cure rates mean 95% 68% 98% 96% Egg reduction mean — 93% 99% 99% uuid:c52d9c86-c809-4b7a-9f94-eaa2c02ee9b4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6704 biolink:treats MONDO:0005799 PMID:41385096 "[{""id"":""uuid:ebb0d954-933a-47e8-b153-61271601047e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9ccf692a-8274-4c1c-ad5f-ce50a4f130f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mebendazole tablets are indicated for the treatment of Enterobius vermicularis (pinworm), Trichuris trichiura (whipworm), Ascaris lumbricoides (common roundworm), Ancylostoma duodenale (common hookworm), Necator americanus (American hookworm) in single or mixed infections. Efficacy varies as a function of such factors as preexisting diarrhea and gastrointestinal transit time, degree of infection, and helminth strains. Efficacy rates derived from various studies are shown in the table below: Pinworm (enterobiasis) Whipworm (trichuriasis) Common Roundworm (ascariasis) Hookworm Cure rates mean 95% 68% 98% 96% Egg reduction mean — 93% 99% 99% uuid:b347e130-7ef2-48ce-8607-11fc18744245 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6704 biolink:treats UMLS:C0027529 PMID:41385096 "[{""id"":""uuid:12ccae82-61cc-4b32-9e34-89535e203ac3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e5ecaf81-2dda-4f34-867b-9c8c4cc4533f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mebendazole tablets are indicated for the treatment of Enterobius vermicularis (pinworm), Trichuris trichiura (whipworm), Ascaris lumbricoides (common roundworm), Ancylostoma duodenale (common hookworm), Necator americanus (American hookworm) in single or mixed infections. Efficacy varies as a function of such factors as preexisting diarrhea and gastrointestinal transit time, degree of infection, and helminth strains. Efficacy rates derived from various studies are shown in the table below: Pinworm (enterobiasis) Whipworm (trichuriasis) Common Roundworm (ascariasis) Hookworm Cure rates mean 95% 68% 98% 96% Egg reduction mean — 93% 99% 99% uuid:4a13b7af-e6f3-40a9-af8a-fb9a9a11c737 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:38562 biolink:treats MONDO:0005439 PMID:41385096 "[{""id"":""uuid:42f04fe6-04cc-4255-8472-f85bbb6f395b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8eb4b836-ee1a-4938-ac80-b3d9152b6f8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol (see National Cholesterol Education Program [NCEP] Treatment Guidelines, below). Hypercholesterolemia (heterozygous familial and nonfamilial) and Mixed Dyslipidemia Lescol ® (fluvastatin sodium) and Lescol ® XL (fluvastatin sodium) are indicated to reduce elevated total cholesterol (Total-C), LDL-C, TG and Apo B levels, and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Type IIa and IIb) whose response to dietary restriction of saturated fat and cholesterol and other nonpharmacological measures has not been adequate. Heterozygous Familial Hypercholesterolemia in Pediatric Patients Lescol and Lescol XL are indicated as an adjunct to diet to reduce Total-C, LDL-C, and Apo B levels in adolescent boys and girls who are at least one year post-menarche, 10-16 years of age, with heterozygous familial hypercholesterolemia whose response to dietary restriction has not been adequate and the following findings are present: LDL-C remains > 190 mg/dL or LDL-C remains > 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other cardiovascular disease risk factors are present. Therapy with lipid-altering agents should be considered only after secondary causes for hyperlipidemia such as poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other medication, or alcoholism, have been excluded. Prior to initiation of fluvastatin sodium, a lipid profile should be performed to measure Total-C, HDL-C and TG. For patients with TG <400 mg/dL (<4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total-C - HDL-C - 1/5 TG For TG levels >400 mg/dL (>4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In many hypertriglyceridemic patients LDL-C may be low or normal despite elevated Total-C. In such cases, Lescol is not indicated. Lipid determinations should be performed at intervals of no less than 4 weeks and dosage adjusted according to the patient’s response to therapy. The National Cholesterol Education Program (NCEP) Treatment Guidelines are summarized below: Table 3 NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD† or CHD risk equivalents (10-year risk >20%) <100 > 100 > 130 (100-129: drug optional)†† 2+ Risk factors (10-year risk < 20%) <130 > 130 10-year risk 10%-20%: >130 10-year risk <10%: > 160 0-1 Risk factor††† <160 > 160 > 190 (160-189: LDL-lowering drug optional) † CHD, coronary heart disease †† Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of <100mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g. , nicotinic acid or fibrate. Clinical judgement also may call for deferring drug therapy in this subcategory. ††† Almost all people with 0-1 risk factor have 10-year risk <10%; thus, 10-year risk assessment in people with 0 -1 risk factor is not necessary. After the LDL-C goal has been achieved, if the TG is still > 200 mg/dL, non-HDL-C (Total-C minus HDL-C) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C level is > 130 mg/dL (NCEP-ATP II). Since the goal of treatment is to lower LDL-C, the NCEP recommends that the LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the Total-C be used to monitor therapy. Table 4 Classification of Hyperlipoproteinemias Lipid Elevations Type Lipoproteins Elevated Major Minor I (rare) Chylomicrons TG ↑→C IIa LDL C – IIb LDL, VLDL C TG III (rare) IDL C/TG – IV VLDL TG ↑→C V (rare) Chylomicrons, VLDL TG ↑→C C = cholesterol, TG = triglycerides, LDL = low density lipoprotein, VLDL = very low density lipoprotein, IDL = intermediate density lipoprotein Neither Lescol nor Lescol XL have been studied in conditions where the major abnormality is elevation of chylomicrons, VLDL, or IDL (i.e., hyperlipoproteinemia Types I, III, IV, or V). The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable Borderline High <170 170-199 > 200 <110 110-129 > 130 Children treated with fluvastatin in adolescence should be re-evaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult treatment goals. Secondary Prevention of Coronary Events In patients with coronary heart disease, Lescol and Lescol XL are indicated to reduce the risk of undergoing coronary revascularization procedures. Atherosclerosis Lescol and Lescol XL are also indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total and LDL cholesterol to target levels. uuid:d525e3da-0dbf-49fe-84e6-c746feb82e98 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:38562 biolink:treats HP:0003119 PMID:41385096 "[{""id"":""uuid:eb8158d6-aa9c-4a02-b0c6-15b034e9fb5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9c4f5215-012b-4ed9-aac6-72eac5e32a97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol (see National Cholesterol Education Program [NCEP] Treatment Guidelines, below). Hypercholesterolemia (heterozygous familial and nonfamilial) and Mixed Dyslipidemia Lescol ® (fluvastatin sodium) and Lescol ® XL (fluvastatin sodium) are indicated to reduce elevated total cholesterol (Total-C), LDL-C, TG and Apo B levels, and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Type IIa and IIb) whose response to dietary restriction of saturated fat and cholesterol and other nonpharmacological measures has not been adequate. Heterozygous Familial Hypercholesterolemia in Pediatric Patients Lescol and Lescol XL are indicated as an adjunct to diet to reduce Total-C, LDL-C, and Apo B levels in adolescent boys and girls who are at least one year post-menarche, 10-16 years of age, with heterozygous familial hypercholesterolemia whose response to dietary restriction has not been adequate and the following findings are present: LDL-C remains > 190 mg/dL or LDL-C remains > 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other cardiovascular disease risk factors are present. Therapy with lipid-altering agents should be considered only after secondary causes for hyperlipidemia such as poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other medication, or alcoholism, have been excluded. Prior to initiation of fluvastatin sodium, a lipid profile should be performed to measure Total-C, HDL-C and TG. For patients with TG <400 mg/dL (<4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total-C - HDL-C - 1/5 TG For TG levels >400 mg/dL (>4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In many hypertriglyceridemic patients LDL-C may be low or normal despite elevated Total-C. In such cases, Lescol is not indicated. Lipid determinations should be performed at intervals of no less than 4 weeks and dosage adjusted according to the patient’s response to therapy. The National Cholesterol Education Program (NCEP) Treatment Guidelines are summarized below: Table 3 NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD† or CHD risk equivalents (10-year risk >20%) <100 > 100 > 130 (100-129: drug optional)†† 2+ Risk factors (10-year risk < 20%) <130 > 130 10-year risk 10%-20%: >130 10-year risk <10%: > 160 0-1 Risk factor††† <160 > 160 > 190 (160-189: LDL-lowering drug optional) † CHD, coronary heart disease †† Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of <100mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g. , nicotinic acid or fibrate. Clinical judgement also may call for deferring drug therapy in this subcategory. ††† Almost all people with 0-1 risk factor have 10-year risk <10%; thus, 10-year risk assessment in people with 0 -1 risk factor is not necessary. After the LDL-C goal has been achieved, if the TG is still > 200 mg/dL, non-HDL-C (Total-C minus HDL-C) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C level is > 130 mg/dL (NCEP-ATP II). Since the goal of treatment is to lower LDL-C, the NCEP recommends that the LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the Total-C be used to monitor therapy. Table 4 Classification of Hyperlipoproteinemias Lipid Elevations Type Lipoproteins Elevated Major Minor I (rare) Chylomicrons TG ↑→C IIa LDL C – IIb LDL, VLDL C TG III (rare) IDL C/TG – IV VLDL TG ↑→C V (rare) Chylomicrons, VLDL TG ↑→C C = cholesterol, TG = triglycerides, LDL = low density lipoprotein, VLDL = very low density lipoprotein, IDL = intermediate density lipoprotein Neither Lescol nor Lescol XL have been studied in conditions where the major abnormality is elevation of chylomicrons, VLDL, or IDL (i.e., hyperlipoproteinemia Types I, III, IV, or V). The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable Borderline High <170 170-199 > 200 <110 110-129 > 130 Children treated with fluvastatin in adolescence should be re-evaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult treatment goals. Secondary Prevention of Coronary Events In patients with coronary heart disease, Lescol and Lescol XL are indicated to reduce the risk of undergoing coronary revascularization procedures. Atherosclerosis Lescol and Lescol XL are also indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total and LDL cholesterol to target levels. uuid:f30c2e82-c645-4df0-a50d-401c32ee40cc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:38562 biolink:treats UMLS:C0342882 PMID:41385096 "[{""id"":""uuid:3bf15884-d684-4ceb-821b-bffd09edb0f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8a051c44-96cd-4161-ad04-dd1adebb42fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol (see National Cholesterol Education Program [NCEP] Treatment Guidelines, below). Hypercholesterolemia (heterozygous familial and nonfamilial) and Mixed Dyslipidemia Lescol ® (fluvastatin sodium) and Lescol ® XL (fluvastatin sodium) are indicated to reduce elevated total cholesterol (Total-C), LDL-C, TG and Apo B levels, and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Type IIa and IIb) whose response to dietary restriction of saturated fat and cholesterol and other nonpharmacological measures has not been adequate. Heterozygous Familial Hypercholesterolemia in Pediatric Patients Lescol and Lescol XL are indicated as an adjunct to diet to reduce Total-C, LDL-C, and Apo B levels in adolescent boys and girls who are at least one year post-menarche, 10-16 years of age, with heterozygous familial hypercholesterolemia whose response to dietary restriction has not been adequate and the following findings are present: LDL-C remains > 190 mg/dL or LDL-C remains > 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other cardiovascular disease risk factors are present. Therapy with lipid-altering agents should be considered only after secondary causes for hyperlipidemia such as poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other medication, or alcoholism, have been excluded. Prior to initiation of fluvastatin sodium, a lipid profile should be performed to measure Total-C, HDL-C and TG. For patients with TG <400 mg/dL (<4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total-C - HDL-C - 1/5 TG For TG levels >400 mg/dL (>4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In many hypertriglyceridemic patients LDL-C may be low or normal despite elevated Total-C. In such cases, Lescol is not indicated. Lipid determinations should be performed at intervals of no less than 4 weeks and dosage adjusted according to the patient’s response to therapy. The National Cholesterol Education Program (NCEP) Treatment Guidelines are summarized below: Table 3 NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD† or CHD risk equivalents (10-year risk >20%) <100 > 100 > 130 (100-129: drug optional)†† 2+ Risk factors (10-year risk < 20%) <130 > 130 10-year risk 10%-20%: >130 10-year risk <10%: > 160 0-1 Risk factor††† <160 > 160 > 190 (160-189: LDL-lowering drug optional) † CHD, coronary heart disease †† Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of <100mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g. , nicotinic acid or fibrate. Clinical judgement also may call for deferring drug therapy in this subcategory. ††† Almost all people with 0-1 risk factor have 10-year risk <10%; thus, 10-year risk assessment in people with 0 -1 risk factor is not necessary. After the LDL-C goal has been achieved, if the TG is still > 200 mg/dL, non-HDL-C (Total-C minus HDL-C) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C level is > 130 mg/dL (NCEP-ATP II). Since the goal of treatment is to lower LDL-C, the NCEP recommends that the LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the Total-C be used to monitor therapy. Table 4 Classification of Hyperlipoproteinemias Lipid Elevations Type Lipoproteins Elevated Major Minor I (rare) Chylomicrons TG ↑→C IIa LDL C – IIb LDL, VLDL C TG III (rare) IDL C/TG – IV VLDL TG ↑→C V (rare) Chylomicrons, VLDL TG ↑→C C = cholesterol, TG = triglycerides, LDL = low density lipoprotein, VLDL = very low density lipoprotein, IDL = intermediate density lipoprotein Neither Lescol nor Lescol XL have been studied in conditions where the major abnormality is elevation of chylomicrons, VLDL, or IDL (i.e., hyperlipoproteinemia Types I, III, IV, or V). The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable Borderline High <170 170-199 > 200 <110 110-129 > 130 Children treated with fluvastatin in adolescence should be re-evaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult treatment goals. Secondary Prevention of Coronary Events In patients with coronary heart disease, Lescol and Lescol XL are indicated to reduce the risk of undergoing coronary revascularization procedures. Atherosclerosis Lescol and Lescol XL are also indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total and LDL cholesterol to target levels. uuid:17a9f96f-0dd5-4c4c-907e-a08068dfa3a7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:38562 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:7998aa6c-a3cc-45c9-8eb4-313aee6f1844"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:228a2786-5e5a-40f0-a4f5-fce93bed6cb4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol (see National Cholesterol Education Program [NCEP] Treatment Guidelines, below). Hypercholesterolemia (heterozygous familial and nonfamilial) and Mixed Dyslipidemia Lescol ® (fluvastatin sodium) and Lescol ® XL (fluvastatin sodium) are indicated to reduce elevated total cholesterol (Total-C), LDL-C, TG and Apo B levels, and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Type IIa and IIb) whose response to dietary restriction of saturated fat and cholesterol and other nonpharmacological measures has not been adequate. Heterozygous Familial Hypercholesterolemia in Pediatric Patients Lescol and Lescol XL are indicated as an adjunct to diet to reduce Total-C, LDL-C, and Apo B levels in adolescent boys and girls who are at least one year post-menarche, 10-16 years of age, with heterozygous familial hypercholesterolemia whose response to dietary restriction has not been adequate and the following findings are present: LDL-C remains > 190 mg/dL or LDL-C remains > 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other cardiovascular disease risk factors are present. Therapy with lipid-altering agents should be considered only after secondary causes for hyperlipidemia such as poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other medication, or alcoholism, have been excluded. Prior to initiation of fluvastatin sodium, a lipid profile should be performed to measure Total-C, HDL-C and TG. For patients with TG <400 mg/dL (<4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total-C - HDL-C - 1/5 TG For TG levels >400 mg/dL (>4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In many hypertriglyceridemic patients LDL-C may be low or normal despite elevated Total-C. In such cases, Lescol is not indicated. Lipid determinations should be performed at intervals of no less than 4 weeks and dosage adjusted according to the patient’s response to therapy. The National Cholesterol Education Program (NCEP) Treatment Guidelines are summarized below: Table 3 NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD† or CHD risk equivalents (10-year risk >20%) <100 > 100 > 130 (100-129: drug optional)†† 2+ Risk factors (10-year risk < 20%) <130 > 130 10-year risk 10%-20%: >130 10-year risk <10%: > 160 0-1 Risk factor††† <160 > 160 > 190 (160-189: LDL-lowering drug optional) † CHD, coronary heart disease †† Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of <100mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g. , nicotinic acid or fibrate. Clinical judgement also may call for deferring drug therapy in this subcategory. ††† Almost all people with 0-1 risk factor have 10-year risk <10%; thus, 10-year risk assessment in people with 0 -1 risk factor is not necessary. After the LDL-C goal has been achieved, if the TG is still > 200 mg/dL, non-HDL-C (Total-C minus HDL-C) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C level is > 130 mg/dL (NCEP-ATP II). Since the goal of treatment is to lower LDL-C, the NCEP recommends that the LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the Total-C be used to monitor therapy. Table 4 Classification of Hyperlipoproteinemias Lipid Elevations Type Lipoproteins Elevated Major Minor I (rare) Chylomicrons TG ↑→C IIa LDL C – IIb LDL, VLDL C TG III (rare) IDL C/TG – IV VLDL TG ↑→C V (rare) Chylomicrons, VLDL TG ↑→C C = cholesterol, TG = triglycerides, LDL = low density lipoprotein, VLDL = very low density lipoprotein, IDL = intermediate density lipoprotein Neither Lescol nor Lescol XL have been studied in conditions where the major abnormality is elevation of chylomicrons, VLDL, or IDL (i.e., hyperlipoproteinemia Types I, III, IV, or V). The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable Borderline High <170 170-199 > 200 <110 110-129 > 130 Children treated with fluvastatin in adolescence should be re-evaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult treatment goals. Secondary Prevention of Coronary Events In patients with coronary heart disease, Lescol and Lescol XL are indicated to reduce the risk of undergoing coronary revascularization procedures. Atherosclerosis Lescol and Lescol XL are also indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total and LDL cholesterol to target levels. uuid:96ad1b24-04db-4daf-930f-c8cde26869a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:38562 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:88e2aeae-2180-4021-b083-6a5e5e44051b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7617914e-f668-4fcd-a4b7-b6384ebd80a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol (see National Cholesterol Education Program [NCEP] Treatment Guidelines, below). Hypercholesterolemia (heterozygous familial and nonfamilial) and Mixed Dyslipidemia Lescol ® (fluvastatin sodium) and Lescol ® XL (fluvastatin sodium) are indicated to reduce elevated total cholesterol (Total-C), LDL-C, TG and Apo B levels, and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Type IIa and IIb) whose response to dietary restriction of saturated fat and cholesterol and other nonpharmacological measures has not been adequate. Heterozygous Familial Hypercholesterolemia in Pediatric Patients Lescol and Lescol XL are indicated as an adjunct to diet to reduce Total-C, LDL-C, and Apo B levels in adolescent boys and girls who are at least one year post-menarche, 10-16 years of age, with heterozygous familial hypercholesterolemia whose response to dietary restriction has not been adequate and the following findings are present: LDL-C remains > 190 mg/dL or LDL-C remains > 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other cardiovascular disease risk factors are present. Therapy with lipid-altering agents should be considered only after secondary causes for hyperlipidemia such as poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other medication, or alcoholism, have been excluded. Prior to initiation of fluvastatin sodium, a lipid profile should be performed to measure Total-C, HDL-C and TG. For patients with TG <400 mg/dL (<4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total-C - HDL-C - 1/5 TG For TG levels >400 mg/dL (>4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In many hypertriglyceridemic patients LDL-C may be low or normal despite elevated Total-C. In such cases, Lescol is not indicated. Lipid determinations should be performed at intervals of no less than 4 weeks and dosage adjusted according to the patient’s response to therapy. The National Cholesterol Education Program (NCEP) Treatment Guidelines are summarized below: Table 3 NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD† or CHD risk equivalents (10-year risk >20%) <100 > 100 > 130 (100-129: drug optional)†† 2+ Risk factors (10-year risk < 20%) <130 > 130 10-year risk 10%-20%: >130 10-year risk <10%: > 160 0-1 Risk factor††† <160 > 160 > 190 (160-189: LDL-lowering drug optional) † CHD, coronary heart disease †† Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of <100mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g. , nicotinic acid or fibrate. Clinical judgement also may call for deferring drug therapy in this subcategory. ††† Almost all people with 0-1 risk factor have 10-year risk <10%; thus, 10-year risk assessment in people with 0 -1 risk factor is not necessary. After the LDL-C goal has been achieved, if the TG is still > 200 mg/dL, non-HDL-C (Total-C minus HDL-C) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C level is > 130 mg/dL (NCEP-ATP II). Since the goal of treatment is to lower LDL-C, the NCEP recommends that the LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the Total-C be used to monitor therapy. Table 4 Classification of Hyperlipoproteinemias Lipid Elevations Type Lipoproteins Elevated Major Minor I (rare) Chylomicrons TG ↑→C IIa LDL C – IIb LDL, VLDL C TG III (rare) IDL C/TG – IV VLDL TG ↑→C V (rare) Chylomicrons, VLDL TG ↑→C C = cholesterol, TG = triglycerides, LDL = low density lipoprotein, VLDL = very low density lipoprotein, IDL = intermediate density lipoprotein Neither Lescol nor Lescol XL have been studied in conditions where the major abnormality is elevation of chylomicrons, VLDL, or IDL (i.e., hyperlipoproteinemia Types I, III, IV, or V). The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable Borderline High <170 170-199 > 200 <110 110-129 > 130 Children treated with fluvastatin in adolescence should be re-evaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult treatment goals. Secondary Prevention of Coronary Events In patients with coronary heart disease, Lescol and Lescol XL are indicated to reduce the risk of undergoing coronary revascularization procedures. Atherosclerosis Lescol and Lescol XL are also indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total and LDL cholesterol to target levels. uuid:ed4a3b7a-76bb-46ba-8db5-bfd09fa57b67 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:38562 biolink:treats MONDO:0021661 PMID:41385096 "[{""id"":""uuid:5bf8036b-3762-4851-9ebe-364d917dd63f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:97f2136f-1e45-484b-ac78-55946f8ca872"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol (see National Cholesterol Education Program [NCEP] Treatment Guidelines, below). Hypercholesterolemia (heterozygous familial and nonfamilial) and Mixed Dyslipidemia Lescol ® (fluvastatin sodium) and Lescol ® XL (fluvastatin sodium) are indicated to reduce elevated total cholesterol (Total-C), LDL-C, TG and Apo B levels, and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Type IIa and IIb) whose response to dietary restriction of saturated fat and cholesterol and other nonpharmacological measures has not been adequate. Heterozygous Familial Hypercholesterolemia in Pediatric Patients Lescol and Lescol XL are indicated as an adjunct to diet to reduce Total-C, LDL-C, and Apo B levels in adolescent boys and girls who are at least one year post-menarche, 10-16 years of age, with heterozygous familial hypercholesterolemia whose response to dietary restriction has not been adequate and the following findings are present: LDL-C remains > 190 mg/dL or LDL-C remains > 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other cardiovascular disease risk factors are present. Therapy with lipid-altering agents should be considered only after secondary causes for hyperlipidemia such as poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other medication, or alcoholism, have been excluded. Prior to initiation of fluvastatin sodium, a lipid profile should be performed to measure Total-C, HDL-C and TG. For patients with TG <400 mg/dL (<4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total-C - HDL-C - 1/5 TG For TG levels >400 mg/dL (>4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In many hypertriglyceridemic patients LDL-C may be low or normal despite elevated Total-C. In such cases, Lescol is not indicated. Lipid determinations should be performed at intervals of no less than 4 weeks and dosage adjusted according to the patient’s response to therapy. The National Cholesterol Education Program (NCEP) Treatment Guidelines are summarized below: Table 3 NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD† or CHD risk equivalents (10-year risk >20%) <100 > 100 > 130 (100-129: drug optional)†† 2+ Risk factors (10-year risk < 20%) <130 > 130 10-year risk 10%-20%: >130 10-year risk <10%: > 160 0-1 Risk factor††† <160 > 160 > 190 (160-189: LDL-lowering drug optional) † CHD, coronary heart disease †† Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of <100mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g. , nicotinic acid or fibrate. Clinical judgement also may call for deferring drug therapy in this subcategory. ††† Almost all people with 0-1 risk factor have 10-year risk <10%; thus, 10-year risk assessment in people with 0 -1 risk factor is not necessary. After the LDL-C goal has been achieved, if the TG is still > 200 mg/dL, non-HDL-C (Total-C minus HDL-C) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C level is > 130 mg/dL (NCEP-ATP II). Since the goal of treatment is to lower LDL-C, the NCEP recommends that the LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the Total-C be used to monitor therapy. Table 4 Classification of Hyperlipoproteinemias Lipid Elevations Type Lipoproteins Elevated Major Minor I (rare) Chylomicrons TG ↑→C IIa LDL C – IIb LDL, VLDL C TG III (rare) IDL C/TG – IV VLDL TG ↑→C V (rare) Chylomicrons, VLDL TG ↑→C C = cholesterol, TG = triglycerides, LDL = low density lipoprotein, VLDL = very low density lipoprotein, IDL = intermediate density lipoprotein Neither Lescol nor Lescol XL have been studied in conditions where the major abnormality is elevation of chylomicrons, VLDL, or IDL (i.e., hyperlipoproteinemia Types I, III, IV, or V). The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable Borderline High <170 170-199 > 200 <110 110-129 > 130 Children treated with fluvastatin in adolescence should be re-evaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult treatment goals. Secondary Prevention of Coronary Events In patients with coronary heart disease, Lescol and Lescol XL are indicated to reduce the risk of undergoing coronary revascularization procedures. Atherosclerosis Lescol and Lescol XL are also indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total and LDL cholesterol to target levels. uuid:2c68f4ff-2a59-476b-b4f0-a9d60474db48 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50848 biolink:treats MONDO:0006604 PMID:41385096 "[{""id"":""uuid:5babae80-9f59-45d1-a4aa-591e7a4a6c74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6d8e6feb-1aa2-4305-bb3e-233e64137da8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LOTEMAX is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. LOTEMAX is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with LOTEMAX experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. The incidence of patients with clinically significant increases in IOP (≥10 mmHg) was 1% with LOTEMAX and 6% with prednisolone acetate 1%. LOTEMAX should not be used in patients who require a more potent corticosteroid for this indication. LOTEMAX is also indicated for the treatment of post-operative inflammation following ocular surgery. uuid:503a4743-6c10-44b6-a1ab-aeb887ec30b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50848 biolink:treats MONDO:0033816 PMID:41385096 "[{""id"":""uuid:abf4de76-d9f0-4b9c-81c5-bf4c4243914e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:47402dd4-f401-4dd7-aaef-e9906089b7a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LOTEMAX is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. LOTEMAX is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with LOTEMAX experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. The incidence of patients with clinically significant increases in IOP (≥10 mmHg) was 1% with LOTEMAX and 6% with prednisolone acetate 1%. LOTEMAX should not be used in patients who require a more potent corticosteroid for this indication. LOTEMAX is also indicated for the treatment of post-operative inflammation following ocular surgery. uuid:37e789d9-4332-4390-8d4a-30c0174aefee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50848 biolink:treats UMLS:C1275687 PMID:41385096 "[{""id"":""uuid:70cd8d0d-e07f-40d4-aff2-2a2592836228"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ca5a856a-6529-486c-afa9-9c73557c3563"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LOTEMAX is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. LOTEMAX is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with LOTEMAX experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. The incidence of patients with clinically significant increases in IOP (≥10 mmHg) was 1% with LOTEMAX and 6% with prednisolone acetate 1%. LOTEMAX should not be used in patients who require a more potent corticosteroid for this indication. LOTEMAX is also indicated for the treatment of post-operative inflammation following ocular surgery. uuid:e6bd1666-cdd8-48f0-8d4e-b46a88b0dde8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50848 biolink:treats MONDO:0006814 PMID:41385096 "[{""id"":""uuid:ddd207e5-2b74-4ecb-a7c7-c6559dc4f523"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ac56f338-20d7-4d00-aec5-0aa3f47385ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LOTEMAX is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. LOTEMAX is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with LOTEMAX experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. The incidence of patients with clinically significant increases in IOP (≥10 mmHg) was 1% with LOTEMAX and 6% with prednisolone acetate 1%. LOTEMAX should not be used in patients who require a more potent corticosteroid for this indication. LOTEMAX is also indicated for the treatment of post-operative inflammation following ocular surgery. uuid:723936d8-8cff-4ee1-a2bd-a579053da274 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50848 biolink:treats UMLS:C0010543 PMID:41385096 "[{""id"":""uuid:4cdd882b-be4c-4998-b454-324e6d27d45e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6d0c0131-bcb0-45a1-be10-338adc984b3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LOTEMAX is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. LOTEMAX is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with LOTEMAX experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. The incidence of patients with clinically significant increases in IOP (≥10 mmHg) was 1% with LOTEMAX and 6% with prednisolone acetate 1%. LOTEMAX should not be used in patients who require a more potent corticosteroid for this indication. LOTEMAX is also indicated for the treatment of post-operative inflammation following ocular surgery. uuid:2006f66b-1355-4441-9d56-b0e7174551e1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50848 biolink:treats MONDO:0006668 PMID:41385096 "[{""id"":""uuid:52b8199b-29d4-4733-b8f6-de51b735868b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9a00ae2b-96a1-4851-9ca4-6cb79a6155b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LOTEMAX is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. LOTEMAX is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with LOTEMAX experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. The incidence of patients with clinically significant increases in IOP (≥10 mmHg) was 1% with LOTEMAX and 6% with prednisolone acetate 1%. LOTEMAX should not be used in patients who require a more potent corticosteroid for this indication. LOTEMAX is also indicated for the treatment of post-operative inflammation following ocular surgery. uuid:eff8a564-6f9c-4033-9474-fb4e69034afc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50848 biolink:treats MONDO:0006651 PMID:41385096 "[{""id"":""uuid:36154a72-1a0f-48c4-8d22-1c046ac60a11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:08828554-3b62-4636-9ed9-f9fef12a0607"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LOTEMAX is indicated for the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation. LOTEMAX is less effective than prednisolone acetate 1% in two 28-day controlled clinical studies in acute anterior uveitis, where 72% of patients treated with LOTEMAX experienced resolution of anterior chamber cells, compared to 87% of patients treated with prednisolone acetate 1%. The incidence of patients with clinically significant increases in IOP (≥10 mmHg) was 1% with LOTEMAX and 6% with prednisolone acetate 1%. LOTEMAX should not be used in patients who require a more potent corticosteroid for this indication. LOTEMAX is also indicated for the treatment of post-operative inflammation following ocular surgery. uuid:d44e00cf-080f-4564-8ba2-1de7145d54b9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49713 biolink:treats HP:0100754 PMID:41385096 "[{""id"":""uuid:c08b3e51-8677-4011-b815-eaa218758cd4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:814dbea7-c43e-4601-aca2-b2c98ce4c479"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lithium carbonate is indicated in the treatment of manic episodes of manic-depressive illness. Maintenance therapy prevents or diminishes the intensity of subsequent episodes in those manic-depressive patients with a history of mania. Typical symptoms of mania include pressure of speech, motor hyperactivity, reduced need for sleep, flight of ideas, grandiosity, elation, poor judgment, aggressiveness and possibly hostility. When given to a patient experiencing a manic episode, lithium carbonate may produce a normalization of symptomatology within 1 to 3 weeks. uuid:8d82bec1-b1ac-4bf2-8a61-b789bfb95bee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:372890 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:7952feac-1f25-49b9-aea6-b1c52fb96b73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:825e889c-5655-41ef-b611-973b9121e740"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metoprolol tartrate and hydrochlorothiazide tablets are indicated for the management of hypertension. This fixed-combination drug is not indicated for initial therapy of hypertension. If the fixed combination represents the dose titrated to the individual patient's needs, therapy with the fixed combination may be more convenient than with the separate components. uuid:50446b4e-d0ba-4519-ad39-b6d6f83d4cbc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0005314 PMID:41385096 "[{""id"":""uuid:9a5e2384-d313-4ad4-9755-2dcf3055bc4c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2ea270cd-770d-47fe-bba7-2814ae32fbc4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler’s syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Nervous System Acute exacerbations of multiple sclerosis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:ec03d376-1bdc-4a5e-bc16-22acad8eea96 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0005316 PMID:41385096 "[{""id"":""uuid:8d3d3f3c-efe7-4b8f-91a7-490345fc28ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:89f58b28-2d6e-4ca8-8caf-4b0e02ea6964"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:5069b69b-e548-4535-a18c-95afa8779268"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] METROGEL-VAGINAL is indicated in the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, ­Gardnerella vaginitis, nonspecific vaginitis, Corynebacterium vaginitis, or anaerobic vaginosis). NOTE: For purposes of this indication, a clinical diagnosis of bacterial vaginosis is usually defined by the presence of a homogeneous vaginal discharge that (a) has a pH of greater than 4.5, (b) emits a “fishy” amine odor when mixed with a 10% KOH solution, and (c) contains clue cells on microscopic examination. Gram’s stain results consistent with a diagnosis of bacterial vaginosis include (a) markedly reduced or absent Lactobacillus morphology, (b) predominance of Gardnerella morphotype, and (c) absent or few white blood cells. Other pathogens commonly associated with vulvovaginitis, e.g., Trichomonas vaginalis , Chlamydia trachomatis , ­ N. gonorrhoeae , Candida albicans , and Herpes simplex virus should be ruled out.|[PMDA] Drugs with a new indication and new dosages for the treatment of bacterial vaginosis. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:a5715327-1e90-48d8-acda-4ffcb6aa25c6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats UMLS:C1622505 PMID:41385096 "[{""id"":""uuid:ae596a35-012f-405a-b3f5-2f7a265d6d5d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dbe381ba-0e82-41ab-a3f7-7642188a9f02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] METROGEL-VAGINAL is indicated in the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, ­Gardnerella vaginitis, nonspecific vaginitis, Corynebacterium vaginitis, or anaerobic vaginosis). NOTE: For purposes of this indication, a clinical diagnosis of bacterial vaginosis is usually defined by the presence of a homogeneous vaginal discharge that (a) has a pH of greater than 4.5, (b) emits a “fishy” amine odor when mixed with a 10% KOH solution, and (c) contains clue cells on microscopic examination. Gram’s stain results consistent with a diagnosis of bacterial vaginosis include (a) markedly reduced or absent Lactobacillus morphology, (b) predominance of Gardnerella morphotype, and (c) absent or few white blood cells. Other pathogens commonly associated with vulvovaginitis, e.g., Trichomonas vaginalis , Chlamydia trachomatis , ­ N. gonorrhoeae , Candida albicans , and Herpes simplex virus should be ruled out. uuid:e63e8af4-86c5-4e5d-8f97-5e619952ee9d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0023557 PMID:41385096 "[{""id"":""uuid:a922a50d-0e03-4132-a95f-7649014eefa5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:37415ee4-04dc-40b8-8519-c5ab5ffb24df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] METROGEL-VAGINAL is indicated in the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, ­Gardnerella vaginitis, nonspecific vaginitis, Corynebacterium vaginitis, or anaerobic vaginosis). NOTE: For purposes of this indication, a clinical diagnosis of bacterial vaginosis is usually defined by the presence of a homogeneous vaginal discharge that (a) has a pH of greater than 4.5, (b) emits a “fishy” amine odor when mixed with a 10% KOH solution, and (c) contains clue cells on microscopic examination. Gram’s stain results consistent with a diagnosis of bacterial vaginosis include (a) markedly reduced or absent Lactobacillus morphology, (b) predominance of Gardnerella morphotype, and (c) absent or few white blood cells. Other pathogens commonly associated with vulvovaginitis, e.g., Trichomonas vaginalis , Chlamydia trachomatis , ­ N. gonorrhoeae , Candida albicans , and Herpes simplex virus should be ruled out. uuid:c16ff8c0-3391-41b2-a266-561a161ca90a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0007019 PMID:41385096 "[{""id"":""uuid:da7df996-17e3-4abe-b8a1-4d4ee20015e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:071dd50a-7648-4a85-a320-75638a249608"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] METROGEL-VAGINAL is indicated in the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, ­Gardnerella vaginitis, nonspecific vaginitis, Corynebacterium vaginitis, or anaerobic vaginosis). NOTE: For purposes of this indication, a clinical diagnosis of bacterial vaginosis is usually defined by the presence of a homogeneous vaginal discharge that (a) has a pH of greater than 4.5, (b) emits a “fishy” amine odor when mixed with a 10% KOH solution, and (c) contains clue cells on microscopic examination. Gram’s stain results consistent with a diagnosis of bacterial vaginosis include (a) markedly reduced or absent Lactobacillus morphology, (b) predominance of Gardnerella morphotype, and (c) absent or few white blood cells. Other pathogens commonly associated with vulvovaginitis, e.g., Trichomonas vaginalis , Chlamydia trachomatis , ­ N. gonorrhoeae , Candida albicans , and Herpes simplex virus should be ruled out. uuid:a10ae45b-7e99-4330-94b9-819561096f41 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29103 biolink:treats MONDO:0012692 PMID:41385096 "[{""id"":""uuid:7afa2234-b15a-4102-8b67-9c51f154f573"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8514650c-1047-4a4e-a4c6-3079c3ad5866"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Urocit ® -K is a citrate salt of potassium indicated for the management of: Renal tubular acidosis (RTA) with calcium stones ( 1.1 ) Hypocitraturic calcium oxalate nephrolithiasis of any etiology ( 1.2 ) Uric acid lithiasis with or without calcium stones ( 1.3 ) uuid:97a4d144-7d40-4f49-971d-1da250015fd9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29103 biolink:treats MONDO:0024647 PMID:41385096 "[{""id"":""uuid:2d088799-28af-4091-a129-4514eb472ef3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1cd75f1e-e9cd-4517-817e-7d57330ccbf6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Urocit ® -K is a citrate salt of potassium indicated for the management of: Renal tubular acidosis (RTA) with calcium stones ( 1.1 ) Hypocitraturic calcium oxalate nephrolithiasis of any etiology ( 1.2 ) Uric acid lithiasis with or without calcium stones ( 1.3 ) uuid:03bfa6e9-5eac-417d-b0a4-78ecde3e3506 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6822 biolink:treats MONDO:0005338 PMID:41385096 "[{""id"":""uuid:76cf325b-635e-43bf-97b2-1922ee6b774f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cf0e5b3a-2ee9-4b28-820a-c69da807dee7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methazolamide is indicated in the treatment of ocular conditions where lowering intraocular pressure is likely to be of therapeutic benefit, such as chronic open-angle glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where lowering the intraocular pressure is desired before surgery. uuid:f2cb889c-10ad-4d6f-8451-f4dd5d51a3ff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6822 biolink:treats UMLS:C0149893 PMID:41385096 "[{""id"":""uuid:616b44a6-b272-4f62-a2b4-118e3eb9ccd7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:89dd326a-ad07-4add-bc8c-bce5d0727624"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methazolamide is indicated in the treatment of ocular conditions where lowering intraocular pressure is likely to be of therapeutic benefit, such as chronic open-angle glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where lowering the intraocular pressure is desired before surgery. uuid:bacd065b-87f3-4f46-8369-2580334e3c4d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6822 biolink:treats MONDO:0001817 PMID:41385096 "[{""id"":""uuid:7f5119be-3c7b-42f9-8bec-55dc9aee3f52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7201f242-aa42-4c82-83ed-4e17b0ceaf12"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methazolamide is indicated in the treatment of ocular conditions where lowering intraocular pressure is likely to be of therapeutic benefit, such as chronic open-angle glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where lowering the intraocular pressure is desired before surgery. uuid:a24f6911-3cd2-4fdb-a240-1c611691398a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0015129 PMID:41385096 "[{""id"":""uuid:d6ee716d-b845-494d-8ff7-f6e7ae70b82d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:25066bce-dc65-4f80-a0a9-21bbdd38cb7d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone tablets are indicated in the following conditions: Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoid where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis Collagen Diseases : During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis Dermatologic Diseases : Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases : Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis Respiratory Diseases : Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis Hematologic Disorders : Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Diseases : For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States : To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases : To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Nervous System: Acute exacerbations of multiple sclerosis Miscellaneous : Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:d6965974-137d-423d-ab57-4e3f349c7e46 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0043370 PMID:41385096 "[{""id"":""uuid:ca15aa9b-a026-403e-a06f-885cd452eac9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:48320997-2cbf-478b-99fb-d8554adc75a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone tablets are indicated in the following conditions: Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoid where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis Collagen Diseases : During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis Dermatologic Diseases : Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases : Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis Respiratory Diseases : Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis Hematologic Disorders : Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Diseases : For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States : To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases : To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Nervous System: Acute exacerbations of multiple sclerosis Miscellaneous : Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:21380540-1e5d-4b4b-8fa0-ebef3ff9fc69 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24847953 biolink:treats HP:0005202 PMID:41385096 "[{""id"":""uuid:85547ad8-8d8c-462c-99e6-4aa128d50125"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:afaca161-9443-40a0-bf6f-6511e7e58720"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a7d333aa-d0dc-4b1d-8783-6dcb22305eb7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The components in PREVPAC (PREVACID, amoxicillin, and clarithromycin) are indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one-year history of a duodenal ulcer) to eradicate H. pylori . Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence (see CLINICAL STUDIES and DOSAGE AND ADMINISTRATION ) . To reduce the development of drug-resistant bacteria and maintain the effectiveness of PREVPAC and other antibacterial drugs, PREVPAC should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Please refer to the full prescribing information for amoxicillin and clarithromycin.|[PMDA] Revision of the dosage for a combination therapy of amoxicillin, clarithromycin, and omeprazole indicated for treatment of Helicobacter pylori infections in patients with gastric ulcer or duodenal ulcer. uuid:9567f90d-dec8-40d7-b16a-bcf6e78eee83 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24847953 biolink:treats MONDO:0005412 PMID:41385096 "[{""id"":""uuid:32422150-ab14-46c4-82cb-ddd0c814cad1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b35c8ff0-540a-4e4e-b15f-234cbaf5eb50"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4a74ab68-2702-4328-9ac8-ac860c6cbc31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The components in PREVPAC (PREVACID, amoxicillin, and clarithromycin) are indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one-year history of a duodenal ulcer) to eradicate H. pylori . Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence (see CLINICAL STUDIES and DOSAGE AND ADMINISTRATION ) . To reduce the development of drug-resistant bacteria and maintain the effectiveness of PREVPAC and other antibacterial drugs, PREVPAC should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Please refer to the full prescribing information for amoxicillin and clarithromycin.|[PMDA] Addition of a new dosage indicated for a combination therapy with sodium rabeprazole, amoxicillin, and clarithromycin to eradicate Helicobacter pylori in patients with gastric or duodenal ulcer. uuid:8461ddfc-513f-430e-b906-687a0f54f401 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9874151 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:a8702e08-2801-48de-bd8d-5b27574b019b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a56f3b8a-863a-4f56-ab45-0462dcd16ddf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gianvi™ (drospirenone and ethinyl estradiol tablets) 3 mg/0.02 mg is indicated for the prevention of pregnancy in women who elect to use an oral contraceptive. Oral contraceptives are highly effective. Table II lists the typical unintended pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization and contraceptive implants and IUDs, depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates. Gianvi™ (drospirenone and ethinyl estradiol tablets) is indicated for the treatment of moderate acne vulgaris in women at least 14 years of age, who have no known contraindications to oral contraceptive therapy and have achieved menarche. Gianvi™ (drospirenone and ethinyl estradiol tablets) should be used for the treatment of acne only if the patient desires an oral contraceptive for birth control. TABLE II: PERCENTAGE OF WOMEN EXPERIENCING AN UNINTENDED PREGNANCY DURING THE FIRST YEAR OF TYPICAL USE AND FIRST YEAR OF PERFECT USE OF CONTRACEPTION AND THE PERCENTAGE CONTINUING USE AT THE END OF THE FIRST YEAR: UNITED STATES. % of Women Experiencing an Unintended Pregnancy Within the First Year of Use % of Women Continuing Use at One Year Method (1) Typical Use (2) Perfect Use (3) (4) Chance 85 85 40 Spermicides 26 6 63 Periodic abstinence 25 Calendar 9 Ovulation method 3 Sympto-thermal 2 Post-ovulation 1 Withdrawal 19 4 Cap With spermicidal cream or jelly. Parous women 40 26 42 Nulliparous women 20 9 56 Sponge Parous women 40 20 42 Nulliparous women 20 9 56 Diaphragm 20 6 56 Condom Female (Reality) 21 5 56 Male 14 3 61 Pill 5 71 progestin only 0.5 combined 0.1 IUD Progesterone T 2 1.5 81 Copper T 380A 0.8 0.6 78 Lng 20 0.1 0.1 81 Depo Provera 0.3 0.3 70 Norplant and Norplant-2 0.05 0.05 88 Female sterilization 0.5 0.5 100 Male sterilization 0.15 0.1 100 Emergency Contraceptive Pills: Treatment initiated within 72 hours after unprotected intercourse reduces the risk of pregnancy by at least 75%. Lactational Amenorrhea Method: LAM is a highly effective, temporary method of contraception. Source: Trussell J, Contraceptive efficacy. In Hatcher RA, Trussell J, Stewart F, Cates W, Stewart GK, Guest F, Kowal D, Contraceptive Technology: Seventeenth Revised Edition . New York NY: Irvington Publishers, 1998. uuid:de9c9610-ab6e-4298-80e5-4e2621765b7d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17303 biolink:treats MONDO:0043775 PMID:41385096 "[{""id"":""uuid:e3351f4e-e87e-495c-a34a-a83093c6e083"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:04604c53-2373-4ce5-8d3d-0605ece90143"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Morphine sulfate oral solution (10 mg per 5 mL and 20 mg per 5 mL) are formulations of morphine, an opioid analgesic, indicated for the relief of moderate to severe acute and chronic pain where use of an opioid analgesic is appropriate. Morphine sulfate oral solution 100 mg per 5 mL (20 mg/mL) is an opioid analgesic indicated for the relief of moderate to severe acute and chronic pain in opioid-tolerant patients. Morphine sulfate oral solution 100 mg per 5 mL (20 mg/mL) may cause fatal respiratory depression when administered to patients not previously exposed to opioids. Patients considered to be opioid tolerant are those who are taking at least 60 mg oral morphine per day, or at least 30 mg of oral oxycodone per day, or at least 12 mg hydromorphone per day, or an equianalgesic dose of another opioid, for a week or longer. uuid:81bad419-8e0e-4e0a-b6a5-98216144eba9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3127 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:95313440-65e4-452e-ab79-b4d148c411b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0bc46abb-d4bc-4469-b76f-f19028c7b447"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BISOPROLOL FUMARATE is indicated in the management of hypertension. It may be used alone or in combination with other antihypertensive agents. uuid:3f07333e-5aad-4af6-b87c-d285430760b2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24783652 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:98f81c59-3988-47a3-a6f9-abaade540742"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3a57f95c-044a-499b-be9e-c1153e9647cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3f39fb88-9628-4bbf-b61f-ddce33c17272"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Losartan potassium and hydrochlorothiazide tablets are indicated for the treatment of hypertension. This fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients (see CLINICAL PHARMACOLOGY , Pharmacodynamics and Clinical Effects , and DOSAGE AND ADMINISTRATION ).|[PMDA] A drug with a new dosage in an additional dosage form. The drug is indicated for the treatment of hypertension. uuid:9da7a065-0358-42de-a7ca-c9cd813ced4f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1154168 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:2b1ab4bd-74a3-4ed5-9dd0-e5c96daf624d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bf0f436d-59fa-4a05-9f3a-3dd25344f7c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For relief of coughs and upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold. uuid:07d2b7e5-b4d8-48f5-999f-f9e036821e06 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1154168 biolink:treats MONDO:0005709 PMID:41385096 "[{""id"":""uuid:fd61edc5-b95e-4061-8873-4238eec17680"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5f0e049d-3cd9-4bb1-a754-3461c251a7a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For relief of coughs and upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold. uuid:c0849bf4-d2f3-4f66-94b9-552a9c59d8c3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:70746 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:ed02b812-4927-4cb4-a9e1-456757b9dcf3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e2beef5d-a67a-4717-8e14-ade2bbf2b9ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:651281ac-fa0c-4936-bc12-c157352a38e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRADAXA is indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.|[EMA] Pradaxa 75 mgPrimary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.Pradaxa 110 mgPrimary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischemic attack (TIA); age ≥ 75 years; heart failure (NYHA Class ≥ II); diabetes mellitus; hypertension.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.Pradaxa 150 mgPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischemic attack (TIA); age ≥ 75 years; heart failure (NYHA Class ≥ II); diabetes mellitus; hypertension.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. uuid:b9093c8c-0ef8-4d9e-96dc-b3a67a431518 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:70746 biolink:treats UMLS:C5400523 PMID:41385096 "[{""id"":""uuid:ee85022b-ee1a-489f-9903-b56d107b4c5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2e079ff2-cccb-44b7-9a0b-753188e5dded"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7ec679eb-137a-473a-b16f-13518b87ef63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRADAXA is indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation.|[PMDA] Drugs with a new active ingredient indicated for prevention of ischemic stroke and systemic embolism in patients with nonvalvular atrial fibrillation. uuid:e055a725-8d8a-4fda-8925-8432253ed1d2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:70746 biolink:treats MONDO:0004981 PMID:41385096 "[{""id"":""uuid:a983a013-4c41-4a4f-b2d0-89d78d9455ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bf9799c7-caa0-438b-9b1c-6c370d1e9202"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRADAXA is indicated to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. uuid:2912ecf6-fc69-4882-b37c-7005fecca42d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28001 biolink:treats UMLS:C0520767 PMID:41385096 "[{""id"":""uuid:222195a5-8345-4369-bd8b-426ce474fb0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fc665591-3e17-4172-b4db-15344c3f919e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vancomycin is indicated for the treatment of serious or severe infections caused by susceptible strains of methicillin-resistant (beta-lactam-resistant) staphylococci. It is indicated for penicillin-allergic patients, for patients who cannot receive or who have failed to respond to other drugs, including the penicillins or cephalosporins, and for infections caused by vancomycin-susceptible organisms that are resistant to other antimicrobial drugs. Vancomycin is indicated for initial therapy when methicillin-resistant staphylococci are suspected, but after susceptibility data are available, therapy should be adjusted accordingly. Vancomycin hydrochloride is effective in the treatment of staphylococcal endocarditis. Its effectiveness has been documented in other infections due to staphylococci, including septicemia, bone infections, lower respiratory tract infections, and skin and skin-structure infections. When staphylococcal infections are localized and purulent, antibiotics are used as adjuncts to appropriate surgical measures. Vancomycin hydrochloride has been reported to be effective alone or in combination with an aminoglycoside for endocarditis caused by S. viridans or S. bovis . For endocarditis caused by enterococci (e.g., E. faecalis ), vancomycin hydrochloride has been reported to be effective only in combination with an aminoglycoside. Vancomycin has been reported to be effective for the treatment of diphtheroid endocarditis. Vancomycin has been used successfully in combination with either rifampin, an aminoglycoside, or both in early-onset prosthetic valve endocarditis caused by S. epidermidis or diphtheroids. Specimens for bacteriologic cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to vancomycin. The parenteral form of Sterile Vancomycin Hydrochloride may be administered orally for treatment of antibiotic-associated pseudomembranous colitis produced by C. difficile and for staphylococcal enterocolitis. Parenteral administration of vancomycin hydrochloride alone is of unproven benefit for these indications. Vancomycin is not effective by the oral route for other types of infection. To reduce the development of drug-resistant bacteria and maintain the effectiveness of vancomycin and other antibacterial drugs, vancomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:7da03a89-93b9-4024-9976-199de7f88964 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28001 biolink:treats MONDO:0700217 PMID:41385096 "[{""id"":""uuid:9e79ebd5-3ba4-4822-8fde-a70a3b35e678"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:deddb096-6c48-4eee-a6ef-e67c8e7f0a88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vancomycin is indicated for the treatment of serious or severe infections caused by susceptible strains of methicillin-resistant (beta-lactam-resistant) staphylococci. It is indicated for penicillin-allergic patients, for patients who cannot receive or who have failed to respond to other drugs, including the penicillins or cephalosporins, and for infections caused by vancomycin-susceptible organisms that are resistant to other antimicrobial drugs. Vancomycin is indicated for initial therapy when methicillin-resistant staphylococci are suspected, but after susceptibility data are available, therapy should be adjusted accordingly. Vancomycin hydrochloride is effective in the treatment of staphylococcal endocarditis. Its effectiveness has been documented in other infections due to staphylococci, including septicemia, bone infections, lower respiratory tract infections, and skin and skin-structure infections. When staphylococcal infections are localized and purulent, antibiotics are used as adjuncts to appropriate surgical measures. Vancomycin hydrochloride has been reported to be effective alone or in combination with an aminoglycoside for endocarditis caused by S. viridans or S. bovis . For endocarditis caused by enterococci (e.g., E. faecalis ), vancomycin hydrochloride has been reported to be effective only in combination with an aminoglycoside. Vancomycin has been reported to be effective for the treatment of diphtheroid endocarditis. Vancomycin has been used successfully in combination with either rifampin, an aminoglycoside, or both in early-onset prosthetic valve endocarditis caused by S. epidermidis or diphtheroids. Specimens for bacteriologic cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to vancomycin. The parenteral form of Sterile Vancomycin Hydrochloride may be administered orally for treatment of antibiotic-associated pseudomembranous colitis produced by C. difficile and for staphylococcal enterocolitis. Parenteral administration of vancomycin hydrochloride alone is of unproven benefit for these indications. Vancomycin is not effective by the oral route for other types of infection. To reduce the development of drug-resistant bacteria and maintain the effectiveness of vancomycin and other antibacterial drugs, vancomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:a5697863-245e-4d0f-9d15-bfb43dcff5e4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28001 biolink:treats MONDO:0005246 PMID:41385096 "[{""id"":""uuid:ee3aaacb-32f1-4ab7-b6f4-eb4c48b4e832"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:20e31957-fdb4-4c8d-a328-e8915f02ab4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:8bc752d6-185b-42f4-9423-6342da9b308f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vancomycin is indicated for the treatment of serious or severe infections caused by susceptible strains of methicillin-resistant (beta-lactam-resistant) staphylococci. It is indicated for penicillin-allergic patients, for patients who cannot receive or who have failed to respond to other drugs, including the penicillins or cephalosporins, and for infections caused by vancomycin-susceptible organisms that are resistant to other antimicrobial drugs. Vancomycin is indicated for initial therapy when methicillin-resistant staphylococci are suspected, but after susceptibility data are available, therapy should be adjusted accordingly. Vancomycin hydrochloride is effective in the treatment of staphylococcal endocarditis. Its effectiveness has been documented in other infections due to staphylococci, including septicemia, bone infections, lower respiratory tract infections, and skin and skin-structure infections. When staphylococcal infections are localized and purulent, antibiotics are used as adjuncts to appropriate surgical measures. Vancomycin hydrochloride has been reported to be effective alone or in combination with an aminoglycoside for endocarditis caused by S. viridans or S. bovis . For endocarditis caused by enterococci (e.g., E. faecalis ), vancomycin hydrochloride has been reported to be effective only in combination with an aminoglycoside. Vancomycin has been reported to be effective for the treatment of diphtheroid endocarditis. Vancomycin has been used successfully in combination with either rifampin, an aminoglycoside, or both in early-onset prosthetic valve endocarditis caused by S. epidermidis or diphtheroids. Specimens for bacteriologic cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to vancomycin. The parenteral form of Sterile Vancomycin Hydrochloride may be administered orally for treatment of antibiotic-associated pseudomembranous colitis produced by C. difficile and for staphylococcal enterocolitis. Parenteral administration of vancomycin hydrochloride alone is of unproven benefit for these indications. Vancomycin is not effective by the oral route for other types of infection. To reduce the development of drug-resistant bacteria and maintain the effectiveness of vancomycin and other antibacterial drugs, vancomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.|[PMDA] A drug with new additional indications for the treatment of: sepsis, infective endocarditis, secondary infection of trauma, burn or surgical wounds, osteomyelitis, arthritis, peritonitis and purulent meningitis caused by vancomycin-sensitive methicillin-resistant coagulase-negative Staphylococcus (MRCNS); or febrile neutropenia which is suspected of MRSA or MRCNS infection. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:018f2703-ea64-4ada-9d6c-c231ccb9b3b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28001 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:3c737ac3-5df4-4538-86b8-80faad56de43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b38491a3-28d4-436e-ab6b-3b1e3b3d18c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vancomycin is indicated for the treatment of serious or severe infections caused by susceptible strains of methicillin-resistant (beta-lactam-resistant) staphylococci. It is indicated for penicillin-allergic patients, for patients who cannot receive or who have failed to respond to other drugs, including the penicillins or cephalosporins, and for infections caused by vancomycin-susceptible organisms that are resistant to other antimicrobial drugs. Vancomycin is indicated for initial therapy when methicillin-resistant staphylococci are suspected, but after susceptibility data are available, therapy should be adjusted accordingly. Vancomycin hydrochloride is effective in the treatment of staphylococcal endocarditis. Its effectiveness has been documented in other infections due to staphylococci, including septicemia, bone infections, lower respiratory tract infections, and skin and skin-structure infections. When staphylococcal infections are localized and purulent, antibiotics are used as adjuncts to appropriate surgical measures. Vancomycin hydrochloride has been reported to be effective alone or in combination with an aminoglycoside for endocarditis caused by S. viridans or S. bovis . For endocarditis caused by enterococci (e.g., E. faecalis ), vancomycin hydrochloride has been reported to be effective only in combination with an aminoglycoside. Vancomycin has been reported to be effective for the treatment of diphtheroid endocarditis. Vancomycin has been used successfully in combination with either rifampin, an aminoglycoside, or both in early-onset prosthetic valve endocarditis caused by S. epidermidis or diphtheroids. Specimens for bacteriologic cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to vancomycin. The parenteral form of Sterile Vancomycin Hydrochloride may be administered orally for treatment of antibiotic-associated pseudomembranous colitis produced by C. difficile and for staphylococcal enterocolitis. Parenteral administration of vancomycin hydrochloride alone is of unproven benefit for these indications. Vancomycin is not effective by the oral route for other types of infection. To reduce the development of drug-resistant bacteria and maintain the effectiveness of vancomycin and other antibacterial drugs, vancomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:f1385bb3-d722-4f55-88db-676dc56d272b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28001 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:c400e7a3-1d75-4602-b836-ce5562db2691"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a34eeb54-44da-4a0a-9136-7bfe8aac07fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vancomycin is indicated for the treatment of serious or severe infections caused by susceptible strains of methicillin-resistant (beta-lactam-resistant) staphylococci. It is indicated for penicillin-allergic patients, for patients who cannot receive or who have failed to respond to other drugs, including the penicillins or cephalosporins, and for infections caused by vancomycin-susceptible organisms that are resistant to other antimicrobial drugs. Vancomycin is indicated for initial therapy when methicillin-resistant staphylococci are suspected, but after susceptibility data are available, therapy should be adjusted accordingly. Vancomycin hydrochloride is effective in the treatment of staphylococcal endocarditis. Its effectiveness has been documented in other infections due to staphylococci, including septicemia, bone infections, lower respiratory tract infections, and skin and skin-structure infections. When staphylococcal infections are localized and purulent, antibiotics are used as adjuncts to appropriate surgical measures. Vancomycin hydrochloride has been reported to be effective alone or in combination with an aminoglycoside for endocarditis caused by S. viridans or S. bovis . For endocarditis caused by enterococci (e.g., E. faecalis ), vancomycin hydrochloride has been reported to be effective only in combination with an aminoglycoside. Vancomycin has been reported to be effective for the treatment of diphtheroid endocarditis. Vancomycin has been used successfully in combination with either rifampin, an aminoglycoside, or both in early-onset prosthetic valve endocarditis caused by S. epidermidis or diphtheroids. Specimens for bacteriologic cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to vancomycin. The parenteral form of Sterile Vancomycin Hydrochloride may be administered orally for treatment of antibiotic-associated pseudomembranous colitis produced by C. difficile and for staphylococcal enterocolitis. Parenteral administration of vancomycin hydrochloride alone is of unproven benefit for these indications. Vancomycin is not effective by the oral route for other types of infection. To reduce the development of drug-resistant bacteria and maintain the effectiveness of vancomycin and other antibacterial drugs, vancomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:fb31ea56-2ef1-4e5e-adb9-b28f36ff330e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28001 biolink:treats MONDO:0005025 PMID:41385096 "[{""id"":""uuid:39e3717e-0fb4-492e-ad3e-c0f27de8bd49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:08dc1e2c-4586-4262-84e7-f802ee7b54b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vancomycin is indicated for the treatment of serious or severe infections caused by susceptible strains of methicillin-resistant (beta-lactam-resistant) staphylococci. It is indicated for penicillin-allergic patients, for patients who cannot receive or who have failed to respond to other drugs, including the penicillins or cephalosporins, and for infections caused by vancomycin-susceptible organisms that are resistant to other antimicrobial drugs. Vancomycin is indicated for initial therapy when methicillin-resistant staphylococci are suspected, but after susceptibility data are available, therapy should be adjusted accordingly. Vancomycin hydrochloride is effective in the treatment of staphylococcal endocarditis. Its effectiveness has been documented in other infections due to staphylococci, including septicemia, bone infections, lower respiratory tract infections, and skin and skin-structure infections. When staphylococcal infections are localized and purulent, antibiotics are used as adjuncts to appropriate surgical measures. Vancomycin hydrochloride has been reported to be effective alone or in combination with an aminoglycoside for endocarditis caused by S. viridans or S. bovis . For endocarditis caused by enterococci (e.g., E. faecalis ), vancomycin hydrochloride has been reported to be effective only in combination with an aminoglycoside. Vancomycin has been reported to be effective for the treatment of diphtheroid endocarditis. Vancomycin has been used successfully in combination with either rifampin, an aminoglycoside, or both in early-onset prosthetic valve endocarditis caused by S. epidermidis or diphtheroids. Specimens for bacteriologic cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to vancomycin. The parenteral form of Sterile Vancomycin Hydrochloride may be administered orally for treatment of antibiotic-associated pseudomembranous colitis produced by C. difficile and for staphylococcal enterocolitis. Parenteral administration of vancomycin hydrochloride alone is of unproven benefit for these indications. Vancomycin is not effective by the oral route for other types of infection. To reduce the development of drug-resistant bacteria and maintain the effectiveness of vancomycin and other antibacterial drugs, vancomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:6ec2798e-4018-41e8-9eda-2ef2bda05f8e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28001 biolink:treats MONDO:0006669 PMID:41385096 "[{""id"":""uuid:6a2dc0ef-7155-4e55-be95-e55630ea715b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2a631608-246b-4dca-b4a1-22fb0fd8ee36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vancomycin is indicated for the treatment of serious or severe infections caused by susceptible strains of methicillin-resistant (beta-lactam-resistant) staphylococci. It is indicated for penicillin-allergic patients, for patients who cannot receive or who have failed to respond to other drugs, including the penicillins or cephalosporins, and for infections caused by vancomycin-susceptible organisms that are resistant to other antimicrobial drugs. Vancomycin is indicated for initial therapy when methicillin-resistant staphylococci are suspected, but after susceptibility data are available, therapy should be adjusted accordingly. Vancomycin hydrochloride is effective in the treatment of staphylococcal endocarditis. Its effectiveness has been documented in other infections due to staphylococci, including septicemia, bone infections, lower respiratory tract infections, and skin and skin-structure infections. When staphylococcal infections are localized and purulent, antibiotics are used as adjuncts to appropriate surgical measures. Vancomycin hydrochloride has been reported to be effective alone or in combination with an aminoglycoside for endocarditis caused by S. viridans or S. bovis . For endocarditis caused by enterococci (e.g., E. faecalis ), vancomycin hydrochloride has been reported to be effective only in combination with an aminoglycoside. Vancomycin has been reported to be effective for the treatment of diphtheroid endocarditis. Vancomycin has been used successfully in combination with either rifampin, an aminoglycoside, or both in early-onset prosthetic valve endocarditis caused by S. epidermidis or diphtheroids. Specimens for bacteriologic cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to vancomycin. The parenteral form of Sterile Vancomycin Hydrochloride may be administered orally for treatment of antibiotic-associated pseudomembranous colitis produced by C. difficile and for staphylococcal enterocolitis. Parenteral administration of vancomycin hydrochloride alone is of unproven benefit for these indications. Vancomycin is not effective by the oral route for other types of infection. To reduce the development of drug-resistant bacteria and maintain the effectiveness of vancomycin and other antibacterial drugs, vancomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:599cf137-e5b4-422f-810f-149a5e3a1d4a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28001 biolink:treats MONDO:0000565 PMID:41385096 "[{""id"":""uuid:a41f4bff-ad51-4b5b-ba68-73fd5b6c5ff6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9d9f8927-647f-42e4-9403-08bbe13ec28d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3b3a2450-a170-41fd-a655-b3a7e06a2424"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vancomycin is indicated for the treatment of serious or severe infections caused by susceptible strains of methicillin-resistant (beta-lactam-resistant) staphylococci. It is indicated for penicillin-allergic patients, for patients who cannot receive or who have failed to respond to other drugs, including the penicillins or cephalosporins, and for infections caused by vancomycin-susceptible organisms that are resistant to other antimicrobial drugs. Vancomycin is indicated for initial therapy when methicillin-resistant staphylococci are suspected, but after susceptibility data are available, therapy should be adjusted accordingly. Vancomycin hydrochloride is effective in the treatment of staphylococcal endocarditis. Its effectiveness has been documented in other infections due to staphylococci, including septicemia, bone infections, lower respiratory tract infections, and skin and skin-structure infections. When staphylococcal infections are localized and purulent, antibiotics are used as adjuncts to appropriate surgical measures. Vancomycin hydrochloride has been reported to be effective alone or in combination with an aminoglycoside for endocarditis caused by S. viridans or S. bovis . For endocarditis caused by enterococci (e.g., E. faecalis ), vancomycin hydrochloride has been reported to be effective only in combination with an aminoglycoside. Vancomycin has been reported to be effective for the treatment of diphtheroid endocarditis. Vancomycin has been used successfully in combination with either rifampin, an aminoglycoside, or both in early-onset prosthetic valve endocarditis caused by S. epidermidis or diphtheroids. Specimens for bacteriologic cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to vancomycin. The parenteral form of Sterile Vancomycin Hydrochloride may be administered orally for treatment of antibiotic-associated pseudomembranous colitis produced by C. difficile and for staphylococcal enterocolitis. Parenteral administration of vancomycin hydrochloride alone is of unproven benefit for these indications. Vancomycin is not effective by the oral route for other types of infection. To reduce the development of drug-resistant bacteria and maintain the effectiveness of vancomycin and other antibacterial drugs, vancomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.|[PMDA] A drug with new additional indications for the treatment of: sepsis, infective endocarditis, secondary infection of trauma, burn or surgical wounds, osteomyelitis, arthritis, peritonitis and purulent meningitis caused by vancomycin-sensitive methicillin-resistant coagulase-negative Staphylococcus (MRCNS); or febrile neutropenia which is suspected of MRSA or MRCNS infection. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:b7f533ca-c0f7-439d-b972-8ff4244ce66c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28001 biolink:treats MONDO:0000705 PMID:41385096 "[{""id"":""uuid:8a7054d1-2059-45d6-8e12-2655f803d1ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:440abb17-bf0b-49a4-a4ce-34c719c38d70"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vancomycin is indicated for the treatment of serious or severe infections caused by susceptible strains of methicillin-resistant (beta-lactam-resistant) staphylococci. It is indicated for penicillin-allergic patients, for patients who cannot receive or who have failed to respond to other drugs, including the penicillins or cephalosporins, and for infections caused by vancomycin-susceptible organisms that are resistant to other antimicrobial drugs. Vancomycin is indicated for initial therapy when methicillin-resistant staphylococci are suspected, but after susceptibility data are available, therapy should be adjusted accordingly. Vancomycin hydrochloride is effective in the treatment of staphylococcal endocarditis. Its effectiveness has been documented in other infections due to staphylococci, including septicemia, bone infections, lower respiratory tract infections, and skin and skin-structure infections. When staphylococcal infections are localized and purulent, antibiotics are used as adjuncts to appropriate surgical measures. Vancomycin hydrochloride has been reported to be effective alone or in combination with an aminoglycoside for endocarditis caused by S. viridans or S. bovis . For endocarditis caused by enterococci (e.g., E. faecalis ), vancomycin hydrochloride has been reported to be effective only in combination with an aminoglycoside. Vancomycin has been reported to be effective for the treatment of diphtheroid endocarditis. Vancomycin has been used successfully in combination with either rifampin, an aminoglycoside, or both in early-onset prosthetic valve endocarditis caused by S. epidermidis or diphtheroids. Specimens for bacteriologic cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to vancomycin. The parenteral form of Sterile Vancomycin Hydrochloride may be administered orally for treatment of antibiotic-associated pseudomembranous colitis produced by C. difficile and for staphylococcal enterocolitis. Parenteral administration of vancomycin hydrochloride alone is of unproven benefit for these indications. Vancomycin is not effective by the oral route for other types of infection. To reduce the development of drug-resistant bacteria and maintain the effectiveness of vancomycin and other antibacterial drugs, vancomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:f744fa93-89fb-456a-bec6-9d7e10528452 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28001 biolink:treats UMLS:C0038157 PMID:41385096 "[{""id"":""uuid:c94c215d-d2db-4c65-89d6-65dc4b6570bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:debb9846-cc3c-4f9b-8956-769e86ac5ed3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vancomycin is indicated for the treatment of serious or severe infections caused by susceptible strains of methicillin-resistant (beta-lactam-resistant) staphylococci. It is indicated for penicillin-allergic patients, for patients who cannot receive or who have failed to respond to other drugs, including the penicillins or cephalosporins, and for infections caused by vancomycin-susceptible organisms that are resistant to other antimicrobial drugs. Vancomycin is indicated for initial therapy when methicillin-resistant staphylococci are suspected, but after susceptibility data are available, therapy should be adjusted accordingly. Vancomycin hydrochloride is effective in the treatment of staphylococcal endocarditis. Its effectiveness has been documented in other infections due to staphylococci, including septicemia, bone infections, lower respiratory tract infections, and skin and skin-structure infections. When staphylococcal infections are localized and purulent, antibiotics are used as adjuncts to appropriate surgical measures. Vancomycin hydrochloride has been reported to be effective alone or in combination with an aminoglycoside for endocarditis caused by S. viridans or S. bovis . For endocarditis caused by enterococci (e.g., E. faecalis ), vancomycin hydrochloride has been reported to be effective only in combination with an aminoglycoside. Vancomycin has been reported to be effective for the treatment of diphtheroid endocarditis. Vancomycin has been used successfully in combination with either rifampin, an aminoglycoside, or both in early-onset prosthetic valve endocarditis caused by S. epidermidis or diphtheroids. Specimens for bacteriologic cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to vancomycin. The parenteral form of Sterile Vancomycin Hydrochloride may be administered orally for treatment of antibiotic-associated pseudomembranous colitis produced by C. difficile and for staphylococcal enterocolitis. Parenteral administration of vancomycin hydrochloride alone is of unproven benefit for these indications. Vancomycin is not effective by the oral route for other types of infection. To reduce the development of drug-resistant bacteria and maintain the effectiveness of vancomycin and other antibacterial drugs, vancomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:d218e594-c816-4ae7-8f61-3987bb8646f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2668 biolink:treats MONDO:0021661 PMID:41385096 "[{""id"":""uuid:6415cbb1-46a5-4c54-bcf3-eb62dfbd4f12"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6399e1be-a7f8-496a-ae70-b6cf78cb26b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NORVASC is a calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of: Hypertension ( 1.1 ) Coronary Artery Disease ( 1.2 ) Chronic Stable Angina Vasospastic Angina (Prinzmetal's or Variant Angina) Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction < 40% uuid:30f93dc3-42e9-48a8-be21-2235008df1d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:H3753190JS biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:734e5f1a-24f8-4cf5-95dd-5b4a482eff93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ba8655c4-7cf9-411e-beca-ae25a1f7133a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Moexipril hydrochloride is indicated for treatment of patients with hypertension. It may be used alone or in combination with thiazide diuretics. In using moexipril hydrochloride, consideration should be given to the fact that another ACE inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that moexipril hydrochloride does not have a similar risk (see WARNINGS ). In considering use of moexipril hydrochloride, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see WARNINGS , Angioedema ). uuid:7bcee82c-cab4-497e-9b46-5b8cac92af4b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:H3753190JS biolink:treats MONDO:0001609 PMID:41385096 "[{""id"":""uuid:df65b58f-65a7-4d5b-8954-cadb9ce05803"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a9b32aea-2a1d-4aa5-85c1-8cd9dc927173"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Moexipril hydrochloride is indicated for treatment of patients with hypertension. It may be used alone or in combination with thiazide diuretics. In using moexipril hydrochloride, consideration should be given to the fact that another ACE inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that moexipril hydrochloride does not have a similar risk (see WARNINGS ). In considering use of moexipril hydrochloride, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see WARNINGS , Angioedema ). uuid:22b53ff9-9356-402b-bb54-bd05a3f23250 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:H3753190JS biolink:treats MONDO:0001343 PMID:41385096 "[{""id"":""uuid:c4b39b18-8a26-475b-a46e-2ee8b77e6041"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:918b6be2-3286-4c75-8007-95a1296a4397"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Moexipril hydrochloride is indicated for treatment of patients with hypertension. It may be used alone or in combination with thiazide diuretics. In using moexipril hydrochloride, consideration should be given to the fact that another ACE inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that moexipril hydrochloride does not have a similar risk (see WARNINGS ). In considering use of moexipril hydrochloride, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see WARNINGS , Angioedema ). uuid:2f496be6-bcaa-4df4-b292-8f63df51b357 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:H3753190JS biolink:treats MONDO:0010481 PMID:41385096 "[{""id"":""uuid:b9f46a82-5591-4157-818c-3e2201c99e25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:04c3f507-794f-40cf-b5fc-55db42bac099"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Moexipril hydrochloride is indicated for treatment of patients with hypertension. It may be used alone or in combination with thiazide diuretics. In using moexipril hydrochloride, consideration should be given to the fact that another ACE inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that moexipril hydrochloride does not have a similar risk (see WARNINGS ). In considering use of moexipril hydrochloride, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see WARNINGS , Angioedema ). uuid:c9390635-bb66-4a73-890b-88af5d43e554 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2639 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:b5fc34ad-eb83-4ffe-a54d-acc91b3fbf69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ea56b103-8972-4266-8c95-b83c4710564f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amiloride HCl is indicated as adjunctive treatment with thiazide diuretics or other kaliuretic-diuretic agents in congestive heart failure or hypertension to: help restore normal serum potassium levels in patients who develop hypokalemia on the kaliuretic diuretic prevent development of hypokalemia in patients who would be exposed to particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias. The use of potassium-conserving agents is often unnecessary in patients receiving diuretics for uncomplicated essential hypertension when such patients have a normal diet. Amiloride HCl has little additive diuretic or antihypertensive effect when added to a thiazide diuretic. Amiloride HCl should rarely be used alone. It has weak (compared with thiazides) diuretic and antihypertensive effects. Used as single agents, potassium sparing diuretics, including amiloride HCl, result in an increased risk of hyperkalemia (approximately 10% with amiloride). Amiloride HCl should be used alone only when persistent hypokalemia has been documented and only with careful titration of the dose and close monitoring of serum electrolytes. uuid:b9a299b0-580d-4269-b4d9-3b6a5715ee67 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2639 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:e0d08c68-ab4e-49a3-aa3b-731b0e326d36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b6a89ace-225a-4a77-a1a2-b3bf9454622a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amiloride HCl is indicated as adjunctive treatment with thiazide diuretics or other kaliuretic-diuretic agents in congestive heart failure or hypertension to: help restore normal serum potassium levels in patients who develop hypokalemia on the kaliuretic diuretic prevent development of hypokalemia in patients who would be exposed to particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias. The use of potassium-conserving agents is often unnecessary in patients receiving diuretics for uncomplicated essential hypertension when such patients have a normal diet. Amiloride HCl has little additive diuretic or antihypertensive effect when added to a thiazide diuretic. Amiloride HCl should rarely be used alone. It has weak (compared with thiazides) diuretic and antihypertensive effects. Used as single agents, potassium sparing diuretics, including amiloride HCl, result in an increased risk of hyperkalemia (approximately 10% with amiloride). Amiloride HCl should be used alone only when persistent hypokalemia has been documented and only with careful titration of the dose and close monitoring of serum electrolytes. uuid:40376e12-37f7-4ef7-881f-78beadecf0a2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2639 biolink:treats MONDO:0003019 PMID:41385096 "[{""id"":""uuid:3e455ea5-15fb-4b2b-86e6-473554f2889d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4c81d621-6f7a-4f69-95db-fac5346cfaf0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amiloride HCl is indicated as adjunctive treatment with thiazide diuretics or other kaliuretic-diuretic agents in congestive heart failure or hypertension to: help restore normal serum potassium levels in patients who develop hypokalemia on the kaliuretic diuretic prevent development of hypokalemia in patients who would be exposed to particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias. The use of potassium-conserving agents is often unnecessary in patients receiving diuretics for uncomplicated essential hypertension when such patients have a normal diet. Amiloride HCl has little additive diuretic or antihypertensive effect when added to a thiazide diuretic. Amiloride HCl should rarely be used alone. It has weak (compared with thiazides) diuretic and antihypertensive effects. Used as single agents, potassium sparing diuretics, including amiloride HCl, result in an increased risk of hyperkalemia (approximately 10% with amiloride). Amiloride HCl should be used alone only when persistent hypokalemia has been documented and only with careful titration of the dose and close monitoring of serum electrolytes. uuid:29aff12e-3961-48b3-90b6-2364e268e4b5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2639 biolink:treats MONDO:0007263 PMID:41385096 "[{""id"":""uuid:76fb2523-b062-4490-b004-7fff3908097a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1a2649ee-0486-460f-9783-b3f632dab206"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amiloride HCl is indicated as adjunctive treatment with thiazide diuretics or other kaliuretic-diuretic agents in congestive heart failure or hypertension to: help restore normal serum potassium levels in patients who develop hypokalemia on the kaliuretic diuretic prevent development of hypokalemia in patients who would be exposed to particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias. The use of potassium-conserving agents is often unnecessary in patients receiving diuretics for uncomplicated essential hypertension when such patients have a normal diet. Amiloride HCl has little additive diuretic or antihypertensive effect when added to a thiazide diuretic. Amiloride HCl should rarely be used alone. It has weak (compared with thiazides) diuretic and antihypertensive effects. Used as single agents, potassium sparing diuretics, including amiloride HCl, result in an increased risk of hyperkalemia (approximately 10% with amiloride). Amiloride HCl should be used alone only when persistent hypokalemia has been documented and only with careful titration of the dose and close monitoring of serum electrolytes. uuid:6bad09f3-ebb8-43a4-8c05-744b7f7435ee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2639 biolink:treats MONDO:0001134 PMID:41385096 "[{""id"":""uuid:b508078a-da1a-4fd5-88cc-66a5fdf2dec7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:40fe8149-2a79-4e87-ba7f-0dcf73dc752b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amiloride HCl is indicated as adjunctive treatment with thiazide diuretics or other kaliuretic-diuretic agents in congestive heart failure or hypertension to: help restore normal serum potassium levels in patients who develop hypokalemia on the kaliuretic diuretic prevent development of hypokalemia in patients who would be exposed to particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias. The use of potassium-conserving agents is often unnecessary in patients receiving diuretics for uncomplicated essential hypertension when such patients have a normal diet. Amiloride HCl has little additive diuretic or antihypertensive effect when added to a thiazide diuretic. Amiloride HCl should rarely be used alone. It has weak (compared with thiazides) diuretic and antihypertensive effects. Used as single agents, potassium sparing diuretics, including amiloride HCl, result in an increased risk of hyperkalemia (approximately 10% with amiloride). Amiloride HCl should be used alone only when persistent hypokalemia has been documented and only with careful titration of the dose and close monitoring of serum electrolytes. uuid:2154083d-23de-4db4-b2b4-87d93b9048e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2639 biolink:treats HP:0002153 PMID:41385096 "[{""id"":""uuid:86f0de87-7e8b-405b-a3c5-3ade0ab03a0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9870ed36-8e89-444e-ba59-fbef3af3046e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amiloride HCl is indicated as adjunctive treatment with thiazide diuretics or other kaliuretic-diuretic agents in congestive heart failure or hypertension to: help restore normal serum potassium levels in patients who develop hypokalemia on the kaliuretic diuretic prevent development of hypokalemia in patients who would be exposed to particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias. The use of potassium-conserving agents is often unnecessary in patients receiving diuretics for uncomplicated essential hypertension when such patients have a normal diet. Amiloride HCl has little additive diuretic or antihypertensive effect when added to a thiazide diuretic. Amiloride HCl should rarely be used alone. It has weak (compared with thiazides) diuretic and antihypertensive effects. Used as single agents, potassium sparing diuretics, including amiloride HCl, result in an increased risk of hyperkalemia (approximately 10% with amiloride). Amiloride HCl should be used alone only when persistent hypokalemia has been documented and only with careful titration of the dose and close monitoring of serum electrolytes. uuid:7628b15e-1bd2-46b1-8cfb-424e278bf7d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6970 biolink:treats MONDO:0011786 PMID:41385096 "[{""id"":""uuid:79e865e0-c435-4068-a3e0-6408b5688194"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:228fb87b-7150-44c7-b686-d436192faf75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:847a31f0-c7a3-4a11-bf1a-fe8ec1eeaaa4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NASONEX is a corticosteroid indicated for: Treatment of Nasal Symptoms of Allergic Rhinitis in patients ≥2 years of age ( 1.1 ) Treatment of Nasal Congestion Associated with Seasonal Allergic Rhinitis in patients ≥2 years of age ( 1.2 ) Prophylaxis of Seasonal Allergic Rhinitis in patients ≥12 years of age ( 1.3 ) Treatment of Nasal Polyps in patients ≥18 years of age ( 1.4 )|[PMDA] Drugs containing a new active ingredient indicated for the treatment of allergic rhinitis. uuid:0d2f941e-4e90-4c13-af2f-e5bfee1e38e1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6970 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:15ae2d29-b569-4866-8e92-218e09bfd439"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e926dd64-c83f-49ef-95ae-75d0ce5d7444"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NASONEX is a corticosteroid indicated for: Treatment of Nasal Symptoms of Allergic Rhinitis in patients ≥2 years of age ( 1.1 ) Treatment of Nasal Congestion Associated with Seasonal Allergic Rhinitis in patients ≥2 years of age ( 1.2 ) Prophylaxis of Seasonal Allergic Rhinitis in patients ≥12 years of age ( 1.3 ) Treatment of Nasal Polyps in patients ≥18 years of age ( 1.4 ) uuid:aed0b245-b756-4ba4-91f8-33068ceb4f4b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6970 biolink:treats MONDO:0006314 PMID:41385096 "[{""id"":""uuid:444c7e62-7581-40e2-a5c2-d4370f2fd9b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:be61bb39-b0af-4ad5-bbb9-eb9cc71979d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NASONEX is a corticosteroid indicated for: Treatment of Nasal Symptoms of Allergic Rhinitis in patients ≥2 years of age ( 1.1 ) Treatment of Nasal Congestion Associated with Seasonal Allergic Rhinitis in patients ≥2 years of age ( 1.2 ) Prophylaxis of Seasonal Allergic Rhinitis in patients ≥12 years of age ( 1.3 ) Treatment of Nasal Polyps in patients ≥18 years of age ( 1.4 ) uuid:b14a7228-6be4-4cb0-a419-81633cebf9ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats MONDO:0600005 PMID:41385096 "[{""id"":""uuid:d195548e-28ed-4130-b48c-8c28522c1c1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ef57044a-3976-49b8-afad-4c0d18087a82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Epinephrine auto-injector is indicated in the emergency treatment of severe allergic reactions (Type I) including anaphylaxis to stinging insects (e.g. order Hymenoptera, which includes bees, wasps, hornets, yellow jackets and fire ants), and biting insects (e.g. triatoma, mosquitos), allergen immunotherapy, foods, drugs, diagnostic testing substances (e.g. radiocontrast media), and other allergens, as well as anaphylaxis to unknown substances (idiopathic anaphylaxis) or exercise-induced anaphylaxis. Epinephrine auto-injector is intended for immediate administration in patients with a history of anaphylactic reactions. Selection of the appropriate dosage strength is determined according to patient body weight (See DOSAGE AND ADMINISTRATION section). Such reactions may occur within minutes after exposure and consist of flushing, apprehension, syncope, tachycardia, thready or unobtainable pulse associated with a fall in blood pressure, convulsions, vomiting, diarrhea and abdominal cramps, involuntary voiding, wheezing, dyspnea due to laryngeal spasm, pruritus, rashes, urticaria, or angioedema. Epinephrine auto-injector is designed as emergency supportive therapy only and is not a replacement or substitute for immediate medical care. uuid:1984dd87-0fa8-43eb-bcaf-b499f9ae141d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats HP:0500096 PMID:41385096 "[{""id"":""uuid:3b8ba13d-2c82-4d40-9e56-21bd3c778450"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4615b624-46ab-473b-9bc5-e2a1c260a2f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Epinephrine auto-injector is indicated in the emergency treatment of severe allergic reactions (Type I) including anaphylaxis to stinging insects (e.g. order Hymenoptera, which includes bees, wasps, hornets, yellow jackets and fire ants), and biting insects (e.g. triatoma, mosquitos), allergen immunotherapy, foods, drugs, diagnostic testing substances (e.g. radiocontrast media), and other allergens, as well as anaphylaxis to unknown substances (idiopathic anaphylaxis) or exercise-induced anaphylaxis. Epinephrine auto-injector is intended for immediate administration in patients with a history of anaphylactic reactions. Selection of the appropriate dosage strength is determined according to patient body weight (See DOSAGE AND ADMINISTRATION section). Such reactions may occur within minutes after exposure and consist of flushing, apprehension, syncope, tachycardia, thready or unobtainable pulse associated with a fall in blood pressure, convulsions, vomiting, diarrhea and abdominal cramps, involuntary voiding, wheezing, dyspnea due to laryngeal spasm, pruritus, rashes, urticaria, or angioedema. Epinephrine auto-injector is designed as emergency supportive therapy only and is not a replacement or substitute for immediate medical care. uuid:ebb1b8f1-25d3-47a4-b27d-352635464b15 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats HP:0500095 PMID:41385096 "[{""id"":""uuid:cec078f2-b54e-4bb4-8b3e-9b03ea4b6fed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:19ef9aac-aeb0-463b-850c-7df66f9a8355"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Epinephrine auto-injector is indicated in the emergency treatment of severe allergic reactions (Type I) including anaphylaxis to stinging insects (e.g. order Hymenoptera, which includes bees, wasps, hornets, yellow jackets and fire ants), and biting insects (e.g. triatoma, mosquitos), allergen immunotherapy, foods, drugs, diagnostic testing substances (e.g. radiocontrast media), and other allergens, as well as anaphylaxis to unknown substances (idiopathic anaphylaxis) or exercise-induced anaphylaxis. Epinephrine auto-injector is intended for immediate administration in patients with a history of anaphylactic reactions. Selection of the appropriate dosage strength is determined according to patient body weight (See DOSAGE AND ADMINISTRATION section). Such reactions may occur within minutes after exposure and consist of flushing, apprehension, syncope, tachycardia, thready or unobtainable pulse associated with a fall in blood pressure, convulsions, vomiting, diarrhea and abdominal cramps, involuntary voiding, wheezing, dyspnea due to laryngeal spasm, pruritus, rashes, urticaria, or angioedema. Epinephrine auto-injector is designed as emergency supportive therapy only and is not a replacement or substitute for immediate medical care. uuid:85ce5743-ae9a-49b4-bdda-97e5e6fb6b28 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats HP:0410149 PMID:41385096 "[{""id"":""uuid:09f5e3f9-148b-487e-aa8a-58c4756595bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:22999382-8470-4f24-809a-220a9998acc1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Epinephrine auto-injector is indicated in the emergency treatment of severe allergic reactions (Type I) including anaphylaxis to stinging insects (e.g. order Hymenoptera, which includes bees, wasps, hornets, yellow jackets and fire ants), and biting insects (e.g. triatoma, mosquitos), allergen immunotherapy, foods, drugs, diagnostic testing substances (e.g. radiocontrast media), and other allergens, as well as anaphylaxis to unknown substances (idiopathic anaphylaxis) or exercise-induced anaphylaxis. Epinephrine auto-injector is intended for immediate administration in patients with a history of anaphylactic reactions. Selection of the appropriate dosage strength is determined according to patient body weight (See DOSAGE AND ADMINISTRATION section). Such reactions may occur within minutes after exposure and consist of flushing, apprehension, syncope, tachycardia, thready or unobtainable pulse associated with a fall in blood pressure, convulsions, vomiting, diarrhea and abdominal cramps, involuntary voiding, wheezing, dyspnea due to laryngeal spasm, pruritus, rashes, urticaria, or angioedema. Epinephrine auto-injector is designed as emergency supportive therapy only and is not a replacement or substitute for immediate medical care. uuid:178ddcfa-5d6a-47bd-be2d-e54bbc9da5b5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats MONDO:0100053 PMID:41385096 "[{""id"":""uuid:2ce2370d-1a57-4be8-bb95-48028c9113e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ce2ad931-de1f-4897-bb15-41ef820dc043"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d58bc75f-6a3f-44c1-9f0a-e7c8a48860c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Epinephrine auto-injector is indicated in the emergency treatment of severe allergic reactions (Type I) including anaphylaxis to stinging insects (e.g. order Hymenoptera, which includes bees, wasps, hornets, yellow jackets and fire ants), and biting insects (e.g. triatoma, mosquitos), allergen immunotherapy, foods, drugs, diagnostic testing substances (e.g. radiocontrast media), and other allergens, as well as anaphylaxis to unknown substances (idiopathic anaphylaxis) or exercise-induced anaphylaxis. Epinephrine auto-injector is intended for immediate administration in patients with a history of anaphylactic reactions. Selection of the appropriate dosage strength is determined according to patient body weight (See DOSAGE AND ADMINISTRATION section). Such reactions may occur within minutes after exposure and consist of flushing, apprehension, syncope, tachycardia, thready or unobtainable pulse associated with a fall in blood pressure, convulsions, vomiting, diarrhea and abdominal cramps, involuntary voiding, wheezing, dyspnea due to laryngeal spasm, pruritus, rashes, urticaria, or angioedema. Epinephrine auto-injector is designed as emergency supportive therapy only and is not a replacement or substitute for immediate medical care.|[PMDA] Addition of its pediatric application and indications for adjunctive therapy for anaphylactic reaction induced by food, drug and others. uuid:7f4608d6-4746-4c48-959d-65965935f311 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats MONDO:0100054 PMID:41385096 "[{""id"":""uuid:73635204-2468-4d61-9473-a70b05a79947"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f920c7ae-d2b2-4afa-97ab-3773ca857237"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Epinephrine auto-injector is indicated in the emergency treatment of severe allergic reactions (Type I) including anaphylaxis to stinging insects (e.g. order Hymenoptera, which includes bees, wasps, hornets, yellow jackets and fire ants), and biting insects (e.g. triatoma, mosquitos), allergen immunotherapy, foods, drugs, diagnostic testing substances (e.g. radiocontrast media), and other allergens, as well as anaphylaxis to unknown substances (idiopathic anaphylaxis) or exercise-induced anaphylaxis. Epinephrine auto-injector is intended for immediate administration in patients with a history of anaphylactic reactions. Selection of the appropriate dosage strength is determined according to patient body weight (See DOSAGE AND ADMINISTRATION section). Such reactions may occur within minutes after exposure and consist of flushing, apprehension, syncope, tachycardia, thready or unobtainable pulse associated with a fall in blood pressure, convulsions, vomiting, diarrhea and abdominal cramps, involuntary voiding, wheezing, dyspnea due to laryngeal spasm, pruritus, rashes, urticaria, or angioedema. Epinephrine auto-injector is designed as emergency supportive therapy only and is not a replacement or substitute for immediate medical care. uuid:f0ff5616-3968-46b8-84d9-ecefd5f545e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats MONDO:0100056 PMID:41385096 "[{""id"":""uuid:3da68187-a042-45ea-8684-d98010049b57"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1a4ff69a-d13b-4728-b4bf-430c4dc85eaf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Epinephrine auto-injector is indicated in the emergency treatment of severe allergic reactions (Type I) including anaphylaxis to stinging insects (e.g. order Hymenoptera, which includes bees, wasps, hornets, yellow jackets and fire ants), and biting insects (e.g. triatoma, mosquitos), allergen immunotherapy, foods, drugs, diagnostic testing substances (e.g. radiocontrast media), and other allergens, as well as anaphylaxis to unknown substances (idiopathic anaphylaxis) or exercise-induced anaphylaxis. Epinephrine auto-injector is intended for immediate administration in patients with a history of anaphylactic reactions. Selection of the appropriate dosage strength is determined according to patient body weight (See DOSAGE AND ADMINISTRATION section). Such reactions may occur within minutes after exposure and consist of flushing, apprehension, syncope, tachycardia, thready or unobtainable pulse associated with a fall in blood pressure, convulsions, vomiting, diarrhea and abdominal cramps, involuntary voiding, wheezing, dyspnea due to laryngeal spasm, pruritus, rashes, urticaria, or angioedema. Epinephrine auto-injector is designed as emergency supportive therapy only and is not a replacement or substitute for immediate medical care. uuid:bd6cc656-8af8-46e9-a6bd-223a4d9dce8e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7459 biolink:treats MONDO:0043775 PMID:41385096 "[{""id"":""uuid:c9cd5d4d-a2bb-463e-b79b-99d6fc8ff6e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:457a4a3f-2073-40fa-a526-20b18fd649a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Naloxone Hydrochloride Injection is indicated for the complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids including propoxyphene, methadone, and certain mixed agonist-antagonist analgesics: nalbuphine, pentazocine, butorphanol and cyclazocine. Naloxone hydrochloride is also indicated for the diagnosis of suspected or known acute opioid overdosage. Naloxone may be useful as an adjunctive agent to increase blood pressure in the management of septic shock (see CLINICAL PHARMACOLOGY, Adjunctive Use in Septic Shock ). uuid:3c80fa0f-1da9-4290-9598-736f89ce8b6f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7459 biolink:treats MONDO:0001881 PMID:41385096 "[{""id"":""uuid:a1c4d2d7-a044-4d1b-9520-7888d68ef812"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:de172ffd-aa01-43e5-ab1e-b2f8c57b6cbd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Naloxone Hydrochloride Injection is indicated for the complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids including propoxyphene, methadone, and certain mixed agonist-antagonist analgesics: nalbuphine, pentazocine, butorphanol and cyclazocine. Naloxone hydrochloride is also indicated for the diagnosis of suspected or known acute opioid overdosage. Naloxone may be useful as an adjunctive agent to increase blood pressure in the management of septic shock (see CLINICAL PHARMACOLOGY, Adjunctive Use in Septic Shock ). uuid:24494c64-fc33-4c68-a8fd-4bc3105e5fe4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3380 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:028662ee-1f29-46d3-8ebc-2332c0d7c255"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9260b4e1-2d1e-4824-b0fc-6a0324e3f248"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension : Captopril tablets USP are indicated for the treatment of hypertension. In using captopril, consideration should be given to the risk of neutropenia/ agranulocytosis (see WARNINGS ). Captopril may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. Captopril is effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of captopril and thiazides are approximately additive. Heart Failure : Captopril tablets are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. The beneficial effect of captopril in heart failure does not require the presence of digitalis, however, most controlled clinical trial experience with captopril has been in patients receiving digitalis, as well as diuretic treatment. Left Ventricular Dysfunction After Myocardial Infarction : Captopril tablets are indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction <40% and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patients. Diabetic Nephropathy : Captopril tablets are indicated for the treatment of diabetic nephropathy (proteinuria > 500 mg/day) in patients with type I insulin-dependent diabetes mellitus and retinopathy. Captopril tablets decreases the rate of progression of renal insufficiency and development of serious adverse clinical outcomes (death or need for renal transplantation or dialysis). In considering use of captopril tablets, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see WARNINGS : Angioedema ). uuid:f0aded01-ddc4-404e-870d-7ed2e0189649 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3380 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:a1d5791d-dc1f-40f8-b06c-b67db1fb50b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:75adc8ae-2adb-4ae8-b9a5-f541141d7176"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension : Captopril tablets USP are indicated for the treatment of hypertension. In using captopril, consideration should be given to the risk of neutropenia/ agranulocytosis (see WARNINGS ). Captopril may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. Captopril is effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of captopril and thiazides are approximately additive. Heart Failure : Captopril tablets are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. The beneficial effect of captopril in heart failure does not require the presence of digitalis, however, most controlled clinical trial experience with captopril has been in patients receiving digitalis, as well as diuretic treatment. Left Ventricular Dysfunction After Myocardial Infarction : Captopril tablets are indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction <40% and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patients. Diabetic Nephropathy : Captopril tablets are indicated for the treatment of diabetic nephropathy (proteinuria > 500 mg/day) in patients with type I insulin-dependent diabetes mellitus and retinopathy. Captopril tablets decreases the rate of progression of renal insufficiency and development of serious adverse clinical outcomes (death or need for renal transplantation or dialysis). In considering use of captopril tablets, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see WARNINGS : Angioedema ). uuid:1c80f377-1d85-4909-9b8a-d8715e0c33be biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3380 biolink:treats MONDO:0001106 PMID:41385096 "[{""id"":""uuid:14f7674d-acc5-488a-a0ff-bc7c85488a13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ab502721-d83c-42ed-af13-11e1eaccda8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension : Captopril tablets USP are indicated for the treatment of hypertension. In using captopril, consideration should be given to the risk of neutropenia/ agranulocytosis (see WARNINGS ). Captopril may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. Captopril is effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of captopril and thiazides are approximately additive. Heart Failure : Captopril tablets are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. The beneficial effect of captopril in heart failure does not require the presence of digitalis, however, most controlled clinical trial experience with captopril has been in patients receiving digitalis, as well as diuretic treatment. Left Ventricular Dysfunction After Myocardial Infarction : Captopril tablets are indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction <40% and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patients. Diabetic Nephropathy : Captopril tablets are indicated for the treatment of diabetic nephropathy (proteinuria > 500 mg/day) in patients with type I insulin-dependent diabetes mellitus and retinopathy. Captopril tablets decreases the rate of progression of renal insufficiency and development of serious adverse clinical outcomes (death or need for renal transplantation or dialysis). In considering use of captopril tablets, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see WARNINGS : Angioedema ). uuid:a8321c14-d9dd-4a65-a3e3-d22ca4a9173c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90972 biolink:treats MONDO:0007263 PMID:41385096 "[{""id"":""uuid:9cb19b2c-6538-44af-b99d-03841924539a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:28ab23fe-e792-4352-af70-ba5673e4ff6c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Glycopyrrolate Injection is indicated for use as a preoperative antimuscarinic to reduce salivary, tracheobronchial, and pharyngeal secretions; to reduce the volume and free acidity of gastric secretions; and to block cardiac vagal inhibitory reflexes during induction of anesthesia and intubation. When indicated, Glycopyrrolate Injection may be used intraoperatively to counteract surgically or drug-induced or vagal reflexes associated arrhythmias. Glycopyrrolate protects against the peripheral muscarinic effects (e.g., bradycardia and excessive secretions) of cholinergic agents such as neostigmine and pyridostigmine given to reverse the neuromuscular blockade due to non-depolarizing muscle relaxants. uuid:78b98014-32cc-47b8-8681-20565826f16f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats EFO:0020918 PMID:41385096 "[{""id"":""uuid:1227a3ab-8b5e-4a01-b6f1-95989e44f7dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:20e93a53-db00-4d51-9ed3-34497af2f1da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Epinephrine Injection, USP is indicated for intravenous injection in (1) treatment of acute hypersensitivity (anaphylactoid reactions to drugs, animal serums and other allergens), (2) treatment of acute asthmatic attacks to relieve bronchospasm not controlled by inhalation or subcutaneous administration of other solutions of the drug and (3) treatment and prophylaxis of cardiac arrest and attacks of transitory atrioventricular (A-V) heart block with syncopal seizures (Stokes-Adams Syndrome). In acute attacks of ventricular standstill, physical measures should be applied first. When external cardiac compression and attempts to restore the circulation by electrical defibrillation or use of a pacemaker fail, intracardiac puncture and intramyocardial injection of epinephrine may be effective. uuid:40c8e1a8-0d4a-4981-bbf5-5d467d44c649 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats MONDO:0004766 PMID:41385096 "[{""id"":""uuid:52316d08-b6ad-4cf1-9f9f-e1876a5937f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ad55ff1f-bd3d-4990-8081-fef63388be9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Epinephrine Injection, USP is indicated for intravenous injection in (1) treatment of acute hypersensitivity (anaphylactoid reactions to drugs, animal serums and other allergens), (2) treatment of acute asthmatic attacks to relieve bronchospasm not controlled by inhalation or subcutaneous administration of other solutions of the drug and (3) treatment and prophylaxis of cardiac arrest and attacks of transitory atrioventricular (A-V) heart block with syncopal seizures (Stokes-Adams Syndrome). In acute attacks of ventricular standstill, physical measures should be applied first. When external cardiac compression and attempts to restore the circulation by electrical defibrillation or use of a pacemaker fail, intracardiac puncture and intramyocardial injection of epinephrine may be effective. uuid:1ebd864a-f64c-4cb6-96dd-61e45a215bf9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats MONDO:0000745 PMID:41385096 "[{""id"":""uuid:ca6ddf5d-6975-4556-97fc-e6d2577f2e1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d88e13d5-ac64-4295-bb52-4db7e7bdb11e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Epinephrine Injection, USP is indicated for intravenous injection in (1) treatment of acute hypersensitivity (anaphylactoid reactions to drugs, animal serums and other allergens), (2) treatment of acute asthmatic attacks to relieve bronchospasm not controlled by inhalation or subcutaneous administration of other solutions of the drug and (3) treatment and prophylaxis of cardiac arrest and attacks of transitory atrioventricular (A-V) heart block with syncopal seizures (Stokes-Adams Syndrome). In acute attacks of ventricular standstill, physical measures should be applied first. When external cardiac compression and attempts to restore the circulation by electrical defibrillation or use of a pacemaker fail, intracardiac puncture and intramyocardial injection of epinephrine may be effective. uuid:497427e6-7b5c-47c7-9586-977f24821eeb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats MONDO:0000465 PMID:41385096 "[{""id"":""uuid:f622874b-68da-47e3-8e5c-79f4ac6c1d0f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:673c2219-efba-4633-9f87-60be1d36fd93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Epinephrine Injection, USP is indicated for intravenous injection in (1) treatment of acute hypersensitivity (anaphylactoid reactions to drugs, animal serums and other allergens), (2) treatment of acute asthmatic attacks to relieve bronchospasm not controlled by inhalation or subcutaneous administration of other solutions of the drug and (3) treatment and prophylaxis of cardiac arrest and attacks of transitory atrioventricular (A-V) heart block with syncopal seizures (Stokes-Adams Syndrome). In acute attacks of ventricular standstill, physical measures should be applied first. When external cardiac compression and attempts to restore the circulation by electrical defibrillation or use of a pacemaker fail, intracardiac puncture and intramyocardial injection of epinephrine may be effective. uuid:d62f3b68-6ab4-4235-a556-9a8f3c473fc9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats UMLS:C4285916 PMID:41385096 "[{""id"":""uuid:06c030ca-dca7-4f77-804a-315283625ecc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e5ef3bf0-2b4a-4330-ad38-1f2c65d873aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Epinephrine Injection, USP is indicated for intravenous injection in (1) treatment of acute hypersensitivity (anaphylactoid reactions to drugs, animal serums and other allergens), (2) treatment of acute asthmatic attacks to relieve bronchospasm not controlled by inhalation or subcutaneous administration of other solutions of the drug and (3) treatment and prophylaxis of cardiac arrest and attacks of transitory atrioventricular (A-V) heart block with syncopal seizures (Stokes-Adams Syndrome). In acute attacks of ventricular standstill, physical measures should be applied first. When external cardiac compression and attempts to restore the circulation by electrical defibrillation or use of a pacemaker fail, intracardiac puncture and intramyocardial injection of epinephrine may be effective. uuid:b15a2372-fcef-4383-b22d-45a493559943 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6539 biolink:treats UMLS:C0086132 PMID:41385096 "[{""id"":""uuid:302ad1f7-c54f-4751-abb4-dd9649de0559"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2d9f9b30-ca66-416a-a8be-e4302b5be100"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lorazepam is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety associated with depressive symptoms. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The effectiveness of lorazepam in long-term use, that is more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. uuid:1c484175-e009-4e54-aa33-4cf2f51279f0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2675 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:b7310ecc-97ba-4126-a00f-991b0b6151b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d9cb5873-5777-4188-a7ec-e53d322ab025"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amoxapine is indicated for the relief of symptoms of depression in patients with neurotic or reactive depressive disorders as well as endogenous and psychotic depressions. It is indicated for depression accompanied by anxiety or agitation. uuid:f783246c-e6c5-4315-81af-a39bf724c36d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2675 biolink:treats MONDO:0024614 PMID:41385096 "[{""id"":""uuid:7c4134a3-e24d-4fe5-90b7-f66c65053897"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8e90a432-df6d-4e41-8cd5-651c2559df0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amoxapine is indicated for the relief of symptoms of depression in patients with neurotic or reactive depressive disorders as well as endogenous and psychotic depressions. It is indicated for depression accompanied by anxiety or agitation. uuid:bdccec8b-ebda-4505-a61b-40c9d0d9ed61 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2675 biolink:treats MONDO:0003265 PMID:41385096 "[{""id"":""uuid:5c1ddc76-c7e0-4673-9543-5ad929dc8682"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4b1d8606-65fa-4022-9e72-f012079e68b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amoxapine is indicated for the relief of symptoms of depression in patients with neurotic or reactive depressive disorders as well as endogenous and psychotic depressions. It is indicated for depression accompanied by anxiety or agitation. uuid:e9be104f-5229-4db1-9cfc-9695a9df71ae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2675 biolink:treats MONDO:0012048 PMID:41385096 "[{""id"":""uuid:b2954730-6a48-40a3-b15c-f6e9c09a1b1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4ac438f4-e91b-40fb-aeb2-85e5966e1fa5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amoxapine is indicated for the relief of symptoms of depression in patients with neurotic or reactive depressive disorders as well as endogenous and psychotic depressions. It is indicated for depression accompanied by anxiety or agitation. uuid:5a8af924-121e-47e2-82ab-4cb7ff764ce7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2675 biolink:treats UMLS:C0743072 PMID:41385096 "[{""id"":""uuid:edb3b757-0239-46c2-87df-6231aa29e0fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1a4f78e3-1482-46b2-b3b7-61e040bdedd1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amoxapine is indicated for the relief of symptoms of depression in patients with neurotic or reactive depressive disorders as well as endogenous and psychotic depressions. It is indicated for depression accompanied by anxiety or agitation. uuid:473e2e4e-003d-4b19-a71a-ea06904664e9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2675 biolink:treats MONDO:0041086 PMID:41385096 "[{""id"":""uuid:88f16532-4db7-4d30-ade6-713bcc587477"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:20943ee0-f2a7-4700-9619-ef6da1918c45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amoxapine is indicated for the relief of symptoms of depression in patients with neurotic or reactive depressive disorders as well as endogenous and psychotic depressions. It is indicated for depression accompanied by anxiety or agitation. uuid:38b1b2d2-4319-40a6-8520-13c7f097eff0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2675 biolink:treats UMLS:C0235136 PMID:41385096 "[{""id"":""uuid:024ad519-a337-4922-add7-46b155d2e1ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4ca44f82-cda5-4272-998a-3fdb492ac83d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amoxapine is indicated for the relief of symptoms of depression in patients with neurotic or reactive depressive disorders as well as endogenous and psychotic depressions. It is indicated for depression accompanied by anxiety or agitation. uuid:4eb2e60e-cca8-446e-aca3-f9964ad83c05 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5001 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:46611a14-bee9-4205-a8c6-7a76ca5ae094"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bc6568fd-bb62-4d03-9890-f76553b1e185"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ef712153-ef89-4e36-95f1-bd262b2c2260"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fenoglide is a peroxisome proliferator receptor alpha (PPARα) activator indicated: as an adjunct to diet to reduce elevated LDL-C, Total-C, TG, and Apo B, and to increase HDL-C in patients with primary hyperlipidemia or mixed dyslipidemia when response to diet and non-pharmacological interventions alone has been inadequate. ( 1.1 ) as an adjunct to diet to treat patients with hypertriglyceridemia. Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually obviate the need for pharmacologic intervention. ( 1.2 ) Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in a large, randomized controlled trial of patients with type 2 diabetes mellitus. ( 1.3 )|[PMDA] Pulverization enables a reduction in the dosage to two thirds of the current dosage for hyperlipidemia (including familial hyperlipidemia). uuid:71540e35-11e6-4e28-a7a0-aa466b8c1571 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5001 biolink:treats MONDO:0005347 PMID:41385096 "[{""id"":""uuid:0a4ba464-2112-4c0a-82c9-d429964780fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7e3f3756-81f9-4330-9ac3-932a9a384897"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fenoglide is a peroxisome proliferator receptor alpha (PPARα) activator indicated: as an adjunct to diet to reduce elevated LDL-C, Total-C, TG, and Apo B, and to increase HDL-C in patients with primary hyperlipidemia or mixed dyslipidemia when response to diet and non-pharmacological interventions alone has been inadequate. ( 1.1 ) as an adjunct to diet to treat patients with hypertriglyceridemia. Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually obviate the need for pharmacologic intervention. ( 1.2 ) Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in a large, randomized controlled trial of patients with type 2 diabetes mellitus. ( 1.3 ) uuid:9d75ceba-0ac6-4634-b576-de4c1f65d3da biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5001 biolink:treats MONDO:0018637 PMID:41385096 "[{""id"":""uuid:5996bd66-c639-4b96-ba91-c53ff9fc13cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7f204902-90c1-4947-8ff4-06d6d1c49dd6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fenoglide is a peroxisome proliferator receptor alpha (PPARα) activator indicated: as an adjunct to diet to reduce elevated LDL-C, Total-C, TG, and Apo B, and to increase HDL-C in patients with primary hyperlipidemia or mixed dyslipidemia when response to diet and non-pharmacological interventions alone has been inadequate. ( 1.1 ) as an adjunct to diet to treat patients with hypertriglyceridemia. Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually obviate the need for pharmacologic intervention. ( 1.2 ) Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in a large, randomized controlled trial of patients with type 2 diabetes mellitus. ( 1.3 ) uuid:e57e646b-ed53-4c86-aaa4-c532a3e936fa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5001 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:cb07b991-4d5a-4d7e-87f8-44cf558b287f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ca3351cc-af64-4520-b791-132fec5924cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fenoglide is a peroxisome proliferator receptor alpha (PPARα) activator indicated: as an adjunct to diet to reduce elevated LDL-C, Total-C, TG, and Apo B, and to increase HDL-C in patients with primary hyperlipidemia or mixed dyslipidemia when response to diet and non-pharmacological interventions alone has been inadequate. ( 1.1 ) as an adjunct to diet to treat patients with hypertriglyceridemia. Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually obviate the need for pharmacologic intervention. ( 1.2 ) Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in a large, randomized controlled trial of patients with type 2 diabetes mellitus. ( 1.3 ) uuid:6be29a54-ebc9-435c-b8ca-549e06a32587 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:204734 biolink:treats MONDO:0005093 PMID:41385096 "[{""id"":""uuid:bf1c728d-e781-4849-b1de-e5097ef777d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:295b081b-baf7-4a96-8257-6a6373185fb2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Desonide cream and ointment are low to medium potency corticosteroids indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. uuid:5cf194ac-7a5a-447b-8dae-3bc4cae96cce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats UMLS:C1720797 PMID:41385096 "[{""id"":""uuid:a32eeeb0-4b74-40e7-8e6a-b3ecabfa9cfe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7ac0dfb4-bce2-4530-b11d-695ead7ce629"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciprofloxacin tablets are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions and patient populations listed below. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Adult Patients Urinary Tract Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, Proteus mirabilis, Providencia rettgeri, Morganella morganii, Citrobacter diversus, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus epidermidis, Staphylococcus saprophyticus, or Enterococcus faecalis. Acute Uncomplicated Cystitis in females caused by Escherichia coli or Staphylococcus saprophyticus. Chronic Bacterial Prostatitis caused by Escherichia coli or Proteus mirabilis. Lower Respiratory Tract Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Pseudomonas aeruginosa, Haemophilus influenzae, Haemophilus parainfluenzae, or penicillin-susceptible Streptococcus pneumoniae. Also, Moraxella catarrhalis for the treatment of acute exacerbations of chronic bronchitis. NOTE: Although effective in clinical trials, ciprofloxacin is not a drug of first choice in the treatment of presumed or confirmed pneumonia secondary to Streptococcus pneumoniae. Acute Sinusitis caused by Haemophilus influenzae, penicillin-susceptible Streptococcus pneumoniae, or Moraxella catarrhalis. Skin and Skin Structure Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Morganella morganii, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible, Staphylococcus aureus, methicillin-susceptible Staphylococcus epidermidis, or Streptococcus pyogenes. Bone and Joint Infections caused by Enterobacter cloacae, Serratia marcescens, or Pseudomonas aeruginosa. Complicated Intra-Abdominal Infections (used in combination with metronidazole) caused by Escherichia coli, Pseudomonas aeruginosa, Proteus mirabilis, Klebsiella pneumoniae, or Bacteroides fragilis. Infectious Diarrhea caused by Escherichia coli (enterotoxigenic strains), Campylobacter jejuni, Shigella boydii 1 , Shigella dysenteriae, Shigella flexneri or Shigella sonnei 1 when antibacterial therapy is indicated. Typhoid Fever (Enteric Fever) caused by Salmonella typhi. NOTE: The efficacy of ciprofloxacin in the eradication of the chronic typhoid carrier state has not been demonstrated. Uncomplicated cervical and urethral gonorrhea due to Neisseria gonorrhoeae. 1 Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients. Pediatric Patients (1 to 17 years of age) Complicated Urinary Tract Infections and Pyelonephritis due to Escherichia coli. Ciprofloxacin is not a drug of first choice in the pediatric population due to an increased incidence of adverse events compared to controls, including events related to joints and/or surrounding tissues. (See WARNINGS , PRECAUTIONS, Pediatric Use , ADVERSE REACTIONS and CLINICAL STUDIES .) Ciprofloxacin, like other fluoroquinolones, is associated with arthropathy and histopathological changes in weight-bearing joints of juvenile animals. (See ANIMAL PHARMACOLOGY .) Adult and Pediatric Patients Inhalational anthrax (post-exposure): To reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. Ciprofloxacin serum concentrations achieved in humans served as a surrogate endpoint reasonably likely to predict clinical benefit and provided the initial basis for approval of this indication.5 Supportive clinical information for ciprofloxacin for anthrax post-exposure prophylaxis was obtained during the anthrax bioterror attacks of October 2001. (See also, INHALATIONAL ANTHRAX - ADDITIONAL INFORMATION ). If anaerobic organisms are suspected of contributing to the infection, appropriate therapy should be administered. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. Therapy with ciprofloxacin hydrochloride may be initiated before results of these tests are known; once results become available appropriate therapy should be continued. As with other drugs, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ciprofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ciprofloxacin tablets and other antibacterial drugs, ciprofloxacin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:78f34c14-6199-49d7-a500-0675f3712a1c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:560e4ca1-e313-417c-a949-82e465aaac2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:921d04ed-6134-4677-88c3-50d4dc79d521"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciprofloxacin tablets are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions and patient populations listed below. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Adult Patients Urinary Tract Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, Proteus mirabilis, Providencia rettgeri, Morganella morganii, Citrobacter diversus, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus epidermidis, Staphylococcus saprophyticus, or Enterococcus faecalis. Acute Uncomplicated Cystitis in females caused by Escherichia coli or Staphylococcus saprophyticus. Chronic Bacterial Prostatitis caused by Escherichia coli or Proteus mirabilis. Lower Respiratory Tract Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Pseudomonas aeruginosa, Haemophilus influenzae, Haemophilus parainfluenzae, or penicillin-susceptible Streptococcus pneumoniae. Also, Moraxella catarrhalis for the treatment of acute exacerbations of chronic bronchitis. NOTE: Although effective in clinical trials, ciprofloxacin is not a drug of first choice in the treatment of presumed or confirmed pneumonia secondary to Streptococcus pneumoniae. Acute Sinusitis caused by Haemophilus influenzae, penicillin-susceptible Streptococcus pneumoniae, or Moraxella catarrhalis. Skin and Skin Structure Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Morganella morganii, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible, Staphylococcus aureus, methicillin-susceptible Staphylococcus epidermidis, or Streptococcus pyogenes. Bone and Joint Infections caused by Enterobacter cloacae, Serratia marcescens, or Pseudomonas aeruginosa. Complicated Intra-Abdominal Infections (used in combination with metronidazole) caused by Escherichia coli, Pseudomonas aeruginosa, Proteus mirabilis, Klebsiella pneumoniae, or Bacteroides fragilis. Infectious Diarrhea caused by Escherichia coli (enterotoxigenic strains), Campylobacter jejuni, Shigella boydii 1 , Shigella dysenteriae, Shigella flexneri or Shigella sonnei 1 when antibacterial therapy is indicated. Typhoid Fever (Enteric Fever) caused by Salmonella typhi. NOTE: The efficacy of ciprofloxacin in the eradication of the chronic typhoid carrier state has not been demonstrated. Uncomplicated cervical and urethral gonorrhea due to Neisseria gonorrhoeae. 1 Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients. Pediatric Patients (1 to 17 years of age) Complicated Urinary Tract Infections and Pyelonephritis due to Escherichia coli. Ciprofloxacin is not a drug of first choice in the pediatric population due to an increased incidence of adverse events compared to controls, including events related to joints and/or surrounding tissues. (See WARNINGS , PRECAUTIONS, Pediatric Use , ADVERSE REACTIONS and CLINICAL STUDIES .) Ciprofloxacin, like other fluoroquinolones, is associated with arthropathy and histopathological changes in weight-bearing joints of juvenile animals. (See ANIMAL PHARMACOLOGY .) Adult and Pediatric Patients Inhalational anthrax (post-exposure): To reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. Ciprofloxacin serum concentrations achieved in humans served as a surrogate endpoint reasonably likely to predict clinical benefit and provided the initial basis for approval of this indication.5 Supportive clinical information for ciprofloxacin for anthrax post-exposure prophylaxis was obtained during the anthrax bioterror attacks of October 2001. (See also, INHALATIONAL ANTHRAX - ADDITIONAL INFORMATION ). If anaerobic organisms are suspected of contributing to the infection, appropriate therapy should be administered. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. Therapy with ciprofloxacin hydrochloride may be initiated before results of these tests are known; once results become available appropriate therapy should be continued. As with other drugs, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ciprofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ciprofloxacin tablets and other antibacterial drugs, ciprofloxacin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:9ce4715b-e1ed-4312-abcb-842e5055d3bd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats UMLS:C0853854 PMID:41385096 "[{""id"":""uuid:a60fe725-dcfb-41fd-ba89-d6f9f32f17eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c2d6565c-e39a-4b4a-9a9f-4b621742db9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciprofloxacin tablets are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions and patient populations listed below. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Adult Patients Urinary Tract Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, Proteus mirabilis, Providencia rettgeri, Morganella morganii, Citrobacter diversus, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus epidermidis, Staphylococcus saprophyticus, or Enterococcus faecalis. Acute Uncomplicated Cystitis in females caused by Escherichia coli or Staphylococcus saprophyticus. Chronic Bacterial Prostatitis caused by Escherichia coli or Proteus mirabilis. Lower Respiratory Tract Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Pseudomonas aeruginosa, Haemophilus influenzae, Haemophilus parainfluenzae, or penicillin-susceptible Streptococcus pneumoniae. Also, Moraxella catarrhalis for the treatment of acute exacerbations of chronic bronchitis. NOTE: Although effective in clinical trials, ciprofloxacin is not a drug of first choice in the treatment of presumed or confirmed pneumonia secondary to Streptococcus pneumoniae. Acute Sinusitis caused by Haemophilus influenzae, penicillin-susceptible Streptococcus pneumoniae, or Moraxella catarrhalis. Skin and Skin Structure Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Morganella morganii, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible, Staphylococcus aureus, methicillin-susceptible Staphylococcus epidermidis, or Streptococcus pyogenes. Bone and Joint Infections caused by Enterobacter cloacae, Serratia marcescens, or Pseudomonas aeruginosa. Complicated Intra-Abdominal Infections (used in combination with metronidazole) caused by Escherichia coli, Pseudomonas aeruginosa, Proteus mirabilis, Klebsiella pneumoniae, or Bacteroides fragilis. Infectious Diarrhea caused by Escherichia coli (enterotoxigenic strains), Campylobacter jejuni, Shigella boydii 1 , Shigella dysenteriae, Shigella flexneri or Shigella sonnei 1 when antibacterial therapy is indicated. Typhoid Fever (Enteric Fever) caused by Salmonella typhi. NOTE: The efficacy of ciprofloxacin in the eradication of the chronic typhoid carrier state has not been demonstrated. Uncomplicated cervical and urethral gonorrhea due to Neisseria gonorrhoeae. 1 Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients. Pediatric Patients (1 to 17 years of age) Complicated Urinary Tract Infections and Pyelonephritis due to Escherichia coli. Ciprofloxacin is not a drug of first choice in the pediatric population due to an increased incidence of adverse events compared to controls, including events related to joints and/or surrounding tissues. (See WARNINGS , PRECAUTIONS, Pediatric Use , ADVERSE REACTIONS and CLINICAL STUDIES .) Ciprofloxacin, like other fluoroquinolones, is associated with arthropathy and histopathological changes in weight-bearing joints of juvenile animals. (See ANIMAL PHARMACOLOGY .) Adult and Pediatric Patients Inhalational anthrax (post-exposure): To reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. Ciprofloxacin serum concentrations achieved in humans served as a surrogate endpoint reasonably likely to predict clinical benefit and provided the initial basis for approval of this indication.5 Supportive clinical information for ciprofloxacin for anthrax post-exposure prophylaxis was obtained during the anthrax bioterror attacks of October 2001. (See also, INHALATIONAL ANTHRAX - ADDITIONAL INFORMATION ). If anaerobic organisms are suspected of contributing to the infection, appropriate therapy should be administered. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. Therapy with ciprofloxacin hydrochloride may be initiated before results of these tests are known; once results become available appropriate therapy should be continued. As with other drugs, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ciprofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ciprofloxacin tablets and other antibacterial drugs, ciprofloxacin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:59f1743b-0427-4911-9e22-be990c683c39 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats HP:0000255 PMID:41385096 "[{""id"":""uuid:10dc77d5-dfdb-40ea-a727-c76ef52106d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cc8a9e91-51f5-47fe-97b5-070054858057"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciprofloxacin tablets are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions and patient populations listed below. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Adult Patients Urinary Tract Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, Proteus mirabilis, Providencia rettgeri, Morganella morganii, Citrobacter diversus, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus epidermidis, Staphylococcus saprophyticus, or Enterococcus faecalis. Acute Uncomplicated Cystitis in females caused by Escherichia coli or Staphylococcus saprophyticus. Chronic Bacterial Prostatitis caused by Escherichia coli or Proteus mirabilis. Lower Respiratory Tract Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Pseudomonas aeruginosa, Haemophilus influenzae, Haemophilus parainfluenzae, or penicillin-susceptible Streptococcus pneumoniae. Also, Moraxella catarrhalis for the treatment of acute exacerbations of chronic bronchitis. NOTE: Although effective in clinical trials, ciprofloxacin is not a drug of first choice in the treatment of presumed or confirmed pneumonia secondary to Streptococcus pneumoniae. Acute Sinusitis caused by Haemophilus influenzae, penicillin-susceptible Streptococcus pneumoniae, or Moraxella catarrhalis. Skin and Skin Structure Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Morganella morganii, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible, Staphylococcus aureus, methicillin-susceptible Staphylococcus epidermidis, or Streptococcus pyogenes. Bone and Joint Infections caused by Enterobacter cloacae, Serratia marcescens, or Pseudomonas aeruginosa. Complicated Intra-Abdominal Infections (used in combination with metronidazole) caused by Escherichia coli, Pseudomonas aeruginosa, Proteus mirabilis, Klebsiella pneumoniae, or Bacteroides fragilis. Infectious Diarrhea caused by Escherichia coli (enterotoxigenic strains), Campylobacter jejuni, Shigella boydii 1 , Shigella dysenteriae, Shigella flexneri or Shigella sonnei 1 when antibacterial therapy is indicated. Typhoid Fever (Enteric Fever) caused by Salmonella typhi. NOTE: The efficacy of ciprofloxacin in the eradication of the chronic typhoid carrier state has not been demonstrated. Uncomplicated cervical and urethral gonorrhea due to Neisseria gonorrhoeae. 1 Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients. Pediatric Patients (1 to 17 years of age) Complicated Urinary Tract Infections and Pyelonephritis due to Escherichia coli. Ciprofloxacin is not a drug of first choice in the pediatric population due to an increased incidence of adverse events compared to controls, including events related to joints and/or surrounding tissues. (See WARNINGS , PRECAUTIONS, Pediatric Use , ADVERSE REACTIONS and CLINICAL STUDIES .) Ciprofloxacin, like other fluoroquinolones, is associated with arthropathy and histopathological changes in weight-bearing joints of juvenile animals. (See ANIMAL PHARMACOLOGY .) Adult and Pediatric Patients Inhalational anthrax (post-exposure): To reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. Ciprofloxacin serum concentrations achieved in humans served as a surrogate endpoint reasonably likely to predict clinical benefit and provided the initial basis for approval of this indication.5 Supportive clinical information for ciprofloxacin for anthrax post-exposure prophylaxis was obtained during the anthrax bioterror attacks of October 2001. (See also, INHALATIONAL ANTHRAX - ADDITIONAL INFORMATION ). If anaerobic organisms are suspected of contributing to the infection, appropriate therapy should be administered. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. Therapy with ciprofloxacin hydrochloride may be initiated before results of these tests are known; once results become available appropriate therapy should be continued. As with other drugs, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ciprofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ciprofloxacin tablets and other antibacterial drugs, ciprofloxacin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:14fe537b-cab5-4b1c-8bc6-b77a97e78e3f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:26f6ed0a-4791-4545-bbc9-1020698bd972"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fd373397-8cb9-4189-aa8e-9961827baadd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciprofloxacin tablets are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions and patient populations listed below. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Adult Patients Urinary Tract Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, Proteus mirabilis, Providencia rettgeri, Morganella morganii, Citrobacter diversus, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus epidermidis, Staphylococcus saprophyticus, or Enterococcus faecalis. Acute Uncomplicated Cystitis in females caused by Escherichia coli or Staphylococcus saprophyticus. Chronic Bacterial Prostatitis caused by Escherichia coli or Proteus mirabilis. Lower Respiratory Tract Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Pseudomonas aeruginosa, Haemophilus influenzae, Haemophilus parainfluenzae, or penicillin-susceptible Streptococcus pneumoniae. Also, Moraxella catarrhalis for the treatment of acute exacerbations of chronic bronchitis. NOTE: Although effective in clinical trials, ciprofloxacin is not a drug of first choice in the treatment of presumed or confirmed pneumonia secondary to Streptococcus pneumoniae. Acute Sinusitis caused by Haemophilus influenzae, penicillin-susceptible Streptococcus pneumoniae, or Moraxella catarrhalis. Skin and Skin Structure Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Morganella morganii, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible, Staphylococcus aureus, methicillin-susceptible Staphylococcus epidermidis, or Streptococcus pyogenes. Bone and Joint Infections caused by Enterobacter cloacae, Serratia marcescens, or Pseudomonas aeruginosa. Complicated Intra-Abdominal Infections (used in combination with metronidazole) caused by Escherichia coli, Pseudomonas aeruginosa, Proteus mirabilis, Klebsiella pneumoniae, or Bacteroides fragilis. Infectious Diarrhea caused by Escherichia coli (enterotoxigenic strains), Campylobacter jejuni, Shigella boydii 1 , Shigella dysenteriae, Shigella flexneri or Shigella sonnei 1 when antibacterial therapy is indicated. Typhoid Fever (Enteric Fever) caused by Salmonella typhi. NOTE: The efficacy of ciprofloxacin in the eradication of the chronic typhoid carrier state has not been demonstrated. Uncomplicated cervical and urethral gonorrhea due to Neisseria gonorrhoeae. 1 Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients. Pediatric Patients (1 to 17 years of age) Complicated Urinary Tract Infections and Pyelonephritis due to Escherichia coli. Ciprofloxacin is not a drug of first choice in the pediatric population due to an increased incidence of adverse events compared to controls, including events related to joints and/or surrounding tissues. (See WARNINGS , PRECAUTIONS, Pediatric Use , ADVERSE REACTIONS and CLINICAL STUDIES .) Ciprofloxacin, like other fluoroquinolones, is associated with arthropathy and histopathological changes in weight-bearing joints of juvenile animals. (See ANIMAL PHARMACOLOGY .) Adult and Pediatric Patients Inhalational anthrax (post-exposure): To reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. Ciprofloxacin serum concentrations achieved in humans served as a surrogate endpoint reasonably likely to predict clinical benefit and provided the initial basis for approval of this indication.5 Supportive clinical information for ciprofloxacin for anthrax post-exposure prophylaxis was obtained during the anthrax bioterror attacks of October 2001. (See also, INHALATIONAL ANTHRAX - ADDITIONAL INFORMATION ). If anaerobic organisms are suspected of contributing to the infection, appropriate therapy should be administered. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. Therapy with ciprofloxacin hydrochloride may be initiated before results of these tests are known; once results become available appropriate therapy should be continued. As with other drugs, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ciprofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ciprofloxacin tablets and other antibacterial drugs, ciprofloxacin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:39ea850f-d5a5-4300-b8f4-f673921ce431 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats UMLS:C0851989 PMID:41385096 "[{""id"":""uuid:2be12354-4828-4c95-8042-f24d250603a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dc383367-16fd-45b2-8bc5-8abaf347373d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciprofloxacin tablets are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions and patient populations listed below. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Adult Patients Urinary Tract Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, Proteus mirabilis, Providencia rettgeri, Morganella morganii, Citrobacter diversus, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus epidermidis, Staphylococcus saprophyticus, or Enterococcus faecalis. Acute Uncomplicated Cystitis in females caused by Escherichia coli or Staphylococcus saprophyticus. Chronic Bacterial Prostatitis caused by Escherichia coli or Proteus mirabilis. Lower Respiratory Tract Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Pseudomonas aeruginosa, Haemophilus influenzae, Haemophilus parainfluenzae, or penicillin-susceptible Streptococcus pneumoniae. Also, Moraxella catarrhalis for the treatment of acute exacerbations of chronic bronchitis. NOTE: Although effective in clinical trials, ciprofloxacin is not a drug of first choice in the treatment of presumed or confirmed pneumonia secondary to Streptococcus pneumoniae. Acute Sinusitis caused by Haemophilus influenzae, penicillin-susceptible Streptococcus pneumoniae, or Moraxella catarrhalis. Skin and Skin Structure Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Morganella morganii, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible, Staphylococcus aureus, methicillin-susceptible Staphylococcus epidermidis, or Streptococcus pyogenes. Bone and Joint Infections caused by Enterobacter cloacae, Serratia marcescens, or Pseudomonas aeruginosa. Complicated Intra-Abdominal Infections (used in combination with metronidazole) caused by Escherichia coli, Pseudomonas aeruginosa, Proteus mirabilis, Klebsiella pneumoniae, or Bacteroides fragilis. Infectious Diarrhea caused by Escherichia coli (enterotoxigenic strains), Campylobacter jejuni, Shigella boydii 1 , Shigella dysenteriae, Shigella flexneri or Shigella sonnei 1 when antibacterial therapy is indicated. Typhoid Fever (Enteric Fever) caused by Salmonella typhi. NOTE: The efficacy of ciprofloxacin in the eradication of the chronic typhoid carrier state has not been demonstrated. Uncomplicated cervical and urethral gonorrhea due to Neisseria gonorrhoeae. 1 Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients. Pediatric Patients (1 to 17 years of age) Complicated Urinary Tract Infections and Pyelonephritis due to Escherichia coli. Ciprofloxacin is not a drug of first choice in the pediatric population due to an increased incidence of adverse events compared to controls, including events related to joints and/or surrounding tissues. (See WARNINGS , PRECAUTIONS, Pediatric Use , ADVERSE REACTIONS and CLINICAL STUDIES .) Ciprofloxacin, like other fluoroquinolones, is associated with arthropathy and histopathological changes in weight-bearing joints of juvenile animals. (See ANIMAL PHARMACOLOGY .) Adult and Pediatric Patients Inhalational anthrax (post-exposure): To reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. Ciprofloxacin serum concentrations achieved in humans served as a surrogate endpoint reasonably likely to predict clinical benefit and provided the initial basis for approval of this indication.5 Supportive clinical information for ciprofloxacin for anthrax post-exposure prophylaxis was obtained during the anthrax bioterror attacks of October 2001. (See also, INHALATIONAL ANTHRAX - ADDITIONAL INFORMATION ). If anaerobic organisms are suspected of contributing to the infection, appropriate therapy should be administered. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. Therapy with ciprofloxacin hydrochloride may be initiated before results of these tests are known; once results become available appropriate therapy should be continued. As with other drugs, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ciprofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ciprofloxacin tablets and other antibacterial drugs, ciprofloxacin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:901591de-e52c-4c69-8eb0-edd5b061f4df biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats MONDO:0001517 PMID:41385096 "[{""id"":""uuid:9517f11f-5f9c-4e71-943b-0995d2d04592"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:23e171e7-a778-4900-8c63-a9eb83e76808"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciprofloxacin tablets are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions and patient populations listed below. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Adult Patients Urinary Tract Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, Proteus mirabilis, Providencia rettgeri, Morganella morganii, Citrobacter diversus, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus epidermidis, Staphylococcus saprophyticus, or Enterococcus faecalis. Acute Uncomplicated Cystitis in females caused by Escherichia coli or Staphylococcus saprophyticus. Chronic Bacterial Prostatitis caused by Escherichia coli or Proteus mirabilis. Lower Respiratory Tract Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Pseudomonas aeruginosa, Haemophilus influenzae, Haemophilus parainfluenzae, or penicillin-susceptible Streptococcus pneumoniae. Also, Moraxella catarrhalis for the treatment of acute exacerbations of chronic bronchitis. NOTE: Although effective in clinical trials, ciprofloxacin is not a drug of first choice in the treatment of presumed or confirmed pneumonia secondary to Streptococcus pneumoniae. Acute Sinusitis caused by Haemophilus influenzae, penicillin-susceptible Streptococcus pneumoniae, or Moraxella catarrhalis. Skin and Skin Structure Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Morganella morganii, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible, Staphylococcus aureus, methicillin-susceptible Staphylococcus epidermidis, or Streptococcus pyogenes. Bone and Joint Infections caused by Enterobacter cloacae, Serratia marcescens, or Pseudomonas aeruginosa. Complicated Intra-Abdominal Infections (used in combination with metronidazole) caused by Escherichia coli, Pseudomonas aeruginosa, Proteus mirabilis, Klebsiella pneumoniae, or Bacteroides fragilis. Infectious Diarrhea caused by Escherichia coli (enterotoxigenic strains), Campylobacter jejuni, Shigella boydii 1 , Shigella dysenteriae, Shigella flexneri or Shigella sonnei 1 when antibacterial therapy is indicated. Typhoid Fever (Enteric Fever) caused by Salmonella typhi. NOTE: The efficacy of ciprofloxacin in the eradication of the chronic typhoid carrier state has not been demonstrated. Uncomplicated cervical and urethral gonorrhea due to Neisseria gonorrhoeae. 1 Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients. Pediatric Patients (1 to 17 years of age) Complicated Urinary Tract Infections and Pyelonephritis due to Escherichia coli. Ciprofloxacin is not a drug of first choice in the pediatric population due to an increased incidence of adverse events compared to controls, including events related to joints and/or surrounding tissues. (See WARNINGS , PRECAUTIONS, Pediatric Use , ADVERSE REACTIONS and CLINICAL STUDIES .) Ciprofloxacin, like other fluoroquinolones, is associated with arthropathy and histopathological changes in weight-bearing joints of juvenile animals. (See ANIMAL PHARMACOLOGY .) Adult and Pediatric Patients Inhalational anthrax (post-exposure): To reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. Ciprofloxacin serum concentrations achieved in humans served as a surrogate endpoint reasonably likely to predict clinical benefit and provided the initial basis for approval of this indication.5 Supportive clinical information for ciprofloxacin for anthrax post-exposure prophylaxis was obtained during the anthrax bioterror attacks of October 2001. (See also, INHALATIONAL ANTHRAX - ADDITIONAL INFORMATION ). If anaerobic organisms are suspected of contributing to the infection, appropriate therapy should be administered. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. Therapy with ciprofloxacin hydrochloride may be initiated before results of these tests are known; once results become available appropriate therapy should be continued. As with other drugs, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ciprofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ciprofloxacin tablets and other antibacterial drugs, ciprofloxacin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:69b44612-a064-40c1-85ce-5a72249b45f0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats MONDO:0005619 PMID:41385096 "[{""id"":""uuid:117a6016-883f-4511-9f23-7d31143815fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:30ec472d-737b-43f9-8364-9b4cd835c8ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciprofloxacin tablets are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions and patient populations listed below. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Adult Patients Urinary Tract Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, Proteus mirabilis, Providencia rettgeri, Morganella morganii, Citrobacter diversus, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus epidermidis, Staphylococcus saprophyticus, or Enterococcus faecalis. Acute Uncomplicated Cystitis in females caused by Escherichia coli or Staphylococcus saprophyticus. Chronic Bacterial Prostatitis caused by Escherichia coli or Proteus mirabilis. Lower Respiratory Tract Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Pseudomonas aeruginosa, Haemophilus influenzae, Haemophilus parainfluenzae, or penicillin-susceptible Streptococcus pneumoniae. Also, Moraxella catarrhalis for the treatment of acute exacerbations of chronic bronchitis. NOTE: Although effective in clinical trials, ciprofloxacin is not a drug of first choice in the treatment of presumed or confirmed pneumonia secondary to Streptococcus pneumoniae. Acute Sinusitis caused by Haemophilus influenzae, penicillin-susceptible Streptococcus pneumoniae, or Moraxella catarrhalis. Skin and Skin Structure Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Morganella morganii, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible, Staphylococcus aureus, methicillin-susceptible Staphylococcus epidermidis, or Streptococcus pyogenes. Bone and Joint Infections caused by Enterobacter cloacae, Serratia marcescens, or Pseudomonas aeruginosa. Complicated Intra-Abdominal Infections (used in combination with metronidazole) caused by Escherichia coli, Pseudomonas aeruginosa, Proteus mirabilis, Klebsiella pneumoniae, or Bacteroides fragilis. Infectious Diarrhea caused by Escherichia coli (enterotoxigenic strains), Campylobacter jejuni, Shigella boydii 1 , Shigella dysenteriae, Shigella flexneri or Shigella sonnei 1 when antibacterial therapy is indicated. Typhoid Fever (Enteric Fever) caused by Salmonella typhi. NOTE: The efficacy of ciprofloxacin in the eradication of the chronic typhoid carrier state has not been demonstrated. Uncomplicated cervical and urethral gonorrhea due to Neisseria gonorrhoeae. 1 Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients. Pediatric Patients (1 to 17 years of age) Complicated Urinary Tract Infections and Pyelonephritis due to Escherichia coli. Ciprofloxacin is not a drug of first choice in the pediatric population due to an increased incidence of adverse events compared to controls, including events related to joints and/or surrounding tissues. (See WARNINGS , PRECAUTIONS, Pediatric Use , ADVERSE REACTIONS and CLINICAL STUDIES .) Ciprofloxacin, like other fluoroquinolones, is associated with arthropathy and histopathological changes in weight-bearing joints of juvenile animals. (See ANIMAL PHARMACOLOGY .) Adult and Pediatric Patients Inhalational anthrax (post-exposure): To reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. Ciprofloxacin serum concentrations achieved in humans served as a surrogate endpoint reasonably likely to predict clinical benefit and provided the initial basis for approval of this indication.5 Supportive clinical information for ciprofloxacin for anthrax post-exposure prophylaxis was obtained during the anthrax bioterror attacks of October 2001. (See also, INHALATIONAL ANTHRAX - ADDITIONAL INFORMATION ). If anaerobic organisms are suspected of contributing to the infection, appropriate therapy should be administered. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. Therapy with ciprofloxacin hydrochloride may be initiated before results of these tests are known; once results become available appropriate therapy should be continued. As with other drugs, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ciprofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ciprofloxacin tablets and other antibacterial drugs, ciprofloxacin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:d2621de0-39d3-458c-bc04-b8a219bdec57 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats MONDO:0004277 PMID:41385096 "[{""id"":""uuid:d3e1d81c-1a14-4183-8847-f7f92e809df8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3853e959-8e8d-47af-9148-836f9c66bb4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciprofloxacin tablets are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions and patient populations listed below. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Adult Patients Urinary Tract Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, Proteus mirabilis, Providencia rettgeri, Morganella morganii, Citrobacter diversus, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus epidermidis, Staphylococcus saprophyticus, or Enterococcus faecalis. Acute Uncomplicated Cystitis in females caused by Escherichia coli or Staphylococcus saprophyticus. Chronic Bacterial Prostatitis caused by Escherichia coli or Proteus mirabilis. Lower Respiratory Tract Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Pseudomonas aeruginosa, Haemophilus influenzae, Haemophilus parainfluenzae, or penicillin-susceptible Streptococcus pneumoniae. Also, Moraxella catarrhalis for the treatment of acute exacerbations of chronic bronchitis. NOTE: Although effective in clinical trials, ciprofloxacin is not a drug of first choice in the treatment of presumed or confirmed pneumonia secondary to Streptococcus pneumoniae. Acute Sinusitis caused by Haemophilus influenzae, penicillin-susceptible Streptococcus pneumoniae, or Moraxella catarrhalis. Skin and Skin Structure Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Morganella morganii, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible, Staphylococcus aureus, methicillin-susceptible Staphylococcus epidermidis, or Streptococcus pyogenes. Bone and Joint Infections caused by Enterobacter cloacae, Serratia marcescens, or Pseudomonas aeruginosa. Complicated Intra-Abdominal Infections (used in combination with metronidazole) caused by Escherichia coli, Pseudomonas aeruginosa, Proteus mirabilis, Klebsiella pneumoniae, or Bacteroides fragilis. Infectious Diarrhea caused by Escherichia coli (enterotoxigenic strains), Campylobacter jejuni, Shigella boydii 1 , Shigella dysenteriae, Shigella flexneri or Shigella sonnei 1 when antibacterial therapy is indicated. Typhoid Fever (Enteric Fever) caused by Salmonella typhi. NOTE: The efficacy of ciprofloxacin in the eradication of the chronic typhoid carrier state has not been demonstrated. Uncomplicated cervical and urethral gonorrhea due to Neisseria gonorrhoeae. 1 Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients. Pediatric Patients (1 to 17 years of age) Complicated Urinary Tract Infections and Pyelonephritis due to Escherichia coli. Ciprofloxacin is not a drug of first choice in the pediatric population due to an increased incidence of adverse events compared to controls, including events related to joints and/or surrounding tissues. (See WARNINGS , PRECAUTIONS, Pediatric Use , ADVERSE REACTIONS and CLINICAL STUDIES .) Ciprofloxacin, like other fluoroquinolones, is associated with arthropathy and histopathological changes in weight-bearing joints of juvenile animals. (See ANIMAL PHARMACOLOGY .) Adult and Pediatric Patients Inhalational anthrax (post-exposure): To reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. Ciprofloxacin serum concentrations achieved in humans served as a surrogate endpoint reasonably likely to predict clinical benefit and provided the initial basis for approval of this indication.5 Supportive clinical information for ciprofloxacin for anthrax post-exposure prophylaxis was obtained during the anthrax bioterror attacks of October 2001. (See also, INHALATIONAL ANTHRAX - ADDITIONAL INFORMATION ). If anaerobic organisms are suspected of contributing to the infection, appropriate therapy should be administered. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. Therapy with ciprofloxacin hydrochloride may be initiated before results of these tests are known; once results become available appropriate therapy should be continued. As with other drugs, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ciprofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ciprofloxacin tablets and other antibacterial drugs, ciprofloxacin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:48751dae-f8bc-4f1c-a658-bb86ca5e5fb1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats MONDO:0006939 PMID:41385096 "[{""id"":""uuid:fe0fd0f3-5668-4768-b3d1-984cb2141a68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2ac30118-551a-4b3d-9910-a684ec8f55ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a57cdf6d-ddc0-4716-9978-06a167abf19a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciprofloxacin tablets are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions and patient populations listed below. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Adult Patients Urinary Tract Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, Proteus mirabilis, Providencia rettgeri, Morganella morganii, Citrobacter diversus, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus epidermidis, Staphylococcus saprophyticus, or Enterococcus faecalis. Acute Uncomplicated Cystitis in females caused by Escherichia coli or Staphylococcus saprophyticus. Chronic Bacterial Prostatitis caused by Escherichia coli or Proteus mirabilis. Lower Respiratory Tract Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Pseudomonas aeruginosa, Haemophilus influenzae, Haemophilus parainfluenzae, or penicillin-susceptible Streptococcus pneumoniae. Also, Moraxella catarrhalis for the treatment of acute exacerbations of chronic bronchitis. NOTE: Although effective in clinical trials, ciprofloxacin is not a drug of first choice in the treatment of presumed or confirmed pneumonia secondary to Streptococcus pneumoniae. Acute Sinusitis caused by Haemophilus influenzae, penicillin-susceptible Streptococcus pneumoniae, or Moraxella catarrhalis. Skin and Skin Structure Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Morganella morganii, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible, Staphylococcus aureus, methicillin-susceptible Staphylococcus epidermidis, or Streptococcus pyogenes. Bone and Joint Infections caused by Enterobacter cloacae, Serratia marcescens, or Pseudomonas aeruginosa. Complicated Intra-Abdominal Infections (used in combination with metronidazole) caused by Escherichia coli, Pseudomonas aeruginosa, Proteus mirabilis, Klebsiella pneumoniae, or Bacteroides fragilis. Infectious Diarrhea caused by Escherichia coli (enterotoxigenic strains), Campylobacter jejuni, Shigella boydii 1 , Shigella dysenteriae, Shigella flexneri or Shigella sonnei 1 when antibacterial therapy is indicated. Typhoid Fever (Enteric Fever) caused by Salmonella typhi. NOTE: The efficacy of ciprofloxacin in the eradication of the chronic typhoid carrier state has not been demonstrated. Uncomplicated cervical and urethral gonorrhea due to Neisseria gonorrhoeae. 1 Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients. Pediatric Patients (1 to 17 years of age) Complicated Urinary Tract Infections and Pyelonephritis due to Escherichia coli. Ciprofloxacin is not a drug of first choice in the pediatric population due to an increased incidence of adverse events compared to controls, including events related to joints and/or surrounding tissues. (See WARNINGS , PRECAUTIONS, Pediatric Use , ADVERSE REACTIONS and CLINICAL STUDIES .) Ciprofloxacin, like other fluoroquinolones, is associated with arthropathy and histopathological changes in weight-bearing joints of juvenile animals. (See ANIMAL PHARMACOLOGY .) Adult and Pediatric Patients Inhalational anthrax (post-exposure): To reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. Ciprofloxacin serum concentrations achieved in humans served as a surrogate endpoint reasonably likely to predict clinical benefit and provided the initial basis for approval of this indication.5 Supportive clinical information for ciprofloxacin for anthrax post-exposure prophylaxis was obtained during the anthrax bioterror attacks of October 2001. (See also, INHALATIONAL ANTHRAX - ADDITIONAL INFORMATION ). If anaerobic organisms are suspected of contributing to the infection, appropriate therapy should be administered. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. Therapy with ciprofloxacin hydrochloride may be initiated before results of these tests are known; once results become available appropriate therapy should be continued. As with other drugs, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ciprofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ciprofloxacin tablets and other antibacterial drugs, ciprofloxacin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.|[PMDA] A drug with a new increased dose for adults indicated for the treatment of sepsis, pneumonia, etc., and also with new indications and new dosages for children for both the treatment of complicated cystitis, pyelonephritis and anthrax, and the improvement of symptoms associated with respiratory infection caused by Pseudomonas aeruginosa in cystic fibrosis. uuid:76a72803-2546-4225-97bc-3e6ac6e9b4b5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats MONDO:0016595 PMID:41385096 "[{""id"":""uuid:61f817f0-9fe6-4430-b4d4-74473d3ffd29"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7ae81355-3de4-4931-a956-42d4fb7294b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciprofloxacin tablets are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions and patient populations listed below. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Adult Patients Urinary Tract Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, Proteus mirabilis, Providencia rettgeri, Morganella morganii, Citrobacter diversus, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus epidermidis, Staphylococcus saprophyticus, or Enterococcus faecalis. Acute Uncomplicated Cystitis in females caused by Escherichia coli or Staphylococcus saprophyticus. Chronic Bacterial Prostatitis caused by Escherichia coli or Proteus mirabilis. Lower Respiratory Tract Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Pseudomonas aeruginosa, Haemophilus influenzae, Haemophilus parainfluenzae, or penicillin-susceptible Streptococcus pneumoniae. Also, Moraxella catarrhalis for the treatment of acute exacerbations of chronic bronchitis. NOTE: Although effective in clinical trials, ciprofloxacin is not a drug of first choice in the treatment of presumed or confirmed pneumonia secondary to Streptococcus pneumoniae. Acute Sinusitis caused by Haemophilus influenzae, penicillin-susceptible Streptococcus pneumoniae, or Moraxella catarrhalis. Skin and Skin Structure Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Morganella morganii, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible, Staphylococcus aureus, methicillin-susceptible Staphylococcus epidermidis, or Streptococcus pyogenes. Bone and Joint Infections caused by Enterobacter cloacae, Serratia marcescens, or Pseudomonas aeruginosa. Complicated Intra-Abdominal Infections (used in combination with metronidazole) caused by Escherichia coli, Pseudomonas aeruginosa, Proteus mirabilis, Klebsiella pneumoniae, or Bacteroides fragilis. Infectious Diarrhea caused by Escherichia coli (enterotoxigenic strains), Campylobacter jejuni, Shigella boydii 1 , Shigella dysenteriae, Shigella flexneri or Shigella sonnei 1 when antibacterial therapy is indicated. Typhoid Fever (Enteric Fever) caused by Salmonella typhi. NOTE: The efficacy of ciprofloxacin in the eradication of the chronic typhoid carrier state has not been demonstrated. Uncomplicated cervical and urethral gonorrhea due to Neisseria gonorrhoeae. 1 Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients. Pediatric Patients (1 to 17 years of age) Complicated Urinary Tract Infections and Pyelonephritis due to Escherichia coli. Ciprofloxacin is not a drug of first choice in the pediatric population due to an increased incidence of adverse events compared to controls, including events related to joints and/or surrounding tissues. (See WARNINGS , PRECAUTIONS, Pediatric Use , ADVERSE REACTIONS and CLINICAL STUDIES .) Ciprofloxacin, like other fluoroquinolones, is associated with arthropathy and histopathological changes in weight-bearing joints of juvenile animals. (See ANIMAL PHARMACOLOGY .) Adult and Pediatric Patients Inhalational anthrax (post-exposure): To reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. Ciprofloxacin serum concentrations achieved in humans served as a surrogate endpoint reasonably likely to predict clinical benefit and provided the initial basis for approval of this indication.5 Supportive clinical information for ciprofloxacin for anthrax post-exposure prophylaxis was obtained during the anthrax bioterror attacks of October 2001. (See also, INHALATIONAL ANTHRAX - ADDITIONAL INFORMATION ). If anaerobic organisms are suspected of contributing to the infection, appropriate therapy should be administered. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. Therapy with ciprofloxacin hydrochloride may be initiated before results of these tests are known; once results become available appropriate therapy should be continued. As with other drugs, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ciprofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ciprofloxacin tablets and other antibacterial drugs, ciprofloxacin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:f5506602-a93a-48fb-a6f2-b93bd91a3a9c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:168396 biolink:treats UMLS:C0345468 PMID:41385096 "[{""id"":""uuid:4b05e0c9-7e75-4c3b-8e8a-26afaa7cad4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e1b3ac21-6d90-4e43-a4ce-be7fe38784a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CellCept is indicated for the prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac or hepatic transplants. CellCept should be used concomitantly with cyclosporine and corticosteroids. CellCept Intravenous is an alternative dosage form to CellCept capsules, tablets and oral suspension. CellCept Intravenous should be administered within 24 hours following transplantation. CellCept Intravenous can be administered for up to 14 days; patients should be switched to oral CellCept as soon as they can tolerate oral medication. uuid:d6201f06-0d2c-40e0-b4cc-f093e5e6f1f0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:168396 biolink:treats UMLS:C0238217 PMID:41385096 "[{""id"":""uuid:1397d10f-2def-47e6-b31f-9618fa617569"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5ec20e5b-801a-43a6-8603-be6b8229a63c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CellCept is indicated for the prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac or hepatic transplants. CellCept should be used concomitantly with cyclosporine and corticosteroids. CellCept Intravenous is an alternative dosage form to CellCept capsules, tablets and oral suspension. CellCept Intravenous should be administered within 24 hours following transplantation. CellCept Intravenous can be administered for up to 14 days; patients should be switched to oral CellCept as soon as they can tolerate oral medication. uuid:3d8a1ab3-e94a-4ac5-a4b3-d260f4807a6d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:168396 biolink:treats UMLS:C0340530 PMID:41385096 "[{""id"":""uuid:e95860b1-f54f-45d8-a74c-b1345325b029"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9b055ff0-ad2b-4dd3-aab9-30429ffca97e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CellCept is indicated for the prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac or hepatic transplants. CellCept should be used concomitantly with cyclosporine and corticosteroids. CellCept Intravenous is an alternative dosage form to CellCept capsules, tablets and oral suspension. CellCept Intravenous should be administered within 24 hours following transplantation. CellCept Intravenous can be administered for up to 14 days; patients should be switched to oral CellCept as soon as they can tolerate oral medication. uuid:731ce71e-facf-4422-8a37-ca698dee095f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:168396 biolink:treats UMLS:C0400968 PMID:41385096 "[{""id"":""uuid:03743d22-e719-4b89-b3b0-2920d1c6df96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:21026add-75fa-4662-bf31-7e605375ca1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CellCept is indicated for the prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac or hepatic transplants. CellCept should be used concomitantly with cyclosporine and corticosteroids. CellCept Intravenous is an alternative dosage form to CellCept capsules, tablets and oral suspension. CellCept Intravenous should be administered within 24 hours following transplantation. CellCept Intravenous can be administered for up to 14 days; patients should be switched to oral CellCept as soon as they can tolerate oral medication. uuid:a1bf6e64-67a7-4c0c-a688-8b07a6a6e88b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1153750 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:68ee65c9-0311-44a9-b5f5-88575ebd754b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9082f6b2-f973-4372-9a80-219c4ddebaf2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENDODAN tablets are indicated for the management of moderate to moderately severe pain. uuid:e2eac7e3-1e73-4b9d-8964-eacd0815f128 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7865 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:06ea85c4-f3f5-4d1a-964d-885bd4ff8a31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fdd52bd6-5a84-4d4e-ae3e-763d7159ca8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OPANA ER is indicated for the relief of moderate to severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time. OPANA ER is not intended for use as a prn analgesic. OPANA ER is not indicated for pain in the immediate post-operative period (12-24 hours following surgery) for patients not previously taking opioids because of the risk of oversedation and respiratory depression requiring reversal with opioid antagonists. OPANA ER is not indicated for pain in the post-operative period if the pain is mild or not expected to persist for an extended period of time. uuid:b51688b5-fc92-4b6a-9415-c82575dc0d09 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:173924 biolink:treats HP:0000371 PMID:41385096 "[{""id"":""uuid:07dadb9a-7518-425d-add5-8d16e97280ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aef8efcf-a1c2-4bf1-a323-dc475ff603ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acute Otitis media of various etiologies -prompt relief of pain and reduction of inflammation in the congestive and serous stages. -adjuvant therapy during systemic antibiotic administration for resolution of the infection. Because of the close anatomical relationship of the eustachian tube to the nasal cavity, otitis media is a frequent problem, especially in children in whom the tube is shorter, wider, and more horizontal than in adults. Removal of Cerumen -facilitates the removal of excessive or impacted cerumen. uuid:c91c6ca6-7266-439f-ab34-07a8c1959b8a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:173924 biolink:treats MONDO:0005441 PMID:41385096 "[{""id"":""uuid:6cb22f54-7401-4426-a544-323b1d965ffd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a8824c2e-01c3-4f0e-af9e-50c7ae1de1f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acute Otitis media of various etiologies -prompt relief of pain and reduction of inflammation in the congestive and serous stages. -adjuvant therapy during systemic antibiotic administration for resolution of the infection. Because of the close anatomical relationship of the eustachian tube to the nasal cavity, otitis media is a frequent problem, especially in children in whom the tube is shorter, wider, and more horizontal than in adults. Removal of Cerumen -facilitates the removal of excessive or impacted cerumen. uuid:dd50ee55-d3ad-4947-a60c-781e77b8534c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0004872 PMID:41385096 "[{""id"":""uuid:7dbc6ff2-b038-4a33-a2f6-f595f9163d03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6f90fda9-2c7e-49de-9d71-a08813be0196"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For use in inflamed hemorrhoids, postirradiation (factitial) proctitis; as an adjunct in the treatment of chronic ulcerative colitis; cryptitis; and other inflammatory conditions of anorectum and pruritus ani. uuid:a7616c39-5bcc-46f0-ae26-4b809d093ced biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0019084 PMID:41385096 "[{""id"":""uuid:9579c620-443b-4c8f-9838-01b669f5e5b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:56911a86-b918-41e5-b200-889eb6124e13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For use in inflamed hemorrhoids, postirradiation (factitial) proctitis; as an adjunct in the treatment of chronic ulcerative colitis; cryptitis; and other inflammatory conditions of anorectum and pruritus ani. uuid:2a2b58fb-3767-428b-a383-9665e88af174 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats UMLS:C2919828 PMID:41385096 "[{""id"":""uuid:73114bac-b38b-4aaa-9c1a-32025c643c5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c901f1d5-8850-4ba9-accb-6c1df45d2220"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For use in inflamed hemorrhoids, postirradiation (factitial) proctitis; as an adjunct in the treatment of chronic ulcerative colitis; cryptitis; and other inflammatory conditions of anorectum and pruritus ani. uuid:78787576-89cd-41fc-bca3-45438d3fbb18 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats UMLS:C1394254 PMID:41385096 "[{""id"":""uuid:57629cb5-f911-47a6-93fd-f775f808fa95"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2921ec03-7b82-4131-b064-ac83d7182af4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For use in inflamed hemorrhoids, postirradiation (factitial) proctitis; as an adjunct in the treatment of chronic ulcerative colitis; cryptitis; and other inflammatory conditions of anorectum and pruritus ani. uuid:33055c48-8f09-4168-9b6d-361ede4548de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:370748 biolink:treats MONDO:0005618 PMID:41385096 "[{""id"":""uuid:53ab193c-ea4f-4db8-9997-7eaa2fa3349b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4fa24af2-0e62-4140-9846-88e8ffe8a8cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lorazepam is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The effectiveness of lorazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. uuid:729b036f-9887-455c-a17c-2e34f5e118aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:370748 biolink:treats MONDO:0011918 PMID:41385096 "[{""id"":""uuid:54c85327-c8d1-4fa8-a5e2-5ca4aa2e0391"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bec7fe62-f14d-4d83-8c1a-bf9187f8e989"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lorazepam is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The effectiveness of lorazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. uuid:d61ff4e8-a57d-48c0-b19f-d954ddc65ce0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:370748 biolink:treats MONDO:0041086 PMID:41385096 "[{""id"":""uuid:52a2b5ab-494a-4c82-a569-e74ea8570559"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3cba3801-3f6d-4caf-a217-441fd0916ace"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lorazepam is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The effectiveness of lorazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. uuid:7f3cf4ed-907f-40ec-af98-561e125b0427 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29007 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:1312e200-e4b3-4cc1-9f72-4f62528dd3dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d6789fc7-0352-4232-b16d-da46cfa4ca29"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection and other antibacterial drugs, ceftriaxone for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ceftriaxone sodium is indicated for the treatment of the following infections when caused by susceptible organisms: Lower Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis or Serratia marcescens. Acute Bacterial Otitis Media caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase producing strains) or Moraxella catarrhalis (including beta-lactamase producing strains). NOTE: In one study lower clinical cure rates were observed with a single dose of ceftriaxone sodium compared to 10 days of oral therapy. In a second study comparable cure rates were observed between single dose ceftriaxone sodium and the comparator. The potentially lower clinical cure rate of ceftriaxone should be balanced against the potential advantages of parenteral therapy (see CLINICAL STUDIES ). Skin And Skin Structure Infections caused by Staphylococcus aureus , Staphylococcus epidermidis , Streptococcus pyogenes , Viridans group streptococci, Escherichia coli , Enterobacter cloacae , Klebsiella oxytoca , Klebsiella pneumoniae , Proteus mirabilis , Morganella morganii Efficacy for this organism in this organ system was studied in fewer than ten infections. , Pseudomonas aeruginosa , Serratia marcescens , Acinetobacter calcoaceticus , Bacteroides fragilis Efficacy for this organism in this organ system was studied in fewer than ten infections. or Peptostreptococcus species. Urinary Tract Infections ( complicated and uncomplicated ) caused by Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii or Klebsiella pneumoniae. Uncomplicated Gonorrhea ( cervical/urethral and rectal ) caused by Neisseria gonorrhoeae , including both penicillinase- and nonpenicillinase-producing strains, and pharyngeal gonorrhea caused by nonpenicillinase-producing strains of Neisseria gonorrhoeae . Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae . Ceftriaxone sodium, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and Chlamydia trachomatis is one of the suspected pathogens, appropriate antichlamydial coverage should be added. Bacterial Septicemia caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae or Klebsiella pneumoniae. Bone And Joint Infections caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae or Enterobacter species. Intra-Abdominal Infections caused by Escherichia coli, Klebsiella pneumoniae , Bacteroides fragilis , Clostridium species (Note: most strains of Clostridium difficile are resistant) or Peptostreptococcus species. Meningitis caused by Haemophilus influenzae, Neisseria meningitidis or Streptococcus pneumoniae. Ceftriaxone has also been used successfully in a limited number of cases of meningitis and shunt infection caused by Staphylococcus epidermidis Efficacy for this organism in this organ system was studied in fewer than ten infections. and Escherichia coli Efficacy for this organism in this organ system was studied in fewer than ten infections. . Surgical Prophylaxis: The preoperative administration of a single 1 gm dose of ceftriaxone sodium may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated (e.g., vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high-risk patients, such as those over 70 years of age, with acute cholecystitis not requiring therapeutic antimicrobials, obstructive jaundice or common duct bile stones) and in surgical patients for whom infection at the operative site would present serious risk (e.g., during coronary artery bypass surgery). Although ceftriaxone has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo-controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of infection following coronary artery bypass surgery. When administered prior to surgical procedures for which it is indicated, a single 1 gm dose of ceftriaxone sodium provides protection from most infections due to susceptible organisms throughout the course of the procedure. uuid:b3184ee0-53b0-4b59-8583-0a91d09110cf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29007 biolink:treats MONDO:0001031 PMID:41385096 "[{""id"":""uuid:7e691d76-cf3d-4396-bf1f-222f92914e90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f6895bc4-d09d-4f4d-a7ba-581a07a58706"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection and other antibacterial drugs, ceftriaxone for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ceftriaxone sodium is indicated for the treatment of the following infections when caused by susceptible organisms: Lower Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis or Serratia marcescens. Acute Bacterial Otitis Media caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase producing strains) or Moraxella catarrhalis (including beta-lactamase producing strains). NOTE: In one study lower clinical cure rates were observed with a single dose of ceftriaxone sodium compared to 10 days of oral therapy. In a second study comparable cure rates were observed between single dose ceftriaxone sodium and the comparator. The potentially lower clinical cure rate of ceftriaxone should be balanced against the potential advantages of parenteral therapy (see CLINICAL STUDIES ). Skin And Skin Structure Infections caused by Staphylococcus aureus , Staphylococcus epidermidis , Streptococcus pyogenes , Viridans group streptococci, Escherichia coli , Enterobacter cloacae , Klebsiella oxytoca , Klebsiella pneumoniae , Proteus mirabilis , Morganella morganii Efficacy for this organism in this organ system was studied in fewer than ten infections. , Pseudomonas aeruginosa , Serratia marcescens , Acinetobacter calcoaceticus , Bacteroides fragilis Efficacy for this organism in this organ system was studied in fewer than ten infections. or Peptostreptococcus species. Urinary Tract Infections ( complicated and uncomplicated ) caused by Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii or Klebsiella pneumoniae. Uncomplicated Gonorrhea ( cervical/urethral and rectal ) caused by Neisseria gonorrhoeae , including both penicillinase- and nonpenicillinase-producing strains, and pharyngeal gonorrhea caused by nonpenicillinase-producing strains of Neisseria gonorrhoeae . Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae . Ceftriaxone sodium, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and Chlamydia trachomatis is one of the suspected pathogens, appropriate antichlamydial coverage should be added. Bacterial Septicemia caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae or Klebsiella pneumoniae. Bone And Joint Infections caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae or Enterobacter species. Intra-Abdominal Infections caused by Escherichia coli, Klebsiella pneumoniae , Bacteroides fragilis , Clostridium species (Note: most strains of Clostridium difficile are resistant) or Peptostreptococcus species. Meningitis caused by Haemophilus influenzae, Neisseria meningitidis or Streptococcus pneumoniae. Ceftriaxone has also been used successfully in a limited number of cases of meningitis and shunt infection caused by Staphylococcus epidermidis Efficacy for this organism in this organ system was studied in fewer than ten infections. and Escherichia coli Efficacy for this organism in this organ system was studied in fewer than ten infections. . Surgical Prophylaxis: The preoperative administration of a single 1 gm dose of ceftriaxone sodium may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated (e.g., vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high-risk patients, such as those over 70 years of age, with acute cholecystitis not requiring therapeutic antimicrobials, obstructive jaundice or common duct bile stones) and in surgical patients for whom infection at the operative site would present serious risk (e.g., during coronary artery bypass surgery). Although ceftriaxone has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo-controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of infection following coronary artery bypass surgery. When administered prior to surgical procedures for which it is indicated, a single 1 gm dose of ceftriaxone sodium provides protection from most infections due to susceptible organisms throughout the course of the procedure. uuid:9bea17b3-9a53-4259-a3b5-009260ab4092 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29007 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:ddb08b97-dae7-4739-8401-57324d430386"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:853291ee-0bf5-4d10-bd2d-a18fa6ae49f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection and other antibacterial drugs, ceftriaxone for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ceftriaxone sodium is indicated for the treatment of the following infections when caused by susceptible organisms: Lower Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis or Serratia marcescens. Acute Bacterial Otitis Media caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase producing strains) or Moraxella catarrhalis (including beta-lactamase producing strains). NOTE: In one study lower clinical cure rates were observed with a single dose of ceftriaxone sodium compared to 10 days of oral therapy. In a second study comparable cure rates were observed between single dose ceftriaxone sodium and the comparator. The potentially lower clinical cure rate of ceftriaxone should be balanced against the potential advantages of parenteral therapy (see CLINICAL STUDIES ). Skin And Skin Structure Infections caused by Staphylococcus aureus , Staphylococcus epidermidis , Streptococcus pyogenes , Viridans group streptococci, Escherichia coli , Enterobacter cloacae , Klebsiella oxytoca , Klebsiella pneumoniae , Proteus mirabilis , Morganella morganii Efficacy for this organism in this organ system was studied in fewer than ten infections. , Pseudomonas aeruginosa , Serratia marcescens , Acinetobacter calcoaceticus , Bacteroides fragilis Efficacy for this organism in this organ system was studied in fewer than ten infections. or Peptostreptococcus species. Urinary Tract Infections ( complicated and uncomplicated ) caused by Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii or Klebsiella pneumoniae. Uncomplicated Gonorrhea ( cervical/urethral and rectal ) caused by Neisseria gonorrhoeae , including both penicillinase- and nonpenicillinase-producing strains, and pharyngeal gonorrhea caused by nonpenicillinase-producing strains of Neisseria gonorrhoeae . Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae . Ceftriaxone sodium, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and Chlamydia trachomatis is one of the suspected pathogens, appropriate antichlamydial coverage should be added. Bacterial Septicemia caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae or Klebsiella pneumoniae. Bone And Joint Infections caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae or Enterobacter species. Intra-Abdominal Infections caused by Escherichia coli, Klebsiella pneumoniae , Bacteroides fragilis , Clostridium species (Note: most strains of Clostridium difficile are resistant) or Peptostreptococcus species. Meningitis caused by Haemophilus influenzae, Neisseria meningitidis or Streptococcus pneumoniae. Ceftriaxone has also been used successfully in a limited number of cases of meningitis and shunt infection caused by Staphylococcus epidermidis Efficacy for this organism in this organ system was studied in fewer than ten infections. and Escherichia coli Efficacy for this organism in this organ system was studied in fewer than ten infections. . Surgical Prophylaxis: The preoperative administration of a single 1 gm dose of ceftriaxone sodium may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated (e.g., vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high-risk patients, such as those over 70 years of age, with acute cholecystitis not requiring therapeutic antimicrobials, obstructive jaundice or common duct bile stones) and in surgical patients for whom infection at the operative site would present serious risk (e.g., during coronary artery bypass surgery). Although ceftriaxone has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo-controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of infection following coronary artery bypass surgery. When administered prior to surgical procedures for which it is indicated, a single 1 gm dose of ceftriaxone sodium provides protection from most infections due to susceptible organisms throughout the course of the procedure. uuid:c345a581-f4fd-4f5f-be6a-a2269c31d562 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29007 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:1cf8ca58-3967-482e-8736-f4943024c559"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:373d1790-328b-4039-91a3-ebbe5d7395cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection and other antibacterial drugs, ceftriaxone for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ceftriaxone sodium is indicated for the treatment of the following infections when caused by susceptible organisms: Lower Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis or Serratia marcescens. Acute Bacterial Otitis Media caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase producing strains) or Moraxella catarrhalis (including beta-lactamase producing strains). NOTE: In one study lower clinical cure rates were observed with a single dose of ceftriaxone sodium compared to 10 days of oral therapy. In a second study comparable cure rates were observed between single dose ceftriaxone sodium and the comparator. The potentially lower clinical cure rate of ceftriaxone should be balanced against the potential advantages of parenteral therapy (see CLINICAL STUDIES ). Skin And Skin Structure Infections caused by Staphylococcus aureus , Staphylococcus epidermidis , Streptococcus pyogenes , Viridans group streptococci, Escherichia coli , Enterobacter cloacae , Klebsiella oxytoca , Klebsiella pneumoniae , Proteus mirabilis , Morganella morganii Efficacy for this organism in this organ system was studied in fewer than ten infections. , Pseudomonas aeruginosa , Serratia marcescens , Acinetobacter calcoaceticus , Bacteroides fragilis Efficacy for this organism in this organ system was studied in fewer than ten infections. or Peptostreptococcus species. Urinary Tract Infections ( complicated and uncomplicated ) caused by Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii or Klebsiella pneumoniae. Uncomplicated Gonorrhea ( cervical/urethral and rectal ) caused by Neisseria gonorrhoeae , including both penicillinase- and nonpenicillinase-producing strains, and pharyngeal gonorrhea caused by nonpenicillinase-producing strains of Neisseria gonorrhoeae . Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae . Ceftriaxone sodium, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and Chlamydia trachomatis is one of the suspected pathogens, appropriate antichlamydial coverage should be added. Bacterial Septicemia caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae or Klebsiella pneumoniae. Bone And Joint Infections caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae or Enterobacter species. Intra-Abdominal Infections caused by Escherichia coli, Klebsiella pneumoniae , Bacteroides fragilis , Clostridium species (Note: most strains of Clostridium difficile are resistant) or Peptostreptococcus species. Meningitis caused by Haemophilus influenzae, Neisseria meningitidis or Streptococcus pneumoniae. Ceftriaxone has also been used successfully in a limited number of cases of meningitis and shunt infection caused by Staphylococcus epidermidis Efficacy for this organism in this organ system was studied in fewer than ten infections. and Escherichia coli Efficacy for this organism in this organ system was studied in fewer than ten infections. . Surgical Prophylaxis: The preoperative administration of a single 1 gm dose of ceftriaxone sodium may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated (e.g., vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high-risk patients, such as those over 70 years of age, with acute cholecystitis not requiring therapeutic antimicrobials, obstructive jaundice or common duct bile stones) and in surgical patients for whom infection at the operative site would present serious risk (e.g., during coronary artery bypass surgery). Although ceftriaxone has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo-controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of infection following coronary artery bypass surgery. When administered prior to surgical procedures for which it is indicated, a single 1 gm dose of ceftriaxone sodium provides protection from most infections due to susceptible organisms throughout the course of the procedure. uuid:217d3379-aafa-49aa-bc1d-338b40f96ed5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29007 biolink:treats MONDO:0004277 PMID:41385096 "[{""id"":""uuid:ce2762cb-cbe8-48e5-b40e-9aee4d6e4ce5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:873017ba-6c36-4188-988c-29a97a02f5fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection and other antibacterial drugs, ceftriaxone for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ceftriaxone sodium is indicated for the treatment of the following infections when caused by susceptible organisms: Lower Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis or Serratia marcescens. Acute Bacterial Otitis Media caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase producing strains) or Moraxella catarrhalis (including beta-lactamase producing strains). NOTE: In one study lower clinical cure rates were observed with a single dose of ceftriaxone sodium compared to 10 days of oral therapy. In a second study comparable cure rates were observed between single dose ceftriaxone sodium and the comparator. The potentially lower clinical cure rate of ceftriaxone should be balanced against the potential advantages of parenteral therapy (see CLINICAL STUDIES ). Skin And Skin Structure Infections caused by Staphylococcus aureus , Staphylococcus epidermidis , Streptococcus pyogenes , Viridans group streptococci, Escherichia coli , Enterobacter cloacae , Klebsiella oxytoca , Klebsiella pneumoniae , Proteus mirabilis , Morganella morganii Efficacy for this organism in this organ system was studied in fewer than ten infections. , Pseudomonas aeruginosa , Serratia marcescens , Acinetobacter calcoaceticus , Bacteroides fragilis Efficacy for this organism in this organ system was studied in fewer than ten infections. or Peptostreptococcus species. Urinary Tract Infections ( complicated and uncomplicated ) caused by Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii or Klebsiella pneumoniae. Uncomplicated Gonorrhea ( cervical/urethral and rectal ) caused by Neisseria gonorrhoeae , including both penicillinase- and nonpenicillinase-producing strains, and pharyngeal gonorrhea caused by nonpenicillinase-producing strains of Neisseria gonorrhoeae . Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae . Ceftriaxone sodium, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and Chlamydia trachomatis is one of the suspected pathogens, appropriate antichlamydial coverage should be added. Bacterial Septicemia caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae or Klebsiella pneumoniae. Bone And Joint Infections caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae or Enterobacter species. Intra-Abdominal Infections caused by Escherichia coli, Klebsiella pneumoniae , Bacteroides fragilis , Clostridium species (Note: most strains of Clostridium difficile are resistant) or Peptostreptococcus species. Meningitis caused by Haemophilus influenzae, Neisseria meningitidis or Streptococcus pneumoniae. Ceftriaxone has also been used successfully in a limited number of cases of meningitis and shunt infection caused by Staphylococcus epidermidis Efficacy for this organism in this organ system was studied in fewer than ten infections. and Escherichia coli Efficacy for this organism in this organ system was studied in fewer than ten infections. . Surgical Prophylaxis: The preoperative administration of a single 1 gm dose of ceftriaxone sodium may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated (e.g., vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high-risk patients, such as those over 70 years of age, with acute cholecystitis not requiring therapeutic antimicrobials, obstructive jaundice or common duct bile stones) and in surgical patients for whom infection at the operative site would present serious risk (e.g., during coronary artery bypass surgery). Although ceftriaxone has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo-controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of infection following coronary artery bypass surgery. When administered prior to surgical procedures for which it is indicated, a single 1 gm dose of ceftriaxone sodium provides protection from most infections due to susceptible organisms throughout the course of the procedure. uuid:99321482-760c-41c3-abae-9a7b2566a931 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29007 biolink:treats MONDO:0000922 PMID:41385096 "[{""id"":""uuid:ea944219-04e1-4617-8a2a-b6d4d52f0849"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:03508d3a-026d-45e5-9b70-d02433ce5f8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection and other antibacterial drugs, ceftriaxone for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ceftriaxone sodium is indicated for the treatment of the following infections when caused by susceptible organisms: Lower Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis or Serratia marcescens. Acute Bacterial Otitis Media caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase producing strains) or Moraxella catarrhalis (including beta-lactamase producing strains). NOTE: In one study lower clinical cure rates were observed with a single dose of ceftriaxone sodium compared to 10 days of oral therapy. In a second study comparable cure rates were observed between single dose ceftriaxone sodium and the comparator. The potentially lower clinical cure rate of ceftriaxone should be balanced against the potential advantages of parenteral therapy (see CLINICAL STUDIES ). Skin And Skin Structure Infections caused by Staphylococcus aureus , Staphylococcus epidermidis , Streptococcus pyogenes , Viridans group streptococci, Escherichia coli , Enterobacter cloacae , Klebsiella oxytoca , Klebsiella pneumoniae , Proteus mirabilis , Morganella morganii Efficacy for this organism in this organ system was studied in fewer than ten infections. , Pseudomonas aeruginosa , Serratia marcescens , Acinetobacter calcoaceticus , Bacteroides fragilis Efficacy for this organism in this organ system was studied in fewer than ten infections. or Peptostreptococcus species. Urinary Tract Infections ( complicated and uncomplicated ) caused by Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii or Klebsiella pneumoniae. Uncomplicated Gonorrhea ( cervical/urethral and rectal ) caused by Neisseria gonorrhoeae , including both penicillinase- and nonpenicillinase-producing strains, and pharyngeal gonorrhea caused by nonpenicillinase-producing strains of Neisseria gonorrhoeae . Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae . Ceftriaxone sodium, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and Chlamydia trachomatis is one of the suspected pathogens, appropriate antichlamydial coverage should be added. Bacterial Septicemia caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae or Klebsiella pneumoniae. Bone And Joint Infections caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae or Enterobacter species. Intra-Abdominal Infections caused by Escherichia coli, Klebsiella pneumoniae , Bacteroides fragilis , Clostridium species (Note: most strains of Clostridium difficile are resistant) or Peptostreptococcus species. Meningitis caused by Haemophilus influenzae, Neisseria meningitidis or Streptococcus pneumoniae. Ceftriaxone has also been used successfully in a limited number of cases of meningitis and shunt infection caused by Staphylococcus epidermidis Efficacy for this organism in this organ system was studied in fewer than ten infections. and Escherichia coli Efficacy for this organism in this organ system was studied in fewer than ten infections. . Surgical Prophylaxis: The preoperative administration of a single 1 gm dose of ceftriaxone sodium may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated (e.g., vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high-risk patients, such as those over 70 years of age, with acute cholecystitis not requiring therapeutic antimicrobials, obstructive jaundice or common duct bile stones) and in surgical patients for whom infection at the operative site would present serious risk (e.g., during coronary artery bypass surgery). Although ceftriaxone has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo-controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of infection following coronary artery bypass surgery. When administered prior to surgical procedures for which it is indicated, a single 1 gm dose of ceftriaxone sodium provides protection from most infections due to susceptible organisms throughout the course of the procedure. uuid:a751caf7-99ef-417e-82d9-859894fc7b43 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29007 biolink:treats UMLS:C0684256 PMID:41385096 "[{""id"":""uuid:416fe5f3-0dcd-4c51-b842-7f2a5bc3373e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:06f714c5-1ac7-4ec1-8a20-27dc74439f87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection and other antibacterial drugs, ceftriaxone for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ceftriaxone sodium is indicated for the treatment of the following infections when caused by susceptible organisms: Lower Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis or Serratia marcescens. Acute Bacterial Otitis Media caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase producing strains) or Moraxella catarrhalis (including beta-lactamase producing strains). NOTE: In one study lower clinical cure rates were observed with a single dose of ceftriaxone sodium compared to 10 days of oral therapy. In a second study comparable cure rates were observed between single dose ceftriaxone sodium and the comparator. The potentially lower clinical cure rate of ceftriaxone should be balanced against the potential advantages of parenteral therapy (see CLINICAL STUDIES ). Skin And Skin Structure Infections caused by Staphylococcus aureus , Staphylococcus epidermidis , Streptococcus pyogenes , Viridans group streptococci, Escherichia coli , Enterobacter cloacae , Klebsiella oxytoca , Klebsiella pneumoniae , Proteus mirabilis , Morganella morganii Efficacy for this organism in this organ system was studied in fewer than ten infections. , Pseudomonas aeruginosa , Serratia marcescens , Acinetobacter calcoaceticus , Bacteroides fragilis Efficacy for this organism in this organ system was studied in fewer than ten infections. or Peptostreptococcus species. Urinary Tract Infections ( complicated and uncomplicated ) caused by Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii or Klebsiella pneumoniae. Uncomplicated Gonorrhea ( cervical/urethral and rectal ) caused by Neisseria gonorrhoeae , including both penicillinase- and nonpenicillinase-producing strains, and pharyngeal gonorrhea caused by nonpenicillinase-producing strains of Neisseria gonorrhoeae . Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae . Ceftriaxone sodium, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and Chlamydia trachomatis is one of the suspected pathogens, appropriate antichlamydial coverage should be added. Bacterial Septicemia caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae or Klebsiella pneumoniae. Bone And Joint Infections caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae or Enterobacter species. Intra-Abdominal Infections caused by Escherichia coli, Klebsiella pneumoniae , Bacteroides fragilis , Clostridium species (Note: most strains of Clostridium difficile are resistant) or Peptostreptococcus species. Meningitis caused by Haemophilus influenzae, Neisseria meningitidis or Streptococcus pneumoniae. Ceftriaxone has also been used successfully in a limited number of cases of meningitis and shunt infection caused by Staphylococcus epidermidis Efficacy for this organism in this organ system was studied in fewer than ten infections. and Escherichia coli Efficacy for this organism in this organ system was studied in fewer than ten infections. . Surgical Prophylaxis: The preoperative administration of a single 1 gm dose of ceftriaxone sodium may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated (e.g., vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high-risk patients, such as those over 70 years of age, with acute cholecystitis not requiring therapeutic antimicrobials, obstructive jaundice or common duct bile stones) and in surgical patients for whom infection at the operative site would present serious risk (e.g., during coronary artery bypass surgery). Although ceftriaxone has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo-controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of infection following coronary artery bypass surgery. When administered prior to surgical procedures for which it is indicated, a single 1 gm dose of ceftriaxone sodium provides protection from most infections due to susceptible organisms throughout the course of the procedure. uuid:dab11ed8-8a01-4c9e-aed2-ad3f51ed3178 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29007 biolink:treats UMLS:C0851989 PMID:41385096 "[{""id"":""uuid:a1aebbc4-3642-404a-8317-a1fe47ed24ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:42d65255-de96-4588-9320-e82e3e8e276c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection and other antibacterial drugs, ceftriaxone for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ceftriaxone sodium is indicated for the treatment of the following infections when caused by susceptible organisms: Lower Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis or Serratia marcescens. Acute Bacterial Otitis Media caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase producing strains) or Moraxella catarrhalis (including beta-lactamase producing strains). NOTE: In one study lower clinical cure rates were observed with a single dose of ceftriaxone sodium compared to 10 days of oral therapy. In a second study comparable cure rates were observed between single dose ceftriaxone sodium and the comparator. The potentially lower clinical cure rate of ceftriaxone should be balanced against the potential advantages of parenteral therapy (see CLINICAL STUDIES ). Skin And Skin Structure Infections caused by Staphylococcus aureus , Staphylococcus epidermidis , Streptococcus pyogenes , Viridans group streptococci, Escherichia coli , Enterobacter cloacae , Klebsiella oxytoca , Klebsiella pneumoniae , Proteus mirabilis , Morganella morganii Efficacy for this organism in this organ system was studied in fewer than ten infections. , Pseudomonas aeruginosa , Serratia marcescens , Acinetobacter calcoaceticus , Bacteroides fragilis Efficacy for this organism in this organ system was studied in fewer than ten infections. or Peptostreptococcus species. Urinary Tract Infections ( complicated and uncomplicated ) caused by Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii or Klebsiella pneumoniae. Uncomplicated Gonorrhea ( cervical/urethral and rectal ) caused by Neisseria gonorrhoeae , including both penicillinase- and nonpenicillinase-producing strains, and pharyngeal gonorrhea caused by nonpenicillinase-producing strains of Neisseria gonorrhoeae . Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae . Ceftriaxone sodium, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and Chlamydia trachomatis is one of the suspected pathogens, appropriate antichlamydial coverage should be added. Bacterial Septicemia caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae or Klebsiella pneumoniae. Bone And Joint Infections caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae or Enterobacter species. Intra-Abdominal Infections caused by Escherichia coli, Klebsiella pneumoniae , Bacteroides fragilis , Clostridium species (Note: most strains of Clostridium difficile are resistant) or Peptostreptococcus species. Meningitis caused by Haemophilus influenzae, Neisseria meningitidis or Streptococcus pneumoniae. Ceftriaxone has also been used successfully in a limited number of cases of meningitis and shunt infection caused by Staphylococcus epidermidis Efficacy for this organism in this organ system was studied in fewer than ten infections. and Escherichia coli Efficacy for this organism in this organ system was studied in fewer than ten infections. . Surgical Prophylaxis: The preoperative administration of a single 1 gm dose of ceftriaxone sodium may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated (e.g., vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high-risk patients, such as those over 70 years of age, with acute cholecystitis not requiring therapeutic antimicrobials, obstructive jaundice or common duct bile stones) and in surgical patients for whom infection at the operative site would present serious risk (e.g., during coronary artery bypass surgery). Although ceftriaxone has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo-controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of infection following coronary artery bypass surgery. When administered prior to surgical procedures for which it is indicated, a single 1 gm dose of ceftriaxone sodium provides protection from most infections due to susceptible organisms throughout the course of the procedure. uuid:e0a027b5-86fe-4e7f-aeaa-2116aae994af biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29007 biolink:treats UMLS:C1112209 PMID:41385096 "[{""id"":""uuid:69cde743-a947-402c-8192-25eadc644941"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6498e403-2a5a-4f55-a2bb-5e7408b52bce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection and other antibacterial drugs, ceftriaxone for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ceftriaxone sodium is indicated for the treatment of the following infections when caused by susceptible organisms: Lower Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis or Serratia marcescens. Acute Bacterial Otitis Media caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase producing strains) or Moraxella catarrhalis (including beta-lactamase producing strains). NOTE: In one study lower clinical cure rates were observed with a single dose of ceftriaxone sodium compared to 10 days of oral therapy. In a second study comparable cure rates were observed between single dose ceftriaxone sodium and the comparator. The potentially lower clinical cure rate of ceftriaxone should be balanced against the potential advantages of parenteral therapy (see CLINICAL STUDIES ). Skin And Skin Structure Infections caused by Staphylococcus aureus , Staphylococcus epidermidis , Streptococcus pyogenes , Viridans group streptococci, Escherichia coli , Enterobacter cloacae , Klebsiella oxytoca , Klebsiella pneumoniae , Proteus mirabilis , Morganella morganii Efficacy for this organism in this organ system was studied in fewer than ten infections. , Pseudomonas aeruginosa , Serratia marcescens , Acinetobacter calcoaceticus , Bacteroides fragilis Efficacy for this organism in this organ system was studied in fewer than ten infections. or Peptostreptococcus species. Urinary Tract Infections ( complicated and uncomplicated ) caused by Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii or Klebsiella pneumoniae. Uncomplicated Gonorrhea ( cervical/urethral and rectal ) caused by Neisseria gonorrhoeae , including both penicillinase- and nonpenicillinase-producing strains, and pharyngeal gonorrhea caused by nonpenicillinase-producing strains of Neisseria gonorrhoeae . Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae . Ceftriaxone sodium, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and Chlamydia trachomatis is one of the suspected pathogens, appropriate antichlamydial coverage should be added. Bacterial Septicemia caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae or Klebsiella pneumoniae. Bone And Joint Infections caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae or Enterobacter species. Intra-Abdominal Infections caused by Escherichia coli, Klebsiella pneumoniae , Bacteroides fragilis , Clostridium species (Note: most strains of Clostridium difficile are resistant) or Peptostreptococcus species. Meningitis caused by Haemophilus influenzae, Neisseria meningitidis or Streptococcus pneumoniae. Ceftriaxone has also been used successfully in a limited number of cases of meningitis and shunt infection caused by Staphylococcus epidermidis Efficacy for this organism in this organ system was studied in fewer than ten infections. and Escherichia coli Efficacy for this organism in this organ system was studied in fewer than ten infections. . Surgical Prophylaxis: The preoperative administration of a single 1 gm dose of ceftriaxone sodium may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated (e.g., vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high-risk patients, such as those over 70 years of age, with acute cholecystitis not requiring therapeutic antimicrobials, obstructive jaundice or common duct bile stones) and in surgical patients for whom infection at the operative site would present serious risk (e.g., during coronary artery bypass surgery). Although ceftriaxone has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo-controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of infection following coronary artery bypass surgery. When administered prior to surgical procedures for which it is indicated, a single 1 gm dose of ceftriaxone sodium provides protection from most infections due to susceptible organisms throughout the course of the procedure. uuid:b7c61b45-4786-49cf-b726-d57f7882119d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29007 biolink:treats MONDO:0021108 PMID:41385096 "[{""id"":""uuid:bfce181d-66b2-475e-ba5f-99120fb4f7be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:66704eb9-723a-4ad1-a980-e8f58fefbdcd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection and other antibacterial drugs, ceftriaxone for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ceftriaxone sodium is indicated for the treatment of the following infections when caused by susceptible organisms: Lower Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis or Serratia marcescens. Acute Bacterial Otitis Media caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase producing strains) or Moraxella catarrhalis (including beta-lactamase producing strains). NOTE: In one study lower clinical cure rates were observed with a single dose of ceftriaxone sodium compared to 10 days of oral therapy. In a second study comparable cure rates were observed between single dose ceftriaxone sodium and the comparator. The potentially lower clinical cure rate of ceftriaxone should be balanced against the potential advantages of parenteral therapy (see CLINICAL STUDIES ). Skin And Skin Structure Infections caused by Staphylococcus aureus , Staphylococcus epidermidis , Streptococcus pyogenes , Viridans group streptococci, Escherichia coli , Enterobacter cloacae , Klebsiella oxytoca , Klebsiella pneumoniae , Proteus mirabilis , Morganella morganii Efficacy for this organism in this organ system was studied in fewer than ten infections. , Pseudomonas aeruginosa , Serratia marcescens , Acinetobacter calcoaceticus , Bacteroides fragilis Efficacy for this organism in this organ system was studied in fewer than ten infections. or Peptostreptococcus species. Urinary Tract Infections ( complicated and uncomplicated ) caused by Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii or Klebsiella pneumoniae. Uncomplicated Gonorrhea ( cervical/urethral and rectal ) caused by Neisseria gonorrhoeae , including both penicillinase- and nonpenicillinase-producing strains, and pharyngeal gonorrhea caused by nonpenicillinase-producing strains of Neisseria gonorrhoeae . Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae . Ceftriaxone sodium, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and Chlamydia trachomatis is one of the suspected pathogens, appropriate antichlamydial coverage should be added. Bacterial Septicemia caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae or Klebsiella pneumoniae. Bone And Joint Infections caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae or Enterobacter species. Intra-Abdominal Infections caused by Escherichia coli, Klebsiella pneumoniae , Bacteroides fragilis , Clostridium species (Note: most strains of Clostridium difficile are resistant) or Peptostreptococcus species. Meningitis caused by Haemophilus influenzae, Neisseria meningitidis or Streptococcus pneumoniae. Ceftriaxone has also been used successfully in a limited number of cases of meningitis and shunt infection caused by Staphylococcus epidermidis Efficacy for this organism in this organ system was studied in fewer than ten infections. and Escherichia coli Efficacy for this organism in this organ system was studied in fewer than ten infections. . Surgical Prophylaxis: The preoperative administration of a single 1 gm dose of ceftriaxone sodium may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated (e.g., vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high-risk patients, such as those over 70 years of age, with acute cholecystitis not requiring therapeutic antimicrobials, obstructive jaundice or common duct bile stones) and in surgical patients for whom infection at the operative site would present serious risk (e.g., during coronary artery bypass surgery). Although ceftriaxone has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo-controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of infection following coronary artery bypass surgery. When administered prior to surgical procedures for which it is indicated, a single 1 gm dose of ceftriaxone sodium provides protection from most infections due to susceptible organisms throughout the course of the procedure. uuid:d3a45177-7912-43fe-8ac6-db0bc8d5593d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29007 biolink:treats MONDO:0021839 PMID:41385096 "[{""id"":""uuid:311209b4-b993-49ec-b688-ad79446d90ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dcf3e3f1-efa2-45e6-bc65-bf9fb54c4679"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection and other antibacterial drugs, ceftriaxone for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ceftriaxone sodium is indicated for the treatment of the following infections when caused by susceptible organisms: Lower Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis or Serratia marcescens. Acute Bacterial Otitis Media caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase producing strains) or Moraxella catarrhalis (including beta-lactamase producing strains). NOTE: In one study lower clinical cure rates were observed with a single dose of ceftriaxone sodium compared to 10 days of oral therapy. In a second study comparable cure rates were observed between single dose ceftriaxone sodium and the comparator. The potentially lower clinical cure rate of ceftriaxone should be balanced against the potential advantages of parenteral therapy (see CLINICAL STUDIES ). Skin And Skin Structure Infections caused by Staphylococcus aureus , Staphylococcus epidermidis , Streptococcus pyogenes , Viridans group streptococci, Escherichia coli , Enterobacter cloacae , Klebsiella oxytoca , Klebsiella pneumoniae , Proteus mirabilis , Morganella morganii Efficacy for this organism in this organ system was studied in fewer than ten infections. , Pseudomonas aeruginosa , Serratia marcescens , Acinetobacter calcoaceticus , Bacteroides fragilis Efficacy for this organism in this organ system was studied in fewer than ten infections. or Peptostreptococcus species. Urinary Tract Infections ( complicated and uncomplicated ) caused by Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii or Klebsiella pneumoniae. Uncomplicated Gonorrhea ( cervical/urethral and rectal ) caused by Neisseria gonorrhoeae , including both penicillinase- and nonpenicillinase-producing strains, and pharyngeal gonorrhea caused by nonpenicillinase-producing strains of Neisseria gonorrhoeae . Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae . Ceftriaxone sodium, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and Chlamydia trachomatis is one of the suspected pathogens, appropriate antichlamydial coverage should be added. Bacterial Septicemia caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae or Klebsiella pneumoniae. Bone And Joint Infections caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae or Enterobacter species. Intra-Abdominal Infections caused by Escherichia coli, Klebsiella pneumoniae , Bacteroides fragilis , Clostridium species (Note: most strains of Clostridium difficile are resistant) or Peptostreptococcus species. Meningitis caused by Haemophilus influenzae, Neisseria meningitidis or Streptococcus pneumoniae. Ceftriaxone has also been used successfully in a limited number of cases of meningitis and shunt infection caused by Staphylococcus epidermidis Efficacy for this organism in this organ system was studied in fewer than ten infections. and Escherichia coli Efficacy for this organism in this organ system was studied in fewer than ten infections. . Surgical Prophylaxis: The preoperative administration of a single 1 gm dose of ceftriaxone sodium may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated (e.g., vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high-risk patients, such as those over 70 years of age, with acute cholecystitis not requiring therapeutic antimicrobials, obstructive jaundice or common duct bile stones) and in surgical patients for whom infection at the operative site would present serious risk (e.g., during coronary artery bypass surgery). Although ceftriaxone has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo-controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of infection following coronary artery bypass surgery. When administered prior to surgical procedures for which it is indicated, a single 1 gm dose of ceftriaxone sodium provides protection from most infections due to susceptible organisms throughout the course of the procedure. uuid:e7ee463c-3152-43f5-ab2e-ed8a2afbe6bd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29007 biolink:treats MONDO:0043994 PMID:41385096 "[{""id"":""uuid:90ba9cb8-1145-4595-94d4-5f3647d905b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:877f6696-dfaa-4c30-9128-fab5593e0344"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection and other antibacterial drugs, ceftriaxone for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ceftriaxone sodium is indicated for the treatment of the following infections when caused by susceptible organisms: Lower Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis or Serratia marcescens. Acute Bacterial Otitis Media caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase producing strains) or Moraxella catarrhalis (including beta-lactamase producing strains). NOTE: In one study lower clinical cure rates were observed with a single dose of ceftriaxone sodium compared to 10 days of oral therapy. In a second study comparable cure rates were observed between single dose ceftriaxone sodium and the comparator. The potentially lower clinical cure rate of ceftriaxone should be balanced against the potential advantages of parenteral therapy (see CLINICAL STUDIES ). Skin And Skin Structure Infections caused by Staphylococcus aureus , Staphylococcus epidermidis , Streptococcus pyogenes , Viridans group streptococci, Escherichia coli , Enterobacter cloacae , Klebsiella oxytoca , Klebsiella pneumoniae , Proteus mirabilis , Morganella morganii Efficacy for this organism in this organ system was studied in fewer than ten infections. , Pseudomonas aeruginosa , Serratia marcescens , Acinetobacter calcoaceticus , Bacteroides fragilis Efficacy for this organism in this organ system was studied in fewer than ten infections. or Peptostreptococcus species. Urinary Tract Infections ( complicated and uncomplicated ) caused by Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii or Klebsiella pneumoniae. Uncomplicated Gonorrhea ( cervical/urethral and rectal ) caused by Neisseria gonorrhoeae , including both penicillinase- and nonpenicillinase-producing strains, and pharyngeal gonorrhea caused by nonpenicillinase-producing strains of Neisseria gonorrhoeae . Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae . Ceftriaxone sodium, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and Chlamydia trachomatis is one of the suspected pathogens, appropriate antichlamydial coverage should be added. Bacterial Septicemia caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae or Klebsiella pneumoniae. Bone And Joint Infections caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae or Enterobacter species. Intra-Abdominal Infections caused by Escherichia coli, Klebsiella pneumoniae , Bacteroides fragilis , Clostridium species (Note: most strains of Clostridium difficile are resistant) or Peptostreptococcus species. Meningitis caused by Haemophilus influenzae, Neisseria meningitidis or Streptococcus pneumoniae. Ceftriaxone has also been used successfully in a limited number of cases of meningitis and shunt infection caused by Staphylococcus epidermidis Efficacy for this organism in this organ system was studied in fewer than ten infections. and Escherichia coli Efficacy for this organism in this organ system was studied in fewer than ten infections. . Surgical Prophylaxis: The preoperative administration of a single 1 gm dose of ceftriaxone sodium may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated (e.g., vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high-risk patients, such as those over 70 years of age, with acute cholecystitis not requiring therapeutic antimicrobials, obstructive jaundice or common duct bile stones) and in surgical patients for whom infection at the operative site would present serious risk (e.g., during coronary artery bypass surgery). Although ceftriaxone has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo-controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of infection following coronary artery bypass surgery. When administered prior to surgical procedures for which it is indicated, a single 1 gm dose of ceftriaxone sodium provides protection from most infections due to susceptible organisms throughout the course of the procedure. uuid:fd0905fa-ec32-4f1d-ae03-db32912447c9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29007 biolink:treats MONDO:0006874 PMID:41385096 "[{""id"":""uuid:c4e50797-46ad-4f7a-ba02-a3943d044470"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fc3f4ad8-aa79-444e-81d9-62250881a709"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection and other antibacterial drugs, ceftriaxone for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ceftriaxone sodium is indicated for the treatment of the following infections when caused by susceptible organisms: Lower Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis or Serratia marcescens. Acute Bacterial Otitis Media caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase producing strains) or Moraxella catarrhalis (including beta-lactamase producing strains). NOTE: In one study lower clinical cure rates were observed with a single dose of ceftriaxone sodium compared to 10 days of oral therapy. In a second study comparable cure rates were observed between single dose ceftriaxone sodium and the comparator. The potentially lower clinical cure rate of ceftriaxone should be balanced against the potential advantages of parenteral therapy (see CLINICAL STUDIES ). Skin And Skin Structure Infections caused by Staphylococcus aureus , Staphylococcus epidermidis , Streptococcus pyogenes , Viridans group streptococci, Escherichia coli , Enterobacter cloacae , Klebsiella oxytoca , Klebsiella pneumoniae , Proteus mirabilis , Morganella morganii Efficacy for this organism in this organ system was studied in fewer than ten infections. , Pseudomonas aeruginosa , Serratia marcescens , Acinetobacter calcoaceticus , Bacteroides fragilis Efficacy for this organism in this organ system was studied in fewer than ten infections. or Peptostreptococcus species. Urinary Tract Infections ( complicated and uncomplicated ) caused by Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii or Klebsiella pneumoniae. Uncomplicated Gonorrhea ( cervical/urethral and rectal ) caused by Neisseria gonorrhoeae , including both penicillinase- and nonpenicillinase-producing strains, and pharyngeal gonorrhea caused by nonpenicillinase-producing strains of Neisseria gonorrhoeae . Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae . Ceftriaxone sodium, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and Chlamydia trachomatis is one of the suspected pathogens, appropriate antichlamydial coverage should be added. Bacterial Septicemia caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae or Klebsiella pneumoniae. Bone And Joint Infections caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae or Enterobacter species. Intra-Abdominal Infections caused by Escherichia coli, Klebsiella pneumoniae , Bacteroides fragilis , Clostridium species (Note: most strains of Clostridium difficile are resistant) or Peptostreptococcus species. Meningitis caused by Haemophilus influenzae, Neisseria meningitidis or Streptococcus pneumoniae. Ceftriaxone has also been used successfully in a limited number of cases of meningitis and shunt infection caused by Staphylococcus epidermidis Efficacy for this organism in this organ system was studied in fewer than ten infections. and Escherichia coli Efficacy for this organism in this organ system was studied in fewer than ten infections. . Surgical Prophylaxis: The preoperative administration of a single 1 gm dose of ceftriaxone sodium may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated (e.g., vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high-risk patients, such as those over 70 years of age, with acute cholecystitis not requiring therapeutic antimicrobials, obstructive jaundice or common duct bile stones) and in surgical patients for whom infection at the operative site would present serious risk (e.g., during coronary artery bypass surgery). Although ceftriaxone has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo-controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of infection following coronary artery bypass surgery. When administered prior to surgical procedures for which it is indicated, a single 1 gm dose of ceftriaxone sodium provides protection from most infections due to susceptible organisms throughout the course of the procedure. uuid:f0d2e4ec-2521-4032-a6cb-a19571332c12 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29007 biolink:treats MONDO:0006699 PMID:41385096 "[{""id"":""uuid:c3bbe172-ff80-444b-915f-54e03605f683"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0356ab0d-d9ce-4860-be95-54c5e780666c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection and other antibacterial drugs, ceftriaxone for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ceftriaxone sodium is indicated for the treatment of the following infections when caused by susceptible organisms: Lower Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis or Serratia marcescens. Acute Bacterial Otitis Media caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase producing strains) or Moraxella catarrhalis (including beta-lactamase producing strains). NOTE: In one study lower clinical cure rates were observed with a single dose of ceftriaxone sodium compared to 10 days of oral therapy. In a second study comparable cure rates were observed between single dose ceftriaxone sodium and the comparator. The potentially lower clinical cure rate of ceftriaxone should be balanced against the potential advantages of parenteral therapy (see CLINICAL STUDIES ). Skin And Skin Structure Infections caused by Staphylococcus aureus , Staphylococcus epidermidis , Streptococcus pyogenes , Viridans group streptococci, Escherichia coli , Enterobacter cloacae , Klebsiella oxytoca , Klebsiella pneumoniae , Proteus mirabilis , Morganella morganii Efficacy for this organism in this organ system was studied in fewer than ten infections. , Pseudomonas aeruginosa , Serratia marcescens , Acinetobacter calcoaceticus , Bacteroides fragilis Efficacy for this organism in this organ system was studied in fewer than ten infections. or Peptostreptococcus species. Urinary Tract Infections ( complicated and uncomplicated ) caused by Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii or Klebsiella pneumoniae. Uncomplicated Gonorrhea ( cervical/urethral and rectal ) caused by Neisseria gonorrhoeae , including both penicillinase- and nonpenicillinase-producing strains, and pharyngeal gonorrhea caused by nonpenicillinase-producing strains of Neisseria gonorrhoeae . Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae . Ceftriaxone sodium, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and Chlamydia trachomatis is one of the suspected pathogens, appropriate antichlamydial coverage should be added. Bacterial Septicemia caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae or Klebsiella pneumoniae. Bone And Joint Infections caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae or Enterobacter species. Intra-Abdominal Infections caused by Escherichia coli, Klebsiella pneumoniae , Bacteroides fragilis , Clostridium species (Note: most strains of Clostridium difficile are resistant) or Peptostreptococcus species. Meningitis caused by Haemophilus influenzae, Neisseria meningitidis or Streptococcus pneumoniae. Ceftriaxone has also been used successfully in a limited number of cases of meningitis and shunt infection caused by Staphylococcus epidermidis Efficacy for this organism in this organ system was studied in fewer than ten infections. and Escherichia coli Efficacy for this organism in this organ system was studied in fewer than ten infections. . Surgical Prophylaxis: The preoperative administration of a single 1 gm dose of ceftriaxone sodium may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated (e.g., vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high-risk patients, such as those over 70 years of age, with acute cholecystitis not requiring therapeutic antimicrobials, obstructive jaundice or common duct bile stones) and in surgical patients for whom infection at the operative site would present serious risk (e.g., during coronary artery bypass surgery). Although ceftriaxone has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo-controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of infection following coronary artery bypass surgery. When administered prior to surgical procedures for which it is indicated, a single 1 gm dose of ceftriaxone sodium provides protection from most infections due to susceptible organisms throughout the course of the procedure. uuid:5126b632-f761-4004-a468-02c44be0ecc7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0005556 PMID:41385096 "[{""id"":""uuid:61ec78f0-ed14-4b8a-92ef-0453520d9b57"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3b89505e-f71e-44bf-bb5d-d8e3e61af25b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection (triamcinolone acetonide injectable suspension, USP) is indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:d4163c4e-ef25-4a24-a368-464c8f665b10 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4858 biolink:treats MONDO:0013600 PMID:41385096 "[{""id"":""uuid:483ce9b9-254b-4ed1-b08c-12833426cce9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5038438d-6d34-41bc-908a-9e764bc11fb9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Estazolam tablets are indicated for the short-term management of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. Both out-patient studies and a sleep laboratory study have shown that estazolam administered at bedtime improved sleep induction and sleep maintenance (see CLINICAL PHARMACOLOGY ). Because insomnia is often transient and intermittent, the prolonged administration of estazolam is generally neither necessary nor recommended. Since insomnia may be a symptom of several other disorders, the possibility that the complaint may be related to a condition for which there is a more specific treatment should be considered. There is evidence to support the ability of estazolam to enhance the duration and quality of sleep for intervals up to 12 weeks (see CLINICAL PHARMACOLOGY ). uuid:d2f4dc61-b766-41fb-a7d1-f9171c6eb8f0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:38545 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:c5a2684e-9e22-43b7-b80f-ae5b2e435fb8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8338e3de-0cad-422a-bc49-a4ffda834ae7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hyperlipidemia and Mixed Dyslipidemia CRESTOR is indicated as adjunctive therapy to diet to reduce elevated total-C, LDL-C, ApoB, nonHDL-C, and triglycerides and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia. Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate. 1.2 Hypertriglyceridemia CRESTOR is indicated as adjunctive therapy to diet for the treatment of adult patients with hypertriglyceridemia. 1.3 Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) CRESTOR is indicated as an adjunct to diet for the treatment of patients with primary dysbetalipoproteinemia (Type III Hyperlipoproteinemia). 1.4 Homozygous Familial Hypercholesterolemia CRESTOR is indicated as adjunctive therapy to other lipid-lowering treatments (e.g., LDL apheresis) or alone if such treatments are unavailable to reduce LDL-C, Total-C, and ApoB in adult patients with homozygous familial hypercholesterolemia. 1.5 Slowing of the Progression of Atherosclerosis CRESTOR is indicated as adjunctive therapy to diet to slow the progression of atherosclerosis in adult patients as part of a treatment strategy to lower Total-C and LDL-C to target levels. 1.6 Limitations of Use The effect of CRESTOR on cardiovascular morbidity and mortality has not been determined. CRESTOR has not been studied in Fredrickson Type I and V dyslipidemias. uuid:9291cf67-557f-4bc1-ae66-8042b37ba1d0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:38545 biolink:treats HP:0003119 PMID:41385096 "[{""id"":""uuid:23e6114b-5dab-44c3-a32b-509eb333e74e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dfc9d933-0baf-4689-8e03-af3e83aa622b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hyperlipidemia and Mixed Dyslipidemia CRESTOR is indicated as adjunctive therapy to diet to reduce elevated total-C, LDL-C, ApoB, nonHDL-C, and triglycerides and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia. Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate. 1.2 Hypertriglyceridemia CRESTOR is indicated as adjunctive therapy to diet for the treatment of adult patients with hypertriglyceridemia. 1.3 Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) CRESTOR is indicated as an adjunct to diet for the treatment of patients with primary dysbetalipoproteinemia (Type III Hyperlipoproteinemia). 1.4 Homozygous Familial Hypercholesterolemia CRESTOR is indicated as adjunctive therapy to other lipid-lowering treatments (e.g., LDL apheresis) or alone if such treatments are unavailable to reduce LDL-C, Total-C, and ApoB in adult patients with homozygous familial hypercholesterolemia. 1.5 Slowing of the Progression of Atherosclerosis CRESTOR is indicated as adjunctive therapy to diet to slow the progression of atherosclerosis in adult patients as part of a treatment strategy to lower Total-C and LDL-C to target levels. 1.6 Limitations of Use The effect of CRESTOR on cardiovascular morbidity and mortality has not been determined. CRESTOR has not been studied in Fredrickson Type I and V dyslipidemias. uuid:7c6c9ab5-1806-4cc1-82f5-bd9a6cb6140b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:38545 biolink:treats MONDO:0005347 PMID:41385096 "[{""id"":""uuid:d7a4be2f-84fb-42eb-b449-bda99914613d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9884377f-1ee9-4428-b4e9-4c60d657f222"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hyperlipidemia and Mixed Dyslipidemia CRESTOR is indicated as adjunctive therapy to diet to reduce elevated total-C, LDL-C, ApoB, nonHDL-C, and triglycerides and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia. Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate. 1.2 Hypertriglyceridemia CRESTOR is indicated as adjunctive therapy to diet for the treatment of adult patients with hypertriglyceridemia. 1.3 Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) CRESTOR is indicated as an adjunct to diet for the treatment of patients with primary dysbetalipoproteinemia (Type III Hyperlipoproteinemia). 1.4 Homozygous Familial Hypercholesterolemia CRESTOR is indicated as adjunctive therapy to other lipid-lowering treatments (e.g., LDL apheresis) or alone if such treatments are unavailable to reduce LDL-C, Total-C, and ApoB in adult patients with homozygous familial hypercholesterolemia. 1.5 Slowing of the Progression of Atherosclerosis CRESTOR is indicated as adjunctive therapy to diet to slow the progression of atherosclerosis in adult patients as part of a treatment strategy to lower Total-C and LDL-C to target levels. 1.6 Limitations of Use The effect of CRESTOR on cardiovascular morbidity and mortality has not been determined. CRESTOR has not been studied in Fredrickson Type I and V dyslipidemias. uuid:eb892fca-55fc-4a16-927a-497903956298 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:38545 biolink:treats MONDO:0018473 PMID:41385096 "[{""id"":""uuid:7634f609-9451-41fc-a047-d45282a37540"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c81d4372-bdc2-4026-be8b-c68427399d1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hyperlipidemia and Mixed Dyslipidemia CRESTOR is indicated as adjunctive therapy to diet to reduce elevated total-C, LDL-C, ApoB, nonHDL-C, and triglycerides and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia. Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate. 1.2 Hypertriglyceridemia CRESTOR is indicated as adjunctive therapy to diet for the treatment of adult patients with hypertriglyceridemia. 1.3 Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) CRESTOR is indicated as an adjunct to diet for the treatment of patients with primary dysbetalipoproteinemia (Type III Hyperlipoproteinemia). 1.4 Homozygous Familial Hypercholesterolemia CRESTOR is indicated as adjunctive therapy to other lipid-lowering treatments (e.g., LDL apheresis) or alone if such treatments are unavailable to reduce LDL-C, Total-C, and ApoB in adult patients with homozygous familial hypercholesterolemia. 1.5 Slowing of the Progression of Atherosclerosis CRESTOR is indicated as adjunctive therapy to diet to slow the progression of atherosclerosis in adult patients as part of a treatment strategy to lower Total-C and LDL-C to target levels. 1.6 Limitations of Use The effect of CRESTOR on cardiovascular morbidity and mortality has not been determined. CRESTOR has not been studied in Fredrickson Type I and V dyslipidemias. uuid:7950dc80-dbbe-42e4-bb5a-8795b5e8b2f4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:38545 biolink:treats MONDO:0018328 PMID:41385096 "[{""id"":""uuid:f5acd2d9-463d-4de7-b6a9-9989f1eff123"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:af248134-0900-4259-88fa-90527325a845"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hyperlipidemia and Mixed Dyslipidemia CRESTOR is indicated as adjunctive therapy to diet to reduce elevated total-C, LDL-C, ApoB, nonHDL-C, and triglycerides and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia. Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate. 1.2 Hypertriglyceridemia CRESTOR is indicated as adjunctive therapy to diet for the treatment of adult patients with hypertriglyceridemia. 1.3 Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) CRESTOR is indicated as an adjunct to diet for the treatment of patients with primary dysbetalipoproteinemia (Type III Hyperlipoproteinemia). 1.4 Homozygous Familial Hypercholesterolemia CRESTOR is indicated as adjunctive therapy to other lipid-lowering treatments (e.g., LDL apheresis) or alone if such treatments are unavailable to reduce LDL-C, Total-C, and ApoB in adult patients with homozygous familial hypercholesterolemia. 1.5 Slowing of the Progression of Atherosclerosis CRESTOR is indicated as adjunctive therapy to diet to slow the progression of atherosclerosis in adult patients as part of a treatment strategy to lower Total-C and LDL-C to target levels. 1.6 Limitations of Use The effect of CRESTOR on cardiovascular morbidity and mortality has not been determined. CRESTOR has not been studied in Fredrickson Type I and V dyslipidemias. uuid:1c4593fa-415c-4f59-aef5-5ed1cbe59bd4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:38545 biolink:treats MONDO:0005311 PMID:41385096 "[{""id"":""uuid:018e59e7-b341-4f2a-a164-e5d61816a83d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e20a6cad-4314-453f-a58f-fe4c46d85479"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hyperlipidemia and Mixed Dyslipidemia CRESTOR is indicated as adjunctive therapy to diet to reduce elevated total-C, LDL-C, ApoB, nonHDL-C, and triglycerides and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia. Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate. 1.2 Hypertriglyceridemia CRESTOR is indicated as adjunctive therapy to diet for the treatment of adult patients with hypertriglyceridemia. 1.3 Primary Dysbetalipoproteinemia (Type III Hyperlipoproteinemia) CRESTOR is indicated as an adjunct to diet for the treatment of patients with primary dysbetalipoproteinemia (Type III Hyperlipoproteinemia). 1.4 Homozygous Familial Hypercholesterolemia CRESTOR is indicated as adjunctive therapy to other lipid-lowering treatments (e.g., LDL apheresis) or alone if such treatments are unavailable to reduce LDL-C, Total-C, and ApoB in adult patients with homozygous familial hypercholesterolemia. 1.5 Slowing of the Progression of Atherosclerosis CRESTOR is indicated as adjunctive therapy to diet to slow the progression of atherosclerosis in adult patients as part of a treatment strategy to lower Total-C and LDL-C to target levels. 1.6 Limitations of Use The effect of CRESTOR on cardiovascular morbidity and mortality has not been determined. CRESTOR has not been studied in Fredrickson Type I and V dyslipidemias. uuid:dff4ce61-eb95-401b-8829-41a82cc3fa8a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8888 biolink:treats MONDO:0005391 PMID:41385096 "[{""id"":""uuid:7ff4e8a8-878f-418b-8fcc-af650734f206"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7a645eae-7da1-4d43-adc1-d6be6833a9d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Parkinson's Disease Ropinirole hydrochloride tablets are indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease. The effectiveness of ropinirole hydrochloride tablets was demonstrated in randomized, controlled trials in patients with early Parkinson's disease who were not receiving concomitant L-dopa therapy as well as in patients with advanced disease on concomitant L-dopa (see CLINICAL PHARMACOLOGY: Clinical Trials ). Restless Legs Syndrome Ropinirole hydrochloride tablets are indicated for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS). Key diagnostic criteria for RLS are: an urge to move the legs usually accompanied or caused by uncomfortable and unpleasant leg sensations; symptoms begin or worsen during periods of rest or inactivity such as lying or sitting; symptoms are partially or totally relieved by movement such as walking or stretching at least as long as the activity continues; and symptoms are worse or occur only in the evening or night. Difficulty falling asleep may frequently be associated with moderate-to-severe RLS. uuid:3ca66ac3-ff79-4a29-8e2e-b11a84e2fff4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats UMLS:C0274435 PMID:41385096 "[{""id"":""uuid:9fb023f6-5c93-471d-a953-e623e7736a17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7fd8729f-7d19-4e20-a297-80f8cf0db5bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal Diseases: To tide the patient over a critical period of the disease in regional enteritis (systemic therapy), ulcerative colitis. Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases: For palliative management of leukemias and lymphomas. Nervous System: Acute exacerbations of multiple sclerosis. Cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases: Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases: Berylliosis, symptomatic sarcoidosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:370b9937-5da6-4fa8-9bc9-a0b3d5b0ea62 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0001705 PMID:41385096 "[{""id"":""uuid:68b6deda-0dc5-4ed9-8122-51194345b273"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:899062fc-c40f-4ac5-adb9-f6c7f622fb7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal Diseases: To tide the patient over a critical period of the disease in regional enteritis (systemic therapy), ulcerative colitis. Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases: For palliative management of leukemias and lymphomas. Nervous System: Acute exacerbations of multiple sclerosis. Cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases: Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases: Berylliosis, symptomatic sarcoidosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:b54be17f-dc22-42b8-9790-7a8625ff9fe0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0006684 PMID:41385096 "[{""id"":""uuid:acc685cb-dec2-4654-9b98-c1b7a61632de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fd77b7ea-7d67-40af-8148-4506a08c9ada"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal Diseases: To tide the patient over a critical period of the disease in regional enteritis (systemic therapy), ulcerative colitis. Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases: For palliative management of leukemias and lymphomas. Nervous System: Acute exacerbations of multiple sclerosis. Cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases: Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases: Berylliosis, symptomatic sarcoidosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:0931ef6e-aacf-40e7-b275-3879de8c5b56 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0008538 PMID:41385096 "[{""id"":""uuid:b9ec85ce-8183-4c43-a10a-874c5c641aec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a408e2ab-cd41-4567-9c78-3068cbfeb578"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal Diseases: To tide the patient over a critical period of the disease in regional enteritis (systemic therapy), ulcerative colitis. Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases: For palliative management of leukemias and lymphomas. Nervous System: Acute exacerbations of multiple sclerosis. Cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases: Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases: Berylliosis, symptomatic sarcoidosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:9c615e80-647c-4703-8cf4-7189d5c22557 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0020283 PMID:41385096 "[{""id"":""uuid:24d9151c-316d-4e3a-b9c6-13293b9c9951"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:175a641d-1745-4c8d-acba-7f69d1954717"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal Diseases: To tide the patient over a critical period of the disease in regional enteritis (systemic therapy), ulcerative colitis. Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases: For palliative management of leukemias and lymphomas. Nervous System: Acute exacerbations of multiple sclerosis. Cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases: Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases: Berylliosis, symptomatic sarcoidosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:93f11b26-f26e-4131-845b-f675b441fc63 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0018170 PMID:41385096 "[{""id"":""uuid:f13cd890-af92-4b40-9c75-2834c5681546"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6333cc7f-476c-48eb-91f6-5ddb9ce75fad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal Diseases: To tide the patient over a critical period of the disease in regional enteritis (systemic therapy), ulcerative colitis. Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases: For palliative management of leukemias and lymphomas. Nervous System: Acute exacerbations of multiple sclerosis. Cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases: Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases: Berylliosis, symptomatic sarcoidosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:88ad6239-3ec3-4316-9456-e6afa691ec27 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0005556 PMID:41385096 "[{""id"":""uuid:60749aab-1a20-4b64-b5c5-76a818b960f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:54334ed7-cd08-4362-9bc3-15ac28f1d743"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal Diseases: To tide the patient over a critical period of the disease in regional enteritis (systemic therapy), ulcerative colitis. Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases: For palliative management of leukemias and lymphomas. Nervous System: Acute exacerbations of multiple sclerosis. Cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases: Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases: Berylliosis, symptomatic sarcoidosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:07ed3319-4236-48da-ab50-4ddd50ec903e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0015927 PMID:41385096 "[{""id"":""uuid:09379128-1503-4ee1-9abf-d4bf8c82975e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c794164e-7edd-4487-a94d-870fee4fa468"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal Diseases: To tide the patient over a critical period of the disease in regional enteritis (systemic therapy), ulcerative colitis. Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases: For palliative management of leukemias and lymphomas. Nervous System: Acute exacerbations of multiple sclerosis. Cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases: Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases: Berylliosis, symptomatic sarcoidosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:7fb23747-0d3a-449d-b757-6fc96293c8a9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats UMLS:C0949083 PMID:41385096 "[{""id"":""uuid:351b735c-1b18-4b14-b11b-6ce22ec5ae63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:36cbd954-e56d-4b58-9e40-5b9549dd1850"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciprofloxacin Injection, USP is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions and patient populations listed below when the intravenous administration offers a route of administration advantageous to the patient. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Adult Patients: Urinary Tract Infections caused by Escherichia coli (including cases with secondary bacteremia), Klebsiella pneumoniae subspecies pneumoniae , Enterobacter cloacae , Serratia marcescens , Proteus mirabilis , Providencia rettgeri , Morganella morganii , Citrobacter diversus , Citrobacter freundii , Pseudomonas aeruginosa , methicillin-susceptible Staphylococcus epidermidis , Staphylococcus saprophyticus , or Enterococcus faecalis . Lower Respiratory Infections caused by Escherichia coli , Klebsiella pneumoniae subspecies pneumoniae , Enterobacter cloacae , Proteus mirabilis , Pseudomonas aeruginosa , Haemophilus influenzae , Haemophilus parainfluenzae , or penicillin-susceptible Streptococcus pneumoniae . Also, Moraxella catarrhalis for the treatment of acute exacerbations of chronic bronchitis. NOTE: Although effective in clinical trials, ciprofloxacin is not a drug of first choice in the treatment of presumed or confirmed pneumonia secondary to Streptococcus pneumoniae . Nosocomial Pneumonia caused by Haemophilus influenzae or Klebsiella pneumoniae . Skin and Skin Structure Infections caused by Escherichia coli , Klebsiella pneumoniae subspecies pneumoniae , Enterobacter cloacae , Proteus mirabilis , Proteus vulgaris , Providencia stuartii , Morganella morganii , Citrobacter freundii , Pseudomonas aeruginosa , methicillin-susceptible Staphylococcus aureus , methicillin-susceptible Staphylococcus epidermidis , or Streptococcus pyogenes . Bone and Joint Infections caused by Enterobacter cloacae , Serratia marcescens , or Pseudomonas aeruginosa . Complicated Intra-Abdominal Infections (used in conjunction with metronidazole) caused by Escherichia coli , Pseudomonas aeruginosa , Proteus mirabilis , Klebsiella pneumoniae , or Bacteroides fragilis . Acute Sinusitis caused by Haemophilus influenzae , penicillin-susceptible Streptococcus pneumoniae , or Moraxella catarrhalis . Chronic Bacterial Prostatitis caused by Escherichia coli or Proteus mirabilis . Empirical Therapy for Febrile Neutropenic Patients in combination with piperacillin sodium. (See CLINICAL STUDIES .) Pediatric Patients (1 to 17 years of age): Complicated Urinary Tract Infections and Pyelonephritis due to Escherichia coli. NOTE: Although effective in clinical trials, ciprofloxacin is not a drug of first choice in the pediatric population due to an increased incidence of adverse events compared to controls, including events related to joints and/or surrounding tissues. (See WARNINGS , PRECAUTIONS: Pediatric Use , ADVERSE REACTIONS , and CLINICAL STUDIES .) Ciprofloxacin, like other fluoroquinolones, is associated with arthropathy and histopathological changes in weight-bearing joints of juvenile animals. (See ANIMAL PHARMACOLOGY .) Adult and Pediatric Patients: Inhalational anthrax (post-exposure): To reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Ciprofloxacin serum concentrations achieved in humans served as a surrogate endpoint reasonably likely to predict clinical benefit and provided the initial basis for approval of this indication. 4 Supportive clinical information for ciprofloxacin for anthrax post-exposure prophylaxis was obtained during the anthrax bioterror attacks of October 2001. (See also, INHALATIONAL ANTHRAX – ADDITIONAL INFORMATION .) If anaerobic organisms are suspected of contributing to the infection, appropriate therapy should be administered. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. Therapy with Ciprofloxacin Injection, USP may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. As with other drugs, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ciprofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ciprofloxacin Injection, USP and other antibacterial drugs, Ciprofloxacin Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:8e8b3639-4673-494c-b21f-8cf8030a2d3a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats UMLS:C0746883 PMID:41385096 "[{""id"":""uuid:e9b6e3fa-7793-4623-9754-0b32b58741f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eee2dcd9-fdca-4fbf-b2c8-c112e1de5fc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciprofloxacin Injection, USP is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions and patient populations listed below when the intravenous administration offers a route of administration advantageous to the patient. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Adult Patients: Urinary Tract Infections caused by Escherichia coli (including cases with secondary bacteremia), Klebsiella pneumoniae subspecies pneumoniae , Enterobacter cloacae , Serratia marcescens , Proteus mirabilis , Providencia rettgeri , Morganella morganii , Citrobacter diversus , Citrobacter freundii , Pseudomonas aeruginosa , methicillin-susceptible Staphylococcus epidermidis , Staphylococcus saprophyticus , or Enterococcus faecalis . Lower Respiratory Infections caused by Escherichia coli , Klebsiella pneumoniae subspecies pneumoniae , Enterobacter cloacae , Proteus mirabilis , Pseudomonas aeruginosa , Haemophilus influenzae , Haemophilus parainfluenzae , or penicillin-susceptible Streptococcus pneumoniae . Also, Moraxella catarrhalis for the treatment of acute exacerbations of chronic bronchitis. NOTE: Although effective in clinical trials, ciprofloxacin is not a drug of first choice in the treatment of presumed or confirmed pneumonia secondary to Streptococcus pneumoniae . Nosocomial Pneumonia caused by Haemophilus influenzae or Klebsiella pneumoniae . Skin and Skin Structure Infections caused by Escherichia coli , Klebsiella pneumoniae subspecies pneumoniae , Enterobacter cloacae , Proteus mirabilis , Proteus vulgaris , Providencia stuartii , Morganella morganii , Citrobacter freundii , Pseudomonas aeruginosa , methicillin-susceptible Staphylococcus aureus , methicillin-susceptible Staphylococcus epidermidis , or Streptococcus pyogenes . Bone and Joint Infections caused by Enterobacter cloacae , Serratia marcescens , or Pseudomonas aeruginosa . Complicated Intra-Abdominal Infections (used in conjunction with metronidazole) caused by Escherichia coli , Pseudomonas aeruginosa , Proteus mirabilis , Klebsiella pneumoniae , or Bacteroides fragilis . Acute Sinusitis caused by Haemophilus influenzae , penicillin-susceptible Streptococcus pneumoniae , or Moraxella catarrhalis . Chronic Bacterial Prostatitis caused by Escherichia coli or Proteus mirabilis . Empirical Therapy for Febrile Neutropenic Patients in combination with piperacillin sodium. (See CLINICAL STUDIES .) Pediatric Patients (1 to 17 years of age): Complicated Urinary Tract Infections and Pyelonephritis due to Escherichia coli. NOTE: Although effective in clinical trials, ciprofloxacin is not a drug of first choice in the pediatric population due to an increased incidence of adverse events compared to controls, including events related to joints and/or surrounding tissues. (See WARNINGS , PRECAUTIONS: Pediatric Use , ADVERSE REACTIONS , and CLINICAL STUDIES .) Ciprofloxacin, like other fluoroquinolones, is associated with arthropathy and histopathological changes in weight-bearing joints of juvenile animals. (See ANIMAL PHARMACOLOGY .) Adult and Pediatric Patients: Inhalational anthrax (post-exposure): To reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Ciprofloxacin serum concentrations achieved in humans served as a surrogate endpoint reasonably likely to predict clinical benefit and provided the initial basis for approval of this indication. 4 Supportive clinical information for ciprofloxacin for anthrax post-exposure prophylaxis was obtained during the anthrax bioterror attacks of October 2001. (See also, INHALATIONAL ANTHRAX – ADDITIONAL INFORMATION .) If anaerobic organisms are suspected of contributing to the infection, appropriate therapy should be administered. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. Therapy with Ciprofloxacin Injection, USP may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. As with other drugs, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ciprofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ciprofloxacin Injection, USP and other antibacterial drugs, Ciprofloxacin Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:a1fe480f-423b-48d8-b961-662681eaa422 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:39669 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:977034f7-2b50-473e-b218-2c7ca06b46ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e415afa6-ce41-495e-a584-50f513059d09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of diflunisal tablets and other treatment options before deciding to use diflunisal tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Diflunisal tablets are indicated for acute or long-term use for symptomatic treatment of the following: Mild to moderate pain Osteoarthritis Rheumatoid arthritis uuid:f52d1f20-8449-42ab-97bf-c7e0565a5a34 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:39669 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:f5a0253a-21ff-495f-aeae-ca6f214b8893"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b10d82e8-07cc-4780-aeb0-c751cf33c11e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of diflunisal tablets and other treatment options before deciding to use diflunisal tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Diflunisal tablets are indicated for acute or long-term use for symptomatic treatment of the following: Mild to moderate pain Osteoarthritis Rheumatoid arthritis uuid:eb3e0f03-2896-4e38-94eb-2c69e6375814 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5775 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:696e6fe0-8e63-4157-9656-b2e058f41626"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7b12d554-954c-411c-914d-6c8e5265b5b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Severe essential hypertension when the drug cannot be given orally or when there is an urgent need to lower blood pressure. uuid:ed80a5fd-a7ce-4b15-953a-043bde7d3da3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4031 biolink:treats MONDO:0006733 PMID:41385096 "[{""id"":""uuid:c9f26ffc-21da-4fc1-be40-f3acac3e5c70"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c3ea2549-81ae-4e40-a152-b4046dadb9f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0861112a-be65-42c7-b4db-b5cbee16c24d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/verkazia""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] RESTASIS ® ophthalmic emulsion is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca. Increased tear production was not seen in patients currently taking topical anti-inflammatory drugs or using punctal plugs.|[EMA] Treatment of severe keratitis in adult patients with dry eye disease, which has not improved despite treatment with tear substitutes. uuid:e711c15a-27ee-4505-b570-597124e9ade2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5062 biolink:treats UMLS:C0426732 PMID:41385096 "[{""id"":""uuid:d8e60756-75ad-40cf-9d86-f55b84655af1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b677cfb5-e1a5-4fe9-83c0-7a7079c47b86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Finasteride is indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to: -Improve symptoms -Reduce the risk of the need for surgery including transurethral resection of the prostate (TURP) and prostatectomy. uuid:495950e4-d70e-42e9-9f8d-7d190b4c9ae3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1157355 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:c26881f1-c00f-4723-a76a-656476f54e74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d842514f-3441-4f16-9ae2-3e197f64a103"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tilia™ Fe is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Tilia™ Fe is indicated for the treatment of moderate acne vulgaris in females, ≥15 years of age, who have no known contraindications to oral contraceptive therapy, desire oral contraception, have achieved menarche, and are unresponsive to topical anti-acne medications. Tilia™ Fe should be used for the treatment of acne only if the patient desires an oral contraceptive for birth control and plans to stay on it for at least 6 months. Oral contraceptives are highly effective for pregnancy prevention. Table 2 lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates. Table 2 Percentage of Women Experiencing an Unintended Pregnancy During the First Year of Typical Use and the First Year of Perfect Use of Contraception and the Percentage Continuing Use at the End of the First Year (United States). % of Women Experiencing an Unintended Pregnancy within the First Year of Use % of Women Continuing Use at One Year 3 Emergency Contraceptives Pills: Treatment initiated within 72 hours after unprotected intercourse reduces the risk of pregnancy by at least 75%. 9 Lactational Amenorrhea Method: LAM is a highly effective, temporary method of contraception. 10 Source: Trussell J, The Essentials of Contraception. In Hatcher RA, Trussell J, Stewart F, Cates W, Stewart GK, Kowel D, Guest F, Contraceptive Technology : Seventeenth Revised Edition. New York NY: Irvington Publishers, 1998. 1 Among typical couples who initiate use of a method (not necessarily for the first time), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason. 2 Among couples who initiate use of a method (not necessarily for the first time) and who use it perfectly (both consistently and correctly), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason. 3 Among couples attempting to avoid pregnancy, the percentage who continue to use a method for 1 year. 4 The percentages becoming pregnant in columns (2) and (3) are based on data from populations where contraception is not used and from women who cease using contraception in order to become pregnant. Among such populations, about 89% become pregnant within one year. This estimate was lowered slightly (to 85%) to represent the percent who would become pregnant within one year among women now relying on reversible methods of contraception if they abandoned contraception altogether. 5 Foams, creams, gels, vaginal suppositories, and vaginal film. 6 Cervical mucus (ovulation) method supplemented by calendar in the pre-ovulatory and basal body temperature in the post-ovulatory phases. 7 With spermicidal cream or jelly. 8 Without spermicides. 9 The treatment schedule is one dose within 72 hours after unprotected intercourse, and a second dose 12 hours after the first dose. The Food and Drug Administration has declared the following brands of oral contraceptives to be safe and effective for emergency contraception: Ovral ®† (1 dose is 2 white pills), Alesse ®† (1 dose is 5 pink pills), Nordette ®† or Levlen ®† (1 dose is 4 light-orange pills), Lo-Ovral ®† (1 dose is 4 white pills), Triphasil ®† or Tri-Levlen ®† (1 dose is 4 yellow pills). 10 However, to maintain effective protection against pregnancy, another method of contraception must be used as soon as menstruation resumes, the frequency or duration of breastfeeds is reduced, bottle feeds are introduced, or the baby reaches 6 months of age. Method Typical Use 1 Perfect Use 2 (1) (2) (3) (4) Chance 4 85 85 Spermicides 5 26 6 40 Periodic Abstinence 25 63 Calendar 9 Ovulation Method 3 Symptothermal 6 2 Post-ovulation 1 Cap 7 Parous Women 40 26 42 Nulliparous Women 20 9 56 Sponge Parous Women 40 20 42 Nulliparous Women 20 9 56 Diaphragm 7 20 6 56 Withdrawal 19 4 Condom 8 Female (Reality ®† ) 21 5 56 Male 14 3 61 Pill 5 71 Progestin only 0.5 Combined 0.1 IUD Progesterone T 2.0 1.5 81 Copper T380A 0.8 0.6 78 LNg 20 0.1 0.1 81 Injectable progestogen 0.3 0.3 70 Implants 0.05 0.05 88 Female Sterilization 0.5 0.5 100 Male Sterilization 0.15 0.10 100 Norethindrone acetate and ethinyl estradiol tablets were evaluated for the treatment of acne vulgaris in two randomized, double-blind, placebo-controlled, multicenter, Phase 3, six (28 day) cycle studies. A total of 295 patients received norethindrone acetate and ethinyl estradiol tablets and 296 received placebo. Mean age at enrollment for both groups was 24 years. At six months each study demonstrated a statistically significant difference between norethindrone acetate and ethinyl estradiol tablets and placebo for mean change from baseline in lesion counts (see Table 3 and Figure 2). Each study also demonstrated overall treatment success in the investigator’s global evaluation. Patients with severe androgen excess were not studied. Table 3: Acne Vulgaris Indication Pooled Data 376-403 and 376-404 Observed Means at Six Months and at Baseline* Intent To Treat Population Norethindrone Acetate and Ethinyl Estradiol Tablets N=296 Placebo N=295 Difference in Counts Between Norethindrone Acetate and Ethinyl Estradiol Tablets and Placebo at Six Months (95% CI)** Number of Lesions Counts % reduction Counts % reduction * Numbers rounded to nearest integer ** Limits for 95% Confidence Interval; not adjusted for baseline differences INFLAMMATORY LESIONS Baseline Mean 29 29 Sixth Month Mean 14 52% 17 41% 3 (± 2) NON-INFLAMMATORY Baseline Mean 44 43 Sixth Month Mean 27 38% 32 25% 5 (± 3.5) TOTAL LESIONS Baseline Mean 74 72 Sixth Month Mean 42 43% 49 32% 7 (± 5) Norethindrone acetate and ethinyl estradiol tablets users who started with about 74 acne lesions had about 42 lesions after 6 months of treatment. Placebo users who started with about 72 acne lesions had about 49 lesions after the same duration of treatment. uuid:de833b0a-b28b-469b-93d5-f93c70f5e478 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2611 biolink:treats MONDO:0044144 PMID:41385096 "[{""id"":""uuid:2241caf2-f609-4971-9e61-fae9fc4ed2c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a87b3770-85ad-4130-b5fd-e365f8ff9480"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Anxiety Disorders Alprazolam tablets are indicated for the management of anxiety disorder (a condition corresponding most closely to the APA Diagnostic and Statistical Manual [DSM-III-R] diagnosis of generalized anxiety disorder) or the short-term relief of symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. Generalized anxiety disorder is characterized by unrealistic or excessive anxiety and worry (apprehensive expectation) about two or more life circumstances, for a period of six months or longer, during which the person has been bothered more days than not by these concerns. At least 6 of the following 18 symptoms are often present in these patients: Motor Tension (trembling, twitching, or feeling shaky; muscle tension, aches, or soreness; restlessness; easy fatigability); Autonomic Hyperactivity (shortness of breath or smothering sensations; palpitations or accelerated heart rate; sweating, or cold clammy hands; dry mouth; dizziness or light-headedness; nausea, diarrhea, or other abdominal distress; flushes or chills; frequent urination; trouble swallowing or ‘lump in throat’); Vigilance and Scanning (feeling keyed up or on edge; exaggerated startle response; difficulty concentrating or ‘mind going blank’ because of anxiety; trouble falling or staying asleep; irritability). These symptoms must not be secondary to another psychiatric disorder or caused by some organic factor. Anxiety associated with depression is responsive to alprazolam. Panic Disorder Alprazolam is also indicated for the treatment of panic disorder, with or without agoraphobia. Studies supporting this claim were conducted in patients whose diagnoses corresponded closely to the DSM-III-R/IV criteria for panic disorder (see CLINICAL STUDIES ). Panic disorder (DSM-IV) is characterized by recurrent unexpected panic attacks, ie, a discrete period of intense fear or discomfort in which four (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) palpitations, pounding heart, or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded, or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes. Demonstrations of the effectiveness of alprazolam by systematic clinical study are limited to 4 months duration for anxiety disorder and 4 to 10 weeks duration for panic disorder; however, patients with panic disorder have been treated on an open basis for up to 8 months without apparent loss of benefit. The physician should periodically reassess the usefulness of the drug for the individual patient. uuid:da2d12d1-8314-47c4-b2b1-a8454641d68b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2611 biolink:treats MONDO:0041086 PMID:41385096 "[{""id"":""uuid:4d11a143-0bc8-4c2c-ac19-59d8b21ba78f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:27cab48d-9590-4590-bd85-0300d3fcea52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Anxiety Disorders Alprazolam tablets are indicated for the management of anxiety disorder (a condition corresponding most closely to the APA Diagnostic and Statistical Manual [DSM-III-R] diagnosis of generalized anxiety disorder) or the short-term relief of symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. Generalized anxiety disorder is characterized by unrealistic or excessive anxiety and worry (apprehensive expectation) about two or more life circumstances, for a period of six months or longer, during which the person has been bothered more days than not by these concerns. At least 6 of the following 18 symptoms are often present in these patients: Motor Tension (trembling, twitching, or feeling shaky; muscle tension, aches, or soreness; restlessness; easy fatigability); Autonomic Hyperactivity (shortness of breath or smothering sensations; palpitations or accelerated heart rate; sweating, or cold clammy hands; dry mouth; dizziness or light-headedness; nausea, diarrhea, or other abdominal distress; flushes or chills; frequent urination; trouble swallowing or ‘lump in throat’); Vigilance and Scanning (feeling keyed up or on edge; exaggerated startle response; difficulty concentrating or ‘mind going blank’ because of anxiety; trouble falling or staying asleep; irritability). These symptoms must not be secondary to another psychiatric disorder or caused by some organic factor. Anxiety associated with depression is responsive to alprazolam. Panic Disorder Alprazolam is also indicated for the treatment of panic disorder, with or without agoraphobia. Studies supporting this claim were conducted in patients whose diagnoses corresponded closely to the DSM-III-R/IV criteria for panic disorder (see CLINICAL STUDIES ). Panic disorder (DSM-IV) is characterized by recurrent unexpected panic attacks, ie, a discrete period of intense fear or discomfort in which four (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) palpitations, pounding heart, or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded, or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes. Demonstrations of the effectiveness of alprazolam by systematic clinical study are limited to 4 months duration for anxiety disorder and 4 to 10 weeks duration for panic disorder; however, patients with panic disorder have been treated on an open basis for up to 8 months without apparent loss of benefit. The physician should periodically reassess the usefulness of the drug for the individual patient. uuid:a4282014-059a-4add-b406-8147c73251fa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6413 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:97458fd8-988e-4954-8f5c-0efa5722c780"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2f879c2b-ebb1-4868-a464-b7d446ff07de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d5917697-d660-4a42-b428-78ae87903a5d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Letrozole tablets are an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer ( 1.1 ) Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy ( 1.2 ) First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer ( 1.3 )|[PMDA] Drugs containing a new active ingredient indicated for the treatment of post-menopausal breast cancer uuid:86c5822d-aef2-43d4-9604-da72348fb8e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6413 biolink:treats UMLS:C3495917 PMID:41385096 "[{""id"":""uuid:dc8f3a99-8c0c-4697-8af6-40cde8ad098e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b09b5c60-5ab3-4112-a552-5dd6f1d6ae5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Letrozole tablets are an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer ( 1.1 ) Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy ( 1.2 ) First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer ( 1.3 ) uuid:639bb0bb-c3b9-457d-a5bc-693f5ff522f5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4W0459ZA4V biolink:treats MONDO:0002258 PMID:41385096 "[{""id"":""uuid:41932d43-6be5-4355-a8af-e87bc6b524f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3d04c040-b5b3-4482-b54f-5e659ce9634e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefprozil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Upper Respiratory Tract: Pharyngitis/Tonsillitis: Caused by Streptococcus pyogenes . NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefprozil is generally effective in the eradication of Streptococcus pyogenes from the nasopharynx; however, substantial data establishing the efficacy of cefprozil in the subsequent prevention of rheumatic fever are not available at present. Otitis Media: Caused by Streptococcus pneumoniae, Haemophilus influenzae (including ß-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). (See CLINICAL STUDIES .) NOTE: In the treatment of otitis media due to ß-lactamase producing organisms, cefprozil had bacteriologic eradication rates somewhat lower than those observed with a product containing a specific ß-lactamase inhibitor. In considering the use of cefprozil, lower overall eradication rates should be balanced against the susceptibility patterns of the common microbes in a given geographic area and the increased potential for toxicity with products containing ß-lactamase inhibitors. Acute Sinusitis: Caused by Streptococcus pneumoniae , Haemophilus influenzae (including ß-lactamase producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). Lower Respiratory Tract: Secondary Bacterial Infection of Acute Bronchitis and Acute Bacterial Exacerbation of Chronic Bronchitis: Caused by Streptococcus pneumoniae, Haemophilus influenzae (including ß-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). Skin and Skin Structure: Uncomplicated Skin and Skin-Structure Infections: Caused by Staphylococcus aureus (including penicillinase producing strains) and Streptococcus pyogenes . Abscesses usually require surgical drainage. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefprozil tablets and other antibacterial drugs, cefprozil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:643c2bd1-0c19-497f-a863-b96159b554fc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4W0459ZA4V biolink:treats MONDO:0001039 PMID:41385096 "[{""id"":""uuid:91bfd95a-28f0-4856-8037-d57ae91bd5a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4c5db8e3-2ddc-4033-acc3-78ad1115796c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefprozil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Upper Respiratory Tract: Pharyngitis/Tonsillitis: Caused by Streptococcus pyogenes . NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefprozil is generally effective in the eradication of Streptococcus pyogenes from the nasopharynx; however, substantial data establishing the efficacy of cefprozil in the subsequent prevention of rheumatic fever are not available at present. Otitis Media: Caused by Streptococcus pneumoniae, Haemophilus influenzae (including ß-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). (See CLINICAL STUDIES .) NOTE: In the treatment of otitis media due to ß-lactamase producing organisms, cefprozil had bacteriologic eradication rates somewhat lower than those observed with a product containing a specific ß-lactamase inhibitor. In considering the use of cefprozil, lower overall eradication rates should be balanced against the susceptibility patterns of the common microbes in a given geographic area and the increased potential for toxicity with products containing ß-lactamase inhibitors. Acute Sinusitis: Caused by Streptococcus pneumoniae , Haemophilus influenzae (including ß-lactamase producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). Lower Respiratory Tract: Secondary Bacterial Infection of Acute Bronchitis and Acute Bacterial Exacerbation of Chronic Bronchitis: Caused by Streptococcus pneumoniae, Haemophilus influenzae (including ß-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). Skin and Skin Structure: Uncomplicated Skin and Skin-Structure Infections: Caused by Staphylococcus aureus (including penicillinase producing strains) and Streptococcus pyogenes . Abscesses usually require surgical drainage. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefprozil tablets and other antibacterial drugs, cefprozil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:ab352810-7248-4711-b0da-1790c51c0521 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4W0459ZA4V biolink:treats MONDO:0021680 PMID:41385096 "[{""id"":""uuid:641c0ac4-f407-451d-a752-a5d6261b95f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:71135bc5-78d9-4e50-b5a7-84bb810b4ab5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefprozil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Upper Respiratory Tract: Pharyngitis/Tonsillitis: Caused by Streptococcus pyogenes . NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefprozil is generally effective in the eradication of Streptococcus pyogenes from the nasopharynx; however, substantial data establishing the efficacy of cefprozil in the subsequent prevention of rheumatic fever are not available at present. Otitis Media: Caused by Streptococcus pneumoniae, Haemophilus influenzae (including ß-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). (See CLINICAL STUDIES .) NOTE: In the treatment of otitis media due to ß-lactamase producing organisms, cefprozil had bacteriologic eradication rates somewhat lower than those observed with a product containing a specific ß-lactamase inhibitor. In considering the use of cefprozil, lower overall eradication rates should be balanced against the susceptibility patterns of the common microbes in a given geographic area and the increased potential for toxicity with products containing ß-lactamase inhibitors. Acute Sinusitis: Caused by Streptococcus pneumoniae , Haemophilus influenzae (including ß-lactamase producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). Lower Respiratory Tract: Secondary Bacterial Infection of Acute Bronchitis and Acute Bacterial Exacerbation of Chronic Bronchitis: Caused by Streptococcus pneumoniae, Haemophilus influenzae (including ß-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). Skin and Skin Structure: Uncomplicated Skin and Skin-Structure Infections: Caused by Staphylococcus aureus (including penicillinase producing strains) and Streptococcus pyogenes . Abscesses usually require surgical drainage. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefprozil tablets and other antibacterial drugs, cefprozil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:2b56fcb5-c86f-4b95-b783-bda2f2807b85 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4W0459ZA4V biolink:treats MONDO:0017767 PMID:41385096 "[{""id"":""uuid:46bfd8c6-8a54-4af5-9d66-0b93aa562e2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fb8356e0-1b29-4c3d-85ee-eb835f8e4f69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefprozil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Upper Respiratory Tract: Pharyngitis/Tonsillitis: Caused by Streptococcus pyogenes . NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefprozil is generally effective in the eradication of Streptococcus pyogenes from the nasopharynx; however, substantial data establishing the efficacy of cefprozil in the subsequent prevention of rheumatic fever are not available at present. Otitis Media: Caused by Streptococcus pneumoniae, Haemophilus influenzae (including ß-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). (See CLINICAL STUDIES .) NOTE: In the treatment of otitis media due to ß-lactamase producing organisms, cefprozil had bacteriologic eradication rates somewhat lower than those observed with a product containing a specific ß-lactamase inhibitor. In considering the use of cefprozil, lower overall eradication rates should be balanced against the susceptibility patterns of the common microbes in a given geographic area and the increased potential for toxicity with products containing ß-lactamase inhibitors. Acute Sinusitis: Caused by Streptococcus pneumoniae , Haemophilus influenzae (including ß-lactamase producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). Lower Respiratory Tract: Secondary Bacterial Infection of Acute Bronchitis and Acute Bacterial Exacerbation of Chronic Bronchitis: Caused by Streptococcus pneumoniae, Haemophilus influenzae (including ß-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). Skin and Skin Structure: Uncomplicated Skin and Skin-Structure Infections: Caused by Staphylococcus aureus (including penicillinase producing strains) and Streptococcus pyogenes . Abscesses usually require surgical drainage. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefprozil tablets and other antibacterial drugs, cefprozil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:3c4d9da6-c738-4a99-af9b-63d83f0be212 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4W0459ZA4V biolink:treats MONDO:0005441 PMID:41385096 "[{""id"":""uuid:df7fe5fe-abdd-480a-9bb4-a79dc6ce562f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:597d1a2c-9d5a-4e13-8dcf-f4ff4603919b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefprozil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Upper Respiratory Tract: Pharyngitis/Tonsillitis: Caused by Streptococcus pyogenes . NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefprozil is generally effective in the eradication of Streptococcus pyogenes from the nasopharynx; however, substantial data establishing the efficacy of cefprozil in the subsequent prevention of rheumatic fever are not available at present. Otitis Media: Caused by Streptococcus pneumoniae, Haemophilus influenzae (including ß-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). (See CLINICAL STUDIES .) NOTE: In the treatment of otitis media due to ß-lactamase producing organisms, cefprozil had bacteriologic eradication rates somewhat lower than those observed with a product containing a specific ß-lactamase inhibitor. In considering the use of cefprozil, lower overall eradication rates should be balanced against the susceptibility patterns of the common microbes in a given geographic area and the increased potential for toxicity with products containing ß-lactamase inhibitors. Acute Sinusitis: Caused by Streptococcus pneumoniae , Haemophilus influenzae (including ß-lactamase producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). Lower Respiratory Tract: Secondary Bacterial Infection of Acute Bronchitis and Acute Bacterial Exacerbation of Chronic Bronchitis: Caused by Streptococcus pneumoniae, Haemophilus influenzae (including ß-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). Skin and Skin Structure: Uncomplicated Skin and Skin-Structure Infections: Caused by Staphylococcus aureus (including penicillinase producing strains) and Streptococcus pyogenes . Abscesses usually require surgical drainage. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefprozil tablets and other antibacterial drugs, cefprozil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:4c55b782-5679-4357-ae11-23ec7e8f8c42 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4W0459ZA4V biolink:treats HP:0000255 PMID:41385096 "[{""id"":""uuid:2d90dec6-a3aa-4dc8-8eff-ad75902fbf80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:135ecfc2-c94a-47c7-bfa4-442f0296e036"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefprozil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Upper Respiratory Tract: Pharyngitis/Tonsillitis: Caused by Streptococcus pyogenes . NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefprozil is generally effective in the eradication of Streptococcus pyogenes from the nasopharynx; however, substantial data establishing the efficacy of cefprozil in the subsequent prevention of rheumatic fever are not available at present. Otitis Media: Caused by Streptococcus pneumoniae, Haemophilus influenzae (including ß-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). (See CLINICAL STUDIES .) NOTE: In the treatment of otitis media due to ß-lactamase producing organisms, cefprozil had bacteriologic eradication rates somewhat lower than those observed with a product containing a specific ß-lactamase inhibitor. In considering the use of cefprozil, lower overall eradication rates should be balanced against the susceptibility patterns of the common microbes in a given geographic area and the increased potential for toxicity with products containing ß-lactamase inhibitors. Acute Sinusitis: Caused by Streptococcus pneumoniae , Haemophilus influenzae (including ß-lactamase producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). Lower Respiratory Tract: Secondary Bacterial Infection of Acute Bronchitis and Acute Bacterial Exacerbation of Chronic Bronchitis: Caused by Streptococcus pneumoniae, Haemophilus influenzae (including ß-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). Skin and Skin Structure: Uncomplicated Skin and Skin-Structure Infections: Caused by Staphylococcus aureus (including penicillinase producing strains) and Streptococcus pyogenes . Abscesses usually require surgical drainage. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefprozil tablets and other antibacterial drugs, cefprozil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:02216541-1ddd-4b76-b69f-8ddbf94bd01e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4W0459ZA4V biolink:treats HP:0012388 PMID:41385096 "[{""id"":""uuid:422b6359-e1c1-4616-bce1-ba00b660da1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9ba7adab-8059-447e-9037-84a293e7d3d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefprozil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Upper Respiratory Tract: Pharyngitis/Tonsillitis: Caused by Streptococcus pyogenes . NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefprozil is generally effective in the eradication of Streptococcus pyogenes from the nasopharynx; however, substantial data establishing the efficacy of cefprozil in the subsequent prevention of rheumatic fever are not available at present. Otitis Media: Caused by Streptococcus pneumoniae, Haemophilus influenzae (including ß-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). (See CLINICAL STUDIES .) NOTE: In the treatment of otitis media due to ß-lactamase producing organisms, cefprozil had bacteriologic eradication rates somewhat lower than those observed with a product containing a specific ß-lactamase inhibitor. In considering the use of cefprozil, lower overall eradication rates should be balanced against the susceptibility patterns of the common microbes in a given geographic area and the increased potential for toxicity with products containing ß-lactamase inhibitors. Acute Sinusitis: Caused by Streptococcus pneumoniae , Haemophilus influenzae (including ß-lactamase producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). Lower Respiratory Tract: Secondary Bacterial Infection of Acute Bronchitis and Acute Bacterial Exacerbation of Chronic Bronchitis: Caused by Streptococcus pneumoniae, Haemophilus influenzae (including ß-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). Skin and Skin Structure: Uncomplicated Skin and Skin-Structure Infections: Caused by Staphylococcus aureus (including penicillinase producing strains) and Streptococcus pyogenes . Abscesses usually require surgical drainage. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefprozil tablets and other antibacterial drugs, cefprozil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:e82a76e6-cd46-413c-9359-38c461c8053f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4W0459ZA4V biolink:treats MONDO:0005607 PMID:41385096 "[{""id"":""uuid:7efed1b7-8a62-4848-9a2d-217d40a9eba6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d4fc5c70-1797-40f3-b839-7f933002e99a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefprozil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Upper Respiratory Tract: Pharyngitis/Tonsillitis: Caused by Streptococcus pyogenes . NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefprozil is generally effective in the eradication of Streptococcus pyogenes from the nasopharynx; however, substantial data establishing the efficacy of cefprozil in the subsequent prevention of rheumatic fever are not available at present. Otitis Media: Caused by Streptococcus pneumoniae, Haemophilus influenzae (including ß-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). (See CLINICAL STUDIES .) NOTE: In the treatment of otitis media due to ß-lactamase producing organisms, cefprozil had bacteriologic eradication rates somewhat lower than those observed with a product containing a specific ß-lactamase inhibitor. In considering the use of cefprozil, lower overall eradication rates should be balanced against the susceptibility patterns of the common microbes in a given geographic area and the increased potential for toxicity with products containing ß-lactamase inhibitors. Acute Sinusitis: Caused by Streptococcus pneumoniae , Haemophilus influenzae (including ß-lactamase producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). Lower Respiratory Tract: Secondary Bacterial Infection of Acute Bronchitis and Acute Bacterial Exacerbation of Chronic Bronchitis: Caused by Streptococcus pneumoniae, Haemophilus influenzae (including ß-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). Skin and Skin Structure: Uncomplicated Skin and Skin-Structure Infections: Caused by Staphylococcus aureus (including penicillinase producing strains) and Streptococcus pyogenes . Abscesses usually require surgical drainage. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefprozil tablets and other antibacterial drugs, cefprozil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:ac7149fd-1d41-46d1-a551-ff89dd667830 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4W0459ZA4V biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:5718b993-a63b-43e8-af99-ddf31868e0dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d524e0b6-6c49-4ef2-b247-d826f528a5e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefprozil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Upper Respiratory Tract: Pharyngitis/Tonsillitis: Caused by Streptococcus pyogenes . NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefprozil is generally effective in the eradication of Streptococcus pyogenes from the nasopharynx; however, substantial data establishing the efficacy of cefprozil in the subsequent prevention of rheumatic fever are not available at present. Otitis Media: Caused by Streptococcus pneumoniae, Haemophilus influenzae (including ß-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). (See CLINICAL STUDIES .) NOTE: In the treatment of otitis media due to ß-lactamase producing organisms, cefprozil had bacteriologic eradication rates somewhat lower than those observed with a product containing a specific ß-lactamase inhibitor. In considering the use of cefprozil, lower overall eradication rates should be balanced against the susceptibility patterns of the common microbes in a given geographic area and the increased potential for toxicity with products containing ß-lactamase inhibitors. Acute Sinusitis: Caused by Streptococcus pneumoniae , Haemophilus influenzae (including ß-lactamase producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). Lower Respiratory Tract: Secondary Bacterial Infection of Acute Bronchitis and Acute Bacterial Exacerbation of Chronic Bronchitis: Caused by Streptococcus pneumoniae, Haemophilus influenzae (including ß-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including ß-lactamase-producing strains). Skin and Skin Structure: Uncomplicated Skin and Skin-Structure Infections: Caused by Staphylococcus aureus (including penicillinase producing strains) and Streptococcus pyogenes . Abscesses usually require surgical drainage. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefprozil tablets and other antibacterial drugs, cefprozil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:34cd11bb-ddec-4d6c-b5f5-20633fc2b2a7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8207 biolink:treats HP:0000217 PMID:41385096 "[{""id"":""uuid:08a12a20-57fd-4005-8aa9-2c4c1f889f6c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f8806490-85c9-4d25-91e4-fe158eb803e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3ee56a65-1dca-4952-af08-e6cc65e1cb2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pilocarpine hydrochloride tablets are indicated for 1) the treatment of symptoms of dry mouth from salivary gland hypofunction caused by radiotherapy for cancer of the head and neck; and 2) the treatment of symptoms of dry mouth in patients with Sjogren's syndrome.|[PMDA] Drug with a new route of oral administration indicated for the treatment of symptoms of dry mouth caused by radiotherapy for head and neck cancer uuid:0a028063-57ed-4c1d-b986-f8dae46868ed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135622 biolink:treats MONDO:0006668 PMID:41385096 "[{""id"":""uuid:d5866147-cd9c-4c36-9520-81b3410320ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1f3b7015-b7b4-4053-8743-238f07fc8677"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Besivance™ (besifloxacin ophthalmic suspension) 0.6%, is indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following bacteria: CDC coryneform group G Corynebacterium pseudodiphtheriticum* Corynebacterium striatum* Haemophilus influenzae Moraxella lacunata* Staphylococcus aureus Staphylococcus epidermidis Staphylococcus hominis* Staphylococcus lugdunensis* Streptococcus mitis group Streptococcus oralis Streptococcus pneumoniae Streptococcus salivarius* *Efficacy for this organism was studied in fewer than 10 infections. uuid:9efc2be8-4b14-4ac0-86b5-a3050d333ced biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47426 biolink:treats MONDO:0002476 PMID:41385096 "[{""id"":""uuid:6408f298-9007-49bd-9f39-da90f3ba8847"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2847ce1e-9fb7-4f80-8da8-e09252708251"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Edema Furosemide tablets, USP is indicated in adults and pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. Furosemide is particularly useful when an agent with greater diuretic potential is desired. Hypertension Furosemide tablets, USP may be used in adults for the treatment of hypertension alone or in combination with other antihypertensive agents. Hypertensive patients who cannot be adequately controlled with thiazides will probably also not be adequately controlled with furosemide alone. CONTRAINDICATIONS Furosemide tablets are contraindicated in patients with anuria and in patients with a history of hypersensitivity to furosemide. uuid:03330836-0fd3-4b6d-8daa-602279a46916 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:36795 biolink:treats UMLS:C0746683 PMID:41385096 "[{""id"":""uuid:e1f1e846-994d-436b-b703-541c807e3b2d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:32ad9c67-1fdf-45fe-bbd3-4e70d89cf5ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cymbalta ® is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for: Major Depressive Disorder (MDD). ( 1.1 ) Efficacy was established in four short-term and one maintenance trial in adults. ( 14.1 ) Generalized Anxiety Disorder (GAD). ( 1.2 ) Efficacy was established in three short-term and one maintenance trial in adults. ( 14.2 ) Diabetic Peripheral Neuropathic Pain (DPNP). ( 1.3 ) Fibromyalgia (FM). ( 1.4 ) Chronic Musculoskeletal Pain. ( 1.5 ) uuid:670030ae-898f-49b0-ab33-1c0d3b5aebaf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6129 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:42d71ced-b861-4c6a-8baf-087789840f27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:95edf5f7-d0b1-4470-9b93-4218b8295ef3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SPRIX is indicated in adult patients for the short term (up to 5 days) management of moderate to moderately severe pain that requires analgesia at the opioid level. uuid:b36098e6-5ea4-4162-bc87-372cc3214916 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9927 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:b7bd9da1-649d-44c0-8e4b-3ae128ec1d93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:33e91f80-af99-45c3-91fe-9fbee4c4d661"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:25025bd7-8783-45cc-964e-25602d90ea6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diovan is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension (1.1) Treatment of heart failure (NYHA class II-IV); Diovan significantly reduced hospitalization for heart failure (1.2) Reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction (1.3)|[PMDA] Drugs with a new additional pediatric dosage. These drugs are indicated for the treatment of hypertension. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:846564ff-a0db-405b-ac01-ca1cfff9bdb6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9927 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:c25d4b28-6576-4885-b3db-d3463ba34c69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9504df38-6740-4db0-bfd1-15fabc9bcd59"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diovan is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension (1.1) Treatment of heart failure (NYHA class II-IV); Diovan significantly reduced hospitalization for heart failure (1.2) Reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction (1.3) uuid:11959d5b-81df-4e08-9345-6634974e0edc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9927 biolink:treats HP:0025169 PMID:41385096 "[{""id"":""uuid:918f658a-d8be-421a-a6c8-3cc4b76b70b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4e4049fb-5eed-4ac1-b2ee-0dc6b22e26ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diovan is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension (1.1) Treatment of heart failure (NYHA class II-IV); Diovan significantly reduced hospitalization for heart failure (1.2) Reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction (1.3) uuid:69d813c4-e414-4b74-8c55-dcc3864b1667 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4031 biolink:treats UMLS:C0345468 PMID:41385096 "[{""id"":""uuid:c941914f-1645-493d-86a5-37a7d0f449f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d6bb31db-51b5-4a43-aed3-ac54b08645a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclosporine Capsules USP MODIFIED are indicated for the prophylaxis of organ rejection in kidney, liver, and heart allogeneic transplants. Cyclosporine Capsules USP MODIFIED have been used in combination with azathioprine and corticosteroids. uuid:25c2a627-6e73-4f47-a1a7-94b874931954 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3568 biolink:treats MONDO:0010030 PMID:41385096 "[{""id"":""uuid:ec5f78d7-d243-41a3-ab65-9c03a563b811"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e71d1a93-aac5-4407-a899-881451b58ce9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cevimeline is indicated for the treatment of symptoms of dry mouth in patients with Sjögren’s Syndrome. uuid:0c8b9bae-38c5-42a8-aa23-1df4dd5cf011 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3568 biolink:treats HP:0000217 PMID:41385096 "[{""id"":""uuid:3385950e-3876-4270-b673-15a1543467a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:44da35df-fbf0-4b70-ad17-0ec5097a5681"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cevimeline is indicated for the treatment of symptoms of dry mouth in patients with Sjögren’s Syndrome. uuid:d027c4e5-706e-45f7-b38c-c85b5ce1ab11 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27690 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:f3a28a04-6593-415d-b31c-d883b3a2b7f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7ddfe391-d27d-4573-90cc-9c9cf82e0374"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. AcetaZOLAMIDE is also indicated for the prevention or amelioration of symptoms associated with acute mountain sickness in climbers attempting rapid ascent and in those who are very susceptible to acute mountain sickness despite gradual ascent. uuid:49a40869-148e-43eb-b3e3-3a651f186554 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27690 biolink:treats MONDO:0010826 PMID:41385096 "[{""id"":""uuid:8c380d01-b023-4504-a714-76a34940800b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e74276c1-9959-495e-a8cc-ef51261d2f8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. AcetaZOLAMIDE is also indicated for the prevention or amelioration of symptoms associated with acute mountain sickness in climbers attempting rapid ascent and in those who are very susceptible to acute mountain sickness despite gradual ascent. uuid:b15cb5f2-033a-4146-af73-4bf1c1d05158 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27690 biolink:treats MONDO:0005338 PMID:41385096 "[{""id"":""uuid:6589e934-3b93-4bee-805d-bcb6015d2984"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:070ec702-87d8-4e2b-8b37-c1a35c32ad4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. AcetaZOLAMIDE is also indicated for the prevention or amelioration of symptoms associated with acute mountain sickness in climbers attempting rapid ascent and in those who are very susceptible to acute mountain sickness despite gradual ascent. uuid:d8606a73-3eef-4175-b4b0-67e2a044aa20 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27690 biolink:treats UMLS:C0149893 PMID:41385096 "[{""id"":""uuid:03323f0e-ae13-40b0-a3c9-e9ea69e84072"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fa52a2e2-a5c4-4c9a-9823-78c05f272aab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. AcetaZOLAMIDE is also indicated for the prevention or amelioration of symptoms associated with acute mountain sickness in climbers attempting rapid ascent and in those who are very susceptible to acute mountain sickness despite gradual ascent. uuid:07ef698b-7799-4e4e-80c3-d724c0aeca5c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27690 biolink:treats MONDO:0001817 PMID:41385096 "[{""id"":""uuid:bb99c1e0-fc4e-42c2-95ac-688f2ded0c31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f6cda863-cbc9-4070-ab48-e1b8ba92b0ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. AcetaZOLAMIDE is also indicated for the prevention or amelioration of symptoms associated with acute mountain sickness in climbers attempting rapid ascent and in those who are very susceptible to acute mountain sickness despite gradual ascent. uuid:e2962f22-bb85-42c9-a79d-dc243d064ef1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27690 biolink:treats MONDO:0021811 PMID:41385096 "[{""id"":""uuid:44cf491b-6d14-4f84-a735-0a49a48cad77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aeb84860-b8d6-404b-a1db-9db97a18741d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. AcetaZOLAMIDE is also indicated for the prevention or amelioration of symptoms associated with acute mountain sickness in climbers attempting rapid ascent and in those who are very susceptible to acute mountain sickness despite gradual ascent. uuid:b3d6956b-f718-4ffd-9272-d8bea8e092bc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15354 biolink:treats MONDO:0850282 PMID:41385096 "[{""id"":""uuid:ee826f24-c5d2-41de-9fda-2f75d6dc75c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9ee31f7c-3011-4a2c-8fcb-bc238a569829"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Theophylline extended-release tablets are indicated for the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis. uuid:cd0355de-41b4-463a-8a12-e096c207753f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15354 biolink:treats MONDO:0004849 PMID:41385096 "[{""id"":""uuid:01704838-aedb-4dc2-9173-d70407f7010f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1a88e19a-700b-4187-9e56-d402537d016a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Theophylline extended-release tablets are indicated for the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis. uuid:61bf5b93-4b3e-4157-ab68-d25ab0697abd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15354 biolink:treats MONDO:0005607 PMID:41385096 "[{""id"":""uuid:ed2046d5-25c5-4756-961d-371080c1a7bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2c5b8b1c-af5f-4c08-acc6-59f8ab11e562"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Theophylline extended-release tablets are indicated for the treatment of the symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis. uuid:f082b029-1ece-4fcb-8cbb-97dc5d5c44d1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1151549 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:96de09f3-e7e0-48f5-8a18-71563b2fbbf1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d487812a-a98a-4020-b29d-1a3f95284d28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydrocodone and acetaminophen tablets are indicated for the relief of moderate to moderately severe pain. uuid:38ffba89-c341-4ce8-ada7-233cab966043 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9943 biolink:treats MONDO:0002444 PMID:41385096 "[{""id"":""uuid:c564e533-e35f-4216-b885-931526cae31b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ed6085ef-5eb5-4c66-967d-13a47a440c1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Venlafaxine hydrochloride tablets are indicated for the treatment of major depressive disorder. The efficacy of venlafaxine hydrochloride in the treatment of major depressive disorder was established in 6-week controlled trials of adult outpatients whose diagnoses corresponded most closely to the DSM-III or DSM-III-R category of major depression and in a 4-week controlled trial of inpatients meeting diagnostic criteria for major depression with melancholia (see CLINICAL TRIALS ). A major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. The efficacy of venlafaxine extended-release capsules in maintaining an antidepressant response for up to 26 weeks following 8 weeks of acute treatment was demonstrated in a placebo-controlled trial. The efficacy of venlafaxine hydrochloride in maintaining an antidepressant response in patients with recurrent depression who had responded and continued to be improved during an initial 26 weeks of treatment and were then followed for a period of up to 52 weeks was demonstrated in a second placebo-controlled trial (see CLINICAL TRIALS ). Nevertheless, the physician who elects to use venlafaxine hydrochloride tablets/ venlafaxine hydrochloride extended-release capsules for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient. uuid:12f898c7-f19d-4682-b576-8b603bddf2c9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9943 biolink:treats UMLS:C0221480 PMID:41385096 "[{""id"":""uuid:fcbd4110-28fb-45ac-84c1-0ce08bf41bdf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3e4c2aa5-85a7-4082-81a5-1118d23eb5f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Venlafaxine hydrochloride tablets are indicated for the treatment of major depressive disorder. The efficacy of venlafaxine hydrochloride in the treatment of major depressive disorder was established in 6-week controlled trials of adult outpatients whose diagnoses corresponded most closely to the DSM-III or DSM-III-R category of major depression and in a 4-week controlled trial of inpatients meeting diagnostic criteria for major depression with melancholia (see CLINICAL TRIALS ). A major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. The efficacy of venlafaxine extended-release capsules in maintaining an antidepressant response for up to 26 weeks following 8 weeks of acute treatment was demonstrated in a placebo-controlled trial. The efficacy of venlafaxine hydrochloride in maintaining an antidepressant response in patients with recurrent depression who had responded and continued to be improved during an initial 26 weeks of treatment and were then followed for a period of up to 52 weeks was demonstrated in a second placebo-controlled trial (see CLINICAL TRIALS ). Nevertheless, the physician who elects to use venlafaxine hydrochloride tablets/ venlafaxine hydrochloride extended-release capsules for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient. uuid:0871ca99-5232-423f-a939-91126c572da8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:92609 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:5a69aee6-520d-449d-9cd4-3b8a68d54942"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6ad978f8-0fb6-447e-bc21-1d7cde774f57"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:bbe6c028-8d5d-4a39-bdd9-d60dd0d2564b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Glimepiride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (see DOSAGE AND ADMINISTRATION ).|[PMDA] Drugs with a new dosage indicated for the treatment of type 2 diabetes mellitus (for use only in patients who have not responded sufficiently to diet and exercise therapies alone). uuid:9e462e0d-e3a6-4d1a-b2c0-0d9ff55d56a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16467 biolink:treats UMLS:C0858004 PMID:41385096 "[{""id"":""uuid:04e9a2de-a33e-4ea0-a419-bfe1d3a68591"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d11ed4a0-73ec-44ee-9f24-3fa56bfd88c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Rimantadine hydrochloride tablet is indicated for the prophylaxis and treatment of illness caused by various strains of influenza A virus in adults (17 years and older). Rimantadine hydrochloride tablet is indicated for prophylaxis against influenza A virus in children (1 year to 16 years of age). PROPHYLAXIS In controlled studies of children (1 year to 16 years of age), healthy adults (17 years and older), and elderly patients (65 years of age and older), rimantadine hydrochloride has been shown to be safe and effective in preventing signs and symptoms of infection caused by various strains of influenza A virus. Since rimantadine hydrochloride does not completely prevent the host immune response to influenza A infection, individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically-related viruses. Following vaccination during an influenza outbreak, rimantadine hydrochloride prophylaxis should be considered for the 2 to 4 week time period required to develop an antibody response. However, the safety and effectiveness of rimantadine hydrochloride prophylaxis have not been demonstrated for longer than 6 weeks. TREATMENT Rimantadine hydrochloride therapy should be considered for adults (17 years and older) who develop an influenza-like illness during known or suspected influenza A infection in the community. When administered within 48 hours after onset of signs and symptoms of infection caused by influenza A virus strains, rimantadine hydrochloride has been shown to reduce the duration of fever and systemic symptoms. The following points should be considered before initiating treatment or prophylaxis with rimantadine hydrochloride: - Rimantadine hydrochloride is not a substitute for early vaccination on an annual basis as recommended by the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices - Influenza viruses change over time. Emergence of resistance mutations could decrease drug effectiveness. Other factors (for example, changes in viral virulence) might also diminish clinical benefit of antiviral drugs. Prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use rimantadine hydrochloride. uuid:465d6633-f387-4814-b137-138464c56311 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16467 biolink:treats UMLS:C0521839 PMID:41385096 "[{""id"":""uuid:e4e715da-6373-485c-8b41-b9e56810dbdc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:58af353b-f69b-4a4e-b043-132f851dfca8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Rimantadine hydrochloride tablet is indicated for the prophylaxis and treatment of illness caused by various strains of influenza A virus in adults (17 years and older). Rimantadine hydrochloride tablet is indicated for prophylaxis against influenza A virus in children (1 year to 16 years of age). PROPHYLAXIS In controlled studies of children (1 year to 16 years of age), healthy adults (17 years and older), and elderly patients (65 years of age and older), rimantadine hydrochloride has been shown to be safe and effective in preventing signs and symptoms of infection caused by various strains of influenza A virus. Since rimantadine hydrochloride does not completely prevent the host immune response to influenza A infection, individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically-related viruses. Following vaccination during an influenza outbreak, rimantadine hydrochloride prophylaxis should be considered for the 2 to 4 week time period required to develop an antibody response. However, the safety and effectiveness of rimantadine hydrochloride prophylaxis have not been demonstrated for longer than 6 weeks. TREATMENT Rimantadine hydrochloride therapy should be considered for adults (17 years and older) who develop an influenza-like illness during known or suspected influenza A infection in the community. When administered within 48 hours after onset of signs and symptoms of infection caused by influenza A virus strains, rimantadine hydrochloride has been shown to reduce the duration of fever and systemic symptoms. The following points should be considered before initiating treatment or prophylaxis with rimantadine hydrochloride: - Rimantadine hydrochloride is not a substitute for early vaccination on an annual basis as recommended by the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices - Influenza viruses change over time. Emergence of resistance mutations could decrease drug effectiveness. Other factors (for example, changes in viral virulence) might also diminish clinical benefit of antiviral drugs. Prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use rimantadine hydrochloride. uuid:8ae06099-496e-4153-84ee-da15a38171e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6904 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:601c58fb-ba0d-4ae2-9cb0-f5112e3fdc70"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d14869d8-c9fa-42b6-8bde-dc5cd5553598"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Hypertension Metoprolol tartrate tablets are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive agents. Angina Pectoris Metoprolol tartrate tablets are indicated in the long-term treatment of angina pectoris. Myocardial Infarction Metoprolol tartrate tablets are indicated in the treatment of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality. Treatment with intravenous metoprolol tartrate can be initiated as soon as the patient's clinical condition allows (see DOSAGE AND ADMINISTRATION, CONTRAINDICATIONS, and WARNINGS). Alternatively, treatment can begin within 3 to 10 days of the acute event (see DOSAGE AND ADMINISTRATION). uuid:0490ccee-6bf0-4bc8-a90c-fb9b2e769623 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9123 biolink:treats MONDO:0005383 PMID:41385096 "[{""id"":""uuid:709f1de0-02f5-4f59-83f1-f430be160f47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3c082c42-5ad6-41a0-96aa-7bd5b20486b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:345786e6-5867-44bd-83f3-03a446627239"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Major Depressive Disorder Sertraline hydrochloride tablets are indicated for the treatment of major depressive disorder in adults. The efficacy of sertraline hydrochloride tablets in the treatment of a major depressive episode was established in six to eight week controlled trials of adult outpatients whose diagnoses corresponded most closely to the DSM-III category of major depressive disorder (see Clinical Trials under CLINICAL PHARMACOLOGY ). A major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. The antidepressant action of sertraline hydrochloride tablets in hospitalized depressed patients has not been adequately studied. The efficacy of sertraline hydrochloride tablets in maintaining an antidepressant response for up to 44 weeks following 8 weeks of open-label acute treatment (52 weeks total) was demonstrated in a placebo-controlled trial. The usefulness of the drug in patients receiving sertraline hydrochloride tablets for extended periods should be reevaluated periodically (see Clinical Trials under CLINICAL PHARMACOLOGY ). Obsessive-Compulsive Disorder Sertraline hydrochloride tablets are indicated for the treatment of obsessions and compulsions in patients with obsessive-compulsive disorder (OCD), as defined in the DSM-III-R; i.e., the obsessions or compulsions cause marked distress, are time-consuming, or significantly interfere with social or occupational functioning. The efficacy of sertraline hydrochloride tablets were established in 12-week trials with obsessive-compulsive outpatients having diagnoses of obsessive-compulsive disorder as defined according to DSM-III or DSM-III-R criteria (see Clinical Trials under CLINICAL PHARMACOLOGY ). Obsessive-compulsive disorder is characterized by recurrent and persistent ideas, thoughts, impulses, or images (obsessions) that are ego-dystonic and/or repetitive, purposeful, and intentional behaviors (compulsions) that are recognized by the person as excessive or unreasonable. The efficacy of sertraline hydrochloride tablets in maintaining a response, in patients with OCD who responded during a 52-week treatment phase while taking sertraline hydrochloride tablets and were then observed for relapse during a period of up to 28 weeks, was demonstrated in a placebo-controlled trial (see Clinical Trials under CLINICAL PHARMACOLOGY ). Nevertheless, the physician who elects to use sertraline hydrochloride tablets for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Panic Disorder Sertraline hydrochloride tablets are indicated for the treatment of panic disorder in adults, with or without agoraphobia, as defined in DSM-IV. Panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. The efficacy of sertraline hydrochloride tablets were established in three 10 to 12 week trials in adult panic disorder patients whose diagnoses corresponded to the DSM-III-R category of panic disorder (see Clinical Trials under CLINICAL PHARMACOLOGY ). Panic disorder (DSM-IV) is characterized by recurrent unexpected panic attacks, i.e., a discrete period of intense fear or discomfort in which four (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) palpitations, pounding heart, or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded, or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes. The efficacy of sertraline hydrochloride tablets in maintaining a response, in adult patients with panic disorder who responded during a 52-week treatment phase while taking sertraline hydrochloride tablets and were then observed for relapse during a period of up to 28 weeks, was demonstrated in a placebo-controlled trial (see Clinical Trials under CLINICAL PHARMACOLOGY ). Nevertheless, the physician who elects to use sertraline hydrochloride tablets for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Posttraumatic Stress Disorder (PTSD) Sertraline hydrochloride tablets are indicated for the treatment of posttraumatic stress disorder in adults. The efficacy of sertraline hydrochloride tablets in the treatment of PTSD was established in two 12-week placebo-controlled trials of adult outpatients whose diagnosis met criteria for the DSM-III-R category of PTSD (see Clinical Trials under CLINICAL PHARMACOLOGY ). PTSD, as defined by DSM-III-R/IV, requires exposure to a traumatic event that involved actual or threatened death or serious injury, or threat to the physical integrity of self or others, and a response which involves intense fear, helplessness, or horror. Symptoms that occur as a result of exposure to the traumatic event include reexperiencing of the event in the form of intrusive thoughts, flashbacks or dreams, and intense psychological distress and physiological reactivity on exposure to cues to the event; avoidance of situations reminiscent of the traumatic event, inability to recall details of the event, and/or numbing of general responsiveness manifested as diminished interest in significant activities, estrangement from others, restricted range of affect, or sense of foreshortened future; and symptoms of autonomic arousal including hypervigilance, exaggerated startle response, sleep disturbance, impaired concentration, and irritability or outbursts of anger. A PTSD diagnosis requires that the symptoms are present for at least a month and that they cause clinically significant distress or impairment in social, occupational, or other important areas of functioning. The efficacy of sertraline hydrochloride tablets in maintaining a response in adult patients with PTSD for up to 28 weeks following 24 weeks of open-label treatment was demonstrated in a placebo-controlled trial. Nevertheless, the physician who elects to use sertraline hydrochloride tablets for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Premenstrual Dysphoric Disorder (PMDD) Sertraline hydrochloride tablets are indicated for the treatment of premenstrual dysphoric disorder (PMDD) in adults. The efficacy of sertraline hydrochloride tablets in the treatment of PMDD was established in 2 placebo-controlled trials of female adult outpatients treated for 3 menstrual cycles who met criteria for the DSM-III-R/IV category of PMDD (see Clinical Trials under CLINICAL PHARMACOLOGY ). The essential features of PMDD include markedly depressed mood, anxiety or tension, affective lability, and persistent anger or irritability. Other features include decreased interest in activities, difficulty concentrating, lack of energy, change in appetite or sleep, and feeling out of control. Physical symptoms associated with PMDD include breast tenderness, headache, joint and muscle pain, bloating and weight gain. These symptoms occur regularly during the luteal phase and remit within a few days following onset of menses; the disturbance markedly interferes with work or school or with usual social activities and relationships with others. In making the diagnosis, care should be taken to rule out other cyclical mood disorders that may be exacerbated by treatment with an antidepressant. The effectiveness of sertraline hydrochloride tablets in long-term use, that is, for more than 3 menstrual cycles, has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use sertraline hydrochloride tablets for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Social Anxiety Disorder Sertraline hydrochloride tablets are indicated for the treatment of social anxiety disorder, also known as social phobia in adults. The efficacy of sertraline hydrochloride tablets in the treatment of social anxiety disorder was established in two placebo-controlled trials of adult outpatients with a diagnosis of social anxiety disorder as defined by DSM-IV criteria (see Clinical Trials under CLINICAL PHARMACOLOGY ). Social anxiety disorder, as defined by DSM-IV, is characterized by marked and persistent fear of social or performance situations involving exposure to unfamiliar people or possible scrutiny by others and by fears of acting in a humiliating or embarrassing way. Exposure to the feared social situation almost always provokes anxiety and feared social or performance situations are avoided or else are endured with intense anxiety or distress. In addition, patients recognize that the fear is excessive or unreasonable and the avoidance and anticipatory anxiety of the feared situation is associated with functional impairment or marked distress. The efficacy of sertraline hydrochloride tablets in maintaining a response in adult patients with social anxiety disorder for up to 24 weeks following 20 weeks of sertraline hydrochloride tablets treatment was demonstrated in a placebo-controlled trial. Physicians who prescribe sertraline hydrochloride tablets for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see Clinical Trials under CLINICAL PHARMACOLOGY ).|[PMDA] Drugs containing a new active ingredient, indicated for depression and panic disorder. uuid:95d9f3a3-fd12-410c-98a2-545f89d5cf75 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9123 biolink:treats MONDO:0005146 PMID:41385096 "[{""id"":""uuid:80bb18e2-fa9d-4d0e-990c-c46f5ab8d55d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:29fe1da9-b8c0-452b-a856-20ea790bbbad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:fe087489-e398-4a60-a73c-9dca4165a463"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Major Depressive Disorder Sertraline hydrochloride tablets are indicated for the treatment of major depressive disorder in adults. The efficacy of sertraline hydrochloride tablets in the treatment of a major depressive episode was established in six to eight week controlled trials of adult outpatients whose diagnoses corresponded most closely to the DSM-III category of major depressive disorder (see Clinical Trials under CLINICAL PHARMACOLOGY ). A major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. The antidepressant action of sertraline hydrochloride tablets in hospitalized depressed patients has not been adequately studied. The efficacy of sertraline hydrochloride tablets in maintaining an antidepressant response for up to 44 weeks following 8 weeks of open-label acute treatment (52 weeks total) was demonstrated in a placebo-controlled trial. The usefulness of the drug in patients receiving sertraline hydrochloride tablets for extended periods should be reevaluated periodically (see Clinical Trials under CLINICAL PHARMACOLOGY ). Obsessive-Compulsive Disorder Sertraline hydrochloride tablets are indicated for the treatment of obsessions and compulsions in patients with obsessive-compulsive disorder (OCD), as defined in the DSM-III-R; i.e., the obsessions or compulsions cause marked distress, are time-consuming, or significantly interfere with social or occupational functioning. The efficacy of sertraline hydrochloride tablets were established in 12-week trials with obsessive-compulsive outpatients having diagnoses of obsessive-compulsive disorder as defined according to DSM-III or DSM-III-R criteria (see Clinical Trials under CLINICAL PHARMACOLOGY ). Obsessive-compulsive disorder is characterized by recurrent and persistent ideas, thoughts, impulses, or images (obsessions) that are ego-dystonic and/or repetitive, purposeful, and intentional behaviors (compulsions) that are recognized by the person as excessive or unreasonable. The efficacy of sertraline hydrochloride tablets in maintaining a response, in patients with OCD who responded during a 52-week treatment phase while taking sertraline hydrochloride tablets and were then observed for relapse during a period of up to 28 weeks, was demonstrated in a placebo-controlled trial (see Clinical Trials under CLINICAL PHARMACOLOGY ). Nevertheless, the physician who elects to use sertraline hydrochloride tablets for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Panic Disorder Sertraline hydrochloride tablets are indicated for the treatment of panic disorder in adults, with or without agoraphobia, as defined in DSM-IV. Panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. The efficacy of sertraline hydrochloride tablets were established in three 10 to 12 week trials in adult panic disorder patients whose diagnoses corresponded to the DSM-III-R category of panic disorder (see Clinical Trials under CLINICAL PHARMACOLOGY ). Panic disorder (DSM-IV) is characterized by recurrent unexpected panic attacks, i.e., a discrete period of intense fear or discomfort in which four (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) palpitations, pounding heart, or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded, or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes. The efficacy of sertraline hydrochloride tablets in maintaining a response, in adult patients with panic disorder who responded during a 52-week treatment phase while taking sertraline hydrochloride tablets and were then observed for relapse during a period of up to 28 weeks, was demonstrated in a placebo-controlled trial (see Clinical Trials under CLINICAL PHARMACOLOGY ). Nevertheless, the physician who elects to use sertraline hydrochloride tablets for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Posttraumatic Stress Disorder (PTSD) Sertraline hydrochloride tablets are indicated for the treatment of posttraumatic stress disorder in adults. The efficacy of sertraline hydrochloride tablets in the treatment of PTSD was established in two 12-week placebo-controlled trials of adult outpatients whose diagnosis met criteria for the DSM-III-R category of PTSD (see Clinical Trials under CLINICAL PHARMACOLOGY ). PTSD, as defined by DSM-III-R/IV, requires exposure to a traumatic event that involved actual or threatened death or serious injury, or threat to the physical integrity of self or others, and a response which involves intense fear, helplessness, or horror. Symptoms that occur as a result of exposure to the traumatic event include reexperiencing of the event in the form of intrusive thoughts, flashbacks or dreams, and intense psychological distress and physiological reactivity on exposure to cues to the event; avoidance of situations reminiscent of the traumatic event, inability to recall details of the event, and/or numbing of general responsiveness manifested as diminished interest in significant activities, estrangement from others, restricted range of affect, or sense of foreshortened future; and symptoms of autonomic arousal including hypervigilance, exaggerated startle response, sleep disturbance, impaired concentration, and irritability or outbursts of anger. A PTSD diagnosis requires that the symptoms are present for at least a month and that they cause clinically significant distress or impairment in social, occupational, or other important areas of functioning. The efficacy of sertraline hydrochloride tablets in maintaining a response in adult patients with PTSD for up to 28 weeks following 24 weeks of open-label treatment was demonstrated in a placebo-controlled trial. Nevertheless, the physician who elects to use sertraline hydrochloride tablets for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Premenstrual Dysphoric Disorder (PMDD) Sertraline hydrochloride tablets are indicated for the treatment of premenstrual dysphoric disorder (PMDD) in adults. The efficacy of sertraline hydrochloride tablets in the treatment of PMDD was established in 2 placebo-controlled trials of female adult outpatients treated for 3 menstrual cycles who met criteria for the DSM-III-R/IV category of PMDD (see Clinical Trials under CLINICAL PHARMACOLOGY ). The essential features of PMDD include markedly depressed mood, anxiety or tension, affective lability, and persistent anger or irritability. Other features include decreased interest in activities, difficulty concentrating, lack of energy, change in appetite or sleep, and feeling out of control. Physical symptoms associated with PMDD include breast tenderness, headache, joint and muscle pain, bloating and weight gain. These symptoms occur regularly during the luteal phase and remit within a few days following onset of menses; the disturbance markedly interferes with work or school or with usual social activities and relationships with others. In making the diagnosis, care should be taken to rule out other cyclical mood disorders that may be exacerbated by treatment with an antidepressant. The effectiveness of sertraline hydrochloride tablets in long-term use, that is, for more than 3 menstrual cycles, has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use sertraline hydrochloride tablets for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Social Anxiety Disorder Sertraline hydrochloride tablets are indicated for the treatment of social anxiety disorder, also known as social phobia in adults. The efficacy of sertraline hydrochloride tablets in the treatment of social anxiety disorder was established in two placebo-controlled trials of adult outpatients with a diagnosis of social anxiety disorder as defined by DSM-IV criteria (see Clinical Trials under CLINICAL PHARMACOLOGY ). Social anxiety disorder, as defined by DSM-IV, is characterized by marked and persistent fear of social or performance situations involving exposure to unfamiliar people or possible scrutiny by others and by fears of acting in a humiliating or embarrassing way. Exposure to the feared social situation almost always provokes anxiety and feared social or performance situations are avoided or else are endured with intense anxiety or distress. In addition, patients recognize that the fear is excessive or unreasonable and the avoidance and anticipatory anxiety of the feared situation is associated with functional impairment or marked distress. The efficacy of sertraline hydrochloride tablets in maintaining a response in adult patients with social anxiety disorder for up to 24 weeks following 20 weeks of sertraline hydrochloride tablets treatment was demonstrated in a placebo-controlled trial. Physicians who prescribe sertraline hydrochloride tablets for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see Clinical Trials under CLINICAL PHARMACOLOGY ).|[PMDA] Drugs with a new additional indication for the treatment of posttraumatic stress disorder. uuid:f885f69d-86de-4651-81b9-65a1cb7db5cc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9123 biolink:treats MONDO:1010182 PMID:41385096 "[{""id"":""uuid:a0ae725b-de0c-4838-b503-02406b2d14fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9a5e07a5-958e-4b75-82cf-0efd4e75e351"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Major Depressive Disorder Sertraline hydrochloride tablets are indicated for the treatment of major depressive disorder in adults. The efficacy of sertraline hydrochloride tablets in the treatment of a major depressive episode was established in six to eight week controlled trials of adult outpatients whose diagnoses corresponded most closely to the DSM-III category of major depressive disorder (see Clinical Trials under CLINICAL PHARMACOLOGY ). A major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. The antidepressant action of sertraline hydrochloride tablets in hospitalized depressed patients has not been adequately studied. The efficacy of sertraline hydrochloride tablets in maintaining an antidepressant response for up to 44 weeks following 8 weeks of open-label acute treatment (52 weeks total) was demonstrated in a placebo-controlled trial. The usefulness of the drug in patients receiving sertraline hydrochloride tablets for extended periods should be reevaluated periodically (see Clinical Trials under CLINICAL PHARMACOLOGY ). Obsessive-Compulsive Disorder Sertraline hydrochloride tablets are indicated for the treatment of obsessions and compulsions in patients with obsessive-compulsive disorder (OCD), as defined in the DSM-III-R; i.e., the obsessions or compulsions cause marked distress, are time-consuming, or significantly interfere with social or occupational functioning. The efficacy of sertraline hydrochloride tablets were established in 12-week trials with obsessive-compulsive outpatients having diagnoses of obsessive-compulsive disorder as defined according to DSM-III or DSM-III-R criteria (see Clinical Trials under CLINICAL PHARMACOLOGY ). Obsessive-compulsive disorder is characterized by recurrent and persistent ideas, thoughts, impulses, or images (obsessions) that are ego-dystonic and/or repetitive, purposeful, and intentional behaviors (compulsions) that are recognized by the person as excessive or unreasonable. The efficacy of sertraline hydrochloride tablets in maintaining a response, in patients with OCD who responded during a 52-week treatment phase while taking sertraline hydrochloride tablets and were then observed for relapse during a period of up to 28 weeks, was demonstrated in a placebo-controlled trial (see Clinical Trials under CLINICAL PHARMACOLOGY ). Nevertheless, the physician who elects to use sertraline hydrochloride tablets for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Panic Disorder Sertraline hydrochloride tablets are indicated for the treatment of panic disorder in adults, with or without agoraphobia, as defined in DSM-IV. Panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. The efficacy of sertraline hydrochloride tablets were established in three 10 to 12 week trials in adult panic disorder patients whose diagnoses corresponded to the DSM-III-R category of panic disorder (see Clinical Trials under CLINICAL PHARMACOLOGY ). Panic disorder (DSM-IV) is characterized by recurrent unexpected panic attacks, i.e., a discrete period of intense fear or discomfort in which four (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) palpitations, pounding heart, or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded, or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes. The efficacy of sertraline hydrochloride tablets in maintaining a response, in adult patients with panic disorder who responded during a 52-week treatment phase while taking sertraline hydrochloride tablets and were then observed for relapse during a period of up to 28 weeks, was demonstrated in a placebo-controlled trial (see Clinical Trials under CLINICAL PHARMACOLOGY ). Nevertheless, the physician who elects to use sertraline hydrochloride tablets for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Posttraumatic Stress Disorder (PTSD) Sertraline hydrochloride tablets are indicated for the treatment of posttraumatic stress disorder in adults. The efficacy of sertraline hydrochloride tablets in the treatment of PTSD was established in two 12-week placebo-controlled trials of adult outpatients whose diagnosis met criteria for the DSM-III-R category of PTSD (see Clinical Trials under CLINICAL PHARMACOLOGY ). PTSD, as defined by DSM-III-R/IV, requires exposure to a traumatic event that involved actual or threatened death or serious injury, or threat to the physical integrity of self or others, and a response which involves intense fear, helplessness, or horror. Symptoms that occur as a result of exposure to the traumatic event include reexperiencing of the event in the form of intrusive thoughts, flashbacks or dreams, and intense psychological distress and physiological reactivity on exposure to cues to the event; avoidance of situations reminiscent of the traumatic event, inability to recall details of the event, and/or numbing of general responsiveness manifested as diminished interest in significant activities, estrangement from others, restricted range of affect, or sense of foreshortened future; and symptoms of autonomic arousal including hypervigilance, exaggerated startle response, sleep disturbance, impaired concentration, and irritability or outbursts of anger. A PTSD diagnosis requires that the symptoms are present for at least a month and that they cause clinically significant distress or impairment in social, occupational, or other important areas of functioning. The efficacy of sertraline hydrochloride tablets in maintaining a response in adult patients with PTSD for up to 28 weeks following 24 weeks of open-label treatment was demonstrated in a placebo-controlled trial. Nevertheless, the physician who elects to use sertraline hydrochloride tablets for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Premenstrual Dysphoric Disorder (PMDD) Sertraline hydrochloride tablets are indicated for the treatment of premenstrual dysphoric disorder (PMDD) in adults. The efficacy of sertraline hydrochloride tablets in the treatment of PMDD was established in 2 placebo-controlled trials of female adult outpatients treated for 3 menstrual cycles who met criteria for the DSM-III-R/IV category of PMDD (see Clinical Trials under CLINICAL PHARMACOLOGY ). The essential features of PMDD include markedly depressed mood, anxiety or tension, affective lability, and persistent anger or irritability. Other features include decreased interest in activities, difficulty concentrating, lack of energy, change in appetite or sleep, and feeling out of control. Physical symptoms associated with PMDD include breast tenderness, headache, joint and muscle pain, bloating and weight gain. These symptoms occur regularly during the luteal phase and remit within a few days following onset of menses; the disturbance markedly interferes with work or school or with usual social activities and relationships with others. In making the diagnosis, care should be taken to rule out other cyclical mood disorders that may be exacerbated by treatment with an antidepressant. The effectiveness of sertraline hydrochloride tablets in long-term use, that is, for more than 3 menstrual cycles, has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use sertraline hydrochloride tablets for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Social Anxiety Disorder Sertraline hydrochloride tablets are indicated for the treatment of social anxiety disorder, also known as social phobia in adults. The efficacy of sertraline hydrochloride tablets in the treatment of social anxiety disorder was established in two placebo-controlled trials of adult outpatients with a diagnosis of social anxiety disorder as defined by DSM-IV criteria (see Clinical Trials under CLINICAL PHARMACOLOGY ). Social anxiety disorder, as defined by DSM-IV, is characterized by marked and persistent fear of social or performance situations involving exposure to unfamiliar people or possible scrutiny by others and by fears of acting in a humiliating or embarrassing way. Exposure to the feared social situation almost always provokes anxiety and feared social or performance situations are avoided or else are endured with intense anxiety or distress. In addition, patients recognize that the fear is excessive or unreasonable and the avoidance and anticipatory anxiety of the feared situation is associated with functional impairment or marked distress. The efficacy of sertraline hydrochloride tablets in maintaining a response in adult patients with social anxiety disorder for up to 24 weeks following 20 weeks of sertraline hydrochloride tablets treatment was demonstrated in a placebo-controlled trial. Physicians who prescribe sertraline hydrochloride tablets for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see Clinical Trials under CLINICAL PHARMACOLOGY ). UMLS:C0520676 uuid:a674d803-47aa-4348-82a4-d7fd651406d7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9123 biolink:treats MONDO:0001247 PMID:41385096 "[{""id"":""uuid:0a17817f-919e-41a0-adfc-d9de1224e3f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4573f34b-9784-44f1-90b7-f2fd8be920fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Major Depressive Disorder Sertraline hydrochloride tablets are indicated for the treatment of major depressive disorder in adults. The efficacy of sertraline hydrochloride tablets in the treatment of a major depressive episode was established in six to eight week controlled trials of adult outpatients whose diagnoses corresponded most closely to the DSM-III category of major depressive disorder (see Clinical Trials under CLINICAL PHARMACOLOGY ). A major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. The antidepressant action of sertraline hydrochloride tablets in hospitalized depressed patients has not been adequately studied. The efficacy of sertraline hydrochloride tablets in maintaining an antidepressant response for up to 44 weeks following 8 weeks of open-label acute treatment (52 weeks total) was demonstrated in a placebo-controlled trial. The usefulness of the drug in patients receiving sertraline hydrochloride tablets for extended periods should be reevaluated periodically (see Clinical Trials under CLINICAL PHARMACOLOGY ). Obsessive-Compulsive Disorder Sertraline hydrochloride tablets are indicated for the treatment of obsessions and compulsions in patients with obsessive-compulsive disorder (OCD), as defined in the DSM-III-R; i.e., the obsessions or compulsions cause marked distress, are time-consuming, or significantly interfere with social or occupational functioning. The efficacy of sertraline hydrochloride tablets were established in 12-week trials with obsessive-compulsive outpatients having diagnoses of obsessive-compulsive disorder as defined according to DSM-III or DSM-III-R criteria (see Clinical Trials under CLINICAL PHARMACOLOGY ). Obsessive-compulsive disorder is characterized by recurrent and persistent ideas, thoughts, impulses, or images (obsessions) that are ego-dystonic and/or repetitive, purposeful, and intentional behaviors (compulsions) that are recognized by the person as excessive or unreasonable. The efficacy of sertraline hydrochloride tablets in maintaining a response, in patients with OCD who responded during a 52-week treatment phase while taking sertraline hydrochloride tablets and were then observed for relapse during a period of up to 28 weeks, was demonstrated in a placebo-controlled trial (see Clinical Trials under CLINICAL PHARMACOLOGY ). Nevertheless, the physician who elects to use sertraline hydrochloride tablets for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Panic Disorder Sertraline hydrochloride tablets are indicated for the treatment of panic disorder in adults, with or without agoraphobia, as defined in DSM-IV. Panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. The efficacy of sertraline hydrochloride tablets were established in three 10 to 12 week trials in adult panic disorder patients whose diagnoses corresponded to the DSM-III-R category of panic disorder (see Clinical Trials under CLINICAL PHARMACOLOGY ). Panic disorder (DSM-IV) is characterized by recurrent unexpected panic attacks, i.e., a discrete period of intense fear or discomfort in which four (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) palpitations, pounding heart, or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded, or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes. The efficacy of sertraline hydrochloride tablets in maintaining a response, in adult patients with panic disorder who responded during a 52-week treatment phase while taking sertraline hydrochloride tablets and were then observed for relapse during a period of up to 28 weeks, was demonstrated in a placebo-controlled trial (see Clinical Trials under CLINICAL PHARMACOLOGY ). Nevertheless, the physician who elects to use sertraline hydrochloride tablets for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Posttraumatic Stress Disorder (PTSD) Sertraline hydrochloride tablets are indicated for the treatment of posttraumatic stress disorder in adults. The efficacy of sertraline hydrochloride tablets in the treatment of PTSD was established in two 12-week placebo-controlled trials of adult outpatients whose diagnosis met criteria for the DSM-III-R category of PTSD (see Clinical Trials under CLINICAL PHARMACOLOGY ). PTSD, as defined by DSM-III-R/IV, requires exposure to a traumatic event that involved actual or threatened death or serious injury, or threat to the physical integrity of self or others, and a response which involves intense fear, helplessness, or horror. Symptoms that occur as a result of exposure to the traumatic event include reexperiencing of the event in the form of intrusive thoughts, flashbacks or dreams, and intense psychological distress and physiological reactivity on exposure to cues to the event; avoidance of situations reminiscent of the traumatic event, inability to recall details of the event, and/or numbing of general responsiveness manifested as diminished interest in significant activities, estrangement from others, restricted range of affect, or sense of foreshortened future; and symptoms of autonomic arousal including hypervigilance, exaggerated startle response, sleep disturbance, impaired concentration, and irritability or outbursts of anger. A PTSD diagnosis requires that the symptoms are present for at least a month and that they cause clinically significant distress or impairment in social, occupational, or other important areas of functioning. The efficacy of sertraline hydrochloride tablets in maintaining a response in adult patients with PTSD for up to 28 weeks following 24 weeks of open-label treatment was demonstrated in a placebo-controlled trial. Nevertheless, the physician who elects to use sertraline hydrochloride tablets for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Premenstrual Dysphoric Disorder (PMDD) Sertraline hydrochloride tablets are indicated for the treatment of premenstrual dysphoric disorder (PMDD) in adults. The efficacy of sertraline hydrochloride tablets in the treatment of PMDD was established in 2 placebo-controlled trials of female adult outpatients treated for 3 menstrual cycles who met criteria for the DSM-III-R/IV category of PMDD (see Clinical Trials under CLINICAL PHARMACOLOGY ). The essential features of PMDD include markedly depressed mood, anxiety or tension, affective lability, and persistent anger or irritability. Other features include decreased interest in activities, difficulty concentrating, lack of energy, change in appetite or sleep, and feeling out of control. Physical symptoms associated with PMDD include breast tenderness, headache, joint and muscle pain, bloating and weight gain. These symptoms occur regularly during the luteal phase and remit within a few days following onset of menses; the disturbance markedly interferes with work or school or with usual social activities and relationships with others. In making the diagnosis, care should be taken to rule out other cyclical mood disorders that may be exacerbated by treatment with an antidepressant. The effectiveness of sertraline hydrochloride tablets in long-term use, that is, for more than 3 menstrual cycles, has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use sertraline hydrochloride tablets for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Social Anxiety Disorder Sertraline hydrochloride tablets are indicated for the treatment of social anxiety disorder, also known as social phobia in adults. The efficacy of sertraline hydrochloride tablets in the treatment of social anxiety disorder was established in two placebo-controlled trials of adult outpatients with a diagnosis of social anxiety disorder as defined by DSM-IV criteria (see Clinical Trials under CLINICAL PHARMACOLOGY ). Social anxiety disorder, as defined by DSM-IV, is characterized by marked and persistent fear of social or performance situations involving exposure to unfamiliar people or possible scrutiny by others and by fears of acting in a humiliating or embarrassing way. Exposure to the feared social situation almost always provokes anxiety and feared social or performance situations are avoided or else are endured with intense anxiety or distress. In addition, patients recognize that the fear is excessive or unreasonable and the avoidance and anticipatory anxiety of the feared situation is associated with functional impairment or marked distress. The efficacy of sertraline hydrochloride tablets in maintaining a response in adult patients with social anxiety disorder for up to 24 weeks following 20 weeks of sertraline hydrochloride tablets treatment was demonstrated in a placebo-controlled trial. Physicians who prescribe sertraline hydrochloride tablets for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see Clinical Trials under CLINICAL PHARMACOLOGY ). uuid:144592ec-3423-467d-a6b3-ec9dfad67285 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46195 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:54917b26-cef8-4cde-a672-7397cf4cb49a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7525f022-ed98-4850-a0e8-e4cf5219d53c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4b2a1dca-5f35-4c25-a712-3ddfc83207c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Acetaminophen and codeine phosphate tablets are indicated for the relief of mild to moderately severe pain.|[PMDA] A drug with a new route of administration indicated for the treatment of pain and pyrexia which cannnot be managed by oral preparations and suppositories. uuid:98c180e8-41ff-45e8-b9e2-66d64dbd7238 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:375910 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:8fde3fd8-cd04-4da0-83ae-6df5bb2dd72e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e659258f-26a8-4bdf-9233-c9dd2209269a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Promethazine hydrochloride and phenylephrine hydrochloride syrup is indicated for the temporary relief of upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold. uuid:396056bb-7e6f-4e35-a62f-65e131c967c3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:375910 biolink:treats MONDO:0005709 PMID:41385096 "[{""id"":""uuid:6c53487e-a92d-4173-bc6f-73041ee6e3bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ef3e856a-7fd9-429b-b5a4-b85847de3333"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Promethazine hydrochloride and phenylephrine hydrochloride syrup is indicated for the temporary relief of upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold. uuid:e065ce49-f671-4eb5-9637-b5eaa884ad78 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8875 biolink:treats MONDO:0005475 PMID:41385096 "[{""id"":""uuid:b8271abc-76d1-4425-8deb-276e2d07b521"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5673e3c1-cf87-4ad3-aba6-9f806b540ad0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MAXALT is indicated for the acute treatment of migraine attacks with or without aura in adults. MAXALT is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS ). Safety and effectiveness of MAXALT have not been established for cluster headache, which is present in an older, predominantly male population. uuid:5e226c56-251f-45bb-b03d-e66cd9f041c5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8875 biolink:treats MONDO:0100431 PMID:41385096 "[{""id"":""uuid:2e0b14a5-b3a6-4a2b-baba-e9a7012c5040"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9c40b708-2f48-4683-803d-7ef7c0d9f9f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MAXALT is indicated for the acute treatment of migraine attacks with or without aura in adults. MAXALT is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS ). Safety and effectiveness of MAXALT have not been established for cluster headache, which is present in an older, predominantly male population. uuid:ee3890d2-1ebf-414b-8543-cc71b64cceb9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8875 biolink:treats MONDO:0018925 PMID:41385096 "[{""id"":""uuid:a5d0d047-71da-4d0d-9f22-3e3aaf38b769"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:93a7af28-ae6d-4f25-ac92-4ec71f5419a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MAXALT is indicated for the acute treatment of migraine attacks with or without aura in adults. MAXALT is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS ). Safety and effectiveness of MAXALT have not been established for cluster headache, which is present in an older, predominantly male population. uuid:9a374ac2-096f-4bb0-9161-e467649ab425 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8875 biolink:treats MONDO:0043219 PMID:41385096 "[{""id"":""uuid:30defd71-ea7b-4f8a-8571-0d86c8aab074"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d8b8fa91-4b5f-4950-b66c-81976680776b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MAXALT is indicated for the acute treatment of migraine attacks with or without aura in adults. MAXALT is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS ). Safety and effectiveness of MAXALT have not been established for cluster headache, which is present in an older, predominantly male population. uuid:104e075e-5681-45f2-b457-6aaf27e90284 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8875 biolink:treats MONDO:0043537 PMID:41385096 "[{""id"":""uuid:9dc17a2d-02d7-464c-bcfb-8ad0157fb853"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1decc7cc-a5e0-482c-8a59-7b14dab7d67a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MAXALT is indicated for the acute treatment of migraine attacks with or without aura in adults. MAXALT is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS ). Safety and effectiveness of MAXALT have not been established for cluster headache, which is present in an older, predominantly male population. uuid:1244d3bc-7e76-46df-9e80-9d7d887dd8a5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:205919 biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:b1edf195-62e6-4b2e-bfb5-1c8ada77c50e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:14d3ffd7-c77c-463e-bee3-cd1523b0d8bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clobetasol propionate foam, 0.05% is a super-potent topical corticosteroid indicated for short-term topical treatment of the inflammatory and pruritic manifestations of moderate to severe corticosteroid- responsive dermatoses of the scalp, and for short-term topical treatment of mild to moderate plaque-type psoriasis on non-scalp regions excluding the face and intertriginous areas. Treatment beyond 2 consecutive weeks is not recommended and the total dosage should not exceed 50 g per week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (HPA) axis. In a controlled pharmacokinetic study, some subjects experienced reversible suppression of the adrenals following 14 days of clobetasol propionate foam, 0.05% therapy (See ADVERSE REACTIONS ). Use in children under 12 years of age is not recommended. uuid:5dcb16d3-48e9-4133-a4f0-60a21a44cf4a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:194135 biolink:treats MONDO:0004795 PMID:41385096 "[{""id"":""uuid:1436db55-9263-478e-88c2-423a3ab260dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:73aefa35-87b8-400e-b0da-d8e93be509e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ofloxacin Otic Solution 0.3% is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the specific conditions listed below: Otitis Externa in adults and pediatric patients, 6 months and older, due to Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aereus . Chronic Suppurative Otitis Media in patients 12 years and older with perforated tympanic membranes due to Proteus mirabilis, Pseudomonas aeruginosa and Staphylococcus aureus . Acute Otitis Media in pediatric patients one year and older with tympanostomy tubes due to Haemophilus influenzae, Moraxella catarrhalis, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae . uuid:a8ee3c3d-2e8c-404c-918e-8cde03f84154 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:194135 biolink:treats MONDO:0001920 PMID:41385096 "[{""id"":""uuid:520a59b2-0dab-4906-9320-5d4ef53eea88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f1e9f037-da41-41a1-90d8-9431eb22a0b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ofloxacin Otic Solution 0.3% is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the specific conditions listed below: Otitis Externa in adults and pediatric patients, 6 months and older, due to Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aereus . Chronic Suppurative Otitis Media in patients 12 years and older with perforated tympanic membranes due to Proteus mirabilis, Pseudomonas aeruginosa and Staphylococcus aureus . Acute Otitis Media in pediatric patients one year and older with tympanostomy tubes due to Haemophilus influenzae, Moraxella catarrhalis, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae . uuid:0365b7ed-f10e-44f1-abfa-35438ee025c5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:194135 biolink:treats HP:0000371 PMID:41385096 "[{""id"":""uuid:b3774560-3a72-4946-bb19-89c9600a0c41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:11d8b87b-ae9b-4cbb-86bc-65db20ba59e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ofloxacin Otic Solution 0.3% is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the specific conditions listed below: Otitis Externa in adults and pediatric patients, 6 months and older, due to Escherichia coli, Pseudomonas aeruginosa, and Staphylococcus aereus . Chronic Suppurative Otitis Media in patients 12 years and older with perforated tympanic membranes due to Proteus mirabilis, Pseudomonas aeruginosa and Staphylococcus aureus . Acute Otitis Media in pediatric patients one year and older with tympanostomy tubes due to Haemophilus influenzae, Moraxella catarrhalis, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae . uuid:1fb7d6dd-4b69-413a-b308-2ef6a7ed57e7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:30742 biolink:treats MONDO:0002203 PMID:41385096 "[{""id"":""uuid:7a634f96-fcf5-4c45-9f5e-6523b43799a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5421a4c8-51dd-420a-9013-43e2df833e47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of occasional constipation. This product should be used for 2 weeks or less or as directed by a physician. uuid:f3e08c95-aea7-4102-9840-9230a92b7a95 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9586 biolink:treats HP:0007359 PMID:41385096 "[{""id"":""uuid:891536c5-19be-40eb-badc-852d0c3b22b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c72bf6aa-f20a-4173-9de1-8619553cf370"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] GABITRIL (tiagabine hydrochloride) is indicated as adjunctive therapy in adults and children 12 years and older in the treatment of partial seizures. uuid:cac91cf7-cb87-4f23-bdb6-9fb40aff3530 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47499 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:39d49afe-e4f6-4c54-9b1b-675a0476ac1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:78a8dfad-5c5d-4eee-9e44-8a6a317e7080"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the relief of symptoms of depression. Endogenous depression is more likely to be alleviated than other depressive states. One to three weeks of treatment may be needed before optimal therapeutic effects are evident. uuid:16471cdf-1df0-4dc6-8fd6-3cd32568607d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47499 biolink:treats MONDO:0012048 PMID:41385096 "[{""id"":""uuid:f8d19951-0b96-4792-b49b-c21f1005b5a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a48b9bf9-f017-484f-9572-5b58d62fdcee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the relief of symptoms of depression. Endogenous depression is more likely to be alleviated than other depressive states. One to three weeks of treatment may be needed before optimal therapeutic effects are evident. uuid:5e9f3c44-8be1-467e-a25e-49fdbdf1546e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9619 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:2f414c18-20df-49d3-903e-8918e3d845f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:424e0baa-aa00-49d7-a118-cc7940d4f17f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of tolmetin sodium tablets and other treatment options before deciding to use tolmetin sodium tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Tolmetin sodium tablets are indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. Tolmetin is indicated in the treatment of acute flares and the long-term management of the chronic disease. Tolmetin is also indicated for treatment of juvenile rheumatoid arthritis. The safety and effectiveness of tolmetin have not been established in pediatric patients under 2 years of age (see PRECAUTIONS: Pediatric Use and DOSAGE AND ADMINISTRATION ). uuid:6741c234-2e9a-46bc-84ae-b77cdab54951 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9619 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:7fdb3298-a094-4edf-95d8-0c550c4d7d06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9b19702c-c764-459c-bb41-99e3ddd84db8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of tolmetin sodium tablets and other treatment options before deciding to use tolmetin sodium tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Tolmetin sodium tablets are indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. Tolmetin is indicated in the treatment of acute flares and the long-term management of the chronic disease. Tolmetin is also indicated for treatment of juvenile rheumatoid arthritis. The safety and effectiveness of tolmetin have not been established in pediatric patients under 2 years of age (see PRECAUTIONS: Pediatric Use and DOSAGE AND ADMINISTRATION ). uuid:54c9afb7-f3f1-4df3-8ce9-db4a469ddec6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9619 biolink:treats MONDO:0011429 PMID:41385096 "[{""id"":""uuid:53d1dee4-5ce3-4bb2-b805-461cf73a1c57"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a0157805-3324-473b-968d-77e56fa8e2d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of tolmetin sodium tablets and other treatment options before deciding to use tolmetin sodium tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Tolmetin sodium tablets are indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. Tolmetin is indicated in the treatment of acute flares and the long-term management of the chronic disease. Tolmetin is also indicated for treatment of juvenile rheumatoid arthritis. The safety and effectiveness of tolmetin have not been established in pediatric patients under 2 years of age (see PRECAUTIONS: Pediatric Use and DOSAGE AND ADMINISTRATION ). uuid:804ad0a0-7e84-4258-a816-ddb9cd97c369 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75922 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:2d176429-5383-4139-979b-e0fd4d0f34ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4c842022-9938-411c-a81e-d8d7cf7e1b78"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NEVANAC ® ophthalmic suspension is indicated for the treatment of pain and inflammation associated with cataract surgery. uuid:99f31e46-dac4-4d88-9cb6-949bc7628d52 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75922 biolink:treats NCIT:C3137 PMID:41385096 "[{""id"":""uuid:18eb6b6f-c56a-4e97-be3d-8451ac45cb3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:980def2e-eb5e-4874-a6eb-50510cf3f575"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NEVANAC ® ophthalmic suspension is indicated for the treatment of pain and inflammation associated with cataract surgery. uuid:c68d7393-a6ab-46d1-b6a0-28a40f5bea37 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:577093 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:781b3243-de22-4755-bbea-fbbcf7ccd70f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:39379601-a9be-4eda-909a-b107293fc4da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:aa8e8228-9265-4cca-88d4-7ed1f806fcdb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/competact""]},{""id"":""uuid:9af9cdd7-c392-4424-96b6-1c361b614dbe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ACTOPLUS MET is a thiazolidinedione and biguanide combination product indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are already treated with a thiazolidinedione and metformin or who have inadequate glycemic control on a thiazolidinedione alone or metformin alone.|[EMA] Competact is indicated in the treatment of type 2 diabetes mellitus patients, particularly overweight patients, who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone.|[PMDA] New combination drugs indicated for the treatment of type 2 diabetes (only when a concomitant use of pioglitazone hydrochloride with metformin hydrochloride is deemed appropriate). uuid:2f922d3e-9971-423e-be05-c75810029dab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1163093 biolink:treats MONDO:0005041 PMID:41385096 "[{""id"":""uuid:a786af3a-a9e4-4391-a216-4eba53f0773b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:04490629-36ce-43e6-9b84-e29bcce90168"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] COMBIGAN ® (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5% is an alpha adrenergic receptor agonist with a beta adrenergic receptor inhibitor indicated for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled IOP; the IOP-lowering of COMBIGAN ® dosed twice a day was slightly less than that seen with the concomitant administration of 0.5% timolol maleate ophthalmic solution dosed twice a day and 0.2% brimonidine tartrate ophthalmic solution dosed three times per day. uuid:609cc3d3-80e2-4a6c-a6f1-7ff978d64369 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1163093 biolink:treats MONDO:0006875 PMID:41385096 "[{""id"":""uuid:71f703f9-31af-4ac5-8250-55ee436db5c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3282306c-2c6f-4b58-8b67-d5da1fd8478f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] COMBIGAN ® (brimonidine tartrate/timolol maleate ophthalmic solution) 0.2%/0.5% is an alpha adrenergic receptor agonist with a beta adrenergic receptor inhibitor indicated for the reduction of elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension who require adjunctive or replacement therapy due to inadequately controlled IOP; the IOP-lowering of COMBIGAN ® dosed twice a day was slightly less than that seen with the concomitant administration of 0.5% timolol maleate ophthalmic solution dosed twice a day and 0.2% brimonidine tartrate ophthalmic solution dosed three times per day. uuid:c757c05b-75ef-4c6a-b613-410ebe1db6b9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18420 biolink:treats MONDO:0006844 PMID:41385096 "[{""id"":""uuid:e9e57883-4def-46db-923c-4f0f22b62000"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ada93321-3e1e-4d6f-a4dd-fd57e8e1afba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Magnesium Sulfate Injection, USP is suitable for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those observed in hypocalcemia. In such cases, the serum magnesium (Mg ++ ) level is usually below the lower limit of normal (1.5 to 2.5 mEq/liter) and the serum calcium (Ca ++ ) level is normal (4.3 to 5.3 mEq/liter) or elevated. In total parenteral nutrition (TPN), magnesium sulfate may be added to the nutrient admixture to correct or prevent hypomagnesemia which can arise during the course of therapy. Magnesium Sulfate Injection, USP is also indicated as a parenteral anticonvulsant for the prevention and control of seizures (convulsions) in severe toxemia of pregnancy. It effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. However, other effective drugs are available for this purpose. uuid:dec45706-987f-4c40-a06a-7f472dd8318d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18420 biolink:treats MONDO:0018100 PMID:41385096 "[{""id"":""uuid:506390e6-573a-4f99-ab32-ffa4f03cc089"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6b336e72-2ea6-4b6b-955b-b2d861f83c8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Magnesium Sulfate Injection, USP is suitable for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those observed in hypocalcemia. In such cases, the serum magnesium (Mg ++ ) level is usually below the lower limit of normal (1.5 to 2.5 mEq/liter) and the serum calcium (Ca ++ ) level is normal (4.3 to 5.3 mEq/liter) or elevated. In total parenteral nutrition (TPN), magnesium sulfate may be added to the nutrient admixture to correct or prevent hypomagnesemia which can arise during the course of therapy. Magnesium Sulfate Injection, USP is also indicated as a parenteral anticonvulsant for the prevention and control of seizures (convulsions) in severe toxemia of pregnancy. It effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. However, other effective drugs are available for this purpose. uuid:86b931f4-c9fc-43ac-90a1-b5647918278d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18420 biolink:treats HP:0001281 PMID:41385096 "[{""id"":""uuid:0215e513-fba2-478f-977d-2a71b5380058"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9b138f4e-dc36-4fdb-83d7-6beabbcbd581"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Magnesium Sulfate Injection, USP is suitable for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those observed in hypocalcemia. In such cases, the serum magnesium (Mg ++ ) level is usually below the lower limit of normal (1.5 to 2.5 mEq/liter) and the serum calcium (Ca ++ ) level is normal (4.3 to 5.3 mEq/liter) or elevated. In total parenteral nutrition (TPN), magnesium sulfate may be added to the nutrient admixture to correct or prevent hypomagnesemia which can arise during the course of therapy. Magnesium Sulfate Injection, USP is also indicated as a parenteral anticonvulsant for the prevention and control of seizures (convulsions) in severe toxemia of pregnancy. It effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. However, other effective drugs are available for this purpose. uuid:5291a6d0-06b5-4894-babc-02641431c415 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18420 biolink:treats HP:0002901 PMID:41385096 "[{""id"":""uuid:b3e41769-ffc5-416c-91a4-d4892e58082a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aa50fbba-3c45-4aeb-bdbb-0042d90aff64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Magnesium Sulfate Injection, USP is suitable for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those observed in hypocalcemia. In such cases, the serum magnesium (Mg ++ ) level is usually below the lower limit of normal (1.5 to 2.5 mEq/liter) and the serum calcium (Ca ++ ) level is normal (4.3 to 5.3 mEq/liter) or elevated. In total parenteral nutrition (TPN), magnesium sulfate may be added to the nutrient admixture to correct or prevent hypomagnesemia which can arise during the course of therapy. Magnesium Sulfate Injection, USP is also indicated as a parenteral anticonvulsant for the prevention and control of seizures (convulsions) in severe toxemia of pregnancy. It effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. However, other effective drugs are available for this purpose. uuid:45e03f0f-a7ed-4a6f-8fd7-71f52f8e24be biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18420 biolink:treats MONDO:0045048 PMID:41385096 "[{""id"":""uuid:1d5a5e00-a915-4596-bc76-1bb6c0f7858d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:685130a4-f5a8-4b83-ae44-3205e140ece0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Magnesium Sulfate Injection, USP is suitable for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those observed in hypocalcemia. In such cases, the serum magnesium (Mg ++ ) level is usually below the lower limit of normal (1.5 to 2.5 mEq/liter) and the serum calcium (Ca ++ ) level is normal (4.3 to 5.3 mEq/liter) or elevated. In total parenteral nutrition (TPN), magnesium sulfate may be added to the nutrient admixture to correct or prevent hypomagnesemia which can arise during the course of therapy. Magnesium Sulfate Injection, USP is also indicated as a parenteral anticonvulsant for the prevention and control of seizures (convulsions) in severe toxemia of pregnancy. It effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. However, other effective drugs are available for this purpose. uuid:e5b1944a-5ad4-44a9-8666-82c42ea49f4b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18420 biolink:treats MONDO:0001754 PMID:41385096 "[{""id"":""uuid:fae0c6c9-3d2e-4432-8158-7d1f6cf043ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2c781faa-57f7-491e-96fb-4bf4d0a62307"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Magnesium Sulfate Injection, USP is suitable for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those observed in hypocalcemia. In such cases, the serum magnesium (Mg ++ ) level is usually below the lower limit of normal (1.5 to 2.5 mEq/liter) and the serum calcium (Ca ++ ) level is normal (4.3 to 5.3 mEq/liter) or elevated. In total parenteral nutrition (TPN), magnesium sulfate may be added to the nutrient admixture to correct or prevent hypomagnesemia which can arise during the course of therapy. Magnesium Sulfate Injection, USP is also indicated as a parenteral anticonvulsant for the prevention and control of seizures (convulsions) in severe toxemia of pregnancy. It effectively prevents and controls the convulsions of eclampsia without producing deleterious depression of the central nervous system of the mother or infant. However, other effective drugs are available for this purpose. uuid:592f3c69-8f97-4064-84ff-c78abe45ef69 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63611 biolink:treats MONDO:0006668 PMID:41385096 "[{""id"":""uuid:cef61d5a-d433-40b7-9863-702712c3b602"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:41198a55-66c1-43db-a87c-3222e6b9ebeb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VIGAMOX® solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Aerobic Gram-positive microorganisms : Corynebacterium species* Micrococcus luteus* Staphylococcus aureus Staphylococcus epidermidis Staphylococcus haemolyticus Staphylococcus hominis Staphylococcus warneri* Streptococcus pneumoniae Streptococcus viridans group Aerobic Gram-negative microorganisms : Acinetobacter lwoffii* Haemophilus influenzae Haemophilus parainfluenzae * Other microorganisms : Chlamydia trachomatis *Efficacy for this organism was studied in fewer than 10 infections. uuid:48c85dd3-cdc8-4f48-8b95-67b66f725280 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9571023 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:19b41d54-ceae-450b-a320-7e8f62a3d276"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4fd42758-78dd-4eb9-9b45-2d06089f6bc8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Tri-Sprintec Tablets are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Tri-Sprintec Tablets are indicated for the treatment of moderate acne vulgaris in females, ≥15 years of age, who have no known contraindications to oral contraceptive therapy, desire contraception, have achieved menarche and are unresponsive to topical anti-acne medications. Oral contraceptives are highly effective. Table I lists the typical accidental pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization, depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates. TABLE I: PERCENTAGE OF WOMEN EXPERIENCING AN UNINTENDED PREGNANCY DURING THE FIRST YEAR OF TYPICAL USE AND THE FIRST YEAR OF PERFECT USE OF CONTRACEPTION AND THE PERCENTAGE CONTINUING USE AT THE END OF THE FIRST YEAR. UNITED STATES. % of Women Experiencing an Unintended Pregnancy within the First Year of Use % of Women Continuing Use at One Year Among couples attempting to avoid pregnancy, the percentage who continue to use a method for one year. Method Typical Use Among typical couples who initiate use of a method (not necessarily for the first time), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason. Perfect Use Among couples who initiate use of a method (not necessarily for the first time) and who use it perfectly (both consistently and correctly), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason. (1) (2) (3) (4) Chance The percents becoming pregnant in columns (2) and (3) are based on data from populations where contraception is not used and from women who cease using contraception in order to become pregnant. Among such populations, about 89% become pregnant within one year. This estimate was lowered slightly (to 85%) to represent the percent who would become pregnant within one year among women now relying on reversible methods of contraception if they abandoned contraception altogether. 85 85 Spermicides Foams, creams, gels, vaginal suppositories, and vaginal film. 26 6 40 Periodic abstinence 25 63 Calendar 9 Ovulation Method 3 Sympto-Thermal Cervical mucus (ovulation) method supplemented by calendar in the pre-ovulatory and basal body temperature in the post-ovulatory phases. 2 Post-Ovulation 1 Withdrawal 19 4 Cap With spermicidal cream or jelly. Parous Women 40 26 42 Nulliparous Women 20 9 56 Sponge Parous Women 40 20 42 Nulliparous Women 20 9 56 Diaphragm 20 6 56 Condom Without spermicides. Female (Reality) 21 5 56 Male 14 3 61 Pill 5 71 Progestin Only 0.5 Combined 0.1 IUD Progesterone T 2 1.5 81 Copper T380A 0.8 0.6 78 LNg 20 0.1 0.1 81 Depo-Provera 0.3 0.3 70 Norplant and Norplant-2 0.05 0.05 88 Female Sterilization 0.5 0.5 100 Male Sterilization 0.15 0.10 100 Adapted from Hatcher et al., 1998 Ref. #1. In four clinical trials with norgestimate and ethinyl estradiol, the use-efficacy pregnancy rate ranged from 0.68 to 1.47 per 100 women-years. In total, 4,756 subjects completed 45,244 cycles and a total of 42 pregnancies were reported. This represents an overall use-efficacy rate of 1.21 per 100 women-years. One of these 4 studies was a randomized comparative clinical trial in which 4,633 subjects completed 22,312 cycles. Of the 2,312 patients on norgestimate and ethinyl estradiol, 8 pregnancies were reported. This represents an overall use-efficacy pregnancy rate of 0.94 per 100 women-years. In two double-blind, placebo-controlled, six month, multicenter clinical trials, norgestimate and ethinyl estradiol showed a statistically significant decrease in inflammatory lesion count and total lesion count (TABLE II). The adverse reaction profile of norgestimate and ethinyl estradiol from these two controlled clinical trials is consistent with what has been noted from previous studies involving norgestimate and ethinyl estradiol and are the known risks associated with oral contraceptives. TABLE II: Acne Vulgaris Indication Combined Results: Two Multicenter, Placebo-Controlled Trials Primary Efficacy Variables: Evaluable-for-Efficacy Population Norgestimate and Ethinyl Estradiol Placebo N=163 N=161 Mean Age at Enrollment 27.3 years 28 Inflammatory Lesions - 56.6 36.6 Mean Percent Reduction Total Lesions - 49.6 30.3 Mean Percent Reduction" uuid:317ba9da-c2e8-40d2-97ef-8519b00a8db4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1157512 biolink:treats MONDO:0005475 PMID:41385096 "[{""id"":""uuid:ccd10963-8888-43e5-9c73-c1d27f6fa7cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d21645db-5254-4ae4-923b-e534d4b34973"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TREXIMET is indicated for the acute treatment of migraine attacks with or without aura in adults. Carefully consider the potential benefits and risks of TREXIMET and other treatment options when deciding to use TREXIMET. TREXIMET is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS). Safety and effectiveness of TREXIMET have not been established for cluster headache. uuid:9d5550ac-74ef-425a-9609-931fe9f91259 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1157512 biolink:treats MONDO:0100431 PMID:41385096 "[{""id"":""uuid:a438ce08-e195-4835-bfaa-1ab113590cba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8bb0c2d9-36d6-4c62-a611-01c9b6dcd810"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TREXIMET is indicated for the acute treatment of migraine attacks with or without aura in adults. Carefully consider the potential benefits and risks of TREXIMET and other treatment options when deciding to use TREXIMET. TREXIMET is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS). Safety and effectiveness of TREXIMET have not been established for cluster headache. uuid:c35e632e-2cfd-40dc-8654-0463b47f8af8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1157512 biolink:treats MONDO:0018925 PMID:41385096 "[{""id"":""uuid:e9476715-6b8e-4af6-b999-eee6ade75f98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1016cd58-c516-4d5f-b137-754c0afb4622"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TREXIMET is indicated for the acute treatment of migraine attacks with or without aura in adults. Carefully consider the potential benefits and risks of TREXIMET and other treatment options when deciding to use TREXIMET. TREXIMET is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS). Safety and effectiveness of TREXIMET have not been established for cluster headache. uuid:5c324739-bd54-4ec5-8d73-3870307aa12b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1157512 biolink:treats MONDO:0043219 PMID:41385096 "[{""id"":""uuid:29fa2c35-1e8b-4342-b099-e3cebdd066cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6b1eafdb-7339-46c8-ac84-1854b21aead0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TREXIMET is indicated for the acute treatment of migraine attacks with or without aura in adults. Carefully consider the potential benefits and risks of TREXIMET and other treatment options when deciding to use TREXIMET. TREXIMET is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS). Safety and effectiveness of TREXIMET have not been established for cluster headache. uuid:4dda5b09-f0b8-4ef3-a795-19528bc33461 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1157512 biolink:treats MONDO:0043537 PMID:41385096 "[{""id"":""uuid:1e0e83eb-cd9e-4462-ad04-e33d0dc30c90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2fcacadc-6f9b-4389-be5b-eed301df1f21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TREXIMET is indicated for the acute treatment of migraine attacks with or without aura in adults. Carefully consider the potential benefits and risks of TREXIMET and other treatment options when deciding to use TREXIMET. TREXIMET is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS). Safety and effectiveness of TREXIMET have not been established for cluster headache. uuid:4df35052-5667-4fb7-b752-28a18b559e96 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8228 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:68b72174-ae84-4574-8d31-629a0f8b8fca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b2571328-420b-4c41-8190-469036de63b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ACTOS is a thiazolidinedione and an agonist for peroxisome proliferator-activated receptor (PPAR) gamma indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings. ( 1.1 , 14 ) Important Limitation of Use: Not for treatment of type 1 diabetes or diabetic ketoacidosis. ( 1.2 ) uuid:35065561-d241-481f-a347-ce75a50d116c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8228 biolink:treats MONDO:0012819 PMID:41385096 "[{""id"":""uuid:c9015ff7-e187-4548-9748-c7a1e6f5f910"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:24c55fa3-8b56-4d2c-b13d-653f5034e228"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ACTOS is a thiazolidinedione and an agonist for peroxisome proliferator-activated receptor (PPAR) gamma indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings. ( 1.1 , 14 ) Important Limitation of Use: Not for treatment of type 1 diabetes or diabetic ketoacidosis. ( 1.2 ) uuid:5c765b2e-5dde-492d-984d-523cc8b94d42 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0008558 PMID:41385096 "[{""id"":""uuid:273508e0-7d73-45b4-8aa6-2bcd9d85b241"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:164ae383-d1ea-4e8f-bb2a-9c713bc4b992"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MethylPREDNISolone Tablets are indicated in the following conditions: Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Psoriatic arthritis Epicondylitis Acute gouty arthritis Post-traumatic osteoarthritis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Contact dermatitis Drug hypersensitivity reactions Bronchial asthma Atopic dermatitis Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Anterior segment inflammation Sympathetic ophthalmia Keratitis Optic neuritis Iritis and iridocyclitis Herpes zoster ophthalmicus Diffuse posterior uveitis and choroiditis Allergic conjunctivitis Chorioretinitis Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis Berylliosis Hematologic Disorders Idiopathic thrombocytopenia purpura in adults Acquired (autoimmune) hemolytic anemia Congenital (erythroid) hypoplastic anemia Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Nervous System Acute exacerbations of multiple sclerosis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:685a16d0-52fb-48a4-8354-ced6eb5e0704 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49662 biolink:treats UMLS:C0149896 PMID:41385096 "[{""id"":""uuid:d5526a26-7a6a-4c2e-b529-ed90b2f04cd6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bf7c89ae-b508-4353-a39a-b060d5051fb8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of Indomethacin Extended-Release Capsules, USP and other treatment options before deciding to use Indomethacin Extended-Release Capsules, USP. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Indomethacin Extended-Release Capsules, USP have been found effective in active stages of the following: 1. Moderate to severe rheumatoid arthritis including acute flares of chronic disease. 2. Moderate to severe ankylosing spondylitis. 3. Moderate to sever osteoarthritis. 4. Acute painful shoulder (bursitis and/or tendonitis). Indomethacin Extended-Release Capsules, USP are not recommended for the treatment of acute gouty arthritis. Indomethacin may enable the reduction of steroid dosage in patients receiving steroids for the more sever forms of rheumatoid arthritis. In such instances the steroid dosage should be reduced slowly and the patients followed very closely for any possible adverse effects. The use of indomethacin in conjunction with aspirin or other salicylates is not recommended. Controlled clinical studies have shown that the combined use of indomethacin and aspirin does not product any greater therapeutic effect than the use of indomethacin alone. Furthermore, in one of these clinical studies, the incidence of gastrointestinal side effects was significantly increased with combined therapy. (see PRECAUTIONS, Drug Interactions ). uuid:e49454db-2da6-40bf-868c-ff1e3d2f1db5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:240107 biolink:treats HP:0200026 PMID:41385096 "[{""id"":""uuid:dde212a4-fbd5-40b3-9cd6-b7785fc7458b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:47ec66bf-c62d-4df1-beca-27a0050aad5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bromday™ (bromfenac ophthalmic solution) 0.09% is indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery. uuid:c2f28914-24d4-499d-bc84-1070fb875834 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:3081207 biolink:treats UMLS:C0393736 PMID:41385096 "[{""id"":""uuid:e142ca1e-a00a-44b8-a485-67c5c9f0f7ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dad55c2f-cd7a-4fcc-aca2-816902e073e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules are indicated for the relief of the symptom complex of tension (or muscle contraction) headache. Evidence supporting the efficacy and safety of Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules in the treatment of multiple recurrent headaches is unavailable. Caution in this regard is required because codeine and butalbital are habit-forming and potentially abusable. uuid:05fa5dc5-175e-49c8-b13a-2c7a2ea5a20f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10124 biolink:treats MONDO:0005277 PMID:41385096 "[{""id"":""uuid:b23d3790-8f3c-4b4f-b2db-27d7db1643f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ad6969b4-4928-4089-819e-c754097fdea7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZOMIG is indicated for the acute treatment of migraine with or without aura in adults. ZOMIG should only be used where a clear diagnosis of migraine has been established. ZOMIG is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS ). Safety and effectiveness of ZOMIG have not been established for cluster headache, which is present in an older, predominantly male population. uuid:4f38fbd1-1036-4f01-b77b-6db4619c39cf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10124 biolink:treats MONDO:0005475 PMID:41385096 "[{""id"":""uuid:0886ca39-3092-4eae-8b76-4e5fe9bf7222"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6be355be-93cb-4b9a-b2fb-7b5e37d392ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZOMIG is indicated for the acute treatment of migraine with or without aura in adults. ZOMIG should only be used where a clear diagnosis of migraine has been established. ZOMIG is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS ). Safety and effectiveness of ZOMIG have not been established for cluster headache, which is present in an older, predominantly male population. uuid:fbf17790-dc41-4171-baa6-d332669be5f1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10124 biolink:treats MONDO:0018925 PMID:41385096 "[{""id"":""uuid:ebb69c82-8c6d-4adc-991b-219de1552f62"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:de2325da-2c16-4955-9d49-810f1a3a8075"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZOMIG is indicated for the acute treatment of migraine with or without aura in adults. ZOMIG should only be used where a clear diagnosis of migraine has been established. ZOMIG is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS ). Safety and effectiveness of ZOMIG have not been established for cluster headache, which is present in an older, predominantly male population. uuid:7f3ab274-f2b9-4621-8cea-a2ab67a62ae3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10124 biolink:treats MONDO:0043219 PMID:41385096 "[{""id"":""uuid:c5ad6e38-2513-4195-bc8f-53693aa1098a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3b9ae921-50b0-4af8-9b38-aae29fdcd0b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZOMIG is indicated for the acute treatment of migraine with or without aura in adults. ZOMIG should only be used where a clear diagnosis of migraine has been established. ZOMIG is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS ). Safety and effectiveness of ZOMIG have not been established for cluster headache, which is present in an older, predominantly male population. uuid:902938a4-8932-49a3-9d19-ecab264dcab5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10124 biolink:treats MONDO:0043537 PMID:41385096 "[{""id"":""uuid:330a5386-031f-4f72-8a88-c394cc40f51e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:091148f5-73d8-4bca-b3b6-7619722eb773"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZOMIG is indicated for the acute treatment of migraine with or without aura in adults. ZOMIG should only be used where a clear diagnosis of migraine has been established. ZOMIG is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS ). Safety and effectiveness of ZOMIG have not been established for cluster headache, which is present in an older, predominantly male population. uuid:05f38e8b-4d63-422b-a083-faf27a4c5d1b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:376076 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:506067bc-2c7e-4c5c-8d4f-04d7193fcf4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:27c1341f-3e97-48a9-9fca-dd64d9846fa2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Promethazine HCl, phenylephrine HCl and codeine phosphate syrup is indicated for the temporary relief of coughs and upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold. uuid:41897944-1ea7-4982-9560-9eaea395f589 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:376076 biolink:treats MONDO:0005709 PMID:41385096 "[{""id"":""uuid:cf69ceb2-8499-49d0-a274-397b1ef9d467"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:da1821cd-4f5a-4145-8989-62338f4b2d99"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Promethazine HCl, phenylephrine HCl and codeine phosphate syrup is indicated for the temporary relief of coughs and upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold. uuid:aae9e987-8069-4ec1-94aa-2ae0d16edd5f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16199 biolink:treats MONDO:0002406 PMID:41385096 "[{""id"":""uuid:840175fb-cc63-4b0b-8dc9-dd5933c2f778"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:08ade330-33f0-4886-a9c2-3057da8136e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For debridement and promotion of normal healing of hyperkeratotic surface lesions, particularly where healing is retarded by local infection, necrotic tissue, fibrinous or purulent debris or eschar. Urea is useful for the treatment of hyperkeratotic conditions such as dry, rough skin, dermatitis, psoriasis, xerosis, ichthyosis, eczema, keratosis, keratoderma, corns and calluses, as well as damaged, devitalized and ingrown nails. uuid:389bb6b1-b669-4826-a887-a7d6979ca9a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16199 biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:30ec0126-ff93-4dc2-ba1b-73a60bc20b23"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f25cb35d-40e0-4a48-8222-ed9650f84192"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For debridement and promotion of normal healing of hyperkeratotic surface lesions, particularly where healing is retarded by local infection, necrotic tissue, fibrinous or purulent debris or eschar. Urea is useful for the treatment of hyperkeratotic conditions such as dry, rough skin, dermatitis, psoriasis, xerosis, ichthyosis, eczema, keratosis, keratoderma, corns and calluses, as well as damaged, devitalized and ingrown nails. uuid:5c50c787-9987-4aae-bc31-aa80a3c6c18c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16199 biolink:treats HP:0000958 PMID:41385096 "[{""id"":""uuid:0c96856d-dcf4-4048-8d06-aafff5f23a09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a8477d6c-e8f6-4669-9c28-c6daac0edf77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For debridement and promotion of normal healing of hyperkeratotic surface lesions, particularly where healing is retarded by local infection, necrotic tissue, fibrinous or purulent debris or eschar. Urea is useful for the treatment of hyperkeratotic conditions such as dry, rough skin, dermatitis, psoriasis, xerosis, ichthyosis, eczema, keratosis, keratoderma, corns and calluses, as well as damaged, devitalized and ingrown nails. uuid:65f11804-5163-491a-8c15-f427230466c7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16199 biolink:treats MONDO:0019269 PMID:41385096 "[{""id"":""uuid:e7ddb6a0-361d-40b5-9d16-7910cc3787fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5fcb74ba-562c-4e58-8171-24c6dc6b2bed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For debridement and promotion of normal healing of hyperkeratotic surface lesions, particularly where healing is retarded by local infection, necrotic tissue, fibrinous or purulent debris or eschar. Urea is useful for the treatment of hyperkeratotic conditions such as dry, rough skin, dermatitis, psoriasis, xerosis, ichthyosis, eczema, keratosis, keratoderma, corns and calluses, as well as damaged, devitalized and ingrown nails. uuid:c2dbb4a8-c659-418f-9561-de7bb844bbf7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16199 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:349bc582-f292-4e46-a697-c9698623ce58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d7e39c42-f908-4bea-81f2-9093a6bbaf04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For debridement and promotion of normal healing of hyperkeratotic surface lesions, particularly where healing is retarded by local infection, necrotic tissue, fibrinous or purulent debris or eschar. Urea is useful for the treatment of hyperkeratotic conditions such as dry, rough skin, dermatitis, psoriasis, xerosis, ichthyosis, eczema, keratosis, keratoderma, corns and calluses, as well as damaged, devitalized and ingrown nails. uuid:70a648ee-1008-4b29-8da3-ce4df42d6168 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16199 biolink:treats MONDO:0006566 PMID:41385096 "[{""id"":""uuid:b25cb6d3-f98e-4f51-b37c-d0ea5270de4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:042f3c25-58f5-4076-96b3-163b3ce12197"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For debridement and promotion of normal healing of hyperkeratotic surface lesions, particularly where healing is retarded by local infection, necrotic tissue, fibrinous or purulent debris or eschar. Urea is useful for the treatment of hyperkeratotic conditions such as dry, rough skin, dermatitis, psoriasis, xerosis, ichthyosis, eczema, keratosis, keratoderma, corns and calluses, as well as damaged, devitalized and ingrown nails. uuid:7a876c7c-a098-499b-b9d2-1d994b165200 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16199 biolink:treats MONDO:0019272 PMID:41385096 "[{""id"":""uuid:67397b5d-a3ff-4cbe-b655-46575a3b323f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:95d358dc-143a-4626-a8e7-868539b4c794"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For debridement and promotion of normal healing of hyperkeratotic surface lesions, particularly where healing is retarded by local infection, necrotic tissue, fibrinous or purulent debris or eschar. Urea is useful for the treatment of hyperkeratotic conditions such as dry, rough skin, dermatitis, psoriasis, xerosis, ichthyosis, eczema, keratosis, keratoderma, corns and calluses, as well as damaged, devitalized and ingrown nails. uuid:53772745-c227-428b-bcfc-6fecd450804e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16199 biolink:treats HP:6000789 PMID:41385096 "[{""id"":""uuid:297c0db3-c3fb-4a30-ba9b-3021df3db68e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0acc4fbd-0280-49e9-84c6-25918e4c221b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For debridement and promotion of normal healing of hyperkeratotic surface lesions, particularly where healing is retarded by local infection, necrotic tissue, fibrinous or purulent debris or eschar. Urea is useful for the treatment of hyperkeratotic conditions such as dry, rough skin, dermatitis, psoriasis, xerosis, ichthyosis, eczema, keratosis, keratoderma, corns and calluses, as well as damaged, devitalized and ingrown nails. uuid:6006f13c-f89b-4493-9466-cc587f6b6abf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16199 biolink:treats MONDO:0007758 PMID:41385096 "[{""id"":""uuid:c761f6f8-63e8-4b11-8172-c2ddc147ebc9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:960d4c29-c910-44b0-bb97-68ecc84a10b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For debridement and promotion of normal healing of hyperkeratotic surface lesions, particularly where healing is retarded by local infection, necrotic tissue, fibrinous or purulent debris or eschar. Urea is useful for the treatment of hyperkeratotic conditions such as dry, rough skin, dermatitis, psoriasis, xerosis, ichthyosis, eczema, keratosis, keratoderma, corns and calluses, as well as damaged, devitalized and ingrown nails. uuid:de34c92c-87cf-46f5-b817-9eb22dd14ada biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16199 biolink:treats HP:0012710 PMID:41385096 "[{""id"":""uuid:dd049964-76ba-48b8-9bd7-c15c93f1aadb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dd5176d8-6270-4ba5-afcc-e1f273700c18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For debridement and promotion of normal healing of hyperkeratotic surface lesions, particularly where healing is retarded by local infection, necrotic tissue, fibrinous or purulent debris or eschar. Urea is useful for the treatment of hyperkeratotic conditions such as dry, rough skin, dermatitis, psoriasis, xerosis, ichthyosis, eczema, keratosis, keratoderma, corns and calluses, as well as damaged, devitalized and ingrown nails. uuid:a4acb881-c7b8-4ac3-82f5-17c699a9873d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9327 biolink:treats MONDO:0006609 PMID:41385096 "[{""id"":""uuid:c44e2d4d-b493-4dfb-9626-1fb77f6bac48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:320be723-8ab4-461f-9e3c-ad5902a0cb81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE: Sodium Sulfacetamide 10% Wash is intended for topical application in the following scaling dematoses: seborrheic dermatitis and sebonthea sicca (dandruff). It also is indicated for the treatment of secondary bacterial infections of the skin due to organisms susceptible to sulfonamides. uuid:0d647be7-57d9-4227-a1be-e14e8d6e5ca7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9327 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:7e8b2685-a516-4129-8699-482d0b3732e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:557e58b2-1319-4205-a6f4-79bfa40bd349"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE: Sodium Sulfacetamide 10% Wash is intended for topical application in the following scaling dematoses: seborrheic dermatitis and sebonthea sicca (dandruff). It also is indicated for the treatment of secondary bacterial infections of the skin due to organisms susceptible to sulfonamides. uuid:583f57ad-7395-49ba-989e-d6625640208e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:379230 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:bf5ed6f3-ba3a-452b-9943-5ecab1df53b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9a14d0c1-d785-495d-9a17-c3091d4fa3de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS: Sodium Sulfacetamide 10% & Sulfur 5% Cleanser is indicated in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis. uuid:b84ecc8e-080d-4c8a-bf3d-7d36c1f9076a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:379230 biolink:treats MONDO:0006604 PMID:41385096 "[{""id"":""uuid:8b744b85-f9b4-4e6f-a775-8f275eb6c74c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:74e8f208-6b92-4573-81aa-707d0596f520"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS: Sodium Sulfacetamide 10% & Sulfur 5% Cleanser is indicated in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis. uuid:83456d6c-93f3-4c90-97df-583adc30dac2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:379230 biolink:treats MONDO:0006608 PMID:41385096 "[{""id"":""uuid:f08ff7df-5c74-4912-9b80-87d8e823ea42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e350a3ef-f4ed-4c02-8987-76e3d0ce26f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS: Sodium Sulfacetamide 10% & Sulfur 5% Cleanser is indicated in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis. uuid:ae0f182e-dabd-4035-b2b6-e43c5750709d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7824 biolink:treats MONDO:0005027 PMID:41385096 "[{""id"":""uuid:60aeea05-3b39-4629-b820-bb8dfa1d0840"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d22b9bd3-4a5f-4080-9bed-618fe5bf373f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e070d63c-4cd7-4d7f-93b6-ec94d3e6cfd0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxcarbazepine is indicated for use as monotherapy or adjunctive therapy in the treatment of partial seizures in adults and as monotherapy in the treatment of partial seizures in children aged 4years and above with epilepsy, and as adjunctive therapy in children aged 2 years and above with epilepsy.|[PMDA] Drugs with a new active ingredient indicated for the use as an adjunctive therapy with other antiepileptic drugs to treat partial seizures (including secondary generalized seizures) in patients with epilepsy who have not responded sufficiently to other antiepileptic drugs. uuid:e2a5ceaf-7b1b-4f47-97b0-d057fb7da690 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7824 biolink:treats HP:0007359 PMID:41385096 "[{""id"":""uuid:32908437-c05e-464a-82c6-70ac3813b22d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:95dc1a3b-fd99-4b48-81a8-67abf0bb8262"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:103ccf9b-68a8-4ee9-9798-2510e86a31ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxcarbazepine is indicated for use as monotherapy or adjunctive therapy in the treatment of partial seizures in adults and as monotherapy in the treatment of partial seizures in children aged 4years and above with epilepsy, and as adjunctive therapy in children aged 2 years and above with epilepsy.|[PMDA] Drugs with a new active ingredient indicated for the use as an adjunctive therapy with other antiepileptic drugs to treat partial seizures (including secondary generalized seizures) in patients with epilepsy who have not responded sufficiently to other antiepileptic drugs. uuid:f32e5702-2aad-4f8b-aa72-b27d3b0528ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6541 biolink:treats HP:0001712 PMID:41385096 "[{""id"":""uuid:730f8974-2c1c-44a4-9bbd-e139835df777"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:47b4a949-b7e6-47b1-aaee-d1076b147f3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Losartan potassium tablets are indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents, including diuretics. Hypertensive Patients with Left Ventricular Hypertrophy Losartan potassium tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients. (See and , PRECAUTIONS Race , CLINICAL PHARMACOLOGY , , .) Pharmacodynamics and Clinical Effects Reduction in the Risk of Stroke Race in 2 Patients Nephropathy Type Diabetic Losartan potassium tablets are indicated for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria (urinary albumin to creatinine ratio ≥300 mg/g) in patients with type 2 diabetes and a history of hypertension. In this population, losartan potassium tablets reduce the rate of progression of nephropathy as measured by the occurrence of doubling of serum creatinine or end stage renal disease (need for dialysis or renal transplantation) (see , CLINICAL PHARMACOLOGY ). Pharmacodynamics and Clinical Effects uuid:d53babe7-c112-459f-995d-1ae2da798df0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6541 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:199b02c5-cba6-4499-9393-db6551ed908f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:256fa739-4aad-43fc-9ee4-c01cc5f0c324"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:6e82bf26-e965-4362-9d99-6a72af3d4809"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Losartan potassium tablets are indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents, including diuretics. Hypertensive Patients with Left Ventricular Hypertrophy Losartan potassium tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients. (See and , PRECAUTIONS Race , CLINICAL PHARMACOLOGY , , .) Pharmacodynamics and Clinical Effects Reduction in the Risk of Stroke Race in 2 Patients Nephropathy Type Diabetic Losartan potassium tablets are indicated for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria (urinary albumin to creatinine ratio ≥300 mg/g) in patients with type 2 diabetes and a history of hypertension. In this population, losartan potassium tablets reduce the rate of progression of nephropathy as measured by the occurrence of doubling of serum creatinine or end stage renal disease (need for dialysis or renal transplantation) (see , CLINICAL PHARMACOLOGY ). Pharmacodynamics and Clinical Effects|[PMDA] Addition of a new indication for diabetic nephropathy in patients with type2 diabetes, hypertension, and proteinuria. uuid:e3b449ea-98c5-4f86-ac61-1c448d8287b4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6541 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:1a23d8d9-612b-4c65-956f-ee5d5298d308"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:317f8743-c069-45ef-b9b5-6d22c8c44eba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Losartan potassium tablets are indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents, including diuretics. Hypertensive Patients with Left Ventricular Hypertrophy Losartan potassium tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients. (See and , PRECAUTIONS Race , CLINICAL PHARMACOLOGY , , .) Pharmacodynamics and Clinical Effects Reduction in the Risk of Stroke Race in 2 Patients Nephropathy Type Diabetic Losartan potassium tablets are indicated for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria (urinary albumin to creatinine ratio ≥300 mg/g) in patients with type 2 diabetes and a history of hypertension. In this population, losartan potassium tablets reduce the rate of progression of nephropathy as measured by the occurrence of doubling of serum creatinine or end stage renal disease (need for dialysis or renal transplantation) (see , CLINICAL PHARMACOLOGY ). Pharmacodynamics and Clinical Effects uuid:f435f24a-02e0-4f69-b30e-94b60eaeaf5a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6541 biolink:treats MONDO:0004375 PMID:41385096 "[{""id"":""uuid:304da23c-6fa3-4fc4-b564-2eace89fc12e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eae7bd39-13fe-4fa4-abb2-9600a9c69d9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Losartan potassium tablets are indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents, including diuretics. Hypertensive Patients with Left Ventricular Hypertrophy Losartan potassium tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients. (See and , PRECAUTIONS Race , CLINICAL PHARMACOLOGY , , .) Pharmacodynamics and Clinical Effects Reduction in the Risk of Stroke Race in 2 Patients Nephropathy Type Diabetic Losartan potassium tablets are indicated for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria (urinary albumin to creatinine ratio ≥300 mg/g) in patients with type 2 diabetes and a history of hypertension. In this population, losartan potassium tablets reduce the rate of progression of nephropathy as measured by the occurrence of doubling of serum creatinine or end stage renal disease (need for dialysis or renal transplantation) (see , CLINICAL PHARMACOLOGY ). Pharmacodynamics and Clinical Effects uuid:0e8d5186-1389-410e-bf94-768db8532183 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0018059 PMID:41385096 "[{""id"":""uuid:3557f394-1ee6-45c4-b21d-6a8bdfddad73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0da9349e-44d9-4ebe-902e-b9b0e1b89671"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline hydrochloride tablets, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydia psittaci. Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Calymmatobacterium granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes. Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species . Minocycline hydrochloride tablets, USP are indicated for the treatment of infections caused by the following gram-positive microorganism when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection). When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections. Infections in women caused by Neisseria gonorrhoeae. Syphilis caused by Treponema pallidum subspecies pallidum. Yaws caused by Treponema pallidum subspecies pertenue. Listeriosis due to Listeria monocytogenes. Anthrax due to Bacillus anthracis. Vincent’s infection caused by Fusobacterium fusiforme. Actinomycosis caused by Actinomyces israelii. Infections caused by Clostridium species . In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum . To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride tablets, USP and other antibacterial drugs, minocycline hydrochloride tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:13168497-7bb5-452c-bfbe-b41f9a01f4a7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0005373 PMID:41385096 "[{""id"":""uuid:dd005055-5923-48e3-b0d1-d65c3ccc8fb4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:49a907a2-556e-4129-82cf-2a3905af66df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline hydrochloride tablets, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydia psittaci. Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Calymmatobacterium granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes. Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species . Minocycline hydrochloride tablets, USP are indicated for the treatment of infections caused by the following gram-positive microorganism when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection). When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections. Infections in women caused by Neisseria gonorrhoeae. Syphilis caused by Treponema pallidum subspecies pallidum. Yaws caused by Treponema pallidum subspecies pertenue. Listeriosis due to Listeria monocytogenes. Anthrax due to Bacillus anthracis. Vincent’s infection caused by Fusobacterium fusiforme. Actinomycosis caused by Actinomyces israelii. Infections caused by Clostridium species . In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum . To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride tablets, USP and other antibacterial drugs, minocycline hydrochloride tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:f589c4a9-6d64-4aef-81d4-69150f5ccc5f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18332 biolink:treats MONDO:0005420 PMID:41385096 "[{""id"":""uuid:62c1b795-3ef8-4408-9891-b2ebd5302efd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:14497e2b-15dd-421f-bf1a-709f5294ace9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:5216d2cc-7d77-4efb-8c03-f0695cbf2c3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levothyroxine sodium is used for the following indications: Hypothyroidism As replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. Specific indications include: primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) hypothyroidism and subclinical hypothyroidism. Primary hypothyroidism may result from functional deficiency, primary atrophy, partial or total congenital absence of the thyroid gland, or from the effects of surgery, radiation, or drugs, with or without the presence of goiter. Pituitary TSH Suppression In the treatment or prevention of various types of euthyroid goiters (see WARNINGS and PRECAUTIONS ), including thyroid nodules (see WARNINGS and PRECAUTIONS ), subacute or chronic lymphocytic thyroiditis (Hashimoto’s thyroiditis), multinodular goiter (see WARNINGS and PRECAUTIONS ) and, as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well differentiated thyroid cancer.|[PMDA] A drug with a new route of administration indicated for the treatment of myxedema coma and hypothyroidism (for hypothyroidism, only in patients ineligible for oral levothyroxine sodium therapy). uuid:ee5e2a32-5797-48d7-a55b-27c1edaa5ee8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18332 biolink:treats MONDO:0018612 PMID:41385096 "[{""id"":""uuid:bff105be-8a3f-49a1-bc70-1d900872e679"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:db015632-4627-4714-8cfe-aa43f156a83c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levothyroxine sodium is used for the following indications: Hypothyroidism As replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. Specific indications include: primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) hypothyroidism and subclinical hypothyroidism. Primary hypothyroidism may result from functional deficiency, primary atrophy, partial or total congenital absence of the thyroid gland, or from the effects of surgery, radiation, or drugs, with or without the presence of goiter. Pituitary TSH Suppression In the treatment or prevention of various types of euthyroid goiters (see WARNINGS and PRECAUTIONS ), including thyroid nodules (see WARNINGS and PRECAUTIONS ), subacute or chronic lymphocytic thyroiditis (Hashimoto’s thyroiditis), multinodular goiter (see WARNINGS and PRECAUTIONS ) and, as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well differentiated thyroid cancer. uuid:6d00cb04-f348-4c43-a98e-9a17f3e44c22 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18332 biolink:treats HP:0000832 PMID:41385096 "[{""id"":""uuid:f96f9987-ac27-4c53-a6a7-a17028653bf5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ff24781c-3213-4824-8264-19117714d60c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levothyroxine sodium is used for the following indications: Hypothyroidism As replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. Specific indications include: primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) hypothyroidism and subclinical hypothyroidism. Primary hypothyroidism may result from functional deficiency, primary atrophy, partial or total congenital absence of the thyroid gland, or from the effects of surgery, radiation, or drugs, with or without the presence of goiter. Pituitary TSH Suppression In the treatment or prevention of various types of euthyroid goiters (see WARNINGS and PRECAUTIONS ), including thyroid nodules (see WARNINGS and PRECAUTIONS ), subacute or chronic lymphocytic thyroiditis (Hashimoto’s thyroiditis), multinodular goiter (see WARNINGS and PRECAUTIONS ) and, as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well differentiated thyroid cancer. uuid:8c721b19-c3e8-4cb0-9c16-c1216330b26d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18332 biolink:treats UMLS:C0854492 PMID:41385096 "[{""id"":""uuid:d63e71e7-b730-45ff-9d4e-57a3236f3907"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8803de06-e302-4b04-a85f-3af122bc294e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levothyroxine sodium is used for the following indications: Hypothyroidism As replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. Specific indications include: primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) hypothyroidism and subclinical hypothyroidism. Primary hypothyroidism may result from functional deficiency, primary atrophy, partial or total congenital absence of the thyroid gland, or from the effects of surgery, radiation, or drugs, with or without the presence of goiter. Pituitary TSH Suppression In the treatment or prevention of various types of euthyroid goiters (see WARNINGS and PRECAUTIONS ), including thyroid nodules (see WARNINGS and PRECAUTIONS ), subacute or chronic lymphocytic thyroiditis (Hashimoto’s thyroiditis), multinodular goiter (see WARNINGS and PRECAUTIONS ) and, as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well differentiated thyroid cancer. uuid:0a67fc31-c896-487c-8aac-d04c4e49794d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18332 biolink:treats HP:0008223 PMID:41385096 "[{""id"":""uuid:1681a23e-4eb7-4df2-ad2e-f18e5f1d7f47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b8afa51c-cbc2-4698-ba62-d7c1700bfee9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levothyroxine sodium is used for the following indications: Hypothyroidism As replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. Specific indications include: primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) hypothyroidism and subclinical hypothyroidism. Primary hypothyroidism may result from functional deficiency, primary atrophy, partial or total congenital absence of the thyroid gland, or from the effects of surgery, radiation, or drugs, with or without the presence of goiter. Pituitary TSH Suppression In the treatment or prevention of various types of euthyroid goiters (see WARNINGS and PRECAUTIONS ), including thyroid nodules (see WARNINGS and PRECAUTIONS ), subacute or chronic lymphocytic thyroiditis (Hashimoto’s thyroiditis), multinodular goiter (see WARNINGS and PRECAUTIONS ) and, as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well differentiated thyroid cancer. uuid:696d9335-de60-4dfe-ac73-6bdf0298ceb4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18332 biolink:treats MONDO:0001658 PMID:41385096 "[{""id"":""uuid:72d1047a-29cd-4c2f-b091-1a4089c6af2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d7d18fbd-4d99-481f-9cce-9220782daa74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levothyroxine sodium is used for the following indications: Hypothyroidism As replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. Specific indications include: primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) hypothyroidism and subclinical hypothyroidism. Primary hypothyroidism may result from functional deficiency, primary atrophy, partial or total congenital absence of the thyroid gland, or from the effects of surgery, radiation, or drugs, with or without the presence of goiter. Pituitary TSH Suppression In the treatment or prevention of various types of euthyroid goiters (see WARNINGS and PRECAUTIONS ), including thyroid nodules (see WARNINGS and PRECAUTIONS ), subacute or chronic lymphocytic thyroiditis (Hashimoto’s thyroiditis), multinodular goiter (see WARNINGS and PRECAUTIONS ) and, as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well differentiated thyroid cancer. uuid:9a2e2618-46f5-4ea8-b4da-427336123123 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18332 biolink:treats HP:0025388 PMID:41385096 "[{""id"":""uuid:db67d39c-e3a7-48ec-9e62-68432093c6b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:da8044c0-f8e6-49d8-8d14-5f6977eb1711"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levothyroxine sodium is used for the following indications: Hypothyroidism As replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. Specific indications include: primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) hypothyroidism and subclinical hypothyroidism. Primary hypothyroidism may result from functional deficiency, primary atrophy, partial or total congenital absence of the thyroid gland, or from the effects of surgery, radiation, or drugs, with or without the presence of goiter. Pituitary TSH Suppression In the treatment or prevention of various types of euthyroid goiters (see WARNINGS and PRECAUTIONS ), including thyroid nodules (see WARNINGS and PRECAUTIONS ), subacute or chronic lymphocytic thyroiditis (Hashimoto’s thyroiditis), multinodular goiter (see WARNINGS and PRECAUTIONS ) and, as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well differentiated thyroid cancer. uuid:091a62c6-90dc-4f87-a441-e265c9c60f3e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18332 biolink:treats MONDO:0007699 PMID:41385096 "[{""id"":""uuid:0100b383-a526-48e1-ba2b-0229c1d6fbb4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2a4b15ba-eec8-4d8e-91da-5673d4505ef2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levothyroxine sodium is used for the following indications: Hypothyroidism As replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. Specific indications include: primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) hypothyroidism and subclinical hypothyroidism. Primary hypothyroidism may result from functional deficiency, primary atrophy, partial or total congenital absence of the thyroid gland, or from the effects of surgery, radiation, or drugs, with or without the presence of goiter. Pituitary TSH Suppression In the treatment or prevention of various types of euthyroid goiters (see WARNINGS and PRECAUTIONS ), including thyroid nodules (see WARNINGS and PRECAUTIONS ), subacute or chronic lymphocytic thyroiditis (Hashimoto’s thyroiditis), multinodular goiter (see WARNINGS and PRECAUTIONS ) and, as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well differentiated thyroid cancer. uuid:1daa44a4-abef-4d84-b1a0-8dcac0c11805 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18332 biolink:treats MONDO:0000334 PMID:41385096 "[{""id"":""uuid:d038d3de-19d5-414d-a788-8cd0d4602951"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e7c9cb38-80a4-4660-9929-8d7594d29d00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levothyroxine sodium is used for the following indications: Hypothyroidism As replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. Specific indications include: primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) hypothyroidism and subclinical hypothyroidism. Primary hypothyroidism may result from functional deficiency, primary atrophy, partial or total congenital absence of the thyroid gland, or from the effects of surgery, radiation, or drugs, with or without the presence of goiter. Pituitary TSH Suppression In the treatment or prevention of various types of euthyroid goiters (see WARNINGS and PRECAUTIONS ), including thyroid nodules (see WARNINGS and PRECAUTIONS ), subacute or chronic lymphocytic thyroiditis (Hashimoto’s thyroiditis), multinodular goiter (see WARNINGS and PRECAUTIONS ) and, as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well differentiated thyroid cancer. uuid:0fdb2fa3-260e-4750-894d-0103b8ba73b2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18332 biolink:treats MONDO:0015447 PMID:41385096 "[{""id"":""uuid:8de16dfb-f43d-413a-8276-14a7f6898d5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b60205c3-6f0c-4b4a-bfce-eb94a4342486"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levothyroxine sodium is used for the following indications: Hypothyroidism As replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. Specific indications include: primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) hypothyroidism and subclinical hypothyroidism. Primary hypothyroidism may result from functional deficiency, primary atrophy, partial or total congenital absence of the thyroid gland, or from the effects of surgery, radiation, or drugs, with or without the presence of goiter. Pituitary TSH Suppression In the treatment or prevention of various types of euthyroid goiters (see WARNINGS and PRECAUTIONS ), including thyroid nodules (see WARNINGS and PRECAUTIONS ), subacute or chronic lymphocytic thyroiditis (Hashimoto’s thyroiditis), multinodular goiter (see WARNINGS and PRECAUTIONS ) and, as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well differentiated thyroid cancer. uuid:11c7a2b2-fff6-4955-b8de-97e9b999a6bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5537 biolink:treats HP:0002018 PMID:41385096 "[{""id"":""uuid:5aea2996-dbc5-4db5-8038-9b7537f3992b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6aca1ccc-453f-4c8c-94ab-c58fe5c33375"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:426e3757-73eb-4ca4-8b44-3c8de309fcdb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/sancuso""]},{""id"":""uuid:5f6c2fea-ad4a-42ed-a654-d9695463bc52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sancuso ® (Granisetron Transdermal System) is indicated for the prevention of nausea and vomiting in patients receiving moderately and/or highly emetogenic chemotherapy regimens of up to 5 consecutive days duration.|[EMA] Prevention of nausea and vomiting in patients receiving moderately or highly emetogenic chemotherapy, with or without cisplatin, for up to five consecutive days.Sancuso may be used in patients receiving their first chemotherapy regimen or in patients who have previously received chemotherapy.|[PMDA] Drugs with a new indication and a new dosage for the treatment of digestive symptoms (nausea and vomiting) after surgery. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:cf12a75c-4d47-4091-b861-48a469975aaa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5537 biolink:treats HP:0002013 PMID:41385096 "[{""id"":""uuid:7dcdc16a-f94a-46fe-a076-e15d7fd03281"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9c6dcd0c-8f8a-4977-8fac-93c79f6b8fc8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:dcc60651-3c62-475a-8158-1b2db13bdccd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/sancuso""]},{""id"":""uuid:37b4c38f-5814-46f2-a251-9406b9ca59f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sancuso ® (Granisetron Transdermal System) is indicated for the prevention of nausea and vomiting in patients receiving moderately and/or highly emetogenic chemotherapy regimens of up to 5 consecutive days duration.|[EMA] Prevention of nausea and vomiting in patients receiving moderately or highly emetogenic chemotherapy, with or without cisplatin, for up to five consecutive days.Sancuso may be used in patients receiving their first chemotherapy regimen or in patients who have previously received chemotherapy.|[PMDA] Drugs with a new indication and a new dosage for the treatment of digestive symptoms (nausea and vomiting) after surgery. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:a7165fa8-8746-4979-96ad-2dbf90022e67 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31159 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:4e780a0d-0501-4c52-b509-7913199cbc87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5da44f17-832f-4ef1-95de-15e7ff593362"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS CLANZA CR is indicated for Rheumatoid arthritis, ankylosing spondylitis, osteoarthritis and periarthritis of scapulohumerous, lumbago, ischiadynia, pain caused by nonaticular rheutism. uuid:90a7fb19-559d-400d-918a-83dcd75a6425 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31159 biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:69c0b36d-53d5-4cd0-be70-e5a36deffc71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7bfba489-9ec4-4a11-a724-1fd1f4017071"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS CLANZA CR is indicated for Rheumatoid arthritis, ankylosing spondylitis, osteoarthritis and periarthritis of scapulohumerous, lumbago, ischiadynia, pain caused by nonaticular rheutism. uuid:7e967e4a-5191-48ad-b1cb-c5f123c026ff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31159 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:bb85de84-042f-4beb-85a1-9e54decbc864"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9878df25-d07f-49cd-97bb-301d92d7da48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS CLANZA CR is indicated for Rheumatoid arthritis, ankylosing spondylitis, osteoarthritis and periarthritis of scapulohumerous, lumbago, ischiadynia, pain caused by nonaticular rheutism. uuid:f60e1ffb-e767-48b0-9f9b-8b2cc6c36de0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31159 biolink:treats MONDO:0006898 PMID:41385096 "[{""id"":""uuid:7d5b2471-2921-4445-b612-c5378e742ee9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9a5e61e7-0d22-4fe1-8bd8-67a3a0554c04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS CLANZA CR is indicated for Rheumatoid arthritis, ankylosing spondylitis, osteoarthritis and periarthritis of scapulohumerous, lumbago, ischiadynia, pain caused by nonaticular rheutism. uuid:daf196ac-96cd-439a-80ec-7367939092ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31159 biolink:treats HP:0003419 PMID:41385096 "[{""id"":""uuid:7e8d96a2-249a-4008-bfc0-11ea9fe10560"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3b933205-0893-4c8e-a2e1-a02f98eb4852"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS CLANZA CR is indicated for Rheumatoid arthritis, ankylosing spondylitis, osteoarthritis and periarthritis of scapulohumerous, lumbago, ischiadynia, pain caused by nonaticular rheutism. uuid:acde71b8-6d88-4732-9a99-a1e7d98fea73 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41774 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:98aa855f-f547-437e-837b-790a40fc48dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0eec1208-4a2b-43e9-9d17-3edb11818ecd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tamoxifen citrate tablets are effective in the treatment of metastatic breast cancer in women and men. In premenopausal women with metastatic breast cancer, tamoxifen is an alternative to oophorectomy or ovarian irradiation. Available evidence indicates that patients whose tumors are estrogen receptor positive are more likely to benefit from tamoxifen therapy. uuid:7fd630bf-d02a-4e89-ab30-097b9f6e1753 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8107 biolink:treats HP:0002069 PMID:41385096 "[{""id"":""uuid:e8ebe579-cf1e-4b8a-a5a0-00578417be3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:56817ae1-b5f1-40ac-a294-479ea054daa2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Phenytoin Oral Suspension is indicated for the control of tonic-clonic (grand mal) and psychomotor (temporal lobe) seizures. Phenytoin serum level determinations may be necessary for optimal dosage adjustments (see DOSAGE AND ADMINISTRATION and CLINICAL PHARMACOLOGY sections). uuid:39bc7e5e-70e4-4928-8c8d-0d00e15a9667 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8107 biolink:treats MONDO:0005115 PMID:41385096 "[{""id"":""uuid:a9ff14e7-3543-4a07-8b2c-a1a5a8e37d09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b07b6aa7-ff12-47b9-9a29-eae5b2abb59d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Phenytoin Oral Suspension is indicated for the control of tonic-clonic (grand mal) and psychomotor (temporal lobe) seizures. Phenytoin serum level determinations may be necessary for optimal dosage adjustments (see DOSAGE AND ADMINISTRATION and CLINICAL PHARMACOLOGY sections). uuid:acc995f6-ee63-41b3-8be2-ccae19399ebd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50693 biolink:treats UMLS:C1609524 PMID:41385096 "[{""id"":""uuid:c5ccc69b-ccce-45b0-8f20-7cf70a9a9dd1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:60def5f3-d084-4906-b51f-bdd88128c608"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Milrinone Lactate Injection is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure. Patients receiving milrinone should be observed closely with appropriate electrocardiographic equipment. The facility for immediate treatment of potential cardiac events, which may include life-threatening ventricular arrhythmias, must be available. The majority of experience with intravenous milrinone has been in patients receiving digoxin and diuretics. There is no experience in controlled trials with infusions of milrinone for periods exceeding 48 hours. uuid:b43ada17-3a7a-412d-b389-db82fe0f37df biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50693 biolink:treats HP:0004308 PMID:41385096 "[{""id"":""uuid:f357b3e1-43ee-4927-8cd2-a78d6bdd49be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:670646d8-bac3-42c4-a43c-7d20a0fa36ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Milrinone Lactate Injection is indicated for the short-term intravenous treatment of patients with acute decompensated heart failure. Patients receiving milrinone should be observed closely with appropriate electrocardiographic equipment. The facility for immediate treatment of potential cardiac events, which may include life-threatening ventricular arrhythmias, must be available. The majority of experience with intravenous milrinone has been in patients receiving digoxin and diuretics. There is no experience in controlled trials with infusions of milrinone for periods exceeding 48 hours. uuid:f5a212ee-f749-4f1f-8d4d-24f1aae0c668 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51230 biolink:treats MONDO:0005338 PMID:41385096 "[{""id"":""uuid:229fb05a-a73c-4406-9382-cfc12f067711"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:992593f9-146d-40e4-885d-fb244152a309"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b389e358-40ad-4dfd-beee-bde1ddd4be47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lumigan""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] LUMIGAN ® 0.01% and 0.03% (bimatoprost ophthalmic solution) is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.|[EMA] Reduction of elevated intraocular pressure in chronic open-angle glaucoma and ocular hypertension (as monotherapy or as adjunctive therapy to beta-blockers)., uuid:8546cf2b-90ad-441d-834c-03230e46e0b1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51230 biolink:treats MONDO:0006875 PMID:41385096 "[{""id"":""uuid:3aa5ecb2-4883-445b-880d-324c3424bdeb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:81f60d9a-2295-4c58-8d25-b11035fc2c46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b77d2898-57e1-4395-80c2-3d8b37043e60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lumigan""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] LUMIGAN ® 0.01% and 0.03% (bimatoprost ophthalmic solution) is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.|[EMA] Reduction of elevated intraocular pressure in chronic open-angle glaucoma and ocular hypertension (as monotherapy or as adjunctive therapy to beta-blockers)., uuid:3d5631bd-6719-41dc-ad59-edb0d70094a1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9919 biolink:treats MONDO:0043653 PMID:41385096 "[{""id"":""uuid:2a56425e-01e5-499a-8670-5a0ba1271d85"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:72ed2ee5-a570-4c55-a31c-f7a0483befb0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Valacyclovir hydrochloride tablets are a nucleoside analogue DNA polymerase inhibitor indicated for: Adult Patients ( 1.1 ) Cold Sores (Herpes Labialis) Genital Herpes Treatment in immunocompetent patients (initial or recurrent episode) Suppression in immunocompetent or HIV-infected patients Reduction of transmission Herpes Zoster Pediatric Patients ( 1.2 ) Cold Sores (Herpes Labialis) Limitations of Use ( 1.3 ) The efficacy and safety of valacyclovir hydrochloride tablets have not been established in immunocompromised patients other than for the suppression of genital herpes in HIV-infected patients. uuid:8d679ec8-1bf7-45bd-9b3e-379b8db668b7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9919 biolink:treats MONDO:0005770 PMID:41385096 "[{""id"":""uuid:0d092507-6b09-43e6-8495-7f0fdb691ab9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:62790d50-132d-4ab0-9371-1b9045b14b71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Valacyclovir hydrochloride tablets are a nucleoside analogue DNA polymerase inhibitor indicated for: Adult Patients ( 1.1 ) Cold Sores (Herpes Labialis) Genital Herpes Treatment in immunocompetent patients (initial or recurrent episode) Suppression in immunocompetent or HIV-infected patients Reduction of transmission Herpes Zoster Pediatric Patients ( 1.2 ) Cold Sores (Herpes Labialis) Limitations of Use ( 1.3 ) The efficacy and safety of valacyclovir hydrochloride tablets have not been established in immunocompromised patients other than for the suppression of genital herpes in HIV-infected patients. uuid:65ce800a-c5c3-4679-8dde-44cc9cb50633 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9919 biolink:treats MONDO:0005609 PMID:41385096 "[{""id"":""uuid:bbb27224-f24b-4c36-af80-42dfe345b246"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d244212b-de0b-4717-afda-18941c7adbd3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2dd7f332-e5ae-4e10-99bd-afabfb71927c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Valacyclovir hydrochloride tablets are a nucleoside analogue DNA polymerase inhibitor indicated for: Adult Patients ( 1.1 ) Cold Sores (Herpes Labialis) Genital Herpes Treatment in immunocompetent patients (initial or recurrent episode) Suppression in immunocompetent or HIV-infected patients Reduction of transmission Herpes Zoster Pediatric Patients ( 1.2 ) Cold Sores (Herpes Labialis) Limitations of Use ( 1.3 ) The efficacy and safety of valacyclovir hydrochloride tablets have not been established in immunocompromised patients other than for the suppression of genital herpes in HIV-infected patients.|[PMDA] Drugs with a new additional indication and revised indications with a new dosage for prevention of herpes simplex virus infection in adult or pediatric haematopoietic stem cell transplant patients, for treatment of herpes simplex /herpes zoster, and for prevention of recurrent genital herpes in pediatric patients. uuid:31e77b6a-ba6e-4ed3-b04c-98bb0e350955 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31547 biolink:treats MONDO:0004781 PMID:41385096 "[{""id"":""uuid:1dfbb675-8ac1-4108-9460-33a8db866957"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:20ede616-2b1c-442a-9759-bcb9657ff9a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Eplerenone is an aldosterone antagonist indicated for: Improving survival of stable patients with LV systolic dysfunction (LVEF ≤40%) and CHF after an acute myocardial infarction. (1.2) Hypertension, alone or combined with other agents. (1.3) uuid:788dd576-309c-4676-b0db-63fdc56dceab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6904 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:1896eb9e-cc3e-40a6-9680-a90cfaac9f31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:64d53ab0-c972-43e8-bfc1-5fdda1070a32"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metoprolol succinate is a beta1-selective adrenoceptor blocking agent. Metoprolol succinate extended-release tablets USP are indicated for the treatment of: Hypertension ( 1.1 ) Angina Pectoris ( 1.2 ) Heart Failure - for the treatment of stable, symptomatic (NYHA Class II or III) heart failure of ischemic, hypertensive, or cardiomyopathic origin.( 1.3 ) uuid:ce3e8e93-aedc-4d87-84da-5c8f55a1efdc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0003799 PMID:41385096 "[{""id"":""uuid:1dcb7fa6-5652-48e2-826a-ee49b33e3875"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:850d83f8-7c53-4102-8bab-deeafb25ea10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisolone acetate ophthalmic suspension 1.0% is indicated for the treatment of steroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe. uuid:377019b8-cd9d-490a-9775-39bce82a02be biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71419 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:a437e647-67c3-4dd0-86b8-993851aeed6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:40b494a9-f9cc-4298-a410-d874236da8a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Phenazopyridine HCl is indicated for the symptomatic relief of pain, burning, urgency, frequency, and other discomforts arising from irritation of the lower urinary tract mucosa caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters. The use of Phenazopyridine HCl for relief of symptoms should not delay definitive diagnosis and treatment of causative conditions. Because it provides only symptomatic relief, prompt appropriate treatment of the cause of pain must be instituted and Phenazopyridine HCl should be discontinued when symptoms are controlled. The analgesic action may reduce or eliminate the need for systemic analgesics or narcotics. It is, however, compatible with antibacterial therapy and can help to relieve pain and discomfort during the interval before antibacterial therapy controls the infection. Treatment of a urinary tract infection with Phenazopyridine HCl should not exceed 2 days because there is a lack of evidence that the combined administration of Phenazopyridine HCl and an antibacterial provides greater benefit than administration of the antibacterial alone after 2 days. (See DOSAGE AND ADMINISTRATION section.) uuid:61aab39b-c28c-40bb-a9aa-6606d64e5d4d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8502 biolink:treats MONDO:0005364 PMID:41385096 "[{""id"":""uuid:8b8c451c-9101-4147-a06f-d6b2f412c2c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f7f76e72-f1aa-45ae-85c4-504cb12dabd4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Propylthiouracil is indicated: in patients with Graves' disease with hyperthyroidism or toxic multinodular goiter who are intolerant of methimazole and for whom surgery or radioactive iodine therapy is not an appropriate treatment option. to ameliorate symptoms of hyperthyroidism in preparation for thyroidectomy or radioactive iodine therapy in patients who are intolerant of methimazole. uuid:2dc3095a-683a-4018-806f-72e9f8f71d43 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8502 biolink:treats MONDO:0001252 PMID:41385096 "[{""id"":""uuid:634f876d-a15b-419b-81c9-28771ea7ff1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:73af291b-df37-4667-a968-ca4134e27e59"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Propylthiouracil is indicated: in patients with Graves' disease with hyperthyroidism or toxic multinodular goiter who are intolerant of methimazole and for whom surgery or radioactive iodine therapy is not an appropriate treatment option. to ameliorate symptoms of hyperthyroidism in preparation for thyroidectomy or radioactive iodine therapy in patients who are intolerant of methimazole. uuid:771cb7ce-241b-4aaa-b1de-893c214ae307 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8502 biolink:treats MONDO:0004425 PMID:41385096 "[{""id"":""uuid:f47b561d-9b93-46e5-925f-f7c9013961a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a4d68a74-7302-4248-8414-b6f3b3e8b2f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Propylthiouracil is indicated: in patients with Graves' disease with hyperthyroidism or toxic multinodular goiter who are intolerant of methimazole and for whom surgery or radioactive iodine therapy is not an appropriate treatment option. to ameliorate symptoms of hyperthyroidism in preparation for thyroidectomy or radioactive iodine therapy in patients who are intolerant of methimazole. uuid:3c2bfe75-01b1-44d1-9307-90055e3b026b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6715 biolink:treats HP:0000938 PMID:41385096 "[{""id"":""uuid:521efd62-bc88-4dd8-bf63-2c2304a1ca12"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:32ad58ae-7ef4-4b3a-acf6-710fcdfe7892"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Medroxyprogesterone Acetate Injectable Suspension, USP is indicated only for the prevention of pregnancy. The loss of bone mineral density (BMD) in women of all ages and the impact on peak bone mass in adolescents should be considered, along with the decrease in BMD that occurs during pregnancy and/or lactation, in the risk/benefit assessment for women who use Medroxyprogesterone Acetate Injectable Suspension, USP long-term [see Warnings and Precautions (5.1) ]. uuid:baafe5af-d345-403b-bc49-75b480f4f2d8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32293 biolink:treats MONDO:0005150 PMID:41385096 "[{""id"":""uuid:28a1ef1f-d895-4773-85b6-62cedeaa970a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a4075864-5586-4ed1-9510-c48135be002b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f45cbaf8-feb6-417d-a818-bdeb3fb5cba5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/visudyne""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Visudyne ® (verteporfin for injection) therapy is indicated for the treatment of patients with predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration, pathologic myopia or presumed ocular histoplasmosis. There is insufficient evidence to indicate Visudyne for the treatment of predominantly occult subfoveal choroidal neovascularization.|[EMA] Visudyne is indicated for the treatment of:adults with exudative (wet) age-related macular degeneration (AMD) with predominantly classic subfoveal choroidal neovascularisation (CNV) or;adults with subfoveal choroidal neovascularisation secondary to pathological myopia. uuid:c1579179-060c-45fc-bc81-7b32ba416e8f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32293 biolink:treats UMLS:C3537442 PMID:41385096 "[{""id"":""uuid:e28a3bdf-adc5-4c1d-9a30-95883bc4e799"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5b19b120-3b1c-4a52-907f-470172c8629d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Visudyne ® (verteporfin for injection) therapy is indicated for the treatment of patients with predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration, pathologic myopia or presumed ocular histoplasmosis. There is insufficient evidence to indicate Visudyne for the treatment of predominantly occult subfoveal choroidal neovascularization. uuid:32f00256-cbe6-4b5c-a27f-5d390acfa8b1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32293 biolink:treats UMLS:C0339403 PMID:41385096 "[{""id"":""uuid:672fa7c6-b1ca-46f9-83f7-75f0ed879975"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6906ba42-4ea9-4158-ae6a-066ae056636c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Visudyne ® (verteporfin for injection) therapy is indicated for the treatment of patients with predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration, pathologic myopia or presumed ocular histoplasmosis. There is insufficient evidence to indicate Visudyne for the treatment of predominantly occult subfoveal choroidal neovascularization. uuid:a623f77d-0418-4bc2-b16f-33c61c66a8f4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats MONDO:0001209 PMID:41385096 "[{""id"":""uuid:163a9864-3ef7-4c98-a6c8-6d29fa84d641"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f6404632-1822-49f9-b074-305bd6fd840a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For Dermatologic Use: SA 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles). For Podiatric Use: SA 6% is a topical aid in the removal of excessive keratin on dorsal and plantar hyperkeratotic lesions. Topical preparations of 6% salicylic acid have been reported to be useful adjunctive therapy for verrucae plantares. uuid:3bf2897b-7a86-4376-bd98-7a034207adfa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats MONDO:0024304 PMID:41385096 "[{""id"":""uuid:7a0c3c82-330d-4ed4-b20a-a76aa41b4441"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4a5dc4f7-709b-4f41-8363-81260c17710f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For Dermatologic Use: SA 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles). For Podiatric Use: SA 6% is a topical aid in the removal of excessive keratin on dorsal and plantar hyperkeratotic lesions. Topical preparations of 6% salicylic acid have been reported to be useful adjunctive therapy for verrucae plantares. uuid:3f1866d1-7112-477a-a426-6a168ed61d38 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats MONDO:0010622 PMID:41385096 "[{""id"":""uuid:d21353ff-c2db-436e-b850-a278e1a50f95"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fc15bd1a-683f-446b-b5d5-00b681a2c3c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For Dermatologic Use: SA 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles). For Podiatric Use: SA 6% is a topical aid in the removal of excessive keratin on dorsal and plantar hyperkeratotic lesions. Topical preparations of 6% salicylic acid have been reported to be useful adjunctive therapy for verrucae plantares. uuid:e9988c6d-e23b-4141-bc88-1a9caddd89ce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats MONDO:0017778 PMID:41385096 "[{""id"":""uuid:6f25c534-0d5a-4b5c-a934-1451b25a2311"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:18448ebf-46b6-4350-962f-7b71fab9fee6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For Dermatologic Use: SA 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles). For Podiatric Use: SA 6% is a topical aid in the removal of excessive keratin on dorsal and plantar hyperkeratotic lesions. Topical preparations of 6% salicylic acid have been reported to be useful adjunctive therapy for verrucae plantares. uuid:dccb4d96-5ee6-41ee-afcd-53eb251a970f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats UMLS:C0856543 PMID:41385096 "[{""id"":""uuid:a8fcef5c-e6f4-448c-9c4c-50723920a551"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cb638840-7a0e-4702-a283-131620380c77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For Dermatologic Use: SA 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles). For Podiatric Use: SA 6% is a topical aid in the removal of excessive keratin on dorsal and plantar hyperkeratotic lesions. Topical preparations of 6% salicylic acid have been reported to be useful adjunctive therapy for verrucae plantares. uuid:10f53239-88b2-4861-9572-3bf1200d5465 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats MONDO:0006590 PMID:41385096 "[{""id"":""uuid:09655512-927f-497c-9c21-90be8e566e33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4611c078-142b-43a5-9aa3-b4e7e0d5cdd9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For Dermatologic Use: SA 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles). For Podiatric Use: SA 6% is a topical aid in the removal of excessive keratin on dorsal and plantar hyperkeratotic lesions. Topical preparations of 6% salicylic acid have been reported to be useful adjunctive therapy for verrucae plantares. uuid:3352d4f9-803c-4d29-b863-32096a4d3a48 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats MONDO:0021036 PMID:41385096 "[{""id"":""uuid:793613d9-b050-43aa-b411-2c9c7cbaea32"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:65369f13-a445-4e0c-a305-9b07d795dbfb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For Dermatologic Use: SA 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles). For Podiatric Use: SA 6% is a topical aid in the removal of excessive keratin on dorsal and plantar hyperkeratotic lesions. Topical preparations of 6% salicylic acid have been reported to be useful adjunctive therapy for verrucae plantares. uuid:4034ea8e-ce29-498b-9ec2-12af5acfa101 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats MONDO:0100017 PMID:41385096 "[{""id"":""uuid:1d25e63d-c250-49f0-b520-ca34123fe5ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:af41e1fb-b489-407f-90dc-f2f7ee60d593"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For Dermatologic Use: SA 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles). For Podiatric Use: SA 6% is a topical aid in the removal of excessive keratin on dorsal and plantar hyperkeratotic lesions. Topical preparations of 6% salicylic acid have been reported to be useful adjunctive therapy for verrucae plantares. uuid:41f0c45c-8d58-40d7-a742-cc2cbddc4a8c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:5ea24a96-65f8-4068-b87b-448b4907782c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:53effaf5-f873-4cc4-8055-fb0e68890ab8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For Dermatologic Use: SA 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles). For Podiatric Use: SA 6% is a topical aid in the removal of excessive keratin on dorsal and plantar hyperkeratotic lesions. Topical preparations of 6% salicylic acid have been reported to be useful adjunctive therapy for verrucae plantares. uuid:f0ad3fc3-57d5-4b87-923a-4527df2d879a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats MONDO:0001795 PMID:41385096 "[{""id"":""uuid:cc974a38-28c7-4a82-a719-b4b179833fc6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fade0a5b-05bf-498a-a8f9-27ae7e2dad78"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For Dermatologic Use: SA 6% is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles). For Podiatric Use: SA 6% is a topical aid in the removal of excessive keratin on dorsal and plantar hyperkeratotic lesions. Topical preparations of 6% salicylic acid have been reported to be useful adjunctive therapy for verrucae plantares. uuid:cbfd1c4b-0de3-498d-9161-a9302686f8d8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5790 biolink:treats NCIT:C34887 PMID:41385096 "[{""id"":""uuid:46f17159-e577-427a-8f11-6190f98dce08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e209e7d4-d6f9-4baf-89db-36a013613795"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EXALGO is an extended-release oral formulation of hydromorphone hydrochloride indicated for the management of moderate to severe pain in opioid tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time. Patients considered opioid tolerant are those who are taking at least 60 mg oral morphine per day, 25 mcg transdermal fentanyl/hour, 30 mg oral oxycodone/day, 8 mg oral hydromorphone/day, 25 mg oral oxymorphone/day or an equianalgesic dose of another opioid, for a week or longer. EXALGO is NOT intended for use as an as-needed analgesic. EXALGO is not indicated for the management of acute or postoperative pain. uuid:f80f0929-18b3-4767-8a73-9a9eca065450 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1090966 biolink:treats MONDO:0005276 PMID:41385096 "[{""id"":""uuid:a336fc02-65f2-43bc-8abc-b368fbc38d04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:61ffe243-b476-451f-a360-f5739e689e6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Supplementation of the diet with vitamins A, C and D. Multi-Vitamin Fluoride Drops 0.25 mg also provide fluoride for caries prophylaxis. The American Academy of Pediatrics recommends that children up to age 16, in areas where drinking water contains less than optimal levels of fluoride, receive daily fluoride supplementation. The American Academy of Pediatrics recommend that infants and young children 6 months to 3 years of age, in areas where drinking water contains less than 0.3 ppm of fluoride, and children 3-6 years of age, in areas where the drinking water contains 0.3 through 0.6 ppm of fluoride, receive 0.25 mg of supplemental fluoride daily which is provided in a dose of 1 mL of Multi-Vitamin Fluoride 0.25 mg drops. (see Dosage and Administration ). Multi-Vitamin Fluoride 0.25 mg drops supply significant amounts of vitamins A, C and D to supplement the diet, and to help assure that nutritional deficiencies of these vitamins will not develop. Thus, in a single easy-to-use preparation, children obtain essential vitamins and fluoride. uuid:9f6ec90b-d717-4784-8738-b8f71bf9c5ac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2922 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:ac4ba76c-2088-47e4-81d0-9548d276e6e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2b06b460-aaa5-45ef-99d2-8c80c11adc55"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RIDAURA (auranofin) is indicated in the management of adults with active classical or definite rheumatoid arthritis (ARA criteria) who have had an insufficient therapeutic response to, or are intolerant of, an adequate trial of full doses of one or more nonsteroidal anti-inflammatory drugs. RIDAURA should be added to a comprehensive baseline program, including non-drug therapies. Unlike anti-inflammatory drugs, RIDAURA does not produce an immediate response. Therapeutic effects may be seen after three to four months of treatment, although improvement has not been seen in some patients before six months. When cartilage and bone damage has already occurred, gold cannot reverse structural damage to joints caused by previous disease. The greatest potential benefit occurs in patients with active synovitis, particularly in its early stage. In controlled clinical trials comparing RIDAURA with injectable gold, RIDAURA was associated with fewer dropouts due to adverse reactions, while injectable gold was associated with fewer dropouts for inadequate or poor therapeutic effect. Physicians should consider these findings when deciding on the use of RIDAURA in patients who are candidates for chrysotherapy. uuid:f30c04a0-cb95-4276-9c44-38b664ce9d66 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71940 biolink:treats MONDO:0010811 PMID:41385096 "[{""id"":""uuid:3d541a4a-b4d0-4e29-95e9-6d034be94da1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e0de4601-254e-4277-9c52-4ab6eb596849"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:76cecbab-6c96-4180-b45d-43975d49fbbf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cialis""]},{""id"":""uuid:4a8d3d7a-672e-46e8-8ca1-fb5cff09dbdd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CIALIS ® is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of: erectile dysfunction (ED) ( 1.1 ) the signs and symptoms of benign prostatic hyperplasia (BPH) ( 1.2 ) ED and the signs and symptoms of BPH (ED/BPH) ( 1.3 )|[EMA] Treatment of erectile dysfunction in adult males.In order for tadalafil to be effective, sexual stimulation is required.Tadalafil Lilly is not indicated for use by women.Treatment of the signs and symptoms of benign prostatic hyperplasia in adult males.|[PMDA] Drugs with a new indication and a new dosage in a new additional dosage form indicated for the treatment of dysuria associated with benign prostatic hypertrophy. uuid:10d70bae-49c5-41c1-acc7-b4324d79b19f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:11949636 biolink:treats MONDO:0043885 PMID:41385096 "[{""id"":""uuid:24b30755-9409-4606-9185-4f12a24774b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1340617a-71e8-4225-ac40-870760aec26b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tobramycin and Dexamethasone Ophthalmic Suspension is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product is active against the following common bacterial eye pathogens: Staphylococci, including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin-resistant strains. Streptococci, including some of the Group A-beta-hemolytic species, some nonhemolytic species, and some Streptococcus pneumoniae . Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii, most Proteus vulgaris strains, Haemophilus influenzae and H. aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus and some Neisseria species . uuid:310d8151-e705-44fd-b4ca-e1205301287b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31897 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:652bb179-a8ad-4b10-8fd7-98613e611ada"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:135adf70-2cdb-48a1-b615-f0ea6b4ce1b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9737dcea-e503-4c4e-aae9-2904ba863d37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nateglinide Tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 diabetes mellitus.|[PMDA] Drugs with a new additional indication for the treatment of postprandial glucose excursions in Type 2 diabetes mellitus (for use only when treatment with thiazolidines in conjunction with dietary and exercise regimens is not sufficiently effective). uuid:3f94303e-252c-4d56-b87a-f84a4a4d1be8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77590 biolink:treats MONDO:0007147 PMID:41385096 "[{""id"":""uuid:9551f206-299b-4bed-8e03-fba4840d8d2d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:757cd50e-be80-45ec-a3bc-fc85fa5e4ed5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NUVIGIL is indicated to improve wakefulness in patients with excessive sleepiness associated with obstructive sleep apnea, narcolepsy and shift work disorder. In OSA, NUVIGIL is indicated as an adjunct to standard treatment(s) for the underlying obstruction. If continuous positive airway pressure (CPAP) is the treatment of choice for a patient, a maximal effort to treat with CPAP for an adequate period of time should be made prior to initiating NUVIGIL. If NUVIGIL is used adjunctively with CPAP, the encouragement of and periodic assessment of CPAP compliance is necessary. In all cases, careful attention to the diagnosis and treatment of the underlying sleep disorder(s) is of utmost importance. Prescribers should be aware that some patients may have more than one sleep disorder contributing to their excessive sleepiness. The effectiveness of NUVIGIL in long-term use (greater than 12 weeks) has not been systematically evaluated in placebo-controlled trials. The physician who elects to prescribe NUVIGIL for an extended time in patients should periodically re-evaluate long-term usefulness for the individual patient. uuid:4e01268d-5178-4bb1-8ad2-36ec089efd11 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77590 biolink:treats MONDO:0021107 PMID:41385096 "[{""id"":""uuid:c2bfcabd-1f13-471e-8b34-84ca4a45c63d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a172a3ab-8192-4401-b8d8-0f9386514168"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NUVIGIL is indicated to improve wakefulness in patients with excessive sleepiness associated with obstructive sleep apnea, narcolepsy and shift work disorder. In OSA, NUVIGIL is indicated as an adjunct to standard treatment(s) for the underlying obstruction. If continuous positive airway pressure (CPAP) is the treatment of choice for a patient, a maximal effort to treat with CPAP for an adequate period of time should be made prior to initiating NUVIGIL. If NUVIGIL is used adjunctively with CPAP, the encouragement of and periodic assessment of CPAP compliance is necessary. In all cases, careful attention to the diagnosis and treatment of the underlying sleep disorder(s) is of utmost importance. Prescribers should be aware that some patients may have more than one sleep disorder contributing to their excessive sleepiness. The effectiveness of NUVIGIL in long-term use (greater than 12 weeks) has not been systematically evaluated in placebo-controlled trials. The physician who elects to prescribe NUVIGIL for an extended time in patients should periodically re-evaluate long-term usefulness for the individual patient. uuid:10028dfb-c5c1-4a28-9273-f9759e96411b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77590 biolink:treats UMLS:C4087539 PMID:41385096 "[{""id"":""uuid:c0986496-3e0c-4b72-a828-c2d27bd98ac3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:384130fe-ccb5-403b-a00e-38dea9cc42e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NUVIGIL is indicated to improve wakefulness in patients with excessive sleepiness associated with obstructive sleep apnea, narcolepsy and shift work disorder. In OSA, NUVIGIL is indicated as an adjunct to standard treatment(s) for the underlying obstruction. If continuous positive airway pressure (CPAP) is the treatment of choice for a patient, a maximal effort to treat with CPAP for an adequate period of time should be made prior to initiating NUVIGIL. If NUVIGIL is used adjunctively with CPAP, the encouragement of and periodic assessment of CPAP compliance is necessary. In all cases, careful attention to the diagnosis and treatment of the underlying sleep disorder(s) is of utmost importance. Prescribers should be aware that some patients may have more than one sleep disorder contributing to their excessive sleepiness. The effectiveness of NUVIGIL in long-term use (greater than 12 weeks) has not been systematically evaluated in placebo-controlled trials. The physician who elects to prescribe NUVIGIL for an extended time in patients should periodically re-evaluate long-term usefulness for the individual patient. uuid:dd2635d2-0a58-4ff6-972a-ce2253936b3b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50275 biolink:treats MONDO:0001126 PMID:41385096 "[{""id"":""uuid:116241e3-518a-4beb-b0e6-e4ffa6510179"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3ce29003-b6ad-467b-8ac5-ff42385215bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f87de73f-ae0d-4492-a8bc-a46651dc03fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NEXIUM is a proton pump inhibitor indicated for the following: Treatment of gastroesophageal reflux disease (GERD) (1.1) Risk reduction of NSAID-associated gastric ulcer (1.2) H. pylori eradication to reduce the risk of duodenal ulcer recurrence (1.3) Pathological hypersecretory conditions, including Zollinger-Ellison syndrome (1.4)|[PMDA] A drug with a new active ingredient indicated for the treatment of gastric ulcer, duodenal ulcer, anastomotic ulcer, reflux esophagitis, non-erosive reflux disease and Zollinger-Ellison syndrome, prevention of recurrence of gastric ulcer or duodenal ulcer in patients treated with nonsteroidal antiinflammatory drugs, and aid to eradication of Helicobacter pylori in patients with gastric ulcer, duodenal ulcer, gastric MALT lymphoma, idiopathic thrombocytopenic purpura, and stomach after endoscopic treatment for early gastric cancer. uuid:ea944cec-5b13-4119-b40d-3ca644001c8a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50275 biolink:treats MONDO:0005412 PMID:41385096 "[{""id"":""uuid:3cded28a-e0c9-49ae-b446-aff90d748362"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f00743e9-20bc-49b4-b599-56a6817b2f5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ace02741-f20e-418f-bda6-ad2738782f60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NEXIUM is a proton pump inhibitor indicated for the following: Treatment of gastroesophageal reflux disease (GERD) (1.1) Risk reduction of NSAID-associated gastric ulcer (1.2) H. pylori eradication to reduce the risk of duodenal ulcer recurrence (1.3) Pathological hypersecretory conditions, including Zollinger-Ellison syndrome (1.4)|[PMDA] A drug with a new active ingredient indicated for the treatment of gastric ulcer, duodenal ulcer, anastomotic ulcer, reflux esophagitis, non-erosive reflux disease and Zollinger-Ellison syndrome, prevention of recurrence of gastric ulcer or duodenal ulcer in patients treated with nonsteroidal antiinflammatory drugs, and aid to eradication of Helicobacter pylori in patients with gastric ulcer, duodenal ulcer, gastric MALT lymphoma, idiopathic thrombocytopenic purpura, and stomach after endoscopic treatment for early gastric cancer. uuid:f585f6cd-375c-4edc-87d4-526e593371a1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:521033 biolink:treats MONDO:0010811 PMID:41385096 "[{""id"":""uuid:d9c38cbc-7ff8-4d15-a14d-668796bd93ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6a4ee77d-ae24-4202-a847-0ebb39386d1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e7105c5a-a85e-47da-8a2e-fd030e8d80fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AVODART is a 5 alpha-reductase inhibitor indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to: (1.1) improve symptoms, reduce the risk of acute urinary retention, and reduce the risk of the need for BPH-related surgery. AVODART in combination with the alpha adrenergic antagonist, tamsulosin, is indicated for the treatment of symptomatic BPH in men with an enlarged prostate. (1.2) Limitations of Use: AVODART is not approved for the prevention of prostate cancer. (1.3)|[PMDA] A drug with a new active ingredient indicated for the treatment of benign prostatic hyperplasia. uuid:c3b4e721-2377-4635-9d0f-7b9c1f41af49 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:521033 biolink:treats UMLS:C0341742 PMID:41385096 "[{""id"":""uuid:a01ac000-cc41-4996-a961-6c16c7376563"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0452dcd7-7c24-457a-9da6-38e470669916"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AVODART is a 5 alpha-reductase inhibitor indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to: (1.1) improve symptoms, reduce the risk of acute urinary retention, and reduce the risk of the need for BPH-related surgery. AVODART in combination with the alpha adrenergic antagonist, tamsulosin, is indicated for the treatment of symptomatic BPH in men with an enlarged prostate. (1.2) Limitations of Use: AVODART is not approved for the prevention of prostate cancer. (1.3) uuid:9597b946-3d16-4fad-a408-466d8c23e772 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9874151 biolink:treats MONDO:1010182 PMID:41385096 "[{""id"":""uuid:d9a8800d-b11a-4c7e-aea8-a7244ab46525"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dfe4e31e-b9b2-448d-88fe-6870ef5cfadc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gianvi is indicated for the prevention of pregnancy in women who elect to use an oral contraceptive. Oral contraceptives are highly effective. Table II lists the typical unintended pregnancy rates for users of combination oral contraceptives and other methods of contraception. The efficacy of these contraceptive methods, except sterilization and contraceptive implants and IUDs, depends upon the reliability with which they are used. Correct and consistent use of methods can result in lower failure rates. Gianvi is also indicated for the treatment of symptoms of premenstrual dysphoric disorder (PMDD) in women who choose to use an oral contraceptive as their method of contraception. The effectiveness of Gianvi for PMDD when used for more than three menstrual cycles has not been evaluated. The essential features of PMDD according to the Diagnostic and Statistical Manual-4 th edition (DSM-IV) include markedly depressed mood, anxiety or tension, affective lability, and persistent anger or irritability. Other features include decreased interest in usual activities, difficulty concentrating, lack of energy, change in appetite or sleep, and feeling out of control. Physical symptoms associated with PMDD include breast tenderness, headache, joint and muscle pain, bloating and weight gain. In this disorder, these symptoms occur regularly during the luteal phase and remit within a few days following onset of menses; the disturbance markedly interferes with work or school, or with usual social activities and relationships with others. Diagnosis is made by healthcare providers according to DSM-IV criteria, with symptomatology assessed prospectively over at least two menstrual cycles. In making the diagnosis, care should be taken to rule out other cyclical mood disorders. Gianvi has not been evaluated for the treatment of premenstrual syndrome (PMS). Gianvi is indicated for the treatment of moderate acne vulgaris in women at least 14 years of age, who have no known contraindications to oral contraceptive therapy and have achieved menarche. Gianvi should be used for the treatment of acne only if the patient desires an oral contraceptive for birth control. TABLE II: Percentage of women experiencing an unintended pregnancy during the first year of typical use and first year of perfect use of contraception and the percentage continuing use at the end of the first year: United States. Source: Trussell J, Contraceptive efficacy. In Hatcher RA, Trussell J, Stewart F, Cates W, Stewart GK, Guest F, Kowal D, Contraceptive Technology: Seventeenth Revised Edition. New York NY: Irvington Publishers, 1998. % of Women Experiencing an Unintended Pregnancy Within the First Year of Use % of Women Continuing Use at One Year Among couples attempting to avoid pregnancy, the percentage who continue to use a method for one year. Method (1) Typical Use Among typical couples who initiate use of a method (not necessarily for the first time), the percentage who experience an accidental pregnancy during the first year if they do not stop use for any other reason. (2) Perfect Use Among couples who initiate use of a method (not necessarily for the first time) and who use it perfectly (both consistently and correctly). The percentage who experience an accidental pregnancy during the first year if they do not stop use for any reason. (3) (4) Chance The percents becoming pregnant in columns (2) and (3) are based on data from populations where contraception is not used and from women who cease using contraception in order to become pregnant. Among such populations, about 89% become pregnant within one year. This estimate was lowered slightly (to 85%) to represent the percentage who would become pregnant within one year among women now relying on reversible methods of contraception if they abandoned contraception altogether. 85 85 Spermicides Foams, creams, gels vaginal suppositories, and vaginal film. 26 6 40 Periodic abstinence 25 63 Calendar 9 Ovulation method 3 Sympto-thermal Cervical mucus (ovulation) method supplemented by calendar in the pre-ovulatory and basal body temperature in the post-ovulatory phases. 2 Post-ovulation 1 Withdrawal 19 4 Cap With spermicidal cream or jelly. Parous women 40 26 42 Nulliparous women 20 9 56 Sponge Parous women 40 20 42 Nulliparous women 20 9 56 Diaphragm 20 6 56 Condom Without spermicides. Female (Reality) 21 5 56 Male 14 3 61 Pill 5 71 progestin only 0.5 combined 0.1 IUD: Progesterone T 2 1.5 81 Copper T 380A 0.8 0.6 78 Lng 20 0.1 0.1 81 Depo Provera 0.3 0.3 70 Norplant and Norplant-2 0.05 0.05 88 Female sterilization 0.5 0.5 100 Male sterilization 0.15 0.1 100 Emergency Contraceptive Pills: Treatment initiated within 72 hours after unprotected intercourse reduces the risk of pregnancy by at least 75%. The treatment schedule is one dose within 72 hours after unprotected intercourse, and a second dose 12 hours after the first dose. The Food and Drug Administration has declared the following brands of oral contraceptives to be safe and effective for emergency contraception: Ovral (1 dose is 2 white pills), Alesse (1 dose is 5 pink pills), Nordette or Levlen (1 dose is 2 light-orange pills), Lo/Ovral (1 dose is 4 white pills), Triphasil or Tri-Levlen (1 dose is 4 yellow pills). Lactational Amenorrhea Method: LAM is a highly effective, temporary method of contraception. However, to maintain effective protection against pregnancy, another method of contraception must be used as soon as menstruation resumes, the frequency or duration of breastfeeds is reduced, bottle feeds are introduced, or the baby reaches six months of age. UMLS:C0520676 uuid:a95c186a-2ba5-4a87-ac49-5af8de27f25a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6129 biolink:treats NCIT:C50476 PMID:41385096 "[{""id"":""uuid:a34eeb41-5f0b-4e74-9071-a76dad4e5b0c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:71b6ab5a-d370-4306-9810-c8eacd02cc4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ketorolac tromethamine ophthalmic solution is indicated for the reduction of ocular pain and burning/stinging following corneal refraction surgery. uuid:346aba7a-d39e-4166-acb3-cd4409634ebf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6129 biolink:treats UMLS:C0677500 PMID:41385096 "[{""id"":""uuid:cb3f3b71-af06-4923-ac70-37d0832b4d14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f849fbaf-e522-4c86-8803-ef1510a4c6db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ketorolac tromethamine ophthalmic solution is indicated for the reduction of ocular pain and burning/stinging following corneal refraction surgery. uuid:26c1692e-3122-496d-a224-7b03e4ad3a45 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5959 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:f9c3af97-cc97-4c0d-9faf-74c4770f6493"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:90a3010b-dab8-4473-bfb9-a154ec0de400"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f9e109b8-7e74-410d-a8e8-5f7611b599a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AVAPRO (irbesartan) is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents.|[PMDA] Drugs containing a new active ingredient indicated for the treatment of hypertension. uuid:679c6dd4-d05a-43d9-8547-1d384e24c61a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4909 biolink:treats MONDO:0011429 PMID:41385096 "[{""id"":""uuid:b97bf724-862b-42cf-bb27-58302588b49c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6ee71864-71ac-46bc-bb0b-a9f901b75116"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of etodolac extended-release tablets and other treatment options before deciding to use etodolac extended-release tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Etodolac extended-release tablets are indicated: * For relief of signs and symptoms of juvenile arthritis * For relief of the signs and symptoms of rheumatoid arthritis * For relief of the signs and symptoms of osteoarthritis uuid:1b035a45-4fc6-43b8-b53a-ea79f7275249 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7798 biolink:treats MONDO:0005812 PMID:41385096 "[{""id"":""uuid:2d99e956-4594-4f9d-bc51-3e80f53e1cd9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:982cee93-80ca-45b1-9392-39e343ee3a4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f98f72e9-6886-425d-bbe8-dd4ddd85a99b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ebilfumin""]},{""id"":""uuid:442364f8-7e6b-4512-b765-3bcb0dae579a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TAMIFLU is an influenza neuraminidase inhibitor indicated for: Treatment of influenza in patients 1 year and older who have been symptomatic for no more than 2 days. ( 1.1 ) Prophylaxis of influenza in patients 1 year and older. ( 1.2 ) Important Limitations of Use : Efficacy not established in patients who begin therapy after 48 hours of symptoms. ( 1.3 ) Not a substitute for annual influenza vaccination. ( 1.3 ) No evidence of efficacy for illness from agents other than influenza viruses types A and B. ( 1.3 ) Consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use. ( 1.3 )|[EMA] Treatment of influenzaIn patients one year of age and older who present with symptoms typical of influenza, when influenza virus is circulating in the community.Ebilfumin is indicated for the treatment of infants less than 1 year of age during a pandemic influenza outbreak (see section 5.2 of the SmPC). The treating physician should take into account the pathogenicity of the circulating strain and the underlying condition of the patient to ensure there is a potential benefit to the child.Prevention of influenzaPost-exposure prevention in individuals 1 year of age or older following contact with a clinically diagnosed influenza case when influenza virus is circulating in the community.The appropriate use of Ebilfumin for prevention of influenza should be determined on a case by case basis by the circumstances and the population requiring protection. In exceptional situations (e.g. in case of a mismatch between the circulating and vaccine virus strains, and a pandemic situation) seasonal prevention could be considered in individuals one year of age or older.Ebilfumin is indicated for post-exposure prevention of influenza in infants less than 1 year of age during a pandemic influenza outbreak (see section 5.2 of the SmPC).Ebilfumin is not a substitute for influenza vaccination.|[PMDA] Drugs with a new additional indication and a new dosage for prophylaxis of influenza A or B virus infections. uuid:10070989-8044-4ef9-a28b-52620e468d55 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4974 biolink:treats MONDO:0043653 PMID:41385096 "[{""id"":""uuid:d605d7b8-46a4-4dda-bb24-8741285bbf33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d084cc9e-bfee-48bc-80e5-8c421ee8536b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Famciclovir tablets, a prodrug of penciclovir, is a nucleoside analog DNA polymerase inhibitor indicated for: Immunocompetent Adult Patients ( 1.1 ) Herpes labialis (cold sores) Treatment of recurrent episodes Genital herpes Treatment of recurrent episodes Suppressive therapy of recurrent episodes Herpes zoster (shingles) HIV-Infected Adult Patients ( 1.2 ) Treatment of recurrent episodes of orolabial or genital herpes Limitation of Use ( 1.3 ) The efficacy and safety of famciclovir tablets has not been established for: Patients < 18 years of age Immunocompromised patients other than for the treatment of recurrent episodes of orolabial or genital herpes in HIV-infected patients Black and African American patients with recurrent genital herpes uuid:410de70f-04af-4617-93a1-5e00e6e9678a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4974 biolink:treats MONDO:0005770 PMID:41385096 "[{""id"":""uuid:943a0699-3d19-4aff-b4c9-e58b6500496d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e71ac7e5-a3eb-4e68-b903-5a2077e7e7a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Famciclovir tablets, a prodrug of penciclovir, is a nucleoside analog DNA polymerase inhibitor indicated for: Immunocompetent Adult Patients ( 1.1 ) Herpes labialis (cold sores) Treatment of recurrent episodes Genital herpes Treatment of recurrent episodes Suppressive therapy of recurrent episodes Herpes zoster (shingles) HIV-Infected Adult Patients ( 1.2 ) Treatment of recurrent episodes of orolabial or genital herpes Limitation of Use ( 1.3 ) The efficacy and safety of famciclovir tablets has not been established for: Patients < 18 years of age Immunocompromised patients other than for the treatment of recurrent episodes of orolabial or genital herpes in HIV-infected patients Black and African American patients with recurrent genital herpes uuid:a444d6ee-c555-4001-9bee-b19ce4db8c99 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4974 biolink:treats MONDO:0005609 PMID:41385096 "[{""id"":""uuid:29ae36e3-bf18-4dbe-ad88-672f1e091aa9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4f927df1-01fe-4753-8e42-65f4fbbe7e35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:494173e7-cdf4-415b-8d9a-653e6040bab7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Famciclovir tablets, a prodrug of penciclovir, is a nucleoside analog DNA polymerase inhibitor indicated for: Immunocompetent Adult Patients ( 1.1 ) Herpes labialis (cold sores) Treatment of recurrent episodes Genital herpes Treatment of recurrent episodes Suppressive therapy of recurrent episodes Herpes zoster (shingles) HIV-Infected Adult Patients ( 1.2 ) Treatment of recurrent episodes of orolabial or genital herpes Limitation of Use ( 1.3 ) The efficacy and safety of famciclovir tablets has not been established for: Patients < 18 years of age Immunocompromised patients other than for the treatment of recurrent episodes of orolabial or genital herpes in HIV-infected patients Black and African American patients with recurrent genital herpes|[PMDA] A drug containing a new active ingredient indicated for the treatment of herpes zoster. uuid:f2929200-721d-4d59-9d8e-6d6d68fd7db9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:848151 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:142fd5ed-6eeb-4cd7-91ef-abb285122fef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5ed4ab7b-0bc8-4ce6-8935-1b66d2a10718"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Exforge HCT (amlodipine, valsartan, hydrochlorothiazide) is indicated for the treatment of hypertension. This fixed combination drug is not indicated for the initial therapy of hypertension [see Dosage and Administration (2)]. uuid:d004636b-53a0-49f7-8597-c1d30cf1bf14 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:284544 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:5f872183-ae99-4b5f-b717-ab611e7d6524"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:32821292-aaef-4cd4-8568-c966cea729a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BenzaClin Topical Gel is indicated for the topical treatment of acne vulgaris. uuid:a1a935ee-375a-49a0-b196-c1702ff75da0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17594 biolink:treats MONDO:0000736 PMID:41385096 "[{""id"":""uuid:4452e156-298c-404b-a779-1d1d85aa9bca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1aa120be-ab0e-4706-a9a0-a27edf145fce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The gradual bleaching of hyperpigmented skin conditions such as chloasma, melasma, freckles, senile lentigines, and other unwanted areas of melanin hyperpigmentation. uuid:6a873a86-072e-4e25-951b-bb44d8967e95 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17594 biolink:treats MONDO:0021582 PMID:41385096 "[{""id"":""uuid:f8d559f4-5afa-40a5-8281-571eaa182d35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4d9ed1e1-be80-4c5c-a4ec-de01e931263c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The gradual bleaching of hyperpigmented skin conditions such as chloasma, melasma, freckles, senile lentigines, and other unwanted areas of melanin hyperpigmentation. uuid:ce6e9d2f-613d-4223-a416-aab76a68c908 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8865 biolink:treats MONDO:0005812 PMID:41385096 "[{""id"":""uuid:b01728bf-e7f2-4373-b754-2db196b4565d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7a986cee-4f33-4642-93a2-4a6df3d794b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Rimantadine hydrochloride tablet is indicated for the prophylaxis and treatment of illness caused by various strains of influenza A virus in adults (17 years and older). Rimantadine hydrochloride tablet is indicated for prophylaxis against influenza A virus in children (1 year to 16 years of age). uuid:60cb8488-e43e-466c-9753-dd3c34d7b2ed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8865 biolink:treats UMLS:C0858004 PMID:41385096 "[{""id"":""uuid:4f4bf6fc-4f49-44e6-9844-83448a20b086"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c72453df-62f2-4aa6-aa8f-96b57686bf52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Rimantadine hydrochloride tablet is indicated for the prophylaxis and treatment of illness caused by various strains of influenza A virus in adults (17 years and older). Rimantadine hydrochloride tablet is indicated for prophylaxis against influenza A virus in children (1 year to 16 years of age). uuid:a8389c4d-9f62-4878-921f-b54e5f6e7766 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50659 biolink:treats MONDO:0004981 PMID:41385096 "[{""id"":""uuid:d6afec02-6bd3-42e5-8db5-f29061238669"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:51295893-0563-4eb6-9992-0207d801bb77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1d6dd61c-9e51-4315-8665-39194d6464f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/multaq-0""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] MULTAQ ® is indicated to reduce the risk of hospitalization for atrial fibrillation in patients in sinus rhythm with a history of paroxysmal or persistent atrial fibrillation (AF) [see Clinical Studies (14) ].|[EMA] Multaq is indicated for the maintenance of sinus rhythm after successful cardioversion in adult clinically stable patients with paroxysmal or persistent atrial fibrillation (AF). Due to its safety profile, Multaq should only be prescribed after alternative treatment options have been considered.Multaq should not be given to patients with left ventricular systolic dysfunction or to patients with current or previous episodes of heart failure. uuid:6df39c0e-b4df-403e-91f5-2bb5f56f34a7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3515 biolink:treats MONDO:0021680 PMID:41385096 "[{""id"":""uuid:ce7cd7fa-6c28-4aa6-8a6b-ad9c6760b335"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:46bd9b57-40a4-4f7e-bfd3-857fdf26d808"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefuroxime axetil and other antibacterial drugs, cefuroxime axetil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. NOTE: CEFUROXIME AXETIL TABLETS AND CEFUROXIME AXETIL FOR ORAL SUSPENSION ARE NOT BIO­EQUIVALENT AND ARE NOT SUBSTITUTABLE ON A MILLIGRAM-PER-MILLIGRAM BASIS (SEE CLINICAL PHARMACOLOGY ). Cefuroxime Axetil Tablets Cefuroxime axetil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Pharyngitis/Tonsillitis caused by Streptococcus pyogenes. NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefuroxime axetil tablets are generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefuroxime in the subsequent prevention of rheumatic fever are not available. Please also note that in all clinical trials, all isolates had to be sensitive to both penicillin and cefuroxime. There are no data from adequate and well-controlled trials to demonstrate the effectiveness of cefuroxime in the treatment of penicillin-resistant strains of Streptococcus pyogenes. Acute Bacterial Otitis Media caused by Streptococcus pneumoniae , Haemophilus influenzae (including beta-lactamase–producing strains), Moraxella catarrhalis (including beta-lactamase–producing strains), or Streptococcus pyogenes. Acute Bacterial Maxillary Sinusitis caused by Streptococcus pneumoniae or Haemophilus influenzae (non-beta-lactamase–producing strains only). (See CLINICAL STUDIES section.) NOTE: In view of the insufficient numbers of isolates of beta-lactamase–producing strains of Haemophilus influenzae and Moraxella catarrhalis that were obtained from clinical trials with cefuroxime axetil tablets for patients with acute bacterial maxillary sinusitis, it was not possible to adequately evaluate the effectiveness of cefuroxime axetil tablets for sinus infections known, suspected, or considered potentially to be caused by beta-lactamase–producing Haemophilus influenzae or Moraxella catarrhalis . Acute Bacterial Exacerbations of Chronic Bronchitis and Secondary Bacterial Infections of Acute Bronchitis caused by Streptococcus pneumoniae , Haemophilus influenzae (beta-lactamase negative strains), or Haemophilus parainfluenzae (beta-lactamase negative strains). (See DOSAGE AND ADMINISTRATION section and CLINICAL STUDIES section.) Uncomplicated Skin and Skin-Structure Infections caused by Staphylococcus aureus (including beta-lactamase–producing strains) or Streptococcus pyogenes. Uncomplicated Urinary Tract Infections caused by Escherichia coli or Klebsiella pneumoniae . Uncomplicated Gonorrhea, urethral and endocervical, caused by penicillinase-producing and non-penicillinase–producing strains of Neisseria gonorrhoeae and uncomplicated gonorrhea, rectal, in females, caused by non-penicillinase–producing strains of Neisseria gonorrhoeae . Early Lyme Disease (erythema migrans) caused by Borrelia burgdorferi. uuid:f65f0936-5707-4179-865d-32977fca52ee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3515 biolink:treats MONDO:0017767 PMID:41385096 "[{""id"":""uuid:a5560d6c-e854-4f6d-aeb5-ffda74838075"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:87d4788d-f30b-487e-869c-c57932d3d4b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefuroxime axetil and other antibacterial drugs, cefuroxime axetil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. NOTE: CEFUROXIME AXETIL TABLETS AND CEFUROXIME AXETIL FOR ORAL SUSPENSION ARE NOT BIO­EQUIVALENT AND ARE NOT SUBSTITUTABLE ON A MILLIGRAM-PER-MILLIGRAM BASIS (SEE CLINICAL PHARMACOLOGY ). Cefuroxime Axetil Tablets Cefuroxime axetil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: Pharyngitis/Tonsillitis caused by Streptococcus pyogenes. NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefuroxime axetil tablets are generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefuroxime in the subsequent prevention of rheumatic fever are not available. Please also note that in all clinical trials, all isolates had to be sensitive to both penicillin and cefuroxime. There are no data from adequate and well-controlled trials to demonstrate the effectiveness of cefuroxime in the treatment of penicillin-resistant strains of Streptococcus pyogenes. Acute Bacterial Otitis Media caused by Streptococcus pneumoniae , Haemophilus influenzae (including beta-lactamase–producing strains), Moraxella catarrhalis (including beta-lactamase–producing strains), or Streptococcus pyogenes. Acute Bacterial Maxillary Sinusitis caused by Streptococcus pneumoniae or Haemophilus influenzae (non-beta-lactamase–producing strains only). (See CLINICAL STUDIES section.) NOTE: In view of the insufficient numbers of isolates of beta-lactamase–producing strains of Haemophilus influenzae and Moraxella catarrhalis that were obtained from clinical trials with cefuroxime axetil tablets for patients with acute bacterial maxillary sinusitis, it was not possible to adequately evaluate the effectiveness of cefuroxime axetil tablets for sinus infections known, suspected, or considered potentially to be caused by beta-lactamase–producing Haemophilus influenzae or Moraxella catarrhalis . Acute Bacterial Exacerbations of Chronic Bronchitis and Secondary Bacterial Infections of Acute Bronchitis caused by Streptococcus pneumoniae , Haemophilus influenzae (beta-lactamase negative strains), or Haemophilus parainfluenzae (beta-lactamase negative strains). (See DOSAGE AND ADMINISTRATION section and CLINICAL STUDIES section.) Uncomplicated Skin and Skin-Structure Infections caused by Staphylococcus aureus (including beta-lactamase–producing strains) or Streptococcus pyogenes. Uncomplicated Urinary Tract Infections caused by Escherichia coli or Klebsiella pneumoniae . Uncomplicated Gonorrhea, urethral and endocervical, caused by penicillinase-producing and non-penicillinase–producing strains of Neisseria gonorrhoeae and uncomplicated gonorrhea, rectal, in females, caused by non-penicillinase–producing strains of Neisseria gonorrhoeae . Early Lyme Disease (erythema migrans) caused by Borrelia burgdorferi. uuid:c132e1a7-b0b0-4d50-80f6-a1fa27f05445 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17303 biolink:treats NCIT:C27003 PMID:41385096 "[{""id"":""uuid:b0c2468c-1009-4240-a8a4-b63912de6022"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5dafa218-34b1-4d06-9a58-a59095cb67a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Morphine sulfate tablets contain morphine, an opioid analgesic, indicated for the relief of moderate to severe acute and chronic pain where use of an opioid analgesic is appropriate. uuid:3b7cd027-bd2a-4807-b759-92d564a02165 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17303 biolink:treats HP:0012532 PMID:41385096 "[{""id"":""uuid:3673715f-c9f1-4060-a090-17d954a10725"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b55ba82a-89d8-4a4a-9242-44ec39a44d81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Morphine sulfate tablets contain morphine, an opioid analgesic, indicated for the relief of moderate to severe acute and chronic pain where use of an opioid analgesic is appropriate. uuid:d78f5146-7678-41c4-bead-034b0bcb6df7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:46878853 biolink:treats HP:0003119 PMID:41385096 "[{""id"":""uuid:0e4f69e7-4749-4a1d-a7e5-db2123e614b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7c01f9d4-5f71-4b83-842a-a1bf9039fb3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Trilipix is a peroxisome proliferator receptor alpha (PPARα) activator indicated: In combination with a statin to reduce TG and increase HDL-C in patients with mixed dyslipidemia and CHD or a CHD risk equivalent who are on optimal statin therapy to achieve their LDL-C goal ( 1.1 ). As monotherapy to reduce TG in patients with severe hypertriglyceridemia ( 1.2 ). As monotherapy to reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDL-C in patients with primary hyperlipidemia or mixed dyslipidemia ( 1.3 ). Important Limitations of Use: No incremental benefit of Trilipix on cardiovascular morbidity and mortality over and above that demonstrated for statin monotherapy has been established. Fenofibrate at a dose equivalent to 135 mg of Trilipix was not shown to reduce coronary heart disease morbidity and mortality in 2 large, randomized controlled trials of patients with type 2 diabetes mellitus. uuid:642fdfa5-7420-410a-8d9a-6713fa40bcb6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:46878853 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:49b05bfe-127f-4d81-ad61-95864571ec93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:05cd00c1-0a06-4690-858b-dcdcb4a41758"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Trilipix is a peroxisome proliferator receptor alpha (PPARα) activator indicated: In combination with a statin to reduce TG and increase HDL-C in patients with mixed dyslipidemia and CHD or a CHD risk equivalent who are on optimal statin therapy to achieve their LDL-C goal ( 1.1 ). As monotherapy to reduce TG in patients with severe hypertriglyceridemia ( 1.2 ). As monotherapy to reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDL-C in patients with primary hyperlipidemia or mixed dyslipidemia ( 1.3 ). Important Limitations of Use: No incremental benefit of Trilipix on cardiovascular morbidity and mortality over and above that demonstrated for statin monotherapy has been established. Fenofibrate at a dose equivalent to 135 mg of Trilipix was not shown to reduce coronary heart disease morbidity and mortality in 2 large, randomized controlled trials of patients with type 2 diabetes mellitus. uuid:04a63779-6968-4e68-aa55-95afe8ce5fd0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:46878853 biolink:treats MONDO:0005347 PMID:41385096 "[{""id"":""uuid:a4232942-8b24-4a46-a4db-6ebd26ca44eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a9773b96-2c03-4c04-9051-0936bb045390"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Trilipix is a peroxisome proliferator receptor alpha (PPARα) activator indicated: In combination with a statin to reduce TG and increase HDL-C in patients with mixed dyslipidemia and CHD or a CHD risk equivalent who are on optimal statin therapy to achieve their LDL-C goal ( 1.1 ). As monotherapy to reduce TG in patients with severe hypertriglyceridemia ( 1.2 ). As monotherapy to reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDL-C in patients with primary hyperlipidemia or mixed dyslipidemia ( 1.3 ). Important Limitations of Use: No incremental benefit of Trilipix on cardiovascular morbidity and mortality over and above that demonstrated for statin monotherapy has been established. Fenofibrate at a dose equivalent to 135 mg of Trilipix was not shown to reduce coronary heart disease morbidity and mortality in 2 large, randomized controlled trials of patients with type 2 diabetes mellitus. uuid:7741bb69-fc60-4bac-a209-636b516ee818 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:46878853 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:5fa40cd3-7489-4021-adae-2c7730d5b4a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bdd00be3-4f96-4bf7-983e-94fd7ba98b9d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Trilipix is a peroxisome proliferator receptor alpha (PPARα) activator indicated: In combination with a statin to reduce TG and increase HDL-C in patients with mixed dyslipidemia and CHD or a CHD risk equivalent who are on optimal statin therapy to achieve their LDL-C goal ( 1.1 ). As monotherapy to reduce TG in patients with severe hypertriglyceridemia ( 1.2 ). As monotherapy to reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDL-C in patients with primary hyperlipidemia or mixed dyslipidemia ( 1.3 ). Important Limitations of Use: No incremental benefit of Trilipix on cardiovascular morbidity and mortality over and above that demonstrated for statin monotherapy has been established. Fenofibrate at a dose equivalent to 135 mg of Trilipix was not shown to reduce coronary heart disease morbidity and mortality in 2 large, randomized controlled trials of patients with type 2 diabetes mellitus. uuid:0b4b069d-772f-4e2e-a479-43c7baa76cd9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:46878853 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:e5df628b-0958-494f-b73f-a2733d085c7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8ddc50d2-237f-4a4b-a890-2ac08fde8c31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Trilipix is a peroxisome proliferator receptor alpha (PPARα) activator indicated: In combination with a statin to reduce TG and increase HDL-C in patients with mixed dyslipidemia and CHD or a CHD risk equivalent who are on optimal statin therapy to achieve their LDL-C goal ( 1.1 ). As monotherapy to reduce TG in patients with severe hypertriglyceridemia ( 1.2 ). As monotherapy to reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDL-C in patients with primary hyperlipidemia or mixed dyslipidemia ( 1.3 ). Important Limitations of Use: No incremental benefit of Trilipix on cardiovascular morbidity and mortality over and above that demonstrated for statin monotherapy has been established. Fenofibrate at a dose equivalent to 135 mg of Trilipix was not shown to reduce coronary heart disease morbidity and mortality in 2 large, randomized controlled trials of patients with type 2 diabetes mellitus. uuid:8fecd5d8-3ad1-4de6-87f9-ded1b5099476 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2648852 biolink:treats MONDO:0010602 PMID:41385096 "[{""id"":""uuid:2d0062e4-2f38-4646-8277-9ce30cc32983"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bdd74964-b435-4b02-8bb6-0dfa918ce453"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The use of RECOMBINATE [Antihemophilic Factor (Recombinant)] is indicated in hemophilia A (classical hemophilia) for the prevention and control of hemorrhagic episodes. 2 RECOMBINATE is also indicated in the perioperative management of patients with hemophilia A (classical hemophilia). RECOMBINATE can be of therapeutic value in patients with acquired Factor VIII inhibitors not exceeding 10 Bethesda Units per mL. 3 In clinical studies with RECOMBINATE, patients with inhibitors who were entered into the previously treated patient trial and those previously untreated children who have developed inhibitor activity on study, showed clinical hemostatic response when the titer of inhibitor was less than 10 Bethesda Units per mL. However, in such uses, the dosage of RECOMBINATE should be controlled by frequent laboratory determinations of circulating Factor VIII levels as well as the clinical status of the patient. RECOMBINATE is not indicated in von Willebrand’s disease. uuid:aa2de7ca-3d1d-4db4-b82a-e84197a77737 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2648852 biolink:treats MONDO:0035735 PMID:41385096 "[{""id"":""uuid:c49c5ced-c3b6-4108-95a2-8e695ee040c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7daee1ad-2270-4b7b-9088-ba1a841c7c71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The use of RECOMBINATE [Antihemophilic Factor (Recombinant)] is indicated in hemophilia A (classical hemophilia) for the prevention and control of hemorrhagic episodes. 2 RECOMBINATE is also indicated in the perioperative management of patients with hemophilia A (classical hemophilia). RECOMBINATE can be of therapeutic value in patients with acquired Factor VIII inhibitors not exceeding 10 Bethesda Units per mL. 3 In clinical studies with RECOMBINATE, patients with inhibitors who were entered into the previously treated patient trial and those previously untreated children who have developed inhibitor activity on study, showed clinical hemostatic response when the titer of inhibitor was less than 10 Bethesda Units per mL. However, in such uses, the dosage of RECOMBINATE should be controlled by frequent laboratory determinations of circulating Factor VIII levels as well as the clinical status of the patient. RECOMBINATE is not indicated in von Willebrand’s disease. uuid:8c3c9ef7-9b67-45b8-8e4f-51d7d5b8ffeb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2648852 biolink:treats MONDO:0024574 PMID:41385096 "[{""id"":""uuid:78fa8d42-c2e4-47ae-9bd2-3c2eed9ecede"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:65bcfb40-e6fe-403a-95b9-83edeedd9b8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The use of RECOMBINATE [Antihemophilic Factor (Recombinant)] is indicated in hemophilia A (classical hemophilia) for the prevention and control of hemorrhagic episodes. 2 RECOMBINATE is also indicated in the perioperative management of patients with hemophilia A (classical hemophilia). RECOMBINATE can be of therapeutic value in patients with acquired Factor VIII inhibitors not exceeding 10 Bethesda Units per mL. 3 In clinical studies with RECOMBINATE, patients with inhibitors who were entered into the previously treated patient trial and those previously untreated children who have developed inhibitor activity on study, showed clinical hemostatic response when the titer of inhibitor was less than 10 Bethesda Units per mL. However, in such uses, the dosage of RECOMBINATE should be controlled by frequent laboratory determinations of circulating Factor VIII levels as well as the clinical status of the patient. RECOMBINATE is not indicated in von Willebrand’s disease. uuid:a12c5c0e-7adf-4e1f-8306-b15e080dc845 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841546 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:43a02497-7fae-4d8e-a26a-3ba3ffa855f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f40cb6e0-3476-4d46-ad9d-096036baf88a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TEVETEN ® HCT is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensives such as calcium channel blockers. This fixed dose combination is not indicated for initial therapy (see DOSAGE AND ADMINISTRATION ). uuid:26c1a8db-d439-434b-9d69-b604e62aef57 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:189563 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:44245b64-f641-4687-a1ef-0cec2bd01b12"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b9e13ab1-2f25-496e-afc9-0201de671a55"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BYSTOLIC is a beta-adrenergic blocking agent indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) uuid:bc1795cc-7dd2-430e-a88f-68955e29b5fb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:189563 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:b8e22943-bde1-48a2-855f-d1dcbe605e48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3865dd0f-dc67-42bf-8a26-b5eeef5a6215"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BYSTOLIC is a beta-adrenergic blocking agent indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) uuid:e93e8ced-f880-4043-8992-eb5ecc264a8e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:189563 biolink:treats MONDO:0006652 PMID:41385096 "[{""id"":""uuid:6f4d6c10-ef91-4131-ab83-f019d304f0d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ef8d5e5b-bdb6-45b1-9638-a8265d5d9e26"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BYSTOLIC is a beta-adrenergic blocking agent indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) uuid:307d64b9-dae1-417e-bb38-b625bf2ebc6d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:216653 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:4e20da92-5099-4844-be24-d35686deeabe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a5fe1a1f-f4fa-41c3-85ea-c353436c4694"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diovan HCT (valsartan and hydrochlorothiazide, USP) is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including hydrochlorothiazide and the ARB class to which valsartan principally belongs. There are no controlled trials demonstrating risk reduction with Diovan HCT. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Diovan HCT may be used in patients whose blood pressure is not adequately controlled on monotherapy. Diovan HCT may be used as initial therapy in patients who are likely to need multiple drugs to achieve blood pressure goals. The choice of Diovan HCT as initial therapy for hypertension should be based on an assessment of potential benefits and risks. Patients with stage 2 hypertension are at a relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from the high dose multifactorial trial [ see Clinical Studies (14.1)] provides estimates of the probability of reaching a target blood pressure with Diovan HCT compared to valsartan or hydrochlorothiazide monotherapy. The figures below provide estimates of the likelihood of achieving systolic or diastolic blood pressure control with Diovan HCT 320/25 mg, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling. The estimated likelihood at the right tail of each curve is less reliable due to small numbers of subjects with high baseline blood pressures. Figure 1 : Probability of Achieving Systolic Blood Pressure <140 mmHg at Week 8 Figure 2 : Probability of Achieving Diastolic Blood Pressure <90 mmHg at Week 8 Figure 3 : Probability of Achieving Systolic Blood Pressure <130 mmHg at Week 8 Figure 4 : Probability of Achieving Diastolic Blood Pressure <80 mmHg at Week 8 For example, a patient with a baseline blood pressure of 160/100 mmHg has about a 41% likelihood of achieving a goal of <140 mmHg (systolic) and 60% likelihood of achieving <90 mmHg (diastolic) on valsartan alone and the likelihood of achieving these goals on HCTZ alone is about 50% (systolic) or 57% (diastolic). The likelihood of achieving these goals on Diovan HCT rises to about 84% (systolic) or 80% (diastolic). The likelihood of achieving these goals on placebo is about 23% (systolic) or 36% (diastolic). uuid:2641751c-d9a6-4f56-bd1b-718a30418750 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:216653 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:7dab503b-177c-45c3-9168-1d3ecfd529b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6b3099ea-b5ca-4ecc-8561-1a23c701ff28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diovan HCT (valsartan and hydrochlorothiazide, USP) is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including hydrochlorothiazide and the ARB class to which valsartan principally belongs. There are no controlled trials demonstrating risk reduction with Diovan HCT. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Diovan HCT may be used in patients whose blood pressure is not adequately controlled on monotherapy. Diovan HCT may be used as initial therapy in patients who are likely to need multiple drugs to achieve blood pressure goals. The choice of Diovan HCT as initial therapy for hypertension should be based on an assessment of potential benefits and risks. Patients with stage 2 hypertension are at a relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from the high dose multifactorial trial [ see Clinical Studies (14.1)] provides estimates of the probability of reaching a target blood pressure with Diovan HCT compared to valsartan or hydrochlorothiazide monotherapy. The figures below provide estimates of the likelihood of achieving systolic or diastolic blood pressure control with Diovan HCT 320/25 mg, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling. The estimated likelihood at the right tail of each curve is less reliable due to small numbers of subjects with high baseline blood pressures. Figure 1 : Probability of Achieving Systolic Blood Pressure <140 mmHg at Week 8 Figure 2 : Probability of Achieving Diastolic Blood Pressure <90 mmHg at Week 8 Figure 3 : Probability of Achieving Systolic Blood Pressure <130 mmHg at Week 8 Figure 4 : Probability of Achieving Diastolic Blood Pressure <80 mmHg at Week 8 For example, a patient with a baseline blood pressure of 160/100 mmHg has about a 41% likelihood of achieving a goal of <140 mmHg (systolic) and 60% likelihood of achieving <90 mmHg (diastolic) on valsartan alone and the likelihood of achieving these goals on HCTZ alone is about 50% (systolic) or 57% (diastolic). The likelihood of achieving these goals on Diovan HCT rises to about 84% (systolic) or 80% (diastolic). The likelihood of achieving these goals on placebo is about 23% (systolic) or 36% (diastolic). uuid:7e250e06-0006-421e-90a1-ea42c75afe8d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:216653 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:6d0caaa6-5c18-41f0-8170-7a1f9b3d8f06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c3a6dde8-a5ce-49b0-b88e-9e326fe7adda"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diovan HCT (valsartan and hydrochlorothiazide, USP) is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including hydrochlorothiazide and the ARB class to which valsartan principally belongs. There are no controlled trials demonstrating risk reduction with Diovan HCT. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Diovan HCT may be used in patients whose blood pressure is not adequately controlled on monotherapy. Diovan HCT may be used as initial therapy in patients who are likely to need multiple drugs to achieve blood pressure goals. The choice of Diovan HCT as initial therapy for hypertension should be based on an assessment of potential benefits and risks. Patients with stage 2 hypertension are at a relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from the high dose multifactorial trial [ see Clinical Studies (14.1)] provides estimates of the probability of reaching a target blood pressure with Diovan HCT compared to valsartan or hydrochlorothiazide monotherapy. The figures below provide estimates of the likelihood of achieving systolic or diastolic blood pressure control with Diovan HCT 320/25 mg, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling. The estimated likelihood at the right tail of each curve is less reliable due to small numbers of subjects with high baseline blood pressures. Figure 1 : Probability of Achieving Systolic Blood Pressure <140 mmHg at Week 8 Figure 2 : Probability of Achieving Diastolic Blood Pressure <90 mmHg at Week 8 Figure 3 : Probability of Achieving Systolic Blood Pressure <130 mmHg at Week 8 Figure 4 : Probability of Achieving Diastolic Blood Pressure <80 mmHg at Week 8 For example, a patient with a baseline blood pressure of 160/100 mmHg has about a 41% likelihood of achieving a goal of <140 mmHg (systolic) and 60% likelihood of achieving <90 mmHg (diastolic) on valsartan alone and the likelihood of achieving these goals on HCTZ alone is about 50% (systolic) or 57% (diastolic). The likelihood of achieving these goals on Diovan HCT rises to about 84% (systolic) or 80% (diastolic). The likelihood of achieving these goals on placebo is about 23% (systolic) or 36% (diastolic). uuid:8c22738c-7368-4998-bbe1-c52e2be92fac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:216653 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:b8a88b88-2f9a-4d38-806b-23e03b39afa4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0c53b616-ca4a-4851-ae05-80e225eac1d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diovan HCT (valsartan and hydrochlorothiazide, USP) is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including hydrochlorothiazide and the ARB class to which valsartan principally belongs. There are no controlled trials demonstrating risk reduction with Diovan HCT. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Diovan HCT may be used in patients whose blood pressure is not adequately controlled on monotherapy. Diovan HCT may be used as initial therapy in patients who are likely to need multiple drugs to achieve blood pressure goals. The choice of Diovan HCT as initial therapy for hypertension should be based on an assessment of potential benefits and risks. Patients with stage 2 hypertension are at a relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from the high dose multifactorial trial [ see Clinical Studies (14.1)] provides estimates of the probability of reaching a target blood pressure with Diovan HCT compared to valsartan or hydrochlorothiazide monotherapy. The figures below provide estimates of the likelihood of achieving systolic or diastolic blood pressure control with Diovan HCT 320/25 mg, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling. The estimated likelihood at the right tail of each curve is less reliable due to small numbers of subjects with high baseline blood pressures. Figure 1 : Probability of Achieving Systolic Blood Pressure <140 mmHg at Week 8 Figure 2 : Probability of Achieving Diastolic Blood Pressure <90 mmHg at Week 8 Figure 3 : Probability of Achieving Systolic Blood Pressure <130 mmHg at Week 8 Figure 4 : Probability of Achieving Diastolic Blood Pressure <80 mmHg at Week 8 For example, a patient with a baseline blood pressure of 160/100 mmHg has about a 41% likelihood of achieving a goal of <140 mmHg (systolic) and 60% likelihood of achieving <90 mmHg (diastolic) on valsartan alone and the likelihood of achieving these goals on HCTZ alone is about 50% (systolic) or 57% (diastolic). The likelihood of achieving these goals on Diovan HCT rises to about 84% (systolic) or 80% (diastolic). The likelihood of achieving these goals on placebo is about 23% (systolic) or 36% (diastolic). uuid:05adc6b6-4e9d-4c9d-a193-a13c53b6eacf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1152286 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:c605dfc1-ef5a-4826-8a41-1a3d97273fed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0a848180-3780-4758-946d-5ce364f7ae72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azor is indicated for the treatment of hypertension, alone or with other antihypertensive agents , to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Azor. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Azor may also be used as initial therapy in patients who are likely to need multiple antihypertensive agents to achieve their blood pressure goals. Patients with moderate or severe hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from an 8-week, placebo-controlled, parallel-group factorial study [see Clinical Studies (14.1) ] provide estimates of the probability of reaching a blood pressure goal with Azor compared to amlodipine or olmesartan medoxomil monotherapy. The figures below provide estimates of the likelihood of achieving the targeted systolic or diastolic blood pressure goals with Azor 10/40 mg compared with amlodipine or olmesartan medoxomil monotherapy, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling from all available data of that treatment group. The right tail of each curve is less reliable because of small numbers of subjects with high baseline blood pressures. Figure 1: Probability of Achieving Systolic Blood Pressure (SBP) <140 mmHg at Week 8 With LOCF Figure 2: Probability of Achieving Diastolic Blood Pressure (DBP) <90 mmHg at Week 8 With LOCF Figure 3: Probability of Achieving Systolic Blood Pressure (SBP) <130 mmHg at Week 8 With LOCF Figure 4: Probability of Achieving Diastolic Blood Pressure (DBP) <80 mmHg at Week 8 With LOCF The figures above provide an approximation of the likelihood of reaching a targeted blood pressure goal (e.g., Week 8 SBP <140 mmHg or <130 mmHg or a DBP <90 mmHg or <80 mmHg) for the high-dose treatment groups evaluated in the study. Azor 5/20 mg, the lowest dose combination treatment group, increases the probability of reaching blood pressure goal compared with the highest dose monotherapies, amlodipine 10 mg and olmesartan medoxomil 40 mg. For example, a patient with a baseline blood pressure of 160/100 mmHg has about a 48% likelihood of achieving a goal of <140 mmHg (systolic) and a 51% likelihood of achieving a goal of <90 mmHg (diastolic) on monotherapy with olmesartan medoxomil 40 mg, and about a 46% likelihood of achieving a goal of <140 mmHg (systolic) and a 60% likelihood of achieving a goal of <90 mmHg (diastolic) on monotherapy with amlodipine 10 mg. The likelihood of achieving these same goals increases to 63% (systolic) and 71% (diastolic) on Azor 5/20 mg, and to 68% (systolic) and 85% (diastolic) on Azor 10/40 mg. uuid:2974caa6-ce63-4f5e-a7ce-294525791a56 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1152286 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:ed172314-0fd1-4037-9949-d38e40bd1e9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2b94a176-a382-461a-a30c-1121f1cd44b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azor is indicated for the treatment of hypertension, alone or with other antihypertensive agents , to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Azor. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Azor may also be used as initial therapy in patients who are likely to need multiple antihypertensive agents to achieve their blood pressure goals. Patients with moderate or severe hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from an 8-week, placebo-controlled, parallel-group factorial study [see Clinical Studies (14.1) ] provide estimates of the probability of reaching a blood pressure goal with Azor compared to amlodipine or olmesartan medoxomil monotherapy. The figures below provide estimates of the likelihood of achieving the targeted systolic or diastolic blood pressure goals with Azor 10/40 mg compared with amlodipine or olmesartan medoxomil monotherapy, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling from all available data of that treatment group. The right tail of each curve is less reliable because of small numbers of subjects with high baseline blood pressures. Figure 1: Probability of Achieving Systolic Blood Pressure (SBP) <140 mmHg at Week 8 With LOCF Figure 2: Probability of Achieving Diastolic Blood Pressure (DBP) <90 mmHg at Week 8 With LOCF Figure 3: Probability of Achieving Systolic Blood Pressure (SBP) <130 mmHg at Week 8 With LOCF Figure 4: Probability of Achieving Diastolic Blood Pressure (DBP) <80 mmHg at Week 8 With LOCF The figures above provide an approximation of the likelihood of reaching a targeted blood pressure goal (e.g., Week 8 SBP <140 mmHg or <130 mmHg or a DBP <90 mmHg or <80 mmHg) for the high-dose treatment groups evaluated in the study. Azor 5/20 mg, the lowest dose combination treatment group, increases the probability of reaching blood pressure goal compared with the highest dose monotherapies, amlodipine 10 mg and olmesartan medoxomil 40 mg. For example, a patient with a baseline blood pressure of 160/100 mmHg has about a 48% likelihood of achieving a goal of <140 mmHg (systolic) and a 51% likelihood of achieving a goal of <90 mmHg (diastolic) on monotherapy with olmesartan medoxomil 40 mg, and about a 46% likelihood of achieving a goal of <140 mmHg (systolic) and a 60% likelihood of achieving a goal of <90 mmHg (diastolic) on monotherapy with amlodipine 10 mg. The likelihood of achieving these same goals increases to 63% (systolic) and 71% (diastolic) on Azor 5/20 mg, and to 68% (systolic) and 85% (diastolic) on Azor 10/40 mg. uuid:3113289b-ee97-4f3c-a3e4-3db18f6d9303 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1152286 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:4cb5a277-4a1b-40b5-9a5d-0555270b4b24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:789cb1f7-e220-49d7-8d18-fcba5531fdea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azor is indicated for the treatment of hypertension, alone or with other antihypertensive agents , to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Azor. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Azor may also be used as initial therapy in patients who are likely to need multiple antihypertensive agents to achieve their blood pressure goals. Patients with moderate or severe hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from an 8-week, placebo-controlled, parallel-group factorial study [see Clinical Studies (14.1) ] provide estimates of the probability of reaching a blood pressure goal with Azor compared to amlodipine or olmesartan medoxomil monotherapy. The figures below provide estimates of the likelihood of achieving the targeted systolic or diastolic blood pressure goals with Azor 10/40 mg compared with amlodipine or olmesartan medoxomil monotherapy, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling from all available data of that treatment group. The right tail of each curve is less reliable because of small numbers of subjects with high baseline blood pressures. Figure 1: Probability of Achieving Systolic Blood Pressure (SBP) <140 mmHg at Week 8 With LOCF Figure 2: Probability of Achieving Diastolic Blood Pressure (DBP) <90 mmHg at Week 8 With LOCF Figure 3: Probability of Achieving Systolic Blood Pressure (SBP) <130 mmHg at Week 8 With LOCF Figure 4: Probability of Achieving Diastolic Blood Pressure (DBP) <80 mmHg at Week 8 With LOCF The figures above provide an approximation of the likelihood of reaching a targeted blood pressure goal (e.g., Week 8 SBP <140 mmHg or <130 mmHg or a DBP <90 mmHg or <80 mmHg) for the high-dose treatment groups evaluated in the study. Azor 5/20 mg, the lowest dose combination treatment group, increases the probability of reaching blood pressure goal compared with the highest dose monotherapies, amlodipine 10 mg and olmesartan medoxomil 40 mg. For example, a patient with a baseline blood pressure of 160/100 mmHg has about a 48% likelihood of achieving a goal of <140 mmHg (systolic) and a 51% likelihood of achieving a goal of <90 mmHg (diastolic) on monotherapy with olmesartan medoxomil 40 mg, and about a 46% likelihood of achieving a goal of <140 mmHg (systolic) and a 60% likelihood of achieving a goal of <90 mmHg (diastolic) on monotherapy with amlodipine 10 mg. The likelihood of achieving these same goals increases to 63% (systolic) and 71% (diastolic) on Azor 5/20 mg, and to 68% (systolic) and 85% (diastolic) on Azor 10/40 mg. uuid:278ac5d6-c5ed-4e6c-bded-68f5bd1ab748 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1152286 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:2b991728-810e-4e8b-bb31-94dd79929502"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a665068c-015f-47a2-bd24-a5bc6080a2c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azor is indicated for the treatment of hypertension, alone or with other antihypertensive agents , to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Azor. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Azor may also be used as initial therapy in patients who are likely to need multiple antihypertensive agents to achieve their blood pressure goals. Patients with moderate or severe hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from an 8-week, placebo-controlled, parallel-group factorial study [see Clinical Studies (14.1) ] provide estimates of the probability of reaching a blood pressure goal with Azor compared to amlodipine or olmesartan medoxomil monotherapy. The figures below provide estimates of the likelihood of achieving the targeted systolic or diastolic blood pressure goals with Azor 10/40 mg compared with amlodipine or olmesartan medoxomil monotherapy, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling from all available data of that treatment group. The right tail of each curve is less reliable because of small numbers of subjects with high baseline blood pressures. Figure 1: Probability of Achieving Systolic Blood Pressure (SBP) <140 mmHg at Week 8 With LOCF Figure 2: Probability of Achieving Diastolic Blood Pressure (DBP) <90 mmHg at Week 8 With LOCF Figure 3: Probability of Achieving Systolic Blood Pressure (SBP) <130 mmHg at Week 8 With LOCF Figure 4: Probability of Achieving Diastolic Blood Pressure (DBP) <80 mmHg at Week 8 With LOCF The figures above provide an approximation of the likelihood of reaching a targeted blood pressure goal (e.g., Week 8 SBP <140 mmHg or <130 mmHg or a DBP <90 mmHg or <80 mmHg) for the high-dose treatment groups evaluated in the study. Azor 5/20 mg, the lowest dose combination treatment group, increases the probability of reaching blood pressure goal compared with the highest dose monotherapies, amlodipine 10 mg and olmesartan medoxomil 40 mg. For example, a patient with a baseline blood pressure of 160/100 mmHg has about a 48% likelihood of achieving a goal of <140 mmHg (systolic) and a 51% likelihood of achieving a goal of <90 mmHg (diastolic) on monotherapy with olmesartan medoxomil 40 mg, and about a 46% likelihood of achieving a goal of <140 mmHg (systolic) and a 60% likelihood of achieving a goal of <90 mmHg (diastolic) on monotherapy with amlodipine 10 mg. The likelihood of achieving these same goals increases to 63% (systolic) and 71% (diastolic) on Azor 5/20 mg, and to 68% (systolic) and 85% (diastolic) on Azor 10/40 mg. uuid:ecb322c6-7a6f-454b-95e6-cc0d1dd565e7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1152286 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:9434a71f-2f8b-485a-91b8-43c572bab779"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:97408199-d5b7-49e9-a7d1-0cddc32666ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azor is indicated for the treatment of hypertension, alone or with other antihypertensive agents , to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Azor. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Azor may also be used as initial therapy in patients who are likely to need multiple antihypertensive agents to achieve their blood pressure goals. Patients with moderate or severe hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from an 8-week, placebo-controlled, parallel-group factorial study [see Clinical Studies (14.1) ] provide estimates of the probability of reaching a blood pressure goal with Azor compared to amlodipine or olmesartan medoxomil monotherapy. The figures below provide estimates of the likelihood of achieving the targeted systolic or diastolic blood pressure goals with Azor 10/40 mg compared with amlodipine or olmesartan medoxomil monotherapy, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling from all available data of that treatment group. The right tail of each curve is less reliable because of small numbers of subjects with high baseline blood pressures. Figure 1: Probability of Achieving Systolic Blood Pressure (SBP) <140 mmHg at Week 8 With LOCF Figure 2: Probability of Achieving Diastolic Blood Pressure (DBP) <90 mmHg at Week 8 With LOCF Figure 3: Probability of Achieving Systolic Blood Pressure (SBP) <130 mmHg at Week 8 With LOCF Figure 4: Probability of Achieving Diastolic Blood Pressure (DBP) <80 mmHg at Week 8 With LOCF The figures above provide an approximation of the likelihood of reaching a targeted blood pressure goal (e.g., Week 8 SBP <140 mmHg or <130 mmHg or a DBP <90 mmHg or <80 mmHg) for the high-dose treatment groups evaluated in the study. Azor 5/20 mg, the lowest dose combination treatment group, increases the probability of reaching blood pressure goal compared with the highest dose monotherapies, amlodipine 10 mg and olmesartan medoxomil 40 mg. For example, a patient with a baseline blood pressure of 160/100 mmHg has about a 48% likelihood of achieving a goal of <140 mmHg (systolic) and a 51% likelihood of achieving a goal of <90 mmHg (diastolic) on monotherapy with olmesartan medoxomil 40 mg, and about a 46% likelihood of achieving a goal of <140 mmHg (systolic) and a 60% likelihood of achieving a goal of <90 mmHg (diastolic) on monotherapy with amlodipine 10 mg. The likelihood of achieving these same goals increases to 63% (systolic) and 71% (diastolic) on Azor 5/20 mg, and to 68% (systolic) and 85% (diastolic) on Azor 10/40 mg. uuid:de1dd06f-11b0-4871-bff5-13f2773ffee6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1152286 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:7334f2fb-f41a-48cc-bb7a-6b121d4f9a3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:757dba53-678d-498a-b011-5f3892784db6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azor is indicated for the treatment of hypertension, alone or with other antihypertensive agents , to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Azor. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Azor may also be used as initial therapy in patients who are likely to need multiple antihypertensive agents to achieve their blood pressure goals. Patients with moderate or severe hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from an 8-week, placebo-controlled, parallel-group factorial study [see Clinical Studies (14.1) ] provide estimates of the probability of reaching a blood pressure goal with Azor compared to amlodipine or olmesartan medoxomil monotherapy. The figures below provide estimates of the likelihood of achieving the targeted systolic or diastolic blood pressure goals with Azor 10/40 mg compared with amlodipine or olmesartan medoxomil monotherapy, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling from all available data of that treatment group. The right tail of each curve is less reliable because of small numbers of subjects with high baseline blood pressures. Figure 1: Probability of Achieving Systolic Blood Pressure (SBP) <140 mmHg at Week 8 With LOCF Figure 2: Probability of Achieving Diastolic Blood Pressure (DBP) <90 mmHg at Week 8 With LOCF Figure 3: Probability of Achieving Systolic Blood Pressure (SBP) <130 mmHg at Week 8 With LOCF Figure 4: Probability of Achieving Diastolic Blood Pressure (DBP) <80 mmHg at Week 8 With LOCF The figures above provide an approximation of the likelihood of reaching a targeted blood pressure goal (e.g., Week 8 SBP <140 mmHg or <130 mmHg or a DBP <90 mmHg or <80 mmHg) for the high-dose treatment groups evaluated in the study. Azor 5/20 mg, the lowest dose combination treatment group, increases the probability of reaching blood pressure goal compared with the highest dose monotherapies, amlodipine 10 mg and olmesartan medoxomil 40 mg. For example, a patient with a baseline blood pressure of 160/100 mmHg has about a 48% likelihood of achieving a goal of <140 mmHg (systolic) and a 51% likelihood of achieving a goal of <90 mmHg (diastolic) on monotherapy with olmesartan medoxomil 40 mg, and about a 46% likelihood of achieving a goal of <140 mmHg (systolic) and a 60% likelihood of achieving a goal of <90 mmHg (diastolic) on monotherapy with amlodipine 10 mg. The likelihood of achieving these same goals increases to 63% (systolic) and 71% (diastolic) on Azor 5/20 mg, and to 68% (systolic) and 85% (diastolic) on Azor 10/40 mg. uuid:3d951f7b-7511-49b7-b5c7-36bf90fde658 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1152286 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:d579fce6-6645-4f48-938f-d58e23e064e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:95e01f6e-65c6-4606-9f5d-84f1cea25c43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azor is indicated for the treatment of hypertension, alone or with other antihypertensive agents , to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Azor. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Azor may also be used as initial therapy in patients who are likely to need multiple antihypertensive agents to achieve their blood pressure goals. Patients with moderate or severe hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from an 8-week, placebo-controlled, parallel-group factorial study [see Clinical Studies (14.1) ] provide estimates of the probability of reaching a blood pressure goal with Azor compared to amlodipine or olmesartan medoxomil monotherapy. The figures below provide estimates of the likelihood of achieving the targeted systolic or diastolic blood pressure goals with Azor 10/40 mg compared with amlodipine or olmesartan medoxomil monotherapy, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling from all available data of that treatment group. The right tail of each curve is less reliable because of small numbers of subjects with high baseline blood pressures. Figure 1: Probability of Achieving Systolic Blood Pressure (SBP) <140 mmHg at Week 8 With LOCF Figure 2: Probability of Achieving Diastolic Blood Pressure (DBP) <90 mmHg at Week 8 With LOCF Figure 3: Probability of Achieving Systolic Blood Pressure (SBP) <130 mmHg at Week 8 With LOCF Figure 4: Probability of Achieving Diastolic Blood Pressure (DBP) <80 mmHg at Week 8 With LOCF The figures above provide an approximation of the likelihood of reaching a targeted blood pressure goal (e.g., Week 8 SBP <140 mmHg or <130 mmHg or a DBP <90 mmHg or <80 mmHg) for the high-dose treatment groups evaluated in the study. Azor 5/20 mg, the lowest dose combination treatment group, increases the probability of reaching blood pressure goal compared with the highest dose monotherapies, amlodipine 10 mg and olmesartan medoxomil 40 mg. For example, a patient with a baseline blood pressure of 160/100 mmHg has about a 48% likelihood of achieving a goal of <140 mmHg (systolic) and a 51% likelihood of achieving a goal of <90 mmHg (diastolic) on monotherapy with olmesartan medoxomil 40 mg, and about a 46% likelihood of achieving a goal of <140 mmHg (systolic) and a 60% likelihood of achieving a goal of <90 mmHg (diastolic) on monotherapy with amlodipine 10 mg. The likelihood of achieving these same goals increases to 63% (systolic) and 71% (diastolic) on Azor 5/20 mg, and to 68% (systolic) and 85% (diastolic) on Azor 10/40 mg. uuid:b8f6744c-f580-4db8-af0e-1aa0ea411f2d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1152286 biolink:treats MONDO:0001106 PMID:41385096 "[{""id"":""uuid:422223e0-5d53-4753-8d0f-b4a8890549e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2485a02f-6616-41cc-8097-923f3a5ddbef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azor is indicated for the treatment of hypertension, alone or with other antihypertensive agents , to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Azor. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Azor may also be used as initial therapy in patients who are likely to need multiple antihypertensive agents to achieve their blood pressure goals. Patients with moderate or severe hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from an 8-week, placebo-controlled, parallel-group factorial study [see Clinical Studies (14.1) ] provide estimates of the probability of reaching a blood pressure goal with Azor compared to amlodipine or olmesartan medoxomil monotherapy. The figures below provide estimates of the likelihood of achieving the targeted systolic or diastolic blood pressure goals with Azor 10/40 mg compared with amlodipine or olmesartan medoxomil monotherapy, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling from all available data of that treatment group. The right tail of each curve is less reliable because of small numbers of subjects with high baseline blood pressures. Figure 1: Probability of Achieving Systolic Blood Pressure (SBP) <140 mmHg at Week 8 With LOCF Figure 2: Probability of Achieving Diastolic Blood Pressure (DBP) <90 mmHg at Week 8 With LOCF Figure 3: Probability of Achieving Systolic Blood Pressure (SBP) <130 mmHg at Week 8 With LOCF Figure 4: Probability of Achieving Diastolic Blood Pressure (DBP) <80 mmHg at Week 8 With LOCF The figures above provide an approximation of the likelihood of reaching a targeted blood pressure goal (e.g., Week 8 SBP <140 mmHg or <130 mmHg or a DBP <90 mmHg or <80 mmHg) for the high-dose treatment groups evaluated in the study. Azor 5/20 mg, the lowest dose combination treatment group, increases the probability of reaching blood pressure goal compared with the highest dose monotherapies, amlodipine 10 mg and olmesartan medoxomil 40 mg. For example, a patient with a baseline blood pressure of 160/100 mmHg has about a 48% likelihood of achieving a goal of <140 mmHg (systolic) and a 51% likelihood of achieving a goal of <90 mmHg (diastolic) on monotherapy with olmesartan medoxomil 40 mg, and about a 46% likelihood of achieving a goal of <140 mmHg (systolic) and a 60% likelihood of achieving a goal of <90 mmHg (diastolic) on monotherapy with amlodipine 10 mg. The likelihood of achieving these same goals increases to 63% (systolic) and 71% (diastolic) on Azor 5/20 mg, and to 68% (systolic) and 85% (diastolic) on Azor 10/40 mg. uuid:03af7390-8a9b-41a9-a644-fd1f56cffba9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1152286 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:c30251f9-bebc-42e2-b636-c124f76e6906"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:114a4824-8637-425c-9ff1-3f0533304efb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azor is indicated for the treatment of hypertension, alone or with other antihypertensive agents , to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Azor. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Azor may also be used as initial therapy in patients who are likely to need multiple antihypertensive agents to achieve their blood pressure goals. Patients with moderate or severe hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from an 8-week, placebo-controlled, parallel-group factorial study [see Clinical Studies (14.1) ] provide estimates of the probability of reaching a blood pressure goal with Azor compared to amlodipine or olmesartan medoxomil monotherapy. The figures below provide estimates of the likelihood of achieving the targeted systolic or diastolic blood pressure goals with Azor 10/40 mg compared with amlodipine or olmesartan medoxomil monotherapy, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling from all available data of that treatment group. The right tail of each curve is less reliable because of small numbers of subjects with high baseline blood pressures. Figure 1: Probability of Achieving Systolic Blood Pressure (SBP) <140 mmHg at Week 8 With LOCF Figure 2: Probability of Achieving Diastolic Blood Pressure (DBP) <90 mmHg at Week 8 With LOCF Figure 3: Probability of Achieving Systolic Blood Pressure (SBP) <130 mmHg at Week 8 With LOCF Figure 4: Probability of Achieving Diastolic Blood Pressure (DBP) <80 mmHg at Week 8 With LOCF The figures above provide an approximation of the likelihood of reaching a targeted blood pressure goal (e.g., Week 8 SBP <140 mmHg or <130 mmHg or a DBP <90 mmHg or <80 mmHg) for the high-dose treatment groups evaluated in the study. Azor 5/20 mg, the lowest dose combination treatment group, increases the probability of reaching blood pressure goal compared with the highest dose monotherapies, amlodipine 10 mg and olmesartan medoxomil 40 mg. For example, a patient with a baseline blood pressure of 160/100 mmHg has about a 48% likelihood of achieving a goal of <140 mmHg (systolic) and a 51% likelihood of achieving a goal of <90 mmHg (diastolic) on monotherapy with olmesartan medoxomil 40 mg, and about a 46% likelihood of achieving a goal of <140 mmHg (systolic) and a 60% likelihood of achieving a goal of <90 mmHg (diastolic) on monotherapy with amlodipine 10 mg. The likelihood of achieving these same goals increases to 63% (systolic) and 71% (diastolic) on Azor 5/20 mg, and to 68% (systolic) and 85% (diastolic) on Azor 10/40 mg. uuid:2dc1ca28-371e-456e-b442-7adbe4ba38e5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9927 biolink:treats HP:0005162 PMID:41385096 "[{""id"":""uuid:42cfe676-4a4b-43c6-b49f-37c7c91f7ea3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:73b71b9d-b331-4fa7-b73d-81125769d312"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diovan is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension , to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.1 ) Treatment of heart failure (NYHA class II-IV); Diovan significantly reduced hospitalization for heart failure ( 1.2 ) Reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction ( 1.3 ) uuid:740258a8-28ec-418f-b13b-7f3886cc200b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9927 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:b4ab3c76-921a-48e7-81d8-055a16a31e05"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8aaed728-66f9-47ed-b7e5-da327be73e2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diovan is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension , to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.1 ) Treatment of heart failure (NYHA class II-IV); Diovan significantly reduced hospitalization for heart failure ( 1.2 ) Reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction ( 1.3 ) uuid:d92a6fb6-70f6-4062-ba11-e812c517cd50 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:722125 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:7d3b61e2-b1cb-4644-9bb3-53c1325f5774"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6ee6cf60-930a-4d10-81cf-be27b4f9620c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:104ad23f-fd7c-4888-b945-835a49fb2abd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Exforge is the combination tablet of amlodipine, a dihydropyridine calcium channel blocker (DHP CCB), and valsartan, an angiotensin II receptor blocker (ARB). Exforge is indicated for the treatment of hypertension: In patients not adequately controlled on monotherapy (1) As initial therapy in patients likely to need multiple drugs to achieve their blood pressure goals (1).|[PMDA] A new combination drug indicated for the treatment of hypertension. uuid:7dd0498f-59bb-4d6e-99b0-bcf3a6bd6d67 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31933 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:bda8107b-ace2-4383-b031-430534fcde78"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:545669ea-be83-4339-82a9-38da9404d965"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PATANASE Nasal Spray is an H 1 receptor antagonist indicated for the relief of the symptoms of seasonal allergic rhinitis in adults and children 6 years of age and older. (1) uuid:70c7da51-c446-4dab-be40-a6cbb2b20777 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7865 biolink:treats NCIT:C27003 PMID:41385096 "[{""id"":""uuid:1cdb31a4-6c7f-41bd-bd83-96a68bed5f92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f454ac3a-c1f1-4868-8ba7-d3ca91ca7a4c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OPANA is indicated for the relief of moderate to severe acute pain where the use of an opioid is appropriate. uuid:4a1ba7ca-6f00-4fa8-a2af-ec31560b2e05 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:601027 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:6f57ab78-cbdd-4017-9c0d-09e98e732935"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:aeb2fc19-cc6a-4ee4-b44b-7805b94c4cc0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0d7c38eb-22d8-4c87-95bd-980a428ae4aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tekturna is a renin inhibitor (RI) indicated for: The treatment of hypertension, to lower blood pressure (1.1) Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.|[PMDA] A drug with a new active ingredient indicated for the treatment of hypertension. uuid:96d74374-1d25-47b0-92ce-b76619116119 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5134 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:1cafeee9-746b-4b10-8992-d41f24a08c21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:57fe310e-c662-4a22-a591-33a7b89e7fe8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FLOVENT ® HFA Inhalation Aerosol is indicated for the maintenance treatment of asthma as prophylactic therapy in patients aged 4 years and older. It is also indicated for patients requiring oral corticosteroid therapy for asthma. Many of these patients may be able to reduce or eliminate their requirement for oral corticosteroids over time. FLOVENT HFA Inhalation Aerosol is NOT indicated for the relief of acute bronchospasm. uuid:4a3d6cb0-f07c-4a9a-97c1-1c925fc0d9a1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3207 biolink:treats MONDO:0005011 PMID:41385096 "[{""id"":""uuid:a00bd320-53c8-4a67-a02e-14c24f48fb57"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:268bc398-f940-48ee-8abd-f1c775d5e502"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENTOCORT EC is indicated for the treatment of mild to moderate active Crohn's disease involving the iluem and/or the ascending colon and the maintenance of clinical remission of mild to moderate Crohn's disease involving the ileum and/or the ascending colon for up to 3 months. uuid:48dd08b4-9da1-421f-8a06-73c7ac6ed2a2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5088 biolink:treats MONDO:0006032 PMID:41385096 "[{""id"":""uuid:dc0c26c5-6ec5-4422-86d7-9f10564a65fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8f98d348-62b9-43cc-89b0-b4154866b2d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Flavoxate hydrochloride tablets are indicated for symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis, urethrocystitis/urethrotrigonitis. Flavoxate hydrochloride tablets are not indicated for definitive treatment, but are compatible with drugs used for the treatment of urinary tract infections. uuid:d99ed525-89ea-4afa-8083-a7af97a8652c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5088 biolink:treats MONDO:0005280 PMID:41385096 "[{""id"":""uuid:10758592-e43f-4c9f-b368-be44aaeaac84"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:81d93c02-b93e-4740-baaa-932dbdc4023a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Flavoxate hydrochloride tablets are indicated for symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis, urethrocystitis/urethrotrigonitis. Flavoxate hydrochloride tablets are not indicated for definitive treatment, but are compatible with drugs used for the treatment of urinary tract infections. uuid:09939e00-204a-4aeb-8aa1-eb1728d25651 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5088 biolink:treats MONDO:0005297 PMID:41385096 "[{""id"":""uuid:0c50c64d-6c9c-4be3-9512-002169fad80b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5806f3e1-8ec2-42ff-a8e6-b99c522d200b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Flavoxate hydrochloride tablets are indicated for symptomatic relief of dysuria, urgency, nocturia, suprapubic pain, frequency and incontinence as may occur in cystitis, prostatitis, urethritis, urethrocystitis/urethrotrigonitis. Flavoxate hydrochloride tablets are not indicated for definitive treatment, but are compatible with drugs used for the treatment of urinary tract infections. uuid:29e80db6-974e-406a-8da7-097372955cf9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:66964 biolink:treats MONDO:0024571 PMID:41385096 "[{""id"":""uuid:a465ab00-46a1-4137-a6fb-bfdec5016e26"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e6f76e00-9c2e-4f4d-b46a-372affff7cd0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dronabinol capsules are indicated for the treatment of: anorexia associated with weight loss in patients with AIDS; and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. uuid:ac350fce-3490-450a-b0e4-7b54e49692ac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:66964 biolink:treats EFO:0006911 PMID:41385096 "[{""id"":""uuid:938bff3a-a4f5-4841-a480-a01dc6ddac5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f861a926-e208-4336-9773-19785478e5c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dronabinol capsules are indicated for the treatment of: anorexia associated with weight loss in patients with AIDS; and nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. uuid:c1ec405b-4375-46eb-a7ad-ac3df4c45540 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4027 biolink:treats MONDO:0005062 PMID:41385096 "[{""id"":""uuid:1a5a49fd-0208-4d3c-a7a1-1e0ea8562ecf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ff0b4967-61df-4465-ba94-2c20b9fa71b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3c5f17b1-97f7-4e69-a842-a385ccf56160"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclophosphamide Tablets USP, 25 mg and 50 mg, although effective alone in susceptible malignancies, are more frequently used concurrently or sequentially with other antineoplastic drugs. The following malignancies are often susceptible to cyclophosphamide treatment: Malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin’s disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma. Multiple myeloma. Leukemias: Chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia in children (cyclophosphamide given during remission is effective in prolonging its duration). Mycosis fungoides (advanced disease). Neuroblastoma (disseminated disease). Adenocarcinoma of the ovary. Retinoblastoma. Carcinoma of the breast.|[PMDA] Drugs with a revised indication and a new dosage for the relief of symptoms of malignant lymphoma. [Expedited review] uuid:db9982d7-de50-4bfd-a1de-ff2ecb91598f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4027 biolink:treats MONDO:0009348 PMID:41385096 "[{""id"":""uuid:f5af23db-0946-4f75-ad4b-d5d819a19b13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8c8e1205-63f6-4d04-8402-83bbf08b047f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclophosphamide Tablets USP, 25 mg and 50 mg, although effective alone in susceptible malignancies, are more frequently used concurrently or sequentially with other antineoplastic drugs. The following malignancies are often susceptible to cyclophosphamide treatment: Malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin’s disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma. Multiple myeloma. Leukemias: Chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia in children (cyclophosphamide given during remission is effective in prolonging its duration). Mycosis fungoides (advanced disease). Neuroblastoma (disseminated disease). Adenocarcinoma of the ovary. Retinoblastoma. Carcinoma of the breast. uuid:ce571403-5e1a-4ca3-ad7c-3618d579e4d0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4027 biolink:treats MONDO:0003864 PMID:41385096 "[{""id"":""uuid:089970e2-be8c-4a8d-9abd-e75cf84f492e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a7ed8a98-aec2-4e8d-b340-4dab773bb70b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclophosphamide Tablets USP, 25 mg and 50 mg, although effective alone in susceptible malignancies, are more frequently used concurrently or sequentially with other antineoplastic drugs. The following malignancies are often susceptible to cyclophosphamide treatment: Malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin’s disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma. Multiple myeloma. Leukemias: Chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia in children (cyclophosphamide given during remission is effective in prolonging its duration). Mycosis fungoides (advanced disease). Neuroblastoma (disseminated disease). Adenocarcinoma of the ovary. Retinoblastoma. Carcinoma of the breast. uuid:d53e7087-8b42-40cf-a782-bcd52d9b0399 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4027 biolink:treats MONDO:0004633 PMID:41385096 "[{""id"":""uuid:e87808fd-132f-4ea2-ba95-4175d4f47a38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c4f9b044-2f9a-4fba-ae53-d4f5a33ef6a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclophosphamide Tablets USP, 25 mg and 50 mg, although effective alone in susceptible malignancies, are more frequently used concurrently or sequentially with other antineoplastic drugs. The following malignancies are often susceptible to cyclophosphamide treatment: Malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin’s disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma. Multiple myeloma. Leukemias: Chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia in children (cyclophosphamide given during remission is effective in prolonging its duration). Mycosis fungoides (advanced disease). Neuroblastoma (disseminated disease). Adenocarcinoma of the ovary. Retinoblastoma. Carcinoma of the breast. uuid:296ac5bd-bfc7-4a24-9103-d04483f624d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4027 biolink:treats MONDO:0004604 PMID:41385096 "[{""id"":""uuid:f661beb6-97d7-4be9-91c9-c84548d752c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dc8e5acd-2a04-43be-97d5-ec40b4da7813"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclophosphamide Tablets USP, 25 mg and 50 mg, although effective alone in susceptible malignancies, are more frequently used concurrently or sequentially with other antineoplastic drugs. The following malignancies are often susceptible to cyclophosphamide treatment: Malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin’s disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma. Multiple myeloma. Leukemias: Chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia in children (cyclophosphamide given during remission is effective in prolonging its duration). Mycosis fungoides (advanced disease). Neuroblastoma (disseminated disease). Adenocarcinoma of the ovary. Retinoblastoma. Carcinoma of the breast. uuid:c7912864-1cc5-4308-bb94-0f9e24acb5d2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4027 biolink:treats MONDO:0006150 PMID:41385096 "[{""id"":""uuid:3afef359-8159-40c6-8a63-c34c1d8097ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4514106d-459a-435d-aadc-f446caf7b8f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclophosphamide Tablets USP, 25 mg and 50 mg, although effective alone in susceptible malignancies, are more frequently used concurrently or sequentially with other antineoplastic drugs. The following malignancies are often susceptible to cyclophosphamide treatment: Malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin’s disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma. Multiple myeloma. Leukemias: Chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia in children (cyclophosphamide given during remission is effective in prolonging its duration). Mycosis fungoides (advanced disease). Neuroblastoma (disseminated disease). Adenocarcinoma of the ovary. Retinoblastoma. Carcinoma of the breast. uuid:4107f46e-5c0f-433e-83d8-85f7bddc738e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4027 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:38c970c7-0345-4354-8539-9ed66884de8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4d9c9bfb-53b8-4e02-821f-9846808cf8cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclophosphamide Tablets USP, 25 mg and 50 mg, although effective alone in susceptible malignancies, are more frequently used concurrently or sequentially with other antineoplastic drugs. The following malignancies are often susceptible to cyclophosphamide treatment: Malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin’s disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma. Multiple myeloma. Leukemias: Chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia in children (cyclophosphamide given during remission is effective in prolonging its duration). Mycosis fungoides (advanced disease). Neuroblastoma (disseminated disease). Adenocarcinoma of the ovary. Retinoblastoma. Carcinoma of the breast. uuid:6f3d0151-12a3-4d04-8df8-c4ccea592b56 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4027 biolink:treats MONDO:0004948 PMID:41385096 "[{""id"":""uuid:75b3c779-e3c8-4391-8b61-a82ed00f9520"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:20d5dd22-2fc9-428f-a7e2-9b95b5d6b0b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclophosphamide Tablets USP, 25 mg and 50 mg, although effective alone in susceptible malignancies, are more frequently used concurrently or sequentially with other antineoplastic drugs. The following malignancies are often susceptible to cyclophosphamide treatment: Malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin’s disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma. Multiple myeloma. Leukemias: Chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia in children (cyclophosphamide given during remission is effective in prolonging its duration). Mycosis fungoides (advanced disease). Neuroblastoma (disseminated disease). Adenocarcinoma of the ovary. Retinoblastoma. Carcinoma of the breast. uuid:f6111bbc-a8f0-4434-a649-7ee0546a3c20 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4027 biolink:treats MONDO:0011996 PMID:41385096 "[{""id"":""uuid:3be4f670-1b1d-43e1-9a55-35638dda63b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2cce9bd8-690d-4991-90d7-32b386192928"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclophosphamide Tablets USP, 25 mg and 50 mg, although effective alone in susceptible malignancies, are more frequently used concurrently or sequentially with other antineoplastic drugs. The following malignancies are often susceptible to cyclophosphamide treatment: Malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin’s disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma. Multiple myeloma. Leukemias: Chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia in children (cyclophosphamide given during remission is effective in prolonging its duration). Mycosis fungoides (advanced disease). Neuroblastoma (disseminated disease). Adenocarcinoma of the ovary. Retinoblastoma. Carcinoma of the breast. uuid:2cba354d-7725-44ed-a5a0-a32490247405 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4027 biolink:treats MONDO:0018871 PMID:41385096 "[{""id"":""uuid:c42ba6ee-696c-4219-bc49-7fd408f63167"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:27bc01fd-0e42-44b6-8aee-66009475aeb9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclophosphamide Tablets USP, 25 mg and 50 mg, although effective alone in susceptible malignancies, are more frequently used concurrently or sequentially with other antineoplastic drugs. The following malignancies are often susceptible to cyclophosphamide treatment: Malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin’s disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma. Multiple myeloma. Leukemias: Chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia in children (cyclophosphamide given during remission is effective in prolonging its duration). Mycosis fungoides (advanced disease). Neuroblastoma (disseminated disease). Adenocarcinoma of the ovary. Retinoblastoma. Carcinoma of the breast. uuid:d1bf4adb-c2e4-4138-9e2e-b305cb50ba14 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4027 biolink:treats MONDO:0004967 PMID:41385096 "[{""id"":""uuid:8138ace4-749b-49a2-b98d-bd6a8642eb6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:065aa8ac-bcf6-40a7-b1e5-d41c499682b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclophosphamide Tablets USP, 25 mg and 50 mg, although effective alone in susceptible malignancies, are more frequently used concurrently or sequentially with other antineoplastic drugs. The following malignancies are often susceptible to cyclophosphamide treatment: Malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin’s disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma. Multiple myeloma. Leukemias: Chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia in children (cyclophosphamide given during remission is effective in prolonging its duration). Mycosis fungoides (advanced disease). Neuroblastoma (disseminated disease). Adenocarcinoma of the ovary. Retinoblastoma. Carcinoma of the breast. uuid:89af7949-16bd-4a22-b41f-c1e4ee54fda3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4027 biolink:treats MONDO:0009691 PMID:41385096 "[{""id"":""uuid:08ac8b49-c04e-4b13-b487-409c70c282a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:851fdf50-1550-4f93-baf7-1e35405d73ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclophosphamide Tablets USP, 25 mg and 50 mg, although effective alone in susceptible malignancies, are more frequently used concurrently or sequentially with other antineoplastic drugs. The following malignancies are often susceptible to cyclophosphamide treatment: Malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin’s disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma. Multiple myeloma. Leukemias: Chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia in children (cyclophosphamide given during remission is effective in prolonging its duration). Mycosis fungoides (advanced disease). Neuroblastoma (disseminated disease). Adenocarcinoma of the ovary. Retinoblastoma. Carcinoma of the breast. uuid:c87ef556-6b9e-47e6-9c6b-ee8db502cd27 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4027 biolink:treats MONDO:0005072 PMID:41385096 "[{""id"":""uuid:1dea8d4a-29e0-45b5-9503-02754ffa027b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d6af4d26-bad3-4693-a94c-36f2a4600d48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclophosphamide Tablets USP, 25 mg and 50 mg, although effective alone in susceptible malignancies, are more frequently used concurrently or sequentially with other antineoplastic drugs. The following malignancies are often susceptible to cyclophosphamide treatment: Malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin’s disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma. Multiple myeloma. Leukemias: Chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia in children (cyclophosphamide given during remission is effective in prolonging its duration). Mycosis fungoides (advanced disease). Neuroblastoma (disseminated disease). Adenocarcinoma of the ovary. Retinoblastoma. Carcinoma of the breast. uuid:85436366-5a01-4278-95cf-2262817faa0a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4027 biolink:treats MONDO:0002752 PMID:41385096 "[{""id"":""uuid:d453c2ff-e701-47d7-9eb3-4cdc899f5d7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5e18b90e-df44-4bf9-8be6-1bde1c65210f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclophosphamide Tablets USP, 25 mg and 50 mg, although effective alone in susceptible malignancies, are more frequently used concurrently or sequentially with other antineoplastic drugs. The following malignancies are often susceptible to cyclophosphamide treatment: Malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin’s disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma. Multiple myeloma. Leukemias: Chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia in children (cyclophosphamide given during remission is effective in prolonging its duration). Mycosis fungoides (advanced disease). Neuroblastoma (disseminated disease). Adenocarcinoma of the ovary. Retinoblastoma. Carcinoma of the breast. uuid:638e7da2-c4da-41cc-8747-e9d8b6dae66e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4027 biolink:treats MONDO:0008380 PMID:41385096 "[{""id"":""uuid:2305361b-b190-4c97-8071-57ee4fabcc81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3c7cc7fa-2e9f-4823-a94e-2bde2453d85b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclophosphamide Tablets USP, 25 mg and 50 mg, although effective alone in susceptible malignancies, are more frequently used concurrently or sequentially with other antineoplastic drugs. The following malignancies are often susceptible to cyclophosphamide treatment: Malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin’s disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma. Multiple myeloma. Leukemias: Chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia in children (cyclophosphamide given during remission is effective in prolonging its duration). Mycosis fungoides (advanced disease). Neuroblastoma (disseminated disease). Adenocarcinoma of the ovary. Retinoblastoma. Carcinoma of the breast. uuid:537de927-1d5d-484f-8365-3f519f9b1eca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4027 biolink:treats MONDO:0004989 PMID:41385096 "[{""id"":""uuid:4ae41d7a-bb27-4700-bc12-2411eb2bbb56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:44713047-e60d-4a6a-ab66-420d1d35d52c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclophosphamide Tablets USP, 25 mg and 50 mg, although effective alone in susceptible malignancies, are more frequently used concurrently or sequentially with other antineoplastic drugs. The following malignancies are often susceptible to cyclophosphamide treatment: Malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin’s disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma. Multiple myeloma. Leukemias: Chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia in children (cyclophosphamide given during remission is effective in prolonging its duration). Mycosis fungoides (advanced disease). Neuroblastoma (disseminated disease). Adenocarcinoma of the ovary. Retinoblastoma. Carcinoma of the breast. uuid:db8357fc-2963-4fd6-8529-5dbd34c66f6c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:61033 biolink:treats HP:0002625 PMID:41385096 "[{""id"":""uuid:63eef463-0ab8-4e3f-909b-b0b3f9cce121"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9d968aec-8a0a-4d45-8ca6-8b5db9f1b510"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:70869926-5d38-41e4-b5eb-ae03d2612347"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/arixtra""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ARIXTRA is a Factor Xa inhibitor (anticoagulant) indicated for: Prophylaxis of deep vein thrombosis (DVT) in patients undergoing hip fracture surgery (including extended prophylaxis), hip replacement surgery, knee replacement surgery, or abdominal surgery. (1.1) Treatment of DVT or acute pulmonary embolism (PE) when administered in conjunction with warfarin. (1.2, 1.3)|[EMA] 1.5-mg/0.3-ml and 2.5-mg/0.5-ml solution for injectionPrevention of venous thromboembolic events (VTE) in adults undergoing major orthopaedic surgery of the lower limbs such as hip fracture, major knee surgery or hip-replacement surgery.Prevention of VTE in adults undergoing abdominal surgery who are judged to be at high risk of thromboembolic complications, such as patients undergoing abdominal cancer surgery.Prevention of VTE in adult medical patients who are judged to be at high risk for VTE and who are immobilised due to acute illness such as cardiac insufficiency and / or acute respiratory disorders, and / or acute infectious or inflammatory disease.Treatment of adults with acute symptomatic spontaneous superficial-vein thrombosis of the lower limbs without concomitant deep-vein thrombosis.2.5-mg/0.5-ml solution for injectionTreatment of unstable angina or non-ST-segment-elevation myocardial infarction (UA/NSTEMI) in adult patients for whom urgent (< 120 mins) invasive management (PCI) is not indicated.infarction (STEMI) in adult patients who are managed with thrombolytics or who initially are to receive no other form of reperfusion therapy.5-mg/0.4-ml, 7.5-mg/0.6-ml and 10-mg/0.8-ml solution for injectionTreatment of adults with acute deep-vein thrombosis (DVT) and treatment of acute pulmonary embolism (PE), except in haemodynamically unstable patients or patients who require thrombolysis or pulmonary embolectomy. uuid:d820d157-c775-4263-8f61-c728ec605935 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:61033 biolink:treats UMLS:C2882221 PMID:41385096 "[{""id"":""uuid:c268ffa9-3180-4a77-9e0a-d9710b7f7fa0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:07ee9c80-3749-4a92-a49d-9ac09af86c6a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ARIXTRA is a Factor Xa inhibitor (anticoagulant) indicated for: Prophylaxis of deep vein thrombosis (DVT) in patients undergoing hip fracture surgery (including extended prophylaxis), hip replacement surgery, knee replacement surgery, or abdominal surgery. (1.1) Treatment of DVT or acute pulmonary embolism (PE) when administered in conjunction with warfarin. (1.2, 1.3) uuid:c80610b4-3033-41d2-8e96-39bd4d39d162 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7447 biolink:treats MONDO:0100073 PMID:41385096 "[{""id"":""uuid:3eda0bfe-b448-4d1b-8ed6-69759733bba9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:010bc5c0-f159-47e1-bfa0-670219bfa5be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nafcillin is indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. Culture and susceptibility tests should be performed initially to determine the causative organism and its susceptibility to the drug (see CLINICAL PHARMACOLOGY - Susceptibility Tests ). Nafcillin may be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of susceptibility test results. Nafcillin should not be used in infections caused by organisms susceptible to penicillin G. If the susceptibility tests indicate that the infection is due to an organism other than a resistant Staphylococcus , therapy should not be continued with Nafcillin for Injection, USP. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Nafcillin for Injection and other antibacterial drugs, Nafcillin for Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:73b7b56b-f902-4f1b-aefd-d638bd06ccd6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18385 biolink:treats MONDO:0006676 PMID:41385096 "[{""id"":""uuid:5b298a01-c5de-4bb9-a71b-930a41d3ada2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dbeab129-c4f0-48a6-85ad-740808bb1f94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thiamine hydrochloride injection is effective for the treatment of thiamine deficiency or beriberi whether of the dry (major symptoms related to the nervous system) or wet (major symptoms related to the cardiovascular system) variety. Thiamine hydrochloride injection should be used where rapid restoration of thiamine is necessary, as in Wernicke’s encephalopathy, infantile beriberi with acute collapse, cardiovascular disease due to thiamine deficiency, or neuritis of pregnancy if vomiting is severe. It is also indicated when giving IV dextrose to individuals with marginal thiamine status to avoid precipitation of heart failure. Thiamine hydrochloride injection is also indicated in patients with established thiamine deficiency who cannot take thiamine orally due to coexisting severe anorexia, nausea, vomiting, or malabsorption. Thiamine hydrochloride injection is not usually indicated for conditions of decreased oral intake or decreased gastrointestinal absorption, because multiple vitamins should usually be given uuid:635894b6-ac34-4b4c-909c-eabee5036e89 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18385 biolink:treats MONDO:0007020 PMID:41385096 "[{""id"":""uuid:ea26079c-4380-4110-b1f0-f0e2f2493c09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c36eb1f1-841b-4db3-a4a7-bec759077c3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thiamine hydrochloride injection is effective for the treatment of thiamine deficiency or beriberi whether of the dry (major symptoms related to the nervous system) or wet (major symptoms related to the cardiovascular system) variety. Thiamine hydrochloride injection should be used where rapid restoration of thiamine is necessary, as in Wernicke’s encephalopathy, infantile beriberi with acute collapse, cardiovascular disease due to thiamine deficiency, or neuritis of pregnancy if vomiting is severe. It is also indicated when giving IV dextrose to individuals with marginal thiamine status to avoid precipitation of heart failure. Thiamine hydrochloride injection is also indicated in patients with established thiamine deficiency who cannot take thiamine orally due to coexisting severe anorexia, nausea, vomiting, or malabsorption. Thiamine hydrochloride injection is not usually indicated for conditions of decreased oral intake or decreased gastrointestinal absorption, because multiple vitamins should usually be given uuid:d726ace7-2ea1-4f0d-867c-38ca6c3e70d2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18385 biolink:treats MONDO:0024183 PMID:41385096 "[{""id"":""uuid:291f1f23-8d50-4d14-b3c2-34a425696887"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:623916f1-99eb-499e-9f7e-8e69403189a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thiamine hydrochloride injection is effective for the treatment of thiamine deficiency or beriberi whether of the dry (major symptoms related to the nervous system) or wet (major symptoms related to the cardiovascular system) variety. Thiamine hydrochloride injection should be used where rapid restoration of thiamine is necessary, as in Wernicke’s encephalopathy, infantile beriberi with acute collapse, cardiovascular disease due to thiamine deficiency, or neuritis of pregnancy if vomiting is severe. It is also indicated when giving IV dextrose to individuals with marginal thiamine status to avoid precipitation of heart failure. Thiamine hydrochloride injection is also indicated in patients with established thiamine deficiency who cannot take thiamine orally due to coexisting severe anorexia, nausea, vomiting, or malabsorption. Thiamine hydrochloride injection is not usually indicated for conditions of decreased oral intake or decreased gastrointestinal absorption, because multiple vitamins should usually be given uuid:a3bec29e-fcc7-4edd-81de-588d7fcd7298 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5280 biolink:treats MONDO:0006668 PMID:41385096 "[{""id"":""uuid:419017b2-2d18-4cb3-87d3-b020b09574ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:40ff5a8e-0bfc-4ce3-9a4a-c16591dba0af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZYMAXID ® (gatifloxacin ophthalmic solution) 0.5% solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Aerobic Gram-Positive Bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus mitis group * Streptococcus oralis * Streptococcus pneumoniae Aerobic Gram-Negative Bacteria: Haemophilus influenzae * Efficacy for this organism was studied in fewer than 10 infections. uuid:f950071d-b680-4e74-8cd1-a0914d3f43c5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3084 biolink:treats HP:0000016 PMID:41385096 "[{""id"":""uuid:2fb9dedb-4b32-458b-a5ec-920eddbf8f12"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a7ee0aca-ad75-4242-a6ba-c04a402af9e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bethanechol chloride is indicated for the treatment of acute postoperative and postpartum nonobstructive (functional) urinary retention and for neurogenic atony of the urinary bladder with retention. uuid:aa33c34d-f9d3-482d-b598-acb37101a4d4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3084 biolink:treats HP:0000011 PMID:41385096 "[{""id"":""uuid:03813d32-f55b-4f9f-bc4f-219db8976038"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e26df52f-74f5-4039-8300-d1e237adc00c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bethanechol chloride is indicated for the treatment of acute postoperative and postpartum nonobstructive (functional) urinary retention and for neurogenic atony of the urinary bladder with retention. uuid:d71b44bf-f9e5-4df9-b0e9-19d7d6666433 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1156610 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:27050b7c-88b6-4947-bb13-7b503390a99f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1e163491-5bee-4f25-b027-31bdb5f45708"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9b27252a-2891-46e9-8711-3dcd83a73ef0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ATACAND HCT is indicated for the treatment of hypertension. This fixed dose combination is not indicated for initial therapy (see DOSAGE AND ADMINISTRATION ).|[PMDA] New combination drugs indicated for the treatment of hypertension. uuid:0c7735dd-60a7-4e66-a209-835ff92b5fe4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3732 biolink:treats MONDO:0002258 PMID:41385096 "[{""id"":""uuid:c243e8bb-2eef-4a56-b8de-3e0df4c11b6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:17c0708a-09b2-4ee2-b6a3-a7ea442e6464"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions as listed below: Adults Pharyngitis/Tonsillitis due to Streptococcus pyogenes (The usual drug of choice in the treatment and prevention of streptococcal infections and the prophylaxis of rheumatic fever is penicillin administered by either the intramuscular or the oral route. Clarithromycin is generally effective in the eradication of S. pyogenes from the nasopharynx; however, data establishing the efficacy of clarithromycin in the subsequent prevention of rheumatic fever are not available at present.) Acute maxillary sinusitis due to Haemophilus influenzae, Moraxella catarrhalis , or Streptococcus pneumoniae Acute bacterial exacerbation of chronic bronchitis due to Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, or Streptococcus pneumoniae Community-Acquired Pneumonia due to Haemophilus influenzae, Mycoplasma pneumoniae, Streptococcus pneumoniae, or Chlamydia pneumoniae (TWAR) Uncomplicated skin and skin structure infections due to Staphylococcus aureus, or Streptococcus pyogenes (Abscesses usually require surgical drainage.) Disseminated mycobacterial infections due to Mycobacterium avium, or Mycobacterium intracellulare Clarithromycin tablets in combination with amoxicillin and lansoprazole or omeprazole delayed-release capsules, as triple therapy, are indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or five-year history of duodenal ulcer) to eradicate H. pylori. Clarithromycin tablets in combination with omeprazole capsules or ranitidine bismuth citrate tablets are also indicated for the treatment of patients with an active duodenal ulcer associated with H. pylori infection. However, regimens which contain clarithromycin as the single antimicrobial agent are more likely to be associated with the development of clarithromycin resistance among patients who fail therapy. Clarithromycin-containing regimens should not be used in patients with known or suspected clarithromycin resistant isolates because the efficacy of treatment is reduced in this setting. In patients who fail therapy, susceptibility testing should be done if possible. If resistance to clarithromycin is demonstrated, a non-clarithromycin-containing therapy is recommended. (For information on development of resistance see Microbiology section.) The eradication of H. pylori has been demonstrated to reduce the risk of duodenal ulcer recurrence. Children Pharyngitis/Tonsillitis due to Streptococcus pyogenes Community-Acquired Pneumonia due to Mycoplasma pneumoniae, Streptococcus pneumoniae, or Chlamydia pneumoniae (TWAR) Acute maxillary sinusitis due to Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae Acute otitis media due to Haemophilus influenzae, Moraxella catarrhalis ,or Streptococcus pneumoniae NOTE: For information on otitis media, see CLINICAL STUDIES: Otitis Media . Uncomplicated skin and skin structure infections due to Staphylococcus aureus, or Streptococcus pyogenes (Abscesses usually require surgical drainage.) Disseminated mycobacterial infections due to Mycobacterium avium, or Mycobacterium intracellulare Prophylaxis Clarithromycin tablets are indicated for the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clarithromycin tablets and other antibacterial drugs, clarithromycin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:d370c76d-f27e-4def-96ad-57e122ffc3ea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3732 biolink:treats MONDO:0001039 PMID:41385096 "[{""id"":""uuid:e87afbb1-64c3-4b72-b769-f32eee4eb8ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b5aaf892-0ef4-47c1-8617-f55350a2db2b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions as listed below: Adults Pharyngitis/Tonsillitis due to Streptococcus pyogenes (The usual drug of choice in the treatment and prevention of streptococcal infections and the prophylaxis of rheumatic fever is penicillin administered by either the intramuscular or the oral route. Clarithromycin is generally effective in the eradication of S. pyogenes from the nasopharynx; however, data establishing the efficacy of clarithromycin in the subsequent prevention of rheumatic fever are not available at present.) Acute maxillary sinusitis due to Haemophilus influenzae, Moraxella catarrhalis , or Streptococcus pneumoniae Acute bacterial exacerbation of chronic bronchitis due to Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, or Streptococcus pneumoniae Community-Acquired Pneumonia due to Haemophilus influenzae, Mycoplasma pneumoniae, Streptococcus pneumoniae, or Chlamydia pneumoniae (TWAR) Uncomplicated skin and skin structure infections due to Staphylococcus aureus, or Streptococcus pyogenes (Abscesses usually require surgical drainage.) Disseminated mycobacterial infections due to Mycobacterium avium, or Mycobacterium intracellulare Clarithromycin tablets in combination with amoxicillin and lansoprazole or omeprazole delayed-release capsules, as triple therapy, are indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or five-year history of duodenal ulcer) to eradicate H. pylori. Clarithromycin tablets in combination with omeprazole capsules or ranitidine bismuth citrate tablets are also indicated for the treatment of patients with an active duodenal ulcer associated with H. pylori infection. However, regimens which contain clarithromycin as the single antimicrobial agent are more likely to be associated with the development of clarithromycin resistance among patients who fail therapy. Clarithromycin-containing regimens should not be used in patients with known or suspected clarithromycin resistant isolates because the efficacy of treatment is reduced in this setting. In patients who fail therapy, susceptibility testing should be done if possible. If resistance to clarithromycin is demonstrated, a non-clarithromycin-containing therapy is recommended. (For information on development of resistance see Microbiology section.) The eradication of H. pylori has been demonstrated to reduce the risk of duodenal ulcer recurrence. Children Pharyngitis/Tonsillitis due to Streptococcus pyogenes Community-Acquired Pneumonia due to Mycoplasma pneumoniae, Streptococcus pneumoniae, or Chlamydia pneumoniae (TWAR) Acute maxillary sinusitis due to Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae Acute otitis media due to Haemophilus influenzae, Moraxella catarrhalis ,or Streptococcus pneumoniae NOTE: For information on otitis media, see CLINICAL STUDIES: Otitis Media . Uncomplicated skin and skin structure infections due to Staphylococcus aureus, or Streptococcus pyogenes (Abscesses usually require surgical drainage.) Disseminated mycobacterial infections due to Mycobacterium avium, or Mycobacterium intracellulare Prophylaxis Clarithromycin tablets are indicated for the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clarithromycin tablets and other antibacterial drugs, clarithromycin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:d5910bfb-439e-4c21-9323-e0dc324f5d39 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3732 biolink:treats MONDO:0002186 PMID:41385096 "[{""id"":""uuid:35fc5059-bfc2-42d5-b144-b8c0489c3cc2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:df2968a5-9222-4709-8cab-7e305363f28f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions as listed below: Adults Pharyngitis/Tonsillitis due to Streptococcus pyogenes (The usual drug of choice in the treatment and prevention of streptococcal infections and the prophylaxis of rheumatic fever is penicillin administered by either the intramuscular or the oral route. Clarithromycin is generally effective in the eradication of S. pyogenes from the nasopharynx; however, data establishing the efficacy of clarithromycin in the subsequent prevention of rheumatic fever are not available at present.) Acute maxillary sinusitis due to Haemophilus influenzae, Moraxella catarrhalis , or Streptococcus pneumoniae Acute bacterial exacerbation of chronic bronchitis due to Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, or Streptococcus pneumoniae Community-Acquired Pneumonia due to Haemophilus influenzae, Mycoplasma pneumoniae, Streptococcus pneumoniae, or Chlamydia pneumoniae (TWAR) Uncomplicated skin and skin structure infections due to Staphylococcus aureus, or Streptococcus pyogenes (Abscesses usually require surgical drainage.) Disseminated mycobacterial infections due to Mycobacterium avium, or Mycobacterium intracellulare Clarithromycin tablets in combination with amoxicillin and lansoprazole or omeprazole delayed-release capsules, as triple therapy, are indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or five-year history of duodenal ulcer) to eradicate H. pylori. Clarithromycin tablets in combination with omeprazole capsules or ranitidine bismuth citrate tablets are also indicated for the treatment of patients with an active duodenal ulcer associated with H. pylori infection. However, regimens which contain clarithromycin as the single antimicrobial agent are more likely to be associated with the development of clarithromycin resistance among patients who fail therapy. Clarithromycin-containing regimens should not be used in patients with known or suspected clarithromycin resistant isolates because the efficacy of treatment is reduced in this setting. In patients who fail therapy, susceptibility testing should be done if possible. If resistance to clarithromycin is demonstrated, a non-clarithromycin-containing therapy is recommended. (For information on development of resistance see Microbiology section.) The eradication of H. pylori has been demonstrated to reduce the risk of duodenal ulcer recurrence. Children Pharyngitis/Tonsillitis due to Streptococcus pyogenes Community-Acquired Pneumonia due to Mycoplasma pneumoniae, Streptococcus pneumoniae, or Chlamydia pneumoniae (TWAR) Acute maxillary sinusitis due to Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae Acute otitis media due to Haemophilus influenzae, Moraxella catarrhalis ,or Streptococcus pneumoniae NOTE: For information on otitis media, see CLINICAL STUDIES: Otitis Media . Uncomplicated skin and skin structure infections due to Staphylococcus aureus, or Streptococcus pyogenes (Abscesses usually require surgical drainage.) Disseminated mycobacterial infections due to Mycobacterium avium, or Mycobacterium intracellulare Prophylaxis Clarithromycin tablets are indicated for the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clarithromycin tablets and other antibacterial drugs, clarithromycin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:a959f474-5ebb-4b04-a7a0-32962f5038b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3732 biolink:treats UMLS:C1735365 PMID:41385096 "[{""id"":""uuid:025e686c-dcbe-46af-a640-719e4e1c7863"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3286e0fe-e90a-4387-ab9e-d180605ed56e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions as listed below: Adults Pharyngitis/Tonsillitis due to Streptococcus pyogenes (The usual drug of choice in the treatment and prevention of streptococcal infections and the prophylaxis of rheumatic fever is penicillin administered by either the intramuscular or the oral route. Clarithromycin is generally effective in the eradication of S. pyogenes from the nasopharynx; however, data establishing the efficacy of clarithromycin in the subsequent prevention of rheumatic fever are not available at present.) Acute maxillary sinusitis due to Haemophilus influenzae, Moraxella catarrhalis , or Streptococcus pneumoniae Acute bacterial exacerbation of chronic bronchitis due to Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, or Streptococcus pneumoniae Community-Acquired Pneumonia due to Haemophilus influenzae, Mycoplasma pneumoniae, Streptococcus pneumoniae, or Chlamydia pneumoniae (TWAR) Uncomplicated skin and skin structure infections due to Staphylococcus aureus, or Streptococcus pyogenes (Abscesses usually require surgical drainage.) Disseminated mycobacterial infections due to Mycobacterium avium, or Mycobacterium intracellulare Clarithromycin tablets in combination with amoxicillin and lansoprazole or omeprazole delayed-release capsules, as triple therapy, are indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or five-year history of duodenal ulcer) to eradicate H. pylori. Clarithromycin tablets in combination with omeprazole capsules or ranitidine bismuth citrate tablets are also indicated for the treatment of patients with an active duodenal ulcer associated with H. pylori infection. However, regimens which contain clarithromycin as the single antimicrobial agent are more likely to be associated with the development of clarithromycin resistance among patients who fail therapy. Clarithromycin-containing regimens should not be used in patients with known or suspected clarithromycin resistant isolates because the efficacy of treatment is reduced in this setting. In patients who fail therapy, susceptibility testing should be done if possible. If resistance to clarithromycin is demonstrated, a non-clarithromycin-containing therapy is recommended. (For information on development of resistance see Microbiology section.) The eradication of H. pylori has been demonstrated to reduce the risk of duodenal ulcer recurrence. Children Pharyngitis/Tonsillitis due to Streptococcus pyogenes Community-Acquired Pneumonia due to Mycoplasma pneumoniae, Streptococcus pneumoniae, or Chlamydia pneumoniae (TWAR) Acute maxillary sinusitis due to Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae Acute otitis media due to Haemophilus influenzae, Moraxella catarrhalis ,or Streptococcus pneumoniae NOTE: For information on otitis media, see CLINICAL STUDIES: Otitis Media . Uncomplicated skin and skin structure infections due to Staphylococcus aureus, or Streptococcus pyogenes (Abscesses usually require surgical drainage.) Disseminated mycobacterial infections due to Mycobacterium avium, or Mycobacterium intracellulare Prophylaxis Clarithromycin tablets are indicated for the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clarithromycin tablets and other antibacterial drugs, clarithromycin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:e0eee4e6-c889-401a-a82b-82d6f98a16f2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3732 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:d9c3758e-74d6-441c-a12d-26c1dd329be9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9f717213-c48a-4ec7-849f-2db946777bf3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions as listed below: Adults Pharyngitis/Tonsillitis due to Streptococcus pyogenes (The usual drug of choice in the treatment and prevention of streptococcal infections and the prophylaxis of rheumatic fever is penicillin administered by either the intramuscular or the oral route. Clarithromycin is generally effective in the eradication of S. pyogenes from the nasopharynx; however, data establishing the efficacy of clarithromycin in the subsequent prevention of rheumatic fever are not available at present.) Acute maxillary sinusitis due to Haemophilus influenzae, Moraxella catarrhalis , or Streptococcus pneumoniae Acute bacterial exacerbation of chronic bronchitis due to Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, or Streptococcus pneumoniae Community-Acquired Pneumonia due to Haemophilus influenzae, Mycoplasma pneumoniae, Streptococcus pneumoniae, or Chlamydia pneumoniae (TWAR) Uncomplicated skin and skin structure infections due to Staphylococcus aureus, or Streptococcus pyogenes (Abscesses usually require surgical drainage.) Disseminated mycobacterial infections due to Mycobacterium avium, or Mycobacterium intracellulare Clarithromycin tablets in combination with amoxicillin and lansoprazole or omeprazole delayed-release capsules, as triple therapy, are indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or five-year history of duodenal ulcer) to eradicate H. pylori. Clarithromycin tablets in combination with omeprazole capsules or ranitidine bismuth citrate tablets are also indicated for the treatment of patients with an active duodenal ulcer associated with H. pylori infection. However, regimens which contain clarithromycin as the single antimicrobial agent are more likely to be associated with the development of clarithromycin resistance among patients who fail therapy. Clarithromycin-containing regimens should not be used in patients with known or suspected clarithromycin resistant isolates because the efficacy of treatment is reduced in this setting. In patients who fail therapy, susceptibility testing should be done if possible. If resistance to clarithromycin is demonstrated, a non-clarithromycin-containing therapy is recommended. (For information on development of resistance see Microbiology section.) The eradication of H. pylori has been demonstrated to reduce the risk of duodenal ulcer recurrence. Children Pharyngitis/Tonsillitis due to Streptococcus pyogenes Community-Acquired Pneumonia due to Mycoplasma pneumoniae, Streptococcus pneumoniae, or Chlamydia pneumoniae (TWAR) Acute maxillary sinusitis due to Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae Acute otitis media due to Haemophilus influenzae, Moraxella catarrhalis ,or Streptococcus pneumoniae NOTE: For information on otitis media, see CLINICAL STUDIES: Otitis Media . Uncomplicated skin and skin structure infections due to Staphylococcus aureus, or Streptococcus pyogenes (Abscesses usually require surgical drainage.) Disseminated mycobacterial infections due to Mycobacterium avium, or Mycobacterium intracellulare Prophylaxis Clarithromycin tablets are indicated for the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clarithromycin tablets and other antibacterial drugs, clarithromycin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:1251bb59-b918-42d1-a967-a542429e887c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3732 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:fae4f530-cef6-4a32-9eaf-33d2fef8d625"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1441e875-34c2-4005-b3c1-66d8f68fb1c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions as listed below: Adults Pharyngitis/Tonsillitis due to Streptococcus pyogenes (The usual drug of choice in the treatment and prevention of streptococcal infections and the prophylaxis of rheumatic fever is penicillin administered by either the intramuscular or the oral route. Clarithromycin is generally effective in the eradication of S. pyogenes from the nasopharynx; however, data establishing the efficacy of clarithromycin in the subsequent prevention of rheumatic fever are not available at present.) Acute maxillary sinusitis due to Haemophilus influenzae, Moraxella catarrhalis , or Streptococcus pneumoniae Acute bacterial exacerbation of chronic bronchitis due to Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, or Streptococcus pneumoniae Community-Acquired Pneumonia due to Haemophilus influenzae, Mycoplasma pneumoniae, Streptococcus pneumoniae, or Chlamydia pneumoniae (TWAR) Uncomplicated skin and skin structure infections due to Staphylococcus aureus, or Streptococcus pyogenes (Abscesses usually require surgical drainage.) Disseminated mycobacterial infections due to Mycobacterium avium, or Mycobacterium intracellulare Clarithromycin tablets in combination with amoxicillin and lansoprazole or omeprazole delayed-release capsules, as triple therapy, are indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or five-year history of duodenal ulcer) to eradicate H. pylori. Clarithromycin tablets in combination with omeprazole capsules or ranitidine bismuth citrate tablets are also indicated for the treatment of patients with an active duodenal ulcer associated with H. pylori infection. However, regimens which contain clarithromycin as the single antimicrobial agent are more likely to be associated with the development of clarithromycin resistance among patients who fail therapy. Clarithromycin-containing regimens should not be used in patients with known or suspected clarithromycin resistant isolates because the efficacy of treatment is reduced in this setting. In patients who fail therapy, susceptibility testing should be done if possible. If resistance to clarithromycin is demonstrated, a non-clarithromycin-containing therapy is recommended. (For information on development of resistance see Microbiology section.) The eradication of H. pylori has been demonstrated to reduce the risk of duodenal ulcer recurrence. Children Pharyngitis/Tonsillitis due to Streptococcus pyogenes Community-Acquired Pneumonia due to Mycoplasma pneumoniae, Streptococcus pneumoniae, or Chlamydia pneumoniae (TWAR) Acute maxillary sinusitis due to Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae Acute otitis media due to Haemophilus influenzae, Moraxella catarrhalis ,or Streptococcus pneumoniae NOTE: For information on otitis media, see CLINICAL STUDIES: Otitis Media . Uncomplicated skin and skin structure infections due to Staphylococcus aureus, or Streptococcus pyogenes (Abscesses usually require surgical drainage.) Disseminated mycobacterial infections due to Mycobacterium avium, or Mycobacterium intracellulare Prophylaxis Clarithromycin tablets are indicated for the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clarithromycin tablets and other antibacterial drugs, clarithromycin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:e6a59049-c69a-4934-b88c-f967d597f1a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3732 biolink:treats MONDO:0020590 PMID:41385096 "[{""id"":""uuid:4a223b21-b378-4884-ac6e-2fc026092e4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4bf36921-cce7-4c87-9a6e-9b04ca82dbc6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions as listed below: Adults Pharyngitis/Tonsillitis due to Streptococcus pyogenes (The usual drug of choice in the treatment and prevention of streptococcal infections and the prophylaxis of rheumatic fever is penicillin administered by either the intramuscular or the oral route. Clarithromycin is generally effective in the eradication of S. pyogenes from the nasopharynx; however, data establishing the efficacy of clarithromycin in the subsequent prevention of rheumatic fever are not available at present.) Acute maxillary sinusitis due to Haemophilus influenzae, Moraxella catarrhalis , or Streptococcus pneumoniae Acute bacterial exacerbation of chronic bronchitis due to Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, or Streptococcus pneumoniae Community-Acquired Pneumonia due to Haemophilus influenzae, Mycoplasma pneumoniae, Streptococcus pneumoniae, or Chlamydia pneumoniae (TWAR) Uncomplicated skin and skin structure infections due to Staphylococcus aureus, or Streptococcus pyogenes (Abscesses usually require surgical drainage.) Disseminated mycobacterial infections due to Mycobacterium avium, or Mycobacterium intracellulare Clarithromycin tablets in combination with amoxicillin and lansoprazole or omeprazole delayed-release capsules, as triple therapy, are indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or five-year history of duodenal ulcer) to eradicate H. pylori. Clarithromycin tablets in combination with omeprazole capsules or ranitidine bismuth citrate tablets are also indicated for the treatment of patients with an active duodenal ulcer associated with H. pylori infection. However, regimens which contain clarithromycin as the single antimicrobial agent are more likely to be associated with the development of clarithromycin resistance among patients who fail therapy. Clarithromycin-containing regimens should not be used in patients with known or suspected clarithromycin resistant isolates because the efficacy of treatment is reduced in this setting. In patients who fail therapy, susceptibility testing should be done if possible. If resistance to clarithromycin is demonstrated, a non-clarithromycin-containing therapy is recommended. (For information on development of resistance see Microbiology section.) The eradication of H. pylori has been demonstrated to reduce the risk of duodenal ulcer recurrence. Children Pharyngitis/Tonsillitis due to Streptococcus pyogenes Community-Acquired Pneumonia due to Mycoplasma pneumoniae, Streptococcus pneumoniae, or Chlamydia pneumoniae (TWAR) Acute maxillary sinusitis due to Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae Acute otitis media due to Haemophilus influenzae, Moraxella catarrhalis ,or Streptococcus pneumoniae NOTE: For information on otitis media, see CLINICAL STUDIES: Otitis Media . Uncomplicated skin and skin structure infections due to Staphylococcus aureus, or Streptococcus pyogenes (Abscesses usually require surgical drainage.) Disseminated mycobacterial infections due to Mycobacterium avium, or Mycobacterium intracellulare Prophylaxis Clarithromycin tablets are indicated for the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clarithromycin tablets and other antibacterial drugs, clarithromycin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:02e91d33-fad3-40da-a625-5c88e34996ee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3732 biolink:treats HP:0005202 PMID:41385096 "[{""id"":""uuid:412756af-0bcd-4adb-8891-c8d9d50a736e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:64506f93-7b78-4a51-9289-ec4ab896c7b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions as listed below: Adults Pharyngitis/Tonsillitis due to Streptococcus pyogenes (The usual drug of choice in the treatment and prevention of streptococcal infections and the prophylaxis of rheumatic fever is penicillin administered by either the intramuscular or the oral route. Clarithromycin is generally effective in the eradication of S. pyogenes from the nasopharynx; however, data establishing the efficacy of clarithromycin in the subsequent prevention of rheumatic fever are not available at present.) Acute maxillary sinusitis due to Haemophilus influenzae, Moraxella catarrhalis , or Streptococcus pneumoniae Acute bacterial exacerbation of chronic bronchitis due to Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, or Streptococcus pneumoniae Community-Acquired Pneumonia due to Haemophilus influenzae, Mycoplasma pneumoniae, Streptococcus pneumoniae, or Chlamydia pneumoniae (TWAR) Uncomplicated skin and skin structure infections due to Staphylococcus aureus, or Streptococcus pyogenes (Abscesses usually require surgical drainage.) Disseminated mycobacterial infections due to Mycobacterium avium, or Mycobacterium intracellulare Clarithromycin tablets in combination with amoxicillin and lansoprazole or omeprazole delayed-release capsules, as triple therapy, are indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or five-year history of duodenal ulcer) to eradicate H. pylori. Clarithromycin tablets in combination with omeprazole capsules or ranitidine bismuth citrate tablets are also indicated for the treatment of patients with an active duodenal ulcer associated with H. pylori infection. However, regimens which contain clarithromycin as the single antimicrobial agent are more likely to be associated with the development of clarithromycin resistance among patients who fail therapy. Clarithromycin-containing regimens should not be used in patients with known or suspected clarithromycin resistant isolates because the efficacy of treatment is reduced in this setting. In patients who fail therapy, susceptibility testing should be done if possible. If resistance to clarithromycin is demonstrated, a non-clarithromycin-containing therapy is recommended. (For information on development of resistance see Microbiology section.) The eradication of H. pylori has been demonstrated to reduce the risk of duodenal ulcer recurrence. Children Pharyngitis/Tonsillitis due to Streptococcus pyogenes Community-Acquired Pneumonia due to Mycoplasma pneumoniae, Streptococcus pneumoniae, or Chlamydia pneumoniae (TWAR) Acute maxillary sinusitis due to Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae Acute otitis media due to Haemophilus influenzae, Moraxella catarrhalis ,or Streptococcus pneumoniae NOTE: For information on otitis media, see CLINICAL STUDIES: Otitis Media . Uncomplicated skin and skin structure infections due to Staphylococcus aureus, or Streptococcus pyogenes (Abscesses usually require surgical drainage.) Disseminated mycobacterial infections due to Mycobacterium avium, or Mycobacterium intracellulare Prophylaxis Clarithromycin tablets are indicated for the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clarithromycin tablets and other antibacterial drugs, clarithromycin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:47df6eba-ed28-42eb-8054-c6ba279ef5b0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3732 biolink:treats MONDO:0005412 PMID:41385096 "[{""id"":""uuid:2e854db0-85a9-4206-85b9-3c59988913b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:08f4c1bb-67f7-4aa2-96bc-ce34f1384333"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions as listed below: Adults Pharyngitis/Tonsillitis due to Streptococcus pyogenes (The usual drug of choice in the treatment and prevention of streptococcal infections and the prophylaxis of rheumatic fever is penicillin administered by either the intramuscular or the oral route. Clarithromycin is generally effective in the eradication of S. pyogenes from the nasopharynx; however, data establishing the efficacy of clarithromycin in the subsequent prevention of rheumatic fever are not available at present.) Acute maxillary sinusitis due to Haemophilus influenzae, Moraxella catarrhalis , or Streptococcus pneumoniae Acute bacterial exacerbation of chronic bronchitis due to Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, or Streptococcus pneumoniae Community-Acquired Pneumonia due to Haemophilus influenzae, Mycoplasma pneumoniae, Streptococcus pneumoniae, or Chlamydia pneumoniae (TWAR) Uncomplicated skin and skin structure infections due to Staphylococcus aureus, or Streptococcus pyogenes (Abscesses usually require surgical drainage.) Disseminated mycobacterial infections due to Mycobacterium avium, or Mycobacterium intracellulare Clarithromycin tablets in combination with amoxicillin and lansoprazole or omeprazole delayed-release capsules, as triple therapy, are indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or five-year history of duodenal ulcer) to eradicate H. pylori. Clarithromycin tablets in combination with omeprazole capsules or ranitidine bismuth citrate tablets are also indicated for the treatment of patients with an active duodenal ulcer associated with H. pylori infection. However, regimens which contain clarithromycin as the single antimicrobial agent are more likely to be associated with the development of clarithromycin resistance among patients who fail therapy. Clarithromycin-containing regimens should not be used in patients with known or suspected clarithromycin resistant isolates because the efficacy of treatment is reduced in this setting. In patients who fail therapy, susceptibility testing should be done if possible. If resistance to clarithromycin is demonstrated, a non-clarithromycin-containing therapy is recommended. (For information on development of resistance see Microbiology section.) The eradication of H. pylori has been demonstrated to reduce the risk of duodenal ulcer recurrence. Children Pharyngitis/Tonsillitis due to Streptococcus pyogenes Community-Acquired Pneumonia due to Mycoplasma pneumoniae, Streptococcus pneumoniae, or Chlamydia pneumoniae (TWAR) Acute maxillary sinusitis due to Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae Acute otitis media due to Haemophilus influenzae, Moraxella catarrhalis ,or Streptococcus pneumoniae NOTE: For information on otitis media, see CLINICAL STUDIES: Otitis Media . Uncomplicated skin and skin structure infections due to Staphylococcus aureus, or Streptococcus pyogenes (Abscesses usually require surgical drainage.) Disseminated mycobacterial infections due to Mycobacterium avium, or Mycobacterium intracellulare Prophylaxis Clarithromycin tablets are indicated for the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clarithromycin tablets and other antibacterial drugs, clarithromycin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:97bc5ea9-b3ab-4f49-aa2a-8594707edd42 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3732 biolink:treats HP:0000371 PMID:41385096 "[{""id"":""uuid:18a33df3-f6d6-461c-b4c4-c0cbcfd832cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0cecf14c-1d37-4538-98fc-df5d56a05b22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions as listed below: Adults Pharyngitis/Tonsillitis due to Streptococcus pyogenes (The usual drug of choice in the treatment and prevention of streptococcal infections and the prophylaxis of rheumatic fever is penicillin administered by either the intramuscular or the oral route. Clarithromycin is generally effective in the eradication of S. pyogenes from the nasopharynx; however, data establishing the efficacy of clarithromycin in the subsequent prevention of rheumatic fever are not available at present.) Acute maxillary sinusitis due to Haemophilus influenzae, Moraxella catarrhalis , or Streptococcus pneumoniae Acute bacterial exacerbation of chronic bronchitis due to Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, or Streptococcus pneumoniae Community-Acquired Pneumonia due to Haemophilus influenzae, Mycoplasma pneumoniae, Streptococcus pneumoniae, or Chlamydia pneumoniae (TWAR) Uncomplicated skin and skin structure infections due to Staphylococcus aureus, or Streptococcus pyogenes (Abscesses usually require surgical drainage.) Disseminated mycobacterial infections due to Mycobacterium avium, or Mycobacterium intracellulare Clarithromycin tablets in combination with amoxicillin and lansoprazole or omeprazole delayed-release capsules, as triple therapy, are indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or five-year history of duodenal ulcer) to eradicate H. pylori. Clarithromycin tablets in combination with omeprazole capsules or ranitidine bismuth citrate tablets are also indicated for the treatment of patients with an active duodenal ulcer associated with H. pylori infection. However, regimens which contain clarithromycin as the single antimicrobial agent are more likely to be associated with the development of clarithromycin resistance among patients who fail therapy. Clarithromycin-containing regimens should not be used in patients with known or suspected clarithromycin resistant isolates because the efficacy of treatment is reduced in this setting. In patients who fail therapy, susceptibility testing should be done if possible. If resistance to clarithromycin is demonstrated, a non-clarithromycin-containing therapy is recommended. (For information on development of resistance see Microbiology section.) The eradication of H. pylori has been demonstrated to reduce the risk of duodenal ulcer recurrence. Children Pharyngitis/Tonsillitis due to Streptococcus pyogenes Community-Acquired Pneumonia due to Mycoplasma pneumoniae, Streptococcus pneumoniae, or Chlamydia pneumoniae (TWAR) Acute maxillary sinusitis due to Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae Acute otitis media due to Haemophilus influenzae, Moraxella catarrhalis ,or Streptococcus pneumoniae NOTE: For information on otitis media, see CLINICAL STUDIES: Otitis Media . Uncomplicated skin and skin structure infections due to Staphylococcus aureus, or Streptococcus pyogenes (Abscesses usually require surgical drainage.) Disseminated mycobacterial infections due to Mycobacterium avium, or Mycobacterium intracellulare Prophylaxis Clarithromycin tablets are indicated for the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clarithromycin tablets and other antibacterial drugs, clarithromycin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:67b1c674-ba4d-4207-81d9-a117a4268831 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3732 biolink:treats MONDO:0005866 PMID:41385096 "[{""id"":""uuid:fa3a1e2d-104b-4eb8-a027-efa7cc84346a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a056f505-fb1f-4b85-8916-8c617ad6e8f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c9ae19f4-fec4-4474-8228-da809b4c263d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clarithromycin tablets are indicated for the treatment of mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions as listed below: Adults Pharyngitis/Tonsillitis due to Streptococcus pyogenes (The usual drug of choice in the treatment and prevention of streptococcal infections and the prophylaxis of rheumatic fever is penicillin administered by either the intramuscular or the oral route. Clarithromycin is generally effective in the eradication of S. pyogenes from the nasopharynx; however, data establishing the efficacy of clarithromycin in the subsequent prevention of rheumatic fever are not available at present.) Acute maxillary sinusitis due to Haemophilus influenzae, Moraxella catarrhalis , or Streptococcus pneumoniae Acute bacterial exacerbation of chronic bronchitis due to Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, or Streptococcus pneumoniae Community-Acquired Pneumonia due to Haemophilus influenzae, Mycoplasma pneumoniae, Streptococcus pneumoniae, or Chlamydia pneumoniae (TWAR) Uncomplicated skin and skin structure infections due to Staphylococcus aureus, or Streptococcus pyogenes (Abscesses usually require surgical drainage.) Disseminated mycobacterial infections due to Mycobacterium avium, or Mycobacterium intracellulare Clarithromycin tablets in combination with amoxicillin and lansoprazole or omeprazole delayed-release capsules, as triple therapy, are indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or five-year history of duodenal ulcer) to eradicate H. pylori. Clarithromycin tablets in combination with omeprazole capsules or ranitidine bismuth citrate tablets are also indicated for the treatment of patients with an active duodenal ulcer associated with H. pylori infection. However, regimens which contain clarithromycin as the single antimicrobial agent are more likely to be associated with the development of clarithromycin resistance among patients who fail therapy. Clarithromycin-containing regimens should not be used in patients with known or suspected clarithromycin resistant isolates because the efficacy of treatment is reduced in this setting. In patients who fail therapy, susceptibility testing should be done if possible. If resistance to clarithromycin is demonstrated, a non-clarithromycin-containing therapy is recommended. (For information on development of resistance see Microbiology section.) The eradication of H. pylori has been demonstrated to reduce the risk of duodenal ulcer recurrence. Children Pharyngitis/Tonsillitis due to Streptococcus pyogenes Community-Acquired Pneumonia due to Mycoplasma pneumoniae, Streptococcus pneumoniae, or Chlamydia pneumoniae (TWAR) Acute maxillary sinusitis due to Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae Acute otitis media due to Haemophilus influenzae, Moraxella catarrhalis ,or Streptococcus pneumoniae NOTE: For information on otitis media, see CLINICAL STUDIES: Otitis Media . Uncomplicated skin and skin structure infections due to Staphylococcus aureus, or Streptococcus pyogenes (Abscesses usually require surgical drainage.) Disseminated mycobacterial infections due to Mycobacterium avium, or Mycobacterium intracellulare Prophylaxis Clarithromycin tablets are indicated for the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clarithromycin tablets and other antibacterial drugs, clarithromycin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.|[PMDA] Drugs with a new indication and a new dosage for non-tuberculous mycobacteriosis including mycobacterium avium complex (MAC) infections. uuid:5999e899-1890-4576-9052-453c7087d900 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82960 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:088a14d0-8656-48e3-afb4-874114e10e8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5848e028-94b4-4629-b4b2-1da0b3aaa602"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ISENTRESS is a human immunodeficiency virus integrase strand transfer inhibitor (HIV-1 INSTI) indicated: In combination with other antiretroviral agents for the treatment of HIV-1 infection ( 1 ). The safety and efficacy of ISENTRESS have not been established in children less than 2 years of age ( 1.2 ). uuid:a18441e1-a921-46aa-8f18-b406ab41e736 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24847846 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:be2cb0d8-efa9-4a5f-bb15-ca71c60a24a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e1181ad0-58a7-44e1-a14b-0c1fd3430d48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TARKA is indicated for the treatment of hypertension. This fixed combination drug is not indicated for the initial therapy of hypertension (see DOSAGE and ADMINISTRATION). In using TARKA, consideration should be given to the fact that an angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that trandolapril does not have similar risk (see WARNINGS -Neutropenia/Agranulocytosis ). uuid:578e5b5e-3a4a-46c5-abb5-a136a7fc4413 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24847846 biolink:treats MONDO:0001609 PMID:41385096 "[{""id"":""uuid:291b1b6e-2ebb-43ea-8bfd-d6ba49e644e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:60681b43-9b3d-476e-8e41-3e49f61c377d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TARKA is indicated for the treatment of hypertension. This fixed combination drug is not indicated for the initial therapy of hypertension (see DOSAGE and ADMINISTRATION). In using TARKA, consideration should be given to the fact that an angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that trandolapril does not have similar risk (see WARNINGS -Neutropenia/Agranulocytosis ). uuid:400f9865-8116-4b40-a5ff-bdb81a1d9631 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:829538 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:7d7e4f79-1408-484a-8aed-033e08053f3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e163b158-a8a9-465c-9da1-4b5b953c02a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3324d4e3-2c0d-4ca3-b4b1-53f905a788b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EPIDUO gel is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older.|[PMDA] A new combination drug indicated for the treatment of acne vulgaris. uuid:09de6337-a7b0-40ff-a0c6-67f5d7042749 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:81916 biolink:treats MONDO:0001684 PMID:41385096 "[{""id"":""uuid:41772402-b63f-46b5-8d21-1d5af081939a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:72c29906-50e0-458e-bf9e-944e6f1efc8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:05769c65-1175-4239-9c55-7bda28b00e95"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CREON ® (pancrelipase) is indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions.|[PMDA] Drugs with a new active ingredient indicated for the replacement of pancreatic digestive enzymes in pancreatic exocrine insufficiency. uuid:291326ce-5ae9-4d84-980a-dfa2752b8f5e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:81916 biolink:treats MONDO:0009061 PMID:41385096 "[{""id"":""uuid:d7274a2c-2917-4909-bebb-839944a87168"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0a7db2d6-0763-4e69-a402-4c17986c0f00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CREON ® (pancrelipase) is indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions. uuid:cd8a4ec5-3c16-4608-ac78-67205859ee38 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:81916 biolink:treats MONDO:0005003 PMID:41385096 "[{""id"":""uuid:0aa867c0-95d5-489a-88e5-74f85a9fddb6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ec403ebf-2a7c-4046-8af6-f5f9de2f4501"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CREON ® (pancrelipase) is indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatectomy, or other conditions. uuid:51053149-53c9-47ec-a0a6-670cc77a6fd6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:f06282a1-a59d-4ae8-b672-36d840f17fdc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fa56aac3-6668-453d-92c3-3872e98c4d23"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Monohydrate Capsules and other antibacterial drugs, Doxycycline Monohydrate Capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes ( formerly Aerobacter aerogenes) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus pneumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species . In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:27382436-f404-442c-960b-a1fb6c1e6e60 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0016595 PMID:41385096 "[{""id"":""uuid:4863a7cf-2df1-4a42-9dae-324b491186a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:15b60eed-822a-4ec7-92d2-3981d6ef7536"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of Doxycycline Monohydrate Capsules and other antibacterial drugs, Doxycycline Monohydrate Capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydia psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis (formerly Pasteurella pestis ). Tularemia due to Francisella tularensis (formerly Pasteurella tularensis ). Cholera caused by Vibrio cholerae (formerly Vibrio comma ). Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes ( formerly Aerobacter aerogenes) Shigella species Acinetobacter species (formerly Mima species and Herellea species) Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus pneumoniae ). Skin and skin structure infections caused by Staphylococcus aureus . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . Doxycycline is not the drug of choice in the treatment of any type of staphylococcal infections. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent’s infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species . In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:bcb7a58e-2968-4c95-a023-947e21697774 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:141521 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:78010f40-cd56-4d89-9779-3fcc2fe9aa1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:edd64057-52f4-4788-a7d7-0da8c41fbf10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MAVIK is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive medication such as hydrochlorothiazide. uuid:687821f0-ac4a-449c-a9f7-b12daca470f0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135931 biolink:treats MONDO:0007186 PMID:41385096 "[{""id"":""uuid:16bcdf19-f795-45eb-a6fa-ca3af9ec6908"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aa0fed52-0bef-43f9-ad09-e7fc48919466"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DEXILANT is a proton pump inhibitor (PPI) indicated for: Healing of all grades of erosive esophagitis (EE). ( 1.1 ) Maintaining healing of EE and relief of heartburn. ( 1.2 ) Treating heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD). ( 1.3 ) uuid:fe8b0143-2740-4dc6-941c-776d9ed901f9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6709 biolink:treats MONDO:0008015 PMID:41385096 "[{""id"":""uuid:4a75a409-152f-4637-8b29-ee85fd1290c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ad731272-d9f3-40a1-b772-3288a88b4a9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the management of nausea and vomiting, and dizziness associated with motion sickness. uuid:f351fd04-17e5-4a0b-89ea-9b8866438f5d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63681 biolink:treats UMLS:C2930826 PMID:41385096 "[{""id"":""uuid:8af875f3-440e-46e6-bd12-e77e1fabc81d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:586bd168-6e28-4643-bdd2-5bb47be57cf1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mefloquine Hydrochloride Tablets are indicated for the treatment of mild to moderate acute malaria caused by mefloquine-susceptible strains of P. falciparum (both chloroquine-susceptible and resistant strains) or by Plasmodium vivax . There are insufficient clinical data to document the effect of mefloquine in malaria caused by P. ovale or P. malariae . Note: Patients with acute P. vivax malaria, treated with Mefloquine Hydrochloride Tablets, are at high risk of relapse because Mefloquine Hydrochloride Tablets do not eliminate exoerythrocytic (hepatic phase) parasites. To avoid relapse, after initial treatment of the acute infection with mefloquine, patients should subsequently be treated with an 8-aminoquinoline derivative (e.g., primaquine). uuid:3a268aa7-ff9b-436b-97e4-53eec3876101 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60311 biolink:treats MONDO:0005420 PMID:41385096 "[{""id"":""uuid:40a64f13-f0ba-4f2f-9188-d2c291d8f8a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:22f0aa68-db43-4b03-a0ce-135eb45fc4dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Armour Thyroid tablets are indicated: As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS ). As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic Iymphocytic thyroiditis (Hashimoto's), multinodular goiter, and in the management of thyroid cancer. PUBCHEM.COMPOUND:53462828 uuid:af6c3f09-e93b-4934-83e2-0852d96a0469 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60311 biolink:treats MONDO:0018612 PMID:41385096 "[{""id"":""uuid:f623d061-9f44-49fe-9422-4b9a08ec0b3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:24d6fc28-b851-4ae8-97e6-8eb5b78ee0ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Armour Thyroid tablets are indicated: As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS ). As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic Iymphocytic thyroiditis (Hashimoto's), multinodular goiter, and in the management of thyroid cancer. PUBCHEM.COMPOUND:53462828 uuid:e1387fd9-dd7d-4227-acdc-9f74d6bc18a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60311 biolink:treats MONDO:0009718 PMID:41385096 "[{""id"":""uuid:2cc0b29e-229a-4105-a451-17bfa3ed01fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:afea4b29-29da-4aa3-8ca6-be66f1ea450a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Armour Thyroid tablets are indicated: As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS ). As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic Iymphocytic thyroiditis (Hashimoto's), multinodular goiter, and in the management of thyroid cancer. PUBCHEM.COMPOUND:53462828 uuid:44464985-147b-402f-ab28-f7bd953da138 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60311 biolink:treats MONDO:0001658 PMID:41385096 "[{""id"":""uuid:58de5495-8279-4f29-b57b-e84847d43220"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eebc1779-d385-4e56-b3b8-260e23348fb9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Armour Thyroid tablets are indicated: As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS ). As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic Iymphocytic thyroiditis (Hashimoto's), multinodular goiter, and in the management of thyroid cancer. PUBCHEM.COMPOUND:53462828 uuid:9a65715a-b74d-4bb2-baf9-08ae69218c77 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60311 biolink:treats HP:0025388 PMID:41385096 "[{""id"":""uuid:a4d63942-020d-48f9-9d59-3ec19d93b6d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d90435ea-1065-4234-8ff2-baaa765d2b58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Armour Thyroid tablets are indicated: As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS ). As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic Iymphocytic thyroiditis (Hashimoto's), multinodular goiter, and in the management of thyroid cancer. PUBCHEM.COMPOUND:53462828 uuid:85bdded0-e2f2-41c0-9d58-fe50fe28fea8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60311 biolink:treats MONDO:0007699 PMID:41385096 "[{""id"":""uuid:50a3cf50-3910-4b28-a7d2-0718b833e7da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ab0c6258-367b-46b7-a31c-e476ccbee0ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Armour Thyroid tablets are indicated: As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS ). As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic Iymphocytic thyroiditis (Hashimoto's), multinodular goiter, and in the management of thyroid cancer. PUBCHEM.COMPOUND:53462828 uuid:f50cee5f-f1ea-49fc-b0c9-4a461b94df83 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60311 biolink:treats MONDO:0000334 PMID:41385096 "[{""id"":""uuid:cf895113-6faf-4267-8e01-94b21ad01aaa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a23ee572-7726-496d-9749-ac6312bd0913"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Armour Thyroid tablets are indicated: As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS ). As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic Iymphocytic thyroiditis (Hashimoto's), multinodular goiter, and in the management of thyroid cancer. PUBCHEM.COMPOUND:53462828 uuid:c0c282b8-b382-4c0a-86ea-3fdad8d4ee49 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60311 biolink:treats MONDO:0002108 PMID:41385096 "[{""id"":""uuid:604be740-2c82-4488-b883-97813c011e56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b79a3274-001e-4a86-a8dc-fabb4e91e4bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Armour Thyroid tablets are indicated: As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS ). As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic Iymphocytic thyroiditis (Hashimoto's), multinodular goiter, and in the management of thyroid cancer. PUBCHEM.COMPOUND:53462828 uuid:d7f5372d-16fd-4057-a30c-7b6aac61c97d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15366 biolink:treats MONDO:0004795 PMID:41385096 "[{""id"":""uuid:2a4723b2-a04b-4b6b-9c58-e6f9ca552e46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ff5cb3f1-fe03-4395-b290-6727209a7f74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of superficial infections of the external auditory canal caused by organisms susceptible to the action of the antimicrobial. uuid:46210525-72fc-49f9-99f5-8c4993ccfc9a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37924 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:d3f1c85c-d663-4ae8-920f-669f04890f53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:117deffa-8ce4-497e-a8d3-f212bf763e0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] REYATAZ ® (atazanavir sulfate) is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. This indication is based on analyses of plasma HIV-1 RNA levels and CD4+ cell counts from controlled studies of 96 weeks duration in antiretroviral-naive and 48 weeks duration in antiretroviral-treatment-experienced adult and pediatric patients at least 6 years of age. The following points should be considered when initiating therapy with REYATAZ: In Study AI424-045, REYATAZ/ritonavir and lopinavir/ritonavir were similar for the primary efficacy outcome measure of time-averaged difference in change from baseline in HIV RNA level. This study was not large enough to reach a definitive conclusion that REYATAZ/ritonavir and lopinavir/ritonavir are equivalent on the secondary efficacy outcome measure of proportions below the HIV RNA lower limit of detection [see Clinical Studies (14.2) ]. The number of baseline primary protease inhibitor mutations affects the virologic response to REYATAZ/ritonavir [see Clinical Pharmacology (12.4) ]. uuid:4ea646dd-f824-4ef8-b781-e918c60ea293 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats MONDO:0003529 PMID:41385096 "[{""id"":""uuid:1987567c-2d49-4158-b780-7c126ab34b4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c867c750-e40c-4127-96d4-34965554a175"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciprofloxacin extended-release tablets are indicated only for the treatment of urinary tract infections, including acute uncomplicated pyelonephritis, caused by susceptible strains of the designated microorganisms as listed below. Ciprofloxacin extended-release tablets and ciprofloxacin immediate-release tablets are not interchangeable. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Uncomplicated Urinary Tract Infections (Acute Cystitis) caused by Escherichia coli, Proteus mirabilis, Enterococcus faecalis, or Staphylococcus saprophyticus Treatment of infections due to this organism in the organ system was studied in fewer than 10 patients. . Complicated Urinary Tract Infections caused by Escherichia coli, Klebsiella pneumoniae, Enterococcus faecalis, Proteus mirabilis, or Pseudomonas aeruginosa . Acute Uncomplicated Pyelonephritis caused by Escherichia coli. THE SAFETY AND EFFICACY OF CIPROFLOXACIN EXTENDED-RELEASE TABLETS IN TREATING INFECTIONS OTHER THAN URINARY TRACT INFECTIONS HAS NOT BEEN DEMONSTRATED. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. Therapy with ciprofloxacin extended-release tablets may be initiated before results of these tests are known; once results become available appropriate therapy should be continued. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ciprofloxacin extended-release tablets and other antibacterial drugs, ciprofloxacin extended-release tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:7cfc52ac-23d0-47ee-b49c-5f36f9e00b6b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:284780 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:b4e8f18b-d895-451f-bcc7-0cd16423b8a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b4f22f48-035a-4af3-a680-a9500ed0b448"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:21f5230d-5739-48ca-a978-6a84c902b482"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Micardis® HCT (telmisartan and hydrochlorothiazide) tablets are indicated for the treatment of hypertension. This fixed dose combination is not indicated for initial therapy (see DOSAGE AND ADMINISTRATION ).|[PMDA] A new combination drug indicated for the treatment of hypertension. uuid:0a28b992-8b81-4603-b386-4878b6f52ca2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135929 biolink:treats MONDO:0010811 PMID:41385096 "[{""id"":""uuid:2195705a-906a-4365-8b24-14de7daf5cf7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:50c59962-10fe-4886-af2e-30fee9470365"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9c92fe97-074a-4aa4-af66-8a3f631b5e2d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/silodosin-recordati""]},{""id"":""uuid:2bb11cf4-0e71-4d2a-8d2e-790ed71cce00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RAPAFLO, a selective alpha-1 adrenergic receptor antagonist, is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) [ see Clinical Studies (14) ]. RAPAFLO is not indicated for the treatment of hypertension.|[EMA] Treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) in adult men.|[PMDA] Drugs containing a new active ingredient indicated for the treatment of urination disorder associated with prostatic hypertrophy uuid:e0c70aac-d3f8-4ea1-ac77-62dece2799fb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8426 biolink:treats MONDO:0005393 PMID:41385096 "[{""id"":""uuid:d2c7df6e-6f1d-4bb9-92ec-d665a5daea2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2b857050-f260-41dc-b1bd-299cb5f82d67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For treatment of the hyperuricemia associated with gout and gouty arthritis. As an adjuvant to therapy with penicillin or with ampicillin, methicillin, oxacillin, cloxacillin, or nafcillin, for elevation and prolongation of plasma levels by whatever route the antibiotic is given. uuid:068703f9-0a30-48b9-a0a5-4cda8f31f442 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8426 biolink:treats HP:0002149 PMID:41385096 "[{""id"":""uuid:b2eae151-f074-4617-b6bb-60b2f0a28840"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3e6585b4-f7e9-4a7e-a12e-871990009d2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For treatment of the hyperuricemia associated with gout and gouty arthritis. As an adjuvant to therapy with penicillin or with ampicillin, methicillin, oxacillin, cloxacillin, or nafcillin, for elevation and prolongation of plasma levels by whatever route the antibiotic is given. uuid:9aff556b-dca0-4689-aadb-92504ce95bc5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5147 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:bbae95ef-55ad-415c-ade4-59520be49255"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bdba8613-eee4-44d0-8420-59f45727fb63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FORADIL AEROLIZER is indicated for the treatment of asthma and in the prevention of bronchospasm only as concomitant therapy with a long-term asthma control medication, such as an inhaled corticosteroid, in adults and children 5 years of age and older with reversible obstructive airways disease, including patients with symptoms of nocturnal asthma. Long-acting beta 2 -adrenergic agonists (LABA), such as formoterol, the active ingredient in FORADIL AEROLIZER, increase the risk of asthma-related death (see WARNINGS). Use of FORADIL AEROLIZER for the treatment of asthma without concomitant use of a long-term asthma control medication, such as an inhaled corticosteroid, is contraindicated. Use FORADIL AEROLIZER only as additional therapy for patients with asthma who are currently taking but are inadequately controlled on a long-term asthma control medication, such as an inhaled corticosteroid. Once asthma control is achieved and maintained, assess the patient at regular intervals and step down therapy (e.g. discontinue FORADIL AEROLIZER) if possible without loss of asthma control, and maintain the patient on a long-term asthma control medication, such as an inhaled corticosteroid. Do not use FORADIL AEROLIZER for patients whose asthma is adequately controlled on low or medium dose inhaled corticosteroids. uuid:49132125-40c8-499c-8891-f2aebb2d70ae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5147 biolink:treats MONDO:0001358 PMID:41385096 "[{""id"":""uuid:7f55ea62-912c-4b21-bd8e-efe6991b90f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5113fa18-cd71-4c43-b040-b6ba03194a96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FORADIL AEROLIZER is indicated for the treatment of asthma and in the prevention of bronchospasm only as concomitant therapy with a long-term asthma control medication, such as an inhaled corticosteroid, in adults and children 5 years of age and older with reversible obstructive airways disease, including patients with symptoms of nocturnal asthma. Long-acting beta 2 -adrenergic agonists (LABA), such as formoterol, the active ingredient in FORADIL AEROLIZER, increase the risk of asthma-related death (see WARNINGS). Use of FORADIL AEROLIZER for the treatment of asthma without concomitant use of a long-term asthma control medication, such as an inhaled corticosteroid, is contraindicated. Use FORADIL AEROLIZER only as additional therapy for patients with asthma who are currently taking but are inadequately controlled on a long-term asthma control medication, such as an inhaled corticosteroid. Once asthma control is achieved and maintained, assess the patient at regular intervals and step down therapy (e.g. discontinue FORADIL AEROLIZER) if possible without loss of asthma control, and maintain the patient on a long-term asthma control medication, such as an inhaled corticosteroid. Do not use FORADIL AEROLIZER for patients whose asthma is adequately controlled on low or medium dose inhaled corticosteroids. uuid:d6266d96-44b0-4dfa-abda-041af23a6605 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5147 biolink:treats MONDO:0956979 PMID:41385096 "[{""id"":""uuid:1f1f5432-6934-40a2-8352-b778680a04cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5b1ce0a4-aedb-4374-9bd9-590b6f746fc8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FORADIL AEROLIZER is indicated for the treatment of asthma and in the prevention of bronchospasm only as concomitant therapy with a long-term asthma control medication, such as an inhaled corticosteroid, in adults and children 5 years of age and older with reversible obstructive airways disease, including patients with symptoms of nocturnal asthma. Long-acting beta 2 -adrenergic agonists (LABA), such as formoterol, the active ingredient in FORADIL AEROLIZER, increase the risk of asthma-related death (see WARNINGS). Use of FORADIL AEROLIZER for the treatment of asthma without concomitant use of a long-term asthma control medication, such as an inhaled corticosteroid, is contraindicated. Use FORADIL AEROLIZER only as additional therapy for patients with asthma who are currently taking but are inadequately controlled on a long-term asthma control medication, such as an inhaled corticosteroid. Once asthma control is achieved and maintained, assess the patient at regular intervals and step down therapy (e.g. discontinue FORADIL AEROLIZER) if possible without loss of asthma control, and maintain the patient on a long-term asthma control medication, such as an inhaled corticosteroid. Do not use FORADIL AEROLIZER for patients whose asthma is adequately controlled on low or medium dose inhaled corticosteroids. uuid:b90fe7c4-a8d2-46e8-9dd3-e764b7bebd51 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10650 biolink:treats MONDO:0005277 PMID:41385096 "[{""id"":""uuid:67b587b7-e82d-45d6-a43b-f0a279417b89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2128ff78-9280-4090-b427-4ee13c23ded8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sumatriptan succinate injection is indicated for 1) the acute treatment of migraine attacks with or without aura and 2) the acute treatment of cluster headache episodes. Sumatriptan succinate injection is not for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS ). uuid:43a4aebc-a596-4980-86e8-de4c85cd0555 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1152283 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:fc357610-29a3-4ce8-8186-26b147f4df2b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8dcba7b7-fb88-43d7-af85-99b92cda7d80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lotrel is a combination tablet of amlodipine, a dihydropyridine calcium channel blocker (DHP CCB) and benazepril, an angiotensin converting enzyme (ACE) inhibitor. Lotrel is indicated for the treatment of hypertension in patients not adequately controlled on monotherapy with either agent ( 1 ) uuid:35f4a6fb-90f2-4237-addd-15f7f0ec1511 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6942 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:80e92ec4-b214-497d-9170-08a2b9d8d7ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7a620f16-8c1b-4cf3-b615-28876fbf9188"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Because of the potential for serious adverse effects, minoxidil tablets are indicated only in the treatment of hypertension that is symptomatic or associated with target organ damage and is not manageable with maximum therapeutic doses of a diuretic plus two other antihypertensive drugs. At the present time use in milder degrees of hypertension is not recommended because the benefit-risk relationship in such patients has not been defined. Minoxidil reduced supine diastolic blood pressure by 20 mm Hg or to 90 mm Hg or less in approximately 75% of patients, most of whom had hypertension that could not be controlled by other drugs. uuid:7a58d2e1-e21c-4faf-84d6-72f58d3cbbe8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4975 biolink:treats UMLS:C0267055 PMID:41385096 "[{""id"":""uuid:8f5bd670-d3db-46f2-b83d-05c16f630b6c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3f0f78c4-7906-41a2-a7d3-e4e32bbe2abc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Famotidine is indicated in: 1. Short-term treatment of active duodenal ulcer. Most adult patients heal within 4 weeks; there is rarely reason to use famotidine at full dosage for longer than 6 to 8 weeks. Studies have not assessed the safety of famotidine in uncomplicated active duodenal ulcer for periods of more than eight weeks. 2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer. Controlled studies in adults have not extended beyond one year. 3. Short-term treatment of active benign gastric ulcer. Most adult patients heal within 6 weeks. Studies have not assessed the safety or efficacy of famotidine in uncomplicated active benign gastric ulcer for periods of more than 8 weeks. 4. Short-term treatment of gastroesophageal reflux disease (GERD). Famotidine is indicated for short-term treatment of patients with symptoms of GERD (see CLINICAL PHARMACOLOGY IN ADULTS, Clinical Studies ). Famotidine is also indicated for the short-term treatment of esophagitis due to GERD including erosive or ulcerative disease diagnosed by endoscopy (see CLINICAL PHARMACOLOGY IN ADULTS, Clinical Studies ). 5. Treatment of pathological hypersecretory conditions (e. g., Zollinger-Ellison Syndrome, multiple endocrine adenomas ) (see CLINICAL PHARMACOLOGY IN ADULTS, Clinical Studies ) . uuid:2acea16b-edef-40f3-9021-2ef03c091419 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1154384 biolink:treats MONDO:0005136 PMID:41385096 "[{""id"":""uuid:f95b72b9-7da3-4d73-b3b1-8a2755a8a7a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6dfe4770-e0e3-4a6a-a4ad-c0583351f8af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:831c23e8-3d34-476b-b474-e6c658fde352"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prevention of Malaria: Atovaquone and proguanil hydrochloride tablets are indicated for the prophylaxis of P. falciparum malaria, including in areas where chloroquine resistance has been reported (see CLINICAL STUDIES ).|[PMDA] A new combination drug with a new active ingredient indicated for the treatment and prevention of malaria. [Priority review] uuid:fcb2eeeb-1a68-4ad9-8c35-a0a1c66c0b57 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats UMLS:C0332686 PMID:41385096 "[{""id"":""uuid:ed2ba333-2665-41ba-bb29-cb33e81a3f8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fdaded2c-958e-451c-9a61-b52a5c2e8aa2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the temporary relief of pain and itching due to: ■ minor burns ■ minor skin irritations ■ scrapes ■ minor cuts ■ sunburn ■ insect bites uuid:0d73abb1-59b6-475d-9491-50570347e8ca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0005093 PMID:41385096 "[{""id"":""uuid:97aacfdb-c878-42bf-a718-042187901b46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:97e11576-b548-417a-b499-13d962a14fb2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the temporary relief of pain and itching due to: ■ minor burns ■ minor skin irritations ■ scrapes ■ minor cuts ■ sunburn ■ insect bites uuid:eca7c1fe-df8a-4bfb-bc1e-cb2b2ae84f23 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0005326 PMID:41385096 "[{""id"":""uuid:2573e3fd-1439-4128-bccf-f8036a4cc22f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3d32006a-4159-434a-b726-339d2f684a20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the temporary relief of pain and itching due to: ■ minor burns ■ minor skin irritations ■ scrapes ■ minor cuts ■ sunburn ■ insect bites uuid:cb378619-6eef-4b88-8f04-ff72e4738df6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats UMLS:C0021564 PMID:41385096 "[{""id"":""uuid:ac565731-e27b-49ff-9f1d-09c4b2270801"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a9b37ea9-e349-4983-bafa-9318656924d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the temporary relief of pain and itching due to: ■ minor burns ■ minor skin irritations ■ scrapes ■ minor cuts ■ sunburn ■ insect bites uuid:6c7c237a-b7ef-4f10-ab6a-18be9ee8c173 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9P1872D4OL biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:d0ffdce2-23e8-420d-baaf-3c24d6c0adfd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e2c12198-b062-41bc-9248-f1731ebedfb4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f12619f3-4c11-41c7-8ecd-6beb1f8e939f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/bydureon""]},{""id"":""uuid:284564d3-12e6-4a93-9a22-936ef9237533"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BYETTA is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Important Limitations of Use Not a substitute for insulin. BYETTA should not be used for the treatment of type 1 diabetes or diabetic ketoacidosis ( 1.2 ). Concurrent use with prandial insulin has not been studied and cannot be recommended ( 1.2 ). Has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis ( 1.2 ).|[EMA] Bydureon is indicated in adults 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products when the therapy in use, together with diet and exercise, does not provide adequate glycaemic control (see section 4.4, 4.5 and 5.1 for available data on different combinations).Bydureon is indicated for treatment of type 2 diabetes mellitus in combination with:MetforminSulphonylureaThiazolidinedioneMetformin and sulphonylureaMetformin and thiazolidinedionein adults who have not achieved adequate glycaemic control on maximally tolerated doses of these oral therapies.|[PMDA] A drug with a new additional indication and a new dosage in a new dosage form for the treatment of type 2 diabetes mellitus. uuid:f658e0c2-fc4f-4028-834e-761048de9405 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9P1872D4OL biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:6c634dc6-b1b7-4e36-801d-cfaf11acaea7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7611cf73-f1c6-4f39-9f07-a55e8d887764"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BYETTA is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Important Limitations of Use Not a substitute for insulin. BYETTA should not be used for the treatment of type 1 diabetes or diabetic ketoacidosis ( 1.2 ). Concurrent use with prandial insulin has not been studied and cannot be recommended ( 1.2 ). Has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis ( 1.2 ). uuid:f37c504c-7821-4ed3-a4bc-908ad06bc159 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9P1872D4OL biolink:treats MONDO:0012819 PMID:41385096 "[{""id"":""uuid:be43fd3d-8257-4818-983a-330cacf3a1b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5566f624-ae49-4742-9619-e72e484b724d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BYETTA is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Important Limitations of Use Not a substitute for insulin. BYETTA should not be used for the treatment of type 1 diabetes or diabetic ketoacidosis ( 1.2 ). Concurrent use with prandial insulin has not been studied and cannot be recommended ( 1.2 ). Has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis ( 1.2 ). uuid:4e4917b6-c23c-4cf7-8687-ff8ce1c7e193 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9P1872D4OL biolink:treats MONDO:0004982 PMID:41385096 "[{""id"":""uuid:af15e896-b89c-4f42-9f09-7e019f2320ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f804eff1-7bba-408e-b6a4-7ef1ee24a5e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BYETTA is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Important Limitations of Use Not a substitute for insulin. BYETTA should not be used for the treatment of type 1 diabetes or diabetic ketoacidosis ( 1.2 ). Concurrent use with prandial insulin has not been studied and cannot be recommended ( 1.2 ). Has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis ( 1.2 ). uuid:693fa501-a11c-49f1-bbd2-6544d6860b16 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32151 biolink:treats EFO:0006865 PMID:41385096 "[{""id"":""uuid:f38abd34-5b7f-4517-9970-b15fbee34f81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f47cf537-981c-4919-baeb-23e0a686805f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:84f84d0a-1593-4147-ade6-7ff96bb6c5af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VESIcare is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.|[PMDA] Drugs with a new active ingredient indicated for treatment of urinary urgency, urinary frequency, and urge urinary incontinence associated with overactive bladder. uuid:22a264e0-52d4-45e6-985a-061773780668 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32151 biolink:treats HP:0100515 PMID:41385096 "[{""id"":""uuid:a7d6168c-df05-48e3-9687-54ee166bd29f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1de4c718-3491-403c-a002-8ed80de23caf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4b917e59-340d-4aba-b862-c33454d660a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VESIcare is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.|[PMDA] Drugs with a new active ingredient indicated for treatment of urinary urgency, urinary frequency, and urge urinary incontinence associated with overactive bladder. uuid:87c1ce59-e824-45bb-95a8-184a19022776 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5062 biolink:treats MONDO:0008315 PMID:41385096 "[{""id"":""uuid:e8c7d0e9-fcf6-4328-81ab-13acded991cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f436374b-7033-4267-b29e-bb5cf8825dfc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Finasteride tablets USP, is a 5α-reductase inhibitor, indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to ( 1.1 ): •Improve symptoms • Reduce the risk of the need for surgery including transurethral resection of the prostate (TURP) and prostatectomy. Limitations of Use: Finasteride tablets USP is not approved for the prevention of prostate cancer ( 1.3 ). uuid:1591d8db-119c-4168-955d-28849cca6b45 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:84043 biolink:treats MONDO:0043455 PMID:41385096 "[{""id"":""uuid:627cd64c-65c3-4a96-86e2-dabb8e2e81e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4f8b19ad-b366-49d6-833a-b3adf6beab9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ganite is indicated for the treatment of clearly symptomatic cancer-related hypercalcemia that has not responded to adequate hydration. In general, patients with a serum calcium (corrected for albumin) < 12 mg/dL would not be expected to be symptomatic. Mild or asymptomatic hypercalcemia may be treated with conservative measures (i.e., saline hydration, with or without diuretics). In the treatment of cancer-related hypercalcemia, it is important first to establish adequate hydration, preferably with intravenous saline, in order to increase the renal excretion of calcium and correct dehydration caused by hypercalcemia. uuid:7d3fc803-0bd4-4159-a358-e8e7dbf29928 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4873 biolink:treats MONDO:0001932 PMID:41385096 "[{""id"":""uuid:2a0c527e-e920-4c8e-b0a8-8d52ec976375"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ee54d7dd-d386-4558-8108-60632a423ce3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Estropipate tablets are indicated in the: Treatment of moderate to severe vasomotor symptoms associated with the menopause. Treatment of moderate to severe symptoms of vulval and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. Prevention of postmenopausal osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate. The mainstays for decreasing the risk of postmenopausal osteoporosis are weight-bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 1500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400-800 IU/day may also be required to ensure adequate daily intake in postmenopausal women. DOID:14275 uuid:bb52ab00-d324-4a92-a7bd-2db4cb470516 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4873 biolink:treats MONDO:0018555 PMID:41385096 "[{""id"":""uuid:fce65798-6a90-416c-b8f0-a1543ea9b547"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4da1bc65-6c8a-49b8-b503-184caed2d518"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Estropipate tablets are indicated in the: Treatment of moderate to severe vasomotor symptoms associated with the menopause. Treatment of moderate to severe symptoms of vulval and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. Prevention of postmenopausal osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate. The mainstays for decreasing the risk of postmenopausal osteoporosis are weight-bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 1500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400-800 IU/day may also be required to ensure adequate daily intake in postmenopausal women. uuid:a47ee192-a5a8-459f-82ff-f7f11dd1b9f2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4873 biolink:treats MONDO:0005387 PMID:41385096 "[{""id"":""uuid:8aebb0c4-636e-44e8-92c3-43254a47d112"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7992d825-36b6-4d87-927a-fa3281d7f80e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Estropipate tablets are indicated in the: Treatment of moderate to severe vasomotor symptoms associated with the menopause. Treatment of moderate to severe symptoms of vulval and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. Prevention of postmenopausal osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate. The mainstays for decreasing the risk of postmenopausal osteoporosis are weight-bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 1500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400-800 IU/day may also be required to ensure adequate daily intake in postmenopausal women. uuid:cb4a59d3-2f89-4a9f-846f-2a78ba8f68d8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4873 biolink:treats MONDO:0008159 PMID:41385096 "[{""id"":""uuid:fbc0e764-e20f-422b-bd72-2f84cfabea93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:85e41987-ad81-4cfc-af4c-2985ea24960e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Estropipate tablets are indicated in the: Treatment of moderate to severe vasomotor symptoms associated with the menopause. Treatment of moderate to severe symptoms of vulval and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. Prevention of postmenopausal osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate. The mainstays for decreasing the risk of postmenopausal osteoporosis are weight-bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 1500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400-800 IU/day may also be required to ensure adequate daily intake in postmenopausal women. uuid:2762d6eb-35dc-474e-88f1-3621b3a8b491 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8875 biolink:treats MONDO:0005277 PMID:41385096 "[{""id"":""uuid:996b2c2a-612b-46db-8776-524325f0600b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d11102c8-9562-4ba3-a562-4bb4a3f7cdc9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MAXALT ® and MAXALT-MLT ® are indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old. Limitations of Use MAXALT should only be used where a clear diagnosis of migraine has been established. If a patient has no response for the first migraine attack treated with MAXALT, the diagnosis of migraine should be reconsidered before MAXALT is administered to treat any subsequent attacks. MAXALT is not indicated for use in the management of hemiplegic or basilar migraine [see Contraindications (4) ] . MAXALT is not indicated for the prevention of migraine attacks. Safety and effectiveness of MAXALT have not been established for cluster headache. uuid:ce861c21-31b9-4211-a3bc-8075caca029b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4702 biolink:treats MONDO:0006875 PMID:41385096 "[{""id"":""uuid:c20ee015-6d49-4ac9-a4af-2db8b498fe31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d149c4e2-dc40-4253-9623-46605bf05854"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dorzolamide HCl Ophthalmic Solution is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. uuid:b007c8c8-1919-4298-84e5-cc4facb6d02c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4702 biolink:treats MONDO:0005338 PMID:41385096 "[{""id"":""uuid:68ebd916-36d3-4f5c-af2d-eb96577765a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a047ee99-0dcd-473d-ad11-4ca007bedea1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dorzolamide HCl Ophthalmic Solution is indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma. uuid:8c1beee2-6023-4458-bf54-93d53d8c8924 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16469 biolink:treats MONDO:0001410 PMID:41385096 "[{""id"":""uuid:75a130f8-e87c-4fc2-9330-5cb966048134"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:12f8a2a0-44fb-417d-98f2-5623c2efcc18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vagifem is an estrogen (estradiol) indicated for the treatment of atrophic vaginitis due to menopause ( 1 ). uuid:17d0d50d-3d88-4167-94b2-90c3fc557f13 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2663 biolink:treats MONDO:0000190 PMID:41385096 "[{""id"":""uuid:b54fb0b0-6a78-4c8b-8d74-6d1092df6f95"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b6b39b6d-6a48-4f5a-91c0-7d0018f9c644"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:6b57f6bf-2048-4d2c-856b-a39fff047d42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amiodarone injection is indicated for initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation (VF) and hemodynamically unstable ventricular tachycardia (VT) in patients refractory to other therapy. Amiodarone also can be used to treat patients with VT/VF for whom oral amiodarone is indicated, but who are unable to take oral medication. During or after treatment with amiodarone, patients may be transferred to oral amiodarone therapy [see Dosage and Administration (2) ] . Use amiodarone for acute treatment until the patient's ventricular arrhythmias are stabilized. Most patients will require this therapy for 48 to 96 hours, but amiodarone may be safely administered for longer periods if necessary.|[PMDA] Drug with a new route of administration, used for emergency treatment of refractory arrhythmias (ventricular fibrillation and hemodynamically unstable ventricular tachycardia). [Orphan Drug] uuid:05a47dfa-412d-40ed-a2be-5257fe468594 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:32f2254a-e7de-4179-b6aa-e5c7d2ec9577"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:02c59d03-fb4d-43fa-a5d0-0ee2509f700d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e0ab803a-ee30-43f0-b854-7fc370e9905a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lidocaine HCl 2% Jelly is indicated for prevention and control of pain in procedures involving the male and female urethra, for topical treatment of painful urethritis, and as an anesthetic lubricant for endotracheal intubation (oral and nasal).|[PMDA] A drug with a new additional indication and a new dosage for pain relief at the resection of molluscum contagiosum. uuid:fe4b10e0-08ae-46c2-92e7-b35f4f749df9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0005297 PMID:41385096 "[{""id"":""uuid:5fef4627-11f3-4aeb-b022-06fcabee075a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:819cdfc3-0269-4148-a39a-779959c751dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lidocaine HCl 2% Jelly is indicated for prevention and control of pain in procedures involving the male and female urethra, for topical treatment of painful urethritis, and as an anesthetic lubricant for endotracheal intubation (oral and nasal). uuid:a2066c86-3ea8-4426-b190-b46448ceb12c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats MONDO:0005475 PMID:41385096 "[{""id"":""uuid:f067082c-32d2-4d4a-9a99-cf98dac2f838"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:949720af-f8dc-4d3c-a0e7-617ee4e4da34"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CAMBIA is a non-steroidal anti-inflammatory (NSAID) drug indicated for the acute treatment of migraine attacks with or without aura in adults 18 years of age or older ( 1.1 ) Important Limitations ( 1.2 ): CAMBIA is not indicated for the prophylactic therapy of migraine Safety and effectiveness of CAMBIA not established for cluster headache, which is present in an older, predominantly male population uuid:a76fb503-a108-48d2-b80a-06042e8a45d1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats MONDO:0100431 PMID:41385096 "[{""id"":""uuid:abbdd4f7-afcf-46a0-b45b-922a174e03bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f2a5c745-0bce-48bd-b470-2262691ecfa3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CAMBIA is a non-steroidal anti-inflammatory (NSAID) drug indicated for the acute treatment of migraine attacks with or without aura in adults 18 years of age or older ( 1.1 ) Important Limitations ( 1.2 ): CAMBIA is not indicated for the prophylactic therapy of migraine Safety and effectiveness of CAMBIA not established for cluster headache, which is present in an older, predominantly male population uuid:900995f7-abc4-4012-9b85-4ecb9a78bec0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats MONDO:0043537 PMID:41385096 "[{""id"":""uuid:0e5978e7-c445-4fb5-87f8-90af96900aad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:226ba957-9894-4842-9f3a-b77b23980dc9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CAMBIA is a non-steroidal anti-inflammatory (NSAID) drug indicated for the acute treatment of migraine attacks with or without aura in adults 18 years of age or older ( 1.1 ) Important Limitations ( 1.2 ): CAMBIA is not indicated for the prophylactic therapy of migraine Safety and effectiveness of CAMBIA not established for cluster headache, which is present in an older, predominantly male population uuid:703b7586-ee2b-408d-88e3-8815093a30ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0009850 PMID:41385096 "[{""id"":""uuid:600c346f-cd5d-4c30-a5a1-a807533d9eea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:57f86061-33e9-49f1-9790-128e7805d575"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxycycline hyclate is indicated for use as an adjunct to scaling and root planing to promote attachment level gain and to reduce pocket depth in patients with adult periodontitis. uuid:643acb0e-4d82-4a57-af13-ba80e51ae9aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2453 biolink:treats MONDO:0043653 PMID:41385096 "[{""id"":""uuid:580f0cd4-a02e-47b6-aba7-a79aa6f16c20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c86ec186-510d-4f6f-8271-9be21d61e063"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZOVIRAX Cream is indicated for the treatment of recurrent herpes labialis (cold sores) in adults and adolescents (12 years of age and older). uuid:700bfddb-b538-4c24-a574-689a158a0aef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90972 biolink:treats MONDO:0004247 PMID:41385096 "[{""id"":""uuid:45821269-a61d-496b-a64c-6dcb9fe3fb4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:940290b7-eb95-4523-87a6-1b2401e11964"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For use as adjunctive therapy in the treatment of peptic ulcer. uuid:0ad98c48-015b-4ab0-a6d3-78b3eebef40c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8059 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:dd8957ee-a5bf-4c1d-b9d9-8d181ae254dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:743a345e-c4f1-405a-86e4-06ce0fbe43bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Phendimetrazine tartrate extended-release capsules are indicated in the management of exogenous obesity as a short term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction in patients with an initial body mass index (BMI) of greater than or equal to 30 kg/m2 or greater than or equal to 27 kg/m2 in the presence of other risk factors (e.g., controlled hypertension, diabetes, hyperlipidemia) who have not responded to appropriate weight reducing regimen (diet and/or exercise) alone. Below is a chart of Body Mass Index (BMI) based on various heights and weights. BMI is calculated by taking the patient's weight, in kilograms (kg), divided by the patient's height, in meters (m), squared. Metric conversions are as follows: pounds ÷ 2.2 = kg; inches × 0.0254 = meters BODY MASS INDEX (BMI), kg/m 2 Height (feet, inches) The usefulness of agents of this class (see CLINICAL PHARMACOLOGY) should be measured against possible risk factors inherent in their use such as those described below. Phendimetrazine tartrate is indicated for use as monotherapy only. uuid:c4c0fe94-38ba-4d76-93ce-a84fed0be07b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8059 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:b064c88f-b623-4187-b934-b9be9cf5337e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9489c4c5-2ae7-483f-9354-5624f56116ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Phendimetrazine tartrate extended-release capsules are indicated in the management of exogenous obesity as a short term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction in patients with an initial body mass index (BMI) of greater than or equal to 30 kg/m2 or greater than or equal to 27 kg/m2 in the presence of other risk factors (e.g., controlled hypertension, diabetes, hyperlipidemia) who have not responded to appropriate weight reducing regimen (diet and/or exercise) alone. Below is a chart of Body Mass Index (BMI) based on various heights and weights. BMI is calculated by taking the patient's weight, in kilograms (kg), divided by the patient's height, in meters (m), squared. Metric conversions are as follows: pounds ÷ 2.2 = kg; inches × 0.0254 = meters BODY MASS INDEX (BMI), kg/m 2 Height (feet, inches) The usefulness of agents of this class (see CLINICAL PHARMACOLOGY) should be measured against possible risk factors inherent in their use such as those described below. Phendimetrazine tartrate is indicated for use as monotherapy only. uuid:4d07015f-8d9a-4453-a8ec-350787b2c74e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8059 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:71a0a927-4a0b-46f2-8f8c-1c21e97e6a32"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f0c6e6f1-0db1-42f9-9bb8-cc6d8fe7b502"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Phendimetrazine tartrate extended-release capsules are indicated in the management of exogenous obesity as a short term adjunct (a few weeks) in a regimen of weight reduction based on caloric restriction in patients with an initial body mass index (BMI) of greater than or equal to 30 kg/m2 or greater than or equal to 27 kg/m2 in the presence of other risk factors (e.g., controlled hypertension, diabetes, hyperlipidemia) who have not responded to appropriate weight reducing regimen (diet and/or exercise) alone. Below is a chart of Body Mass Index (BMI) based on various heights and weights. BMI is calculated by taking the patient's weight, in kilograms (kg), divided by the patient's height, in meters (m), squared. Metric conversions are as follows: pounds ÷ 2.2 = kg; inches × 0.0254 = meters BODY MASS INDEX (BMI), kg/m 2 Height (feet, inches) The usefulness of agents of this class (see CLINICAL PHARMACOLOGY) should be measured against possible risk factors inherent in their use such as those described below. Phendimetrazine tartrate is indicated for use as monotherapy only. uuid:12ab7208-cd0e-460d-9f08-6ba86ece559d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135920 biolink:treats EFO:0006865 PMID:41385096 "[{""id"":""uuid:2fb0c92b-9262-43a9-9927-43ddca54305b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fc9c9631-de1d-47c4-b599-ef901f7edd4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:be900fce-b0ec-4306-8578-3d33dcbbe4f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Toviaz ® is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.|[PMDA] Drugs with a new active ingredient indicated for the treatment of urinary urgency, urinary frequency, and urge urinary incontinence associated with overactive bladder. uuid:f155580f-fb17-428c-bc20-21fd5288ae43 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4659 biolink:treats MONDO:0007079 PMID:41385096 "[{""id"":""uuid:e572632d-fc8a-4a3d-98e4-f7208115f338"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9ace0057-613f-447d-b7f4-de3b6ddbb555"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Disulfiram is an aid in the management of selected chronic alcohol patients who want to remain in a state of enforced sobriety so that supportive and psychotherapeutic treatment may be applied to best advantage. Disulfiram is not a cure for alcoholism. When used alone, without proper motivation and supportive therapy, it is unlikely that it will have any substantive effect on the drinking pattern of the chronic alcoholic. uuid:c2ea669f-1e6d-417c-be57-139ff4869f55 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15367 biolink:treats MONDO:0005173 PMID:41385096 "[{""id"":""uuid:455fb900-8f95-43a5-82f5-ecc8e9441f82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:667aac59-d72a-45d8-a37c-b7f9fefe23bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] (To understand fully the indication for this product, please read the entire INDICATIONS AND USAGE section of the labeling.) RENOVA ® (tretinoin cream) 0.02% is indicated as an adjunctive agent (see second bullet point below) for use in the mitigation (palliation) of fine facial wrinkles in patients who use comprehensive skin care and sunlight avoidance programs. RENOVA ® (tretinoin cream) 0.02% DOES NOT ELIMINATE WRINKLES, REPAIR SUN-DAMAGED SKIN, REVERSE PHOTOAGING, or RESTORE MORE YOUTHFUL or YOUNGER SKIN. In double-blinded, vehicle-controlled clinical studies, many patients in the vehicle group achieved desired palliative effects on fine wrinkling of facial skin with the use of comprehensive skin care and sunlight avoidance programs including sunscreens, protective clothing, and non-prescription emollient creams. RENOVA ® (tretinoin cream) 0.02% has NOT DEMONSTRATED A MITIGATING EFFECT on significant signs of chronic sunlight exposure such as coarse or deep wrinkling, tactile roughness, mottled hyperpigmentation, lentigines, telangiectasia, skin laxity, keratinocytic atypia, melanocytic atypia, or dermal elastosis. RENOVA ® (tretinoin cream) 0.02% should be used under medical supervision as an adjunct to a comprehensive skin care and sunlight avoidance program that includes the use of effective sunscreens (minimum SPF of 15) and protective clothing. Patients with visible actinic keratoses and patients with a history of skin cancer were excluded from clinical trials of RENOVA ® (tretinoin cream) 0.02%. Thus the effectiveness and safety of RENOVA ® (tretinoin cream) 0.02% in these populations are not known at this time. Neither the safety nor the effectiveness of RENOVA ® (tretinoin cream) 0.02% for the prevention or treatment of actinic keratoses or skin neoplasms has been established. Neither the safety nor the efficacy of RENOVA ® (tretinoin cream) 0.02% daily for greater than 52 weeks has been established, and daily use beyond 52 weeks has not been systematically and histologically investigated in adequate and well-controlled trials. (See WARNINGS section.) uuid:181084cc-a346-40e1-9aa4-5800fdabae47 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15367 biolink:treats MONDO:0002898 PMID:41385096 "[{""id"":""uuid:6540c780-b830-483d-bf91-2752720ba5d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:38c0bff2-f7c1-4de6-9730-26b059ea70a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] (To understand fully the indication for this product, please read the entire INDICATIONS AND USAGE section of the labeling.) RENOVA ® (tretinoin cream) 0.02% is indicated as an adjunctive agent (see second bullet point below) for use in the mitigation (palliation) of fine facial wrinkles in patients who use comprehensive skin care and sunlight avoidance programs. RENOVA ® (tretinoin cream) 0.02% DOES NOT ELIMINATE WRINKLES, REPAIR SUN-DAMAGED SKIN, REVERSE PHOTOAGING, or RESTORE MORE YOUTHFUL or YOUNGER SKIN. In double-blinded, vehicle-controlled clinical studies, many patients in the vehicle group achieved desired palliative effects on fine wrinkling of facial skin with the use of comprehensive skin care and sunlight avoidance programs including sunscreens, protective clothing, and non-prescription emollient creams. RENOVA ® (tretinoin cream) 0.02% has NOT DEMONSTRATED A MITIGATING EFFECT on significant signs of chronic sunlight exposure such as coarse or deep wrinkling, tactile roughness, mottled hyperpigmentation, lentigines, telangiectasia, skin laxity, keratinocytic atypia, melanocytic atypia, or dermal elastosis. RENOVA ® (tretinoin cream) 0.02% should be used under medical supervision as an adjunct to a comprehensive skin care and sunlight avoidance program that includes the use of effective sunscreens (minimum SPF of 15) and protective clothing. Patients with visible actinic keratoses and patients with a history of skin cancer were excluded from clinical trials of RENOVA ® (tretinoin cream) 0.02%. Thus the effectiveness and safety of RENOVA ® (tretinoin cream) 0.02% in these populations are not known at this time. Neither the safety nor the effectiveness of RENOVA ® (tretinoin cream) 0.02% for the prevention or treatment of actinic keratoses or skin neoplasms has been established. Neither the safety nor the efficacy of RENOVA ® (tretinoin cream) 0.02% daily for greater than 52 weeks has been established, and daily use beyond 52 weeks has not been systematically and histologically investigated in adequate and well-controlled trials. (See WARNINGS section.) uuid:3aa66b73-c2f7-4d0f-a8cd-7a5b923563f9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15367 biolink:treats MONDO:0002531 PMID:41385096 "[{""id"":""uuid:3a45a82b-5bf7-4887-a9dc-c956fde7462e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:20e1cb48-246b-4600-b656-7a5cc9ecbf08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] (To understand fully the indication for this product, please read the entire INDICATIONS AND USAGE section of the labeling.) RENOVA ® (tretinoin cream) 0.02% is indicated as an adjunctive agent (see second bullet point below) for use in the mitigation (palliation) of fine facial wrinkles in patients who use comprehensive skin care and sunlight avoidance programs. RENOVA ® (tretinoin cream) 0.02% DOES NOT ELIMINATE WRINKLES, REPAIR SUN-DAMAGED SKIN, REVERSE PHOTOAGING, or RESTORE MORE YOUTHFUL or YOUNGER SKIN. In double-blinded, vehicle-controlled clinical studies, many patients in the vehicle group achieved desired palliative effects on fine wrinkling of facial skin with the use of comprehensive skin care and sunlight avoidance programs including sunscreens, protective clothing, and non-prescription emollient creams. RENOVA ® (tretinoin cream) 0.02% has NOT DEMONSTRATED A MITIGATING EFFECT on significant signs of chronic sunlight exposure such as coarse or deep wrinkling, tactile roughness, mottled hyperpigmentation, lentigines, telangiectasia, skin laxity, keratinocytic atypia, melanocytic atypia, or dermal elastosis. RENOVA ® (tretinoin cream) 0.02% should be used under medical supervision as an adjunct to a comprehensive skin care and sunlight avoidance program that includes the use of effective sunscreens (minimum SPF of 15) and protective clothing. Patients with visible actinic keratoses and patients with a history of skin cancer were excluded from clinical trials of RENOVA ® (tretinoin cream) 0.02%. Thus the effectiveness and safety of RENOVA ® (tretinoin cream) 0.02% in these populations are not known at this time. Neither the safety nor the effectiveness of RENOVA ® (tretinoin cream) 0.02% for the prevention or treatment of actinic keratoses or skin neoplasms has been established. Neither the safety nor the efficacy of RENOVA ® (tretinoin cream) 0.02% daily for greater than 52 weeks has been established, and daily use beyond 52 weeks has not been systematically and histologically investigated in adequate and well-controlled trials. (See WARNINGS section.) uuid:559965dc-bd51-4275-b27a-c0da32ceb1e5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18332 biolink:treats MONDO:0002108 PMID:41385096 "[{""id"":""uuid:c91d6b19-7236-415f-8fc6-498459ac5fc9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:373342d6-8ce0-43da-bf92-c50dcd5dafd8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levothyroxine sodium is used for the following indications: Hypothyroidism - As replacement or supplemental therapy in congenital or acquired hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. Specific indications include: primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) hypothyroidism and subclinical hypothyroidism. Primary hypothyroidism may result from functional deficiency, primary atrophy, partial or total congenital absence of the thyroid gland, or from the effects of surgery, radiation, or drugs, with or without the presence of goiter. Pituitary TSH Suppression - In the treatment or prevention of various types of euthyroid goiters (see WARNINGS and PRECAUTIONS ), including thyroid nodules (see WARNINGS and PRECAUTIONS ), subacute or chronic Iymphocytic thyroiditis (Hashimoto's thyroiditis), multinodular goiter (see WARNINGS and PRECAUTIONS ), and, as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. uuid:60f908da-768f-4dc3-8669-34806761ab69 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5391 biolink:treats UMLS:C4728082 PMID:41385096 "[{""id"":""uuid:40fe4f10-4f82-42b3-abbd-d9f09507a3fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f4043bc9-b81f-4bd1-b750-6341b99a35f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Glucagon is indicated as a treatment for severe hypoglycemia. Because patients with type 1 diabetes may have less of an increase in blood glucose levels compared with a stable type 2 patient, supplementary carbohydrate should be given as soon as possible, especially to a pediatric patient. uuid:171d8eb2-1528-41f8-9519-ed7b795aa61e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5391 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:1d07de27-a716-4a51-956c-7ea0508aab85"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:934d668e-a5b0-4808-bb13-f9ab87bfc235"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Glucagon is indicated as a treatment for severe hypoglycemia. Because patients with type 1 diabetes may have less of an increase in blood glucose levels compared with a stable type 2 patient, supplementary carbohydrate should be given as soon as possible, especially to a pediatric patient. uuid:01e62345-c5f2-4823-b74a-6b6a80b0db59 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5391 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:16ba092c-0523-46e6-b5ff-a458237c9867"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:818428f2-0249-4534-b820-73d3e0a2c2d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Glucagon is indicated as a treatment for severe hypoglycemia. Because patients with type 1 diabetes may have less of an increase in blood glucose levels compared with a stable type 2 patient, supplementary carbohydrate should be given as soon as possible, especially to a pediatric patient. uuid:47830626-ca02-43fc-ab49-1811d0780bd5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1152283 biolink:treats NCIT:C50995 PMID:41385096 "[{""id"":""uuid:fa700b29-71ce-48a6-a04f-95ccc3e319b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bad5ab1d-f02d-4564-b216-95996363fcb6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] {template} uuid:3e9642ae-92a6-44bf-9d4c-d56a1b2b4e15 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27882 biolink:treats MONDO:0005393 PMID:41385096 "[{""id"":""uuid:a7176634-1c0e-41cb-8ed7-06243a081411"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e6e55f87-5914-47ec-a842-ba55fa4c5b28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] COLCRYS (colchicine, USP) tablets are an alkaloid indicated for: Prophylaxis and Treatment of Gout Flares in adults ( 1.1 ). Familial Mediterranean fever (FMF) in adults and children 4 years or older ( 1.2 ). COLCRYS is not an analgesic medication and should not be used to treat pain from other causes. uuid:9b2e386a-d985-441e-9c3b-084d6c8fe3e7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27882 biolink:treats MONDO:0018088 PMID:41385096 "[{""id"":""uuid:55592910-76b4-4a3b-a822-8e3eb58b18e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:803d78c1-e96d-4aea-871c-ec6acae2bb5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:60aef454-c39b-46f5-b690-f027c70b96a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] COLCRYS (colchicine, USP) tablets are an alkaloid indicated for: Prophylaxis and Treatment of Gout Flares in adults ( 1.1 ). Familial Mediterranean fever (FMF) in adults and children 4 years or older ( 1.2 ). COLCRYS is not an analgesic medication and should not be used to treat pain from other causes.|[PMDA] A drug with a new additional indication and a new dosage for the treatment of familial Mediterranean fever. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:3d7f2081-70dd-444c-aa15-d81b6e5c2717 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64354 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:18d77e0c-c97c-4eea-a496-c7be08bb0e64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:94ee0272-05ac-4ccd-ab2f-a2a071332493"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metolazone tablets USP are indicated for the treatment of salt and water retention including: • edema accompanying congestive heart failure; • edema accompanying renal diseases, including the nephrotic syndrome and states of diminished renal function. Metolazone tablets USP are also indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs of a different class. Mykrox ® tablets, a more rapidly available form of metolazone, are intended for the treatment of new patients with mild to moderate hypertension. A dose titration is necessary if Mykrox ® tablets are to be substituted for Zaroxolyn ® tablets and other formulations of metolazone that share its slow and incomplete bioavailability, in the treatment of hypertension. uuid:ec1fe928-39a5-4fd6-99df-32fd4a5c48d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64354 biolink:treats MONDO:0005240 PMID:41385096 "[{""id"":""uuid:171e6e68-dd8c-4cfc-ad81-4eada8799c8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:84b67da1-9c8b-4720-b4fe-d34f8dcf7b03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metolazone tablets USP are indicated for the treatment of salt and water retention including: • edema accompanying congestive heart failure; • edema accompanying renal diseases, including the nephrotic syndrome and states of diminished renal function. Metolazone tablets USP are also indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs of a different class. Mykrox ® tablets, a more rapidly available form of metolazone, are intended for the treatment of new patients with mild to moderate hypertension. A dose titration is necessary if Mykrox ® tablets are to be substituted for Zaroxolyn ® tablets and other formulations of metolazone that share its slow and incomplete bioavailability, in the treatment of hypertension. uuid:35517759-3535-4eb1-bd73-c473ccc96beb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64354 biolink:treats MONDO:0005377 PMID:41385096 "[{""id"":""uuid:50755672-0c5a-459e-a5d3-11cdde2f9cc8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1fc16dcf-aca9-4008-a6d0-cc727e8bd1ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metolazone tablets USP are indicated for the treatment of salt and water retention including: • edema accompanying congestive heart failure; • edema accompanying renal diseases, including the nephrotic syndrome and states of diminished renal function. Metolazone tablets USP are also indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs of a different class. Mykrox ® tablets, a more rapidly available form of metolazone, are intended for the treatment of new patients with mild to moderate hypertension. A dose titration is necessary if Mykrox ® tablets are to be substituted for Zaroxolyn ® tablets and other formulations of metolazone that share its slow and incomplete bioavailability, in the treatment of hypertension. uuid:01e1632c-1a95-422f-be67-c218a667ab4b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64354 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:e31d096e-0ea5-4056-9649-4385178eb00a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5e70d43b-2099-4403-b4f5-1e2b8d9baa4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metolazone tablets USP are indicated for the treatment of salt and water retention including: • edema accompanying congestive heart failure; • edema accompanying renal diseases, including the nephrotic syndrome and states of diminished renal function. Metolazone tablets USP are also indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs of a different class. Mykrox ® tablets, a more rapidly available form of metolazone, are intended for the treatment of new patients with mild to moderate hypertension. A dose titration is necessary if Mykrox ® tablets are to be substituted for Zaroxolyn ® tablets and other formulations of metolazone that share its slow and incomplete bioavailability, in the treatment of hypertension. uuid:ed7e686c-ac38-4844-816e-e8a33881cbbc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2567 biolink:treats MONDO:0008159 PMID:41385096 "[{""id"":""uuid:2530d305-b87e-436b-946a-263ca93a6f4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:432ad6d6-debc-47e0-9cd7-cdb25b5f12b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Alendronate sodium tablets are indicated for: Treatment and prevention of osteoporosis in postmenopausal women For the treatment of osteoporosis, alendronate sodium tablets increase bone mass and reduce the incidence of fractures, including those of the hip and spine (vertebral compression fractures). Osteoporosis may be confirmed by the finding of low bone mass (for example, at least 2 standard deviations below the premenopausal mean) or by the presence or history of osteoporotic fracture (see CLINICAL PHARMACOLOGY , Pharmacodynamics ). For the prevention of osteoporosis, alendronate sodium tablets may be considered in postmenopausal women who are at risk of developing osteoporosis and for whom the desired clinical outcome is to maintain bone mass and to reduce the risk of future fracture. Bone loss is particularly rapid in postmenopausal women younger than age 60. Risk factors often associated with the development of postmenopausal osteoporosis include early menopause; moderately low bone mass (for example, at least 1 standard deviation below the mean for healthy young adult women); thin body build; Caucasian or Asian race; and family history of osteoporosis. The presence of such risk factors may be important when considering the use of alendronate sodium for prevention of osteoporosis. Treatment to increase bone mass in men with osteoporosis Treatment of glucocorticoid-induced osteoporosis in men and women receiving glucocorticoids in a daily dosage equivalent to 7.5 mg or greater of prednisone and who have low bone mineral density (see PRECAUTIONS , Glucocorticoid-induced osteoporosis ). Patients treated with glucocorticoids should receive adequate amounts of calcium and vitamin D. Treatment of Paget’s disease of bone in men and women Treatment is indicated in patients with Paget’s disease of bone having alkaline phosphatase at least two times the upper limit of normal, or those who are symptomatic, or those at risk for future complications from their disease. The safety and effectiveness of alendronate sodium tablets for the treatment of osteoporosis are based on clinical data of four years duration. The optimal duration of use has not been determined. All patients on bisphosphonate therapy should have the need for continued therapy re-evaluated on a periodic basis. uuid:bd5f5863-a4f5-493a-b1d1-f6b6b665e2e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0004670 PMID:41385096 "[{""id"":""uuid:16a7fdf1-3f90-4dfc-885b-3ddb614b47ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:336dab03-271e-4349-97b5-da40429305f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisolone Sodium Phosphate Oral Solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under “Allergic States”), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren’s syndrome, relapsing polychrondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). uuid:83d49e6e-4cb2-442f-9d96-81c795c1a740 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0018170 PMID:41385096 "[{""id"":""uuid:8140c1d3-77b0-4fd5-b4d6-e11b5b997616"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cb9c3fd6-a802-4c5a-a33e-5b9aa422bd2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisolone Sodium Phosphate Oral Solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under “Allergic States”), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren’s syndrome, relapsing polychrondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). uuid:9cb5563b-e479-43fd-b8fe-3bbd40d102bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0001705 PMID:41385096 "[{""id"":""uuid:970ceb20-b64d-465b-a1cf-aa0d94f6a441"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a98b8e0e-f6cd-4c15-afda-6d8b085c5377"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisolone Sodium Phosphate Oral Solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under “Allergic States”), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren’s syndrome, relapsing polychrondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). uuid:4060b7ef-0fa2-4591-8689-bba0f3da4b74 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0017595 PMID:41385096 "[{""id"":""uuid:4838233b-381f-4988-bb7b-2d1d47834b45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9b6ba216-65ad-4369-91d2-5b36dcdb44cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisolone Sodium Phosphate Oral Solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under “Allergic States”), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren’s syndrome, relapsing polychrondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). uuid:419fe6b4-ea84-4060-88ae-9cc1cc54db4d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0020283 PMID:41385096 "[{""id"":""uuid:b3162721-e626-4770-9acc-60afff4e874b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2413a2f1-2e52-445e-ba61-b46e1c1f00aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisolone Sodium Phosphate Oral Solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under “Allergic States”), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren’s syndrome, relapsing polychrondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). uuid:519d109a-3cd4-4b34-a5bd-81838d9c0beb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0008538 PMID:41385096 "[{""id"":""uuid:c50ab88c-48a5-4de5-b762-b0fa083e8295"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d8d7c774-f70e-476e-a6be-70d558048826"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisolone Sodium Phosphate Oral Solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under “Allergic States”), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren’s syndrome, relapsing polychrondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). uuid:d1860d83-8d09-4ad5-843f-193ea791d2ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0015927 PMID:41385096 "[{""id"":""uuid:253bfaf9-9e9f-4b23-8a9a-913c374ace20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5307b7c3-0bba-4f9d-ae2f-80c43f36a470"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisolone Sodium Phosphate Oral Solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under “Allergic States”), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren’s syndrome, relapsing polychrondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). uuid:b94d9a0d-3db2-430e-8680-7558089ab789 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0017853 PMID:41385096 "[{""id"":""uuid:72159675-954f-4670-bdcf-401b5a70a943"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:64d1662f-5ea3-4916-9a86-188abd96a7b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisolone Sodium Phosphate Oral Solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under “Allergic States”), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren’s syndrome, relapsing polychrondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). uuid:97f316f7-71b6-4be3-8340-b8649f11ef93 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0002771 PMID:41385096 "[{""id"":""uuid:22afb456-e526-4407-be30-99549690f213"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0afc219e-6e90-4704-881b-6eff8b1749e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisolone Sodium Phosphate Oral Solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under “Allergic States”), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren’s syndrome, relapsing polychrondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). uuid:08fecbc1-23d2-46d7-9dc1-080afc547127 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats UMLS:C0340044 PMID:41385096 "[{""id"":""uuid:d423ee3a-1106-4383-a669-6f450953110e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:50451092-5c73-4e37-be82-7d5f9f89745d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisolone Sodium Phosphate Oral Solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under “Allergic States”), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren’s syndrome, relapsing polychrondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). uuid:21d37e28-4940-4f18-94e8-a79348ee6644 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0019121 PMID:41385096 "[{""id"":""uuid:95cf6503-4d01-4d1d-944e-ab0ec7562c73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c85c38c1-a3bc-4152-afef-30a0a9f162bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisolone Sodium Phosphate Oral Solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under “Allergic States”), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren’s syndrome, relapsing polychrondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). uuid:6fc4f9e7-1781-4e01-b357-56521f873a1d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0015243 PMID:41385096 "[{""id"":""uuid:8745955a-3e28-4114-a304-c282a30b7183"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cc21db6c-ef11-4125-8196-c5be8c8bce34"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisolone Sodium Phosphate Oral Solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under “Allergic States”), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren’s syndrome, relapsing polychrondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). uuid:8f75316a-002e-4abc-b70d-203a97efdab8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0015264 PMID:41385096 "[{""id"":""uuid:303b5d75-0412-41ec-8c5b-78bee6699767"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:048629e1-000f-4850-a3ee-392e0bd53196"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisolone Sodium Phosphate Oral Solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under “Allergic States”), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren’s syndrome, relapsing polychrondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). uuid:0164eb21-f88f-43a1-ad73-8a6dae5b1213 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0019735 PMID:41385096 "[{""id"":""uuid:a4fe6e1f-1368-4a9a-9367-e2c42f1ee567"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1efa4df4-01c4-4806-849b-aac41eb819e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisolone Sodium Phosphate Oral Solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under “Allergic States”), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren’s syndrome, relapsing polychrondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). uuid:b9c8db97-2b9f-4aeb-9ffd-cbc3cfdb2258 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0010030 PMID:41385096 "[{""id"":""uuid:703d9fa8-d412-4c88-9076-34dece41614d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fcaad14f-af13-4daf-b688-e9cc0014d0e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisolone Sodium Phosphate Oral Solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under “Allergic States”), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren’s syndrome, relapsing polychrondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). uuid:db6fae77-270d-4b14-80f9-76305c7cda40 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0019125 PMID:41385096 "[{""id"":""uuid:d95b6914-8b0d-434e-85a5-9eed5c9de2c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:361291ee-3192-4dbb-9a9c-b96d48aefdb4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisolone Sodium Phosphate Oral Solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under “Allergic States”), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren’s syndrome, relapsing polychrondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). uuid:3abbf876-5728-4898-8b98-048c2944ff5e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0018882 PMID:41385096 "[{""id"":""uuid:d2612321-fd5f-42c5-950f-ee8d865b0de5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0f1309eb-c067-4f62-940d-5cc6d70d8365"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisolone Sodium Phosphate Oral Solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under “Allergic States”), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren’s syndrome, relapsing polychrondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). uuid:37d1c1c4-3b6d-40d6-b1fd-ee427aae8195 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0018310 PMID:41385096 "[{""id"":""uuid:42eb72b2-dc45-412a-b653-110701f8dc03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a60783b4-d28f-4768-9353-5b7937325598"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisolone Sodium Phosphate Oral Solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under “Allergic States”), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren’s syndrome, relapsing polychrondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). uuid:be2c0fef-3922-4f02-a769-9d86a5ac994c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0005922 PMID:41385096 "[{""id"":""uuid:be48f383-f3d2-4aeb-ba64-8bb88cf10f65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4c805ccb-d3d3-4a7c-ba95-81d0fd08d414"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisolone Sodium Phosphate Oral Solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under “Allergic States”), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren’s syndrome, relapsing polychrondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). uuid:c74dfb5a-c9be-4bbe-90c0-fd2b2780bf79 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0005903 PMID:41385096 "[{""id"":""uuid:b9b0b29b-256e-41dc-9686-abd23bc5dc95"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:616495c0-8b55-4b79-aae6-06d975ce2779"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisolone Sodium Phosphate Oral Solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under “Allergic States”), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren’s syndrome, relapsing polychrondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). uuid:4f4e045a-ca7d-4b01-ba50-8c932deea023 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:142290 biolink:treats MONDO:0008554 PMID:41385096 "[{""id"":""uuid:23ebb209-5b32-48f7-b893-ee282fed5e38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1c6d5985-8497-4d6e-8aec-e5d8e364e21f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Anagrelide hydrochloride capsules are indicated for the treatment of patients with thrombocythemia, secondary to myeloproliferative disorders, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events (see CLINICAL STUDIES , DOSAGE AND ADMINISTRATION ). uuid:2c94eaf7-eff7-4cc3-8e78-6dfd9fb81237 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:142290 biolink:treats MONDO:0000831 PMID:41385096 "[{""id"":""uuid:6d9dcdd4-c624-4305-a252-c9ce9e7bd529"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2f6eb48c-89e8-4806-a212-d49526a78242"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Anagrelide hydrochloride capsules are indicated for the treatment of patients with thrombocythemia, secondary to myeloproliferative disorders, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events (see CLINICAL STUDIES , DOSAGE AND ADMINISTRATION ). uuid:8a932b9f-7e60-4bff-b6a8-29fe9a6fae82 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:142290 biolink:treats UMLS:C1868936 PMID:41385096 "[{""id"":""uuid:c0584474-825d-48f9-aa46-7dd8397a9afa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ad038033-ee1a-4b9b-aa43-55f2ad229351"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Anagrelide hydrochloride capsules are indicated for the treatment of patients with thrombocythemia, secondary to myeloproliferative disorders, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombo-hemorrhagic events (see CLINICAL STUDIES , DOSAGE AND ADMINISTRATION ). uuid:15ea530a-80dd-4b81-8167-861450b02541 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3207 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:58b97c96-45e8-4f4f-b752-270bd2feb71c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d0cbc565-f551-4392-b88d-0fc5ecd3a06d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0be848dd-2c72-4dcd-9945-5cb1e872a845"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Budesonide inhalation suspension is an inhaled corticosteroid indicated for: Maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years of age ( 1.1 ) Important Limitations of Use : Not indicated for the relief of acute bronchospasm ( 1.1 )|[PMDA] Drugs with new dosages and dosage forms indicated for use in children from 6 months and under 5 years of age to treat asthma. [Expedited Review] uuid:319a542d-d19c-40de-926f-a906928583b8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7465 biolink:treats MONDO:0007079 PMID:41385096 "[{""id"":""uuid:ea6cc47c-213c-44b8-b307-4e34cc98cb5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8a42384d-5c0e-4cfa-8616-3b894532df75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Naltrexone hydrochloride tablets are indicated in the treatment of alcohol dependence and for the blockade of the effects of exogenously administered opioids. Naltrexone has not been shown to provide any therapeutic benefit except as part of an appropriate plan of management for the addictions. uuid:2efa66cd-8219-4e8c-a624-7cc4c412d851 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7465 biolink:treats MONDO:0005530 PMID:41385096 "[{""id"":""uuid:4eba3201-9a8f-4aaf-82fa-3993c47fdcdb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:17ebe718-4d4b-424d-b53c-f75724c27e93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Naltrexone hydrochloride tablets are indicated in the treatment of alcohol dependence and for the blockade of the effects of exogenously administered opioids. Naltrexone has not been shown to provide any therapeutic benefit except as part of an appropriate plan of management for the addictions. uuid:04359266-3c08-4db6-bc13-07bf1eff60b9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3181 biolink:treats MONDO:0001836 PMID:41385096 "[{""id"":""uuid:6e70e49d-d380-4ceb-a914-3ac6efe1f59e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5b77659f-5a26-4e1d-af65-2fbac3848754"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bromocriptine mesylate tablets and capsules are indicated for the treatment of dysfunctions associated with hyperprolactinemia including amenorrhea with or without galactorrhea, infertility or hypogonadism . Bromocriptine treatment is indicated in patients with prolactin-secreting adenomas , which may be the basic underlying endocrinopathy contributing to the above clinical presentations. Reduction in tumor size has been demonstrated in both male and female patients with macroadenomas. In cases where adenectomy is elected, a course of bromocriptine therapy may be used to reduce the tumor mass prior to surgery. uuid:9e5a1d72-2240-43ed-a237-3f7ad8ba8e7e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3181 biolink:treats MONDO:0009256 PMID:41385096 "[{""id"":""uuid:f9dfd8f3-cb13-4c40-b5ad-862ef561e3d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2eb143d8-8695-4cf5-a5b9-452f3c7eb067"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bromocriptine mesylate tablets and capsules are indicated for the treatment of dysfunctions associated with hyperprolactinemia including amenorrhea with or without galactorrhea, infertility or hypogonadism . Bromocriptine treatment is indicated in patients with prolactin-secreting adenomas , which may be the basic underlying endocrinopathy contributing to the above clinical presentations. Reduction in tumor size has been demonstrated in both male and female patients with macroadenomas. In cases where adenectomy is elected, a course of bromocriptine therapy may be used to reduce the tumor mass prior to surgery. uuid:07fc47db-fd2b-4f03-bfc6-b08794f83c5f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3181 biolink:treats MONDO:0005047 PMID:41385096 "[{""id"":""uuid:32ed2ab3-1c38-4032-97cd-57b9e8763b79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a9312a12-72db-4fa1-83a0-ee41223ea7a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bromocriptine mesylate tablets and capsules are indicated for the treatment of dysfunctions associated with hyperprolactinemia including amenorrhea with or without galactorrhea, infertility or hypogonadism . Bromocriptine treatment is indicated in patients with prolactin-secreting adenomas , which may be the basic underlying endocrinopathy contributing to the above clinical presentations. Reduction in tumor size has been demonstrated in both male and female patients with macroadenomas. In cases where adenectomy is elected, a course of bromocriptine therapy may be used to reduce the tumor mass prior to surgery. uuid:6831943f-3fd7-4ab3-89ea-6bfb41ff685d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3181 biolink:treats MONDO:0002146 PMID:41385096 "[{""id"":""uuid:96f1b152-95aa-446e-9634-8435b68e7534"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a5b3728e-32ac-45d8-9dd6-19682eaf2481"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bromocriptine mesylate tablets and capsules are indicated for the treatment of dysfunctions associated with hyperprolactinemia including amenorrhea with or without galactorrhea, infertility or hypogonadism . Bromocriptine treatment is indicated in patients with prolactin-secreting adenomas , which may be the basic underlying endocrinopathy contributing to the above clinical presentations. Reduction in tumor size has been demonstrated in both male and female patients with macroadenomas. In cases where adenectomy is elected, a course of bromocriptine therapy may be used to reduce the tumor mass prior to surgery. uuid:4ee0f9ea-3464-47a4-b64c-276952fa41a5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3181 biolink:treats MONDO:0010911 PMID:41385096 "[{""id"":""uuid:c340e382-1d0e-4c02-9bc8-1ec9f6d0132b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3209160b-1c4b-4604-b562-5296b64bd702"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bromocriptine mesylate tablets and capsules are indicated for the treatment of dysfunctions associated with hyperprolactinemia including amenorrhea with or without galactorrhea, infertility or hypogonadism . Bromocriptine treatment is indicated in patients with prolactin-secreting adenomas , which may be the basic underlying endocrinopathy contributing to the above clinical presentations. Reduction in tumor size has been demonstrated in both male and female patients with macroadenomas. In cases where adenectomy is elected, a course of bromocriptine therapy may be used to reduce the tumor mass prior to surgery. uuid:54b58fdc-a18b-4c50-8d3f-fc1a8148ab6d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3181 biolink:treats HP:0025693 PMID:41385096 "[{""id"":""uuid:bc91b90f-f4d1-4d0d-b4df-87a4f807232e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1059c5e7-0259-4489-ae8a-0432d0390455"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bromocriptine mesylate tablets and capsules are indicated for the treatment of dysfunctions associated with hyperprolactinemia including amenorrhea with or without galactorrhea, infertility or hypogonadism . Bromocriptine treatment is indicated in patients with prolactin-secreting adenomas , which may be the basic underlying endocrinopathy contributing to the above clinical presentations. Reduction in tumor size has been demonstrated in both male and female patients with macroadenomas. In cases where adenectomy is elected, a course of bromocriptine therapy may be used to reduce the tumor mass prior to surgery. uuid:2068b9e2-b53f-48eb-aaa5-f1a079623cac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:616538 biolink:treats MONDO:0005412 PMID:41385096 "[{""id"":""uuid:9265851d-8b03-4ac6-a61c-37fd4caffe76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b88a47c8-5640-4eab-b7be-fae9c0b23817"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZEGERID is a proton pump inhibitor indicated for: Short-term treatment of active duodenal ulcer ( 1.1 ) Short-term treatment of active benign gastric ulcer ( 1.2 ) Treatment of gastroesophageal reflux disease (GERD) ( 1.3 ) Maintenance of healing of erosive esophagitis ( 1.4 ) Reduction of risk of upper GI bleeding in critically ill patients ( 1.5 ) The safety and effectiveness of ZEGERID in pediatric patients (<18 years of age) have not been established. ( 8.4 ) uuid:23699a5f-6f60-4c17-bb54-a30afe111087 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:616538 biolink:treats MONDO:0001126 PMID:41385096 "[{""id"":""uuid:7fbcbb70-fe52-42b0-8a9d-09ab87c15f06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:baecc7ef-5a31-4e48-b01b-25eff10c22e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZEGERID is a proton pump inhibitor indicated for: Short-term treatment of active duodenal ulcer ( 1.1 ) Short-term treatment of active benign gastric ulcer ( 1.2 ) Treatment of gastroesophageal reflux disease (GERD) ( 1.3 ) Maintenance of healing of erosive esophagitis ( 1.4 ) Reduction of risk of upper GI bleeding in critically ill patients ( 1.5 ) The safety and effectiveness of ZEGERID in pediatric patients (<18 years of age) have not been established. ( 8.4 ) uuid:b612073c-eb66-4db5-b719-f2e9f7598141 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:616538 biolink:treats UMLS:C0267055 PMID:41385096 "[{""id"":""uuid:96342822-9062-4e36-8f30-79598eeb2b12"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9fac1e8c-f668-40c4-b82e-55503b8ba7da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZEGERID is a proton pump inhibitor indicated for: Short-term treatment of active duodenal ulcer ( 1.1 ) Short-term treatment of active benign gastric ulcer ( 1.2 ) Treatment of gastroesophageal reflux disease (GERD) ( 1.3 ) Maintenance of healing of erosive esophagitis ( 1.4 ) Reduction of risk of upper GI bleeding in critically ill patients ( 1.5 ) The safety and effectiveness of ZEGERID in pediatric patients (<18 years of age) have not been established. ( 8.4 ) uuid:154b9465-12fc-43ff-b740-9db25b35d967 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:616538 biolink:treats UMLS:C0041909 PMID:41385096 "[{""id"":""uuid:f5db3c87-490e-4e46-8fec-0be6987ff93d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bd24f1b9-ef1a-4deb-ba95-073787f2356d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZEGERID is a proton pump inhibitor indicated for: Short-term treatment of active duodenal ulcer ( 1.1 ) Short-term treatment of active benign gastric ulcer ( 1.2 ) Treatment of gastroesophageal reflux disease (GERD) ( 1.3 ) Maintenance of healing of erosive esophagitis ( 1.4 ) Reduction of risk of upper GI bleeding in critically ill patients ( 1.5 ) The safety and effectiveness of ZEGERID in pediatric patients (<18 years of age) have not been established. ( 8.4 ) uuid:a85129dd-2bfa-4a57-a7a2-fb9f492ecb79 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:48390 biolink:treats MONDO:0012004 PMID:41385096 "[{""id"":""uuid:69a2eac9-8062-4e06-bef2-b3ecb966bd97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7b018598-483b-4cd5-bbf4-fb5404c77333"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:57734506-c538-481b-9a2c-f65b8c9de4b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d4863874-991f-41a3-bc36-9e96eae088cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sensipar is a calcium-sensing receptor agonist indicated for: Secondary Hyperparathyroidism (HPT) in patients with chronic kidney disease (CKD) on dialysis. ( 1.1 ) Hypercalcemia in patients with Parathyroid Carcinoma (PC). ( 1.2 ) Severe hypercalcemia in patients with primary HPT who are unable to undergo parathyroidectomy. ( 1.3 )|[EMA] Secondary hyperparathyroidismAdultsTreatment of secondary hyperparathyroidism (HPT) in adult patients with end-stage renal disease (ESRD) on maintenance dialysis therapy.Paediatric populationTreatment of secondary hyperparathyroidism (HPT) in children aged 3 years and older with end-stage renal disease (ESRD) on maintenance dialysis therapy in whom secondary HPT is not adequately controlled with standard of care therapy (see section 4.4).Cinacalcet Accordpharma may be used as part of a therapeutic regimen including phosphate binders and/or Vitamin D sterols, as appropriate (see section 5.1).Parathyroid carcinoma and primary hyperparathyroidism in adultsReduction of hypercalcaemia in adult patients with:parathyroid carcinoma.primary HPT for whom parathyroidectomy would be indicated on the basis of serum calcium levels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is contraindicated.|[PMDA] Drugs with a new additional indication and a new dosage for the treatment of hypercalcemia in patients with parathyroid carcinoma, and hypercalcemia in patients with primary hyperparathyroidism (HPT) who are unable to undergo parathyroidectomy or who experience recurrent primary HPT after the surgery. [Orphan drug] uuid:ee9b1e35-9dec-4e16-88f8-2f1e03a18a96 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:48390 biolink:treats MONDO:0010837 PMID:41385096 "[{""id"":""uuid:ad6206b4-12a9-482c-8f2c-c4e2abf7a13e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cf26b4c7-8b6b-4e2c-b34c-e3c41599eb4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:49b70c33-b606-4957-bcbd-dbdbf952a2fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:dcdf8954-4ba9-4ff8-adb9-1d10e676ceca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sensipar is a calcium-sensing receptor agonist indicated for: Secondary Hyperparathyroidism (HPT) in patients with chronic kidney disease (CKD) on dialysis. ( 1.1 ) Hypercalcemia in patients with Parathyroid Carcinoma (PC). ( 1.2 ) Severe hypercalcemia in patients with primary HPT who are unable to undergo parathyroidectomy. ( 1.3 )|[EMA] Secondary hyperparathyroidismAdultsTreatment of secondary hyperparathyroidism (HPT) in adult patients with end-stage renal disease (ESRD) on maintenance dialysis therapy.Paediatric populationTreatment of secondary hyperparathyroidism (HPT) in children aged 3 years and older with end-stage renal disease (ESRD) on maintenance dialysis therapy in whom secondary HPT is not adequately controlled with standard of care therapy (see section 4.4).Cinacalcet Accordpharma may be used as part of a therapeutic regimen including phosphate binders and/or Vitamin D sterols, as appropriate (see section 5.1).Parathyroid carcinoma and primary hyperparathyroidism in adultsReduction of hypercalcaemia in adult patients with:parathyroid carcinoma.primary HPT for whom parathyroidectomy would be indicated on the basis of serum calcium levels (as defined by relevant treatment guidelines), but in whom parathyroidectomy is not clinically appropriate or is contraindicated.|[PMDA] Drugs with a new additional indication and a new dosage for the treatment of hypercalcemia in patients with parathyroid carcinoma, and hypercalcemia in patients with primary hyperparathyroidism (HPT) who are unable to undergo parathyroidectomy or who experience recurrent primary HPT after the surgery. [Orphan drug] uuid:7f001b1b-26f1-43c2-a017-ab2e350b0135 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:36560 biolink:treats MONDO:0000736 PMID:41385096 "[{""id"":""uuid:a4b402fd-466a-4ec4-9232-ee9a3d8c688b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b0fe4805-4722-4a8e-bcac-39989b358e66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The gradual bleaching of hyperpigmented skin conditions such as chloasma, melasma, freckles, senile lentigines, and other unwanted areas of melanin hyperpigmentation. uuid:cfb36839-6a86-423e-88cd-aba137682dcf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:36560 biolink:treats MONDO:0021582 PMID:41385096 "[{""id"":""uuid:143f3452-d612-4c18-a440-e59f2fa790c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8c242271-de9a-44d5-9400-9e4aa5363c43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The gradual bleaching of hyperpigmented skin conditions such as chloasma, melasma, freckles, senile lentigines, and other unwanted areas of melanin hyperpigmentation. uuid:3abed9b8-04e6-46da-990b-a45baddc0474 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29688 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:ae8bcc3b-1318-42b8-bf9f-f251b24006be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4cdb7a15-2b08-43a3-ba68-fbecd0c6bf40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KETEK tablets are indicated for the treatment of community-acquired pneumonia (of mild to moderate severity) due to Streptococcus pneumoniae , (including multi-drug resistant isolates [MDRSP MDRSP, Multi-drug resistant Streptococcus pneumoniae includes isolates known as PRSP (penicillin-resistant Streptococcus pneumoniae ), and are isolates resistant to two or more of the following antibiotics: penicillin, 2 nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. ]), Haemophilus influenzae , Moraxella catarrhalis , Chlamydophila pneumoniae , or Mycoplasma pneumoniae , for patients 18 years old and above. To reduce the development of drug-resistant bacteria and maintain the effectiveness of KETEK and other antibacterial drugs, KETEK should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:c5884077-8a9d-430f-b9a0-558ec6ef102d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29688 biolink:treats MONDO:0005114 PMID:41385096 "[{""id"":""uuid:2e337683-030c-4c79-81bb-66290434590b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:403082b7-0bde-4dfd-82ee-bc4525772a7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KETEK tablets are indicated for the treatment of community-acquired pneumonia (of mild to moderate severity) due to Streptococcus pneumoniae , (including multi-drug resistant isolates [MDRSP MDRSP, Multi-drug resistant Streptococcus pneumoniae includes isolates known as PRSP (penicillin-resistant Streptococcus pneumoniae ), and are isolates resistant to two or more of the following antibiotics: penicillin, 2 nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. ]), Haemophilus influenzae , Moraxella catarrhalis , Chlamydophila pneumoniae , or Mycoplasma pneumoniae , for patients 18 years old and above. To reduce the development of drug-resistant bacteria and maintain the effectiveness of KETEK and other antibacterial drugs, KETEK should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:dc69a06e-dba4-42cf-837f-c954c19894fc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29688 biolink:treats MONDO:0006878 PMID:41385096 "[{""id"":""uuid:c1187280-3329-4b40-b9ee-da425c0db284"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:81a8af5a-a92c-4a0a-b061-aa6581869fad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KETEK tablets are indicated for the treatment of community-acquired pneumonia (of mild to moderate severity) due to Streptococcus pneumoniae , (including multi-drug resistant isolates [MDRSP MDRSP, Multi-drug resistant Streptococcus pneumoniae includes isolates known as PRSP (penicillin-resistant Streptococcus pneumoniae ), and are isolates resistant to two or more of the following antibiotics: penicillin, 2 nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. ]), Haemophilus influenzae , Moraxella catarrhalis , Chlamydophila pneumoniae , or Mycoplasma pneumoniae , for patients 18 years old and above. To reduce the development of drug-resistant bacteria and maintain the effectiveness of KETEK and other antibacterial drugs, KETEK should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:187fc64b-7cb4-4bab-9a6c-cf7ca133e851 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29688 biolink:treats MONDO:0025598 PMID:41385096 "[{""id"":""uuid:bccafed3-9ac1-4fc3-8d8b-74a18fd59928"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4ccdd8ae-acb3-4299-804b-3d0fa1e12412"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KETEK tablets are indicated for the treatment of community-acquired pneumonia (of mild to moderate severity) due to Streptococcus pneumoniae , (including multi-drug resistant isolates [MDRSP MDRSP, Multi-drug resistant Streptococcus pneumoniae includes isolates known as PRSP (penicillin-resistant Streptococcus pneumoniae ), and are isolates resistant to two or more of the following antibiotics: penicillin, 2 nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. ]), Haemophilus influenzae , Moraxella catarrhalis , Chlamydophila pneumoniae , or Mycoplasma pneumoniae , for patients 18 years old and above. To reduce the development of drug-resistant bacteria and maintain the effectiveness of KETEK and other antibacterial drugs, KETEK should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:aed5849f-ea90-4f54-9c47-50bd35d11920 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29688 biolink:treats MONDO:0005867 PMID:41385096 "[{""id"":""uuid:3b94406b-a43c-43a6-8fb5-f66b7196f9e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9ccc4bd0-91d9-466f-83b3-f7b885680663"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KETEK tablets are indicated for the treatment of community-acquired pneumonia (of mild to moderate severity) due to Streptococcus pneumoniae , (including multi-drug resistant isolates [MDRSP MDRSP, Multi-drug resistant Streptococcus pneumoniae includes isolates known as PRSP (penicillin-resistant Streptococcus pneumoniae ), and are isolates resistant to two or more of the following antibiotics: penicillin, 2 nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. ]), Haemophilus influenzae , Moraxella catarrhalis , Chlamydophila pneumoniae , or Mycoplasma pneumoniae , for patients 18 years old and above. To reduce the development of drug-resistant bacteria and maintain the effectiveness of KETEK and other antibacterial drugs, KETEK should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:9a801dff-e9bb-40e1-86fd-2a5b77eccba6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18067 biolink:treats MONDO:0006874 PMID:41385096 "[{""id"":""uuid:f6b3f840-9c58-4dfc-9daf-56d6fe3b4089"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2bde22b8-38cd-4b74-98d1-6185a04da3ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MEPHYTON is indicated in the following coagulation disorders which are due to faulty formation of factors II,VII, IX and X when caused by vitamin K deficiency or interference with vitamin K activity. MEPHYTON tablets are indicated in: – anticoagulant-induced prothrombin deficiency caused by coumarin or indanedione derivatives; – hypoprothrombinemia secondary to antibacterial therapy; – hypoprothrombinemia secondary to administration of salicylates; – hypoprothrombinemia secondary to obstructive jaundice or biliary fistulas but only if bile salts are administered concurrently, since otherwise the oral vitamin K will not be absorbed. uuid:5d109568-7c5d-48cd-bb18-865539979ec7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18067 biolink:treats UMLS:C0005417 PMID:41385096 "[{""id"":""uuid:6812dce8-dd0a-4fc0-ab19-6716f1b1b6e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:25faabae-35fd-473b-9a89-f88592b4270a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MEPHYTON is indicated in the following coagulation disorders which are due to faulty formation of factors II,VII, IX and X when caused by vitamin K deficiency or interference with vitamin K activity. MEPHYTON tablets are indicated in: – anticoagulant-induced prothrombin deficiency caused by coumarin or indanedione derivatives; – hypoprothrombinemia secondary to antibacterial therapy; – hypoprothrombinemia secondary to administration of salicylates; – hypoprothrombinemia secondary to obstructive jaundice or biliary fistulas but only if bile salts are administered concurrently, since otherwise the oral vitamin K will not be absorbed. uuid:52e6106f-410b-4036-a69f-e11477fe44c1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17051 biolink:treats MONDO:0000605 PMID:41385096 "[{""id"":""uuid:45deae2c-803b-4ac4-be6d-5e03f9700ebd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9a164ffb-80d0-4c25-9985-7ac70d78daf8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Helps prevent dental caries and hypersensitivity. uuid:cfee7e41-5093-47a3-8203-030133e98832 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31859 biolink:treats UMLS:C4087539 PMID:41385096 "[{""id"":""uuid:a63ba3da-68ea-43aa-b93b-742e40f03846"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a2ea8ed1-c446-48f0-bf44-1be071564bfc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Modafinil is indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy, obstructive sleep apnea, and shift work disorder. In OSA, modafinil is indicated as an adjunct to standard treatment(s) for the underlying obstruction. If continuous positive airway pressure (CPAP) is the treatment of choice for a patient, a maximal effort to treat with CPAP for an adequate period of time should be made prior to initiating modafinil. If modafinil is used adjunctively with CPAP, the encouragement of and periodic assessment of CPAP compliance is necessary. In all cases, careful attention to the diagnosis and treatment of the underlying sleep disorder(s) is of utmost importance. Prescribers should be aware that some patients may have more than one sleep disorder contributing to their excessive sleepiness. The effectiveness of modafinil in long-term use (greater than 9 weeks in Narcolepsy clinical trials and 12 weeks in OSA and SWD clinical trials) has not been systematically evaluated in placebo-controlled trials. The physician who elects to prescribe modafinil for an extended time in patients with Narcolepsy, OSA, or SWD should periodically reevaluate long-term usefulness for the individual patient. uuid:8b197f37-f96b-41ce-8fb2-ba76ecc4b97a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3082 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:32d6d163-deec-4182-8aae-72e3833437bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d78503ad-ebe8-44d7-9afd-f4984ccb8740"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Betaxolol is indicated in the management of hypertension. It may be used alone or concomitantly with other antihypertensive agents, particularly thiazide-type diuretics. uuid:d3a07bd2-c863-44b3-a56d-89853186dc35 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:11679580 biolink:treats MONDO:0010811 PMID:41385096 "[{""id"":""uuid:1a6626dd-eb6d-45bc-9c36-7e7775dc6bc0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:17958e6a-8341-4ea1-9302-1bca2982c66e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] JALYN is a combination of dutasteride, a 5 alpha-reductase inhibitor, and tamsulosin, an alpha adrenergic antagonist, indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate. (1.1) Limitations of Use: Dutasteride-containing products, including JALYN, are not approved for the prevention of prostate cancer. (1.2) uuid:a9550d09-7696-47e1-8f17-44112cd0b3a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:11679580 biolink:treats MONDO:0008315 PMID:41385096 "[{""id"":""uuid:5c407a0b-3bf6-4408-b606-10fb77b89890"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:994417cf-fffe-447f-915b-ed3be0f15820"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] JALYN is a combination of dutasteride, a 5 alpha-reductase inhibitor, and tamsulosin, an alpha adrenergic antagonist, indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate. (1.1) Limitations of Use: Dutasteride-containing products, including JALYN, are not approved for the prevention of prostate cancer. (1.2) uuid:64ce356d-66da-4a55-8315-ad42e7168816 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8412 biolink:treats HP:0002069 PMID:41385096 "[{""id"":""uuid:420d1331-4961-4643-9118-48c71f3551a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a8ddfadf-8cf3-4389-8993-f603f53a4811"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Primidone, used alone or concomitantly with other anticonvulsants, is indicated in the control of grand mal, psychomotor, and focal epileptic seizures. It may control grand mal seizures refractory to other anticonvulsant therapy. uuid:0fb2ed57-e4ad-40b1-9fcc-21f5a8543756 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8412 biolink:treats MONDO:0006710 PMID:41385096 "[{""id"":""uuid:e5133207-d33c-4dc6-9857-812f060a82b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:94e23551-1f3f-4f22-969f-98f4d42f46f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Primidone, used alone or concomitantly with other anticonvulsants, is indicated in the control of grand mal, psychomotor, and focal epileptic seizures. It may control grand mal seizures refractory to other anticonvulsant therapy. uuid:bc371a64-3e7b-418f-a7c5-c2dff0bc1259 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8412 biolink:treats MONDO:0005384 PMID:41385096 "[{""id"":""uuid:69d3f23e-f927-4296-bc13-00b5e5c6f1b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b64bacd8-0963-4c63-914b-25ac31b8c94a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Primidone, used alone or concomitantly with other anticonvulsants, is indicated in the control of grand mal, psychomotor, and focal epileptic seizures. It may control grand mal seizures refractory to other anticonvulsant therapy. uuid:781300be-1ab6-4366-8269-f972b066ff45 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5108 biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:1b6e0c3b-e90f-48c0-b59f-015ed791db06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cd8f972d-4329-4ec4-82bb-a8cf612e26f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluocinolone Acetonide 0.01% Topical Oil is a low to medium potency corticosteroid indicated: In adult patients for the treatment of psoriasis of the scalp (Scalp Oil). uuid:d9d6dfa7-921a-472a-ba6a-1fdac8a80895 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63608 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:f2434736-cd6f-4cf8-aef3-621420b596fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:54db5949-8818-47bb-8470-a1bf702c68ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SELZENTRY, in combination with other antiretroviral agents, is indicated for adult patients infected with only CCR5-tropic HIV-1. This indication is based on analyses of plasma HIV-1 RNA levels in two controlled studies of SELZENTRY in treatment-experienced subjects and one study in treatment-naïve subjects. Both studies in treatment-experienced subjects were conducted in clinically advanced, 3-class antiretroviral-experienced (NRTI, NNRTI, PI, or enfuvirtide) adults with evidence of HIV-1 replication despite ongoing antiretroviral therapy. The following points should be considered when initiating therapy with SELZENTRY: Adult patients infected with only CCR5-tropic HIV-1 should use SELZENTRY. Tropism testing must be conducted with a highly sensitive tropism assay that has demonstrated the ability to identify patients appropriate for SELZENTRY use. Outgrowth of pre-existing low-level CXCR4- or dual/mixed-tropic HIV-1 not detected by tropism testing at screening has been associated with virologic failure on SELZENTRY. [see Microbiology (12.4) Clinical Studies (14.3) ] . Use of SELZENTRY is not recommended in subjects with dual/mixed or CXCR4-tropic HIV-1 as efficacy was not demonstrated in a phase 2 study of this patient group. The safety and efficacy of SELZENTRY have not been established in pediatric patients. In treatment-naïve subjects, more subjects treated with SELZENTRY experienced virologic failure and developed lamivudine resistance compared to efavirenz. [see Microbiology (12.4) Clinical Studies (14.3) ] uuid:52555308-c6d3-4bc8-91c1-06cf00d21524 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:42a12077-e75b-46e8-b512-972e1b8a79a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5b7c99a1-5bff-43f4-9270-b4941df759a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bicillin C-R and other antibacterial drugs, Bicillin C-R should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. This drug is indicated in the treatment of moderately severe infections due to penicillin-G-susceptible microorganisms that are susceptible to serum levels common to this particular dosage form. Therapy should be guided by bacteriological studies (including susceptibility testing) and by clinical response. Bicillin C-R is indicated in the treatment of the following in adults and pediatric patients: Moderately severe to severe infections of the upper-respiratory tract, scarlet fever, erysipelas, and skin and soft-tissue infections due to susceptible streptococci. NOTE: Streptococci in Groups A, C, G, H, L, and M are very sensitive to penicillin G. Other groups, including Group D (enterococci), are resistant. Penicillin G sodium or potassium is recommended for streptococcal infections with bacteremia. Moderately severe pneumonia and otitis media due to susceptible pneumococci. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, peritonitis, and arthritis of pneumococcal etiology are better treated with penicillin G sodium or potassium during the acute stage. When high, sustained serum levels are required, penicillin G sodium or potassium, either IM or IV, should be used. This drug should not be used in the treatment of venereal diseases, including syphilis, gonorrhea, yaws, bejel, and pinta. CHEBI:18208 uuid:8f88259a-871d-4832-a5ce-494616373c13 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0005952 PMID:41385096 "[{""id"":""uuid:a7a2a3ba-36e8-4d3a-8863-4dc29ea5e18a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3463f286-b17b-4c6e-9241-be98bb6d783c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bicillin C-R and other antibacterial drugs, Bicillin C-R should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. This drug is indicated in the treatment of moderately severe infections due to penicillin-G-susceptible microorganisms that are susceptible to serum levels common to this particular dosage form. Therapy should be guided by bacteriological studies (including susceptibility testing) and by clinical response. Bicillin C-R is indicated in the treatment of the following in adults and pediatric patients: Moderately severe to severe infections of the upper-respiratory tract, scarlet fever, erysipelas, and skin and soft-tissue infections due to susceptible streptococci. NOTE: Streptococci in Groups A, C, G, H, L, and M are very sensitive to penicillin G. Other groups, including Group D (enterococci), are resistant. Penicillin G sodium or potassium is recommended for streptococcal infections with bacteremia. Moderately severe pneumonia and otitis media due to susceptible pneumococci. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, peritonitis, and arthritis of pneumococcal etiology are better treated with penicillin G sodium or potassium during the acute stage. When high, sustained serum levels are required, penicillin G sodium or potassium, either IM or IV, should be used. This drug should not be used in the treatment of venereal diseases, including syphilis, gonorrhea, yaws, bejel, and pinta. CHEBI:18208 uuid:25edbc5a-88d8-48a3-98c0-b37fbb2d6667 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0001266 PMID:41385096 "[{""id"":""uuid:eccf527c-97d2-48b9-bf0e-0715c76da868"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f5889cd6-9687-4539-a128-f8ea1a748843"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bicillin C-R and other antibacterial drugs, Bicillin C-R should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. This drug is indicated in the treatment of moderately severe infections due to penicillin-G-susceptible microorganisms that are susceptible to serum levels common to this particular dosage form. Therapy should be guided by bacteriological studies (including susceptibility testing) and by clinical response. Bicillin C-R is indicated in the treatment of the following in adults and pediatric patients: Moderately severe to severe infections of the upper-respiratory tract, scarlet fever, erysipelas, and skin and soft-tissue infections due to susceptible streptococci. NOTE: Streptococci in Groups A, C, G, H, L, and M are very sensitive to penicillin G. Other groups, including Group D (enterococci), are resistant. Penicillin G sodium or potassium is recommended for streptococcal infections with bacteremia. Moderately severe pneumonia and otitis media due to susceptible pneumococci. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, peritonitis, and arthritis of pneumococcal etiology are better treated with penicillin G sodium or potassium during the acute stage. When high, sustained serum levels are required, penicillin G sodium or potassium, either IM or IV, should be used. This drug should not be used in the treatment of venereal diseases, including syphilis, gonorrhea, yaws, bejel, and pinta. CHEBI:18208 uuid:78d7d000-e174-49e7-852b-de2b88bceda4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:6655e1c7-3ac0-4679-8426-198d3c9f3ba8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3dffe749-f130-4d0d-bace-d409521e906d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bicillin C-R and other antibacterial drugs, Bicillin C-R should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. This drug is indicated in the treatment of moderately severe infections due to penicillin-G-susceptible microorganisms that are susceptible to serum levels common to this particular dosage form. Therapy should be guided by bacteriological studies (including susceptibility testing) and by clinical response. Bicillin C-R is indicated in the treatment of the following in adults and pediatric patients: Moderately severe to severe infections of the upper-respiratory tract, scarlet fever, erysipelas, and skin and soft-tissue infections due to susceptible streptococci. NOTE: Streptococci in Groups A, C, G, H, L, and M are very sensitive to penicillin G. Other groups, including Group D (enterococci), are resistant. Penicillin G sodium or potassium is recommended for streptococcal infections with bacteremia. Moderately severe pneumonia and otitis media due to susceptible pneumococci. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, peritonitis, and arthritis of pneumococcal etiology are better treated with penicillin G sodium or potassium during the acute stage. When high, sustained serum levels are required, penicillin G sodium or potassium, either IM or IV, should be used. This drug should not be used in the treatment of venereal diseases, including syphilis, gonorrhea, yaws, bejel, and pinta. CHEBI:18208 uuid:a5c6acd7-eb56-4ec1-b93b-050e25ecc657 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:51c72a8e-d270-49bf-b98e-14d542916031"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:43483b8d-fe98-4e57-a9aa-1e0279824ff6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bicillin C-R and other antibacterial drugs, Bicillin C-R should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. This drug is indicated in the treatment of moderately severe infections due to penicillin-G-susceptible microorganisms that are susceptible to serum levels common to this particular dosage form. Therapy should be guided by bacteriological studies (including susceptibility testing) and by clinical response. Bicillin C-R is indicated in the treatment of the following in adults and pediatric patients: Moderately severe to severe infections of the upper-respiratory tract, scarlet fever, erysipelas, and skin and soft-tissue infections due to susceptible streptococci. NOTE: Streptococci in Groups A, C, G, H, L, and M are very sensitive to penicillin G. Other groups, including Group D (enterococci), are resistant. Penicillin G sodium or potassium is recommended for streptococcal infections with bacteremia. Moderately severe pneumonia and otitis media due to susceptible pneumococci. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, peritonitis, and arthritis of pneumococcal etiology are better treated with penicillin G sodium or potassium during the acute stage. When high, sustained serum levels are required, penicillin G sodium or potassium, either IM or IV, should be used. This drug should not be used in the treatment of venereal diseases, including syphilis, gonorrhea, yaws, bejel, and pinta. CHEBI:18208 uuid:07ef82f4-4332-424f-9f5d-0a2e0985fe89 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0005441 PMID:41385096 "[{""id"":""uuid:03347606-1274-403f-a4b6-5944ebf44982"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cd8881f9-6311-4177-9ff6-7ab72c23955b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bicillin C-R and other antibacterial drugs, Bicillin C-R should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. This drug is indicated in the treatment of moderately severe infections due to penicillin-G-susceptible microorganisms that are susceptible to serum levels common to this particular dosage form. Therapy should be guided by bacteriological studies (including susceptibility testing) and by clinical response. Bicillin C-R is indicated in the treatment of the following in adults and pediatric patients: Moderately severe to severe infections of the upper-respiratory tract, scarlet fever, erysipelas, and skin and soft-tissue infections due to susceptible streptococci. NOTE: Streptococci in Groups A, C, G, H, L, and M are very sensitive to penicillin G. Other groups, including Group D (enterococci), are resistant. Penicillin G sodium or potassium is recommended for streptococcal infections with bacteremia. Moderately severe pneumonia and otitis media due to susceptible pneumococci. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, peritonitis, and arthritis of pneumococcal etiology are better treated with penicillin G sodium or potassium during the acute stage. When high, sustained serum levels are required, penicillin G sodium or potassium, either IM or IV, should be used. This drug should not be used in the treatment of venereal diseases, including syphilis, gonorrhea, yaws, bejel, and pinta. CHEBI:18208 uuid:37bcc1ab-e027-40a8-9175-6c09b85fe546 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0005976 PMID:41385096 "[{""id"":""uuid:d9f34414-58a2-466f-978c-2864fe0be54c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:68fca33e-9cce-475e-8730-fc8a69efaaaf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c540f613-16b3-4db6-87bb-d95db4ab7efd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bicillin C-R and other antibacterial drugs, Bicillin C-R should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. This drug is indicated in the treatment of moderately severe infections due to penicillin-G-susceptible microorganisms that are susceptible to serum levels common to this particular dosage form. Therapy should be guided by bacteriological studies (including susceptibility testing) and by clinical response. Bicillin C-R is indicated in the treatment of the following in adults and pediatric patients: Moderately severe to severe infections of the upper-respiratory tract, scarlet fever, erysipelas, and skin and soft-tissue infections due to susceptible streptococci. NOTE: Streptococci in Groups A, C, G, H, L, and M are very sensitive to penicillin G. Other groups, including Group D (enterococci), are resistant. Penicillin G sodium or potassium is recommended for streptococcal infections with bacteremia. Moderately severe pneumonia and otitis media due to susceptible pneumococci. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, peritonitis, and arthritis of pneumococcal etiology are better treated with penicillin G sodium or potassium during the acute stage. When high, sustained serum levels are required, penicillin G sodium or potassium, either IM or IV, should be used. This drug should not be used in the treatment of venereal diseases, including syphilis, gonorrhea, yaws, bejel, and pinta.|[PMDA] Drugs with a new route of administration indicated for the treatment of syphilis (excluding neurosyphilis) caused by Treponema pallidum . CHEBI:18208 uuid:b21425f0-a0ec-443e-b425-e0845c036444 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0004277 PMID:41385096 "[{""id"":""uuid:9ea31a8e-16e6-48b9-abff-eac272229121"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7585989f-4a75-4591-b799-acdbc9723c64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bicillin C-R and other antibacterial drugs, Bicillin C-R should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. This drug is indicated in the treatment of moderately severe infections due to penicillin-G-susceptible microorganisms that are susceptible to serum levels common to this particular dosage form. Therapy should be guided by bacteriological studies (including susceptibility testing) and by clinical response. Bicillin C-R is indicated in the treatment of the following in adults and pediatric patients: Moderately severe to severe infections of the upper-respiratory tract, scarlet fever, erysipelas, and skin and soft-tissue infections due to susceptible streptococci. NOTE: Streptococci in Groups A, C, G, H, L, and M are very sensitive to penicillin G. Other groups, including Group D (enterococci), are resistant. Penicillin G sodium or potassium is recommended for streptococcal infections with bacteremia. Moderately severe pneumonia and otitis media due to susceptible pneumococci. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, peritonitis, and arthritis of pneumococcal etiology are better treated with penicillin G sodium or potassium during the acute stage. When high, sustained serum levels are required, penicillin G sodium or potassium, either IM or IV, should be used. This drug should not be used in the treatment of venereal diseases, including syphilis, gonorrhea, yaws, bejel, and pinta. CHEBI:18208 uuid:1baddafa-acba-4952-b007-c2aa6acadabd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0006019 PMID:41385096 "[{""id"":""uuid:50a38dd6-56af-4f19-aa56-c1a8a01cfeac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:33cc9c94-40af-4b89-9f9f-a7fdeb176472"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bicillin C-R and other antibacterial drugs, Bicillin C-R should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. This drug is indicated in the treatment of moderately severe infections due to penicillin-G-susceptible microorganisms that are susceptible to serum levels common to this particular dosage form. Therapy should be guided by bacteriological studies (including susceptibility testing) and by clinical response. Bicillin C-R is indicated in the treatment of the following in adults and pediatric patients: Moderately severe to severe infections of the upper-respiratory tract, scarlet fever, erysipelas, and skin and soft-tissue infections due to susceptible streptococci. NOTE: Streptococci in Groups A, C, G, H, L, and M are very sensitive to penicillin G. Other groups, including Group D (enterococci), are resistant. Penicillin G sodium or potassium is recommended for streptococcal infections with bacteremia. Moderately severe pneumonia and otitis media due to susceptible pneumococci. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, peritonitis, and arthritis of pneumococcal etiology are better treated with penicillin G sodium or potassium during the acute stage. When high, sustained serum levels are required, penicillin G sodium or potassium, either IM or IV, should be used. This drug should not be used in the treatment of venereal diseases, including syphilis, gonorrhea, yaws, bejel, and pinta. CHEBI:18208 uuid:782bb4a3-84d6-4468-80a8-a8c7e4aff48b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0001714 PMID:41385096 "[{""id"":""uuid:f628916a-71a5-4a1e-a7e8-e15b775d77cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1705025c-047e-49ce-8264-697a790c002b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bicillin C-R and other antibacterial drugs, Bicillin C-R should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. This drug is indicated in the treatment of moderately severe infections due to penicillin-G-susceptible microorganisms that are susceptible to serum levels common to this particular dosage form. Therapy should be guided by bacteriological studies (including susceptibility testing) and by clinical response. Bicillin C-R is indicated in the treatment of the following in adults and pediatric patients: Moderately severe to severe infections of the upper-respiratory tract, scarlet fever, erysipelas, and skin and soft-tissue infections due to susceptible streptococci. NOTE: Streptococci in Groups A, C, G, H, L, and M are very sensitive to penicillin G. Other groups, including Group D (enterococci), are resistant. Penicillin G sodium or potassium is recommended for streptococcal infections with bacteremia. Moderately severe pneumonia and otitis media due to susceptible pneumococci. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, peritonitis, and arthritis of pneumococcal etiology are better treated with penicillin G sodium or potassium during the acute stage. When high, sustained serum levels are required, penicillin G sodium or potassium, either IM or IV, should be used. This drug should not be used in the treatment of venereal diseases, including syphilis, gonorrhea, yaws, bejel, and pinta. CHEBI:18208 uuid:e82b17d7-4bc0-466d-a855-c7a006b22f94 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0000979 PMID:41385096 "[{""id"":""uuid:935c6405-e114-4e3f-8202-9945c8436311"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2a95e36c-e5e1-44cd-a14e-0fbd55036a31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bicillin C-R and other antibacterial drugs, Bicillin C-R should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. This drug is indicated in the treatment of moderately severe infections due to penicillin-G-susceptible microorganisms that are susceptible to serum levels common to this particular dosage form. Therapy should be guided by bacteriological studies (including susceptibility testing) and by clinical response. Bicillin C-R is indicated in the treatment of the following in adults and pediatric patients: Moderately severe to severe infections of the upper-respiratory tract, scarlet fever, erysipelas, and skin and soft-tissue infections due to susceptible streptococci. NOTE: Streptococci in Groups A, C, G, H, L, and M are very sensitive to penicillin G. Other groups, including Group D (enterococci), are resistant. Penicillin G sodium or potassium is recommended for streptococcal infections with bacteremia. Moderately severe pneumonia and otitis media due to susceptible pneumococci. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, peritonitis, and arthritis of pneumococcal etiology are better treated with penicillin G sodium or potassium during the acute stage. When high, sustained serum levels are required, penicillin G sodium or potassium, either IM or IV, should be used. This drug should not be used in the treatment of venereal diseases, including syphilis, gonorrhea, yaws, bejel, and pinta. CHEBI:18208 uuid:af58001c-ce8c-4521-ae58-5e0d2a486bd0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9831783 biolink:treats HP:0100660 PMID:41385096 "[{""id"":""uuid:00cd206d-0e0a-475b-931f-2e808eeea1d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:93da94a8-2fda-496e-a67e-c072bbbf5dd1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] To substitute (with equivalent strength of each of the three components) for immediate-release carbidopa/levodopa and entacapone previously administered as individual products. To replace immediate-release carbidopa/levodopa therapy (without entacapone) when patients experience the signs and symptoms of end-of-dose ""wearing-off"" (only for patients taking a total daily dose of levodopa of 600 mg or less and not experiencing dyskinesias, see DOSAGE AND ADMINISTRATION )." uuid:c0878d2d-19ac-44f8-9bfa-f17c4973c913 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45924 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:ccb29742-dbb6-4bad-bbd4-fd291fd8368d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2a0d1fdf-6e32-405a-b67a-37dd46df8073"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of initial episodes of uncomplicated urinary tract infections due to susceptible strains of the following organisms: Escherichiacoli, Proteus mirabilis, Klebsiella pneumoniae, Enterobacter species and coagulase-negative Staphylococcus species, including S. saprophyticus. Cultures and susceptibility tests should be performed to determine the susceptibility of the bacteria to trimethoprim. Therapy may be initiated prior to obtaining the results of these tests. uuid:cc75f7f8-b82f-427c-9a46-2251ab890126 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45924 biolink:treats MONDO:0020920 PMID:41385096 "[{""id"":""uuid:8362ceb7-2090-45e5-b4c6-f095065dedbd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0a93b35f-a3fe-45e3-a2d3-7d179ae393f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of initial episodes of uncomplicated urinary tract infections due to susceptible strains of the following organisms: Escherichiacoli, Proteus mirabilis, Klebsiella pneumoniae, Enterobacter species and coagulase-negative Staphylococcus species, including S. saprophyticus. Cultures and susceptibility tests should be performed to determine the susceptibility of the bacteria to trimethoprim. Therapy may be initiated prior to obtaining the results of these tests. uuid:a5ceccf6-e443-450f-8c4d-09cc23156658 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45924 biolink:treats UMLS:C0276078 PMID:41385096 "[{""id"":""uuid:a927fdb1-81d1-426f-8052-e1e1979eed77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:36f5e2e1-5ad8-4f34-aeed-9739561c81c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of initial episodes of uncomplicated urinary tract infections due to susceptible strains of the following organisms: Escherichiacoli, Proteus mirabilis, Klebsiella pneumoniae, Enterobacter species and coagulase-negative Staphylococcus species, including S. saprophyticus. Cultures and susceptibility tests should be performed to determine the susceptibility of the bacteria to trimethoprim. Therapy may be initiated prior to obtaining the results of these tests. uuid:4ff5dbe8-52f2-4361-afb2-4b1f7e0ae5bc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45924 biolink:treats UMLS:C0948802 PMID:41385096 "[{""id"":""uuid:473f9487-82a8-427d-bd01-060b7ecb4565"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f764f55e-b819-48c6-b534-3b42c3723430"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of initial episodes of uncomplicated urinary tract infections due to susceptible strains of the following organisms: Escherichiacoli, Proteus mirabilis, Klebsiella pneumoniae, Enterobacter species and coagulase-negative Staphylococcus species, including S. saprophyticus. Cultures and susceptibility tests should be performed to determine the susceptibility of the bacteria to trimethoprim. Therapy may be initiated prior to obtaining the results of these tests. uuid:a4205ac1-9d39-432b-a309-fe8231188e7a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45924 biolink:treats UMLS:C0948205 PMID:41385096 "[{""id"":""uuid:cca19bd5-9fe8-4477-a1ed-55b830db6563"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:64f33d89-6320-4cfd-9d0c-6d0f1cdf3f54"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of initial episodes of uncomplicated urinary tract infections due to susceptible strains of the following organisms: Escherichiacoli, Proteus mirabilis, Klebsiella pneumoniae, Enterobacter species and coagulase-negative Staphylococcus species, including S. saprophyticus. Cultures and susceptibility tests should be performed to determine the susceptibility of the bacteria to trimethoprim. Therapy may be initiated prior to obtaining the results of these tests. uuid:5380e43f-681c-4f8f-a8e1-1215e37fed80 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45924 biolink:treats MONDO:0024313 PMID:41385096 "[{""id"":""uuid:0a52bef4-48a9-447e-b2c6-cb44bd4bb53f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:72c96ea4-bff2-486a-8ce4-551949aa9111"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of initial episodes of uncomplicated urinary tract infections due to susceptible strains of the following organisms: Escherichiacoli, Proteus mirabilis, Klebsiella pneumoniae, Enterobacter species and coagulase-negative Staphylococcus species, including S. saprophyticus. Cultures and susceptibility tests should be performed to determine the susceptibility of the bacteria to trimethoprim. Therapy may be initiated prior to obtaining the results of these tests. uuid:cb442702-1123-48ad-899b-706c7e2aabb6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49375 biolink:treats MONDO:0011996 PMID:41385096 "[{""id"":""uuid:a9fcffa6-7614-4c8f-8a94-c6f66e2db83e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:eb10a86f-3a9e-4119-8eb1-ccc96a9ce765"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2ea85e5b-332d-41f5-abbe-213ac8b6094d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:dbc26ea5-3138-4854-ac89-f9508b7f1f20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SPRYCEL ® (dasatinib) is indicated for the treatment of adults with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. The effectiveness of SPRYCEL is based on cytogenetic response and major molecular response rates [see Clinical Studies (14.1) ] . The trial is ongoing and further data will be required to determine long-term outcome. chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.|[EMA] Sprycel is indicated for the treatment of paediatric patients with:newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukaemia in chronic phase (Ph+ CML CP) or Ph+ CML CP resistant or intolerant to prior therapy including imatinib.newly diagnosed Ph+ acute lymphoblastic leukaemia (ALL) in combination with chemotherapy.Sprycel is indicated for the treatment of adult patients with:newly diagnosed Philadelphia-chromosome-positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase;chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib mesilate;Ph+ acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy.Sprycel is indicated for the treatment of paediatric patients with:newly diagnosed Ph+ CML in chronic phase (Ph+ CML-CP) or Ph+ CML-CP resistant or intolerant to prior therapy including imatinib.|[PMDA] Drugs with a new additional indication and a new dosage for the treatment of chronic myelocytic leukemia. uuid:ca898608-fa68-42c8-ab2f-1dc08072b3b9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49375 biolink:treats MONDO:0004967 PMID:41385096 "[{""id"":""uuid:6e9d24c5-b40b-4eac-8ab9-700bc40ad590"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:357e4ed5-00e2-4d0b-a144-c0fa9694026b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:92d1bedb-bc86-41e4-8523-b1d809249931"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SPRYCEL ® (dasatinib) is indicated for the treatment of adults with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. The effectiveness of SPRYCEL is based on cytogenetic response and major molecular response rates [see Clinical Studies (14.1) ] . The trial is ongoing and further data will be required to determine long-term outcome. chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy.|[EMA] Sprycel is indicated for the treatment of paediatric patients with:newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukaemia in chronic phase (Ph+ CML CP) or Ph+ CML CP resistant or intolerant to prior therapy including imatinib.newly diagnosed Ph+ acute lymphoblastic leukaemia (ALL) in combination with chemotherapy.Sprycel is indicated for the treatment of adult patients with:newly diagnosed Philadelphia-chromosome-positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase;chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib mesilate;Ph+ acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy.Sprycel is indicated for the treatment of paediatric patients with:newly diagnosed Ph+ CML in chronic phase (Ph+ CML-CP) or Ph+ CML-CP resistant or intolerant to prior therapy including imatinib. uuid:2b7ef793-211d-4d9f-bfe8-1e6f718093ef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29007 biolink:treats UMLS:C1141920 PMID:41385096 "[{""id"":""uuid:65f3d3e9-b692-4c13-88c2-49dd1dc9060c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8f7cc026-b91b-4ccd-ac98-3dabc3fb475f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection and other antibacterial drugs, ceftriaxone for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ceftriaxone sodium is indicated for the treatment of the following infections when caused by susceptible organisms: Lower Respiratory Tract Infections caused by Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis or Serratia marcescens. Acute Bacterial Otitis Media caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase producing strains) or Moraxella catarrhalis (including beta-lactamase producing strains). NOTE: In one study lower clinical cure rates were observed with a single dose of ceftriaxone sodium compared to 10 days of oral therapy. In a second study comparable cure rates were observed between single dose ceftriaxone sodium and the comparator. The potentially lower clinical cure rate of ceftriaxone should be balanced against the potential advantages of parenteral therapy (see CLINICAL STUDIES ). Skin And Skin Structure Infections caused by Staphylococcus aureus , Staphylococcus epidermidis , Streptococcus pyogenes , Viridans group streptococci, Escherichia coli , Enterobacter cloacae , Klebsiella oxytoca , Klebsiella pneumoniae , Proteus mirabilis , Morganella morganii Efficacy for this organism in this organ system was studied in fewer than ten infections. , Pseudomonas aeruginosa , Serratia marcescens , Acinetobacter calcoaceticus , Bacteroides fragilis or Peptostreptococcus species. Urinary Tract Infections ( complicated and uncomplicated ) caused by Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii or Klebsiella pneumoniae. Uncomplicated Gonorrhea ( cervical/urethral and rectal ) caused by Neisseria gonorrhoeae , including both penicillinase- and nonpenicillinase-producing strains, and pharyngeal gonorrhea caused by nonpenicillinase-producing strains of Neisseria gonorrhoeae . Pelvic Inflammatory Disease caused by Neisseria gonorrhoeae . Ceftriaxone sodium, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and Chlamydia trachomatis is one of the suspected pathogens, appropriate antichlamydial coverage should be added. Bacterial Septicemia caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae or Klebsiella pneumoniae. Bone And Joint Infections caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae or Enterobacter species. Intra-Abdominal Infections caused by Escherichia coli, Klebsiella pneumoniae , Bacteroides fragilis , Clostridium species (Note: most strains of Clostridium difficile are resistant) or Peptostreptococcus species. Meningitis caused by Haemophilus influenzae, Neisseria meningitidis or Streptococcus pneumoniae. Ceftriaxone has also been used successfully in a limited number of cases of meningitis and shunt infection caused by Staphylococcus epidermidis and Escherichia coli . Surgical Prophylaxis: The preoperative administration of a single 1 gm dose of ceftriaxone sodium may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated (e.g., vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high-risk patients, such as those over 70 years of age, with acute cholecystitis not requiring therapeutic antimicrobials, obstructive jaundice or common duct bile stones) and in surgical patients for whom infection at the operative site would present serious risk (e.g., during coronary artery bypass surgery). Although ceftriaxone has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo-controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of infection following coronary artery bypass surgery. When administered prior to surgical procedures for which it is indicated, a single 1 gm dose of ceftriaxone sodium provides protection from most infections due to susceptible organisms throughout the course of the procedure. uuid:eaf76f9d-df9e-4d22-a16f-d7fd419f8bb4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31348 biolink:treats MONDO:0021063 PMID:41385096 "[{""id"":""uuid:2eb1b05f-6a94-464d-ab35-dc6480cf6cb2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:49c0c7b3-9cae-4646-b19f-d8dbd905aecb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XELODA (capecitabine) is a nucleoside metabolic inhibitor with antineoplastic activity indicated for: Adjuvant Colon Cancer ( 1.1 ) – Patients with Dukes' C colon cancer Metastatic Colorectal Cancer ( 1.1 ) – First-line as monotherapy when treatment with fluoropyrimidine therapy alone is preferred Metastatic Breast Cancer ( 1.2 ) – In combination with docetaxel after failure of prior anthracycline-containing therapy – As monotherapy in patients resistant to both paclitaxel and an anthracycline-containing regimen uuid:f5099819-523a-468f-9ef8-f0e8bf470695 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31348 biolink:treats EFO:1001480 PMID:41385096 "[{""id"":""uuid:9dddfded-97e0-42d5-8001-acb9a81bd827"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d622433a-885f-493d-bf1a-1c2a7a750ec9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XELODA (capecitabine) is a nucleoside metabolic inhibitor with antineoplastic activity indicated for: Adjuvant Colon Cancer ( 1.1 ) – Patients with Dukes' C colon cancer Metastatic Colorectal Cancer ( 1.1 ) – First-line as monotherapy when treatment with fluoropyrimidine therapy alone is preferred Metastatic Breast Cancer ( 1.2 ) – In combination with docetaxel after failure of prior anthracycline-containing therapy – As monotherapy in patients resistant to both paclitaxel and an anthracycline-containing regimen uuid:2d328ff1-adff-4a1a-9af3-fb2588d85a2f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31348 biolink:treats UMLS:C0278488 PMID:41385096 "[{""id"":""uuid:2c71923e-c983-4a2d-8b63-64c1aae6850d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:29a43086-2bd8-4d33-ab29-4904668b1683"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XELODA (capecitabine) is a nucleoside metabolic inhibitor with antineoplastic activity indicated for: Adjuvant Colon Cancer ( 1.1 ) – Patients with Dukes' C colon cancer Metastatic Colorectal Cancer ( 1.1 ) – First-line as monotherapy when treatment with fluoropyrimidine therapy alone is preferred Metastatic Breast Cancer ( 1.2 ) – In combination with docetaxel after failure of prior anthracycline-containing therapy – As monotherapy in patients resistant to both paclitaxel and an anthracycline-containing regimen uuid:0dda258d-92f5-4c3f-97af-7441936b4a71 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:28697 biolink:treats MONDO:0004247 PMID:41385096 "[{""id"":""uuid:0b656f92-dc24-4f91-adcd-99418c534133"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4c625a65-6fd8-40b0-baa8-ca373df80a6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of this drug by the National Academy of Sciences – National Research Council and/or other information, FDA has classified the indications as follows: ""Possibly"" effective: as adjunctive therapy in the treatment of peptic ulcer and in the treatment of the irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis. Final classification of the less-than-effective indications requires further investigation." uuid:276e65dd-0b11-4c7d-93fe-0eb06227a5c3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:28697 biolink:treats MONDO:0005052 PMID:41385096 "[{""id"":""uuid:174fd87d-82dd-4e83-874d-f5ea907d43f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:115c597a-4d84-4e3e-b752-8610d54df164"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of this drug by the National Academy of Sciences – National Research Council and/or other information, FDA has classified the indications as follows: ""Possibly"" effective: as adjunctive therapy in the treatment of peptic ulcer and in the treatment of the irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis. Final classification of the less-than-effective indications requires further investigation." uuid:47e3e9ce-1cb4-4c95-91b9-2e0a6bb1c592 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:28697 biolink:treats UMLS:C0856217 PMID:41385096 "[{""id"":""uuid:e7529927-1eaa-4510-b9bd-448f9f97abbc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:04cb86f0-6654-4c79-babd-1d5ff8e33e81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of this drug by the National Academy of Sciences – National Research Council and/or other information, FDA has classified the indications as follows: ""Possibly"" effective: as adjunctive therapy in the treatment of peptic ulcer and in the treatment of the irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis. Final classification of the less-than-effective indications requires further investigation." uuid:ca38c026-c982-47d7-a109-d5ac46c0d7cb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:28697 biolink:treats UMLS:C3203466 PMID:41385096 "[{""id"":""uuid:bf86f326-673c-4b5f-9b70-f5a33f526880"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c9f17d1d-f443-4aa6-8abd-23e6e26679cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Based on a review of this drug by the National Academy of Sciences – National Research Council and/or other information, FDA has classified the indications as follows: ""Possibly"" effective: as adjunctive therapy in the treatment of peptic ulcer and in the treatment of the irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis. Final classification of the less-than-effective indications requires further investigation." uuid:2cdf18a0-758f-4eb2-b487-a6629fc307d1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0010643 PMID:41385096 "[{""id"":""uuid:9b806f8f-c549-47e0-a5e1-7202309f6680"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2aae3548-9a79-4ba9-a62c-0bd76a53209e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisone tablets are indicated in the following conditions: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Endocrine disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis Rheumatic disorders During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis Collagen diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Dermatologic diseases Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions Allergic states Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Ophthalmic diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis Respiratory diseases Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Hematologic disorders For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Neoplastic diseases To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Edematous states To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Gastrointestinal diseases Acute exacerbations of multiple sclerosis Nervous System Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement Miscellaneous uuid:27d4b8af-507e-4142-b1fa-4222e4aa94b7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44423 biolink:treats MONDO:0005105 PMID:41385096 "[{""id"":""uuid:c3461b1e-6d93-4511-a80d-b2775002b1a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5d1d48de-a5ce-4c58-9707-18c86aff624b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Significant tumor response to hydroxyurea capsules USP has been demonstrated in melanoma, resistant chronic myelocytic leukemia, and recurrent, metastatic, or inoperable carcinoma of the ovary. Hydroxyurea, USP used concomitantly with irradiation therapy is intended for use in the local control of primary squamous cell (epidermoid) carcinomas of the head and neck, excluding the lip. uuid:55bfa181-6474-4a5b-af5c-cbb5ed506379 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44423 biolink:treats MONDO:0011996 PMID:41385096 "[{""id"":""uuid:9711a59c-d6b5-44f0-b45c-bbd86bd7cbea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8dc23f44-e4bb-49f1-99ff-7888f13ac139"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Significant tumor response to hydroxyurea capsules USP has been demonstrated in melanoma, resistant chronic myelocytic leukemia, and recurrent, metastatic, or inoperable carcinoma of the ovary. Hydroxyurea, USP used concomitantly with irradiation therapy is intended for use in the local control of primary squamous cell (epidermoid) carcinomas of the head and neck, excluding the lip. uuid:f3a97f3e-45b3-4d20-b026-6140f3603dd0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44423 biolink:treats MONDO:0005140 PMID:41385096 "[{""id"":""uuid:4bdb3a26-4890-4446-82b1-9315d9c416f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7aafeca8-2487-4989-beab-1053e073d40d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Significant tumor response to hydroxyurea capsules USP has been demonstrated in melanoma, resistant chronic myelocytic leukemia, and recurrent, metastatic, or inoperable carcinoma of the ovary. Hydroxyurea, USP used concomitantly with irradiation therapy is intended for use in the local control of primary squamous cell (epidermoid) carcinomas of the head and neck, excluding the lip. uuid:38cdd2ec-1783-41c5-af34-177eea25143f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44423 biolink:treats MONDO:0010150 PMID:41385096 "[{""id"":""uuid:9d8c00e7-fdfd-429d-93a8-2f08780304a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b51fc953-e49b-47b2-916c-606bc8fa667f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Significant tumor response to hydroxyurea capsules USP has been demonstrated in melanoma, resistant chronic myelocytic leukemia, and recurrent, metastatic, or inoperable carcinoma of the ovary. Hydroxyurea, USP used concomitantly with irradiation therapy is intended for use in the local control of primary squamous cell (epidermoid) carcinomas of the head and neck, excluding the lip. uuid:263c791c-a278-4a81-8c4e-e5f01a425ee9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28971 biolink:treats MONDO:0004277 PMID:41385096 "[{""id"":""uuid:0549ee73-7e25-4472-9e00-739d0fce67b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dd2e2541-f3b5-4967-a456-89488652c7fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ampicillin Capsules, USP are indicated in the treatment of infections caused by susceptible strains of the designated organism listed below: INFECTIONS OF THE GENITOURINARY TRACT INCLUDING GONORRHEA: E. coli, P. mirabilis, enterococci, Shigella, S. typhosa and other Salmonella , and nonpenicillinaseproducing N. gonorrhoeae . INFECTIONS OF THE RESPIRATORY TRACT: Nonpenicillinase- producing H. influenzae and staphylococci, and streptococci including streptococcus pneumoniae . INFECTIONS OF THE GASTROINTESTINAL TRACT: Shigella, S. typhosa and other Salmonella, E. coli, P. mirabilis, and enterococci. MENINGITIS: N. Meningitides . To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin and other antibacterial drugs, ampicillin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to the results of susceptibility testing. uuid:a63e3911-e5fc-4264-82d1-c8f4d7f0333a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28971 biolink:treats MONDO:0021108 PMID:41385096 "[{""id"":""uuid:eb1d3f22-c3b5-4974-aafb-31a888f6757a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:732539d2-442c-45c5-8f24-2b211d809fad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ampicillin Capsules, USP are indicated in the treatment of infections caused by susceptible strains of the designated organism listed below: INFECTIONS OF THE GENITOURINARY TRACT INCLUDING GONORRHEA: E. coli, P. mirabilis, enterococci, Shigella, S. typhosa and other Salmonella , and nonpenicillinaseproducing N. gonorrhoeae . INFECTIONS OF THE RESPIRATORY TRACT: Nonpenicillinase- producing H. influenzae and staphylococci, and streptococci including streptococcus pneumoniae . INFECTIONS OF THE GASTROINTESTINAL TRACT: Shigella, S. typhosa and other Salmonella, E. coli, P. mirabilis, and enterococci. MENINGITIS: N. Meningitides . To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin and other antibacterial drugs, ampicillin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to the results of susceptibility testing. uuid:634ba3a8-c541-41a4-95c7-3794d7be42c0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:48131 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:cfbe77e3-d227-4126-b27f-e894e34dce0f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6e17958a-d541-4c69-99bf-0655d4982dd9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AZELEX ® Cream is indicated for the topical treatment of mild-to-moderate inflammatory acne vulgaris. uuid:b8cf3b59-aee4-4d86-9681-36f313c23b64 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6438 biolink:treats MONDO:0005338 PMID:41385096 "[{""id"":""uuid:84176a8a-f667-421f-929f-0170f302ed3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e518d303-8843-40e8-8d41-94cf407ebfee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levobunolol Hydrochloride Ophthalmic Solution has been shown to be effective in lowering intraocular pressure and may be used in patients with chronic open-angle glaucoma or ocular hypertension. uuid:6ed9f99f-7c53-4fe9-b985-9700dc233ff6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6438 biolink:treats MONDO:0006875 PMID:41385096 "[{""id"":""uuid:f247efa7-df25-4ffa-b196-da2288f687dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8f93abd8-4477-49ae-94c0-cde7c8d1f7c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levobunolol Hydrochloride Ophthalmic Solution has been shown to be effective in lowering intraocular pressure and may be used in patients with chronic open-angle glaucoma or ocular hypertension. uuid:b7ffae7a-5229-459e-94ba-e1e9ebe02265 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135598 biolink:treats MONDO:0024644 PMID:41385096 "[{""id"":""uuid:0f55536b-8aa4-448e-8c50-a1737eba8527"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:49e59d40-c96e-4370-9094-f4bae99887dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tetrofosmin is a diagnostic agent used to assess areas of reversible myocardial ischemia in the presence or absence of infracted myocardium and is also used to assess ventricular function. PHYSICAL HALF-LIFE & TARGET ORGANS The physical half-life of technetium, Tc99m, is 6 hours and has a principal radiation emission of gamma photons with a mean energy of 140 KeV. Estimated Absorbed Radiation Dose (Technetium Tc99m Tetrofosmin Injection) Absorbed radiation dose Exercise Rest Target organ rad/mCi µGy/MBq rad/mCi µGy/MBq Gall bladder wall 0.123 33.2 0.180 48.6 Upper large intestine 0.075 20.1 0.113 30.4 Bladder wall 0.058 15.6 0.071 19.3 Lower large intestine 0.057 15.3 0.082 22.2 Small intestine 0.045 12.1 0.063 17.0 Kidney 0.039 10.4 0.046 12.5 Salivary glands 0.030 8.04 0.043 11.6 Ovaries 0.029 7.88 0.035 9.55 Uterus 0.027 7.34 0.031 8.36 Bone surface 0.023 6.23 0.021 5.58 Pancreas 0.019 5.00 0.018 4.98 Stomach 0.017 4.60 0.017 4.63 Thyroid 0.016 4.34 0.022 5.83 Adrenals 0.016 4.32 0.015 4.11 Heart wall 0.015 4.14 0.015 3.93 Red marrow 0.015 4.14 0.015 3.97 Spleen 0.015 4.12 0.014 3.82 Muscle 0.013 3.52 0.012 3.32 Testes 0.013 3.41 0.011 3.05 Liver 0.012 3.22 0.015 4.15 Thymus 0.012 3.11 0.009 2.54 Brain 0.010 2.72 0.008 2.15 Lungs 0.008 2.27 0.008 2.08 Skin 0.008 2.22 0.007 1.91 Breasts 0.008 2.22 0.007 1.83 Dose calculations were performed using the standard MIRD method (MIRD Pamphlet No.1 (rev),Society of Nuclear Medicine, 1976). Effective dose equivalents (EDE) were calculated in accordance with ICRP 53 (Ann. ICRP 18 (1-4),1988) and gave values of 8.61 × 10-3 mSV/MBq and 1.12 × 10-2 mSV/MBq after exercise and rest, respectively. uuid:e0d93a84-794d-4218-81ef-73bfc3b9f8eb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135598 biolink:treats MONDO:0024643 PMID:41385096 "[{""id"":""uuid:1a6bcbfd-6a47-4856-af8c-a6495d58a857"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b3aecb77-0040-4be8-9aca-f3efa2d20c88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tetrofosmin is a diagnostic agent used to assess areas of reversible myocardial ischemia in the presence or absence of infracted myocardium and is also used to assess ventricular function. PHYSICAL HALF-LIFE & TARGET ORGANS The physical half-life of technetium, Tc99m, is 6 hours and has a principal radiation emission of gamma photons with a mean energy of 140 KeV. Estimated Absorbed Radiation Dose (Technetium Tc99m Tetrofosmin Injection) Absorbed radiation dose Exercise Rest Target organ rad/mCi µGy/MBq rad/mCi µGy/MBq Gall bladder wall 0.123 33.2 0.180 48.6 Upper large intestine 0.075 20.1 0.113 30.4 Bladder wall 0.058 15.6 0.071 19.3 Lower large intestine 0.057 15.3 0.082 22.2 Small intestine 0.045 12.1 0.063 17.0 Kidney 0.039 10.4 0.046 12.5 Salivary glands 0.030 8.04 0.043 11.6 Ovaries 0.029 7.88 0.035 9.55 Uterus 0.027 7.34 0.031 8.36 Bone surface 0.023 6.23 0.021 5.58 Pancreas 0.019 5.00 0.018 4.98 Stomach 0.017 4.60 0.017 4.63 Thyroid 0.016 4.34 0.022 5.83 Adrenals 0.016 4.32 0.015 4.11 Heart wall 0.015 4.14 0.015 3.93 Red marrow 0.015 4.14 0.015 3.97 Spleen 0.015 4.12 0.014 3.82 Muscle 0.013 3.52 0.012 3.32 Testes 0.013 3.41 0.011 3.05 Liver 0.012 3.22 0.015 4.15 Thymus 0.012 3.11 0.009 2.54 Brain 0.010 2.72 0.008 2.15 Lungs 0.008 2.27 0.008 2.08 Skin 0.008 2.22 0.007 1.91 Breasts 0.008 2.22 0.007 1.83 Dose calculations were performed using the standard MIRD method (MIRD Pamphlet No.1 (rev),Society of Nuclear Medicine, 1976). Effective dose equivalents (EDE) were calculated in accordance with ICRP 53 (Ann. ICRP 18 (1-4),1988) and gave values of 8.61 × 10-3 mSV/MBq and 1.12 × 10-2 mSV/MBq after exercise and rest, respectively. uuid:acedc679-26b2-4d26-89ee-e2a73137de22 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31974 biolink:treats MONDO:0008228 PMID:41385096 "[{""id"":""uuid:f85abbf9-427c-408a-b5ee-1175164e3fcf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:87b8af75-8630-4b05-88f9-1c67677d3301"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Anacidity (diagnosis) —Pentagastrin is indicated as a diagnostic aid for evaluation of gastric acid secretory function. It is effective in testing for anacidity (achlorhydria) in patients with suspected pernicious anemia, atrophic gastritis, or gastric carcinoma. It is also effective in determining the reduction in acid output after operations for peptic ulcer, such as vagotomy or gastric resection. Hypersecretory conditions, gastric (diagnosis) —Pentagastrin is indicated as a diagnostic aid in testing for gastric hypersecretion in patients with suspected duodenal ulcer or postoperative stomal ulcer, and for the diagnosis of Zollinger-Ellison tumor uuid:edd3cd66-196b-4442-a865-7e5533b78d54 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31974 biolink:treats MONDO:0006665 PMID:41385096 "[{""id"":""uuid:8a0a4729-1540-4d2e-afd5-de280a068c04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9597d7f7-1076-434c-8769-816ae4586f19"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Anacidity (diagnosis) —Pentagastrin is indicated as a diagnostic aid for evaluation of gastric acid secretory function. It is effective in testing for anacidity (achlorhydria) in patients with suspected pernicious anemia, atrophic gastritis, or gastric carcinoma. It is also effective in determining the reduction in acid output after operations for peptic ulcer, such as vagotomy or gastric resection. Hypersecretory conditions, gastric (diagnosis) —Pentagastrin is indicated as a diagnostic aid in testing for gastric hypersecretion in patients with suspected duodenal ulcer or postoperative stomal ulcer, and for the diagnosis of Zollinger-Ellison tumor uuid:fd46a7ec-3fbb-4317-9eb4-baf07a11a5bd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31974 biolink:treats MONDO:0004716 PMID:41385096 "[{""id"":""uuid:aaabe059-072f-46bd-86fb-111964b544bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b1fad91d-8de3-41cd-aab4-b4fb7f67190c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Anacidity (diagnosis) —Pentagastrin is indicated as a diagnostic aid for evaluation of gastric acid secretory function. It is effective in testing for anacidity (achlorhydria) in patients with suspected pernicious anemia, atrophic gastritis, or gastric carcinoma. It is also effective in determining the reduction in acid output after operations for peptic ulcer, such as vagotomy or gastric resection. Hypersecretory conditions, gastric (diagnosis) —Pentagastrin is indicated as a diagnostic aid in testing for gastric hypersecretion in patients with suspected duodenal ulcer or postoperative stomal ulcer, and for the diagnosis of Zollinger-Ellison tumor uuid:6bd9e104-968f-405a-b21e-e0332e3eba81 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31974 biolink:treats MONDO:0004247 PMID:41385096 "[{""id"":""uuid:8fc6ccee-4e2b-4f95-a30d-45127111e29f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:63986d7c-94cc-42e6-acb8-d32336a4541a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Anacidity (diagnosis) —Pentagastrin is indicated as a diagnostic aid for evaluation of gastric acid secretory function. It is effective in testing for anacidity (achlorhydria) in patients with suspected pernicious anemia, atrophic gastritis, or gastric carcinoma. It is also effective in determining the reduction in acid output after operations for peptic ulcer, such as vagotomy or gastric resection. Hypersecretory conditions, gastric (diagnosis) —Pentagastrin is indicated as a diagnostic aid in testing for gastric hypersecretion in patients with suspected duodenal ulcer or postoperative stomal ulcer, and for the diagnosis of Zollinger-Ellison tumor uuid:3e020c00-2b79-422f-be23-770e0bde5a1a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31974 biolink:treats MONDO:0005412 PMID:41385096 "[{""id"":""uuid:6afa6469-cd6f-4353-9d22-5038bfa65693"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6e96169a-ca65-462c-8b87-1bfa54cfdc16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Anacidity (diagnosis) —Pentagastrin is indicated as a diagnostic aid for evaluation of gastric acid secretory function. It is effective in testing for anacidity (achlorhydria) in patients with suspected pernicious anemia, atrophic gastritis, or gastric carcinoma. It is also effective in determining the reduction in acid output after operations for peptic ulcer, such as vagotomy or gastric resection. Hypersecretory conditions, gastric (diagnosis) —Pentagastrin is indicated as a diagnostic aid in testing for gastric hypersecretion in patients with suspected duodenal ulcer or postoperative stomal ulcer, and for the diagnosis of Zollinger-Ellison tumor uuid:37eb1e79-b5b8-4c50-abf9-4500cce7d1b9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:39N9K8S2A4 biolink:treats MONDO:0019297 PMID:41385096 "[{""id"":""uuid:0ae1e6cb-f675-4221-a950-8388bbc35bb9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8a00c03d-4c78-4a25-bef8-d539b452f55a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isosulfan Blue 1% Injection delineates the lymphatic vessels following subcutaneous administration. It is an adjunct to lymphography (in primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; and lymph node response to therapeutic modalities) for visualization to the lymphatic system draining the region of injection uuid:636f426a-c7c5-4500-b70c-b636ff512258 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:39N9K8S2A4 biolink:treats UMLS:C0159075 PMID:41385096 "[{""id"":""uuid:a3e0574f-353b-495c-a53e-4bb8e63b3aff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ff1a4b98-afef-4a4a-8d2c-366a772c67d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isosulfan Blue 1% Injection delineates the lymphatic vessels following subcutaneous administration. It is an adjunct to lymphography (in primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; and lymph node response to therapeutic modalities) for visualization to the lymphatic system draining the region of injection uuid:487f7974-f394-45d8-bb98-fe1a8d1a1367 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:39N9K8S2A4 biolink:treats MONDO:0008829 PMID:41385096 "[{""id"":""uuid:d6bac448-052a-4b0c-ad83-0d6c613d580b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:72f26949-3060-42cd-8eb0-b6b1931f91e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isosulfan Blue 1% Injection delineates the lymphatic vessels following subcutaneous administration. It is an adjunct to lymphography (in primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; and lymph node response to therapeutic modalities) for visualization to the lymphatic system draining the region of injection uuid:7773d139-913b-455b-ad1e-1e9d90203aa2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:39N9K8S2A4 biolink:treats HP:0010310 PMID:41385096 "[{""id"":""uuid:d769face-06ae-43cd-8f86-a1836ce6a355"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ea31826b-edae-4105-833c-5f3c4a11f2b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isosulfan Blue 1% Injection delineates the lymphatic vessels following subcutaneous administration. It is an adjunct to lymphography (in primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; and lymph node response to therapeutic modalities) for visualization to the lymphatic system draining the region of injection uuid:e94995a4-81ef-493f-863a-4d3a8484edf8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:39N9K8S2A4 biolink:treats MONDO:0005438 PMID:41385096 "[{""id"":""uuid:4f6ac891-6af1-4739-af40-12f437354c37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fddb62c1-8de3-4378-a653-b0e54f1696e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isosulfan Blue 1% Injection delineates the lymphatic vessels following subcutaneous administration. It is an adjunct to lymphography (in primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; and lymph node response to therapeutic modalities) for visualization to the lymphatic system draining the region of injection uuid:a8d57689-55e9-45cf-978e-aab1ed90aaa1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:119915 biolink:treats HP:0032149 PMID:41385096 "[{""id"":""uuid:08ee2fb0-cb3c-4dff-90a7-8999e4da3216"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2ac3fb69-6d30-4a80-84cd-8aaeaa6e7a7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e05daf39-6010-41b8-9707-6d2de8c2aeab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lazanda (fentanyl) nasal spray is indicated for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. Patients considered opioid tolerant are those who are taking at least: 60 mg of oral morphine/day, 25 mcg of transdermal fentanyl/hour, 30 mg oral oxycodone/day, 8 mg oral hydromorphone/day, 25 mg oral oxymorphone/day, or an equianalgesic dose of another opioid for a week or longer. Patients must remain on around-the-clock opioids when taking Lazanda. Lazanda is contraindicated for patients who are not already tolerant to opioids because life-threatening respiratory depression and death could occur in patients not taking chronic opioids. For this reason, Lazanda is contraindicated in the management of acute or postoperative pain, including headache/migraine, or dental pain. [ 4 ] Lazanda is intended to be prescribed only by healthcare professionals who are knowledgeable of and skilled in the use of Schedule II opioids to treat cancer pain.|[PMDA] Drugs with a new dosage in a new dosage form indicated for analgesia of breakthrough pain in patients with cancer receiving a potent opioid analgesic at fixed time. uuid:04752d76-0fb9-433a-81d4-8c889b7c778b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6030 biolink:treats UMLS:C0343751 PMID:41385096 "[{""id"":""uuid:f4a22f1b-f573-4070-983e-d68ce1e3a860"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:55e85d70-2295-4b70-aa70-43db924c5b50"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isoniazid is recommended for all forms of tuberculosis in which organisms are susceptible. However, active tuberculosis must be treated with multiple concomitant antituberculosis medications to prevent the emergence of drug resistance. Single-drug treatment of active tuberculosis with isoniazid, or any other medication, is inadequate therapy. Isoniazid is recommended as preventive therapy for the following groups, regardless of age. (Note: the criterion for a positive reaction to a skin test (in millimeters of induration) for each group is given in parentheses): Persons with human immunodeficiency virus (HIV) infection (≥ 5 mm) and persons with risk factors for HIV infection whose HIV infection status is unknown but who are suspected of having HIV infection. Preventive therapy may be considered for HIV infected persons who are tuberculin-negative but belong to groups in which the prevalence of tuberculosis infection is high. Candidates for preventive therapy who have HIV infection should have a minimum of 12 months of therapy. Close contacts of persons with newly diagnosed infectious tuberculosis (≥ 5 mm). In addition, tuberculin-negative (< 5 mm) children and adolescents who have been close contacts of infectious persons within the past 3 months are candidates for preventive therapy until a repeat tuberculin skin test is done 12 weeks after contact with the infectious source. If the repeat skin test is positive (> 5 mm), therapy should be continued. Recent converters, as indicated by a tuberculin skin test (≥ 10 mm increase within a 2-year period for those < 35 years old; ≥ 15 mm increase for those ≥ 35 years of age). All infants and children younger than 4 years of age with a > 10 mm skin test are included in this category. Persons with abnormal chest radiographs that show fibrotic lesions likely to represent old healed tuberculosis (≥ 5 mm). Candidates for preventive therapy who have fibrotic pulmonary lesions consistent with healed tuberculosis or who have pulmonary silicosis should have 12 months of isoniazid or 4 months of isoniazid and rifampin, concomitantly. Intravenous drug users known to be HIV-seronegative (> 10 mm). Persons with the following medical conditions that have been reported to increase the risk of tuberculosis (≥ 10 mm): silicosis; diabetes mellitus; prolonged therapy with adrenocorticosteroids; immunosuppressive therapy; some hematologic and reticuloendothelial diseases, such as leukemia or Hodgkin's disease; end-stage renal disease; clinical situations associated with substantial rapid weight loss or chronic under nutrition (including: intestinal bypass surgery for obesity, the postgastrectomy state (with or without weight loss), chronic peptic ulcer disease, chronic malabsorption syndromes, and carcinomas of the oropharynx and upper gastrointestinal tract that prevent adequate nutritional intake). Candidates for preventive therapy who have fibrotic pulmonary lesions consistent with healed tuberculosis or who have pulmonary silicosis should have 12 months of isoniazid or 4 months of isoniazid and rifampin, concomitantly. Additionally, in the absence of any of the above risk factors, persons under the age of 35 with a tuberculin skin test reaction of 10 mm or more are also appropriate candidates for preventive therapy if they are a member of any of the following high-incidence groups: Foreign-born persons from high-prevalence countries who never received BCG vaccine. Medically underserved low-income populations, including high-risk racial or ethnic minority populations, especially blacks, Hispanics, and Native Americans. Residents of facilities for long-term care (e.g., correctional institutions, nursing homes, and mental institutions). Children who are less than 4 years old are candidates for isoniazid preventive therapy if they have > 10 mm induration from a PPD Mantoux tuberculin skin test. Finally, persons under the age of 35 who a) have none of the above risk factors (1-6); b) belong to none of the high-incidence groups; and c) have a tuberculin skin test reaction of 15 mm or more, are appropriate candidates for preventive therapy. The risk of hepatitis must be weighed against the risk of tuberculosis in positive tuberculin reactors over the age of 35. However, the use of isoniazid is recommended for those with the additional risk factors listed above (1-6) and on an individual basis in situations where there is likelihood of serious consequences to contacts who may become infected. uuid:359501bc-c9dd-4700-a902-77b88d42deeb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C4534619 biolink:treats MONDO:0002898 PMID:41385096 "[{""id"":""uuid:25b891dd-2a0d-46ef-a1f3-d33532ab03de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:35722e48-5fa3-4c58-9dfe-787ab574b524"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Helps prevent sunburn. If used as directed, with other sun protection measures (see Directions ), decreases the risk of skin cancer and early skin aging caused by the sun. uuid:ff80079b-a6a9-47b5-be0f-e6971e87937f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C4534619 biolink:treats MONDO:0019303 PMID:41385096 "[{""id"":""uuid:f550b360-f467-4776-abec-f1d2286d2264"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9b7bdf24-deca-4ef1-a1e3-6041e494e6de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Helps prevent sunburn. If used as directed, with other sun protection measures (see Directions ), decreases the risk of skin cancer and early skin aging caused by the sun. uuid:f5b3cc7b-4c4c-4fd9-a5a1-2881353bbcee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4856 biolink:treats MONDO:0004981 PMID:41385096 "[{""id"":""uuid:90cf23fd-e867-453d-bf70-30d11b845e3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b6460fe6-bc74-4c7a-899e-518590c5a120"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Esmolol hydrochloride is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. Esmolol hydrochloride is also indicated in noncompensatory sinus tachycardia where, in the physician’s judgment, the rapid heart rate requires specific intervention. Esmolol hydrochloride is not intended for use in chronic settings where transfer to another agent is anticipated. uuid:86bcca96-fd69-405b-ac07-c04ebc127c68 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4856 biolink:treats MONDO:0005310 PMID:41385096 "[{""id"":""uuid:2fa25c69-3b4d-4c2f-96a4-9f624c53aa3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:15cb7a84-74fd-4354-b093-008def7d369c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Esmolol hydrochloride is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. Esmolol hydrochloride is also indicated in noncompensatory sinus tachycardia where, in the physician’s judgment, the rapid heart rate requires specific intervention. Esmolol hydrochloride is not intended for use in chronic settings where transfer to another agent is anticipated. uuid:750d6887-8088-4422-a3e6-43a5e513ee70 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4856 biolink:treats HP:0040182 PMID:41385096 "[{""id"":""uuid:c8f444ff-9e3e-4f0b-aff9-16993229c5e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9b7b7f43-a982-430a-a3f5-dae1bd77fc8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Esmolol hydrochloride is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. Esmolol hydrochloride is also indicated in noncompensatory sinus tachycardia where, in the physician’s judgment, the rapid heart rate requires specific intervention. Esmolol hydrochloride is not intended for use in chronic settings where transfer to another agent is anticipated. uuid:4dcd5448-e026-4b06-b3f8-9ed8d5c49d6f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8364 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:89f04a62-3a28-47d4-a74f-62b4ed3e9478"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:360c7127-6ec2-48bc-99f2-43b20e4513ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prazosin hydrochloride capsules are indicated in the treatment of hypertension. They can be used alone or in combination with other antihypertensive drugs such as diuretics or beta-adrenergic blocking agents. uuid:b0afbb82-76f6-4c2f-ade4-d817785363fb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9328 biolink:treats UMLS:C0332687 PMID:41385096 "[{""id"":""uuid:0d2df9da-9db3-4629-b563-3a62cedd54cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4a751093-481c-4582-abe2-07ce0af77b60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Silver Sulfadiazine Cream is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second and third degree burns. uuid:15a8c0f6-1537-4c85-b3f0-52ce413a9f8d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9328 biolink:treats UMLS:C0433445 PMID:41385096 "[{""id"":""uuid:86f07026-4fef-408e-9e72-e4f377a54fac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2700028a-f08e-4a83-b5fa-2eee65c621d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Silver Sulfadiazine Cream is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second and third degree burns. uuid:1c5ab437-dd82-42b2-8fff-3b0aeae752b8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4975 biolink:treats MONDO:0001409 PMID:41385096 "[{""id"":""uuid:fbbe2810-6c63-437a-b6ce-33d771faea50"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5daa898e-2498-4766-9f4f-0a8db5578993"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Famotidine tablets are indicated in: 1. Short term treatment of active duodenal ulcer . Most adult patients heal within 4 weeks; there is rarely reason to use famotidine at full dosage for longer than 6 to 8 weeks. Studies have not assessed the safety of famotidine in uncomplicated active duodenal ulcer for periods of more than eight weeks. 2. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer. Controlled studies in adults have not extended beyond one year. 3. Short term treatment of active benign gastric ulcer . Most adult patients heal within 6 weeks. Studies have not assessed the safety or efficacy of famotidine in uncomplicated active benign gastric ulcer for periods of more than 8 weeks. 4. Short term treatment of gastroesophageal reflux disease (GERD). Famotidine is indicated for short term treatment of patients with symptoms of GERD (see CLINICAL PHARMACOLOGY IN ADULTS, Clinical Studies ). Famotidine is also indicated for the short term treatment of esophagitis due to GERD including erosive or ulcerative disease diagnosed by endoscopy (see CLINICAL PHARMACOLOGY IN ADULTS, Clinical Studies ). 5. Treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison Syndrome, multiple endocrine adenomas ) (see CLINICAL PHARMACOLOGY IN ADULTS, Clinical Studies ). uuid:405c292c-848b-4743-a06f-789cbe453c6b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1165173 biolink:treats UMLS:C5442256 PMID:41385096 "[{""id"":""uuid:6e898e51-772c-4f2b-9ea5-da50f4172988"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7eb32a25-7f32-4ec1-a082-2e686717baec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Estradiol/Norethindrone Acetate Tablets 1.0 mg/0.5 mg and 0.5 mg/0.1 mg are indicated in women who have a uterus for the: Treatment of moderate to severe vasomotor symptoms associated with menopause. Prevention of postmenopausal osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and non-estrogen medications should be carefully considered. The mainstays for decreasing the risk of postmenopausal osteoporosis are weight bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 1500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400-800 IU/day may also be required to ensure adequate daily intake in postmenopausal women. Estradiol/Norethindrone Acetate Tablets 1.0 mg/0.5 mg is also indicated in women who have a uterus for the: 3. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with menopause. When used solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. uuid:86d6a409-0bfc-486c-a8dc-58fba73236f5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1165173 biolink:treats MONDO:0008159 PMID:41385096 "[{""id"":""uuid:32e6f3a0-f60c-4a94-8611-ab8a227f3de8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b25ecdd1-780a-44ee-b967-beb0a00c1ccd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Estradiol/Norethindrone Acetate Tablets 1.0 mg/0.5 mg and 0.5 mg/0.1 mg are indicated in women who have a uterus for the: Treatment of moderate to severe vasomotor symptoms associated with menopause. Prevention of postmenopausal osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and non-estrogen medications should be carefully considered. The mainstays for decreasing the risk of postmenopausal osteoporosis are weight bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 1500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400-800 IU/day may also be required to ensure adequate daily intake in postmenopausal women. Estradiol/Norethindrone Acetate Tablets 1.0 mg/0.5 mg is also indicated in women who have a uterus for the: 3. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with menopause. When used solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. uuid:4f47e619-99be-43fb-a938-62d601f7ffbb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3419 biolink:treats MONDO:0002081 PMID:41385096 "[{""id"":""uuid:3c931663-e437-4473-8c99-25bb93bc876d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:385318c4-b286-4039-ba81-b0c01a40830c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carisoprodol Tablets, USP are indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. Carisoprodol Tablets should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration. [see DOSAGE AND ADMINISTRATION (2)]. uuid:e260dde8-1b7e-4989-bdf1-222d54fac791 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9328 biolink:treats UMLS:C1141927 PMID:41385096 "[{""id"":""uuid:aa798640-f901-4a7c-86e5-9a43aaf1913d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b4998ecd-9ede-4009-82b4-5c338a70a6c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thermazene Cream is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second and third degree burns. uuid:b95f2ed8-caf8-4e64-a1fd-b39032639f53 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:378729 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:c120f641-e1d0-4b6c-a85f-f8d5121ba5df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1703bc9c-8772-4a7e-8823-10aed2877ab1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] After consultation with a healthcare professional who has considered and advised the patient of the risks and benefits of rosiglitazone, AVANDAMET ® is indicated as an adjunct to diet and exercise to improve glycemic control when treatment with both rosiglitazone and metformin is appropriate in adults with type 2 diabetes mellitus who either are: already taking rosiglitazone, or not already taking rosiglitazone and unable to achieve glycemic control on other diabetes medications and, in consultation with their healthcare provider, have decided not to take pioglitazone (ACTOS ® ) or pioglitazone-containing products (ACTOPLUS MET ® , ACTOPLUS MET XR ® , DUETACT ® ) for medical reasons. Other Important Limitations of Use: Due to its mechanism of action, rosiglitazone is active only in the presence of endogenous insulin. Therefore, AVANDAMET should not be used in patients with type 1 diabetes. Coadministration of AVANDAMET with insulin is not recommended [see Warnings and Precautions (5.2, 5.3)] . uuid:b149cdea-6e7d-48b1-ad1c-9e9414ab9a70 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:378729 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:426bf64a-f54a-4390-bda7-4840891766d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7c020124-e62b-413b-9472-e2c39c080a4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] After consultation with a healthcare professional who has considered and advised the patient of the risks and benefits of rosiglitazone, AVANDAMET ® is indicated as an adjunct to diet and exercise to improve glycemic control when treatment with both rosiglitazone and metformin is appropriate in adults with type 2 diabetes mellitus who either are: already taking rosiglitazone, or not already taking rosiglitazone and unable to achieve glycemic control on other diabetes medications and, in consultation with their healthcare provider, have decided not to take pioglitazone (ACTOS ® ) or pioglitazone-containing products (ACTOPLUS MET ® , ACTOPLUS MET XR ® , DUETACT ® ) for medical reasons. Other Important Limitations of Use: Due to its mechanism of action, rosiglitazone is active only in the presence of endogenous insulin. Therefore, AVANDAMET should not be used in patients with type 1 diabetes. Coadministration of AVANDAMET with insulin is not recommended [see Warnings and Precautions (5.2, 5.3)] . uuid:e0fadb58-e2dc-4a31-94af-e0ab7b7be236 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28864 biolink:treats MONDO:0000462 PMID:41385096 "[{""id"":""uuid:a8524534-cbe4-495a-88c2-40129c3ff199"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2a4fc799-1fe2-41cc-ac8e-0aadb0a6bb16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tobramycin Ophthalmic Solution USP, 0.3% is a topical antibiotic indicated in the treatment of external infections of the eye and its adnexa caused by susceptible bacteria. Appropriate monitoring of bacterial response to topical antibiotic therapy should accompany the use of Tobramycin Ophthalmic Solution USP, 0.3%. Clinical studies have shown tobramycin to be safe and effective for use in pediatric patients. uuid:f7e23fa4-adbf-46e1-8828-abe63b38e77b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16469 biolink:treats MONDO:0005159 PMID:41385096 "[{""id"":""uuid:dd4064a2-262d-4575-9824-a13fe5d7b1dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7713d438-b74c-4260-8ff4-cec934450e06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Estradiol tablets are indicated in the: 1. Treatment of moderate to severe vasomotor symptoms associated with the menopause. 2. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribed solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. 3. Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. 4. Treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. 5. Treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). 6. Prevention of osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate (See CLINICAL PHARMACOLOGY, Clinical Studies .) The mainstays for decreasing the risk of postmenopausal osteoporosis are weight bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 1500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400 to 800 IU/day may also be required to ensure adequate daily intake in postmenopausal women. uuid:71d3e3fd-d303-425c-872c-d6e9f5a1d7b8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5106 biolink:treats UMLS:C1322281 PMID:41385096 "[{""id"":""uuid:beac7b21-ac31-4945-9701-2f1926f4ae47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:110664d6-112e-4821-9050-88c48510ffd1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Flunisolide nasal solution is indicated for the treatment of the nasal symptoms of seasonal or perennial rhinitis. Flunisolide nasal solution should not be used in the presence of untreated localized infection involving nasal mucosa. uuid:57a85383-b47e-4a49-84d1-9c68164c7916 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5106 biolink:treats UMLS:C0848309 PMID:41385096 "[{""id"":""uuid:77a4e63a-ec0e-4a78-a1c2-b77dfc3c10c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fc4c703d-04e3-4519-b07c-ad6f9fdb6634"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Flunisolide nasal solution is indicated for the treatment of the nasal symptoms of seasonal or perennial rhinitis. Flunisolide nasal solution should not be used in the presence of untreated localized infection involving nasal mucosa. uuid:3dffd1ea-0074-43a8-8961-b2f61e4dde67 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1154384 biolink:treats MONDO:0005920 PMID:41385096 "[{""id"":""uuid:fa467fed-c421-4b8b-b718-00d774b94840"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d0c39b7a-67e1-487a-a31f-255cbbc6c232"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atovaquone and proguanil hydrochloride tablets are indicated for the prophylaxis of P. falciparum malaria, including in areas where chloroquine resistance has been reported (see CLINICAL STUDIES ). uuid:9c3bc116-43e3-44b3-b0f6-a01d6ed2e8d7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50848 biolink:treats UMLS:C0339164 PMID:41385096 "[{""id"":""uuid:b5bc4b36-ef53-435d-9634-5435ec81478e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2309f64d-c473-4924-9dd6-b247d9138d95"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ALREX Ophthalmic Suspension is indicated for the temporary relief of the signs and symptoms of seasonal allergic conjunctivitis. uuid:09ce5958-3fe0-4a62-ad18-4bafbd52a2b7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3213 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:6f3e7405-723d-41e3-a325-b6f61a8dc37b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0e25fe7b-6128-490a-bd6e-a37071014590"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bumetanide tablets USP are indicated for the treatment of edema associated with congestive heart failure, hepatic and renal disease, including the nephrotic syndrome. Almost equal diuretic response occurs after oral and parenteral administration of bumetanide. Therefore, if impaired gastrointestinal absorption is suspected or oral administration is not practical, bumetanide should be given by the intramuscular or intravenous route. Successful treatment with bumetanide tablets USP following instances of allergic reactions to furosemide suggests a lack of cross-sensitivity. uuid:e77921bc-09bd-4ea1-9a19-3d57278b9615 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3213 biolink:treats MONDO:0005154 PMID:41385096 "[{""id"":""uuid:eeb4d746-b559-485b-a7db-9a3a1911e828"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6542aadb-b5ce-459a-b239-1c7b452807c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bumetanide tablets USP are indicated for the treatment of edema associated with congestive heart failure, hepatic and renal disease, including the nephrotic syndrome. Almost equal diuretic response occurs after oral and parenteral administration of bumetanide. Therefore, if impaired gastrointestinal absorption is suspected or oral administration is not practical, bumetanide should be given by the intramuscular or intravenous route. Successful treatment with bumetanide tablets USP following instances of allergic reactions to furosemide suggests a lack of cross-sensitivity. uuid:95510f0b-0d9c-4d62-ad22-609ad8c7efae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3213 biolink:treats MONDO:0005240 PMID:41385096 "[{""id"":""uuid:5d6e7e5e-b569-4a90-bce5-e295d5bd2f71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b395fc7f-6777-441f-8621-51f47f08bb36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bumetanide tablets USP are indicated for the treatment of edema associated with congestive heart failure, hepatic and renal disease, including the nephrotic syndrome. Almost equal diuretic response occurs after oral and parenteral administration of bumetanide. Therefore, if impaired gastrointestinal absorption is suspected or oral administration is not practical, bumetanide should be given by the intramuscular or intravenous route. Successful treatment with bumetanide tablets USP following instances of allergic reactions to furosemide suggests a lack of cross-sensitivity. uuid:2e3d99bd-04e0-4489-9613-4a4b19665263 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3213 biolink:treats MONDO:0005377 PMID:41385096 "[{""id"":""uuid:0fd38cee-8409-4fb7-b8b5-7a1e47a68624"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8b7cd03e-96f7-471b-bc4e-12b1c118c7dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bumetanide tablets USP are indicated for the treatment of edema associated with congestive heart failure, hepatic and renal disease, including the nephrotic syndrome. Almost equal diuretic response occurs after oral and parenteral administration of bumetanide. Therefore, if impaired gastrointestinal absorption is suspected or oral administration is not practical, bumetanide should be given by the intramuscular or intravenous route. Successful treatment with bumetanide tablets USP following instances of allergic reactions to furosemide suggests a lack of cross-sensitivity. uuid:bc93bd4f-2e4e-4947-b5a7-5e5c03d6054b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41948 biolink:treats HP:0001007 PMID:41385096 "[{""id"":""uuid:54ad4bb8-ac23-4cd5-8a34-bd01fcbc3ea6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c9a479c1-a501-4439-be40-d12f5e5657ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VANIQA (eflornithine hydrochloride) Cream, 13.9% is indicated for the reduction of unwanted facial hair in women. VANIQA has only been studied on the face and adjacent involved areas under the chin of affected individuals. Usage should be limited to these areas of involvement. uuid:ec12271b-edc2-4ebd-96bb-0de8f7890260 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6722 biolink:treats MONDO:0004989 PMID:41385096 "[{""id"":""uuid:af895cbe-0d52-43b5-978b-aa18a0e9a656"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:06758866-cd8e-41e4-988a-8fbd174b5802"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Megestrol acetate tablets are indicated for the palliative treatment of advanced carcinoma of the breast or endometrium (ie, recurrent, inoperable, or metastatic disease). It should not be used in lieu of currently accepted procedures such as surgery, radiation, or chemotherapy. uuid:9d3751a0-0852-4145-b3a3-bc7dab63c8ce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2379 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:af99da91-4b6b-4506-a8d5-bf5f3796053d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:10218fba-19f7-4067-8fba-fe3c52c598d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] HYPERTENSION: Acebutolol hydrochloride capsules are indicated for the management of hypertension in adults. It may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. VENTRICULAR ARRHYTHMIAS: Acebutolol hydrochloride capsules are indicated in the management of ventricular premature beats; it reduces the total number of premature beats, as well as the number of paired and multiform ventricular ectopic beats, and R-on-T beats. uuid:d197ff0a-6622-4dde-aafc-c300b1c1d3ef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2379 biolink:treats HP:0006682 PMID:41385096 "[{""id"":""uuid:0ae72e85-cd4c-4ab2-a75f-08d7b4e5babc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:88f61efe-e193-4375-a106-f541ae91676d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] HYPERTENSION: Acebutolol hydrochloride capsules are indicated for the management of hypertension in adults. It may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. VENTRICULAR ARRHYTHMIAS: Acebutolol hydrochloride capsules are indicated in the management of ventricular premature beats; it reduces the total number of premature beats, as well as the number of paired and multiform ventricular ectopic beats, and R-on-T beats. uuid:e7bbb71d-ad43-4558-8356-6c14b23601f6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28939 biolink:treats UMLS:C1265792 PMID:41385096 "[{""id"":""uuid:20b31c71-9214-47e8-85f7-00b3332b08f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ff176940-0a1a-4590-9da7-a8ac2e1f4e1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acetylcysteine is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization) uuid:df86e432-60f5-4ecb-96c7-b1d3c04e89ef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28939 biolink:treats UMLS:C0155874 PMID:41385096 "[{""id"":""uuid:e0955da1-b856-4b49-b778-e27f4e3fdea8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3889a651-c8ff-4ce1-ad8c-fe43c0ad0fc8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acetylcysteine is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization) uuid:2685560a-b63a-4343-8302-f398ffc0d734 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28939 biolink:treats UMLS:C0264348 PMID:41385096 "[{""id"":""uuid:ea75f369-a50b-4526-9f4f-e9c2cd222b66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:43d4b9cd-16ac-4662-a507-44b562d9ecc9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acetylcysteine is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization) uuid:3b90eddb-35ec-4206-b1e3-2abd39879ba3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28939 biolink:treats MONDO:0018076 PMID:41385096 "[{""id"":""uuid:2e781a3f-4557-4bda-afed-39594b239c32"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:159edf97-565f-49bd-9f84-3bb00e981553"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acetylcysteine is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization) uuid:402948a5-14b8-4d25-bf82-db4a548274e5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28939 biolink:treats MONDO:0004822 PMID:41385096 "[{""id"":""uuid:b8fde22b-f6f5-472f-b823-658e48efa773"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0e727444-772d-4709-906e-5c7423f5efa7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acetylcysteine is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization) uuid:3ef63ae0-fe62-4001-b281-a2f9dac97a65 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28939 biolink:treats MONDO:0019438 PMID:41385096 "[{""id"":""uuid:eaf3f409-e798-465c-ba61-823e3e936e26"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e806d4da-14f1-4374-aac0-c0aaa08fc6e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acetylcysteine is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization) uuid:f31ad977-9f5d-433b-9545-261a5119d193 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28939 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:2e463181-2670-4d57-92b2-353d28b61b64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:63007da0-b86a-48eb-aad1-5e799373e658"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acetylcysteine is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization) uuid:299d01a7-c7bf-4d71-90b4-2a99bacd7376 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28939 biolink:treats MONDO:0003781 PMID:41385096 "[{""id"":""uuid:2a44c71c-a394-4638-b49b-46d86d407650"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ed43d907-5090-44ff-89f5-26eb038b4d34"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acetylcysteine is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization) uuid:2d3a53de-68cd-4f05-80de-3386bd7a5ffa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28939 biolink:treats MONDO:0021925 PMID:41385096 "[{""id"":""uuid:123d23e4-f971-4e43-9499-e0a845198ce6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bc64e0cb-cca0-4cb4-a3fa-a19915fc5163"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acetylcysteine is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization) uuid:7a3494c5-e5d5-4e20-9c96-200e0a9a3483 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28939 biolink:treats MONDO:0009061 PMID:41385096 "[{""id"":""uuid:0e178548-ef1f-40de-a94f-1889b76e06e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e6095508-a282-4468-988d-8c1221401f69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acetylcysteine is indicated as adjuvant therapy for patients with abnormal, viscid, or inspissated mucous secretions in such conditions as: Chronic bronchopulmonary disease (chronic emphysema, emphysema with bronchitis, chronic asthmatic bronchitis, tuberculosis, bronchiectasis and primary amyloidosis of the lung) Acute bronchopulmonary disease (pneumonia, bronchitis, tracheobronchitis) Pulmonary complications of cystic fibrosis Tracheostomy care Pulmonary complications associated with surgery Use during anesthesia Post-traumatic chest conditions Atelectasis due to mucous obstruction Diagnostic bronchial studies (bronchograms, bronchospirometry, and bronchial wedge catheterization) uuid:bd405fbb-ff2e-4472-bafa-f96efba8557f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9012 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:b3e97e28-346f-464d-b854-555fc9dcbf24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9592d8f6-d242-47c5-af20-9e206a55787a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SEREVENT DISKUS is a LABA indicated for: Treatment of asthma in patients aged 4 years and older. (1.1) Prevention of exercise-induced bronchospasm (EIB) in patients aged 4 years and older. (1.2) Maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD). (1.3) Important limitation: Not indicated for the relief of acute bronchospasm. (1.1, 1.3) uuid:c1e9ec70-b8f0-41cf-852f-8028a0c915ef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9012 biolink:treats MONDO:0850286 PMID:41385096 "[{""id"":""uuid:3affb4e3-e16c-4c47-bc9f-8ef5c476b1f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3f3bc4eb-cd82-4d73-bb3f-ff92587d2b35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SEREVENT DISKUS is a LABA indicated for: Treatment of asthma in patients aged 4 years and older. (1.1) Prevention of exercise-induced bronchospasm (EIB) in patients aged 4 years and older. (1.2) Maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD). (1.3) Important limitation: Not indicated for the relief of acute bronchospasm. (1.1, 1.3) UMLS:C0015263 uuid:1e5865ae-80a5-43de-b527-16c8f49c617e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9012 biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:48b2f9c1-7b6f-4cde-a462-5da1aa4ce804"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eb5a194b-654f-4116-8855-d3735eb6aec2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SEREVENT DISKUS is a LABA indicated for: Treatment of asthma in patients aged 4 years and older. (1.1) Prevention of exercise-induced bronchospasm (EIB) in patients aged 4 years and older. (1.2) Maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD). (1.3) Important limitation: Not indicated for the relief of acute bronchospasm. (1.1, 1.3) uuid:42f4e57a-bdc9-46fa-8f99-bceb9df5c9c9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7936 biolink:treats MONDO:0001942 PMID:41385096 "[{""id"":""uuid:fddab322-8f64-4d3e-8822-bd727e5c246f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:932e6708-226e-40aa-8b38-3d96ca06a9d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Major Depressive Disorder Paroxetine tablets, USP are indicated for the treatment of major depressive disorder. The efficacy of paroxetine in the treatment of a major depressive episode was established in 6-week controlled trials of outpatients whose diagnoses corresponded most closely to the DSM-III category of major depressive disorder (see CLINICAL PHARMACOLOGY: Clinical Trials ). A major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: Change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. The effects of paroxetine in hospitalized depressed patients have not been adequately studied. The efficacy of paroxetine in maintaining a response in major depressive disorder for up to 1 year was demonstrated in a placebo-controlled trial (see CLINICAL PHARMACOLOGY: Clinical Trials ). Nevertheless, the physician who elects to use paroxetine for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient. Obsessive Compulsive Disorder Paroxetine tablets, USP are indicated for the treatment of obsessions and compulsions in patients with obsessive compulsive disorder (OCD) as defined in the DSM-IV. The obsessions or compulsions cause marked distress, are time-consuming, or significantly interfere with social or occupational functioning. The efficacy of paroxetine was established in two 12-week trials with obsessive compulsive outpatients whose diagnoses corresponded most closely to the DSM-IIIR category of obsessive compulsive disorder (see CLINICAL PHARMACOLOGY: Clinical Trials ). Obsessive compulsive disorder is characterized by recurrent and persistent ideas, thoughts, impulses, or images (obsessions) that are ego-dystonic and/or repetitive, purposeful, and intentional behaviors (compulsions) that are recognized by the person as excessive or unreasonable. Long-term maintenance of efficacy was demonstrated in a 6-month relapse prevention trial. In this trial, patients assigned to paroxetine showed a lower relapse rate compared to patients on placebo (see CLINICAL PHARMACOLOGY: Clinical Trials ). Nevertheless, the physician who elects to use paroxetine for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Panic Disorder Paroxetine tablets, USP are indicated for the treatment of panic disorder, with or without agoraphobia, as defined in DSM-IV. Panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. The efficacy of paroxetine was established in three 10- to 12-week trials in panic disorder patients whose diagnoses corresponded to the DSM-IIIR category of panic disorder (see CLINICAL PHARMACOLOGY: Clinical Trials ). Panic disorder (DSM-IV) is characterized by recurrent unexpected panic attacks, i.e., a discrete period of intense fear or discomfort in which 4 (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) palpitations, pounding heart, or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded, or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes. Long-term maintenance of efficacy was demonstrated in a 3-month relapse prevention trial. In this trial, patients with panic disorder assigned to paroxetine demonstrated a lower relapse rate compared to patients on placebo (see CLINICAL PHARMACOLOGY: Clinical Trials ). Nevertheless, the physician who prescribes paroxetine for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Generalized Anxiety Disorder Paroxetine tablets, USP are indicated for the treatment of Generalized Anxiety Disorder (GAD), as defined in DSM-IV. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The efficacy of paroxetine in the treatment of GAD was established in two 8-week placebo-controlled trials in adults with GAD. Paroxetine has not been studied in children or adolescents with Generalized Anxiety Disorder (see CLINICAL PHARMACOLOGY: Clinical Trials ). Generalized Anxiety Disorder (DSM-IV) is characterized by excessive anxiety and worry (apprehensive expectation) that is persistent for at least 6 months and which the person finds difficult to control. It must be associated with at least 3 of the following 6 symptoms: Restlessness or feeling keyed up or on edge, being easily fatigued, difficulty concentrating or mind going blank, irritability, muscle tension, sleep disturbance. The efficacy of paroxetine in maintaining a response in patients with Generalized Anxiety Disorder, who responded during an 8-week acute treatment phase while taking paroxetine and were then observed for relapse during a period of up to 24 weeks, was demonstrated in a placebo-controlled trial (see CLINICAL PHARMACOLOGY: Clinical Trials ). Nevertheless, the physician who elects to use paroxetine for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). uuid:a15c508b-5f25-4ae0-beb3-9382a7d5779c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4798 biolink:treats MONDO:0005180 PMID:41385096 "[{""id"":""uuid:4c5bfa8d-f50f-4171-af20-d94dba749d9d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ae105657-734b-426f-b119-5c94974c44bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1ba0f849-f4a9-4620-a891-6b49f0186620"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/entacapone-orion""]},{""id"":""uuid:adc6dc66-fc8b-48c8-8b30-654735bb9442"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Entacapone Tablets are indicated as an adjunct to levodopa and carbidopa to treat patients with idiopathic Parkinson’s Disease who experience the signs and symptoms of end-of-dose ""wearing-off"" (see CLINICAL PHARMACOLOGY, Clinical Studies ). Entacapone Tablets’ effectiveness has not been systematically evaluated in patients with idiopathic Parkinson’s Disease who do not experience end-of-dose ""wearing-off"".|[EMA] Entacapone is indicated as an adjunct to standard preparations of levodopa / benserazide or levodopa / carbidopa for use in adult patients with Parkinson's disease and end-of-dose motor fluctuations, who cannot be stabilised on those combinations.|[PMDA] Drug containing a new active ingredient used in combination with levodopa/carbidopa or levodopa/benserazide hydrochloride to improve daily fluctuation, or 'wearing-off' phenomena, in Parkinson’ s disease." uuid:6b939f7d-56ba-4c02-920d-324c80d847b1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3216 biolink:treats MONDO:0005530 PMID:41385096 "[{""id"":""uuid:39670375-90d2-4e8d-8464-c0910f5b15a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:8caa7125-7abf-464b-ab96-68f01031fd5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1ecb0d26-eedc-4e08-b202-fb102568ba81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/buvidal""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] SUBOXONE and SUBUTEX are indicated for the treatment of opioid dependence.|[EMA] Treatment of opioid dependence within a framework of medical, social and psychological treatment. Treatment is intended for use in adults and adolescents aged 16 years or over. uuid:54daec35-4294-4a3e-a222-b4ca4aa2f5da biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9887103 biolink:treats MONDO:0004247 PMID:41385096 "[{""id"":""uuid:9dcdff49-a4c4-40f0-b7f8-35d0ec17437a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aaf3b4b4-b46a-4ec6-b90a-1f1736efedae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For use as adjunctive therapy in the treatment of peptic ulcer. uuid:4bc772d5-9821-4ef4-b0fe-eec096f666ea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2208 biolink:treats MONDO:0004967 PMID:41385096 "[{""id"":""uuid:afe1a11c-cec5-4c95-a096-da294b6794c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:8fea0f53-887e-4c6a-a03b-c40ccb11d785"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:34b687d1-1255-487d-b4d0-f4f41c9b8350"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mercaptopurine tablets are indicated for maintenance therapy of acute lymphatic (lymphocytic, lymphoblastic) leukemia as part of a combination regimen. The response to this agent depends upon the particular subclassification of acute lymphatic leukemia and the age of the patient (pediatric or adult). Mercaptopurine is not effective for prophylaxis or treatment of central nervous system leukemia. Mercaptopurine is not effective in acute myelogenous leukemia, chronic lymphatic leukemia, the lymphomas (including Hodgkins Disease), or solid tumors.|[EMA] Xaluprine is indicated for the treatment of acute lymphoblastic leukaemia (ALL) in adults, adolescents and children. uuid:5c9890b3-57f9-4faa-9dbe-bb4b4630da20 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2208 biolink:treats MONDO:0001606 PMID:41385096 "[{""id"":""uuid:e0655147-b5a5-4775-8104-283ffa0d617e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a53c84b4-310a-4132-b81d-0ce145415636"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mercaptopurine tablets are indicated for maintenance therapy of acute lymphatic (lymphocytic, lymphoblastic) leukemia as part of a combination regimen. The response to this agent depends upon the particular subclassification of acute lymphatic leukemia and the age of the patient (pediatric or adult). Mercaptopurine is not effective for prophylaxis or treatment of central nervous system leukemia. Mercaptopurine is not effective in acute myelogenous leukemia, chronic lymphatic leukemia, the lymphomas (including Hodgkins Disease), or solid tumors. uuid:f246976a-e72f-4161-8e46-51c11b5d8f57 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2208 biolink:treats MONDO:0018874 PMID:41385096 "[{""id"":""uuid:30057f42-9abd-4b97-8c7d-5fcbebb68a13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9d39eea3-a456-4eb0-b039-fdd5c768f7f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mercaptopurine tablets are indicated for maintenance therapy of acute lymphatic (lymphocytic, lymphoblastic) leukemia as part of a combination regimen. The response to this agent depends upon the particular subclassification of acute lymphatic leukemia and the age of the patient (pediatric or adult). Mercaptopurine is not effective for prophylaxis or treatment of central nervous system leukemia. Mercaptopurine is not effective in acute myelogenous leukemia, chronic lymphatic leukemia, the lymphomas (including Hodgkins Disease), or solid tumors. uuid:332ccb79-fbae-4da0-95fa-9cdd70541f8e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2208 biolink:treats MONDO:0004948 PMID:41385096 "[{""id"":""uuid:2975763c-ad78-450e-ba70-7a27bf394849"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:29f57e8e-9af3-4794-a510-b5ac41df9cca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mercaptopurine tablets are indicated for maintenance therapy of acute lymphatic (lymphocytic, lymphoblastic) leukemia as part of a combination regimen. The response to this agent depends upon the particular subclassification of acute lymphatic leukemia and the age of the patient (pediatric or adult). Mercaptopurine is not effective for prophylaxis or treatment of central nervous system leukemia. Mercaptopurine is not effective in acute myelogenous leukemia, chronic lymphatic leukemia, the lymphomas (including Hodgkins Disease), or solid tumors. uuid:0bfeb030-9cbc-4efd-872d-c23793ac00a5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2208 biolink:treats MONDO:0009348 PMID:41385096 "[{""id"":""uuid:ebe3d9ba-c71f-494f-ba0f-8b78b372ae6a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:da593468-7728-4e49-b703-88aef65a88ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mercaptopurine tablets are indicated for maintenance therapy of acute lymphatic (lymphocytic, lymphoblastic) leukemia as part of a combination regimen. The response to this agent depends upon the particular subclassification of acute lymphatic leukemia and the age of the patient (pediatric or adult). Mercaptopurine is not effective for prophylaxis or treatment of central nervous system leukemia. Mercaptopurine is not effective in acute myelogenous leukemia, chronic lymphatic leukemia, the lymphomas (including Hodgkins Disease), or solid tumors. uuid:14c7941c-3893-4e67-b3d0-939b7c4854c4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:453011 biolink:treats MONDO:0001405 PMID:41385096 "[{""id"":""uuid:1698ba86-0c82-40f0-ba1e-d74088ed28f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:97d2ad15-127f-4b89-b7a0-1de01c60df82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciclopirox olamine cream is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum , and Microsporum canis ; candidiasis (moniliasis) due to Candida albicans ; and tinea (pityriasis) vesicolor due to Malassezia furfur. uuid:152ebe47-f0fb-4e80-88a2-891a32d83d1c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:453011 biolink:treats MONDO:0001461 PMID:41385096 "[{""id"":""uuid:f0bb1aa7-ed98-4795-8c05-7f3edf6d653f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5c05fba7-7fe6-4ad9-be80-c1d48508f636"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciclopirox olamine cream is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum , and Microsporum canis ; candidiasis (moniliasis) due to Candida albicans ; and tinea (pityriasis) vesicolor due to Malassezia furfur. uuid:79508792-3751-41c3-895e-b42c3f91a869 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:453011 biolink:treats UMLS:C0343886 PMID:41385096 "[{""id"":""uuid:ff88ebc5-42ca-4a67-8915-c575a351e265"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ba7e42ef-a6cf-4e43-9d0f-c5fde3454e13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciclopirox olamine cream is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum , and Microsporum canis ; candidiasis (moniliasis) due to Candida albicans ; and tinea (pityriasis) vesicolor due to Malassezia furfur. uuid:c1f6c1c4-d11a-478b-ac99-7c9edbbb5ef4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:453011 biolink:treats MONDO:0005915 PMID:41385096 "[{""id"":""uuid:c2aafc51-ef96-4e94-ad7d-365903104d1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d8c0db8f-72df-405d-8eab-4989fd879307"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciclopirox olamine cream is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum , and Microsporum canis ; candidiasis (moniliasis) due to Candida albicans ; and tinea (pityriasis) vesicolor due to Malassezia furfur. uuid:21ae433f-a40c-4c5a-b227-02f31bf58d8c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7444 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:54999f7b-2b8e-4b74-918e-337a9abe2a7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9f89ded9-d767-40d9-b6ad-3a2b50f0fec4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Angina Pectoris Nadolol tablets are indicated for the long-term management of patients with angina pectoris. Hypertension Nadolol tablets are indicated in the management of hypertension; it may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. uuid:a8d5d7e0-c81e-4c8d-8251-bc82da5aa06c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77363 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:6c639b05-64a7-4686-b979-9720c1768e3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cca2eaf6-5477-4e63-b8ff-481e07171c78"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ramipril Capsules USP are indicated for the treatment of hypertension. It may be used alone or in combination with thiazide diuretics (1.1). uuid:c87a9cf1-61e3-4064-89db-997e7d33d0db biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:151176 biolink:treats HP:0003124 PMID:41385096 "[{""id"":""uuid:7f361c55-ebf2-4709-b9dd-7a927aad34a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:96596dfa-8162-4573-9c02-0205f0f29d07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk-factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate (see also Table 8 and the NCEP treatment guidelines 1 ). uuid:8ad6f4cc-4b24-4a9e-b24a-6de1601a708a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4887 biolink:treats MONDO:0010826 PMID:41385096 "[{""id"":""uuid:2fddfac9-c8b7-4c5b-acb1-802693d1c29c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c5550529-3ec9-4ea9-a3fc-14e7f2ef8bb4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ethosuximide capsule is indicated for the control of absence (petit mal) epilepsy. uuid:c590fbc0-e7a4-4353-8495-23c5c7ba1c54 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:36560 biolink:treats MONDO:0002898 PMID:41385096 "[{""id"":""uuid:f393f8fc-4a21-4629-856b-06a8055baaf9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0fba65fd-49f6-4d41-96c2-e398424c9528"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] helps prevent sunburn if used as directed wiht other sun protection measures (see Directions ), decreases the risk of skin cancer and early skin aging caused by the sun. uuid:43026f79-b92c-4a02-b33c-ad7e19d1ee8f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:36560 biolink:treats MONDO:0019303 PMID:41385096 "[{""id"":""uuid:37e64b03-fb5a-4fb4-b39f-6eac641957b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:793ebfa4-e8dd-4b89-9c63-7597098ad227"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] helps prevent sunburn if used as directed wiht other sun protection measures (see Directions ), decreases the risk of skin cancer and early skin aging caused by the sun. uuid:9deab91f-797d-40b4-9116-af4d020596a0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:26751 biolink:treats MONDO:0004992 PMID:41385096 "[{""id"":""uuid:003d50c5-77b4-41c4-98cf-18a6ebdad7cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5788d9aa-d1bd-42a2-ab93-788fcda63428"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] P32 chromic phosphate is indicated for intracavitary instillation for the treatment of peritoneal or pleural effusions caused by metastatic disease, and may be injected interstitially for the treatment of cancer. It is also used in hemophilia patients for intraarticular injections. uuid:3b87bf28-07a9-4e14-9063-10d44c9f5137 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:26751 biolink:treats MONDO:0018660 PMID:41385096 "[{""id"":""uuid:06b83c9e-ffdd-4a3a-a86d-f1da3f05f412"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:17dad8c0-5599-43a3-ada6-d9fc698d646e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] P32 chromic phosphate is indicated for intracavitary instillation for the treatment of peritoneal or pleural effusions caused by metastatic disease, and may be injected interstitially for the treatment of cancer. It is also used in hemophilia patients for intraarticular injections. uuid:e715dc73-6391-48ca-826c-b76c9752cb65 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:26751 biolink:treats MONDO:0009891 PMID:41385096 "[{""id"":""uuid:0cbb22e1-5fa4-4329-957d-e3e648bdba97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c8ad5e38-facd-4e06-bfdc-d8c5e2871fa3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] P32 sodium phosphate is indicated for the treatment of polycythemia vera and is effective for the treatment of chronic myelocytic leukemia and chronic lymphocytic leukemia. It may also be used in the palliative treatment of selected patients with multiple areas of skeletal metastases uuid:41777742-b7d0-453a-b1c4-02c50ab9841c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:26751 biolink:treats MONDO:0011996 PMID:41385096 "[{""id"":""uuid:3364aabd-5538-480e-8db7-243897428253"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a04665d6-8942-44d9-9c83-47cc32d03cd4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] P32 sodium phosphate is indicated for the treatment of polycythemia vera and is effective for the treatment of chronic myelocytic leukemia and chronic lymphocytic leukemia. It may also be used in the palliative treatment of selected patients with multiple areas of skeletal metastases uuid:48bd1f48-cbd1-4bfb-9399-6ce94ef7fcb0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:26751 biolink:treats MONDO:0004948 PMID:41385096 "[{""id"":""uuid:fd444131-0a1c-4277-80a4-9b9d37772686"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cc262c5d-af04-49c8-bf79-b35d63f88666"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] P32 sodium phosphate is indicated for the treatment of polycythemia vera and is effective for the treatment of chronic myelocytic leukemia and chronic lymphocytic leukemia. It may also be used in the palliative treatment of selected patients with multiple areas of skeletal metastases uuid:e5bac1b0-31d3-46e3-a7ae-372cdab746a7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:26751 biolink:treats UMLS:C0153690 PMID:41385096 "[{""id"":""uuid:f8dff8f9-c63a-41c7-a508-83c3ab6ce85b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eebbc8d2-a09e-41fb-9461-5c882fc91ceb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] P32 sodium phosphate is indicated for the treatment of polycythemia vera and is effective for the treatment of chronic myelocytic leukemia and chronic lymphocytic leukemia. It may also be used in the palliative treatment of selected patients with multiple areas of skeletal metastases uuid:ca991587-d02b-49ef-b24a-ad5cff3dbb30 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3FYP5M0IJX biolink:treats MONDO:0002203 PMID:41385096 "[{""id"":""uuid:07cd1f45-9a9c-4c01-8d79-d90feedb095d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4a97afc6-700e-4292-92c5-015237ab6266"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] relieves occasional constipation (irregularity) generally produces a bowel movement in 6-12 hours uuid:d4360428-a0e0-46ec-9be0-345c0d93621e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:367163 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:aea81158-5f3e-4b14-b1ea-e529fbcd2f86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5503a6e2-d3a1-48c3-97d6-6fe9062316ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PREZISTA is a human immunodeficiency virus (HIV-1) protease inhibitor indicated for the treatment of HIV-1 infection in adult patients. PREZISTA is also indicated for the treatment of HIV-1 infection in pediatric patients 3 years of age and older. PREZISTA must be co-administered with ritonavir (PREZISTA/ritonavir) and with other antiretroviral agents. ( 1 ) uuid:bae8f815-d2ae-4b36-a6f9-ffac280067f7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24757947 biolink:treats MONDO:0003664 PMID:41385096 "[{""id"":""uuid:76e462a6-54be-4892-bfbf-f3de4135aef4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9026c565-50f7-46b2-83b2-d50723717f41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cr51 is indicated for use in determining red blood cell volume or mass, studying red blood cell survival time (in conditions such as hemolytic anemia), and evaluating blood loss uuid:1aa5b384-af9b-43bc-bab8-6cd3475fd314 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:35940 biolink:treats MONDO:0006869 PMID:41385096 "[{""id"":""uuid:610537c3-0a57-4efe-bd98-810c635bf2ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cf55cb9b-0dd4-47f0-9a54-c6ca87bc39ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRH is indicated as an adjunctive agent in the diagnostic assessment of thyroid function. As an adjunct to other diagnostic procedures, testing with TRH (protirelin) may yield useful information in patients with pituitary or hypothalamic dysfunction. TRH is indicated as an adjunct to evaluate the effectiveness of thyrotropin suppression with a particular dose of T4 in patients with nodular or diffuse goiter. A normal TSH baseline value and a minimal difference between the 30 minute and baseline response to TRH injection would indicate adequate suppression of the pituitary secretion of TSH. TRH may be used, adjunctively, for adjustment of thyroid hormone dosage given to patients with primary hypothyroidism. A normal or slightly blunted TSH response, thirty minutes following TRH injection, would indicate adequate replacement therapy. uuid:b84bce82-869d-46b5-97b8-e7f9688c3d17 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:35940 biolink:treats UMLS:C0342114 PMID:41385096 "[{""id"":""uuid:4ac99734-cfc4-4911-af1b-e1bed3f4f76d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:905b6f0e-2b9a-4807-a21b-3944c1bd9ea8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRH is indicated as an adjunctive agent in the diagnostic assessment of thyroid function. As an adjunct to other diagnostic procedures, testing with TRH (protirelin) may yield useful information in patients with pituitary or hypothalamic dysfunction. TRH is indicated as an adjunct to evaluate the effectiveness of thyrotropin suppression with a particular dose of T4 in patients with nodular or diffuse goiter. A normal TSH baseline value and a minimal difference between the 30 minute and baseline response to TRH injection would indicate adequate suppression of the pituitary secretion of TSH. TRH may be used, adjunctively, for adjustment of thyroid hormone dosage given to patients with primary hypothyroidism. A normal or slightly blunted TSH response, thirty minutes following TRH injection, would indicate adequate replacement therapy. uuid:84a53238-835e-4c92-9521-0ae09afde70f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:35940 biolink:treats HP:0000832 PMID:41385096 "[{""id"":""uuid:1b754a9d-94a3-4dea-bb87-a30cb5773ec0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:99a8fb4a-328d-4f1a-99b3-657ccd94be36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRH is indicated as an adjunctive agent in the diagnostic assessment of thyroid function. As an adjunct to other diagnostic procedures, testing with TRH (protirelin) may yield useful information in patients with pituitary or hypothalamic dysfunction. TRH is indicated as an adjunct to evaluate the effectiveness of thyrotropin suppression with a particular dose of T4 in patients with nodular or diffuse goiter. A normal TSH baseline value and a minimal difference between the 30 minute and baseline response to TRH injection would indicate adequate suppression of the pituitary secretion of TSH. TRH may be used, adjunctively, for adjustment of thyroid hormone dosage given to patients with primary hypothyroidism. A normal or slightly blunted TSH response, thirty minutes following TRH injection, would indicate adequate replacement therapy. uuid:35ed137f-162b-4d2f-8706-10e0d63819b4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29101 biolink:treats UMLS:C0948840 PMID:41385096 "[{""id"":""uuid:671b245c-feb0-4ecf-882b-d0dcd3a039a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:777682e6-fd64-4551-aee9-a0ee49ece69f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Elliotts B Solution is indicated as a diluent for the intrathecal administration of methotrexate sodium and cytarabine for the prevention or treatment of meningeal leukemia or lymphocytic lymphoma. uuid:34ddbe7f-f32f-4fdd-b04c-98a7a6271abc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29101 biolink:treats MONDO:0003864 PMID:41385096 "[{""id"":""uuid:5cfca632-0976-444e-ae39-0b4bc5e1fe21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:11e7efce-62dc-418b-97c0-a681a813daed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Elliotts B Solution is indicated as a diluent for the intrathecal administration of methotrexate sodium and cytarabine for the prevention or treatment of meningeal leukemia or lymphocytic lymphoma. uuid:5e20b278-ca2b-43e7-b31c-ce966b639d75 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:520985 biolink:treats MONDO:0005277 PMID:41385096 "[{""id"":""uuid:c1e2e6d5-9887-449e-9f9e-7978dedf9c2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0f713097-e2b5-4082-8d69-e9ef33b27814"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AXERT ® is a 5HT 1B/1D receptor agonist (triptan) indicated for: Acute treatment of migraine attacks in adults with a history of migraine with or without aura ( 1.1 ) Acute treatment of migraine headache pain in adolescents age 12 to 17 years with a history of migraine with or without aura, and who have migraine attacks usually lasting 4 hours or more ( 1.1 ) Important limitations: Use only after a clear diagnosis of migraine has been established ( 1.2 ) In adolescents age 12 to 17 years, efficacy of AXERT ® on migraine-associated symptoms was not established ( 1.2 ) Not intended for the prophylactic therapy of migraine ( 1.2 ) Not indicated for the treatment of cluster headache ( 1.2 ) uuid:1cf5ff65-df72-45e9-bfea-edab1f459f9d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:520985 biolink:treats MONDO:0043537 PMID:41385096 "[{""id"":""uuid:7124d1fd-90d6-4e03-9311-a4edf6954b04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8103c994-3166-4fd4-a41e-32df2d176b2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AXERT ® is a 5HT 1B/1D receptor agonist (triptan) indicated for: Acute treatment of migraine attacks in adults with a history of migraine with or without aura ( 1.1 ) Acute treatment of migraine headache pain in adolescents age 12 to 17 years with a history of migraine with or without aura, and who have migraine attacks usually lasting 4 hours or more ( 1.1 ) Important limitations: Use only after a clear diagnosis of migraine has been established ( 1.2 ) In adolescents age 12 to 17 years, efficacy of AXERT ® on migraine-associated symptoms was not established ( 1.2 ) Not intended for the prophylactic therapy of migraine ( 1.2 ) Not indicated for the treatment of cluster headache ( 1.2 ) uuid:d76f7832-5470-4c4d-97db-fe5f7aca80e1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7025 biolink:treats MONDO:0100073 PMID:41385096 "[{""id"":""uuid:1cad7aa8-d5d8-4331-b435-4afaaaf865d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:626d7f09-0948-4df8-aec6-e23b577158ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BACTROBAN NASAL is indicated for the eradication of nasal colonization with methicillin-resistant S. aureus in adult patients and health care workers as part of a comprehensive infection control program to reduce the risk of infection among patients at high risk of methicillin-resistant S. aureus infection during institutional outbreaks of infections with this pathogen. NOTE: There are insufficient data at this time to establish that this product is safe and effective as part of an intervention program to prevent autoinfection of high-risk patients from their own nasal colonization with S. aureus . There are insufficient data at this time to recommend use of BACTROBAN NASAL for general prophylaxis of any infection in any patient population. Greater than 90% of subjects/patients in clinical trials had eradication of nasal colonization 2 to 4 days after therapy was completed. Approximately 30% recolonization was reported in 1 domestic study within 4 weeks after completion of therapy. These eradication rates were clinically and statistically superior to those reported in subjects/patients in the vehicle-treated arms of the adequate and well-controlled studies. Those treated with vehicle had eradication rates of 5% to 30% at 2 to 4 days post-therapy with 85% to 100% recolonization within 4 weeks. All adequate and well-controlled trials of this product were vehicle-controlled; therefore, no data from direct, head-to-head comparisons with other products are available at this time. uuid:f91994c9-ec21-42f8-84ed-ae871c8d4d1f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:88667 biolink:treats MONDO:0002898 PMID:41385096 "[{""id"":""uuid:c9e4f6ed-19ac-4856-ae89-dd5778ca6c59"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dfe57593-0658-4049-b055-4a278627f7b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Directions apply liberally 15 minutes bfore sun exposure reapply at least every 2 hours. use a water resistant sunscreen if swimming or sweating. children under 6 months of age: Ask a doctor. Sun Protection Measures. Spending time in the sun increases your risk of skin cancer and early skin aging. To decrease this risk, regularly use a sunscreen with a Broad Spectrum SPF value of 15 or higher and other sun protection measures including: limit time in the sun, especially from 10 a.m.–2 p.m. wear long-sleeved shirts, pants, hats, and sunglasses uuid:04f9cc2f-2c50-4299-a296-cbda1d1b2ce7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:88667 biolink:treats MONDO:0019303 PMID:41385096 "[{""id"":""uuid:261aedc5-c159-459b-b2e6-53efab9211da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:673d75cc-fe66-47f7-8c4d-c8722a9eb527"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Directions apply liberally 15 minutes bfore sun exposure reapply at least every 2 hours. use a water resistant sunscreen if swimming or sweating. children under 6 months of age: Ask a doctor. Sun Protection Measures. Spending time in the sun increases your risk of skin cancer and early skin aging. To decrease this risk, regularly use a sunscreen with a Broad Spectrum SPF value of 15 or higher and other sun protection measures including: limit time in the sun, especially from 10 a.m.–2 p.m. wear long-sleeved shirts, pants, hats, and sunglasses uuid:c0e56378-2e73-48b6-b2cc-f57362ec252d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:83527 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:738c87e5-2cea-4293-9fcd-53eabddb807a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bc6d5148-21b5-4e57-8c90-867c18853455"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRISTIQ, a selective serotonin and norepinephrine reuptake inhibitor (SNRI), is indicated for the treatment of major depressive disorder (MDD) [ see Clinical Studies ( 14 ) and Dosage and Administration ( 2.1 ) ]. The efficacy of PRISTIQ has been established in four 8-week, placebo-controlled studies of outpatients who met DSM-IV criteria for major depressive disorder. A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least 5 of the following 9 symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, or a suicide attempt or suicidal ideation. uuid:9410792c-8aff-468d-b1fa-11c11d8c821f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32130 biolink:treats MONDO:0001209 PMID:41385096 "[{""id"":""uuid:90754d0f-fcb3-48a5-aaf9-e4551cabb5a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:08aa11c4-3c90-4209-993c-47ad4dddc6df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Repara ® ​Silver Nitrate Applicators are useful for cauterization of skin or mucous membrane and for the removal of granulation tissue, warts and verrucae. uuid:40f86019-b9b7-4bf1-9262-86b24a8a2937 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:RWM8CCW8GP biolink:treats MONDO:0019933 PMID:41385096 "[{""id"":""uuid:b3d65ce2-c5bb-4b75-8404-e37d9aaf4f31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2bb971f1-7931-40cd-9f51-4f208054d600"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c654c7b6-7c5e-406d-9da2-12524f01d5b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ff329f44-96e9-40e0-898f-e00633f38541"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Octreotide acetate injection is indicated to reduce blood levels of growth hormone and IGF-I (somatomedin C) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses. The goal is to achieve normalization of growth hormone and IGF-I (somatomedin C) levels ( see DOSAGE AND ADMINISTRATION ). In patients with acromegaly, octreotide acetate reduces growth hormone to within normal ranges in 50% of patients and reduces IGF-I (somatomedin C) to within normal ranges in 50%-60% of patients. Since the effects of pituitary irradiation may not become maximal for several years, adjunctive therapy with octreotide acetate to reduce blood levels of growth hormone and IGF-I (somatomedin C) offers potential benefit before the effects of irradiation are manifested. Improvement in clinical signs and symptoms or reduction in tumor size or rate of growth were not shown in clinical trials performed with octreotide acetate; these trials were not optimally designed to detect such effects.|[EMA] Mycapssa is indicated for maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogues.|[PMDA] New form drug with a new administration route administered once every four weeks and which has the following indications: alleviation of various symptoms associated with gastrointestinal hormone-producing tumors and alleviation of excessive secretions of growth hormone and somatomedin-C and other various symptoms in acromegaly and pituitary gigantism uuid:05162891-0bcc-4f2c-a0ba-e9b689b32f40 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:378788 biolink:treats MONDO:0008159 PMID:41385096 "[{""id"":""uuid:a065955a-810c-4a58-8719-3b950cc6a371"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:efaea169-f384-41c6-b744-96a9367c184a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PREMPRO/PREMPHASE is an estrogen/progestin indicated in women with intact uteri for: Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause ( 1.1 ) Treatment of Moderate to Severe Vulvar and Vaginal Atrophy due to Menopause ( 1.2 ) Prevention of Postmenopausal Osteoporosis ( 1.3 ) uuid:fcfe55dd-7a08-4a95-94d4-ee342764aefb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135934 biolink:treats MONDO:0005915 PMID:41385096 "[{""id"":""uuid:631fa4f7-dc91-431a-af5f-9f406a1d3f5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:19a88eb1-a8b8-431b-9e19-d047127da373"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of tinea versicolor, seborrheic dermatitis of the scalp, and dandruff. uuid:2320d52a-7831-4b2f-b964-b6c8312afa6a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135934 biolink:treats MONDO:0006608 PMID:41385096 "[{""id"":""uuid:e1b9683a-cb6e-420e-8a79-1cb3645634f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:17451718-5902-405b-9fe6-bfe73f2a24ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of tinea versicolor, seborrheic dermatitis of the scalp, and dandruff. uuid:c78aa374-22a7-47d7-a4ba-fc80ba8226ca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135934 biolink:treats MONDO:0006609 PMID:41385096 "[{""id"":""uuid:8ffc5224-97fc-487d-a518-dff0dab38a20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3dd355a8-572b-4853-924a-8e8c12c619a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of tinea versicolor, seborrheic dermatitis of the scalp, and dandruff. uuid:f9656da9-1135-4134-ac9f-1dd5a3734ef1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63618 biolink:treats MONDO:0005311 PMID:41385096 "[{""id"":""uuid:1ccb105f-e7a6-46b5-b121-a864320e9192"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:12c46b35-dfd7-4cc5-88dd-777dfcac09e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. uuid:82015648-b9c5-400a-afef-41e3b768308b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17823 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:3a22e8ae-c7be-463a-9d6d-ffd383502d72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:96460568-35fb-4414-8999-d5ea6a838c5d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Predialysis Patients Rocaltrol is indicated in the management of secondary hyperparathyroidism and resultant metabolic bone disease in patients with moderate to severe chronic renal failure (Ccr 15 to 55 mL/min) not yet on dialysis. In children, the creatinine clearance value must be corrected for a surface area of 1.73 square meters. A serum iPTH level of ≥ 100 pg/mL is strongly suggestive of secondary hyperparathyroidism. Dialysis Patients Rocaltrol is indicated in the management of hypocalcemia and the resultant metabolic bone disease in patients undergoing chronic renal dialysis. In these patients, Rocaltrol administration enhances calcium absorption, reduces serum alkaline phosphatase levels, and may reduce elevated parathyroid hormone levels and the histological manifestations of osteitis fibrosa cystica and defective mineralization. Hypoparathyroidism Patients Rocaltrol is also indicated in the management of hypocalcemia and its clinical manifestations in patients with postsurgical hypoparathyroidism, idiopathic hypoparathyroidism, and pseudohypoparathyroidism. uuid:48591e03-25a7-4f6b-91d9-3210b8534135 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:8ed5af93-66b7-4127-b3e6-c1457f19c30b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ac9ea267-f240-4b67-9a97-7c37956be3e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4240e898-a159-4cc5-b536-fd44118a7101"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria ( 1 , 12.4 ). Pneumonia: nosocomial ( 1.1 ) and community acquired ( 1.2 , 1.3 ) Acute bacterial sinusitis ( 1.4 ) Acute bacterial exacerbation of chronic bronchitis ( 1.5 ) Skin and skin structure infections: complicated ( 1.6 ) and uncomplicated ( 1.7 ) Chronic bacterial prostatitis ( 1.8 ) Urinary tract infections: complicated ( 1.9 , 1.10 ) and uncomplicated ( 1.12 ) Acute pyelonephritis ( 1.11 ) Inhalational anthrax, post-exposure ( 1.13 ) Plague ( 1.14 )|[PMDA] Drugs with a new route of administration indicated for the treatment of pneumonia, secondary infection of chronic respiratory disease, typhoid, paratyphoid, anthrax, brucellosis, plague, tularemia and Q fever. uuid:8fc0a150-d369-46fc-b33f-1a18162af14e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats UMLS:C0949083 PMID:41385096 "[{""id"":""uuid:1f1157c6-b009-4849-89f3-bb3c0a065114"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eb62a3cc-1752-4fa6-9db2-86390b748d6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria ( 1 , 12.4 ). Pneumonia: nosocomial ( 1.1 ) and community acquired ( 1.2 , 1.3 ) Acute bacterial sinusitis ( 1.4 ) Acute bacterial exacerbation of chronic bronchitis ( 1.5 ) Skin and skin structure infections: complicated ( 1.6 ) and uncomplicated ( 1.7 ) Chronic bacterial prostatitis ( 1.8 ) Urinary tract infections: complicated ( 1.9 , 1.10 ) and uncomplicated ( 1.12 ) Acute pyelonephritis ( 1.11 ) Inhalational anthrax, post-exposure ( 1.13 ) Plague ( 1.14 ) uuid:e76931e0-f52b-44f0-aae2-83c364195dee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats UMLS:C0694549 PMID:41385096 "[{""id"":""uuid:36f9ce27-22aa-476a-9be6-5487edc0c5b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f1ad0dff-4e50-4688-b1c2-bad7946bdea0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria ( 1 , 12.4 ). Pneumonia: nosocomial ( 1.1 ) and community acquired ( 1.2 , 1.3 ) Acute bacterial sinusitis ( 1.4 ) Acute bacterial exacerbation of chronic bronchitis ( 1.5 ) Skin and skin structure infections: complicated ( 1.6 ) and uncomplicated ( 1.7 ) Chronic bacterial prostatitis ( 1.8 ) Urinary tract infections: complicated ( 1.9 , 1.10 ) and uncomplicated ( 1.12 ) Acute pyelonephritis ( 1.11 ) Inhalational anthrax, post-exposure ( 1.13 ) Plague ( 1.14 ) uuid:b780fc75-1bbe-4b0a-bb71-29b235ddbb10 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats UMLS:C0275556 PMID:41385096 "[{""id"":""uuid:eb0e0842-41b6-4470-abd2-8b2bdbbab453"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:36479a52-d22c-45a5-a19b-889ca4ff7e62"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria ( 1 , 12.4 ). Pneumonia: nosocomial ( 1.1 ) and community acquired ( 1.2 , 1.3 ) Acute bacterial sinusitis ( 1.4 ) Acute bacterial exacerbation of chronic bronchitis ( 1.5 ) Skin and skin structure infections: complicated ( 1.6 ) and uncomplicated ( 1.7 ) Chronic bacterial prostatitis ( 1.8 ) Urinary tract infections: complicated ( 1.9 , 1.10 ) and uncomplicated ( 1.12 ) Acute pyelonephritis ( 1.11 ) Inhalational anthrax, post-exposure ( 1.13 ) Plague ( 1.14 ) uuid:f067da1e-2dc6-48d2-9d9d-83851c6103ef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats UMLS:C1735365 PMID:41385096 "[{""id"":""uuid:4c03f140-022c-4af3-ab17-26eeb10dd751"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:221d904e-5ad6-4a92-b7bd-43a33d8db84d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria ( 1 , 12.4 ). Pneumonia: nosocomial ( 1.1 ) and community acquired ( 1.2 , 1.3 ) Acute bacterial sinusitis ( 1.4 ) Acute bacterial exacerbation of chronic bronchitis ( 1.5 ) Skin and skin structure infections: complicated ( 1.6 ) and uncomplicated ( 1.7 ) Chronic bacterial prostatitis ( 1.8 ) Urinary tract infections: complicated ( 1.9 , 1.10 ) and uncomplicated ( 1.12 ) Acute pyelonephritis ( 1.11 ) Inhalational anthrax, post-exposure ( 1.13 ) Plague ( 1.14 ) uuid:f68afc1a-66a9-42bd-8c67-9df77bafb646 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:a6416e8d-8b6d-4f48-96a4-84702f5b90c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:81d79928-9959-4d49-82a8-3ef933231c5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria ( 1 , 12.4 ). Pneumonia: nosocomial ( 1.1 ) and community acquired ( 1.2 , 1.3 ) Acute bacterial sinusitis ( 1.4 ) Acute bacterial exacerbation of chronic bronchitis ( 1.5 ) Skin and skin structure infections: complicated ( 1.6 ) and uncomplicated ( 1.7 ) Chronic bacterial prostatitis ( 1.8 ) Urinary tract infections: complicated ( 1.9 , 1.10 ) and uncomplicated ( 1.12 ) Acute pyelonephritis ( 1.11 ) Inhalational anthrax, post-exposure ( 1.13 ) Plague ( 1.14 ) uuid:a516450d-1073-41a9-aa17-69f7c5df0178 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats UMLS:C1720797 PMID:41385096 "[{""id"":""uuid:4aac792d-a8b2-4fca-97c7-46800d13f28d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:acb21958-c8d6-4e67-a757-faca06480498"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria ( 1 , 12.4 ). Pneumonia: nosocomial ( 1.1 ) and community acquired ( 1.2 , 1.3 ) Acute bacterial sinusitis ( 1.4 ) Acute bacterial exacerbation of chronic bronchitis ( 1.5 ) Skin and skin structure infections: complicated ( 1.6 ) and uncomplicated ( 1.7 ) Chronic bacterial prostatitis ( 1.8 ) Urinary tract infections: complicated ( 1.9 , 1.10 ) and uncomplicated ( 1.12 ) Acute pyelonephritis ( 1.11 ) Inhalational anthrax, post-exposure ( 1.13 ) Plague ( 1.14 ) uuid:30bc2825-aa79-47bd-920e-d5c0af637eb5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:3e43cd57-a6d4-47a4-b2a0-4c827c718c97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:227a1ec4-8048-4efa-883c-fb4eb50fa013"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria ( 1 , 12.4 ). Pneumonia: nosocomial ( 1.1 ) and community acquired ( 1.2 , 1.3 ) Acute bacterial sinusitis ( 1.4 ) Acute bacterial exacerbation of chronic bronchitis ( 1.5 ) Skin and skin structure infections: complicated ( 1.6 ) and uncomplicated ( 1.7 ) Chronic bacterial prostatitis ( 1.8 ) Urinary tract infections: complicated ( 1.9 , 1.10 ) and uncomplicated ( 1.12 ) Acute pyelonephritis ( 1.11 ) Inhalational anthrax, post-exposure ( 1.13 ) Plague ( 1.14 ) uuid:0d82a3a9-c113-4d0c-a1b7-5849c29096a8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0003529 PMID:41385096 "[{""id"":""uuid:03e28dca-4849-45ac-a758-9313c6ca7de0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3b129631-53b7-4038-afd8-ffc64eaf0983"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria ( 1 , 12.4 ). Pneumonia: nosocomial ( 1.1 ) and community acquired ( 1.2 , 1.3 ) Acute bacterial sinusitis ( 1.4 ) Acute bacterial exacerbation of chronic bronchitis ( 1.5 ) Skin and skin structure infections: complicated ( 1.6 ) and uncomplicated ( 1.7 ) Chronic bacterial prostatitis ( 1.8 ) Urinary tract infections: complicated ( 1.9 , 1.10 ) and uncomplicated ( 1.12 ) Acute pyelonephritis ( 1.11 ) Inhalational anthrax, post-exposure ( 1.13 ) Plague ( 1.14 ) uuid:943bcb14-ac7c-49cf-b720-2ba61d56f6db biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0016595 PMID:41385096 "[{""id"":""uuid:9033087f-b5f7-4d4a-ae29-ce27ce8bba35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d47fcb23-479f-4278-9122-86e475da00c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria ( 1 , 12.4 ). Pneumonia: nosocomial ( 1.1 ) and community acquired ( 1.2 , 1.3 ) Acute bacterial sinusitis ( 1.4 ) Acute bacterial exacerbation of chronic bronchitis ( 1.5 ) Skin and skin structure infections: complicated ( 1.6 ) and uncomplicated ( 1.7 ) Chronic bacterial prostatitis ( 1.8 ) Urinary tract infections: complicated ( 1.9 , 1.10 ) and uncomplicated ( 1.12 ) Acute pyelonephritis ( 1.11 ) Inhalational anthrax, post-exposure ( 1.13 ) Plague ( 1.14 ) uuid:00f0fbba-3863-47eb-8521-273c4671155d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0019095 PMID:41385096 "[{""id"":""uuid:0ac98b39-09cb-4326-a0c1-04f1cfaf9e9d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5d9e055e-5521-421f-9817-27d57df79d56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f3db26d9-8fa5-4681-9894-d88d1754d61c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin is a fluoroquinolone antibacterial indicated in adults (≥18 years of age) with infections caused by designated, susceptible bacteria ( 1 , 12.4 ). Pneumonia: nosocomial ( 1.1 ) and community acquired ( 1.2 , 1.3 ) Acute bacterial sinusitis ( 1.4 ) Acute bacterial exacerbation of chronic bronchitis ( 1.5 ) Skin and skin structure infections: complicated ( 1.6 ) and uncomplicated ( 1.7 ) Chronic bacterial prostatitis ( 1.8 ) Urinary tract infections: complicated ( 1.9 , 1.10 ) and uncomplicated ( 1.12 ) Acute pyelonephritis ( 1.11 ) Inhalational anthrax, post-exposure ( 1.13 ) Plague ( 1.14 )|[PMDA] Drugs with a new route of administration indicated for the treatment of pneumonia, secondary infection of chronic respiratory disease, typhoid, paratyphoid, anthrax, brucellosis, plague, tularemia and Q fever. uuid:ca30989e-f86b-4ea9-984a-69ce9a8dffa9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2904 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:695faa13-13ef-4b1a-8c4f-2ea722fcea9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b9ea4379-d673-4c1d-ab64-aa59efb25211"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atenolol is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including atenolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Atenolol may be administered with other antihypertensive agents. uuid:ef64e4e3-10db-4b8d-b99e-d0fbfad50a97 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2904 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:44e31538-be90-418e-a84d-0c2066578ece"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3d33fe44-a626-46df-b3b2-5170ba24d2e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atenolol is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including atenolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Atenolol may be administered with other antihypertensive agents. uuid:5729f6b7-a266-4e8c-acbd-acd922165833 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2904 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:e9371199-afb6-4107-ac2b-81b4c3464fd0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c8a5cbb1-9898-43f8-ac23-8d3d4cd050fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atenolol is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including atenolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Atenolol may be administered with other antihypertensive agents. uuid:03310471-a980-47ea-b087-1fa813ac0822 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3515 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:ad288885-d62e-426a-a318-2f6d02842dbb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9c01833d-397e-4e22-96f9-8ee566ae7383"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefuroxime for Injection, USP is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: Lower Respiratory Tract Infections, including pneumonia, caused by Streptococcus pneumoniae, Haemophilus influenzae (including ampicillin-resistant strains), Klebsiella spp., Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), Streptococcus pyogenes , and Escherichia coli . Urinary Tract Infections caused by Escherichia coli and Klebsiella spp. Skin and Skin Structure Infections caused by Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), Streptococcus pyogenes , Escherichia coli, Klebsiella spp., and Enterobacter spp. Septicemia caused by Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae (including ampicillin-resistant strains), and Klebsiella spp. Meningitis caused by Streptococcus pneumoniae, Haemophilus influenzae (including ampicillin-resistant strains), Neisseria meningitidis , and Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains). Gonorrhea: Uncomplicated and disseminated gonococcal infections due to Neisseria gonorrhoeae (penicillinase- and non-penicillinase-producing strains) in both males and females. Bone and Joint Infections caused by Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains). Clinical microbiological studies in skin and skin-structure infections frequently reveal the growth of susceptible strains of both aerobic and anaerobic organisms. Cefuroxime for Injection, USP has been used successfully in these mixed infections in which several organisms have been isolated. In certain cases of confirmed or suspected gram-positive or gram-negative sepsis or in patients with other serious infections in which the causative organism has not been identified, Cefuroxime for Injection may be used concomitantly with an aminoglycoside (see PRECAUTIONS). The recommended doses of both antibiotics may be given depending on the severity of the infection and the patient’s condition. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefuroxime for Injection, USP and other antibacterial drugs, Cefuroxime for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Prevention: The preoperative prophylactic administration of Cefuroxime for Injection, USP may prevent the growth of susceptible disease-causing bacteria and thereby may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures (e.g., vaginal hysterectomy) that are classified as clean-contaminated or potentially contaminated procedures. Effective prophylactic use of antibiotics in surgery depends on the time of administration. Cefuroxime for Injection, USP should usually be given one-half to 1 hour before the operation to allow sufficient time to achieve effective antibiotic concentrations in the wound tissues during the procedure. The dose should be repeated intraoperatively if the surgical procedure is lengthy. Prophylactic administration is usually not required after the surgical procedure ends and should be stopped within 24 hours. In the majority of surgical procedures, continuing prophylactic administration of any antibiotic does not reduce the incidence of subsequent infections but will increase the possibility of adverse reactions and the development of bacterial resistance. The perioperative use of Cefuroxime for Injection, USP has also been effective during open heart surgery for surgical patients in whom infections at the operative site would present a serious risk. For these patients it is recommended that therapy with Cefuroxime for Injection, USP be continued for at least 48 hours after the surgical procedure ends. If an infection is present, specimens for culture should be obtained for the identification of the causative organism, and appropriate antimicrobial therapy should be instituted. uuid:f84a33ce-f9fa-48da-803f-fb4c0917fd68 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3515 biolink:treats MONDO:0700217 PMID:41385096 "[{""id"":""uuid:d32d358a-60bf-4d4d-b829-7bc86ef477d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4c26f218-7337-4633-a3eb-641ca51c8e7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefuroxime for Injection, USP is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: Lower Respiratory Tract Infections, including pneumonia, caused by Streptococcus pneumoniae, Haemophilus influenzae (including ampicillin-resistant strains), Klebsiella spp., Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), Streptococcus pyogenes , and Escherichia coli . Urinary Tract Infections caused by Escherichia coli and Klebsiella spp. Skin and Skin Structure Infections caused by Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), Streptococcus pyogenes , Escherichia coli, Klebsiella spp., and Enterobacter spp. Septicemia caused by Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae (including ampicillin-resistant strains), and Klebsiella spp. Meningitis caused by Streptococcus pneumoniae, Haemophilus influenzae (including ampicillin-resistant strains), Neisseria meningitidis , and Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains). Gonorrhea: Uncomplicated and disseminated gonococcal infections due to Neisseria gonorrhoeae (penicillinase- and non-penicillinase-producing strains) in both males and females. Bone and Joint Infections caused by Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains). Clinical microbiological studies in skin and skin-structure infections frequently reveal the growth of susceptible strains of both aerobic and anaerobic organisms. Cefuroxime for Injection, USP has been used successfully in these mixed infections in which several organisms have been isolated. In certain cases of confirmed or suspected gram-positive or gram-negative sepsis or in patients with other serious infections in which the causative organism has not been identified, Cefuroxime for Injection may be used concomitantly with an aminoglycoside (see PRECAUTIONS). The recommended doses of both antibiotics may be given depending on the severity of the infection and the patient’s condition. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefuroxime for Injection, USP and other antibacterial drugs, Cefuroxime for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Prevention: The preoperative prophylactic administration of Cefuroxime for Injection, USP may prevent the growth of susceptible disease-causing bacteria and thereby may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures (e.g., vaginal hysterectomy) that are classified as clean-contaminated or potentially contaminated procedures. Effective prophylactic use of antibiotics in surgery depends on the time of administration. Cefuroxime for Injection, USP should usually be given one-half to 1 hour before the operation to allow sufficient time to achieve effective antibiotic concentrations in the wound tissues during the procedure. The dose should be repeated intraoperatively if the surgical procedure is lengthy. Prophylactic administration is usually not required after the surgical procedure ends and should be stopped within 24 hours. In the majority of surgical procedures, continuing prophylactic administration of any antibiotic does not reduce the incidence of subsequent infections but will increase the possibility of adverse reactions and the development of bacterial resistance. The perioperative use of Cefuroxime for Injection, USP has also been effective during open heart surgery for surgical patients in whom infections at the operative site would present a serious risk. For these patients it is recommended that therapy with Cefuroxime for Injection, USP be continued for at least 48 hours after the surgical procedure ends. If an infection is present, specimens for culture should be obtained for the identification of the causative organism, and appropriate antimicrobial therapy should be instituted. uuid:34a2f380-5470-4291-afe4-579eb8e24826 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3515 biolink:treats MONDO:0021108 PMID:41385096 "[{""id"":""uuid:a091379b-b83f-46ad-8a3d-f62c3bfee2f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5032e80f-2250-4b90-a352-428e03de4f08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefuroxime for Injection, USP is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: Lower Respiratory Tract Infections, including pneumonia, caused by Streptococcus pneumoniae, Haemophilus influenzae (including ampicillin-resistant strains), Klebsiella spp., Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), Streptococcus pyogenes , and Escherichia coli . Urinary Tract Infections caused by Escherichia coli and Klebsiella spp. Skin and Skin Structure Infections caused by Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), Streptococcus pyogenes , Escherichia coli, Klebsiella spp., and Enterobacter spp. Septicemia caused by Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae (including ampicillin-resistant strains), and Klebsiella spp. Meningitis caused by Streptococcus pneumoniae, Haemophilus influenzae (including ampicillin-resistant strains), Neisseria meningitidis , and Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains). Gonorrhea: Uncomplicated and disseminated gonococcal infections due to Neisseria gonorrhoeae (penicillinase- and non-penicillinase-producing strains) in both males and females. Bone and Joint Infections caused by Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains). Clinical microbiological studies in skin and skin-structure infections frequently reveal the growth of susceptible strains of both aerobic and anaerobic organisms. Cefuroxime for Injection, USP has been used successfully in these mixed infections in which several organisms have been isolated. In certain cases of confirmed or suspected gram-positive or gram-negative sepsis or in patients with other serious infections in which the causative organism has not been identified, Cefuroxime for Injection may be used concomitantly with an aminoglycoside (see PRECAUTIONS). The recommended doses of both antibiotics may be given depending on the severity of the infection and the patient’s condition. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefuroxime for Injection, USP and other antibacterial drugs, Cefuroxime for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Prevention: The preoperative prophylactic administration of Cefuroxime for Injection, USP may prevent the growth of susceptible disease-causing bacteria and thereby may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures (e.g., vaginal hysterectomy) that are classified as clean-contaminated or potentially contaminated procedures. Effective prophylactic use of antibiotics in surgery depends on the time of administration. Cefuroxime for Injection, USP should usually be given one-half to 1 hour before the operation to allow sufficient time to achieve effective antibiotic concentrations in the wound tissues during the procedure. The dose should be repeated intraoperatively if the surgical procedure is lengthy. Prophylactic administration is usually not required after the surgical procedure ends and should be stopped within 24 hours. In the majority of surgical procedures, continuing prophylactic administration of any antibiotic does not reduce the incidence of subsequent infections but will increase the possibility of adverse reactions and the development of bacterial resistance. The perioperative use of Cefuroxime for Injection, USP has also been effective during open heart surgery for surgical patients in whom infections at the operative site would present a serious risk. For these patients it is recommended that therapy with Cefuroxime for Injection, USP be continued for at least 48 hours after the surgical procedure ends. If an infection is present, specimens for culture should be obtained for the identification of the causative organism, and appropriate antimicrobial therapy should be instituted. uuid:5b4dd302-1cf7-4c3c-89bd-0f7c8a53b40b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3515 biolink:treats UMLS:C0851989 PMID:41385096 "[{""id"":""uuid:cf0deb0a-0900-4314-bcc5-29d3fa4da92a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d17ee450-e4f1-4210-b536-bf8a0b273461"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefuroxime for Injection, USP is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: Lower Respiratory Tract Infections, including pneumonia, caused by Streptococcus pneumoniae, Haemophilus influenzae (including ampicillin-resistant strains), Klebsiella spp., Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), Streptococcus pyogenes , and Escherichia coli . Urinary Tract Infections caused by Escherichia coli and Klebsiella spp. Skin and Skin Structure Infections caused by Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), Streptococcus pyogenes , Escherichia coli, Klebsiella spp., and Enterobacter spp. Septicemia caused by Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae (including ampicillin-resistant strains), and Klebsiella spp. Meningitis caused by Streptococcus pneumoniae, Haemophilus influenzae (including ampicillin-resistant strains), Neisseria meningitidis , and Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains). Gonorrhea: Uncomplicated and disseminated gonococcal infections due to Neisseria gonorrhoeae (penicillinase- and non-penicillinase-producing strains) in both males and females. Bone and Joint Infections caused by Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains). Clinical microbiological studies in skin and skin-structure infections frequently reveal the growth of susceptible strains of both aerobic and anaerobic organisms. Cefuroxime for Injection, USP has been used successfully in these mixed infections in which several organisms have been isolated. In certain cases of confirmed or suspected gram-positive or gram-negative sepsis or in patients with other serious infections in which the causative organism has not been identified, Cefuroxime for Injection may be used concomitantly with an aminoglycoside (see PRECAUTIONS). The recommended doses of both antibiotics may be given depending on the severity of the infection and the patient’s condition. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefuroxime for Injection, USP and other antibacterial drugs, Cefuroxime for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Prevention: The preoperative prophylactic administration of Cefuroxime for Injection, USP may prevent the growth of susceptible disease-causing bacteria and thereby may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures (e.g., vaginal hysterectomy) that are classified as clean-contaminated or potentially contaminated procedures. Effective prophylactic use of antibiotics in surgery depends on the time of administration. Cefuroxime for Injection, USP should usually be given one-half to 1 hour before the operation to allow sufficient time to achieve effective antibiotic concentrations in the wound tissues during the procedure. The dose should be repeated intraoperatively if the surgical procedure is lengthy. Prophylactic administration is usually not required after the surgical procedure ends and should be stopped within 24 hours. In the majority of surgical procedures, continuing prophylactic administration of any antibiotic does not reduce the incidence of subsequent infections but will increase the possibility of adverse reactions and the development of bacterial resistance. The perioperative use of Cefuroxime for Injection, USP has also been effective during open heart surgery for surgical patients in whom infections at the operative site would present a serious risk. For these patients it is recommended that therapy with Cefuroxime for Injection, USP be continued for at least 48 hours after the surgical procedure ends. If an infection is present, specimens for culture should be obtained for the identification of the causative organism, and appropriate antimicrobial therapy should be instituted. uuid:dfab6d76-e788-4d21-9868-423a0d1d6b61 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3515 biolink:treats MONDO:0021839 PMID:41385096 "[{""id"":""uuid:7d65d37a-3de1-40a9-82cc-0bcb92557cc4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1898f0f6-a7a4-4add-bdce-548a8098c40a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefuroxime for Injection, USP is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: Lower Respiratory Tract Infections, including pneumonia, caused by Streptococcus pneumoniae, Haemophilus influenzae (including ampicillin-resistant strains), Klebsiella spp., Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), Streptococcus pyogenes , and Escherichia coli . Urinary Tract Infections caused by Escherichia coli and Klebsiella spp. Skin and Skin Structure Infections caused by Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), Streptococcus pyogenes , Escherichia coli, Klebsiella spp., and Enterobacter spp. Septicemia caused by Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae (including ampicillin-resistant strains), and Klebsiella spp. Meningitis caused by Streptococcus pneumoniae, Haemophilus influenzae (including ampicillin-resistant strains), Neisseria meningitidis , and Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains). Gonorrhea: Uncomplicated and disseminated gonococcal infections due to Neisseria gonorrhoeae (penicillinase- and non-penicillinase-producing strains) in both males and females. Bone and Joint Infections caused by Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains). Clinical microbiological studies in skin and skin-structure infections frequently reveal the growth of susceptible strains of both aerobic and anaerobic organisms. Cefuroxime for Injection, USP has been used successfully in these mixed infections in which several organisms have been isolated. In certain cases of confirmed or suspected gram-positive or gram-negative sepsis or in patients with other serious infections in which the causative organism has not been identified, Cefuroxime for Injection may be used concomitantly with an aminoglycoside (see PRECAUTIONS). The recommended doses of both antibiotics may be given depending on the severity of the infection and the patient’s condition. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefuroxime for Injection, USP and other antibacterial drugs, Cefuroxime for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Prevention: The preoperative prophylactic administration of Cefuroxime for Injection, USP may prevent the growth of susceptible disease-causing bacteria and thereby may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures (e.g., vaginal hysterectomy) that are classified as clean-contaminated or potentially contaminated procedures. Effective prophylactic use of antibiotics in surgery depends on the time of administration. Cefuroxime for Injection, USP should usually be given one-half to 1 hour before the operation to allow sufficient time to achieve effective antibiotic concentrations in the wound tissues during the procedure. The dose should be repeated intraoperatively if the surgical procedure is lengthy. Prophylactic administration is usually not required after the surgical procedure ends and should be stopped within 24 hours. In the majority of surgical procedures, continuing prophylactic administration of any antibiotic does not reduce the incidence of subsequent infections but will increase the possibility of adverse reactions and the development of bacterial resistance. The perioperative use of Cefuroxime for Injection, USP has also been effective during open heart surgery for surgical patients in whom infections at the operative site would present a serious risk. For these patients it is recommended that therapy with Cefuroxime for Injection, USP be continued for at least 48 hours after the surgical procedure ends. If an infection is present, specimens for culture should be obtained for the identification of the causative organism, and appropriate antimicrobial therapy should be instituted. uuid:97888458-86c9-4223-a602-a9b10fed1753 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:37789 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:1e1ae313-e2a0-426c-956e-d457adb1e318"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ed853343-4370-4daa-8c9c-9c255b0f35a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atenolol and chlorthalidone tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including atenolol and chlorthalidone. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed dose combination drug is not indicated for initial therapy of hypertension. If the fixed dose combination represents the dose appropriate to the individual patient's needs, it may be more convenient than the separate components. uuid:1cefb577-3123-428f-ad81-ef70c1917e66 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:37789 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:19fcb045-f4a9-4cdd-9862-ba7df0ae2bbc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1c9b309c-6316-4ed0-a0d9-6d4a69ecfff2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atenolol and chlorthalidone tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including atenolol and chlorthalidone. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed dose combination drug is not indicated for initial therapy of hypertension. If the fixed dose combination represents the dose appropriate to the individual patient's needs, it may be more convenient than the separate components. uuid:4c505900-0a3b-495f-af45-691d2f2f2291 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:37789 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:34e572c1-36a2-4207-b16a-7407a02c1230"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9e5d01f7-b807-405d-acb4-122f84f73b82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atenolol and chlorthalidone tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including atenolol and chlorthalidone. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed dose combination drug is not indicated for initial therapy of hypertension. If the fixed dose combination represents the dose appropriate to the individual patient's needs, it may be more convenient than the separate components. uuid:dbacfae8-f82f-49ab-a618-f904f2401d07 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:37789 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:fcf1f5ce-3fbd-4a54-943d-ca11a06b4322"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:39f0acff-b13a-413f-9a9f-512c45e7f98e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atenolol and chlorthalidone tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including atenolol and chlorthalidone. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed dose combination drug is not indicated for initial therapy of hypertension. If the fixed dose combination represents the dose appropriate to the individual patient's needs, it may be more convenient than the separate components. uuid:d38c560d-f87d-4d22-ad6d-d0d1a89f06d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:37789 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:fdc1ad10-c9b0-4ce4-901f-92353010dc8e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c9ebcdb4-79af-484a-b0d3-f75228815291"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atenolol and chlorthalidone tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including atenolol and chlorthalidone. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed dose combination drug is not indicated for initial therapy of hypertension. If the fixed dose combination represents the dose appropriate to the individual patient's needs, it may be more convenient than the separate components. uuid:3693b4e6-1cf5-40d3-bfd1-57e006fc784c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:37789 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:46e2e63b-37aa-42ec-a4f6-03dea9615231"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7b7dbde6-4587-4c28-9c4d-19506efc0a33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atenolol and chlorthalidone tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including atenolol and chlorthalidone. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed dose combination drug is not indicated for initial therapy of hypertension. If the fixed dose combination represents the dose appropriate to the individual patient's needs, it may be more convenient than the separate components. uuid:19a1570e-a1bb-4812-875e-cfdda6907364 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:37789 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:d707edc1-d90a-4b0d-a0c8-5af72c58ade5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:25fce04d-fbca-4a04-8b60-cfc3d4aad01d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atenolol and chlorthalidone tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including atenolol and chlorthalidone. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed dose combination drug is not indicated for initial therapy of hypertension. If the fixed dose combination represents the dose appropriate to the individual patient's needs, it may be more convenient than the separate components. uuid:4a2f49f4-f64b-4b5d-b90b-e809a8abb25f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15367 biolink:treats UMLS:C0344328 PMID:41385096 "[{""id"":""uuid:00f918d7-0e53-4551-8fa0-761adb4582bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6dcbab0f-4549-463a-ac22-e633d4829269"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] (To understand fully the indication for this product, please read the entire INDICATIONS AND USAGE section of the labeling.) Tretinoin Cream, USP (Emollient) 0.05% is indicated as an adjunctive agent (see second bullet point below) for use in the mitigation (palliation) of fine wrinkles, mottled hyperpigmentation, and tactile roughness of facial skin in patients who use comprehensive skin care and sunlight avoidance programs (see bullet 3 for populations in which effectiveness has not been established ). TRETINOIN CREAM, USP (EMOLLIENT) DOES NOT ELIMINATE WRINKLES, REPAIR SUN-DAMAGED SKIN, REVERSE PHOTOAGING, or RESTORE MORE YOUTHFUL or YOUNGER SKIN . In double-blinded, vehicle-controlled clinical studies, many patients in the vehicle group achieved desired palliative effects on fine wrinkling, mottled hyperpigmentation, and tactile roughness of facial skin with the use of comprehensive skin care and sunlight avoidance programs including sunscreens, protective clothing, and non-prescription emollient creams. Tretinoin Cream, USP (Emollient) 0.05% has NOT DEMONSTRATED A MITIGATING EFFECT on significant signs of chronic sun exposure such as coarse or deep wrinkling, skin yellowing, lentigines, telangiectasia, skin laxity, keratinocytic atypia, melanocytic atypia, or dermal elastosis. Tretinoin Cream, USP (Emollient) 0.05% should be used under medical supervision as an adjunct to a comprehensive skin care and sunlight avoidance program that includes the use of effective sunscreens (minimum SPF of 15) and protective clothing when desired results on fine wrinkles, mottled hyperpigmentation, and roughness of facial skin have not been achieved with a comprehensive skin care and sunlight avoidance program alone. The effectiveness of Tretinoin Cream, USP (Emollient) 0.05% in the mitigation of fine wrinkles, mottled hyperpigmentation, and tactile roughness of facial skin has not been established in people greater than 50 years of age OR in people with moderately to heavily pigmented skin. In addition, patients with visible actinic keratoses and patients with a history of skin cancer were excluded from clinical trials of Tretinoin Cream, USP (Emollient) 0.05%. Thus the effectiveness and safety of Tretinoin Cream, USP (Emollient) 0.05% in these populations are not known at this time. Neither the safety nor the effectiveness of Tretinoin Cream, USP (Emollient) for the prevention or treatment of actinic keratoses or skin neoplasms has been established. Neither the safety nor the efficacy of using Tretinoin Cream, USP (Emollient) 0.05% daily for greater than 48 weeks has been established, and daily use beyond 48 weeks has not been systematically and histologically investigated in adequate and well-controlled trials. (see WARNINGS section.) uuid:8f8346b7-f27b-4ebd-93cd-6ae058171d11 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15367 biolink:treats MONDO:0019289 PMID:41385096 "[{""id"":""uuid:95a03a08-25f9-4933-bc7c-b97776739063"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:39d39c51-7441-4fc1-8131-86ed78e56409"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] (To understand fully the indication for this product, please read the entire INDICATIONS AND USAGE section of the labeling.) Tretinoin Cream, USP (Emollient) 0.05% is indicated as an adjunctive agent (see second bullet point below) for use in the mitigation (palliation) of fine wrinkles, mottled hyperpigmentation, and tactile roughness of facial skin in patients who use comprehensive skin care and sunlight avoidance programs (see bullet 3 for populations in which effectiveness has not been established ). TRETINOIN CREAM, USP (EMOLLIENT) DOES NOT ELIMINATE WRINKLES, REPAIR SUN-DAMAGED SKIN, REVERSE PHOTOAGING, or RESTORE MORE YOUTHFUL or YOUNGER SKIN . In double-blinded, vehicle-controlled clinical studies, many patients in the vehicle group achieved desired palliative effects on fine wrinkling, mottled hyperpigmentation, and tactile roughness of facial skin with the use of comprehensive skin care and sunlight avoidance programs including sunscreens, protective clothing, and non-prescription emollient creams. Tretinoin Cream, USP (Emollient) 0.05% has NOT DEMONSTRATED A MITIGATING EFFECT on significant signs of chronic sun exposure such as coarse or deep wrinkling, skin yellowing, lentigines, telangiectasia, skin laxity, keratinocytic atypia, melanocytic atypia, or dermal elastosis. Tretinoin Cream, USP (Emollient) 0.05% should be used under medical supervision as an adjunct to a comprehensive skin care and sunlight avoidance program that includes the use of effective sunscreens (minimum SPF of 15) and protective clothing when desired results on fine wrinkles, mottled hyperpigmentation, and roughness of facial skin have not been achieved with a comprehensive skin care and sunlight avoidance program alone. The effectiveness of Tretinoin Cream, USP (Emollient) 0.05% in the mitigation of fine wrinkles, mottled hyperpigmentation, and tactile roughness of facial skin has not been established in people greater than 50 years of age OR in people with moderately to heavily pigmented skin. In addition, patients with visible actinic keratoses and patients with a history of skin cancer were excluded from clinical trials of Tretinoin Cream, USP (Emollient) 0.05%. Thus the effectiveness and safety of Tretinoin Cream, USP (Emollient) 0.05% in these populations are not known at this time. Neither the safety nor the effectiveness of Tretinoin Cream, USP (Emollient) for the prevention or treatment of actinic keratoses or skin neoplasms has been established. Neither the safety nor the efficacy of using Tretinoin Cream, USP (Emollient) 0.05% daily for greater than 48 weeks has been established, and daily use beyond 48 weeks has not been systematically and histologically investigated in adequate and well-controlled trials. (see WARNINGS section.) uuid:d7b6078f-c7da-4e83-8903-363e08da7393 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6367 biolink:treats HP:0007334 PMID:41385096 "[{""id"":""uuid:ac7c5927-098b-49ee-871c-6b73c78f0547"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5322b113-b994-4970-ba12-f03e12b8ecf1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4f153ef0-b07e-4768-bb98-1d46551776b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lamotrigine extended-release tablet is an antiepileptic drug (AED) indicated for: adjunctive therapy for partial onset seizures with or without secondary generalization in patients ≥13 years of age. ( 1.1 ) Limitation of use: Safety and effectiveness in patients less than 13 years of age have not been established. (1.3)|[PMDA] Drugs with a new additional indication and a new dosage for use in the monotherapy for treatment of partial seizures (including secondary generalized seizure) and tonic-clonic seizures in patients with epilepsy. uuid:702f17f8-79aa-42fd-b475-0a58f85caf2d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:81579 biolink:treats UMLS:C5438213 PMID:41385096 "[{""id"":""uuid:d92cc91a-3607-4904-b713-02ed4e68f9e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b8d06b1d-22f8-4f7e-88a4-c357f9eb070d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROCRIT is an erythropoiesis-stimulating agent (ESA) indicated for: Treatment of anemia due to - Chronic Kidney Disease (CKD) in patients on dialysis and not on dialysis ( 1.1 ). - Zidovudine in HIV-infected patients ( 1.2 ). - The effects of concomitant myelosuppressive chemotherapy and upon initiation, there is a minimum of two additional months of planned chemotherapy ( 1.3 ). Reduction of allogeneic RBC transfusions in patients undergoing elective, noncardiac, nonvascular surgery ( 1.4 ). Limitations of Use PROCRIT has not been shown to improve quality of life, fatigue, or patient well-being ( 1.5 ). PROCRIT is not indicated for use: In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy ( 1.5 ). In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure ( 1.5 ). In patients scheduled for surgery who are willing to donate autologous blood ( 1.5 ). In patients undergoing cardiac or vascular surgery ( 1.5 ). As a substitute for RBC transfusions in patients who require immediate correction of anemia ( 1.5 ). uuid:41dab62f-d9e6-423c-92dd-925fdf659592 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5790 biolink:treats NCIT:C27003 PMID:41385096 "[{""id"":""uuid:d622cb1c-7608-492f-a3a0-c87288a55a27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ff347d57-5b64-427a-a95c-872bad30e7a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EXALGO is indicated for the management of moderate to severe pain in opioid tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time. Patients considered opioid tolerant are those who are taking at least 60 mg oral morphine per day, 25 mcg transdermal fentanyl/hour, 30 mg oral oxycodone/day, 8 mg oral hydromorphone/day, 25 mg oral oxymorphone/day or an equianalgesic dose of another opioid, for a week or longer. Limitations of Use EXALGO is not for use: As an as-needed (prn) analgesic For pain that is mild or not expected to persist for an extended period of time For acute pain For postoperative pain. uuid:faf64ad3-3809-4e34-a145-1f6867e33cb3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1155722 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:e6d717d6-363e-486d-b025-7b9b1522800e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6d205ba9-3484-41e5-b19a-9df786a6b60c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For relief of coughs and upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold. uuid:b66aafd7-1987-4c80-9c91-ee79d378fdef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1155722 biolink:treats MONDO:0005709 PMID:41385096 "[{""id"":""uuid:524f8cd3-ec03-4720-af76-a19eb16c9543"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eb505e8e-7e9c-4fc6-984d-57c3649c8a7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For relief of coughs and upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold. uuid:048562c9-a4b8-42fb-8b74-a5992601a927 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50673 biolink:treats MONDO:0005364 PMID:41385096 "[{""id"":""uuid:3aa2ceae-52ae-42fc-82a0-853030e396a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:79996698-e605-48cb-8212-1f07e77267bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methimazole is indicated: In patients with Graves’ disease with hyperthyroidism or toxic multinodular goiter for whom surgery or radioactive iodine therapy is not an appropriate treatment option To ameliorate symptoms of hyperthyroidism in preparation for thyroidectomy or radioactive iodine therapy uuid:cfb16ae1-39eb-4ad5-9eeb-1f921082c47c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50673 biolink:treats MONDO:0001252 PMID:41385096 "[{""id"":""uuid:245a44e3-5aa1-4ca6-92ca-2f2f69cfe1c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:529f69b1-a511-4e5b-a7e3-59df57b45025"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methimazole is indicated: In patients with Graves’ disease with hyperthyroidism or toxic multinodular goiter for whom surgery or radioactive iodine therapy is not an appropriate treatment option To ameliorate symptoms of hyperthyroidism in preparation for thyroidectomy or radioactive iodine therapy uuid:a3b166af-a3ca-4ee0-b667-f8bf672a10d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31932 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:8323adb0-9129-454c-85ec-11bbf0e94d41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5e29d055-0117-4c4a-949b-ca7c82dcc5ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Benicar is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Benicar. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. It may be used alone or in combination with other antihypertensive agents. uuid:3b19501c-1fc9-4c88-9cd5-e41ffedbb955 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31932 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:2161e62e-03db-43b5-9bcf-ed3c8dfad786"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:452a17ae-c547-4cb2-b377-c39447fa7841"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Benicar is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Benicar. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. It may be used alone or in combination with other antihypertensive agents. uuid:8045efd5-91d1-4b16-8761-8989c54db494 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31932 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:92cfd4a3-f261-4d7c-8020-17b233bcf869"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e342cab8-7bde-43a5-b483-917434524aee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Benicar is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Benicar. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. It may be used alone or in combination with other antihypertensive agents. uuid:53c634bb-be7b-4981-8010-03f053bcdf1b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31932 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:b0a948a1-aa16-48cd-8be9-5a900f6349ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c7602ba4-d1f1-4d9d-841e-39b24cf9640d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Benicar is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Benicar. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. It may be used alone or in combination with other antihypertensive agents. uuid:9d3d5acc-8cc9-4215-88a3-da9ae08a7e01 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31932 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:4958d63f-bcd2-4092-a705-6e8747047ffd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4abf287e-3a3d-4f77-864c-627a3abd9f94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Benicar is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Benicar. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. It may be used alone or in combination with other antihypertensive agents. uuid:5baa67f9-3ac4-44e3-bc4b-c17454f35311 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2904 biolink:treats MONDO:0021661 PMID:41385096 "[{""id"":""uuid:3721311f-44d1-4415-82b6-caf70114ad87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:65d6b785-7dcb-47a7-a586-61b564cee7e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Atenolol tablets, USP are indicated in the management of hypertension. They may be used alone or concomitantly with other antihypertensive agents, particularly with a thiazide-type diuretic. Angina Pectoris Due to Coronary Atherosclerosis Atenolol tablets, USP are indicated for the long-term management of patients with angina pectoris. Acute Myocardial Infarction Atenolol tablets, USP are indicated in the management of hemodynamically stable patients with definite or suspected acute myocardial infarction to reduce cardiovascular mortality. Treatment can be initiated as soon as the patient’s clinical condition allows. (See DOSAGE AND ADMINISTRATION , CONTRAINDICATIONS , and WARNINGS .) In general, there is no basis for treating patients like those who were excluded from the ISIS-1 trial (blood pressure less than 100 mmHg systolic, heart rate less than 50 bpm) or have other reasons to avoid beta-blockade. As noted above, some subgroups (e.g., elderly patients with systolic blood pressure below 120 mmHg) seemed less likely to benefit. uuid:b356ea25-1ac6-4bbb-bbab-dc74ec9970fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3380 biolink:treats HP:0005162 PMID:41385096 "[{""id"":""uuid:98bfbbfb-234c-4182-905b-97d0badac557"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:16398755-1d60-46ef-b760-1707c31d7d40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension: Captopril tablets, USP are indicated for the treatment of hypertension. In using captopril, consideration should be given to the risk of neutropenia/ agranulocytosis (see WARNINGS ). Captopril may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. Captopril is effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of captopril and thiazides are approximately additive. Heart Failure: Captopril tablets are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. The beneficial effect of captopril in heart failure does not require the presence of digitalis, however, most controlled clinical trial experience with captopril has been in patients receiving digitalis, as well as diuretic treatment. Left Ventricular Dysfunction After Myocardial Infarction: Captopril tablets are indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction ≤40% and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patients. Diabetic Nephropathy: Captopril tablets are indicated for the treatment of diabetic nephropathy (proteinuria > 500 mg/day) in patients with type I insulin-dependent diabetes mellitus and retinopathy. Captopril tablets decreases the rate of progression of renal insufficiency and development of serious adverse clinical outcomes (death or need for renal transplantation or dialysis). In considering use of captopril tablets, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see WARNINGS: Head and Neck Angioedema and Intestinal Angioedema ). uuid:829ac411-6f77-4ccc-b68a-94cd94adced9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3380 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:c3d3b1e4-2718-4031-a4a7-8fdb9e45f5cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:34c9f4ff-3618-4ab1-a1e9-b9adb7ae0190"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension: Captopril tablets, USP are indicated for the treatment of hypertension. In using captopril, consideration should be given to the risk of neutropenia/ agranulocytosis (see WARNINGS ). Captopril may be used as initial therapy for patients with normal renal function, in whom the risk is relatively low. In patients with impaired renal function, particularly those with collagen vascular disease, captopril should be reserved for hypertensives who have either developed unacceptable side effects on other drugs, or have failed to respond satisfactorily to drug combinations. Captopril is effective alone and in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of captopril and thiazides are approximately additive. Heart Failure: Captopril tablets are indicated in the treatment of congestive heart failure usually in combination with diuretics and digitalis. The beneficial effect of captopril in heart failure does not require the presence of digitalis, however, most controlled clinical trial experience with captopril has been in patients receiving digitalis, as well as diuretic treatment. Left Ventricular Dysfunction After Myocardial Infarction: Captopril tablets are indicated to improve survival following myocardial infarction in clinically stable patients with left ventricular dysfunction manifested as an ejection fraction ≤40% and to reduce the incidence of overt heart failure and subsequent hospitalizations for congestive heart failure in these patients. Diabetic Nephropathy: Captopril tablets are indicated for the treatment of diabetic nephropathy (proteinuria > 500 mg/day) in patients with type I insulin-dependent diabetes mellitus and retinopathy. Captopril tablets decreases the rate of progression of renal insufficiency and development of serious adverse clinical outcomes (death or need for renal transplantation or dialysis). In considering use of captopril tablets, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see WARNINGS: Head and Neck Angioedema and Intestinal Angioedema ). uuid:786f0c19-65fb-4f9d-9d64-c6bbb98e90cf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:116962 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:c7fe6cf5-fe4c-4b3e-a8bb-9ef5e439d2ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:939daf7d-c22f-4182-8780-6ec54bc0d7bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fosinopril sodium tablets are indicated for the treatment of hypertension. They may be used alone or in combination with thiazide diuretics. Fosinopril sodium tablets are indicated in the management of heart failure as adjunctive therapy when added to conventional therapy including diuretics with or without digitalis (see DOSAGE AND ADMINISTRATION ). In using fosinopril sodium, consideration should be given to the fact that another angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that fosinopril sodium does not have a similar risk (see WARNINGS ). In considering use of fosinopril sodium, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see WARNINGS , Head and Neck Angioedema and Intestinal Angioedema ). uuid:93e8d3b3-d55e-40a2-923d-63a120b35c6e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27779 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:b4de2d1a-cea2-49bb-b203-b6b9c3936dfa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:29da03aa-c764-4963-be10-52e773ecb71d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Major indications for Griseofulvin Oral Suspension are: Griseofulvin inhibits the growth of those genera of fungi that commonly cause ringworm infections of the hair, skin, and nails, such as: Note: Prior to therapy, the type of fungi responsible for the infection should be identified. The use of the drug is not justified in minor or trivial infections which will respond to topical antifungal agents alone. It is not effective in: uuid:50fe0cf5-8978-43c7-8704-596185d444cc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:119486 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:9f675c08-77ae-475d-a0de-2da66664ebb6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c5165a25-6ffc-491d-8b1a-6f04f3eefaef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SUSTIVA ® (efavirenz) in combination with other antiretroviral agents is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. This indication is based on two clinical trials of at least one year duration that demonstrated prolonged suppression of HIV RNA [see Clinical Studies (14) ]. uuid:84e427cf-3471-4585-8a6b-2dccda3f6542 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0005642 PMID:41385096 "[{""id"":""uuid:ee5f126e-04de-4050-97fb-15e44f308e8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5ebf0907-019e-416f-8940-37357fd6a31a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRED MILD ® is indicated for the treatment of mild to moderate noninfectious allergic and inflammatory disorders of the lid, conjunctiva, cornea, and sclera (including chemical and thermal burns). uuid:23110e5d-c4f2-4966-be57-6215922e62ee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0001269 PMID:41385096 "[{""id"":""uuid:18d762f8-4cfb-43e8-bb11-8522841eba99"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:adf92377-a9e7-4517-8585-5230a2d091ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRED MILD ® is indicated for the treatment of mild to moderate noninfectious allergic and inflammatory disorders of the lid, conjunctiva, cornea, and sclera (including chemical and thermal burns). uuid:c96e1966-b315-4f65-86eb-fd85e0b4c969 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0003382 PMID:41385096 "[{""id"":""uuid:a7091696-09c9-4412-83c0-9919a8615d34"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b8409fe8-759c-4ba3-bb16-db2b752182e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRED MILD ® is indicated for the treatment of mild to moderate noninfectious allergic and inflammatory disorders of the lid, conjunctiva, cornea, and sclera (including chemical and thermal burns). uuid:31eb3661-f512-4030-ab90-5f0cee105f06 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats UMLS:C0006435 PMID:41385096 "[{""id"":""uuid:cf8879e4-1ea1-4a5c-a942-97e9be584dca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ef8b2890-030d-48ba-a564-203b4158bd24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRED MILD ® is indicated for the treatment of mild to moderate noninfectious allergic and inflammatory disorders of the lid, conjunctiva, cornea, and sclera (including chemical and thermal burns). uuid:ac51dc90-b6ad-40c0-a099-69d16ed178b1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats UMLS:C0701836 PMID:41385096 "[{""id"":""uuid:f44b014f-aeb0-4ce8-a0e3-3a9023023199"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4f24ab9f-cea0-4a1e-99fd-c9555c12e22b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRED MILD ® is indicated for the treatment of mild to moderate noninfectious allergic and inflammatory disorders of the lid, conjunctiva, cornea, and sclera (including chemical and thermal burns). uuid:04f9d8d6-d03b-4d40-af19-49dfed368340 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:11954236 biolink:treats MONDO:0012268 PMID:41385096 "[{""id"":""uuid:00672a7f-e370-4e67-a817-85570ebaef9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f262a53d-6872-4a68-aed7-8f7bf89143ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRUVADA is a combination of EMTRIVA and VIREAD, both nucleoside analog HIV-1 reverse transcriptase inhibitors. TRUVADA is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older. ( 1 ) TRUVADA is indicated in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults at high risk. ( 1 ) uuid:6584b49c-a7f5-4414-ac53-3ce894112787 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77363 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:5d88e30b-e05a-4081-ba1c-f89b7c20494f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:051bca05-f311-4d99-8745-df83667d271f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ramipril capsules USP are indicated for the treatment of hypertension. It may be used alone or in combination with thiazide diuretics ( 1.1 ). Ramipril capsules USP are indicated in stable patients who have demonstrated clinical signs of congestive heart failure post-myocardial infarction ( 1.3 ). uuid:0dc01baf-7289-48dd-8ced-5ef8a9402308 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:132041 biolink:treats MONDO:0001134 PMID:41385096 "[{""id"":""uuid:9db98708-ba05-4ffc-a92d-728a49561992"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8bfb5637-9e9a-4aaa-bdb9-07e883d42feb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ACEON is indicated for the treatment of patients with essential hypertension ( 1.1 ) ACEON is indicated for treatment of patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or nonfatal myocardial infarction ( 1.2 ) uuid:6c913478-1b8c-489b-b346-1d5338f52ffc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:132041 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:cdb9d161-77e2-4ee1-aa76-c1aa855c3043"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bebe44e3-3808-46d1-b9e4-0b8a94e9619b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ACEON is indicated for the treatment of patients with essential hypertension ( 1.1 ) ACEON is indicated for treatment of patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or nonfatal myocardial infarction ( 1.2 ) uuid:035ba51b-0948-4543-b501-bee8daa91b7d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:132041 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:b3edb09c-3c74-41f5-b920-011398e8f8e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:09d9514d-3d33-4790-ac89-82c040dfc88f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ACEON is indicated for the treatment of patients with essential hypertension ( 1.1 ) ACEON is indicated for treatment of patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or nonfatal myocardial infarction ( 1.2 ) uuid:56428082-8f0a-4376-9019-27f31665fe9b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1145800 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:2dfe1611-69a5-4a6f-b88a-69b0178ece37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:84ab0144-9140-4d26-858f-d55d2393ffc8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] COMPLERA ® (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) is indicated for use as a complete regimen for the treatment of HIV-1 infection in antiretroviral treatment-naive adult patients with HIV-1 RNA less than or equal to 100,000 copies/mL at the start of therapy. This indication is based on safety and efficacy analyses through 96 weeks from 2 randomized, double-blind, active controlled, Phase 3 trials in treatment-naive subjects comparing rilpivirine to efavirenz [See Clinical Studies (14) ] . The following points should be considered when initiating therapy with COMPLERA: More rilpivirine-treated subjects with HIV-1 RNA greater than 100,000 copies/mL at the start of therapy experienced virologic failure (HIV-1 RNA ≥50 copies/mL) compared to rilpivirine-treated subjects with HIV-1 RNA less than or equal to 100,000 copies/mL [See Clinical Studies (14) ] . Regardless of HIV-1 RNA level at the start of therapy, more rilpivirine-treated subjects with CD4+ cell count less than 200 cells/mm 3 experienced virologic failure compared to rilpivirine-treated subjects with CD4+ cell count greater than or equal to 200 cells/mm 3 [See Clinical Studies (14) ] . The observed virologic failure rate in rilpivirine-treated subjects conferred a higher rate of overall treatment resistance and cross-resistance to the NNRTI class compared to efavirenz [See Microbiology (12.4) ] . More subjects treated with rilpivirine developed tenofovir and lamivudine/emtricitabine associated resistance compared to efavirenz [See Microbiology (12.4) ] . COMPLERA is not recommended for patients less than 18 years of age [See Use in Specific Populations (8.4) ]. uuid:8d3b8a06-79f8-4124-93b0-3f19ac85c36d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:46878853 biolink:treats HP:0003124 PMID:41385096 "[{""id"":""uuid:042a4ce7-4d59-48fc-9dd5-06ff607fa9fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:70c70f4d-f19d-48b4-b873-e2ce82daf120"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FIBRICOR is a peroxisome proliferator receptor alpha (PPARα) activator indicated as an adjunct to diet: to reduce triglyceride (TG) levels in adult patients with severe hypertriglyceridemia (≥ 500 mg/dL) ( 1.1 ). to reduce elevated total cholesterol (TC), low-density-lipoprotein cholesterol (LDL-C), TG and apolipoprotein (Apo) B and to increase high-density lipoprotein cholesterol (HDL-C) in adult patients with primary hypercholesterolemia or mixed dyslipidemia ( 1.2 ). Important Limitations of Use: Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus ( 1.3 ). uuid:ce8fbd98-ce74-4657-b77b-8d0163e9e6fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16794 biolink:treats MONDO:0008015 PMID:41385096 "[{""id"":""uuid:6851b2f9-5984-4b95-ae09-830f1d813ecb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0e0f1bf7-082a-4b3d-867e-9f97268590ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Transderm Scōp is indicated in adults for prevention of nausea and vomiting associated with motion sickness and recovery from anesthesia and surgery. The patch should be applied only to skin in the postauricular area. uuid:a10a4085-fd20-4df9-b243-679313253380 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16794 biolink:treats HP:0002018 PMID:41385096 "[{""id"":""uuid:b10f0c96-9319-46d8-8f26-406ada36f44a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dd80651f-08ee-4c75-958f-167f60498e66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Transderm Scōp is indicated in adults for prevention of nausea and vomiting associated with motion sickness and recovery from anesthesia and surgery. The patch should be applied only to skin in the postauricular area. uuid:77e89f7c-43b0-439f-9032-bed3d2210cbf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16794 biolink:treats HP:0002013 PMID:41385096 "[{""id"":""uuid:f5ed5e32-42be-45d6-9dc1-46368a7de268"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:93fc51a0-810f-4f6d-beab-f05ab6cbdb63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Transderm Scōp is indicated in adults for prevention of nausea and vomiting associated with motion sickness and recovery from anesthesia and surgery. The patch should be applied only to skin in the postauricular area. uuid:596eb2a8-9f55-4dc6-aa81-59e97bcd2bc6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1152398 biolink:treats MONDO:0005277 PMID:41385096 "[{""id"":""uuid:c1422ed9-2de8-4dbd-b7f5-553b1f085d58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2c4d861e-377b-42ea-9b88-ac95aded615e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Indicated as therapy to abort or prevent vascular headache, e.g., migraine, migraine variants or so-called “histaminic cephalalgia”. uuid:26e4d6bc-76cc-42c5-b58f-9724db7bf9de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1152398 biolink:treats MONDO:0043537 PMID:41385096 "[{""id"":""uuid:b223dd4e-95c0-49be-92e3-9bb41b9e2c40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ce1a79d2-89e1-465d-8442-cfbe95cd27bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Indicated as therapy to abort or prevent vascular headache, e.g., migraine, migraine variants or so-called “histaminic cephalalgia”. uuid:d0699f7b-a170-4951-9352-401053be9d94 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:R581OT55EA biolink:treats MONDO:0005393 PMID:41385096 "[{""id"":""uuid:fb7b4aae-c218-42bc-a32b-facd02c39b13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c1a4dbb6-e1e5-45cc-a702-e10c269c0d7d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KRYSTEXXA® (pegloticase) is a PEGylated uric acid specific enzyme indicated for the treatment of chronic gout in adult patients refractory to conventional therapy. Gout refractory to conventional therapy occurs in patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated. Important Limitations of Use: KRYSTEXXA is not recommended for the treatment of asymptomatic hyperuricemia. uuid:3c1bb503-9c44-4420-8d6c-c82cc4f94f4d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:R581OT55EA biolink:treats HP:0002149 PMID:41385096 "[{""id"":""uuid:63ef7aae-66d4-4867-9b1a-d8989e89bcb9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dee8c57d-b1db-42f9-9051-12e5fea94898"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KRYSTEXXA® (pegloticase) is a PEGylated uric acid specific enzyme indicated for the treatment of chronic gout in adult patients refractory to conventional therapy. Gout refractory to conventional therapy occurs in patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with xanthine oxidase inhibitors at the maximum medically appropriate dose or for whom these drugs are contraindicated. Important Limitations of Use: KRYSTEXXA is not recommended for the treatment of asymptomatic hyperuricemia. uuid:ab3ec378-1afb-401f-aed8-6f12aab0644b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8069 biolink:treats MONDO:0005754 PMID:41385096 "[{""id"":""uuid:f90889d0-f421-4f35-a441-8f6687e2b8c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:113be1c5-ff75-408c-a05c-a9fb56e761c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sedative Anticonvulsant – For the treatment of generalized and partial seizures. uuid:b0e3615e-2af2-4c54-a71d-3fd2b064c250 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8069 biolink:treats HP:0007359 PMID:41385096 "[{""id"":""uuid:180a1019-db40-4d3e-92a1-70295903844c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7493f9bc-a8da-4e52-ad54-4e172840ab95"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sedative Anticonvulsant – For the treatment of generalized and partial seizures. uuid:bb178876-a081-4ef0-bf10-53d1dee059b4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1161287 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:ac7c9bbe-2911-4799-8753-055680fa2646"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c974b35f-39e6-4604-860e-3017d31359fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ATRIPLA ® is indicated for use alone as a complete regimen or in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older. uuid:3415cd5b-92f4-4a42-9569-595adcd48c97 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6538 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:e6a75707-f945-46c4-af79-15aa1d419115"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c3567505-7ac2-417f-b08b-0770fc6ed30d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: runny nose sneezing itchy, watery eyes itching of the nose or throat uuid:94763274-e904-40cf-8949-a33234a7325a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6538 biolink:treats MONDO:0004867 PMID:41385096 "[{""id"":""uuid:3189105f-669b-4c51-9425-122cef5eb8e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b1e46617-5154-48fc-8f5f-af040c6db212"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: runny nose sneezing itchy, watery eyes itching of the nose or throat uuid:be495b97-3198-4b41-a69b-ca5f500a1eca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:116962 biolink:treats UMLS:C3888796 PMID:41385096 "[{""id"":""uuid:5ad56923-e52d-45c3-8b5f-b3eae82623e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:11b89640-71ab-40ee-92b3-e839e53eb7c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fosinopril sodium tablets are indicated for the treatment of hypertension. It may be used alone or in combination with thiazide diuretics. Fosinopril sodium tablets are indicated in the management of heart failure as adjunctive therapy when added to conventional therapy including diuretics with or without digitalis (see ). DOSAGE AND ADMINISTRATION In using fosinopril sodium, consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen-vascular disease. Available data are insufficient to show that fosinopril sodium does not have a similar risk (see ). WARNINGS In considering use of fosinopril sodium, it should be noted that in controlled trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non- blacks. In addition, ACE inhibitors (for which adequate data are available) cause a higher rate of angioedema in black than in non-black patients (see ). WARNINGS : Head and Neck Angioedema and Intestinal Angioedema uuid:c362754d-b77b-48c7-b26f-5b181661cb34 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB11601 biolink:treats MONDO:0018076 PMID:41385096 "[{""id"":""uuid:05983462-ceb6-4861-9538-149d85b3dbf0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a49ac418-5c90-412d-8b26-4e1aae7dac99"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TUBERSOL, Tuberculin Purified Protein Derivative (Mantoux), is indicated to aid diagnosis of tuberculosis infection (TB) in persons at increased risk of developing active disease. The Centers for Disease Control and Prevention (CDC) have published guidelines regarding populations that would benefit from tuberculin skin testing (TST). Current recommendations can be accessed at: http://www.cdc.gov/tb/publications/factsheets/testing.htm. Previous BCG vaccination is not a contraindication to tuberculin testing. The skin-test results of BCG vaccinated persons can be used to support or exclude the diagnosis of TB infection. However, an FDA-approved interferon gamma release assay is preferred over tuberculin skin test for persons 5 years of age and older who were previously vaccinated with BCG. (9) uuid:41b7eb75-d0c7-4807-812d-01d174ada734 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3534 biolink:treats MONDO:0005114 PMID:41385096 "[{""id"":""uuid:9ab5994f-d830-40ad-9773-9076cfacdc67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a5c20488-07f1-49b8-b163-7a1a1ee1706d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cephalexin Capsules USP are indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Respiratory tract infections caused by Streptococcus pneumoniae and Streptococcus pyogenes . (Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.) Otitis media due to Streptococcus pneumoniae , Haemophilus influenzae , Staphylococcus aureus , Streptococcus pyogenes , and Moraxella catarrhalis . Skin and skin structure infections caused by Staphylococcus aureus and/or Streptococcus pyogenes . Bone infections caused by Staphylococcus aureus and/or Proteus mirabilis . Genitourinary tract infections, including acute prostatitis, caused by Escherichia coli , Proteus mirabilis , and Klebsiella pneumoniae. Note – Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cephalexin capsules and other antibacterial drugs, cephalexin capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:a934f0b2-b382-4e22-8f62-a7beac0ff348 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3534 biolink:treats HP:0005376 PMID:41385096 "[{""id"":""uuid:ef66326d-b633-409e-8ad4-5cf089d68b70"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b5859210-e8c2-423d-9689-c00a87f0ce8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cephalexin Capsules USP are indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Respiratory tract infections caused by Streptococcus pneumoniae and Streptococcus pyogenes . (Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.) Otitis media due to Streptococcus pneumoniae , Haemophilus influenzae , Staphylococcus aureus , Streptococcus pyogenes , and Moraxella catarrhalis . Skin and skin structure infections caused by Staphylococcus aureus and/or Streptococcus pyogenes . Bone infections caused by Staphylococcus aureus and/or Proteus mirabilis . Genitourinary tract infections, including acute prostatitis, caused by Escherichia coli , Proteus mirabilis , and Klebsiella pneumoniae. Note – Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cephalexin capsules and other antibacterial drugs, cephalexin capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:adecfc75-b91c-4b54-8cf2-a49804c65126 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3534 biolink:treats MONDO:0005545 PMID:41385096 "[{""id"":""uuid:409a9bca-f6f0-4bad-8fc1-f7c0fe086e7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:47aae4b0-aad4-4255-aa1a-ee12fb54a16a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cephalexin Capsules USP are indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Respiratory tract infections caused by Streptococcus pneumoniae and Streptococcus pyogenes . (Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.) Otitis media due to Streptococcus pneumoniae , Haemophilus influenzae , Staphylococcus aureus , Streptococcus pyogenes , and Moraxella catarrhalis . Skin and skin structure infections caused by Staphylococcus aureus and/or Streptococcus pyogenes . Bone infections caused by Staphylococcus aureus and/or Proteus mirabilis . Genitourinary tract infections, including acute prostatitis, caused by Escherichia coli , Proteus mirabilis , and Klebsiella pneumoniae. Note – Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cephalexin capsules and other antibacterial drugs, cephalexin capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:0d26f6af-eada-46e2-baaa-77db152b398c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3534 biolink:treats UMLS:C0852874 PMID:41385096 "[{""id"":""uuid:15803588-0caa-474c-b150-77ef17af5053"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a3aff963-9aad-4615-9376-5cda78ea3f7d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cephalexin Capsules USP are indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Respiratory tract infections caused by Streptococcus pneumoniae and Streptococcus pyogenes . (Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.) Otitis media due to Streptococcus pneumoniae , Haemophilus influenzae , Staphylococcus aureus , Streptococcus pyogenes , and Moraxella catarrhalis . Skin and skin structure infections caused by Staphylococcus aureus and/or Streptococcus pyogenes . Bone infections caused by Staphylococcus aureus and/or Proteus mirabilis . Genitourinary tract infections, including acute prostatitis, caused by Escherichia coli , Proteus mirabilis , and Klebsiella pneumoniae. Note – Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cephalexin capsules and other antibacterial drugs, cephalexin capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:17958e8f-df6b-4619-a8d0-8a4bdd37cc74 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3534 biolink:treats MONDO:0006929 PMID:41385096 "[{""id"":""uuid:cff09429-fd59-44ac-ba8c-5b09ed6b53cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:77854bf0-93dd-4228-857f-363e3905092b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cephalexin Capsules USP are indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Respiratory tract infections caused by Streptococcus pneumoniae and Streptococcus pyogenes . (Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.) Otitis media due to Streptococcus pneumoniae , Haemophilus influenzae , Staphylococcus aureus , Streptococcus pyogenes , and Moraxella catarrhalis . Skin and skin structure infections caused by Staphylococcus aureus and/or Streptococcus pyogenes . Bone infections caused by Staphylococcus aureus and/or Proteus mirabilis . Genitourinary tract infections, including acute prostatitis, caused by Escherichia coli , Proteus mirabilis , and Klebsiella pneumoniae. Note – Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cephalexin capsules and other antibacterial drugs, cephalexin capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:a49b4509-b2cb-412a-9154-cc128a6a2a59 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3534 biolink:treats MONDO:0020920 PMID:41385096 "[{""id"":""uuid:7c9d995e-2135-4a52-9b3f-129b38a34d21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e8536678-1b5a-4df3-a6dc-7d7a9f65b81c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cephalexin Capsules USP are indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Respiratory tract infections caused by Streptococcus pneumoniae and Streptococcus pyogenes . (Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.) Otitis media due to Streptococcus pneumoniae , Haemophilus influenzae , Staphylococcus aureus , Streptococcus pyogenes , and Moraxella catarrhalis . Skin and skin structure infections caused by Staphylococcus aureus and/or Streptococcus pyogenes . Bone infections caused by Staphylococcus aureus and/or Proteus mirabilis . Genitourinary tract infections, including acute prostatitis, caused by Escherichia coli , Proteus mirabilis , and Klebsiella pneumoniae. Note – Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cephalexin capsules and other antibacterial drugs, cephalexin capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:4d95c8bc-5a36-4f57-aa29-751655a596c8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3534 biolink:treats MONDO:0030602 PMID:41385096 "[{""id"":""uuid:213fa1e3-3a66-4790-a105-f9bd1cc16b69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6cb32e19-8556-47c6-ae8c-984a8ee43213"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cephalexin Capsules USP are indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Respiratory tract infections caused by Streptococcus pneumoniae and Streptococcus pyogenes . (Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.) Otitis media due to Streptococcus pneumoniae , Haemophilus influenzae , Staphylococcus aureus , Streptococcus pyogenes , and Moraxella catarrhalis . Skin and skin structure infections caused by Staphylococcus aureus and/or Streptococcus pyogenes . Bone infections caused by Staphylococcus aureus and/or Proteus mirabilis . Genitourinary tract infections, including acute prostatitis, caused by Escherichia coli , Proteus mirabilis , and Klebsiella pneumoniae. Note – Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cephalexin capsules and other antibacterial drugs, cephalexin capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:714acdd3-c48f-407f-9852-77504465f0d2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59343 biolink:treats UMLS:C1735365 PMID:41385096 "[{""id"":""uuid:92a14ad6-0475-475e-985a-714e70d22877"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:32051556-c60f-4c86-b4dd-5588bf5c680b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SPECTRACEF® (cefditoren pivoxil) is indicated for the treatment of mild to moderate infections in adults and adolescents (12 years of age or older) which are caused by susceptible strains of the designated microorganisms in the conditions listed below. Acute Bacterial Exacerbation of Chronic Bronchitis caused by Haemophilus influenzae (including ß-lactamase-producing strains), Haemophilus parainfluenzae (including ß-lactamase producing strains), Streptococcus pneumoniae (penicillin susceptible strains only), or Moraxella catarrhalis (including ß-lactamase-producing strains). Community-Acquired Pneumonia caused by Haemophilus influenzae (including ß-lactamase-producing strains), Haemophilus parainfluenzae (including ß-lactamase-producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), or Moraxella catarrhalis (including ß-lactamase producing strains). Pharyngitis/Tonsillitis caused by Streptococcus pyogenes . NOTE: SPECTRACEF® is effective in the eradication of Streptococcus pyogenes from the oropharynx. SPECTRACEF® has not been studied for the prevention of rheumatic fever following Streptococcus pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. Uncomplicated Skin and Skin-Structure Infections caused by Staphylococcus aureus (including ß-lactamase-producing strains) or Streptococcus pyogenes. To reduce the development of drug-resistant bacteria and maintain the effectiveness of SPECTRACEF® and other antibacterial drugs, SPECTRACEF® should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:fb5bb4f7-9bf5-47d0-a44b-a16ed9480bd3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59343 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:6781eb16-c6b9-4450-ab47-f77e1c94478e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1e74a205-9a07-46c5-8e14-2f1ad3f7f93a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b14a97b2-dcb5-4d4b-98c4-6b2d27d65cf5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SPECTRACEF® (cefditoren pivoxil) is indicated for the treatment of mild to moderate infections in adults and adolescents (12 years of age or older) which are caused by susceptible strains of the designated microorganisms in the conditions listed below. Acute Bacterial Exacerbation of Chronic Bronchitis caused by Haemophilus influenzae (including ß-lactamase-producing strains), Haemophilus parainfluenzae (including ß-lactamase producing strains), Streptococcus pneumoniae (penicillin susceptible strains only), or Moraxella catarrhalis (including ß-lactamase-producing strains). Community-Acquired Pneumonia caused by Haemophilus influenzae (including ß-lactamase-producing strains), Haemophilus parainfluenzae (including ß-lactamase-producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), or Moraxella catarrhalis (including ß-lactamase producing strains). Pharyngitis/Tonsillitis caused by Streptococcus pyogenes . NOTE: SPECTRACEF® is effective in the eradication of Streptococcus pyogenes from the oropharynx. SPECTRACEF® has not been studied for the prevention of rheumatic fever following Streptococcus pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. Uncomplicated Skin and Skin-Structure Infections caused by Staphylococcus aureus (including ß-lactamase-producing strains) or Streptococcus pyogenes. To reduce the development of drug-resistant bacteria and maintain the effectiveness of SPECTRACEF® and other antibacterial drugs, SPECTRACEF® should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.|[PMDA] A drug with a new additional dosage for the treatment of pneumonia, otitis media, and sinusitis. uuid:9e4ba416-849b-4a35-8ec9-a8637e970ea0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59343 biolink:treats MONDO:0002258 PMID:41385096 "[{""id"":""uuid:9988bc86-dab9-4fa0-929d-b5b5a2d9f52c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9a58a7ed-f8a7-44db-a97b-60ba7b03d6d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SPECTRACEF® (cefditoren pivoxil) is indicated for the treatment of mild to moderate infections in adults and adolescents (12 years of age or older) which are caused by susceptible strains of the designated microorganisms in the conditions listed below. Acute Bacterial Exacerbation of Chronic Bronchitis caused by Haemophilus influenzae (including ß-lactamase-producing strains), Haemophilus parainfluenzae (including ß-lactamase producing strains), Streptococcus pneumoniae (penicillin susceptible strains only), or Moraxella catarrhalis (including ß-lactamase-producing strains). Community-Acquired Pneumonia caused by Haemophilus influenzae (including ß-lactamase-producing strains), Haemophilus parainfluenzae (including ß-lactamase-producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), or Moraxella catarrhalis (including ß-lactamase producing strains). Pharyngitis/Tonsillitis caused by Streptococcus pyogenes . NOTE: SPECTRACEF® is effective in the eradication of Streptococcus pyogenes from the oropharynx. SPECTRACEF® has not been studied for the prevention of rheumatic fever following Streptococcus pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. Uncomplicated Skin and Skin-Structure Infections caused by Staphylococcus aureus (including ß-lactamase-producing strains) or Streptococcus pyogenes. To reduce the development of drug-resistant bacteria and maintain the effectiveness of SPECTRACEF® and other antibacterial drugs, SPECTRACEF® should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:a619d385-6558-4f21-8033-601a1e2db9b5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59343 biolink:treats MONDO:0001039 PMID:41385096 "[{""id"":""uuid:d5f94f1d-064f-402c-af46-3c456064550e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:33299b21-274e-44c3-a1a5-2d9463f3eb8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SPECTRACEF® (cefditoren pivoxil) is indicated for the treatment of mild to moderate infections in adults and adolescents (12 years of age or older) which are caused by susceptible strains of the designated microorganisms in the conditions listed below. Acute Bacterial Exacerbation of Chronic Bronchitis caused by Haemophilus influenzae (including ß-lactamase-producing strains), Haemophilus parainfluenzae (including ß-lactamase producing strains), Streptococcus pneumoniae (penicillin susceptible strains only), or Moraxella catarrhalis (including ß-lactamase-producing strains). Community-Acquired Pneumonia caused by Haemophilus influenzae (including ß-lactamase-producing strains), Haemophilus parainfluenzae (including ß-lactamase-producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), or Moraxella catarrhalis (including ß-lactamase producing strains). Pharyngitis/Tonsillitis caused by Streptococcus pyogenes . NOTE: SPECTRACEF® is effective in the eradication of Streptococcus pyogenes from the oropharynx. SPECTRACEF® has not been studied for the prevention of rheumatic fever following Streptococcus pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. Uncomplicated Skin and Skin-Structure Infections caused by Staphylococcus aureus (including ß-lactamase-producing strains) or Streptococcus pyogenes. To reduce the development of drug-resistant bacteria and maintain the effectiveness of SPECTRACEF® and other antibacterial drugs, SPECTRACEF® should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:0d5af380-0de8-46f4-acc3-9d013d59d3ad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59343 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:c36d7fdc-e38a-4d9c-aea9-7744a3ec4783"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7be3c294-67fd-4dec-8d67-96bfc2cd3e67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SPECTRACEF® (cefditoren pivoxil) is indicated for the treatment of mild to moderate infections in adults and adolescents (12 years of age or older) which are caused by susceptible strains of the designated microorganisms in the conditions listed below. Acute Bacterial Exacerbation of Chronic Bronchitis caused by Haemophilus influenzae (including ß-lactamase-producing strains), Haemophilus parainfluenzae (including ß-lactamase producing strains), Streptococcus pneumoniae (penicillin susceptible strains only), or Moraxella catarrhalis (including ß-lactamase-producing strains). Community-Acquired Pneumonia caused by Haemophilus influenzae (including ß-lactamase-producing strains), Haemophilus parainfluenzae (including ß-lactamase-producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), or Moraxella catarrhalis (including ß-lactamase producing strains). Pharyngitis/Tonsillitis caused by Streptococcus pyogenes . NOTE: SPECTRACEF® is effective in the eradication of Streptococcus pyogenes from the oropharynx. SPECTRACEF® has not been studied for the prevention of rheumatic fever following Streptococcus pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. Uncomplicated Skin and Skin-Structure Infections caused by Staphylococcus aureus (including ß-lactamase-producing strains) or Streptococcus pyogenes. To reduce the development of drug-resistant bacteria and maintain the effectiveness of SPECTRACEF® and other antibacterial drugs, SPECTRACEF® should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:88ef79b1-ee41-40ce-bb65-064bdea5af80 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5062 biolink:treats MONDO:0004907 PMID:41385096 "[{""id"":""uuid:0dcbebe2-2b5f-4dc9-a439-f8bfd36a5343"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ddb8f0a7-b027-432b-aea7-c207af471bf5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROPECIA ® is indicated for the treatment of male pattern hair loss (androgenetic alopecia) in MEN ONLY . Efficacy in bitemporal recession has not been established. PROPECIA is not indicated for use in women. uuid:7ef11bbe-2229-447f-bd9c-9a8ada9c2c24 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5062 biolink:treats MONDO:0005339 PMID:41385096 "[{""id"":""uuid:a3ffd6f6-0327-4465-bd67-724043daafbf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7691de16-f146-48e0-8d57-94a67fe3548e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:de2f198c-f4d3-43e5-b366-e04390ce2e59"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROPECIA ® is indicated for the treatment of male pattern hair loss (androgenetic alopecia) in MEN ONLY . Efficacy in bitemporal recession has not been established. PROPECIA is not indicated for use in women.|[PMDA] Drugs containing a new active ingredient used for delaying progression of male pattern alopecia in men. uuid:cb4b7300-5774-45b6-9db5-bc93ac291e6f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:94559 biolink:treats MONDO:0044212 PMID:41385096 "[{""id"":""uuid:18e498b3-2140-461c-81aa-e55da0ebe419"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:00ff6a44-42ec-439a-b010-bfdb98b3fbe3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levocetirizine dihydrochloride tablets are a histamine H 1 -receptor antagonist indicated for: The treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria ( 1.3 ) uuid:737bc534-18b8-411f-a9d7-e73aca64b8d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:122173976 biolink:treats UMLS:C0080032 PMID:41385096 "[{""id"":""uuid:57b48fa0-2d64-4c6c-b747-569e4202139e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:98826b4c-27b8-423d-931c-4f55c8f9ad88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f450578a-9b1c-45d9-8a68-1969e4418faf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sclerosol® Intrapleural Aerosol, administered by aerosol during thoracoscopy or open thoracotomy, is indicated to prevent recurrence of malignant pleural effusions in symptomatic patients.|[PMDA] A drug with a new active ingredient indicated for the suppression of recurrence of malignant pleural effusions. uuid:068e3d22-e35d-4255-8f5a-8fe738abaaca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17347 biolink:treats HP:0000823 PMID:41385096 "[{""id"":""uuid:d3b65509-5cc3-42ee-b579-dd1677b2f854"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cea59924-0c3b-4651-8135-4861fe408c8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MALES Androgens are indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone. a. Primary hypogonadism (congenital or acquired) - testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testes syndrome; or orchiectomy. b. Hypogonadotrophic hypogonadism (congenital or acquired) - idiopathic or gonadotropic LHRH deficiency, or pituitary - hypothalamic injury from tumors, trauma or radiation. If the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sex characteristics. Prolonged androgen treatment will be required to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty. c. Androgens may be used to stimulate puberty in carefully selected males with clearly delayed puberty. These patients usually have a familial pattern of delayed puberty that is not secondary to a pathological disorder; puberty is expected to occur spontaneously at a relatively late date. Brief treatment with conservative doses may occasionally be justified in these patients if they do not respond to psychological support. The potential adverse effect on bone maturation should be discussed with the patient and parents prior to androgen administration. An x-ray of the hand and wrist to determine bone age should be taken every 6 months to assess the effect of treatment on epiphyseal centers (see WARNINGS ). uuid:a337056d-af4e-4309-b42d-5c31ed9a7016 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17347 biolink:treats UMLS:C1963961 PMID:41385096 "[{""id"":""uuid:af6f91b0-a9bf-4ba6-8de5-6ef3ff4a6492"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3680af37-1297-401b-906b-771e83d08725"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MALES Androgens are indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone. a. Primary hypogonadism (congenital or acquired) - testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testes syndrome; or orchiectomy. b. Hypogonadotrophic hypogonadism (congenital or acquired) - idiopathic or gonadotropic LHRH deficiency, or pituitary - hypothalamic injury from tumors, trauma or radiation. If the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sex characteristics. Prolonged androgen treatment will be required to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty. c. Androgens may be used to stimulate puberty in carefully selected males with clearly delayed puberty. These patients usually have a familial pattern of delayed puberty that is not secondary to a pathological disorder; puberty is expected to occur spontaneously at a relatively late date. Brief treatment with conservative doses may occasionally be justified in these patients if they do not respond to psychological support. The potential adverse effect on bone maturation should be discussed with the patient and parents prior to androgen administration. An x-ray of the hand and wrist to determine bone age should be taken every 6 months to assess the effect of treatment on epiphyseal centers (see WARNINGS ). uuid:19a07e39-2c70-42cf-9004-b3968af3f41d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64356 biolink:treats UMLS:C0740447 PMID:41385096 "[{""id"":""uuid:5d39e7b9-816b-4156-be24-6fa1e12dbdbc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:760b689f-4c41-4187-8cd8-c18fdbe6a8ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LYRICA is indicated for: Management of neuropathic pain associated with diabetic peripheral neuropathy Management of postherpetic neuralgia Adjunctive therapy for adult patients with partial onset seizures Management of fibromyalgia Management of neuropathic pain associated with spinal cord injury uuid:155e7b44-850d-4102-9099-17b6dfb50b2a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64356 biolink:treats MONDO:0041052 PMID:41385096 "[{""id"":""uuid:e33fbc9d-5377-4b91-992d-c80c00a06d59"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:770a36a0-0e39-4163-af2e-afd51fe53f2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b8204378-98ba-485f-83f6-1ba123d1fa15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LYRICA is indicated for: Management of neuropathic pain associated with diabetic peripheral neuropathy Management of postherpetic neuralgia Adjunctive therapy for adult patients with partial onset seizures Management of fibromyalgia Management of neuropathic pain associated with spinal cord injury|[PMDA] Drugs with a new active ingredient indicated for the treatment of postherpetic neuralgia. uuid:2a53eb93-3156-43c5-8ee7-fd504da5ec36 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64356 biolink:treats HP:0007359 PMID:41385096 "[{""id"":""uuid:55c06cf6-c0c5-40d3-b9a3-c32ef120b97c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6fbc9624-3ef1-4c42-94a4-c132f94ebbae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LYRICA is indicated for: Management of neuropathic pain associated with diabetic peripheral neuropathy Management of postherpetic neuralgia Adjunctive therapy for adult patients with partial onset seizures Management of fibromyalgia Management of neuropathic pain associated with spinal cord injury uuid:4bfebb55-7c4f-4c82-bd83-ca85f6e5e496 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64356 biolink:treats MONDO:0005546 PMID:41385096 "[{""id"":""uuid:738732c0-0766-41ad-b532-f3cc7d6460a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:048ead07-aae4-41ee-aaff-7aaa23221b90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e7654fd0-7f94-427d-9401-c0385821ee20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LYRICA is indicated for: Management of neuropathic pain associated with diabetic peripheral neuropathy Management of postherpetic neuralgia Adjunctive therapy for adult patients with partial onset seizures Management of fibromyalgia Management of neuropathic pain associated with spinal cord injury|[PMDA] Drugs with a new additional indication and a new dosage for the treatment of pain associated with fibromyalgia. [Priority review] uuid:af634e02-e706-4796-9710-ae1dd86c4e71 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3996 biolink:treats HP:0001257 PMID:41385096 "[{""id"":""uuid:bfdad38b-9b75-490b-b98e-086e020665a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0b29e85d-6a4e-4468-989d-aaa15dc20d2d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclobenzaprine hydrochloride tablets, USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride tablets, USP should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets, USP have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy. uuid:c27888be-26ce-4052-b5cd-81f2cbb9526d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:85783 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:ac40b99e-fc0d-45df-a00d-5506de2a73fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b2829067-00a7-400d-a3a8-c97343d9029f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lisinopril and hydrochlorothiazide tablets USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including lisinopril and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in Black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. These fixed-dose combinations are not indicated for initial therapy (see DOSAGE AND ADMINISTRATION ). In using lisinopril and hydrochlorothiazide, consideration should be given to the fact that an angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that lisinopril does not have a similar risk (see WARNINGS ). In considering the use of lisinopril and hydrochlorothiazide, it should be noted that ACE inhibitors have been associated with a higher rate of angioedema in Black than in non-Black patients (see WARNINGS, Lisinopril ). uuid:e27f4541-aede-4919-b62b-6c4049dfed8a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:85783 biolink:treats MONDO:0006652 PMID:41385096 "[{""id"":""uuid:8b19b7b3-03ce-4aa4-be54-54c9e83c69c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f4782b95-a265-4c15-9a6c-5be92e212772"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lisinopril and hydrochlorothiazide tablets USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including lisinopril and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in Black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. These fixed-dose combinations are not indicated for initial therapy (see DOSAGE AND ADMINISTRATION ). In using lisinopril and hydrochlorothiazide, consideration should be given to the fact that an angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that lisinopril does not have a similar risk (see WARNINGS ). In considering the use of lisinopril and hydrochlorothiazide, it should be noted that ACE inhibitors have been associated with a higher rate of angioedema in Black than in non-Black patients (see WARNINGS, Lisinopril ). uuid:dd0057e1-9c48-450e-9105-16dd764bf8da biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:85783 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:86c1928c-343c-4dd4-b63a-e68397633595"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:33fc48cb-e89c-4dd8-bd0c-228501e6ebb6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lisinopril and hydrochlorothiazide tablets USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including lisinopril and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in Black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. These fixed-dose combinations are not indicated for initial therapy (see DOSAGE AND ADMINISTRATION ). In using lisinopril and hydrochlorothiazide, consideration should be given to the fact that an angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that lisinopril does not have a similar risk (see WARNINGS ). In considering the use of lisinopril and hydrochlorothiazide, it should be noted that ACE inhibitors have been associated with a higher rate of angioedema in Black than in non-Black patients (see WARNINGS, Lisinopril ). uuid:342895c3-f2d1-4f95-abab-eb15904b4b24 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:85783 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:377c6c7c-9e92-4b03-a5de-a0856e89ce4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b46fd2c3-965c-429d-bbfe-d296b0260cf9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lisinopril and hydrochlorothiazide tablets USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including lisinopril and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in Black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. These fixed-dose combinations are not indicated for initial therapy (see DOSAGE AND ADMINISTRATION ). In using lisinopril and hydrochlorothiazide, consideration should be given to the fact that an angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that lisinopril does not have a similar risk (see WARNINGS ). In considering the use of lisinopril and hydrochlorothiazide, it should be noted that ACE inhibitors have been associated with a higher rate of angioedema in Black than in non-Black patients (see WARNINGS, Lisinopril ). uuid:68c3c8bd-5eb0-4c94-ad76-b3b02477c804 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:43755 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:43d59f86-d770-42cf-99fc-c9445cd1fb11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:65e5adf7-5c96-4a77-a289-ebbe2e01bb9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lisinopril tablets USP are indicated for the treatment of hypertension to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including lisinopril. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in Black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Lisinopril tablets USP may be administered alone or with other antihypertensive agents. uuid:9fda75f5-c495-41b5-a642-d8fee836f094 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:43755 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:918f5922-af23-4fd6-94d2-9fea921b0757"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8fbd08f9-488c-452b-b26b-0906558642d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lisinopril tablets USP are indicated for the treatment of hypertension to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including lisinopril. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in Black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Lisinopril tablets USP may be administered alone or with other antihypertensive agents. uuid:1cb6a5ab-353b-44c1-8a2f-2dcfacbe0c2a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:43755 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:bfd8fe20-fa31-4901-bcdf-5f064e10b579"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3c0748b3-19d3-42a5-ac77-4b05a4981dea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lisinopril tablets USP are indicated for the treatment of hypertension to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including lisinopril. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in Black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Lisinopril tablets USP may be administered alone or with other antihypertensive agents. uuid:e8ea9ab2-f11f-4f2a-8b79-8570070267aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:43755 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:110bb724-220f-445d-8e62-cff8c0e876ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7bf8802a-4ee4-4e3a-88ea-4b6b1197b7db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lisinopril tablets USP are indicated for the treatment of hypertension to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including lisinopril. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in Black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Lisinopril tablets USP may be administered alone or with other antihypertensive agents. uuid:7400caaa-a602-44e2-8481-b8b6cd2ce11c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:216653 biolink:treats MONDO:0006652 PMID:41385096 "[{""id"":""uuid:ab1a8481-e838-4d4e-af1e-dee281c01657"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a02f5a8f-7bd9-4f7e-b831-6804a75ea4ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Valsartan and hydrochlorothiazide tablet USP is the combination tablet of valsartan, an angiotensin II receptor blocker (ARB) and hydrochlorothiazide (HCTZ), a diuretic. Valsartan and hydrochlorothiazide tablet USP is indicated for the treatment of hypertension, to lower blood pressure: In patients not adequately controlled with monotherapy ( 1 ) As initial therapy in patients likely to need multiple drugs to achieve their blood pressure goals ( 1 ) Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. uuid:c9009fdc-3927-4dc2-b37a-0de17b3a351e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3515 biolink:treats MONDO:0004592 PMID:41385096 "[{""id"":""uuid:73ad6cbd-1701-4820-b809-c08b9e762952"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:229d01cc-287b-46e9-964f-f82f7613cf19"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NOTE: CEFUROXIME AXETIL TABLETS AND CEFUROXIME AXETIL FOR ORAL SUSPENSION ARE NOT BIOEQUIVALENT AND ARE NOT SUBSTITUTABLE ON A MILLIGRAM-PER-MILLIGRAM BASIS (SEE CLINICAL PHARMACOLOGY). Cefuroxime axetil for oral suspension is indicated for the treatment of pediatric patients 3 months to 12 years of age with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. The safety and effectiveness of cefuroxime axetil for oral suspension in the treatment of infections other than those specifically listed below have not been established either by adequate and well-controlled trials or by pharmacokinetic data with which to determine an effective and safe dosing regimen. Pharyngitis/Tonsillitis caused by Streptococcus pyogenes. NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefuroxime axetil for oral suspension is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cefuroxime in the subsequent prevention of rheumatic fever are not available. Please also note that in all clinical trials, all isolates had to be sensitive to both penicillin and cefuroxime. There are no data from adequate and well-controlled trials to demonstrate the effectiveness of cefuroxime in the treatment of penicillin-resistant strains of Streptococcus pyogenes. Acute Bacterial Otitis Media caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase-producing strains), Moraxella catarrhalis (including beta-lactamase-producing strains), or Streptococcus pyogenes. Impetigo caused by Staphylococcus aureus (including beta-lactamase-producing strains) or Streptococcus pyogenes. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefuroxime axetil for oral suspension and other antibacterial drugs, cefuroxime axetil for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:a0e35685-a0aa-4d66-b120-91193a0a0cd0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3996 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:d7242f44-ab97-4ac1-882a-d98ef4fc3955"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ffdc22f8-e9ee-467b-9658-2db7b6120ef7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclobenzaprine Hydrochloride Tablets USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine Hydrochloride Tablets USP should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine Hydrochloride Tablets USP have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy. uuid:22055872-da3a-4afd-b03e-29921cd890b1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3996 biolink:treats HP:0031058 PMID:41385096 "[{""id"":""uuid:decb5ad9-b2ad-4ae4-9f8a-08590caf1ec6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9a623716-4a93-4e3b-b9d0-f16266519daf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclobenzaprine Hydrochloride Tablets USP are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine Hydrochloride Tablets USP should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine Hydrochloride Tablets USP have not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy. uuid:dca9dd01-9fc4-40fe-80d8-5eed8d66b69c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6741 biolink:treats MONDO:0011429 PMID:41385096 "[{""id"":""uuid:e83ba167-5976-4909-8a80-00a23638556b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:85531594-3585-41b2-b0da-7b867d775469"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Meloxicam is a non-steroidal anti-inflammatory drug indicated for: • Osteoarthritis (OA) (1.1) • Rheumatoid Arthritis (RA) (1.2) • Juvenile Rheumatoid Arthritis (JRA) in patients 2 years of age or older (1.3) uuid:f9602ecb-0a4c-46d0-b617-9d7bb227f8a9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2904 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:efef2170-98e5-4886-bd76-65aa751fde96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:62c8a7eb-2def-4696-be03-860dc93b9e02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atenolol tablets USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including atenolol, USP. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Atenolol tablets USP may be administered with other antihypertensive agents. uuid:92c5ec6c-2a3b-449a-b8bc-09d61af3118f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5818 biolink:treats MONDO:0005492 PMID:41385096 "[{""id"":""uuid:c2cd3833-eb84-45c1-b023-a45150bc58d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5671f926-40ad-4435-a61e-023cd3045e21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For symptomatic relief of anxiety and tension associated with psychoneurosis and as an adjunct in organic disease states in which anxiety is manifested. Useful in the management of pruritus due to allergic conditions such as chronic urticarial and atopic and contact dermatoses and in histamine-mediated pruritus. As a sedative when used as a premedication and following general anesthesia, hydroxyzine may potentiate meperidine and barbiturates , so their use in pre-anesthetic adjunctive therapy should be modified on an individual basis. Atropine and other belladonna alkaloids are not affected by the drug. Hydroxyzine is not known to interfere with the action of digitalis in any way and it may be used concurrently with this agent. The effectiveness of hydroxyzine as an antianxiety agent for long term use, that is more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient. uuid:03e773e4-97f1-4bd4-a804-870743c07af7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6709 biolink:treats MONDO:0004900 PMID:41385096 "[{""id"":""uuid:ca82ec84-c461-4595-9df7-68d3e884ac5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0abd7c6f-d125-4e09-82cf-6193801e361b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS Based on a review of this drug by the National Academy of Sciences – National Research Council and/or other information, FDA has classified the indications as follows: Effective: Management of nausea and vomiting, and dizziness associated with motion sickness. Possibly Effective: Management of vertigo associated with diseases affecting the vestibular system. Final classification of the less than effective indications required further investigation. uuid:21ae0dfa-6668-40dc-8f49-5e1352b1e057 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3696 biolink:treats MONDO:0000878 PMID:41385096 "[{""id"":""uuid:de8d4f9a-d0a9-47aa-84ab-3c71db9b9fec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fd8539fc-7ea3-47df-b2c7-3255fa1f7327"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VISTIDE is indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). THE SAFETY AND EFFICACY OF VISTIDE HAVE NOT BEEN ESTABLISHED FOR TREATMENT OF OTHER CMV INFECTIONS (SUCH AS PNEUMONITIS OR GASTROENTERITIS), CONGENITAL OR NEONATAL CMV DISEASE, OR CMV DISEASE IN NON-HIV-INFECTED INDIVIDUALS. uuid:04d07ee0-dcd3-47ac-8ae1-15673c3ebf75 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3696 biolink:treats MONDO:0012268 PMID:41385096 "[{""id"":""uuid:24fcaac1-1a7e-4aab-a89b-2dc72cb2a1fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:82dca09c-542b-47b6-a228-0fac5de6644f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VISTIDE is indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). THE SAFETY AND EFFICACY OF VISTIDE HAVE NOT BEEN ESTABLISHED FOR TREATMENT OF OTHER CMV INFECTIONS (SUCH AS PNEUMONITIS OR GASTROENTERITIS), CONGENITAL OR NEONATAL CMV DISEASE, OR CMV DISEASE IN NON-HIV-INFECTED INDIVIDUALS. uuid:a6978790-fb17-42b7-907d-363aed57bc2c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:215703 biolink:treats MONDO:0020920 PMID:41385096 "[{""id"":""uuid:ecdb4a88-4bdc-436d-95a9-d7fad9f4adcd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:82bf3ef7-0b90-4a45-9cfc-c3b4e1c9f109"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A steroid/anti-infective combination is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular antibacterial drug in this product is active against the following common bacterial eye pathogens: Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus (viridans group ), Haemophilus influenzae, Klebsiella species , and Enterobacter species. This product does not provide adequate coverage against: Neisseria species , Pseudomonas species, and Serratia marcescens . A significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. uuid:f6ed288c-2f94-46e3-a6e5-9c15b30bbc3a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:215703 biolink:treats MONDO:0005545 PMID:41385096 "[{""id"":""uuid:ab2af762-c5e0-48fb-aea3-6744d7d18e16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:990340bf-c3cc-41f8-87e1-eec1e967ab4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A steroid/anti-infective combination is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular antibacterial drug in this product is active against the following common bacterial eye pathogens: Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus (viridans group ), Haemophilus influenzae, Klebsiella species , and Enterobacter species. This product does not provide adequate coverage against: Neisseria species , Pseudomonas species, and Serratia marcescens . A significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. uuid:b406be8e-d13c-4ba7-9df9-723cd9a0115a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:215703 biolink:treats MONDO:0005114 PMID:41385096 "[{""id"":""uuid:7e71721e-6aad-4516-9510-5b6f179bee68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:52133a13-65d8-4d75-850b-5d337f250a30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A steroid/anti-infective combination is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular antibacterial drug in this product is active against the following common bacterial eye pathogens: Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus (viridans group ), Haemophilus influenzae, Klebsiella species , and Enterobacter species. This product does not provide adequate coverage against: Neisseria species , Pseudomonas species, and Serratia marcescens . A significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. uuid:e235bc21-8dc1-4051-952b-4e026de81b08 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:215703 biolink:treats UMLS:C1096266 PMID:41385096 "[{""id"":""uuid:11a3f79a-fe5f-4010-bc3e-ca52fa0d5561"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:11f9a686-9c05-4862-93fa-840fbd9831ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A steroid/anti-infective combination is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular antibacterial drug in this product is active against the following common bacterial eye pathogens: Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus (viridans group ), Haemophilus influenzae, Klebsiella species , and Enterobacter species. This product does not provide adequate coverage against: Neisseria species , Pseudomonas species, and Serratia marcescens . A significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. uuid:d1adccde-b39a-4a94-a8c6-cbc264c84d3e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:215703 biolink:treats UMLS:C0348321 PMID:41385096 "[{""id"":""uuid:6c55ad92-d124-474e-b97c-b015ae8af0ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3803e0fe-a515-443a-964b-83d641103fa4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A steroid/anti-infective combination is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular antibacterial drug in this product is active against the following common bacterial eye pathogens: Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus (viridans group ), Haemophilus influenzae, Klebsiella species , and Enterobacter species. This product does not provide adequate coverage against: Neisseria species , Pseudomonas species, and Serratia marcescens . A significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. uuid:8e8f2682-ec5d-4645-967d-7fba38e5b7aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:215703 biolink:treats MONDO:0030603 PMID:41385096 "[{""id"":""uuid:960cf4d8-051c-4232-8c79-62d0751d7460"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bdb1ba3e-2ab1-4878-baed-36d1ee5b8738"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A steroid/anti-infective combination is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular antibacterial drug in this product is active against the following common bacterial eye pathogens: Escherichia coli, Staphylococcus aureus, Streptococcus pneumoniae, Streptococcus (viridans group ), Haemophilus influenzae, Klebsiella species , and Enterobacter species. This product does not provide adequate coverage against: Neisseria species , Pseudomonas species, and Serratia marcescens . A significant percentage of staphylococcal isolates are completely resistant to sulfa drugs. uuid:addaf0ea-595b-4433-82b0-0ccac0f1f352 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1155432 biolink:treats MONDO:0005578 PMID:41385096 "[{""id"":""uuid:abf17c2e-4433-4ef5-b6ea-896da30cbb03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:99a7e40b-4c96-4c25-8ba9-b81714e45b16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] USES: FOR THE TEMPORARY RELIEF OF MINOR ACHES AND PAINS OF MUSCLES AND JOINTS ASSOCIATED WITH ARTHRITIS, SIMPLE BACKACHE, STRAINS, SPRAINS, MUSCLE SORENESS AND STIFFNESS. uuid:92b842e7-1e53-4f04-be1f-02bbc4306aa2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1155432 biolink:treats UMLS:C0038045 PMID:41385096 "[{""id"":""uuid:1bcecf09-834a-4d4c-955b-5f003bcdd0ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3af4ed4e-c3bd-4560-a1da-a0e4eed8b1b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] USES: FOR THE TEMPORARY RELIEF OF MINOR ACHES AND PAINS OF MUSCLES AND JOINTS ASSOCIATED WITH ARTHRITIS, SIMPLE BACKACHE, STRAINS, SPRAINS, MUSCLE SORENESS AND STIFFNESS. uuid:b093140c-7dd2-4915-b5ef-e15b61819778 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1155432 biolink:treats HP:0003326 PMID:41385096 "[{""id"":""uuid:07dc3aec-77a0-4126-b6e8-3f9c5b3672db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7488c285-2bf8-40cc-b842-424a1cb05ac7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] USES: FOR THE TEMPORARY RELIEF OF MINOR ACHES AND PAINS OF MUSCLES AND JOINTS ASSOCIATED WITH ARTHRITIS, SIMPLE BACKACHE, STRAINS, SPRAINS, MUSCLE SORENESS AND STIFFNESS. uuid:e46103c5-d576-4dcd-b926-3b0935d517a0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1155432 biolink:treats HP:0003552 PMID:41385096 "[{""id"":""uuid:c04e0a33-1881-49f0-b243-78bdd6d60704"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:083db426-7fd5-4e00-952e-40d51548a482"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] USES: FOR THE TEMPORARY RELIEF OF MINOR ACHES AND PAINS OF MUSCLES AND JOINTS ASSOCIATED WITH ARTHRITIS, SIMPLE BACKACHE, STRAINS, SPRAINS, MUSCLE SORENESS AND STIFFNESS. uuid:4a17c67c-1b40-4c9c-a283-4de15940beaf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27446 biolink:treats MONDO:0004867 PMID:41385096 "[{""id"":""uuid:e16bd622-0f93-4500-bd65-b5e4704a0459"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c8c3000a-2204-49b6-8f17-65d4eeaadb64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Penicillin V Potassium Tablets, Penicillin V Potassium for Oral Solution and other antibacterial drugs, Penicillin V Potassium Tablets, and Penicillin V Potassium for Oral Solution should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antimicrobial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V Potassium Tablets, USP and Penicillin V Potassium for Oral Solution, USP, are indicated in the treatment of mild to moderately severe infections due to penicillin G sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following Infections will usually respond to adequate dosage of Penicillin V: Streptococcal infections (without bacteremia): Mild to moderate infections of the upper respiratory tract, scarlet fever and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus) are resistant. Pneumococcal infections: Mild to moderately severe infections of the respiratory tract. Staphylococcal infections - penicillin G sensitive: Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent's gingivitis and pharyngitis): Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involving the gum tissue. Medical conditions in which oral penicillin therapy is indicated as prophylaxis: For the prevention of recurrence following rheumatic fever and/or chorea: Prophylaxis with oral penicillin on a continuing basis has proven effective in preventing recurrence of these conditions. Although no controlled clinical efficacy studies have been conducted, penicillin V has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients with congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract. 1 Oral penicillin should not be used in those patients at particularly high risk for endocarditis (e.g. those with prosthetic heart valves or surgically constructed systemic pulmonary shunts). Penicillin V should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower-intestinal tract surgery, sigmoidoscopy, and childbirth. Since it may happen that alpha haemolytic streptococci relatively resistant to penicillin may be found when patients are receiving continuous oral penicillin for secondary prevention of rheumatic fever, prophylactic agents, other than penicillin may be chosen for these patients and prescribed in addition to their continuous rheumatic fever prophylactic regimen. NOTE: When selecting antibiotics for the prevention of bacterial endocarditis, the physician or dentist should read the full joint statement of the American Heart Association and the American Dental Association. 1 uuid:973ec903-5f6a-4388-bd60-a4ce33352880 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27446 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:4b59d357-33fe-40ec-82a2-8799901455c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cbbc1d11-cc29-493b-9de7-6f5fad944800"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Penicillin V Potassium Tablets, Penicillin V Potassium for Oral Solution and other antibacterial drugs, Penicillin V Potassium Tablets, and Penicillin V Potassium for Oral Solution should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antimicrobial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V Potassium Tablets, USP and Penicillin V Potassium for Oral Solution, USP, are indicated in the treatment of mild to moderately severe infections due to penicillin G sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following Infections will usually respond to adequate dosage of Penicillin V: Streptococcal infections (without bacteremia): Mild to moderate infections of the upper respiratory tract, scarlet fever and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus) are resistant. Pneumococcal infections: Mild to moderately severe infections of the respiratory tract. Staphylococcal infections - penicillin G sensitive: Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent's gingivitis and pharyngitis): Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involving the gum tissue. Medical conditions in which oral penicillin therapy is indicated as prophylaxis: For the prevention of recurrence following rheumatic fever and/or chorea: Prophylaxis with oral penicillin on a continuing basis has proven effective in preventing recurrence of these conditions. Although no controlled clinical efficacy studies have been conducted, penicillin V has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients with congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract. 1 Oral penicillin should not be used in those patients at particularly high risk for endocarditis (e.g. those with prosthetic heart valves or surgically constructed systemic pulmonary shunts). Penicillin V should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower-intestinal tract surgery, sigmoidoscopy, and childbirth. Since it may happen that alpha haemolytic streptococci relatively resistant to penicillin may be found when patients are receiving continuous oral penicillin for secondary prevention of rheumatic fever, prophylactic agents, other than penicillin may be chosen for these patients and prescribed in addition to their continuous rheumatic fever prophylactic regimen. NOTE: When selecting antibiotics for the prevention of bacterial endocarditis, the physician or dentist should read the full joint statement of the American Heart Association and the American Dental Association. 1 uuid:d150c1c6-9b33-4e38-aa88-136f71dfe9d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27446 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:6ab09e1e-c247-434f-954d-279c7dc39b41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f529454f-cbe9-4527-89f4-760eeb4be21b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Penicillin V Potassium Tablets, Penicillin V Potassium for Oral Solution and other antibacterial drugs, Penicillin V Potassium Tablets, and Penicillin V Potassium for Oral Solution should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antimicrobial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Penicillin V Potassium Tablets, USP and Penicillin V Potassium for Oral Solution, USP, are indicated in the treatment of mild to moderately severe infections due to penicillin G sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following Infections will usually respond to adequate dosage of Penicillin V: Streptococcal infections (without bacteremia): Mild to moderate infections of the upper respiratory tract, scarlet fever and mild erysipelas. NOTE: Streptococci in groups A, C, G, H, L, and M are very sensitive to penicillin. Other groups, including group D (enterococcus) are resistant. Pneumococcal infections: Mild to moderately severe infections of the respiratory tract. Staphylococcal infections - penicillin G sensitive: Mild infections of the skin and soft tissues. NOTE: Reports indicate an increasing number of strains of staphylococci resistant to penicillin G, emphasizing the need for culture and sensitivity studies in treating suspected staphylococcal infections. Fusospirochetosis (Vincent's gingivitis and pharyngitis): Mild to moderately severe infections of the oropharynx usually respond to therapy with oral penicillin. NOTE: Necessary dental care should be accomplished in infections involving the gum tissue. Medical conditions in which oral penicillin therapy is indicated as prophylaxis: For the prevention of recurrence following rheumatic fever and/or chorea: Prophylaxis with oral penicillin on a continuing basis has proven effective in preventing recurrence of these conditions. Although no controlled clinical efficacy studies have been conducted, penicillin V has been suggested by the American Heart Association and the American Dental Association for use as an oral regimen for prophylaxis against bacterial endocarditis in patients with congenital heart disease or rheumatic or other acquired valvular heart disease when they undergo dental procedures and surgical procedures of the upper respiratory tract. 1 Oral penicillin should not be used in those patients at particularly high risk for endocarditis (e.g. those with prosthetic heart valves or surgically constructed systemic pulmonary shunts). Penicillin V should not be used as adjunctive prophylaxis for genitourinary instrumentation or surgery, lower-intestinal tract surgery, sigmoidoscopy, and childbirth. Since it may happen that alpha haemolytic streptococci relatively resistant to penicillin may be found when patients are receiving continuous oral penicillin for secondary prevention of rheumatic fever, prophylactic agents, other than penicillin may be chosen for these patients and prescribed in addition to their continuous rheumatic fever prophylactic regimen. NOTE: When selecting antibiotics for the prevention of bacterial endocarditis, the physician or dentist should read the full joint statement of the American Heart Association and the American Dental Association. 1 uuid:b5171cba-7ca5-4788-bb61-b988e84ea2ee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151399 biolink:treats MONDO:0043579 PMID:41385096 "[{""id"":""uuid:562dfc98-37da-49a3-919e-5698b3eea5e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:692dd4a8-a0ef-4e77-9e32-1752e66981ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets, USP and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Urinary Tract Infections: For the treatment of urinary tract infections due to susceptible strains of the following organisms: Escherichia coli , Klebsiella species, Enterobacter species, Morganella morganii , Proteus mirabilis and Proteus vulgaris . It is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. Acute Otitis Media: For the treatment of acute otitis media in pediatric patients due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of other antimicrobial agents. To date, there are limited data on the safety of repeated use of sulfamethoxazole and trimethoprim in pediatric patients under two years of age. Sulfamethoxazole and trimethoprim is not indicated for prophylactic or prolonged administration in otitis media at any age. Acute Exacerbations of Chronic Bronchitis in Adults: For the treatment of acute exacerbations of chronic bronchitis due to susceptible strains of Streptococcus pneumoniae or Haemophilus influenzae when in the judgment of the physician sulfamethoxazole and trimethoprim offers some advantage over the use of a single antimicrobial agent. Shigellosis: For the treatment of enteritis caused by susceptible strains of Shigella flexneri and Shigella sonnei when antibacterial therapy is indicated. Pneumocystis Jiroveci Pneumonia: For the treatment of documented Pneumocystis jiroveci pneumonia and for prophylaxis against Pneumocystis jiroveci pneumonia in individuals who are immunosuppressed and considered to be at an increased risk of developing Pneumocystis jiroveci pneumonia. Traveler’s Diarrhea in Adults: For the treatment of traveler’s diarrhea due to susceptible strains of enterotoxigenic E. coli . uuid:ffc68bce-194c-44fc-993f-f0f7f8131f94 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63619 biolink:treats HP:0001692 PMID:41385096 "[{""id"":""uuid:293d2cf2-d59e-4e4f-afbc-a3d91759002a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1f9169f6-95da-4481-aaf7-7c270153f27e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In patients without structural heart disease, propafenone is indicated to prolong the time to recurrence of – paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms. – paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms. As with other agents, some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional AV refractory period is recommended. The use of propafenone HCl in patients with chronic atrial fibrillation has not been evaluated. Propafenone HCl should not be used to control ventricular rate during atrial fibrillation. Propafenone HCl is also indicated for the treatment of – documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgment of the physician, are life-threatening. Because of the proarrhythmic effects of propafenone HCl, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks. Initiation of propafenone HCl treatment, as with other antiarrhythmics used to treat life-threatening ventricular arrhythmias, should be carried out in the hospital. Propafenone HCl, like other antiarrhythmic drugs, has not been shown to enhance survival in patients with ventricular or atrial arrhythmias. uuid:e7271144-2c9b-4bd3-950e-13edf1904b51 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:85783 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:7d28f8b9-115c-4a58-95f5-a4513714b1a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:47959862-8212-45b9-a1a5-4935e54ac043"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lisinopril and hydrochlorothiazide tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including lisinopril and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (eg, on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. These fixed-dose combinations are not indicated for initial therapy (see DOSAGE AND ADMINISTRATION ). In using lisinopril and hydrochlorothiazide tablets, USP, consideration should be given to the fact that an angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that lisinopril does not have a similar risk (See WARNINGS ). In considering the use of lisinopril and hydrochlorothiazide tablets, USP, it should be noted that ACE inhibitors have been associated with a higher rate of angioedema in black than in nonblack patients (see WARNINGS, Lisinopril ). uuid:ce1eb02f-510c-49ab-9c31-445610715cbb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:85783 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:e159466b-bca7-4dc1-837d-b428a7f5fb26"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:70120195-f295-43f7-b6dc-f64e72b5483b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lisinopril and hydrochlorothiazide tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including lisinopril and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (eg, on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. These fixed-dose combinations are not indicated for initial therapy (see DOSAGE AND ADMINISTRATION ). In using lisinopril and hydrochlorothiazide tablets, USP, consideration should be given to the fact that an angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that lisinopril does not have a similar risk (See WARNINGS ). In considering the use of lisinopril and hydrochlorothiazide tablets, USP, it should be noted that ACE inhibitors have been associated with a higher rate of angioedema in black than in nonblack patients (see WARNINGS, Lisinopril ). uuid:8062b411-fc5d-440d-b062-5923f44e82c3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:85783 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:b8064270-7c56-4bac-bfcc-341cdb9dee30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a9c9d2a4-ac12-4fa8-a8fe-259242d6ba67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lisinopril and hydrochlorothiazide tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including lisinopril and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (eg, on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. These fixed-dose combinations are not indicated for initial therapy (see DOSAGE AND ADMINISTRATION ). In using lisinopril and hydrochlorothiazide tablets, USP, consideration should be given to the fact that an angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that lisinopril does not have a similar risk (See WARNINGS ). In considering the use of lisinopril and hydrochlorothiazide tablets, USP, it should be noted that ACE inhibitors have been associated with a higher rate of angioedema in black than in nonblack patients (see WARNINGS, Lisinopril ). uuid:c3602367-0f18-470f-9f4a-be68cc16f17b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:85783 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:1edbb615-52e3-47b0-892e-779959d1c5ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b7df6fad-2ff0-459c-a389-0b4e7ddec76d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lisinopril and hydrochlorothiazide tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including lisinopril and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (eg, on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. These fixed-dose combinations are not indicated for initial therapy (see DOSAGE AND ADMINISTRATION ). In using lisinopril and hydrochlorothiazide tablets, USP, consideration should be given to the fact that an angiotensin-converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that lisinopril does not have a similar risk (See WARNINGS ). In considering the use of lisinopril and hydrochlorothiazide tablets, USP, it should be noted that ACE inhibitors have been associated with a higher rate of angioedema in black than in nonblack patients (see WARNINGS, Lisinopril ). uuid:52d028aa-4642-4967-9170-742531d4e0e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22652 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:d84699ba-e4cb-4e50-9b55-12f6b7d75c8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:859a2ecc-26a6-4d26-9a4c-36cec585ceea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In the wasting syndrome in chronic renal failure; uremia; impaired metabolic functions of the kidney and to maintain levels when dietary intake of vitamins is inadequate or excretion or loss in excessive. Also, highly effective as a stress vitamin. uuid:66fba8bd-162d-47e5-8768-ccd64c605239 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22652 biolink:treats MONDO:0007008 PMID:41385096 "[{""id"":""uuid:7f881210-d451-4f14-9eca-3cca9dc2e04e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f83ee0a5-4bdf-485e-8cbc-f237f9360ded"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In the wasting syndrome in chronic renal failure; uremia; impaired metabolic functions of the kidney and to maintain levels when dietary intake of vitamins is inadequate or excretion or loss in excessive. Also, highly effective as a stress vitamin. uuid:fa4e6533-950c-463f-bc02-0d02a7fd9c7f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3213 biolink:treats HP:0000969 PMID:41385096 "[{""id"":""uuid:0359cd70-d28f-4056-9baa-ef90f1a83d95"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6e97baf7-1ffe-4e72-9e6c-370a03d29541"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bumetanide tablets are indicated for the treatment of edema associated with congestive heart failure, hepatic and renal disease, including the nephrotic syndrome. Almost equal diuretic response occurs after oral and parenteral administration of bumetanide. Therefore, if impaired gastrointestinal absorption is suspected or oral administration is not practical, bumetanide should be given by the intramuscular or intravenous route. Successful treatment with bumetanide following instances of allergic reactions to furosemide suggests a lack of cross-sensitivity. uuid:93b11793-60bb-4a4a-a5c3-d37f7ae18f42 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3044 biolink:treats NCIT:C120380 PMID:41385096 "[{""id"":""uuid:0efa12d2-ed46-4b26-a721-a79435248666"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:58dc48b3-8eea-41f0-89cd-971a913c0aac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Benzphetamine Hydrochloride Tablets are indicated in the management of exogenous obesity as a short term (a few weeks) adjunct in a regimen of weight reduction based on caloric restriction in patients with an initial body mass index (BMI) of 30 kg/m2 or higher who have not responded to appropriate weight reducing regimen (diet and/or exercise) alone. Below is a chart of Body Mass Index (BMI) based on various heights and weights. BMI is calculated by taking the patient's weight, in kilograms (kg), divided by the patient's height, in meters (m), squared. Metric conversions are as follows: pounds ÷2.2 = kg; inches × 0.0254 = meters. The limited usefulness of agents of this class (See CLINICAL PHARMACOLOGY ) should be weighed against possible risks inherent in their use such as those described below. BODY MASS INDEX (BMI), kg/m 2 Weight (pounds) Height (feet, inches) 5'0"" 5'3"" 5'6"" 5'9"" 6'0"" 6'3"" 140 27 25 23 21 19 18 150 29 27 24 22 20 19 160 31 28 26 24 22 20 170 33 30 28 25 23 21 180 35 32 29 27 25 23 190 37 34 31 28 26 24 200 39 36 32 30 27 25 210 41 37 34 31 29 26 220 43 39 36 33 30 28 230 45 41 37 34 31 29 240 47 43 39 36 33 30 250 49 44 40 37 34 31 Benzphetamine Hydrochloride Tablets are indicated for use as monotherapy only." uuid:d6d91bd0-76b8-4de3-8934-2a8331bd8e80 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5296 biolink:treats MONDO:0007750 PMID:41385096 "[{""id"":""uuid:71d4b57d-dd0d-483e-b3a8-42f0b80f3c21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:be633b37-9b42-45d9-aaed-3c745c210dc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gemfibrozil tablets, USP are indicated as adjunctive therapy to diet for: Treatment of adult patients with very high elevations of serum triglyceride levels (Types IV and V hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Patients who present such risk typically have serum triglycerides over 2000 mg/dL and have elevations of VLDL-cholesterol as well as fasting chylomicrons (Type V hyperlipidemia). Subjects who consistently have total serum or plasma triglycerides below 1000 mg/dL are unlikely to present a risk of pancreatitis. Gemfibrozil therapy may be considered for those subjects with triglyceride elevations between 1000 and 2000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. It is recognized that some Type IV patients with triglycerides under 1000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of gemfibrozil therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia. Reducing the risk of developing coronary heart disease only in Type IIb patients without history of or symptoms of existing coronary heart disease who have had an inadequate response to weight loss, dietary therapy, exercise, and other pharmacologic agents (such as bile acid sequestrants and nicotinic acid, known to reduce LDL- and raise HDL-cholesterol) and who have the following triad of lipid abnormalities: low HDL-cholesterol levels in addition to elevated LDL-cholesterol and elevated triglycerides (see WARNINGS , PRECAUTIONS , and CLINICAL PHARMACOLOGY ). The National Cholesterol Education Program has defined a serum HDL-cholesterol value that is consistently below 35 mg/dL as constituting an independent risk factor for coronary heart disease. Patients with significantly elevated triglycerides should be closely observed when treated with gemfibrozil. In some patients with high triglyceride levels, treatment with gemfibrozil is associated with a significant increase in LDL-cholesterol. BECAUSE OF POTENTIAL TOXICITY SUCH AS MALIGNANCY, GALLBLADDER DISEASE, ABDOMINAL PAIN LEADING TO APPENDECTOMY AND OTHER ABDOMINAL SURGERIES, AN INCREASED INCIDENCE IN NON-CORONARY MORTALITY, AND THE 44% RELATIVE INCREASE DURING THE TRIAL PERIOD IN AGE-ADJUSTED ALL-CAUSE MORTALITY SEEN WITH THE CHEMICALLY AND PHARMACOLOGICALLY RELATED DRUG, CLOFIBRATE, THE POTENTIAL BENEFIT OF GEMFIBROZIL IN TREATING TYPE IIA PATIENTS WITH ELEVATIONS OF LDL-CHOLESTEROL ONLY IS NOT LIKELY TO OUTWEIGH THE RISKS. GEMFIBROZIL IS ALSO NOT INDICATED FOR THE TREATMENT OF PATIENTS WITH LOW HDL-CHOLESTEROL AS THEIR ONLY LIPID ABNORMALITY. In a subgroup analysis of patients in the Helsinki Heart Study with above-median HDL-cholesterol values at baseline (greater than 46.4 mg/dL), the incidence of serious coronary events was similar for gemfibrozil and placebo subgroups (see Table I). The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcohol intake may be important factors in hypertriglyceridemia and should be managed prior to any drug therapy. Physical exercise can be an important ancillary measure, and has been associated with rises in HDL-cholesterol. Diseases contributory to hyperlipidemia such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy is sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of estrogen therapy may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with nondrug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet. uuid:8055566b-df9e-45e7-9c2a-2c0f1352b981 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63618 biolink:treats UMLS:C0342882 PMID:41385096 "[{""id"":""uuid:f15f6ea6-0f4d-4ba4-b1fb-1de0f3375600"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e10a8f0c-42cc-43a6-a9e7-242c43778b19"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pravastatin sodium tablet is an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: Reduce the risk of MI, revascularization, and cardiovascular mortality in hypercholesterolemic patients without clinically evident CHD. ( 1.1 ) Reduce elevated Total-C, LDL-C, ApoB, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia. ( 1.2 ) Reduce elevated serum TG levels in patients with hypertriglyceridemia. ( 1.2 ) Treat patients with primary dysbetalipoproteinemia who are not responding to diet. ( 1.2 ) Treat children and adolescent patients ages 8 years and older with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy. ( 1.2 ) Limitations of use: Pravastatin sodium tablets have not been studied in Fredrickson Types I and V dyslipidemias. ( 1.3 ) uuid:0c56707d-12e3-4137-9ae2-fe211ba2e554 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7660 biolink:treats UMLS:C0343886 PMID:41385096 "[{""id"":""uuid:92f61fdd-a319-4854-ab39-8acd00533f9d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d1a8e218-0d90-4ef5-9f4f-6f401f9ce7c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nystatin tablets are intended for the treatment of non-esophageal mucus membrane gastrointestinal candidiasis. uuid:66106f60-81ad-4643-bc42-2acfcf7a6dba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:43755 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:e49eee46-46d0-4869-b0e3-dd254a894ddb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0918570c-282c-4837-85af-65c8194715f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lisinopril tablets USP are indicated for the treatment of hypertension to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including lisinopril. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g, on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Lisinopril tablets USP may be administered alone or with other antihypertensive agents. uuid:ee508ab6-307d-4f55-8a33-89dbcf1b667f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:43755 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:6a321ce4-f7ce-45b6-abb3-42d403218f56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dde55a7c-3652-4908-a3a0-886b2bebbf1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lisinopril tablets USP are indicated for the treatment of hypertension to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including lisinopril. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g, on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Lisinopril tablets USP may be administered alone or with other antihypertensive agents. uuid:38749dd9-27a3-4459-afc4-aa115d7cc1c3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8364 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:9344e9e5-314b-4afe-9dc9-d5038c641f22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4a747e79-a029-4d58-b920-dc761a688f52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prazosin hydrochloride capsules are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Prazosin hydrochloride capsules can be used alone or in combination with other antihypertensive drugs such as diuretics or beta-adrenergic blocking agents. uuid:db982a3c-602b-4b9b-a965-057d46896442 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8364 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:aea96825-7eb4-40d6-8427-b01be2f48911"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:66b37795-f4c8-4f25-82e4-47ac1c4330ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prazosin hydrochloride capsules are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Prazosin hydrochloride capsules can be used alone or in combination with other antihypertensive drugs such as diuretics or beta-adrenergic blocking agents. uuid:f2d7969a-8ed5-4fb5-a7a9-9506d68da58c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8364 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:39d40288-0ce1-4457-9248-10bd03b221ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6b9bbb28-be34-4987-9e15-6437ca2732a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prazosin hydrochloride capsules are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Prazosin hydrochloride capsules can be used alone or in combination with other antihypertensive drugs such as diuretics or beta-adrenergic blocking agents. uuid:f6551772-9c60-4e60-9126-42b473224ed6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8364 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:3aa88b8e-7b1f-440e-a0a2-aa6df4562c0c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8e597a2e-b8d4-4257-9f2f-2e07be8ea65e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prazosin hydrochloride capsules are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Prazosin hydrochloride capsules can be used alone or in combination with other antihypertensive drugs such as diuretics or beta-adrenergic blocking agents. uuid:d14ba720-a3c0-4386-bace-6599e73bbe83 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8364 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:10421dae-1db8-407e-85f7-8a66c1a22b18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:472d0b6d-2721-425c-9e5f-c6ec33589574"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prazosin hydrochloride capsules are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Prazosin hydrochloride capsules can be used alone or in combination with other antihypertensive drugs such as diuretics or beta-adrenergic blocking agents. uuid:d53794d5-e7e4-4113-ad5d-2c622c8e9eee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8364 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:4203143f-f9db-457a-905a-58ea0ce6f0cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8df6c861-718f-43f5-b576-44621a95742f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prazosin hydrochloride capsules are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Prazosin hydrochloride capsules can be used alone or in combination with other antihypertensive drugs such as diuretics or beta-adrenergic blocking agents. uuid:14413ecf-ccc4-496b-821b-2611a0e83fb6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8364 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:2c61e9ac-f146-4802-8f66-adb73251e8b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fb20834c-5b43-407a-a201-0a960f422cf8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prazosin hydrochloride capsules are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Prazosin hydrochloride capsules can be used alone or in combination with other antihypertensive drugs such as diuretics or beta-adrenergic blocking agents. uuid:ebef6d61-ef30-454e-8664-1ea6c62df3ea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0005136 PMID:41385096 "[{""id"":""uuid:91507e9a-dd85-4c6f-a8fb-31c54c0e719f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1f2dec76-78b8-45d0-86ea-7b7ac466ad63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline hyclate tablets and other antibacterial drugs, doxycycline hyclate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment: Doxycycline is indicated for the treatment of the following infections: • Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae. • Respiratory tract infections caused by Mycoplasma pneumoniae. • Lymphogranuloma venereum caused by Chlamydia trachomatis . • Psittacosis (ornithosis) caused by Chlamydophila psittaci . • Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. • Inclusion conjunctivitis caused by Chlamydia trachomatis . • Uncomplicated urethral, endocervical, or rectal infections in adults caused by Chlamydia trachomatis . • Nongonococcal urethritis caused by Ureaplasma urealyticum . • Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: • Chancroid caused by Haemophilus ducreyi . • Plague due to Yersinia pestis . • Tularemia due to Francisella tularensis . • Cholera caused by Vibrio cholerae . • Campylobacter fetus infections caused by Campylobacter fetus (formerly Vibrio fetus ). • Brucellosis due to Brucella species (in conjunction with streptomycin). • Bartonellosis due to Bartonella bacilliformis . • Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative bacteria, when bacteriologic testing indicates appropriate susceptibility to the drug: • Escherichia coli . • Enterobacter aerogenes (formerly Aerobacter aerogenes ). • Shigella species. • Acinetobacter species. • Respiratory tract infections caused by Haemophilus influenzae . • Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: • Upper respiratory infections caused by Streptococcus pneumoniae (formerly Diplococcus pneumoniae ). • Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: • Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . • Syphilis caused by Treponema pallidum . • Yaws caused by Treponema pertenue . • Listeriosis due to Listeria monocytogenes . • Vincent’s infection caused by Fusobacterium fusiforme . • Actinomycosis caused by Actinomyces israelii . • Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. Prophylaxis: Doxycycline is indicated for the prophylaxis of malaria due to Plasmodium falciparum in short-term travelers (<4 months) to areas with chloroquine and/or pyrimethamine-sulfadoxine resistant strains. (See DOSAGE AND ADMINISTRATION section and Information for Patients subsection of the PRECAUTIONS section.) uuid:1437526f-a3f5-470a-a5ff-e5cf365651bd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77363 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:fd3a6c5e-1b32-4b49-aded-3d04270aeed2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:56c04d15-3460-43c8-b781-69fa0c242864"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ramipril capsules, USP is an angiotensin converting enzyme (ACE) inhibitor indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. It may be used alone or in combination with thiazide diuretics (1.1) . Ramipril capsules, USP are indicated in stable patients who have demonstrated clinical signs of congestive heart failure post-myocardial infarction (1.3) . uuid:267612da-690d-4edc-b4a2-c4e45eeb308a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77363 biolink:treats MONDO:0006652 PMID:41385096 "[{""id"":""uuid:81a00ac7-7c56-4783-b1d9-c33f86947002"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6706e361-52da-4974-8a19-005f1a204e63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ramipril capsules, USP is an angiotensin converting enzyme (ACE) inhibitor indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. It may be used alone or in combination with thiazide diuretics (1.1) . Ramipril capsules, USP are indicated in stable patients who have demonstrated clinical signs of congestive heart failure post-myocardial infarction (1.3) . uuid:2c7a3020-bd29-4ab4-b917-24d6d24b0a40 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9334 biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:16e9aa93-37e3-4e7c-a84a-3dcadc297416"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ee5db4af-ae0a-4d8d-b70d-b7fbc5cefdde"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sulfasalazine tablets, USP are indicated: in the treatment of mild to moderate ulcerative colitis, and as adjunctive therapy in severe ulcerative colitis; and for the prolongation of the remission period between acute attacks of ulcerative colitis. uuid:67598966-6167-4caa-b5be-a1e4f91934ee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats HP:0000989 PMID:41385096 "[{""id"":""uuid:9f2beb2a-de36-4ac4-be0b-a0208cbd44ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8fbd4ddd-2611-4c72-adbb-ee496466cfe2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Anesthetic for relief of pruritus, pruritic eczemas, abrasions, minor burns, insect bites, pain, soreness and discomfort due to pruritus ani, pruritus vulvae,hemorrhoids, anal fissures, and similar conditions of the skin and mucous membranes. uuid:92dfe76e-efcd-4259-98fc-d0196d86114c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0002406 PMID:41385096 "[{""id"":""uuid:9d470234-b767-4793-91d9-eecb5aa0a18c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2c457676-470a-432d-aef8-c35c1766a71d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Anesthetic for relief of pruritus, pruritic eczemas, abrasions, minor burns, insect bites, pain, soreness and discomfort due to pruritus ani, pruritus vulvae,hemorrhoids, anal fissures, and similar conditions of the skin and mucous membranes. uuid:84b8c47c-bca1-4cc3-a03c-3dd2a72f0ab5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats NCIT:C50748 PMID:41385096 "[{""id"":""uuid:da61dc17-b489-49e1-ac44-165d0efcc6b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c53b5928-c8c3-44f3-b4f1-38e55ff08d29"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Anesthetic for relief of pruritus, pruritic eczemas, abrasions, minor burns, insect bites, pain, soreness and discomfort due to pruritus ani, pruritus vulvae,hemorrhoids, anal fissures, and similar conditions of the skin and mucous membranes. uuid:4bb342f9-8a45-4e07-90b1-4aed39fe58d1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0001918 PMID:41385096 "[{""id"":""uuid:1769232e-dc0a-4214-9c74-872cd679f176"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9c555e66-4b65-443f-bb19-f0960e1a4c98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Anesthetic for relief of pruritus, pruritic eczemas, abrasions, minor burns, insect bites, pain, soreness and discomfort due to pruritus ani, pruritus vulvae,hemorrhoids, anal fissures, and similar conditions of the skin and mucous membranes. uuid:10927ac9-06e2-4377-a0fa-45da7d906a28 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats HP:0032004 PMID:41385096 "[{""id"":""uuid:ff22777a-c75f-4a99-a812-a1b1ba8ff610"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4c33ff29-5901-43df-a754-ebcd1c4fd73e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Anesthetic for relief of pruritus, pruritic eczemas, abrasions, minor burns, insect bites, pain, soreness and discomfort due to pruritus ani, pruritus vulvae,hemorrhoids, anal fissures, and similar conditions of the skin and mucous membranes. uuid:db849f5e-d1d7-487b-83a6-f329d9a078f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0004872 PMID:41385096 "[{""id"":""uuid:64b4a313-09cc-42c4-a15c-8d843f96b9ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ae321a50-6493-4598-b906-845f6377bab7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Anesthetic for relief of pruritus, pruritic eczemas, abrasions, minor burns, insect bites, pain, soreness and discomfort due to pruritus ani, pruritus vulvae,hemorrhoids, anal fissures, and similar conditions of the skin and mucous membranes. uuid:ae935ca9-8302-4f73-ad38-306bbdb42415 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats HP:0012390 PMID:41385096 "[{""id"":""uuid:aac99d8d-ee1b-4370-86f1-b6cf9b0800e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:770fef03-923b-4849-9e8e-57ce4b409faf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Anesthetic for relief of pruritus, pruritic eczemas, abrasions, minor burns, insect bites, pain, soreness and discomfort due to pruritus ani, pruritus vulvae,hemorrhoids, anal fissures, and similar conditions of the skin and mucous membranes. uuid:3779282e-ddc3-42b9-a30b-7dffb8edd52c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats MONDO:0001358 PMID:41385096 "[{""id"":""uuid:e056bf2c-b10c-44b0-ad8b-e96b1b4423f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8ebda2a2-1420-401a-9fc9-0247ed17518f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In general, the most common uses of epinephrine are to relieve respiratory distress due to bronchospasm, to provide rapid relief of hypersensitivity reactions to drugs and other allergens, and to prolong the action of infiltration anesthetics. Its cardiac effects may be of use in restoring cardiac rhythm in cardiac arrest due to various causes, but it is not used in cardiac failure or in hemorrhagic, traumatic, or cardiogenic shock. Epinephrine is used as a hemostatic agent. It is also used in treating mucosal congestion of hay fever, rhinitis and acute sinusitis; to relieve bronchial asthmatic paroxysms; in syncope due to complete heart block or carotid sinus hypersensitivity; for symptomatic relief of serum sickness, urticaria, angioneurotic edema; for resuscitation in cardiac arrest following anesthetic accidents; in simple (open angle) glaucoma; for relaxation of uterine musculature and to inhibit uterine contractions. Epinephrine injection can be utilized to prolong the action of local anesthetics (see CONTRAINDICATIONS). uuid:4d41bf3f-f177-4434-b9a4-7476d2bcf3f6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats MONDO:0000605 PMID:41385096 "[{""id"":""uuid:0efd3724-3096-455f-899e-e31bf6697bc4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d82ef4cc-55fe-49ff-8270-95d8a49c28e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In general, the most common uses of epinephrine are to relieve respiratory distress due to bronchospasm, to provide rapid relief of hypersensitivity reactions to drugs and other allergens, and to prolong the action of infiltration anesthetics. Its cardiac effects may be of use in restoring cardiac rhythm in cardiac arrest due to various causes, but it is not used in cardiac failure or in hemorrhagic, traumatic, or cardiogenic shock. Epinephrine is used as a hemostatic agent. It is also used in treating mucosal congestion of hay fever, rhinitis and acute sinusitis; to relieve bronchial asthmatic paroxysms; in syncope due to complete heart block or carotid sinus hypersensitivity; for symptomatic relief of serum sickness, urticaria, angioneurotic edema; for resuscitation in cardiac arrest following anesthetic accidents; in simple (open angle) glaucoma; for relaxation of uterine musculature and to inhibit uterine contractions. Epinephrine injection can be utilized to prolong the action of local anesthetics (see CONTRAINDICATIONS). uuid:e2515bf0-4cb4-4b70-9532-4082de19942a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:c0376031-3f5a-4ef8-87c9-2b192af2c084"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a005f475-a3da-414a-b5fe-7ac236a25c69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In general, the most common uses of epinephrine are to relieve respiratory distress due to bronchospasm, to provide rapid relief of hypersensitivity reactions to drugs and other allergens, and to prolong the action of infiltration anesthetics. Its cardiac effects may be of use in restoring cardiac rhythm in cardiac arrest due to various causes, but it is not used in cardiac failure or in hemorrhagic, traumatic, or cardiogenic shock. Epinephrine is used as a hemostatic agent. It is also used in treating mucosal congestion of hay fever, rhinitis and acute sinusitis; to relieve bronchial asthmatic paroxysms; in syncope due to complete heart block or carotid sinus hypersensitivity; for symptomatic relief of serum sickness, urticaria, angioneurotic edema; for resuscitation in cardiac arrest following anesthetic accidents; in simple (open angle) glaucoma; for relaxation of uterine musculature and to inhibit uterine contractions. Epinephrine injection can be utilized to prolong the action of local anesthetics (see CONTRAINDICATIONS). uuid:157dbded-f956-4fa6-9f9b-458d11d8fe39 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats MONDO:0003014 PMID:41385096 "[{""id"":""uuid:20350894-732c-45de-a1c6-76b8a925bda3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c5d52b1b-3c1e-4568-8160-ae6d10052bbd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In general, the most common uses of epinephrine are to relieve respiratory distress due to bronchospasm, to provide rapid relief of hypersensitivity reactions to drugs and other allergens, and to prolong the action of infiltration anesthetics. Its cardiac effects may be of use in restoring cardiac rhythm in cardiac arrest due to various causes, but it is not used in cardiac failure or in hemorrhagic, traumatic, or cardiogenic shock. Epinephrine is used as a hemostatic agent. It is also used in treating mucosal congestion of hay fever, rhinitis and acute sinusitis; to relieve bronchial asthmatic paroxysms; in syncope due to complete heart block or carotid sinus hypersensitivity; for symptomatic relief of serum sickness, urticaria, angioneurotic edema; for resuscitation in cardiac arrest following anesthetic accidents; in simple (open angle) glaucoma; for relaxation of uterine musculature and to inhibit uterine contractions. Epinephrine injection can be utilized to prolong the action of local anesthetics (see CONTRAINDICATIONS). uuid:9257715c-b2b5-4a8b-8942-04f360b1ecd9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats HP:0000255 PMID:41385096 "[{""id"":""uuid:5735e69a-fedf-4c0c-85f4-1ca6088a2766"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e9c6c284-f363-4295-84fc-2f37ff92fd48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In general, the most common uses of epinephrine are to relieve respiratory distress due to bronchospasm, to provide rapid relief of hypersensitivity reactions to drugs and other allergens, and to prolong the action of infiltration anesthetics. Its cardiac effects may be of use in restoring cardiac rhythm in cardiac arrest due to various causes, but it is not used in cardiac failure or in hemorrhagic, traumatic, or cardiogenic shock. Epinephrine is used as a hemostatic agent. It is also used in treating mucosal congestion of hay fever, rhinitis and acute sinusitis; to relieve bronchial asthmatic paroxysms; in syncope due to complete heart block or carotid sinus hypersensitivity; for symptomatic relief of serum sickness, urticaria, angioneurotic edema; for resuscitation in cardiac arrest following anesthetic accidents; in simple (open angle) glaucoma; for relaxation of uterine musculature and to inhibit uterine contractions. Epinephrine injection can be utilized to prolong the action of local anesthetics (see CONTRAINDICATIONS). uuid:3418f612-d254-4949-b5c6-a2eaf017ad1a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:baa419a9-34ba-46b7-a967-f6a6a245d9bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0293dcfd-c75c-4549-a2f4-9558b91f944a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In general, the most common uses of epinephrine are to relieve respiratory distress due to bronchospasm, to provide rapid relief of hypersensitivity reactions to drugs and other allergens, and to prolong the action of infiltration anesthetics. Its cardiac effects may be of use in restoring cardiac rhythm in cardiac arrest due to various causes, but it is not used in cardiac failure or in hemorrhagic, traumatic, or cardiogenic shock. Epinephrine is used as a hemostatic agent. It is also used in treating mucosal congestion of hay fever, rhinitis and acute sinusitis; to relieve bronchial asthmatic paroxysms; in syncope due to complete heart block or carotid sinus hypersensitivity; for symptomatic relief of serum sickness, urticaria, angioneurotic edema; for resuscitation in cardiac arrest following anesthetic accidents; in simple (open angle) glaucoma; for relaxation of uterine musculature and to inhibit uterine contractions. Epinephrine injection can be utilized to prolong the action of local anesthetics (see CONTRAINDICATIONS). uuid:68cf62b5-e2b8-49a0-b609-f64b773212bb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats HP:0001279 PMID:41385096 "[{""id"":""uuid:0ad8196d-4cfb-4953-b5f9-6fb755757ad0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:32a85825-9891-43a3-8c4c-a6773dc621e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In general, the most common uses of epinephrine are to relieve respiratory distress due to bronchospasm, to provide rapid relief of hypersensitivity reactions to drugs and other allergens, and to prolong the action of infiltration anesthetics. Its cardiac effects may be of use in restoring cardiac rhythm in cardiac arrest due to various causes, but it is not used in cardiac failure or in hemorrhagic, traumatic, or cardiogenic shock. Epinephrine is used as a hemostatic agent. It is also used in treating mucosal congestion of hay fever, rhinitis and acute sinusitis; to relieve bronchial asthmatic paroxysms; in syncope due to complete heart block or carotid sinus hypersensitivity; for symptomatic relief of serum sickness, urticaria, angioneurotic edema; for resuscitation in cardiac arrest following anesthetic accidents; in simple (open angle) glaucoma; for relaxation of uterine musculature and to inhibit uterine contractions. Epinephrine injection can be utilized to prolong the action of local anesthetics (see CONTRAINDICATIONS). uuid:445bebd0-e774-4610-bc07-bd1776971fc2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats MONDO:0043789 PMID:41385096 "[{""id"":""uuid:83e80786-ba17-4f08-a77e-8515f6a422ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d135b882-6783-4f02-9df1-5d2db34f910f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In general, the most common uses of epinephrine are to relieve respiratory distress due to bronchospasm, to provide rapid relief of hypersensitivity reactions to drugs and other allergens, and to prolong the action of infiltration anesthetics. Its cardiac effects may be of use in restoring cardiac rhythm in cardiac arrest due to various causes, but it is not used in cardiac failure or in hemorrhagic, traumatic, or cardiogenic shock. Epinephrine is used as a hemostatic agent. It is also used in treating mucosal congestion of hay fever, rhinitis and acute sinusitis; to relieve bronchial asthmatic paroxysms; in syncope due to complete heart block or carotid sinus hypersensitivity; for symptomatic relief of serum sickness, urticaria, angioneurotic edema; for resuscitation in cardiac arrest following anesthetic accidents; in simple (open angle) glaucoma; for relaxation of uterine musculature and to inhibit uterine contractions. Epinephrine injection can be utilized to prolong the action of local anesthetics (see CONTRAINDICATIONS). uuid:9767496d-62b5-454a-a007-0d86159b0d03 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats MONDO:0005492 PMID:41385096 "[{""id"":""uuid:a02a81f0-fd48-4704-99da-ce32e93cc4b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:efaba81f-2be6-4a8c-96a1-40f85817aad1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In general, the most common uses of epinephrine are to relieve respiratory distress due to bronchospasm, to provide rapid relief of hypersensitivity reactions to drugs and other allergens, and to prolong the action of infiltration anesthetics. Its cardiac effects may be of use in restoring cardiac rhythm in cardiac arrest due to various causes, but it is not used in cardiac failure or in hemorrhagic, traumatic, or cardiogenic shock. Epinephrine is used as a hemostatic agent. It is also used in treating mucosal congestion of hay fever, rhinitis and acute sinusitis; to relieve bronchial asthmatic paroxysms; in syncope due to complete heart block or carotid sinus hypersensitivity; for symptomatic relief of serum sickness, urticaria, angioneurotic edema; for resuscitation in cardiac arrest following anesthetic accidents; in simple (open angle) glaucoma; for relaxation of uterine musculature and to inhibit uterine contractions. Epinephrine injection can be utilized to prolong the action of local anesthetics (see CONTRAINDICATIONS). uuid:755c6155-71a6-473d-8db9-c2ceb77050e5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats MONDO:0010481 PMID:41385096 "[{""id"":""uuid:c014f356-05ad-403f-81ab-2617b93a7888"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1abd59c8-a6c6-4a7b-9442-ac959629bf09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In general, the most common uses of epinephrine are to relieve respiratory distress due to bronchospasm, to provide rapid relief of hypersensitivity reactions to drugs and other allergens, and to prolong the action of infiltration anesthetics. Its cardiac effects may be of use in restoring cardiac rhythm in cardiac arrest due to various causes, but it is not used in cardiac failure or in hemorrhagic, traumatic, or cardiogenic shock. Epinephrine is used as a hemostatic agent. It is also used in treating mucosal congestion of hay fever, rhinitis and acute sinusitis; to relieve bronchial asthmatic paroxysms; in syncope due to complete heart block or carotid sinus hypersensitivity; for symptomatic relief of serum sickness, urticaria, angioneurotic edema; for resuscitation in cardiac arrest following anesthetic accidents; in simple (open angle) glaucoma; for relaxation of uterine musculature and to inhibit uterine contractions. Epinephrine injection can be utilized to prolong the action of local anesthetics (see CONTRAINDICATIONS). uuid:79190499-95ba-4f5e-bb3a-954b655a16dd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats MONDO:0005041 PMID:41385096 "[{""id"":""uuid:3274dd60-24d7-42a7-83e2-2189e3cff9d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8172dcb3-58f9-4e3c-b279-f2526f0874cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In general, the most common uses of epinephrine are to relieve respiratory distress due to bronchospasm, to provide rapid relief of hypersensitivity reactions to drugs and other allergens, and to prolong the action of infiltration anesthetics. Its cardiac effects may be of use in restoring cardiac rhythm in cardiac arrest due to various causes, but it is not used in cardiac failure or in hemorrhagic, traumatic, or cardiogenic shock. Epinephrine is used as a hemostatic agent. It is also used in treating mucosal congestion of hay fever, rhinitis and acute sinusitis; to relieve bronchial asthmatic paroxysms; in syncope due to complete heart block or carotid sinus hypersensitivity; for symptomatic relief of serum sickness, urticaria, angioneurotic edema; for resuscitation in cardiac arrest following anesthetic accidents; in simple (open angle) glaucoma; for relaxation of uterine musculature and to inhibit uterine contractions. Epinephrine injection can be utilized to prolong the action of local anesthetics (see CONTRAINDICATIONS). uuid:dfd8363f-9367-4c76-9bb2-752c55e7a8be biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17439 biolink:treats MONDO:0001356 PMID:41385096 "[{""id"":""uuid:fad46992-9c61-410b-b397-42ae2c01ff55"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7aebd9a7-056e-4b5b-b87c-03a5c5ceccaa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Myferon 150 Forte is indicated for the prevention and treatment of iron deficiency anemia and/or nutritional megaloblastic anemias. uuid:6d10f0f7-4e05-4155-9f60-3afa35d50ec5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17439 biolink:treats MONDO:0001700 PMID:41385096 "[{""id"":""uuid:b7f0e5ac-43e2-4d94-9963-553c1d131d3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9febb440-99c2-4fda-ad7a-211dd08b6369"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Myferon 150 Forte is indicated for the prevention and treatment of iron deficiency anemia and/or nutritional megaloblastic anemias. uuid:d7935570-38e5-442a-8ecb-f6d4a4ce419c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:421707 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:faf173d2-da2c-4e47-8a4a-d542b3b4b7a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1c14c3a3-c8fa-4991-a1ff-018ce9f71fe6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Abacavir tablets, in combination with other antiretroviral agents, are indicated for the treatment of human immunodeficiency virus (HIV-1) infection. Additional important information on the use of abacavir tablets for treatment of HIV-1 infection: Abacavir tablets are one of multiple products containing abacavir. Before starting abacavir tablets, review medical history for prior exposure to any abacavir-containing product in order to avoid reintroduction in a patient with a history of hypersensitivity to abacavir [see Warnings and Precautions (5.1) , Adverse Reactions (6) ]. uuid:2a5b8f4b-8334-4a0a-9298-f343d5e27be3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3387 biolink:treats MONDO:0010826 PMID:41385096 "[{""id"":""uuid:de93804d-8937-4d33-8be5-3283fecf7445"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7e3c026f-380f-42a3-bc65-deeefe099b96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carbamazepine is indicated for use as an anticonvulsant drug. Evidence supporting efficacy of carbamazepine as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types: 1. Partial seizures with complex symptomatology (psychomotor, temporal lobe). Patients with these seizures appear to show greater improvement than those with other types. 2. Generalized tonic-clonic seizures (grand mal). 3. Mixed seizure patterns which include the above, or other partial or generalized seizures. Absence seizures (petit mal) do not appear to be controlled by carbamazepine (see PRECAUTIONS, General ). uuid:ba169144-3bcf-41ff-b84d-85c046536420 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:38545 biolink:treats UMLS:C0342882 PMID:41385096 "[{""id"":""uuid:3e5a894e-6490-465d-8485-f2c083e1124d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:39ca973f-8bcb-45d9-b4a1-93b03b632da3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CRESTOR is an HMG Co‑A reductase inhibitor indicated for: • patients with primary hyperlipidemia and mixed dyslipidemia as an adjunct to diet to reduce elevated total‑C, LDL‑C, ApoB, nonHDL‑C, and TG levels and to increase HDL‑C (1.1) • patients with hypertriglyceridemia as an adjunct to diet (1.2) • patients with primary dysbetalipoproteinemia (Type III hyperlipoproteinemia) as an adjunct to diet (1.3) • patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL‑C, total-C, and ApoB (1.4) • slowing the progression of atherosclerosis as part of a treatment strategy to lower total‑C and LDL‑C as an adjunct to diet (1.5) • pediatric patients 10 to 17 years of age with heterozygous familial hypercholesterolemia (HeFH) to reduce elevated total‑C, LDL‑C and ApoB after failing an adequate trial of diet therapy (1.1) • risk reduction of MI, stroke, and arterial revascularization procedures in patients without clinically evident CHD, but with multiple risk factors (1.6) Limitations of use (1.7) : • CRESTOR has not been studied in Fredrickson Type I and V dyslipidemias. uuid:4704ac6d-c592-458d-8377-ced49fc98b9b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:144551 biolink:treats HP:0100518 PMID:41385096 "[{""id"":""uuid:593030d9-d408-4ff6-8226-2189b28e567f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ca7264a0-a6d8-4d5d-8e01-0b1ff0051149"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxybutynin chloride is indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria). uuid:cd0dc226-50df-4825-bc17-f0d9b2276269 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:144551 biolink:treats NCIT:C118167 PMID:41385096 "[{""id"":""uuid:0e05255c-1ba8-4321-8a16-7d0ccc13b1e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8b7e3040-05e7-45a8-b674-756535a8b493"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxybutynin chloride is indicated for the relief of symptoms of bladder instability associated with voiding in patients with uninhibited neurogenic or reflex neurogenic bladder (i.e., urgency, frequency, urinary leakage, urge incontinence, dysuria). uuid:f6de0009-06d1-4dbd-9bc8-b7676c57eaca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9150 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:ead3d485-3edc-439a-b9bc-1cfbd05fdb0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:38f49127-a103-4595-9a2c-2ef29eadf681"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Simvastatin tablets are an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: Reduce the risk of total mortality by reducing CHD deaths and reduce the risk of non-fatal myocardial infarction, stroke, and the need for revascularization procedures in patients at high risk of coronary events. ( 1.1 ) Reduce elevated total-C, LDL-C, Apo B, TG and increase HDL-C in patients with primary hyperlipidemia (heterozygous familial and nonfamilial) and mixed dyslipidemia. ( 1.2 ) Reduce elevated TG in patients with hypertriglyceridemia and reduce TG and VLDL-C in patients with primary dysbetalipoproteinemia. ( 1.2 ) Reduce total-C and LDL-C in adult patients with homozygous familial hypercholesterolemia. ( 1.2 ) Reduce elevated total-C, LDL-C, and Apo B in boys and postmenarchal girls, 10 to 17 years of age with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy. ( 1.2 , 1.3 ) Limitations of Use Simvastatin tablets have not been studied in Fredrickson Types I and V dyslipidemias. ( 1.4 ) uuid:5ddd9763-23f2-4f55-96c9-ee1296fa69e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9150 biolink:treats MONDO:0001336 PMID:41385096 "[{""id"":""uuid:a93a4e53-37e6-4004-9ebc-85da7aabef97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:632dd819-44b5-4267-9f75-e9a5714e56ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Simvastatin tablets are an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: Reduce the risk of total mortality by reducing CHD deaths and reduce the risk of non-fatal myocardial infarction, stroke, and the need for revascularization procedures in patients at high risk of coronary events. ( 1.1 ) Reduce elevated total-C, LDL-C, Apo B, TG and increase HDL-C in patients with primary hyperlipidemia (heterozygous familial and nonfamilial) and mixed dyslipidemia. ( 1.2 ) Reduce elevated TG in patients with hypertriglyceridemia and reduce TG and VLDL-C in patients with primary dysbetalipoproteinemia. ( 1.2 ) Reduce total-C and LDL-C in adult patients with homozygous familial hypercholesterolemia. ( 1.2 ) Reduce elevated total-C, LDL-C, and Apo B in boys and postmenarchal girls, 10 to 17 years of age with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy. ( 1.2 , 1.3 ) Limitations of Use Simvastatin tablets have not been studied in Fredrickson Types I and V dyslipidemias. ( 1.4 ) uuid:4a096624-0a24-4722-b295-8e89de935e5a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9150 biolink:treats MONDO:0007788 PMID:41385096 "[{""id"":""uuid:2b2da30f-170e-4522-a6d6-85b04b9b6214"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:020000d4-57be-4b33-b7cf-927139d146ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Simvastatin tablets are an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: Reduce the risk of total mortality by reducing CHD deaths and reduce the risk of non-fatal myocardial infarction, stroke, and the need for revascularization procedures in patients at high risk of coronary events. ( 1.1 ) Reduce elevated total-C, LDL-C, Apo B, TG and increase HDL-C in patients with primary hyperlipidemia (heterozygous familial and nonfamilial) and mixed dyslipidemia. ( 1.2 ) Reduce elevated TG in patients with hypertriglyceridemia and reduce TG and VLDL-C in patients with primary dysbetalipoproteinemia. ( 1.2 ) Reduce total-C and LDL-C in adult patients with homozygous familial hypercholesterolemia. ( 1.2 ) Reduce elevated total-C, LDL-C, and Apo B in boys and postmenarchal girls, 10 to 17 years of age with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy. ( 1.2 , 1.3 ) Limitations of Use Simvastatin tablets have not been studied in Fredrickson Types I and V dyslipidemias. ( 1.4 ) uuid:dbfb4a98-5939-4dc9-ae06-375282f99714 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9150 biolink:treats MONDO:0007762 PMID:41385096 "[{""id"":""uuid:2c4dfdfd-2703-402e-9948-a17b03add40f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8e258c91-630d-41c5-af33-bf9b0b690932"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Simvastatin tablets are an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: Reduce the risk of total mortality by reducing CHD deaths and reduce the risk of non-fatal myocardial infarction, stroke, and the need for revascularization procedures in patients at high risk of coronary events. ( 1.1 ) Reduce elevated total-C, LDL-C, Apo B, TG and increase HDL-C in patients with primary hyperlipidemia (heterozygous familial and nonfamilial) and mixed dyslipidemia. ( 1.2 ) Reduce elevated TG in patients with hypertriglyceridemia and reduce TG and VLDL-C in patients with primary dysbetalipoproteinemia. ( 1.2 ) Reduce total-C and LDL-C in adult patients with homozygous familial hypercholesterolemia. ( 1.2 ) Reduce elevated total-C, LDL-C, and Apo B in boys and postmenarchal girls, 10 to 17 years of age with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy. ( 1.2 , 1.3 ) Limitations of Use Simvastatin tablets have not been studied in Fredrickson Types I and V dyslipidemias. ( 1.4 ) uuid:89fe916a-06f3-40f7-ad3a-1925102a46ee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9720 biolink:treats MONDO:0021095 PMID:41385096 "[{""id"":""uuid:1dc27c63-bfc7-4d5b-99da-eb8ab03fe798"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7ece6ae0-112a-44a4-95aa-83c37b8a1f52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] This drug is indicated as an adjunct in the treatment of all forms of parkinsonism (postencephalitic, arteriosclerotic, and idiopathic). It is often useful as adjuvant therapy when treating these forms of parkinsonism with levodopa. Additionally, it is indicated for the control of extrapyramidal disorders caused by central nervous system drugs such as the dibenzoxazepines, phenothiazines, thioxanthenes, and butyrophenones. uuid:0fe7581a-8f3b-4fcb-8c6b-3712441df17f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9720 biolink:treats MONDO:0001945 PMID:41385096 "[{""id"":""uuid:bd7ec65a-8656-41df-ab95-cc1efb68fdc2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:15a432a6-bd42-4334-97a3-e18771689ffb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] This drug is indicated as an adjunct in the treatment of all forms of parkinsonism (postencephalitic, arteriosclerotic, and idiopathic). It is often useful as adjuvant therapy when treating these forms of parkinsonism with levodopa. Additionally, it is indicated for the control of extrapyramidal disorders caused by central nervous system drugs such as the dibenzoxazepines, phenothiazines, thioxanthenes, and butyrophenones. uuid:d4a7b56b-beef-4b42-8ddb-db5acf0ea5b0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9720 biolink:treats MONDO:0956980 PMID:41385096 "[{""id"":""uuid:b06ae23c-2108-43f2-87bd-35c4516944f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:60601179-2996-48cf-9b6d-4cef0202facb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] This drug is indicated as an adjunct in the treatment of all forms of parkinsonism (postencephalitic, arteriosclerotic, and idiopathic). It is often useful as adjuvant therapy when treating these forms of parkinsonism with levodopa. Additionally, it is indicated for the control of extrapyramidal disorders caused by central nervous system drugs such as the dibenzoxazepines, phenothiazines, thioxanthenes, and butyrophenones. uuid:84798508-637e-4156-ad69-0899119618b2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9720 biolink:treats MONDO:0005180 PMID:41385096 "[{""id"":""uuid:898b4583-1343-4345-8469-08e926771284"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6b0f64f9-262d-4430-a905-ce4eaa9a2b1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] This drug is indicated as an adjunct in the treatment of all forms of parkinsonism (postencephalitic, arteriosclerotic, and idiopathic). It is often useful as adjuvant therapy when treating these forms of parkinsonism with levodopa. Additionally, it is indicated for the control of extrapyramidal disorders caused by central nervous system drugs such as the dibenzoxazepines, phenothiazines, thioxanthenes, and butyrophenones. uuid:1a602dcd-9809-4bc9-877a-6eeb62d04481 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9720 biolink:treats HP:0002071 PMID:41385096 "[{""id"":""uuid:c962800b-1859-4b45-b4d1-157c0dadc2e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7c3815dc-27b3-46e2-b6aa-32baea783c72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] This drug is indicated as an adjunct in the treatment of all forms of parkinsonism (postencephalitic, arteriosclerotic, and idiopathic). It is often useful as adjuvant therapy when treating these forms of parkinsonism with levodopa. Additionally, it is indicated for the control of extrapyramidal disorders caused by central nervous system drugs such as the dibenzoxazepines, phenothiazines, thioxanthenes, and butyrophenones. uuid:c22c47d6-acbc-4604-a4f6-f2df67ee557f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27446 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:351b9f42-0d14-4044-b5f0-85e7e09ea57c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:347ffda2-9781-4c1d-8773-e16ba559bdcf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Penicillin V potassium tablets are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. uuid:2f4c2627-f56d-4ece-8949-ca468a91032f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27446 biolink:treats MONDO:0005242 PMID:41385096 "[{""id"":""uuid:0d91ced1-b466-47af-ad51-d71885446aa8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7937cb6d-7f6c-4c56-8f85-f6451ec6b55f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Penicillin V potassium tablets are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. uuid:cfe60112-2133-4ab2-ab11-cee39e5d9516 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27446 biolink:treats MONDO:0005229 PMID:41385096 "[{""id"":""uuid:061d9885-8bbd-461d-8986-ec16e8fe966f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a5236984-9001-43a2-9b31-6f92591a165f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Penicillin V potassium tablets are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. uuid:ea71bc13-1089-48c4-94e1-6ab227b4378f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27446 biolink:treats MONDO:0005904 PMID:41385096 "[{""id"":""uuid:18a3be64-ce4b-4edb-b6ec-a315f4b4310d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:01547085-89ee-4ed1-a53d-a65ac8ee629e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Penicillin V potassium tablets are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. uuid:ba215098-088f-4da2-9fb5-69e577ae454d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27446 biolink:treats MONDO:0021108 PMID:41385096 "[{""id"":""uuid:7eddf099-4322-45e7-af20-239253a9b9b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:17f9c478-c523-48e9-a55f-179b5ab3ff54"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Penicillin V potassium tablets are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. uuid:c9ac8faf-ddf8-44e4-84d5-197565f59fd7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27446 biolink:treats MONDO:0005578 PMID:41385096 "[{""id"":""uuid:19e99327-34ef-4480-9f50-467b530767d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:538db3c9-53aa-4a14-97aa-aa82c2b89c72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Penicillin V potassium tablets are indicated in the treatment of mild to moderately severe infections due to penicillin G-sensitive microorganisms. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. NOTE: Severe pneumonia, empyema, bacteremia, pericarditis, meningitis, and arthritis should not be treated with penicillin V during the acute stage. Indicated surgical procedures should be performed. The following infections will usually respond to adequate dosage of penicillin V. uuid:7a696e0c-9f19-4af8-aab6-7567d5f4e8fc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:284904 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:3bedb82f-d23f-4dc7-970e-94ba38fd970f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:20f338db-17c5-4d70-8d91-1a3c14d60bfb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRIZIVIR is indicated in combination with other antiretrovirals or alone for the treatment of HIV-1 infection. Additional important information on the use of TRIZIVIR for treatment of HIV-1 infection: • TRIZIVIR is one of multiple products containing abacavir. Before starting TRIZIVIR, review medical history for prior exposure to any abacavir-containing product in order to avoid reintroduction in a patient with a history of hypersensitivity to abacavir [see Warnings and Precautions (5.1), Adverse Reactions (6)] . • TRIZIVIR is a fixed-dose combination of 3 nucleoside analogues: abacavir, lamivudine, and zidovudine and is intended only for patients whose regimen would otherwise include these 3 components. • Limited data exist on the use of TRIZIVIR alone in patients with higher baseline viral load levels (>100,000 copies/mL) [see Clinical Studies (14)] . uuid:3328953e-d154-4974-beb7-4a78fe95e5ce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9241 biolink:treats MONDO:0021511 PMID:41385096 "[{""id"":""uuid:f7567336-00a1-412a-98ce-00d645da54cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:97154724-5773-4e4a-8900-a0c708374544"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone tablets, USP are indicated in the management of: Primary hyperaldosteronism for: Establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. Short-term preoperative treatment of patients with primary hyperaldosteronism. Long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. Long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). Edematous conditions for patients with: Congestive heart failure: For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. Spironolactone tablets, USP are also indicated for patients with congestive heart failure taking digitalis when other therapies are considered inappropriate. Cirrhosis of the liver accompanied by edema and/or ascites: Aldosterone levels may be exceptionally high in this condition. Spironolactone tablets, USP are indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. Nephrotic syndrome: For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response. Essential hypertension Spironolactone tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Usually in combination with other drugs, spironolactone tablets, USP are indicated for patients who cannot be treated adequately with other agents or for whom other agents are considered inappropriate. Hypokalemia For the treatment of patients with hypokalemia when other measures are considered inappropriate or inadequate. Spironolactone tablets, USP are also indicated for the prophylaxis of hypokalemia in patients taking digitalis when other measures are considered inadequate or inappropriate. Severe heart failure (NYHA class III – IV) To increase survival, and to reduce the need for hospitalization for heart failure when used in addition to standard therapy. Usage in Pregnancy The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developing toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Spironolactone tablets, USP are indicated in pregnancy when edema is due to pathologic causes just as it is in the absence of pregnancy (however, see Precautions: Pregnancy ). Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is unsupported and unnecessary. There is hypervolemia during normal pregnancy which is not harmful to either the fetus or the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort that is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate. uuid:9992ba20-46e7-46ea-bc6f-24230ae961e4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9241 biolink:treats HP:0008221 PMID:41385096 "[{""id"":""uuid:f4751fbf-20ce-4d21-bf9d-bea18b898c96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c160c104-cf82-4f30-8165-c1b44e7ace82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone tablets, USP are indicated in the management of: Primary hyperaldosteronism for: Establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. Short-term preoperative treatment of patients with primary hyperaldosteronism. Long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. Long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). Edematous conditions for patients with: Congestive heart failure: For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. Spironolactone tablets, USP are also indicated for patients with congestive heart failure taking digitalis when other therapies are considered inappropriate. Cirrhosis of the liver accompanied by edema and/or ascites: Aldosterone levels may be exceptionally high in this condition. Spironolactone tablets, USP are indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. Nephrotic syndrome: For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response. Essential hypertension Spironolactone tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Usually in combination with other drugs, spironolactone tablets, USP are indicated for patients who cannot be treated adequately with other agents or for whom other agents are considered inappropriate. Hypokalemia For the treatment of patients with hypokalemia when other measures are considered inappropriate or inadequate. Spironolactone tablets, USP are also indicated for the prophylaxis of hypokalemia in patients taking digitalis when other measures are considered inadequate or inappropriate. Severe heart failure (NYHA class III – IV) To increase survival, and to reduce the need for hospitalization for heart failure when used in addition to standard therapy. Usage in Pregnancy The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developing toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Spironolactone tablets, USP are indicated in pregnancy when edema is due to pathologic causes just as it is in the absence of pregnancy (however, see Precautions: Pregnancy ). Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is unsupported and unnecessary. There is hypervolemia during normal pregnancy which is not harmful to either the fetus or the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort that is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate. uuid:8236cb8b-714e-4f1e-a004-9fb14a4a468f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9241 biolink:treats MONDO:0001134 PMID:41385096 "[{""id"":""uuid:8a8c7cda-645a-4575-b0cc-a9cfe9187307"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d034fcf4-f864-4584-aaa6-8658de357d7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7083a09e-6164-48ee-a4f9-b22b2e9de436"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/qaialdo""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone tablets, USP are indicated in the management of: Primary hyperaldosteronism for: Establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. Short-term preoperative treatment of patients with primary hyperaldosteronism. Long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. Long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). Edematous conditions for patients with: Congestive heart failure: For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. Spironolactone tablets, USP are also indicated for patients with congestive heart failure taking digitalis when other therapies are considered inappropriate. Cirrhosis of the liver accompanied by edema and/or ascites: Aldosterone levels may be exceptionally high in this condition. Spironolactone tablets, USP are indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. Nephrotic syndrome: For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response. Essential hypertension Spironolactone tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Usually in combination with other drugs, spironolactone tablets, USP are indicated for patients who cannot be treated adequately with other agents or for whom other agents are considered inappropriate. Hypokalemia For the treatment of patients with hypokalemia when other measures are considered inappropriate or inadequate. Spironolactone tablets, USP are also indicated for the prophylaxis of hypokalemia in patients taking digitalis when other measures are considered inadequate or inappropriate. Severe heart failure (NYHA class III – IV) To increase survival, and to reduce the need for hospitalization for heart failure when used in addition to standard therapy. Usage in Pregnancy The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developing toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Spironolactone tablets, USP are indicated in pregnancy when edema is due to pathologic causes just as it is in the absence of pregnancy (however, see Precautions: Pregnancy ). Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is unsupported and unnecessary. There is hypervolemia during normal pregnancy which is not harmful to either the fetus or the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort that is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate.|[EMA] In the management of refractory oedema associated with congestive cardiac failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, diagnosis and treatment of primary aldosteronism, essential hypertension.Neonates, children and adolescents should only be treated under guidance of a paediatric specialist (see sections 5.1 and 5.2). uuid:9f7c2c32-8542-4a03-a1fb-454f77efe45f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9241 biolink:treats MONDO:0003019 PMID:41385096 "[{""id"":""uuid:7e584bc3-cdc4-4c0c-804a-5998ffed4492"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3d6e5cb3-a5f2-4674-b44c-356a8c948ed6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone tablets, USP are indicated in the management of: Primary hyperaldosteronism for: Establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. Short-term preoperative treatment of patients with primary hyperaldosteronism. Long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. Long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). Edematous conditions for patients with: Congestive heart failure: For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. Spironolactone tablets, USP are also indicated for patients with congestive heart failure taking digitalis when other therapies are considered inappropriate. Cirrhosis of the liver accompanied by edema and/or ascites: Aldosterone levels may be exceptionally high in this condition. Spironolactone tablets, USP are indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. Nephrotic syndrome: For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response. Essential hypertension Spironolactone tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Usually in combination with other drugs, spironolactone tablets, USP are indicated for patients who cannot be treated adequately with other agents or for whom other agents are considered inappropriate. Hypokalemia For the treatment of patients with hypokalemia when other measures are considered inappropriate or inadequate. Spironolactone tablets, USP are also indicated for the prophylaxis of hypokalemia in patients taking digitalis when other measures are considered inadequate or inappropriate. Severe heart failure (NYHA class III – IV) To increase survival, and to reduce the need for hospitalization for heart failure when used in addition to standard therapy. Usage in Pregnancy The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developing toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Spironolactone tablets, USP are indicated in pregnancy when edema is due to pathologic causes just as it is in the absence of pregnancy (however, see Precautions: Pregnancy ). Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is unsupported and unnecessary. There is hypervolemia during normal pregnancy which is not harmful to either the fetus or the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort that is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate. uuid:842b2edd-3cc4-4b5a-b591-24f12cdb4ae9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9241 biolink:treats MONDO:0045048 PMID:41385096 "[{""id"":""uuid:f2a45a4b-8faf-4201-8240-33062bac81a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:49ffcbb3-6508-49a7-9c5a-c56c45b2be37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone tablets, USP are indicated in the management of: Primary hyperaldosteronism for: Establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. Short-term preoperative treatment of patients with primary hyperaldosteronism. Long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. Long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). Edematous conditions for patients with: Congestive heart failure: For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. Spironolactone tablets, USP are also indicated for patients with congestive heart failure taking digitalis when other therapies are considered inappropriate. Cirrhosis of the liver accompanied by edema and/or ascites: Aldosterone levels may be exceptionally high in this condition. Spironolactone tablets, USP are indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. Nephrotic syndrome: For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response. Essential hypertension Spironolactone tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Usually in combination with other drugs, spironolactone tablets, USP are indicated for patients who cannot be treated adequately with other agents or for whom other agents are considered inappropriate. Hypokalemia For the treatment of patients with hypokalemia when other measures are considered inappropriate or inadequate. Spironolactone tablets, USP are also indicated for the prophylaxis of hypokalemia in patients taking digitalis when other measures are considered inadequate or inappropriate. Severe heart failure (NYHA class III – IV) To increase survival, and to reduce the need for hospitalization for heart failure when used in addition to standard therapy. Usage in Pregnancy The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developing toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Spironolactone tablets, USP are indicated in pregnancy when edema is due to pathologic causes just as it is in the absence of pregnancy (however, see Precautions: Pregnancy ). Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is unsupported and unnecessary. There is hypervolemia during normal pregnancy which is not harmful to either the fetus or the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort that is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate. uuid:62c3cf33-72b9-479f-99c2-8f10144898a8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9241 biolink:treats MONDO:0005081 PMID:41385096 "[{""id"":""uuid:68449ddb-33e2-4607-8bd3-4163236577d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:edabd568-a5b9-4f1c-855a-17fecce4ba96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone tablets, USP are indicated in the management of: Primary hyperaldosteronism for: Establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. Short-term preoperative treatment of patients with primary hyperaldosteronism. Long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. Long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). Edematous conditions for patients with: Congestive heart failure: For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. Spironolactone tablets, USP are also indicated for patients with congestive heart failure taking digitalis when other therapies are considered inappropriate. Cirrhosis of the liver accompanied by edema and/or ascites: Aldosterone levels may be exceptionally high in this condition. Spironolactone tablets, USP are indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. Nephrotic syndrome: For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response. Essential hypertension Spironolactone tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Usually in combination with other drugs, spironolactone tablets, USP are indicated for patients who cannot be treated adequately with other agents or for whom other agents are considered inappropriate. Hypokalemia For the treatment of patients with hypokalemia when other measures are considered inappropriate or inadequate. Spironolactone tablets, USP are also indicated for the prophylaxis of hypokalemia in patients taking digitalis when other measures are considered inadequate or inappropriate. Severe heart failure (NYHA class III – IV) To increase survival, and to reduce the need for hospitalization for heart failure when used in addition to standard therapy. Usage in Pregnancy The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developing toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Spironolactone tablets, USP are indicated in pregnancy when edema is due to pathologic causes just as it is in the absence of pregnancy (however, see Precautions: Pregnancy ). Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is unsupported and unnecessary. There is hypervolemia during normal pregnancy which is not harmful to either the fetus or the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort that is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate. uuid:9ad91d85-bd97-4e98-9842-8737ffee250b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9YCX42I8IU biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:42bf8e23-7336-41af-a71c-8bc90110567b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5d50c999-302e-4fb1-8efb-4815c0088257"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RENAGEL ® Renagel is a Registered Trademark of Genzyme Corporation. (sevelamer hydrochloride) is indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis. The safety and efficacy of Renagel in CKD patients who are not on dialysis have not been studied. uuid:fbce3d6a-f340-48ef-a95a-0c438266ef61 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0005993 PMID:41385096 "[{""id"":""uuid:470d9782-720a-408d-b6a4-8bd5a9510dd2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:724ef5a1-9995-4864-b1a2-10b6d4d7fa49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metronidazole Tablets USP are indicated for the treatment of T. vaginalis infection in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). uuid:c5cc9ba3-d6bb-4246-97d5-4981264bb00f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22652 biolink:treats MONDO:0005351 PMID:41385096 "[{""id"":""uuid:6f1576e7-96a8-447b-aedf-36411c32ec1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aecd38aa-8990-41dc-be4a-afb53a15dbed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BACMIN is indicated for prophylactic or therapeutic nutritional supplementation in physiologically stressful conditions. These include: Conditions causing depletion, reduced absorption or bioavailability of essential vitamins and minerals- Inadequate intake due to highly restricted or unbalanced diets such as those frequently associated with anorexic conditions and other states of severe malnutrition. Gastrointestinal disorders, chronic alcoholism, chronic or acute infections (especially those involving febrile illness), prolonged or wasting disease, congestive heart failure, hyperthyroidism, poorly controlled diabetes or other physiologic stress. Also, patients on estrogenic oral contraceptives or other estrogen therapy, anti-bacterials which affect intestinal microflora, or other interfering drugs. Certain conditions resulting from severe B-Vitamin or ascorbic acid deficiency- Recovery from surgery or trauma involving severe burns, fractures or other extensive tissue damage. Also, pregnant women and those with heavy menstrual bleeding. uuid:9ac6f2a1-ec6a-44b0-824d-4dcf9ae1c9fa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22652 biolink:treats MONDO:0005137 PMID:41385096 "[{""id"":""uuid:ad83f462-6ed0-4d37-a14e-a0b9f73628f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b4284dcc-a260-4088-a93d-e6f7f5119349"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BACMIN is indicated for prophylactic or therapeutic nutritional supplementation in physiologically stressful conditions. These include: Conditions causing depletion, reduced absorption or bioavailability of essential vitamins and minerals- Inadequate intake due to highly restricted or unbalanced diets such as those frequently associated with anorexic conditions and other states of severe malnutrition. Gastrointestinal disorders, chronic alcoholism, chronic or acute infections (especially those involving febrile illness), prolonged or wasting disease, congestive heart failure, hyperthyroidism, poorly controlled diabetes or other physiologic stress. Also, patients on estrogenic oral contraceptives or other estrogen therapy, anti-bacterials which affect intestinal microflora, or other interfering drugs. Certain conditions resulting from severe B-Vitamin or ascorbic acid deficiency- Recovery from surgery or trauma involving severe burns, fractures or other extensive tissue damage. Also, pregnant women and those with heavy menstrual bleeding. uuid:b2f154bd-bcfb-4d84-95b8-ab207d1d190d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22652 biolink:treats MONDO:0004335 PMID:41385096 "[{""id"":""uuid:99be5a5f-905f-42fe-ba0f-606994f209ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b3b3d8a6-4aac-44f9-87e7-853ffb37c885"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BACMIN is indicated for prophylactic or therapeutic nutritional supplementation in physiologically stressful conditions. These include: Conditions causing depletion, reduced absorption or bioavailability of essential vitamins and minerals- Inadequate intake due to highly restricted or unbalanced diets such as those frequently associated with anorexic conditions and other states of severe malnutrition. Gastrointestinal disorders, chronic alcoholism, chronic or acute infections (especially those involving febrile illness), prolonged or wasting disease, congestive heart failure, hyperthyroidism, poorly controlled diabetes or other physiologic stress. Also, patients on estrogenic oral contraceptives or other estrogen therapy, anti-bacterials which affect intestinal microflora, or other interfering drugs. Certain conditions resulting from severe B-Vitamin or ascorbic acid deficiency- Recovery from surgery or trauma involving severe burns, fractures or other extensive tissue damage. Also, pregnant women and those with heavy menstrual bleeding. uuid:cf2f32c3-b460-40a6-8f06-4a5862d87d7b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22652 biolink:treats MONDO:0007079 PMID:41385096 "[{""id"":""uuid:6507451b-bf60-4aac-b696-d701279f7244"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:70238d3d-759c-4d5b-bdeb-fc9bc8a4c868"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BACMIN is indicated for prophylactic or therapeutic nutritional supplementation in physiologically stressful conditions. These include: Conditions causing depletion, reduced absorption or bioavailability of essential vitamins and minerals- Inadequate intake due to highly restricted or unbalanced diets such as those frequently associated with anorexic conditions and other states of severe malnutrition. Gastrointestinal disorders, chronic alcoholism, chronic or acute infections (especially those involving febrile illness), prolonged or wasting disease, congestive heart failure, hyperthyroidism, poorly controlled diabetes or other physiologic stress. Also, patients on estrogenic oral contraceptives or other estrogen therapy, anti-bacterials which affect intestinal microflora, or other interfering drugs. Certain conditions resulting from severe B-Vitamin or ascorbic acid deficiency- Recovery from surgery or trauma involving severe burns, fractures or other extensive tissue damage. Also, pregnant women and those with heavy menstrual bleeding. uuid:09731592-20be-4b32-b30a-25f3a58e6b7d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22652 biolink:treats UMLS:C0743841 PMID:41385096 "[{""id"":""uuid:cd64f3e8-99b7-41a0-af34-71887e17058f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6bed7073-856b-49e6-bb16-c0a97d524c16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BACMIN is indicated for prophylactic or therapeutic nutritional supplementation in physiologically stressful conditions. These include: Conditions causing depletion, reduced absorption or bioavailability of essential vitamins and minerals- Inadequate intake due to highly restricted or unbalanced diets such as those frequently associated with anorexic conditions and other states of severe malnutrition. Gastrointestinal disorders, chronic alcoholism, chronic or acute infections (especially those involving febrile illness), prolonged or wasting disease, congestive heart failure, hyperthyroidism, poorly controlled diabetes or other physiologic stress. Also, patients on estrogenic oral contraceptives or other estrogen therapy, anti-bacterials which affect intestinal microflora, or other interfering drugs. Certain conditions resulting from severe B-Vitamin or ascorbic acid deficiency- Recovery from surgery or trauma involving severe burns, fractures or other extensive tissue damage. Also, pregnant women and those with heavy menstrual bleeding. uuid:016feb4d-7f50-46bd-9a9b-f490265e8df4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22652 biolink:treats MONDO:0001327 PMID:41385096 "[{""id"":""uuid:2b939937-fa82-428c-9621-a35338751aef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5bded42f-b64d-4a02-822f-4ba227628cf1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BACMIN is indicated for prophylactic or therapeutic nutritional supplementation in physiologically stressful conditions. These include: Conditions causing depletion, reduced absorption or bioavailability of essential vitamins and minerals- Inadequate intake due to highly restricted or unbalanced diets such as those frequently associated with anorexic conditions and other states of severe malnutrition. Gastrointestinal disorders, chronic alcoholism, chronic or acute infections (especially those involving febrile illness), prolonged or wasting disease, congestive heart failure, hyperthyroidism, poorly controlled diabetes or other physiologic stress. Also, patients on estrogenic oral contraceptives or other estrogen therapy, anti-bacterials which affect intestinal microflora, or other interfering drugs. Certain conditions resulting from severe B-Vitamin or ascorbic acid deficiency- Recovery from surgery or trauma involving severe burns, fractures or other extensive tissue damage. Also, pregnant women and those with heavy menstrual bleeding. uuid:7c288031-2c7b-4c15-8ceb-b4fd30adc497 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22652 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:cc3e1221-8791-4321-9627-0471c36ae7c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:68317630-4b8d-4793-a567-3ae5935d4cf4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BACMIN is indicated for prophylactic or therapeutic nutritional supplementation in physiologically stressful conditions. These include: Conditions causing depletion, reduced absorption or bioavailability of essential vitamins and minerals- Inadequate intake due to highly restricted or unbalanced diets such as those frequently associated with anorexic conditions and other states of severe malnutrition. Gastrointestinal disorders, chronic alcoholism, chronic or acute infections (especially those involving febrile illness), prolonged or wasting disease, congestive heart failure, hyperthyroidism, poorly controlled diabetes or other physiologic stress. Also, patients on estrogenic oral contraceptives or other estrogen therapy, anti-bacterials which affect intestinal microflora, or other interfering drugs. Certain conditions resulting from severe B-Vitamin or ascorbic acid deficiency- Recovery from surgery or trauma involving severe burns, fractures or other extensive tissue damage. Also, pregnant women and those with heavy menstrual bleeding. uuid:959ec9a6-7a8f-4c4b-8e14-06e7aa7847c4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22652 biolink:treats MONDO:0004425 PMID:41385096 "[{""id"":""uuid:9c60303b-783a-4682-a34d-12446afcf452"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a6d17a1f-76b9-45d7-b8e5-9b535f5473cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BACMIN is indicated for prophylactic or therapeutic nutritional supplementation in physiologically stressful conditions. These include: Conditions causing depletion, reduced absorption or bioavailability of essential vitamins and minerals- Inadequate intake due to highly restricted or unbalanced diets such as those frequently associated with anorexic conditions and other states of severe malnutrition. Gastrointestinal disorders, chronic alcoholism, chronic or acute infections (especially those involving febrile illness), prolonged or wasting disease, congestive heart failure, hyperthyroidism, poorly controlled diabetes or other physiologic stress. Also, patients on estrogenic oral contraceptives or other estrogen therapy, anti-bacterials which affect intestinal microflora, or other interfering drugs. Certain conditions resulting from severe B-Vitamin or ascorbic acid deficiency- Recovery from surgery or trauma involving severe burns, fractures or other extensive tissue damage. Also, pregnant women and those with heavy menstrual bleeding. uuid:23afd8ac-a175-47f6-a0d2-2e15626d370d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22652 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:2636bf03-2c3b-4a52-9c99-8b4780ac2890"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a616b01e-5fc6-4f09-9532-3729840573ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BACMIN is indicated for prophylactic or therapeutic nutritional supplementation in physiologically stressful conditions. These include: Conditions causing depletion, reduced absorption or bioavailability of essential vitamins and minerals- Inadequate intake due to highly restricted or unbalanced diets such as those frequently associated with anorexic conditions and other states of severe malnutrition. Gastrointestinal disorders, chronic alcoholism, chronic or acute infections (especially those involving febrile illness), prolonged or wasting disease, congestive heart failure, hyperthyroidism, poorly controlled diabetes or other physiologic stress. Also, patients on estrogenic oral contraceptives or other estrogen therapy, anti-bacterials which affect intestinal microflora, or other interfering drugs. Certain conditions resulting from severe B-Vitamin or ascorbic acid deficiency- Recovery from surgery or trauma involving severe burns, fractures or other extensive tissue damage. Also, pregnant women and those with heavy menstrual bleeding. uuid:de2eb44e-845c-4700-9ac1-b1b2fcf8a054 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22652 biolink:treats HP:0020110 PMID:41385096 "[{""id"":""uuid:de3baa61-c65f-45a5-913f-12956f4e1cd2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e917cd74-3eb7-4da1-8c29-686641e27c4c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BACMIN is indicated for prophylactic or therapeutic nutritional supplementation in physiologically stressful conditions. These include: Conditions causing depletion, reduced absorption or bioavailability of essential vitamins and minerals- Inadequate intake due to highly restricted or unbalanced diets such as those frequently associated with anorexic conditions and other states of severe malnutrition. Gastrointestinal disorders, chronic alcoholism, chronic or acute infections (especially those involving febrile illness), prolonged or wasting disease, congestive heart failure, hyperthyroidism, poorly controlled diabetes or other physiologic stress. Also, patients on estrogenic oral contraceptives or other estrogen therapy, anti-bacterials which affect intestinal microflora, or other interfering drugs. Certain conditions resulting from severe B-Vitamin or ascorbic acid deficiency- Recovery from surgery or trauma involving severe burns, fractures or other extensive tissue damage. Also, pregnant women and those with heavy menstrual bleeding. uuid:397347f8-9432-44de-9d9d-12cc2a31ae71 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8707 biolink:treats MONDO:0005090 PMID:41385096 "[{""id"":""uuid:f1efec6b-13ac-48a5-a288-86c2d94efbd7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e1ebcb14-bb58-409c-9301-1fa734b4ad45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Quetiapine Fumarate Tablets are an atypical antipsychotic indicated for the treatment of: • Schizophrenia ( 1.1 ) • Bipolar I disorder manic episodes ( 1.2 ) • Bipolar disorder, depressive episodes ( 1.2 ) uuid:01abeae1-39b8-4bb0-a086-036e6da9f189 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8707 biolink:treats MONDO:0004985 PMID:41385096 "[{""id"":""uuid:459c40fc-518c-4b76-9d46-10279604be1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f7cd5b34-a925-435e-a252-12962a222268"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3ba8a64c-a721-4579-9d61-92bc819f2adf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Quetiapine Fumarate Tablets are an atypical antipsychotic indicated for the treatment of: • Schizophrenia ( 1.1 ) • Bipolar I disorder manic episodes ( 1.2 ) • Bipolar disorder, depressive episodes ( 1.2 )|[PMDA] Drugs with a new indication in new dosage form indicated for the improvement of depressive symptoms in patients with bipolar disorder. uuid:7c7c312b-b94c-490b-ae60-56842f10c635 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:6473866 biolink:treats UMLS:C0345468 PMID:41385096 "[{""id"":""uuid:aaa8ef0c-0e5f-4be5-b35b-44d248985292"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:843c3a78-ecbb-45bf-9319-b383da6e867b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prograf is a calcineurin-inhibitor immunosuppressant indicated for • Prophylaxis of organ rejection in patients receiving allogeneic liver, kidney or heart transplants ( 1.1 , 1.2 , 1.3 ) • Use concomitantly with adrenal corticosteroids; in kidney and heart transplant, use in conjunction with azathioprine or mycophenolate mofetil (MMF) ( 1.1 , 1.2 , 1.3 ) • Limitations of Use ( 1.4 ): ∘ Do not use simultaneously with cyclosporine ∘ Intravenous use reserved for patients who can not tolerate capsules orally ∘ Use with sirolimus is not recommended in liver and heart transplant; use with sirolimus in kidney transplant has not been established uuid:07d9a919-6238-4c9b-9cc1-dd802e249d73 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:967089 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:d1e14758-967c-49e6-b0c0-a7db425ac3b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8c7e1047-b9ba-4e1c-89e2-8bd655545dad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures. uuid:2adf2205-71d7-4df7-9eb6-20034b89f4c0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0023628 PMID:41385096 "[{""id"":""uuid:031c1d75-0136-493b-a156-3b41857b4b3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4a87728c-2ea6-451a-8649-1b42907920a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydrocortisone acetate suppositories are indicated for the use in inflamed hemorrhoids, post-irradiation (factitial) proctitis; as an adjunct in the treatment of chronic ulcerative colitis; cryptitis; and other inflammatory conditions of anorectum and puritus ani. uuid:3ab8e06e-3550-4038-b71b-95d54594de8f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2904 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:3ea3bfd5-af59-4c1c-b8d7-e5795ea44be6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:30f5c3ac-898f-4c1a-89fb-744c39a2c76a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atenolol tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including atenolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (eg, on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Atenolol tablets, USP may be administered with other antihypertensive agents. uuid:3415dcf5-f1a4-456f-b28e-c59cc24e07d9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2904 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:8d81ee42-9546-4c9c-bf76-8697e384148c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ed24c2c4-cad4-4021-911a-cc7e16ef7ff5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atenolol tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including atenolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (eg, on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Atenolol tablets, USP may be administered with other antihypertensive agents. uuid:0416df95-5daf-4e02-9629-d8e3d3cf2b36 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0019359 PMID:41385096 "[{""id"":""uuid:0eb3613e-1b9c-4dc9-96c5-a91a53c71f90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d5f0452f-382c-409a-8ef8-49b75fd7933e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:d2e8d7df-c85e-47c9-9602-679fb86918b0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0001246 PMID:41385096 "[{""id"":""uuid:209aa077-ecec-4ecf-9b6d-494d8489a27e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bf2cb5ae-b4ab-47f0-abbc-452fca4f6769"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:9b2611e5-c8a2-428b-b7b5-99b34322ac38 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0019186 PMID:41385096 "[{""id"":""uuid:03a5f439-3636-4ef3-a2af-3fc9497f1426"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:984df1ae-e5cf-405c-be1a-e7fa8b43a899"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:da1cbdf0-07a6-49ba-9534-94c324886c78 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0019360 PMID:41385096 "[{""id"":""uuid:b1dc5fc1-a2aa-4310-947c-462e9fae1a51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eeee4305-f368-4f8f-bada-9d0572db2c32"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:86b40e1a-f917-4c5c-8d86-6c7294ce1238 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0025294 PMID:41385096 "[{""id"":""uuid:d6978ba3-5996-4772-8ef4-38bedecc4e6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7f9f743e-c947-4a99-b2fd-a4d6d91aacfd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:bb6ba431-c9f9-46c0-9622-c80d1f372edc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:a6c65d02-4e5d-45dc-b7af-cc02beba757c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:724a5665-e3a6-42a3-869a-e586bce36eb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:d28919e7-05e9-4425-83ac-b9f8abe54f33 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0005834 PMID:41385096 "[{""id"":""uuid:e8f124c5-0d33-46c1-8875-09f354fdec72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ea571ff2-50a7-4f86-9954-6ccc2601d972"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:46fa2aa8-c0eb-4357-9b4b-b5a20235ab9d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0005888 PMID:41385096 "[{""id"":""uuid:5d43c04c-8bfd-4c34-971f-a4a5da46799a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9063762e-d3c7-461c-9666-ef8efb990252"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:9ba2a0fa-81a3-4847-b338-3448f094232a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0001249 PMID:41385096 "[{""id"":""uuid:f3dddd0a-038f-495c-80ee-e21f2468d4c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4be8c671-bfdd-4946-829d-ad21fde1688e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:60b808c3-0956-4d48-add9-b67c44a7c055 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0005808 PMID:41385096 "[{""id"":""uuid:f2098750-ffba-4c90-9800-5622d02791c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:efe0c9cf-be95-4c3a-8599-b684ce2b527c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:6a66979c-96eb-4f4d-9539-a727e541fca6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0005297 PMID:41385096 "[{""id"":""uuid:53a4db89-9326-48d0-a7f4-54a37a92637b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dc9d3279-6f32-40cc-b221-aa595f42decb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:44743f9f-2783-4cc2-8269-1b59ed00c9fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0019633 PMID:41385096 "[{""id"":""uuid:684a2951-20db-4c2e-befd-57bdcc2a4306"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6a3546cc-fe20-4975-8a75-f9b0b72d6385"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:a570a64a-61d6-4847-85e6-62603c2d832c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0001797 PMID:41385096 "[{""id"":""uuid:e0e3b67b-c459-4f9c-a2a9-1468bfb66398"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ffe78e36-fad2-48a2-a96a-89f9235d732e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:8b991c5a-a7b0-4c39-82ea-808f20360a1b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0019095 PMID:41385096 "[{""id"":""uuid:2a217981-340a-4991-b3b0-5e7cd93350a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:699d3192-c1a9-4194-97b3-13f88bc858ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:50d32186-06ae-4809-b468-6a453e581272 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0018077 PMID:41385096 "[{""id"":""uuid:415b1386-0339-4bcf-ac61-5341f78d071e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:99ae7276-225d-418b-b407-63b67012d329"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:b636a5b2-8e79-4d2c-a4af-ea92f5a463d9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0015766 PMID:41385096 "[{""id"":""uuid:f4a660a0-2821-4b57-82d5-3c930fc07b37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:88e24175-55e3-478a-b410-a6582116509c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:2305407f-508c-4617-a5da-a9a7a99b882e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0040728 PMID:41385096 "[{""id"":""uuid:492a034c-9ce9-4a6b-b899-c139a863c246"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:46e58beb-9e32-4481-a067-74aed07ed1d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:8d8e7c6f-7898-4aa1-9c03-c698c854b78d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0005683 PMID:41385096 "[{""id"":""uuid:3bfc5afc-a3db-4baf-b55d-75c05e82212d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e9c82024-f6a6-4484-bb7d-61627f1606c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:3ab53581-d13b-464e-9674-eb6b3f19d97c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0005664 PMID:41385096 "[{""id"":""uuid:de08ea1c-1675-4258-91db-94c9c8a9a03a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:772c3995-1c0d-4c92-b5cd-76e45c4346f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:033ecc0a-34ed-47c5-867a-3ff487d41e89 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0005777 PMID:41385096 "[{""id"":""uuid:89b01453-7d9c-42ae-b75b-5ce38c1c275c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e50dab28-5d34-41d3-af2d-77d227c127b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:2e7e6115-4f9d-4227-b02e-316ce751c9e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats UMLS:C0041912 PMID:41385096 "[{""id"":""uuid:26de8250-e8c1-49f9-8ce7-707e3eb2171c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6ec61ef4-0a79-428b-b0b8-94b928fba068"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:ac3a8757-6915-4a75-84e3-0d10a0a0a56a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:e0b0aaab-6b2f-4f8a-8c05-879333940ded"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cf4fd3d5-e7b5-4d39-979f-1221283b9556"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:dadf21f3-edd4-4e00-bacf-8743154e4d5e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0004277 PMID:41385096 "[{""id"":""uuid:87f651fa-2bf2-45fe-9efc-76e947f65e32"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bfeac07c-ccc7-4d75-a4cc-9327991d7a9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:1cfa2765-9c63-466c-afcf-7bcffd36291b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0005976 PMID:41385096 "[{""id"":""uuid:6888e077-7761-4f09-881b-d9a51ba4a406"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b60da6cd-9df1-4ace-bd3e-611071c14625"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:22a5fad4-f5e9-4fb7-ac04-3dadbda3d1ac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0006019 PMID:41385096 "[{""id"":""uuid:eec5ae07-f9a4-4884-8430-3fa1c13e9d8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:56f214b7-e451-4b0f-ae08-8a1cc71dfacc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:d6975b5e-b7a4-4658-8fa0-4ad1b875b93e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0005828 PMID:41385096 "[{""id"":""uuid:62ccacb8-ff39-432c-a8e9-c951901d8564"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7491e73a-ef57-4342-bfe4-1e3562c18293"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:b850c617-246c-4d19-95e6-d96e1fbae025 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0005119 PMID:41385096 "[{""id"":""uuid:e6b0f602-f8fc-40b0-bc8f-2bd5e8869e46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:51cd9ffd-2d6f-4bea-8370-ee17326fecb7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:bb2408ab-4aa7-432b-b48d-f11346e61679 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0005631 PMID:41385096 "[{""id"":""uuid:2199b195-4265-4fc9-97c8-20c9e63c38aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5af25fa7-4296-4bc5-aa6e-5e0cfd0acced"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:76387ea4-121f-42a7-89bb-686a115b0fea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0024388 PMID:41385096 "[{""id"":""uuid:39ca6e31-b0bb-402e-8a38-2e8715ad5219"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5fe48d4e-5e79-416e-b92d-4e7e4ea198ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:501a0cf9-ffe8-4659-a5a8-ad9ec7b7ee2d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0005644 PMID:41385096 "[{""id"":""uuid:af23487d-effb-44a1-b32c-e00311497bad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b579059c-9423-4e4e-8c8d-9cf5286d6919"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:7cd4276b-2707-467b-97e8-85448df6ba34 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:7d5bf773-feec-4c13-ab88-f42d29ee6d66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:89308cf0-c1ad-4feb-b639-ef38e4d6d4e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets and other antibacterial drugs, demeclocycline hydrochloride tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Demeclocycline hydrochloride is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by ; Lymphogranuloma venereum due to ; Psittacosis (Ornithosis) due to ; Trachoma due to , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by ; Nongonococcal urethritis in adults caused by or ; Relapsing fever due to ; Chancroid caused by ; Plague due to ; Tularemia due to ; Cholera caused by ; Campylobacter fetus infections caused by ; Brucellosis due to species (in conjunction with streptomycin); Bartonellosis due to ; Granuloma inguinale caused by ; Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: ; ; species; species; Respiratory tract infections caused by ; Respiratory tract and urinary tract infections caused by species. Demeclocycline hydrochloride is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by pneumoniae; Skin and skin structure infections caused by . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by ; Syphilis caused by subspecies ; Yaws caused by subspecies ; Listeriosis due to ; Anthrax due to ; Vincent’s infection caused by ; Actinomycosis caused by ; Clostridial diseases caused by species. In acute intestinal amebiasis, demeclocycline hydrochloride may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride may be a useful adjunctive therapy. Mycoplasma pneumoniae Chlamydia trachomatis Chlamydia psittaci Chlamydia trachomatis Chlamydia trachomatis Ureaplasma urealyticum Chlamydia trachomatis Borrelia recurrentis Haemophilus ducreyi Yersinia pestis Francisella tularensis Vibrio cholerae Campylobacter fetus Brucella Bartonella bacilliformis Calymmatobacterium granulomatis Escherichia coli Enterobacter aerogenes Shigella Acinetobacter Haemophilus influenzae Klebsiella Streptococcus Staphylococcus aureus Neisseria gonorrhoeae Neisseria gonorrhoeae Treponema pallidum pallidum Treponema pallidum pertenue Listeria monocytogenes Bacillus anthracis Fusobacterium fusiforme Actinomyces israelii Clostridium uuid:6f88c179-4d05-4d21-9dbc-2ff793b5ec5d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17544 biolink:treats MONDO:0000440 PMID:41385096 "[{""id"":""uuid:d2a617e5-362d-4fa9-b36d-c52c57b3fa59"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a0f5e9d5-91ec-4f8e-88d7-c071397ecc1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of blood pigments. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis ― e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial ― e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:da097cd1-6d5f-4818-a5a1-17d32df1f982 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17544 biolink:treats MONDO:0001106 PMID:41385096 "[{""id"":""uuid:d3e715c4-e36f-4f71-95fd-7dbc7037121b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7d54eb8a-547a-4b05-bd6e-c45e454680fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of blood pigments. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis ― e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial ― e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:7a6c106b-6339-4f36-a652-5aad2bab67b8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17544 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:a08def97-c97c-4050-a07a-63902312cec3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4609eee6-0e57-4ba2-b996-ef04bf8f5390"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of blood pigments. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis ― e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial ― e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:75dc1c97-2709-476e-9a35-c7a1996f4661 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17544 biolink:treats HP:0031273 PMID:41385096 "[{""id"":""uuid:a2c20349-4b5d-485a-97b9-f949980c27f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1bc306d1-be4e-4c40-99de-3b318a083969"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of blood pigments. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis ― e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial ― e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:656d2faa-6e36-48aa-97df-5ff5cfbddae7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17544 biolink:treats UMLS:C3472181 PMID:41385096 "[{""id"":""uuid:97a5b137-1bbd-4357-a146-d1b67a906722"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6bf1ba5d-eacd-4082-bade-2f4b9c3e9e6a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of blood pigments. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis ― e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial ― e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:3fcff247-e954-4f28-b94c-e1de1458b263 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17544 biolink:treats MONDO:0000745 PMID:41385096 "[{""id"":""uuid:9274bfb7-fc9c-4cfd-b1ed-d6938d364e75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:178ee710-e900-44db-81f4-996d64ee4a32"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of blood pigments. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis ― e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial ― e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:d757faf9-5afc-4d35-9180-e0bdf2f3f7d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17544 biolink:treats MONDO:0006040 PMID:41385096 "[{""id"":""uuid:377abc44-2fa1-4c08-9920-e36752079047"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c29eb883-922c-4c94-8cd6-200d903923aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of blood pigments. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis ― e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial ― e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:7dea667d-4963-44aa-883b-02d64507a6e2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17544 biolink:treats EFO:0009574 PMID:41385096 "[{""id"":""uuid:dc979aaf-fe87-4bc9-a6e8-33fe4421c14d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f9f5dc1b-fdc9-430c-929b-07e440d9b6fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of blood pigments. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis ― e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial ― e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:4b937ec0-9f9e-439e-b301-c70d724f5287 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17544 biolink:treats UMLS:C0161558 PMID:41385096 "[{""id"":""uuid:7591b716-170c-46e7-be2f-5e6c8b4a670a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:87f8946b-61a3-43f3-ab16-82e601ff338b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of blood pigments. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis ― e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial ― e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:7477d6cf-11a1-4ab8-8587-d2f369ce9a7b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17544 biolink:treats UMLS:C0161544 PMID:41385096 "[{""id"":""uuid:aeb63b9c-1532-418b-8b26-3cb180cd703d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:62a8af9c-19f5-4160-a484-45f7da2516a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of blood pigments. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis ― e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial ― e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:a55f6bd6-0c4f-48c3-b428-933191862c4a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17544 biolink:treats UMLS:C0161680 PMID:41385096 "[{""id"":""uuid:b0fa79f7-d8ab-47e9-ba6c-71c898375624"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:01716c2d-9977-473f-b23c-566cf999b79a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of blood pigments. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis ― e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial ― e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:31c566bb-358e-4a5a-9708-b12e5b5e83cd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17544 biolink:treats UMLS:C0235575 PMID:41385096 "[{""id"":""uuid:64380c86-a409-41e6-aaf8-0752cefb2f8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2422e9b4-02d3-4f56-ab97-5e3bf5ff4bd0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of blood pigments. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis ― e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial ― e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:7cc714c0-f432-4c06-9ac9-ab60d5f1b523 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17544 biolink:treats UMLS:C1443924 PMID:41385096 "[{""id"":""uuid:4fa1fe70-3d34-4d59-9bd2-94914c91cd77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9638ccab-09ca-4250-9d2e-7360d02a4180"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of blood pigments. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis ― e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial ― e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:9c295c07-3a7e-4771-99be-9a28f30ad085 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17544 biolink:treats MONDO:0012819 PMID:41385096 "[{""id"":""uuid:0a3d4490-5b69-4f85-8518-1325750b78ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:36a2b912-4bb3-4efe-a8e5-ca2fa6a7e650"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of blood pigments. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis ― e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial ― e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:3e6cbdf5-76d4-41f2-81fe-929fbb613feb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6824 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:e6c79e1f-044e-446c-a1f6-993b559ad8d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5401db50-e35f-4a3b-aa39-7c4f40c7636b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methenamine hippurate tablets, USP are indicated for prophylactic or suppressive treatment of frequently recurring urinary tract infections when long-term therapy is considered necessary. This drug should only be used after eradication of the infection by other appropriate antimicrobial agents. To reduce the development of drug-resistant bacteria and maintain the effectiveness of methenamine hippurate tablets, USP and other antibacterial drugs, methenamine hippurate tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:2528d6af-0928-4df2-a050-32dd97f7eedd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4975 biolink:treats MONDO:0043839 PMID:41385096 "[{""id"":""uuid:33fc804d-29e9-42d1-9f81-a41865d86d93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:282e83dc-6ef1-41c7-8c95-546d9e5042f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Famotidine is indicated in: 1. Most adult patients heal within 4 weeks; there is rarely reason to use famotidine at full dosage for longer than 6 to 8 weeks. Studies have not assessed the safety of famotidine in uncomplicated active duodenal ulcer for periods of more than eight weeks. Short-term treatment of active duodenal ulcer. 2. Controlled studies in adults have not extended beyond one year. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of an active ulcer. 3. Most adult patients heal within 6 weeks. Studies have not assessed the safety or efficacy of famotidine in uncomplicated active benign gastric ulcer for periods of more than 8 weeks. Short-term treatment of active benign gastric ulcer. 4. Famotidine is indicated for short-term treatment of patients with symptoms of GERD (see Famotidine is also indicated for the short-term treatment of esophagitis due to GERD including erosive or ulcerative disease diagnosed by endoscopy (see ). Short-term treatment of gastroesophageal reflux disease (GERD). ). CLINICAL PHARMACOLOGY IN ADULTS, Clinical Studies CLINICAL PHARMACOLOGY IN ADULTS, Clinical Studies 5. (see ) Treatment of pathological hypersecretory conditions (e. g., Zollinger-Ellison Syndrome, multiple endocrine adenomas ) CLINICAL PHARMACOLOGY IN ADULTS, Clinical Studies . uuid:e7230348-8bb4-418b-9d04-ccb85b7a792f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:38562 biolink:treats HP:0003124 PMID:41385096 "[{""id"":""uuid:8d1c0001-ee8c-44ac-987e-366a149433f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:74b0ea7f-fb67-416d-a44a-f42c96d40277"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other non-pharmacologic measures alone has been inadequate. uuid:1e5b8967-56d2-4c2e-9f33-e79a3d93a9f9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0006926 PMID:41385096 "[{""id"":""uuid:24e45c9c-4601-4588-b39b-acd48f9680f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:88917df5-2955-4cfd-91f0-7c2fbff6dc63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydia psittaci. Trachoma caused by , although the infectious agent is not always eliminated, as judged by immunofluorescence. Chlamydia trachomatis Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by or Ureaplasma urealyticum Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to species (in conjunction with streptomycin). Brucella Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Calymmatobacterium granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes. species. Shigella species. Acinetobacter Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by species. Klebsiella Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by . Streptococcus pneumoniae Skin and skin structure infections caused by (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) Staphylococcus aureus. When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to and for the treatment of other gonococcal infections. Neisseria gonorrhoeae Infections in women caused by . Neisseria gonorrhoeae Syphilis caused by subspecies Treponema pallidum pallidum. Yaws caused by subspecies Treponema pallidum pertenue. Listeriosis due to Listeria monocytogenes. Anthrax due to . Bacillus anthracis Vincent’s infection caused by Fusobacterium fusiforme. Actinomycosis caused by Actinomyces israelii. Infections caused by species Clostridium . In acute minocycline may be a useful adjunct to amebicides. intestinal amebiasis, In severe minocycline may be useful adjunctive therapy. acne, Oral minocycline is indicated in the treatment of asymptomatic carriers of to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Neisseria meningitidis Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:6fd7582f-2dac-43be-86c4-0653c8f4c457 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:140296 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:36a6b8a8-03c5-4231-b4bf-08568ff3ab59"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bfed4c44-1207-49de-bff1-a7b381e40224"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Quinapril hydrochloride is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with quinapril hydrochloride. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Quinapril hydrochloride may be used alone or in combination with thiazide diuretics. uuid:5baf44ed-c6dc-428c-b91b-176dea35657b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:140296 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:33dbabf0-aa1b-4a4c-99ce-7d178f8d8de5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:40809540-b61e-448a-b54f-f1b659ee0735"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Quinapril hydrochloride is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with quinapril hydrochloride. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Quinapril hydrochloride may be used alone or in combination with thiazide diuretics. uuid:9ce48bf6-a835-4c4c-bbd6-4f090711e050 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:140296 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:5d2a72ab-9dc6-473b-a0d8-6c9490bbbcde"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:21309281-00d3-4d34-8cbf-cefac50f8d0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Quinapril hydrochloride is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with quinapril hydrochloride. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Quinapril hydrochloride may be used alone or in combination with thiazide diuretics. uuid:6dc60322-377e-4264-a366-717b35a2be11 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:140296 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:8f0dcbea-01a5-4eff-9320-4731bddc0d08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5795de4c-f1d2-4478-86bf-ff02540695b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Quinapril hydrochloride is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with quinapril hydrochloride. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Quinapril hydrochloride may be used alone or in combination with thiazide diuretics. uuid:8d68f4c9-df95-4d21-9e20-e0b553854dcc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:140296 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:3ae4e15d-084f-4534-bdd0-fd0e2494dc05"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:68953bb6-359e-4f60-af2d-2ced0b55ff00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Quinapril hydrochloride is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with quinapril hydrochloride. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Quinapril hydrochloride may be used alone or in combination with thiazide diuretics. uuid:0230e326-7269-4841-9c61-65c7c8978dcf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:140296 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:b545a2c3-a05f-4609-a17c-13ef3c9a1a82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e61dc92b-d9fe-4626-8c1b-5f4a6b7e31f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Quinapril hydrochloride is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with quinapril hydrochloride. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Quinapril hydrochloride may be used alone or in combination with thiazide diuretics. uuid:ea022623-1372-4af4-9ecb-d4e4532b2bdd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:140296 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:9f44b38b-bbae-4e08-8c20-b4092010808f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b4f65859-b099-4034-8f66-270a12191a41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Quinapril hydrochloride is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with quinapril hydrochloride. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Quinapril hydrochloride may be used alone or in combination with thiazide diuretics. uuid:7fdee040-8a8f-4a95-994a-6c43d4dbf972 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9014 biolink:treats UMLS:C3495832 PMID:41385096 "[{""id"":""uuid:f0c60898-9301-4848-8129-b1d6650fae1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b9565269-3990-4554-99e4-e67bb8c732ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of Salsalate tablets, USP and other treatment options before deciding to use Salsalate tablets, USP. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see ). Salsalate is indicated for relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis and related rheumatic disorder. WARNINGS uuid:0ac60f19-c3e2-48d0-bdad-fb12d0b1e552 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4315 biolink:treats MONDO:0005133 PMID:41385096 "[{""id"":""uuid:c307a301-00f9-4543-bf2d-91cdc45db228"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:604f1862-4aac-4ce3-b468-8abca75c8caf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endometriosis Danazol capsules are indicated for the treatment of endometriosis amenable to hormonal management. Fibrocystic Breast Disease Most cases of symptomatic fibrocystic breast disease may be treated by simple measures (e.g., padded brassieres and analgesics). In infrequent patients, symptoms of pain and tenderness may be severe enough to warrant treatment by suppression of ovarian function. Danazol capsules are usually effective in decreasing nodularity, pain, and tenderness. It should be stressed to the patient that this treatment is not innocuous in that it involves considerable alterations of hormone levels and that recurrence of symptoms is very common after cessation of therapy. Hereditary Angioedema Danazol capsules are indicated for the prevention of attacks of angioedema of all types (cutaneous, abdominal, laryngeal) in males and females. uuid:ee0db13d-ae33-45c6-9565-799b5207697f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4315 biolink:treats MONDO:0005219 PMID:41385096 "[{""id"":""uuid:a850053b-b1ed-4024-bb03-f85231a5ef8e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:70f74cde-8f88-4514-8412-c07697844c4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endometriosis Danazol capsules are indicated for the treatment of endometriosis amenable to hormonal management. Fibrocystic Breast Disease Most cases of symptomatic fibrocystic breast disease may be treated by simple measures (e.g., padded brassieres and analgesics). In infrequent patients, symptoms of pain and tenderness may be severe enough to warrant treatment by suppression of ovarian function. Danazol capsules are usually effective in decreasing nodularity, pain, and tenderness. It should be stressed to the patient that this treatment is not innocuous in that it involves considerable alterations of hormone levels and that recurrence of symptoms is very common after cessation of therapy. Hereditary Angioedema Danazol capsules are indicated for the prevention of attacks of angioedema of all types (cutaneous, abdominal, laryngeal) in males and females. uuid:aba602c2-5540-4450-a5db-ff1ffbc8b712 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4315 biolink:treats MONDO:0019623 PMID:41385096 "[{""id"":""uuid:cbaeb607-bc3c-40a0-859d-0e06997ac907"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:14ba4908-0078-41ea-9e3c-e4c47aaf7b79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endometriosis Danazol capsules are indicated for the treatment of endometriosis amenable to hormonal management. Fibrocystic Breast Disease Most cases of symptomatic fibrocystic breast disease may be treated by simple measures (e.g., padded brassieres and analgesics). In infrequent patients, symptoms of pain and tenderness may be severe enough to warrant treatment by suppression of ovarian function. Danazol capsules are usually effective in decreasing nodularity, pain, and tenderness. It should be stressed to the patient that this treatment is not innocuous in that it involves considerable alterations of hormone levels and that recurrence of symptoms is very common after cessation of therapy. Hereditary Angioedema Danazol capsules are indicated for the prevention of attacks of angioedema of all types (cutaneous, abdominal, laryngeal) in males and females. uuid:0648db89-00ba-4934-b5da-f31ae10d7fed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0030720 PMID:41385096 "[{""id"":""uuid:4ef6c6e6-3628-4548-821f-a8d6a56ee1ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4e4fda37-292c-43b6-9a2d-c803d824e2fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metronidazole Tablets USP are indicated for the treatment of infection in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). T. vaginalis uuid:9bc93a00-52cf-4f18-9283-7f130736405e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:465284 biolink:treats MONDO:0005132 PMID:41385096 "[{""id"":""uuid:b5ffd6aa-0245-4070-818e-21504e744d7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:19beece0-5b53-4c25-97e3-6ccf06af6fbf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ganciclovir capsules are indicated for the prevention of CMV disease in solid organ transplant recipients and in individuals with advanced HIV infection at risk for developing CMV disease. Ganciclovir capsules are also indicated as an alternative to the intravenous formulation for maintenance treatment of CMV retinitis in immunocompromised patients, including patients with AIDS, in whom retinitis is stable following appropriate induction therapy and for whom the risk of more rapid progression is balanced by the benefit associated with avoiding daily IV infusions (see CLINICAL TRIALS ). SAFETY AND EFFICACY OF GANCICLOVIR HAVE NOT BEEN ESTABLISHED FOR CONGENITAL OR NEONATAL CMV DISEASE; NOT FOR THE TREATMENT OF ESTABLISHED CMV DISEASE OTHER THAN RETINITIS; NOR FOR USE IN NON-IMMUNOCOMPROMISED INDIVIDUALS. THE SAFETY AND EFFICACY OF GANCICLOVIR CAPSULES HAVE NOT BEEN ESTABLISHED FOR TREATING ANY MANIFESTATION OF CMV DISEASE OTHER THAN MAINTENANCE TREATMENT OF CMV RETINITIS. uuid:631d75b8-ffdc-4e3d-bcba-ac77756ec26a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:465284 biolink:treats MONDO:0000878 PMID:41385096 "[{""id"":""uuid:f9fbcd0e-a4d6-4c61-aea2-ff50f4eaed8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5a6f90cc-3b0c-4541-8a74-5cf38de83252"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ganciclovir capsules are indicated for the prevention of CMV disease in solid organ transplant recipients and in individuals with advanced HIV infection at risk for developing CMV disease. Ganciclovir capsules are also indicated as an alternative to the intravenous formulation for maintenance treatment of CMV retinitis in immunocompromised patients, including patients with AIDS, in whom retinitis is stable following appropriate induction therapy and for whom the risk of more rapid progression is balanced by the benefit associated with avoiding daily IV infusions (see CLINICAL TRIALS ). SAFETY AND EFFICACY OF GANCICLOVIR HAVE NOT BEEN ESTABLISHED FOR CONGENITAL OR NEONATAL CMV DISEASE; NOT FOR THE TREATMENT OF ESTABLISHED CMV DISEASE OTHER THAN RETINITIS; NOR FOR USE IN NON-IMMUNOCOMPROMISED INDIVIDUALS. THE SAFETY AND EFFICACY OF GANCICLOVIR CAPSULES HAVE NOT BEEN ESTABLISHED FOR TREATING ANY MANIFESTATION OF CMV DISEASE OTHER THAN MAINTENANCE TREATMENT OF CMV RETINITIS. uuid:97ed38bf-e107-4beb-b917-e7e978092d03 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:465284 biolink:treats MONDO:0012268 PMID:41385096 "[{""id"":""uuid:3794b8a3-a54b-4eee-b461-559e69fb9dc3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8b36c565-db27-4f89-ab0e-4bb5f7aa2d60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ganciclovir capsules are indicated for the prevention of CMV disease in solid organ transplant recipients and in individuals with advanced HIV infection at risk for developing CMV disease. Ganciclovir capsules are also indicated as an alternative to the intravenous formulation for maintenance treatment of CMV retinitis in immunocompromised patients, including patients with AIDS, in whom retinitis is stable following appropriate induction therapy and for whom the risk of more rapid progression is balanced by the benefit associated with avoiding daily IV infusions (see CLINICAL TRIALS ). SAFETY AND EFFICACY OF GANCICLOVIR HAVE NOT BEEN ESTABLISHED FOR CONGENITAL OR NEONATAL CMV DISEASE; NOT FOR THE TREATMENT OF ESTABLISHED CMV DISEASE OTHER THAN RETINITIS; NOR FOR USE IN NON-IMMUNOCOMPROMISED INDIVIDUALS. THE SAFETY AND EFFICACY OF GANCICLOVIR CAPSULES HAVE NOT BEEN ESTABLISHED FOR TREATING ANY MANIFESTATION OF CMV DISEASE OTHER THAN MAINTENANCE TREATMENT OF CMV RETINITIS. uuid:15dbfe13-b273-4c4a-bd76-6b91f7960cb1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16236 biolink:treats MONDO:0004992 PMID:41385096 "[{""id"":""uuid:c8699750-92a7-4366-88ad-dbc35c89501b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a5891188-2ab0-4cdf-86d3-ba4042ce6380"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dehydrated Alcohol Injection is indicated for therapeutic neurolysis of nerves or ganglia for the relief of intractable chronic pain in such conditions as inoperable cancer and trigeminal neuralgia (ticdouloureux), in patients for whom neurosurgical procedures are contraindicated. Relief of trigeminal neuralgia usually is only temporary. Other conditions for which injection of alcohol has been reported include glossopharyngeal neuralgia, angina pectoris and severe claudication due to peripheral vascular insufficiency. Alcohol concentrations of 40 to 50% (prepared by appropriate dilution of dehydrated alcohol) have been used for epidural or individual motor nerve injections to control certain manifestations of cerebral palsy and spastic paraplegia. Similar concentrations also have been injected for celiac plexus block to relieve pain of inoperable upper abdominal cancer, and have been injected intra-and subcutaneously for relief of intractable pruritus ani. uuid:69bedfcd-3ad4-4f60-86e4-9757539f63e7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16236 biolink:treats MONDO:0008599 PMID:41385096 "[{""id"":""uuid:edc45f1d-05e3-45c7-92dc-7e32846b7f12"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c4a9e295-2bf1-4907-ba54-b98faede128c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dehydrated Alcohol Injection is indicated for therapeutic neurolysis of nerves or ganglia for the relief of intractable chronic pain in such conditions as inoperable cancer and trigeminal neuralgia (ticdouloureux), in patients for whom neurosurgical procedures are contraindicated. Relief of trigeminal neuralgia usually is only temporary. Other conditions for which injection of alcohol has been reported include glossopharyngeal neuralgia, angina pectoris and severe claudication due to peripheral vascular insufficiency. Alcohol concentrations of 40 to 50% (prepared by appropriate dilution of dehydrated alcohol) have been used for epidural or individual motor nerve injections to control certain manifestations of cerebral palsy and spastic paraplegia. Similar concentrations also have been injected for celiac plexus block to relieve pain of inoperable upper abdominal cancer, and have been injected intra-and subcutaneously for relief of intractable pruritus ani. uuid:5c453e68-6328-4788-b8ac-278ab2144de5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16236 biolink:treats MONDO:0016372 PMID:41385096 "[{""id"":""uuid:d19cdb0b-e33a-4bcb-ade8-b6d1268bd605"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:08fc6315-d2d0-41a1-b913-88ce310c5505"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dehydrated Alcohol Injection is indicated for therapeutic neurolysis of nerves or ganglia for the relief of intractable chronic pain in such conditions as inoperable cancer and trigeminal neuralgia (ticdouloureux), in patients for whom neurosurgical procedures are contraindicated. Relief of trigeminal neuralgia usually is only temporary. Other conditions for which injection of alcohol has been reported include glossopharyngeal neuralgia, angina pectoris and severe claudication due to peripheral vascular insufficiency. Alcohol concentrations of 40 to 50% (prepared by appropriate dilution of dehydrated alcohol) have been used for epidural or individual motor nerve injections to control certain manifestations of cerebral palsy and spastic paraplegia. Similar concentrations also have been injected for celiac plexus block to relieve pain of inoperable upper abdominal cancer, and have been injected intra-and subcutaneously for relief of intractable pruritus ani. uuid:3a172f82-1dc7-4aa4-97bb-8d4b705ecb19 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16236 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:1dcc12ae-dbbd-4db4-96e5-dc3276cb5de4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7ac9fc4e-1e34-4de6-9377-db8c899f1f88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dehydrated Alcohol Injection is indicated for therapeutic neurolysis of nerves or ganglia for the relief of intractable chronic pain in such conditions as inoperable cancer and trigeminal neuralgia (ticdouloureux), in patients for whom neurosurgical procedures are contraindicated. Relief of trigeminal neuralgia usually is only temporary. Other conditions for which injection of alcohol has been reported include glossopharyngeal neuralgia, angina pectoris and severe claudication due to peripheral vascular insufficiency. Alcohol concentrations of 40 to 50% (prepared by appropriate dilution of dehydrated alcohol) have been used for epidural or individual motor nerve injections to control certain manifestations of cerebral palsy and spastic paraplegia. Similar concentrations also have been injected for celiac plexus block to relieve pain of inoperable upper abdominal cancer, and have been injected intra-and subcutaneously for relief of intractable pruritus ani. uuid:9e794600-2919-47dc-8a4f-0adf60d9aae8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16236 biolink:treats MONDO:0005294 PMID:41385096 "[{""id"":""uuid:c426f99c-23b5-476b-82ba-9cf33b5c2e7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5dda4b4e-9809-4230-bcec-1c4341cb1adb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dehydrated Alcohol Injection is indicated for therapeutic neurolysis of nerves or ganglia for the relief of intractable chronic pain in such conditions as inoperable cancer and trigeminal neuralgia (ticdouloureux), in patients for whom neurosurgical procedures are contraindicated. Relief of trigeminal neuralgia usually is only temporary. Other conditions for which injection of alcohol has been reported include glossopharyngeal neuralgia, angina pectoris and severe claudication due to peripheral vascular insufficiency. Alcohol concentrations of 40 to 50% (prepared by appropriate dilution of dehydrated alcohol) have been used for epidural or individual motor nerve injections to control certain manifestations of cerebral palsy and spastic paraplegia. Similar concentrations also have been injected for celiac plexus block to relieve pain of inoperable upper abdominal cancer, and have been injected intra-and subcutaneously for relief of intractable pruritus ani. uuid:b89aa279-cd51-4db7-a15e-6a1e4a1f365f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16236 biolink:treats MONDO:0006497 PMID:41385096 "[{""id"":""uuid:e98a54ee-ab4b-45bb-8b09-a72fbe852eff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c962bf66-a30c-409e-b4a9-78d7a231e9eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dehydrated Alcohol Injection is indicated for therapeutic neurolysis of nerves or ganglia for the relief of intractable chronic pain in such conditions as inoperable cancer and trigeminal neuralgia (ticdouloureux), in patients for whom neurosurgical procedures are contraindicated. Relief of trigeminal neuralgia usually is only temporary. Other conditions for which injection of alcohol has been reported include glossopharyngeal neuralgia, angina pectoris and severe claudication due to peripheral vascular insufficiency. Alcohol concentrations of 40 to 50% (prepared by appropriate dilution of dehydrated alcohol) have been used for epidural or individual motor nerve injections to control certain manifestations of cerebral palsy and spastic paraplegia. Similar concentrations also have been injected for celiac plexus block to relieve pain of inoperable upper abdominal cancer, and have been injected intra-and subcutaneously for relief of intractable pruritus ani. uuid:b7d2220c-4d5a-4579-bb97-dc86f7c7b1d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16236 biolink:treats HP:0001258 PMID:41385096 "[{""id"":""uuid:cbc12364-98d4-4100-8ed1-742fbb45b341"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f9ed660d-e04d-4e83-af6c-7392b2401449"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dehydrated Alcohol Injection is indicated for therapeutic neurolysis of nerves or ganglia for the relief of intractable chronic pain in such conditions as inoperable cancer and trigeminal neuralgia (ticdouloureux), in patients for whom neurosurgical procedures are contraindicated. Relief of trigeminal neuralgia usually is only temporary. Other conditions for which injection of alcohol has been reported include glossopharyngeal neuralgia, angina pectoris and severe claudication due to peripheral vascular insufficiency. Alcohol concentrations of 40 to 50% (prepared by appropriate dilution of dehydrated alcohol) have been used for epidural or individual motor nerve injections to control certain manifestations of cerebral palsy and spastic paraplegia. Similar concentrations also have been injected for celiac plexus block to relieve pain of inoperable upper abdominal cancer, and have been injected intra-and subcutaneously for relief of intractable pruritus ani. uuid:e695e2af-7d87-4051-93c0-cb7209432463 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3738 biolink:treats MONDO:0011786 PMID:41385096 "[{""id"":""uuid:fcb56465-f0ae-4ca4-8bf4-87368a34dcee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b13fc02a-4c95-4458-b58e-74c9ab412463"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clemastine Fumarate Tablets 1.34 mg are indicated for the relief of symptoms associated with allergic rhinitis such as sneezing, rhinorrhea, pruritus, and lacrimation. Clemastine Fumarate Tablets 2.68 mg are indicated for the relief of symptoms associated with allergic rhinitis such as sneezing, rhinorrhea, pruritus, and lacrimation. Clemastine Fumarate Tablets 2.68 mg are also indicated for the relief of mild, uncomplicated allergic skin manifestations of urticaria and angioedema. It should be noted that clemastine fumarate is indicated for the dermatologic indications at the 2.68 mg dosage level only. uuid:376f62b9-c034-45e2-9bf6-9238b005ea2f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3738 biolink:treats MONDO:0005492 PMID:41385096 "[{""id"":""uuid:e2766876-9e18-4992-8582-4abbb3d803af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:85410388-a106-4445-b668-771a83972ffc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clemastine Fumarate Tablets 1.34 mg are indicated for the relief of symptoms associated with allergic rhinitis such as sneezing, rhinorrhea, pruritus, and lacrimation. Clemastine Fumarate Tablets 2.68 mg are indicated for the relief of symptoms associated with allergic rhinitis such as sneezing, rhinorrhea, pruritus, and lacrimation. Clemastine Fumarate Tablets 2.68 mg are also indicated for the relief of mild, uncomplicated allergic skin manifestations of urticaria and angioedema. It should be noted that clemastine fumarate is indicated for the dermatologic indications at the 2.68 mg dosage level only. uuid:7ada7555-c5e6-4b52-baa1-3ae8350c33a8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3738 biolink:treats MONDO:0010481 PMID:41385096 "[{""id"":""uuid:af3d4525-0e14-40c4-bd0d-fe32f1b800bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9d5fd7d0-9dee-43af-a54d-af8a38b33672"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clemastine Fumarate Tablets 1.34 mg are indicated for the relief of symptoms associated with allergic rhinitis such as sneezing, rhinorrhea, pruritus, and lacrimation. Clemastine Fumarate Tablets 2.68 mg are indicated for the relief of symptoms associated with allergic rhinitis such as sneezing, rhinorrhea, pruritus, and lacrimation. Clemastine Fumarate Tablets 2.68 mg are also indicated for the relief of mild, uncomplicated allergic skin manifestations of urticaria and angioedema. It should be noted that clemastine fumarate is indicated for the dermatologic indications at the 2.68 mg dosage level only. uuid:cc1f368a-356c-4e65-819a-3ff8f447a3ae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63618 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:84271c1b-9ad8-4980-88d8-3b44e5323304"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:51bc4cb2-0fa8-4121-9304-2f71f87d4c4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. Prevention of Cardiovascular Disease In hypercholesterolemic patients without clinically evident coronary heart disease (CHD), pravastatin sodium tablets are indicated to: reduce the risk of myocardial infarction (MI). reduce the risk of undergoing myocardial revascularization procedures. reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes. Hyperlipidemia Pravastatin sodium tablets are indicated: as an adjunct to diet to reduce elevated total cholesterol (Total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (ApoB), and triglyceride (TG) levels and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Types IIa and IIb).1 as an adjunct to diet for the treatment of patients with elevated serum TG levels (Fredrickson Type IV). for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet. as an adjunct to diet and lifestyle modification for treatment of heterozygous familial hypercholesterolemia (HeFH) in children and adolescent patients ages 8 years and older if after an adequate trial of diet the following findings are present: a. LDL-C remains ≥ 190 mg/dL or b. LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease (CVD) or two or more other CVD risk factors are present in the patient. Limitations of Use Pravastatin sodium has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:b69019bb-a696-4fcb-b8e2-81fa8ae4628b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7476 biolink:treats MONDO:0005578 PMID:41385096 "[{""id"":""uuid:9f38fc88-373f-409c-ab2d-a7fd936efb1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:abf543a3-70c7-49df-9be2-8ad829757fd8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Active ingredient (in each tablet) Naproxen sodium 220 mg (naproxen 200 mg) (NSAID)* *nonsteroidal anti-inflammatory drug Purpose Pain reliever/fever reducer Uses •temporarily relieves minor aches and pains due to: •minor pain of arthritis •muscular aches •backache •menstrual cramps •headache •toothache •the common cold •temporarily reduces fever uuid:7fcf9020-17ec-4859-8689-ff613771e829 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7476 biolink:treats HP:0003326 PMID:41385096 "[{""id"":""uuid:32bdb20b-82d1-4eb3-9b69-d39dbdb7a6a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6a2fcefe-1ded-405c-9e94-d325c167b670"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Active ingredient (in each tablet) Naproxen sodium 220 mg (naproxen 200 mg) (NSAID)* *nonsteroidal anti-inflammatory drug Purpose Pain reliever/fever reducer Uses •temporarily relieves minor aches and pains due to: •minor pain of arthritis •muscular aches •backache •menstrual cramps •headache •toothache •the common cold •temporarily reduces fever uuid:e23756cc-54d5-493d-882f-84d6016c6831 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7476 biolink:treats HP:0003418 PMID:41385096 "[{""id"":""uuid:99509562-3da5-43e3-967c-5ad630cb4739"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9e5a4aee-f86b-44e3-bd9b-8cd27a24678a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Active ingredient (in each tablet) Naproxen sodium 220 mg (naproxen 200 mg) (NSAID)* *nonsteroidal anti-inflammatory drug Purpose Pain reliever/fever reducer Uses •temporarily relieves minor aches and pains due to: •minor pain of arthritis •muscular aches •backache •menstrual cramps •headache •toothache •the common cold •temporarily reduces fever uuid:26fa1ef3-6e28-4c6e-920e-99e79aee4edb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7476 biolink:treats HP:0100607 PMID:41385096 "[{""id"":""uuid:ce4eb095-0fca-433c-a5e2-c5c7aae2ed47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5e8b0cfc-4367-48d5-ad80-9f04a3ff4351"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Active ingredient (in each tablet) Naproxen sodium 220 mg (naproxen 200 mg) (NSAID)* *nonsteroidal anti-inflammatory drug Purpose Pain reliever/fever reducer Uses •temporarily relieves minor aches and pains due to: •minor pain of arthritis •muscular aches •backache •menstrual cramps •headache •toothache •the common cold •temporarily reduces fever uuid:5e2f11e3-0ee6-4dbc-af85-b539ad8c05b2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7476 biolink:treats HP:0002315 PMID:41385096 "[{""id"":""uuid:9e6bbe20-803c-424b-8b97-96e799b35568"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:46ae7aa6-c583-46d6-8e66-be12583f6a25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Active ingredient (in each tablet) Naproxen sodium 220 mg (naproxen 200 mg) (NSAID)* *nonsteroidal anti-inflammatory drug Purpose Pain reliever/fever reducer Uses •temporarily relieves minor aches and pains due to: •minor pain of arthritis •muscular aches •backache •menstrual cramps •headache •toothache •the common cold •temporarily reduces fever uuid:273b0272-494e-4086-a34b-b74ddb37894b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7476 biolink:treats EFO:0010072 PMID:41385096 "[{""id"":""uuid:6be6367e-7049-44a8-b71b-5ca7010f1ae5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f16e5e67-b13f-4963-b55e-909c7820e6c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Active ingredient (in each tablet) Naproxen sodium 220 mg (naproxen 200 mg) (NSAID)* *nonsteroidal anti-inflammatory drug Purpose Pain reliever/fever reducer Uses •temporarily relieves minor aches and pains due to: •minor pain of arthritis •muscular aches •backache •menstrual cramps •headache •toothache •the common cold •temporarily reduces fever uuid:d98ad31c-b771-4537-963c-e3ec1aa7296a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7476 biolink:treats MONDO:0005709 PMID:41385096 "[{""id"":""uuid:5f77871a-d7af-436e-bbed-e16f02ba49c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b4a4b2d7-4e32-4433-9f1d-af96424c16d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Active ingredient (in each tablet) Naproxen sodium 220 mg (naproxen 200 mg) (NSAID)* *nonsteroidal anti-inflammatory drug Purpose Pain reliever/fever reducer Uses •temporarily relieves minor aches and pains due to: •minor pain of arthritis •muscular aches •backache •menstrual cramps •headache •toothache •the common cold •temporarily reduces fever uuid:2c461952-799d-4a85-aa29-beb3ee7ff4ca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7476 biolink:treats HP:0001945 PMID:41385096 "[{""id"":""uuid:0971be0c-db2a-4543-876f-b50356409d3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c0664a58-0bc0-4551-940b-958b8ef20892"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Active ingredient (in each tablet) Naproxen sodium 220 mg (naproxen 200 mg) (NSAID)* *nonsteroidal anti-inflammatory drug Purpose Pain reliever/fever reducer Uses •temporarily relieves minor aches and pains due to: •minor pain of arthritis •muscular aches •backache •menstrual cramps •headache •toothache •the common cold •temporarily reduces fever uuid:03c98f32-169c-4f27-a752-40b9e07e3244 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15940 biolink:treats MONDO:0004995 PMID:41385096 "[{""id"":""uuid:2f755fe6-3dca-4483-9909-c598949c3de5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e05288f1-8426-4e81-ad1a-99804e81f548"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. Niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. NIASPAN is indicated to reduce elevated TC, LDL-C, Apo B and TG levels, and to increase HDL-C in patients with primary hyperlipidemia and mixed dyslipidemia. NIASPAN in combination with simvastatin or lovastatin is indicated for the treatment of primary hyperlipidemia and mixed dyslipidemia when treatment with NIASPAN, simvastatin, or lovastatin monotherapy is considered inadequate. In patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. In patients with a history of coronary artery disease (CAD) and hyperlipidemia, niacin, in combination with a bile acid binding resin, is indicated to slow progression or promote regression of atherosclerotic disease. NIASPAN in combination with a bile acid binding resin is indicated to reduce elevated TC and LDL-C levels in adult patients with primary hyperlipidemia. Niacin is also indicated as adjunctive therapy for treatment of adult patients with severe hypertriglyceridemia who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Limitations of Use No incremental benefit of NIASPAN coadministered with simvastatin or lovastatin on cardiovascular morbidity and mortality over and above that demonstrated for niacin, simvastatin, or lovastatin monotherapy has been established. NIASPAN, at doses of 1,500-2,000 mg/day, in combination with simvastatin, did not reduce the incidence of cardiovascular events more than simvastatin in a randomized controlled trial of patients with cardiovascular disease and mean baseline LDL-C levels of 74 mg per deciliter . [see Warnings and Precautions ] (5.1) uuid:a9c3f9d7-c9d2-4cb4-bfaf-ae89787cc33b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50841 biolink:treats MONDO:0005090 PMID:41385096 "[{""id"":""uuid:2ce63592-cef3-4f68-9823-c15ad8987820"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a02724a1-6e99-4264-99dd-54fcfc8c131f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:defb81d7-8d5b-4956-a7f4-01d9cc2e6977"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/adasuve""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Loxapine Capsules USP are indicated for the treatment of schizophrenia. The efficacy of loxapine in schizophrenia was established in clinical studies which enrolled newly hospitalized and chronically hospitalized acutely ill schizophrenic patients as subjects.|[EMA] Adasuve is indicated for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder. Patients should receive regular treatment immediately after control of acute agitation symptoms. uuid:a68cd289-48e5-46fe-b4da-216b629aee42 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7770 biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:50a32a38-4c2d-4409-a887-a0d96c47940c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bb5cefd3-4a8f-483f-bea3-b3fb259bb928"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Olsalazine is indicated for the maintenance of remission of ulcerative colitis in patients who are intolerant of sulfasalazine. uuid:25e533c4-acda-44a5-9db8-1c737ea7d717 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47499 biolink:treats MONDO:0000022 PMID:41385096 "[{""id"":""uuid:d55a2e8b-5fd5-45cd-bb9e-891814e45b64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:89c50837-29d8-4856-901d-1214d7e81870"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the relief of symptoms of depression. Endogenous depression is more likely to be alleviated than other depressive states. One to three weeks of treatment may be needed before optimal therapeutic effects are evident. Depression: May be useful as temporary adjunctive therapy in reducing enuresis in children aged 6 years and older, after possible organic causes have been excludedby appropriate tests. In patients having daytime symptoms of frequency and urgency, examination should include voiding cystourethrography and cystoscopy, as necessary. The effectiveness of treatment may decrease with continued drug administration. Childhood Enuresis: uuid:0d2056ff-4022-4f2c-8266-0750e7892951 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7662KG2R6K biolink:treats MONDO:0100187 PMID:41385096 "[{""id"":""uuid:ace9d850-7fd8-4427-973d-3057eb5a52b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3aff5aee-9f2e-401f-811f-9e7abd96a80c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amitiza is a chloride channel activator indicated for: Treatment of chronic idiopathic constipation in adults • (1.1) Treatment of opioid-induced constipation in adults with chronic, non-cancer pain ( ) • 1.2 Treatment of irritable bowel syndrome with constipation in women ≥ 18 years old • (1.3) Limitations of Use: Effectiveness of Amitiza in the treatment of opioid-induced constipation in patients taking diphenylheptane opioids (e.g., methadone) has not been established ( ) ( ) 1 14.2 uuid:4aa046c9-e019-4ec0-8c46-cbd377b83086 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7565 biolink:treats UMLS:C0577698 PMID:41385096 "[{""id"":""uuid:b47c564c-8286-4680-8ad5-a986aed9ddca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5b6af8ff-e83d-4a7f-a2ee-7524ac2b3cce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] I. Vasospastic Angina Nifedipine is indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. In those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. Nifedipine may also be used where the clinical presentation suggests a possible vasospastic component but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion or when angina is refractory to nitrates and/or adequate doses of beta blockers. II. Chronic Stable Angina (Classical Effort-Associated Angina) Nifedipine is indicated for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm in patients who remain symptomatic despite adequate doses of beta blockers and/or organic nitrates or who cannot tolerate those agents. In chronic stable angina (effort-associated angina) nifedipine has been effective in controlled trials of up to eight weeks duration in reducing angina frequency and increasing exercise tolerance, but confirmation of sustained effectiveness and evaluation of long-term safety in these patients are incomplete. Controlled studies in small numbers of patients suggest concomitant use of nifedipine and betablocking agents may be beneficial in patients with chronic stable angina, but available information is not sufficient to predict with confidence the effects of concurrent treatment, especially in patients with compromised left ventricular function or cardiac conduction abnormalities. When introducing such concomitant therapy, care must be taken to monitor blood pressure closely since severe hypotension can occur from the combined effects of the drugs. (See ). WARNINGS uuid:b0fe9c65-2da9-4810-b081-edfd6cdcc311 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5779 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:5b32620e-fbb5-44b0-8a6d-2de9911eb242"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5e0627a2-c26c-4aba-bb2d-569fe4dba158"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZOHYDRO ® ER (hydrocodone bitartrate) is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations, reserve ZOHYDRO ER for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. ZOHYDRO ER is not indicated as an as-needed (prn) analgesic. uuid:84a16696-3dcf-4647-aa96-313d870fe868 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6073 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:9345fab4-bb1a-434c-91f8-6d5e687deb87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1be2c26e-8fb5-4f1a-8574-ce2ff6dc074c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isradipine is indicated in the management of hypertension. It may be used alone or concurrently with thiazide-type diuretics. uuid:322bcccf-385c-41e4-b8ca-bd2bf90c74a7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49575 biolink:treats MONDO:0011918 PMID:41385096 "[{""id"":""uuid:cbea54f2-d27b-4b4c-a2fc-6f621501f313"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9769afb2-461a-45b0-bc76-43c6fb3ec7cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diazepam Tablets USP are indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. In acute alcohol withdrawal, Diazepam Tablets USP may be useful in the symptomatic relief of acute agitation, tremor, impending or acute delirium tremens and hallucinosis. Diazepam Tablets USP are a useful adjunct for the relief of skeletal muscle spasm due to reflex spasm to local pathology (such as inflammation of the muscles or joints, or secondary to trauma), spasticity caused by upper motor neuron disorders (such as cerebral palsy and paraplegia), athetosis, and stiff-man syndrome. Oral diazepam may be used adjunctively in convulsive disorders, although it has not proved useful as the sole therapy. The effectiveness of Diazepam Tablets USP in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should periodically reassess the usefulness of the drug for the individual patient. uuid:fe2bd533-f5c6-4386-a4c8-3808f1d55c07 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5123 biolink:treats MONDO:0005485 PMID:41385096 "[{""id"":""uuid:7b52f067-e3fc-4413-b479-db752678e13c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bbe8fcb0-a6d4-466c-b4a8-e6eef814db89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluphenazine HCl is indicated in the management of manifestations of psychotic disorders. Fluphenazine HCl has not been shown effective in the management of behavioral complications in patients with mental retardation. uuid:9cc367fa-6aa8-4213-9ccd-73c64d47caec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5123 biolink:treats MONDO:0001071 PMID:41385096 "[{""id"":""uuid:7ded016d-777f-43bc-9d41-e66cb5a1f395"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d6ac06a7-d425-4f62-aa9c-eedfe787c0d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluphenazine HCl is indicated in the management of manifestations of psychotic disorders. Fluphenazine HCl has not been shown effective in the management of behavioral complications in patients with mental retardation. uuid:cc087b3d-1948-4dcb-bdc1-e1b102d33458 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42797 biolink:treats MONDO:0021667 PMID:41385096 "[{""id"":""uuid:eab6396f-3e21-4025-b38f-86f89132bc42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:50736628-8114-4813-bc54-535a030c5bdc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Postherpetic Neuralgia Gabapentin is indicated for the management of postherpetic neuralgia in adults. uuid:e01993dc-ceb3-4149-b269-07cebc8530b2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3534 biolink:treats MONDO:0006878 PMID:41385096 "[{""id"":""uuid:359c0f7e-8949-4a97-b494-2c455633c522"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f364e2e7-a691-404d-8066-d64f40cc2b4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cephalexin capsules are indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Respiratory tract infections caused by and (Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.) Streptococcus pneumoniae Streptococcus pyogenes Otitis media due to Streptococcus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Streptococcus pyogenes, and Moraxella catarrhalis Skin and skin structure infections caused by and/or Staphylococcus aureus Streptococcus pyogenes Bone infections caused by and/or Staphylococcus aureus Proteus mirabilis Genitourinary tract infections, including acute prostatitis, caused by Escherichia coli, Proteus mirabilis, and Klebsiella pneumoniae Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. Note: To reduce the development of drug-resistant bacteria and maintain the effectiveness of cephalexin and other antibacterial drugs, cephalexin capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:74af508d-f720-4379-9d55-55c01f9f8c70 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5004 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:f94302a1-cd12-4ef6-85e1-f21c9b3ee48b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ad53ab15-6835-4994-ae40-13d01aa0b21d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of Fenoprofen Calcium and other treatment options before deciding to use Fenoprofen Calcium. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Fenoprofen Calcium is indicated: For relief of mild to moderate pain in adults. For relief of the signs and symptoms of rheumatoid arthritis. For relief of the signs and symptoms of osteoarthritis. uuid:7622761c-cf6c-4d24-972b-e348ff537927 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5004 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:2281ab54-e6e2-4468-ac89-32d86f6634e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:09be7b4c-7770-4e8e-864c-e7eadf6b85b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of Fenoprofen Calcium and other treatment options before deciding to use Fenoprofen Calcium. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Fenoprofen Calcium is indicated: For relief of mild to moderate pain in adults. For relief of the signs and symptoms of rheumatoid arthritis. For relief of the signs and symptoms of osteoarthritis. uuid:9e521797-3b38-4e93-a9fb-f8bb7df940dd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5004 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:b275a32e-4df2-49f4-a8a4-6723436a0cf3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:488d8db0-0e60-467b-af54-2500f4a4d460"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of Fenoprofen Calcium and other treatment options before deciding to use Fenoprofen Calcium. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Fenoprofen Calcium is indicated: For relief of mild to moderate pain in adults. For relief of the signs and symptoms of rheumatoid arthritis. For relief of the signs and symptoms of osteoarthritis. uuid:3664025a-188d-47e1-b336-d850f1d70739 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10119 biolink:treats MONDO:0005478 PMID:41385096 "[{""id"":""uuid:52dc5440-00b7-4f88-8442-03feebecf32d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4a10ce32-f3f2-4831-804b-d4cd9b42cbb3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ziprasidone hydrochloride capsules are indicated for the treatment of schizophrenia. When deciding among the alternative treatments available for the condition needing treatment, the prescriber should consider the finding of ziprasidone's greater capacity to prolong the QT/QTc interval compared to several other antipsychotic drugs [see ]. Prolongation of the QTc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia, and sudden death. In many cases this would lead to the conclusion that other drugs should be tried first. Whether ziprasidone will cause torsade de pointes or increase the rate of sudden death is not yet known [see ] WARNINGS AND PRECAUTIONS ( ) 5.2 WARNINGS AND PRECAUTIONS ( ) 5.2 uuid:73100075-b571-43b5-8b02-7b2fe110e440 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10119 biolink:treats MONDO:0005477 PMID:41385096 "[{""id"":""uuid:d2d6520d-ddb7-478f-af1e-35ae1f82edaf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8dc6a901-6dfa-479b-9cbf-c851e1644053"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ziprasidone hydrochloride capsules are indicated for the treatment of schizophrenia. When deciding among the alternative treatments available for the condition needing treatment, the prescriber should consider the finding of ziprasidone's greater capacity to prolong the QT/QTc interval compared to several other antipsychotic drugs [see ]. Prolongation of the QTc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia, and sudden death. In many cases this would lead to the conclusion that other drugs should be tried first. Whether ziprasidone will cause torsade de pointes or increase the rate of sudden death is not yet known [see ] WARNINGS AND PRECAUTIONS ( ) 5.2 WARNINGS AND PRECAUTIONS ( ) 5.2 uuid:b8406b63-72f1-4105-89b6-39f8334d1a1a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3766 biolink:treats MONDO:0005090 PMID:41385096 "[{""id"":""uuid:d24fff02-89ee-4086-9200-6d765e9884e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6db7b26d-ef85-4011-868b-c78f3fe61ed2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:6d1e2a63-781b-4499-be1a-b9dc99073547"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CLOZARIL is an atypical antipsychotic indicated for: Treatment-resistant schizophrenia. Efficacy was established in an active-controlled study. ( , ) 1.1 14.1 Reducing suicidal behavior in patients with schizophrenia or schizoaffective disorder. Efficacy was established in an active-controlled study. ( , ) 1.2 14.2|[PMDA] Drugs with a new active ingredient indicated for the treatment of treatment-resistant schizophrenia. uuid:e09d28fd-3823-4579-9993-e0101a9f7307 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3766 biolink:treats MONDO:0005487 PMID:41385096 "[{""id"":""uuid:529948e3-659b-4b76-ac3d-08e729af0ad8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f90845d0-a198-4617-8b07-990fb9f17968"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CLOZARIL is an atypical antipsychotic indicated for: Treatment-resistant schizophrenia. Efficacy was established in an active-controlled study. ( , ) 1.1 14.1 Reducing suicidal behavior in patients with schizophrenia or schizoaffective disorder. Efficacy was established in an active-controlled study. ( , ) 1.2 14.2 uuid:b34c1fdd-c6d5-41a1-a214-8fd0b30cc7d9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3485 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:18c41b18-d90e-47fb-961b-c8957b0b39b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:580c0f96-92f0-418f-987a-d6c13a66b139"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir capsules and other antibacterial drugs, cefdinir capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Cefdinir capsules are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Adults and Adolescents Community-Acquired Pneumonia caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains) (see CLINICAL STUDIES). Acute Exacerbations of Chronic Bronchitis caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). Acute Maxillary Sinusitis caused by Haemophilus influenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). NOTE: For information on use in pediatric patients, see Pediatric Use and DOSAGE ANDADMINISTRATION. Pharyngitis/Tonsillitis caused by Streptococcus pyogenes (see CLINICAL STUDIES). NOTE: Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever following S. pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (including β-lactamase producing strains) and Streptococcus pyogenes. Pediatric Patients Acute Bacterial Otitis Media caused by Haemophilus influenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). Pharyngitis/Tonsillitis caused by Streptococcus pyogenes (see CLINICAL STUDIES). NOTE: Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever following S. pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (including β-lactamase producing strains) and Streptococcus pyogenes. uuid:9f74575c-51f7-40b5-958e-ebaf305a082c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3485 biolink:treats UMLS:C0853854 PMID:41385096 "[{""id"":""uuid:9bbb5cd6-68ca-4901-ad1d-1f9c8a3f5e6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d461863b-e47e-460b-9d5a-c24ec86bdbd3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir capsules and other antibacterial drugs, cefdinir capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Cefdinir capsules are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Adults and Adolescents Community-Acquired Pneumonia caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains) (see CLINICAL STUDIES). Acute Exacerbations of Chronic Bronchitis caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). Acute Maxillary Sinusitis caused by Haemophilus influenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). NOTE: For information on use in pediatric patients, see Pediatric Use and DOSAGE ANDADMINISTRATION. Pharyngitis/Tonsillitis caused by Streptococcus pyogenes (see CLINICAL STUDIES). NOTE: Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever following S. pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (including β-lactamase producing strains) and Streptococcus pyogenes. Pediatric Patients Acute Bacterial Otitis Media caused by Haemophilus influenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). Pharyngitis/Tonsillitis caused by Streptococcus pyogenes (see CLINICAL STUDIES). NOTE: Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever following S. pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (including β-lactamase producing strains) and Streptococcus pyogenes. uuid:f84b6945-7c01-442c-9ec6-be31d1efc96a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3485 biolink:treats MONDO:0002186 PMID:41385096 "[{""id"":""uuid:82ae230c-f7f1-46de-8ef7-690a94c8a9c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c4a91db7-94cc-4330-9d51-256c33a3f215"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir capsules and other antibacterial drugs, cefdinir capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Cefdinir capsules are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Adults and Adolescents Community-Acquired Pneumonia caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains) (see CLINICAL STUDIES). Acute Exacerbations of Chronic Bronchitis caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). Acute Maxillary Sinusitis caused by Haemophilus influenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). NOTE: For information on use in pediatric patients, see Pediatric Use and DOSAGE ANDADMINISTRATION. Pharyngitis/Tonsillitis caused by Streptococcus pyogenes (see CLINICAL STUDIES). NOTE: Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever following S. pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (including β-lactamase producing strains) and Streptococcus pyogenes. Pediatric Patients Acute Bacterial Otitis Media caused by Haemophilus influenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). Pharyngitis/Tonsillitis caused by Streptococcus pyogenes (see CLINICAL STUDIES). NOTE: Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever following S. pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (including β-lactamase producing strains) and Streptococcus pyogenes. uuid:099a9962-4229-4a3d-a023-af7a014a438e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3485 biolink:treats MONDO:0002258 PMID:41385096 "[{""id"":""uuid:d05042f2-90df-46c2-b25a-2a66abe06b6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:82ea3197-a713-4a8e-aa88-1532a8796f6a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir capsules and other antibacterial drugs, cefdinir capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Cefdinir capsules are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Adults and Adolescents Community-Acquired Pneumonia caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains) (see CLINICAL STUDIES). Acute Exacerbations of Chronic Bronchitis caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). Acute Maxillary Sinusitis caused by Haemophilus influenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). NOTE: For information on use in pediatric patients, see Pediatric Use and DOSAGE ANDADMINISTRATION. Pharyngitis/Tonsillitis caused by Streptococcus pyogenes (see CLINICAL STUDIES). NOTE: Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever following S. pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (including β-lactamase producing strains) and Streptococcus pyogenes. Pediatric Patients Acute Bacterial Otitis Media caused by Haemophilus influenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). Pharyngitis/Tonsillitis caused by Streptococcus pyogenes (see CLINICAL STUDIES). NOTE: Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever following S. pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (including β-lactamase producing strains) and Streptococcus pyogenes. uuid:39d7829b-57da-4e61-8fb4-482a38ca9398 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3485 biolink:treats MONDO:0001039 PMID:41385096 "[{""id"":""uuid:04808505-fc28-464c-a0c9-bf8d2214b57e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9199ab5a-399b-42a8-830d-e96353bd609f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir capsules and other antibacterial drugs, cefdinir capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Cefdinir capsules are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Adults and Adolescents Community-Acquired Pneumonia caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains) (see CLINICAL STUDIES). Acute Exacerbations of Chronic Bronchitis caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). Acute Maxillary Sinusitis caused by Haemophilus influenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). NOTE: For information on use in pediatric patients, see Pediatric Use and DOSAGE ANDADMINISTRATION. Pharyngitis/Tonsillitis caused by Streptococcus pyogenes (see CLINICAL STUDIES). NOTE: Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever following S. pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (including β-lactamase producing strains) and Streptococcus pyogenes. Pediatric Patients Acute Bacterial Otitis Media caused by Haemophilus influenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). Pharyngitis/Tonsillitis caused by Streptococcus pyogenes (see CLINICAL STUDIES). NOTE: Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever following S. pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (including β-lactamase producing strains) and Streptococcus pyogenes. uuid:3d956d7d-ffea-4bf9-905a-05058314713f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3485 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:d28f638c-8660-4790-8dec-225508543bd2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:044c941d-72d8-4f62-832c-145b8d81dbe4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir capsules and other antibacterial drugs, cefdinir capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Cefdinir capsules are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Adults and Adolescents Community-Acquired Pneumonia caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains) (see CLINICAL STUDIES). Acute Exacerbations of Chronic Bronchitis caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). Acute Maxillary Sinusitis caused by Haemophilus influenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). NOTE: For information on use in pediatric patients, see Pediatric Use and DOSAGE ANDADMINISTRATION. Pharyngitis/Tonsillitis caused by Streptococcus pyogenes (see CLINICAL STUDIES). NOTE: Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever following S. pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (including β-lactamase producing strains) and Streptococcus pyogenes. Pediatric Patients Acute Bacterial Otitis Media caused by Haemophilus influenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). Pharyngitis/Tonsillitis caused by Streptococcus pyogenes (see CLINICAL STUDIES). NOTE: Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever following S. pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (including β-lactamase producing strains) and Streptococcus pyogenes. uuid:178294a2-81f2-4a45-83d8-6ffe99b9ce5f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3485 biolink:treats MONDO:0001031 PMID:41385096 "[{""id"":""uuid:399a85e6-16e5-4b0a-9a17-2d2cea5278f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b4035e89-2c62-46fe-b862-b7cde0e81f02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir capsules and other antibacterial drugs, cefdinir capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Cefdinir capsules are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Adults and Adolescents Community-Acquired Pneumonia caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains) (see CLINICAL STUDIES). Acute Exacerbations of Chronic Bronchitis caused by Haemophilus influenzae (including β-lactamase producing strains), Haemophilus parainfluenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). Acute Maxillary Sinusitis caused by Haemophilus influenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). NOTE: For information on use in pediatric patients, see Pediatric Use and DOSAGE ANDADMINISTRATION. Pharyngitis/Tonsillitis caused by Streptococcus pyogenes (see CLINICAL STUDIES). NOTE: Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever following S. pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (including β-lactamase producing strains) and Streptococcus pyogenes. Pediatric Patients Acute Bacterial Otitis Media caused by Haemophilus influenzae (including β-lactamase producing strains), Streptococcus pneumoniae (penicillin-susceptible strains only), and Moraxella catarrhalis (including β-lactamase producing strains). Pharyngitis/Tonsillitis caused by Streptococcus pyogenes (see CLINICAL STUDIES). NOTE: Cefdinir is effective in the eradication of S. pyogenes from the oropharynx. Cefdinir has not, however, been studied for the prevention of rheumatic fever following S. pyogenes pharyngitis/tonsillitis. Only intramuscular penicillin has been demonstrated to be effective for the prevention of rheumatic fever. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (including β-lactamase producing strains) and Streptococcus pyogenes. uuid:8f9dcec3-8f52-4016-a081-7b7308154b47 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3756 biolink:treats MONDO:0003709 PMID:41385096 "[{""id"":""uuid:d71de741-752b-45fa-a32a-b233822d0d38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4ff43ca5-67f9-42de-9bd0-1d7a5d96bffa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clonazepam tablets, USP are useful alone or as an adjunct in the treatment of the Lennox-Gastaut syndrome (petit mal variant), akinetic and myoclonic seizures. In patients with absence seizures (petit mal) who have failed to respond to succinimides, clonazepam may be useful. Seizure Disorders: In some studies, up to 30% of patients have shown a loss of anticonvulsant activity, often within 3 months of administration. In some cases, dosage adjustment may reestablish efficacy. Clonazepam tablets, USP are indicated for the treatment of panic disorder, with or without agoraphobia, as defined in DSM-IV. Panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. Panic Disorder: The efficacy of clonazepam was established in two 6- to 9-week trials in panic disorder patients whose diagnoses corresponded to the DSM-IIIR category of panic disorder (see ). CLlNICAL PHARMACOLOGY: Clinical Trials Panic disorder (DSM-IV) is characterized by recurrent unexpected panic attacks, ie, a discrete period of intense fear or discomfort in which four (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) palpitations, pounding heart or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes. The effectiveness of clonazepam in long-term use, that is, for more than 9 weeks, has not been systematically studied in controlled clinical trials. The physician who elects to use clonazepam for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual patient (see ). DOSAGE AND ADMINISTRATION uuid:c375145c-2729-45d1-8512-06dcee44f8de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5613 biolink:treats MONDO:0005090 PMID:41385096 "[{""id"":""uuid:781f2599-bca9-4899-a3e6-26688074c530"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:480bf2cf-a58b-4168-82e1-e7fb46735e03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Haloperidol is indicated for use in the treatment of schizophrenia. Haloperidol is indicated for the control of tics and vocal utterances of Tourette's Disorder. uuid:456ff550-bff7-4927-a6af-044727a70c22 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5391 biolink:treats MONDO:0004946 PMID:41385096 "[{""id"":""uuid:e3432425-5188-4f16-8668-4a97fc9e46b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b1e27c11-7ee9-47cd-88ca-884e591f4d30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:10006909-aa80-4259-99cf-daf4cda5b7a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ogluo""]},{""id"":""uuid:7dc7756a-73a9-4354-b1e3-04e21b60979a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of hypoglycemia: Glucagon is indicated as a treatment for severe hypoglycemia. Because patients with type 1 diabetes may have less of an increase in blood glucose levels compared with a stable type 2 patient, supplementary carbohydrate should be given as soon as possible, especially to a pediatric patient.|[EMA] Ogluo is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus.|[PMDA] A drug with a new route of administration indicated for the emergency treatment of hypoglycemia. uuid:c1d6e057-facc-4d57-80e4-bc19b16f6319 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7476 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:f7da0b1e-2a06-48c6-a4df-e4c98f4ee5ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3097387c-86e3-47c7-89b3-6a5e76f8eb7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of Naproxen Sodium Tablets, USP and other treatment options before deciding to use Naproxen Sodium Tablets, USP. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS). Naproxen suspension is recommended for juvenile rheumatoid arthritis in order to obtain the maximum dosage flexibility based on the patient's weight. Naproxen as naproxen sodium tablets are indicated: • For the relief of the signs and symptoms of rheumatoid arthritis • For the relief of the signs and symptoms of osteoarthritis • For the relief of the signs and symptoms of ankylosing spondylitis • For the relief of the signs and symptoms of juvenile arthritis • For relief of the signs and symptoms of tendonitis • For relief of the signs and symptoms of bursitis • For relief of the signs and symptoms of acute gout • For the management of pain • For the management of primary dysmenorrhea uuid:066010dc-e097-4ac1-b5a2-e35d8478c1ce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:66545969 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:c3f2fdcd-3aa7-4d75-bc8d-00eb6a5d39ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a0091c0c-f88b-4665-ab56-566af1d70e04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] STRIBILD ® is indicated as a complete regimen for the treatment of HIV-1 infection in adults who are antiretroviral treatment-naïve. uuid:77f83be0-4946-40ca-b38a-b4537dda9852 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63577 biolink:treats MONDO:0005366 PMID:41385096 "[{""id"":""uuid:6fb036f5-df73-4315-a06f-c461ba83ca17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:594e4472-e9ad-4eb7-a63d-96343465ac6d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7b82bb57-5c09-45f7-a609-fbf9b18e215d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lamivudine-teva-pharma-bv""]},{""id"":""uuid:0e77961b-2103-42e4-a404-d6f9aebaffa3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EPIVIR-HBV is indicated for the treatment of chronic hepatitis B virus (HBV) infection associated with evidence of hepatitis B viral replication and active liver inflammation [see Clinical Studies (14.1, 14.2)]. The following points should be considered when initiating therapy with EPIVIR-HBV: • Due to high rates of resistance development in treated patients, initiation of treatment with EPIVIR-HBV should only be considered when the use of an alternative antiviral agent with a higher genetic barrier to resistance is not available or appropriate. • EPIVIR-HBV has not been evaluated in patients co-infected with HIV, hepatitis C virus (HCV), or hepatitis delta virus. • EPIVIR-HBV has not been evaluated in liver transplant recipients or in patients with chronic hepatitis B virus infection with decompensated liver disease. • EPIVIR-HBV has not been evaluated in pediatric patients younger than 2 years of age with chronic HBV infection.|[EMA] Lamivudine Teva is indicated for the treatment of chronic hepatitis B in adults with:compensated liver disease with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active liver inflammation and / or fibrosis. Initiation of lamivudine treatment should only be considered when the use of an alternative antiviral agent with a higher genetic barrier is not available or appropriate (see in section 5.1).|[PMDA] Addition to indications for improving the levels of viral markers and hepatic function in chronic hepatitis B and hepatitis B cirrhosis in which an abnormality of the hepatic function with persistent regrowth of type B hepatitis viruses has been confirmed during administration of this drug combined with adefovir pivoxil. uuid:20327135-ae8d-4ac5-9407-a35e3263a955 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63577 biolink:treats MONDO:0005344 PMID:41385096 "[{""id"":""uuid:a57d7195-d3bb-4a5b-8631-276523250e0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7be7dd89-c4c1-4857-bbe6-0be40fdb0306"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:96324b17-7b69-47e7-aa24-f7d1e9f50777"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EPIVIR-HBV is indicated for the treatment of chronic hepatitis B virus (HBV) infection associated with evidence of hepatitis B viral replication and active liver inflammation [see Clinical Studies (14.1, 14.2)]. The following points should be considered when initiating therapy with EPIVIR-HBV: • Due to high rates of resistance development in treated patients, initiation of treatment with EPIVIR-HBV should only be considered when the use of an alternative antiviral agent with a higher genetic barrier to resistance is not available or appropriate. • EPIVIR-HBV has not been evaluated in patients co-infected with HIV, hepatitis C virus (HCV), or hepatitis delta virus. • EPIVIR-HBV has not been evaluated in liver transplant recipients or in patients with chronic hepatitis B virus infection with decompensated liver disease. • EPIVIR-HBV has not been evaluated in pediatric patients younger than 2 years of age with chronic HBV infection.|[PMDA] A new indication for “improving viral markers in patients with hepatitis B cirrhosis complicated by proliferation of hepatitis B virus and with abnormal hepatic function to be confirmed” in monotherapy [Priority review] uuid:c6c7a102-7890-43b5-a01e-97713840f7ff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63577 biolink:treats MONDO:0002251 PMID:41385096 "[{""id"":""uuid:bdbcb0c0-61f2-40f9-b680-4cd3b73528eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:88807f5b-aba3-411b-a11c-30416837a114"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EPIVIR-HBV is indicated for the treatment of chronic hepatitis B virus (HBV) infection associated with evidence of hepatitis B viral replication and active liver inflammation [see Clinical Studies (14.1, 14.2)]. The following points should be considered when initiating therapy with EPIVIR-HBV: • Due to high rates of resistance development in treated patients, initiation of treatment with EPIVIR-HBV should only be considered when the use of an alternative antiviral agent with a higher genetic barrier to resistance is not available or appropriate. • EPIVIR-HBV has not been evaluated in patients co-infected with HIV, hepatitis C virus (HCV), or hepatitis delta virus. • EPIVIR-HBV has not been evaluated in liver transplant recipients or in patients with chronic hepatitis B virus infection with decompensated liver disease. • EPIVIR-HBV has not been evaluated in pediatric patients younger than 2 years of age with chronic HBV infection. uuid:1279147b-5692-45ab-aec5-b754e2c3451a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63577 biolink:treats MONDO:0005354 PMID:41385096 "[{""id"":""uuid:8463a878-f52f-4f91-901a-b3fcb0652090"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8bfe3ce1-a833-4abc-9ed9-82341eb41d76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EPIVIR-HBV is indicated for the treatment of chronic hepatitis B virus (HBV) infection associated with evidence of hepatitis B viral replication and active liver inflammation [see Clinical Studies (14.1, 14.2)]. The following points should be considered when initiating therapy with EPIVIR-HBV: • Due to high rates of resistance development in treated patients, initiation of treatment with EPIVIR-HBV should only be considered when the use of an alternative antiviral agent with a higher genetic barrier to resistance is not available or appropriate. • EPIVIR-HBV has not been evaluated in patients co-infected with HIV, hepatitis C virus (HCV), or hepatitis delta virus. • EPIVIR-HBV has not been evaluated in liver transplant recipients or in patients with chronic hepatitis B virus infection with decompensated liver disease. • EPIVIR-HBV has not been evaluated in pediatric patients younger than 2 years of age with chronic HBV infection. uuid:a427c7a4-1068-4862-83b3-f49de8e780ef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63577 biolink:treats MONDO:0005789 PMID:41385096 "[{""id"":""uuid:6b8f6e22-d2bf-4104-9689-bac50d7de510"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2c3b90ae-473e-4bd4-9030-ecfc5b8e9d6c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EPIVIR-HBV is indicated for the treatment of chronic hepatitis B virus (HBV) infection associated with evidence of hepatitis B viral replication and active liver inflammation [see Clinical Studies (14.1, 14.2)]. The following points should be considered when initiating therapy with EPIVIR-HBV: • Due to high rates of resistance development in treated patients, initiation of treatment with EPIVIR-HBV should only be considered when the use of an alternative antiviral agent with a higher genetic barrier to resistance is not available or appropriate. • EPIVIR-HBV has not been evaluated in patients co-infected with HIV, hepatitis C virus (HCV), or hepatitis delta virus. • EPIVIR-HBV has not been evaluated in liver transplant recipients or in patients with chronic hepatitis B virus infection with decompensated liver disease. • EPIVIR-HBV has not been evaluated in pediatric patients younger than 2 years of age with chronic HBV infection. uuid:cbd679a0-7677-484d-a74f-a75c8d970f6f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8060 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:fc08e1f3-ae63-4f5f-ad1b-f77576aed2ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c0c9c0b7-0754-409f-a7fa-f5130614f960"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Phenelzine Sulfate Tablets, USP has been found to be effective in depressed patients clinically characterized as “atypical,” “nonendogenous,” or “neurotic.” These patients often have mixed anxiety and depression and phobic or hypochondriacal features. There is less conclusive evidence of its usefulness with severely depressed patients with endogenous features. Phenelzine Sulfate Tablets should rarely be the first antidepressant drug used. Rather, it is more suitable for use with patients who have failed to respond to the drugs more commonly used for these conditions. uuid:cbf58d52-ee56-4387-8541-37136bd4f9d7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8060 biolink:treats MONDO:0011918 PMID:41385096 "[{""id"":""uuid:f4b5fa52-8333-4fe7-b89b-abc72364a31a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0268d92d-3831-4cd4-9622-86e974f37daf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Phenelzine Sulfate Tablets, USP has been found to be effective in depressed patients clinically characterized as “atypical,” “nonendogenous,” or “neurotic.” These patients often have mixed anxiety and depression and phobic or hypochondriacal features. There is less conclusive evidence of its usefulness with severely depressed patients with endogenous features. Phenelzine Sulfate Tablets should rarely be the first antidepressant drug used. Rather, it is more suitable for use with patients who have failed to respond to the drugs more commonly used for these conditions. uuid:9ffc468f-998b-48ce-93d7-c0e11f4b389b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8060 biolink:treats MONDO:0003699 PMID:41385096 "[{""id"":""uuid:0650c839-0c42-421c-9a20-7e37df4fd8c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:75e11cd9-37a7-4834-a301-94f606127a6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Phenelzine Sulfate Tablets, USP has been found to be effective in depressed patients clinically characterized as “atypical,” “nonendogenous,” or “neurotic.” These patients often have mixed anxiety and depression and phobic or hypochondriacal features. There is less conclusive evidence of its usefulness with severely depressed patients with endogenous features. Phenelzine Sulfate Tablets should rarely be the first antidepressant drug used. Rather, it is more suitable for use with patients who have failed to respond to the drugs more commonly used for these conditions. uuid:a585e99e-ad06-4848-8e7b-d202641f323e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8060 biolink:treats MONDO:0001596 PMID:41385096 "[{""id"":""uuid:3aead9ba-cfce-4fc5-8d94-4bf7a12de6a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d75722cd-6375-44fa-83a1-0ce5bb25d171"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Phenelzine Sulfate Tablets, USP has been found to be effective in depressed patients clinically characterized as “atypical,” “nonendogenous,” or “neurotic.” These patients often have mixed anxiety and depression and phobic or hypochondriacal features. There is less conclusive evidence of its usefulness with severely depressed patients with endogenous features. Phenelzine Sulfate Tablets should rarely be the first antidepressant drug used. Rather, it is more suitable for use with patients who have failed to respond to the drugs more commonly used for these conditions. uuid:cf7a3e0d-c4cd-4107-93d0-20fd0ef5243a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37510 biolink:treats UMLS:C0406326 PMID:41385096 "[{""id"":""uuid:06819930-9fd0-4ad3-94b6-785232306f2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a9efce79-a8f8-4bf0-bce1-e8d7551ba0aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Zithranol Shampoo for the treatment of scalp psoriasis in subjects 12 years of age and older (see PRECAUTIONS). Patients should be instructed to use Zithranol Shampoo for the minimum time period necessary to achieve the desired results. uuid:ec7c2945-f6e2-469c-82c0-85e97616622c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5558 biolink:treats MONDO:0007743 PMID:41385096 "[{""id"":""uuid:07dbc39e-6205-4a37-a4c7-046efd2ec3e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c37dd418-cfd2-4205-bbd6-c55667412683"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1da067e9-0457-4b2b-ab8f-c57a94566a90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INTUNIV is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications. The efficacy of INTUNIV was studied for the treatment of ADHD in three controlled monotherapy clinical trials (up to 8 weeks in duration) and one controlled adjunctive trial with psychostimulants (8 weeks in duration) in children and adolescents ages 6-17 who met DSM-IV criteria for ADHD [ ]. The effectiveness of INTUNIV for longer-term use (more than 8 weeks) has not been systematically evaluated in controlled trials. ® ® ® see Clinical Studies (14) ®|[EMA] Intuniv is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6 17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective., , Intuniv must be used as a part of a comprehensive ADHD treatment programme, typically including psychological, educational and social measures., uuid:f487f1f5-9264-49b4-968a-be5f20ad9056 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5558 biolink:treats MONDO:0005302 PMID:41385096 "[{""id"":""uuid:a16b8572-f2f9-4f84-9a96-d61479307367"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f695ee05-d055-4ab6-8cfb-ffb65c283314"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:05ec20d3-3181-4070-a318-bf06b5eee45d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INTUNIV is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications. The efficacy of INTUNIV was studied for the treatment of ADHD in three controlled monotherapy clinical trials (up to 8 weeks in duration) and one controlled adjunctive trial with psychostimulants (8 weeks in duration) in children and adolescents ages 6-17 who met DSM-IV criteria for ADHD [ ]. The effectiveness of INTUNIV for longer-term use (more than 8 weeks) has not been systematically evaluated in controlled trials. ® ® ® see Clinical Studies (14) ®|[PMDA] Drugs with a new active ingredient indicated for the treatment of pediatric attention deficit/hyperactivity disorder (AD/HD). uuid:d1b26ce8-631b-4e0a-97dd-8cd9aa6dce6d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50690 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:ef346d77-86f1-44e6-80f4-d674a9589192"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:365a8b2d-c880-40cf-95bb-babcc9784976"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In patients with clinically evident coronary heart disease, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin Calcium Tablets is indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C remains ≥ 190 mg/dL or LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin Calcium Tablets has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:4df2c518-785e-44a4-8d99-71e9f456c9ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50690 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:a241a3db-27f4-4fe3-8169-2fd95f72a1df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0244cb71-4bcc-43d7-b3e7-768f6807a09b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In patients with clinically evident coronary heart disease, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin Calcium Tablets is indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C remains ≥ 190 mg/dL or LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin Calcium Tablets has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:58452684-13e8-446d-8398-d4c8514c4cfd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50690 biolink:treats HP:0012592 PMID:41385096 "[{""id"":""uuid:b4d0f71c-a646-47b0-8b7e-9154a0caafef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fda529d2-a513-4d64-a261-34c101674243"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In patients with clinically evident coronary heart disease, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin Calcium Tablets is indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C remains ≥ 190 mg/dL or LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin Calcium Tablets has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:a33fd4f9-ed83-4b5d-83a5-e2ac6bc395f1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50690 biolink:treats UMLS:C0342879 PMID:41385096 "[{""id"":""uuid:313b8969-ba67-4ec7-9c3c-7355e257fc62"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0c349110-6514-4c83-b81b-0bdb016e96b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In patients with clinically evident coronary heart disease, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin Calcium Tablets is indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C remains ≥ 190 mg/dL or LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin Calcium Tablets has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:a12f3cf2-1487-4fb9-a53b-e930a6e9676d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50690 biolink:treats UMLS:C0342882 PMID:41385096 "[{""id"":""uuid:ec696a29-a939-449e-a77e-0f7c371b4176"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5e0f111f-ddf9-4fbb-9a16-7fc45f8889f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In patients with clinically evident coronary heart disease, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin Calcium Tablets is indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C remains ≥ 190 mg/dL or LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin Calcium Tablets has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:ae54360c-8ad3-46dd-9149-253958f2996f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50690 biolink:treats HP:0003119 PMID:41385096 "[{""id"":""uuid:a1a8e341-251d-426d-904a-a31dae7c99a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3225dcaa-db69-47b2-bb12-f31c5ecd8d9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In patients with clinically evident coronary heart disease, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin Calcium Tablets is indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C remains ≥ 190 mg/dL or LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin Calcium Tablets has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:f5f6eabc-0fac-47ea-a899-9f68c8a8af22 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50690 biolink:treats MONDO:0007750 PMID:41385096 "[{""id"":""uuid:c8bb4547-4dff-4b9a-b2c4-b03b392d878b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:da2e69f1-1351-476a-b91a-1b844c5b471d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In patients with clinically evident coronary heart disease, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin Calcium Tablets is indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C remains ≥ 190 mg/dL or LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin Calcium Tablets has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:e0c3bb1b-fca9-4f0d-8441-8f479ce2e9e5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50690 biolink:treats MONDO:0007759 PMID:41385096 "[{""id"":""uuid:f1fc0bc5-a928-4e47-9d22-9abb01213242"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5fe9ec8a-20ba-47c3-88b0-50bcfcba9624"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In patients with clinically evident coronary heart disease, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin Calcium Tablets is indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C remains ≥ 190 mg/dL or LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin Calcium Tablets has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:5f328c30-a4e3-4803-b9f8-515ae821b67e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50690 biolink:treats MONDO:0037748 PMID:41385096 "[{""id"":""uuid:06bb141b-f51f-4a06-9542-db96de220044"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:46ac65a0-66f4-4119-aa1f-30b6060fd641"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In patients with clinically evident coronary heart disease, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin Calcium Tablets is indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C remains ≥ 190 mg/dL or LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin Calcium Tablets has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:3e598298-4b39-4442-a18d-2659a46c7cac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50690 biolink:treats MONDO:0018473 PMID:41385096 "[{""id"":""uuid:fc8e5ac7-8d8b-4af8-8c1b-9fbccd1053ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c8356436-6387-4c0d-b88b-06a0d3ee9818"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In patients with clinically evident coronary heart disease, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin Calcium Tablets is indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C remains ≥ 190 mg/dL or LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin Calcium Tablets has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:ed6aa9a4-06fa-441c-8c40-2a7b1d2549dd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50690 biolink:treats MONDO:0018328 PMID:41385096 "[{""id"":""uuid:0969f9aa-ca9f-4124-b293-35f85d752c77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6368681b-dbef-4568-9481-7db5e2bac843"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In patients with clinically evident coronary heart disease, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin Calcium Tablets is indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C remains ≥ 190 mg/dL or LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin Calcium Tablets has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:74de88e3-6ac0-49b6-a1a6-bd47f3531b81 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50690 biolink:treats MONDO:0007788 PMID:41385096 "[{""id"":""uuid:80e88567-6395-419b-bdab-e5257c8f420d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ca185b55-d9dc-47e7-b1a4-b7ceb1c43d29"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In patients with clinically evident coronary heart disease, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin Calcium Tablets is indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C remains ≥ 190 mg/dL or LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin Calcium Tablets has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:a64c24b9-7523-4828-89a9-a28e3fc20a00 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50690 biolink:treats MONDO:0007762 PMID:41385096 "[{""id"":""uuid:ac9a172b-1503-42f9-b534-8c3f28db6b48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:61a2bd9c-b695-497b-87a5-6f315f860eb9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In patients with clinically evident coronary heart disease, Atorvastatin Calcium Tablets is indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin Calcium Tablets is indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: LDL-C remains ≥ 190 mg/dL or LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin Calcium Tablets has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:00f2cf9f-4a1b-4a5c-8769-c1ba2af5c9b9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3534 biolink:treats MONDO:0030603 PMID:41385096 "[{""id"":""uuid:fc4fd4bb-9697-4f1c-8727-833648c0e142"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c10eaa14-cb41-4a72-8e22-2f151cb29ac1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cephalexin Capsules USP are indicated for the treatment of the following infections when caused by susceptible strains of the designated microorganisms: Respiratory tract infections caused by and . (Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cephalexin is generally effective in the eradication of streptococci from the nasopharynx; however, substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present.) Streptococcus pneumoniae Streptococcus pyogenes Otitis media due to , , , , and . Streptococcus pneumoniae Haemophilus influenzae Staphylococcus aureus Streptococcus pyogenes Moraxella catarrhalis Skin and skin structure infections caused by and/or . Staphylococcus aureus Streptococcus pyogenes Bone infections caused by and/or . Staphylococcus aureus Proteus mirabilis Genitourinary tract infections, including acute prostatitis, caused by , , and pneumoniae. Escherichia coli Proteus mirabilis Klebsiella Note – Culture and susceptibility tests should be initiated prior to and during therapy. Renal function studies should be performed when indicated. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cephalexin capsules and other antibacterial drugs, cephalexin capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:f01b3293-602c-42ee-977e-a1e09cf31eab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32016 biolink:treats MONDO:0002771 PMID:41385096 "[{""id"":""uuid:a36762fd-06c1-43bb-96e1-dbd657ac7a43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0c04c3a7-30ed-41cd-9e78-179ab6e1f6f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e530fd22-287e-459d-b4bc-f42e56df5ff4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/pirfenidone-viatris""]},{""id"":""uuid:d60dd53b-e280-4d81-98aa-daae3d3796eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ESBRIET is indicated for the treatment of idiopathic pulmonary fibrosis (IPF).|[EMA] Esbriet is indicated in adults for the treatment of idiopathic pulmonary fibrosis.|[PMDA] A drug containing a new active ingredient indicated for the treatment of idiopathic pulmonary fibrosis. [Orphan drug] uuid:4f741b70-d8ec-4bad-a4a4-e24af3560c37 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3647 biolink:treats HP:0002018 PMID:41385096 "[{""id"":""uuid:d1adceb5-e42e-4875-9d47-6926c11e6172"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4a27ddad-848b-4b91-aa40-de6ccdc5ca79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of schizophrenia; to control nausea and vomiting; for relief of restlessness and apprehension before surgery; for acute intermittent porphyria; as an adjunct in the treatment of tetanus; to control the manifestations of the manic type of manic-depressive illness; for relief of intractable hiccups; for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance. uuid:0a8ea9e1-f89b-45e8-9257-1a04a0f3b967 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3647 biolink:treats HP:0002013 PMID:41385096 "[{""id"":""uuid:9353a899-88dd-4237-9f80-6a712649f46c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3ddf97f8-bfec-4cf3-bffc-510526bdefe5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of schizophrenia; to control nausea and vomiting; for relief of restlessness and apprehension before surgery; for acute intermittent porphyria; as an adjunct in the treatment of tetanus; to control the manifestations of the manic type of manic-depressive illness; for relief of intractable hiccups; for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance. uuid:f5f48392-72f5-4bf0-baa7-a610196bebff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3647 biolink:treats UMLS:C0744896 PMID:41385096 "[{""id"":""uuid:4d68686d-4946-424c-933b-865a56d042b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:65a01342-7b1f-4e71-bfa2-2a7728ac989d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of schizophrenia; to control nausea and vomiting; for relief of restlessness and apprehension before surgery; for acute intermittent porphyria; as an adjunct in the treatment of tetanus; to control the manifestations of the manic type of manic-depressive illness; for relief of intractable hiccups; for the treatment of severe behavioral problems in children (1 to 12 years of age) marked by combativeness and/or explosive hyperexcitable behavior (out of proportion to immediate provocations), and in the short-term treatment of hyperactive children who show excessive motor activity with accompanying conduct disorders consisting of some or all of the following symptoms: impulsivity, difficulty sustaining attention, aggressivity, mood lability, and poor frustration tolerance. uuid:54be97ff-e220-4a28-ac86-80373a0d4ae0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9139 biolink:treats MONDO:0015924 PMID:41385096 "[{""id"":""uuid:c4e39b2b-b23e-4c2d-b5bb-80041f98f023"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:86690441-4706-4cc4-9191-b2f34057a56c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:46808781-7556-4a36-a13b-f6b00e747006"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/revatio""]},{""id"":""uuid:31ad36eb-d5e9-4571-ac1a-8f8bf1da0e45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sildenafil tablets are indicated for the treatment of pulmonary arterial hypertension (WHO Group I) in adults to improve exercise ability and delay clinical worsening. The delay in clinical worsening was demonstrated when sildenafil tablets were added to background epoprostenol therapy [see Clinical Studies (14)]. Studies establishing effectiveness were short-term (12 to 16 weeks), and included predominately patients with New York Heart Association (NYHA) Functional Class II-III symptoms and idiopathic etiology (71%) or associated with connective tissue disease (CTD) (25%). Limitation of Use The efficacy of sildenafil tablets in the treatment of pulmonary arterial hypertension (PAH) has not been adequately evaluated in patients taking bosentan.|[EMA] Treatment of adult patients with pulmonary arterial hypertension classified as World Health Organization (WHO) functional class II and III, to improve exercise capacity. Efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease.Paediatric populationTreatment of paediatric patients aged one year to 17 years old with pulmonary arterial hypertension. Efficacy in terms of improvement of exercise capacity or pulmonary haemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease.Revatio solution for injection is for the treatment of adult patients with pulmonary arterial hypertension who are currently prescribed oral Revatio and who are temporarily unable to take oral therapy, but are otherwise clinically and haemodynamically stable.Revatio (oral) is indicated for treatment of adult patients with pulmonary arterial hypertension classified as WHO functional class II and III, to improve exercise capacity. Efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease.|[PMDA] A drug with a new indication and dosage for the treatment of pulmonary arterial hypertension. [Orphan drug] uuid:83b53a87-f90d-4c9f-af3a-b870b07c182b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9139 biolink:treats MONDO:0003900 PMID:41385096 "[{""id"":""uuid:b2e5e080-96c7-4fa1-93e4-9386ee884f3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d6e558a9-3baf-40a3-b3f2-c4493d9c402d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sildenafil tablets are indicated for the treatment of pulmonary arterial hypertension (WHO Group I) in adults to improve exercise ability and delay clinical worsening. The delay in clinical worsening was demonstrated when sildenafil tablets were added to background epoprostenol therapy [see Clinical Studies (14)]. Studies establishing effectiveness were short-term (12 to 16 weeks), and included predominately patients with New York Heart Association (NYHA) Functional Class II-III symptoms and idiopathic etiology (71%) or associated with connective tissue disease (CTD) (25%). Limitation of Use The efficacy of sildenafil tablets in the treatment of pulmonary arterial hypertension (PAH) has not been adequately evaluated in patients taking bosentan. uuid:fbd3dc1a-d5ca-4a19-888a-3abd61bde96e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8707 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:c6a34c7a-a6db-49e8-9ede-7c1bcd0e7d94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0db65e90-d846-402f-b459-d0b284a4d19b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SEROQUEL XR is an atypical antipsychotic indicated for the treatment of: Schizophrenia • (1.1) Bipolar I disorder, manic or mixed episodes • (1.2) Bipolar disorder, depressive episodes • (1.2) Major depressive disorder, adjunctive therapy with antidepressants • (1.3) uuid:d9bfacb9-f810-4b91-84f5-97aad64a1a41 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5123 biolink:treats MONDO:0005090 PMID:41385096 "[{""id"":""uuid:df3d35c4-7831-4363-bf91-06e248086e82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7da6fd02-e86c-40e9-a2f0-31d85ff29f8e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluphenazine Decanoate Injection is a long-acting parenteral antipsychotic drug intended for use in the management of patients requiring prolonged parenteral neuroleptic therapy (e.g., chronic schizophrenics). Fluphenazine Decanoate Injection has not been shown effective in the management of behavioral complications in patients with mental retardation. uuid:35b73093-45bb-482c-ad77-deb3a5ded5a1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB09100 biolink:treats MONDO:0005420 PMID:41385096 "[{""id"":""uuid:db94e984-8ccd-40d1-9955-975d8fcb1109"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d5598db3-0ef6-4598-b741-22290e2d0962"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Armour Thyroid tablets are indicated: As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (SeeWARNINGS). As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic Iymphocytic thyroiditis (Hashimoto's), multinodular goiter, and in the management of thyroid cancer. uuid:7c839bc9-6dbe-41d7-91d2-576861bcf7d4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB09100 biolink:treats MONDO:0018612 PMID:41385096 "[{""id"":""uuid:f7cefccb-9f3b-40e7-9fdc-336d9391d66d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ea71fee1-9c99-4b63-9651-c0cf2f852df6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Armour Thyroid tablets are indicated: As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (SeeWARNINGS). As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic Iymphocytic thyroiditis (Hashimoto's), multinodular goiter, and in the management of thyroid cancer. uuid:dc8a3fdb-ba92-42b3-9963-2f6d60ddf255 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB09100 biolink:treats MONDO:0009718 PMID:41385096 "[{""id"":""uuid:5ade51e6-0b00-450f-b135-901691458981"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dfe84aa4-af3a-4f4e-a9d1-43d74a64aae3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Armour Thyroid tablets are indicated: As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (SeeWARNINGS). As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic Iymphocytic thyroiditis (Hashimoto's), multinodular goiter, and in the management of thyroid cancer. uuid:d984242e-4c77-418e-85e8-57f21763d09b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB09100 biolink:treats MONDO:0001658 PMID:41385096 "[{""id"":""uuid:d3107d7b-ddef-4ae9-84f0-8776452da928"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cc15d876-e260-4989-b98b-27698d6733cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Armour Thyroid tablets are indicated: As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (SeeWARNINGS). As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic Iymphocytic thyroiditis (Hashimoto's), multinodular goiter, and in the management of thyroid cancer. uuid:55072b18-393a-45e8-b5fc-b2d7cec35294 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB09100 biolink:treats HP:0025388 PMID:41385096 "[{""id"":""uuid:560c3a07-3f87-4e56-b6ee-807ab20ab9dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e2993bcd-7e46-4a58-a52c-a878853393f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Armour Thyroid tablets are indicated: As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (SeeWARNINGS). As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic Iymphocytic thyroiditis (Hashimoto's), multinodular goiter, and in the management of thyroid cancer. uuid:f44405f3-d213-4a6e-90d9-0c00ea6bf3f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB09100 biolink:treats MONDO:0007699 PMID:41385096 "[{""id"":""uuid:aaf74fc1-cf18-4c77-bbb2-08a415ea725a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:268be66b-472b-43ee-8dd3-7f00008a04e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Armour Thyroid tablets are indicated: As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (SeeWARNINGS). As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic Iymphocytic thyroiditis (Hashimoto's), multinodular goiter, and in the management of thyroid cancer. uuid:9c43471b-fe8a-4fa6-9226-88ce9bca1af6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB09100 biolink:treats MONDO:0000334 PMID:41385096 "[{""id"":""uuid:0da672b9-febc-48d4-ac30-95c726d5e4d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c96e5cf7-1160-4982-a410-59cfb73b5d8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Armour Thyroid tablets are indicated: As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (SeeWARNINGS). As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic Iymphocytic thyroiditis (Hashimoto's), multinodular goiter, and in the management of thyroid cancer. uuid:fc62918f-26ad-442f-8058-b16f7f7ab4dc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB09100 biolink:treats MONDO:0002108 PMID:41385096 "[{""id"":""uuid:b110bb7c-d1bc-495e-9322-94c0609aa132"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0e27929e-44ec-4ad5-a5fe-122e0a0d6284"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Armour Thyroid tablets are indicated: As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (SeeWARNINGS). As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic Iymphocytic thyroiditis (Hashimoto's), multinodular goiter, and in the management of thyroid cancer. uuid:b9b1130d-dfc1-448e-a29b-7f42c24812a5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1593740 biolink:treats MONDO:0100471 PMID:41385096 "[{""id"":""uuid:29bc2d0e-94ba-4668-9254-13ccaf1e8801"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:95f691b2-a514-4e41-b011-1c035064069a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciferex is indicated for dietary management of patients with unique nutritional needs requiring increased folate levels, Vitamin D deficiency or are in need of Vitamin D supplementation and other nutritional supplementation. uuid:3b6029eb-45ae-4084-87a5-3a33162458a0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63618 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:7d7ae977-12bd-4ed8-84fb-2856690cb4d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bacf092b-1c82-40fd-8e08-b07a4d090cd0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.1 Prevention of Cardiovascular Disease In hypercholesterolemic patients without clinically evident coronary heart disease (CHD), pravastatin sodium tablets, USP are indicated to: reduce the risk of myocardial infarction (MI). reduce the risk of undergoing myocardial revascularization procedures. reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes. In patients with clinically evident CHD, pravastatin sodium tablet is indicated to: reduce the risk of total mortality by reducing coronary death. reduce the risk of MI. reduce the risk of undergoing myocardial revascularization procedures. reduce the risk of stroke and stroke/transient ischemic attack (TIA). slow the progression of coronary atherosclerosis. 1.2 Hyperlipidemia Pravastatin sodium tablet is indicated: as an adjunct to diet to reduce elevated total cholesterol (Total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (ApoB), and triglyceride (TG) levels and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Types IIa and IIb).1 as an adjunct to diet for the treatment of patients with elevated serum TG levels (Fredrickson Type IV). for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet. as an adjunct to diet and lifestyle modification for treatment of heterozygous familial hypercholesterolemia (HeFH) in children and adolescent patients ages 8 years and older if after an adequate trial of diet the following findings are present: a. LDL-C remains ≥ 190 mg/dL or b. LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease (CVD) or two or more other CVD risk factors are present in the patient. 1.3 Limitations of Use Pravastatin sodium has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:e750b91b-6cb9-46d9-aae8-ae3fb4bba548 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63618 biolink:treats MONDO:0005264 PMID:41385096 "[{""id"":""uuid:bf74e29c-914a-46ec-8b27-6fefb6c07eba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f611d42f-66da-4135-9551-702ecffe03aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.1 Prevention of Cardiovascular Disease In hypercholesterolemic patients without clinically evident coronary heart disease (CHD), pravastatin sodium tablets, USP are indicated to: reduce the risk of myocardial infarction (MI). reduce the risk of undergoing myocardial revascularization procedures. reduce the risk of cardiovascular mortality with no increase in death from non-cardiovascular causes. In patients with clinically evident CHD, pravastatin sodium tablet is indicated to: reduce the risk of total mortality by reducing coronary death. reduce the risk of MI. reduce the risk of undergoing myocardial revascularization procedures. reduce the risk of stroke and stroke/transient ischemic attack (TIA). slow the progression of coronary atherosclerosis. 1.2 Hyperlipidemia Pravastatin sodium tablet is indicated: as an adjunct to diet to reduce elevated total cholesterol (Total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (ApoB), and triglyceride (TG) levels and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hypercholesterolemia and mixed dyslipidemia (Fredrickson Types IIa and IIb).1 as an adjunct to diet for the treatment of patients with elevated serum TG levels (Fredrickson Type IV). for the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet. as an adjunct to diet and lifestyle modification for treatment of heterozygous familial hypercholesterolemia (HeFH) in children and adolescent patients ages 8 years and older if after an adequate trial of diet the following findings are present: a. LDL-C remains ≥ 190 mg/dL or b. LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease (CVD) or two or more other CVD risk factors are present in the patient. 1.3 Limitations of Use Pravastatin sodium has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:ca6a2bac-d66b-4975-ba2e-76b2318bc0b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9927 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:3df6cf17-1e1f-4a27-955e-b84093a4983e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e2d17433-0662-49df-993f-fce9dbf4465b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hypertension Valsartan tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which valsartan principally belongs. There are no controlled trials in hypertensive patients demonstrating risk reduction with valsartan tablets, USP. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Valsartan tablets, USP may be used alone or in combination with other antihypertensive agents. 1.2 Heart Failure Valsartan tablets, USP are indicated for the treatment of heart failure (NYHA class II-IV). In a controlled clinical trial, valsartan tablets, USP significantly reduced hospitalizations for heart failure. There is no evidence that valsartan tablets, USP provide added benefits when it is used with an adequate dose of an ACE inhibitor. [See Clinical Studies (14.2)] uuid:5bca0443-3756-4790-9985-16a57324b3c1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9927 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:939c80fb-7e44-4ad7-a2c2-a0a11fc12a16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9a583040-7d44-4db3-9083-a9b7064f570f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hypertension Valsartan tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which valsartan principally belongs. There are no controlled trials in hypertensive patients demonstrating risk reduction with valsartan tablets, USP. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Valsartan tablets, USP may be used alone or in combination with other antihypertensive agents. 1.2 Heart Failure Valsartan tablets, USP are indicated for the treatment of heart failure (NYHA class II-IV). In a controlled clinical trial, valsartan tablets, USP significantly reduced hospitalizations for heart failure. There is no evidence that valsartan tablets, USP provide added benefits when it is used with an adequate dose of an ACE inhibitor. [See Clinical Studies (14.2)] uuid:5cdd116b-2834-4913-ae9f-59824e8ee23b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:375139 biolink:treats MONDO:0005093 PMID:41385096 "[{""id"":""uuid:ecb659cc-dc54-44b2-8d8f-0ed138e4c679"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d0094a8e-969e-4969-99cd-729751abd342"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Temporary relief of pain associated with minor cuts, scrapes and minor skin irritations uuid:b5c02328-4ff9-4966-a894-f900ec6b8d55 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7931 biolink:treats MONDO:0006964 PMID:41385096 "[{""id"":""uuid:388b5a70-ea7a-40a8-b299-d5214fc38ac9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4219443a-e490-4ad6-a810-5ef830e9e5d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Paricalcitol capsules is a vitamin D analog indicated for the prevention and treatment of secondary hyperparathyroidism associated with Chronic kidney disease (CKD) Stages 3 and 4 ( 1.1 ). CKD Stage 5 in patients on hemodialysis (HD) or peritoneal dialysis (PD) ( 1.2 ). uuid:7f34120b-9e01-4e8c-a5f8-1cbf60a758a0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7931 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:1f0f651d-3dd2-4d78-b3a2-daa39b5b01d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e63d6469-84d3-450e-8aff-950d4303ae53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Paricalcitol capsules is a vitamin D analog indicated for the prevention and treatment of secondary hyperparathyroidism associated with Chronic kidney disease (CKD) Stages 3 and 4 ( 1.1 ). CKD Stage 5 in patients on hemodialysis (HD) or peritoneal dialysis (PD) ( 1.2 ). uuid:782e5bff-096a-4fbd-b7e7-f9cef17e02bc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7931 biolink:treats MONDO:0004375 PMID:41385096 "[{""id"":""uuid:8cdc6a0c-ec52-48be-a997-d8dcb9416756"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:30f3d497-d45b-4202-9177-e6d3dabc0c42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Paricalcitol capsules is a vitamin D analog indicated for the prevention and treatment of secondary hyperparathyroidism associated with Chronic kidney disease (CKD) Stages 3 and 4 ( 1.1 ). CKD Stage 5 in patients on hemodialysis (HD) or peritoneal dialysis (PD) ( 1.2 ). uuid:219f3031-89eb-4e4d-ad09-bf29c55f645d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4786 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:6981555a-6f2f-4861-8f4e-08359624e8d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:70656224-e667-4607-a969-04b4459e21ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Enalapril maleate is indicated for the treatment of hypertension. Enalapril maleate is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of enalapril maleate and thiazides are approximately additive. Heart Failure Enalapril maleate is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. In these patients enalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization (see CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials). Asymptomatic Left Ventricular Dysfunction In clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure (see CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials). In using enalapril maleate consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril maleate does not have a similar risk (see WARNINGS). In considering use of enalapril maleate it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see WARNINGS, Head and Neck Angioedema). uuid:9d9a5350-1848-46b1-997e-5bca8669934c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4786 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:d57ef4d1-d167-42a8-a576-56e8ae18470b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a12ddab5-fcd9-40a4-bfda-4d1e51f1def7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Enalapril maleate is indicated for the treatment of hypertension. Enalapril maleate is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of enalapril maleate and thiazides are approximately additive. Heart Failure Enalapril maleate is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. In these patients enalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization (see CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials). Asymptomatic Left Ventricular Dysfunction In clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure (see CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials). In using enalapril maleate consideration should be given to the fact that another angiotensin converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that enalapril maleate does not have a similar risk (see WARNINGS). In considering use of enalapril maleate it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see WARNINGS, Head and Neck Angioedema). uuid:8103e305-97f0-4be1-8aee-6273c26200f6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2668 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:dd22b1de-315f-4f0a-8c3d-b75b5d0f4624"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e3c805b5-8936-4825-9b79-8e661c5325e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amlodipine besylate tablets USP are a calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of: Hypertension ( 1.1 ) Amlodipine besylate tablets USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Coronary Artery Disease ( 1.2 ) Chronic Stable Angina Vasospastic Angina (Prinzmetal's or Variant Angina) Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction < 40% uuid:c79a95f7-70e3-4f15-9d5c-f24ca022127f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2668 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:2cd9e656-2496-47d2-93ba-92ca0b36b4f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c916d672-9563-4fc7-af9e-fedd4fbe4e40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amlodipine besylate tablets USP are a calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of: Hypertension ( 1.1 ) Amlodipine besylate tablets USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Coronary Artery Disease ( 1.2 ) Chronic Stable Angina Vasospastic Angina (Prinzmetal's or Variant Angina) Angiographically Documented Coronary Artery Disease in patients without heart failure or an ejection fraction < 40% uuid:ba95625c-db49-4775-9bd2-aa4a84bc53c0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77733 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:bafff1bd-3232-4333-a1c9-26cb81285bea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c5e1d944-7aac-4acc-8f3c-fead7b4b4ede"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Verapamil hydrochloride extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. uuid:fcf41ef7-2966-45e5-b4bf-84cd271ed2d8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77733 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:d6ae3023-1e35-4ea5-bf93-e26698d921e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9386bb26-8f3e-4d38-a755-f42ad42743d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Verapamil hydrochloride extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. uuid:8b311b02-6d5f-4b4a-a678-04edc76130ad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77733 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:2c08b7fd-bb10-470f-b04d-6c40f7ccec4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1ffe46de-81fc-4645-a271-b9059e9be605"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Verapamil hydrochloride extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. uuid:d3238f89-650b-48e7-8000-83409141c218 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77733 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:be28e97c-025e-485b-ad33-1b1d708ef196"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c16b70b9-24e7-42a4-b4c7-7b45cf9969fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Verapamil hydrochloride extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. uuid:1c6d9b4b-ca17-4c4d-9a90-c8cae4018200 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77733 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:0084ca0f-f1ae-4359-97a2-08b0dd6bfb6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:393649b3-172a-437e-905d-31d35db8a99f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Verapamil hydrochloride extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. uuid:936dbb8e-3dc4-4599-bbde-60981a16d335 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0005227 PMID:41385096 "[{""id"":""uuid:ca0920ce-a32e-46e9-b796-1c9e1e957ffb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:023a9ef1-a8df-478f-8134-ab30e22bdf7c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Levofloxacin tablets are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. Culture and susceptibility testing Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see Microbiology(12.4)]. Therapy with levofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected. As with other drugs in this class, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with levofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance. 1.1 Nosocomial Pneumonia Levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillinsusceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an antipseudomonal β-lactam is recommended [see Clinical Studies (14.1)]. 1.2 Community-Acquired Pneumonia: 7-14 day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multidrug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.2)]. MDRSP isolates are strains resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. 1.3 Community-Acquired Pneumonia: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (excluding multi-drug-resistant strains [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Dosage and Administration (2.1)and Clinical Studies (14.3)]. 1.4 Acute Bacterial Sinusitis: 5-day and 10-14 day Treatment Regimens Levofloxacin is indicated for the treatment of acute bacterial sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis [see Clinical Studies (14.4)]. 1.5 Acute Bacterial Exacerbation of Chronic Bronchitis Levofloxacin is indicated for the treatment of acute bacterial exacerbation of chronic bronchitis due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis. 1.6 Complicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis [see Clinical Studies (14.5)]. 1.7 Uncomplicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, or Streptococcus pyogenes. 1.8 Chronic Bacterial Prostatitis Levofloxacin is indicated for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin-susceptible Staphylococcus epidermidis [see Clinical Studies (14.6)]. 1.9 Complicated Urinary Tract Infections: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis [see Clinical Studies (14.7)]. 1.10 Complicated Urinary Tract Infections: 10-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa [see Clinical Studies (14.8)]. 1.11 Acute Pyelonephritis: 5 or 10-day Treatment Regimen Levofloxacin is indicated for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia [see Clinical Studies(14.7, 14.8)].]. 1.12 Uncomplicated Urinary Tract Infections Levofloxacin is indicated for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus. 1.13 Inhalational Anthrax (Post-Exposure) Levofloxacin is indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. The effectiveness of levofloxacin is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin has not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of levofloxacin in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged levofloxacin therapy should only be used when the benefit outweighs the risk [see Dosage and Administration(2.1, 2.2) and Clinical Studies (14.9)]. 1.14 Plague Levofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older. Efficacy studies of levofloxacin could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals [seeDosage and Administration (2.1, 2.2) and Clinical Studies (14.10)]. uuid:9aacca5d-fcc2-4686-8556-9c79bbdb74d9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0005230 PMID:41385096 "[{""id"":""uuid:c86ab2fe-5745-44fb-b80e-fba8571b90ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2010c73f-84ef-4ab1-a051-5b2aced119b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Levofloxacin tablets are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. Culture and susceptibility testing Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see Microbiology(12.4)]. Therapy with levofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected. As with other drugs in this class, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with levofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance. 1.1 Nosocomial Pneumonia Levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillinsusceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an antipseudomonal β-lactam is recommended [see Clinical Studies (14.1)]. 1.2 Community-Acquired Pneumonia: 7-14 day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multidrug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.2)]. MDRSP isolates are strains resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. 1.3 Community-Acquired Pneumonia: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (excluding multi-drug-resistant strains [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Dosage and Administration (2.1)and Clinical Studies (14.3)]. 1.4 Acute Bacterial Sinusitis: 5-day and 10-14 day Treatment Regimens Levofloxacin is indicated for the treatment of acute bacterial sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis [see Clinical Studies (14.4)]. 1.5 Acute Bacterial Exacerbation of Chronic Bronchitis Levofloxacin is indicated for the treatment of acute bacterial exacerbation of chronic bronchitis due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis. 1.6 Complicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis [see Clinical Studies (14.5)]. 1.7 Uncomplicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, or Streptococcus pyogenes. 1.8 Chronic Bacterial Prostatitis Levofloxacin is indicated for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin-susceptible Staphylococcus epidermidis [see Clinical Studies (14.6)]. 1.9 Complicated Urinary Tract Infections: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis [see Clinical Studies (14.7)]. 1.10 Complicated Urinary Tract Infections: 10-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa [see Clinical Studies (14.8)]. 1.11 Acute Pyelonephritis: 5 or 10-day Treatment Regimen Levofloxacin is indicated for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia [see Clinical Studies(14.7, 14.8)].]. 1.12 Uncomplicated Urinary Tract Infections Levofloxacin is indicated for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus. 1.13 Inhalational Anthrax (Post-Exposure) Levofloxacin is indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. The effectiveness of levofloxacin is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin has not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of levofloxacin in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged levofloxacin therapy should only be used when the benefit outweighs the risk [see Dosage and Administration(2.1, 2.2) and Clinical Studies (14.9)]. 1.14 Plague Levofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older. Efficacy studies of levofloxacin could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals [seeDosage and Administration (2.1, 2.2) and Clinical Studies (14.10)]. uuid:1336fdac-452e-4570-9b16-64a315161de5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats HP:0020083 PMID:41385096 "[{""id"":""uuid:9824b82f-cd9a-44c6-b4e5-b0a22acf21bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fe13a979-a472-4292-b9bf-d6c86f88b207"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Levofloxacin tablets are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. Culture and susceptibility testing Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see Microbiology(12.4)]. Therapy with levofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected. As with other drugs in this class, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with levofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance. 1.1 Nosocomial Pneumonia Levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillinsusceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an antipseudomonal β-lactam is recommended [see Clinical Studies (14.1)]. 1.2 Community-Acquired Pneumonia: 7-14 day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multidrug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.2)]. MDRSP isolates are strains resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. 1.3 Community-Acquired Pneumonia: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (excluding multi-drug-resistant strains [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Dosage and Administration (2.1)and Clinical Studies (14.3)]. 1.4 Acute Bacterial Sinusitis: 5-day and 10-14 day Treatment Regimens Levofloxacin is indicated for the treatment of acute bacterial sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis [see Clinical Studies (14.4)]. 1.5 Acute Bacterial Exacerbation of Chronic Bronchitis Levofloxacin is indicated for the treatment of acute bacterial exacerbation of chronic bronchitis due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis. 1.6 Complicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis [see Clinical Studies (14.5)]. 1.7 Uncomplicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, or Streptococcus pyogenes. 1.8 Chronic Bacterial Prostatitis Levofloxacin is indicated for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin-susceptible Staphylococcus epidermidis [see Clinical Studies (14.6)]. 1.9 Complicated Urinary Tract Infections: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis [see Clinical Studies (14.7)]. 1.10 Complicated Urinary Tract Infections: 10-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa [see Clinical Studies (14.8)]. 1.11 Acute Pyelonephritis: 5 or 10-day Treatment Regimen Levofloxacin is indicated for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia [see Clinical Studies(14.7, 14.8)].]. 1.12 Uncomplicated Urinary Tract Infections Levofloxacin is indicated for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus. 1.13 Inhalational Anthrax (Post-Exposure) Levofloxacin is indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. The effectiveness of levofloxacin is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin has not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of levofloxacin in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged levofloxacin therapy should only be used when the benefit outweighs the risk [see Dosage and Administration(2.1, 2.2) and Clinical Studies (14.9)]. 1.14 Plague Levofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older. Efficacy studies of levofloxacin could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals [seeDosage and Administration (2.1, 2.2) and Clinical Studies (14.10)]. uuid:6849f132-9ad8-4a41-ab47-4b8a9aef6df4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0004592 PMID:41385096 "[{""id"":""uuid:4e79a0b2-e2e7-4458-a511-3a2e8f0ae6c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8e9354c8-f7d5-4e42-bad1-ed8e68d45e18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Levofloxacin tablets are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. Culture and susceptibility testing Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see Microbiology(12.4)]. Therapy with levofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected. As with other drugs in this class, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with levofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance. 1.1 Nosocomial Pneumonia Levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillinsusceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an antipseudomonal β-lactam is recommended [see Clinical Studies (14.1)]. 1.2 Community-Acquired Pneumonia: 7-14 day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multidrug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.2)]. MDRSP isolates are strains resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. 1.3 Community-Acquired Pneumonia: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (excluding multi-drug-resistant strains [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Dosage and Administration (2.1)and Clinical Studies (14.3)]. 1.4 Acute Bacterial Sinusitis: 5-day and 10-14 day Treatment Regimens Levofloxacin is indicated for the treatment of acute bacterial sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis [see Clinical Studies (14.4)]. 1.5 Acute Bacterial Exacerbation of Chronic Bronchitis Levofloxacin is indicated for the treatment of acute bacterial exacerbation of chronic bronchitis due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis. 1.6 Complicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis [see Clinical Studies (14.5)]. 1.7 Uncomplicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, or Streptococcus pyogenes. 1.8 Chronic Bacterial Prostatitis Levofloxacin is indicated for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin-susceptible Staphylococcus epidermidis [see Clinical Studies (14.6)]. 1.9 Complicated Urinary Tract Infections: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis [see Clinical Studies (14.7)]. 1.10 Complicated Urinary Tract Infections: 10-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa [see Clinical Studies (14.8)]. 1.11 Acute Pyelonephritis: 5 or 10-day Treatment Regimen Levofloxacin is indicated for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia [see Clinical Studies(14.7, 14.8)].]. 1.12 Uncomplicated Urinary Tract Infections Levofloxacin is indicated for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus. 1.13 Inhalational Anthrax (Post-Exposure) Levofloxacin is indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. The effectiveness of levofloxacin is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin has not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of levofloxacin in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged levofloxacin therapy should only be used when the benefit outweighs the risk [see Dosage and Administration(2.1, 2.2) and Clinical Studies (14.9)]. 1.14 Plague Levofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older. Efficacy studies of levofloxacin could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals [seeDosage and Administration (2.1, 2.2) and Clinical Studies (14.10)]. uuid:7b370745-2f06-4618-9f0a-b74da07885b2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0002922 PMID:41385096 "[{""id"":""uuid:991bc6eb-9b7d-4b08-81b5-98479b2f2d6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3352deaa-f931-4719-a792-b545c7c56cce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Levofloxacin tablets are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. Culture and susceptibility testing Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see Microbiology(12.4)]. Therapy with levofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected. As with other drugs in this class, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with levofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance. 1.1 Nosocomial Pneumonia Levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillinsusceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an antipseudomonal β-lactam is recommended [see Clinical Studies (14.1)]. 1.2 Community-Acquired Pneumonia: 7-14 day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multidrug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.2)]. MDRSP isolates are strains resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. 1.3 Community-Acquired Pneumonia: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (excluding multi-drug-resistant strains [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Dosage and Administration (2.1)and Clinical Studies (14.3)]. 1.4 Acute Bacterial Sinusitis: 5-day and 10-14 day Treatment Regimens Levofloxacin is indicated for the treatment of acute bacterial sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis [see Clinical Studies (14.4)]. 1.5 Acute Bacterial Exacerbation of Chronic Bronchitis Levofloxacin is indicated for the treatment of acute bacterial exacerbation of chronic bronchitis due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis. 1.6 Complicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis [see Clinical Studies (14.5)]. 1.7 Uncomplicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, or Streptococcus pyogenes. 1.8 Chronic Bacterial Prostatitis Levofloxacin is indicated for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin-susceptible Staphylococcus epidermidis [see Clinical Studies (14.6)]. 1.9 Complicated Urinary Tract Infections: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis [see Clinical Studies (14.7)]. 1.10 Complicated Urinary Tract Infections: 10-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa [see Clinical Studies (14.8)]. 1.11 Acute Pyelonephritis: 5 or 10-day Treatment Regimen Levofloxacin is indicated for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia [see Clinical Studies(14.7, 14.8)].]. 1.12 Uncomplicated Urinary Tract Infections Levofloxacin is indicated for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus. 1.13 Inhalational Anthrax (Post-Exposure) Levofloxacin is indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. The effectiveness of levofloxacin is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin has not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of levofloxacin in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged levofloxacin therapy should only be used when the benefit outweighs the risk [see Dosage and Administration(2.1, 2.2) and Clinical Studies (14.9)]. 1.14 Plague Levofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older. Efficacy studies of levofloxacin could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals [seeDosage and Administration (2.1, 2.2) and Clinical Studies (14.10)]. uuid:a5be9890-77ac-4b2c-b73f-43cb96333062 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0024313 PMID:41385096 "[{""id"":""uuid:33223fe6-b89c-4344-b53e-020be3dd1a96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b0e5dfe4-d840-4816-8bf6-ea8dc0efcee9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Levofloxacin tablets are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. Culture and susceptibility testing Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see Microbiology(12.4)]. Therapy with levofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected. As with other drugs in this class, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with levofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance. 1.1 Nosocomial Pneumonia Levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillinsusceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an antipseudomonal β-lactam is recommended [see Clinical Studies (14.1)]. 1.2 Community-Acquired Pneumonia: 7-14 day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multidrug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.2)]. MDRSP isolates are strains resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. 1.3 Community-Acquired Pneumonia: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (excluding multi-drug-resistant strains [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Dosage and Administration (2.1)and Clinical Studies (14.3)]. 1.4 Acute Bacterial Sinusitis: 5-day and 10-14 day Treatment Regimens Levofloxacin is indicated for the treatment of acute bacterial sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis [see Clinical Studies (14.4)]. 1.5 Acute Bacterial Exacerbation of Chronic Bronchitis Levofloxacin is indicated for the treatment of acute bacterial exacerbation of chronic bronchitis due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis. 1.6 Complicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis [see Clinical Studies (14.5)]. 1.7 Uncomplicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, or Streptococcus pyogenes. 1.8 Chronic Bacterial Prostatitis Levofloxacin is indicated for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin-susceptible Staphylococcus epidermidis [see Clinical Studies (14.6)]. 1.9 Complicated Urinary Tract Infections: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis [see Clinical Studies (14.7)]. 1.10 Complicated Urinary Tract Infections: 10-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa [see Clinical Studies (14.8)]. 1.11 Acute Pyelonephritis: 5 or 10-day Treatment Regimen Levofloxacin is indicated for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia [see Clinical Studies(14.7, 14.8)].]. 1.12 Uncomplicated Urinary Tract Infections Levofloxacin is indicated for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus. 1.13 Inhalational Anthrax (Post-Exposure) Levofloxacin is indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. The effectiveness of levofloxacin is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin has not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of levofloxacin in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged levofloxacin therapy should only be used when the benefit outweighs the risk [see Dosage and Administration(2.1, 2.2) and Clinical Studies (14.9)]. 1.14 Plague Levofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older. Efficacy studies of levofloxacin could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals [seeDosage and Administration (2.1, 2.2) and Clinical Studies (14.10)]. uuid:218840bb-315e-466a-80ab-770f810b10b0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0001024 PMID:41385096 "[{""id"":""uuid:b8f4204c-1d6c-48b1-9020-7738b7d95619"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:942e7d94-c12b-49fe-a69a-586f9ae3da98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Levofloxacin tablets are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. Culture and susceptibility testing Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see Microbiology(12.4)]. Therapy with levofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected. As with other drugs in this class, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with levofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance. 1.1 Nosocomial Pneumonia Levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillinsusceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an antipseudomonal β-lactam is recommended [see Clinical Studies (14.1)]. 1.2 Community-Acquired Pneumonia: 7-14 day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multidrug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.2)]. MDRSP isolates are strains resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. 1.3 Community-Acquired Pneumonia: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (excluding multi-drug-resistant strains [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Dosage and Administration (2.1)and Clinical Studies (14.3)]. 1.4 Acute Bacterial Sinusitis: 5-day and 10-14 day Treatment Regimens Levofloxacin is indicated for the treatment of acute bacterial sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis [see Clinical Studies (14.4)]. 1.5 Acute Bacterial Exacerbation of Chronic Bronchitis Levofloxacin is indicated for the treatment of acute bacterial exacerbation of chronic bronchitis due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis. 1.6 Complicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis [see Clinical Studies (14.5)]. 1.7 Uncomplicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, or Streptococcus pyogenes. 1.8 Chronic Bacterial Prostatitis Levofloxacin is indicated for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin-susceptible Staphylococcus epidermidis [see Clinical Studies (14.6)]. 1.9 Complicated Urinary Tract Infections: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis [see Clinical Studies (14.7)]. 1.10 Complicated Urinary Tract Infections: 10-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa [see Clinical Studies (14.8)]. 1.11 Acute Pyelonephritis: 5 or 10-day Treatment Regimen Levofloxacin is indicated for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia [see Clinical Studies(14.7, 14.8)].]. 1.12 Uncomplicated Urinary Tract Infections Levofloxacin is indicated for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus. 1.13 Inhalational Anthrax (Post-Exposure) Levofloxacin is indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. The effectiveness of levofloxacin is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin has not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of levofloxacin in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged levofloxacin therapy should only be used when the benefit outweighs the risk [see Dosage and Administration(2.1, 2.2) and Clinical Studies (14.9)]. 1.14 Plague Levofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older. Efficacy studies of levofloxacin could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals [seeDosage and Administration (2.1, 2.2) and Clinical Studies (14.10)]. uuid:f547043b-c27a-4845-b3c0-2d2cc8eed048 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0005956 PMID:41385096 "[{""id"":""uuid:3a4a20c8-9c39-4af8-af67-abc1792ef0b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:643ff7d8-69b0-4c97-b14f-a3758a633988"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Levofloxacin tablets are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. Culture and susceptibility testing Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see Microbiology(12.4)]. Therapy with levofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected. As with other drugs in this class, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with levofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance. 1.1 Nosocomial Pneumonia Levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillinsusceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an antipseudomonal β-lactam is recommended [see Clinical Studies (14.1)]. 1.2 Community-Acquired Pneumonia: 7-14 day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multidrug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.2)]. MDRSP isolates are strains resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. 1.3 Community-Acquired Pneumonia: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (excluding multi-drug-resistant strains [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Dosage and Administration (2.1)and Clinical Studies (14.3)]. 1.4 Acute Bacterial Sinusitis: 5-day and 10-14 day Treatment Regimens Levofloxacin is indicated for the treatment of acute bacterial sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis [see Clinical Studies (14.4)]. 1.5 Acute Bacterial Exacerbation of Chronic Bronchitis Levofloxacin is indicated for the treatment of acute bacterial exacerbation of chronic bronchitis due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis. 1.6 Complicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis [see Clinical Studies (14.5)]. 1.7 Uncomplicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, or Streptococcus pyogenes. 1.8 Chronic Bacterial Prostatitis Levofloxacin is indicated for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin-susceptible Staphylococcus epidermidis [see Clinical Studies (14.6)]. 1.9 Complicated Urinary Tract Infections: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis [see Clinical Studies (14.7)]. 1.10 Complicated Urinary Tract Infections: 10-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa [see Clinical Studies (14.8)]. 1.11 Acute Pyelonephritis: 5 or 10-day Treatment Regimen Levofloxacin is indicated for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia [see Clinical Studies(14.7, 14.8)].]. 1.12 Uncomplicated Urinary Tract Infections Levofloxacin is indicated for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus. 1.13 Inhalational Anthrax (Post-Exposure) Levofloxacin is indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. The effectiveness of levofloxacin is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin has not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of levofloxacin in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged levofloxacin therapy should only be used when the benefit outweighs the risk [see Dosage and Administration(2.1, 2.2) and Clinical Studies (14.9)]. 1.14 Plague Levofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older. Efficacy studies of levofloxacin could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals [seeDosage and Administration (2.1, 2.2) and Clinical Studies (14.10)]. uuid:fe12aaf6-92aa-4808-82f9-6152a618bd33 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77363 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:df5c6de7-c39e-4d04-8fb5-35bcd5b9a2bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b799d365-1edf-4e05-93cb-6a7ec682943d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Ramipril capsules USP are indicated for the treatment of hypertension. It may be used alone or in combination with thiazide diuretics. Heart Failure Post-Myocardial Infarction Ramipril capsules USP are indicated in stable patients who have demonstrated clinical signs of congestive heart failure within the first few days after sustaining acute myocardial infarction. Administration of ramipril to such patients has been shown to decrease the risk of death (principally cardiovascular death) and to decrease the risks of failure-related hospitalization and progression to severe/resistant heart failure [see Clinical Studies (14.3)]. uuid:23bc3466-4e6d-4031-ae35-b174ed8633cb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77363 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:e1dde6a5-ff86-4a4f-afb7-ab228052a0d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:954ddeb0-ae05-4471-9d73-a107f554b6e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Ramipril capsules USP are indicated for the treatment of hypertension. It may be used alone or in combination with thiazide diuretics. Heart Failure Post-Myocardial Infarction Ramipril capsules USP are indicated in stable patients who have demonstrated clinical signs of congestive heart failure within the first few days after sustaining acute myocardial infarction. Administration of ramipril to such patients has been shown to decrease the risk of death (principally cardiovascular death) and to decrease the risks of failure-related hospitalization and progression to severe/resistant heart failure [see Clinical Studies (14.3)]. uuid:02d7f2e5-1caf-4999-a0d1-f525c57a238b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1602752 biolink:treats MONDO:0005420 PMID:41385096 "[{""id"":""uuid:4a364b1a-55c6-414a-89fe-af99dcafdfa4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c1bad803-e315-4900-b2ef-c0d95d62d148"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE: NP Thyroid tablets (thyroid tablets, USP) are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS). 2. As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic Iymphocytic thyroiditis (Hashimoto’s), multinodular goiter, and in the management of thyroid cancer. 3. As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy. uuid:4711bbb1-0815-43b2-ae72-f6ae5b150acc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1602752 biolink:treats MONDO:0018612 PMID:41385096 "[{""id"":""uuid:c4876400-2886-4535-9934-adc91775cb98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bd10e031-2f7a-4e66-8f4b-3cac1fb1cbfd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE: NP Thyroid tablets (thyroid tablets, USP) are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS). 2. As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic Iymphocytic thyroiditis (Hashimoto’s), multinodular goiter, and in the management of thyroid cancer. 3. As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy. uuid:c2b911ab-016a-4081-ba33-8cad4d6c15f0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1602752 biolink:treats MONDO:0009718 PMID:41385096 "[{""id"":""uuid:ff827eee-d286-44b8-8dc8-3faa1235828f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:087ea01d-5c3e-48ca-a721-9d7afee72e07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE: NP Thyroid tablets (thyroid tablets, USP) are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS). 2. As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic Iymphocytic thyroiditis (Hashimoto’s), multinodular goiter, and in the management of thyroid cancer. 3. As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy. uuid:63820533-5088-47ca-bccc-85cd1385b714 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1602752 biolink:treats MONDO:0001658 PMID:41385096 "[{""id"":""uuid:5b929e80-8a9d-4a26-8f11-96e62469bb85"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:be327f6e-da5b-4539-8722-18d870f9164d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE: NP Thyroid tablets (thyroid tablets, USP) are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS). 2. As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic Iymphocytic thyroiditis (Hashimoto’s), multinodular goiter, and in the management of thyroid cancer. 3. As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy. uuid:d6fe8b9c-c753-4cda-9b66-d20ccd2cef4c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1602752 biolink:treats HP:0025388 PMID:41385096 "[{""id"":""uuid:2ad2435a-0a48-4821-ad9b-b0b19fb4d149"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ceee74b0-e6e7-4517-bd97-3cf323c2b662"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE: NP Thyroid tablets (thyroid tablets, USP) are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS). 2. As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic Iymphocytic thyroiditis (Hashimoto’s), multinodular goiter, and in the management of thyroid cancer. 3. As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy. uuid:a7d3a5f8-353d-46ae-a778-e6d371ea2832 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1602752 biolink:treats MONDO:0007699 PMID:41385096 "[{""id"":""uuid:3393a4ec-5716-4f54-a83e-f3712fb8df4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1173e5fe-d58c-46ad-948e-a42042aac203"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE: NP Thyroid tablets (thyroid tablets, USP) are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS). 2. As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic Iymphocytic thyroiditis (Hashimoto’s), multinodular goiter, and in the management of thyroid cancer. 3. As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy. uuid:5f0538af-406d-4f6a-a03b-f88635be9eb3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1602752 biolink:treats MONDO:0000334 PMID:41385096 "[{""id"":""uuid:f739b8ea-b684-40ff-9134-78464b5dc14b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3c8ad6aa-e6a9-45b1-bd66-428eebeab1ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE: NP Thyroid tablets (thyroid tablets, USP) are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS). 2. As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic Iymphocytic thyroiditis (Hashimoto’s), multinodular goiter, and in the management of thyroid cancer. 3. As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy. uuid:c3e9a2db-51f3-4b57-a93f-8dd0547023f5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1602752 biolink:treats MONDO:0002108 PMID:41385096 "[{""id"":""uuid:933ea196-c3b8-4525-8a51-f4d5dec2dc7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:335d9621-986b-4cc5-a81d-e751a63628cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE: NP Thyroid tablets (thyroid tablets, USP) are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS). 2. As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic Iymphocytic thyroiditis (Hashimoto’s), multinodular goiter, and in the management of thyroid cancer. 3. As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy. uuid:df826206-f827-4317-aaa2-cd4a83e68f5f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1602752 biolink:treats MONDO:0006982 PMID:41385096 "[{""id"":""uuid:584c2d9b-d6d7-41e0-a905-614887f29632"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fe229d9f-4bc9-4292-adc0-019d424a2f38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE: NP Thyroid tablets (thyroid tablets, USP) are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS). 2. As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic Iymphocytic thyroiditis (Hashimoto’s), multinodular goiter, and in the management of thyroid cancer. 3. As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy. uuid:32b20d7a-d49e-4717-bdb6-63f2fd588438 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1602752 biolink:treats MONDO:0004425 PMID:41385096 "[{""id"":""uuid:b7ca072a-43b8-4bde-be55-afd31e22da75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0e405d1a-38fa-4885-9ad9-be415c483b91"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE: NP Thyroid tablets (thyroid tablets, USP) are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS). 2. As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic Iymphocytic thyroiditis (Hashimoto’s), multinodular goiter, and in the management of thyroid cancer. 3. As diagnostic agents in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy. uuid:71a615cb-2da5-4766-9786-6fa13bf2c6f3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB11218 biolink:treats HP:0002829 PMID:41385096 "[{""id"":""uuid:20248bac-c116-45e0-89aa-486a6bc3815d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:34ff3c9e-c367-4665-ae58-df975d2d67bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the temporary relief of arthritic pain & relief of muscular aches & pains, including symptomatic relief of lower back pains. May also assist with increased joint mobility & reduce inflammation and swelling associated with arthritis and gout. uuid:1e893309-9d32-4a7e-a904-2013f833cab7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB11218 biolink:treats HP:0003326 PMID:41385096 "[{""id"":""uuid:d2c62ab9-824c-40a5-b807-f00692c6b158"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8e1e0053-0ee5-443f-8cf1-412d857adf5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the temporary relief of arthritic pain & relief of muscular aches & pains, including symptomatic relief of lower back pains. May also assist with increased joint mobility & reduce inflammation and swelling associated with arthritis and gout. uuid:28d46ae3-e79f-460f-97b3-ffdb896578ce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB11218 biolink:treats HP:0003419 PMID:41385096 "[{""id"":""uuid:ef8c0fc8-fbc7-4699-a44b-658ec77a857e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a504178e-fb20-49a6-8f4e-d1f82db2912b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the temporary relief of arthritic pain & relief of muscular aches & pains, including symptomatic relief of lower back pains. May also assist with increased joint mobility & reduce inflammation and swelling associated with arthritis and gout. uuid:9bb14499-2404-4e02-83ef-bdf2b978aaa4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB11218 biolink:treats MONDO:0005578 PMID:41385096 "[{""id"":""uuid:d535e92f-e668-49a7-86f6-ad4597248531"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:95a24fcb-d5ef-447d-926f-b78470823ee3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the temporary relief of arthritic pain & relief of muscular aches & pains, including symptomatic relief of lower back pains. May also assist with increased joint mobility & reduce inflammation and swelling associated with arthritis and gout. uuid:b68b0757-9985-416e-9ac2-fd36416b4b01 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB11218 biolink:treats MONDO:0005393 PMID:41385096 "[{""id"":""uuid:a4a51b30-1a63-4a44-98ba-78e6ce83f6cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:57dfa15a-bd02-45fb-a2b3-69ab5f492706"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the temporary relief of arthritic pain & relief of muscular aches & pains, including symptomatic relief of lower back pains. May also assist with increased joint mobility & reduce inflammation and swelling associated with arthritis and gout. uuid:cc49c532-6ba5-47d5-aa5b-a8c11bc19d2f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31617 biolink:treats MONDO:0005027 PMID:41385096 "[{""id"":""uuid:2f0e32d1-4ec3-48d6-9430-1a87a2a37f47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:492ac9f5-4e2c-4af8-ae52-d1cdcd11b9fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fludeoxyglucose F 18 Injection,USP is indicated in PET (positron emission tomography) for: 1. Identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures. 2. Assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer. 3. Assessment of patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging, for the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function. Fludeoxyglucose F 18 Injection, USP is not indicated for distinguishing epileptogenic foci from brain tumors or other brain lesions which may cause seizures. uuid:982d4bd2-caef-48d0-b8b7-42ae0eb00002 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31617 biolink:treats MONDO:0004992 PMID:41385096 "[{""id"":""uuid:aa1bfee0-344a-4e73-b380-6d736032fa1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:94f598a8-1e7c-4e72-b577-54f263c567f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fludeoxyglucose F 18 Injection,USP is indicated in PET (positron emission tomography) for: 1. Identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures. 2. Assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer. 3. Assessment of patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging, for the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function. Fludeoxyglucose F 18 Injection, USP is not indicated for distinguishing epileptogenic foci from brain tumors or other brain lesions which may cause seizures. uuid:5beedfb6-ec2a-402f-ba7a-aeaaf0a10993 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31617 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:a0ca1813-9b6c-4577-975b-eb44989c0bb6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d3d21809-b0f8-4430-9080-46c4a6599852"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fludeoxyglucose F 18 Injection,USP is indicated in PET (positron emission tomography) for: 1. Identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures. 2. Assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer. 3. Assessment of patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging, for the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function. Fludeoxyglucose F 18 Injection, USP is not indicated for distinguishing epileptogenic foci from brain tumors or other brain lesions which may cause seizures. uuid:509c4387-11c4-4fb5-82c6-0679cba05f86 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31617 biolink:treats HP:0005162 PMID:41385096 "[{""id"":""uuid:3bfdc7e8-185b-458b-b979-8fdc8fd6f971"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b25ab2f3-2b48-449d-bd83-484cb8c13eff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fludeoxyglucose F 18 Injection,USP is indicated in PET (positron emission tomography) for: 1. Identification of regions of abnormal glucose metabolism associated with foci of epileptic seizures. 2. Assessment of abnormal glucose metabolism to assist in the evaluation of malignancy in patients with known or suspected abnormalities found by other testing modalities, or in patients with an existing diagnosis of cancer. 3. Assessment of patients with coronary artery disease and left ventricular dysfunction, when used together with myocardial perfusion imaging, for the identification of left ventricular myocardium with residual glucose metabolism and reversible loss of systolic function. Fludeoxyglucose F 18 Injection, USP is not indicated for distinguishing epileptogenic foci from brain tumors or other brain lesions which may cause seizures. uuid:5f49f787-1556-43be-8fe6-be941f04353b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5296 biolink:treats MONDO:0011817 PMID:41385096 "[{""id"":""uuid:f910a95d-82a6-409d-b253-dae1636f9577"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e524e0b2-78e2-47ee-88cc-1e45eb928768"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gemfibrozil (Gemfibrozil tablets, USP) is indicated as adjunctive therapy to diet for: Treatment of adult patients with very high elevations of serum triglyceride levels (Types IV and V hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Patients who present such risk typically have serum triglycerides over 2000 mg/dL and have elevations of VLDL-cholesterol as well as fasting chylomicrons (Type V hyperlipidemia). Subjects who consistently have total serum or plasma triglycerides below 1000 mg/dL are unlikely to present a risk of pancreatitis. Gemfibrozil therapy may be considered for those subjects with triglyceride elevations between 1000 and 2000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. It is recognized that some Type IV patients with triglycerides under 1000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of Gemfibrozil therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia. Reducing the risk of developing coronary heart disease only in Type IIb patients without history of or symptoms of existing coronary heart disease who have had an inadequate response to weight loss, dietary therapy, exercise, and other pharmacologic agents (such as bile acid sequestrants and nicotinic acid, known to reduce LDL- and raise HDL-cholesterol) and who have the following triad of lipid abnormalities: low HDL-cholesterol levels in addition to elevated LDL-cholesterol and elevated triglycerides (see WARNINGS , PRECAUTIONS , and CLINICAL PHARMACOLOGY ). The National Cholesterol Education Program has defined a serum HDL-cholesterol value that is consistently below 35 mg/dL as constituting an independent risk factor for coronary heart disease. Patients with significantly elevated triglycerides should be closely observed when treated with Gemfibrozil. In some patients with high triglyceride levels, treatment with Gemfibrozil is associated with a significant increase in LDL-cholesterol. BECAUSE OF POTENTIAL TOXICITY SUCH AS MALIGNANCY, GALLBLADDER DISEASE, ABDOMINAL PAIN LEADING TO APPENDECTOMY AND OTHER ABDOMINAL SURGERIES, AN INCREASED INCIDENCE IN NON-CORONARY MORTALITY, AND THE 44% RELATIVE INCREASE DURING THE TRIAL PERIOD IN AGE-ADJUSTED ALL-CAUSE MORTALITY SEEN WITH THE CHEMICALLY AND PHARMACOLOGICALLY RELATED DRUG, CLOFIBRATE, THE POTENTIAL BENEFIT OF GEMFIBROZIL IN TREATING TYPE IIA PATIENTS WITH ELEVATIONS OF LDL-CHOLESTEROL ONLY IS NOT LIKELY TO OUTWEIGH THE RISKS. GEMFIBROZIL IS ALSO NOT INDICATED FOR THE TREATMENT OF PATIENTS WITH LOW HDL- CHOLESTEROL AS THEIR ONLY LIPID ABNORMALITY. In a subgroup analysis of patients in the Helsinki Heart Study with above-median HDL-cholesterol values at baseline (greater than 46.4 mg/dL), the incidence of serious coronary events was similar for Gemfibrozil and placebo subgroups (see Table I). The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcohol intake may be important factors in hypertriglyceridemia and should be managed prior to any drug therapy. Physical exercise can be an important ancillary measure, and has been associated with rises in HDL-cholesterol. Diseases contributory to hyperlipidemia such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy is sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of estrogen therapy may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with nondrug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet. uuid:065d8608-8251-433e-93b5-ba0119e65979 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5296 biolink:treats MONDO:0005281 PMID:41385096 "[{""id"":""uuid:341ebb90-9489-4d56-88c8-c6e9a3564b0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9601356c-50f3-47d3-80a9-1552d9473dac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gemfibrozil (Gemfibrozil tablets, USP) is indicated as adjunctive therapy to diet for: Treatment of adult patients with very high elevations of serum triglyceride levels (Types IV and V hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Patients who present such risk typically have serum triglycerides over 2000 mg/dL and have elevations of VLDL-cholesterol as well as fasting chylomicrons (Type V hyperlipidemia). Subjects who consistently have total serum or plasma triglycerides below 1000 mg/dL are unlikely to present a risk of pancreatitis. Gemfibrozil therapy may be considered for those subjects with triglyceride elevations between 1000 and 2000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. It is recognized that some Type IV patients with triglycerides under 1000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of Gemfibrozil therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia. Reducing the risk of developing coronary heart disease only in Type IIb patients without history of or symptoms of existing coronary heart disease who have had an inadequate response to weight loss, dietary therapy, exercise, and other pharmacologic agents (such as bile acid sequestrants and nicotinic acid, known to reduce LDL- and raise HDL-cholesterol) and who have the following triad of lipid abnormalities: low HDL-cholesterol levels in addition to elevated LDL-cholesterol and elevated triglycerides (see WARNINGS , PRECAUTIONS , and CLINICAL PHARMACOLOGY ). The National Cholesterol Education Program has defined a serum HDL-cholesterol value that is consistently below 35 mg/dL as constituting an independent risk factor for coronary heart disease. Patients with significantly elevated triglycerides should be closely observed when treated with Gemfibrozil. In some patients with high triglyceride levels, treatment with Gemfibrozil is associated with a significant increase in LDL-cholesterol. BECAUSE OF POTENTIAL TOXICITY SUCH AS MALIGNANCY, GALLBLADDER DISEASE, ABDOMINAL PAIN LEADING TO APPENDECTOMY AND OTHER ABDOMINAL SURGERIES, AN INCREASED INCIDENCE IN NON-CORONARY MORTALITY, AND THE 44% RELATIVE INCREASE DURING THE TRIAL PERIOD IN AGE-ADJUSTED ALL-CAUSE MORTALITY SEEN WITH THE CHEMICALLY AND PHARMACOLOGICALLY RELATED DRUG, CLOFIBRATE, THE POTENTIAL BENEFIT OF GEMFIBROZIL IN TREATING TYPE IIA PATIENTS WITH ELEVATIONS OF LDL-CHOLESTEROL ONLY IS NOT LIKELY TO OUTWEIGH THE RISKS. GEMFIBROZIL IS ALSO NOT INDICATED FOR THE TREATMENT OF PATIENTS WITH LOW HDL- CHOLESTEROL AS THEIR ONLY LIPID ABNORMALITY. In a subgroup analysis of patients in the Helsinki Heart Study with above-median HDL-cholesterol values at baseline (greater than 46.4 mg/dL), the incidence of serious coronary events was similar for Gemfibrozil and placebo subgroups (see Table I). The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcohol intake may be important factors in hypertriglyceridemia and should be managed prior to any drug therapy. Physical exercise can be an important ancillary measure, and has been associated with rises in HDL-cholesterol. Diseases contributory to hyperlipidemia such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy is sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of estrogen therapy may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with nondrug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet. uuid:114ae4ed-e3c1-41cc-8138-756ba33148af biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:23742 biolink:treats HP:0007430 PMID:41385096 "[{""id"":""uuid:4b5feae3-93dd-4d87-b147-b1a1cf6f8e69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:363987dc-ef83-4e8d-8bcc-2a726a257723"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] This fixed combination drug is not indicated for the initial therapy of edema or hypertension except in individuals in whom the development of hypokalemia cannot be risked. 1. Triamterene and hydrochlorothiazide tablets are indicated for the treatment of hypertension or edema in patients who develop hypokalemia on hydrochlorothiazide alone. 2. Triamterene and hydrochlorothiazide is also indicated for those patients who require a thiazide diuretic and in whom the development of hypokalemia cannot be risked (e.g., patients on concomitant digitalis preparations, or with a history of cardiac arrhythmias, etc.). Triamterene and hydrochlorothiazide may be used alone or in combination with other antihypertensive drugs such as beta-blockers. Since triamterene and hydrochlorothiazide may enhance the actions of these drugs, dosage adjustments may be necessary. Usage in Pregnancy: The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia in pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. Edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. Thiazides are indicated in pregnancy when edema is due to pathologic causes, just as they are in the absence of pregnancy. Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort which is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate. uuid:5b806139-4408-4d70-b629-731bede1aaa5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1155432 biolink:treats UMLS:C0427008 PMID:41385096 "[{""id"":""uuid:77c6545f-d45e-4d8a-b1fa-1708406180f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:af1eaa24-f3a0-4d2a-872e-95c7dff91060"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] USES : Use for temporary relief of minor aches and muscle pains associated with arthritis, simple backache, strains, sprains, muscle soreness and stiffness uuid:b9c06b59-157c-4f61-99b4-747ea5c6e7f7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5001 biolink:treats MONDO:0004982 PMID:41385096 "[{""id"":""uuid:5764e1ba-cb35-4fbc-b3c3-58a38aeee0a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ac3b73f0-1d8f-4288-bebb-6a0f05657e6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment of Hypercholesterolemia Fenofibrate tablets, USP are indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C, Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate (See National Cholesterol Education Program [NCEP] Treatment Guidelines, below). Treatment of Hypertriglyceridemia Fenofibrate tablets, USP are also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually reduce fasting triglycerides and eliminate chylomicronemia thereby obviating the need for pharmacologic intervention. Markedly elevated levels of serum triglycerides (e.g. > 2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate tablet, USP therapy on reducing this risk has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV and V hyperlipoproteinemia2. The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcoholic intake may be important factors in hypertriglyceridemia and should be addressed prior to any drug therapy. Physical exercise can be an important ancillary measure. Diseases contributory to hyperlipidemia, such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy, thiazide diuretics and beta-blockers, are sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of the specific etiologic agent may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with non-drug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet. (See WARNINGS and PRECAUTIONS). Please review the manufacturer's complete information (studies, figures, tables) here:http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a9c5062d-e8ad-44e7-a709-af0092f73d52 uuid:32fa7cd6-b1da-4503-ac24-27d8b045aca4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5001 biolink:treats MONDO:0005420 PMID:41385096 "[{""id"":""uuid:a5d25cda-20bb-488f-bbc1-176efe4c7744"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:44e6179f-e888-4c3f-abac-0230f25b3f01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment of Hypercholesterolemia Fenofibrate tablets, USP are indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C, Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate (See National Cholesterol Education Program [NCEP] Treatment Guidelines, below). Treatment of Hypertriglyceridemia Fenofibrate tablets, USP are also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually reduce fasting triglycerides and eliminate chylomicronemia thereby obviating the need for pharmacologic intervention. Markedly elevated levels of serum triglycerides (e.g. > 2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate tablet, USP therapy on reducing this risk has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV and V hyperlipoproteinemia2. The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcoholic intake may be important factors in hypertriglyceridemia and should be addressed prior to any drug therapy. Physical exercise can be an important ancillary measure. Diseases contributory to hyperlipidemia, such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy, thiazide diuretics and beta-blockers, are sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of the specific etiologic agent may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with non-drug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet. (See WARNINGS and PRECAUTIONS). Please review the manufacturer's complete information (studies, figures, tables) here:http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a9c5062d-e8ad-44e7-a709-af0092f73d52 uuid:e829a633-b432-4bc1-b9b9-d7c830879418 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5001 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:fc04b1b6-f729-47a1-b86c-de7e09b0b111"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:897e77f4-7dbd-47ce-8690-c49202e3aa74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment of Hypercholesterolemia Fenofibrate tablets, USP are indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C, Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate (See National Cholesterol Education Program [NCEP] Treatment Guidelines, below). Treatment of Hypertriglyceridemia Fenofibrate tablets, USP are also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually reduce fasting triglycerides and eliminate chylomicronemia thereby obviating the need for pharmacologic intervention. Markedly elevated levels of serum triglycerides (e.g. > 2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate tablet, USP therapy on reducing this risk has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV and V hyperlipoproteinemia2. The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcoholic intake may be important factors in hypertriglyceridemia and should be addressed prior to any drug therapy. Physical exercise can be an important ancillary measure. Diseases contributory to hyperlipidemia, such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy, thiazide diuretics and beta-blockers, are sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of the specific etiologic agent may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with non-drug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet. (See WARNINGS and PRECAUTIONS). Please review the manufacturer's complete information (studies, figures, tables) here:http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a9c5062d-e8ad-44e7-a709-af0092f73d52 uuid:e4ec2f5d-090e-4cb0-b48c-255dabbec4f7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3387 biolink:treats HP:0007359 PMID:41385096 "[{""id"":""uuid:3e5951bb-5480-4278-948a-de11c8508c33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:07a9d125-f6d9-4b7e-b285-150405250eb5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Epilepsy Carbamazepine tablets, USP are indicated for use as an anticonvulsant drug. Evidence supporting efficacy of carbamazepine as an anticonvulsant was derived from active drug-controlled studies that enrolled patients with the following seizure types: Partial seizures with complex symptomatology (psychomotor, temporal lobe). Patients with these seizures appear to show greater improvement than those with other types. Generalized tonic-clonic seizures (grand mal). Mixed seizure patterns which include the above, or other partial or generalized seizures. Absence seizures (petit mal) do not appear to be controlled by carbamazepine (see PRECAUTIONS, General). Trigeminal Neuralgia Carbamazepine tablets, USP are indicated in the treatment of the pain associated with true trigeminal neuralgia. Beneficial results have also been reported in glossopharyngeal neuralgia. This drug is not a simple analgesic and should not be used for the relief of trivial aches or pains. uuid:5262b58f-9dfb-4aed-a332-3f507bf8a02a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16240 biolink:treats HP:0033050 PMID:41385096 "[{""id"":""uuid:6fa0071e-2370-4858-9bb1-8581d9f016b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6f8bd2d8-df93-40ef-b77e-8cd051e83580"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Aids in the removal of phlegm, mucus, or other secretions in the temporary relief of discomfort due to occasional sore throat and sore mouth. uuid:e7c43dac-37c5-4174-860a-c909d0875eba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16240 biolink:treats UMLS:C1579838 PMID:41385096 "[{""id"":""uuid:6c8e949c-fa3b-4278-bdd5-140f3b3e72e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6868d425-7931-4896-a5e7-f6da028f70c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Aids in the removal of phlegm, mucus, or other secretions in the temporary relief of discomfort due to occasional sore throat and sore mouth. uuid:0d0383fd-d54b-433d-a172-d6e053e01249 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:f7888168-5b8b-4e64-a111-bbb4284787ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d4aaf90e-46b7-4d4d-981d-e8c354700647"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:7248fcbc-0072-4df8-ae5a-5c9a9f27eb53 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:f96626a9-bb5d-466f-b4ed-2246d8f06e16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9b34a5a9-cfef-4be8-a516-61c2432383c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:62d805b0-b467-4404-a8ee-a36a469745ae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0005480 PMID:41385096 "[{""id"":""uuid:c5032d46-f7d5-4846-bbd3-8cc633c9a52f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0bff09f2-b55b-47cf-9c12-ec2547adabb3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:5efdb3db-70ec-45d3-addc-c22bb46514d0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0000775 PMID:41385096 "[{""id"":""uuid:164f7dd5-33f1-45a1-becf-055b4202c0ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ec0d7f97-2cee-46d3-bee5-5ad3e5aa5c34"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:00e58b24-1cfe-4456-903c-50e872a61d2d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:6e4d3258-bf67-46fb-8a3b-e3f91a4b4518"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2c141aed-b369-4092-a2f2-fe354001a0d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:9decd702-ab70-4136-baf5-2f4fbd67f8b7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0024332 PMID:41385096 "[{""id"":""uuid:02d32aba-35d2-4a1d-8224-a9327fdc1585"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a3716a19-0e18-4b69-b47d-c3107d9e9237"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:172b2fb2-933a-4d95-853e-060e3d2f85d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0043789 PMID:41385096 "[{""id"":""uuid:363dc5d6-e882-4474-a129-a58782c85097"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6bcfa9e6-af4c-49f7-9279-c06a1e439e41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:3960572a-500d-440e-ad9d-acf53a4e5450 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats UMLS:C0274435 PMID:41385096 "[{""id"":""uuid:aaf0f6bd-3135-46e1-816c-1d335b564806"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:86cd6a68-72e9-4225-a737-4cae62a62a03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:ad1134d0-39c0-499d-a6c4-7d921eb68dc9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0015614 PMID:41385096 "[{""id"":""uuid:94d2372f-935d-4dda-b4b3-fa3f346bdd1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5e28f671-ed07-49d6-8570-c31dab1a1f59"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:96c273e2-1f64-41f6-a90c-9df4b38a38f1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0043233 PMID:41385096 "[{""id"":""uuid:091d0ba9-2248-4e99-be7a-0521a2353234"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6b2e165b-5cc8-4260-83a2-37fc5665d23a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:1e884a28-2668-4e6e-a7bb-963b88ec5a78 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0009691 PMID:41385096 "[{""id"":""uuid:e4a85361-191b-4e26-9dd5-ae52a1449b46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6345dfa8-6ef2-4bbf-80cf-14d4dc841989"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:52c5f4ce-ed2e-4bad-9a5f-59b39a77b2fb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0006594 PMID:41385096 "[{""id"":""uuid:038f70c2-b72f-4b04-9558-8f26ba399e3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6f2c27bc-b731-448c-99e6-87752a5481ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:4805ab96-4dc9-4609-acc7-33cd9747477f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0018229 PMID:41385096 "[{""id"":""uuid:a7de2f7b-1945-4c62-a756-508cc0c5a4b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:83762647-ead2-44f0-9612-ef74f20dff7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:0cc267a9-792c-4834-ac07-923210dad680 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0015129 PMID:41385096 "[{""id"":""uuid:fb992e0c-b7b2-442d-9cba-ca101878f4c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:017071e3-2b5c-4958-b1c8-7adffac133b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:a77bbebe-9355-446e-a115-80826b7caf0e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0043370 PMID:41385096 "[{""id"":""uuid:5f8a7754-4369-4e7d-9ed2-d5f2707cafc4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:60c2ada0-a49a-42ac-a3fe-d6d8017a7dd0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:f74aa200-dec9-4c91-acb4-02b8684a4e84 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0018479 PMID:41385096 "[{""id"":""uuid:4c8f89ad-bab2-4f74-a331-305dedc5b469"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1f9c655f-5ab6-448b-9169-b98ab9b06869"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:dc9ff9db-6b01-428e-ac62-86b89b4dc404 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0043455 PMID:41385096 "[{""id"":""uuid:461f9efb-066e-4458-9288-9c7958665b37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0899e90e-a7ba-4a8c-ac1c-5f4f6c822dd5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:cd932f0d-32e1-418e-84de-5766b809b272 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0004126 PMID:41385096 "[{""id"":""uuid:a1a7e8a3-9f85-41f0-aedd-9a5182f7fe87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e686ce65-ff8a-4595-92ec-0797f3a75e86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:a1dfd28b-798b-4e76-9980-255e22360e22 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats UMLS:C0678202 PMID:41385096 "[{""id"":""uuid:224202e6-7a09-40da-86df-1fc4fa803675"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cec12f5f-f418-4454-a507-eb8c70303407"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:df8bdebf-cfb0-4340-acd4-0fccb1626cc4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:fa4d1e7f-1f97-47ff-b6ad-a05d86ee28a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0aba9051-5cd6-4f31-97a0-34bc06e096de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:1c30bcd5-03a1-4f2a-a658-52bcf0ce27b8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0020108 PMID:41385096 "[{""id"":""uuid:8e6e9a27-b0e6-4716-ad1a-5927450d4ef3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6ef3ac1f-393f-462d-b919-cf0a6987c7cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:722e4144-b0ae-4ee7-a11f-f0d5db189541 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0015253 PMID:41385096 "[{""id"":""uuid:4236d309-920e-41d0-956e-08a068120786"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fc33f16b-c21d-41fe-8e3f-5cb0f9f4b7a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:d1c5efd7-6ac7-4cfa-bde9-48add3e88a90 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0001705 PMID:41385096 "[{""id"":""uuid:1f429884-123d-420e-88f7-93bc7519a68a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a9db08a2-3091-4d1f-a65b-2943a040721c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:610d5997-f799-4f10-a7bb-497d6b049b3d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0001198 PMID:41385096 "[{""id"":""uuid:ef46d503-0ef3-4ea7-b16d-5fabd042a891"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:893d4074-18a5-4d58-b0d9-ae3c613cacb7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:0462361d-0224-456a-8f80-7e6a1ffea09a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0019444 PMID:41385096 "[{""id"":""uuid:a6a5bbf8-42d0-4a95-a7b1-f9a5c7c3f040"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4997b3de-bfd8-4808-93d0-09b2d7c4e9d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:4082af70-36cc-41bc-8e8e-72c5fe83e752 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0006042 PMID:41385096 "[{""id"":""uuid:969edc7e-c1b5-48c9-85d3-2620b397fe7d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:661b004b-8034-4cf0-8a5a-dfe3280d441b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:de91f732-c39f-470f-98af-6ed05f1a9a86 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0005059 PMID:41385096 "[{""id"":""uuid:ecaddb46-756e-4a18-b304-61417053234f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aa982303-f311-4393-aa1b-35fc3f7aa24e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:2359f2e7-5886-42e6-b168-1aec46c03136 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0004095 PMID:41385096 "[{""id"":""uuid:0c01a2a1-5afc-42c4-9c1e-57304a04e331"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8ba79bea-2a36-4920-af0f-0733e6333eed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:f9735ca2-64aa-44e6-b21a-3dfbeab9c3e6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0005314 PMID:41385096 "[{""id"":""uuid:a02505ac-f19c-4ed7-b4c4-3c82e31ad140"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:43c95172-d235-4b4c-89ce-3bc7973e34b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:526a237c-916f-4088-a14f-06a5b4ce6b14 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0006684 PMID:41385096 "[{""id"":""uuid:854d405a-9f32-4c2a-97c7-e79d79ed58e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:88aaac02-5d12-4e48-8ec3-0837633d540e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:761f1e08-d527-4ca1-88f1-a1086c232a32 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0019198 PMID:41385096 "[{""id"":""uuid:75e06975-31d5-4c4d-a6e7-9d155a7f5106"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d1c7b3c0-0719-418f-bd1f-54e444c51d8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:9c2f2e3c-f3d2-4164-9a32-fa6b4a197ce9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0008538 PMID:41385096 "[{""id"":""uuid:c48d48cb-72be-44b2-bd86-65db285daa02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e98e1250-bfae-4d8b-b32d-5b9a6ac9936f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:928f8431-a5b4-4cfd-92b3-e761ddee1c0a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0020283 PMID:41385096 "[{""id"":""uuid:5f88e55f-3103-4de0-aee1-ae7187f207e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0646f197-4c1e-47d8-babf-ce3c4add1a14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:984537c5-905c-47a2-8079-432db9f646c0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0018170 PMID:41385096 "[{""id"":""uuid:65ef5ef7-bf70-4b89-843c-2a5bd3b4c6d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:21ef059b-6481-4f42-acd3-8e6961f68e8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:9dd72472-a0aa-46e4-8a4a-f056e82b1958 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0005556 PMID:41385096 "[{""id"":""uuid:e0541db2-250b-4d98-89b6-195fa876b89e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d019d872-1fdb-44c0-aa00-01f7851ee26b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:a2738be9-63a2-4603-8276-03b6bbfb05ab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0015274 PMID:41385096 "[{""id"":""uuid:a52a1c51-1169-49ef-86d9-2aa14e0c8854"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9114a64d-67b3-4f93-8fbf-1520a86b1dd4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:1b76e372-67f3-41fb-bfb0-f6fe32e41f58 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0006052 PMID:41385096 "[{""id"":""uuid:46a4a08c-4d46-4e8e-9863-3decddd73141"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:09f2fdec-4d4d-49f8-8035-7bafc608f52e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:ef9dfcda-557a-4882-b2f8-6ef13a8c1126 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0005848 PMID:41385096 "[{""id"":""uuid:ec7fbaaa-a6b7-4979-a715-39195f991901"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9e2f1612-7740-46cf-9dd0-27752e5f9fbd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:9256dcb2-8c21-45f3-b678-31b8a5b6d904 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0015927 PMID:41385096 "[{""id"":""uuid:122cd4ef-c316-4d6d-95f9-cc7bab627e08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:035299dd-f916-43eb-bdfa-fa9141397ede"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:fbee4700-91f0-4367-92e8-beea3023e79d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0019338 PMID:41385096 "[{""id"":""uuid:9ef4e82a-6a37-439c-9583-e3113242c9a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3d479777-3329-4e1a-b060-04105434fcc0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:e5584ca9-fb88-46c5-b07e-2f197f40e90e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats UMLS:C0149896 PMID:41385096 "[{""id"":""uuid:0f5d502d-761f-40c4-a77a-4f2f6c12f256"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0e801603-f1d8-401f-bb1c-69767e19cfff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:d1418323-6930-45fa-9539-cb11beb484ac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats UMLS:C5441648 PMID:41385096 "[{""id"":""uuid:9f49a251-3bb9-4f32-95c4-cec029c02d60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:acc68307-fdd6-42b5-b8b4-bae70a000c02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:74a42b77-0655-4293-ba66-8fdf7e37680b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:99cca28f-bc6c-4f03-bcf4-5749f3f5381e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:12dd0301-7af1-4e20-a81c-08a829fe9a76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:5ec0ed14-ae1e-495b-95ef-4dacac7d90cc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:ea593636-9d95-4b23-8029-d578063cf2cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:de87d0de-8414-4c9e-ae6b-42b1a60d84b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:444a1df7-ff03-48fa-8fd9-ddb652011416 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:a26571ad-b5d8-4751-8c0d-5687596ac986"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c506a6d4-7c86-4ae2-bea6-bc6542729f0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:5e6eb8bf-7977-4a85-a0dd-1dd5e9be2a8f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0011429 PMID:41385096 "[{""id"":""uuid:028db0fc-4ee7-4793-be9c-3a99d4219038"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:07d34cae-7c51-4c30-8133-c347d37fe008"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:a07aa83d-610f-45d9-a482-c8e87ebfc62b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0016367 PMID:41385096 "[{""id"":""uuid:92bcaea0-8f0d-4201-98c5-663ea5158390"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f43d8568-06e5-4ca1-a9dc-a691d3edbe40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:1c13672d-f6ae-416d-9066-737d47ba3268 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0019127 PMID:41385096 "[{""id"":""uuid:7473c67e-c5d8-4eb6-aa2d-fe83bd344480"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:566a9da5-ed0c-4c6e-b9cf-567d5387b5cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of DEPO-MEDROL Sterile Aqueous Suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:f2d1b601-900e-4159-b093-9e46bdaf8ab6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5134 biolink:treats MONDO:0004514 PMID:41385096 "[{""id"":""uuid:57a071a6-afc0-44d4-97de-41092fdfebc6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8e374d85-a860-4212-a547-600ef19dfac4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluticasone propionate nasal spray, USP is indicated for the management of the nasal symptoms of perennial nonallergic rhinitis in adult and pediatric patients aged 4 years and older. uuid:ef49cde9-16db-4406-abcd-5e1a08ec62d4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3561 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:63a8eafd-bb6a-4a17-801d-5cadac759b5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7dbed5af-22d8-4cbd-b167-98486ee4fc13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: runny nose sneezing itchy, watery eyes itching of the nose or throat uuid:cbcc970e-72ca-4fb3-94ea-5b81af1a5586 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3561 biolink:treats MONDO:0004867 PMID:41385096 "[{""id"":""uuid:46cdd9e2-a160-43e6-899b-3ac156d8733a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1c006192-6911-4e3e-9608-117c5dd4a2db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: runny nose sneezing itchy, watery eyes itching of the nose or throat uuid:09e4fc7b-6546-45ac-bd13-f343009eaf82 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5855 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:e055a076-c381-49b9-abbb-804b18c4bdbc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0c181078-5e4d-4c47-b70f-d955a89317f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oral prasterone (200mg per day) in female patients with active systemic lupus erythematosus (SLE) has in several blinded, placebo-controlled randomized clinical studies been associated with a reduced risk of auto-immune flare, §§ 6.2 , 14.1.1 , a reduced risk of breast cancer and a reduced risk of death from any cause, §§ 6.4 , 14.2 . Patients with SLE may have depressed serum levels of 5-dehydroepiandrosterone sulfate (5-DHEAS). Oral prasterone has been shown to restore SLE patients' serum 5-DHEAS levels. Prastera® oral softgels are intended for use in patients for whom medical evaluation shows a depressed serum level of DHEA and thus a distinctive need for exogenous DHEA. Prastera® oral prasterone softgels are intended to be used under medical supervision, for a patient receiving active and ongoing medical supervision, wherein the patient obtains medical care on a recurring basis for, among other things, instructions on the use of this product. Prastera® oral prasterone softgels are intended for the dietary management of SLE by meeting the distinctive nutritional requirement of women with mild-to-moderate active SLE. Prastera® oral prasterone softgels are intended for oral intake only. Prastera® does not cure, treat, mitigate or prevent SLE. To the contrary, patients taking Prastera® will continue to have SLE, and thus may continue to require other appropriate therapy . uuid:d15d4465-f7b0-42e6-947a-721060bdf0e3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8805 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:9c83b20d-c39c-47cc-8e22-a21282071373"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f185728f-7618-4330-a10a-954d6d2b5535"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2e32d33d-50ba-406e-bc18-24884112a8d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/repaglinide-krka""]},{""id"":""uuid:0fc41dce-bf9b-4d69-bb87-366b1554ef22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRANDIN is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.|[EMA] Repaglinide is indicated in patients with type-2 diabetes (non-insulin-dependent diabetes mellitus (NIDDM)) whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reduction and exercise.Treatment should be initiated as an adjunct to diet and exercise to lower the blood glucose in relation to meals.|[PMDA] Drugs with a new active ingredient indicated for the improvement of postprandial changes of blood glucose in type 2 diabetes mellitus (for use only in patients who have not responded sufficiently to either [1] diet and exercise therapies alone or [2] alpha-glucosidase inhibitors along with diet and exercise therapies). uuid:9b60712e-e639-41be-a753-213f4f578ef4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats UMLS:C0853854 PMID:41385096 "[{""id"":""uuid:65f9f137-0509-4152-8989-40082876e2c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0836f50d-8618-4454-9ca5-a6e551841866"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin tablets USP and other antibacterial drugs, azithromycin tablets USP should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Azithromycin tablets USP are a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications [see Dosage and Administration (2)]. 1.1 Adult Patients Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae. Acute bacterial sinusitis due to Haemophilus influenzae, Moraxella catarrhalis. or Streptococcus pneumoniae. Community-acquired pneumonia due to Chlamydophila pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae, or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. Uncomplicated skin and skin structure infections due to Staphylococcus aureus, Streptococcus pyogenes, or Streptococcus agalactiae. Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae. Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. 1.2 Pediatric Patients [see Use in Specific Populations (8.4) and Clinical Studies (14.2)] Acute otitis media (> 6 months of age) caused by Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae Community-acquired pneumonia (> 6 months of age) due to Chlamydophila pneumoniae, Haemophilus influenzae, Mycoplasma pneumonia, or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis (> 2 years of age) caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. 1.3 Limitations of Use Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomial infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). uuid:662c0161-fdbe-4974-8f93-5ffa6bb2718e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats MONDO:0009061 PMID:41385096 "[{""id"":""uuid:0aa0f7d0-1798-42cf-a072-343c42b9c344"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8e2ebbab-2fc2-4231-8c24-1709a9d054b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin tablets USP and other antibacterial drugs, azithromycin tablets USP should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Azithromycin tablets USP are a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications [see Dosage and Administration (2)]. 1.1 Adult Patients Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae. Acute bacterial sinusitis due to Haemophilus influenzae, Moraxella catarrhalis. or Streptococcus pneumoniae. Community-acquired pneumonia due to Chlamydophila pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae, or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. Uncomplicated skin and skin structure infections due to Staphylococcus aureus, Streptococcus pyogenes, or Streptococcus agalactiae. Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae. Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. 1.2 Pediatric Patients [see Use in Specific Populations (8.4) and Clinical Studies (14.2)] Acute otitis media (> 6 months of age) caused by Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae Community-acquired pneumonia (> 6 months of age) due to Chlamydophila pneumoniae, Haemophilus influenzae, Mycoplasma pneumonia, or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis (> 2 years of age) caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. 1.3 Limitations of Use Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomial infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). uuid:ac5d5d04-e093-4de7-9178-2cdb5988f0e6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats MONDO:0043544 PMID:41385096 "[{""id"":""uuid:de22632d-dde0-4bf8-9b8f-101803c630d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b57a5563-9ceb-4b62-8d6f-b2ed1182a5a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin tablets USP and other antibacterial drugs, azithromycin tablets USP should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Azithromycin tablets USP are a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications [see Dosage and Administration (2)]. 1.1 Adult Patients Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae. Acute bacterial sinusitis due to Haemophilus influenzae, Moraxella catarrhalis. or Streptococcus pneumoniae. Community-acquired pneumonia due to Chlamydophila pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae, or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. Uncomplicated skin and skin structure infections due to Staphylococcus aureus, Streptococcus pyogenes, or Streptococcus agalactiae. Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae. Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. 1.2 Pediatric Patients [see Use in Specific Populations (8.4) and Clinical Studies (14.2)] Acute otitis media (> 6 months of age) caused by Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae Community-acquired pneumonia (> 6 months of age) due to Chlamydophila pneumoniae, Haemophilus influenzae, Mycoplasma pneumonia, or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis (> 2 years of age) caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. 1.3 Limitations of Use Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomial infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). uuid:7260d8ec-ee62-43ca-9575-fa21ce63966e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats MONDO:0005229 PMID:41385096 "[{""id"":""uuid:8b2fe817-03e9-4cf4-b832-a64de11ee125"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bfa1b112-8ead-4d8d-a0a3-4316bb1b368c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin tablets USP and other antibacterial drugs, azithromycin tablets USP should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Azithromycin tablets USP are a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications [see Dosage and Administration (2)]. 1.1 Adult Patients Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae. Acute bacterial sinusitis due to Haemophilus influenzae, Moraxella catarrhalis. or Streptococcus pneumoniae. Community-acquired pneumonia due to Chlamydophila pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae, or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. Uncomplicated skin and skin structure infections due to Staphylococcus aureus, Streptococcus pyogenes, or Streptococcus agalactiae. Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae. Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. 1.2 Pediatric Patients [see Use in Specific Populations (8.4) and Clinical Studies (14.2)] Acute otitis media (> 6 months of age) caused by Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae Community-acquired pneumonia (> 6 months of age) due to Chlamydophila pneumoniae, Haemophilus influenzae, Mycoplasma pneumonia, or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis (> 2 years of age) caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. 1.3 Limitations of Use Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomial infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). uuid:a1f7e5b2-0cce-426d-a316-ff8714de8775 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7852 biolink:treats NCIT:C27003 PMID:41385096 "[{""id"":""uuid:55c1277f-96b3-45e1-86ab-2887a5b91bde"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:41119691-021f-4ced-ab51-1e81cf9a530f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxycodone hydrochloride oral solution USP, 100 mg per 5 mL (20 mg per mL) an opioid agonist is indicated for the relief of moderate to severe acute and chronic pain in opioid-tolerant patients. Oxycodone hydrochloride oral solution USP, 100 mg per 5 mL (20 mg per mL) may cause fatal respiratory depression when administered to patients not previously exposed to opioids. Patients considered to be opioid tolerant are those who are taking at least 30 mg of oral oxycodone per day, or at least 60 mg oral morphine per day, or at least 12 mg hydromorphone per day, or an equianalgesic dose of another opioid, for a week or longer. uuid:a5e8c94f-eda5-4074-96b7-95acfa41c823 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7852 biolink:treats HP:0012532 PMID:41385096 "[{""id"":""uuid:9f78df1d-bc5d-4435-af57-34750fe8e0ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:731e0ffa-2bf9-4250-9c0e-5facadfb47fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4cfc138f-34fb-4ac2-b875-1de7af80b382"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxycodone hydrochloride oral solution USP, 100 mg per 5 mL (20 mg per mL) an opioid agonist is indicated for the relief of moderate to severe acute and chronic pain in opioid-tolerant patients. Oxycodone hydrochloride oral solution USP, 100 mg per 5 mL (20 mg per mL) may cause fatal respiratory depression when administered to patients not previously exposed to opioids. Patients considered to be opioid tolerant are those who are taking at least 30 mg of oral oxycodone per day, or at least 60 mg oral morphine per day, or at least 12 mg hydromorphone per day, or an equianalgesic dose of another opioid, for a week or longer.|[PMDA] Drugs with a new indication and a new dosage for analgesia in moderate to severe chronic pain which cannot be managed by treatment with non-opioid analgesics or other opioid analgesics. uuid:1d1ad969-82b4-43b9-84f3-7f1ac4269d39 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82405 biolink:treats MONDO:0012865 PMID:41385096 "[{""id"":""uuid:1d146de4-5a36-44ed-8a86-5c14c2838949"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b6b6b94f-206a-4578-a66f-8f0855bfa320"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ACNE AND SHAVING BUMPS. uuid:28613b01-cdfe-4641-957c-85c5cd89d138 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:ed2c9545-0f35-47b6-a430-1f4451d88a12"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:23bc3e6c-68d3-492a-a984-205c6dca91dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ECZEMA, SPECIFIC DRY SKIN, AND SPECIFIC SKIN IRRITATIONS. uuid:7cf0e06b-1b90-44fc-90a9-5bfc7271f1ac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats HP:0000958 PMID:41385096 "[{""id"":""uuid:ba0c0e5d-5768-4ac3-a270-705c097aac68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c8d757b4-adca-4f2b-bced-8616a786ae5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ECZEMA, SPECIFIC DRY SKIN, AND SPECIFIC SKIN IRRITATIONS. uuid:66c280c8-6c44-45dc-99fa-bfe4c76275d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15676 biolink:treats MONDO:0005093 PMID:41385096 "[{""id"":""uuid:535ca8b9-5f0d-4804-a08a-72f07e9ff3d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a704e5d0-38a0-4f8f-b878-5f36cc2534c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Uses - Scar Management - Temporarily protects minor cuts , scrapes and burns - Temporary relief of pain associated with minor cuts, scrapes and minor skin irritations uuid:2cc47054-2d1b-47e4-ac5a-53e17a83c4cb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2676 biolink:treats UMLS:C0877637 PMID:41385096 "[{""id"":""uuid:a242ce0f-53a5-412a-b5ac-fa82eb3837d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9313ae9a-89da-42a8-bc66-89c0e79d0c08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin tablets, USP and other antibacterial drugs, amoxicillin tablets, USP should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Amoxicillin tablets, USP are indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of the designated bacteria in the conditions listed below: 1.1 Infections of the Ear, Nose, and Throat Due to Streptococcus species (α- and β-hemolytic isolates only), Streptococcus pneumoniae, Staphylococcus spp., or Haemophilus influenzae. 1.2 Infections of the Genitourinary Tract Due to Escherichia coli, Proteus mirabilis, or Enterococcus faecalis. 1.3 Infections of the Skin and Skin Structure Due to Streptococcus spp. (α- and β-hemolytic isolates only), Staphylococcus spp., or E. coli. 1.4 Infections of the Lower Respiratory Tract Due to Streptococcus spp. (α- and β-hemolytic isolates only), S. pneumoniae, Staphylococcus spp., or H. influenzae. 1.5 Gonorrhea, Acute Uncomplicated (ano-genital and urethral infections) due to Neisseria gonorrhoeae. Because of high rates of amoxicillin resistance, amoxicillin tablets, USP are not recommended for empiric treatment of gonorrhea. Amoxicillin tablets, USP use should be limited to situations where N. gonorrhoeae isolates are known to be susceptible to amoxicillin. 1.6 Triple Therapy for Helicobacter pylori with Clarithromycin and Lansoprazole Amoxicillin tablets, USP, in combination with clarithromycin plus lansoprazole as triple therapy, are indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. 1.7 Dual Therapy for H. pylori with Lansoprazole Amoxicillin tablets, USP, in combination with lansoprazole delayed-release capsules as dual therapy, are indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. uuid:dac9fd3f-b945-44ea-99c8-df6aa7817658 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6367 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:98e75dd7-6858-423a-ae2e-090b8135e39d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e0674979-175b-4623-96a4-47b6f986e1c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Epilepsy Adjunctive Therapy: Lamotrigine tablets are indicated as adjunctive therapy for the following seizure types in patients ≥ 2 years of age: partial seizures primary generalized tonic-clonic seizures generalized seizures of Lennox-Gastaut syndrome Monotherapy: Lamotrigine tablets are indicated for conversion to monotherapy in adults (≥16 years of age) with partial seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug (AED). Safety and effectiveness of lamotrigine tablets have not been established (1) as initial monotherapy; (2) for conversion to monotherapy from AEDs other than carbamazepine, phenytoin, phenobarbital, primidone, or valproate; or (3) for simultaneous conversion to monotherapy from 2 or more concomitant AEDs. 1.2 Bipolar Disorder Lamotrigine tablets are indicated for the maintenance treatment of Bipolar I Disorder to delay the time to occurrence of mood episodes (depression, mania, hypomania, mixed episodes) in adults (≥18 years of age) treated for acute mood episodes with standard therapy. The effectiveness of lamotrigine tablets in the acute treatment of mood episodes has not been established. The effectiveness of lamotrigine tablets as maintenance treatment was established in 2 placebo-controlled trials in patients with Bipolar I Disorder as defined by DSM-IV [see Clinical Studies (14.2)]. The physician who elects to prescribe lamotrigine tablets for periods extending beyond 16 weeks should periodically re-evaluate the long-term usefulness of the drug for the individual patient. uuid:4608c991-361b-4a1b-8e7a-281fe44c6ecf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6367 biolink:treats HP:0100754 PMID:41385096 "[{""id"":""uuid:0bced0b8-9c52-41ae-a397-4606657312c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5a2fc2a3-b9f1-4421-8abf-f2415839ef6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Epilepsy Adjunctive Therapy: Lamotrigine tablets are indicated as adjunctive therapy for the following seizure types in patients ≥ 2 years of age: partial seizures primary generalized tonic-clonic seizures generalized seizures of Lennox-Gastaut syndrome Monotherapy: Lamotrigine tablets are indicated for conversion to monotherapy in adults (≥16 years of age) with partial seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug (AED). Safety and effectiveness of lamotrigine tablets have not been established (1) as initial monotherapy; (2) for conversion to monotherapy from AEDs other than carbamazepine, phenytoin, phenobarbital, primidone, or valproate; or (3) for simultaneous conversion to monotherapy from 2 or more concomitant AEDs. 1.2 Bipolar Disorder Lamotrigine tablets are indicated for the maintenance treatment of Bipolar I Disorder to delay the time to occurrence of mood episodes (depression, mania, hypomania, mixed episodes) in adults (≥18 years of age) treated for acute mood episodes with standard therapy. The effectiveness of lamotrigine tablets in the acute treatment of mood episodes has not been established. The effectiveness of lamotrigine tablets as maintenance treatment was established in 2 placebo-controlled trials in patients with Bipolar I Disorder as defined by DSM-IV [see Clinical Studies (14.2)]. The physician who elects to prescribe lamotrigine tablets for periods extending beyond 16 weeks should periodically re-evaluate the long-term usefulness of the drug for the individual patient. uuid:127e06c6-3660-4177-876d-fe42d7e433f5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6367 biolink:treats UMLS:C0865305 PMID:41385096 "[{""id"":""uuid:c811f9e9-f39c-4051-b43e-bc45be7605aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c455c73e-bc8a-40c8-a7d4-bcf8d619f78e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Epilepsy Adjunctive Therapy: Lamotrigine tablets are indicated as adjunctive therapy for the following seizure types in patients ≥ 2 years of age: partial seizures primary generalized tonic-clonic seizures generalized seizures of Lennox-Gastaut syndrome Monotherapy: Lamotrigine tablets are indicated for conversion to monotherapy in adults (≥16 years of age) with partial seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug (AED). Safety and effectiveness of lamotrigine tablets have not been established (1) as initial monotherapy; (2) for conversion to monotherapy from AEDs other than carbamazepine, phenytoin, phenobarbital, primidone, or valproate; or (3) for simultaneous conversion to monotherapy from 2 or more concomitant AEDs. 1.2 Bipolar Disorder Lamotrigine tablets are indicated for the maintenance treatment of Bipolar I Disorder to delay the time to occurrence of mood episodes (depression, mania, hypomania, mixed episodes) in adults (≥18 years of age) treated for acute mood episodes with standard therapy. The effectiveness of lamotrigine tablets in the acute treatment of mood episodes has not been established. The effectiveness of lamotrigine tablets as maintenance treatment was established in 2 placebo-controlled trials in patients with Bipolar I Disorder as defined by DSM-IV [see Clinical Studies (14.2)]. The physician who elects to prescribe lamotrigine tablets for periods extending beyond 16 weeks should periodically re-evaluate the long-term usefulness of the drug for the individual patient. uuid:ca5de5cd-8828-460f-a5ef-25f0261cb049 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8707 biolink:treats MONDO:0001866 PMID:41385096 "[{""id"":""uuid:1213f83b-2222-4bea-82e1-2f700dbda823"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:91c9a942-3cc8-49e6-b0fe-3f1b31ffdaa9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Schizophrenia Quetiapine fumarate tablet is indicated for the treatment of schizophrenia. The efficacy of quetiapine fumarate tablets in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents (13 to 17 years). The effectiveness of quetiapine fumarate tablets for the maintenance treatment of schizophrenia has not been systematically evaluated in controlled clinical trials. [see Clinical Studies (14.1)] 1.2 Bipolar Disorder Quetiapine fumarate tablet is indicated for the acute treatment of manic episodes associated with bipolar I disorder, both as monotherapy and as an adjunct to lithium or divalproex. Efficacy was established in two 12-week monotherapy trials in adults, in one 3-week adjunctive trial in adults, and in one 3-week monotherapy trial in pediatric patients (10 to 17 years) [ see Clinical Studies (14.2)] . Quetiapine fumarate tablet is indicated as monotherapy for the acute treatment of depressive episodes associated with bipolar disorder. Efficacy was established in two 8-week monotherapy trials in adult patients with bipolar I and bipolar II disorder [ see Clinical Studies (14.2)] . Quetiapine fumarate tablet is indicated for the maintenance treatment of bipolar I disorder, as an adjunct to lithium or divalproex. Efficacy was established in two maintenance trials in adults. The effectiveness of quetiapine fumarate tablets as monotherapy for the maintenance treatment of bipolar disorder has not been systematically evaluated in controlled clinical trials. [ see Clinical Studies (14.2)] . 1.3 Special Considerations in Treating Pediatric Schizophrenia and Bipolar I Disorder Pediatric schizophrenia and bipolar I disorder are serious mental disorders, however, diagnosis can be challenging. For pediatric schizophrenia, symptom profiles can be variable, and for bipolar I disorder, patients may have variable patterns of periodicity of manic or mixed symptoms. It is recommended that medication therapy for pediatric schizophrenia and bipolar I disorder be initiated only after a thorough diagnostic evaluation has been performed and careful consideration given to the risks associated with medication treatment. Medication treatment for both pediatric schizophrenia and bipolar I disorder is indicated as part of a total treatment program that often includes psychological, educational and social interventions. uuid:a6665235-7a1b-4e9b-8330-9d21a00f9052 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8707 biolink:treats MONDO:0024613 PMID:41385096 "[{""id"":""uuid:b89744cb-7a98-4e62-b5bb-39f6a0c07dc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:47e4e206-1f36-45c5-8b55-6babc566b163"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Schizophrenia Quetiapine fumarate tablet is indicated for the treatment of schizophrenia. The efficacy of quetiapine fumarate tablets in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents (13 to 17 years). The effectiveness of quetiapine fumarate tablets for the maintenance treatment of schizophrenia has not been systematically evaluated in controlled clinical trials. [see Clinical Studies (14.1)] 1.2 Bipolar Disorder Quetiapine fumarate tablet is indicated for the acute treatment of manic episodes associated with bipolar I disorder, both as monotherapy and as an adjunct to lithium or divalproex. Efficacy was established in two 12-week monotherapy trials in adults, in one 3-week adjunctive trial in adults, and in one 3-week monotherapy trial in pediatric patients (10 to 17 years) [ see Clinical Studies (14.2)] . Quetiapine fumarate tablet is indicated as monotherapy for the acute treatment of depressive episodes associated with bipolar disorder. Efficacy was established in two 8-week monotherapy trials in adult patients with bipolar I and bipolar II disorder [ see Clinical Studies (14.2)] . Quetiapine fumarate tablet is indicated for the maintenance treatment of bipolar I disorder, as an adjunct to lithium or divalproex. Efficacy was established in two maintenance trials in adults. The effectiveness of quetiapine fumarate tablets as monotherapy for the maintenance treatment of bipolar disorder has not been systematically evaluated in controlled clinical trials. [ see Clinical Studies (14.2)] . 1.3 Special Considerations in Treating Pediatric Schizophrenia and Bipolar I Disorder Pediatric schizophrenia and bipolar I disorder are serious mental disorders, however, diagnosis can be challenging. For pediatric schizophrenia, symptom profiles can be variable, and for bipolar I disorder, patients may have variable patterns of periodicity of manic or mixed symptoms. It is recommended that medication therapy for pediatric schizophrenia and bipolar I disorder be initiated only after a thorough diagnostic evaluation has been performed and careful consideration given to the risks associated with medication treatment. Medication treatment for both pediatric schizophrenia and bipolar I disorder is indicated as part of a total treatment program that often includes psychological, educational and social interventions. uuid:fcfb60eb-e003-4453-ac60-1dcf44c7ba8a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8707 biolink:treats MONDO:0000693 PMID:41385096 "[{""id"":""uuid:323d8455-4e66-455b-aeba-aa46f774c190"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:66117384-61a1-437b-bf09-d870b0577a51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Schizophrenia Quetiapine fumarate tablet is indicated for the treatment of schizophrenia. The efficacy of quetiapine fumarate tablets in schizophrenia was established in three 6-week trials in adults and one 6-week trial in adolescents (13 to 17 years). The effectiveness of quetiapine fumarate tablets for the maintenance treatment of schizophrenia has not been systematically evaluated in controlled clinical trials. [see Clinical Studies (14.1)] 1.2 Bipolar Disorder Quetiapine fumarate tablet is indicated for the acute treatment of manic episodes associated with bipolar I disorder, both as monotherapy and as an adjunct to lithium or divalproex. Efficacy was established in two 12-week monotherapy trials in adults, in one 3-week adjunctive trial in adults, and in one 3-week monotherapy trial in pediatric patients (10 to 17 years) [ see Clinical Studies (14.2)] . Quetiapine fumarate tablet is indicated as monotherapy for the acute treatment of depressive episodes associated with bipolar disorder. Efficacy was established in two 8-week monotherapy trials in adult patients with bipolar I and bipolar II disorder [ see Clinical Studies (14.2)] . Quetiapine fumarate tablet is indicated for the maintenance treatment of bipolar I disorder, as an adjunct to lithium or divalproex. Efficacy was established in two maintenance trials in adults. The effectiveness of quetiapine fumarate tablets as monotherapy for the maintenance treatment of bipolar disorder has not been systematically evaluated in controlled clinical trials. [ see Clinical Studies (14.2)] . 1.3 Special Considerations in Treating Pediatric Schizophrenia and Bipolar I Disorder Pediatric schizophrenia and bipolar I disorder are serious mental disorders, however, diagnosis can be challenging. For pediatric schizophrenia, symptom profiles can be variable, and for bipolar I disorder, patients may have variable patterns of periodicity of manic or mixed symptoms. It is recommended that medication therapy for pediatric schizophrenia and bipolar I disorder be initiated only after a thorough diagnostic evaluation has been performed and careful consideration given to the risks associated with medication treatment. Medication treatment for both pediatric schizophrenia and bipolar I disorder is indicated as part of a total treatment program that often includes psychological, educational and social interventions. uuid:42287e07-c41a-4381-b016-8acae551a7b9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:94559 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:e782d7cb-eca5-473d-ab07-7e533cb1c9a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:27363e71-4cd2-4e81-80aa-270e73afa798"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levocetirizine dihydrochloride tablets are a histamine H 1 -receptor antagonist indicated for: • The relief of symptoms associated with seasonal and perennial allergic rhinitis (1.1, 1.2) • The treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria (1.3) uuid:7f61499b-ab48-47dd-8a79-ca99941ae9e5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:94559 biolink:treats MONDO:0024332 PMID:41385096 "[{""id"":""uuid:2a090fb5-27f7-4aa5-a758-631f2e40a2c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8fcafff4-fa80-44d8-b393-ab80b30c6411"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levocetirizine dihydrochloride tablets are a histamine H 1 -receptor antagonist indicated for: • The relief of symptoms associated with seasonal and perennial allergic rhinitis (1.1, 1.2) • The treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria (1.3) uuid:e3c8a5dc-3aaa-4b54-ace5-4db0ccb44720 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:25187 biolink:treats MONDO:0005578 PMID:41385096 "[{""id"":""uuid:ebe46c85-ddc0-4aae-bc5a-360e1a62f9fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:92f662b8-b280-466c-8e68-d991c4428881"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS For the temporary relief of minor pain of muscles and joints associated with: Arthritis Simple Backache Strains Sprains Bruises uuid:582d5ab1-87ea-4617-be15-dfaa610074ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:25187 biolink:treats UMLS:C0038045 PMID:41385096 "[{""id"":""uuid:d3447353-3301-4f2f-8540-316627ade56b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:81e7e1bd-966e-43a7-8acf-f996d5a2c906"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS For the temporary relief of minor pain of muscles and joints associated with: Arthritis Simple Backache Strains Sprains Bruises uuid:0387c89f-6313-478d-99c6-a337557bc3f4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:25187 biolink:treats UMLS:C0009938 PMID:41385096 "[{""id"":""uuid:4c194503-6e0d-4040-87e3-f8b04f132d10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:925c423c-57bd-4c9a-a903-6cbc90eff3f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS For the temporary relief of minor pain of muscles and joints associated with: Arthritis Simple Backache Strains Sprains Bruises uuid:a223a033-6e25-47a1-af3e-0f8d11273612 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats MONDO:0005578 PMID:41385096 "[{""id"":""uuid:7f380df4-f96a-4f46-983b-5f7a38349696"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c19a6ee1-eed8-4c4d-9416-36e8f8dec828"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS For the temporary relief of minor pain of muscles and joints associated with: Arthritis Simple Backache Strains Sprains Bruises DIRECTIONS Adults and children over 18 years: Apply generously to affected area Massage into painful area until thoroughly absorbed into skin Repeat as necessary, not more than 3-4 times daily. Wash hands with soap and water immediately after use. Children 18 years or younger: ask a doctor Store at 20°-25°C (68°-77 °F). Avoid direct sunlight. uuid:296008dc-bc10-49d9-a7c5-fb3b65c0648a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats UMLS:C0038045 PMID:41385096 "[{""id"":""uuid:864f45f8-bbd7-4389-b122-6b21828d5a24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e4b585e2-8f22-4075-9bf8-16739337eeea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS For the temporary relief of minor pain of muscles and joints associated with: Arthritis Simple Backache Strains Sprains Bruises DIRECTIONS Adults and children over 18 years: Apply generously to affected area Massage into painful area until thoroughly absorbed into skin Repeat as necessary, not more than 3-4 times daily. Wash hands with soap and water immediately after use. Children 18 years or younger: ask a doctor Store at 20°-25°C (68°-77 °F). Avoid direct sunlight. uuid:6f6cb190-bbba-4264-810c-63ea9dda3f36 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats UMLS:C0009938 PMID:41385096 "[{""id"":""uuid:5dbe8111-64c5-487c-85e2-ef9a36dde1a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:973c4479-4d65-4cb1-9706-cfa8b2c778e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS For the temporary relief of minor pain of muscles and joints associated with: Arthritis Simple Backache Strains Sprains Bruises DIRECTIONS Adults and children over 18 years: Apply generously to affected area Massage into painful area until thoroughly absorbed into skin Repeat as necessary, not more than 3-4 times daily. Wash hands with soap and water immediately after use. Children 18 years or younger: ask a doctor Store at 20°-25°C (68°-77 °F). Avoid direct sunlight. uuid:4a017f39-0712-430b-be11-d30d11bda64b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:375139 biolink:treats MONDO:0005578 PMID:41385096 "[{""id"":""uuid:89dde123-d746-4e7d-a8c1-740267ed17f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:db86cbb5-c4b6-46b5-b07d-c5bbb4fbe1dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS For the temporary relief of pain of muscles and joints associated with: Arthritis Simple Backache Strains Sprains Bruises DIRECTIONS Adults and children over 12 years Apply generously to affected area Massage into painful area until thoroughly absorbed into skin, repeat as necessary, not more than 3-4 times daily Store at 20°-25°C (68°-77 °F). Avoid direct sunlight. uuid:4e24ddc1-a8f6-4cb7-9d49-68e995cd238b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:375139 biolink:treats UMLS:C0038045 PMID:41385096 "[{""id"":""uuid:27877307-b51b-496e-ad8a-8e04e8d9ad4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:58eaa5a7-8fe4-4ba5-83f7-cec659e9f748"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS For the temporary relief of pain of muscles and joints associated with: Arthritis Simple Backache Strains Sprains Bruises DIRECTIONS Adults and children over 12 years Apply generously to affected area Massage into painful area until thoroughly absorbed into skin, repeat as necessary, not more than 3-4 times daily Store at 20°-25°C (68°-77 °F). Avoid direct sunlight. uuid:74cd0d4f-4c63-4f86-a5bc-6f539f874e3d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:375139 biolink:treats UMLS:C0009938 PMID:41385096 "[{""id"":""uuid:014bd7aa-d47b-4d30-bb61-5765c2cd0684"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:999ba379-a2ca-4973-a449-4f4242bc210b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS For the temporary relief of pain of muscles and joints associated with: Arthritis Simple Backache Strains Sprains Bruises DIRECTIONS Adults and children over 12 years Apply generously to affected area Massage into painful area until thoroughly absorbed into skin, repeat as necessary, not more than 3-4 times daily Store at 20°-25°C (68°-77 °F). Avoid direct sunlight. uuid:a25a3433-96a3-4b10-9f29-13512e2a379d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17051 biolink:treats MONDO:0004059 PMID:41385096 "[{""id"":""uuid:38514981-4caf-4b88-9cb4-56e35a503d1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7c935e19-5333-46a0-aa3d-e5d6c9c87598"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] This is a fluoride and potassium nitrate gel intended to aid in the prevention of dental decay and to help treat tooth sensitivity to cold, heat, sweets, acids, or contact. uuid:def9f603-ff5a-4c12-a766-9417c7aa346e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9241 biolink:treats HP:0000969 PMID:41385096 "[{""id"":""uuid:a60b1159-f854-48b0-b60c-d9582314ec04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f7039309-de39-4d47-a334-4405e3d9be62"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone tablets, USP are indicated in the management of: for: Primary Hyperaldosteronism Establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. Short-term preoperative treatment of patients with primary hyperaldosteronism. Long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. Long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). for Patients with: Edematous Conditions For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. Spironolactone tablets, USP are also indicated for patients with congestive heart failure taking digitalis when other therapies are considered inappropriate. Congestive Heart Failure: Spironolactone levels may be exceptionally high in this condition. Spironolactone tablets, USP are indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. Cirrhosis of the Liver Accompanied by Edema and/or Ascites: : For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response. Nephrotic Syndrome uuid:00d978df-4dbf-49a1-9803-9541b5b12335 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9241 biolink:treats UMLS:C4722157 PMID:41385096 "[{""id"":""uuid:bc5d378e-1581-40a1-9404-dbef9d17389f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dacfb165-3501-4b02-93f1-0efdaa2c8745"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone tablets, USP are indicated in the management of: for: Primary Hyperaldosteronism Establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. Short-term preoperative treatment of patients with primary hyperaldosteronism. Long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. Long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). for Patients with: Edematous Conditions For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. Spironolactone tablets, USP are also indicated for patients with congestive heart failure taking digitalis when other therapies are considered inappropriate. Congestive Heart Failure: Spironolactone levels may be exceptionally high in this condition. Spironolactone tablets, USP are indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. Cirrhosis of the Liver Accompanied by Edema and/or Ascites: : For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response. Nephrotic Syndrome uuid:699f58c4-fab8-405f-9457-810f5cf70173 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:5efcc7b9-aa00-4707-b283-7e131c30719c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:50ab6c20-b475-4589-8a25-2409312d1184"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azithromycin for oral suspension USP is indicated for the treatment of patients with mild to moderate infections (pneumonia: see WARNINGS ) caused by susceptible strains of the designated microorganisms in the specific conditions listed below. As recommended dosages, durations of therapy and applicable patient populations vary among these infections, please see DOSAGE AND ADMINISTRATION for specific dosing recommendations. Adults Acute bacterial exacerbations of chronic obstructive pulmonary disease due to Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae. Acute bacterial sinusitis due to Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae. Community-acquired pneumonia due to Chlamydophila pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae or Streptococcus pneumoniae in patients appropriate for oral therapy. NOTE: Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomially acquired infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of Streptococcus pyogenes infection and the prophylaxis of rheumatic fever. Azithromycin for oral suspension USP is often effective in the eradication of susceptible strains of Streptococcus pyogenes from the nasopharynx. Because some strains are resistant to azithromycin for oral suspension USP, susceptibility tests should be performed when patients are treated with azithromycin for oral suspension USP. Data establishing efficacy of azithromycin in subsequent prevention of rheumatic fever are not available. Uncomplicated skin and skin structure infections due to Staphylococcus aureus, Streptococcus pyogenes, or Streptococcus agalactiae. Abscesses usually require surgical drainage. Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae. Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. Azithromycin for oral suspension USP, at the recommended dose, should not be relied upon to treat syphilis. Antimicrobial agents used in high doses for short periods of time to treat non-gonococcal urethritis may mask or delay the symptoms of incubating syphilis. All patients with sexually-transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate cultures for gonorrhea performed at the time of diagnosis. Appropriate antimicrobial therapy and follow-up tests for these diseases should be initiated if infection is confirmed. Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin, USP. Therapy with azithromycin for oral suspension USP may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly. To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin for oral suspension USP and other antibacterial drugs, azithromycin for oral suspension USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Pediatric Patients See PRECAUTIONS, Pediatric Use and CLINICAL STUDIES, Pediatric Patients. Acute otitis media caused by Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) Community-acquired pneumonia due to Chlamydophila pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae or Streptococcus pneumoniae in patients appropriate for oral therapy. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) NOTE: Azithromycin should not be used in pediatric patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomially acquired infections, patients with known or suspected bacteremia, patients requiring hospitalization, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of Streptococcus pyogenes infection and the prophylaxis of rheumatic fever. Azithromycin for oral suspension USP is often effective in the eradication of susceptible strains of Streptococcus pyogenes from the nasopharynx. Because some strains are resistant to azithromycin for oral suspension USP, susceptibility tests should be performed when patients are treated with azithromycin for oral suspension USP. Data establishing efficacy of azithromycin in subsequent prevention of rheumatic fever are not available. Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin. Therapy with azithromycin for oral suspension USP may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly. uuid:cd4471fa-167d-4f4c-974c-8b9bc339490a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats MONDO:0005976 PMID:41385096 "[{""id"":""uuid:d8862322-24b8-44bb-aecd-687578ea6f88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5bee2aa4-fa07-4671-a748-2f06e8d4a1e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azithromycin for oral suspension USP is indicated for the treatment of patients with mild to moderate infections (pneumonia: see WARNINGS ) caused by susceptible strains of the designated microorganisms in the specific conditions listed below. As recommended dosages, durations of therapy and applicable patient populations vary among these infections, please see DOSAGE AND ADMINISTRATION for specific dosing recommendations. Adults Acute bacterial exacerbations of chronic obstructive pulmonary disease due to Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae. Acute bacterial sinusitis due to Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae. Community-acquired pneumonia due to Chlamydophila pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae or Streptococcus pneumoniae in patients appropriate for oral therapy. NOTE: Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomially acquired infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of Streptococcus pyogenes infection and the prophylaxis of rheumatic fever. Azithromycin for oral suspension USP is often effective in the eradication of susceptible strains of Streptococcus pyogenes from the nasopharynx. Because some strains are resistant to azithromycin for oral suspension USP, susceptibility tests should be performed when patients are treated with azithromycin for oral suspension USP. Data establishing efficacy of azithromycin in subsequent prevention of rheumatic fever are not available. Uncomplicated skin and skin structure infections due to Staphylococcus aureus, Streptococcus pyogenes, or Streptococcus agalactiae. Abscesses usually require surgical drainage. Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae. Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. Azithromycin for oral suspension USP, at the recommended dose, should not be relied upon to treat syphilis. Antimicrobial agents used in high doses for short periods of time to treat non-gonococcal urethritis may mask or delay the symptoms of incubating syphilis. All patients with sexually-transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate cultures for gonorrhea performed at the time of diagnosis. Appropriate antimicrobial therapy and follow-up tests for these diseases should be initiated if infection is confirmed. Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin, USP. Therapy with azithromycin for oral suspension USP may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly. To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin for oral suspension USP and other antibacterial drugs, azithromycin for oral suspension USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Pediatric Patients See PRECAUTIONS, Pediatric Use and CLINICAL STUDIES, Pediatric Patients. Acute otitis media caused by Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) Community-acquired pneumonia due to Chlamydophila pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae or Streptococcus pneumoniae in patients appropriate for oral therapy. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) NOTE: Azithromycin should not be used in pediatric patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomially acquired infections, patients with known or suspected bacteremia, patients requiring hospitalization, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. (For specific dosage recommendation, see DOSAGE AND ADMINISTRATION .) NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of Streptococcus pyogenes infection and the prophylaxis of rheumatic fever. Azithromycin for oral suspension USP is often effective in the eradication of susceptible strains of Streptococcus pyogenes from the nasopharynx. Because some strains are resistant to azithromycin for oral suspension USP, susceptibility tests should be performed when patients are treated with azithromycin for oral suspension USP. Data establishing efficacy of azithromycin in subsequent prevention of rheumatic fever are not available. Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin. Therapy with azithromycin for oral suspension USP may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly. uuid:484db335-9e36-4064-bdd8-2dbcc33cc296 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:478164 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:f06e83d9-aa31-4ada-a1e7-e7fc5f0e2ac7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f585d8e9-6329-40a9-a732-684898250200"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefepime for injection, USP is indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms (see also PRECAUTIONS: Pediatric Use and DOSAGE AND ADMINISTRATION ): Pneumonia (moderate to severe) caused by Streptococcus pneumoniae , including cases associated with concurrent bacteremia, Pseudomonas aeruginosa , Klebsiella pneumoniae , or Enterobacter species. Empiric Therapy for Febrile Neutropenic Patients. Cefepime as monotherapy is indicated for empiric treatment of febrile neutropenic patients. In patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate. Insufficient data exist to support the efficacy of cefepime monotherapy in such patients. (See CLINICAL STUDIES .) Uncomplicated and Complicated Urinary Tract Infections (including pyelonephritis) caused by Escherichia coli or Klebsiella pneumoniae , when the infection is severe, or caused by Escherichia coli, Klebsiella pneumoniae , or Proteus mirabilis , when the infection is mild to moderate, including cases associated with concurrent bacteremia with these microorganisms. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes . Complicated Intra-abdominal Infections (used in combination with metronidazole) caused by Escherichia coli , viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae , Enterobacter species, or Bacteroides fragilis . (See CLINICAL STUDIES .) To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefepime for injection, USP and other antibacterial drugs, cefepime for injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:80ddc493-9612-44b7-af7a-47fa5723e03e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:478164 biolink:treats UMLS:C0746883 PMID:41385096 "[{""id"":""uuid:8a68ce56-580f-4c0a-80a1-a03667787739"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:62a4ea97-0d82-4aff-80ed-4aa25dc4af15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:993ce732-3703-4f8f-9270-c444a59b0432"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefepime for injection, USP is indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms (see also PRECAUTIONS: Pediatric Use and DOSAGE AND ADMINISTRATION ): Pneumonia (moderate to severe) caused by Streptococcus pneumoniae , including cases associated with concurrent bacteremia, Pseudomonas aeruginosa , Klebsiella pneumoniae , or Enterobacter species. Empiric Therapy for Febrile Neutropenic Patients. Cefepime as monotherapy is indicated for empiric treatment of febrile neutropenic patients. In patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate. Insufficient data exist to support the efficacy of cefepime monotherapy in such patients. (See CLINICAL STUDIES .) Uncomplicated and Complicated Urinary Tract Infections (including pyelonephritis) caused by Escherichia coli or Klebsiella pneumoniae , when the infection is severe, or caused by Escherichia coli, Klebsiella pneumoniae , or Proteus mirabilis , when the infection is mild to moderate, including cases associated with concurrent bacteremia with these microorganisms. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes . Complicated Intra-abdominal Infections (used in combination with metronidazole) caused by Escherichia coli , viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae , Enterobacter species, or Bacteroides fragilis . (See CLINICAL STUDIES .) To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefepime for injection, USP and other antibacterial drugs, cefepime for injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.|[PMDA] Addition of indications on febrile neutropenia uuid:974c575f-5b23-4350-a193-bf46fa4eda2c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:478164 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:14441c39-581f-411d-ab74-e0b399749096"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9100fc22-67fc-42e4-ae69-1b7ee155b524"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefepime for injection, USP is indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms (see also PRECAUTIONS: Pediatric Use and DOSAGE AND ADMINISTRATION ): Pneumonia (moderate to severe) caused by Streptococcus pneumoniae , including cases associated with concurrent bacteremia, Pseudomonas aeruginosa , Klebsiella pneumoniae , or Enterobacter species. Empiric Therapy for Febrile Neutropenic Patients. Cefepime as monotherapy is indicated for empiric treatment of febrile neutropenic patients. In patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate. Insufficient data exist to support the efficacy of cefepime monotherapy in such patients. (See CLINICAL STUDIES .) Uncomplicated and Complicated Urinary Tract Infections (including pyelonephritis) caused by Escherichia coli or Klebsiella pneumoniae , when the infection is severe, or caused by Escherichia coli, Klebsiella pneumoniae , or Proteus mirabilis , when the infection is mild to moderate, including cases associated with concurrent bacteremia with these microorganisms. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes . Complicated Intra-abdominal Infections (used in combination with metronidazole) caused by Escherichia coli , viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae , Enterobacter species, or Bacteroides fragilis . (See CLINICAL STUDIES .) To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefepime for injection, USP and other antibacterial drugs, cefepime for injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:bff875d4-def9-430e-9c4a-1f2c3c622cc6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:478164 biolink:treats MONDO:0006939 PMID:41385096 "[{""id"":""uuid:bc44a7a0-1e5c-4c5e-81c6-a4626179f627"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bfb5dd03-917d-461e-8b2c-963b197c5f77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefepime for injection, USP is indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms (see also PRECAUTIONS: Pediatric Use and DOSAGE AND ADMINISTRATION ): Pneumonia (moderate to severe) caused by Streptococcus pneumoniae , including cases associated with concurrent bacteremia, Pseudomonas aeruginosa , Klebsiella pneumoniae , or Enterobacter species. Empiric Therapy for Febrile Neutropenic Patients. Cefepime as monotherapy is indicated for empiric treatment of febrile neutropenic patients. In patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate. Insufficient data exist to support the efficacy of cefepime monotherapy in such patients. (See CLINICAL STUDIES .) Uncomplicated and Complicated Urinary Tract Infections (including pyelonephritis) caused by Escherichia coli or Klebsiella pneumoniae , when the infection is severe, or caused by Escherichia coli, Klebsiella pneumoniae , or Proteus mirabilis , when the infection is mild to moderate, including cases associated with concurrent bacteremia with these microorganisms. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes . Complicated Intra-abdominal Infections (used in combination with metronidazole) caused by Escherichia coli , viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae , Enterobacter species, or Bacteroides fragilis . (See CLINICAL STUDIES .) To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefepime for injection, USP and other antibacterial drugs, cefepime for injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:c26fe382-85ec-417c-a41d-a658ae1b11ed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:478164 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:8ef7382d-f149-43eb-a6f7-8bd2f4bdc711"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e70b2edb-1753-4f6b-a89c-cf0377a22c40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefepime for injection, USP is indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms (see also PRECAUTIONS: Pediatric Use and DOSAGE AND ADMINISTRATION ): Pneumonia (moderate to severe) caused by Streptococcus pneumoniae , including cases associated with concurrent bacteremia, Pseudomonas aeruginosa , Klebsiella pneumoniae , or Enterobacter species. Empiric Therapy for Febrile Neutropenic Patients. Cefepime as monotherapy is indicated for empiric treatment of febrile neutropenic patients. In patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate. Insufficient data exist to support the efficacy of cefepime monotherapy in such patients. (See CLINICAL STUDIES .) Uncomplicated and Complicated Urinary Tract Infections (including pyelonephritis) caused by Escherichia coli or Klebsiella pneumoniae , when the infection is severe, or caused by Escherichia coli, Klebsiella pneumoniae , or Proteus mirabilis , when the infection is mild to moderate, including cases associated with concurrent bacteremia with these microorganisms. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes . Complicated Intra-abdominal Infections (used in combination with metronidazole) caused by Escherichia coli , viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae , Enterobacter species, or Bacteroides fragilis . (See CLINICAL STUDIES .) To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefepime for injection, USP and other antibacterial drugs, cefepime for injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:8892c162-b87e-4073-8caa-04f32585651b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats MONDO:0005412 PMID:41385096 "[{""id"":""uuid:20a14290-01d0-47c4-bfcc-4a5519bd81b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dbd67119-b05d-4ff4-b496-9c6fa4568959"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ranitidine is indicated in: Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo-controlled comparative studies have been carried out for periods of longer than 1 year. The treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and systemic mastocytosis). Short-term treatment of active, benign gastric ulcer. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. Studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled studies have been carried out for 1 year. Treatment of GERD. Symptomatic relief commonly occurs within 24 hours after starting therapy with ranitidine 150 mg two times a day. Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with ranitidine 150 mg 4 times daily. Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks. Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis. uuid:5b09610c-30a8-4e3c-b182-0f7ca1940f54 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats MONDO:0016586 PMID:41385096 "[{""id"":""uuid:8c1830b3-cfd5-4c40-a683-ced98954ff4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2e61f0c9-cca8-4aca-b846-57a65080af54"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ranitidine is indicated in: Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo-controlled comparative studies have been carried out for periods of longer than 1 year. The treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and systemic mastocytosis). Short-term treatment of active, benign gastric ulcer. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. Studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled studies have been carried out for 1 year. Treatment of GERD. Symptomatic relief commonly occurs within 24 hours after starting therapy with ranitidine 150 mg two times a day. Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with ranitidine 150 mg 4 times daily. Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks. Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis. uuid:ea71d23a-5fd4-45cc-87e8-17c79fb6a1f4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats MONDO:0001126 PMID:41385096 "[{""id"":""uuid:d076841e-211f-4b8e-ade3-09ca01b7258c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1946d10b-53c0-4c31-94b5-f74c90ccf24d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ranitidine is indicated in: Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo-controlled comparative studies have been carried out for periods of longer than 1 year. The treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and systemic mastocytosis). Short-term treatment of active, benign gastric ulcer. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. Studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled studies have been carried out for 1 year. Treatment of GERD. Symptomatic relief commonly occurs within 24 hours after starting therapy with ranitidine 150 mg two times a day. Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with ranitidine 150 mg 4 times daily. Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks. Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis. uuid:1bf95d9b-2d47-44ee-8ff2-4ad19357abd8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats UMLS:C0267055 PMID:41385096 "[{""id"":""uuid:dbb6fee4-fb08-4ff9-8266-745463aa556d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:12a3bd87-9b92-485c-be75-db38ab517cd1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ranitidine is indicated in: Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo-controlled comparative studies have been carried out for periods of longer than 1 year. The treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and systemic mastocytosis). Short-term treatment of active, benign gastric ulcer. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. Studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled studies have been carried out for 1 year. Treatment of GERD. Symptomatic relief commonly occurs within 24 hours after starting therapy with ranitidine 150 mg two times a day. Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with ranitidine 150 mg 4 times daily. Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks. Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis. uuid:a6f6d7f0-2176-471f-8d45-8300d787427a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats MONDO:0007186 PMID:41385096 "[{""id"":""uuid:c99187ef-ecae-40f1-a7c0-80e9bfa5a8dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2d361afd-a0fe-44de-866f-3812fbd4fbbf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ranitidine is indicated in: Short-term treatment of active duodenal ulcer. Most patients heal within 4 weeks. Studies available to date have not assessed the safety of ranitidine in uncomplicated duodenal ulcer for periods of more than 8 weeks. Maintenance therapy for duodenal ulcer patients at reduced dosage after healing of acute ulcers. No placebo-controlled comparative studies have been carried out for periods of longer than 1 year. The treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome and systemic mastocytosis). Short-term treatment of active, benign gastric ulcer. Most patients heal within 6 weeks and the usefulness of further treatment has not been demonstrated. Studies available to date have not assessed the safety of ranitidine in uncomplicated, benign gastric ulcer for periods of more than 6 weeks. Maintenance therapy for gastric ulcer patients at reduced dosage after healing of acute ulcers. Placebo-controlled studies have been carried out for 1 year. Treatment of GERD. Symptomatic relief commonly occurs within 24 hours after starting therapy with ranitidine 150 mg two times a day. Treatment of endoscopically diagnosed erosive esophagitis. Symptomatic relief of heartburn commonly occurs within 24 hours of therapy initiation with ranitidine 150 mg 4 times daily. Maintenance of healing of erosive esophagitis. Placebo-controlled trials have been carried out for 48 weeks. Concomitant antacids should be given as needed for pain relief to patients with active duodenal ulcer; active, benign gastric ulcer; hypersecretory states; GERD; and erosive esophagitis. uuid:1c5ab81c-ab03-42e5-ade7-a0a2be5e0740 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:25681 biolink:treats MONDO:0005347 PMID:41385096 "[{""id"":""uuid:9ec848c9-ec1c-4e32-b5f8-54f4434154f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:20af5f80-8e00-4da7-afed-608f7cfaf83b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Omega-3-acid ethyl esters capsules, USP are indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia (HTG). Usage Considerations : Patients should be placed on an appropriate lipid-lowering diet before receiving omega-3-acid ethyl esters capsules, USP and should continue this diet during treatment with omega-3-acid ethyl esters capsules, USP. Laboratory studies should be done to ascertain that the lipid levels are consistently abnormal before instituting therapy with omega-3-acid ethyl esters. Every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that are contributing to the lipid abnormalities. Medications known to exacerbate hypertriglyceridemia (such as beta blockers, thiazides, estrogens) should be discontinued or changed if possible prior to consideration of triglyceride-lowering drug therapy. Limitations of Use: Sections or subsections omitted from the full prescribing information are not listed. The effect of omega-3-acid ethyl esters capsules, USP on the risk for pancreatitis has not been determined. The effect of omega-3-acid ethyl esters capsules, USP on cardiovascular mortality and morbidity has not been determined. uuid:4a087359-e417-482f-a93e-319773ddf1b8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:25681 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:a44b5e5c-b32e-4f73-85b5-c45b02b06049"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:58176439-96ab-4345-ace9-1bcd2a03cdc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Omega-3-acid ethyl esters capsules, USP are indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia (HTG). Usage Considerations : Patients should be placed on an appropriate lipid-lowering diet before receiving omega-3-acid ethyl esters capsules, USP and should continue this diet during treatment with omega-3-acid ethyl esters capsules, USP. Laboratory studies should be done to ascertain that the lipid levels are consistently abnormal before instituting therapy with omega-3-acid ethyl esters. Every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that are contributing to the lipid abnormalities. Medications known to exacerbate hypertriglyceridemia (such as beta blockers, thiazides, estrogens) should be discontinued or changed if possible prior to consideration of triglyceride-lowering drug therapy. Limitations of Use: Sections or subsections omitted from the full prescribing information are not listed. The effect of omega-3-acid ethyl esters capsules, USP on the risk for pancreatitis has not been determined. The effect of omega-3-acid ethyl esters capsules, USP on cardiovascular mortality and morbidity has not been determined. uuid:3ab6f50c-5fa3-4b2d-b650-27f29cb84524 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:25681 biolink:treats MONDO:0005420 PMID:41385096 "[{""id"":""uuid:958e4b87-601c-4f25-b7ce-197a85a3931f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3597ceae-b801-407f-ae3f-5091f04e9421"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Omega-3-acid ethyl esters capsules, USP are indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia (HTG). Usage Considerations : Patients should be placed on an appropriate lipid-lowering diet before receiving omega-3-acid ethyl esters capsules, USP and should continue this diet during treatment with omega-3-acid ethyl esters capsules, USP. Laboratory studies should be done to ascertain that the lipid levels are consistently abnormal before instituting therapy with omega-3-acid ethyl esters. Every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that are contributing to the lipid abnormalities. Medications known to exacerbate hypertriglyceridemia (such as beta blockers, thiazides, estrogens) should be discontinued or changed if possible prior to consideration of triglyceride-lowering drug therapy. Limitations of Use: Sections or subsections omitted from the full prescribing information are not listed. The effect of omega-3-acid ethyl esters capsules, USP on the risk for pancreatitis has not been determined. The effect of omega-3-acid ethyl esters capsules, USP on cardiovascular mortality and morbidity has not been determined. uuid:fb5b3c32-e83c-4c35-985d-bf63061cb93e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4995 biolink:treats MONDO:0005027 PMID:41385096 "[{""id"":""uuid:a011f3a5-11b4-470b-8aed-a10fb5682bfa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cdaf880b-2e8c-4005-b819-39415f56cf07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Felbamate tablets, USP are not indicated as a first line antiepileptic treatment (see Warnings ). Felbamate tablets, USP are recommended for use only in those patients who respond inadequately to alternative treatments and whose epilepsy is so severe that a substantial risk of aplastic anemia and/or liver failure is deemed acceptable in light of the benefits conferred by its use. If these criteria are met and the patient has been fully advised of the risk, and has provided written acknowledgment, felbamate tablets, USP can be considered for either monotherapy or adjunctive therapy in the treatment of partial seizures, with and without generalization, in adults with epilepsy and as adjunctive therapy in the treatment of partial and generalized seizures associated with Lennox-Gastaut syndrome in children. uuid:7f3fa07d-2454-4433-b289-028575c74a87 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4995 biolink:treats HP:0007359 PMID:41385096 "[{""id"":""uuid:643ffb80-679e-4d11-baa5-f9ae0fe65d92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5128fed4-a42a-44a9-93b1-30ab27271bb7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Felbamate tablets, USP are not indicated as a first line antiepileptic treatment (see Warnings ). Felbamate tablets, USP are recommended for use only in those patients who respond inadequately to alternative treatments and whose epilepsy is so severe that a substantial risk of aplastic anemia and/or liver failure is deemed acceptable in light of the benefits conferred by its use. If these criteria are met and the patient has been fully advised of the risk, and has provided written acknowledgment, felbamate tablets, USP can be considered for either monotherapy or adjunctive therapy in the treatment of partial seizures, with and without generalization, in adults with epilepsy and as adjunctive therapy in the treatment of partial and generalized seizures associated with Lennox-Gastaut syndrome in children. uuid:89c274c7-92f2-4b6b-abbc-8f542ff657fb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4995 biolink:treats MONDO:0015909 PMID:41385096 "[{""id"":""uuid:fb73e79e-7c3e-4dd7-a461-5d2eb59e00da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:27283f67-6769-47a6-998c-f41c22065532"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Felbamate tablets, USP are not indicated as a first line antiepileptic treatment (see Warnings ). Felbamate tablets, USP are recommended for use only in those patients who respond inadequately to alternative treatments and whose epilepsy is so severe that a substantial risk of aplastic anemia and/or liver failure is deemed acceptable in light of the benefits conferred by its use. If these criteria are met and the patient has been fully advised of the risk, and has provided written acknowledgment, felbamate tablets, USP can be considered for either monotherapy or adjunctive therapy in the treatment of partial seizures, with and without generalization, in adults with epilepsy and as adjunctive therapy in the treatment of partial and generalized seizures associated with Lennox-Gastaut syndrome in children. uuid:84400044-da5d-432a-8101-793fc268197b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4995 biolink:treats MONDO:0100192 PMID:41385096 "[{""id"":""uuid:10224992-9e7b-4875-a20f-24ed45ff9c60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f1c0ce54-367d-4a87-ab91-71774aa95f2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Felbamate tablets, USP are not indicated as a first line antiepileptic treatment (see Warnings ). Felbamate tablets, USP are recommended for use only in those patients who respond inadequately to alternative treatments and whose epilepsy is so severe that a substantial risk of aplastic anemia and/or liver failure is deemed acceptable in light of the benefits conferred by its use. If these criteria are met and the patient has been fully advised of the risk, and has provided written acknowledgment, felbamate tablets, USP can be considered for either monotherapy or adjunctive therapy in the treatment of partial seizures, with and without generalization, in adults with epilepsy and as adjunctive therapy in the treatment of partial and generalized seizures associated with Lennox-Gastaut syndrome in children. uuid:4078cf20-9def-4fdd-b669-5c82093193fb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:453011 biolink:treats MONDO:0000879 PMID:41385096 "[{""id"":""uuid:eaa5c30d-47a5-4308-bfb3-f4a051146679"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d4d53a50-ccf4-48f3-92e6-a3800a54c075"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciclopirox Topical Suspension USP, 0.77% (Lotion) is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to Trichophyton rubrum , Trichophyton mentagrophytes , Epidermophyton floccosum , and Microsporum canis ; cutaneous candidiasis (moniliasis) due to Candida albicans ; and tinea (pityriasis) versicolor due to Malassezia furfur . uuid:393a70ad-e79e-4722-a4f9-1eeb5b9d2d21 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1151145 biolink:treats UMLS:C0341178 PMID:41385096 "[{""id"":""uuid:4e08530c-6272-40b1-8a8a-e271eb213c5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d578607e-6c0c-48aa-b072-141ed0657304"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of diclofenac sodium and misoprostol delayed-release tablets and other treatment options before deciding to use diclofenac sodium and misoprostol delayed-release tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Diclofenac sodium and misoprostol delayed-release tablets are indicated for treatment of the signs and symptoms of osteoarthritis or rheumatoid arthritis in patients at high risk of developing NSAID-induced gastric and duodenal ulcers and their complications. See WARNINGS , Gastrointestinal Effects - Risk of Ulceration, Bleeding, and Perforation for a list of factors that may increase the risk of NSAID-induced gastric and duodenal ulcers and their complications. uuid:d0fb8620-8bda-4a31-bee5-1717d2b68977 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15365 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:27634d24-66f3-41bc-892b-136bbd480a81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a3be2d56-9a58-4190-a351-7ddfd3c1f436"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DURLAZA is indicated to: Reduce the risk of death and myocardial infarction (MI) in patients with chronic coronary artery disease, such as patients with a history of MI or unstable angina pectoris or with chronic stable angina Reduce the risk of death and recurrent stroke in patients who have had an ischemic stroke or transient ischemic attack Limitation of Use : Use immediate-release aspirin, not DURLAZA in situations where a rapid onset of action is required (such as acute treatment of myocardial infarction or before percutaneous coronary intervention). uuid:fe398605-03e3-48aa-9704-a4b54862d905 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15365 biolink:treats MONDO:0006805 PMID:41385096 "[{""id"":""uuid:9dbbd7f4-bd10-4bee-84bb-fbf31bd74059"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5ca244c1-5ddb-4b46-a141-08aab7c7800a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DURLAZA is indicated to: Reduce the risk of death and myocardial infarction (MI) in patients with chronic coronary artery disease, such as patients with a history of MI or unstable angina pectoris or with chronic stable angina Reduce the risk of death and recurrent stroke in patients who have had an ischemic stroke or transient ischemic attack Limitation of Use : Use immediate-release aspirin, not DURLAZA in situations where a rapid onset of action is required (such as acute treatment of myocardial infarction or before percutaneous coronary intervention). uuid:cb5b2eb9-d6e3-43a8-8a31-01396aa650ce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15365 biolink:treats HP:0002140 PMID:41385096 "[{""id"":""uuid:6ae291c6-3904-490e-83fb-bcb6b31113cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:416f8b50-7c31-4d18-a878-3e1bc55d1df1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DURLAZA is indicated to: Reduce the risk of death and myocardial infarction (MI) in patients with chronic coronary artery disease, such as patients with a history of MI or unstable angina pectoris or with chronic stable angina Reduce the risk of death and recurrent stroke in patients who have had an ischemic stroke or transient ischemic attack Limitation of Use : Use immediate-release aspirin, not DURLAZA in situations where a rapid onset of action is required (such as acute treatment of myocardial infarction or before percutaneous coronary intervention). uuid:f1ca9a11-c798-439a-b97c-47ed7599752d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15365 biolink:treats MONDO:0005264 PMID:41385096 "[{""id"":""uuid:cf1805fb-2ef3-4ea2-b080-bdd0b945f8cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:96a4ad88-5af8-4593-b001-d7f864c99397"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DURLAZA is indicated to: Reduce the risk of death and myocardial infarction (MI) in patients with chronic coronary artery disease, such as patients with a history of MI or unstable angina pectoris or with chronic stable angina Reduce the risk of death and recurrent stroke in patients who have had an ischemic stroke or transient ischemic attack Limitation of Use : Use immediate-release aspirin, not DURLAZA in situations where a rapid onset of action is required (such as acute treatment of myocardial infarction or before percutaneous coronary intervention). uuid:b307f7b0-7d2f-4d90-9ebb-7783eb9c74bc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0019359 PMID:41385096 "[{""id"":""uuid:b5ae6d58-199a-445f-bba3-31ca88bf2503"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5ea81048-e8c7-4f23-91e2-31e25f993b9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:ca82ea7a-2fae-4ba9-a6ac-ff7ac6bb0441 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0001246 PMID:41385096 "[{""id"":""uuid:28484eea-3b87-4f44-beab-c98e3e4be98b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f6f21464-bad3-4ca8-aab6-fbdb9f59e052"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:62e02687-41f0-4e5a-a0ce-191667b3b446 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0019186 PMID:41385096 "[{""id"":""uuid:a0254801-69d6-4dcc-84b9-4ceb42d62d12"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fef43dab-6bfa-4ab9-aeb9-a9c60e37f32c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:4e5183c2-fccd-4ac1-bdfd-87093e32d097 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0019360 PMID:41385096 "[{""id"":""uuid:d0c5aa84-45ed-4e26-9fd8-c127ef48c1b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e028774e-94a0-423a-9ece-9da6ee236f29"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:114a3606-5293-494a-9775-fcc7d1da6a4c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0025294 PMID:41385096 "[{""id"":""uuid:dbfa194b-95d9-4bf0-b768-c653b1144f72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:92fad51c-f593-4136-aa76-1d1a4d173220"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:e64f1bcc-5071-4dbb-9675-0ebce96ca0e5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:3d2defde-f3c9-42c5-9126-d70c5c69bdba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f2388f2d-5e64-4675-acef-d7ae3f73eb2b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:6110a849-6779-4e7c-8410-fc1c2dd8e0f6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0005834 PMID:41385096 "[{""id"":""uuid:cacf8054-8ff2-4352-a4d2-f25e93ba780d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:18dca2fe-ca6c-4477-a4f7-e59590ecd98e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:6d83709c-3038-4da5-9208-5004af348f5f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0005888 PMID:41385096 "[{""id"":""uuid:b14ad4ac-c35c-4838-ad98-6b8d3e243c8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b3b87a32-6cc5-4710-84e7-6088cae9677f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:0dfb6024-2017-4de2-ae14-a65b684adbc8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0001249 PMID:41385096 "[{""id"":""uuid:21689485-0320-4b02-b7aa-21cceee7838f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0308d07c-bd10-4421-a7ec-117b1e4a642e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:4e0bd469-99b4-4b56-988c-5bb8ca91070b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0005808 PMID:41385096 "[{""id"":""uuid:b4a70f00-8e52-4d02-b0a4-bf3c3fb7c0ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f9291062-80fc-42a7-8218-d32f10ec459c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:467d95a4-9af9-49af-8a8e-5df48c74d75e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0021697 PMID:41385096 "[{""id"":""uuid:9ce943f8-752c-46f0-8d26-5ebb763c14ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bff47d3f-58bc-4d1f-907d-91184850af43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:abde5a67-fbbf-4e50-a656-d4e220c33ce8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0005297 PMID:41385096 "[{""id"":""uuid:030c3924-87b4-43f7-bf8d-9d2e6a6dec0f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:47e8b74d-cc59-4c32-97eb-444ba895b052"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:4c783da0-208e-450f-bdc8-35be673e101a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0019633 PMID:41385096 "[{""id"":""uuid:da9ec3e8-cbce-47bc-ab45-5eb8250ff0a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e9631422-81cd-46f2-8801-c1dca977d931"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:52cbc141-6b3e-42fd-a2ee-fc36af6f1a4c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0001797 PMID:41385096 "[{""id"":""uuid:48a6a1a5-26d4-40f1-a67e-e00fe5cbfa90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:479b6941-cad1-4b9f-94d2-1050d3719d4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:c5d79097-1b00-4c86-a41f-ff6ed4f28018 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0019095 PMID:41385096 "[{""id"":""uuid:5fc5186a-251d-4347-979a-ffc6aac4ae05"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f8d8dec2-d837-4b3f-9b0c-102f119c83c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:6a16820b-0077-489c-b89b-5caab2e5504e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0018077 PMID:41385096 "[{""id"":""uuid:ca4aaf64-6d89-4ec9-a7f9-7baded87b80b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1332fc60-200c-468f-99bb-beee674e877f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:53cf246c-8133-49f4-987e-bc0a8f143f83 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0015766 PMID:41385096 "[{""id"":""uuid:a1807d1a-09a5-4117-a3d3-afcd89d749b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e2af758d-b1b0-40d9-9297-24486c0e5e04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:72313bef-adf2-4d00-b96f-c4bf04add69b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0040728 PMID:41385096 "[{""id"":""uuid:1d41f1b5-c6a0-4a5c-981c-9c2fb1d682fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d5da7420-e6a6-46a1-b0a5-9615b6f5a32b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:219ae3c5-60dc-4891-b694-fa49024d833d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0005683 PMID:41385096 "[{""id"":""uuid:fcab3167-99bb-46e4-9f82-86de3a8bfe31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:458b66d7-2cee-4cf4-9c2f-04edea7a26ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:47802dc3-1de9-4a8f-9d3d-d9a872b58632 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0005664 PMID:41385096 "[{""id"":""uuid:b36b64c2-6cd0-4060-9791-107934a8b318"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1e3712e3-1beb-4d0b-8a0c-c7c10540411e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:8f35c396-ab36-4383-a749-8aa1cd4afcf0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0005777 PMID:41385096 "[{""id"":""uuid:51b80a8d-e75b-4301-81bd-295cc64937c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:952ed8b0-8aba-4ecc-a737-6bd984540742"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:ce126879-a4a0-4e79-a012-8c9a9133f1d0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0020920 PMID:41385096 "[{""id"":""uuid:0f4a7b57-46fc-46ed-8610-1cb0469be193"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0eaafe35-f6af-4538-9b2d-265f44f43ae8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:bd8890c5-0621-4874-b38d-b15103002fe4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0019345 PMID:41385096 "[{""id"":""uuid:cc97a646-2381-4524-ade5-61a1af746dd8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:150b0bb6-af7f-4e94-98c3-d2e9ec044136"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:7b83a8e6-ec39-4393-af6a-0801c68a0279 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0006635 PMID:41385096 "[{""id"":""uuid:05a1920e-048c-4e9e-a124-836f24147f6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:074325d8-b7c4-4592-a704-a261980bad93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:6840ee88-f5db-4b77-a7be-46de409d82f6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats HP:0005376 PMID:41385096 "[{""id"":""uuid:8c205d2c-6f71-4f1e-bfeb-b7c26a1e2c20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:24b951f2-d532-47e2-8d65-befbff39d349"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:7b65e954-bc6d-49bd-9cb4-352201a29a91 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:7bd2c35c-2c16-4e55-9fa4-6709c850caf6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:895d3cac-68e6-45fd-b80b-ef3316500e2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:cb2ff487-d565-4ff8-adb6-459b0e554ba3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0030603 PMID:41385096 "[{""id"":""uuid:dbcaacbe-fb5c-4146-9f58-eff62445b068"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7c71aae4-d7b9-4088-8679-618cd15b2424"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:2cc92cc5-724f-4ecd-9bf6-4ddc4399e587 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats UMLS:C0041912 PMID:41385096 "[{""id"":""uuid:97f78fcb-03d6-4704-a1f2-f67b5f2490d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:58fad529-6b04-443f-ae04-8901337fff80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:7d7a9f4b-439b-459e-b942-6b589bb27267 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0005119 PMID:41385096 "[{""id"":""uuid:ad527cfc-4068-4293-875b-63740763cf97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c8ccaf40-f80e-48a5-8c88-4785091e469a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:ea98b12b-56b3-4dc2-8d80-8b6ac65044e9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0004277 PMID:41385096 "[{""id"":""uuid:f081abc2-28e5-441c-ac23-a34806b249b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e792e843-c310-4dfc-bd7a-ef3f54f581f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:c59cdfb4-9f82-4cf1-bf7f-72b3ad3d3ee7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0005976 PMID:41385096 "[{""id"":""uuid:f3f08ac6-a4cb-422f-bb95-f32c3b4895a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:160e7d9f-9ab2-4e93-a88f-a9a4e2444872"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:08843cdb-fe28-492e-9d70-421389dca520 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0006019 PMID:41385096 "[{""id"":""uuid:f37a00be-471b-454b-af53-a234bc1716b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:da8668b8-b356-4109-a2ad-599727ecfbe1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:a6e89049-9786-4752-9e81-a6745044a679 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0005828 PMID:41385096 "[{""id"":""uuid:1b25e392-a441-4559-bfb2-367db0f625c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bddfac64-3f15-449c-ab4b-598ef9740068"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:52d957bb-f3d5-49f0-8546-534c543c263d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0005631 PMID:41385096 "[{""id"":""uuid:fa6eeff3-9643-4b28-8ca6-83c7e8bc65a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e7a8a58d-2fb2-4ece-a9b4-660d396bea77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:7661be54-16b0-46c7-8397-82e3690b1e03 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0024388 PMID:41385096 "[{""id"":""uuid:b8ac1eb1-3e14-4312-adc8-0d54597d71af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0b2ab6b7-6add-4445-bf0a-5bb1b21c5cb3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:2fdcf968-da79-4171-bee0-1ac053dc01e9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0005644 PMID:41385096 "[{""id"":""uuid:10ab1026-9380-4739-af28-5e5181fea4fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ae17e4d6-82b2-47f9-bc20-4ab0ba422d4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:da8ee0be-ad29-44a2-8eaf-d2cb32ccf491 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60648 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:f5a50e8b-034a-46ee-9376-804f018dd140"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f9d53755-690a-4529-99bd-3d2547d1c68b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline tablets and other antibacterial drugs, doxycycline tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated for the treatment of the following infections: Rocky mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by Rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (ornithosis) caused by Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Uncomplicated urethral, endocervical or rectal infections in adults caused by Chlamydia trachomatis . Nongonococcal urethritis caused by Ureaplasma urealyticum . Relapsing fever due to Borrelia recurrentis . Doxycycline is also indicated for the treatment of infections caused by the following gram-negative microorganisms: Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Calymmatobacterium granulomatis . Because many strains of the following groups of microorganisms have been shown to be resistant to doxycycline, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae . Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of the following infections: Uncomplicated gonorrhea caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum . Yaws caused by Treponema pertenue . Listeriosis due to Listeria monocytogenes . Vincent's infection caused by Fusobacterium fusiforme . Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. In severe acne, doxycycline may be useful adjunctive therapy. uuid:08a05c0f-7bfa-433b-99f3-77dde0af1939 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50275 biolink:treats UMLS:C0267055 PMID:41385096 "[{""id"":""uuid:556653c1-9da7-43a0-ad55-0b064e255769"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5d465bef-82ee-4198-9ed0-6dddfb37a154"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Treatment of Gastroesophageal Reflux Disease (GERD) Healing of Erosive Esophagitis Esomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis. For those patients who have not healed after 4 to 8 weeks of treatment, an additional 4 to 8 week course of esomeprazole magnesium delayed-release capsules may be considered. In infants 1 month to less than 1 year, esomeprazole magnesium delayed-release capsules are indicated for short-term treatment (up to 6 weeks) of erosive esophagitis due to acid-mediated GERD. Maintenance of Healing of Erosive Esophagitis Esomeprazole magnesium delayed-release capsules are indicated to maintain symptom resolution and healing of erosive esophagitis. Controlled studies do not extend beyond 6 months. Symptomatic Gastroesophageal Reflux Disease Esomeprazole magnesium delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with GERD in adults and children 1 year or older. 1.2 Risk Reduction of NSAID-Associated Gastric Ulcer Esomeprazole magnesium delayed-release capsules are indicated for the reduction in the occurrence of gastric ulcers associated with continuous NSAID therapy in patients at risk for developing gastric ulcers. Patients are considered to be at risk due to their age (≥ 60) and/or documented history of gastric ulcers. Controlled studies do not extend beyond 6 months. 1.4 Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome Esomeprazole magnesium delayed-release capsule USP is indicated for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison Syndrome. uuid:31dd2e65-9c13-4c68-a476-87ab060ff84d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50275 biolink:treats UMLS:C0341178 PMID:41385096 "[{""id"":""uuid:b9e3190a-104a-468e-92cf-2249e291a709"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:19b22763-bc7f-4fa4-b927-5e51391683f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Treatment of Gastroesophageal Reflux Disease (GERD) Healing of Erosive Esophagitis Esomeprazole magnesium delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis. For those patients who have not healed after 4 to 8 weeks of treatment, an additional 4 to 8 week course of esomeprazole magnesium delayed-release capsules may be considered. In infants 1 month to less than 1 year, esomeprazole magnesium delayed-release capsules are indicated for short-term treatment (up to 6 weeks) of erosive esophagitis due to acid-mediated GERD. Maintenance of Healing of Erosive Esophagitis Esomeprazole magnesium delayed-release capsules are indicated to maintain symptom resolution and healing of erosive esophagitis. Controlled studies do not extend beyond 6 months. Symptomatic Gastroesophageal Reflux Disease Esomeprazole magnesium delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with GERD in adults and children 1 year or older. 1.2 Risk Reduction of NSAID-Associated Gastric Ulcer Esomeprazole magnesium delayed-release capsules are indicated for the reduction in the occurrence of gastric ulcers associated with continuous NSAID therapy in patients at risk for developing gastric ulcers. Patients are considered to be at risk due to their age (≥ 60) and/or documented history of gastric ulcers. Controlled studies do not extend beyond 6 months. 1.4 Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome Esomeprazole magnesium delayed-release capsule USP is indicated for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison Syndrome. uuid:36dffbe8-4b5e-4215-9895-8468d045bbf4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41423 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:7599119b-ad29-4f1a-a993-1af39f301768"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:74fbe4af-e81c-4a23-8f8e-ba6e3630b2c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2f0c6848-ac06-43a9-9cf6-39c77e44a873"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of celecoxib and other treatment options before deciding to use celecoxib. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals [see Warnings and Precautions (5) ] 1.1 Osteoarthritis (OA) Celecoxib is indicated for relief of the signs and symptoms of OA [see Clinical Studies (14.1) ] 1.2 Rheumatoid Arthritis (RA) Celecoxib is indicated for relief of the signs and symptoms of RA [see Clinical Studies (14.2) ] 1.3 Juvenile Rheumatoid Arthritis (JRA) Celecoxib is indicated for relief of the signs and symptoms of JRA in patients 2 years and older [see Clinical Studies (14.3) ] 1.4 Ankylosing Spondylitis (AS) Celecoxib is indicated for the relief of signs and symptoms of AS [see Clinical Studies (14.4) ] 1.5 Acute Pain (AP) Celecoxib is indicated for the management of AP in adults [see Clinical Studies (14.5) ] 1.6 Primary Dysmenorrhea (PD) Celecoxib is indicated for the treatment of PD [see Clinical Studies (14.5) ]|[PMDA] Drugs with a new active ingredient indicated for relief of inflammation and pain associated with rheumatoid arthritis and osteoarthritis. uuid:4329a3c2-019e-4ce8-ac26-d4da994aa852 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41423 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:76126542-981a-4a24-a344-9823f7d26f27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e672a6ca-394d-4f52-ae6f-5791f39fdc0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:6788c4f7-04be-4f4f-b0c7-1bf93a9e42da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of celecoxib and other treatment options before deciding to use celecoxib. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals [see Warnings and Precautions (5) ] 1.1 Osteoarthritis (OA) Celecoxib is indicated for relief of the signs and symptoms of OA [see Clinical Studies (14.1) ] 1.2 Rheumatoid Arthritis (RA) Celecoxib is indicated for relief of the signs and symptoms of RA [see Clinical Studies (14.2) ] 1.3 Juvenile Rheumatoid Arthritis (JRA) Celecoxib is indicated for relief of the signs and symptoms of JRA in patients 2 years and older [see Clinical Studies (14.3) ] 1.4 Ankylosing Spondylitis (AS) Celecoxib is indicated for the relief of signs and symptoms of AS [see Clinical Studies (14.4) ] 1.5 Acute Pain (AP) Celecoxib is indicated for the management of AP in adults [see Clinical Studies (14.5) ] 1.6 Primary Dysmenorrhea (PD) Celecoxib is indicated for the treatment of PD [see Clinical Studies (14.5) ]|[PMDA] Drugs with a new active ingredient indicated for relief of inflammation and pain associated with rheumatoid arthritis and osteoarthritis. uuid:31d9c726-534d-40b4-ba9f-db2bec531644 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41423 biolink:treats MONDO:0011429 PMID:41385096 "[{""id"":""uuid:cc0fcbb8-f1bf-424c-a5a5-c8861a5e0d71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:734fcd53-8092-4156-a1a3-7d54b782b32b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of celecoxib and other treatment options before deciding to use celecoxib. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals [see Warnings and Precautions (5) ] 1.1 Osteoarthritis (OA) Celecoxib is indicated for relief of the signs and symptoms of OA [see Clinical Studies (14.1) ] 1.2 Rheumatoid Arthritis (RA) Celecoxib is indicated for relief of the signs and symptoms of RA [see Clinical Studies (14.2) ] 1.3 Juvenile Rheumatoid Arthritis (JRA) Celecoxib is indicated for relief of the signs and symptoms of JRA in patients 2 years and older [see Clinical Studies (14.3) ] 1.4 Ankylosing Spondylitis (AS) Celecoxib is indicated for the relief of signs and symptoms of AS [see Clinical Studies (14.4) ] 1.5 Acute Pain (AP) Celecoxib is indicated for the management of AP in adults [see Clinical Studies (14.5) ] 1.6 Primary Dysmenorrhea (PD) Celecoxib is indicated for the treatment of PD [see Clinical Studies (14.5) ] uuid:c7622519-825a-43b3-a113-9a0e59a490bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41423 biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:7694498e-134c-4fc0-a76c-4cd78a1a59da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cc623ee5-00d6-4e7f-9e01-b74574b69ae0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of celecoxib and other treatment options before deciding to use celecoxib. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals [see Warnings and Precautions (5) ] 1.1 Osteoarthritis (OA) Celecoxib is indicated for relief of the signs and symptoms of OA [see Clinical Studies (14.1) ] 1.2 Rheumatoid Arthritis (RA) Celecoxib is indicated for relief of the signs and symptoms of RA [see Clinical Studies (14.2) ] 1.3 Juvenile Rheumatoid Arthritis (JRA) Celecoxib is indicated for relief of the signs and symptoms of JRA in patients 2 years and older [see Clinical Studies (14.3) ] 1.4 Ankylosing Spondylitis (AS) Celecoxib is indicated for the relief of signs and symptoms of AS [see Clinical Studies (14.4) ] 1.5 Acute Pain (AP) Celecoxib is indicated for the management of AP in adults [see Clinical Studies (14.5) ] 1.6 Primary Dysmenorrhea (PD) Celecoxib is indicated for the treatment of PD [see Clinical Studies (14.5) ] uuid:7934d139-0d8b-426e-8ff9-298aca2f8e61 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41423 biolink:treats NCIT:C27003 PMID:41385096 "[{""id"":""uuid:ff9cc573-0b06-4187-a212-67a396deb8b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5f11b4c8-09e6-4024-8ded-998da4a081c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of celecoxib and other treatment options before deciding to use celecoxib. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals [see Warnings and Precautions (5) ] 1.1 Osteoarthritis (OA) Celecoxib is indicated for relief of the signs and symptoms of OA [see Clinical Studies (14.1) ] 1.2 Rheumatoid Arthritis (RA) Celecoxib is indicated for relief of the signs and symptoms of RA [see Clinical Studies (14.2) ] 1.3 Juvenile Rheumatoid Arthritis (JRA) Celecoxib is indicated for relief of the signs and symptoms of JRA in patients 2 years and older [see Clinical Studies (14.3) ] 1.4 Ankylosing Spondylitis (AS) Celecoxib is indicated for the relief of signs and symptoms of AS [see Clinical Studies (14.4) ] 1.5 Acute Pain (AP) Celecoxib is indicated for the management of AP in adults [see Clinical Studies (14.5) ] 1.6 Primary Dysmenorrhea (PD) Celecoxib is indicated for the treatment of PD [see Clinical Studies (14.5) ] uuid:989a6492-273c-4fdd-a844-81e5f5dff2ef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41423 biolink:treats MONDO:1060206 PMID:41385096 "[{""id"":""uuid:5600957b-df1e-4138-8dfa-d9977e9c3b8e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9ec948e7-b9bb-4f59-8aa8-6972f091dd92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of celecoxib and other treatment options before deciding to use celecoxib. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals [see Warnings and Precautions (5) ] 1.1 Osteoarthritis (OA) Celecoxib is indicated for relief of the signs and symptoms of OA [see Clinical Studies (14.1) ] 1.2 Rheumatoid Arthritis (RA) Celecoxib is indicated for relief of the signs and symptoms of RA [see Clinical Studies (14.2) ] 1.3 Juvenile Rheumatoid Arthritis (JRA) Celecoxib is indicated for relief of the signs and symptoms of JRA in patients 2 years and older [see Clinical Studies (14.3) ] 1.4 Ankylosing Spondylitis (AS) Celecoxib is indicated for the relief of signs and symptoms of AS [see Clinical Studies (14.4) ] 1.5 Acute Pain (AP) Celecoxib is indicated for the management of AP in adults [see Clinical Studies (14.5) ] 1.6 Primary Dysmenorrhea (PD) Celecoxib is indicated for the treatment of PD [see Clinical Studies (14.5) ] UMLS:C0149875 uuid:4c92d993-fb44-4c67-979d-6830410df066 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0004646 PMID:41385096 "[{""id"":""uuid:b582c088-ff96-443b-a382-11df1b963fd4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:60a8ae88-77dc-4a69-a0d6-bd676605c4f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Stage I - IV pressure ulcers Venous stasis ulcers Ulcerations caused by mixed vascular etiologies Diabetic skin ulcers First and second degree burns Post-surgical incisions, cuts and abrasions. uuid:2692330f-d963-48f2-930e-44111e8e4d2b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats UMLS:C0042344 PMID:41385096 "[{""id"":""uuid:3bcb6c2d-fbd8-4887-83d9-ef155fb810fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:152311b5-c1bc-468d-8109-9e65307b2a80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Stage I - IV pressure ulcers Venous stasis ulcers Ulcerations caused by mixed vascular etiologies Diabetic skin ulcers First and second degree burns Post-surgical incisions, cuts and abrasions. uuid:f1d1358e-0466-4b37-8f73-c88955ccb236 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0004605 PMID:41385096 "[{""id"":""uuid:15b411f8-2853-4a33-8d37-7eab31787153"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:af94f9ad-f0d7-4866-bd7f-d62775bef12a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Stage I - IV pressure ulcers Venous stasis ulcers Ulcerations caused by mixed vascular etiologies Diabetic skin ulcers First and second degree burns Post-surgical incisions, cuts and abrasions. uuid:4ea28de1-1323-4fa5-bb7c-63f12ed4e54d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:92609 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:9a3657ae-d1b5-4003-a6d2-2f0827bf0444"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b703f2a9-8f18-4383-aa03-50229a8e98bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Glimepiride tablets USP are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [see Clinical Studies (14.1) ]. 1.1 Important Limitations of Use Glimepiride tablets USP should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis, as it would not be effective in these settings. uuid:e9dcdec2-371f-4760-9fd3-e6b5165cb9e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:92609 biolink:treats MONDO:0012819 PMID:41385096 "[{""id"":""uuid:78b28eeb-b34d-4fd2-99d4-a32a671c092d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f4b5ad06-7f74-4bef-ae52-d0a5aea09370"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Glimepiride tablets USP are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [see Clinical Studies (14.1) ]. 1.1 Important Limitations of Use Glimepiride tablets USP should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis, as it would not be effective in these settings. uuid:ebafb49e-59d2-407f-9b10-89f0f02bc208 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5001 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:95e8a3e5-7df8-4f16-a099-7f5ad0affa03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5416fa64-453a-40b3-815c-298e8271ed91"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment of Hypercholesterolemia Fenofibrate tablets, USP are indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C, Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate (See National Cholesterol Education Program [NCEP] Treatment Guidelines, below). Treatment of Hypertriglyceridemia Fenofibrate tablets, USP are also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually reduce fasting triglycerides and eliminate chylomicronemia thereby obviating the need for pharmacologic intervention. Markedly elevated levels of serum triglycerides (e.g. > 2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate tablet, USP therapy on reducing this risk has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV and V hyperlipoproteinemia2. The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcoholic intake may be important factors in hypertriglyceridemia and should be addressed prior to any drug therapy. Physical exercise can be an important ancillary measure. Diseases contributory to hyperlipidemia, such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy, thiazide diuretics and beta-blockers, are sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of the specific etiologic agent may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with non-drug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet. (See WARNINGS and PRECAUTIONS). Fredrickson Classification of Hyperlipoproteinemias C = cholesterol TG = triglycerides LDL = low density lipoprotein VLDL = very low density lipoprotein IDL = intermediate density lipoprotein Lipid Elevation Type Lipoprotein Elevated Major Minor I (rare) chylomicrons TG ↑↔C IIa LDL C - IIb LDL, VLDL C TG III (rare) IDL C, TG - IV VLDL TG ↑↔C V (rare) chylomicrons, VLDL TG ↑↔ NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories †CHD = coronary heart disease ††Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of < 100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgment also may call for deferring drug therapy in this subcategory. †††Almost all people with 0 to 1 risk factor have 10-year risk < 10%; thus, 10-year risk assessment in people with 0 to 1 risk factor is not necessary. Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD† or CHD risk equivalents (10-years risk > 20%) < 100 ≥ 100 ≥ 130 (100 to 129: drug optional)†† 2+ Risk Factors (10-year risk ≤ 20%) < 130 ≥ 130 10-year risk 10% to 20%: ≥ 130 10-year risk < 10%: ≥ 160 0 to 1 Risk Factor††† < 160 ≥ 160 ≥ 190 (160 to 189: LDL- lowering drug optional) After the LDL-C goal has been achieved, if the TG is still ≥ 200 mg/dL, non HDL-C (total-C minus HDL-C) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. uuid:eb41a650-89f0-4862-892d-a380556dfedd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49468 biolink:treats UMLS:C1141927 PMID:41385096 "[{""id"":""uuid:9f5462fb-620f-4534-98f4-402a9edee40e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f2f62c2e-dac2-49cf-ad9c-77b7c9eb0c57"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Silver sulfadiazine cream, USP 1% is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second and third degree burns. uuid:b081e9d5-b1a7-4ba5-a6fd-a73d8da84bbe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49468 biolink:treats UMLS:C0332687 PMID:41385096 "[{""id"":""uuid:5e6952e7-f1c1-43ca-9704-e482a94c017d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:71361291-146e-4826-b965-332ba4766b21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Silver sulfadiazine cream, USP 1% is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second and third degree burns. uuid:569fbad8-df32-4fb9-9f58-602cfca43de7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49468 biolink:treats UMLS:C0433445 PMID:41385096 "[{""id"":""uuid:e0fcc32b-5e48-4890-8a10-3306433cba91"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ff328d6c-25c3-4d7b-bce9-82335508c93f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Silver sulfadiazine cream, USP 1% is a topical antimicrobial drug indicated as an adjunct for the prevention and treatment of wound sepsis in patients with second and third degree burns. uuid:f21ee334-927b-44c6-b791-c5b73a5693ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31498 biolink:treats MONDO:0005093 PMID:41385096 "[{""id"":""uuid:71de27a0-aaff-4f25-be94-69c6ec638034"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:38f5efe6-a9ae-4814-a4f5-27c5ab73c1fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Triamcinolone acetonide cream is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. uuid:a92d31a5-8768-4f82-b1b9-6a77775ed83c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6375 biolink:treats MONDO:0005412 PMID:41385096 "[{""id"":""uuid:2ecece28-b052-4683-a8d5-1018043026a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2b9a0ab1-3b5c-4d52-a7cd-bf82f53e5258"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4779c308-72d4-42ad-9402-506edec77d10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Short-Term Treatment of Active Duodenal Ulcer Lansoprazole is indicated for short-term treatment (for 4 weeks) for healing and symptom relief of active duodenal ulcer [see CLINICAL STUDIES (14)]. 1.2 H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Triple Therapy: Lansoprazole/amoxicillin/clarithromycin Lansoprazole in combination with amoxicillin plus clarithromycin as triple therapy is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see CLINICAL STUDIES (14)]. Please refer to the full prescribing information for amoxicillin and clarithromycin. Dual Therapy: Lansoprazole/amoxicillin Lansoprazole in combination with amoxicillin as dual therapy is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected (see the clarithromycin package insert, MICROBIOLOGY section). Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see CLINICAL STUDIES (14)]. Please refer to the full prescribing information for amoxicillin. 1.3 Maintenance of Healed Duodenal Ulcers Lansoprazole is indicated to maintain healing of duodenal ulcers. Controlled studies do not extend beyond 12 months [see CLINICAL STUDIES (14)]. 1.4 Short-Term Treatment of Active Benign Gastric Ulcer Lansoprazole is indicated for short-term treatment (up to 8 weeks) for healing and symptom relief of active benign gastric ulcer [see CLINICAL STUDIES (14)]. 1.5 Healing of NSAID-Associated Gastric Ulcer Lansoprazole is indicated for the treatment of NSAID-associated gastric ulcer in patients who continue NSAID use. Controlled studies did not extend beyond 8 weeks [see CLINICAL STUDIES (14)]. 1.6 Risk Reduction of NSAID-Associated Gastric Ulcer Lansoprazole is indicated for reducing the risk of NSAID-associated gastric ulcers in patients with a history of a documented gastric ulcer who require the use of an NSAID. Controlled studies did not extend beyond 12 weeks [see CLINICAL STUDIES (14)]. 1.7 Gastroesophageal Reflux Disease (GERD) Short-Term Treatment of Symptomatic GERD Lansoprazole is indicated for the treatment of heartburn and other symptoms associated with GERD for up to 8 weeks [see CLINICAL STUDIES (14)]. Short-Term Treatment of Erosive Esophagitis Lansoprazole is indicated for short-term treatment (up to 8 weeks) for healing and symptom relief of all grades of erosive esophagitis. For patients who do not heal with Lansoprazole for 8 weeks (5 to 10%), it may be helpful to give an additional 8 weeks of treatment. If there is a recurrence of erosive esophagitis an additional 8 week course of Lansoprazole may be considered [see CLINICAL STUDIES (14)]. 1.8 Maintenance of Healing of Erosive Esophagitis (EE) Lansoprazole is indicated to maintain healing of erosive esophagitis. Controlled studies did not extend beyond 12 months [see CLINICAL STUDIES (14)]. 1.9 Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome(ZES) Lansoprazole is indicated for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome [see CLINICAL STUDIES (14)].|[PMDA] Drug with a new route of administration indicated for patients with gastric ulcer, duodenal ulcer, acute stress ulcer and acute gastric mucosal lesion with bleeding who are unable to take the oral formulations. uuid:5ca4e91b-8b7b-4ff2-bcca-e96127e95a5d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6375 biolink:treats HP:0005202 PMID:41385096 "[{""id"":""uuid:fe5ab7bc-b3a0-4b26-9625-08bc550ce4fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:95690e82-7071-430b-a537-55270ee23704"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:87e53432-44a9-4e40-ab6a-31f25ffa0445"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Short-Term Treatment of Active Duodenal Ulcer Lansoprazole is indicated for short-term treatment (for 4 weeks) for healing and symptom relief of active duodenal ulcer [see CLINICAL STUDIES (14)]. 1.2 H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Triple Therapy: Lansoprazole/amoxicillin/clarithromycin Lansoprazole in combination with amoxicillin plus clarithromycin as triple therapy is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see CLINICAL STUDIES (14)]. Please refer to the full prescribing information for amoxicillin and clarithromycin. Dual Therapy: Lansoprazole/amoxicillin Lansoprazole in combination with amoxicillin as dual therapy is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected (see the clarithromycin package insert, MICROBIOLOGY section). Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see CLINICAL STUDIES (14)]. Please refer to the full prescribing information for amoxicillin. 1.3 Maintenance of Healed Duodenal Ulcers Lansoprazole is indicated to maintain healing of duodenal ulcers. Controlled studies do not extend beyond 12 months [see CLINICAL STUDIES (14)]. 1.4 Short-Term Treatment of Active Benign Gastric Ulcer Lansoprazole is indicated for short-term treatment (up to 8 weeks) for healing and symptom relief of active benign gastric ulcer [see CLINICAL STUDIES (14)]. 1.5 Healing of NSAID-Associated Gastric Ulcer Lansoprazole is indicated for the treatment of NSAID-associated gastric ulcer in patients who continue NSAID use. Controlled studies did not extend beyond 8 weeks [see CLINICAL STUDIES (14)]. 1.6 Risk Reduction of NSAID-Associated Gastric Ulcer Lansoprazole is indicated for reducing the risk of NSAID-associated gastric ulcers in patients with a history of a documented gastric ulcer who require the use of an NSAID. Controlled studies did not extend beyond 12 weeks [see CLINICAL STUDIES (14)]. 1.7 Gastroesophageal Reflux Disease (GERD) Short-Term Treatment of Symptomatic GERD Lansoprazole is indicated for the treatment of heartburn and other symptoms associated with GERD for up to 8 weeks [see CLINICAL STUDIES (14)]. Short-Term Treatment of Erosive Esophagitis Lansoprazole is indicated for short-term treatment (up to 8 weeks) for healing and symptom relief of all grades of erosive esophagitis. For patients who do not heal with Lansoprazole for 8 weeks (5 to 10%), it may be helpful to give an additional 8 weeks of treatment. If there is a recurrence of erosive esophagitis an additional 8 week course of Lansoprazole may be considered [see CLINICAL STUDIES (14)]. 1.8 Maintenance of Healing of Erosive Esophagitis (EE) Lansoprazole is indicated to maintain healing of erosive esophagitis. Controlled studies did not extend beyond 12 months [see CLINICAL STUDIES (14)]. 1.9 Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome(ZES) Lansoprazole is indicated for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome [see CLINICAL STUDIES (14)].|[PMDA] Drugs with a new indication and dosage for use as a secondary eradication therapy for infection with Helicobacter pylori (3-drug combination therapy consisting of one-week dosing of a proton pump inhibitor (PPI), amoxicillin (AMPC), and metronidazole to patients in whom primary eradication therapy with PPI, AMPC, and clarithromycin was unsuccessful). uuid:8727ae31-e8e0-402d-8dfb-f81c44be5b02 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6375 biolink:treats MONDO:0001126 PMID:41385096 "[{""id"":""uuid:9663929a-51d8-460c-b713-eb077fece386"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2d8846ff-d0c3-4449-bdb8-bb253733e4bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:df35b14f-ee89-457a-a04c-749ab40f48f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Short-Term Treatment of Active Duodenal Ulcer Lansoprazole is indicated for short-term treatment (for 4 weeks) for healing and symptom relief of active duodenal ulcer [see CLINICAL STUDIES (14)]. 1.2 H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Triple Therapy: Lansoprazole/amoxicillin/clarithromycin Lansoprazole in combination with amoxicillin plus clarithromycin as triple therapy is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see CLINICAL STUDIES (14)]. Please refer to the full prescribing information for amoxicillin and clarithromycin. Dual Therapy: Lansoprazole/amoxicillin Lansoprazole in combination with amoxicillin as dual therapy is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected (see the clarithromycin package insert, MICROBIOLOGY section). Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see CLINICAL STUDIES (14)]. Please refer to the full prescribing information for amoxicillin. 1.3 Maintenance of Healed Duodenal Ulcers Lansoprazole is indicated to maintain healing of duodenal ulcers. Controlled studies do not extend beyond 12 months [see CLINICAL STUDIES (14)]. 1.4 Short-Term Treatment of Active Benign Gastric Ulcer Lansoprazole is indicated for short-term treatment (up to 8 weeks) for healing and symptom relief of active benign gastric ulcer [see CLINICAL STUDIES (14)]. 1.5 Healing of NSAID-Associated Gastric Ulcer Lansoprazole is indicated for the treatment of NSAID-associated gastric ulcer in patients who continue NSAID use. Controlled studies did not extend beyond 8 weeks [see CLINICAL STUDIES (14)]. 1.6 Risk Reduction of NSAID-Associated Gastric Ulcer Lansoprazole is indicated for reducing the risk of NSAID-associated gastric ulcers in patients with a history of a documented gastric ulcer who require the use of an NSAID. Controlled studies did not extend beyond 12 weeks [see CLINICAL STUDIES (14)]. 1.7 Gastroesophageal Reflux Disease (GERD) Short-Term Treatment of Symptomatic GERD Lansoprazole is indicated for the treatment of heartburn and other symptoms associated with GERD for up to 8 weeks [see CLINICAL STUDIES (14)]. Short-Term Treatment of Erosive Esophagitis Lansoprazole is indicated for short-term treatment (up to 8 weeks) for healing and symptom relief of all grades of erosive esophagitis. For patients who do not heal with Lansoprazole for 8 weeks (5 to 10%), it may be helpful to give an additional 8 weeks of treatment. If there is a recurrence of erosive esophagitis an additional 8 week course of Lansoprazole may be considered [see CLINICAL STUDIES (14)]. 1.8 Maintenance of Healing of Erosive Esophagitis (EE) Lansoprazole is indicated to maintain healing of erosive esophagitis. Controlled studies did not extend beyond 12 months [see CLINICAL STUDIES (14)]. 1.9 Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome(ZES) Lansoprazole is indicated for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome [see CLINICAL STUDIES (14)].|[PMDA] Drug with a new route of administration indicated for patients with gastric ulcer, duodenal ulcer, acute stress ulcer and acute gastric mucosal lesion with bleeding who are unable to take the oral formulations. uuid:c8398d32-3ad1-4d7f-b447-40ccfac4f59f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6375 biolink:treats MONDO:0007186 PMID:41385096 "[{""id"":""uuid:d581d661-c3b7-4cee-9e62-2c247b67db32"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8509ef57-bc0f-414a-a196-29c5aa79c63a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:103db79b-a102-4b72-b4be-835a27563307"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Short-Term Treatment of Active Duodenal Ulcer Lansoprazole is indicated for short-term treatment (for 4 weeks) for healing and symptom relief of active duodenal ulcer [see CLINICAL STUDIES (14)]. 1.2 H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Triple Therapy: Lansoprazole/amoxicillin/clarithromycin Lansoprazole in combination with amoxicillin plus clarithromycin as triple therapy is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see CLINICAL STUDIES (14)]. Please refer to the full prescribing information for amoxicillin and clarithromycin. Dual Therapy: Lansoprazole/amoxicillin Lansoprazole in combination with amoxicillin as dual therapy is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected (see the clarithromycin package insert, MICROBIOLOGY section). Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see CLINICAL STUDIES (14)]. Please refer to the full prescribing information for amoxicillin. 1.3 Maintenance of Healed Duodenal Ulcers Lansoprazole is indicated to maintain healing of duodenal ulcers. Controlled studies do not extend beyond 12 months [see CLINICAL STUDIES (14)]. 1.4 Short-Term Treatment of Active Benign Gastric Ulcer Lansoprazole is indicated for short-term treatment (up to 8 weeks) for healing and symptom relief of active benign gastric ulcer [see CLINICAL STUDIES (14)]. 1.5 Healing of NSAID-Associated Gastric Ulcer Lansoprazole is indicated for the treatment of NSAID-associated gastric ulcer in patients who continue NSAID use. Controlled studies did not extend beyond 8 weeks [see CLINICAL STUDIES (14)]. 1.6 Risk Reduction of NSAID-Associated Gastric Ulcer Lansoprazole is indicated for reducing the risk of NSAID-associated gastric ulcers in patients with a history of a documented gastric ulcer who require the use of an NSAID. Controlled studies did not extend beyond 12 weeks [see CLINICAL STUDIES (14)]. 1.7 Gastroesophageal Reflux Disease (GERD) Short-Term Treatment of Symptomatic GERD Lansoprazole is indicated for the treatment of heartburn and other symptoms associated with GERD for up to 8 weeks [see CLINICAL STUDIES (14)]. Short-Term Treatment of Erosive Esophagitis Lansoprazole is indicated for short-term treatment (up to 8 weeks) for healing and symptom relief of all grades of erosive esophagitis. For patients who do not heal with Lansoprazole for 8 weeks (5 to 10%), it may be helpful to give an additional 8 weeks of treatment. If there is a recurrence of erosive esophagitis an additional 8 week course of Lansoprazole may be considered [see CLINICAL STUDIES (14)]. 1.8 Maintenance of Healing of Erosive Esophagitis (EE) Lansoprazole is indicated to maintain healing of erosive esophagitis. Controlled studies did not extend beyond 12 months [see CLINICAL STUDIES (14)]. 1.9 Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome(ZES) Lansoprazole is indicated for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome [see CLINICAL STUDIES (14)].|[PMDA] Drugs with a new indication and dosage for treatment of non-erosive reflux disease. uuid:98d84d46-d685-49ee-97cd-07ac4abf06f0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6375 biolink:treats UMLS:C0267055 PMID:41385096 "[{""id"":""uuid:d85a2b74-c3ad-48b7-8d7d-538d7d258e6a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e14f37a1-5259-4d30-8e09-61cfdfdab270"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Short-Term Treatment of Active Duodenal Ulcer Lansoprazole is indicated for short-term treatment (for 4 weeks) for healing and symptom relief of active duodenal ulcer [see CLINICAL STUDIES (14)]. 1.2 H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Triple Therapy: Lansoprazole/amoxicillin/clarithromycin Lansoprazole in combination with amoxicillin plus clarithromycin as triple therapy is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see CLINICAL STUDIES (14)]. Please refer to the full prescribing information for amoxicillin and clarithromycin. Dual Therapy: Lansoprazole/amoxicillin Lansoprazole in combination with amoxicillin as dual therapy is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or one year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected (see the clarithromycin package insert, MICROBIOLOGY section). Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see CLINICAL STUDIES (14)]. Please refer to the full prescribing information for amoxicillin. 1.3 Maintenance of Healed Duodenal Ulcers Lansoprazole is indicated to maintain healing of duodenal ulcers. Controlled studies do not extend beyond 12 months [see CLINICAL STUDIES (14)]. 1.4 Short-Term Treatment of Active Benign Gastric Ulcer Lansoprazole is indicated for short-term treatment (up to 8 weeks) for healing and symptom relief of active benign gastric ulcer [see CLINICAL STUDIES (14)]. 1.5 Healing of NSAID-Associated Gastric Ulcer Lansoprazole is indicated for the treatment of NSAID-associated gastric ulcer in patients who continue NSAID use. Controlled studies did not extend beyond 8 weeks [see CLINICAL STUDIES (14)]. 1.6 Risk Reduction of NSAID-Associated Gastric Ulcer Lansoprazole is indicated for reducing the risk of NSAID-associated gastric ulcers in patients with a history of a documented gastric ulcer who require the use of an NSAID. Controlled studies did not extend beyond 12 weeks [see CLINICAL STUDIES (14)]. 1.7 Gastroesophageal Reflux Disease (GERD) Short-Term Treatment of Symptomatic GERD Lansoprazole is indicated for the treatment of heartburn and other symptoms associated with GERD for up to 8 weeks [see CLINICAL STUDIES (14)]. Short-Term Treatment of Erosive Esophagitis Lansoprazole is indicated for short-term treatment (up to 8 weeks) for healing and symptom relief of all grades of erosive esophagitis. For patients who do not heal with Lansoprazole for 8 weeks (5 to 10%), it may be helpful to give an additional 8 weeks of treatment. If there is a recurrence of erosive esophagitis an additional 8 week course of Lansoprazole may be considered [see CLINICAL STUDIES (14)]. 1.8 Maintenance of Healing of Erosive Esophagitis (EE) Lansoprazole is indicated to maintain healing of erosive esophagitis. Controlled studies did not extend beyond 12 months [see CLINICAL STUDIES (14)]. 1.9 Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome(ZES) Lansoprazole is indicated for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome [see CLINICAL STUDIES (14)]. uuid:60919754-8bcf-4e65-b35b-a7d4c83be7c3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16469 biolink:treats UMLS:C0278488 PMID:41385096 "[{""id"":""uuid:1a0d0a35-c51d-4112-b382-c458fcac1171"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0cb3968c-1fbe-41f2-bc63-d1978a751f9d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Estradiol Tablets USP are indicated in the: Treatment of moderate to severe vasomotor symptoms associated with the menopause. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. Treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. Treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). Prevention of osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate. (See CLINICAL PHARMACOLOGY, Clinical Studies.) The mainstays for decreasing the risk of postmenopausal osteoporosis are weight bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400-800 IU/day may also be required to ensure adequate daily intake in postmenopausal women. uuid:7dfe109b-fb74-437f-a210-4cfdde510200 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:521033 biolink:treats MONDO:0008315 PMID:41385096 "[{""id"":""uuid:0477953f-0566-46bf-bcb9-cd1b49f96d51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:531c96e9-f2e2-47c2-9c2f-6090cc5ab0ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dutasteride is a 5 alpha-reductase inhibitor indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to: ( 1.1 ) improve symptoms, reduce the risk of acute urinary retention, and reduce the risk of the need for BPH-related surgery. Dutasteride in combination with the alpha adrenergic antagonist, tamsulosin, is indicated for the treatment of symptomatic BPH in men with an enlarged prostate. ( 1.2 ) Limitations of Use: Dutasteride is not approved for the prevention of prostate cancer. ( 1.3 ) uuid:4f2c79ca-3718-420e-9719-66aac2be96bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31498 biolink:treats MONDO:0004592 PMID:41385096 "[{""id"":""uuid:78021ad6-50d2-4c49-bdee-05889c8a160b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ef45502e-eaf4-496c-9cbb-1a9c21f259dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mupirocin Ointment USP, 2% is indicated for the topical treatment of impetigo due to: S. aureus and S. pyogenes . uuid:66b45351-fed3-4943-ab96-e9b88a8a8237 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31498 biolink:treats MONDO:0005545 PMID:41385096 "[{""id"":""uuid:470e9523-a501-44f4-b2b4-9f22c2e42602"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f1edbc38-b11d-40bf-ba4d-6b5d929f9398"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mupirocin Ointment USP, 2% is indicated for the topical treatment of impetigo due to: S. aureus and S. pyogenes . uuid:2b1fc3fd-7489-4931-8c73-e964fa47ca4e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3732 biolink:treats MONDO:0017767 PMID:41385096 "[{""id"":""uuid:523073e6-ce3f-4146-bd7f-441de92c0769"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:844dd166-388c-4dc3-abf3-20f831265344"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clarithromycin Tablets, USP are indicated for the treatment of mild to moderate infections caused by susceptible isolates of the designated bacteria in the conditions as listed below: Adults (Clarithromycin Tablets, USP) Pharyngitis/Tonsillitis due to Streptococcus pyogenes (The usual drug of choice in the treatment and prevention of streptococcal infections and the prophylaxis of rheumatic fever is penicillin administered by either the intramuscular or the oral route. Clarithromycin Tablets, USP are generally effective in the eradication of S. pyogenes from the nasopharynx; however, data establishing the efficacy of Clarithromycin Tablets, USP in the subsequent prevention of rheumatic fever are not available at present.) Acute maxillary sinusitis due to Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae. Acute bacterial exacerbation of chronic bronchitis due to Haemophilus influenzae,Haemophilus parainfluenzae, Moraxella catarrhalis , or Streptococcus pneumoniae. Community-Acquired Pneumonia due to Haemophilus influenzae, Mycoplasma pneumoniae, Streptococcus pneumoniae , or Chlamydophila pneumoniae (TWAR). Uncomplicated skin and skin structure infections due to Staphylococcus aureus , or Streptococcus pyogenes (Abscesses usually require surgical drainage). Disseminated mycobacterial infections due to Mycobacterium avium , or Mycobacterium intracellulare. Clarithromycin Tablets, USP in combination with amoxicillin and PREVACID (lansoprazole) or PRILOSEC (omeprazole) Delayed-Release Capsules, as triple therapy, are indicated for the treatment of patients with Helicobacter pylori infection and duodenal ulcer disease (active or five-year history of duodenal ulcer) to eradicate H. pylori . Clarithromycin Tablets, USP in combination with PRILOSEC (omeprazole) capsules or TIRTEC (ranitidine bismuth citrate) tablets are also indicated for the treatment of patients with an active duodenal ulcer associated with H. pylori infection. However, regimens which contain Clarithromycin Tablets, USP as the single antimicrobial agent are more likely to be associated with the development of clarithromycin resistance among patients who fail therapy. Clarithromycin-containing regimens should not be used in patients with known or suspected clarithromycin resistant isolates because the efficacy of treatment is reduced in this setting. In patients who fail therapy, susceptibility testing should be done if possible. If resistance to Clarithromycin Tablets, USP is demonstrated, a non-clarithromycin-containing therapy is recommended. (For information on development of resistance see MICROBIOLOGY section.) The eradication of H. pylori has been demonstrated to reduce the risk of duodenal ulcer recurrence. Children (Clarithromycin Tablets, USP) Pharyngitis/Tonsillitis due to Streptococcus pyogenes. Community-Acquired Pneumonia due to Mycoplasma pneumoniae, Streptococcus pneumoniae , or Chlamydophila pneumoniae (TWAR). Acute maxillary sinusitis due to Haemophilus influenzae, Moraxella catarrhalis , or Streptococcus pneumoniae. Acute otitis media due to Haemophilus influenzae, Moraxella catarrhalis , or Streptococcus pneumoniae. NOTE : For information on otitis media, see CLINICAL STUDIES – Otitis Media . Uncomplicated skin and skin structure infections due to Staphylococcus aureus , or Streptococcus pyogenes (Abscesses usually require surgical drainage). Disseminated mycobacterial infections due to Mycobacterium avium , or Mycobacterium intracellulare. Prophylaxis Clarithromycin Tablets, USP are indicated for the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Clarithromycin Tablets, USP and other antibacterial drugs, Clarithromycin Tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:5bfef9c2-9e80-47a1-906d-487586f17355 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:57773 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:d3d2f980-bc34-4e26-b30c-a4d9a76c96e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b00e9a1e-6fd3-4d27-a51a-0e6358a9b605"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ampicillin and Sulbactam for Injection, USP is indicated for the treatment of infections due to susceptible strains of the designated microorganisms in the conditions listed below. Skin and Skin Structure Infections caused by beta-lactamase producing strains of Staphylococcus aureus, Escherichia coli, 2 Klebsiella spp. 2 (including K. pneumoniae 2 ), Proteus mirabilis, 2 Bacteroides fragilis, 2 Enterobacter spp., 2 and Acinetobacter calcoaceticus. 2 NOTE: For information on use in pediatric patients see PRECAUTIONS – Pediatric Use and CLINICAL STUDIES sections. Intra-Abdominal Infections caused by beta-lactamase producing strains of Escherichia coli, Klebsiella spp. (including K. pneumoniae 2 ), Bacteroides spp. (including B. fragilis ), and Enterobacter spp. 2 Gynecological Infections caused by beta-lactamase producing strains of Escherichia coli, 2 and Bacteroides spp. 2 (including B. fragilis 2 ). __________ 2 Efficacy for this microorganism in this organ system was studied in fewer than 10 infections. While Ampicillin and Sulbactam for Injection USP is indicated only for the conditions listed above, infections caused by ampicillin susceptible organisms are also amenable to treatment with Ampicillin and Sulbactam for Injection USP due to its ampicillin content. Therefore, mixed infections caused by ampicillin-susceptible organisms and beta-lactamase producing organisms susceptible to Ampicillin and Sulbactam for Injection USP should not require the addition of another antibacterial. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify the organisms causing infection and to determine their susceptibility to Ampicillin and Sulbactam. Therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies, when there is reason to believe the infection may involve any of the beta-lactamase producing organisms listed above in the indicated organ systems. Once the results are known, therapy should be adjusted if appropriate. To reduce the development of drug-resistant bacteria and maintain effectiveness of Ampicillin and Sulbactam and other antibacterial drugs, Ampicillin and Sulbactam for Injection USP should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:6d973100-e14d-4b9f-a9ac-b37bc9a67730 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:57773 biolink:treats UMLS:C1112209 PMID:41385096 "[{""id"":""uuid:6e6b4a57-ebb5-4f9e-b087-01160337de5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3f26f161-1fa6-4e0c-abae-5ce4b724117e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ampicillin and Sulbactam for Injection, USP is indicated for the treatment of infections due to susceptible strains of the designated microorganisms in the conditions listed below. Skin and Skin Structure Infections caused by beta-lactamase producing strains of Staphylococcus aureus, Escherichia coli, 2 Klebsiella spp. 2 (including K. pneumoniae 2 ), Proteus mirabilis, 2 Bacteroides fragilis, 2 Enterobacter spp., 2 and Acinetobacter calcoaceticus. 2 NOTE: For information on use in pediatric patients see PRECAUTIONS – Pediatric Use and CLINICAL STUDIES sections. Intra-Abdominal Infections caused by beta-lactamase producing strains of Escherichia coli, Klebsiella spp. (including K. pneumoniae 2 ), Bacteroides spp. (including B. fragilis ), and Enterobacter spp. 2 Gynecological Infections caused by beta-lactamase producing strains of Escherichia coli, 2 and Bacteroides spp. 2 (including B. fragilis 2 ). __________ 2 Efficacy for this microorganism in this organ system was studied in fewer than 10 infections. While Ampicillin and Sulbactam for Injection USP is indicated only for the conditions listed above, infections caused by ampicillin susceptible organisms are also amenable to treatment with Ampicillin and Sulbactam for Injection USP due to its ampicillin content. Therefore, mixed infections caused by ampicillin-susceptible organisms and beta-lactamase producing organisms susceptible to Ampicillin and Sulbactam for Injection USP should not require the addition of another antibacterial. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify the organisms causing infection and to determine their susceptibility to Ampicillin and Sulbactam. Therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies, when there is reason to believe the infection may involve any of the beta-lactamase producing organisms listed above in the indicated organ systems. Once the results are known, therapy should be adjusted if appropriate. To reduce the development of drug-resistant bacteria and maintain effectiveness of Ampicillin and Sulbactam and other antibacterial drugs, Ampicillin and Sulbactam for Injection USP should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:137d49bb-222e-4c0f-9caf-0e7ac4776dbe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:57773 biolink:treats UMLS:C1262234 PMID:41385096 "[{""id"":""uuid:d7b05790-7ac0-408d-8841-1e8b2c2b75a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ba621a10-3384-4e53-987c-18c7f1d3dd95"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ampicillin and Sulbactam for Injection, USP is indicated for the treatment of infections due to susceptible strains of the designated microorganisms in the conditions listed below. Skin and Skin Structure Infections caused by beta-lactamase producing strains of Staphylococcus aureus, Escherichia coli, 2 Klebsiella spp. 2 (including K. pneumoniae 2 ), Proteus mirabilis, 2 Bacteroides fragilis, 2 Enterobacter spp., 2 and Acinetobacter calcoaceticus. 2 NOTE: For information on use in pediatric patients see PRECAUTIONS – Pediatric Use and CLINICAL STUDIES sections. Intra-Abdominal Infections caused by beta-lactamase producing strains of Escherichia coli, Klebsiella spp. (including K. pneumoniae 2 ), Bacteroides spp. (including B. fragilis ), and Enterobacter spp. 2 Gynecological Infections caused by beta-lactamase producing strains of Escherichia coli, 2 and Bacteroides spp. 2 (including B. fragilis 2 ). __________ 2 Efficacy for this microorganism in this organ system was studied in fewer than 10 infections. While Ampicillin and Sulbactam for Injection USP is indicated only for the conditions listed above, infections caused by ampicillin susceptible organisms are also amenable to treatment with Ampicillin and Sulbactam for Injection USP due to its ampicillin content. Therefore, mixed infections caused by ampicillin-susceptible organisms and beta-lactamase producing organisms susceptible to Ampicillin and Sulbactam for Injection USP should not require the addition of another antibacterial. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify the organisms causing infection and to determine their susceptibility to Ampicillin and Sulbactam. Therapy may be instituted prior to obtaining the results from bacteriological and susceptibility studies, when there is reason to believe the infection may involve any of the beta-lactamase producing organisms listed above in the indicated organ systems. Once the results are known, therapy should be adjusted if appropriate. To reduce the development of drug-resistant bacteria and maintain effectiveness of Ampicillin and Sulbactam and other antibacterial drugs, Ampicillin and Sulbactam for Injection USP should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:ce860ca1-f44f-4311-804c-7ae16e88b4e6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9907 biolink:treats MONDO:0005388 PMID:41385096 "[{""id"":""uuid:7a66077f-404c-48b3-aa57-4e266b62a32f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a64dfecb-db5a-4331-9f74-38e32715adf0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ursodiol tablets, USP are indicated for the treatment of patients with primary biliary cirrhosis (PBC). uuid:5279419d-4500-433c-bebf-934248e5d99a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9907 biolink:treats MONDO:0007193 PMID:41385096 "[{""id"":""uuid:30ae14a5-f011-415e-b41c-aee12db8272f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c2b90abd-9ec8-47b4-8060-6b3fa8900fd9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ursodiol tablets, USP are indicated for the treatment of patients with primary biliary cirrhosis (PBC). uuid:f98dc6ae-112e-4de2-9427-0f9044ad01d2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4876 biolink:treats HP:0000969 PMID:41385096 "[{""id"":""uuid:39243ffd-7ab2-420a-95ae-8cdeec54d444"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e002d798-cec9-42ce-af49-16ef22c103b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EDECRIN is indicated for treatment of edema when an agent with greater diuretic potential than those commonly employed is required. 1. Treatment of the edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. 2. Short-term management of ascites due to malignancy, idiopathic edema, and lymphedema. 3. Short-term management of hospitalized pediatric patients, other than infants, with congenital heart disease or the nephrotic syndrome. 4. Intravenous SODIUM EDECRIN is indicated when a rapid onset of diuresis is desired, e.g., in acute pulmonary edema, or when gastrointestinal absorption is impaired or oral medication is not practicable. uuid:f44dece2-5c5e-4570-a08d-65fea4eadac4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4876 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:0e31f833-c858-4e69-9824-1000f032f715"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:075d1dc2-b3bf-4f60-8a3b-e9abaa5d2614"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EDECRIN is indicated for treatment of edema when an agent with greater diuretic potential than those commonly employed is required. 1. Treatment of the edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. 2. Short-term management of ascites due to malignancy, idiopathic edema, and lymphedema. 3. Short-term management of hospitalized pediatric patients, other than infants, with congenital heart disease or the nephrotic syndrome. 4. Intravenous SODIUM EDECRIN is indicated when a rapid onset of diuresis is desired, e.g., in acute pulmonary edema, or when gastrointestinal absorption is impaired or oral medication is not practicable. uuid:1c2442dd-ced1-4e68-ae82-6e96dff6e351 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4876 biolink:treats MONDO:0005155 PMID:41385096 "[{""id"":""uuid:b56998f8-77c1-4856-82ed-9c9a63ec3323"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d33e80f9-82c3-48e5-8087-488d894eeb33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EDECRIN is indicated for treatment of edema when an agent with greater diuretic potential than those commonly employed is required. 1. Treatment of the edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. 2. Short-term management of ascites due to malignancy, idiopathic edema, and lymphedema. 3. Short-term management of hospitalized pediatric patients, other than infants, with congenital heart disease or the nephrotic syndrome. 4. Intravenous SODIUM EDECRIN is indicated when a rapid onset of diuresis is desired, e.g., in acute pulmonary edema, or when gastrointestinal absorption is impaired or oral medication is not practicable. uuid:b6101df1-bbeb-4f25-a4a8-9693aa730e15 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4876 biolink:treats MONDO:0005240 PMID:41385096 "[{""id"":""uuid:acdb5f63-e51f-4121-9765-d0c1541aaf71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:97804f42-2850-4236-80cb-aa48277bba71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EDECRIN is indicated for treatment of edema when an agent with greater diuretic potential than those commonly employed is required. 1. Treatment of the edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. 2. Short-term management of ascites due to malignancy, idiopathic edema, and lymphedema. 3. Short-term management of hospitalized pediatric patients, other than infants, with congenital heart disease or the nephrotic syndrome. 4. Intravenous SODIUM EDECRIN is indicated when a rapid onset of diuresis is desired, e.g., in acute pulmonary edema, or when gastrointestinal absorption is impaired or oral medication is not practicable. uuid:3e9107fd-f79b-4a84-a8c4-beda600aed12 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4876 biolink:treats MONDO:0005377 PMID:41385096 "[{""id"":""uuid:cee0efaa-0f88-4876-a4fa-b5436bb029d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3a9390c4-5002-4ad9-8d96-f8f503ca6c78"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EDECRIN is indicated for treatment of edema when an agent with greater diuretic potential than those commonly employed is required. 1. Treatment of the edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. 2. Short-term management of ascites due to malignancy, idiopathic edema, and lymphedema. 3. Short-term management of hospitalized pediatric patients, other than infants, with congenital heart disease or the nephrotic syndrome. 4. Intravenous SODIUM EDECRIN is indicated when a rapid onset of diuresis is desired, e.g., in acute pulmonary edema, or when gastrointestinal absorption is impaired or oral medication is not practicable. uuid:c8199d03-02d3-477a-bd6e-73739db935d7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4876 biolink:treats UMLS:C0238094 PMID:41385096 "[{""id"":""uuid:ffc50a16-ae4e-46b6-a0f0-fcdda708b640"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6031bfc3-f5a2-45c2-9e7d-ab4a74a8342b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EDECRIN is indicated for treatment of edema when an agent with greater diuretic potential than those commonly employed is required. 1. Treatment of the edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. 2. Short-term management of ascites due to malignancy, idiopathic edema, and lymphedema. 3. Short-term management of hospitalized pediatric patients, other than infants, with congenital heart disease or the nephrotic syndrome. 4. Intravenous SODIUM EDECRIN is indicated when a rapid onset of diuresis is desired, e.g., in acute pulmonary edema, or when gastrointestinal absorption is impaired or oral medication is not practicable. uuid:4ec05108-cbce-4723-a1e0-aef49abf7c44 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4876 biolink:treats MONDO:0019297 PMID:41385096 "[{""id"":""uuid:1257ea66-a7c5-4133-8ee1-bcb9f3e7e521"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9803fd85-2c77-4cf4-9f46-f5dffaa03525"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EDECRIN is indicated for treatment of edema when an agent with greater diuretic potential than those commonly employed is required. 1. Treatment of the edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. 2. Short-term management of ascites due to malignancy, idiopathic edema, and lymphedema. 3. Short-term management of hospitalized pediatric patients, other than infants, with congenital heart disease or the nephrotic syndrome. 4. Intravenous SODIUM EDECRIN is indicated when a rapid onset of diuresis is desired, e.g., in acute pulmonary edema, or when gastrointestinal absorption is impaired or oral medication is not practicable. uuid:ffcb6f50-53a7-4fd4-814f-5b0ed1aba6e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4876 biolink:treats MONDO:0005453 PMID:41385096 "[{""id"":""uuid:af24daa2-c8cd-46ff-98bb-955e30806f66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1ad46050-79bd-44dc-87b7-d95841d5c59a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EDECRIN is indicated for treatment of edema when an agent with greater diuretic potential than those commonly employed is required. 1. Treatment of the edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. 2. Short-term management of ascites due to malignancy, idiopathic edema, and lymphedema. 3. Short-term management of hospitalized pediatric patients, other than infants, with congenital heart disease or the nephrotic syndrome. 4. Intravenous SODIUM EDECRIN is indicated when a rapid onset of diuresis is desired, e.g., in acute pulmonary edema, or when gastrointestinal absorption is impaired or oral medication is not practicable. uuid:4e7ca80a-a786-493c-ac36-28a97f1b793c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4876 biolink:treats UMLS:C0155919 PMID:41385096 "[{""id"":""uuid:3a8a3488-e9bd-439b-b871-65e31c3cb61f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fbb95dbf-3a9d-4938-8bc4-ea1def8c1576"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EDECRIN is indicated for treatment of edema when an agent with greater diuretic potential than those commonly employed is required. 1. Treatment of the edema associated with congestive heart failure, cirrhosis of the liver, and renal disease, including the nephrotic syndrome. 2. Short-term management of ascites due to malignancy, idiopathic edema, and lymphedema. 3. Short-term management of hospitalized pediatric patients, other than infants, with congenital heart disease or the nephrotic syndrome. 4. Intravenous SODIUM EDECRIN is indicated when a rapid onset of diuresis is desired, e.g., in acute pulmonary edema, or when gastrointestinal absorption is impaired or oral medication is not practicable. uuid:1bef86ab-3729-495c-9b6f-86879b587d2b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats UMLS:C1112209 PMID:41385096 "[{""id"":""uuid:1f00c0db-cbb3-46ad-82c3-ef0fb940a85c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:20cc7288-1af4-4f2c-8749-a838aeb2bc3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Symptomatic Trichomoniasis. Metronidazole tablets are indicated for the treatment of T. vaginalis infection in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis. Metronidazole tablets are indicated in the treatment of asymptomatic T. vaginalis infection in females when the organism is associated with endocervicitis, cervicitis, or cervical erosion. Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. Treatment of Asymptomatic Sexual Partners. T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her sexual partner is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the sexual partner should be treated with metronidazole tablets in cases of reinfection. Amebiasis. Metronidazole tablets are indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. In amebic liver abscess, metronidazole tablet therapy does not obviate the need for aspiration or drainage of pus. Anaerobic Bacterial Infections. Metronidazole tablets are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with metronidazole tablet therapy. In a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole tablets. INTRA-ABDOMINAL INFECTIONS, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species including the B. fragilis group ( B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus ), Clostridium species, Eubacterium species, Peptococcus species, and Peptostreptococcus species. SKIN AND SKIN STRUCTURE INFECTIONS caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus species, Peptostreptococcus species, and Fusobacterium species. GYNECOLOGIC INFECTIONS, including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus species, Peptostreptococcus species, and Fusobacterium species. BACTERIAL SEPTICEMIA caused by Bacteroides species including the B. fragilis group and Clostridium species. BONE AND JOINT INFECTIONS, (as adjunctive therapy), caused by Bacteroides species including the B. fragilis group. CENTRAL NERVOUS SYSTEM (CNS) INFECTIONS, including meningitis and brain abscess, caused by Bacteroides species including the B. fragilis group. LOWER RESPIRATORY TRACT INFECTIONS, including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group. ENDOCARDITIS caused by Bacteroides species including the B. fragilis group. To reduce the development of drug-resistant bacteria and maintain the effectiveness of metronidazole tablets and other antibacterial drugs, metronidazole tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:3f4a681a-a7c0-4352-bc7f-c4089892afc6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0005113 PMID:41385096 "[{""id"":""uuid:bc326320-a828-40bc-92a1-a3b1a3606c9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1bada137-f69d-435c-9b3c-41e3ed6de4df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Symptomatic Trichomoniasis. Metronidazole tablets are indicated for the treatment of T. vaginalis infection in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis. Metronidazole tablets are indicated in the treatment of asymptomatic T. vaginalis infection in females when the organism is associated with endocervicitis, cervicitis, or cervical erosion. Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. Treatment of Asymptomatic Sexual Partners. T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her sexual partner is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the sexual partner should be treated with metronidazole tablets in cases of reinfection. Amebiasis. Metronidazole tablets are indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. In amebic liver abscess, metronidazole tablet therapy does not obviate the need for aspiration or drainage of pus. Anaerobic Bacterial Infections. Metronidazole tablets are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with metronidazole tablet therapy. In a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole tablets. INTRA-ABDOMINAL INFECTIONS, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species including the B. fragilis group ( B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus ), Clostridium species, Eubacterium species, Peptococcus species, and Peptostreptococcus species. SKIN AND SKIN STRUCTURE INFECTIONS caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus species, Peptostreptococcus species, and Fusobacterium species. GYNECOLOGIC INFECTIONS, including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus species, Peptostreptococcus species, and Fusobacterium species. BACTERIAL SEPTICEMIA caused by Bacteroides species including the B. fragilis group and Clostridium species. BONE AND JOINT INFECTIONS, (as adjunctive therapy), caused by Bacteroides species including the B. fragilis group. CENTRAL NERVOUS SYSTEM (CNS) INFECTIONS, including meningitis and brain abscess, caused by Bacteroides species including the B. fragilis group. LOWER RESPIRATORY TRACT INFECTIONS, including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group. ENDOCARDITIS caused by Bacteroides species including the B. fragilis group. To reduce the development of drug-resistant bacteria and maintain the effectiveness of metronidazole tablets and other antibacterial drugs, metronidazole tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:c570b7ef-7fa3-4b1a-8a1b-4b3071e85801 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0024619 PMID:41385096 "[{""id"":""uuid:42e8e3b6-7778-4cd3-bd03-5a3c5797dd4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4f73b304-e6b0-4037-b779-1b7a14cf3cb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Symptomatic Trichomoniasis. Metronidazole tablets are indicated for the treatment of T. vaginalis infection in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis. Metronidazole tablets are indicated in the treatment of asymptomatic T. vaginalis infection in females when the organism is associated with endocervicitis, cervicitis, or cervical erosion. Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. Treatment of Asymptomatic Sexual Partners. T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her sexual partner is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the sexual partner should be treated with metronidazole tablets in cases of reinfection. Amebiasis. Metronidazole tablets are indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. In amebic liver abscess, metronidazole tablet therapy does not obviate the need for aspiration or drainage of pus. Anaerobic Bacterial Infections. Metronidazole tablets are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with metronidazole tablet therapy. In a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole tablets. INTRA-ABDOMINAL INFECTIONS, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species including the B. fragilis group ( B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus ), Clostridium species, Eubacterium species, Peptococcus species, and Peptostreptococcus species. SKIN AND SKIN STRUCTURE INFECTIONS caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus species, Peptostreptococcus species, and Fusobacterium species. GYNECOLOGIC INFECTIONS, including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus species, Peptostreptococcus species, and Fusobacterium species. BACTERIAL SEPTICEMIA caused by Bacteroides species including the B. fragilis group and Clostridium species. BONE AND JOINT INFECTIONS, (as adjunctive therapy), caused by Bacteroides species including the B. fragilis group. CENTRAL NERVOUS SYSTEM (CNS) INFECTIONS, including meningitis and brain abscess, caused by Bacteroides species including the B. fragilis group. LOWER RESPIRATORY TRACT INFECTIONS, including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group. ENDOCARDITIS caused by Bacteroides species including the B. fragilis group. To reduce the development of drug-resistant bacteria and maintain the effectiveness of metronidazole tablets and other antibacterial drugs, metronidazole tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:f7fd77cd-e35f-4189-95ae-51e35c3c1708 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:bc2599e2-8822-4de9-a7dc-f0b6a4ff3e45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:61be7eb5-7844-42b8-980f-9dcb6750c604"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Symptomatic Trichomoniasis. Metronidazole tablets are indicated for the treatment of T. vaginalis infection in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis. Metronidazole tablets are indicated in the treatment of asymptomatic T. vaginalis infection in females when the organism is associated with endocervicitis, cervicitis, or cervical erosion. Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. Treatment of Asymptomatic Sexual Partners. T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her sexual partner is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the sexual partner should be treated with metronidazole tablets in cases of reinfection. Amebiasis. Metronidazole tablets are indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. In amebic liver abscess, metronidazole tablet therapy does not obviate the need for aspiration or drainage of pus. Anaerobic Bacterial Infections. Metronidazole tablets are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with metronidazole tablet therapy. In a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole tablets. INTRA-ABDOMINAL INFECTIONS, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species including the B. fragilis group ( B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus ), Clostridium species, Eubacterium species, Peptococcus species, and Peptostreptococcus species. SKIN AND SKIN STRUCTURE INFECTIONS caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus species, Peptostreptococcus species, and Fusobacterium species. GYNECOLOGIC INFECTIONS, including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus species, Peptostreptococcus species, and Fusobacterium species. BACTERIAL SEPTICEMIA caused by Bacteroides species including the B. fragilis group and Clostridium species. BONE AND JOINT INFECTIONS, (as adjunctive therapy), caused by Bacteroides species including the B. fragilis group. CENTRAL NERVOUS SYSTEM (CNS) INFECTIONS, including meningitis and brain abscess, caused by Bacteroides species including the B. fragilis group. LOWER RESPIRATORY TRACT INFECTIONS, including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group. ENDOCARDITIS caused by Bacteroides species including the B. fragilis group. To reduce the development of drug-resistant bacteria and maintain the effectiveness of metronidazole tablets and other antibacterial drugs, metronidazole tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:4db62095-bd72-4f9a-b8cb-c361b4090977 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28001 biolink:treats MONDO:0024313 PMID:41385096 "[{""id"":""uuid:1ff7ec57-a0fa-428b-9de0-c7235b6f86e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dcacac14-c439-4738-8ede-fb46117d81fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vancomycin is indicated for the treatment of serious or severe infections caused by susceptible strains of methicillin-resistant (beta-lactam-resistant) staphylococci. It is indicated for penicillin-allergic patients, for patients who cannot receive or who have failed to respond to other drugs, including the penicillins or cephalosporins, and for infections caused by vancomycin-susceptible organisms that are resistant to other antimicrobial drugs. Vancomycin is indicated for initial therapy when methicillin-resistant staphylococci are suspected, but after susceptibility data are available, therapy should be adjusted accordingly. Vancomycin is effective in the treatment of staphylococcal endocarditis. Its effectiveness has been documented in other infections due to staphylococci, including septicemia, bone infections, lower respiratory tract infections, skin and skin structure infections. When staphylococcal infections are localized and purulent, antibiotics are used as adjuncts to appropriate surgical measures. Vancomycin has been reported to be effective alone or in combination with an aminoglycoside for endocarditis caused by Streptococcus viridans or S. bovis . For endocarditis caused by enterococci ( e.g., E. faecalis ), vancomycin has been reported to be effective only in combination with an aminoglycoside. Vancomycin has been reported to be effective for the treatment of diphtheroid endocarditis. Vancomycin has been used successfully in combination with either rifampin, an aminoglycoside, or both in early-onset prosthetic valve endocarditis caused by S. epidermidis or diphtheroids. Specimens for bacteriologic cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to vancomycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of vancomycin and other antibacterial drugs, vancomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection oftherapy. The parenteral form of Vancomycin Hydrochloride for Injection, USP may be administered orally for treatment of antibiotic-associated pseudomembranous colitis produced by C. difficile and for staphylococcal enterocolitis. Parenteral administration of vancomycin hydrochloride alone is of unproven benefit for these indications. Vancomycin is not effective by the oral route for other types of infection. uuid:f45c6f0e-3473-4d30-b1c1-846bedc52b10 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77733 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:a2c48d90-e292-4a40-ac41-f9d661e620e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:81b6efab-654b-4968-964a-57e8a77e6f8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Verapamil hydrochloride sustained-release capsules are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. uuid:256ff5fe-d282-4c23-b4a4-cc5d0843ea81 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77733 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:0444b75d-e08d-45c6-9b93-e1346f578925"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:55b04eaa-cf73-49a1-926c-b3723a1e5448"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Verapamil hydrochloride sustained-release capsules are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. uuid:de503e43-1ce6-466a-aeae-c1633cf343a5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2618 biolink:treats MONDO:0005812 PMID:41385096 "[{""id"":""uuid:f72ecdee-ce5c-43ba-8686-95d2064fbf01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bee164a6-d70e-4b01-9f3d-dbafe2084cc2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amantadine hydrochloride oral solution USP is indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine hydrochloride is also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions. uuid:d9630d3d-857a-4a27-a2e8-47a14778e54f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:253342 biolink:treats MONDO:0005052 PMID:41385096 "[{""id"":""uuid:672011f4-58e4-46aa-b4b0-9aca2fb33059"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:754eee48-a5e6-4efb-91f5-9bfa66b4ea2b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LOTRONEX is indicated only for women with severe diarrhea-predominant irritable bowel syndrome (IBS) who have: chronic IBS symptoms (generally lasting 6 months or longer), had anatomic or biochemical abnormalities of the gastrointestinal tract excluded, and not responded adequately to conventional therapy. Diarrhea-predominant IBS is severe if it includes diarrhea and one or more of the following: frequent and severe abdominal pain/discomfort, frequent bowel urgency or fecal incontinence, disability or restriction of daily activities due to IBS. Because of infrequent but serious gastrointestinal adverse reactions associated with LOTRONEX, the indication is restricted to those patients for whom the benefit-to-risk balance is most favorable. Clinical studies have not been performed to adequately confirm the benefits of LOTRONEX in men. uuid:4eadccb7-264b-4fc0-9dd8-e244708e96c9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:253342 biolink:treats HP:0002027 PMID:41385096 "[{""id"":""uuid:662d5054-c5a5-40d1-b96e-1004e3b9ddb7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:adab6701-ab30-4ee0-8339-a8950f1e5955"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LOTRONEX is indicated only for women with severe diarrhea-predominant irritable bowel syndrome (IBS) who have: chronic IBS symptoms (generally lasting 6 months or longer), had anatomic or biochemical abnormalities of the gastrointestinal tract excluded, and not responded adequately to conventional therapy. Diarrhea-predominant IBS is severe if it includes diarrhea and one or more of the following: frequent and severe abdominal pain/discomfort, frequent bowel urgency or fecal incontinence, disability or restriction of daily activities due to IBS. Because of infrequent but serious gastrointestinal adverse reactions associated with LOTRONEX, the indication is restricted to those patients for whom the benefit-to-risk balance is most favorable. Clinical studies have not been performed to adequately confirm the benefits of LOTRONEX in men. uuid:ee999160-096d-4320-ab0d-8f743ac9ca04 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:253342 biolink:treats HP:0012701 PMID:41385096 "[{""id"":""uuid:ee5ba124-3b9f-4ecc-b380-94a62180bab8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a6cf5edf-ba17-4172-bcf1-7d8af60c1e95"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LOTRONEX is indicated only for women with severe diarrhea-predominant irritable bowel syndrome (IBS) who have: chronic IBS symptoms (generally lasting 6 months or longer), had anatomic or biochemical abnormalities of the gastrointestinal tract excluded, and not responded adequately to conventional therapy. Diarrhea-predominant IBS is severe if it includes diarrhea and one or more of the following: frequent and severe abdominal pain/discomfort, frequent bowel urgency or fecal incontinence, disability or restriction of daily activities due to IBS. Because of infrequent but serious gastrointestinal adverse reactions associated with LOTRONEX, the indication is restricted to those patients for whom the benefit-to-risk balance is most favorable. Clinical studies have not been performed to adequately confirm the benefits of LOTRONEX in men. uuid:8ffcb1d1-1a75-4426-a2f1-7ca44fb5fd9a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:253342 biolink:treats HP:0002607 PMID:41385096 "[{""id"":""uuid:f0ae9e64-960c-4406-9d99-a10cbeeeb775"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f249cdc7-1351-4cd8-ba72-08d8796f426c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LOTRONEX is indicated only for women with severe diarrhea-predominant irritable bowel syndrome (IBS) who have: chronic IBS symptoms (generally lasting 6 months or longer), had anatomic or biochemical abnormalities of the gastrointestinal tract excluded, and not responded adequately to conventional therapy. Diarrhea-predominant IBS is severe if it includes diarrhea and one or more of the following: frequent and severe abdominal pain/discomfort, frequent bowel urgency or fecal incontinence, disability or restriction of daily activities due to IBS. Because of infrequent but serious gastrointestinal adverse reactions associated with LOTRONEX, the indication is restricted to those patients for whom the benefit-to-risk balance is most favorable. Clinical studies have not been performed to adequately confirm the benefits of LOTRONEX in men. uuid:29f951f9-504b-43a4-b311-041f2e019bf5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:1678OK0E08 biolink:treats MONDO:0005302 PMID:41385096 "[{""id"":""uuid:2f6ade1b-712c-433e-82f1-1dbb68e613b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:78a252a1-ced9-458c-b72f-c7613a1e2e2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dexmethylphenidate hydrochloride extended-release capsules are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 years and older. The effectiveness of dexmethylphenidate hydrochloride extended-release capsules in the treatment of ADHD in patients aged 6 years and older was established in 2 placebo-controlled studies in patients meeting DSM-IV criteria for ADHD [ see Clinical Studies (14) ]. A diagnosis of Attention Deficit Hyperactivity Disorder (ADHD; DSM-IV) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. The symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in 2 or more settings, e.g., school (or work) and at home. The symptoms must not be better accounted for by another mental disorder. For the Inattentive Type, at least 6 of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effort; loses things; easily distracted; forgetful. For the Hyperactive-Impulsive Type, at least 6 of the following symptoms must have persisted for at least 6 months: fidgeting/squirming; leaving seat; inappropriate running/climbing; difficulty with quiet activities; “on the go”; excessive talking; blurting answers; can’t wait turn; intrusive. The Combined Types requires both inattentive and hyperactive-impulsive criteria to be met. Special Diagnostic Considerations Specific etiology of this syndrome is unknown, and there is no single diagnostic test. Adequate diagnosis requires the use not only of medical but of special psychological, educational, and social resources. Learning may or may not be impaired. The diagnosis must be based upon a complete history and evaluation of the child and not solely on the presence of the required number of DSM-IV characteristics. Need for Comprehensive Treatment Program Dexmethylphenidate hydrochloride extended-release capsules are indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, social) for patients with this syndrome. Drug treatment may not be indicated for all children with this syndrome. Stimulants are not intended for use in the child who exhibits symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis. Appropriate educational placement is essential and psychosocial intervention is often helpful. When remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physician’s assessment of the chronicity and severity of the child’s symptoms. Long-Term Use The effectiveness of dexmethylphenidate hydrochloride extended-release capsules for long-term use, i.e., for more than 7 weeks, has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use dexmethylphenidate hydrochloride extended-release capsules for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual patient [ see Dosage and Administration (2.3) ]. CHEMBL.COMPOUND:CHEMBL904 uuid:3446768b-b381-46cf-b082-4bfc04274447 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8310 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:068ce01e-b0e6-4b96-ae0c-fb1f940a6048"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c8212db0-57bf-4263-a4c7-525176300c83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acute Infections Caused by Susceptible Strains of Pseudomonas aeruginosa. Polymyxin B sulfate is a drug of choice in the treatment of infections of the urinary tract, meninges, and bloodstream caused by susceptible strains of Ps. aeruginosa . It may also be used topically and subconjunctivally in the treatment of infections of the eye caused by susceptible strains of Ps. aeruginosa . It may be indicated in serious infections caused by susceptible strains of the following organisms, when less potentially toxic drugs are ineffective or contraindicated: H influenzae , specifically meningeal infections. Escherichia coli , specifically urinary tract infections. Aerobacter aerogenes , specifically bacteremia. Klebsiella pneumoniae , specifically bacteremia. NOTE: IN MENINGEAL INFECTIONS, POLYMYXIN B SULFATE SHOULD BE ADMINISTERED ONLY BY THE INTRATHECAL ROUTE. To reduce the development of drug-resistant bacteria and maintain the effectiveness of polymyxin B and other antibacterial drugs, polymyxin B should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:c590d6c2-5352-417e-a333-c84c5ee7d6e5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8310 biolink:treats MONDO:0021108 PMID:41385096 "[{""id"":""uuid:93c1c960-518e-4504-bfe9-426d1ae205a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b3aa071e-f13c-410a-9d51-87aff428354d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acute Infections Caused by Susceptible Strains of Pseudomonas aeruginosa. Polymyxin B sulfate is a drug of choice in the treatment of infections of the urinary tract, meninges, and bloodstream caused by susceptible strains of Ps. aeruginosa . It may also be used topically and subconjunctivally in the treatment of infections of the eye caused by susceptible strains of Ps. aeruginosa . It may be indicated in serious infections caused by susceptible strains of the following organisms, when less potentially toxic drugs are ineffective or contraindicated: H influenzae , specifically meningeal infections. Escherichia coli , specifically urinary tract infections. Aerobacter aerogenes , specifically bacteremia. Klebsiella pneumoniae , specifically bacteremia. NOTE: IN MENINGEAL INFECTIONS, POLYMYXIN B SULFATE SHOULD BE ADMINISTERED ONLY BY THE INTRATHECAL ROUTE. To reduce the development of drug-resistant bacteria and maintain the effectiveness of polymyxin B and other antibacterial drugs, polymyxin B should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:67ef3371-fd0e-43a0-bfd4-dfbd67866cbd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8310 biolink:treats MONDO:0043885 PMID:41385096 "[{""id"":""uuid:4e99e36b-5c63-4b45-9007-7e265a28e723"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4bc15b63-0f06-4b24-a0e8-959f759c663a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acute Infections Caused by Susceptible Strains of Pseudomonas aeruginosa. Polymyxin B sulfate is a drug of choice in the treatment of infections of the urinary tract, meninges, and bloodstream caused by susceptible strains of Ps. aeruginosa . It may also be used topically and subconjunctivally in the treatment of infections of the eye caused by susceptible strains of Ps. aeruginosa . It may be indicated in serious infections caused by susceptible strains of the following organisms, when less potentially toxic drugs are ineffective or contraindicated: H influenzae , specifically meningeal infections. Escherichia coli , specifically urinary tract infections. Aerobacter aerogenes , specifically bacteremia. Klebsiella pneumoniae , specifically bacteremia. NOTE: IN MENINGEAL INFECTIONS, POLYMYXIN B SULFATE SHOULD BE ADMINISTERED ONLY BY THE INTRATHECAL ROUTE. To reduce the development of drug-resistant bacteria and maintain the effectiveness of polymyxin B and other antibacterial drugs, polymyxin B should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:5c3b51f0-ad66-4bbb-a615-a29f7baa55b8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8310 biolink:treats MONDO:0005229 PMID:41385096 "[{""id"":""uuid:d9d9b615-8034-4d8f-8786-23f08ef90a40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fa312c46-823c-4d1d-a9b4-fc2ca9e78d6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acute Infections Caused by Susceptible Strains of Pseudomonas aeruginosa. Polymyxin B sulfate is a drug of choice in the treatment of infections of the urinary tract, meninges, and bloodstream caused by susceptible strains of Ps. aeruginosa . It may also be used topically and subconjunctivally in the treatment of infections of the eye caused by susceptible strains of Ps. aeruginosa . It may be indicated in serious infections caused by susceptible strains of the following organisms, when less potentially toxic drugs are ineffective or contraindicated: H influenzae , specifically meningeal infections. Escherichia coli , specifically urinary tract infections. Aerobacter aerogenes , specifically bacteremia. Klebsiella pneumoniae , specifically bacteremia. NOTE: IN MENINGEAL INFECTIONS, POLYMYXIN B SULFATE SHOULD BE ADMINISTERED ONLY BY THE INTRATHECAL ROUTE. To reduce the development of drug-resistant bacteria and maintain the effectiveness of polymyxin B and other antibacterial drugs, polymyxin B should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:07daf194-690d-4e47-bd40-5b60a1892af8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:25681 biolink:treats MONDO:0004982 PMID:41385096 "[{""id"":""uuid:6f4bdd4e-151f-448b-a9a5-58623d6106af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6898a9d7-31d1-4d8e-9e3e-ee5912ed4e58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Omega-3-acid ethyl esters capsules, USP are indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia (HTG). Patients should be placed on an appropriate lipid-lowering diet before receiving omega-3-acid ethyl esters capsules, USP and should continue this diet during treatment with omega-3-acid ethyl esters capsules, USP. Usage Considerations: Laboratory studies should be done to ascertain that the lipid levels are consistently abnormal before instituting therapy with omega-3-acid ethyl esters capsules, USP. Every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that are contributing to the lipid abnormalities. Medications known to exacerbate hypertriglyceridemia (such as beta blockers, thiazides, estrogens) should be discontinued or changed if possible prior to consideration of triglyceride-lowering drug therapy. Limitations of Use: The effect of omega-3-acid ethyl esters capsules, USP on the risk for pancreatitis has not been determined. The effect of omega-3-acid ethyl esters capsules, USP on cardiovascular mortality and morbidity has not been determined. uuid:2d0845b2-c177-48f0-9204-09c4d9567f6a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45285 biolink:treats MONDO:0100481 PMID:41385096 "[{""id"":""uuid:353cf16a-a2ec-464e-b55e-152241bfc7f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e753a050-9f48-4795-bdd7-64c5f5bdbd9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pyrazinamide is indicated for the initial treatment of active tuberculosis in adults and children when combined with other antituberculous agents. (The current recommendation of the CDC for drug-susceptible disease is to use a six-month regimen for initial treatment of active tuberculosis, consisting of isoniazid, rifampin and pyrazinamide given for 2 months, followed by isoniazid and rifampin for 4 months. *4 ) (Patients with drug-resistant disease should be treated with regimens individualized to their situation. Pyrazinamide frequently will be an important component of such therapy.) (In patients with concomitant HIV infection, the physician should be aware of current recommendation of CDC. It is possible these patients may require a longer course of treatment). It is also indicated after treatment failure with other primary drugs in any form of active tuberculosis. Pyrazinamide should only be used in conjunction with other effective antituberculous agents. *See recommendations of Center for Disease Control (CDC) and American Thoracic Society for complete regimen and dosage recommendations. 4 uuid:5acb8dfc-ced9-43e1-aa97-1a50fcf513fc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45285 biolink:treats MONDO:0005861 PMID:41385096 "[{""id"":""uuid:00d232ef-fb71-4a35-ac77-cb269fe80250"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2dfd62d5-6346-45e4-a7c2-8e1fd68e7782"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pyrazinamide is indicated for the initial treatment of active tuberculosis in adults and children when combined with other antituberculous agents. (The current recommendation of the CDC for drug-susceptible disease is to use a six-month regimen for initial treatment of active tuberculosis, consisting of isoniazid, rifampin and pyrazinamide given for 2 months, followed by isoniazid and rifampin for 4 months. *4 ) (Patients with drug-resistant disease should be treated with regimens individualized to their situation. Pyrazinamide frequently will be an important component of such therapy.) (In patients with concomitant HIV infection, the physician should be aware of current recommendation of CDC. It is possible these patients may require a longer course of treatment). It is also indicated after treatment failure with other primary drugs in any form of active tuberculosis. Pyrazinamide should only be used in conjunction with other effective antituberculous agents. *See recommendations of Center for Disease Control (CDC) and American Thoracic Society for complete regimen and dosage recommendations. 4 uuid:7d253e39-0584-4703-a135-1f6d29f9a1a2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6078 biolink:treats MONDO:0005974 PMID:41385096 "[{""id"":""uuid:c3a1aebe-257c-4114-ae5e-18e8e82a1d5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4bb85dbd-b972-4077-9cb1-3be1f02cc60f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] STROMECTOL is indicated for the treatment of the following infections: Strongyloidiasis of the intestinal tract . STROMECTOL is indicated for the treatment of intestinal (i.e., nondisseminated) strongyloidiasis due to the nematode parasite Strongyloides stercoralis . This indication is based on clinical studies of both comparative and open-label designs, in which 64-100% of infected patients were cured following a single 200-mcg/kg dose of ivermectin. (See CLINICAL PHARMACOLOGY, Clinical Studies .) Onchocerciasis . STROMECTOL is indicated for the treatment of onchocerciasis due to the nematode parasite Onchocerca volvulus . This indication is based on randomized, double-blind, placebo-controlled and comparative studies conducted in 1427 patients in onchocerciasis-endemic areas of West Africa. The comparative studies used diethylcarbamazine citrate (DEC-C). NOTE: STROMECTOL has no activity against adult Onchocerca volvulus parasites. The adult parasites reside in subcutaneous nodules which are infrequently palpable. Surgical excision of these nodules (nodulectomy) may be considered in the management of patients with onchocerciasis, since this procedure will eliminate the microfilariae-producing adult parasites. uuid:62e99fcb-91b1-4fa4-a4c3-2efccaf8062c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6078 biolink:treats UMLS:C0348997 PMID:41385096 "[{""id"":""uuid:972a16fd-44cd-4897-ac42-54b5f9919929"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c254a236-34d2-47d1-b288-59a4f6611d10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] STROMECTOL is indicated for the treatment of the following infections: Strongyloidiasis of the intestinal tract . STROMECTOL is indicated for the treatment of intestinal (i.e., nondisseminated) strongyloidiasis due to the nematode parasite Strongyloides stercoralis . This indication is based on clinical studies of both comparative and open-label designs, in which 64-100% of infected patients were cured following a single 200-mcg/kg dose of ivermectin. (See CLINICAL PHARMACOLOGY, Clinical Studies .) Onchocerciasis . STROMECTOL is indicated for the treatment of onchocerciasis due to the nematode parasite Onchocerca volvulus . This indication is based on randomized, double-blind, placebo-controlled and comparative studies conducted in 1427 patients in onchocerciasis-endemic areas of West Africa. The comparative studies used diethylcarbamazine citrate (DEC-C). NOTE: STROMECTOL has no activity against adult Onchocerca volvulus parasites. The adult parasites reside in subcutaneous nodules which are infrequently palpable. Surgical excision of these nodules (nodulectomy) may be considered in the management of patients with onchocerciasis, since this procedure will eliminate the microfilariae-producing adult parasites. uuid:0c0de694-e39b-4ca1-9b62-38533377884a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6078 biolink:treats MONDO:0017137 PMID:41385096 "[{""id"":""uuid:879925a7-d92b-4c7c-83cd-3631c5c051d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0a428092-5978-4259-bb37-6e87af46465b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] STROMECTOL is indicated for the treatment of the following infections: Strongyloidiasis of the intestinal tract . STROMECTOL is indicated for the treatment of intestinal (i.e., nondisseminated) strongyloidiasis due to the nematode parasite Strongyloides stercoralis . This indication is based on clinical studies of both comparative and open-label designs, in which 64-100% of infected patients were cured following a single 200-mcg/kg dose of ivermectin. (See CLINICAL PHARMACOLOGY, Clinical Studies .) Onchocerciasis . STROMECTOL is indicated for the treatment of onchocerciasis due to the nematode parasite Onchocerca volvulus . This indication is based on randomized, double-blind, placebo-controlled and comparative studies conducted in 1427 patients in onchocerciasis-endemic areas of West Africa. The comparative studies used diethylcarbamazine citrate (DEC-C). NOTE: STROMECTOL has no activity against adult Onchocerca volvulus parasites. The adult parasites reside in subcutaneous nodules which are infrequently palpable. Surgical excision of these nodules (nodulectomy) may be considered in the management of patients with onchocerciasis, since this procedure will eliminate the microfilariae-producing adult parasites. uuid:0251d5bb-6cba-41a9-8311-668c0a421c84 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:473990 biolink:treats MONDO:0005366 PMID:41385096 "[{""id"":""uuid:f552af4d-729f-4b2d-9c70-b863c035cf11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2b6ace62-4499-4439-a728-2b75f2c20faa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b3c47211-71b4-496b-b5f7-fd662807fbbf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:cc4a6af4-f3fb-4995-908b-95a1c9981ac1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Entecavir tablets are indicated for the treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. The following points should be considered when initiating therapy with Entecavir tablets: In adult patients, this indication is based on clinical trial data in nucleoside-inhibitor-treatment-naïve and lamivudine-resistant subjects with HBeAg-positive and HBeAg-negative HBV infection and compensated liver disease and a more limited number of subjects with decompensated liver disease [see Clinical Studies (14.1) ]. Pediatric use information is approved for Bristol-Myers Squibb Company’s Baraclude (entecavir) tablets. However, due to Bristol-Myers Squibb Company’s marketing exclusivity rights, this drug product is not labeled with that information.|[EMA] Entecavir Mylan is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults with:compensated liver disease and evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis.decompensated liver disease.For both compensated and decompensated liver disease, this indication is based on clinical trial data in nucleoside naive patients with HBeAg positive and HBeAg negative HBV infection. With respect to patients with lamivudine-refractory hepatitis B.Entecavir Mylan is also indicated for the treatment of chronic HBV infection in nucleoside naive paediatric patients from 2 to|[PMDA] Drug containing a new active ingredient indicated for use to improve levels of viral marker, liver function, and the histology of the liver affected by chronic hepatitis B in patients with evidence of hepatitis B virus replication and associated abnormal liver function. [Priority Review] uuid:7001f74d-6bc7-4e3d-a9dd-d1b47bded8cb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:473990 biolink:treats UMLS:C3839044 PMID:41385096 "[{""id"":""uuid:aa1f7ed8-0cec-47e7-a22f-60d7b2b395f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7d37e263-9074-475d-88a5-46765e8011a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Entecavir tablets are indicated for the treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. The following points should be considered when initiating therapy with Entecavir tablets: In adult patients, this indication is based on clinical trial data in nucleoside-inhibitor-treatment-naïve and lamivudine-resistant subjects with HBeAg-positive and HBeAg-negative HBV infection and compensated liver disease and a more limited number of subjects with decompensated liver disease [see Clinical Studies (14.1) ]. Pediatric use information is approved for Bristol-Myers Squibb Company’s Baraclude (entecavir) tablets. However, due to Bristol-Myers Squibb Company’s marketing exclusivity rights, this drug product is not labeled with that information. uuid:b1ff2397-86e9-4009-8d34-7e0814665c1d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:473990 biolink:treats MONDO:0100192 PMID:41385096 "[{""id"":""uuid:b89e1e60-ada3-4ee0-a728-e1cea7b9b91f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0681df44-48cf-4fd3-aff9-2fa4317139ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3f3ef8f6-2619-44bd-a802-12fbc1a0f447"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Entecavir tablets are indicated for the treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. The following points should be considered when initiating therapy with Entecavir tablets: In adult patients, this indication is based on clinical trial data in nucleoside-inhibitor-treatment-naïve and lamivudine-resistant subjects with HBeAg-positive and HBeAg-negative HBV infection and compensated liver disease and a more limited number of subjects with decompensated liver disease [see Clinical Studies (14.1) ]. Pediatric use information is approved for Bristol-Myers Squibb Company’s Baraclude (entecavir) tablets. However, due to Bristol-Myers Squibb Company’s marketing exclusivity rights, this drug product is not labeled with that information.|[EMA] Entecavir Mylan is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults with:compensated liver disease and evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis.decompensated liver disease.For both compensated and decompensated liver disease, this indication is based on clinical trial data in nucleoside naive patients with HBeAg positive and HBeAg negative HBV infection. With respect to patients with lamivudine-refractory hepatitis B.Entecavir Mylan is also indicated for the treatment of chronic HBV infection in nucleoside naive paediatric patients from 2 to uuid:c26fdd12-cb8c-48f9-b5b4-bcd3da3a9d20 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15940 biolink:treats MONDO:0004982 PMID:41385096 "[{""id"":""uuid:d097c006-b9c9-47ae-a2cb-e2c18aa4e8c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c121422c-99fe-40f9-89ac-0bc0bf90ac34"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. Niacin therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. Niacin extended-release tablets are indicated to reduce elevated TC, LDL-C, Apo B and TG levels, and to increase HDL-C in patients with primary hyperlipidemia and mixed dyslipidemia. In patients with a history of myocardial infarction and hyperlipidemia, niacin is indicated to reduce the risk of recurrent nonfatal myocardial infarction. In patients with a history of coronary artery disease (CAD) and hyperlipidemia, niacin, in combination with a bile acid binding resin, is indicated to slow progression or promote regression of atherosclerotic disease. Niacin extended-release tablets in combination with a bile acid binding resin is indicated to reduce elevated TC and LDL-C levels in adult patients with primary hyperlipidemia. Niacin is also indicated as adjunctive therapy for treatment of adult patients with severe hypertriglyceridemia who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Limitations of Use Addition of niacin extended-release tablets did not reduce cardiovascular morbidity or mortality among patients treated with simvastatin in a large, randomized controlled trial (AIM-HIGH) [see Warnings and Precautions (5.1) ] . uuid:74c5e917-835c-40ba-bd8d-09526a096e32 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72564 biolink:treats MONDO:0018177 PMID:41385096 "[{""id"":""uuid:d83695d8-143a-4e6f-bf3b-f7b2c42e2229"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9a519103-742a-40d3-bea2-baf37bbda713"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:79f95267-a300-4440-8262-92a6b6fc59d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/temozolomide-accord""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Temozolomide is an alkylating drug indicated for the treatment of adult patients with: Newly diagnosed glioblastoma multiforme (GBM) concomitantly with radiotherapy and then as maintenance treatment. ( 1.1 ) Refractory anaplastic astrocytoma patients who have experienced disease progression on a drug regimen containing nitrosourea and procarbazine. ( 1.2 )|[EMA] For the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy (RT) and subsequently as monotherapy treatment.For the treatment of children from the age of three years, adolescents and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy. uuid:29b31940-bb66-4705-8493-b143d59d235c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72564 biolink:treats MONDO:0016684 PMID:41385096 "[{""id"":""uuid:6ba3ed92-410a-4ede-b6ec-05f3cb3afbc0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:62c495a7-bd58-4071-96aa-2c6a2a8a62d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ffa2b180-4ede-492c-a59b-af11f3a78d96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/temozolomide-accord""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Temozolomide is an alkylating drug indicated for the treatment of adult patients with: Newly diagnosed glioblastoma multiforme (GBM) concomitantly with radiotherapy and then as maintenance treatment. ( 1.1 ) Refractory anaplastic astrocytoma patients who have experienced disease progression on a drug regimen containing nitrosourea and procarbazine. ( 1.2 )|[EMA] For the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy (RT) and subsequently as monotherapy treatment.For the treatment of children from the age of three years, adolescents and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy. uuid:3195121f-2f57-4fb9-a918-e56074ada1e1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24847800 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:be953a9c-b7cd-440c-a4e0-0c787d04b479"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d4b42340-2234-42f0-af67-5dc3d1b818b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nadolol and bendroflumethiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the classes to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with nadolol and bendroflumethiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Nadolol and bendroflumethiazide tablets are not indicated for initial therapy of hypertension. If the fixed combination represents the dose titrated to the individual patient's needs, it may be more convenient than the separate components. uuid:54f685ce-4fcf-4fdf-9c40-a84e8f67e982 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24847800 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:ed214921-3d4f-480a-b26e-afe37d9ac6ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:746bbd1e-b935-47fd-8af1-c091e7ee7e74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nadolol and bendroflumethiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the classes to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with nadolol and bendroflumethiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Nadolol and bendroflumethiazide tablets are not indicated for initial therapy of hypertension. If the fixed combination represents the dose titrated to the individual patient's needs, it may be more convenient than the separate components. uuid:14d4d30d-65cd-4e8a-9a32-09bb6093a90c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24847800 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:ba0530bb-e41b-4b06-afb0-b8032f0dd006"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b25b328e-1100-45d6-9f16-78a46b811874"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nadolol and bendroflumethiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the classes to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with nadolol and bendroflumethiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Nadolol and bendroflumethiazide tablets are not indicated for initial therapy of hypertension. If the fixed combination represents the dose titrated to the individual patient's needs, it may be more convenient than the separate components. uuid:ee686689-b131-4db6-92df-d7f079f1d0cb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24847800 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:21e5e88a-914f-4964-bb5b-8f90c7ffae9d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e2a0cbb7-b103-4303-a43f-35f3828d8fae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nadolol and bendroflumethiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the classes to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with nadolol and bendroflumethiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Nadolol and bendroflumethiazide tablets are not indicated for initial therapy of hypertension. If the fixed combination represents the dose titrated to the individual patient's needs, it may be more convenient than the separate components. uuid:a4ebb57b-fda0-4f3c-9a58-e505f172f67e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24847800 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:935d3c39-8dee-4b90-bece-6b8a8636b4d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:51f322c1-0e21-42ba-873c-8323e8377e30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nadolol and bendroflumethiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the classes to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with nadolol and bendroflumethiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Nadolol and bendroflumethiazide tablets are not indicated for initial therapy of hypertension. If the fixed combination represents the dose titrated to the individual patient's needs, it may be more convenient than the separate components. uuid:09ff6ffa-600a-41dd-a31f-12fa217315c5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5127 biolink:treats MONDO:0005093 PMID:41385096 "[{""id"":""uuid:7d8b2367-a7a5-4c92-804d-2d8d39ad895c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9fcf35c6-215f-42d0-943e-257105831efb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Flurandrenolide Cream is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. uuid:8a7a1415-490a-4d57-ad66-5964e4b8091b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7934 biolink:treats MONDO:0005644 PMID:41385096 "[{""id"":""uuid:6647e102-55fa-498b-99a1-0dd56098086d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bbdfeeec-f199-4639-a002-b7f11e3eea2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Paromomycin sulfate is indicated for intestinal amebiasis–acute and chronic (NOTE-It is not effective in extraintestinal amebiasis); management of hepatic coma–as adjunctive therapy. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Paromomycin Sulfate Capsules and other antibacterial drugs, Paromomycin Sulfate Capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:89f3cabb-1fc7-49e4-9da0-bad6b14025f1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7934 biolink:treats MONDO:0001548 PMID:41385096 "[{""id"":""uuid:088467fa-2954-417b-85ef-e0d04c110954"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fa080ebe-3881-4ad3-9cd5-846e6d69630d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Paromomycin sulfate is indicated for intestinal amebiasis–acute and chronic (NOTE-It is not effective in extraintestinal amebiasis); management of hepatic coma–as adjunctive therapy. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Paromomycin Sulfate Capsules and other antibacterial drugs, Paromomycin Sulfate Capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:c59f5a3f-4035-423e-88d8-e71a26ab8158 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:1D1822L42I biolink:treats HP:0002153 PMID:41385096 "[{""id"":""uuid:dd06f63a-4293-4824-9929-87fbd5fb29c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:18379770-ef59-40ea-8f78-49be6e610c3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Polystyrene Sulfonate, USP is indicated for the treatment of hyperkalemia. uuid:ea59accf-5a96-41b9-ba87-0989bff6de91 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46081 biolink:treats MONDO:0005886 PMID:41385096 "[{""id"":""uuid:e77d27db-cdd8-470d-885d-e9102121eeab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2ab2dc4e-bf1b-4863-9b60-521f5238ccea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluconazole is indicated for the treatment of: Vaginal candidiasis (vaginal yeast infections due to ). Candida Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole was also effective for the treatment of urinary tract infections, peritonitis, and systemic infections including candidemia, disseminated candidiasis, and pneumonia. Candida Candida Cryptococcal meningitis. Before prescribing fluconazole for AIDS patients with cryptococcal meningitis, please see section. Studies comparing fluconazole to amphotericin B in non-HIV infected patients have not been conducted. CLINICAL STUDIES uuid:fc2e52dd-21ea-4296-8caf-124a27315da6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46081 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:0902120e-4a78-4d90-be60-6420e1183d26"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6a159624-7e49-48ae-89c7-b575c009c654"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluconazole is indicated for the treatment of: Vaginal candidiasis (vaginal yeast infections due to ). Candida Oropharyngeal and esophageal candidiasis. In open noncomparative studies of relatively small numbers of patients, fluconazole was also effective for the treatment of urinary tract infections, peritonitis, and systemic infections including candidemia, disseminated candidiasis, and pneumonia. Candida Candida Cryptococcal meningitis. Before prescribing fluconazole for AIDS patients with cryptococcal meningitis, please see section. Studies comparing fluconazole to amphotericin B in non-HIV infected patients have not been conducted. CLINICAL STUDIES uuid:01bfaedd-720f-47a2-9b59-69a284ce4bfe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB11601 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:62f044e9-8562-45d8-b466-60a952180054"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:76a0b4c9-18c3-4e7c-9f44-90fec2457d98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tuberculin PPD is indicated as an aid in the detection of infection with . The standard tuberculin test employs the intradermal (Mantoux) test using a 5 TU dose of tuberculin PPD. The 0.1 mL test dose of Aplisol (tuberculin PPD, diluted) is equivalent to the 5 TU dose which has been clinically utilized and standardized with PPD-S. Tuberculin skin testing is not contraindicated for persons who have been vaccinated with BCG and the skin-test results of such persons are used to support or exclude the diagnosis of infections. HIV infection is a strong risk factor for the development of TB disease in persons having TB infection. All HIV-infected persons should receive a PPD-tuberculin skin test. Mycobacterium tuberculosis 7 M. tuberculosis 4 3 uuid:dfaa6c1f-3395-476d-955c-fa430f8d4524 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0008109 PMID:41385096 "[{""id"":""uuid:59d9dc6f-2a13-4ad3-99c7-b0763d217307"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f14f4b5e-f27a-4db2-beba-2c75cd2aa83d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of Methylprednisolone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:491ca3fc-585b-4817-8599-0f57f4cf3c6a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7551 biolink:treats UMLS:C0577698 PMID:41385096 "[{""id"":""uuid:47365824-5c48-4e71-817d-e7a30b0f7595"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b399020c-6176-4369-9df0-690c97aa18e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nicardipine hydrochloride capsules are indicated for the management of patients with chronic stable angina (effort-associated angina). They may be used alone or in combination with beta-blockers. uuid:d30555b6-cdc8-43eb-93ef-a2008ca1dbf5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8768 biolink:treats MONDO:0006896 PMID:41385096 "[{""id"":""uuid:96181839-60e7-437d-a737-8a3238575a30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cf42f412-3063-4164-86e9-08d0e1a24064"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4dbd62e7-ca8b-4ec9-b449-65d5ffe57f72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ACIPHEX delayed-release tablets is a proton-pump inhibitor (PPI) indicated in adults for: Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD) ( 1.1 ). Maintenance of Healing of Erosive or Ulcerative GERD ( 1.2 ). Treatment of Symptomatic GERD ( 1.3 ). Healing of Duodenal Ulcers ( 1.4 ). Helicobacter pylori Eradication to Reduce Risk of Duodenal Ulcer Recurrence ( 1.5 ). Treatment of Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome ( 1.6 ). In adolescent patients 12 years of age and older for: Short-term Treatment of Symptomatic GERD ( 1.7 ).|[PMDA] Drugs with a new dosage indicated for the treatment of reflux esophagitis. uuid:1273f652-c9b7-4dc3-9935-21d5e125c7b1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8768 biolink:treats MONDO:0005412 PMID:41385096 "[{""id"":""uuid:df51f007-158a-43c2-8c98-d9c67ec7ffa3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:096448b1-5457-4ef1-bfaa-721942ae9536"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:81a9c7f4-3571-4c00-9071-ab4c9b175ca5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ACIPHEX delayed-release tablets is a proton-pump inhibitor (PPI) indicated in adults for: Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD) ( 1.1 ). Maintenance of Healing of Erosive or Ulcerative GERD ( 1.2 ). Treatment of Symptomatic GERD ( 1.3 ). Healing of Duodenal Ulcers ( 1.4 ). Helicobacter pylori Eradication to Reduce Risk of Duodenal Ulcer Recurrence ( 1.5 ). Treatment of Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome ( 1.6 ). In adolescent patients 12 years of age and older for: Short-term Treatment of Symptomatic GERD ( 1.7 ).|[PMDA] A drug with a new additional indication and a new dosage in a newly-added dosage form, and a drug with a new additional indication and a new dosage for the prevention of recurrence of gastric ulcer or duodenal ulcer in patients treated with low-dose aspirin. uuid:b164f2b4-bd9a-4ce4-8305-07b3fe133210 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:36795 biolink:treats UMLS:C0740447 PMID:41385096 "[{""id"":""uuid:5dc0647a-f7bc-4953-b4c9-4f17561097f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:240d7b53-b007-4216-9ed7-065aba7b7a89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CYMBALTA ® is indicated for the treatment of: Major Depressive Disorder [see Clinical Studies ( 14.1 )] Generalized Anxiety Disorder [see Clinical Studies ( 14.2 )] Diabetic Peripheral Neuropathy [see Clinical Studies ( 14.3 )] Fibromyalgia [see Clinical Studies ( 14.4 )] Chronic Musculoskeletal Pain [see Clinical Studies ( 14.5 )] uuid:d2a82fae-f339-4d78-8cda-a57ef4a34e76 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:160e8a87-fe31-4846-ab9a-bd647b952edd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a71e3d84-51ee-4c3a-bcff-0a188a66048a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydrocortisone tablets are indicated in the following conditions. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis Collagen Disease During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Nervous System Acute exacerbations of multiple sclerosis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:170d24f3-ec98-4beb-a896-b12943e6b277 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9YCX42I8IU biolink:treats MONDO:0000328 PMID:41385096 "[{""id"":""uuid:7a32eac8-13fc-4255-a6d1-ec511dce5fcd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0b80f766-8f8e-415c-96ce-9a1a881ee22b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Renvela ® (sevelamer carbonate) is indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis. uuid:e1fef0a7-a09e-410e-b1dc-a154a5e6471e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31236 biolink:treats MONDO:0007661 PMID:41385096 "[{""id"":""uuid:878b34dc-e22e-4700-a010-83f5db1127f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9352c780-6cfa-4c82-a0e0-5fb9b4df429b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ABILIFY Oral Tablets, Orally-Disintegrating Tablets, and Oral Solution are indicated for the treatment of: • Schizophrenia [see CLINICAL STUDIES (14.1) ] • Acute Treatment of Manic and Mixed Episodes associated with Bipolar I Disorder [see CLINICAL STUDIES (14.2) ] • Adjunctive Treatment of Major Depressive Disorder [see CLINICAL STUDIES (14.3) ] • Irritability Associated with Autistic Disorder [see CLINICAL STUDIES (14.4) ] • Treatment of Tourette’s Disorder [see CLINICAL STUDIES (14.5) ] ABILIFY Injection is indicated for the treatment of: • Agitation associated with schizophrenia or bipolar mania [see CLINICAL STUDIES (14.6) ] uuid:14d4d4ca-1ee2-4cd6-b07d-c098ade4efaf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31236 biolink:treats HP:0100754 PMID:41385096 "[{""id"":""uuid:63ad0d03-d592-4e1f-b369-c290e63885da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7142901f-64e3-4d71-be5d-d936882f79cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ABILIFY Oral Tablets, Orally-Disintegrating Tablets, and Oral Solution are indicated for the treatment of: • Schizophrenia [see CLINICAL STUDIES (14.1) ] • Acute Treatment of Manic and Mixed Episodes associated with Bipolar I Disorder [see CLINICAL STUDIES (14.2) ] • Adjunctive Treatment of Major Depressive Disorder [see CLINICAL STUDIES (14.3) ] • Irritability Associated with Autistic Disorder [see CLINICAL STUDIES (14.4) ] • Treatment of Tourette’s Disorder [see CLINICAL STUDIES (14.5) ] ABILIFY Injection is indicated for the treatment of: • Agitation associated with schizophrenia or bipolar mania [see CLINICAL STUDIES (14.6) ] uuid:1ff8ac73-be7c-4bd0-b6c9-2d77ec7381d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9588 biolink:treats UMLS:C0242129 PMID:41385096 "[{""id"":""uuid:bfd0eb35-ab53-4f9d-a361-7dbb36004b11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:00ab28da-5f28-4083-8996-5f0bab441c6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ticlopidine Hydrochloride Tablets USP are indicated: to reduce the risk of thrombotic stroke (fatal or nonfatal) in patients who have experienced stroke precursors, and in patients who have had a completed thrombotic stroke. Because ticlopidine is associated with a risk of life-threatening blood dyscrasias including thrombotic thrombocytopenic purpura (TTP), neutropenia/agranulocytosis and aplastic anemia (see and ), ticlopidine should be reserved for patients who are intolerant or allergic to aspirin therapy or who have failed aspirin therapy. BOXED WARNING WARNINGS as adjunctive therapy with aspirin to reduce the incidence of subacute stent thrombosis in patients undergoing successful coronary stent implantation (see ). CLINICAL TRIALS uuid:099ab3f6-d1bf-48ee-b5b4-9cd3d03e8ca9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9588 biolink:treats MONDO:0018896 PMID:41385096 "[{""id"":""uuid:475d7f31-48ce-46b7-9a92-3137af0b4531"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8e42765e-6de5-4510-bd9f-d6d61ca58428"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ticlopidine Hydrochloride Tablets USP are indicated: to reduce the risk of thrombotic stroke (fatal or nonfatal) in patients who have experienced stroke precursors, and in patients who have had a completed thrombotic stroke. Because ticlopidine is associated with a risk of life-threatening blood dyscrasias including thrombotic thrombocytopenic purpura (TTP), neutropenia/agranulocytosis and aplastic anemia (see and ), ticlopidine should be reserved for patients who are intolerant or allergic to aspirin therapy or who have failed aspirin therapy. BOXED WARNING WARNINGS as adjunctive therapy with aspirin to reduce the incidence of subacute stent thrombosis in patients undergoing successful coronary stent implantation (see ). CLINICAL TRIALS uuid:f7eb056d-022d-4175-a1ee-5874c4cbe107 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9588 biolink:treats MONDO:0015909 PMID:41385096 "[{""id"":""uuid:8d22a8e5-7366-40a5-a0c1-9e9754867606"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dd8ea5ee-d725-468d-8bea-f084bedff586"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ticlopidine Hydrochloride Tablets USP are indicated: to reduce the risk of thrombotic stroke (fatal or nonfatal) in patients who have experienced stroke precursors, and in patients who have had a completed thrombotic stroke. Because ticlopidine is associated with a risk of life-threatening blood dyscrasias including thrombotic thrombocytopenic purpura (TTP), neutropenia/agranulocytosis and aplastic anemia (see and ), ticlopidine should be reserved for patients who are intolerant or allergic to aspirin therapy or who have failed aspirin therapy. BOXED WARNING WARNINGS as adjunctive therapy with aspirin to reduce the incidence of subacute stent thrombosis in patients undergoing successful coronary stent implantation (see ). CLINICAL TRIALS uuid:e6e292bd-d47e-4faf-a0ca-264776183c13 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9588 biolink:treats NCIT:C123441 PMID:41385096 "[{""id"":""uuid:efe7cfab-d291-4920-afd8-0b008ef9b88f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:864764f7-96d2-4d10-a735-9329dfb2d352"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ticlopidine Hydrochloride Tablets USP are indicated: to reduce the risk of thrombotic stroke (fatal or nonfatal) in patients who have experienced stroke precursors, and in patients who have had a completed thrombotic stroke. Because ticlopidine is associated with a risk of life-threatening blood dyscrasias including thrombotic thrombocytopenic purpura (TTP), neutropenia/agranulocytosis and aplastic anemia (see and ), ticlopidine should be reserved for patients who are intolerant or allergic to aspirin therapy or who have failed aspirin therapy. BOXED WARNING WARNINGS as adjunctive therapy with aspirin to reduce the incidence of subacute stent thrombosis in patients undergoing successful coronary stent implantation (see ). CLINICAL TRIALS uuid:7a582107-f1dc-4b0a-bfaf-5cd464c2805c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8214 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:21135877-3e7e-4728-9162-817cfacba51d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f94acaf5-9b0d-4caf-a52b-f5638cba5c60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pindolol tablets are indicated in the management of hypertension. It may be used alone or concomitantly with other antihypertensive agents, particularly with a thiazide-type diuretic. uuid:254dd58d-5aee-4cdc-bae9-a3db951601c0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3347 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:f96f2736-4273-4aaa-9434-bb6bd76e1051"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:de254cbf-527e-4978-8efc-21e275c3b5aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:aa51da34-b504-4c03-babc-9a3269e3d302"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Candesartan cilexetil tablets are an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension in adults and children 1 to <17 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions (1.1) . • Treatment of heart failure (NYHA class II-IV); candesartan cilexetil tablets reduce cardiovascular death and heart failure hospitalization (1.2) .|[PMDA] Drugs with a new additional pediatric dosage indicated for the treatment of hypertension. [Public knowledge-based application after preliminary assessment by the Pharmaceutical Affairs and Food Sanitation Council (PAFSC)] uuid:c82bcf83-7842-4c51-986f-d3875f5d7aaf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3347 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:9e29fe76-aae7-4669-8398-675f19109a4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c98850b3-ac9f-4354-a549-7f11b66a10e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Candesartan cilexetil tablets are an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension in adults and children 1 to <17 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions (1.1) . • Treatment of heart failure (NYHA class II-IV); candesartan cilexetil tablets reduce cardiovascular death and heart failure hospitalization (1.2) . uuid:559c8567-ec9e-4b57-85fc-f5fb61ff82f6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6367 biolink:treats MONDO:0006710 PMID:41385096 "[{""id"":""uuid:bb9033cd-6316-4505-8646-96c03b20e713"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9dc69016-a8ba-4138-8d3b-86d7eecc784c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lamotrigine tablets (chewable, dispersible) are indicated for: Epilepsy—adjunctive therapy in patients aged 2 years and older: • partial-onset seizures. • primary generalized tonic-clonic seizures. • generalized seizures of Lennox-Gastaut syndrome. ( 1.1 ) Epilepsy—monotherapy in patients aged 16 years and older: Conversion to monotherapy in patients with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single AED. ( 1.1 ) Bipolar disorder: Maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard therapy. ( 1.2 ) Limitations of Use: Treatment of acute manic or mixed episodes is not recommended. Effectiveness of lamotrigine tablets (chewable, dispersible) in the acute treatment of mood episodes has not been established. uuid:72cb0073-071a-438d-811a-e74e182a2331 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:46878853 biolink:treats UMLS:C0342879 PMID:41385096 "[{""id"":""uuid:5a68a9c5-ed9a-4e20-9d77-7649583907de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d3d621b6-3fb4-4a2e-a146-de2468dfacc7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fenofibrate tablets for oral use are a peroxisome proliferator receptor alpha (PPARα) activator indicated as an adjunct to diet: To reduce elevated LDL-C, Total-C, TG and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (1.1) . For treatment of adult patients with severe hypertriglyceridemia (1.2) . Important Limitations of Use: Fenofibrate was not shown to reduce coronary heart disease morbidity and mortality in patients with type 2 diabetes mellitus (5.1) . uuid:edfd77dd-d8ec-48aa-913c-cbbfe4570989 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3347 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:4cb572bd-fb1f-4fa2-825b-ef8f38e0a99c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:137fc6cf-7286-44a5-b2d5-8ef66c65c970"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ATACAND is an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension in adults and children 1 to < 17 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions (1.1) . • Treatment of heart failure (NYHA class II-IV); ATACAND reduces cardiovascular death and heart failure hospitalization (1.2) . uuid:6a9393a3-856f-4ae3-be19-494b4b5b884c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3347 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:e7a849d9-85b3-4ec8-8c9c-7b3b0c538d69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3c99a444-91a5-44c9-af24-faff24a17164"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ATACAND is an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension in adults and children 1 to < 17 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions (1.1) . • Treatment of heart failure (NYHA class II-IV); ATACAND reduces cardiovascular death and heart failure hospitalization (1.2) . uuid:aafe525f-c70f-440c-ae23-a84d5f381aa2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51041 biolink:treats MONDO:0007079 PMID:41385096 "[{""id"":""uuid:eacb48ec-e037-4e75-949d-68a53f87357c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d3e926f7-5ee9-4e7f-a0c7-20dbe63404ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e490caec-15ac-448c-8b20-46b61b223e73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Campral® is indicated for the maintenance of abstinence from alcohol in patients with alcohol dependence who are abstinent at treatment initiation. Treatment with Campral should be part of a comprehensive management program that includes psychosocial support. The efficacy of Campral in promoting abstinence has not been demonstrated in subjects who have not undergone detoxification and not achieved alcohol abstinence prior to beginning Campral treatment. The efficacy of Campral in promoting abstinence from alcohol in polysubstance abusers has not been adequately assessed.|[PMDA] A drug with a new active ingredient indicated for use as an aid for maintenance of abstinence in patients with alcohol dependence. uuid:0623ebeb-4d4d-4988-b8ff-33a60cb9eb1c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42797 biolink:treats MONDO:0005609 PMID:41385096 "[{""id"":""uuid:42028312-9504-498f-8bf3-20527f4e1005"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:585205ef-c919-4f65-a321-e83e7ee4edcf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Gabapentin Tablets, USP Read the Medication Guide before you start taking gabapentin and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment. What is the most important information I should know about gabapentin? Do not stop taking gabapentin without first talking to your healthcare provider. Stopping gabapentin suddenly can cause serious problems. Gabapentin can cause serious side effects including: 1. Like other antiepileptic drugs, gabapentin may cause suicidal thoughts or actions in a very small number of people, about 1 in 500. Call a healthcare provider right away if you have any of these symptoms, especially if they are new, worse, or worry you: thoughts about suicide or dying attempts to commit suicide new or worse depression new or worse anxiety feeling agitated or restless panic attacks trouble sleeping (insomnia) new or worse irritability acting aggressive, being angry, or violent acting on dangerous impulses an extreme increase in activity and talking (mania) other unusual changes in behavior or mood How can I watch for early symptoms of suicidal thoughts and actions? Pay attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. Keep all follow-up visits with your healthcare provider as scheduled. Call your healthcare provider between visits as needed, especially if you are worried about symptoms. Do not stop taking gabapentin without first talking to a healthcare provider. Stopping gabapentin suddenly can cause serious problems. Stopping a seizure medicine suddenly in a patient who has epilepsy can cause seizures that will not stop (status epilepticus). Suicidal thoughts or actions can be caused by things other than medicines. If you have suicidal thoughts or actions, your healthcare provider may check for other causes. 2. Changes in behavior and thinking - Using gabapentin in children 3 to 12 years of age can cause emotional changes, aggressive behavior, problems with concentration, restlessness, changes in school performance, and hyperactivity. What is gabapentin? Gabapentin is a prescription medicine used to treat: Pain from damaged nerves (postherpetic pain) that follows healing of shingles (a painful rash that comes after a herpes zoster infection) in adults. Partial seizures when taken together with other medicines in adults and children 3 years of age and older. Who should not take gabapentin? Do not take gabapentin if you are allergic to gabapentin or any of the other ingredients in gabapentin. See the end of this Medication Guide for a complete list of ingredients in gabapentin. What should I tell my healthcare provider before taking gabapentin? Before taking gabapentin, tell your healthcare provider if you: have or have had kidney problems or are on hemodialysis have or have had depression, mood problems, or suicidal thoughts or behavior are pregnant or plan to become pregnant. It is not known if gabapentin can harm your unborn baby. Tell your healthcare provider right away if you become pregnant while taking gabapentin. You and your healthcare provider will decide if you should take gabapentin while you are pregnant. If you become pregnant while taking gabapentin, talk to your healthcare provider about registering with the North American Antiepileptic Drug (NAAED) Pregnancy Registry. The purpose of this registry is to collect information about the safety of antiepileptic drugs during pregnancy. You can enroll in this registry by calling 1-888-233-2334. are breastfeeding or plan to breastfeed. Gabapentin can pass into breast milk. You and your healthcare provider should decide how you will feed your baby while you take gabapentin. Tell your healthcare provider about all the medicines you take , including prescription and non-prescription medicines, vitamins, and herbal supplements. Taking gabapentin with certain other medicines can cause side effects or affect how well they work. Do not start or stop other medicines without talking to your healthcare provider. Know the medicines you take. Keep a list of them and show it to your healthcare provider and pharmacist when you get a new medicine. How should I take gabapentin? Take gabapentin exactly as prescribed. Your healthcare provider will tell you how much gabapentin to take. Do not change your dose of gabapentin without talking to your healthcare provider. If you break a tablet in half the unused half of the tablet should be taken at your next scheduled dose. Half tablets not used within several days of breaking should be thrown away. Gabapentin can be taken with or without food. If you take an antacid containing aluminum and magnesium, such as Maalox®, Mylanta®, Gelusil®, Gaviscon®, or Di-Gel®, you should wait at least 2 hours before taking your next dose of gabapentin. If you take too much gabapentin, call your healthcare provider or your local Poison Control Center right away. What should I avoid while taking gabapentin? Do not drink alcohol or take other medicines that make you sleepy or dizzy while taking gabapentin without first talking with your healthcare provider. Taking gabapentin with alcohol or drugs that cause sleepiness or dizziness may make your sleepiness or dizziness worse. Do not drive, operate heavy machinery, or do other dangerous activities until you know how gabapentin affects you. Gabapentin can slow your thinking and motor skills. What are the possible side effects of gabapentin? See ""What is the most important information I should know about gabapentin?"" The most common side effects of gabapentin include: dizziness lack of coordination viral infection feeling drowsy feeling tired fever jerky movements difficulty with speaking temporary loss of memory (amnesia) tremor difficulty with coordination double vision unusual eye movement Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of gabapentin. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store gabapentin? Store gabapentin tablets at 20° to 25°C (68° to 77°F). [See USP controlled room temperature]. Keep gabapentin and all medicines out of the reach of children. General information about the safe and effective use of gabapentin Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use gabapentin for a condition for which it was not prescribed. Do not give gabapentin to other people, even if they have the same symptoms that you have. It may harm them. This Medication Guide summarizes the most important information about gabapentin. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about gabapentin that was written for healthcare professionals. For more information about gabapentin tablets, or to report side effects regarding gabapentin tablets, please call Exelan Pharmaceuticals Inc. at 1-855-295-7455. What are the ingredients in gabapentin Tablets? Active ingredient: Gabapentin, USP Inactive ingredients: Mannitol, Hydroxypropyl Cellulose, Crospovidone, Talc, Magnesium Stearate and Aquarius® BP18114 Cool Vanilla." uuid:e3178b83-6bc0-4ec2-b78d-54a6ff1ac234 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42797 biolink:treats MONDO:0002125 PMID:41385096 "[{""id"":""uuid:e053b66e-b65e-4758-84fd-48fa13e9c8d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:54c21a02-4f87-4114-9cd0-2dac0cd0bd5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Gabapentin Tablets, USP Read the Medication Guide before you start taking gabapentin and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment. What is the most important information I should know about gabapentin? Do not stop taking gabapentin without first talking to your healthcare provider. Stopping gabapentin suddenly can cause serious problems. Gabapentin can cause serious side effects including: 1. Like other antiepileptic drugs, gabapentin may cause suicidal thoughts or actions in a very small number of people, about 1 in 500. Call a healthcare provider right away if you have any of these symptoms, especially if they are new, worse, or worry you: thoughts about suicide or dying attempts to commit suicide new or worse depression new or worse anxiety feeling agitated or restless panic attacks trouble sleeping (insomnia) new or worse irritability acting aggressive, being angry, or violent acting on dangerous impulses an extreme increase in activity and talking (mania) other unusual changes in behavior or mood How can I watch for early symptoms of suicidal thoughts and actions? Pay attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. Keep all follow-up visits with your healthcare provider as scheduled. Call your healthcare provider between visits as needed, especially if you are worried about symptoms. Do not stop taking gabapentin without first talking to a healthcare provider. Stopping gabapentin suddenly can cause serious problems. Stopping a seizure medicine suddenly in a patient who has epilepsy can cause seizures that will not stop (status epilepticus). Suicidal thoughts or actions can be caused by things other than medicines. If you have suicidal thoughts or actions, your healthcare provider may check for other causes. 2. Changes in behavior and thinking - Using gabapentin in children 3 to 12 years of age can cause emotional changes, aggressive behavior, problems with concentration, restlessness, changes in school performance, and hyperactivity. What is gabapentin? Gabapentin is a prescription medicine used to treat: Pain from damaged nerves (postherpetic pain) that follows healing of shingles (a painful rash that comes after a herpes zoster infection) in adults. Partial seizures when taken together with other medicines in adults and children 3 years of age and older. Who should not take gabapentin? Do not take gabapentin if you are allergic to gabapentin or any of the other ingredients in gabapentin. See the end of this Medication Guide for a complete list of ingredients in gabapentin. What should I tell my healthcare provider before taking gabapentin? Before taking gabapentin, tell your healthcare provider if you: have or have had kidney problems or are on hemodialysis have or have had depression, mood problems, or suicidal thoughts or behavior are pregnant or plan to become pregnant. It is not known if gabapentin can harm your unborn baby. Tell your healthcare provider right away if you become pregnant while taking gabapentin. You and your healthcare provider will decide if you should take gabapentin while you are pregnant. If you become pregnant while taking gabapentin, talk to your healthcare provider about registering with the North American Antiepileptic Drug (NAAED) Pregnancy Registry. The purpose of this registry is to collect information about the safety of antiepileptic drugs during pregnancy. You can enroll in this registry by calling 1-888-233-2334. are breastfeeding or plan to breastfeed. Gabapentin can pass into breast milk. You and your healthcare provider should decide how you will feed your baby while you take gabapentin. Tell your healthcare provider about all the medicines you take , including prescription and non-prescription medicines, vitamins, and herbal supplements. Taking gabapentin with certain other medicines can cause side effects or affect how well they work. Do not start or stop other medicines without talking to your healthcare provider. Know the medicines you take. Keep a list of them and show it to your healthcare provider and pharmacist when you get a new medicine. How should I take gabapentin? Take gabapentin exactly as prescribed. Your healthcare provider will tell you how much gabapentin to take. Do not change your dose of gabapentin without talking to your healthcare provider. If you break a tablet in half the unused half of the tablet should be taken at your next scheduled dose. Half tablets not used within several days of breaking should be thrown away. Gabapentin can be taken with or without food. If you take an antacid containing aluminum and magnesium, such as Maalox®, Mylanta®, Gelusil®, Gaviscon®, or Di-Gel®, you should wait at least 2 hours before taking your next dose of gabapentin. If you take too much gabapentin, call your healthcare provider or your local Poison Control Center right away. What should I avoid while taking gabapentin? Do not drink alcohol or take other medicines that make you sleepy or dizzy while taking gabapentin without first talking with your healthcare provider. Taking gabapentin with alcohol or drugs that cause sleepiness or dizziness may make your sleepiness or dizziness worse. Do not drive, operate heavy machinery, or do other dangerous activities until you know how gabapentin affects you. Gabapentin can slow your thinking and motor skills. What are the possible side effects of gabapentin? See ""What is the most important information I should know about gabapentin?"" The most common side effects of gabapentin include: dizziness lack of coordination viral infection feeling drowsy feeling tired fever jerky movements difficulty with speaking temporary loss of memory (amnesia) tremor difficulty with coordination double vision unusual eye movement Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all the possible side effects of gabapentin. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store gabapentin? Store gabapentin tablets at 20° to 25°C (68° to 77°F). [See USP controlled room temperature]. Keep gabapentin and all medicines out of the reach of children. General information about the safe and effective use of gabapentin Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use gabapentin for a condition for which it was not prescribed. Do not give gabapentin to other people, even if they have the same symptoms that you have. It may harm them. This Medication Guide summarizes the most important information about gabapentin. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider or pharmacist for information about gabapentin that was written for healthcare professionals. For more information about gabapentin tablets, or to report side effects regarding gabapentin tablets, please call Exelan Pharmaceuticals Inc. at 1-855-295-7455. What are the ingredients in gabapentin Tablets? Active ingredient: Gabapentin, USP Inactive ingredients: Mannitol, Hydroxypropyl Cellulose, Crospovidone, Talc, Magnesium Stearate and Aquarius® BP18114 Cool Vanilla." uuid:b089920a-e661-47ed-83a9-3bab7bf14f40 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:43968 biolink:treats UMLS:C1112209 PMID:41385096 "[{""id"":""uuid:83fc2eb9-bfc0-4706-9ed4-e62347952861"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:37eb5bcb-37a1-4680-8090-b59e415aa94a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Meropenem for Injection and other antibacterial drugs, Meropenem for Injection should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Meropenem for Injection is useful as presumptive therapy in the indicated condition (e.g. intra-abdominal infections) prior to the identification of the causative organisms because of its broad spectrum of bactericidal activity. For information regarding use in pediatric patients see Indications and Usage (1.1) , (1.2) or (1.3) ; Dosage and Administration (2.3) , Adverse Reactions (6.1) , and Clinical Pharmacology (12.3) . uuid:b7d1b119-f1ea-46cd-af2a-54ba77965151 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135927 biolink:treats MONDO:0001627 PMID:41385096 "[{""id"":""uuid:a8f63c4e-7d27-4ce9-8890-4b4e79b998a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:21126182-e181-4054-9a45-ce5328006a13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A proportion of individuals over sixty who manifest signs and symptoms of an idiopathic decline in mental capacity (i.e., cognitive and interpersonal skills, mood, self-care, apparent motivation) can experience some symptomatic relief upon treatment with ergoloid mesylates preparations. The identity of the specific trait(s) or condition(s), if any, which would usefully predict a response to ergoloid mesylates therapy is not known. It appears, however, that those individuals who do respond come from groups of patients who would be considered clinically to suffer from some ill-defined process related to aging or to have some underlying dementing condition (i.e., primary progressive dementia, Alzheimer's dementia, senile onset, multi-infarct dementia). Before prescribing ergoloid mesylates, the physician should exclude the possibility that the patient's signs and symptoms arise from a potentially reversible and treatable condition. Particular care should be taken to exclude delirium and dementiform illness secondary to systemic disease, primary neurological disease, or primary disturbance of mood. Ergoloid mesylates preparations are not indicated in the treatment of acute or chronic psychosis, regardless of etiology (see CONTRAINDICATIONS ). The decision to use ergoloid mesylates in the treatment of an individual with a symptomatic decline in mental capacity of unknown etiology should be continually reviewed since the presenting clinical picture may subsequently evolve sufficiently to allow a specific diagnosis and a specific alternative treatment. In addition, continued clinical evaluation is required to determine whether any initial benefit conferred by ergoloid mesylates therapy persists with time. The efficacy of ergoloid mesylates was evaluated using a special rating scale known as the SCAG (Sandoz Clinical Assessment-Geriatric). The specific items on this scale on which modest but statistically significant changes were observed at the end of twelve weeks include: mental alertness, confusion, recent memory, orientation, emotional lability, self-care, depression, anxiety/fears, cooperation, sociability, appetite, dizziness, fatigue, bothersome(ness), and an overall impression of clinical status. uuid:1e04d625-6224-41ac-b1f5-643ed05eb11f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135927 biolink:treats MONDO:0004975 PMID:41385096 "[{""id"":""uuid:026ee460-9e69-499e-867a-dff99ac69738"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6d6b5416-91ed-4102-987a-163d0d0c13af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A proportion of individuals over sixty who manifest signs and symptoms of an idiopathic decline in mental capacity (i.e., cognitive and interpersonal skills, mood, self-care, apparent motivation) can experience some symptomatic relief upon treatment with ergoloid mesylates preparations. The identity of the specific trait(s) or condition(s), if any, which would usefully predict a response to ergoloid mesylates therapy is not known. It appears, however, that those individuals who do respond come from groups of patients who would be considered clinically to suffer from some ill-defined process related to aging or to have some underlying dementing condition (i.e., primary progressive dementia, Alzheimer's dementia, senile onset, multi-infarct dementia). Before prescribing ergoloid mesylates, the physician should exclude the possibility that the patient's signs and symptoms arise from a potentially reversible and treatable condition. Particular care should be taken to exclude delirium and dementiform illness secondary to systemic disease, primary neurological disease, or primary disturbance of mood. Ergoloid mesylates preparations are not indicated in the treatment of acute or chronic psychosis, regardless of etiology (see CONTRAINDICATIONS ). The decision to use ergoloid mesylates in the treatment of an individual with a symptomatic decline in mental capacity of unknown etiology should be continually reviewed since the presenting clinical picture may subsequently evolve sufficiently to allow a specific diagnosis and a specific alternative treatment. In addition, continued clinical evaluation is required to determine whether any initial benefit conferred by ergoloid mesylates therapy persists with time. The efficacy of ergoloid mesylates was evaluated using a special rating scale known as the SCAG (Sandoz Clinical Assessment-Geriatric). The specific items on this scale on which modest but statistically significant changes were observed at the end of twelve weeks include: mental alertness, confusion, recent memory, orientation, emotional lability, self-care, depression, anxiety/fears, cooperation, sociability, appetite, dizziness, fatigue, bothersome(ness), and an overall impression of clinical status. uuid:3e2e0c6a-44ad-49cf-b8e1-1c9322283348 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135927 biolink:treats MONDO:0043224 PMID:41385096 "[{""id"":""uuid:7aa4d3ca-cfcf-4012-a76e-131c30607082"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3f3d4abd-32c9-4b89-8734-c99f8e4a495c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A proportion of individuals over sixty who manifest signs and symptoms of an idiopathic decline in mental capacity (i.e., cognitive and interpersonal skills, mood, self-care, apparent motivation) can experience some symptomatic relief upon treatment with ergoloid mesylates preparations. The identity of the specific trait(s) or condition(s), if any, which would usefully predict a response to ergoloid mesylates therapy is not known. It appears, however, that those individuals who do respond come from groups of patients who would be considered clinically to suffer from some ill-defined process related to aging or to have some underlying dementing condition (i.e., primary progressive dementia, Alzheimer's dementia, senile onset, multi-infarct dementia). Before prescribing ergoloid mesylates, the physician should exclude the possibility that the patient's signs and symptoms arise from a potentially reversible and treatable condition. Particular care should be taken to exclude delirium and dementiform illness secondary to systemic disease, primary neurological disease, or primary disturbance of mood. Ergoloid mesylates preparations are not indicated in the treatment of acute or chronic psychosis, regardless of etiology (see CONTRAINDICATIONS ). The decision to use ergoloid mesylates in the treatment of an individual with a symptomatic decline in mental capacity of unknown etiology should be continually reviewed since the presenting clinical picture may subsequently evolve sufficiently to allow a specific diagnosis and a specific alternative treatment. In addition, continued clinical evaluation is required to determine whether any initial benefit conferred by ergoloid mesylates therapy persists with time. The efficacy of ergoloid mesylates was evaluated using a special rating scale known as the SCAG (Sandoz Clinical Assessment-Geriatric). The specific items on this scale on which modest but statistically significant changes were observed at the end of twelve weeks include: mental alertness, confusion, recent memory, orientation, emotional lability, self-care, depression, anxiety/fears, cooperation, sociability, appetite, dizziness, fatigue, bothersome(ness), and an overall impression of clinical status. uuid:d24461df-b235-4853-9f75-90ab8c7ac50b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135927 biolink:treats MONDO:0045057 PMID:41385096 "[{""id"":""uuid:753461e8-d5f9-4716-8c85-aea8caa87af9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dc8785e1-7b48-40ce-bfd9-948a3c47ee4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A proportion of individuals over sixty who manifest signs and symptoms of an idiopathic decline in mental capacity (i.e., cognitive and interpersonal skills, mood, self-care, apparent motivation) can experience some symptomatic relief upon treatment with ergoloid mesylates preparations. The identity of the specific trait(s) or condition(s), if any, which would usefully predict a response to ergoloid mesylates therapy is not known. It appears, however, that those individuals who do respond come from groups of patients who would be considered clinically to suffer from some ill-defined process related to aging or to have some underlying dementing condition (i.e., primary progressive dementia, Alzheimer's dementia, senile onset, multi-infarct dementia). Before prescribing ergoloid mesylates, the physician should exclude the possibility that the patient's signs and symptoms arise from a potentially reversible and treatable condition. Particular care should be taken to exclude delirium and dementiform illness secondary to systemic disease, primary neurological disease, or primary disturbance of mood. Ergoloid mesylates preparations are not indicated in the treatment of acute or chronic psychosis, regardless of etiology (see CONTRAINDICATIONS ). The decision to use ergoloid mesylates in the treatment of an individual with a symptomatic decline in mental capacity of unknown etiology should be continually reviewed since the presenting clinical picture may subsequently evolve sufficiently to allow a specific diagnosis and a specific alternative treatment. In addition, continued clinical evaluation is required to determine whether any initial benefit conferred by ergoloid mesylates therapy persists with time. The efficacy of ergoloid mesylates was evaluated using a special rating scale known as the SCAG (Sandoz Clinical Assessment-Geriatric). The specific items on this scale on which modest but statistically significant changes were observed at the end of twelve weeks include: mental alertness, confusion, recent memory, orientation, emotional lability, self-care, depression, anxiety/fears, cooperation, sociability, appetite, dizziness, fatigue, bothersome(ness), and an overall impression of clinical status. uuid:4a1cb5b7-7010-4d39-92c6-c3ca4cc3e5da biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135927 biolink:treats UMLS:C0281774 PMID:41385096 "[{""id"":""uuid:c047f897-8a50-4ba8-a9d6-895f9e0f4fe1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:08bbfa34-2f6a-4abc-a9f1-20a1d55ddaca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A proportion of individuals over sixty who manifest signs and symptoms of an idiopathic decline in mental capacity (i.e., cognitive and interpersonal skills, mood, self-care, apparent motivation) can experience some symptomatic relief upon treatment with ergoloid mesylates preparations. The identity of the specific trait(s) or condition(s), if any, which would usefully predict a response to ergoloid mesylates therapy is not known. It appears, however, that those individuals who do respond come from groups of patients who would be considered clinically to suffer from some ill-defined process related to aging or to have some underlying dementing condition (i.e., primary progressive dementia, Alzheimer's dementia, senile onset, multi-infarct dementia). Before prescribing ergoloid mesylates, the physician should exclude the possibility that the patient's signs and symptoms arise from a potentially reversible and treatable condition. Particular care should be taken to exclude delirium and dementiform illness secondary to systemic disease, primary neurological disease, or primary disturbance of mood. Ergoloid mesylates preparations are not indicated in the treatment of acute or chronic psychosis, regardless of etiology (see CONTRAINDICATIONS ). The decision to use ergoloid mesylates in the treatment of an individual with a symptomatic decline in mental capacity of unknown etiology should be continually reviewed since the presenting clinical picture may subsequently evolve sufficiently to allow a specific diagnosis and a specific alternative treatment. In addition, continued clinical evaluation is required to determine whether any initial benefit conferred by ergoloid mesylates therapy persists with time. The efficacy of ergoloid mesylates was evaluated using a special rating scale known as the SCAG (Sandoz Clinical Assessment-Geriatric). The specific items on this scale on which modest but statistically significant changes were observed at the end of twelve weeks include: mental alertness, confusion, recent memory, orientation, emotional lability, self-care, depression, anxiety/fears, cooperation, sociability, appetite, dizziness, fatigue, bothersome(ness), and an overall impression of clinical status. uuid:a905ffdd-1c1b-4194-ae4a-6e6229a66a53 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135927 biolink:treats UMLS:C0221764 PMID:41385096 "[{""id"":""uuid:df04203f-383e-4bd1-a97f-fd7cf0386ebd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c5691b6f-6abe-45b6-a8b5-c367234e8685"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A proportion of individuals over sixty who manifest signs and symptoms of an idiopathic decline in mental capacity (i.e., cognitive and interpersonal skills, mood, self-care, apparent motivation) can experience some symptomatic relief upon treatment with ergoloid mesylates preparations. The identity of the specific trait(s) or condition(s), if any, which would usefully predict a response to ergoloid mesylates therapy is not known. It appears, however, that those individuals who do respond come from groups of patients who would be considered clinically to suffer from some ill-defined process related to aging or to have some underlying dementing condition (i.e., primary progressive dementia, Alzheimer's dementia, senile onset, multi-infarct dementia). Before prescribing ergoloid mesylates, the physician should exclude the possibility that the patient's signs and symptoms arise from a potentially reversible and treatable condition. Particular care should be taken to exclude delirium and dementiform illness secondary to systemic disease, primary neurological disease, or primary disturbance of mood. Ergoloid mesylates preparations are not indicated in the treatment of acute or chronic psychosis, regardless of etiology (see CONTRAINDICATIONS ). The decision to use ergoloid mesylates in the treatment of an individual with a symptomatic decline in mental capacity of unknown etiology should be continually reviewed since the presenting clinical picture may subsequently evolve sufficiently to allow a specific diagnosis and a specific alternative treatment. In addition, continued clinical evaluation is required to determine whether any initial benefit conferred by ergoloid mesylates therapy persists with time. The efficacy of ergoloid mesylates was evaluated using a special rating scale known as the SCAG (Sandoz Clinical Assessment-Geriatric). The specific items on this scale on which modest but statistically significant changes were observed at the end of twelve weeks include: mental alertness, confusion, recent memory, orientation, emotional lability, self-care, depression, anxiety/fears, cooperation, sociability, appetite, dizziness, fatigue, bothersome(ness), and an overall impression of clinical status. uuid:fe8ce7be-787f-4800-86d1-7bd51e43ff7b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6076 biolink:treats MONDO:0005672 PMID:41385096 "[{""id"":""uuid:ff91bbd4-1e1c-4756-82fd-cd81879343c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:88b2b025-fdf5-4b32-8e44-62a0565d0e76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7d43cdbc-f5f4-4862-94ea-41e99c7ff1d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Itraconazole Capsules are indicated for the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: Blastomycosis, pulmonary and extrapulmonary Histoplasmosis, including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosis, and Aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin B therapy. Specimens for fungal cultures and other relevant laboratory studies (wet mount, histopathology, serology) should be obtained before therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, antiinfective therapy should be adjusted accordingly. Itraconazole Capsules are also indicated for the treatment of the following fungal infections in non-immunocompromised patients: Onychomycosis of the toenail, with or without fingernail involvement, due to dermatophytes (tinea unguium), and Onychomycosis of the fingernail due to dermatophytes (tinea unguium). Prior to initiating treatment, appropriate nail specimens for laboratory testing (KOH preparation, fungal culture, or nail biopsy) should be obtained to confirm the diagnosis of onychomycosis. (See CLINICAL PHARMACOLOGY: Special Populations , CONTRAINDICATIONS , WARNINGS , and ADVERSE REACTIONS: Post-marketing Experience for more information.)|[PMDA] Drug with a new route of administration indicated for treatment of fungemia, respiratory mycosis, gastrointestinal mycosis, urinary tract mycosis, fungal meningitis, esophageal candidiasis, blastomycosis, and histoplasmosis, caused by Aspergillus species, Candida species, Cryptococcus species, Blastomyces species or Histoplasma species and febrile neutropenia suspected of having fungal infections. uuid:95dee909-9aa1-4c5d-9968-75ddb5dee9d4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6076 biolink:treats MONDO:0018312 PMID:41385096 "[{""id"":""uuid:225ce367-561b-446b-8cc8-6d08ad376d17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d50909db-d60f-486d-be9f-48205aa82b45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f8d798f5-1719-4d0e-a956-3d78423d3fac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Itraconazole Capsules are indicated for the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: Blastomycosis, pulmonary and extrapulmonary Histoplasmosis, including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosis, and Aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin B therapy. Specimens for fungal cultures and other relevant laboratory studies (wet mount, histopathology, serology) should be obtained before therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, antiinfective therapy should be adjusted accordingly. Itraconazole Capsules are also indicated for the treatment of the following fungal infections in non-immunocompromised patients: Onychomycosis of the toenail, with or without fingernail involvement, due to dermatophytes (tinea unguium), and Onychomycosis of the fingernail due to dermatophytes (tinea unguium). Prior to initiating treatment, appropriate nail specimens for laboratory testing (KOH preparation, fungal culture, or nail biopsy) should be obtained to confirm the diagnosis of onychomycosis. (See CLINICAL PHARMACOLOGY: Special Populations , CONTRAINDICATIONS , WARNINGS , and ADVERSE REACTIONS: Post-marketing Experience for more information.)|[PMDA] Drug with a new route of administration indicated for treatment of fungemia, respiratory mycosis, gastrointestinal mycosis, urinary tract mycosis, fungal meningitis, esophageal candidiasis, blastomycosis, and histoplasmosis, caused by Aspergillus species, Candida species, Cryptococcus species, Blastomyces species or Histoplasma species and febrile neutropenia suspected of having fungal infections. uuid:3dd586aa-a91f-4304-b7c0-688c04232a8f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6076 biolink:treats MONDO:0005657 PMID:41385096 "[{""id"":""uuid:16f871c2-7e70-472a-bfb2-ea18c7a5a935"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9adfc856-3faf-4d20-a761-64d4d640e3d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Itraconazole Capsules are indicated for the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: Blastomycosis, pulmonary and extrapulmonary Histoplasmosis, including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosis, and Aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin B therapy. Specimens for fungal cultures and other relevant laboratory studies (wet mount, histopathology, serology) should be obtained before therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, antiinfective therapy should be adjusted accordingly. Itraconazole Capsules are also indicated for the treatment of the following fungal infections in non-immunocompromised patients: Onychomycosis of the toenail, with or without fingernail involvement, due to dermatophytes (tinea unguium), and Onychomycosis of the fingernail due to dermatophytes (tinea unguium). Prior to initiating treatment, appropriate nail specimens for laboratory testing (KOH preparation, fungal culture, or nail biopsy) should be obtained to confirm the diagnosis of onychomycosis. (See CLINICAL PHARMACOLOGY: Special Populations , CONTRAINDICATIONS , WARNINGS , and ADVERSE REACTIONS: Post-marketing Experience for more information.) uuid:5e11dfb6-5369-443a-aed8-303a1a011db0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6076 biolink:treats MONDO:0001628 PMID:41385096 "[{""id"":""uuid:ffbd3581-0acf-4a72-8561-a9f2834c8389"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9428c408-86d1-4595-a22a-f2650a5bb13f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Itraconazole Capsules are indicated for the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: Blastomycosis, pulmonary and extrapulmonary Histoplasmosis, including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosis, and Aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin B therapy. Specimens for fungal cultures and other relevant laboratory studies (wet mount, histopathology, serology) should be obtained before therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, antiinfective therapy should be adjusted accordingly. Itraconazole Capsules are also indicated for the treatment of the following fungal infections in non-immunocompromised patients: Onychomycosis of the toenail, with or without fingernail involvement, due to dermatophytes (tinea unguium), and Onychomycosis of the fingernail due to dermatophytes (tinea unguium). Prior to initiating treatment, appropriate nail specimens for laboratory testing (KOH preparation, fungal culture, or nail biopsy) should be obtained to confirm the diagnosis of onychomycosis. (See CLINICAL PHARMACOLOGY: Special Populations , CONTRAINDICATIONS , WARNINGS , and ADVERSE REACTIONS: Post-marketing Experience for more information.) uuid:ce22b90d-14b4-4d39-86ad-d8e555f87c4c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:891521 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:8cc65c8e-5207-4186-a562-04ed3702f247"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2bc43907-9e77-4608-b180-a2d472e62c83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mynephron capsule is indicated in the wasting syndrome of chronic renal failure, uremia and impaired metabolic functions of the kidney, and to maintain levels when the dietary intake of vitamins is inadequate or excretion (loss) is excessive. Mynephron is also highly effective as a stress vitamin. uuid:adf39031-5372-40ae-b03e-fb3bb48b6c33 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:891521 biolink:treats MONDO:0007008 PMID:41385096 "[{""id"":""uuid:4f6849b6-4950-4c5a-93ec-594d4514cff0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:506fbe56-38b1-4f4e-ad48-2971fa77bad2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mynephron capsule is indicated in the wasting syndrome of chronic renal failure, uremia and impaired metabolic functions of the kidney, and to maintain levels when the dietary intake of vitamins is inadequate or excretion (loss) is excessive. Mynephron is also highly effective as a stress vitamin. uuid:7fbe2c9d-da69-4107-8f4d-6df91b82f4d1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:585948 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:868dda01-4318-4d5b-a59b-0b62945fa799"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2c5db550-2cd3-4d9f-add8-76d53e5c62f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Felodipine extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including felodipine. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Felodipine extended-release tablets may be administered with other antihypertensive agents. uuid:2beae160-db3f-4843-b17f-5bda92618777 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:585948 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:bbf2094c-2986-4afc-a8ad-b39fcca0037d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7018f94e-e1ff-4c9f-9866-cb7f9c900d67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Felodipine extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including felodipine. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Felodipine extended-release tablets may be administered with other antihypertensive agents. uuid:ce2a1e88-d60b-444b-81de-30d910df5043 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:585948 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:df9cfe45-1e1b-4091-90fb-2f59cf04ef5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5f265c56-2f1c-4adb-8c9a-bab01828e82c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Felodipine extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including felodipine. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Felodipine extended-release tablets may be administered with other antihypertensive agents. uuid:743ca85e-46aa-4a23-a17c-23bc0583b9b9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:585948 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:0317672b-c170-4f96-8c58-659755baeded"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6c0145e8-6568-41b8-959e-689b41bea0a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Felodipine extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including felodipine. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Felodipine extended-release tablets may be administered with other antihypertensive agents. uuid:06e0efec-e28b-499b-bb58-0bf95db6c8b1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9086 biolink:treats MONDO:0005180 PMID:41385096 "[{""id"":""uuid:c7938295-be5a-4ff0-bf8b-97401f9f2393"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9af6a4ad-aa6e-4982-aa34-52067de62c71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3f5b087b-ce11-48bd-89cb-50cc7907a07a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Selegiline is indicated as an adjunct in the management of Parkinsonian patients being treated with levodopa/carbidopa who exhibit deterioration in the quality of their response to this therapy. There is no evidence from controlled studies that selegiline has any beneficial effect in the absence of concurrent levodopa therapy. Evidence supporting this claim was obtained in randomized controlled clinical investigations that compared the effects of added selegiline or placebo in patients receiving levodopa/carbidopa. Selegiline was significantly superior to placebo on all three principal outcome measures employed: change from baseline in daily levodopa/carbidopa dose, the amount of ‘off’ time, and patient self-rating of treatment success. Beneficial effects were also observed on other measures of treatment success (e.g., measures of reduced end of dose akinesia, decreased tremor and sialorrhea, improved speech and dressing ability and improved overall disability as assessed by walking and comparison to previous state).|[PMDA] A drug with a revised indication and a new dosage for the treatment of Parkinson's disease (When used in combination with levodopa-containing products; patients are classified as Stage I to IV on the Hoehn and Yahr scale, and when not used in combination with levodopa-containing products; patients are classified as Stage I to III on the Hoehn and Yahr scale). uuid:430af48e-26a4-4483-81b7-04db3e0bd24c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9086 biolink:treats HP:0001337 PMID:41385096 "[{""id"":""uuid:aa527a92-7e7d-4342-8422-129228bc6920"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d8a49ae6-7923-49a1-bcab-27d31055b3eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Selegiline is indicated as an adjunct in the management of Parkinsonian patients being treated with levodopa/carbidopa who exhibit deterioration in the quality of their response to this therapy. There is no evidence from controlled studies that selegiline has any beneficial effect in the absence of concurrent levodopa therapy. Evidence supporting this claim was obtained in randomized controlled clinical investigations that compared the effects of added selegiline or placebo in patients receiving levodopa/carbidopa. Selegiline was significantly superior to placebo on all three principal outcome measures employed: change from baseline in daily levodopa/carbidopa dose, the amount of ‘off’ time, and patient self-rating of treatment success. Beneficial effects were also observed on other measures of treatment success (e.g., measures of reduced end of dose akinesia, decreased tremor and sialorrhea, improved speech and dressing ability and improved overall disability as assessed by walking and comparison to previous state). uuid:0b6325c2-84b1-4c81-86ac-609b3e317478 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9086 biolink:treats HP:0002307 PMID:41385096 "[{""id"":""uuid:9f2080f3-6408-4cd6-a4e5-1cef11edd5de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:93340dee-99a3-43df-a258-0e628726279d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Selegiline is indicated as an adjunct in the management of Parkinsonian patients being treated with levodopa/carbidopa who exhibit deterioration in the quality of their response to this therapy. There is no evidence from controlled studies that selegiline has any beneficial effect in the absence of concurrent levodopa therapy. Evidence supporting this claim was obtained in randomized controlled clinical investigations that compared the effects of added selegiline or placebo in patients receiving levodopa/carbidopa. Selegiline was significantly superior to placebo on all three principal outcome measures employed: change from baseline in daily levodopa/carbidopa dose, the amount of ‘off’ time, and patient self-rating of treatment success. Beneficial effects were also observed on other measures of treatment success (e.g., measures of reduced end of dose akinesia, decreased tremor and sialorrhea, improved speech and dressing ability and improved overall disability as assessed by walking and comparison to previous state). uuid:1c8d4427-f2f4-4b41-aa00-fe2f6009dc75 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:30769 biolink:treats MONDO:0008629 PMID:41385096 "[{""id"":""uuid:485dbf7c-2bda-4258-be5e-e59dfd1e47e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:226f222b-afbf-4e83-901a-0f0989507779"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CYTRA-K CRYSTALS is an effective alkalinizing agent useful in those conditions where long-term maintenance of an alkaline urine is desirable, such as in patients with uric acid and cystine calculi of the urinary tract, especially when the administration of sodium salts is undesirable or contraindicated. In addition, it is a valuable adjuvant when administered with uricosuric agents in gout therapy, since urates tend to crystallize out of an acid urine. It is also effective in correcting the acidosis of certain renal tubular disorders where the administration of potassium citrate may be preferable. CYTRA-K CRYSTALS is highly concentrated, and when administered after meals and before bedtime, allows one to maintain an alkaline urinary pH around the clock, usually without the necessity of a 2 A.M. dose. CYTRA-K CRYSTALS alkalinizes the urine without producing a systemic alkalosis in recommended dosage. It is highly palatable, pleasant tasting, and tolerable, even when administered for long periods. Potassium citrate does not neutralize the gastric juice or disturb digestion. uuid:825bb8e7-0779-47b7-80e8-7e9d4c128bfb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:30769 biolink:treats EFO:0010826 PMID:41385096 "[{""id"":""uuid:8f5f8bf5-0d9a-4d86-bfed-16c3c42d42b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8242a834-35bb-4425-b268-da242ff24222"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CYTRA-K CRYSTALS is an effective alkalinizing agent useful in those conditions where long-term maintenance of an alkaline urine is desirable, such as in patients with uric acid and cystine calculi of the urinary tract, especially when the administration of sodium salts is undesirable or contraindicated. In addition, it is a valuable adjuvant when administered with uricosuric agents in gout therapy, since urates tend to crystallize out of an acid urine. It is also effective in correcting the acidosis of certain renal tubular disorders where the administration of potassium citrate may be preferable. CYTRA-K CRYSTALS is highly concentrated, and when administered after meals and before bedtime, allows one to maintain an alkaline urinary pH around the clock, usually without the necessity of a 2 A.M. dose. CYTRA-K CRYSTALS alkalinizes the urine without producing a systemic alkalosis in recommended dosage. It is highly palatable, pleasant tasting, and tolerable, even when administered for long periods. Potassium citrate does not neutralize the gastric juice or disturb digestion. uuid:ea79af4d-29c2-4402-96df-d651997de0b7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:30769 biolink:treats MONDO:0005393 PMID:41385096 "[{""id"":""uuid:afa296ea-fb9c-4048-a5dd-a66717dcefd4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:68b9c4d8-5994-4606-9dd5-350a40a84141"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CYTRA-K CRYSTALS is an effective alkalinizing agent useful in those conditions where long-term maintenance of an alkaline urine is desirable, such as in patients with uric acid and cystine calculi of the urinary tract, especially when the administration of sodium salts is undesirable or contraindicated. In addition, it is a valuable adjuvant when administered with uricosuric agents in gout therapy, since urates tend to crystallize out of an acid urine. It is also effective in correcting the acidosis of certain renal tubular disorders where the administration of potassium citrate may be preferable. CYTRA-K CRYSTALS is highly concentrated, and when administered after meals and before bedtime, allows one to maintain an alkaline urinary pH around the clock, usually without the necessity of a 2 A.M. dose. CYTRA-K CRYSTALS alkalinizes the urine without producing a systemic alkalosis in recommended dosage. It is highly palatable, pleasant tasting, and tolerable, even when administered for long periods. Potassium citrate does not neutralize the gastric juice or disturb digestion. uuid:779c16fe-c3ff-4e85-984d-86a128a7f722 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:30769 biolink:treats MONDO:0001909 PMID:41385096 "[{""id"":""uuid:93878547-3dc4-4277-8612-ab5e75e3221b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0c9d78b8-4501-4f7c-bbc9-c7aa0410718c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CYTRA-K CRYSTALS is an effective alkalinizing agent useful in those conditions where long-term maintenance of an alkaline urine is desirable, such as in patients with uric acid and cystine calculi of the urinary tract, especially when the administration of sodium salts is undesirable or contraindicated. In addition, it is a valuable adjuvant when administered with uricosuric agents in gout therapy, since urates tend to crystallize out of an acid urine. It is also effective in correcting the acidosis of certain renal tubular disorders where the administration of potassium citrate may be preferable. CYTRA-K CRYSTALS is highly concentrated, and when administered after meals and before bedtime, allows one to maintain an alkaline urinary pH around the clock, usually without the necessity of a 2 A.M. dose. CYTRA-K CRYSTALS alkalinizes the urine without producing a systemic alkalosis in recommended dosage. It is highly palatable, pleasant tasting, and tolerable, even when administered for long periods. Potassium citrate does not neutralize the gastric juice or disturb digestion. uuid:54f9f00d-7e24-433b-9d7c-d2c51894d386 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2453 biolink:treats MONDO:0004609 PMID:41385096 "[{""id"":""uuid:0a2eb671-1a96-40c8-bc8e-4ae981705111"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e821694a-24de-451c-892a-47a231b61e85"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:47c768ae-cec7-4461-8ded-b801c28fac93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Adult Patients Cold Sores (Herpes Labialis) Valacyclovir tablets, USP are indicated for treatment of cold sores (herpes labialis). The efficacy of valacyclovir tablets, USP initiated after the development of clinical signs of a cold sore (e.g., papule, vesicle, or ulcer) has not been established. Genital Herpes Initial Episode Valacyclovir tablets, USP are indicated for treatment of the initial episode of genital herpes in immunocompetent adults. The efficacy of treatment with valacyclovir tablets, USP when initiated more than 72 hours after the onset of signs and symptoms has not been established. Recurrent Episodes Valacyclovir tablets, USP are indicated for treatment of recurrent episodes of genital herpes in immunocompetent adults. The efficacy of treatment with valacyclovir tablets, USP when initiated more than 24 hours after the onset of signs and symptoms has not been established. Suppressive Therapy Valacyclovir tablets, USP are indicated for chronic suppressive therapy of recurrent episodes of genital herpes in immunocompetent and in HIV-infected adults. The efficacy and safety of valacyclovir tablets, USP for the suppression of genital herpes beyond 1 year in immunocompetent patients and beyond 6 months in HIV-infected patients have not been established. Reduction of Transmission Valacyclovir tablets, USP are indicated for the reduction of transmission of genital herpes in immunocompetent adults. The efficacy of valacyclovir tablets, USP for the reduction of transmission of genital herpes beyond 8 months in discordant couples has not been established. The efficacy of valacyclovir tablets, USP for the reduction of transmission of genital herpes in individuals with multiple partners and non-heterosexual couples has not been established. Safer sex practices should be used with suppressive therapy (see current Centers for Disease Control and Prevention [CDC] Sexually Transmitted Diseases Treatment Guidelines). Herpes Zoster Valacyclovir tablets, USP are indicated for the treatment of herpes zoster (shingles) in immunocompetent adults. The efficacy of valacyclovir tablets, USP when initiated more than 72 hours after the onset of rash and the efficacy and safety of valacyclovir tablets, USP for treatment of disseminated herpes zoster have not been established. 1.2 Pediatric Patients Cold Sores (Herpes Labialis) Valacyclovir tablets, USP are indicated for the treatment of cold sores (herpes labialis) in pediatric patients ≥12 years of age. The efficacy of valacyclovir tablets, USP initiated after the development of clinical signs of a cold sore (e.g., papule, vesicle, or ulcer) has not been established. Chickenpox Valacyclovir tablets, USP is indicated for the treatment of chickenpox in immunocompetent pediatric patients 2 to < 18 years of age. Based on efficacy data from clinical studies with oral acyclovir, treatment with valacyclovir tablets, USP should be initiated within 24 hours after the onset of rash [see Clinical Studies (14.4)] 1.3 Limitations of Use The efficacy and safety of valacyclovir tablets, USP have not been established in: Immunocompromised patients other than for the suppression of genital herpes in HIV-infected patients with a CD4+ cell count ≥100 cells/mm 3. Patients <12 years of age with cold sores (herpes labialis). Patients <2 years of age or ≥ 18 years of age with chickenpox. Patients <18 years of age with genital herpes. Patients <18 years of age with herpes zoster. Neonates and infants as suppressive therapy following neonatal herpes simplex virus (HSV) infection.|[PMDA] Drugs with new additional indications and a new additional dosage for herpes simplex, prevention of herpes simplex virus infection in hematopoietic stem cell transplantation, herpes zoster, and prevention of recurrence of genital herpes (oral dosage form), and neonatal herpes simplex virus infection (injectable dosage form) based on the discussion of the Investigational Committee on Pediatric Drug Therapies. uuid:53d62d41-668e-44de-b1fc-ed647c4c28b8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31355 biolink:treats UMLS:C5237199 PMID:41385096 "[{""id"":""uuid:4ef67a06-c914-4d37-b2e2-60013e216933"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0dcfb505-0f89-4538-a4e3-c46964660c44"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Initial Treatment of Advanced Ovarian Carcinoma Carboplatin injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. One established combination regimen consists of carboplatin injection and cyclophosphamide. Two randomized controlled studies conducted by the NCIC and SWOG with carboplatin, USP vs. cisplatin, both in combination with cyclophosphamide, have demonstrated equivalent overall survival between the two groups (see CLINICAL STUDIES ). There is limited statistical power to demonstrate equivalence in overall pathologic complete response rates and long term survival (≥ 3 years) because of the small number of patients with these outcomes: the small number of patients with residual tumor < 2 cm after initial surgery also limits the statistical power to demonstrate equivalence in this subgroup. Secondary Treatment of Advanced Ovarian Carcinoma Carboplatin injection is indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with cisplatin. Within the group of patients previously treated with cisplatin, those who have developed progressive disease while receiving cisplatin therapy may have a decreased response rate. uuid:b40fbfb4-b6f6-4a70-97f9-5c2024ba0dbe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31355 biolink:treats MONDO:0005140 PMID:41385096 "[{""id"":""uuid:4a627af9-f849-4d94-886d-1f241b0f8fa4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f8d794be-b91f-4dec-8a47-f603b206bc1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Initial Treatment of Advanced Ovarian Carcinoma Carboplatin injection is indicated for the initial treatment of advanced ovarian carcinoma in established combination with other approved chemotherapeutic agents. One established combination regimen consists of carboplatin injection and cyclophosphamide. Two randomized controlled studies conducted by the NCIC and SWOG with carboplatin, USP vs. cisplatin, both in combination with cyclophosphamide, have demonstrated equivalent overall survival between the two groups (see CLINICAL STUDIES ). There is limited statistical power to demonstrate equivalence in overall pathologic complete response rates and long term survival (≥ 3 years) because of the small number of patients with these outcomes: the small number of patients with residual tumor < 2 cm after initial surgery also limits the statistical power to demonstrate equivalence in this subgroup. Secondary Treatment of Advanced Ovarian Carcinoma Carboplatin injection is indicated for the palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy, including patients who have been previously treated with cisplatin. Within the group of patients previously treated with cisplatin, those who have developed progressive disease while receiving cisplatin therapy may have a decreased response rate. uuid:38e2c182-2c9d-4e1e-a756-c7439d16ed07 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45863 biolink:treats MONDO:0008170 PMID:41385096 "[{""id"":""uuid:187ef586-438d-4af7-9192-a1d2d3b97035"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3bff54c9-163b-43c2-808a-a208b224d0e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7bbd1499-0f08-46b0-a61d-cae0f4f1399c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Paclitaxel Injection, USP is indicated as subsequent therapy for the treatment of advanced carcinoma of the ovary. As first-line therapy, paclitaxel is indicated in combination with cisplatin. Paclitaxel is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy. In the clinical trial, there was an overall favorable effect on disease-free and overall survival in the total population of patients with receptor-positive and receptor-negative tumors, but the benefit has been specifically demonstrated by available data (median follow-up 30 months) only in the patients with estrogen and progesterone receptornegative tumors. (See CLINICAL STUDIES: Breast Carcinoma. ) Paclitaxel Injection, USP is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. Paclitaxel, in combination with cisplatin, is indicated for the first-line treatment of nonsmall cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy. Paclitaxel is indicated for the second-line treatment of AIDS-related Kaposi’s sarcoma.|[PMDA] Drugs with new additional indications and new dosages for the treatment of relapsed or metastatic head and neck cancer, relapsed or metastatic esophagus cancer, angiosarcoma, advanced or relapsed cervical cancer. A new dosage for once- weekly administration for ovarian cancer has also been added. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:9e8765a6-6587-490f-b17e-b53e5a1a0ba2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45863 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:e76367cb-8ed1-42e4-a0bf-e5cd408fc47a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:72f4b64a-3876-40fa-8b8e-816fd93b5d90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1aae420b-b01e-4782-89c0-3f0b1d85e2ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Paclitaxel Injection, USP is indicated as subsequent therapy for the treatment of advanced carcinoma of the ovary. As first-line therapy, paclitaxel is indicated in combination with cisplatin. Paclitaxel is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy. In the clinical trial, there was an overall favorable effect on disease-free and overall survival in the total population of patients with receptor-positive and receptor-negative tumors, but the benefit has been specifically demonstrated by available data (median follow-up 30 months) only in the patients with estrogen and progesterone receptornegative tumors. (See CLINICAL STUDIES: Breast Carcinoma. ) Paclitaxel Injection, USP is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. Paclitaxel, in combination with cisplatin, is indicated for the first-line treatment of nonsmall cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy. Paclitaxel is indicated for the second-line treatment of AIDS-related Kaposi’s sarcoma.|[PMDA] A drug in a new dosage form and with a new dosage indicated for the treatment of breast cancer. uuid:15ad2fda-e035-4ddb-96a2-a0f9ccf24ff5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45863 biolink:treats MONDO:0024880 PMID:41385096 "[{""id"":""uuid:3bb6cd19-82ab-4e61-bcf1-88a2392331a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b4b48b9a-5be5-4070-9f1b-a16eb592c4f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Paclitaxel Injection, USP is indicated as subsequent therapy for the treatment of advanced carcinoma of the ovary. As first-line therapy, paclitaxel is indicated in combination with cisplatin. Paclitaxel is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy. In the clinical trial, there was an overall favorable effect on disease-free and overall survival in the total population of patients with receptor-positive and receptor-negative tumors, but the benefit has been specifically demonstrated by available data (median follow-up 30 months) only in the patients with estrogen and progesterone receptornegative tumors. (See CLINICAL STUDIES: Breast Carcinoma. ) Paclitaxel Injection, USP is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. Paclitaxel, in combination with cisplatin, is indicated for the first-line treatment of nonsmall cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy. Paclitaxel is indicated for the second-line treatment of AIDS-related Kaposi’s sarcoma. uuid:13f35431-e308-41db-ad9b-f536db744d8b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45863 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:22efa1bc-5e5a-4ae6-9100-a41d845d50b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:68a023ba-ca29-4aaa-a5a6-ec75cec8e743"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7e7f3ce7-049b-4394-a4b7-29cb4ef162a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/apealea""]},{""id"":""uuid:074eedea-ec40-4b54-8a32-6361cd7a0050"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Paclitaxel Injection, USP is indicated as subsequent therapy for the treatment of advanced carcinoma of the ovary. As first-line therapy, paclitaxel is indicated in combination with cisplatin. Paclitaxel is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy. In the clinical trial, there was an overall favorable effect on disease-free and overall survival in the total population of patients with receptor-positive and receptor-negative tumors, but the benefit has been specifically demonstrated by available data (median follow-up 30 months) only in the patients with estrogen and progesterone receptornegative tumors. (See CLINICAL STUDIES: Breast Carcinoma. ) Paclitaxel Injection, USP is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. Paclitaxel, in combination with cisplatin, is indicated for the first-line treatment of nonsmall cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy. Paclitaxel is indicated for the second-line treatment of AIDS-related Kaposi’s sarcoma.|[EMA] Abraxane monotherapy is indicated for the treatment of metastatic breast cancer in adult patients who have failed first-line treatment for metastatic disease and for whom standard, anthracycline containing therapy is not indicated.Abraxane in combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas.Abraxane in combination with carboplatin is indicated for the first-line treatment of non-small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy.|[PMDA] A drug with new additional indications and a new dosage for the treatment of gastric cancer and non-small cell lung cancer. uuid:5a2414f6-c1ea-4cfd-831d-e6051933cac9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45863 biolink:treats MONDO:0005055 PMID:41385096 "[{""id"":""uuid:f02a5082-e906-448e-88e6-519d1c03c89d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e43bc161-007f-42fa-9d31-0b69f6647573"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Paclitaxel Injection, USP is indicated as subsequent therapy for the treatment of advanced carcinoma of the ovary. As first-line therapy, paclitaxel is indicated in combination with cisplatin. Paclitaxel is indicated for the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination chemotherapy. In the clinical trial, there was an overall favorable effect on disease-free and overall survival in the total population of patients with receptor-positive and receptor-negative tumors, but the benefit has been specifically demonstrated by available data (median follow-up 30 months) only in the patients with estrogen and progesterone receptornegative tumors. (See CLINICAL STUDIES: Breast Carcinoma. ) Paclitaxel Injection, USP is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. Paclitaxel, in combination with cisplatin, is indicated for the first-line treatment of nonsmall cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy. Paclitaxel is indicated for the second-line treatment of AIDS-related Kaposi’s sarcoma. uuid:93c691cb-22e5-495d-8001-cc838b0eda4e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0020920 PMID:41385096 "[{""id"":""uuid:eb3cbb15-b3ba-4e4c-9bc4-3a56adbe7759"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:abb8f389-9ee2-41cb-948f-d7c6098e55cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Demeclocycline hydrochloride tablets USP is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by Mycoplasma pneumoniae ; Lymphogranuloma venereum due to Chlamydia trachomatis ; Psittacosis (Ornithosis) due to Chlamydia psittaci ; Trachoma due to Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by Chlamydia trachomatis ; Nongonococcal urethritis in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis ; Relapsing fever due to Borrelia recurrentis ; Chancroid caused by Haemophilus ducreyi ; Plague due to Yersinia pestis ; Tularemia due to Francisella tularensis ; Cholera caused by Vibrio cholerae ; Campylobacter fetus infections caused by Campylobacter fetus ; Brucellosis due to Brucella species (in conjunction with streptomycin); Bartonellosis due to Bartonella bacilliformis ; Granuloma inguinale caused by Calymmatobacterium granulomatis ; Demeclocycline hydrochloride tablets USP is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli ; Enterobacter aerogenes ; Shigella species; Acinetobacter species; Respiratory tract infections caused by Haemophilus influenzae ; Respiratory tract and urinary tract infections caused by Klebsiella species. Demeclocycline hydrochloride tablets USP is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae; Skin and skin structure infections caused by Staphylococcus aureus . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by Neisseria gonorrhoeae ; Syphilis caused by Treponema pallidum subspecies pallidum ; Yaws caused by Treponema pallidum subspecies pertenue ; Listeriosis due to Listeria monocytogenes ; Anthrax due to Bacillus anthracis ; Vincent’s infection caused by Fusobacterium fusiforme ; Actinomycosis caused by Actinomyces israelii ; Clostridial diseases caused by Clostridium species. In acute intestinal amebiasis, demeclocycline hydrochloride tablets USP may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride tablets USP may be a useful adjunctive therapy. To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets USP and other antibacterial drugs, demeclocycline hydrochloride tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:3b7eea4f-102c-4bf2-a38c-91c96144ae2e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0019345 PMID:41385096 "[{""id"":""uuid:a556c620-9f97-4c5c-bc1e-2eaa806ab412"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d38021c0-9081-4e1e-9112-f6d0241ac47e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Demeclocycline hydrochloride tablets USP is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by Mycoplasma pneumoniae ; Lymphogranuloma venereum due to Chlamydia trachomatis ; Psittacosis (Ornithosis) due to Chlamydia psittaci ; Trachoma due to Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by Chlamydia trachomatis ; Nongonococcal urethritis in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis ; Relapsing fever due to Borrelia recurrentis ; Chancroid caused by Haemophilus ducreyi ; Plague due to Yersinia pestis ; Tularemia due to Francisella tularensis ; Cholera caused by Vibrio cholerae ; Campylobacter fetus infections caused by Campylobacter fetus ; Brucellosis due to Brucella species (in conjunction with streptomycin); Bartonellosis due to Bartonella bacilliformis ; Granuloma inguinale caused by Calymmatobacterium granulomatis ; Demeclocycline hydrochloride tablets USP is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli ; Enterobacter aerogenes ; Shigella species; Acinetobacter species; Respiratory tract infections caused by Haemophilus influenzae ; Respiratory tract and urinary tract infections caused by Klebsiella species. Demeclocycline hydrochloride tablets USP is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae; Skin and skin structure infections caused by Staphylococcus aureus . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by Neisseria gonorrhoeae ; Syphilis caused by Treponema pallidum subspecies pallidum ; Yaws caused by Treponema pallidum subspecies pertenue ; Listeriosis due to Listeria monocytogenes ; Anthrax due to Bacillus anthracis ; Vincent’s infection caused by Fusobacterium fusiforme ; Actinomycosis caused by Actinomyces israelii ; Clostridial diseases caused by Clostridium species. In acute intestinal amebiasis, demeclocycline hydrochloride tablets USP may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride tablets USP may be a useful adjunctive therapy. To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets USP and other antibacterial drugs, demeclocycline hydrochloride tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:694349dc-3c00-49ac-9496-4b2d7e0bd0c3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0006635 PMID:41385096 "[{""id"":""uuid:2325c73c-b98a-4bb1-8c98-30fffd23fb47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:55c0e4a2-d811-45dd-b3c9-8a696dbfdeac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Demeclocycline hydrochloride tablets USP is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by Mycoplasma pneumoniae ; Lymphogranuloma venereum due to Chlamydia trachomatis ; Psittacosis (Ornithosis) due to Chlamydia psittaci ; Trachoma due to Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by Chlamydia trachomatis ; Nongonococcal urethritis in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis ; Relapsing fever due to Borrelia recurrentis ; Chancroid caused by Haemophilus ducreyi ; Plague due to Yersinia pestis ; Tularemia due to Francisella tularensis ; Cholera caused by Vibrio cholerae ; Campylobacter fetus infections caused by Campylobacter fetus ; Brucellosis due to Brucella species (in conjunction with streptomycin); Bartonellosis due to Bartonella bacilliformis ; Granuloma inguinale caused by Calymmatobacterium granulomatis ; Demeclocycline hydrochloride tablets USP is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli ; Enterobacter aerogenes ; Shigella species; Acinetobacter species; Respiratory tract infections caused by Haemophilus influenzae ; Respiratory tract and urinary tract infections caused by Klebsiella species. Demeclocycline hydrochloride tablets USP is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae; Skin and skin structure infections caused by Staphylococcus aureus . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by Neisseria gonorrhoeae ; Syphilis caused by Treponema pallidum subspecies pallidum ; Yaws caused by Treponema pallidum subspecies pertenue ; Listeriosis due to Listeria monocytogenes ; Anthrax due to Bacillus anthracis ; Vincent’s infection caused by Fusobacterium fusiforme ; Actinomycosis caused by Actinomyces israelii ; Clostridial diseases caused by Clostridium species. In acute intestinal amebiasis, demeclocycline hydrochloride tablets USP may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride tablets USP may be a useful adjunctive therapy. To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets USP and other antibacterial drugs, demeclocycline hydrochloride tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:176e712c-48bb-49bd-bc96-8ecec78246f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats HP:0005376 PMID:41385096 "[{""id"":""uuid:a9c7772f-2a36-4f58-9da9-337db2033d89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:51f3b09f-87b0-4bc9-8397-50a0cd5ac735"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Demeclocycline hydrochloride tablets USP is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by Mycoplasma pneumoniae ; Lymphogranuloma venereum due to Chlamydia trachomatis ; Psittacosis (Ornithosis) due to Chlamydia psittaci ; Trachoma due to Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by Chlamydia trachomatis ; Nongonococcal urethritis in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis ; Relapsing fever due to Borrelia recurrentis ; Chancroid caused by Haemophilus ducreyi ; Plague due to Yersinia pestis ; Tularemia due to Francisella tularensis ; Cholera caused by Vibrio cholerae ; Campylobacter fetus infections caused by Campylobacter fetus ; Brucellosis due to Brucella species (in conjunction with streptomycin); Bartonellosis due to Bartonella bacilliformis ; Granuloma inguinale caused by Calymmatobacterium granulomatis ; Demeclocycline hydrochloride tablets USP is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli ; Enterobacter aerogenes ; Shigella species; Acinetobacter species; Respiratory tract infections caused by Haemophilus influenzae ; Respiratory tract and urinary tract infections caused by Klebsiella species. Demeclocycline hydrochloride tablets USP is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae; Skin and skin structure infections caused by Staphylococcus aureus . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by Neisseria gonorrhoeae ; Syphilis caused by Treponema pallidum subspecies pallidum ; Yaws caused by Treponema pallidum subspecies pertenue ; Listeriosis due to Listeria monocytogenes ; Anthrax due to Bacillus anthracis ; Vincent’s infection caused by Fusobacterium fusiforme ; Actinomycosis caused by Actinomyces israelii ; Clostridial diseases caused by Clostridium species. In acute intestinal amebiasis, demeclocycline hydrochloride tablets USP may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride tablets USP may be a useful adjunctive therapy. To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets USP and other antibacterial drugs, demeclocycline hydrochloride tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:e0e78b65-7e45-4f4f-b146-d90d303698e4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4392 biolink:treats MONDO:0030603 PMID:41385096 "[{""id"":""uuid:eaa5cb0f-04de-4d57-bbdb-15900d6e5bee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:58d4ccdc-54c1-4ce4-bdc7-dca3e95c28e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Demeclocycline hydrochloride tablets USP is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions below: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox, and tick fevers caused by rickettsiae; Respiratory tract infections caused by Mycoplasma pneumoniae ; Lymphogranuloma venereum due to Chlamydia trachomatis ; Psittacosis (Ornithosis) due to Chlamydia psittaci ; Trachoma due to Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence; Inclusion conjunctivitis caused by Chlamydia trachomatis ; Nongonococcal urethritis in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis ; Relapsing fever due to Borrelia recurrentis ; Chancroid caused by Haemophilus ducreyi ; Plague due to Yersinia pestis ; Tularemia due to Francisella tularensis ; Cholera caused by Vibrio cholerae ; Campylobacter fetus infections caused by Campylobacter fetus ; Brucellosis due to Brucella species (in conjunction with streptomycin); Bartonellosis due to Bartonella bacilliformis ; Granuloma inguinale caused by Calymmatobacterium granulomatis ; Demeclocycline hydrochloride tablets USP is indicated for treatment of infections caused by the following gram-negative microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli ; Enterobacter aerogenes ; Shigella species; Acinetobacter species; Respiratory tract infections caused by Haemophilus influenzae ; Respiratory tract and urinary tract infections caused by Klebsiella species. Demeclocycline hydrochloride tablets USP is indicated for treatment of infections caused by the following gram-positive microorganisms, when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory infections caused by Streptococcus pneumoniae; Skin and skin structure infections caused by Staphylococcus aureus . (Note: Tetracyclines, including demeclocycline, are not the drugs of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, tetracyclines, including demeclocycline hydrochloride, are alternative drugs in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae , and for the treatment of other uncomplicated gonococcal infections; Infections in women caused by Neisseria gonorrhoeae ; Syphilis caused by Treponema pallidum subspecies pallidum ; Yaws caused by Treponema pallidum subspecies pertenue ; Listeriosis due to Listeria monocytogenes ; Anthrax due to Bacillus anthracis ; Vincent’s infection caused by Fusobacterium fusiforme ; Actinomycosis caused by Actinomyces israelii ; Clostridial diseases caused by Clostridium species. In acute intestinal amebiasis, demeclocycline hydrochloride tablets USP may be a useful adjunct to amebicides. In severe acne, demeclocycline hydrochloride tablets USP may be a useful adjunctive therapy. To reduce the development of drug-resistant bacteria and maintain the effectiveness of demeclocycline hydrochloride tablets USP and other antibacterial drugs, demeclocycline hydrochloride tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:2cb63a5e-98b5-4745-b37e-1e71ccb9dd54 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5959 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:375e7371-66b8-4e37-bd78-3b9ff4f2dc38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bee017ea-eb6b-4b41-81f2-dfe668927cbf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Irbesartan is an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) • Treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes, an elevated serum creatinine, and proteinuria. ( 1.2 ) uuid:c17990f9-0cb6-490b-bd3c-52c264e676b6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:187893 biolink:treats HP:0001257 PMID:41385096 "[{""id"":""uuid:0b828192-a2d9-4d82-acf8-7c66c5ed9dee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5f6e2bb7-ed4c-4191-8a33-5bae60c0d7cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9311ae70-c5b5-46a5-9d21-91c179ad5a87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LIORESAL INTRATHECAL (baclofen injection) is indicated for use in the management of severe spasticity. Patients should first respond to a screening dose of intrathecal baclofen prior to consideration for long term infusion via an implantable pump. For spasticity of spinal cord origin, chronic infusion of LIORESAL INTRATHECAL via an implantable pump should be reserved for patients unresponsive to oral baclofen therapy, or those who experience intolerable CNS side effects at effective doses. Patients with spasticity due to traumatic brain injury should wait at least one year after the injury before consideration of long term intrathecal baclofen therapy. LIORESAL INTRATHECAL is intended for use by the intrathecal route in single bolus test doses (via spinal catheter or lumbar puncture) and, for chronic use, only in implantable pumps approved by the FDA specifically for the administration of LIORESAL INTRATHECAL into the intrathecal space. Spasticity of Spinal Cord Origin: Evidence supporting the efficacy of LIORESAL INTRATHECAL was obtained in randomized, controlled investigations that compared the effects of either a single intrathecal dose or a three day intrathecal infusion of LIORESAL INTRATHECAL to placebo in patients with severe spasticity and spasms due to either spinal cord trauma or multiple sclerosis. LIORESAL INTRATHECAL was superior to placebo on both principal outcome measures employed: change from baseline in the Ashworth rating of spasticity and the frequency of spasms. Spasticity of Cerebral Origin: The efficacy of LIORESAL INTRATHECAL was investigated in three controlled clinical trials; two enrolled patients with cerebral palsy and one enrolled patients with spasticity due to previous brain injury. The first study, a randomized controlled cross-over trial of 51 patients with cerebral palsy, provided strong, statistically significant results; LIORESAL INTRATHECAL was superior to placebo in reducing spasticity as measured by the Ashworth Scale. A second cross-over study was conducted in 11 patients with spasticity arising from brain injury. Despite the small sample size, the study yielded a nearly significant test statistic (p=0.066) and provided directionally favorable results. The last study, however, did not provide data that could be reliably analyzed. LIORESAL INTRATHECAL therapy may be considered an alternative to destructive neurosurgical procedures. Prior to implantation of a device for chronic intrathecal infusion of LIORESAL INTRATHECAL, patients must show a response to LIORESAL INTRATHECAL in a screening trial (see Dosage and Administration).|[PMDA] Drugs with a new route of intrathecal infusion indicated for the treatment of severe spasticity resulting from cerebrospinal diseases [Orphan drug] uuid:4dd86fd7-cb5f-4999-a2d9-36d61fe0b47e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:187893 biolink:treats MONDO:0043510 PMID:41385096 "[{""id"":""uuid:4bfe45b5-67f9-47a9-97c6-f5f19aaa110c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cd2c0c37-6b54-4b7f-ba86-c02ee6cf9827"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LIORESAL INTRATHECAL (baclofen injection) is indicated for use in the management of severe spasticity. Patients should first respond to a screening dose of intrathecal baclofen prior to consideration for long term infusion via an implantable pump. For spasticity of spinal cord origin, chronic infusion of LIORESAL INTRATHECAL via an implantable pump should be reserved for patients unresponsive to oral baclofen therapy, or those who experience intolerable CNS side effects at effective doses. Patients with spasticity due to traumatic brain injury should wait at least one year after the injury before consideration of long term intrathecal baclofen therapy. LIORESAL INTRATHECAL is intended for use by the intrathecal route in single bolus test doses (via spinal catheter or lumbar puncture) and, for chronic use, only in implantable pumps approved by the FDA specifically for the administration of LIORESAL INTRATHECAL into the intrathecal space. Spasticity of Spinal Cord Origin: Evidence supporting the efficacy of LIORESAL INTRATHECAL was obtained in randomized, controlled investigations that compared the effects of either a single intrathecal dose or a three day intrathecal infusion of LIORESAL INTRATHECAL to placebo in patients with severe spasticity and spasms due to either spinal cord trauma or multiple sclerosis. LIORESAL INTRATHECAL was superior to placebo on both principal outcome measures employed: change from baseline in the Ashworth rating of spasticity and the frequency of spasms. Spasticity of Cerebral Origin: The efficacy of LIORESAL INTRATHECAL was investigated in three controlled clinical trials; two enrolled patients with cerebral palsy and one enrolled patients with spasticity due to previous brain injury. The first study, a randomized controlled cross-over trial of 51 patients with cerebral palsy, provided strong, statistically significant results; LIORESAL INTRATHECAL was superior to placebo in reducing spasticity as measured by the Ashworth Scale. A second cross-over study was conducted in 11 patients with spasticity arising from brain injury. Despite the small sample size, the study yielded a nearly significant test statistic (p=0.066) and provided directionally favorable results. The last study, however, did not provide data that could be reliably analyzed. LIORESAL INTRATHECAL therapy may be considered an alternative to destructive neurosurgical procedures. Prior to implantation of a device for chronic intrathecal infusion of LIORESAL INTRATHECAL, patients must show a response to LIORESAL INTRATHECAL in a screening trial (see Dosage and Administration). uuid:c7a8a17d-8a5e-4831-8590-c7134a0ed60d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats MONDO:0019095 PMID:41385096 "[{""id"":""uuid:5566d3d4-6afc-4012-a3f8-94002a991597"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7b096de0-ae18-4ba5-8e2d-0ed0ba61f535"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciprofloxacin is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the conditions and patient populations listed below. 1.1 Urinary Tract Infections Ciprofloxacin is indicated in adult patients for treatment of urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, Proteus mirabilis, Providencia rettgeri, Morganella morganii, Citrobacter koseri, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus epidermidis, Staphylococcus saprophyticus, or Enterococcus faecalis. 1.2 Acute Uncomplicated Cystitis Ciprofloxacin is indicated in adult female patients for treatment of acute uncomplicated cystitis caused by Escherichia coli or Staphylococcus saprophyticus. 1.3 Chronic Bacterial Prostatitis Ciprofloxacin is indicated in adult patients for treatment of chronic bacterial prostatitis caused by Escherichia coli or Proteus mirabilis. 1.4 Lower Respiratory Tract Infections Ciprofloxacin is indicated in adult patients for treatment of lower respiratory tract infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Pseudomonas aeruginosa, Haemophilus influenzae, Haemophilus parainfluenzae, or Streptococcus pneumoniae. Also, ciprofloxacin is indicated for the treatment of acute exacerbations of chronic bronchitis caused by Moraxella catarrhalis [see INDICATIONS AND USAGE (1.15)]. 1.5 Acute Sinusitis Ciprofloxacin is indicated in adult patients for treatment of acute sinusitis caused by Haemophilus influenzae, Streptococcus pneumoniae, or Moraxella catarrhalis. 1.6 Skin and Skin Structure Infections Ciprofloxacin is indicated in adult patients for treatment of skin and skin structure infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Morganella morganii, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus aureus, methicillin-susceptible Staphylococcus epidermidis, or Streptococcus pyogenes. 1.7 Bone and Joint Infections Ciprofloxacin is indicated in adult patients for treatment of bone and joint infections caused by Enterobacter cloacae, Serratia marcescens, or Pseudomonas aeruginosa. 1.8 Complicated Intra-Abdominal Infections Ciprofloxacin is indicated in adult patients for treatment of complicated intra-abdominal infections (used in combination with metronidazole) caused by Escherichia coli, Pseudomonas aeruginosa, Proteus mirabilis, Klebsiella pneumoniae, or Bacteroides fragilis. 1.9 Infectious Diarrhea Ciprofloxacin is indicated in adult patients for treatment of infectious diarrhea caused by Escherichia coli (enterotoxigenic isolates), Campylobacter jejuni, Shigella boydii † , Shigella dysenteriae, Shigella flexneri or Shigella sonnei† when antibacterial therapy is indicated. †Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients. 1.10 Typhoid Fever (Enteric Fever) Ciprofloxacin is indicated in adult patients for treatment of typhoid fever (enteric fever) caused by Salmonella typhi. The efficacy of ciprofloxacin in the eradication of the chronic typhoid carrier state has not been demonstrated. 1.11 Uncomplicated Cervical and Urethral Gonorrhea Ciprofloxacin is indicated in adult patients for treatment of uncomplicated cervical and urethral gonorrhea due to Neisseria gonorrhoeae [see WARNINGS AND PRECAUTIONS (5.16)]. 1.12 Complicated Urinary Tract Infections and Pyelonephritis Ciprofloxacin is indicated in pediatric patients one to 17 years of age for treatment of complicated urinary tract infections (cUTI) and pyelonephritis due to Escherichia coli [see INDICATIONS AND USAGE (1.15) and USE IN SPECIFIC POPULATIONS (8.4)]. 1.13 Inhalational Anthrax (post-exposure) Ciprofloxacin is indicated in adults and pediatric patients from birth to 17 years of age for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. Ciprofloxacin serum concentrations achieved in humans served as a surrogate endpoint reasonably likely to predict clinical benefit and provided the initial basis for approval of this indication.1 Supportive clinical information for ciprofloxacin for anthrax post-exposure prophylaxis was obtained during the anthrax bioterror attacks of October 2001. [See CLINICAL STUDIES (14.2).] 1.14 Plague Ciprofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients from birth to 17 years of age. Efficacy studies of ciprofloxacin could not be conducted in humans with plague for feasibility reasons. Therefore this indication is based on an efficacy study conducted in animals only [see CLINICAL STUDIES (14.3) ]. 1.15 Limitation of Use Use in Pediatric Patients Although effective in clinical trials, ciprofloxacin is not a drug of first choice in the pediatric population due to an increased incidence of adverse events compared to controls, including events related to joints and/or surrounding tissues. Ciprofloxacin, like other fluoroquinolones, is associated with arthropathy and histopathological changes in weight-bearing joints of juvenile animals [see WARNINGS AND PRECAUTIONS (5.11), ADVERSE REACTIONS (6.1), USE IN SPECIFIC POPULATIONS (8.4) and NONCLINICAL TOXICOLOGY (13.2)]. Lower Respiratory Tract Infections Ciprofloxacin is not a drug of first choice in the treatment of presumed or confirmed pneumonia secondary to Streptococcus pneumoniae [see INDICATIONS AND USAGE (1.4)]. 1.16 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of ciprofloxacin and other antibacterial drugs ciprofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. If anaerobic organisms are suspected of contributing to the infection, appropriate therapy should be administered. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. Therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available appropriate therapy should be continued. As with other drugs, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ciprofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. uuid:c7931d4c-2fcb-4733-8441-d2591e00cad4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats MONDO:0001024 PMID:41385096 "[{""id"":""uuid:54b27aca-9b5a-49d1-b995-e5bd4ccb14d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:11587e39-7563-4525-ab08-1c85ba5b1746"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciprofloxacin is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the conditions and patient populations listed below. 1.1 Urinary Tract Infections Ciprofloxacin is indicated in adult patients for treatment of urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, Proteus mirabilis, Providencia rettgeri, Morganella morganii, Citrobacter koseri, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus epidermidis, Staphylococcus saprophyticus, or Enterococcus faecalis. 1.2 Acute Uncomplicated Cystitis Ciprofloxacin is indicated in adult female patients for treatment of acute uncomplicated cystitis caused by Escherichia coli or Staphylococcus saprophyticus. 1.3 Chronic Bacterial Prostatitis Ciprofloxacin is indicated in adult patients for treatment of chronic bacterial prostatitis caused by Escherichia coli or Proteus mirabilis. 1.4 Lower Respiratory Tract Infections Ciprofloxacin is indicated in adult patients for treatment of lower respiratory tract infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Pseudomonas aeruginosa, Haemophilus influenzae, Haemophilus parainfluenzae, or Streptococcus pneumoniae. Also, ciprofloxacin is indicated for the treatment of acute exacerbations of chronic bronchitis caused by Moraxella catarrhalis [see INDICATIONS AND USAGE (1.15)]. 1.5 Acute Sinusitis Ciprofloxacin is indicated in adult patients for treatment of acute sinusitis caused by Haemophilus influenzae, Streptococcus pneumoniae, or Moraxella catarrhalis. 1.6 Skin and Skin Structure Infections Ciprofloxacin is indicated in adult patients for treatment of skin and skin structure infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Morganella morganii, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus aureus, methicillin-susceptible Staphylococcus epidermidis, or Streptococcus pyogenes. 1.7 Bone and Joint Infections Ciprofloxacin is indicated in adult patients for treatment of bone and joint infections caused by Enterobacter cloacae, Serratia marcescens, or Pseudomonas aeruginosa. 1.8 Complicated Intra-Abdominal Infections Ciprofloxacin is indicated in adult patients for treatment of complicated intra-abdominal infections (used in combination with metronidazole) caused by Escherichia coli, Pseudomonas aeruginosa, Proteus mirabilis, Klebsiella pneumoniae, or Bacteroides fragilis. 1.9 Infectious Diarrhea Ciprofloxacin is indicated in adult patients for treatment of infectious diarrhea caused by Escherichia coli (enterotoxigenic isolates), Campylobacter jejuni, Shigella boydii † , Shigella dysenteriae, Shigella flexneri or Shigella sonnei† when antibacterial therapy is indicated. †Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients. 1.10 Typhoid Fever (Enteric Fever) Ciprofloxacin is indicated in adult patients for treatment of typhoid fever (enteric fever) caused by Salmonella typhi. The efficacy of ciprofloxacin in the eradication of the chronic typhoid carrier state has not been demonstrated. 1.11 Uncomplicated Cervical and Urethral Gonorrhea Ciprofloxacin is indicated in adult patients for treatment of uncomplicated cervical and urethral gonorrhea due to Neisseria gonorrhoeae [see WARNINGS AND PRECAUTIONS (5.16)]. 1.12 Complicated Urinary Tract Infections and Pyelonephritis Ciprofloxacin is indicated in pediatric patients one to 17 years of age for treatment of complicated urinary tract infections (cUTI) and pyelonephritis due to Escherichia coli [see INDICATIONS AND USAGE (1.15) and USE IN SPECIFIC POPULATIONS (8.4)]. 1.13 Inhalational Anthrax (post-exposure) Ciprofloxacin is indicated in adults and pediatric patients from birth to 17 years of age for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. Ciprofloxacin serum concentrations achieved in humans served as a surrogate endpoint reasonably likely to predict clinical benefit and provided the initial basis for approval of this indication.1 Supportive clinical information for ciprofloxacin for anthrax post-exposure prophylaxis was obtained during the anthrax bioterror attacks of October 2001. [See CLINICAL STUDIES (14.2).] 1.14 Plague Ciprofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients from birth to 17 years of age. Efficacy studies of ciprofloxacin could not be conducted in humans with plague for feasibility reasons. Therefore this indication is based on an efficacy study conducted in animals only [see CLINICAL STUDIES (14.3) ]. 1.15 Limitation of Use Use in Pediatric Patients Although effective in clinical trials, ciprofloxacin is not a drug of first choice in the pediatric population due to an increased incidence of adverse events compared to controls, including events related to joints and/or surrounding tissues. Ciprofloxacin, like other fluoroquinolones, is associated with arthropathy and histopathological changes in weight-bearing joints of juvenile animals [see WARNINGS AND PRECAUTIONS (5.11), ADVERSE REACTIONS (6.1), USE IN SPECIFIC POPULATIONS (8.4) and NONCLINICAL TOXICOLOGY (13.2)]. Lower Respiratory Tract Infections Ciprofloxacin is not a drug of first choice in the treatment of presumed or confirmed pneumonia secondary to Streptococcus pneumoniae [see INDICATIONS AND USAGE (1.4)]. 1.16 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of ciprofloxacin and other antibacterial drugs ciprofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. If anaerobic organisms are suspected of contributing to the infection, appropriate therapy should be administered. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. Therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available appropriate therapy should be continued. As with other drugs, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ciprofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. uuid:5e152bfb-a582-4f71-aced-36b954dd6c00 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats MONDO:0005956 PMID:41385096 "[{""id"":""uuid:cf4e87db-15f3-4f07-ab73-b36639d11beb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8351ad5e-d22e-40a0-be34-dfee7abc19c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciprofloxacin is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the conditions and patient populations listed below. 1.1 Urinary Tract Infections Ciprofloxacin is indicated in adult patients for treatment of urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, Proteus mirabilis, Providencia rettgeri, Morganella morganii, Citrobacter koseri, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus epidermidis, Staphylococcus saprophyticus, or Enterococcus faecalis. 1.2 Acute Uncomplicated Cystitis Ciprofloxacin is indicated in adult female patients for treatment of acute uncomplicated cystitis caused by Escherichia coli or Staphylococcus saprophyticus. 1.3 Chronic Bacterial Prostatitis Ciprofloxacin is indicated in adult patients for treatment of chronic bacterial prostatitis caused by Escherichia coli or Proteus mirabilis. 1.4 Lower Respiratory Tract Infections Ciprofloxacin is indicated in adult patients for treatment of lower respiratory tract infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Pseudomonas aeruginosa, Haemophilus influenzae, Haemophilus parainfluenzae, or Streptococcus pneumoniae. Also, ciprofloxacin is indicated for the treatment of acute exacerbations of chronic bronchitis caused by Moraxella catarrhalis [see INDICATIONS AND USAGE (1.15)]. 1.5 Acute Sinusitis Ciprofloxacin is indicated in adult patients for treatment of acute sinusitis caused by Haemophilus influenzae, Streptococcus pneumoniae, or Moraxella catarrhalis. 1.6 Skin and Skin Structure Infections Ciprofloxacin is indicated in adult patients for treatment of skin and skin structure infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Morganella morganii, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus aureus, methicillin-susceptible Staphylococcus epidermidis, or Streptococcus pyogenes. 1.7 Bone and Joint Infections Ciprofloxacin is indicated in adult patients for treatment of bone and joint infections caused by Enterobacter cloacae, Serratia marcescens, or Pseudomonas aeruginosa. 1.8 Complicated Intra-Abdominal Infections Ciprofloxacin is indicated in adult patients for treatment of complicated intra-abdominal infections (used in combination with metronidazole) caused by Escherichia coli, Pseudomonas aeruginosa, Proteus mirabilis, Klebsiella pneumoniae, or Bacteroides fragilis. 1.9 Infectious Diarrhea Ciprofloxacin is indicated in adult patients for treatment of infectious diarrhea caused by Escherichia coli (enterotoxigenic isolates), Campylobacter jejuni, Shigella boydii † , Shigella dysenteriae, Shigella flexneri or Shigella sonnei† when antibacterial therapy is indicated. †Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients. 1.10 Typhoid Fever (Enteric Fever) Ciprofloxacin is indicated in adult patients for treatment of typhoid fever (enteric fever) caused by Salmonella typhi. The efficacy of ciprofloxacin in the eradication of the chronic typhoid carrier state has not been demonstrated. 1.11 Uncomplicated Cervical and Urethral Gonorrhea Ciprofloxacin is indicated in adult patients for treatment of uncomplicated cervical and urethral gonorrhea due to Neisseria gonorrhoeae [see WARNINGS AND PRECAUTIONS (5.16)]. 1.12 Complicated Urinary Tract Infections and Pyelonephritis Ciprofloxacin is indicated in pediatric patients one to 17 years of age for treatment of complicated urinary tract infections (cUTI) and pyelonephritis due to Escherichia coli [see INDICATIONS AND USAGE (1.15) and USE IN SPECIFIC POPULATIONS (8.4)]. 1.13 Inhalational Anthrax (post-exposure) Ciprofloxacin is indicated in adults and pediatric patients from birth to 17 years of age for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. Ciprofloxacin serum concentrations achieved in humans served as a surrogate endpoint reasonably likely to predict clinical benefit and provided the initial basis for approval of this indication.1 Supportive clinical information for ciprofloxacin for anthrax post-exposure prophylaxis was obtained during the anthrax bioterror attacks of October 2001. [See CLINICAL STUDIES (14.2).] 1.14 Plague Ciprofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients from birth to 17 years of age. Efficacy studies of ciprofloxacin could not be conducted in humans with plague for feasibility reasons. Therefore this indication is based on an efficacy study conducted in animals only [see CLINICAL STUDIES (14.3) ]. 1.15 Limitation of Use Use in Pediatric Patients Although effective in clinical trials, ciprofloxacin is not a drug of first choice in the pediatric population due to an increased incidence of adverse events compared to controls, including events related to joints and/or surrounding tissues. Ciprofloxacin, like other fluoroquinolones, is associated with arthropathy and histopathological changes in weight-bearing joints of juvenile animals [see WARNINGS AND PRECAUTIONS (5.11), ADVERSE REACTIONS (6.1), USE IN SPECIFIC POPULATIONS (8.4) and NONCLINICAL TOXICOLOGY (13.2)]. Lower Respiratory Tract Infections Ciprofloxacin is not a drug of first choice in the treatment of presumed or confirmed pneumonia secondary to Streptococcus pneumoniae [see INDICATIONS AND USAGE (1.4)]. 1.16 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of ciprofloxacin and other antibacterial drugs ciprofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. If anaerobic organisms are suspected of contributing to the infection, appropriate therapy should be administered. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. Therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available appropriate therapy should be continued. As with other drugs, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ciprofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. uuid:c6bf38f2-fa52-42a0-be13-a932ac1f562c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:35ffbbaf-85c3-4aec-8755-18d495c188dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:97ee4339-f950-43a1-b209-9e13565cff4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:36a3492f-a223-442a-ba8e-20384585e6de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciprofloxacin is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the conditions and patient populations listed below. 1.1 Urinary Tract Infections Ciprofloxacin is indicated in adult patients for treatment of urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, Proteus mirabilis, Providencia rettgeri, Morganella morganii, Citrobacter koseri, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus epidermidis, Staphylococcus saprophyticus, or Enterococcus faecalis. 1.2 Acute Uncomplicated Cystitis Ciprofloxacin is indicated in adult female patients for treatment of acute uncomplicated cystitis caused by Escherichia coli or Staphylococcus saprophyticus. 1.3 Chronic Bacterial Prostatitis Ciprofloxacin is indicated in adult patients for treatment of chronic bacterial prostatitis caused by Escherichia coli or Proteus mirabilis. 1.4 Lower Respiratory Tract Infections Ciprofloxacin is indicated in adult patients for treatment of lower respiratory tract infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Pseudomonas aeruginosa, Haemophilus influenzae, Haemophilus parainfluenzae, or Streptococcus pneumoniae. Also, ciprofloxacin is indicated for the treatment of acute exacerbations of chronic bronchitis caused by Moraxella catarrhalis [see INDICATIONS AND USAGE (1.15)]. 1.5 Acute Sinusitis Ciprofloxacin is indicated in adult patients for treatment of acute sinusitis caused by Haemophilus influenzae, Streptococcus pneumoniae, or Moraxella catarrhalis. 1.6 Skin and Skin Structure Infections Ciprofloxacin is indicated in adult patients for treatment of skin and skin structure infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis, Proteus vulgaris, Providencia stuartii, Morganella morganii, Citrobacter freundii, Pseudomonas aeruginosa, methicillin-susceptible Staphylococcus aureus, methicillin-susceptible Staphylococcus epidermidis, or Streptococcus pyogenes. 1.7 Bone and Joint Infections Ciprofloxacin is indicated in adult patients for treatment of bone and joint infections caused by Enterobacter cloacae, Serratia marcescens, or Pseudomonas aeruginosa. 1.8 Complicated Intra-Abdominal Infections Ciprofloxacin is indicated in adult patients for treatment of complicated intra-abdominal infections (used in combination with metronidazole) caused by Escherichia coli, Pseudomonas aeruginosa, Proteus mirabilis, Klebsiella pneumoniae, or Bacteroides fragilis. 1.9 Infectious Diarrhea Ciprofloxacin is indicated in adult patients for treatment of infectious diarrhea caused by Escherichia coli (enterotoxigenic isolates), Campylobacter jejuni, Shigella boydii † , Shigella dysenteriae, Shigella flexneri or Shigella sonnei† when antibacterial therapy is indicated. †Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients. 1.10 Typhoid Fever (Enteric Fever) Ciprofloxacin is indicated in adult patients for treatment of typhoid fever (enteric fever) caused by Salmonella typhi. The efficacy of ciprofloxacin in the eradication of the chronic typhoid carrier state has not been demonstrated. 1.11 Uncomplicated Cervical and Urethral Gonorrhea Ciprofloxacin is indicated in adult patients for treatment of uncomplicated cervical and urethral gonorrhea due to Neisseria gonorrhoeae [see WARNINGS AND PRECAUTIONS (5.16)]. 1.12 Complicated Urinary Tract Infections and Pyelonephritis Ciprofloxacin is indicated in pediatric patients one to 17 years of age for treatment of complicated urinary tract infections (cUTI) and pyelonephritis due to Escherichia coli [see INDICATIONS AND USAGE (1.15) and USE IN SPECIFIC POPULATIONS (8.4)]. 1.13 Inhalational Anthrax (post-exposure) Ciprofloxacin is indicated in adults and pediatric patients from birth to 17 years of age for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. Ciprofloxacin serum concentrations achieved in humans served as a surrogate endpoint reasonably likely to predict clinical benefit and provided the initial basis for approval of this indication.1 Supportive clinical information for ciprofloxacin for anthrax post-exposure prophylaxis was obtained during the anthrax bioterror attacks of October 2001. [See CLINICAL STUDIES (14.2).] 1.14 Plague Ciprofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients from birth to 17 years of age. Efficacy studies of ciprofloxacin could not be conducted in humans with plague for feasibility reasons. Therefore this indication is based on an efficacy study conducted in animals only [see CLINICAL STUDIES (14.3) ]. 1.15 Limitation of Use Use in Pediatric Patients Although effective in clinical trials, ciprofloxacin is not a drug of first choice in the pediatric population due to an increased incidence of adverse events compared to controls, including events related to joints and/or surrounding tissues. Ciprofloxacin, like other fluoroquinolones, is associated with arthropathy and histopathological changes in weight-bearing joints of juvenile animals [see WARNINGS AND PRECAUTIONS (5.11), ADVERSE REACTIONS (6.1), USE IN SPECIFIC POPULATIONS (8.4) and NONCLINICAL TOXICOLOGY (13.2)]. Lower Respiratory Tract Infections Ciprofloxacin is not a drug of first choice in the treatment of presumed or confirmed pneumonia secondary to Streptococcus pneumoniae [see INDICATIONS AND USAGE (1.4)]. 1.16 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of ciprofloxacin and other antibacterial drugs ciprofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. If anaerobic organisms are suspected of contributing to the infection, appropriate therapy should be administered. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to ciprofloxacin. Therapy with ciprofloxacin may be initiated before results of these tests are known; once results become available appropriate therapy should be continued. As with other drugs, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ciprofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance.|[PMDA] A drug with a new increased dose for adults indicated for the treatment of sepsis, pneumonia, etc., and also with new indications and new dosages for children for both the treatment of complicated cystitis, pyelonephritis and anthrax, and the improvement of symptoms associated with respiratory infection caused by Pseudomonas aeruginosa in cystic fibrosis. uuid:40336afb-5967-4c4d-8790-9fa2ba7719cb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8772 biolink:treats MONDO:0005298 PMID:41385096 "[{""id"":""uuid:4aa0e66b-daa7-46bd-b4c5-4f7d3959cb07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:65b36fdf-f27e-41d8-bc9a-008e219aaa74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:201b425c-29b3-4110-9d38-4a2ab9978638"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Raloxifene hydrochloride tablet, USP is an estrogen agonist/antagonist indicated for: Treatment of osteoporosis in postmenopausal women. ( 1.1 )|[EMA] Optruma is indicated for the treatment and prevention of osteoporosis in post-menopausal women. A significant reduction in the incidence of vertebral, but not hip fractures has been demonstrated. When determining the choice of Optruma or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits (see section 5.1). uuid:995ce5bf-4c68-43df-a952-59963d0bd90b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8772 biolink:treats MONDO:0008159 PMID:41385096 "[{""id"":""uuid:0a2b48b2-e998-4f3a-a369-b30834386bbf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f9bba002-1479-4173-88c1-9d314450b200"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Raloxifene hydrochloride tablet, USP is an estrogen agonist/antagonist indicated for: Treatment of osteoporosis in postmenopausal women. ( 1.1 ) uuid:4a9a5f91-25dd-4b15-931b-596c3ddb243e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:36795 biolink:treats UMLS:C0457949 PMID:41385096 "[{""id"":""uuid:65e5f17c-c29e-4dde-a14f-9561fbdbcb58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:09ab019e-7eb7-483e-aabd-a74af9eda391"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:af7fbaef-1c92-49c5-8117-ebe1de6ad437"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Major Depressive Disorder Duloxetine Delayed-release Capsules are indicated for the treatment of major depressive disorder (MDD). The efficacy of Duloxetine Delayed-release Capsules was established in four short-term and one maintenance trial in adults [see Clinical Studies (14.1) ]. A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least 5 of the following 9 symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, or a suicide attempt or suicidal ideation. 1.2 Generalized Anxiety Disorder Duloxetine Delayed-release Capsules are indicated for the treatment of generalized anxiety disorder (GAD). The efficacy of Duloxetine Delayed-release Capsules was established in three short-term trials and one maintenance trial in adults [see Clinical Studies (14.2) ]. Generalized anxiety disorder is defined by the DSM-IV as excessive anxiety and worry, present more days than not, for at least 6 months. The excessive anxiety and worry must be difficult to control and must cause significant distress or impairment in normal functioning. It must be associated with at least 3 of the following 6 symptoms: restlessness or feeling keyed up or on edge, being easily fatigued, difficulty concentrating or mind going blank, irritability, muscle tension, and/or sleep disturbance. 1.3 Diabetic Peripheral Neuropathic Pain Duloxetine Delayed-release Capsules are indicated for the management of neuropathic pain (DPNP) associated with diabetic peripheral neuropathy [see Clinical Studies (14.3) ]. 1.5 Chronic Musculoskeletal Pain Duloxetine Delayed-release Capsules are indicated for the management of chronic musculoskeletal pain. This has been established in studies in patients with chronic low back pain (CLBP) and chronic pain due to osteoarthritis [see Clinical Studies (14.5) ].|[PMDA] Drugs with a new additional indication for the treatment of pain associated with chronic low back pain. uuid:f85f092f-78b9-4bb0-8717-9f4d9cb0cbf2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:36795 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:baedcb99-fa75-4ed8-998a-bdaa2e6d664f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6b52c41a-f344-4e60-aaaf-8633ee0383bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Major Depressive Disorder Duloxetine Delayed-release Capsules are indicated for the treatment of major depressive disorder (MDD). The efficacy of Duloxetine Delayed-release Capsules was established in four short-term and one maintenance trial in adults [see Clinical Studies (14.1) ]. A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least 5 of the following 9 symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, or a suicide attempt or suicidal ideation. 1.2 Generalized Anxiety Disorder Duloxetine Delayed-release Capsules are indicated for the treatment of generalized anxiety disorder (GAD). The efficacy of Duloxetine Delayed-release Capsules was established in three short-term trials and one maintenance trial in adults [see Clinical Studies (14.2) ]. Generalized anxiety disorder is defined by the DSM-IV as excessive anxiety and worry, present more days than not, for at least 6 months. The excessive anxiety and worry must be difficult to control and must cause significant distress or impairment in normal functioning. It must be associated with at least 3 of the following 6 symptoms: restlessness or feeling keyed up or on edge, being easily fatigued, difficulty concentrating or mind going blank, irritability, muscle tension, and/or sleep disturbance. 1.3 Diabetic Peripheral Neuropathic Pain Duloxetine Delayed-release Capsules are indicated for the management of neuropathic pain (DPNP) associated with diabetic peripheral neuropathy [see Clinical Studies (14.3) ]. 1.5 Chronic Musculoskeletal Pain Duloxetine Delayed-release Capsules are indicated for the management of chronic musculoskeletal pain. This has been established in studies in patients with chronic low back pain (CLBP) and chronic pain due to osteoarthritis [see Clinical Studies (14.5) ]. uuid:b761e678-2b64-4f07-9119-4a8e98acddf8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9123 biolink:treats MONDO:0003709 PMID:41385096 "[{""id"":""uuid:b5c0b499-bead-484e-ac70-583bae95f612"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0a8b37fe-1ca4-4124-8036-b1f38b1ad12e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Major Depressive Disorder – Sertraline hydrochloride is indicated for the treatment of major depressive disorder in adults. The efficacy of Sertraline hydrochloride in the treatment of a major depressive episode was established in six to eight week controlled trials of adult outpatients whose diagnoses corresponded most closely to the DSM-III category of major depressive disorder (see Clinical Trials under CLINICAL PHARMACOLOGY). A major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. The antidepressant action of sertraline hydrochloride in hospitalized depressed patients has not been adequately studied. The efficacy of sertraline hydrochloride in maintaining an antidepressant response for up to 44 weeks following 8 weeks of open-label acute treatment (52 weeks total) was demonstrated in a placebo-controlled trial. The usefulness of the drug in patients receiving sertraline hydrochloride for extended periods should be reevaluated periodically (see Clinical Trials under CLINICAL PHARMACOLOGY). Obsessive-Compulsive Disorder– Sertraline hydrochloride is indicated for the treatment of obsessions and compulsions in patients with obsessive-compulsive disorder (OCD), as defined in the DSM-III-R; i.e., the obsessions or compulsions cause marked distress, are time-consuming, or significantly interfere with social or occupational functioning. The efficacy of Sertraline hydrochloride was established in 12-week trials with obsessive-compulsive outpatients having diagnoses of obsessive-compulsive disorder as defined according to DSM-III or DSM-III-R criteria (see Clinical Trials under CLINICAL PHARMACOLOGY). Obsessive-compulsive disorder is characterized by recurrent and persistent ideas, thoughts, impulses, or images (obsessions) that are ego-dystonic and/or repetitive, purposeful, and intentional behaviors (compulsions) that are recognized by the person as excessive or unreasonable. The efficacy of Sertraline hydrochloride in maintaining a response, in patients with OCD who responded during a 52-week treatment phase while taking Sertraline hydrochloride and were then observed for relapse during a period of up to 28 weeks, was demonstrated in a placebo-controlled trial (see Clinical Trials under CLINICAL PHARMACOLOGY). Nevertheless, the physician who elects to use Sertraline hydrochloride for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION). Panic Disorder– Sertraline hydrochloride is indicated for the treatment of panic disorder in adults, with or without agoraphobia, as defined in DSM-IV. Panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. The efficacy of Sertraline hydrochloride was established in three 10-12 week trials in adult panic disorder patients whose diagnoses corresponded to the DSM-III-R category of panic disorder (see Clinical Trials under CLINICAL PHARMACOLOGY). Panic disorder (DSM-IV) is characterized by recurrent unexpected panic attacks, i.e., a discrete period of intense fear or discomfort in which four (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) palpitations, pounding heart, or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded, or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes. The efficacy of Sertraline hydrochloride in maintaining a response, in adult patients with panic disorder who responded during a 52-week treatment phase while taking Sertraline hydrochloride and were then observed for relapse during a period of up to 28 weeks, was demonstrated in a placebo-controlled trial (see Clinical Trials under CLINICAL PHARMACOLOGY). Nevertheless, the physician who elects to use Sertraline hydrochloride for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION). Posttraumatic Stress Disorder (PTSD) – Sertraline hydrochloride (sertraline hydrochloride) is indicated for the treatment of posttraumatic stress disorder in adults. The efficacy of Sertraline hydrochloride in the treatment of PTSD was established in two 12-week placebo-controlled trials of adult outpatients whose diagnosis met criteria for the DSM-III-R category of PTSD (see Clinical Trials under CLINICAL PHARMACOLOGY). PTSD, as defined by DSM-III-R/IV, requires exposure to a traumatic event that involved actual or threatened death or serious injury, or threat to the physical integrity of self or others, and a response which involves intense fear, helplessness, or horror. Symptoms that occur as a result of exposure to the traumatic event include reexperiencing of the event in the form of intrusive thoughts, flashbacks or dreams, and intense psychological distress and physiological reactivity on exposure to cues to the event; avoidance of situations reminiscent of the traumatic event, inability to recall details of the event, and/or numbing of general responsiveness manifested as diminished interest in significant activities, estrangement from others, restricted range of affect, or sense of foreshortened future; and symptoms of autonomic arousal including hypervigilance, exaggerated startle response, sleep disturbance, impaired concentration, and irritability or outbursts of anger. A PTSD diagnosis requires that the symptoms are present for at least a month and that they cause clinically significant distress or impairment in social, occupational, or other important areas of functioning. The efficacy of Sertraline hydrochloride in maintaining a response in adult patients with PTSD for up to 28 weeks following 24 weeks of open-label treatment was demonstrated in a placebo-controlled trial. Nevertheless, the physician who elects to use Sertraline hydrochloride for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION). Premenstrual Dysphoric Disorder (PMDD) – Sertraline hydrochloride is indicated for the treatment of premenstrual dysphoric disorder (PMDD) in adults. The efficacy of sertraline hydrochloride in the treatment of PMDD was established in 2 placebo-controlled trials of female adult outpatients treated for 3 menstrual cycles who met criteria for the DSM-IIIR/IV category of PMDD (see Clinical Trials under CLINICAL PHARMACOLOGY). The essential features of PMDD include markedly depressed mood, anxiety or tension, affective lability, and persistent anger or irritability. Other features include decreased interest in activities, difficulty concentrating, lack of energy, change in appetite or sleep, and feeling out of control. Physical symptoms associated with PMDD include breast tenderness, headache, joint and muscle pain, bloating and weight gain. These symptoms occur regularly during the luteal phase and remit within a few days following onset of menses; the disturbance markedly interferes with work or school or with usual social activities and relationships with others. In making the diagnosis, care should be taken to rule out other cyclical mood disorders that may be exacerbated by treatment with an antidepressant. The effectiveness of Sertraline hydrochloride in long-term use, that is, for more than 3 menstrual cycles, has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use Sertraline hydrochloride for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION). Social Anxiety Disorder – Sertraline hydrochloride is indicated for the treatment of social anxiety disorder, also known as social phobia in adults. The efficacy of Sertraline hydrochloride in the treatment of social anxiety disorder was established in two placebo-controlled trials of adult outpatients with a diagnosis of social anxiety disorder as defined by DSM-IV criteria (see Clinical Trials under CLINICAL PHARMACOLOGY). Social anxiety disorder, as defined by DSM-IV, is characterized by marked and persistent fear of social or performance situations involving exposure to unfamiliar people or possible scrutiny by others and by fears of acting in a humiliating or embarrassing way. Exposure to the feared social situation almost always provokes anxiety and feared social or performance situations are avoided or else are endured with intense anxiety or distress. In addition, patients recognize that the fear is excessive or unreasonable and the avoidance and anticipatory anxiety of the feared situation is associated with functional impairment or marked distress. The efficacy of Sertraline hydrochloride in maintaining a response in adult patients with social anxiety disorder for up to 24 weeks following 20 weeks of Sertraline hydrochloride treatment was demonstrated in a placebo-controlled trial. Physicians who prescribe Sertraline hydrochloride for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual patient (see Clinical Trials under CLINICAL PHARMACOLOGY). uuid:c1dc6857-b653-4364-8bc0-1f8d3b18fa70 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6532 biolink:treats MONDO:0044751 PMID:41385096 "[{""id"":""uuid:2bacb3b4-a415-43f6-b2e4-ac7c977e8fd4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c33cbab5-462b-46fa-b84f-558bb9aeea58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Loperamide hydrochloride capsules are indicated for the control and symptomatic relief of acute nonspecific diarrhea in patients 2 years of age and older and of chronic diarrhea in adults associated with inflammatory bowel disease. Loperamide hydrochloride capsules are also indicated for reducing the volume of discharge from ileostomies. uuid:c32280b6-4be5-4aac-871d-f7c7ef2edd47 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50275 biolink:treats HP:0005202 PMID:41385096 "[{""id"":""uuid:da087373-86da-4cfd-8706-16695180df0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b79b3cf1-cb74-4e9b-afcc-89b636430ff4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Treatment of Gastroesophageal Reflux Disease (GERD) in Adults Healing of Erosive Esophagitis Esomeprazole strontium is indicated for the short-term treatment (4 to 8 weeks) in the healing and symptomatic resolution of diagnostically confirmed erosive esophagitis. For those patients who have not healed after 4 to 8 weeks of treatment, an additional 4 to 8 week course of esomeprazole strontium may be considered. Maintenance of Healing of Erosive Esophagitis Esomeprazole strontium is indicated to maintain symptom resolution and healing of erosive esophagitis. Controlled studies do not extend beyond 6 months. Symptomatic Gastroesophageal Reflux Disease Esomeprazole strontium is indicated for short-term treatment (4 to 8 weeks) of heartburn and other symptoms associated with GERD in adults. 1.2 Risk Reduction of NSAID-Associated Gastric Ulcer in Adults Esomeprazole strontium is indicated for the reduction in the occurrence of gastric ulcers associated with continuous NSAID therapy in patients at risk for developing gastric ulcers. Patients are considered to be at risk either due to their age (≥60) and/or documented history of gastric ulcers. Controlled studies do not extend beyond 6 months. 1.3 H. pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence in Adults Triple Therapy (esomeprazole strontium plus amoxicillin and clarithromycin): esomeprazole strontium, in combination with amoxicillin and clarithromycin, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see Dosage and Administration (2) and Clinical Studies (14)]. In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted [see Clinical Pharmacology (12.4) and the prescribing information for clarithromycin]. 1.4 Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome in Adults Esomeprazole strontium is indicated for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison Syndrome. uuid:f86d3c6e-ea00-47ba-ae1e-a322779f46eb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:577093 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:12af7e95-ad7f-40f5-a4d0-5662ea9068cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f276e188-d6a7-4388-98a8-1dbe5826e68a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pioglitazone and metformin hydrochloride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both pioglitazone and metformin is appropriate [see CLINICAL STUDIES (14) ]. Important Limitations of Use Pioglitazone exerts its antihyperglycemic effect only in the presence of endogenous insulin. Pioglitazone and metformin hydrochloride tablets should not be used to treat type 1 diabetes or diabetic ketoacidosis, as it would not be effective in these settings. Use caution in patients with liver disease [see WARNINGS AND PRECAUTIONS (5.5) ]. uuid:c54b7ff1-d839-49ff-950f-5742231bb2cd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:577093 biolink:treats MONDO:0012819 PMID:41385096 "[{""id"":""uuid:bbfb8c96-a243-418a-a770-5101830cf510"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2d0eca2d-dfac-42af-b866-3046850d8c9d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pioglitazone and metformin hydrochloride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both pioglitazone and metformin is appropriate [see CLINICAL STUDIES (14) ]. Important Limitations of Use Pioglitazone exerts its antihyperglycemic effect only in the presence of endogenous insulin. Pioglitazone and metformin hydrochloride tablets should not be used to treat type 1 diabetes or diabetic ketoacidosis, as it would not be effective in these settings. Use caution in patients with liver disease [see WARNINGS AND PRECAUTIONS (5.5) ]. uuid:67b45878-4603-436c-b769-e2c643a28899 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8428 biolink:treats HP:0004308 PMID:41385096 "[{""id"":""uuid:ad44ddba-e819-4166-a17c-55452a586d97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:11ec830b-ffaf-4d96-93f2-a773102c266f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Procainamide hydrochloride injection is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgement of the physician, are life-threatening. Because of the proarrhythmic effects of procainamide, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of procainamide treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. Because procainamide has the potential to produce serious hematological disorders (0.5 percent) particularly leukopenia or agranulocytosis (sometimes fatal), its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment clearly outweigh the risks. (see WARNINGS and Boxed Warning.) uuid:41aaefa9-a555-4c76-bef1-460a88a1b0e4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8428 biolink:treats UMLS:C0750197 PMID:41385096 "[{""id"":""uuid:1b737404-6fb2-46f8-a8cd-8fa58d3d80d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e61aaa77-9950-49a8-ad65-2233e816c304"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Procainamide hydrochloride injection is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgement of the physician, are life-threatening. Because of the proarrhythmic effects of procainamide, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of procainamide treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. Because procainamide has the potential to produce serious hematological disorders (0.5 percent) particularly leukopenia or agranulocytosis (sometimes fatal), its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment clearly outweigh the risks. (see WARNINGS and Boxed Warning.) uuid:0523a0c6-6169-422f-b7d0-e8429e2da597 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8428 biolink:treats HP:0006682 PMID:41385096 "[{""id"":""uuid:5169e69f-7e93-435d-8de7-d1ab72d4e9f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2529fabb-2793-4add-bf7b-17c47aee9a5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Procainamide hydrochloride injection is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgement of the physician, are life-threatening. Because of the proarrhythmic effects of procainamide, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of procainamide treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. Because procainamide has the potential to produce serious hematological disorders (0.5 percent) particularly leukopenia or agranulocytosis (sometimes fatal), its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment clearly outweigh the risks. (see WARNINGS and Boxed Warning.) uuid:5c02775f-e4f5-42d3-9c59-86746d59d044 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8428 biolink:treats MONDO:0003785 PMID:41385096 "[{""id"":""uuid:0402dd0c-725e-42aa-8e1f-d79e0f2306a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ae1942a5-1d4c-44a1-bbf0-4c96c2b24b4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Procainamide hydrochloride injection is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgement of the physician, are life-threatening. Because of the proarrhythmic effects of procainamide, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of procainamide treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. Because procainamide has the potential to produce serious hematological disorders (0.5 percent) particularly leukopenia or agranulocytosis (sometimes fatal), its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment clearly outweigh the risks. (see WARNINGS and Boxed Warning.) uuid:f6bd2a03-d4e7-44ae-b9c3-6f26443e627a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8428 biolink:treats MONDO:0001609 PMID:41385096 "[{""id"":""uuid:a326da75-edc7-43d8-8259-32763cada449"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0f575019-e373-4642-a02f-9b55942b8803"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Procainamide hydrochloride injection is indicated for the treatment of documented ventricular arrhythmias, such as sustained ventricular tachycardia, that, in the judgement of the physician, are life-threatening. Because of the proarrhythmic effects of procainamide, its use with lesser arrhythmias is generally not recommended. Treatment of patients with asymptomatic ventricular premature contractions should be avoided. Initiation of procainamide treatment, as with other antiarrhythmic agents used to treat life-threatening arrhythmias, should be carried out in the hospital. Antiarrhythmic drugs have not been shown to enhance survival in patients with ventricular arrhythmias. Because procainamide has the potential to produce serious hematological disorders (0.5 percent) particularly leukopenia or agranulocytosis (sometimes fatal), its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment clearly outweigh the risks. (see WARNINGS and Boxed Warning.) uuid:abdf931e-c378-456a-abc7-26041b758619 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2646319 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:8b652b7f-b679-48b9-b09d-12a06d33e47d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2dad3236-e5b8-4937-bfe5-49a326fcc971"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hyophen ™ tablets are indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures. uuid:f3869ab9-1450-43aa-b06c-8d0ca6dbacab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:25187 biolink:treats MONDO:0005277 PMID:41385096 "[{""id"":""uuid:6eca81ca-9368-4aab-b606-652982cc3a35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ed0438f6-eeb6-4c55-91d8-3244d72cb909"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sumatriptan tablets are indicated for the acute treatment of migraine attacks with or without aura in adults. Sumatriptan tablets are not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS ). Safety and effectiveness of sumatriptan tablets have not been established for cluster headache, which is present in an older, predominantly male population. uuid:0aa3a866-4234-401a-aadb-69187cfe432b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:25187 biolink:treats MONDO:0018925 PMID:41385096 "[{""id"":""uuid:d14832ca-1e59-434f-8a83-1941dc8912c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:63f0ceef-dd97-413e-8ec1-f702d5cea29b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sumatriptan tablets are indicated for the acute treatment of migraine attacks with or without aura in adults. Sumatriptan tablets are not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS ). Safety and effectiveness of sumatriptan tablets have not been established for cluster headache, which is present in an older, predominantly male population. uuid:57f433b5-d105-4e16-a0ef-aaef6d1142ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:25187 biolink:treats MONDO:0043219 PMID:41385096 "[{""id"":""uuid:462a3321-27ba-4bc7-8fd6-3c7b238593a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c5eda860-dccf-4564-af40-81ff3012344c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sumatriptan tablets are indicated for the acute treatment of migraine attacks with or without aura in adults. Sumatriptan tablets are not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS ). Safety and effectiveness of sumatriptan tablets have not been established for cluster headache, which is present in an older, predominantly male population. uuid:21d9368d-aa0a-4cdf-8785-0223258dc324 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:25187 biolink:treats MONDO:0043537 PMID:41385096 "[{""id"":""uuid:440823ac-ded4-4cdd-aade-8ba143903e8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8ddf07ac-801b-442a-b0d7-ba0c87149203"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sumatriptan tablets are indicated for the acute treatment of migraine attacks with or without aura in adults. Sumatriptan tablets are not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine (see CONTRAINDICATIONS ). Safety and effectiveness of sumatriptan tablets have not been established for cluster headache, which is present in an older, predominantly male population. uuid:1ba8c462-49fb-4bd4-8c06-e63885e3a318 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4856 biolink:treats HP:0001649 PMID:41385096 "[{""id"":""uuid:86d0a6d3-9659-49bc-a7b0-0a46fe569a51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5fe96f80-330f-46e8-a326-dd6c21aea869"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Supraventricular Tachycardia Esmolol hydrochloride is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. Esmolol hydrochloride is also indicated in noncompensatory sinus tachycardia where, in the physician’s judgment, the rapid heart rate requires specific intervention. Esmolol hydrochloride is not intended for use in chronic settings where transfer to another agent is anticipated. Intraoperative and Postoperative Tachycardia and/or Hypertension Esmolol hydrochloride is indicated for the treatment of tachycardia and hypertension that occur during induction and tracheal intubation, during surgery, on emergence from anesthesia, and in the postoperative period, when in the physician’s judgment such specific intervention is considered indicated. Use of esmolol hydrochloride to prevent such events is not recommended. uuid:8b573c38-d19c-4aa5-b3a9-062c6ff55f32 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4856 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:cfe52797-1d1b-4226-a877-e14e418b9a46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ef3a1084-9d2c-41fd-b507-1740dc3e3026"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Supraventricular Tachycardia Esmolol hydrochloride is indicated for the rapid control of ventricular rate in patients with atrial fibrillation or atrial flutter in perioperative, postoperative, or other emergent circumstances where short term control of ventricular rate with a short-acting agent is desirable. Esmolol hydrochloride is also indicated in noncompensatory sinus tachycardia where, in the physician’s judgment, the rapid heart rate requires specific intervention. Esmolol hydrochloride is not intended for use in chronic settings where transfer to another agent is anticipated. Intraoperative and Postoperative Tachycardia and/or Hypertension Esmolol hydrochloride is indicated for the treatment of tachycardia and hypertension that occur during induction and tracheal intubation, during surgery, on emergence from anesthesia, and in the postoperative period, when in the physician’s judgment such specific intervention is considered indicated. Use of esmolol hydrochloride to prevent such events is not recommended. uuid:656f22bd-dab8-4ffe-976a-7d95a46b8550 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18067 biolink:treats MONDO:0006784 PMID:41385096 "[{""id"":""uuid:27326aa7-0020-4f34-ae06-362fd20bad91"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:27832db5-2471-4f53-a97e-b06a5b8142b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Phytonadione is indicated in the following coagulation disorders which are due to faulty formation of factors II, VII, IX and X when caused by vitamin K deficiency or interference with vitamin K activity. Phytonadione Injectable Emulsion, USP is indicated in: - anticoagulant-induced prothrombin deficiency caused by coumarin or indanedione derivatives; - prophylaxis and therapy of hemorrhagic disease of the newborn; - hypoprothrombinemia due to antibacterial therapy; - hypoprothrombinemia secondary to factors limiting absorption or synthesis of vitamin K, e.g., obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal resection, cystic fibrosis of the pancreas, and regional enteritis; - other drug-induced hypoprothombinemia where it is definately shown that the result is due to interference with vitamin K metabolism, e.g., salicylates. uuid:1e6cdeb2-07b5-4593-9c80-282a96addb9b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18067 biolink:treats UMLS:C0205707 PMID:41385096 "[{""id"":""uuid:f2bec110-4f77-4563-a85f-60be6db98a52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:81fe90ea-2dc2-45c7-bcf9-842958dc7a2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Phytonadione is indicated in the following coagulation disorders which are due to faulty formation of factors II, VII, IX and X when caused by vitamin K deficiency or interference with vitamin K activity. Phytonadione Injectable Emulsion, USP is indicated in: - anticoagulant-induced prothrombin deficiency caused by coumarin or indanedione derivatives; - prophylaxis and therapy of hemorrhagic disease of the newborn; - hypoprothrombinemia due to antibacterial therapy; - hypoprothrombinemia secondary to factors limiting absorption or synthesis of vitamin K, e.g., obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal resection, cystic fibrosis of the pancreas, and regional enteritis; - other drug-induced hypoprothombinemia where it is definately shown that the result is due to interference with vitamin K metabolism, e.g., salicylates. uuid:742ea755-7fa5-4923-80bf-c542323a4c08 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18067 biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:07e8ab4d-9643-4a65-97a8-8b75a82f5a01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c0f4ab0d-9b60-4374-8c54-e791a9a31620"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Phytonadione is indicated in the following coagulation disorders which are due to faulty formation of factors II, VII, IX and X when caused by vitamin K deficiency or interference with vitamin K activity. Phytonadione Injectable Emulsion, USP is indicated in: - anticoagulant-induced prothrombin deficiency caused by coumarin or indanedione derivatives; - prophylaxis and therapy of hemorrhagic disease of the newborn; - hypoprothrombinemia due to antibacterial therapy; - hypoprothrombinemia secondary to factors limiting absorption or synthesis of vitamin K, e.g., obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal resection, cystic fibrosis of the pancreas, and regional enteritis; - other drug-induced hypoprothombinemia where it is definately shown that the result is due to interference with vitamin K metabolism, e.g., salicylates. uuid:aacef278-928a-40ed-88bb-dedce3b06126 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18067 biolink:treats MONDO:0005130 PMID:41385096 "[{""id"":""uuid:0be2b21e-3025-4d2a-96dd-20884fd3703b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f30dcefc-2d49-4c44-b73a-52604d7fa840"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Phytonadione is indicated in the following coagulation disorders which are due to faulty formation of factors II, VII, IX and X when caused by vitamin K deficiency or interference with vitamin K activity. Phytonadione Injectable Emulsion, USP is indicated in: - anticoagulant-induced prothrombin deficiency caused by coumarin or indanedione derivatives; - prophylaxis and therapy of hemorrhagic disease of the newborn; - hypoprothrombinemia due to antibacterial therapy; - hypoprothrombinemia secondary to factors limiting absorption or synthesis of vitamin K, e.g., obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal resection, cystic fibrosis of the pancreas, and regional enteritis; - other drug-induced hypoprothombinemia where it is definately shown that the result is due to interference with vitamin K metabolism, e.g., salicylates. uuid:c1e17fad-7c55-4057-80ee-1a53c90fda02 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18067 biolink:treats UMLS:C1527396 PMID:41385096 "[{""id"":""uuid:f5e246c0-8340-4650-b7ff-48cf0ca4c334"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1db6a118-5d17-4aed-827c-67586b7d055c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Phytonadione is indicated in the following coagulation disorders which are due to faulty formation of factors II, VII, IX and X when caused by vitamin K deficiency or interference with vitamin K activity. Phytonadione Injectable Emulsion, USP is indicated in: - anticoagulant-induced prothrombin deficiency caused by coumarin or indanedione derivatives; - prophylaxis and therapy of hemorrhagic disease of the newborn; - hypoprothrombinemia due to antibacterial therapy; - hypoprothrombinemia secondary to factors limiting absorption or synthesis of vitamin K, e.g., obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal resection, cystic fibrosis of the pancreas, and regional enteritis; - other drug-induced hypoprothombinemia where it is definately shown that the result is due to interference with vitamin K metabolism, e.g., salicylates. uuid:499acdb3-e7ba-418c-98ba-7d65bed5847e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18067 biolink:treats UMLS:C0678202 PMID:41385096 "[{""id"":""uuid:402e44fb-8cb8-49e8-8e97-a8b0d3b706c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d46ad546-0540-4029-ba53-17796cde1ca1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Phytonadione is indicated in the following coagulation disorders which are due to faulty formation of factors II, VII, IX and X when caused by vitamin K deficiency or interference with vitamin K activity. Phytonadione Injectable Emulsion, USP is indicated in: - anticoagulant-induced prothrombin deficiency caused by coumarin or indanedione derivatives; - prophylaxis and therapy of hemorrhagic disease of the newborn; - hypoprothrombinemia due to antibacterial therapy; - hypoprothrombinemia secondary to factors limiting absorption or synthesis of vitamin K, e.g., obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal resection, cystic fibrosis of the pancreas, and regional enteritis; - other drug-induced hypoprothombinemia where it is definately shown that the result is due to interference with vitamin K metabolism, e.g., salicylates. uuid:2d2aea78-abb8-4688-b7ff-7b70fa0abc56 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18067 biolink:treats MONDO:0001531 PMID:41385096 "[{""id"":""uuid:d3275052-5db2-45f8-9b1f-71b548872664"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:db3f204e-ddcc-4680-9f40-2dec8dd1d7ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Phytonadione is indicated in the following coagulation disorders which are due to faulty formation of factors II, VII, IX and X when caused by vitamin K deficiency or interference with vitamin K activity. Phytonadione Injectable Emulsion, USP is indicated in: anticoagulant-induced prothrombin deficiency caused by coumarin or indanedione derivatives; prophylaxis and therapy of hemorrhagic disease of the newborn; hypoprothrombinemia due to antibacterial therapy; hypoprothrombinemia secondary to factors limiting absorption or synthesis of vitamin K, e.g., obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal resection, cystic fibrosis of the pancreas, and regional enteritis; other drug-induced hypoprothrombinemia where it is definitely shown that the result is due to interference with vitamin K metabolism, e.g., salicylates. uuid:40fc1292-1d99-4387-a754-081ea6a0e227 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28304 biolink:treats MONDO:0004981 PMID:41385096 "[{""id"":""uuid:7f4e01a4-2673-4a6b-9187-c205708c28bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b4ef9ba5-dff7-4d99-a5f7-179af8ee4f53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Heparin Sodium Injection is indicated for: Anticoagulant therapy in prophylaxis and treatment of venous thrombosis and its extension; Low-dose regimen for prevention of postoperative deep venous thrombosis and pulmonary embolism in patients undergoing major abdominothoracic surgery or who, for other reasons, are at risk of developing thromboembolic disease (see DOSAGE AND ADMINISTRATION) Prophylaxis and treatment of pulmonary embolism; Atrial fibrilation with embolization; Diagnosis and treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation); Prevention of clotting in arterial and cardiac surgery; Prophylaxis and treatment of peripheral arterial embolism. Heparin may also be employed as an anticoagulant in blood transfusions, extracorporeal circulation, and dialysis procedures and in blood samples for laboratory purposes. uuid:43844997-0ac8-4bef-9a2e-0166715966e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:11979316 biolink:treats MONDO:0004782 PMID:41385096 "[{""id"":""uuid:aa60476c-d4de-4803-a9f1-cac8f9f8b023"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5ca2f64f-7549-44b5-a275-d873ae80f33f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vasopressin Injection, USP is indicated for prevention and treatment of postoperative abdominal distention, in abdominal roentgenography to dispel interfering gas shadows and in diabetes insipidus. uuid:3ad7ee76-cb58-4cbe-a324-3d9a6ff3f306 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77733 biolink:treats HP:0004755 PMID:41385096 "[{""id"":""uuid:6caa37fd-4393-49b7-9c22-ce4a24a9377a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:88928b3e-6ba4-4032-a8ea-fc67e516c3e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Verapamil is indicated for the treatment of supraventricular tachyarrhythmias, including: Rapid conversion to sinus rhythm of paroxysmal supraventricular tachycardias, including those associated with accessory bypass tracts (Wolff-Parkinson-White [WPW] and Lown-Ganong-Levine [LGL] syndromes). When clinically advisable, appropriate vagal maneuvers (e.g., Valsalva maneuver) should be attempted prior to Verapamil administration. Temporary control of rapid ventricular rate in atrial flutter or atrial fibrillation, except when the atrial flutter and/or atrial fibrillation are associated with accessory bypass tracts (Wolff-Parkinson-White [WPW] and Lown-Ganong-Levine [LGL] syndromes). In controlled studies in the U.S., about 60% of patients with supraventricular tachycardia converted to normal sinus rhythm within 10 minutes after intravenous Verapamil hydrochloride. Uncontrolled studies reported in the world literature describe a conversion rate of about 80%. About 70% of patients with atrial flutter and/or fibrillation with a fast ventricular rate respond with a decrease in heart rate of at least 20%. Conversion of atrial flutter or fibrillation to sinus rhythm is uncommon (about 10%) after Verapamil hydrochloride and may reflect the spontaneous conversion rate, since the conversion rate after placebo was similar. The effect of a single injection lasts for 30–60 minutes when conversion to sinus rhythm does not occur. Because a small fraction (<1.0%) of patients treated with Verapamil hydrochloride respond with life-threatening adverse responses (rapid ventricular rate in atrial flutter/fibrillation with an accessory bypass tract, marked hypotension, or extreme bradycardia/asystole- see Contraindications and Warnings ), the initial use of intravenous Verapamil hydrochloride should, if possible, be in a treatment setting with monitoring and resuscitation facilities, including DC-cardioversion capability (see Suggested Treatment of Acute Cardiovascular Adverse Reactions ) . As familiarity with the patient’s response is gained, an office setting may be acceptable. Cardioversion has been used safely and effectively after intravenous Verapamil. uuid:0924c2da-ec18-4e82-a63b-5586f5b41dce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9150 biolink:treats UMLS:C0856526 PMID:41385096 "[{""id"":""uuid:e101d7b1-482e-4b60-ae88-29d0e3229b47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0a9a3b70-5875-451a-b6e4-50d444e5c293"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Simvastatin is an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: Reduce the risk of total mortality by reducing CHD deaths and reduce the risk of non-fatal myocardial infarction, stroke, and the need for revascularization procedures in patients at high risk of coronary events. ( 1.1 ) Reduce elevated total-C, LDL-C, Apo B, TG and increase HDL-C in patients with primary hyperlipidemia (heterozygous familial and nonfamilial) and mixed dyslipidemia. ( 1.2 ) Reduce elevated TG in patients with hypertriglyceridemia and reduce TG and VLDL-C in patients with primary dysbetalipoproteinemia. ( 1.2 ) Reduce total-C and LDL-C in adult patients with homozygous familial hypercholesterolemia. ( 1.2 ) Reduce elevated total-C, LDL-C, and Apo B in boys and postmenarchal girls, 10 to 17 years of age with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy. ( 1.2 , 1.3 ) Limitations of Use Simvastatin has not been studied in Fredrickson Types I and V dyslipidemias. ( 1.4 ) uuid:3125859b-3287-4789-8f03-dc7271575ee4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1153890 biolink:treats HP:0012735 PMID:41385096 "[{""id"":""uuid:db1f4820-94e5-406b-b02e-855e9e3d8612"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ce0a24b1-a714-4f7c-8eaa-e297db21843a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE is indicated for the relief of cough and symptoms associated with upper respiratory allergies or a common cold in adults 18 years of age and older. Important Limitations of Use Not indicated for pediatric patients under 18 years of age [see Use in Special Population ( 8.4 )] uuid:1f7f945a-5d26-431a-9c5c-0e7de9b210e5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1153890 biolink:treats MONDO:0004867 PMID:41385096 "[{""id"":""uuid:96167bcc-4038-43ea-9dc3-68c1f46da71b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:079a0085-dfea-4a61-9335-29d972b44545"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE is indicated for the relief of cough and symptoms associated with upper respiratory allergies or a common cold in adults 18 years of age and older. Important Limitations of Use Not indicated for pediatric patients under 18 years of age [see Use in Special Population ( 8.4 )] uuid:2f4be6da-3005-45a2-a828-59a8399695c1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1153890 biolink:treats MONDO:0005709 PMID:41385096 "[{""id"":""uuid:a57fdaed-fd50-40af-856f-91d45a2a1c8e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d2efbead-e5d3-495d-a539-6c2eae94c720"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE is indicated for the relief of cough and symptoms associated with upper respiratory allergies or a common cold in adults 18 years of age and older. Important Limitations of Use Not indicated for pediatric patients under 18 years of age [see Use in Special Population ( 8.4 )] uuid:bd04bbe7-7a37-4efb-a7eb-95fd674141c3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5109 biolink:treats MONDO:0006604 PMID:41385096 "[{""id"":""uuid:4b42c9af-a4e1-48a9-bed7-8b2204cf3a9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2a2fdc73-45a9-4558-bf88-e46612aecd61"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluocinonide cream USP, 0.1% is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses in patients 12 years of age or older. ( 1 ) Limitation of Use: Treatment beyond 2 consecutive weeks is not recommended and the total dosage should not exceed 60 g per week because of the potential for the drug to suppress the hypothalamic-pituitary-adrenal (HPA) axis. ( 1 ) Avoid use on the face, groin, or axillae. ( 1.2 ) Avoid use in perioral dermatitis or rosacea. uuid:20b03278-d4d4-4e12-940f-a816b38fab8f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats MONDO:0005173 PMID:41385096 "[{""id"":""uuid:d709141d-5a35-49f7-bc10-1ce81da52544"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dbfbd675-3541-415b-835a-0ad29655cb60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diclofenac Sodium Gel is indicated for the topical treatment of actinic keratoses (AK). Sun avoidance is indicated during therapy. uuid:6ba5dabe-8e74-4b3e-b76a-fb4ca3601e05 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats UMLS:C0582412 PMID:41385096 "[{""id"":""uuid:5fba5da4-a069-4324-8914-291ff6547bcf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:33aad8bf-1b72-43aa-ba7d-a3ffe67785de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diclofenac Sodium Gel is indicated for the topical treatment of actinic keratoses (AK). Sun avoidance is indicated during therapy. uuid:58741f08-91a8-4a32-860a-7f1616ca78d2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63618 biolink:treats MONDO:0004781 PMID:41385096 "[{""id"":""uuid:8f3e3380-8b88-414e-a594-468a870af83c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2962445c-525d-4f4e-a84c-d6cc22b4416a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pravastatin sodium tablet, USP is an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: Reduce the risk of MI, revascularization, and cardiovascular mortality in hypercholesterolemic patients without clinically evident CHD. ( 1.1 ) Reduce the risk of total mortality by reducing coronary death, MI, revascularization, stroke/TIA, and the progression of coronary atherosclerosis in patients with clinically evident CHD. ( 1.1 ) Reduce elevated Total-C, LDL-C, ApoB, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia. ( 1.2 ) Reduce elevated serum TG levels in patients with hypertriglyceridemia. ( 1.2 ) Treat patients with primary dysbetalipoproteinemia who are not responding to diet. ( 1.2 ) Treat children and adolescent patients ages 8 years and older with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy. ( 1.2 ) Limitations of use: Pravastatin sodium tablet, USP has not been studied in Fredrickson Types I and V dyslipidemias. ( 1.3 ) uuid:fe4265a9-63e7-4d22-bc61-b91364d6f283 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63618 biolink:treats MONDO:0021661 PMID:41385096 "[{""id"":""uuid:35083381-978d-4419-9ae5-737ce529ea86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:81d88835-efa4-418b-8a4b-205837b4d512"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pravastatin sodium tablet, USP is an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: Reduce the risk of MI, revascularization, and cardiovascular mortality in hypercholesterolemic patients without clinically evident CHD. ( 1.1 ) Reduce the risk of total mortality by reducing coronary death, MI, revascularization, stroke/TIA, and the progression of coronary atherosclerosis in patients with clinically evident CHD. ( 1.1 ) Reduce elevated Total-C, LDL-C, ApoB, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia. ( 1.2 ) Reduce elevated serum TG levels in patients with hypertriglyceridemia. ( 1.2 ) Treat patients with primary dysbetalipoproteinemia who are not responding to diet. ( 1.2 ) Treat children and adolescent patients ages 8 years and older with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy. ( 1.2 ) Limitations of use: Pravastatin sodium tablet, USP has not been studied in Fredrickson Types I and V dyslipidemias. ( 1.3 ) uuid:80dbeae9-62b7-4bcb-9472-bcea9279ce30 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46557 biolink:treats MONDO:0043455 PMID:41385096 "[{""id"":""uuid:bac928d8-b186-45ca-86f1-0899a5e34ca9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:bc0fa96e-0b4e-44cb-9cee-4188b322af37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c84481de-5763-4717-9578-20324bbb87f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Zoledronic acid Injectionis a bisphosphonate indicated for the treatment of: • Hypercalcemia of malignancy. ( 1.1 ) • Patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy. ( 1.2 ) Limitations of use : The safety and efficacy of Zoledronic acid Injection has not been established for use in hyperparathyroidism or non-tumor-related hypercalcemia.|[EMA] Prevention of skeletal-related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone.Treatment of adult patients with tumour-induced hypercalcaemia. uuid:b4bfedef-e050-4159-9c95-e5b0f23dd9a9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46557 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:9a3fd582-f3b6-4fce-9c0c-20421cdb7116"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fca38edc-3b6f-4d2d-bd43-467a8b77d2ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:cb4f320f-617f-4595-a8a4-8870b8337599"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Zoledronic acid Injectionis a bisphosphonate indicated for the treatment of: • Hypercalcemia of malignancy. ( 1.1 ) • Patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy. ( 1.2 ) Limitations of use : The safety and efficacy of Zoledronic acid Injection has not been established for use in hyperparathyroidism or non-tumor-related hypercalcemia.|[PMDA] Drug with a new indication and revised dosage indicated for bone lesions of multiple myeloma or bone metastasis from solid cancers. uuid:55d0de42-ed85-4190-a27c-93200a500e7c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46557 biolink:treats UMLS:C0153690 PMID:41385096 "[{""id"":""uuid:ace24754-b964-42db-8e01-ef175aa93d4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5330a811-602f-486a-bf21-1a5ac9314703"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e297573e-cd24-4227-8653-c92d976e27f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Zoledronic acid Injectionis a bisphosphonate indicated for the treatment of: • Hypercalcemia of malignancy. ( 1.1 ) • Patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy. ( 1.2 ) Limitations of use : The safety and efficacy of Zoledronic acid Injection has not been established for use in hyperparathyroidism or non-tumor-related hypercalcemia.|[PMDA] Drug with a new indication and revised dosage indicated for bone lesions of multiple myeloma or bone metastasis from solid cancers. uuid:7d28ef29-8db4-44b1-ad3b-157969a18765 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46557 biolink:treats MONDO:0008315 PMID:41385096 "[{""id"":""uuid:cfa3e946-72f3-4049-b617-b4208cdc1f7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bf11cacd-f1fe-48b1-9e95-b0bf29bd7ba8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Zoledronic acid Injectionis a bisphosphonate indicated for the treatment of: • Hypercalcemia of malignancy. ( 1.1 ) • Patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy. Prostate cancer should have progressed after treatment with at least one hormonal therapy. ( 1.2 ) Limitations of use : The safety and efficacy of Zoledronic acid Injection has not been established for use in hyperparathyroidism or non-tumor-related hypercalcemia. uuid:42c5b7bb-2afb-467d-b8a8-3b86740ae973 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4681 biolink:treats MONDO:0004981 PMID:41385096 "[{""id"":""uuid:385fe769-a304-493d-b8c2-cf1c87a0b96e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e9fe168b-a44e-476c-837d-12050b827045"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TIKOSYN is indicated for the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation/atrial flutter [AF/AFl]) in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm. Because TIKOSYN can cause life threatening ventricular arrhythmias, it should be reserved for patients in whom atrial fibrillation/atrial flutter is highly symptomatic. In general, antiarrhythmic therapy for atrial fibrillation/atrial flutter aims to prolong the time in normal sinus rhythm. Recurrence is expected in some patients (see CLINICAL STUDIES ). uuid:2902dd72-d04d-450b-a684-aef336a7c480 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4681 biolink:treats MONDO:0005310 PMID:41385096 "[{""id"":""uuid:274a3ad0-9b6e-4837-9b6a-ef208eacd4b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:38c0d028-3837-414c-b4a8-f99817f74248"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TIKOSYN is indicated for the maintenance of normal sinus rhythm (delay in time to recurrence of atrial fibrillation/atrial flutter [AF/AFl]) in patients with atrial fibrillation/atrial flutter of greater than one week duration who have been converted to normal sinus rhythm. Because TIKOSYN can cause life threatening ventricular arrhythmias, it should be reserved for patients in whom atrial fibrillation/atrial flutter is highly symptomatic. In general, antiarrhythmic therapy for atrial fibrillation/atrial flutter aims to prolong the time in normal sinus rhythm. Recurrence is expected in some patients (see CLINICAL STUDIES ). uuid:dc6ad599-fb8c-4acf-8bd8-25bd5f7cfc9f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:65173 biolink:treats MONDO:0005090 PMID:41385096 "[{""id"":""uuid:6c2c3e54-5f27-4f6f-8ac6-5a33c112367f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a4ffa6d6-f893-4847-93c2-2e647d80e9ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FANAPT ® tablets are indicated for the treatment of adults with schizophrenia. Efficacy was established in two short-term (4- and 6-week) placebo-and active-controlled studies of adult patients with schizophrenia [see Clinical Studies ( 14 )] . When deciding among the alternative treatments available for this condition, the prescriber should consider the finding that FANAPT is associated with prolongation of the QTc interval [see Warnings and Precautions ( 5.2 )] . Prolongation of the QTc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia which can result in sudden death. In many cases this would lead to the conclusion that other drugs should be tried first. Whether FANAPT will cause torsade de pointes or increase the rate of sudden death is not yet known. Patients must be titrated to an effective dose of FANAPT. Thus, control of symptoms may be delayed during the first 1 to 2 weeks of treatment compared to some other antipsychotic drugs that do not require a similar titration. Prescribers should be mindful of this delay when selecting an antipsychotic drug for the treatment of schizophrenia [see Dosage and Administration ( 2.1 ) and Clinical Studies ( 14 )] . The effectiveness of FANAPT in long-term use, that is, for more than 6 weeks, has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use FANAPT for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient [see Dosage and Administration ( 2.3 )] . uuid:38caec47-bb14-4d96-ab5e-1ce874f74e35 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9599 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:833f1a38-1d5e-404b-98c2-416f0997d888"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a9120e8f-8282-4615-9fd6-1c877ffac412"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Timolol maleate tablets are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. uuid:b07234b1-9ec8-4557-bc33-8ea21eedbcfb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6904 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:b7f9f63e-c5e5-4a82-94b2-a452f34f2413"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:740edf28-d1de-4751-b5e4-bb5772ce9493"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hypertension Metoprolol succinate extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (eg, on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Metoprolol succinate extended-release tablets may be administered with other antihypertensive agents. 1.2 Angina Pectoris Metoprolol succinate extended-release tablets are indicated in the long-term treatment of angina pectoris, to reduce angina attacks and to improve exercise tolerance. 1.3 Heart Failure Metoprolol succinate extended-release tablets are indicated for the treatment of stable, symptomatic (NYHA Class II or III) heart failure of ischemic, hypertensive, or cardiomyopathic origin. It was studied in patients already receiving ACE inhibitors, diuretics, and, in the majority of cases, digitalis. In this population, metoprolol succinate extended-release tablets decreased the rate of mortality plus hospitalization, largely through a reduction in cardiovascular mortality and hospitalizations for heart failure. Please review the manufacturer's complete drug information available from the FDA at www.fda.gov Permanent Link: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=71c1d33e-be6f-6d59-b715-45075445891a uuid:6114b960-adea-4159-b1c2-f254e3b23029 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6904 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:a8ee6063-ee2a-4c0d-9b95-57d7d9f8c916"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b11f7b17-7504-4916-8692-e89d5a5001aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hypertension Metoprolol succinate extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (eg, on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Metoprolol succinate extended-release tablets may be administered with other antihypertensive agents. 1.2 Angina Pectoris Metoprolol succinate extended-release tablets are indicated in the long-term treatment of angina pectoris, to reduce angina attacks and to improve exercise tolerance. 1.3 Heart Failure Metoprolol succinate extended-release tablets are indicated for the treatment of stable, symptomatic (NYHA Class II or III) heart failure of ischemic, hypertensive, or cardiomyopathic origin. It was studied in patients already receiving ACE inhibitors, diuretics, and, in the majority of cases, digitalis. In this population, metoprolol succinate extended-release tablets decreased the rate of mortality plus hospitalization, largely through a reduction in cardiovascular mortality and hospitalizations for heart failure. Please review the manufacturer's complete drug information available from the FDA at www.fda.gov Permanent Link: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=71c1d33e-be6f-6d59-b715-45075445891a uuid:4772040b-6d05-4f26-9638-cf2590841149 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5108 biolink:treats MONDO:0005093 PMID:41385096 "[{""id"":""uuid:bb21ba4b-c544-40c6-b514-51a7e103cb63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fbe3c840-5bc6-41f6-a66b-1966a56104a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluocinolone Acetonide Topical Solution is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. uuid:4f5e19cc-ac78-4897-b081-8e5f23835bcb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:73139 biolink:treats MONDO:0005812 PMID:41385096 "[{""id"":""uuid:4b6ce4bf-ae27-45d8-a9c8-fd0abd08149a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1c200b8c-ea21-4f41-a93e-431edb5311a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oseltamivir phosphate is an influenza neuraminidase (NAI) inhibitor indicated for: Treatment of acute, uncomplicated influenza A and B in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. ( 1.1 ) Prophylaxis of influenza A and B in patients 1 year and older. ( 1.2 ) Limitations of Use: Not a substitute for annual influenza vaccination. ( 1.3 ) Consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use. ( 1.3 ) Not recommended for patients with end-stage renal disease not undergoing dialysis. ( 1.3 ) uuid:4b37f82a-e31e-4e2f-b06d-09ea352255c7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:73139 biolink:treats UMLS:C0276353 PMID:41385096 "[{""id"":""uuid:8df53990-e1c7-4bfa-b53d-1900f7de25c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:70177fa8-3fb5-4834-b2e6-dfdc3ece4d9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oseltamivir phosphate is an influenza neuraminidase (NAI) inhibitor indicated for: Treatment of acute, uncomplicated influenza A and B in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours. ( 1.1 ) Prophylaxis of influenza A and B in patients 1 year and older. ( 1.2 ) Limitations of Use: Not a substitute for annual influenza vaccination. ( 1.3 ) Consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use. ( 1.3 ) Not recommended for patients with end-stage renal disease not undergoing dialysis. ( 1.3 ) uuid:65c00928-24e3-4fa5-b264-fc4ec6b4b169 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40303 biolink:treats MONDO:0007759 PMID:41385096 "[{""id"":""uuid:4d6ae00f-e036-47c7-91b8-37126d8a3cd9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6e7553a7-4a4b-4a4b-94d5-9928d5917066"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lovastatin tablets USP should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin tablets USP should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C and below average HDL-C, lovastatin tablets USP are indicated to reduce the risk of: -Myocardial infarction -Unstable angina -Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies). Coronary Heart Disease Lovastatin tablets USP are indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Lovastatin tablets USP are indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2 ), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. 2 Classification of Hyperlipoproteinemias IDL = intermediate-density lipoprotein. Type Lipoproteins elevated Lipid Elevations major minor I chylomicrons TG ↑→C IIa LDL C — IIb LDL,VLDL C TG III (rare) IDL C/TG — IV VLDL TG ↑→C V (rare) chylomicrons,VLDL TG ↑→C Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin tablets USP are indicated as an adjunct to diet to reduce total-C, LDL-C and apolipoprotein B levels in adolescent boys and girls who are at least one year post-menarche, 10 to 17 years of age, with heFH if after an adequate trial of diet therapy the following findings are present: 1. LDL-C remains >189 mg/dL or 2. LDL-C remains >160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the adolescent patient General Recommendations Prior to initiating therapy with lovastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total-C, HDL-C, and TG. For patients with TG less than 400 mg / dL (<4.5 mmol / L), LDL-C can be estimated using the following equation: LDL-C = total-C – [0.2 × (TG) + HDL-C] For TG levels >400 mg/dL (>4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated total-C. In such cases, lovastatin tablets USP are not indicated. The National Cholesterol Education Program (NCEP) Treatment Guidelines are summarized below: † CHD, coronary heart disease † † Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of <100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgment also may call for deferring drug therapy in this subcategory. † † † Almost all people with 0 to 1 risk factor have a 10-year risk <10%; thus, 10-year risk assessment in people with 0 to 1 risk factor is not necessary. NCEP Treatment Guidelines : LDL - C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal ( mg / dL ) LDL Level at Which to Initiate Therapeutic Lifestyle Changes ( mg / dL ) LDL Level at Which to Consider Drug Therapy ( mg / dL ) CHD † or CHD risk equivalents (10-year risk >20%) <100 ≥100 ≥130 (100 to 129: drug optional) † † 2+ Risk factors (10-year risk ≤20%) <130 ≥130 10-year risk 10 to 20%: ≥130 10-year risk <10%: ≥160 0 to 1 Risk factor † † † <160 ≥160 ≥190 (160 to 189: LDL-lowering drug optional) After the LDL-C goal has been achieved, if the TG is still ≥200 mg/dL, non-HDL-C (total-C minus HDL-C) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is ≥130 mg/dL (see NCEP Guidelines above). Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the total-C be used to monitor therapy. Although lovastatin tablets USP may be useful to reduce elevated LDL-C levels in patients with combined hypercholesterolemia and hypertriglyceridemia where hypercholesterolemia is the major abnormality (Type IIb hyperlipoproteinemia), it has not been studied in conditions where the major abnormality is elevation of chylomicrons, VLDL or IDL (i.e., hyperlipoproteinemia types I, III, IV, or V). 2 The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total - C ( mg / dL ) LDL - C ( mg / dL ) Acceptable <170 <110 Borderline 170 to 199 110 to 129 High ≥200 ≥130 Children treated with lovastatin in adolescence should be re-evaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult goals for LDL-C. uuid:38975aa0-4b57-4b7a-8b89-d531527af002 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7931 biolink:treats MONDO:0001530 PMID:41385096 "[{""id"":""uuid:b2659d0c-b677-4480-83e5-aa21987d349d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3d4ef8fd-96bc-45e6-8315-c4d5ed8055a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Chronic Kidney Disease Stages 3 and 4 Paricalcitol Capsules are indicated in adults for the prevention and treatment of secondary hyperparathyroidism associated with Chronic Kidney Disease (CKD) Stages 3 and 4. Pediatric use information for patients 10 to 16 years of age is approved for AbbVie Inc.’s Zemplar (Paricalcitol) capsules. However, due to AbbVie Inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. 1.2 Chronic Kidney Disease Stage 5 Paricalcitol Capsules are indicated in adults for the prevention and treatment of secondary hyperparathyroidism associated with CKD Stage 5 in patients on hemodialysis (HD) or peritoneal dialysis (PD). Pediatric use information for patients 10 to 16 years of age is approved for AbbVie Inc.’s Zemplar (Paricalcitol) capsules. However, due to AbbVie Inc.’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. uuid:36b6f5f5-9864-4210-b350-050de7d72295 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4YBM839JAC biolink:treats MONDO:0018048 PMID:41385096 "[{""id"":""uuid:994f0240-f925-4b0d-8e3a-20ec0374c4b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ac50d0c6-f4cc-49b4-811e-4132cd08adef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Argatroban is a direct thrombin inhibitor indicated: For prophylaxis or treatment of thrombosis in adult patients with heparin-induced thrombocytopenia (HIT) (1.1) As an anticoagulant in adults patients with or at risk for HIT undergoing percutaneous coronary intervention (PCI) (1.2) uuid:6bb22986-0f46-4034-8809-effe2b3a342f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4YBM839JAC biolink:treats MONDO:0000831 PMID:41385096 "[{""id"":""uuid:47647d78-5ec9-43b9-96a2-d2989ba63849"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2278c39b-832e-4589-a6f3-39b3faa3e669"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Argatroban is a direct thrombin inhibitor indicated: For prophylaxis or treatment of thrombosis in adult patients with heparin-induced thrombocytopenia (HIT) (1.1) As an anticoagulant in adults patients with or at risk for HIT undergoing percutaneous coronary intervention (PCI) (1.2) uuid:5c9f0227-8a1c-44b2-8cd4-1f1441f36575 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31941 biolink:treats MONDO:0021063 PMID:41385096 "[{""id"":""uuid:36176cf6-68a6-475a-9e3d-f62a07699398"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1af2aa4f-64c9-4b56-b94e-8df542850dbe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ede4d7ab-a49a-4042-8028-2e8a41f494ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxaliplatin for injection USP, used in combination with infusional 5-fluorouracil/leucovorin, is indicated for: - adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. - treatment of advanced colorectal cancer.|[PMDA] A drug containing a new active ingredient with indications for colonic and rectal cancers. uuid:0c8de283-5497-4af3-a2ee-76398308110c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31941 biolink:treats MONDO:0005575 PMID:41385096 "[{""id"":""uuid:890321ac-50cb-4586-9ccf-f3acc7b08299"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4d80faec-2722-482c-9b6e-45023f8c8889"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:205c15f7-4d90-45af-8a0a-5862186f18bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxaliplatin for injection USP, used in combination with infusional 5-fluorouracil/leucovorin, is indicated for: - adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. - treatment of advanced colorectal cancer.|[PMDA] Drugs with a new additional indication and a new additional dosage and administration for combination therapy with other anticancer drugs (XELOX + BV regimen) for advanced or recurrent colorectal cancer not suited for curative resection. uuid:4d97e24e-f6be-46a3-baef-a6553a0275cb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8228 biolink:treats MONDO:0005154 PMID:41385096 "[{""id"":""uuid:84cc59fb-5bcb-412f-a9bb-f6a56df42ed8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9e58a8a0-07ce-443b-a89d-5b01d5c14f7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Monotherapy and Combination Therapy Pioglitazone tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus in multiple clinical settings [ see Clinical Studies (14) ]. Important Limitations of Use Pioglitazone tablets exert their antihyperglycemic effect only in the presence of endogenous insulin. Pioglitazone tablets should not be used to treat type 1 diabetes or diabetic ketoacidosis, as it would not be effective in these settings. Use caution in patients with liver disease [ see Warnings and Precautions (5.3) ]. uuid:c2292343-164f-4810-9867-b1b50fc2bdeb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7565 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:ff656fb1-9f6a-485f-9628-aafe68c8b15b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9a0f6023-3244-474c-99d2-2d2f7cf1cdb0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] I. Vasospastic Angina Nifedipine Extended-release Tablet is indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. In those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. Nifedipine Extended-release Tablet may also be used where the clinical presentation suggests a possible vasospastic component, but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion, or in unstable angina where electrocardiographic findings are compatible with intermittent vasospasm, or when angina is refractory to nitrates and/or adequate doses of beta-blockers. II. Chronic Stable Angina (Classical Effort-Associated Angina) Nifedipine Extended-release Tablet is indicated for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm in patients who remain symptomatic despite adequate doses of beta-blockers and/or organic nitrates or who cannot tolerate those agents. In chronic stable angina (effort-associated angina), nifedipine has been effective in controlled trials of up to eight weeks duration in reducing angina frequency and increasing exercise tolerance, but confirmation of sustained effectiveness and evaluation of long-term safety in these patients is incomplete. Controlled studies in small numbers of patients suggest concomitant use of nifedipine and beta-blocking agents may be beneficial in patients with chronic stable angina, but available information is not sufficient to predict with confidence the effects of concurrent treatment, especially in patients with compromised left ventricular function or cardiac conduction abnormalities. When introducing such concomitant therapy, care must be taken to monitor blood pressure closely, since severe hypotension can occur from the combined effects of the drugs. (see WARNINGS.) III. Hypertension Nifedipine Extended-release Tablet is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including Nifedipine Extended-release Tablet. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Nifedipine Extended-release Tablet may be used alone or in combination with other antihypertensive agents. uuid:7d40b17e-94b3-45d7-ad44-75a5c739ab22 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7565 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:3eb7a284-15c7-4df3-980b-2e9b49066af4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:80b569bf-448f-4945-9c6e-b66b35edd589"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] I. Vasospastic Angina Nifedipine Extended-release Tablet is indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. In those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. Nifedipine Extended-release Tablet may also be used where the clinical presentation suggests a possible vasospastic component, but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion, or in unstable angina where electrocardiographic findings are compatible with intermittent vasospasm, or when angina is refractory to nitrates and/or adequate doses of beta-blockers. II. Chronic Stable Angina (Classical Effort-Associated Angina) Nifedipine Extended-release Tablet is indicated for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm in patients who remain symptomatic despite adequate doses of beta-blockers and/or organic nitrates or who cannot tolerate those agents. In chronic stable angina (effort-associated angina), nifedipine has been effective in controlled trials of up to eight weeks duration in reducing angina frequency and increasing exercise tolerance, but confirmation of sustained effectiveness and evaluation of long-term safety in these patients is incomplete. Controlled studies in small numbers of patients suggest concomitant use of nifedipine and beta-blocking agents may be beneficial in patients with chronic stable angina, but available information is not sufficient to predict with confidence the effects of concurrent treatment, especially in patients with compromised left ventricular function or cardiac conduction abnormalities. When introducing such concomitant therapy, care must be taken to monitor blood pressure closely, since severe hypotension can occur from the combined effects of the drugs. (see WARNINGS.) III. Hypertension Nifedipine Extended-release Tablet is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including Nifedipine Extended-release Tablet. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Nifedipine Extended-release Tablet may be used alone or in combination with other antihypertensive agents. uuid:df2098a6-460c-4d06-875d-cf23631809ff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7565 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:6ff3c9b1-fa5f-451a-b264-fa8d1e211ad4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:420d82e6-c698-473d-b9d9-d52cc8657f22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] I. Vasospastic Angina Nifedipine Extended-release Tablet is indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. In those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. Nifedipine Extended-release Tablet may also be used where the clinical presentation suggests a possible vasospastic component, but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion, or in unstable angina where electrocardiographic findings are compatible with intermittent vasospasm, or when angina is refractory to nitrates and/or adequate doses of beta-blockers. II. Chronic Stable Angina (Classical Effort-Associated Angina) Nifedipine Extended-release Tablet is indicated for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm in patients who remain symptomatic despite adequate doses of beta-blockers and/or organic nitrates or who cannot tolerate those agents. In chronic stable angina (effort-associated angina), nifedipine has been effective in controlled trials of up to eight weeks duration in reducing angina frequency and increasing exercise tolerance, but confirmation of sustained effectiveness and evaluation of long-term safety in these patients is incomplete. Controlled studies in small numbers of patients suggest concomitant use of nifedipine and beta-blocking agents may be beneficial in patients with chronic stable angina, but available information is not sufficient to predict with confidence the effects of concurrent treatment, especially in patients with compromised left ventricular function or cardiac conduction abnormalities. When introducing such concomitant therapy, care must be taken to monitor blood pressure closely, since severe hypotension can occur from the combined effects of the drugs. (see WARNINGS.) III. Hypertension Nifedipine Extended-release Tablet is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including Nifedipine Extended-release Tablet. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Nifedipine Extended-release Tablet may be used alone or in combination with other antihypertensive agents. uuid:84fc4399-dea6-4372-8a68-25fe75adf8bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6541 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:65c1cdb5-89a0-4375-b334-a6d7e2547992"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e79fea1f-35f4-46b0-b3d2-76066c80182d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Losartan potassium tablets are an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) • Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. ( 1.2 ) • Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. ( 1.3 ) uuid:82f28f80-73aa-478e-ae83-bfe4d526a534 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6541 biolink:treats MONDO:0006652 PMID:41385096 "[{""id"":""uuid:5087f982-97e2-456e-bced-a861fa5090e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3b3ee819-27dd-474f-a8da-19c8dc1fb2d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Losartan potassium tablets are an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) • Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. ( 1.2 ) • Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. ( 1.3 ) uuid:7f12c59e-67d6-46fb-9ab8-cd119922dbd9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5100 biolink:treats MONDO:0700217 PMID:41385096 "[{""id"":""uuid:ea468ea7-0dfc-483e-af82-8acd6f29a034"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d3929263-385c-489b-90fa-6814daeb2727"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Flucytosine Capsules are indicated only in the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus . Candida: Septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. Limited trials in pulmonary infections justify the use of flucytosine. Cryptococcus: Meningitis and pulmonary infections have been treated effectively. Studies in septicemias and urinary tract infections are limited, but good responses have been reported. Flucytosine Capsules should be used in combination with amphotericin B for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to Flucytosine Capsules (see MICROBIOLOGY ). uuid:62dcae89-1331-408f-87b1-daff8baac2f3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5100 biolink:treats MONDO:0005025 PMID:41385096 "[{""id"":""uuid:c4a3965d-5b7b-4c57-8cd3-3e607dbb63ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d8617f05-f9d4-411a-a573-73e619d24f92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Flucytosine Capsules are indicated only in the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus . Candida: Septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. Limited trials in pulmonary infections justify the use of flucytosine. Cryptococcus: Meningitis and pulmonary infections have been treated effectively. Studies in septicemias and urinary tract infections are limited, but good responses have been reported. Flucytosine Capsules should be used in combination with amphotericin B for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to Flucytosine Capsules (see MICROBIOLOGY ). uuid:1f7dd6a7-8f6b-4a95-bc6d-12593704051b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5100 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:3a52106a-8754-46f2-99e6-c3465d89c293"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:29b8c793-d1e6-4720-8489-7542b2b22f47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Flucytosine Capsules are indicated only in the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus . Candida: Septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. Limited trials in pulmonary infections justify the use of flucytosine. Cryptococcus: Meningitis and pulmonary infections have been treated effectively. Studies in septicemias and urinary tract infections are limited, but good responses have been reported. Flucytosine Capsules should be used in combination with amphotericin B for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to Flucytosine Capsules (see MICROBIOLOGY ). uuid:dd2d2fb5-46eb-4a38-b597-641eb73e4e3b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5100 biolink:treats MONDO:0021108 PMID:41385096 "[{""id"":""uuid:d8eb5393-2c82-45e6-85ed-bb9994870c5d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ae38167e-b145-4685-a581-65ca7bd08602"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Flucytosine Capsules are indicated only in the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus . Candida: Septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. Limited trials in pulmonary infections justify the use of flucytosine. Cryptococcus: Meningitis and pulmonary infections have been treated effectively. Studies in septicemias and urinary tract infections are limited, but good responses have been reported. Flucytosine Capsules should be used in combination with amphotericin B for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to Flucytosine Capsules (see MICROBIOLOGY ). uuid:f34c6b92-70f6-481f-84fd-9d136bd144d3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5100 biolink:treats MONDO:0042233 PMID:41385096 "[{""id"":""uuid:635fee6f-fc17-410b-8bf6-7df7218bbf90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eafcad40-3124-4470-b639-92f9e78ca6b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Flucytosine Capsules are indicated only in the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus . Candida: Septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. Limited trials in pulmonary infections justify the use of flucytosine. Cryptococcus: Meningitis and pulmonary infections have been treated effectively. Studies in septicemias and urinary tract infections are limited, but good responses have been reported. Flucytosine Capsules should be used in combination with amphotericin B for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to Flucytosine Capsules (see MICROBIOLOGY ). uuid:e6617c04-5c7a-435e-a87f-14193c806ee0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5100 biolink:treats MONDO:0005724 PMID:41385096 "[{""id"":""uuid:56940ef9-87ff-47be-8bd6-c5d41a95a9fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a96b6c80-dae0-4e71-b82b-9beb8881d04b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Flucytosine Capsules are indicated only in the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus . Candida: Septicemia, endocarditis and urinary system infections have been effectively treated with flucytosine. Limited trials in pulmonary infections justify the use of flucytosine. Cryptococcus: Meningitis and pulmonary infections have been treated effectively. Studies in septicemias and urinary tract infections are limited, but good responses have been reported. Flucytosine Capsules should be used in combination with amphotericin B for the treatment of systemic candidiasis and cryptococcosis because of the emergence of resistance to Flucytosine Capsules (see MICROBIOLOGY ). uuid:a7fbfd07-4201-4fd9-abda-c630cc3f7519 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6541 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:e4ed7b68-5ba3-4893-a895-9c54525da3ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3b87a9b0-a379-4f0c-86c5-29f86bb03ca5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Losartan potassium tablets are an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. (1.1) Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. (1.2) Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension. (1.3) uuid:3b36f79b-7560-4733-b5b6-089629b7ea96 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9671 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:1a5be9ab-08f6-4f1d-9017-c6c6a651eac1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:972a4b5a-d578-439c-b1b1-9ac170ce3ae1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dyrenium (triamterene) is indicated in the treatment of edema associated with congestive heart failure, cirrhosis of the liver and the nephrotic syndrome; steroid-induced edema, idiopathic edema and edema due to secondary hyperaldosteronism. Dyrenium may be used alone or with other diuretics, either for its added diuretic effect or its potassium-sparing potential. It also promotes increased diuresis when patients prove resistant or only partially responsive to thiazides or other diuretics because of secondary hyperaldosteronism. Usage in Pregnancy . The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. Edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. Diuretics are indicated in pregnancy (however, see PRECAUTIONS below) when edema is due to pathologic causes, just as they are in the absence of pregnancy. Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort which is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate. uuid:4276865b-beee-4a09-a066-a88091a91e85 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9671 biolink:treats MONDO:0005155 PMID:41385096 "[{""id"":""uuid:3c0fcc2c-7b2e-449f-99d1-4e3867a98859"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3aeb9d9e-bb81-42e7-9266-c5a40f051e7d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dyrenium (triamterene) is indicated in the treatment of edema associated with congestive heart failure, cirrhosis of the liver and the nephrotic syndrome; steroid-induced edema, idiopathic edema and edema due to secondary hyperaldosteronism. Dyrenium may be used alone or with other diuretics, either for its added diuretic effect or its potassium-sparing potential. It also promotes increased diuresis when patients prove resistant or only partially responsive to thiazides or other diuretics because of secondary hyperaldosteronism. Usage in Pregnancy . The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. Edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. Diuretics are indicated in pregnancy (however, see PRECAUTIONS below) when edema is due to pathologic causes, just as they are in the absence of pregnancy. Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort which is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate. uuid:694f86c4-eae1-418c-ae3f-a681d737b179 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9671 biolink:treats MONDO:0005377 PMID:41385096 "[{""id"":""uuid:f2e826f8-a12d-428f-a6a7-11857d31c752"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b47ea31d-6f6b-4e49-9365-e8375d944d31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dyrenium (triamterene) is indicated in the treatment of edema associated with congestive heart failure, cirrhosis of the liver and the nephrotic syndrome; steroid-induced edema, idiopathic edema and edema due to secondary hyperaldosteronism. Dyrenium may be used alone or with other diuretics, either for its added diuretic effect or its potassium-sparing potential. It also promotes increased diuresis when patients prove resistant or only partially responsive to thiazides or other diuretics because of secondary hyperaldosteronism. Usage in Pregnancy . The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. Edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. Diuretics are indicated in pregnancy (however, see PRECAUTIONS below) when edema is due to pathologic causes, just as they are in the absence of pregnancy. Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort which is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate. uuid:98978649-bce8-41f1-b1bd-13975974f7c8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9671 biolink:treats UMLS:C0238094 PMID:41385096 "[{""id"":""uuid:b49270fd-3030-4575-a305-0d605a679f01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ebcf60b9-8f73-47c4-8649-aca8b1b187ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dyrenium (triamterene) is indicated in the treatment of edema associated with congestive heart failure, cirrhosis of the liver and the nephrotic syndrome; steroid-induced edema, idiopathic edema and edema due to secondary hyperaldosteronism. Dyrenium may be used alone or with other diuretics, either for its added diuretic effect or its potassium-sparing potential. It also promotes increased diuresis when patients prove resistant or only partially responsive to thiazides or other diuretics because of secondary hyperaldosteronism. Usage in Pregnancy . The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. Edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. Diuretics are indicated in pregnancy (however, see PRECAUTIONS below) when edema is due to pathologic causes, just as they are in the absence of pregnancy. Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort which is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate. uuid:c12bb15e-a92f-4ffb-aad6-118b82feb10e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9671 biolink:treats MONDO:0003009 PMID:41385096 "[{""id"":""uuid:a73a6b78-8f38-4334-87e9-2a395c16c5c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4fa28a73-0f43-4eb7-b11e-ed5c665d721c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dyrenium (triamterene) is indicated in the treatment of edema associated with congestive heart failure, cirrhosis of the liver and the nephrotic syndrome; steroid-induced edema, idiopathic edema and edema due to secondary hyperaldosteronism. Dyrenium may be used alone or with other diuretics, either for its added diuretic effect or its potassium-sparing potential. It also promotes increased diuresis when patients prove resistant or only partially responsive to thiazides or other diuretics because of secondary hyperaldosteronism. Usage in Pregnancy . The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. Edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. Diuretics are indicated in pregnancy (however, see PRECAUTIONS below) when edema is due to pathologic causes, just as they are in the absence of pregnancy. Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort which is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate. uuid:a0288c53-ec0e-428e-998e-cf1e4e91b7b4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9671 biolink:treats MONDO:0045048 PMID:41385096 "[{""id"":""uuid:551d7970-ce3b-4f8e-a724-1ce591985f50"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:111e2d89-dc00-4e29-abd1-e217ac924eaf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dyrenium (triamterene) is indicated in the treatment of edema associated with congestive heart failure, cirrhosis of the liver and the nephrotic syndrome; steroid-induced edema, idiopathic edema and edema due to secondary hyperaldosteronism. Dyrenium may be used alone or with other diuretics, either for its added diuretic effect or its potassium-sparing potential. It also promotes increased diuresis when patients prove resistant or only partially responsive to thiazides or other diuretics because of secondary hyperaldosteronism. Usage in Pregnancy . The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. Edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. Diuretics are indicated in pregnancy (however, see PRECAUTIONS below) when edema is due to pathologic causes, just as they are in the absence of pregnancy. Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort which is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate. uuid:3bca7ba5-f747-4eb3-858c-dc048eb0c7a2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9671 biolink:treats MONDO:0005081 PMID:41385096 "[{""id"":""uuid:21d767f1-5cec-425e-9e3f-0db3997da13c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6a42f404-813c-4b75-961c-349cb118fd48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dyrenium (triamterene) is indicated in the treatment of edema associated with congestive heart failure, cirrhosis of the liver and the nephrotic syndrome; steroid-induced edema, idiopathic edema and edema due to secondary hyperaldosteronism. Dyrenium may be used alone or with other diuretics, either for its added diuretic effect or its potassium-sparing potential. It also promotes increased diuresis when patients prove resistant or only partially responsive to thiazides or other diuretics because of secondary hyperaldosteronism. Usage in Pregnancy . The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. Edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. Diuretics are indicated in pregnancy (however, see PRECAUTIONS below) when edema is due to pathologic causes, just as they are in the absence of pregnancy. Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort which is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate. uuid:68df22c4-add1-477b-bfbc-7e7d9d2a483e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9671 biolink:treats UMLS:C0341960 PMID:41385096 "[{""id"":""uuid:39ca9d97-ba55-4de5-a056-5a57007e5673"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e0758464-494b-429f-a7b4-160a745e595b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dyrenium (triamterene) is indicated in the treatment of edema associated with congestive heart failure, cirrhosis of the liver and the nephrotic syndrome; steroid-induced edema, idiopathic edema and edema due to secondary hyperaldosteronism. Dyrenium may be used alone or with other diuretics, either for its added diuretic effect or its potassium-sparing potential. It also promotes increased diuresis when patients prove resistant or only partially responsive to thiazides or other diuretics because of secondary hyperaldosteronism. Usage in Pregnancy . The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. Edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. Diuretics are indicated in pregnancy (however, see PRECAUTIONS below) when edema is due to pathologic causes, just as they are in the absence of pregnancy. Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort which is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate. uuid:eba25a78-5550-4ee2-8c39-e65262a84a2e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9671 biolink:treats HP:0007430 PMID:41385096 "[{""id"":""uuid:240f9d1c-eb80-4a1a-a224-5fa5d901367e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ae79732f-d096-4d70-80ab-43231cd5f277"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dyrenium (triamterene) is indicated in the treatment of edema associated with congestive heart failure, cirrhosis of the liver and the nephrotic syndrome; steroid-induced edema, idiopathic edema and edema due to secondary hyperaldosteronism. Dyrenium may be used alone or with other diuretics, either for its added diuretic effect or its potassium-sparing potential. It also promotes increased diuresis when patients prove resistant or only partially responsive to thiazides or other diuretics because of secondary hyperaldosteronism. Usage in Pregnancy . The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. Edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. Diuretics are indicated in pregnancy (however, see PRECAUTIONS below) when edema is due to pathologic causes, just as they are in the absence of pregnancy. Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort which is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate. uuid:ec961d78-ac2a-42ba-8761-7172227a50c2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29101 biolink:treats MONDO:0005412 PMID:41385096 "[{""id"":""uuid:c393dec4-ecea-49a7-a6c0-6b122e45545e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8f597656-0deb-45a9-b4b8-72f0f04a2085"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Omeprazole and sodium bicarbonate is a proton pump inhibitor indicated for: Short-term treatment of active duodenal ulcer ( 1.1 ) Short-term treatment of active benign gastric ulcer ( 1.2 ) Treatment of gastroesophageal reflux disease (GERD) ( 1.3 ) Maintenance of healing of erosive esophagitis (1.4) The safety and effectiveness of omeprazole and sodium bicarbonate capsules in pediatric patients (<18 years of age) have not been established. ( 8.4 ) uuid:28103e42-aa72-48e1-a7a4-ab798b06b85f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29101 biolink:treats MONDO:0001126 PMID:41385096 "[{""id"":""uuid:cfe419d3-8534-4108-ba3b-e2a16f9d7a10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5cf04cd0-1074-4825-bb49-cc0e7d1bc4f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Omeprazole and sodium bicarbonate is a proton pump inhibitor indicated for: Short-term treatment of active duodenal ulcer ( 1.1 ) Short-term treatment of active benign gastric ulcer ( 1.2 ) Treatment of gastroesophageal reflux disease (GERD) ( 1.3 ) Maintenance of healing of erosive esophagitis (1.4) The safety and effectiveness of omeprazole and sodium bicarbonate capsules in pediatric patients (<18 years of age) have not been established. ( 8.4 ) uuid:f4ce0beb-ec7f-4c78-af29-abfc53d0b8b2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29101 biolink:treats UMLS:C0267055 PMID:41385096 "[{""id"":""uuid:667d922b-f0e1-4860-8af3-f1b4182d67bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:342c131b-5225-4eb8-8cb7-9f2e4e26bbbc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Omeprazole and sodium bicarbonate is a proton pump inhibitor indicated for: Short-term treatment of active duodenal ulcer ( 1.1 ) Short-term treatment of active benign gastric ulcer ( 1.2 ) Treatment of gastroesophageal reflux disease (GERD) ( 1.3 ) Maintenance of healing of erosive esophagitis (1.4) The safety and effectiveness of omeprazole and sodium bicarbonate capsules in pediatric patients (<18 years of age) have not been established. ( 8.4 ) uuid:07b2ad71-ae28-4ffb-9f7f-46f31cdfa835 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0019801 PMID:41385096 "[{""id"":""uuid:375d17ec-456a-4f0c-9b0f-88c9ad656dae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fadc21b7-4984-42ff-abcb-93d333e27f88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:ec8fcde9-b8a6-4328-b69d-5cddb9df3cbf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:8d58e6d2-1744-419f-8a7d-74ae94032999"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b24e3b85-af30-4568-bc3d-9a5428821f66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:1ebb18ad-f032-4343-bc65-3aac5b847d84 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0040698 PMID:41385096 "[{""id"":""uuid:ea1440f8-c42e-45dc-93ef-5ce5a9a0b7f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f16104bd-b401-41f4-a241-62589945add4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:d5f144b6-5371-4e18-b1a0-0a76da3ab991 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0001875 PMID:41385096 "[{""id"":""uuid:874566bc-f23d-4265-9c6e-54865f2490b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a3ba7945-7a19-4617-940e-e096127c4c0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:2f68f0a2-c87b-45a1-8e0a-54c32d62a6e3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0004855 PMID:41385096 "[{""id"":""uuid:f72db26b-d4f5-4712-be0c-1df71fd7895f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b49ea18a-1a3e-42d6-aeaa-47211baf51c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:bbc71210-e052-4f8b-a6dd-51a06320a39e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0006545 PMID:41385096 "[{""id"":""uuid:68bfea29-2146-45e3-b326-4117c57e4fcd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:24808fde-9fa5-4745-8e90-3434e11418ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:2359d315-fc96-4a8f-91cf-9f93ec9f7804 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0006608 PMID:41385096 "[{""id"":""uuid:7a430e4f-9a64-405a-88fc-c0ec65ecddc9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:25950810-2260-463e-8f90-9184d45ed031"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:1620dc8d-efd9-4e6e-a932-0530111cc650 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:d87fb12c-3697-4827-8a89-d84feef4bf7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0b2a8afd-9735-4242-98ad-438d3cc88620"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:edce65fb-e612-43b9-af44-e2077c0c399b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0011786 PMID:41385096 "[{""id"":""uuid:7dc0b696-1d30-47b8-8305-1738c61298ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9debd80e-5958-4c14-b5bd-32c0d2b7a15b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:fde62692-e314-4fe9-9b03-a183318c9d23 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats UMLS:C0274440 PMID:41385096 "[{""id"":""uuid:cb3c9a3c-5b24-43a1-994f-477362ddc5e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fc60bd89-f4e8-4ded-8a87-19722410fe46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:eaf23fad-e269-4ae1-95de-91ba84a9e255 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0005883 PMID:41385096 "[{""id"":""uuid:d3a29b13-2528-49ed-bef4-6b2318dff05c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f0284405-e9c8-469c-912d-e13f78afbca5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:ed7ff697-9569-40c1-a104-5b651eb145b8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0004773 PMID:41385096 "[{""id"":""uuid:35333c37-459f-4be2-9ef0-34f4ca168769"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eeab1c7e-590d-4f43-9c4f-0c13747f3340"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:29f521a6-46d2-4bae-af40-57257d702fd3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0004674 PMID:41385096 "[{""id"":""uuid:9f7a4ea2-93bc-43b9-88c2-5cf3896398de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:402def79-03c2-4a6a-b4bd-7127bf1074a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:bf80904c-302f-405e-8d6d-fd1dad0b9c1a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0005885 PMID:41385096 "[{""id"":""uuid:28f461bf-0eb9-4852-9aa8-2e30bec44347"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e19743c9-cba9-45b6-a67a-496ed531f0a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:a3ad74e3-541e-4901-98cd-022e53450045 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0006651 PMID:41385096 "[{""id"":""uuid:0fea80c0-18db-4f6e-8574-761ed549369e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7174423c-b1e3-4d54-aedd-cee38ebef5cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:e887b4ab-2f29-42ce-b4e4-aa6ec51521f7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0003085 PMID:41385096 "[{""id"":""uuid:29e6b6e4-776d-446c-b0bf-1b40144d2f4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2ae2e8fc-bc69-4ee2-939f-e606f8e4c9a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:fd0f1391-8f4e-45c7-bf42-b28db78edca9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0001034 PMID:41385096 "[{""id"":""uuid:dc751762-ce91-4f9b-8823-e469de88daf2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4ba9f0c7-5ced-483d-8380-889f8ef1df9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:fcee79a2-f5ab-4c73-915c-75bcb701311c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0005848 PMID:41385096 "[{""id"":""uuid:c2b16723-3b09-4002-a71e-40310d21487d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a316122c-07bb-4d7b-8808-75e84df21596"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:cc7874e1-8f6b-4614-a1cb-2749d53a6be0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0002572 PMID:41385096 "[{""id"":""uuid:cb18fe86-d125-41ea-a6ed-eb9ec22448e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:97039c4d-8d4c-4692-80d6-c5ce17f0dcdd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:8c1ac708-3015-46ca-93ac-c6811adcebec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats UMLS:C0002879 PMID:41385096 "[{""id"":""uuid:b1a28a69-6842-4a92-afef-cd2ae926b4b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cc00073f-43a3-474e-9800-22d58feaf50a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:415c7e02-7904-42c0-a04a-fb4c51f6215a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0002280 PMID:41385096 "[{""id"":""uuid:c7811ab0-a83d-4f7b-b1b2-13b67519cb00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:34a50a41-0170-47da-ae49-df5851621269"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:8cb763e3-fc99-42b7-9344-d88600d4311d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0015253 PMID:41385096 "[{""id"":""uuid:607d07ae-c686-412b-9c87-51a95a3a0136"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9e80d774-fdb2-4c69-8163-56cf0c81e902"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:9902466c-7d23-46b1-aee1-478c0e80d33e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats HP:0001908 PMID:41385096 "[{""id"":""uuid:781f640c-3596-4ce0-979d-8f6adfb8a649"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8551fd30-11d4-4854-9876-378e8b488e36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:60a55df4-198c-4ad0-a31d-6b7101fe46de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0004355 PMID:41385096 "[{""id"":""uuid:a70dea0c-34e2-4bb9-b148-dc58075b0e42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dba4cbbd-a662-4960-8aa5-7a2c3e02bb52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:25351930-83f5-464d-91df-41a6f6927be9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0005377 PMID:41385096 "[{""id"":""uuid:522a47f5-d92e-4dee-a469-c7795b552970"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1e22ba5c-601f-4c12-80d7-66a89a85013e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:ea1a8555-4fd6-4602-b70e-20c60fb131ee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4450 biolink:treats HP:0001959 PMID:41385096 "[{""id"":""uuid:eecf3115-7636-4c9a-8420-e169a130e3bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8bfbf6d6-f50f-4fb8-90f3-36de0ddb7a5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Desmopressin acetate tablets are indicated as antidiuretic replacement therapy in the management of central diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. Desmopressin acetate is ineffective for the treatment of nephrogenic diabetes insipidus. Patients were selected for therapy based on the diagnosis by means of the water deprivation test, the hypertonic saline infusion test, and/or response to antidiuretic hormone. Continued response to desmopressin acetate can be monitored by measuring urine volume and osmolality. uuid:45a507fd-2b1d-48b8-8547-b74f108b471c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3561 biolink:treats MONDO:0044212 PMID:41385096 "[{""id"":""uuid:bc50d569-795d-4f2f-990d-ee72e88aa668"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:149d0f0a-b5d6-467f-bc24-529169508bce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Perennial Allergic Rhinitis: Cetirizine hydrochloride is indicated for the relief of symptoms associated with perennial allergic rhinitis due to allergens such as dust mites, animal dander and molds in children 6 to 23 months of age. Symptoms treated effectively include sneezing, rhinorrhea, postnasal discharge, nasal pruritus, ocular pruritus, and tearing. Chronic Urticaria: Cetirizine hydrochloride is indicated for the treatment of the uncomplicated skin manifestations of chronic idiopathic urticaria in children 6 months to 5 years of age. It significantly reduces the occurrence, severity, and duration of hives and significantly reduces pruritus. uuid:76cff9ae-7e04-449d-8756-5126bfc4ce6b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9938610 biolink:treats MONDO:0006805 PMID:41385096 "[{""id"":""uuid:d75bf0e0-0b24-479b-b6e4-40163c184ef0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b0087e9f-dcea-45ec-92d3-1374286e5005"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clopidogrel bisulfate is a P2Y12 platelet inhibitor indicated for: • Acute coronary syndrome - For patients with non-ST-segment elevation ACS [unstable angina (UA)/non-ST-elevation myocardial infarction (NSTEMI)], clopidogrel bisulfate has been shown to reduce the rate of myocardial infarction (MI) and stroke. ( 1.1 ) - For patients with ST-elevation myocardial infarction (STEMI), clopidogrel bisulfate has been shown to reduce the rate of MI and stroke. ( 1.1 ) • Recent MI, recent stroke, or established peripheral arterial disease. Clopidogrel bisulfate has been shown to reduce the rate of MI and stroke. ( 1.2 ) uuid:37d83853-488c-4b62-a125-d4ddbeba3762 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9938610 biolink:treats MONDO:0000990 PMID:41385096 "[{""id"":""uuid:ca20f7f5-da15-496b-8769-97f389573afc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:606ac9fa-a35b-4689-994b-d92a9138504c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clopidogrel bisulfate is a P2Y12 platelet inhibitor indicated for: • Acute coronary syndrome - For patients with non-ST-segment elevation ACS [unstable angina (UA)/non-ST-elevation myocardial infarction (NSTEMI)], clopidogrel bisulfate has been shown to reduce the rate of myocardial infarction (MI) and stroke. ( 1.1 ) - For patients with ST-elevation myocardial infarction (STEMI), clopidogrel bisulfate has been shown to reduce the rate of MI and stroke. ( 1.1 ) • Recent MI, recent stroke, or established peripheral arterial disease. Clopidogrel bisulfate has been shown to reduce the rate of MI and stroke. ( 1.2 ) uuid:db886183-4ca4-4ec8-addc-bb76aa8d2b37 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9938610 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:2039bec7-ac52-4d7d-9c1d-97075030b5cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1a80c477-4676-416e-9bbe-2e9857843b6d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clopidogrel bisulfate is a P2Y12 platelet inhibitor indicated for: • Acute coronary syndrome - For patients with non-ST-segment elevation ACS [unstable angina (UA)/non-ST-elevation myocardial infarction (NSTEMI)], clopidogrel bisulfate has been shown to reduce the rate of myocardial infarction (MI) and stroke. ( 1.1 ) - For patients with ST-elevation myocardial infarction (STEMI), clopidogrel bisulfate has been shown to reduce the rate of MI and stroke. ( 1.1 ) • Recent MI, recent stroke, or established peripheral arterial disease. Clopidogrel bisulfate has been shown to reduce the rate of MI and stroke. ( 1.2 ) uuid:1516a243-cb17-4ef9-a99a-6714422ddd8c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9938610 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:4e1189f3-b407-4af0-b6d1-edce9a030e65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aba3365f-5384-46e8-869c-feeeac147d9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clopidogrel bisulfate is a P2Y12 platelet inhibitor indicated for: • Acute coronary syndrome - For patients with non-ST-segment elevation ACS [unstable angina (UA)/non-ST-elevation myocardial infarction (NSTEMI)], clopidogrel bisulfate has been shown to reduce the rate of myocardial infarction (MI) and stroke. ( 1.1 ) - For patients with ST-elevation myocardial infarction (STEMI), clopidogrel bisulfate has been shown to reduce the rate of MI and stroke. ( 1.1 ) • Recent MI, recent stroke, or established peripheral arterial disease. Clopidogrel bisulfate has been shown to reduce the rate of MI and stroke. ( 1.2 ) uuid:70179682-518e-4e75-b12d-ded35750b08d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9938610 biolink:treats MONDO:0041656 PMID:41385096 "[{""id"":""uuid:0a8f1145-9766-4f4a-a8e2-283c25242f80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:37e9fc0a-00db-4f2b-8b0f-543a9e276e51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clopidogrel bisulfate is a P2Y12 platelet inhibitor indicated for: • Acute coronary syndrome - For patients with non-ST-segment elevation ACS [unstable angina (UA)/non-ST-elevation myocardial infarction (NSTEMI)], clopidogrel bisulfate has been shown to reduce the rate of myocardial infarction (MI) and stroke. ( 1.1 ) - For patients with ST-elevation myocardial infarction (STEMI), clopidogrel bisulfate has been shown to reduce the rate of MI and stroke. ( 1.1 ) • Recent MI, recent stroke, or established peripheral arterial disease. Clopidogrel bisulfate has been shown to reduce the rate of MI and stroke. ( 1.2 ) uuid:47ef6c71-3691-4df3-b919-a317409ddacd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9938610 biolink:treats MONDO:0005386 PMID:41385096 "[{""id"":""uuid:104c7c43-c1df-4a90-a1df-66280540ebb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3495c030-178d-4eb6-894d-39c756afeab5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clopidogrel bisulfate is a P2Y12 platelet inhibitor indicated for: • Acute coronary syndrome - For patients with non-ST-segment elevation ACS [unstable angina (UA)/non-ST-elevation myocardial infarction (NSTEMI)], clopidogrel bisulfate has been shown to reduce the rate of myocardial infarction (MI) and stroke. ( 1.1 ) - For patients with ST-elevation myocardial infarction (STEMI), clopidogrel bisulfate has been shown to reduce the rate of MI and stroke. ( 1.1 ) • Recent MI, recent stroke, or established peripheral arterial disease. Clopidogrel bisulfate has been shown to reduce the rate of MI and stroke. ( 1.2 ) uuid:9eec582d-375e-4b41-ae8e-c1aa8d2d2a5e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10119 biolink:treats MONDO:0100511 PMID:41385096 "[{""id"":""uuid:66e1e726-3824-4ada-9f67-ee1b65d5b120"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7367af4f-6c92-49c9-b3f2-6227c4f203ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ziprasidone hydrochloride capsules are indicated for the treatment of schizophrenia. When deciding among the alternative treatments available for the condition needing treatment, the prescriber should consider the finding of ziprasidone’ s greater capacity to prolong the QT/QTc interval compared to several other antipsychotic drugs [ see Warnings and Precautions (5.2) ]. Prolongation of the QTc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia, and sudden death. In many cases this would lead to the conclusion that other drugs should be tried first. Whether ziprasidone will cause torsade de pointes or increase the rate of sudden death is not yet known [ see Warnings and Precautions (5.2) ] uuid:d405845d-9ee5-4b78-9534-f064cdde1576 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats UMLS:C0856695 PMID:41385096 "[{""id"":""uuid:7696d5da-f653-4df0-aa52-22f27460a5fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:35cd24ac-83bd-4023-9976-b2fc648f85b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciprofloxacin tablets are a fluoroquinolone antibacterial indicated in adults (greater than or equal to 18 years of age) with the following infections caused by designated, susceptible bacteria and in pediatric patients where indicated: Skin and Skin Structure Infections ( 1.1 ) Bone and Joint Infections ( 1.2 ) Complicated Intra-Abdominal Infections ( 1.3 ) Infectious Diarrhea ( 1.4 ) Typhoid Fever (Enteric Fever) ( 1.5 ) Uncomplicated Cervical and Urethral Gonorrhea ( 1.6 ) Inhalational Anthrax post-exposure in adult and pediatric patients ( 1.7 ) Plague in adult and pediatric patients ( 1.8 ) Chronic Bacterial Prostatitis ( 1.9 ) Lower Respiratory Tract Infections ( 1.10 ) ○ Acute Exacerbation of Chronic Bronchitis Urinary Tract Infections ( 1.11 ) ○ Urinary Tract Infections (UTI) ○ Acute Uncomplicated Cystitis ○ Complicated UTI and Pyelonephritis in Pediatric Patients Acute Sinusitis ( 1.12 ) Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of ciprofloxacin tablets and other antibacterial drugs, ciprofloxacin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.13 ) uuid:94026625-29c5-4c93-99b3-c82f06e86083 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats UMLS:C4524049 PMID:41385096 "[{""id"":""uuid:92ebcac5-908f-4b57-abe4-6c74c7cac08b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8eea5829-15db-4997-90de-da1bdf5ef501"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciprofloxacin tablets are a fluoroquinolone antibacterial indicated in adults (greater than or equal to 18 years of age) with the following infections caused by designated, susceptible bacteria and in pediatric patients where indicated: Skin and Skin Structure Infections ( 1.1 ) Bone and Joint Infections ( 1.2 ) Complicated Intra-Abdominal Infections ( 1.3 ) Infectious Diarrhea ( 1.4 ) Typhoid Fever (Enteric Fever) ( 1.5 ) Uncomplicated Cervical and Urethral Gonorrhea ( 1.6 ) Inhalational Anthrax post-exposure in adult and pediatric patients ( 1.7 ) Plague in adult and pediatric patients ( 1.8 ) Chronic Bacterial Prostatitis ( 1.9 ) Lower Respiratory Tract Infections ( 1.10 ) ○ Acute Exacerbation of Chronic Bronchitis Urinary Tract Infections ( 1.11 ) ○ Urinary Tract Infections (UTI) ○ Acute Uncomplicated Cystitis ○ Complicated UTI and Pyelonephritis in Pediatric Patients Acute Sinusitis ( 1.12 ) Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of ciprofloxacin tablets and other antibacterial drugs, ciprofloxacin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.13 ) uuid:478fc1f6-d942-428d-9c10-348df0189a3e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28177 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:93644e8b-91ac-4642-9389-ee4b5dda4f74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:67d95767-1a68-4592-b62d-e17ea26aff9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Theophylline in 5% Dextrose Injection USP is indicated as an adjunct to inhaled beta-2 selective agonists and systemically administered corticosteroids for the treatment of acute exacerbations of the symptoms and reversible airflow obstruction associated with asthma and other chronic lung diseases, e.g., emphysema and chronic bronchitis. uuid:ef15b2d3-a96d-4fec-bc61-dfe4001c8ba4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7444 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:76359e60-6dcb-4e1a-b159-a6ac9e50c68d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ef3554c0-9e5c-45f6-8533-c597653b9c06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Angina Pectoris Nadolol tablets, USP are indicated for the long-term management of patients with angina pectoris. Hypertension Nadolol is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Nadolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Nadolol may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. uuid:d27adde1-2d49-40d9-a283-cd3b9f033483 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7444 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:a3cbc40b-7dc6-4967-85a7-1f5ffb168f53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ef6c10dd-f1a5-45b2-81c6-4c0e8b6eae66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Angina Pectoris Nadolol tablets, USP are indicated for the long-term management of patients with angina pectoris. Hypertension Nadolol is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Nadolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Nadolol may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. uuid:6628c5b6-b09d-462c-b9b4-7fdc5d8000ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7444 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:13dfeb1e-d926-4077-983c-c8f322f79256"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b46b0ee6-d94c-4bbc-8d4a-ac6902864c11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Angina Pectoris Nadolol tablets, USP are indicated for the long-term management of patients with angina pectoris. Hypertension Nadolol is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Nadolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Nadolol may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. uuid:96d01640-08a7-4def-bc15-a811ded9d993 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7444 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:536b1b67-9354-4758-99d1-36b880ff195c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7726f8d7-eac7-4951-917a-0baa1e82ead9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Angina Pectoris Nadolol tablets, USP are indicated for the long-term management of patients with angina pectoris. Hypertension Nadolol is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Nadolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Nadolol may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. uuid:e937dbdd-9b44-43ba-b3e0-0ae8d5b186df biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:91583 biolink:treats MONDO:0044345 PMID:41385096 "[{""id"":""uuid:3ff3777b-e5ce-4a2f-86bd-4fda270cbeba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ca5d672a-94db-4360-9c06-8d46ff97b60e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BILTRICIDE is indicated for the treatment of infections due to: all species of schistosoma (for example, Schistosoma mekongi, Schistosoma japonicum, Schistosoma mansoni and Schistosoma hematobium ), and infections due to the liver flukes, Clonorchis sinensis/Opisthorchis viverrini (approval of this indication was based on studies in which the two species were not differentiated). uuid:e17d2c4e-87bf-4897-96a4-b53432f480c5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:91583 biolink:treats MONDO:0006001 PMID:41385096 "[{""id"":""uuid:69b11098-0439-4d5c-8ba8-34f8f7118c0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:16905b96-43f1-4a07-8194-7f9daefb18dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BILTRICIDE is indicated for the treatment of infections due to: all species of schistosoma (for example, Schistosoma mekongi, Schistosoma japonicum, Schistosoma mansoni and Schistosoma hematobium ), and infections due to the liver flukes, Clonorchis sinensis/Opisthorchis viverrini (approval of this indication was based on studies in which the two species were not differentiated). uuid:d01e59e5-a4c0-486e-9c81-7536753eca3e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:91583 biolink:treats MONDO:0005705 PMID:41385096 "[{""id"":""uuid:674f3d20-c0e1-4a2d-936a-c62c5aa26db8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c9352946-baf7-4f58-885c-4ce67fbf00fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BILTRICIDE is indicated for the treatment of infections due to: all species of schistosoma (for example, Schistosoma mekongi, Schistosoma japonicum, Schistosoma mansoni and Schistosoma hematobium ), and infections due to the liver flukes, Clonorchis sinensis/Opisthorchis viverrini (approval of this indication was based on studies in which the two species were not differentiated). uuid:a5740a98-e16b-4d5e-8404-453db71425c1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:91583 biolink:treats MONDO:0005884 PMID:41385096 "[{""id"":""uuid:2c0108fc-8f0e-4327-9f23-58904f0fe1a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:70337687-930c-4172-8e62-af993444458c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BILTRICIDE is indicated for the treatment of infections due to: all species of schistosoma (for example, Schistosoma mekongi, Schistosoma japonicum, Schistosoma mansoni and Schistosoma hematobium ), and infections due to the liver flukes, Clonorchis sinensis/Opisthorchis viverrini (approval of this indication was based on studies in which the two species were not differentiated). uuid:95003d23-f79d-4e77-a46e-7cb932b09649 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:718834 biolink:treats MONDO:0005920 PMID:41385096 "[{""id"":""uuid:2b67c2ee-b21c-486b-a97f-8e65c7086d63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1d596241-ecac-4d25-a50b-afc2b7951c8e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Coartem (artemether/lumefantrine) Tablets are indicated for treatment of acute, uncomplicated malaria infections due to Plasmodium falciparum in patients of 5 kg bodyweight and above . Coartem Tablets have been shown to be effective in geographical regions where resistance to chloroquine has been reported [ see Clinical Studies (14.1) ]. Limitations of Use : Coartem Tablets are not approved for patients with severe or complicated P. falciparum malaria. Coartem Tablets are not approved for the prevention of malaria. uuid:6ac7af2f-297f-420a-a7d9-e9d743b6b2d4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8405 biolink:treats MONDO:0005921 PMID:41385096 "[{""id"":""uuid:cb1e68a4-0876-4464-86e4-1164ae3925a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:82c96b68-1200-4e3a-a917-e2131e80d768"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:532248e5-1725-4b19-9516-ec645118ae36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Primaquine phosphate is indicated for the radical cure (prevention of relapse) of vivax malaria.|[PMDA] A drug with a new active ingredient indicated for the treatment of malaria caused by Plasmodium vivax and Plasmodium oval . uuid:7ff062fe-adc0-4386-99cc-a45fc3fd2e28 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16664 biolink:treats UMLS:C0338437 PMID:41385096 "[{""id"":""uuid:bfa8e6fb-1ca7-4c9f-93c0-5f3c1e3165ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:befd1d33-0f9f-4ad7-9784-141d4044e206"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ALBENZA is an anthelmintic drug indicated for: Treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium . ( 1.1 ) Treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus . ( 1.2 ) uuid:f6543a83-c6c2-4f04-a199-87ecf7024e97 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16664 biolink:treats MONDO:0018408 PMID:41385096 "[{""id"":""uuid:66ab3ef6-9ec8-4848-90a0-d770ca2a4f61"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:671b21c0-566e-4f83-a885-7c5e84bb24bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ALBENZA is an anthelmintic drug indicated for: Treatment of parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm, Taenia solium . ( 1.1 ) Treatment of cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm, Echinococcus granulosus . ( 1.2 ) uuid:d3b145f3-0f56-4dbe-8d7b-97a204d1a46c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats MONDO:0020590 PMID:41385096 "[{""id"":""uuid:0f0eecab-a1ca-4305-8937-1d9cb269079a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:887aa839-13f2-458e-b379-600358e6fbb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azithromycin is a macrolide antibacterial indicated for mild to moderate infections caused by designated, susceptible bacteria: Mycobacterial Infections ( 1.2 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin tablets and other antibacterial drugs, azithromycin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. uuid:9703f682-e43e-452a-bb9d-889475cd2939 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17303 biolink:treats MONDO:0001673 PMID:41385096 "[{""id"":""uuid:cd629c87-b811-49e6-9dc6-e2fdc6d7bce5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:202456e9-849b-42de-b9a7-663da8467683"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Opium tincture is useful for the treatment of diarrhea. uuid:9e382416-a871-4443-88e1-2632634315ea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9637 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:7f5b8419-fc67-4f36-8f91-8222f177b748"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9dd07884-bb79-4ecc-bd92-eddd7ec21bd9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Torsemide is a loop diuretic indicated for: • the treatment of edema associated with heart failure, renal disease or hepatic disease. ( 1.1 ) • the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.2 ) uuid:c59cb400-ed05-4bca-8dfc-ff8988621f7b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9637 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:822b1587-fd6c-4060-9de9-cef4b9a9bdb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3c05ee31-46c9-4732-bcc8-a10923602dd8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Torsemide is a loop diuretic indicated for: • the treatment of edema associated with heart failure, renal disease or hepatic disease. ( 1.1 ) • the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.2 ) uuid:9fec3227-5681-468f-a146-95b82fb052cd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9637 biolink:treats MONDO:0006652 PMID:41385096 "[{""id"":""uuid:5b1cead1-8ce9-46c9-9073-806b89ae433f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1cc937af-d671-469f-8c8a-6a51f9994f97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Torsemide is a loop diuretic indicated for: • the treatment of edema associated with heart failure, renal disease or hepatic disease. ( 1.1 ) • the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.2 ) uuid:9efeec01-152b-47b1-b303-52a3796d08b2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32270 biolink:treats EFO:0006865 PMID:41385096 "[{""id"":""uuid:ed770ae5-5eca-49a5-b8b4-766efc6aeb89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:087091e7-1461-4716-b3ca-1dcb49f04e87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Trospium chloride tablets USP are a muscarinic antagonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. uuid:4ed6c4c3-11f6-418b-8d0d-20ef0a3b85b7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32270 biolink:treats HP:0100515 PMID:41385096 "[{""id"":""uuid:8bbe7831-abc7-455f-ac79-ed9f21ba88ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8d62c5a4-98db-49ca-89d3-c4e4ced29305"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Trospium chloride tablets USP are a muscarinic antagonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. uuid:bb6d8b7e-5eef-4176-929f-daaa24be9d68 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:6473866 biolink:treats UMLS:C0400968 PMID:41385096 "[{""id"":""uuid:17a0dd5e-0fcf-45fe-922d-de393b72de87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0897d560-6735-4bba-8d10-54af3392256c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tacrolimus capsules, USP are a calcineurin-inhibitor immunosuppressant indicated for: • Prophylaxis of organ rejection in patients receiving allogeneic liver, kidney or heart transplants ( 1.1 , 1.2 , 1.3 ) • Use concomitantly with adrenal corticosteroids; in kidney and heart transplant, use in conjunction with azathioprine or mycophenolate mofetil (MMF) ( 1.1 , 1.2 , 1.3 ) • Limitations of Use ( 1.4 ): • Do not use simultaneously with cyclosporine • Intravenous use reserved for patients who cannot tolerate capsules orally • Use with sirolimus is not recommended in liver and heart transplant; use with sirolimus in kidney transplant has not been established uuid:8cbfb810-46a4-41b4-9c45-dfad338dc513 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:6473866 biolink:treats UMLS:C0238217 PMID:41385096 "[{""id"":""uuid:6cb7ea8e-5117-4e91-81f0-23bb331ddca3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5d6ede37-d925-4f2c-acee-61e19f66e8dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tacrolimus capsules, USP are a calcineurin-inhibitor immunosuppressant indicated for: • Prophylaxis of organ rejection in patients receiving allogeneic liver, kidney or heart transplants ( 1.1 , 1.2 , 1.3 ) • Use concomitantly with adrenal corticosteroids; in kidney and heart transplant, use in conjunction with azathioprine or mycophenolate mofetil (MMF) ( 1.1 , 1.2 , 1.3 ) • Limitations of Use ( 1.4 ): • Do not use simultaneously with cyclosporine • Intravenous use reserved for patients who cannot tolerate capsules orally • Use with sirolimus is not recommended in liver and heart transplant; use with sirolimus in kidney transplant has not been established uuid:2ec6bbd5-3609-414c-973a-7fb8201ee942 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:6473866 biolink:treats UMLS:C0340530 PMID:41385096 "[{""id"":""uuid:9935aa75-16ba-4e25-8687-376dc26914c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e24c62c5-6f37-4dd7-a5ec-4f0420ab8210"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tacrolimus capsules, USP are a calcineurin-inhibitor immunosuppressant indicated for: • Prophylaxis of organ rejection in patients receiving allogeneic liver, kidney or heart transplants ( 1.1 , 1.2 , 1.3 ) • Use concomitantly with adrenal corticosteroids; in kidney and heart transplant, use in conjunction with azathioprine or mycophenolate mofetil (MMF) ( 1.1 , 1.2 , 1.3 ) • Limitations of Use ( 1.4 ): • Do not use simultaneously with cyclosporine • Intravenous use reserved for patients who cannot tolerate capsules orally • Use with sirolimus is not recommended in liver and heart transplant; use with sirolimus in kidney transplant has not been established uuid:f070b895-b9dd-47a3-aedd-f934de9a935c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32184 biolink:treats HP:0100678 PMID:41385096 "[{""id"":""uuid:ce87a44b-ede3-49ff-91b8-3f7c1df39ab0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1816b6c5-7c43-4002-947c-d4b5dc1342a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tazarotene cream, 0.1% is indicated as an adjunctive agent for use in the mitigation (palliation) of facial fine wrinkling, facial mottled hyper-and hypopigmentation, and benign facial lentigines in patients who use comprehensive skin care and sunlight avoidance programs. uuid:ee8cc050-ae38-4651-8a9a-c44012718e19 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32184 biolink:treats MONDO:0019289 PMID:41385096 "[{""id"":""uuid:1923fa1c-434a-453d-bbee-0f3055eeaf39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:68ec2266-0312-4c02-a3fe-b5507956cc06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tazarotene cream, 0.1% is indicated as an adjunctive agent for use in the mitigation (palliation) of facial fine wrinkling, facial mottled hyper-and hypopigmentation, and benign facial lentigines in patients who use comprehensive skin care and sunlight avoidance programs. uuid:e092909f-02a3-4d0c-96b1-68a3518d74a2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32184 biolink:treats MONDO:0019290 PMID:41385096 "[{""id"":""uuid:d9309e5f-706c-4dbd-a07a-c9fd00385fbe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e4acd6a8-1c6f-4b56-88c5-0eafd3cc5c2b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tazarotene cream, 0.1% is indicated as an adjunctive agent for use in the mitigation (palliation) of facial fine wrinkling, facial mottled hyper-and hypopigmentation, and benign facial lentigines in patients who use comprehensive skin care and sunlight avoidance programs. uuid:139b1d2a-fa4e-4ca4-896a-951037cdd3bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32184 biolink:treats MONDO:0021582 PMID:41385096 "[{""id"":""uuid:784d098b-ae55-45d3-a099-c70f2f94e60c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:08160035-145e-4806-873a-c846240f9b01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tazarotene cream, 0.1% is indicated as an adjunctive agent for use in the mitigation (palliation) of facial fine wrinkling, facial mottled hyper-and hypopigmentation, and benign facial lentigines in patients who use comprehensive skin care and sunlight avoidance programs. uuid:299916f7-9652-4cca-b800-70a8babfdfa8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9566 biolink:treats MONDO:0005090 PMID:41385096 "[{""id"":""uuid:016e01dc-014e-4157-af65-2ec1116cbf60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e599394e-8f13-42b2-aa38-b605a7524f0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thioridazine hydrochloride tablets are indicated for the management of schizophrenic patients who fail to respond adequately to treatment with other antipsychotic drugs. Due to the risk of significant, potentially life threatening, proarrhythmic effects with thioridazine treatment, thioridazine hydrochloride tablets should be used only in patients who have failed to respond adequately to treatment with appropriate courses of other antipsychotic drugs, either because of insufficient effectiveness or the inability to achieve an effective dose due to intolerable adverse effects from those drugs. Consequently, before initiating treatment with thioridazine hydrochloride tablets, it is strongly recommended that a patient be given at least two trials, each with a different antipsychotic drug product, at an adequate dose, and for an adequate duration (see WARNINGS and CONTRAINDICATIONS ). However, the prescriber should be aware that thioridazine hydrochloride tablets have not been systematically evaluated in controlled trials in treatment refractory schizophrenic patients and its efficacy in such patients is unknown. uuid:5aa12c2e-8ff9-4103-a765-510001f8e22b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9566 biolink:treats MONDO:0005414 PMID:41385096 "[{""id"":""uuid:146fb637-766d-4af3-8e2e-88c86f5835dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c150af28-f8e2-417e-bef8-38063e0ea808"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thioridazine hydrochloride tablets are indicated for the management of schizophrenic patients who fail to respond adequately to treatment with other antipsychotic drugs. Due to the risk of significant, potentially life threatening, proarrhythmic effects with thioridazine treatment, thioridazine hydrochloride tablets should be used only in patients who have failed to respond adequately to treatment with appropriate courses of other antipsychotic drugs, either because of insufficient effectiveness or the inability to achieve an effective dose due to intolerable adverse effects from those drugs. Consequently, before initiating treatment with thioridazine hydrochloride tablets, it is strongly recommended that a patient be given at least two trials, each with a different antipsychotic drug product, at an adequate dose, and for an adequate duration (see WARNINGS and CONTRAINDICATIONS ). However, the prescriber should be aware that thioridazine hydrochloride tablets have not been systematically evaluated in controlled trials in treatment refractory schizophrenic patients and its efficacy in such patients is unknown. uuid:4cf62b82-6335-457d-b1c7-5a51d0bfb93a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16199 biolink:treats UMLS:C0406446 PMID:41385096 "[{""id"":""uuid:f44fc56c-b90a-4380-aaa9-7805b4c4776d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b230c8d9-26db-4e47-81dc-8c3d81ced3b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For debridement and promotion of normal healing of hyperkeratotic surface lesions, particularly where healing is retarded by local infection, necrotic tissue, fibrinous or prurient debris or eschar. Urea is useful for the treatment of hyperkeratotic conditions such as dry, rough skin, dermatitis, psoriasis, xerosis, ichthyosis, eczema, keratosis, keratoderma, corns and calluses, as well as damaged, ingrown and devitalized nails. uuid:804a504e-a302-4d4f-94e2-742ba0e31b8d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16199 biolink:treats MONDO:0002884 PMID:41385096 "[{""id"":""uuid:1b22e3d4-6099-4152-a168-8c6cbb815567"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8032a652-8553-495e-bb2a-015d96834d8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For debridement and promotion of normal healing of hyperkeratotic surface lesions, particularly where healing is retarded by local infection, necrotic tissue, fibrinous or prurient debris or eschar. Urea is useful for the treatment of hyperkeratotic conditions such as dry, rough skin, dermatitis, psoriasis, xerosis, ichthyosis, eczema, keratosis, keratoderma, corns and calluses, as well as damaged, ingrown and devitalized nails. uuid:65643bef-e43d-4e7b-91a9-723fbd81b246 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5108 biolink:treats MONDO:0002406 PMID:41385096 "[{""id"":""uuid:0e5a94d0-a5aa-4675-9f92-565953c647a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:49fc67c6-48bb-463f-97b0-3b3bafef904f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the management of hypertrophic tissues, keloid tissues, dermatitis and dermatoses. This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent disease. uuid:0ee58512-5c53-4e75-8f26-621527433f68 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7983 biolink:treats MONDO:0013600 PMID:41385096 "[{""id"":""uuid:b686befd-5460-4cb3-bef8-e8a6f545e217"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ec43477c-78ff-46e3-a29e-77601e357c19"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Sedatives. Hypnotics, for the short-term treatment of insomnia, since they appear to lose their effectiveness for sleep induction and sleep maintenance after 2 weeks. (See "" Clinical Pharmacology "" section.) Preanesthetics. Anticonvulsant, in anesthetic doses, in the emergency control of certain acute convulsive episodes, e.g., those associated with status epilepticus, cholera, eclampsia, meningitis, tetanus, and toxic reactions to strychnine or local anesthetics." uuid:331f99e5-9bcd-4394-b513-39dfc5e1321d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7983 biolink:treats MONDO:0002125 PMID:41385096 "[{""id"":""uuid:8399d583-2701-46dd-b2b1-03ccc17d9d63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:905979bb-15ca-4f86-8fa5-9ec684244d7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Sedatives. Hypnotics, for the short-term treatment of insomnia, since they appear to lose their effectiveness for sleep induction and sleep maintenance after 2 weeks. (See "" Clinical Pharmacology "" section.) Preanesthetics. Anticonvulsant, in anesthetic doses, in the emergency control of certain acute convulsive episodes, e.g., those associated with status epilepticus, cholera, eclampsia, meningitis, tetanus, and toxic reactions to strychnine or local anesthetics." uuid:9f4696fd-a79a-4b28-8a12-946ec605f17b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7983 biolink:treats MONDO:0015766 PMID:41385096 "[{""id"":""uuid:aa09e834-57e4-46de-84e7-29cdef216cae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:01c53315-639b-4fd7-bf46-3cad04f5d211"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Sedatives. Hypnotics, for the short-term treatment of insomnia, since they appear to lose their effectiveness for sleep induction and sleep maintenance after 2 weeks. (See "" Clinical Pharmacology "" section.) Preanesthetics. Anticonvulsant, in anesthetic doses, in the emergency control of certain acute convulsive episodes, e.g., those associated with status epilepticus, cholera, eclampsia, meningitis, tetanus, and toxic reactions to strychnine or local anesthetics." uuid:7780b86c-939a-435b-9bf8-8988213eca26 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7983 biolink:treats MONDO:0001754 PMID:41385096 "[{""id"":""uuid:0b4990b4-8481-46ec-abd9-dbb29c782fb4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fa22e2f7-295c-45c8-91c8-41e93f8b2760"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Sedatives. Hypnotics, for the short-term treatment of insomnia, since they appear to lose their effectiveness for sleep induction and sleep maintenance after 2 weeks. (See "" Clinical Pharmacology "" section.) Preanesthetics. Anticonvulsant, in anesthetic doses, in the emergency control of certain acute convulsive episodes, e.g., those associated with status epilepticus, cholera, eclampsia, meningitis, tetanus, and toxic reactions to strychnine or local anesthetics." uuid:83e08419-edc5-48f1-a86f-5401e448225a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7983 biolink:treats MONDO:0021108 PMID:41385096 "[{""id"":""uuid:c674bb7d-882e-4b74-867f-03db37dc0591"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:321964dc-ccee-4aca-afd0-c67e4f0511f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Sedatives. Hypnotics, for the short-term treatment of insomnia, since they appear to lose their effectiveness for sleep induction and sleep maintenance after 2 weeks. (See "" Clinical Pharmacology "" section.) Preanesthetics. Anticonvulsant, in anesthetic doses, in the emergency control of certain acute convulsive episodes, e.g., those associated with status epilepticus, cholera, eclampsia, meningitis, tetanus, and toxic reactions to strychnine or local anesthetics." uuid:72e78dfe-de95-44b7-9a93-78b8a9e0ea02 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7983 biolink:treats MONDO:0005526 PMID:41385096 "[{""id"":""uuid:457de0e7-e122-41be-86aa-d70e02df21d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:74872796-980c-44f7-8362-e2660d1cdeca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Sedatives. Hypnotics, for the short-term treatment of insomnia, since they appear to lose their effectiveness for sleep induction and sleep maintenance after 2 weeks. (See "" Clinical Pharmacology "" section.) Preanesthetics. Anticonvulsant, in anesthetic doses, in the emergency control of certain acute convulsive episodes, e.g., those associated with status epilepticus, cholera, eclampsia, meningitis, tetanus, and toxic reactions to strychnine or local anesthetics." uuid:4acb03c6-36a8-4cde-a9e4-e35c5685e03d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:370642 biolink:treats UMLS:C0278140 PMID:41385096 "[{""id"":""uuid:a4c87288-9eb9-4499-b1b2-4494a9593939"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c477f3e0-e1bd-4df1-a56a-36b8171ea34c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydrocodone Bitartrate and Acetaminophen Tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses [see WARNINGS ], reserve Hydrocodone Bitartrate and Acetaminophen Tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics): • have not been tolerated, or are not expected to be tolerated • have not provided adequate analgesia, or are not expected to provide adequate analgesia uuid:c1782355-7f1b-4cb2-a82f-40bc7f0005a0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6904 biolink:treats MONDO:0006652 PMID:41385096 "[{""id"":""uuid:99341504-0774-429a-9ac7-281036fe00aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8d56edf6-6a86-49ec-b171-8d80c7554eca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hypertension Metoprolol succinate extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (eg, on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Metoprolol succinate extended-release tablets may be administered with other antihypertensive agents. 1.2 Angina Pectoris Metoprolol succinate extended-release tablets are indicated in the long-term treatment of angina pectoris, to reduce angina attacks and to improve exercise tolerance. 1.3 Heart Failure Metoprolol succinate extended-release tablets are indicated for the treatment of stable, symptomatic (NYHA Class II or III) heart failure of ischemic, hypertensive, or cardiomyopathic origin. It was studied in patients already receiving ACE inhibitors, diuretics, and, in the majority of cases, digitalis. In this population, metoprolol succinate extended-release tablets decreased the rate of mortality plus hospitalization, largely through a reduction in cardiovascular mortality and hospitalizations for heart failure. uuid:fec54510-e29e-4866-a9c1-a6c1cb00138b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6874 biolink:treats UMLS:C0426265 PMID:41385096 "[{""id"":""uuid:744179b1-d61c-4fcf-a403-c58d8d2cb3c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:293548c2-f1b8-4831-96f8-2f732361cf0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Following delivery of placenta, for routine management of uterine atony, hemorrhage and subinvolution of the uterus. For control of uterine hemorrhage in the second stage of labor following delivery of the anterior shoulder. uuid:425ddc7d-28f3-4a0d-aa36-494016b41cde biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6874 biolink:treats UMLS:C0042134 PMID:41385096 "[{""id"":""uuid:7824024c-7b0d-4f66-a188-8a8cbc3ea746"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1cd7f53e-c027-4550-887c-39fb2ad28018"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Following delivery of placenta, for routine management of uterine atony, hemorrhage and subinvolution of the uterus. For control of uterine hemorrhage in the second stage of labor following delivery of the anterior shoulder. uuid:e41de47b-edfe-4705-80a7-856a6aa6f26f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18332 biolink:treats MONDO:0004425 PMID:41385096 "[{""id"":""uuid:255772d1-8278-4550-8c7a-9cfe45fd5942"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:afabf57f-2d9c-4ef6-96cc-8c7813ce5920"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypothyroidism SYNTHROID is indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin (Thyroid‑Stimulating Hormone, TSH) Suppression SYNTHROID is indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. Limitations of Use: SYNTHROID is not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with SYNTHROID may induce hyperthyroidism [see Warnings and Precautions (5.4) ] . SYNTHROID is not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis. uuid:625b4b18-8fdf-492b-95f2-505e2dd5cc43 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18332 biolink:treats MONDO:0006982 PMID:41385096 "[{""id"":""uuid:c6a44172-45a8-49f2-b108-1cf88fa46ad7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f46eaf14-66ee-4d5f-bbfa-072a73cc1f30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypothyroidism SYNTHROID is indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin (Thyroid‑Stimulating Hormone, TSH) Suppression SYNTHROID is indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. Limitations of Use: SYNTHROID is not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with SYNTHROID may induce hyperthyroidism [see Warnings and Precautions (5.4) ] . SYNTHROID is not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis. uuid:f95667b0-2cf5-4551-955e-f3cec7b0fcd4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37941 biolink:treats MONDO:0004781 PMID:41385096 "[{""id"":""uuid:8a6acb5b-6b94-4631-9784-88653e29a65a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:14be85c1-15c0-4641-bab8-075b44eeaf85"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4c7c0507-32e3-4c10-9f3c-0856e3990a30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Acute Coronary Syndrome (ACS) • Clopidogrel is indicated to reduce the rate of myocardial infarction (MI) and stroke in patients with non-ST-segment elevation ACS [unstable angina (UA)/non-ST-elevation myocardial infarction (NSTEMI)], including patients who are to be managed medically and those who are to be managed with coronary revascularization. Clopidogrel should be administered in conjunction with aspirin. • Clopidogrel is indicated to reduce the rate of myocardial infarction and stroke in patients with acute ST-elevation myocardial infarction (STEMI) who are to be managed medically. Clopidogrel should be administered in conjunction with aspirin. 1.2 Recent MI, Recent Stroke, or Established Peripheral Arterial Disease In patients with established peripheral arterial disease or with a history of recent myocardial infarction (MI) or recent stroke clopidogrel is indicated to reduce the rate of MI and stroke.|[PMDA] Drugs with a new indication and dosage for the treatment of acute coronary syndrome (unstable angina and non-ST-elevation myocardial infarction) in patients in whom percutaneous coronary intervention (PCI) is considered. [Priority review] uuid:2eecbfb2-f669-4af0-bfab-d0b8dc307d23 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:39585 biolink:treats MONDO:0005180 PMID:41385096 "[{""id"":""uuid:3c5a1a13-dd7b-45f0-bacf-d002dbe2a9fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9c223558-71dc-4a66-a91b-84da50279cd3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Carbidopa tablets are indicated for use with carbidopa-levodopa or with levodopa in the treatment of the symptoms of idiopathic Parkinson's disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication. Carbidopa is for use with carbidopa-levodopa in patients for whom the dosage of carbidopa-levodopa provides less than adequate daily dosage (usually 70 mg daily) of carbidopa. Carbidopa is for use with levodopa in the occasional patient whose dosage requirement of carbidopa and levodopa necessitates separate titration of each medication. Carbidopa is used with carbidopa-levodopa or with levodopa to permit the administration of lower doses of levodopa with reduced nausea and vomiting, more rapid dosage titration, and with a somewhat smoother response. However, patients with markedly irregular (""on-off"") responses to levodopa have not been shown to benefit from the addition of carbidopa. Since carbidopa prevents the reversal of levodopa effects caused by pyridoxine, supplemental pyridoxine (vitamin B 6 ), can be given to patients when they are receiving carbidopa and levodopa concomitantly or as carbidopa-levodopa. Although the administration of carbidopa permits control of parkinsonism and Parkinson's disease with much lower doses of levodopa, there is no conclusive evidence at present that this is beneficial other than in reducing nausea and vomiting, permitting more rapid titration, and providing a somewhat smoother response to levodopa. Certain patients who responded poorly to levodopa alone have improved when carbidopa and levodopa were given concurrently. This was most likely due to decreased peripheral decarboxylation of levodopa rather than to a primary effect of carbidopa on the peripheral nervous system. Carbidopa has not been shown to enhance the intrinsic efficacy of levodopa. In deciding whether to give carbidopa with carbidopa-levodopa or with levodopa to patients who have nausea and/or vomiting, the physician should be aware that, while many patients may be expected to improve, some may not. Since one cannot predict which patients are likely to improve, this can only be determined by a trial of therapy. It should be further noted that in controlled trials comparing carbidopa and levodopa with levodopa alone, about half the patients with nausea and/or vomiting on levodopa alone improved spontaneously despite being retained on the same dose of levodopa during the controlled portion of the trial." uuid:10ab0652-a3e2-443e-a878-717455b6c536 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:39585 biolink:treats MONDO:0001945 PMID:41385096 "[{""id"":""uuid:abd0f47c-f63b-4441-96d0-47b95887b7ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aaa35dc0-bbbc-45c9-b667-6b7fc6b19b49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Carbidopa tablets are indicated for use with carbidopa-levodopa or with levodopa in the treatment of the symptoms of idiopathic Parkinson's disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication. Carbidopa is for use with carbidopa-levodopa in patients for whom the dosage of carbidopa-levodopa provides less than adequate daily dosage (usually 70 mg daily) of carbidopa. Carbidopa is for use with levodopa in the occasional patient whose dosage requirement of carbidopa and levodopa necessitates separate titration of each medication. Carbidopa is used with carbidopa-levodopa or with levodopa to permit the administration of lower doses of levodopa with reduced nausea and vomiting, more rapid dosage titration, and with a somewhat smoother response. However, patients with markedly irregular (""on-off"") responses to levodopa have not been shown to benefit from the addition of carbidopa. Since carbidopa prevents the reversal of levodopa effects caused by pyridoxine, supplemental pyridoxine (vitamin B 6 ), can be given to patients when they are receiving carbidopa and levodopa concomitantly or as carbidopa-levodopa. Although the administration of carbidopa permits control of parkinsonism and Parkinson's disease with much lower doses of levodopa, there is no conclusive evidence at present that this is beneficial other than in reducing nausea and vomiting, permitting more rapid titration, and providing a somewhat smoother response to levodopa. Certain patients who responded poorly to levodopa alone have improved when carbidopa and levodopa were given concurrently. This was most likely due to decreased peripheral decarboxylation of levodopa rather than to a primary effect of carbidopa on the peripheral nervous system. Carbidopa has not been shown to enhance the intrinsic efficacy of levodopa. In deciding whether to give carbidopa with carbidopa-levodopa or with levodopa to patients who have nausea and/or vomiting, the physician should be aware that, while many patients may be expected to improve, some may not. Since one cannot predict which patients are likely to improve, this can only be determined by a trial of therapy. It should be further noted that in controlled trials comparing carbidopa and levodopa with levodopa alone, about half the patients with nausea and/or vomiting on levodopa alone improved spontaneously despite being retained on the same dose of levodopa during the controlled portion of the trial." uuid:ad5d4072-617f-41f1-a100-113b6db0e91d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:39585 biolink:treats MONDO:0021095 PMID:41385096 "[{""id"":""uuid:4356b82b-e35a-4e18-8cb7-dce7062fc246"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bfc5c3a5-9f8d-4f0a-9f04-dfa138961236"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Carbidopa tablets are indicated for use with carbidopa-levodopa or with levodopa in the treatment of the symptoms of idiopathic Parkinson's disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication. Carbidopa is for use with carbidopa-levodopa in patients for whom the dosage of carbidopa-levodopa provides less than adequate daily dosage (usually 70 mg daily) of carbidopa. Carbidopa is for use with levodopa in the occasional patient whose dosage requirement of carbidopa and levodopa necessitates separate titration of each medication. Carbidopa is used with carbidopa-levodopa or with levodopa to permit the administration of lower doses of levodopa with reduced nausea and vomiting, more rapid dosage titration, and with a somewhat smoother response. However, patients with markedly irregular (""on-off"") responses to levodopa have not been shown to benefit from the addition of carbidopa. Since carbidopa prevents the reversal of levodopa effects caused by pyridoxine, supplemental pyridoxine (vitamin B 6 ), can be given to patients when they are receiving carbidopa and levodopa concomitantly or as carbidopa-levodopa. Although the administration of carbidopa permits control of parkinsonism and Parkinson's disease with much lower doses of levodopa, there is no conclusive evidence at present that this is beneficial other than in reducing nausea and vomiting, permitting more rapid titration, and providing a somewhat smoother response to levodopa. Certain patients who responded poorly to levodopa alone have improved when carbidopa and levodopa were given concurrently. This was most likely due to decreased peripheral decarboxylation of levodopa rather than to a primary effect of carbidopa on the peripheral nervous system. Carbidopa has not been shown to enhance the intrinsic efficacy of levodopa. In deciding whether to give carbidopa with carbidopa-levodopa or with levodopa to patients who have nausea and/or vomiting, the physician should be aware that, while many patients may be expected to improve, some may not. Since one cannot predict which patients are likely to improve, this can only be determined by a trial of therapy. It should be further noted that in controlled trials comparing carbidopa and levodopa with levodopa alone, about half the patients with nausea and/or vomiting on levodopa alone improved spontaneously despite being retained on the same dose of levodopa during the controlled portion of the trial." uuid:731b56b3-7648-46a2-8d78-59e32aed61f4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50690 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:b3c4ad9b-66df-42b5-a9a7-fece0114345e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1c1849af-21ec-4a6d-ab81-3b4879063a9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In patients with clinically evident coronary heart disease, atorvastatin calcium tablets is indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin calcium tablets is indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: a. LDL-C remains ≥ 190 mg/dL or b. LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin calcium tablets has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:3095692e-8f6e-4847-9e06-f56c68082071 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50690 biolink:treats MONDO:0004995 PMID:41385096 "[{""id"":""uuid:61ea2825-5e9d-487d-8e3d-157270e46bc1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4b862299-aa85-4691-94e6-906b7c43978e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets is indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In patients with clinically evident coronary heart disease, atorvastatin calcium tablets is indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin calcium tablets is indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present: a. LDL-C remains ≥ 190 mg/dL or b. LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin calcium tablets has not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:41ce87cb-c991-42a3-92d1-1a0198130730 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9887103 biolink:treats MONDO:0007263 PMID:41385096 "[{""id"":""uuid:33dd0960-b988-44f6-a307-ca278cd38cbc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ef0ecadb-fcf5-498e-8009-2105f428d57c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ROBINUL Injection is indicated for use as a preoperative antimuscarinic to reduce salivary, tracheobronchial, and pharyngeal secretions; to reduce the volume and free acidity of gastric secretions; and to block cardiac vagal inhibitory reflexes during induction of anesthesia and intubation. When indicated, ROBINUL Injection may be used intraoperatively to counteract surgically or drug-induced or vagal reflexes associated arrhythmias. Glycopyrrolate protects against the peripheral muscarinic effects (e.g., bradycardia and excessive secretions) of cholinergic agents such as neostigmine and pyridostigmine given to reverse the neuromuscular blockade due to non-depolarizing muscle relaxants. uuid:db1ffb18-71cc-4374-a6dd-a41cd1885c1a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50690 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:b09bca87-f125-4533-b352-818336d4e775"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:057639f5-17c9-4dc7-8be7-532d2ab22809"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease in Adults In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In adult patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In adult patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin calcium tablets are indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in adult patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of adult patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of adult patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH) as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in pediatric patients, 10 years to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH) if after an adequate trial of diet therapy the following findings are present: a. LDL-C remains ≥ 190 mg/dL or b. LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin calcium tablets have not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:70d2ebac-5e70-484f-a5c9-cdac3a68362a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50690 biolink:treats UMLS:C0860248 PMID:41385096 "[{""id"":""uuid:dfe90290-4e97-4d8f-b82b-f716fac2965b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f0a6d983-5d40-457b-8c94-a82527ac4669"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease in Adults In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In adult patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In adult patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin calcium tablets are indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in adult patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of adult patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of adult patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH) as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in pediatric patients, 10 years to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH) if after an adequate trial of diet therapy the following findings are present: a. LDL-C remains ≥ 190 mg/dL or b. LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin calcium tablets have not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:ccb88ed3-d030-4d1e-b23d-ff549caa8f84 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50690 biolink:treats UMLS:C0856526 PMID:41385096 "[{""id"":""uuid:ac1a8fa0-0443-4804-8569-4636f27d2b0c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:42d93898-9863-40b9-b92a-fa69932b6283"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease in Adults In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In adult patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In adult patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin calcium tablets are indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in adult patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of adult patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of adult patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH) as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in pediatric patients, 10 years to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH) if after an adequate trial of diet therapy the following findings are present: a. LDL-C remains ≥ 190 mg/dL or b. LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin calcium tablets have not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:06b92a25-8a6d-4b3c-8ee9-9890577fb87e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8412 biolink:treats MONDO:0005754 PMID:41385096 "[{""id"":""uuid:5ea4eda5-4f01-4313-8dcb-26f02e84121b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7cd3ed96-474b-4caa-9084-7606a14eb909"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Primidone tablets, used alone or concomitantly with other anticonvulsants, are indicated in the control of grand mal, psychomotor, and focal epileptic seizures. It may control grand mal seizures refractory to other anticonvulsant therapy. uuid:91bb4617-e82d-477e-ade3-ee9849035058 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8412 biolink:treats NCIT:C117194 PMID:41385096 "[{""id"":""uuid:a38468e2-5d32-4a6c-9d94-15bd3b70c7d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2f88d5ae-7ab0-4147-ba37-aa524d79fa34"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Primidone tablets, used alone or concomitantly with other anticonvulsants, are indicated in the control of grand mal, psychomotor, and focal epileptic seizures. It may control grand mal seizures refractory to other anticonvulsant therapy. uuid:6735ee4d-8c1f-47d8-a765-ef6a3ab37f6e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0015129 PMID:41385096 "[{""id"":""uuid:2c2cf394-97be-4a32-a4d5-852465db3345"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c2ad5671-c989-4fda-a9ee-af42dafd56b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:ade53742-89aa-401f-9360-58db9cd398d2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0043370 PMID:41385096 "[{""id"":""uuid:f7e8b22b-3813-485b-a006-e8d65d6550f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2ea87e5d-e72c-4ec9-814b-e4564e81c93b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:90fb45dc-9855-484b-a02f-5dcd246ec1fb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0019801 PMID:41385096 "[{""id"":""uuid:112ca145-48f1-464b-b0d0-39c756335123"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eb640727-4fa4-4cc9-a945-7759538cb646"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:1cdc0369-1c8e-4eb8-93f3-0e0caf9a49eb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0000004 PMID:41385096 "[{""id"":""uuid:55935bde-b3f7-441b-a385-8f923a42ceb5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:603459b3-298a-4838-89d4-bf8dbc82aaed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:adac403a-463e-4615-910d-35907b7c5058 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0018479 PMID:41385096 "[{""id"":""uuid:80d7c711-3d3e-40c1-b451-58c1f816b69b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9affb3c8-7474-4599-99d4-53c0a3fda686"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:4e52bc19-d42f-4db9-b413-33b2757cd701 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0006982 PMID:41385096 "[{""id"":""uuid:b58e8034-9e84-44b8-ac37-f56df19c5d3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dcf8a406-5c02-4914-bfc6-28f8de95714e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:00fcfd71-9a3f-4d0d-8248-9f32cf28ba3a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0043455 PMID:41385096 "[{""id"":""uuid:e005f262-e71e-4c37-a044-7eb1efb83d3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:32558fb8-e94c-403a-b326-cfedd84f4991"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:eda0702e-9627-4497-a3e8-c43d0a8bfe25 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:555c63ba-c5b5-43f3-9031-f14d69943e90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4ef0f42e-fece-43b9-af7e-337cc66c5a8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:8fce6f56-cff8-4961-b1b0-60451a479323 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:7d70aefe-f9d4-4345-84fe-dcb70c7fbde2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:301f46c3-f2ad-47d0-81d7-6d673fd6d468"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:c14bda3e-6880-4ae0-b4f7-fa631a933d19 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0011429 PMID:41385096 "[{""id"":""uuid:2bf78e29-88e0-4db7-b265-fed197bebf4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6b615e68-9040-414e-9a8a-1bff06b6f516"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:55575f70-6926-4a0f-92ca-3177d2ae0d4b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats UMLS:C1290158 PMID:41385096 "[{""id"":""uuid:3865ee69-62fa-4fe8-90fb-06133691803c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e06981c6-4c46-4113-862a-de8d14c32d97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:de2d2488-d6ab-46ed-8a94-6309fcc89cf7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0040698 PMID:41385096 "[{""id"":""uuid:ef2f2d79-25dc-48a8-85a2-acdd318c6b2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e2516d95-787b-455e-992f-39f7905f3dce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:159f850e-93d3-476c-941b-7cfbcb4f9cf7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0001875 PMID:41385096 "[{""id"":""uuid:44986c40-024d-42b2-b034-aacd4705a34d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d3c436e5-cc24-48a4-9bcc-cd91885d8f79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:712cbf0d-919a-4d57-a948-ba29130dc2ed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0004855 PMID:41385096 "[{""id"":""uuid:38908ddb-c914-4059-9afc-4b5a46465914"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a12424a7-a3df-4c61-af0a-fbcbd73ba93d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:8723358a-b638-4089-a45e-5f88420db6ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats UMLS:C0149896 PMID:41385096 "[{""id"":""uuid:524cb7f8-4a4c-45e7-9d0e-3e57bdc4860d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:92c94237-a709-48de-95c9-cb0246dbfc59"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:19a73463-0d5e-4055-be2e-062c4e83195c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:44b1de97-0da3-4d48-a3f9-0796ab45983e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:60a545f2-4d1a-430e-8999-f2bc20b3aa6d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:74dac46e-2140-435b-8c87-e26f34750a22 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:05b1e036-31a0-49bb-96f9-71c3b6d42f75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2a762933-d9e2-4a79-829e-1effd8157b6d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:16a1cd52-84e5-4dfd-b2a8-0e6f10199f4b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats UMLS:C5441648 PMID:41385096 "[{""id"":""uuid:e169296c-e4c4-40e2-ba94-95f058a84cb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1ff9febb-74ea-4d86-aaf1-9418e5dae70d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:31085f9f-d2ba-4678-b901-7201f995d8c1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0006594 PMID:41385096 "[{""id"":""uuid:a11c054a-f381-4b22-98a4-e433bb6a129f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4338897e-fa28-44bb-84ea-79996af6dc71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:a9798b28-bca5-48d6-bc16-2a7a03cc2245 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0006545 PMID:41385096 "[{""id"":""uuid:df7d33c8-6431-473f-b8e7-12239e138626"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:566d3653-0707-4e9e-b99c-ad1cc8af3822"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:1c4b121b-de4c-46b4-9e4b-ac66c0e53259 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0018229 PMID:41385096 "[{""id"":""uuid:71649197-9332-445a-a308-0c7206605634"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8171fa84-fb5c-479e-9af8-7b5987614afe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:1ddc0555-1323-49d9-a95c-81e914b506ad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0043233 PMID:41385096 "[{""id"":""uuid:9380c5f1-0dce-400b-a37f-b6225b93e904"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7a4999fa-8dfd-49e6-be65-30d38f28740e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:460ee4cf-d360-4c51-8379-abeb19f504e7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0015614 PMID:41385096 "[{""id"":""uuid:2b16965b-b03f-4ff8-ba45-a1c758a2f74b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:74d1cb0e-5af2-48a2-9e09-2b92f06d2172"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:e8c143dd-6d21-49a8-9701-9e59c3613d52 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0006608 PMID:41385096 "[{""id"":""uuid:68fbdff5-2b0c-4d47-937a-3d62fba4509c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e8b91890-48e4-4cd1-9956-83efb7990d73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:340fc6f7-9dc3-42fb-909f-c6d94509750a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:845bf42c-b70e-420c-be17-1ba77ccd19f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:38270746-0eb4-43ac-b50b-01569d785901"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:ce6fa6a7-4f97-456a-90a6-5ade80330bb1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0009691 PMID:41385096 "[{""id"":""uuid:6c57275b-c528-438b-a39e-97f2c685786b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aeecabfd-ff03-49ea-8455-b88eef9523cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:8623d8e0-f2c1-4d42-b9a4-e1f8761408c5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:9de0e189-5766-4f2b-8fa0-439d8e361936"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a7331a55-88bc-4b54-ad72-e570d2d79315"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:8d04f0c2-5736-423f-bfd3-b144b4fb8b5c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0005480 PMID:41385096 "[{""id"":""uuid:e679fb8d-dd0b-4335-9cac-3302b44441d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:02a6ae9b-8bf6-4b4f-b84c-5322fc5ac1fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:1ca37d40-26d8-4f62-86eb-a2981e4fef71 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:09a393c3-054d-4db8-ac5c-883683272192"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3b8f3bb2-d052-4109-aeda-53bfb103f435"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:1fcb4964-9d18-4c7f-9997-7025d994eac8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0043789 PMID:41385096 "[{""id"":""uuid:e46a28e9-ecfe-446f-bd30-6e2d06de98a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a1831cc8-5b7f-417b-8f50-ce11eaaf7200"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:f52cfb0d-12f9-4745-ac59-e7a71f32b4ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:fca21036-c7bb-4822-877f-0e8bf3400935"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:51261acc-a996-4e2f-8276-394af34d0964"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:8d6ea7af-70cc-44e0-9961-f14656100578 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0024332 PMID:41385096 "[{""id"":""uuid:b439ebfa-bd8b-4d68-820e-ce828e1961a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1d479c36-34c8-4ebf-9f9b-cccc7a533a1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:78b14c23-b15a-4dd1-aefe-a73a7e2ff8e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0000775 PMID:41385096 "[{""id"":""uuid:5194f4d9-e7b7-43f1-94a0-2eeed22fcd2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b40743dc-a8ac-40f3-992c-8938597c4df6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:e99ea987-07c9-46a5-b39a-ee5182f8700a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats UMLS:C0274440 PMID:41385096 "[{""id"":""uuid:8eec8a93-4300-4b78-a562-a05942f775c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f031a953-a113-4e76-a1fb-c6fb98f5c2a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:b72c1ea3-6c52-43a4-8822-e98aa1418d86 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0005883 PMID:41385096 "[{""id"":""uuid:55de85a1-8dfe-4bed-b72a-7d4dcaebf382"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4f8e36a6-fed9-40c2-812c-2ca9e50c04af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:d461f3b8-6979-46f8-85b0-e9879b8c0764 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0006814 PMID:41385096 "[{""id"":""uuid:6c741b39-225b-4643-a7e2-400e8e1cf8a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a0dffcb6-ff73-4532-a915-dd099f786796"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:4fa64aab-923f-469a-973d-9c581d3e8480 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0004773 PMID:41385096 "[{""id"":""uuid:93e44644-4fa1-43da-90d1-bb2ce18d3659"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:89a2bc48-117a-4dbe-9680-55ad72227f8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:bce49a49-51c7-4cf7-b6f1-babe0ee01996 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0004674 PMID:41385096 "[{""id"":""uuid:b9692e2f-7f59-43e0-afd4-dc764d36efe0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0caf00a9-f79b-4616-8e41-02f8ce61b37b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:480de18e-b67c-4d9c-933e-4daa65bddd83 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0006918 PMID:41385096 "[{""id"":""uuid:1ba1e83a-c91a-49ee-866a-7885074e4d9d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e40526d1-6a03-4b2e-8894-05a1101153b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:76a6e763-4ec1-4c0a-9fca-1171daa856ed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0001280 PMID:41385096 "[{""id"":""uuid:98fe3c06-517e-47c6-ac2e-9154fc249717"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f398eb61-853f-484f-a730-3ed36d5d76cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:2af2de76-2700-450d-8368-1e70f113029a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0005885 PMID:41385096 "[{""id"":""uuid:6c05c77d-d68d-4315-87c2-36a91bd2b283"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:00a759cc-0e2c-42c9-995a-ac7d0a846be4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:9ffc8af4-80e2-42d0-935b-67e81032ecaf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0019198 PMID:41385096 "[{""id"":""uuid:f8357daf-25ff-4cab-9e53-71ac5e7a1d57"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:211a816d-ce36-4399-8e02-6b048b482876"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:b4f943a0-476c-4aee-bcec-362e8b903c33 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0006651 PMID:41385096 "[{""id"":""uuid:375b7c0e-a73f-4b7f-b22d-b590cc64659a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6a713e99-eea6-4a97-8886-9c02a6dc2952"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:8f1de475-a690-4d5a-8050-5b41581f31d3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0003085 PMID:41385096 "[{""id"":""uuid:db45934c-c4b2-4f94-93b9-d0b6330b526c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4b002135-4c7d-45ac-a967-00ad60dd9c0f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:1f0045f3-cdd0-4faf-91e0-670e9eb01242 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0001034 PMID:41385096 "[{""id"":""uuid:47911354-17fd-4ac9-922d-3e42b2f239b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8caf4c4a-240d-43cd-a0ea-cfe9f4ce449a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:63abe018-584f-4cca-8573-5db307a2270f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:b43f0ae5-00a0-4903-b634-6cb8aefcca3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f11b4104-ac32-4082-b045-bac751567368"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:636a815c-78c3-40d5-a667-4bfc9bf2ae28 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats UMLS:C0678202 PMID:41385096 "[{""id"":""uuid:1dce1f02-9a87-47db-a066-57a8aca85b9d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bae4f238-5966-4dc1-a11d-a92bd05db9ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:cae91e76-5f09-4163-b2dd-357fc1c05aa4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0019338 PMID:41385096 "[{""id"":""uuid:6e2c6fae-4261-4457-bcae-79a7631171b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0bf80dfa-441c-445c-a920-fe5e8637b1ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:c9d2c0df-e378-46cf-8a09-718b86cdd6f2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0015274 PMID:41385096 "[{""id"":""uuid:8c34f6ef-a6cd-4908-8f8c-c129cbb81b22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:71ead4e5-3502-41b4-8811-392a071b1956"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:1c2390b1-3e19-4f79-85ef-353267422199 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0006052 PMID:41385096 "[{""id"":""uuid:54b77142-251e-403c-9baf-b083a3b66866"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2d02dddd-8aba-4f95-9dd5-319f855e41d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:1b2ef4e5-3c47-4770-81b4-5e2c14481110 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0005848 PMID:41385096 "[{""id"":""uuid:8a8ef7af-bc6a-403e-a7fe-c5d814b60b5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:59b9a993-69ef-4501-bb72-6d2eea2b0575"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:ea7468b2-d288-475f-83bc-a1dde83ba12f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0002572 PMID:41385096 "[{""id"":""uuid:82565616-1e13-4adb-a724-6346605d66ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:854b025b-79bc-4d3c-9aa4-a92ee5fbc60f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:7655b007-ff4c-4318-8dfd-1750cbef0606 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats UMLS:C0002879 PMID:41385096 "[{""id"":""uuid:31e9c03d-3722-41d4-9c15-65ad99f1948f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:566abab7-1ba6-4c57-a0ae-943261337888"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:f9152e03-3b99-49f7-be7e-dc0382072506 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0020108 PMID:41385096 "[{""id"":""uuid:16a327f9-ce4a-4744-88a4-8d5f8b405a0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:183cb662-1d70-43a0-8d19-400588f3de23"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:59994e55-1e5a-4a20-8a1c-75d6d4d07cec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0019098 PMID:41385096 "[{""id"":""uuid:7a74ea18-2bdb-465c-b775-814dc9ef373e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5ad33aa6-40d4-41f5-96ee-75c8347428e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:2bba31ca-5b93-4e9d-9a91-2edf10718234 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0001198 PMID:41385096 "[{""id"":""uuid:5bd88ebb-aa75-4f2c-8cbd-92445c664a04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c7ef824c-f0c6-470e-a0cb-f4e704d5855e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:4da40fc3-cecd-4382-89fe-5b9a51ed4301 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0002280 PMID:41385096 "[{""id"":""uuid:c85a0dc0-53fc-4b46-8694-88e54cf13a00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9cc40ca1-2599-4d68-a629-8eb5200110c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:62880771-53d6-4fe7-8e28-9dffc713463c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0015253 PMID:41385096 "[{""id"":""uuid:ff09bfcd-0323-471f-9a48-b11b2ae47d4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c8f84eff-fae9-4a3f-bf7a-0fbdb89e22dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:3601f379-4f72-4089-a6e1-10b65692d4a5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats HP:0001908 PMID:41385096 "[{""id"":""uuid:f1971799-9c46-4b30-88b3-7954f879d578"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:103596c3-c6e4-4248-9390-3cd6d31eb3f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:77a19464-120a-40dd-aa1e-f0f4519cc69e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0005059 PMID:41385096 "[{""id"":""uuid:eeed1c13-4543-464a-be03-7044ba4d30f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:69b9f562-c89e-4dc7-8f69-bb496defb37b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:23ab6f39-328b-44de-a3c0-af123d5025fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0004095 PMID:41385096 "[{""id"":""uuid:84f40566-3003-4d35-922e-e287576b8377"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:acd25454-b3b6-4991-95b9-edd16767324e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:476e9f9e-4251-41e3-ba4d-f4ecb6c7805c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0004355 PMID:41385096 "[{""id"":""uuid:c85c648c-edad-4153-ad0c-926893992eb8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:69133551-0a78-4dbf-b622-b14fa7ab5e49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:6f678cb6-6d4f-4896-8db6-490fb73d74bc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0005377 PMID:41385096 "[{""id"":""uuid:60b4c612-dfe7-4a94-bd35-071a281b0ebc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b545e697-d833-45c6-a017-11799440a534"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:88c196fd-f54d-41ad-bb3e-290fcc340526 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0006042 PMID:41385096 "[{""id"":""uuid:7440664d-c203-4d32-b466-04042c9e2aae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fb417506-3eab-48f6-bd93-1be9e8031c1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:4eeb6efa-03b9-4bb0-8521-0c6bfc456e29 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0019444 PMID:41385096 "[{""id"":""uuid:03ab72ba-49bc-45e4-9d60-f9319d7e3e1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ae26b68d-a635-4857-9751-d7a609641782"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:87e8fbce-2fa1-42ec-a092-ddf1bbe106f7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0006684 PMID:41385096 "[{""id"":""uuid:6660f231-3b32-4fdb-aa93-e3117baaf3b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:22f9defb-44db-48d7-980c-bde4df500e4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:fe90e5e8-c08d-485d-891c-88c8da6001ee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0021211 PMID:41385096 "[{""id"":""uuid:62d0d1a5-caf4-4a3f-8324-62152c98cc32"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:032928ac-2bb5-4737-b5b6-cf41f998d1e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: Endocrine Disorders​ Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:5651c101-631d-4599-b4dc-3c93ec15f8f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64354 biolink:treats HP:0000969 PMID:41385096 "[{""id"":""uuid:81801d9b-7e01-4930-b00f-c1337ee58d6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e1241335-8fe5-4335-a6d0-572659a39db1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metolazone tablets are indicated for the treatment of salt and water retention including: • edema accompanying congestive heart failure; • edema accompanying renal diseases, including the nephrotic syndrome and states of diminished renal function. Metolazone tablets are also indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs of a different class. Mykrox ® tablets, a more rapidly available form of metolazone, are intended for the treatment of new patients with mild to moderate hypertension. A dose titration is necessary if Mykrox ® tablets are to be substituted for Zaroxolyn ® tablets and other formulations of metolazone that share its slow and incomplete bioavailability, in the treatment of hypertension. uuid:5c2fff3e-858e-43ad-8d3c-b5c3c32650c9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64354 biolink:treats UMLS:C0235415 PMID:41385096 "[{""id"":""uuid:4a0427a9-105f-474d-abad-847a2a4097d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ac68847d-477e-402e-af25-03f8d1a4ecff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metolazone tablets are indicated for the treatment of salt and water retention including: • edema accompanying congestive heart failure; • edema accompanying renal diseases, including the nephrotic syndrome and states of diminished renal function. Metolazone tablets are also indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs of a different class. Mykrox ® tablets, a more rapidly available form of metolazone, are intended for the treatment of new patients with mild to moderate hypertension. A dose titration is necessary if Mykrox ® tablets are to be substituted for Zaroxolyn ® tablets and other formulations of metolazone that share its slow and incomplete bioavailability, in the treatment of hypertension. uuid:c7b32730-be3f-410f-842d-be0f4305de78 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3654 biolink:treats MONDO:0001644 PMID:41385096 "[{""id"":""uuid:3f778269-7401-428d-905c-e0dff2169acd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6f55a293-1a35-4fe5-9494-57b5ffb6e7e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diuretics such as chlorthalidone are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension. Chlorthalidone is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Chlorthalidone has also been found useful in edema due to various forms of renal dysfunction, such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Usage in Pregnancy The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Chlorthalidone is indicated in pregnancy when edema is due to pathologic causes, just as it is in the absence of pregnancy (however, see PRECAUTIONS, below). Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy that is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but that is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort that is not relieved by rest. In these cases, a short course of diuretics may provide relief and be appropriate. uuid:b314d111-61e5-4006-8687-e5b3abeb8efc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3654 biolink:treats HP:0007430 PMID:41385096 "[{""id"":""uuid:c40b6af8-f626-4002-8970-313157b0971f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:20835f7c-6537-4d8f-98e9-965575694d2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diuretics such as chlorthalidone are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension. Chlorthalidone is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Chlorthalidone has also been found useful in edema due to various forms of renal dysfunction, such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Usage in Pregnancy The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Chlorthalidone is indicated in pregnancy when edema is due to pathologic causes, just as it is in the absence of pregnancy (however, see PRECAUTIONS, below). Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy that is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but that is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort that is not relieved by rest. In these cases, a short course of diuretics may provide relief and be appropriate. uuid:6fc8b08a-b39c-49f9-bff7-43cfd3cd2241 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47519 biolink:treats MONDO:0001628 PMID:41385096 "[{""id"":""uuid:98c35dad-98c9-4a75-9726-d572a94cec6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:91686c28-a200-46ed-8f15-c3d6769febd3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ketoconazole tablets are not indicated for treatment of onychomycosis, cutaneous dermatophyte infections, or Candida infections. Ketoconazole tablets should be used only when other effective antifungal therapy is not available or tolerated and the potential benefits are considered to outweigh the potential risks. Ketoconazole tablets are indicated for the treatment of the following systemic fungal infections in patients who have failed or who are intolerant to other therapies: blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis. Ketoconazole tablets should not be used for fungal meningitis because it penetrates poorly into the cerebrospinal fluid. uuid:c80f6641-4a5f-4cb1-ba66-94050e7c769d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47519 biolink:treats MONDO:0006764 PMID:41385096 "[{""id"":""uuid:ab9c7bda-5d73-4147-8b31-6acea1145077"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:64e3aaef-5a84-488d-b3d9-b62cb1478217"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ketoconazole tablets are not indicated for treatment of onychomycosis, cutaneous dermatophyte infections, or Candida infections. Ketoconazole tablets should be used only when other effective antifungal therapy is not available or tolerated and the potential benefits are considered to outweigh the potential risks. Ketoconazole tablets are indicated for the treatment of the following systemic fungal infections in patients who have failed or who are intolerant to other therapies: blastomycosis, coccidioidomycosis, histoplasmosis, chromomycosis, and paracoccidioidomycosis. Ketoconazole tablets should not be used for fungal meningitis because it penetrates poorly into the cerebrospinal fluid. uuid:5d4ecb3d-03b0-4d90-82af-63e8a33903ab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:585948 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:9a7178f0-a5e1-44cd-88b8-a8a802db9551"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4d6fb9f5-b295-4872-8202-aadf1d807c7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Felodipine tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including felodipine. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (eg, on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Felodipine tablets may be administered with other antihypertensive agents. uuid:25b3d104-c696-4efa-83f0-7ce307990a15 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:585948 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:57e64f2a-2742-44b1-b7cb-7262b78b64f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c57f7e89-d82a-4b5f-bc5f-9b03ee75396e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Felodipine tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including felodipine. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (eg, on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Felodipine tablets may be administered with other antihypertensive agents. uuid:56c8db0d-7b5b-49ef-a7b3-98d1beaf9ca8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:585948 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:44c0e2e9-85f5-49df-9632-8919c6bd129d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f18816b3-dd9f-41b4-8732-afde4abdf5f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Felodipine tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including felodipine. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (eg, on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Felodipine tablets may be administered with other antihypertensive agents. uuid:b4c362ea-de3c-4af9-8c87-c0dbb4ddff69 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8805 biolink:treats MONDO:0012819 PMID:41385096 "[{""id"":""uuid:e4ed8504-1512-48a3-8684-56031e94c42d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:856595e9-f67a-4246-87d3-8af892ad1e94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRANDIN is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitation of Use: PRANDIN should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. uuid:8e38d820-b9b8-4636-96e2-b138ecfd9766 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8107 biolink:treats MONDO:0002125 PMID:41385096 "[{""id"":""uuid:476c75c2-84d5-43e8-abf3-f1412026649c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fadc5e32-e757-46c8-96c9-af67ef5b1813"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fosphenytoin Sodium Injection, USP is indicated for the treatment of generalized tonic-clonic status epilepticus and prevention and treatment of seizures occurring during neurosurgery. Fosphenytoin Sodium Injection, USP can also be substituted, short-term, for oral phenytoin. Fosphenytoin Sodium Injection, USP should be used only when oral phenytoin administration is not possible [see Dosage and Administration (2.4) and Warnings and Precautions (5.2) ]. uuid:c9e7ef03-4a65-42bf-9a3e-f036414c2e9f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:30746 biolink:treats HP:0008281 PMID:41385096 "[{""id"":""uuid:136ed106-0405-4ddd-ab9c-1b0c90a5b9d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f6a3c1f1-1449-464b-9582-f42daecf6ff1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AMMONUL is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. During acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [ see Warnings and Precautions (5) ]. uuid:8219023d-7361-4bbb-8213-654b176d9b32 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64028 biolink:treats MONDO:0007739 PMID:41385096 "[{""id"":""uuid:bf0e803f-9f70-4ba6-9d93-65e2fbd18500"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:364f8e91-2557-4612-83fe-6cba1eec76a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b057a837-276d-4048-bd2b-1461bc9b1e25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tetrabenazine tablets are indicated for the treatment of chorea associated with Huntington's disease.|[PMDA] A drug with a new active ingredient indicated for the treatment of chorea associated with Huntington's disease. [Orphan drug] uuid:87c070e4-ffd6-43e3-90a8-4ff5bd585f8f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49662 biolink:treats NCIT:C27003 PMID:41385096 "[{""id"":""uuid:b884b339-987c-4e4f-b4d5-05b29367cd64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f65913ad-59d6-48cd-9b8c-fbe9c61853ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TIVORBEX is indicated for treatment of mild to moderate acute pain in adults. uuid:9b91ecd5-44ef-406c-b4f7-1ec574445016 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3757 biolink:treats MONDO:0005302 PMID:41385096 "[{""id"":""uuid:b8abfba4-1d97-434c-ae89-ac9c9d2f8ec1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6d0d1e2f-c7e1-478e-899a-e43b4b008e0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clonidine hydrochloride extended-release tablets are indicated for the treatment of attention deficit hyperactivity disorder (ADHD) as monotherapy and as adjunctive therapy to stimulant medications [see Clinical Studies (14)]. uuid:93459ba7-c791-4ecc-81d9-cd00e9f15fd5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats UMLS:C1290158 PMID:41385096 "[{""id"":""uuid:a3b3d061-f397-43d0-868b-4f38ac5d3b65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:538e2fa9-e1b2-4fbb-a2a0-a40ed32d10ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis Collagen Diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Dermatologic Diseases: Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Diseases: Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis Hematologic Disorders: Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Diseases: For palliative management of: Leukemia and lymphomas in adults Acute leukemia of childhood Edematous States: To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases: To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous: Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement Diagnostic testing of adrenocortical hyperfunction. uuid:bf9e0291-7091-4988-86fb-f41279f89fdf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0006918 PMID:41385096 "[{""id"":""uuid:905bd515-0895-43ce-a7d9-fdde398a9dc3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0873189f-b4b7-42dc-aab5-ee67c1076526"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis Collagen Diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Dermatologic Diseases: Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Diseases: Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis Hematologic Disorders: Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Diseases: For palliative management of: Leukemia and lymphomas in adults Acute leukemia of childhood Edematous States: To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases: To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous: Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement Diagnostic testing of adrenocortical hyperfunction. uuid:ba8b3464-df95-47ec-9d97-dcdd6ae8acf8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0001280 PMID:41385096 "[{""id"":""uuid:34cb439f-6188-47b6-9314-1f2736232e80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:46d7151b-8c40-449e-9b86-6de683b87c67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis Collagen Diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Dermatologic Diseases: Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Respiratory Diseases: Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis Hematologic Disorders: Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Diseases: For palliative management of: Leukemia and lymphomas in adults Acute leukemia of childhood Edematous States: To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases: To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous: Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement Diagnostic testing of adrenocortical hyperfunction. uuid:bdf72fbd-96d6-4b13-a3ee-d000bb2ab661 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16684 biolink:treats MONDO:0001673 PMID:41385096 "[{""id"":""uuid:34f7ef7c-e485-4473-a468-ff3f8016bb8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:947d60cf-a2e2-4048-af6c-72605ff2d7a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diphenoxylate Hydrochloride and Atropine Sulfate Tablets USP are indicated as adjunctive therapy in the management of diarrhea in patients 13 years of age and older. uuid:f86c8025-1687-4d6c-bbfb-b1327dec4e81 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4356 biolink:treats UMLS:C1739382 PMID:41385096 "[{""id"":""uuid:4f675525-5dce-4e33-874e-29c4c76ad436"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e5e9f22e-322e-48ed-a504-b3dd4b73e1bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Deferoxamine mesylate for injection, USP, is indicated for the treatment of acute iron intoxication and of chronic iron overload due to transfusion-dependent anemias. Acute Iron Intoxication Deferoxamine mesylate is an adjunct to, and not a substitute for, standard measures used in treating acute iron intoxication, which may include the following: induction of emesis with syrup of ipecac; gastric lavage; suction and maintenance of a clear airway; control of shock with intravenous fluids, blood, oxygen, and vasopressors; and correction of acidosis. Chronic Iron Overload Deferoxamine mesylate can promote iron excretion in patients with secondary iron overload from multiple transfusions (as may occur in the treatment of some chronic anemias, including thalassemia). Long-term therapy with deferoxamine mesylate slows accumulation of hepatic iron and retards or eliminates progression of hepatic fibrosis. Iron mobilization with deferoxamine mesylate is relatively poor in patients under the age of 3 years with relatively little iron overload. The drug should ordinarily not be given to such patients unless significant iron mobilization (e.g., 1 mg or more of iron per day) can be demonstrated. Deferoxamine mesylate is not indicated for the treatment of primary hemochromatosis, since phlebotomy is the method of choice for removing excess iron in this disorder. uuid:517b0947-364a-4b24-952b-5da5c0264e97 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4356 biolink:treats MONDO:0000984 PMID:41385096 "[{""id"":""uuid:b260be5d-6682-4d7d-91d0-cbcfe2b7fb8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0499e20c-9345-41bf-bca8-2ededfa98e66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Deferoxamine mesylate for injection, USP, is indicated for the treatment of acute iron intoxication and of chronic iron overload due to transfusion-dependent anemias. Acute Iron Intoxication Deferoxamine mesylate is an adjunct to, and not a substitute for, standard measures used in treating acute iron intoxication, which may include the following: induction of emesis with syrup of ipecac; gastric lavage; suction and maintenance of a clear airway; control of shock with intravenous fluids, blood, oxygen, and vasopressors; and correction of acidosis. Chronic Iron Overload Deferoxamine mesylate can promote iron excretion in patients with secondary iron overload from multiple transfusions (as may occur in the treatment of some chronic anemias, including thalassemia). Long-term therapy with deferoxamine mesylate slows accumulation of hepatic iron and retards or eliminates progression of hepatic fibrosis. Iron mobilization with deferoxamine mesylate is relatively poor in patients under the age of 3 years with relatively little iron overload. The drug should ordinarily not be given to such patients unless significant iron mobilization (e.g., 1 mg or more of iron per day) can be demonstrated. Deferoxamine mesylate is not indicated for the treatment of primary hemochromatosis, since phlebotomy is the method of choice for removing excess iron in this disorder. uuid:e9972e9e-9486-4714-9f72-c0985a9bf17d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4356 biolink:treats MONDO:0006507 PMID:41385096 "[{""id"":""uuid:fb5d31a2-9a53-4966-a56b-fe2fe246f71e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5946b815-e0e7-4c87-aaaf-5d0f44d42210"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Deferoxamine mesylate for injection, USP, is indicated for the treatment of acute iron intoxication and of chronic iron overload due to transfusion-dependent anemias. Acute Iron Intoxication Deferoxamine mesylate is an adjunct to, and not a substitute for, standard measures used in treating acute iron intoxication, which may include the following: induction of emesis with syrup of ipecac; gastric lavage; suction and maintenance of a clear airway; control of shock with intravenous fluids, blood, oxygen, and vasopressors; and correction of acidosis. Chronic Iron Overload Deferoxamine mesylate can promote iron excretion in patients with secondary iron overload from multiple transfusions (as may occur in the treatment of some chronic anemias, including thalassemia). Long-term therapy with deferoxamine mesylate slows accumulation of hepatic iron and retards or eliminates progression of hepatic fibrosis. Iron mobilization with deferoxamine mesylate is relatively poor in patients under the age of 3 years with relatively little iron overload. The drug should ordinarily not be given to such patients unless significant iron mobilization (e.g., 1 mg or more of iron per day) can be demonstrated. Deferoxamine mesylate is not indicated for the treatment of primary hemochromatosis, since phlebotomy is the method of choice for removing excess iron in this disorder. uuid:ad23a5f9-fa7c-4ebb-9dff-313a7e40b4f0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats MONDO:0000775 PMID:41385096 "[{""id"":""uuid:918c7ab8-4b13-426c-9058-e0ecee8d7068"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d22be4cd-17c2-4024-9cdd-c2c686d90932"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Epinephrine is used to relieve respiratory distress due to bronchospasm, to provide rapid relief of hypersensitivity reactions to drugs and other allergens, and to prolong the action of anesthetics. Its cardiac effects may be of use in restoring cardiac rhythm in cardiac arrest due to various causes, but it is not used in cardiac failure or in hemorrhagic, traumatic, or cardiogenic shock. Epinephrine is used as a hemostatic agent. It is also used in treating mucosal congestion of hay fever, rhinitis, and acute sinusitis; to relieve bronchial asthmatic paroxysms; in syncope due to complete heart block or carotid sinus hypersensitivity; for symptomatic relief of serum sickness, urticaria, angioneurotic edema; for resuscitation in cardiac arrest following anesthetic accidents; in simple (open angle) glaucoma; for relaxation of uterine musculature and to inhibit uterine contractions. Epinephrine Injection can be utilized to prolong the action of anesthetics used in local and regional anesthesia. uuid:3fdd12e2-9427-496e-957a-1d7157008e3e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:974fb651-fdde-484d-968c-a11b3e98ce7c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:246e900b-7109-457a-81f5-2d5b76c69695"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Epinephrine is used to relieve respiratory distress due to bronchospasm, to provide rapid relief of hypersensitivity reactions to drugs and other allergens, and to prolong the action of anesthetics. Its cardiac effects may be of use in restoring cardiac rhythm in cardiac arrest due to various causes, but it is not used in cardiac failure or in hemorrhagic, traumatic, or cardiogenic shock. Epinephrine is used as a hemostatic agent. It is also used in treating mucosal congestion of hay fever, rhinitis, and acute sinusitis; to relieve bronchial asthmatic paroxysms; in syncope due to complete heart block or carotid sinus hypersensitivity; for symptomatic relief of serum sickness, urticaria, angioneurotic edema; for resuscitation in cardiac arrest following anesthetic accidents; in simple (open angle) glaucoma; for relaxation of uterine musculature and to inhibit uterine contractions. Epinephrine Injection can be utilized to prolong the action of anesthetics used in local and regional anesthesia. uuid:d8afaf7f-558d-4596-9ce9-2634f8d09a2c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats MONDO:0000468 PMID:41385096 "[{""id"":""uuid:7dcd97c0-7e58-4632-be48-177c39f8ed6c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6efc79fd-9cdc-435e-b051-a99336a3117d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Epinephrine is used to relieve respiratory distress due to bronchospasm, to provide rapid relief of hypersensitivity reactions to drugs and other allergens, and to prolong the action of anesthetics. Its cardiac effects may be of use in restoring cardiac rhythm in cardiac arrest due to various causes, but it is not used in cardiac failure or in hemorrhagic, traumatic, or cardiogenic shock. Epinephrine is used as a hemostatic agent. It is also used in treating mucosal congestion of hay fever, rhinitis, and acute sinusitis; to relieve bronchial asthmatic paroxysms; in syncope due to complete heart block or carotid sinus hypersensitivity; for symptomatic relief of serum sickness, urticaria, angioneurotic edema; for resuscitation in cardiac arrest following anesthetic accidents; in simple (open angle) glaucoma; for relaxation of uterine musculature and to inhibit uterine contractions. Epinephrine Injection can be utilized to prolong the action of anesthetics used in local and regional anesthesia. uuid:eb07c050-3c4b-401c-a0ae-5d6dfafaecbf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats HP:0012669 PMID:41385096 "[{""id"":""uuid:51781e37-55ab-4680-b54e-785b3c020b88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:123d6997-74fd-4175-884f-e1b6ef4f65fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Epinephrine is used to relieve respiratory distress due to bronchospasm, to provide rapid relief of hypersensitivity reactions to drugs and other allergens, and to prolong the action of anesthetics. Its cardiac effects may be of use in restoring cardiac rhythm in cardiac arrest due to various causes, but it is not used in cardiac failure or in hemorrhagic, traumatic, or cardiogenic shock. Epinephrine is used as a hemostatic agent. It is also used in treating mucosal congestion of hay fever, rhinitis, and acute sinusitis; to relieve bronchial asthmatic paroxysms; in syncope due to complete heart block or carotid sinus hypersensitivity; for symptomatic relief of serum sickness, urticaria, angioneurotic edema; for resuscitation in cardiac arrest following anesthetic accidents; in simple (open angle) glaucoma; for relaxation of uterine musculature and to inhibit uterine contractions. Epinephrine Injection can be utilized to prolong the action of anesthetics used in local and regional anesthesia. uuid:bb738d5f-db96-4876-a166-f2cb8c37228f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats MONDO:0005338 PMID:41385096 "[{""id"":""uuid:8719b1fd-7670-4cb1-8a84-50af401f17fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:06b117c8-1024-4780-b791-1ca8e28dd839"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Epinephrine is used to relieve respiratory distress due to bronchospasm, to provide rapid relief of hypersensitivity reactions to drugs and other allergens, and to prolong the action of anesthetics. Its cardiac effects may be of use in restoring cardiac rhythm in cardiac arrest due to various causes, but it is not used in cardiac failure or in hemorrhagic, traumatic, or cardiogenic shock. Epinephrine is used as a hemostatic agent. It is also used in treating mucosal congestion of hay fever, rhinitis, and acute sinusitis; to relieve bronchial asthmatic paroxysms; in syncope due to complete heart block or carotid sinus hypersensitivity; for symptomatic relief of serum sickness, urticaria, angioneurotic edema; for resuscitation in cardiac arrest following anesthetic accidents; in simple (open angle) glaucoma; for relaxation of uterine musculature and to inhibit uterine contractions. Epinephrine Injection can be utilized to prolong the action of anesthetics used in local and regional anesthesia. uuid:0ec5414b-05da-4448-a118-a25fbb03ca08 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64354 biolink:treats MONDO:0045048 PMID:41385096 "[{""id"":""uuid:08cf9714-f0a9-4539-875c-2dcfe4e2a197"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3a99a62a-251e-422e-8058-721805a869df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Upstate's metolazone tablets, USP, are indicated for the treatment of salt and water retention including: edema accompanying congestive heart failure; edema accompanying renal diseases, including the nephrotic syndrome and states of diminished renal function. Metolazone tablets, USP, are also indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs of a different class. MYKROX Tablets, a more rapidly available form of metolazone, are intended for the treatment of new patients with mild to moderate hypertension. A dose titration is necessary if MYKROX Tablets are to be substituted for Upstate's metolazone tablets, USP, in the treatment of hypertension. See package circular for MYKROX Tablets (UCB). Usage In Pregnancy The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no evidence that they are useful in the treatment of developed toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Metolazone tablets, USP, are indicated in pregnancy when edema is due to pathologic causes, just as it is in the absence of pregnancy (see PRECAUTIONS). Dependent edema in pregnancy resulting from restriction of venous return by the expanded uterus is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort which is not relieved by rest. In these cases, a short course of diuretics may be appropriate. uuid:539c8073-448e-4e2f-b5ff-c81d6ee3adb1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64354 biolink:treats MONDO:0005081 PMID:41385096 "[{""id"":""uuid:48b2035f-7d6c-4245-bc70-5381768f8e6a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d57a4eb5-b3e6-4b27-b3df-b37fde46f251"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Upstate's metolazone tablets, USP, are indicated for the treatment of salt and water retention including: edema accompanying congestive heart failure; edema accompanying renal diseases, including the nephrotic syndrome and states of diminished renal function. Metolazone tablets, USP, are also indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs of a different class. MYKROX Tablets, a more rapidly available form of metolazone, are intended for the treatment of new patients with mild to moderate hypertension. A dose titration is necessary if MYKROX Tablets are to be substituted for Upstate's metolazone tablets, USP, in the treatment of hypertension. See package circular for MYKROX Tablets (UCB). Usage In Pregnancy The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no evidence that they are useful in the treatment of developed toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Metolazone tablets, USP, are indicated in pregnancy when edema is due to pathologic causes, just as it is in the absence of pregnancy (see PRECAUTIONS). Dependent edema in pregnancy resulting from restriction of venous return by the expanded uterus is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort which is not relieved by rest. In these cases, a short course of diuretics may be appropriate. uuid:97e38f95-d27d-4750-831c-b019ff05685e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64354 biolink:treats HP:0007430 PMID:41385096 "[{""id"":""uuid:b2a23943-f30e-4e5a-8222-cd4c1782cac1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b7ccff3c-6822-4e13-9451-5228e0fba358"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Upstate's metolazone tablets, USP, are indicated for the treatment of salt and water retention including: edema accompanying congestive heart failure; edema accompanying renal diseases, including the nephrotic syndrome and states of diminished renal function. Metolazone tablets, USP, are also indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs of a different class. MYKROX Tablets, a more rapidly available form of metolazone, are intended for the treatment of new patients with mild to moderate hypertension. A dose titration is necessary if MYKROX Tablets are to be substituted for Upstate's metolazone tablets, USP, in the treatment of hypertension. See package circular for MYKROX Tablets (UCB). Usage In Pregnancy The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no evidence that they are useful in the treatment of developed toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Metolazone tablets, USP, are indicated in pregnancy when edema is due to pathologic causes, just as it is in the absence of pregnancy (see PRECAUTIONS). Dependent edema in pregnancy resulting from restriction of venous return by the expanded uterus is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort which is not relieved by rest. In these cases, a short course of diuretics may be appropriate. uuid:00f06af7-8224-4f51-bbda-bb62d9ff6b2a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:205919 biolink:treats MONDO:0006604 PMID:41385096 "[{""id"":""uuid:05f0595e-99b6-42b2-8980-ec6afe40fa1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c5f4ed8c-4a88-42ca-b9e7-c03e446f8a38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clobetasol Propionate Topical Spray, 0.05% is a corticosteroid indicated for the topical treatment of moderate to severe plaque psoriasis affecting up to 20% body surface area (BSA) in patients 18 years of age or older. ( 1.1 ) Limitations of Use: Do not use on the face, axillae or groin. ( 1.2 ) Do not use if atrophy is present at the treatment site.( 1.2 ) Do not use for rosacea or perioral dermatitis. ( 1.2 ) uuid:4dbfbdfa-ea12-4a73-b9dc-ab516c2027da biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:499361 biolink:treats HP:0002018 PMID:41385096 "[{""id"":""uuid:3a06c95a-c0ca-48eb-90f8-f76543e97687"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:83e20593-7209-4318-af5d-5ae2d75e7b37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f267e875-4cfc-458c-92ca-e1b79fc2ab61"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EMEND ® for injection, in combination with other antiemetic agents, is indicated in adults for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC).|[PMDA] Drugs with a new active ingredient indicated for the treatment of digestive symptoms (nausea and vomiting, including delayed phase) resulting from the administration of antineoplastic agents (cisplatin, etc.). uuid:462d0150-93c3-4bf3-80a6-dabd4fe5cb90 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:499361 biolink:treats HP:0002013 PMID:41385096 "[{""id"":""uuid:6e0fbfc4-4b92-4d25-bafd-6f8f486a0e22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9d6ed8be-360b-4c6f-87c2-751e8af07314"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d226b94d-e72a-42a1-a2ad-6a1ea87c9215"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EMEND ® for injection, in combination with other antiemetic agents, is indicated in adults for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC).|[PMDA] Drugs with a new active ingredient indicated for the treatment of digestive symptoms (nausea and vomiting, including delayed phase) resulting from the administration of antineoplastic agents (cisplatin, etc.). uuid:072db841-325a-486d-b89e-8631d9b9f18a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0006640 PMID:41385096 "[{""id"":""uuid:8267086c-a872-48de-98a5-48ed1b062941"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:15c4b82c-da8f-491b-84c2-06503f7cb25e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:2f78b54f-8133-42ee-a2be-b9e1256be5e7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1593740 biolink:treats MONDO:0001860 PMID:41385096 "[{""id"":""uuid:254fc194-6c3b-464d-8695-64f490232e1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9ffa54fd-f60c-4385-a92f-a25324a760ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Noxifol-D is indicated for dietary management of patients with unique nutritional needs requiring increased folate levels, Vitamin D levels, or used in improving the nutritional status of patients with folic acid and vitamin D deficiency This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent disease. uuid:a832d91b-f33a-40e9-901d-2171eb06bc75 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0001225 PMID:41385096 "[{""id"":""uuid:67ad7c28-0ffb-4d21-acd2-65a5616e8bee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c08ec247-bbd0-4e08-8e34-984b18e62c06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment with naltrexone implants should be part of a comprehensive management program that includes psychological and psychosocial support. Naltrexone tablets were initially approved by the FDA in 1985 for the treatment of abuse and addiction of opioids. Naltrexone in oral and extended release injection forms have been approved by the FDA for the treatment and abuse of alcohol. Naltrexone implants may be useful for the treatment of alcohol or opioid dependence in patients who are able to abstain from opioid or alcohol in an outpatient setting prior to initiation of treatment. Patients should not be actively drinking or be on any opioids at the time of initial naltrexone implant administration. uuid:10f51ebb-b23f-4c70-b02a-27237668f23d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0002046 PMID:41385096 "[{""id"":""uuid:91ba5f99-ed40-4b53-8e9d-1025facb15b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b15ad887-5494-41be-8edb-2121165c61a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment with naltrexone implants should be part of a comprehensive management program that includes psychological and psychosocial support. Naltrexone tablets were initially approved by the FDA in 1985 for the treatment of abuse and addiction of opioids. Naltrexone in oral and extended release injection forms have been approved by the FDA for the treatment and abuse of alcohol. Naltrexone implants may be useful for the treatment of alcohol or opioid dependence in patients who are able to abstain from opioid or alcohol in an outpatient setting prior to initiation of treatment. Patients should not be actively drinking or be on any opioids at the time of initial naltrexone implant administration. uuid:98f2d9be-7577-4505-8648-75d4dbb313cf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0007079 PMID:41385096 "[{""id"":""uuid:dcfe21e7-6382-4a66-ba73-ea5012a39e1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e609b015-721c-4807-bf1f-88b26c3e35fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment with naltrexone implants should be part of a comprehensive management program that includes psychological and psychosocial support. Naltrexone tablets were initially approved by the FDA in 1985 for the treatment of abuse and addiction of opioids. Naltrexone in oral and extended release injection forms have been approved by the FDA for the treatment and abuse of alcohol. Naltrexone implants may be useful for the treatment of alcohol or opioid dependence in patients who are able to abstain from opioid or alcohol in an outpatient setting prior to initiation of treatment. Patients should not be actively drinking or be on any opioids at the time of initial naltrexone implant administration. uuid:df2784e8-cdc6-4c28-940f-5a90230bfe07 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0005530 PMID:41385096 "[{""id"":""uuid:c1cc8dd4-b96c-423e-9b7f-db511ab817a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7dbb19e6-7ff1-4e54-bfc4-b66c53eb7e54"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment with naltrexone implants should be part of a comprehensive management program that includes psychological and psychosocial support. Naltrexone tablets were initially approved by the FDA in 1985 for the treatment of abuse and addiction of opioids. Naltrexone in oral and extended release injection forms have been approved by the FDA for the treatment and abuse of alcohol. Naltrexone implants may be useful for the treatment of alcohol or opioid dependence in patients who are able to abstain from opioid or alcohol in an outpatient setting prior to initiation of treatment. Patients should not be actively drinking or be on any opioids at the time of initial naltrexone implant administration. uuid:df63db6f-1260-495e-8229-e3e40cc402ac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8772 biolink:treats MONDO:0006256 PMID:41385096 "[{""id"":""uuid:07a387e8-3c9f-429c-8e6e-4d72385451d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7239ed0f-c822-41bd-bcb0-a04861505bcb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Raloxifene hydrochloride tablets, USP is an estrogen agonist/antagonist indicated for: Treatment and prevention of osteoporosis in postmenopausal women. ( 1.1 ) Reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis. ( 1.2 ) Reduction in risk of invasive breast cancer in postmenopausal women at high risk for invasive breast cancer. ( 1.3 ) Important Limitations: Raloxifene hydrochloride tablets, USP is not indicated for the treatment of invasive breast cancer, reduction of the risk of recurrence of breast cancer, or reduction of risk of noninvasive breast cancer. uuid:7cb78d80-243a-4bb3-9f76-330cdfb9658a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17347 biolink:treats HP:0008213 PMID:41385096 "[{""id"":""uuid:3859f69b-0e7d-4b5c-bc7f-993020cebd63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d312b224-13ac-49a1-afec-b22b5d110ec3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Testosterone gel is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: Primary Hypogonadism (congenital or acquired) - testicular failure due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter’s syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle stimulating hormone (FSH), luteinizing hormone (LH)) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired) - gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum concentrations but have gonadotropins in the normal or low range. Limitations of use: Safety and efficacy of testosterone gel in men with ""age-related hypogonadism"" (also referred to as ""late-onset hypogonadism"") have not been established. Safety and efficacy of testosterone gel in males less than 18 years old have not been established [ see Use in Specific Populations (8.4) ]. Topical testosterone products may have different doses, strengths, or application instructions that may result in different systemic exposure. (1, 12.3)" uuid:3d771e32-6f58-4bd5-8fc3-5a16d9c91d9d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0009197 PMID:41385096 "[{""id"":""uuid:2a4ed26b-b049-41d5-a256-f82e440cd41d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f0589210-00dd-4a5b-b144-b47598343cd6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Atopic dermatitis, Bronchial asthma, Contact dermatitis, Drug hypersensitivity reactions, Seasonal or perennial allergic rhinitis, and Serum sickness. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus, and Acute rheumatic carditis. Dermatologic Diseases Bullous dermatitis herpetiformis, Exfoliative dermatitis, Mycosis fungoides, Pemphigus, Severe erythema multiforme (Stevens-Johnson syndrome), Severe psoriasis, and Severe seborrheic dermatitis. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), Congenital adrenal hyperplasia, Hypercalcemia associated with cancer, and Nonsuppurative thyroiditis. Gastrointestinal diseases To tide the patient over a critical period of the disease in: Ulcerative colitis, and Regional enteritis. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults, Secondary thrombocytopenia in adults, Acquired (autoimmune) hemolytic anemia, Erythroblastopenia (RBC anemia), and Congenital (erythroid) hypoplastic anemia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy, and Trichinosis with neurologic or myocardial involvement. Neoplastic Diseases For palliative management of: Leukemia and lymphomas in adults, and Acute leukemia of childhood. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis, Keratitis, Allergic corneal marginal ulcers, Herpes zoster ophthalmicus, Iritis and iridocyclitis, Chorioretinitis, Anterior segment inflammation, Diffuse posterior uveitis and choroiditis, Optic neuritis, and Sympathetic ophthalmia. Respiratory Diseases Symptomatic sarcoidosis, Loeffler's syndrome not manageable by other means, Berylliosis, Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, and Aspiration pneumonitis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis, Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy), Ankylosing spondylitis, Acute and subacute bursitis, Acute nonspecific tenosynovitis, Acute gouty arthritis, Post-traumatic osteoarthritis, Synovitis of osteoarthritis, and Epicondylitis. uuid:3bf890d5-3c1b-41dc-8d31-e41ea5870ca9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:192254 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:108c03dc-ad67-4650-9037-6c3f6e174187"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f872490a-e404-4938-80a0-1a4fd54f08b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:bf77396a-3ead-443f-b012-42d4feca1f40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lamivudine-zidovudine-teva""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lamivudine and zidovudine tablets, a combination of 2 nucleoside analogues, is indicated in combination with other antiretrovirals for the treatment of human immunodeficiency virus type 1 (HIV‑1) infection.|[EMA] Combivir is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection., uuid:bd1a776e-36a6-4719-b66a-6ca285c10822 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3752 biolink:treats MONDO:0021348 PMID:41385096 "[{""id"":""uuid:d8538835-06a1-48f4-ad82-9aa3144aa924"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4d625c1c-a686-4e98-96f8-c3e197973ba6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clomiphene citrate tablets USP is indicated for the treatment of ovulatory dysfunction in women desiring pregnancy. Impediments to achieving pregnancy must be excluded or adequately treated before beginning clomiphene citrate tablets USP therapy. Those patients most likely to achieve success with clomiphene therapy include patients with polycystic ovary syndrome (see WARNINGS: Ovarian Hyperstimulation Syndrome ), amenorrhea-galactorrhea syndrome, psychogenic amenorrhea, post-oral-contraceptive amenorrhea, and certain cases of secondary amenorrhea of undetermined etiology. Properly timed coitus in relationship to ovulation is important. A basal body temperature graph or other appropriate tests may help the patient and her physician determine if ovulation occurred. Once ovulation has been established, each course of clomiphene citrate tablets USP should be started on or about the 5th day of the cycle. Long-term cyclic therapy is not recommended beyond a total of about six cycles (including three ovulatory cycles). (See DOSAGE AND ADMINISTRATION and PRECAUTIONS .) Clomiphene citrate tablets USP is indicated only in patients with demonstrated ovulatory dysfunction who meet the conditions described below: 1. Patients who are not pregnant. 2. Patients without ovarian cysts. Clomiphene citrate tablets USP should not be used in patients with ovarian enlargement except those with polycystic ovary syndrome. Pelvic examination is necessary prior to the first and each subsequent course of clomiphene citrate tablets USP treatment. 3. Patients without abnormal vaginal bleeding. If abnormal vaginal bleeding is present, the patient should be carefully evaluated to ensure that neoplastic lesions are not present. 4. Patients with normal liver function. In addition, patients selected for clomiphene citrate tablets USP therapy should be evaluated in regard to the following: 1. Estrogen Levels. Patients should have adequate levels of endogenous estrogen (as estimated from vaginal smears, endometrial biopsy, assay of urinary estrogen, or from bleeding in response to progesterone). Reduced estrogen levels, while less favorable, do not preclude successful therapy. 2. Primary Pituitary or Ovarian Failure. Clomiphene citrate tablets USP therapy cannot be expected to substitute for specific treatment of other causes of ovulatory failure. 3. Endometriosis and Endometrial Carcinoma. The incidence of endometriosis and endometrial carcinoma increases with age as does the incidence of ovulatory disorders. Endometrial biopsy should always be performed prior to clomiphene citrate tablets USP therapy in this population. 4. Other Impediments to Pregnancy. Impediments to pregnancy can include thyroid disorders, adrenal disorders, hyperprolactinemia, and male factor infertility. 5. Uterine Fibroids. Caution should be exercised when using clomiphene citrate tablets USP in patients with uterine fibroids due to the potential for further enlargement of the fibroids. There are no adequate or well-controlled studies that demonstrate the effectiveness of clomiphene citrate tablets USP in the treatment of male infertility. In addition, testicular tumors and gynecomastia have been reported in males using clomiphene. The cause and effect relationship between reports of testicular tumors and the administration of clomiphene citrate tablets USP is not known. Although the medical literature suggests various methods, there is no universally accepted standard regimen for combined therapy (ie, clomiphene citrate tablets USP in conjunction with other ovulation-inducing drugs). Similarly, there is no standard clomiphene citrate tablets USP regimen for ovulation induction in in vitro fertilization programs to produce ova for fertilization and reintroduction. Therefore, clomiphene citrate tablets USP is not recommended for these uses. uuid:c5cf21d8-3cda-47a6-810d-e4ba84477de4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0006956 PMID:41385096 "[{""id"":""uuid:c4951a3d-d894-4946-8858-081f3d07cf15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:db45054b-835d-4263-a79e-d1997982c3de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ACTICLATE ® and ACTICLATE ® CAP are tetracycline class drugs indicated for: Rickettsial infections ( 1.1 ) Sexually transmitted infections ( 1.2 ) Respiratory tract infections ( 1.3 ) Specific bacterial infections ( 1.4 ) Ophthalmic infections ( 1.5 ) Anthrax, including inhalational anthrax (post-exposure) ( 1.6 ) Alternative treatment for selected infections when penicillin is contraindicated ( 1.7 ) Adjunctive therapy for acute intestinal amebiasis and severe acne ( 1.8 ) Prophylaxis of malaria ( 1.9 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of ACTICLATE and ACTICLATE CAP and other antibacterial drugs, ACTICLATE and ACTICLATE CAP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.10 ) uuid:f3aca5d8-59c9-41e1-89ae-62a14a195aec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0021681 PMID:41385096 "[{""id"":""uuid:25e4e205-a852-4d05-8e22-61186baac88a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:63c10628-8f37-4dc4-9e90-54cbbfb3a2e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ACTICLATE ® and ACTICLATE ® CAP are tetracycline class drugs indicated for: Rickettsial infections ( 1.1 ) Sexually transmitted infections ( 1.2 ) Respiratory tract infections ( 1.3 ) Specific bacterial infections ( 1.4 ) Ophthalmic infections ( 1.5 ) Anthrax, including inhalational anthrax (post-exposure) ( 1.6 ) Alternative treatment for selected infections when penicillin is contraindicated ( 1.7 ) Adjunctive therapy for acute intestinal amebiasis and severe acne ( 1.8 ) Prophylaxis of malaria ( 1.9 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of ACTICLATE and ACTICLATE CAP and other antibacterial drugs, ACTICLATE and ACTICLATE CAP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.10 ) uuid:5a968f67-2cca-4cc5-9779-004fed3556dd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0043885 PMID:41385096 "[{""id"":""uuid:6e6cc2c6-1bd9-4a9f-985d-92ed5a635652"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0379e781-9989-49f9-a91b-59afc6548d62"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ACTICLATE ® and ACTICLATE ® CAP are tetracycline class drugs indicated for: Rickettsial infections ( 1.1 ) Sexually transmitted infections ( 1.2 ) Respiratory tract infections ( 1.3 ) Specific bacterial infections ( 1.4 ) Ophthalmic infections ( 1.5 ) Anthrax, including inhalational anthrax (post-exposure) ( 1.6 ) Alternative treatment for selected infections when penicillin is contraindicated ( 1.7 ) Adjunctive therapy for acute intestinal amebiasis and severe acne ( 1.8 ) Prophylaxis of malaria ( 1.9 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of ACTICLATE and ACTICLATE CAP and other antibacterial drugs, ACTICLATE and ACTICLATE CAP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.10 ) uuid:c3372831-e8e1-4e46-a9bf-cf219ccd071a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63611 biolink:treats UMLS:C3840140 PMID:41385096 "[{""id"":""uuid:62f4ce3b-233b-4918-9b85-6ef8ae79a90c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ab519930-acc5-47a9-8c68-fd9a8a62a146"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Moxifloxacin ophthalmic solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species* Micrococcus luteus* Staphylococcus aureus Staphylococcus epidermidis Staphylococcus haemolyticus Staphylococcus hominis Staphylococcus warneri* Streptococcus pneumoniae Streptococcus viridans group Acinetobacter lwoffii* Haemophilus influenza Haemophilus parainfluenzae* Chlamydia trachomatis *Efficacy for this organism was studied in fewer than 10 infections. uuid:01b49892-a1c8-4a08-a7d3-e21e43e267d4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63611 biolink:treats MONDO:0005545 PMID:41385096 "[{""id"":""uuid:905b052f-3e74-4912-b056-4a66cdf7c7ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1081fa38-eee5-44bf-af09-545ade4d63d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Moxifloxacin ophthalmic solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species* Micrococcus luteus* Staphylococcus aureus Staphylococcus epidermidis Staphylococcus haemolyticus Staphylococcus hominis Staphylococcus warneri* Streptococcus pneumoniae Streptococcus viridans group Acinetobacter lwoffii* Haemophilus influenza Haemophilus parainfluenzae* Chlamydia trachomatis *Efficacy for this organism was studied in fewer than 10 infections. uuid:ec22cae6-86d4-4881-bfe1-0d5c9c7d4af5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63611 biolink:treats UMLS:C5924387 PMID:41385096 "[{""id"":""uuid:fe0bba45-188e-4006-a784-90e2b8b9c4ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5ae7fba8-feb8-48cd-83a3-d8caadd69527"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Moxifloxacin ophthalmic solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species* Micrococcus luteus* Staphylococcus aureus Staphylococcus epidermidis Staphylococcus haemolyticus Staphylococcus hominis Staphylococcus warneri* Streptococcus pneumoniae Streptococcus viridans group Acinetobacter lwoffii* Haemophilus influenza Haemophilus parainfluenzae* Chlamydia trachomatis *Efficacy for this organism was studied in fewer than 10 infections. uuid:d2eb914d-acd6-4dc1-93e6-698e29a3c3bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63611 biolink:treats MONDO:0005114 PMID:41385096 "[{""id"":""uuid:5220aed6-3981-4b5c-b383-d76de19606bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:90efdb09-8038-4959-8ec2-28849b4ff773"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Moxifloxacin ophthalmic solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species* Micrococcus luteus* Staphylococcus aureus Staphylococcus epidermidis Staphylococcus haemolyticus Staphylococcus hominis Staphylococcus warneri* Streptococcus pneumoniae Streptococcus viridans group Acinetobacter lwoffii* Haemophilus influenza Haemophilus parainfluenzae* Chlamydia trachomatis *Efficacy for this organism was studied in fewer than 10 infections. uuid:72f3e1af-4a2a-4746-8d37-c10567e5180c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63611 biolink:treats UMLS:C1096266 PMID:41385096 "[{""id"":""uuid:5ef0d6a1-0a15-4a13-9734-9f4a488be309"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:048dd4de-b505-4ab4-b3c2-ea2a12afbe9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Moxifloxacin ophthalmic solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species* Micrococcus luteus* Staphylococcus aureus Staphylococcus epidermidis Staphylococcus haemolyticus Staphylococcus hominis Staphylococcus warneri* Streptococcus pneumoniae Streptococcus viridans group Acinetobacter lwoffii* Haemophilus influenza Haemophilus parainfluenzae* Chlamydia trachomatis *Efficacy for this organism was studied in fewer than 10 infections. uuid:a5b362f2-39a9-4104-8f23-11fc79379899 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63611 biolink:treats UMLS:C0348321 PMID:41385096 "[{""id"":""uuid:bcef5bb7-ba56-4a3c-919a-f7514beb468c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b60aff4f-ad4f-4585-bdbf-e1f62fe2dd93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Moxifloxacin ophthalmic solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species* Micrococcus luteus* Staphylococcus aureus Staphylococcus epidermidis Staphylococcus haemolyticus Staphylococcus hominis Staphylococcus warneri* Streptococcus pneumoniae Streptococcus viridans group Acinetobacter lwoffii* Haemophilus influenza Haemophilus parainfluenzae* Chlamydia trachomatis *Efficacy for this organism was studied in fewer than 10 infections. uuid:404ca4f5-3cb4-4dd6-b752-d4d602c7181a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63611 biolink:treats MONDO:0005701 PMID:41385096 "[{""id"":""uuid:ef6ff6b4-ea1d-4b27-aeb2-55ed1fd9f144"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:26b8e4cc-8133-4466-a936-9b31ca8addb8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Moxifloxacin ophthalmic solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species* Micrococcus luteus* Staphylococcus aureus Staphylococcus epidermidis Staphylococcus haemolyticus Staphylococcus hominis Staphylococcus warneri* Streptococcus pneumoniae Streptococcus viridans group Acinetobacter lwoffii* Haemophilus influenza Haemophilus parainfluenzae* Chlamydia trachomatis *Efficacy for this organism was studied in fewer than 10 infections. uuid:a4dc604d-74ea-4da3-95a3-b0fcaa0e9182 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1811627 biolink:treats HP:0002140 PMID:41385096 "[{""id"":""uuid:0be3d834-887a-4b96-a463-561cacc19d09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4f9ec8b7-8636-470d-b705-9244a7803bd6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] YOSPRALA, a combination of aspirin and omeprazole, is indicated for patients who require aspirin for secondary prevention of cardiovascular and cerebrovascular events and who are at risk of developing aspirin associated gastric ulcers. The aspirin component of YOSPRALA is indicated for: reducing the combined risk of death and nonfatal stroke in patients who have had ischemic stroke or transient ischemia of the brain due to fibrin platelet emboli, reducing the combined risk of death and nonfatal MI in patients with a previous MI or unstable angina pectoris, reducing the combined risk of MI and sudden death in patients with chronic stable angina pectoris, use in patients who have undergone revascularization procedures (Coronary Artery Bypass Graft [CABG] or Percutaneous Transluminal Coronary Angioplasty [PTCA]) when there is a pre-existing condition for which aspirin is already indicated. The omeprazole component of YOSPRALA is indicated for decreasing the risk of developing aspirin-associated gastric ulcers in patients at risk for developing aspirin-associated gastric ulcers due to age (≥ 55) or documented history of gastric ulcers. Limitations of Use : YOSPRALA contains a delayed-release formulation of aspirin and it is not for use as the initial dose of aspirin therapy during onset of acute coronary syndrome, acute myocardial infarction or before percutaneous coronary intervention (PCI), for which immediate-release aspirin therapy is appropriate. YOSPRALA has not been shown to reduce the risk of gastrointestinal bleeding due to aspirin. Do not substitute YOSPRALA with the single-ingredient products of aspirin and omeprazole. uuid:17168571-b195-4ffc-a21b-7344efa18fa0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1811627 biolink:treats MONDO:0005299 PMID:41385096 "[{""id"":""uuid:e2cb7cbf-9036-41f4-b38c-30f2ef97562e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e5876764-8bcf-43a2-aff1-7fa32d2828a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] YOSPRALA, a combination of aspirin and omeprazole, is indicated for patients who require aspirin for secondary prevention of cardiovascular and cerebrovascular events and who are at risk of developing aspirin associated gastric ulcers. The aspirin component of YOSPRALA is indicated for: reducing the combined risk of death and nonfatal stroke in patients who have had ischemic stroke or transient ischemia of the brain due to fibrin platelet emboli, reducing the combined risk of death and nonfatal MI in patients with a previous MI or unstable angina pectoris, reducing the combined risk of MI and sudden death in patients with chronic stable angina pectoris, use in patients who have undergone revascularization procedures (Coronary Artery Bypass Graft [CABG] or Percutaneous Transluminal Coronary Angioplasty [PTCA]) when there is a pre-existing condition for which aspirin is already indicated. The omeprazole component of YOSPRALA is indicated for decreasing the risk of developing aspirin-associated gastric ulcers in patients at risk for developing aspirin-associated gastric ulcers due to age (≥ 55) or documented history of gastric ulcers. Limitations of Use : YOSPRALA contains a delayed-release formulation of aspirin and it is not for use as the initial dose of aspirin therapy during onset of acute coronary syndrome, acute myocardial infarction or before percutaneous coronary intervention (PCI), for which immediate-release aspirin therapy is appropriate. YOSPRALA has not been shown to reduce the risk of gastrointestinal bleeding due to aspirin. Do not substitute YOSPRALA with the single-ingredient products of aspirin and omeprazole. uuid:6a33d454-143c-43e2-b2ed-c4fb729918dc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1811627 biolink:treats MONDO:0006805 PMID:41385096 "[{""id"":""uuid:afc5ca2c-2155-403b-9429-21363a035239"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ac48703f-7e81-434d-99e3-6d0967834f00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] YOSPRALA, a combination of aspirin and omeprazole, is indicated for patients who require aspirin for secondary prevention of cardiovascular and cerebrovascular events and who are at risk of developing aspirin associated gastric ulcers. The aspirin component of YOSPRALA is indicated for: reducing the combined risk of death and nonfatal stroke in patients who have had ischemic stroke or transient ischemia of the brain due to fibrin platelet emboli, reducing the combined risk of death and nonfatal MI in patients with a previous MI or unstable angina pectoris, reducing the combined risk of MI and sudden death in patients with chronic stable angina pectoris, use in patients who have undergone revascularization procedures (Coronary Artery Bypass Graft [CABG] or Percutaneous Transluminal Coronary Angioplasty [PTCA]) when there is a pre-existing condition for which aspirin is already indicated. The omeprazole component of YOSPRALA is indicated for decreasing the risk of developing aspirin-associated gastric ulcers in patients at risk for developing aspirin-associated gastric ulcers due to age (≥ 55) or documented history of gastric ulcers. Limitations of Use : YOSPRALA contains a delayed-release formulation of aspirin and it is not for use as the initial dose of aspirin therapy during onset of acute coronary syndrome, acute myocardial infarction or before percutaneous coronary intervention (PCI), for which immediate-release aspirin therapy is appropriate. YOSPRALA has not been shown to reduce the risk of gastrointestinal bleeding due to aspirin. Do not substitute YOSPRALA with the single-ingredient products of aspirin and omeprazole. uuid:50987725-6566-4161-ac66-d216fd618128 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1811627 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:af77e5da-45ae-4fe1-9b3b-e1462753e94b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d9652d96-99df-45c8-b99e-c26c8f059fe9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] YOSPRALA, a combination of aspirin and omeprazole, is indicated for patients who require aspirin for secondary prevention of cardiovascular and cerebrovascular events and who are at risk of developing aspirin associated gastric ulcers. The aspirin component of YOSPRALA is indicated for: reducing the combined risk of death and nonfatal stroke in patients who have had ischemic stroke or transient ischemia of the brain due to fibrin platelet emboli, reducing the combined risk of death and nonfatal MI in patients with a previous MI or unstable angina pectoris, reducing the combined risk of MI and sudden death in patients with chronic stable angina pectoris, use in patients who have undergone revascularization procedures (Coronary Artery Bypass Graft [CABG] or Percutaneous Transluminal Coronary Angioplasty [PTCA]) when there is a pre-existing condition for which aspirin is already indicated. The omeprazole component of YOSPRALA is indicated for decreasing the risk of developing aspirin-associated gastric ulcers in patients at risk for developing aspirin-associated gastric ulcers due to age (≥ 55) or documented history of gastric ulcers. Limitations of Use : YOSPRALA contains a delayed-release formulation of aspirin and it is not for use as the initial dose of aspirin therapy during onset of acute coronary syndrome, acute myocardial infarction or before percutaneous coronary intervention (PCI), for which immediate-release aspirin therapy is appropriate. YOSPRALA has not been shown to reduce the risk of gastrointestinal bleeding due to aspirin. Do not substitute YOSPRALA with the single-ingredient products of aspirin and omeprazole. uuid:e3f25979-2776-4d90-9ab5-10b2363a469b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1811627 biolink:treats UMLS:C0341178 PMID:41385096 "[{""id"":""uuid:09af5068-7319-4f36-8fa3-b888f7dab130"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:75ed0753-75df-49e8-921a-81908b6fd01c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] YOSPRALA, a combination of aspirin and omeprazole, is indicated for patients who require aspirin for secondary prevention of cardiovascular and cerebrovascular events and who are at risk of developing aspirin associated gastric ulcers. The aspirin component of YOSPRALA is indicated for: reducing the combined risk of death and nonfatal stroke in patients who have had ischemic stroke or transient ischemia of the brain due to fibrin platelet emboli, reducing the combined risk of death and nonfatal MI in patients with a previous MI or unstable angina pectoris, reducing the combined risk of MI and sudden death in patients with chronic stable angina pectoris, use in patients who have undergone revascularization procedures (Coronary Artery Bypass Graft [CABG] or Percutaneous Transluminal Coronary Angioplasty [PTCA]) when there is a pre-existing condition for which aspirin is already indicated. The omeprazole component of YOSPRALA is indicated for decreasing the risk of developing aspirin-associated gastric ulcers in patients at risk for developing aspirin-associated gastric ulcers due to age (≥ 55) or documented history of gastric ulcers. Limitations of Use : YOSPRALA contains a delayed-release formulation of aspirin and it is not for use as the initial dose of aspirin therapy during onset of acute coronary syndrome, acute myocardial infarction or before percutaneous coronary intervention (PCI), for which immediate-release aspirin therapy is appropriate. YOSPRALA has not been shown to reduce the risk of gastrointestinal bleeding due to aspirin. Do not substitute YOSPRALA with the single-ingredient products of aspirin and omeprazole. uuid:baf998f8-8a38-45e9-bc34-a53da5b7d797 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1811627 biolink:treats MONDO:0005542 PMID:41385096 "[{""id"":""uuid:74768792-56e1-419c-9362-a35ed52ee83f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:be200f8f-80ef-4605-a634-2929da71fffe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] YOSPRALA, a combination of aspirin and omeprazole, is indicated for patients who require aspirin for secondary prevention of cardiovascular and cerebrovascular events and who are at risk of developing aspirin associated gastric ulcers. The aspirin component of YOSPRALA is indicated for: reducing the combined risk of death and nonfatal stroke in patients who have had ischemic stroke or transient ischemia of the brain due to fibrin platelet emboli, reducing the combined risk of death and nonfatal MI in patients with a previous MI or unstable angina pectoris, reducing the combined risk of MI and sudden death in patients with chronic stable angina pectoris, use in patients who have undergone revascularization procedures (Coronary Artery Bypass Graft [CABG] or Percutaneous Transluminal Coronary Angioplasty [PTCA]) when there is a pre-existing condition for which aspirin is already indicated. The omeprazole component of YOSPRALA is indicated for decreasing the risk of developing aspirin-associated gastric ulcers in patients at risk for developing aspirin-associated gastric ulcers due to age (≥ 55) or documented history of gastric ulcers. Limitations of Use : YOSPRALA contains a delayed-release formulation of aspirin and it is not for use as the initial dose of aspirin therapy during onset of acute coronary syndrome, acute myocardial infarction or before percutaneous coronary intervention (PCI), for which immediate-release aspirin therapy is appropriate. YOSPRALA has not been shown to reduce the risk of gastrointestinal bleeding due to aspirin. Do not substitute YOSPRALA with the single-ingredient products of aspirin and omeprazole. uuid:5dabac8b-4a57-4e80-be03-891f0f2e6ac3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1811627 biolink:treats MONDO:0004781 PMID:41385096 "[{""id"":""uuid:04be92b5-0747-42fb-85c4-0e2ef540f137"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5a66f8f1-a116-4456-ba3f-3cb4827b7224"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] YOSPRALA, a combination of aspirin and omeprazole, is indicated for patients who require aspirin for secondary prevention of cardiovascular and cerebrovascular events and who are at risk of developing aspirin associated gastric ulcers. The aspirin component of YOSPRALA is indicated for: reducing the combined risk of death and nonfatal stroke in patients who have had ischemic stroke or transient ischemia of the brain due to fibrin platelet emboli, reducing the combined risk of death and nonfatal MI in patients with a previous MI or unstable angina pectoris, reducing the combined risk of MI and sudden death in patients with chronic stable angina pectoris, use in patients who have undergone revascularization procedures (Coronary Artery Bypass Graft [CABG] or Percutaneous Transluminal Coronary Angioplasty [PTCA]) when there is a pre-existing condition for which aspirin is already indicated. The omeprazole component of YOSPRALA is indicated for decreasing the risk of developing aspirin-associated gastric ulcers in patients at risk for developing aspirin-associated gastric ulcers due to age (≥ 55) or documented history of gastric ulcers. Limitations of Use : YOSPRALA contains a delayed-release formulation of aspirin and it is not for use as the initial dose of aspirin therapy during onset of acute coronary syndrome, acute myocardial infarction or before percutaneous coronary intervention (PCI), for which immediate-release aspirin therapy is appropriate. YOSPRALA has not been shown to reduce the risk of gastrointestinal bleeding due to aspirin. Do not substitute YOSPRALA with the single-ingredient products of aspirin and omeprazole. uuid:7c797513-3439-4ae0-b2e4-6b2538dd44b6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:LYO9XZ250J biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:ed5cdd77-eddc-4658-b465-f38d13603515"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a6bbf736-6e35-412f-9f1d-af9725448381"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZEMDRI is an aminoglycoside antibacterial indicated for the treatment of patients 18 years of age or older with Complicated Urinary Tract Infections (cUTI) including Pyelonephritis. ( 1.1 ) As only limited clinical safety and efficacy data are available, reserve ZEMDRI for use in patients who have limited or no alternative treatment options. ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain effectiveness of ZEMDRI and other antibacterial drugs, ZEMDRI should be used only to treat infections that are proven or strongly suspected to be caused by susceptible microorganisms. ( 1.2 ) uuid:9d6e2e33-b147-4d03-8bf2-a52c8e85ccf0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:LYO9XZ250J biolink:treats MONDO:0006939 PMID:41385096 "[{""id"":""uuid:947f5753-31ee-44e4-a8fb-ef850c7c9223"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d83a019f-f25c-494a-93ba-6e3fa639d5d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZEMDRI is an aminoglycoside antibacterial indicated for the treatment of patients 18 years of age or older with Complicated Urinary Tract Infections (cUTI) including Pyelonephritis. ( 1.1 ) As only limited clinical safety and efficacy data are available, reserve ZEMDRI for use in patients who have limited or no alternative treatment options. ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain effectiveness of ZEMDRI and other antibacterial drugs, ZEMDRI should be used only to treat infections that are proven or strongly suspected to be caused by susceptible microorganisms. ( 1.2 ) uuid:b33f07c9-8414-443f-8fda-218ee5683b75 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75722 biolink:treats HP:0030858 PMID:41385096 "[{""id"":""uuid:dd6686c1-192c-4b8f-ba01-8551427e604e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7e573f3b-ba7e-4979-a8b5-8cfcbca945a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tramadol hydrochloride tablets are indicated for the management of pain in adults that is severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses ( see WARNINGS ), reserve tramadol hydrochloride tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics]: • Have not been tolerated, or are not expected to be tolerated. • Have not provided adequate analgesia, or are not expected to provide adequate analgesia. uuid:126d54e5-70ab-4d65-a786-2844b344fddf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75722 biolink:treats MONDO:0002491 PMID:41385096 "[{""id"":""uuid:fa392e03-03bb-46c6-aa1b-3dc0f52cb31c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dcf0aaf3-f0d9-4397-96b0-261c9cecd138"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tramadol hydrochloride tablets are indicated for the management of pain in adults that is severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses ( see WARNINGS ), reserve tramadol hydrochloride tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics]: • Have not been tolerated, or are not expected to be tolerated. • Have not provided adequate analgesia, or are not expected to provide adequate analgesia. uuid:1c90c227-cea9-4a7b-9ad9-6dccf9dc633b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75722 biolink:treats EFO:0011049 PMID:41385096 "[{""id"":""uuid:9748f6dd-3a95-4afb-8fe4-2fad60be154a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3ae31ae8-6e40-47c8-a289-4743f245cb9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tramadol hydrochloride tablets are indicated for the management of pain in adults that is severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses ( see WARNINGS ), reserve tramadol hydrochloride tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics]: • Have not been tolerated, or are not expected to be tolerated. • Have not provided adequate analgesia, or are not expected to provide adequate analgesia. uuid:1aaf8b00-edd7-49d3-af4c-29a9042ca1ae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5801 biolink:treats MONDO:0005920 PMID:41385096 "[{""id"":""uuid:c81ceea1-c5ce-4610-b61d-13459a51ed98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:595a46ae-e7be-4c5d-bff6-3b1012fff037"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydroxychloroquine sulfate tablets, USP are indicated for the treatment of uncomplicated malaria due to P. falciparum , P. malariae , P. ovale , and P. vivax . Hydroxychloroquine sulfate tablets, USP are indicated for the prophylaxis of malaria in geographic areas where chloroquine resistance is not reported. Limitations of Use in Malaria Hydroxychloroquine sulfate tablets, USP are not recommended for the treatment of complicated malaria. Hydroxychloroquine sulfate tablets, USP are not effective against chloroquine or hydroxychloroquine-resistant strains of Plasmodium species (see CLINICAL PHARMACOLOGY – Microbiology ) . Hydroxychloroquine sulfate tablets, USP are not recommended for the treatment of malaria acquired in geographic areas where chloroquine resistance occurs or when the Plasmodium species has not been identified. Hydroxychloroquine sulfate tablets, USP are not recommended for malaria prophylaxis in geographic areas where chloroquine resistance occurs. Hydroxychloroquine sulfate tablets, USP do not prevent relapses of P. vivax or P. ovale because it is not active against the hypnozoite forms of these parasites. For radical cure of P. vivax and P. ovale infections, concomitant therapy with an 8-aminoquinoline compound is necessary (see CLINICAL PHARMACOLOGY – Microbiology ). Prior to prescribing hydroxychloroquine sulfate tablets, USP for the treatment or prophylaxis of malaria, consult the Centers for Disease Control and Prevention (CDC) Malaria website (http://www.cdc.gov/malaria). uuid:08bf0964-390f-4de8-8bc1-86eed59dc405 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5801 biolink:treats MONDO:0001943 PMID:41385096 "[{""id"":""uuid:464d3878-3dc3-409a-9d24-5c7891ce6861"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0e7641ed-903c-4f4c-84bf-a18e65a1922d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydroxychloroquine sulfate tablets, USP are indicated for the treatment of uncomplicated malaria due to P. falciparum , P. malariae , P. ovale , and P. vivax . Hydroxychloroquine sulfate tablets, USP are indicated for the prophylaxis of malaria in geographic areas where chloroquine resistance is not reported. Limitations of Use in Malaria Hydroxychloroquine sulfate tablets, USP are not recommended for the treatment of complicated malaria. Hydroxychloroquine sulfate tablets, USP are not effective against chloroquine or hydroxychloroquine-resistant strains of Plasmodium species (see CLINICAL PHARMACOLOGY – Microbiology ) . Hydroxychloroquine sulfate tablets, USP are not recommended for the treatment of malaria acquired in geographic areas where chloroquine resistance occurs or when the Plasmodium species has not been identified. Hydroxychloroquine sulfate tablets, USP are not recommended for malaria prophylaxis in geographic areas where chloroquine resistance occurs. Hydroxychloroquine sulfate tablets, USP do not prevent relapses of P. vivax or P. ovale because it is not active against the hypnozoite forms of these parasites. For radical cure of P. vivax and P. ovale infections, concomitant therapy with an 8-aminoquinoline compound is necessary (see CLINICAL PHARMACOLOGY – Microbiology ). Prior to prescribing hydroxychloroquine sulfate tablets, USP for the treatment or prophylaxis of malaria, consult the Centers for Disease Control and Prevention (CDC) Malaria website (http://www.cdc.gov/malaria). uuid:d6223c87-cc13-4b85-bd9d-582d9986eac9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5801 biolink:treats MONDO:0001601 PMID:41385096 "[{""id"":""uuid:622fb43d-64fa-4fcf-9c19-5a6b106b65ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2dd54570-a465-48c3-bbf7-e959b31318c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydroxychloroquine sulfate tablets, USP are indicated for the treatment of uncomplicated malaria due to P. falciparum , P. malariae , P. ovale , and P. vivax . Hydroxychloroquine sulfate tablets, USP are indicated for the prophylaxis of malaria in geographic areas where chloroquine resistance is not reported. Limitations of Use in Malaria Hydroxychloroquine sulfate tablets, USP are not recommended for the treatment of complicated malaria. Hydroxychloroquine sulfate tablets, USP are not effective against chloroquine or hydroxychloroquine-resistant strains of Plasmodium species (see CLINICAL PHARMACOLOGY – Microbiology ) . Hydroxychloroquine sulfate tablets, USP are not recommended for the treatment of malaria acquired in geographic areas where chloroquine resistance occurs or when the Plasmodium species has not been identified. Hydroxychloroquine sulfate tablets, USP are not recommended for malaria prophylaxis in geographic areas where chloroquine resistance occurs. Hydroxychloroquine sulfate tablets, USP do not prevent relapses of P. vivax or P. ovale because it is not active against the hypnozoite forms of these parasites. For radical cure of P. vivax and P. ovale infections, concomitant therapy with an 8-aminoquinoline compound is necessary (see CLINICAL PHARMACOLOGY – Microbiology ). Prior to prescribing hydroxychloroquine sulfate tablets, USP for the treatment or prophylaxis of malaria, consult the Centers for Disease Control and Prevention (CDC) Malaria website (http://www.cdc.gov/malaria). uuid:33283d9e-5063-4b6e-8d0c-8890b612c4fc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5801 biolink:treats MONDO:0005921 PMID:41385096 "[{""id"":""uuid:2482bdd4-64ed-4ab9-9d06-47d13c5053de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4db11a99-db90-448c-a2d8-2cbeff9bdf86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydroxychloroquine sulfate tablets, USP are indicated for the treatment of uncomplicated malaria due to P. falciparum , P. malariae , P. ovale , and P. vivax . Hydroxychloroquine sulfate tablets, USP are indicated for the prophylaxis of malaria in geographic areas where chloroquine resistance is not reported. Limitations of Use in Malaria Hydroxychloroquine sulfate tablets, USP are not recommended for the treatment of complicated malaria. Hydroxychloroquine sulfate tablets, USP are not effective against chloroquine or hydroxychloroquine-resistant strains of Plasmodium species (see CLINICAL PHARMACOLOGY – Microbiology ) . Hydroxychloroquine sulfate tablets, USP are not recommended for the treatment of malaria acquired in geographic areas where chloroquine resistance occurs or when the Plasmodium species has not been identified. Hydroxychloroquine sulfate tablets, USP are not recommended for malaria prophylaxis in geographic areas where chloroquine resistance occurs. Hydroxychloroquine sulfate tablets, USP do not prevent relapses of P. vivax or P. ovale because it is not active against the hypnozoite forms of these parasites. For radical cure of P. vivax and P. ovale infections, concomitant therapy with an 8-aminoquinoline compound is necessary (see CLINICAL PHARMACOLOGY – Microbiology ). Prior to prescribing hydroxychloroquine sulfate tablets, USP for the treatment or prophylaxis of malaria, consult the Centers for Disease Control and Prevention (CDC) Malaria website (http://www.cdc.gov/malaria). uuid:801790b3-4aef-4b5f-adbe-d1157227f457 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5801 biolink:treats UMLS:C2747816 PMID:41385096 "[{""id"":""uuid:1ab472d7-43cd-4bab-91c2-6ef83586a034"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3f00bc1b-ed9e-4e0a-8d69-12a103c179f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydroxychloroquine sulfate tablets, USP are indicated for the treatment of uncomplicated malaria due to P. falciparum , P. malariae , P. ovale , and P. vivax . Hydroxychloroquine sulfate tablets, USP are indicated for the prophylaxis of malaria in geographic areas where chloroquine resistance is not reported. Limitations of Use in Malaria Hydroxychloroquine sulfate tablets, USP are not recommended for the treatment of complicated malaria. Hydroxychloroquine sulfate tablets, USP are not effective against chloroquine or hydroxychloroquine-resistant strains of Plasmodium species (see CLINICAL PHARMACOLOGY – Microbiology ) . Hydroxychloroquine sulfate tablets, USP are not recommended for the treatment of malaria acquired in geographic areas where chloroquine resistance occurs or when the Plasmodium species has not been identified. Hydroxychloroquine sulfate tablets, USP are not recommended for malaria prophylaxis in geographic areas where chloroquine resistance occurs. Hydroxychloroquine sulfate tablets, USP do not prevent relapses of P. vivax or P. ovale because it is not active against the hypnozoite forms of these parasites. For radical cure of P. vivax and P. ovale infections, concomitant therapy with an 8-aminoquinoline compound is necessary (see CLINICAL PHARMACOLOGY – Microbiology ). Prior to prescribing hydroxychloroquine sulfate tablets, USP for the treatment or prophylaxis of malaria, consult the Centers for Disease Control and Prevention (CDC) Malaria website (http://www.cdc.gov/malaria). uuid:61e1e18e-721c-4fc2-af5f-b1b3fd287a6c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5118 biolink:treats UMLS:C2063866 PMID:41385096 "[{""id"":""uuid:a2a21956-ea9c-420a-b2ec-605d170228f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f7658d67-8fec-4655-94c8-c58da024cd5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluoxetine capsules are indicated for the treatment of: Acute and maintenance treatment of Major Depressive Disorder [see Clinical Studies (14.1) ] . Acute and maintenance treatment of obsessions and compulsions in patients with Obsessive Compulsive Disorder (OCD) [see Clinical Studies (14.2) ] . Acute and maintenance treatment of binge-eating and vomiting behaviors in patients with moderate to severe Bulimia Nervosa [see Clinical Studies (14.3) ] . Acute treatment of Panic Disorder, with or without agoraphobia [see Clinical Studies (14.4) ] . Fluoxetine capsules and Olanzapine in Combination are indicated for the treatment of: Acute treatment of depressive episodes associated with Bipolar I Disorder. Treatment resistant depression (Major Depressive Disorder in patients, who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode). Fluoxetine capsules monotherapy is not indicated for the treatment of depressive episodes associated with Bipolar I Disorder or the treatment of treatment resistant depression. When using fluoxetine capsules and olanzapine in combination, also refer to the Clinical Studies section of the package insert for Symbyax ® . uuid:0d495920-0b5c-41f8-967b-b236936053cc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7476 biolink:treats MONDO:0018456 PMID:41385096 "[{""id"":""uuid:9dd5ee1d-f58b-4a68-af0d-aa009f915e6d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5ce262c5-e53f-41e9-8867-78f2b6fd5315"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Naproxen sodium tablets are indicated for: the relief of the signs and symptoms of: rheumatoid arthritis osteoarthritis ankylosing spondylitis Polyarticular Juvenile Idiopathic Arthritis Naproxen sodium tablets are also indicated for: the relief of signs and symptoms of: tendonitis bursitis acute gout the management of: pain primary dysmenorrhea uuid:48ccc2a0-4ae9-4752-8233-0ba7857a0f72 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:141474 biolink:treats MONDO:0003471 PMID:41385096 "[{""id"":""uuid:63f39208-14ca-435f-9fe7-7953f39ee65f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f5102e8d-8255-4323-838f-19c82cd149c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OVIDE Lotion is indicated for patients infected with Pediculus humanus capitis (head lice and their ova) of the scalp hair. uuid:d1b4fc62-b0d3-4179-8673-859f8e5a706c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8356 biolink:treats MONDO:0005391 PMID:41385096 "[{""id"":""uuid:fa7cec1b-079f-4d0f-946d-3027069380e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f7182e17-e7cd-4c81-a27a-a2739d49197c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a1bfda71-5e8b-44b5-a360-b667a0fe7f81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:024cd423-2a80-43d1-9a72-16b6d736bb8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] PRAMIPEXOLE DIHYDROCHLORIDE tablets are a non-ergot dopamine agonist indicated for the treatment of: Parkinson’s disease (PD) ( 1.1 ) Moderate-to-severe primary Restless Legs Syndrome (RLS) ( 1.2 )|[EMA] Oprymea is indicated for treatment of the signs and symptoms of idiopathic Parkinson's disease, alone (without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or ""on off"" fluctuations).Oprymea is indicated in adults for symptomatic treatment of moderate to severe idiopathic Restless Legs Syndrome in doses up to 0.54 mg of base (0.75 mg of salt) (see section 4.2).|[PMDA] Drugs with a new additional indication and a new dosage for the treatment of moderate to severe idiopathic restless legs syndrome." uuid:0a5fa56d-2abf-41a2-ab86-1d09880e0dd1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9241 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:1522fd11-b7e6-44a0-a7e8-90e96636e55f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8c93587a-b1e4-4442-86b3-2c8eb9f4c268"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone tablets are an aldosterone antagonist indicated for: The treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure ( 1.1 ). Use as an add-on therapy for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.2 ). The management of edema in adult patients who are cirrhotic when edema is not responsive to fluid and sodium restrictions and in the setting of nephrotic syndrome when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics produce an inadequate response ( 1.3 ). Treatment of primary hyperaldosternism for: ( 1.4 ) Short-term preoperative treatment Long-term maintenance for patients with discrete aldosterone-producing adrenal adenomas who are not candidates for surgery and patients with bilateral micro or macronodular adrenal hyperplasia uuid:6803ebf8-96cc-41dd-9c0b-a362d03402b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9241 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:1d77cc6e-2cdb-4487-854c-be6cfe2ce16a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:642965fc-1079-4efc-9855-b34e3a35a359"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone tablets are an aldosterone antagonist indicated for: The treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure ( 1.1 ). Use as an add-on therapy for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.2 ). The management of edema in adult patients who are cirrhotic when edema is not responsive to fluid and sodium restrictions and in the setting of nephrotic syndrome when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics produce an inadequate response ( 1.3 ). Treatment of primary hyperaldosternism for: ( 1.4 ) Short-term preoperative treatment Long-term maintenance for patients with discrete aldosterone-producing adrenal adenomas who are not candidates for surgery and patients with bilateral micro or macronodular adrenal hyperplasia uuid:f8c76309-c61e-490f-b992-3c406cbce934 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16586 biolink:treats HP:0004859 PMID:41385096 "[{""id"":""uuid:31fa0100-d719-401e-84d5-3d7f15df7f7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f75503fc-ed2f-43ce-b142-d7210fcb8cc2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AMICAR is useful in enhancing hemostasis when fibrinolysis contributes to bleeding. In life-threatening situations, transfusion of appropriate blood products and other emergency measures may be required. Fibrinolytic bleeding may frequently be associated with surgical complications following heart surgery (with or without cardiac bypass procedures) and portacaval shunt; hematological disorders such as amegakaryocytic thrombocytopenia (accompanying aplastic anemia); acute and life-threatening abruptio placentae; hepatic cirrhosis; and neoplastic disease such as carcinoma of the prostate, lung, stomach, and cervix. Urinary fibrinolysis, usually a normal physiological phenomenon, may contribute to excessive urinary tract fibrinolytic bleeding associated with surgical hematuria (following prostatectomy and nephrectomy) or nonsurgical hematuria (accompanying polycystic or neoplastic diseases of the genitourinary system). (See WARNINGS .) uuid:de6915e0-9fa8-4d3f-ab43-bef7c26c55d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16586 biolink:treats MONDO:0015909 PMID:41385096 "[{""id"":""uuid:fd0d0a32-64ec-4248-8744-b66f8a793083"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:931893de-4715-4a8d-84ea-df672201c744"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AMICAR is useful in enhancing hemostasis when fibrinolysis contributes to bleeding. In life-threatening situations, transfusion of appropriate blood products and other emergency measures may be required. Fibrinolytic bleeding may frequently be associated with surgical complications following heart surgery (with or without cardiac bypass procedures) and portacaval shunt; hematological disorders such as amegakaryocytic thrombocytopenia (accompanying aplastic anemia); acute and life-threatening abruptio placentae; hepatic cirrhosis; and neoplastic disease such as carcinoma of the prostate, lung, stomach, and cervix. Urinary fibrinolysis, usually a normal physiological phenomenon, may contribute to excessive urinary tract fibrinolytic bleeding associated with surgical hematuria (following prostatectomy and nephrectomy) or nonsurgical hematuria (accompanying polycystic or neoplastic diseases of the genitourinary system). (See WARNINGS .) uuid:78541d07-b5e4-4052-a89a-42c223a99962 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16586 biolink:treats MONDO:0004846 PMID:41385096 "[{""id"":""uuid:5ee00d3f-b585-4251-b974-77bd3acbb2f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:226b529e-b713-4757-8ff9-91f0eaddc9f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AMICAR is useful in enhancing hemostasis when fibrinolysis contributes to bleeding. In life-threatening situations, transfusion of appropriate blood products and other emergency measures may be required. Fibrinolytic bleeding may frequently be associated with surgical complications following heart surgery (with or without cardiac bypass procedures) and portacaval shunt; hematological disorders such as amegakaryocytic thrombocytopenia (accompanying aplastic anemia); acute and life-threatening abruptio placentae; hepatic cirrhosis; and neoplastic disease such as carcinoma of the prostate, lung, stomach, and cervix. Urinary fibrinolysis, usually a normal physiological phenomenon, may contribute to excessive urinary tract fibrinolytic bleeding associated with surgical hematuria (following prostatectomy and nephrectomy) or nonsurgical hematuria (accompanying polycystic or neoplastic diseases of the genitourinary system). (See WARNINGS .) uuid:f7f6ff39-ac90-4504-870b-6d181a157314 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16586 biolink:treats MONDO:0005155 PMID:41385096 "[{""id"":""uuid:5de5bb68-e6e5-4596-a2b0-89ad6ca90536"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c6147a2c-1db9-4b58-8654-7429be9f28c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AMICAR is useful in enhancing hemostasis when fibrinolysis contributes to bleeding. In life-threatening situations, transfusion of appropriate blood products and other emergency measures may be required. Fibrinolytic bleeding may frequently be associated with surgical complications following heart surgery (with or without cardiac bypass procedures) and portacaval shunt; hematological disorders such as amegakaryocytic thrombocytopenia (accompanying aplastic anemia); acute and life-threatening abruptio placentae; hepatic cirrhosis; and neoplastic disease such as carcinoma of the prostate, lung, stomach, and cervix. Urinary fibrinolysis, usually a normal physiological phenomenon, may contribute to excessive urinary tract fibrinolytic bleeding associated with surgical hematuria (following prostatectomy and nephrectomy) or nonsurgical hematuria (accompanying polycystic or neoplastic diseases of the genitourinary system). (See WARNINGS .) uuid:798176ba-7254-48d1-9ab8-c3df4e6fe218 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16586 biolink:treats MONDO:0005159 PMID:41385096 "[{""id"":""uuid:9a398690-a4ca-406d-a5a5-9d4ed4d831fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:165a9b25-f5b4-4227-8fe6-f8ed88472633"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AMICAR is useful in enhancing hemostasis when fibrinolysis contributes to bleeding. In life-threatening situations, transfusion of appropriate blood products and other emergency measures may be required. Fibrinolytic bleeding may frequently be associated with surgical complications following heart surgery (with or without cardiac bypass procedures) and portacaval shunt; hematological disorders such as amegakaryocytic thrombocytopenia (accompanying aplastic anemia); acute and life-threatening abruptio placentae; hepatic cirrhosis; and neoplastic disease such as carcinoma of the prostate, lung, stomach, and cervix. Urinary fibrinolysis, usually a normal physiological phenomenon, may contribute to excessive urinary tract fibrinolytic bleeding associated with surgical hematuria (following prostatectomy and nephrectomy) or nonsurgical hematuria (accompanying polycystic or neoplastic diseases of the genitourinary system). (See WARNINGS .) uuid:4b4278d9-c907-4ef2-beae-ac76859975df biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16586 biolink:treats MONDO:0006279 PMID:41385096 "[{""id"":""uuid:183c11f8-63ae-45e4-98c3-589529e855aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:332188ea-65e1-4cd7-8544-d8ae6c46d90f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AMICAR is useful in enhancing hemostasis when fibrinolysis contributes to bleeding. In life-threatening situations, transfusion of appropriate blood products and other emergency measures may be required. Fibrinolytic bleeding may frequently be associated with surgical complications following heart surgery (with or without cardiac bypass procedures) and portacaval shunt; hematological disorders such as amegakaryocytic thrombocytopenia (accompanying aplastic anemia); acute and life-threatening abruptio placentae; hepatic cirrhosis; and neoplastic disease such as carcinoma of the prostate, lung, stomach, and cervix. Urinary fibrinolysis, usually a normal physiological phenomenon, may contribute to excessive urinary tract fibrinolytic bleeding associated with surgical hematuria (following prostatectomy and nephrectomy) or nonsurgical hematuria (accompanying polycystic or neoplastic diseases of the genitourinary system). (See WARNINGS .) uuid:a118ab8f-ced6-4f23-9506-b658ff23366b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16586 biolink:treats MONDO:0004950 PMID:41385096 "[{""id"":""uuid:e58f9e85-0e24-4c67-a303-1985e86519bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cf115753-52ca-4d03-95f0-e1d4e26f6566"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AMICAR is useful in enhancing hemostasis when fibrinolysis contributes to bleeding. In life-threatening situations, transfusion of appropriate blood products and other emergency measures may be required. Fibrinolytic bleeding may frequently be associated with surgical complications following heart surgery (with or without cardiac bypass procedures) and portacaval shunt; hematological disorders such as amegakaryocytic thrombocytopenia (accompanying aplastic anemia); acute and life-threatening abruptio placentae; hepatic cirrhosis; and neoplastic disease such as carcinoma of the prostate, lung, stomach, and cervix. Urinary fibrinolysis, usually a normal physiological phenomenon, may contribute to excessive urinary tract fibrinolytic bleeding associated with surgical hematuria (following prostatectomy and nephrectomy) or nonsurgical hematuria (accompanying polycystic or neoplastic diseases of the genitourinary system). (See WARNINGS .) uuid:0971f0f3-f0cc-41c0-b5f1-75372c477751 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16586 biolink:treats MONDO:0016276 PMID:41385096 "[{""id"":""uuid:ebddc596-14b7-4932-a53f-faaec9cab99c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b6772de9-f57a-43ab-91a6-4c33d915a0ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AMICAR is useful in enhancing hemostasis when fibrinolysis contributes to bleeding. In life-threatening situations, transfusion of appropriate blood products and other emergency measures may be required. Fibrinolytic bleeding may frequently be associated with surgical complications following heart surgery (with or without cardiac bypass procedures) and portacaval shunt; hematological disorders such as amegakaryocytic thrombocytopenia (accompanying aplastic anemia); acute and life-threatening abruptio placentae; hepatic cirrhosis; and neoplastic disease such as carcinoma of the prostate, lung, stomach, and cervix. Urinary fibrinolysis, usually a normal physiological phenomenon, may contribute to excessive urinary tract fibrinolytic bleeding associated with surgical hematuria (following prostatectomy and nephrectomy) or nonsurgical hematuria (accompanying polycystic or neoplastic diseases of the genitourinary system). (See WARNINGS .) uuid:89d14fda-8594-4a55-a9f0-e0c8ea66a0c7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16586 biolink:treats MONDO:0020642 PMID:41385096 "[{""id"":""uuid:1375a157-e2b3-401e-8ccd-6d4d8dd8d568"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b772d40e-e9d3-4f42-b672-1a9d83da0e4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AMICAR is useful in enhancing hemostasis when fibrinolysis contributes to bleeding. In life-threatening situations, transfusion of appropriate blood products and other emergency measures may be required. Fibrinolytic bleeding may frequently be associated with surgical complications following heart surgery (with or without cardiac bypass procedures) and portacaval shunt; hematological disorders such as amegakaryocytic thrombocytopenia (accompanying aplastic anemia); acute and life-threatening abruptio placentae; hepatic cirrhosis; and neoplastic disease such as carcinoma of the prostate, lung, stomach, and cervix. Urinary fibrinolysis, usually a normal physiological phenomenon, may contribute to excessive urinary tract fibrinolytic bleeding associated with surgical hematuria (following prostatectomy and nephrectomy) or nonsurgical hematuria (accompanying polycystic or neoplastic diseases of the genitourinary system). (See WARNINGS .) uuid:ab3baa59-8bcd-47e2-b2a4-a9a2d7a14a2c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16586 biolink:treats MONDO:0002118 PMID:41385096 "[{""id"":""uuid:b9351b2d-8f63-42f3-9c4d-eb19e9e68f5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8ee12536-30f3-4040-83a7-7fb3e0ca13d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AMICAR is useful in enhancing hemostasis when fibrinolysis contributes to bleeding. In life-threatening situations, transfusion of appropriate blood products and other emergency measures may be required. Fibrinolytic bleeding may frequently be associated with surgical complications following heart surgery (with or without cardiac bypass procedures) and portacaval shunt; hematological disorders such as amegakaryocytic thrombocytopenia (accompanying aplastic anemia); acute and life-threatening abruptio placentae; hepatic cirrhosis; and neoplastic disease such as carcinoma of the prostate, lung, stomach, and cervix. Urinary fibrinolysis, usually a normal physiological phenomenon, may contribute to excessive urinary tract fibrinolytic bleeding associated with surgical hematuria (following prostatectomy and nephrectomy) or nonsurgical hematuria (accompanying polycystic or neoplastic diseases of the genitourinary system). (See WARNINGS .) uuid:3fd4b2e3-b577-4a3f-95e6-c1c5a7c800e4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75722 biolink:treats EFO:0020911 PMID:41385096 "[{""id"":""uuid:8c4a9df1-fd57-404e-849c-6c81340dafe2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:664058cf-9767-41dc-8635-f92ba21593b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tramadol hydrochloride is an opioid agonist indicated for the management of pain severe enough to require daily around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. (1) Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations, reserve tramadol hydrochloride extended-release tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. (1) Tramadol hydrochloride extended-release tablets are not indicated as an as-needed (prn) analgesic. (1) uuid:8af329ec-1208-4462-a83e-550b2e8e2e91 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18420 biolink:treats MONDO:0005081 PMID:41385096 "[{""id"":""uuid:12d229c0-d1f7-435e-922d-49e79e27b8bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:711843b9-32aa-423f-8cf6-eeaa3fb1bcde"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Magnesium Sulfate Injection, USP is suitable for replacement therapy in magnesium deficiency, especially in acute hypomagnesemia accompanied by signs of tetany similar to those observed in hypocalcemia. In such cases, the serum magnesium level is usually below the lower limit of normal (1.5 to 2.5 mEq/L) and the serum calcium level is normal (4.3 to 5.3 mEq/L) or elevated. In total parenteral nutrition (TPN), magnesium sulfate may be added to the nutrient admixture to correct or prevent hypomagnesemia which can arise during the course of therapy. Magnesium sulfate injection is also indicated for the prevention and control of seizures in pre-eclampsia and eclampsia, respectively. uuid:874fa96b-a4c0-4e98-80d4-e5f449e5cb20 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4856 biolink:treats HP:0004755 PMID:41385096 "[{""id"":""uuid:38753286-49c7-404a-abfd-38f61094bc39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:67424094-7b29-476e-8b4a-d456654b3baf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f645ffaa-cfae-4a69-80db-e4fdbfcc41fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Esmolol hydrochloride in sodium chloride injection is a beta adrenergic blocker indicated for the short-term treatment of: • Control of ventricular rate in supraventricular tachycardia including atrial fibrillation and atrial flutter and control of heart rate in noncompensatory sinus tachycardia ( 1.1 ) • Control of perioperative tachycardia and hypertension ( 1.2 )|[PMDA] A drug with a new dosage indicated for the emergency treatment of supraventricular tachyarrhythmia occurring during surgery. uuid:56daf229-1eae-4886-8a49-de1065b401e9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2676 biolink:treats MONDO:0024623 PMID:41385096 "[{""id"":""uuid:514bf7af-fd6d-4cec-8a9c-8e8a9af40d65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:156ebbb4-ba63-4834-98e0-33fcd5cbde5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Infections of the Ear, Nose, and Throat Amoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of Streptococcus species. (α- and β-hemolytic isolates only),Streptococcus pneumoniae, Staphylococcus spp., or Haemophilus influenzae. 1.2 Infections of the Genitourinary Tract Amoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of Escherichia coli, Proteus mirabilis, or Enterococcus faecalis. 1.3 Infections of the Skin and Skin Structure Amoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of Streptococcus spp. (α- and β-hemolytic isolates only), Staphylococcusspp., or E. coli. 1.4 Infections of the Lower Respiratory Tract Amoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of Streptococcus spp. (α- and β-hemolytic isolates only), S. pneumoniae, Staphylococcus spp., or H. influenzae. 1.5 Helicobacter pylori Infection Triple therapy for Helicobacter pylori with clarithromycin and lansoprazole: Amoxicillin capsules in combination with clarithromycin plus lansoprazole as triple therapy, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. Dual therapy for H. pylori with lansoprazole: Amoxicillin capsules, in combination with lansoprazole delayed-release capsules as dual therapy, is indicated for the treatment of patients with H. pyloriinfection and duodenal ulcer disease (active or 1-year history of a duodenal ulcer) who are either allergic or intolerant to clarithromycin or in whom resistance to clarithromycin is known or suspected. (See the clarithromycin package insert, MICROBIOLOGY.) Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. 1.6 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin capsules and other antibacterial drugs, amoxicillin capsules should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:3cbed4fd-390f-415a-9f16-20ab9188f02e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:48390 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:a95c0955-db59-4f57-99d8-e835ee15fc6c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8f9f275a-a06a-43c8-a176-2d4afb7394e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cinacalcet is a calcium-sensing receptor agonist indicated for: Secondary Hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on dialysis. ( 1.1 ) Limitations of Use : Cinacalcet hydrochloride tablets are not indicated for use in patients with CKD who are not on dialysis. Hypercalcemia in adult patients with Parathyroid Carcinoma (PC). ( 1.2 ) Severe hypercalcemia in adult patients with primary HPT who are unable to undergo parathyroidectomy. ( 1.3 ) uuid:863a87a2-781a-42e8-9391-02d81690ffea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3001 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:22ed2aa9-0e7f-4792-8b31-779ce306ffc6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e438b856-892f-4921-b312-437734fa364d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] QVAR ® is indicated in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older. Important Limitations of Use: QVAR is NOT indicated for the relief of acute bronchospasm. uuid:0052b84a-1839-4b89-ba22-045c6abcd7e7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3001 biolink:treats UMLS:C0741804 PMID:41385096 "[{""id"":""uuid:9e03a2e5-6cc7-48a1-9c31-3652730b5b58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2249531f-0815-4b67-95dc-081421ec68e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] QVAR ® is indicated in the maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older. Important Limitations of Use: QVAR is NOT indicated for the relief of acute bronchospasm. uuid:5edc8ef2-2b08-4ba0-8ef0-a987bb2461ff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18332 biolink:treats MONDO:0006107 PMID:41385096 "[{""id"":""uuid:e9a51e3b-8129-44b2-a4d8-c56f0686804b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f5bdb9df-c390-4eee-9bb8-49a91e36fbab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression Levothyroxine sodium tablets are indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. Limitations of Use: • Levothyroxine sodium tablets are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with levothyroxine sodium tablets may induce hyperthyroidism [see Warnings and Precautions (5.4)]. • Levothyroxine sodium tablets are not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis. uuid:7e314382-d87c-4377-aa64-ea922f99bac2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18332 biolink:treats UMLS:C5779675 PMID:41385096 "[{""id"":""uuid:b072cf10-fada-40f9-a3e5-c2e0fb52f2f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:39122f93-f3bc-464d-8232-086f25121147"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypothyroidism Levothyroxine sodium tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary) and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression Levothyroxine sodium tablets are indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. Limitations of Use: • Levothyroxine sodium tablets are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with levothyroxine sodium tablets may induce hyperthyroidism [see Warnings and Precautions (5.4)]. • Levothyroxine sodium tablets are not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis. uuid:deb9ff6b-605c-4d0a-86a1-9a934ceab631 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64317 biolink:treats MONDO:0008848 PMID:41385096 "[{""id"":""uuid:bfea682c-a751-44f1-b8f4-b066329c2083"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ab85d228-8aa6-45d2-95c5-56328de33662"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isoproterenol hydrochloride injection is indicated: For mild or transient episodes of heart block that do not require electric shock or pacemaker therapy. For serious episodes of heart block and Adams-Stokes attacks (except when caused by ventricular tachycardia or fibrillation). (See CONTRAINDICATIONS.) For use in cardiac arrest until electric shock or pacemaker therapy, the treatments of choice, is available. (See CONTRAINDICATIONS.) For bronchospasm occurring during anesthesia. As an adjunct to fluid and electrolyte replacement therapy and the use of other drugs and procedures in the treatment of hypovolemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure, and cardiogenic shock. (See WARNINGS.) uuid:86baa1f2-a3a0-4887-979f-fd30b7ded75f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64317 biolink:treats MONDO:0043475 PMID:41385096 "[{""id"":""uuid:97ea800f-40cc-4682-9794-82a33ac25289"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:32769367-9b4c-4124-9078-2e9fa33868c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isoproterenol hydrochloride injection is indicated: For mild or transient episodes of heart block that do not require electric shock or pacemaker therapy. For serious episodes of heart block and Adams-Stokes attacks (except when caused by ventricular tachycardia or fibrillation). (See CONTRAINDICATIONS.) For use in cardiac arrest until electric shock or pacemaker therapy, the treatments of choice, is available. (See CONTRAINDICATIONS.) For bronchospasm occurring during anesthesia. As an adjunct to fluid and electrolyte replacement therapy and the use of other drugs and procedures in the treatment of hypovolemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure, and cardiogenic shock. (See WARNINGS.) uuid:a14b7083-b17e-486e-aaab-e10f8eb44cc1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64317 biolink:treats MONDO:0000745 PMID:41385096 "[{""id"":""uuid:f9fe9d4d-4ce3-4403-9359-74c3959a454b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e4f9eee0-dd0e-42e4-b5fa-baaab17e74fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isoproterenol hydrochloride injection is indicated: For mild or transient episodes of heart block that do not require electric shock or pacemaker therapy. For serious episodes of heart block and Adams-Stokes attacks (except when caused by ventricular tachycardia or fibrillation). (See CONTRAINDICATIONS.) For use in cardiac arrest until electric shock or pacemaker therapy, the treatments of choice, is available. (See CONTRAINDICATIONS.) For bronchospasm occurring during anesthesia. As an adjunct to fluid and electrolyte replacement therapy and the use of other drugs and procedures in the treatment of hypovolemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure, and cardiogenic shock. (See WARNINGS.) uuid:85274969-651d-418b-9b77-748c32fb1d9e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64317 biolink:treats MONDO:0001358 PMID:41385096 "[{""id"":""uuid:bb940b1a-76aa-4894-8304-af640358e3b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2d94b6cf-8c73-4a8d-a38f-adb254a631a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isoproterenol hydrochloride injection is indicated: For mild or transient episodes of heart block that do not require electric shock or pacemaker therapy. For serious episodes of heart block and Adams-Stokes attacks (except when caused by ventricular tachycardia or fibrillation). (See CONTRAINDICATIONS.) For use in cardiac arrest until electric shock or pacemaker therapy, the treatments of choice, is available. (See CONTRAINDICATIONS.) For bronchospasm occurring during anesthesia. As an adjunct to fluid and electrolyte replacement therapy and the use of other drugs and procedures in the treatment of hypovolemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure, and cardiogenic shock. (See WARNINGS.) uuid:3cde9f69-97e1-4249-be1c-b14c160fe640 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64317 biolink:treats HP:0031274 PMID:41385096 "[{""id"":""uuid:0c51ab2d-7c23-4eb3-a02a-b1639692d719"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:86260af6-a904-4599-b8d5-fb308f93892c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isoproterenol hydrochloride injection is indicated: For mild or transient episodes of heart block that do not require electric shock or pacemaker therapy. For serious episodes of heart block and Adams-Stokes attacks (except when caused by ventricular tachycardia or fibrillation). (See CONTRAINDICATIONS.) For use in cardiac arrest until electric shock or pacemaker therapy, the treatments of choice, is available. (See CONTRAINDICATIONS.) For bronchospasm occurring during anesthesia. As an adjunct to fluid and electrolyte replacement therapy and the use of other drugs and procedures in the treatment of hypovolemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure, and cardiogenic shock. (See WARNINGS.) uuid:0a325543-9446-4e1e-a4bc-3c189a88dbcc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64317 biolink:treats MONDO:0001881 PMID:41385096 "[{""id"":""uuid:6691f9aa-55e6-4d29-9fa0-a1b4da9002db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bcef7bfb-3efd-4264-bbd7-aa61e6a6a0ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isoproterenol hydrochloride injection is indicated: For mild or transient episodes of heart block that do not require electric shock or pacemaker therapy. For serious episodes of heart block and Adams-Stokes attacks (except when caused by ventricular tachycardia or fibrillation). (See CONTRAINDICATIONS.) For use in cardiac arrest until electric shock or pacemaker therapy, the treatments of choice, is available. (See CONTRAINDICATIONS.) For bronchospasm occurring during anesthesia. As an adjunct to fluid and electrolyte replacement therapy and the use of other drugs and procedures in the treatment of hypovolemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure, and cardiogenic shock. (See WARNINGS.) uuid:a6286dae-58c9-4611-9f1c-932b829012fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64317 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:7de8d401-d8bd-47cd-9a83-a22b7392bba0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:30669148-8a0a-4471-9803-b3015eef88f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isoproterenol hydrochloride injection is indicated: For mild or transient episodes of heart block that do not require electric shock or pacemaker therapy. For serious episodes of heart block and Adams-Stokes attacks (except when caused by ventricular tachycardia or fibrillation). (See CONTRAINDICATIONS.) For use in cardiac arrest until electric shock or pacemaker therapy, the treatments of choice, is available. (See CONTRAINDICATIONS.) For bronchospasm occurring during anesthesia. As an adjunct to fluid and electrolyte replacement therapy and the use of other drugs and procedures in the treatment of hypovolemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure, and cardiogenic shock. (See WARNINGS.) uuid:909773e2-12cd-4f5e-bdec-9c5fcabaadca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64317 biolink:treats MONDO:0800175 PMID:41385096 "[{""id"":""uuid:8e3d8a62-633b-47f3-bca0-9ddb3d7e6b77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fea23677-6b52-4b89-bdd7-ddec9a8cc6ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isoproterenol hydrochloride injection is indicated: For mild or transient episodes of heart block that do not require electric shock or pacemaker therapy. For serious episodes of heart block and Adams-Stokes attacks (except when caused by ventricular tachycardia or fibrillation). (See CONTRAINDICATIONS.) For use in cardiac arrest until electric shock or pacemaker therapy, the treatments of choice, is available. (See CONTRAINDICATIONS.) For bronchospasm occurring during anesthesia. As an adjunct to fluid and electrolyte replacement therapy and the use of other drugs and procedures in the treatment of hypovolemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure, and cardiogenic shock. (See WARNINGS.) uuid:3239d9a5-8462-4b27-a811-05759454b1cf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats MONDO:0002406 PMID:41385096 "[{""id"":""uuid:88fdc8c3-a69f-4da7-bf63-21605e4db765"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:664286e6-580b-419a-8c1c-12f228b76faf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] An external treatment for the inflammation and irritation associated with many common forms of dermatitis, including certain eczematoid conditions. These conditions include complications associated with pyodermas. Indicated also in the treatment of insect bites, burns and fungal infections. uuid:146fb948-1229-445e-8c45-2521e04df71d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats MONDO:0002922 PMID:41385096 "[{""id"":""uuid:6a596911-4c1f-4683-a232-468822e46976"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b9087896-96b4-4c00-b076-aa1ea6100300"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] An external treatment for the inflammation and irritation associated with many common forms of dermatitis, including certain eczematoid conditions. These conditions include complications associated with pyodermas. Indicated also in the treatment of insect bites, burns and fungal infections. uuid:13b7a9d0-6d25-4e71-a256-837dfba0c280 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats UMLS:C0021564 PMID:41385096 "[{""id"":""uuid:77fb0fcb-7a93-4421-a0e5-e48483a5e53e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ecec4310-6824-462a-8590-0a2708e5b132"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] An external treatment for the inflammation and irritation associated with many common forms of dermatitis, including certain eczematoid conditions. These conditions include complications associated with pyodermas. Indicated also in the treatment of insect bites, burns and fungal infections. uuid:08605588-4b1f-40cf-acf0-980ecee6f773 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats MONDO:0002041 PMID:41385096 "[{""id"":""uuid:8d2ae9ac-dd10-4398-b67f-bf215153d157"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a5fa1d97-9613-4d1a-b8e9-ad44dc8353ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] An external treatment for the inflammation and irritation associated with many common forms of dermatitis, including certain eczematoid conditions. These conditions include complications associated with pyodermas. Indicated also in the treatment of insect bites, burns and fungal infections. uuid:62c07820-b9db-49df-b684-5b61fd4d13b0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:UMD7G2653W biolink:treats MONDO:0008159 PMID:41385096 "[{""id"":""uuid:183275fd-7490-4cb7-bc47-693fbf0d4009"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1a61ad9c-74b8-4cdb-a9af-e117acdb1762"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ibandronate sodium injection is a bisphosphonate indicated for the treatment of osteoporosis in postmenopausal women. ( 1.1 ) Limitations of Use Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use ( 1.2 ) uuid:0b0d7268-cc5f-4d0c-baed-f6a58ab94b5b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9139 biolink:treats MONDO:0017147 PMID:41385096 "[{""id"":""uuid:28bc2e12-aabd-4869-8e4f-c76172736c5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6363f22e-54f4-44de-95dc-45796634658c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sildenafil citrate is a phosphodiesterase-5 (PDE-5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group I) in adults to improve exercise ability and delay clinical worsening. Studies establishing effectiveness were short-term (12 to 16 weeks), and included predominately patients with NYHA Functional Class II-III symptoms. Etiologies were idiopathic (71%) or associated with connective tissue disease (25%). (1) Limitation of Use : Adding sildenafil to bosentan therapy does not result in any beneficial effect on exercise capacity. (1, 14) uuid:475355fe-6edc-4602-af2b-cb172f21034d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9139 biolink:treats UMLS:C3697982 PMID:41385096 "[{""id"":""uuid:b7234024-78a9-439e-8336-23272d1c52fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7a795461-d3f6-4176-8b3d-bfe7cdeeb378"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sildenafil citrate is a phosphodiesterase-5 (PDE-5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group I) in adults to improve exercise ability and delay clinical worsening. Studies establishing effectiveness were short-term (12 to 16 weeks), and included predominately patients with NYHA Functional Class II-III symptoms. Etiologies were idiopathic (71%) or associated with connective tissue disease (25%). (1) Limitation of Use : Adding sildenafil to bosentan therapy does not result in any beneficial effect on exercise capacity. (1, 14) uuid:a806e0e5-3eb7-4bd3-bdb0-6a92160174c4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31498 biolink:treats UMLS:C0011974 PMID:41385096 "[{""id"":""uuid:765a3168-109b-4e91-85bc-e098ac815355"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:723d5e5a-29c2-47b8-8f12-e0324430423d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment and/or prevention of diaper rash Temporarily protects and helps relieve chapped or cracked skin uuid:8963848d-df4f-44d0-8519-4c535b5a62c1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31498 biolink:treats UMLS:C0549202 PMID:41385096 "[{""id"":""uuid:18daf940-8e79-401c-8ebe-89a5efc8786f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:de3f01a1-67a4-4466-b9a0-6cc685b4802a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment and/or prevention of diaper rash Temporarily protects and helps relieve chapped or cracked skin uuid:ab17a37d-4491-4881-af32-8bef719701cd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31498 biolink:treats HP:0031057 PMID:41385096 "[{""id"":""uuid:13f74948-6a91-4267-85c0-f1e0bd413a9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3426f892-db2e-4880-8fd8-a3f290393305"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment and/or prevention of diaper rash Temporarily protects and helps relieve chapped or cracked skin uuid:f89e3f79-d7d9-497e-8a90-07ad76e48d65 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2453 biolink:treats NCIT:C141249 PMID:41385096 "[{""id"":""uuid:dc59befd-9555-4c5d-ab71-dbd0dddec5a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f41059c5-8b43-43a8-bb11-55782f087c88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acyclovir Sodium Injection is indicated for the treatment of initial and recurrent mucosal and cutaneous herpes simplex (HSV-1 and HSV-2) in immunocompromised patients. uuid:4bfed9af-0f6f-43ea-a3a4-7087fa282fa8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2453 biolink:treats NCIT:C188484 PMID:41385096 "[{""id"":""uuid:38dbc814-b4d6-4c28-bf5f-33fcd5878add"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:794ec595-26b9-455a-bcdd-4e304f986dd8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acyclovir Sodium Injection is indicated for the treatment of initial and recurrent mucosal and cutaneous herpes simplex (HSV-1 and HSV-2) in immunocompromised patients. uuid:44761213-688a-47c9-b945-1447944b25c9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4710 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:5b2d7c09-1876-4caf-a12b-d2786e067f8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:180fff35-29f5-41aa-a810-0ec6a530042f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRUDOXIN ® Cream is indicated for the short-term (up to 8 days) management of moderate pruritus in adult patients with atopic dermatitis or lichen simplex chronicus. (See DOSAGE AND ADMINISTRATION .) uuid:3d71d8cd-379f-4986-909a-96319ce9441d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4710 biolink:treats UMLS:C0149922 PMID:41385096 "[{""id"":""uuid:b62b7790-8669-4e76-bb87-e33f5a9e7da5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:88e44e0b-7d28-44d0-ba9e-16cd1271a8f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRUDOXIN ® Cream is indicated for the short-term (up to 8 days) management of moderate pruritus in adult patients with atopic dermatitis or lichen simplex chronicus. (See DOSAGE AND ADMINISTRATION .) uuid:379168ab-df91-44a8-b9f9-4cd218369499 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0007005 PMID:41385096 "[{""id"":""uuid:9cd9de4e-cbb6-4a15-8e31-e10cc3d49952"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:25d06952-41bb-4115-896e-40e4d12e4114"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydrocortisone Rectal Suspension, USP is indicated as adjunctive therapy in the treatment of ulcerative colitis, especially distal forms, including ulcerative proctitis, ulcerative proctosigmoiditis, and left-sided ulcerative colitis. It has proved useful also in some cases involving the transverse and ascending colons. uuid:5ebde0ff-d71b-4ded-9159-58e07d445de3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5132 biolink:treats MONDO:0004956 PMID:41385096 "[{""id"":""uuid:045865da-0914-440d-ba02-a82e1f04cdf0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dfd29123-f7b1-4148-9a3a-3916fd4a4e89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Flutamide capsules are indicated for use in combination with LHRH agonists for the management of locally confined Stage B 2 -C and Stage D 2 metastatic carcinoma of the prostate. uuid:59d7140f-8094-4d4d-803f-ec28120d6f26 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5132 biolink:treats MONDO:0005159 PMID:41385096 "[{""id"":""uuid:34afe598-d1d5-4a8e-9ffd-837872ab0131"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0c123ee8-4423-411e-be6d-e76186c44d39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Flutamide capsules are indicated for use in combination with LHRH agonists for the management of locally confined Stage B 2 -C and Stage D 2 metastatic carcinoma of the prostate. uuid:99b85467-2763-4055-b498-3d74b96c8e08 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32588 biolink:treats MONDO:0003019 PMID:41385096 "[{""id"":""uuid:f52bd602-b546-4389-8f23-55e5018ba242"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:345ee9ee-fdc5-4b1d-a742-27aa26e12af4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Potassium Chloride is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient. uuid:66d46e44-0271-434a-b6b9-9e54880c8de0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32588 biolink:treats HP:0200114 PMID:41385096 "[{""id"":""uuid:fbfeed3d-e17e-4099-8b2b-0bfb07170c4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4d16a365-c2e4-4bf5-842b-5a6fd9e2512f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Potassium Chloride is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient. uuid:6c43c0c0-ef74-4873-85ba-1617b9955fea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:187893 biolink:treats MONDO:0014115 PMID:41385096 "[{""id"":""uuid:33bb5163-d2de-4eb8-9abd-62afc09e37e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bd1871b3-9652-4a3a-ae8a-e1e572bdc299"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Baclofen Injection (Intrathecal) is indicated for use in the management of severe spasticity. Patients should first respond to a screening dose of intrathecal baclofen prior to consideration for long term infusion via an implantable pump. For spasticity of spinal cord origin, chronic infusion of Baclofen Injection (Intrathecal) via an implantable pump should be reserved for patients unresponsive to oral baclofen therapy, or those who experience intolerable CNS side effects at effective doses. Patients with spasticity due to traumatic brain injury should wait at least one year after the injury before consideration of long term intrathecal baclofen therapy. Baclofen Injection (Intrathecal) is intended for use by the intrathecal route in single bolus test doses (via spinal catheter or lumbar puncture) and, for chronic use, only in implantable pumps approved by the FDA specifically for the administration of Baclofen Injection (Intrathecal) into the intrathecal space. uuid:5f920f16-cdce-4c33-809c-12f79f684658 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8093 biolink:treats MONDO:0005468 PMID:41385096 "[{""id"":""uuid:b06f713a-e66c-4cd5-8c1c-af44f7463ab3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:03ceb299-a141-4e5b-bc1d-f133c5489207"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Phenylephrine hydrochloride is an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. ( 1 ) uuid:c71d830b-f397-4ec8-8cde-58d02fd2758c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7596 biolink:treats HP:0100735 PMID:41385096 "[{""id"":""uuid:b34c7b25-203e-4334-8c24-dc507242b766"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1398e109-189d-43ac-a84d-c853a3075493"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium nitroprusside is indicated for the immediate reduction of blood pressure of adult and pediatric patients in hypertensive crises. Concomitant longer-acting antihypertensive medication should be administered so that the duration of treatment with sodium nitroprusside can be minimized. Sodium nitroprusside is also indicated for producing controlled hypotension in order to reduce bleeding during surgery. Sodium nitroprusside is also indicated for the treatment of acute congestive heart failure. uuid:a9e13a3c-b615-49ff-b3dd-ecd14611e30f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7596 biolink:treats UMLS:C0264719 PMID:41385096 "[{""id"":""uuid:5f62fa7b-d742-4478-a8a1-f0a7f812b040"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:406103a1-04ca-4464-91a0-919e0cbe473f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium nitroprusside is indicated for the immediate reduction of blood pressure of adult and pediatric patients in hypertensive crises. Concomitant longer-acting antihypertensive medication should be administered so that the duration of treatment with sodium nitroprusside can be minimized. Sodium nitroprusside is also indicated for producing controlled hypotension in order to reduce bleeding during surgery. Sodium nitroprusside is also indicated for the treatment of acute congestive heart failure. uuid:8a59c7e6-236f-477d-aa6c-f893a5c71a1a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:WA16A5Y52X biolink:treats MONDO:0002629 PMID:41385096 "[{""id"":""uuid:4e23272b-971e-4eae-bec4-7727d6bc7b22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fd7c3b79-5680-4a4a-8b91-fdd0c14c1a33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levoleucovorin injection is a folate analog. Levoleucovorin injection rescue is indicated after high-dose methotrexate therapy in osteosarcoma. Levoleucovorin injection is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists. Levoleucovorin injection is indicated for use in combination chemotherapy with 5-fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancer. PUBCHEM.COMPOUND:135465090 uuid:51d49dc0-b86d-47b9-8760-f5f985b07ea4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:WA16A5Y52X biolink:treats MONDO:0005575 PMID:41385096 "[{""id"":""uuid:86f0f192-3346-44f8-80e8-c87a2345f510"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ac6af4fa-b8d8-4577-a4d8-746b7f29899c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levoleucovorin injection is a folate analog. Levoleucovorin injection rescue is indicated after high-dose methotrexate therapy in osteosarcoma. Levoleucovorin injection is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosage of folic acid antagonists. Levoleucovorin injection is indicated for use in combination chemotherapy with 5-fluorouracil in the palliative treatment of patients with advanced metastatic colorectal cancer. PUBCHEM.COMPOUND:135465090 uuid:6b417cb0-ffeb-481b-9cfe-22c31adbc6c0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2038 biolink:treats MONDO:0005272 PMID:41385096 "[{""id"":""uuid:4f729d58-1a44-417a-b839-d5e66cd76f14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:de134d65-c1b9-47e0-ac5d-709820c2fc4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azacitidine for injection is a nucleoside metabolic inhibitor indicated for the treatment of patients with the following FAB myelodysplastic syndrome (MDS) subtypes: Refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL). (1) uuid:ed7df72d-e250-48c8-b08a-b5587217b348 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2038 biolink:treats MONDO:0019157 PMID:41385096 "[{""id"":""uuid:243cc653-20c0-445c-8003-330972baa677"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e229cfce-49cc-4d85-8af9-c01e0e6c2d20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azacitidine for injection is a nucleoside metabolic inhibitor indicated for the treatment of patients with the following FAB myelodysplastic syndrome (MDS) subtypes: Refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL). (1) uuid:6f5bfc2d-82a6-4533-909f-db7250fef99e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2038 biolink:treats MONDO:0019454 PMID:41385096 "[{""id"":""uuid:33bb4b3e-e1a5-45b6-991e-0de930bdad4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:15d9c64d-c1ce-4bbf-989f-7470423efb66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:94b3b4ab-16f5-4031-8016-8d6a7ee5d348"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/azacitidine-mylan""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azacitidine for injection is a nucleoside metabolic inhibitor indicated for the treatment of patients with the following FAB myelodysplastic syndrome (MDS) subtypes: Refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL). (1)|[EMA] Vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with: intermediate 2 and high-risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS),chronic myelomonocytic leukaemia (CMML) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (AML) with 20 30 % blasts and multi-lineage dysplasia, according to World Health Organisation (WHO) classification.Vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for HSCT with AML with >30% marrow blasts according to the WHO classification. uuid:8414a7c8-bc4a-4ac3-b4b2-a8f121a6e017 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2038 biolink:treats MONDO:0015692 PMID:41385096 "[{""id"":""uuid:0643a1a7-1875-4f10-83d0-afe656424dcb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e1154441-0dab-4c19-93a8-cdcb53769c15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azacitidine for injection is a nucleoside metabolic inhibitor indicated for the treatment of patients with the following FAB myelodysplastic syndrome (MDS) subtypes: Refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL). (1) uuid:b34a86a1-3832-4a41-b9ec-4bad429e4618 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2038 biolink:treats MONDO:0020311 PMID:41385096 "[{""id"":""uuid:c8898818-1142-4b30-8728-8715b218323c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:50331bde-ce41-45f9-9159-07207a649fab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:080fe4e1-ab47-4a18-b6e5-0999e4752d15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/azacitidine-mylan""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azacitidine for injection is a nucleoside metabolic inhibitor indicated for the treatment of patients with the following FAB myelodysplastic syndrome (MDS) subtypes: Refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL). (1)|[EMA] Azacitidine Mylan is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with:intermediate 2 and high risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS),chronic myelomonocytic leukaemia (CMML) with 10 29% marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (AML) with 20 30% blasts and multi lineage dysplasia, according to World Health Organisation (WHO) classification,AML with > 30% marrow blasts according to the WHO classification. uuid:93f41689-e824-43c2-bcf0-ebc18e0743be biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4B33BGI082 biolink:treats HP:0003124 PMID:41385096 "[{""id"":""uuid:159a185e-d6af-43d9-a18f-667b27098c6c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f8553a7a-c609-49c1-92dc-acc01eadf3a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1) Cholestyramine for oral suspension USP light powder, is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Cholestyramine for oral suspension USP light powder may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. Excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. Prior to initiating therapy with cholestyramine for oral suspension USP light powder secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism), should be excluded, and a lipid profile performed to assess Total cholesterol, HDL-C, and triglycerides (TG). For individuals with TG less than 400 mg/dL (< 4.5 mmol/L), LDL-C can be estimated using the following equation:- LDL-C = Total cholesterol – [(TG/5) + HDL-C] For TG levels > 400 mg/dL, this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases cholestyramine for oral suspension USP light powder may not be indicated. Serum cholesterol and triglyceride levels should be determined periodically based on NCEP guidelines to confirm initial and adequate long-term response. A favorable trend in cholesterol reduction should occur during the first month of cholestyramine for oral suspension USP light powder therapy. The therapy should be continued to sustain cholesterol reduction. If adequate cholesterol reduction is not attained, increasing the dosage of cholestyramine for oral suspension USP light powder or adding other lipid-lowering agents in combination with cholestyramine for oral suspension USP light powder should be considered. Since the goal of treatment is to lower LDL-C, the NCEP 4 recommends that LDL-C levels be used to initiate and assess treatment response. If LDL-C levels are not available then Total-C alone may be used to monitor long-term therapy. A lipoprotein analysis (including LDL-C determination) should be carried out once a year. The NCEP treatment guidelines are summarized below. * Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). * * Other risk factors for coronary heart disease (CHD) include: age (males ≥ 45 years; females ≥ 55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C < 35 mg/dL (< 0.91 mmol/L); and diabetes mellitus. Subtract one risk factor if HDL-C is ≥ 60 mg/dL (≥ 1.6 mmol/L). LDL - Cholesterol mg / dL ( mmol / L ) Definite Atherosclerotic Disease * Two or More Other Risk Factors ** Initiation Level Goal NO NO ≥ 190 (≥ 4.9) < 160 (< 4.1) NO YES ≥ 160 (≥ 4.1) < 130 (< 3.4) YES YES OR NO ≥ 130 (≥ 3.4) ≤ 100 ( ≤ 2.6) Cholestyramine for oral suspension USP light powder monotherapy has been demonstrated to retard the rate of progression 2,3 and increase the rate of regression 3 of coronary atherosclerosis. 2) Cholestyramine for oral suspension USP light powder is indicated for the relief of pruritus associated with partial biliary obstruction. Cholestyramine for oral suspension USP light powder has been shown to have a variable effect on serum cholesterol in these patients. Patients with primary biliary cirrhosis may exhibit an elevated cholesterol as part of their disease. uuid:06541bec-221b-4eaa-bebe-8c35db55315d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4B33BGI082 biolink:treats MONDO:0021661 PMID:41385096 "[{""id"":""uuid:853a3105-5b63-4cf5-a5b4-2c79bf64b31a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:501fa588-eb56-4131-9430-bd025e8d0a3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1) Cholestyramine for oral suspension USP light powder, is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Cholestyramine for oral suspension USP light powder may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. Excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. Prior to initiating therapy with cholestyramine for oral suspension USP light powder secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism), should be excluded, and a lipid profile performed to assess Total cholesterol, HDL-C, and triglycerides (TG). For individuals with TG less than 400 mg/dL (< 4.5 mmol/L), LDL-C can be estimated using the following equation:- LDL-C = Total cholesterol – [(TG/5) + HDL-C] For TG levels > 400 mg/dL, this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases cholestyramine for oral suspension USP light powder may not be indicated. Serum cholesterol and triglyceride levels should be determined periodically based on NCEP guidelines to confirm initial and adequate long-term response. A favorable trend in cholesterol reduction should occur during the first month of cholestyramine for oral suspension USP light powder therapy. The therapy should be continued to sustain cholesterol reduction. If adequate cholesterol reduction is not attained, increasing the dosage of cholestyramine for oral suspension USP light powder or adding other lipid-lowering agents in combination with cholestyramine for oral suspension USP light powder should be considered. Since the goal of treatment is to lower LDL-C, the NCEP 4 recommends that LDL-C levels be used to initiate and assess treatment response. If LDL-C levels are not available then Total-C alone may be used to monitor long-term therapy. A lipoprotein analysis (including LDL-C determination) should be carried out once a year. The NCEP treatment guidelines are summarized below. * Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). * * Other risk factors for coronary heart disease (CHD) include: age (males ≥ 45 years; females ≥ 55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C < 35 mg/dL (< 0.91 mmol/L); and diabetes mellitus. Subtract one risk factor if HDL-C is ≥ 60 mg/dL (≥ 1.6 mmol/L). LDL - Cholesterol mg / dL ( mmol / L ) Definite Atherosclerotic Disease * Two or More Other Risk Factors ** Initiation Level Goal NO NO ≥ 190 (≥ 4.9) < 160 (< 4.1) NO YES ≥ 160 (≥ 4.1) < 130 (< 3.4) YES YES OR NO ≥ 130 (≥ 3.4) ≤ 100 ( ≤ 2.6) Cholestyramine for oral suspension USP light powder monotherapy has been demonstrated to retard the rate of progression 2,3 and increase the rate of regression 3 of coronary atherosclerosis. 2) Cholestyramine for oral suspension USP light powder is indicated for the relief of pruritus associated with partial biliary obstruction. Cholestyramine for oral suspension USP light powder has been shown to have a variable effect on serum cholesterol in these patients. Patients with primary biliary cirrhosis may exhibit an elevated cholesterol as part of their disease. uuid:868b230f-cdbb-4d1e-91aa-dfd0b4e09ac8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:284544 biolink:treats HP:0040137 PMID:41385096 "[{""id"":""uuid:18a81526-756f-4c7d-ad88-8222b4e9b19a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:752cc765-792e-45c8-b59a-e50377b6d84f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clindamycin phosphate and benzoyl peroxide gel is a combination of clindamycin phosphate (a lincosamide antibacterial) and benzoyl peroxide indicated for the topical treatment of inflammatory acne vulgaris. ( 1.1 ) Limitation of Use: Clindamycin phosphate and benzoyl peroxide gel has not been demonstrated to have any additional benefit when compared with benzoyl peroxide alone in the same vehicle when used for the treatment of non-inflammatory acne. ( 1.2 ) uuid:8c8f4867-657f-4979-acf3-b0ce0eea4267 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63632 biolink:treats MONDO:0008433 PMID:41385096 "[{""id"":""uuid:e489320a-ef2b-4d16-8d8e-988be937df74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0a23126b-fb4e-4a49-9bb6-2af356ef4e14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:dfb47ae3-dbe5-4f15-847f-08254a1644e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/hycamtin""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Topotecan hydrochloride for injection is indicated for the treatment of: Small cell lung cancer sensitive disease after failure of first-line chemotherapy. In clinical studies submitted to support approval, sensitive disease was defined as disease responding to chemotherapy but subsequently progressing at least 60 days (in the Phase 3 study) or at least 90 days (in the Phase 2 studies) after chemotherapy [see Clinical Studies (14 ) ]. Topotecan hydrochloride for injection in combination with cisplatin is indicated for the treatment of: stage IV-B, recurrent, or persistent carcinoma of the cervix which is not amenable to curative treatment with surgery and/or radiation therapy.|[EMA] Hycamtin capsules are indicated as monotherapy for the treatment of adult patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate.Topotecan is indicated for the treatment of patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy.Hycamtin capsules are indicated as monotherapy for the treatment of adult patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate. uuid:6cad61c5-63e8-4c75-9041-00c9c5e3e0d9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63632 biolink:treats MONDO:0016276 PMID:41385096 "[{""id"":""uuid:56fa72e9-9e2d-4dce-91b1-9f3e47a981d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a2e4ac2a-4ca5-4f2d-beb5-c1e309e2201b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Topotecan hydrochloride for injection is indicated for the treatment of: Small cell lung cancer sensitive disease after failure of first-line chemotherapy. In clinical studies submitted to support approval, sensitive disease was defined as disease responding to chemotherapy but subsequently progressing at least 60 days (in the Phase 3 study) or at least 90 days (in the Phase 2 studies) after chemotherapy [see Clinical Studies (14 ) ]. Topotecan hydrochloride for injection in combination with cisplatin is indicated for the treatment of: stage IV-B, recurrent, or persistent carcinoma of the cervix which is not amenable to curative treatment with surgery and/or radiation therapy. uuid:b0c61572-22d9-4871-b1ad-bd77a5589601 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63618 biolink:treats UMLS:C0856526 PMID:41385096 "[{""id"":""uuid:74f8fa42-c931-497c-8130-0c7fab6594cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b0b8a80d-d39d-45b1-8900-e59d21da4551"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: Reduce the risk of MI, revascularization, and cardiovascular mortality in hypercholesterolemic patients without clinically evident CHD. ( 1.1 ) Reduce the risk of total mortality by reducing coronary death, MI, revascularization, stroke/TIA, and the progression of coronary atherosclerosis in patients with clinically evident CHD. ( 1.1 ) Reduce elevated Total-C, LDL-C, ApoB, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia. ( 1.2 ) Reduce elevated serum TG levels in patients with hypertriglyceridemia.( 1.2 ) Treat patients with primary dysbetalipoproteinemia who are not responding to diet. ( 1.2 ) Treat children and adolescent patients ages 8 years and older with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy. ( 1.2 ) Limitations of use: Pravastatin sodium tablets have not been studied in Fredrickson Types I and V dyslipidemias. ( 1.3 ) uuid:dee9ec22-2f7d-40ed-8e5d-9ee5c7408b36 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63618 biolink:treats MONDO:0007762 PMID:41385096 "[{""id"":""uuid:7bf3fac5-523d-4895-8d7e-9a9b78ada8a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:117c0768-64c7-4223-8a22-f040a30d8643"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pravastatin sodium tablets are an HMG-CoA reductase inhibitor (statin) indicated as an adjunctive therapy to diet to: Reduce the risk of MI, revascularization, and cardiovascular mortality in hypercholesterolemic patients without clinically evident CHD. ( 1.1 ) Reduce the risk of total mortality by reducing coronary death, MI, revascularization, stroke/TIA, and the progression of coronary atherosclerosis in patients with clinically evident CHD. ( 1.1 ) Reduce elevated Total-C, LDL-C, ApoB, and TG levels and to increase HDL-C in patients with primary hypercholesterolemia and mixed dyslipidemia. ( 1.2 ) Reduce elevated serum TG levels in patients with hypertriglyceridemia.( 1.2 ) Treat patients with primary dysbetalipoproteinemia who are not responding to diet. ( 1.2 ) Treat children and adolescent patients ages 8 years and older with heterozygous familial hypercholesterolemia after failing an adequate trial of diet therapy. ( 1.2 ) Limitations of use: Pravastatin sodium tablets have not been studied in Fredrickson Types I and V dyslipidemias. ( 1.3 ) uuid:80a8eecf-ed4a-4c4d-8d13-053082914606 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85157 biolink:treats HP:0002018 PMID:41385096 "[{""id"":""uuid:8a7151b8-3824-438a-9fb8-9fbdfad69fcf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c862a871-e946-447d-86f2-4b4c039c7bfc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:402056f4-387a-45ee-87ea-2976fd87b7db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:fa783580-635d-4cdf-ab40-02f2f5e0458c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Palonosetron Hydrochloride (HCl) Injection is a serotonin-3 (5-HT 3 ) receptor antagonist indicated in adults for: • Moderately emetogenic cancer chemotherapy – prevention of acute and delayed nausea and vomiting associated with initial and repeat courses ( 1.1 ) • Highly emetogenic cancer chemotherapy – prevention of acute nausea and vomiting associated with initial and repeat courses ( 1.1 )|[EMA] Aloxi is indicated in adults for:the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy,the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.Aloxi is indicated in paediatric patients 1 month of age and older for:the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.|[PMDA] A drug with a new active ingredient indicated for the treatment of digestive symptoms (nausea and vomiting, including delayed phase) resulting from the administration of antineoplastic agents (cisplatin, etc.). uuid:9b257b11-3b80-4875-bc23-6e13093d3d79 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85157 biolink:treats HP:0002013 PMID:41385096 "[{""id"":""uuid:2b5585e5-1d00-4c7f-8209-ceec5c318fa4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:74d7edff-8d39-4377-9cca-a5fc321ca5a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:6de8cf09-5c8a-4649-a7eb-d14af8c7343d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:38164744-f82c-49e7-b5b0-58469a9a2c92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Palonosetron Hydrochloride (HCl) Injection is a serotonin-3 (5-HT 3 ) receptor antagonist indicated in adults for: • Moderately emetogenic cancer chemotherapy – prevention of acute and delayed nausea and vomiting associated with initial and repeat courses ( 1.1 ) • Highly emetogenic cancer chemotherapy – prevention of acute nausea and vomiting associated with initial and repeat courses ( 1.1 )|[EMA] Aloxi is indicated in adults for:the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy,the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.Aloxi is indicated in paediatric patients 1 month of age and older for:the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.|[PMDA] A drug with a new active ingredient indicated for the treatment of digestive symptoms (nausea and vomiting, including delayed phase) resulting from the administration of antineoplastic agents (cisplatin, etc.). uuid:d297a8d8-327d-4af5-96c3-801277ecd26b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:218445 biolink:treats MONDO:0000257 PMID:41385096 "[{""id"":""uuid:d220f79a-b60e-4d27-b8c7-e2bab1568a00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:df7fb8b4-2e7a-4a18-9c7c-39ecf290051a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MOTOFEN® is indicated as adjunctive therapy in the management of acute nonspecific diarrhea and acute exacerbations of chronic functional diarrhea. uuid:0a3f4cfe-0bb1-4517-9a71-b315411ed43f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:218445 biolink:treats MONDO:0001272 PMID:41385096 "[{""id"":""uuid:9a071da8-7b48-4c9b-9da6-6bc1a46161a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a5974c07-d508-45ea-ad38-dc14f884c9b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MOTOFEN® is indicated as adjunctive therapy in the management of acute nonspecific diarrhea and acute exacerbations of chronic functional diarrhea. uuid:64421f98-9fd0-495d-ad4a-feb3ee09bfdc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7773 biolink:treats HP:0002017 PMID:41385096 "[{""id"":""uuid:4f9c2c51-9a47-46c5-8ccc-c6c99ff59a08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d8c35e2b-d42e-471b-999b-2b37d170e70f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ondansetron Injection, USP is a 5-HT 3 receptor antagonist indicated for the prevention of: • nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy. ( 1.1 ) • postoperative nausea and/or vomiting. ( 1.2 ) uuid:8c54877b-3b6c-4de7-9ff8-5eebd8ec2589 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7773 biolink:treats EFO:0004888 PMID:41385096 "[{""id"":""uuid:65fc9b2b-3fa9-4df3-adf4-7216aaf6d008"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:472f9ae0-ef04-4761-810a-9b3259ab1420"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ondansetron Injection, USP is a 5-HT 3 receptor antagonist indicated for the prevention of: • nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy. ( 1.1 ) • postoperative nausea and/or vomiting. ( 1.2 ) uuid:9899dc95-f9fd-4851-a1fd-3247dc9c9fb0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7575 biolink:treats MONDO:0005099 PMID:41385096 "[{""id"":""uuid:bc91c065-5121-438f-99ac-3515d0306cc7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:17ae5e54-eb97-4727-852b-b42956c8101b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nimodipine is indicated for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition (i.e., Hunt and Hess Grades I-V). uuid:4261d98c-b97a-499c-861e-3663e65e828e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7575 biolink:treats MONDO:0005299 PMID:41385096 "[{""id"":""uuid:3afd28c6-b055-40d7-975b-925f556f4887"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:544b5534-a59b-411a-8942-c655715f3e9d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nimodipine is indicated for the improvement of neurological outcome by reducing the incidence and severity of ischemic deficits in patients with subarachnoid hemorrhage from ruptured intracranial berry aneurysms regardless of their post-ictus neurological condition (i.e., Hunt and Hess Grades I-V). uuid:17fa8edc-6167-4722-8776-eea6ab16516d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63613 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:afca30d9-f795-4f7f-9b34-e415dd5346ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cd26f702-d575-4ee1-a261-2bde03e8e8ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nevirapine is an NNRTI indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection in adults and pediatric patients 15 days and older. ( 1 ) Limitations of Use: Based on serious and life-threatening hepatotoxicity observed in controlled and uncontrolled trials, nevirapine is not recommended to be initiated, unless the benefit outweighs the risk, in: adult females with CD4 + cell counts greater than 250 cells/mm 3 adult males with CD4 + cell counts greater than 400 cells/mm 3 ( 1 , 5.1 ) uuid:a5679561-3f7d-4b3a-844b-b6cd2c25f65b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:114785 biolink:treats UMLS:C0278987 PMID:41385096 "[{""id"":""uuid:71006670-2062-4510-97ae-1d1ca3ddb1e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:14713196-bf0c-43d9-8d44-954dccdced23"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TARCEVA is a kinase inhibitor indicated for: • The treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen. ( 1.1 ) • First-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer, in combination with gemcitabine. ( 1.2 ) Limitations of Use: • Safety and efficacy of TARCEVA have not been established in patients with NSCLC whose tumors have other EGFR mutations. ( 1.1 ) • TARCEVA is not recommended for use in combination with platinum-based chemotherapy. ( 1.1 ) uuid:8eb00ddb-fbde-4ca5-982d-52c53cffe426 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:114785 biolink:treats MONDO:0009831 PMID:41385096 "[{""id"":""uuid:a70c3e92-1987-4dcc-887b-23f33d48bf51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:bd38cd93-3fe6-460a-a701-795785565201"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d5aa71d3-515a-4f60-8a72-0e02c128c996"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tarceva""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] TARCEVA is a kinase inhibitor indicated for: • The treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen. ( 1.1 ) • First-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer, in combination with gemcitabine. ( 1.2 ) Limitations of Use: • Safety and efficacy of TARCEVA have not been established in patients with NSCLC whose tumors have other EGFR mutations. ( 1.1 ) • TARCEVA is not recommended for use in combination with platinum-based chemotherapy. ( 1.1 )|[EMA] Non-small cell lung cancer (NSCLC)Tarceva is also indicated for switch maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer with EGFR activating mutations and stable disease after first-line chemotherapy.Tarceva is also indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.In patients with tumours without EGFR activating mutations, Tarceva is indicated when other treatment options are not considered suitable.When prescribing Tarceva, factors associated with prolonged survival should be taken into account.No survival benefit or other clinically relevant effects of the treatment have been demonstrated in patients with Epidermal Growth Factor Receptor (EGFR)-IHC - negative tumours.Pancreatic cancerTarceva in combination with gemcitabine is indicated for the treatment of patients with metastatic pancreatic cancer.When prescribing Tarceva, factors associated with prolonged survival should be taken into account. uuid:c0e97c0c-f887-4c6d-8a6d-e0ec50ff8805 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1152286 biolink:treats MONDO:0006652 PMID:41385096 "[{""id"":""uuid:4470b593-b419-43fa-9ffa-d92d73ba9999"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ed70234f-b5e7-48b2-927e-18a4b969edb9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amlodipine and olmesartan medoxomil tablets are indicated for the treatment of hypertension, alone or with other antihypertensive agents, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with amlodipine and olmesartan medoxomil tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Amlodipine and olmesartan medoxomil tablets may also be used as initial therapy in patients who are likely to need multiple antihypertensive agents to achieve their blood pressure goals. Patients with moderate or severe hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from an 8-week, placebo-controlled, parallel-group factorial study [ see Clinical Studies ( 14.1 ) ] provide estimates of the probability of reaching a blood pressure goal with amlodipine and olmesartan medoxomil tablets compared to amlodipine or olmesartan medoxomil monotherapy. The figures below provide estimates of the likelihood of achieving the targeted systolic or diastolic blood pressure goals with amlodipine and olmesartan medoxomil tablets, 10 mg/40 mg compared with amlodipine or olmesartan medoxomil monotherapy, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling from all available data of that treatment group. The right tail of each curve is less reliable because of small numbers of subjects with high baseline blood pressures. The figures above provide an approximation of the likelihood of reaching a targeted blood pressure goal (e.g., Week 8 SBP < 140 mmHg or < 130 mmHg or a DBP < 90 mmHg or < 80 mmHg) for the high-dose treatment groups evaluated in the study. Amlodipine and olmesartan medoxomil tablets, 5 mg/20 mg, the lowest dose combination treatment group, increases the probability of reaching blood pressure goal compared with the highest dose monotherapies, amlodipine 10 mg and olmesartan medoxomil 40 mg. For example, a patient with a baseline blood pressure of 160/100 mmHg has about a 48% likelihood of achieving a goal of < 140 mmHg (systolic) and a 51% likelihood of achieving a goal of < 90 mmHg (diastolic) on monotherapy with olmesartan medoxomil 40 mg, and about a 46% likelihood of achieving a goal of < 140 mmHg (systolic) and a 60% likelihood of achieving a goal of < 90 mmHg (diastolic) on monotherapy with amlodipine 10 mg. The likelihood of achieving these same goals increases to 63% (systolic) and 71% (diastolic) on amlodipine and olmesartan medoxomil tablets, 5 mg/20 mg, and to 68% (systolic) and 85% (diastolic) on amlodipine and olmesartan medoxomil tablets, 10 mg/40 mg. uuid:a343c302-77c7-4841-ba4a-ae3e1cc35202 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0010643 PMID:41385096 "[{""id"":""uuid:5fec1abd-1c56-4be2-9167-65dd0d5c4480"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:967179ae-3ab3-4895-8365-b9e5718c86d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases: Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases: Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders: Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases: For palliative management of: Leukemia and lymphomas in adults Acute leukemia of childhood 10. Edematous States: To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases: To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous: Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement 13. Diagnostic testing of adrenocortical hyperfunction. uuid:ef73f248-cb2f-42c0-815b-045c46cea9b1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:722125 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:b3acfd64-a4bd-4e52-b43b-a8daf35aff88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d6fd8031-5a6e-4dd9-845d-c1901e08616b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amlodipine and valsartan tablet is the combination tablet of amlodipine, a dihydropyridine calcium channel blocker (DHP CCB), and valsartan, an angiotensin II receptor blocker (ARB). Amlodipine and valsartan tablets are indicated for the treatment of hypertension, to lower blood pressure: In patients not adequately controlled on monotherapy ( 1 ) As initial therapy in patients likely to need multiple drugs to achieve their blood pressure goals ( 1 ). Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. uuid:631f9133-4a26-4ab2-87ba-8781db93affd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:722125 biolink:treats MONDO:0006652 PMID:41385096 "[{""id"":""uuid:59bd4231-1a91-4951-af21-bb62d2c5f458"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3b6f92c9-93a9-4614-af8a-5b04df6b2dd2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amlodipine and valsartan tablet is the combination tablet of amlodipine, a dihydropyridine calcium channel blocker (DHP CCB), and valsartan, an angiotensin II receptor blocker (ARB). Amlodipine and valsartan tablets are indicated for the treatment of hypertension, to lower blood pressure: In patients not adequately controlled on monotherapy ( 1 ) As initial therapy in patients likely to need multiple drugs to achieve their blood pressure goals ( 1 ). Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. uuid:ab090271-25b3-4aca-ad88-741a0cfb5ca8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9434 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:f901df50-df21-47ec-bf6d-dd5b4f1ac3f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a269519a-2c7c-409d-867b-b12915d6bf42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Telmisartanis an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions(1.1) uuid:1c3c92e3-582b-426f-8659-c8dc18c0c2ca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9434 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:b0e6f289-a316-482f-a4aa-8bff69729228"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:8f17d9e7-6285-438e-8443-1f4799c3051f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c987489a-3b81-4703-a70f-698e1fad28c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/telmisartan-actavis""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Telmisartanis an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions(1.1)|[EMA] HypertensionTreatment of essential hypertension in adults.Cardiovascular preventionReduction of cardiovascular morbidity in patients with:manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or;type 2 diabetes mellitus with documented target organ damage. uuid:80d56dd7-f067-42c7-8c8c-5215ad49560e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9434 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:623c7d25-280e-4435-b60d-12827f0e484c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:634ac7ee-0b0b-4092-9b8c-4d642631f0ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Telmisartanis an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions(1.1) uuid:8a31eb81-cedf-4a8a-ba8e-7942dfe0e019 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:RWM8CCW8GP biolink:treats MONDO:0019960 PMID:41385096 "[{""id"":""uuid:1a5ef2fc-be79-4bfd-8f21-6838d97662df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:43b7eb47-5319-493b-bc46-dc5a49165a5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acromegaly Octreotide acetate injection is indicated to reduce blood levels of growth hormone and IGF-I (somatomedin C) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses. The goal is to achieve normalization of growth hormone and IGF-I (somatomedin C) levels ( see DOSAGE AND ADMINISTRATION ). In patients with acromegaly, octreotide acetate injection reduces growth hormone to within normal ranges in 50% of patients and reduces IGF-I (somatomedin C) to within normal ranges in 50% to 60% of patients. Since the effects of pituitary irradiation may not become maximal for several years, adjunctive therapy with octreotide acetate injection to reduce blood levels of growth hormone and IGF-I (somatomedin C) offers potential benefit before the effects of irradiation are manifested. Improvement in clinical signs and symptoms or reduction in tumor size or rate of growth were not shown in clinical trials performed with octreotide acetate injection; these trials were not optimally designed to detect such effects. Carcinoid Tumors Octreotide acetate injection is indicated for the symptomatic treatment of patients with metastatic carcinoid tumors where it suppresses or inhibits the severe diarrhea and flushing episodes associated with the disease. Octreotide acetate injection studies were not designed to show an effect on the size, rate of growth or development of metastases. Vasoactive Intestinal Peptide Tumors (VIPomas) Octreotide acetate injection is indicated for the treatment of the profuse watery diarrhea associated with VIP-secreting tumors. Octreotide acetate injection studies were not designed to show an effect on the size, rate of growth or development of metastases. uuid:5552210d-1b57-4b7f-a7c6-63606894ce5a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7915 biolink:treats MONDO:0006896 PMID:41385096 "[{""id"":""uuid:25262bbf-3868-4a98-ac1c-6c6961041850"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:079db400-6f9d-49d0-817b-1cd699e37749"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pantoprazole sodium delayed-release tablets, USP are a proton pump inhibitor (PPI) indicated for the following: Short-Term Treatment of Erosive Esophagitis Associated with Gastroesophageal Reflux Disease (GERD) ( 1.1 ) Maintenance of Healing of Erosive Esophagitis ( 1.2 ) Pathological Hypersecretory Conditions Including Zollinger-Ellison (ZE) Syndrome ( 1.3 ) uuid:c221227f-93a4-4923-ba36-875cb8c72afa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6359 biolink:treats MONDO:0001711 PMID:41385096 "[{""id"":""uuid:6320222b-814a-480c-833b-e439d18e9100"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:afe91ac6-3629-4940-9b7f-db2796214b3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the prevention and treatment of portal-systemic encephalopathy, including the stages of hepatic pre-coma and coma. Controlled studies have shown that lactulose solution therapy reduces the blood ammonia levels by 25 to 50%; this is generally paralleled by an improvement in the patients' mental state and by an improvement in EEG patterns. The clinical response has been observed in about 75% of patients, which is at least as satisfactory as that resulting from neomycin therapy. An increase in patients' protein tolerance is also frequently observed with lactulose solution therapy. In the treatment of chronic portal-systemic encephalopathy, lactulose solution has been given for over 2 years in controlled studies. uuid:d8c17bf9-9a13-4a1f-b5be-13663ffad0dd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6359 biolink:treats HP:0001259 PMID:41385096 "[{""id"":""uuid:4134f3d4-4ec1-40eb-b600-8655d82ea7d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:95ed202e-a622-4248-bbac-2f3a1a914afb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the prevention and treatment of portal-systemic encephalopathy, including the stages of hepatic pre-coma and coma. Controlled studies have shown that lactulose solution therapy reduces the blood ammonia levels by 25 to 50%; this is generally paralleled by an improvement in the patients' mental state and by an improvement in EEG patterns. The clinical response has been observed in about 75% of patients, which is at least as satisfactory as that resulting from neomycin therapy. An increase in patients' protein tolerance is also frequently observed with lactulose solution therapy. In the treatment of chronic portal-systemic encephalopathy, lactulose solution has been given for over 2 years in controlled studies. uuid:b02328f5-778b-4035-85df-10c0476c5e60 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31663 biolink:treats MONDO:0005093 PMID:41385096 "[{""id"":""uuid:2d10b666-1f74-44e6-b6cd-cfbe40e37ab1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7d3f0337-f8f2-43f3-a17f-1e3de9a03931"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] HALOG (Halcinonide Cream, USP) 0.1% is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. uuid:481bf5c0-f3d2-4f7a-acd5-080140eebf9b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5383 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:a415477a-d4de-4b06-ac5e-14eaa76f0aeb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9c02ffd8-9625-450d-9fac-22fb988d9c19"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Glimepiride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [see Clinical Studies ( 14.1)]. 1.1 Important Limitations of Use Glimepiride tablets should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis, as it would not be effective in these settings. uuid:01d48b39-0e56-4115-8192-a7551ae6d5de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5383 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:b9d7df8b-00b8-42c4-ab66-73126c3a4fea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:91e06f82-afe7-4097-86d2-1964c992dc69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Glimepiride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [see Clinical Studies ( 14.1)]. 1.1 Important Limitations of Use Glimepiride tablets should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis, as it would not be effective in these settings. uuid:d2481b35-8ede-47ef-9552-3982dbc9bf75 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5383 biolink:treats MONDO:0012819 PMID:41385096 "[{""id"":""uuid:6c11644f-8507-4911-a218-0cc252c67820"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:82593a42-1b79-4d39-844f-53f5aee3aaeb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Glimepiride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [see Clinical Studies ( 14.1)]. 1.1 Important Limitations of Use Glimepiride tablets should not be used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis, as it would not be effective in these settings. uuid:0c1adab8-bcde-4487-a748-167911e60de0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1119566 biolink:treats MONDO:0005347 PMID:41385096 "[{""id"":""uuid:3473c377-8bb8-48a2-bd20-c0f60f14ff02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e1954bd2-d31a-46d3-9d71-6030c062acb5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Omega-3-acid ethyl esters capsules, USP are indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia (HTG). Usage Considerations : Patients should be placed on an appropriate lipid-lowering diet before receiving omega-3-acid ethyl esters capsules, USP and should continue this diet during treatment with omega-3-acid ethyl esters capsules, USP. Laboratory studies should be done to ascertain that the lipid levels are consistently abnormal before instituting therapy with omega-3-acid ethyl esters. Every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that are contributing to the lipid abnormalities. Medications known to exacerbate hypertriglyceridemia (such as beta blockers, thiazides, estrogens) should be discontinued or changed if possible prior to consideration of triglyceride-lowering drug therapy. Limitations of Use: Sections or subsections omitted from the full prescribing information are not listed. The effect of omega-3-acid ethyl esters capsules, USP on the risk for pancreatitis has not been determined. The effect of omega-3-acid ethyl esters capsules, USP on cardiovascular mortality and morbidity has not been determined. uuid:6799ffc2-9e6a-401a-a14c-971d6184ca93 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1119566 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:52d5d5d2-4e50-4640-9820-d33c6d57f9c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b286421c-8e7a-402e-ad13-defc9fdc88dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Omega-3-acid ethyl esters capsules, USP are indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia (HTG). Usage Considerations : Patients should be placed on an appropriate lipid-lowering diet before receiving omega-3-acid ethyl esters capsules, USP and should continue this diet during treatment with omega-3-acid ethyl esters capsules, USP. Laboratory studies should be done to ascertain that the lipid levels are consistently abnormal before instituting therapy with omega-3-acid ethyl esters. Every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that are contributing to the lipid abnormalities. Medications known to exacerbate hypertriglyceridemia (such as beta blockers, thiazides, estrogens) should be discontinued or changed if possible prior to consideration of triglyceride-lowering drug therapy. Limitations of Use: Sections or subsections omitted from the full prescribing information are not listed. The effect of omega-3-acid ethyl esters capsules, USP on the risk for pancreatitis has not been determined. The effect of omega-3-acid ethyl esters capsules, USP on cardiovascular mortality and morbidity has not been determined. uuid:0f8fe435-37a0-455f-86ba-c959c814f8c0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1119566 biolink:treats MONDO:0005420 PMID:41385096 "[{""id"":""uuid:be5a26f9-5d33-4c82-a366-1c901ffbd4be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f4308051-1cd7-4d3b-9105-2c9b585406b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Omega-3-acid ethyl esters capsules, USP are indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia (HTG). Usage Considerations : Patients should be placed on an appropriate lipid-lowering diet before receiving omega-3-acid ethyl esters capsules, USP and should continue this diet during treatment with omega-3-acid ethyl esters capsules, USP. Laboratory studies should be done to ascertain that the lipid levels are consistently abnormal before instituting therapy with omega-3-acid ethyl esters. Every attempt should be made to control serum lipids with appropriate diet, exercise, weight loss in obese patients, and control of any medical problems such as diabetes mellitus and hypothyroidism that are contributing to the lipid abnormalities. Medications known to exacerbate hypertriglyceridemia (such as beta blockers, thiazides, estrogens) should be discontinued or changed if possible prior to consideration of triglyceride-lowering drug therapy. Limitations of Use: Sections or subsections omitted from the full prescribing information are not listed. The effect of omega-3-acid ethyl esters capsules, USP on the risk for pancreatitis has not been determined. The effect of omega-3-acid ethyl esters capsules, USP on cardiovascular mortality and morbidity has not been determined. uuid:c27448cb-8888-4004-8523-f4b6392e79c3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:44476258 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:24f8ddd6-5274-4ea6-baa3-cd500d3827af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6368c83c-f4ff-43ca-a88c-872c878144b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets are indicated for the treatment of hypertension, alone or with other antihypertensive agents, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Limitations of Use This fixed combination drug is not indicated for the initial therapy of hypertension. uuid:28f63cf7-f146-492f-908b-e4fc16e9d588 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:44476258 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:5eec2bcf-6d0a-44ed-8afe-20591748b92c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6b3e17f4-d035-4eee-97e7-34f5fe069902"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets are indicated for the treatment of hypertension, alone or with other antihypertensive agents, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Limitations of Use This fixed combination drug is not indicated for the initial therapy of hypertension. uuid:cd5900e3-5f5c-44fa-bf8e-99ba866c478d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:44476258 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:d0997d0e-8297-4638-8a8a-7f262410ea99"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:861d3a72-ee40-4ae8-b09f-40d770a4020c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets are indicated for the treatment of hypertension, alone or with other antihypertensive agents, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Limitations of Use This fixed combination drug is not indicated for the initial therapy of hypertension. uuid:b7f480e0-4c86-46b2-b90a-7fc97f396db7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:44476258 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:233bef2d-6771-4341-9d38-2847c13137b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c057184c-cc12-4d4d-a5ca-d17d46c6e262"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets are indicated for the treatment of hypertension, alone or with other antihypertensive agents, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Limitations of Use This fixed combination drug is not indicated for the initial therapy of hypertension. uuid:5830be8a-4027-4b73-9562-2a222982bf23 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:137329 biolink:treats HP:0002140 PMID:41385096 "[{""id"":""uuid:f9913c97-f28e-4fa9-9a6a-0c0c57916ad9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3f8b11d4-587b-41ec-a3aa-75f459f2b0c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Aspirin and extended-release dipyridamole capsules are indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis. uuid:4cc70635-642c-444f-8fcd-2c7cb3bc6177 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45409 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:1a581b56-666f-4371-82f5-a56ceadb9e18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4957485f-da2b-4937-97d1-122aa1bd278d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NORVIR tablets and oral solution are indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. NORVIR oral powder is indicated in combination with other antiretroviral agents for the treatment of pediatric patients with HIV-1 infection. uuid:a96681b6-df25-4784-9585-84d0aff5612e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3441 biolink:treats MONDO:0010811 PMID:41385096 "[{""id"":""uuid:d4744320-cba3-4258-9914-f0cd2ab9d657"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:287c9384-4b62-4c35-8394-9ec3669bca9a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Monotherapy Finasteride tablets 5 mg are indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to: Improve symptoms Reduce the risk of the need for surgery including transurethral resection of the prostate (TURP) and prostatectomy. 1.2 Combination with Alpha-Blocker Finasteride tablets 5 mg administered in combination with the alpha-blocker doxazosin is indicated to reduce the risk of symptomatic progression of BPH (a confirmed ≥4 point increase in American Urological Association (AUA) symptom score). 1.3 Limitations of Use Finasteride is not approved for the prevention of prostate cancer. uuid:3980c594-1ab1-4a4a-97a3-e0af254346f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3441 biolink:treats MONDO:0008315 PMID:41385096 "[{""id"":""uuid:716c8c51-ced5-406b-945c-17c0b4f3e617"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b55ee610-5026-4ed4-bb40-dccd4d395ed6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Monotherapy Finasteride tablets 5 mg are indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to: Improve symptoms Reduce the risk of the need for surgery including transurethral resection of the prostate (TURP) and prostatectomy. 1.2 Combination with Alpha-Blocker Finasteride tablets 5 mg administered in combination with the alpha-blocker doxazosin is indicated to reduce the risk of symptomatic progression of BPH (a confirmed ≥4 point increase in American Urological Association (AUA) symptom score). 1.3 Limitations of Use Finasteride is not approved for the prevention of prostate cancer. uuid:e8eca3c2-68c1-4a38-a34e-4a9c865992d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76010 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:414e3f64-a132-4e9c-9d0e-a5a732458ed0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6edeeb78-3329-4e18-be3d-b4baf1c4553c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7cca07ca-1b5f-428e-b27a-d148479dd702"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tivicay""]},{""id"":""uuid:835865b0-e68e-44b2-813d-822ef52fbf5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TIVICAY is indicated in combination with: • other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and in pediatric patients weighing at least 30 kg [see Microbiology ( 12.4 )] . • rilpivirine as a complete regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure or known substitutions associated with resistance to either antiretroviral agent.|[EMA] Tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults, adolescents and children of at least 6 years of age or older and weighing at least 14 kg.Tivicay is indicated in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected adults, adolescents and children of at least 4 weeks of age or older and weighing at least 3 kg.|[PMDA] A drug with a new active ingredient indicated for the treatment of HIV infection. [Orphan drug] uuid:9bc5ce3e-a103-455d-9b95-003d8f07eed6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76010 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:7f326005-6ae1-4cc5-aaa3-da46958ee54e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8c3b73db-ee31-45e5-ba2c-2be3a0431935"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TIVICAY is indicated in combination with: • other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and in pediatric patients weighing at least 30 kg [see Microbiology ( 12.4 )] . • rilpivirine as a complete regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure or known substitutions associated with resistance to either antiretroviral agent. uuid:920bb085-c9b5-4b16-ad49-56f97202920e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0008109 PMID:41385096 "[{""id"":""uuid:5c87046b-2e3a-4983-98bb-2621eacac225"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6501c610-3e1e-47cd-ac33-31f2c30b0ca0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Prednisolone sodium phosphate oral solution is indicated in the following conditions: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. Dermatologic Diseases: Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. Edematous States: To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. Gastrointestinal Diseases: To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. Hematologic Disorders: Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. Neoplastic Diseases: For the treatment of acute leukemia and aggressive lymphomas in adults and children. Nervous System: Acute exacerbations of multiple sclerosis. Ophthalmic Diseases: Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. Respiratory Diseases: Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under "" Allergic States ""), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. Rheumatic Disorders: As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren's syndrome, relapsing polychrondritis, and certain cases of vasculitis. Miscellaneous: Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); Trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents)." uuid:44af917d-fe99-4bbd-a2ff-51dd49f70b06 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5801 biolink:treats MONDO:0005136 PMID:41385096 "[{""id"":""uuid:8a08e0f3-77fe-4e68-81d6-aad1fe833049"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b72609ce-b35c-45be-80e6-0fe51cab56d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Malaria Hydroxychloroquine sulfate tablets are indicated for the treatment of uncomplicated malaria due to P. falclparum, P. malariae, P. ovale, and P. vlvax. Hydroxychloroquine sulfate tablets are indicated for the prophylaxis of malaria in geographic areas where chloroquine resistance is not reported. Limitations of Use in Malaria • Hydroxychloroquine sulfate tablets are not recommended for the treatment of complicated malaria. • Hydroxychloroquine sulfate tablets are not effective against chloroquine or hydroxychloroquine-resistant strains of Plasmodium species ( see CLINICAL PHARMACOLOGY - Microbiology ). Hydroxychloroquine sulfate tablets are not recommended for the treatment of malaria acquired in geographic areas where chloroquine resistance occurs or when the Plasmodium species has not been identified. • Hydroxychloroquine sulfate tablets are not recommended for malaria prophylaxis in geographic areas where chloroquine resistance occurs. • Hydroxychloroquine sulfate tablets do not prevent relapses of P. vivaxor P. ovale because it is not active againstthe hypnozoite forms of these parasites. Forradical cure of P. vivaxand P. ovale infections, concomitant therapy with an 8-aminoquinoline compound is necessary (see CLINICAL PHARMACOLOGY - Microbiology ). Prior to prescribing hydroxychloroquine sulfate tablets for the treatment or prophylaxis of malaria, consult the Centers for Disease Control and Prevention (CDC) Malaria website ( http://www.cdc.gov/malaria ). Lupus Erythematosus Hydroxychloroquine sulfate tablets are indicated for the treatment of chronic discoid lupus erythematosus and systemic lupus erythematosus in adults. Rheumatoid Arthritis Hydroxychloroquine sulfate tablets are indicated for the treatment of acute and chronic rheumatoid arthritis in adults. uuid:d95f8cab-25ae-438f-a0cd-3382dfec6c0e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5801 biolink:treats UMLS:C5554310 PMID:41385096 "[{""id"":""uuid:d656ab46-9323-45e4-9ba7-863d0a6d602c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a01e73b3-9722-4529-abbf-dc4284a46f20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Malaria Hydroxychloroquine sulfate tablets are indicated for the treatment of uncomplicated malaria due to P. falclparum, P. malariae, P. ovale, and P. vlvax. Hydroxychloroquine sulfate tablets are indicated for the prophylaxis of malaria in geographic areas where chloroquine resistance is not reported. Limitations of Use in Malaria • Hydroxychloroquine sulfate tablets are not recommended for the treatment of complicated malaria. • Hydroxychloroquine sulfate tablets are not effective against chloroquine or hydroxychloroquine-resistant strains of Plasmodium species ( see CLINICAL PHARMACOLOGY - Microbiology ). Hydroxychloroquine sulfate tablets are not recommended for the treatment of malaria acquired in geographic areas where chloroquine resistance occurs or when the Plasmodium species has not been identified. • Hydroxychloroquine sulfate tablets are not recommended for malaria prophylaxis in geographic areas where chloroquine resistance occurs. • Hydroxychloroquine sulfate tablets do not prevent relapses of P. vivaxor P. ovale because it is not active againstthe hypnozoite forms of these parasites. Forradical cure of P. vivaxand P. ovale infections, concomitant therapy with an 8-aminoquinoline compound is necessary (see CLINICAL PHARMACOLOGY - Microbiology ). Prior to prescribing hydroxychloroquine sulfate tablets for the treatment or prophylaxis of malaria, consult the Centers for Disease Control and Prevention (CDC) Malaria website ( http://www.cdc.gov/malaria ). Lupus Erythematosus Hydroxychloroquine sulfate tablets are indicated for the treatment of chronic discoid lupus erythematosus and systemic lupus erythematosus in adults. Rheumatoid Arthritis Hydroxychloroquine sulfate tablets are indicated for the treatment of acute and chronic rheumatoid arthritis in adults. uuid:c839270f-6fbf-430a-84d2-2ccdb538b52c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5801 biolink:treats MONDO:0019558 PMID:41385096 "[{""id"":""uuid:b7270738-523b-4fed-a63f-688297b56d2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0061a866-7410-466e-888a-72f71c3e2a82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Malaria Hydroxychloroquine sulfate tablets are indicated for the treatment of uncomplicated malaria due to P. falclparum, P. malariae, P. ovale, and P. vlvax. Hydroxychloroquine sulfate tablets are indicated for the prophylaxis of malaria in geographic areas where chloroquine resistance is not reported. Limitations of Use in Malaria • Hydroxychloroquine sulfate tablets are not recommended for the treatment of complicated malaria. • Hydroxychloroquine sulfate tablets are not effective against chloroquine or hydroxychloroquine-resistant strains of Plasmodium species ( see CLINICAL PHARMACOLOGY - Microbiology ). Hydroxychloroquine sulfate tablets are not recommended for the treatment of malaria acquired in geographic areas where chloroquine resistance occurs or when the Plasmodium species has not been identified. • Hydroxychloroquine sulfate tablets are not recommended for malaria prophylaxis in geographic areas where chloroquine resistance occurs. • Hydroxychloroquine sulfate tablets do not prevent relapses of P. vivaxor P. ovale because it is not active againstthe hypnozoite forms of these parasites. Forradical cure of P. vivaxand P. ovale infections, concomitant therapy with an 8-aminoquinoline compound is necessary (see CLINICAL PHARMACOLOGY - Microbiology ). Prior to prescribing hydroxychloroquine sulfate tablets for the treatment or prophylaxis of malaria, consult the Centers for Disease Control and Prevention (CDC) Malaria website ( http://www.cdc.gov/malaria ). Lupus Erythematosus Hydroxychloroquine sulfate tablets are indicated for the treatment of chronic discoid lupus erythematosus and systemic lupus erythematosus in adults. Rheumatoid Arthritis Hydroxychloroquine sulfate tablets are indicated for the treatment of acute and chronic rheumatoid arthritis in adults. uuid:86ceff09-7db8-466d-a4d2-95fd09b9f16d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5801 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:6eb06254-4a73-4cbc-88a5-b8876cb8953c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:99f4e0db-9002-42d1-a127-e5db7bba7431"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Malaria Hydroxychloroquine sulfate tablets are indicated for the treatment of uncomplicated malaria due to P. falclparum, P. malariae, P. ovale, and P. vlvax. Hydroxychloroquine sulfate tablets are indicated for the prophylaxis of malaria in geographic areas where chloroquine resistance is not reported. Limitations of Use in Malaria • Hydroxychloroquine sulfate tablets are not recommended for the treatment of complicated malaria. • Hydroxychloroquine sulfate tablets are not effective against chloroquine or hydroxychloroquine-resistant strains of Plasmodium species ( see CLINICAL PHARMACOLOGY - Microbiology ). Hydroxychloroquine sulfate tablets are not recommended for the treatment of malaria acquired in geographic areas where chloroquine resistance occurs or when the Plasmodium species has not been identified. • Hydroxychloroquine sulfate tablets are not recommended for malaria prophylaxis in geographic areas where chloroquine resistance occurs. • Hydroxychloroquine sulfate tablets do not prevent relapses of P. vivaxor P. ovale because it is not active againstthe hypnozoite forms of these parasites. Forradical cure of P. vivaxand P. ovale infections, concomitant therapy with an 8-aminoquinoline compound is necessary (see CLINICAL PHARMACOLOGY - Microbiology ). Prior to prescribing hydroxychloroquine sulfate tablets for the treatment or prophylaxis of malaria, consult the Centers for Disease Control and Prevention (CDC) Malaria website ( http://www.cdc.gov/malaria ). Lupus Erythematosus Hydroxychloroquine sulfate tablets are indicated for the treatment of chronic discoid lupus erythematosus and systemic lupus erythematosus in adults. Rheumatoid Arthritis Hydroxychloroquine sulfate tablets are indicated for the treatment of acute and chronic rheumatoid arthritis in adults. uuid:a5e3a57d-8f78-4b7c-ba54-43d4e3870e99 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18332 biolink:treats MONDO:1010100 PMID:41385096 "[{""id"":""uuid:fb29a559-7e09-4546-b312-23ba0c5f1d83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a7aeacc2-ac85-41ed-9620-b46672f55bac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d6e51923-54bd-41df-b853-aed3dd96cc79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levothyroxine Sodium for Injection is indicated for the treatment of myxedema coma. Important Limitations of Use: The relative bioavailability between Levothyroxine Sodium for Injection and oral levothyroxine products has not been established. Caution should be used when switching patients from oral levothyroxine products to Levothyroxine Sodium for Injection as accurate dosing conversion has not been studied.|[PMDA] A drug with a new route of administration indicated for the treatment of myxedema coma and hypothyroidism (for hypothyroidism, only in patients ineligible for oral levothyroxine sodium therapy). UMLS:C0238298 uuid:1cb6e950-8c01-4c9f-8dec-5eaf5f6d43c5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32111 biolink:treats MONDO:0005276 PMID:41385096 "[{""id"":""uuid:dd6226ec-641b-4a6d-b27c-d74ffc53c9f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0b0a1b3a-9ce0-470c-8d56-be2a28e31790"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Aids in the prevention of dental cavities. This is an anti-cavity (preventive treatment gel, not a toothpaste. Read directions carefully before using. Clinical studies have shown that 1.1% sodium fluoride is safe and effective as an anti-cavity agent when used topically. This product should be applied with a toothbrush after brushing with a dentifrice toothpaste. It can be used in areas where drinking water is fluoridated since topical fluorides do not produce fluorosis when used as directed. Adults and children 6 years of age and older: Use once daily after brushing with a dentifrice toothpaste. Apply a thin ribbon of gel to toothbrush and brush teeth thoroughly. Allow the gel to reamin on your teeth for 1 minute and then spit out. Do not swallow gel. For best effectiveness, do not eat or drink for 30 minutes after brushing. Supervise children less than 12 years of age as necessary when using this product to minimize swallowing. Children under 6 years of age - consult a dentist or physician. uuid:d04c0aeb-1590-4089-89b8-f0ec7a886909 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:RWM8CCW8GP biolink:treats MONDO:0000249 PMID:41385096 "[{""id"":""uuid:e7d9b276-8cf1-4225-af33-d8048c5b7d1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eb915a09-25fa-4433-aad4-cbb05c682262"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acromegaly Octreotide acetate injection is indicated to reduce blood levels of growth hormone and IGF-I (somatomedin C) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses. The goal is to achieve normalization of growth hormone and IGF-I (somatomedin C) levels (see DOSAGE AND ADMINISTRATION ). In patients with acromegaly, octreotide acetate injection reduces growth hormone to within normal ranges in 50% of patients and reduces IGF-I (somatomedin C) to within normal ranges in 50% to 60% of patients. Since the effects of pituitary irradiation may not become maximal for several years, adjunctive therapy with octreotide acetate injection to reduce blood levels of growth hormone and IGF-I (somatomedin C) offers potential benefit before the effects of irradiation are manifested. Improvement in clinical signs and symptoms or reduction in tumor size or rate of growth were not shown in clinical trials performed with octreotide acetate injection; these trials were not optimally designed to detect such effects. Carcinoid Tumors Octreotide acetate injection is indicated for the symptomatic treatment of patients with metastatic carcinoid tumors where it suppresses or inhibits the severe diarrhea and flushing episodes associated with the disease. Octreotide acetate injection studies were not designed to show an effect on the size, rate of growth or development of metastases. Vasoactive Intestinal Peptide Tumors (VIPomas) Octreotide acetate injection is indicated for the treatment of the profuse watery diarrhea associated with VIP-secreting tumors. Octreotide acetate injection studies were not designed to show an effect on the size, rate of growth or development of metastases. uuid:f290f41f-03f5-4f97-9bc9-47ed098f989f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats NCIT:C50743 PMID:41385096 "[{""id"":""uuid:05ba0e33-b3f1-4432-83c0-8071bf8d1972"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:323b599c-b9c1-4409-99b3-35a94b7425e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the temporary relief of pain and itching associated with minor burns, sunburn, minor cuts, scrapes, insect bites, and minor skin irritation. uuid:eb64aecf-3370-4fbb-b256-f2443de57d08 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16134 biolink:treats HP:0001279 PMID:41385096 "[{""id"":""uuid:6f104aec-e5de-4cc0-b359-71ba5822b48a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d3ca31be-7cae-4950-aa78-e0d2c6d1a55a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To prevent or treat fainting uuid:58efac8d-d5e6-4e71-92f2-26168f93abd1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29108 biolink:treats HP:0002901 PMID:41385096 "[{""id"":""uuid:465d18c4-861f-4e13-a625-8e07a7b9b0f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:be1a0975-7939-4f49-a31f-3ef0393bacfe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Calcium Gluconate Injection is indicated for pediatric and adult patients for the treatment of acute symptomatic hypocalcemia. Limitations of Use The safety of Calcium Gluconate Injection for long term use has not been established. uuid:d54df665-4140-4b91-b779-23d22d6e78d2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats MONDO:0006566 PMID:41385096 "[{""id"":""uuid:7f1b39fe-05b5-4c2b-aeb9-796d99525279"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:517f5dfc-3904-4b90-aab2-fbf5f743127d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS: For the topical treatmentof active keratosis. uuid:736ccbfe-5c0f-44d7-8272-3164a34c3796 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats HP:0003326 PMID:41385096 "[{""id"":""uuid:036050c6-b760-4d03-bd38-6748eb145496"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:17d2c5ed-8899-4172-b787-55935d12ef2d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] USES: FOR THE TEMPORARY RELIEF OF MINOR ACHES AND PAINS OF MUSCLES AND JOINTS ASSOCIATED WITH ARTHRITIS, SIMPLE BACKACHE, STRAINS, SPRAINS, MUSCLE SORENESS AND STIFFNESS. uuid:1c244400-bd98-42e4-b684-7a153153994f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats HP:0003552 PMID:41385096 "[{""id"":""uuid:55af2b77-883f-42b8-a849-8e322251b17b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a92dbc71-0558-4e6b-80b0-2af789ffc3ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] USES: FOR THE TEMPORARY RELIEF OF MINOR ACHES AND PAINS OF MUSCLES AND JOINTS ASSOCIATED WITH ARTHRITIS, SIMPLE BACKACHE, STRAINS, SPRAINS, MUSCLE SORENESS AND STIFFNESS. uuid:296f192f-b5ff-4221-a9cc-c518cf21acb1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0005578 PMID:41385096 "[{""id"":""uuid:62f3f250-4c49-4c0f-b77b-7a72719b7a1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:50faa2e1-5cb6-4109-9600-7986abfa042b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] USES: For temporary relief of minor aches and muscle pains associated with arthritis, simple backache, strains, muscle soreness, and stiffness. uuid:42654be8-49f7-412f-a9f1-79df70612f13 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats HP:0003326 PMID:41385096 "[{""id"":""uuid:fd6c0dea-dc30-4f13-a8a3-1c040e4a4e13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ed93b308-14d5-4c35-82c9-2ca06d8e73b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] USES: For temporary relief of minor aches and muscle pains associated with arthritis, simple backache, strains, muscle soreness, and stiffness. uuid:ec8516c3-905d-4482-858a-c24cc21f9767 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats UMLS:C0427008 PMID:41385096 "[{""id"":""uuid:e37663da-32ea-4643-b27a-39f69c71c5e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dff79638-3e08-4bdb-8854-759ca821a4be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] USES: For temporary relief of minor aches and muscle pains associated with arthritis, simple backache, strains, muscle soreness, and stiffness. uuid:243ed418-1120-4740-8f2c-7072d3bf4d51 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2691 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:e1b3d91a-91bf-4328-bc15-9809eb77efc8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c9170967-a45d-4cdb-b17f-b9880536d97e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amyl nitrite is indicated for the rapid relief of angina pectoris. Its effect appears within 30 seconds and lasts for approximately 3 to 5 minutes. uuid:60dd2c02-d111-47d0-8e55-c325108446f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3441 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:02ae1d4f-5dd3-422e-addc-1c3f5e7da0df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4944ef14-3d04-4ca5-aa6f-b5a7c437b279"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Heart Failure Carvedilol tablets are indicated for the treatment of mild-to-severe chronic heart failure of ischemic or cardiomyopathic origin, usually in addition to diuretics, ACE inhibitors, and digitalis, to increase survival and, also, to reduce the risk of hospitalization [see Drug Interactions (7.4), Clinical Studies (14.1)]. 1.2 Left Ventricular Dysfunction following Myocardial Infarction Carvedilol tablets are indicated to reduce cardiovascular mortality in clinically stable patients who have survived the acute phase of a myocardial infarction and have a left ventricular ejection fraction of less than or equal to 40% (with or without symptomatic heart failure) [see Clinical Studies (14.2)]. 1.3 Hypertension Carvedilol tablets are indicated for the management of essential hypertension [see Clinical Studies (14.3, 14.4)]. It can be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics [see Drug Interactions (7.2)]. uuid:56218292-05c1-4afe-85a7-2591984aa205 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45783 biolink:treats MONDO:0011996 PMID:41385096 "[{""id"":""uuid:cee21165-83ab-46f8-96d6-2a1c26e877e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a75e049b-ef6e-4a68-81e7-1297984cd938"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:5b9f5f9f-26e2-4569-82ed-da4df78b43c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/glivec""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Imatinib mesylate is a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase ( 1.1 ) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy ( 1.2 ) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) ( 1.3 ) Adult patients with myelodysplastic/ myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements as determined with an FDA-approved test ( 1.5 ) Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation as determined with an FDA-approved test or with c-Kit mutational status unknown ( 1.6 ) Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown ( 1.7) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP) ( 1.8 )|[EMA] Glivec is indicated for the treatment of, , , adult and paediatric patients with newly diagnosed Philadelphia-chromosome (bcr-abl)-positive (Ph+) chronic myeloid leukaemia (CML) for whom bone-marrow transplantation is not considered as the first line of treatment;, adult and paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult and paediatric patients with newly diagnosed Philadelphia-chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy;, adult patients with relapsed or refractory Ph+ ALL as monotherapy;, adult patients with myelodysplastic / myeloproliferative diseases (MDS / MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (HES) and / or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFRa rearrangement., , , The effect of Glivec on the outcome of bone-marrow transplantation has not been determined., , Glivec is indicated for:, , , the treatment of adult patients with Kit (CD 117)-positive unresectable and / or metastatic malignant gastrointestinal stromal tumours (GIST);, the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST. Patients who have a low or very low risk of recurrence should not receive adjuvant treatment;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and / or metastatic DFSP who are not eligible for surgery., , , In adult and paediatric patients, the effectiveness of Glivec is based on overall haematological and cytogenetic response rates and progression-free survival in CML, on haematological and cytogenetic response rates in Ph+ ALL, MDS / MPD, on haematological response rates in HES / CEL and on objective response rates in adult patients with unresectable and / or metastatic GIST and DFSP and on recurrence-free survival in adjuvant GIST. The experience with Glivec in patients with MDS / MPD associated with PDGFR gene re-arrangements is very limited (see section 5.1). Except in newly diagnosed chronic phase CML, there are no controlled trials demonstrating a clinical benefit or increased survival for these diseases., uuid:7ceb2434-aa7e-48da-b969-26205f657a63 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45783 biolink:treats HP:0004848 PMID:41385096 "[{""id"":""uuid:16babd79-59f7-45bc-be44-86c2d1d3f4f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b83e4d7e-61d8-4201-a264-8b2cc02da4be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Imatinib mesylate is a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase ( 1.1 ) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy ( 1.2 ) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) ( 1.3 ) Adult patients with myelodysplastic/ myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements as determined with an FDA-approved test ( 1.5 ) Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation as determined with an FDA-approved test or with c-Kit mutational status unknown ( 1.6 ) Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown ( 1.7) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP) ( 1.8 ) uuid:b0390b3f-6e11-4f94-88b0-bdf6954fe606 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45783 biolink:treats MONDO:0006311 PMID:41385096 "[{""id"":""uuid:324bf240-2f41-4c39-8c0e-c629194a0a62"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:efb79feb-5f28-4588-953e-409e6dc1f887"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Imatinib mesylate is a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase ( 1.1 ) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy ( 1.2 ) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) ( 1.3 ) Adult patients with myelodysplastic/ myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements as determined with an FDA-approved test ( 1.5 ) Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation as determined with an FDA-approved test or with c-Kit mutational status unknown ( 1.6 ) Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown ( 1.7) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP) ( 1.8 ) uuid:711b5887-90d3-49ec-b59a-af2b57f0e60a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45783 biolink:treats MONDO:0020333 PMID:41385096 "[{""id"":""uuid:0d248d18-291e-46ba-a8fb-bde4b859ad3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5c0832a2-6945-455f-b795-c7d44cc25a98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Imatinib mesylate is a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase ( 1.1 ) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy ( 1.2 ) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) ( 1.3 ) Adult patients with myelodysplastic/ myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements as determined with an FDA-approved test ( 1.5 ) Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation as determined with an FDA-approved test or with c-Kit mutational status unknown ( 1.6 ) Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown ( 1.7) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP) ( 1.8 ) uuid:ac7cc978-bb15-4c5c-b160-a3fa17082c9f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45783 biolink:treats MONDO:0011895 PMID:41385096 "[{""id"":""uuid:31dcbd38-1a33-4825-aaf5-3aabd65a1cd1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ff2a8364-bcf8-4d84-864d-25559586d44c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Imatinib mesylate is a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase ( 1.1 ) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy ( 1.2 ) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) ( 1.3 ) Adult patients with myelodysplastic/ myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements as determined with an FDA-approved test ( 1.5 ) Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation as determined with an FDA-approved test or with c-Kit mutational status unknown ( 1.6 ) Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown ( 1.7) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP) ( 1.8 ) uuid:4d86fc55-a482-4ce7-b71c-7596acf1b9fa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45783 biolink:treats MONDO:0015687 PMID:41385096 "[{""id"":""uuid:4b7a61e9-ebc2-488e-85f1-69b342a2ab0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e2af174b-fe0d-4630-88ff-1a184f9cde1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4ba8955e-a831-4a06-a531-be40485cfd61"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/glivec""]},{""id"":""uuid:3f3c5e2f-61ab-4c58-94ca-decf77c41fc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Imatinib mesylate is a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase ( 1.1 ) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy ( 1.2 ) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) ( 1.3 ) Adult patients with myelodysplastic/ myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements as determined with an FDA-approved test ( 1.5 ) Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation as determined with an FDA-approved test or with c-Kit mutational status unknown ( 1.6 ) Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown ( 1.7) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP) ( 1.8 )|[EMA] Glivec is indicated for the treatment of, , , adult and paediatric patients with newly diagnosed Philadelphia-chromosome (bcr-abl)-positive (Ph+) chronic myeloid leukaemia (CML) for whom bone-marrow transplantation is not considered as the first line of treatment;, adult and paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult and paediatric patients with newly diagnosed Philadelphia-chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy;, adult patients with relapsed or refractory Ph+ ALL as monotherapy;, adult patients with myelodysplastic / myeloproliferative diseases (MDS / MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (HES) and / or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFRa rearrangement., , , The effect of Glivec on the outcome of bone-marrow transplantation has not been determined., , Glivec is indicated for:, , , the treatment of adult patients with Kit (CD 117)-positive unresectable and / or metastatic malignant gastrointestinal stromal tumours (GIST);, the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST. Patients who have a low or very low risk of recurrence should not receive adjuvant treatment;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and / or metastatic DFSP who are not eligible for surgery., , , In adult and paediatric patients, the effectiveness of Glivec is based on overall haematological and cytogenetic response rates and progression-free survival in CML, on haematological and cytogenetic response rates in Ph+ ALL, MDS / MPD, on haematological response rates in HES / CEL and on objective response rates in adult patients with unresectable and / or metastatic GIST and DFSP and on recurrence-free survival in adjuvant GIST. The experience with Glivec in patients with MDS / MPD associated with PDGFR gene re-arrangements is very limited (see section 5.1). Except in newly diagnosed chronic phase CML, there are no controlled trials demonstrating a clinical benefit or increased survival for these diseases.,|[PMDA] A drug with new additional indications and a new dosage for the treatment of FIP1L1-PDGFRα- positive hypereosinophilic syndrome or chronic eosinophilic leukemia. [Public knowledge-based application after PAFSC's preliminary assessment] [Orphan drug] uuid:81a7728a-080a-4b8d-89ee-230b47ca9ff7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45783 biolink:treats MONDO:0011934 PMID:41385096 "[{""id"":""uuid:334757d5-f40c-4a0d-aee4-b62f54a5a699"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:7cd81d83-6a59-4457-bb9e-82c3bead8a88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:bcddcb60-e504-4138-836b-b7ec12af3977"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/glivec""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Imatinib mesylate is a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase ( 1.1 ) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy ( 1.2 ) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) ( 1.3 ) Adult patients with myelodysplastic/ myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements as determined with an FDA-approved test ( 1.5 ) Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation as determined with an FDA-approved test or with c-Kit mutational status unknown ( 1.6 ) Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1-PDGFRα fusion kinase negative or unknown ( 1.7) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP) ( 1.8 )|[EMA] Glivec is indicated for the treatment of, , , adult and paediatric patients with newly diagnosed Philadelphia-chromosome (bcr-abl)-positive (Ph+) chronic myeloid leukaemia (CML) for whom bone-marrow transplantation is not considered as the first line of treatment;, adult and paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult and paediatric patients with newly diagnosed Philadelphia-chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy;, adult patients with relapsed or refractory Ph+ ALL as monotherapy;, adult patients with myelodysplastic / myeloproliferative diseases (MDS / MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (HES) and / or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFRa rearrangement., , , The effect of Glivec on the outcome of bone-marrow transplantation has not been determined., , Glivec is indicated for:, , , the treatment of adult patients with Kit (CD 117)-positive unresectable and / or metastatic malignant gastrointestinal stromal tumours (GIST);, the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST. Patients who have a low or very low risk of recurrence should not receive adjuvant treatment;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and / or metastatic DFSP who are not eligible for surgery., , , In adult and paediatric patients, the effectiveness of Glivec is based on overall haematological and cytogenetic response rates and progression-free survival in CML, on haematological and cytogenetic response rates in Ph+ ALL, MDS / MPD, on haematological response rates in HES / CEL and on objective response rates in adult patients with unresectable and / or metastatic GIST and DFSP and on recurrence-free survival in adjuvant GIST. The experience with Glivec in patients with MDS / MPD associated with PDGFR gene re-arrangements is very limited (see section 5.1). Except in newly diagnosed chronic phase CML, there are no controlled trials demonstrating a clinical benefit or increased survival for these diseases., uuid:255b8009-a24b-4618-889e-81363f952aae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9831783 biolink:treats MONDO:0005180 PMID:41385096 "[{""id"":""uuid:a2f4a7a4-3c8b-4a4f-bf41-c4189555f0bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:251aa54d-d8b3-468c-a685-153b94fe560c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carbidopa, levodopa and entacapone tablets, a combination drug consisting of levodopa, carbidopa (dopa decarboxylase inhibitor), and entacapone (catechol-O-methyltransferase-COMT inhibitor) is indicated for the treatment of Parkinson’s disease. Carbidopa, levodopa and entacapone tablets can be used: To substitute (with equivalent strengths of each of the three components) carbidopa/levodopa and entacapone previously administered as individual products. To replace carbidopa/levodopa therapy (without entacapone) when patients experience the signs and symptoms of end-of-dose “wearing-off” and when they have been taking a total daily dose of levodopa of 600 mg or less and have not been experiencing dyskinesias. uuid:3a660535-eaa8-437f-a2af-6cf0e73cbafa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6367 biolink:treats MONDO:0005027 PMID:41385096 "[{""id"":""uuid:034adb86-e399-4fb3-8826-569c98bf6604"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:862f3250-3680-4e3d-b5b9-94fd47db7fad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:8f193892-b7ef-4ad7-8029-a0b19f397822"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Epilepsy Adjunctive Therapy Lamotrigine tablets, USP is indicated as adjunctive therapy for the following seizure types in patients aged 2 years and older: Monotherapy Lamotrigine tablets, USP is indicated for conversion to monotherapy in adults (aged 16 years and older) with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug (AED). Safety and effectiveness of lamotrigine tablets, USP have not been established (1) as initial monotherapy; (2) for conversion to monotherapy from AEDs other than carbamazepine, phenytoin, phenobarbital, primidone, or valproate; or (3) for simultaneous conversion to monotherapy from 2 or more concomitant AEDs. 1.2 Bipolar Disorder Lamotrigine tablets, USP is indicated for the maintenance treatment of Bipolar I disorder to delay the time to occurrence of mood episodes (depression, mania, hypomania, mixed episodes) in patients treated for acute mood episodes with standard therapy [SEE CLINICAL STUDIES (14.1)]. Limitations of Use Treatment of acute manic or mixed episodes is not recommended. Effectiveness of lamotrigine tablets, USP in the acute treatment of mood episodes has not been established.|[PMDA] Drugs with a new additional indication and a new dosage for use in the monotherapy for treatment of partial seizures (including secondary generalized seizure) and tonic-clonic seizures in patients with epilepsy. uuid:78001273-5abc-4442-b4cc-145c7b5b7d99 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9887103 biolink:treats HP:0001662 PMID:41385096 "[{""id"":""uuid:8dcaae33-4bf8-4e77-bfc4-6fd27538e60d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:41244f57-9949-4838-97fa-ea4babcf8c1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In Anesthesia Glycopyrrolate injection is indicated for use as a preoperative antimuscarinic to reduce salivary, tracheobronchial, and pharyngeal secretions; to reduce the volume and free acidity of gastric secretions; and to block cardiac vagal inhibitory reflexes during induction of anesthesia and intubation. When indicated, glycopyrrolate injection may be used intraoperatively to counteract surgically or drug-induced or vagal reflexes associated arrhythmias. Glycopyrrolate protects against the peripheral muscarinic effects (e.g., bradycardia and excessive secretions) of cholinergic agents such as neostigmine and pyridostigmine given to reverse the neuromuscular blockade due to non-depolarizing muscle relaxants. In Peptic Ulcer For use in adults as adjunctive therapy for the treatment of peptic ulcer when rapid anticholinergic effect is desired or when oral medication is not tolerated. uuid:25b92002-671f-46b7-ad9a-4c33eaec58d2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8665 biolink:treats MONDO:0009688 PMID:41385096 "[{""id"":""uuid:cdc50169-6c10-4f7c-8e41-07103d804bfc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6b83f63f-e744-471f-a520-84f753c3646e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pyridostigmine Bromide Oral Solution, USP is useful in the treatment of myasthenia gravis. uuid:0fceba19-8cb3-47c6-93ef-ca4d562752d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63619 biolink:treats HP:0004754 PMID:41385096 "[{""id"":""uuid:b798a27e-6335-4e0a-be51-08f412eb530b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a81025fd-7dc7-4a2b-a1a3-5d8396f0bff7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Propafenone hydrochloride is indicated to: prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. prolong the time to recurrence of paroxysmal supraventricular tachycardia (PSVT) associated with disabling symptoms in patients without structural heart disease. treat documented ventricular arrhythmias, such as sustained ventricular tachycardia that, in the judgment of the physician, are life-threatening. Initiate treatment in the hospital. Usage Considerations: The use of propafenone hydrochloride tablets in patients with permanent atrial fibrillation (AF) or in patients exclusively with atrial flutter or PSVT has not been evaluated. Do not use propafenone hydrochloride tablets to control ventricular rate during AF. Some patients with atrial flutter treated with propafenone have developed 1:1 conduction, producing an increase in ventricular rate. Concomitant treatment with drugs that increase the functional atrioventricular (AV) nodal refractory period is recommended. The use of propafenone hydrochloride tablets in patients with chronic atrial fibrillation has not been evaluated. Because of the proarrhythmic effects of propafenone hydrochloride, its use with lesser ventricular arrhythmias is not recommended, even if patients are symptomatic, and any use of the drug should be reserved for patients in whom, in the opinion of the physician, the potential benefits outweigh the risks. The effect of propafenone on mortality has not been determined [see Boxed Warning ]. uuid:d7ec47d2-62a5-42b8-aed2-28c9b57941db biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16240 biolink:treats MONDO:0008420 PMID:41385096 "[{""id"":""uuid:ecc7fc68-5991-48a7-aeec-4f14133be330"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8019fdaf-9353-4555-92a5-dba4a5fa90b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ESKATA is indicated for the treatment of seborrheic keratoses that are raised. uuid:553e7207-5e2d-4cf2-8f8e-34080774b7b0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB09422 biolink:treats UMLS:C0342919 PMID:41385096 "[{""id"":""uuid:0f8732c7-895c-4f54-a628-58473ff49193"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:50d513d1-4af8-4872-9a34-f2313a5a5ddb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intralipid ® 20% Pharmacy Bulk Package is indicated for use in a pharmacy admixture program for the preparation of three-inone or total nutrition admixtures (TNAs) to provide a source of calories and essential fatty acids for patients requiring parenteral nutrition for extended periods of time (usually for more than 5 days) and a source of essential fatty acids for prevention of EFAD. uuid:70e13345-67e7-4578-b4f1-27282eafe000 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0005096 PMID:41385096 "[{""id"":""uuid:a6fe5a66-b545-46b0-a471-e249cc73008d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:75c446bd-20f5-46f0-bee6-f232b26c6f91"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin for injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for injection has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:e4651868-d400-4f05-b9a7-3f427d1710bd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0005627 PMID:41385096 "[{""id"":""uuid:0af43e63-5bda-4260-9bb5-9af35c360f38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:89536580-f510-47ac-bf13-8836684c9a09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin for injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for injection has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:c914beb2-313a-43e0-a3d1-9ecc50abe81f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0005515 PMID:41385096 "[{""id"":""uuid:75112590-5961-4ae0-ac4d-e03946d43ae8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3a894ac7-daa4-42e3-9d9c-3d4d2ef8891f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin for injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for injection has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:5a6a0354-0523-4173-849a-dcb30902b739 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0004631 PMID:41385096 "[{""id"":""uuid:4191f320-0680-4359-bfb8-f95685859d11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7ba8924b-8613-4e9c-9638-45a82437924b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin for injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for injection has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:427362e0-02bf-45d2-8963-9223a1334d27 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0006998 PMID:41385096 "[{""id"":""uuid:345bbdba-a17f-4ee7-a9ac-b605ffce73cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5a5494d9-350a-4a74-bc57-b00054ec8c1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin for injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for injection has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:81484881-5f57-45f0-8ce3-5940effcffab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0021315 PMID:41385096 "[{""id"":""uuid:59b398eb-9841-40db-a800-4a2f9c45d1de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e3e20aa5-d14e-46e7-ae57-d0ff01e155cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin for injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for injection has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:eac6a7e9-dab2-495e-90c4-79d756b51919 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0004608 PMID:41385096 "[{""id"":""uuid:6b3bc117-248a-45db-b4c3-b3493e1f97b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b85eb37c-c4dd-4ede-acf0-0c85da330d8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin for injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for injection has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:b9bfe71d-8535-4485-9427-12f4c30b4dea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0020669 PMID:41385096 "[{""id"":""uuid:31be9371-cdc7-4615-91c8-b6ebcae43dc9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f63fbbb6-9dab-4eb3-a6a7-200769fa5189"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin for injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for injection has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:ea32543c-d5de-41bf-83e1-b78058bce759 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0006834 PMID:41385096 "[{""id"":""uuid:de80551d-3cd7-441c-a5ea-cd0fdba8f826"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:16d4128d-52ac-4a9e-bde8-673f8c922563"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin for injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for injection has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:5d4d0650-d1d6-4e9e-bdbc-6eb4b40c18fe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0004645 PMID:41385096 "[{""id"":""uuid:56fd3c4d-657f-445a-a8a9-485a97b7df96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9c64ebe4-7e5e-43ff-b4be-c006efd9f9cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin for injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for injection has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:9f54b6b7-4363-489d-b34c-461d509e28ca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0004473 PMID:41385096 "[{""id"":""uuid:8be6a064-77f1-4ca9-971f-7f5f02acb7a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bf5b1123-e2de-499c-a265-cb65e534141a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin for injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for injection has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:f54cd758-c9d1-4617-a87e-8fa35e48af62 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0002898 PMID:41385096 "[{""id"":""uuid:9aa37463-3d95-4f51-8b47-6807411b9235"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d8204ab0-d6a2-4262-abcc-1a3592947641"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin for injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for injection has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:a4a6b4bb-ed3c-45a8-a7ec-c96309b8fc32 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0002352 PMID:41385096 "[{""id"":""uuid:b55afc76-c9c2-4579-8433-e80b69a035be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f97f4f69-77b3-4091-95b5-d6a1171b3004"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin for injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for injection has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:ef216396-4a78-43f2-8d66-d9a3dd972818 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0001325 PMID:41385096 "[{""id"":""uuid:a0365640-b343-408f-8ccd-8bfec4f62bc1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6100b6cb-3345-4b40-8701-f3e6b9fc1388"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin for injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for injection has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:95d7b66c-9e55-4991-a139-af55f7953afc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0005131 PMID:41385096 "[{""id"":""uuid:f12140e5-5a42-4977-9dbd-4705806097a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:041f2dab-515e-40c8-941f-81df04a409e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin for injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for injection has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:24d71a35-61e9-4676-a95f-0ed25b79e7ea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0001528 PMID:41385096 "[{""id"":""uuid:ce1323f7-aefc-4130-9189-be09ba7fb9df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1a001068-c7f1-48a3-a4d5-39ae916ba5f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin for injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for injection has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:19155958-ce16-41fe-9087-2a85af5d5089 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0004095 PMID:41385096 "[{""id"":""uuid:420caff3-e318-4e89-baca-5e69a616e8fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8ad18ecf-3849-4223-a63b-5acc6e310353"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin for injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for injection has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:eaa64030-0c82-488a-a900-4d22c46fe97f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0009348 PMID:41385096 "[{""id"":""uuid:644f793a-11b9-4d0b-b2fd-8d886a1aff30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ad8c5dfa-7082-40b6-8da6-7c73a65bd509"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin for injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for injection has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:aa03d2fd-034b-43d1-814c-753288ee3e7c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0018908 PMID:41385096 "[{""id"":""uuid:e4912ad8-4c77-4acb-ab68-a8d988778d22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a74ac1fc-5616-4d61-813b-c4fe130747fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin for injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for injection has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:7b037b59-5569-411d-8782-bbfd898f7f60 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0005447 PMID:41385096 "[{""id"":""uuid:ceb5891d-a6c2-4bb4-93f9-1e3d25c51178"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e1ee6c7d-53ec-4086-808a-559c9b287c22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin for injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for injection has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:63719afb-01e4-4fc6-beba-04eedd206651 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0005440 PMID:41385096 "[{""id"":""uuid:8e4fca7c-c5c0-4196-ad62-dc5eb7bf417a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ef98e65a-5290-40ac-81d2-36c440aa48c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin for injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for injection has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:42785afd-9fde-401f-9f42-5ec4e893d0af biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0005207 PMID:41385096 "[{""id"":""uuid:0f659fe7-cdcc-4bce-ac67-bf28d7153317"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:98f3b556-27ee-4fe4-a9da-2a68ffe58565"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin for injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for injection has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:86cde7fc-9580-405e-8e01-df9d52751ed7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0002599 PMID:41385096 "[{""id"":""uuid:06503bf6-0c2f-43fd-881e-1f818930d44b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f7533b87-2b68-4686-84b5-de6c7a7ceb33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin for injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for injection has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:ab2c73c4-ac4a-4d58-b44b-cc99434634f3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats UMLS:C0080032 PMID:41385096 "[{""id"":""uuid:d008e64b-ae93-4e54-be39-e118ff03fc83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:96b3d8dd-1afa-433a-8efd-03d09ea0d755"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma: Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin for injection is poorer in patients with previously irradiated head and neck cancer. Lymphomas: Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma: Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin for injection has also been shown to be useful in the management of: Malignant Pleural Effusion: Bleomycin for injection is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:2bce0cca-6727-472c-afce-2460e2766554 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1151550 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:743d89eb-7202-4531-bcd9-c3dfe09e59c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:10a8768d-0339-4105-84a6-cfdc10bb8de2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydrocodone bitartrate and acetaminophen tablets are indicated for the management of, pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses [see WARNINGS], reserve hydrocodone bitartrate and acetaminophen tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics] Have not been tolerated, or are not expected to be tolerated, Have not provided adequate analgesia, or are not expected to provide adequate analgesia uuid:e59d5fe1-a221-4473-8a34-1ff501fb38b7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats NCIT:C27003 PMID:41385096 "[{""id"":""uuid:de784555-20e8-466d-a535-96c7eb95b6d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:79c8edc6-2d25-4b73-bedd-4a30dd450250"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZORVOLEX is indicated for: Management of mild to moderate acute pain Management of osteoarthritis pain uuid:36421ab3-4d63-432b-86c7-c4e215fb2932 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0004577 PMID:41385096 "[{""id"":""uuid:d04b8d9e-8fc8-40d2-8f77-7e745e69887a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f2c4b5ce-d27d-4bc5-a747-f7d55db4effb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b7a311d1-1eb9-4d78-a7db-2108b801850c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin ophthalmic solution is indicated for the treatment of corneal ulcer caused by susceptible strains of the following bacteria: Gram-positive bacteria: Corynebacterium species Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumonia Viridans group streptococci* Gram-negative bacteria: Pseudomonas aeruginosa Serratia marcescens* * Efficacy for this organism was studied in fewer than 10 infections|[PMDA] A drug with a new dosage of the 1.5% formulation for the treatment of blepharitis, dacryocystitis, hordeolum, conjunctivitis, meibomianitis, and keratitis (including corneal ulcer) and sterilization during the ophthalmic perioperative period. uuid:28dbb98d-ce1f-4c17-96c5-5437a4bdbb3a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0005545 PMID:41385096 "[{""id"":""uuid:4345e625-a013-472e-935b-a64ae0814207"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0b0826da-276b-4b57-acea-8edb759ef2aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin ophthalmic solution is indicated for the treatment of corneal ulcer caused by susceptible strains of the following bacteria: Gram-positive bacteria: Corynebacterium species Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumonia Viridans group streptococci* Gram-negative bacteria: Pseudomonas aeruginosa Serratia marcescens* * Efficacy for this organism was studied in fewer than 10 infections uuid:00756c88-540e-4778-b217-bf93dd7237f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0005972 PMID:41385096 "[{""id"":""uuid:6932cc63-58cb-44c1-b3c2-5529d51432cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7156a75f-ac7f-4fbc-80ed-de077d75f8e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin ophthalmic solution is indicated for the treatment of corneal ulcer caused by susceptible strains of the following bacteria: Gram-positive bacteria: Corynebacterium species Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumonia Viridans group streptococci* Gram-negative bacteria: Pseudomonas aeruginosa Serratia marcescens* * Efficacy for this organism was studied in fewer than 10 infections uuid:cd8ffb4f-80ab-4ba2-bb68-6f8ac1ac74be biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0040732 PMID:41385096 "[{""id"":""uuid:2301d47b-a0e8-4583-9992-efe09a9906a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b01c2f15-0793-45d5-aa00-d1880a2a200d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3f4e749f-3142-41bc-a568-f3f07c71c8f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/quinsair""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin ophthalmic solution is indicated for the treatment of corneal ulcer caused by susceptible strains of the following bacteria: Gram-positive bacteria: Corynebacterium species Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumonia Viridans group streptococci* Gram-negative bacteria: Pseudomonas aeruginosa Serratia marcescens* * Efficacy for this organism was studied in fewer than 10 infections|[EMA] Quinsair is indicated for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:7cbff08c-97dc-4c80-8567-a3d10db3638d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:85783 biolink:treats MONDO:0004781 PMID:41385096 "[{""id"":""uuid:c193e0be-8643-4ad8-b107-2c086c616bcb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f3470372-3291-4eeb-b372-b24f37f2385b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hypertension Lisinopril is indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Lisinopril may be administered alone or with other antihypertensive agents [see Clinical Studies (14.1)]. 1.2 Heart Failure Lisinopril is indicated to reduce signs and symptoms of systolic heart failure [see Clinical Studies (14.2)]. 1.3 Reduction of Mortality in Acute Myocardial Infarction Lisinopril is indicated for the reduction of mortality in treatment of hemodynamically stable patients within 24 hours of acute myocardial infarction. Patients should receive, as appropriate, the standard recommended treatments such as thrombolytics, aspirin and beta-blockers [see Clinical Studies (14.3)]. uuid:7fb29270-5a98-44bf-b6e8-2adf3514afcb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3SY5LH9PMK biolink:treats MONDO:0005277 PMID:41385096 "[{""id"":""uuid:1a849e59-be67-4994-9806-5dfd5d2edac3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1ecbb48b-acb0-4501-91ba-e8cc5aa355b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Rizatriptan benzoate tablets are indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old. Limitations of Use Rizatriptan benzoate tablets should only be used where a clear diagnosis of migraine has been established. If a patient has no response for the first migraine attack treated with rizatriptan benzoate tablets, the diagnosis of migraine should be reconsidered before rizatriptan benzoate tablets are administered to treat any subsequent attacks. Rizatriptan benzoate tablets are not indicated for use in the management of hemiplegic or basilar migraine [see Contraindications (4)]. Rizatriptan benzoate tablets are not indicated for the prevention of migraine attacks. Safety and effectiveness of rizatriptan benzoate tablets has not been established for cluster headache. uuid:ffc17099-77bf-4de0-8d58-16a2008576e4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3SY5LH9PMK biolink:treats MONDO:0018925 PMID:41385096 "[{""id"":""uuid:b2e00a7e-c6ce-4550-806c-a6af39c84c94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bcf7b4aa-34a7-4964-b5b7-d5b0e47ff73e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Rizatriptan benzoate tablets are indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old. Limitations of Use Rizatriptan benzoate tablets should only be used where a clear diagnosis of migraine has been established. If a patient has no response for the first migraine attack treated with rizatriptan benzoate tablets, the diagnosis of migraine should be reconsidered before rizatriptan benzoate tablets are administered to treat any subsequent attacks. Rizatriptan benzoate tablets are not indicated for use in the management of hemiplegic or basilar migraine [see Contraindications (4)]. Rizatriptan benzoate tablets are not indicated for the prevention of migraine attacks. Safety and effectiveness of rizatriptan benzoate tablets has not been established for cluster headache. uuid:1f8ece71-613e-46e1-b114-06735bccdc26 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3SY5LH9PMK biolink:treats MONDO:0043219 PMID:41385096 "[{""id"":""uuid:698b1546-4a49-44c8-9786-6f05139cb6ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a561deb7-585c-46c3-ae99-3f2954fabf7d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Rizatriptan benzoate tablets are indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old. Limitations of Use Rizatriptan benzoate tablets should only be used where a clear diagnosis of migraine has been established. If a patient has no response for the first migraine attack treated with rizatriptan benzoate tablets, the diagnosis of migraine should be reconsidered before rizatriptan benzoate tablets are administered to treat any subsequent attacks. Rizatriptan benzoate tablets are not indicated for use in the management of hemiplegic or basilar migraine [see Contraindications (4)]. Rizatriptan benzoate tablets are not indicated for the prevention of migraine attacks. Safety and effectiveness of rizatriptan benzoate tablets has not been established for cluster headache. uuid:c651ecd1-e9bc-408d-a051-dd61f3eacd1d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3SY5LH9PMK biolink:treats MONDO:0043537 PMID:41385096 "[{""id"":""uuid:f1625e0c-b8dc-45f7-8d4c-92c703334134"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:faf4c372-8c4f-4119-8935-8c39005cc9df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Rizatriptan benzoate tablets are indicated for the acute treatment of migraine with or without aura in adults and in pediatric patients 6 to 17 years old. Limitations of Use Rizatriptan benzoate tablets should only be used where a clear diagnosis of migraine has been established. If a patient has no response for the first migraine attack treated with rizatriptan benzoate tablets, the diagnosis of migraine should be reconsidered before rizatriptan benzoate tablets are administered to treat any subsequent attacks. Rizatriptan benzoate tablets are not indicated for use in the management of hemiplegic or basilar migraine [see Contraindications (4)]. Rizatriptan benzoate tablets are not indicated for the prevention of migraine attacks. Safety and effectiveness of rizatriptan benzoate tablets has not been established for cluster headache. uuid:16a50d6d-af30-4393-ab38-91da6ee3005f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:141521 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:2459b018-d7aa-4f64-b9a0-707a7492d2a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:50beb5f5-ee3d-4e1f-8685-f26bd2ef059b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Trandolapril tablets USP are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive medication such as hydrochlorothiazide. Heart Failure Post Myocardial Infarction or Left-Ventricular Dysfunction Post Myocardial Infarction Trandolapril tablets USP are indicated in stable patients who have evidence of left-ventricular systolic dysfunction (identified by wall motion abnormalities) or who are symptomatic from congestive heart failure within the first few days after sustaining acute myocardial infarction. Administration of trandolapril to Caucasian patients has been shown to decrease the risk of death (principally cardiovascular death) and to decrease the risk of heart failure-related hospitalization (see CLINICAL PHARMACOLOGY -Heart Failure or Left-Ventricular Dysfunction Post Myocardial Infarction for details of the survival trial). uuid:996f053f-77c2-4d60-9c6e-ecc3977bf4a8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:141521 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:11c7fbd3-11db-45cd-beed-f48120e0f1a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:af5f5ffe-c18f-475f-9780-b8e9a94153fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Trandolapril tablets USP are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive medication such as hydrochlorothiazide. Heart Failure Post Myocardial Infarction or Left-Ventricular Dysfunction Post Myocardial Infarction Trandolapril tablets USP are indicated in stable patients who have evidence of left-ventricular systolic dysfunction (identified by wall motion abnormalities) or who are symptomatic from congestive heart failure within the first few days after sustaining acute myocardial infarction. Administration of trandolapril to Caucasian patients has been shown to decrease the risk of death (principally cardiovascular death) and to decrease the risk of heart failure-related hospitalization (see CLINICAL PHARMACOLOGY -Heart Failure or Left-Ventricular Dysfunction Post Myocardial Infarction for details of the survival trial). uuid:5a9d234b-43f7-4964-aef0-778a2a72fbca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:141521 biolink:treats MONDO:0004781 PMID:41385096 "[{""id"":""uuid:c91c3599-6a45-419e-978a-8842497ade42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:16c01d0a-9a76-428f-befd-ebdaa60460da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Trandolapril tablets USP are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive medication such as hydrochlorothiazide. Heart Failure Post Myocardial Infarction or Left-Ventricular Dysfunction Post Myocardial Infarction Trandolapril tablets USP are indicated in stable patients who have evidence of left-ventricular systolic dysfunction (identified by wall motion abnormalities) or who are symptomatic from congestive heart failure within the first few days after sustaining acute myocardial infarction. Administration of trandolapril to Caucasian patients has been shown to decrease the risk of death (principally cardiovascular death) and to decrease the risk of heart failure-related hospitalization (see CLINICAL PHARMACOLOGY -Heart Failure or Left-Ventricular Dysfunction Post Myocardial Infarction for details of the survival trial). uuid:daa6a356-71e5-4442-9fe2-e15c4af601ad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:38545 biolink:treats MONDO:0007788 PMID:41385096 "[{""id"":""uuid:1101f42b-c8a5-46c3-bfe0-ca40916b35b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d22f6727-8d96-40ff-8ca2-c6ca214c225d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Rosuvastatin tablets are an HMG Co-A reductase inhibitor indicated for: adult patients with hypertriglyceridemia as an adjunct to diet ( 1.3 ) adult patients with primary dysbetalipoproteinemia (Type III hyperlipoproteinemia) as an adjunct to diet ( 1.4 ) adult patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C, total-C, and ApoB ( 1.5 ) Limitations of use ( 1.8 ): Rosuvastatin tablets have not been studied in Fredrickson Type I and V dyslipidemias. uuid:ba7af871-ed6a-4b71-8e12-44b0c39cc73d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:38545 biolink:treats MONDO:0007762 PMID:41385096 "[{""id"":""uuid:cba7a8ab-a137-4583-99e5-59df84f06b24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2ae89956-1fe4-4564-9679-785568aae1e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Rosuvastatin tablets are an HMG Co-A reductase inhibitor indicated for: adult patients with hypertriglyceridemia as an adjunct to diet ( 1.3 ) adult patients with primary dysbetalipoproteinemia (Type III hyperlipoproteinemia) as an adjunct to diet ( 1.4 ) adult patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C, total-C, and ApoB ( 1.5 ) Limitations of use ( 1.8 ): Rosuvastatin tablets have not been studied in Fredrickson Type I and V dyslipidemias. uuid:cc019d5f-271f-45dc-9d97-93e13c24df7d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5384 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:dc0b0ebd-9248-4f45-8217-62a86764c6b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:648e68ab-b11f-4b51-9525-6f9bcfae9f63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Glipizide extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. 1.1 Limitations of Use Glipizide extended-release tablets are not recommended for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis. uuid:e4c05c35-5798-4a58-b106-a94d73f274c8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5384 biolink:treats MONDO:0012819 PMID:41385096 "[{""id"":""uuid:3411a622-3e8e-4681-aa3e-17dc871d5da2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4c5de721-affa-43d5-9e67-c5f091f97a2b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Glipizide extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. 1.1 Limitations of Use Glipizide extended-release tablets are not recommended for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis. uuid:211d165c-5742-4008-bbd1-9301f52c2728 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PF9462I9HX biolink:treats UMLS:C0280100 PMID:41385096 "[{""id"":""uuid:dd5ba585-4263-4034-b51d-145bb2da3d57"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9d6b9b49-5fbb-4717-ab60-a843149a83e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VITRAKVI is indicated for the treatment of adult and pediatric patients with solid tumors that: • have a neurotrophic receptor tyrosine kinase ( NTRK ) gene fusion without a known acquired resistance mutation, • are metastatic or where surgical resection is likely to result in severe morbidity, and • have no satisfactory alternative treatments or that have progressed following treatment. This indication is approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies ( 14 )] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. uuid:2f2f3688-b50e-475b-8116-9e16998fe04e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63611 biolink:treats MONDO:0019095 PMID:41385096 "[{""id"":""uuid:7a7ff6c0-4d90-4bcc-aac8-b621e5632ac1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9adb8306-96c9-47ca-afa0-284d9f40f069"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Moxifloxacin tablets are a fluoroquinolone antibacterial indicated for treating infections in adults 18 years of age and older caused by designated susceptible bacteria, in the conditions listed below: Community Acquired Pneumonia ( 1.1 ) Skin and Skin Structure Infections: Uncomplicated ( 1.2 ) and Complicated ( 1.3 ) Complicated Intra-Abdominal Infections ( 1.4 ) Plague ( 1.5 ) Acute Bacterial Sinusitis ( 1.6 ) Acute Bacterial Exacerbation of Chronic Bronchitis ( 1.7 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of moxifloxacin hydrochloride and other antibacterial drugs. Moxifloxacin hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.8 ) uuid:4478c5c3-ffa8-4a45-a43d-6ee9a5514ed8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4325 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:bc3daed4-f5be-4b40-81f0-f7b2768b8603"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c97d8d3e-3ca1-4ac6-9236-3e18205ad8b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dapsone Gel, 5%, is indicated for the topical treatment of acne vulgaris. uuid:43c2b80e-9e4d-465a-97f2-c23d01b35d9d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7447 biolink:treats MONDO:0005545 PMID:41385096 "[{""id"":""uuid:becd422f-144d-4966-b2a9-84d453d8e110"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ab38ea50-5ab4-42af-9b77-dd6393cd2054"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nafcillin is indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. Culture and susceptibility tests should be performed initially to determine the causative organism and its susceptibility to the drug (see CLINICAL PHARMACOLOGY , Susceptibility Testing ). Nafcillin should not be used in infections caused by organisms susceptible to penicillin G. If the susceptibility tests indicate that the infection is due to a methicillin-resistant Staphylococcus sp., therapy with Nafcillin for Injection should be discontinued and alternative therapy provided. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Nafcillin for Injection and other antibacterial drugs, Nafcillin for Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:db8e62db-a3fc-4c0a-9336-034f49d9eac4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7447 biolink:treats MONDO:0005113 PMID:41385096 "[{""id"":""uuid:86744da1-5677-4935-8bd4-1b0a8be9f8b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e5958c65-3966-4c5a-929d-a01baeda029f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nafcillin is indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. Culture and susceptibility tests should be performed initially to determine the causative organism and its susceptibility to the drug (see CLINICAL PHARMACOLOGY , Susceptibility Testing ). Nafcillin should not be used in infections caused by organisms susceptible to penicillin G. If the susceptibility tests indicate that the infection is due to a methicillin-resistant Staphylococcus sp., therapy with Nafcillin for Injection should be discontinued and alternative therapy provided. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Nafcillin for Injection and other antibacterial drugs, Nafcillin for Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:09575c8d-a9fb-47cb-9e18-0727141c3069 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:18680304 biolink:treats MONDO:0004605 PMID:41385096 "[{""id"":""uuid:20fd2bd6-ae64-4f2a-80d0-0cc34aae4c2b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5e792637-8da3-45a0-895e-19c54ebeaf9a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Collagenase Santyl ◊ Ointment is indicated for debriding chronic dermal ulcers 2, 3, 4, 5, 6, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 and severely burned areas. 3, 4, 5, 7, 16, 19, 20, 21 uuid:019ec3b8-902d-45cb-86ab-bd2b9e3ef303 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:18680304 biolink:treats UMLS:C0006434 PMID:41385096 "[{""id"":""uuid:43061495-5b93-4f9c-a528-6c089bcaa006"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:81f60e6a-8c63-4b40-ae59-e73338f4508a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Collagenase Santyl ◊ Ointment is indicated for debriding chronic dermal ulcers 2, 3, 4, 5, 6, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 and severely burned areas. 3, 4, 5, 7, 16, 19, 20, 21 uuid:b77058d3-3d38-401e-be01-6f08cdeabae8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0301513 biolink:treats UMLS:C0936249 PMID:41385096 "[{""id"":""uuid:5f51f6ea-09a4-4f78-8ae7-2d3e853de12d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d452ffc4-c697-4491-9d92-9f04e81658d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VIGIV (vaccinia immune globulin intravenous, human) is indicated for the treatment and/or modification of the following conditions: • Eczema vaccinatum • Progressive vaccinia • Severe generalized vaccinia • Vaccinia infections in individuals who have skin conditions such as burns, impetigo, varicella-zoster, or poison ivy; or in individuals who have eczematous skin lesions because of either the activity or extensiveness of such lesions • Aberrant infections induced by vaccinia virus that include its accidental implantation in eyes (except in cases of isolated keratitis), mouth, or other areas where vaccinia infection would constitute a special hazard. VIGIV is not considered to be effective in the treatment of postvaccinial encephalitis. DRUGBANK:DB14112 uuid:e693a24d-dae6-46a4-b7bc-f49d1a18d1d8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0301513 biolink:treats UMLS:C2721678 PMID:41385096 "[{""id"":""uuid:04bbe235-fe9d-4ebf-bf15-14949d0b209e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ecae3d34-c101-4827-8223-26ce955f9399"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VIGIV (vaccinia immune globulin intravenous, human) is indicated for the treatment and/or modification of the following conditions: • Eczema vaccinatum • Progressive vaccinia • Severe generalized vaccinia • Vaccinia infections in individuals who have skin conditions such as burns, impetigo, varicella-zoster, or poison ivy; or in individuals who have eczematous skin lesions because of either the activity or extensiveness of such lesions • Aberrant infections induced by vaccinia virus that include its accidental implantation in eyes (except in cases of isolated keratitis), mouth, or other areas where vaccinia infection would constitute a special hazard. VIGIV is not considered to be effective in the treatment of postvaccinial encephalitis. DRUGBANK:DB14112 uuid:d9368455-d2f0-43e1-a44f-20453759560d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0301513 biolink:treats MONDO:0002595 PMID:41385096 "[{""id"":""uuid:0d4515a9-75d0-4c9f-b24a-556a30bd2080"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fd3e1a7a-3edc-47ad-99a9-7e32b16e5841"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VIGIV (vaccinia immune globulin intravenous, human) is indicated for the treatment and/or modification of the following conditions: • Eczema vaccinatum • Progressive vaccinia • Severe generalized vaccinia • Vaccinia infections in individuals who have skin conditions such as burns, impetigo, varicella-zoster, or poison ivy; or in individuals who have eczematous skin lesions because of either the activity or extensiveness of such lesions • Aberrant infections induced by vaccinia virus that include its accidental implantation in eyes (except in cases of isolated keratitis), mouth, or other areas where vaccinia infection would constitute a special hazard. VIGIV is not considered to be effective in the treatment of postvaccinial encephalitis. DRUGBANK:DB14112 uuid:1918943e-4b0d-4820-bce9-69d0f31700d4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0301513 biolink:treats MONDO:0001773 PMID:41385096 "[{""id"":""uuid:cbe013ef-f818-43d5-8f2a-d6ad890a4dc4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9d59c616-7f32-421e-92d7-969775e9f32f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VIGIV (vaccinia immune globulin intravenous, human) is indicated for the treatment and/or modification of the following conditions: • Eczema vaccinatum • Progressive vaccinia • Severe generalized vaccinia • Vaccinia infections in individuals who have skin conditions such as burns, impetigo, varicella-zoster, or poison ivy; or in individuals who have eczematous skin lesions because of either the activity or extensiveness of such lesions • Aberrant infections induced by vaccinia virus that include its accidental implantation in eyes (except in cases of isolated keratitis), mouth, or other areas where vaccinia infection would constitute a special hazard. VIGIV is not considered to be effective in the treatment of postvaccinial encephalitis. DRUGBANK:DB14112 uuid:0b0a27aa-d6a1-4a2a-9527-91c08f5e910f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31498 biolink:treats UMLS:C0406317 PMID:41385096 "[{""id"":""uuid:a52d0552-0ca6-4672-a166-6f4a94e6d14b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:354d1ae7-8916-40ce-8d58-be40a8078df5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Calcipotriene Cream, 0.005%, is indicated for the treatment of plaque psoriasis. The safety and effectiveness of topical calcipotriene in dermatoses other than psoriasis have not been established. uuid:ae3d99f6-cb99-4de7-a584-1fa853591e31 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9706 biolink:treats MONDO:0010200 PMID:41385096 "[{""id"":""uuid:0c0e6034-8730-44dc-b0a9-2b24fdf2482c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a3b6ae4f-d8be-4f1e-96c4-02962c3ef1ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b038cc25-5f04-4ccd-8263-c722029024b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Trientine hydrochloride capsules USP 250 mg is indicated in the treatment of patients with Wilson's disease who are intolerant of penicillamine. Clinical experience with trientine hydrochloride capsules USP 250 mg is limited and alternate dosing regimens have not been well-characterized; all endpoints in determining an individual patient's dose have not been well defined. Trientine hydrochloride capsules USP 250 mg and penicillamine cannot be considered interchangeable. Trientine hydrochloride capsules USP 250 mg should be used when continued treatment with penicillamine is no longer possible because of intolerable or life endangering side effects. Unlike penicillamine, trientine hydrochloride capsules USP 250 mg is not recommended in cystinuria or rheumatoid arthritis. The absence ofa sulfhydryl moiety renders it incapable of binding cystine and, therefore, it is of no use in cystinuria. In 15 patients with rheumatoid arthritis, trientine hydrochloride capsules USP 250 mg was reported not to be effective in improving any clinical or biochemical parameter after 12 weeks of treatment. Trientine hydrochloride capsules USP 250 mg is not indicated for treatment of biliary cirrhosis.|[EMA] Cuprior is indicated for the treatment of Wilson's disease in adults, adolescents and children ≥ 5 years intolerant to D-penicillamine therapy., uuid:2cd98545-108d-4592-b486-d0b538909529 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9706 biolink:treats MONDO:0009067 PMID:41385096 "[{""id"":""uuid:0428ccb8-220f-4be8-bbba-4f0848d4c50e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:91cf5f86-dd1e-441d-8ae6-26ecc5523f9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Trientine hydrochloride capsules USP 250 mg is indicated in the treatment of patients with Wilson's disease who are intolerant of penicillamine. Clinical experience with trientine hydrochloride capsules USP 250 mg is limited and alternate dosing regimens have not been well-characterized; all endpoints in determining an individual patient's dose have not been well defined. Trientine hydrochloride capsules USP 250 mg and penicillamine cannot be considered interchangeable. Trientine hydrochloride capsules USP 250 mg should be used when continued treatment with penicillamine is no longer possible because of intolerable or life endangering side effects. Unlike penicillamine, trientine hydrochloride capsules USP 250 mg is not recommended in cystinuria or rheumatoid arthritis. The absence ofa sulfhydryl moiety renders it incapable of binding cystine and, therefore, it is of no use in cystinuria. In 15 patients with rheumatoid arthritis, trientine hydrochloride capsules USP 250 mg was reported not to be effective in improving any clinical or biochemical parameter after 12 weeks of treatment. Trientine hydrochloride capsules USP 250 mg is not indicated for treatment of biliary cirrhosis. uuid:cf2c2c83-70b6-4475-bafd-586da4ee9fc5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9706 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:cf4f0b69-e81c-4fa8-bae4-592a2948b743"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:20c0711f-2666-4fb6-b289-c930223f3a12"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Trientine hydrochloride capsules USP 250 mg is indicated in the treatment of patients with Wilson's disease who are intolerant of penicillamine. Clinical experience with trientine hydrochloride capsules USP 250 mg is limited and alternate dosing regimens have not been well-characterized; all endpoints in determining an individual patient's dose have not been well defined. Trientine hydrochloride capsules USP 250 mg and penicillamine cannot be considered interchangeable. Trientine hydrochloride capsules USP 250 mg should be used when continued treatment with penicillamine is no longer possible because of intolerable or life endangering side effects. Unlike penicillamine, trientine hydrochloride capsules USP 250 mg is not recommended in cystinuria or rheumatoid arthritis. The absence ofa sulfhydryl moiety renders it incapable of binding cystine and, therefore, it is of no use in cystinuria. In 15 patients with rheumatoid arthritis, trientine hydrochloride capsules USP 250 mg was reported not to be effective in improving any clinical or biochemical parameter after 12 weeks of treatment. Trientine hydrochloride capsules USP 250 mg is not indicated for treatment of biliary cirrhosis. uuid:75fe50b3-0ce5-42d5-ba5f-d58f9cec0c9d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9706 biolink:treats MONDO:0005388 PMID:41385096 "[{""id"":""uuid:9dd65021-c0c0-43b8-854d-d6927b253a87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:52cc02e8-64b6-476a-9161-79cf341fda25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Trientine hydrochloride capsules USP 250 mg is indicated in the treatment of patients with Wilson's disease who are intolerant of penicillamine. Clinical experience with trientine hydrochloride capsules USP 250 mg is limited and alternate dosing regimens have not been well-characterized; all endpoints in determining an individual patient's dose have not been well defined. Trientine hydrochloride capsules USP 250 mg and penicillamine cannot be considered interchangeable. Trientine hydrochloride capsules USP 250 mg should be used when continued treatment with penicillamine is no longer possible because of intolerable or life endangering side effects. Unlike penicillamine, trientine hydrochloride capsules USP 250 mg is not recommended in cystinuria or rheumatoid arthritis. The absence ofa sulfhydryl moiety renders it incapable of binding cystine and, therefore, it is of no use in cystinuria. In 15 patients with rheumatoid arthritis, trientine hydrochloride capsules USP 250 mg was reported not to be effective in improving any clinical or biochemical parameter after 12 weeks of treatment. Trientine hydrochloride capsules USP 250 mg is not indicated for treatment of biliary cirrhosis. uuid:4bb5de95-0c24-4cf0-b818-241ae5507543 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75722 biolink:treats MONDO:0005530 PMID:41385096 "[{""id"":""uuid:84f78a9e-367e-4693-8673-2419c05d8faf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:de3c2439-10b7-4c33-8514-5800e5e8794b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tramadol hydrochloride tablets are indicated in adults for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see Warnings and Precautions (5.1) ] , reserve tramadol hydrochloride tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics]: Have not been tolerated or are not expected to be tolerated. Have not provided adequate analgesia or are not expected to provide adequate analgesia. uuid:0e75cd91-4379-4f6a-985e-2ec56e37388a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63631 biolink:treats MONDO:0006710 PMID:41385096 "[{""id"":""uuid:ccc3a8c5-1133-4086-a7ee-ca1a323fa7f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:77cd9096-4e87-4d08-ad63-bf0007e2224a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Monotherapy Epilepsy Topiramate tablets and topiramate capsules are indicated as initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older. 1.2 Adjunctive Therapy Epilepsy Topiramate tablets and topiramate capsules are indicated as adjunctive therapy for for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, and seizures associated with Lennox-Gastaut syndrome in patients 2 years of age and older. 1.3 Migraine Topiramate tablets and topiramate capsules are indicated for the preventive treatment of migraine in patients 12 years of age and older. uuid:4a835890-52bc-4ba9-bbc1-434c6f967449 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:48669 biolink:treats MONDO:0018660 PMID:41385096 "[{""id"":""uuid:6dff7663-018d-4d4d-994e-0b6a05e1789e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1d9921d8-6323-42ad-8226-bfaa647999a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tranexamic Acid in Sodium Chloride Injection is indicated in patients with hemophilia for short-term use (two to eight days) to reduce the risk of hemorrhage during and following tooth extraction. uuid:ae2d8b6c-0125-4f19-b4c0-301c33c86725 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:48669 biolink:treats NCIT:C26791 PMID:41385096 "[{""id"":""uuid:6d8d4249-c37a-42fc-b447-878e50ef90ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f12f321b-9f7f-4b1b-8ecb-b68ae042232a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tranexamic Acid in Sodium Chloride Injection is indicated in patients with hemophilia for short-term use (two to eight days) to reduce the risk of hemorrhage during and following tooth extraction. uuid:d41de0ff-58f8-4b3a-856c-dc42070d1877 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:M89N0Q7EQR biolink:treats UMLS:C4721698 PMID:41385096 "[{""id"":""uuid:e513dfad-9489-4b55-aa6f-cc770a14d884"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:62694cca-7a51-4203-b3f3-50b5d20f6286"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Proleukin ® (aldesleukin) is indicated for the treatment of adults with metastatic renal cell carcinoma (metastatic RCC). Proleukin is indicated for the treatment of adults with metastatic melanoma. Careful patient selection is mandatory prior to the administration of Proleukin. See “ CONTRAINDICATIONS ”, “ WARNINGS ” and “ PRECAUTIONS ” sections regarding patient screening, including recommended cardiac and pulmonary function tests and laboratory tests. Evaluation of clinical studies to date reveals that patients with more favorable ECOG performance status (ECOG PS 0) at treatment initiation respond better to Proleukin, with a higher response rate and lower toxicity (See “ CLINICAL PHARMACOLOGY ” section, “ CLINICAL STUDIES ” section and “ ADVERSE REACTIONS ” section). Therefore, selection of patients for treatment should include assessment of performance status. Experience in patients with ECOG PS >1 is extremely limited. uuid:4c3e55e2-836a-4057-b0aa-c550d066c9c5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:M89N0Q7EQR biolink:treats MONDO:0005191 PMID:41385096 "[{""id"":""uuid:bd38b617-8b7b-4005-b462-9d4d7e4a387f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fda5cd14-3bd7-449c-955d-548670d414e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Proleukin ® (aldesleukin) is indicated for the treatment of adults with metastatic renal cell carcinoma (metastatic RCC). Proleukin is indicated for the treatment of adults with metastatic melanoma. Careful patient selection is mandatory prior to the administration of Proleukin. See “ CONTRAINDICATIONS ”, “ WARNINGS ” and “ PRECAUTIONS ” sections regarding patient screening, including recommended cardiac and pulmonary function tests and laboratory tests. Evaluation of clinical studies to date reveals that patients with more favorable ECOG performance status (ECOG PS 0) at treatment initiation respond better to Proleukin, with a higher response rate and lower toxicity (See “ CLINICAL PHARMACOLOGY ” section, “ CLINICAL STUDIES ” section and “ ADVERSE REACTIONS ” section). Therefore, selection of patients for treatment should include assessment of performance status. Experience in patients with ECOG PS >1 is extremely limited. uuid:001addc0-214a-4eb2-9073-702494483ff4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7596 biolink:treats UMLS:C0264714 PMID:41385096 "[{""id"":""uuid:7f23ca22-7f71-407d-91e3-22857850c1af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9cc7b770-7859-40a6-a637-43d4fd7f200b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium nitroprusside is a direct acting vasodilator indicated for: • Immediate reduction of blood pressure ( 1.1 ) • Producing controlled hypotension to reduce bleeding during surgery. ( 1.2 ) • Treatment of acute heart failure to reduce left ventricular end-diastolic pressure, pulmonary capillary wedge pressure, peripheral vascular resistance and mean arterial blood pressure. ( 1.3 ) uuid:6667c6b6-d3a5-4fe2-adcf-b9ee6de5c87b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1162777 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:2a582d03-ec7b-4237-a7ff-dfc2ba69547c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7093d42b-7fc9-47bd-9124-93ba770f48d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Olmesartan medoxomil and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Olmesartan medoxomil and hydrochlorothiazide tablets are not indicated for the initial therapy of hypertension [see Dosage and Administration (2) ] . Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Olmesartan medoxomil and hydrochlorothiazide tablets may be used alone, or in combination with other antihypertensive drugs. uuid:3d0eace9-c2b2-433b-a5d7-9a3b3d96e908 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1162777 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:19fcbb14-e0a9-4304-9e40-0b3c9620e6c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b671f570-77a7-41ab-bcef-b7e8279708ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Olmesartan medoxomil and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Olmesartan medoxomil and hydrochlorothiazide tablets are not indicated for the initial therapy of hypertension [see Dosage and Administration (2) ] . Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Olmesartan medoxomil and hydrochlorothiazide tablets may be used alone, or in combination with other antihypertensive drugs. uuid:998d5e5b-cca4-41fc-945c-947cb0b2c3dd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1162777 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:e2da96e1-dbdf-4738-885b-683126fb154f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:df26683a-8294-4f28-a98b-4aa1a62ddd09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Olmesartan medoxomil and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Olmesartan medoxomil and hydrochlorothiazide tablets are not indicated for the initial therapy of hypertension [see Dosage and Administration (2) ] . Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Olmesartan medoxomil and hydrochlorothiazide tablets may be used alone, or in combination with other antihypertensive drugs. uuid:4503f701-fbb0-4c4b-88f9-f089d419beee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1162777 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:f13bca59-752f-4845-821d-13893e510a36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2d6bbf5f-25c7-47dc-a74b-42ead2a02434"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Olmesartan medoxomil and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Olmesartan medoxomil and hydrochlorothiazide tablets are not indicated for the initial therapy of hypertension [see Dosage and Administration (2) ] . Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Olmesartan medoxomil and hydrochlorothiazide tablets may be used alone, or in combination with other antihypertensive drugs. uuid:ee1c777c-22a6-48ca-af8c-7aa728985c24 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41423 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:8d4e1e4c-665e-4118-9eda-a694b49cbbc6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1f134e28-5d6f-43c9-91f0-a2aa57ad7fb2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS Cardiovascular Thrombotic Events • Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction, and stroke, which can be fatal. This risk may occur early in the treatment and may increase with duration of use. [see Warnings and Precautions (5.1)] • Celecoxib capsules are contraindicated in the setting of coronary artery bypass graft (CABG) surgery. [see Contraindications (4) and Warnings and Precautions (5.1)] Gastrointestinal Bleeding, Ulceration, and Perforation • NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events. [see Warnings and Precautions (5.2)] uuid:d679502e-7272-4226-8a72-13b3247b4809 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41423 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:f2e52273-b7ee-45b6-a709-72504a3ac7fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6677a4c2-8399-448f-ac72-4184fbb63799"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS Cardiovascular Thrombotic Events • Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction, and stroke, which can be fatal. This risk may occur early in the treatment and may increase with duration of use. [see Warnings and Precautions (5.1)] • Celecoxib capsules are contraindicated in the setting of coronary artery bypass graft (CABG) surgery. [see Contraindications (4) and Warnings and Precautions (5.1)] Gastrointestinal Bleeding, Ulceration, and Perforation • NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events. [see Warnings and Precautions (5.2)] uuid:902152f7-596f-4852-81c3-58685b6b55bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41423 biolink:treats MONDO:0004247 PMID:41385096 "[{""id"":""uuid:97e0f2c3-02b0-486d-844c-68122b8576e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:92db67fc-54c7-421e-b7d3-41e727848500"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS Cardiovascular Thrombotic Events • Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction, and stroke, which can be fatal. This risk may occur early in the treatment and may increase with duration of use. [see Warnings and Precautions (5.1)] • Celecoxib capsules are contraindicated in the setting of coronary artery bypass graft (CABG) surgery. [see Contraindications (4) and Warnings and Precautions (5.1)] Gastrointestinal Bleeding, Ulceration, and Perforation • NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events. [see Warnings and Precautions (5.2)] uuid:d91d39b8-306a-4910-b711-47a0c8917819 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41423 biolink:treats HP:0002239 PMID:41385096 "[{""id"":""uuid:4ef77552-5d1c-43cb-9ac2-5d2004db2f19"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f1e519ba-72a4-44c4-90ba-4ee2cdc9f014"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS Cardiovascular Thrombotic Events • Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction, and stroke, which can be fatal. This risk may occur early in the treatment and may increase with duration of use. [see Warnings and Precautions (5.1)] • Celecoxib capsules are contraindicated in the setting of coronary artery bypass graft (CABG) surgery. [see Contraindications (4) and Warnings and Precautions (5.1)] Gastrointestinal Bleeding, Ulceration, and Perforation • NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events. [see Warnings and Precautions (5.2)] uuid:f283b97b-e3ec-4e39-abfe-e97359354966 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:34246 biolink:treats MONDO:0006668 PMID:41385096 "[{""id"":""uuid:1eeebabe-b609-4f74-aee7-73e0da2d4dcc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9e2784a6-fd57-401d-b7e7-3be7d238f8e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Trimethoprim Sulfate and Polymyxin B Sulfate Ophthalmic Solution is indicated in the treatment of surface ocular bacterial infections, including acute bacterial conjunctivitis, and blepharoconjunctivitis, caused by susceptible strains of the following microorganisms: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus viridans, Haemophilus influenza and Pseudomonas aeruginosa.* *Efficacy for this organism in this organ system was studied in fewer than 10 infections. uuid:542399a6-8f25-40d2-8ac5-eac1a9d2630a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:34246 biolink:treats MONDO:0002307 PMID:41385096 "[{""id"":""uuid:3a0faa25-c35d-48da-bebb-be3c59c77bcf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:33399e1c-68bb-4dcc-809d-b23bbddc001f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Trimethoprim Sulfate and Polymyxin B Sulfate Ophthalmic Solution is indicated in the treatment of surface ocular bacterial infections, including acute bacterial conjunctivitis, and blepharoconjunctivitis, caused by susceptible strains of the following microorganisms: Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, Streptococcus viridans, Haemophilus influenza and Pseudomonas aeruginosa.* *Efficacy for this organism in this organ system was studied in fewer than 10 infections. uuid:5c6ed18d-ca3e-4c5e-9141-ac2055f318b6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5134 biolink:treats UMLS:C0741804 PMID:41385096 "[{""id"":""uuid:87e0fc5e-bc34-4761-987c-825e598dca88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:33803860-d569-4bb7-b876-394f9d4426cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Flovent DISKUS is indicated for the maintenance treatment of asthma as prophylactic therapy in patients aged 4 years and older. Important Limitation of Use FLOVENT DISKUS is NOT indicated for the relief of acute bronchospasm. uuid:627bc4df-392f-4ad6-aeb3-d2f6967269a8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75722 biolink:treats MONDO:0001225 PMID:41385096 "[{""id"":""uuid:fed5edfa-8ed6-438f-b5d1-d467cc839712"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:982b024c-d0e9-4d65-96b8-2bd333ba41fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tramadol hydrochloride tablets are indicated in adults for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see Warnings and Precautions (5.1)], reserve tramadol hydrochloride tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics]: Have not been tolerated or are not expected to be tolerated. Have not provided adequate analgesia or are not expected to provide adequate analgesia. uuid:baa9c32b-e692-4a2f-8a44-4f6d4d5131df biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135939 biolink:treats MONDO:0006710 PMID:41385096 "[{""id"":""uuid:58582953-0d24-403c-88ba-c76989059e15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:10a4c0e8-88c2-4a24-b491-13c435b860ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VIMPAT is indicated for the treatment of partial-onset seizures in patients 4 years of age and older. As the safety of VIMPAT injection in pediatric patients has not been established, VIMPAT injection is indicated for the treatment of partial-onset seizures only in adult patients (17 years of age and older). uuid:ccec37c6-66b4-402f-bfb3-cf8b00ccaf44 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64356 biolink:treats MONDO:0006710 PMID:41385096 "[{""id"":""uuid:0ea17d07-5efa-4b92-a565-45409f4ac405"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:55c34f63-db73-4c25-8e9d-2160bc9488d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pregabalin capsules are indicated for: • Management of neuropathic pain associated with diabetic peripheral neuropathy • Management of postherpetic neuralgia • Adjunctive therapy for the treatment of partial-onset seizures in patients 17 years of age and older • Management of fibromyalgia • Management of neuropathic pain associated with spinal cord injury Pediatric use information is approved for Pfizer’s LYRICA (pregabalin) Capsules and Oral Solution products. However, due to Pfizer’s marketing exclusivity rights, this drug product is not labeled with that pediatric information. uuid:4de0f3fb-bb8a-4795-9bb2-8b335126aa0b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24783652 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:0a6dadac-8cb8-4946-803f-c1dc5d5bf817"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:11591948-289e-4d5a-b33c-7f63136c5848"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hypertension Losartan potassium and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in Black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients [see CLINICAL STUDIES (14) and DOSAGE AND ADMINISTRATION (2.1)]. Losartan potassium and hydrochlorothiazide tablets may be administered with other antihypertensive agents. 1.2 Hypertensive Patients with Left Ventricular Hypertrophy Losartan potassium and hydrochlorothiazide tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients [see USE IN SPECIFIC POPULATIONS (8.6), CLINICAL PHARMACOLOGY (12.3), and DOSAGE AND ADMINISTRATION (2.2)]. uuid:19786749-a9b8-4a31-b95d-3b54a734eb11 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24783652 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:6fc87c21-727c-49bf-b5e5-7f3866ba6c07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b03665d4-31a0-4c56-9275-f55f6787cbe1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hypertension Losartan potassium and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in Black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients [see CLINICAL STUDIES (14) and DOSAGE AND ADMINISTRATION (2.1)]. Losartan potassium and hydrochlorothiazide tablets may be administered with other antihypertensive agents. 1.2 Hypertensive Patients with Left Ventricular Hypertrophy Losartan potassium and hydrochlorothiazide tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients [see USE IN SPECIFIC POPULATIONS (8.6), CLINICAL PHARMACOLOGY (12.3), and DOSAGE AND ADMINISTRATION (2.2)]. uuid:9124311a-2c95-4843-9f31-8baeb31b7b36 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24783652 biolink:treats HP:0001712 PMID:41385096 "[{""id"":""uuid:a0aa2738-b2dd-4e7a-8c9c-4331dbba68fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:faab7bb1-7870-4474-a71f-65a5e8431470"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hypertension Losartan potassium and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in Black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients [see CLINICAL STUDIES (14) and DOSAGE AND ADMINISTRATION (2.1)]. Losartan potassium and hydrochlorothiazide tablets may be administered with other antihypertensive agents. 1.2 Hypertensive Patients with Left Ventricular Hypertrophy Losartan potassium and hydrochlorothiazide tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients [see USE IN SPECIFIC POPULATIONS (8.6), CLINICAL PHARMACOLOGY (12.3), and DOSAGE AND ADMINISTRATION (2.2)]. uuid:4cff7824-997d-4a73-a0bd-1bcf8be3735e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24783652 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:8dab5598-0365-4a64-96dd-25e35e2e988c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7be0dd8e-fce0-4bbb-83ec-57ecc6fa9df6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hypertension Losartan potassium and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in Black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients [see CLINICAL STUDIES (14) and DOSAGE AND ADMINISTRATION (2.1)]. Losartan potassium and hydrochlorothiazide tablets may be administered with other antihypertensive agents. 1.2 Hypertensive Patients with Left Ventricular Hypertrophy Losartan potassium and hydrochlorothiazide tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients [see USE IN SPECIFIC POPULATIONS (8.6), CLINICAL PHARMACOLOGY (12.3), and DOSAGE AND ADMINISTRATION (2.2)]. uuid:e50f2384-9653-4c29-a50f-d7fb24384bf7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24783652 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:02e34c0a-4e5f-4b6f-a5a3-9f0610a2527e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3abafbd6-60af-4f46-aee9-044091055965"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hypertension Losartan potassium and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in Black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients [see CLINICAL STUDIES (14) and DOSAGE AND ADMINISTRATION (2.1)]. Losartan potassium and hydrochlorothiazide tablets may be administered with other antihypertensive agents. 1.2 Hypertensive Patients with Left Ventricular Hypertrophy Losartan potassium and hydrochlorothiazide tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients [see USE IN SPECIFIC POPULATIONS (8.6), CLINICAL PHARMACOLOGY (12.3), and DOSAGE AND ADMINISTRATION (2.2)]. uuid:e14eafb5-e2ec-4cab-9459-b354e3fd8741 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24783652 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:f8367913-d71a-4b2f-8c66-d4bc9e897329"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fa5e9724-13c8-430a-8d0b-672a5b140535"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hypertension Losartan potassium and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in Black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients [see CLINICAL STUDIES (14) and DOSAGE AND ADMINISTRATION (2.1)]. Losartan potassium and hydrochlorothiazide tablets may be administered with other antihypertensive agents. 1.2 Hypertensive Patients with Left Ventricular Hypertrophy Losartan potassium and hydrochlorothiazide tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients [see USE IN SPECIFIC POPULATIONS (8.6), CLINICAL PHARMACOLOGY (12.3), and DOSAGE AND ADMINISTRATION (2.2)]. uuid:b43504a0-4f5a-42f1-8d10-3d5b4371aea2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24783652 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:b4a56f55-cd21-4cbb-b9e7-33944daa180f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a3ecf1aa-e822-4d45-9337-b5b6dc541505"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hypertension Losartan potassium and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in Black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients [see CLINICAL STUDIES (14) and DOSAGE AND ADMINISTRATION (2.1)]. Losartan potassium and hydrochlorothiazide tablets may be administered with other antihypertensive agents. 1.2 Hypertensive Patients with Left Ventricular Hypertrophy Losartan potassium and hydrochlorothiazide tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients [see USE IN SPECIFIC POPULATIONS (8.6), CLINICAL PHARMACOLOGY (12.3), and DOSAGE AND ADMINISTRATION (2.2)]. uuid:c498682d-718b-4c08-b3f1-6aa095e70480 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24783652 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:a815b5b7-2513-4018-ab0b-81d1e425fc14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c2648c06-61fd-4b9a-957e-e0bcad2894ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hypertension Losartan potassium and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in Black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients [see CLINICAL STUDIES (14) and DOSAGE AND ADMINISTRATION (2.1)]. Losartan potassium and hydrochlorothiazide tablets may be administered with other antihypertensive agents. 1.2 Hypertensive Patients with Left Ventricular Hypertrophy Losartan potassium and hydrochlorothiazide tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients [see USE IN SPECIFIC POPULATIONS (8.6), CLINICAL PHARMACOLOGY (12.3), and DOSAGE AND ADMINISTRATION (2.2)]. uuid:911d0604-957e-44ab-9585-3c3df2ad5156 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17594 biolink:treats MONDO:0019289 PMID:41385096 "[{""id"":""uuid:b3a84b4f-cf81-4844-93c8-9e8bf2615659"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:791fb480-e123-4223-b0c2-afcd8d1bce51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] HELPS LIGHTEN DARK PATCHES OF SKIN SUCH AS AGE SPOTS, MELASMA, FRECKLES AND HYPERPIGMENTATION THAT CAN OCCUR AS A RESULT OF PREGNANCY, USE OF ORAL CONTRACEPTIVES OR INJURY TO THE SKIN. RX ONLY. FOR EXTERNAL USE ONLY. uuid:82a2c062-60d4-42ae-abfc-ba5af58aa463 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6375 biolink:treats MONDO:0019610 PMID:41385096 "[{""id"":""uuid:c7d5d4c3-f836-4c60-b068-1d92e64e9c65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a1fb5fa4-434a-4543-be03-5c30aa531bd7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lansoprazole delayed-release capsule is a proton pump inhibitor (PPIs) indicated for the: • Treatment of active duodenal ulcer in adults. ( 1.1 ) • Eradication of H. pylori to reduce the risk of duodenal ulcer recurrence in adults. ( 1.2 ) • Maintenance of healed duodenal ulcers in adults. ( 1.3 ) • Treatment of active benign gastric ulcer in adults. ( 1.4 ) • Healing of non-steroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults. ( 1.5 ) • Risk reduction of NSAID-associated gastric ulcer in adults. ( 1.6 ) • Treatment of symptomatic gastroesophageal reflux disease (GERD) in adults and pediatric patients 1 year of age and older.( 1.7 ) • Treatment of erosive esophagitis (EE) in adults and pediatric patients 1 year of age and older. ( 1.8 ) • Maintenance of healing of EE in adults. ( 1.9 ) • Pathological hypersecretory conditions, including Zollinger-Ellison syndrome (ZES) in adults. ( 1.10 ) uuid:4521d36a-699c-4cbf-b9eb-777d173c1c54 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:87715 biolink:treats MONDO:0000990 PMID:41385096 "[{""id"":""uuid:8235e19e-a272-4072-833e-33929b1791a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:cdcf2677-c5a0-4042-a1ef-2c088ac734a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:55b40cb4-6ed0-4dc2-989a-17fcf089fdf0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/efient""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prasugrel tablets is a P2Y 12 platelet inhibitor indicated for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome who are to be managed with PCI as follows: • Patients with unstable angina or non-ST-elevation myocardial infarction (NSTEMI) ( 1.1 ). • Patients with ST-elevation myocardial infarction (STEMI) when managed with either primary or delayed PCI ( 1.1 ).|[EMA] Efient, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in patients with acute coronary syndrome (i.e. unstable angina, non-ST-segment-elevation myocardial infarction [UA / NSTEMI] or ST-segment-elevation myocardial infarction [STEMI]) undergoing primary or delayed percutaneous coronary intervention (PCI). uuid:42974fb3-dd40-42ba-a31b-4940406700ac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:87715 biolink:treats MONDO:0041656 PMID:41385096 "[{""id"":""uuid:d57d8502-72b1-4b5a-ae5d-b58e72dd8a71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5f40e69b-28d4-4b57-941a-07b33956030d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ac2be091-84af-4b0b-8004-c39be068149b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/efient""]},{""id"":""uuid:092716d6-bf88-4bf3-b5c0-1159e7de0154"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prasugrel tablets is a P2Y 12 platelet inhibitor indicated for the reduction of thrombotic cardiovascular events (including stent thrombosis) in patients with acute coronary syndrome who are to be managed with PCI as follows: • Patients with unstable angina or non-ST-elevation myocardial infarction (NSTEMI) ( 1.1 ). • Patients with ST-elevation myocardial infarction (STEMI) when managed with either primary or delayed PCI ( 1.1 ).|[EMA] Efient, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in patients with acute coronary syndrome (i.e. unstable angina, non-ST-segment-elevation myocardial infarction [UA / NSTEMI] or ST-segment-elevation myocardial infarction [STEMI]) undergoing primary or delayed percutaneous coronary intervention (PCI).|[PMDA] Drugs with a new active ingredient indicated for the treatment of the following ischemic heart diseases managed with percutaneous coronary intervention (PCI): acute coronary syndrome (unstable angina, non ST-segment elevation myocardial infarction, ST- segment elevation myocardial infarction), stable angina, old myocardial infarction. uuid:bedb3157-cc77-4a9d-9c98-bad07e9a7008 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47426 biolink:treats UMLS:C0155919 PMID:41385096 "[{""id"":""uuid:cc49ec43-c0b7-43f6-9e51-e6ac390d05f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:198988f3-7456-4302-8b6e-dc1f5e302942"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Parenteral therapy should be reserved for patients unable to take oral medication or for patients in emergency clinical situations. Edema Furosemide is indicated in adults and pediatric patients for the treatment of edema associated with congestive heart failure, cirrhosis of the liver and renal disease, including the nephrotic syndrome. Furosemide is particularly useful when an agent with greater diuretic potential is desired. Furosemide is indicated as adjunctive therapy in acute pulmonary edema. The intravenous administration of furosemide is indicated when a rapid onset of diuresis is desired, e.g., in acute pulmonary edema. If gastrointestinal absorption is impaired or oral medication is not practical for any reason, furosemide is indicated by the intravenous or intramuscular route. Parenteral use should be replaced with oral furosemide as soon as practical. uuid:33efcf35-39e8-48d6-93cb-fbdaa7306ddd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63630 biolink:treats MONDO:0005180 PMID:41385096 "[{""id"":""uuid:ac4bd182-b44f-4251-8291-f23a7608c89e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:671ca0bd-de39-41d6-89f3-8a3c3c7f976e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:19a335c9-53d3-4f3c-9931-8aca62307810"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tasmar""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tolcapone tablets, USP is indicated as an adjunct to levodopa and carbidopa for the treatment of the signs and symptoms of idiopathic Parkinson's disease. Because of the risk of potentially fatal, acute fulminant liver failure, tolcapone tablets, USP should ordinarily be used in patients with Parkinson's disease on l-dopa/carbidopa who are experiencing symptom fluctuations and are not responding satisfactorily to or are not appropriate candidates for other adjunctive therapies. Because of the risk of liver injury and because tolcapone tablets, USP, when it is effective, provides an observable symptomatic benefit, the patient who fails to show substantial clinical benefit within 3 weeks of initiation of treatment, should be withdrawn from tolcapone tablets, USP. The effectiveness of tolcapone tablets, USP was demonstrated in randomized controlled trials in patients receiving concomitant levodopa therapy with carbidopa or another aromatic amino acid decarboxylase inhibitor who experienced end of dose wearing-off phenomena as well as in patients who did not experience such phenomena (see CLINICAL PHARMACOLOGY : Clinical Studies ).|[EMA] Tasmar is indicated in combination with levodopa / benserazide or levodopa / carbidopa for use in patients with levodopa-responsive idiopathic Parkinson’s disease and motor fluctuations, who failed to respond to or are intolerant of other catechol-O-methyltransferase (COMT) inhibitors.Because of the risk of potentially fatal, acute liver injury, Tasmar should not be considered as a first-line adjunct therapy to levodopa / benserazide or levodopa / carbidopa.Since Tasmar should be used only in combination with levodopa / benserazide and levodopa / carbidopa, the prescribing information for these levodopa preparations is also applicable to their concomitant use with Tasmar. uuid:4695fded-c8eb-4224-b639-05469d44bafa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63630 biolink:treats MONDO:0019542 PMID:41385096 "[{""id"":""uuid:46997866-a0d3-4990-8c02-9fd8ad92c84d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9dc7d036-1813-48f3-baba-d97cad3f0d8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tolcapone tablets, USP is indicated as an adjunct to levodopa and carbidopa for the treatment of the signs and symptoms of idiopathic Parkinson's disease. Because of the risk of potentially fatal, acute fulminant liver failure, tolcapone tablets, USP should ordinarily be used in patients with Parkinson's disease on l-dopa/carbidopa who are experiencing symptom fluctuations and are not responding satisfactorily to or are not appropriate candidates for other adjunctive therapies. Because of the risk of liver injury and because tolcapone tablets, USP, when it is effective, provides an observable symptomatic benefit, the patient who fails to show substantial clinical benefit within 3 weeks of initiation of treatment, should be withdrawn from tolcapone tablets, USP. The effectiveness of tolcapone tablets, USP was demonstrated in randomized controlled trials in patients receiving concomitant levodopa therapy with carbidopa or another aromatic amino acid decarboxylase inhibitor who experienced end of dose wearing-off phenomena as well as in patients who did not experience such phenomena (see CLINICAL PHARMACOLOGY : Clinical Studies ). uuid:42206ccb-a0ed-42a4-8ec8-4389c457e347 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3508 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:7c8fab4e-507d-4cd2-b669-4b3e7c020d72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6afe1f60-642f-42a7-897f-ab76e3b18dac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FORTAZ is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: 1. Lower Respiratory Tract Infections, including pneumonia, caused by Pseudomonas aeruginosa and other Pseudomonas spp.; Haemophilus influenzae , including ampicillin-resistant strains; Klebsiella spp.; Enterobacter spp.; Proteus mirabilis ; Escherichia coli ; Serratia spp.; Citrobacter spp.; Streptococcus pneumoniae ; and Staphylococcus aureus (methicillin-susceptible strains). 2. Skin and Skin-Structure Infections caused by Pseudomonas aeruginosa ; Klebsiella spp.; Escherichia coli ; Proteus spp., including Proteus mirabilis and indole-positive Proteus ; Enterobacter spp.; Serratia spp.; Staphylococcus aureus (methicillin-susceptible strains); and Streptococcus pyogenes (group A beta-hemolytic streptococci). 3. Urinary Tract Infections, both complicated and uncomplicated, caused by Pseudomonas aeruginosa ; Enterobacter spp.; Proteus spp., including Proteus mirabilis and indole-positive Proteus ; Klebsiella spp.; and Escherichia coli . 4. Bacterial Septicemia caused by Pseudomonas aeruginosa , Klebsiella spp., Haemophilus influenzae, Escherichia coli , Serratia spp., Streptococcus pneumoniae, and Staphylococcus aureus (methicillin-susceptible strains). 5. Bone and Joint Infections caused by Pseudomonas aeruginosa, Klebsiella spp., Enterobacter spp., and Staphylococcus aureus (methicillin-susceptible strains). 6. Gynecologic Infections, including endometritis, pelvic cellulitis, and other infections of the female genital tract caused by Escherichia coli . 7. Intra-abdominal Infections, including peritonitis caused by Escherichia coli , Klebsiella spp., and Staphylococcus aureus (methicillin-susceptible strains) and polymicrobial infections caused by aerobic and anaerobic organisms and Bacteroides spp. (many strains of Bacteroides fragilis are resistant). 8. Central Nervous System Infections, including meningitis, caused by Haemophilus influenzae and Neisseria meningitidis . Ceftazidime has also been used successfully in a limited number of cases of meningitis due to Pseudomonas aeruginosa and Streptococcus pneumoniae. FORTAZ may be used alone in cases of confirmed or suspected sepsis. Ceftazidime has been used successfully in clinical trials as empiric therapy in cases where various concomitant therapies with other antibacterial drugs have been used. FORTAZ may also be used concomitantly with other antibacterial drugs, such as aminoglycosides, vancomycin, and clindamycin; in severe and life-threatening infections; and in the immunocompromised patient. When such concomitant treatment is appropriate, prescribing information in the labeling for the other antibacterial drugs should be followed. The dose depends on the severity of the infection and the patient's condition. To reduce the development of drug-resistant bacteria and maintain the effectiveness of FORTAZ and other antibacterial drugs, FORTAZ should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:43c81c34-d592-45ee-b566-76b4164c9953 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3508 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:aa22def6-75b4-46b4-98f5-cbdfdc45ac3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9542f083-796b-4472-84dd-da1a022bcf3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FORTAZ is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: 1. Lower Respiratory Tract Infections, including pneumonia, caused by Pseudomonas aeruginosa and other Pseudomonas spp.; Haemophilus influenzae , including ampicillin-resistant strains; Klebsiella spp.; Enterobacter spp.; Proteus mirabilis ; Escherichia coli ; Serratia spp.; Citrobacter spp.; Streptococcus pneumoniae ; and Staphylococcus aureus (methicillin-susceptible strains). 2. Skin and Skin-Structure Infections caused by Pseudomonas aeruginosa ; Klebsiella spp.; Escherichia coli ; Proteus spp., including Proteus mirabilis and indole-positive Proteus ; Enterobacter spp.; Serratia spp.; Staphylococcus aureus (methicillin-susceptible strains); and Streptococcus pyogenes (group A beta-hemolytic streptococci). 3. Urinary Tract Infections, both complicated and uncomplicated, caused by Pseudomonas aeruginosa ; Enterobacter spp.; Proteus spp., including Proteus mirabilis and indole-positive Proteus ; Klebsiella spp.; and Escherichia coli . 4. Bacterial Septicemia caused by Pseudomonas aeruginosa , Klebsiella spp., Haemophilus influenzae, Escherichia coli , Serratia spp., Streptococcus pneumoniae, and Staphylococcus aureus (methicillin-susceptible strains). 5. Bone and Joint Infections caused by Pseudomonas aeruginosa, Klebsiella spp., Enterobacter spp., and Staphylococcus aureus (methicillin-susceptible strains). 6. Gynecologic Infections, including endometritis, pelvic cellulitis, and other infections of the female genital tract caused by Escherichia coli . 7. Intra-abdominal Infections, including peritonitis caused by Escherichia coli , Klebsiella spp., and Staphylococcus aureus (methicillin-susceptible strains) and polymicrobial infections caused by aerobic and anaerobic organisms and Bacteroides spp. (many strains of Bacteroides fragilis are resistant). 8. Central Nervous System Infections, including meningitis, caused by Haemophilus influenzae and Neisseria meningitidis . Ceftazidime has also been used successfully in a limited number of cases of meningitis due to Pseudomonas aeruginosa and Streptococcus pneumoniae. FORTAZ may be used alone in cases of confirmed or suspected sepsis. Ceftazidime has been used successfully in clinical trials as empiric therapy in cases where various concomitant therapies with other antibacterial drugs have been used. FORTAZ may also be used concomitantly with other antibacterial drugs, such as aminoglycosides, vancomycin, and clindamycin; in severe and life-threatening infections; and in the immunocompromised patient. When such concomitant treatment is appropriate, prescribing information in the labeling for the other antibacterial drugs should be followed. The dose depends on the severity of the infection and the patient's condition. To reduce the development of drug-resistant bacteria and maintain the effectiveness of FORTAZ and other antibacterial drugs, FORTAZ should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:58be6e7d-1abb-466b-a3b7-39c281497df0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3508 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:51ac51ab-01a8-4e7b-9e57-818c60f914ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4cf8fdbc-8a58-42b3-9167-d1a2bdeb7080"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FORTAZ is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: 1. Lower Respiratory Tract Infections, including pneumonia, caused by Pseudomonas aeruginosa and other Pseudomonas spp.; Haemophilus influenzae , including ampicillin-resistant strains; Klebsiella spp.; Enterobacter spp.; Proteus mirabilis ; Escherichia coli ; Serratia spp.; Citrobacter spp.; Streptococcus pneumoniae ; and Staphylococcus aureus (methicillin-susceptible strains). 2. Skin and Skin-Structure Infections caused by Pseudomonas aeruginosa ; Klebsiella spp.; Escherichia coli ; Proteus spp., including Proteus mirabilis and indole-positive Proteus ; Enterobacter spp.; Serratia spp.; Staphylococcus aureus (methicillin-susceptible strains); and Streptococcus pyogenes (group A beta-hemolytic streptococci). 3. Urinary Tract Infections, both complicated and uncomplicated, caused by Pseudomonas aeruginosa ; Enterobacter spp.; Proteus spp., including Proteus mirabilis and indole-positive Proteus ; Klebsiella spp.; and Escherichia coli . 4. Bacterial Septicemia caused by Pseudomonas aeruginosa , Klebsiella spp., Haemophilus influenzae, Escherichia coli , Serratia spp., Streptococcus pneumoniae, and Staphylococcus aureus (methicillin-susceptible strains). 5. Bone and Joint Infections caused by Pseudomonas aeruginosa, Klebsiella spp., Enterobacter spp., and Staphylococcus aureus (methicillin-susceptible strains). 6. Gynecologic Infections, including endometritis, pelvic cellulitis, and other infections of the female genital tract caused by Escherichia coli . 7. Intra-abdominal Infections, including peritonitis caused by Escherichia coli , Klebsiella spp., and Staphylococcus aureus (methicillin-susceptible strains) and polymicrobial infections caused by aerobic and anaerobic organisms and Bacteroides spp. (many strains of Bacteroides fragilis are resistant). 8. Central Nervous System Infections, including meningitis, caused by Haemophilus influenzae and Neisseria meningitidis . Ceftazidime has also been used successfully in a limited number of cases of meningitis due to Pseudomonas aeruginosa and Streptococcus pneumoniae. FORTAZ may be used alone in cases of confirmed or suspected sepsis. Ceftazidime has been used successfully in clinical trials as empiric therapy in cases where various concomitant therapies with other antibacterial drugs have been used. FORTAZ may also be used concomitantly with other antibacterial drugs, such as aminoglycosides, vancomycin, and clindamycin; in severe and life-threatening infections; and in the immunocompromised patient. When such concomitant treatment is appropriate, prescribing information in the labeling for the other antibacterial drugs should be followed. The dose depends on the severity of the infection and the patient's condition. To reduce the development of drug-resistant bacteria and maintain the effectiveness of FORTAZ and other antibacterial drugs, FORTAZ should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:b7c34e94-4bfa-4afc-b707-ab965e3af95a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3508 biolink:treats UMLS:C0684256 PMID:41385096 "[{""id"":""uuid:fc91f64d-c6e4-4ab3-9c8b-347018f312bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e1dff7d5-9484-4d36-85bb-f305ef0054a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FORTAZ is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: 1. Lower Respiratory Tract Infections, including pneumonia, caused by Pseudomonas aeruginosa and other Pseudomonas spp.; Haemophilus influenzae , including ampicillin-resistant strains; Klebsiella spp.; Enterobacter spp.; Proteus mirabilis ; Escherichia coli ; Serratia spp.; Citrobacter spp.; Streptococcus pneumoniae ; and Staphylococcus aureus (methicillin-susceptible strains). 2. Skin and Skin-Structure Infections caused by Pseudomonas aeruginosa ; Klebsiella spp.; Escherichia coli ; Proteus spp., including Proteus mirabilis and indole-positive Proteus ; Enterobacter spp.; Serratia spp.; Staphylococcus aureus (methicillin-susceptible strains); and Streptococcus pyogenes (group A beta-hemolytic streptococci). 3. Urinary Tract Infections, both complicated and uncomplicated, caused by Pseudomonas aeruginosa ; Enterobacter spp.; Proteus spp., including Proteus mirabilis and indole-positive Proteus ; Klebsiella spp.; and Escherichia coli . 4. Bacterial Septicemia caused by Pseudomonas aeruginosa , Klebsiella spp., Haemophilus influenzae, Escherichia coli , Serratia spp., Streptococcus pneumoniae, and Staphylococcus aureus (methicillin-susceptible strains). 5. Bone and Joint Infections caused by Pseudomonas aeruginosa, Klebsiella spp., Enterobacter spp., and Staphylococcus aureus (methicillin-susceptible strains). 6. Gynecologic Infections, including endometritis, pelvic cellulitis, and other infections of the female genital tract caused by Escherichia coli . 7. Intra-abdominal Infections, including peritonitis caused by Escherichia coli , Klebsiella spp., and Staphylococcus aureus (methicillin-susceptible strains) and polymicrobial infections caused by aerobic and anaerobic organisms and Bacteroides spp. (many strains of Bacteroides fragilis are resistant). 8. Central Nervous System Infections, including meningitis, caused by Haemophilus influenzae and Neisseria meningitidis . Ceftazidime has also been used successfully in a limited number of cases of meningitis due to Pseudomonas aeruginosa and Streptococcus pneumoniae. FORTAZ may be used alone in cases of confirmed or suspected sepsis. Ceftazidime has been used successfully in clinical trials as empiric therapy in cases where various concomitant therapies with other antibacterial drugs have been used. FORTAZ may also be used concomitantly with other antibacterial drugs, such as aminoglycosides, vancomycin, and clindamycin; in severe and life-threatening infections; and in the immunocompromised patient. When such concomitant treatment is appropriate, prescribing information in the labeling for the other antibacterial drugs should be followed. The dose depends on the severity of the infection and the patient's condition. To reduce the development of drug-resistant bacteria and maintain the effectiveness of FORTAZ and other antibacterial drugs, FORTAZ should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:dd5d90f5-4a37-4585-822a-eb13ed59a43e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3508 biolink:treats UMLS:C0851989 PMID:41385096 "[{""id"":""uuid:e91f113b-4467-485d-b697-2768dfc922d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:81e65729-2ae1-4ff1-8934-e4e13bdcfcdf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FORTAZ is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: 1. Lower Respiratory Tract Infections, including pneumonia, caused by Pseudomonas aeruginosa and other Pseudomonas spp.; Haemophilus influenzae , including ampicillin-resistant strains; Klebsiella spp.; Enterobacter spp.; Proteus mirabilis ; Escherichia coli ; Serratia spp.; Citrobacter spp.; Streptococcus pneumoniae ; and Staphylococcus aureus (methicillin-susceptible strains). 2. Skin and Skin-Structure Infections caused by Pseudomonas aeruginosa ; Klebsiella spp.; Escherichia coli ; Proteus spp., including Proteus mirabilis and indole-positive Proteus ; Enterobacter spp.; Serratia spp.; Staphylococcus aureus (methicillin-susceptible strains); and Streptococcus pyogenes (group A beta-hemolytic streptococci). 3. Urinary Tract Infections, both complicated and uncomplicated, caused by Pseudomonas aeruginosa ; Enterobacter spp.; Proteus spp., including Proteus mirabilis and indole-positive Proteus ; Klebsiella spp.; and Escherichia coli . 4. Bacterial Septicemia caused by Pseudomonas aeruginosa , Klebsiella spp., Haemophilus influenzae, Escherichia coli , Serratia spp., Streptococcus pneumoniae, and Staphylococcus aureus (methicillin-susceptible strains). 5. Bone and Joint Infections caused by Pseudomonas aeruginosa, Klebsiella spp., Enterobacter spp., and Staphylococcus aureus (methicillin-susceptible strains). 6. Gynecologic Infections, including endometritis, pelvic cellulitis, and other infections of the female genital tract caused by Escherichia coli . 7. Intra-abdominal Infections, including peritonitis caused by Escherichia coli , Klebsiella spp., and Staphylococcus aureus (methicillin-susceptible strains) and polymicrobial infections caused by aerobic and anaerobic organisms and Bacteroides spp. (many strains of Bacteroides fragilis are resistant). 8. Central Nervous System Infections, including meningitis, caused by Haemophilus influenzae and Neisseria meningitidis . Ceftazidime has also been used successfully in a limited number of cases of meningitis due to Pseudomonas aeruginosa and Streptococcus pneumoniae. FORTAZ may be used alone in cases of confirmed or suspected sepsis. Ceftazidime has been used successfully in clinical trials as empiric therapy in cases where various concomitant therapies with other antibacterial drugs have been used. FORTAZ may also be used concomitantly with other antibacterial drugs, such as aminoglycosides, vancomycin, and clindamycin; in severe and life-threatening infections; and in the immunocompromised patient. When such concomitant treatment is appropriate, prescribing information in the labeling for the other antibacterial drugs should be followed. The dose depends on the severity of the infection and the patient's condition. To reduce the development of drug-resistant bacteria and maintain the effectiveness of FORTAZ and other antibacterial drugs, FORTAZ should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:8e5566af-ca42-4a03-ae27-d0ce464028e7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3508 biolink:treats MONDO:0000918 PMID:41385096 "[{""id"":""uuid:b911efe0-5218-484b-86ce-4c5fb661b67b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:644d562c-d31e-41f5-96c4-5b2add63d307"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FORTAZ is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: 1. Lower Respiratory Tract Infections, including pneumonia, caused by Pseudomonas aeruginosa and other Pseudomonas spp.; Haemophilus influenzae , including ampicillin-resistant strains; Klebsiella spp.; Enterobacter spp.; Proteus mirabilis ; Escherichia coli ; Serratia spp.; Citrobacter spp.; Streptococcus pneumoniae ; and Staphylococcus aureus (methicillin-susceptible strains). 2. Skin and Skin-Structure Infections caused by Pseudomonas aeruginosa ; Klebsiella spp.; Escherichia coli ; Proteus spp., including Proteus mirabilis and indole-positive Proteus ; Enterobacter spp.; Serratia spp.; Staphylococcus aureus (methicillin-susceptible strains); and Streptococcus pyogenes (group A beta-hemolytic streptococci). 3. Urinary Tract Infections, both complicated and uncomplicated, caused by Pseudomonas aeruginosa ; Enterobacter spp.; Proteus spp., including Proteus mirabilis and indole-positive Proteus ; Klebsiella spp.; and Escherichia coli . 4. Bacterial Septicemia caused by Pseudomonas aeruginosa , Klebsiella spp., Haemophilus influenzae, Escherichia coli , Serratia spp., Streptococcus pneumoniae, and Staphylococcus aureus (methicillin-susceptible strains). 5. Bone and Joint Infections caused by Pseudomonas aeruginosa, Klebsiella spp., Enterobacter spp., and Staphylococcus aureus (methicillin-susceptible strains). 6. Gynecologic Infections, including endometritis, pelvic cellulitis, and other infections of the female genital tract caused by Escherichia coli . 7. Intra-abdominal Infections, including peritonitis caused by Escherichia coli , Klebsiella spp., and Staphylococcus aureus (methicillin-susceptible strains) and polymicrobial infections caused by aerobic and anaerobic organisms and Bacteroides spp. (many strains of Bacteroides fragilis are resistant). 8. Central Nervous System Infections, including meningitis, caused by Haemophilus influenzae and Neisseria meningitidis . Ceftazidime has also been used successfully in a limited number of cases of meningitis due to Pseudomonas aeruginosa and Streptococcus pneumoniae. FORTAZ may be used alone in cases of confirmed or suspected sepsis. Ceftazidime has been used successfully in clinical trials as empiric therapy in cases where various concomitant therapies with other antibacterial drugs have been used. FORTAZ may also be used concomitantly with other antibacterial drugs, such as aminoglycosides, vancomycin, and clindamycin; in severe and life-threatening infections; and in the immunocompromised patient. When such concomitant treatment is appropriate, prescribing information in the labeling for the other antibacterial drugs should be followed. The dose depends on the severity of the infection and the patient's condition. To reduce the development of drug-resistant bacteria and maintain the effectiveness of FORTAZ and other antibacterial drugs, FORTAZ should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:1313c540-cb6a-45e2-83f0-6461320d0541 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3508 biolink:treats MONDO:0006887 PMID:41385096 "[{""id"":""uuid:0608acbd-d348-462f-acd6-2c73535252b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4d837941-81de-49c0-854d-29136d0e582f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FORTAZ is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: 1. Lower Respiratory Tract Infections, including pneumonia, caused by Pseudomonas aeruginosa and other Pseudomonas spp.; Haemophilus influenzae , including ampicillin-resistant strains; Klebsiella spp.; Enterobacter spp.; Proteus mirabilis ; Escherichia coli ; Serratia spp.; Citrobacter spp.; Streptococcus pneumoniae ; and Staphylococcus aureus (methicillin-susceptible strains). 2. Skin and Skin-Structure Infections caused by Pseudomonas aeruginosa ; Klebsiella spp.; Escherichia coli ; Proteus spp., including Proteus mirabilis and indole-positive Proteus ; Enterobacter spp.; Serratia spp.; Staphylococcus aureus (methicillin-susceptible strains); and Streptococcus pyogenes (group A beta-hemolytic streptococci). 3. Urinary Tract Infections, both complicated and uncomplicated, caused by Pseudomonas aeruginosa ; Enterobacter spp.; Proteus spp., including Proteus mirabilis and indole-positive Proteus ; Klebsiella spp.; and Escherichia coli . 4. Bacterial Septicemia caused by Pseudomonas aeruginosa , Klebsiella spp., Haemophilus influenzae, Escherichia coli , Serratia spp., Streptococcus pneumoniae, and Staphylococcus aureus (methicillin-susceptible strains). 5. Bone and Joint Infections caused by Pseudomonas aeruginosa, Klebsiella spp., Enterobacter spp., and Staphylococcus aureus (methicillin-susceptible strains). 6. Gynecologic Infections, including endometritis, pelvic cellulitis, and other infections of the female genital tract caused by Escherichia coli . 7. Intra-abdominal Infections, including peritonitis caused by Escherichia coli , Klebsiella spp., and Staphylococcus aureus (methicillin-susceptible strains) and polymicrobial infections caused by aerobic and anaerobic organisms and Bacteroides spp. (many strains of Bacteroides fragilis are resistant). 8. Central Nervous System Infections, including meningitis, caused by Haemophilus influenzae and Neisseria meningitidis . Ceftazidime has also been used successfully in a limited number of cases of meningitis due to Pseudomonas aeruginosa and Streptococcus pneumoniae. FORTAZ may be used alone in cases of confirmed or suspected sepsis. Ceftazidime has been used successfully in clinical trials as empiric therapy in cases where various concomitant therapies with other antibacterial drugs have been used. FORTAZ may also be used concomitantly with other antibacterial drugs, such as aminoglycosides, vancomycin, and clindamycin; in severe and life-threatening infections; and in the immunocompromised patient. When such concomitant treatment is appropriate, prescribing information in the labeling for the other antibacterial drugs should be followed. The dose depends on the severity of the infection and the patient's condition. To reduce the development of drug-resistant bacteria and maintain the effectiveness of FORTAZ and other antibacterial drugs, FORTAZ should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:7d9c197f-8d0f-4650-a77c-c4e0ee958c06 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3508 biolink:treats UMLS:C1112209 PMID:41385096 "[{""id"":""uuid:7757be09-af88-4934-b47a-362e0aae089d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3480fdc4-1d00-4950-9b39-71eeced64db0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FORTAZ is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: 1. Lower Respiratory Tract Infections, including pneumonia, caused by Pseudomonas aeruginosa and other Pseudomonas spp.; Haemophilus influenzae , including ampicillin-resistant strains; Klebsiella spp.; Enterobacter spp.; Proteus mirabilis ; Escherichia coli ; Serratia spp.; Citrobacter spp.; Streptococcus pneumoniae ; and Staphylococcus aureus (methicillin-susceptible strains). 2. Skin and Skin-Structure Infections caused by Pseudomonas aeruginosa ; Klebsiella spp.; Escherichia coli ; Proteus spp., including Proteus mirabilis and indole-positive Proteus ; Enterobacter spp.; Serratia spp.; Staphylococcus aureus (methicillin-susceptible strains); and Streptococcus pyogenes (group A beta-hemolytic streptococci). 3. Urinary Tract Infections, both complicated and uncomplicated, caused by Pseudomonas aeruginosa ; Enterobacter spp.; Proteus spp., including Proteus mirabilis and indole-positive Proteus ; Klebsiella spp.; and Escherichia coli . 4. Bacterial Septicemia caused by Pseudomonas aeruginosa , Klebsiella spp., Haemophilus influenzae, Escherichia coli , Serratia spp., Streptococcus pneumoniae, and Staphylococcus aureus (methicillin-susceptible strains). 5. Bone and Joint Infections caused by Pseudomonas aeruginosa, Klebsiella spp., Enterobacter spp., and Staphylococcus aureus (methicillin-susceptible strains). 6. Gynecologic Infections, including endometritis, pelvic cellulitis, and other infections of the female genital tract caused by Escherichia coli . 7. Intra-abdominal Infections, including peritonitis caused by Escherichia coli , Klebsiella spp., and Staphylococcus aureus (methicillin-susceptible strains) and polymicrobial infections caused by aerobic and anaerobic organisms and Bacteroides spp. (many strains of Bacteroides fragilis are resistant). 8. Central Nervous System Infections, including meningitis, caused by Haemophilus influenzae and Neisseria meningitidis . Ceftazidime has also been used successfully in a limited number of cases of meningitis due to Pseudomonas aeruginosa and Streptococcus pneumoniae. FORTAZ may be used alone in cases of confirmed or suspected sepsis. Ceftazidime has been used successfully in clinical trials as empiric therapy in cases where various concomitant therapies with other antibacterial drugs have been used. FORTAZ may also be used concomitantly with other antibacterial drugs, such as aminoglycosides, vancomycin, and clindamycin; in severe and life-threatening infections; and in the immunocompromised patient. When such concomitant treatment is appropriate, prescribing information in the labeling for the other antibacterial drugs should be followed. The dose depends on the severity of the infection and the patient's condition. To reduce the development of drug-resistant bacteria and maintain the effectiveness of FORTAZ and other antibacterial drugs, FORTAZ should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:14710710-3850-452f-bca9-a4ad5a62319a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3508 biolink:treats MONDO:0004522 PMID:41385096 "[{""id"":""uuid:0007ed74-e010-4e1f-8662-3e9dcde92868"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4befd336-6db6-4c30-b979-b801a22730b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FORTAZ is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: 1. Lower Respiratory Tract Infections, including pneumonia, caused by Pseudomonas aeruginosa and other Pseudomonas spp.; Haemophilus influenzae , including ampicillin-resistant strains; Klebsiella spp.; Enterobacter spp.; Proteus mirabilis ; Escherichia coli ; Serratia spp.; Citrobacter spp.; Streptococcus pneumoniae ; and Staphylococcus aureus (methicillin-susceptible strains). 2. Skin and Skin-Structure Infections caused by Pseudomonas aeruginosa ; Klebsiella spp.; Escherichia coli ; Proteus spp., including Proteus mirabilis and indole-positive Proteus ; Enterobacter spp.; Serratia spp.; Staphylococcus aureus (methicillin-susceptible strains); and Streptococcus pyogenes (group A beta-hemolytic streptococci). 3. Urinary Tract Infections, both complicated and uncomplicated, caused by Pseudomonas aeruginosa ; Enterobacter spp.; Proteus spp., including Proteus mirabilis and indole-positive Proteus ; Klebsiella spp.; and Escherichia coli . 4. Bacterial Septicemia caused by Pseudomonas aeruginosa , Klebsiella spp., Haemophilus influenzae, Escherichia coli , Serratia spp., Streptococcus pneumoniae, and Staphylococcus aureus (methicillin-susceptible strains). 5. Bone and Joint Infections caused by Pseudomonas aeruginosa, Klebsiella spp., Enterobacter spp., and Staphylococcus aureus (methicillin-susceptible strains). 6. Gynecologic Infections, including endometritis, pelvic cellulitis, and other infections of the female genital tract caused by Escherichia coli . 7. Intra-abdominal Infections, including peritonitis caused by Escherichia coli , Klebsiella spp., and Staphylococcus aureus (methicillin-susceptible strains) and polymicrobial infections caused by aerobic and anaerobic organisms and Bacteroides spp. (many strains of Bacteroides fragilis are resistant). 8. Central Nervous System Infections, including meningitis, caused by Haemophilus influenzae and Neisseria meningitidis . Ceftazidime has also been used successfully in a limited number of cases of meningitis due to Pseudomonas aeruginosa and Streptococcus pneumoniae. FORTAZ may be used alone in cases of confirmed or suspected sepsis. Ceftazidime has been used successfully in clinical trials as empiric therapy in cases where various concomitant therapies with other antibacterial drugs have been used. FORTAZ may also be used concomitantly with other antibacterial drugs, such as aminoglycosides, vancomycin, and clindamycin; in severe and life-threatening infections; and in the immunocompromised patient. When such concomitant treatment is appropriate, prescribing information in the labeling for the other antibacterial drugs should be followed. The dose depends on the severity of the infection and the patient's condition. To reduce the development of drug-resistant bacteria and maintain the effectiveness of FORTAZ and other antibacterial drugs, FORTAZ should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:4e69a3a4-9336-40e8-b3c9-c0d07138ca9a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3508 biolink:treats MONDO:0024619 PMID:41385096 "[{""id"":""uuid:a88c243d-54e7-4b00-a3a5-fd21b0a5f49d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:904b640d-1c0b-4215-a48b-aa4c93e342f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FORTAZ is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: 1. Lower Respiratory Tract Infections, including pneumonia, caused by Pseudomonas aeruginosa and other Pseudomonas spp.; Haemophilus influenzae , including ampicillin-resistant strains; Klebsiella spp.; Enterobacter spp.; Proteus mirabilis ; Escherichia coli ; Serratia spp.; Citrobacter spp.; Streptococcus pneumoniae ; and Staphylococcus aureus (methicillin-susceptible strains). 2. Skin and Skin-Structure Infections caused by Pseudomonas aeruginosa ; Klebsiella spp.; Escherichia coli ; Proteus spp., including Proteus mirabilis and indole-positive Proteus ; Enterobacter spp.; Serratia spp.; Staphylococcus aureus (methicillin-susceptible strains); and Streptococcus pyogenes (group A beta-hemolytic streptococci). 3. Urinary Tract Infections, both complicated and uncomplicated, caused by Pseudomonas aeruginosa ; Enterobacter spp.; Proteus spp., including Proteus mirabilis and indole-positive Proteus ; Klebsiella spp.; and Escherichia coli . 4. Bacterial Septicemia caused by Pseudomonas aeruginosa , Klebsiella spp., Haemophilus influenzae, Escherichia coli , Serratia spp., Streptococcus pneumoniae, and Staphylococcus aureus (methicillin-susceptible strains). 5. Bone and Joint Infections caused by Pseudomonas aeruginosa, Klebsiella spp., Enterobacter spp., and Staphylococcus aureus (methicillin-susceptible strains). 6. Gynecologic Infections, including endometritis, pelvic cellulitis, and other infections of the female genital tract caused by Escherichia coli . 7. Intra-abdominal Infections, including peritonitis caused by Escherichia coli , Klebsiella spp., and Staphylococcus aureus (methicillin-susceptible strains) and polymicrobial infections caused by aerobic and anaerobic organisms and Bacteroides spp. (many strains of Bacteroides fragilis are resistant). 8. Central Nervous System Infections, including meningitis, caused by Haemophilus influenzae and Neisseria meningitidis . Ceftazidime has also been used successfully in a limited number of cases of meningitis due to Pseudomonas aeruginosa and Streptococcus pneumoniae. FORTAZ may be used alone in cases of confirmed or suspected sepsis. Ceftazidime has been used successfully in clinical trials as empiric therapy in cases where various concomitant therapies with other antibacterial drugs have been used. FORTAZ may also be used concomitantly with other antibacterial drugs, such as aminoglycosides, vancomycin, and clindamycin; in severe and life-threatening infections; and in the immunocompromised patient. When such concomitant treatment is appropriate, prescribing information in the labeling for the other antibacterial drugs should be followed. The dose depends on the severity of the infection and the patient's condition. To reduce the development of drug-resistant bacteria and maintain the effectiveness of FORTAZ and other antibacterial drugs, FORTAZ should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:9d687f18-ea72-4355-bbb1-646e3ebbefdf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3508 biolink:treats MONDO:0021108 PMID:41385096 "[{""id"":""uuid:04021719-ca08-4542-97fd-650e0ba76843"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e5b5bded-0fdd-4b70-b076-9d7cdb0cb359"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FORTAZ is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: 1. Lower Respiratory Tract Infections, including pneumonia, caused by Pseudomonas aeruginosa and other Pseudomonas spp.; Haemophilus influenzae , including ampicillin-resistant strains; Klebsiella spp.; Enterobacter spp.; Proteus mirabilis ; Escherichia coli ; Serratia spp.; Citrobacter spp.; Streptococcus pneumoniae ; and Staphylococcus aureus (methicillin-susceptible strains). 2. Skin and Skin-Structure Infections caused by Pseudomonas aeruginosa ; Klebsiella spp.; Escherichia coli ; Proteus spp., including Proteus mirabilis and indole-positive Proteus ; Enterobacter spp.; Serratia spp.; Staphylococcus aureus (methicillin-susceptible strains); and Streptococcus pyogenes (group A beta-hemolytic streptococci). 3. Urinary Tract Infections, both complicated and uncomplicated, caused by Pseudomonas aeruginosa ; Enterobacter spp.; Proteus spp., including Proteus mirabilis and indole-positive Proteus ; Klebsiella spp.; and Escherichia coli . 4. Bacterial Septicemia caused by Pseudomonas aeruginosa , Klebsiella spp., Haemophilus influenzae, Escherichia coli , Serratia spp., Streptococcus pneumoniae, and Staphylococcus aureus (methicillin-susceptible strains). 5. Bone and Joint Infections caused by Pseudomonas aeruginosa, Klebsiella spp., Enterobacter spp., and Staphylococcus aureus (methicillin-susceptible strains). 6. Gynecologic Infections, including endometritis, pelvic cellulitis, and other infections of the female genital tract caused by Escherichia coli . 7. Intra-abdominal Infections, including peritonitis caused by Escherichia coli , Klebsiella spp., and Staphylococcus aureus (methicillin-susceptible strains) and polymicrobial infections caused by aerobic and anaerobic organisms and Bacteroides spp. (many strains of Bacteroides fragilis are resistant). 8. Central Nervous System Infections, including meningitis, caused by Haemophilus influenzae and Neisseria meningitidis . Ceftazidime has also been used successfully in a limited number of cases of meningitis due to Pseudomonas aeruginosa and Streptococcus pneumoniae. FORTAZ may be used alone in cases of confirmed or suspected sepsis. Ceftazidime has been used successfully in clinical trials as empiric therapy in cases where various concomitant therapies with other antibacterial drugs have been used. FORTAZ may also be used concomitantly with other antibacterial drugs, such as aminoglycosides, vancomycin, and clindamycin; in severe and life-threatening infections; and in the immunocompromised patient. When such concomitant treatment is appropriate, prescribing information in the labeling for the other antibacterial drugs should be followed. The dose depends on the severity of the infection and the patient's condition. To reduce the development of drug-resistant bacteria and maintain the effectiveness of FORTAZ and other antibacterial drugs, FORTAZ should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:bf8b45be-8378-41a5-8b52-440da105285b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3508 biolink:treats HP:0100806 PMID:41385096 "[{""id"":""uuid:fb269519-a6a2-4a89-8d94-56591fb1c91a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:70a0e341-c0c5-4a97-8f7e-429f76037fc6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FORTAZ is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: 1. Lower Respiratory Tract Infections, including pneumonia, caused by Pseudomonas aeruginosa and other Pseudomonas spp.; Haemophilus influenzae , including ampicillin-resistant strains; Klebsiella spp.; Enterobacter spp.; Proteus mirabilis ; Escherichia coli ; Serratia spp.; Citrobacter spp.; Streptococcus pneumoniae ; and Staphylococcus aureus (methicillin-susceptible strains). 2. Skin and Skin-Structure Infections caused by Pseudomonas aeruginosa ; Klebsiella spp.; Escherichia coli ; Proteus spp., including Proteus mirabilis and indole-positive Proteus ; Enterobacter spp.; Serratia spp.; Staphylococcus aureus (methicillin-susceptible strains); and Streptococcus pyogenes (group A beta-hemolytic streptococci). 3. Urinary Tract Infections, both complicated and uncomplicated, caused by Pseudomonas aeruginosa ; Enterobacter spp.; Proteus spp., including Proteus mirabilis and indole-positive Proteus ; Klebsiella spp.; and Escherichia coli . 4. Bacterial Septicemia caused by Pseudomonas aeruginosa , Klebsiella spp., Haemophilus influenzae, Escherichia coli , Serratia spp., Streptococcus pneumoniae, and Staphylococcus aureus (methicillin-susceptible strains). 5. Bone and Joint Infections caused by Pseudomonas aeruginosa, Klebsiella spp., Enterobacter spp., and Staphylococcus aureus (methicillin-susceptible strains). 6. Gynecologic Infections, including endometritis, pelvic cellulitis, and other infections of the female genital tract caused by Escherichia coli . 7. Intra-abdominal Infections, including peritonitis caused by Escherichia coli , Klebsiella spp., and Staphylococcus aureus (methicillin-susceptible strains) and polymicrobial infections caused by aerobic and anaerobic organisms and Bacteroides spp. (many strains of Bacteroides fragilis are resistant). 8. Central Nervous System Infections, including meningitis, caused by Haemophilus influenzae and Neisseria meningitidis . Ceftazidime has also been used successfully in a limited number of cases of meningitis due to Pseudomonas aeruginosa and Streptococcus pneumoniae. FORTAZ may be used alone in cases of confirmed or suspected sepsis. Ceftazidime has been used successfully in clinical trials as empiric therapy in cases where various concomitant therapies with other antibacterial drugs have been used. FORTAZ may also be used concomitantly with other antibacterial drugs, such as aminoglycosides, vancomycin, and clindamycin; in severe and life-threatening infections; and in the immunocompromised patient. When such concomitant treatment is appropriate, prescribing information in the labeling for the other antibacterial drugs should be followed. The dose depends on the severity of the infection and the patient's condition. To reduce the development of drug-resistant bacteria and maintain the effectiveness of FORTAZ and other antibacterial drugs, FORTAZ should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:00a4abf4-ca15-42b5-95f4-487f768b898f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3W5S57M958 biolink:treats UMLS:C0853854 PMID:41385096 "[{""id"":""uuid:eea919ac-14c5-4e37-907c-52c023d713fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f68df322-9643-4f19-ac7e-6eb5163e9ac5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azithromycin tablets are a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications. [see DOSAGE AND ADMINISTRATION (2)] 1.1 Adult Patients Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae , Moraxella catarrhalis, or Streptococcus pneumoniae . Acute bacterial sinusitis due to Haemophilus influenzae , Moraxella catarrhalis or Streptococcus pneumoniae . Community-acquired pneumonia due to Chlamydophila pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae, or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. Uncomplicated skin and skin structure infections due to Staphylococcus aureus , Streptococcus pyogenes , or Streptococcus agalactiae . Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae . Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. 1.2 Pediatric Patients [see USE IN SPECIFIC POPULATIONS (8.4) and CLINICAL STUDIES (14.2)] Acute otitis media (>6 months of age) caused by Haemophilus influenzae , Moraxella catarrhalis, or Streptococcus pneumoniae. Community-acquired pneumonia (>6 months ofage) due to Chlamydophila pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae , or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis (>2 years of age) caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. 1.3 Limitations of Use Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomial infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). 1.4 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. PUBCHEM.COMPOUND:16156 uuid:7114c2f2-29ba-4d9b-a9a7-7801ca37597d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3W5S57M958 biolink:treats UMLS:C0275556 PMID:41385096 "[{""id"":""uuid:f973e8b6-8184-46c8-8d7e-190bf97dfe18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:730bce33-4ef9-40c8-a682-7839b4b02834"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azithromycin tablets are a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications. [see DOSAGE AND ADMINISTRATION (2)] 1.1 Adult Patients Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae , Moraxella catarrhalis, or Streptococcus pneumoniae . Acute bacterial sinusitis due to Haemophilus influenzae , Moraxella catarrhalis or Streptococcus pneumoniae . Community-acquired pneumonia due to Chlamydophila pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae, or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. Uncomplicated skin and skin structure infections due to Staphylococcus aureus , Streptococcus pyogenes , or Streptococcus agalactiae . Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae . Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. 1.2 Pediatric Patients [see USE IN SPECIFIC POPULATIONS (8.4) and CLINICAL STUDIES (14.2)] Acute otitis media (>6 months of age) caused by Haemophilus influenzae , Moraxella catarrhalis, or Streptococcus pneumoniae. Community-acquired pneumonia (>6 months ofage) due to Chlamydophila pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae , or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis (>2 years of age) caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. 1.3 Limitations of Use Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomial infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). 1.4 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. PUBCHEM.COMPOUND:16156 uuid:d44a402c-54f3-4465-af18-5a33b92b75e9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3W5S57M958 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:2713bdc9-9040-40c5-ab19-7bab625d9eec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:48aa2496-4611-4149-9ba8-075b0382b2af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azithromycin tablets are a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications. [see DOSAGE AND ADMINISTRATION (2)] 1.1 Adult Patients Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae , Moraxella catarrhalis, or Streptococcus pneumoniae . Acute bacterial sinusitis due to Haemophilus influenzae , Moraxella catarrhalis or Streptococcus pneumoniae . Community-acquired pneumonia due to Chlamydophila pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae, or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. Uncomplicated skin and skin structure infections due to Staphylococcus aureus , Streptococcus pyogenes , or Streptococcus agalactiae . Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae . Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. 1.2 Pediatric Patients [see USE IN SPECIFIC POPULATIONS (8.4) and CLINICAL STUDIES (14.2)] Acute otitis media (>6 months of age) caused by Haemophilus influenzae , Moraxella catarrhalis, or Streptococcus pneumoniae. Community-acquired pneumonia (>6 months ofage) due to Chlamydophila pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae , or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis (>2 years of age) caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. 1.3 Limitations of Use Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomial infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). 1.4 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. PUBCHEM.COMPOUND:16156 uuid:52d91edb-2309-4a88-9e86-400766f702ae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3W5S57M958 biolink:treats MONDO:0002258 PMID:41385096 "[{""id"":""uuid:b0ef9f8a-be18-4223-bc7a-ba9bf52a383c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2264fb25-8071-4a7d-925c-e54fb22b9654"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azithromycin tablets are a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications. [see DOSAGE AND ADMINISTRATION (2)] 1.1 Adult Patients Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae , Moraxella catarrhalis, or Streptococcus pneumoniae . Acute bacterial sinusitis due to Haemophilus influenzae , Moraxella catarrhalis or Streptococcus pneumoniae . Community-acquired pneumonia due to Chlamydophila pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae, or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. Uncomplicated skin and skin structure infections due to Staphylococcus aureus , Streptococcus pyogenes , or Streptococcus agalactiae . Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae . Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. 1.2 Pediatric Patients [see USE IN SPECIFIC POPULATIONS (8.4) and CLINICAL STUDIES (14.2)] Acute otitis media (>6 months of age) caused by Haemophilus influenzae , Moraxella catarrhalis, or Streptococcus pneumoniae. Community-acquired pneumonia (>6 months ofage) due to Chlamydophila pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae , or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis (>2 years of age) caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. 1.3 Limitations of Use Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomial infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). 1.4 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. PUBCHEM.COMPOUND:16156 uuid:0b499a32-7671-485a-bb05-79c3adb09451 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3W5S57M958 biolink:treats MONDO:0001039 PMID:41385096 "[{""id"":""uuid:898fb476-4cec-4a4b-8857-df45f15c8739"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:21a4d20d-5427-45ce-859a-cf86e9ff1549"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azithromycin tablets are a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications. [see DOSAGE AND ADMINISTRATION (2)] 1.1 Adult Patients Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae , Moraxella catarrhalis, or Streptococcus pneumoniae . Acute bacterial sinusitis due to Haemophilus influenzae , Moraxella catarrhalis or Streptococcus pneumoniae . Community-acquired pneumonia due to Chlamydophila pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae, or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. Uncomplicated skin and skin structure infections due to Staphylococcus aureus , Streptococcus pyogenes , or Streptococcus agalactiae . Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae . Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. 1.2 Pediatric Patients [see USE IN SPECIFIC POPULATIONS (8.4) and CLINICAL STUDIES (14.2)] Acute otitis media (>6 months of age) caused by Haemophilus influenzae , Moraxella catarrhalis, or Streptococcus pneumoniae. Community-acquired pneumonia (>6 months ofage) due to Chlamydophila pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae , or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis (>2 years of age) caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. 1.3 Limitations of Use Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomial infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). 1.4 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. PUBCHEM.COMPOUND:16156 uuid:33f59e48-8eb1-4112-8b4e-05d66ff8f5f4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3W5S57M958 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:67e67d28-48b3-4aa9-b9de-25757cabba37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:63f16794-4684-4a00-a270-ae320482186d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azithromycin tablets are a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications. [see DOSAGE AND ADMINISTRATION (2)] 1.1 Adult Patients Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae , Moraxella catarrhalis, or Streptococcus pneumoniae . Acute bacterial sinusitis due to Haemophilus influenzae , Moraxella catarrhalis or Streptococcus pneumoniae . Community-acquired pneumonia due to Chlamydophila pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae, or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. Uncomplicated skin and skin structure infections due to Staphylococcus aureus , Streptococcus pyogenes , or Streptococcus agalactiae . Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae . Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. 1.2 Pediatric Patients [see USE IN SPECIFIC POPULATIONS (8.4) and CLINICAL STUDIES (14.2)] Acute otitis media (>6 months of age) caused by Haemophilus influenzae , Moraxella catarrhalis, or Streptococcus pneumoniae. Community-acquired pneumonia (>6 months ofage) due to Chlamydophila pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae , or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis (>2 years of age) caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. 1.3 Limitations of Use Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomial infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). 1.4 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. PUBCHEM.COMPOUND:16156 uuid:8ddbfa3a-4179-4609-8ee4-fbf4d92108be biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3W5S57M958 biolink:treats MONDO:0005297 PMID:41385096 "[{""id"":""uuid:56af0cdd-5fd2-4db1-bc3f-93e68a2577b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:042dc297-a98c-4abb-b5bc-63a91a0bb499"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azithromycin tablets are a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications. [see DOSAGE AND ADMINISTRATION (2)] 1.1 Adult Patients Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae , Moraxella catarrhalis, or Streptococcus pneumoniae . Acute bacterial sinusitis due to Haemophilus influenzae , Moraxella catarrhalis or Streptococcus pneumoniae . Community-acquired pneumonia due to Chlamydophila pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae, or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. Uncomplicated skin and skin structure infections due to Staphylococcus aureus , Streptococcus pyogenes , or Streptococcus agalactiae . Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae . Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. 1.2 Pediatric Patients [see USE IN SPECIFIC POPULATIONS (8.4) and CLINICAL STUDIES (14.2)] Acute otitis media (>6 months of age) caused by Haemophilus influenzae , Moraxella catarrhalis, or Streptococcus pneumoniae. Community-acquired pneumonia (>6 months ofage) due to Chlamydophila pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae , or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis (>2 years of age) caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. 1.3 Limitations of Use Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomial infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). 1.4 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. PUBCHEM.COMPOUND:16156 uuid:6c566bb6-6e54-41fe-a3a8-cb58398731bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3W5S57M958 biolink:treats MONDO:0002345 PMID:41385096 "[{""id"":""uuid:68583a92-6c4d-4278-8466-f0c534093374"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a7192d4d-acb8-4cef-bb0c-fd20b3915e9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azithromycin tablets are a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications. [see DOSAGE AND ADMINISTRATION (2)] 1.1 Adult Patients Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae , Moraxella catarrhalis, or Streptococcus pneumoniae . Acute bacterial sinusitis due to Haemophilus influenzae , Moraxella catarrhalis or Streptococcus pneumoniae . Community-acquired pneumonia due to Chlamydophila pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae, or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. Uncomplicated skin and skin structure infections due to Staphylococcus aureus , Streptococcus pyogenes , or Streptococcus agalactiae . Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae . Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. 1.2 Pediatric Patients [see USE IN SPECIFIC POPULATIONS (8.4) and CLINICAL STUDIES (14.2)] Acute otitis media (>6 months of age) caused by Haemophilus influenzae , Moraxella catarrhalis, or Streptococcus pneumoniae. Community-acquired pneumonia (>6 months ofage) due to Chlamydophila pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae , or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis (>2 years of age) caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. 1.3 Limitations of Use Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomial infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). 1.4 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. PUBCHEM.COMPOUND:16156 uuid:55abeb23-e8dd-4a45-a1e0-d6418da93d54 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3W5S57M958 biolink:treats MONDO:0001797 PMID:41385096 "[{""id"":""uuid:81d0591d-764c-4186-bdda-6c8599fb19b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f1566754-ad26-4990-983b-c43131162f03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azithromycin tablets are a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications. [see DOSAGE AND ADMINISTRATION (2)] 1.1 Adult Patients Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae , Moraxella catarrhalis, or Streptococcus pneumoniae . Acute bacterial sinusitis due to Haemophilus influenzae , Moraxella catarrhalis or Streptococcus pneumoniae . Community-acquired pneumonia due to Chlamydophila pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae, or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. Uncomplicated skin and skin structure infections due to Staphylococcus aureus , Streptococcus pyogenes , or Streptococcus agalactiae . Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae . Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. 1.2 Pediatric Patients [see USE IN SPECIFIC POPULATIONS (8.4) and CLINICAL STUDIES (14.2)] Acute otitis media (>6 months of age) caused by Haemophilus influenzae , Moraxella catarrhalis, or Streptococcus pneumoniae. Community-acquired pneumonia (>6 months ofage) due to Chlamydophila pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae , or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis (>2 years of age) caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. 1.3 Limitations of Use Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomial infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). 1.4 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. PUBCHEM.COMPOUND:16156 uuid:b2e64673-b01a-42b8-85bd-fdb290983359 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3W5S57M958 biolink:treats HP:0000371 PMID:41385096 "[{""id"":""uuid:53f57487-a3c9-46db-8fc7-525d49775b5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:011f3a00-b5fe-4974-9fbf-c8df9b20a5f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azithromycin tablets are a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications. [see DOSAGE AND ADMINISTRATION (2)] 1.1 Adult Patients Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae , Moraxella catarrhalis, or Streptococcus pneumoniae . Acute bacterial sinusitis due to Haemophilus influenzae , Moraxella catarrhalis or Streptococcus pneumoniae . Community-acquired pneumonia due to Chlamydophila pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae, or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. Uncomplicated skin and skin structure infections due to Staphylococcus aureus , Streptococcus pyogenes , or Streptococcus agalactiae . Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae . Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. 1.2 Pediatric Patients [see USE IN SPECIFIC POPULATIONS (8.4) and CLINICAL STUDIES (14.2)] Acute otitis media (>6 months of age) caused by Haemophilus influenzae , Moraxella catarrhalis, or Streptococcus pneumoniae. Community-acquired pneumonia (>6 months ofage) due to Chlamydophila pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae , or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis (>2 years of age) caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. 1.3 Limitations of Use Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomial infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). 1.4 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. PUBCHEM.COMPOUND:16156 uuid:73ca6af4-8cb0-43d2-bc3d-dfdadc9be4d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3W5S57M958 biolink:treats MONDO:0009061 PMID:41385096 "[{""id"":""uuid:d6a3c9c3-af70-4f1e-b5b1-b609bd33e503"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:03d0e89c-363b-4f46-b266-01cbe163fd16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azithromycin tablets are a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications. [see DOSAGE AND ADMINISTRATION (2)] 1.1 Adult Patients Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae , Moraxella catarrhalis, or Streptococcus pneumoniae . Acute bacterial sinusitis due to Haemophilus influenzae , Moraxella catarrhalis or Streptococcus pneumoniae . Community-acquired pneumonia due to Chlamydophila pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae, or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. Uncomplicated skin and skin structure infections due to Staphylococcus aureus , Streptococcus pyogenes , or Streptococcus agalactiae . Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae . Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. 1.2 Pediatric Patients [see USE IN SPECIFIC POPULATIONS (8.4) and CLINICAL STUDIES (14.2)] Acute otitis media (>6 months of age) caused by Haemophilus influenzae , Moraxella catarrhalis, or Streptococcus pneumoniae. Community-acquired pneumonia (>6 months ofage) due to Chlamydophila pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae , or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis (>2 years of age) caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. 1.3 Limitations of Use Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomial infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). 1.4 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. PUBCHEM.COMPOUND:16156 uuid:6607333a-b42a-4643-b9f1-ce4920d0c658 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3W5S57M958 biolink:treats MONDO:0043544 PMID:41385096 "[{""id"":""uuid:4580ec19-28bc-4e99-8284-017f21b43708"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:513b9085-a779-474c-8d12-2f8c75de3e48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azithromycin tablets are a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications. [see DOSAGE AND ADMINISTRATION (2)] 1.1 Adult Patients Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae , Moraxella catarrhalis, or Streptococcus pneumoniae . Acute bacterial sinusitis due to Haemophilus influenzae , Moraxella catarrhalis or Streptococcus pneumoniae . Community-acquired pneumonia due to Chlamydophila pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae, or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. Uncomplicated skin and skin structure infections due to Staphylococcus aureus , Streptococcus pyogenes , or Streptococcus agalactiae . Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae . Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. 1.2 Pediatric Patients [see USE IN SPECIFIC POPULATIONS (8.4) and CLINICAL STUDIES (14.2)] Acute otitis media (>6 months of age) caused by Haemophilus influenzae , Moraxella catarrhalis, or Streptococcus pneumoniae. Community-acquired pneumonia (>6 months ofage) due to Chlamydophila pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae , or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis (>2 years of age) caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. 1.3 Limitations of Use Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomial infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). 1.4 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. PUBCHEM.COMPOUND:16156 uuid:6864e568-6641-4055-baee-5ded36720eaf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3W5S57M958 biolink:treats MONDO:0005229 PMID:41385096 "[{""id"":""uuid:7aece0ed-98eb-4069-ac49-27c13b07b4ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a2a1713c-a134-4db5-87d8-af1bdc20fa5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azithromycin tablets are a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Recommended dosages and durations of therapy in adult and pediatric patient populations vary in these indications. [see DOSAGE AND ADMINISTRATION (2)] 1.1 Adult Patients Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae , Moraxella catarrhalis, or Streptococcus pneumoniae . Acute bacterial sinusitis due to Haemophilus influenzae , Moraxella catarrhalis or Streptococcus pneumoniae . Community-acquired pneumonia due to Chlamydophila pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae, or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. Uncomplicated skin and skin structure infections due to Staphylococcus aureus , Streptococcus pyogenes , or Streptococcus agalactiae . Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae . Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. 1.2 Pediatric Patients [see USE IN SPECIFIC POPULATIONS (8.4) and CLINICAL STUDIES (14.2)] Acute otitis media (>6 months of age) caused by Haemophilus influenzae , Moraxella catarrhalis, or Streptococcus pneumoniae. Community-acquired pneumonia (>6 months ofage) due to Chlamydophila pneumoniae , Haemophilus influenzae , Mycoplasma pneumoniae , or Streptococcus pneumoniae in patients appropriate for oral therapy. Pharyngitis/tonsillitis (>2 years of age) caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. 1.3 Limitations of Use Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomial infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). 1.4 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin and other antibacterial drugs, azithromycin should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. PUBCHEM.COMPOUND:16156 uuid:0c16e291-9a7c-4270-81a8-11ffa4b8d719 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59173 biolink:treats MONDO:0018048 PMID:41385096 "[{""id"":""uuid:7fa0c1c9-0372-45d6-bf0a-dcc39ea4fb91"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c3ed3199-34c8-4322-aad1-4a4c10cfaf9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bivalirudin for injection is indicated for use as an anticoagulant for use in patients undergoing percutaneous coronary intervention (PCI) including patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. uuid:17ef5a8f-17d0-4bec-a4f8-32f60f93090d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59173 biolink:treats UMLS:C0272275 PMID:41385096 "[{""id"":""uuid:b5b05b00-6821-4ad3-919b-f1c84487a085"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c5d94006-16a1-41b3-ab01-f21c4b004ffa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bivalirudin for injection is indicated for use as an anticoagulant for use in patients undergoing percutaneous coronary intervention (PCI) including patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome. uuid:e8d7d5ae-4316-4fb1-9238-19174cff948d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4875 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:891063ff-5442-4d06-b1dc-797e6f3d6a74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fb48232e-cc0c-4012-951a-e459ea5a68fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2cacefee-4f7e-41e7-b9c1-b390ac82bd26"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/enbrel""]},{""id"":""uuid:5a5b64d9-490f-4a33-944c-4687d0a2760e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Enbrel is a tumor necrosis factor (TNF) blocker indicated for the treatment of: Rheumatoid Arthritis (RA) ( 1.1 ) Polyarticular Juvenile Idiopathic Arthritis (JIA) in patients aged 2 years or older ( 1.2 ) Psoriatic Arthritis (PsA) ( 1.3 ) Ankylosing Spondylitis (AS) ( 1.4 ) Plaque Psoriasis (PsO) in patients 4 years or older ( 1.5 )|[EMA] Rheumatoid arthritis, , Enbrel in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults when the response to disease-modifying antirheumatic drugs, including methotrexate (unless contraindicated), has been inadequate., , Enbrel can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate., , Enbrel is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate., , Enbrel, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function., , Juvenile idiopathic arthritis, , Treatment of polyarthritis (rheumatoid-factor-positive or -negative) and extended oligoarthritis in children and adolescents from the age of two years who have had an inadequate response to, or who have proved intolerant of, methotrexate., , Treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate., , Treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy., , Enbrel has not been studied in children aged less than two years., , Psoriatic arthritis, , Treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. Enbrel has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease., , Axial spondyloarthritis, , Ankylosing spondylitis (AS), , Treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy., , Non-radiographic axial spondyloarthritis, , Treatment of adults with severe non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to nonsteroidal anti-inflammatory drugs (NSAIDs). , , Plaque psoriasis , , Treatment of adults with moderate to severe plaque psoriasis who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy, including ciclosporin, methotrexate or psoralen and ultraviolet-A light (PUVA)., , Paediatric plaque psoriasis , , Treatment of chronic severe plaque psoriasis in children and adolescents from the age of six years who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.,|[PMDA] A drug containing a new active ingredient, humanized fusion protein having an inhibitory action on the binding of the tumor necrosis factor (TNF) to a TNF receptor that has indications for rheumatoid arthritis uuid:8796e513-cd31-42c8-bbe3-d7eff520077b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4875 biolink:treats MONDO:0018456 PMID:41385096 "[{""id"":""uuid:ac4c3255-9abe-4396-b4a8-e35b69ed78c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4a8bdc66-49c3-42dc-95f2-0e19dd86cf8e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Enbrel is a tumor necrosis factor (TNF) blocker indicated for the treatment of: Rheumatoid Arthritis (RA) ( 1.1 ) Polyarticular Juvenile Idiopathic Arthritis (JIA) in patients aged 2 years or older ( 1.2 ) Psoriatic Arthritis (PsA) ( 1.3 ) Ankylosing Spondylitis (AS) ( 1.4 ) Plaque Psoriasis (PsO) in patients 4 years or older ( 1.5 ) uuid:780e8ad9-a4ae-4b88-8cdf-f3f5e1d980fa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4875 biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:d3fa4d0d-2d30-4224-a6af-046f8867abfc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e4f5492b-0368-4a6c-96b0-a576b60d99d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:48bf5652-0b7d-4e1c-903d-4045da17ae77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/enbrel""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Enbrel is a tumor necrosis factor (TNF) blocker indicated for the treatment of: Rheumatoid Arthritis (RA) ( 1.1 ) Polyarticular Juvenile Idiopathic Arthritis (JIA) in patients aged 2 years or older ( 1.2 ) Psoriatic Arthritis (PsA) ( 1.3 ) Ankylosing Spondylitis (AS) ( 1.4 ) Plaque Psoriasis (PsO) in patients 4 years or older ( 1.5 )|[EMA] Rheumatoid arthritis, , Enbrel in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults when the response to disease-modifying antirheumatic drugs, including methotrexate (unless contraindicated), has been inadequate., , Enbrel can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate., , Enbrel is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate., , Enbrel, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function., , Juvenile idiopathic arthritis, , Treatment of polyarthritis (rheumatoid-factor-positive or -negative) and extended oligoarthritis in children and adolescents from the age of two years who have had an inadequate response to, or who have proved intolerant of, methotrexate., , Treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate., , Treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy., , Enbrel has not been studied in children aged less than two years., , Psoriatic arthritis, , Treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. Enbrel has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease., , Axial spondyloarthritis, , Ankylosing spondylitis (AS), , Treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy., , Non-radiographic axial spondyloarthritis, , Treatment of adults with severe non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to nonsteroidal anti-inflammatory drugs (NSAIDs). , , Plaque psoriasis , , Treatment of adults with moderate to severe plaque psoriasis who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy, including ciclosporin, methotrexate or psoralen and ultraviolet-A light (PUVA)., , Paediatric plaque psoriasis , , Treatment of chronic severe plaque psoriasis in children and adolescents from the age of six years who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies., uuid:cd865701-7602-48ef-8564-f14d30a127c8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4875 biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:e9b844aa-a650-47f6-9ec9-c055ed6118ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d309b821-4c53-4418-ac51-9844d9d5f5b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2632021c-f17f-4ba8-b35d-cc1ba6943fb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/enbrel""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Enbrel is a tumor necrosis factor (TNF) blocker indicated for the treatment of: Rheumatoid Arthritis (RA) ( 1.1 ) Polyarticular Juvenile Idiopathic Arthritis (JIA) in patients aged 2 years or older ( 1.2 ) Psoriatic Arthritis (PsA) ( 1.3 ) Ankylosing Spondylitis (AS) ( 1.4 ) Plaque Psoriasis (PsO) in patients 4 years or older ( 1.5 )|[EMA] Rheumatoid arthritis, , Enbrel in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults when the response to disease-modifying antirheumatic drugs, including methotrexate (unless contraindicated), has been inadequate., , Enbrel can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate., , Enbrel is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate., , Enbrel, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function., , Juvenile idiopathic arthritis, , Treatment of polyarthritis (rheumatoid-factor-positive or -negative) and extended oligoarthritis in children and adolescents from the age of two years who have had an inadequate response to, or who have proved intolerant of, methotrexate., , Treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate., , Treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy., , Enbrel has not been studied in children aged less than two years., , Psoriatic arthritis, , Treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. Enbrel has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease., , Axial spondyloarthritis, , Ankylosing spondylitis (AS), , Treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy., , Non-radiographic axial spondyloarthritis, , Treatment of adults with severe non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to nonsteroidal anti-inflammatory drugs (NSAIDs). , , Plaque psoriasis , , Treatment of adults with moderate to severe plaque psoriasis who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy, including ciclosporin, methotrexate or psoralen and ultraviolet-A light (PUVA)., , Paediatric plaque psoriasis , , Treatment of chronic severe plaque psoriasis in children and adolescents from the age of six years who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies., uuid:abfccb6e-7b3e-42ad-a52c-d8d6928a1be0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4875 biolink:treats UMLS:C0406317 PMID:41385096 "[{""id"":""uuid:2a276c23-b496-4c27-b9b7-3b167448bef2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1a624218-6148-4299-acbb-a6b540d29dc9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Enbrel is a tumor necrosis factor (TNF) blocker indicated for the treatment of: Rheumatoid Arthritis (RA) ( 1.1 ) Polyarticular Juvenile Idiopathic Arthritis (JIA) in patients aged 2 years or older ( 1.2 ) Psoriatic Arthritis (PsA) ( 1.3 ) Ankylosing Spondylitis (AS) ( 1.4 ) Plaque Psoriasis (PsO) in patients 4 years or older ( 1.5 ) uuid:2787e744-5fe0-4894-96db-f43a693308f1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27690 biolink:treats MONDO:0100574 PMID:41385096 "[{""id"":""uuid:689e0d30-eb2e-4b5f-a146-04cfb56c6193"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6f0de9af-bb36-4874-808f-0c0f66ecbc18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For adjunctive treatment of: edema due to congestive heart failure; drug-induced edema; centrencephalic epilepsies (petit mal, unlocalized seizures); chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. Acetazolamide Tablets are also indicated for the prevention or amelioration of symptoms associated with acute mountain sickness in climbers attempting rapid ascent and in those who are very susceptible to acute mountain sickness despite gradual ascent. uuid:e661915b-3ced-49d3-80a0-28625ee9c754 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats HP:0004308 PMID:41385096 "[{""id"":""uuid:cfe9f929-48b9-4598-87dd-05ef2e227ba8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e5ddc4de-1447-4959-9d51-dde82e81944d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lidocaine hydrochloride administered intravenously is specifically indicated in the acute management of (1) ventricular arrhythmias occurring during cardiac manipulations, such as cardiac surgery and (2) life-threatening arrhythmias which are ventricular in origin, such as occur during acute myocardial infarction. uuid:9ef579a3-6fde-4135-92db-6ccca35a5036 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0007263 PMID:41385096 "[{""id"":""uuid:a18d9216-bb30-4214-9f6d-b8cf6367bd27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c67834e7-2fd8-46b8-bf98-caac5ed5513c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lidocaine hydrochloride administered intravenously is specifically indicated in the acute management of (1) ventricular arrhythmias occurring during cardiac manipulations, such as cardiac surgery and (2) life-threatening arrhythmias which are ventricular in origin, such as occur during acute myocardial infarction. uuid:76a8227f-7135-4a51-8188-2cf30006a507 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0004781 PMID:41385096 "[{""id"":""uuid:354b1736-5c4e-4d12-ab62-11a8558e216e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:556b21f4-c590-4698-8f3e-f46ba981d74c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lidocaine hydrochloride administered intravenously is specifically indicated in the acute management of (1) ventricular arrhythmias occurring during cardiac manipulations, such as cardiac surgery and (2) life-threatening arrhythmias which are ventricular in origin, such as occur during acute myocardial infarction. uuid:870e722d-6ea1-45e4-ac28-a2baaebb3665 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42355 biolink:treats MONDO:0003799 PMID:41385096 "[{""id"":""uuid:0ee454c7-5c41-43e0-99da-af81ba281066"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dc31da22-4f15-4220-9dd4-44b88a8a3a82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by organisms susceptible to erythromycin. For prophylaxis of ophthalmia neonatorum due to N. gonorrhoeae or C. trachomatis. The effectiveness of erythromycin in the prevention of ophthalmia caused by penicillinase-producing N. gonorrheae is not established. For infants born to mothers with clinically apparent gonorrhea, intravenous or intramuscular injections of aqueous crystalline penicillin G should be given; a single dose of 50,000 units for term infants or 20,000 units for infants of low birth weight. Topical prophylaxis alone is inadequate for these infants. uuid:9a7b0cf9-c26d-4570-897a-29941e35e89e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42355 biolink:treats MONDO:0023865 PMID:41385096 "[{""id"":""uuid:645f6c3d-bd37-4667-9563-b0cb8fa42595"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:986c5d61-9476-4aa4-be8d-59c067935131"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of superficial ocular infections involving the conjunctiva and/or cornea caused by organisms susceptible to erythromycin. For prophylaxis of ophthalmia neonatorum due to N. gonorrhoeae or C. trachomatis. The effectiveness of erythromycin in the prevention of ophthalmia caused by penicillinase-producing N. gonorrheae is not established. For infants born to mothers with clinically apparent gonorrhea, intravenous or intramuscular injections of aqueous crystalline penicillin G should be given; a single dose of 50,000 units for term infants or 20,000 units for infants of low birth weight. Topical prophylaxis alone is inadequate for these infants. uuid:1289c77b-9a07-41e4-a7af-7d9497e6dacc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59773 biolink:treats MONDO:0019085 PMID:41385096 "[{""id"":""uuid:5bf71e1e-f610-433a-a879-314c45ecb9c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f095f988-2e7b-46c2-8bd6-c3a98d018ff0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cromolyn Sodium Ophthalmic Solution USP, 4% is indicated in the treatment of vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis. uuid:c2faf47a-2a47-4136-b729-9e6f80842ffb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59773 biolink:treats MONDO:0002313 PMID:41385096 "[{""id"":""uuid:adc4f6c6-7af0-46b3-9af4-dbd21b3c9055"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:52656f3e-74b5-4046-8188-701549980de6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cromolyn Sodium Ophthalmic Solution USP, 4% is indicated in the treatment of vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis. uuid:1eb4d746-d243-41f5-9b25-a3ca9a8399d3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2618 biolink:treats MONDO:0006012 PMID:41385096 "[{""id"":""uuid:8604d58c-feef-4793-aee4-6a1a9377ddc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9217d418-02c4-4089-a572-942524a17421"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amantadine hydrochloride capsules are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine hydrochloride capsules are also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions. Influenza A Prophylaxis Amantadine hydrochloride capsules are indicated for chemoprophylaxis against signs and symptoms of influenza A virus infection. Because amantadine does not completely prevent the host immune response to influenza A infection, individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically related viruses. Following vaccination during an influenza A outbreak, amantadine prophylaxis should be considered for the 2- to 4-week time period required to develop an antibody response. Influenza A Treatment Amantadine hydrochloride capsules are also indicated in the treatment of uncomplicated respiratory tract illness caused by influenza A virus strains especially when administered early in the course of illness. There are no well-controlled clinical studies demonstrating that treatment with amantadine hydrochloride capsules will avoid the development of influenza A virus pneumonitis or other complications in high risk patients. There is no clinical evidence indicating that amantadine hydrochloride capsules are effective in the prophylaxis or treatment of viral respiratory tract illnesses other than those caused by influenza A virus strains. The following points should be considered before initiating treatment or prophylaxis with amantadine hydrochloride capsules. • Amantadine hydrochloride capsules are not a substitute for early vaccination on an annual basis as recommended by the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices. • Influenza viruses change over time. Emergence of resistance mutations could decrease drug effectiveness. Other factors (for example, changes in viral virulence) might also diminish clinical benefit of antiviral drugs. Prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use amantadine hydrochloride capsules. Parkinson’s Disease/Syndrome Amantadine hydrochloride capsules are indicated in the treatment of idiopathic Parkinson’s disease (Paralysis Agitans), postencephalitic parkinsonism and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication. It is indicated in those elderly patients believed to develop parkinsonism in association with cerebral arteriosclerosis. In the treatment of Parkinson’s disease, amantadine is less effective than levodopa, (-)-3-(3,4-dihydroxyphenyl)-L-alanine, and its efficacy in comparison with the anticholinergic antiparkinson drugs has not yet been established. Drug-Induced Extrapyramidal Reactions Amantadine hydrochloride is indicated in the treatment of drug-induced extrapyramidal reactions. Although anticholinergic-type side effects have been noted with amantadine when used in patients with drug-induced extrapyramidal reactions, there is a lower incidence of these side effects than that observed with the anticholinergic antiparkinson drugs. uuid:1462d074-47c1-49ba-9e71-8a11dcbd7599 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24783652 biolink:treats MONDO:0001302 PMID:41385096 "[{""id"":""uuid:d45f0d14-1821-4221-a9b5-3cb84b5c57b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f51bdf53-0c57-4364-a36f-c21b8d276a0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Losartan Potassium and Hydrochlorothiazide Tablets are indicated for the treatment of hypertension. This fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients (see CLINICAL PHARMACOLOGY, Pharmacodynamics and Clinical Effects, and DOSAGE AND ADMINISTRATION). Hypertensive Patients with Left Ventricular Hypertrophy Losartan Potassium and Hydrochlorothiazide Tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients. (See PRECAUTIONS, Race, CLINICAL PHARMACOLOGY, Pharmacodynamics and Clinical Effects, Losartan Potassium, Reduction in the Risk of Stroke, Race, and DOSAGE AND ADMINISTRATION.) uuid:a045cbe3-a43a-4427-8838-b0399772410a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49166 biolink:treats MONDO:0021095 PMID:41385096 "[{""id"":""uuid:9f04bc57-945b-402b-bff1-a3ee664d6610"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:53917a02-fb9f-49e0-86b1-b604cf16f6eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluorodopa F 18 Injection is indicated for use in positron emission tomography (PET) to visualize dopaminergic nerve terminals in the striatum for the evaluation of adult patients with suspected Parkinsonian syndromes (PS). Fluorodopa F 18 PET is an adjunct to other diagnostic evaluations. uuid:c129e727-77f5-4d4d-9edb-18b676645cea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:43968 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:96742911-0ab6-45c4-a25e-e5b0f8376b71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a5d3955b-b0f2-4a75-866a-766810d15609"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Meropenem for injection (I.V.) is a penem antibacterial indicated for the treatment of: • Complicated skin and skin structure infections (adult patients and pediatric patients 3 months of age and older only). (1.1) • Complicated intra-abdominal infections (adult and pediatric patients). (1.2) • Bacterial meningitis (pediatric patients 3 months of age and older only). (1.3) To reduce the development of drug-resistant bacteria and maintain the effectiveness of meropenem for injection (I.V.) and other antibacterial drugs, meropenem for injection (I.V.) should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. uuid:a21591e0-87d3-469a-9964-2530f0d9ba4b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:43968 biolink:treats MONDO:0006670 PMID:41385096 "[{""id"":""uuid:b78f9b9d-2252-4049-b20d-7e7b2772ca39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:249fcb8c-1538-46f2-9d86-d8075828150e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Meropenem for injection (I.V.) is a penem antibacterial indicated for the treatment of: • Complicated skin and skin structure infections (adult patients and pediatric patients 3 months of age and older only). (1.1) • Complicated intra-abdominal infections (adult and pediatric patients). (1.2) • Bacterial meningitis (pediatric patients 3 months of age and older only). (1.3) To reduce the development of drug-resistant bacteria and maintain the effectiveness of meropenem for injection (I.V.) and other antibacterial drugs, meropenem for injection (I.V.) should only be used to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. uuid:231328e2-fc9e-484a-9c84-797af6cb95a2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6935 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:c1d74977-d02a-40b8-ba31-23fe9a8d59cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b2874607-1c87-459e-8ce4-3098b21d9e43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4f90af79-1e56-4d8f-ad99-299ca037789a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Miglitol tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.|[PMDA] Drugs containing a new active ingredient, an -glucosidase inhibitor, indicated for improving postprandial hyperglycemia in patients with type 2 diabetes. uuid:bcc54c4d-2ac4-4a1e-bda1-b099621009a1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:375139 biolink:treats UMLS:C0332686 PMID:41385096 "[{""id"":""uuid:73af695b-9142-4623-8fdd-bb0be74ac6a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:829919d7-9f90-4f9d-bbf3-a22440867618"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lidocaine Ointment USP, 5% is indicated for production of anesthesia of accessible mucous membranes of the oropharynx. It is also useful as an anesthetic lubricant for intubation and for the temporary relief of pain associated with minor burns, including sunburn, abrasions of the skin, and insect bites. uuid:07f6a841-ffee-41e5-bd0e-c06c08a27568 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:375139 biolink:treats MONDO:0005326 PMID:41385096 "[{""id"":""uuid:feaf2e9f-bb6e-4525-b6f4-778d27e40551"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:418357d7-7b19-4d78-ac25-38dd72bbe14a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lidocaine Ointment USP, 5% is indicated for production of anesthesia of accessible mucous membranes of the oropharynx. It is also useful as an anesthetic lubricant for intubation and for the temporary relief of pain associated with minor burns, including sunburn, abrasions of the skin, and insect bites. uuid:0f0c7ab4-8e34-4614-add9-ce1f79977594 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:375139 biolink:treats UMLS:C0021564 PMID:41385096 "[{""id"":""uuid:8311471a-24be-44ae-bd1f-e04174d3baef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c889c780-16b8-43c3-bc28-f2b851da47ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lidocaine Ointment USP, 5% is indicated for production of anesthesia of accessible mucous membranes of the oropharynx. It is also useful as an anesthetic lubricant for intubation and for the temporary relief of pain associated with minor burns, including sunburn, abrasions of the skin, and insect bites. uuid:a517ec4c-7a69-4811-a3f2-2de80e210bf9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats UMLS:C0267055 PMID:41385096 "[{""id"":""uuid:85357da3-bd79-43b0-87f1-a8944b5f462a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6ea42bdf-be83-4736-b470-a34c71eed285"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pantoprazole sodium delayed-release tablets USP are indicated for: 1.1 Short-Term Treatment of Erosive Esophagitis Associated With Gastroesophageal Reflux Disease (GERD) Pantoprazole sodium delayed-release tablets USP are indicated in adults for the short-term treatment (up to 8 weeks) in the healing and symptomatic relief of erosive esophagitis. For those adult patients who have not healed after 8 weeks of treatment, an additional 8 week course of pantoprazole sodium delayed-release tablets USP may be considered. Safety of treatment beyond 8 weeks in pediatric patients has not been established. 1.2 Maintenance of Healing of Erosive Esophagitis Pantoprazole sodium delayed-release tablets USP are indicated for maintenance of healing of erosive esophagitis and reduction in relapse rates of daytime and nighttime heartburn symptoms in adult patients with GERD. Controlled studies did not extend beyond 12 months. 1.3 Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome Pantoprazole sodium delayed-release tablets USP are indicated for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome. uuid:11b75888-c96e-49f2-b3cc-a20c59ab3a46 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10124 biolink:treats MONDO:0100431 PMID:41385096 "[{""id"":""uuid:b3e22d6f-df82-4e1b-8aef-8d51736a0974"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6b8ce7b7-83c5-4160-8acb-441cc5280244"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Zolmitriptan is serotonin (5-HT) 1B/1D receptor agonist (triptan) indicated for the acute treatment of migraine with or without aura in adults ( 1 ) Limitations of Use : Use only after a clear diagnosis of migraine has been established ( 1 ) Not indicated for the prophylactic therapy of migraine ( 1 ) Not indicated for the treatment of cluster headache ( 1 ) uuid:c96a06c2-2485-4e2a-8828-59ea230413e7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6030 biolink:treats MONDO:0004247 PMID:41385096 "[{""id"":""uuid:0a2575b1-2144-47d9-bdf0-11ec980087a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c6e796c4-a439-44c1-b615-00bb38b46194"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isoniazid tablets are recommended for all forms of tuberculosis in which organisms are susceptible. However, active tuberculosis must be treated with multiple concomitant anti-tuberculosis medications to prevent the emergence of drug resistance. Single-drug treatment of active tuberculosis with isoniazid or any other medication, is inadequate therapy. Isoniazid tablets are recommended as preventive therapy for the following groups, regardless of age. (Note: the criterion for a positive reaction to a skin test (in millimeters of induration) for each group is given in parenthesis): 1. Persons with human immunodeficiency virus (HIV) infection (greater than or equal to 5 mm) and persons with risk factors for HIV infection whose HIV infection status is unknown but who are suspected of having HIV infection. Preventive therapy may be considered for HIV infected persons who are tuberculin-negative but belong to groups in which the prevalence of tuberculosis infection is high. Candidates for preventive therapy who have HIV infection should have a minimum of 12 months of therapy. 2. Close contacts of persons with newly diagnosed infectious tuberculosis (greater than or equal to 5 mm). In addition, tuberculin-negative (less than 5 mm) children and adolescents who have been close contacts of infectious persons within the past 3 months are candidates for preventive therapy until a repeat tuberculin skin test is done 12 weeks after contact with the infectious source. If the repeat skin test is positive (greater than 5 mm), therapy should be continued. 3. Recent converters, as indicated by a tuberculin skin test (greater than or equal to 10 mm increase within a 2-year period for those less than 35 years old; greater than or equal to 15 mm increase for those greater than or equal to 35 years of age). All infants and children younger than 4 years of age with a greater than 10 mm skin test are included in this category. 4. Persons with abnormal chest radiographs that show fibrotic lesions likely to represent old healed tuberculosis (greater than or equal to 5 mm). Candidates for preventive therapy who have fibrotic pulmonary lesions consistent with healed tuberculosis or who have pulmonary silicosis should have 12 months of isoniazid or 4 months of isoniazid and rifampin, concomitantly. 5. Intravenous drug users known to be HIV-seronegative (greater than 10 mm). 6. Persons with the following medical conditions that have been reported to increase the risk of tuberculosis (greater than or equal to 10 mm): silicosis; diabetes mellitus; prolonged therapy with adrenocorticosteroids; immunosuppressive therapy; some hematologic and reticuloendothelial diseases, such as leukemia or Hodgkin’s disease; end-stage renal disease; clinical situations associated with substantial rapid weight loss or chronic undernutrition (including: intestinal bypass surgery for obesity, the postgastrectomy state [with or without weight loss], chronic peptic ulcer disease, chronic malabsorption syndromes and carcinomas of the oropharynx and upper gastrointestinal tract that prevent adequate nutritional intake). Candidates for preventive therapy who have fibrotic pulmonary lesions consistent with healed tuberculosis or who have pulmonary silicosis should have 12 months of isoniazid or 4 months of isoniazid and rifampin, concomitantly. Additionally, in the absence of any of the above risk factors, persons under the age of 35 with a tuberculin skin test reaction of 10 mm or more are also appropriate candidates for preventive therapy if they are a member of any of the following high-incidence groups: 1. Foreign-born persons from high-prevalence countries who never received BCG vaccine. 2. Medically underserved low-income populations, including high-risk racial or ethnic minority populations, especially blacks, Hispanics and Native Americans. 3. Residents of facilities for long-term care (e.g., correctional institutions, nursing homes and mental institutions). Children who are less than 4 years old are candidates for isoniazid preventive therapy if they have greater than 10 mm induration from a PPD Mantoux tuberculin skin test. Finally, persons under the age of 35 who a) have none of the above risk factors (1 to 6); b) belong to none of the high-incidence groups; and c) have a tuberculin skin test reaction of 15 mm or more, are appropriate candidates for preventive therapy. The risk of hepatitis must be weighed against the risk of tuberculosis in positive tuberculin reactors over the age of 35. However, the use of isoniazid is recommended for those with the additional risk factors listed above (1 to 6) and on an individual basis in situations where there is likelihood of serious consequences to contacts who may become infected. uuid:ab08bef3-a351-41f2-9ab7-bf280e69dbf9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6030 biolink:treats MONDO:0020598 PMID:41385096 "[{""id"":""uuid:074e80a4-d01a-42ed-91f3-ec626f8c264a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aed56064-4db1-422c-ae9c-efa713f6b3c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isoniazid tablets are recommended for all forms of tuberculosis in which organisms are susceptible. However, active tuberculosis must be treated with multiple concomitant anti-tuberculosis medications to prevent the emergence of drug resistance. Single-drug treatment of active tuberculosis with isoniazid or any other medication, is inadequate therapy. Isoniazid tablets are recommended as preventive therapy for the following groups, regardless of age. (Note: the criterion for a positive reaction to a skin test (in millimeters of induration) for each group is given in parenthesis): 1. Persons with human immunodeficiency virus (HIV) infection (greater than or equal to 5 mm) and persons with risk factors for HIV infection whose HIV infection status is unknown but who are suspected of having HIV infection. Preventive therapy may be considered for HIV infected persons who are tuberculin-negative but belong to groups in which the prevalence of tuberculosis infection is high. Candidates for preventive therapy who have HIV infection should have a minimum of 12 months of therapy. 2. Close contacts of persons with newly diagnosed infectious tuberculosis (greater than or equal to 5 mm). In addition, tuberculin-negative (less than 5 mm) children and adolescents who have been close contacts of infectious persons within the past 3 months are candidates for preventive therapy until a repeat tuberculin skin test is done 12 weeks after contact with the infectious source. If the repeat skin test is positive (greater than 5 mm), therapy should be continued. 3. Recent converters, as indicated by a tuberculin skin test (greater than or equal to 10 mm increase within a 2-year period for those less than 35 years old; greater than or equal to 15 mm increase for those greater than or equal to 35 years of age). All infants and children younger than 4 years of age with a greater than 10 mm skin test are included in this category. 4. Persons with abnormal chest radiographs that show fibrotic lesions likely to represent old healed tuberculosis (greater than or equal to 5 mm). Candidates for preventive therapy who have fibrotic pulmonary lesions consistent with healed tuberculosis or who have pulmonary silicosis should have 12 months of isoniazid or 4 months of isoniazid and rifampin, concomitantly. 5. Intravenous drug users known to be HIV-seronegative (greater than 10 mm). 6. Persons with the following medical conditions that have been reported to increase the risk of tuberculosis (greater than or equal to 10 mm): silicosis; diabetes mellitus; prolonged therapy with adrenocorticosteroids; immunosuppressive therapy; some hematologic and reticuloendothelial diseases, such as leukemia or Hodgkin’s disease; end-stage renal disease; clinical situations associated with substantial rapid weight loss or chronic undernutrition (including: intestinal bypass surgery for obesity, the postgastrectomy state [with or without weight loss], chronic peptic ulcer disease, chronic malabsorption syndromes and carcinomas of the oropharynx and upper gastrointestinal tract that prevent adequate nutritional intake). Candidates for preventive therapy who have fibrotic pulmonary lesions consistent with healed tuberculosis or who have pulmonary silicosis should have 12 months of isoniazid or 4 months of isoniazid and rifampin, concomitantly. Additionally, in the absence of any of the above risk factors, persons under the age of 35 with a tuberculin skin test reaction of 10 mm or more are also appropriate candidates for preventive therapy if they are a member of any of the following high-incidence groups: 1. Foreign-born persons from high-prevalence countries who never received BCG vaccine. 2. Medically underserved low-income populations, including high-risk racial or ethnic minority populations, especially blacks, Hispanics and Native Americans. 3. Residents of facilities for long-term care (e.g., correctional institutions, nursing homes and mental institutions). Children who are less than 4 years old are candidates for isoniazid preventive therapy if they have greater than 10 mm induration from a PPD Mantoux tuberculin skin test. Finally, persons under the age of 35 who a) have none of the above risk factors (1 to 6); b) belong to none of the high-incidence groups; and c) have a tuberculin skin test reaction of 15 mm or more, are appropriate candidates for preventive therapy. The risk of hepatitis must be weighed against the risk of tuberculosis in positive tuberculin reactors over the age of 35. However, the use of isoniazid is recommended for those with the additional risk factors listed above (1 to 6) and on an individual basis in situations where there is likelihood of serious consequences to contacts who may become infected. uuid:1a25e470-88c8-491a-a794-08c1422e83f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:114785 biolink:treats MONDO:0021040 PMID:41385096 "[{""id"":""uuid:f0c0037d-59ce-4bfa-8c6f-bcba8cb7168d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ccfb3eaf-8d37-4f3e-8242-12c4060ccba7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Erlotinib tablets are kinase inhibitors indicated for: • The treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test receiving first-line, maintenance, or second or greater line treatment after progression following at least one prior chemotherapy regimen. (1.1) • First-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer, in combination with gemcitabine. (1.2) Limitations of Use : • Safety and efficacy of erlotinib tablets have not been established in patients with NSCLC whose tumors have other EGFR mutations. (1.1) • Erlotinib tablets are not recommended for use in combination with platinum-based chemotherapy. (1.1) uuid:0af24722-f8bb-4552-ab44-8da471517bcb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1162127 biolink:treats MONDO:0006652 PMID:41385096 "[{""id"":""uuid:6571309b-5d85-4222-aba3-f7e6e0010a5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:61617ed0-351d-4fe8-abc7-aeabfdf3c42d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Losartan potassium and hydrochlorothiazide tablets USP are a combination of losartan, an angiotensin II receptor blocker (ARB) and hydrochlorothiazide, a diuretic indicated for: · Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. (1.1) · Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. (1.2) uuid:498dcdf5-5ce8-4dc4-accb-9fdb5f8f8a16 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:46878853 biolink:treats MONDO:0005420 PMID:41385096 "[{""id"":""uuid:e1a10cb6-2994-4456-a10a-5becf082b2f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7b688ed3-8ec5-4db0-8d27-335680b67c6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment of Hypercholesterolemia Fenofibrate tablets, USP are indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C, Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate (See National Cholesterol Education Program [NCEP] Treatment Guidelines, below). Treatment of Hypertriglyceridemia Fenofibrate tablets, USP are also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually reduce fasting triglycerides and eliminate chylomicronemia thereby obviating the need for pharmacologic intervention. Markedly elevated levels of serum triglycerides (e.g. > 2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate tablet, USP therapy on reducing this risk has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV and V hyperlipoproteinemia 2 . The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcoholic intake may be important factors in hypertriglyceridemia and should be addressed prior to any drug therapy. Physical exercise can be an important ancillary measure. Diseases contributory to hyperlipidemia, such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy, thiazide diuretics and beta-blockers, are sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of the specific etiologic agent may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with non-drug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet. (See WARNINGS and PRECAUTIONS ). Fredrickson Classification of Hyperlipoproteinemias C = cholesterol TG = triglycerides LDL = low density lipoprotein VLDL = very low density lipoprotein IDL = intermediate density lipoprotein Lipid Elevation Type Lipoprotein Elevated Major Minor I (rare) chylomicrons TG ↑↔C IIa LDL C - IIb LDL, VLDL C TG III (rare) IDL C, TG - IV VLDL TG ↑↔C V (rare) chylomicrons, VLDL TG ↑↔ NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories † CHD = coronary heart disease †† Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of < 100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgment also may call for deferring drug therapy in this subcategory. ††† Almost all people with 0 to 1 risk factor have 10-year risk < 10%; thus, 10-year risk assessment in people with 0 to 1 risk factor is not necessary. Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD † or CHD risk equivalents (10-years risk > 20%) < 100 ≥ 100 ≥ 130 (100 to 129: drug optional) †† 2+ Risk Factors (10-year risk ≤ 20%) < 130 ≥ 130 10-year risk 10% to 20%: ≥ 130 10-year risk < 10%: ≥ 160 0 to 1 Risk Factor ††† < 160 ≥ 160 ≥ 190 (160 to 189: LDL- lowering drug optional) After the LDL-C goal has been achieved, if the TG is still ≥ 200 mg/dL, non HDL-C (total-C minus HDL-C) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. uuid:fb16d9a1-eacf-4754-8c5f-7b6df2c992db biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:46878853 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:ac9d48bc-a975-4ebe-880a-b725dbe9a51c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6781c686-a8b7-4faa-8d9d-1c160a895c04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment of Hypercholesterolemia Fenofibrate tablets, USP are indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C, Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate (See National Cholesterol Education Program [NCEP] Treatment Guidelines, below). Treatment of Hypertriglyceridemia Fenofibrate tablets, USP are also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually reduce fasting triglycerides and eliminate chylomicronemia thereby obviating the need for pharmacologic intervention. Markedly elevated levels of serum triglycerides (e.g. > 2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate tablet, USP therapy on reducing this risk has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV and V hyperlipoproteinemia 2 . The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcoholic intake may be important factors in hypertriglyceridemia and should be addressed prior to any drug therapy. Physical exercise can be an important ancillary measure. Diseases contributory to hyperlipidemia, such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy, thiazide diuretics and beta-blockers, are sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of the specific etiologic agent may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with non-drug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet. (See WARNINGS and PRECAUTIONS ). Fredrickson Classification of Hyperlipoproteinemias C = cholesterol TG = triglycerides LDL = low density lipoprotein VLDL = very low density lipoprotein IDL = intermediate density lipoprotein Lipid Elevation Type Lipoprotein Elevated Major Minor I (rare) chylomicrons TG ↑↔C IIa LDL C - IIb LDL, VLDL C TG III (rare) IDL C, TG - IV VLDL TG ↑↔C V (rare) chylomicrons, VLDL TG ↑↔ NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories † CHD = coronary heart disease †† Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of < 100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgment also may call for deferring drug therapy in this subcategory. ††† Almost all people with 0 to 1 risk factor have 10-year risk < 10%; thus, 10-year risk assessment in people with 0 to 1 risk factor is not necessary. Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD † or CHD risk equivalents (10-years risk > 20%) < 100 ≥ 100 ≥ 130 (100 to 129: drug optional) †† 2+ Risk Factors (10-year risk ≤ 20%) < 130 ≥ 130 10-year risk 10% to 20%: ≥ 130 10-year risk < 10%: ≥ 160 0 to 1 Risk Factor ††† < 160 ≥ 160 ≥ 190 (160 to 189: LDL- lowering drug optional) After the LDL-C goal has been achieved, if the TG is still ≥ 200 mg/dL, non HDL-C (total-C minus HDL-C) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. uuid:e39ca39b-2ddf-4368-bebc-126990a39ffb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4735 biolink:treats MONDO:0006604 PMID:41385096 "[{""id"":""uuid:39de71c4-da68-4589-8c23-6b1d092d2fef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d91b1426-a9c0-4e56-9807-a15c74baab9a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. uuid:661bef17-8c3a-48fb-9851-69525021ed48 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4735 biolink:treats MONDO:0033816 PMID:41385096 "[{""id"":""uuid:9a2a7bc1-c820-4d5f-9946-8347b8c0931c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3d2cdf4c-5b13-44cd-b3c1-d62557e536e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. uuid:278a43db-30e1-4ceb-9249-07eb104215e1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4735 biolink:treats UMLS:C1275687 PMID:41385096 "[{""id"":""uuid:f0ab2d36-bb53-4a09-98fd-3536a26136c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dd467efd-89e6-4925-b18b-c7a560b33df4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. uuid:ff288d40-3c1b-4777-a09f-427474cf85e2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4735 biolink:treats MONDO:0006814 PMID:41385096 "[{""id"":""uuid:a9970fee-b398-443c-be68-44c081b2110a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f72b489d-24f2-48eb-b218-d2eaa0a7d4ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. uuid:e6b57c82-fa31-4dbc-a0bd-573e8fa7f4e1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4735 biolink:treats UMLS:C0010543 PMID:41385096 "[{""id"":""uuid:273b5750-c744-434e-865d-32117d14e17c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d5ce5c3b-939e-4d00-a8f4-e4a271cad22c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. uuid:e7b6bc48-ed0d-4e43-9ea7-e36bd17b9029 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4735 biolink:treats MONDO:0006668 PMID:41385096 "[{""id"":""uuid:c8d9d5cf-db67-4b90-b21b-8f5b92258437"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d71d810d-70c2-42c4-950e-90218672625a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. uuid:8c50d498-51fb-4ece-bc46-2fd12223314b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4735 biolink:treats UMLS:C0339289 PMID:41385096 "[{""id"":""uuid:98eef633-e539-4829-b240-defd630e5a76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3117151e-75ac-4c74-ba2c-b452dcae4c9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, selected infective conjunctivitides, when the inherent hazard of steroid use is accepted to obtain an advisable diminution in edema and inflammation; corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. uuid:3017bbbe-764b-4e35-9809-8382439a4870 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats HP:0005202 PMID:41385096 "[{""id"":""uuid:4ef60b45-d0c2-4ee5-8e9e-66e59c7dde1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6e42de71-72a7-44e1-a17f-4a587f60bb74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The components of Bismuth Subsalicylate Chewable Tablets/ Metronidazole Tablets/Tetracycline Hydrochloride Capsules (bismuth subsalicylate, metronidazole, and tetracycline hydrochloride), in combination with an H 2 antagonist, are indicated for the eradication of H. pylori for treatment of patients with H. pylori infection and duodenal ulcer disease (active or a history of duodenal ulcer). The eradication of H. pylori has been demonstrated to reduce the risk of duodenal ulcer recurrence in patients with active duodenal ulcer disease (see CLINICAL STUDIES and DOSAGE AND ADMINISTRATION ). To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bismuth Subsalicylate Chewable Tablets/Metronidazole Tablets/Tetracycline Hydrochloride Capsules and other antibacterial drugs, Bismuth Subsalicylate Chewable Tablets/Metronidazole Tablets/Tetracycline Hydrochloride Capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:1b353f10-2c6f-4130-b92c-2f04eff4d2b0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats MONDO:0005412 PMID:41385096 "[{""id"":""uuid:57dbacb8-01cc-4529-9731-c2b223baeda4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d595d887-2ae3-4d75-be57-3cd8d30c45d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The components of Bismuth Subsalicylate Chewable Tablets/ Metronidazole Tablets/Tetracycline Hydrochloride Capsules (bismuth subsalicylate, metronidazole, and tetracycline hydrochloride), in combination with an H 2 antagonist, are indicated for the eradication of H. pylori for treatment of patients with H. pylori infection and duodenal ulcer disease (active or a history of duodenal ulcer). The eradication of H. pylori has been demonstrated to reduce the risk of duodenal ulcer recurrence in patients with active duodenal ulcer disease (see CLINICAL STUDIES and DOSAGE AND ADMINISTRATION ). To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bismuth Subsalicylate Chewable Tablets/Metronidazole Tablets/Tetracycline Hydrochloride Capsules and other antibacterial drugs, Bismuth Subsalicylate Chewable Tablets/Metronidazole Tablets/Tetracycline Hydrochloride Capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:3245b1db-2c41-4661-af91-a06eec1fd7ea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats UMLS:C0033775 PMID:41385096 "[{""id"":""uuid:7c5f6f11-be6d-48c5-9a15-1b8f82782698"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ceb74a9a-93e6-40c3-82ef-31d9177fb101"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pruritus, pruritic eczemas, abrasions, minor burns, insect bites, pain, soreness and discomfort due to pruritus ani, pruritus vulvae, hemorrhoids, anal fissures, and similar conditions of the skin and mucous membranes. uuid:40785e8e-5a48-4068-b677-ce7123de6a2a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7862 biolink:treats MONDO:0006604 PMID:41385096 "[{""id"":""uuid:1a4b4c68-589c-4c41-ba83-86c4962c7d34"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1df0703e-632d-40c4-8795-9f29ceb91d7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RHOFADE ® (oxymetazoline hydrochloride) cream, 1% is indicated for the topical treatment of persistent facial erythema associated with rosacea in adults. uuid:138b6f08-264d-436c-9a06-61de8367afa4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1152781 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:26696dab-f035-4180-8575-ce4a8119cc24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:54b5a9bf-73a8-4a2e-ace3-e591b8351a02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZIANA Gel is indicated for the topical treatment of acne vulgaris in patients 12 years or older. uuid:f75ef2e0-5539-4dcb-b772-519dd993d1e5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:23742 biolink:treats MONDO:0045048 PMID:41385096 "[{""id"":""uuid:831f718f-b678-44f4-8517-b0499cc0ce52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:32c2b470-fc43-4da7-a0a9-54a8cd0d8d4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] This fixed combination drug is not indicated for the initial therapy of edema or hyper tension except in individuals in whom the developme nt of hypokalemia cannot be ris ked. Triamterene and hydrochlorothiazide capsules, USP are indicated for the treatment of hypertension or edema in patients who develop hypokalemia on hydrochlorothiazide alone. Triamterene and hydrochlorothiazide capsules, USP are also indicated for those patients who require a thiazide diuretic and in whom the development of hypokalemia cannot be risked. Triamterene and hydrochlorothiazide capsules, USP may be used alone or as an adjunct to other antihypertensive drugs, such as beta-blockers. Since triamterene and hydrochlorothiazide capsules, USP may enhance the action of these agents, dosage adjustments may be necessary. Us age in Pregnancy: The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. Edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. Diuretics are indicated in pregnancy when edema is due to pathologic causes, just as they are in the absence of pregnancy. Dependent edema in pregnancy resulting from restriction of venous return by the expanded uterus is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances this edema may cause extreme discomfort which is not relieved by rest. In these cases a short course of diuretics may provide relief and may be appropriate. uuid:5ac8e59f-c91b-4b56-b4d7-29abc5cec014 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:66964 biolink:treats MONDO:0005351 PMID:41385096 "[{""id"":""uuid:675dba79-92b1-4594-ac27-172f5527b1a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9ec086f6-c5fa-44eb-bc4f-2a87afd9ff5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SYNDROS is indicated in adults for the treatment of: anorexia associated with weight loss in patients with Acquired Immune Deficiency Syndrome (AIDS). nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. uuid:c3c49026-6943-486a-93cd-572541cdbce4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:66964 biolink:treats MONDO:0012268 PMID:41385096 "[{""id"":""uuid:5209d219-23a4-4f6e-8e68-7d3e215b091f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:85704869-adf6-41d7-ad7e-5307ad579d01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SYNDROS is indicated in adults for the treatment of: anorexia associated with weight loss in patients with Acquired Immune Deficiency Syndrome (AIDS). nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. uuid:863ce371-5f98-4097-a695-27a243ea6ef7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:66964 biolink:treats HP:0002018 PMID:41385096 "[{""id"":""uuid:4a83c367-b39d-4d87-a4f5-4f76f3977c4c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6682274d-d252-44d7-9e27-444a60a2e422"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SYNDROS is indicated in adults for the treatment of: anorexia associated with weight loss in patients with Acquired Immune Deficiency Syndrome (AIDS). nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. uuid:e5afcd4d-0566-44cd-bb2d-358256622993 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:66964 biolink:treats HP:0002013 PMID:41385096 "[{""id"":""uuid:1823ff4e-e108-4c5a-9db4-9cea92fbbca3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:76c2f944-3db7-4b10-ad37-68d4107c85ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SYNDROS is indicated in adults for the treatment of: anorexia associated with weight loss in patients with Acquired Immune Deficiency Syndrome (AIDS). nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. uuid:8bed23b8-f622-4805-8fc8-9def4d56d116 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71940 biolink:treats MONDO:0015924 PMID:41385096 "[{""id"":""uuid:b1ea7fbb-2e76-4ae0-b8bb-712ffdb6adb3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1bb97f56-0f66-4158-be68-66c2d37a4f2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ba23eba6-cdb5-4888-8511-e3373c870f48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cialis""]},{""id"":""uuid:e0cc72b0-7289-4261-8a30-0ad60a0bb2bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ADCIRCA is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability. Studies establishing effectiveness included predominately patients with NYHA Functional Class II – III symptoms and etiologies of idiopathic or heritable PAH (61%) or PAH associated with connective tissue diseases (23%). ( 1.1 )|[EMA] Talmanco is indicated in adults for the treatment of pulmonary arterial hypertension (PAH) classified as WHO functional class II and III, to improve exercise capacity. Efficacy has been shown in idiopathic PAH (IPAH) and in PAH related to collagen vascular disease.|[PMDA] A drug with a new indication and a new dosage for the treatment of pulmonary arterial hypertension. uuid:73c133ce-b120-41bf-b272-9562bebe47d4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71940 biolink:treats MONDO:0017147 PMID:41385096 "[{""id"":""uuid:68303482-7b16-4230-b0a1-7e20f8731f57"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6644e5a4-ed33-4af6-b81b-2725a44d3063"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d31b6220-a45f-4ffb-b4d3-971a9216632b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cialis""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ADCIRCA is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability. Studies establishing effectiveness included predominately patients with NYHA Functional Class II – III symptoms and etiologies of idiopathic or heritable PAH (61%) or PAH associated with connective tissue diseases (23%). ( 1.1 )|[EMA] Talmanco is indicated in adults for the treatment of pulmonary arterial hypertension (PAH) classified as WHO functional class II and III, to improve exercise capacity. Efficacy has been shown in idiopathic PAH (IPAH) and in PAH related to collagen vascular disease. uuid:2af9f940-cbcb-4fab-a8b7-1c59e4216399 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71940 biolink:treats MONDO:0017148 PMID:41385096 "[{""id"":""uuid:5d1c62b9-fb7a-4063-a41a-fbee666eeec3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:07ac57ab-c36c-4db5-b554-9f6960f46a2d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ADCIRCA is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability. Studies establishing effectiveness included predominately patients with NYHA Functional Class II – III symptoms and etiologies of idiopathic or heritable PAH (61%) or PAH associated with connective tissue diseases (23%). ( 1.1 ) uuid:df2e798c-fb99-4f90-8fc2-3ecabfd04661 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10023 biolink:treats MONDO:0000240 PMID:41385096 "[{""id"":""uuid:f45669f6-edec-475f-b6d5-48201d96803f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e0712776-58cd-4612-a2dc-0f58f4b470d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:20ed4016-ce2e-4525-8f5e-0339eb5eaaaa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vfend""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Voriconazole is an azole antifungal drug indicated for use in the treatment of: Invasive aspergillosis ( 1.1 ) Candidemia (non-neutropenics) and disseminated candidiasis in skin, abdomen, kidney, bladder wall and wounds ( 1.2 ) Esophageal candidiasis ( 1.3 ) Serious infections caused by Scedosporium apiospermum and Fusarium species including Fusarium solani , in patients intolerant of, or refractory to, other therapy ( 1.4 )|[EMA] Voriconazole, is a broad spectrum, triazole antifungal agent and is indicated in adults and children aged 2 years and above as follows:treatment of invasive aspergillosis;treatment of in candidaemianon-neutropenic patients;treatment of fluconazole-resistant serious invasive Candida infections (including C. krusei);Treatment of serious fungal infections caused by Scedosporium spp. and Fusarium spp.Vfend should be administered primarily to patients with progressive, possibly life-threatening infections.Prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (HSCT) recipients. uuid:b0a04dd0-7ecb-460b-ab1b-d401e16a1535 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10023 biolink:treats MONDO:0044070 PMID:41385096 "[{""id"":""uuid:34568535-695f-4f2a-b297-affdf3bce014"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:124e9600-8041-4ba3-90b6-613118ef6bf7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:90dac1a0-18ce-48b5-957f-356f4f2a599a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vfend""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Voriconazole is an azole antifungal drug indicated for use in the treatment of: Invasive aspergillosis ( 1.1 ) Candidemia (non-neutropenics) and disseminated candidiasis in skin, abdomen, kidney, bladder wall and wounds ( 1.2 ) Esophageal candidiasis ( 1.3 ) Serious infections caused by Scedosporium apiospermum and Fusarium species including Fusarium solani , in patients intolerant of, or refractory to, other therapy ( 1.4 )|[EMA] Voriconazole, is a broad spectrum, triazole antifungal agent and is indicated in adults and children aged 2 years and above as follows:treatment of invasive aspergillosis;treatment of in candidaemianon-neutropenic patients;treatment of fluconazole-resistant serious invasive Candida infections (including C. krusei);Treatment of serious fungal infections caused by Scedosporium spp. and Fusarium spp.Vfend should be administered primarily to patients with progressive, possibly life-threatening infections.Prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (HSCT) recipients. uuid:5b56d447-b4d8-4a53-9ada-13a68ec1fbb7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10023 biolink:treats MONDO:0042233 PMID:41385096 "[{""id"":""uuid:59e1ad98-8347-4582-a815-74fddf136268"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ca708779-4c50-44f0-a0c7-de098a372acf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Voriconazole is an azole antifungal drug indicated for use in the treatment of: Invasive aspergillosis ( 1.1 ) Candidemia (non-neutropenics) and disseminated candidiasis in skin, abdomen, kidney, bladder wall and wounds ( 1.2 ) Esophageal candidiasis ( 1.3 ) Serious infections caused by Scedosporium apiospermum and Fusarium species including Fusarium solani , in patients intolerant of, or refractory to, other therapy ( 1.4 ) uuid:ebef4972-3926-4076-87fe-6014db73d67c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10023 biolink:treats MONDO:0001648 PMID:41385096 "[{""id"":""uuid:16181375-bde9-463c-b413-d21bd4fdc44c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3f0e47cb-cad4-4387-a9dd-4b7a1efb6b89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Voriconazole is an azole antifungal drug indicated for use in the treatment of: Invasive aspergillosis ( 1.1 ) Candidemia (non-neutropenics) and disseminated candidiasis in skin, abdomen, kidney, bladder wall and wounds ( 1.2 ) Esophageal candidiasis ( 1.3 ) Serious infections caused by Scedosporium apiospermum and Fusarium species including Fusarium solani , in patients intolerant of, or refractory to, other therapy ( 1.4 ) uuid:0b1bc330-80d5-49ee-91f8-967301181f3c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10023 biolink:treats MONDO:0001215 PMID:41385096 "[{""id"":""uuid:27f5d431-1d1f-474e-8c58-d48d614ddb6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:16ebbcc7-96ca-49f6-beb5-c2c1113d91bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Voriconazole is an azole antifungal drug indicated for use in the treatment of: Invasive aspergillosis ( 1.1 ) Candidemia (non-neutropenics) and disseminated candidiasis in skin, abdomen, kidney, bladder wall and wounds ( 1.2 ) Esophageal candidiasis ( 1.3 ) Serious infections caused by Scedosporium apiospermum and Fusarium species including Fusarium solani , in patients intolerant of, or refractory to, other therapy ( 1.4 ) UMLS:C0276706 uuid:6d6e8869-dd9b-40e8-815a-08549e919607 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10023 biolink:treats MONDO:0016426 PMID:41385096 "[{""id"":""uuid:6fc05d35-0d66-41e3-8561-c5f218f17be3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:623f30a2-35bb-4059-bf6b-c1b661847312"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4c1ae470-092b-40ed-9348-198c57553a03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vfend""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Voriconazole is an azole antifungal drug indicated for use in the treatment of: Invasive aspergillosis ( 1.1 ) Candidemia (non-neutropenics) and disseminated candidiasis in skin, abdomen, kidney, bladder wall and wounds ( 1.2 ) Esophageal candidiasis ( 1.3 ) Serious infections caused by Scedosporium apiospermum and Fusarium species including Fusarium solani , in patients intolerant of, or refractory to, other therapy ( 1.4 )|[EMA] Voriconazole, is a broad spectrum, triazole antifungal agent and is indicated in adults and children aged 2 years and above as follows:treatment of invasive aspergillosis;treatment of in candidaemianon-neutropenic patients;treatment of fluconazole-resistant serious invasive Candida infections (including C. krusei);Treatment of serious fungal infections caused by Scedosporium spp. and Fusarium spp.Vfend should be administered primarily to patients with progressive, possibly life-threatening infections.Prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (HSCT) recipients. uuid:33fa76d3-7f8f-40ec-be49-2cd584e881e7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C3848548 biolink:treats MONDO:0006733 PMID:41385096 "[{""id"":""uuid:49f21cb5-5d52-48d5-94b8-574c792beb64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d691e30d-2047-4a05-91d4-da79f2b9a6cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Rose Bengal ophthalmic strips are used as a diagnostic agent in routine ocular examinations or when superficial conjunctiva or corneal tissue change is suspected. Rose Bengal ophthalmic strips can also serve as an effective aid in the diagnosis of keratoconjunctivitis sicca, keratitis, abrasions or corrosions as well as the detection of foreign bodies. uuid:c5ccdbd3-0a6b-4b72-a4a1-ee4e1aa29590 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C3848548 biolink:treats MONDO:0003085 PMID:41385096 "[{""id"":""uuid:afb3d31e-a628-4376-9678-c9838579b06b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0c04a1a9-304c-4a8a-a9c9-1c5f36d4d803"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Rose Bengal ophthalmic strips are used as a diagnostic agent in routine ocular examinations or when superficial conjunctiva or corneal tissue change is suspected. Rose Bengal ophthalmic strips can also serve as an effective aid in the diagnosis of keratoconjunctivitis sicca, keratitis, abrasions or corrosions as well as the detection of foreign bodies. uuid:60af7c0a-b5b6-486d-95b6-255acccfbef2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17544 biolink:treats MONDO:0003019 PMID:41385096 "[{""id"":""uuid:d2f2ccde-8b41-4966-9690-0a2e7a547db1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:58a174d3-6e27-4232-a60c-40dfe8dba269"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For therapeutic use in patients with hypokalemia with or without metabolic alkalosis; in chronic digitalis intoxication; and in patients with hypokalemic familial periodic paralysis. For prevention of potassium depletion when the dietary intake of potassium ion is inadequate in the following conditions; patients receiving digitalis and diuretics for congestive heart failure; hepatic cirrhosis with ascites; states of aldosterone excess with normal renal function; potassiumlosing nephropathy, and certain diarrheal states; long-term corticosteroid therapy. The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension or receiving certain antibiotics is often unnecessary when such patients have a normal dietary pattern. Serum potassium should be checked periodically, however, and, if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases supplementation with potassium salts may be indicated. uuid:93f4870a-f8e3-4605-a27e-c0a93bf2f1c0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17544 biolink:treats HP:0200114 PMID:41385096 "[{""id"":""uuid:a4f14c0e-7ece-46bc-8430-a522c2004097"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:98a8b7b9-bed0-4765-b3b4-986169c9cb58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For therapeutic use in patients with hypokalemia with or without metabolic alkalosis; in chronic digitalis intoxication; and in patients with hypokalemic familial periodic paralysis. For prevention of potassium depletion when the dietary intake of potassium ion is inadequate in the following conditions; patients receiving digitalis and diuretics for congestive heart failure; hepatic cirrhosis with ascites; states of aldosterone excess with normal renal function; potassiumlosing nephropathy, and certain diarrheal states; long-term corticosteroid therapy. The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension or receiving certain antibiotics is often unnecessary when such patients have a normal dietary pattern. Serum potassium should be checked periodically, however, and, if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases supplementation with potassium salts may be indicated. uuid:13347ad2-9a64-4bda-ae86-fb98ea81b3cc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17544 biolink:treats MONDO:0008223 PMID:41385096 "[{""id"":""uuid:bbade0f6-9bb4-4193-a7df-1fcc8f26674c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4521b484-1170-4b90-b0e8-1b712b00c696"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For therapeutic use in patients with hypokalemia with or without metabolic alkalosis; in chronic digitalis intoxication; and in patients with hypokalemic familial periodic paralysis. For prevention of potassium depletion when the dietary intake of potassium ion is inadequate in the following conditions; patients receiving digitalis and diuretics for congestive heart failure; hepatic cirrhosis with ascites; states of aldosterone excess with normal renal function; potassiumlosing nephropathy, and certain diarrheal states; long-term corticosteroid therapy. The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension or receiving certain antibiotics is often unnecessary when such patients have a normal dietary pattern. Serum potassium should be checked periodically, however, and, if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases supplementation with potassium salts may be indicated. uuid:3ceae2a6-b743-42ba-99a4-fd237c12b097 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17544 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:5a4290fe-3d6f-4989-9e22-8f0efa0ff592"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4f44591a-b7a8-458e-8f58-dda312c7ca5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For therapeutic use in patients with hypokalemia with or without metabolic alkalosis; in chronic digitalis intoxication; and in patients with hypokalemic familial periodic paralysis. For prevention of potassium depletion when the dietary intake of potassium ion is inadequate in the following conditions; patients receiving digitalis and diuretics for congestive heart failure; hepatic cirrhosis with ascites; states of aldosterone excess with normal renal function; potassiumlosing nephropathy, and certain diarrheal states; long-term corticosteroid therapy. The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension or receiving certain antibiotics is often unnecessary when such patients have a normal dietary pattern. Serum potassium should be checked periodically, however, and, if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases supplementation with potassium salts may be indicated. uuid:5b2bea2b-0af3-4dfb-bd52-e29381b9b98d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17544 biolink:treats MONDO:0005155 PMID:41385096 "[{""id"":""uuid:4005a1aa-ccd5-4963-ae06-a0c10d9b6176"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:42e68823-f28b-42fc-ab92-99c4f7249164"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For therapeutic use in patients with hypokalemia with or without metabolic alkalosis; in chronic digitalis intoxication; and in patients with hypokalemic familial periodic paralysis. For prevention of potassium depletion when the dietary intake of potassium ion is inadequate in the following conditions; patients receiving digitalis and diuretics for congestive heart failure; hepatic cirrhosis with ascites; states of aldosterone excess with normal renal function; potassiumlosing nephropathy, and certain diarrheal states; long-term corticosteroid therapy. The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension or receiving certain antibiotics is often unnecessary when such patients have a normal dietary pattern. Serum potassium should be checked periodically, however, and, if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases supplementation with potassium salts may be indicated. uuid:6eb11675-215e-4d1b-aa4a-92b4bcf8d49f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17544 biolink:treats MONDO:0001673 PMID:41385096 "[{""id"":""uuid:6c5d3c36-8602-420e-8831-974608b5933f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:243993d9-56a8-4155-8809-8d57faf1399c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For therapeutic use in patients with hypokalemia with or without metabolic alkalosis; in chronic digitalis intoxication; and in patients with hypokalemic familial periodic paralysis. For prevention of potassium depletion when the dietary intake of potassium ion is inadequate in the following conditions; patients receiving digitalis and diuretics for congestive heart failure; hepatic cirrhosis with ascites; states of aldosterone excess with normal renal function; potassiumlosing nephropathy, and certain diarrheal states; long-term corticosteroid therapy. The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension or receiving certain antibiotics is often unnecessary when such patients have a normal dietary pattern. Serum potassium should be checked periodically, however, and, if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases supplementation with potassium salts may be indicated. uuid:8d530162-a2a7-414f-9fe4-2be0765dfc1f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17544 biolink:treats MONDO:0001134 PMID:41385096 "[{""id"":""uuid:f18f3e25-5671-48c2-9395-51824c6283b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c8b21b0a-32ab-4dc1-be13-0f666d166b0c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For therapeutic use in patients with hypokalemia with or without metabolic alkalosis; in chronic digitalis intoxication; and in patients with hypokalemic familial periodic paralysis. For prevention of potassium depletion when the dietary intake of potassium ion is inadequate in the following conditions; patients receiving digitalis and diuretics for congestive heart failure; hepatic cirrhosis with ascites; states of aldosterone excess with normal renal function; potassiumlosing nephropathy, and certain diarrheal states; long-term corticosteroid therapy. The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension or receiving certain antibiotics is often unnecessary when such patients have a normal dietary pattern. Serum potassium should be checked periodically, however, and, if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases supplementation with potassium salts may be indicated. uuid:4a27481c-679a-42cd-a466-bb5de05b5bbc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31624 biolink:treats UMLS:C0339289 PMID:41385096 "[{""id"":""uuid:54f8443d-2a08-4241-acd5-90152a1beb48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4ff831bb-abf0-4d2b-933d-e30e7a29a9dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For staining the anterior segment of the eye in disclosing corneal injury, in applanation tonometry and when fitting contact lenses. uuid:cc7e854a-0b7a-4827-a4ed-817238688a77 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75275 biolink:treats MONDO:0008638 PMID:41385096 "[{""id"":""uuid:e561c46e-385c-4770-90a0-38693c4859ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ea578f72-7a2e-4931-b2c3-dc1af9bbdef2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sotradecol (sodium tetradecyl sulfate injection) is indicated in the treatment of small uncomplicated varicose veins of the lower extremities that show simple dilation with competent valves. The benefit-to-risk ratio should be considered in selected patients who are great surgical risks. uuid:c59eed6d-ff5f-416a-bc8e-2aa3038b44d3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:M4EN45951F biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:6d868db8-44e7-4f94-a129-67e2deff1887"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9e5b0e05-fd7a-4a7e-ac6a-d9b9f73783c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SUPRAX (cefixime) is a cephalosporin antibacterial drug indicated in the treatment of adults and pediatric patients six months and older with the following infections: Uncomplicated Urinary Tract Infections ( 1.1 ) Otitis Media ( 1.2 ) Pharyngitis and Tonsillitis ( 1.3 ) Acute Exacerbations of Chronic Bronchitis ( 1.4 ) Uncomplicated Gonorrhea (cervical/urethral) ( 1.5 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of SUPRAX and other antibacterial drugs, SUPRAX should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 ) uuid:82b54e2b-3539-49f1-bea8-c2bac339f491 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:M4EN45951F biolink:treats MONDO:0005441 PMID:41385096 "[{""id"":""uuid:8cbda3c2-f668-43f9-9a90-442f9fcf095c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:11ade2b7-85bc-4f96-9ee5-d110e29be8da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SUPRAX (cefixime) is a cephalosporin antibacterial drug indicated in the treatment of adults and pediatric patients six months and older with the following infections: Uncomplicated Urinary Tract Infections ( 1.1 ) Otitis Media ( 1.2 ) Pharyngitis and Tonsillitis ( 1.3 ) Acute Exacerbations of Chronic Bronchitis ( 1.4 ) Uncomplicated Gonorrhea (cervical/urethral) ( 1.5 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of SUPRAX and other antibacterial drugs, SUPRAX should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 ) uuid:d3681c23-24e2-46e3-b182-98f542014e6b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:M4EN45951F biolink:treats MONDO:0002258 PMID:41385096 "[{""id"":""uuid:8072ec39-76d9-4ccb-bbec-664ea743f715"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4160b86c-1a25-4697-a68b-08c37eee886d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SUPRAX (cefixime) is a cephalosporin antibacterial drug indicated in the treatment of adults and pediatric patients six months and older with the following infections: Uncomplicated Urinary Tract Infections ( 1.1 ) Otitis Media ( 1.2 ) Pharyngitis and Tonsillitis ( 1.3 ) Acute Exacerbations of Chronic Bronchitis ( 1.4 ) Uncomplicated Gonorrhea (cervical/urethral) ( 1.5 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of SUPRAX and other antibacterial drugs, SUPRAX should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 ) uuid:7ec0134d-c375-4789-92bd-1ff0eafef5f0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:M4EN45951F biolink:treats MONDO:0001039 PMID:41385096 "[{""id"":""uuid:b0f4365b-9c75-4a48-8f7c-a8845c0533c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:beaedb3e-9ed7-4868-8f7c-43c22f0cc88b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SUPRAX (cefixime) is a cephalosporin antibacterial drug indicated in the treatment of adults and pediatric patients six months and older with the following infections: Uncomplicated Urinary Tract Infections ( 1.1 ) Otitis Media ( 1.2 ) Pharyngitis and Tonsillitis ( 1.3 ) Acute Exacerbations of Chronic Bronchitis ( 1.4 ) Uncomplicated Gonorrhea (cervical/urethral) ( 1.5 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of SUPRAX and other antibacterial drugs, SUPRAX should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 ) uuid:08c15dd8-b535-4c2d-a9a1-fb4e16d90360 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:M4EN45951F biolink:treats UMLS:C0853854 PMID:41385096 "[{""id"":""uuid:b0b74f32-4345-4758-af93-7040c6fc322b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:39d2432c-32b5-463a-beb4-e0ad59baae68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SUPRAX (cefixime) is a cephalosporin antibacterial drug indicated in the treatment of adults and pediatric patients six months and older with the following infections: Uncomplicated Urinary Tract Infections ( 1.1 ) Otitis Media ( 1.2 ) Pharyngitis and Tonsillitis ( 1.3 ) Acute Exacerbations of Chronic Bronchitis ( 1.4 ) Uncomplicated Gonorrhea (cervical/urethral) ( 1.5 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of SUPRAX and other antibacterial drugs, SUPRAX should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 ) uuid:2fdadec5-8e91-4bda-b3a4-c71d7d045d8a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:M4EN45951F biolink:treats MONDO:0004277 PMID:41385096 "[{""id"":""uuid:ccbbd430-eb29-45ee-a8b9-f89b3c32157d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8e2044af-92ab-4164-b9d6-be99ca8c94bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SUPRAX (cefixime) is a cephalosporin antibacterial drug indicated in the treatment of adults and pediatric patients six months and older with the following infections: Uncomplicated Urinary Tract Infections ( 1.1 ) Otitis Media ( 1.2 ) Pharyngitis and Tonsillitis ( 1.3 ) Acute Exacerbations of Chronic Bronchitis ( 1.4 ) Uncomplicated Gonorrhea (cervical/urethral) ( 1.5 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of SUPRAX and other antibacterial drugs, SUPRAX should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 ) uuid:229eb3ac-509c-4c47-a90e-3ab225dfa5a5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16217 biolink:treats MONDO:0006678 PMID:41385096 "[{""id"":""uuid:97beb4f6-0906-40c3-8ddb-fcfb35060087"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:458db3f1-2cc4-40e8-acd1-add75e084022"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Renacidin is indicated for dissolution of bladder calculi of the struvite or apatite variety by local intermittent irrigation through a urethral catheter or cystostomy tube as an alternative or adjunct to surgical procedures. Renacidin is also indicated for use as an intermittent irrigating solution to prevent encrustations of indwelling urethral catheters and cystostomy tubes. uuid:3dad28c2-0c17-44a0-ae58-97d1b35e76f2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29007 biolink:treats MONDO:0042485 PMID:41385096 "[{""id"":""uuid:d7ec5d57-7ad1-480c-8f5d-da5fedbc0f50"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8f567af5-9796-4726-b918-324842db454e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Before instituting treatment with Ceftriaxone for Injection, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ceftriaxone for Injection and other antibacterial drugs, Ceftriaxone for Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ceftriaxone for Injection is indicated for the treatment of the following infections when caused by susceptible organisms: LOWER RESPIRATORY TRACT INFECTIONS caused by Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis or Serratia marcescens. ACUTE BACTERIAL OTITIS MEDIA caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase producing strains) or Moraxella catarrhalis (including beta-lactamase producing strains). NOTE : In one study lower clinical cure rates were observed with a single dose of Ceftriaxone for Injection compared to 10 days of oral therapy. In a second study comparable cure rates were observed between single dose Ceftriaxone for Injection and the comparator. The potentially lower clinical cure rate of Ceftriaxone for Injection should be balanced against the potential advantages of parenteral therapy (see CLINICAL STUDIES ). SKIN AND SKIN STRUCTURE INFECTIONS caused by Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Viridans group streptococci , Escherichia coli, Enterobacter cloacae, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Morganella morganii, * Pseudomonas aeruginosa, Serratia marcescens, Acinetobacter calcoaceticus, Bacteroides fragilis * or Peptostreptococcus species . URINARY TRACT INFECTIONS (complicated and uncomplicated) caused by Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii or Klebsiella pneumoniae. UNCOMPLICATED GONORRHEA (cervical/urethral and rectal) caused by Neisseria gonorrhoeae, including both penicillinase- and nonpenicillinase-producing strains, and pharyngeal gonorrhea caused by nonpenicillinase-producing strains of Neisseria gonorrhoeae. PELVIC INFLAMMATORY DISEASE caused by Neisseria gonorrhoeae. Ceftriaxone for Injection, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and Chlamydia trachomatis is one of the suspected pathogens, appropriate antichlamydial coverage should be added. BACTERIAL SEPTICEMIA caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae or Klebsiella pneumoniae. BONE AND JOINT INFECTIONS caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae or Enterobacter species. INTRA-ABDOMINAL INFECTIONS caused by Escherichia coli, Klebsiella pneumoniae, Bacteroides fragilis, Clostridium species (Note: most strains of Clostridium difficile are resistant) or Peptostreptococcus species. MENINGITIS caused by Haemophilus influenzae, Neisseria meningitidis or Streptococcus pneumoniae. Ceftriaxone for Injection has also been used successfully in a limited number of cases of meningitis and shunt infection caused by Staphylococcus epidermidis* and Escherichia coli*. * Efficacy for this organism in this organ system was studied in fewer than ten infections. SURGICAL PROPHYLAXIS: The preoperative administration of a single 1 g dose of Ceftriaxone for Injection may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated (e.g. , vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high-risk patients, such as those over 70 years of age, with acute cholecystitis not requiring therapeutic antimicrobials, obstructive jaundice or common duct bile stones) and in surgical patients for whom infection at the operative site would present serious risk (e.g. , during coronary artery bypass surgery). Although Ceftriaxone for Injection has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo-controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of infection following coronary artery bypass surgery. When administered prior to surgical procedures for which it is indicated, a single 1 g dose of Ceftriaxone for Injection provides protection from most infections due to susceptible organisms throughout the course of the procedure. uuid:a4562b94-587d-491e-b8d3-670a14be35a2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29007 biolink:treats UMLS:C0392618 PMID:41385096 "[{""id"":""uuid:c988dd32-7c98-4310-b8d6-26586e1a436a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1bca348f-f230-4f15-adb6-f1f09eaf1d73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Before instituting treatment with Ceftriaxone for Injection, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ceftriaxone for Injection and other antibacterial drugs, Ceftriaxone for Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ceftriaxone for Injection is indicated for the treatment of the following infections when caused by susceptible organisms: LOWER RESPIRATORY TRACT INFECTIONS caused by Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis or Serratia marcescens. ACUTE BACTERIAL OTITIS MEDIA caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase producing strains) or Moraxella catarrhalis (including beta-lactamase producing strains). NOTE : In one study lower clinical cure rates were observed with a single dose of Ceftriaxone for Injection compared to 10 days of oral therapy. In a second study comparable cure rates were observed between single dose Ceftriaxone for Injection and the comparator. The potentially lower clinical cure rate of Ceftriaxone for Injection should be balanced against the potential advantages of parenteral therapy (see CLINICAL STUDIES ). SKIN AND SKIN STRUCTURE INFECTIONS caused by Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes, Viridans group streptococci , Escherichia coli, Enterobacter cloacae, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Morganella morganii, * Pseudomonas aeruginosa, Serratia marcescens, Acinetobacter calcoaceticus, Bacteroides fragilis * or Peptostreptococcus species . URINARY TRACT INFECTIONS (complicated and uncomplicated) caused by Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii or Klebsiella pneumoniae. UNCOMPLICATED GONORRHEA (cervical/urethral and rectal) caused by Neisseria gonorrhoeae, including both penicillinase- and nonpenicillinase-producing strains, and pharyngeal gonorrhea caused by nonpenicillinase-producing strains of Neisseria gonorrhoeae. PELVIC INFLAMMATORY DISEASE caused by Neisseria gonorrhoeae. Ceftriaxone for Injection, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and Chlamydia trachomatis is one of the suspected pathogens, appropriate antichlamydial coverage should be added. BACTERIAL SEPTICEMIA caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae or Klebsiella pneumoniae. BONE AND JOINT INFECTIONS caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae or Enterobacter species. INTRA-ABDOMINAL INFECTIONS caused by Escherichia coli, Klebsiella pneumoniae, Bacteroides fragilis, Clostridium species (Note: most strains of Clostridium difficile are resistant) or Peptostreptococcus species. MENINGITIS caused by Haemophilus influenzae, Neisseria meningitidis or Streptococcus pneumoniae. Ceftriaxone for Injection has also been used successfully in a limited number of cases of meningitis and shunt infection caused by Staphylococcus epidermidis* and Escherichia coli*. * Efficacy for this organism in this organ system was studied in fewer than ten infections. SURGICAL PROPHYLAXIS: The preoperative administration of a single 1 g dose of Ceftriaxone for Injection may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated (e.g. , vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high-risk patients, such as those over 70 years of age, with acute cholecystitis not requiring therapeutic antimicrobials, obstructive jaundice or common duct bile stones) and in surgical patients for whom infection at the operative site would present serious risk (e.g. , during coronary artery bypass surgery). Although Ceftriaxone for Injection has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo-controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of infection following coronary artery bypass surgery. When administered prior to surgical procedures for which it is indicated, a single 1 g dose of Ceftriaxone for Injection provides protection from most infections due to susceptible organisms throughout the course of the procedure. uuid:422f05c0-b61d-4a94-af74-ab17ae5d75fa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4712 biolink:treats MONDO:0006964 PMID:41385096 "[{""id"":""uuid:5f49185f-4a39-4fd6-95b4-09c8daba09ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d4fc5d1e-9c29-4754-bd26-472c5aee5a56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxercalciferol injection is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis. uuid:2ee7c426-4862-4b67-a126-9a02b603347d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4712 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:04200b6b-5b3b-4877-9209-0fd9e9bfcc48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3000243e-4d6c-4ae5-83bc-8b9fa415e087"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxercalciferol injection is indicated for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease on dialysis. uuid:a885af74-c7b9-4db8-abaa-5016548b1872 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31625 biolink:treats MONDO:0006170 PMID:41385096 "[{""id"":""uuid:fc58d59b-4452-4e5c-aa2d-77a69d4a9eba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a3741f51-aa12-42c4-9b7d-9e15a14de1a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FLAREX (fluorometholone acetate ophthalmic suspension) is indicated for use in the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the eye. uuid:07936ecd-1a84-4da8-8bc3-116b89fd07f5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31625 biolink:treats MONDO:0001718 PMID:41385096 "[{""id"":""uuid:655b9c55-4d52-4532-8170-eb24c3b681a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fb075453-fdd4-41f6-9db0-55efceb0f601"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FLAREX (fluorometholone acetate ophthalmic suspension) is indicated for use in the treatment of steroid responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the eye. uuid:4c2b7c30-430e-4cea-9bad-c8e2763df339 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:291902 biolink:treats MONDO:0005542 PMID:41385096 "[{""id"":""uuid:3d2dc3b6-47d2-493f-80a7-1b3f63c47956"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:26314ae6-4529-4cbb-b716-6b6b43740ba4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Eptifibatide injection is a platelet aggregation inhibitor indicated for: Treatment of acute coronary syndrome (ACS) managed medically or with percutaneous coronary intervention (PCI) ( 1.1 ) Treatment of patients undergoing PCI (including intracoronary stenting) ( 1.2 ) uuid:8ea40a34-4d69-4547-a495-ba09439df4d3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:607 biolink:treats MONDO:0007743 PMID:41385096 "[{""id"":""uuid:58bf3a36-8d26-4962-81f8-359590ba22c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:15e4921c-0b3f-4cfd-92c0-d94a388e909f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) and Narcolepsy. MESH:C090411 uuid:f09c6d18-6f93-4b76-be43-bf45c11d56e3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63632 biolink:treats UMLS:C4721779 PMID:41385096 "[{""id"":""uuid:d5ade75e-12cb-416f-8921-a803643252e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:41c9845a-c578-4522-a62c-54cdc3b20e99"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Topotecan Hydrochloride for Injection is a topoisomerase inhibitor indicated for treatment of: Patients with metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy, as a single agent ( 1.1 ) Patients with small cell lung cancer (SCLC) platinum-sensitive disease who progressed at least 60 days after initiation of first-line chemotherapy, as a single agent ( 1.2 ) Patients with Stage IV-B, recurrent, or persistent cervical cancer which is not amenable to curative treatment, in combination with cisplatin ( 1.3 ) uuid:71cbb07c-1473-41f8-8d05-36ef1ec18448 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63632 biolink:treats MONDO:0002974 PMID:41385096 "[{""id"":""uuid:9bac490a-87a0-4ae2-8f28-3b4592b8c8c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5562493b-3e18-46ed-bd8c-b4780ae7a93c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Topotecan Hydrochloride for Injection is a topoisomerase inhibitor indicated for treatment of: Patients with metastatic ovarian cancer after disease progression on or after initial or subsequent chemotherapy, as a single agent ( 1.1 ) Patients with small cell lung cancer (SCLC) platinum-sensitive disease who progressed at least 60 days after initiation of first-line chemotherapy, as a single agent ( 1.2 ) Patients with Stage IV-B, recurrent, or persistent cervical cancer which is not amenable to curative treatment, in combination with cisplatin ( 1.3 ) uuid:ae03c7f4-12cc-4f5d-83a0-3d6de7de4093 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:132233 biolink:treats MONDO:0021107 PMID:41385096 "[{""id"":""uuid:d92f120c-f84b-48ab-8b79-d9ad96e790b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dcdba69d-47a3-45e1-aff3-9f30bb3c1035"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amphetamine sulfate tablets are indicated for: Narcolepsy Attention Deficit Disorder with Hyperactivity as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of the syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Non-localizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or not be warranted. Exogenous Obesity as a short-term (a few weeks) adjuncts in a regimen of weight reduction based on caloric restriction for patients refractory to alternative therapy, e.g., repeated diets, group programs, and other drugs. The limited usefulness of amphetamines (see CLINICAL PHARMACOLOGY ) should be weighed against possible risks inherent in the use of the drug, such as those described below. uuid:88abc4d7-1953-485c-bb61-a783cd9c2ab5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:132233 biolink:treats MONDO:0007743 PMID:41385096 "[{""id"":""uuid:61b7b1a9-dd26-46e4-9380-15f4e3a12532"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6b39025b-b5d0-4ef0-8d30-53bdaf386018"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amphetamine sulfate tablets are indicated for: Narcolepsy Attention Deficit Disorder with Hyperactivity as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of the syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Non-localizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or not be warranted. Exogenous Obesity as a short-term (a few weeks) adjuncts in a regimen of weight reduction based on caloric restriction for patients refractory to alternative therapy, e.g., repeated diets, group programs, and other drugs. The limited usefulness of amphetamines (see CLINICAL PHARMACOLOGY ) should be weighed against possible risks inherent in the use of the drug, such as those described below. uuid:75d4b8f7-283c-44d1-bc27-52c35c8998ad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:132233 biolink:treats NCIT:C120380 PMID:41385096 "[{""id"":""uuid:544e91ab-c504-449c-95be-7a20bda9b43c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:516dac70-aacb-4ed6-b192-33e4c884860c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amphetamine sulfate tablets are indicated for: Narcolepsy Attention Deficit Disorder with Hyperactivity as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in children with behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of the syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Non-localizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or not be warranted. Exogenous Obesity as a short-term (a few weeks) adjuncts in a regimen of weight reduction based on caloric restriction for patients refractory to alternative therapy, e.g., repeated diets, group programs, and other drugs. The limited usefulness of amphetamines (see CLINICAL PHARMACOLOGY ) should be weighed against possible risks inherent in the use of the drug, such as those described below. uuid:620540a4-6149-4ac2-aec1-6afa3d5865b7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:175901 biolink:treats MONDO:0008170 PMID:41385096 "[{""id"":""uuid:ece975f3-987f-4cb5-806a-da976cdb4ace"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5e67c88f-08f4-4bcf-9c14-f9e5d4f998a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d4db1c62-ad08-446f-bc82-25c8f46a009d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gemcitabine Injection is a nucleoside metabolic inhibitor indicated: in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ( 1.1 ) in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. ( 1.2 ) in combination with cisplatin for the treatment of non-small cell lung cancer. ( 1.3 ) as a single-agent for the treatment of pancreatic cancer. ( 1.4 )|[PMDA] Drugs with a new additional indication and a new dosage for the treatment of ovarian cancer which has progressed after cancer chemotherapy. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:e2976f48-b241-4341-b1ac-ff1835ea924a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:175901 biolink:treats UMLS:C0278488 PMID:41385096 "[{""id"":""uuid:d4862bdc-e0d8-47be-863e-5b39761d5eca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fef33702-8dd8-47c8-99e9-0476348e3793"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gemcitabine Injection is a nucleoside metabolic inhibitor indicated: in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ( 1.1 ) in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. ( 1.2 ) in combination with cisplatin for the treatment of non-small cell lung cancer. ( 1.3 ) as a single-agent for the treatment of pancreatic cancer. ( 1.4 ) uuid:24cc5f8d-5e59-4e7b-a7a5-e94fd42a8620 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:175901 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:e9698a37-fe98-4604-98df-c3803bd9cce1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3f639dc8-4808-42c9-aa51-297a19afb6bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b63ec94e-a48c-4acb-8174-9e5b753b2f92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gemcitabine Injection is a nucleoside metabolic inhibitor indicated: in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ( 1.1 ) in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. ( 1.2 ) in combination with cisplatin for the treatment of non-small cell lung cancer. ( 1.3 ) as a single-agent for the treatment of pancreatic cancer. ( 1.4 )|[PMDA] Drugs with a new dosage indicated for the treatment of non-small cell lung cancer. uuid:35fc0bbe-36ea-4303-b6a6-52ba4f4a73f3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:175901 biolink:treats MONDO:0021040 PMID:41385096 "[{""id"":""uuid:0fe4eb06-6c1b-4d60-b868-a791b18ea526"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:90de8690-0eee-4e39-9aca-f5665c1c916a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gemcitabine Injection is a nucleoside metabolic inhibitor indicated: in combination with carboplatin, for the treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy. ( 1.1 ) in combination with paclitaxel, for first-line treatment of metastatic breast cancer after failure of prior anthracycline containing adjuvant chemotherapy, unless anthracyclines were clinically contraindicated. ( 1.2 ) in combination with cisplatin for the treatment of non-small cell lung cancer. ( 1.3 ) as a single-agent for the treatment of pancreatic cancer. ( 1.4 ) uuid:a804c3f7-2209-4bdb-a0ec-dc0798a1ab09 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2668 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:4a4b6206-a049-4708-b376-0f5d8ffc90ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4c60896b-9161-42f5-ad9d-eda8f37f3ef6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:5c90af45-d568-47a7-be7d-7c13bc756de4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hypertension Amlodipine besylate tablets USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine besylate tablets USP. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Amlodipine besylate tablets USP may be used alone or in combination with other antihypertensive agents. 1.2 Coronary Artery Disease (CAD) Chronic Stable Angina Amlodipine besylate tablets USP are indicated for the symptomatic treatment of chronic stable angina. Amlodipine besylate tablets USP may be used alone or in combination with other antianginal agents. Vasospastic Angina (Prinzmetal's or Variant Angina) Amlodipine besylate tablets USP are indicated for the treatment of confirmed or suspected vasospastic angina. Amlodipine besylate tablets USP may be used as monotherapy or in combination with other antianginal agents. Angiographically Documented CAD In patients with recently documented CAD by angiography and without heart failure or an ejection fraction <40%, amlodipine besylate tablets USP are indicated to reduce the risk of hospitalization for angina and to reduce the risk of a coronary revascularization procedure.|[PMDA] Drugs with a new dosage indicated for the treatment of hypertension and angina pectoris. uuid:bf7c3159-645e-410c-ab22-bfbeb511e789 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4672 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:ce261fa0-8285-4ad8-9fd6-2dd974eb7560"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bc163236-eaad-42ce-b010-375465c7fe4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:61b09bfc-e939-47b0-ac13-d779509113f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/docetaxel-kabi""]},{""id"":""uuid:1c219d9e-8f3b-43ca-bfe0-47d65b5a6007"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Docetaxel injection is a microtubule inhibitor indicated for: Breast Cancer (BC) : single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) Non-small Cell Lung Cancer (NSCLC) : single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) Castration-Resistant Prostate Cancer (CRPC) : with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) Gastric Adenocarcinoma (GC) : with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) Squamous Cell Carcinoma of the Head and Neck (SCCHN) : with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 )|[EMA] Breast cancerDocetaxel Kabi in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.For patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.Docetaxel Kabi in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.Docetaxel Kabi monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.Docetaxel Kabi in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease.Docetaxel Kabi in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.Non-small-cell lung cancerDocetaxel Kabi is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of prior chemotherapy.Docetaxel Kabi in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small-cell lung cancer, in patients who have not previously received chemotherapy for this condition.Prostate cancerDocetaxel Kabi in combination with prednisone or prednisolone is indicated for the treatment of patients with castration-resistant metastatic prostate cancer.Docetaxel Kabi in combination with androgen-deprivation therapy (ADT), with or without prednisone or prednisolone, is indicated for the treatment of patients with metastatic hormone-sensitive prostate cancer.Gastric adenocarcinomaDocetaxel Kabi in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.Head and neck cancerDocetaxel Kabi in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.|[PMDA] Drugs with new dosages for the treatment of breast cancer, non-small cell lung cancer, gastric cancer, head and neck cancer and ovarian cancer. uuid:ea951371-e71a-4c83-9d0e-3fa2fdfd5d33 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4672 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:adec1e68-377f-4c96-aeb7-02f9775f5d30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9c84b285-a366-4e4d-ae4e-1dd71258aa5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b1ba1400-2bac-46cd-9da6-b8a9d4771998"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/docetaxel-kabi""]},{""id"":""uuid:c0a5aae0-e4c8-40e1-beba-0d73388faebc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Docetaxel injection is a microtubule inhibitor indicated for: Breast Cancer (BC) : single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) Non-small Cell Lung Cancer (NSCLC) : single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) Castration-Resistant Prostate Cancer (CRPC) : with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) Gastric Adenocarcinoma (GC) : with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) Squamous Cell Carcinoma of the Head and Neck (SCCHN) : with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 )|[EMA] Breast cancerDocetaxel Kabi in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.For patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.Docetaxel Kabi in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.Docetaxel Kabi monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.Docetaxel Kabi in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease.Docetaxel Kabi in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.Non-small-cell lung cancerDocetaxel Kabi is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of prior chemotherapy.Docetaxel Kabi in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small-cell lung cancer, in patients who have not previously received chemotherapy for this condition.Prostate cancerDocetaxel Kabi in combination with prednisone or prednisolone is indicated for the treatment of patients with castration-resistant metastatic prostate cancer.Docetaxel Kabi in combination with androgen-deprivation therapy (ADT), with or without prednisone or prednisolone, is indicated for the treatment of patients with metastatic hormone-sensitive prostate cancer.Gastric adenocarcinomaDocetaxel Kabi in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.Head and neck cancerDocetaxel Kabi in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.|[PMDA] Drugs with new dosages for the treatment of breast cancer, non-small cell lung cancer, gastric cancer, head and neck cancer and ovarian cancer. uuid:9e853045-d772-44ac-84fe-130f424f2016 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4672 biolink:treats MONDO:0005036 PMID:41385096 "[{""id"":""uuid:22e1721f-3842-4650-9a1b-26eca051bc43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:fb372802-e136-42a2-8705-44013c743ed3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:848ba77b-9c34-4006-9111-33969ccedd3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/docetaxel-kabi""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Docetaxel injection is a microtubule inhibitor indicated for: Breast Cancer (BC) : single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) Non-small Cell Lung Cancer (NSCLC) : single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) Castration-Resistant Prostate Cancer (CRPC) : with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) Gastric Adenocarcinoma (GC) : with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) Squamous Cell Carcinoma of the Head and Neck (SCCHN) : with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 )|[EMA] Breast cancerDocetaxel Kabi in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.For patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.Docetaxel Kabi in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.Docetaxel Kabi monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.Docetaxel Kabi in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease.Docetaxel Kabi in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.Non-small-cell lung cancerDocetaxel Kabi is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of prior chemotherapy.Docetaxel Kabi in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small-cell lung cancer, in patients who have not previously received chemotherapy for this condition.Prostate cancerDocetaxel Kabi in combination with prednisone or prednisolone is indicated for the treatment of patients with castration-resistant metastatic prostate cancer.Docetaxel Kabi in combination with androgen-deprivation therapy (ADT), with or without prednisone or prednisolone, is indicated for the treatment of patients with metastatic hormone-sensitive prostate cancer.Gastric adenocarcinomaDocetaxel Kabi in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.Head and neck cancerDocetaxel Kabi in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck. uuid:89fb87c3-8459-4faa-9797-a00e8130f168 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4672 biolink:treats MONDO:0010150 PMID:41385096 "[{""id"":""uuid:c673d2ea-ed62-4c68-9da9-28ace6250329"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:addb2c97-03db-4226-aefa-d3394840f7cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Docetaxel injection is a microtubule inhibitor indicated for: Breast Cancer (BC) : single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC ( 1.1 ) Non-small Cell Lung Cancer (NSCLC) : single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC ( 1.2 ) Castration-Resistant Prostate Cancer (CRPC) : with prednisone in metastatic castration-resistant prostate cancer ( 1.3 ) Gastric Adenocarcinoma (GC) : with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction ( 1.4 ) Squamous Cell Carcinoma of the Head and Neck (SCCHN) : with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN ( 1.5 ) uuid:3050ed0b-e9e9-4609-94cf-a2a1a5763d76 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2663 biolink:treats HP:0001649 PMID:41385096 "[{""id"":""uuid:1c9ac51e-c445-4d2f-9301-aab4ec4cf59b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b70284ca-2c32-4346-b291-7969b12034a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amiodarone hydrochloride tablets are indicated for the treatment of documented, life-threatening recurrent ventricular fibrillation and life-threatening recurrent hemodynamically unstable tachycardia in adults who have not responded to adequate doses of other available antiarrhythmics or when alternative agents cannot be tolerated. uuid:206d267f-fde1-476b-b3d6-f24779be5356 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:163203584 biolink:treats MONDO:0008228 PMID:41385096 "[{""id"":""uuid:8c73af10-88ce-49f9-85fe-94d89d4a4beb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ff6d68c8-818f-41a2-bcff-cd8e5e7e6201"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pernicious anemia, both uncomplicated and accompanied by nervous system involvement. Dietary deficiency of Vitamin B 12 , occurring in strict vegetarians and in their breast-fed infants. (Isolated vitamin B 12 deficiency is very rare). Malabsorption of vitamin B 12 , resulting from structural or functional damage to the stomach, where intrinsic factor is secreted or to the ileum, where intrinsic factor facilitates vitamin B 12 absorption. These conditions include tropical sprue, and nontropical sprue (idiopathic steatorrhea, gluten-induced enteropathy). Folate deficiency in these patients is usually more severe than vitamin B 12 deficiency. Inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric atrophy (such as multiple sclerosis, certain endocrine disorders, iron deficiency, and subtotal gastrectomy). Total gastrectomy always produces vitamin B 12 deficiency. Structural lesions leading to vitamin B 12 deficiency include regional ileitis, ileal resections, malignancies, etc. Competition for Vitamin B 12 by intestinal parasites or bacteria. The fish tapeworm (Diphyllobothrium latum) absorbs huge quantities of vitamin B 12 and infested patients often have associated gastric atrophy. The blind-loop syndrome may produce deficiency of Vitamin B 12 or folate. Inadequate utilization of vitamin B 12 . This may occur if antimetabolites for the vitamin are employed in the treatment of neoplasia. For the Schilling Test. uuid:e1cceb17-a688-40cc-beb4-342538210110 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:163203584 biolink:treats MONDO:0020696 PMID:41385096 "[{""id"":""uuid:0050e94d-6362-47ef-adce-bb110b0a8f92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4567be31-34bd-4f92-918e-181c778e9979"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pernicious anemia, both uncomplicated and accompanied by nervous system involvement. Dietary deficiency of Vitamin B 12 , occurring in strict vegetarians and in their breast-fed infants. (Isolated vitamin B 12 deficiency is very rare). Malabsorption of vitamin B 12 , resulting from structural or functional damage to the stomach, where intrinsic factor is secreted or to the ileum, where intrinsic factor facilitates vitamin B 12 absorption. These conditions include tropical sprue, and nontropical sprue (idiopathic steatorrhea, gluten-induced enteropathy). Folate deficiency in these patients is usually more severe than vitamin B 12 deficiency. Inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric atrophy (such as multiple sclerosis, certain endocrine disorders, iron deficiency, and subtotal gastrectomy). Total gastrectomy always produces vitamin B 12 deficiency. Structural lesions leading to vitamin B 12 deficiency include regional ileitis, ileal resections, malignancies, etc. Competition for Vitamin B 12 by intestinal parasites or bacteria. The fish tapeworm (Diphyllobothrium latum) absorbs huge quantities of vitamin B 12 and infested patients often have associated gastric atrophy. The blind-loop syndrome may produce deficiency of Vitamin B 12 or folate. Inadequate utilization of vitamin B 12 . This may occur if antimetabolites for the vitamin are employed in the treatment of neoplasia. For the Schilling Test. uuid:db6d7ee5-ecb3-40a5-9edd-b521e818161c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:163203584 biolink:treats MONDO:0001078 PMID:41385096 "[{""id"":""uuid:0a8f4247-0f60-45ca-b99e-a6a690f6b7b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1740b783-a378-4f85-a601-3a43e32d8ac7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pernicious anemia, both uncomplicated and accompanied by nervous system involvement. Dietary deficiency of Vitamin B 12 , occurring in strict vegetarians and in their breast-fed infants. (Isolated vitamin B 12 deficiency is very rare). Malabsorption of vitamin B 12 , resulting from structural or functional damage to the stomach, where intrinsic factor is secreted or to the ileum, where intrinsic factor facilitates vitamin B 12 absorption. These conditions include tropical sprue, and nontropical sprue (idiopathic steatorrhea, gluten-induced enteropathy). Folate deficiency in these patients is usually more severe than vitamin B 12 deficiency. Inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric atrophy (such as multiple sclerosis, certain endocrine disorders, iron deficiency, and subtotal gastrectomy). Total gastrectomy always produces vitamin B 12 deficiency. Structural lesions leading to vitamin B 12 deficiency include regional ileitis, ileal resections, malignancies, etc. Competition for Vitamin B 12 by intestinal parasites or bacteria. The fish tapeworm (Diphyllobothrium latum) absorbs huge quantities of vitamin B 12 and infested patients often have associated gastric atrophy. The blind-loop syndrome may produce deficiency of Vitamin B 12 or folate. Inadequate utilization of vitamin B 12 . This may occur if antimetabolites for the vitamin are employed in the treatment of neoplasia. For the Schilling Test. uuid:1d5b0f12-4e1c-4d69-b50c-3dba4f0f75d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:163203584 biolink:treats MONDO:0005130 PMID:41385096 "[{""id"":""uuid:ddeb34d9-9413-4dbd-9ce5-77c400e1140d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9cf21814-65d0-4d51-90be-02ceae0dcdaa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pernicious anemia, both uncomplicated and accompanied by nervous system involvement. Dietary deficiency of Vitamin B 12 , occurring in strict vegetarians and in their breast-fed infants. (Isolated vitamin B 12 deficiency is very rare). Malabsorption of vitamin B 12 , resulting from structural or functional damage to the stomach, where intrinsic factor is secreted or to the ileum, where intrinsic factor facilitates vitamin B 12 absorption. These conditions include tropical sprue, and nontropical sprue (idiopathic steatorrhea, gluten-induced enteropathy). Folate deficiency in these patients is usually more severe than vitamin B 12 deficiency. Inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric atrophy (such as multiple sclerosis, certain endocrine disorders, iron deficiency, and subtotal gastrectomy). Total gastrectomy always produces vitamin B 12 deficiency. Structural lesions leading to vitamin B 12 deficiency include regional ileitis, ileal resections, malignancies, etc. Competition for Vitamin B 12 by intestinal parasites or bacteria. The fish tapeworm (Diphyllobothrium latum) absorbs huge quantities of vitamin B 12 and infested patients often have associated gastric atrophy. The blind-loop syndrome may produce deficiency of Vitamin B 12 or folate. Inadequate utilization of vitamin B 12 . This may occur if antimetabolites for the vitamin are employed in the treatment of neoplasia. For the Schilling Test. uuid:c6450dea-be12-48ca-a555-d572c2a385a9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:163203584 biolink:treats MONDO:0001075 PMID:41385096 "[{""id"":""uuid:9eb2372c-d3db-4ddd-9bd6-532c9723a5f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:edb9950f-bebb-4a7c-8c86-6d29dea8de85"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pernicious anemia, both uncomplicated and accompanied by nervous system involvement. Dietary deficiency of Vitamin B 12 , occurring in strict vegetarians and in their breast-fed infants. (Isolated vitamin B 12 deficiency is very rare). Malabsorption of vitamin B 12 , resulting from structural or functional damage to the stomach, where intrinsic factor is secreted or to the ileum, where intrinsic factor facilitates vitamin B 12 absorption. These conditions include tropical sprue, and nontropical sprue (idiopathic steatorrhea, gluten-induced enteropathy). Folate deficiency in these patients is usually more severe than vitamin B 12 deficiency. Inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric atrophy (such as multiple sclerosis, certain endocrine disorders, iron deficiency, and subtotal gastrectomy). Total gastrectomy always produces vitamin B 12 deficiency. Structural lesions leading to vitamin B 12 deficiency include regional ileitis, ileal resections, malignancies, etc. Competition for Vitamin B 12 by intestinal parasites or bacteria. The fish tapeworm (Diphyllobothrium latum) absorbs huge quantities of vitamin B 12 and infested patients often have associated gastric atrophy. The blind-loop syndrome may produce deficiency of Vitamin B 12 or folate. Inadequate utilization of vitamin B 12 . This may occur if antimetabolites for the vitamin are employed in the treatment of neoplasia. For the Schilling Test. uuid:b1a4cdb3-360e-4a83-8307-688243678c9d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:163203584 biolink:treats MONDO:0001860 PMID:41385096 "[{""id"":""uuid:e2ce3330-28b4-4c92-aad4-b0fa25665fee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a595077c-bf0e-4162-bdbb-b3b2aab3bdaa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pernicious anemia, both uncomplicated and accompanied by nervous system involvement. Dietary deficiency of Vitamin B 12 , occurring in strict vegetarians and in their breast-fed infants. (Isolated vitamin B 12 deficiency is very rare). Malabsorption of vitamin B 12 , resulting from structural or functional damage to the stomach, where intrinsic factor is secreted or to the ileum, where intrinsic factor facilitates vitamin B 12 absorption. These conditions include tropical sprue, and nontropical sprue (idiopathic steatorrhea, gluten-induced enteropathy). Folate deficiency in these patients is usually more severe than vitamin B 12 deficiency. Inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric atrophy (such as multiple sclerosis, certain endocrine disorders, iron deficiency, and subtotal gastrectomy). Total gastrectomy always produces vitamin B 12 deficiency. Structural lesions leading to vitamin B 12 deficiency include regional ileitis, ileal resections, malignancies, etc. Competition for Vitamin B 12 by intestinal parasites or bacteria. The fish tapeworm (Diphyllobothrium latum) absorbs huge quantities of vitamin B 12 and infested patients often have associated gastric atrophy. The blind-loop syndrome may produce deficiency of Vitamin B 12 or folate. Inadequate utilization of vitamin B 12 . This may occur if antimetabolites for the vitamin are employed in the treatment of neoplasia. For the Schilling Test. uuid:a7cf892a-48ca-4b76-ae5d-5c890f4b91a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:163203584 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:0de0d800-2d56-4879-84e0-99f6043fa82b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9fb59fe0-bc7f-4228-a9c0-2963debf89b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pernicious anemia, both uncomplicated and accompanied by nervous system involvement. Dietary deficiency of Vitamin B 12 , occurring in strict vegetarians and in their breast-fed infants. (Isolated vitamin B 12 deficiency is very rare). Malabsorption of vitamin B 12 , resulting from structural or functional damage to the stomach, where intrinsic factor is secreted or to the ileum, where intrinsic factor facilitates vitamin B 12 absorption. These conditions include tropical sprue, and nontropical sprue (idiopathic steatorrhea, gluten-induced enteropathy). Folate deficiency in these patients is usually more severe than vitamin B 12 deficiency. Inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric atrophy (such as multiple sclerosis, certain endocrine disorders, iron deficiency, and subtotal gastrectomy). Total gastrectomy always produces vitamin B 12 deficiency. Structural lesions leading to vitamin B 12 deficiency include regional ileitis, ileal resections, malignancies, etc. Competition for Vitamin B 12 by intestinal parasites or bacteria. The fish tapeworm (Diphyllobothrium latum) absorbs huge quantities of vitamin B 12 and infested patients often have associated gastric atrophy. The blind-loop syndrome may produce deficiency of Vitamin B 12 or folate. Inadequate utilization of vitamin B 12 . This may occur if antimetabolites for the vitamin are employed in the treatment of neoplasia. For the Schilling Test. uuid:ca215ccd-2557-4e36-b371-5eaee1c80896 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:163203584 biolink:treats UMLS:C0240066 PMID:41385096 "[{""id"":""uuid:15156c15-e1b8-4c86-a78c-3afb5488e0f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b169c646-772a-4c9e-9ee0-703275f7b7a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pernicious anemia, both uncomplicated and accompanied by nervous system involvement. Dietary deficiency of Vitamin B 12 , occurring in strict vegetarians and in their breast-fed infants. (Isolated vitamin B 12 deficiency is very rare). Malabsorption of vitamin B 12 , resulting from structural or functional damage to the stomach, where intrinsic factor is secreted or to the ileum, where intrinsic factor facilitates vitamin B 12 absorption. These conditions include tropical sprue, and nontropical sprue (idiopathic steatorrhea, gluten-induced enteropathy). Folate deficiency in these patients is usually more severe than vitamin B 12 deficiency. Inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric atrophy (such as multiple sclerosis, certain endocrine disorders, iron deficiency, and subtotal gastrectomy). Total gastrectomy always produces vitamin B 12 deficiency. Structural lesions leading to vitamin B 12 deficiency include regional ileitis, ileal resections, malignancies, etc. Competition for Vitamin B 12 by intestinal parasites or bacteria. The fish tapeworm (Diphyllobothrium latum) absorbs huge quantities of vitamin B 12 and infested patients often have associated gastric atrophy. The blind-loop syndrome may produce deficiency of Vitamin B 12 or folate. Inadequate utilization of vitamin B 12 . This may occur if antimetabolites for the vitamin are employed in the treatment of neoplasia. For the Schilling Test. uuid:b29e3b7a-7841-4e33-9250-bf3ef39b600e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:163203584 biolink:treats MONDO:0000709 PMID:41385096 "[{""id"":""uuid:2a5f445f-b37e-4771-a6ae-375931e2fc1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:68d02d5d-9a48-44c8-89ac-923c14ce95bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pernicious anemia, both uncomplicated and accompanied by nervous system involvement. Dietary deficiency of Vitamin B 12 , occurring in strict vegetarians and in their breast-fed infants. (Isolated vitamin B 12 deficiency is very rare). Malabsorption of vitamin B 12 , resulting from structural or functional damage to the stomach, where intrinsic factor is secreted or to the ileum, where intrinsic factor facilitates vitamin B 12 absorption. These conditions include tropical sprue, and nontropical sprue (idiopathic steatorrhea, gluten-induced enteropathy). Folate deficiency in these patients is usually more severe than vitamin B 12 deficiency. Inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric atrophy (such as multiple sclerosis, certain endocrine disorders, iron deficiency, and subtotal gastrectomy). Total gastrectomy always produces vitamin B 12 deficiency. Structural lesions leading to vitamin B 12 deficiency include regional ileitis, ileal resections, malignancies, etc. Competition for Vitamin B 12 by intestinal parasites or bacteria. The fish tapeworm (Diphyllobothrium latum) absorbs huge quantities of vitamin B 12 and infested patients often have associated gastric atrophy. The blind-loop syndrome may produce deficiency of Vitamin B 12 or folate. Inadequate utilization of vitamin B 12 . This may occur if antimetabolites for the vitamin are employed in the treatment of neoplasia. For the Schilling Test. uuid:fcdc66b8-a8cf-43ba-8a09-93dff587d1c0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:163203584 biolink:treats MONDO:0006665 PMID:41385096 "[{""id"":""uuid:67855879-8af2-4665-8693-e65ac1487e82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a335b2d7-e450-4d78-b867-f18daf0d5f9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pernicious anemia, both uncomplicated and accompanied by nervous system involvement. Dietary deficiency of Vitamin B 12 , occurring in strict vegetarians and in their breast-fed infants. (Isolated vitamin B 12 deficiency is very rare). Malabsorption of vitamin B 12 , resulting from structural or functional damage to the stomach, where intrinsic factor is secreted or to the ileum, where intrinsic factor facilitates vitamin B 12 absorption. These conditions include tropical sprue, and nontropical sprue (idiopathic steatorrhea, gluten-induced enteropathy). Folate deficiency in these patients is usually more severe than vitamin B 12 deficiency. Inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric atrophy (such as multiple sclerosis, certain endocrine disorders, iron deficiency, and subtotal gastrectomy). Total gastrectomy always produces vitamin B 12 deficiency. Structural lesions leading to vitamin B 12 deficiency include regional ileitis, ileal resections, malignancies, etc. Competition for Vitamin B 12 by intestinal parasites or bacteria. The fish tapeworm (Diphyllobothrium latum) absorbs huge quantities of vitamin B 12 and infested patients often have associated gastric atrophy. The blind-loop syndrome may produce deficiency of Vitamin B 12 or folate. Inadequate utilization of vitamin B 12 . This may occur if antimetabolites for the vitamin are employed in the treatment of neoplasia. For the Schilling Test. uuid:f7289b50-a9e6-4cee-9ede-d7ee95c3ab9b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats MONDO:0021094 PMID:41385096 "[{""id"":""uuid:19d9d832-2691-4eeb-b4ef-f9364d55a5ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c056ff61-dbd6-40a4-9b54-696e0feb7c71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae. • Acute bacterial sinusitis due to Haemophilus influenzae, Moraxella catarrhalis. or Streptococcus pneumoniae. • Community-acquired pneumonia due to Chlamydophila pneumoniae, Haemophilus influenzae,Mycoplasma pneumoniae, or Streptococcus pneumoniae in patients appropriate for oral therapy. • Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. • Uncomplicated skin and skin structure infections due to Staphylococcus aureus, Streptococcus pyogenes, or Streptococcus agalactiae. • Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae. • Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. 1.2 Pediatric Patients [see Use in Specific Populations (8.4) and Clinical Studies (14.2)] • Acute otitis media (> 6 months of age) caused by Haemophilus influenzae, Moraxella catarrhalis, orStreptococcus pneumoniae • Community-acquired pneumonia (> 6 months of age) due to Chlamydophila pneumoniae,Haemophilus influenzae, Mycoplasma pneumonia, or Streptococcus pneumoniae in patients appropriate for oral therapy. • Pharyngitis/tonsillitis (> 2 years of age) caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. 1.3 Limitations of Use Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: • patients with cystic fibrosis, • patients with nosocomial infections, • patients with known or suspected bacteremia, • patients requiring hospitalization, • elderly or debilitated patients, or • patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). uuid:556a836c-e782-4769-ab74-177ff4a8de88 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats UMLS:C0272405 PMID:41385096 "[{""id"":""uuid:563d5f7d-5699-4298-8e84-f3a982b19e18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c4fe2625-e8e0-4554-8a1b-7927c583a147"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae. • Acute bacterial sinusitis due to Haemophilus influenzae, Moraxella catarrhalis. or Streptococcus pneumoniae. • Community-acquired pneumonia due to Chlamydophila pneumoniae, Haemophilus influenzae,Mycoplasma pneumoniae, or Streptococcus pneumoniae in patients appropriate for oral therapy. • Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. • Uncomplicated skin and skin structure infections due to Staphylococcus aureus, Streptococcus pyogenes, or Streptococcus agalactiae. • Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae. • Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. 1.2 Pediatric Patients [see Use in Specific Populations (8.4) and Clinical Studies (14.2)] • Acute otitis media (> 6 months of age) caused by Haemophilus influenzae, Moraxella catarrhalis, orStreptococcus pneumoniae • Community-acquired pneumonia (> 6 months of age) due to Chlamydophila pneumoniae,Haemophilus influenzae, Mycoplasma pneumonia, or Streptococcus pneumoniae in patients appropriate for oral therapy. • Pharyngitis/tonsillitis (> 2 years of age) caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. 1.3 Limitations of Use Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: • patients with cystic fibrosis, • patients with nosocomial infections, • patients with known or suspected bacteremia, • patients requiring hospitalization, • elderly or debilitated patients, or • patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). uuid:2883d97f-aed1-4ea4-90b1-85f532e4bc4b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats UMLS:C0018674 PMID:41385096 "[{""id"":""uuid:68a909e9-3bb3-4db4-8c37-6adbe6a2ecac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b4afe6c3-89f1-4ed1-926c-249feafc65b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus uuid:5929f31c-e78b-4977-bc68-9bd04912fcb4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:375581 biolink:treats UMLS:C0278140 PMID:41385096 "[{""id"":""uuid:a3a6a8a4-d566-4e47-b2d0-50c2713abbab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:96154efb-bd34-4fd5-b305-96826aa73fc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxycodone Hydrochloride and Acetaminophen Tablets is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses [see WARNINGS], reserve Oxycodone Hydrochloride and Acetaminophen Tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics] Have not been tolerated, or are not expected to be tolerated, Have not provided adequate analgesia, or are not expected to provide adequate analgesia uuid:0a350ae4-cd3b-4184-89f5-39ea8de270f0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:119915 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:0d25c4be-6b6a-4313-b0b5-f87df12127f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a4a62fc3-0dc9-4dc8-becd-f50c9aba2322"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fentanyl transdermal system is indicated for the management of pain in opioid-tolerant patients, severe enough to require daily, around-the-clock, long- term opioid treatment and for which alternative treatment options are inadequate. Patients considered opioid-tolerant are those who are taking, for one week or longer, at least 60 mg of morphine daily, or at least 30 mg of oral oxycodone daily, or at least 8 mg of oral hydromorphone daily, or an equianalgesic dose of another opioid. Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations, reserve fentanyl transdermal system for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. uuid:23f2a212-ddee-46db-be8c-67dc92f945e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3286 biolink:treats MONDO:0006373 PMID:41385096 "[{""id"":""uuid:04ccc145-2f2c-48e4-8f7f-97d8ef67b95f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:45f93de6-aff3-43bc-ab1a-43b153c45cb2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cabergoline Tablets are indicated for the treatment of hyperprolactinemic disorders, either idiopathic or due to pituitary adenomas. uuid:3ca5b1af-5ba5-4fb2-927d-87c741bb8f78 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63611 biolink:treats MONDO:0001024 PMID:41385096 "[{""id"":""uuid:c7ad3a3e-0d96-45e3-b857-bc01add2bae4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fb6cb127-fd4d-42a8-add8-8566056b5d2d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Community Acquired Pneumonia Moxifloxacin Hydrochloride is indicated in adult patients for the treatment of Community Acquired Pneumonia caused by susceptible isolates of Streptococcus pneumoniae (including multi-drug resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Moraxella catarrhalis, methicillin-susceptible Staphylococcus aureus, Klebsiella pneumoniae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Clinical Studies (14.3)]. MDRSP isolates are isolates resistant to two or more of the following antibacterial drugs: penicillin (minimum inhibitory concentrations [MIC] ≥ 2 mcg/mL), 2nd generation cephalosporins (for example, cefuroxime), macrolides, tetracyclines, and trimethoprim/sulfamethoxazole. 1.2 Uncomplicated Skin and Skin Structure Infections Moxifloxacin Hydrochloride is indicated in adult patients for the treatment of Uncomplicated Skin and Skin Structure Infections caused by susceptible isolates of methicillin-susceptible Staphylococcus aureus or Streptococcus pyogenes [see Clinical Studies (14.4)]. 1.3 Complicated Skin and Skin Structure Infections Moxifloxacin Hydrochloride is indicated in adult patients for the treatment of Complicated Skin and Skin Structure Infections caused by susceptible isolates of methicillin-susceptible Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, or Enterobacter cloacae[see Clinical Studies (14.5)]. 1.4 Complicated Intra-Abdominal Infections Moxifloxacin Hydrochloride is indicated in adult patients for the treatment of Complicated Intra-Abdominal Infections (cIAI) including polymicrobial infections such as abscess caused by susceptible isolates of Escherichia coli, Bacteroides fragilis, Streptococcus anginosus, Streptococcus constellatus, Enterococcus faecalis, Proteus mirabilis, Clostridium perfringens, Bacteroides thetaiotaomicron, or Peptostreptococcus species [see Clinical Studies (14.6)]. 1.5 Plague Moxifloxacin Hydrochloride is indicated in adult patients for the treatment of plague, including pneumonic and septicemic plague, due to susceptible isolates of Yersinia pestis and prophylaxis of plague in adult patients. Efficacy studies of moxifloxacin could not be conducted in humans with plague for feasibility reasons. Therefore this indication is based on an efficacy study conducted in animals only [see Clinical Studies (14.7)]. 1.6 Acute Bacterial Sinusitis Moxifloxacin Hydrochloride is indicated in adult patients (18 years of age and older) for the treatment of acute bacterial sinusitis (ABS) caused by susceptible isolates of Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis [see Clinical Studies (14.1)]. Because fluoroquinolones, including Moxifloxacin Hydrochloride, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.13)] and for some patients ABS is self-limiting, reserve Moxifloxacin Hydrochloride for treatment of ABS in patients who have no alternative treatment options. 1.7 Acute Bacterial Exacerbation of Chronic Bronchitis Moxifloxacin Hydrochloride is indicated in adult patients for the treatment of Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB) caused by susceptible isolates of Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, methicillin-susceptible Staphylococcus aureus, or Moraxella catarrhalis [see Clinical Studies (14.2)]. Because fluoroquinolones, including Moxifloxacin Hydrochloride, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.13)] and for some patients ABECB is self-limiting, reserve Moxifloxacin Hydrochloride for treatment of ABECB in patients who have no alternative treatment options. 1.8 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of Moxifloxacin Hydrochloride and other antibacterial drugs, Moxifloxacin Hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:08afc984-96fb-454f-83b7-d933f1bc1e5d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63611 biolink:treats MONDO:0005956 PMID:41385096 "[{""id"":""uuid:23122ddf-fe34-4daa-82d9-7beb3c71abac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:34ef7f75-596e-4dab-affc-85ebbeb36065"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Community Acquired Pneumonia Moxifloxacin Hydrochloride is indicated in adult patients for the treatment of Community Acquired Pneumonia caused by susceptible isolates of Streptococcus pneumoniae (including multi-drug resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Moraxella catarrhalis, methicillin-susceptible Staphylococcus aureus, Klebsiella pneumoniae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Clinical Studies (14.3)]. MDRSP isolates are isolates resistant to two or more of the following antibacterial drugs: penicillin (minimum inhibitory concentrations [MIC] ≥ 2 mcg/mL), 2nd generation cephalosporins (for example, cefuroxime), macrolides, tetracyclines, and trimethoprim/sulfamethoxazole. 1.2 Uncomplicated Skin and Skin Structure Infections Moxifloxacin Hydrochloride is indicated in adult patients for the treatment of Uncomplicated Skin and Skin Structure Infections caused by susceptible isolates of methicillin-susceptible Staphylococcus aureus or Streptococcus pyogenes [see Clinical Studies (14.4)]. 1.3 Complicated Skin and Skin Structure Infections Moxifloxacin Hydrochloride is indicated in adult patients for the treatment of Complicated Skin and Skin Structure Infections caused by susceptible isolates of methicillin-susceptible Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae, or Enterobacter cloacae[see Clinical Studies (14.5)]. 1.4 Complicated Intra-Abdominal Infections Moxifloxacin Hydrochloride is indicated in adult patients for the treatment of Complicated Intra-Abdominal Infections (cIAI) including polymicrobial infections such as abscess caused by susceptible isolates of Escherichia coli, Bacteroides fragilis, Streptococcus anginosus, Streptococcus constellatus, Enterococcus faecalis, Proteus mirabilis, Clostridium perfringens, Bacteroides thetaiotaomicron, or Peptostreptococcus species [see Clinical Studies (14.6)]. 1.5 Plague Moxifloxacin Hydrochloride is indicated in adult patients for the treatment of plague, including pneumonic and septicemic plague, due to susceptible isolates of Yersinia pestis and prophylaxis of plague in adult patients. Efficacy studies of moxifloxacin could not be conducted in humans with plague for feasibility reasons. Therefore this indication is based on an efficacy study conducted in animals only [see Clinical Studies (14.7)]. 1.6 Acute Bacterial Sinusitis Moxifloxacin Hydrochloride is indicated in adult patients (18 years of age and older) for the treatment of acute bacterial sinusitis (ABS) caused by susceptible isolates of Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis [see Clinical Studies (14.1)]. Because fluoroquinolones, including Moxifloxacin Hydrochloride, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.13)] and for some patients ABS is self-limiting, reserve Moxifloxacin Hydrochloride for treatment of ABS in patients who have no alternative treatment options. 1.7 Acute Bacterial Exacerbation of Chronic Bronchitis Moxifloxacin Hydrochloride is indicated in adult patients for the treatment of Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB) caused by susceptible isolates of Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, methicillin-susceptible Staphylococcus aureus, or Moraxella catarrhalis [see Clinical Studies (14.2)]. Because fluoroquinolones, including Moxifloxacin Hydrochloride, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.13)] and for some patients ABECB is self-limiting, reserve Moxifloxacin Hydrochloride for treatment of ABECB in patients who have no alternative treatment options. 1.8 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of Moxifloxacin Hydrochloride and other antibacterial drugs, Moxifloxacin Hydrochloride should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:b1ffe92b-16b1-4f36-b0c7-d31b889ad6f2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77363 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:132fa5e2-31b9-4b29-b777-5701e4d0c3dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3a46496c-34c9-4867-a202-24350e6dc8fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hypertension Ramipril capsules USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Ramipril capsules USP may be used alone or in combination with thiazide diuretics. 1.3 Heart Failure Post-Myocardial Infarction Ramipril capsules USP are indicated in stable patients who have demonstrated clinical signs of congestive heart failure within the first few days after sustaining acute myocardial infarction. Administration of ramipril capsule USP to such patients has been shown to decrease the risk of death (principally cardiovascular death) and to decrease the risks of failure-related hospitalization and progression to severe/resistant heart failure [see CLINICAL STUDIES ( 14.3 )]. uuid:08925461-56b8-4003-90a3-e7c699d8bca0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71416 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:f3ca71e6-09b1-43b9-a4d7-1a821c9ea4f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ffde63a1-8758-4046-8806-8afb3a3d72ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Phenazopyridine HCl is indicated for the symptomatic relief of pain, burning, urgency, frequency, and other discomforts arising from irritation of the lower urinary tract mucosa caused by infection, trauma, surgery, endoscopic procedures, or the passage of sounds or catheters. The use of Phenazopyridine HCl for relief of symptoms should not delay definitive diagnosis and treatment of causative conditions. Because it provides only symptomatic relief, prompt appropriate treatment of the cause of pain must be instituted and Phenazopyridine HCl should be discontinued when symptoms are controlled. The analgesic action may reduce or eliminate the need for systemic analgesics or narcotics. It is, however, compatible with antibacterial therapy and can help to relieve pain and discomfort during the interval before antibacterial therapy controls the infection. Treatment of a urinary tract infection with Phenazopyridine HCl should not exceed 2 days because there is a lack of evidence that the combined administration of Phenazopyridine HCl and an antibacterial provides greater benefit than administration of the antibacterial alone after 2 days. (See DOSAGE AND ADMINISTRATION section). uuid:b8017c68-551d-49e5-b995-e49b61363dc1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:73005609 biolink:treats MONDO:0011122 PMID:41385096 "[{""id"":""uuid:9cb06c6c-c91b-4df3-ba12-7a5d38618d29"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:63535775-3630-4aaa-a901-b0b65530dc8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CONTRAVE is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of: 30 kg/m 2 or greater (obese) or 27 kg/m 2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia). Limitations of Use: The effect of CONTRAVE on cardiovascular morbidity and mortality has not been established. The safety and effectiveness of CONTRAVE in combination with other products intended for weight loss, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established. uuid:a42948a8-204f-4a00-9270-91c134c225c8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:73005609 biolink:treats EFO:0005935 PMID:41385096 "[{""id"":""uuid:beab6957-9adc-47c3-a697-332045ac28f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8a84d777-dcb0-43d7-85da-bc096fd0318c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CONTRAVE is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of: 30 kg/m 2 or greater (obese) or 27 kg/m 2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia). Limitations of Use: The effect of CONTRAVE on cardiovascular morbidity and mortality has not been established. The safety and effectiveness of CONTRAVE in combination with other products intended for weight loss, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established. uuid:6398c25d-45c3-48c9-87b9-cb7a7e48f4f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:73005609 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:5839efc2-45a1-42e4-a74c-94143144aa15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b7a90e1b-df19-4c1a-bbbf-f58368fd02dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CONTRAVE is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of: 30 kg/m 2 or greater (obese) or 27 kg/m 2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia). Limitations of Use: The effect of CONTRAVE on cardiovascular morbidity and mortality has not been established. The safety and effectiveness of CONTRAVE in combination with other products intended for weight loss, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established. uuid:df63c883-9667-4daa-9399-e7282ef21105 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:73005609 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:7e2b7ab5-04d3-4848-999a-a2ec3ae8bbec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a77c35f4-58a7-4b27-a226-f1e38a8a2263"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CONTRAVE is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of: 30 kg/m 2 or greater (obese) or 27 kg/m 2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia). Limitations of Use: The effect of CONTRAVE on cardiovascular morbidity and mortality has not been established. The safety and effectiveness of CONTRAVE in combination with other products intended for weight loss, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established. uuid:6043bc64-bf56-4fed-b184-aff5fd19eb3c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:73005609 biolink:treats HP:0003119 PMID:41385096 "[{""id"":""uuid:50fcd492-7247-492b-8b00-5b22ee0cc4a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b7c9dd07-9b73-4c18-82e3-ea340a274510"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CONTRAVE is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of: 30 kg/m 2 or greater (obese) or 27 kg/m 2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia). Limitations of Use: The effect of CONTRAVE on cardiovascular morbidity and mortality has not been established. The safety and effectiveness of CONTRAVE in combination with other products intended for weight loss, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established. uuid:bf8c3a45-dd9b-4e6c-956d-f71813cf11d0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10119 biolink:treats MONDO:0001866 PMID:41385096 "[{""id"":""uuid:290e4587-f612-457b-83b1-45a5cdce044f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c6e3333c-3c38-44cf-8ac9-0b836d9e5647"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ziprasidone hydrochloride capsules are indicated for the treatment of schizophrenia. When deciding among the alternative treatments available for the condition needing treatment, the prescriber should consider the finding of ziprasidone’ s greater capacity to prolong the QT/QTc interval compared to several other antipsychotic drugs [ see Warnings and Precautions (5.3) ]. Prolongation of the QTc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia, and sudden death. In many cases this would lead to the conclusion that other drugs should be tried first. Whether ziprasidone will cause torsade de pointes or increase the rate of sudden death is not yet known [ see Warnings and Precautions (5.3) ] Schizophrenia Ziprasidone hydrochloride capsules are indicated for the treatment of schizophrenia in adults [see Clinical Studies ( 14.1 )]. Bipolar I Disorder (Acute Mixed or Manic Episodes and Maintenance Treatment as an Adjunct to Lithium or Valproate) Ziprasidone hydrochloride capsules are indicated as monotherapy for the acute treatment of adults with manic or mixed episodes associated with bipolar I disorder [see Clinical Studies ( 14.2 )]. Ziprasidone hydrochloride capsules are indicated as an adjunct to lithium or valproate for the maintenance treatment of bipolar I disorder in adults [see Clinical Studies ( 14.2 )]. uuid:e1ca80d6-0652-4e57-ac75-1c97f4ed4396 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49713 biolink:treats MONDO:0024612 PMID:41385096 "[{""id"":""uuid:c01251be-b8ae-4275-b665-dc7d6429a101"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8e7af29d-7a62-4f38-af65-22874b19dfc7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lithium is a mood-stabilizing agent indicated for the treatment of manic episodes and as maintenance treatment for Bipolar I Disorder. uuid:1bc3f46f-c70e-4554-9684-d7f98f6acf76 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49713 biolink:treats MONDO:0001866 PMID:41385096 "[{""id"":""uuid:4aaa94ad-fc96-40ce-9023-cc407d8f0a67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7dcf22f9-e8da-44e2-9da0-9f2f2e6c0f9d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lithium is a mood-stabilizing agent indicated for the treatment of manic episodes and as maintenance treatment for Bipolar I Disorder. uuid:def69224-58c7-4d0e-ab73-781de52a2ce5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29007 biolink:treats UMLS:C0275665 PMID:41385096 "[{""id"":""uuid:0608cc56-4156-4dc4-9713-d9b466c747f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3d23f380-6c0b-4387-bc7e-5a41f6af6082"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:8854f0a4-2e26-4170-aac0-c75939493b6d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Before instituting treatment with Ceftriaxone for Injection, USP, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ceftriaxone for Injection, USP and other antibacterial drugs, Ceftriaxone for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ceftriaxone for Injection, USP is indicated for the treatment of the following infections when caused by susceptible organisms: LOWER RESPIRATORY TRACT INFECTIONS caused by Streptococcus pneumoniae, Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis or Serratia marcescens. ACUTE BACTERIAL OTITIS MEDIA caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta‑lactamase producing strains) or Moraxella catarrhalis (including beta-lactamase producing strains). NOTE: In one study lower clinical cure rates were observed with a single dose of Ceftriaxone for Injection, USP compared to 10 days of oral therapy. In a second study comparable cure rates were observed between single dose of Ceftriaxone for Injection, USP and the comparator. The potentially lower clinical cure rate of Ceftriaxone for Injection, USP should be balanced against the potential advantages of parenteral therapy (see CLINICAL STUDIES ). SKIN AND SKIN STRUCTURE INFECTIONS caused by Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes , Viridans group streptococci, Escherichia coli, Enterobacter cloacae, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Morganella morganii 1 , Pseudomonas aeruginosa, Serratia marcescens, Acinetobacter calcoaceticus, Bacteroides fragilis 1 or Peptostreptococcus species. URINARY TRACT INFECTIONS (complicated and uncomplicated) caused by Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii or Klebsiella pneumoniae. UNCOMPLICATED GONORRHEA (cervical/urethral and rectal) caused by Neisseria gonorrhoeae, including both penicillinase- and nonpenicillinase-producing strains, and pharyngeal gonorrhea caused by nonpenicillinase‑producing strains of Neisseria gonorrhoeae. PELVIC INFLAMMATORY DISEASE caused by Neisseria gonorrhoeae. Ceftriaxone for Injection, USP, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and Chlamydia trachomatis is one of the suspected pathogens, appropriate antichlamydial coverage should be added. BACTERIAL SEPTICEMIA caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae or Klebsiella pneumoniae. BONE AND JOINT INFECTIONS caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae or Enterobacter species. INTRA-ABDOMINAL INFECTIONS caused by Escherichia coli, Klebsiella pneumoniae, Bacteroides fragilis, Clostridium species (Note: most strains of Clostridium difficile are resistant) or Peptostreptococcus species. MENINGITIS caused by Haemophilus influenzae, Neisseria meningitidis or Streptococcus pneumoniae. Ceftriaxone for Injection, USP has also been used successfully in a limited number of cases of meningitis and shunt infection caused by Staphylococcus epidermidis 1 and Escherichia coli. 1 1 Efficacy for this organism in this organ system was studied in fewer than ten infections.|[PMDA] Addition of indications for gonococcus and gonococcal pharyngitis, gonococcal urethritis, gonococcal uterine cervicitis, gonococcal pelvic inflammatory diseases, gonococcal epididymitis, gonococcal proctitis, and to dosage regimen. uuid:3bee5c48-e746-46f5-9022-25ee9aa3e4cb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4450 biolink:treats MONDO:0010602 PMID:41385096 "[{""id"":""uuid:e1a9136c-15cc-46e2-974f-d44c00cf752c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8bbc44e0-9a1a-4e4b-8816-a966c9511ea6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hemophilia A: Desmopressin Acetate Injection 4 mcg/mL is indicated for patients with hemophilia A with factor VIII coagulant activity levels greater than 5%. Desmopressin acetate injection will often maintain hemostasis in patients with hemophilia A during surgical procedures and postoperatively when administered 30 minutes prior to scheduled procedure. Desmopressin acetate injection will also stop bleeding in hemophilia A patients with episodes of spontaneous or trauma-induced injuries such as hemarthroses, intramuscular hematomas or mucosal bleeding. Desmopressin acetate injection is not indicated for the treatment of hemophilia A with factor VIII coagulant activity levels equal to or less than 5%, or for the treatment of hemophilia B, or in patients who have factor VIII antibodies. In certain clinical situations, it may be justified to try desmopressin acetate injection in patients with factor VIII levels between 2% to 5%; however, these patients should be carefully monitored. von Willebrand’s Disease (Type I): Desmopressin acetate injection 4 mcg/mL is indicated for patients with mild to moderate classic von Willebrand’s disease (Type I) with factor VIII levels greater than 5%. Desmopressin acetate injection will often maintain hemostasis in patients with mild to moderate von Willebrand’s disease during surgical procedures and postoperatively when administered 30 minutes prior to the scheduled procedure. Desmopressin acetate injection will usually stop bleeding in mild to moderate von Willebrand’s patients with episodes of spontaneous or trauma-induced injuries such as hemarthroses, intramuscular hematomas or mucosal bleeding. Those von Willebrand’s disease patients who are least likely to respond are those with severe homozygous von Willebrand’s disease with factor VIII coagulant activity and factor VIII von Willebrand factor antigen levels less than 1%. Other patients may respond in a variable fashion depending on the type of molecular defect they have. Bleeding time and factor VIII coagulant activity, ristocetin cofactor activity, and von Willebrand factor antigen should be checked during administration of desmopressin acetate injection to ensure that adequate levels are being achieved. Desmopressin acetate injection is not indicated for the treatment of severe classic von Willebrand’s disease (Type I) and when there is evidence of an abnormal molecular form of factor VIII antigen. ( See WARNINGS . ) Diabetes Insipidus: Desmopressin acetate injection 4 mcg/mL is indicated as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. Desmopressin acetate injection is ineffective for the treatment of nephrogenic diabetes insipidus. Desmopressin acetate is also available as an intranasal preparation. However, this means of delivery can be compromised by a variety of factors that can make nasal insufflation ineffective or inappropriate. These include poor intranasal absorption, nasal congestion and blockage, nasal discharge, atrophy of nasal mucosa, and severe atrophic rhinitis. Intranasal delivery may be inappropriate where there is an impaired level of consciousness. In addition, cranial surgical procedures, such as transsphenoidal hypophysectomy, create situations where an alternative route of administration is needed as in cases of nasal packing or recovery from surgery. uuid:d74bd487-b3f5-46a8-a3a6-2c762a34ce1e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4450 biolink:treats MONDO:0024574 PMID:41385096 "[{""id"":""uuid:26193ed1-0995-481c-b824-fbefe5780181"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:887755a9-3c6c-46cc-8741-54c8585407ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hemophilia A: Desmopressin Acetate Injection 4 mcg/mL is indicated for patients with hemophilia A with factor VIII coagulant activity levels greater than 5%. Desmopressin acetate injection will often maintain hemostasis in patients with hemophilia A during surgical procedures and postoperatively when administered 30 minutes prior to scheduled procedure. Desmopressin acetate injection will also stop bleeding in hemophilia A patients with episodes of spontaneous or trauma-induced injuries such as hemarthroses, intramuscular hematomas or mucosal bleeding. Desmopressin acetate injection is not indicated for the treatment of hemophilia A with factor VIII coagulant activity levels equal to or less than 5%, or for the treatment of hemophilia B, or in patients who have factor VIII antibodies. In certain clinical situations, it may be justified to try desmopressin acetate injection in patients with factor VIII levels between 2% to 5%; however, these patients should be carefully monitored. von Willebrand’s Disease (Type I): Desmopressin acetate injection 4 mcg/mL is indicated for patients with mild to moderate classic von Willebrand’s disease (Type I) with factor VIII levels greater than 5%. Desmopressin acetate injection will often maintain hemostasis in patients with mild to moderate von Willebrand’s disease during surgical procedures and postoperatively when administered 30 minutes prior to the scheduled procedure. Desmopressin acetate injection will usually stop bleeding in mild to moderate von Willebrand’s patients with episodes of spontaneous or trauma-induced injuries such as hemarthroses, intramuscular hematomas or mucosal bleeding. Those von Willebrand’s disease patients who are least likely to respond are those with severe homozygous von Willebrand’s disease with factor VIII coagulant activity and factor VIII von Willebrand factor antigen levels less than 1%. Other patients may respond in a variable fashion depending on the type of molecular defect they have. Bleeding time and factor VIII coagulant activity, ristocetin cofactor activity, and von Willebrand factor antigen should be checked during administration of desmopressin acetate injection to ensure that adequate levels are being achieved. Desmopressin acetate injection is not indicated for the treatment of severe classic von Willebrand’s disease (Type I) and when there is evidence of an abnormal molecular form of factor VIII antigen. ( See WARNINGS . ) Diabetes Insipidus: Desmopressin acetate injection 4 mcg/mL is indicated as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. Desmopressin acetate injection is ineffective for the treatment of nephrogenic diabetes insipidus. Desmopressin acetate is also available as an intranasal preparation. However, this means of delivery can be compromised by a variety of factors that can make nasal insufflation ineffective or inappropriate. These include poor intranasal absorption, nasal congestion and blockage, nasal discharge, atrophy of nasal mucosa, and severe atrophic rhinitis. Intranasal delivery may be inappropriate where there is an impaired level of consciousness. In addition, cranial surgical procedures, such as transsphenoidal hypophysectomy, create situations where an alternative route of administration is needed as in cases of nasal packing or recovery from surgery. uuid:1ab3bf03-32b4-4d9c-a7ac-79972bdfb0bb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4450 biolink:treats MONDO:0004431 PMID:41385096 "[{""id"":""uuid:8bf8965c-4f35-4fc7-bd4d-3384a3a02975"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:03d4effe-346c-423c-b5f0-8d7908362473"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hemophilia A: Desmopressin Acetate Injection 4 mcg/mL is indicated for patients with hemophilia A with factor VIII coagulant activity levels greater than 5%. Desmopressin acetate injection will often maintain hemostasis in patients with hemophilia A during surgical procedures and postoperatively when administered 30 minutes prior to scheduled procedure. Desmopressin acetate injection will also stop bleeding in hemophilia A patients with episodes of spontaneous or trauma-induced injuries such as hemarthroses, intramuscular hematomas or mucosal bleeding. Desmopressin acetate injection is not indicated for the treatment of hemophilia A with factor VIII coagulant activity levels equal to or less than 5%, or for the treatment of hemophilia B, or in patients who have factor VIII antibodies. In certain clinical situations, it may be justified to try desmopressin acetate injection in patients with factor VIII levels between 2% to 5%; however, these patients should be carefully monitored. von Willebrand’s Disease (Type I): Desmopressin acetate injection 4 mcg/mL is indicated for patients with mild to moderate classic von Willebrand’s disease (Type I) with factor VIII levels greater than 5%. Desmopressin acetate injection will often maintain hemostasis in patients with mild to moderate von Willebrand’s disease during surgical procedures and postoperatively when administered 30 minutes prior to the scheduled procedure. Desmopressin acetate injection will usually stop bleeding in mild to moderate von Willebrand’s patients with episodes of spontaneous or trauma-induced injuries such as hemarthroses, intramuscular hematomas or mucosal bleeding. Those von Willebrand’s disease patients who are least likely to respond are those with severe homozygous von Willebrand’s disease with factor VIII coagulant activity and factor VIII von Willebrand factor antigen levels less than 1%. Other patients may respond in a variable fashion depending on the type of molecular defect they have. Bleeding time and factor VIII coagulant activity, ristocetin cofactor activity, and von Willebrand factor antigen should be checked during administration of desmopressin acetate injection to ensure that adequate levels are being achieved. Desmopressin acetate injection is not indicated for the treatment of severe classic von Willebrand’s disease (Type I) and when there is evidence of an abnormal molecular form of factor VIII antigen. ( See WARNINGS . ) Diabetes Insipidus: Desmopressin acetate injection 4 mcg/mL is indicated as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. Desmopressin acetate injection is ineffective for the treatment of nephrogenic diabetes insipidus. Desmopressin acetate is also available as an intranasal preparation. However, this means of delivery can be compromised by a variety of factors that can make nasal insufflation ineffective or inappropriate. These include poor intranasal absorption, nasal congestion and blockage, nasal discharge, atrophy of nasal mucosa, and severe atrophic rhinitis. Intranasal delivery may be inappropriate where there is an impaired level of consciousness. In addition, cranial surgical procedures, such as transsphenoidal hypophysectomy, create situations where an alternative route of administration is needed as in cases of nasal packing or recovery from surgery. uuid:f067fde6-15ab-4ec2-87a7-ba7a4ab7e528 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4450 biolink:treats HP:0012233 PMID:41385096 "[{""id"":""uuid:ce743041-cce4-4b5d-b889-9b12fb909853"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:38901ce3-00d2-4f1f-b8ba-a925078b9a4c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hemophilia A: Desmopressin Acetate Injection 4 mcg/mL is indicated for patients with hemophilia A with factor VIII coagulant activity levels greater than 5%. Desmopressin acetate injection will often maintain hemostasis in patients with hemophilia A during surgical procedures and postoperatively when administered 30 minutes prior to scheduled procedure. Desmopressin acetate injection will also stop bleeding in hemophilia A patients with episodes of spontaneous or trauma-induced injuries such as hemarthroses, intramuscular hematomas or mucosal bleeding. Desmopressin acetate injection is not indicated for the treatment of hemophilia A with factor VIII coagulant activity levels equal to or less than 5%, or for the treatment of hemophilia B, or in patients who have factor VIII antibodies. In certain clinical situations, it may be justified to try desmopressin acetate injection in patients with factor VIII levels between 2% to 5%; however, these patients should be carefully monitored. von Willebrand’s Disease (Type I): Desmopressin acetate injection 4 mcg/mL is indicated for patients with mild to moderate classic von Willebrand’s disease (Type I) with factor VIII levels greater than 5%. Desmopressin acetate injection will often maintain hemostasis in patients with mild to moderate von Willebrand’s disease during surgical procedures and postoperatively when administered 30 minutes prior to the scheduled procedure. Desmopressin acetate injection will usually stop bleeding in mild to moderate von Willebrand’s patients with episodes of spontaneous or trauma-induced injuries such as hemarthroses, intramuscular hematomas or mucosal bleeding. Those von Willebrand’s disease patients who are least likely to respond are those with severe homozygous von Willebrand’s disease with factor VIII coagulant activity and factor VIII von Willebrand factor antigen levels less than 1%. Other patients may respond in a variable fashion depending on the type of molecular defect they have. Bleeding time and factor VIII coagulant activity, ristocetin cofactor activity, and von Willebrand factor antigen should be checked during administration of desmopressin acetate injection to ensure that adequate levels are being achieved. Desmopressin acetate injection is not indicated for the treatment of severe classic von Willebrand’s disease (Type I) and when there is evidence of an abnormal molecular form of factor VIII antigen. ( See WARNINGS . ) Diabetes Insipidus: Desmopressin acetate injection 4 mcg/mL is indicated as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. Desmopressin acetate injection is ineffective for the treatment of nephrogenic diabetes insipidus. Desmopressin acetate is also available as an intranasal preparation. However, this means of delivery can be compromised by a variety of factors that can make nasal insufflation ineffective or inappropriate. These include poor intranasal absorption, nasal congestion and blockage, nasal discharge, atrophy of nasal mucosa, and severe atrophic rhinitis. Intranasal delivery may be inappropriate where there is an impaired level of consciousness. In addition, cranial surgical procedures, such as transsphenoidal hypophysectomy, create situations where an alternative route of administration is needed as in cases of nasal packing or recovery from surgery. uuid:c23c051e-8bc0-40b2-b108-570a546993f7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4450 biolink:treats UMLS:C2748540 PMID:41385096 "[{""id"":""uuid:6e737227-2bbd-4795-b6f2-d5a1c956d493"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9436d6b6-c497-406b-b32f-419a4cbb2c3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hemophilia A: Desmopressin Acetate Injection 4 mcg/mL is indicated for patients with hemophilia A with factor VIII coagulant activity levels greater than 5%. Desmopressin acetate injection will often maintain hemostasis in patients with hemophilia A during surgical procedures and postoperatively when administered 30 minutes prior to scheduled procedure. Desmopressin acetate injection will also stop bleeding in hemophilia A patients with episodes of spontaneous or trauma-induced injuries such as hemarthroses, intramuscular hematomas or mucosal bleeding. Desmopressin acetate injection is not indicated for the treatment of hemophilia A with factor VIII coagulant activity levels equal to or less than 5%, or for the treatment of hemophilia B, or in patients who have factor VIII antibodies. In certain clinical situations, it may be justified to try desmopressin acetate injection in patients with factor VIII levels between 2% to 5%; however, these patients should be carefully monitored. von Willebrand’s Disease (Type I): Desmopressin acetate injection 4 mcg/mL is indicated for patients with mild to moderate classic von Willebrand’s disease (Type I) with factor VIII levels greater than 5%. Desmopressin acetate injection will often maintain hemostasis in patients with mild to moderate von Willebrand’s disease during surgical procedures and postoperatively when administered 30 minutes prior to the scheduled procedure. Desmopressin acetate injection will usually stop bleeding in mild to moderate von Willebrand’s patients with episodes of spontaneous or trauma-induced injuries such as hemarthroses, intramuscular hematomas or mucosal bleeding. Those von Willebrand’s disease patients who are least likely to respond are those with severe homozygous von Willebrand’s disease with factor VIII coagulant activity and factor VIII von Willebrand factor antigen levels less than 1%. Other patients may respond in a variable fashion depending on the type of molecular defect they have. Bleeding time and factor VIII coagulant activity, ristocetin cofactor activity, and von Willebrand factor antigen should be checked during administration of desmopressin acetate injection to ensure that adequate levels are being achieved. Desmopressin acetate injection is not indicated for the treatment of severe classic von Willebrand’s disease (Type I) and when there is evidence of an abnormal molecular form of factor VIII antigen. ( See WARNINGS . ) Diabetes Insipidus: Desmopressin acetate injection 4 mcg/mL is indicated as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. Desmopressin acetate injection is ineffective for the treatment of nephrogenic diabetes insipidus. Desmopressin acetate is also available as an intranasal preparation. However, this means of delivery can be compromised by a variety of factors that can make nasal insufflation ineffective or inappropriate. These include poor intranasal absorption, nasal congestion and blockage, nasal discharge, atrophy of nasal mucosa, and severe atrophic rhinitis. Intranasal delivery may be inappropriate where there is an impaired level of consciousness. In addition, cranial surgical procedures, such as transsphenoidal hypophysectomy, create situations where an alternative route of administration is needed as in cases of nasal packing or recovery from surgery. uuid:38b3eab0-a21c-4946-82bc-3b8d4f0fd06f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4450 biolink:treats MONDO:0004782 PMID:41385096 "[{""id"":""uuid:68d0be44-9466-4e93-9e17-fe9dfc25e19f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:766a40ba-1cd6-4fda-9827-6e78ca248ab6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hemophilia A: Desmopressin Acetate Injection 4 mcg/mL is indicated for patients with hemophilia A with factor VIII coagulant activity levels greater than 5%. Desmopressin acetate injection will often maintain hemostasis in patients with hemophilia A during surgical procedures and postoperatively when administered 30 minutes prior to scheduled procedure. Desmopressin acetate injection will also stop bleeding in hemophilia A patients with episodes of spontaneous or trauma-induced injuries such as hemarthroses, intramuscular hematomas or mucosal bleeding. Desmopressin acetate injection is not indicated for the treatment of hemophilia A with factor VIII coagulant activity levels equal to or less than 5%, or for the treatment of hemophilia B, or in patients who have factor VIII antibodies. In certain clinical situations, it may be justified to try desmopressin acetate injection in patients with factor VIII levels between 2% to 5%; however, these patients should be carefully monitored. von Willebrand’s Disease (Type I): Desmopressin acetate injection 4 mcg/mL is indicated for patients with mild to moderate classic von Willebrand’s disease (Type I) with factor VIII levels greater than 5%. Desmopressin acetate injection will often maintain hemostasis in patients with mild to moderate von Willebrand’s disease during surgical procedures and postoperatively when administered 30 minutes prior to the scheduled procedure. Desmopressin acetate injection will usually stop bleeding in mild to moderate von Willebrand’s patients with episodes of spontaneous or trauma-induced injuries such as hemarthroses, intramuscular hematomas or mucosal bleeding. Those von Willebrand’s disease patients who are least likely to respond are those with severe homozygous von Willebrand’s disease with factor VIII coagulant activity and factor VIII von Willebrand factor antigen levels less than 1%. Other patients may respond in a variable fashion depending on the type of molecular defect they have. Bleeding time and factor VIII coagulant activity, ristocetin cofactor activity, and von Willebrand factor antigen should be checked during administration of desmopressin acetate injection to ensure that adequate levels are being achieved. Desmopressin acetate injection is not indicated for the treatment of severe classic von Willebrand’s disease (Type I) and when there is evidence of an abnormal molecular form of factor VIII antigen. ( See WARNINGS . ) Diabetes Insipidus: Desmopressin acetate injection 4 mcg/mL is indicated as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. Desmopressin acetate injection is ineffective for the treatment of nephrogenic diabetes insipidus. Desmopressin acetate is also available as an intranasal preparation. However, this means of delivery can be compromised by a variety of factors that can make nasal insufflation ineffective or inappropriate. These include poor intranasal absorption, nasal congestion and blockage, nasal discharge, atrophy of nasal mucosa, and severe atrophic rhinitis. Intranasal delivery may be inappropriate where there is an impaired level of consciousness. In addition, cranial surgical procedures, such as transsphenoidal hypophysectomy, create situations where an alternative route of administration is needed as in cases of nasal packing or recovery from surgery. uuid:cd51c012-3ee2-4f50-95a0-d7a0a7f016e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3746 biolink:treats UMLS:C1262234 PMID:41385096 "[{""id"":""uuid:65b449a7-a487-4e96-9c74-99fb12688c94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:78f6497e-d24a-492e-a520-e31a2b9d56cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin Injection, USP is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of antibiotic-associated pseudomembranous colitis, as described in the BOXED WARNING , before selecting clindamycin the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. Indicated surgical procedures should be performed in conjunction with antibiotic therapy. Clindamycin Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated organisms in the conditions listed below: Lower respiratory tract infections including pneumonia, empyema, and lung abscess caused by anaerobes, Streptococcus pneumoniae , other streptococci (except E. faecalis ), and Staphylococcus aureus . Skin and skin structure infections caused by Streptococcus pyogenes , Staphylococcus aureus , and anaerobes. Gynecological infections including endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection caused by susceptible anaerobes. Intra-abdominal infections including peritonitis and intra-abdominal abscess caused by susceptible anaerobic organisms. Septicemia caused by Staphylococcus aureus , streptococci (except Enterococcus faecalis ), and susceptible anaerobes. Bone and joint infections including acute hematogenous osteomyelitis caused by Staphylococcus aureus and as adjunctive therapy in the surgical treatment of chronic bone and joint infections due to susceptible organisms. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin and other antibacterial drugs, clindamycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:9299d546-8dd8-4e13-9e7e-1a1084dc8b82 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:204928 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:a9908cd1-e5fc-4cc4-b8cb-087ffb559dd6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:56d1974a-7bbf-48b6-bf56-1ed3156254c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment Cefotaxime for injection, USP is indicated for the treatment of patients with serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections , including pneumonia, caused by Streptococcus pneumoniae (formerly Diplococcus pneumoniae ), Streptococcus pyogenes * (Group A streptococci) and other streptococci (excluding enterococci, e.g., Enterococcus faecalis ), Staphylococcus aureus (penicillinase and non-penicillinase producing), Escherichia coli , Klebsiella species, Haemophilus influenzae (including ampicillin resistant strains), Haemophilus parainfluenzae , Proteus mirabilis , Serratia marcescens *, Enterobacter species, indole positive Proteus and Pseudomonas species (including P. aeruginosa ). (2) Genitourinary infections . Urinary tract infections caused by Enterococcus species, Staphylococcus epidermidis , Staphylococcus aureus *, (penicillinase and non-penicillinase producing), Citrobacter species, Enterobacter species, Escherichia coli , Klebsiella species, Proteus mirabilis , Proteus vulgaris *, Providencia stuartii , Morganella morganii *, Providencia rettgeri *, Serratia marcescens and Pseudomonas species (including P. aeruginosa ). Also, uncomplicated gonorrhea (cervical/urethral and rectal) caused by Neisseria gonorrhoeae , including penicillinase producing strains. (3) Gynecologic infections , including pelvic inflammatory disease, endometritis and pelvic cellulitis caused by Staphylococcus epidermidis , Streptococcus species, Enterococcus species, Enterobacter species*, Klebsiella species*, Escherichia coli , Proteus mirabilis , Bacteroides species (including Bacteroides fragilis *), Clostridium species, and anaerobic cocci (including Peptostreptococcus species and Peptococcus species) and Fusobacterium species (including F. nucleatum *). Cefotaxime for injection, USP, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (4) Bacteremia/Septicemia caused by Escherichia coli , Klebsiella species, and Serratia marcescens , Staphylococcus aureus and Streptococcus species (including S. pneumonia ). (5) Skin and skin structure infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing), Staphylococcus epidermidis , Streptococcus pyogenes (Group A streptococci) and other streptococci, Enterococcus species, Acinetobacter species*, Escherichia coli , Citrobacter species (including C. freundii *), Enterobacter species, Klebsiella species, Proteus mirabilis , Proteus vulgaris *, Morganella morganii , Providencia rettgeri *, Pseudomonas species, Serratia marcescens , Bacteroides species, and anaerobic cocci (including Peptostreptococcus * species and Peptococcus species). (6) Intra-abdominal infections including peritonitis caused by Streptococcus species*, Escherichia coli , Klebsiella species, Bacteroides species, and anaerobic cocci (including Peptostreptococcus * species and Peptococcus * species) Proteus mirabilis *, and Clostridium species*. (7) Bone and/or joint infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing strains), Streptococcus species (including S. pyogenes *), Pseudomonas species (including P. aeruginosa *), and Proteus mirabilis *. (8) Central nervous system infections , e.g., meningitis and ventriculitis, caused by Neisseria meningitidis , Haemophilus influenzae , Streptococcus pneumoniae , Klebsiella pneumoniae * and Escherichia coli *. (*) Efficacy for this organism, in this organ system, has been studied in fewer than 10 infections. Although many strains of enterococci (e.g., S. faecalis ) and Pseudomonas species are resistant to cefotaxime sodium in vitro , cefotaxime for injection, USP has been used successfully in treating patients with infections caused by susceptible organisms. Specimens for bacteriologic culture should be obtained prior to therapy in order to isolate and identify causative organisms and to determine their susceptibilities to cefotaxime for injection, USP. Therapy may be instituted before results of susceptibility studies are known; however, once these results become available, the antibiotic treatment should be adjusted accordingly. In certain cases of confirmed or suspected gram-positive or gram-negative sepsis or in patients with other serious infections in which the causative organism has not been identified, cefotaxime for injection, USP may be used concomitantly with an aminoglycoside. The dosage recommended in the labeling of both antibiotics may be given and depends on the severity of the infection and the patient's condition. Renal function should be carefully monitored, especially if higher dosages of the aminoglycosides are to be administered or if therapy is prolonged, because of the potential nephrotoxicity and ototoxicity of aminoglycoside antibiotics. It is possible that nephrotoxicity may be potentiated if cefotaxime for injection, USP is used concomitantly with an aminoglycoside. uuid:85c0bf0e-173d-4429-ae74-652f89be1417 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:204928 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:8f112951-b614-4915-9dc1-06091af8df73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8d9e4730-3a78-45ec-a3f7-dcd5c98e1952"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment Cefotaxime for injection, USP is indicated for the treatment of patients with serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections , including pneumonia, caused by Streptococcus pneumoniae (formerly Diplococcus pneumoniae ), Streptococcus pyogenes * (Group A streptococci) and other streptococci (excluding enterococci, e.g., Enterococcus faecalis ), Staphylococcus aureus (penicillinase and non-penicillinase producing), Escherichia coli , Klebsiella species, Haemophilus influenzae (including ampicillin resistant strains), Haemophilus parainfluenzae , Proteus mirabilis , Serratia marcescens *, Enterobacter species, indole positive Proteus and Pseudomonas species (including P. aeruginosa ). (2) Genitourinary infections . Urinary tract infections caused by Enterococcus species, Staphylococcus epidermidis , Staphylococcus aureus *, (penicillinase and non-penicillinase producing), Citrobacter species, Enterobacter species, Escherichia coli , Klebsiella species, Proteus mirabilis , Proteus vulgaris *, Providencia stuartii , Morganella morganii *, Providencia rettgeri *, Serratia marcescens and Pseudomonas species (including P. aeruginosa ). Also, uncomplicated gonorrhea (cervical/urethral and rectal) caused by Neisseria gonorrhoeae , including penicillinase producing strains. (3) Gynecologic infections , including pelvic inflammatory disease, endometritis and pelvic cellulitis caused by Staphylococcus epidermidis , Streptococcus species, Enterococcus species, Enterobacter species*, Klebsiella species*, Escherichia coli , Proteus mirabilis , Bacteroides species (including Bacteroides fragilis *), Clostridium species, and anaerobic cocci (including Peptostreptococcus species and Peptococcus species) and Fusobacterium species (including F. nucleatum *). Cefotaxime for injection, USP, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (4) Bacteremia/Septicemia caused by Escherichia coli , Klebsiella species, and Serratia marcescens , Staphylococcus aureus and Streptococcus species (including S. pneumonia ). (5) Skin and skin structure infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing), Staphylococcus epidermidis , Streptococcus pyogenes (Group A streptococci) and other streptococci, Enterococcus species, Acinetobacter species*, Escherichia coli , Citrobacter species (including C. freundii *), Enterobacter species, Klebsiella species, Proteus mirabilis , Proteus vulgaris *, Morganella morganii , Providencia rettgeri *, Pseudomonas species, Serratia marcescens , Bacteroides species, and anaerobic cocci (including Peptostreptococcus * species and Peptococcus species). (6) Intra-abdominal infections including peritonitis caused by Streptococcus species*, Escherichia coli , Klebsiella species, Bacteroides species, and anaerobic cocci (including Peptostreptococcus * species and Peptococcus * species) Proteus mirabilis *, and Clostridium species*. (7) Bone and/or joint infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing strains), Streptococcus species (including S. pyogenes *), Pseudomonas species (including P. aeruginosa *), and Proteus mirabilis *. (8) Central nervous system infections , e.g., meningitis and ventriculitis, caused by Neisseria meningitidis , Haemophilus influenzae , Streptococcus pneumoniae , Klebsiella pneumoniae * and Escherichia coli *. (*) Efficacy for this organism, in this organ system, has been studied in fewer than 10 infections. Although many strains of enterococci (e.g., S. faecalis ) and Pseudomonas species are resistant to cefotaxime sodium in vitro , cefotaxime for injection, USP has been used successfully in treating patients with infections caused by susceptible organisms. Specimens for bacteriologic culture should be obtained prior to therapy in order to isolate and identify causative organisms and to determine their susceptibilities to cefotaxime for injection, USP. Therapy may be instituted before results of susceptibility studies are known; however, once these results become available, the antibiotic treatment should be adjusted accordingly. In certain cases of confirmed or suspected gram-positive or gram-negative sepsis or in patients with other serious infections in which the causative organism has not been identified, cefotaxime for injection, USP may be used concomitantly with an aminoglycoside. The dosage recommended in the labeling of both antibiotics may be given and depends on the severity of the infection and the patient's condition. Renal function should be carefully monitored, especially if higher dosages of the aminoglycosides are to be administered or if therapy is prolonged, because of the potential nephrotoxicity and ototoxicity of aminoglycoside antibiotics. It is possible that nephrotoxicity may be potentiated if cefotaxime for injection, USP is used concomitantly with an aminoglycoside. uuid:2ef130f1-fe04-4218-9233-49840870e895 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:204928 biolink:treats MONDO:0004277 PMID:41385096 "[{""id"":""uuid:0b516ffe-1e61-48bd-b217-414a15a65eca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8268aeb1-a203-44c8-80f6-5eeeb582ef14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment Cefotaxime for injection, USP is indicated for the treatment of patients with serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections , including pneumonia, caused by Streptococcus pneumoniae (formerly Diplococcus pneumoniae ), Streptococcus pyogenes * (Group A streptococci) and other streptococci (excluding enterococci, e.g., Enterococcus faecalis ), Staphylococcus aureus (penicillinase and non-penicillinase producing), Escherichia coli , Klebsiella species, Haemophilus influenzae (including ampicillin resistant strains), Haemophilus parainfluenzae , Proteus mirabilis , Serratia marcescens *, Enterobacter species, indole positive Proteus and Pseudomonas species (including P. aeruginosa ). (2) Genitourinary infections . Urinary tract infections caused by Enterococcus species, Staphylococcus epidermidis , Staphylococcus aureus *, (penicillinase and non-penicillinase producing), Citrobacter species, Enterobacter species, Escherichia coli , Klebsiella species, Proteus mirabilis , Proteus vulgaris *, Providencia stuartii , Morganella morganii *, Providencia rettgeri *, Serratia marcescens and Pseudomonas species (including P. aeruginosa ). Also, uncomplicated gonorrhea (cervical/urethral and rectal) caused by Neisseria gonorrhoeae , including penicillinase producing strains. (3) Gynecologic infections , including pelvic inflammatory disease, endometritis and pelvic cellulitis caused by Staphylococcus epidermidis , Streptococcus species, Enterococcus species, Enterobacter species*, Klebsiella species*, Escherichia coli , Proteus mirabilis , Bacteroides species (including Bacteroides fragilis *), Clostridium species, and anaerobic cocci (including Peptostreptococcus species and Peptococcus species) and Fusobacterium species (including F. nucleatum *). Cefotaxime for injection, USP, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (4) Bacteremia/Septicemia caused by Escherichia coli , Klebsiella species, and Serratia marcescens , Staphylococcus aureus and Streptococcus species (including S. pneumonia ). (5) Skin and skin structure infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing), Staphylococcus epidermidis , Streptococcus pyogenes (Group A streptococci) and other streptococci, Enterococcus species, Acinetobacter species*, Escherichia coli , Citrobacter species (including C. freundii *), Enterobacter species, Klebsiella species, Proteus mirabilis , Proteus vulgaris *, Morganella morganii , Providencia rettgeri *, Pseudomonas species, Serratia marcescens , Bacteroides species, and anaerobic cocci (including Peptostreptococcus * species and Peptococcus species). (6) Intra-abdominal infections including peritonitis caused by Streptococcus species*, Escherichia coli , Klebsiella species, Bacteroides species, and anaerobic cocci (including Peptostreptococcus * species and Peptococcus * species) Proteus mirabilis *, and Clostridium species*. (7) Bone and/or joint infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing strains), Streptococcus species (including S. pyogenes *), Pseudomonas species (including P. aeruginosa *), and Proteus mirabilis *. (8) Central nervous system infections , e.g., meningitis and ventriculitis, caused by Neisseria meningitidis , Haemophilus influenzae , Streptococcus pneumoniae , Klebsiella pneumoniae * and Escherichia coli *. (*) Efficacy for this organism, in this organ system, has been studied in fewer than 10 infections. Although many strains of enterococci (e.g., S. faecalis ) and Pseudomonas species are resistant to cefotaxime sodium in vitro , cefotaxime for injection, USP has been used successfully in treating patients with infections caused by susceptible organisms. Specimens for bacteriologic culture should be obtained prior to therapy in order to isolate and identify causative organisms and to determine their susceptibilities to cefotaxime for injection, USP. Therapy may be instituted before results of susceptibility studies are known; however, once these results become available, the antibiotic treatment should be adjusted accordingly. In certain cases of confirmed or suspected gram-positive or gram-negative sepsis or in patients with other serious infections in which the causative organism has not been identified, cefotaxime for injection, USP may be used concomitantly with an aminoglycoside. The dosage recommended in the labeling of both antibiotics may be given and depends on the severity of the infection and the patient's condition. Renal function should be carefully monitored, especially if higher dosages of the aminoglycosides are to be administered or if therapy is prolonged, because of the potential nephrotoxicity and ototoxicity of aminoglycoside antibiotics. It is possible that nephrotoxicity may be potentiated if cefotaxime for injection, USP is used concomitantly with an aminoglycoside. uuid:3570cc34-4e74-4ba2-beb2-c638592cdce4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:204928 biolink:treats MONDO:0000922 PMID:41385096 "[{""id"":""uuid:2b576d4a-7dbc-4583-8f2f-dfba160c34d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:52dcbc54-c78b-404e-9eea-5f6b5e7831ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment Cefotaxime for injection, USP is indicated for the treatment of patients with serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections , including pneumonia, caused by Streptococcus pneumoniae (formerly Diplococcus pneumoniae ), Streptococcus pyogenes * (Group A streptococci) and other streptococci (excluding enterococci, e.g., Enterococcus faecalis ), Staphylococcus aureus (penicillinase and non-penicillinase producing), Escherichia coli , Klebsiella species, Haemophilus influenzae (including ampicillin resistant strains), Haemophilus parainfluenzae , Proteus mirabilis , Serratia marcescens *, Enterobacter species, indole positive Proteus and Pseudomonas species (including P. aeruginosa ). (2) Genitourinary infections . Urinary tract infections caused by Enterococcus species, Staphylococcus epidermidis , Staphylococcus aureus *, (penicillinase and non-penicillinase producing), Citrobacter species, Enterobacter species, Escherichia coli , Klebsiella species, Proteus mirabilis , Proteus vulgaris *, Providencia stuartii , Morganella morganii *, Providencia rettgeri *, Serratia marcescens and Pseudomonas species (including P. aeruginosa ). Also, uncomplicated gonorrhea (cervical/urethral and rectal) caused by Neisseria gonorrhoeae , including penicillinase producing strains. (3) Gynecologic infections , including pelvic inflammatory disease, endometritis and pelvic cellulitis caused by Staphylococcus epidermidis , Streptococcus species, Enterococcus species, Enterobacter species*, Klebsiella species*, Escherichia coli , Proteus mirabilis , Bacteroides species (including Bacteroides fragilis *), Clostridium species, and anaerobic cocci (including Peptostreptococcus species and Peptococcus species) and Fusobacterium species (including F. nucleatum *). Cefotaxime for injection, USP, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (4) Bacteremia/Septicemia caused by Escherichia coli , Klebsiella species, and Serratia marcescens , Staphylococcus aureus and Streptococcus species (including S. pneumonia ). (5) Skin and skin structure infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing), Staphylococcus epidermidis , Streptococcus pyogenes (Group A streptococci) and other streptococci, Enterococcus species, Acinetobacter species*, Escherichia coli , Citrobacter species (including C. freundii *), Enterobacter species, Klebsiella species, Proteus mirabilis , Proteus vulgaris *, Morganella morganii , Providencia rettgeri *, Pseudomonas species, Serratia marcescens , Bacteroides species, and anaerobic cocci (including Peptostreptococcus * species and Peptococcus species). (6) Intra-abdominal infections including peritonitis caused by Streptococcus species*, Escherichia coli , Klebsiella species, Bacteroides species, and anaerobic cocci (including Peptostreptococcus * species and Peptococcus * species) Proteus mirabilis *, and Clostridium species*. (7) Bone and/or joint infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing strains), Streptococcus species (including S. pyogenes *), Pseudomonas species (including P. aeruginosa *), and Proteus mirabilis *. (8) Central nervous system infections , e.g., meningitis and ventriculitis, caused by Neisseria meningitidis , Haemophilus influenzae , Streptococcus pneumoniae , Klebsiella pneumoniae * and Escherichia coli *. (*) Efficacy for this organism, in this organ system, has been studied in fewer than 10 infections. Although many strains of enterococci (e.g., S. faecalis ) and Pseudomonas species are resistant to cefotaxime sodium in vitro , cefotaxime for injection, USP has been used successfully in treating patients with infections caused by susceptible organisms. Specimens for bacteriologic culture should be obtained prior to therapy in order to isolate and identify causative organisms and to determine their susceptibilities to cefotaxime for injection, USP. Therapy may be instituted before results of susceptibility studies are known; however, once these results become available, the antibiotic treatment should be adjusted accordingly. In certain cases of confirmed or suspected gram-positive or gram-negative sepsis or in patients with other serious infections in which the causative organism has not been identified, cefotaxime for injection, USP may be used concomitantly with an aminoglycoside. The dosage recommended in the labeling of both antibiotics may be given and depends on the severity of the infection and the patient's condition. Renal function should be carefully monitored, especially if higher dosages of the aminoglycosides are to be administered or if therapy is prolonged, because of the potential nephrotoxicity and ototoxicity of aminoglycoside antibiotics. It is possible that nephrotoxicity may be potentiated if cefotaxime for injection, USP is used concomitantly with an aminoglycoside. uuid:38c37ef5-4d86-4db3-afab-7bc5c1c7c9d8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:204928 biolink:treats MONDO:0000918 PMID:41385096 "[{""id"":""uuid:6b11958d-1d21-4683-94f0-1856715c9327"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:026a4c4e-e5f9-49b3-9a6c-435a4220a0cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment Cefotaxime for injection, USP is indicated for the treatment of patients with serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections , including pneumonia, caused by Streptococcus pneumoniae (formerly Diplococcus pneumoniae ), Streptococcus pyogenes * (Group A streptococci) and other streptococci (excluding enterococci, e.g., Enterococcus faecalis ), Staphylococcus aureus (penicillinase and non-penicillinase producing), Escherichia coli , Klebsiella species, Haemophilus influenzae (including ampicillin resistant strains), Haemophilus parainfluenzae , Proteus mirabilis , Serratia marcescens *, Enterobacter species, indole positive Proteus and Pseudomonas species (including P. aeruginosa ). (2) Genitourinary infections . Urinary tract infections caused by Enterococcus species, Staphylococcus epidermidis , Staphylococcus aureus *, (penicillinase and non-penicillinase producing), Citrobacter species, Enterobacter species, Escherichia coli , Klebsiella species, Proteus mirabilis , Proteus vulgaris *, Providencia stuartii , Morganella morganii *, Providencia rettgeri *, Serratia marcescens and Pseudomonas species (including P. aeruginosa ). Also, uncomplicated gonorrhea (cervical/urethral and rectal) caused by Neisseria gonorrhoeae , including penicillinase producing strains. (3) Gynecologic infections , including pelvic inflammatory disease, endometritis and pelvic cellulitis caused by Staphylococcus epidermidis , Streptococcus species, Enterococcus species, Enterobacter species*, Klebsiella species*, Escherichia coli , Proteus mirabilis , Bacteroides species (including Bacteroides fragilis *), Clostridium species, and anaerobic cocci (including Peptostreptococcus species and Peptococcus species) and Fusobacterium species (including F. nucleatum *). Cefotaxime for injection, USP, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (4) Bacteremia/Septicemia caused by Escherichia coli , Klebsiella species, and Serratia marcescens , Staphylococcus aureus and Streptococcus species (including S. pneumonia ). (5) Skin and skin structure infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing), Staphylococcus epidermidis , Streptococcus pyogenes (Group A streptococci) and other streptococci, Enterococcus species, Acinetobacter species*, Escherichia coli , Citrobacter species (including C. freundii *), Enterobacter species, Klebsiella species, Proteus mirabilis , Proteus vulgaris *, Morganella morganii , Providencia rettgeri *, Pseudomonas species, Serratia marcescens , Bacteroides species, and anaerobic cocci (including Peptostreptococcus * species and Peptococcus species). (6) Intra-abdominal infections including peritonitis caused by Streptococcus species*, Escherichia coli , Klebsiella species, Bacteroides species, and anaerobic cocci (including Peptostreptococcus * species and Peptococcus * species) Proteus mirabilis *, and Clostridium species*. (7) Bone and/or joint infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing strains), Streptococcus species (including S. pyogenes *), Pseudomonas species (including P. aeruginosa *), and Proteus mirabilis *. (8) Central nervous system infections , e.g., meningitis and ventriculitis, caused by Neisseria meningitidis , Haemophilus influenzae , Streptococcus pneumoniae , Klebsiella pneumoniae * and Escherichia coli *. (*) Efficacy for this organism, in this organ system, has been studied in fewer than 10 infections. Although many strains of enterococci (e.g., S. faecalis ) and Pseudomonas species are resistant to cefotaxime sodium in vitro , cefotaxime for injection, USP has been used successfully in treating patients with infections caused by susceptible organisms. Specimens for bacteriologic culture should be obtained prior to therapy in order to isolate and identify causative organisms and to determine their susceptibilities to cefotaxime for injection, USP. Therapy may be instituted before results of susceptibility studies are known; however, once these results become available, the antibiotic treatment should be adjusted accordingly. In certain cases of confirmed or suspected gram-positive or gram-negative sepsis or in patients with other serious infections in which the causative organism has not been identified, cefotaxime for injection, USP may be used concomitantly with an aminoglycoside. The dosage recommended in the labeling of both antibiotics may be given and depends on the severity of the infection and the patient's condition. Renal function should be carefully monitored, especially if higher dosages of the aminoglycosides are to be administered or if therapy is prolonged, because of the potential nephrotoxicity and ototoxicity of aminoglycoside antibiotics. It is possible that nephrotoxicity may be potentiated if cefotaxime for injection, USP is used concomitantly with an aminoglycoside. uuid:6d1fb8a3-f250-4399-b60c-23d6392aa3fa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:204928 biolink:treats MONDO:0006887 PMID:41385096 "[{""id"":""uuid:8e929485-147c-4670-bd67-c7556045cd4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:475586a7-aa19-4b83-9a83-fe34bea17f98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment Cefotaxime for injection, USP is indicated for the treatment of patients with serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections , including pneumonia, caused by Streptococcus pneumoniae (formerly Diplococcus pneumoniae ), Streptococcus pyogenes * (Group A streptococci) and other streptococci (excluding enterococci, e.g., Enterococcus faecalis ), Staphylococcus aureus (penicillinase and non-penicillinase producing), Escherichia coli , Klebsiella species, Haemophilus influenzae (including ampicillin resistant strains), Haemophilus parainfluenzae , Proteus mirabilis , Serratia marcescens *, Enterobacter species, indole positive Proteus and Pseudomonas species (including P. aeruginosa ). (2) Genitourinary infections . Urinary tract infections caused by Enterococcus species, Staphylococcus epidermidis , Staphylococcus aureus *, (penicillinase and non-penicillinase producing), Citrobacter species, Enterobacter species, Escherichia coli , Klebsiella species, Proteus mirabilis , Proteus vulgaris *, Providencia stuartii , Morganella morganii *, Providencia rettgeri *, Serratia marcescens and Pseudomonas species (including P. aeruginosa ). Also, uncomplicated gonorrhea (cervical/urethral and rectal) caused by Neisseria gonorrhoeae , including penicillinase producing strains. (3) Gynecologic infections , including pelvic inflammatory disease, endometritis and pelvic cellulitis caused by Staphylococcus epidermidis , Streptococcus species, Enterococcus species, Enterobacter species*, Klebsiella species*, Escherichia coli , Proteus mirabilis , Bacteroides species (including Bacteroides fragilis *), Clostridium species, and anaerobic cocci (including Peptostreptococcus species and Peptococcus species) and Fusobacterium species (including F. nucleatum *). Cefotaxime for injection, USP, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (4) Bacteremia/Septicemia caused by Escherichia coli , Klebsiella species, and Serratia marcescens , Staphylococcus aureus and Streptococcus species (including S. pneumonia ). (5) Skin and skin structure infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing), Staphylococcus epidermidis , Streptococcus pyogenes (Group A streptococci) and other streptococci, Enterococcus species, Acinetobacter species*, Escherichia coli , Citrobacter species (including C. freundii *), Enterobacter species, Klebsiella species, Proteus mirabilis , Proteus vulgaris *, Morganella morganii , Providencia rettgeri *, Pseudomonas species, Serratia marcescens , Bacteroides species, and anaerobic cocci (including Peptostreptococcus * species and Peptococcus species). (6) Intra-abdominal infections including peritonitis caused by Streptococcus species*, Escherichia coli , Klebsiella species, Bacteroides species, and anaerobic cocci (including Peptostreptococcus * species and Peptococcus * species) Proteus mirabilis *, and Clostridium species*. (7) Bone and/or joint infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing strains), Streptococcus species (including S. pyogenes *), Pseudomonas species (including P. aeruginosa *), and Proteus mirabilis *. (8) Central nervous system infections , e.g., meningitis and ventriculitis, caused by Neisseria meningitidis , Haemophilus influenzae , Streptococcus pneumoniae , Klebsiella pneumoniae * and Escherichia coli *. (*) Efficacy for this organism, in this organ system, has been studied in fewer than 10 infections. Although many strains of enterococci (e.g., S. faecalis ) and Pseudomonas species are resistant to cefotaxime sodium in vitro , cefotaxime for injection, USP has been used successfully in treating patients with infections caused by susceptible organisms. Specimens for bacteriologic culture should be obtained prior to therapy in order to isolate and identify causative organisms and to determine their susceptibilities to cefotaxime for injection, USP. Therapy may be instituted before results of susceptibility studies are known; however, once these results become available, the antibiotic treatment should be adjusted accordingly. In certain cases of confirmed or suspected gram-positive or gram-negative sepsis or in patients with other serious infections in which the causative organism has not been identified, cefotaxime for injection, USP may be used concomitantly with an aminoglycoside. The dosage recommended in the labeling of both antibiotics may be given and depends on the severity of the infection and the patient's condition. Renal function should be carefully monitored, especially if higher dosages of the aminoglycosides are to be administered or if therapy is prolonged, because of the potential nephrotoxicity and ototoxicity of aminoglycoside antibiotics. It is possible that nephrotoxicity may be potentiated if cefotaxime for injection, USP is used concomitantly with an aminoglycoside. uuid:5b11421a-81e1-4340-8b30-1cf2e329839e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:204928 biolink:treats MONDO:0005229 PMID:41385096 "[{""id"":""uuid:95236261-f2ce-48c2-9269-237a0f70b409"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a9f6069d-0990-41d6-a675-cd32bde6fdb8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment Cefotaxime for injection, USP is indicated for the treatment of patients with serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections , including pneumonia, caused by Streptococcus pneumoniae (formerly Diplococcus pneumoniae ), Streptococcus pyogenes * (Group A streptococci) and other streptococci (excluding enterococci, e.g., Enterococcus faecalis ), Staphylococcus aureus (penicillinase and non-penicillinase producing), Escherichia coli , Klebsiella species, Haemophilus influenzae (including ampicillin resistant strains), Haemophilus parainfluenzae , Proteus mirabilis , Serratia marcescens *, Enterobacter species, indole positive Proteus and Pseudomonas species (including P. aeruginosa ). (2) Genitourinary infections . Urinary tract infections caused by Enterococcus species, Staphylococcus epidermidis , Staphylococcus aureus *, (penicillinase and non-penicillinase producing), Citrobacter species, Enterobacter species, Escherichia coli , Klebsiella species, Proteus mirabilis , Proteus vulgaris *, Providencia stuartii , Morganella morganii *, Providencia rettgeri *, Serratia marcescens and Pseudomonas species (including P. aeruginosa ). Also, uncomplicated gonorrhea (cervical/urethral and rectal) caused by Neisseria gonorrhoeae , including penicillinase producing strains. (3) Gynecologic infections , including pelvic inflammatory disease, endometritis and pelvic cellulitis caused by Staphylococcus epidermidis , Streptococcus species, Enterococcus species, Enterobacter species*, Klebsiella species*, Escherichia coli , Proteus mirabilis , Bacteroides species (including Bacteroides fragilis *), Clostridium species, and anaerobic cocci (including Peptostreptococcus species and Peptococcus species) and Fusobacterium species (including F. nucleatum *). Cefotaxime for injection, USP, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (4) Bacteremia/Septicemia caused by Escherichia coli , Klebsiella species, and Serratia marcescens , Staphylococcus aureus and Streptococcus species (including S. pneumonia ). (5) Skin and skin structure infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing), Staphylococcus epidermidis , Streptococcus pyogenes (Group A streptococci) and other streptococci, Enterococcus species, Acinetobacter species*, Escherichia coli , Citrobacter species (including C. freundii *), Enterobacter species, Klebsiella species, Proteus mirabilis , Proteus vulgaris *, Morganella morganii , Providencia rettgeri *, Pseudomonas species, Serratia marcescens , Bacteroides species, and anaerobic cocci (including Peptostreptococcus * species and Peptococcus species). (6) Intra-abdominal infections including peritonitis caused by Streptococcus species*, Escherichia coli , Klebsiella species, Bacteroides species, and anaerobic cocci (including Peptostreptococcus * species and Peptococcus * species) Proteus mirabilis *, and Clostridium species*. (7) Bone and/or joint infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing strains), Streptococcus species (including S. pyogenes *), Pseudomonas species (including P. aeruginosa *), and Proteus mirabilis *. (8) Central nervous system infections , e.g., meningitis and ventriculitis, caused by Neisseria meningitidis , Haemophilus influenzae , Streptococcus pneumoniae , Klebsiella pneumoniae * and Escherichia coli *. (*) Efficacy for this organism, in this organ system, has been studied in fewer than 10 infections. Although many strains of enterococci (e.g., S. faecalis ) and Pseudomonas species are resistant to cefotaxime sodium in vitro , cefotaxime for injection, USP has been used successfully in treating patients with infections caused by susceptible organisms. Specimens for bacteriologic culture should be obtained prior to therapy in order to isolate and identify causative organisms and to determine their susceptibilities to cefotaxime for injection, USP. Therapy may be instituted before results of susceptibility studies are known; however, once these results become available, the antibiotic treatment should be adjusted accordingly. In certain cases of confirmed or suspected gram-positive or gram-negative sepsis or in patients with other serious infections in which the causative organism has not been identified, cefotaxime for injection, USP may be used concomitantly with an aminoglycoside. The dosage recommended in the labeling of both antibiotics may be given and depends on the severity of the infection and the patient's condition. Renal function should be carefully monitored, especially if higher dosages of the aminoglycosides are to be administered or if therapy is prolonged, because of the potential nephrotoxicity and ototoxicity of aminoglycoside antibiotics. It is possible that nephrotoxicity may be potentiated if cefotaxime for injection, USP is used concomitantly with an aminoglycoside. uuid:798f73c1-a4a0-45e9-b06d-3e151d804ebc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:204928 biolink:treats MONDO:0700217 PMID:41385096 "[{""id"":""uuid:73960210-ac1c-4d33-8238-3c7cb7ad292c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ec0c7eb5-6df1-4f6f-845d-1f65c588dda5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment Cefotaxime for injection, USP is indicated for the treatment of patients with serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections , including pneumonia, caused by Streptococcus pneumoniae (formerly Diplococcus pneumoniae ), Streptococcus pyogenes * (Group A streptococci) and other streptococci (excluding enterococci, e.g., Enterococcus faecalis ), Staphylococcus aureus (penicillinase and non-penicillinase producing), Escherichia coli , Klebsiella species, Haemophilus influenzae (including ampicillin resistant strains), Haemophilus parainfluenzae , Proteus mirabilis , Serratia marcescens *, Enterobacter species, indole positive Proteus and Pseudomonas species (including P. aeruginosa ). (2) Genitourinary infections . Urinary tract infections caused by Enterococcus species, Staphylococcus epidermidis , Staphylococcus aureus *, (penicillinase and non-penicillinase producing), Citrobacter species, Enterobacter species, Escherichia coli , Klebsiella species, Proteus mirabilis , Proteus vulgaris *, Providencia stuartii , Morganella morganii *, Providencia rettgeri *, Serratia marcescens and Pseudomonas species (including P. aeruginosa ). Also, uncomplicated gonorrhea (cervical/urethral and rectal) caused by Neisseria gonorrhoeae , including penicillinase producing strains. (3) Gynecologic infections , including pelvic inflammatory disease, endometritis and pelvic cellulitis caused by Staphylococcus epidermidis , Streptococcus species, Enterococcus species, Enterobacter species*, Klebsiella species*, Escherichia coli , Proteus mirabilis , Bacteroides species (including Bacteroides fragilis *), Clostridium species, and anaerobic cocci (including Peptostreptococcus species and Peptococcus species) and Fusobacterium species (including F. nucleatum *). Cefotaxime for injection, USP, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (4) Bacteremia/Septicemia caused by Escherichia coli , Klebsiella species, and Serratia marcescens , Staphylococcus aureus and Streptococcus species (including S. pneumonia ). (5) Skin and skin structure infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing), Staphylococcus epidermidis , Streptococcus pyogenes (Group A streptococci) and other streptococci, Enterococcus species, Acinetobacter species*, Escherichia coli , Citrobacter species (including C. freundii *), Enterobacter species, Klebsiella species, Proteus mirabilis , Proteus vulgaris *, Morganella morganii , Providencia rettgeri *, Pseudomonas species, Serratia marcescens , Bacteroides species, and anaerobic cocci (including Peptostreptococcus * species and Peptococcus species). (6) Intra-abdominal infections including peritonitis caused by Streptococcus species*, Escherichia coli , Klebsiella species, Bacteroides species, and anaerobic cocci (including Peptostreptococcus * species and Peptococcus * species) Proteus mirabilis *, and Clostridium species*. (7) Bone and/or joint infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing strains), Streptococcus species (including S. pyogenes *), Pseudomonas species (including P. aeruginosa *), and Proteus mirabilis *. (8) Central nervous system infections , e.g., meningitis and ventriculitis, caused by Neisseria meningitidis , Haemophilus influenzae , Streptococcus pneumoniae , Klebsiella pneumoniae * and Escherichia coli *. (*) Efficacy for this organism, in this organ system, has been studied in fewer than 10 infections. Although many strains of enterococci (e.g., S. faecalis ) and Pseudomonas species are resistant to cefotaxime sodium in vitro , cefotaxime for injection, USP has been used successfully in treating patients with infections caused by susceptible organisms. Specimens for bacteriologic culture should be obtained prior to therapy in order to isolate and identify causative organisms and to determine their susceptibilities to cefotaxime for injection, USP. Therapy may be instituted before results of susceptibility studies are known; however, once these results become available, the antibiotic treatment should be adjusted accordingly. In certain cases of confirmed or suspected gram-positive or gram-negative sepsis or in patients with other serious infections in which the causative organism has not been identified, cefotaxime for injection, USP may be used concomitantly with an aminoglycoside. The dosage recommended in the labeling of both antibiotics may be given and depends on the severity of the infection and the patient's condition. Renal function should be carefully monitored, especially if higher dosages of the aminoglycosides are to be administered or if therapy is prolonged, because of the potential nephrotoxicity and ototoxicity of aminoglycoside antibiotics. It is possible that nephrotoxicity may be potentiated if cefotaxime for injection, USP is used concomitantly with an aminoglycoside. uuid:dd3c679c-2e21-48eb-8c86-cf48ebfad9d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:204928 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:6f12b6f6-1b1e-4ead-b0d1-3253409d8662"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b7e5467e-bd0c-494f-9fa7-c3aaa4597fc1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment Cefotaxime for injection, USP is indicated for the treatment of patients with serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections , including pneumonia, caused by Streptococcus pneumoniae (formerly Diplococcus pneumoniae ), Streptococcus pyogenes * (Group A streptococci) and other streptococci (excluding enterococci, e.g., Enterococcus faecalis ), Staphylococcus aureus (penicillinase and non-penicillinase producing), Escherichia coli , Klebsiella species, Haemophilus influenzae (including ampicillin resistant strains), Haemophilus parainfluenzae , Proteus mirabilis , Serratia marcescens *, Enterobacter species, indole positive Proteus and Pseudomonas species (including P. aeruginosa ). (2) Genitourinary infections . Urinary tract infections caused by Enterococcus species, Staphylococcus epidermidis , Staphylococcus aureus *, (penicillinase and non-penicillinase producing), Citrobacter species, Enterobacter species, Escherichia coli , Klebsiella species, Proteus mirabilis , Proteus vulgaris *, Providencia stuartii , Morganella morganii *, Providencia rettgeri *, Serratia marcescens and Pseudomonas species (including P. aeruginosa ). Also, uncomplicated gonorrhea (cervical/urethral and rectal) caused by Neisseria gonorrhoeae , including penicillinase producing strains. (3) Gynecologic infections , including pelvic inflammatory disease, endometritis and pelvic cellulitis caused by Staphylococcus epidermidis , Streptococcus species, Enterococcus species, Enterobacter species*, Klebsiella species*, Escherichia coli , Proteus mirabilis , Bacteroides species (including Bacteroides fragilis *), Clostridium species, and anaerobic cocci (including Peptostreptococcus species and Peptococcus species) and Fusobacterium species (including F. nucleatum *). Cefotaxime for injection, USP, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (4) Bacteremia/Septicemia caused by Escherichia coli , Klebsiella species, and Serratia marcescens , Staphylococcus aureus and Streptococcus species (including S. pneumonia ). (5) Skin and skin structure infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing), Staphylococcus epidermidis , Streptococcus pyogenes (Group A streptococci) and other streptococci, Enterococcus species, Acinetobacter species*, Escherichia coli , Citrobacter species (including C. freundii *), Enterobacter species, Klebsiella species, Proteus mirabilis , Proteus vulgaris *, Morganella morganii , Providencia rettgeri *, Pseudomonas species, Serratia marcescens , Bacteroides species, and anaerobic cocci (including Peptostreptococcus * species and Peptococcus species). (6) Intra-abdominal infections including peritonitis caused by Streptococcus species*, Escherichia coli , Klebsiella species, Bacteroides species, and anaerobic cocci (including Peptostreptococcus * species and Peptococcus * species) Proteus mirabilis *, and Clostridium species*. (7) Bone and/or joint infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing strains), Streptococcus species (including S. pyogenes *), Pseudomonas species (including P. aeruginosa *), and Proteus mirabilis *. (8) Central nervous system infections , e.g., meningitis and ventriculitis, caused by Neisseria meningitidis , Haemophilus influenzae , Streptococcus pneumoniae , Klebsiella pneumoniae * and Escherichia coli *. (*) Efficacy for this organism, in this organ system, has been studied in fewer than 10 infections. Although many strains of enterococci (e.g., S. faecalis ) and Pseudomonas species are resistant to cefotaxime sodium in vitro , cefotaxime for injection, USP has been used successfully in treating patients with infections caused by susceptible organisms. Specimens for bacteriologic culture should be obtained prior to therapy in order to isolate and identify causative organisms and to determine their susceptibilities to cefotaxime for injection, USP. Therapy may be instituted before results of susceptibility studies are known; however, once these results become available, the antibiotic treatment should be adjusted accordingly. In certain cases of confirmed or suspected gram-positive or gram-negative sepsis or in patients with other serious infections in which the causative organism has not been identified, cefotaxime for injection, USP may be used concomitantly with an aminoglycoside. The dosage recommended in the labeling of both antibiotics may be given and depends on the severity of the infection and the patient's condition. Renal function should be carefully monitored, especially if higher dosages of the aminoglycosides are to be administered or if therapy is prolonged, because of the potential nephrotoxicity and ototoxicity of aminoglycoside antibiotics. It is possible that nephrotoxicity may be potentiated if cefotaxime for injection, USP is used concomitantly with an aminoglycoside. uuid:14aef0db-7d78-4cf2-b10d-117fab9f137a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:204928 biolink:treats UMLS:C1112209 PMID:41385096 "[{""id"":""uuid:eee6fd40-c719-4bd0-95dd-ad232989c400"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2eb09187-3fbc-476d-9ade-ae5c8ff88959"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment Cefotaxime for injection, USP is indicated for the treatment of patients with serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections , including pneumonia, caused by Streptococcus pneumoniae (formerly Diplococcus pneumoniae ), Streptococcus pyogenes * (Group A streptococci) and other streptococci (excluding enterococci, e.g., Enterococcus faecalis ), Staphylococcus aureus (penicillinase and non-penicillinase producing), Escherichia coli , Klebsiella species, Haemophilus influenzae (including ampicillin resistant strains), Haemophilus parainfluenzae , Proteus mirabilis , Serratia marcescens *, Enterobacter species, indole positive Proteus and Pseudomonas species (including P. aeruginosa ). (2) Genitourinary infections . Urinary tract infections caused by Enterococcus species, Staphylococcus epidermidis , Staphylococcus aureus *, (penicillinase and non-penicillinase producing), Citrobacter species, Enterobacter species, Escherichia coli , Klebsiella species, Proteus mirabilis , Proteus vulgaris *, Providencia stuartii , Morganella morganii *, Providencia rettgeri *, Serratia marcescens and Pseudomonas species (including P. aeruginosa ). Also, uncomplicated gonorrhea (cervical/urethral and rectal) caused by Neisseria gonorrhoeae , including penicillinase producing strains. (3) Gynecologic infections , including pelvic inflammatory disease, endometritis and pelvic cellulitis caused by Staphylococcus epidermidis , Streptococcus species, Enterococcus species, Enterobacter species*, Klebsiella species*, Escherichia coli , Proteus mirabilis , Bacteroides species (including Bacteroides fragilis *), Clostridium species, and anaerobic cocci (including Peptostreptococcus species and Peptococcus species) and Fusobacterium species (including F. nucleatum *). Cefotaxime for injection, USP, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (4) Bacteremia/Septicemia caused by Escherichia coli , Klebsiella species, and Serratia marcescens , Staphylococcus aureus and Streptococcus species (including S. pneumonia ). (5) Skin and skin structure infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing), Staphylococcus epidermidis , Streptococcus pyogenes (Group A streptococci) and other streptococci, Enterococcus species, Acinetobacter species*, Escherichia coli , Citrobacter species (including C. freundii *), Enterobacter species, Klebsiella species, Proteus mirabilis , Proteus vulgaris *, Morganella morganii , Providencia rettgeri *, Pseudomonas species, Serratia marcescens , Bacteroides species, and anaerobic cocci (including Peptostreptococcus * species and Peptococcus species). (6) Intra-abdominal infections including peritonitis caused by Streptococcus species*, Escherichia coli , Klebsiella species, Bacteroides species, and anaerobic cocci (including Peptostreptococcus * species and Peptococcus * species) Proteus mirabilis *, and Clostridium species*. (7) Bone and/or joint infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing strains), Streptococcus species (including S. pyogenes *), Pseudomonas species (including P. aeruginosa *), and Proteus mirabilis *. (8) Central nervous system infections , e.g., meningitis and ventriculitis, caused by Neisseria meningitidis , Haemophilus influenzae , Streptococcus pneumoniae , Klebsiella pneumoniae * and Escherichia coli *. (*) Efficacy for this organism, in this organ system, has been studied in fewer than 10 infections. Although many strains of enterococci (e.g., S. faecalis ) and Pseudomonas species are resistant to cefotaxime sodium in vitro , cefotaxime for injection, USP has been used successfully in treating patients with infections caused by susceptible organisms. Specimens for bacteriologic culture should be obtained prior to therapy in order to isolate and identify causative organisms and to determine their susceptibilities to cefotaxime for injection, USP. Therapy may be instituted before results of susceptibility studies are known; however, once these results become available, the antibiotic treatment should be adjusted accordingly. In certain cases of confirmed or suspected gram-positive or gram-negative sepsis or in patients with other serious infections in which the causative organism has not been identified, cefotaxime for injection, USP may be used concomitantly with an aminoglycoside. The dosage recommended in the labeling of both antibiotics may be given and depends on the severity of the infection and the patient's condition. Renal function should be carefully monitored, especially if higher dosages of the aminoglycosides are to be administered or if therapy is prolonged, because of the potential nephrotoxicity and ototoxicity of aminoglycoside antibiotics. It is possible that nephrotoxicity may be potentiated if cefotaxime for injection, USP is used concomitantly with an aminoglycoside. uuid:22fb4d89-7cc1-414e-8832-e72707b272ff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:204928 biolink:treats MONDO:0004522 PMID:41385096 "[{""id"":""uuid:83657c03-8d40-42ed-84cf-48c5d8a44b76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b7527413-a252-4a92-894c-7e32ade5d554"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment Cefotaxime for injection, USP is indicated for the treatment of patients with serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections , including pneumonia, caused by Streptococcus pneumoniae (formerly Diplococcus pneumoniae ), Streptococcus pyogenes * (Group A streptococci) and other streptococci (excluding enterococci, e.g., Enterococcus faecalis ), Staphylococcus aureus (penicillinase and non-penicillinase producing), Escherichia coli , Klebsiella species, Haemophilus influenzae (including ampicillin resistant strains), Haemophilus parainfluenzae , Proteus mirabilis , Serratia marcescens *, Enterobacter species, indole positive Proteus and Pseudomonas species (including P. aeruginosa ). (2) Genitourinary infections . Urinary tract infections caused by Enterococcus species, Staphylococcus epidermidis , Staphylococcus aureus *, (penicillinase and non-penicillinase producing), Citrobacter species, Enterobacter species, Escherichia coli , Klebsiella species, Proteus mirabilis , Proteus vulgaris *, Providencia stuartii , Morganella morganii *, Providencia rettgeri *, Serratia marcescens and Pseudomonas species (including P. aeruginosa ). Also, uncomplicated gonorrhea (cervical/urethral and rectal) caused by Neisseria gonorrhoeae , including penicillinase producing strains. (3) Gynecologic infections , including pelvic inflammatory disease, endometritis and pelvic cellulitis caused by Staphylococcus epidermidis , Streptococcus species, Enterococcus species, Enterobacter species*, Klebsiella species*, Escherichia coli , Proteus mirabilis , Bacteroides species (including Bacteroides fragilis *), Clostridium species, and anaerobic cocci (including Peptostreptococcus species and Peptococcus species) and Fusobacterium species (including F. nucleatum *). Cefotaxime for injection, USP, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (4) Bacteremia/Septicemia caused by Escherichia coli , Klebsiella species, and Serratia marcescens , Staphylococcus aureus and Streptococcus species (including S. pneumonia ). (5) Skin and skin structure infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing), Staphylococcus epidermidis , Streptococcus pyogenes (Group A streptococci) and other streptococci, Enterococcus species, Acinetobacter species*, Escherichia coli , Citrobacter species (including C. freundii *), Enterobacter species, Klebsiella species, Proteus mirabilis , Proteus vulgaris *, Morganella morganii , Providencia rettgeri *, Pseudomonas species, Serratia marcescens , Bacteroides species, and anaerobic cocci (including Peptostreptococcus * species and Peptococcus species). (6) Intra-abdominal infections including peritonitis caused by Streptococcus species*, Escherichia coli , Klebsiella species, Bacteroides species, and anaerobic cocci (including Peptostreptococcus * species and Peptococcus * species) Proteus mirabilis *, and Clostridium species*. (7) Bone and/or joint infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing strains), Streptococcus species (including S. pyogenes *), Pseudomonas species (including P. aeruginosa *), and Proteus mirabilis *. (8) Central nervous system infections , e.g., meningitis and ventriculitis, caused by Neisseria meningitidis , Haemophilus influenzae , Streptococcus pneumoniae , Klebsiella pneumoniae * and Escherichia coli *. (*) Efficacy for this organism, in this organ system, has been studied in fewer than 10 infections. Although many strains of enterococci (e.g., S. faecalis ) and Pseudomonas species are resistant to cefotaxime sodium in vitro , cefotaxime for injection, USP has been used successfully in treating patients with infections caused by susceptible organisms. Specimens for bacteriologic culture should be obtained prior to therapy in order to isolate and identify causative organisms and to determine their susceptibilities to cefotaxime for injection, USP. Therapy may be instituted before results of susceptibility studies are known; however, once these results become available, the antibiotic treatment should be adjusted accordingly. In certain cases of confirmed or suspected gram-positive or gram-negative sepsis or in patients with other serious infections in which the causative organism has not been identified, cefotaxime for injection, USP may be used concomitantly with an aminoglycoside. The dosage recommended in the labeling of both antibiotics may be given and depends on the severity of the infection and the patient's condition. Renal function should be carefully monitored, especially if higher dosages of the aminoglycosides are to be administered or if therapy is prolonged, because of the potential nephrotoxicity and ototoxicity of aminoglycoside antibiotics. It is possible that nephrotoxicity may be potentiated if cefotaxime for injection, USP is used concomitantly with an aminoglycoside. uuid:8b8ddd8d-12ea-4ad8-a566-e88e5e4c2075 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:204928 biolink:treats MONDO:0005246 PMID:41385096 "[{""id"":""uuid:1a20e006-fe73-4113-8158-7c04b55be266"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5ad97ffc-ea47-4bf4-b925-0984a6b31ff1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment Cefotaxime for injection, USP is indicated for the treatment of patients with serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections , including pneumonia, caused by Streptococcus pneumoniae (formerly Diplococcus pneumoniae ), Streptococcus pyogenes * (Group A streptococci) and other streptococci (excluding enterococci, e.g., Enterococcus faecalis ), Staphylococcus aureus (penicillinase and non-penicillinase producing), Escherichia coli , Klebsiella species, Haemophilus influenzae (including ampicillin resistant strains), Haemophilus parainfluenzae , Proteus mirabilis , Serratia marcescens *, Enterobacter species, indole positive Proteus and Pseudomonas species (including P. aeruginosa ). (2) Genitourinary infections . Urinary tract infections caused by Enterococcus species, Staphylococcus epidermidis , Staphylococcus aureus *, (penicillinase and non-penicillinase producing), Citrobacter species, Enterobacter species, Escherichia coli , Klebsiella species, Proteus mirabilis , Proteus vulgaris *, Providencia stuartii , Morganella morganii *, Providencia rettgeri *, Serratia marcescens and Pseudomonas species (including P. aeruginosa ). Also, uncomplicated gonorrhea (cervical/urethral and rectal) caused by Neisseria gonorrhoeae , including penicillinase producing strains. (3) Gynecologic infections , including pelvic inflammatory disease, endometritis and pelvic cellulitis caused by Staphylococcus epidermidis , Streptococcus species, Enterococcus species, Enterobacter species*, Klebsiella species*, Escherichia coli , Proteus mirabilis , Bacteroides species (including Bacteroides fragilis *), Clostridium species, and anaerobic cocci (including Peptostreptococcus species and Peptococcus species) and Fusobacterium species (including F. nucleatum *). Cefotaxime for injection, USP, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (4) Bacteremia/Septicemia caused by Escherichia coli , Klebsiella species, and Serratia marcescens , Staphylococcus aureus and Streptococcus species (including S. pneumonia ). (5) Skin and skin structure infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing), Staphylococcus epidermidis , Streptococcus pyogenes (Group A streptococci) and other streptococci, Enterococcus species, Acinetobacter species*, Escherichia coli , Citrobacter species (including C. freundii *), Enterobacter species, Klebsiella species, Proteus mirabilis , Proteus vulgaris *, Morganella morganii , Providencia rettgeri *, Pseudomonas species, Serratia marcescens , Bacteroides species, and anaerobic cocci (including Peptostreptococcus * species and Peptococcus species). (6) Intra-abdominal infections including peritonitis caused by Streptococcus species*, Escherichia coli , Klebsiella species, Bacteroides species, and anaerobic cocci (including Peptostreptococcus * species and Peptococcus * species) Proteus mirabilis *, and Clostridium species*. (7) Bone and/or joint infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing strains), Streptococcus species (including S. pyogenes *), Pseudomonas species (including P. aeruginosa *), and Proteus mirabilis *. (8) Central nervous system infections , e.g., meningitis and ventriculitis, caused by Neisseria meningitidis , Haemophilus influenzae , Streptococcus pneumoniae , Klebsiella pneumoniae * and Escherichia coli *. (*) Efficacy for this organism, in this organ system, has been studied in fewer than 10 infections. Although many strains of enterococci (e.g., S. faecalis ) and Pseudomonas species are resistant to cefotaxime sodium in vitro , cefotaxime for injection, USP has been used successfully in treating patients with infections caused by susceptible organisms. Specimens for bacteriologic culture should be obtained prior to therapy in order to isolate and identify causative organisms and to determine their susceptibilities to cefotaxime for injection, USP. Therapy may be instituted before results of susceptibility studies are known; however, once these results become available, the antibiotic treatment should be adjusted accordingly. In certain cases of confirmed or suspected gram-positive or gram-negative sepsis or in patients with other serious infections in which the causative organism has not been identified, cefotaxime for injection, USP may be used concomitantly with an aminoglycoside. The dosage recommended in the labeling of both antibiotics may be given and depends on the severity of the infection and the patient's condition. Renal function should be carefully monitored, especially if higher dosages of the aminoglycosides are to be administered or if therapy is prolonged, because of the potential nephrotoxicity and ototoxicity of aminoglycoside antibiotics. It is possible that nephrotoxicity may be potentiated if cefotaxime for injection, USP is used concomitantly with an aminoglycoside. uuid:f51f2110-ef14-473e-8b16-288743c248c7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:204928 biolink:treats MONDO:0021108 PMID:41385096 "[{""id"":""uuid:2fda3212-31e7-4e80-b969-0ad05b749715"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e3f92c0a-f384-4324-bb2a-d2cdfc1bebc1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment Cefotaxime for injection, USP is indicated for the treatment of patients with serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections , including pneumonia, caused by Streptococcus pneumoniae (formerly Diplococcus pneumoniae ), Streptococcus pyogenes * (Group A streptococci) and other streptococci (excluding enterococci, e.g., Enterococcus faecalis ), Staphylococcus aureus (penicillinase and non-penicillinase producing), Escherichia coli , Klebsiella species, Haemophilus influenzae (including ampicillin resistant strains), Haemophilus parainfluenzae , Proteus mirabilis , Serratia marcescens *, Enterobacter species, indole positive Proteus and Pseudomonas species (including P. aeruginosa ). (2) Genitourinary infections . Urinary tract infections caused by Enterococcus species, Staphylococcus epidermidis , Staphylococcus aureus *, (penicillinase and non-penicillinase producing), Citrobacter species, Enterobacter species, Escherichia coli , Klebsiella species, Proteus mirabilis , Proteus vulgaris *, Providencia stuartii , Morganella morganii *, Providencia rettgeri *, Serratia marcescens and Pseudomonas species (including P. aeruginosa ). Also, uncomplicated gonorrhea (cervical/urethral and rectal) caused by Neisseria gonorrhoeae , including penicillinase producing strains. (3) Gynecologic infections , including pelvic inflammatory disease, endometritis and pelvic cellulitis caused by Staphylococcus epidermidis , Streptococcus species, Enterococcus species, Enterobacter species*, Klebsiella species*, Escherichia coli , Proteus mirabilis , Bacteroides species (including Bacteroides fragilis *), Clostridium species, and anaerobic cocci (including Peptostreptococcus species and Peptococcus species) and Fusobacterium species (including F. nucleatum *). Cefotaxime for injection, USP, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (4) Bacteremia/Septicemia caused by Escherichia coli , Klebsiella species, and Serratia marcescens , Staphylococcus aureus and Streptococcus species (including S. pneumonia ). (5) Skin and skin structure infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing), Staphylococcus epidermidis , Streptococcus pyogenes (Group A streptococci) and other streptococci, Enterococcus species, Acinetobacter species*, Escherichia coli , Citrobacter species (including C. freundii *), Enterobacter species, Klebsiella species, Proteus mirabilis , Proteus vulgaris *, Morganella morganii , Providencia rettgeri *, Pseudomonas species, Serratia marcescens , Bacteroides species, and anaerobic cocci (including Peptostreptococcus * species and Peptococcus species). (6) Intra-abdominal infections including peritonitis caused by Streptococcus species*, Escherichia coli , Klebsiella species, Bacteroides species, and anaerobic cocci (including Peptostreptococcus * species and Peptococcus * species) Proteus mirabilis *, and Clostridium species*. (7) Bone and/or joint infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing strains), Streptococcus species (including S. pyogenes *), Pseudomonas species (including P. aeruginosa *), and Proteus mirabilis *. (8) Central nervous system infections , e.g., meningitis and ventriculitis, caused by Neisseria meningitidis , Haemophilus influenzae , Streptococcus pneumoniae , Klebsiella pneumoniae * and Escherichia coli *. (*) Efficacy for this organism, in this organ system, has been studied in fewer than 10 infections. Although many strains of enterococci (e.g., S. faecalis ) and Pseudomonas species are resistant to cefotaxime sodium in vitro , cefotaxime for injection, USP has been used successfully in treating patients with infections caused by susceptible organisms. Specimens for bacteriologic culture should be obtained prior to therapy in order to isolate and identify causative organisms and to determine their susceptibilities to cefotaxime for injection, USP. Therapy may be instituted before results of susceptibility studies are known; however, once these results become available, the antibiotic treatment should be adjusted accordingly. In certain cases of confirmed or suspected gram-positive or gram-negative sepsis or in patients with other serious infections in which the causative organism has not been identified, cefotaxime for injection, USP may be used concomitantly with an aminoglycoside. The dosage recommended in the labeling of both antibiotics may be given and depends on the severity of the infection and the patient's condition. Renal function should be carefully monitored, especially if higher dosages of the aminoglycosides are to be administered or if therapy is prolonged, because of the potential nephrotoxicity and ototoxicity of aminoglycoside antibiotics. It is possible that nephrotoxicity may be potentiated if cefotaxime for injection, USP is used concomitantly with an aminoglycoside. uuid:102f1928-10a2-4016-9029-cac87e9fc93f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:204928 biolink:treats UMLS:C1455718 PMID:41385096 "[{""id"":""uuid:9743165a-a80b-4514-ad10-036b73a88b3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:916767f7-6971-4b6c-8ef3-6d8a55b63bfe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment Cefotaxime for injection, USP is indicated for the treatment of patients with serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections , including pneumonia, caused by Streptococcus pneumoniae (formerly Diplococcus pneumoniae ), Streptococcus pyogenes * (Group A streptococci) and other streptococci (excluding enterococci, e.g., Enterococcus faecalis ), Staphylococcus aureus (penicillinase and non-penicillinase producing), Escherichia coli , Klebsiella species, Haemophilus influenzae (including ampicillin resistant strains), Haemophilus parainfluenzae , Proteus mirabilis , Serratia marcescens *, Enterobacter species, indole positive Proteus and Pseudomonas species (including P. aeruginosa ). (2) Genitourinary infections . Urinary tract infections caused by Enterococcus species, Staphylococcus epidermidis , Staphylococcus aureus *, (penicillinase and non-penicillinase producing), Citrobacter species, Enterobacter species, Escherichia coli , Klebsiella species, Proteus mirabilis , Proteus vulgaris *, Providencia stuartii , Morganella morganii *, Providencia rettgeri *, Serratia marcescens and Pseudomonas species (including P. aeruginosa ). Also, uncomplicated gonorrhea (cervical/urethral and rectal) caused by Neisseria gonorrhoeae , including penicillinase producing strains. (3) Gynecologic infections , including pelvic inflammatory disease, endometritis and pelvic cellulitis caused by Staphylococcus epidermidis , Streptococcus species, Enterococcus species, Enterobacter species*, Klebsiella species*, Escherichia coli , Proteus mirabilis , Bacteroides species (including Bacteroides fragilis *), Clostridium species, and anaerobic cocci (including Peptostreptococcus species and Peptococcus species) and Fusobacterium species (including F. nucleatum *). Cefotaxime for injection, USP, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (4) Bacteremia/Septicemia caused by Escherichia coli , Klebsiella species, and Serratia marcescens , Staphylococcus aureus and Streptococcus species (including S. pneumonia ). (5) Skin and skin structure infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing), Staphylococcus epidermidis , Streptococcus pyogenes (Group A streptococci) and other streptococci, Enterococcus species, Acinetobacter species*, Escherichia coli , Citrobacter species (including C. freundii *), Enterobacter species, Klebsiella species, Proteus mirabilis , Proteus vulgaris *, Morganella morganii , Providencia rettgeri *, Pseudomonas species, Serratia marcescens , Bacteroides species, and anaerobic cocci (including Peptostreptococcus * species and Peptococcus species). (6) Intra-abdominal infections including peritonitis caused by Streptococcus species*, Escherichia coli , Klebsiella species, Bacteroides species, and anaerobic cocci (including Peptostreptococcus * species and Peptococcus * species) Proteus mirabilis *, and Clostridium species*. (7) Bone and/or joint infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing strains), Streptococcus species (including S. pyogenes *), Pseudomonas species (including P. aeruginosa *), and Proteus mirabilis *. (8) Central nervous system infections , e.g., meningitis and ventriculitis, caused by Neisseria meningitidis , Haemophilus influenzae , Streptococcus pneumoniae , Klebsiella pneumoniae * and Escherichia coli *. (*) Efficacy for this organism, in this organ system, has been studied in fewer than 10 infections. Although many strains of enterococci (e.g., S. faecalis ) and Pseudomonas species are resistant to cefotaxime sodium in vitro , cefotaxime for injection, USP has been used successfully in treating patients with infections caused by susceptible organisms. Specimens for bacteriologic culture should be obtained prior to therapy in order to isolate and identify causative organisms and to determine their susceptibilities to cefotaxime for injection, USP. Therapy may be instituted before results of susceptibility studies are known; however, once these results become available, the antibiotic treatment should be adjusted accordingly. In certain cases of confirmed or suspected gram-positive or gram-negative sepsis or in patients with other serious infections in which the causative organism has not been identified, cefotaxime for injection, USP may be used concomitantly with an aminoglycoside. The dosage recommended in the labeling of both antibiotics may be given and depends on the severity of the infection and the patient's condition. Renal function should be carefully monitored, especially if higher dosages of the aminoglycosides are to be administered or if therapy is prolonged, because of the potential nephrotoxicity and ototoxicity of aminoglycoside antibiotics. It is possible that nephrotoxicity may be potentiated if cefotaxime for injection, USP is used concomitantly with an aminoglycoside. uuid:2efe1ed4-6f7a-4854-becf-c16266deda02 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:61276 biolink:treats MONDO:0004247 PMID:41385096 "[{""id"":""uuid:3e829695-de16-4e72-9095-272152e31cba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c2298266-4a7f-4e8c-9707-4622c65b4bd7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Adjunctive therapy for the treatment of peptic ulcer. METHSCOPOLAMINE BROMIDE HAS NOT BEEN SHOWN TO BE EFFECTIVE IN CONTRIBUTING TO THE HEALING OF PEPTIC ULCER, DECREASING THE RATE OF RECURRENCE OR PREVENTING COMPLICATIONS. uuid:a0ff5648-e028-49bf-895c-91a50bab7f93 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1811627 biolink:treats MONDO:0001126 PMID:41385096 "[{""id"":""uuid:c5227fc2-ad52-4d9e-9e15-0d2533dc3ac5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:068e33e6-dfe7-435b-8db6-196d319e6685"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] YOSPRALA, a combination of aspirin and omeprazole, is indicated for patients who require aspirin for secondary prevention of cardiovascular and cerebrovascular events and who are at risk of developing aspirin associated gastric ulcers. The aspirin component of YOSPRALA is indicated for: reducing the combined risk of death and nonfatal stroke in patients who have had ischemic stroke or transient ischemia of the brain due to fibrin platelet emboli, reducing the combined risk of death and nonfatal MI in patients with a previous MI or unstable angina pectoris, reducing the combined risk of MI and sudden death in patients with chronic stable angina pectoris, use in patients who have undergone revascularization procedures (Coronary Artery Bypass Graft [CABG] or Percutaneous Transluminal Coronary Angioplasty [PTCA]) when there is a pre-existing condition for which aspirin is already indicated. The omeprazole component of YOSPRALA is indicated for decreasing the risk of developing aspirin-associated gastric ulcers in patients at risk for developing aspirin-associated gastric ulcers due to age (≥ 55) or documented history of gastric ulcers. uuid:02a3b7d2-90dc-42bd-a6ab-eb353e81a354 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0005093 PMID:41385096 "[{""id"":""uuid:cd30baec-548a-49f0-b2f1-8dcbd70659c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8b17b21b-929e-4f08-97ce-bfaa8835eec1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] U-cort ® , (Hydrocortisone Acetate Cream USP, 1%) is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. uuid:b14a21d6-45ea-400c-8cce-256f80bfe0a5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6923 biolink:treats UMLS:C0011974 PMID:41385096 "[{""id"":""uuid:38f948c8-b3b6-40ee-bb51-d27edd7e1029"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3e0def2b-fcfb-4fdc-b13b-4b2c2d2a998f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] • VUSION Ointment is indicated for adjunctive treatment of diaper dermatitis when complicated by documented candidiasis (microscopic evidence of pseudohyphae and /or budding yeast) in immunocompetent pediatric patients 4 weeks and older. ( 1.1 ) • VUSION Ointment should not be used as a substitute for frequent diaper changes. ( 1.1 ) • VUSION Ointment should not be used to prevent the occurrence of diaper dermatitis, since preventative use may result in the development of drug resistance. ( 1.2 ) uuid:56559ae5-9ee7-442f-a9ff-806814c33b83 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats UMLS:C0274435 PMID:41385096 "[{""id"":""uuid:53dac49f-6195-4b8f-8427-8b0161fd9fc4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4340db37-be27-4db2-8cdf-c6b1fed7c4bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection and Kenalog-80 Injection (triamcinolone acetonide injectable suspension, USP) are indicated for intramuscular use as follows: Allergic states : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases : To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders : Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases : For the palliative management of leukemias and lymphomas. Nervous system : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases : Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Intra-Articular The intra-articular or soft tis sue administration of Kenalog-40 Injection and Kenalog-80 Injection are indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. uuid:0df15a8f-cc63-4753-9931-19e7226bb462 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0001705 PMID:41385096 "[{""id"":""uuid:cd381524-479f-4d74-8f01-58e834af98f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:875bc9a1-a74a-495e-adf6-dd1e1f4f3a4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection and Kenalog-80 Injection (triamcinolone acetonide injectable suspension, USP) are indicated for intramuscular use as follows: Allergic states : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases : To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders : Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases : For the palliative management of leukemias and lymphomas. Nervous system : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases : Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Intra-Articular The intra-articular or soft tis sue administration of Kenalog-40 Injection and Kenalog-80 Injection are indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. uuid:b1258a4f-ffa4-47f2-88f9-3bfcc042e4e7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0005314 PMID:41385096 "[{""id"":""uuid:d44bb6bd-b6ec-47e7-a65b-a7eee87f8719"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d8884f25-5015-411b-9de9-a40a4c9de5a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection and Kenalog-80 Injection (triamcinolone acetonide injectable suspension, USP) are indicated for intramuscular use as follows: Allergic states : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases : To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders : Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases : For the palliative management of leukemias and lymphomas. Nervous system : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases : Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Intra-Articular The intra-articular or soft tis sue administration of Kenalog-40 Injection and Kenalog-80 Injection are indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. uuid:872c5082-c115-4336-b510-18c495959a37 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0008538 PMID:41385096 "[{""id"":""uuid:13cdb8aa-e83e-4635-bc14-fab462a76d5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a833a696-4f0b-484e-b6ac-f2105978e91d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection and Kenalog-80 Injection (triamcinolone acetonide injectable suspension, USP) are indicated for intramuscular use as follows: Allergic states : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases : To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders : Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases : For the palliative management of leukemias and lymphomas. Nervous system : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases : Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Intra-Articular The intra-articular or soft tis sue administration of Kenalog-40 Injection and Kenalog-80 Injection are indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. uuid:ee387dea-4452-47ff-a240-d7273e142c8b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0020283 PMID:41385096 "[{""id"":""uuid:4b366415-175d-4ecd-9563-af5a549dbd7d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1422ef28-199f-41f0-b76c-a177ab0fdaf0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection and Kenalog-80 Injection (triamcinolone acetonide injectable suspension, USP) are indicated for intramuscular use as follows: Allergic states : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases : To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders : Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases : For the palliative management of leukemias and lymphomas. Nervous system : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases : Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Intra-Articular The intra-articular or soft tis sue administration of Kenalog-40 Injection and Kenalog-80 Injection are indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. uuid:2ea47aed-75f8-4b82-9b97-2c3304bc955f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0008109 PMID:41385096 "[{""id"":""uuid:0194b58a-252f-4ebf-aa03-6947d15aee06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4227272c-ffad-4c81-9515-28f08ecf759f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection and Kenalog-80 Injection (triamcinolone acetonide injectable suspension, USP) are indicated for intramuscular use as follows: Allergic states : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases : To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders : Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases : For the palliative management of leukemias and lymphomas. Nervous system : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases : Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Intra-Articular The intra-articular or soft tis sue administration of Kenalog-40 Injection and Kenalog-80 Injection are indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. uuid:24dac11a-78c8-4afd-a9bd-f0af9eb693b1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0018170 PMID:41385096 "[{""id"":""uuid:889ef740-0c18-4bac-99c0-feca879fdbb8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0d87813e-f5ff-4020-a76a-aea6ab091ff0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection and Kenalog-80 Injection (triamcinolone acetonide injectable suspension, USP) are indicated for intramuscular use as follows: Allergic states : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases : To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders : Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases : For the palliative management of leukemias and lymphomas. Nervous system : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases : Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Intra-Articular The intra-articular or soft tis sue administration of Kenalog-40 Injection and Kenalog-80 Injection are indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. uuid:969aebca-8305-4fa1-818e-da4e3a8bc68b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0005556 PMID:41385096 "[{""id"":""uuid:334fc3e6-67fc-4075-9072-0961e3df5608"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a0545448-f91f-43bc-a38e-dc781704b60b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection and Kenalog-80 Injection (triamcinolone acetonide injectable suspension, USP) are indicated for intramuscular use as follows: Allergic states : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases : To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders : Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases : For the palliative management of leukemias and lymphomas. Nervous system : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases : Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Intra-Articular The intra-articular or soft tis sue administration of Kenalog-40 Injection and Kenalog-80 Injection are indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. uuid:af632cf0-2bc8-44ba-83a2-1b10359458ef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0015927 PMID:41385096 "[{""id"":""uuid:a11742fb-3cc0-4111-96e1-1c2d324998ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:600aeebc-f457-47fd-8318-0743a839ea37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection and Kenalog-80 Injection (triamcinolone acetonide injectable suspension, USP) are indicated for intramuscular use as follows: Allergic states : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases : To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders : Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases : For the palliative management of leukemias and lymphomas. Nervous system : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases : Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Intra-Articular The intra-articular or soft tis sue administration of Kenalog-40 Injection and Kenalog-80 Injection are indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. uuid:82a5dff7-4c09-4be7-918b-4584afe16fad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0016367 PMID:41385096 "[{""id"":""uuid:1bd83bbd-799a-4972-8e70-80f625124f89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:326dec52-a91b-48a0-8da8-bdd3963392e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection and Kenalog-80 Injection (triamcinolone acetonide injectable suspension, USP) are indicated for intramuscular use as follows: Allergic states : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases : To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders : Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases : For the palliative management of leukemias and lymphomas. Nervous system : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases : Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Intra-Articular The intra-articular or soft tis sue administration of Kenalog-40 Injection and Kenalog-80 Injection are indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. uuid:c819e40b-fd28-4d27-bfdc-b1b002971e09 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0019127 PMID:41385096 "[{""id"":""uuid:8503416c-7ddb-4ad5-9fc3-e04e44686eb0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:59b3c276-27d3-45a8-a93f-09cedc105db4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection and Kenalog-80 Injection (triamcinolone acetonide injectable suspension, USP) are indicated for intramuscular use as follows: Allergic states : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases : To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders : Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases : For the palliative management of leukemias and lymphomas. Nervous system : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases : Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Intra-Articular The intra-articular or soft tis sue administration of Kenalog-40 Injection and Kenalog-80 Injection are indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. uuid:e4403ccb-9dde-4389-8caf-e9a94f3a1246 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0006982 PMID:41385096 "[{""id"":""uuid:85898493-f9c7-4b1b-994c-3b2dce319d65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2a9c4545-c46d-4bfe-9bc5-5af3546164f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection and Kenalog-80 Injection (triamcinolone acetonide injectable suspension, USP) are indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Intra-Articular The intra-articular or soft tis sue administration of Kenalog-40 Injection and Kenalog-80 Injection are indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. uuid:e8f274af-1e9a-47cb-b8d9-754b1a9af633 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0008109 PMID:41385096 "[{""id"":""uuid:28f3ed9e-95ad-416e-9ad4-4e6dd8ceef8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:43b12e18-f89b-40af-b509-f543306cb60c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection and Kenalog-80 Injection (triamcinolone acetonide injectable suspension, USP) are indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Intra-Articular The intra-articular or soft tis sue administration of Kenalog-40 Injection and Kenalog-80 Injection are indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. uuid:96b37dfc-50e6-473b-a8bf-f667a296d3c4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0040698 PMID:41385096 "[{""id"":""uuid:9e892f17-3df7-4d5f-9402-54cc03ca5e71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:603baa92-b9a6-47e5-a9c0-eaea8494e723"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection and Kenalog-80 Injection (triamcinolone acetonide injectable suspension, USP) are indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Intra-Articular The intra-articular or soft tis sue administration of Kenalog-40 Injection and Kenalog-80 Injection are indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. uuid:60ffb506-1062-497d-95e2-7950bea8f918 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0004855 PMID:41385096 "[{""id"":""uuid:5efc1987-0062-44c7-bf9b-a6d5cdeb7e70"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:29184a67-e14d-4b7a-a582-ebce585122c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection and Kenalog-80 Injection (triamcinolone acetonide injectable suspension, USP) are indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Intra-Articular The intra-articular or soft tis sue administration of Kenalog-40 Injection and Kenalog-80 Injection are indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. uuid:355a162d-b785-4e69-9422-6ee7562f277b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0001875 PMID:41385096 "[{""id"":""uuid:6dad1b83-4d0b-4428-8846-3ba936da8575"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:df307fd3-4a0d-4312-ba5b-fac495bb7c1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection and Kenalog-80 Injection (triamcinolone acetonide injectable suspension, USP) are indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Intra-Articular The intra-articular or soft tis sue administration of Kenalog-40 Injection and Kenalog-80 Injection are indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. uuid:01479c8e-41b7-47ed-9563-e24de42fcb68 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:d4dd2048-083d-41af-aa46-edb08b48c97d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:33d35ee1-264f-434c-a4ca-fbed6fa0e6f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intramuscular Where oral therapy is not feasible, injectable corticosteroid therapy, including Kenalog-40 Injection and Kenalog-80 Injection (triamcinolone acetonide injectable suspension, USP) are indicated for intramuscular use as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous system: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. Intra-Articular The intra-articular or soft tis sue administration of Kenalog-40 Injection and Kenalog-80 Injection are indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. uuid:9cab5d2b-3c79-4dbf-b3fb-94561f46aa17 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40279 biolink:treats MONDO:0003652 PMID:41385096 "[{""id"":""uuid:56f6d158-d46f-4566-9f8c-d692fbb27f03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d22621f6-7d16-40c8-90c6-51ea2f3791b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] THIS IS NOT AN INNOCUOUS DRUG. IT IS NOT RECOMMENDED FOR THE TREATMENT OF ASYMPTOMATIC HYPERURICEMIA. Allopurinol tablets USP reduces serum and urinary uric acid concentrations. Its use should be individualized for each patient and requires an understanding of its mode of action and pharmacokinetics (see CLINICAL PHARMACOLOGY , CONTRAINDICATIONS , WARNINGS , and PRECAUTIONS ). Allopurinol tablet USP is indicated in: 1. the management of patients with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy). 2. the management of patients with leukemia, lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels. Treatment with allopurinol tablets USP should be discontinued when the potential for overproduction of uric acid is no longer present. 3. the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 800 mg/day in male patients and 750 mg/day in female patients. Therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks. uuid:6d6eae11-0bcb-42ac-b452-4c8ac29622df biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4636 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:2356bd20-7750-4a34-ac2d-1b447c3393d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:849a9667-82c1-4140-9721-4440962ded6c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diphenhydramine hydrochloride in the injectable form is effective in adults and pediatric patients, other than premature infants and neonates, for the following conditions when diphenhydramine hydrochloride in the oral form is impractical. Antihistaminic: For amelioration of allergic reactions to blood or plasma, in anaphylaxis as an adjunct to epinephrine and other standard measures after the acute symptoms have been controlled, and for other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated. Motion sickness: For active treatment of motion sickness. Antiparkinsonism: For use in parkinsonism, when oral therapy is impossible or contraindicated, as follows: parkinsonism in the elderly who are unable to tolerate more potent agents; mild cases of parkinsonism in other age groups, and in other cases of parkinsonism in combination with centrally acting anticholinergic agents. uuid:af862db2-a0b9-4ba4-aa30-8e3839bf1081 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4636 biolink:treats MONDO:0100053 PMID:41385096 "[{""id"":""uuid:c315c1b2-6408-45cf-aade-417ee0b61fb3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c8ba72f3-0854-4497-8089-12099ebe60be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diphenhydramine hydrochloride in the injectable form is effective in adults and pediatric patients, other than premature infants and neonates, for the following conditions when diphenhydramine hydrochloride in the oral form is impractical. Antihistaminic: For amelioration of allergic reactions to blood or plasma, in anaphylaxis as an adjunct to epinephrine and other standard measures after the acute symptoms have been controlled, and for other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated. Motion sickness: For active treatment of motion sickness. Antiparkinsonism: For use in parkinsonism, when oral therapy is impossible or contraindicated, as follows: parkinsonism in the elderly who are unable to tolerate more potent agents; mild cases of parkinsonism in other age groups, and in other cases of parkinsonism in combination with centrally acting anticholinergic agents. uuid:53bb8438-7d72-42a0-9ac2-e14c8af0a5e2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4636 biolink:treats UMLS:C0851444 PMID:41385096 "[{""id"":""uuid:079eb400-2a69-46e7-ab3a-2b28eb49881f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2f9e082b-3d79-428f-9c0a-23e824b30573"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diphenhydramine hydrochloride in the injectable form is effective in adults and pediatric patients, other than premature infants and neonates, for the following conditions when diphenhydramine hydrochloride in the oral form is impractical. Antihistaminic: For amelioration of allergic reactions to blood or plasma, in anaphylaxis as an adjunct to epinephrine and other standard measures after the acute symptoms have been controlled, and for other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated. Motion sickness: For active treatment of motion sickness. Antiparkinsonism: For use in parkinsonism, when oral therapy is impossible or contraindicated, as follows: parkinsonism in the elderly who are unable to tolerate more potent agents; mild cases of parkinsonism in other age groups, and in other cases of parkinsonism in combination with centrally acting anticholinergic agents. uuid:bd89c125-8b03-44e8-9cbc-24c6955747ff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4636 biolink:treats MONDO:0008015 PMID:41385096 "[{""id"":""uuid:877525bc-ed2b-48a4-a12a-b752155cb9d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:64302230-e975-40aa-8aba-2ed7b9c1fcb6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diphenhydramine hydrochloride in the injectable form is effective in adults and pediatric patients, other than premature infants and neonates, for the following conditions when diphenhydramine hydrochloride in the oral form is impractical. Antihistaminic: For amelioration of allergic reactions to blood or plasma, in anaphylaxis as an adjunct to epinephrine and other standard measures after the acute symptoms have been controlled, and for other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated. Motion sickness: For active treatment of motion sickness. Antiparkinsonism: For use in parkinsonism, when oral therapy is impossible or contraindicated, as follows: parkinsonism in the elderly who are unable to tolerate more potent agents; mild cases of parkinsonism in other age groups, and in other cases of parkinsonism in combination with centrally acting anticholinergic agents. uuid:17c15eb5-a7e2-42c4-9072-0c97f95a4d7b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4636 biolink:treats MONDO:0021095 PMID:41385096 "[{""id"":""uuid:eec81640-b8a2-44c5-984c-2c53890cc459"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ff48bb02-23ed-4027-acfd-66bf32ca5087"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diphenhydramine hydrochloride in the injectable form is effective in adults and pediatric patients, other than premature infants and neonates, for the following conditions when diphenhydramine hydrochloride in the oral form is impractical. Antihistaminic: For amelioration of allergic reactions to blood or plasma, in anaphylaxis as an adjunct to epinephrine and other standard measures after the acute symptoms have been controlled, and for other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated. Motion sickness: For active treatment of motion sickness. Antiparkinsonism: For use in parkinsonism, when oral therapy is impossible or contraindicated, as follows: parkinsonism in the elderly who are unable to tolerate more potent agents; mild cases of parkinsonism in other age groups, and in other cases of parkinsonism in combination with centrally acting anticholinergic agents. uuid:bb8a4629-abd0-42b7-ae51-d8645df3f8a1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4735 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:da82a3aa-2e39-45ee-98c5-b8e6bb353c77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:52d102b0-b490-4323-af2e-a3de1ce0176d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Labetalol HCl injection is indicated for control of blood pressure in severe hypertension. uuid:fb8a97a2-21e8-476a-92ac-978765449a0b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1152251 biolink:treats HP:0012228 PMID:41385096 "[{""id"":""uuid:787eebc2-8b54-43c0-a9e5-8f81c21d61c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f85ffa4a-aa5f-41a9-a68f-d86170aea318"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules are indicated for the management of the symptom complex of tension (or muscle contraction) headache when non-opioid analgesic and alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids and butalbital, even at recommended doses [see Warnings and Precautions (5.1)], reserve Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules for use in patients for whom alternative treatment options [e.g., non-opioid, non-barbiturate analgesics]: • Have not been tolerated or are not expected to be tolerated, • Have not provided adequate analgesia or are not expected to provide adequate analgesia. uuid:a6c7c111-a51b-4373-bdea-58b1699df858 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16684 biolink:treats MONDO:0001428 PMID:41385096 "[{""id"":""uuid:a5aad451-adad-4bd5-8fc3-15069b0267e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:646ff363-8c10-4efb-ad51-cc4ba4b72b08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atropine Sulfate Injection, USP, may be given parenterally as a pre-anesthetic medication in surgical patients to reduce salivation and bronchial secretions. It may also be used to suppress vagal activity associated with the use of halogenated hydrocarbons during inhalation anesthesia and reflex excitation arising from mechanical stimulation during surgery. The antispasmodic action of atropine is useful in pylorospasm and other spastic conditions of the gastrointestinal tract. For ureteral and biliary colic, atropine concomitantly with morphine may be indicated. Atropine relaxes the upper GI tract and colon during hypotonic radiography. In poisoning by the organic phosphate cholinesterase inhibitors found in certain insecticides and by chemical warfare nerve gases, large doses of atropine relieve the muscarine-like symptoms and some of the central nervous system manifestations. It is also used as an antidote for mushroom poisoning due to muscarine in certain species such as Amanita muscaria. uuid:c1faa237-3df7-4288-b3c7-97e9d882e555 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16684 biolink:treats MONDO:0007009 PMID:41385096 "[{""id"":""uuid:5bc87f2f-4eeb-4f87-97c5-ab4a26b257ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f77bfa6e-1ed2-46de-87e7-d93791f57879"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atropine Sulfate Injection, USP, may be given parenterally as a pre-anesthetic medication in surgical patients to reduce salivation and bronchial secretions. It may also be used to suppress vagal activity associated with the use of halogenated hydrocarbons during inhalation anesthesia and reflex excitation arising from mechanical stimulation during surgery. The antispasmodic action of atropine is useful in pylorospasm and other spastic conditions of the gastrointestinal tract. For ureteral and biliary colic, atropine concomitantly with morphine may be indicated. Atropine relaxes the upper GI tract and colon during hypotonic radiography. In poisoning by the organic phosphate cholinesterase inhibitors found in certain insecticides and by chemical warfare nerve gases, large doses of atropine relieve the muscarine-like symptoms and some of the central nervous system manifestations. It is also used as an antidote for mushroom poisoning due to muscarine in certain species such as Amanita muscaria. uuid:9f2199d9-4df8-4453-ae33-65c52f99cb47 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16684 biolink:treats UMLS:C0151824 PMID:41385096 "[{""id"":""uuid:9a08deec-6ba5-4731-b99e-075215d2293d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e6737b23-12f1-48a6-8a01-ca5c49738da4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atropine Sulfate Injection, USP, may be given parenterally as a pre-anesthetic medication in surgical patients to reduce salivation and bronchial secretions. It may also be used to suppress vagal activity associated with the use of halogenated hydrocarbons during inhalation anesthesia and reflex excitation arising from mechanical stimulation during surgery. The antispasmodic action of atropine is useful in pylorospasm and other spastic conditions of the gastrointestinal tract. For ureteral and biliary colic, atropine concomitantly with morphine may be indicated. Atropine relaxes the upper GI tract and colon during hypotonic radiography. In poisoning by the organic phosphate cholinesterase inhibitors found in certain insecticides and by chemical warfare nerve gases, large doses of atropine relieve the muscarine-like symptoms and some of the central nervous system manifestations. It is also used as an antidote for mushroom poisoning due to muscarine in certain species such as Amanita muscaria. uuid:b143e17e-5665-4b6b-aa87-5377dc19a8e6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16684 biolink:treats EFO:0010581 PMID:41385096 "[{""id"":""uuid:43cc0158-0f78-4344-813d-636dd17ef786"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1e022795-2935-4f32-abc3-36c983d5f6c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atropine Sulfate Injection, USP, may be given parenterally as a pre-anesthetic medication in surgical patients to reduce salivation and bronchial secretions. It may also be used to suppress vagal activity associated with the use of halogenated hydrocarbons during inhalation anesthesia and reflex excitation arising from mechanical stimulation during surgery. The antispasmodic action of atropine is useful in pylorospasm and other spastic conditions of the gastrointestinal tract. For ureteral and biliary colic, atropine concomitantly with morphine may be indicated. Atropine relaxes the upper GI tract and colon during hypotonic radiography. In poisoning by the organic phosphate cholinesterase inhibitors found in certain insecticides and by chemical warfare nerve gases, large doses of atropine relieve the muscarine-like symptoms and some of the central nervous system manifestations. It is also used as an antidote for mushroom poisoning due to muscarine in certain species such as Amanita muscaria. uuid:bb62db7a-2b1d-4900-af74-cd3eef91bcba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49544 biolink:treats UMLS:C0268093 PMID:41385096 "[{""id"":""uuid:c1abf0cc-b64d-41e9-9cc9-f82b2b269aca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:828accbd-4bda-496e-b5e6-dd08419c311c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chromium 4 mcg/mL (Chromic Chloride Injection, USP) is indicated for use as a supplement to intravenous solutions given for TPN. Administration helps to maintain chromium serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms. uuid:e915540e-00b2-4199-a4a9-40d0c304d36b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0004126 PMID:41385096 "[{""id"":""uuid:1d6dd642-5f51-4bcb-88cb-0bdd15c8e5b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8f154f5f-02c3-41fa-bd4b-aa5f7975c408"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A. For Intramuscular Administration When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of Methylprednisolone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of: leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. B. For Intra-articular Or Soft Tissue Administration (See WARNINGS .) Methylprednisolone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. C. For Intralesional Administration Methylprednisolone Acetate Injectable Suspension is indicated for intralesional use in alopecia areata, discoid lupus erythematosus; keloids, localized hypertrophic, infiltrated inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis) and psoriatic plaques; necrobiosis lipoidica diabeticorum. Methylprednisolone Acetate Injectable Suspension also may be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:259f5654-930b-4936-818c-e542910f31ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0005340 PMID:41385096 "[{""id"":""uuid:e36758c2-c122-4c4a-a2f2-4e3fc378ca7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2697c076-48a4-4d94-ba72-e9c0b2a0efd1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A. For Intramuscular Administration When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of Methylprednisolone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of: leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. B. For Intra-articular Or Soft Tissue Administration (See WARNINGS .) Methylprednisolone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. C. For Intralesional Administration Methylprednisolone Acetate Injectable Suspension is indicated for intralesional use in alopecia areata, discoid lupus erythematosus; keloids, localized hypertrophic, infiltrated inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis) and psoriatic plaques; necrobiosis lipoidica diabeticorum. Methylprednisolone Acetate Injectable Suspension also may be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:ec68db6d-d70c-45ad-ad9e-0c28c6fe9ebe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0019558 PMID:41385096 "[{""id"":""uuid:a9273dc6-c385-4351-8ae3-5a8554c3d1b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7ee54b5a-2839-4ede-a37f-a9eb60250212"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A. For Intramuscular Administration When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of Methylprednisolone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of: leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. B. For Intra-articular Or Soft Tissue Administration (See WARNINGS .) Methylprednisolone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. C. For Intralesional Administration Methylprednisolone Acetate Injectable Suspension is indicated for intralesional use in alopecia areata, discoid lupus erythematosus; keloids, localized hypertrophic, infiltrated inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis) and psoriatic plaques; necrobiosis lipoidica diabeticorum. Methylprednisolone Acetate Injectable Suspension also may be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:e948700d-5468-4a96-ac5a-167b1c4f1669 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0005348 PMID:41385096 "[{""id"":""uuid:d5c15bcd-5243-4e13-aac1-0417e60cae14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5517928b-e598-4d9b-91c1-15db7c1996cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A. For Intramuscular Administration When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of Methylprednisolone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of: leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. B. For Intra-articular Or Soft Tissue Administration (See WARNINGS .) Methylprednisolone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. C. For Intralesional Administration Methylprednisolone Acetate Injectable Suspension is indicated for intralesional use in alopecia areata, discoid lupus erythematosus; keloids, localized hypertrophic, infiltrated inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis) and psoriatic plaques; necrobiosis lipoidica diabeticorum. Methylprednisolone Acetate Injectable Suspension also may be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:c5c4fea7-6f10-4ed5-b28c-0b7b4a3941ac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0006554 PMID:41385096 "[{""id"":""uuid:a76a87d0-e896-4a3b-b3ba-900779884564"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c2dd32bd-41af-4693-af6f-a2e1166be237"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A. For Intramuscular Administration When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of Methylprednisolone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of: leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. B. For Intra-articular Or Soft Tissue Administration (See WARNINGS .) Methylprednisolone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. C. For Intralesional Administration Methylprednisolone Acetate Injectable Suspension is indicated for intralesional use in alopecia areata, discoid lupus erythematosus; keloids, localized hypertrophic, infiltrated inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis) and psoriatic plaques; necrobiosis lipoidica diabeticorum. Methylprednisolone Acetate Injectable Suspension also may be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:ed41a986-0126-43f8-b6e8-eeaba2cbf323 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0006572 PMID:41385096 "[{""id"":""uuid:745ac776-891c-46ff-a2d3-f1188aa915a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:560d1ca5-1d07-4100-b585-c27fb23befbf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A. For Intramuscular Administration When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of Methylprednisolone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of: leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. B. For Intra-articular Or Soft Tissue Administration (See WARNINGS .) Methylprednisolone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. C. For Intralesional Administration Methylprednisolone Acetate Injectable Suspension is indicated for intralesional use in alopecia areata, discoid lupus erythematosus; keloids, localized hypertrophic, infiltrated inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis) and psoriatic plaques; necrobiosis lipoidica diabeticorum. Methylprednisolone Acetate Injectable Suspension also may be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:8bcf5f94-ba45-4612-989b-8b6816bc3201 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0006585 PMID:41385096 "[{""id"":""uuid:14b2a16b-2b72-4f0d-b048-d55ea38edd38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2e39a728-2fa2-4316-8187-1f01333967db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A. For Intramuscular Administration When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of Methylprednisolone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of: leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. B. For Intra-articular Or Soft Tissue Administration (See WARNINGS .) Methylprednisolone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. C. For Intralesional Administration Methylprednisolone Acetate Injectable Suspension is indicated for intralesional use in alopecia areata, discoid lupus erythematosus; keloids, localized hypertrophic, infiltrated inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis) and psoriatic plaques; necrobiosis lipoidica diabeticorum. Methylprednisolone Acetate Injectable Suspension also may be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:b4c1213e-6d47-4652-9394-49ad7c4198da biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats UMLS:C0392445 PMID:41385096 "[{""id"":""uuid:7cb4cd9d-1be5-459c-ba68-cc47541e34fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d3eeb553-6570-4537-a9d7-b59df2ea10c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A. For Intramuscular Administration When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of Methylprednisolone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of: leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic opthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. B. For Intra-articular Or Soft Tissue Administration (See WARNINGS .) Methylprednisolone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. C. For Intralesional Administration Methylprednisolone Acetate Injectable Suspension is indicated for intralesional use in alopecia areata, discoid lupus erythematosus; keloids, localized hypertrophic, infiltrated inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis) and psoriatic plaques; necrobiosis lipoidica diabeticorum. Methylprednisolone Acetate Injectable Suspension also may be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:47b238d3-f8bf-40b1-b7b0-bfee6052ea30 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7459 biolink:treats UMLS:C0572061 PMID:41385096 "[{""id"":""uuid:089aba9f-14c2-4b9e-9218-545bb35aa966"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:add35b67-2f3f-448b-bd01-77ec1e8e2145"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EVZIO is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression in adults and pediatric patients. EVZIO is intended for immediate administration as emergency therapy in settings where opioids may be present. EVZIO is not a substitute for emergency medical care. uuid:a3858e2b-b6a1-4fd2-8d04-640ed39c212f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6129 biolink:treats NCIT:C34887 PMID:41385096 "[{""id"":""uuid:55782799-ebc1-4d29-9d12-b2ba61da2615"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:13e9e7c0-9a86-4ad3-b6c2-2ca7ae8406d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks ketorolac tromethamine and other treatment options before deciding to use ketorolac. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS). Acute Pain in Adult Patients Ketorolac tromethamine is indicated for the short-term (≤5 days) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting. Therapy should always be initiated with IV or IM dosing of ketorolac tromethamine and oral ketorolac tromethamine is to be used only as continuation treatment, if necessary. The total combined duration of use of ketorolac tromethamine injection and oral ketorolac tromethamine is not to exceed 5 days of use because of the potential of increasing the frequency and severity of adverse reactions associated with the recommended doses (see WARNINGS, PRECAUTIONS, DOSAGE AND ADMINISTRATION, and ADVERSE REACTIONS). Patients should be switched to alternative analgesics as soon as possible, but ketorolac tromethamine therapy is not to exceed 5 days. (see DOSAGE AND ADMINISTRATION -Pharmaceutical Information for Ketorolac Tromethamine Injection). uuid:1f14cd91-2e7e-4e4e-92f4-b9ed6a174cf7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68554 biolink:treats MONDO:0859316 PMID:41385096 "[{""id"":""uuid:f88344ad-aef9-46be-b748-0cf20f2a6a74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f028021d-1e75-4aeb-9ffa-8b64637392e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FERRIPROX ® is indicated for the treatment of patients with transfusional iron overload due to thalassemia syndromes when current chelation therapy is inadequate. Approval is based on a reduction in serum ferritin levels. There are no controlled trials demonstrating a direct treatment benefit, such as improvement in disease-related symptoms, functioning, or increased survival [see Clinical Studies (14) ] . Limitations of Use Safety and effectiveness have not been established for the treatment of transfusional iron overload in patients with other chronic anemias. uuid:e8336885-4e5c-455c-98d2-059332171a80 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9570 biolink:treats MONDO:0004988 PMID:41385096 "[{""id"":""uuid:03d26901-ca81-45e5-b54f-20e21e8a9ba3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9e2904ca-24bf-4004-8878-79744bfc55bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thiotepa for injection is an alkylating drug indicated: For treatment of adenocarcinoma of the breast or ovary. ( 1.2 ) For controlling intracavitary effusions secondary to diffuse or localized neoplastic diseases of various serosal cavities. ( 1.3 ) For treatment of superficial papillary carcinoma of the urinary bladder. ( 1.4 ) uuid:8180b8c5-8f1c-4e27-b726-3307bf3f628f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9570 biolink:treats MONDO:0002752 PMID:41385096 "[{""id"":""uuid:23d65a23-54a0-406f-a711-e94330a18ff9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:632c7931-fc30-446b-a32a-20a5e8cc4e0f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thiotepa for injection is an alkylating drug indicated: For treatment of adenocarcinoma of the breast or ovary. ( 1.2 ) For controlling intracavitary effusions secondary to diffuse or localized neoplastic diseases of various serosal cavities. ( 1.3 ) For treatment of superficial papillary carcinoma of the urinary bladder. ( 1.4 ) uuid:237e6c43-2d2c-4266-8a4b-61ccb99cf7be biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9570 biolink:treats MONDO:0004200 PMID:41385096 "[{""id"":""uuid:835f5170-23bd-4806-a83f-c06cd983d838"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9f59269c-a5ea-456e-bd03-a7ed0fd0c84c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thiotepa for injection is an alkylating drug indicated: For treatment of adenocarcinoma of the breast or ovary. ( 1.2 ) For controlling intracavitary effusions secondary to diffuse or localized neoplastic diseases of various serosal cavities. ( 1.3 ) For treatment of superficial papillary carcinoma of the urinary bladder. ( 1.4 ) uuid:00dc7569-42ea-4985-84cc-538a12299f38 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:140296 biolink:treats MONDO:0001609 PMID:41385096 "[{""id"":""uuid:ff625786-f63b-40e7-b2e9-01ba96975022"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d8f12c94-4ba9-42c8-be78-fad6976161c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Quinapril tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with quinapril tablets, USP. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Quinapril tablets, USP may be used alone or in combination with thiazide diuretics . Heart Failure Quinapril tablets, USP are indicated in the management of heart failure as adjunctive therapy when added to conventional therapy including diuretics and/or digitalis. In using quinapril tablets, USP consideration should be given to the fact that another ACE inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease. Available data are insufficient to show that quinapril tablets, USP do not have a similar risk (see WARNINGS ). Angioedema in Black Patients Black patients receiving ACE inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to non-blacks. It should also be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. uuid:05ea690f-fd61-4d29-8656-bc6e5ac3c1fa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:140296 biolink:treats MONDO:0010481 PMID:41385096 "[{""id"":""uuid:e683b2d6-c345-4da3-868f-ae66df070188"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2846ce95-da1b-4831-b900-b02518a0f994"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Quinapril tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with quinapril tablets, USP. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Quinapril tablets, USP may be used alone or in combination with thiazide diuretics . Heart Failure Quinapril tablets, USP are indicated in the management of heart failure as adjunctive therapy when added to conventional therapy including diuretics and/or digitalis. In using quinapril tablets, USP consideration should be given to the fact that another ACE inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease. Available data are insufficient to show that quinapril tablets, USP do not have a similar risk (see WARNINGS ). Angioedema in Black Patients Black patients receiving ACE inhibitor monotherapy have been reported to have a higher incidence of angioedema compared to non-blacks. It should also be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. uuid:b67e7395-c763-409f-be73-2e07443276a7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4450 biolink:treats MONDO:0010191 PMID:41385096 "[{""id"":""uuid:2ee27698-83a6-474e-8105-ec0f72bca78b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1085ec32-b54a-47f0-8a91-3804b041c982"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hemophilia A: Desmopressin Acetate Injection 4 mcg/mL is indicated for patients with hemophilia A with factor VIII coagulant activity levels greater than 5%. Desmopressin Acetate Injection will often maintain hemostasis in patients with hemophilia A during surgical procedures and postoperatively when administered 30 minutes prior to scheduled procedure. Desmopressin Acetate Injection will also stop bleeding in hemophilia A patients with episodes of spontaneous or trauma-induced injuries such as hemarthroses, intramuscular hematomas or mucosal bleeding. Desmopressin Acetate Injection is not indicated for the treatment of hemophilia A with factor VIII coagulant activity levels equal to or less than 5%, or for the treatment of hemophilia B, or in patients who have factor VIII antibodies. In certain clinical situations, it may be justified to try Desmopressin Acetate Injection in patients with factor VIII levels between 2% to 5%; however, these patients should be carefully monitored. von Willebrands Disease (Type I): Desmopressin Acetate Injection 4 mcg/mL is indicated for patients with mild to moderate classic von Willebrands disease (Type I) with factor VIII levels greater than 5%. Desmopressin Acetate Injection will often maintain hemostasis in patients with mild to moderate von Willebrands disease during surgical procedures and postoperatively when administered 30 minutes prior to the scheduled procedure. Desmopressin Acetate Injection will usually stop bleeding in mild to moderate von Willebrands patients with episodes of spontaneous or trauma-induced injuries such as hemarthroses, intramuscular hematomas or mucosal bleeding. Those von Willebrands disease patients who are least likely to respond are those with severe homozygous von Willebrands disease with factor VIII coagulant activity and factor VIII von Willebrand factor antigen levels less than 1%. Other patients may respond in a variable fashion depending on the type of molecular defect they have. Bleeding time and factor VIII coagulant activity, ristocetin cofactor activity, and von Willebrand factor antigen should be checked during administration of Desmopressin Acetate Injection to ensure that adequate levels are being achieved. Desmopressin Acetate Injection is not indicated for the treatment of severe classic von Willebrands disease (Type I) and when there is evidence of an abnormal molecular form of factor VIII antigen. (See WARNINGS . ) Diabetes Insipidus: Desmopressin Acetate Injection 4 mcg/mL is indicated as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. Desmopressin Acetate Injection is ineffective for the treatment of nephrogenic diabetes insipidus. Desmopressin Acetate Injection is also available as an intranasal preparation. However, this means of delivery can be compromised by a variety of factors that can make nasal insufflation ineffective or inappropriate. These include poor intranasal absorption, nasal congestion and blockage, nasal discharge, atrophy of nasal mucosa, and severe atrophic rhinitis. Intranasal delivery may be inappropriate where there is an impaired level of consciousness. In addition, cranial surgical procedures, such as transsphenoidal hypophysectomy, create situations where an alternative route of administration is needed as in cases of nasal packing or recovery from surgery. uuid:8295d93d-1543-48d7-ae3e-b6b86c1c981f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49470 biolink:treats HP:0000225 PMID:41385096 "[{""id"":""uuid:dcf99967-d778-4641-89a6-dfdac8f1047e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a98d2789-b172-4fd4-8515-e48e9d094188"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nephro-Stat is a topical astringent solution of Aluminum Chloride. Gingival retraction can be achieved using a plain gingival retraction cord moistened with Nephro-Stat. Stops gingival bleeding fast. If you should inadvertently damage the gingival margin during tooth preparation or while placing a strip, a band or a cervical matrix, moisten the area with Nephro-Stat which will control and stop bleeding quickly. Nephro-Stat contains no epinephrine. The use of vasoconstrictors for gingival retractions and bleeding is potentially dangerous and should be avoided. A plain gingival retraction cord can be dipped in Nephro-Stat solution and then placed into the gingival sulcus for its hemostatic action. uuid:72a315fb-2b7c-4f0c-9f51-0d41030b2bba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4975 biolink:treats MONDO:0004247 PMID:41385096 "[{""id"":""uuid:591858ac-6f00-410d-a83d-b4356948947f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:45d03eb6-53dc-4dd0-828b-4f0a70da27b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Famotidine for oral suspension is indicated in adults for the treatment of: active duodenal ulcer (DU). active gastric ulcer (GU). symptomatic nonerosive gastroesophageal reflux disease (GERD). erosive esophagitis due to GERD, diagnosed by biopsy. treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). reduction of the risk of duodenal ulcer recurrence. Famotidine for oral suspension is indicated in pediatric patients 1 year of age and older for the treatment of: peptic ulcer disease. GERD with or without esophagitis and ulcerations. Famotidine for oral suspension is indicated in pediatric patients from birth to less than 1 year of age for the treatment of: GERD. uuid:38c9bcec-3c87-40f1-8a8e-a3976c622e08 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37943 biolink:treats MONDO:0005141 PMID:41385096 "[{""id"":""uuid:e93e21fa-f13d-4094-9d1f-c16f7ee5c0c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4e560dfe-808d-4a7b-934e-cc36823d36dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:331e5b36-1787-415d-aa85-2a5b5a8e74b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Colistimethate for Injection, USP is indicated for the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli. It is particularly indicated when the infection is caused by sensitive strains of Pseudomonas aeruginosa . This antibiotic is not indicated for infections due to Proteus or Neisseria . Colistimethate for Injection, USP has proven clinically effective in treatment of infections due to the following gram-negative organisms: Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa . Colistimethate for Injection, USP may be used to initiate therapy in serious infections that are suspected to be due to gram-negative organisms and in the treatment of infections due to susceptible gram-negative pathogenic bacilli. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Colistimethate for Injection, USP and other antibacterial drugs, Colistimethate for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.|[PMDA] A drug with a new route of administration indicated for the treatment of infections caused by colistin- sensitive Escherichia coli, Citrobacter, Klebsiella, Enterobacter, Pseudomonas aeruginosa, and Acinetobacter (limited to the strains resistant to other antimicrobial drugs). [Orphan drug] uuid:8128ab9f-e70d-44ff-a98b-a4053f579e65 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37943 biolink:treats MONDO:0020920 PMID:41385096 "[{""id"":""uuid:eeee5533-4ddb-4a42-93b5-d50f24809602"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:232275d2-e8dc-4e3c-a3e8-f79461e675ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c122a495-d802-4368-af17-89da9b6d82e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Colistimethate for Injection, USP is indicated for the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli. It is particularly indicated when the infection is caused by sensitive strains of Pseudomonas aeruginosa . This antibiotic is not indicated for infections due to Proteus or Neisseria . Colistimethate for Injection, USP has proven clinically effective in treatment of infections due to the following gram-negative organisms: Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa . Colistimethate for Injection, USP may be used to initiate therapy in serious infections that are suspected to be due to gram-negative organisms and in the treatment of infections due to susceptible gram-negative pathogenic bacilli. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Colistimethate for Injection, USP and other antibacterial drugs, Colistimethate for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.|[PMDA] A drug with a new route of administration indicated for the treatment of infections caused by colistin- sensitive Escherichia coli, Citrobacter, Klebsiella, Enterobacter, Pseudomonas aeruginosa, and Acinetobacter (limited to the strains resistant to other antimicrobial drugs). [Orphan drug] uuid:a6b772b5-579c-4dfb-8723-57fbde8f6c72 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37943 biolink:treats MONDO:0030602 PMID:41385096 "[{""id"":""uuid:2299b3fa-0c3e-4ab4-97da-1e2a2f4ea0de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:076b59dc-b270-4d79-8f3f-c0280819fa12"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Colistimethate for Injection, USP is indicated for the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli. It is particularly indicated when the infection is caused by sensitive strains of Pseudomonas aeruginosa . This antibiotic is not indicated for infections due to Proteus or Neisseria . Colistimethate for Injection, USP has proven clinically effective in treatment of infections due to the following gram-negative organisms: Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa . Colistimethate for Injection, USP may be used to initiate therapy in serious infections that are suspected to be due to gram-negative organisms and in the treatment of infections due to susceptible gram-negative pathogenic bacilli. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Colistimethate for Injection, USP and other antibacterial drugs, Colistimethate for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:46b01983-aee3-4458-88cd-ee0674e34dd8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63580 biolink:treats MONDO:0001577 PMID:41385096 "[{""id"":""uuid:c79bc570-3581-49c0-a329-d6932982961b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:403af124-7c87-4204-b8b2-ec9d21317683"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ribavirin for Inhalation Solution, USP is indicated for the treatment of hospitalized infants and young children with severe lower respiratory tract infections due to RSV. Treatment early in the course of severe lower respiratory tract infection may be necessary to achieve efficacy. Only severe RSV lower respiratory tract infection should be treated with Ribavirin for Inhalation Solution, USP. The vast majority of infants and children with RSV infection have disease that is mild, self-limited, and does not require hospitalization or antiviral treatment. Many children with mild lower respiratory tract involvement will require shorter hospitalization than would be required for a full course of Ribavirin for Inhalation Solution, USP aerosol (3 to 7 days) and should not be treated with the drug. Thus the decision to treat with Ribavirin for Inhalation Solution, USP should be based on the severity of the RSV infection. The presence of an underlying condition such as prematurity, immunosuppression or cardiopulmonary disease may increase the severity of clinical manifestations and complications of RSV infection. Use of aerosolized Ribavirin for Inhalation Solution, USP in patients requiring mechanical ventilator assistance should be undertaken only by physicians and support staff familiar with this mode of administration and the specific ventilator being used (see WARNINGS and DOSAGE AND ADMINISTRATION ). uuid:3508ed2d-13f5-4717-a51b-fb05963507e2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:310870 biolink:treats MONDO:0005480 PMID:41385096 "[{""id"":""uuid:b321b82b-fb98-4d29-b701-6b1f399cb05a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:04d0363f-cbd7-4fa9-985f-1b2bedc372bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] INDICATIONS AND USAGE Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; infantile eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis, bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis, intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:a103ed6f-5906-474c-81e4-5cc61f205c9e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:310870 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:68a7bd6e-1a2c-47fc-bcd4-201b8f98683d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9d0fd43a-b676-4f56-a9fa-da2f56716470"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] INDICATIONS AND USAGE Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; infantile eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis, bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis, intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:68e31265-995c-46df-b78a-7b66697f74fc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:310870 biolink:treats MONDO:0002406 PMID:41385096 "[{""id"":""uuid:98492fc6-d0e9-413d-bfbb-096e6c22f9e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e5efa49c-08d6-4c4f-be0c-b2f0c526f957"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] INDICATIONS AND USAGE Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; infantile eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis, bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis, intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:56f97e9c-f675-40f6-aa28-40fcade01c1a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:310870 biolink:treats HP:0033120 PMID:41385096 "[{""id"":""uuid:495b8218-1ba3-4d40-8b8c-033e85e7eb95"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f27ac3f3-f5bf-4f7e-befb-9420766489ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] INDICATIONS AND USAGE Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; infantile eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis, bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis, intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:5f9a6eec-1fc2-4c66-9e8c-aa4b9bb95054 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:310870 biolink:treats HP:0033564 PMID:41385096 "[{""id"":""uuid:1a0ac251-2710-4dbc-b970-87a5a693cfa0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:990eab6b-ccb4-4fc9-afdb-38e645b795be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] INDICATIONS AND USAGE Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; infantile eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis, bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis, intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:12261890-1c06-4652-8489-359147119b98 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:310870 biolink:treats MONDO:0002922 PMID:41385096 "[{""id"":""uuid:c91a2c54-9784-4c24-b692-cf897d6368e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3c5e7d61-6a40-459d-a1b8-cb970df236eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] INDICATIONS AND USAGE Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; infantile eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis, bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis, intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:a15c5a52-ef4b-423a-bffd-d9f4182171c7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:310870 biolink:treats MONDO:0004795 PMID:41385096 "[{""id"":""uuid:ff28fa17-14c0-4b6c-9f2c-a67273765d67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8bb4e185-bfae-4f82-986b-4d18d0c0e894"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] INDICATIONS AND USAGE Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; infantile eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis, bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis, intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:3099cac1-8f84-4ffc-8fd4-0404134172f0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:310870 biolink:treats UMLS:C0406297 PMID:41385096 "[{""id"":""uuid:42a6e4eb-f198-47b6-a2d9-0d7b41e082c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c4233dbc-4999-40c5-9fcd-54b276822a24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] INDICATIONS AND USAGE Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; infantile eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis, bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis, intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:bc893856-2a86-4869-9050-1949a2ef5aca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:310870 biolink:treats MONDO:0006585 PMID:41385096 "[{""id"":""uuid:efee9811-3d58-484b-8967-48221e46b25a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c55c538a-d399-4a7a-87ba-4858fd5527b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] INDICATIONS AND USAGE Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; infantile eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis, bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis, intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:17365c26-abcd-439c-a0eb-d8f0498875e6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:310870 biolink:treats UMLS:C0149922 PMID:41385096 "[{""id"":""uuid:78be24f6-36d9-43b6-9694-994433fd0c1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4250392d-8561-400e-8e31-a8837962ed06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] INDICATIONS AND USAGE Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; infantile eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis, bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis, intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:a2019081-1544-40c9-89ba-e19fe1db5f2d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:310870 biolink:treats UMLS:C0003107 PMID:41385096 "[{""id"":""uuid:ebc19f23-1680-48e6-97b4-09d25222ef1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f33d9ccb-7b45-484c-beb9-3ac69a96c366"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] INDICATIONS AND USAGE Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; infantile eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis, bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis, intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:d9f97ee6-e1f3-4898-9899-41551e265a2c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:310870 biolink:treats MONDO:0006552 PMID:41385096 "[{""id"":""uuid:e1ff89bf-7ae0-4ad5-ac45-474c091a3bcd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aa418270-139a-4a9e-a921-6ac75cc97f69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] INDICATIONS AND USAGE Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; infantile eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis, bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis, intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:8d9de2fd-d124-4e27-b889-f17e052d2dd6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:310870 biolink:treats MONDO:0002967 PMID:41385096 "[{""id"":""uuid:9ff54aa6-76ab-4336-8ab6-123519301c34"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:92f5c83a-6db2-4e35-a992-56a801d19666"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] INDICATIONS AND USAGE Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; infantile eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis, bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis, intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:ea7cf05c-eddb-4b58-b637-f5c13f92106e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:310870 biolink:treats MONDO:0001405 PMID:41385096 "[{""id"":""uuid:4d285fcd-a85e-4a7b-9c02-5eb3e64884d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:61e609b5-a5a7-4587-8c46-0d379b307337"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] INDICATIONS AND USAGE Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; infantile eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis, bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis, intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:907b0085-6544-4f6a-9e5e-4d401ab15341 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:310870 biolink:treats MONDO:0001461 PMID:41385096 "[{""id"":""uuid:03903de1-4b28-4253-9df4-50e8dad7fd1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7395fc84-6797-473e-8315-974393581dcf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] INDICATIONS AND USAGE Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; infantile eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis, bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis, intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:2b295b14-9dab-44c0-a2b3-e5bdd6f64f98 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:310870 biolink:treats MONDO:0005984 PMID:41385096 "[{""id"":""uuid:6d8dcfbc-00bb-4291-a8ac-bee9da45121d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:48b611b4-0f6e-48f8-b92a-49fda27b06d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] INDICATIONS AND USAGE Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; infantile eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis, bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis, intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:4df95188-5cd6-4c33-bfcf-6cf8cf86b647 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:310870 biolink:treats UMLS:C0343886 PMID:41385096 "[{""id"":""uuid:7626c8ef-1eda-49d8-846b-569708ea9ff6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d82f142c-8378-4fdd-b424-0e506a83da4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] INDICATIONS AND USAGE Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; infantile eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis, bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis, intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:c581416b-bade-4eb1-9fef-e9384751f8d1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:310870 biolink:treats MONDO:0021340 PMID:41385096 "[{""id"":""uuid:e0f1a58f-ed3a-48d2-bf2a-01c58770e222"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:43084199-dd15-4e5c-9182-65685b338045"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] INDICATIONS AND USAGE Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: ""Possibly"" Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; infantile eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis, bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis, intertrigo. Final classification of the less-than-effective indications requires further investigation." uuid:2b9647a8-cec1-4f38-b4cb-e1ec493eaadc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1156610 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:fb9ddca3-7d76-45d6-b65c-735bed6c19ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a49310b9-7dbd-4503-b015-520ffa0efd58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ATACAND HCT is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with ATACAND HCT. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed dose combination is not indicated for initial therapy (see DOSAGE AND ADMINISTRATION ). uuid:8e19d044-47cd-49c6-83fa-72045e3855de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1156610 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:f2e20985-e63d-40e0-be77-2f2058595764"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:62962df4-ad72-45ad-be5c-5ae7a209da56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ATACAND HCT is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with ATACAND HCT. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed dose combination is not indicated for initial therapy (see DOSAGE AND ADMINISTRATION ). uuid:3608a23d-ea0e-4dc0-ae12-cc039c45faab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1156610 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:063f9f92-17c9-4eb5-87fd-0c53c4162ff6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4cab4d17-e1ce-4070-9e3f-1c632a759db1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ATACAND HCT is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with ATACAND HCT. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed dose combination is not indicated for initial therapy (see DOSAGE AND ADMINISTRATION ). uuid:294a6196-d4a3-4712-bf76-a49026019eb9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1156610 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:b7d4e40a-f1d4-40df-833e-1ee0ab4feb68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d9c0bb15-8deb-494b-8e81-4f6b73445e38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ATACAND HCT is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with ATACAND HCT. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed dose combination is not indicated for initial therapy (see DOSAGE AND ADMINISTRATION ). uuid:5dec9d85-72d4-49fe-bcd6-d14db68a3643 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1156610 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:a4b83898-b971-4fd4-8ae3-74a88daedd24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:deef95a3-8648-4aba-9144-1bd05d84d53b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ATACAND HCT is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with ATACAND HCT. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed dose combination is not indicated for initial therapy (see DOSAGE AND ADMINISTRATION ). uuid:a1e0d400-7167-4b81-9eff-a9c02bae20b7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1156610 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:9c01ea62-b0cc-4b42-9143-1c3f40ac96f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:163f2a92-d2ce-4598-bd6b-aea75888fa5d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ATACAND HCT is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with ATACAND HCT. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed dose combination is not indicated for initial therapy (see DOSAGE AND ADMINISTRATION ). uuid:970eb312-cc4f-4608-b1a8-a43a3196cb97 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1156610 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:06a36c40-0d1c-40e1-9f09-ca3bedde830d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:09bb517a-a055-49a3-b4c1-2247e773bc91"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ATACAND HCT is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with ATACAND HCT. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed dose combination is not indicated for initial therapy (see DOSAGE AND ADMINISTRATION ). uuid:462284a9-9149-444a-a709-5a4706e4cb8d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15544 biolink:treats MONDO:0009931 PMID:41385096 "[{""id"":""uuid:4ecc6a45-8513-47b9-9156-a663e736c881"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:acfab0ce-4f09-4fba-8a04-9a526228fa28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROSTIN VR PEDIATRIC Sterile Solution is indicated for palliative, not definitive, therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival. Such congenital heart defects include pulmonary atresia, pulmonary stenosis, tricuspid atresia, tetralogy of Fallot, interruption of the aortic arch, coarctation of the aorta, or transposition of the great vessels with or without other defects. In infants with restricted pulmonary blood flow, the increase in blood oxygenation is inversely proportional to pretreatment pO 2 values; that is, patients with low pO 2 values respond best, and patients with pO 2 values of 40 torr or more usually have little response. PROSTIN VR PEDIATRIC should be administered only by trained personnel in facilities that provide pediatric intensive care. uuid:f3c9c9ee-be04-4c16-8bb9-d4720e886bf7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15544 biolink:treats MONDO:0009938 PMID:41385096 "[{""id"":""uuid:2317567d-4311-464a-ad8d-f59370cb627c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9ff1449b-9945-49ae-9c05-6b21dc822d17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROSTIN VR PEDIATRIC Sterile Solution is indicated for palliative, not definitive, therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival. Such congenital heart defects include pulmonary atresia, pulmonary stenosis, tricuspid atresia, tetralogy of Fallot, interruption of the aortic arch, coarctation of the aorta, or transposition of the great vessels with or without other defects. In infants with restricted pulmonary blood flow, the increase in blood oxygenation is inversely proportional to pretreatment pO 2 values; that is, patients with low pO 2 values respond best, and patients with pO 2 values of 40 torr or more usually have little response. PROSTIN VR PEDIATRIC should be administered only by trained personnel in facilities that provide pediatric intensive care. uuid:d4368fef-8911-4bd5-ba66-7489036512d4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15544 biolink:treats MONDO:0011514 PMID:41385096 "[{""id"":""uuid:8a442fd2-d57f-4fbc-88b3-e76e88c00202"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6eeebe80-de98-4028-aace-bef5f7e7319c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROSTIN VR PEDIATRIC Sterile Solution is indicated for palliative, not definitive, therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival. Such congenital heart defects include pulmonary atresia, pulmonary stenosis, tricuspid atresia, tetralogy of Fallot, interruption of the aortic arch, coarctation of the aorta, or transposition of the great vessels with or without other defects. In infants with restricted pulmonary blood flow, the increase in blood oxygenation is inversely proportional to pretreatment pO 2 values; that is, patients with low pO 2 values respond best, and patients with pO 2 values of 40 torr or more usually have little response. PROSTIN VR PEDIATRIC should be administered only by trained personnel in facilities that provide pediatric intensive care. uuid:3c2e0ce3-e371-4e55-ab9d-5f3e46438c5b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15544 biolink:treats MONDO:0008542 PMID:41385096 "[{""id"":""uuid:37b361b4-6e95-4751-a245-30338c478d18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e85b6f1d-f273-4203-97de-355618268e13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROSTIN VR PEDIATRIC Sterile Solution is indicated for palliative, not definitive, therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival. Such congenital heart defects include pulmonary atresia, pulmonary stenosis, tricuspid atresia, tetralogy of Fallot, interruption of the aortic arch, coarctation of the aorta, or transposition of the great vessels with or without other defects. In infants with restricted pulmonary blood flow, the increase in blood oxygenation is inversely proportional to pretreatment pO 2 values; that is, patients with low pO 2 values respond best, and patients with pO 2 values of 40 torr or more usually have little response. PROSTIN VR PEDIATRIC should be administered only by trained personnel in facilities that provide pediatric intensive care. uuid:031ceef1-50ee-48ae-97c8-dee2ca1c77dd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15544 biolink:treats MONDO:0009010 PMID:41385096 "[{""id"":""uuid:f5b0e175-9d62-45f0-9d57-3094aeb30023"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a649a977-bd2c-417c-8dfa-3b9449ac1d88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROSTIN VR PEDIATRIC Sterile Solution is indicated for palliative, not definitive, therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival. Such congenital heart defects include pulmonary atresia, pulmonary stenosis, tricuspid atresia, tetralogy of Fallot, interruption of the aortic arch, coarctation of the aorta, or transposition of the great vessels with or without other defects. In infants with restricted pulmonary blood flow, the increase in blood oxygenation is inversely proportional to pretreatment pO 2 values; that is, patients with low pO 2 values respond best, and patients with pO 2 values of 40 torr or more usually have little response. PROSTIN VR PEDIATRIC should be administered only by trained personnel in facilities that provide pediatric intensive care. uuid:efdb713c-6a3d-4856-aacb-b7385d299070 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15544 biolink:treats MONDO:0007345 PMID:41385096 "[{""id"":""uuid:f6f46e27-74b3-45f5-b5e8-f9051eecbdc3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d137b78f-92f9-477a-a918-1a1ebffe4fcb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROSTIN VR PEDIATRIC Sterile Solution is indicated for palliative, not definitive, therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival. Such congenital heart defects include pulmonary atresia, pulmonary stenosis, tricuspid atresia, tetralogy of Fallot, interruption of the aortic arch, coarctation of the aorta, or transposition of the great vessels with or without other defects. In infants with restricted pulmonary blood flow, the increase in blood oxygenation is inversely proportional to pretreatment pO 2 values; that is, patients with low pO 2 values respond best, and patients with pO 2 values of 40 torr or more usually have little response. PROSTIN VR PEDIATRIC should be administered only by trained personnel in facilities that provide pediatric intensive care. uuid:0ecc3d6a-9092-4392-8313-50f1d2724bfa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15544 biolink:treats MONDO:0000153 PMID:41385096 "[{""id"":""uuid:ed60f7ff-5689-4609-b3b8-2130e1c0e187"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:65a53261-0751-4aa5-b341-5ba2642b3749"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROSTIN VR PEDIATRIC Sterile Solution is indicated for palliative, not definitive, therapy to temporarily maintain the patency of the ductus arteriosus until corrective or palliative surgery can be performed in neonates who have congenital heart defects and who depend upon the patent ductus for survival. Such congenital heart defects include pulmonary atresia, pulmonary stenosis, tricuspid atresia, tetralogy of Fallot, interruption of the aortic arch, coarctation of the aorta, or transposition of the great vessels with or without other defects. In infants with restricted pulmonary blood flow, the increase in blood oxygenation is inversely proportional to pretreatment pO 2 values; that is, patients with low pO 2 values respond best, and patients with pO 2 values of 40 torr or more usually have little response. PROSTIN VR PEDIATRIC should be administered only by trained personnel in facilities that provide pediatric intensive care. uuid:31d23061-267c-4530-bf56-5c543544e596 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18385 biolink:treats UMLS:C0342936 PMID:41385096 "[{""id"":""uuid:31dad26e-05cd-4067-aaf3-3a23247a283e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:910cbb2c-793c-42e2-8231-3d25593e30de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thiamine hydrochloride injection is effective for the treatment of thiamine deficiency or beriberi whether of the dry (major symptoms related to the nervous system) or wet (major symptoms related to the cardiovascular system) variety. Thiamine hydrochloride injection should be used where rapid restoration of thiamine is necessary, as in Wernicke’s encephalopathy, infantile beriberi with acute collapse, cardiovascular disease due to thiamine deficiency, or neuritis of pregnancy if vomiting is severe. It is also indicated when giving IV dextrose to individuals with marginal thiamine status to avoid precipitation of heart failure. Thiamine hydrochloride injection is also indicated in patients with established thiamine deficiency who cannot take thiamine orally due to coexisting severe anorexia, nausea, vomiting, or malabsorption. Thiamine hydrochloride injection is not usually indicated for conditions of decreased oral intake or decreased gastrointestinal absorption, because multiple vitamins should usually be given. uuid:417aeeed-0f6c-4ef1-8b1b-87352a10002d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18385 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:c99602e4-d303-469c-b54e-dda76de37d5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:af3282ca-814d-4050-9d93-75ddfce6d809"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thiamine hydrochloride injection is effective for the treatment of thiamine deficiency or beriberi whether of the dry (major symptoms related to the nervous system) or wet (major symptoms related to the cardiovascular system) variety. Thiamine hydrochloride injection should be used where rapid restoration of thiamine is necessary, as in Wernicke’s encephalopathy, infantile beriberi with acute collapse, cardiovascular disease due to thiamine deficiency, or neuritis of pregnancy if vomiting is severe. It is also indicated when giving IV dextrose to individuals with marginal thiamine status to avoid precipitation of heart failure. Thiamine hydrochloride injection is also indicated in patients with established thiamine deficiency who cannot take thiamine orally due to coexisting severe anorexia, nausea, vomiting, or malabsorption. Thiamine hydrochloride injection is not usually indicated for conditions of decreased oral intake or decreased gastrointestinal absorption, because multiple vitamins should usually be given. uuid:222b4fe9-3d9f-4cee-b47d-fc33c7e6a373 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0700217 PMID:41385096 "[{""id"":""uuid:3b285505-9b02-4895-b777-7d62d3742d20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:de41084c-e9b4-4feb-9c25-70471fda6027"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Penicillin G Sodium for Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Sodium for Injection, USP may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below, however, once these results become available, appropriate therapy should be continued. Clinical Indication Infecting Organism Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non- penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico- facial disease and thoracic and abdominal disease) Actinomyces Israelil Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopthiae Fusospirochetosis (severe infections of the oropharynx [Vincent’s], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat-bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococcal meningitis and/or septicemia Neisseria meningitidis Gram-negative bacillary infections (bacteremias) Escherichia coli, Enterobacter aerogenes, Alcaligenes faecalis, salmonella, shigella and Proteus mirabilis, Penicillin G is not the drug of choice in the treatment of gram-negative bacillary infections. To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin G sodium and other antibacterial drugs, penicillin G sodium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. CHEBI:18208 uuid:b24a4b71-87c5-4c59-a33c-f8924d993d49 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0005242 PMID:41385096 "[{""id"":""uuid:cc54837a-c61a-426a-9b85-96ce0da7496d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:733411b7-a280-4c16-bd3a-c656764570e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Penicillin G Sodium for Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Sodium for Injection, USP may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below, however, once these results become available, appropriate therapy should be continued. Clinical Indication Infecting Organism Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non- penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico- facial disease and thoracic and abdominal disease) Actinomyces Israelil Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopthiae Fusospirochetosis (severe infections of the oropharynx [Vincent’s], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat-bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococcal meningitis and/or septicemia Neisseria meningitidis Gram-negative bacillary infections (bacteremias) Escherichia coli, Enterobacter aerogenes, Alcaligenes faecalis, salmonella, shigella and Proteus mirabilis, Penicillin G is not the drug of choice in the treatment of gram-negative bacillary infections. To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin G sodium and other antibacterial drugs, penicillin G sodium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. CHEBI:18208 uuid:eceb07c5-0fb6-4835-a69a-dee34021f5a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0005904 PMID:41385096 "[{""id"":""uuid:8e497ec0-4d96-4641-825f-3862b6b3a5b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:daeb0f6f-899d-4fa8-b818-68c16267abac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Penicillin G Sodium for Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Sodium for Injection, USP may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below, however, once these results become available, appropriate therapy should be continued. Clinical Indication Infecting Organism Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non- penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico- facial disease and thoracic and abdominal disease) Actinomyces Israelil Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopthiae Fusospirochetosis (severe infections of the oropharynx [Vincent’s], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat-bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococcal meningitis and/or septicemia Neisseria meningitidis Gram-negative bacillary infections (bacteremias) Escherichia coli, Enterobacter aerogenes, Alcaligenes faecalis, salmonella, shigella and Proteus mirabilis, Penicillin G is not the drug of choice in the treatment of gram-negative bacillary infections. To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin G sodium and other antibacterial drugs, penicillin G sodium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. CHEBI:18208 uuid:a46d63fb-7e28-40ba-8319-acfb6095bae7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0005025 PMID:41385096 "[{""id"":""uuid:5c72e95c-5cdc-42b7-b36b-a8d4911aa41c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:038bc590-738b-4a9b-8833-41af110d1333"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Penicillin G Sodium for Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Sodium for Injection, USP may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below, however, once these results become available, appropriate therapy should be continued. Clinical Indication Infecting Organism Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non- penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico- facial disease and thoracic and abdominal disease) Actinomyces Israelil Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopthiae Fusospirochetosis (severe infections of the oropharynx [Vincent’s], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat-bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococcal meningitis and/or septicemia Neisseria meningitidis Gram-negative bacillary infections (bacteremias) Escherichia coli, Enterobacter aerogenes, Alcaligenes faecalis, salmonella, shigella and Proteus mirabilis, Penicillin G is not the drug of choice in the treatment of gram-negative bacillary infections. To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin G sodium and other antibacterial drugs, penicillin G sodium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. CHEBI:18208 uuid:1b1e23e5-376e-4e55-a02d-f00e1acd9f8d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0021108 PMID:41385096 "[{""id"":""uuid:c00b817b-146a-425c-bab1-770e2b7c8d05"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e5f6a246-fcfe-4626-adf0-1776dd1035b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Penicillin G Sodium for Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Sodium for Injection, USP may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below, however, once these results become available, appropriate therapy should be continued. Clinical Indication Infecting Organism Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non- penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico- facial disease and thoracic and abdominal disease) Actinomyces Israelil Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopthiae Fusospirochetosis (severe infections of the oropharynx [Vincent’s], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat-bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococcal meningitis and/or septicemia Neisseria meningitidis Gram-negative bacillary infections (bacteremias) Escherichia coli, Enterobacter aerogenes, Alcaligenes faecalis, salmonella, shigella and Proteus mirabilis, Penicillin G is not the drug of choice in the treatment of gram-negative bacillary infections. To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin G sodium and other antibacterial drugs, penicillin G sodium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. CHEBI:18208 uuid:945babe5-4432-4b49-889b-6700de19bfdd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0005119 PMID:41385096 "[{""id"":""uuid:3b512c08-2b87-4e8c-ba33-e65b04de590b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:319690ec-e940-4adf-bbea-84c1d251558c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Penicillin G Sodium for Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Sodium for Injection, USP may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below, however, once these results become available, appropriate therapy should be continued. Clinical Indication Infecting Organism Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non- penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico- facial disease and thoracic and abdominal disease) Actinomyces Israelil Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopthiae Fusospirochetosis (severe infections of the oropharynx [Vincent’s], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat-bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococcal meningitis and/or septicemia Neisseria meningitidis Gram-negative bacillary infections (bacteremias) Escherichia coli, Enterobacter aerogenes, Alcaligenes faecalis, salmonella, shigella and Proteus mirabilis, Penicillin G is not the drug of choice in the treatment of gram-negative bacillary infections. To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin G sodium and other antibacterial drugs, penicillin G sodium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. CHEBI:18208 uuid:fd0c1d1a-430a-4394-bc7e-67b3cc3dddad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0005498 PMID:41385096 "[{""id"":""uuid:1de7d218-d9b7-4501-871b-bed19e85b54e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d68ab966-92de-4824-8584-d52ea64236e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Penicillin G Sodium for Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Sodium for Injection, USP may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below, however, once these results become available, appropriate therapy should be continued. Clinical Indication Infecting Organism Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non- penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico- facial disease and thoracic and abdominal disease) Actinomyces Israelil Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopthiae Fusospirochetosis (severe infections of the oropharynx [Vincent’s], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat-bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococcal meningitis and/or septicemia Neisseria meningitidis Gram-negative bacillary infections (bacteremias) Escherichia coli, Enterobacter aerogenes, Alcaligenes faecalis, salmonella, shigella and Proteus mirabilis, Penicillin G is not the drug of choice in the treatment of gram-negative bacillary infections. To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin G sodium and other antibacterial drugs, penicillin G sodium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. CHEBI:18208 uuid:f91cd919-d6ab-45f0-9228-2f617d87141d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0005767 PMID:41385096 "[{""id"":""uuid:2484ea88-b9ad-4d6a-a827-3cd9b17c4faf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a4599ae6-3e1c-4229-b4c1-bce98885ca82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Penicillin G Sodium for Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Sodium for Injection, USP may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below, however, once these results become available, appropriate therapy should be continued. Clinical Indication Infecting Organism Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non- penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico- facial disease and thoracic and abdominal disease) Actinomyces Israelil Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopthiae Fusospirochetosis (severe infections of the oropharynx [Vincent’s], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat-bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococcal meningitis and/or septicemia Neisseria meningitidis Gram-negative bacillary infections (bacteremias) Escherichia coli, Enterobacter aerogenes, Alcaligenes faecalis, salmonella, shigella and Proteus mirabilis, Penicillin G is not the drug of choice in the treatment of gram-negative bacillary infections. To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin G sodium and other antibacterial drugs, penicillin G sodium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. CHEBI:18208 uuid:0b341ba4-6f7d-4643-ad03-26d800b4f05e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0005526 PMID:41385096 "[{""id"":""uuid:3583ec15-3765-4748-87be-85abe4251828"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:593e0d1e-f968-41e2-9831-32b611e68d39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Penicillin G Sodium for Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Sodium for Injection, USP may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below, however, once these results become available, appropriate therapy should be continued. Clinical Indication Infecting Organism Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non- penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico- facial disease and thoracic and abdominal disease) Actinomyces Israelil Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopthiae Fusospirochetosis (severe infections of the oropharynx [Vincent’s], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat-bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococcal meningitis and/or septicemia Neisseria meningitidis Gram-negative bacillary infections (bacteremias) Escherichia coli, Enterobacter aerogenes, Alcaligenes faecalis, salmonella, shigella and Proteus mirabilis, Penicillin G is not the drug of choice in the treatment of gram-negative bacillary infections. To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin G sodium and other antibacterial drugs, penicillin G sodium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. CHEBI:18208 uuid:2ce4e651-b581-4b8a-b8b1-ca7977532546 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0005504 PMID:41385096 "[{""id"":""uuid:c2dfe0dd-a53f-4e6f-b2ac-fb54e6264413"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:561dcf62-eaa4-419e-a299-5db788090049"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Penicillin G Sodium for Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Sodium for Injection, USP may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below, however, once these results become available, appropriate therapy should be continued. Clinical Indication Infecting Organism Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non- penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico- facial disease and thoracic and abdominal disease) Actinomyces Israelil Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopthiae Fusospirochetosis (severe infections of the oropharynx [Vincent’s], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat-bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococcal meningitis and/or septicemia Neisseria meningitidis Gram-negative bacillary infections (bacteremias) Escherichia coli, Enterobacter aerogenes, Alcaligenes faecalis, salmonella, shigella and Proteus mirabilis, Penicillin G is not the drug of choice in the treatment of gram-negative bacillary infections. To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin G sodium and other antibacterial drugs, penicillin G sodium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. CHEBI:18208 uuid:8e813710-1cfd-437e-8f02-7e357558be5d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0006669 PMID:41385096 "[{""id"":""uuid:02e6c52d-6810-45fe-baf9-263744093bef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:646d40b6-525c-43c0-ab47-75e6e0e7701b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Penicillin G Sodium for Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Sodium for Injection, USP may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below, however, once these results become available, appropriate therapy should be continued. Clinical Indication Infecting Organism Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non- penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico- facial disease and thoracic and abdominal disease) Actinomyces Israelil Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopthiae Fusospirochetosis (severe infections of the oropharynx [Vincent’s], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat-bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococcal meningitis and/or septicemia Neisseria meningitidis Gram-negative bacillary infections (bacteremias) Escherichia coli, Enterobacter aerogenes, Alcaligenes faecalis, salmonella, shigella and Proteus mirabilis, Penicillin G is not the drug of choice in the treatment of gram-negative bacillary infections. To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin G sodium and other antibacterial drugs, penicillin G sodium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. CHEBI:18208 uuid:f31c648b-7a63-4a5c-b451-6386b486b42c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0005828 PMID:41385096 "[{""id"":""uuid:78ea9ff8-923c-4afa-8d0e-77d870b7c4c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e9f13d31-d7b0-443f-b6e8-55068b5f6b22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Penicillin G Sodium for Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Sodium for Injection, USP may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below, however, once these results become available, appropriate therapy should be continued. Clinical Indication Infecting Organism Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non- penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico- facial disease and thoracic and abdominal disease) Actinomyces Israelil Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopthiae Fusospirochetosis (severe infections of the oropharynx [Vincent’s], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat-bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococcal meningitis and/or septicemia Neisseria meningitidis Gram-negative bacillary infections (bacteremias) Escherichia coli, Enterobacter aerogenes, Alcaligenes faecalis, salmonella, shigella and Proteus mirabilis, Penicillin G is not the drug of choice in the treatment of gram-negative bacillary infections. To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin G sodium and other antibacterial drugs, penicillin G sodium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. CHEBI:18208 uuid:841755ff-cd4d-4cec-b9e9-465f5049b68a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0005901 PMID:41385096 "[{""id"":""uuid:e1ad226e-75e3-4d1a-9b95-57cd2a71c732"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:70eba252-372c-429c-b6b4-abcbc3a4fb4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Penicillin G Sodium for Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Sodium for Injection, USP may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below, however, once these results become available, appropriate therapy should be continued. Clinical Indication Infecting Organism Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non- penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico- facial disease and thoracic and abdominal disease) Actinomyces Israelil Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopthiae Fusospirochetosis (severe infections of the oropharynx [Vincent’s], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat-bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococcal meningitis and/or septicemia Neisseria meningitidis Gram-negative bacillary infections (bacteremias) Escherichia coli, Enterobacter aerogenes, Alcaligenes faecalis, salmonella, shigella and Proteus mirabilis, Penicillin G is not the drug of choice in the treatment of gram-negative bacillary infections. To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin G sodium and other antibacterial drugs, penicillin G sodium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. CHEBI:18208 uuid:fed6b3f8-883d-46e6-b01d-56fe43d1dabd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0020533 PMID:41385096 "[{""id"":""uuid:33f0cf01-1d5a-43bd-a7d9-2050727d782b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b33cfe0b-31a2-45c3-bc32-1484bf518839"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Penicillin G Sodium for Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Sodium for Injection, USP may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below, however, once these results become available, appropriate therapy should be continued. Clinical Indication Infecting Organism Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non- penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico- facial disease and thoracic and abdominal disease) Actinomyces Israelil Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopthiae Fusospirochetosis (severe infections of the oropharynx [Vincent’s], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat-bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococcal meningitis and/or septicemia Neisseria meningitidis Gram-negative bacillary infections (bacteremias) Escherichia coli, Enterobacter aerogenes, Alcaligenes faecalis, salmonella, shigella and Proteus mirabilis, Penicillin G is not the drug of choice in the treatment of gram-negative bacillary infections. To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin G sodium and other antibacterial drugs, penicillin G sodium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. CHEBI:18208 uuid:e0cfa7b7-d1d5-4cda-9b53-c5635862a86c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0006941 PMID:41385096 "[{""id"":""uuid:f93d59c0-999d-4fa0-a03b-6fd287e0a42e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d09faab8-ab33-4c44-bf64-01b16623d769"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Penicillin G Sodium for Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Sodium for Injection, USP may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below, however, once these results become available, appropriate therapy should be continued. Clinical Indication Infecting Organism Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non- penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico- facial disease and thoracic and abdominal disease) Actinomyces Israelil Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopthiae Fusospirochetosis (severe infections of the oropharynx [Vincent’s], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat-bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococcal meningitis and/or septicemia Neisseria meningitidis Gram-negative bacillary infections (bacteremias) Escherichia coli, Enterobacter aerogenes, Alcaligenes faecalis, salmonella, shigella and Proteus mirabilis, Penicillin G is not the drug of choice in the treatment of gram-negative bacillary infections. To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin G sodium and other antibacterial drugs, penicillin G sodium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. CHEBI:18208 uuid:1f438c4a-bc88-4190-ac51-1e3b7e2cd5b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0018059 PMID:41385096 "[{""id"":""uuid:e665164d-4d52-45c3-b0f9-03f639cfd2ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e80f5493-7ff6-4552-93aa-a794390efb93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Penicillin G Sodium for Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Sodium for Injection, USP may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below, however, once these results become available, appropriate therapy should be continued. Clinical Indication Infecting Organism Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non- penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico- facial disease and thoracic and abdominal disease) Actinomyces Israelil Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopthiae Fusospirochetosis (severe infections of the oropharynx [Vincent’s], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat-bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococcal meningitis and/or septicemia Neisseria meningitidis Gram-negative bacillary infections (bacteremias) Escherichia coli, Enterobacter aerogenes, Alcaligenes faecalis, salmonella, shigella and Proteus mirabilis, Penicillin G is not the drug of choice in the treatment of gram-negative bacillary infections. To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin G sodium and other antibacterial drugs, penicillin G sodium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. CHEBI:18208 uuid:56df4965-3e68-464d-8f46-d51cb4fb0825 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0005229 PMID:41385096 "[{""id"":""uuid:9481feb0-08cd-48a5-9a04-d470e5f5326b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5d08a91a-559e-41d4-bc42-72b7c87d600d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Penicillin G Sodium for Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Sodium for Injection, USP may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below, however, once these results become available, appropriate therapy should be continued. Clinical Indication Infecting Organism Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non- penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico- facial disease and thoracic and abdominal disease) Actinomyces Israelil Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopthiae Fusospirochetosis (severe infections of the oropharynx [Vincent’s], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat-bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococcal meningitis and/or septicemia Neisseria meningitidis Gram-negative bacillary infections (bacteremias) Escherichia coli, Enterobacter aerogenes, Alcaligenes faecalis, salmonella, shigella and Proteus mirabilis, Penicillin G is not the drug of choice in the treatment of gram-negative bacillary infections. To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin G sodium and other antibacterial drugs, penicillin G sodium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. CHEBI:18208 uuid:539db123-1cb6-46c0-80fe-554d9be7b8ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:5QS67N4551 biolink:treats MONDO:0019623 PMID:41385096 "[{""id"":""uuid:92eba7f5-424f-4652-a3ef-7158a657e3de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0199280d-240a-44d9-aa6f-975f146015b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f2ff7dc8-4267-4984-8db5-30e52252e7b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RUCONEST is a C1 esterase inhibitor [recombinant] indicated for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema (HAE). Limitation of Use: Effectiveness was not established in HAE patients with laryngeal attacks.|[EMA] Ruconest is indicated for treatment of acute angioedema attacks in adults with hereditary angioedema (HAE) due to C1-esterase-inhibitor deficiency. uuid:3ccb10a7-1fb0-4d08-8df1-c0c3cb857271 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:5QS67N4551 biolink:treats MONDO:0012526 PMID:41385096 "[{""id"":""uuid:991631c1-0988-4b70-9c7d-a44710ea8142"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2a705049-c42b-4bcd-8233-5f12b0568b92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RUCONEST is a C1 esterase inhibitor [recombinant] indicated for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema (HAE). Limitation of Use: Effectiveness was not established in HAE patients with laryngeal attacks. uuid:c8291985-ce94-4456-868b-0da488fa8e68 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51043 biolink:treats MONDO:0005052 PMID:41385096 "[{""id"":""uuid:5522c90d-3752-45ff-ac87-6a76aff73ec8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:03591979-3e89-4be7-b45f-d3047d98aa7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZELNORM is indicated for the treatment of adult women less than 65 years of age with irritable bowel syndrome with constipation (IBS-C). Limitations of Use The safety and effectiveness of ZELNORM in men with IBS-C have not been established [see Clinical Studies ( 14 )] . uuid:4e8cb685-9aac-4ca3-bc8d-e3b8ccf13839 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:34825 biolink:treats MONDO:0005984 PMID:41385096 "[{""id"":""uuid:7b6de9e5-14fe-403a-8eb0-c25ac1b8fe6c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b04dd588-0ae1-430b-9b22-050903f78afe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Luliconazole Cream, 1% is indicated for the topical treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum and Epidermophyton floccosum . uuid:e63c0ab7-b3df-44fd-ba9e-e46dac12dc52 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:34825 biolink:treats MONDO:0001405 PMID:41385096 "[{""id"":""uuid:50f87061-4524-43c6-867e-3efa5ad0cb92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2b301969-c3f5-4062-9b33-16cd08dca6f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Luliconazole Cream, 1% is indicated for the topical treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum and Epidermophyton floccosum . uuid:ec9df4be-db36-4a97-80df-aea9f3143b28 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:34825 biolink:treats MONDO:0001461 PMID:41385096 "[{""id"":""uuid:a294d369-33b5-49dd-93ba-5a8da5510ade"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dba47bed-c2ac-4689-9e3d-9bcc7b7439b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Luliconazole Cream, 1% is indicated for the topical treatment of interdigital tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum and Epidermophyton floccosum . uuid:0425b277-aa52-42b9-a00e-145847d8163b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3640 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:9468f7f8-8006-455c-aa61-9cb2241d5897"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:076ae6a6-abba-4963-9f66-e595a8ed6d93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chlorothiazide sodium for injection, USP is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Chlorothiazide sodium for injection, USP has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. uuid:1351d478-1035-4315-bb97-42bdb302aafd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3640 biolink:treats MONDO:0005155 PMID:41385096 "[{""id"":""uuid:66b4f64c-7d4d-44f6-8121-3c4fa863d60c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a977e13e-e41c-414b-b96e-e8671b3a5ec5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chlorothiazide sodium for injection, USP is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Chlorothiazide sodium for injection, USP has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. uuid:32976324-160e-4104-b322-c0861460b4c1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3640 biolink:treats MONDO:0005377 PMID:41385096 "[{""id"":""uuid:7c02b9f7-798d-492b-852e-ba218eee2bfb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b4fb0e76-61a4-47a2-a2ac-076188d77086"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chlorothiazide sodium for injection, USP is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Chlorothiazide sodium for injection, USP has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. uuid:73e8a3f4-9f4f-433f-9937-fd0f26ab363e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3640 biolink:treats UMLS:C0156221 PMID:41385096 "[{""id"":""uuid:82537dfc-9475-4ac6-85a4-08abf02e3308"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b963a8e5-3df8-4dac-8df1-875eb752d7e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chlorothiazide sodium for injection, USP is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Chlorothiazide sodium for injection, USP has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. uuid:5a08a510-0eda-4808-a9ce-f3aeff32b389 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3640 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:2e7529f8-faf5-4f88-884f-7af66a04a111"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b7a6cc8b-b51b-4068-bdcb-def53a04834c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chlorothiazide sodium for injection, USP is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Chlorothiazide sodium for injection, USP has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. uuid:5291d307-a363-468d-b026-5bbc1e852238 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0005867 PMID:41385096 "[{""id"":""uuid:c498a56c-5fbc-4a5e-9bbd-3470cdf9c61a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:568dbe10-629e-49a5-ba0f-a805ed7763fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Doxycycline for Injection, USP and other antibacterial drugs, Doxycycline for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline for Injection, USP is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever, and the typhus group, Q fever, rickettsial pox and tick fevers). Mycoplasma pneumoniae (PPLO, Eaton Agent). Agents of psittacosis and ornithosis. Agents of lymphogranuloma venereum and granuloma inguinale. The spirochetal agent of relapsing fever (Borrelia recurrentis) . The following gram-negative microorganisms: Haemophilus ducreyi (chancroid). Yersinia pestis (formerly Pasteurella pestis ) and Francisella tularensis (formerly Pasteurella tularensis ). Bartonella bacilliformis . Bacteroides species. Vibrio cholerae (formerly Vibrio comma ) and Campylobacter fetus (formerly Vibrio fetus ). Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli . Enterobacter aerogenes (formerly Aerobacter aerogenes ). Shigella species. Acinetobacter species (formerly Mima species and Herellea species). Haemophilus influenzae (respiratory infections). Klebsiella species (respiratory and urinary infections). Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Enterococcus faecalis (formerly Streptococcus faecalis ) have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Streptococcus pneumoniae (formerly Diplococcus pneumoniae ). Staphylococcus aureus , respiratory, skin and soft tissue infections. Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections. Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of infections due to: Neisseria gonorrhoeae and N. meningitidis . Treponema pallidum and Treponema pertenue (syphilis and yaws). Listeria monocytogenes . Clostridium species. Fusobacterium fusiforme (Vincent's infection). Actinomyces species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. Doxycycline is indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. uuid:d598e56d-25d1-45b2-bea0-493834b26654 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0006926 PMID:41385096 "[{""id"":""uuid:c8fd079d-b0a1-4a16-beb7-a35cae810bb3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:73556892-2413-4ca7-bf16-75c397cf5869"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Doxycycline for Injection, USP and other antibacterial drugs, Doxycycline for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline for Injection, USP is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever, and the typhus group, Q fever, rickettsial pox and tick fevers). Mycoplasma pneumoniae (PPLO, Eaton Agent). Agents of psittacosis and ornithosis. Agents of lymphogranuloma venereum and granuloma inguinale. The spirochetal agent of relapsing fever (Borrelia recurrentis) . The following gram-negative microorganisms: Haemophilus ducreyi (chancroid). Yersinia pestis (formerly Pasteurella pestis ) and Francisella tularensis (formerly Pasteurella tularensis ). Bartonella bacilliformis . Bacteroides species. Vibrio cholerae (formerly Vibrio comma ) and Campylobacter fetus (formerly Vibrio fetus ). Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli . Enterobacter aerogenes (formerly Aerobacter aerogenes ). Shigella species. Acinetobacter species (formerly Mima species and Herellea species). Haemophilus influenzae (respiratory infections). Klebsiella species (respiratory and urinary infections). Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Enterococcus faecalis (formerly Streptococcus faecalis ) have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Streptococcus pneumoniae (formerly Diplococcus pneumoniae ). Staphylococcus aureus , respiratory, skin and soft tissue infections. Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections. Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of infections due to: Neisseria gonorrhoeae and N. meningitidis . Treponema pallidum and Treponema pertenue (syphilis and yaws). Listeria monocytogenes . Clostridium species. Fusobacterium fusiforme (Vincent's infection). Actinomyces species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. Doxycycline is indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. uuid:be39a5de-94bd-4a7d-94d2-cde94249e1c5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0021680 PMID:41385096 "[{""id"":""uuid:5f41813f-a137-44a3-83f0-59678394f897"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:80f3df6a-1a59-4634-9403-50cbf670fdc1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Doxycycline for Injection, USP and other antibacterial drugs, Doxycycline for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline for Injection, USP is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever, and the typhus group, Q fever, rickettsial pox and tick fevers). Mycoplasma pneumoniae (PPLO, Eaton Agent). Agents of psittacosis and ornithosis. Agents of lymphogranuloma venereum and granuloma inguinale. The spirochetal agent of relapsing fever (Borrelia recurrentis) . The following gram-negative microorganisms: Haemophilus ducreyi (chancroid). Yersinia pestis (formerly Pasteurella pestis ) and Francisella tularensis (formerly Pasteurella tularensis ). Bartonella bacilliformis . Bacteroides species. Vibrio cholerae (formerly Vibrio comma ) and Campylobacter fetus (formerly Vibrio fetus ). Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli . Enterobacter aerogenes (formerly Aerobacter aerogenes ). Shigella species. Acinetobacter species (formerly Mima species and Herellea species). Haemophilus influenzae (respiratory infections). Klebsiella species (respiratory and urinary infections). Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Enterococcus faecalis (formerly Streptococcus faecalis ) have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Streptococcus pneumoniae (formerly Diplococcus pneumoniae ). Staphylococcus aureus , respiratory, skin and soft tissue infections. Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections. Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of infections due to: Neisseria gonorrhoeae and N. meningitidis . Treponema pallidum and Treponema pertenue (syphilis and yaws). Listeria monocytogenes . Clostridium species. Fusobacterium fusiforme (Vincent's infection). Actinomyces species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. Doxycycline is indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. uuid:9715affd-5c60-4037-a23f-98261c0b6ce2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0005121 PMID:41385096 "[{""id"":""uuid:d66edaee-d8a5-46fb-b319-d031e03472b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:71551603-c439-462e-8437-2c841c6437ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Doxycycline for Injection, USP and other antibacterial drugs, Doxycycline for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline for Injection, USP is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever, and the typhus group, Q fever, rickettsial pox and tick fevers). Mycoplasma pneumoniae (PPLO, Eaton Agent). Agents of psittacosis and ornithosis. Agents of lymphogranuloma venereum and granuloma inguinale. The spirochetal agent of relapsing fever (Borrelia recurrentis) . The following gram-negative microorganisms: Haemophilus ducreyi (chancroid). Yersinia pestis (formerly Pasteurella pestis ) and Francisella tularensis (formerly Pasteurella tularensis ). Bartonella bacilliformis . Bacteroides species. Vibrio cholerae (formerly Vibrio comma ) and Campylobacter fetus (formerly Vibrio fetus ). Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli . Enterobacter aerogenes (formerly Aerobacter aerogenes ). Shigella species. Acinetobacter species (formerly Mima species and Herellea species). Haemophilus influenzae (respiratory infections). Klebsiella species (respiratory and urinary infections). Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Enterococcus faecalis (formerly Streptococcus faecalis ) have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Streptococcus pneumoniae (formerly Diplococcus pneumoniae ). Staphylococcus aureus , respiratory, skin and soft tissue infections. Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections. Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of infections due to: Neisseria gonorrhoeae and N. meningitidis . Treponema pallidum and Treponema pertenue (syphilis and yaws). Listeria monocytogenes . Clostridium species. Fusobacterium fusiforme (Vincent's infection). Actinomyces species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. Doxycycline is indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. uuid:e6a927c1-68f7-4b2b-b1d0-ff98509bf5a8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0005114 PMID:41385096 "[{""id"":""uuid:f670064a-0dce-47ba-bf63-b12095f861b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a21e7a7c-e58f-49b2-bb01-e77430dcd764"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Doxycycline for Injection, USP and other antibacterial drugs, Doxycycline for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline for Injection, USP is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever, and the typhus group, Q fever, rickettsial pox and tick fevers). Mycoplasma pneumoniae (PPLO, Eaton Agent). Agents of psittacosis and ornithosis. Agents of lymphogranuloma venereum and granuloma inguinale. The spirochetal agent of relapsing fever (Borrelia recurrentis) . The following gram-negative microorganisms: Haemophilus ducreyi (chancroid). Yersinia pestis (formerly Pasteurella pestis ) and Francisella tularensis (formerly Pasteurella tularensis ). Bartonella bacilliformis . Bacteroides species. Vibrio cholerae (formerly Vibrio comma ) and Campylobacter fetus (formerly Vibrio fetus ). Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli . Enterobacter aerogenes (formerly Aerobacter aerogenes ). Shigella species. Acinetobacter species (formerly Mima species and Herellea species). Haemophilus influenzae (respiratory infections). Klebsiella species (respiratory and urinary infections). Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Enterococcus faecalis (formerly Streptococcus faecalis ) have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Streptococcus pneumoniae (formerly Diplococcus pneumoniae ). Staphylococcus aureus , respiratory, skin and soft tissue infections. Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections. Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of infections due to: Neisseria gonorrhoeae and N. meningitidis . Treponema pallidum and Treponema pertenue (syphilis and yaws). Listeria monocytogenes . Clostridium species. Fusobacterium fusiforme (Vincent's infection). Actinomyces species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. Doxycycline is indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. uuid:28ee0b73-475c-4cff-b690-de61947780f1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0005545 PMID:41385096 "[{""id"":""uuid:3a0d9a5f-c243-4ff1-b843-155b9531d3d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:26282853-e368-4b21-b818-ebdb6172a29f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Doxycycline for Injection, USP and other antibacterial drugs, Doxycycline for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline for Injection, USP is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever, and the typhus group, Q fever, rickettsial pox and tick fevers). Mycoplasma pneumoniae (PPLO, Eaton Agent). Agents of psittacosis and ornithosis. Agents of lymphogranuloma venereum and granuloma inguinale. The spirochetal agent of relapsing fever (Borrelia recurrentis) . The following gram-negative microorganisms: Haemophilus ducreyi (chancroid). Yersinia pestis (formerly Pasteurella pestis ) and Francisella tularensis (formerly Pasteurella tularensis ). Bartonella bacilliformis . Bacteroides species. Vibrio cholerae (formerly Vibrio comma ) and Campylobacter fetus (formerly Vibrio fetus ). Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli . Enterobacter aerogenes (formerly Aerobacter aerogenes ). Shigella species. Acinetobacter species (formerly Mima species and Herellea species). Haemophilus influenzae (respiratory infections). Klebsiella species (respiratory and urinary infections). Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Enterococcus faecalis (formerly Streptococcus faecalis ) have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Streptococcus pneumoniae (formerly Diplococcus pneumoniae ). Staphylococcus aureus , respiratory, skin and soft tissue infections. Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections. Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of infections due to: Neisseria gonorrhoeae and N. meningitidis . Treponema pallidum and Treponema pertenue (syphilis and yaws). Listeria monocytogenes . Clostridium species. Fusobacterium fusiforme (Vincent's infection). Actinomyces species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. Doxycycline is indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. uuid:d7b5acba-099e-4ad9-89d7-ea06c1769574 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0021108 PMID:41385096 "[{""id"":""uuid:d648d5b9-35d5-4557-bac7-c3080d01e377"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b5594a6e-bfcc-4bca-9df1-30cc3adc7cae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Doxycycline for Injection, USP and other antibacterial drugs, Doxycycline for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline for Injection, USP is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever, and the typhus group, Q fever, rickettsial pox and tick fevers). Mycoplasma pneumoniae (PPLO, Eaton Agent). Agents of psittacosis and ornithosis. Agents of lymphogranuloma venereum and granuloma inguinale. The spirochetal agent of relapsing fever (Borrelia recurrentis) . The following gram-negative microorganisms: Haemophilus ducreyi (chancroid). Yersinia pestis (formerly Pasteurella pestis ) and Francisella tularensis (formerly Pasteurella tularensis ). Bartonella bacilliformis . Bacteroides species. Vibrio cholerae (formerly Vibrio comma ) and Campylobacter fetus (formerly Vibrio fetus ). Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli . Enterobacter aerogenes (formerly Aerobacter aerogenes ). Shigella species. Acinetobacter species (formerly Mima species and Herellea species). Haemophilus influenzae (respiratory infections). Klebsiella species (respiratory and urinary infections). Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Enterococcus faecalis (formerly Streptococcus faecalis ) have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Streptococcus pneumoniae (formerly Diplococcus pneumoniae ). Staphylococcus aureus , respiratory, skin and soft tissue infections. Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections. Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of infections due to: Neisseria gonorrhoeae and N. meningitidis . Treponema pallidum and Treponema pertenue (syphilis and yaws). Listeria monocytogenes . Clostridium species. Fusobacterium fusiforme (Vincent's infection). Actinomyces species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. Doxycycline is indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. uuid:1d9a2713-ee19-4f5e-b1cc-9db4c0b4a949 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0018984 PMID:41385096 "[{""id"":""uuid:250abf92-d477-4581-9cc5-88f11cbf02c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cca23d66-ee15-479e-a914-11447c609111"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Doxycycline for Injection, USP and other antibacterial drugs, Doxycycline for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline for Injection, USP is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever, and the typhus group, Q fever, rickettsial pox and tick fevers). Mycoplasma pneumoniae (PPLO, Eaton Agent). Agents of psittacosis and ornithosis. Agents of lymphogranuloma venereum and granuloma inguinale. The spirochetal agent of relapsing fever (Borrelia recurrentis) . The following gram-negative microorganisms: Haemophilus ducreyi (chancroid). Yersinia pestis (formerly Pasteurella pestis ) and Francisella tularensis (formerly Pasteurella tularensis ). Bartonella bacilliformis . Bacteroides species. Vibrio cholerae (formerly Vibrio comma ) and Campylobacter fetus (formerly Vibrio fetus ). Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli . Enterobacter aerogenes (formerly Aerobacter aerogenes ). Shigella species. Acinetobacter species (formerly Mima species and Herellea species). Haemophilus influenzae (respiratory infections). Klebsiella species (respiratory and urinary infections). Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Enterococcus faecalis (formerly Streptococcus faecalis ) have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Streptococcus pneumoniae (formerly Diplococcus pneumoniae ). Staphylococcus aureus , respiratory, skin and soft tissue infections. Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections. Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of infections due to: Neisseria gonorrhoeae and N. meningitidis . Treponema pallidum and Treponema pertenue (syphilis and yaws). Listeria monocytogenes . Clostridium species. Fusobacterium fusiforme (Vincent's infection). Actinomyces species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. Doxycycline is indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. uuid:d5b650cf-f839-4fe9-a050-3764bf4b3022 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0006671 PMID:41385096 "[{""id"":""uuid:20a8dfda-fec5-4e7d-97ac-8aa8018dbaa6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ad2e2e44-9fa5-45c8-b9d6-feb081633eb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Doxycycline for Injection, USP and other antibacterial drugs, Doxycycline for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline for Injection, USP is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever, and the typhus group, Q fever, rickettsial pox and tick fevers). Mycoplasma pneumoniae (PPLO, Eaton Agent). Agents of psittacosis and ornithosis. Agents of lymphogranuloma venereum and granuloma inguinale. The spirochetal agent of relapsing fever (Borrelia recurrentis) . The following gram-negative microorganisms: Haemophilus ducreyi (chancroid). Yersinia pestis (formerly Pasteurella pestis ) and Francisella tularensis (formerly Pasteurella tularensis ). Bartonella bacilliformis . Bacteroides species. Vibrio cholerae (formerly Vibrio comma ) and Campylobacter fetus (formerly Vibrio fetus ). Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli . Enterobacter aerogenes (formerly Aerobacter aerogenes ). Shigella species. Acinetobacter species (formerly Mima species and Herellea species). Haemophilus influenzae (respiratory infections). Klebsiella species (respiratory and urinary infections). Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Enterococcus faecalis (formerly Streptococcus faecalis ) have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Streptococcus pneumoniae (formerly Diplococcus pneumoniae ). Staphylococcus aureus , respiratory, skin and soft tissue infections. Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections. Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of infections due to: Neisseria gonorrhoeae and N. meningitidis . Treponema pallidum and Treponema pertenue (syphilis and yaws). Listeria monocytogenes . Clostridium species. Fusobacterium fusiforme (Vincent's infection). Actinomyces species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. Doxycycline is indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. uuid:c1cfcfab-d328-42d9-ae99-f92c3f62841e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:209807 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:f5954fc5-b88c-4ea8-a6b8-ccf0740c7b4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bcf003a1-faef-4ce1-9c3c-3253fdd8d569"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefoxitin for Injection, USP is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections , including pneumonia and lung abscess, caused by Streptococcus pneumoniae , other streptococci (excluding enterococci, e.g., Enterococcus faecalis [formerly Streptococcus faecalis ]), Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli , Klebsiella species, Haemophilus influenzae, and Bacteroides species. (2) Urinary tract infections caused by Escherichia coli , Klebsiella species, Proteus mirabilis , Morganella morganii , Proteus vulgaris and Providencia species (including P. rettgeri ). (3) Intra-abdominal infections, including peritonitis and intra-abdominal abscess, caused by Escherichia coli , Klebsiella species, Bacteroides species including Bacteroides fragilis , and Clostridium species. (4) Gynecological infections, including endometritis, pelvic cellulitis, and pelvic inflammatory disease caused by Escherichia coli , Neisseria gonorrhoeae (including penicillinase-producing strains), Bacteroides species including B. fragilis , Clostridium species, Peptococcus niger , Peptostreptococcus species, and Streptococcus agalactiae . Cefoxitin for Injection, USP, like cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when Cefoxitin for Injection, USP is used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (5) Septicemia caused by Streptococcus pneumoniae , Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli , Klebsiella species, and Bacteroides species including B. fragilis. (6) Bone and joint infections caused by Staphylococcus aureus (including penicillinase-producing strains). (7) Skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains), Staphylococcus epidermidis , Streptococcus pyogenes and other streptococci (excluding enterococci e.g., Enterococcus faecalis [formerly Streptococcus faecalis ]), Escherichia coli , Proteus mirabilis , Klebsiella species, Bacteroides species including B. fragilis , Clostridium species, Peptococcus niger , and Peptostreptococcus species. Appropriate culture and susceptibility studies should be performed to determine the susceptibility of the causative organisms to Cefoxitin for Injection, USP. Therapy may be started while awaiting the results of these studies. In randomized comparative studies, Cefoxitin for Injection, USP and cephalothin were comparably safe and effective in the management of infections caused by gram-positive cocci and gram-negative rods susceptible to the cephalosporins. Cefoxitin for Injection, USP has a high degree of stability in the presence of bacterial beta-lactamases, both penicillinases and cephalosporinases. Many infections caused by aerobic and anaerobic gram-negative bacteria resistant to some cephalosporins respond to Cefoxitin for Injection, USP. Similarly, many infections caused by aerobic and anaerobic bacteria resistant to some penicillin antibiotics (ampicillin, carbenicillin, penicillin G) respond to treatment with Cefoxitin for Injection, USP. Many infections caused by mixtures of susceptible aerobic and anaerobic bacteria respond to treatment with Cefoxitin for Injection, USP. uuid:f81c1a22-e5d1-4a62-870e-b38fdaa781b8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:209807 biolink:treats MONDO:0000744 PMID:41385096 "[{""id"":""uuid:599fcd84-b351-4f45-95bc-47c1e91ba166"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e0df2365-d54c-440b-b580-592c603f2863"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefoxitin for Injection, USP is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections , including pneumonia and lung abscess, caused by Streptococcus pneumoniae , other streptococci (excluding enterococci, e.g., Enterococcus faecalis [formerly Streptococcus faecalis ]), Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli , Klebsiella species, Haemophilus influenzae, and Bacteroides species. (2) Urinary tract infections caused by Escherichia coli , Klebsiella species, Proteus mirabilis , Morganella morganii , Proteus vulgaris and Providencia species (including P. rettgeri ). (3) Intra-abdominal infections, including peritonitis and intra-abdominal abscess, caused by Escherichia coli , Klebsiella species, Bacteroides species including Bacteroides fragilis , and Clostridium species. (4) Gynecological infections, including endometritis, pelvic cellulitis, and pelvic inflammatory disease caused by Escherichia coli , Neisseria gonorrhoeae (including penicillinase-producing strains), Bacteroides species including B. fragilis , Clostridium species, Peptococcus niger , Peptostreptococcus species, and Streptococcus agalactiae . Cefoxitin for Injection, USP, like cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when Cefoxitin for Injection, USP is used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (5) Septicemia caused by Streptococcus pneumoniae , Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli , Klebsiella species, and Bacteroides species including B. fragilis. (6) Bone and joint infections caused by Staphylococcus aureus (including penicillinase-producing strains). (7) Skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains), Staphylococcus epidermidis , Streptococcus pyogenes and other streptococci (excluding enterococci e.g., Enterococcus faecalis [formerly Streptococcus faecalis ]), Escherichia coli , Proteus mirabilis , Klebsiella species, Bacteroides species including B. fragilis , Clostridium species, Peptococcus niger , and Peptostreptococcus species. Appropriate culture and susceptibility studies should be performed to determine the susceptibility of the causative organisms to Cefoxitin for Injection, USP. Therapy may be started while awaiting the results of these studies. In randomized comparative studies, Cefoxitin for Injection, USP and cephalothin were comparably safe and effective in the management of infections caused by gram-positive cocci and gram-negative rods susceptible to the cephalosporins. Cefoxitin for Injection, USP has a high degree of stability in the presence of bacterial beta-lactamases, both penicillinases and cephalosporinases. Many infections caused by aerobic and anaerobic gram-negative bacteria resistant to some cephalosporins respond to Cefoxitin for Injection, USP. Similarly, many infections caused by aerobic and anaerobic bacteria resistant to some penicillin antibiotics (ampicillin, carbenicillin, penicillin G) respond to treatment with Cefoxitin for Injection, USP. Many infections caused by mixtures of susceptible aerobic and anaerobic bacteria respond to treatment with Cefoxitin for Injection, USP. uuid:4cd7ae88-6a8d-4997-ba05-47c65674a525 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:209807 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:318d9be2-4e56-4dec-9201-c14c56587817"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c3c61240-f43f-46e6-8480-2b9ddf534582"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefoxitin for Injection, USP is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections , including pneumonia and lung abscess, caused by Streptococcus pneumoniae , other streptococci (excluding enterococci, e.g., Enterococcus faecalis [formerly Streptococcus faecalis ]), Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli , Klebsiella species, Haemophilus influenzae, and Bacteroides species. (2) Urinary tract infections caused by Escherichia coli , Klebsiella species, Proteus mirabilis , Morganella morganii , Proteus vulgaris and Providencia species (including P. rettgeri ). (3) Intra-abdominal infections, including peritonitis and intra-abdominal abscess, caused by Escherichia coli , Klebsiella species, Bacteroides species including Bacteroides fragilis , and Clostridium species. (4) Gynecological infections, including endometritis, pelvic cellulitis, and pelvic inflammatory disease caused by Escherichia coli , Neisseria gonorrhoeae (including penicillinase-producing strains), Bacteroides species including B. fragilis , Clostridium species, Peptococcus niger , Peptostreptococcus species, and Streptococcus agalactiae . Cefoxitin for Injection, USP, like cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when Cefoxitin for Injection, USP is used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (5) Septicemia caused by Streptococcus pneumoniae , Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli , Klebsiella species, and Bacteroides species including B. fragilis. (6) Bone and joint infections caused by Staphylococcus aureus (including penicillinase-producing strains). (7) Skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains), Staphylococcus epidermidis , Streptococcus pyogenes and other streptococci (excluding enterococci e.g., Enterococcus faecalis [formerly Streptococcus faecalis ]), Escherichia coli , Proteus mirabilis , Klebsiella species, Bacteroides species including B. fragilis , Clostridium species, Peptococcus niger , and Peptostreptococcus species. Appropriate culture and susceptibility studies should be performed to determine the susceptibility of the causative organisms to Cefoxitin for Injection, USP. Therapy may be started while awaiting the results of these studies. In randomized comparative studies, Cefoxitin for Injection, USP and cephalothin were comparably safe and effective in the management of infections caused by gram-positive cocci and gram-negative rods susceptible to the cephalosporins. Cefoxitin for Injection, USP has a high degree of stability in the presence of bacterial beta-lactamases, both penicillinases and cephalosporinases. Many infections caused by aerobic and anaerobic gram-negative bacteria resistant to some cephalosporins respond to Cefoxitin for Injection, USP. Similarly, many infections caused by aerobic and anaerobic bacteria resistant to some penicillin antibiotics (ampicillin, carbenicillin, penicillin G) respond to treatment with Cefoxitin for Injection, USP. Many infections caused by mixtures of susceptible aerobic and anaerobic bacteria respond to treatment with Cefoxitin for Injection, USP. uuid:2d1d90cb-593a-4042-9bd1-01bd8aaabde7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:209807 biolink:treats MONDO:0004522 PMID:41385096 "[{""id"":""uuid:6c90de0a-436c-4642-aa72-b936704c89e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:04c81895-a02d-461b-9edb-6b5150cb75ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefoxitin for Injection, USP is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections , including pneumonia and lung abscess, caused by Streptococcus pneumoniae , other streptococci (excluding enterococci, e.g., Enterococcus faecalis [formerly Streptococcus faecalis ]), Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli , Klebsiella species, Haemophilus influenzae, and Bacteroides species. (2) Urinary tract infections caused by Escherichia coli , Klebsiella species, Proteus mirabilis , Morganella morganii , Proteus vulgaris and Providencia species (including P. rettgeri ). (3) Intra-abdominal infections, including peritonitis and intra-abdominal abscess, caused by Escherichia coli , Klebsiella species, Bacteroides species including Bacteroides fragilis , and Clostridium species. (4) Gynecological infections, including endometritis, pelvic cellulitis, and pelvic inflammatory disease caused by Escherichia coli , Neisseria gonorrhoeae (including penicillinase-producing strains), Bacteroides species including B. fragilis , Clostridium species, Peptococcus niger , Peptostreptococcus species, and Streptococcus agalactiae . Cefoxitin for Injection, USP, like cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when Cefoxitin for Injection, USP is used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (5) Septicemia caused by Streptococcus pneumoniae , Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli , Klebsiella species, and Bacteroides species including B. fragilis. (6) Bone and joint infections caused by Staphylococcus aureus (including penicillinase-producing strains). (7) Skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains), Staphylococcus epidermidis , Streptococcus pyogenes and other streptococci (excluding enterococci e.g., Enterococcus faecalis [formerly Streptococcus faecalis ]), Escherichia coli , Proteus mirabilis , Klebsiella species, Bacteroides species including B. fragilis , Clostridium species, Peptococcus niger , and Peptostreptococcus species. Appropriate culture and susceptibility studies should be performed to determine the susceptibility of the causative organisms to Cefoxitin for Injection, USP. Therapy may be started while awaiting the results of these studies. In randomized comparative studies, Cefoxitin for Injection, USP and cephalothin were comparably safe and effective in the management of infections caused by gram-positive cocci and gram-negative rods susceptible to the cephalosporins. Cefoxitin for Injection, USP has a high degree of stability in the presence of bacterial beta-lactamases, both penicillinases and cephalosporinases. Many infections caused by aerobic and anaerobic gram-negative bacteria resistant to some cephalosporins respond to Cefoxitin for Injection, USP. Similarly, many infections caused by aerobic and anaerobic bacteria resistant to some penicillin antibiotics (ampicillin, carbenicillin, penicillin G) respond to treatment with Cefoxitin for Injection, USP. Many infections caused by mixtures of susceptible aerobic and anaerobic bacteria respond to treatment with Cefoxitin for Injection, USP. uuid:2f399324-0e9d-4225-9451-3f741added63 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:209807 biolink:treats MONDO:0000918 PMID:41385096 "[{""id"":""uuid:02eea8a0-c1b2-48c9-853e-e66bab6d4a0c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bb183e5f-b107-4e69-8364-2448c2ce606b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefoxitin for Injection, USP is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections , including pneumonia and lung abscess, caused by Streptococcus pneumoniae , other streptococci (excluding enterococci, e.g., Enterococcus faecalis [formerly Streptococcus faecalis ]), Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli , Klebsiella species, Haemophilus influenzae, and Bacteroides species. (2) Urinary tract infections caused by Escherichia coli , Klebsiella species, Proteus mirabilis , Morganella morganii , Proteus vulgaris and Providencia species (including P. rettgeri ). (3) Intra-abdominal infections, including peritonitis and intra-abdominal abscess, caused by Escherichia coli , Klebsiella species, Bacteroides species including Bacteroides fragilis , and Clostridium species. (4) Gynecological infections, including endometritis, pelvic cellulitis, and pelvic inflammatory disease caused by Escherichia coli , Neisseria gonorrhoeae (including penicillinase-producing strains), Bacteroides species including B. fragilis , Clostridium species, Peptococcus niger , Peptostreptococcus species, and Streptococcus agalactiae . Cefoxitin for Injection, USP, like cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when Cefoxitin for Injection, USP is used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (5) Septicemia caused by Streptococcus pneumoniae , Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli , Klebsiella species, and Bacteroides species including B. fragilis. (6) Bone and joint infections caused by Staphylococcus aureus (including penicillinase-producing strains). (7) Skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains), Staphylococcus epidermidis , Streptococcus pyogenes and other streptococci (excluding enterococci e.g., Enterococcus faecalis [formerly Streptococcus faecalis ]), Escherichia coli , Proteus mirabilis , Klebsiella species, Bacteroides species including B. fragilis , Clostridium species, Peptococcus niger , and Peptostreptococcus species. Appropriate culture and susceptibility studies should be performed to determine the susceptibility of the causative organisms to Cefoxitin for Injection, USP. Therapy may be started while awaiting the results of these studies. In randomized comparative studies, Cefoxitin for Injection, USP and cephalothin were comparably safe and effective in the management of infections caused by gram-positive cocci and gram-negative rods susceptible to the cephalosporins. Cefoxitin for Injection, USP has a high degree of stability in the presence of bacterial beta-lactamases, both penicillinases and cephalosporinases. Many infections caused by aerobic and anaerobic gram-negative bacteria resistant to some cephalosporins respond to Cefoxitin for Injection, USP. Similarly, many infections caused by aerobic and anaerobic bacteria resistant to some penicillin antibiotics (ampicillin, carbenicillin, penicillin G) respond to treatment with Cefoxitin for Injection, USP. Many infections caused by mixtures of susceptible aerobic and anaerobic bacteria respond to treatment with Cefoxitin for Injection, USP. uuid:562697c2-fb85-462d-874b-a4bab67100aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:209807 biolink:treats MONDO:0006887 PMID:41385096 "[{""id"":""uuid:ba4d0d53-03a4-4f6a-af26-f76b551e5b7c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:048c9d58-f21b-4255-9d82-c204f332b295"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefoxitin for Injection, USP is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections , including pneumonia and lung abscess, caused by Streptococcus pneumoniae , other streptococci (excluding enterococci, e.g., Enterococcus faecalis [formerly Streptococcus faecalis ]), Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli , Klebsiella species, Haemophilus influenzae, and Bacteroides species. (2) Urinary tract infections caused by Escherichia coli , Klebsiella species, Proteus mirabilis , Morganella morganii , Proteus vulgaris and Providencia species (including P. rettgeri ). (3) Intra-abdominal infections, including peritonitis and intra-abdominal abscess, caused by Escherichia coli , Klebsiella species, Bacteroides species including Bacteroides fragilis , and Clostridium species. (4) Gynecological infections, including endometritis, pelvic cellulitis, and pelvic inflammatory disease caused by Escherichia coli , Neisseria gonorrhoeae (including penicillinase-producing strains), Bacteroides species including B. fragilis , Clostridium species, Peptococcus niger , Peptostreptococcus species, and Streptococcus agalactiae . Cefoxitin for Injection, USP, like cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when Cefoxitin for Injection, USP is used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (5) Septicemia caused by Streptococcus pneumoniae , Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli , Klebsiella species, and Bacteroides species including B. fragilis. (6) Bone and joint infections caused by Staphylococcus aureus (including penicillinase-producing strains). (7) Skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains), Staphylococcus epidermidis , Streptococcus pyogenes and other streptococci (excluding enterococci e.g., Enterococcus faecalis [formerly Streptococcus faecalis ]), Escherichia coli , Proteus mirabilis , Klebsiella species, Bacteroides species including B. fragilis , Clostridium species, Peptococcus niger , and Peptostreptococcus species. Appropriate culture and susceptibility studies should be performed to determine the susceptibility of the causative organisms to Cefoxitin for Injection, USP. Therapy may be started while awaiting the results of these studies. In randomized comparative studies, Cefoxitin for Injection, USP and cephalothin were comparably safe and effective in the management of infections caused by gram-positive cocci and gram-negative rods susceptible to the cephalosporins. Cefoxitin for Injection, USP has a high degree of stability in the presence of bacterial beta-lactamases, both penicillinases and cephalosporinases. Many infections caused by aerobic and anaerobic gram-negative bacteria resistant to some cephalosporins respond to Cefoxitin for Injection, USP. Similarly, many infections caused by aerobic and anaerobic bacteria resistant to some penicillin antibiotics (ampicillin, carbenicillin, penicillin G) respond to treatment with Cefoxitin for Injection, USP. Many infections caused by mixtures of susceptible aerobic and anaerobic bacteria respond to treatment with Cefoxitin for Injection, USP. uuid:a0b82e06-2772-45bb-9f6d-4fb715259b72 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:209807 biolink:treats MONDO:0000922 PMID:41385096 "[{""id"":""uuid:e47724e8-a1b3-417c-93f2-8082e023ae96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:60661a96-0157-4395-be07-d6c8a0a58ceb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefoxitin for Injection, USP is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections , including pneumonia and lung abscess, caused by Streptococcus pneumoniae , other streptococci (excluding enterococci, e.g., Enterococcus faecalis [formerly Streptococcus faecalis ]), Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli , Klebsiella species, Haemophilus influenzae, and Bacteroides species. (2) Urinary tract infections caused by Escherichia coli , Klebsiella species, Proteus mirabilis , Morganella morganii , Proteus vulgaris and Providencia species (including P. rettgeri ). (3) Intra-abdominal infections, including peritonitis and intra-abdominal abscess, caused by Escherichia coli , Klebsiella species, Bacteroides species including Bacteroides fragilis , and Clostridium species. (4) Gynecological infections, including endometritis, pelvic cellulitis, and pelvic inflammatory disease caused by Escherichia coli , Neisseria gonorrhoeae (including penicillinase-producing strains), Bacteroides species including B. fragilis , Clostridium species, Peptococcus niger , Peptostreptococcus species, and Streptococcus agalactiae . Cefoxitin for Injection, USP, like cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when Cefoxitin for Injection, USP is used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (5) Septicemia caused by Streptococcus pneumoniae , Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli , Klebsiella species, and Bacteroides species including B. fragilis. (6) Bone and joint infections caused by Staphylococcus aureus (including penicillinase-producing strains). (7) Skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains), Staphylococcus epidermidis , Streptococcus pyogenes and other streptococci (excluding enterococci e.g., Enterococcus faecalis [formerly Streptococcus faecalis ]), Escherichia coli , Proteus mirabilis , Klebsiella species, Bacteroides species including B. fragilis , Clostridium species, Peptococcus niger , and Peptostreptococcus species. Appropriate culture and susceptibility studies should be performed to determine the susceptibility of the causative organisms to Cefoxitin for Injection, USP. Therapy may be started while awaiting the results of these studies. In randomized comparative studies, Cefoxitin for Injection, USP and cephalothin were comparably safe and effective in the management of infections caused by gram-positive cocci and gram-negative rods susceptible to the cephalosporins. Cefoxitin for Injection, USP has a high degree of stability in the presence of bacterial beta-lactamases, both penicillinases and cephalosporinases. Many infections caused by aerobic and anaerobic gram-negative bacteria resistant to some cephalosporins respond to Cefoxitin for Injection, USP. Similarly, many infections caused by aerobic and anaerobic bacteria resistant to some penicillin antibiotics (ampicillin, carbenicillin, penicillin G) respond to treatment with Cefoxitin for Injection, USP. Many infections caused by mixtures of susceptible aerobic and anaerobic bacteria respond to treatment with Cefoxitin for Injection, USP. uuid:1f1a2b8a-31e3-4173-8bb1-9f435f9e5b28 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:209807 biolink:treats MONDO:0700217 PMID:41385096 "[{""id"":""uuid:e895105c-7386-44bc-8fea-c98e01004876"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9cdf325b-5b2c-42bd-9221-3b4696817aaf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefoxitin for Injection, USP is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections , including pneumonia and lung abscess, caused by Streptococcus pneumoniae , other streptococci (excluding enterococci, e.g., Enterococcus faecalis [formerly Streptococcus faecalis ]), Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli , Klebsiella species, Haemophilus influenzae, and Bacteroides species. (2) Urinary tract infections caused by Escherichia coli , Klebsiella species, Proteus mirabilis , Morganella morganii , Proteus vulgaris and Providencia species (including P. rettgeri ). (3) Intra-abdominal infections, including peritonitis and intra-abdominal abscess, caused by Escherichia coli , Klebsiella species, Bacteroides species including Bacteroides fragilis , and Clostridium species. (4) Gynecological infections, including endometritis, pelvic cellulitis, and pelvic inflammatory disease caused by Escherichia coli , Neisseria gonorrhoeae (including penicillinase-producing strains), Bacteroides species including B. fragilis , Clostridium species, Peptococcus niger , Peptostreptococcus species, and Streptococcus agalactiae . Cefoxitin for Injection, USP, like cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when Cefoxitin for Injection, USP is used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (5) Septicemia caused by Streptococcus pneumoniae , Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli , Klebsiella species, and Bacteroides species including B. fragilis. (6) Bone and joint infections caused by Staphylococcus aureus (including penicillinase-producing strains). (7) Skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains), Staphylococcus epidermidis , Streptococcus pyogenes and other streptococci (excluding enterococci e.g., Enterococcus faecalis [formerly Streptococcus faecalis ]), Escherichia coli , Proteus mirabilis , Klebsiella species, Bacteroides species including B. fragilis , Clostridium species, Peptococcus niger , and Peptostreptococcus species. Appropriate culture and susceptibility studies should be performed to determine the susceptibility of the causative organisms to Cefoxitin for Injection, USP. Therapy may be started while awaiting the results of these studies. In randomized comparative studies, Cefoxitin for Injection, USP and cephalothin were comparably safe and effective in the management of infections caused by gram-positive cocci and gram-negative rods susceptible to the cephalosporins. Cefoxitin for Injection, USP has a high degree of stability in the presence of bacterial beta-lactamases, both penicillinases and cephalosporinases. Many infections caused by aerobic and anaerobic gram-negative bacteria resistant to some cephalosporins respond to Cefoxitin for Injection, USP. Similarly, many infections caused by aerobic and anaerobic bacteria resistant to some penicillin antibiotics (ampicillin, carbenicillin, penicillin G) respond to treatment with Cefoxitin for Injection, USP. Many infections caused by mixtures of susceptible aerobic and anaerobic bacteria respond to treatment with Cefoxitin for Injection, USP. uuid:7bde78ba-4ff3-4a6b-a13b-e3e191cf35b5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:209807 biolink:treats UMLS:C0851989 PMID:41385096 "[{""id"":""uuid:3be18c47-9adf-4be7-a1e5-8900ab7a109c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c04a3c23-e8e6-41cb-b704-8f9901483473"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefoxitin for Injection, USP is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections , including pneumonia and lung abscess, caused by Streptococcus pneumoniae , other streptococci (excluding enterococci, e.g., Enterococcus faecalis [formerly Streptococcus faecalis ]), Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli , Klebsiella species, Haemophilus influenzae, and Bacteroides species. (2) Urinary tract infections caused by Escherichia coli , Klebsiella species, Proteus mirabilis , Morganella morganii , Proteus vulgaris and Providencia species (including P. rettgeri ). (3) Intra-abdominal infections, including peritonitis and intra-abdominal abscess, caused by Escherichia coli , Klebsiella species, Bacteroides species including Bacteroides fragilis , and Clostridium species. (4) Gynecological infections, including endometritis, pelvic cellulitis, and pelvic inflammatory disease caused by Escherichia coli , Neisseria gonorrhoeae (including penicillinase-producing strains), Bacteroides species including B. fragilis , Clostridium species, Peptococcus niger , Peptostreptococcus species, and Streptococcus agalactiae . Cefoxitin for Injection, USP, like cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when Cefoxitin for Injection, USP is used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (5) Septicemia caused by Streptococcus pneumoniae , Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli , Klebsiella species, and Bacteroides species including B. fragilis. (6) Bone and joint infections caused by Staphylococcus aureus (including penicillinase-producing strains). (7) Skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains), Staphylococcus epidermidis , Streptococcus pyogenes and other streptococci (excluding enterococci e.g., Enterococcus faecalis [formerly Streptococcus faecalis ]), Escherichia coli , Proteus mirabilis , Klebsiella species, Bacteroides species including B. fragilis , Clostridium species, Peptococcus niger , and Peptostreptococcus species. Appropriate culture and susceptibility studies should be performed to determine the susceptibility of the causative organisms to Cefoxitin for Injection, USP. Therapy may be started while awaiting the results of these studies. In randomized comparative studies, Cefoxitin for Injection, USP and cephalothin were comparably safe and effective in the management of infections caused by gram-positive cocci and gram-negative rods susceptible to the cephalosporins. Cefoxitin for Injection, USP has a high degree of stability in the presence of bacterial beta-lactamases, both penicillinases and cephalosporinases. Many infections caused by aerobic and anaerobic gram-negative bacteria resistant to some cephalosporins respond to Cefoxitin for Injection, USP. Similarly, many infections caused by aerobic and anaerobic bacteria resistant to some penicillin antibiotics (ampicillin, carbenicillin, penicillin G) respond to treatment with Cefoxitin for Injection, USP. Many infections caused by mixtures of susceptible aerobic and anaerobic bacteria respond to treatment with Cefoxitin for Injection, USP. uuid:a19a79f6-2e78-40ab-b93f-9554d6546be7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:209807 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:f7b11420-7d9c-4462-9f9d-bcbdf8241534"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:619d8a30-1611-4655-b8d5-79e99b488833"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefoxitin for Injection, USP is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections , including pneumonia and lung abscess, caused by Streptococcus pneumoniae , other streptococci (excluding enterococci, e.g., Enterococcus faecalis [formerly Streptococcus faecalis ]), Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli , Klebsiella species, Haemophilus influenzae, and Bacteroides species. (2) Urinary tract infections caused by Escherichia coli , Klebsiella species, Proteus mirabilis , Morganella morganii , Proteus vulgaris and Providencia species (including P. rettgeri ). (3) Intra-abdominal infections, including peritonitis and intra-abdominal abscess, caused by Escherichia coli , Klebsiella species, Bacteroides species including Bacteroides fragilis , and Clostridium species. (4) Gynecological infections, including endometritis, pelvic cellulitis, and pelvic inflammatory disease caused by Escherichia coli , Neisseria gonorrhoeae (including penicillinase-producing strains), Bacteroides species including B. fragilis , Clostridium species, Peptococcus niger , Peptostreptococcus species, and Streptococcus agalactiae . Cefoxitin for Injection, USP, like cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when Cefoxitin for Injection, USP is used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (5) Septicemia caused by Streptococcus pneumoniae , Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli , Klebsiella species, and Bacteroides species including B. fragilis. (6) Bone and joint infections caused by Staphylococcus aureus (including penicillinase-producing strains). (7) Skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains), Staphylococcus epidermidis , Streptococcus pyogenes and other streptococci (excluding enterococci e.g., Enterococcus faecalis [formerly Streptococcus faecalis ]), Escherichia coli , Proteus mirabilis , Klebsiella species, Bacteroides species including B. fragilis , Clostridium species, Peptococcus niger , and Peptostreptococcus species. Appropriate culture and susceptibility studies should be performed to determine the susceptibility of the causative organisms to Cefoxitin for Injection, USP. Therapy may be started while awaiting the results of these studies. In randomized comparative studies, Cefoxitin for Injection, USP and cephalothin were comparably safe and effective in the management of infections caused by gram-positive cocci and gram-negative rods susceptible to the cephalosporins. Cefoxitin for Injection, USP has a high degree of stability in the presence of bacterial beta-lactamases, both penicillinases and cephalosporinases. Many infections caused by aerobic and anaerobic gram-negative bacteria resistant to some cephalosporins respond to Cefoxitin for Injection, USP. Similarly, many infections caused by aerobic and anaerobic bacteria resistant to some penicillin antibiotics (ampicillin, carbenicillin, penicillin G) respond to treatment with Cefoxitin for Injection, USP. Many infections caused by mixtures of susceptible aerobic and anaerobic bacteria respond to treatment with Cefoxitin for Injection, USP. uuid:69a5f3e8-ae91-4fa6-925a-2b0ea50b84fc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50922 biolink:treats MONDO:0005277 PMID:41385096 "[{""id"":""uuid:0e445bb2-ac12-47eb-8639-19a3c4a28f8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2a4a6c6a-3434-415c-ba6f-c25cee77697f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Eletriptan hydrobromide tablets are indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use: • Use only if a clear diagnosis of migraine has been established. If a patient has no response to the first migraine attack treated with eletriptan hydrobromide tablets, reconsider the diagnosis of migraine before eletriptan hydrobromide tablets are administered to treat any subsequent attacks. • Eletriptan hydrobromide tablets are not intended for the prevention of migraine attacks. • Safety and effectiveness of eletriptan hydrobromide tablets have not been established for cluster headache. uuid:fa3f35eb-6b86-42ad-beb5-e6eee23c3ef6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0005314 PMID:41385096 "[{""id"":""uuid:b8fa590f-65ad-4c1a-a91c-c681e352255e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:caa8d1b1-fe5f-41c6-af3c-589da2899732"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycisis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamon-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:4ca9e791-df90-4761-9b3a-60480920afdc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0021632 PMID:41385096 "[{""id"":""uuid:0fbf55f3-1fc4-4158-a38f-526a547e7bf5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2c989634-6bf4-431f-b2e6-7acafaefc89b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycisis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamon-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:fb0b4ffb-2ada-4e7c-b9f5-154f05d46069 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:1040026 PMID:41385096 "[{""id"":""uuid:56fe963d-aa9e-4e73-94f9-54a5a9f1628d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:400cb52a-868d-4733-86e6-c4ec3bf9b951"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, seasonal or perennial allergic rhinitis and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycisis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamon-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:42d74228-9e47-4498-b946-6208559b107b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0006640 PMID:41385096 "[{""id"":""uuid:74b92d88-cb32-4095-897d-20dda7618973"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:060d296b-89e3-45f8-b347-032abeeb6da1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:155242b7-184e-44ea-b589-29161390200a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68540 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:5a2462f1-97b2-4cbb-afee-5bc6e3835a76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:47ac97aa-a2ae-442a-8c8f-785e980c96f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:09f9e869-bf46-47e2-9228-43e7bd9cab99"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/aubagio""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Teriflunomide tablets are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.|[EMA] AUBAGIO is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (MS) (please refer to section 5.1 for important information on the population for which efficacy has been established). uuid:ba5cad24-c7a8-4404-b8eb-b2a355b24791 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68540 biolink:treats UMLS:C2921627 PMID:41385096 "[{""id"":""uuid:903f8eef-d487-4353-ac36-0d6a7ee9c318"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f96521cb-f807-4cdb-be13-b91c5283b898"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Teriflunomide tablets are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. uuid:651f006e-9b15-47ae-844c-1ff9e3934105 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68540 biolink:treats MONDO:0000450 PMID:41385096 "[{""id"":""uuid:ecdc3910-d287-469a-a854-a29ccef74b69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ee8b211e-38f8-4c0e-a8a0-c46e5b49d727"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Teriflunomide tablets are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. uuid:70936a27-1bbb-4a78-aef6-5f5eb556efc0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31498 biolink:treats UMLS:C0554628 PMID:41385096 "[{""id"":""uuid:1ae50184-efc5-489c-9cbd-56559f517b14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5684ac84-b601-4ad7-99d9-5787da98fb81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mupirocin ointment is indicated for the topical treatment of impetigo due to susceptible isolates of Staphylococcus aureus (S. aureus) and Streptococcus pyogenes (S. pyogenes) . uuid:6bf67d71-6b08-4814-b16f-7e5c141e3261 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6437 biolink:treats MONDO:0006710 PMID:41385096 "[{""id"":""uuid:a0aa596c-b432-4ae3-8e03-67cdc4e48366"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:aedfa453-8823-4d91-a1b5-cd1ce87f3cce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9f17c852-096e-4770-83a4-83ddef686992"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/levetiracetam-sun""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levetiracetam is indicated for the treatment of partial-onset seizures in patients 1 month of age and older (1.1) Levetiracetam is indicated for adjunctive therapy for the treatment of: • Myoclonic seizures in patients 12 years of age and older with juvenile myoclonic epilepsy (1.2) • Primary generalized tonic-clonic seizures in patients 6 years of age and older with idiopathic generalized epilepsy (1.3)|[EMA] Levetiracetam Hospira is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in adults and adolescents from 16 years of age with newly diagnosed epilepsy.Levetiracetam Hospira is indicated as adjunctive therapyin the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.Levetiracetam Hospira concentrate is an alternative for patients when oral administration is temporarily not feasible. uuid:46749c2d-adff-4900-a001-1e6bf9b33005 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64356 biolink:treats MONDO:0001583 PMID:41385096 "[{""id"":""uuid:b00f2937-012f-4614-a129-aa3983e14dc7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0c8e2170-788e-48d6-8018-de7da05fbeed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pregabalin capsules are indicated for: Management of neuropathic pain associated with diabetic peripheral neuropathy Management of postherpetic neuralgia Adjunctive therapy for the treatment of partial-onset seizures in patients 17 years of age and older Management of fibromyalgia Management of neuropathic pain associated with spinal cord injury Pediatric use information is approved for Pfizer's LYRICA (pregabalin) Capsules and Oral Solution products. However, due to Pfizer's marketing exclusivity rights, this drug product is not labeled with that pediatric information. uuid:fc14baf7-f54c-4457-8de2-a5d1590ac0dd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:35A26E427H biolink:treats UMLS:C0581126 PMID:41385096 "[{""id"":""uuid:3bf6c834-7f7d-40da-b412-41e6928319b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d35c6c20-981f-475d-9245-5991917fd77e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CINQAIR ® is indicated for the add-on maintenance treatment of patients with severe asthma aged 18 years and older with an eosinophilic phenotype [see Clinical Studies ( 14 )] . Limitation of Use: CINQAIR is not indicated for treatment of other eosinophilic conditions. CINQAIR is not indicated for the relief of acute bronchospasm or status asthmaticus [see Warnings and Precautions ( 5.2 )] . uuid:419e1442-a45e-4d4c-87e4-c2687738b562 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats UMLS:C0406317 PMID:41385096 "[{""id"":""uuid:e3aba3fb-4c01-4ad4-967a-6a6a334c1f7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2c82ecce-6576-4826-a32a-d4ecae036a7d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Betamethasone dipropionate spray is indicated for the treatment of mild to moderate plaque psoriasis in patients 18 years of age or older. uuid:59f7b265-81f9-4eeb-950b-31e71e10a158 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0005348 PMID:41385096 "[{""id"":""uuid:1bfaabd7-9989-4025-a4d9-02639ec353dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4831cfb1-393f-4745-84d3-ba9de28e266a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A. By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia. Nonsuppurative thyroiditis. Hypercalcemia associated with cancer. 2. Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis. Synovitis of osteoarthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis. Epicondylitis. Acute nonspecific tenosynovitis. Acute gouty arthritis. Psoriatic arthritis. Ankylosing spondylitis. 3. Collagen Diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Acute rheumatic carditis. 4. Dermatologic Diseases: Pemphigus. Severe erythema multiforme. (Stevens-Johnson Syndrome) Exfoliative dermatitis. Bullous dermatitis herpetiformis. Severe seborrheic dermatitis. Severe psoriasis. Mycosis fungoides. 5. Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma. Contact dermatitis. Atopic dermatitis. Serum sickness. Seasonal or perennial allergic rhinitis. Drug hypersensitivity reactions. Urticarial transfusion reactions. Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases: Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus. Iritis, iridocyclitis. Chorioretinitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Sympathetic ophthalmia. Anterior segment inflammation. Allergic conjunctivitis. Keratitis. Allergic corneal marginal ulcers. 7. Gastrointestinal Diseases: To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy). Regional enteritis (systemic therapy). 8. Respiratory Diseases: Symptomatic sarcoidosis. Berylliosis. Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler's syndrome not manageable by other means. Aspiration pneumonitis. 9. Hematologic Disorders: Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults. Erythroblastopenia (RBC anemia). Congenital (erythroid) hypoplastic anemia. 10. Neoplastic Diseases: For palliative management of: Leukemias and lymphomas in adults. Acute leukemia of childhood. 11. Edematous States: To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous: Tuberculosis meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. B. By intra-articular or soft tissue injection: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Synovitis of osteoarthritis. Rheumatoid arthritis. Acute and subacute bursitis. Acute gouty arthritis. Epicondylitis. Acute nonspecific tenosynovitis. Post-traumatic osteoarthritis. C. By intralesional injection: Keloids. Localized hypertrophic, infiltrated, inflammatory lesions of: lichen planus, psoriatic plaques, granuloma annulare, and lichen simplex chronicus (neurodermatitis). Discoid lupus erythematosus. Necrobiosis lipoidica diabeticorum. Alopecia areata. May also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:6359e2a6-7f69-4458-b387-6a8dfe2a9b96 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0006572 PMID:41385096 "[{""id"":""uuid:4bffc1d4-fcf3-459a-b57c-dcfdd8131717"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9e12bb94-73c6-43ec-8816-8907cc7bae30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A. By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia. Nonsuppurative thyroiditis. Hypercalcemia associated with cancer. 2. Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis. Synovitis of osteoarthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis. Epicondylitis. Acute nonspecific tenosynovitis. Acute gouty arthritis. Psoriatic arthritis. Ankylosing spondylitis. 3. Collagen Diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Acute rheumatic carditis. 4. Dermatologic Diseases: Pemphigus. Severe erythema multiforme. (Stevens-Johnson Syndrome) Exfoliative dermatitis. Bullous dermatitis herpetiformis. Severe seborrheic dermatitis. Severe psoriasis. Mycosis fungoides. 5. Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma. Contact dermatitis. Atopic dermatitis. Serum sickness. Seasonal or perennial allergic rhinitis. Drug hypersensitivity reactions. Urticarial transfusion reactions. Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases: Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus. Iritis, iridocyclitis. Chorioretinitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Sympathetic ophthalmia. Anterior segment inflammation. Allergic conjunctivitis. Keratitis. Allergic corneal marginal ulcers. 7. Gastrointestinal Diseases: To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy). Regional enteritis (systemic therapy). 8. Respiratory Diseases: Symptomatic sarcoidosis. Berylliosis. Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler's syndrome not manageable by other means. Aspiration pneumonitis. 9. Hematologic Disorders: Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults. Erythroblastopenia (RBC anemia). Congenital (erythroid) hypoplastic anemia. 10. Neoplastic Diseases: For palliative management of: Leukemias and lymphomas in adults. Acute leukemia of childhood. 11. Edematous States: To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous: Tuberculosis meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. B. By intra-articular or soft tissue injection: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Synovitis of osteoarthritis. Rheumatoid arthritis. Acute and subacute bursitis. Acute gouty arthritis. Epicondylitis. Acute nonspecific tenosynovitis. Post-traumatic osteoarthritis. C. By intralesional injection: Keloids. Localized hypertrophic, infiltrated, inflammatory lesions of: lichen planus, psoriatic plaques, granuloma annulare, and lichen simplex chronicus (neurodermatitis). Discoid lupus erythematosus. Necrobiosis lipoidica diabeticorum. Alopecia areata. May also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:6d3f183a-8609-43e7-8688-d4b48ce4bb6d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0006554 PMID:41385096 "[{""id"":""uuid:0bb52a8e-a267-488d-9ef1-3721ce359605"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e8a0bccb-a80c-434a-b66b-0576118e2b5d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A. By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia. Nonsuppurative thyroiditis. Hypercalcemia associated with cancer. 2. Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis. Synovitis of osteoarthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis. Epicondylitis. Acute nonspecific tenosynovitis. Acute gouty arthritis. Psoriatic arthritis. Ankylosing spondylitis. 3. Collagen Diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Acute rheumatic carditis. 4. Dermatologic Diseases: Pemphigus. Severe erythema multiforme. (Stevens-Johnson Syndrome) Exfoliative dermatitis. Bullous dermatitis herpetiformis. Severe seborrheic dermatitis. Severe psoriasis. Mycosis fungoides. 5. Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma. Contact dermatitis. Atopic dermatitis. Serum sickness. Seasonal or perennial allergic rhinitis. Drug hypersensitivity reactions. Urticarial transfusion reactions. Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases: Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus. Iritis, iridocyclitis. Chorioretinitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Sympathetic ophthalmia. Anterior segment inflammation. Allergic conjunctivitis. Keratitis. Allergic corneal marginal ulcers. 7. Gastrointestinal Diseases: To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy). Regional enteritis (systemic therapy). 8. Respiratory Diseases: Symptomatic sarcoidosis. Berylliosis. Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler's syndrome not manageable by other means. Aspiration pneumonitis. 9. Hematologic Disorders: Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults. Erythroblastopenia (RBC anemia). Congenital (erythroid) hypoplastic anemia. 10. Neoplastic Diseases: For palliative management of: Leukemias and lymphomas in adults. Acute leukemia of childhood. 11. Edematous States: To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous: Tuberculosis meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. B. By intra-articular or soft tissue injection: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Synovitis of osteoarthritis. Rheumatoid arthritis. Acute and subacute bursitis. Acute gouty arthritis. Epicondylitis. Acute nonspecific tenosynovitis. Post-traumatic osteoarthritis. C. By intralesional injection: Keloids. Localized hypertrophic, infiltrated, inflammatory lesions of: lichen planus, psoriatic plaques, granuloma annulare, and lichen simplex chronicus (neurodermatitis). Discoid lupus erythematosus. Necrobiosis lipoidica diabeticorum. Alopecia areata. May also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:b29944a7-6217-403f-b053-9d3c5ec1fefd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats UMLS:C0149922 PMID:41385096 "[{""id"":""uuid:471c11d8-0b22-40c4-a675-4f359bbbdecf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7ae7aa02-6a67-4d47-bb5f-9a1011c91b51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A. By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia. Nonsuppurative thyroiditis. Hypercalcemia associated with cancer. 2. Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis. Synovitis of osteoarthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis. Epicondylitis. Acute nonspecific tenosynovitis. Acute gouty arthritis. Psoriatic arthritis. Ankylosing spondylitis. 3. Collagen Diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Acute rheumatic carditis. 4. Dermatologic Diseases: Pemphigus. Severe erythema multiforme. (Stevens-Johnson Syndrome) Exfoliative dermatitis. Bullous dermatitis herpetiformis. Severe seborrheic dermatitis. Severe psoriasis. Mycosis fungoides. 5. Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma. Contact dermatitis. Atopic dermatitis. Serum sickness. Seasonal or perennial allergic rhinitis. Drug hypersensitivity reactions. Urticarial transfusion reactions. Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases: Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus. Iritis, iridocyclitis. Chorioretinitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Sympathetic ophthalmia. Anterior segment inflammation. Allergic conjunctivitis. Keratitis. Allergic corneal marginal ulcers. 7. Gastrointestinal Diseases: To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy). Regional enteritis (systemic therapy). 8. Respiratory Diseases: Symptomatic sarcoidosis. Berylliosis. Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler's syndrome not manageable by other means. Aspiration pneumonitis. 9. Hematologic Disorders: Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults. Erythroblastopenia (RBC anemia). Congenital (erythroid) hypoplastic anemia. 10. Neoplastic Diseases: For palliative management of: Leukemias and lymphomas in adults. Acute leukemia of childhood. 11. Edematous States: To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous: Tuberculosis meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. B. By intra-articular or soft tissue injection: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Synovitis of osteoarthritis. Rheumatoid arthritis. Acute and subacute bursitis. Acute gouty arthritis. Epicondylitis. Acute nonspecific tenosynovitis. Post-traumatic osteoarthritis. C. By intralesional injection: Keloids. Localized hypertrophic, infiltrated, inflammatory lesions of: lichen planus, psoriatic plaques, granuloma annulare, and lichen simplex chronicus (neurodermatitis). Discoid lupus erythematosus. Necrobiosis lipoidica diabeticorum. Alopecia areata. May also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:77532aec-ce4c-4cb0-8249-7ff448e9b868 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0006585 PMID:41385096 "[{""id"":""uuid:67ea2468-704d-4741-8f7a-1e1f56d105c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:60529f2e-ff53-418b-ac5c-f892cef732f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A. By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia. Nonsuppurative thyroiditis. Hypercalcemia associated with cancer. 2. Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis. Synovitis of osteoarthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis. Epicondylitis. Acute nonspecific tenosynovitis. Acute gouty arthritis. Psoriatic arthritis. Ankylosing spondylitis. 3. Collagen Diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Acute rheumatic carditis. 4. Dermatologic Diseases: Pemphigus. Severe erythema multiforme. (Stevens-Johnson Syndrome) Exfoliative dermatitis. Bullous dermatitis herpetiformis. Severe seborrheic dermatitis. Severe psoriasis. Mycosis fungoides. 5. Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma. Contact dermatitis. Atopic dermatitis. Serum sickness. Seasonal or perennial allergic rhinitis. Drug hypersensitivity reactions. Urticarial transfusion reactions. Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases: Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus. Iritis, iridocyclitis. Chorioretinitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Sympathetic ophthalmia. Anterior segment inflammation. Allergic conjunctivitis. Keratitis. Allergic corneal marginal ulcers. 7. Gastrointestinal Diseases: To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy). Regional enteritis (systemic therapy). 8. Respiratory Diseases: Symptomatic sarcoidosis. Berylliosis. Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler's syndrome not manageable by other means. Aspiration pneumonitis. 9. Hematologic Disorders: Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults. Erythroblastopenia (RBC anemia). Congenital (erythroid) hypoplastic anemia. 10. Neoplastic Diseases: For palliative management of: Leukemias and lymphomas in adults. Acute leukemia of childhood. 11. Edematous States: To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous: Tuberculosis meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. B. By intra-articular or soft tissue injection: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Synovitis of osteoarthritis. Rheumatoid arthritis. Acute and subacute bursitis. Acute gouty arthritis. Epicondylitis. Acute nonspecific tenosynovitis. Post-traumatic osteoarthritis. C. By intralesional injection: Keloids. Localized hypertrophic, infiltrated, inflammatory lesions of: lichen planus, psoriatic plaques, granuloma annulare, and lichen simplex chronicus (neurodermatitis). Discoid lupus erythematosus. Necrobiosis lipoidica diabeticorum. Alopecia areata. May also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:6bdfa0e1-cca0-4fdf-b0f6-649e2265bbbc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0019558 PMID:41385096 "[{""id"":""uuid:a6ddcfe5-db0f-4cab-8166-99c627346a5d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4359befa-5513-4ebd-b6de-f501c14b5b4c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A. By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia. Nonsuppurative thyroiditis. Hypercalcemia associated with cancer. 2. Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis. Synovitis of osteoarthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis. Epicondylitis. Acute nonspecific tenosynovitis. Acute gouty arthritis. Psoriatic arthritis. Ankylosing spondylitis. 3. Collagen Diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Acute rheumatic carditis. 4. Dermatologic Diseases: Pemphigus. Severe erythema multiforme. (Stevens-Johnson Syndrome) Exfoliative dermatitis. Bullous dermatitis herpetiformis. Severe seborrheic dermatitis. Severe psoriasis. Mycosis fungoides. 5. Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma. Contact dermatitis. Atopic dermatitis. Serum sickness. Seasonal or perennial allergic rhinitis. Drug hypersensitivity reactions. Urticarial transfusion reactions. Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases: Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus. Iritis, iridocyclitis. Chorioretinitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Sympathetic ophthalmia. Anterior segment inflammation. Allergic conjunctivitis. Keratitis. Allergic corneal marginal ulcers. 7. Gastrointestinal Diseases: To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy). Regional enteritis (systemic therapy). 8. Respiratory Diseases: Symptomatic sarcoidosis. Berylliosis. Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler's syndrome not manageable by other means. Aspiration pneumonitis. 9. Hematologic Disorders: Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults. Erythroblastopenia (RBC anemia). Congenital (erythroid) hypoplastic anemia. 10. Neoplastic Diseases: For palliative management of: Leukemias and lymphomas in adults. Acute leukemia of childhood. 11. Edematous States: To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous: Tuberculosis meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. B. By intra-articular or soft tissue injection: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Synovitis of osteoarthritis. Rheumatoid arthritis. Acute and subacute bursitis. Acute gouty arthritis. Epicondylitis. Acute nonspecific tenosynovitis. Post-traumatic osteoarthritis. C. By intralesional injection: Keloids. Localized hypertrophic, infiltrated, inflammatory lesions of: lichen planus, psoriatic plaques, granuloma annulare, and lichen simplex chronicus (neurodermatitis). Discoid lupus erythematosus. Necrobiosis lipoidica diabeticorum. Alopecia areata. May also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:d044a106-3418-4b3d-afe0-c8c8d38d6fda biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats UMLS:C0392445 PMID:41385096 "[{""id"":""uuid:36e2de18-2729-4ece-b142-cb364e923535"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d17f2d6c-91b5-4300-9e54-385eb5916142"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A. By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia. Nonsuppurative thyroiditis. Hypercalcemia associated with cancer. 2. Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis. Synovitis of osteoarthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis. Epicondylitis. Acute nonspecific tenosynovitis. Acute gouty arthritis. Psoriatic arthritis. Ankylosing spondylitis. 3. Collagen Diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Acute rheumatic carditis. 4. Dermatologic Diseases: Pemphigus. Severe erythema multiforme. (Stevens-Johnson Syndrome) Exfoliative dermatitis. Bullous dermatitis herpetiformis. Severe seborrheic dermatitis. Severe psoriasis. Mycosis fungoides. 5. Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma. Contact dermatitis. Atopic dermatitis. Serum sickness. Seasonal or perennial allergic rhinitis. Drug hypersensitivity reactions. Urticarial transfusion reactions. Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases: Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus. Iritis, iridocyclitis. Chorioretinitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Sympathetic ophthalmia. Anterior segment inflammation. Allergic conjunctivitis. Keratitis. Allergic corneal marginal ulcers. 7. Gastrointestinal Diseases: To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy). Regional enteritis (systemic therapy). 8. Respiratory Diseases: Symptomatic sarcoidosis. Berylliosis. Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler's syndrome not manageable by other means. Aspiration pneumonitis. 9. Hematologic Disorders: Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults. Erythroblastopenia (RBC anemia). Congenital (erythroid) hypoplastic anemia. 10. Neoplastic Diseases: For palliative management of: Leukemias and lymphomas in adults. Acute leukemia of childhood. 11. Edematous States: To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous: Tuberculosis meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. B. By intra-articular or soft tissue injection: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Synovitis of osteoarthritis. Rheumatoid arthritis. Acute and subacute bursitis. Acute gouty arthritis. Epicondylitis. Acute nonspecific tenosynovitis. Post-traumatic osteoarthritis. C. By intralesional injection: Keloids. Localized hypertrophic, infiltrated, inflammatory lesions of: lichen planus, psoriatic plaques, granuloma annulare, and lichen simplex chronicus (neurodermatitis). Discoid lupus erythematosus. Necrobiosis lipoidica diabeticorum. Alopecia areata. May also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:fb8b5edc-f767-4c22-afa8-2c0ced71d0ce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0005340 PMID:41385096 "[{""id"":""uuid:928eff80-aa8f-418c-aa60-17fe91311b8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:85943d36-a9d8-41fd-a82d-7fc51ddfba96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A. By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia. Nonsuppurative thyroiditis. Hypercalcemia associated with cancer. 2. Rheumatic Disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis. Synovitis of osteoarthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis. Epicondylitis. Acute nonspecific tenosynovitis. Acute gouty arthritis. Psoriatic arthritis. Ankylosing spondylitis. 3. Collagen Diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Acute rheumatic carditis. 4. Dermatologic Diseases: Pemphigus. Severe erythema multiforme. (Stevens-Johnson Syndrome) Exfoliative dermatitis. Bullous dermatitis herpetiformis. Severe seborrheic dermatitis. Severe psoriasis. Mycosis fungoides. 5. Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma. Contact dermatitis. Atopic dermatitis. Serum sickness. Seasonal or perennial allergic rhinitis. Drug hypersensitivity reactions. Urticarial transfusion reactions. Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases: Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus. Iritis, iridocyclitis. Chorioretinitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Sympathetic ophthalmia. Anterior segment inflammation. Allergic conjunctivitis. Keratitis. Allergic corneal marginal ulcers. 7. Gastrointestinal Diseases: To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy). Regional enteritis (systemic therapy). 8. Respiratory Diseases: Symptomatic sarcoidosis. Berylliosis. Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler's syndrome not manageable by other means. Aspiration pneumonitis. 9. Hematologic Disorders: Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults. Erythroblastopenia (RBC anemia). Congenital (erythroid) hypoplastic anemia. 10. Neoplastic Diseases: For palliative management of: Leukemias and lymphomas in adults. Acute leukemia of childhood. 11. Edematous States: To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous: Tuberculosis meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. B. By intra-articular or soft tissue injection: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Synovitis of osteoarthritis. Rheumatoid arthritis. Acute and subacute bursitis. Acute gouty arthritis. Epicondylitis. Acute nonspecific tenosynovitis. Post-traumatic osteoarthritis. C. By intralesional injection: Keloids. Localized hypertrophic, infiltrated, inflammatory lesions of: lichen planus, psoriatic plaques, granuloma annulare, and lichen simplex chronicus (neurodermatitis). Discoid lupus erythematosus. Necrobiosis lipoidica diabeticorum. Alopecia areata. May also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:54e784f5-b610-4a92-9013-b303541084ca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44185 biolink:treats MONDO:0004967 PMID:41385096 "[{""id"":""uuid:6d4bd0ae-610f-45eb-954f-61c523d8dbdc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:1cef0e8e-bb98-41f0-ad5d-a7246a9d330e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d82b5d2e-c125-40ff-b149-b01eedf3fd41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/nordimet""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methotrexate tablets are a dihydrofolate reductase inhibitor indicated for the: Treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen ( 1.1 ) Treatment of adults with mycosis fungoides ( 1.1 ) Treatment of adults with relapsed or refractory non-Hodgkin lymphoma as part of a metronomic combination regimen ( 1.1 ) Treatment of adults with rheumatoid arthritis ( 1.2 ) Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA) ( 1.3 ) Treatment of adults with severe psoriasis ( 1.4 )|[EMA] In rheumatological and dermatological diseasesActive rheumatoid arthritis in adult patients.Polyarthritic forms of active, severe juvenile idiopathic arthritis (JIA) in adolescents and children aged 3 years and over when the response to non-steroidal anti-inflammatory drugs (NSAIDs) has been inadequate.Severe, treatment-refractory, disabling psoriasis which does not respond sufficiently to other forms of treatment such as phototherapy, psoralen and ultraviolet A radiation (PUVA) therapy and retinoids, and severe psoriatic arthritis in adult patients.In oncologyMaintenance treatment of acute lymphoblastic leukaemia (ALL) in adults, adolescents and children aged 3 years and over. uuid:d0201d20-a35e-479b-b1d2-915d7e5a6813 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44185 biolink:treats MONDO:0009691 PMID:41385096 "[{""id"":""uuid:b0f359e2-b293-489d-9c8a-39a10e5a021b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4f3988b2-dc8c-4943-a1ca-a885c250d754"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methotrexate tablets are a dihydrofolate reductase inhibitor indicated for the: Treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen ( 1.1 ) Treatment of adults with mycosis fungoides ( 1.1 ) Treatment of adults with relapsed or refractory non-Hodgkin lymphoma as part of a metronomic combination regimen ( 1.1 ) Treatment of adults with rheumatoid arthritis ( 1.2 ) Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA) ( 1.3 ) Treatment of adults with severe psoriasis ( 1.4 ) uuid:b8782c48-bf59-4b57-92db-4ce8a22e4a08 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44185 biolink:treats MONDO:0018908 PMID:41385096 "[{""id"":""uuid:6f12c523-c573-4258-9aab-f05d0f8fcf72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3423bfab-54df-4d40-ae23-161c8753fb24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methotrexate tablets are a dihydrofolate reductase inhibitor indicated for the: Treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen ( 1.1 ) Treatment of adults with mycosis fungoides ( 1.1 ) Treatment of adults with relapsed or refractory non-Hodgkin lymphoma as part of a metronomic combination regimen ( 1.1 ) Treatment of adults with rheumatoid arthritis ( 1.2 ) Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA) ( 1.3 ) Treatment of adults with severe psoriasis ( 1.4 ) uuid:25f02b1e-a08c-4412-9b71-352f8a4f0c0c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44185 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:7219641b-62a8-4589-9d59-d71de57b1b58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cd4b6159-e0ef-43e8-af98-aa9723071e6c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c9702e42-799e-416d-a166-5cd10f2d7289"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/nordimet""]},{""id"":""uuid:ef35be21-6247-47ff-b9b2-9bb8633ced2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methotrexate tablets are a dihydrofolate reductase inhibitor indicated for the: Treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen ( 1.1 ) Treatment of adults with mycosis fungoides ( 1.1 ) Treatment of adults with relapsed or refractory non-Hodgkin lymphoma as part of a metronomic combination regimen ( 1.1 ) Treatment of adults with rheumatoid arthritis ( 1.2 ) Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA) ( 1.3 ) Treatment of adults with severe psoriasis ( 1.4 )|[EMA] Nordimet is indicated for the treatment of:active rheumatoid arthritis in adult patients,polyarthritic forms of severe, active juvenile idiopathic arthritis (JIA), when the response to nonsteroidal anti-inflammatory drugs (NSAIDs) has been inadequate,moderate to severe plaque psoriasis in adults who are candidates for systemic therapy, and severe psoriatic arthritis in adult patients, induction of remission in moderate steroid-dependent Crohn's disease in adult patients, in combination with corticosteroids and for maintenance of remission, as monotherapy, in patients who have responded to methotrexate.|[PMDA] Drugs with a new indication and a new dosage in an additional dosage form for the treatment of rheumatoid arthritis. uuid:63f393f0-6e73-420a-b291-9dde1651132c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44185 biolink:treats MONDO:0018456 PMID:41385096 "[{""id"":""uuid:a082b96b-e639-47b9-b9a2-461ddab2d4b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:07ee5bfd-32c8-402a-86b7-a1038509df4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methotrexate tablets are a dihydrofolate reductase inhibitor indicated for the: Treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen ( 1.1 ) Treatment of adults with mycosis fungoides ( 1.1 ) Treatment of adults with relapsed or refractory non-Hodgkin lymphoma as part of a metronomic combination regimen ( 1.1 ) Treatment of adults with rheumatoid arthritis ( 1.2 ) Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA) ( 1.3 ) Treatment of adults with severe psoriasis ( 1.4 ) uuid:7029f4a4-72db-460e-8620-8466b39ec5d0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44185 biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:34b7f38e-4361-4eef-b206-4fbd51789e03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9a24f523-c5d6-4f38-82f5-65faa24d219b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b07ec5e4-3935-4f53-b511-9595e04714fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/nordimet""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methotrexate tablets are a dihydrofolate reductase inhibitor indicated for the: Treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen ( 1.1 ) Treatment of adults with mycosis fungoides ( 1.1 ) Treatment of adults with relapsed or refractory non-Hodgkin lymphoma as part of a metronomic combination regimen ( 1.1 ) Treatment of adults with rheumatoid arthritis ( 1.2 ) Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA) ( 1.3 ) Treatment of adults with severe psoriasis ( 1.4 )|[EMA] Nordimet is indicated for the treatment of:active rheumatoid arthritis in adult patients,polyarthritic forms of severe, active juvenile idiopathic arthritis (JIA), when the response to nonsteroidal anti-inflammatory drugs (NSAIDs) has been inadequate,moderate to severe plaque psoriasis in adults who are candidates for systemic therapy, and severe psoriatic arthritis in adult patients, induction of remission in moderate steroid-dependent Crohn's disease in adult patients, in combination with corticosteroids and for maintenance of remission, as monotherapy, in patients who have responded to methotrexate. uuid:7012709d-d4b0-4b86-9a4d-45188e56599e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28680 biolink:treats MONDO:0018874 PMID:41385096 "[{""id"":""uuid:b0845b2b-d2de-4323-ab89-4b5b46e0faa3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:20319968-e199-4a9e-805e-3561818459bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cytarabine Injection in combination with other approved anti-cancer drugs is indicated for remission induction in acute non-lymphocytic leukemia of adults and pediatric patients. It has also been found useful in the treatment of acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia. Intrathecal administration of Cytarabine Injection (preservative free preparations only) is indicated in the prophylaxis and treatment of meningeal leukemia. uuid:36d9ded6-f4ad-467a-bbb8-7fcd93c23fee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28680 biolink:treats MONDO:0004967 PMID:41385096 "[{""id"":""uuid:712a8f21-b2b1-45cb-8a65-cb76d43d233c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fefca1ab-666d-44d2-b9cf-41623ad28345"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cytarabine Injection in combination with other approved anti-cancer drugs is indicated for remission induction in acute non-lymphocytic leukemia of adults and pediatric patients. It has also been found useful in the treatment of acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia. Intrathecal administration of Cytarabine Injection (preservative free preparations only) is indicated in the prophylaxis and treatment of meningeal leukemia. uuid:f00cdcea-bb44-458f-9e81-85eb7f8ab477 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28680 biolink:treats MONDO:0006115 PMID:41385096 "[{""id"":""uuid:91dae5fe-ef42-44c5-aa24-1263e4e7ec74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:576b16bc-4fda-4402-95fe-3fd87ff48b4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0a61d774-aa6e-4b42-a2a5-52865e233d3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cytarabine Injection in combination with other approved anti-cancer drugs is indicated for remission induction in acute non-lymphocytic leukemia of adults and pediatric patients. It has also been found useful in the treatment of acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia. Intrathecal administration of Cytarabine Injection (preservative free preparations only) is indicated in the prophylaxis and treatment of meningeal leukemia.|[PMDA] Drugs with a new dosage indicated for the treatment of acute leukemia (including erythroleukemia and blast crisis of chronic myeloid leukemia). [Public knowledge-based application] uuid:e8801829-5919-4c89-a803-c1fb3639d441 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28680 biolink:treats UMLS:C0948840 PMID:41385096 "[{""id"":""uuid:5ca6d70b-d297-4428-870e-02247114f271"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:97fa6b65-af4f-495b-a8e9-bcd0670d1eb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cytarabine Injection in combination with other approved anti-cancer drugs is indicated for remission induction in acute non-lymphocytic leukemia of adults and pediatric patients. It has also been found useful in the treatment of acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia. Intrathecal administration of Cytarabine Injection (preservative free preparations only) is indicated in the prophylaxis and treatment of meningeal leukemia. uuid:a33cb5d0-1516-490d-abbd-4a7238cb19bc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4B33BGI082 biolink:treats HP:0000989 PMID:41385096 "[{""id"":""uuid:9fc35cd0-2a5b-4126-bda7-26c77ac6c27f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:104029ab-c6ee-40bb-a9fb-3a7c39e8b852"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1) Prevalite ® (cholestyramine for oral suspension, USP) powder is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Prevalite ® (cholestyramine for oral suspension, USP) powder may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. Excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. Prior to initiating therapy with cholestyramine resin, secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism), should be excluded and a lipid profile performed to assess Total Cholesterol, HDL-C and triglycerides (TG). For individuals with TG less than 400 mg/dL (<4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total Cholesterol - [(TG/5) + HDL-C] For TG levels > 400 mg/dL, this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases cholestyramine resin may not be indicated. Serum cholesterol and triglyceride levels should be determined periodically based on NCEP guidelines to confirm initial and adequate long-term response. A favorable trend in cholesterol reduction should occur during the first month of cholestyramine resin therapy. The therapy should be continued to sustain cholesterol reduction. If adequate cholesterol reduction is not attained, increasing the dosage of cholestyramine resin or adding other lipid-lowering agents in combination with cholestyramine resin should be considered. Since the goal of treatment is to lower LDL-C, the NCEP 4 recommends that LDL-C levels be used to initiate and assess treatment response. If LDL-C levels are not available then Total-C alone may be used to monitor long-term therapy. A lipoprotein analysis (including LDL-C determination) should be carried out once a year. The NCEP treatment guidelines are summarized below. LDL-Cholesterol mg/dL (mmol/L) Definite Atherosclerotic Disease Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease) Two or More Other Risk Factors Other risk factors for coronary heart disease (CHD) include: age (males ≥45 years; females: ≥55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C <35 mg/dL (<0.91 mmol/L); and diabetes mellitus. Subtract one risk factor if HDL-C is ≥60 mg/dL (≥1.6 mmol/L). Initiation Level Goal No No ≥190 (≥4.9) <160 (<4.1) No Yes ≥160 (≥4.1) <130 (<3.4) Yes Yes or No ≥130 (≥3.4) ≤100 (≤2.6) Cholestyramine resin monotherapy has been demonstrated to retard the rate of progression 2,3 and increase the rate of regression 3 of coronary atherosclerosis. 2) Prevalite ® (cholestyramine for oral suspension, USP) powder is indicated for the relief of pruritus associated with partial biliary obstruction. Cholestyramine resin has been shown to have a variable effect on serum cholesterol in these patients. Patients with primary biliary cirrhosis may exhibit an elevated cholesterol as part of their disease. uuid:4258ef72-8d48-4329-8145-c20fc3fe1b6d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4B33BGI082 biolink:treats MONDO:0005230 PMID:41385096 "[{""id"":""uuid:430ef3df-49d1-4fc3-9311-83a927245fb7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f13a23c2-5d52-4c25-87ad-fc0bffea5191"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1) Prevalite ® (cholestyramine for oral suspension, USP) powder is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Prevalite ® (cholestyramine for oral suspension, USP) powder may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. Excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. Prior to initiating therapy with cholestyramine resin, secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism), should be excluded and a lipid profile performed to assess Total Cholesterol, HDL-C and triglycerides (TG). For individuals with TG less than 400 mg/dL (<4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total Cholesterol - [(TG/5) + HDL-C] For TG levels > 400 mg/dL, this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases cholestyramine resin may not be indicated. Serum cholesterol and triglyceride levels should be determined periodically based on NCEP guidelines to confirm initial and adequate long-term response. A favorable trend in cholesterol reduction should occur during the first month of cholestyramine resin therapy. The therapy should be continued to sustain cholesterol reduction. If adequate cholesterol reduction is not attained, increasing the dosage of cholestyramine resin or adding other lipid-lowering agents in combination with cholestyramine resin should be considered. Since the goal of treatment is to lower LDL-C, the NCEP 4 recommends that LDL-C levels be used to initiate and assess treatment response. If LDL-C levels are not available then Total-C alone may be used to monitor long-term therapy. A lipoprotein analysis (including LDL-C determination) should be carried out once a year. The NCEP treatment guidelines are summarized below. LDL-Cholesterol mg/dL (mmol/L) Definite Atherosclerotic Disease Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease) Two or More Other Risk Factors Other risk factors for coronary heart disease (CHD) include: age (males ≥45 years; females: ≥55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C <35 mg/dL (<0.91 mmol/L); and diabetes mellitus. Subtract one risk factor if HDL-C is ≥60 mg/dL (≥1.6 mmol/L). Initiation Level Goal No No ≥190 (≥4.9) <160 (<4.1) No Yes ≥160 (≥4.1) <130 (<3.4) Yes Yes or No ≥130 (≥3.4) ≤100 (≤2.6) Cholestyramine resin monotherapy has been demonstrated to retard the rate of progression 2,3 and increase the rate of regression 3 of coronary atherosclerosis. 2) Prevalite ® (cholestyramine for oral suspension, USP) powder is indicated for the relief of pruritus associated with partial biliary obstruction. Cholestyramine resin has been shown to have a variable effect on serum cholesterol in these patients. Patients with primary biliary cirrhosis may exhibit an elevated cholesterol as part of their disease. uuid:4675b2c9-7b58-4c7e-a451-d88c7a1c75c1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:681569 biolink:treats MONDO:0004967 PMID:41385096 "[{""id"":""uuid:74283673-8fb2-45ac-b4ee-246194e4d431"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1ec1670e-94dc-4242-b6a9-b19e787ec52b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ae9da658-4be4-463e-836d-8b170e45a61d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/evoltra""]},{""id"":""uuid:de292729-5638-41e2-93ff-cc874691fc4c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clofarabine Injection is indicated for the treatment of pediatric patients 1 to 21 years old with relapsed or refractory acute lymphoblastic leukemia after at least two prior regimens. This indication is based upon response rate. There are no trials verifying an improvement in disease-related symptoms or increased survival with Clofarabine Injection.|[EMA] Treatment of acute lymphoblastic leukaemia (ALL) in paediatric patients who have relapsed or are refractory after receiving at least two prior regimens and where there is no other treatment option anticipated to result in a durable response. Safety and efficacy have been assessed in studies of patients ≤ 21 years old at initial diagnosis.|[PMDA] A drug with a new active ingredient for the treatment of recurrent or refractory acute lymphoblastic leukemia. [Orphan drug] uuid:d857a5e3-2595-4b14-b107-8b10611b0c59 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135949 biolink:treats MONDO:0015924 PMID:41385096 "[{""id"":""uuid:a1908ed4-dd71-4012-a582-a2ccd253e08f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4c2df637-d7b3-4d43-ba47-2c6414bd5d34"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:215c4901-5de0-4291-9f59-40cdab63ec26"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/volibris""]},{""id"":""uuid:6426196a-e47e-452d-a558-d30bb4d4121d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ambrisentan tablet is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1): To improve exercise ability and delay clinical worsening. Studies establishing effectiveness included trials predominantly in patients with WHO Functional Class II–III symptoms and etiologies of idiopathic or heritable PAH (60%) or PAH associated with connective tissue diseases (34%) ( 1 ).|[EMA] Volibris is indicated for treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III, including use in combination treatment (see section 5.1). Efficacy has been shown in idiopathic PAH (IPAH) and in PAH associated with connective tissue disease.Volibris is indicated for treatment of PAH in adolescents and children (aged 8 to less than 18 years) of WHO Functional Class (FC) II to III including use in combination treatment. Efficacy has been shown in IPAH, familial, corrected congenital and in PAH associated with connective tissue disease (see section 5.1).|[PMDA] A drug with a new active ingredient indicated for the treatment of pulmonary arterial hypertension. [Orphan drug] uuid:d823a1ed-56a7-4e64-94ea-eb29b5a49ce2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135949 biolink:treats MONDO:0017147 PMID:41385096 "[{""id"":""uuid:374fd7b5-e98d-4f10-950e-b5f8633f9ea2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ce674821-4e7a-4d14-bc06-f7ef56711374"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3cda08fd-1617-43ab-baca-15b51fea9d88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/volibris""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ambrisentan tablet is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1): To improve exercise ability and delay clinical worsening. Studies establishing effectiveness included trials predominantly in patients with WHO Functional Class II–III symptoms and etiologies of idiopathic or heritable PAH (60%) or PAH associated with connective tissue diseases (34%) ( 1 ).|[EMA] Volibris is indicated for treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III, including use in combination treatment (see section 5.1). Efficacy has been shown in idiopathic PAH (IPAH) and in PAH associated with connective tissue disease.Volibris is indicated for treatment of PAH in adolescents and children (aged 8 to less than 18 years) of WHO Functional Class (FC) II to III including use in combination treatment. Efficacy has been shown in IPAH, familial, corrected congenital and in PAH associated with connective tissue disease (see section 5.1). uuid:4d509301-c766-4d31-9db5-9bd63effacee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135949 biolink:treats MONDO:0017148 PMID:41385096 "[{""id"":""uuid:2656f677-7e10-4269-b17c-5bc9ff87a02b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:18904e22-55b7-408c-96cc-8fd5073d26d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ambrisentan tablet is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1): To improve exercise ability and delay clinical worsening. Studies establishing effectiveness included trials predominantly in patients with WHO Functional Class II–III symptoms and etiologies of idiopathic or heritable PAH (60%) or PAH associated with connective tissue diseases (34%) ( 1 ). uuid:0b2bb892-256c-424e-a3eb-2a9844ebc286 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85157 biolink:treats EFO:0006911 PMID:41385096 "[{""id"":""uuid:c65a17cd-4b01-456a-99a4-bd00afb9f85b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c60be916-ff99-4e54-b7d0-19738194127b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Palonosetron hydrochloride injection is indicated in adults for prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). acute nausea and vomiting associated with initial and repeat courses highly emetogenic cancer chemotherapy (HEC). postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated. As with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and vomiting must be avoided during the postoperative period, palonosetron hydrochloride injection is recommended even where the incidence of postoperative nausea and/or vomiting is low. Palonosetron hydrochloride injection is indicated in pediatric patients 1 month to less than 17 years of age for prevention of: acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy. uuid:9d33266a-2f2f-4544-9f73-b9b70374d9bb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85157 biolink:treats EFO:0004888 PMID:41385096 "[{""id"":""uuid:6c92fa34-10bd-4568-9a34-554d1158e325"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fc05baba-e23e-4efe-a262-4d42564f8a4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Palonosetron hydrochloride injection is indicated in adults for prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). acute nausea and vomiting associated with initial and repeat courses highly emetogenic cancer chemotherapy (HEC). postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated. As with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and vomiting must be avoided during the postoperative period, palonosetron hydrochloride injection is recommended even where the incidence of postoperative nausea and/or vomiting is low. Palonosetron hydrochloride injection is indicated in pediatric patients 1 month to less than 17 years of age for prevention of: acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy. uuid:a752433f-3548-4d7b-a4ce-f528048ed9cf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50131 biolink:treats MONDO:0018881 PMID:41385096 "[{""id"":""uuid:0187ab15-042a-461e-b079-1739eb31ca8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:226d6733-f700-4956-a812-b941d6f15cf6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Decitabine for Injection is indicated for treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups. uuid:600fee69-2d0e-4393-bc92-e2348c8cc17e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50131 biolink:treats MONDO:0005272 PMID:41385096 "[{""id"":""uuid:0f6082f8-04b7-4e03-86e5-223eb673f91f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ea5aa25d-4fcb-4ea5-9a38-015b0d3e032a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Decitabine for Injection is indicated for treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups. uuid:8e228a6e-0de5-46dc-9fa7-0f2c2d6aed11 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50131 biolink:treats MONDO:0019157 PMID:41385096 "[{""id"":""uuid:b7de46d3-482c-4a7b-8b14-50280420d21f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:81f3ecb3-cbd3-4b09-bca2-f9da103d7d3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Decitabine for Injection is indicated for treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups. uuid:110d2d7d-624b-4c2b-aa20-30fe6d0e933c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50131 biolink:treats MONDO:0019454 PMID:41385096 "[{""id"":""uuid:0d2a908f-6446-4770-8fb7-2a5752092cc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e9f74674-6a11-47c0-b246-fb0f43e4352d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Decitabine for Injection is indicated for treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups. uuid:ddee6f4f-21cf-4247-bd2c-d25c92527016 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50131 biolink:treats MONDO:0015692 PMID:41385096 "[{""id"":""uuid:6b4f13fc-4a78-4e17-88d7-ba6e845b45c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9cbf1833-0534-442f-a171-8dcade5dbbbc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Decitabine for Injection is indicated for treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups. uuid:90adc353-a180-4e2d-b94d-e322e06ca95f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50131 biolink:treats MONDO:0020311 PMID:41385096 "[{""id"":""uuid:68fc5210-8dcd-4a4e-9dc5-608d32d54c5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ef0001bb-250f-4e0a-a54d-e0a89a2f767e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Decitabine for Injection is indicated for treatment of adult patients with myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS of all French-American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups. uuid:01e239c2-caa5-4170-b8f9-4556221eedf1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4975 biolink:treats MONDO:0019610 PMID:41385096 "[{""id"":""uuid:db7be3df-3bba-4a53-97a7-ad864b142674"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:48944f73-6ca8-4df8-96cc-763556aa34a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Famotidine tablets are indicated in adult and pediatric patients 40 kg and above for the treatment of: • active duodenal ulcer. • active gastric ulcer. • symptomatic non-erosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. Famotidine tablets are indicated in adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger- Ellison Syndrome, multiple endocrine neoplasias). • reduction of the risk of duodenal ulcer recurrence. uuid:b9f2a103-5f8d-4110-a090-96e05cf269dd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1152239 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:649e8451-0f56-4c91-bdaa-0e6dbe810453"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:188e4a2e-fdb1-451b-8707-7c777c864c0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tramadol hydrochloride and acetaminophen tablets are indicated for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Tramadol hydrochloride and acetaminophen tablets are indicated for short-term use of five days or less. Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see Warnings and Precautions ( 5.1 )] , reserve tramadol hydrochloride and acetaminophen tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics]: Have not been tolerated, or are not expected to be tolerated, Have not provided adequate analgesia, or are not expected to provide adequate analgesia. uuid:ca07e2a5-e253-4c82-8fbb-d885d3a4ef68 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135782 biolink:treats UMLS:C0406317 PMID:41385096 "[{""id"":""uuid:a54e292b-7ece-4260-ab5c-a34cda5d0564"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f9bffe9b-31d7-47c8-a217-54cde79a6c46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BRYHALI ® (halobetasol propionate) lotion, 0.01% is indicated for the topical treatment of plaque psoriasis in adults. uuid:d6169dc3-950b-4d48-ad1b-8cb7eadf828d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46557 biolink:treats MONDO:0008159 PMID:41385096 "[{""id"":""uuid:3b3393a8-25c9-4a6d-a48b-4cb658ee2d99"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:799abba3-3d0a-4abb-86ed-b03f16414ed7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Zoledronic acid injection is a bisphosphonate indicated for: •Treatment and prevention of postmenopausal osteoporosis ( 1.1 , 1.2 ) •Treatment to increase bone mass in men with osteoporosis ( 1.3 ) •Treatment and prevention of glucocorticoid-induced osteoporosis ( 1.4 ) •Treatment of Paget’s disease of bone in men and women ( 1.5 ) Limitations of Use Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use ( 1.6 ) uuid:97a6dae4-b39f-4765-9ec9-dd490f66ec2d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46557 biolink:treats MONDO:0005298 PMID:41385096 "[{""id"":""uuid:b627d74e-4416-4724-b13e-cbbdd42702f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4f12139c-2a18-4c6f-8c06-879817ca2569"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:92414312-ba38-4955-bbe4-8753c22b3974"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:8584fca2-09ab-4fe0-b415-5b10fde76c6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Zoledronic acid injection is a bisphosphonate indicated for: •Treatment and prevention of postmenopausal osteoporosis ( 1.1 , 1.2 ) •Treatment to increase bone mass in men with osteoporosis ( 1.3 ) •Treatment and prevention of glucocorticoid-induced osteoporosis ( 1.4 ) •Treatment of Paget’s disease of bone in men and women ( 1.5 ) Limitations of Use Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use ( 1.6 )|[EMA] Treatment of osteoporosis:, , , in post-menopausal women;, in men;, , , at increased risk of fracture, including those with a recent low-trauma hip fracture., , Treatment of osteoporosis associated with long-term systemic glucocorticoid therapy in post-menopausal women and in men at increased risk of fracture., , Treatment of Paget's disease of the bone.,|[PMDA] A drug with a new indication and a new dosage in an additional dosage form indicated for the treatment of osteoporosis. uuid:29f9a90b-292f-4489-ad3a-57b088234f6c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46557 biolink:treats MONDO:0024651 PMID:41385096 "[{""id"":""uuid:0ad13629-f7d8-4675-a9c7-39366ad920a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3ef81630-c47d-4b1c-82a1-302037d1d217"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Zoledronic acid injection is a bisphosphonate indicated for: •Treatment and prevention of postmenopausal osteoporosis ( 1.1 , 1.2 ) •Treatment to increase bone mass in men with osteoporosis ( 1.3 ) •Treatment and prevention of glucocorticoid-induced osteoporosis ( 1.4 ) •Treatment of Paget’s disease of bone in men and women ( 1.5 ) Limitations of Use Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use ( 1.6 ) uuid:13f07f28-c21c-49f6-b2a1-f19f8d3bd3fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46557 biolink:treats MONDO:0005382 PMID:41385096 "[{""id"":""uuid:4cf8555e-69de-4a84-b9b3-837eeef30dd5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:df3fe110-6809-4dc5-9114-ea9b2e7a478d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:5a373c33-cfec-4e57-8d91-9d978174d2cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Zoledronic acid injection is a bisphosphonate indicated for: •Treatment and prevention of postmenopausal osteoporosis ( 1.1 , 1.2 ) •Treatment to increase bone mass in men with osteoporosis ( 1.3 ) •Treatment and prevention of glucocorticoid-induced osteoporosis ( 1.4 ) •Treatment of Paget’s disease of bone in men and women ( 1.5 ) Limitations of Use Optimal duration of use has not been determined. For patients at low-risk for fracture, consider drug discontinuation after 3 to 5 years of use ( 1.6 )|[EMA] Treatment of osteoporosis:, , , in post-menopausal women;, in men;, , , at increased risk of fracture, including those with a recent low-trauma hip fracture., , Treatment of osteoporosis associated with long-term systemic glucocorticoid therapy in post-menopausal women and in men at increased risk of fracture., , Treatment of Paget's disease of the bone., uuid:6330762d-19e4-4f3f-810b-4b50d3d1384a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10112 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:9cb4867e-4fdb-4663-bdb9-fa4d10b6b429"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7acbdcd7-7073-48c2-a527-567eab81ba0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Zileuton extended-release tabletis indicated for the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older. Zileuton extended-release tabletis not indicated for use in the reversal of bronchospasm in acute asthma attacks. Therapy with zileuton extended-release tablet can be continued during acute exacerbations of asthma. uuid:962ea215-f75d-4677-8eea-86f6dee0509c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10112 biolink:treats MONDO:0850283 PMID:41385096 "[{""id"":""uuid:bf567dd5-047a-4cb5-8679-e5abf3a20170"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eb6caaff-5893-4159-82c4-3f3132f744d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Zileuton extended-release tabletis indicated for the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older. Zileuton extended-release tabletis not indicated for use in the reversal of bronchospasm in acute asthma attacks. Therapy with zileuton extended-release tablet can be continued during acute exacerbations of asthma. uuid:9461d935-895a-4272-b4d0-312ce586884a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8863 biolink:treats MONDO:0004976 PMID:41385096 "[{""id"":""uuid:3b2663de-83d2-4263-acd0-580c767f2923"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4c75cd87-73e2-4e1b-97f9-20a07b9d6877"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:27838054-b6d4-4025-a865-c6e08985496e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/rilutek""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Riluzole tablets, USP are indicated for the treatment of amyotrophic lateral sclerosis (ALS).|[EMA] Rilutek is indicated to extend life or the time to mechanical ventilation for patients with amyotrophic lateral sclerosis (ALS).Clinical trials have demonstrated that Rilutek extends survival for patients with ALS.Survival was defined as patients who were alive, not intubated for mechanical ventilation and tracheotomy-free.There is no evidence that Rilutek exerts a therapeutic effect on motor function, lung function, fasciculations, muscle strength and motor symptoms.Rilutek has not been shown to be effective in the late stages of ALS.Safety and efficacy of Rilutek has only been studied in ALS. Therefore, Rilutek should not be used in patients with any other form of motor-neurone disease. uuid:b6d372d9-c25b-4ec3-accf-85e3ad71d79d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8863 biolink:treats MONDO:0008781 PMID:41385096 "[{""id"":""uuid:3756aade-b8d4-4a40-85eb-2e13c08b10db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:857ae8fa-3a7d-4192-abc4-557bb65378cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Riluzole tablets, USP are indicated for the treatment of amyotrophic lateral sclerosis (ALS). uuid:ddd4cc78-7bad-4125-b857-43976c98b04b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41774 biolink:treats MONDO:0005023 PMID:41385096 "[{""id"":""uuid:328fbe65-1bff-44eb-b78e-8b7bedafc87d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c3d6419d-e7c7-45eb-bb19-918e36fc933e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metastatic Breast Cancer: Tamoxifen citrate tablets are effective in the treatment of metastatic breast cancer in women and men. In premenopausal women with metastatic breast cancer, tamoxifen citrate tablets are an alternative to oophorectomy or ovarian irradiation. Available evidence indicates that patients whose tumors are estrogen receptor positive are more likely to benefit from tamoxifen citrate tablets therapy. Adjuvant Treatment of Breast Cancer: Tamoxifen citrate tablets are indicated for the treatment of node-positive breast cancer in women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. In some tamoxifen citrate adjuvant studies, most of the benefit to date has been in the subgroup with four or more positive axillary nodes. Tamoxifen citrate tablets are indicated for the treatment of axillary node-negative breast cancer in women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. The estrogen and progesterone receptor values may help to predict whether adjuvant tamoxifen citrate tablets therapy are likely to be beneficial. Tamoxifen citrate tablets reduces the occurrence of contralateral breast cancer in patients receiving adjuvant tamoxifen citrate tablets therapy for breast cancer. Ductal Carcinoma in Situ (DCIS): In women with DCIS, following breast surgery and radiation, tamoxifen citrate tablets are indicated to reduce the risk of invasive breast cancer (see BOXED WARNING at the beginning of the label). The decision regarding therapy with tamoxifen citrate tablets for the reduction in breast cancer incidence should be based upon an individual assessment of the benefits and risks of tamoxifen citrate tablets therapy. Current data from clinical trials support five years of adjuvant tamoxifen citrate tablets therapy for patients with breast cancer. Reduction in Breast Cancer Incidence in High Risk Women: Tamoxifen citrate tablets are indicated to reduce the incidence of breast cancer in women at high risk for breast cancer. This effect was shown in a study of 5 years planned duration with a median follow-up of 4.2 years. Twenty-five percent of the participants received drug for 5 years. The longer-term effects are not known. In this study, there was no impact of tamoxifen on overall or breast cancer-related mortality (see BOXED WARNING at the beginning of the label). Tamoxifen citrate tablets are indicated only for high-risk women. “High risk” is defined as women at least 35 years of age with a 5-year predicted risk of breast cancer ≥ 1.67%, as calculated by the Gail Model. Examples of combinations of factors predicting a 5-year risk ≥ 1.67% are: Age 35 or older and any of the following combination of factors: One first degree relative with a history of breast cancer, 2 or more benign biopsies, and a history of a breast biopsy showing atypical hyperplasia; or At least 2 first degree relatives with a history of breast cancer, and a personal history of at least one breast biopsy; or LCIS Age 40 or older and any of the following combination of factors: One first degree relative with a history of breast cancer, 2 or more benign biopsies, age at first live birth 25 or older, and age at menarche 11 or younger; or At least 2 first degree relatives with a history of breast cancer, and age at first live birth 19 or younger; or One first degree relative with a history of breast cancer, and a personal history of a breast biopsy showing atypical hyperplasia. Age 45 or older and any of the following combination of factors: At least 2 first degree relatives with a history of breast cancer and age at first live birth 24 or younger; or One first degree relative with a history of breast cancer with a personal history of a benign breast biopsy, age at menarche 11 or less and age at first live birth 20 or more. Age 50 or older and any of the following combination of factors: At least 2 first degree relatives with a history of breast cancer; or History of one breast biopsy showing atypical hyperplasia, and age at first live birth 30 or older and age at menarche 11 or less; or History of at least two breast biopsies with a history of atypical hyperplasia, and age at first live birth 30 or more. Age 55 or older and any of the following combination of factors: One first degree relative with a history of breast cancer with a personal history of a benign breast biopsy, and age at menarche 11 or less; or History of at least 2 breast biopsies with a history of atypical hyperplasia, and age at first live birth 20 or older. Age 60 or older and: 5-year predicted risk of breast cancer ≥ 1.67%, as calculated by the Gail Model. For women whose risk factors are not described in the above examples, the Gail Model is necessary to estimate absolute breast cancer risk. Health Care Professionals can obtain a Gail Model Risk Assessment Tool by dialing 1-866-850-2876. There are insufficient data available regarding the effect of tamoxifen citrate tablets on breast cancer incidence in women with inherited mutations (BRCA1, BRCA2) to be able to make specific recommendations on the effectiveness of tamoxifen citrate in these patients. After an assessment of the risk of developing breast cancer, the decision regarding therapy with tamoxifen citrate tablets for the reduction in breast cancer incidence should be based upon an individual assessment of the benefits and risks of tamoxifen citrate tablets therapy. In the NSABP P-1 trial, tamoxifen citrate tablets treatment lowered the risk of developing breast cancer during the follow-up period of the trial, but did not eliminate breast cancer risk (See Table 3 in CLINICAL PHARMACOLOGY ). uuid:4c9ff196-8bc6-4369-9723-6fc6f6afe042 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41774 biolink:treats MONDO:0006256 PMID:41385096 "[{""id"":""uuid:38195284-093d-40f0-a9ab-09ce9332c6a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:77ee7850-5ba6-4ad6-a0c4-7cee4c7cd842"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metastatic Breast Cancer: Tamoxifen citrate tablets are effective in the treatment of metastatic breast cancer in women and men. In premenopausal women with metastatic breast cancer, tamoxifen citrate tablets are an alternative to oophorectomy or ovarian irradiation. Available evidence indicates that patients whose tumors are estrogen receptor positive are more likely to benefit from tamoxifen citrate tablets therapy. Adjuvant Treatment of Breast Cancer: Tamoxifen citrate tablets are indicated for the treatment of node-positive breast cancer in women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. In some tamoxifen citrate adjuvant studies, most of the benefit to date has been in the subgroup with four or more positive axillary nodes. Tamoxifen citrate tablets are indicated for the treatment of axillary node-negative breast cancer in women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. The estrogen and progesterone receptor values may help to predict whether adjuvant tamoxifen citrate tablets therapy are likely to be beneficial. Tamoxifen citrate tablets reduces the occurrence of contralateral breast cancer in patients receiving adjuvant tamoxifen citrate tablets therapy for breast cancer. Ductal Carcinoma in Situ (DCIS): In women with DCIS, following breast surgery and radiation, tamoxifen citrate tablets are indicated to reduce the risk of invasive breast cancer (see BOXED WARNING at the beginning of the label). The decision regarding therapy with tamoxifen citrate tablets for the reduction in breast cancer incidence should be based upon an individual assessment of the benefits and risks of tamoxifen citrate tablets therapy. Current data from clinical trials support five years of adjuvant tamoxifen citrate tablets therapy for patients with breast cancer. Reduction in Breast Cancer Incidence in High Risk Women: Tamoxifen citrate tablets are indicated to reduce the incidence of breast cancer in women at high risk for breast cancer. This effect was shown in a study of 5 years planned duration with a median follow-up of 4.2 years. Twenty-five percent of the participants received drug for 5 years. The longer-term effects are not known. In this study, there was no impact of tamoxifen on overall or breast cancer-related mortality (see BOXED WARNING at the beginning of the label). Tamoxifen citrate tablets are indicated only for high-risk women. “High risk” is defined as women at least 35 years of age with a 5-year predicted risk of breast cancer ≥ 1.67%, as calculated by the Gail Model. Examples of combinations of factors predicting a 5-year risk ≥ 1.67% are: Age 35 or older and any of the following combination of factors: One first degree relative with a history of breast cancer, 2 or more benign biopsies, and a history of a breast biopsy showing atypical hyperplasia; or At least 2 first degree relatives with a history of breast cancer, and a personal history of at least one breast biopsy; or LCIS Age 40 or older and any of the following combination of factors: One first degree relative with a history of breast cancer, 2 or more benign biopsies, age at first live birth 25 or older, and age at menarche 11 or younger; or At least 2 first degree relatives with a history of breast cancer, and age at first live birth 19 or younger; or One first degree relative with a history of breast cancer, and a personal history of a breast biopsy showing atypical hyperplasia. Age 45 or older and any of the following combination of factors: At least 2 first degree relatives with a history of breast cancer and age at first live birth 24 or younger; or One first degree relative with a history of breast cancer with a personal history of a benign breast biopsy, age at menarche 11 or less and age at first live birth 20 or more. Age 50 or older and any of the following combination of factors: At least 2 first degree relatives with a history of breast cancer; or History of one breast biopsy showing atypical hyperplasia, and age at first live birth 30 or older and age at menarche 11 or less; or History of at least two breast biopsies with a history of atypical hyperplasia, and age at first live birth 30 or more. Age 55 or older and any of the following combination of factors: One first degree relative with a history of breast cancer with a personal history of a benign breast biopsy, and age at menarche 11 or less; or History of at least 2 breast biopsies with a history of atypical hyperplasia, and age at first live birth 20 or older. Age 60 or older and: 5-year predicted risk of breast cancer ≥ 1.67%, as calculated by the Gail Model. For women whose risk factors are not described in the above examples, the Gail Model is necessary to estimate absolute breast cancer risk. Health Care Professionals can obtain a Gail Model Risk Assessment Tool by dialing 1-866-850-2876. There are insufficient data available regarding the effect of tamoxifen citrate tablets on breast cancer incidence in women with inherited mutations (BRCA1, BRCA2) to be able to make specific recommendations on the effectiveness of tamoxifen citrate in these patients. After an assessment of the risk of developing breast cancer, the decision regarding therapy with tamoxifen citrate tablets for the reduction in breast cancer incidence should be based upon an individual assessment of the benefits and risks of tamoxifen citrate tablets therapy. In the NSABP P-1 trial, tamoxifen citrate tablets treatment lowered the risk of developing breast cancer during the follow-up period of the trial, but did not eliminate breast cancer risk (See Table 3 in CLINICAL PHARMACOLOGY ). uuid:0c42850a-9228-456c-a316-b3a0d6055e2c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9635 biolink:treats UMLS:C0278488 PMID:41385096 "[{""id"":""uuid:21c43dcd-bfd9-44c8-bd20-c70055e8aeb2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6e8a150a-6bd8-430b-a1de-6104d001d328"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Toremifene citrate tablets are estrogen agonist/antagonist indicated for the treatment of metastatic breast cancer in postmenopausal women with estrogen-receptor positive or unknown tumors. uuid:58a26018-beae-4b58-aefa-8a11ac44ac43 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9635 biolink:treats MONDO:0006512 PMID:41385096 "[{""id"":""uuid:45379e64-11f9-4b5d-a2a5-84f15782365c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:67a5d87f-892a-4d59-a714-37a6946f0cc8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Toremifene citrate tablets are estrogen agonist/antagonist indicated for the treatment of metastatic breast cancer in postmenopausal women with estrogen-receptor positive or unknown tumors. uuid:b5d44037-15f6-4d22-854a-9568f5a42dab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:39585 biolink:treats MONDO:0008193 PMID:41385096 "[{""id"":""uuid:f95bf1a7-c79c-4e06-a3de-7382c935561e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ffc2c65d-e9d7-49c6-acba-cc287d21c738"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carbidopa tablets are indicated for use with carbidopa-levodopa or with levodopa in the treatment of the symptoms of idiopathic Parkinson’s disease (paralysis agitans), postencephalitic parkinsonism, and symptomatic parkinsonism, which may follow injury to the nervous system by carbon monoxide intoxication and/or manganese intoxication. Carbidopa is for use with carbidopa-levodopa in patients for whom the dosage of carbidopa-levodopa provides less than adequate daily dosage (usually 70 mg daily) of carbidopa. Carbidopa is for use with levodopa in the occasional patient whose dosage requirement of carbidopa and levodopa necessitates separate titration of each medication. Carbidopa is used with carbidopa-levodopa or with levodopa to permit the administration of lower doses of levodopa with reduced nausea and vomiting, more rapid dosage titration, and with a somewhat smoother response. However, patients with markedly irregular (“on-off”) responses to levodopa have not been shown to benefit from the addition of carbidopa. Since carbidopa prevents the reversal of levodopa effects caused by pyridoxine, supplemental pyridoxine (vitamin B 6 ), can be given to patients when they are receiving carbidopa and levodopa concomitantly or as carbidopa-levodopa. Although the administration of carbidopa permits control of parkinsonism and Parkinson’s disease with much lower doses of levodopa, there is no conclusive evidence at present that this is beneficial other than in reducing nausea and vomiting, permitting more rapid titration, and providing a somewhat smoother response to levodopa. Certain patients who responded poorly to levodopa alone have improved when carbidopa and levodopa were given concurrently. This was most likely due to decreased peripheral decarboxylation of levodopa rather than to a primary effect of carbidopa on the peripheral nervous system. Carbidopa has not been shown to enhance the intrinsic efficacy of levodopa. In deciding whether to give carbidopa with carbidopa-levodopa or with levodopa to patients who have nausea and/or vomiting, the physician should be aware that, while many patients may be expected to improve, some may not. Since one cannot predict which patients are likely to improve, this can only be determined by a trial of therapy. It should be further noted that in controlled trials comparing carbidopa and levodopa with levodopa alone, about half the patients with nausea and/or vomiting on levodopa alone improved spontaneously despite being retained on the same dose of levodopa during the controlled portion of the trial. uuid:c2b9442d-d7cf-4f97-ae75-7566f7513b30 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:520985 biolink:treats MONDO:0005475 PMID:41385096 "[{""id"":""uuid:4484b89f-a95b-4695-acb6-3959f3a193f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bb68c225-d6cf-4aa9-ba4d-fe2a47e33c23"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Almotriptan malate tablets are a 5HT 1B/1D receptor agonist (triptan) indicated for: Acute treatment of migraine attacks in adults with a history of migraine with or without aura ( 1.1 ) Acute treatment of migraine headache pain in adolescents age 12 to 17 years with a history of migraine with or without aura, and who have migraine attacks usually lasting 4 hours or more ( 1.1 ) Important limitations: Use only after a clear diagnosis of migraine has been established ( 1.2 ) In adolescents age 12 to 17 years, efficacy of almotriptan malate tablets on migraine-associated symptoms was not established ( 1.2 ) Not intended for the prophylactic therapy of migraine ( 1.2 ) Not indicated for the treatment of cluster headache ( 1.2 ) uuid:be7d8d85-dfa3-4f58-bbe5-3cb60a32617b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:520985 biolink:treats MONDO:0100431 PMID:41385096 "[{""id"":""uuid:9de189ec-e86e-4aac-a059-53e66dfdae40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d40a6d6c-d7d9-45f3-926c-7ef26bc41469"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Almotriptan malate tablets are a 5HT 1B/1D receptor agonist (triptan) indicated for: Acute treatment of migraine attacks in adults with a history of migraine with or without aura ( 1.1 ) Acute treatment of migraine headache pain in adolescents age 12 to 17 years with a history of migraine with or without aura, and who have migraine attacks usually lasting 4 hours or more ( 1.1 ) Important limitations: Use only after a clear diagnosis of migraine has been established ( 1.2 ) In adolescents age 12 to 17 years, efficacy of almotriptan malate tablets on migraine-associated symptoms was not established ( 1.2 ) Not intended for the prophylactic therapy of migraine ( 1.2 ) Not indicated for the treatment of cluster headache ( 1.2 ) uuid:ab7ee0bb-9f2e-4ba7-8a4c-c000aace2d00 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:393355 biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:1c9bed0c-832b-4ae7-835e-f0eefdb3e6af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e4d88fb2-042d-49fa-8e14-9410c87227fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Calcipotriene and Betamethasone Dipropionate Topical Suspension is indicated for the topical treatment of plaque psoriasis of the scalp in patients 12 years and older and plaque psoriasis of the scalp and body in patients 18 years and older. Additional pediatric use information is approved for LEO Pharma A/S's Taclonex ® (calcipotriene and betamethasone dipropionate) Topical Suspension. However, due to LEO Pharma A/S's marketing exclusivity rights, this drug product is not labeled with that information. uuid:a727a3dd-3972-4fd0-b040-84908834f664 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:998422 biolink:treats MONDO:0043653 PMID:41385096 "[{""id"":""uuid:461a2496-c824-4853-868e-c1b5a4d7a943"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8bc69eaa-0876-490b-b768-7eec087c085c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XERESE, a combination of acyclovir, a herpes simplex virus deoxynucleoside analog DNA polymerase inhibitor, and hydrocortisone, a corticosteroid, is indicated for the early treatment of recurrent herpes labialis (cold sores) to reduce the likelihood of ulcerative cold sores and to shorten the lesion healing time in adults and children (6 years of age and older). uuid:746672a7-27ec-45e2-9be5-88a913a4a102 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:53426 biolink:treats MONDO:0018935 PMID:41385096 "[{""id"":""uuid:e451c313-b87c-48f9-a44a-243ad1b73c23"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:461f92d5-d945-4a62-9ae3-afc9e06cc728"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LUMOXITI is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA). uuid:65953fc0-abaa-49da-a7f0-9e34c6bb7fdd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:53426 biolink:treats MONDO:0004110 PMID:41385096 "[{""id"":""uuid:10aa57b7-005f-40ff-814c-7da599ceb7a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f0e5a7f4-f8ca-4eea-8280-cda878ec475c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LUMOXITI is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA). uuid:4aa3aeb7-4cc7-4a30-995e-47a39dfaf179 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16684 biolink:treats UMLS:C0274707 PMID:41385096 "[{""id"":""uuid:cfb220d8-4bd1-4071-91e1-3587f59edbf3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6fbfd215-41e6-41a1-b1c5-1096dbee0d64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atropine sulfate is given parenterally as a preanesthetic medication to decrease salivation and bronchial secretions. It is useful in pylorospasm and other spastic conditions of the gastrointestinal tract. For ureteral and biliary colic, atropine sulfate given with morphine may be indicated. Atropine sulfate is indicated for relaxation of the upper gastrointestinal tract and colon during hypotonic radiography. Atropine is used as an antidote for pilocarpine, physostigmine, isoflurophate, choline esters, certain species of aminata and in poisoning by the organic phosphate cholinesterase inhibitors found in certain insecticides and by chemical warfare “nerve gases”. Large doses relieve the muscarine-like symptoms and some of the central nervous system manifestations. uuid:65b8e665-3678-46a0-bc2e-4ef25f6ce5c1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16684 biolink:treats UMLS:C0274702 PMID:41385096 "[{""id"":""uuid:cc9b2c07-0973-4a0a-bed0-01bb47997ec5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:981cf364-cfd0-438f-b1e3-c9f7e2555b00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atropine sulfate is given parenterally as a preanesthetic medication to decrease salivation and bronchial secretions. It is useful in pylorospasm and other spastic conditions of the gastrointestinal tract. For ureteral and biliary colic, atropine sulfate given with morphine may be indicated. Atropine sulfate is indicated for relaxation of the upper gastrointestinal tract and colon during hypotonic radiography. Atropine is used as an antidote for pilocarpine, physostigmine, isoflurophate, choline esters, certain species of aminata and in poisoning by the organic phosphate cholinesterase inhibitors found in certain insecticides and by chemical warfare “nerve gases”. Large doses relieve the muscarine-like symptoms and some of the central nervous system manifestations. uuid:44cfcbf4-a952-4d9b-a154-da6d5768bd10 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16684 biolink:treats MONDO:0042497 PMID:41385096 "[{""id"":""uuid:5fdacb49-6d13-406a-a186-65e866fec0ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d6169783-b97b-4686-a96c-b3148ec11db2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atropine sulfate is given parenterally as a preanesthetic medication to decrease salivation and bronchial secretions. It is useful in pylorospasm and other spastic conditions of the gastrointestinal tract. For ureteral and biliary colic, atropine sulfate given with morphine may be indicated. Atropine sulfate is indicated for relaxation of the upper gastrointestinal tract and colon during hypotonic radiography. Atropine is used as an antidote for pilocarpine, physostigmine, isoflurophate, choline esters, certain species of aminata and in poisoning by the organic phosphate cholinesterase inhibitors found in certain insecticides and by chemical warfare “nerve gases”. Large doses relieve the muscarine-like symptoms and some of the central nervous system manifestations. uuid:94e04ffa-b2c8-4805-8df6-2a1bfcb7b419 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29034 biolink:treats MONDO:0004375 PMID:41385096 "[{""id"":""uuid:5d62d196-674b-4424-9b8e-92a7984a3a5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:384c7067-b699-4dac-905c-42f6351a2eb6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Triferic is an iron replacement product indicated for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease (HDD-CKD). uuid:9b1a2702-4ec2-4a15-86b3-e25210de5b4b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7573 biolink:treats MONDO:0004956 PMID:41385096 "[{""id"":""uuid:dd4aaa7d-7868-4a5e-bb7d-e9147f707e6d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:78954fc9-687f-4456-8cb6-ba995acbdabd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metastatic Prostate Cancer Nilutamide Tablets are indicated for use in combination with surgical castration for the treatment of metastatic prostate cancer (Stage D 2 ). For maximum benefit, treatment with Nilutamide Tablets must begin on the same day as or on the day after surgical castration. uuid:7dc2fe6c-9c27-45ba-bc69-629d2a5a6b07 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:167574 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:54722450-2a50-4f0c-a8c8-28bf803b59e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e0218043-8778-49ed-97b7-6a9b6b3dfb08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:5c5bcb73-a2b2-4ca3-8294-6d17a43a84bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/wegovy""]},{""id"":""uuid:f7b23be3-fa16-454e-a556-ad4500733bf0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OZEMPIC is indicated: • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [see Clinical Studies ( 14.1 )] . • to reduce the risk of major adverse cardiovascular events ( cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease [see Clinical Studies ( 14.4 )]. Limitations of Use • OZEMPIC has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis [see Warnings and Precautions ( 5.2 )] . • OZEMPIC is not a substitute for insulin. OZEMPIC is not indicated for use in patients with type 1 diabetes mellitus or for the treatment of patients with diabetic ketoacidosis, as it would not be effective in these settings.|[EMA] Rybelsus is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin combination with other medicinal products for the treatment of diabetes.For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.|[PMDA] A drug with a new active ingredient indicated for the treatment of type 2 diabetes mellitus. uuid:837aea21-384a-4a57-8d46-8f4a942cd5cb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:167574 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:f63cf6eb-6a8a-4cee-8ce9-afa655f37d8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8c73ced4-8d57-4f7d-961c-a646c09e7c7c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OZEMPIC is indicated: • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [see Clinical Studies ( 14.1 )] . • to reduce the risk of major adverse cardiovascular events ( cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease [see Clinical Studies ( 14.4 )]. Limitations of Use • OZEMPIC has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis [see Warnings and Precautions ( 5.2 )] . • OZEMPIC is not a substitute for insulin. OZEMPIC is not indicated for use in patients with type 1 diabetes mellitus or for the treatment of patients with diabetic ketoacidosis, as it would not be effective in these settings. uuid:dea9439a-85e7-409a-9105-4d9cf21861bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:167574 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:92ad1c71-4969-43bb-97b5-4d4c9297a793"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8304ba21-8757-4887-aaf4-e3588815f623"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OZEMPIC is indicated: • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [see Clinical Studies ( 14.1 )] . • to reduce the risk of major adverse cardiovascular events ( cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease [see Clinical Studies ( 14.4 )]. Limitations of Use • OZEMPIC has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis [see Warnings and Precautions ( 5.2 )] . • OZEMPIC is not a substitute for insulin. OZEMPIC is not indicated for use in patients with type 1 diabetes mellitus or for the treatment of patients with diabetic ketoacidosis, as it would not be effective in these settings. uuid:ee923bfd-c7b9-46dd-9c02-7d07c376bbb9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:167574 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:568d0160-36ef-4dbf-b84d-fd21b328cc7c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f92c333d-0b65-4273-bdf1-256e9716851c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OZEMPIC is indicated: • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [see Clinical Studies ( 14.1 )] . • to reduce the risk of major adverse cardiovascular events ( cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease [see Clinical Studies ( 14.4 )]. Limitations of Use • OZEMPIC has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis [see Warnings and Precautions ( 5.2 )] . • OZEMPIC is not a substitute for insulin. OZEMPIC is not indicated for use in patients with type 1 diabetes mellitus or for the treatment of patients with diabetic ketoacidosis, as it would not be effective in these settings. uuid:71dd12c8-ee60-4a82-8ad5-bc68dfc484e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:167574 biolink:treats MONDO:0012819 PMID:41385096 "[{""id"":""uuid:1648c93e-6e38-475e-abce-29bd839f0035"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e229f2a9-ba49-4ac2-a5b4-4985ac2831ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OZEMPIC is indicated: • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [see Clinical Studies ( 14.1 )] . • to reduce the risk of major adverse cardiovascular events ( cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease [see Clinical Studies ( 14.4 )]. Limitations of Use • OZEMPIC has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis [see Warnings and Precautions ( 5.2 )] . • OZEMPIC is not a substitute for insulin. OZEMPIC is not indicated for use in patients with type 1 diabetes mellitus or for the treatment of patients with diabetic ketoacidosis, as it would not be effective in these settings. uuid:76ceaff4-1508-4752-a9d8-35d89b66fb8f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1152251 biolink:treats UMLS:C0393736 PMID:41385096 "[{""id"":""uuid:11181b30-ade0-4b89-bfd5-c9848e0350f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6003023d-f315-48e2-b7b6-c3e297e0d8ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules are indicated for the management of the symptom complex of tension (or muscle contraction) headache when non-opioid analgesic and alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids and butalbital, even at recommended doses [see Warnings and Precautions (5.1) ], reserve Butalbital, Acetaminophen, Caffeine, and Codeine Phosphate Capsules for use in patients for whom alternative treatment options [e.g., non-opioid, non-barbiturate analgesics]: Have not been tolerated, or are not expected to be tolerated, Have not provided adequate analgesia, or are not expected to provide adequate analgesia. uuid:ca0e7b86-6727-48f6-98db-5f4cc3e5d401 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27470 biolink:treats UMLS:C0271930 PMID:41385096 "[{""id"":""uuid:03aaf028-2f28-4fbc-a090-7a15165167e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:347cdf27-e23d-4c83-8c6a-8936728acf74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Folic acid is effective in the treatment of megaloblastic anemias due to a deficiency of folic acid (as may be seen in tropical or nontropical sprue) and in anemia of nutritional origin, pregnancy, infancy, or childhood. uuid:48e42194-6fe0-4d78-9737-0d6998dc023d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27470 biolink:treats UMLS:C0475725 PMID:41385096 "[{""id"":""uuid:e0b51408-536b-4861-a16d-531b1162b912"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7601020a-95b7-4afe-9eed-87832292f9a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Folic acid is effective in the treatment of megaloblastic anemias due to a deficiency of folic acid (as may be seen in tropical or nontropical sprue) and in anemia of nutritional origin, pregnancy, infancy, or childhood. uuid:e0b1f639-c045-4830-aa6f-eccaaae14ce9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27470 biolink:treats MONDO:0002280 PMID:41385096 "[{""id"":""uuid:4aa1c72a-498d-4097-ba32-3942c57e1b21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:69b745aa-0444-4bbf-9257-1248b3532b5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Folic acid is effective in the treatment of megaloblastic anemias due to a deficiency of folic acid (as may be seen in tropical or nontropical sprue) and in anemia of nutritional origin, pregnancy, infancy, or childhood. uuid:8d0aded8-acf1-475c-bf14-9fd8478ef66b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50211 biolink:treats MONDO:0007016 PMID:41385096 "[{""id"":""uuid:ef3ee63d-5a88-42d3-a372-27f437bc2521"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:be966c85-7b85-4ccd-beae-6e57f6546ed1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Vitamin A injection is effective for the treatment of vitamin A deficiency. The parenteral administration is indicated when the oral administration is not feasible as in anorexia, nausea, vomiting, pre- and postoperative conditions, or it is not available as in the ""Malabsorption Syndrome"" with accompanying steatorrhea. Pediatric Use: Vitamin A treatment for deficiency states has been recognized as an especially effective and important therapy in the pediatric population. Vitamin A supplementation for deficiency states in this population has been addressed by the Committee on Clinical Practice Issues of the American Society for Clinical Nutrition, by the American Society for Parenteral and Enteral Nutrition, and by the World Health Organization." uuid:d15a99dc-22ee-4625-b572-e4eb847f70bc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50211 biolink:treats MONDO:0005351 PMID:41385096 "[{""id"":""uuid:caa65be1-c4f5-4300-88a7-c8fb7baa7ec0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:69f41418-cb32-4c77-be55-9d80604163db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Vitamin A injection is effective for the treatment of vitamin A deficiency. The parenteral administration is indicated when the oral administration is not feasible as in anorexia, nausea, vomiting, pre- and postoperative conditions, or it is not available as in the ""Malabsorption Syndrome"" with accompanying steatorrhea. Pediatric Use: Vitamin A treatment for deficiency states has been recognized as an especially effective and important therapy in the pediatric population. Vitamin A supplementation for deficiency states in this population has been addressed by the Committee on Clinical Practice Issues of the American Society for Clinical Nutrition, by the American Society for Parenteral and Enteral Nutrition, and by the World Health Organization." uuid:042bff06-2906-4c5e-bb18-b7f6daa41c4e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50211 biolink:treats HP:0002018 PMID:41385096 "[{""id"":""uuid:a82db4a3-01e4-4552-a965-e63082142744"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:19c6373f-e3ec-4175-aad5-a7e16b03cd39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Vitamin A injection is effective for the treatment of vitamin A deficiency. The parenteral administration is indicated when the oral administration is not feasible as in anorexia, nausea, vomiting, pre- and postoperative conditions, or it is not available as in the ""Malabsorption Syndrome"" with accompanying steatorrhea. Pediatric Use: Vitamin A treatment for deficiency states has been recognized as an especially effective and important therapy in the pediatric population. Vitamin A supplementation for deficiency states in this population has been addressed by the Committee on Clinical Practice Issues of the American Society for Clinical Nutrition, by the American Society for Parenteral and Enteral Nutrition, and by the World Health Organization." uuid:ef0a55b2-0ada-4a48-95d7-50442bfa4870 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50211 biolink:treats HP:0002013 PMID:41385096 "[{""id"":""uuid:07b9b6fc-868d-4a3c-967e-ef6d1e566a45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:938549e8-9bce-4529-aa60-2e1d242631d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Vitamin A injection is effective for the treatment of vitamin A deficiency. The parenteral administration is indicated when the oral administration is not feasible as in anorexia, nausea, vomiting, pre- and postoperative conditions, or it is not available as in the ""Malabsorption Syndrome"" with accompanying steatorrhea. Pediatric Use: Vitamin A treatment for deficiency states has been recognized as an especially effective and important therapy in the pediatric population. Vitamin A supplementation for deficiency states in this population has been addressed by the Committee on Clinical Practice Issues of the American Society for Clinical Nutrition, by the American Society for Parenteral and Enteral Nutrition, and by the World Health Organization." uuid:ac1b57c1-e3c9-491b-b75a-12d1fffb6b65 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50211 biolink:treats MONDO:0020598 PMID:41385096 "[{""id"":""uuid:785ea09a-e2b1-4c30-afac-540d845e0c6a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:88f4b487-1d98-433b-bd07-b33ee0e5e4c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Vitamin A injection is effective for the treatment of vitamin A deficiency. The parenteral administration is indicated when the oral administration is not feasible as in anorexia, nausea, vomiting, pre- and postoperative conditions, or it is not available as in the ""Malabsorption Syndrome"" with accompanying steatorrhea. Pediatric Use: Vitamin A treatment for deficiency states has been recognized as an especially effective and important therapy in the pediatric population. Vitamin A supplementation for deficiency states in this population has been addressed by the Committee on Clinical Practice Issues of the American Society for Clinical Nutrition, by the American Society for Parenteral and Enteral Nutrition, and by the World Health Organization." uuid:fb70ec67-a80e-4025-84c0-85e823d5f4ac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50211 biolink:treats MONDO:0001075 PMID:41385096 "[{""id"":""uuid:cd77bfe3-37f1-4085-b1eb-5d3e6d296c68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1d25593b-6cae-48c8-9862-8e5fcb9e890c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Vitamin A injection is effective for the treatment of vitamin A deficiency. The parenteral administration is indicated when the oral administration is not feasible as in anorexia, nausea, vomiting, pre- and postoperative conditions, or it is not available as in the ""Malabsorption Syndrome"" with accompanying steatorrhea. Pediatric Use: Vitamin A treatment for deficiency states has been recognized as an especially effective and important therapy in the pediatric population. Vitamin A supplementation for deficiency states in this population has been addressed by the Committee on Clinical Practice Issues of the American Society for Clinical Nutrition, by the American Society for Parenteral and Enteral Nutrition, and by the World Health Organization." uuid:34e3b645-0e66-4eca-9521-342c86ee1841 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41423 biolink:treats MONDO:0005475 PMID:41385096 "[{""id"":""uuid:8d2cf2d4-be54-4056-bbe7-0c065f500184"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:101a0fc7-f55a-4ac0-af5f-79d08c7964b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ELYXYB is indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use ELYXYB is not indicated for the preventive treatment of migraine. uuid:f50fc378-0ffb-43af-9e03-602e47dd9421 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41423 biolink:treats MONDO:0100431 PMID:41385096 "[{""id"":""uuid:265a732f-5c18-48d2-86e2-934e8b9e97ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:00081b3a-04c1-410f-aa2d-6ff6c9081d7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ELYXYB is indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use ELYXYB is not indicated for the preventive treatment of migraine. uuid:ef9d0afd-9e40-42b8-bb82-53180c62769e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71415 biolink:treats MONDO:0020920 PMID:41385096 "[{""id"":""uuid:9f6a207c-bb90-40fa-bbb1-41d39afad687"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:abb556e3-1dd7-4ae5-9fd4-f7201fe623d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nitrofurantoin capsules (macrocrystals) are specifically indicated for the treatment of urinary tract infections when due to susceptible strains of Escherichia coli, enterococci , Staphylococcus aureus , and certain susceptible strains of Klebsiella and Enterobacter species. Nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses. To reduce the development of drug-resistant bacteria and maintain the effectiveness of nitrofurantoin capsules (macrocrystals) and other antibacterial drugs, nitrofurantoin capsules (macrocrystals) should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Nitrofurantoins lack the broader tissue distribution of other therapeutic agents approved for urinary tract infections. Consequently, many patients who are treated with nitrofurantoin capsules (macrocrystals) are predisposed to persistence or reappearance of bacteriuria. Urine specimens for culture and susceptibility testing should be obtained before and after completion of therapy. If persistence or reappearance of bacteriuria occurs after treatment with nitrofurantoin capsules (macrocrystals), other therapeutic agents with broader tissue distribution should be selected. In considering the use of nitrofurantoin capsules (macrocrystals), lower eradication rates should be balanced against the increased potential for systemic toxicity and for the development of antimicrobial resistance when agents with broader tissue distribution are utilized. uuid:83bafbac-ad30-410a-8b0b-7bdb67943db8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71415 biolink:treats UMLS:C0851881 PMID:41385096 "[{""id"":""uuid:53ee0e2d-a330-4b42-9acf-6a127a474785"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cfc9b390-034e-4eb2-adb6-0b06eb5efc37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nitrofurantoin capsules (macrocrystals) are specifically indicated for the treatment of urinary tract infections when due to susceptible strains of Escherichia coli, enterococci , Staphylococcus aureus , and certain susceptible strains of Klebsiella and Enterobacter species. Nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses. To reduce the development of drug-resistant bacteria and maintain the effectiveness of nitrofurantoin capsules (macrocrystals) and other antibacterial drugs, nitrofurantoin capsules (macrocrystals) should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Nitrofurantoins lack the broader tissue distribution of other therapeutic agents approved for urinary tract infections. Consequently, many patients who are treated with nitrofurantoin capsules (macrocrystals) are predisposed to persistence or reappearance of bacteriuria. Urine specimens for culture and susceptibility testing should be obtained before and after completion of therapy. If persistence or reappearance of bacteriuria occurs after treatment with nitrofurantoin capsules (macrocrystals), other therapeutic agents with broader tissue distribution should be selected. In considering the use of nitrofurantoin capsules (macrocrystals), lower eradication rates should be balanced against the increased potential for systemic toxicity and for the development of antimicrobial resistance when agents with broader tissue distribution are utilized. uuid:f2a6a173-4340-4c96-888d-404c324bdde2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71415 biolink:treats MONDO:0005545 PMID:41385096 "[{""id"":""uuid:9010a053-ebad-4c15-aa35-d0ceaebedb84"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:73641d11-b6e3-4494-881b-519344b195c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nitrofurantoin capsules (macrocrystals) are specifically indicated for the treatment of urinary tract infections when due to susceptible strains of Escherichia coli, enterococci , Staphylococcus aureus , and certain susceptible strains of Klebsiella and Enterobacter species. Nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses. To reduce the development of drug-resistant bacteria and maintain the effectiveness of nitrofurantoin capsules (macrocrystals) and other antibacterial drugs, nitrofurantoin capsules (macrocrystals) should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Nitrofurantoins lack the broader tissue distribution of other therapeutic agents approved for urinary tract infections. Consequently, many patients who are treated with nitrofurantoin capsules (macrocrystals) are predisposed to persistence or reappearance of bacteriuria. Urine specimens for culture and susceptibility testing should be obtained before and after completion of therapy. If persistence or reappearance of bacteriuria occurs after treatment with nitrofurantoin capsules (macrocrystals), other therapeutic agents with broader tissue distribution should be selected. In considering the use of nitrofurantoin capsules (macrocrystals), lower eradication rates should be balanced against the increased potential for systemic toxicity and for the development of antimicrobial resistance when agents with broader tissue distribution are utilized. uuid:e8410808-71a1-481c-81b3-26e1b884abda biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71415 biolink:treats MONDO:0030603 PMID:41385096 "[{""id"":""uuid:7b369728-e96c-44a2-94e8-df28f15b5327"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8823ced2-b021-43b1-9a97-edff772edffc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nitrofurantoin capsules (macrocrystals) are specifically indicated for the treatment of urinary tract infections when due to susceptible strains of Escherichia coli, enterococci , Staphylococcus aureus , and certain susceptible strains of Klebsiella and Enterobacter species. Nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses. To reduce the development of drug-resistant bacteria and maintain the effectiveness of nitrofurantoin capsules (macrocrystals) and other antibacterial drugs, nitrofurantoin capsules (macrocrystals) should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Nitrofurantoins lack the broader tissue distribution of other therapeutic agents approved for urinary tract infections. Consequently, many patients who are treated with nitrofurantoin capsules (macrocrystals) are predisposed to persistence or reappearance of bacteriuria. Urine specimens for culture and susceptibility testing should be obtained before and after completion of therapy. If persistence or reappearance of bacteriuria occurs after treatment with nitrofurantoin capsules (macrocrystals), other therapeutic agents with broader tissue distribution should be selected. In considering the use of nitrofurantoin capsules (macrocrystals), lower eradication rates should be balanced against the increased potential for systemic toxicity and for the development of antimicrobial resistance when agents with broader tissue distribution are utilized. uuid:2c970461-d4cd-45dd-81c8-090db83a3eeb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71415 biolink:treats UMLS:C0948205 PMID:41385096 "[{""id"":""uuid:6ddc91be-d206-4384-8c4d-4d5d06f3bce3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7b38e3b8-301d-432c-a5a1-27600f712557"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nitrofurantoin capsules (macrocrystals) are specifically indicated for the treatment of urinary tract infections when due to susceptible strains of Escherichia coli, enterococci , Staphylococcus aureus , and certain susceptible strains of Klebsiella and Enterobacter species. Nitrofurantoin is not indicated for the treatment of pyelonephritis or perinephric abscesses. To reduce the development of drug-resistant bacteria and maintain the effectiveness of nitrofurantoin capsules (macrocrystals) and other antibacterial drugs, nitrofurantoin capsules (macrocrystals) should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Nitrofurantoins lack the broader tissue distribution of other therapeutic agents approved for urinary tract infections. Consequently, many patients who are treated with nitrofurantoin capsules (macrocrystals) are predisposed to persistence or reappearance of bacteriuria. Urine specimens for culture and susceptibility testing should be obtained before and after completion of therapy. If persistence or reappearance of bacteriuria occurs after treatment with nitrofurantoin capsules (macrocrystals), other therapeutic agents with broader tissue distribution should be selected. In considering the use of nitrofurantoin capsules (macrocrystals), lower eradication rates should be balanced against the increased potential for systemic toxicity and for the development of antimicrobial resistance when agents with broader tissue distribution are utilized. uuid:4037fcef-2993-4b6a-b74e-f5f5af983045 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4W0459ZA4V biolink:treats UMLS:C1735365 PMID:41385096 "[{""id"":""uuid:0de67598-6c82-409d-b3cd-018d1b893bef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:965a94d8-2580-45fe-b97d-bcc9a5ca7ce6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefprozil and other antibacterial drugs, cefprozil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Cefprozil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: UPPER RESPIRATORY TRACT Pharyngitis/tonsillitis caused by Streptococcus pyogenes . NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefprozil is generally effective in the eradication of Streptococcus pyogenes from the nasopharynx; however, substantial data establishing the efficacy of cefprozil in the subsequent prevention of rheumatic fever are not available at present. Otitis Media caused by Streptococcus pneumoniae , Haemophilus influenzae (including β-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including β-lactamase-producing strains). (See CLINICAL STUDIES .) NOTE: In the treatment of otitis media due to β-lactamase producing organisms, cefprozil had bacteriologic eradication rates somewhat lower than those observed with a product containing a specific β-lactamase inhibitor. In considering the use of cefprozil, lower overall eradication rates should be balanced against the susceptibility patterns of the common microbes in a given geographic area and the increased potential for toxicity with products containing β-lactamase inhibitors. Acute Sinusitis caused by Streptococcus pneumoniae , Haemophilus influenzae (including β-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including β-lactamase-producing strains). LOWER RESPIRATORY TRACT Acute Bacterial Exacerbation of Chronic Bronchitis caused by Streptococcus pneumoniae , Haemophilus influenzae (including β-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including β-lactamase-producing strains). SKIN AND SKIN STRUCTURE Uncomplicated Skin and Skin-Structure Infections caused by Staphylococcus aureus (including penicillinase-producing strains) and Streptococcus pyogenes . Abscesses usually require surgical drainage. uuid:d3aefee7-dc43-4e9c-a2ff-9566cd226e77 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4W0459ZA4V biolink:treats MONDO:0005227 PMID:41385096 "[{""id"":""uuid:b559b30f-2cb7-42bc-aa40-42c295a6925e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f552edfd-9f60-40e4-9a92-9173122cde48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefprozil and other antibacterial drugs, cefprozil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Cefprozil tablets are indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below: UPPER RESPIRATORY TRACT Pharyngitis/tonsillitis caused by Streptococcus pyogenes . NOTE: The usual drug of choice in the treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever, is penicillin given by the intramuscular route. Cefprozil is generally effective in the eradication of Streptococcus pyogenes from the nasopharynx; however, substantial data establishing the efficacy of cefprozil in the subsequent prevention of rheumatic fever are not available at present. Otitis Media caused by Streptococcus pneumoniae , Haemophilus influenzae (including β-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including β-lactamase-producing strains). (See CLINICAL STUDIES .) NOTE: In the treatment of otitis media due to β-lactamase producing organisms, cefprozil had bacteriologic eradication rates somewhat lower than those observed with a product containing a specific β-lactamase inhibitor. In considering the use of cefprozil, lower overall eradication rates should be balanced against the susceptibility patterns of the common microbes in a given geographic area and the increased potential for toxicity with products containing β-lactamase inhibitors. Acute Sinusitis caused by Streptococcus pneumoniae , Haemophilus influenzae (including β-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including β-lactamase-producing strains). LOWER RESPIRATORY TRACT Acute Bacterial Exacerbation of Chronic Bronchitis caused by Streptococcus pneumoniae , Haemophilus influenzae (including β-lactamase-producing strains), and Moraxella (Branhamella) catarrhalis (including β-lactamase-producing strains). SKIN AND SKIN STRUCTURE Uncomplicated Skin and Skin-Structure Infections caused by Staphylococcus aureus (including penicillinase-producing strains) and Streptococcus pyogenes . Abscesses usually require surgical drainage. uuid:0b647bad-1081-4e3d-8d96-60f80f6b737d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:136051 biolink:treats MONDO:0002049 PMID:41385096 "[{""id"":""uuid:7604cbf5-965a-41ff-adc0-4688467211b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:38f70478-4b85-4cac-8e09-b5e7fccdbe49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:734b837b-64a8-47c2-b326-f65681dc3555"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/mulpleo""]},{""id"":""uuid:6acafffe-b8c3-4d70-96a5-090930cac6bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MULPLETA is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure.|[EMA] Mulpleo is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease undergoing invasive procedures|[PMDA] A drug with a new active ingredient indicated for the improvement of thrombocytopenia in patients with chronic liver disease for whom an elective invasive procedure is planned. uuid:df74d9ed-43fd-4998-811b-22e5b1161da7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:136051 biolink:treats UMLS:C0341439 PMID:41385096 "[{""id"":""uuid:27e52a0c-24dd-4a55-81f0-1c7f5c4a1fd3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6123509b-87eb-45a7-bb49-6d4facca17e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MULPLETA is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure. uuid:dec2d34a-c2b9-4944-b3c8-6df20b4d3c93 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5062 biolink:treats UMLS:C0341742 PMID:41385096 "[{""id"":""uuid:3f484f68-009b-4222-8aff-d33e243f169b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:26866997-9db1-4fcf-9192-e2edec39b302"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Finasteride tablets is a 5α-reductase inhibitor, indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to (1.1) : Improve symptoms Reduce the risk of acute urinary retention Reduce the risk of the need for surgery including transurethral resection of the prostate (TURP) and prostatectomy. Finasteride tablets administered in combination with the alpha-blocker doxazosin is indicated to reduce the risk of symptomatic progression of BPH (a confirmed ≥4 point increase in American Urological Association (AUA) symptom score) (1.2) . Limitations of Use: Finasteride tablets is not approved for the prevention of prostate cancer (1.3) . uuid:13c10a0c-62fb-4d37-ba0f-69caec857e3b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:232408 biolink:treats MONDO:0008233 PMID:41385096 "[{""id"":""uuid:425b6dcb-18fa-4c83-a8c7-5df7b82111a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f4ca23e0-79a3-45a5-906a-ff61b1cf04ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metyrosine capsules are indicated in the treatment of patients with pheochromocytoma for: 1. Preoperative preparation of patients for surgery. 2. Management of patients when surgery is contraindicated. 3. Chronic treatment of patients with malignant pheochromocytoma. Metyrosine capsules are not recommended for the control of essential hypertension. uuid:49c86f00-dc44-4214-8786-54a716dbf231 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:232408 biolink:treats MONDO:0006288 PMID:41385096 "[{""id"":""uuid:3630f14d-3cb2-4720-91bc-963fdccc335c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:858d645a-036e-4e2b-b514-ac820c8e77ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metyrosine capsules are indicated in the treatment of patients with pheochromocytoma for: 1. Preoperative preparation of patients for surgery. 2. Management of patients when surgery is contraindicated. 3. Chronic treatment of patients with malignant pheochromocytoma. Metyrosine capsules are not recommended for the control of essential hypertension. uuid:04d0c3f0-905a-4fc7-acdb-234ea66970be biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0005699 PMID:41385096 "[{""id"":""uuid:f45a7650-e42f-4eb0-8447-ad4037e96cf3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ced577c3-d252-470d-abd4-a37afefb2ca4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Buffered penicillin G potassium for injection is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Buffered penicillin G potassium for injection may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below, however, once these results become available, appropriate therapy should be continued. CLINICAL INDICATION INFECTING ORGANISM Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A beta-hemolytic streptococcus ), other beta-hemolytic streptococci including groups C, H, G, L and M, Streptococcus pneumoniae and Staphylococcus species (non-penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervicofacial disease and thoracic and abdominal disease) Actinomyces Israelil Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopthiae Fusospirochetosis (severe infections of the oropharynx [Vincent’s], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat-bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococcal meningitis and/or septicemia Neisseria meningitidis Gram-negative bacillary infections (bacteremias) Escherichia coli, Enterobacter aerogenes, Alcaligenes faecalis, salmonella, shigella and Proteus mirabilis, Penicillin G is not the drug of choice in the treatment of gram-negative bacillary infections. To reduce the development of drug-resistant bacteria and maintain the effectiveness of penicillin G potassium and other antibacterial drugs, penicillin G potassium should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. CHEBI:18208 uuid:c8b265d8-88c7-42c0-ad33-40af1547957d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1164043 biolink:treats MONDO:0004857 PMID:41385096 "[{""id"":""uuid:ecf1e55a-466b-4a91-856c-70b4d92ce0e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c96f1e58-7c5e-411f-bab1-ec2ff3859c47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lidothol is a formulation used to assist patients in the treatment of mild to moderate acute or chronic aches or pain. Muscle or joint pain can be due to muscle or ligament strains, simple backache, tendonitis, osteoarthritis, rheumatoid arthritis, peripheral neuropathies such as diabetic neuropathy or post herpetic neuralgia, and other complex regional pains. It can also be used to help with certain types of headaches, but use with caution when applying in order to avoid eye contact. Other uses may be considered if deemed clinically relevant. uuid:347418e0-9503-4c63-87c6-4b36af9ac8e9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1164043 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:c4bf5174-648f-4c47-8c27-fd769c3a332b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aa21f941-cfb7-4ed8-8006-fa49e878d166"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lidothol is a formulation used to assist patients in the treatment of mild to moderate acute or chronic aches or pain. Muscle or joint pain can be due to muscle or ligament strains, simple backache, tendonitis, osteoarthritis, rheumatoid arthritis, peripheral neuropathies such as diabetic neuropathy or post herpetic neuralgia, and other complex regional pains. It can also be used to help with certain types of headaches, but use with caution when applying in order to avoid eye contact. Other uses may be considered if deemed clinically relevant. uuid:87e26303-44cd-44bf-b876-a1184269a569 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1164043 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:c713e95b-4d78-497d-82f1-06e41c337cfa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1a9fbc9f-3ee2-4d68-8c93-05a0dc2f384b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lidothol is a formulation used to assist patients in the treatment of mild to moderate acute or chronic aches or pain. Muscle or joint pain can be due to muscle or ligament strains, simple backache, tendonitis, osteoarthritis, rheumatoid arthritis, peripheral neuropathies such as diabetic neuropathy or post herpetic neuralgia, and other complex regional pains. It can also be used to help with certain types of headaches, but use with caution when applying in order to avoid eye contact. Other uses may be considered if deemed clinically relevant. uuid:0a2f78ae-5e59-416e-87ee-3588b711f14f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1164043 biolink:treats MONDO:0006626 PMID:41385096 "[{""id"":""uuid:b6146a5d-4e56-4cad-9c24-3c49edbe3dcc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:971d46a0-4939-428f-87bf-5e312dabe3d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lidothol is a formulation used to assist patients in the treatment of mild to moderate acute or chronic aches or pain. Muscle or joint pain can be due to muscle or ligament strains, simple backache, tendonitis, osteoarthritis, rheumatoid arthritis, peripheral neuropathies such as diabetic neuropathy or post herpetic neuralgia, and other complex regional pains. It can also be used to help with certain types of headaches, but use with caution when applying in order to avoid eye contact. Other uses may be considered if deemed clinically relevant. uuid:9054909b-6a63-4803-88f8-7eb7f34cd5d2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1164043 biolink:treats MONDO:0041052 PMID:41385096 "[{""id"":""uuid:c3ac4098-16d0-4b23-b30c-fb1fd8e41b5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:23104507-1e80-4afb-a679-e7a4298d38e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lidothol is a formulation used to assist patients in the treatment of mild to moderate acute or chronic aches or pain. Muscle or joint pain can be due to muscle or ligament strains, simple backache, tendonitis, osteoarthritis, rheumatoid arthritis, peripheral neuropathies such as diabetic neuropathy or post herpetic neuralgia, and other complex regional pains. It can also be used to help with certain types of headaches, but use with caution when applying in order to avoid eye contact. Other uses may be considered if deemed clinically relevant. uuid:f13d06b5-5f9f-4e19-85e1-f1f527e8af0c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1164043 biolink:treats MONDO:0021146 PMID:41385096 "[{""id"":""uuid:75bdc190-bb1d-4173-bb20-5ca8b7aab46f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:34fda9d9-7222-4a92-a005-b98ac1aa4bcc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lidothol is a formulation used to assist patients in the treatment of mild to moderate acute or chronic aches or pain. Muscle or joint pain can be due to muscle or ligament strains, simple backache, tendonitis, osteoarthritis, rheumatoid arthritis, peripheral neuropathies such as diabetic neuropathy or post herpetic neuralgia, and other complex regional pains. It can also be used to help with certain types of headaches, but use with caution when applying in order to avoid eye contact. Other uses may be considered if deemed clinically relevant. uuid:a635f746-0a23-4fb3-a245-fa069bb63d8c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28689 biolink:treats UMLS:C0423747 PMID:41385096 "[{""id"":""uuid:bac3faeb-14f7-4e41-ba3d-4d8d86ef25db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4052ca1a-a3a0-4589-bb54-c1d691a39b17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INTRAROSA ® is a steroid indicated for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause. uuid:0d474059-a795-4adf-8a3e-fced6506a05a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28689 biolink:treats MONDO:0001932 PMID:41385096 "[{""id"":""uuid:116880ff-b812-44a4-9058-67036e9a2c3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f103a616-5f2c-4317-a339-05e47022befb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ec7b9593-5a73-4ff8-a974-5092018e3163"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/intrarosa""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] INTRAROSA ® is a steroid indicated for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause.|[EMA] Intrarosa is indicated for the treatment of vulvar and vaginal atrophy in postmenopausal women having moderate to severe symptoms., DOID:14275 uuid:f8cb2c80-e1d6-49cc-b6e6-7618ee1644d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27666 biolink:treats MONDO:0006058 PMID:41385096 "[{""id"":""uuid:d6a0c69d-921d-4e16-b200-456a3c3ded44"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a0e8ff05-f045-4442-8d1f-24787312c886"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dactinomycin for Injection is an actinomycin indicated for the treatment of: adult and pediatric patients with Wilms tumor, as part of a multi-phase, combination chemotherapy regimen. ( 1.1 ) adult and pediatric patients with rhabdomyosarcoma, as part of a multi-phase, combination chemotherapy regimen. ( 1.2 ) adult and pediatric patients with Ewing sarcoma, as part of a multi-phase, combination chemotherapy regimen. ( 1.3 ) adult and pediatric patients with metastatic, nonseminomatous testicular cancer, as part of a multi-phase, combination chemotherapy regimen. ( 1.4 ) post-menarchal patients with gestational trophoblastic neoplasia, as a single agent or as part of a combination chemotherapy regimen. ( 1.5 ) adult patients with locally recurrent or locoregional solid malignancies, as a component of palliative or adjunctive regional perfusion. ( 1.6 ) uuid:281cb53e-4147-4a41-8338-c6301863b6ab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27666 biolink:treats MONDO:0005212 PMID:41385096 "[{""id"":""uuid:71dd16b6-a609-4521-9291-9541bffbfe75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dbeb41c1-e8ee-42b3-aafd-a5af00553f53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dactinomycin for Injection is an actinomycin indicated for the treatment of: adult and pediatric patients with Wilms tumor, as part of a multi-phase, combination chemotherapy regimen. ( 1.1 ) adult and pediatric patients with rhabdomyosarcoma, as part of a multi-phase, combination chemotherapy regimen. ( 1.2 ) adult and pediatric patients with Ewing sarcoma, as part of a multi-phase, combination chemotherapy regimen. ( 1.3 ) adult and pediatric patients with metastatic, nonseminomatous testicular cancer, as part of a multi-phase, combination chemotherapy regimen. ( 1.4 ) post-menarchal patients with gestational trophoblastic neoplasia, as a single agent or as part of a combination chemotherapy regimen. ( 1.5 ) adult patients with locally recurrent or locoregional solid malignancies, as a component of palliative or adjunctive regional perfusion. ( 1.6 ) uuid:c8e4b602-2e43-43e3-8f9f-256bcd00d77d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27666 biolink:treats MONDO:0012817 PMID:41385096 "[{""id"":""uuid:03c7e484-8b08-49b1-9fba-9df0482ed56d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dfaeab80-ec36-426b-ba3a-808a12472fbf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dactinomycin for Injection is an actinomycin indicated for the treatment of: adult and pediatric patients with Wilms tumor, as part of a multi-phase, combination chemotherapy regimen. ( 1.1 ) adult and pediatric patients with rhabdomyosarcoma, as part of a multi-phase, combination chemotherapy regimen. ( 1.2 ) adult and pediatric patients with Ewing sarcoma, as part of a multi-phase, combination chemotherapy regimen. ( 1.3 ) adult and pediatric patients with metastatic, nonseminomatous testicular cancer, as part of a multi-phase, combination chemotherapy regimen. ( 1.4 ) post-menarchal patients with gestational trophoblastic neoplasia, as a single agent or as part of a combination chemotherapy regimen. ( 1.5 ) adult patients with locally recurrent or locoregional solid malignancies, as a component of palliative or adjunctive regional perfusion. ( 1.6 ) uuid:31a11671-dbd9-433c-9b15-e03389f0a8cf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27666 biolink:treats MONDO:0018944 PMID:41385096 "[{""id"":""uuid:984224b7-a3de-408f-90ed-c4645314b708"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:52d28e04-262c-45fa-acf2-708e3d3dc860"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dactinomycin for Injection is an actinomycin indicated for the treatment of: adult and pediatric patients with Wilms tumor, as part of a multi-phase, combination chemotherapy regimen. ( 1.1 ) adult and pediatric patients with rhabdomyosarcoma, as part of a multi-phase, combination chemotherapy regimen. ( 1.2 ) adult and pediatric patients with Ewing sarcoma, as part of a multi-phase, combination chemotherapy regimen. ( 1.3 ) adult and pediatric patients with metastatic, nonseminomatous testicular cancer, as part of a multi-phase, combination chemotherapy regimen. ( 1.4 ) post-menarchal patients with gestational trophoblastic neoplasia, as a single agent or as part of a combination chemotherapy regimen. ( 1.5 ) adult patients with locally recurrent or locoregional solid malignancies, as a component of palliative or adjunctive regional perfusion. ( 1.6 ) uuid:898221d2-0e22-4dd3-8438-b39b75d5f9a7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:79699 biolink:treats MONDO:0005086 PMID:41385096 "[{""id"":""uuid:4dc11891-0f81-4326-bc52-98e77bcbdf9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:18bd6d77-7319-4a27-b1ac-0a431c73a5a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:65e26842-a194-45ee-898e-2e07be0491f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/torisel""]},{""id"":""uuid:153f3f07-8db3-4cd4-8ffb-fd5ea8ffa65d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Temsirolimus injection is indicated for the treatment of advanced renal cell carcinoma.|[EMA] Renal-cell carcinomaTorisel is indicated for the first-line treatment of adult patients with advanced renal-cell carcinoma (RCC) who have at least three of six prognostic risk factors.Mantle-cell lymphomaTorisel is indicated for the treatment of adult patients with relapsed and / or refractory mantle-cell lymphoma (MCL).|[PMDA] A drug with a new active ingredient indicated for the treatment of unresectable or metastatic renal cell carcinoma. uuid:01d679cb-7c73-4d47-baf8-02c957af87cc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:WA16A5Y52X biolink:treats EFO:1001480 PMID:41385096 "[{""id"":""uuid:28cfe959-390f-476b-ab29-cb384ec9ced3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fb11edd7-7832-472d-9a7d-a9fcaff06a9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levoleucovorin injection is indicated for: rescue after high-dose methotrexate therapy in adult and pediatric patients with osteosarcoma. diminishing the toxicity associated with overdosage of folic acid antagonists or impaired methotrexate elimination in adult and pediatric patients. the treatment of adults with metastatic colorectal cancer in combination with fluorouracil. Limitations of Use Levoleucovorin injection is not indicated for pernicious anemia and megaloblastic anemia secondary to the lack of vitamin B 12 , because of the risk of progression of neurologic manifestations despite hematologic remission. PUBCHEM.COMPOUND:135465090 uuid:20e0cd1e-e11e-4660-b8fa-3ee130a8dec4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:WA16A5Y52X biolink:treats MONDO:0008228 PMID:41385096 "[{""id"":""uuid:47588b1a-db35-4a9a-b013-b4f534769544"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0b185280-db40-4f6e-9473-cfb8d8532eef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levoleucovorin injection is indicated for: rescue after high-dose methotrexate therapy in adult and pediatric patients with osteosarcoma. diminishing the toxicity associated with overdosage of folic acid antagonists or impaired methotrexate elimination in adult and pediatric patients. the treatment of adults with metastatic colorectal cancer in combination with fluorouracil. Limitations of Use Levoleucovorin injection is not indicated for pernicious anemia and megaloblastic anemia secondary to the lack of vitamin B 12 , because of the risk of progression of neurologic manifestations despite hematologic remission. PUBCHEM.COMPOUND:135465090 uuid:516313e0-7ecf-4524-8ff6-9b6e5cd6067e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:WA16A5Y52X biolink:treats UMLS:C0815316 PMID:41385096 "[{""id"":""uuid:f5506250-ac49-4522-a51e-a0709cdb4688"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:11bf34c0-f13b-4a79-95ff-2ea30c08e4be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levoleucovorin injection is indicated for: rescue after high-dose methotrexate therapy in adult and pediatric patients with osteosarcoma. diminishing the toxicity associated with overdosage of folic acid antagonists or impaired methotrexate elimination in adult and pediatric patients. the treatment of adults with metastatic colorectal cancer in combination with fluorouracil. Limitations of Use Levoleucovorin injection is not indicated for pernicious anemia and megaloblastic anemia secondary to the lack of vitamin B 12 , because of the risk of progression of neurologic manifestations despite hematologic remission. PUBCHEM.COMPOUND:135465090 uuid:4f0754e7-47b7-476c-ae73-0cef75459990 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15640 biolink:treats MONDO:0002629 PMID:41385096 "[{""id"":""uuid:3315ec94-7efe-4705-9f6a-17a67c2dba2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:006b2ffa-4d09-442a-b959-217e468bb7eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Leucovorin calcium rescue is indicated after high-dose methotrexate therapy in osteosarcoma. Leucovorin Calcium for Injection is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists. Leucovorin Calcium for Injection is indicated in the treatment of megaloblastic anemias due to folic acid deficiency when oral therapy is not feasible. Leucovorin Calcium for Injection is also indicated for use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer. Leucovorin Calcium for Injection should not be mixed in the same infusion as 5-fluorouracil because a precipitate may form. uuid:6947b80c-128a-462c-ab8a-7a6343b5344f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15640 biolink:treats MONDO:0001860 PMID:41385096 "[{""id"":""uuid:75da7e43-be40-4e4d-8b6d-dcdae21ddc48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1f2ceafb-637c-4b08-b626-d34218bfc479"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Leucovorin calcium rescue is indicated after high-dose methotrexate therapy in osteosarcoma. Leucovorin Calcium for Injection is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists. Leucovorin Calcium for Injection is indicated in the treatment of megaloblastic anemias due to folic acid deficiency when oral therapy is not feasible. Leucovorin Calcium for Injection is also indicated for use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer. Leucovorin Calcium for Injection should not be mixed in the same infusion as 5-fluorouracil because a precipitate may form. uuid:9bb070d8-d279-4b5e-aa7a-512b02af4ab5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15640 biolink:treats EFO:1001480 PMID:41385096 "[{""id"":""uuid:73b494a8-7afe-4de4-8fe5-14fb914b3265"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5881fffd-0aa2-410e-9953-4f41829c9202"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Leucovorin calcium rescue is indicated after high-dose methotrexate therapy in osteosarcoma. Leucovorin Calcium for Injection is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists. Leucovorin Calcium for Injection is indicated in the treatment of megaloblastic anemias due to folic acid deficiency when oral therapy is not feasible. Leucovorin Calcium for Injection is also indicated for use in combination with 5-fluorouracil to prolong survival in the palliative treatment of patients with advanced colorectal cancer. Leucovorin Calcium for Injection should not be mixed in the same infusion as 5-fluorouracil because a precipitate may form. uuid:f7bebaf7-2ceb-4452-897a-64657760c54f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46195 biolink:treats HP:0001945 PMID:41385096 "[{""id"":""uuid:dd83c720-668a-4c2f-8033-f4210a9712b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4de486ba-5a81-495b-9d5f-771c2a96d7db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:95ff0aab-8c81-47c9-aea8-cb7701afaa38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acetaminophen injection is indicated for • the management of mild to moderate pain in adult and pediatric patients 2 years and older • the management of moderate to severe pain with adjunctive opioid analgesics in adult and pediatric patients 2 years and older • the reduction of fever in adult and pediatric patients.|[PMDA] A drug with a new route of administration indicated for the treatment of pain and pyrexia which cannnot be managed by oral preparations and suppositories. uuid:b14cba51-ca29-4f35-8426-a4a1673a5c0d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4562 biolink:treats MONDO:0005475 PMID:41385096 "[{""id"":""uuid:c940086c-641a-4d68-942c-e969d7c0f85b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5e3dd575-625d-41b6-97cb-96f64a5abca7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dihydroergotamine mesylate nasal spray is indicated for the acute treatment of migraine headaches with or without aura. Dihydroergotamine mesylate nasal spray is not intended for the prophylactic therapy of migraine or for the management of hemiplegic or basilar migraine. uuid:e689dc20-e9da-4ae2-90eb-dc4a786b6852 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4562 biolink:treats MONDO:0100431 PMID:41385096 "[{""id"":""uuid:39bf9c30-5957-4100-87cc-0be26d7d173f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ad49fd0e-ba50-4231-924e-a0a5cb3a723d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dihydroergotamine mesylate nasal spray is indicated for the acute treatment of migraine headaches with or without aura. Dihydroergotamine mesylate nasal spray is not intended for the prophylactic therapy of migraine or for the management of hemiplegic or basilar migraine. uuid:254e5279-46c5-4911-af3f-8038fb6f9ecb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4562 biolink:treats MONDO:0018925 PMID:41385096 "[{""id"":""uuid:a3f946ca-5947-4fac-bac5-5d6c6999109c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a843f0d7-f2ac-455b-91ea-13d5e0b0ab97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dihydroergotamine mesylate nasal spray is indicated for the acute treatment of migraine headaches with or without aura. Dihydroergotamine mesylate nasal spray is not intended for the prophylactic therapy of migraine or for the management of hemiplegic or basilar migraine. uuid:5f5ed497-f793-4068-891b-dda81985cbb9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4562 biolink:treats MONDO:0043219 PMID:41385096 "[{""id"":""uuid:84cb73df-1d38-48a0-8b19-0e0f2f67dcee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:35b6df20-d5ee-4690-91c8-413f378ddfa5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dihydroergotamine mesylate nasal spray is indicated for the acute treatment of migraine headaches with or without aura. Dihydroergotamine mesylate nasal spray is not intended for the prophylactic therapy of migraine or for the management of hemiplegic or basilar migraine. uuid:a96ef6c1-9cbe-4a9d-bab8-9457db1fa771 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18385 biolink:treats MONDO:0005351 PMID:41385096 "[{""id"":""uuid:8a51a40c-98a4-4d79-ab93-e40364dcae52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c879fee3-f735-425b-81f2-ee8058986676"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thiamine hydrochloride injection is effective for the treatment of thiamine deficiency or beriberi whether of the dry (major symptoms related to the nervous system) or wet (major symptoms related to the cardiovascular system) variety. Thiamine hydrochloride injection should be used where rapid restoration of thiamine is necessary, as in Wernicke's encephalopathy, infantile beriberi with acute collapse, cardiovascular disease due to thiamine deficiency, or neuritis of pregnancy if vomiting is severe. It is also indicated when giving IV dextrose to individuals with marginal thiamine status to avoid precipitation of heart failure. Thiamine hydrochloride injection is also indicated in patients with established thiamine deficiency who cannot take thiamine orally due to coexisting severe anorexia, nausea, vomiting, or malabsorption. Thiamine hydrochloride injection is not usually indicated for conditions of decreased oral intake or decreased gastrointestinal absorption, because multiple vitamins should usually be given. uuid:afcb9d6e-e825-446b-ab91-3d114adef5d7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18385 biolink:treats HP:0002018 PMID:41385096 "[{""id"":""uuid:681e4902-b1e4-4df2-babd-63aafca255d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4f2445e4-6eea-4309-9f86-890f6e94f97b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thiamine hydrochloride injection is effective for the treatment of thiamine deficiency or beriberi whether of the dry (major symptoms related to the nervous system) or wet (major symptoms related to the cardiovascular system) variety. Thiamine hydrochloride injection should be used where rapid restoration of thiamine is necessary, as in Wernicke's encephalopathy, infantile beriberi with acute collapse, cardiovascular disease due to thiamine deficiency, or neuritis of pregnancy if vomiting is severe. It is also indicated when giving IV dextrose to individuals with marginal thiamine status to avoid precipitation of heart failure. Thiamine hydrochloride injection is also indicated in patients with established thiamine deficiency who cannot take thiamine orally due to coexisting severe anorexia, nausea, vomiting, or malabsorption. Thiamine hydrochloride injection is not usually indicated for conditions of decreased oral intake or decreased gastrointestinal absorption, because multiple vitamins should usually be given. uuid:05624c71-60cf-4489-9109-1a75aefb20cd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18385 biolink:treats HP:0002013 PMID:41385096 "[{""id"":""uuid:6483ab58-1a51-4193-93e6-5137a30e8a45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e0f93dfe-b363-42b9-899d-3b6c414ccff6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thiamine hydrochloride injection is effective for the treatment of thiamine deficiency or beriberi whether of the dry (major symptoms related to the nervous system) or wet (major symptoms related to the cardiovascular system) variety. Thiamine hydrochloride injection should be used where rapid restoration of thiamine is necessary, as in Wernicke's encephalopathy, infantile beriberi with acute collapse, cardiovascular disease due to thiamine deficiency, or neuritis of pregnancy if vomiting is severe. It is also indicated when giving IV dextrose to individuals with marginal thiamine status to avoid precipitation of heart failure. Thiamine hydrochloride injection is also indicated in patients with established thiamine deficiency who cannot take thiamine orally due to coexisting severe anorexia, nausea, vomiting, or malabsorption. Thiamine hydrochloride injection is not usually indicated for conditions of decreased oral intake or decreased gastrointestinal absorption, because multiple vitamins should usually be given. uuid:08f1b72d-f46a-46a3-a095-fa8ae58ae653 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18385 biolink:treats HP:0002024 PMID:41385096 "[{""id"":""uuid:46adb0d7-decc-4c64-8391-70ba2251a3e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4bbb18fa-7411-4841-9fa3-cec41f22fee4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thiamine hydrochloride injection is effective for the treatment of thiamine deficiency or beriberi whether of the dry (major symptoms related to the nervous system) or wet (major symptoms related to the cardiovascular system) variety. Thiamine hydrochloride injection should be used where rapid restoration of thiamine is necessary, as in Wernicke's encephalopathy, infantile beriberi with acute collapse, cardiovascular disease due to thiamine deficiency, or neuritis of pregnancy if vomiting is severe. It is also indicated when giving IV dextrose to individuals with marginal thiamine status to avoid precipitation of heart failure. Thiamine hydrochloride injection is also indicated in patients with established thiamine deficiency who cannot take thiamine orally due to coexisting severe anorexia, nausea, vomiting, or malabsorption. Thiamine hydrochloride injection is not usually indicated for conditions of decreased oral intake or decreased gastrointestinal absorption, because multiple vitamins should usually be given. uuid:cc95dbef-31ad-4bba-9392-423252228470 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63627 biolink:treats MONDO:0002154 PMID:41385096 "[{""id"":""uuid:eee3f93c-10f3-42ba-ab0a-c6a59f268f25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:43c79fab-a92b-45f3-a9f4-abb1d847c6ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tinidazole is a nitroimidazole antimicrobial indicated for: Trichomoniasis ( 1.1 ) Giardiasis: in patients age 3 and older ( 1.2 ) Amebiasis: in patients age 3 and older ( 1.3 ) Bacterial Vaginosis: in non-pregnant, adult women ( 1.4 , 8.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of tinidazole tablets and other antibacterial drugs, tinidazole tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. (1.5) uuid:00078200-cf99-4788-b12d-cdc4d0b3140b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63627 biolink:treats MONDO:0001103 PMID:41385096 "[{""id"":""uuid:d0ceb227-2aa3-45a5-8a33-0ed7730e9c17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a2d8be64-8d7f-4a96-af35-64ee99ab4b22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tinidazole is a nitroimidazole antimicrobial indicated for: Trichomoniasis ( 1.1 ) Giardiasis: in patients age 3 and older ( 1.2 ) Amebiasis: in patients age 3 and older ( 1.3 ) Bacterial Vaginosis: in non-pregnant, adult women ( 1.4 , 8.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of tinidazole tablets and other antibacterial drugs, tinidazole tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. (1.5) uuid:93069c89-8470-485b-9549-e19df7c173e9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63627 biolink:treats MONDO:0005644 PMID:41385096 "[{""id"":""uuid:e803103a-6dd3-4ae0-bae9-d5370ca77d52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:df3ce8ff-a340-4503-aeb9-35874571b7b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tinidazole is a nitroimidazole antimicrobial indicated for: Trichomoniasis ( 1.1 ) Giardiasis: in patients age 3 and older ( 1.2 ) Amebiasis: in patients age 3 and older ( 1.3 ) Bacterial Vaginosis: in non-pregnant, adult women ( 1.4 , 8.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of tinidazole tablets and other antibacterial drugs, tinidazole tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. (1.5) uuid:825143cf-1f41-4b42-9322-d5d70678e236 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63627 biolink:treats MONDO:0005316 PMID:41385096 "[{""id"":""uuid:f04b7969-cb7a-47a5-bfde-c6c3f1a433cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f2bd9c32-09d6-4f12-a395-bb5bc1736789"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tinidazole is a nitroimidazole antimicrobial indicated for: Trichomoniasis ( 1.1 ) Giardiasis: in patients age 3 and older ( 1.2 ) Amebiasis: in patients age 3 and older ( 1.3 ) Bacterial Vaginosis: in non-pregnant, adult women ( 1.4 , 8.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of tinidazole tablets and other antibacterial drugs, tinidazole tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. (1.5) uuid:a1a449a8-e775-4189-8a46-0b5104ef60cd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85157 biolink:treats HP:0002017 PMID:41385096 "[{""id"":""uuid:1c1279a6-7229-40bf-a5ac-5dc57fb1ec86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:95e480ee-dc63-49c7-abec-060fadcae6a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Palonosetron hydrochloride injection is a serotonin-3 (5-HT 3 ) receptor antagonist indicated in: Adults for prevention of : acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). ( 1 ) acute nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC). ( 1 ) postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated ( 1 ) Pediatric patients aged 1 month to less than 17 years for prevention of : acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy (HEC). ( 1 ) uuid:0c69258e-3429-405a-a59e-1b51a752d0d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85157 biolink:treats NCIT:C107517 PMID:41385096 "[{""id"":""uuid:ad7aaef5-cd30-4392-bc98-460c3161d453"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5bd452f1-5a80-429c-9cd4-6bbb6c95400b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Palonosetron hydrochloride injection is a serotonin-3 (5-HT 3 ) receptor antagonist indicated in: Adults for prevention of : acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). ( 1 ) acute nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC). ( 1 ) postoperative nausea and vomiting (PONV) for up to 24 hours following surgery. Efficacy beyond 24 hours has not been demonstrated ( 1 ) Pediatric patients aged 1 month to less than 17 years for prevention of : acute nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including highly emetogenic cancer chemotherapy (HEC). ( 1 ) uuid:b50afc2d-4794-4bb2-b8d9-e2929687606f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8077 biolink:treats MONDO:0008233 PMID:41385096 "[{""id"":""uuid:a2e88343-9782-4328-9ae4-7946e60bba6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aa191ea4-7c10-437f-8a74-acc41a81b71a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Phenoxybenzamine hydrochloride capsules are indicated in the treatment of pheochromocytoma, to control episodes of hypertension and sweating. If tachycardia is excessive, it may be necessary to use a beta -blocking agent concomitantly. uuid:4298f475-f302-4db0-8332-bab3c8180221 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8077 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:219df4a8-4e73-4016-89c1-8bded8effc0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7c1babdb-1379-4888-b619-f9e64ca4f604"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Phenoxybenzamine hydrochloride capsules are indicated in the treatment of pheochromocytoma, to control episodes of hypertension and sweating. If tachycardia is excessive, it may be necessary to use a beta -blocking agent concomitantly. uuid:112ec8d4-019e-4211-b458-128a1b20bcae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85083 biolink:treats MONDO:0005354 PMID:41385096 "[{""id"":""uuid:bec2d934-29eb-46c0-b99f-ad63431f935a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:665f4bdd-4bdc-48ff-8b21-0040f36f6080"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:27f508ed-fdf1-4405-9c29-91e467c11d1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/sovaldi""]},{""id"":""uuid:9f8fee71-68be-4fe7-b2fc-8134de0b6063"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SOVALDI is a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor indicated for the treatment of: Adult patients with genotype 1, 2, 3 or 4 chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis as a component of a combination antiviral treatment regimen. ( 1 ) Pediatric patients 12 years of age and older or weighing at least 35 kg with genotype 2 or 3 chronic HCV infection without cirrhosis or with compensated cirrhosis in combination with ribavirin. ( 1 )|[EMA] Sovaldi is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adult and paediatric patients aged 3 years and above (see sections 4.2, 4.4 and 5.1).For hepatitis C virus (HCV) genotype specific activity, see sections 4.4 and 5.1.Sovaldi is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults and paediatric patients aged 3 years and above (see sections 4.2, 4.4 and 5.1).For hepatitis C virus (HCV) genotype specific activity, see sections 4.4 and 5.1.|[PMDA] A drug with a new active ingredient indicated for the improvement of viremia in patients with chronic hepatitis C or compensated cirrhosis type C in serogroup 2 (genotype 2) . [Priority review] uuid:0e919457-5b74-4376-81f5-d958f081691f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1156069 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:b684c035-5458-4e28-8eb0-c918d499cc1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:175b181e-895c-4a65-93a4-906141bb37f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE INHALATION AEROSOL is a combination product containing a corticosteroid and a long-acting beta 2 -adrenergic agonist indicated for: • Treatment of asthma in patients 6 years of age and older. ( 1.1 ) • Maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD) including chronic bronchitis and/or emphysema. ( 1.2 ) Important limitations: • Not indicated for the relief of acute bronchospasm. ( 1.1 , 1.2 ) uuid:7c5d7fa3-159a-464a-9870-0df9511dc1f6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1156069 biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:852e6841-a8d7-437c-943c-6bfaac47f4bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1c2948ed-69f9-4969-b47a-3725243915c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE INHALATION AEROSOL is a combination product containing a corticosteroid and a long-acting beta 2 -adrenergic agonist indicated for: • Treatment of asthma in patients 6 years of age and older. ( 1.1 ) • Maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD) including chronic bronchitis and/or emphysema. ( 1.2 ) Important limitations: • Not indicated for the relief of acute bronchospasm. ( 1.1 , 1.2 ) uuid:99698743-8996-4e92-96c9-e9627089012b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1156069 biolink:treats MONDO:0005607 PMID:41385096 "[{""id"":""uuid:c433b218-cd8a-4847-956d-d7e73ee45572"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:84da6f66-3025-4014-be76-1bdb46024e0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE INHALATION AEROSOL is a combination product containing a corticosteroid and a long-acting beta 2 -adrenergic agonist indicated for: • Treatment of asthma in patients 6 years of age and older. ( 1.1 ) • Maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD) including chronic bronchitis and/or emphysema. ( 1.2 ) Important limitations: • Not indicated for the relief of acute bronchospasm. ( 1.1 , 1.2 ) uuid:a991be2e-6355-4a32-9b02-2a4c1ddf976c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1156069 biolink:treats MONDO:0004849 PMID:41385096 "[{""id"":""uuid:985eab34-4b27-4af5-9ae2-a4ec74ea58e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b0a9ca2d-9e23-4c93-870b-0ce291505551"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE INHALATION AEROSOL is a combination product containing a corticosteroid and a long-acting beta 2 -adrenergic agonist indicated for: • Treatment of asthma in patients 6 years of age and older. ( 1.1 ) • Maintenance treatment of airflow obstruction and reducing exacerbations in patients with chronic obstructive pulmonary disease (COPD) including chronic bronchitis and/or emphysema. ( 1.2 ) Important limitations: • Not indicated for the relief of acute bronchospasm. ( 1.1 , 1.2 ) uuid:1a9c6141-c6f7-4542-aabd-a2b6d1d23905 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59773 biolink:treats MONDO:0001673 PMID:41385096 "[{""id"":""uuid:b575e2b7-fb56-406d-8a2c-f49587a3b571"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:90326b2c-a369-4fd5-a4cf-52c3b10da6c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cromolyn Sodium Oral Solution (Concentrate) is indicated in the management of patients with mastocytosis. Use of this product has been associated with improvement in diarrhea, flushing, headaches, vomiting, urticaria, abdominal pain, nausea, and itching in some patients. uuid:85397867-fe7f-4dd8-a47c-0df07284eb8f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59773 biolink:treats MONDO:0007623 PMID:41385096 "[{""id"":""uuid:70967ab4-5d90-4f6c-9365-1a269fbcc5cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d0fe96ff-6300-4abf-892c-103d2e5c766b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cromolyn Sodium Oral Solution (Concentrate) is indicated in the management of patients with mastocytosis. Use of this product has been associated with improvement in diarrhea, flushing, headaches, vomiting, urticaria, abdominal pain, nausea, and itching in some patients. uuid:d8497731-fc7c-493f-ae29-423f2aaee772 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59773 biolink:treats MONDO:0021146 PMID:41385096 "[{""id"":""uuid:3642d34e-d83b-4c26-8dfd-65f269998c9d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:49912a90-4c1d-44a7-8916-ec16e8dfc07d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cromolyn Sodium Oral Solution (Concentrate) is indicated in the management of patients with mastocytosis. Use of this product has been associated with improvement in diarrhea, flushing, headaches, vomiting, urticaria, abdominal pain, nausea, and itching in some patients. uuid:b8e20c66-c7a5-4ac6-a6dc-7ff1c1ec1bfc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59773 biolink:treats HP:0002013 PMID:41385096 "[{""id"":""uuid:ba440527-a4a3-4f59-a380-ba51d08e88b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d736feb5-9e87-44ac-8696-ff82a61a86ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cromolyn Sodium Oral Solution (Concentrate) is indicated in the management of patients with mastocytosis. Use of this product has been associated with improvement in diarrhea, flushing, headaches, vomiting, urticaria, abdominal pain, nausea, and itching in some patients. uuid:d4aba83b-9211-402d-b162-b3980aff457b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59773 biolink:treats MONDO:0005492 PMID:41385096 "[{""id"":""uuid:94b51e47-87f5-431d-991d-d73b609e0b3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:42935877-6df6-437d-aa7c-1f147ac1e721"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cromolyn Sodium Oral Solution (Concentrate) is indicated in the management of patients with mastocytosis. Use of this product has been associated with improvement in diarrhea, flushing, headaches, vomiting, urticaria, abdominal pain, nausea, and itching in some patients. uuid:b081cbed-dd8c-4e2f-9fc6-6a1b0ee7b30d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59773 biolink:treats HP:0002027 PMID:41385096 "[{""id"":""uuid:d2607fcd-f586-4337-9452-f51ccf2e5b6a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1ccebfac-2ea9-44de-a32f-4176836bfd17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cromolyn Sodium Oral Solution (Concentrate) is indicated in the management of patients with mastocytosis. Use of this product has been associated with improvement in diarrhea, flushing, headaches, vomiting, urticaria, abdominal pain, nausea, and itching in some patients. uuid:71565bf6-0d18-4084-bf15-4bf16cb0ebbd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59773 biolink:treats HP:0002018 PMID:41385096 "[{""id"":""uuid:a0a89066-edb9-436a-a723-9a8f1a3e029f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:140e3489-c9dd-4afc-94b9-fbc40c3348a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cromolyn Sodium Oral Solution (Concentrate) is indicated in the management of patients with mastocytosis. Use of this product has been associated with improvement in diarrhea, flushing, headaches, vomiting, urticaria, abdominal pain, nausea, and itching in some patients. uuid:dc65b026-e019-4b99-9dd6-3bcf23ec9012 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59773 biolink:treats HP:0000989 PMID:41385096 "[{""id"":""uuid:6de3a3cb-2402-4b20-a698-c8b1fd5c6fb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:28208c0e-be29-4523-91fc-75e0ad12ee31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cromolyn Sodium Oral Solution (Concentrate) is indicated in the management of patients with mastocytosis. Use of this product has been associated with improvement in diarrhea, flushing, headaches, vomiting, urticaria, abdominal pain, nausea, and itching in some patients. uuid:04b5171d-380e-4093-a477-1fe7dbbb793d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31547 biolink:treats UMLS:C3839346 PMID:41385096 "[{""id"":""uuid:4494824d-ba66-4826-9604-3e0c2e8fdb0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5db721b3-3f5b-4775-9287-0b3a6a417a4c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Eplerenone tablets is an aldosterone antagonist indicated for: • Improving survival of stable patients with symptomatic heart failure with reduced ejection fraction (HFrEF) after an acute myocardial infarction. (1.1) • The treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. (1.2) uuid:986bcb06-d31e-4925-a62a-744b00c3cb74 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31547 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:984c2847-5522-4bac-ae68-91e842bebee6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5575b88e-2187-466c-93d5-8b4a9d95183d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Eplerenone tablets is an aldosterone antagonist indicated for: • Improving survival of stable patients with symptomatic heart failure with reduced ejection fraction (HFrEF) after an acute myocardial infarction. (1.1) • The treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. (1.2) uuid:30f67a8c-e870-4994-8e24-0334ed1dd838 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31547 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:368d9a7e-d09b-43c0-841c-ec78849ae86e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:908edc10-a84b-454b-a137-6501ab4c0452"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Eplerenone tablets is an aldosterone antagonist indicated for: • Improving survival of stable patients with symptomatic heart failure with reduced ejection fraction (HFrEF) after an acute myocardial infarction. (1.1) • The treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. (1.2) uuid:42311ce0-d938-4ac7-8522-a34d42e279f5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49005 biolink:treats MONDO:0859316 PMID:41385096 "[{""id"":""uuid:3ce8db1d-f41a-44e9-b67f-b89f1e0a6971"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0194499e-a768-4870-a7c1-5729b8de01f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Deferasirox tablets are an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older. ( 1.1 ) Deferasirox tablets are indicated for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes, and with a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight (Fe/g dw) and a serum ferritin greater than 300 mcg/L.( 1.2 ) Limitations of Use The safety and efficacy of deferasirox tablets when administered with other iron chelation therapy have not been established. ( 1.3 ) uuid:6b2e1bda-8071-40a7-a81d-a43f28bdb209 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49005 biolink:treats MONDO:0008787 PMID:41385096 "[{""id"":""uuid:d6cc9930-0ecb-4a0b-a991-0f749cc4ad84"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:702ad470-a991-4dfd-95d2-57d637381918"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Deferasirox tablets are an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older. ( 1.1 ) Deferasirox tablets are indicated for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes, and with a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight (Fe/g dw) and a serum ferritin greater than 300 mcg/L.( 1.2 ) Limitations of Use The safety and efficacy of deferasirox tablets when administered with other iron chelation therapy have not been established. ( 1.3 ) uuid:9b294998-1dd9-446f-8435-a84305245710 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:600103 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:a1d4bf61-2e68-4003-a22f-4540b5b82776"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0db3e2b6-6c85-40c2-a855-c3b847031741"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3cb853c5-918e-4dea-b67c-3eb65658e301"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cubicin""]},{""id"":""uuid:354b7f60-263e-4610-9744-10fc642393c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Daptomycin for injection is a lipopeptide antibacterial indicated for the treatment of: • Complicated skin and skin structure infections (cSSSI) in adult and pediatric patients (1 to 17 years of age) ( 1.1 ) and, • Staphylococcus aureus bloodstream infections (bacteremia), in adult patients including those with right-sided infective endocarditis, ( 1.2 ) • Staphylococcus aureus bloodstream infections (bacteremia) in pediatric patients (1 to 17 years of age). ( 1.3 ) Limitations of Use : • Daptomycin for injection is not indicated for the treatment of pneumonia. ( 1.4 ) • Daptomycin for injection is not indicated for the treatment of left-sided infective endocarditis due to S. aureus . ( 1.4 ) • Daptomycin for injection is not recommended in pediatric patients younger than one year of age due to the risk of potential effects on muscular, neuromuscular, and/or nervous systems (either peripheral and/or central) observed in neonatal dogs. ( 1.4 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of daptomycin for injection and other antibacterial drugs, daptomycin for injection should be used to treat infections that are proven or strongly suspected to be caused by bacteria. ( 1.5 )|[EMA] Cubicin is indicated for the treatment of the following infections.Adult and paediatric (1 to 17 years of age) patients with complicated skin and soft-tissue infections (cSSTI).Adult patients with right-sided infective endocarditis (RIE) due to Staphylococcus aureus.It is recommended that the decision to use daptomycin should take into account the antibacterial susceptibility of the organism and should be based on expert advice.Adult and paediatric (1 to 17 years of age) patients with Staphylococcus aureus bacteraemia (SAB). In adults, use in bacteraemia should be associated with RIE or with cSSTI, while in paediatric patients, use in bacteraemia should be associated with cSSTI.Daptomycin is active against Gram positive bacteria only. In mixed infections where Gram negative and/or certain types of anaerobic bacteria are suspected, Cubicin should be co-administered with appropriate antibacterial agent(s). Consideration should be given to official guidance on the appropriate use of antibacterial agents.|[PMDA] A drug with a new active ingredient indicated for the treatment of sepsis, infective endocarditis, deep skin infection, secondary infection of trauma, burn, and surgical wounds, and secondary infection of erosion and ulcer caused by daptomycin-sensitive methicillin-resistant Staphylococcus aureus (MRSA). uuid:888b3315-7d33-4a44-86f3-4c4e7aee4f78 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:600103 biolink:treats MONDO:0005545 PMID:41385096 "[{""id"":""uuid:fa5ab87b-831e-45cd-9b92-42e48fe4161e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4498aa89-130f-40f5-ae8f-42413e21310c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:fe64803e-d825-4f5a-8dc7-a147ad48957c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cubicin""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Daptomycin for injection is a lipopeptide antibacterial indicated for the treatment of: • Complicated skin and skin structure infections (cSSSI) in adult and pediatric patients (1 to 17 years of age) ( 1.1 ) and, • Staphylococcus aureus bloodstream infections (bacteremia), in adult patients including those with right-sided infective endocarditis, ( 1.2 ) • Staphylococcus aureus bloodstream infections (bacteremia) in pediatric patients (1 to 17 years of age). ( 1.3 ) Limitations of Use : • Daptomycin for injection is not indicated for the treatment of pneumonia. ( 1.4 ) • Daptomycin for injection is not indicated for the treatment of left-sided infective endocarditis due to S. aureus . ( 1.4 ) • Daptomycin for injection is not recommended in pediatric patients younger than one year of age due to the risk of potential effects on muscular, neuromuscular, and/or nervous systems (either peripheral and/or central) observed in neonatal dogs. ( 1.4 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of daptomycin for injection and other antibacterial drugs, daptomycin for injection should be used to treat infections that are proven or strongly suspected to be caused by bacteria. ( 1.5 )|[EMA] Cubicin is indicated for the treatment of the following infections.Adult and paediatric (1 to 17 years of age) patients with complicated skin and soft-tissue infections (cSSTI).Adult patients with right-sided infective endocarditis (RIE) due to Staphylococcus aureus.It is recommended that the decision to use daptomycin should take into account the antibacterial susceptibility of the organism and should be based on expert advice.Adult and paediatric (1 to 17 years of age) patients with Staphylococcus aureus bacteraemia (SAB). In adults, use in bacteraemia should be associated with RIE or with cSSTI, while in paediatric patients, use in bacteraemia should be associated with cSSTI.Daptomycin is active against Gram positive bacteria only. In mixed infections where Gram negative and/or certain types of anaerobic bacteria are suspected, Cubicin should be co-administered with appropriate antibacterial agent(s). Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:a2254905-0d66-4278-9594-3e9b86a375b4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:600103 biolink:treats MONDO:0005229 PMID:41385096 "[{""id"":""uuid:e6dfcf2c-424d-45e8-9aae-0117c25d73b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d7ec37f5-f82a-4ec1-b399-4c8b4b1445ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Daptomycin for injection is a lipopeptide antibacterial indicated for the treatment of: • Complicated skin and skin structure infections (cSSSI) in adult and pediatric patients (1 to 17 years of age) ( 1.1 ) and, • Staphylococcus aureus bloodstream infections (bacteremia), in adult patients including those with right-sided infective endocarditis, ( 1.2 ) • Staphylococcus aureus bloodstream infections (bacteremia) in pediatric patients (1 to 17 years of age). ( 1.3 ) Limitations of Use : • Daptomycin for injection is not indicated for the treatment of pneumonia. ( 1.4 ) • Daptomycin for injection is not indicated for the treatment of left-sided infective endocarditis due to S. aureus . ( 1.4 ) • Daptomycin for injection is not recommended in pediatric patients younger than one year of age due to the risk of potential effects on muscular, neuromuscular, and/or nervous systems (either peripheral and/or central) observed in neonatal dogs. ( 1.4 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of daptomycin for injection and other antibacterial drugs, daptomycin for injection should be used to treat infections that are proven or strongly suspected to be caused by bacteria. ( 1.5 ) uuid:e6994d98-10bd-428d-ba6a-19ced3a26326 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:600103 biolink:treats MONDO:0000565 PMID:41385096 "[{""id"":""uuid:5f582c4a-14b0-429d-9a98-a9623220206d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d8bcd57f-044e-4e9e-9e54-86add4c2481a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:fee4b60b-5df3-4282-bba2-606f09c42e0c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cubicin""]},{""id"":""uuid:12e31762-666d-4513-8ccf-6e1d9f3a519e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Daptomycin for injection is a lipopeptide antibacterial indicated for the treatment of: • Complicated skin and skin structure infections (cSSSI) in adult and pediatric patients (1 to 17 years of age) ( 1.1 ) and, • Staphylococcus aureus bloodstream infections (bacteremia), in adult patients including those with right-sided infective endocarditis, ( 1.2 ) • Staphylococcus aureus bloodstream infections (bacteremia) in pediatric patients (1 to 17 years of age). ( 1.3 ) Limitations of Use : • Daptomycin for injection is not indicated for the treatment of pneumonia. ( 1.4 ) • Daptomycin for injection is not indicated for the treatment of left-sided infective endocarditis due to S. aureus . ( 1.4 ) • Daptomycin for injection is not recommended in pediatric patients younger than one year of age due to the risk of potential effects on muscular, neuromuscular, and/or nervous systems (either peripheral and/or central) observed in neonatal dogs. ( 1.4 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of daptomycin for injection and other antibacterial drugs, daptomycin for injection should be used to treat infections that are proven or strongly suspected to be caused by bacteria. ( 1.5 )|[EMA] Cubicin is indicated for the treatment of the following infections.Adult and paediatric (1 to 17 years of age) patients with complicated skin and soft-tissue infections (cSSTI).Adult patients with right-sided infective endocarditis (RIE) due to Staphylococcus aureus.It is recommended that the decision to use daptomycin should take into account the antibacterial susceptibility of the organism and should be based on expert advice.Adult and paediatric (1 to 17 years of age) patients with Staphylococcus aureus bacteraemia (SAB). In adults, use in bacteraemia should be associated with RIE or with cSSTI, while in paediatric patients, use in bacteraemia should be associated with cSSTI.Daptomycin is active against Gram positive bacteria only. In mixed infections where Gram negative and/or certain types of anaerobic bacteria are suspected, Cubicin should be co-administered with appropriate antibacterial agent(s). Consideration should be given to official guidance on the appropriate use of antibacterial agents.|[PMDA] A drug with a new active ingredient indicated for the treatment of sepsis, infective endocarditis, deep skin infection, secondary infection of trauma, burn, and surgical wounds, and secondary infection of erosion and ulcer caused by daptomycin-sensitive methicillin-resistant Staphylococcus aureus (MRSA). uuid:6698067b-a6a1-474d-ba6c-22ec7e12e708 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7565 biolink:treats MONDO:0005356 PMID:41385096 "[{""id"":""uuid:9dbe018a-3ce0-4a4c-be5f-000071415084"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c0399247-2c4a-4e62-b887-930d93a3187e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] I. Vasospastic Angina Nifedipine Extended-Release Tablets, USP are indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. In those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. Nifedipine Extended-Release Tablets, USP may also be used where the clinical presentation suggests a possible vasospastic component, but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion, or in unstable angina where electrocardiographic findings are compatible with intermittent vasospasm, or when angina is refractory to nitrates and/or adequate doses of beta blockers. II. Chronic Stable Angina (Classical Effort-Associated Angina) Nifedipine Extended-Release Tablets, USP are indicated for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm in patients who remain symptomatic despite adequate doses of beta blockers and/or organic nitrates or who cannot tolerate those agents. In chronic stable angina (effort-associated angina), nifedipine has been effective in controlled trials of up to eight weeks duration in reducing angina frequency and increasing exercise tolerance, but confirmation of sustained effectiveness and evaluation of long-term safety in these patients is incomplete. Controlled studies in small numbers of patients suggest concomitant use of nifedipine and beta-blocking agents may be beneficial in patients with chronic stable angina, but available information is not sufficient to predict with confidence the effects of concurrent treatment, especially in patients with compromised left ventricular function or cardiac conduction abnormalities. When introducing such concomitant therapy, care must be taken to monitor blood pressure closely, since severe hypotension can occur from the combined effects of the drugs (see WARNINGS ). III. Hypertension Nifedipine Extended-Release Tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including Nifedipine Extended-Release Tablets, USP. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Nifedipine Extended-Release Tablets, USP may be used alone or in combination with other antihypertensive agents. uuid:d06910fd-51e1-44e2-b518-810db3611c30 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7959 biolink:treats MONDO:0010200 PMID:41385096 "[{""id"":""uuid:004d209d-2af0-4dfc-8def-a17f13402342"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:59576040-ab19-47e7-9451-831178f20755"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Penicillamine Capsules are indicated in the treatment of Wilson's disease, cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy. Available evidence suggests that Penicillamine Capsules are not of value in ankylosing spondylitis. uuid:825ec66b-e32f-45bb-82aa-69f85de4ab93 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7959 biolink:treats MONDO:0009067 PMID:41385096 "[{""id"":""uuid:1b662d1c-67ff-4761-a30d-c975c0bf9335"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6ee63ef1-5597-41a3-aba0-9511e344f04c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Penicillamine Capsules are indicated in the treatment of Wilson's disease, cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy. Available evidence suggests that Penicillamine Capsules are not of value in ankylosing spondylitis. uuid:ce91b26e-ce7e-4ed8-9a90-92575d89e842 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7959 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:7b9f9f6d-5a00-4706-8249-6b548bfba6fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cf08b641-fbf4-4a1f-b378-b0feb78b3025"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Penicillamine Capsules are indicated in the treatment of Wilson's disease, cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy. Available evidence suggests that Penicillamine Capsules are not of value in ankylosing spondylitis. uuid:5f2c81f5-78da-46c2-ac3f-dbe183e697ea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1162127 biolink:treats HP:0001712 PMID:41385096 "[{""id"":""uuid:ab92a782-392c-4f44-8835-04e2a65e241e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8b0746be-6e94-4b65-8a8a-98de8134945e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Losartan potassium and hydrochlorothiazide is a combination of losartan, an angiotensin II receptor blocker (ARB) and hydrochlorothiazide, a diuretic indicated for: • Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) • Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. ( 1.2 ) uuid:36c73481-a8d4-479b-9794-c4d8399aeae0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3732 biolink:treats UMLS:C0348321 PMID:41385096 "[{""id"":""uuid:e24be1af-361f-4da3-9818-bf73880838e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4538cf7f-e71a-4d1b-8f1f-0b1b54012e93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clarithromycin tablets are indicated in adults for the treatment of mild to moderate infections caused by susceptible isolates due to Haemophilus influenzae , Haemophilus parainfluenzae , Moraxella catarrhalis , or Streptococcus pneumoniae. uuid:04460c6b-e818-418f-9077-7cd24de2e7dc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3732 biolink:treats UMLS:C1096597 PMID:41385096 "[{""id"":""uuid:0a9dda07-9cce-467e-8903-6cdaf667e269"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:43143a13-9a0e-48bd-ab6a-94413a940d69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clarithromycin tablets are indicated in adults for the treatment of mild to moderate infections caused by susceptible isolates due to Haemophilus influenzae , Haemophilus parainfluenzae , Moraxella catarrhalis , or Streptococcus pneumoniae. uuid:d0323fe4-6f3b-479a-bd67-d6da1d7070af biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3732 biolink:treats UMLS:C1096746 PMID:41385096 "[{""id"":""uuid:756429e3-9f94-46d9-a7d0-3e68a166c8a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4a3f66de-5f41-4384-8f36-4b7de31435f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clarithromycin tablets are indicated in adults for the treatment of mild to moderate infections caused by susceptible isolates due to Haemophilus influenzae , Haemophilus parainfluenzae , Moraxella catarrhalis , or Streptococcus pneumoniae. uuid:4a9a931a-f2f0-499e-b505-6508c7b946d0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3732 biolink:treats MONDO:0005114 PMID:41385096 "[{""id"":""uuid:87a27071-708c-4717-a3d3-ae28981f7f31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:33764ac5-bfa2-4efe-aeb3-b3b32c46aeb7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clarithromycin tablets are indicated in adults for the treatment of mild to moderate infections caused by susceptible isolates due to Haemophilus influenzae , Haemophilus parainfluenzae , Moraxella catarrhalis , or Streptococcus pneumoniae. uuid:0a9b341b-f975-4c23-bc5e-e6e2d82f57fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2676 biolink:treats MONDO:0021680 PMID:41385096 "[{""id"":""uuid:b6410918-328f-49df-874f-60d5174dcc2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:74fdd3b0-8123-483b-a343-3ff973da0dd5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of Streptococcus species. (α- and β-hemolytic isolates only), Streptococcus pneumoniae , Staphylococcus spp., or Haemophilus influenzae . uuid:adcf451a-73ec-4270-aee8-3ecd27590438 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2676 biolink:treats MONDO:0005114 PMID:41385096 "[{""id"":""uuid:81a5de14-6d4a-42bc-abe0-4be74d8d1931"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5f90ee67-a03d-4a11-b0a5-cb3af02f3bcd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of Streptococcus species. (α- and β-hemolytic isolates only), Streptococcus pneumoniae , Staphylococcus spp., or Haemophilus influenzae . uuid:ffc2f77b-b5f9-410d-aca0-2d8cb949b3d1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2676 biolink:treats MONDO:0024313 PMID:41385096 "[{""id"":""uuid:f2ddc712-8ffe-48ca-8b90-28da0d95a5d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9abf4641-f798-412c-8465-0955bdd29fd8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of Streptococcus species. (α- and β-hemolytic isolates only), Streptococcus pneumoniae , Staphylococcus spp., or Haemophilus influenzae . uuid:54dcf181-5556-44d6-87fc-525e0e256e32 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2676 biolink:treats HP:0005376 PMID:41385096 "[{""id"":""uuid:d286b1b4-15eb-4f73-8465-25a5276f0666"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ce34af03-6bfa-4700-b137-2cafad40b8c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amoxicillin capsules are indicated in the treatment of infections due to susceptible (ONLY β-lactamase–negative) isolates of Streptococcus species. (α- and β-hemolytic isolates only), Streptococcus pneumoniae , Staphylococcus spp., or Haemophilus influenzae . uuid:6fb5df8d-da43-496e-a6fd-24ea0895cd3f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77776 biolink:treats MONDO:0001405 PMID:41385096 "[{""id"":""uuid:768b8320-849d-46b4-8057-fbee4b147a16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a28e08bc-3dc1-4c31-a526-69672d287a71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SULCONAZOLE NITRATE topical solution 1.0% is a broad-spectrum antifungal agent indicated for the treatment of tinea cruris and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, and Microsporum canis; and for the treatment of tinea versicolor. Effectiveness has not been proven in tinea pedis (athlete's foot). Symptomatic relief usually occurs within a few days after starting SULCONAZOLE NITRATE topical solution and clinical improvement usually occurs within one week. uuid:5d558ddb-ec8b-4eac-9be3-fd76d47c9227 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77776 biolink:treats MONDO:0001461 PMID:41385096 "[{""id"":""uuid:afc1f3e8-972b-4af9-97f7-afefd8fc45be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6cd70e8c-9fdd-4fd6-a8c7-2d0f55d488d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SULCONAZOLE NITRATE topical solution 1.0% is a broad-spectrum antifungal agent indicated for the treatment of tinea cruris and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, and Microsporum canis; and for the treatment of tinea versicolor. Effectiveness has not been proven in tinea pedis (athlete's foot). Symptomatic relief usually occurs within a few days after starting SULCONAZOLE NITRATE topical solution and clinical improvement usually occurs within one week. uuid:8dc41283-da98-408b-af96-0a91ddc62e26 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77776 biolink:treats MONDO:0005915 PMID:41385096 "[{""id"":""uuid:b290ca0b-77d9-44b2-a060-b981b79ec179"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:73b7355d-0c57-4f11-a990-e901fd3cc012"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SULCONAZOLE NITRATE topical solution 1.0% is a broad-spectrum antifungal agent indicated for the treatment of tinea cruris and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, and Microsporum canis; and for the treatment of tinea versicolor. Effectiveness has not been proven in tinea pedis (athlete's foot). Symptomatic relief usually occurs within a few days after starting SULCONAZOLE NITRATE topical solution and clinical improvement usually occurs within one week. uuid:483bc9b2-e7ca-462a-abac-1ae4164a305e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49468 biolink:treats MONDO:0001209 PMID:41385096 "[{""id"":""uuid:81e7c57b-8a6b-428a-8848-d4e0fd144ebc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a6e19157-5bc3-4964-845d-03682494f54e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Caustic applicators are useful for cauterization of skin or mucous membrane and for the removal of granulation tissue, warts and verrucae. uuid:813ea723-dbb3-45e1-b946-b3dd23ef04d2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0003996 PMID:41385096 "[{""id"":""uuid:fddc02a7-a44e-4eb7-94d0-6d10f1207471"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:03d9b174-0451-4184-b46f-5a293e07de21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or intramuscular administration. When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: Endocrine disorders. Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia. Nonsuppurative thyroiditis. Hypercalcemia associated with cancer. Rheumatic disorders. As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis. Synovitis of osteoarthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis. Epicondylitis. Acute nonspecific tenosynovitis. Acute gouty arthritis. Psoriatic arthritis. Ankylosing spondylitis. Collagen diseases. During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Acute rheumatic carditis. Dermatologic diseases. Pemphigus. Severe erythema multiforme (Stevens-Johnson Syndrome). Exfoliative dermatitis. Bullous dermatitis herpetiformis. Severe seborrheic dermatitis. Severe psoriasis. Mycosis fungoides. Allergic states. Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma. Contact dermatitis. Atopic dermatitis. Serum sickness. Seasonal or perennial allergic rhinitis. Drug hypersensitivity reactions. Urticarial transfusion reactions. Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). Ophthalmic diseases. Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus. Iritis, iridocyclitis. Chorioretinitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Sympathetic ophthalmia. Anterior segment inflammation. Allergic conjunctivitis. Allergic corneal marginal ulcers. Keratitis. Gastrointestinal diseases. To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy). Regional enteritis (systemic therapy). Respiratory diseases. Symptomatic Sarcoidosis. Berylliosis. Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate anti-tuberculosis chemotherapy. Loeffler's syndrome not manageable by other means. Aspiration pneumonitis. Hematologic disorders. Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (I.V. only; I.M. administration is contraindicated). Secondary thrombocytopenia in adults. Erythroblastopenia (RBC anemia). Congenital (erythroid) hypoplastic anemia. Neoplastic diseases. For palliative management of: Leukemias and lymphomas in adults. Acute leukemia of childhood. Edematous states. To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. Nervous system. Acute exacerbations of multiple sclerosis. Miscellaneous. Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate anti-tuberculosis chemotherapy. Trichinosis with neurologic or myocardial involvement. Diagnostic testing of adrenocortical hyperfunction. Cerebral edema of diverse etiologies in conjunction with adequate neurological evaluation and management. Intra-articular or soft tissue administration. When the strength and dosage form of the drug lend the preparation to the treatment of the condition, those products labeled for intra-articular or soft tissue administration are indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Synovitis osteoarthritis. Rheumatoid arthritis. Acute and subacute bursitis. Acute gouty arthritis. Epicondylitis. Acute nonspecific tenosynovitis. Post-traumatic osteoarthritis. Intralesional administration. When the strength and dosage form of the drug lend the preparation to the treatment of the condition, those products labeled for intralesional administration are indicated for: Keloids. Localized hypertrophic, infiltrated, inflammatory lesions of: lichen planus, psoriatic plaques, granuloma annulare, and lichen simplex chronicus (neurodermatitis). Discoid lupus erythematosus. Necrobiosis lipoidica diabeticorum. Alopecia areata. They also may be useful in cystic tumors of an aponeurosis tendon (ganglia). uuid:a6180c20-bd69-4f57-b0a9-86e10823824b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3614 biolink:treats MONDO:0005076 PMID:41385096 "[{""id"":""uuid:42220087-8402-4fbb-ad9f-9f21b7c2a84c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:23177d53-5701-4d89-aed0-eb03f77a40c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PerioGard® (Chlorhexidine Gluconate Oral Rinse USP, 0.12%) is indicated for use between dental visits as part of a professional program for the treatment of gingivitis as characterized by redness and swelling of the gingivae, including gingival bleeding upon probing. PerioGard® has not been tested among patients with acute necrotizing ulcerative gingivitis (ANUG). For patients having coexisting gingivitis and periodontitis, see PRECAUTIONS . uuid:fe439a51-721f-4f5b-8c84-da8d24956b07 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:NS6Q291771 biolink:treats MONDO:0019297 PMID:41385096 "[{""id"":""uuid:c62a93b6-215a-4cf9-8a15-a27efda12d76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bd72811c-de51-4f5d-a165-ca6b90900513"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isosulfan blue injection 1% upon subcutaneous administration, delineates the lymphatic vessels draining the region of injection. It is an adjunct to lymphography in: primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; lymph node response to therapeutic modalities ( 1.1 ). PUBCHEM.COMPOUND:52946590 uuid:74c8a810-1537-445b-8556-e4b70f6561a1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:NS6Q291771 biolink:treats UMLS:C0159075 PMID:41385096 "[{""id"":""uuid:cdd45bc3-377c-492a-b88d-cdf572c9e00e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b5fad369-8077-4e44-b151-610febce3426"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isosulfan blue injection 1% upon subcutaneous administration, delineates the lymphatic vessels draining the region of injection. It is an adjunct to lymphography in: primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; lymph node response to therapeutic modalities ( 1.1 ). PUBCHEM.COMPOUND:52946590 uuid:9bc4e397-f954-4dea-8bc2-0f8bc09bec06 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:NS6Q291771 biolink:treats MONDO:0008829 PMID:41385096 "[{""id"":""uuid:5f1ed94e-eecc-4e25-9a0a-cba182bc7b79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:507b7247-69a7-4ac4-9e9a-2aafb78dea45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isosulfan blue injection 1% upon subcutaneous administration, delineates the lymphatic vessels draining the region of injection. It is an adjunct to lymphography in: primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; lymph node response to therapeutic modalities ( 1.1 ). PUBCHEM.COMPOUND:52946590 uuid:1ac5748d-d263-46c2-af2f-7463ec904c96 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:NS6Q291771 biolink:treats HP:0010310 PMID:41385096 "[{""id"":""uuid:599a1652-7dc7-45ee-8edf-47f29b2bc8af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cfdd6254-8069-4693-9b85-fad6602d00f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isosulfan blue injection 1% upon subcutaneous administration, delineates the lymphatic vessels draining the region of injection. It is an adjunct to lymphography in: primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; lymph node response to therapeutic modalities ( 1.1 ). PUBCHEM.COMPOUND:52946590 uuid:4e927384-7b15-4f65-8923-7b0621817670 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:NS6Q291771 biolink:treats MONDO:0005438 PMID:41385096 "[{""id"":""uuid:3e6a7459-9f62-4e96-ad9c-7cf3f81ce33c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5bf64459-b879-49ab-b206-9e8181291576"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isosulfan blue injection 1% upon subcutaneous administration, delineates the lymphatic vessels draining the region of injection. It is an adjunct to lymphography in: primary and secondary lymphedema of the extremities; chyluria, chylous ascites or chylothorax; lymph node involvement by primary or secondary neoplasm; lymph node response to therapeutic modalities ( 1.1 ). PUBCHEM.COMPOUND:52946590 uuid:4a4aa20e-f0d9-4052-b235-4ecd6cf4bf79 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63632 biolink:treats UMLS:C5706270 PMID:41385096 "[{""id"":""uuid:b8a82aa0-9a50-4e76-8816-09b0e1ac2b18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ff78c891-9d96-42e5-a2d1-cd8c57587753"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Topotecan Injection is indicated for the treatment of patients with small cell lung cancer (SCLC) with platinum-sensitive disease who progressed at least 60 days after initiation of first-line chemotherapy. uuid:a81e88ee-835c-41a4-b7a5-0ea1b14c6b39 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:70735 biolink:treats MONDO:0005090 PMID:41385096 "[{""id"":""uuid:81836245-aa13-442a-a54b-48b8b74bd8bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0d267355-28cb-4d4e-8d66-e26b2c634d82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a6587596-077a-403b-b990-fb01a306b57e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/latuda""]},{""id"":""uuid:f15f28a7-27ae-4dc8-889d-5e6c4e8c854e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LATUDA is indicated for: Treatment of adult and adolescent patients (13 to 17 years) with schizophrenia [see Clinical Studies ( 14.1 )] . Monotherapy treatment of adult and pediatric patients (10 to 17 years) with major depressive episode associated with bipolar I disorder (bipolar depression) [see Clinical Studies ( 14.2 )] . Adjunctive treatment with lithium or valproate in adult patients with major depressive episode associated with bipolar I disorder (bipolar depression) [see Clinical Studies ( 14.2 )] .|[EMA] Treatment of schizophrenia in adults aged 18 years and over.|[PMDA] Drugs with a new active ingredient indicated for the treatment of schizophrenia and the improvement of depressive symptoms in patients with bipolar disorder. uuid:744f5e1f-53cf-4209-b80c-40b67515b0b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:70735 biolink:treats MONDO:0024613 PMID:41385096 "[{""id"":""uuid:5c4a2dfb-d804-411a-9c12-2c48d62a3965"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9e752209-6d37-484d-a7c8-c31b03aa7756"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LATUDA is indicated for: Treatment of adult and adolescent patients (13 to 17 years) with schizophrenia [see Clinical Studies ( 14.1 )] . Monotherapy treatment of adult and pediatric patients (10 to 17 years) with major depressive episode associated with bipolar I disorder (bipolar depression) [see Clinical Studies ( 14.2 )] . Adjunctive treatment with lithium or valproate in adult patients with major depressive episode associated with bipolar I disorder (bipolar depression) [see Clinical Studies ( 14.2 )] . uuid:93a81e74-ada5-45bb-8482-21536db2ffef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:48669 biolink:treats HP:0000132 PMID:41385096 "[{""id"":""uuid:11ff21d3-d39f-419e-9362-9434ad4ae09c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b15bc00e-b9b7-4d1c-8fad-45079d0fdfd8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tranexamic acid tablets are indicated for the treatment of cyclic heavy menstrual bleeding in females of reproductive potential [see Clinical Studies ( 14 )] uuid:22668529-65f7-4f92-ae13-45c44e852de1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats MONDO:0000190 PMID:41385096 "[{""id"":""uuid:c3c924af-9fc9-40a8-aedb-14794d2730b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cc18301e-5bba-4bef-9cbb-84f4cdc80297"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EPINEPHRINE Epinephrine’s cardiac effects may be of use in the treatment and prophylaxis of cardiac arrest due to various causes in the absence of ventricular fibrillation and attacks of transitory atrioventricular (AV) heart block with syncopal seizures (Stokes-Adams syndrome), but it is not used in cardiac failure or in hemorrhagic, traumatic or in cardiogenic shock. Epinephrine may be used to stimulate the heart in syncope due to complete heart block or carotid sinus hypersensitivity. Epinephrine is also used for resuscitation in cardiac arrest following anesthetic accidents. In cardiopulmonary resuscitation, intracardiac puncture and intramyocardial injection of epinephrine may be effective when external cardiac compression and attempts to restore the circulation by electrical defibillation or use of a pacemaker fail. Epinephrine is seldom used as a vasopressor except in the treatment of anaphylactic shock and under certain conditions in insulin shock. uuid:05595f63-de68-4882-b275-dd817237a2c0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats UMLS:C0741983 PMID:41385096 "[{""id"":""uuid:9bd213d5-7548-437c-ac17-1f02efa2eacf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3cb6ebe0-fd03-436a-a0d7-4cb53214484a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EPINEPHRINE Epinephrine’s cardiac effects may be of use in the treatment and prophylaxis of cardiac arrest due to various causes in the absence of ventricular fibrillation and attacks of transitory atrioventricular (AV) heart block with syncopal seizures (Stokes-Adams syndrome), but it is not used in cardiac failure or in hemorrhagic, traumatic or in cardiogenic shock. Epinephrine may be used to stimulate the heart in syncope due to complete heart block or carotid sinus hypersensitivity. Epinephrine is also used for resuscitation in cardiac arrest following anesthetic accidents. In cardiopulmonary resuscitation, intracardiac puncture and intramyocardial injection of epinephrine may be effective when external cardiac compression and attempts to restore the circulation by electrical defibillation or use of a pacemaker fail. Epinephrine is seldom used as a vasopressor except in the treatment of anaphylactic shock and under certain conditions in insulin shock. uuid:f3fde895-cb3e-40a4-8551-254751285646 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats UMLS:C1527401 PMID:41385096 "[{""id"":""uuid:dfd8efc5-7497-4d5f-909e-53996af82ee9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:252ed8c5-0fe9-48c7-bb7f-1d67151192bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EPINEPHRINE Epinephrine’s cardiac effects may be of use in the treatment and prophylaxis of cardiac arrest due to various causes in the absence of ventricular fibrillation and attacks of transitory atrioventricular (AV) heart block with syncopal seizures (Stokes-Adams syndrome), but it is not used in cardiac failure or in hemorrhagic, traumatic or in cardiogenic shock. Epinephrine may be used to stimulate the heart in syncope due to complete heart block or carotid sinus hypersensitivity. Epinephrine is also used for resuscitation in cardiac arrest following anesthetic accidents. In cardiopulmonary resuscitation, intracardiac puncture and intramyocardial injection of epinephrine may be effective when external cardiac compression and attempts to restore the circulation by electrical defibillation or use of a pacemaker fail. Epinephrine is seldom used as a vasopressor except in the treatment of anaphylactic shock and under certain conditions in insulin shock. uuid:9284134f-f322-4c50-90c7-4dba3f824cd0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:700516 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:a2c83083-8bda-4f11-b1ff-35c227740207"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:572b379b-c107-423e-b8c3-52daf45db736"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:16287057-3374-4566-be9c-409ac9dad9da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] JANUMET ® XR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.|[PMDA] New combination drugs indicated for the treatment of type 2 diabetes mellitus (only when a concomitant use of anagliptin with metformin hydrochloride is deemed appropriate). uuid:bb816337-00a1-4e13-a6ac-6e1799520d8f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18357 biolink:treats MONDO:0017373 PMID:41385096 "[{""id"":""uuid:bfdee88a-6eaf-4c8b-88e8-b2f6b71eabc2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3fadabd8-0ffc-4441-9b67-f12faff317eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For blood pressure control in certain acute hypotensive states (e.g., pheochromocytomectomy, sympathectomy, poliomyelitis, spinal anesthesia, myocardial infarction, septicemia, blood transfusion, and drug reactions). As an adjunct in the treatment of cardiac arrest and profound hypotension. uuid:37697f4b-b8a3-4747-b796-d38ca7b27f53 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18357 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:448b0d38-a161-4b83-b7b2-e5f7d9bbd692"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5803505b-3625-4e26-95df-c00bb69cb0ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For blood pressure control in certain acute hypotensive states (e.g., pheochromocytomectomy, sympathectomy, poliomyelitis, spinal anesthesia, myocardial infarction, septicemia, blood transfusion, and drug reactions). As an adjunct in the treatment of cardiac arrest and profound hypotension. uuid:2ad6ed6b-9af2-4c16-b6d1-a2ae857ab514 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18357 biolink:treats MONDO:0700217 PMID:41385096 "[{""id"":""uuid:b2e511f7-9941-4703-8ba6-8497bc041fc4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7fe81997-488c-4a49-80f1-b67e6f8888a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For blood pressure control in certain acute hypotensive states (e.g., pheochromocytomectomy, sympathectomy, poliomyelitis, spinal anesthesia, myocardial infarction, septicemia, blood transfusion, and drug reactions). As an adjunct in the treatment of cardiac arrest and profound hypotension. uuid:1f597442-1bc4-448f-93ef-bfe49e78cc4a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18357 biolink:treats MONDO:0000745 PMID:41385096 "[{""id"":""uuid:f45d7fab-f04f-4c39-a59c-514c6000fdd4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8140aa56-f51b-4395-96d5-9c24cb3cc1de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For blood pressure control in certain acute hypotensive states (e.g., pheochromocytomectomy, sympathectomy, poliomyelitis, spinal anesthesia, myocardial infarction, septicemia, blood transfusion, and drug reactions). As an adjunct in the treatment of cardiac arrest and profound hypotension. uuid:6cce02d2-e8fa-4046-940e-1d4c787c31d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18357 biolink:treats MONDO:0005468 PMID:41385096 "[{""id"":""uuid:c2b1a270-6e19-441a-a85f-52d544bd2f45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3cf02849-93b1-4627-a7e7-040ccb201d5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For blood pressure control in certain acute hypotensive states (e.g., pheochromocytomectomy, sympathectomy, poliomyelitis, spinal anesthesia, myocardial infarction, septicemia, blood transfusion, and drug reactions). As an adjunct in the treatment of cardiac arrest and profound hypotension. uuid:fb2bc4f4-9609-48f5-a504-85e240b56b80 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5391 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:73d734e3-9c45-483c-8dca-70957d1e676f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:63332396-b1a9-4f09-8291-7933ce1a7baa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:89993205-c86b-4f1c-ae52-e898e3dc8912"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ogluo""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of severe hypoglycemia: Glucagon is indicated as a treatment for severe hypoglycemia (low blood sugar) which may occur in patients with diabetes mellitus. Because patients with type 1 diabetes may have less of an increase in blood glucose levels compared with a stable type 2 patient, supplementary carbohydrate should be given as soon as possible, especially to a pediatric patient. For use as a diagnostic aid: Glucagon is indicated as a diagnostic aid in the radiologic examination of the stomach, duodenum, small bowel, and colon when diminished intestinal motility would be advantageous. Glucagon is as effective for this examination as are the anticholinergic drugs. However, as use of glucagon in combination with anticholinergic drugs may result in increased side effects, the use of glucagon in combination with anticholinergic drugs is not recommended.|[EMA] Ogluo is indicated for the treatment of severe hypoglycaemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. uuid:97c41bc7-d0f7-43fb-a943-f0209f4bf9c9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45285 biolink:treats MONDO:0018076 PMID:41385096 "[{""id"":""uuid:e2634619-d6ad-4202-93ff-5e11d86777c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0262e0c7-8b34-450d-a2d4-15641610ecdc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pyrazinamide is indicated for the initial treatment of active tuberculosis in adults and children when combined with other antituberculous agents. (The current recommendation of the CDC for drug-susceptible disease is to use a six-month regimen for initial treatment of active tuberculosis, consisting of isoniazid, rifampin and pyrazinamide given for 2 months, followed by isoniazid and rifampin for 4 months.* 4 ) (Patients with drug-resistant disease should be treated with regimens individualized to their situation. Pyrazinamide frequently will be an important component of such therapy.) (In patients with concomitant HIV infection, the physician should be aware of current recommendations of CDC. It is possible these patients may require a longer course of treatment.) It is also indicated after treatment failure with other primary drugs in any form of active tuberculosis. Pyrazinamide should only be used in conjunction with other effective antituberculous agents. *See recommendations of Center for Disease Control (CDC) and American Thoracic Society for complete regimen and dosage recommendations. 4 uuid:e53f348a-5fb5-4a5c-8e6a-c5a0ed6262b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45285 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:a9c20801-b830-4b98-b452-95bdaec6b71a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c8b54e34-b7d3-490d-bd78-7a7878845e38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pyrazinamide is indicated for the initial treatment of active tuberculosis in adults and children when combined with other antituberculous agents. (The current recommendation of the CDC for drug-susceptible disease is to use a six-month regimen for initial treatment of active tuberculosis, consisting of isoniazid, rifampin and pyrazinamide given for 2 months, followed by isoniazid and rifampin for 4 months.* 4 ) (Patients with drug-resistant disease should be treated with regimens individualized to their situation. Pyrazinamide frequently will be an important component of such therapy.) (In patients with concomitant HIV infection, the physician should be aware of current recommendations of CDC. It is possible these patients may require a longer course of treatment.) It is also indicated after treatment failure with other primary drugs in any form of active tuberculosis. Pyrazinamide should only be used in conjunction with other effective antituberculous agents. *See recommendations of Center for Disease Control (CDC) and American Thoracic Society for complete regimen and dosage recommendations. 4 uuid:452bf550-2dd4-4b4e-9163-24acda79a82a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31524 biolink:treats MONDO:0005180 PMID:41385096 "[{""id"":""uuid:f3d37ebd-c0e7-4d36-832b-9881d2e5f251"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cf9d5630-6187-4dd3-a5b6-fa0f36795ed0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Droxidopa capsules are indicated for the treatment of orthostatic dizziness, lightheadedness, or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure (Parkinson's disease [PD], multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy. Effectiveness beyond 2 weeks of treatment has not been established. The continued effectiveness of Droxidopa should be assessed periodically. uuid:f5a36861-3192-41a5-ab3c-b6eecb535f7b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31524 biolink:treats MONDO:0007803 PMID:41385096 "[{""id"":""uuid:d51718f2-9d18-4813-89b8-d60e28af8932"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:37254b34-7584-41e1-b6cc-d60085348bcc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Droxidopa capsules are indicated for the treatment of orthostatic dizziness, lightheadedness, or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure (Parkinson's disease [PD], multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy. Effectiveness beyond 2 weeks of treatment has not been established. The continued effectiveness of Droxidopa should be assessed periodically. uuid:99c8f9db-2ad6-41fd-97e3-06c9a27c0169 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31524 biolink:treats MONDO:0018608 PMID:41385096 "[{""id"":""uuid:032e7407-b7ed-4a45-8adb-f791f7085dad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f3931577-8818-43d7-b578-0f28c5afa98c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Droxidopa capsules are indicated for the treatment of orthostatic dizziness, lightheadedness, or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure (Parkinson's disease [PD], multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy. Effectiveness beyond 2 weeks of treatment has not been established. The continued effectiveness of Droxidopa should be assessed periodically. uuid:34d4fddc-295e-42a2-acbd-94030961d07b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31524 biolink:treats MONDO:0001300 PMID:41385096 "[{""id"":""uuid:73e92674-abb0-454f-978c-6474068c089f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0c0a64e6-8845-436a-82b3-19c50401bd8e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Droxidopa capsules are indicated for the treatment of orthostatic dizziness, lightheadedness, or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure (Parkinson's disease [PD], multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy. Effectiveness beyond 2 weeks of treatment has not been established. The continued effectiveness of Droxidopa should be assessed periodically. uuid:354bd81e-4337-468f-86c1-9b747ef488d4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31524 biolink:treats MONDO:0005469 PMID:41385096 "[{""id"":""uuid:a75dd878-5933-44f3-bf12-702764e246ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:87774d92-4b46-49e0-8587-e5ef2de50e59"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Droxidopa capsules are indicated for the treatment of orthostatic dizziness, lightheadedness, or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure (Parkinson's disease [PD], multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy. Effectiveness beyond 2 weeks of treatment has not been established. The continued effectiveness of Droxidopa should be assessed periodically. uuid:cf17f789-e3fb-420a-a450-d7f46dfcddca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2618 biolink:treats MONDO:0024352 PMID:41385096 "[{""id"":""uuid:6fd2cf19-58e8-41a0-b84b-542f6706133e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:118d6ba9-7fd3-447a-ac21-7a7cb4d5dea0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amantadine Hydrochloride is indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine Hydrochloride is also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions. Influenza A Prophylaxis Amantadine Hydrochloride is indicated for chemoprophylaxis against signs and symptoms of influenza A virus infection. Because Amantadine Hydrochloride Tablets do not completely prevent the host immune response to influenza A infection, individuals who take this drug may still develop immune responses to natural disease or vaccination and may be protected when later exposed to antigenically related viruses. Following vaccination during an influenza A outbreak, Amantadine Hydrochloride Tablets prophylaxis should be considered for the 2- to 4- week time period required to develop an antibody response. Influenza A Treatment Amantadine Hydrochloride is also indicated in the treatment of uncomplicated respiratory tract illness caused by influenza A virus strains especially when administered early in the course of illness. There are no well-controlled clinical studies demonstrating that treatment with Amantadine Hydrochloride will avoid the development of influenza A virus pneumonitis or other complications in high risk patients. There is no clinical evidence indicating that Amantadine Hydrochloride Tablets and Capsules are effective in the prophylaxis or treatment of viral respiratory tract illnesses other than those caused by influenza A virus strains. The following points should be considered before initiating treatment or prophylaxis with Amantadine Hydrochloride: Amantadine Hydrochloride is not a substitute for early vaccination on an annual basis as recommended by the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices. Influenza viruses change over time. Emergence of resistance mutations could decrease drug effectiveness. Other factors (for example, changes in viral virulence) might also diminish clinical benefit of antiviral drugs. Prescribers should consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use Amantadine Hydrochloride. Parkinson's Disease / Syndrome Amantadine Hydrochloride is indicated in the treatment of idiopathic Parkinson's disease (Paralysis Agitans), postencephalitic parkinsonism, and symptomatic parkinsonism which may follow injury to the nervous system by carbon monoxide intoxication. It is indicated in those elderly patients believed to develop parkinsonism in association with cerebral arteriosclerosis. In the treatment of Parkinson's disease, Amantadine Hydrochloride is less effective than levodopa, (-)-3-(3,4-dihydroxyphenyl)-L-alanine, and its efficacy in comparison with the anticholinergic antiparkinson drugs has not yet been established. Drug-Induced Extrapyramidal Reactions Amantadine Hydrochloride is indicated in the treatment of drug-induced extrapyramidal reactions. Although anticholinergic-type side effects have been noted with Amantadine Hydrochloride Tablets when used in patients with drug-induced extrapyramidal reactions, there is a lower incidence of these side effects than that observed with the anticholinergic antiparkinson drugs. uuid:318b9339-ee0e-4251-bb48-112a034d9ad9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7824 biolink:treats MONDO:0006710 PMID:41385096 "[{""id"":""uuid:76cd6d96-5d14-41c8-92cc-f2ee2ede28b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:68fc39ea-7521-4766-9b7c-af3c3e195c00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxcarbazepine tablets are indicated for use as monotherapy or adjunctive therapy in the treatment of partial-onset seizures in adults and as monotherapy in the treatment of partial-onset seizures in pediatric patients aged 4 years and above, and as adjunctive therapy in pediatric patients aged 2 years and above with partial-onset seizures. uuid:59e86c6b-3ffd-4127-972d-98ebf508eaab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28001 biolink:treats MONDO:0005545 PMID:41385096 "[{""id"":""uuid:c7a5d92b-7483-4d6b-8466-5d56b4a59b36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:67f714ee-8e6d-4b74-b058-2d3e5055e580"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vancomycin Hydrochloride for Oral Solution is administered orally for treatment of enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains) and antibiotic-associated pseudomembranous colitis caused by C. difficile . Parenteral administration of vancomycin is not effective for the above indications; therefore, Vancomycin Hydrochloride for Oral Solution must be given orally for these infections. Orally administered Vancomycin Hydrochloride for Oral Solution is not effective for other types of infection. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Vancomycin Hydrochloride for Oral Solution and other antibacterial drugs, Vancomycin Hydrochloride for Oral Solution should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:188aacbd-7927-49b4-b4b0-450f969b177e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:375139 biolink:treats MONDO:0004857 PMID:41385096 "[{""id"":""uuid:d4d3b4ce-e3cc-4e82-95ca-c5a1564763db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:53b53733-3d63-4e78-af5d-9c407942cf44"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lidothol is a formulation used to assist patients in the treatment of mild to moderate acute or chronic aches or pain. Muscle or joint pain can be due to muscle or ligament strains, simple backache, tendonitis, osteoarthritis, rheumatoid arthritis, peripheral neuropathies such as diabetic neuropathy or post herpetic neuralgia, and other complex regional pains. It can also be used to help with certain types of headaches, but use with caution when applying in order to avoid eye contact. Other uses may be considered if deemed clinically relevant. uuid:20d81ada-7ab6-4d42-b2d3-e8dd3da45ce2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:375139 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:388e9e74-2dd1-4f35-9879-e23367b51c7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3c115bf4-0305-48e0-81dc-65f819271ab1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lidothol is a formulation used to assist patients in the treatment of mild to moderate acute or chronic aches or pain. Muscle or joint pain can be due to muscle or ligament strains, simple backache, tendonitis, osteoarthritis, rheumatoid arthritis, peripheral neuropathies such as diabetic neuropathy or post herpetic neuralgia, and other complex regional pains. It can also be used to help with certain types of headaches, but use with caution when applying in order to avoid eye contact. Other uses may be considered if deemed clinically relevant. uuid:14ef602b-e93e-480b-a312-b2be4c6f95f9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:375139 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:5c091201-4898-4a18-bfb5-9c18682add11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:51611d31-ea99-4da2-b140-2b37e99040de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lidothol is a formulation used to assist patients in the treatment of mild to moderate acute or chronic aches or pain. Muscle or joint pain can be due to muscle or ligament strains, simple backache, tendonitis, osteoarthritis, rheumatoid arthritis, peripheral neuropathies such as diabetic neuropathy or post herpetic neuralgia, and other complex regional pains. It can also be used to help with certain types of headaches, but use with caution when applying in order to avoid eye contact. Other uses may be considered if deemed clinically relevant. uuid:4faeed57-ecef-4926-9210-421622919236 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:375139 biolink:treats MONDO:0006626 PMID:41385096 "[{""id"":""uuid:6af108c5-6aac-4843-b004-1d66c7156e52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:51e0eac4-959d-41c8-b34a-fc89ceab3d8e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lidothol is a formulation used to assist patients in the treatment of mild to moderate acute or chronic aches or pain. Muscle or joint pain can be due to muscle or ligament strains, simple backache, tendonitis, osteoarthritis, rheumatoid arthritis, peripheral neuropathies such as diabetic neuropathy or post herpetic neuralgia, and other complex regional pains. It can also be used to help with certain types of headaches, but use with caution when applying in order to avoid eye contact. Other uses may be considered if deemed clinically relevant. uuid:29831ced-003e-4028-a8b6-113a295bba79 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:375139 biolink:treats MONDO:0041052 PMID:41385096 "[{""id"":""uuid:06ae7520-a3c3-48e1-a584-d334d734cefd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:32855378-8143-4db9-8177-db12c8799f7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lidothol is a formulation used to assist patients in the treatment of mild to moderate acute or chronic aches or pain. Muscle or joint pain can be due to muscle or ligament strains, simple backache, tendonitis, osteoarthritis, rheumatoid arthritis, peripheral neuropathies such as diabetic neuropathy or post herpetic neuralgia, and other complex regional pains. It can also be used to help with certain types of headaches, but use with caution when applying in order to avoid eye contact. Other uses may be considered if deemed clinically relevant. uuid:d050f523-decd-4e8a-bb73-1c23ac8605cf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:375139 biolink:treats MONDO:0021146 PMID:41385096 "[{""id"":""uuid:a1095cbb-a623-4a50-b8fe-961d91a874ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bc59f765-f54d-4376-b1d5-3076a49049bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lidothol is a formulation used to assist patients in the treatment of mild to moderate acute or chronic aches or pain. Muscle or joint pain can be due to muscle or ligament strains, simple backache, tendonitis, osteoarthritis, rheumatoid arthritis, peripheral neuropathies such as diabetic neuropathy or post herpetic neuralgia, and other complex regional pains. It can also be used to help with certain types of headaches, but use with caution when applying in order to avoid eye contact. Other uses may be considered if deemed clinically relevant. uuid:a1cf6edc-202b-44a4-8900-13a243c00a82 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1090966 biolink:treats MONDO:0007016 PMID:41385096 "[{""id"":""uuid:7c349f56-3a91-4bee-b2c9-ea348222612a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c55d7ab5-1f31-404b-9bad-b56acc7a83d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Supplementation of the diet with ten essential vitamins. Supplementation of the diet with fluoride for caries prophylaxis. Multivitamin with 1.0 mg Fluoride Chewable Tablets provide 1.0 mg fluoride in tablet form for children 6-16 years of age in areas where the water fluoride level is less than 0.3 ppm. Multivitamin with 1.0 mg Fluoride Chewable Tablets supply significant amounts of Vitamins A, C, D, E, thiamine, riboflavin, niacin, vitamin B 6, vitamin B 12, and folate to supplement the diet, and to help assure that nutritional deficiencies of these vitamins will not develop. Thus, in a single easy-to-use preparation, children obtain ten essential vitamins and the important mineral, fluoride. The American Academy of Pediatrics recommends that children up to age 16, in areas where drinking water contains less than optimal levels of fluoride, receive daily fluoride supplements. Children using Multivitamin with 1.0 mg Fluoride Chewable Tablets regularly should receive semiannual dental examinations. The regular brushing of teeth and attention to good oral hygiene practices are also essential. Multivitamin with Fluoride Chewable Tablets is a prescription product for the clinical dietary management of the metabolic processes of caries prophylaxis and provides supplementation of the diet with ten essential vitamins. uuid:94766327-34ec-4755-81c9-3b68b7d5b6a7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1090966 biolink:treats MONDO:0009412 PMID:41385096 "[{""id"":""uuid:fbf3b102-f400-4b18-9a4d-f01bba7898f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f263b109-0b23-44b5-b46b-d86479793e2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Supplementation of the diet with ten essential vitamins. Supplementation of the diet with fluoride for caries prophylaxis. Multivitamin with 1.0 mg Fluoride Chewable Tablets provide 1.0 mg fluoride in tablet form for children 6-16 years of age in areas where the water fluoride level is less than 0.3 ppm. Multivitamin with 1.0 mg Fluoride Chewable Tablets supply significant amounts of Vitamins A, C, D, E, thiamine, riboflavin, niacin, vitamin B 6, vitamin B 12, and folate to supplement the diet, and to help assure that nutritional deficiencies of these vitamins will not develop. Thus, in a single easy-to-use preparation, children obtain ten essential vitamins and the important mineral, fluoride. The American Academy of Pediatrics recommends that children up to age 16, in areas where drinking water contains less than optimal levels of fluoride, receive daily fluoride supplements. Children using Multivitamin with 1.0 mg Fluoride Chewable Tablets regularly should receive semiannual dental examinations. The regular brushing of teeth and attention to good oral hygiene practices are also essential. Multivitamin with Fluoride Chewable Tablets is a prescription product for the clinical dietary management of the metabolic processes of caries prophylaxis and provides supplementation of the diet with ten essential vitamins. uuid:7035e0d9-8845-4fed-848b-25aacb24e987 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1090966 biolink:treats MONDO:0100471 PMID:41385096 "[{""id"":""uuid:0748ebaf-961e-4d29-9920-80b926d0c3c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:103586b7-be0b-4215-b709-54bb3bdba2a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Supplementation of the diet with ten essential vitamins. Supplementation of the diet with fluoride for caries prophylaxis. Multivitamin with 1.0 mg Fluoride Chewable Tablets provide 1.0 mg fluoride in tablet form for children 6-16 years of age in areas where the water fluoride level is less than 0.3 ppm. Multivitamin with 1.0 mg Fluoride Chewable Tablets supply significant amounts of Vitamins A, C, D, E, thiamine, riboflavin, niacin, vitamin B 6, vitamin B 12, and folate to supplement the diet, and to help assure that nutritional deficiencies of these vitamins will not develop. Thus, in a single easy-to-use preparation, children obtain ten essential vitamins and the important mineral, fluoride. The American Academy of Pediatrics recommends that children up to age 16, in areas where drinking water contains less than optimal levels of fluoride, receive daily fluoride supplements. Children using Multivitamin with 1.0 mg Fluoride Chewable Tablets regularly should receive semiannual dental examinations. The regular brushing of teeth and attention to good oral hygiene practices are also essential. Multivitamin with Fluoride Chewable Tablets is a prescription product for the clinical dietary management of the metabolic processes of caries prophylaxis and provides supplementation of the diet with ten essential vitamins. uuid:d8833e15-73bf-4498-b4a4-c6f33c12fe01 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1090966 biolink:treats MONDO:0024298 PMID:41385096 "[{""id"":""uuid:3eed1b06-00ae-4f3f-8edc-4694140f4d3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c8a44a1a-9e70-485b-af53-d8344b33c86e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Supplementation of the diet with ten essential vitamins. Supplementation of the diet with fluoride for caries prophylaxis. Multivitamin with 1.0 mg Fluoride Chewable Tablets provide 1.0 mg fluoride in tablet form for children 6-16 years of age in areas where the water fluoride level is less than 0.3 ppm. Multivitamin with 1.0 mg Fluoride Chewable Tablets supply significant amounts of Vitamins A, C, D, E, thiamine, riboflavin, niacin, vitamin B 6, vitamin B 12, and folate to supplement the diet, and to help assure that nutritional deficiencies of these vitamins will not develop. Thus, in a single easy-to-use preparation, children obtain ten essential vitamins and the important mineral, fluoride. The American Academy of Pediatrics recommends that children up to age 16, in areas where drinking water contains less than optimal levels of fluoride, receive daily fluoride supplements. Children using Multivitamin with 1.0 mg Fluoride Chewable Tablets regularly should receive semiannual dental examinations. The regular brushing of teeth and attention to good oral hygiene practices are also essential. Multivitamin with Fluoride Chewable Tablets is a prescription product for the clinical dietary management of the metabolic processes of caries prophylaxis and provides supplementation of the diet with ten essential vitamins. uuid:889e8923-70f9-4e17-a437-61a69a36e3f7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1090966 biolink:treats MONDO:0042976 PMID:41385096 "[{""id"":""uuid:2b2b9589-d733-4212-b391-7a6eaf5ba193"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:df95edb9-0ecb-4285-8c57-d3a292358acd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Supplementation of the diet with ten essential vitamins. Supplementation of the diet with fluoride for caries prophylaxis. Multivitamin with 1.0 mg Fluoride Chewable Tablets provide 1.0 mg fluoride in tablet form for children 6-16 years of age in areas where the water fluoride level is less than 0.3 ppm. Multivitamin with 1.0 mg Fluoride Chewable Tablets supply significant amounts of Vitamins A, C, D, E, thiamine, riboflavin, niacin, vitamin B 6, vitamin B 12, and folate to supplement the diet, and to help assure that nutritional deficiencies of these vitamins will not develop. Thus, in a single easy-to-use preparation, children obtain ten essential vitamins and the important mineral, fluoride. The American Academy of Pediatrics recommends that children up to age 16, in areas where drinking water contains less than optimal levels of fluoride, receive daily fluoride supplements. Children using Multivitamin with 1.0 mg Fluoride Chewable Tablets regularly should receive semiannual dental examinations. The regular brushing of teeth and attention to good oral hygiene practices are also essential. Multivitamin with Fluoride Chewable Tablets is a prescription product for the clinical dietary management of the metabolic processes of caries prophylaxis and provides supplementation of the diet with ten essential vitamins. uuid:07f5d141-94a7-4713-8479-06c275e82644 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1090966 biolink:treats MONDO:0004573 PMID:41385096 "[{""id"":""uuid:0cf8fa81-0884-4fd1-a7fc-668794ec7d40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:63a74fa4-abd6-46ec-b3b9-c17fe4166757"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Supplementation of the diet with ten essential vitamins. Supplementation of the diet with fluoride for caries prophylaxis. Multivitamin with 1.0 mg Fluoride Chewable Tablets provide 1.0 mg fluoride in tablet form for children 6-16 years of age in areas where the water fluoride level is less than 0.3 ppm. Multivitamin with 1.0 mg Fluoride Chewable Tablets supply significant amounts of Vitamins A, C, D, E, thiamine, riboflavin, niacin, vitamin B 6, vitamin B 12, and folate to supplement the diet, and to help assure that nutritional deficiencies of these vitamins will not develop. Thus, in a single easy-to-use preparation, children obtain ten essential vitamins and the important mineral, fluoride. The American Academy of Pediatrics recommends that children up to age 16, in areas where drinking water contains less than optimal levels of fluoride, receive daily fluoride supplements. Children using Multivitamin with 1.0 mg Fluoride Chewable Tablets regularly should receive semiannual dental examinations. The regular brushing of teeth and attention to good oral hygiene practices are also essential. Multivitamin with Fluoride Chewable Tablets is a prescription product for the clinical dietary management of the metabolic processes of caries prophylaxis and provides supplementation of the diet with ten essential vitamins. uuid:988c8104-42cc-425a-89f9-a6f560dded50 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1090966 biolink:treats MONDO:0019975 PMID:41385096 "[{""id"":""uuid:ec4be940-e436-487f-87af-76d25bb9b275"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6dd596ad-48fe-4c37-8a5d-ec3f50627ac2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Supplementation of the diet with ten essential vitamins. Supplementation of the diet with fluoride for caries prophylaxis. Multivitamin with 1.0 mg Fluoride Chewable Tablets provide 1.0 mg fluoride in tablet form for children 6-16 years of age in areas where the water fluoride level is less than 0.3 ppm. Multivitamin with 1.0 mg Fluoride Chewable Tablets supply significant amounts of Vitamins A, C, D, E, thiamine, riboflavin, niacin, vitamin B 6, vitamin B 12, and folate to supplement the diet, and to help assure that nutritional deficiencies of these vitamins will not develop. Thus, in a single easy-to-use preparation, children obtain ten essential vitamins and the important mineral, fluoride. The American Academy of Pediatrics recommends that children up to age 16, in areas where drinking water contains less than optimal levels of fluoride, receive daily fluoride supplements. Children using Multivitamin with 1.0 mg Fluoride Chewable Tablets regularly should receive semiannual dental examinations. The regular brushing of teeth and attention to good oral hygiene practices are also essential. Multivitamin with Fluoride Chewable Tablets is a prescription product for the clinical dietary management of the metabolic processes of caries prophylaxis and provides supplementation of the diet with ten essential vitamins. uuid:23ad1823-0868-41c3-8f13-e49cff055e11 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1090966 biolink:treats MONDO:0004574 PMID:41385096 "[{""id"":""uuid:219b6e44-da03-4327-ab86-9162c5a81e6a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2898ccc3-29ce-4967-b68f-3f02406e99c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Supplementation of the diet with ten essential vitamins. Supplementation of the diet with fluoride for caries prophylaxis. Multivitamin with 1.0 mg Fluoride Chewable Tablets provide 1.0 mg fluoride in tablet form for children 6-16 years of age in areas where the water fluoride level is less than 0.3 ppm. Multivitamin with 1.0 mg Fluoride Chewable Tablets supply significant amounts of Vitamins A, C, D, E, thiamine, riboflavin, niacin, vitamin B 6, vitamin B 12, and folate to supplement the diet, and to help assure that nutritional deficiencies of these vitamins will not develop. Thus, in a single easy-to-use preparation, children obtain ten essential vitamins and the important mineral, fluoride. The American Academy of Pediatrics recommends that children up to age 16, in areas where drinking water contains less than optimal levels of fluoride, receive daily fluoride supplements. Children using Multivitamin with 1.0 mg Fluoride Chewable Tablets regularly should receive semiannual dental examinations. The regular brushing of teeth and attention to good oral hygiene practices are also essential. Multivitamin with Fluoride Chewable Tablets is a prescription product for the clinical dietary management of the metabolic processes of caries prophylaxis and provides supplementation of the diet with ten essential vitamins. uuid:273b28b9-6b24-4284-a588-ec10604ec143 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1090966 biolink:treats MONDO:0020696 PMID:41385096 "[{""id"":""uuid:b2164a4f-edb8-4d98-9c51-131dd2df4321"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5f48e4f2-d3a5-49a1-ad88-b3b7dfb511bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Supplementation of the diet with ten essential vitamins. Supplementation of the diet with fluoride for caries prophylaxis. Multivitamin with 1.0 mg Fluoride Chewable Tablets provide 1.0 mg fluoride in tablet form for children 6-16 years of age in areas where the water fluoride level is less than 0.3 ppm. Multivitamin with 1.0 mg Fluoride Chewable Tablets supply significant amounts of Vitamins A, C, D, E, thiamine, riboflavin, niacin, vitamin B 6, vitamin B 12, and folate to supplement the diet, and to help assure that nutritional deficiencies of these vitamins will not develop. Thus, in a single easy-to-use preparation, children obtain ten essential vitamins and the important mineral, fluoride. The American Academy of Pediatrics recommends that children up to age 16, in areas where drinking water contains less than optimal levels of fluoride, receive daily fluoride supplements. Children using Multivitamin with 1.0 mg Fluoride Chewable Tablets regularly should receive semiannual dental examinations. The regular brushing of teeth and attention to good oral hygiene practices are also essential. Multivitamin with Fluoride Chewable Tablets is a prescription product for the clinical dietary management of the metabolic processes of caries prophylaxis and provides supplementation of the diet with ten essential vitamins. uuid:da9c5d17-08a3-472b-9542-0504ed563a62 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1090966 biolink:treats MONDO:0001860 PMID:41385096 "[{""id"":""uuid:e7813303-1bab-4549-9563-89a977d5f938"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eb7be9b7-eff2-4265-9841-f4f985601b48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Supplementation of the diet with ten essential vitamins. Supplementation of the diet with fluoride for caries prophylaxis. Multivitamin with 1.0 mg Fluoride Chewable Tablets provide 1.0 mg fluoride in tablet form for children 6-16 years of age in areas where the water fluoride level is less than 0.3 ppm. Multivitamin with 1.0 mg Fluoride Chewable Tablets supply significant amounts of Vitamins A, C, D, E, thiamine, riboflavin, niacin, vitamin B 6, vitamin B 12, and folate to supplement the diet, and to help assure that nutritional deficiencies of these vitamins will not develop. Thus, in a single easy-to-use preparation, children obtain ten essential vitamins and the important mineral, fluoride. The American Academy of Pediatrics recommends that children up to age 16, in areas where drinking water contains less than optimal levels of fluoride, receive daily fluoride supplements. Children using Multivitamin with 1.0 mg Fluoride Chewable Tablets regularly should receive semiannual dental examinations. The regular brushing of teeth and attention to good oral hygiene practices are also essential. Multivitamin with Fluoride Chewable Tablets is a prescription product for the clinical dietary management of the metabolic processes of caries prophylaxis and provides supplementation of the diet with ten essential vitamins. uuid:99db2b71-cbe3-4f5a-9194-e7ad2168f617 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5801 biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:44cd596a-2e39-41fd-8054-f02b41edf87e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4c975395-8e02-4a18-9973-9523b9e51b62"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Malaria Hydroxychloroquine sulfate tablets are indicated for the treatment of uncomplicated malaria due to P. falciparum, P. malariae, P. ovale, and P. vivax. Hydroxychloroquine sulfate tablets are indicated for the prophylaxis of malaria in geographic areas where chloroquine resistance is not reported. Limitations of Use in Malaria • Hydroxychloroquine sulfate tablets are not recommended for the treatment of complicated malaria. • Hydroxychloroquine sulfate tablets are not effective against chloroquine or hydroxychloroquineresistant strains of Plasmodium species (see CLINICAL PHARMACOLOGY – Microbiology). Hydroxychloroquine sulfate tablets are not recommended for the treatment of malaria acquired in geographic areas where chloroquine resistance occurs or when the Plasmodium species has not been identified. • Hydroxychloroquine sulfate tablets are not recommended for malaria prophylaxis in geographic areas where chloroquine resistance occurs. • Hydroxychloroquine sulfate tablets do not prevent relapses of P. vivax or P. ovale because it is not active against the hypnozoite forms of these parasites. For radical cure of P. vivax and P. ovale infections, concomitant therapy with an 8-aminoquinoline compound is necessary (see CLINICAL PHARMACOLOGY – Microbiology). Prior to prescribing hydroxychloroquine sulfate tablets for the treatment or prophylaxis of malaria, consult the Centers for Disease Control and Prevention (CDC) Malaria website (http://www.cdc.gov/malaria). Lupus Erythematosus Hydroxychloroquine sulfate tablets are indicated for the treatment of chronic discoid lupus erythematosus and systemic lupus erythematosus in adults. Rheumatoid Arthritis Hydroxychloroquine sulfate tablets are indicated for the treatment of acute and chronic rheumatoid arthritis in adults. CONTRAINDICATIONS Use of hydroxychloroquine sulfate tablets are contraindicated in patients with known hypersensitivity to 4-aminoquinoline compounds. WARNINGS Resistant strains of malaria: hydroxychloroquine sulfate tablets are not effective against chloroquineresistant strains of P. falciparum (see CLINICAL PHARMACOLOGY – Microbiology). Ocular: Irreversible retinal damage has been observed in some patients who had received hydroxychloroquine sulfate. Significant risk factors for retinal damage include daily doses of hydroxychloroquine sulfate greater than 6.5 mg/kg (5 mg/kg base) of actual body weight, durations of use greater than five years, subnormal glomerular filtration, use of some concomitant drug products such as tamoxifen citrate and concurrent macular disease. A baseline ocular examination is recommended within the first year of starting hydroxychloroquine sulfate tablets. The baseline exam should include: best corrected distance visual acuity (BCVA), an automated threshold visual field (VF) of the central 10 degrees (with retesting if an abnormality is noted), and spectral domain ocular coherence tomography (SD‑OCT). For individuals with significant risk factors (daily dose of hydroxychloroquine sulfate greater than 5.0 mg/kg base of actual body weight, subnormal glomerular filtration, use of tamoxifen citrate or concurrent macular disease) monitoring should include annual examinations which include BCVA, VF and SD-OCT. For individuals without significant risk factors, annual exams can usually be deferred until five years of treatment. In individuals of Asian descent, retinal toxicity may first be noticed outside the macula. In patients of Asian descent, it is recommended that visual field testing be performed in the central 24 degrees instead of the central 10 degrees. It is recommended that hydroxychloroquine be discontinued if ocular toxicity is suspected and the patient should be closely observed given that retinal changes (and visual disturbances) may progress even after cessation of therapy. Cardiac Effects, including Cardiomyopathy and QT prolongation: Postmarketing cases of life-threatening and fatal cardiomyopathy have been reported with use of hydroxychloroquine sulfate tablets as well as with use of chloroquine. Patients may present with atrioventricular block, pulmonary hypertension, sick sinus syndrome or with cardiac complications. ECG findings may include atrioventricular, right or left bundle branch block. Signs or symptoms of cardiac compromise have appeared during acute and chronic treatment. Clinical monitoring for signs and symptoms of cardiomyopathy is advised, including use of appropriate diagnostic tools such as ECG to monitor patients for cardiomyopathy during Hydroxychloroquine Sulfate Tablets therapy. Chronic toxicity should be considered when conduction disorders (bundle branch block/atrio-ventricular heart block) or biventricular hypertrophy are diagnosed. If cardiotoxicity is suspected, prompt discontinuation of hydroxychloroquine sulfate tablets may prevent lifethreatening complications. Hydroxychloroquine sulfate tablets prolong the QT interval. Ventricular arrhythmias and torsades de pointes have been reported in patients taking Hydroxychloroquine Sulfate Tablets (see OVERDOSAGE). Therefore, hydroxychloroquine sulfate tablets should not be administered with other drugs that have the potential to prolong the QT interval (see DRUG INTERACTIONS). Worsening of psoriasis and porphyria: Use of hydroxychloroquine sulfate tablets in patients with psoriasis may precipitate a severe attack of psoriasis. When used in patients with porphyria the condition may be exacerbated. The preparation should not be used in these conditions unless in the judgment of the physician the benefit to the patient outweighs the possible hazard. Proximal Myopathy and Neuropathy: Skeletal muscle myopathy or neuropathy leading to progressive weakness and atrophy of proximal muscle groups, depressed tendon reflexes, and abnormal nerve conduction, have been reported. Muscle and nerve biopsies have been associated with curvilinear bodies and muscle fiber atrophy with vacuolar changes. Assess muscle strength and deep tendon reflexes periodically in patients on long-term therapy with hydroxychloroquine sulfate tablets. Neuropsychiatric events, including suicidality: Suicidal behavior has been rarely reported in patients treated with hydroxychloroquine sulfate tablets. Hypoglycemia: hydroxychloroquine sulfate tablets have been shown to cause severe hypoglycemia including loss of consciousness that could be life threatening in patients treated with or without antidiabetic medications (see DRUG INTERACTIONS and ADVERSE REACTIONS). Patients treated with hydroxychloroquine sulfate tablets should be warned about the risk of hypoglycemia and the associated clinical signs and symptoms. Patients presenting with clinical symptoms suggestive of hypoglycemia during treatment with hydroxychloroquine sulfate tablets should have their blood glucose checked and treatment reviewed as necessary. uuid:98fc3e50-7c6d-44c9-ba30-9d3efb4c8d0d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5801 biolink:treats MONDO:0019142 PMID:41385096 "[{""id"":""uuid:c5a2cdfc-b638-4ebd-ab2a-4e8646b2ee39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4622f420-d2b5-420a-baa4-4fc6fff2b895"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Malaria Hydroxychloroquine sulfate tablets are indicated for the treatment of uncomplicated malaria due to P. falciparum, P. malariae, P. ovale, and P. vivax. Hydroxychloroquine sulfate tablets are indicated for the prophylaxis of malaria in geographic areas where chloroquine resistance is not reported. Limitations of Use in Malaria • Hydroxychloroquine sulfate tablets are not recommended for the treatment of complicated malaria. • Hydroxychloroquine sulfate tablets are not effective against chloroquine or hydroxychloroquineresistant strains of Plasmodium species (see CLINICAL PHARMACOLOGY – Microbiology). Hydroxychloroquine sulfate tablets are not recommended for the treatment of malaria acquired in geographic areas where chloroquine resistance occurs or when the Plasmodium species has not been identified. • Hydroxychloroquine sulfate tablets are not recommended for malaria prophylaxis in geographic areas where chloroquine resistance occurs. • Hydroxychloroquine sulfate tablets do not prevent relapses of P. vivax or P. ovale because it is not active against the hypnozoite forms of these parasites. For radical cure of P. vivax and P. ovale infections, concomitant therapy with an 8-aminoquinoline compound is necessary (see CLINICAL PHARMACOLOGY – Microbiology). Prior to prescribing hydroxychloroquine sulfate tablets for the treatment or prophylaxis of malaria, consult the Centers for Disease Control and Prevention (CDC) Malaria website (http://www.cdc.gov/malaria). Lupus Erythematosus Hydroxychloroquine sulfate tablets are indicated for the treatment of chronic discoid lupus erythematosus and systemic lupus erythematosus in adults. Rheumatoid Arthritis Hydroxychloroquine sulfate tablets are indicated for the treatment of acute and chronic rheumatoid arthritis in adults. CONTRAINDICATIONS Use of hydroxychloroquine sulfate tablets are contraindicated in patients with known hypersensitivity to 4-aminoquinoline compounds. WARNINGS Resistant strains of malaria: hydroxychloroquine sulfate tablets are not effective against chloroquineresistant strains of P. falciparum (see CLINICAL PHARMACOLOGY – Microbiology). Ocular: Irreversible retinal damage has been observed in some patients who had received hydroxychloroquine sulfate. Significant risk factors for retinal damage include daily doses of hydroxychloroquine sulfate greater than 6.5 mg/kg (5 mg/kg base) of actual body weight, durations of use greater than five years, subnormal glomerular filtration, use of some concomitant drug products such as tamoxifen citrate and concurrent macular disease. A baseline ocular examination is recommended within the first year of starting hydroxychloroquine sulfate tablets. The baseline exam should include: best corrected distance visual acuity (BCVA), an automated threshold visual field (VF) of the central 10 degrees (with retesting if an abnormality is noted), and spectral domain ocular coherence tomography (SD‑OCT). For individuals with significant risk factors (daily dose of hydroxychloroquine sulfate greater than 5.0 mg/kg base of actual body weight, subnormal glomerular filtration, use of tamoxifen citrate or concurrent macular disease) monitoring should include annual examinations which include BCVA, VF and SD-OCT. For individuals without significant risk factors, annual exams can usually be deferred until five years of treatment. In individuals of Asian descent, retinal toxicity may first be noticed outside the macula. In patients of Asian descent, it is recommended that visual field testing be performed in the central 24 degrees instead of the central 10 degrees. It is recommended that hydroxychloroquine be discontinued if ocular toxicity is suspected and the patient should be closely observed given that retinal changes (and visual disturbances) may progress even after cessation of therapy. Cardiac Effects, including Cardiomyopathy and QT prolongation: Postmarketing cases of life-threatening and fatal cardiomyopathy have been reported with use of hydroxychloroquine sulfate tablets as well as with use of chloroquine. Patients may present with atrioventricular block, pulmonary hypertension, sick sinus syndrome or with cardiac complications. ECG findings may include atrioventricular, right or left bundle branch block. Signs or symptoms of cardiac compromise have appeared during acute and chronic treatment. Clinical monitoring for signs and symptoms of cardiomyopathy is advised, including use of appropriate diagnostic tools such as ECG to monitor patients for cardiomyopathy during Hydroxychloroquine Sulfate Tablets therapy. Chronic toxicity should be considered when conduction disorders (bundle branch block/atrio-ventricular heart block) or biventricular hypertrophy are diagnosed. If cardiotoxicity is suspected, prompt discontinuation of hydroxychloroquine sulfate tablets may prevent lifethreatening complications. Hydroxychloroquine sulfate tablets prolong the QT interval. Ventricular arrhythmias and torsades de pointes have been reported in patients taking Hydroxychloroquine Sulfate Tablets (see OVERDOSAGE). Therefore, hydroxychloroquine sulfate tablets should not be administered with other drugs that have the potential to prolong the QT interval (see DRUG INTERACTIONS). Worsening of psoriasis and porphyria: Use of hydroxychloroquine sulfate tablets in patients with psoriasis may precipitate a severe attack of psoriasis. When used in patients with porphyria the condition may be exacerbated. The preparation should not be used in these conditions unless in the judgment of the physician the benefit to the patient outweighs the possible hazard. Proximal Myopathy and Neuropathy: Skeletal muscle myopathy or neuropathy leading to progressive weakness and atrophy of proximal muscle groups, depressed tendon reflexes, and abnormal nerve conduction, have been reported. Muscle and nerve biopsies have been associated with curvilinear bodies and muscle fiber atrophy with vacuolar changes. Assess muscle strength and deep tendon reflexes periodically in patients on long-term therapy with hydroxychloroquine sulfate tablets. Neuropsychiatric events, including suicidality: Suicidal behavior has been rarely reported in patients treated with hydroxychloroquine sulfate tablets. Hypoglycemia: hydroxychloroquine sulfate tablets have been shown to cause severe hypoglycemia including loss of consciousness that could be life threatening in patients treated with or without antidiabetic medications (see DRUG INTERACTIONS and ADVERSE REACTIONS). Patients treated with hydroxychloroquine sulfate tablets should be warned about the risk of hypoglycemia and the associated clinical signs and symptoms. Patients presenting with clinical symptoms suggestive of hypoglycemia during treatment with hydroxychloroquine sulfate tablets should have their blood glucose checked and treatment reviewed as necessary. uuid:13a6719a-6c95-4deb-a538-74c6ceccc81b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4786 biolink:treats HP:0005162 PMID:41385096 "[{""id"":""uuid:6421f44d-26fd-497e-b2b5-db7c802c8885"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9f4b6d4a-909d-44a0-afe9-00f229849b3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Enalapril Maleate Tablets are indicated for the treatment of hypertension. Enalapril Maleate Tablets are effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. The blood pressure lowering effects of Enalapril Maleate Tablets and thiazides are approximately additive. Heart Failure Enalapril Maleate Tablets are indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. In these patients Enalapril Maleate Tablets improve symptoms, increases survival, and decreases the frequency of hospitalization (see CLINICAL PHARMACOLOGY, Heart Failure, Mortality Trials for details and limitations of survival trials). Asymptomatic Left Ventricular Dysfunction In clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), Enalapril Maleate Tablets decrease the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure (see CLINICAL PHARMACOLOGY , Heart Failure , Mortality Trials for details and limitations of survival trials). In using Enalapril Maleate Tablets consideration should be given to the fact that another angiotensin- converting enzyme inhibitor, captopril, has caused agranulocytosis, particularly in patients with renal impairment or collagen vascular disease, and that available data are insufficient to show that Enalapril Maleate Tablets do not have a similar risk (see WARNINGS , Neutropenia/Agranulocytosis ). In considering use of Enalapril Maleate Tablets, it should be noted that in controlled clinical trials ACE inhibitors have an effect on blood pressure that is less in black patients than in non-blacks. In addition, it should be noted that black patients receiving ACE inhibitors have been reported to have a higher incidence of angioedema compared to non-blacks (see WARNINGS , Head and Neck Angioedema ). uuid:307d5842-c2a7-4814-995a-8aa1de492043 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2118728 biolink:treats NCIT:C27003 PMID:41385096 "[{""id"":""uuid:248c2ab7-cbb7-43d9-acf6-2853ded24927"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:70e2b1f5-56f3-4fac-8603-df7c37ca5040"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] APADAZ is indicated for the short-term (no more than 14 days) management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [ see Warnings and Precautions (5.1) ], reserve APADAZ for use in patients for whom alternative treatment options [e.g., non-opioid analgesics]: Have not been tolerated, or are not expected to be tolerated, Have not provided adequate analgesia, or are not expected to provide adequate analgesia. uuid:cd7b8041-8219-4032-a73e-3c669fa509ca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42355 biolink:treats MONDO:0006669 PMID:41385096 "[{""id"":""uuid:23cdd5b7-267a-466e-8d3d-e5b082ddc704"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:065f7954-d87c-4820-b2fe-a5a7cd3a2c98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Erythromycin lactobionate for injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below when oral administration is not possible or when the severity of the infection requires immediate high serum levels of erythromycin. Intravenous therapy should be replaced by oral administration at the appropriate time. Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes (Group A beta-hemolytic streptococci); Streptococcus pneumoniae (Diplococcus pneumoniae); Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower respiratory tract infections of mild to moderate severity caused by Streptococcus pyogenes (Group A beta-hemolytic streptococci); Streptococcus pneumoniae (Diplococcus pneumoniae). Respiratory tract infections due to Mycoplasma pneumoniae. Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes and Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: As an adjunct to antitoxin infections due to Corynebacterium diphtheriae to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum . Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae : Erythromycin lactobionate for injection followed by erythromycin stearate or erythromycin base orally, as an alternative drug in treatment of acute pelvic inflammatory disease caused by N. gonorrhoeae in female patients with a history of sensitivity to penicillin. Before treatment of gonorrhea, patients who are suspected of also having syphilis should have a microscopic examination for T. pallidum (by immunofluorescence or darkfield) before receiving erythromycin and monthly serologic tests for a minimum of 4 months thereafter. Legionnaires' Disease caused by Legionella pneumophila. Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Prevention of Initial Attacks of Rheumatic Fever Penicillin is considered by the American Heart Association to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of Group A beta-hemolytic streptococcal infections of the upper respiratory tract e.g., tonsillitis, or pharyngitis). 1 Erythromycin is indicated for the treatment of penicillin-allergic patients. The therapeutic dose should be administered for ten days. Prevention of Recurrent Attacks of Rheumatic Fever Penicillin or sulfonamides are considered by the American Heart Association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. In patients who are allergic to penicillin and sulfonamides, oral erythromycin is recommended by the American Heart Association in the long-term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever). 1 Prevention of Bacterial Endocarditis Although no controlled clinical efficacy trials have been conducted, oral erythromycin has been recommended by the American Heart Association for prevention of bacterial endocarditis in penicillin- allergic patients with prosthetic cardiac valves, most congenital cardiac malformations, surgically constructed systemic pulmonary shunts, rheumatic or other acquired valvular dysfunction, idiopathic hypertrophic subaortic stenosis (IHSS), previous history of bacterial endocarditis and mitral valve prolapse with insufficiency when they undergo dental procedures and surgical procedures of the upper respiratory tract. 2 To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin and other antibacterial drugs, erythromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:7e1d698d-34e4-4e1f-9d93-5c240a283023 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44185 biolink:treats MONDO:0020550 PMID:41385096 "[{""id"":""uuid:93c458f2-0468-4caf-a949-85033bc8e800"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e83fb6af-93d3-4397-b81f-82b2e58b3241"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methotrexate is indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole. In acute lymphocytic leukemia, methotrexate is indicated for use in maintenance therapy in combination with other chemotherapeutic agents. Methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides (cutaneous T cell lymphoma), and lung cancer, particularly squamous cell and small cell types. Methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-Hodgkin’s lymphomas. Methotrexate in high doses followed by leucovorin rescue in combination with other chemotherapeutic agents is effective in prolonging relapse-free survival in patients with non-metastatic osteosarcoma who have undergone surgical resection or amputation for the primary tumor. uuid:63e55138-74cf-4cf8-96ee-17149751ce3c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44185 biolink:treats MONDO:0020549 PMID:41385096 "[{""id"":""uuid:95261f48-6972-4723-8d93-02ef70aff32c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:96a8852e-cda6-4b87-a732-e63ea689ebdb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methotrexate is indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole. In acute lymphocytic leukemia, methotrexate is indicated for use in maintenance therapy in combination with other chemotherapeutic agents. Methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides (cutaneous T cell lymphoma), and lung cancer, particularly squamous cell and small cell types. Methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-Hodgkin’s lymphomas. Methotrexate in high doses followed by leucovorin rescue in combination with other chemotherapeutic agents is effective in prolonging relapse-free survival in patients with non-metastatic osteosarcoma who have undergone surgical resection or amputation for the primary tumor. uuid:ce97afaa-9204-46ed-813b-e34349c55d1a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44185 biolink:treats MONDO:0006248 PMID:41385096 "[{""id"":""uuid:132dd815-4577-4188-afdb-cab3ebb409d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3cba0ee2-0607-470f-895b-29fca968c25a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methotrexate is indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole. In acute lymphocytic leukemia, methotrexate is indicated for use in maintenance therapy in combination with other chemotherapeutic agents. Methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides (cutaneous T cell lymphoma), and lung cancer, particularly squamous cell and small cell types. Methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-Hodgkin’s lymphomas. Methotrexate in high doses followed by leucovorin rescue in combination with other chemotherapeutic agents is effective in prolonging relapse-free survival in patients with non-metastatic osteosarcoma who have undergone surgical resection or amputation for the primary tumor. uuid:eaab0d84-0fc7-473f-bb13-465c5f3ea0d2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44185 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:70da29b5-fadf-47e5-8f59-f7369c48989c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0e40656a-af3a-4cb7-a583-c1d3b2b1942e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methotrexate is indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole. In acute lymphocytic leukemia, methotrexate is indicated for use in maintenance therapy in combination with other chemotherapeutic agents. Methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides (cutaneous T cell lymphoma), and lung cancer, particularly squamous cell and small cell types. Methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-Hodgkin’s lymphomas. Methotrexate in high doses followed by leucovorin rescue in combination with other chemotherapeutic agents is effective in prolonging relapse-free survival in patients with non-metastatic osteosarcoma who have undergone surgical resection or amputation for the primary tumor. uuid:2a3c60d8-409f-49d5-9f6d-86646534634e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44185 biolink:treats MONDO:0010150 PMID:41385096 "[{""id"":""uuid:bd5b6891-27e9-4ff7-afc8-78d228745d8e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d18be862-8417-4a6e-b592-cb638571b52d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methotrexate is indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole. In acute lymphocytic leukemia, methotrexate is indicated for use in maintenance therapy in combination with other chemotherapeutic agents. Methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides (cutaneous T cell lymphoma), and lung cancer, particularly squamous cell and small cell types. Methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-Hodgkin’s lymphomas. Methotrexate in high doses followed by leucovorin rescue in combination with other chemotherapeutic agents is effective in prolonging relapse-free survival in patients with non-metastatic osteosarcoma who have undergone surgical resection or amputation for the primary tumor. uuid:f0041956-c4e9-4f87-9ea9-b8d3d6b3442b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44185 biolink:treats MONDO:0008903 PMID:41385096 "[{""id"":""uuid:e229d316-49ea-4ac3-b224-f60d7c799f06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e04af5e0-8190-406b-9192-2d864c6566cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methotrexate is indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole. In acute lymphocytic leukemia, methotrexate is indicated for use in maintenance therapy in combination with other chemotherapeutic agents. Methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides (cutaneous T cell lymphoma), and lung cancer, particularly squamous cell and small cell types. Methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-Hodgkin’s lymphomas. Methotrexate in high doses followed by leucovorin rescue in combination with other chemotherapeutic agents is effective in prolonging relapse-free survival in patients with non-metastatic osteosarcoma who have undergone surgical resection or amputation for the primary tumor. uuid:639023e7-cc83-43e6-8e67-144e1b61437e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44185 biolink:treats MONDO:0005097 PMID:41385096 "[{""id"":""uuid:488fca78-125f-4f51-9e9c-3d776a454daf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:06ed9620-ec16-421d-bb0f-09e47eabb28e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methotrexate is indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole. In acute lymphocytic leukemia, methotrexate is indicated for use in maintenance therapy in combination with other chemotherapeutic agents. Methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides (cutaneous T cell lymphoma), and lung cancer, particularly squamous cell and small cell types. Methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-Hodgkin’s lymphomas. Methotrexate in high doses followed by leucovorin rescue in combination with other chemotherapeutic agents is effective in prolonging relapse-free survival in patients with non-metastatic osteosarcoma who have undergone surgical resection or amputation for the primary tumor. uuid:15fc2439-23c3-4f6a-9a71-aed03fcfc245 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44185 biolink:treats MONDO:0008433 PMID:41385096 "[{""id"":""uuid:d4e9505b-6037-431e-a57d-f631f0e8ce1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:efc8cfcf-6f46-422c-9c34-84feb51550a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methotrexate is indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole. In acute lymphocytic leukemia, methotrexate is indicated for use in maintenance therapy in combination with other chemotherapeutic agents. Methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides (cutaneous T cell lymphoma), and lung cancer, particularly squamous cell and small cell types. Methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-Hodgkin’s lymphomas. Methotrexate in high doses followed by leucovorin rescue in combination with other chemotherapeutic agents is effective in prolonging relapse-free survival in patients with non-metastatic osteosarcoma who have undergone surgical resection or amputation for the primary tumor. uuid:904b4388-f7dc-4ebc-b435-42060cd20c64 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44185 biolink:treats MONDO:0002629 PMID:41385096 "[{""id"":""uuid:e1d63193-3fd5-4390-a37b-d5dfb37e129c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:200ebe78-f0cc-4d7f-846f-f82515a021fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methotrexate is indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole. In acute lymphocytic leukemia, methotrexate is indicated for use in maintenance therapy in combination with other chemotherapeutic agents. Methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides (cutaneous T cell lymphoma), and lung cancer, particularly squamous cell and small cell types. Methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-Hodgkin’s lymphomas. Methotrexate in high doses followed by leucovorin rescue in combination with other chemotherapeutic agents is effective in prolonging relapse-free survival in patients with non-metastatic osteosarcoma who have undergone surgical resection or amputation for the primary tumor. uuid:b1e47d2d-f8ac-4d2f-a583-0a189c6a956e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:205919 biolink:treats UMLS:C0406326 PMID:41385096 "[{""id"":""uuid:19e27890-1c21-49e5-ab31-a8f571f01a36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a962475b-aa1a-418d-a55e-3e9e752d3ae9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clobetasol propionate shampoo, 0.05% is a corticosteroid indicated for the treatment of moderate to severe scalp psoriasis in subjects 18 years of age and older ( 1 ). Limitations of Use: Do not use on the face, axillae or groin. ( 1.2 ) Avoid any contact with the eyes and lips. ( 1.2 ) uuid:4ae2921e-1875-4dff-a715-ece28d9a438c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:XII270YC6M biolink:treats MONDO:0005344 PMID:41385096 "[{""id"":""uuid:cf7758ab-591a-4740-82ab-57290ec4b2b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e0b51039-dea8-43fb-9b79-9b6dd4c6f36c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a84f6719-ae99-4659-8683-980efb088477"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zutectra""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] HepaGam B [Hepatitis B immune globulin intravenous (Human)] is an intravenous immune globulin indicated for the following:|[EMA] Prevention of hepatitis B virus (HBV) re-infection in HBsAg and HBV-DNA negative adult patients at least one week after liver transplantation for hepatitis B induced liver failure. HBV-DNA negative status should be confirmed within the last 3 months prior to OLT. Patients should be HBsAg negative before treatment start., , The concomitant use of adequate virostatic agents should be considered as standard of hepatitis B re-infection prophylaxis., uuid:3c63df02-54a3-47d4-89f7-fdabdb3f50f6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135934 biolink:treats UMLS:C0847631 PMID:41385096 "[{""id"":""uuid:74c1221c-c70c-44fb-85bd-e52ba176eed2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e238ad12-799c-4ef5-a33f-f7813edf7859"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Selenium Sulfide 2.3% Shampoo is a liquid antiseborrheic, antifungal preparation useful for the treatment of seborrheic dermatitis of the scalp, dandruff and tinea versicolor. Urea hydrates and is useful for conditions such as dry scalp. uuid:61450102-0e23-43af-9204-6c40f5c4f0c8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3504 biolink:treats HP:0000371 PMID:41385096 "[{""id"":""uuid:cc7366dc-eb87-48e3-938c-797dad02dddc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e2d2e483-4e29-4b7a-ba03-b9014dac42f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute otitis media caused by Streptococcus pneumoniae (excluding penicillin-resistant strains), Streptococcus pyogenes, Haemophilus influenzae (including beta-lactamase-producing strains), or Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains). Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes . NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever are not available. Community-acquired pneumonia caused by S.pneumoniae or H.influenzae (including beta-lactamase-producing strains). Acute bacterial exacerbation of chronic bronchitis caused by S.pneumoniae, H.influenzae (non-beta-lactamase-producing strains only), or M.catarrhalis . Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of H.influenzae . Acute, uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains). Acute, uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains). NOTE: The efficacy of cefpodoxime in treating male patients with rectal infections caused by N.gonorrhoeae has not been established. Data do not support the use of cefpodoxime proxetil in the treatment of pharyngeal infections due to N.gonorrhoeae in men or women. Uncomplicated skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains) or Streptococcus pyogenes . Abscesses should be surgically drained as clinically indicated. NOTE: In clinical trials, successful treatment of uncomplicated skin and skin structure infections was dose-related. The effective therapeutic dose for skin infections was higher than those used in other recommended indications (see DOSAGE AND ADMINISTRATION ). Acute maxillary sinusitis caused by Haemophilus influenzae (including beta-lactamase-producing strains), Streptococcus pneumoniae, and Moraxella catarrhalis . Uncomplicated urinary tract infections (cystitis) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis , or Staphylococcus saprophyticus . NOTE: In considering the use of cefpodoxime proxetil in the treatment of cystitis, cefpodoxime proxetil’s lower bacterial eradication rates should be weighed against the increased eradication rates and different safety profiles of some other classes of approved agents (see CLINICAL STUDIES section). Appropriate specimens for bacteriological examination should be obtained in order to isolate and identify causative organisms and to determine their susceptibility to cefpodoxime. Therapy may be instituted while awaiting the results of these studies. Once these results become available, antimicrobial therapy should be adjusted accordingly. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefpodoxime proxetil tablets and other antibacterial drugs, Cefpodoxime proxetil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:ea22238c-fc6c-452e-963b-93340b851b02 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3504 biolink:treats MONDO:0002258 PMID:41385096 "[{""id"":""uuid:d9088974-f443-49c2-ad38-549d068f55af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7819370e-2f35-4035-a82e-7cbb9c7dce25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute otitis media caused by Streptococcus pneumoniae (excluding penicillin-resistant strains), Streptococcus pyogenes, Haemophilus influenzae (including beta-lactamase-producing strains), or Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains). Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes . NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever are not available. Community-acquired pneumonia caused by S.pneumoniae or H.influenzae (including beta-lactamase-producing strains). Acute bacterial exacerbation of chronic bronchitis caused by S.pneumoniae, H.influenzae (non-beta-lactamase-producing strains only), or M.catarrhalis . Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of H.influenzae . Acute, uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains). Acute, uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains). NOTE: The efficacy of cefpodoxime in treating male patients with rectal infections caused by N.gonorrhoeae has not been established. Data do not support the use of cefpodoxime proxetil in the treatment of pharyngeal infections due to N.gonorrhoeae in men or women. Uncomplicated skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains) or Streptococcus pyogenes . Abscesses should be surgically drained as clinically indicated. NOTE: In clinical trials, successful treatment of uncomplicated skin and skin structure infections was dose-related. The effective therapeutic dose for skin infections was higher than those used in other recommended indications (see DOSAGE AND ADMINISTRATION ). Acute maxillary sinusitis caused by Haemophilus influenzae (including beta-lactamase-producing strains), Streptococcus pneumoniae, and Moraxella catarrhalis . Uncomplicated urinary tract infections (cystitis) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis , or Staphylococcus saprophyticus . NOTE: In considering the use of cefpodoxime proxetil in the treatment of cystitis, cefpodoxime proxetil’s lower bacterial eradication rates should be weighed against the increased eradication rates and different safety profiles of some other classes of approved agents (see CLINICAL STUDIES section). Appropriate specimens for bacteriological examination should be obtained in order to isolate and identify causative organisms and to determine their susceptibility to cefpodoxime. Therapy may be instituted while awaiting the results of these studies. Once these results become available, antimicrobial therapy should be adjusted accordingly. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefpodoxime proxetil tablets and other antibacterial drugs, Cefpodoxime proxetil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:744c305c-1a4d-40ac-b900-2237a1b1802a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3504 biolink:treats MONDO:0001039 PMID:41385096 "[{""id"":""uuid:b6b99ac8-4f6b-447c-9ff8-00557dffef5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:603b1b49-310f-4cbe-8980-ccba31d0fef7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute otitis media caused by Streptococcus pneumoniae (excluding penicillin-resistant strains), Streptococcus pyogenes, Haemophilus influenzae (including beta-lactamase-producing strains), or Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains). Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes . NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever are not available. Community-acquired pneumonia caused by S.pneumoniae or H.influenzae (including beta-lactamase-producing strains). Acute bacterial exacerbation of chronic bronchitis caused by S.pneumoniae, H.influenzae (non-beta-lactamase-producing strains only), or M.catarrhalis . Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of H.influenzae . Acute, uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains). Acute, uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains). NOTE: The efficacy of cefpodoxime in treating male patients with rectal infections caused by N.gonorrhoeae has not been established. Data do not support the use of cefpodoxime proxetil in the treatment of pharyngeal infections due to N.gonorrhoeae in men or women. Uncomplicated skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains) or Streptococcus pyogenes . Abscesses should be surgically drained as clinically indicated. NOTE: In clinical trials, successful treatment of uncomplicated skin and skin structure infections was dose-related. The effective therapeutic dose for skin infections was higher than those used in other recommended indications (see DOSAGE AND ADMINISTRATION ). Acute maxillary sinusitis caused by Haemophilus influenzae (including beta-lactamase-producing strains), Streptococcus pneumoniae, and Moraxella catarrhalis . Uncomplicated urinary tract infections (cystitis) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis , or Staphylococcus saprophyticus . NOTE: In considering the use of cefpodoxime proxetil in the treatment of cystitis, cefpodoxime proxetil’s lower bacterial eradication rates should be weighed against the increased eradication rates and different safety profiles of some other classes of approved agents (see CLINICAL STUDIES section). Appropriate specimens for bacteriological examination should be obtained in order to isolate and identify causative organisms and to determine their susceptibility to cefpodoxime. Therapy may be instituted while awaiting the results of these studies. Once these results become available, antimicrobial therapy should be adjusted accordingly. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefpodoxime proxetil tablets and other antibacterial drugs, Cefpodoxime proxetil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:2c7a35d8-efe2-4617-bf14-018ea627012d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3504 biolink:treats MONDO:0017767 PMID:41385096 "[{""id"":""uuid:d8e728f2-cf72-4769-bf27-d76b5ba1afaa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4b9d590c-270c-42ab-afa8-da392d3bbdcc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute otitis media caused by Streptococcus pneumoniae (excluding penicillin-resistant strains), Streptococcus pyogenes, Haemophilus influenzae (including beta-lactamase-producing strains), or Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains). Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes . NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever are not available. Community-acquired pneumonia caused by S.pneumoniae or H.influenzae (including beta-lactamase-producing strains). Acute bacterial exacerbation of chronic bronchitis caused by S.pneumoniae, H.influenzae (non-beta-lactamase-producing strains only), or M.catarrhalis . Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of H.influenzae . Acute, uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains). Acute, uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains). NOTE: The efficacy of cefpodoxime in treating male patients with rectal infections caused by N.gonorrhoeae has not been established. Data do not support the use of cefpodoxime proxetil in the treatment of pharyngeal infections due to N.gonorrhoeae in men or women. Uncomplicated skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains) or Streptococcus pyogenes . Abscesses should be surgically drained as clinically indicated. NOTE: In clinical trials, successful treatment of uncomplicated skin and skin structure infections was dose-related. The effective therapeutic dose for skin infections was higher than those used in other recommended indications (see DOSAGE AND ADMINISTRATION ). Acute maxillary sinusitis caused by Haemophilus influenzae (including beta-lactamase-producing strains), Streptococcus pneumoniae, and Moraxella catarrhalis . Uncomplicated urinary tract infections (cystitis) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis , or Staphylococcus saprophyticus . NOTE: In considering the use of cefpodoxime proxetil in the treatment of cystitis, cefpodoxime proxetil’s lower bacterial eradication rates should be weighed against the increased eradication rates and different safety profiles of some other classes of approved agents (see CLINICAL STUDIES section). Appropriate specimens for bacteriological examination should be obtained in order to isolate and identify causative organisms and to determine their susceptibility to cefpodoxime. Therapy may be instituted while awaiting the results of these studies. Once these results become available, antimicrobial therapy should be adjusted accordingly. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefpodoxime proxetil tablets and other antibacterial drugs, Cefpodoxime proxetil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:cd6fc9e2-ce85-4b96-9244-e85ee92aaba7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3504 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:a2c7b52d-16b6-4f47-b1b7-ed995fa90f11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c2724e5e-e7b3-46a6-8983-8bac6ff3c947"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute otitis media caused by Streptococcus pneumoniae (excluding penicillin-resistant strains), Streptococcus pyogenes, Haemophilus influenzae (including beta-lactamase-producing strains), or Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains). Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes . NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever are not available. Community-acquired pneumonia caused by S.pneumoniae or H.influenzae (including beta-lactamase-producing strains). Acute bacterial exacerbation of chronic bronchitis caused by S.pneumoniae, H.influenzae (non-beta-lactamase-producing strains only), or M.catarrhalis . Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of H.influenzae . Acute, uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains). Acute, uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains). NOTE: The efficacy of cefpodoxime in treating male patients with rectal infections caused by N.gonorrhoeae has not been established. Data do not support the use of cefpodoxime proxetil in the treatment of pharyngeal infections due to N.gonorrhoeae in men or women. Uncomplicated skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains) or Streptococcus pyogenes . Abscesses should be surgically drained as clinically indicated. NOTE: In clinical trials, successful treatment of uncomplicated skin and skin structure infections was dose-related. The effective therapeutic dose for skin infections was higher than those used in other recommended indications (see DOSAGE AND ADMINISTRATION ). Acute maxillary sinusitis caused by Haemophilus influenzae (including beta-lactamase-producing strains), Streptococcus pneumoniae, and Moraxella catarrhalis . Uncomplicated urinary tract infections (cystitis) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis , or Staphylococcus saprophyticus . NOTE: In considering the use of cefpodoxime proxetil in the treatment of cystitis, cefpodoxime proxetil’s lower bacterial eradication rates should be weighed against the increased eradication rates and different safety profiles of some other classes of approved agents (see CLINICAL STUDIES section). Appropriate specimens for bacteriological examination should be obtained in order to isolate and identify causative organisms and to determine their susceptibility to cefpodoxime. Therapy may be instituted while awaiting the results of these studies. Once these results become available, antimicrobial therapy should be adjusted accordingly. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefpodoxime proxetil tablets and other antibacterial drugs, Cefpodoxime proxetil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:3af859cb-d202-4fa4-b23a-b6472ba6f8d3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3504 biolink:treats UMLS:C1735365 PMID:41385096 "[{""id"":""uuid:507a77b4-d774-430a-868d-0c3e33cc5cb2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e575e77b-971e-438a-949f-ba0712634270"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute otitis media caused by Streptococcus pneumoniae (excluding penicillin-resistant strains), Streptococcus pyogenes, Haemophilus influenzae (including beta-lactamase-producing strains), or Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains). Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes . NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever are not available. Community-acquired pneumonia caused by S.pneumoniae or H.influenzae (including beta-lactamase-producing strains). Acute bacterial exacerbation of chronic bronchitis caused by S.pneumoniae, H.influenzae (non-beta-lactamase-producing strains only), or M.catarrhalis . Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of H.influenzae . Acute, uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains). Acute, uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains). NOTE: The efficacy of cefpodoxime in treating male patients with rectal infections caused by N.gonorrhoeae has not been established. Data do not support the use of cefpodoxime proxetil in the treatment of pharyngeal infections due to N.gonorrhoeae in men or women. Uncomplicated skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains) or Streptococcus pyogenes . Abscesses should be surgically drained as clinically indicated. NOTE: In clinical trials, successful treatment of uncomplicated skin and skin structure infections was dose-related. The effective therapeutic dose for skin infections was higher than those used in other recommended indications (see DOSAGE AND ADMINISTRATION ). Acute maxillary sinusitis caused by Haemophilus influenzae (including beta-lactamase-producing strains), Streptococcus pneumoniae, and Moraxella catarrhalis . Uncomplicated urinary tract infections (cystitis) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis , or Staphylococcus saprophyticus . NOTE: In considering the use of cefpodoxime proxetil in the treatment of cystitis, cefpodoxime proxetil’s lower bacterial eradication rates should be weighed against the increased eradication rates and different safety profiles of some other classes of approved agents (see CLINICAL STUDIES section). Appropriate specimens for bacteriological examination should be obtained in order to isolate and identify causative organisms and to determine their susceptibility to cefpodoxime. Therapy may be instituted while awaiting the results of these studies. Once these results become available, antimicrobial therapy should be adjusted accordingly. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefpodoxime proxetil tablets and other antibacterial drugs, Cefpodoxime proxetil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:5bd502a4-f64d-4e54-9dee-9b635eb1fb51 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3504 biolink:treats MONDO:0004277 PMID:41385096 "[{""id"":""uuid:3ae82686-ebaa-460d-9636-d91e6938f42f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:318ca8cc-0993-424b-a718-f61b77774162"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute otitis media caused by Streptococcus pneumoniae (excluding penicillin-resistant strains), Streptococcus pyogenes, Haemophilus influenzae (including beta-lactamase-producing strains), or Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains). Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes . NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever are not available. Community-acquired pneumonia caused by S.pneumoniae or H.influenzae (including beta-lactamase-producing strains). Acute bacterial exacerbation of chronic bronchitis caused by S.pneumoniae, H.influenzae (non-beta-lactamase-producing strains only), or M.catarrhalis . Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of H.influenzae . Acute, uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains). Acute, uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains). NOTE: The efficacy of cefpodoxime in treating male patients with rectal infections caused by N.gonorrhoeae has not been established. Data do not support the use of cefpodoxime proxetil in the treatment of pharyngeal infections due to N.gonorrhoeae in men or women. Uncomplicated skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains) or Streptococcus pyogenes . Abscesses should be surgically drained as clinically indicated. NOTE: In clinical trials, successful treatment of uncomplicated skin and skin structure infections was dose-related. The effective therapeutic dose for skin infections was higher than those used in other recommended indications (see DOSAGE AND ADMINISTRATION ). Acute maxillary sinusitis caused by Haemophilus influenzae (including beta-lactamase-producing strains), Streptococcus pneumoniae, and Moraxella catarrhalis . Uncomplicated urinary tract infections (cystitis) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis , or Staphylococcus saprophyticus . NOTE: In considering the use of cefpodoxime proxetil in the treatment of cystitis, cefpodoxime proxetil’s lower bacterial eradication rates should be weighed against the increased eradication rates and different safety profiles of some other classes of approved agents (see CLINICAL STUDIES section). Appropriate specimens for bacteriological examination should be obtained in order to isolate and identify causative organisms and to determine their susceptibility to cefpodoxime. Therapy may be instituted while awaiting the results of these studies. Once these results become available, antimicrobial therapy should be adjusted accordingly. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefpodoxime proxetil tablets and other antibacterial drugs, Cefpodoxime proxetil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:e5475a71-0d16-46e7-9eee-fc97d90be81e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3504 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:8cd375a9-2e95-4c93-a44b-74221c0a5c42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1641b122-bb16-4df1-bbbc-04a0416d65c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute otitis media caused by Streptococcus pneumoniae (excluding penicillin-resistant strains), Streptococcus pyogenes, Haemophilus influenzae (including beta-lactamase-producing strains), or Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains). Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes . NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever are not available. Community-acquired pneumonia caused by S.pneumoniae or H.influenzae (including beta-lactamase-producing strains). Acute bacterial exacerbation of chronic bronchitis caused by S.pneumoniae, H.influenzae (non-beta-lactamase-producing strains only), or M.catarrhalis . Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of H.influenzae . Acute, uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains). Acute, uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains). NOTE: The efficacy of cefpodoxime in treating male patients with rectal infections caused by N.gonorrhoeae has not been established. Data do not support the use of cefpodoxime proxetil in the treatment of pharyngeal infections due to N.gonorrhoeae in men or women. Uncomplicated skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains) or Streptococcus pyogenes . Abscesses should be surgically drained as clinically indicated. NOTE: In clinical trials, successful treatment of uncomplicated skin and skin structure infections was dose-related. The effective therapeutic dose for skin infections was higher than those used in other recommended indications (see DOSAGE AND ADMINISTRATION ). Acute maxillary sinusitis caused by Haemophilus influenzae (including beta-lactamase-producing strains), Streptococcus pneumoniae, and Moraxella catarrhalis . Uncomplicated urinary tract infections (cystitis) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis , or Staphylococcus saprophyticus . NOTE: In considering the use of cefpodoxime proxetil in the treatment of cystitis, cefpodoxime proxetil’s lower bacterial eradication rates should be weighed against the increased eradication rates and different safety profiles of some other classes of approved agents (see CLINICAL STUDIES section). Appropriate specimens for bacteriological examination should be obtained in order to isolate and identify causative organisms and to determine their susceptibility to cefpodoxime. Therapy may be instituted while awaiting the results of these studies. Once these results become available, antimicrobial therapy should be adjusted accordingly. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefpodoxime proxetil tablets and other antibacterial drugs, Cefpodoxime proxetil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:13f7fb2a-c3a7-4367-9367-17b5abb00871 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3504 biolink:treats MONDO:0002186 PMID:41385096 "[{""id"":""uuid:655ba51c-951d-422c-898d-c944efe75e0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:37f73545-d2b9-425d-9bcb-877a1cd3407c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute otitis media caused by Streptococcus pneumoniae (excluding penicillin-resistant strains), Streptococcus pyogenes, Haemophilus influenzae (including beta-lactamase-producing strains), or Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains). Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes . NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever are not available. Community-acquired pneumonia caused by S.pneumoniae or H.influenzae (including beta-lactamase-producing strains). Acute bacterial exacerbation of chronic bronchitis caused by S.pneumoniae, H.influenzae (non-beta-lactamase-producing strains only), or M.catarrhalis . Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of H.influenzae . Acute, uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains). Acute, uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains). NOTE: The efficacy of cefpodoxime in treating male patients with rectal infections caused by N.gonorrhoeae has not been established. Data do not support the use of cefpodoxime proxetil in the treatment of pharyngeal infections due to N.gonorrhoeae in men or women. Uncomplicated skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains) or Streptococcus pyogenes . Abscesses should be surgically drained as clinically indicated. NOTE: In clinical trials, successful treatment of uncomplicated skin and skin structure infections was dose-related. The effective therapeutic dose for skin infections was higher than those used in other recommended indications (see DOSAGE AND ADMINISTRATION ). Acute maxillary sinusitis caused by Haemophilus influenzae (including beta-lactamase-producing strains), Streptococcus pneumoniae, and Moraxella catarrhalis . Uncomplicated urinary tract infections (cystitis) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis , or Staphylococcus saprophyticus . NOTE: In considering the use of cefpodoxime proxetil in the treatment of cystitis, cefpodoxime proxetil’s lower bacterial eradication rates should be weighed against the increased eradication rates and different safety profiles of some other classes of approved agents (see CLINICAL STUDIES section). Appropriate specimens for bacteriological examination should be obtained in order to isolate and identify causative organisms and to determine their susceptibility to cefpodoxime. Therapy may be instituted while awaiting the results of these studies. Once these results become available, antimicrobial therapy should be adjusted accordingly. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefpodoxime proxetil tablets and other antibacterial drugs, Cefpodoxime proxetil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:df0ea51f-7c67-4979-8bdf-bde5f160cefe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3504 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:34257141-32d0-4da9-b53b-dfad08c3fdcd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9402d966-2b0e-4a36-b0f3-a4b52cb4c3d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute otitis media caused by Streptococcus pneumoniae (excluding penicillin-resistant strains), Streptococcus pyogenes, Haemophilus influenzae (including beta-lactamase-producing strains), or Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains). Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes . NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever are not available. Community-acquired pneumonia caused by S.pneumoniae or H.influenzae (including beta-lactamase-producing strains). Acute bacterial exacerbation of chronic bronchitis caused by S.pneumoniae, H.influenzae (non-beta-lactamase-producing strains only), or M.catarrhalis . Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of H.influenzae . Acute, uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains). Acute, uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains). NOTE: The efficacy of cefpodoxime in treating male patients with rectal infections caused by N.gonorrhoeae has not been established. Data do not support the use of cefpodoxime proxetil in the treatment of pharyngeal infections due to N.gonorrhoeae in men or women. Uncomplicated skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains) or Streptococcus pyogenes . Abscesses should be surgically drained as clinically indicated. NOTE: In clinical trials, successful treatment of uncomplicated skin and skin structure infections was dose-related. The effective therapeutic dose for skin infections was higher than those used in other recommended indications (see DOSAGE AND ADMINISTRATION ). Acute maxillary sinusitis caused by Haemophilus influenzae (including beta-lactamase-producing strains), Streptococcus pneumoniae, and Moraxella catarrhalis . Uncomplicated urinary tract infections (cystitis) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis , or Staphylococcus saprophyticus . NOTE: In considering the use of cefpodoxime proxetil in the treatment of cystitis, cefpodoxime proxetil’s lower bacterial eradication rates should be weighed against the increased eradication rates and different safety profiles of some other classes of approved agents (see CLINICAL STUDIES section). Appropriate specimens for bacteriological examination should be obtained in order to isolate and identify causative organisms and to determine their susceptibility to cefpodoxime. Therapy may be instituted while awaiting the results of these studies. Once these results become available, antimicrobial therapy should be adjusted accordingly. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefpodoxime proxetil tablets and other antibacterial drugs, Cefpodoxime proxetil tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:c81c5310-e305-42f6-9233-4321945b7135 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7956 biolink:treats MONDO:0005770 PMID:41385096 "[{""id"":""uuid:c21b5045-10ee-4fc5-8860-88e39ffaa6a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:173cbc44-7cab-4604-968e-d7faef451a31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Famciclovir tablet, a prodrug of penciclovir, is a deoxynucleoside analog DNA polymerase inhibitor indicated for: Immunocompetent Adult Patients ( 1.1 ) • Herpes labialis (cold sores) o Treatment of recurrent episodes • Genital herpes o Treatment of recurrent episodes o Suppressive therapy of recurrent episodes • Herpes zoster (shingles) Human Immunodeficiency Virus (HIV)-Infected Adult Patients ( 1.2 ) • Treatment of recurrent episodes of orolabial or genital herpes Limitation of Use The efficacy and safety of famciclovir tablets have not been established for: • Patients with first episode of genital herpes • Patients with ophthalmic zoster • Immunocompromised patients other than for the treatment of recurrent episodes of orolabial or genital herpes in HIV-infected patients • Black and African American patients with recurrent genital herpes uuid:db0b1585-fcfc-41af-94ef-6da3a1057b12 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7956 biolink:treats MONDO:0005609 PMID:41385096 "[{""id"":""uuid:4288f897-0676-4481-a12f-5d7b860347cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4e524217-8fba-4d91-9134-56278e3977c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Famciclovir tablet, a prodrug of penciclovir, is a deoxynucleoside analog DNA polymerase inhibitor indicated for: Immunocompetent Adult Patients ( 1.1 ) • Herpes labialis (cold sores) o Treatment of recurrent episodes • Genital herpes o Treatment of recurrent episodes o Suppressive therapy of recurrent episodes • Herpes zoster (shingles) Human Immunodeficiency Virus (HIV)-Infected Adult Patients ( 1.2 ) • Treatment of recurrent episodes of orolabial or genital herpes Limitation of Use The efficacy and safety of famciclovir tablets have not been established for: • Patients with first episode of genital herpes • Patients with ophthalmic zoster • Immunocompromised patients other than for the treatment of recurrent episodes of orolabial or genital herpes in HIV-infected patients • Black and African American patients with recurrent genital herpes uuid:bd1e4da2-4673-42ff-b990-27859c0b29e4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44185 biolink:treats UMLS:C0948840 PMID:41385096 "[{""id"":""uuid:3bad90a9-08fb-4b87-b714-4716d70766de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9ba4cb5f-d5cf-423f-9b77-168ea45c21ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methotrexate is indicated in the treatment of gestational choriocarcinoma, chorioadenoma destruens and hydatidiform mole. In acute lymphocytic leukemia, methotrexate is indicated in the prophylaxis of meningeal leukemia and is used in maintenance therapy in combination with other chemotherapeutic agents. Methotrexate is also indicated in the treatment of meningeal leukemia. Methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides (cutaneous T cell lymphoma), and lung cancer, particularly squamous cell and small cell types. Methotrexate is also used in combination with other chemotherapeutic agents in the treatment of advanced stage non-Hodgkin’s lymphomas. Methotrexate in high doses followed by leucovorin rescue in combination with other chemotherapeutic agents is effective in prolonging relapse-free survival in patients with non-metastatic osteosarcoma who have undergone surgical resection or amputation for the primary tumor. uuid:6536785e-1dc7-496b-b631-8949b77b718e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15940 biolink:treats HP:0003124 PMID:41385096 "[{""id"":""uuid:2fc5a7bd-11fa-438c-b9c2-c3b385fc265b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:805c65ee-5837-45ce-bdfe-afdf511444f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] I. Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Nicotinic acid, alone or in combination with a bile-acid binding resin, is indicated as an adjunct to diet for the reduction of elevated total and LDL cholesterol levels in patients with primary hypercholesterolemia (Types IIa and IIb) † , when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate (see also the NCEP treatment guidelines 6 ). Prior to initiating therapy with nicotinic acid, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total cholesterol, HDL cholesterol, and triglycerides. II. Nicotinic acid is also indicated as adjunctive therapy for the treatment of adult patients with very high serum triglyceride levels (Types IV and V hyperlipidemia)† who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Such patients typically have serum triglyceride levels over 2,000 mg/dL and have elevations of VLDL cholesterol as well as fasting chylomicrons (Type V hyperlipidemia) † . Subjects who consistently have total serum or plasma triglycerides below 1,000 mg/dL are unlikely to develop pancreatitis. Therapy with nicotinic acid may be considered for those subjects with triglyceride elevations between 1,000 and 2,000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. Some Type IV patients with triglycerides under 1,000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of nicotinic acid therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of VLDL. Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia 7 . † Classification of Hyperlipoproteinemias Lipoproteins Lipid Elevations Type Elevated Major Minor C = cholesterol, TG = triglycerides LDL = low-density lipoprotein VLDL = very low-density lipoprotein IDL = intermediate-density lipoprotein I (rare) Chylomicrons TG ↑→ C IIa LDL C ..... IIb LDL, VLDL C TG III (rare) IDL C/TG ..... IV VLDL TG ↑→ C V (rare) Chylomicrons, VLD TG ↑→ C uuid:aa198366-82af-43dc-92f0-6526df8ef3c7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15940 biolink:treats UMLS:C0342879 PMID:41385096 "[{""id"":""uuid:ca22466f-8510-47ae-b9a8-7a7d4ea8cc5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a178aae4-5ea0-4612-a0d3-6e8bd44cb727"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] I. Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Nicotinic acid, alone or in combination with a bile-acid binding resin, is indicated as an adjunct to diet for the reduction of elevated total and LDL cholesterol levels in patients with primary hypercholesterolemia (Types IIa and IIb) † , when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate (see also the NCEP treatment guidelines 6 ). Prior to initiating therapy with nicotinic acid, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total cholesterol, HDL cholesterol, and triglycerides. II. Nicotinic acid is also indicated as adjunctive therapy for the treatment of adult patients with very high serum triglyceride levels (Types IV and V hyperlipidemia)† who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Such patients typically have serum triglyceride levels over 2,000 mg/dL and have elevations of VLDL cholesterol as well as fasting chylomicrons (Type V hyperlipidemia) † . Subjects who consistently have total serum or plasma triglycerides below 1,000 mg/dL are unlikely to develop pancreatitis. Therapy with nicotinic acid may be considered for those subjects with triglyceride elevations between 1,000 and 2,000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. Some Type IV patients with triglycerides under 1,000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of nicotinic acid therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of VLDL. Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia 7 . † Classification of Hyperlipoproteinemias Lipoproteins Lipid Elevations Type Elevated Major Minor C = cholesterol, TG = triglycerides LDL = low-density lipoprotein VLDL = very low-density lipoprotein IDL = intermediate-density lipoprotein I (rare) Chylomicrons TG ↑→ C IIa LDL C ..... IIb LDL, VLDL C TG III (rare) IDL C/TG ..... IV VLDL TG ↑→ C V (rare) Chylomicrons, VLD TG ↑→ C uuid:875f5695-5703-4b2e-91d6-db03949ee7cc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15940 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:d5b78804-f2fc-4d5f-a226-954b18cc2d11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6eaaa6a3-1485-434e-8ae3-e8a2484cb3c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] I. Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Nicotinic acid, alone or in combination with a bile-acid binding resin, is indicated as an adjunct to diet for the reduction of elevated total and LDL cholesterol levels in patients with primary hypercholesterolemia (Types IIa and IIb) † , when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate (see also the NCEP treatment guidelines 6 ). Prior to initiating therapy with nicotinic acid, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total cholesterol, HDL cholesterol, and triglycerides. II. Nicotinic acid is also indicated as adjunctive therapy for the treatment of adult patients with very high serum triglyceride levels (Types IV and V hyperlipidemia)† who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Such patients typically have serum triglyceride levels over 2,000 mg/dL and have elevations of VLDL cholesterol as well as fasting chylomicrons (Type V hyperlipidemia) † . Subjects who consistently have total serum or plasma triglycerides below 1,000 mg/dL are unlikely to develop pancreatitis. Therapy with nicotinic acid may be considered for those subjects with triglyceride elevations between 1,000 and 2,000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. Some Type IV patients with triglycerides under 1,000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of nicotinic acid therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of VLDL. Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia 7 . † Classification of Hyperlipoproteinemias Lipoproteins Lipid Elevations Type Elevated Major Minor C = cholesterol, TG = triglycerides LDL = low-density lipoprotein VLDL = very low-density lipoprotein IDL = intermediate-density lipoprotein I (rare) Chylomicrons TG ↑→ C IIa LDL C ..... IIb LDL, VLDL C TG III (rare) IDL C/TG ..... IV VLDL TG ↑→ C V (rare) Chylomicrons, VLD TG ↑→ C uuid:43c15989-f7f5-47fb-9e99-4443612e3e72 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15940 biolink:treats MONDO:0005420 PMID:41385096 "[{""id"":""uuid:698efd49-92d2-4af2-a689-44595e9f1134"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6f98194c-3a66-4b54-9572-3bf951be7966"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] I. Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Nicotinic acid, alone or in combination with a bile-acid binding resin, is indicated as an adjunct to diet for the reduction of elevated total and LDL cholesterol levels in patients with primary hypercholesterolemia (Types IIa and IIb) † , when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate (see also the NCEP treatment guidelines 6 ). Prior to initiating therapy with nicotinic acid, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total cholesterol, HDL cholesterol, and triglycerides. II. Nicotinic acid is also indicated as adjunctive therapy for the treatment of adult patients with very high serum triglyceride levels (Types IV and V hyperlipidemia)† who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Such patients typically have serum triglyceride levels over 2,000 mg/dL and have elevations of VLDL cholesterol as well as fasting chylomicrons (Type V hyperlipidemia) † . Subjects who consistently have total serum or plasma triglycerides below 1,000 mg/dL are unlikely to develop pancreatitis. Therapy with nicotinic acid may be considered for those subjects with triglyceride elevations between 1,000 and 2,000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. Some Type IV patients with triglycerides under 1,000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of nicotinic acid therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of VLDL. Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia 7 . † Classification of Hyperlipoproteinemias Lipoproteins Lipid Elevations Type Elevated Major Minor C = cholesterol, TG = triglycerides LDL = low-density lipoprotein VLDL = very low-density lipoprotein IDL = intermediate-density lipoprotein I (rare) Chylomicrons TG ↑→ C IIa LDL C ..... IIb LDL, VLDL C TG III (rare) IDL C/TG ..... IV VLDL TG ↑→ C V (rare) Chylomicrons, VLD TG ↑→ C uuid:f7761943-1066-4079-9d14-aab141872322 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15940 biolink:treats MONDO:0005377 PMID:41385096 "[{""id"":""uuid:9fcf7fc4-ab19-4552-9882-693ebca6e525"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:69f7e4e0-5d29-42ce-bc9c-2fa494bb11b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] I. Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Nicotinic acid, alone or in combination with a bile-acid binding resin, is indicated as an adjunct to diet for the reduction of elevated total and LDL cholesterol levels in patients with primary hypercholesterolemia (Types IIa and IIb) † , when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate (see also the NCEP treatment guidelines 6 ). Prior to initiating therapy with nicotinic acid, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total cholesterol, HDL cholesterol, and triglycerides. II. Nicotinic acid is also indicated as adjunctive therapy for the treatment of adult patients with very high serum triglyceride levels (Types IV and V hyperlipidemia)† who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Such patients typically have serum triglyceride levels over 2,000 mg/dL and have elevations of VLDL cholesterol as well as fasting chylomicrons (Type V hyperlipidemia) † . Subjects who consistently have total serum or plasma triglycerides below 1,000 mg/dL are unlikely to develop pancreatitis. Therapy with nicotinic acid may be considered for those subjects with triglyceride elevations between 1,000 and 2,000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. Some Type IV patients with triglycerides under 1,000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of nicotinic acid therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of VLDL. Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia 7 . † Classification of Hyperlipoproteinemias Lipoproteins Lipid Elevations Type Elevated Major Minor C = cholesterol, TG = triglycerides LDL = low-density lipoprotein VLDL = very low-density lipoprotein IDL = intermediate-density lipoprotein I (rare) Chylomicrons TG ↑→ C IIa LDL C ..... IIb LDL, VLDL C TG III (rare) IDL C/TG ..... IV VLDL TG ↑→ C V (rare) Chylomicrons, VLD TG ↑→ C uuid:49d10f9e-62e6-43f3-9b04-aec507b86793 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15940 biolink:treats UMLS:C0259744 PMID:41385096 "[{""id"":""uuid:9244249b-3e09-41a9-a9ce-91ccb7b3286b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3ba83ceb-8c1f-45ef-97ae-a4e598446af6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] I. Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Nicotinic acid, alone or in combination with a bile-acid binding resin, is indicated as an adjunct to diet for the reduction of elevated total and LDL cholesterol levels in patients with primary hypercholesterolemia (Types IIa and IIb) † , when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate (see also the NCEP treatment guidelines 6 ). Prior to initiating therapy with nicotinic acid, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total cholesterol, HDL cholesterol, and triglycerides. II. Nicotinic acid is also indicated as adjunctive therapy for the treatment of adult patients with very high serum triglyceride levels (Types IV and V hyperlipidemia)† who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Such patients typically have serum triglyceride levels over 2,000 mg/dL and have elevations of VLDL cholesterol as well as fasting chylomicrons (Type V hyperlipidemia) † . Subjects who consistently have total serum or plasma triglycerides below 1,000 mg/dL are unlikely to develop pancreatitis. Therapy with nicotinic acid may be considered for those subjects with triglyceride elevations between 1,000 and 2,000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. Some Type IV patients with triglycerides under 1,000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of nicotinic acid therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of VLDL. Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia 7 . † Classification of Hyperlipoproteinemias Lipoproteins Lipid Elevations Type Elevated Major Minor C = cholesterol, TG = triglycerides LDL = low-density lipoprotein VLDL = very low-density lipoprotein IDL = intermediate-density lipoprotein I (rare) Chylomicrons TG ↑→ C IIa LDL C ..... IIb LDL, VLDL C TG III (rare) IDL C/TG ..... IV VLDL TG ↑→ C V (rare) Chylomicrons, VLD TG ↑→ C uuid:bcf9e9ca-34a3-48bb-8641-61a2ad58b8dd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15940 biolink:treats MONDO:0006874 PMID:41385096 "[{""id"":""uuid:725dcec2-fe09-45f6-ba54-732740affd4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:00f7d04b-ee78-4e02-a312-5e650b371f61"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] I. Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Nicotinic acid, alone or in combination with a bile-acid binding resin, is indicated as an adjunct to diet for the reduction of elevated total and LDL cholesterol levels in patients with primary hypercholesterolemia (Types IIa and IIb) † , when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate (see also the NCEP treatment guidelines 6 ). Prior to initiating therapy with nicotinic acid, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total cholesterol, HDL cholesterol, and triglycerides. II. Nicotinic acid is also indicated as adjunctive therapy for the treatment of adult patients with very high serum triglyceride levels (Types IV and V hyperlipidemia)† who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Such patients typically have serum triglyceride levels over 2,000 mg/dL and have elevations of VLDL cholesterol as well as fasting chylomicrons (Type V hyperlipidemia) † . Subjects who consistently have total serum or plasma triglycerides below 1,000 mg/dL are unlikely to develop pancreatitis. Therapy with nicotinic acid may be considered for those subjects with triglyceride elevations between 1,000 and 2,000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. Some Type IV patients with triglycerides under 1,000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of nicotinic acid therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of VLDL. Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia 7 . † Classification of Hyperlipoproteinemias Lipoproteins Lipid Elevations Type Elevated Major Minor C = cholesterol, TG = triglycerides LDL = low-density lipoprotein VLDL = very low-density lipoprotein IDL = intermediate-density lipoprotein I (rare) Chylomicrons TG ↑→ C IIa LDL C ..... IIb LDL, VLDL C TG III (rare) IDL C/TG ..... IV VLDL TG ↑→ C V (rare) Chylomicrons, VLD TG ↑→ C uuid:90dcf559-4b6e-4e64-9d09-bb20a90b94c9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15940 biolink:treats MONDO:0009387 PMID:41385096 "[{""id"":""uuid:853bc658-3218-4415-98d3-4919b861f6e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:34a48031-5d8f-4e57-9938-fc3fadd4d4d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] I. Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Nicotinic acid, alone or in combination with a bile-acid binding resin, is indicated as an adjunct to diet for the reduction of elevated total and LDL cholesterol levels in patients with primary hypercholesterolemia (Types IIa and IIb) † , when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate (see also the NCEP treatment guidelines 6 ). Prior to initiating therapy with nicotinic acid, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total cholesterol, HDL cholesterol, and triglycerides. II. Nicotinic acid is also indicated as adjunctive therapy for the treatment of adult patients with very high serum triglyceride levels (Types IV and V hyperlipidemia)† who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Such patients typically have serum triglyceride levels over 2,000 mg/dL and have elevations of VLDL cholesterol as well as fasting chylomicrons (Type V hyperlipidemia) † . Subjects who consistently have total serum or plasma triglycerides below 1,000 mg/dL are unlikely to develop pancreatitis. Therapy with nicotinic acid may be considered for those subjects with triglyceride elevations between 1,000 and 2,000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. Some Type IV patients with triglycerides under 1,000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of nicotinic acid therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of VLDL. Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia 7 . † Classification of Hyperlipoproteinemias Lipoproteins Lipid Elevations Type Elevated Major Minor C = cholesterol, TG = triglycerides LDL = low-density lipoprotein VLDL = very low-density lipoprotein IDL = intermediate-density lipoprotein I (rare) Chylomicrons TG ↑→ C IIa LDL C ..... IIb LDL, VLDL C TG III (rare) IDL C/TG ..... IV VLDL TG ↑→ C V (rare) Chylomicrons, VLD TG ↑→ C uuid:796439c4-087f-4f1f-85a8-2b11b4f9d6d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82702 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:32ae9c2d-32d9-45b6-a657-73b34c4d7651"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c4a95051-9201-44b4-9117-2773a4e06ac9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZONTIVITY is a protease-activated receptor-1 (PAR-1) antagonist indicated for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). ZONTIVITY has been shown to reduce the rate of a combined endpoint of cardiovascular death, MI, stroke, and urgent coronary revascularization. ( 1.1 ) uuid:07a8ec96-c2fe-4082-8241-5f91a62bf6c8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82702 biolink:treats MONDO:0005386 PMID:41385096 "[{""id"":""uuid:67f2d554-c9fd-4694-90a7-57b5d1c1abb2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c218feb5-60d2-404e-a188-7d9adfef411d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZONTIVITY is a protease-activated receptor-1 (PAR-1) antagonist indicated for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). ZONTIVITY has been shown to reduce the rate of a combined endpoint of cardiovascular death, MI, stroke, and urgent coronary revascularization. ( 1.1 ) uuid:389920e1-76d2-4090-8315-a74cdbcb9c13 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82702 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:ba140242-417f-4bfb-ade6-b1a2fe6d69c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b51ff02f-4c08-4e0c-ab0d-1dcf376721a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZONTIVITY is a protease-activated receptor-1 (PAR-1) antagonist indicated for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). ZONTIVITY has been shown to reduce the rate of a combined endpoint of cardiovascular death, MI, stroke, and urgent coronary revascularization. ( 1.1 ) uuid:2be8bb5f-b868-4dc2-95d4-3c1d3576d27d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32139 biolink:treats MONDO:0000440 PMID:41385096 "[{""id"":""uuid:61700739-3f83-4a4c-9744-747bc4ff027c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:15444fac-2ae6-45f5-83bf-f61f4f67e9f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial – e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:651eae0c-1d3e-4bfe-bb84-d9b228202e7d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32139 biolink:treats MONDO:0001106 PMID:41385096 "[{""id"":""uuid:acd3e8bb-6ca7-47cd-8a3a-9b721b67e7e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f0993e20-9fd6-4cf0-a7be-d15dfc0b9efb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial – e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:6f93c34f-9c8f-4ce9-9163-fd0b8879312a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32139 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:984ea826-087f-4725-a88e-81bb2e4ba794"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e326ce3d-fc04-49da-b382-e0921c618668"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial – e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:96b50f9e-aed1-4ea5-bb48-1bcc5a7dcf57 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32139 biolink:treats HP:0031273 PMID:41385096 "[{""id"":""uuid:e6041c1d-3b74-4fa5-8195-e79ea891f051"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b1b72a54-0c2e-4cce-ac33-a9de28d0b3c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial – e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:371403b8-0d04-43e5-bd68-17f5638f88eb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32139 biolink:treats UMLS:C3472181 PMID:41385096 "[{""id"":""uuid:a3c9f141-df63-4ff0-b2f0-2cf8a3355276"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6b0f6daa-7d33-412d-93d7-28cc0196b73b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial – e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:3b4ff36c-da0d-4a6a-ba2d-c0d6e83c7fff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32139 biolink:treats MONDO:0000745 PMID:41385096 "[{""id"":""uuid:4ad94448-d6cd-4898-8326-123757736291"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9c2e4206-3c9d-4f50-b844-99781ce80604"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial – e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:8f4aa821-8f9d-4106-96d0-c4c66075e2cd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32139 biolink:treats MONDO:0006040 PMID:41385096 "[{""id"":""uuid:cff07a97-3319-4d07-9851-3519ae22200b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f507a62b-f6b6-4ab1-90eb-5953de44ca16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial – e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:64522cbf-f4c7-4efb-9191-9cb45472ad6d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32139 biolink:treats EFO:0009574 PMID:41385096 "[{""id"":""uuid:cc15ac39-fe86-4770-b576-35254d8e5a07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:af4a59bf-6e2e-4ee8-826e-6373c02037ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial – e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:3150fbc6-f0f5-4bc4-abb8-c84cb0d8f253 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32139 biolink:treats UMLS:C0161558 PMID:41385096 "[{""id"":""uuid:84a44125-c780-4508-a697-c9704022737d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:90ce9deb-3f9d-4d34-8658-d3bd1401660c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial – e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:f0637069-b103-4086-9e0a-cac92296d2d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32139 biolink:treats UMLS:C0161544 PMID:41385096 "[{""id"":""uuid:73cc0851-1079-46af-a324-e5fa375c982b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:10926a1c-0926-495b-819d-42554a3bb15d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial – e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:d92a9def-c20d-4e41-8f02-17db036e6459 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32139 biolink:treats UMLS:C0161680 PMID:41385096 "[{""id"":""uuid:4824b4fb-2da1-415c-941d-67b17a781cfb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a4c6f665-5362-401b-8d37-27a275445550"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial – e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:056800b3-5618-4c88-b4b3-fa58f2553750 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32139 biolink:treats UMLS:C0235575 PMID:41385096 "[{""id"":""uuid:a06e4b05-e8fb-4fc7-a512-a60fe8185ce9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a40e190d-f0d9-4b79-a412-a17ed2829d70"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial – e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:328e8379-3f32-4759-a8fd-c914cf1d1e70 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32139 biolink:treats UMLS:C1443924 PMID:41385096 "[{""id"":""uuid:6c1aab9c-d896-4e54-8030-a0cb99807790"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:59b5a269-5677-4d2e-9308-ce472faa8c6c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial – e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:6411a103-ea20-4d4e-8c93-93818fe86a5c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32139 biolink:treats MONDO:0012819 PMID:41385096 "[{""id"":""uuid:87fc246e-3cb1-4929-abc4-03a7f3892106"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:75baf0bf-2330-43f5-b5a0-3b8622bccfda"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial – e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:2a652080-c727-4da1-b580-dcc4f75d4cca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50690 biolink:treats MONDO:0005347 PMID:41385096 "[{""id"":""uuid:3db61fbf-5b32-4fbf-9ee5-4a9c00d4b94c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3538fbd2-abef-4f08-ac30-706936d028cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atorvastatin calcium tablets are an HMG-CoA reductase inhibitor indicated as an adjunct therapy to diet to: Reduce the risk of MI, stroke, revascularization procedures, and angina in adult patients without CHD, but with multiple risk factors ( 1.1 ). Reduce the risk of MI and stroke in adult patients with type 2 diabetes without CHD, but with multiple risk factors ( 1.1 ). Reduce the risk of non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for CHF, and angina in adult patients with CHD ( 1.1 ). Reduce elevated total-C, LDL-C, apo B, and TG levels and increase HDL-C in adult patients with primary hyperlipidemia (heterozygous familial and nonfamilial) and mixed dyslipidemia ( 1.2 ). Reduce elevated TG in adult patients with hypertriglyceridemia and primary dysbetalipoproteinemia ( 1.2 ). Reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH) ( 1.2 ). Reduce elevated total-C, LDL-C, and apo B levels in pediatric patients, 10 years to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH) after failing an adequate trial of diet therapy ( 1.2 ). L i mitations of Use Atorvastatin calcium tablets have not been studied in Fredrickson Types I and V dyslipidemias ( 1.3 ). uuid:8272329d-6907-4885-895a-c6916adbf483 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50690 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:3a8a8884-3cb5-4d54-9b77-8d12109fac6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:525a3223-e2db-46a0-b1f7-9fa10aa80939"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atorvastatin calcium tablets are an HMG-CoA reductase inhibitor indicated as an adjunct therapy to diet to: Reduce the risk of MI, stroke, revascularization procedures, and angina in adult patients without CHD, but with multiple risk factors ( 1.1 ). Reduce the risk of MI and stroke in adult patients with type 2 diabetes without CHD, but with multiple risk factors ( 1.1 ). Reduce the risk of non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for CHF, and angina in adult patients with CHD ( 1.1 ). Reduce elevated total-C, LDL-C, apo B, and TG levels and increase HDL-C in adult patients with primary hyperlipidemia (heterozygous familial and nonfamilial) and mixed dyslipidemia ( 1.2 ). Reduce elevated TG in adult patients with hypertriglyceridemia and primary dysbetalipoproteinemia ( 1.2 ). Reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH) ( 1.2 ). Reduce elevated total-C, LDL-C, and apo B levels in pediatric patients, 10 years to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH) after failing an adequate trial of diet therapy ( 1.2 ). L i mitations of Use Atorvastatin calcium tablets have not been studied in Fredrickson Types I and V dyslipidemias ( 1.3 ). uuid:1d3c3230-e6da-4b79-bbf9-8b76c93e765a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16684 biolink:treats MONDO:0021095 PMID:41385096 "[{""id"":""uuid:7c570328-28a4-4540-b95c-c8586de13bc1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3828d2f9-df1f-4121-b338-30f75e4e8c7c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In the treatment of parkinsonism. Rigidity and tremor relieved by the apparently selective depressant action. In the gastrointestinal tract to relieve pylorospasm, hypertonicity of the small intestine and the hypermotility of the colon. To relieve hypertonicity of the uterine muscle. To relax the spasm of biliary and uretered colic and bronchial spasm. To diminish the tone of the detrusor muscle of the urinary bladder in the treatment of urinary tract disorders. To control the crying and laughing episodes in patients with brain lesions. In cases of closed head injuries which cause acetylcholine to be released or to be present in cerebrospinal fluid which in turn causes abnormal EEG patterns, stupor and neurological signs. In the management of peptic ulcer. In anesthesia to control excessive salivation and bronchial secretions. To control rhinorrhea of acute rhinitis or hay fever. As an antidote for pilocarpine, physostigmine, isoflurophate, choline esters, certain species of Aminata and in cases of anticholinesterase insecticide poisoning. In poisoning by the organic phosphate cholinesterase inhibitors found in certain insecticides and by chemical warfare “nerve gases”, large doses of atropine relieve the muscarine-like symptoms and some of the central-nervous-system manifestations. Adults suspected of contact with organic phosphorus insecticides of the parathion type should be given atropine sulfate, 0.8 mg, intramuscularly. If an atropine effect is not apparent within thirty minutes or if definite symptoms of the poisoning occur (nausea, vomiting, diarrhea, pupillary constriction, pulmonary edema, fasciculations of eyelids and tongue, jerky ocular movements, and excessive sweating, salivation, and bronchial secretion), atropine sulfate, 2 mg, should be given intramuscularly at hourly intervals until signs of atropinization are observed. Up to two or three times this dose (4 to 6 mg) may be required in severe cases. Removing contaminated clothing, washing the skin, and commencing artificial respiration and supportive therapy are also indicated. uuid:b640b6dc-3b6c-4528-b23b-2a00286d2473 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16684 biolink:treats MONDO:0004247 PMID:41385096 "[{""id"":""uuid:219e16de-66f4-4bb4-a017-d9a5cdb73ee7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ab4d0380-1c78-492c-8105-ae0ec6b1ac9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In the treatment of parkinsonism. Rigidity and tremor relieved by the apparently selective depressant action. In the gastrointestinal tract to relieve pylorospasm, hypertonicity of the small intestine and the hypermotility of the colon. To relieve hypertonicity of the uterine muscle. To relax the spasm of biliary and uretered colic and bronchial spasm. To diminish the tone of the detrusor muscle of the urinary bladder in the treatment of urinary tract disorders. To control the crying and laughing episodes in patients with brain lesions. In cases of closed head injuries which cause acetylcholine to be released or to be present in cerebrospinal fluid which in turn causes abnormal EEG patterns, stupor and neurological signs. In the management of peptic ulcer. In anesthesia to control excessive salivation and bronchial secretions. To control rhinorrhea of acute rhinitis or hay fever. As an antidote for pilocarpine, physostigmine, isoflurophate, choline esters, certain species of Aminata and in cases of anticholinesterase insecticide poisoning. In poisoning by the organic phosphate cholinesterase inhibitors found in certain insecticides and by chemical warfare “nerve gases”, large doses of atropine relieve the muscarine-like symptoms and some of the central-nervous-system manifestations. Adults suspected of contact with organic phosphorus insecticides of the parathion type should be given atropine sulfate, 0.8 mg, intramuscularly. If an atropine effect is not apparent within thirty minutes or if definite symptoms of the poisoning occur (nausea, vomiting, diarrhea, pupillary constriction, pulmonary edema, fasciculations of eyelids and tongue, jerky ocular movements, and excessive sweating, salivation, and bronchial secretion), atropine sulfate, 2 mg, should be given intramuscularly at hourly intervals until signs of atropinization are observed. Up to two or three times this dose (4 to 6 mg) may be required in severe cases. Removing contaminated clothing, washing the skin, and commencing artificial respiration and supportive therapy are also indicated. uuid:1c3a902e-aa22-40d4-a36b-80d560ef7795 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16684 biolink:treats MONDO:0005709 PMID:41385096 "[{""id"":""uuid:b5cda4f9-86d5-406b-9fda-b924b5d8f3b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6753bfaa-23c2-4b4b-b9f8-92b2a57dfc5d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In the treatment of parkinsonism. Rigidity and tremor relieved by the apparently selective depressant action. In the gastrointestinal tract to relieve pylorospasm, hypertonicity of the small intestine and the hypermotility of the colon. To relieve hypertonicity of the uterine muscle. To relax the spasm of biliary and uretered colic and bronchial spasm. To diminish the tone of the detrusor muscle of the urinary bladder in the treatment of urinary tract disorders. To control the crying and laughing episodes in patients with brain lesions. In cases of closed head injuries which cause acetylcholine to be released or to be present in cerebrospinal fluid which in turn causes abnormal EEG patterns, stupor and neurological signs. In the management of peptic ulcer. In anesthesia to control excessive salivation and bronchial secretions. To control rhinorrhea of acute rhinitis or hay fever. As an antidote for pilocarpine, physostigmine, isoflurophate, choline esters, certain species of Aminata and in cases of anticholinesterase insecticide poisoning. In poisoning by the organic phosphate cholinesterase inhibitors found in certain insecticides and by chemical warfare “nerve gases”, large doses of atropine relieve the muscarine-like symptoms and some of the central-nervous-system manifestations. Adults suspected of contact with organic phosphorus insecticides of the parathion type should be given atropine sulfate, 0.8 mg, intramuscularly. If an atropine effect is not apparent within thirty minutes or if definite symptoms of the poisoning occur (nausea, vomiting, diarrhea, pupillary constriction, pulmonary edema, fasciculations of eyelids and tongue, jerky ocular movements, and excessive sweating, salivation, and bronchial secretion), atropine sulfate, 2 mg, should be given intramuscularly at hourly intervals until signs of atropinization are observed. Up to two or three times this dose (4 to 6 mg) may be required in severe cases. Removing contaminated clothing, washing the skin, and commencing artificial respiration and supportive therapy are also indicated. uuid:46f354e3-3cb4-42ae-8198-d6223516dfa1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16684 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:f7dfadbf-adca-45b2-98eb-9bbe4f0a5033"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5c2f26b8-24c9-46ff-8aac-081361b909b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In the treatment of parkinsonism. Rigidity and tremor relieved by the apparently selective depressant action. In the gastrointestinal tract to relieve pylorospasm, hypertonicity of the small intestine and the hypermotility of the colon. To relieve hypertonicity of the uterine muscle. To relax the spasm of biliary and uretered colic and bronchial spasm. To diminish the tone of the detrusor muscle of the urinary bladder in the treatment of urinary tract disorders. To control the crying and laughing episodes in patients with brain lesions. In cases of closed head injuries which cause acetylcholine to be released or to be present in cerebrospinal fluid which in turn causes abnormal EEG patterns, stupor and neurological signs. In the management of peptic ulcer. In anesthesia to control excessive salivation and bronchial secretions. To control rhinorrhea of acute rhinitis or hay fever. As an antidote for pilocarpine, physostigmine, isoflurophate, choline esters, certain species of Aminata and in cases of anticholinesterase insecticide poisoning. In poisoning by the organic phosphate cholinesterase inhibitors found in certain insecticides and by chemical warfare “nerve gases”, large doses of atropine relieve the muscarine-like symptoms and some of the central-nervous-system manifestations. Adults suspected of contact with organic phosphorus insecticides of the parathion type should be given atropine sulfate, 0.8 mg, intramuscularly. If an atropine effect is not apparent within thirty minutes or if definite symptoms of the poisoning occur (nausea, vomiting, diarrhea, pupillary constriction, pulmonary edema, fasciculations of eyelids and tongue, jerky ocular movements, and excessive sweating, salivation, and bronchial secretion), atropine sulfate, 2 mg, should be given intramuscularly at hourly intervals until signs of atropinization are observed. Up to two or three times this dose (4 to 6 mg) may be required in severe cases. Removing contaminated clothing, washing the skin, and commencing artificial respiration and supportive therapy are also indicated. uuid:2247751b-a80a-4d6a-838e-024421aab391 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5523 biolink:treats MONDO:0005159 PMID:41385096 "[{""id"":""uuid:ba987c7b-97c2-4e31-b3b4-50cfe9f91857"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:790344f9-a84f-435a-a0f5-d28b754e8b21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZOLADEX is a Gonadotropin Releasing Hormone (GnRH) agonist indicated for: Use in combination with flutamide for the management of locally confined carcinoma of the prostate ( 1.1 ) Palliative treatment of advanced carcinoma of the prostate ( 1.2 ) The management of endometriosis ( 1.3 ) Use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding ( 1.4 ) Use in the palliative treatment of advanced breast cancer in pre- and perimenopausal women ( 1.5 ) uuid:561c32bc-1819-497d-9260-08ff99eaeb43 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5523 biolink:treats MONDO:0005133 PMID:41385096 "[{""id"":""uuid:8ce4beec-68bb-4064-b56a-06484ba0ffea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3370e8aa-6d4b-4262-9428-89efed8a48fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZOLADEX is a Gonadotropin Releasing Hormone (GnRH) agonist indicated for: Use in combination with flutamide for the management of locally confined carcinoma of the prostate ( 1.1 ) Palliative treatment of advanced carcinoma of the prostate ( 1.2 ) The management of endometriosis ( 1.3 ) Use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding ( 1.4 ) Use in the palliative treatment of advanced breast cancer in pre- and perimenopausal women ( 1.5 ) uuid:bd8bfd8a-7ee5-40a8-b2e1-d5a259dc59d9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5523 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:651f53eb-8463-4c0d-b7b1-72419d18026b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:359d1319-5b88-4290-a0d4-87f22fb2753d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZOLADEX is a Gonadotropin Releasing Hormone (GnRH) agonist indicated for: Use in combination with flutamide for the management of locally confined carcinoma of the prostate ( 1.1 ) Palliative treatment of advanced carcinoma of the prostate ( 1.2 ) The management of endometriosis ( 1.3 ) Use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding ( 1.4 ) Use in the palliative treatment of advanced breast cancer in pre- and perimenopausal women ( 1.5 ) uuid:fb631d10-b2bf-47dc-a08c-62bfc9231e40 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29007 biolink:treats MONDO:0005113 PMID:41385096 "[{""id"":""uuid:e2e67673-8bff-40c6-9541-101e4662520c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7213b1ad-ab48-45ce-838b-d663c3786858"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Before instituting treatment with ceftriaxone, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ceftriaxone for injection, USP and other antibacterial drugs, ceftriaxone for injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ceftriaxone for injection, USP is indicated for the treatment of the following infections when caused by susceptible organisms: uuid:77a864a9-1fbf-4445-97fb-281aa043e235 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29034 biolink:treats MONDO:0001356 PMID:41385096 "[{""id"":""uuid:7564c0ad-60f0-4654-9716-c089dacd1b6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4de5aae1-be34-48e3-977b-579983924145"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Venofer is indicated for the treatment of iron deficiency anemia (IDA) in patients with chronic kidney disease (CKD). uuid:963eab7d-1e34-4290-92f3-a94ac6f15474 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29034 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:91d4db69-e3c3-40ea-8ad6-002b10c6448e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:435aae37-990f-4693-b94b-532159253a93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Venofer is indicated for the treatment of iron deficiency anemia (IDA) in patients with chronic kidney disease (CKD). uuid:ebddef03-b899-4fec-a10a-5b653daf6b7e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:505CXM6OHG biolink:treats MONDO:0005812 PMID:41385096 "[{""id"":""uuid:067169b3-2741-4624-a305-31492fd07d23"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2767463e-4179-4c7f-b3bf-ef6a8737887d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d705129f-3ebf-49bb-a7c0-f29489620eb5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/xofluza""]},{""id"":""uuid:c341499b-c41b-4fed-ad15-9dcb3aae3eeb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XOFLUZA is an influenza virus polymerase acidic (PA) endonuclease inhibitor indicated for: Treatment of acute uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours and who are: otherwise healthy, or at high risk of developing influenza-related complications. ( 1.1 ) Post-exposure prophylaxis of influenza in patients 12 years of age and older following contact with an individual who has influenza. ( 1.2 ) Limitations of Use Influenza viruses change over time, and factors such as the virus type or subtype, emergence of resistance, or changes in viral virulence could diminish the clinical benefit of antiviral drugs. Consider available information on drug susceptibility patterns for circulating influenza virus strains when deciding whether to use XOFLUZA. ( 1.3 )|[EMA] Treatment of influenzaXofluza is indicated for the treatment of uncomplicated influenza in patients aged 1 year and above.Post exposure prophylaxis of influenzaXofluza is indicated for post-exposure prophylaxis of influenza in individuals aged 1 year and above.Xofluza should be used in accordance with official recommendations.|[PMDA] Drugs with a new active ingredient indicated for the treatment of influenza A or B virus infections. [SAKIGAKE designation] uuid:603cccbb-1dd7-4631-b7bb-fc115b53a3bb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:127780 biolink:treats MONDO:0000878 PMID:41385096 "[{""id"":""uuid:3d41fe3c-772b-45b1-a25d-6980f5c8d95a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4e6b0362-e8b2-410d-a82c-6866671a47a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CMV Retinitis Foscarnet sodium Injection is indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). Combination therapy with foscarnet sodium Injection and ganciclovir is indicated for patients who have relapsed after monotherapy with either drug. SAFETY AND EFFICACY OF FOSCARNET SODIUM INJECTION HAVE NOT BEEN ESTABLISHED FOR TREATMENT OF OTHER CMV INFECTIONS (e.g., PNEUMONITIS, GASTROENTERITIS); CONGENITAL OR NEONATAL CMV DISEASE; OR NONIMMUNOCOMPROMISED INDIVIDUALS. Mucocutaneous Acyclovir Resistant HSV Infections Foscarnet sodium Injection is indicated for the treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients. SAFETY AND EFFICACY OF FOSCARNET SODIUM INJECTION HAVE NOT BEEN ESTABLISHED FOR TREATMENT OF OTHER HSV INFECTIONS (e.g., RETINITIS, ENCEPHALITIS); CONGENITAL OR NEONATAL HSV DISEASE; OR HSV IN NONIMMUNOCOMPROMISED INDIVIDUALS. uuid:4e1fb916-a76f-4724-966d-f97c1b0597d9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:127780 biolink:treats MONDO:0012268 PMID:41385096 "[{""id"":""uuid:2b961a04-e6f4-4b9b-b23e-795a56e0d310"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6127a222-a20b-481a-b749-489cbc1f6914"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CMV Retinitis Foscarnet sodium Injection is indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). Combination therapy with foscarnet sodium Injection and ganciclovir is indicated for patients who have relapsed after monotherapy with either drug. SAFETY AND EFFICACY OF FOSCARNET SODIUM INJECTION HAVE NOT BEEN ESTABLISHED FOR TREATMENT OF OTHER CMV INFECTIONS (e.g., PNEUMONITIS, GASTROENTERITIS); CONGENITAL OR NEONATAL CMV DISEASE; OR NONIMMUNOCOMPROMISED INDIVIDUALS. Mucocutaneous Acyclovir Resistant HSV Infections Foscarnet sodium Injection is indicated for the treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients. SAFETY AND EFFICACY OF FOSCARNET SODIUM INJECTION HAVE NOT BEEN ESTABLISHED FOR TREATMENT OF OTHER HSV INFECTIONS (e.g., RETINITIS, ENCEPHALITIS); CONGENITAL OR NEONATAL HSV DISEASE; OR HSV IN NONIMMUNOCOMPROMISED INDIVIDUALS. uuid:0d3d6dfa-a81d-405c-9e6e-9954b31f853d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:36704 biolink:treats UMLS:C0343730 PMID:41385096 "[{""id"":""uuid:57820f62-a9e1-4562-b25f-1f10857d1b89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1ceada85-62d4-4d2d-993e-2ad0c4e791f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] • Imiquimod Cream, 3.75% is indicated for the topical treatment of clinically typical, visible or palpable actinic keratoses (AK) of the full face or balding scalp in immunocompetent adults. ( 1.1 ) • Imiquimod Cream, 3.75% is also indicated for the topical treatment of external genital and perianal warts/condyloma acuminata (EGW) in patients 12 years or older. ( 1.2 ) • Limitations of Use: Efficacy of imiquimod cream was not demonstrated for molluscum contagiosum in children 2 to 12 years of age. ( 1.3 , 8.4 ) uuid:c3fa4f5b-26f1-48fa-91ca-07714aa17cc3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0001713 PMID:41385096 "[{""id"":""uuid:b476d541-479f-458a-b822-964a065b32f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bd0e9762-a163-405a-805a-22b15ef8c527"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of methylprednisolone sodium succinate for injection, USP is indicated as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous System: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus. uuid:91a94ab3-63f3-49e8-a3a7-a84c6d257e5d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0004670 PMID:41385096 "[{""id"":""uuid:144a4bac-f3d7-4b8e-8c49-d0bf1e7a06b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a60570bd-8b29-4fe4-9246-c04d73882df7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of methylprednisolone sodium succinate for injection, USP is indicated as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous System: Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus. uuid:4c0b7059-0e34-4945-915c-cacc2ecebdf6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:WA16A5Y52X biolink:treats MONDO:0034212 PMID:41385096 "[{""id"":""uuid:8c141de7-ca80-48f7-a824-3ff2de33b3f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:12a0b411-8153-499d-a12e-18b96019cc80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levoleucovorin for Injection is indicated for: rescue after high-dose methotrexate therapy in adult and pediatric patients with osteosarcoma. diminishing the toxicity associated with overdosage of folic acid antagonists or impaired methotrexate elimination in adult and pediatric patients. the treatment of adults with metastatic colorectal cancer in combination with fluorouracil. Limitations of Use Levoleucovorin for Injection is not indicated for pernicious anemia and megaloblastic anemia secondary to the lack of vitamin B12, because of the risk of progression of neurologic manifestations despite hematologic remission. PUBCHEM.COMPOUND:135465090 uuid:7adcf744-247e-4949-8d68-cc812d253b58 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3207 biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:d3a1afb6-e23e-40f0-976a-be197444f312"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c45429f6-9e59-4708-8de2-a9b9b403e241"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:6707f5fc-d42c-4456-ad0a-b8283ab48f86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] UCERIS rectal foam is indicated for the induction of remission in patients with active mild to moderate distal ulcerative colitis extending up to 40 cm from the anal verge.|[PMDA] A drug with a new route of administration indicated for the treatment of active ulcerative colitis (excluding severe cases). uuid:301f50b4-9b40-46c7-b4d2-f623e8f53fd1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28262 biolink:treats MONDO:0018301 PMID:41385096 "[{""id"":""uuid:a8fc94ee-2407-4498-b71f-c2c07de38e47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7f7cfe7b-4ccd-458e-b9b7-ddc96e367bc9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:517e02e2-8cf3-4b12-b63b-ee48fcfee1f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RIMSO-50 ® (dimethyl sulfoxide) is indicated for the symptomatic relief of patients with interstitial cystitis. RIMSO-50 ® has not been approved as being safe and effective for any other indication. There is no clinical evidence of effectiveness of dimethyl sulfoxide in the treatment of bacterial infections of the urinary tract.|[PMDA] A drug with a new active ingredient indicated for the improvement of symptoms (chronic pelvic pain, pressure and discomfort perceived to be related to the urinary bladder; lower urinary tract symptoms such as persistent urge to void and urinary frequency) in patients with interstitial cystitis (Hunner type). [Orphan drug] uuid:fa84a7b2-fa81-4df1-a1da-bb830dcbf3af biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:26710 biolink:treats HP:0002902 PMID:41385096 "[{""id"":""uuid:272abda3-2554-4b74-9f84-ccac1adc226e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6a1998c3-2735-435f-af54-364dbf42e526"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 14.6% Sodium Chloride Injection, USP Additive Solution is indicated for parenteral restoration of sodium ion in patients with restricted oral intake. Sodium replacement is specifically indicated in patients with hyponatremia or low salt syndrome. 14.6% Sodium Chloride Additive Solution may also be added to compatible carbohydrate solutions such as dextrose in water to provide electrolytes. uuid:79cdee26-3e4d-4ea7-b7f7-20b2c79d2a98 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:39211 biolink:treats MONDO:0003471 PMID:41385096 "[{""id"":""uuid:c6feff26-f0e5-4e1b-babd-49c3de4cfe9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a1f776d5-78d8-4641-8572-82de155c07d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NATROBA is a pediculicide indicated for the topical treatment of head lice infestations in adult and pediatric patients 6 months of age and older. ( 1.1 ) NATROBA is a scabicide indicated for the topical treatment of scabies infestations in adult and pediatric patients 4 years of age and older, ( 1.2 ) uuid:5124fd83-c601-47c4-bd56-28f22bcb682c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:39211 biolink:treats MONDO:0004525 PMID:41385096 "[{""id"":""uuid:841d9170-2fd7-4b85-bf5b-cd723beec820"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ac5e4be4-5f6d-4d0a-b66d-3274aa148eef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NATROBA is a pediculicide indicated for the topical treatment of head lice infestations in adult and pediatric patients 6 months of age and older. ( 1.1 ) NATROBA is a scabicide indicated for the topical treatment of scabies infestations in adult and pediatric patients 4 years of age and older, ( 1.2 ) uuid:afcd5bc7-5151-4625-a857-f27ee4a99ba3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:26710 biolink:treats MONDO:0015129 PMID:41385096 "[{""id"":""uuid:302b74bb-f285-41d3-bb42-4dd426696c9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2929d052-f44d-4bf4-99dd-2f22286f90c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Chloride Injection, USP, 23.4%, is indicated as an additive in parenteral fluid therapy for use in patients who have special problems of sodium electrolyte intake or excretion. It is intended to meet the specific requirements of the patient with unusual fluid and electrolyte needs. After available clinical and laboratory information is considered and correlated, the appropriate number of milliequivalents of sodium chloride required can be withdrawn from Sodium Chloride Injection, USP, 23.4% and diluted for use. Sodium Chloride Injection is indicated for the treatment of sodium, chloride and water deficiencies that commonly occur in many diseases. Isotonic Sodium Chloride Injection should be limited to cases in which the chloride loss is greater than the sodium loss, as in vomiting from pyloric obstruction, or in which the loss is about equal, as in vomiting from duodenal, jejunal or ileal obstruction and in the replacement of aspirated gastrointestinal fluids. The toxic symptoms that follow various forms of intestinal obstruction are accompanied by a marked reduction of blood chloride and often sodium chloride has a lifesaving effect. Symptoms of sodium chloride deficiency are very similar to those of Addison’s disease and large doses of sodium chloride will produce temporary alleviation of the symptoms. Other disorders in which sodium chloride is therapeutically useful include extensive burns, failure of gastric secretion and postoperative intestinal paralysis. uuid:805fbb13-5a7f-4a10-b8c9-f1d340a83f64 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:26710 biolink:treats UMLS:C0856633 PMID:41385096 "[{""id"":""uuid:1f0eb683-89f5-4229-ae79-1f3be0f34e52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:22833b38-597c-4930-9dee-adbe68781f5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Chloride Injection, USP, 23.4%, is indicated as an additive in parenteral fluid therapy for use in patients who have special problems of sodium electrolyte intake or excretion. It is intended to meet the specific requirements of the patient with unusual fluid and electrolyte needs. After available clinical and laboratory information is considered and correlated, the appropriate number of milliequivalents of sodium chloride required can be withdrawn from Sodium Chloride Injection, USP, 23.4% and diluted for use. Sodium Chloride Injection is indicated for the treatment of sodium, chloride and water deficiencies that commonly occur in many diseases. Isotonic Sodium Chloride Injection should be limited to cases in which the chloride loss is greater than the sodium loss, as in vomiting from pyloric obstruction, or in which the loss is about equal, as in vomiting from duodenal, jejunal or ileal obstruction and in the replacement of aspirated gastrointestinal fluids. The toxic symptoms that follow various forms of intestinal obstruction are accompanied by a marked reduction of blood chloride and often sodium chloride has a lifesaving effect. Symptoms of sodium chloride deficiency are very similar to those of Addison’s disease and large doses of sodium chloride will produce temporary alleviation of the symptoms. Other disorders in which sodium chloride is therapeutically useful include extensive burns, failure of gastric secretion and postoperative intestinal paralysis. uuid:d37e5ae4-9d5f-401d-b94a-3b15c3ba14f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:26710 biolink:treats MONDO:0004565 PMID:41385096 "[{""id"":""uuid:21546e3f-0b3b-419a-a313-bc96f32e02f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1571b319-aceb-4c17-9040-f35606c3356a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Chloride Injection, USP, 23.4%, is indicated as an additive in parenteral fluid therapy for use in patients who have special problems of sodium electrolyte intake or excretion. It is intended to meet the specific requirements of the patient with unusual fluid and electrolyte needs. After available clinical and laboratory information is considered and correlated, the appropriate number of milliequivalents of sodium chloride required can be withdrawn from Sodium Chloride Injection, USP, 23.4% and diluted for use. Sodium Chloride Injection is indicated for the treatment of sodium, chloride and water deficiencies that commonly occur in many diseases. Isotonic Sodium Chloride Injection should be limited to cases in which the chloride loss is greater than the sodium loss, as in vomiting from pyloric obstruction, or in which the loss is about equal, as in vomiting from duodenal, jejunal or ileal obstruction and in the replacement of aspirated gastrointestinal fluids. The toxic symptoms that follow various forms of intestinal obstruction are accompanied by a marked reduction of blood chloride and often sodium chloride has a lifesaving effect. Symptoms of sodium chloride deficiency are very similar to those of Addison’s disease and large doses of sodium chloride will produce temporary alleviation of the symptoms. Other disorders in which sodium chloride is therapeutically useful include extensive burns, failure of gastric secretion and postoperative intestinal paralysis. uuid:cda34ff9-a1c2-422f-b3be-65c105fe7462 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:26710 biolink:treats MONDO:0004568 PMID:41385096 "[{""id"":""uuid:d47fadc0-46e8-45f5-b35e-6d00aacd4011"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7f79c09e-e4dc-44bf-b624-abee24482f89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Chloride Injection, USP, 23.4%, is indicated as an additive in parenteral fluid therapy for use in patients who have special problems of sodium electrolyte intake or excretion. It is intended to meet the specific requirements of the patient with unusual fluid and electrolyte needs. After available clinical and laboratory information is considered and correlated, the appropriate number of milliequivalents of sodium chloride required can be withdrawn from Sodium Chloride Injection, USP, 23.4% and diluted for use. Sodium Chloride Injection is indicated for the treatment of sodium, chloride and water deficiencies that commonly occur in many diseases. Isotonic Sodium Chloride Injection should be limited to cases in which the chloride loss is greater than the sodium loss, as in vomiting from pyloric obstruction, or in which the loss is about equal, as in vomiting from duodenal, jejunal or ileal obstruction and in the replacement of aspirated gastrointestinal fluids. The toxic symptoms that follow various forms of intestinal obstruction are accompanied by a marked reduction of blood chloride and often sodium chloride has a lifesaving effect. Symptoms of sodium chloride deficiency are very similar to those of Addison’s disease and large doses of sodium chloride will produce temporary alleviation of the symptoms. Other disorders in which sodium chloride is therapeutically useful include extensive burns, failure of gastric secretion and postoperative intestinal paralysis. uuid:dc3d9c45-2d62-4706-82db-29063883358e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:26710 biolink:treats UMLS:C1971019 PMID:41385096 "[{""id"":""uuid:62b57924-a6df-4d02-a2da-7162b14bd2db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e42e5fa7-d047-476a-b8d6-e10d0db6316b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Chloride Injection, USP, 23.4%, is indicated as an additive in parenteral fluid therapy for use in patients who have special problems of sodium electrolyte intake or excretion. It is intended to meet the specific requirements of the patient with unusual fluid and electrolyte needs. After available clinical and laboratory information is considered and correlated, the appropriate number of milliequivalents of sodium chloride required can be withdrawn from Sodium Chloride Injection, USP, 23.4% and diluted for use. Sodium Chloride Injection is indicated for the treatment of sodium, chloride and water deficiencies that commonly occur in many diseases. Isotonic Sodium Chloride Injection should be limited to cases in which the chloride loss is greater than the sodium loss, as in vomiting from pyloric obstruction, or in which the loss is about equal, as in vomiting from duodenal, jejunal or ileal obstruction and in the replacement of aspirated gastrointestinal fluids. The toxic symptoms that follow various forms of intestinal obstruction are accompanied by a marked reduction of blood chloride and often sodium chloride has a lifesaving effect. Symptoms of sodium chloride deficiency are very similar to those of Addison’s disease and large doses of sodium chloride will produce temporary alleviation of the symptoms. Other disorders in which sodium chloride is therapeutically useful include extensive burns, failure of gastric secretion and postoperative intestinal paralysis. uuid:3f91f8c2-467a-456b-a78b-2eddcf9ed2e9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:26710 biolink:treats UMLS:C0342921 PMID:41385096 "[{""id"":""uuid:8c613e6a-87f5-4653-b8b1-ddccdffd9ed2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9119b489-c99f-421b-9d4d-7501a968d574"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Chloride Injection, USP, 23.4%, is indicated as an additive in parenteral fluid therapy for use in patients who have special problems of sodium electrolyte intake or excretion. It is intended to meet the specific requirements of the patient with unusual fluid and electrolyte needs. After available clinical and laboratory information is considered and correlated, the appropriate number of milliequivalents of sodium chloride required can be withdrawn from Sodium Chloride Injection, USP, 23.4% and diluted for use. Sodium Chloride Injection is indicated for the treatment of sodium, chloride and water deficiencies that commonly occur in many diseases. Isotonic Sodium Chloride Injection should be limited to cases in which the chloride loss is greater than the sodium loss, as in vomiting from pyloric obstruction, or in which the loss is about equal, as in vomiting from duodenal, jejunal or ileal obstruction and in the replacement of aspirated gastrointestinal fluids. The toxic symptoms that follow various forms of intestinal obstruction are accompanied by a marked reduction of blood chloride and often sodium chloride has a lifesaving effect. Symptoms of sodium chloride deficiency are very similar to those of Addison’s disease and large doses of sodium chloride will produce temporary alleviation of the symptoms. Other disorders in which sodium chloride is therapeutically useful include extensive burns, failure of gastric secretion and postoperative intestinal paralysis. uuid:fffc8861-5dfe-4b7c-bdf5-d3fd9f684152 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77942 biolink:treats MONDO:0001628 PMID:41385096 "[{""id"":""uuid:7b670ac2-8738-4aa8-b5d6-9bbdffdc35d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bb156453-2b58-4171-9104-a4fe3b0b8e83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tavaborole topical solution, 5% is an oxaborole antifungal indicated for the treatment of onychomycosis of the toenails due to Trichophyton rubrum or Trichophyton mentagrophytes . uuid:c85c6844-cafb-48ba-ac17-c5a427e3cb60 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77942 biolink:treats UMLS:C5192601 PMID:41385096 "[{""id"":""uuid:1962a40f-a893-499b-88a5-c127367b5df6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:83b24427-37b1-48d2-abca-9cd4ddcdc3ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tavaborole topical solution, 5% is an oxaborole antifungal indicated for the treatment of onychomycosis of the toenails due to Trichophyton rubrum or Trichophyton mentagrophytes . uuid:75cee910-f2be-479a-8db5-139bb1bb8b11 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3478 biolink:treats UMLS:C0853854 PMID:41385096 "[{""id"":""uuid:40b1b319-72ba-4d48-b85b-098fd23a3c76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:603a5f92-2aae-43a9-86c2-47ff6505913d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefaclor extended-release tablets USP and other antibacterial drugs, cefaclor extended-release tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. The safety and effectiveness of cefaclor extended-release tablets in treating some of the indications and pathogens for which other formulations of cefaclor are approved have NOT been established. When administered at the recommended dosages and durations of therapy, cefaclor extended-release tablets are indicated for the treatment of patients with the following mild to moderate infections when caused by susceptible strains of the designated organisms. (See DOSAGE AND ADMINISTRATION and CLINICAL STUDIES sections.) Acute bacterial exacerbations of chronic bronchitis due to Haemophilus influenzae (excluding ß-lactamase-negative, ampicillin-resistant isolates), Moraxella catarrhalis, or Streptococcus pneumoniae . NOTE: In view of the insufficient numbers of isolates of ß-lactamase-producing isolates of Haemophilus influenzae that were obtained from clinical trials with cefaclor extended-release tablets for patients with acute bacterial exacerbations of chronic bronchitis, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for bronchitis known, suspected, or considered potentially to be caused by ß-lactamase-producing H. influenzae . Pharyngitis and tonsillitis due to Streptococcus pyogenes . NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefaclor extended-release tablets are generally effective in the eradication of S. pyogenes from the oropharynx; however, data establishing the efficacy of cefaclor extended-release tablets for the prophylaxis of subsequent rheumatic fever are not available. Uncomplicated skin and skin and structure infections due to Staphylococcus aureus (methicillin-susceptible only). NOTE: In view of the insufficient numbers of isolates of Streptococcus pyogenes that were obtained from clinical trials with cefaclor extended-release tablets for patients with uncomplicated skin and skin structure infections, it was not possible to adequately evaluate the effectiveness of cefaclor extended-release tablets for skin infections known, suspected, or considered potentially to be caused by S. pyogenes . uuid:4c9f15e0-8f29-48b7-9417-df6d56f90977 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:149836 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:8f165508-ac7d-4cdb-87d3-cea005edf7fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6174377b-aead-476e-8c98-6db8bfce88b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a743b323-d965-4c08-bd7c-254b4066d541"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tigecycline for Injection is a tetracycline class antibacterial indicated in patients 18 years of age and older for: Complicated skin and skin structure infections ( 1.1 ) Complicated intra-abdominal infections ( 1.2 ) Community-acquired bacterial pneumonia ( 1.3 ) Limitations of Use : Tigecycline for Injection is not indicated for treatment of diabetic foot infection or hospital-acquired pneumonia, including ventilator-associated pneumonia. ( 1.4 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Tigecycline for Injection and other antibacterial drugs, Tigecycline for Injection should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. ( 1.5 )|[PMDA] A drug with a new active ingredient indicated for the treatment of deep skin infection, chronic pyoderma, secondary infection of trauma, burn, and surgical wounds, secondary infection of erosion and ulcer, peritonitis, intraperitoneal abscess, and cholecystitis. [Priority review] uuid:c6c5790b-26cb-4961-8992-a82c2d9fbb58 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:149836 biolink:treats MONDO:0004652 PMID:41385096 "[{""id"":""uuid:dec5aeaf-b43f-4a23-9882-d290416a8c6c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:41349e99-ddc4-4612-9186-c919d4185456"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tigecycline for Injection is a tetracycline class antibacterial indicated in patients 18 years of age and older for: Complicated skin and skin structure infections ( 1.1 ) Complicated intra-abdominal infections ( 1.2 ) Community-acquired bacterial pneumonia ( 1.3 ) Limitations of Use : Tigecycline for Injection is not indicated for treatment of diabetic foot infection or hospital-acquired pneumonia, including ventilator-associated pneumonia. ( 1.4 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Tigecycline for Injection and other antibacterial drugs, Tigecycline for Injection should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. ( 1.5 ) uuid:a8332b8d-4630-431e-bccb-5029233f6237 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:149836 biolink:treats UMLS:C0744130 PMID:41385096 "[{""id"":""uuid:3b6ae4f6-a301-4562-87b6-d0500f6b3c5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5293cf10-0d62-44ef-a13a-441b9d9f665d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tigecycline for Injection is a tetracycline class antibacterial indicated in patients 18 years of age and older for: Complicated skin and skin structure infections ( 1.1 ) Complicated intra-abdominal infections ( 1.2 ) Community-acquired bacterial pneumonia ( 1.3 ) Limitations of Use : Tigecycline for Injection is not indicated for treatment of diabetic foot infection or hospital-acquired pneumonia, including ventilator-associated pneumonia. ( 1.4 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Tigecycline for Injection and other antibacterial drugs, Tigecycline for Injection should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. ( 1.5 ) uuid:24c54973-67c2-4792-bfbd-298b8b59b9ca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3757 biolink:treats EFO:0801084 PMID:41385096 "[{""id"":""uuid:ec5b9e44-6b5f-4cb1-9101-da2bebbf2e46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6bdfeebd-9d25-45a4-8f76-0bfbd8ca8802"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Duraclon is indicated in combination with opiates for the treatment of severe pain in cancer patients that is not adequately relieved by opioid analgesics alone. Epidural clonidine is more likely to be effective in patients with neuropathic pain than somatic or visceral pain (see Clinical Trials ). The safety of this drug product has only been established in a highly selected group of cancer patients, and only after an adequate trial of opioid analgesia. Other use is of unproven safety and is not recommended. In a rare patient, the potential benefits may outweigh the known risks (see WARNINGS ). uuid:d4a6130a-57a8-43ba-b0a8-4eebd7701e84 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9605 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:b349e9a9-d96c-42a5-9852-8c79bc64c1b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c2ac2d7c-1c7b-475d-9050-de42fb3d8749"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tirofiban hydrochloride injection is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS) . uuid:5fa43aaf-7e85-4493-b48b-5d5a7f38bed6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9605 biolink:treats UMLS:C1112767 PMID:41385096 "[{""id"":""uuid:090e86ac-ef86-4a7f-8d62-4d8dc7aaf404"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:415092d7-6be3-4582-99b7-71af75daec80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tirofiban hydrochloride injection is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS) . uuid:d3aced7c-bf7d-4e5b-a451-00958c6964c2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9605 biolink:treats MONDO:0005542 PMID:41385096 "[{""id"":""uuid:c5fae4f1-286a-43bd-8159-d8f4331630c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:10d2a038-7f40-4d3e-ab01-f322cb944cec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tirofiban hydrochloride injection is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS) . uuid:015c193c-31c4-4b64-9099-508a82816283 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:74170 biolink:treats UMLS:C1112209 PMID:41385096 "[{""id"":""uuid:b8c83206-f5ea-4fbe-b918-da1b24d32e6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:45a29e18-44a9-473e-802c-f9568a0a78e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Piperacillin and tazobactam for injection is a combination of piperacillin, a penicillin-class antibacterial and tazobactam, a beta-lactamase inhibitor, indicated for the treatment of: Intra-abdominal infections in adult and pediatric patients 2 months of age and older ( 1.1 ) Nosocomial pneumonia in adult and pediatric patients 2 months of age and older ( 1.2 ) Skin and skin structure infections in adults ( 1.3 ) Female pelvic infections in adults ( 1.4 ) Community-acquired pneumonia in adults ( 1.5 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of piperacillin and tazobactam for injection and other antibacterial drugs, piperacillin and tazobactam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 ) uuid:ec5ea06e-9828-4d23-a396-6d82b1d4a36c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:74170 biolink:treats UMLS:C0949083 PMID:41385096 "[{""id"":""uuid:05a8fdec-add6-49e8-ab3b-f61b7b4a77da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c2a6ee87-6ffc-4717-bb15-44d0aa3f60cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Piperacillin and tazobactam for injection is a combination of piperacillin, a penicillin-class antibacterial and tazobactam, a beta-lactamase inhibitor, indicated for the treatment of: Intra-abdominal infections in adult and pediatric patients 2 months of age and older ( 1.1 ) Nosocomial pneumonia in adult and pediatric patients 2 months of age and older ( 1.2 ) Skin and skin structure infections in adults ( 1.3 ) Female pelvic infections in adults ( 1.4 ) Community-acquired pneumonia in adults ( 1.5 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of piperacillin and tazobactam for injection and other antibacterial drugs, piperacillin and tazobactam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 ) uuid:9c301f61-cfa4-4acd-af2b-dda99c5031f4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:74170 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:c5d4406a-48e6-4ad7-aa2a-99ead05c5526"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4c1b1993-2455-454c-b3bc-3b267974f67d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9968407a-c05d-4f2b-b479-ee880fd41f78"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Piperacillin and tazobactam for injection is a combination of piperacillin, a penicillin-class antibacterial and tazobactam, a beta-lactamase inhibitor, indicated for the treatment of: Intra-abdominal infections in adult and pediatric patients 2 months of age and older ( 1.1 ) Nosocomial pneumonia in adult and pediatric patients 2 months of age and older ( 1.2 ) Skin and skin structure infections in adults ( 1.3 ) Female pelvic infections in adults ( 1.4 ) Community-acquired pneumonia in adults ( 1.5 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of piperacillin and tazobactam for injection and other antibacterial drugs, piperacillin and tazobactam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 )|[PMDA] Drugs with additional indications and new dosages for the treatment of ""bacterial skin infections mainly involving the dermis and/or subcutaneous tissues"" and ""secondary bacterial infections of pre-existing skin ulcers and/or erosion""." uuid:091a6410-04a6-4fe8-aa83-5c7de60cb7be biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:74170 biolink:treats MONDO:0000922 PMID:41385096 "[{""id"":""uuid:9271afe8-e839-42e7-b904-60cf8f9e1304"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:01064a72-2cf4-496a-ad23-63d35486f5b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Piperacillin and tazobactam for injection is a combination of piperacillin, a penicillin-class antibacterial and tazobactam, a beta-lactamase inhibitor, indicated for the treatment of: Intra-abdominal infections in adult and pediatric patients 2 months of age and older ( 1.1 ) Nosocomial pneumonia in adult and pediatric patients 2 months of age and older ( 1.2 ) Skin and skin structure infections in adults ( 1.3 ) Female pelvic infections in adults ( 1.4 ) Community-acquired pneumonia in adults ( 1.5 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of piperacillin and tazobactam for injection and other antibacterial drugs, piperacillin and tazobactam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 ) uuid:083bb82b-b7bb-43cd-8d6a-d827470c2812 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:74170 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:f32e59a2-8097-44d3-a57c-e6c8878f2bf9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9e5379f5-c20d-4773-9205-fb448b45e82b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Piperacillin and tazobactam for injection is a combination of piperacillin, a penicillin-class antibacterial and tazobactam, a beta-lactamase inhibitor, indicated for the treatment of: Intra-abdominal infections in adult and pediatric patients 2 months of age and older ( 1.1 ) Nosocomial pneumonia in adult and pediatric patients 2 months of age and older ( 1.2 ) Skin and skin structure infections in adults ( 1.3 ) Female pelvic infections in adults ( 1.4 ) Community-acquired pneumonia in adults ( 1.5 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of piperacillin and tazobactam for injection and other antibacterial drugs, piperacillin and tazobactam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 ) uuid:f22e085b-c1ad-4562-ab6e-c10b00e932bb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:575568 biolink:treats MONDO:0019121 PMID:41385096 "[{""id"":""uuid:d02c958b-6c43-452b-8dad-5ba4837cf9aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b68585f6-06c6-4518-be06-153cc475589f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7431d7cb-ccee-450a-ad69-b527e347a331"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atovaquone oral suspension is a quinone antimicrobial drug indicated for: Prevention of Pneumocystis jirovecii pneumonia (PCP) in adults and adolescents aged 13 years and older who cannot tolerate trimethoprim-sulfamethoxazole (TMP-SMX). ( 1.1 ) Treatment of mild-to-moderate PCP in adults and adolescents aged 13 years and older who cannot tolerate TMP-SMX. ( 1.2 ) Limitations of Use ( 1.3 ): Treatment of severe PCP (alveolar arterial oxygen diffusion gradient [(A-a)DO 2 ] >45 mm Hg) with atovaquone oral suspension has not been studied. The efficacy of atovaquone oral suspension in subjects who are failing therapy with TMP-SMX has also not been studied.|[PMDA] A drug with a new active ingredient indicated for the treatment and prevention of Pneumocystis pneumonia. [Priority review] uuid:bd1aa2e1-1192-4131-b623-98bf06f35559 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:616538 biolink:treats MONDO:0007186 PMID:41385096 "[{""id"":""uuid:d9dca9da-ecee-4d7b-b1e6-a18d5d8d6852"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:19d9b2be-3b65-4899-8e09-ecc4102a4182"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Omeprazole and Sodium Bicarbonate capsules are indicated in adults for the: short-term treatment of active duodenal ulcer. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy. short-term treatment (4 to 8 weeks) of active benign gastric ulcer. treatment of heartburn and other symptoms associated with GERD for up to 4 weeks. short-term treatment (4 to 8 weeks) of EE due to acid-mediated GERD which has been diagnosed by endoscopy in adults. The efficacy of Omeprazole and Sodium Bicarbonate capsules used for longer than 8 weeks in patient with EE has not been established. If a patient does not respond to 8 weeks of treatment, an additional 4 weeks of treatment may be given. If there is recurrence of EE or GERD symptoms (e.g., heartburn), additional 4 to 8-week courses of Omeprazole and Sodium Bicarbonate capsules may be considered. maintenance of healing of EE due to acid-mediated GERD. Controlled studies do not extend beyond 12 months uuid:31070b87-14d5-437f-b9c3-3716e253615f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72296 biolink:treats MONDO:0004981 PMID:41385096 "[{""id"":""uuid:af2f44b6-6b1c-4eb4-8dc6-b255ebb8b704"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dca3424f-c073-4714-9a97-8d205356ccb0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Apixaban is a factor Xa inhibitor indicated: to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. ( 1.1 ) for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. ( 1.2 ) for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy. ( 1.3 , 1.4 , 1.5 ) uuid:7ad0a6e3-6f49-4e92-9c50-8b626447c0c1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72296 biolink:treats HP:0002625 PMID:41385096 "[{""id"":""uuid:9a5d5bf6-8234-4b32-8e71-1001c8d5df3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:67ea881d-2557-4066-b356-93747d27d504"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:31e78d2d-a9f0-4245-9548-a4eda88a0fac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Apixaban is a factor Xa inhibitor indicated: to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. ( 1.1 ) for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. ( 1.2 ) for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy. ( 1.3 , 1.4 , 1.5 )|[PMDA] Drugs with a new additional indication and a new dosage for the treatment and prevention of the recurrence of venous thromboembolism (deep vein thrombosis and pulmonary thromboembolism). uuid:0e9f0a89-d69c-46b2-beba-a7a0ad7e5592 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72296 biolink:treats MONDO:0005279 PMID:41385096 "[{""id"":""uuid:5134603c-2453-4fef-95d4-6757702c5cb4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4f934bd5-51a7-490c-ab7f-2332e2efbc93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:5be3b9c6-5c63-4fef-8a9a-7550ec4b4e77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/eliquis""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Apixaban is a factor Xa inhibitor indicated: to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. ( 1.1 ) for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. ( 1.2 ) for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy. ( 1.3 , 1.4 , 1.5 )|[EMA] For Eliquis 2.5 mg film-coated tablets:Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery.Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II).Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients).For Eliquis 5 mg film-coated tablets:Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II).Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients). uuid:331f62c5-0eae-4c27-bb99-bf0ed91117df biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72296 biolink:treats HP:0004850 PMID:41385096 "[{""id"":""uuid:71a9d3d2-5fdd-4e83-b54d-9897c62a83dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:15773d4f-ccc9-4fe4-9fe7-bfec31b7fbfe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Apixaban is a factor Xa inhibitor indicated: to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. ( 1.1 ) for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. ( 1.2 ) for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy. ( 1.3 , 1.4 , 1.5 ) uuid:68515e08-2bfe-431b-9610-8138874a3c04 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72296 biolink:treats UMLS:C1735914 PMID:41385096 "[{""id"":""uuid:2fc6a37d-34a1-482c-895b-45f08074551b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e6e5aa3f-0c40-483f-a964-2f7e205bf7ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Apixaban is a factor Xa inhibitor indicated: to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. ( 1.1 ) for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. ( 1.2 ) for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy. ( 1.3 , 1.4 , 1.5 ) uuid:5872bb21-0b3b-470d-b9b0-9012deef34e4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50848 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:5f31925d-6cf2-4ed9-a5b1-f48f5c95546e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4cccb051-63af-43d1-b58a-0be3defeadea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Loteprednol Etabonate Ophthalmic Gel is a corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery. uuid:032f28a7-f315-44de-82f4-2331594fc9ca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7936 biolink:treats MONDO:0005146 PMID:41385096 "[{""id"":""uuid:233a3f51-289b-445f-829b-70af7801c386"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c80e5e24-8efb-481c-aa1b-98446f09bc0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9ef45bf7-e6d4-4e57-9502-fd8697dfaecd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Major Depressive Disorder Paroxetine tablets, USP are indicated for the treatment of major depressive disorder. The efficacy of paroxetine in the treatment of a major depressive episode was established in 6-week controlled trials of outpatients whose diagnoses corresponded most closely to the DSM-III category of major depressive disorder (see CLINICAL PHARMACOLOGY: Clinical Trials ). A major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: Change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. The effects of paroxetine in hospitalized depressed patients have not been adequately studied. The efficacy of paroxetine in maintaining a response in major depressive disorder for up to 1 year was demonstrated in a placebo-controlled trial (see CLINICAL PHARMACOLOGY: Clinical Trials ). Nevertheless, the physician who elects to use paroxetine for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient. Obsessive Compulsive Disorder Paroxetine tablets, USP are indicated for the treatment of obsessions and compulsions in patients with obsessive compulsive disorder (OCD) as defined in the DSM-IV. The obsessions or compulsions cause marked distress, are time-consuming, or significantly interfere with social or occupational functioning. The efficacy of paroxetine was established in two 12-week trials with obsessive compulsive outpatients whose diagnoses corresponded most closely to the DSM-IIIR category of obsessive compulsive disorder (see CLINICAL PHARMACOLOGY: Clinical Trials ). Obsessive compulsive disorder is characterized by recurrent and persistent ideas, thoughts, impulses, or images (obsessions) that are ego-dystonic and/or repetitive, purposeful, and intentional behaviors (compulsions) that are recognized by the person as excessive or unreasonable. Long-term maintenance of efficacy was demonstrated in a 6-month relapse prevention trial. In this trial, patients assigned to paroxetine showed a lower relapse rate compared to patients on placebo (see CLINICAL PHARMACOLOGY: Clinical Trials ). Nevertheless, the physician who elects to use paroxetine for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Panic Disorder Paroxetine tablets, USP are indicated for the treatment of panic disorder, with or without agoraphobia, as defined in DSM-IV. Panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. The efficacy of paroxetine was established in three 10- to 12-week trials in panic disorder patients whose diagnoses corresponded to the DSM-IIIR category of panic disorder (see CLINICAL PHARMACOLOGY: Clinical Trials ). Panic disorder (DSM-IV) is characterized by recurrent unexpected panic attacks, i.e., a discrete period of intense fear or discomfort in which 4 (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) palpitations, pounding heart, or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded, or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes. Long-term maintenance of efficacy was demonstrated in a 3-month relapse prevention trial. In this trial, patients with panic disorder assigned to paroxetine demonstrated a lower relapse rate compared to patients on placebo (see CLINICAL PHARMACOLOGY: Clinical Trials ). Nevertheless, the physician who prescribes paroxetine for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Social Anxiety Disorder Paroxetine tablets are indicated for the treatment of social anxiety disorder, also known as social phobia, as defined in DSM-IV (300.23). Social anxiety disorder is characterized by a marked and persistent fear of 1 or more social or performance situations in which the person is exposed to unfamiliar people or to possible scrutiny by others. Exposure to the feared situation almost invariably provokes anxiety, which may approach the intensity of a panic attack. The feared situations are avoided or endured with intense anxiety or distress. The avoidance, anxious anticipation, or distress in the feared situation(s) interferes significantly with the person's normal routine, occupational or academic functioning, or social activities or relationships, or there is marked distress about having the phobias. Lesser degrees of performance anxiety or shyness generally do not require psychopharmacological treatment. The efficacy of paroxetine was established in three 12-week trials in adult patients with social anxiety disorder (DSM-IV). Paroxetine has not been studied in children or adolescents with social phobia (see CLINICAL PHARMACOLOGY: Clinical Trials ). The effectiveness of paroxetine in long-term treatment of social anxiety disorder, i.e., for more than 12 weeks, has not been systematically evaluated in adequate and well-controlled trials. Therefore, the physician who elects to prescribe paroxetine for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Generalized Anxiety Disorder Paroxetine tablets, USP are indicated for the treatment of Generalized Anxiety Disorder (GAD), as defined in DSM-IV. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The efficacy of paroxetine in the treatment of GAD was established in two 8-week placebo-controlled trials in adults with GAD. Paroxetine has not been studied in children or adolescents with Generalized Anxiety Disorder (see CLINICAL PHARMACOLOGY: Clinical Trials ). Generalized Anxiety Disorder (DSM-IV) is characterized by excessive anxiety and worry (apprehensive expectation) that is persistent for at least 6 months and which the person finds difficult to control. It must be associated with at least 3 of the following 6 symptoms: Restlessness or feeling keyed up or on edge, being easily fatigued, difficulty concentrating or mind going blank, irritability, muscle tension, sleep disturbance. The efficacy of paroxetine in maintaining a response in patients with Generalized Anxiety Disorder, who responded during an 8-week acute treatment phase while taking paroxetine and were then observed for relapse during a period of up to 24 weeks, was demonstrated in a placebo-controlled trial (see CLINICAL PHARMACOLOGY: Clinical Trials ). Nevertheless, the physician who elects to use paroxetine for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ). Posttraumatic Stress Disorder Paroxetine tablets are indicated for the treatment of Posttraumatic Stress Disorder (PTSD). The efficacy of paroxetine in the treatment of PTSD was established in two 12-week placebo-controlled trials in adults with PTSD (DSM-IV) (see CLINICAL PHARMACOLOGY: Clinical Trials ). PTSD, as defined by DSM-IV, requires exposure to a traumatic event that involved actual or threatened death or serious injury, or threat to the physical integrity of self or others, and a response that involves intense fear, helplessness, or horror. Symptoms that occur as a result of exposure to the traumatic event include reexperiencing of the event in the form of intrusive thoughts, flashbacks, or dreams, and intense psychological distress and physiological reactivity on exposure to cues to the event; avoidance of situations reminiscent of the traumatic event, inability to recall details of the event, and/or numbing of general responsiveness manifested as diminished interest in significant activities, estrangement from others, restricted range of affect, or sense of foreshortened future; and symptoms of autonomic arousal including hypervigilance, exaggerated startle response, sleep disturbance, impaired concentration, and irritability or outbursts of anger. A PTSD diagnosis requires that the symptoms are present for at least a month and that they cause clinically significant distress or impairment in social, occupational, or other important areas of functioning. The efficacy of paroxetine in longer-term treatment of PTSD, i.e., for more than 12 weeks, has not been systematically evaluated in placebo-controlled trials. Therefore, the physician who elects to prescribe paroxetine for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient (see DOSAGE AND ADMINISTRATION ).|[PMDA] Drugs with a new additional indication and a new dosage for the treatment of posttraumatic stress disorder. uuid:9714aa5e-a8fd-4b58-8e9e-17f06a3664a0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:70746 biolink:treats HP:0002625 PMID:41385096 "[{""id"":""uuid:a9aa6b9b-6ca9-4a66-818e-5bc0850fd5bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b4e8bf9d-20ee-450e-9704-9b7634a6c919"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:94f3e1f5-181c-4d98-91c3-6eb579903295"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRADAXA is a direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation ( 1.1 ) For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for 5-10 days ( 1.2 ) To reduce the risk of recurrence of DVT and PE in patients who have been previously treated ( 1.3 ) For the prophylaxis of DVT and PE in patients who have undergone hip replacement surgery ( 1.4 )|[EMA] Pradaxa 75 mgPrimary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.Pradaxa 110 mgPrimary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischemic attack (TIA); age ≥ 75 years; heart failure (NYHA Class ≥ II); diabetes mellitus; hypertension.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.Pradaxa 150 mgPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischemic attack (TIA); age ≥ 75 years; heart failure (NYHA Class ≥ II); diabetes mellitus; hypertension.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. uuid:34562b50-4dd3-4784-99e3-5f32d54244b1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:70746 biolink:treats MONDO:0005279 PMID:41385096 "[{""id"":""uuid:9b88b5a0-27e7-4095-ab6c-d5a423d3ddb0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:841d5e12-fcf8-4838-a4f8-7d8d3055b2bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e9bf5816-e934-436b-a55f-955cbc6d0378"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRADAXA is a direct thrombin inhibitor indicated: To reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation ( 1.1 ) For the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for 5-10 days ( 1.2 ) To reduce the risk of recurrence of DVT and PE in patients who have been previously treated ( 1.3 ) For the prophylaxis of DVT and PE in patients who have undergone hip replacement surgery ( 1.4 )|[EMA] Pradaxa 75 mgPrimary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.Pradaxa 110 mgPrimary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischemic attack (TIA); age ≥ 75 years; heart failure (NYHA Class ≥ II); diabetes mellitus; hypertension.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.Pradaxa 150 mgPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischemic attack (TIA); age ≥ 75 years; heart failure (NYHA Class ≥ II); diabetes mellitus; hypertension.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. uuid:e2cf3ed9-b212-4f89-ab7e-1ccd3ee8f479 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27504 biolink:treats MONDO:0005036 PMID:41385096 "[{""id"":""uuid:a0d4f5a3-35d1-4107-ac25-32beead77f18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:19c725da-f9e0-4a37-b3b8-90ce7275caac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mitomycin for Injection is not recommended as single-agent, primary therapy. It has been shown to be useful in the therapy of disseminated adenocarcinoma of the stomach or pancreas in proven combinations with other approved chemotherapeutic agents and as palliative treatment when other modalities have failed. Mitomycin is not recommended to replace appropriate surgery and/or radiotherapy. uuid:911ab7f8-fec9-4ca7-9a10-7c3ceffcd21c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27504 biolink:treats MONDO:0006047 PMID:41385096 "[{""id"":""uuid:c0ee8e1f-ede9-4d98-95e9-9681cbf40f29"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:082fcac1-4a25-43a8-8cfa-38f8bf3f093f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mitomycin for Injection is not recommended as single-agent, primary therapy. It has been shown to be useful in the therapy of disseminated adenocarcinoma of the stomach or pancreas in proven combinations with other approved chemotherapeutic agents and as palliative treatment when other modalities have failed. Mitomycin is not recommended to replace appropriate surgery and/or radiotherapy. uuid:48b89b29-37f5-486a-9c6e-221cccbf6996 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3654 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:55b8dec5-1293-4451-ba78-7018e92459bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3053e158-3797-4a5b-afd8-0691ad62004a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] THALITONE is a thiazide-like diuretic indicated: • For the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions (1.1). • as adjunctive therapy in edema associated with heart failure, cirrhosis of the liver, and renal disease, including nephrotic syndrome (1.2). uuid:2855ec91-8f49-40fb-9a25-3f650a3feaef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3654 biolink:treats MONDO:0005240 PMID:41385096 "[{""id"":""uuid:3ab340f3-1b32-4866-a0eb-0d9a58128c7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:80a1513d-58bf-43f0-a613-5c61adbf2f2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] THALITONE is a thiazide-like diuretic indicated: • For the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions (1.1). • as adjunctive therapy in edema associated with heart failure, cirrhosis of the liver, and renal disease, including nephrotic syndrome (1.2). uuid:a69d418f-a802-4792-8b66-07129faf5e2b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7936 biolink:treats UMLS:C5442256 PMID:41385096 "[{""id"":""uuid:e8168e64-bf5d-4cbf-8498-dda87d8a7d60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:85912f07-80bc-487c-9fef-d310d8eafd7c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Paroxetine Capsules are indicated for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause. Limitation of Use : Paroxetine Capsules are not indicated for the treatment of any psychiatric condition. Paroxetine Capsules contain a lower dose of paroxetine than that used to treat depression, obsessive compulsive disorder, panic disorder, generalized anxiety disorder, social anxiety disorder, and post-traumatic stress disorder. The safety and efficacy of this lower dose of paroxetine in Paroxetine Capsules have not been established for any psychiatric condition. Patients who require paroxetine for treatment of a psychiatric condition should discontinue Paroxetine Capsules and initiate a paroxetine-containing medication that is indicated for such use. uuid:dd12b659-fd95-4e55-b9e0-15553941ba46 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:35828 biolink:treats MONDO:0012883 PMID:41385096 "[{""id"":""uuid:1837430e-ab29-497a-a8fa-297fe28774fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2a4636c4-6eae-4d0e-b25a-b6e1e8b577af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Arsenic Trioxide Injection is an arsenical indicated: For induction of remission and consolidation in patients with APL who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression. ( 1.2 ) uuid:2d3c5bac-47ce-4c52-a3b2-ddfa3a9401c1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:131512 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:3d412119-1d19-4cfa-a2ab-e9da5ab26db6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fa7d235c-d601-4169-bd3e-9b0e6553f939"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tranylcypromine tablets are indicated for the treatment of major depressive disorder (MDD) in adult patients who have not responded adequately to other antidepressants. Tranylcypromine tablets are not indicated for the initial treatment of MDD due to the potential for serious adverse reactions and drug interactions, and the need for dietary restrictions [see Contraindications (4), Warnings and Precautions (5), and Drug Interactions (7)] . uuid:3e4afdd2-9c9b-412c-9d69-453eff854ddb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:375719 biolink:treats HP:0012735 PMID:41385096 "[{""id"":""uuid:ffdee321-ad7d-408e-9f55-d7cff9099654"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:74800ad4-e1ea-4dcb-a1c7-ce457b42ed0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Promethazine HCl and Codeine Phosphate Oral Solution is indicated for the temporary relief of coughs and upper respiratory symptoms associated with allergy or the common cold in patients 18 years of age and older. Important Limitations of Use Not indicated for pediatric patients under 18 years of age [see Use in Specific Populations (8.4) ]. Contraindicated in pediatric patients under 12 years of age [see Contraindications (4) , Use in Specific Populations (8.4) ]. Contraindicated in pediatric patients 12 to 18 years of age after tonsillectomy or adenoidectomy [see Contraindications (4) , Use in Specific Populations (8.4) ]. Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see Warnings and Precautions (5.1) ], reserve Promethazine HCl and Codeine Phosphate Oral Solution for use in adult patients for whom the benefits of cough suppression are expected to outweigh the risks, and in whom an adequate assessment of the etiology of the cough has been made. uuid:1c81a4b5-2675-4635-b206-b765131fc72b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:393355 biolink:treats UMLS:C0406317 PMID:41385096 "[{""id"":""uuid:63816589-d079-4dca-a6a8-81334f6cf9a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:30d55f1b-c83a-473a-a054-747c5fc9fa16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Taclonex ® Topical Suspension is indicated for the topical treatment of plaque psoriasis of the scalp and body in patients 12 years and older. uuid:31846ec3-687a-4796-9712-e54a68850210 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17439 biolink:treats UMLS:C2959722 PMID:41385096 "[{""id"":""uuid:8251fa1f-5651-47f8-94ef-2b579c784c83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6139b9e6-2e43-463a-b812-635952a636f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyanocobalamin is indicated for Vitamin B 12 deficiencies due to malabsorption which may be associated with the following conditions: Addisonian (pernicious) anemia Gastrointestinal pathology, dysfunction, or surgery, including gluten enteropathy or sprue, small bowel bacterial overgrowth, total or partial gastrectomy Fish tapeworm infestation Malignancy of pancreas or bowel Folic acid deficiency It may be possible to treat the underlying disease by surgical correction of anatomic lesions leading to small bowel bacterial overgrowth, expulsion of fish tapeworm, discontinuation of drugs leading to vitamin malabsorption (see Drug/Laboratory Test Interactions ), use of a gluten-free diet in nontropical sprue, or administration of antibiotics in tropical sprue. Such measures remove the need for long-term administration of cyanocobalamin. Requirements of Vitamin B 12 in excess of normal (due to pregnancy, thyrotoxicosis, hemolytic anemia, hemorrhage, malignancy, hepatic and renal disease) can usually be met with oral supplementation. Cyanocobalamin injection is also suitable for the Vitamin B 12 absorption test (Schilling test). uuid:2b9bd8bf-c634-4beb-8aef-261896781a59 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:167450 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:9ca39cac-2289-4a9f-a18d-757e0b113e1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:734a12dc-e37e-4ee3-9765-a3b1f4d3f727"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dimethyl fumarate delayed-release capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. uuid:7e50aff4-8312-40e9-bae9-6b5500fb884b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:167450 biolink:treats UMLS:C2921627 PMID:41385096 "[{""id"":""uuid:a19fd3d7-5c1a-4282-ac4a-f06e233b222f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b19159f8-56a5-41ce-b06a-6a61850a9827"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dimethyl fumarate delayed-release capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. uuid:f393412e-e325-4eb3-b2a7-d6eba6ae8060 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:167450 biolink:treats MONDO:0000450 PMID:41385096 "[{""id"":""uuid:e4738163-bbb7-462e-9b39-71c41f6b16bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:986fa9a0-6a08-4789-aeab-749dabe850dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dimethyl fumarate delayed-release capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. uuid:a8d7dcf5-ecfc-4e1b-b6dd-223d29904359 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:187893 biolink:treats MONDO:0011267 PMID:41385096 "[{""id"":""uuid:32a7514f-3d0b-421a-8958-18b059a452af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8cb760aa-6da9-4873-8b30-f5278caa5cde"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Baclofen injection (intrathecal) is indicated for use in the management of severe spasticity. Patients should first respond to a screening dose of intrathecal baclofen prior to consideration for long term infusion via an implantable pump. For spasticity of spinal cord origin, chronic infusion of baclofen injection (intrathecal) via an implantable pump should be reserved for patients unresponsive to oral baclofen therapy, or those who experience intolerable CNS side effects at effective doses. Patients with spasticity due to traumatic brain injury should wait at least one year after the injury before consideration of long term intrathecal baclofen therapy. Baclofen injection (intrathecal) is intended for use by the intrathecal route in single bolus test doses (via spinal catheter or lumbar puncture) and, for chronic use, only in implantable pumps approved by the FDA specifically for the administration of baclofen injection (intrathecal) into the intrathecal space. uuid:06e33ef2-e070-40be-b772-6c043fe6f115 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135929 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:36e82961-6f0d-4034-b2b8-fe03645525ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8ff47146-fbc4-4c04-9548-5080db4dcaf4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Silodosin capsule, a selective alpha-1 adrenergic receptor antagonist, is indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) [see CLINICAL STUDIES (14)] . Silodosin capsule is not indicated for the treatment of hypertension. uuid:cbc8bb76-f94a-431a-ae65-9d49c34dc9c1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28939 biolink:treats MONDO:0005359 PMID:41385096 "[{""id"":""uuid:08d7d824-0077-47ce-8aee-cd8ff3a53cb7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cb3c8e4c-6c4d-4a62-a447-fd0d5463c898"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acetylcysteine injection is indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in patients with acute ingestion or from repeated supratherapeutic ingestion (RSI). uuid:aa3f447a-f612-42a8-9509-4f8a8a5a9609 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5108 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:2713ff49-163b-49ae-9f96-159365bb626f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3f555112-04cb-47d1-8c0d-eb08e88d12cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluocinolone acetonide topical oil is a corticosteroid indicated for the topical treatment of atopic dermatitis in adult patients ( 1.1 ) topical treatment of moderate to severe atopic dermatitis in pediatric patients 3 months and older for up to 4 weeks ( 1.2 ) Limitations of Use: Apply the least amount to cover affected areas. Discontinue when disease is controlled. ( 1.3 ) Do not use in the diaper area. ( 1.3 ) Do not use on the face, axillae, or groin. ( 1.3 , 6.2 , 8.4 ) uuid:ad3b997a-b466-4b0c-867c-a4900cb65cb3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28787 biolink:treats UMLS:C3661921 PMID:41385096 "[{""id"":""uuid:8a24c233-5e6e-48b0-850e-ad520a8e5612"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4825ade0-31c7-4dd6-a1f9-168fceb4f829"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nitroglycerin Injection is indicated for treatment of peri-operative hypertension; for control of congestive heart failure in the setting of acute myocardial infarction; for treatment of angina pectoris in patients who have not responded to sublingual nitroglycerin and β -blockers; and for induction of intraoperative hypotension. uuid:d1a75f2c-a71d-40b0-b2e3-37c2ed6d12ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28787 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:109a5a52-f7b4-4433-a32b-0a91143ce2bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:56c126bb-79b9-4e18-a948-a7f130aba9af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nitroglycerin Injection is indicated for treatment of peri-operative hypertension; for control of congestive heart failure in the setting of acute myocardial infarction; for treatment of angina pectoris in patients who have not responded to sublingual nitroglycerin and β -blockers; and for induction of intraoperative hypotension. uuid:12b45cd7-e2fb-460b-beba-1ab558b4c10f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28787 biolink:treats MONDO:0004781 PMID:41385096 "[{""id"":""uuid:a8fbd4fe-9358-434a-86f8-cbbc6f1f2053"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b441f28a-e9c1-4ac0-8a0c-b347693226d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nitroglycerin Injection is indicated for treatment of peri-operative hypertension; for control of congestive heart failure in the setting of acute myocardial infarction; for treatment of angina pectoris in patients who have not responded to sublingual nitroglycerin and β -blockers; and for induction of intraoperative hypotension. uuid:93e8b963-6248-4619-a673-0402490c7750 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85990 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:cf042f3d-c1ce-4738-b6b3-90b702f317d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ba4bd3f5-c33e-4139-ad56-a44fd4b7c50c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d83cd4cf-75ef-4197-8511-d07370079867"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:8d099a08-b357-4e94-bd9d-bd114b7e8015"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FARYDAK, a histone deacetylase inhibitor, in combination with bortezomib and dexamethasone, is indicated for the treatment of patients with multiple myeloma who have received at least 2 prior regimens, including bortezomib and an immunomodulatory agent. This indication is approved under accelerated approval based on progression free survival [see Clinical Studies ( 14.1 )] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.|[EMA] Farydak, in combination with bortezomib and dexamethasone, is indicated for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent.Farydak, in combination with bortezomib and dexamethasone, is indicated for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent.|[PMDA] Drugs with a new active ingredient indicated for the treatment of relapsed or refractory multiple myeloma. [Orphan drug] uuid:1777371e-ace7-4875-9ee8-c47365775d32 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18367 biolink:treats MONDO:0000313 PMID:41385096 "[{""id"":""uuid:ec914651-7572-4770-8cd8-46b11c0aee53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c07b5fe8-a60d-4b00-8eba-75dc7c410e88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Phosphates Injection, USP is indicated as a source of phosphate, for addition to large volume intravenous fluids, to prevent or correct hypophosphatemia in patients with restricted or no oral intake. It is also useful as an additive for preparing specific parenteral fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions. The concomitant amount of sodium (4 mEq/mL) must be calculated into total electrolyte dose of such prepared solutions. uuid:c99aac04-a2b5-41ec-bcdd-19438ea9d3c7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16684 biolink:treats UMLS:C0344132 PMID:41385096 "[{""id"":""uuid:66aad496-55ae-45c9-be6c-edb72d7747ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1a14ab45-10cf-415b-8280-d40503e79d3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atropine is indicated for temporary blockade of severe or life threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus, carbamate, or muscarinic mushroom poisoning, and to treat symptomatic bradycardia. uuid:5b61a9a4-342d-4b43-b0e8-735d55f696ac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16684 biolink:treats UMLS:C0026865 PMID:41385096 "[{""id"":""uuid:9ccbddc1-004b-4f6b-a27a-767f77560985"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d5cdd188-d351-4e8e-96f8-9df4c42b8334"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atropine is indicated for temporary blockade of severe or life threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus, carbamate, or muscarinic mushroom poisoning, and to treat symptomatic bradycardia. uuid:2f5b136f-a20e-49d9-8f55-31c712a64da9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2950 biolink:treats MONDO:0024332 PMID:41385096 "[{""id"":""uuid:bf79c267-749f-47d1-8836-24162aaf092a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:24b96646-9484-4017-8744-a40bd29d92a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azelastine hydrochloride nasal spray is an H 1 -receptor antagonist indicated for the relief of the symptoms of: Seasonal allergic rhinitis in patients 6 years of age and older. ( 1.1 ) Perennial allergic rhinitis in patients 6 years of age and older. ( 1.1 ) uuid:e2cbc7af-ad77-4e8d-a541-9963ea24598f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31485 biolink:treats MONDO:0006651 PMID:41385096 "[{""id"":""uuid:6bfdaa14-5c03-4c1a-93ed-3532a298a33e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5f2f27a2-78e4-458c-bc16-2f3a4f6d84e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Difluprednate ophthalmic emulsion is a topical corticosteroid that is indicated for: The treatment of inflammation and pain associated with ocular surgery ( 1.1 ) The treatment of endogenous anterior uveitis ( 1.2 ) uuid:8d99c728-be89-41e8-9c21-62378a489fde biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9570 biolink:treats MONDO:0004638 PMID:41385096 "[{""id"":""uuid:e98cdffa-b1a8-42bc-a78c-bc3e5fdb13e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:13dee3ca-d3af-48c6-899a-e518ee54c525"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thiotepa for Injection has been tried with varying results in the palliation of a wide variety of neoplastic diseases. However, the most consistent results have been seen in the following tumors: Adenocarcinoma of the breast. Adenocarcinoma of the ovary. For controlling intracavitary effusions secondary to diffuse or localized neoplastic diseases of various serosal cavities. For the treatment of superficial papillary carcinoma of the urinary bladder. While now largely superseded by other treatments, Thiotepa for Injection has been effective against other lymphomas, such as lymphosarcoma and Hodgkin's disease. uuid:5ec2314e-18c3-4f4d-96f2-3a02de96e99e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9570 biolink:treats MONDO:0009348 PMID:41385096 "[{""id"":""uuid:774dbd72-5414-4fac-b0a9-859749bc262e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8d3706ce-e959-4210-9ce3-d889d3007bf3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thiotepa for Injection has been tried with varying results in the palliation of a wide variety of neoplastic diseases. However, the most consistent results have been seen in the following tumors: Adenocarcinoma of the breast. Adenocarcinoma of the ovary. For controlling intracavitary effusions secondary to diffuse or localized neoplastic diseases of various serosal cavities. For the treatment of superficial papillary carcinoma of the urinary bladder. While now largely superseded by other treatments, Thiotepa for Injection has been effective against other lymphomas, such as lymphosarcoma and Hodgkin's disease. uuid:63b97655-fdd1-4f1f-a105-adcca8acb2e3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46345 biolink:treats MONDO:0005008 PMID:41385096 "[{""id"":""uuid:02d6642a-f530-4378-8e69-674ab6f4dd1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1e661230-03bc-4729-8f48-f6ac69b2bd3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluorouracil is indicated for the treatment of patients with: 1.1 Adenocarcinoma of the Colon and Rectum 1.2 Adenocarcinoma of the Breast 1.3 Gastric Adenocarcinoma 1.4 Pancreatic Adenocarcinoma uuid:d51fb33f-5490-4142-9ab4-ac79953ac8ef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46345 biolink:treats MONDO:0004988 PMID:41385096 "[{""id"":""uuid:698b89ed-0bf0-427d-ae7c-393d56047153"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3a09d8ce-9431-4f77-9cf6-eaaf53c67310"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluorouracil is indicated for the treatment of patients with: 1.1 Adenocarcinoma of the Colon and Rectum 1.2 Adenocarcinoma of the Breast 1.3 Gastric Adenocarcinoma 1.4 Pancreatic Adenocarcinoma uuid:0885c6f0-1ff4-4e9c-a1e5-3f31ce6adad0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46345 biolink:treats MONDO:0005036 PMID:41385096 "[{""id"":""uuid:452d97b3-e94c-40d5-b1e9-e3d0033c3a5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:737b115d-332c-4be2-98bf-4b796cb782cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluorouracil is indicated for the treatment of patients with: 1.1 Adenocarcinoma of the Colon and Rectum 1.2 Adenocarcinoma of the Breast 1.3 Gastric Adenocarcinoma 1.4 Pancreatic Adenocarcinoma uuid:e64eb356-2aa7-47a6-b630-42e43dbbe714 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46345 biolink:treats MONDO:0006047 PMID:41385096 "[{""id"":""uuid:2ca696fa-d8bc-4454-b71a-7304e17f532d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1655e559-6c29-436a-8403-274aecef7972"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluorouracil is indicated for the treatment of patients with: 1.1 Adenocarcinoma of the Colon and Rectum 1.2 Adenocarcinoma of the Breast 1.3 Gastric Adenocarcinoma 1.4 Pancreatic Adenocarcinoma uuid:9a9e5722-fcb4-4965-afa7-c4140b94f527 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27363 biolink:treats EFO:1000003 PMID:41385096 "[{""id"":""uuid:a309554b-4e37-4db1-931a-5b17a4d9bc78"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a78f0914-68b0-43d4-8c2f-11ea55b558c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Zinc Chloride Injection, USP, 1 mg/mL is indicated for use as a supplement to intravenous solutions given for TPN. Administration helps to maintain zinc serum levels and to prevent depletion of endogenous stores, and subsequent deficiency symptoms. uuid:5ba5d8b3-cf17-4703-a96d-56fc964c74c1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3176 biolink:treats MONDO:0006875 PMID:41385096 "[{""id"":""uuid:68b2b22a-5f29-4b6d-a0e9-a164f934f0a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c0bdadf7-3437-44fe-90cb-ea7b970da28a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e0f9c607-6b72-478c-a91c-a33b2c0a3c04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/azopt""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Brinzolamide ophthalmic suspension is a carbonic anhydrase inhibitor indicated in the treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma.|[EMA] Azopt is indicated to decrease elevated intraocular pressure in:ocular hypertension;open-angle glaucomaas monotherapy in adult patients unresponsive to beta-blockers or in adult patients in whom beta-blockers are contraindicated, or as adjunctive therapy to beta-blockers or prostaglandin analogues. uuid:73e93bee-eee4-4504-87f9-2de648af2967 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3176 biolink:treats MONDO:0005338 PMID:41385096 "[{""id"":""uuid:0dc057d5-1504-4d82-974c-78316eedead5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a473dd86-2e1d-4704-aec4-053d114f80a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9a99e974-28af-498b-a183-500ee55efa02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/azopt""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Brinzolamide ophthalmic suspension is a carbonic anhydrase inhibitor indicated in the treatment of elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma.|[EMA] Azopt is indicated to decrease elevated intraocular pressure in:ocular hypertension;open-angle glaucomaas monotherapy in adult patients unresponsive to beta-blockers or in adult patients in whom beta-blockers are contraindicated, or as adjunctive therapy to beta-blockers or prostaglandin analogues. uuid:f81f6f2a-cbe8-42c7-8d5c-41f883df1c66 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71253 biolink:treats MONDO:0024612 PMID:41385096 "[{""id"":""uuid:c5cbb94a-4076-479b-a6ce-52bf70f19193"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c95be2a0-ca9b-4baa-b27e-4f20c936f787"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Asenapine sublingual tablets are indicated for: Schizophrenia in adults [see Clinical Studies (14.1) ] Bipolar I disorder [see Clinical Studies (14.2) ] Acute monotherapy of manic or mixed episodes, in adults and pediatric patients 10 to 17 years of age Adjunctive treatment to lithium or valproate in adults Maintenance monotherapy treatment in adults uuid:e457f4db-21d2-4c3a-92ff-24ddacdda0b2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4450 biolink:treats MONDO:0003014 PMID:41385096 "[{""id"":""uuid:74a1a12b-fe27-4294-98c6-a83d31356e1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:22905a8f-5cac-4eb4-a33a-19aef7c96d88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Desmopressin nasal spray solution is indicated as antidiuretic replacement therapy in the management of central diabetes insipidus in adults and pediatric patients 4 years of age and older. Limitations of Use: Desmopressin nasal spray solution is not indicated for: • Treatment of nephrogenic diabetes insipidus, • Treatment of primary nocturnal enuresis [ see Warnings and Precautions (5.1) ], • Use in patients with conditions that compromise the intranasal route of administration (e.g., severe nasal congestion and blockage, nasal mucosa atrophy, severe atrophic rhinitis, recent nasal surgery such as transsphenoidal hypophysectomy) [see Warnings and Precautions (5.2) ], • Use in patients with an impaired level of consciousness, • Use in patients requiring doses less than 10 mcg or doses that are not multiples of 10 mcg [see Dosage Forms and Strengths (3)]. uuid:5b675eee-26d2-4e02-ad98-695b2d7294ff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4450 biolink:treats UMLS:C0919923 PMID:41385096 "[{""id"":""uuid:170720db-5602-4cf4-b81d-24654c097166"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:253ec8d9-5a11-4555-acf9-84eaf96af409"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Desmopressin nasal spray solution is indicated as antidiuretic replacement therapy in the management of central diabetes insipidus in adults and pediatric patients 4 years of age and older. Limitations of Use: Desmopressin nasal spray solution is not indicated for: • Treatment of nephrogenic diabetes insipidus, • Treatment of primary nocturnal enuresis [ see Warnings and Precautions (5.1) ], • Use in patients with conditions that compromise the intranasal route of administration (e.g., severe nasal congestion and blockage, nasal mucosa atrophy, severe atrophic rhinitis, recent nasal surgery such as transsphenoidal hypophysectomy) [see Warnings and Precautions (5.2) ], • Use in patients with an impaired level of consciousness, • Use in patients requiring doses less than 10 mcg or doses that are not multiples of 10 mcg [see Dosage Forms and Strengths (3)]. uuid:513065ec-52b9-446a-b718-2b216236e4ea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28918 biolink:treats MONDO:0001881 PMID:41385096 "[{""id"":""uuid:2be2eb99-e782-4a85-970b-3d390fa07dd6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c88371f5-b82d-4b5c-adb7-c308320a85e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Epinephrine is a non-selective alpha and beta adrenergic agonist indicated: • To increase mean arterial blood pressure in adult patients with hypotension associated with septic shock. ( 1.1 ) • For emergency treatment of allergic reactions (Type 1), including anaphylaxis. ( 1.2 ) • For induction and maintenance of mydriasis during intraocular surgery. ( 1.3 ) uuid:bebc1b56-710f-41d1-b373-e8aa7ab98104 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4031 biolink:treats UMLS:C0238217 PMID:41385096 "[{""id"":""uuid:58e77334-b646-4ef8-8337-0168293f195b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ee8c3255-c8ca-4f58-b7c7-cadb76fe205e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclosporine capsules, USP [MODIFIED] and cyclosporine oral solution, USP [MODIFIED] are indicated for the prophylaxis of organ rejection in kidney, liver, and heart allogeneic transplants. Cyclosporine capsules, USP [MODIFIED] and cyclosporine oral solution, USP [MODIFIED] have been used in combination with azathioprine and corticosteroids. uuid:8615131e-6c61-4d1e-b9b4-5a629ae0010a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4031 biolink:treats UMLS:C0340530 PMID:41385096 "[{""id"":""uuid:81290117-1250-41b9-b68f-2b0a08abcb28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2ceb679a-01cc-4fad-b352-c9b0d1c90adb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclosporine capsules, USP [MODIFIED] and cyclosporine oral solution, USP [MODIFIED] are indicated for the prophylaxis of organ rejection in kidney, liver, and heart allogeneic transplants. Cyclosporine capsules, USP [MODIFIED] and cyclosporine oral solution, USP [MODIFIED] have been used in combination with azathioprine and corticosteroids. uuid:779bc2c0-033a-4202-80e3-5f347b087fa1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3SY5LH9PMK biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:61f8ea82-157a-4327-add3-2b398f67fa19"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d7587030-99f6-4769-8c02-77cd2013ebb4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Benazepril hydrochloride tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. It may be used alone or in combination with thiazide diuretics. uuid:38f97fac-57a5-439e-9776-2e821acf54a5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3SY5LH9PMK biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:a4275a10-6c78-4736-b173-a5ed2d2cecd2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6382c6ea-8638-4874-91f1-46e867eda8e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Benazepril hydrochloride tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. It may be used alone or in combination with thiazide diuretics. uuid:31f35dce-6587-4e80-9319-83954e9b1a65 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3SY5LH9PMK biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:7865c7ef-d2fd-4be6-a591-efdaef66ddea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:29f26318-fb4c-43e8-85cf-13e0c0a78d5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Benazepril hydrochloride tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. It may be used alone or in combination with thiazide diuretics. uuid:8a2445fe-77f4-431d-99b8-2973e0e9bcc8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3SY5LH9PMK biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:80bb5da0-1dab-4e03-b81c-a597fac8f50c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:54689efa-8b38-41b0-97ae-9dbfff33d61d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Benazepril hydrochloride tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. It may be used alone or in combination with thiazide diuretics. uuid:3185777d-a0d4-49a9-a3ba-af82919bf610 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3SY5LH9PMK biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:7c66c2f1-bd4c-4beb-86c4-b99d2afcbdaf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e5c7ff0b-ddba-467e-9785-2c21c95972db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Benazepril hydrochloride tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. It may be used alone or in combination with thiazide diuretics. uuid:77719bfa-0ef8-4960-835b-692c658bbf8d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:46878853 biolink:treats MONDO:0007788 PMID:41385096 "[{""id"":""uuid:88a3ec90-a9db-489d-8d50-39a2fed6015b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:04203cc8-f5c6-4d8b-b322-018e162c295b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment of Hypercholesterolemia Fenofibrate capsules are indicated as adjunctive therapy to diet for the reduction of LDL-C, Total-C, Triglycerides and Apo B in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate (see National Cholesterol Education Program [NCEP] Treatment Guidelines, below). Treatment of Hypertriglyceridemia Fenofibrate capsules are also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually reduce fasting triglycerides and eliminate chylomicronemia thereby obviating the need for pharmacologic intervention. Markedly elevated levels of serum triglycerides (e.g. > 2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate capsules therapy on reducing this risk has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV and V hyperlipoproteinemia 2 . The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcoholic intake may be important factors in hypertriglyceridemia and should be addressed prior to any drug therapy. Physical exercise can be an important ancillary measure. Diseases contributory to hyperlipidemia, such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy, like thiazide diuretics and beta-blockers, is sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of the specific etiologic agent may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with non-drug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet (See WARNINGS and PRECAUTIONS ). Fredrickson Classification of Hyperlipoproteinemias C = cholesterol TG = triglycerides LDL = low density lipoprotein VLDL = very low density lipoprotein IDL = intermediate density lipoprotein Lipid Elevation Type Lipoprotein Elevated Major Minor I (rare) chylomicrons TG ↑ ↔ C IIa LDL C — IIb LDL, VLDL C TG III (rare) IDL C, TG — IV VLDL TG ↑ ↔ C V (rare) chylomicrons, VLDL TG ↑ ↔ The NCEP Treatment Guidelines a) Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease) b) Other risk factors for coronary heart disease (CHD) include age (males: ≥45 years females: ≥55 years or premature menopause without estrogen replacement therapy); family history of premature CHD, current cigarette smoking; hypertension; confirmed HDL-C is <35 mg/dL (< 0.91 mmol/L), and diabetes mellitus. Subtract 1 risk factor if HDL-C is >60 mg/dL (≥1.6 mmol/L) c) in CHD patients with LDL-C levels 100 to 129 mg/dL the physician should exercise clinical judgment in deciding whether to initiate drug treatment Definite Athlerosclerotic Disease a Two or More Other Risk Factors b LDL-Cholesterol mg/dL (mmol/L) Initiation Level Goal No No ≥ 190 (≥ 4.9) < 160 (< 4.1) No Yes ≥ 160 (≥ 4.1) < 130 (< 3.4) Yes Yes or No ≥ 130 c (≥ 3.4) < 100 (< 2.6) uuid:b045ee49-6bae-4580-949e-12d0ba270b66 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:46878853 biolink:treats MONDO:0007762 PMID:41385096 "[{""id"":""uuid:67aaab7e-56e3-4503-8cb2-f1b5f9465c4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:60db7f4f-4a76-4a3d-b3c4-8ae7d84acb72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment of Hypercholesterolemia Fenofibrate capsules are indicated as adjunctive therapy to diet for the reduction of LDL-C, Total-C, Triglycerides and Apo B in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate (see National Cholesterol Education Program [NCEP] Treatment Guidelines, below). Treatment of Hypertriglyceridemia Fenofibrate capsules are also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually reduce fasting triglycerides and eliminate chylomicronemia thereby obviating the need for pharmacologic intervention. Markedly elevated levels of serum triglycerides (e.g. > 2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate capsules therapy on reducing this risk has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV and V hyperlipoproteinemia 2 . The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcoholic intake may be important factors in hypertriglyceridemia and should be addressed prior to any drug therapy. Physical exercise can be an important ancillary measure. Diseases contributory to hyperlipidemia, such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy, like thiazide diuretics and beta-blockers, is sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of the specific etiologic agent may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with non-drug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet (See WARNINGS and PRECAUTIONS ). Fredrickson Classification of Hyperlipoproteinemias C = cholesterol TG = triglycerides LDL = low density lipoprotein VLDL = very low density lipoprotein IDL = intermediate density lipoprotein Lipid Elevation Type Lipoprotein Elevated Major Minor I (rare) chylomicrons TG ↑ ↔ C IIa LDL C — IIb LDL, VLDL C TG III (rare) IDL C, TG — IV VLDL TG ↑ ↔ C V (rare) chylomicrons, VLDL TG ↑ ↔ The NCEP Treatment Guidelines a) Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease) b) Other risk factors for coronary heart disease (CHD) include age (males: ≥45 years females: ≥55 years or premature menopause without estrogen replacement therapy); family history of premature CHD, current cigarette smoking; hypertension; confirmed HDL-C is <35 mg/dL (< 0.91 mmol/L), and diabetes mellitus. Subtract 1 risk factor if HDL-C is >60 mg/dL (≥1.6 mmol/L) c) in CHD patients with LDL-C levels 100 to 129 mg/dL the physician should exercise clinical judgment in deciding whether to initiate drug treatment Definite Athlerosclerotic Disease a Two or More Other Risk Factors b LDL-Cholesterol mg/dL (mmol/L) Initiation Level Goal No No ≥ 190 (≥ 4.9) < 160 (< 4.1) No Yes ≥ 160 (≥ 4.1) < 130 (< 3.4) Yes Yes or No ≥ 130 c (≥ 3.4) < 100 (< 2.6) uuid:8be4413a-1bde-4806-89f8-994190eeabbb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:46878853 biolink:treats MONDO:0009387 PMID:41385096 "[{""id"":""uuid:32999060-2651-4600-8385-27cd304d36fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0c8d80bc-7b5e-47a2-b892-27969e65a050"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment of Hypercholesterolemia Fenofibrate capsules are indicated as adjunctive therapy to diet for the reduction of LDL-C, Total-C, Triglycerides and Apo B in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate (see National Cholesterol Education Program [NCEP] Treatment Guidelines, below). Treatment of Hypertriglyceridemia Fenofibrate capsules are also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually reduce fasting triglycerides and eliminate chylomicronemia thereby obviating the need for pharmacologic intervention. Markedly elevated levels of serum triglycerides (e.g. > 2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate capsules therapy on reducing this risk has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV and V hyperlipoproteinemia 2 . The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcoholic intake may be important factors in hypertriglyceridemia and should be addressed prior to any drug therapy. Physical exercise can be an important ancillary measure. Diseases contributory to hyperlipidemia, such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy, like thiazide diuretics and beta-blockers, is sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of the specific etiologic agent may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with non-drug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet (See WARNINGS and PRECAUTIONS ). Fredrickson Classification of Hyperlipoproteinemias C = cholesterol TG = triglycerides LDL = low density lipoprotein VLDL = very low density lipoprotein IDL = intermediate density lipoprotein Lipid Elevation Type Lipoprotein Elevated Major Minor I (rare) chylomicrons TG ↑ ↔ C IIa LDL C — IIb LDL, VLDL C TG III (rare) IDL C, TG — IV VLDL TG ↑ ↔ C V (rare) chylomicrons, VLDL TG ↑ ↔ The NCEP Treatment Guidelines a) Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease) b) Other risk factors for coronary heart disease (CHD) include age (males: ≥45 years females: ≥55 years or premature menopause without estrogen replacement therapy); family history of premature CHD, current cigarette smoking; hypertension; confirmed HDL-C is <35 mg/dL (< 0.91 mmol/L), and diabetes mellitus. Subtract 1 risk factor if HDL-C is >60 mg/dL (≥1.6 mmol/L) c) in CHD patients with LDL-C levels 100 to 129 mg/dL the physician should exercise clinical judgment in deciding whether to initiate drug treatment Definite Athlerosclerotic Disease a Two or More Other Risk Factors b LDL-Cholesterol mg/dL (mmol/L) Initiation Level Goal No No ≥ 190 (≥ 4.9) < 160 (< 4.1) No Yes ≥ 160 (≥ 4.1) < 130 (< 3.4) Yes Yes or No ≥ 130 c (≥ 3.4) < 100 (< 2.6) uuid:787ca82d-38c7-4dde-97a5-0ef32f65b92e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:46878853 biolink:treats MONDO:0005294 PMID:41385096 "[{""id"":""uuid:432bb8a0-7549-4aae-bce4-3bf9c2a73c22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a47bd819-5728-4440-8253-24ef6625fd21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment of Hypercholesterolemia Fenofibrate capsules are indicated as adjunctive therapy to diet for the reduction of LDL-C, Total-C, Triglycerides and Apo B in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate (see National Cholesterol Education Program [NCEP] Treatment Guidelines, below). Treatment of Hypertriglyceridemia Fenofibrate capsules are also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually reduce fasting triglycerides and eliminate chylomicronemia thereby obviating the need for pharmacologic intervention. Markedly elevated levels of serum triglycerides (e.g. > 2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate capsules therapy on reducing this risk has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV and V hyperlipoproteinemia 2 . The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcoholic intake may be important factors in hypertriglyceridemia and should be addressed prior to any drug therapy. Physical exercise can be an important ancillary measure. Diseases contributory to hyperlipidemia, such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy, like thiazide diuretics and beta-blockers, is sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of the specific etiologic agent may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with non-drug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet (See WARNINGS and PRECAUTIONS ). Fredrickson Classification of Hyperlipoproteinemias C = cholesterol TG = triglycerides LDL = low density lipoprotein VLDL = very low density lipoprotein IDL = intermediate density lipoprotein Lipid Elevation Type Lipoprotein Elevated Major Minor I (rare) chylomicrons TG ↑ ↔ C IIa LDL C — IIb LDL, VLDL C TG III (rare) IDL C, TG — IV VLDL TG ↑ ↔ C V (rare) chylomicrons, VLDL TG ↑ ↔ The NCEP Treatment Guidelines a) Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease) b) Other risk factors for coronary heart disease (CHD) include age (males: ≥45 years females: ≥55 years or premature menopause without estrogen replacement therapy); family history of premature CHD, current cigarette smoking; hypertension; confirmed HDL-C is <35 mg/dL (< 0.91 mmol/L), and diabetes mellitus. Subtract 1 risk factor if HDL-C is >60 mg/dL (≥1.6 mmol/L) c) in CHD patients with LDL-C levels 100 to 129 mg/dL the physician should exercise clinical judgment in deciding whether to initiate drug treatment Definite Athlerosclerotic Disease a Two or More Other Risk Factors b LDL-Cholesterol mg/dL (mmol/L) Initiation Level Goal No No ≥ 190 (≥ 4.9) < 160 (< 4.1) No Yes ≥ 160 (≥ 4.1) < 130 (< 3.4) Yes Yes or No ≥ 130 c (≥ 3.4) < 100 (< 2.6) uuid:23e87408-06ac-4b3d-b407-ed65e770e9c1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:46878853 biolink:treats MONDO:0005269 PMID:41385096 "[{""id"":""uuid:83d7b79a-fb7d-40af-b5f4-391cea23c59b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c27898c6-f749-46cb-b64c-fb9043f51ec2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment of Hypercholesterolemia Fenofibrate capsules are indicated as adjunctive therapy to diet for the reduction of LDL-C, Total-C, Triglycerides and Apo B in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate (see National Cholesterol Education Program [NCEP] Treatment Guidelines, below). Treatment of Hypertriglyceridemia Fenofibrate capsules are also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually reduce fasting triglycerides and eliminate chylomicronemia thereby obviating the need for pharmacologic intervention. Markedly elevated levels of serum triglycerides (e.g. > 2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate capsules therapy on reducing this risk has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV and V hyperlipoproteinemia 2 . The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcoholic intake may be important factors in hypertriglyceridemia and should be addressed prior to any drug therapy. Physical exercise can be an important ancillary measure. Diseases contributory to hyperlipidemia, such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy, like thiazide diuretics and beta-blockers, is sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of the specific etiologic agent may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with non-drug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet (See WARNINGS and PRECAUTIONS ). Fredrickson Classification of Hyperlipoproteinemias C = cholesterol TG = triglycerides LDL = low density lipoprotein VLDL = very low density lipoprotein IDL = intermediate density lipoprotein Lipid Elevation Type Lipoprotein Elevated Major Minor I (rare) chylomicrons TG ↑ ↔ C IIa LDL C — IIb LDL, VLDL C TG III (rare) IDL C, TG — IV VLDL TG ↑ ↔ C V (rare) chylomicrons, VLDL TG ↑ ↔ The NCEP Treatment Guidelines a) Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease) b) Other risk factors for coronary heart disease (CHD) include age (males: ≥45 years females: ≥55 years or premature menopause without estrogen replacement therapy); family history of premature CHD, current cigarette smoking; hypertension; confirmed HDL-C is <35 mg/dL (< 0.91 mmol/L), and diabetes mellitus. Subtract 1 risk factor if HDL-C is >60 mg/dL (≥1.6 mmol/L) c) in CHD patients with LDL-C levels 100 to 129 mg/dL the physician should exercise clinical judgment in deciding whether to initiate drug treatment Definite Athlerosclerotic Disease a Two or More Other Risk Factors b LDL-Cholesterol mg/dL (mmol/L) Initiation Level Goal No No ≥ 190 (≥ 4.9) < 160 (< 4.1) No Yes ≥ 160 (≥ 4.1) < 130 (< 3.4) Yes Yes or No ≥ 130 c (≥ 3.4) < 100 (< 2.6) uuid:479d9d03-91ab-4141-a116-5ddc20a5bb42 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:46878853 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:5a52677c-59c2-440b-a366-497895faab6c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:913f826a-973b-4f1e-93d0-a387a7c321e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment of Hypercholesterolemia Fenofibrate capsules are indicated as adjunctive therapy to diet for the reduction of LDL-C, Total-C, Triglycerides and Apo B in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate (see National Cholesterol Education Program [NCEP] Treatment Guidelines, below). Treatment of Hypertriglyceridemia Fenofibrate capsules are also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually reduce fasting triglycerides and eliminate chylomicronemia thereby obviating the need for pharmacologic intervention. Markedly elevated levels of serum triglycerides (e.g. > 2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate capsules therapy on reducing this risk has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV and V hyperlipoproteinemia 2 . The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcoholic intake may be important factors in hypertriglyceridemia and should be addressed prior to any drug therapy. Physical exercise can be an important ancillary measure. Diseases contributory to hyperlipidemia, such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy, like thiazide diuretics and beta-blockers, is sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of the specific etiologic agent may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with non-drug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet (See WARNINGS and PRECAUTIONS ). Fredrickson Classification of Hyperlipoproteinemias C = cholesterol TG = triglycerides LDL = low density lipoprotein VLDL = very low density lipoprotein IDL = intermediate density lipoprotein Lipid Elevation Type Lipoprotein Elevated Major Minor I (rare) chylomicrons TG ↑ ↔ C IIa LDL C — IIb LDL, VLDL C TG III (rare) IDL C, TG — IV VLDL TG ↑ ↔ C V (rare) chylomicrons, VLDL TG ↑ ↔ The NCEP Treatment Guidelines a) Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease) b) Other risk factors for coronary heart disease (CHD) include age (males: ≥45 years females: ≥55 years or premature menopause without estrogen replacement therapy); family history of premature CHD, current cigarette smoking; hypertension; confirmed HDL-C is <35 mg/dL (< 0.91 mmol/L), and diabetes mellitus. Subtract 1 risk factor if HDL-C is >60 mg/dL (≥1.6 mmol/L) c) in CHD patients with LDL-C levels 100 to 129 mg/dL the physician should exercise clinical judgment in deciding whether to initiate drug treatment Definite Athlerosclerotic Disease a Two or More Other Risk Factors b LDL-Cholesterol mg/dL (mmol/L) Initiation Level Goal No No ≥ 190 (≥ 4.9) < 160 (< 4.1) No Yes ≥ 160 (≥ 4.1) < 130 (< 3.4) Yes Yes or No ≥ 130 c (≥ 3.4) < 100 (< 2.6) uuid:6faba204-8e78-4374-8ae0-645b21c1321a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28364 biolink:treats MONDO:0005347 PMID:41385096 "[{""id"":""uuid:900c701b-3a02-4a06-81d3-d76cc64b28c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6a37869d-7774-4687-899c-fcc9528a4c9a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Icosapent ethyl capsules are indicated: as an adjunct to diet to reduce TG levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia. Limitations of Use: The effect of icosapent ethyl capsules on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined. uuid:cbbff328-f2ef-4086-a91f-47653833e913 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28364 biolink:treats MONDO:0004982 PMID:41385096 "[{""id"":""uuid:5317c226-1b8b-464c-b407-7e36688848e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b974f499-59d4-4074-a2c4-0df3d8daf55b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Icosapent ethyl capsules are indicated: as an adjunct to diet to reduce TG levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia. Limitations of Use: The effect of icosapent ethyl capsules on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined. uuid:b0cb6561-4940-4216-871a-6c4376af1fa6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27899 biolink:treats MONDO:0005447 PMID:41385096 "[{""id"":""uuid:75643be5-3cd4-4f9c-86b3-b88e70dbcbc7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0af6321c-2fc6-4800-a831-3eae80f938c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cisplatin for injection is a platinum-based drug indicated for the treatment of: • Advanced testicular cancer ( 1.1 ) • Advanced ovarian cancer ( 1.2 ) • Advanced bladder cancer ( 1.3 ) uuid:396d3fae-d43a-402a-ad67-712078236953 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27899 biolink:treats MONDO:0008170 PMID:41385096 "[{""id"":""uuid:afd6bc92-21d9-4179-a7a5-3ac1fce56ab3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d5dcc3c7-2ace-4590-9742-08832ebb299a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cisplatin for injection is a platinum-based drug indicated for the treatment of: • Advanced testicular cancer ( 1.1 ) • Advanced ovarian cancer ( 1.2 ) • Advanced bladder cancer ( 1.3 ) uuid:07826ac8-1e2e-40f4-b5ca-297dfa81ce06 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27899 biolink:treats UMLS:C5554305 PMID:41385096 "[{""id"":""uuid:f3ecd9ab-d554-46a0-8bf1-7d280126c5d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ac383c43-ca87-4f7c-8c6d-bf4b99c26599"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cisplatin for injection is a platinum-based drug indicated for the treatment of: • Advanced testicular cancer ( 1.1 ) • Advanced ovarian cancer ( 1.2 ) • Advanced bladder cancer ( 1.3 ) uuid:3bbb493f-8f71-4dc7-9465-15dfe955b65c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3347 biolink:treats MONDO:0006652 PMID:41385096 "[{""id"":""uuid:5ca4ead4-93da-45b0-891d-43185787a028"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1e1e95d3-33dc-4fde-b240-ebba8c67b11b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Candesartan cilexetil tablets are an angiotensin II receptor blocker (ARB) indicated for: · Treatment of hypertension in adults and children 1 to <17 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions (1.1). · Treatment of heart failure (NYHA class II-IV); candesartan cilexetil tablets reduces cardiovascular death and heart failure hospitalization (1.2). uuid:43005ca3-870a-46d0-9d67-987a04df018b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:474053 biolink:treats MONDO:0021839 PMID:41385096 "[{""id"":""uuid:32645d82-ad1d-4daa-99c0-8e57c71857d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:47a3cf38-a7f5-49cb-a431-84fcbfcd2586"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefazolin for Injection, USP is indicated for the treatment of the following serious infections due to susceptible organisms. Respiratory Tract Infections: Due to S. pneumoniae, Klebsiella species , H. influenzae, S. aureus (penicillin-sensitive and penicillin-resistant), and group A beta-hemolytic streptococci. Injectable benzathine penicillin is considered the drug of choice in treatment and prevention of streptococcal infections, including the prophylaxis of rheumatic fever. Cefazolin for Injection, USP is effective in the eradication of streptococci from the nasopharynx; however, data establishing the efficacy of Cefazolin for Injection, USP in the subsequent prevention of rheumatic fever are not available at present. Urinary Tract Infections: Due to E. coli, P. mirabilis, Klebsiella species, and some strains of enterobacter and enterococci. Skin and Skin Structure Infections: Due to S. aureus (penicillin‑sensitive and penicillin-resistant), group A beta‑hemolytic streptococci, and other strains of streptococci. Biliary Tract Infections: Due to E. coli , various strains of streptococci, P. mirabilis , Klebsiella species, and S. aureus . Bone and Joint Infections: Due to S. aureus . Genital Infections: (i.e., prostatitis, epididymitis) due to E. coli , P. mirabilis , Klebsiella species, and some strains of enterococci. Septicemia: Due to S. pneumoniae , S. aureus (penicillin‑sensitive and penicillin‑resistant), P. mirabilis , E. coli , and Klebsiella species. Endocarditis: Due to S. aureus (penicillin‑sensitive and penicillin‑resistant) and group A beta‑hemolytic streptococci. Perioperative Prophylaxis: The prophylactic administration of Cefazolin for Injection, USP preoperatively, intraoperatively, and postoperatively may reduce the incidence of certain postoperative infections in patients undergoing surgical procedures which are classified as contaminated or potentially contaminated (e.g., vaginal hysterectomy, and cholecystectomy in high‑risk patients such as those older than 70 years, with acute cholecystitis, obstructive jaundice, or common duct bile stones). The perioperative use of Cefazolin for Injection, USP may also be effective in surgical patients in whom infection at the operative site would present a serious risk (e.g., during open‑heart surgery and prosthetic arthroplasty). The prophylactic administration of Cefazolin for Injection, USP should usually be discontinued within a 24‑hour period after the surgical procedure. In surgery where the occurrence of infection may be particularly devastating (e.g., open-heart surgery and prosthetic arthroplasty), the prophylactic administration of Cefazolin for Injection, USP may be continued for 3 to 5 days following the completion of surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism so that appropriate therapy may be instituted. (See DOSAGE AND ADMINISTRATION.) To reduce the development of drug‑resistant bacteria and maintain the effectiveness of Cefazolin for Injection, USP and other antibacterial drugs, Cefazolin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:caafba7d-72a5-46cc-a36f-e6ef32af06d3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:474180 biolink:treats MONDO:0002041 PMID:41385096 "[{""id"":""uuid:567fde62-d015-4fd7-86b8-ffa4324b718a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f04491bd-5dc3-43cc-a3b4-174fddb9a29d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Caspofungin acetate for Injection is an echinocandin antifungal indicated in adults and pediatric patients (3 months of age and older) for: Empirical therapy for presumed fungal infections in febrile, neutropenic patients. ( 1 ) Treatment of candidemia and the following Candida infections: intra-abdominal abscesses, peritonitis and pleural space infections. ( 1 ) Treatment of esophageal candidiasis. ( 1 ) Treatment of invasive aspergillosis in patients who are refractory to or intolerant of other therapies. ( 1 ) uuid:712a7a13-76ac-4097-8ebd-8296a69ae13b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:474180 biolink:treats MONDO:0044070 PMID:41385096 "[{""id"":""uuid:a6773f02-2959-468e-853e-c1ec1f8f2f22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6750137e-d9a3-474c-aaa6-1d759b27f92c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Caspofungin acetate for Injection is an echinocandin antifungal indicated in adults and pediatric patients (3 months of age and older) for: Empirical therapy for presumed fungal infections in febrile, neutropenic patients. ( 1 ) Treatment of candidemia and the following Candida infections: intra-abdominal abscesses, peritonitis and pleural space infections. ( 1 ) Treatment of esophageal candidiasis. ( 1 ) Treatment of invasive aspergillosis in patients who are refractory to or intolerant of other therapies. ( 1 ) uuid:d950c495-172e-47b3-8e3e-01a13628c961 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:474180 biolink:treats MONDO:0002026 PMID:41385096 "[{""id"":""uuid:01e46de2-82af-439f-a995-7c6ceeffac06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:291287c5-0219-49f7-bc16-9ddf8f477589"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Caspofungin acetate for Injection is an echinocandin antifungal indicated in adults and pediatric patients (3 months of age and older) for: Empirical therapy for presumed fungal infections in febrile, neutropenic patients. ( 1 ) Treatment of candidemia and the following Candida infections: intra-abdominal abscesses, peritonitis and pleural space infections. ( 1 ) Treatment of esophageal candidiasis. ( 1 ) Treatment of invasive aspergillosis in patients who are refractory to or intolerant of other therapies. ( 1 ) uuid:d6111e08-dca7-45f0-ba89-877c3bd14554 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:474180 biolink:treats EFO:1001753 PMID:41385096 "[{""id"":""uuid:f9cfc18e-0fe5-49ec-a9ab-6e9e67238e25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4237c439-3015-49e1-9f60-35085c04ef20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Caspofungin acetate for Injection is an echinocandin antifungal indicated in adults and pediatric patients (3 months of age and older) for: Empirical therapy for presumed fungal infections in febrile, neutropenic patients. ( 1 ) Treatment of candidemia and the following Candida infections: intra-abdominal abscesses, peritonitis and pleural space infections. ( 1 ) Treatment of esophageal candidiasis. ( 1 ) Treatment of invasive aspergillosis in patients who are refractory to or intolerant of other therapies. ( 1 ) uuid:672b6850-44e2-4d6d-86e1-df300fe1d6da biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:474180 biolink:treats MONDO:0004522 PMID:41385096 "[{""id"":""uuid:96134128-68fd-4b0a-bd26-ac673287be3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7687acf4-30b5-4123-aa0d-5353bbdec774"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Caspofungin acetate for Injection is an echinocandin antifungal indicated in adults and pediatric patients (3 months of age and older) for: Empirical therapy for presumed fungal infections in febrile, neutropenic patients. ( 1 ) Treatment of candidemia and the following Candida infections: intra-abdominal abscesses, peritonitis and pleural space infections. ( 1 ) Treatment of esophageal candidiasis. ( 1 ) Treatment of invasive aspergillosis in patients who are refractory to or intolerant of other therapies. ( 1 ) uuid:4210de8c-4859-48fd-aaa5-df3922568c5e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:474180 biolink:treats MONDO:0018667 PMID:41385096 "[{""id"":""uuid:804037b5-6554-4b6e-aaf3-813e5c1e215c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b5f6236c-4440-4fab-af03-c95fb26ff553"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Caspofungin acetate for Injection is an echinocandin antifungal indicated in adults and pediatric patients (3 months of age and older) for: Empirical therapy for presumed fungal infections in febrile, neutropenic patients. ( 1 ) Treatment of candidemia and the following Candida infections: intra-abdominal abscesses, peritonitis and pleural space infections. ( 1 ) Treatment of esophageal candidiasis. ( 1 ) Treatment of invasive aspergillosis in patients who are refractory to or intolerant of other therapies. ( 1 ) uuid:ccf80562-bc45-4462-9706-e2fcd08c2a5a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:474180 biolink:treats MONDO:0001648 PMID:41385096 "[{""id"":""uuid:2173e7df-81f4-4662-bc96-028e3d9cd88c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:67377d6d-021e-48c5-a586-7817837dea5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d72e4939-524e-490c-bd32-c80d9daac0e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Caspofungin acetate for Injection is an echinocandin antifungal indicated in adults and pediatric patients (3 months of age and older) for: Empirical therapy for presumed fungal infections in febrile, neutropenic patients. ( 1 ) Treatment of candidemia and the following Candida infections: intra-abdominal abscesses, peritonitis and pleural space infections. ( 1 ) Treatment of esophageal candidiasis. ( 1 ) Treatment of invasive aspergillosis in patients who are refractory to or intolerant of other therapies. ( 1 )|[PMDA] Drugs with a new active ingredient indicated for the treatment of febrile neutropenia suspected of a fungal infection and fungal infections due to Candida or Aspergillus (esophageal candidiasis, invasive candidiasis, aspergillosis). uuid:60f6ebdd-b705-48df-9373-e71b5948bd89 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:474180 biolink:treats MONDO:0000240 PMID:41385096 "[{""id"":""uuid:109ba827-88f8-4603-ba08-ad2cdc1a5394"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9ce829c2-21e1-40fe-a24d-8ff2918192b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Caspofungin acetate for Injection is an echinocandin antifungal indicated in adults and pediatric patients (3 months of age and older) for: Empirical therapy for presumed fungal infections in febrile, neutropenic patients. ( 1 ) Treatment of candidemia and the following Candida infections: intra-abdominal abscesses, peritonitis and pleural space infections. ( 1 ) Treatment of esophageal candidiasis. ( 1 ) Treatment of invasive aspergillosis in patients who are refractory to or intolerant of other therapies. ( 1 ) uuid:3e19fa1e-f2db-40d1-ab7d-f7c49862228d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:691037 biolink:treats UMLS:C0406317 PMID:41385096 "[{""id"":""uuid:3b64ccf9-e5b7-464f-b359-071efcd8e127"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1a6a2815-22b4-4cf2-9965-47a1fc9929f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Topicort ® Topical Spray is a corticosteroid indicated for the treatment of plaque psoriasis in patients 18 years of age or older. uuid:430a0f9d-a882-4407-9f9d-91af99b04cb1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17303 biolink:treats UMLS:C0278140 PMID:41385096 "[{""id"":""uuid:35725e70-02d2-4803-a6ad-538b1fda425e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2e43597f-773a-421b-9b6e-e03c0f10d097"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Morphine sulfate is indicated for the relief of severe pain. It is used preoperatively to sedate the patient and allay apprehension, facilitate anesthesia induction and reduce anesthetic dosage. It is likewise effective in the control of post-operative pain. The use of morphine for the relief of pain should be reserved for the more severe manifestations of pain, as in myocardial infarction, severe injuries, or in severe chronic pain associated with terminal cancer after all non-narcotic analgesics have failed. Effective analgesic therapy of severe chronic pain associated with terminal cancer continues to be a difficult problem. Intermittent administration of intramuscular morphine may be effective; however, the mode of therapy has significant limitations. Morphine has a short plasma half-life of 2.5 to 3.0 hours; therefore, frequent administration (every 1 to 2 hours) often becomes necessary to control severe pain associated with cancer. Tolerance develops to the analgesic effects and increasingly higher doses of morphine are required to produce analgesia. The higher morphine doses produce significant and often life-threatening side effects (see ADVERSE REACTIONS ) . The peak and trough effects produced by intermittent administration cause fluctuations in pain control. Repeated intramuscular injections are frequently unacceptable due to the lack of muscle mass in the debilitated patient, the tendency for bruising and bleeding at the injection site, and the anxiety and pain associated with the injection. Continuous intravenous infusion of morphine (see DOSAGE AND ADMINISTRATION ) has been employed as an alternative to traditional modes of administration. Lower doses of morphine produce uniform pain control because a steady morphine concentration is maintained. Titration of the dosage to the patient's needs is easily achieved by adjusting the infusion rate. The lag time between the patient's request for pain medication and administration of the dose and the amount of nursing time necessary for preparation and administration of frequent doses are reduced. The degree of respiratory depression and sedation may be decreased, and the anxiety experienced by the patient in anticipation of intramuscular administration is avoided. Some Investigators feel that tolerance to the analgesic effects may develop more slowly with continuous intravenous infusion. In addition to analgesia, the drug may relieve anxiety and reduce left ventricular work by reducing preload pressure. Morphine is also used in the therapy of dyspnea associated with acute left ventricular and pulmonary edema. Care must be taken to avoid inducing respiratory depression in such patients. For open-heart surgery, especially in high risk patients with cardiac disease, some anesthesiologists use morphine to produce anesthesia. uuid:d2841078-b138-48e4-9037-93f99d8a9f6f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17303 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:4280e093-e00d-4903-8fcc-1919dded2209"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d1f6b57c-8949-415f-b636-82a158889c35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Morphine sulfate is indicated for the relief of severe pain. It is used preoperatively to sedate the patient and allay apprehension, facilitate anesthesia induction and reduce anesthetic dosage. It is likewise effective in the control of post-operative pain. The use of morphine for the relief of pain should be reserved for the more severe manifestations of pain, as in myocardial infarction, severe injuries, or in severe chronic pain associated with terminal cancer after all non-narcotic analgesics have failed. Effective analgesic therapy of severe chronic pain associated with terminal cancer continues to be a difficult problem. Intermittent administration of intramuscular morphine may be effective; however, the mode of therapy has significant limitations. Morphine has a short plasma half-life of 2.5 to 3.0 hours; therefore, frequent administration (every 1 to 2 hours) often becomes necessary to control severe pain associated with cancer. Tolerance develops to the analgesic effects and increasingly higher doses of morphine are required to produce analgesia. The higher morphine doses produce significant and often life-threatening side effects (see ADVERSE REACTIONS ) . The peak and trough effects produced by intermittent administration cause fluctuations in pain control. Repeated intramuscular injections are frequently unacceptable due to the lack of muscle mass in the debilitated patient, the tendency for bruising and bleeding at the injection site, and the anxiety and pain associated with the injection. Continuous intravenous infusion of morphine (see DOSAGE AND ADMINISTRATION ) has been employed as an alternative to traditional modes of administration. Lower doses of morphine produce uniform pain control because a steady morphine concentration is maintained. Titration of the dosage to the patient's needs is easily achieved by adjusting the infusion rate. The lag time between the patient's request for pain medication and administration of the dose and the amount of nursing time necessary for preparation and administration of frequent doses are reduced. The degree of respiratory depression and sedation may be decreased, and the anxiety experienced by the patient in anticipation of intramuscular administration is avoided. Some Investigators feel that tolerance to the analgesic effects may develop more slowly with continuous intravenous infusion. In addition to analgesia, the drug may relieve anxiety and reduce left ventricular work by reducing preload pressure. Morphine is also used in the therapy of dyspnea associated with acute left ventricular and pulmonary edema. Care must be taken to avoid inducing respiratory depression in such patients. For open-heart surgery, especially in high risk patients with cardiac disease, some anesthesiologists use morphine to produce anesthesia. uuid:f4c711f9-638e-444a-945b-1fe7c516cf36 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17303 biolink:treats EFO:0801084 PMID:41385096 "[{""id"":""uuid:4450bfc7-d396-47f5-83f8-10dfbfa491fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1307c7bf-4483-46a9-8d97-5db17c55a052"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:678d0955-0e0a-4fe8-ad6a-9b59a54876eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Morphine sulfate is indicated for the relief of severe pain. It is used preoperatively to sedate the patient and allay apprehension, facilitate anesthesia induction and reduce anesthetic dosage. It is likewise effective in the control of post-operative pain. The use of morphine for the relief of pain should be reserved for the more severe manifestations of pain, as in myocardial infarction, severe injuries, or in severe chronic pain associated with terminal cancer after all non-narcotic analgesics have failed. Effective analgesic therapy of severe chronic pain associated with terminal cancer continues to be a difficult problem. Intermittent administration of intramuscular morphine may be effective; however, the mode of therapy has significant limitations. Morphine has a short plasma half-life of 2.5 to 3.0 hours; therefore, frequent administration (every 1 to 2 hours) often becomes necessary to control severe pain associated with cancer. Tolerance develops to the analgesic effects and increasingly higher doses of morphine are required to produce analgesia. The higher morphine doses produce significant and often life-threatening side effects (see ADVERSE REACTIONS ) . The peak and trough effects produced by intermittent administration cause fluctuations in pain control. Repeated intramuscular injections are frequently unacceptable due to the lack of muscle mass in the debilitated patient, the tendency for bruising and bleeding at the injection site, and the anxiety and pain associated with the injection. Continuous intravenous infusion of morphine (see DOSAGE AND ADMINISTRATION ) has been employed as an alternative to traditional modes of administration. Lower doses of morphine produce uniform pain control because a steady morphine concentration is maintained. Titration of the dosage to the patient's needs is easily achieved by adjusting the infusion rate. The lag time between the patient's request for pain medication and administration of the dose and the amount of nursing time necessary for preparation and administration of frequent doses are reduced. The degree of respiratory depression and sedation may be decreased, and the anxiety experienced by the patient in anticipation of intramuscular administration is avoided. Some Investigators feel that tolerance to the analgesic effects may develop more slowly with continuous intravenous infusion. In addition to analgesia, the drug may relieve anxiety and reduce left ventricular work by reducing preload pressure. Morphine is also used in the therapy of dyspnea associated with acute left ventricular and pulmonary edema. Care must be taken to avoid inducing respiratory depression in such patients. For open-heart surgery, especially in high risk patients with cardiac disease, some anesthesiologists use morphine to produce anesthesia.|[PMDA] A new formulation of opioid drug for daily administration with indications as analgesia for moderate to severe pain in various cancers. uuid:97386172-35bb-45a8-9b9e-77c18eaae5d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17303 biolink:treats MONDO:0006932 PMID:41385096 "[{""id"":""uuid:1407486d-f506-4b53-bb2b-ba5c03fa23fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a669da04-4799-4982-94f0-336e0ace87aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Morphine sulfate is indicated for the relief of severe pain. It is used preoperatively to sedate the patient and allay apprehension, facilitate anesthesia induction and reduce anesthetic dosage. It is likewise effective in the control of post-operative pain. The use of morphine for the relief of pain should be reserved for the more severe manifestations of pain, as in myocardial infarction, severe injuries, or in severe chronic pain associated with terminal cancer after all non-narcotic analgesics have failed. Effective analgesic therapy of severe chronic pain associated with terminal cancer continues to be a difficult problem. Intermittent administration of intramuscular morphine may be effective; however, the mode of therapy has significant limitations. Morphine has a short plasma half-life of 2.5 to 3.0 hours; therefore, frequent administration (every 1 to 2 hours) often becomes necessary to control severe pain associated with cancer. Tolerance develops to the analgesic effects and increasingly higher doses of morphine are required to produce analgesia. The higher morphine doses produce significant and often life-threatening side effects (see ADVERSE REACTIONS ) . The peak and trough effects produced by intermittent administration cause fluctuations in pain control. Repeated intramuscular injections are frequently unacceptable due to the lack of muscle mass in the debilitated patient, the tendency for bruising and bleeding at the injection site, and the anxiety and pain associated with the injection. Continuous intravenous infusion of morphine (see DOSAGE AND ADMINISTRATION ) has been employed as an alternative to traditional modes of administration. Lower doses of morphine produce uniform pain control because a steady morphine concentration is maintained. Titration of the dosage to the patient's needs is easily achieved by adjusting the infusion rate. The lag time between the patient's request for pain medication and administration of the dose and the amount of nursing time necessary for preparation and administration of frequent doses are reduced. The degree of respiratory depression and sedation may be decreased, and the anxiety experienced by the patient in anticipation of intramuscular administration is avoided. Some Investigators feel that tolerance to the analgesic effects may develop more slowly with continuous intravenous infusion. In addition to analgesia, the drug may relieve anxiety and reduce left ventricular work by reducing preload pressure. Morphine is also used in the therapy of dyspnea associated with acute left ventricular and pulmonary edema. Care must be taken to avoid inducing respiratory depression in such patients. For open-heart surgery, especially in high risk patients with cardiac disease, some anesthesiologists use morphine to produce anesthesia. uuid:30c6c16c-2123-4215-833c-bbe9fd86c54d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17303 biolink:treats MONDO:0005267 PMID:41385096 "[{""id"":""uuid:b3b6a38a-d476-48e3-a1c0-e60054e19e9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1badd59f-10ce-4d02-b802-e4e0d8f60d87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Morphine sulfate is indicated for the relief of severe pain. It is used preoperatively to sedate the patient and allay apprehension, facilitate anesthesia induction and reduce anesthetic dosage. It is likewise effective in the control of post-operative pain. The use of morphine for the relief of pain should be reserved for the more severe manifestations of pain, as in myocardial infarction, severe injuries, or in severe chronic pain associated with terminal cancer after all non-narcotic analgesics have failed. Effective analgesic therapy of severe chronic pain associated with terminal cancer continues to be a difficult problem. Intermittent administration of intramuscular morphine may be effective; however, the mode of therapy has significant limitations. Morphine has a short plasma half-life of 2.5 to 3.0 hours; therefore, frequent administration (every 1 to 2 hours) often becomes necessary to control severe pain associated with cancer. Tolerance develops to the analgesic effects and increasingly higher doses of morphine are required to produce analgesia. The higher morphine doses produce significant and often life-threatening side effects (see ADVERSE REACTIONS ) . The peak and trough effects produced by intermittent administration cause fluctuations in pain control. Repeated intramuscular injections are frequently unacceptable due to the lack of muscle mass in the debilitated patient, the tendency for bruising and bleeding at the injection site, and the anxiety and pain associated with the injection. Continuous intravenous infusion of morphine (see DOSAGE AND ADMINISTRATION ) has been employed as an alternative to traditional modes of administration. Lower doses of morphine produce uniform pain control because a steady morphine concentration is maintained. Titration of the dosage to the patient's needs is easily achieved by adjusting the infusion rate. The lag time between the patient's request for pain medication and administration of the dose and the amount of nursing time necessary for preparation and administration of frequent doses are reduced. The degree of respiratory depression and sedation may be decreased, and the anxiety experienced by the patient in anticipation of intramuscular administration is avoided. Some Investigators feel that tolerance to the analgesic effects may develop more slowly with continuous intravenous infusion. In addition to analgesia, the drug may relieve anxiety and reduce left ventricular work by reducing preload pressure. Morphine is also used in the therapy of dyspnea associated with acute left ventricular and pulmonary edema. Care must be taken to avoid inducing respiratory depression in such patients. For open-heart surgery, especially in high risk patients with cardiac disease, some anesthesiologists use morphine to produce anesthesia. uuid:d7ee679b-fd44-4318-8c3e-bb7d75cc6bd0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:449763 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:6d0b764e-da5c-4be7-9b90-aad15846dfcc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:034b7a5e-1361-4cb8-9093-54a1f4b4206d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Myocardial Imaging: Kit for the preparation of Technetium Tc 99m Sestamibi Injection is a myocardial perfusion agent that is indicated for detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects), in evaluating myocardial function and developing information for use in patient management decisions. Technetium Tc 99m Sestamibi evaluation of myocardial ischemia can be accomplished with rest and cardiovascular stress techniques (e.g., exercise or pharmacologic stress in accordance with the pharmacologic stress agents labeling). It is usually not possible to determine the age of a myocardial infarction or to differentiate a recent myocardial infarction from ischemia. Breast Imaging: Kit for the preparation of Technetium Tc 99m Sestamibi Injection is indicated for planar imaging as a second line diagnostic drug after mammography to assist in the evaluation of breast lesions in patients with an abnormal mammogram or a palpable breast mass. Kit for the preparation of Technetium Tc 99m Sestamibi Injection is not indicated for breast cancer screening, to confirm the presence or absence of malignancy, and it is not an alternative to biopsy. uuid:db23e5e7-fd16-4844-9bde-30cd088309de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:449763 biolink:treats MONDO:0024644 PMID:41385096 "[{""id"":""uuid:5ca093e9-3e4e-4a35-940d-0c2e9dc8cdbb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2d939266-c75a-41e2-ae45-5e8e29935cd9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Myocardial Imaging: Kit for the preparation of Technetium Tc 99m Sestamibi Injection is a myocardial perfusion agent that is indicated for detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects), in evaluating myocardial function and developing information for use in patient management decisions. Technetium Tc 99m Sestamibi evaluation of myocardial ischemia can be accomplished with rest and cardiovascular stress techniques (e.g., exercise or pharmacologic stress in accordance with the pharmacologic stress agents labeling). It is usually not possible to determine the age of a myocardial infarction or to differentiate a recent myocardial infarction from ischemia. Breast Imaging: Kit for the preparation of Technetium Tc 99m Sestamibi Injection is indicated for planar imaging as a second line diagnostic drug after mammography to assist in the evaluation of breast lesions in patients with an abnormal mammogram or a palpable breast mass. Kit for the preparation of Technetium Tc 99m Sestamibi Injection is not indicated for breast cancer screening, to confirm the presence or absence of malignancy, and it is not an alternative to biopsy. uuid:4f1583ad-a954-4836-a124-5fa32239a2e5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:449763 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:cacdb261-7ff0-43b3-9134-41f72a1c1262"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:78604cb4-f6eb-43b9-a60a-e71ad60dc9d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Myocardial Imaging: Kit for the preparation of Technetium Tc 99m Sestamibi Injection is a myocardial perfusion agent that is indicated for detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects), in evaluating myocardial function and developing information for use in patient management decisions. Technetium Tc 99m Sestamibi evaluation of myocardial ischemia can be accomplished with rest and cardiovascular stress techniques (e.g., exercise or pharmacologic stress in accordance with the pharmacologic stress agents labeling). It is usually not possible to determine the age of a myocardial infarction or to differentiate a recent myocardial infarction from ischemia. Breast Imaging: Kit for the preparation of Technetium Tc 99m Sestamibi Injection is indicated for planar imaging as a second line diagnostic drug after mammography to assist in the evaluation of breast lesions in patients with an abnormal mammogram or a palpable breast mass. Kit for the preparation of Technetium Tc 99m Sestamibi Injection is not indicated for breast cancer screening, to confirm the presence or absence of malignancy, and it is not an alternative to biopsy. uuid:76ff066c-24ec-4f29-90cc-3cdd17e13e41 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:449763 biolink:treats NCIT:C159594 PMID:41385096 "[{""id"":""uuid:9f61659a-ad62-4855-a379-12a9fa415f8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:87122116-7b74-4fc7-a577-ccad8c44438d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Myocardial Imaging: Kit for the preparation of Technetium Tc 99m Sestamibi Injection is a myocardial perfusion agent that is indicated for detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects), in evaluating myocardial function and developing information for use in patient management decisions. Technetium Tc 99m Sestamibi evaluation of myocardial ischemia can be accomplished with rest and cardiovascular stress techniques (e.g., exercise or pharmacologic stress in accordance with the pharmacologic stress agents labeling). It is usually not possible to determine the age of a myocardial infarction or to differentiate a recent myocardial infarction from ischemia. Breast Imaging: Kit for the preparation of Technetium Tc 99m Sestamibi Injection is indicated for planar imaging as a second line diagnostic drug after mammography to assist in the evaluation of breast lesions in patients with an abnormal mammogram or a palpable breast mass. Kit for the preparation of Technetium Tc 99m Sestamibi Injection is not indicated for breast cancer screening, to confirm the presence or absence of malignancy, and it is not an alternative to biopsy. uuid:3681714a-7604-47f2-ba1a-0eb47f839f06 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:449763 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:77a9eb4f-af34-473b-b49a-7b87b79e5ffa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:21f87fbb-77f2-4a42-89ad-60610c9d6b4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Myocardial Imaging: Kit for the preparation of Technetium Tc 99m Sestamibi Injection is a myocardial perfusion agent that is indicated for detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects), in evaluating myocardial function and developing information for use in patient management decisions. Technetium Tc 99m Sestamibi evaluation of myocardial ischemia can be accomplished with rest and cardiovascular stress techniques (e.g., exercise or pharmacologic stress in accordance with the pharmacologic stress agents labeling). It is usually not possible to determine the age of a myocardial infarction or to differentiate a recent myocardial infarction from ischemia. Breast Imaging: Kit for the preparation of Technetium Tc 99m Sestamibi Injection is indicated for planar imaging as a second line diagnostic drug after mammography to assist in the evaluation of breast lesions in patients with an abnormal mammogram or a palpable breast mass. Kit for the preparation of Technetium Tc 99m Sestamibi Injection is not indicated for breast cancer screening, to confirm the presence or absence of malignancy, and it is not an alternative to biopsy. uuid:27e1e3b2-5346-41de-94a9-5479be742087 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:11979316 biolink:treats UMLS:C5400441 PMID:41385096 "[{""id"":""uuid:acbfeab8-c987-499d-b7af-0f8f0d4acda8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:acee686e-1cec-4954-8793-691fe298d6c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vasostrict® is indicated to increase blood pressure in adults with vasodilatory shock (e.g., post-cardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines. uuid:f54815b4-eb3f-4f02-9d08-a5738c236c23 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:11979316 biolink:treats MONDO:0800175 PMID:41385096 "[{""id"":""uuid:5e88ce7b-7f31-43f8-970b-5f40312a60b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ae244f61-0a21-470a-943a-f3976feb2f1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vasostrict® is indicated to increase blood pressure in adults with vasodilatory shock (e.g., post-cardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines. uuid:7ab40e48-bfec-4d99-943c-abd6677e187e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:11979316 biolink:treats MONDO:0001881 PMID:41385096 "[{""id"":""uuid:0bf29435-a804-4714-87fb-eb1219fa2c36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:80b3b424-0c82-4d16-9c5d-9e3732c04802"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vasostrict® is indicated to increase blood pressure in adults with vasodilatory shock (e.g., post-cardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines. uuid:45db87ae-07ed-4f3b-8c26-6f352e03cd27 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3508 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:586e294f-1ff0-479a-adaf-08950e6c0fdc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d5fa1fd4-fc95-448b-9039-8013f05f1165"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tazicef (ceftazidime for injection, USP) is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: 1. Lower Respiratory Tract Infections, including pneumonia, caused by Pseudomonas aeruginosa and other Pseudomonas spp.; Haemophilus influenzae , including ampicillin-resistant strains; Klebsiella spp.; Enterobacter spp.; Proteus mirabilis ; Escherichia coli ; Serratia spp.; Citrobacter spp.; Streptococcus pneumoniae ; and Staphylococcus aureus (methicillin-susceptible strains). 2. Skin and Skin-Structure Infections caused by Pseudomonas aeruginosa ; Klebsiella spp.; Escherichia coli ; Proteus spp., including Proteus mirabilis and indole-positive Proteus ; Enterobacter spp.; Serratia spp.; Staphylococcus aureus (methicillin-susceptible strains); and Streptococcus pyogenes (group A beta-hemolytic streptococci). 3. Urinary Tract Infections, both complicated and uncomplicated, caused by Pseudomonas aeruginosa ; Enterobacter spp.; Proteus spp., including Proteus mirabilis and indole-positive Proteus ; Klebsiella spp.; and Escherichia coli . 4. Bacterial Septicemia caused by Pseudomonas aeruginosa , Klebsiella spp., Haemophilus influenzae , Escherichia coli , Serratia spp., Streptococcus pneumoniae , and Staphylococcus aureus (methicillin-susceptible strains). 5. Bone and Joint Infections caused by Pseudomonas aeruginosa, Klebsiella spp., Enterobacter spp., and Staphylococcus aureus (methicillin-susceptible strains). 6. Gynecologic Infections, including endometritis, pelvic cellulitis, and other infections of the female genital tract caused by Escherichia coli . 7. Intra-abdominal Infections, including peritonitis caused by Escherichia coli , Klebsiella spp., and Staphylococcus aureus (methicillin-susceptible strains) and polymicrobial infections caused by aerobic and anaerobic organisms and Bacteroides spp. (many strains of Bacteroides fragilis are resistant). 8. Central Nervous System Infections, including meningitis, caused by Haemophilus influenzae and Neisseria meningitidis . Ceftazidime has also been used successfully in a limited number of cases of meningitis due to Pseudomonas aeruginosa and Streptococcus pneumoniae . Tazicef (ceftazidime for injection, USP) may be used alone in cases of confirmed or suspected sepsis. Ceftazidime has been used successfully in clinical trials as empiric therapy in cases where various concomitant therapies with other antibacterial drugs have been used. Tazicef (ceftazidime for injection, USP) may also be used concomitantly with other antibacterial drugs, such as aminoglycosides, vancomycin, and clindamycin; in severe and life-threatening infections; and in the immunocompromised patient. When such concomitant treatment is appropriate, prescribing information in the labeling for the other antibacterial drugs should be followed. The dose depends on the severity of the infection and the patient's condition. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Tazicef (ceftazidime for injection, USP) and other antibacterial drugs, Tazicef (ceftazidime for injection, USP) should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:c6cc18a1-cb2c-4168-994b-f5ef6c3408c5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4712 biolink:treats HP:0012625 PMID:41385096 "[{""id"":""uuid:bab5e647-bc35-40f8-b276-e33cb54d8267"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e1ac59bf-e4b0-4ff1-a81a-8138d1b964f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxercalciferol capsules are indicated for the treatment of secondary hyperparathyroidism in adult patients with Stage 3 or Stage 4 chronic kidney disease (CKD) and adult patients with CKD on dialysis. uuid:4488e893-69c2-448c-b34e-3a98720702c8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4712 biolink:treats HP:0012626 PMID:41385096 "[{""id"":""uuid:0af8746a-6d05-426b-b6a1-da895a74a1b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:59f80347-acee-4d5c-973d-ae63d13206a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxercalciferol capsules are indicated for the treatment of secondary hyperparathyroidism in adult patients with Stage 3 or Stage 4 chronic kidney disease (CKD) and adult patients with CKD on dialysis. uuid:0346f696-369f-47e6-856a-0231188f982d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:122361353 biolink:treats MONDO:0015129 PMID:41385096 "[{""id"":""uuid:653ccda2-3e64-4081-80d2-124c60fac98c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2d414128-de5f-4fe6-ab20-10094d74c8de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CORTROSYN™ (cosyntropin) for Injection is intended for use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency. Because of its rapid effect on the adrenal cortex it may be utilized to perform a 30-minute test of adrenal function (plasma cortisol response) as an office or outpatient procedure, using only 2 venipunctures (seeDOSAGE AND ADMINISTRATION section). Severe hypofunction of the pituitary - adrenal axis is usually associated with subnormal plasma cortisol values but a low basal level is not per se evidence of adrenal insufficiency and does not suffice to make the diagnosis. Many patients with proven insufficiency will have normal basal levels and will develop signs of insufficiency only when stressed. For this reason a criterion which should be used in establishing the diagnosis is the failure to respond to adequate corticotropin stimulation. When presumptive adrenal insufficiency is diagnosed by a subnormal CORTROSYN™ test, further studies are indicated to determine if it is primary or secondary. Primary adrenal insufficiency (Addison's disease) is the result of an intrinsic disease process, such as tuberculosis within the gland. The production of adrenocortical hormones is deficient despite high ACTH levels (feedback mechanism). Secondary or relative insufficiency arises as the result of defective production of ACTH leading in turn to disuse atrophy of the adrenal cortex. It is commonly seen, for example, as result of corticosteroid therapy, Sheehan's syndrome and pituitary tumors or ablation. The differentiation of both types is based on the premise that a primarily defective gland cannot be stimulated by ACTH whereas a secondarily defective gland is potentially functional and will respond to adequate stimulation with ACTH. Patients selected for further study as the result of a subnormal CORTROSYN™ test should be given a 3 or 4 day course of treatment with Repository Corticotropin Injection USP and then retested. Suggested doses are 40 USP units twice daily for 4 days or 60 USP units twice daily for 3 days. Under these conditions little or no increase in plasma cortisol levels will be seen in Addison's disease whereas higher or even normal levels will be seen in cases with secondary adrenal insufficiency. uuid:c35cb909-ee7b-41c8-b84e-142488d9752c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29101 biolink:treats HP:0001944 PMID:41385096 "[{""id"":""uuid:1892fb0a-3ed5-401c-b498-719c2b6f7f7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a45eb964-7315-47e8-8647-b11ee107c7ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] This solution is indicated for use in adults and pediatric patients as a source of electrolytes and water for hydration. uuid:7c3d1096-1f1e-469c-bf07-9ff6f5585e94 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:53796 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:3bc67309-68b1-4d60-8b9c-218b7b2ebd18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:826a1e69-46ad-45c5-a525-f15d938b485b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LEVAMLODIPINE TABLETS is calcium channel blocker and may be used alone or in combination with other antihypertensive agents for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. uuid:a6a086a1-eace-4531-9cba-4805bd9df62f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:53796 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:9f56742a-2769-4cbb-9130-c0bedb51b95a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6263366d-384f-4dd6-acb8-18dc2945f70a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LEVAMLODIPINE TABLETS is calcium channel blocker and may be used alone or in combination with other antihypertensive agents for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. uuid:194aed63-d5f2-48a6-a863-860b4a84bc52 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:53796 biolink:treats MONDO:0006652 PMID:41385096 "[{""id"":""uuid:3c8aa8be-f9ff-4fb7-9f6c-96b5a8469874"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0c931c8d-64ee-4cc6-9bfa-e95226092fc2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LEVAMLODIPINE TABLETS is calcium channel blocker and may be used alone or in combination with other antihypertensive agents for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. uuid:578cad9e-1196-4e79-bda8-dda28035a0f4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3996 biolink:treats MONDO:0002081 PMID:41385096 "[{""id"":""uuid:1bd38950-737f-4c0d-87f3-c2a46426adec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b6f5e72b-94bf-4539-a892-18a14db88d66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclobenzaprine hydrochloride tablets, USP is indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living. Cyclobenzaprine hydrochloride, tablets should be used only for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use is not available and because muscle spasm associated with acute, painful musculoskeletal conditions is generally of short duration and specific therapy for longer periods is seldom warranted. Cyclobenzaprine hydrochloride tablets has not been found effective in the treatment of spasticity associated with cerebral or spinal cord disease, or in children with cerebral palsy. uuid:778821ef-b1c1-4463-b901-cd0598d7043e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:61080 biolink:treats MONDO:0015758 PMID:41385096 "[{""id"":""uuid:32ade0c2-9d2f-4ab7-9a96-b45053c4ae35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:77d30647-8303-46ca-aa7f-df72e507498f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Romidepsin for injection is indicated for the treatment of cutaneous T-cell lymphoma (CTCL) in adult patients who have received at least one prior systemic therapy. uuid:fe4a5b84-8558-46f4-b5f5-9b7ce8c0ac3b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:61080 biolink:treats MONDO:0009691 PMID:41385096 "[{""id"":""uuid:59c1dfc4-cfce-47e1-8ec6-ff6c2e582dd8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:412f1a66-1eea-4a50-90e1-15eb9c7f7a4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Romidepsin for injection is indicated for the treatment of cutaneous T-cell lymphoma (CTCL) in adult patients who have received at least one prior systemic therapy. uuid:ead64c23-d01c-44e4-baec-ffc57df91616 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:101278 biolink:treats MONDO:0004981 PMID:41385096 "[{""id"":""uuid:842bc5f5-3116-4372-8183-689f599f9fcc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cb79e2bf-cb1d-458a-acb8-b5ff204858ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diltiazem Hydrochloride in Dextrose Injection is a non-dihydropyridine calcium-channel blocker indicated for the following: • Temporary control of rapid ventricular rate in atrial fibrillation or atrial flutter. ( 1.1) • Rapid conversion of paroxysmal supraventricular tachycardias (PSVT) to sinus rhythm. ( 1.2 ) uuid:2ef304ff-b9aa-4c0c-863e-afe18826e58d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:101278 biolink:treats MONDO:0005310 PMID:41385096 "[{""id"":""uuid:3a4655a5-3f06-4635-a2a3-ac3827a58724"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ee2eb91e-b202-4473-9e2e-750b83333600"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diltiazem Hydrochloride in Dextrose Injection is a non-dihydropyridine calcium-channel blocker indicated for the following: • Temporary control of rapid ventricular rate in atrial fibrillation or atrial flutter. ( 1.1) • Rapid conversion of paroxysmal supraventricular tachycardias (PSVT) to sinus rhythm. ( 1.2 ) uuid:c8d9db47-bd21-4e39-97d3-c88708cac7cf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:101278 biolink:treats HP:0004763 PMID:41385096 "[{""id"":""uuid:c0093e79-6f2c-46d2-b7ec-7d8eb81b9ba5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a52d6e9d-14f0-437c-b5bd-e5bca4cb17a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diltiazem Hydrochloride in Dextrose Injection is a non-dihydropyridine calcium-channel blocker indicated for the following: • Temporary control of rapid ventricular rate in atrial fibrillation or atrial flutter. ( 1.1) • Rapid conversion of paroxysmal supraventricular tachycardias (PSVT) to sinus rhythm. ( 1.2 ) uuid:735b852f-9ddf-4925-b034-1b8b34194113 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32354 biolink:treats MONDO:0005318 PMID:41385096 "[{""id"":""uuid:87281301-816b-46cd-a1a5-95ff99db967a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7f3574a8-2c45-4e87-8862-f2af6dbdef2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Debacterol is indicated in the topical treatment of ulcerating lesions of the oral cavity such as Recurrent Aphthous Stomatitis (Canker Sores). Debacterol provides relief from the pain and discomfort of oral mucosal ulcers. Debacterol is not intended for the treatment of vesicular lesions, such as Cold Sores or Fever Blisters . uuid:846cdccc-9863-4bab-8934-0fb8644ff1e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32354 biolink:treats HP:0000155 PMID:41385096 "[{""id"":""uuid:4700aa16-2199-4a45-934d-1e10b17e0265"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:12c35f67-2546-47c6-b320-b2e548045abb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Debacterol is indicated in the topical treatment of ulcerating lesions of the oral cavity such as Recurrent Aphthous Stomatitis (Canker Sores). Debacterol provides relief from the pain and discomfort of oral mucosal ulcers. Debacterol is not intended for the treatment of vesicular lesions, such as Cold Sores or Fever Blisters . uuid:e27dd8fc-8e00-4dd5-bcdf-ceb80645eef9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41774 biolink:treats MONDO:0006512 PMID:41385096 "[{""id"":""uuid:0a779609-8aa2-41c8-bdb4-12e7232a7f49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fa8830af-e2bb-4e58-84f7-9b95f15e8b3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SOLTAMOX is an estrogen agonist/antagonist indicated: For treatment of adult patients with estrogen receptor-positive metastatic breast cancer ( 1.1 ) For adjuvant treatment of adult patients with early stage estrogen receptor- positive breast cancer ( 1.2 ) To reduce risk of invasive breast cancer following breast surgery and radiation in adult women with ductal carcinoma in situ (DCIS) ( 1.3 ) To reduce the incidence of breast cancer in adult women at high risk ( 1.4 ) uuid:dd7d7fa0-126d-410c-ac0d-ec0316c66a3b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8673 biolink:treats MONDO:0005989 PMID:41385096 "[{""id"":""uuid:ec120b9d-6f8f-4274-86a4-fc0b98438bf6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a9cafddf-0322-4b54-9848-3bd87ba1be9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment of Toxoplasmosis: Pyrimethamine is indicated for the treatment of toxoplasmosis when used conjointly with a sulfonamide, since synergism exists with this combination. uuid:dfc14a93-71b1-41e7-908f-6c7ab6c5adce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2453 biolink:treats MONDO:0012521 PMID:41385096 "[{""id"":""uuid:e3eedefc-54af-4f1a-86a8-d771231f14df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:af54e813-04c7-48ac-bf61-e9b3f3f77ad7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Herpes Simplex Infections in Immunocompromised Patients Acyclovir Sodium Injection is indicated for the treatment of initial and recurrent mucosal and cutaneous herpes simplex (HSV-1 and HSV-2) in immunocompromised patients. Initial Episodes of Herpes Genitalis Acyclovir Sodium Injection is indicated for the treatment of severe initial clinical episodes of herpes genitalis in immunocompetent patients. Herpes Simplex Encephalitis Acyclovir Sodium Injection is indicated for the treatment of herpes simplex encephalitis. Neonatal Herpes Simplex Virus Infection Acyclovir Sodium Injection is indicated for the treatment of neonates and infants with herpes simplex infections. Varicella-Zoster Infections in Immunocompromised Patients Acyclovir Sodium Injection is indicated for the treatment of varicella-zoster (shingles) infections in immunocompromised patients. uuid:deb05cb1-4de0-4124-8e83-1e3286a9ee56 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2453 biolink:treats MONDO:0005794 PMID:41385096 "[{""id"":""uuid:94b83c4b-0955-4f30-a1a7-89fe9dd60da8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0fd797ac-aeb3-4c8d-b3a7-69c18406b291"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Herpes Simplex Infections in Immunocompromised Patients Acyclovir Sodium Injection is indicated for the treatment of initial and recurrent mucosal and cutaneous herpes simplex (HSV-1 and HSV-2) in immunocompromised patients. Initial Episodes of Herpes Genitalis Acyclovir Sodium Injection is indicated for the treatment of severe initial clinical episodes of herpes genitalis in immunocompetent patients. Herpes Simplex Encephalitis Acyclovir Sodium Injection is indicated for the treatment of herpes simplex encephalitis. Neonatal Herpes Simplex Virus Infection Acyclovir Sodium Injection is indicated for the treatment of neonates and infants with herpes simplex infections. Varicella-Zoster Infections in Immunocompromised Patients Acyclovir Sodium Injection is indicated for the treatment of varicella-zoster (shingles) infections in immunocompromised patients. uuid:4551307f-1cda-4baa-8846-023252abd39e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7959 biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:0f4741d7-13ae-4edd-bf36-2a4717164467"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4e15a166-7085-4118-b952-e20bcbed8df2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Penicillamine capsules are indicated in the treatment of Wilson's disease, cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy. Available evidence suggests that penicillamine capsules are not of value in ankylosing spondylitis. Wilson’s Disease — Wilson’s disease (hepatolenticular degeneration) occurs in individuals who have inherited an autosomal recessive defect that leads to an accumulation of copper far in excess of metabolic requirements. The excess copper is deposited in several organs and tissues, and eventually produces pathological effects primarily in the liver, where damage progresses to postnecrotic cirrhosis, and in the brain, where degeneration is widespread. Copper is also deposited as characteristic, asymptomatic, golden-brown Kayser-Fleischer rings in the corneas of all patients with cerebral symptomatology and some patients who are either asymptomatic or manifest only hepatic symptomatology. Two types of patients require treatment for Wilson's disease: (1) the symptomatic, and (2) the asymptomatic in whom it can be assumed the disease will develop in the future if the patient is not treated. The diagnosis, if suspected on the basis of family or individual history or physical examination, can be confirmed if the plasma copper-protein ceruloplasmin** is <20 mg/dL and either a quantitative determination in a liver biopsy specimen shows an abnormally high concentration of copper (>250 mcg/g dry weight) or Kayser-Fleischer rings are present. Treatment has two objectives: (1) to minimize dietary intake of copper; (2) to promote excretion and complex formation (i.e., detoxification) of excess tissue copper. The first objective is attained by a daily diet that contains no more than one or two milligrams of copper. Such a diet should exclude, most importantly, chocolate, nuts, shellfish, mushrooms, liver, molasses, broccoli, and cereals and dietary supplements enriched with copper, and be composed to as great an extent as possible of foods with a low copper content. Distilled or demineralized water should be used if the patient's drinking water contains more than 0.1 mg of copper per liter. For the second objective, a copper chelating agent is used. In symptomatic patients this treatment usually produces marked neurologic improvement, fading of Kayser-Fleischer rings, and gradual amelioration of hepatic dysfunction and psychic disturbances. Clinical experience to date suggests that life is prolonged with the above regimen. Noticeable improvement may not occur for one to three months. Occasionally, neurologic symptoms become worse during initiation of therapy with penicillamine capsules. Despite this, the drug should not be withdrawn. Temporary interruption carries an increased risk of developing a sensitivity reaction upon resumption of therapy, although it may result in clinical improvement of neurological symptoms (see WARNINGS ). If the neurological symptoms and signs continue to worsen for a month after the initiation of penicillamine capsules therapy, several short courses of treatment with 2,3 - dimercaprol (BAL) while continuing penicillamine capsules may be considered. Treatment of asymptomatic patients has been carried out for over thirty years. Symptoms and signs of the disease appear to be prevented indefinitely if daily treatment with penicillamine capsules is continued. Cystinuria — Cystinuria is characterized by excessive urinary excretion of the dibasic amino acids, arginine, lysine, ornithine, and cystine, and the mixed disulfide of cysteine and homocysteine. The metabolic defect that leads to cystinuria is inherited as an autosomal, recessive trait. Metabolism of the affected amino acids is influenced by at least two abnormal factors: (1) defective gastrointestinal absorption and (2) renal tubular dysfunction. Arginine, lysine, ornithine, and cysteine are soluble substances, readily excreted. There is no apparent pathology connected with their excretion in excessive quantities. Cystine, however, is so slightly soluble at the usual range of urinary pH that it is not excreted readily, and so crystallizes and forms stones in the urinary tract. Stone formation is the only known pathology in cystinuria. Normal daily output of cystine is 40 to 80 mg. In cystinuria, output is greatly increased and may exceed 1 g/day. At 500 to 600 mg/day, stone formation is almost certain. When it is more than 300 mg/day, treatment is indicated. Conventional treatment is directed at keeping urinary cystine diluted enough to prevent stone formation, keeping the urine alkaline enough to dissolve as much cystine as possible, and minimizing cystine production by a diet low in methionine (the major dietary precursor of cystine). Patients must drink enough fluid to keep urine specific gravity below 1.010, take enough alkali to keep urinary pH at 7.5 to 8, and maintain a diet low in methionine. This diet is not recommended in growing children and probably is contraindicated in pregnancy because of its low protein content (see PRECAUTIONS) . When these measures are inadequate to control recurrent stone formation, penicillamine capsules may be used as additional therapy, and when patients refuse to adhere to conventional treatment, penicillamine capsules may be a useful substitute. It is capable of keeping cystine excretion to near normal values, thereby hindering stone formation and the serious consequences of pyelonephritis and impaired renal function that develop in some patients. Bartter and colleagues depict the process by which penicillamine interacts with cystine to form penicillaminecysteine mixed disulfide as: CSSC = cystine CS ′ = deprotonated cysteine PSSP = penicillamine disulfide PS ′ = deprotonated penicillamine sulfhydryl CSSP = penicillamine-cysteine mixed disulfide In this process, it is assumed that the deprotonated form of penicillamine, PS', is the active factor in bringing about the disulfide interchange. Rheumatoid Arthritis — Because penicillamine capsules can cause severe adverse reactions, its use in rheumatoid arthritis should be restricted to patients who have severe, active disease and who have failed to respond to an adequate trial of conventional therapy. Even then, benefit-to-risk ratio should be carefully considered. Other measures, such as rest, physiotherapy, salicylates, and corticosteroids should be used, when indicated, in conjunction with penicillamine capsules (see PRECAUTIONS ). uuid:b195629b-8446-4c6a-8186-a4d7697aa093 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7959 biolink:treats MONDO:0006939 PMID:41385096 "[{""id"":""uuid:926b7970-01a5-4dbb-b7ed-3ff9bf490d00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:31a98029-9935-4f73-bc38-dd4d3b76a208"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Penicillamine capsules are indicated in the treatment of Wilson's disease, cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy. Available evidence suggests that penicillamine capsules are not of value in ankylosing spondylitis. Wilson’s Disease — Wilson’s disease (hepatolenticular degeneration) occurs in individuals who have inherited an autosomal recessive defect that leads to an accumulation of copper far in excess of metabolic requirements. The excess copper is deposited in several organs and tissues, and eventually produces pathological effects primarily in the liver, where damage progresses to postnecrotic cirrhosis, and in the brain, where degeneration is widespread. Copper is also deposited as characteristic, asymptomatic, golden-brown Kayser-Fleischer rings in the corneas of all patients with cerebral symptomatology and some patients who are either asymptomatic or manifest only hepatic symptomatology. Two types of patients require treatment for Wilson's disease: (1) the symptomatic, and (2) the asymptomatic in whom it can be assumed the disease will develop in the future if the patient is not treated. The diagnosis, if suspected on the basis of family or individual history or physical examination, can be confirmed if the plasma copper-protein ceruloplasmin** is <20 mg/dL and either a quantitative determination in a liver biopsy specimen shows an abnormally high concentration of copper (>250 mcg/g dry weight) or Kayser-Fleischer rings are present. Treatment has two objectives: (1) to minimize dietary intake of copper; (2) to promote excretion and complex formation (i.e., detoxification) of excess tissue copper. The first objective is attained by a daily diet that contains no more than one or two milligrams of copper. Such a diet should exclude, most importantly, chocolate, nuts, shellfish, mushrooms, liver, molasses, broccoli, and cereals and dietary supplements enriched with copper, and be composed to as great an extent as possible of foods with a low copper content. Distilled or demineralized water should be used if the patient's drinking water contains more than 0.1 mg of copper per liter. For the second objective, a copper chelating agent is used. In symptomatic patients this treatment usually produces marked neurologic improvement, fading of Kayser-Fleischer rings, and gradual amelioration of hepatic dysfunction and psychic disturbances. Clinical experience to date suggests that life is prolonged with the above regimen. Noticeable improvement may not occur for one to three months. Occasionally, neurologic symptoms become worse during initiation of therapy with penicillamine capsules. Despite this, the drug should not be withdrawn. Temporary interruption carries an increased risk of developing a sensitivity reaction upon resumption of therapy, although it may result in clinical improvement of neurological symptoms (see WARNINGS ). If the neurological symptoms and signs continue to worsen for a month after the initiation of penicillamine capsules therapy, several short courses of treatment with 2,3 - dimercaprol (BAL) while continuing penicillamine capsules may be considered. Treatment of asymptomatic patients has been carried out for over thirty years. Symptoms and signs of the disease appear to be prevented indefinitely if daily treatment with penicillamine capsules is continued. Cystinuria — Cystinuria is characterized by excessive urinary excretion of the dibasic amino acids, arginine, lysine, ornithine, and cystine, and the mixed disulfide of cysteine and homocysteine. The metabolic defect that leads to cystinuria is inherited as an autosomal, recessive trait. Metabolism of the affected amino acids is influenced by at least two abnormal factors: (1) defective gastrointestinal absorption and (2) renal tubular dysfunction. Arginine, lysine, ornithine, and cysteine are soluble substances, readily excreted. There is no apparent pathology connected with their excretion in excessive quantities. Cystine, however, is so slightly soluble at the usual range of urinary pH that it is not excreted readily, and so crystallizes and forms stones in the urinary tract. Stone formation is the only known pathology in cystinuria. Normal daily output of cystine is 40 to 80 mg. In cystinuria, output is greatly increased and may exceed 1 g/day. At 500 to 600 mg/day, stone formation is almost certain. When it is more than 300 mg/day, treatment is indicated. Conventional treatment is directed at keeping urinary cystine diluted enough to prevent stone formation, keeping the urine alkaline enough to dissolve as much cystine as possible, and minimizing cystine production by a diet low in methionine (the major dietary precursor of cystine). Patients must drink enough fluid to keep urine specific gravity below 1.010, take enough alkali to keep urinary pH at 7.5 to 8, and maintain a diet low in methionine. This diet is not recommended in growing children and probably is contraindicated in pregnancy because of its low protein content (see PRECAUTIONS) . When these measures are inadequate to control recurrent stone formation, penicillamine capsules may be used as additional therapy, and when patients refuse to adhere to conventional treatment, penicillamine capsules may be a useful substitute. It is capable of keeping cystine excretion to near normal values, thereby hindering stone formation and the serious consequences of pyelonephritis and impaired renal function that develop in some patients. Bartter and colleagues depict the process by which penicillamine interacts with cystine to form penicillaminecysteine mixed disulfide as: CSSC = cystine CS ′ = deprotonated cysteine PSSP = penicillamine disulfide PS ′ = deprotonated penicillamine sulfhydryl CSSP = penicillamine-cysteine mixed disulfide In this process, it is assumed that the deprotonated form of penicillamine, PS', is the active factor in bringing about the disulfide interchange. Rheumatoid Arthritis — Because penicillamine capsules can cause severe adverse reactions, its use in rheumatoid arthritis should be restricted to patients who have severe, active disease and who have failed to respond to an adequate trial of conventional therapy. Even then, benefit-to-risk ratio should be carefully considered. Other measures, such as rest, physiotherapy, salicylates, and corticosteroids should be used, when indicated, in conjunction with penicillamine capsules (see PRECAUTIONS ). uuid:8d82363d-1f42-46a3-a984-71bd1e761010 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:65307 biolink:treats MONDO:0018912 PMID:41385096 "[{""id"":""uuid:23ea5a5f-60c7-4869-a3c6-412fbdc17597"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4fe218dc-69c7-4304-8040-32a8e7ca17a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ACTHREL® is indicated for use in differentiating pituitary and ectopic production of ACTH in patients with ACTH-dependent Cushing's syndrome. uuid:f8efd72f-7431-4559-8e77-b9402ce02ba9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31897 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:7f7e4b93-bf74-49c5-b395-38b98b9ec3b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d8c111c5-ab67-4666-8683-ab5bea877d51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nateglinide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use : Nateglinide tablets should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. uuid:f5b15b81-3912-4695-ab4c-66286a2c82ee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31897 biolink:treats MONDO:0012819 PMID:41385096 "[{""id"":""uuid:6676f91a-4215-4693-ac95-9443c2820752"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ab878f24-0cef-454f-a2e1-f2bc52eba729"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nateglinide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use : Nateglinide tablets should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. uuid:31fd585d-564b-4ce5-8f50-ca84776c10d8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16236 biolink:treats MONDO:0005045 PMID:41385096 "[{""id"":""uuid:8146a3eb-3ac6-49ac-9df6-caab992797f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:17bada59-a1a8-45cc-935b-fd0896ac9f99"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ABLYSINOL ® is indicated to induce controlled cardiac septal infarction to improve exercise capacity in adults with symptomatic hypertrophic obstructive cardiomyopathy who are not candidates for surgical myectomy. uuid:4163d561-8c75-4191-8cf8-e0e5ba02eb93 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:Y68179SY2L biolink:treats MONDO:0019496 PMID:41385096 "[{""id"":""uuid:d912aa16-b8a1-4218-beb5-fa190ad954d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:81c038b4-7a48-4cb2-9e28-61df78742e21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ga 68 DOTATOC Injection is indicated for use with positron emission tomography (PET) for the localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult and pediatric patients. uuid:fcbe5b2b-f468-4797-8e7b-20fe4461dd1d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6824 biolink:treats MONDO:0006939 PMID:41385096 "[{""id"":""uuid:83551d8c-ad1e-4b52-8370-5f957d354ba9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:82d36652-b7a3-4cba-a9bd-b65aeb536557"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methenamine mandelate, USP is indicated for the suppression or elimination of bacteriuria associated with pyelonephritis, cystitis, and other chronic urinary tract infections; also for infected residual urine sometimes accompanying neurologic diseases. When used as recommended, methenamine mandelate, USP is particularly suitable for long-term therapy because of its safety and because resistance to the nonspecific bactericidal action of formaldehyde does not develop. Pathogens resistant to other antibacterial agents may respond to methenamine mandelate, USP because of the nonspecific effect of formaldehyde formed in an acid urine. Prophylactic Use Rationale: Urine is a good culture medium for many urinary pathogens. Inoculation by a few organisms (relapse or reinfection) may lead to bacteriuria in susceptible individuals. Thus, the rationale of management in recurring urinary tract infection (bacteriuria) is to change the urine from a growth-supporting to a growth-inhibiting medium. There is a growing body of evidence that long-term administration of methenamine mandelate, USP can prevent the recurrence of bacteriuria in patients with chronic pyelonephritis. Therapeutic Use Rationale: Methenamine mandelate, USP helps to sterilize the urine, and in some situations in which underlying pathologic conditions prevent sterilization by any means, it can help to suppress the bacteriuria. Methenamine mandelate, USP should not be used alone for acute infections with parenchymal involvement causing systemic symptoms such as chills and fever. A thorough diagnostic investigation as a part of the overall management of the urinary tract infection should accompany the use of methenamine mandelate, USP. uuid:cec8b6bf-6d0c-4369-b01f-8e7f19f11357 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6824 biolink:treats MONDO:0006032 PMID:41385096 "[{""id"":""uuid:622b0359-573b-424a-9e2b-37b8f099addc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2878cccd-e0d3-4cff-b66d-3bc4f5238726"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methenamine mandelate, USP is indicated for the suppression or elimination of bacteriuria associated with pyelonephritis, cystitis, and other chronic urinary tract infections; also for infected residual urine sometimes accompanying neurologic diseases. When used as recommended, methenamine mandelate, USP is particularly suitable for long-term therapy because of its safety and because resistance to the nonspecific bactericidal action of formaldehyde does not develop. Pathogens resistant to other antibacterial agents may respond to methenamine mandelate, USP because of the nonspecific effect of formaldehyde formed in an acid urine. Prophylactic Use Rationale: Urine is a good culture medium for many urinary pathogens. Inoculation by a few organisms (relapse or reinfection) may lead to bacteriuria in susceptible individuals. Thus, the rationale of management in recurring urinary tract infection (bacteriuria) is to change the urine from a growth-supporting to a growth-inhibiting medium. There is a growing body of evidence that long-term administration of methenamine mandelate, USP can prevent the recurrence of bacteriuria in patients with chronic pyelonephritis. Therapeutic Use Rationale: Methenamine mandelate, USP helps to sterilize the urine, and in some situations in which underlying pathologic conditions prevent sterilization by any means, it can help to suppress the bacteriuria. Methenamine mandelate, USP should not be used alone for acute infections with parenchymal involvement causing systemic symptoms such as chills and fever. A thorough diagnostic investigation as a part of the overall management of the urinary tract infection should accompany the use of methenamine mandelate, USP. uuid:54e3a986-695f-4a6b-9025-a579a8caf10f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6824 biolink:treats UMLS:C0262421 PMID:41385096 "[{""id"":""uuid:1532393a-1233-4fb7-a15f-1e5cf93daabb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:734a5ff9-b396-49a5-8eb7-528aecbd9863"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methenamine mandelate, USP is indicated for the suppression or elimination of bacteriuria associated with pyelonephritis, cystitis, and other chronic urinary tract infections; also for infected residual urine sometimes accompanying neurologic diseases. When used as recommended, methenamine mandelate, USP is particularly suitable for long-term therapy because of its safety and because resistance to the nonspecific bactericidal action of formaldehyde does not develop. Pathogens resistant to other antibacterial agents may respond to methenamine mandelate, USP because of the nonspecific effect of formaldehyde formed in an acid urine. Prophylactic Use Rationale: Urine is a good culture medium for many urinary pathogens. Inoculation by a few organisms (relapse or reinfection) may lead to bacteriuria in susceptible individuals. Thus, the rationale of management in recurring urinary tract infection (bacteriuria) is to change the urine from a growth-supporting to a growth-inhibiting medium. There is a growing body of evidence that long-term administration of methenamine mandelate, USP can prevent the recurrence of bacteriuria in patients with chronic pyelonephritis. Therapeutic Use Rationale: Methenamine mandelate, USP helps to sterilize the urine, and in some situations in which underlying pathologic conditions prevent sterilization by any means, it can help to suppress the bacteriuria. Methenamine mandelate, USP should not be used alone for acute infections with parenchymal involvement causing systemic symptoms such as chills and fever. A thorough diagnostic investigation as a part of the overall management of the urinary tract infection should accompany the use of methenamine mandelate, USP. uuid:40a6a3b1-a0ed-49dc-811e-d44e76ef287b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6824 biolink:treats MONDO:0001882 PMID:41385096 "[{""id"":""uuid:42d99e56-5ca7-4d2c-b550-f18fb6b0baa2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b341862f-809f-45c8-9808-557b68694a80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methenamine mandelate, USP is indicated for the suppression or elimination of bacteriuria associated with pyelonephritis, cystitis, and other chronic urinary tract infections; also for infected residual urine sometimes accompanying neurologic diseases. When used as recommended, methenamine mandelate, USP is particularly suitable for long-term therapy because of its safety and because resistance to the nonspecific bactericidal action of formaldehyde does not develop. Pathogens resistant to other antibacterial agents may respond to methenamine mandelate, USP because of the nonspecific effect of formaldehyde formed in an acid urine. Prophylactic Use Rationale: Urine is a good culture medium for many urinary pathogens. Inoculation by a few organisms (relapse or reinfection) may lead to bacteriuria in susceptible individuals. Thus, the rationale of management in recurring urinary tract infection (bacteriuria) is to change the urine from a growth-supporting to a growth-inhibiting medium. There is a growing body of evidence that long-term administration of methenamine mandelate, USP can prevent the recurrence of bacteriuria in patients with chronic pyelonephritis. Therapeutic Use Rationale: Methenamine mandelate, USP helps to sterilize the urine, and in some situations in which underlying pathologic conditions prevent sterilization by any means, it can help to suppress the bacteriuria. Methenamine mandelate, USP should not be used alone for acute infections with parenchymal involvement causing systemic symptoms such as chills and fever. A thorough diagnostic investigation as a part of the overall management of the urinary tract infection should accompany the use of methenamine mandelate, USP. uuid:0d72b3ab-6cc8-4adf-af61-fea5ef1713f7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4B33BGI082 biolink:treats MONDO:0037748 PMID:41385096 "[{""id"":""uuid:f011ae2c-6519-4698-bcc6-9eebd90a5c4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cc6abf2a-3eb4-4a50-9fe3-34e1165038c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1) Cholestyramine for Oral Suspension, USP Light powder is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [LDL] cholesterol) who do not respond adequately to diet. Cholestyramine for Oral Suspension, USP Light powder may be useful to lower LDL cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. Excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. Prior to initiating therapy with cholestyramine resin, secondary causes of hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism), should be excluded and a lipid profile performed to assess Total cholesterol, HDL-C and triglycerides (TG). For individuals with TG less than 400 mg/dL (<4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = Total cholesterol - [(TG/5) + HDL-C] For TG levels > 400 mg/dL, this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated Total-C. In such cases cholestyramine resin may not be indicated. Serum cholesterol and triglyceride levels should be determined periodically based on NCEP guidelines to confirm initial and adequate long-term response. A favorable trend in cholesterol reduction should occur during the first month of cholestyramine resin therapy. The therapy should be continued to sustain cholesterol reduction. If adequate cholesterol reduction is not attained, increasing the dosage of cholestyramine resin or adding other lipid-lowering agents in combination with cholestyramine resin should be considered. Since the goal of treatment is to lower LDL-C, the NCEP4 recommends that LDL-C levels be used to initiate and assess treatment response. If LDL-C levels are not available then Total-C alone may be used to monitor long-term therapy. A lipoprotein analysis (including LDL-C determination) should be carried out once a year. The NCEP treatment guidelines are summarized below. Definite Atherosclerotic Disease * Two or More Other Risk Factors † LDL-Cholesterol mg/dL (mmol/L) Initiation Level Goal No No ≥ 190 (4.9) ≥ 60 (4.1) No Yes ≥ 160 (4.1) ≥ 130 (3.4) Yes Yes or No ≥ 130 (3.4) ≥ 100 (‑2.6) * Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). † Other risk factors for coronary heart disease (CHD) include: age (males 45 years; females: 55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C <35 mg/dL (<0.91 mmol/L); and diabetes mellitus. Subtract one risk factor if HDL-C is 60 mg/dL (1.6 mmol/L). Cholestyramine resin monotherapy has been demonstrated to retard the rate of progression 2,3 and increase the rate of regression 3 of coronary atherosclerosis. 2) Cholestyramine for Oral Suspension, USP Light powder, is indicated for the relief of pruritus associated with partial biliary obstruction. Cholestyramine resin has been shown to have a variable effect on serum cholesterol in these patients. Patients with primary biliary cirrhosis may exhibit an elevated cholesterol as part of their disease. uuid:4530f296-8928-49c6-99b7-9f27da9b59a8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4469 biolink:treats MONDO:0004681 PMID:41385096 "[{""id"":""uuid:e1d77927-04da-4add-9505-d298c3faa7b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8daf8680-7045-45a0-a4a5-b6ff4e3e04dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dextroamphetamine Sulfate Tablets USP are indicated for: Narcolepsy . Attention Deficit Disorder with Hyperactivity , as an integral part of a total treatment program which typically includes other remedial measures (psychological, educational, social) for a stabilizing effect in pediatric patients (ages 3 to 16 years) with a behavioral syndrome characterized by the following group of developmentally inappropriate symptoms: moderate to severe distractibility, short attention span, hyperactivity, emotional lability, and impulsivity. The diagnosis of this syndrome should not be made with finality when these symptoms are only of comparatively recent origin. Nonlocalizing (soft) neurological signs, learning disability, and abnormal EEG may or may not be present, and a diagnosis of central nervous system dysfunction may or may not be warranted. uuid:988c1007-4018-43a3-9da0-bdf186feebf2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4469 biolink:treats MONDO:0005302 PMID:41385096 "[{""id"":""uuid:2a60a759-7ccc-4ca3-bd36-0e60c25f72de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1419a822-76fc-4520-83a2-c740cf904262"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Dextroamphetamine sulfate extended-release capsules are indicated in: Narcolepsy Attention Deficit Disorder with Hyperactivity As an integral part of a total treatment program that typically includes other measures (psychological, educational, social) for patients (ages 6 years to 16 years) with this syndrome. A diagnosis of Attention Deficit Hyperactivity Disorder (ADHD; DSM-IV) implies the presence of the hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. The symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in 2 or more settings, e.g., school (or work) and at home. The symptoms must not be better accounted for by another mental disorder. For the Inattentive Type, at least 6 of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effort; loses things; easily distracted; forgetful. For the Hyperactive-Impulsive Type, at least 6 of the following symptoms must have persisted for at least 6 months: fidgeting/squirming; leaving seat; inappropriate running/climbing; difficulty with quiet activities; ""on the go""; excessive talking; blurting answers; can't wait turn; intrusive. The Combined Type requires both inattentive and hyperactive-impulsive criteria to be met. Special Diagnostic Considerations Specific etiology of this syndrome is unknown, and there is no single diagnostic test. Adequate diagnosis requires the use of medical and special psychological, educational, and social resources. Learning may or may not be impaired. The diagnosis must be based upon a complete history and evaluation of the patient and not solely on the presences of the required number of DSM-IV characteristics. Need for Comprehensive Treatment Program Dextroamphetamine sulfate extended-release capsules are indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, social) for patients with this syndrome. Drug treatment may not be indicated for all patients with this syndrome. Stimulants are not intended for use in patients who exhibit symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis. Appropriate educational placement is essential and psychosocial intervention is often helpful. When remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physician's assessment of the chronicity and severity of the patient's symptoms." uuid:fa31ff9f-b39b-4918-a074-25322439a4dc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50859 biolink:treats MONDO:0015758 PMID:41385096 "[{""id"":""uuid:eefa73e1-1625-4b56-a668-50a6cc7056a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2d32aeb4-e3c5-4637-851b-9f9b00e1729f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d57c7d5f-5cd2-46cd-bcbf-62afa5774cd7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/targretin""]},{""id"":""uuid:8f2b12ef-0070-45cb-9c2f-67fd907abcb0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bexarotene capsules are indicated for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma in patients who are refractory to at least one prior systemic therapy.|[EMA] Targretin capsules are indicated for the treatment of skin manifestations of advanced stage cutaneous T-cell lymphoma (CTCL) patients refractory to at least one systemic treatment.|[PMDA] A drug with a new active ingredient indicated for the treatment of cutaneous T-cell lymphoma. [Orphan drug] uuid:acd50212-3b9b-446c-b4c5-e3eae5302c3e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17303 biolink:treats HP:0030858 PMID:41385096 "[{""id"":""uuid:44c42944-5daf-46c4-ab14-07a0a3d67e11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d2831c6d-1744-44f0-914c-92d16f1da560"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Morphine sulfate extended-release tablets are an opioid agonist product indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. ( 1 ) Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations, reserve morphine sulfate extended-release tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. ( 1 ) Morphine sulfate extended-release tablets are not indicated as an as-needed (prn) analgesic. ( 1 ) uuid:560d0b36-9393-4759-9048-95a9080769a9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17303 biolink:treats MONDO:0002491 PMID:41385096 "[{""id"":""uuid:4515c237-6a00-4ba7-a0d0-aeca0829bcfb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:77253150-a7cd-405a-8551-e091fe7c75a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Morphine sulfate extended-release tablets are an opioid agonist product indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. ( 1 ) Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations, reserve morphine sulfate extended-release tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. ( 1 ) Morphine sulfate extended-release tablets are not indicated as an as-needed (prn) analgesic. ( 1 ) uuid:1d4e637c-bdad-44b5-bc23-f2ed6322525e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17303 biolink:treats EFO:0011049 PMID:41385096 "[{""id"":""uuid:f7edc2fe-5809-4b2d-8893-76ffa1dba0d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b0f84489-a9fd-483c-b578-505c79b59801"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Morphine sulfate extended-release tablets are an opioid agonist product indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. ( 1 ) Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations, reserve morphine sulfate extended-release tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. ( 1 ) Morphine sulfate extended-release tablets are not indicated as an as-needed (prn) analgesic. ( 1 ) uuid:6aab70d7-a277-4142-870d-d00bbdf60b35 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17303 biolink:treats EFO:0020911 PMID:41385096 "[{""id"":""uuid:acd57fc0-4157-455d-995e-788046fc63ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:66daf9c0-5af2-42e0-ac7d-83de4b73964f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Morphine sulfate extended-release tablets are an opioid agonist product indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. ( 1 ) Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations, reserve morphine sulfate extended-release tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. ( 1 ) Morphine sulfate extended-release tablets are not indicated as an as-needed (prn) analgesic. ( 1 ) uuid:f9526c3f-90bd-48b8-944a-1dc5559de993 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:647208 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:ccc498aa-ac31-4901-93c7-ab5c2b26b997"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ee9d609c-b127-490e-951e-5eaab8ca0cc8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:72e7bf86-14ba-44da-817d-3db9172b8967"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tandemact""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pioglitazone and glimepiride tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are already treated with a thiazolidinedione and sulfonylurea or who have inadequate glycemic control on a thiazolidinedione alone or a sulfonylurea alone [see Clinical Studies (14) ] .|[EMA] Tandemact is indicated for the treatment of patients with type-2 diabetes mellitus who show intolerance to metformin or for whom metformin is contraindicated and who are already treated with a combination of pioglitazone and glimepiride. uuid:b47e2a41-6bc7-4385-bca0-cfcbccc9ddf9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15940 biolink:treats MONDO:0007788 PMID:41385096 "[{""id"":""uuid:9a552748-273e-4f6c-9006-2629b4bf8514"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c1ced68a-f54f-4d4d-9be3-dc9fa5659853"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] I. Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Nicotinic acid, alone or in combination with a bile-acid binding resin, is indicated as an adjunct to diet for the reduction of elevated total and LDL cholesterol levels in patients with primary hypercholesterolemia (Types IIa and IIb) † , when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate (see also the NCEP treatment guidelines 6 ). Prior to initiating therapy with nicotinic acid, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total cholesterol, HDL cholesterol, and triglycerides. II. Nicotinic acid is also indicated as adjunctive therapy for the treatment of adult patients with very high serum triglyceride levels (Types IV and V hyperlipidemia) † who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Such patients typically have serum triglyceride levels over 2,000 mg/dL and have elevations of VLDL cholesterol as well as fasting chylomicrons (Type V hyperlipidemia) † . Subjects who consistently have total serum or plasma triglycerides below 1,000 mg/dL are unlikely to develop pancreatitis. Therapy with nicotinic acid may be considered for those subjects with triglyceride elevations between 1,000 and 2,000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. Some Type IV patients with triglycerides under 1,000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of nicotinic acid therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of VLDL. Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia 7 . † Classification of Hyperlipoproteinemias Lipoproteins Lipid Elevations Type Elevated Major Minor C = cholesterol, TG = triglycerides LDL = low-density lipoprotein VLDL = very low-density lipoprotein IDL = intermediate-density lipoprotein I (rare) Chylomicrons TG ↑→ C IIa LDL C ..... IIb LDL, VLDL C TG III (rare) IDL C/TG ..... IV VLDL TG ↑→ C V (rare) Chylomicrons, VLDL TG ↑→ C uuid:e8018fbf-3f4c-45b7-9c4e-e5f57eeccf4f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15940 biolink:treats MONDO:0007762 PMID:41385096 "[{""id"":""uuid:722e42c5-07ee-4e12-9410-31f91788ce8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:46469f7c-fddd-4960-9dac-4ff30951d8ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] I. Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Nicotinic acid, alone or in combination with a bile-acid binding resin, is indicated as an adjunct to diet for the reduction of elevated total and LDL cholesterol levels in patients with primary hypercholesterolemia (Types IIa and IIb) † , when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate (see also the NCEP treatment guidelines 6 ). Prior to initiating therapy with nicotinic acid, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total cholesterol, HDL cholesterol, and triglycerides. II. Nicotinic acid is also indicated as adjunctive therapy for the treatment of adult patients with very high serum triglyceride levels (Types IV and V hyperlipidemia) † who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Such patients typically have serum triglyceride levels over 2,000 mg/dL and have elevations of VLDL cholesterol as well as fasting chylomicrons (Type V hyperlipidemia) † . Subjects who consistently have total serum or plasma triglycerides below 1,000 mg/dL are unlikely to develop pancreatitis. Therapy with nicotinic acid may be considered for those subjects with triglyceride elevations between 1,000 and 2,000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. Some Type IV patients with triglycerides under 1,000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of nicotinic acid therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of VLDL. Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia 7 . † Classification of Hyperlipoproteinemias Lipoproteins Lipid Elevations Type Elevated Major Minor C = cholesterol, TG = triglycerides LDL = low-density lipoprotein VLDL = very low-density lipoprotein IDL = intermediate-density lipoprotein I (rare) Chylomicrons TG ↑→ C IIa LDL C ..... IIb LDL, VLDL C TG III (rare) IDL C/TG ..... IV VLDL TG ↑→ C V (rare) Chylomicrons, VLDL TG ↑→ C uuid:41f4f058-41e5-4c9f-9ab5-e2400bac2a6e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63627 biolink:treats UMLS:C0023886 PMID:41385096 "[{""id"":""uuid:b4a86aab-2901-4fc1-a9b1-ca081ccc4022"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3b4312e1-7590-4ed1-9272-78937c0df88f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1 INDICATIONS AND USAGE 1.1 Trichomoniasis Tinidazole is indicated for the treatment of trichomoniasis caused by Trichomonas vaginalis. The organism should be identified by appropriate diagnostic procedures. Because trichomoniasis is a sexually transmitted disease with potentially serious sequelae, partners of infected patients should be treated simultaneously in order to prevent re-infection [see Clinical Studies (14.1)]. 1.2 Giardiasis Tinidazole is indicated for the treatment of giardiasis caused by Giardia duodenalis (also termed G. lamblia) in both adults and pediatric patients older than three years of age [see Clinical Studies (14.2)]. 1.3 Amebiasis Tinidazole is indicated for the treatment of intestinal amebiasis and amebic liver abscess caused by Entamoeba histolytica in both adults and pediatric patients older than three years of age. It is not indicated in the treatment of asymptomatic cyst passage [see Clinical Studies (14.3, 14.4)]. 1.4 Bacterial Vaginosis Tinidazole is indicated for the treatment of bacterial vaginosis (formerly referred to as Haemophilus vaginitis, Gardnerella vaginitis, nonspecific vaginitis, or anaerobic vaginosis) in adult women [see Use in Specific Populations (8.1) and Clinical Studies (14.5)]. Other pathogens commonly associated with vulvovaginitis such as Trichomonas vaginalis, Chlamydia trachomatis, Neisseria gonorrhoeae, Candida albicans and Herpes simplex virus should be ruled out. 1.5 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of Tindamax and other antibacterial drugs, Tindamax should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:2c6e263f-106b-41f7-ab5a-e3365df7de6e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:131884828 biolink:treats MONDO:0008224 PMID:41385096 "[{""id"":""uuid:c64476b3-ceba-4b2e-85b9-7272ae413601"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8a05ad52-b251-4be4-bd4a-91449ebc4e6d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEVEYIS is indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants. uuid:13ffbce6-87da-4226-9c18-10078b4b7a50 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:131884828 biolink:treats MONDO:0008223 PMID:41385096 "[{""id"":""uuid:f30259a1-226b-4282-b615-598a51c9430e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a9ea5c6e-d417-4630-abbd-264fbfeede86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEVEYIS is indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants. uuid:2bfdb960-97cf-4248-9dcc-e7d0d2de36cc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28971 biolink:treats MONDO:0020920 PMID:41385096 "[{""id"":""uuid:3ed55dc6-d764-4ea1-b0c8-3db1af905c44"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:41c5b1ff-f851-4fdf-a528-df5816828043"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin capsules, ampicillin for oral suspension and other antibacterial drugs, ampicillin capsules and ampicillin for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting of modifying antimicrobial therapy, in the absence of such data, local epidemiology and susceptibility patterns contribute to the empiric selection of therapy. Ampicillin capsules and ampicillin for oral suspension are indicated in the treatment of infections caused by susceptible strains of the designated organisms listed below: Infections of the genitourinary tract including gonorrhea: E. coli, P. mirabilis, enterococci , Shigella, S. typhosa and other Salmonella , and nonpenicillinase producing N. gonorrhoeae . Infections of the respiratory tract: Nonpenicillinase- producing H. influenzae and staphylococci, and streptococci including streptococcus pneumoniae . Infections of the gastrointestinal tract: Shigella, S. typhosa and other Salmonella, E. coli, P. mirabilis, and enterococci . Meningitis: N. Meningitides . Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to the results of susceptibility testing. uuid:a5c31745-3cb1-4ab8-9728-976ddd5f015a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28971 biolink:treats MONDO:0019345 PMID:41385096 "[{""id"":""uuid:dfa248a6-2259-4e30-9f57-d56044df96b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fc1a459f-016a-42c5-a585-a2c71b1c180f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin capsules, ampicillin for oral suspension and other antibacterial drugs, ampicillin capsules and ampicillin for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting of modifying antimicrobial therapy, in the absence of such data, local epidemiology and susceptibility patterns contribute to the empiric selection of therapy. Ampicillin capsules and ampicillin for oral suspension are indicated in the treatment of infections caused by susceptible strains of the designated organisms listed below: Infections of the genitourinary tract including gonorrhea: E. coli, P. mirabilis, enterococci , Shigella, S. typhosa and other Salmonella , and nonpenicillinase producing N. gonorrhoeae . Infections of the respiratory tract: Nonpenicillinase- producing H. influenzae and staphylococci, and streptococci including streptococcus pneumoniae . Infections of the gastrointestinal tract: Shigella, S. typhosa and other Salmonella, E. coli, P. mirabilis, and enterococci . Meningitis: N. Meningitides . Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to the results of susceptibility testing. uuid:81df3d95-459b-4dae-b142-b81867d07d40 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28971 biolink:treats MONDO:0000827 PMID:41385096 "[{""id"":""uuid:a022efaa-d729-46ce-bb61-542d4201e570"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:286a069a-5757-474a-99b9-d456a1110e82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin capsules, ampicillin for oral suspension and other antibacterial drugs, ampicillin capsules and ampicillin for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting of modifying antimicrobial therapy, in the absence of such data, local epidemiology and susceptibility patterns contribute to the empiric selection of therapy. Ampicillin capsules and ampicillin for oral suspension are indicated in the treatment of infections caused by susceptible strains of the designated organisms listed below: Infections of the genitourinary tract including gonorrhea: E. coli, P. mirabilis, enterococci , Shigella, S. typhosa and other Salmonella , and nonpenicillinase producing N. gonorrhoeae . Infections of the respiratory tract: Nonpenicillinase- producing H. influenzae and staphylococci, and streptococci including streptococcus pneumoniae . Infections of the gastrointestinal tract: Shigella, S. typhosa and other Salmonella, E. coli, P. mirabilis, and enterococci . Meningitis: N. Meningitides . Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to the results of susceptibility testing. uuid:0a093063-530d-4048-a65f-bf4e68d34813 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28971 biolink:treats HP:0005376 PMID:41385096 "[{""id"":""uuid:38442cce-b555-459c-8303-7563bd980e34"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3cadc579-dbb0-453e-b57d-6d1c964ad055"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin capsules, ampicillin for oral suspension and other antibacterial drugs, ampicillin capsules and ampicillin for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting of modifying antimicrobial therapy, in the absence of such data, local epidemiology and susceptibility patterns contribute to the empiric selection of therapy. Ampicillin capsules and ampicillin for oral suspension are indicated in the treatment of infections caused by susceptible strains of the designated organisms listed below: Infections of the genitourinary tract including gonorrhea: E. coli, P. mirabilis, enterococci , Shigella, S. typhosa and other Salmonella , and nonpenicillinase producing N. gonorrhoeae . Infections of the respiratory tract: Nonpenicillinase- producing H. influenzae and staphylococci, and streptococci including streptococcus pneumoniae . Infections of the gastrointestinal tract: Shigella, S. typhosa and other Salmonella, E. coli, P. mirabilis, and enterococci . Meningitis: N. Meningitides . Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to the results of susceptibility testing. uuid:c6a812a2-2ca6-40ae-b19f-32a7f53afcec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28971 biolink:treats MONDO:0024313 PMID:41385096 "[{""id"":""uuid:09a1bb2b-fd78-4d9c-9bbe-b5f1c034cd44"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:02bea06a-1d9a-49a7-9214-200985ae9bef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin capsules, ampicillin for oral suspension and other antibacterial drugs, ampicillin capsules and ampicillin for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting of modifying antimicrobial therapy, in the absence of such data, local epidemiology and susceptibility patterns contribute to the empiric selection of therapy. Ampicillin capsules and ampicillin for oral suspension are indicated in the treatment of infections caused by susceptible strains of the designated organisms listed below: Infections of the genitourinary tract including gonorrhea: E. coli, P. mirabilis, enterococci , Shigella, S. typhosa and other Salmonella , and nonpenicillinase producing N. gonorrhoeae . Infections of the respiratory tract: Nonpenicillinase- producing H. influenzae and staphylococci, and streptococci including streptococcus pneumoniae . Infections of the gastrointestinal tract: Shigella, S. typhosa and other Salmonella, E. coli, P. mirabilis, and enterococci . Meningitis: N. Meningitides . Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to the results of susceptibility testing. uuid:c786c853-e890-41a5-8e92-69b1417d91d3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28971 biolink:treats MONDO:0021679 PMID:41385096 "[{""id"":""uuid:b8ebc917-3912-4047-8e13-7997e1898a71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:224cd700-39a0-4a00-8611-fc8e952d4437"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin capsules, ampicillin for oral suspension and other antibacterial drugs, ampicillin capsules and ampicillin for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting of modifying antimicrobial therapy, in the absence of such data, local epidemiology and susceptibility patterns contribute to the empiric selection of therapy. Ampicillin capsules and ampicillin for oral suspension are indicated in the treatment of infections caused by susceptible strains of the designated organisms listed below: Infections of the genitourinary tract including gonorrhea: E. coli, P. mirabilis, enterococci , Shigella, S. typhosa and other Salmonella , and nonpenicillinase producing N. gonorrhoeae . Infections of the respiratory tract: Nonpenicillinase- producing H. influenzae and staphylococci, and streptococci including streptococcus pneumoniae . Infections of the gastrointestinal tract: Shigella, S. typhosa and other Salmonella, E. coli, P. mirabilis, and enterococci . Meningitis: N. Meningitides . Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to the results of susceptibility testing. uuid:46e38234-c703-4fea-8fbc-ddf09a698ee3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28971 biolink:treats MONDO:0005114 PMID:41385096 "[{""id"":""uuid:100b93f1-f751-4ce6-95dd-87518b5d4a52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:812b1f85-6a64-4874-96eb-36f78554c0e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of ampicillin capsules, ampicillin for oral suspension and other antibacterial drugs, ampicillin capsules and ampicillin for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting of modifying antimicrobial therapy, in the absence of such data, local epidemiology and susceptibility patterns contribute to the empiric selection of therapy. Ampicillin capsules and ampicillin for oral suspension are indicated in the treatment of infections caused by susceptible strains of the designated organisms listed below: Infections of the genitourinary tract including gonorrhea: E. coli, P. mirabilis, enterococci , Shigella, S. typhosa and other Salmonella , and nonpenicillinase producing N. gonorrhoeae . Infections of the respiratory tract: Nonpenicillinase- producing H. influenzae and staphylococci, and streptococci including streptococcus pneumoniae . Infections of the gastrointestinal tract: Shigella, S. typhosa and other Salmonella, E. coli, P. mirabilis, and enterococci . Meningitis: N. Meningitides . Bacteriology studies to determine the causative organisms and their susceptibility to ampicillin should be performed. Therapy may be instituted prior to the results of susceptibility testing. uuid:85d99a3c-0144-41ab-831d-a8d9f3629e36 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72296 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:dee74edc-7d4c-4365-a7c0-106415401c24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e7b86887-1f2e-4d9a-abde-029103071a9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:76a60e7c-9980-4129-9d2b-7c9225569c6a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/eliquis""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ELIQUIS is a factor Xa inhibitor indicated: • to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. (1.1) • for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. (1.2) • for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy. (1.3 , 1.4 , 1.5)|[EMA] For Eliquis 2.5 mg film-coated tablets:Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery.Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II).Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients).For Eliquis 5 mg film-coated tablets:Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II).Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients). uuid:c25de466-ab97-4df4-b8e7-04362fec107f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72296 biolink:treats UMLS:C5400523 PMID:41385096 "[{""id"":""uuid:541835ae-2e18-4a67-9306-55462834a448"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:848af478-4260-4aa0-bf2e-c92b65c58482"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e15959c1-9b31-4a1d-ac71-81238afac0a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ELIQUIS is a factor Xa inhibitor indicated: • to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. (1.1) • for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in patients who have undergone hip or knee replacement surgery. (1.2) • for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE following initial therapy. (1.3 , 1.4 , 1.5)|[PMDA] Drugs with a new active ingredient indicated for prevention of ischemic stroke and systemic embolism in patients with nonvalvular atrial fibrillation. uuid:1cb82a84-1728-49c0-8c1b-682e9cae41eb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats MONDO:0019269 PMID:41385096 "[{""id"":""uuid:be4865f7-0ad4-4af8-afd7-5c6936ac66e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cb9d9ce5-bcec-429f-b280-be1d827e1299"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SALVAX is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders, including verrucae and the various ichthyoses, keratosis palmaris and plantaris, keratosis pilaris, pityriasis rubra pilaris, and psoriasis. uuid:a24d7fa4-f465-4956-b762-f7edfbe56594 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7459 biolink:treats UMLS:C0151559 PMID:41385096 "[{""id"":""uuid:bd0ac89b-30d4-49fb-ad90-ccaaa25336f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a63d949d-78e4-44ba-9b07-b9beaab927ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Naloxone HCl Nasal Spray is indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. Naloxone HCl Nasal Spray is intended for immediate administration as emergency therapy in settings where opioids may be present. Naloxone HCl Nasal Spray is not a substitute for emergency medical care. uuid:0ee4abe9-8ace-497f-bce3-1e9d9bba7daf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9570 biolink:treats MONDO:0002657 PMID:41385096 "[{""id"":""uuid:70982eb2-9f70-4726-91ba-751dbe4415d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:22739b15-4560-45bd-9cd7-843d9789b8c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thiotepa for injection is an alkylating drug indicated: • For treatment of adenocarcinoma of the breast or ovary. ( 1.2 ) • For controlling intracavitary effusions secondary to diffuse or localized neoplastic diseases of various serosal cavities. ( 1.3 ) • For treatment of superficial papillary carcinoma of the urinary bladder. ( 1.4 ) uuid:e1670e18-5499-4f23-8290-c293baf30292 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:30769 biolink:treats MONDO:0957318 PMID:41385096 "[{""id"":""uuid:03175bdc-ddc7-4d94-8e4a-61714e29ab23"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:db2dd3dc-3790-4206-9575-bd502d3b92c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Potassium Citrate Extended-Release Tablets are a citrate salt of potassium indicated for the management of: • Renal tubular acidosis (RTA) with calcium stones ( 1.1 ) • Hypocitraturic calcium oxalate nephrolithiasis of any etiology ( 1.2 ) • Uric acid lithiasis with or without calcium stones ( 1.3 ) uuid:81c47d68-86c9-4eb5-ab45-5d6d1d3107f5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:30769 biolink:treats MONDO:0012692 PMID:41385096 "[{""id"":""uuid:8dd148f5-ecee-4a05-bc09-e80f2df7e312"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7f6b35f3-6df9-431b-83aa-aea4484a2a1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Potassium citrate extended-release tablets is a citrate salt of potassium indicated for the management of: Renal tubular acidosis (RTA) with calcium stones (1.1) Hypocitraturic calcium oxalate nephrolithiasis of any etiology (1.2) Uric acid lithiasis with or without calcium stones (1.3) uuid:3ce277f6-47f4-4ccb-9539-6b11c9e5036f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:30769 biolink:treats MONDO:0024647 PMID:41385096 "[{""id"":""uuid:aca28ac9-ded4-4e0f-b620-4cd6e735a22e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:add3156f-8410-4284-ac81-8bb5599f303d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Potassium citrate extended-release tablets is a citrate salt of potassium indicated for the management of: Renal tubular acidosis (RTA) with calcium stones (1.1) Hypocitraturic calcium oxalate nephrolithiasis of any etiology (1.2) Uric acid lithiasis with or without calcium stones (1.3) uuid:7b6c0649-7658-482f-a05f-4b5c404ed822 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:25939 biolink:treats UMLS:C0043255 PMID:41385096 "[{""id"":""uuid:d3572106-d330-4260-a6f8-87ed2a248abb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a2b7816b-2318-4acc-bda4-c5c51fa13fd6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Astringent, Alkaline, for superficial and deep festering wounds. for 1st, 2nd and 3rd ulcers and burns. grade. Ideal for people with diabetes.Úpply directly without diluting, on the affected area or use an impregnated gauze. uuid:20d1204e-68dd-4e82-b4f7-4bbe70998aed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:25939 biolink:treats MONDO:0043839 PMID:41385096 "[{""id"":""uuid:d2fff5d4-0653-4ca6-aa39-9900f4e2ce6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:461b2336-48c2-4613-9070-69d55142de2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Astringent, Alkaline, for superficial and deep festering wounds. for 1st, 2nd and 3rd ulcers and burns. grade. Ideal for people with diabetes.Úpply directly without diluting, on the affected area or use an impregnated gauze. uuid:929480c3-4a8c-4764-bf5e-5fcac6376559 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:c1b6192f-79eb-4333-b069-f2c468afb775"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2020aca6-e0c3-4abb-839e-eb66347009e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes. Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections. Infections in women caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum subspecies pallidum . Yaws caused by Treponema pallidum subspecies pertenue . Listeriosis due to Listeria monocytogenes . Anthrax due to Bacillus anthracis . Vincent's infection caused by Fusobacterium fusiforme . � Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection . Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum . To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules, USP and other antibacterial drugs, minocycline hydrochloride capsules, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:6d2e82fa-2907-4380-bf12-03cb9812fb0c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0005114 PMID:41385096 "[{""id"":""uuid:07d5c02f-ba5d-44e0-afe3-40f7cd6ffa41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e2180083-1e1a-481f-bc95-87afebcdca81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes. Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections. Infections in women caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum subspecies pallidum . Yaws caused by Treponema pallidum subspecies pertenue . Listeriosis due to Listeria monocytogenes . Anthrax due to Bacillus anthracis . Vincent's infection caused by Fusobacterium fusiforme . � Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection . Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum . To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules, USP and other antibacterial drugs, minocycline hydrochloride capsules, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:3b6d7144-dd43-4e2d-9e98-c51d70839ee3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0005545 PMID:41385096 "[{""id"":""uuid:527bded6-3be3-4dc7-a355-25392247866f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:70e41174-6ed2-4ca3-94ac-4f2de294eb28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline hydrochloride capsules, USP are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae . Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis . Relapsing fever due to Borrelia recurrentis . Chancroid caused by Haemophilus ducreyi . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes. Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules, USP are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae . Skin and skin structure infections caused by Staphylococcus aureus . (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections. Infections in women caused by Neisseria gonorrhoeae . Syphilis caused by Treponema pallidum subspecies pallidum . Yaws caused by Treponema pallidum subspecies pertenue . Listeriosis due to Listeria monocytogenes . Anthrax due to Bacillus anthracis . Vincent's infection caused by Fusobacterium fusiforme . � Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species. In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection . Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum . To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules, USP and other antibacterial drugs, minocycline hydrochloride capsules, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:94043dba-dce1-4caa-8e4f-f7d892d99fca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17347 biolink:treats HP:0012287 PMID:41385096 "[{""id"":""uuid:64b43c76-5b58-4cb4-a632-c597b3873d0f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:178666f3-0e5e-4024-93bc-25a97937930e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Testosterone gel, 1.62% is indicated for replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired): testicular failure due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum concentrations, but have gonadotropins in the normal or low range. Limitations of use: Safety and efficacy of testosterone gel, 1.62% in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established. Safety and efficacy of testosterone gel, 1.62% in males less than 18 years old have not been established [see Use in Specific Populations ( 8.4 )] . Topical testosterone products may have different doses, strengths, or application instructions that may result in different systemic exposure [see Indications and Usage ( 1 ), and Clinical Pharmacology ( 12.3 )]. uuid:96650db2-7359-466c-8caf-d1f86077a336 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:9fb06f30-6270-47b6-b842-55350c9c7061"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:dd61eafc-13b1-45b8-9fe3-90f509f2853b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d1b5e061-16ab-433e-844f-f9623a6476c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d01e0624-01ca-4295-b787-ce76d8fe4b15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxorubicin hydrochloride (HCl) is an anthracycline topoisomerase II inhibitor indicated: as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer (1.1). for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma (1.2).|[EMA] Zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. Zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. Zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• Kaposi’s sarcoma in patients with AIDS who have a very damaged immune system. Kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs.Zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. This means that it is similar to a ‘reference medicine’ containing the same active substance called Adriamycin. However, in Zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for Adriamycin.|[PMDA] Drugs with a new dosage indicated for the treatment of breast cancer (preoperative or postoperative chemotherapy in patients with operable breast cancer). [Public knowledge-based application] uuid:b1dcf043-8fd0-4162-9e8a-1c0d6096c354 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats MONDO:0004967 PMID:41385096 "[{""id"":""uuid:21d972b7-7697-4573-903d-70ffde77bd7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aa1252d5-7203-41aa-b2f4-2049e800253f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxorubicin hydrochloride (HCl) is an anthracycline topoisomerase II inhibitor indicated: as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer (1.1). for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma (1.2). uuid:f30b56ef-cf60-4386-9db7-2f4848f48c6a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats MONDO:0005224 PMID:41385096 "[{""id"":""uuid:cf3e8baf-0fac-481d-a7be-a36f45981a6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cda06420-6a7d-418f-812e-7e73542b5540"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxorubicin hydrochloride (HCl) is an anthracycline topoisomerase II inhibitor indicated: as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer (1.1). for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma (1.2). uuid:eefb80a2-2afa-4df2-a55f-96a48a919144 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats MONDO:0009348 PMID:41385096 "[{""id"":""uuid:790b60ff-788a-4b11-addb-a50a620dd584"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:15d76920-8d9d-412d-af8f-2dd9b92de498"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxorubicin hydrochloride (HCl) is an anthracycline topoisomerase II inhibitor indicated: as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer (1.1). for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma (1.2). uuid:749395be-fb38-4714-aa5d-92cca411bab8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats MONDO:0018908 PMID:41385096 "[{""id"":""uuid:ff22abd3-1362-48cd-bdf9-ce4869225942"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7dec3096-23e6-41ff-9fe8-66da291aab9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxorubicin hydrochloride (HCl) is an anthracycline topoisomerase II inhibitor indicated: as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer (1.1). for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma (1.2). uuid:788cabbf-ce03-42c8-8607-798795a7d745 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats UMLS:C0278488 PMID:41385096 "[{""id"":""uuid:ff80dff2-4c98-4258-94b3-e90936772cf5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:87d94943-9c3b-42da-be82-e3606da51ba3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxorubicin hydrochloride (HCl) is an anthracycline topoisomerase II inhibitor indicated: as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer (1.1). for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma (1.2). uuid:776a587d-3ede-4aad-ae27-392c6e287964 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats MONDO:0006058 PMID:41385096 "[{""id"":""uuid:54e52874-d252-4919-9ea8-0b202c82d103"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:279b7f8c-a825-43bd-823a-c3feae3e9101"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxorubicin hydrochloride (HCl) is an anthracycline topoisomerase II inhibitor indicated: as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer (1.1). for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma (1.2). uuid:abbb9149-ecd7-4240-a171-4d30f315712e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats MONDO:0005072 PMID:41385096 "[{""id"":""uuid:bb5f53f3-69b3-4cb8-95a9-6ea0f6f18fa2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ffe46783-4ec0-4e25-b637-d23949e98dfe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxorubicin hydrochloride (HCl) is an anthracycline topoisomerase II inhibitor indicated: as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer (1.1). for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma (1.2). uuid:1a137c9e-d63c-4cca-a1f0-530935941d1b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats MONDO:0018078 PMID:41385096 "[{""id"":""uuid:f0b8e8b2-9ef5-4598-b8bb-059fade7b322"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3a22f9ae-0089-4a0a-af27-423d25470b29"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxorubicin hydrochloride (HCl) is an anthracycline topoisomerase II inhibitor indicated: as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer (1.1). for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma (1.2). uuid:b0993851-3e2d-4afc-a064-9b7f074ee8a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats MONDO:0021054 PMID:41385096 "[{""id"":""uuid:dbebee70-6efb-4001-9b88-93df6cfb994a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:59bbb57c-86b2-4671-9b77-6459011ea2cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxorubicin hydrochloride (HCl) is an anthracycline topoisomerase II inhibitor indicated: as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer (1.1). for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma (1.2). uuid:76bbc047-43cd-4616-9f24-390f554b8cf7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats MONDO:0005140 PMID:41385096 "[{""id"":""uuid:59bbcdb0-99c6-4606-b9fc-0181b043ad05"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2f8793b5-94c0-4565-a327-b502c44bd1f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxorubicin hydrochloride (HCl) is an anthracycline topoisomerase II inhibitor indicated: as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer (1.1). for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma (1.2). uuid:2df5cb04-d859-43e5-93b2-dd3fee549b6e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats MONDO:0005611 PMID:41385096 "[{""id"":""uuid:a59f6508-8b06-43fd-8b8c-fc38a33c70a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bc047a79-86c4-4f3a-b0b2-674548541097"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxorubicin hydrochloride (HCl) is an anthracycline topoisomerase II inhibitor indicated: as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer (1.1). for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma (1.2). uuid:188aa502-6edf-4fc4-9acc-526b237ec785 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats MONDO:0015075 PMID:41385096 "[{""id"":""uuid:ff9d9414-87fa-4fe1-a6a1-282b69804427"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7ac7bad4-6049-482a-9b4f-242b8418c558"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxorubicin hydrochloride (HCl) is an anthracycline topoisomerase II inhibitor indicated: as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer (1.1). for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma (1.2). uuid:4ffdfba2-6800-41e4-b36b-8aef6eefdfa1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats MONDO:0004716 PMID:41385096 "[{""id"":""uuid:fc235aa3-7499-4b61-a73d-0ded6d44184b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d7984f1c-a97a-490b-99f7-ddcbe0c3fa5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxorubicin hydrochloride (HCl) is an anthracycline topoisomerase II inhibitor indicated: as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer (1.1). for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma (1.2). uuid:053276cd-256d-4d87-a9d0-b687300cbcad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats MONDO:0002806 PMID:41385096 "[{""id"":""uuid:6309ba60-0b8a-4b8f-b4a4-f79fa5ab56d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:859d893e-1f05-4fac-8b79-d1777228e2f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxorubicin hydrochloride (HCl) is an anthracycline topoisomerase II inhibitor indicated: as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer (1.1). for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms’ tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma (1.2). uuid:08d8f2e3-bf57-4d72-8be8-668b064c95d0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C3537689 biolink:treats MONDO:0005412 PMID:41385096 "[{""id"":""uuid:940fa4fc-e794-466e-82b6-d48c26ed2e62"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6ad09dbb-f97a-496a-9bf9-417b15bf70cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Treatment of Active Duodenal Ulcer Omeprazole delayed-release capsules are indicated for short-term treatment of active duodenal ulcer in adults. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy. 1.2 Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. Triple Therapy Omeprazole delayed-release capsules in combination with clarithromycin and amoxicillin, are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease (active or up to 1-year history) to eradicate H. pylori in adults. Dual Therapy Omeprazole delayed-release capsules in combination with clarithromycin are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease to eradicate H. pylori in adults. Among patients who fail therapy, omeprazole delayed-release capsules are with clarithromycin is more likely to be associated with the development of clarithromycin resistance as compared with triple therapy. In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted [see Clinical Pharmacology (12.4) and the clarithromycin prescribing information, Microbiology section]. 1.3 Treatment of Active Benign Gastric Ulcer Omeprazole delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of active benign gastric ulcer in adults. 1.4 Treatment of Symptomatic Gastroesophageal Reflux Disease (GERD) Omeprazole delayed-release capsules are indicated for the treatment of heartburn and other symptoms associated with GERD for up to 4 weeks in patients 2 years of age and older. 1.5 Treatment of Erosive Esophagitis (EE) Due to Acid-Mediated GERD Pediatric Patients 2 Years of Age to Adults Omeprazole delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) of EE due to acid-mediated GERD that has been diagnosed by endoscopy in patients 2 years of age and older. The efficacy of omeprazole delayed-release capsules used for longer than 8 weeks in patients with EE has not been established. If a patient does not respond to 8 weeks of treatment, an additional 4 weeks of treatment may be given. If there is recurrence of EE or GERD symptoms (e.g., heartburn), additional 4 to 8 week courses of omeprazole delayed-release capsules may be considered. 1.6 Maintenance of Healing of EE Due to Acid-Mediated GERD Omeprazole delayed-release capsules are indicated for the maintenance healing of EE due to acid-mediated GERD in patients 2 years of age and older. Controlled studies do not extend beyond 12 months. 1.7 Pathological Hypersecretory Conditions Omeprazole delayed-release capsules are indicated for the long-term treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine adenomas and systemic mastocytosis) in adults. uuid:c488702a-f341-41a9-8753-bd6b001cc664 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C3537689 biolink:treats HP:0005202 PMID:41385096 "[{""id"":""uuid:b75b5084-fae2-44a5-895e-8dd0c8457b99"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:05227a31-fd70-4e3c-aaaa-df71048e9b53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Treatment of Active Duodenal Ulcer Omeprazole delayed-release capsules are indicated for short-term treatment of active duodenal ulcer in adults. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy. 1.2 Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. Triple Therapy Omeprazole delayed-release capsules in combination with clarithromycin and amoxicillin, are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease (active or up to 1-year history) to eradicate H. pylori in adults. Dual Therapy Omeprazole delayed-release capsules in combination with clarithromycin are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease to eradicate H. pylori in adults. Among patients who fail therapy, omeprazole delayed-release capsules are with clarithromycin is more likely to be associated with the development of clarithromycin resistance as compared with triple therapy. In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted [see Clinical Pharmacology (12.4) and the clarithromycin prescribing information, Microbiology section]. 1.3 Treatment of Active Benign Gastric Ulcer Omeprazole delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of active benign gastric ulcer in adults. 1.4 Treatment of Symptomatic Gastroesophageal Reflux Disease (GERD) Omeprazole delayed-release capsules are indicated for the treatment of heartburn and other symptoms associated with GERD for up to 4 weeks in patients 2 years of age and older. 1.5 Treatment of Erosive Esophagitis (EE) Due to Acid-Mediated GERD Pediatric Patients 2 Years of Age to Adults Omeprazole delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) of EE due to acid-mediated GERD that has been diagnosed by endoscopy in patients 2 years of age and older. The efficacy of omeprazole delayed-release capsules used for longer than 8 weeks in patients with EE has not been established. If a patient does not respond to 8 weeks of treatment, an additional 4 weeks of treatment may be given. If there is recurrence of EE or GERD symptoms (e.g., heartburn), additional 4 to 8 week courses of omeprazole delayed-release capsules may be considered. 1.6 Maintenance of Healing of EE Due to Acid-Mediated GERD Omeprazole delayed-release capsules are indicated for the maintenance healing of EE due to acid-mediated GERD in patients 2 years of age and older. Controlled studies do not extend beyond 12 months. 1.7 Pathological Hypersecretory Conditions Omeprazole delayed-release capsules are indicated for the long-term treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine adenomas and systemic mastocytosis) in adults. uuid:3f8d66cc-5ff9-4904-b280-223a10cd0368 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C3537689 biolink:treats MONDO:0001126 PMID:41385096 "[{""id"":""uuid:aed75ecc-314c-4ed4-8846-a6d50bf29b81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cf4246b6-7cc2-4e86-a401-bb2968e30ef5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Treatment of Active Duodenal Ulcer Omeprazole delayed-release capsules are indicated for short-term treatment of active duodenal ulcer in adults. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy. 1.2 Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. Triple Therapy Omeprazole delayed-release capsules in combination with clarithromycin and amoxicillin, are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease (active or up to 1-year history) to eradicate H. pylori in adults. Dual Therapy Omeprazole delayed-release capsules in combination with clarithromycin are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease to eradicate H. pylori in adults. Among patients who fail therapy, omeprazole delayed-release capsules are with clarithromycin is more likely to be associated with the development of clarithromycin resistance as compared with triple therapy. In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted [see Clinical Pharmacology (12.4) and the clarithromycin prescribing information, Microbiology section]. 1.3 Treatment of Active Benign Gastric Ulcer Omeprazole delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of active benign gastric ulcer in adults. 1.4 Treatment of Symptomatic Gastroesophageal Reflux Disease (GERD) Omeprazole delayed-release capsules are indicated for the treatment of heartburn and other symptoms associated with GERD for up to 4 weeks in patients 2 years of age and older. 1.5 Treatment of Erosive Esophagitis (EE) Due to Acid-Mediated GERD Pediatric Patients 2 Years of Age to Adults Omeprazole delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) of EE due to acid-mediated GERD that has been diagnosed by endoscopy in patients 2 years of age and older. The efficacy of omeprazole delayed-release capsules used for longer than 8 weeks in patients with EE has not been established. If a patient does not respond to 8 weeks of treatment, an additional 4 weeks of treatment may be given. If there is recurrence of EE or GERD symptoms (e.g., heartburn), additional 4 to 8 week courses of omeprazole delayed-release capsules may be considered. 1.6 Maintenance of Healing of EE Due to Acid-Mediated GERD Omeprazole delayed-release capsules are indicated for the maintenance healing of EE due to acid-mediated GERD in patients 2 years of age and older. Controlled studies do not extend beyond 12 months. 1.7 Pathological Hypersecretory Conditions Omeprazole delayed-release capsules are indicated for the long-term treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine adenomas and systemic mastocytosis) in adults. uuid:e342c85c-058e-47c8-a3e8-1fb97f57af62 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C3537689 biolink:treats MONDO:0007186 PMID:41385096 "[{""id"":""uuid:91727c36-bab7-439f-b044-0c24aeb29b6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e6f9cd82-1095-4e79-9fa3-99df5138c1ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Treatment of Active Duodenal Ulcer Omeprazole delayed-release capsules are indicated for short-term treatment of active duodenal ulcer in adults. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy. 1.2 Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. Triple Therapy Omeprazole delayed-release capsules in combination with clarithromycin and amoxicillin, are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease (active or up to 1-year history) to eradicate H. pylori in adults. Dual Therapy Omeprazole delayed-release capsules in combination with clarithromycin are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease to eradicate H. pylori in adults. Among patients who fail therapy, omeprazole delayed-release capsules are with clarithromycin is more likely to be associated with the development of clarithromycin resistance as compared with triple therapy. In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted [see Clinical Pharmacology (12.4) and the clarithromycin prescribing information, Microbiology section]. 1.3 Treatment of Active Benign Gastric Ulcer Omeprazole delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of active benign gastric ulcer in adults. 1.4 Treatment of Symptomatic Gastroesophageal Reflux Disease (GERD) Omeprazole delayed-release capsules are indicated for the treatment of heartburn and other symptoms associated with GERD for up to 4 weeks in patients 2 years of age and older. 1.5 Treatment of Erosive Esophagitis (EE) Due to Acid-Mediated GERD Pediatric Patients 2 Years of Age to Adults Omeprazole delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) of EE due to acid-mediated GERD that has been diagnosed by endoscopy in patients 2 years of age and older. The efficacy of omeprazole delayed-release capsules used for longer than 8 weeks in patients with EE has not been established. If a patient does not respond to 8 weeks of treatment, an additional 4 weeks of treatment may be given. If there is recurrence of EE or GERD symptoms (e.g., heartburn), additional 4 to 8 week courses of omeprazole delayed-release capsules may be considered. 1.6 Maintenance of Healing of EE Due to Acid-Mediated GERD Omeprazole delayed-release capsules are indicated for the maintenance healing of EE due to acid-mediated GERD in patients 2 years of age and older. Controlled studies do not extend beyond 12 months. 1.7 Pathological Hypersecretory Conditions Omeprazole delayed-release capsules are indicated for the long-term treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine adenomas and systemic mastocytosis) in adults. uuid:3e8fb666-7a18-474f-9fec-22183969fb97 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C3537689 biolink:treats UMLS:C0267055 PMID:41385096 "[{""id"":""uuid:394d586b-2a64-40e0-a7f4-60ada52461ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:92cfce72-5710-4243-bfb0-3f9719a28293"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Treatment of Active Duodenal Ulcer Omeprazole delayed-release capsules are indicated for short-term treatment of active duodenal ulcer in adults. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy. 1.2 Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. Triple Therapy Omeprazole delayed-release capsules in combination with clarithromycin and amoxicillin, are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease (active or up to 1-year history) to eradicate H. pylori in adults. Dual Therapy Omeprazole delayed-release capsules in combination with clarithromycin are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease to eradicate H. pylori in adults. Among patients who fail therapy, omeprazole delayed-release capsules are with clarithromycin is more likely to be associated with the development of clarithromycin resistance as compared with triple therapy. In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted [see Clinical Pharmacology (12.4) and the clarithromycin prescribing information, Microbiology section]. 1.3 Treatment of Active Benign Gastric Ulcer Omeprazole delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of active benign gastric ulcer in adults. 1.4 Treatment of Symptomatic Gastroesophageal Reflux Disease (GERD) Omeprazole delayed-release capsules are indicated for the treatment of heartburn and other symptoms associated with GERD for up to 4 weeks in patients 2 years of age and older. 1.5 Treatment of Erosive Esophagitis (EE) Due to Acid-Mediated GERD Pediatric Patients 2 Years of Age to Adults Omeprazole delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) of EE due to acid-mediated GERD that has been diagnosed by endoscopy in patients 2 years of age and older. The efficacy of omeprazole delayed-release capsules used for longer than 8 weeks in patients with EE has not been established. If a patient does not respond to 8 weeks of treatment, an additional 4 weeks of treatment may be given. If there is recurrence of EE or GERD symptoms (e.g., heartburn), additional 4 to 8 week courses of omeprazole delayed-release capsules may be considered. 1.6 Maintenance of Healing of EE Due to Acid-Mediated GERD Omeprazole delayed-release capsules are indicated for the maintenance healing of EE due to acid-mediated GERD in patients 2 years of age and older. Controlled studies do not extend beyond 12 months. 1.7 Pathological Hypersecretory Conditions Omeprazole delayed-release capsules are indicated for the long-term treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine adenomas and systemic mastocytosis) in adults. uuid:851ce79b-dfd4-401f-93b0-1c235c87febe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C3537689 biolink:treats MONDO:0017169 PMID:41385096 "[{""id"":""uuid:1894f68e-f861-49a4-be88-f2392b665620"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7cb339e5-f629-40a6-a376-ee76dc45ebb9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Treatment of Active Duodenal Ulcer Omeprazole delayed-release capsules are indicated for short-term treatment of active duodenal ulcer in adults. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy. 1.2 Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. Triple Therapy Omeprazole delayed-release capsules in combination with clarithromycin and amoxicillin, are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease (active or up to 1-year history) to eradicate H. pylori in adults. Dual Therapy Omeprazole delayed-release capsules in combination with clarithromycin are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease to eradicate H. pylori in adults. Among patients who fail therapy, omeprazole delayed-release capsules are with clarithromycin is more likely to be associated with the development of clarithromycin resistance as compared with triple therapy. In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted [see Clinical Pharmacology (12.4) and the clarithromycin prescribing information, Microbiology section]. 1.3 Treatment of Active Benign Gastric Ulcer Omeprazole delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of active benign gastric ulcer in adults. 1.4 Treatment of Symptomatic Gastroesophageal Reflux Disease (GERD) Omeprazole delayed-release capsules are indicated for the treatment of heartburn and other symptoms associated with GERD for up to 4 weeks in patients 2 years of age and older. 1.5 Treatment of Erosive Esophagitis (EE) Due to Acid-Mediated GERD Pediatric Patients 2 Years of Age to Adults Omeprazole delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) of EE due to acid-mediated GERD that has been diagnosed by endoscopy in patients 2 years of age and older. The efficacy of omeprazole delayed-release capsules used for longer than 8 weeks in patients with EE has not been established. If a patient does not respond to 8 weeks of treatment, an additional 4 weeks of treatment may be given. If there is recurrence of EE or GERD symptoms (e.g., heartburn), additional 4 to 8 week courses of omeprazole delayed-release capsules may be considered. 1.6 Maintenance of Healing of EE Due to Acid-Mediated GERD Omeprazole delayed-release capsules are indicated for the maintenance healing of EE due to acid-mediated GERD in patients 2 years of age and older. Controlled studies do not extend beyond 12 months. 1.7 Pathological Hypersecretory Conditions Omeprazole delayed-release capsules are indicated for the long-term treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine adenomas and systemic mastocytosis) in adults. uuid:2990c793-478f-435f-8fdf-a34a0c9b1d00 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C3537689 biolink:treats MONDO:0016586 PMID:41385096 "[{""id"":""uuid:c3a1e342-9edd-444d-93a8-633de99b82be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a27d99a5-e615-4fb7-beb0-896ea1b12680"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Treatment of Active Duodenal Ulcer Omeprazole delayed-release capsules are indicated for short-term treatment of active duodenal ulcer in adults. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy. 1.2 Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. Triple Therapy Omeprazole delayed-release capsules in combination with clarithromycin and amoxicillin, are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease (active or up to 1-year history) to eradicate H. pylori in adults. Dual Therapy Omeprazole delayed-release capsules in combination with clarithromycin are indicated for treatment of patients with H. pylori infection and duodenal ulcer disease to eradicate H. pylori in adults. Among patients who fail therapy, omeprazole delayed-release capsules are with clarithromycin is more likely to be associated with the development of clarithromycin resistance as compared with triple therapy. In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted [see Clinical Pharmacology (12.4) and the clarithromycin prescribing information, Microbiology section]. 1.3 Treatment of Active Benign Gastric Ulcer Omeprazole delayed-release capsules are indicated for short-term treatment (4 to 8 weeks) of active benign gastric ulcer in adults. 1.4 Treatment of Symptomatic Gastroesophageal Reflux Disease (GERD) Omeprazole delayed-release capsules are indicated for the treatment of heartburn and other symptoms associated with GERD for up to 4 weeks in patients 2 years of age and older. 1.5 Treatment of Erosive Esophagitis (EE) Due to Acid-Mediated GERD Pediatric Patients 2 Years of Age to Adults Omeprazole delayed-release capsules are indicated for the short-term treatment (4 to 8 weeks) of EE due to acid-mediated GERD that has been diagnosed by endoscopy in patients 2 years of age and older. The efficacy of omeprazole delayed-release capsules used for longer than 8 weeks in patients with EE has not been established. If a patient does not respond to 8 weeks of treatment, an additional 4 weeks of treatment may be given. If there is recurrence of EE or GERD symptoms (e.g., heartburn), additional 4 to 8 week courses of omeprazole delayed-release capsules may be considered. 1.6 Maintenance of Healing of EE Due to Acid-Mediated GERD Omeprazole delayed-release capsules are indicated for the maintenance healing of EE due to acid-mediated GERD in patients 2 years of age and older. Controlled studies do not extend beyond 12 months. 1.7 Pathological Hypersecretory Conditions Omeprazole delayed-release capsules are indicated for the long-term treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine adenomas and systemic mastocytosis) in adults. uuid:7aba6311-f3ba-49c4-9d73-e84234ac9de4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9150 biolink:treats MONDO:0004995 PMID:41385096 "[{""id"":""uuid:10184d48-5120-4429-98ca-a3c7ba8db085"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cc4a64a4-ea9a-44ef-9821-14201f8c82ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with coronary heart disease (CHD) or at high risk of CHD, simvastatin tablets can be started simultaneously with diet. 1.1 Reductions in Risk of CHD Mortality and Cardiovascular Events In patients at high risk of coronary events because of existing coronary heart disease, diabetes, peripheral vessel disease, history of stroke or other cerebrovascular disease, simvastatin tablets are indicated to: Reduce the risk of total mortality by reducing CHD deaths. Reduce the risk of non-fatal myocardial infarction and stroke. Reduce the need for coronary and non-coronary revascularization procedures. 1.2 Hyperlipidemia Simvastatin tablets are indicated to: Reduce elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), and triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C) in patients with primary hyperlipidemia (Fredrickson type IIa, heterozygous familial and nonfamilial) or mixed dyslipidemia (Fredrickson type IIb). Reduce elevated TG in patients with hypertriglyceridemia (Fredrickson type lV hyperlipidemia). Reduce elevated TG and VLDL-C in patients with primary dysbetalipoproteinemia (Fredrickson type III hyperlipidemia). Reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH) as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable. 1.3 Adolescent Patients with Heterozygous Familial Hypercholesterolemia (HeFH) Simvastatin tablets are indicated as an adjunct to diet to reduce total-C, LDL-C, and Apo B levels in adolescent boys and girls who are at least one year post-menarche, 10 to 17 years of age, with HeFH, if after an adequate trial of diet therapy the following findings are present: LDL cholesterol remains ≥190 mg/dL; or LDL cholesterol remains ≥160 mg/dL and There is a positive family history of premature cardiovascular disease (CVD) or Two or more other CVD risk factors are present in the adolescent patient. The minimum goal of treatment in pediatric and adolescent patients is to achieve a mean LDL-C <130 mg/dL. The optimal age at which to initiate lipid-lowering therapy to decrease the risk of symptomatic adulthood CAD has not been determined. 1.4 Limitations of Use Simvastatin tablets have not been studied in conditions where the major abnormality is elevation of chylomicrons (i.e., hyperlipidemia Fredrickson types I and V). uuid:58804c80-aa40-442b-97ba-f43711eb8b81 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4710 biolink:treats MONDO:0013600 PMID:41385096 "[{""id"":""uuid:fc40c33b-81ce-4e23-bdef-755c4d56dc4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fcf53012-5c21-4c48-9830-0488498dd38e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxepin HCl Tablets is indicated for the treatment of insomnia characterized by difficulty with sleep maintenance. The clinical trials performed in support of efficacy were up to 3 months in duration. uuid:926210f4-7eb7-4e2b-a908-c0abf91079e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3745 biolink:treats MONDO:0005242 PMID:41385096 "[{""id"":""uuid:33491829-c5c0-451c-8236-3a984633dbda"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:974b7714-ddb5-4dc9-be8f-4c49d201b3b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING, before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin HCl and other antibacterial drugs, clindamycin HCl capsules, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:f0941d5f-25ff-4cf9-99d4-7afdd14309a8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3745 biolink:treats MONDO:0004649 PMID:41385096 "[{""id"":""uuid:dbcbeee9-2f4b-4ede-99f8-07293014bfea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b083a644-a2f1-4abf-8796-e7caf1652f7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING, before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin HCl and other antibacterial drugs, clindamycin HCl capsules, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:c459c202-4f62-414b-bc2f-775c82b05f28 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3745 biolink:treats MONDO:0000744 PMID:41385096 "[{""id"":""uuid:1847ed19-cff9-4c79-890c-a45fbb7502b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3a608fab-07e8-4f36-8870-11a2d949fe86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING, before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin HCl and other antibacterial drugs, clindamycin HCl capsules, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:3ae6dcad-a79c-4739-ae9b-46e1174a0b76 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3745 biolink:treats MONDO:0018602 PMID:41385096 "[{""id"":""uuid:f719f812-93bf-486a-bba5-839a74011f08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:61c48a64-80cc-4452-9ae8-77037348fff3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING, before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin HCl and other antibacterial drugs, clindamycin HCl capsules, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:c4388eed-5eb6-4629-8b66-87fe81ff395f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3745 biolink:treats MONDO:0700217 PMID:41385096 "[{""id"":""uuid:1fa2e014-c136-4fd2-94b2-9110962c7518"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5b7955e7-c42d-4c1b-ab70-5b2946227a0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING, before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin HCl and other antibacterial drugs, clindamycin HCl capsules, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:3b572fab-3427-4b97-a56d-4b7587727d04 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3745 biolink:treats MONDO:0004522 PMID:41385096 "[{""id"":""uuid:b2578415-698b-416b-a6ea-e3d5c5a412aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:154e6268-575b-4fb3-b9ee-024d81931322"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING, before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin HCl and other antibacterial drugs, clindamycin HCl capsules, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:f057f680-8bdb-494b-ad58-662e1b5fb93b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3745 biolink:treats MONDO:0000918 PMID:41385096 "[{""id"":""uuid:8286ea8f-364e-48ee-932e-a90c11391ded"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d2ac7eb3-a68b-4a9a-953f-c422ca926d84"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING, before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin HCl and other antibacterial drugs, clindamycin HCl capsules, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:af13b255-e1a8-4690-9937-77da82d26b58 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3745 biolink:treats HP:0034493 PMID:41385096 "[{""id"":""uuid:713897b1-2e44-44d8-97ec-bbec4c669b2d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:11a33083-e188-4e78-8275-5a4ce2e2c452"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING, before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin HCl and other antibacterial drugs, clindamycin HCl capsules, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:5bd18c20-9381-4791-a9cd-80d9451ced42 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3745 biolink:treats MONDO:0006887 PMID:41385096 "[{""id"":""uuid:4a0026b0-4e2f-4cc4-a055-4490da13f277"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4a10a3ec-e676-4cca-b87f-8f35b075c165"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING, before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin HCl and other antibacterial drugs, clindamycin HCl capsules, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:53d5d373-d3bd-4ea7-96b4-ec7e05d710c5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3745 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:81d2832b-2490-413b-99f0-434e718d12ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2bb6938b-006f-4e16-80f7-981d2842bac5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clindamycin is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Clindamycin is also indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of colitis, as described in the BOXED WARNING, before selecting clindamycin, the physician should consider the nature of the infection and the suitability of less toxic alternatives (e.g., erythromycin). Anaerobes: Serious respiratory tract infections such as empyema, anaerobic pneumonitis, and lung abscess; serious skin and soft tissue infections; septicemia; intra-abdominal infections such as peritonitis and intra-abdominal abscess (typically resulting from anaerobic organisms resident in the normal gastrointestinal tract); infections of the female pelvis and genital tract such as endometritis, nongonococcal tubo-ovarian abscess, pelvic cellulitis, and postsurgical vaginal cuff infection. Streptococci: Serious respiratory tract infections; serious skin and soft tissue infections. Staphylococci: Serious respiratory tract infections; serious skin and soft tissue infections. Pneumococci: Serious respiratory tract infections. Bacteriologic studies should be performed to determine the causative organisms and their susceptibility to clindamycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of clindamycin HCl and other antibacterial drugs, clindamycin HCl capsules, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:dbcd4dab-2e24-40c3-a293-e1999e43f17b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2682 biolink:treats MONDO:0005657 PMID:41385096 "[{""id"":""uuid:dd05527a-07af-4244-8a49-053ef8528849"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:adb0bd28-9f9d-42d6-a25b-050cbff6c4fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0106c2a3-1003-4982-8d07-a0cdb0038aae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amphotericin B for Injection USP should be administered primarily to patients with progressive, potentially life-threatening fungal infections. This potent drug should not be used to treat noninvasive fungal infections, such as oral thrush, vaginal candidiasis and esophageal candidiasis in patients with normal neutrophil counts. Amphotericin B for Injection USP is specifically intended to treat potentially life-threatening fungal infections: aspergillosis, cryptococcosis (torulosis), North American blastomycosis, systemic candidiasis, coccidioido-mycosis, histoplasmosis, zygomycosis including mucormycosis due to susceptible species of the genera Absidia , Mucor and Rhizopus , and infections due to related susceptible species of Conidiobolus and Basidiobolus , and sporotrichosis. Amphotericin B may be useful in the treatment of American mucocutaneous leishmaniasis, but it is not the drug of choice as primary therapy.|[PMDA] Various infections caused by Aspergillus species, Candida species or Cryptococcus species (drug with a new dosage and dosage form). uuid:cce8d633-184e-402d-87f1-add282d1440c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2682 biolink:treats MONDO:0005724 PMID:41385096 "[{""id"":""uuid:bc083838-158f-4ae3-9131-8d8e9346133d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a367c256-fd1f-47cd-a0a3-2b4b67f25ec0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ca16ad6e-f01f-496b-955d-37dc8bf6066f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amphotericin B for Injection USP should be administered primarily to patients with progressive, potentially life-threatening fungal infections. This potent drug should not be used to treat noninvasive fungal infections, such as oral thrush, vaginal candidiasis and esophageal candidiasis in patients with normal neutrophil counts. Amphotericin B for Injection USP is specifically intended to treat potentially life-threatening fungal infections: aspergillosis, cryptococcosis (torulosis), North American blastomycosis, systemic candidiasis, coccidioido-mycosis, histoplasmosis, zygomycosis including mucormycosis due to susceptible species of the genera Absidia , Mucor and Rhizopus , and infections due to related susceptible species of Conidiobolus and Basidiobolus , and sporotrichosis. Amphotericin B may be useful in the treatment of American mucocutaneous leishmaniasis, but it is not the drug of choice as primary therapy.|[PMDA] Various infections caused by Aspergillus species, Candida species or Cryptococcus species (drug with a new dosage and dosage form). uuid:494614cc-8c3d-4e2c-8fcd-5a32360f8ffc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2682 biolink:treats MONDO:0005672 PMID:41385096 "[{""id"":""uuid:373f9d58-4b1b-4bac-9c79-2dde2c622d3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b5e6f951-786b-4337-afbb-07cdbc9fe3a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:5c18113c-fe21-4e13-b91a-342fdd8e9c5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amphotericin B for Injection USP should be administered primarily to patients with progressive, potentially life-threatening fungal infections. This potent drug should not be used to treat noninvasive fungal infections, such as oral thrush, vaginal candidiasis and esophageal candidiasis in patients with normal neutrophil counts. Amphotericin B for Injection USP is specifically intended to treat potentially life-threatening fungal infections: aspergillosis, cryptococcosis (torulosis), North American blastomycosis, systemic candidiasis, coccidioido-mycosis, histoplasmosis, zygomycosis including mucormycosis due to susceptible species of the genera Absidia , Mucor and Rhizopus , and infections due to related susceptible species of Conidiobolus and Basidiobolus , and sporotrichosis. Amphotericin B may be useful in the treatment of American mucocutaneous leishmaniasis, but it is not the drug of choice as primary therapy.|[PMDA] A drug with new additional indications and a new dosage for the treatment of fungal infections caused by Mucor species, Absidia species, Rhizopus species, Rhizomucor species, Cladosporium species, Cladophialophora species, Fonsecaea species, Phialophora species, Exophiala species, Coccidioides species, Histoplasma species, and Blastomyces species and visceral leishmaniasis. uuid:b00abf6e-016a-480b-924b-a56e25ae4a2d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2682 biolink:treats MONDO:0042233 PMID:41385096 "[{""id"":""uuid:fec50697-6432-4e21-b483-0bdeb9b6783d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:997dabc1-6f36-4cdb-ae3c-65113de0d9cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amphotericin B for Injection USP should be administered primarily to patients with progressive, potentially life-threatening fungal infections. This potent drug should not be used to treat noninvasive fungal infections, such as oral thrush, vaginal candidiasis and esophageal candidiasis in patients with normal neutrophil counts. Amphotericin B for Injection USP is specifically intended to treat potentially life-threatening fungal infections: aspergillosis, cryptococcosis (torulosis), North American blastomycosis, systemic candidiasis, coccidioido-mycosis, histoplasmosis, zygomycosis including mucormycosis due to susceptible species of the genera Absidia , Mucor and Rhizopus , and infections due to related susceptible species of Conidiobolus and Basidiobolus , and sporotrichosis. Amphotericin B may be useful in the treatment of American mucocutaneous leishmaniasis, but it is not the drug of choice as primary therapy. uuid:7503130d-8fc1-4744-862f-81a1663c27fc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2682 biolink:treats MONDO:0005706 PMID:41385096 "[{""id"":""uuid:25983d5d-df52-4db9-8626-a5bdaa5c9708"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6b4ab525-e217-4b14-bd1c-f1ae311ab776"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:8db0f449-5be1-4846-979e-fdf41d6eed4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amphotericin B for Injection USP should be administered primarily to patients with progressive, potentially life-threatening fungal infections. This potent drug should not be used to treat noninvasive fungal infections, such as oral thrush, vaginal candidiasis and esophageal candidiasis in patients with normal neutrophil counts. Amphotericin B for Injection USP is specifically intended to treat potentially life-threatening fungal infections: aspergillosis, cryptococcosis (torulosis), North American blastomycosis, systemic candidiasis, coccidioido-mycosis, histoplasmosis, zygomycosis including mucormycosis due to susceptible species of the genera Absidia , Mucor and Rhizopus , and infections due to related susceptible species of Conidiobolus and Basidiobolus , and sporotrichosis. Amphotericin B may be useful in the treatment of American mucocutaneous leishmaniasis, but it is not the drug of choice as primary therapy.|[PMDA] A drug with new additional indications and a new dosage for the treatment of fungal infections caused by Mucor species, Absidia species, Rhizopus species, Rhizomucor species, Cladosporium species, Cladophialophora species, Fonsecaea species, Phialophora species, Exophiala species, Coccidioides species, Histoplasma species, and Blastomyces species and visceral leishmaniasis. uuid:4db139c0-5321-4f59-8e2b-483942de8975 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2682 biolink:treats MONDO:0018312 PMID:41385096 "[{""id"":""uuid:71f62b67-4e4f-4b18-979f-d61ca49963a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:320565d5-c87a-4484-923c-60e19174ef42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:419fc033-3401-41b6-b635-9af67b57922b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amphotericin B for Injection USP should be administered primarily to patients with progressive, potentially life-threatening fungal infections. This potent drug should not be used to treat noninvasive fungal infections, such as oral thrush, vaginal candidiasis and esophageal candidiasis in patients with normal neutrophil counts. Amphotericin B for Injection USP is specifically intended to treat potentially life-threatening fungal infections: aspergillosis, cryptococcosis (torulosis), North American blastomycosis, systemic candidiasis, coccidioido-mycosis, histoplasmosis, zygomycosis including mucormycosis due to susceptible species of the genera Absidia , Mucor and Rhizopus , and infections due to related susceptible species of Conidiobolus and Basidiobolus , and sporotrichosis. Amphotericin B may be useful in the treatment of American mucocutaneous leishmaniasis, but it is not the drug of choice as primary therapy.|[PMDA] A drug with new additional indications and a new dosage for the treatment of fungal infections caused by Mucor species, Absidia species, Rhizopus species, Rhizomucor species, Cladosporium species, Cladophialophora species, Fonsecaea species, Phialophora species, Exophiala species, Coccidioides species, Histoplasma species, and Blastomyces species and visceral leishmaniasis. uuid:3b396979-541c-4fbd-99c6-e5d0b6aa8a4e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2682 biolink:treats MONDO:0019136 PMID:41385096 "[{""id"":""uuid:3a261755-ca5f-4a1e-b65d-bf85756c3f51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:24fd38f5-3296-4fba-bef4-175a19a4829d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ed92bf1a-08d3-4882-86f6-d4575d819427"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amphotericin B for Injection USP should be administered primarily to patients with progressive, potentially life-threatening fungal infections. This potent drug should not be used to treat noninvasive fungal infections, such as oral thrush, vaginal candidiasis and esophageal candidiasis in patients with normal neutrophil counts. Amphotericin B for Injection USP is specifically intended to treat potentially life-threatening fungal infections: aspergillosis, cryptococcosis (torulosis), North American blastomycosis, systemic candidiasis, coccidioido-mycosis, histoplasmosis, zygomycosis including mucormycosis due to susceptible species of the genera Absidia , Mucor and Rhizopus , and infections due to related susceptible species of Conidiobolus and Basidiobolus , and sporotrichosis. Amphotericin B may be useful in the treatment of American mucocutaneous leishmaniasis, but it is not the drug of choice as primary therapy.|[PMDA] A drug with new additional indications and a new dosage for the treatment of fungal infections caused by Mucor species, Absidia species, Rhizopus species, Rhizomucor species, Cladosporium species, Cladophialophora species, Fonsecaea species, Phialophora species, Exophiala species, Coccidioides species, Histoplasma species, and Blastomyces species and visceral leishmaniasis. uuid:bb82ff32-0834-4918-aba7-ffeed79b6435 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2682 biolink:treats MONDO:0005968 PMID:41385096 "[{""id"":""uuid:daa0b69d-6f5b-47a7-af4c-d44082ce99c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1c1328bd-174c-4e8e-aec8-9e379f2eaf2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amphotericin B for Injection USP should be administered primarily to patients with progressive, potentially life-threatening fungal infections. This potent drug should not be used to treat noninvasive fungal infections, such as oral thrush, vaginal candidiasis and esophageal candidiasis in patients with normal neutrophil counts. Amphotericin B for Injection USP is specifically intended to treat potentially life-threatening fungal infections: aspergillosis, cryptococcosis (torulosis), North American blastomycosis, systemic candidiasis, coccidioido-mycosis, histoplasmosis, zygomycosis including mucormycosis due to susceptible species of the genera Absidia , Mucor and Rhizopus , and infections due to related susceptible species of Conidiobolus and Basidiobolus , and sporotrichosis. Amphotericin B may be useful in the treatment of American mucocutaneous leishmaniasis, but it is not the drug of choice as primary therapy. uuid:641d39f0-c491-45f5-b803-d8093331c3a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2682 biolink:treats MONDO:0005859 PMID:41385096 "[{""id"":""uuid:89e1c59f-e373-48c0-bef7-2c0bc9dc5f15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b29ff21c-ee7e-4a96-becf-75bfff65a00d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amphotericin B for Injection USP should be administered primarily to patients with progressive, potentially life-threatening fungal infections. This potent drug should not be used to treat noninvasive fungal infections, such as oral thrush, vaginal candidiasis and esophageal candidiasis in patients with normal neutrophil counts. Amphotericin B for Injection USP is specifically intended to treat potentially life-threatening fungal infections: aspergillosis, cryptococcosis (torulosis), North American blastomycosis, systemic candidiasis, coccidioido-mycosis, histoplasmosis, zygomycosis including mucormycosis due to susceptible species of the genera Absidia , Mucor and Rhizopus , and infections due to related susceptible species of Conidiobolus and Basidiobolus , and sporotrichosis. Amphotericin B may be useful in the treatment of American mucocutaneous leishmaniasis, but it is not the drug of choice as primary therapy. uuid:5152d889-ad8d-46a5-bd60-a3357e0534fa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9241 biolink:treats HP:0007430 PMID:41385096 "[{""id"":""uuid:0b22bc2e-7b7c-4094-8657-b1293964e388"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:80b72b66-d556-4960-bef6-fc793a0c042e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone tablets are indicated in the management of: Primary hyperaldosteronism for: Establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. Short-term preoperative treatment of patients with primary hyperaldosteronism. Long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. Long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). Edematous conditions for patients with: Congestive heart failure: For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. Spironolactone tablets are also indicated for patients with congestive heart failure taking digitalis when other therapies are considered inappropriate. Cirrhosis of the liver accompanied by edema and/or ascites: Aldosterone levels may be exceptionally high in this condition. Spironolactone tablets are indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. Nephrotic syndrome: For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response. Essential hypertension Spironolactone tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Usually in combination with other drugs, spironolactone tablets are indicated for patients who cannot be treated adequately with other agents or for whom other agents are considered inappropriate. Hypokalemia For the treatment of patients with hypokalemia when other measures are considered inappropriate or inadequate. Spironolactone tablets are also indicated for the prophylaxis of hypokalemia in patients taking digitalis when other measures are considered inadequate or inappropriate. Severe heart failure (NYHA class III – IV) To increase survival, and to reduce the need for hospitalization for heart failure when used in addition to standard therapy. Usage in Pregnancy. The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developing toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Spironolactone tablets are indicated in pregnancy when edema is due to pathologic causes just as it is in the absence of pregnancy (however, see PRECAUTIONS: PREGNANCY). Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is unsupported and unnecessary. There is hypervolemia during normal pregnancy which is not harmful to either the fetus or the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort that is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate. uuid:5e4562b9-5492-4b90-b3cd-8ba0a80646ee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6GNT3Y5LMF biolink:treats UMLS:C0949083 PMID:41385096 "[{""id"":""uuid:377b47b1-1e0a-4101-9dc9-4c2ff1145655"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:67371edf-e317-4447-a07e-19ca67f152aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. 1.1 Nosocomial Pneumonia Levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillin susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see Clinical Studies (14.1)]. 1.2 Community-Acquired Pneumonia: 7–14 day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multi-drug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.2)]. MDRSP isolates are strains resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. 1.3 Community-Acquired Pneumonia: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (excluding multi-drug-resistant isolates [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.3)] 1.4 Complicated Skin and Skin Structure Infections Levofloxacin s indicated for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis [see Clinical Studies (14.5)]. 1.5 Uncomplicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, or Streptococcus pyogenes. 1.6 Chronic Bacterial Prostatitis Levofloxacin is indicated for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin-susceptible Staphylococcus epidermidis [see Clinical Studies (14.6)]. 1.7 Inhalational Anthrax (Post-Exposure) Levofloxacin is indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. The effectiveness of levofloxacin is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin has not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of levofloxacin in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged levofloxacin therapy should only be used when the benefit outweighs the risk [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.9)]. 1.8 Plague Levofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older. Efficacy studies of levofloxacin could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.10)]. 1.9 Complicated Urinary Tract Infections: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis [see Clinical Studies (14.7)]. 1.10 Complicated Urinary Tract Infections: 10-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa [see Clinical Studies (14.8)]. 1.11 Acute Pyelonephritis: 5 or 10-day Treatment Regimen Levofloxacin s indicated for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia [see Clinical Studies (14.7, 14.8)]. 1.12 Uncomplicated Urinary Tract Infections Levofloxacin is indicated for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1- 5.15)] and for some patients uncomplicated urinary tract infection is self-limiting, reserve levofloxacin for treatment of uncomplicated urinary tract infections in patients who have no alternative treatment options. 1.13 Acute Bacterial Exacerbation of Chronic Bronchitis Levofloxacin is indicated for the treatment of acute bacterial exacerbation of chronic bronchitis (ABECB) due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis. [see CLINICAL STUDIES (14.4)] Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.15)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.14 Acute Bacterial Sinusitis: 5-day and 10–14 day Treatment Regimens Levofloxacin is indicated for the treatment of acute bacterial sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis [see Clinical Studies (14.4)]. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.14)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.15 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Culture and susceptibility testing Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see Microbiology (12.4)]. Therapy with levofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected. As with other drugs in this class, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with levofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance. uuid:4b4c3b4e-8f21-478a-8601-6d89037d9494 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6GNT3Y5LMF biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:2ca05c7d-e876-46fa-a303-389a7808132d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c9dc4bb5-88e6-48d2-94ec-1c008fedb6c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. 1.1 Nosocomial Pneumonia Levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillin susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see Clinical Studies (14.1)]. 1.2 Community-Acquired Pneumonia: 7–14 day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multi-drug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.2)]. MDRSP isolates are strains resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. 1.3 Community-Acquired Pneumonia: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (excluding multi-drug-resistant isolates [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.3)] 1.4 Complicated Skin and Skin Structure Infections Levofloxacin s indicated for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis [see Clinical Studies (14.5)]. 1.5 Uncomplicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, or Streptococcus pyogenes. 1.6 Chronic Bacterial Prostatitis Levofloxacin is indicated for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin-susceptible Staphylococcus epidermidis [see Clinical Studies (14.6)]. 1.7 Inhalational Anthrax (Post-Exposure) Levofloxacin is indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. The effectiveness of levofloxacin is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin has not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of levofloxacin in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged levofloxacin therapy should only be used when the benefit outweighs the risk [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.9)]. 1.8 Plague Levofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older. Efficacy studies of levofloxacin could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.10)]. 1.9 Complicated Urinary Tract Infections: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis [see Clinical Studies (14.7)]. 1.10 Complicated Urinary Tract Infections: 10-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa [see Clinical Studies (14.8)]. 1.11 Acute Pyelonephritis: 5 or 10-day Treatment Regimen Levofloxacin s indicated for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia [see Clinical Studies (14.7, 14.8)]. 1.12 Uncomplicated Urinary Tract Infections Levofloxacin is indicated for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1- 5.15)] and for some patients uncomplicated urinary tract infection is self-limiting, reserve levofloxacin for treatment of uncomplicated urinary tract infections in patients who have no alternative treatment options. 1.13 Acute Bacterial Exacerbation of Chronic Bronchitis Levofloxacin is indicated for the treatment of acute bacterial exacerbation of chronic bronchitis (ABECB) due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis. [see CLINICAL STUDIES (14.4)] Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.15)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.14 Acute Bacterial Sinusitis: 5-day and 10–14 day Treatment Regimens Levofloxacin is indicated for the treatment of acute bacterial sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis [see Clinical Studies (14.4)]. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.14)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.15 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Culture and susceptibility testing Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see Microbiology (12.4)]. Therapy with levofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected. As with other drugs in this class, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with levofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance. uuid:7da71822-5d6e-4d20-82d3-1e6173a6bd84 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6GNT3Y5LMF biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:dbb14421-9e36-4b3c-a34c-b019eb23c493"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eec91c0d-ebed-418f-a077-2bc24a6f3365"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. 1.1 Nosocomial Pneumonia Levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillin susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see Clinical Studies (14.1)]. 1.2 Community-Acquired Pneumonia: 7–14 day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multi-drug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.2)]. MDRSP isolates are strains resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. 1.3 Community-Acquired Pneumonia: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (excluding multi-drug-resistant isolates [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.3)] 1.4 Complicated Skin and Skin Structure Infections Levofloxacin s indicated for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis [see Clinical Studies (14.5)]. 1.5 Uncomplicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, or Streptococcus pyogenes. 1.6 Chronic Bacterial Prostatitis Levofloxacin is indicated for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin-susceptible Staphylococcus epidermidis [see Clinical Studies (14.6)]. 1.7 Inhalational Anthrax (Post-Exposure) Levofloxacin is indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. The effectiveness of levofloxacin is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin has not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of levofloxacin in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged levofloxacin therapy should only be used when the benefit outweighs the risk [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.9)]. 1.8 Plague Levofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older. Efficacy studies of levofloxacin could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.10)]. 1.9 Complicated Urinary Tract Infections: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis [see Clinical Studies (14.7)]. 1.10 Complicated Urinary Tract Infections: 10-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa [see Clinical Studies (14.8)]. 1.11 Acute Pyelonephritis: 5 or 10-day Treatment Regimen Levofloxacin s indicated for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia [see Clinical Studies (14.7, 14.8)]. 1.12 Uncomplicated Urinary Tract Infections Levofloxacin is indicated for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1- 5.15)] and for some patients uncomplicated urinary tract infection is self-limiting, reserve levofloxacin for treatment of uncomplicated urinary tract infections in patients who have no alternative treatment options. 1.13 Acute Bacterial Exacerbation of Chronic Bronchitis Levofloxacin is indicated for the treatment of acute bacterial exacerbation of chronic bronchitis (ABECB) due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis. [see CLINICAL STUDIES (14.4)] Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.15)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.14 Acute Bacterial Sinusitis: 5-day and 10–14 day Treatment Regimens Levofloxacin is indicated for the treatment of acute bacterial sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis [see Clinical Studies (14.4)]. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.14)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.15 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Culture and susceptibility testing Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see Microbiology (12.4)]. Therapy with levofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected. As with other drugs in this class, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with levofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance. uuid:3b0b1c2b-86f0-4d66-801d-377db86b3395 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6GNT3Y5LMF biolink:treats MONDO:0005227 PMID:41385096 "[{""id"":""uuid:f5ff87b3-335f-4617-b021-bb8f757d7616"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ad43959a-f36f-4ac1-a7cc-2b2bf8526fe1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. 1.1 Nosocomial Pneumonia Levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillin susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see Clinical Studies (14.1)]. 1.2 Community-Acquired Pneumonia: 7–14 day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multi-drug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.2)]. MDRSP isolates are strains resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. 1.3 Community-Acquired Pneumonia: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (excluding multi-drug-resistant isolates [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.3)] 1.4 Complicated Skin and Skin Structure Infections Levofloxacin s indicated for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis [see Clinical Studies (14.5)]. 1.5 Uncomplicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, or Streptococcus pyogenes. 1.6 Chronic Bacterial Prostatitis Levofloxacin is indicated for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin-susceptible Staphylococcus epidermidis [see Clinical Studies (14.6)]. 1.7 Inhalational Anthrax (Post-Exposure) Levofloxacin is indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. The effectiveness of levofloxacin is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin has not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of levofloxacin in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged levofloxacin therapy should only be used when the benefit outweighs the risk [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.9)]. 1.8 Plague Levofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older. Efficacy studies of levofloxacin could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.10)]. 1.9 Complicated Urinary Tract Infections: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis [see Clinical Studies (14.7)]. 1.10 Complicated Urinary Tract Infections: 10-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa [see Clinical Studies (14.8)]. 1.11 Acute Pyelonephritis: 5 or 10-day Treatment Regimen Levofloxacin s indicated for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia [see Clinical Studies (14.7, 14.8)]. 1.12 Uncomplicated Urinary Tract Infections Levofloxacin is indicated for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1- 5.15)] and for some patients uncomplicated urinary tract infection is self-limiting, reserve levofloxacin for treatment of uncomplicated urinary tract infections in patients who have no alternative treatment options. 1.13 Acute Bacterial Exacerbation of Chronic Bronchitis Levofloxacin is indicated for the treatment of acute bacterial exacerbation of chronic bronchitis (ABECB) due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis. [see CLINICAL STUDIES (14.4)] Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.15)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.14 Acute Bacterial Sinusitis: 5-day and 10–14 day Treatment Regimens Levofloxacin is indicated for the treatment of acute bacterial sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis [see Clinical Studies (14.4)]. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.14)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.15 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Culture and susceptibility testing Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see Microbiology (12.4)]. Therapy with levofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected. As with other drugs in this class, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with levofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance. uuid:f696504e-a1d6-41f2-a205-aa96a3fe8dc0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6GNT3Y5LMF biolink:treats MONDO:0005230 PMID:41385096 "[{""id"":""uuid:8654b93f-cfbe-499c-b437-bdb235486c7c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fa362c2a-3b03-456a-a1d5-95ec27db1077"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. 1.1 Nosocomial Pneumonia Levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillin susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see Clinical Studies (14.1)]. 1.2 Community-Acquired Pneumonia: 7–14 day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multi-drug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.2)]. MDRSP isolates are strains resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. 1.3 Community-Acquired Pneumonia: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (excluding multi-drug-resistant isolates [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.3)] 1.4 Complicated Skin and Skin Structure Infections Levofloxacin s indicated for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis [see Clinical Studies (14.5)]. 1.5 Uncomplicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, or Streptococcus pyogenes. 1.6 Chronic Bacterial Prostatitis Levofloxacin is indicated for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin-susceptible Staphylococcus epidermidis [see Clinical Studies (14.6)]. 1.7 Inhalational Anthrax (Post-Exposure) Levofloxacin is indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. The effectiveness of levofloxacin is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin has not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of levofloxacin in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged levofloxacin therapy should only be used when the benefit outweighs the risk [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.9)]. 1.8 Plague Levofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older. Efficacy studies of levofloxacin could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.10)]. 1.9 Complicated Urinary Tract Infections: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis [see Clinical Studies (14.7)]. 1.10 Complicated Urinary Tract Infections: 10-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa [see Clinical Studies (14.8)]. 1.11 Acute Pyelonephritis: 5 or 10-day Treatment Regimen Levofloxacin s indicated for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia [see Clinical Studies (14.7, 14.8)]. 1.12 Uncomplicated Urinary Tract Infections Levofloxacin is indicated for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1- 5.15)] and for some patients uncomplicated urinary tract infection is self-limiting, reserve levofloxacin for treatment of uncomplicated urinary tract infections in patients who have no alternative treatment options. 1.13 Acute Bacterial Exacerbation of Chronic Bronchitis Levofloxacin is indicated for the treatment of acute bacterial exacerbation of chronic bronchitis (ABECB) due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis. [see CLINICAL STUDIES (14.4)] Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.15)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.14 Acute Bacterial Sinusitis: 5-day and 10–14 day Treatment Regimens Levofloxacin is indicated for the treatment of acute bacterial sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis [see Clinical Studies (14.4)]. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.14)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.15 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Culture and susceptibility testing Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see Microbiology (12.4)]. Therapy with levofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected. As with other drugs in this class, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with levofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance. uuid:19aa866b-9bec-4dcf-85d4-4122d3b36588 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6GNT3Y5LMF biolink:treats HP:0020083 PMID:41385096 "[{""id"":""uuid:c779ec7c-5813-47a4-bd70-3d9fe79f667f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6c7c7601-024c-4bc1-be63-2fcf6c60e966"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. 1.1 Nosocomial Pneumonia Levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillin susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see Clinical Studies (14.1)]. 1.2 Community-Acquired Pneumonia: 7–14 day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multi-drug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.2)]. MDRSP isolates are strains resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. 1.3 Community-Acquired Pneumonia: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (excluding multi-drug-resistant isolates [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.3)] 1.4 Complicated Skin and Skin Structure Infections Levofloxacin s indicated for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis [see Clinical Studies (14.5)]. 1.5 Uncomplicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, or Streptococcus pyogenes. 1.6 Chronic Bacterial Prostatitis Levofloxacin is indicated for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin-susceptible Staphylococcus epidermidis [see Clinical Studies (14.6)]. 1.7 Inhalational Anthrax (Post-Exposure) Levofloxacin is indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. The effectiveness of levofloxacin is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin has not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of levofloxacin in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged levofloxacin therapy should only be used when the benefit outweighs the risk [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.9)]. 1.8 Plague Levofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older. Efficacy studies of levofloxacin could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.10)]. 1.9 Complicated Urinary Tract Infections: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis [see Clinical Studies (14.7)]. 1.10 Complicated Urinary Tract Infections: 10-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa [see Clinical Studies (14.8)]. 1.11 Acute Pyelonephritis: 5 or 10-day Treatment Regimen Levofloxacin s indicated for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia [see Clinical Studies (14.7, 14.8)]. 1.12 Uncomplicated Urinary Tract Infections Levofloxacin is indicated for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1- 5.15)] and for some patients uncomplicated urinary tract infection is self-limiting, reserve levofloxacin for treatment of uncomplicated urinary tract infections in patients who have no alternative treatment options. 1.13 Acute Bacterial Exacerbation of Chronic Bronchitis Levofloxacin is indicated for the treatment of acute bacterial exacerbation of chronic bronchitis (ABECB) due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis. [see CLINICAL STUDIES (14.4)] Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.15)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.14 Acute Bacterial Sinusitis: 5-day and 10–14 day Treatment Regimens Levofloxacin is indicated for the treatment of acute bacterial sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis [see Clinical Studies (14.4)]. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.14)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.15 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Culture and susceptibility testing Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see Microbiology (12.4)]. Therapy with levofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected. As with other drugs in this class, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with levofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance. uuid:9fbe6254-52af-4428-b985-80f1fe233e1f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6GNT3Y5LMF biolink:treats MONDO:0004592 PMID:41385096 "[{""id"":""uuid:ceaa6c8e-2cb1-41e2-a084-94d6611c630d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3138a4c0-320a-4eeb-b48a-77a615e8937f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. 1.1 Nosocomial Pneumonia Levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillin susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see Clinical Studies (14.1)]. 1.2 Community-Acquired Pneumonia: 7–14 day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multi-drug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.2)]. MDRSP isolates are strains resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. 1.3 Community-Acquired Pneumonia: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (excluding multi-drug-resistant isolates [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.3)] 1.4 Complicated Skin and Skin Structure Infections Levofloxacin s indicated for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis [see Clinical Studies (14.5)]. 1.5 Uncomplicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, or Streptococcus pyogenes. 1.6 Chronic Bacterial Prostatitis Levofloxacin is indicated for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin-susceptible Staphylococcus epidermidis [see Clinical Studies (14.6)]. 1.7 Inhalational Anthrax (Post-Exposure) Levofloxacin is indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. The effectiveness of levofloxacin is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin has not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of levofloxacin in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged levofloxacin therapy should only be used when the benefit outweighs the risk [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.9)]. 1.8 Plague Levofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older. Efficacy studies of levofloxacin could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.10)]. 1.9 Complicated Urinary Tract Infections: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis [see Clinical Studies (14.7)]. 1.10 Complicated Urinary Tract Infections: 10-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa [see Clinical Studies (14.8)]. 1.11 Acute Pyelonephritis: 5 or 10-day Treatment Regimen Levofloxacin s indicated for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia [see Clinical Studies (14.7, 14.8)]. 1.12 Uncomplicated Urinary Tract Infections Levofloxacin is indicated for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1- 5.15)] and for some patients uncomplicated urinary tract infection is self-limiting, reserve levofloxacin for treatment of uncomplicated urinary tract infections in patients who have no alternative treatment options. 1.13 Acute Bacterial Exacerbation of Chronic Bronchitis Levofloxacin is indicated for the treatment of acute bacterial exacerbation of chronic bronchitis (ABECB) due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis. [see CLINICAL STUDIES (14.4)] Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.15)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.14 Acute Bacterial Sinusitis: 5-day and 10–14 day Treatment Regimens Levofloxacin is indicated for the treatment of acute bacterial sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis [see Clinical Studies (14.4)]. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.14)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.15 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Culture and susceptibility testing Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see Microbiology (12.4)]. Therapy with levofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected. As with other drugs in this class, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with levofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance. uuid:e6c97018-6afe-489b-a3be-e65c61d2c72b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6GNT3Y5LMF biolink:treats MONDO:0002922 PMID:41385096 "[{""id"":""uuid:6ce32eeb-cf54-4d10-9260-700c7ff5b213"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:76eb012d-9c01-461c-99d5-aacd034101a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. 1.1 Nosocomial Pneumonia Levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillin susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see Clinical Studies (14.1)]. 1.2 Community-Acquired Pneumonia: 7–14 day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multi-drug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.2)]. MDRSP isolates are strains resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. 1.3 Community-Acquired Pneumonia: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (excluding multi-drug-resistant isolates [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.3)] 1.4 Complicated Skin and Skin Structure Infections Levofloxacin s indicated for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis [see Clinical Studies (14.5)]. 1.5 Uncomplicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, or Streptococcus pyogenes. 1.6 Chronic Bacterial Prostatitis Levofloxacin is indicated for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin-susceptible Staphylococcus epidermidis [see Clinical Studies (14.6)]. 1.7 Inhalational Anthrax (Post-Exposure) Levofloxacin is indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. The effectiveness of levofloxacin is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin has not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of levofloxacin in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged levofloxacin therapy should only be used when the benefit outweighs the risk [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.9)]. 1.8 Plague Levofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older. Efficacy studies of levofloxacin could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.10)]. 1.9 Complicated Urinary Tract Infections: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis [see Clinical Studies (14.7)]. 1.10 Complicated Urinary Tract Infections: 10-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa [see Clinical Studies (14.8)]. 1.11 Acute Pyelonephritis: 5 or 10-day Treatment Regimen Levofloxacin s indicated for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia [see Clinical Studies (14.7, 14.8)]. 1.12 Uncomplicated Urinary Tract Infections Levofloxacin is indicated for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1- 5.15)] and for some patients uncomplicated urinary tract infection is self-limiting, reserve levofloxacin for treatment of uncomplicated urinary tract infections in patients who have no alternative treatment options. 1.13 Acute Bacterial Exacerbation of Chronic Bronchitis Levofloxacin is indicated for the treatment of acute bacterial exacerbation of chronic bronchitis (ABECB) due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis. [see CLINICAL STUDIES (14.4)] Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.15)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.14 Acute Bacterial Sinusitis: 5-day and 10–14 day Treatment Regimens Levofloxacin is indicated for the treatment of acute bacterial sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis [see Clinical Studies (14.4)]. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.14)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.15 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Culture and susceptibility testing Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see Microbiology (12.4)]. Therapy with levofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected. As with other drugs in this class, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with levofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance. uuid:365e34b3-825d-4bf3-b048-8281370cd1c4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6GNT3Y5LMF biolink:treats MONDO:0024313 PMID:41385096 "[{""id"":""uuid:dc617e5d-e2a6-4c81-9635-cc255982b431"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:83c65044-c709-4ebf-bd94-87e4fa656ff5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. 1.1 Nosocomial Pneumonia Levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillin susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see Clinical Studies (14.1)]. 1.2 Community-Acquired Pneumonia: 7–14 day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multi-drug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.2)]. MDRSP isolates are strains resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. 1.3 Community-Acquired Pneumonia: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (excluding multi-drug-resistant isolates [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.3)] 1.4 Complicated Skin and Skin Structure Infections Levofloxacin s indicated for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis [see Clinical Studies (14.5)]. 1.5 Uncomplicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, or Streptococcus pyogenes. 1.6 Chronic Bacterial Prostatitis Levofloxacin is indicated for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin-susceptible Staphylococcus epidermidis [see Clinical Studies (14.6)]. 1.7 Inhalational Anthrax (Post-Exposure) Levofloxacin is indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. The effectiveness of levofloxacin is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin has not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of levofloxacin in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged levofloxacin therapy should only be used when the benefit outweighs the risk [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.9)]. 1.8 Plague Levofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older. Efficacy studies of levofloxacin could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.10)]. 1.9 Complicated Urinary Tract Infections: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis [see Clinical Studies (14.7)]. 1.10 Complicated Urinary Tract Infections: 10-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa [see Clinical Studies (14.8)]. 1.11 Acute Pyelonephritis: 5 or 10-day Treatment Regimen Levofloxacin s indicated for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia [see Clinical Studies (14.7, 14.8)]. 1.12 Uncomplicated Urinary Tract Infections Levofloxacin is indicated for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1- 5.15)] and for some patients uncomplicated urinary tract infection is self-limiting, reserve levofloxacin for treatment of uncomplicated urinary tract infections in patients who have no alternative treatment options. 1.13 Acute Bacterial Exacerbation of Chronic Bronchitis Levofloxacin is indicated for the treatment of acute bacterial exacerbation of chronic bronchitis (ABECB) due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis. [see CLINICAL STUDIES (14.4)] Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.15)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.14 Acute Bacterial Sinusitis: 5-day and 10–14 day Treatment Regimens Levofloxacin is indicated for the treatment of acute bacterial sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis [see Clinical Studies (14.4)]. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.14)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.15 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Culture and susceptibility testing Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see Microbiology (12.4)]. Therapy with levofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected. As with other drugs in this class, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with levofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance. uuid:d36fb96a-6362-4efc-9708-377a6b316994 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6GNT3Y5LMF biolink:treats UMLS:C1720797 PMID:41385096 "[{""id"":""uuid:ae3f0ea1-98a1-4420-af68-675dcec0918b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ebb3dc75-925c-47b9-998a-87b9d7883332"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. 1.1 Nosocomial Pneumonia Levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillin susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see Clinical Studies (14.1)]. 1.2 Community-Acquired Pneumonia: 7–14 day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multi-drug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.2)]. MDRSP isolates are strains resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. 1.3 Community-Acquired Pneumonia: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (excluding multi-drug-resistant isolates [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.3)] 1.4 Complicated Skin and Skin Structure Infections Levofloxacin s indicated for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis [see Clinical Studies (14.5)]. 1.5 Uncomplicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, or Streptococcus pyogenes. 1.6 Chronic Bacterial Prostatitis Levofloxacin is indicated for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin-susceptible Staphylococcus epidermidis [see Clinical Studies (14.6)]. 1.7 Inhalational Anthrax (Post-Exposure) Levofloxacin is indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. The effectiveness of levofloxacin is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin has not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of levofloxacin in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged levofloxacin therapy should only be used when the benefit outweighs the risk [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.9)]. 1.8 Plague Levofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older. Efficacy studies of levofloxacin could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.10)]. 1.9 Complicated Urinary Tract Infections: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis [see Clinical Studies (14.7)]. 1.10 Complicated Urinary Tract Infections: 10-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa [see Clinical Studies (14.8)]. 1.11 Acute Pyelonephritis: 5 or 10-day Treatment Regimen Levofloxacin s indicated for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia [see Clinical Studies (14.7, 14.8)]. 1.12 Uncomplicated Urinary Tract Infections Levofloxacin is indicated for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1- 5.15)] and for some patients uncomplicated urinary tract infection is self-limiting, reserve levofloxacin for treatment of uncomplicated urinary tract infections in patients who have no alternative treatment options. 1.13 Acute Bacterial Exacerbation of Chronic Bronchitis Levofloxacin is indicated for the treatment of acute bacterial exacerbation of chronic bronchitis (ABECB) due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis. [see CLINICAL STUDIES (14.4)] Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.15)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.14 Acute Bacterial Sinusitis: 5-day and 10–14 day Treatment Regimens Levofloxacin is indicated for the treatment of acute bacterial sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis [see Clinical Studies (14.4)]. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.14)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.15 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Culture and susceptibility testing Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see Microbiology (12.4)]. Therapy with levofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected. As with other drugs in this class, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with levofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance. uuid:26f69a14-a0cc-48de-b5d8-e5a6426b8957 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6GNT3Y5LMF biolink:treats MONDO:0016595 PMID:41385096 "[{""id"":""uuid:e5b7312e-34d3-4d5b-bf6b-d8e3f4ea06bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5672684b-6195-4971-830e-449b3452fcd1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. 1.1 Nosocomial Pneumonia Levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillin susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see Clinical Studies (14.1)]. 1.2 Community-Acquired Pneumonia: 7–14 day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multi-drug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.2)]. MDRSP isolates are strains resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. 1.3 Community-Acquired Pneumonia: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (excluding multi-drug-resistant isolates [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.3)] 1.4 Complicated Skin and Skin Structure Infections Levofloxacin s indicated for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis [see Clinical Studies (14.5)]. 1.5 Uncomplicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, or Streptococcus pyogenes. 1.6 Chronic Bacterial Prostatitis Levofloxacin is indicated for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin-susceptible Staphylococcus epidermidis [see Clinical Studies (14.6)]. 1.7 Inhalational Anthrax (Post-Exposure) Levofloxacin is indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. The effectiveness of levofloxacin is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin has not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of levofloxacin in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged levofloxacin therapy should only be used when the benefit outweighs the risk [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.9)]. 1.8 Plague Levofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older. Efficacy studies of levofloxacin could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.10)]. 1.9 Complicated Urinary Tract Infections: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis [see Clinical Studies (14.7)]. 1.10 Complicated Urinary Tract Infections: 10-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa [see Clinical Studies (14.8)]. 1.11 Acute Pyelonephritis: 5 or 10-day Treatment Regimen Levofloxacin s indicated for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia [see Clinical Studies (14.7, 14.8)]. 1.12 Uncomplicated Urinary Tract Infections Levofloxacin is indicated for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1- 5.15)] and for some patients uncomplicated urinary tract infection is self-limiting, reserve levofloxacin for treatment of uncomplicated urinary tract infections in patients who have no alternative treatment options. 1.13 Acute Bacterial Exacerbation of Chronic Bronchitis Levofloxacin is indicated for the treatment of acute bacterial exacerbation of chronic bronchitis (ABECB) due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis. [see CLINICAL STUDIES (14.4)] Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.15)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.14 Acute Bacterial Sinusitis: 5-day and 10–14 day Treatment Regimens Levofloxacin is indicated for the treatment of acute bacterial sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis [see Clinical Studies (14.4)]. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.14)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.15 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Culture and susceptibility testing Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see Microbiology (12.4)]. Therapy with levofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected. As with other drugs in this class, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with levofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance. uuid:64fc836c-8a12-44fd-8e99-8050e3b1a77d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6GNT3Y5LMF biolink:treats MONDO:0019095 PMID:41385096 "[{""id"":""uuid:c94b60df-d4af-45df-b9dc-a6c2c145c14a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6bd72fbe-0426-49e4-850c-4b5eb41b1cee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. 1.1 Nosocomial Pneumonia Levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillin susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see Clinical Studies (14.1)]. 1.2 Community-Acquired Pneumonia: 7–14 day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multi-drug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.2)]. MDRSP isolates are strains resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. 1.3 Community-Acquired Pneumonia: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (excluding multi-drug-resistant isolates [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.3)] 1.4 Complicated Skin and Skin Structure Infections Levofloxacin s indicated for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis [see Clinical Studies (14.5)]. 1.5 Uncomplicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, or Streptococcus pyogenes. 1.6 Chronic Bacterial Prostatitis Levofloxacin is indicated for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin-susceptible Staphylococcus epidermidis [see Clinical Studies (14.6)]. 1.7 Inhalational Anthrax (Post-Exposure) Levofloxacin is indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. The effectiveness of levofloxacin is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin has not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of levofloxacin in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged levofloxacin therapy should only be used when the benefit outweighs the risk [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.9)]. 1.8 Plague Levofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older. Efficacy studies of levofloxacin could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.10)]. 1.9 Complicated Urinary Tract Infections: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis [see Clinical Studies (14.7)]. 1.10 Complicated Urinary Tract Infections: 10-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa [see Clinical Studies (14.8)]. 1.11 Acute Pyelonephritis: 5 or 10-day Treatment Regimen Levofloxacin s indicated for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia [see Clinical Studies (14.7, 14.8)]. 1.12 Uncomplicated Urinary Tract Infections Levofloxacin is indicated for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1- 5.15)] and for some patients uncomplicated urinary tract infection is self-limiting, reserve levofloxacin for treatment of uncomplicated urinary tract infections in patients who have no alternative treatment options. 1.13 Acute Bacterial Exacerbation of Chronic Bronchitis Levofloxacin is indicated for the treatment of acute bacterial exacerbation of chronic bronchitis (ABECB) due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis. [see CLINICAL STUDIES (14.4)] Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.15)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.14 Acute Bacterial Sinusitis: 5-day and 10–14 day Treatment Regimens Levofloxacin is indicated for the treatment of acute bacterial sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis [see Clinical Studies (14.4)]. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.14)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.15 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Culture and susceptibility testing Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see Microbiology (12.4)]. Therapy with levofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected. As with other drugs in this class, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with levofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance. uuid:239504e5-cce9-4ac4-917d-09bc6bde670d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6GNT3Y5LMF biolink:treats MONDO:0001024 PMID:41385096 "[{""id"":""uuid:f817943a-cc47-4141-8099-55f904a744c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bd250f25-4a9a-4ca0-baf6-a49f5a7ae3a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. 1.1 Nosocomial Pneumonia Levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillin susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see Clinical Studies (14.1)]. 1.2 Community-Acquired Pneumonia: 7–14 day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multi-drug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.2)]. MDRSP isolates are strains resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. 1.3 Community-Acquired Pneumonia: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (excluding multi-drug-resistant isolates [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.3)] 1.4 Complicated Skin and Skin Structure Infections Levofloxacin s indicated for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis [see Clinical Studies (14.5)]. 1.5 Uncomplicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, or Streptococcus pyogenes. 1.6 Chronic Bacterial Prostatitis Levofloxacin is indicated for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin-susceptible Staphylococcus epidermidis [see Clinical Studies (14.6)]. 1.7 Inhalational Anthrax (Post-Exposure) Levofloxacin is indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. The effectiveness of levofloxacin is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin has not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of levofloxacin in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged levofloxacin therapy should only be used when the benefit outweighs the risk [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.9)]. 1.8 Plague Levofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older. Efficacy studies of levofloxacin could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.10)]. 1.9 Complicated Urinary Tract Infections: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis [see Clinical Studies (14.7)]. 1.10 Complicated Urinary Tract Infections: 10-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa [see Clinical Studies (14.8)]. 1.11 Acute Pyelonephritis: 5 or 10-day Treatment Regimen Levofloxacin s indicated for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia [see Clinical Studies (14.7, 14.8)]. 1.12 Uncomplicated Urinary Tract Infections Levofloxacin is indicated for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1- 5.15)] and for some patients uncomplicated urinary tract infection is self-limiting, reserve levofloxacin for treatment of uncomplicated urinary tract infections in patients who have no alternative treatment options. 1.13 Acute Bacterial Exacerbation of Chronic Bronchitis Levofloxacin is indicated for the treatment of acute bacterial exacerbation of chronic bronchitis (ABECB) due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis. [see CLINICAL STUDIES (14.4)] Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.15)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.14 Acute Bacterial Sinusitis: 5-day and 10–14 day Treatment Regimens Levofloxacin is indicated for the treatment of acute bacterial sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis [see Clinical Studies (14.4)]. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.14)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.15 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Culture and susceptibility testing Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see Microbiology (12.4)]. Therapy with levofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected. As with other drugs in this class, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with levofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance. uuid:1b0061a7-dada-4380-856a-e4db8b7bb819 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6GNT3Y5LMF biolink:treats MONDO:0005956 PMID:41385096 "[{""id"":""uuid:43fbd06a-59ee-4180-abb6-e89560a7437e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ff92b259-a1c5-4fc1-b6e4-55b403695b9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. 1.1 Nosocomial Pneumonia Levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillin susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see Clinical Studies (14.1)]. 1.2 Community-Acquired Pneumonia: 7–14 day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multi-drug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.2)]. MDRSP isolates are strains resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. 1.3 Community-Acquired Pneumonia: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (excluding multi-drug-resistant isolates [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.3)] 1.4 Complicated Skin and Skin Structure Infections Levofloxacin s indicated for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis [see Clinical Studies (14.5)]. 1.5 Uncomplicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, or Streptococcus pyogenes. 1.6 Chronic Bacterial Prostatitis Levofloxacin is indicated for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin-susceptible Staphylococcus epidermidis [see Clinical Studies (14.6)]. 1.7 Inhalational Anthrax (Post-Exposure) Levofloxacin is indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. The effectiveness of levofloxacin is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin has not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of levofloxacin in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged levofloxacin therapy should only be used when the benefit outweighs the risk [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.9)]. 1.8 Plague Levofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older. Efficacy studies of levofloxacin could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.10)]. 1.9 Complicated Urinary Tract Infections: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis [see Clinical Studies (14.7)]. 1.10 Complicated Urinary Tract Infections: 10-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa [see Clinical Studies (14.8)]. 1.11 Acute Pyelonephritis: 5 or 10-day Treatment Regimen Levofloxacin s indicated for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia [see Clinical Studies (14.7, 14.8)]. 1.12 Uncomplicated Urinary Tract Infections Levofloxacin is indicated for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1- 5.15)] and for some patients uncomplicated urinary tract infection is self-limiting, reserve levofloxacin for treatment of uncomplicated urinary tract infections in patients who have no alternative treatment options. 1.13 Acute Bacterial Exacerbation of Chronic Bronchitis Levofloxacin is indicated for the treatment of acute bacterial exacerbation of chronic bronchitis (ABECB) due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis. [see CLINICAL STUDIES (14.4)] Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.15)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.14 Acute Bacterial Sinusitis: 5-day and 10–14 day Treatment Regimens Levofloxacin is indicated for the treatment of acute bacterial sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis [see Clinical Studies (14.4)]. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.14)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.15 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Culture and susceptibility testing Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see Microbiology (12.4)]. Therapy with levofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected. As with other drugs in this class, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with levofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance. uuid:e93b6ee8-0c1f-41e4-9354-41f31d70ac29 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6GNT3Y5LMF biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:38baf00e-1b96-475d-8103-547c1ee6491a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bb2ccc38-8a0e-4b9b-b612-8dd03adf3029"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. 1.1 Nosocomial Pneumonia Levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillin susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see Clinical Studies (14.1)]. 1.2 Community-Acquired Pneumonia: 7–14 day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multi-drug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.2)]. MDRSP isolates are strains resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. 1.3 Community-Acquired Pneumonia: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (excluding multi-drug-resistant isolates [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.3)] 1.4 Complicated Skin and Skin Structure Infections Levofloxacin s indicated for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis [see Clinical Studies (14.5)]. 1.5 Uncomplicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, or Streptococcus pyogenes. 1.6 Chronic Bacterial Prostatitis Levofloxacin is indicated for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin-susceptible Staphylococcus epidermidis [see Clinical Studies (14.6)]. 1.7 Inhalational Anthrax (Post-Exposure) Levofloxacin is indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. The effectiveness of levofloxacin is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin has not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of levofloxacin in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged levofloxacin therapy should only be used when the benefit outweighs the risk [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.9)]. 1.8 Plague Levofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older. Efficacy studies of levofloxacin could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.10)]. 1.9 Complicated Urinary Tract Infections: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis [see Clinical Studies (14.7)]. 1.10 Complicated Urinary Tract Infections: 10-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa [see Clinical Studies (14.8)]. 1.11 Acute Pyelonephritis: 5 or 10-day Treatment Regimen Levofloxacin s indicated for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia [see Clinical Studies (14.7, 14.8)]. 1.12 Uncomplicated Urinary Tract Infections Levofloxacin is indicated for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1- 5.15)] and for some patients uncomplicated urinary tract infection is self-limiting, reserve levofloxacin for treatment of uncomplicated urinary tract infections in patients who have no alternative treatment options. 1.13 Acute Bacterial Exacerbation of Chronic Bronchitis Levofloxacin is indicated for the treatment of acute bacterial exacerbation of chronic bronchitis (ABECB) due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis. [see CLINICAL STUDIES (14.4)] Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.15)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.14 Acute Bacterial Sinusitis: 5-day and 10–14 day Treatment Regimens Levofloxacin is indicated for the treatment of acute bacterial sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis [see Clinical Studies (14.4)]. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.14)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.15 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Culture and susceptibility testing Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see Microbiology (12.4)]. Therapy with levofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected. As with other drugs in this class, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with levofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance. uuid:cd2c2e98-21a4-4365-b3f9-71c66dc832cf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6GNT3Y5LMF biolink:treats MONDO:0003529 PMID:41385096 "[{""id"":""uuid:7cff4fa8-e5e3-4aaf-949f-70c8a4814674"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6965e115-bb41-493a-acae-dfd6d515481b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. 1.1 Nosocomial Pneumonia Levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillin susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see Clinical Studies (14.1)]. 1.2 Community-Acquired Pneumonia: 7–14 day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multi-drug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.2)]. MDRSP isolates are strains resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. 1.3 Community-Acquired Pneumonia: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (excluding multi-drug-resistant isolates [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.3)] 1.4 Complicated Skin and Skin Structure Infections Levofloxacin s indicated for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis [see Clinical Studies (14.5)]. 1.5 Uncomplicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, or Streptococcus pyogenes. 1.6 Chronic Bacterial Prostatitis Levofloxacin is indicated for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin-susceptible Staphylococcus epidermidis [see Clinical Studies (14.6)]. 1.7 Inhalational Anthrax (Post-Exposure) Levofloxacin is indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. The effectiveness of levofloxacin is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin has not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of levofloxacin in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged levofloxacin therapy should only be used when the benefit outweighs the risk [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.9)]. 1.8 Plague Levofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older. Efficacy studies of levofloxacin could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.10)]. 1.9 Complicated Urinary Tract Infections: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis [see Clinical Studies (14.7)]. 1.10 Complicated Urinary Tract Infections: 10-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa [see Clinical Studies (14.8)]. 1.11 Acute Pyelonephritis: 5 or 10-day Treatment Regimen Levofloxacin s indicated for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia [see Clinical Studies (14.7, 14.8)]. 1.12 Uncomplicated Urinary Tract Infections Levofloxacin is indicated for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1- 5.15)] and for some patients uncomplicated urinary tract infection is self-limiting, reserve levofloxacin for treatment of uncomplicated urinary tract infections in patients who have no alternative treatment options. 1.13 Acute Bacterial Exacerbation of Chronic Bronchitis Levofloxacin is indicated for the treatment of acute bacterial exacerbation of chronic bronchitis (ABECB) due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis. [see CLINICAL STUDIES (14.4)] Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.15)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.14 Acute Bacterial Sinusitis: 5-day and 10–14 day Treatment Regimens Levofloxacin is indicated for the treatment of acute bacterial sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis [see Clinical Studies (14.4)]. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.14)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.15 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Culture and susceptibility testing Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see Microbiology (12.4)]. Therapy with levofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected. As with other drugs in this class, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with levofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance. uuid:ecbbe95a-b596-4a97-b314-a4f39393e71a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6GNT3Y5LMF biolink:treats UMLS:C1735365 PMID:41385096 "[{""id"":""uuid:cad04419-ab40-425a-908e-1d9610b55a48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:93d6485f-4ee4-42bc-8cf9-5c2c740b9239"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. 1.1 Nosocomial Pneumonia Levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillin susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see Clinical Studies (14.1)]. 1.2 Community-Acquired Pneumonia: 7–14 day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multi-drug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.2)]. MDRSP isolates are strains resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. 1.3 Community-Acquired Pneumonia: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (excluding multi-drug-resistant isolates [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.3)] 1.4 Complicated Skin and Skin Structure Infections Levofloxacin s indicated for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis [see Clinical Studies (14.5)]. 1.5 Uncomplicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, or Streptococcus pyogenes. 1.6 Chronic Bacterial Prostatitis Levofloxacin is indicated for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin-susceptible Staphylococcus epidermidis [see Clinical Studies (14.6)]. 1.7 Inhalational Anthrax (Post-Exposure) Levofloxacin is indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. The effectiveness of levofloxacin is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin has not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of levofloxacin in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged levofloxacin therapy should only be used when the benefit outweighs the risk [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.9)]. 1.8 Plague Levofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older. Efficacy studies of levofloxacin could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.10)]. 1.9 Complicated Urinary Tract Infections: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis [see Clinical Studies (14.7)]. 1.10 Complicated Urinary Tract Infections: 10-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa [see Clinical Studies (14.8)]. 1.11 Acute Pyelonephritis: 5 or 10-day Treatment Regimen Levofloxacin s indicated for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia [see Clinical Studies (14.7, 14.8)]. 1.12 Uncomplicated Urinary Tract Infections Levofloxacin is indicated for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1- 5.15)] and for some patients uncomplicated urinary tract infection is self-limiting, reserve levofloxacin for treatment of uncomplicated urinary tract infections in patients who have no alternative treatment options. 1.13 Acute Bacterial Exacerbation of Chronic Bronchitis Levofloxacin is indicated for the treatment of acute bacterial exacerbation of chronic bronchitis (ABECB) due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis. [see CLINICAL STUDIES (14.4)] Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.15)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.14 Acute Bacterial Sinusitis: 5-day and 10–14 day Treatment Regimens Levofloxacin is indicated for the treatment of acute bacterial sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis [see Clinical Studies (14.4)]. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.14)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.15 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Culture and susceptibility testing Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see Microbiology (12.4)]. Therapy with levofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected. As with other drugs in this class, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with levofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance. uuid:86ffad15-161a-4861-bed7-903ffb0cecb8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6GNT3Y5LMF biolink:treats UMLS:C0275556 PMID:41385096 "[{""id"":""uuid:604101fb-e72c-4bf6-8395-8d951f625bf1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5983f61f-f14a-49df-85be-83b88f8abc38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin are indicated for the treatment of adults (≥18 years of age) with mild, moderate, and severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section. 1.1 Nosocomial Pneumonia Levofloxacin is indicated for the treatment of nosocomial pneumonia due to methicillin susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Escherichia coli, Klebsiella pneumoniae, Haemophilus influenzae, or Streptococcus pneumoniae. Adjunctive therapy should be used as clinically indicated. Where Pseudomonas aeruginosa is a documented or presumptive pathogen, combination therapy with an anti-pseudomonal β-lactam is recommended [see Clinical Studies (14.1)]. 1.2 Community-Acquired Pneumonia: 7–14 day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae (including multi-drug-resistant Streptococcus pneumoniae [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Moraxella catarrhalis, Chlamydophila pneumoniae, Legionella pneumophila, or Mycoplasma pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.2)]. MDRSP isolates are strains resistant to two or more of the following antibacterials: penicillin (MIC ≥2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime, macrolides, tetracyclines and trimethoprim/sulfamethoxazole. 1.3 Community-Acquired Pneumonia: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of community-acquired pneumonia due to Streptococcus pneumoniae (excluding multi-drug-resistant isolates [MDRSP]), Haemophilus influenzae, Haemophilus parainfluenzae, Mycoplasma pneumoniae, or Chlamydophila pneumoniae [see Dosage and Administration (2.1) and Clinical Studies (14.3)] 1.4 Complicated Skin and Skin Structure Infections Levofloxacin s indicated for the treatment of complicated skin and skin structure infections due to methicillin-susceptible Staphylococcus aureus, Enterococcus faecalis, Streptococcus pyogenes, or Proteus mirabilis [see Clinical Studies (14.5)]. 1.5 Uncomplicated Skin and Skin Structure Infections Levofloxacin is indicated for the treatment of uncomplicated skin and skin structure infections (mild to moderate) including abscesses, cellulitis, furuncles, impetigo, pyoderma, wound infections, due to methicillin-susceptible Staphylococcus aureus, or Streptococcus pyogenes. 1.6 Chronic Bacterial Prostatitis Levofloxacin is indicated for the treatment of chronic bacterial prostatitis due to Escherichia coli, Enterococcus faecalis, or methicillin-susceptible Staphylococcus epidermidis [see Clinical Studies (14.6)]. 1.7 Inhalational Anthrax (Post-Exposure) Levofloxacin is indicated for inhalational anthrax (post-exposure) to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. The effectiveness of levofloxacin is based on plasma concentrations achieved in humans, a surrogate endpoint reasonably likely to predict clinical benefit. Levofloxacin has not been tested in humans for the post-exposure prevention of inhalation anthrax. The safety of levofloxacin in adults for durations of therapy beyond 28 days or in pediatric patients for durations of therapy beyond 14 days has not been studied. Prolonged levofloxacin therapy should only be used when the benefit outweighs the risk [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.9)]. 1.8 Plague Levofloxacin is indicated for treatment of plague, including pneumonic and septicemic plague, due to Yersinia pestis (Y. pestis) and prophylaxis for plague in adults and pediatric patients, 6 months of age and older. Efficacy studies of levofloxacin could not be conducted in humans with plague for ethical and feasibility reasons. Therefore, approval of this indication was based on an efficacy study conducted in animals [see Dosage and Administration (2.1, 2.2) and Clinical Studies (14.10)]. 1.9 Complicated Urinary Tract Infections: 5-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections due to Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis [see Clinical Studies (14.7)]. 1.10 Complicated Urinary Tract Infections: 10-day Treatment Regimen Levofloxacin is indicated for the treatment of complicated urinary tract infections (mild to moderate) due to Enterococcus faecalis, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa [see Clinical Studies (14.8)]. 1.11 Acute Pyelonephritis: 5 or 10-day Treatment Regimen Levofloxacin s indicated for the treatment of acute pyelonephritis caused by Escherichia coli, including cases with concurrent bacteremia [see Clinical Studies (14.7, 14.8)]. 1.12 Uncomplicated Urinary Tract Infections Levofloxacin is indicated for the treatment of uncomplicated urinary tract infections (mild to moderate) due to Escherichia coli, Klebsiella pneumoniae, or Staphylococcus saprophyticus. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1- 5.15)] and for some patients uncomplicated urinary tract infection is self-limiting, reserve levofloxacin for treatment of uncomplicated urinary tract infections in patients who have no alternative treatment options. 1.13 Acute Bacterial Exacerbation of Chronic Bronchitis Levofloxacin is indicated for the treatment of acute bacterial exacerbation of chronic bronchitis (ABECB) due to methicillin-susceptible Staphylococcus aureus, Streptococcus pneumoniae, Haemophilus influenzae, Haemophilus parainfluenzae, or Moraxella catarrhalis. [see CLINICAL STUDIES (14.4)] Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.15)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.14 Acute Bacterial Sinusitis: 5-day and 10–14 day Treatment Regimens Levofloxacin is indicated for the treatment of acute bacterial sinusitis due to Streptococcus pneumoniae, Haemophilus influenzae, or Moraxella catarrhalis [see Clinical Studies (14.4)]. Because fluoroquinolones, including levofloxacin, have been associated with serious adverse reactions [see Warnings and Precautions (5.1-5.14)] and for some patients ABECB is self-limiting, reserve levofloxacin for treatment of ABECB in patients who have no alternative treatment options. 1.15 Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin and other antibacterial drugs, levofloxacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Culture and susceptibility testing Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see Microbiology (12.4)]. Therapy with levofloxacin may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected. As with other drugs in this class, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with levofloxacin. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance. uuid:3b15cee9-7433-4d2a-9b1c-6950eb85cce1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats UMLS:C3495878 PMID:41385096 "[{""id"":""uuid:4f0a7ebf-c616-4f00-8278-772990d32e27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:42761cef-505e-4f82-a818-2bb102485c94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Salicylic Acid 6% (w/w) Cream is a topical aid in the removal of excessive keratin in hyperkeratotic skin disorders, including verrucae, and the various ichthyoses (vulgaris, sex-linked and lamellar), keratosis palmaris and plantaris, keratosis pilaris, pityriasis rubra pilaris, and psoriasis (including body, scalp, palms and soles). For Podiatric Use: Salicylic Acid 6% (w/w) Cream is a topical aid in the removal of excessive keratin on the dorsal and plantar hyperkeratotic lesions. Topical preparations of 6% salicylic acid have been reported to be useful adjunctive therapy for verrucae plantares. uuid:6d41d561-377a-404e-81b5-acfa0fcd8c52 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0006668 PMID:41385096 "[{""id"":""uuid:6734f179-7d40-4a2b-8f96-65c5b4fbff58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d7d79b39-eb53-48bf-a230-c149a8815282"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levofloxacin ophthalmic solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Gram-positive bacteria Corynebacterium species* Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumonia Streptococcus (Groups C/F) Streptococcus (Group G) Viridans group streptococci* Gram-negative bacteria Acinetobacter lwoffii* Haemophilus influenzae Serratia marcescens* * Efficacy for this organism was studied in fewer than 10 infections. uuid:fda9349a-8f4c-434d-9048-7ad80510d09e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28915 biolink:treats MONDO:0001650 PMID:41385096 "[{""id"":""uuid:d9d1804e-403a-40fd-9e75-3d749f4a15c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c1e7583d-19b0-4a4c-8d3a-78adb828489f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fosfomycin tromethamine granules for oral solution is indicated only for the treatment of uncomplicated urinary tract infections (acute cystitis) in women due to susceptible strains of Escherichia coli and Enterococcus faecalis . Fosfomycin tromethamine granules for oral solution is not indicated for the treatment of pyelonephritis or perinephric abscess. If persistence or reappearance of bacteriuria occurs after treatment with fosfomycin tromethamine granules for oral solution, other therapeutic agents should be selected. (See PRECAUTIONS and CLINICAL STUDIES sections.) uuid:1dcb2d8c-06f5-42ea-a979-721ae252d378 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28915 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:67d7959d-ff77-432d-9aa9-a7f7334ad414"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c5820fa1-90ed-4c0e-9403-881f3246ea29"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fosfomycin tromethamine granules for oral solution is indicated only for the treatment of uncomplicated urinary tract infections (acute cystitis) in women due to susceptible strains of Escherichia coli and Enterococcus faecalis . Fosfomycin tromethamine granules for oral solution is not indicated for the treatment of pyelonephritis or perinephric abscess. If persistence or reappearance of bacteriuria occurs after treatment with fosfomycin tromethamine granules for oral solution, other therapeutic agents should be selected. (See PRECAUTIONS and CLINICAL STUDIES sections.) uuid:ed269281-e8ef-4d3e-8ca6-3f1710bcabf3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28915 biolink:treats MONDO:0006939 PMID:41385096 "[{""id"":""uuid:2e3bc0a7-e504-49f7-a8be-a8a3e5738ffa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dab2d7d9-01d1-4718-b188-94514d2d6e01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fosfomycin tromethamine granules for oral solution is indicated only for the treatment of uncomplicated urinary tract infections (acute cystitis) in women due to susceptible strains of Escherichia coli and Enterococcus faecalis . Fosfomycin tromethamine granules for oral solution is not indicated for the treatment of pyelonephritis or perinephric abscess. If persistence or reappearance of bacteriuria occurs after treatment with fosfomycin tromethamine granules for oral solution, other therapeutic agents should be selected. (See PRECAUTIONS and CLINICAL STUDIES sections.) uuid:495db6c0-5853-4004-bb1d-025274c08d16 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28915 biolink:treats HP:0032619 PMID:41385096 "[{""id"":""uuid:31c91329-ca2a-48d5-89a8-b379cf1db9e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1461e9c5-a56f-4fcf-bf43-97aa03e963a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fosfomycin tromethamine granules for oral solution is indicated only for the treatment of uncomplicated urinary tract infections (acute cystitis) in women due to susceptible strains of Escherichia coli and Enterococcus faecalis . Fosfomycin tromethamine granules for oral solution is not indicated for the treatment of pyelonephritis or perinephric abscess. If persistence or reappearance of bacteriuria occurs after treatment with fosfomycin tromethamine granules for oral solution, other therapeutic agents should be selected. (See PRECAUTIONS and CLINICAL STUDIES sections.) uuid:65e990c9-2f96-4ffd-8591-0526157ffe57 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1164001 biolink:treats MONDO:0004872 PMID:41385096 "[{""id"":""uuid:0ee6f0d4-b418-478a-9fbf-af6a68b24d66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3a273ff0-4b62-45ba-87eb-f8a3625f6402"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydrocortisone acetate and pramoxine hydrochloride suppositories are indicated for use in inflamed hemorrhoids, post-irradiation (factitial) proctitis; as an adjunct in the treatment of chronic ulcerative colitis; cryptitis; and other inflammatory conditions of anorectum and pruritus ani. uuid:bb6cb488-489f-4c8f-a9ef-565bc8ed4054 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1164001 biolink:treats MONDO:0019084 PMID:41385096 "[{""id"":""uuid:b7c2e386-04af-40e0-b6a7-03f82e225c8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2940454b-65de-4375-a075-ea64604081e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydrocortisone acetate and pramoxine hydrochloride suppositories are indicated for use in inflamed hemorrhoids, post-irradiation (factitial) proctitis; as an adjunct in the treatment of chronic ulcerative colitis; cryptitis; and other inflammatory conditions of anorectum and pruritus ani. uuid:08ab664f-a3cb-4f27-af16-474220217583 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1164001 biolink:treats UMLS:C2919828 PMID:41385096 "[{""id"":""uuid:f7049995-ee21-4d0a-aa22-8db01d09ebcc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5c74ccaa-0146-492e-b115-138954c96443"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydrocortisone acetate and pramoxine hydrochloride suppositories are indicated for use in inflamed hemorrhoids, post-irradiation (factitial) proctitis; as an adjunct in the treatment of chronic ulcerative colitis; cryptitis; and other inflammatory conditions of anorectum and pruritus ani. uuid:11317208-d9b8-41b9-b597-3c3b978fbd60 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1164001 biolink:treats UMLS:C1394254 PMID:41385096 "[{""id"":""uuid:f8eb623f-2d2c-483d-a48d-bc368365ac8e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:09225754-3254-403d-8bd3-da2c417932c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydrocortisone acetate and pramoxine hydrochloride suppositories are indicated for use in inflamed hemorrhoids, post-irradiation (factitial) proctitis; as an adjunct in the treatment of chronic ulcerative colitis; cryptitis; and other inflammatory conditions of anorectum and pruritus ani. uuid:cc8a9f4e-77bc-4078-97b1-d9ccea574d7c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1164001 biolink:treats UMLS:C0033775 PMID:41385096 "[{""id"":""uuid:f784b4b2-c41f-4877-9586-f9db8047898c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d11143d1-2ca9-4893-a5c7-c0b4a16dfd30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydrocortisone acetate and pramoxine hydrochloride suppositories are indicated for use in inflamed hemorrhoids, post-irradiation (factitial) proctitis; as an adjunct in the treatment of chronic ulcerative colitis; cryptitis; and other inflammatory conditions of anorectum and pruritus ani. uuid:a109c632-b9cd-431c-b52f-fe82f12858f0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17051 biolink:treats MONDO:0002508 PMID:41385096 "[{""id"":""uuid:221dbcf5-4cc0-4f98-b2f6-33453fcede71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c4371107-afb1-4a47-b3a5-58765ff83847"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Aids in the prevention of dental decay. Helps prevent gingivitis. Helps control plaque bacteria. Increases protection against painful tooth sensitivity. This product mist be used under the supervision of a dentist. uuid:7005e227-0e92-4517-94be-c2287adaa697 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:NQX9KB6PCL biolink:treats UMLS:C0043046 PMID:41385096 "[{""id"":""uuid:59c52fb2-3af2-4c6a-98b8-bc24c7cb284c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7d005248-442f-4bdf-8658-159da123bb9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SEROSTIM (somatropin) is indicated for the treatment of HIV patients with wasting or cachexia to increase lean body mass and body weight, and improve physical endurance. Concomitant antiretroviral therapy is necessary. uuid:04a083f0-0a5a-4756-a630-bf388bd7c87f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:NQX9KB6PCL biolink:treats MONDO:0005797 PMID:41385096 "[{""id"":""uuid:72974758-4243-47c7-a064-f6b490ba156a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6f15901b-4973-4af3-952c-1e2e4440772f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SEROSTIM (somatropin) is indicated for the treatment of HIV patients with wasting or cachexia to increase lean body mass and body weight, and improve physical endurance. Concomitant antiretroviral therapy is necessary. uuid:636ab0e2-3d61-4d86-8ba4-5dca11f6bad7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:86545 biolink:treats MONDO:0004739 PMID:41385096 "[{""id"":""uuid:86e95e31-1df0-476f-b475-11a0784758be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:57b9695a-0718-400b-9173-be5d5a515db9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Phenylbutyrate Powder is indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). It is indicated in all patients with neonatal-onset deficiency (complete enzymatic deficiency, presenting within the first 28 days of life). It is also indicated in patients with late-onset disease (partial enzymatic deficiency, presenting after the first month of life) who have a history of hyperammonemic encephalopathy. It is important that the diagnosis be made early and treatment initiated immediately to improve survival. Any episode of acute hyperammonemia should be treated as a life-threatening emergency. Sodium Phenylbutyrate Powder must be combined with dietary protein restriction and, in some cases, essential amino acid supplementation. (See Nutritional Supplementation subsection of the DOSAGE AND ADMINISTRATION section.) Previously, neonatal-onset disease was almost universally fatal within the first year of life, even when treated with peritoneal dialysis and essential amino acids or their nitrogen-free analogs. However, with hemodialysis, use of alternative waste nitrogen excretion pathways (sodium phenylbutyrate, sodium benzoate, and sodium phenylacetate), dietary protein restriction, and, in some cases, essential amino acid supplementation, the survival rate in newborns diagnosed after birth but within the first month of life is almost 80%. Most deaths have occurred during an episode of acute hyperammonemic encephalopathy. Patients with neonatal-onset disease have a high incidence of mental retardation. Those who had IQ tests administered had an incidence of mental retardation as follows: ornithine transcarbamylase deficiency, 100% (14/14 patients tested); argininosuccinic acid synthetase deficiency, 88% (15/17 patients tested); and carbamylphosphate synthetase deficiency, 57% (4/7 patients tested). Retardation was severe in the majority of the retarded patients. In patients diagnosed during gestation and treated prior to any episode of hyperammonemic encephalopathy, survival is 100%, but even in these patients, most subsequently demonstrate cognitive impairment or other neurologic deficits. In late-onset deficiency patients, including females heterozygous for ornithine transcarbamylase deficiency, who recover from hyperammonemic encephalopathy and are then treated chronically with sodium phenylbutyrate and dietary protein restriction, the survival rate is 98%. The two deaths in this group of patients occurred during episodes of hyperammonemic encephalopathy. However, compliance with the therapeutic regimen has not been adequately documented to allow evaluation of the potential for Sodium Phenylbutyrate Powder and dietary protein restriction to prevent mental deterioration and recurrence of hyperammonemic encephalopathy if carefully adhered to. The majority of these patients tested (30/46 or 65%) have IQ's in the average to low average/borderline mentally retarded range. Reversal of pre-existing neurologic impairment is not likely to occur with treatment and neurologic deterioration may continue in some patients. Even on therapy, acute hyperammonemic encephalopathy recurred in the majority of patients for whom the drug is indicated. Sodium Phenylbutyrate Powder may be required life-long unless orthotopic liver transplantation is elected. (See CLINICAL PHARMACOLOGY , Pharmacodynamics subsection for the biochemical effects of Sodium Phenylbutyrate Powder). uuid:bac914c0-bf40-423e-ae06-906f1f7b90d4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:86545 biolink:treats MONDO:0009376 PMID:41385096 "[{""id"":""uuid:0d9ac51c-bf6c-4cf0-b7c8-81dc57c0487c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4bdafd76-5e1c-4449-b8b0-7e30104c91cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Phenylbutyrate Powder is indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). It is indicated in all patients with neonatal-onset deficiency (complete enzymatic deficiency, presenting within the first 28 days of life). It is also indicated in patients with late-onset disease (partial enzymatic deficiency, presenting after the first month of life) who have a history of hyperammonemic encephalopathy. It is important that the diagnosis be made early and treatment initiated immediately to improve survival. Any episode of acute hyperammonemia should be treated as a life-threatening emergency. Sodium Phenylbutyrate Powder must be combined with dietary protein restriction and, in some cases, essential amino acid supplementation. (See Nutritional Supplementation subsection of the DOSAGE AND ADMINISTRATION section.) Previously, neonatal-onset disease was almost universally fatal within the first year of life, even when treated with peritoneal dialysis and essential amino acids or their nitrogen-free analogs. However, with hemodialysis, use of alternative waste nitrogen excretion pathways (sodium phenylbutyrate, sodium benzoate, and sodium phenylacetate), dietary protein restriction, and, in some cases, essential amino acid supplementation, the survival rate in newborns diagnosed after birth but within the first month of life is almost 80%. Most deaths have occurred during an episode of acute hyperammonemic encephalopathy. Patients with neonatal-onset disease have a high incidence of mental retardation. Those who had IQ tests administered had an incidence of mental retardation as follows: ornithine transcarbamylase deficiency, 100% (14/14 patients tested); argininosuccinic acid synthetase deficiency, 88% (15/17 patients tested); and carbamylphosphate synthetase deficiency, 57% (4/7 patients tested). Retardation was severe in the majority of the retarded patients. In patients diagnosed during gestation and treated prior to any episode of hyperammonemic encephalopathy, survival is 100%, but even in these patients, most subsequently demonstrate cognitive impairment or other neurologic deficits. In late-onset deficiency patients, including females heterozygous for ornithine transcarbamylase deficiency, who recover from hyperammonemic encephalopathy and are then treated chronically with sodium phenylbutyrate and dietary protein restriction, the survival rate is 98%. The two deaths in this group of patients occurred during episodes of hyperammonemic encephalopathy. However, compliance with the therapeutic regimen has not been adequately documented to allow evaluation of the potential for Sodium Phenylbutyrate Powder and dietary protein restriction to prevent mental deterioration and recurrence of hyperammonemic encephalopathy if carefully adhered to. The majority of these patients tested (30/46 or 65%) have IQ's in the average to low average/borderline mentally retarded range. Reversal of pre-existing neurologic impairment is not likely to occur with treatment and neurologic deterioration may continue in some patients. Even on therapy, acute hyperammonemic encephalopathy recurred in the majority of patients for whom the drug is indicated. Sodium Phenylbutyrate Powder may be required life-long unless orthotopic liver transplantation is elected. (See CLINICAL PHARMACOLOGY , Pharmacodynamics subsection for the biochemical effects of Sodium Phenylbutyrate Powder). uuid:f5b7e144-2c38-4633-8e83-4573a84823f9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:86545 biolink:treats MONDO:0010703 PMID:41385096 "[{""id"":""uuid:4180f58b-e27e-4e04-af00-aee617d9962f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2c734020-79f1-442f-ac80-129cdc00515f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Phenylbutyrate Powder is indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). It is indicated in all patients with neonatal-onset deficiency (complete enzymatic deficiency, presenting within the first 28 days of life). It is also indicated in patients with late-onset disease (partial enzymatic deficiency, presenting after the first month of life) who have a history of hyperammonemic encephalopathy. It is important that the diagnosis be made early and treatment initiated immediately to improve survival. Any episode of acute hyperammonemia should be treated as a life-threatening emergency. Sodium Phenylbutyrate Powder must be combined with dietary protein restriction and, in some cases, essential amino acid supplementation. (See Nutritional Supplementation subsection of the DOSAGE AND ADMINISTRATION section.) Previously, neonatal-onset disease was almost universally fatal within the first year of life, even when treated with peritoneal dialysis and essential amino acids or their nitrogen-free analogs. However, with hemodialysis, use of alternative waste nitrogen excretion pathways (sodium phenylbutyrate, sodium benzoate, and sodium phenylacetate), dietary protein restriction, and, in some cases, essential amino acid supplementation, the survival rate in newborns diagnosed after birth but within the first month of life is almost 80%. Most deaths have occurred during an episode of acute hyperammonemic encephalopathy. Patients with neonatal-onset disease have a high incidence of mental retardation. Those who had IQ tests administered had an incidence of mental retardation as follows: ornithine transcarbamylase deficiency, 100% (14/14 patients tested); argininosuccinic acid synthetase deficiency, 88% (15/17 patients tested); and carbamylphosphate synthetase deficiency, 57% (4/7 patients tested). Retardation was severe in the majority of the retarded patients. In patients diagnosed during gestation and treated prior to any episode of hyperammonemic encephalopathy, survival is 100%, but even in these patients, most subsequently demonstrate cognitive impairment or other neurologic deficits. In late-onset deficiency patients, including females heterozygous for ornithine transcarbamylase deficiency, who recover from hyperammonemic encephalopathy and are then treated chronically with sodium phenylbutyrate and dietary protein restriction, the survival rate is 98%. The two deaths in this group of patients occurred during episodes of hyperammonemic encephalopathy. However, compliance with the therapeutic regimen has not been adequately documented to allow evaluation of the potential for Sodium Phenylbutyrate Powder and dietary protein restriction to prevent mental deterioration and recurrence of hyperammonemic encephalopathy if carefully adhered to. The majority of these patients tested (30/46 or 65%) have IQ's in the average to low average/borderline mentally retarded range. Reversal of pre-existing neurologic impairment is not likely to occur with treatment and neurologic deterioration may continue in some patients. Even on therapy, acute hyperammonemic encephalopathy recurred in the majority of patients for whom the drug is indicated. Sodium Phenylbutyrate Powder may be required life-long unless orthotopic liver transplantation is elected. (See CLINICAL PHARMACOLOGY , Pharmacodynamics subsection for the biochemical effects of Sodium Phenylbutyrate Powder). uuid:486776e5-00be-4f5a-8612-8128fb0fa78b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:86545 biolink:treats MONDO:0015991 PMID:41385096 "[{""id"":""uuid:97631df4-ef42-4e2a-bfd7-d51d1b1832c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:290c5e18-987e-490c-916b-6b72582db57f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Phenylbutyrate Powder is indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). It is indicated in all patients with neonatal-onset deficiency (complete enzymatic deficiency, presenting within the first 28 days of life). It is also indicated in patients with late-onset disease (partial enzymatic deficiency, presenting after the first month of life) who have a history of hyperammonemic encephalopathy. It is important that the diagnosis be made early and treatment initiated immediately to improve survival. Any episode of acute hyperammonemia should be treated as a life-threatening emergency. Sodium Phenylbutyrate Powder must be combined with dietary protein restriction and, in some cases, essential amino acid supplementation. (See Nutritional Supplementation subsection of the DOSAGE AND ADMINISTRATION section.) Previously, neonatal-onset disease was almost universally fatal within the first year of life, even when treated with peritoneal dialysis and essential amino acids or their nitrogen-free analogs. However, with hemodialysis, use of alternative waste nitrogen excretion pathways (sodium phenylbutyrate, sodium benzoate, and sodium phenylacetate), dietary protein restriction, and, in some cases, essential amino acid supplementation, the survival rate in newborns diagnosed after birth but within the first month of life is almost 80%. Most deaths have occurred during an episode of acute hyperammonemic encephalopathy. Patients with neonatal-onset disease have a high incidence of mental retardation. Those who had IQ tests administered had an incidence of mental retardation as follows: ornithine transcarbamylase deficiency, 100% (14/14 patients tested); argininosuccinic acid synthetase deficiency, 88% (15/17 patients tested); and carbamylphosphate synthetase deficiency, 57% (4/7 patients tested). Retardation was severe in the majority of the retarded patients. In patients diagnosed during gestation and treated prior to any episode of hyperammonemic encephalopathy, survival is 100%, but even in these patients, most subsequently demonstrate cognitive impairment or other neurologic deficits. In late-onset deficiency patients, including females heterozygous for ornithine transcarbamylase deficiency, who recover from hyperammonemic encephalopathy and are then treated chronically with sodium phenylbutyrate and dietary protein restriction, the survival rate is 98%. The two deaths in this group of patients occurred during episodes of hyperammonemic encephalopathy. However, compliance with the therapeutic regimen has not been adequately documented to allow evaluation of the potential for Sodium Phenylbutyrate Powder and dietary protein restriction to prevent mental deterioration and recurrence of hyperammonemic encephalopathy if carefully adhered to. The majority of these patients tested (30/46 or 65%) have IQ's in the average to low average/borderline mentally retarded range. Reversal of pre-existing neurologic impairment is not likely to occur with treatment and neurologic deterioration may continue in some patients. Even on therapy, acute hyperammonemic encephalopathy recurred in the majority of patients for whom the drug is indicated. Sodium Phenylbutyrate Powder may be required life-long unless orthotopic liver transplantation is elected. (See CLINICAL PHARMACOLOGY , Pharmacodynamics subsection for the biochemical effects of Sodium Phenylbutyrate Powder). uuid:cfaa9a7f-ef1d-4a81-84ef-6db2ec1c7823 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:86545 biolink:treats UMLS:C1960448 PMID:41385096 "[{""id"":""uuid:1357f90f-bfac-4600-993c-f07b2100300f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ec45c74b-4019-4de0-89c5-1bf991fd5d9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Phenylbutyrate Powder is indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). It is indicated in all patients with neonatal-onset deficiency (complete enzymatic deficiency, presenting within the first 28 days of life). It is also indicated in patients with late-onset disease (partial enzymatic deficiency, presenting after the first month of life) who have a history of hyperammonemic encephalopathy. It is important that the diagnosis be made early and treatment initiated immediately to improve survival. Any episode of acute hyperammonemia should be treated as a life-threatening emergency. Sodium Phenylbutyrate Powder must be combined with dietary protein restriction and, in some cases, essential amino acid supplementation. (See Nutritional Supplementation subsection of the DOSAGE AND ADMINISTRATION section.) Previously, neonatal-onset disease was almost universally fatal within the first year of life, even when treated with peritoneal dialysis and essential amino acids or their nitrogen-free analogs. However, with hemodialysis, use of alternative waste nitrogen excretion pathways (sodium phenylbutyrate, sodium benzoate, and sodium phenylacetate), dietary protein restriction, and, in some cases, essential amino acid supplementation, the survival rate in newborns diagnosed after birth but within the first month of life is almost 80%. Most deaths have occurred during an episode of acute hyperammonemic encephalopathy. Patients with neonatal-onset disease have a high incidence of mental retardation. Those who had IQ tests administered had an incidence of mental retardation as follows: ornithine transcarbamylase deficiency, 100% (14/14 patients tested); argininosuccinic acid synthetase deficiency, 88% (15/17 patients tested); and carbamylphosphate synthetase deficiency, 57% (4/7 patients tested). Retardation was severe in the majority of the retarded patients. In patients diagnosed during gestation and treated prior to any episode of hyperammonemic encephalopathy, survival is 100%, but even in these patients, most subsequently demonstrate cognitive impairment or other neurologic deficits. In late-onset deficiency patients, including females heterozygous for ornithine transcarbamylase deficiency, who recover from hyperammonemic encephalopathy and are then treated chronically with sodium phenylbutyrate and dietary protein restriction, the survival rate is 98%. The two deaths in this group of patients occurred during episodes of hyperammonemic encephalopathy. However, compliance with the therapeutic regimen has not been adequately documented to allow evaluation of the potential for Sodium Phenylbutyrate Powder and dietary protein restriction to prevent mental deterioration and recurrence of hyperammonemic encephalopathy if carefully adhered to. The majority of these patients tested (30/46 or 65%) have IQ's in the average to low average/borderline mentally retarded range. Reversal of pre-existing neurologic impairment is not likely to occur with treatment and neurologic deterioration may continue in some patients. Even on therapy, acute hyperammonemic encephalopathy recurred in the majority of patients for whom the drug is indicated. Sodium Phenylbutyrate Powder may be required life-long unless orthotopic liver transplantation is elected. (See CLINICAL PHARMACOLOGY , Pharmacodynamics subsection for the biochemical effects of Sodium Phenylbutyrate Powder). uuid:47164e44-e5ce-4841-aeb3-428d71bc82d8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:86545 biolink:treats MONDO:0001071 PMID:41385096 "[{""id"":""uuid:05e92fd7-b39a-4b7a-a843-bd61ae8c3e61"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ea65b4ec-d5fa-4088-ac26-05ad71c74c2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Phenylbutyrate Powder is indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). It is indicated in all patients with neonatal-onset deficiency (complete enzymatic deficiency, presenting within the first 28 days of life). It is also indicated in patients with late-onset disease (partial enzymatic deficiency, presenting after the first month of life) who have a history of hyperammonemic encephalopathy. It is important that the diagnosis be made early and treatment initiated immediately to improve survival. Any episode of acute hyperammonemia should be treated as a life-threatening emergency. Sodium Phenylbutyrate Powder must be combined with dietary protein restriction and, in some cases, essential amino acid supplementation. (See Nutritional Supplementation subsection of the DOSAGE AND ADMINISTRATION section.) Previously, neonatal-onset disease was almost universally fatal within the first year of life, even when treated with peritoneal dialysis and essential amino acids or their nitrogen-free analogs. However, with hemodialysis, use of alternative waste nitrogen excretion pathways (sodium phenylbutyrate, sodium benzoate, and sodium phenylacetate), dietary protein restriction, and, in some cases, essential amino acid supplementation, the survival rate in newborns diagnosed after birth but within the first month of life is almost 80%. Most deaths have occurred during an episode of acute hyperammonemic encephalopathy. Patients with neonatal-onset disease have a high incidence of mental retardation. Those who had IQ tests administered had an incidence of mental retardation as follows: ornithine transcarbamylase deficiency, 100% (14/14 patients tested); argininosuccinic acid synthetase deficiency, 88% (15/17 patients tested); and carbamylphosphate synthetase deficiency, 57% (4/7 patients tested). Retardation was severe in the majority of the retarded patients. In patients diagnosed during gestation and treated prior to any episode of hyperammonemic encephalopathy, survival is 100%, but even in these patients, most subsequently demonstrate cognitive impairment or other neurologic deficits. In late-onset deficiency patients, including females heterozygous for ornithine transcarbamylase deficiency, who recover from hyperammonemic encephalopathy and are then treated chronically with sodium phenylbutyrate and dietary protein restriction, the survival rate is 98%. The two deaths in this group of patients occurred during episodes of hyperammonemic encephalopathy. However, compliance with the therapeutic regimen has not been adequately documented to allow evaluation of the potential for Sodium Phenylbutyrate Powder and dietary protein restriction to prevent mental deterioration and recurrence of hyperammonemic encephalopathy if carefully adhered to. The majority of these patients tested (30/46 or 65%) have IQ's in the average to low average/borderline mentally retarded range. Reversal of pre-existing neurologic impairment is not likely to occur with treatment and neurologic deterioration may continue in some patients. Even on therapy, acute hyperammonemic encephalopathy recurred in the majority of patients for whom the drug is indicated. Sodium Phenylbutyrate Powder may be required life-long unless orthotopic liver transplantation is elected. (See CLINICAL PHARMACOLOGY , Pharmacodynamics subsection for the biochemical effects of Sodium Phenylbutyrate Powder). uuid:f55d2005-e15c-41c3-a0e9-8522b97e5f83 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:86545 biolink:treats HP:0100543 PMID:41385096 "[{""id"":""uuid:70596d27-a467-45cc-8afa-7a7ca708f24e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ce0dbe83-1ecb-4ba6-913f-0d7f92d39883"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Phenylbutyrate Powder is indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). It is indicated in all patients with neonatal-onset deficiency (complete enzymatic deficiency, presenting within the first 28 days of life). It is also indicated in patients with late-onset disease (partial enzymatic deficiency, presenting after the first month of life) who have a history of hyperammonemic encephalopathy. It is important that the diagnosis be made early and treatment initiated immediately to improve survival. Any episode of acute hyperammonemia should be treated as a life-threatening emergency. Sodium Phenylbutyrate Powder must be combined with dietary protein restriction and, in some cases, essential amino acid supplementation. (See Nutritional Supplementation subsection of the DOSAGE AND ADMINISTRATION section.) Previously, neonatal-onset disease was almost universally fatal within the first year of life, even when treated with peritoneal dialysis and essential amino acids or their nitrogen-free analogs. However, with hemodialysis, use of alternative waste nitrogen excretion pathways (sodium phenylbutyrate, sodium benzoate, and sodium phenylacetate), dietary protein restriction, and, in some cases, essential amino acid supplementation, the survival rate in newborns diagnosed after birth but within the first month of life is almost 80%. Most deaths have occurred during an episode of acute hyperammonemic encephalopathy. Patients with neonatal-onset disease have a high incidence of mental retardation. Those who had IQ tests administered had an incidence of mental retardation as follows: ornithine transcarbamylase deficiency, 100% (14/14 patients tested); argininosuccinic acid synthetase deficiency, 88% (15/17 patients tested); and carbamylphosphate synthetase deficiency, 57% (4/7 patients tested). Retardation was severe in the majority of the retarded patients. In patients diagnosed during gestation and treated prior to any episode of hyperammonemic encephalopathy, survival is 100%, but even in these patients, most subsequently demonstrate cognitive impairment or other neurologic deficits. In late-onset deficiency patients, including females heterozygous for ornithine transcarbamylase deficiency, who recover from hyperammonemic encephalopathy and are then treated chronically with sodium phenylbutyrate and dietary protein restriction, the survival rate is 98%. The two deaths in this group of patients occurred during episodes of hyperammonemic encephalopathy. However, compliance with the therapeutic regimen has not been adequately documented to allow evaluation of the potential for Sodium Phenylbutyrate Powder and dietary protein restriction to prevent mental deterioration and recurrence of hyperammonemic encephalopathy if carefully adhered to. The majority of these patients tested (30/46 or 65%) have IQ's in the average to low average/borderline mentally retarded range. Reversal of pre-existing neurologic impairment is not likely to occur with treatment and neurologic deterioration may continue in some patients. Even on therapy, acute hyperammonemic encephalopathy recurred in the majority of patients for whom the drug is indicated. Sodium Phenylbutyrate Powder may be required life-long unless orthotopic liver transplantation is elected. (See CLINICAL PHARMACOLOGY , Pharmacodynamics subsection for the biochemical effects of Sodium Phenylbutyrate Powder). uuid:61ff011f-e6ff-4c9c-9171-3a8d2daf6e46 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:86545 biolink:treats MONDO:0005071 PMID:41385096 "[{""id"":""uuid:dcc9a350-09c0-4800-89cc-c63e230123fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:69543f23-d613-442e-b9c2-3be7e3fa0584"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Phenylbutyrate Powder is indicated as adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic acid synthetase (AS). It is indicated in all patients with neonatal-onset deficiency (complete enzymatic deficiency, presenting within the first 28 days of life). It is also indicated in patients with late-onset disease (partial enzymatic deficiency, presenting after the first month of life) who have a history of hyperammonemic encephalopathy. It is important that the diagnosis be made early and treatment initiated immediately to improve survival. Any episode of acute hyperammonemia should be treated as a life-threatening emergency. Sodium Phenylbutyrate Powder must be combined with dietary protein restriction and, in some cases, essential amino acid supplementation. (See Nutritional Supplementation subsection of the DOSAGE AND ADMINISTRATION section.) Previously, neonatal-onset disease was almost universally fatal within the first year of life, even when treated with peritoneal dialysis and essential amino acids or their nitrogen-free analogs. However, with hemodialysis, use of alternative waste nitrogen excretion pathways (sodium phenylbutyrate, sodium benzoate, and sodium phenylacetate), dietary protein restriction, and, in some cases, essential amino acid supplementation, the survival rate in newborns diagnosed after birth but within the first month of life is almost 80%. Most deaths have occurred during an episode of acute hyperammonemic encephalopathy. Patients with neonatal-onset disease have a high incidence of mental retardation. Those who had IQ tests administered had an incidence of mental retardation as follows: ornithine transcarbamylase deficiency, 100% (14/14 patients tested); argininosuccinic acid synthetase deficiency, 88% (15/17 patients tested); and carbamylphosphate synthetase deficiency, 57% (4/7 patients tested). Retardation was severe in the majority of the retarded patients. In patients diagnosed during gestation and treated prior to any episode of hyperammonemic encephalopathy, survival is 100%, but even in these patients, most subsequently demonstrate cognitive impairment or other neurologic deficits. In late-onset deficiency patients, including females heterozygous for ornithine transcarbamylase deficiency, who recover from hyperammonemic encephalopathy and are then treated chronically with sodium phenylbutyrate and dietary protein restriction, the survival rate is 98%. The two deaths in this group of patients occurred during episodes of hyperammonemic encephalopathy. However, compliance with the therapeutic regimen has not been adequately documented to allow evaluation of the potential for Sodium Phenylbutyrate Powder and dietary protein restriction to prevent mental deterioration and recurrence of hyperammonemic encephalopathy if carefully adhered to. The majority of these patients tested (30/46 or 65%) have IQ's in the average to low average/borderline mentally retarded range. Reversal of pre-existing neurologic impairment is not likely to occur with treatment and neurologic deterioration may continue in some patients. Even on therapy, acute hyperammonemic encephalopathy recurred in the majority of patients for whom the drug is indicated. Sodium Phenylbutyrate Powder may be required life-long unless orthotopic liver transplantation is elected. (See CLINICAL PHARMACOLOGY , Pharmacodynamics subsection for the biochemical effects of Sodium Phenylbutyrate Powder). uuid:6d1f4c7c-06ac-4a5a-85c6-b48a3dfd247e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:21659 biolink:treats MONDO:0005545 PMID:41385096 "[{""id"":""uuid:a7490a02-7214-40bc-b94f-61fbcca62096"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ad1ea7fc-bbb5-4fcc-b0f1-c21f53f11274"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Neomycin and Polymyxin B Sulfates, Bacitracin Zinc, and Hydrocortisone Ophthalmic Ointment is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye (see CLINICAL PHARMACOLOGY: Microbiology ). The particular anti-infective drugs in this product are active against the following common bacterial eye pathogens: Staphylococcus aureus , streptococci, including Streptococcus pneumoniae , Escherichia coli , Haemophilus influenzae , Klebsiella/Enterobacter species , Neisseria species , and Pseudomonas aeruginosa . The product does not provide adequate coverage against Serratia marcescens . uuid:31d3ca82-fc05-4315-8d0c-5fdfebca8881 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:21659 biolink:treats MONDO:0005114 PMID:41385096 "[{""id"":""uuid:487fb833-dcf4-4c3f-a7e0-2e119a2dde4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8fa5c3b2-34c3-4bbe-9392-a36eebbde573"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Neomycin and Polymyxin B Sulfates, Bacitracin Zinc, and Hydrocortisone Ophthalmic Ointment is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye (see CLINICAL PHARMACOLOGY: Microbiology ). The particular anti-infective drugs in this product are active against the following common bacterial eye pathogens: Staphylococcus aureus , streptococci, including Streptococcus pneumoniae , Escherichia coli , Haemophilus influenzae , Klebsiella/Enterobacter species , Neisseria species , and Pseudomonas aeruginosa . The product does not provide adequate coverage against Serratia marcescens . uuid:b6007cce-0020-4742-93bd-9559c5e5eb5f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:21659 biolink:treats MONDO:0020920 PMID:41385096 "[{""id"":""uuid:04a7af66-f432-424e-a5bc-4d3ceafac874"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d42a3442-9b94-42c8-9c1a-ec1cd03d496a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Neomycin and Polymyxin B Sulfates, Bacitracin Zinc, and Hydrocortisone Ophthalmic Ointment is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye (see CLINICAL PHARMACOLOGY: Microbiology ). The particular anti-infective drugs in this product are active against the following common bacterial eye pathogens: Staphylococcus aureus , streptococci, including Streptococcus pneumoniae , Escherichia coli , Haemophilus influenzae , Klebsiella/Enterobacter species , Neisseria species , and Pseudomonas aeruginosa . The product does not provide adequate coverage against Serratia marcescens . uuid:2043244f-04c9-493e-a7e1-d1ceb4deaed1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:21659 biolink:treats UMLS:C0348321 PMID:41385096 "[{""id"":""uuid:580ae19b-5a25-401f-b5df-b897890dd383"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:89db1316-6130-42b8-a1ee-da6929b83ea0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Neomycin and Polymyxin B Sulfates, Bacitracin Zinc, and Hydrocortisone Ophthalmic Ointment is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye (see CLINICAL PHARMACOLOGY: Microbiology ). The particular anti-infective drugs in this product are active against the following common bacterial eye pathogens: Staphylococcus aureus , streptococci, including Streptococcus pneumoniae , Escherichia coli , Haemophilus influenzae , Klebsiella/Enterobacter species , Neisseria species , and Pseudomonas aeruginosa . The product does not provide adequate coverage against Serratia marcescens . uuid:12cf8691-2dae-42a2-bc59-f10fe807e005 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:21659 biolink:treats UMLS:C0854135 PMID:41385096 "[{""id"":""uuid:5e2f71ea-7a0a-49ee-88cb-571d85d237e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:12c84bc4-4efe-4d96-a784-2cec5eb13d3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Neomycin and Polymyxin B Sulfates, Bacitracin Zinc, and Hydrocortisone Ophthalmic Ointment is indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial infection or a risk of bacterial infection exists. Ocular corticosteroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe where the inherent risk of corticosteroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation, or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye (see CLINICAL PHARMACOLOGY: Microbiology ). The particular anti-infective drugs in this product are active against the following common bacterial eye pathogens: Staphylococcus aureus , streptococci, including Streptococcus pneumoniae , Escherichia coli , Haemophilus influenzae , Klebsiella/Enterobacter species , Neisseria species , and Pseudomonas aeruginosa . The product does not provide adequate coverage against Serratia marcescens . uuid:e7cc0485-36bc-4755-8277-e8be3588e342 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63608 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:ba696089-d16e-4b6f-b072-f09eff7e7563"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6556c3b7-b175-4cfb-bf37-3be0d8d1a1ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Maraviroc tablets are indicated in combination with other antiretroviral agents for the treatment of only CCR5-tropic human immunodeficiency virus type 1 (HIV-1) infection in adult and pediatric patients 2 years of age and older weighing at least 10 kg. Limitations of Use: • Maraviroc tablets are not recommended in patients with dual/mixed- or CXCR4-tropic HIV-1 [ see Microbiology ( 12.4 ) ]. uuid:e982ca62-b83e-4141-b4d9-73f111111806 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:26710 biolink:treats HP:0200114 PMID:41385096 "[{""id"":""uuid:bfd99860-9e74-4559-9b3b-d4398a6eb2aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:26c24093-effd-4cc0-9b91-da28d6fe0d9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] These intravenous solutions are indicated for use in adults and pediatric patients as sources of electrolytes and water for hydration. 0.9% Sodium Chloride Injection USP is indicated for extracellular fluid replacement, treatment of metabolic alkalosis in the presence of fluid loss and mild sodium depletion. 0.9% Sodium Chloride Injection USP is also indicated for use as a priming solution in hemodialysis procedures and may be used to initiate and terminate blood transfusions without hemolyzing red blood cells. 0.45% Sodium Chloride Injection USP is primarily a hydrating solution and may be used to assess the status of the kidneys, since more water is provided than is required for excretion of salt. It may also be used in the treatment of hyperosmolar diabetes where the use of dextrose is inadvisable and there is a need for large amounts of fluid without an excess of sodium ions. Sodium Chloride Injections USP are also indicated as pharmaceutic aids and diluents for the infusion of compatible drug additives. Refer to prescribing information accompanying additive drugs. uuid:d0e7fc72-10a3-40de-9ba0-870586d133cf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:26710 biolink:treats UMLS:C0020457 PMID:41385096 "[{""id"":""uuid:5733099d-0388-4983-86a3-0c95702d1283"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6b76cd39-b659-407f-9569-11d7a85ef243"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] These intravenous solutions are indicated for use in adults and pediatric patients as sources of electrolytes and water for hydration. 0.9% Sodium Chloride Injection USP is indicated for extracellular fluid replacement, treatment of metabolic alkalosis in the presence of fluid loss and mild sodium depletion. 0.9% Sodium Chloride Injection USP is also indicated for use as a priming solution in hemodialysis procedures and may be used to initiate and terminate blood transfusions without hemolyzing red blood cells. 0.45% Sodium Chloride Injection USP is primarily a hydrating solution and may be used to assess the status of the kidneys, since more water is provided than is required for excretion of salt. It may also be used in the treatment of hyperosmolar diabetes where the use of dextrose is inadvisable and there is a need for large amounts of fluid without an excess of sodium ions. Sodium Chloride Injections USP are also indicated as pharmaceutic aids and diluents for the infusion of compatible drug additives. Refer to prescribing information accompanying additive drugs. uuid:51a38ff9-e900-4a52-bab7-a7642ac313dd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63451 biolink:treats MONDO:0019087 PMID:41385096 "[{""id"":""uuid:f19e59cc-1418-4fd0-8e32-ae9fb4320a8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fd337521-68ec-4036-8bc6-d6ade6abdb9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRUSELTIQ is indicated for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test [see Dosage and Administration ( 2.1 )] . This indication is approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies ( 14.1 )] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). uuid:4647a737-700a-4b2b-9c3a-564e027e6b89 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:194135 biolink:treats UMLS:C0853854 PMID:41385096 "[{""id"":""uuid:be92b58a-435f-49b8-92a0-86589e2a9cc2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6792c54c-8560-431c-bbc6-ae3129af6271"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of ofloxacin tablets, USP and other antibacterial drugs, ofloxacin tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ofloxacin tablets, USP are indicated for the treatment of adults with mild to moderate infections (unless otherwise indicated) caused by susceptible strains of the designated microorganisms in the infections listed below. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute Bacterial Exacerbations of Chronic Bronchitis (ABECB) due to Haemophilus influenzae or Streptococcus pneumoniae. Because fluoroquinolones, including ofloxacin, have been associated with serious adverse reactions (see Warnings ), -and for some patients ABECB is self-limiting, reserve ofloxacin for treatment of ABECB in patients who have no alternative treatment options. Community-Acquired Pneumonia due to Haemophilus influenzae or Streptococcus pneumoniae. Uncomplicated Skin and Skin Structure Infections due to methicillin-susceptible Staphylococcus aureus, Streptococcus pyogenes, or Proteus mirabilis. Acute, Uncomplicated Urethral and Cervical Gonorrhea due to Neisseria gonorrhoeae (see WARNINGS ). Nongonococcal Urethritis and Cervicitis due to Chlamydia trachomatis (see WARNINGS ). Mixed Infections of the Urethra and Cervix due to Chlamydia trachomatis and Neisseria gonorrhoeae (see WARNINGS ). Acute Pelvic Inflammatory Disease (including severe infection) due to Chlamydia trachomatis and/or Neisseria gonorrhoeae (see WARNINGS ). NOTE: If anaerobic microorganisms are suspected of contributing to the infection, appropriate therapy for anaerobic pathogens should be administered. Uncomplicated Cystitis due to Citrobacter diversus, Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa. Because fluoroquinolones, including ofloxacin, have been associated with serious adverse reactions (see WARNINGS ), and for some patients uncomplicated cystitis is self-limiting, reserve ofloxacin for treatment of uncomplicated cystitis in patients who have no alternative treatment options. Complicated Urinary Tract Infections due to Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Citrobacter diversus, Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients. or Pseudomonas aeruginosa. Prostatitis due to Escherichia coli. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to ofloxacin, USP. Therapy with ofloxacin, USP may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. As with other drugs in this class, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ofloxacin, USP. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. uuid:e9fad770-05b0-4776-a548-8c8cb3c3014e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:194135 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:f44261ef-6da9-429e-b23f-216105e28c97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:16e3a78d-e101-4658-a0b5-46a930425e96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of ofloxacin tablets, USP and other antibacterial drugs, ofloxacin tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ofloxacin tablets, USP are indicated for the treatment of adults with mild to moderate infections (unless otherwise indicated) caused by susceptible strains of the designated microorganisms in the infections listed below. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute Bacterial Exacerbations of Chronic Bronchitis (ABECB) due to Haemophilus influenzae or Streptococcus pneumoniae. Because fluoroquinolones, including ofloxacin, have been associated with serious adverse reactions (see Warnings ), -and for some patients ABECB is self-limiting, reserve ofloxacin for treatment of ABECB in patients who have no alternative treatment options. Community-Acquired Pneumonia due to Haemophilus influenzae or Streptococcus pneumoniae. Uncomplicated Skin and Skin Structure Infections due to methicillin-susceptible Staphylococcus aureus, Streptococcus pyogenes, or Proteus mirabilis. Acute, Uncomplicated Urethral and Cervical Gonorrhea due to Neisseria gonorrhoeae (see WARNINGS ). Nongonococcal Urethritis and Cervicitis due to Chlamydia trachomatis (see WARNINGS ). Mixed Infections of the Urethra and Cervix due to Chlamydia trachomatis and Neisseria gonorrhoeae (see WARNINGS ). Acute Pelvic Inflammatory Disease (including severe infection) due to Chlamydia trachomatis and/or Neisseria gonorrhoeae (see WARNINGS ). NOTE: If anaerobic microorganisms are suspected of contributing to the infection, appropriate therapy for anaerobic pathogens should be administered. Uncomplicated Cystitis due to Citrobacter diversus, Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa. Because fluoroquinolones, including ofloxacin, have been associated with serious adverse reactions (see WARNINGS ), and for some patients uncomplicated cystitis is self-limiting, reserve ofloxacin for treatment of uncomplicated cystitis in patients who have no alternative treatment options. Complicated Urinary Tract Infections due to Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Citrobacter diversus, Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients. or Pseudomonas aeruginosa. Prostatitis due to Escherichia coli. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to ofloxacin, USP. Therapy with ofloxacin, USP may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. As with other drugs in this class, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ofloxacin, USP. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. uuid:5a7b58f8-f492-4bfa-9231-9257c291f8ab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:194135 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:8d918400-f7c0-48ab-b39d-71bbc48cdf20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:14a49a6f-3b14-42a1-8d2a-852b4b207218"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of ofloxacin tablets, USP and other antibacterial drugs, ofloxacin tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ofloxacin tablets, USP are indicated for the treatment of adults with mild to moderate infections (unless otherwise indicated) caused by susceptible strains of the designated microorganisms in the infections listed below. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute Bacterial Exacerbations of Chronic Bronchitis (ABECB) due to Haemophilus influenzae or Streptococcus pneumoniae. Because fluoroquinolones, including ofloxacin, have been associated with serious adverse reactions (see Warnings ), -and for some patients ABECB is self-limiting, reserve ofloxacin for treatment of ABECB in patients who have no alternative treatment options. Community-Acquired Pneumonia due to Haemophilus influenzae or Streptococcus pneumoniae. Uncomplicated Skin and Skin Structure Infections due to methicillin-susceptible Staphylococcus aureus, Streptococcus pyogenes, or Proteus mirabilis. Acute, Uncomplicated Urethral and Cervical Gonorrhea due to Neisseria gonorrhoeae (see WARNINGS ). Nongonococcal Urethritis and Cervicitis due to Chlamydia trachomatis (see WARNINGS ). Mixed Infections of the Urethra and Cervix due to Chlamydia trachomatis and Neisseria gonorrhoeae (see WARNINGS ). Acute Pelvic Inflammatory Disease (including severe infection) due to Chlamydia trachomatis and/or Neisseria gonorrhoeae (see WARNINGS ). NOTE: If anaerobic microorganisms are suspected of contributing to the infection, appropriate therapy for anaerobic pathogens should be administered. Uncomplicated Cystitis due to Citrobacter diversus, Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa. Because fluoroquinolones, including ofloxacin, have been associated with serious adverse reactions (see WARNINGS ), and for some patients uncomplicated cystitis is self-limiting, reserve ofloxacin for treatment of uncomplicated cystitis in patients who have no alternative treatment options. Complicated Urinary Tract Infections due to Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Citrobacter diversus, Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients. or Pseudomonas aeruginosa. Prostatitis due to Escherichia coli. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to ofloxacin, USP. Therapy with ofloxacin, USP may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. As with other drugs in this class, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ofloxacin, USP. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. uuid:4fb8d7fd-6322-4c94-8965-39ccafae7bef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:194135 biolink:treats MONDO:0004277 PMID:41385096 "[{""id"":""uuid:26d8d37b-878d-4a02-b895-df2601572426"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bca382d6-feba-4131-a3b4-d34b9a68e392"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of ofloxacin tablets, USP and other antibacterial drugs, ofloxacin tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ofloxacin tablets, USP are indicated for the treatment of adults with mild to moderate infections (unless otherwise indicated) caused by susceptible strains of the designated microorganisms in the infections listed below. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute Bacterial Exacerbations of Chronic Bronchitis (ABECB) due to Haemophilus influenzae or Streptococcus pneumoniae. Because fluoroquinolones, including ofloxacin, have been associated with serious adverse reactions (see Warnings ), -and for some patients ABECB is self-limiting, reserve ofloxacin for treatment of ABECB in patients who have no alternative treatment options. Community-Acquired Pneumonia due to Haemophilus influenzae or Streptococcus pneumoniae. Uncomplicated Skin and Skin Structure Infections due to methicillin-susceptible Staphylococcus aureus, Streptococcus pyogenes, or Proteus mirabilis. Acute, Uncomplicated Urethral and Cervical Gonorrhea due to Neisseria gonorrhoeae (see WARNINGS ). Nongonococcal Urethritis and Cervicitis due to Chlamydia trachomatis (see WARNINGS ). Mixed Infections of the Urethra and Cervix due to Chlamydia trachomatis and Neisseria gonorrhoeae (see WARNINGS ). Acute Pelvic Inflammatory Disease (including severe infection) due to Chlamydia trachomatis and/or Neisseria gonorrhoeae (see WARNINGS ). NOTE: If anaerobic microorganisms are suspected of contributing to the infection, appropriate therapy for anaerobic pathogens should be administered. Uncomplicated Cystitis due to Citrobacter diversus, Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa. Because fluoroquinolones, including ofloxacin, have been associated with serious adverse reactions (see WARNINGS ), and for some patients uncomplicated cystitis is self-limiting, reserve ofloxacin for treatment of uncomplicated cystitis in patients who have no alternative treatment options. Complicated Urinary Tract Infections due to Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Citrobacter diversus, Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients. or Pseudomonas aeruginosa. Prostatitis due to Escherichia coli. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to ofloxacin, USP. Therapy with ofloxacin, USP may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. As with other drugs in this class, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ofloxacin, USP. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. uuid:0c3aa22b-5926-4ff6-a1cd-9273d5c2ec00 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:194135 biolink:treats MONDO:0005297 PMID:41385096 "[{""id"":""uuid:0c9befa0-43c5-4d67-8920-5ce3a4331802"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:36250578-30b6-42d0-853c-6ce93bf06285"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of ofloxacin tablets, USP and other antibacterial drugs, ofloxacin tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ofloxacin tablets, USP are indicated for the treatment of adults with mild to moderate infections (unless otherwise indicated) caused by susceptible strains of the designated microorganisms in the infections listed below. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute Bacterial Exacerbations of Chronic Bronchitis (ABECB) due to Haemophilus influenzae or Streptococcus pneumoniae. Because fluoroquinolones, including ofloxacin, have been associated with serious adverse reactions (see Warnings ), -and for some patients ABECB is self-limiting, reserve ofloxacin for treatment of ABECB in patients who have no alternative treatment options. Community-Acquired Pneumonia due to Haemophilus influenzae or Streptococcus pneumoniae. Uncomplicated Skin and Skin Structure Infections due to methicillin-susceptible Staphylococcus aureus, Streptococcus pyogenes, or Proteus mirabilis. Acute, Uncomplicated Urethral and Cervical Gonorrhea due to Neisseria gonorrhoeae (see WARNINGS ). Nongonococcal Urethritis and Cervicitis due to Chlamydia trachomatis (see WARNINGS ). Mixed Infections of the Urethra and Cervix due to Chlamydia trachomatis and Neisseria gonorrhoeae (see WARNINGS ). Acute Pelvic Inflammatory Disease (including severe infection) due to Chlamydia trachomatis and/or Neisseria gonorrhoeae (see WARNINGS ). NOTE: If anaerobic microorganisms are suspected of contributing to the infection, appropriate therapy for anaerobic pathogens should be administered. Uncomplicated Cystitis due to Citrobacter diversus, Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa. Because fluoroquinolones, including ofloxacin, have been associated with serious adverse reactions (see WARNINGS ), and for some patients uncomplicated cystitis is self-limiting, reserve ofloxacin for treatment of uncomplicated cystitis in patients who have no alternative treatment options. Complicated Urinary Tract Infections due to Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Citrobacter diversus, Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients. or Pseudomonas aeruginosa. Prostatitis due to Escherichia coli. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to ofloxacin, USP. Therapy with ofloxacin, USP may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. As with other drugs in this class, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ofloxacin, USP. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. uuid:224aeb85-d601-41cb-a1fa-ad05e72c2d9f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:194135 biolink:treats UMLS:C1960274 PMID:41385096 "[{""id"":""uuid:f1eae0e0-10be-466d-a893-6cb441cf36b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6b865214-88b5-4a8e-bb46-ab6f732f53f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of ofloxacin tablets, USP and other antibacterial drugs, ofloxacin tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ofloxacin tablets, USP are indicated for the treatment of adults with mild to moderate infections (unless otherwise indicated) caused by susceptible strains of the designated microorganisms in the infections listed below. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute Bacterial Exacerbations of Chronic Bronchitis (ABECB) due to Haemophilus influenzae or Streptococcus pneumoniae. Because fluoroquinolones, including ofloxacin, have been associated with serious adverse reactions (see Warnings ), -and for some patients ABECB is self-limiting, reserve ofloxacin for treatment of ABECB in patients who have no alternative treatment options. Community-Acquired Pneumonia due to Haemophilus influenzae or Streptococcus pneumoniae. Uncomplicated Skin and Skin Structure Infections due to methicillin-susceptible Staphylococcus aureus, Streptococcus pyogenes, or Proteus mirabilis. Acute, Uncomplicated Urethral and Cervical Gonorrhea due to Neisseria gonorrhoeae (see WARNINGS ). Nongonococcal Urethritis and Cervicitis due to Chlamydia trachomatis (see WARNINGS ). Mixed Infections of the Urethra and Cervix due to Chlamydia trachomatis and Neisseria gonorrhoeae (see WARNINGS ). Acute Pelvic Inflammatory Disease (including severe infection) due to Chlamydia trachomatis and/or Neisseria gonorrhoeae (see WARNINGS ). NOTE: If anaerobic microorganisms are suspected of contributing to the infection, appropriate therapy for anaerobic pathogens should be administered. Uncomplicated Cystitis due to Citrobacter diversus, Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa. Because fluoroquinolones, including ofloxacin, have been associated with serious adverse reactions (see WARNINGS ), and for some patients uncomplicated cystitis is self-limiting, reserve ofloxacin for treatment of uncomplicated cystitis in patients who have no alternative treatment options. Complicated Urinary Tract Infections due to Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Citrobacter diversus, Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients. or Pseudomonas aeruginosa. Prostatitis due to Escherichia coli. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to ofloxacin, USP. Therapy with ofloxacin, USP may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. As with other drugs in this class, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ofloxacin, USP. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. uuid:065a5a83-300d-4abe-888b-c93f412dc94e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:194135 biolink:treats MONDO:0100128 PMID:41385096 "[{""id"":""uuid:3e802eff-dd7c-4b09-92d5-a9989fc97caa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1bbb0c50-49e0-475b-8972-95fd98243320"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of ofloxacin tablets, USP and other antibacterial drugs, ofloxacin tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ofloxacin tablets, USP are indicated for the treatment of adults with mild to moderate infections (unless otherwise indicated) caused by susceptible strains of the designated microorganisms in the infections listed below. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute Bacterial Exacerbations of Chronic Bronchitis (ABECB) due to Haemophilus influenzae or Streptococcus pneumoniae. Because fluoroquinolones, including ofloxacin, have been associated with serious adverse reactions (see Warnings ), -and for some patients ABECB is self-limiting, reserve ofloxacin for treatment of ABECB in patients who have no alternative treatment options. Community-Acquired Pneumonia due to Haemophilus influenzae or Streptococcus pneumoniae. Uncomplicated Skin and Skin Structure Infections due to methicillin-susceptible Staphylococcus aureus, Streptococcus pyogenes, or Proteus mirabilis. Acute, Uncomplicated Urethral and Cervical Gonorrhea due to Neisseria gonorrhoeae (see WARNINGS ). Nongonococcal Urethritis and Cervicitis due to Chlamydia trachomatis (see WARNINGS ). Mixed Infections of the Urethra and Cervix due to Chlamydia trachomatis and Neisseria gonorrhoeae (see WARNINGS ). Acute Pelvic Inflammatory Disease (including severe infection) due to Chlamydia trachomatis and/or Neisseria gonorrhoeae (see WARNINGS ). NOTE: If anaerobic microorganisms are suspected of contributing to the infection, appropriate therapy for anaerobic pathogens should be administered. Uncomplicated Cystitis due to Citrobacter diversus, Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa. Because fluoroquinolones, including ofloxacin, have been associated with serious adverse reactions (see WARNINGS ), and for some patients uncomplicated cystitis is self-limiting, reserve ofloxacin for treatment of uncomplicated cystitis in patients who have no alternative treatment options. Complicated Urinary Tract Infections due to Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Citrobacter diversus, Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients. or Pseudomonas aeruginosa. Prostatitis due to Escherichia coli. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to ofloxacin, USP. Therapy with ofloxacin, USP may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. As with other drugs in this class, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ofloxacin, USP. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. uuid:f0d9c0d0-1f88-411f-8697-5cd98222630d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:194135 biolink:treats UMLS:C0149959 PMID:41385096 "[{""id"":""uuid:dc873ed4-1226-416e-a7f5-c468036c2886"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0811c910-c02d-427f-87a8-193ca3cc2a29"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of ofloxacin tablets, USP and other antibacterial drugs, ofloxacin tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ofloxacin tablets, USP are indicated for the treatment of adults with mild to moderate infections (unless otherwise indicated) caused by susceptible strains of the designated microorganisms in the infections listed below. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute Bacterial Exacerbations of Chronic Bronchitis (ABECB) due to Haemophilus influenzae or Streptococcus pneumoniae. Because fluoroquinolones, including ofloxacin, have been associated with serious adverse reactions (see Warnings ), -and for some patients ABECB is self-limiting, reserve ofloxacin for treatment of ABECB in patients who have no alternative treatment options. Community-Acquired Pneumonia due to Haemophilus influenzae or Streptococcus pneumoniae. Uncomplicated Skin and Skin Structure Infections due to methicillin-susceptible Staphylococcus aureus, Streptococcus pyogenes, or Proteus mirabilis. Acute, Uncomplicated Urethral and Cervical Gonorrhea due to Neisseria gonorrhoeae (see WARNINGS ). Nongonococcal Urethritis and Cervicitis due to Chlamydia trachomatis (see WARNINGS ). Mixed Infections of the Urethra and Cervix due to Chlamydia trachomatis and Neisseria gonorrhoeae (see WARNINGS ). Acute Pelvic Inflammatory Disease (including severe infection) due to Chlamydia trachomatis and/or Neisseria gonorrhoeae (see WARNINGS ). NOTE: If anaerobic microorganisms are suspected of contributing to the infection, appropriate therapy for anaerobic pathogens should be administered. Uncomplicated Cystitis due to Citrobacter diversus, Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa. Because fluoroquinolones, including ofloxacin, have been associated with serious adverse reactions (see WARNINGS ), and for some patients uncomplicated cystitis is self-limiting, reserve ofloxacin for treatment of uncomplicated cystitis in patients who have no alternative treatment options. Complicated Urinary Tract Infections due to Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Citrobacter diversus, Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients. or Pseudomonas aeruginosa. Prostatitis due to Escherichia coli. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to ofloxacin, USP. Therapy with ofloxacin, USP may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. As with other drugs in this class, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ofloxacin, USP. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. uuid:ba443ac1-eea2-4046-9225-070f1ccdb8ad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:194135 biolink:treats UMLS:C5769488 PMID:41385096 "[{""id"":""uuid:5c940bec-7edc-4059-b4e6-9f0e72f338f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f4a8fa21-7f5a-416c-9e1c-965b40b1540e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of ofloxacin tablets, USP and other antibacterial drugs, ofloxacin tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ofloxacin tablets, USP are indicated for the treatment of adults with mild to moderate infections (unless otherwise indicated) caused by susceptible strains of the designated microorganisms in the infections listed below. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute Bacterial Exacerbations of Chronic Bronchitis (ABECB) due to Haemophilus influenzae or Streptococcus pneumoniae. Because fluoroquinolones, including ofloxacin, have been associated with serious adverse reactions (see Warnings ), -and for some patients ABECB is self-limiting, reserve ofloxacin for treatment of ABECB in patients who have no alternative treatment options. Community-Acquired Pneumonia due to Haemophilus influenzae or Streptococcus pneumoniae. Uncomplicated Skin and Skin Structure Infections due to methicillin-susceptible Staphylococcus aureus, Streptococcus pyogenes, or Proteus mirabilis. Acute, Uncomplicated Urethral and Cervical Gonorrhea due to Neisseria gonorrhoeae (see WARNINGS ). Nongonococcal Urethritis and Cervicitis due to Chlamydia trachomatis (see WARNINGS ). Mixed Infections of the Urethra and Cervix due to Chlamydia trachomatis and Neisseria gonorrhoeae (see WARNINGS ). Acute Pelvic Inflammatory Disease (including severe infection) due to Chlamydia trachomatis and/or Neisseria gonorrhoeae (see WARNINGS ). NOTE: If anaerobic microorganisms are suspected of contributing to the infection, appropriate therapy for anaerobic pathogens should be administered. Uncomplicated Cystitis due to Citrobacter diversus, Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa. Because fluoroquinolones, including ofloxacin, have been associated with serious adverse reactions (see WARNINGS ), and for some patients uncomplicated cystitis is self-limiting, reserve ofloxacin for treatment of uncomplicated cystitis in patients who have no alternative treatment options. Complicated Urinary Tract Infections due to Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Citrobacter diversus, Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients. or Pseudomonas aeruginosa. Prostatitis due to Escherichia coli. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to ofloxacin, USP. Therapy with ofloxacin, USP may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. As with other drugs in this class, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ofloxacin, USP. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. uuid:78565268-8378-445e-8d78-6946efae2ea1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:194135 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:dbf3f55e-3b43-4348-8c51-0701aa1be86e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2e38b63a-2c56-4dea-b88c-4c0f434953b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of ofloxacin tablets, USP and other antibacterial drugs, ofloxacin tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ofloxacin tablets, USP are indicated for the treatment of adults with mild to moderate infections (unless otherwise indicated) caused by susceptible strains of the designated microorganisms in the infections listed below. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute Bacterial Exacerbations of Chronic Bronchitis (ABECB) due to Haemophilus influenzae or Streptococcus pneumoniae. Because fluoroquinolones, including ofloxacin, have been associated with serious adverse reactions (see Warnings ), -and for some patients ABECB is self-limiting, reserve ofloxacin for treatment of ABECB in patients who have no alternative treatment options. Community-Acquired Pneumonia due to Haemophilus influenzae or Streptococcus pneumoniae. Uncomplicated Skin and Skin Structure Infections due to methicillin-susceptible Staphylococcus aureus, Streptococcus pyogenes, or Proteus mirabilis. Acute, Uncomplicated Urethral and Cervical Gonorrhea due to Neisseria gonorrhoeae (see WARNINGS ). Nongonococcal Urethritis and Cervicitis due to Chlamydia trachomatis (see WARNINGS ). Mixed Infections of the Urethra and Cervix due to Chlamydia trachomatis and Neisseria gonorrhoeae (see WARNINGS ). Acute Pelvic Inflammatory Disease (including severe infection) due to Chlamydia trachomatis and/or Neisseria gonorrhoeae (see WARNINGS ). NOTE: If anaerobic microorganisms are suspected of contributing to the infection, appropriate therapy for anaerobic pathogens should be administered. Uncomplicated Cystitis due to Citrobacter diversus, Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa. Because fluoroquinolones, including ofloxacin, have been associated with serious adverse reactions (see WARNINGS ), and for some patients uncomplicated cystitis is self-limiting, reserve ofloxacin for treatment of uncomplicated cystitis in patients who have no alternative treatment options. Complicated Urinary Tract Infections due to Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Citrobacter diversus, Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients. or Pseudomonas aeruginosa. Prostatitis due to Escherichia coli. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to ofloxacin, USP. Therapy with ofloxacin, USP may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. As with other drugs in this class, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ofloxacin, USP. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. uuid:7fc278fe-d2e0-4d37-b9d5-1bc595c7968b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:194135 biolink:treats MONDO:0005280 PMID:41385096 "[{""id"":""uuid:c04ece47-2b3a-459b-93c5-7f1464a87988"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:843b6d77-7209-4be8-8d71-7156be8a0a3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of ofloxacin tablets, USP and other antibacterial drugs, ofloxacin tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ofloxacin tablets, USP are indicated for the treatment of adults with mild to moderate infections (unless otherwise indicated) caused by susceptible strains of the designated microorganisms in the infections listed below. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute Bacterial Exacerbations of Chronic Bronchitis (ABECB) due to Haemophilus influenzae or Streptococcus pneumoniae. Because fluoroquinolones, including ofloxacin, have been associated with serious adverse reactions (see Warnings ), -and for some patients ABECB is self-limiting, reserve ofloxacin for treatment of ABECB in patients who have no alternative treatment options. Community-Acquired Pneumonia due to Haemophilus influenzae or Streptococcus pneumoniae. Uncomplicated Skin and Skin Structure Infections due to methicillin-susceptible Staphylococcus aureus, Streptococcus pyogenes, or Proteus mirabilis. Acute, Uncomplicated Urethral and Cervical Gonorrhea due to Neisseria gonorrhoeae (see WARNINGS ). Nongonococcal Urethritis and Cervicitis due to Chlamydia trachomatis (see WARNINGS ). Mixed Infections of the Urethra and Cervix due to Chlamydia trachomatis and Neisseria gonorrhoeae (see WARNINGS ). Acute Pelvic Inflammatory Disease (including severe infection) due to Chlamydia trachomatis and/or Neisseria gonorrhoeae (see WARNINGS ). NOTE: If anaerobic microorganisms are suspected of contributing to the infection, appropriate therapy for anaerobic pathogens should be administered. Uncomplicated Cystitis due to Citrobacter diversus, Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa. Because fluoroquinolones, including ofloxacin, have been associated with serious adverse reactions (see WARNINGS ), and for some patients uncomplicated cystitis is self-limiting, reserve ofloxacin for treatment of uncomplicated cystitis in patients who have no alternative treatment options. Complicated Urinary Tract Infections due to Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Citrobacter diversus, Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients. or Pseudomonas aeruginosa. Prostatitis due to Escherichia coli. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to ofloxacin, USP. Therapy with ofloxacin, USP may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. As with other drugs in this class, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ofloxacin, USP. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. uuid:72bd2f55-82b1-45e4-baa9-739f1346431b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:131169 biolink:treats MONDO:0003864 PMID:41385096 "[{""id"":""uuid:b0866f7a-0878-4bf1-b45c-2ed3971abf56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:664db02f-7a7e-4c8d-9fcc-d8e869ccd8c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] COPIKTRA is a kinase inhibitor indicated for the treatment of adult patients with: Relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies. ( 1.1 ). Relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. ( 1.2 ). This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. uuid:22a1a327-be0a-4ec5-bc5c-cb6ed3884f0f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:131169 biolink:treats MONDO:0018906 PMID:41385096 "[{""id"":""uuid:73a5f4ee-92c7-4be2-9e67-93b9c46cfeab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:df74344c-0263-4fd8-b8fe-312fc23d3d15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e4e0c90c-2329-4e6e-9265-e244a3ed8060"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/copiktra""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] COPIKTRA is a kinase inhibitor indicated for the treatment of adult patients with: Relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior therapies. ( 1.1 ). Relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. ( 1.2 ). This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.|[EMA] Copiktra monotherapy is indicated for the treatment of adult patients with: Relapsed or refractory chronic lymphocytic leukaemia (CLL) after at least two prior therapies. Follicular lymphoma (FL) that is refractory to at least two prior systemic therapies. uuid:c971b364-c889-49d8-987d-0f1a22f74428 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5280 biolink:treats MONDO:0005545 PMID:41385096 "[{""id"":""uuid:9d7fa464-12ea-4f65-b080-ed3b73ec2879"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:34a0b20c-aec7-4960-bb32-c2ca847369af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gatifloxacin ophthalmic solution 0.5% is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: • Aerobic gram-positive bacteria Staphylococcus aureus Staphylococcus epidermidis Streptococcus mitis group * Streptococcus oralis * Streptococcus pneumoniae • Aerobic gram-negative bacteria Haemophilus influenzae * Efficacy for these organisms were studied in fewer than 10 infections. uuid:9ef57559-a620-405a-b820-129228c17ee4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5280 biolink:treats UMLS:C3840159 PMID:41385096 "[{""id"":""uuid:4e5fc3fe-0b71-4b82-b75f-3ab33daf958c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c2cddf3c-7e7d-42bc-bcc8-2568245a4e6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gatifloxacin ophthalmic solution 0.5% is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: • Aerobic gram-positive bacteria Staphylococcus aureus Staphylococcus epidermidis Streptococcus mitis group * Streptococcus oralis * Streptococcus pneumoniae • Aerobic gram-negative bacteria Haemophilus influenzae * Efficacy for these organisms were studied in fewer than 10 infections. uuid:86dd9b49-371e-4ca8-9868-9bd030096559 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5280 biolink:treats MONDO:0005114 PMID:41385096 "[{""id"":""uuid:36cb60e3-8a43-40aa-abed-74e8ac00d79c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:49f01bc2-6faf-4027-8f36-e0b23487920d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gatifloxacin ophthalmic solution 0.5% is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: • Aerobic gram-positive bacteria Staphylococcus aureus Staphylococcus epidermidis Streptococcus mitis group * Streptococcus oralis * Streptococcus pneumoniae • Aerobic gram-negative bacteria Haemophilus influenzae * Efficacy for these organisms were studied in fewer than 10 infections. uuid:13aa612d-6c02-4ed3-81a0-8e246f9ed20a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27436 biolink:treats MONDO:0009420 PMID:41385096 "[{""id"":""uuid:1c8d6886-26e4-47c8-b323-83e63d756d00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bc02003e-3f9e-4f2c-af60-8dcd1fa8c4ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Males Androgens are indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) — testicular failure due to cryptorchidism, bilateral torsions, orchitis, vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired) — gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary hypothalamic injury from tumors, trauma, or radiation. (Appropriate adrenal cortical and thyroid hormone replacement therapy are still necessary, however, and are actually of primary importance.) If the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sexual characteristics. Prolonged androgen treatment will be required to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty. Safety and efficacy of methyltestosterone in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established. Androgens may be used to stimulate puberty in carefully selected males with clearly delayed puberty. These patients usually have a familial pattern of delayed puberty that is not secondary to a pathological disorder; puberty is expected to occur spontaneously at a relatively late date. Brief treatment with conservative doses may occasionally be justified in these patients if they do not respond to psychological support. The potential adverse effect on bone maturation should be discussed with the patient and parents prior to androgen administration. An X-ray of the hand and wrist to determine bone age should be obtained every 6 months to assess the effect of treatment on the epiphyseal centers (see WARNINGS ). 2. Females Androgens may be used secondarily in women with advancing inoperable metastatic (skeletal) mammary cancer who are 1 to 5 years postmenopausal. Primary goals of therapy in these women include ablation of the ovaries. Other methods of counteracting estrogen activity are adrenalectomy, hypophysectomy, and/or antiestrogen therapy. This treatment has also been used in premenopausal women with breast cancer who have benefitted from oophorectomy and are considered to have a hormone-responsive tumor. Judgment concerning androgen therapy should be made by an oncologist with expertise in this field. uuid:acadc670-d74e-4783-b109-2792db3c4cd1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27436 biolink:treats MONDO:0023554 PMID:41385096 "[{""id"":""uuid:6230372f-59bc-486d-a220-916ac31e9498"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:906ca45b-7d70-43c9-8d43-e2da09d71536"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Males Androgens are indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) — testicular failure due to cryptorchidism, bilateral torsions, orchitis, vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired) — gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary hypothalamic injury from tumors, trauma, or radiation. (Appropriate adrenal cortical and thyroid hormone replacement therapy are still necessary, however, and are actually of primary importance.) If the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sexual characteristics. Prolonged androgen treatment will be required to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty. Safety and efficacy of methyltestosterone in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established. Androgens may be used to stimulate puberty in carefully selected males with clearly delayed puberty. These patients usually have a familial pattern of delayed puberty that is not secondary to a pathological disorder; puberty is expected to occur spontaneously at a relatively late date. Brief treatment with conservative doses may occasionally be justified in these patients if they do not respond to psychological support. The potential adverse effect on bone maturation should be discussed with the patient and parents prior to androgen administration. An X-ray of the hand and wrist to determine bone age should be obtained every 6 months to assess the effect of treatment on the epiphyseal centers (see WARNINGS ). 2. Females Androgens may be used secondarily in women with advancing inoperable metastatic (skeletal) mammary cancer who are 1 to 5 years postmenopausal. Primary goals of therapy in these women include ablation of the ovaries. Other methods of counteracting estrogen activity are adrenalectomy, hypophysectomy, and/or antiestrogen therapy. This treatment has also been used in premenopausal women with breast cancer who have benefitted from oophorectomy and are considered to have a hormone-responsive tumor. Judgment concerning androgen therapy should be made by an oncologist with expertise in this field. uuid:c66c4020-8371-4d02-8fe1-ead66b2745ca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27436 biolink:treats MONDO:0009047 PMID:41385096 "[{""id"":""uuid:291bd255-63b5-4257-b726-70b76503c2c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:43b6d94f-ee8b-4c76-bf7a-99cee45375a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Males Androgens are indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) — testicular failure due to cryptorchidism, bilateral torsions, orchitis, vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired) — gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary hypothalamic injury from tumors, trauma, or radiation. (Appropriate adrenal cortical and thyroid hormone replacement therapy are still necessary, however, and are actually of primary importance.) If the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sexual characteristics. Prolonged androgen treatment will be required to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty. Safety and efficacy of methyltestosterone in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established. Androgens may be used to stimulate puberty in carefully selected males with clearly delayed puberty. These patients usually have a familial pattern of delayed puberty that is not secondary to a pathological disorder; puberty is expected to occur spontaneously at a relatively late date. Brief treatment with conservative doses may occasionally be justified in these patients if they do not respond to psychological support. The potential adverse effect on bone maturation should be discussed with the patient and parents prior to androgen administration. An X-ray of the hand and wrist to determine bone age should be obtained every 6 months to assess the effect of treatment on the epiphyseal centers (see WARNINGS ). 2. Females Androgens may be used secondarily in women with advancing inoperable metastatic (skeletal) mammary cancer who are 1 to 5 years postmenopausal. Primary goals of therapy in these women include ablation of the ovaries. Other methods of counteracting estrogen activity are adrenalectomy, hypophysectomy, and/or antiestrogen therapy. This treatment has also been used in premenopausal women with breast cancer who have benefitted from oophorectomy and are considered to have a hormone-responsive tumor. Judgment concerning androgen therapy should be made by an oncologist with expertise in this field. uuid:1090da4d-209e-43df-bd9e-b4d45d2af03f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27436 biolink:treats MONDO:0006882 PMID:41385096 "[{""id"":""uuid:c92de608-5770-4804-b257-ceb96db8a5d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:af6f3036-98f7-4d93-ba4c-61923a6a646a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Males Androgens are indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) — testicular failure due to cryptorchidism, bilateral torsions, orchitis, vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired) — gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary hypothalamic injury from tumors, trauma, or radiation. (Appropriate adrenal cortical and thyroid hormone replacement therapy are still necessary, however, and are actually of primary importance.) If the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sexual characteristics. Prolonged androgen treatment will be required to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty. Safety and efficacy of methyltestosterone in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established. Androgens may be used to stimulate puberty in carefully selected males with clearly delayed puberty. These patients usually have a familial pattern of delayed puberty that is not secondary to a pathological disorder; puberty is expected to occur spontaneously at a relatively late date. Brief treatment with conservative doses may occasionally be justified in these patients if they do not respond to psychological support. The potential adverse effect on bone maturation should be discussed with the patient and parents prior to androgen administration. An X-ray of the hand and wrist to determine bone age should be obtained every 6 months to assess the effect of treatment on the epiphyseal centers (see WARNINGS ). 2. Females Androgens may be used secondarily in women with advancing inoperable metastatic (skeletal) mammary cancer who are 1 to 5 years postmenopausal. Primary goals of therapy in these women include ablation of the ovaries. Other methods of counteracting estrogen activity are adrenalectomy, hypophysectomy, and/or antiestrogen therapy. This treatment has also been used in premenopausal women with breast cancer who have benefitted from oophorectomy and are considered to have a hormone-responsive tumor. Judgment concerning androgen therapy should be made by an oncologist with expertise in this field. uuid:e5b12ef0-eeae-41da-b5ae-a55e00387b84 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27436 biolink:treats MONDO:8000015 PMID:41385096 "[{""id"":""uuid:97981602-5a60-42b5-9817-d32f7ff9eae5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aae8220e-ad94-487b-9e7f-4f6905c6714a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Males Androgens are indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) — testicular failure due to cryptorchidism, bilateral torsions, orchitis, vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired) — gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary hypothalamic injury from tumors, trauma, or radiation. (Appropriate adrenal cortical and thyroid hormone replacement therapy are still necessary, however, and are actually of primary importance.) If the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sexual characteristics. Prolonged androgen treatment will be required to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty. Safety and efficacy of methyltestosterone in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established. Androgens may be used to stimulate puberty in carefully selected males with clearly delayed puberty. These patients usually have a familial pattern of delayed puberty that is not secondary to a pathological disorder; puberty is expected to occur spontaneously at a relatively late date. Brief treatment with conservative doses may occasionally be justified in these patients if they do not respond to psychological support. The potential adverse effect on bone maturation should be discussed with the patient and parents prior to androgen administration. An X-ray of the hand and wrist to determine bone age should be obtained every 6 months to assess the effect of treatment on the epiphyseal centers (see WARNINGS ). 2. Females Androgens may be used secondarily in women with advancing inoperable metastatic (skeletal) mammary cancer who are 1 to 5 years postmenopausal. Primary goals of therapy in these women include ablation of the ovaries. Other methods of counteracting estrogen activity are adrenalectomy, hypophysectomy, and/or antiestrogen therapy. This treatment has also been used in premenopausal women with breast cancer who have benefitted from oophorectomy and are considered to have a hormone-responsive tumor. Judgment concerning androgen therapy should be made by an oncologist with expertise in this field. uuid:3be34590-770a-44ce-9f73-9ee43004f0fc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27436 biolink:treats MONDO:0018555 PMID:41385096 "[{""id"":""uuid:b5495454-4770-4a95-9661-8974f0f7e137"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:80e0b03c-1156-4d17-b033-58ef92692b10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Males Androgens are indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) — testicular failure due to cryptorchidism, bilateral torsions, orchitis, vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired) — gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary hypothalamic injury from tumors, trauma, or radiation. (Appropriate adrenal cortical and thyroid hormone replacement therapy are still necessary, however, and are actually of primary importance.) If the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sexual characteristics. Prolonged androgen treatment will be required to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty. Safety and efficacy of methyltestosterone in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established. Androgens may be used to stimulate puberty in carefully selected males with clearly delayed puberty. These patients usually have a familial pattern of delayed puberty that is not secondary to a pathological disorder; puberty is expected to occur spontaneously at a relatively late date. Brief treatment with conservative doses may occasionally be justified in these patients if they do not respond to psychological support. The potential adverse effect on bone maturation should be discussed with the patient and parents prior to androgen administration. An X-ray of the hand and wrist to determine bone age should be obtained every 6 months to assess the effect of treatment on the epiphyseal centers (see WARNINGS ). 2. Females Androgens may be used secondarily in women with advancing inoperable metastatic (skeletal) mammary cancer who are 1 to 5 years postmenopausal. Primary goals of therapy in these women include ablation of the ovaries. Other methods of counteracting estrogen activity are adrenalectomy, hypophysectomy, and/or antiestrogen therapy. This treatment has also been used in premenopausal women with breast cancer who have benefitted from oophorectomy and are considered to have a hormone-responsive tumor. Judgment concerning androgen therapy should be made by an oncologist with expertise in this field. uuid:883d652e-86c9-4ad9-a198-6543c5bdccfa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27436 biolink:treats HP:0008213 PMID:41385096 "[{""id"":""uuid:b3117d6b-ea00-46c2-b06d-761531d85a35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f1ce81fc-c113-481a-a064-4945a626647a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Males Androgens are indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) — testicular failure due to cryptorchidism, bilateral torsions, orchitis, vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired) — gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary hypothalamic injury from tumors, trauma, or radiation. (Appropriate adrenal cortical and thyroid hormone replacement therapy are still necessary, however, and are actually of primary importance.) If the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sexual characteristics. Prolonged androgen treatment will be required to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty. Safety and efficacy of methyltestosterone in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established. Androgens may be used to stimulate puberty in carefully selected males with clearly delayed puberty. These patients usually have a familial pattern of delayed puberty that is not secondary to a pathological disorder; puberty is expected to occur spontaneously at a relatively late date. Brief treatment with conservative doses may occasionally be justified in these patients if they do not respond to psychological support. The potential adverse effect on bone maturation should be discussed with the patient and parents prior to androgen administration. An X-ray of the hand and wrist to determine bone age should be obtained every 6 months to assess the effect of treatment on the epiphyseal centers (see WARNINGS ). 2. Females Androgens may be used secondarily in women with advancing inoperable metastatic (skeletal) mammary cancer who are 1 to 5 years postmenopausal. Primary goals of therapy in these women include ablation of the ovaries. Other methods of counteracting estrogen activity are adrenalectomy, hypophysectomy, and/or antiestrogen therapy. This treatment has also been used in premenopausal women with breast cancer who have benefitted from oophorectomy and are considered to have a hormone-responsive tumor. Judgment concerning androgen therapy should be made by an oncologist with expertise in this field. uuid:833f23a1-a60b-4265-a430-7d25d24fe849 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27436 biolink:treats UMLS:C3714660 PMID:41385096 "[{""id"":""uuid:c1897bce-4a16-4cae-a9f8-49d1c7544c0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:97b2b2f1-0a95-4944-bed2-d8ed5f5debf9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Males Androgens are indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) — testicular failure due to cryptorchidism, bilateral torsions, orchitis, vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired) — gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary hypothalamic injury from tumors, trauma, or radiation. (Appropriate adrenal cortical and thyroid hormone replacement therapy are still necessary, however, and are actually of primary importance.) If the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sexual characteristics. Prolonged androgen treatment will be required to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty. Safety and efficacy of methyltestosterone in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established. Androgens may be used to stimulate puberty in carefully selected males with clearly delayed puberty. These patients usually have a familial pattern of delayed puberty that is not secondary to a pathological disorder; puberty is expected to occur spontaneously at a relatively late date. Brief treatment with conservative doses may occasionally be justified in these patients if they do not respond to psychological support. The potential adverse effect on bone maturation should be discussed with the patient and parents prior to androgen administration. An X-ray of the hand and wrist to determine bone age should be obtained every 6 months to assess the effect of treatment on the epiphyseal centers (see WARNINGS ). 2. Females Androgens may be used secondarily in women with advancing inoperable metastatic (skeletal) mammary cancer who are 1 to 5 years postmenopausal. Primary goals of therapy in these women include ablation of the ovaries. Other methods of counteracting estrogen activity are adrenalectomy, hypophysectomy, and/or antiestrogen therapy. This treatment has also been used in premenopausal women with breast cancer who have benefitted from oophorectomy and are considered to have a hormone-responsive tumor. Judgment concerning androgen therapy should be made by an oncologist with expertise in this field. uuid:5c59aef8-515e-4304-85ce-2f9abd76eee7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27436 biolink:treats MONDO:0043459 PMID:41385096 "[{""id"":""uuid:6913fdf5-e3c0-4ae0-8fb0-d9448e74d75b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d86fbd1d-d025-4a56-89bd-9ac90fbd4204"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Males Androgens are indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) — testicular failure due to cryptorchidism, bilateral torsions, orchitis, vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired) — gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary hypothalamic injury from tumors, trauma, or radiation. (Appropriate adrenal cortical and thyroid hormone replacement therapy are still necessary, however, and are actually of primary importance.) If the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sexual characteristics. Prolonged androgen treatment will be required to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty. Safety and efficacy of methyltestosterone in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established. Androgens may be used to stimulate puberty in carefully selected males with clearly delayed puberty. These patients usually have a familial pattern of delayed puberty that is not secondary to a pathological disorder; puberty is expected to occur spontaneously at a relatively late date. Brief treatment with conservative doses may occasionally be justified in these patients if they do not respond to psychological support. The potential adverse effect on bone maturation should be discussed with the patient and parents prior to androgen administration. An X-ray of the hand and wrist to determine bone age should be obtained every 6 months to assess the effect of treatment on the epiphyseal centers (see WARNINGS ). 2. Females Androgens may be used secondarily in women with advancing inoperable metastatic (skeletal) mammary cancer who are 1 to 5 years postmenopausal. Primary goals of therapy in these women include ablation of the ovaries. Other methods of counteracting estrogen activity are adrenalectomy, hypophysectomy, and/or antiestrogen therapy. This treatment has also been used in premenopausal women with breast cancer who have benefitted from oophorectomy and are considered to have a hormone-responsive tumor. Judgment concerning androgen therapy should be made by an oncologist with expertise in this field. uuid:e93941db-b68c-4166-b7ec-3c87f5c4690a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27436 biolink:treats HP:0000823 PMID:41385096 "[{""id"":""uuid:9710d4ea-8e5c-4303-8c58-dd8b48b69af9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1e7a0d29-de8e-4e8e-a783-892e333eec4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Males Androgens are indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) — testicular failure due to cryptorchidism, bilateral torsions, orchitis, vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired) — gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary hypothalamic injury from tumors, trauma, or radiation. (Appropriate adrenal cortical and thyroid hormone replacement therapy are still necessary, however, and are actually of primary importance.) If the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sexual characteristics. Prolonged androgen treatment will be required to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty. Safety and efficacy of methyltestosterone in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established. Androgens may be used to stimulate puberty in carefully selected males with clearly delayed puberty. These patients usually have a familial pattern of delayed puberty that is not secondary to a pathological disorder; puberty is expected to occur spontaneously at a relatively late date. Brief treatment with conservative doses may occasionally be justified in these patients if they do not respond to psychological support. The potential adverse effect on bone maturation should be discussed with the patient and parents prior to androgen administration. An X-ray of the hand and wrist to determine bone age should be obtained every 6 months to assess the effect of treatment on the epiphyseal centers (see WARNINGS ). 2. Females Androgens may be used secondarily in women with advancing inoperable metastatic (skeletal) mammary cancer who are 1 to 5 years postmenopausal. Primary goals of therapy in these women include ablation of the ovaries. Other methods of counteracting estrogen activity are adrenalectomy, hypophysectomy, and/or antiestrogen therapy. This treatment has also been used in premenopausal women with breast cancer who have benefitted from oophorectomy and are considered to have a hormone-responsive tumor. Judgment concerning androgen therapy should be made by an oncologist with expertise in this field. uuid:86333031-80c2-437c-8492-fae1467531af biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27436 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:9114c64d-092d-4c47-af3b-79b16609b4ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8cacae2b-7cc4-40a6-b9da-8daf24f97b5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Males Androgens are indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) — testicular failure due to cryptorchidism, bilateral torsions, orchitis, vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired) — gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary hypothalamic injury from tumors, trauma, or radiation. (Appropriate adrenal cortical and thyroid hormone replacement therapy are still necessary, however, and are actually of primary importance.) If the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sexual characteristics. Prolonged androgen treatment will be required to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty. Safety and efficacy of methyltestosterone in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established. Androgens may be used to stimulate puberty in carefully selected males with clearly delayed puberty. These patients usually have a familial pattern of delayed puberty that is not secondary to a pathological disorder; puberty is expected to occur spontaneously at a relatively late date. Brief treatment with conservative doses may occasionally be justified in these patients if they do not respond to psychological support. The potential adverse effect on bone maturation should be discussed with the patient and parents prior to androgen administration. An X-ray of the hand and wrist to determine bone age should be obtained every 6 months to assess the effect of treatment on the epiphyseal centers (see WARNINGS ). 2. Females Androgens may be used secondarily in women with advancing inoperable metastatic (skeletal) mammary cancer who are 1 to 5 years postmenopausal. Primary goals of therapy in these women include ablation of the ovaries. Other methods of counteracting estrogen activity are adrenalectomy, hypophysectomy, and/or antiestrogen therapy. This treatment has also been used in premenopausal women with breast cancer who have benefitted from oophorectomy and are considered to have a hormone-responsive tumor. Judgment concerning androgen therapy should be made by an oncologist with expertise in this field. uuid:355b4a13-0ab4-4627-8fd6-5cc872a4b0aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46195 biolink:treats MONDO:0005578 PMID:41385096 "[{""id"":""uuid:c9422eef-e77f-40af-a25f-b48ff85a9d72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:513c59d1-27d5-4e07-89c6-46b225742812"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] • temporarily relieves minor aches and pains due to: • minor pain of arthritis • muscular aches • backache • premenstrual and menstrual cramps • the common cold • headache • toothache • temporarily reduces fever uuid:10a89a40-2be5-4f95-8ef8-82c765917a22 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46195 biolink:treats HP:0003326 PMID:41385096 "[{""id"":""uuid:bd4c116e-9c2f-456f-8ab7-0ad94d7feb79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:963e1619-7fc1-43f1-83a7-84f717c865ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] • temporarily relieves minor aches and pains due to: • minor pain of arthritis • muscular aches • backache • premenstrual and menstrual cramps • the common cold • headache • toothache • temporarily reduces fever uuid:40e22ff4-8407-4688-b4c7-648b53375c9b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46195 biolink:treats HP:0003418 PMID:41385096 "[{""id"":""uuid:6b02c35f-2147-49e3-8ab3-f4746b48ef89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d1ec5f8c-b01a-4be9-976a-2b30d68e1b0f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] • temporarily relieves minor aches and pains due to: • minor pain of arthritis • muscular aches • backache • premenstrual and menstrual cramps • the common cold • headache • toothache • temporarily reduces fever uuid:f2a4dc97-250f-4dfb-8bce-9b6ac3f841e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46195 biolink:treats UMLS:C1698508 PMID:41385096 "[{""id"":""uuid:a1eec71f-a3a2-4e10-8171-607b5bf71acd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:15664722-eed2-4f2e-8120-18e6c86e0dc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] • temporarily relieves minor aches and pains due to: • minor pain of arthritis • muscular aches • backache • premenstrual and menstrual cramps • the common cold • headache • toothache • temporarily reduces fever uuid:f536d126-0a43-45a5-8ee6-2c0cc14fcba5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46195 biolink:treats HP:0100607 PMID:41385096 "[{""id"":""uuid:14311a8c-a4e0-47b5-865e-820c9f183c21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d8dbefdb-1603-4de6-902d-93fb700584c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] • temporarily relieves minor aches and pains due to: • minor pain of arthritis • muscular aches • backache • premenstrual and menstrual cramps • the common cold • headache • toothache • temporarily reduces fever uuid:c08bdce0-a5c4-4919-b4c3-63304f4617bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46195 biolink:treats MONDO:0005709 PMID:41385096 "[{""id"":""uuid:7616261b-5515-4995-bae7-3ba604a36ee5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e2209719-3f9b-4211-88f2-5415d2c13071"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] • temporarily relieves minor aches and pains due to: • minor pain of arthritis • muscular aches • backache • premenstrual and menstrual cramps • the common cold • headache • toothache • temporarily reduces fever uuid:d3d632a7-4bb5-42eb-ab7b-326745f3a4d9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46195 biolink:treats HP:0002315 PMID:41385096 "[{""id"":""uuid:f525dc58-8c6d-4aa6-8fd4-1e3c3ca72a06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e89b29de-4e50-4d7f-9a85-ae6e2ccba4d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] • temporarily relieves minor aches and pains due to: • minor pain of arthritis • muscular aches • backache • premenstrual and menstrual cramps • the common cold • headache • toothache • temporarily reduces fever uuid:28665c13-a48f-408a-bc85-6f3bd12ef61b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46195 biolink:treats EFO:0010072 PMID:41385096 "[{""id"":""uuid:b2cc744a-5b9d-432c-b401-e37b882ac9c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:051ba2bf-969c-439f-b0cc-6204a323c59e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] • temporarily relieves minor aches and pains due to: • minor pain of arthritis • muscular aches • backache • premenstrual and menstrual cramps • the common cold • headache • toothache • temporarily reduces fever uuid:43fcb070-bbbb-43ac-9c87-71e95f1b688b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:48538 biolink:treats MONDO:0005180 PMID:41385096 "[{""id"":""uuid:796aa45d-ef18-4eed-a529-6cc4e37e6cd5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9e4662db-82ad-4798-a2a6-738466884098"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Apomorphine hydrochloride injection is indicated for the acute, intermittent treatment of hypomobility, ""off"" episodes (""end-of-dose wearing off"" and unpredictable ""on/off"" episodes) in patients with advanced Parkinson's disease. Apomorphine hydrocloride inejction has been studied as an adjunct to other medications [see Clinical Studies (14) ] ." uuid:a99350b1-15a0-45ff-9cfd-c0af4ba826c1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:48538 biolink:treats UMLS:C0391852 PMID:41385096 "[{""id"":""uuid:10490547-6c4d-44ae-a3c7-7eba677d7597"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:47ff2140-c909-4f15-9d45-924e2d1ea366"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Apomorphine hydrochloride injection is indicated for the acute, intermittent treatment of hypomobility, ""off"" episodes (""end-of-dose wearing off"" and unpredictable ""on/off"" episodes) in patients with advanced Parkinson's disease. Apomorphine hydrocloride inejction has been studied as an adjunct to other medications [see Clinical Studies (14) ] ." uuid:46b090fd-3b26-4ba8-9419-cf2f7423275d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:48538 biolink:treats UMLS:C5681154 PMID:41385096 "[{""id"":""uuid:5ff1d3fb-4aca-44d1-a3ed-6410e3f1a8aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:af61baba-89d3-4885-a0a0-38461862fbe6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Apomorphine hydrochloride injection is indicated for the acute, intermittent treatment of hypomobility, ""off"" episodes (""end-of-dose wearing off"" and unpredictable ""on/off"" episodes) in patients with advanced Parkinson's disease. Apomorphine hydrocloride inejction has been studied as an adjunct to other medications [see Clinical Studies (14) ] ." uuid:4e222420-131e-478e-9ddc-7dd9027adc21 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:48538 biolink:treats UMLS:C1504539 PMID:41385096 "[{""id"":""uuid:02bcbbc9-2b90-424e-aa83-bbd8f2e3e821"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6ca0d269-1c1d-4f79-b87b-1dd1c2886295"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Apomorphine hydrochloride injection is indicated for the acute, intermittent treatment of hypomobility, ""off"" episodes (""end-of-dose wearing off"" and unpredictable ""on/off"" episodes) in patients with advanced Parkinson's disease. Apomorphine hydrocloride inejction has been studied as an adjunct to other medications [see Clinical Studies (14) ] ." uuid:617c6f38-a249-41c8-878d-e58604e66f6d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4562 biolink:treats MONDO:0005277 PMID:41385096 "[{""id"":""uuid:03833dbb-3f84-436c-83ca-2c41788dda4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ddc794dd-de14-4326-a810-ed16dc94cb29"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dihydroergotamine Mesylate Injection, USP is indicated for the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes. uuid:53fa5c17-43d4-4b8a-a7f9-e36a2806be76 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4562 biolink:treats MONDO:0043537 PMID:41385096 "[{""id"":""uuid:d05d2c2e-0d8f-48ac-b35e-e7939b95119e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:555fd5d0-9706-47b9-a519-90568ad997f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dihydroergotamine Mesylate Injection, USP is indicated for the acute treatment of migraine headaches with or without aura and the acute treatment of cluster headache episodes. uuid:c39063cd-87df-4c9c-b71a-083a3703c0f6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0000004 PMID:41385096 "[{""id"":""uuid:7457057a-2ecc-4cb9-b05b-d8b0625f415f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fa8a60b6-c5c8-45d0-b124-8b897e3536f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:794196e9-1887-4c9b-9b06-2b1b49cbcdde biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0019801 PMID:41385096 "[{""id"":""uuid:14f37e89-63d8-4186-9b4f-558652016a6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:50fcc87d-3e60-4da4-865d-bc278e59a09e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:eb43d77c-9998-425e-8245-c5a3499c85bc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0018479 PMID:41385096 "[{""id"":""uuid:3c40f3a1-7884-4742-a580-d810f1e99e2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:82ed79ff-60e3-48c8-8da7-af735d980fef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:b785be75-cb47-4e91-8ed5-f5cd20afe648 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0043455 PMID:41385096 "[{""id"":""uuid:2798bf46-207f-4fee-9b02-65b03e17b225"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c0784982-8938-46e3-beb2-690ef941a7f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:f2491c4b-0127-4fad-a99d-1191d0f817ea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:92e51276-cfdd-4a76-8e6d-ef935cec1f86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a07f398c-00ae-4981-bffd-5184c0d59e1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:d968bd18-95e2-4ead-a53a-378632e6b01b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:de670a0b-5546-4128-955d-ef623c29904a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5fd76887-c6f1-4ccc-9e0a-f16d991c7184"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:775e5d4f-fdff-469a-ae13-5f603d89cf2a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0011429 PMID:41385096 "[{""id"":""uuid:827f829a-3021-422c-80e2-8f3c2eec06c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9caf0a44-0a25-48ac-b525-b2c28c90ac18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:15adc18b-4604-4aa2-a66d-3717c7f68c5d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0040698 PMID:41385096 "[{""id"":""uuid:046af431-3ed1-4d34-a0a2-af800db08d95"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fad80edb-9868-48fe-93fe-a3e4dbc57059"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:c2150c51-e965-4c9b-ba50-400cf1bfcefd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0001875 PMID:41385096 "[{""id"":""uuid:4d40b772-caaf-4a0a-92b7-bf748f56d0c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2019891d-f565-499d-be89-305de522b13a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:4a44089f-2982-403f-bd98-6956ffa1d054 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0004855 PMID:41385096 "[{""id"":""uuid:1ea2b95f-4299-4bf0-9bd8-457676ef90e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f409063a-964d-457d-83e5-40e2dc1946db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:9c616653-e334-42c0-98d3-f8a39e269909 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats UMLS:C0149896 PMID:41385096 "[{""id"":""uuid:1d505a60-cc57-4f6d-a1bf-ef656902f990"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:39b7d2e4-d87e-407f-ba9b-598718d3a8a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:d6ef73f1-6ae3-4138-a399-214de27900b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:47f50279-fcfa-44f5-86db-3755ab510423"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3472827c-350e-479d-9819-94a4581ca7b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:fadf368a-902d-4f63-b15a-82ce724f202d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:b94e6ff0-8c6f-4f95-b883-ecbf0658c3ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5e57592a-ec0c-46b7-a948-6d258da69aa7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:9d1b204e-f1b8-4539-bc57-fd96c5c9aa4f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats UMLS:C5441648 PMID:41385096 "[{""id"":""uuid:d02486ab-39d1-4213-aade-1219dae5c4be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:85b863e3-4627-407a-90ef-d4e3e1a4704f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:eedfb639-01c4-4691-b11b-8536538bd1e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0006594 PMID:41385096 "[{""id"":""uuid:715d590c-2f18-4584-b884-d3e8d09aa683"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:662e931d-53e1-43db-b6af-3ffe11869552"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:bf1ae100-b43d-4b76-86dc-3f35c9bd8495 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0006545 PMID:41385096 "[{""id"":""uuid:53d41264-c69d-453c-bac5-d4e97d4e7a93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:767b7203-6bab-4538-818e-c90f84a749b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:ddd9220c-6049-439b-81f8-e8cc78aa52e4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0018229 PMID:41385096 "[{""id"":""uuid:1c9f8aed-1b3c-427e-9923-1fd2b8a7798e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b1864232-d647-49cd-947c-788167f2d3aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:43cf9f90-6036-406c-83f1-54869d0fbe8b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0043233 PMID:41385096 "[{""id"":""uuid:edb71ada-c8ff-4b7c-af48-a4ae339a5b8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ab537835-f4e2-4f59-bd9b-8aa623660ff8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:c58539be-e1fc-4d07-b7fe-e41158eaa2f1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0015614 PMID:41385096 "[{""id"":""uuid:9203b87d-9113-475c-a429-48b141ca9583"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f0620457-4177-4dd6-9888-37e1700fb890"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:fe8eed04-9689-41c9-a82b-ba8c121c5967 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0006608 PMID:41385096 "[{""id"":""uuid:cc28430b-98fb-4e2b-9c7f-756a8eedd5c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a233f376-fff2-4562-a197-b7d0c790eda3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:a5164f83-0bc9-48ff-8abe-ef755b0d7edd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:c4196173-4686-45ce-819b-49a9d7eeca18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5c85c3f1-d965-4152-bb32-80b2cefd99dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:5b48b01a-fdec-4d66-ba62-265db3c94ccc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0009691 PMID:41385096 "[{""id"":""uuid:7f05196e-d5a2-494d-89a8-df8cb36bc510"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d597fc06-a5dd-487e-96b1-0e2a3a4e91b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:193ab7b7-f23f-4d62-95f1-17b4e9a5b280 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:6cafecca-713d-444d-9052-7d002a343c7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3bbb7238-31a9-46f9-ae45-ba2689b99f43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:9c2be5a1-6332-4494-a72c-8ad1f380fd32 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0005480 PMID:41385096 "[{""id"":""uuid:9a2da0ae-903b-4e61-a94c-229eeff7b8f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:99a1bd7a-8156-4c2f-a6d6-262edf29a449"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:32fa6208-459a-41bf-b79b-80ff0e857b87 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:ee1a063a-2d74-4ca3-ac05-8522546b5664"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:138c00ce-64a7-4c39-a5a0-c52a08f19ad3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:e0e20f73-f9be-46c3-9f3e-f2046762da2a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0043789 PMID:41385096 "[{""id"":""uuid:73116492-313e-4507-a91f-fa38d93bc489"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7c8d88b5-d290-448b-910d-927dc79728a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:060dae4e-300a-4486-a237-7af33a024ee6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0011786 PMID:41385096 "[{""id"":""uuid:9a11d3aa-6472-40ea-8976-50fca6b9bd5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:284075c9-fc1b-4a28-aadb-c868a0fec24d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:e546fb5b-1690-4a13-9f2a-079fec844dac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0000775 PMID:41385096 "[{""id"":""uuid:c0d37f1b-e390-4f78-b934-05f8835ab22f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bfb76321-3937-4dcd-bf70-033664813991"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:4d830086-1f92-46f5-9a61-5bbc2150eb4b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats UMLS:C0274440 PMID:41385096 "[{""id"":""uuid:be28ddd8-14b6-46f2-b602-e15f16e55e41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4e44733e-6cd6-47f5-a332-98597a436588"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:0b70b467-a2df-467e-bedb-90f71a030f66 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0005883 PMID:41385096 "[{""id"":""uuid:3f30f4cd-056a-4586-8cbf-179a902da5f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dc0edbb7-9a22-45b0-b107-7a329453b04f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:b30576e0-f4f6-4530-ae07-04f5e7c8aee7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0006814 PMID:41385096 "[{""id"":""uuid:cf0d2226-7828-4645-9ef1-dcd57ca69943"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ce780480-4a82-4aeb-a2c8-e6c75059feab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:026484c2-e36e-42b5-83cc-302771638028 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0004773 PMID:41385096 "[{""id"":""uuid:25bc2b46-a5d5-4a2e-a8ee-f3e2e54063a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8dbf695d-531e-4193-9980-e490703702b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:32b86d94-d1da-499c-b5b2-066aa105b4f4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0004674 PMID:41385096 "[{""id"":""uuid:9cc255f4-b2ad-498d-8943-2518c2cd9f4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b2a52f52-c3c2-4990-9e52-d30ddde08cd5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:7a1cf780-f337-4b88-99a8-6095870c168c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0005885 PMID:41385096 "[{""id"":""uuid:9c394250-bac6-49ea-ada8-0ebe0c7d5d9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a7b17110-5fe5-49a3-b8b6-a6957852fe29"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:932e0910-7dca-47bb-9683-42434ad5fcf8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0019198 PMID:41385096 "[{""id"":""uuid:a02c5a11-fa0d-44fa-b211-2f47b8d77f43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8bd520a0-e884-4ea0-9183-3d490428602b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:3d6d2850-5625-4517-8645-9e1722866373 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0006651 PMID:41385096 "[{""id"":""uuid:01dac715-5520-41a0-83e9-70eff47932b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2bc1a29a-6b3b-46b6-b0d2-827839eebf4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:2007b6f7-994b-4e6d-9952-7bb84b8c2ede biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0003085 PMID:41385096 "[{""id"":""uuid:97047a12-8f58-4714-86fb-c573085c3309"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:104b1fa9-16cc-473f-8b33-a707c7738ad3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:5db3a8b0-db4e-425c-82ea-3664a97e5095 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0001034 PMID:41385096 "[{""id"":""uuid:53766ab5-54af-49a5-a19e-eaf09761183a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3f84c667-90e9-4443-8c80-26c122f655fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:0d5f6fb4-5b4c-4c49-b95d-d87aa0434cd8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:4d5e01e9-c0b3-4d81-943a-2995691a4d85"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aa1c3c46-504c-4a43-a0a8-dde92aa782ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:af8a3aaa-f0ec-43af-8dae-260f09f6ed6e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats UMLS:C0678202 PMID:41385096 "[{""id"":""uuid:2c042c94-0868-45a3-a6d1-73d304c2342c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5ba841f2-cb79-49bb-9ac8-c8b87548ad15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:a874b4d9-57fd-4e58-aa55-133d9f9f598f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0019338 PMID:41385096 "[{""id"":""uuid:f17ff4b8-7660-4b2e-8914-73978c0afa52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:415fc1f9-c34a-40df-9442-635b91fd59f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:5c384ee4-051a-4139-821b-a8d2596e3942 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0015274 PMID:41385096 "[{""id"":""uuid:e7f7a30c-ff98-4db1-a365-d14c5d0a620a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7ca3f646-15b8-4212-a98d-e4ce2b256338"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:b62ca208-fb9b-40eb-906d-1ad62528c6c7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0006052 PMID:41385096 "[{""id"":""uuid:8be41d5d-a8a0-4604-9edd-a5ff5f67b95e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c01d9c5b-ceb5-4cae-a54f-c8d0845aad83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:26daffd5-d642-4e26-9410-6365639ed436 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0005848 PMID:41385096 "[{""id"":""uuid:657512f6-4efd-438a-bc91-e43167827904"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:504537e6-99ab-4281-8fc2-8c33bc6ea93d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:798de56c-ea9a-4e23-bde0-d2299025b5e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0002572 PMID:41385096 "[{""id"":""uuid:b1353cd8-5ab0-4a39-b79a-e4c00a7f3d28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aa23b2f5-4f9d-415c-b5fa-80f71fe9da60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:3688c194-9f18-4e12-86ae-8d9cc4bb6e0a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats UMLS:C0002879 PMID:41385096 "[{""id"":""uuid:dec21fff-37f2-404f-96c6-334b0c96b3bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6298f878-9c04-4c10-9e98-6aa8bd8da30e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:e2ff4cfb-332e-4729-9ef1-1b8872dba8c0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0020108 PMID:41385096 "[{""id"":""uuid:394b2faa-cb87-4b21-89de-feb966c89b7d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:45e1dfc4-a37f-4046-9a5b-4736c065d3ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:232ebb8f-9535-4d2e-9f14-6c7eeeadc8d3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0019098 PMID:41385096 "[{""id"":""uuid:8b0903fe-a8dc-4a61-8d48-b14862b45761"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:091d6516-db59-4a21-8b24-72b3535170eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:117b2d74-be6f-4acb-a5d2-75e60a18cdcc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0001198 PMID:41385096 "[{""id"":""uuid:22e87593-49ef-4b69-8a3e-85252c1d9f76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1009299e-9d84-4a93-b7c9-f97c26ecbf28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:15423d7c-2cd7-4981-9ae6-8a80b78cc596 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0002280 PMID:41385096 "[{""id"":""uuid:67b926e8-f012-4919-b15d-a62e942aa225"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d83a4bc2-1eb3-4113-93d1-27e18001ddd1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:49d10fba-6909-408b-ab09-db5c10c054dd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0015253 PMID:41385096 "[{""id"":""uuid:ea011534-0b1e-41dd-bff3-91c6dd02466e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cbbd2be8-434e-49ed-afb4-4dfb7e2e98b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:7d3a67a7-d3fa-4c00-adff-a566f11b6edc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats HP:0001908 PMID:41385096 "[{""id"":""uuid:a5a58edb-2178-4a05-8ebe-fee6035ffa2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0f615be9-54d3-48d4-b6f7-e3661bc126b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:af4a623b-4a2d-4f6f-8ad4-66605f987cd9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0005059 PMID:41385096 "[{""id"":""uuid:562d3d8d-9d35-4b84-a5ea-12201b0a0205"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d0865389-c057-46bc-aafc-291a226726b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:8a161afa-aba9-47e9-af74-d275caad79f0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0004095 PMID:41385096 "[{""id"":""uuid:0064723c-cdba-425a-885f-e89ac6d06a0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dad00934-80ee-4728-9345-52a914c7ee15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:8f96a3bd-3f7c-41fa-bdd3-f408e7525216 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0004355 PMID:41385096 "[{""id"":""uuid:2e1a6451-c5e6-49f5-8e1b-577e3ce03fc6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:68126f90-653e-47dc-bf56-9079ac8a7dea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:ad91e80d-2d88-4d36-a98a-166275611815 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0005377 PMID:41385096 "[{""id"":""uuid:dce9f63b-abd5-4e22-bdaa-77246cc2668c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:20caa764-b80c-42f7-9411-80ef57872c66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:d46218e0-60bd-43a7-b5f6-ed0449f28d6d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0006042 PMID:41385096 "[{""id"":""uuid:aab857de-e9b0-482c-8766-860243355629"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2895d2a1-192e-4e78-a476-8f1a9ffe48ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:42837a58-d58a-47e1-bc6e-0f51008b7158 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0019444 PMID:41385096 "[{""id"":""uuid:c529a3cc-789d-485f-82ed-7479288c99dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:13a4ad2a-9a59-4055-a014-2bdc4a9e25f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:c0a83088-5096-490e-a12d-1905fe45b868 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats MONDO:0006684 PMID:41385096 "[{""id"":""uuid:7d98ddfa-0302-4768-b46e-6892443ae5b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:22154a60-b990-4332-911c-3736f55eb273"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Intravenous or Intramuscular Injection When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, those products labeled for intravenous or intramuscular use are indicated as follows: • Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance) Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used) Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer • Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis • Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis • Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides • Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice) • Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers • Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (Systemic therapy) Regional enteritis (Systemic therapy) • Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Loeffler’s syndrome not manageable by other means Aspiration pneumonitis • Hematologic Disorders Acquired (autoimmune) hemolytic anemia Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated) Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia • Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood • Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type, or that due to lupus erythematosus • Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement • Diagnostic testing of adrenocortical hyperfunction • Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:fc9ddfcc-2737-48a3-b0de-8892d499e2af biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1155345 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:0f2199f3-85e8-4cbd-95b9-8acc9502bcb0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c0eea3dc-201a-4af1-962f-b456a157c42b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lidocaine HCI 2% Jelly is indicated for prevention and control of pain in procedures involving the male and female urethra, for topical treatment of painful urethritis, and as an anesthetic lubricant for endotracheal intubation (oral and nasal). uuid:2c1cd5d5-07a7-4ec0-865b-edb79244d0ca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1155345 biolink:treats MONDO:0005297 PMID:41385096 "[{""id"":""uuid:b3db0e8a-8dba-43c5-8567-04ba44789bc1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a5010397-4126-4f11-89b9-6da2358b5cf7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lidocaine HCI 2% Jelly is indicated for prevention and control of pain in procedures involving the male and female urethra, for topical treatment of painful urethritis, and as an anesthetic lubricant for endotracheal intubation (oral and nasal). uuid:af9b207c-c668-4153-beb5-91508de987bc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9241 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:c62a2b03-ff1a-4dc2-b4c2-184022c4fb43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:31d1b77f-556e-4db5-a6ff-881d10ac93cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Heart Failure Spironolactone tablets are indicated for treatment of NYHA Class III–IV heart failure and reduced ejection fraction to increase survival, manage edema, and reduce the need for hospitalization for heart failure. Spironolactone tablets are usually administered in conjunction with other heart failure therapies. 1.2 Hypertension Spironolactone tablets are indicated as add-on therapy for the treatment of hypertension, to lower blood pressure in patients who are not adequately controlled on other agents. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. 1.3 Edema Associated with Hepatic Cirrhosis or Nephrotic Syndrome Spironolactone tablets are indicated for the management of edema in the following settings: Cirrhosis of the liver when edema is not responsive to fluid and sodium restriction. Nephrotic syndrome when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics produce an inadequate response. Because it increases serum potassium, spironolactone tablets may be useful for treating edema when administration of other diuretics has caused hypokalemia. 1.4 Primary Hyperaldosteronism Spironolactone tablets are indicated in the following settings: Short-term preoperative treatment of patients with primary hyperaldosteronism. Long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are not candidates for surgery. Long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). uuid:6f4e0a8c-5772-48ed-bb8e-4fa34e78b6ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9241 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:6d8706a6-bda6-40bb-a157-ce2b111c4754"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2762759a-de02-4b13-9403-29ac3cbac5f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Heart Failure Spironolactone tablets are indicated for treatment of NYHA Class III–IV heart failure and reduced ejection fraction to increase survival, manage edema, and reduce the need for hospitalization for heart failure. Spironolactone tablets are usually administered in conjunction with other heart failure therapies. 1.2 Hypertension Spironolactone tablets are indicated as add-on therapy for the treatment of hypertension, to lower blood pressure in patients who are not adequately controlled on other agents. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. 1.3 Edema Associated with Hepatic Cirrhosis or Nephrotic Syndrome Spironolactone tablets are indicated for the management of edema in the following settings: Cirrhosis of the liver when edema is not responsive to fluid and sodium restriction. Nephrotic syndrome when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics produce an inadequate response. Because it increases serum potassium, spironolactone tablets may be useful for treating edema when administration of other diuretics has caused hypokalemia. 1.4 Primary Hyperaldosteronism Spironolactone tablets are indicated in the following settings: Short-term preoperative treatment of patients with primary hyperaldosteronism. Long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are not candidates for surgery. Long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). uuid:81908907-950a-48fe-8d64-b14f63f88d94 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15407 biolink:treats MONDO:0005468 PMID:41385096 "[{""id"":""uuid:abed8988-9e1f-4239-8f60-d85e52f1d23c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fc490b5a-e02e-4a4c-83be-f5b26b8f2496"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:61062458-8b17-4fd5-99fb-791c0d4b2881"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ephedrine sulfate injection is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia.|[PMDA] Drugs with a new indication and route of administration, or the intravenous route for the treatment of hypotension occurring during anesthesia,G20 and without intramuscular injection administered for their approved indications. uuid:59714e97-52fd-4e65-a581-9ff0d5ff88b5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DQ448MW7KS biolink:treats MONDO:0000270 PMID:41385096 "[{""id"":""uuid:d953c978-5426-4e91-9e14-f77f2aaa6841"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d1294c5f-32c0-449c-91b6-7a9fa38e01ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Synagis is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients: with a history of premature birth (less than or equal to 35 weeks gestational age) and who are 6 months of age or younger at the beginning of RSV season, with bronchopulmonary dysplasia (BPD) that required medical treatment within the previous 6 months and who are 24 months of age or younger at the beginning of RSV season, with hemodynamically significant congenital heart disease (CHD) and who are 24 months of age or younger at the beginning of RSV season [see Clinical Studies ( 14 ) ]. uuid:ebb28351-cecf-4e8a-b517-e69e1fdd856a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DQ448MW7KS biolink:treats MONDO:0019091 PMID:41385096 "[{""id"":""uuid:eefb64d3-9432-4883-b8bf-1b9e94628438"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:8ef76b0e-de19-459e-8247-bcfa066dae6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1027d3ef-bb5a-447d-8087-5daa605f1d5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/synagis""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Synagis is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients: with a history of premature birth (less than or equal to 35 weeks gestational age) and who are 6 months of age or younger at the beginning of RSV season, with bronchopulmonary dysplasia (BPD) that required medical treatment within the previous 6 months and who are 24 months of age or younger at the beginning of RSV season, with hemodynamically significant congenital heart disease (CHD) and who are 24 months of age or younger at the beginning of RSV season [see Clinical Studies ( 14 ) ].|[EMA] Synagis is indicated for the prevention of serious lower-respiratory-tract disease requiring hospitalisation caused by respiratory syncytial virus (RSV) in children at high risk for RSV disease:children born at 35 weeks of gestation or less and less than six months of age at the onset of the RSV season;children less than two years of age and requiring treatment for bronchopulmonary dysplasia within the last six months;children less than two years of age and with haemodynamically significant congenital heart disease. uuid:4e30a454-82c8-4119-ab14-968a10c4d2ad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DQ448MW7KS biolink:treats MONDO:0005453 PMID:41385096 "[{""id"":""uuid:7ecbd6a3-cdbf-4c71-b14e-6b94a44381d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:715b54ec-e0d6-4476-bfec-3b47eae68f0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a25ab68d-04f8-412a-9111-ba102f41ecc0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/synagis""]},{""id"":""uuid:ab339af1-cd97-4c67-9d9a-4e8ab3d68a20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Synagis is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in pediatric patients: with a history of premature birth (less than or equal to 35 weeks gestational age) and who are 6 months of age or younger at the beginning of RSV season, with bronchopulmonary dysplasia (BPD) that required medical treatment within the previous 6 months and who are 24 months of age or younger at the beginning of RSV season, with hemodynamically significant congenital heart disease (CHD) and who are 24 months of age or younger at the beginning of RSV season [see Clinical Studies ( 14 ) ].|[EMA] Synagis is indicated for the prevention of serious lower-respiratory-tract disease requiring hospitalisation caused by respiratory syncytial virus (RSV) in children at high risk for RSV disease:children born at 35 weeks of gestation or less and less than six months of age at the onset of the RSV season;children less than two years of age and requiring treatment for bronchopulmonary dysplasia within the last six months;children less than two years of age and with haemodynamically significant congenital heart disease.|[PMDA] Drugs with a new indication for preventing serious lower respiratory tract disease caused by RS virus infections in newborns, infants and children under 24 months of age with haemodynamically significant congenital heart disease [Priority review drug] uuid:a62ba77f-abc3-44fe-9a3c-a44105e58a95 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9599 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:7de44c7d-76f8-409a-92d7-9c97da44fd9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ab401659-c4c4-4c93-b4d4-893679bbe4b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Timolol maleate tablets are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. Myocardial Infarction Timolol is indicated in patients who have survived the acute phase of myocardial infarction, and are clinically stable, to reduce cardiovascular mortality and the risk of reinfarction. Migraine Timolol is indicated for the prophylaxis of migraine headache. uuid:bc7accc6-cd8f-427d-92fe-32b0b973a92f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9599 biolink:treats MONDO:0005277 PMID:41385096 "[{""id"":""uuid:bdb9666d-c598-4531-92c2-bf1ddb23f3b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bfc7ae69-b4ed-427b-aa4b-cef71c478aa9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Timolol maleate tablets are indicated for the treatment of hypertension. They may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. Myocardial Infarction Timolol is indicated in patients who have survived the acute phase of myocardial infarction, and are clinically stable, to reduce cardiovascular mortality and the risk of reinfarction. Migraine Timolol is indicated for the prophylaxis of migraine headache. uuid:f2402ee4-3d6a-410e-b580-f497aea80aed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29101 biolink:treats MONDO:0000313 PMID:41385096 "[{""id"":""uuid:fff065a2-f64c-44f7-91db-fb363dc55195"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f6466f27-a4bb-47fa-92d3-20aa87ac601a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Phosphates Injection, USP, 3 mM P/mL is indicated as a source of phosphorus, for addition to large volume intravenous fluids, to prevent or correct hypophosphatemia in patients with restricted or no oral intake. It is also useful as an additive for preparing specific parenteral fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions. The concomitant amount of sodium (Na + 4 mEq/mL) must be calculated into total electrolyte dose of such prepared solutions. uuid:70dd48c4-9de0-45d0-a79a-e805cbc60065 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0010643 PMID:41385096 "[{""id"":""uuid:d3f3cc9b-cabc-44c6-b9ca-d8b3e215ff9a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1c49df50-3ee1-42a5-b0b8-bafe6cbde206"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6 . Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7 . Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler's syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:4d1fd10e-4624-44a1-9d16-768e2c227ce2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:161680 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:64029c8f-57f9-41be-a3f4-faf3397fd2d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3478cc71-9b1d-45af-8602-30918dbd7dc7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of aztreonam for injection, USP and other antibacterial drugs, aztreonam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Aztreonam for Injection is indicated for the treatment of the following infections caused by susceptible Gram-negative microorganisms: Urinary Tract Infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Enterobacter cloacae, Klebsiella oxytoca *, Citrobacter species*, and Serratia marcescens *. Lower Respiratory Tract Infections , including pneumonia and bronchitis caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, and Serratia marcescens *. Septicemia caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis *, Serratia marcescens *, and Enterobacter species. Skin and Skin-Structure Infections , including those associated with postoperative wounds, ulcers, and burns, caused by Escherichia coli, Proteus mirabilis, Serratia marcescens, Enterobacter species, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Citrobacter species*. * Efficacy for this organism in this organ system was studied in fewer than 10 infections. Intra-abdominal Infections , including peritonitis caused by Escherichia coli, Klebsiella species including K. pneumoniae, Enterobacter species including E. cloacae *, Pseudomonas aeruginosa, Citrobacter species* including C. freundii *, and Serratia species* including S. marcescens *. Gynecologic Infections , including endometritis and pelvic cellulitis caused by Escherichia coli, Klebsiella pneumoniae *, Enterobacter species* including E. cloacae *, and Proteus mirabilis *. Aztreonam for injection is indicated for adjunctive therapy to surgery in the management of infections caused by susceptible organisms, including abscesses, infections complicating hollow viscus perforations, cutaneous infections, and infections of serous surfaces. Aztreonam for injection is effective against most of the commonly encountered Gram-negative aerobic pathogens seen in general surgery. uuid:7fd42d4f-3265-4c6f-be7b-c0802e90e530 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:161680 biolink:treats MONDO:0006939 PMID:41385096 "[{""id"":""uuid:959e9fb6-ca68-4467-9edc-1b855b9b8ead"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1f4cce13-aee1-4554-8be1-bebec23afed1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of aztreonam for injection, USP and other antibacterial drugs, aztreonam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Aztreonam for Injection is indicated for the treatment of the following infections caused by susceptible Gram-negative microorganisms: Urinary Tract Infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Enterobacter cloacae, Klebsiella oxytoca *, Citrobacter species*, and Serratia marcescens *. Lower Respiratory Tract Infections , including pneumonia and bronchitis caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, and Serratia marcescens *. Septicemia caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis *, Serratia marcescens *, and Enterobacter species. Skin and Skin-Structure Infections , including those associated with postoperative wounds, ulcers, and burns, caused by Escherichia coli, Proteus mirabilis, Serratia marcescens, Enterobacter species, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Citrobacter species*. * Efficacy for this organism in this organ system was studied in fewer than 10 infections. Intra-abdominal Infections , including peritonitis caused by Escherichia coli, Klebsiella species including K. pneumoniae, Enterobacter species including E. cloacae *, Pseudomonas aeruginosa, Citrobacter species* including C. freundii *, and Serratia species* including S. marcescens *. Gynecologic Infections , including endometritis and pelvic cellulitis caused by Escherichia coli, Klebsiella pneumoniae *, Enterobacter species* including E. cloacae *, and Proteus mirabilis *. Aztreonam for injection is indicated for adjunctive therapy to surgery in the management of infections caused by susceptible organisms, including abscesses, infections complicating hollow viscus perforations, cutaneous infections, and infections of serous surfaces. Aztreonam for injection is effective against most of the commonly encountered Gram-negative aerobic pathogens seen in general surgery. uuid:bd6fe3d1-348d-46b6-adb6-27018c53b14d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:161680 biolink:treats MONDO:0006032 PMID:41385096 "[{""id"":""uuid:326c4c14-d802-4d63-b505-1c2bb2c78496"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:664c5c68-17f8-454e-9f52-26c497bb14b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of aztreonam for injection, USP and other antibacterial drugs, aztreonam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Aztreonam for Injection is indicated for the treatment of the following infections caused by susceptible Gram-negative microorganisms: Urinary Tract Infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Enterobacter cloacae, Klebsiella oxytoca *, Citrobacter species*, and Serratia marcescens *. Lower Respiratory Tract Infections , including pneumonia and bronchitis caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, and Serratia marcescens *. Septicemia caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis *, Serratia marcescens *, and Enterobacter species. Skin and Skin-Structure Infections , including those associated with postoperative wounds, ulcers, and burns, caused by Escherichia coli, Proteus mirabilis, Serratia marcescens, Enterobacter species, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Citrobacter species*. * Efficacy for this organism in this organ system was studied in fewer than 10 infections. Intra-abdominal Infections , including peritonitis caused by Escherichia coli, Klebsiella species including K. pneumoniae, Enterobacter species including E. cloacae *, Pseudomonas aeruginosa, Citrobacter species* including C. freundii *, and Serratia species* including S. marcescens *. Gynecologic Infections , including endometritis and pelvic cellulitis caused by Escherichia coli, Klebsiella pneumoniae *, Enterobacter species* including E. cloacae *, and Proteus mirabilis *. Aztreonam for injection is indicated for adjunctive therapy to surgery in the management of infections caused by susceptible organisms, including abscesses, infections complicating hollow viscus perforations, cutaneous infections, and infections of serous surfaces. Aztreonam for injection is effective against most of the commonly encountered Gram-negative aerobic pathogens seen in general surgery. uuid:514d5300-7856-417b-9e05-6195d3a72445 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:161680 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:1d68b62a-0698-4e28-a87c-50e968b9ee11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:46cfedca-6619-4aac-8d24-8073c33d5b23"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of aztreonam for injection, USP and other antibacterial drugs, aztreonam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Aztreonam for Injection is indicated for the treatment of the following infections caused by susceptible Gram-negative microorganisms: Urinary Tract Infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Enterobacter cloacae, Klebsiella oxytoca *, Citrobacter species*, and Serratia marcescens *. Lower Respiratory Tract Infections , including pneumonia and bronchitis caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, and Serratia marcescens *. Septicemia caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis *, Serratia marcescens *, and Enterobacter species. Skin and Skin-Structure Infections , including those associated with postoperative wounds, ulcers, and burns, caused by Escherichia coli, Proteus mirabilis, Serratia marcescens, Enterobacter species, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Citrobacter species*. * Efficacy for this organism in this organ system was studied in fewer than 10 infections. Intra-abdominal Infections , including peritonitis caused by Escherichia coli, Klebsiella species including K. pneumoniae, Enterobacter species including E. cloacae *, Pseudomonas aeruginosa, Citrobacter species* including C. freundii *, and Serratia species* including S. marcescens *. Gynecologic Infections , including endometritis and pelvic cellulitis caused by Escherichia coli, Klebsiella pneumoniae *, Enterobacter species* including E. cloacae *, and Proteus mirabilis *. Aztreonam for injection is indicated for adjunctive therapy to surgery in the management of infections caused by susceptible organisms, including abscesses, infections complicating hollow viscus perforations, cutaneous infections, and infections of serous surfaces. Aztreonam for injection is effective against most of the commonly encountered Gram-negative aerobic pathogens seen in general surgery. uuid:87dce231-b970-438b-a2c9-b8ce65105791 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:161680 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:1566fe20-6f43-4ff6-b3a2-5a3da9f19ef4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:88fc0f6e-7652-4cd9-8683-67a726100b04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of aztreonam for injection, USP and other antibacterial drugs, aztreonam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Aztreonam for Injection is indicated for the treatment of the following infections caused by susceptible Gram-negative microorganisms: Urinary Tract Infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Enterobacter cloacae, Klebsiella oxytoca *, Citrobacter species*, and Serratia marcescens *. Lower Respiratory Tract Infections , including pneumonia and bronchitis caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, and Serratia marcescens *. Septicemia caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis *, Serratia marcescens *, and Enterobacter species. Skin and Skin-Structure Infections , including those associated with postoperative wounds, ulcers, and burns, caused by Escherichia coli, Proteus mirabilis, Serratia marcescens, Enterobacter species, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Citrobacter species*. * Efficacy for this organism in this organ system was studied in fewer than 10 infections. Intra-abdominal Infections , including peritonitis caused by Escherichia coli, Klebsiella species including K. pneumoniae, Enterobacter species including E. cloacae *, Pseudomonas aeruginosa, Citrobacter species* including C. freundii *, and Serratia species* including S. marcescens *. Gynecologic Infections , including endometritis and pelvic cellulitis caused by Escherichia coli, Klebsiella pneumoniae *, Enterobacter species* including E. cloacae *, and Proteus mirabilis *. Aztreonam for injection is indicated for adjunctive therapy to surgery in the management of infections caused by susceptible organisms, including abscesses, infections complicating hollow viscus perforations, cutaneous infections, and infections of serous surfaces. Aztreonam for injection is effective against most of the commonly encountered Gram-negative aerobic pathogens seen in general surgery. uuid:51ac4a83-d0b0-400c-8634-718c34048da9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:161680 biolink:treats MONDO:0003781 PMID:41385096 "[{""id"":""uuid:f316dc29-0858-4ce7-b827-ad3ba0bc909a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ac745fd2-4ae2-417e-8958-854ec91c5215"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of aztreonam for injection, USP and other antibacterial drugs, aztreonam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Aztreonam for Injection is indicated for the treatment of the following infections caused by susceptible Gram-negative microorganisms: Urinary Tract Infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Enterobacter cloacae, Klebsiella oxytoca *, Citrobacter species*, and Serratia marcescens *. Lower Respiratory Tract Infections , including pneumonia and bronchitis caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, and Serratia marcescens *. Septicemia caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis *, Serratia marcescens *, and Enterobacter species. Skin and Skin-Structure Infections , including those associated with postoperative wounds, ulcers, and burns, caused by Escherichia coli, Proteus mirabilis, Serratia marcescens, Enterobacter species, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Citrobacter species*. * Efficacy for this organism in this organ system was studied in fewer than 10 infections. Intra-abdominal Infections , including peritonitis caused by Escherichia coli, Klebsiella species including K. pneumoniae, Enterobacter species including E. cloacae *, Pseudomonas aeruginosa, Citrobacter species* including C. freundii *, and Serratia species* including S. marcescens *. Gynecologic Infections , including endometritis and pelvic cellulitis caused by Escherichia coli, Klebsiella pneumoniae *, Enterobacter species* including E. cloacae *, and Proteus mirabilis *. Aztreonam for injection is indicated for adjunctive therapy to surgery in the management of infections caused by susceptible organisms, including abscesses, infections complicating hollow viscus perforations, cutaneous infections, and infections of serous surfaces. Aztreonam for injection is effective against most of the commonly encountered Gram-negative aerobic pathogens seen in general surgery. uuid:d78e96a4-b149-4cc3-b845-16d3f6e1078a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:161680 biolink:treats MONDO:0700217 PMID:41385096 "[{""id"":""uuid:16e52b6e-cedc-46f4-93a1-99397796095c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7ea48220-4252-458d-8aaf-288bc60c7901"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of aztreonam for injection, USP and other antibacterial drugs, aztreonam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Aztreonam for Injection is indicated for the treatment of the following infections caused by susceptible Gram-negative microorganisms: Urinary Tract Infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Enterobacter cloacae, Klebsiella oxytoca *, Citrobacter species*, and Serratia marcescens *. Lower Respiratory Tract Infections , including pneumonia and bronchitis caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, and Serratia marcescens *. Septicemia caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis *, Serratia marcescens *, and Enterobacter species. Skin and Skin-Structure Infections , including those associated with postoperative wounds, ulcers, and burns, caused by Escherichia coli, Proteus mirabilis, Serratia marcescens, Enterobacter species, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Citrobacter species*. * Efficacy for this organism in this organ system was studied in fewer than 10 infections. Intra-abdominal Infections , including peritonitis caused by Escherichia coli, Klebsiella species including K. pneumoniae, Enterobacter species including E. cloacae *, Pseudomonas aeruginosa, Citrobacter species* including C. freundii *, and Serratia species* including S. marcescens *. Gynecologic Infections , including endometritis and pelvic cellulitis caused by Escherichia coli, Klebsiella pneumoniae *, Enterobacter species* including E. cloacae *, and Proteus mirabilis *. Aztreonam for injection is indicated for adjunctive therapy to surgery in the management of infections caused by susceptible organisms, including abscesses, infections complicating hollow viscus perforations, cutaneous infections, and infections of serous surfaces. Aztreonam for injection is effective against most of the commonly encountered Gram-negative aerobic pathogens seen in general surgery. uuid:24814d10-636d-4a46-82b1-9e0bd6b63ddc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:161680 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:4bd05720-bd6f-42e2-b356-a101c2260345"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4354c2c5-8dee-4754-ac94-a3380921c083"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of aztreonam for injection, USP and other antibacterial drugs, aztreonam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Aztreonam for Injection is indicated for the treatment of the following infections caused by susceptible Gram-negative microorganisms: Urinary Tract Infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Enterobacter cloacae, Klebsiella oxytoca *, Citrobacter species*, and Serratia marcescens *. Lower Respiratory Tract Infections , including pneumonia and bronchitis caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, and Serratia marcescens *. Septicemia caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis *, Serratia marcescens *, and Enterobacter species. Skin and Skin-Structure Infections , including those associated with postoperative wounds, ulcers, and burns, caused by Escherichia coli, Proteus mirabilis, Serratia marcescens, Enterobacter species, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Citrobacter species*. * Efficacy for this organism in this organ system was studied in fewer than 10 infections. Intra-abdominal Infections , including peritonitis caused by Escherichia coli, Klebsiella species including K. pneumoniae, Enterobacter species including E. cloacae *, Pseudomonas aeruginosa, Citrobacter species* including C. freundii *, and Serratia species* including S. marcescens *. Gynecologic Infections , including endometritis and pelvic cellulitis caused by Escherichia coli, Klebsiella pneumoniae *, Enterobacter species* including E. cloacae *, and Proteus mirabilis *. Aztreonam for injection is indicated for adjunctive therapy to surgery in the management of infections caused by susceptible organisms, including abscesses, infections complicating hollow viscus perforations, cutaneous infections, and infections of serous surfaces. Aztreonam for injection is effective against most of the commonly encountered Gram-negative aerobic pathogens seen in general surgery. uuid:a2029392-e9cb-47cb-bd09-a5dc5aec85cf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:161680 biolink:treats MONDO:0043839 PMID:41385096 "[{""id"":""uuid:f4404fc7-292e-47ec-b863-536d301d223d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d3f1143d-1e88-460c-8428-e918f0077b88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of aztreonam for injection, USP and other antibacterial drugs, aztreonam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Aztreonam for Injection is indicated for the treatment of the following infections caused by susceptible Gram-negative microorganisms: Urinary Tract Infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Enterobacter cloacae, Klebsiella oxytoca *, Citrobacter species*, and Serratia marcescens *. Lower Respiratory Tract Infections , including pneumonia and bronchitis caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, and Serratia marcescens *. Septicemia caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis *, Serratia marcescens *, and Enterobacter species. Skin and Skin-Structure Infections , including those associated with postoperative wounds, ulcers, and burns, caused by Escherichia coli, Proteus mirabilis, Serratia marcescens, Enterobacter species, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Citrobacter species*. * Efficacy for this organism in this organ system was studied in fewer than 10 infections. Intra-abdominal Infections , including peritonitis caused by Escherichia coli, Klebsiella species including K. pneumoniae, Enterobacter species including E. cloacae *, Pseudomonas aeruginosa, Citrobacter species* including C. freundii *, and Serratia species* including S. marcescens *. Gynecologic Infections , including endometritis and pelvic cellulitis caused by Escherichia coli, Klebsiella pneumoniae *, Enterobacter species* including E. cloacae *, and Proteus mirabilis *. Aztreonam for injection is indicated for adjunctive therapy to surgery in the management of infections caused by susceptible organisms, including abscesses, infections complicating hollow viscus perforations, cutaneous infections, and infections of serous surfaces. Aztreonam for injection is effective against most of the commonly encountered Gram-negative aerobic pathogens seen in general surgery. uuid:eeb27d24-6564-49fd-9cca-9334764ee8f6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:161680 biolink:treats UMLS:C1112209 PMID:41385096 "[{""id"":""uuid:ab3db9f7-89e3-47c6-a93f-253d4a37debf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:51d81c85-83ab-4c06-a41a-d8bf989434a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of aztreonam for injection, USP and other antibacterial drugs, aztreonam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Aztreonam for Injection is indicated for the treatment of the following infections caused by susceptible Gram-negative microorganisms: Urinary Tract Infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Enterobacter cloacae, Klebsiella oxytoca *, Citrobacter species*, and Serratia marcescens *. Lower Respiratory Tract Infections , including pneumonia and bronchitis caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, and Serratia marcescens *. Septicemia caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis *, Serratia marcescens *, and Enterobacter species. Skin and Skin-Structure Infections , including those associated with postoperative wounds, ulcers, and burns, caused by Escherichia coli, Proteus mirabilis, Serratia marcescens, Enterobacter species, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Citrobacter species*. * Efficacy for this organism in this organ system was studied in fewer than 10 infections. Intra-abdominal Infections , including peritonitis caused by Escherichia coli, Klebsiella species including K. pneumoniae, Enterobacter species including E. cloacae *, Pseudomonas aeruginosa, Citrobacter species* including C. freundii *, and Serratia species* including S. marcescens *. Gynecologic Infections , including endometritis and pelvic cellulitis caused by Escherichia coli, Klebsiella pneumoniae *, Enterobacter species* including E. cloacae *, and Proteus mirabilis *. Aztreonam for injection is indicated for adjunctive therapy to surgery in the management of infections caused by susceptible organisms, including abscesses, infections complicating hollow viscus perforations, cutaneous infections, and infections of serous surfaces. Aztreonam for injection is effective against most of the commonly encountered Gram-negative aerobic pathogens seen in general surgery. uuid:c3569854-9a4f-413a-b64c-a4a3f0c884ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:161680 biolink:treats MONDO:0004522 PMID:41385096 "[{""id"":""uuid:68e39180-a755-4e93-94e0-b8f143e8bc45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:368c853f-f2af-41e2-be4d-2fc109eb7566"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of aztreonam for injection, USP and other antibacterial drugs, aztreonam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Aztreonam for Injection is indicated for the treatment of the following infections caused by susceptible Gram-negative microorganisms: Urinary Tract Infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Enterobacter cloacae, Klebsiella oxytoca *, Citrobacter species*, and Serratia marcescens *. Lower Respiratory Tract Infections , including pneumonia and bronchitis caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, and Serratia marcescens *. Septicemia caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis *, Serratia marcescens *, and Enterobacter species. Skin and Skin-Structure Infections , including those associated with postoperative wounds, ulcers, and burns, caused by Escherichia coli, Proteus mirabilis, Serratia marcescens, Enterobacter species, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Citrobacter species*. * Efficacy for this organism in this organ system was studied in fewer than 10 infections. Intra-abdominal Infections , including peritonitis caused by Escherichia coli, Klebsiella species including K. pneumoniae, Enterobacter species including E. cloacae *, Pseudomonas aeruginosa, Citrobacter species* including C. freundii *, and Serratia species* including S. marcescens *. Gynecologic Infections , including endometritis and pelvic cellulitis caused by Escherichia coli, Klebsiella pneumoniae *, Enterobacter species* including E. cloacae *, and Proteus mirabilis *. Aztreonam for injection is indicated for adjunctive therapy to surgery in the management of infections caused by susceptible organisms, including abscesses, infections complicating hollow viscus perforations, cutaneous infections, and infections of serous surfaces. Aztreonam for injection is effective against most of the commonly encountered Gram-negative aerobic pathogens seen in general surgery. uuid:d051c44e-fed0-49f5-a4be-775dacab5642 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:161680 biolink:treats MONDO:0000918 PMID:41385096 "[{""id"":""uuid:5985b449-8fa2-4264-9c03-18a8840db6c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b44f8b12-dfc2-4a90-bdaf-8bfe5fc8c233"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of aztreonam for injection, USP and other antibacterial drugs, aztreonam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Aztreonam for Injection is indicated for the treatment of the following infections caused by susceptible Gram-negative microorganisms: Urinary Tract Infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Enterobacter cloacae, Klebsiella oxytoca *, Citrobacter species*, and Serratia marcescens *. Lower Respiratory Tract Infections , including pneumonia and bronchitis caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, and Serratia marcescens *. Septicemia caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis *, Serratia marcescens *, and Enterobacter species. Skin and Skin-Structure Infections , including those associated with postoperative wounds, ulcers, and burns, caused by Escherichia coli, Proteus mirabilis, Serratia marcescens, Enterobacter species, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Citrobacter species*. * Efficacy for this organism in this organ system was studied in fewer than 10 infections. Intra-abdominal Infections , including peritonitis caused by Escherichia coli, Klebsiella species including K. pneumoniae, Enterobacter species including E. cloacae *, Pseudomonas aeruginosa, Citrobacter species* including C. freundii *, and Serratia species* including S. marcescens *. Gynecologic Infections , including endometritis and pelvic cellulitis caused by Escherichia coli, Klebsiella pneumoniae *, Enterobacter species* including E. cloacae *, and Proteus mirabilis *. Aztreonam for injection is indicated for adjunctive therapy to surgery in the management of infections caused by susceptible organisms, including abscesses, infections complicating hollow viscus perforations, cutaneous infections, and infections of serous surfaces. Aztreonam for injection is effective against most of the commonly encountered Gram-negative aerobic pathogens seen in general surgery. uuid:865a5345-d85a-4733-bc8a-b644ca66c8d9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:161680 biolink:treats MONDO:0006887 PMID:41385096 "[{""id"":""uuid:55b433c8-444b-4a97-9f95-ff3a41fd760d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9a4cc9f3-00a0-49e3-894b-0a3803c04ab6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of aztreonam for injection, USP and other antibacterial drugs, aztreonam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Aztreonam for Injection is indicated for the treatment of the following infections caused by susceptible Gram-negative microorganisms: Urinary Tract Infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Enterobacter cloacae, Klebsiella oxytoca *, Citrobacter species*, and Serratia marcescens *. Lower Respiratory Tract Infections , including pneumonia and bronchitis caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, and Serratia marcescens *. Septicemia caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis *, Serratia marcescens *, and Enterobacter species. Skin and Skin-Structure Infections , including those associated with postoperative wounds, ulcers, and burns, caused by Escherichia coli, Proteus mirabilis, Serratia marcescens, Enterobacter species, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Citrobacter species*. * Efficacy for this organism in this organ system was studied in fewer than 10 infections. Intra-abdominal Infections , including peritonitis caused by Escherichia coli, Klebsiella species including K. pneumoniae, Enterobacter species including E. cloacae *, Pseudomonas aeruginosa, Citrobacter species* including C. freundii *, and Serratia species* including S. marcescens *. Gynecologic Infections , including endometritis and pelvic cellulitis caused by Escherichia coli, Klebsiella pneumoniae *, Enterobacter species* including E. cloacae *, and Proteus mirabilis *. Aztreonam for injection is indicated for adjunctive therapy to surgery in the management of infections caused by susceptible organisms, including abscesses, infections complicating hollow viscus perforations, cutaneous infections, and infections of serous surfaces. Aztreonam for injection is effective against most of the commonly encountered Gram-negative aerobic pathogens seen in general surgery. uuid:9631d8d8-b5ed-42a8-85e1-353c9e05049f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:161680 biolink:treats MONDO:0005227 PMID:41385096 "[{""id"":""uuid:fd081db4-825e-4893-a5e3-59ba19cfbc3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a8c0c959-ac6b-4b05-bfe5-9b5e52303392"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of aztreonam for injection, USP and other antibacterial drugs, aztreonam for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Aztreonam for Injection is indicated for the treatment of the following infections caused by susceptible Gram-negative microorganisms: Urinary Tract Infections (complicated and uncomplicated), including pyelonephritis and cystitis (initial and recurrent) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Enterobacter cloacae, Klebsiella oxytoca *, Citrobacter species*, and Serratia marcescens *. Lower Respiratory Tract Infections , including pneumonia and bronchitis caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, and Serratia marcescens *. Septicemia caused by Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Proteus mirabilis *, Serratia marcescens *, and Enterobacter species. Skin and Skin-Structure Infections , including those associated with postoperative wounds, ulcers, and burns, caused by Escherichia coli, Proteus mirabilis, Serratia marcescens, Enterobacter species, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Citrobacter species*. * Efficacy for this organism in this organ system was studied in fewer than 10 infections. Intra-abdominal Infections , including peritonitis caused by Escherichia coli, Klebsiella species including K. pneumoniae, Enterobacter species including E. cloacae *, Pseudomonas aeruginosa, Citrobacter species* including C. freundii *, and Serratia species* including S. marcescens *. Gynecologic Infections , including endometritis and pelvic cellulitis caused by Escherichia coli, Klebsiella pneumoniae *, Enterobacter species* including E. cloacae *, and Proteus mirabilis *. Aztreonam for injection is indicated for adjunctive therapy to surgery in the management of infections caused by susceptible organisms, including abscesses, infections complicating hollow viscus perforations, cutaneous infections, and infections of serous surfaces. Aztreonam for injection is effective against most of the commonly encountered Gram-negative aerobic pathogens seen in general surgery. uuid:fcec5ff9-5071-4378-9ca1-e13718e9298f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:404903 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:3b2df698-4f16-45c1-bfa0-a91b6c866154"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5a358884-fc70-4da9-b322-29f3875dd577"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ertapenem for injection is a penem antibacterial indicated in adult patients and pediatric patients (3 months of age and older) for the treatment of the following moderate to severe infections caused by susceptible bacteria: • Complicated intra-abdominal infections. ( 1.1 ) • Complicated skin and skin structure infections, including diabetic foot infections without osteomyelitis. ( 1.2 ) • Community-acquired pneumonia. ( 1.3 ) • Complicated urinary tract infections including pyelonephritis. ( 1.4 ) • Acute pelvic infections including postpartum endomyometritis, septic abortion and post-surgical gynecologic infections. ( 1.5 ) Ertapenem for injection is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery. ( 1.6 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ertapenem for injection and other antibacterial drugs, Ertapenem for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.7 ) uuid:099528f8-3af8-4ae9-a469-e892abd8f133 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:404903 biolink:treats EFO:1001459 PMID:41385096 "[{""id"":""uuid:012bb2d7-2f2c-4a6d-ae2f-ee720789dc60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:72db4b3e-b745-4f96-9496-0de97edc61ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ertapenem for injection is a penem antibacterial indicated in adult patients and pediatric patients (3 months of age and older) for the treatment of the following moderate to severe infections caused by susceptible bacteria: • Complicated intra-abdominal infections. ( 1.1 ) • Complicated skin and skin structure infections, including diabetic foot infections without osteomyelitis. ( 1.2 ) • Community-acquired pneumonia. ( 1.3 ) • Complicated urinary tract infections including pyelonephritis. ( 1.4 ) • Acute pelvic infections including postpartum endomyometritis, septic abortion and post-surgical gynecologic infections. ( 1.5 ) Ertapenem for injection is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery. ( 1.6 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ertapenem for injection and other antibacterial drugs, Ertapenem for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.7 ) uuid:05f9df7f-5df2-42b8-bf1a-107248c75404 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:404903 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:2f287a6b-36fe-40ab-93ad-b920af6d178c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2e01c47b-6c57-4a11-a3a1-9f1efe737a63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ertapenem for injection is a penem antibacterial indicated in adult patients and pediatric patients (3 months of age and older) for the treatment of the following moderate to severe infections caused by susceptible bacteria: • Complicated intra-abdominal infections. ( 1.1 ) • Complicated skin and skin structure infections, including diabetic foot infections without osteomyelitis. ( 1.2 ) • Community-acquired pneumonia. ( 1.3 ) • Complicated urinary tract infections including pyelonephritis. ( 1.4 ) • Acute pelvic infections including postpartum endomyometritis, septic abortion and post-surgical gynecologic infections. ( 1.5 ) Ertapenem for injection is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery. ( 1.6 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ertapenem for injection and other antibacterial drugs, Ertapenem for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.7 ) uuid:a4452b74-65f7-4f55-a036-79b7559a5cf4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:404903 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:130d94d5-a3b8-4938-9693-fd70c4af3635"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:75f1cf29-e658-4943-94b9-c3a0b8ba2d37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ertapenem for injection is a penem antibacterial indicated in adult patients and pediatric patients (3 months of age and older) for the treatment of the following moderate to severe infections caused by susceptible bacteria: • Complicated intra-abdominal infections. ( 1.1 ) • Complicated skin and skin structure infections, including diabetic foot infections without osteomyelitis. ( 1.2 ) • Community-acquired pneumonia. ( 1.3 ) • Complicated urinary tract infections including pyelonephritis. ( 1.4 ) • Acute pelvic infections including postpartum endomyometritis, septic abortion and post-surgical gynecologic infections. ( 1.5 ) Ertapenem for injection is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery. ( 1.6 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ertapenem for injection and other antibacterial drugs, Ertapenem for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.7 ) uuid:7a6cc8df-f0ba-4bc6-b165-d9de50afb12e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:404903 biolink:treats MONDO:0006939 PMID:41385096 "[{""id"":""uuid:6d845753-f22e-44bd-9d12-02e6b6a7986f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c6c304dc-71a6-4a49-b0da-1fd7f0b59a41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ertapenem for injection is a penem antibacterial indicated in adult patients and pediatric patients (3 months of age and older) for the treatment of the following moderate to severe infections caused by susceptible bacteria: • Complicated intra-abdominal infections. ( 1.1 ) • Complicated skin and skin structure infections, including diabetic foot infections without osteomyelitis. ( 1.2 ) • Community-acquired pneumonia. ( 1.3 ) • Complicated urinary tract infections including pyelonephritis. ( 1.4 ) • Acute pelvic infections including postpartum endomyometritis, septic abortion and post-surgical gynecologic infections. ( 1.5 ) Ertapenem for injection is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery. ( 1.6 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ertapenem for injection and other antibacterial drugs, Ertapenem for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.7 ) uuid:515bd9a3-ef2a-47f9-a78b-31b158bde097 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:404903 biolink:treats MONDO:0000922 PMID:41385096 "[{""id"":""uuid:c3c2c2bd-fd7f-442d-adc2-55da62cee799"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e70f369b-a7d2-40bb-ad0a-fa2b7f20de33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ertapenem for injection is a penem antibacterial indicated in adult patients and pediatric patients (3 months of age and older) for the treatment of the following moderate to severe infections caused by susceptible bacteria: • Complicated intra-abdominal infections. ( 1.1 ) • Complicated skin and skin structure infections, including diabetic foot infections without osteomyelitis. ( 1.2 ) • Community-acquired pneumonia. ( 1.3 ) • Complicated urinary tract infections including pyelonephritis. ( 1.4 ) • Acute pelvic infections including postpartum endomyometritis, septic abortion and post-surgical gynecologic infections. ( 1.5 ) Ertapenem for injection is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery. ( 1.6 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ertapenem for injection and other antibacterial drugs, Ertapenem for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.7 ) uuid:2d7fd1b8-f4af-4b0d-880f-038de00d917e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:404903 biolink:treats MONDO:0042451 PMID:41385096 "[{""id"":""uuid:cb0c794e-28b9-4b57-984e-3828af14a593"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0d380713-67d5-4355-bb54-9a4b0fa96e19"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ertapenem for injection is a penem antibacterial indicated in adult patients and pediatric patients (3 months of age and older) for the treatment of the following moderate to severe infections caused by susceptible bacteria: • Complicated intra-abdominal infections. ( 1.1 ) • Complicated skin and skin structure infections, including diabetic foot infections without osteomyelitis. ( 1.2 ) • Community-acquired pneumonia. ( 1.3 ) • Complicated urinary tract infections including pyelonephritis. ( 1.4 ) • Acute pelvic infections including postpartum endomyometritis, septic abortion and post-surgical gynecologic infections. ( 1.5 ) Ertapenem for injection is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery. ( 1.6 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ertapenem for injection and other antibacterial drugs, Ertapenem for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.7 ) uuid:45841f82-37c9-41ab-a7ef-ced6bfadc951 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:404903 biolink:treats DOID:2910 PMID:41385096 "[{""id"":""uuid:0023213d-233a-413f-870d-da18a8055bf9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e57a71fa-e266-47f1-8862-ca10320f2da7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ertapenem for injection is a penem antibacterial indicated in adult patients and pediatric patients (3 months of age and older) for the treatment of the following moderate to severe infections caused by susceptible bacteria: • Complicated intra-abdominal infections. ( 1.1 ) • Complicated skin and skin structure infections, including diabetic foot infections without osteomyelitis. ( 1.2 ) • Community-acquired pneumonia. ( 1.3 ) • Complicated urinary tract infections including pyelonephritis. ( 1.4 ) • Acute pelvic infections including postpartum endomyometritis, septic abortion and post-surgical gynecologic infections. ( 1.5 ) Ertapenem for injection is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery. ( 1.6 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ertapenem for injection and other antibacterial drugs, Ertapenem for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.7 ) uuid:7e57fbea-0ae7-408b-8189-e8f45561906d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:404903 biolink:treats UMLS:C0038941 PMID:41385096 "[{""id"":""uuid:fcfc4670-e6aa-4475-872a-de778a4e30f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4b305eae-ae2f-4a38-be10-91fdc25e1608"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ertapenem for injection is a penem antibacterial indicated in adult patients and pediatric patients (3 months of age and older) for the treatment of the following moderate to severe infections caused by susceptible bacteria: • Complicated intra-abdominal infections. ( 1.1 ) • Complicated skin and skin structure infections, including diabetic foot infections without osteomyelitis. ( 1.2 ) • Community-acquired pneumonia. ( 1.3 ) • Complicated urinary tract infections including pyelonephritis. ( 1.4 ) • Acute pelvic infections including postpartum endomyometritis, septic abortion and post-surgical gynecologic infections. ( 1.5 ) Ertapenem for injection is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery. ( 1.6 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ertapenem for injection and other antibacterial drugs, Ertapenem for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.7 ) uuid:13753983-90b0-4a0b-8308-284943fa7a3f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27568 biolink:treats UMLS:C0238421 PMID:41385096 "[{""id"":""uuid:2122a2a1-9d6d-41df-8646-c8acd3e118d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3f730a5c-d255-404e-8221-95313b0ab324"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Selenium Injection is indicated for use as a supplement to intravenous solutions given for total parenteral nutrition (TPN). Administration of selenium in TPN solutions helps to maintain plasma selenium levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms. uuid:9f8f984d-8c8a-444b-a301-b81b2520ee6f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1161552 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:3924b135-62e4-453d-92f5-e802867e1574"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f40af98f-4806-451b-bb90-c8fa77d23646"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isosorbide dinitrate and hydralazine hydrochloride tablets are a combination of isosorbide dinitrate, a nitrate vasodilator, and hydralazine hydrochloride, an arteriolar vasodilator, indicated for: the treatment of heart failure as an adjunct therapy to standard therapy in self-identified black patients to improve survival, prolong time to hospitalization for heart failure and to improve patient-reported functional status ( 1.1 ) Limitations of use: There is little experience in patients with NYHA class IV heart failure ( 1.2 ) uuid:f7a69821-3d62-4fb9-9802-64025678964c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231032 biolink:treats MONDO:0004651 PMID:41385096 "[{""id"":""uuid:16be15ce-3c43-452e-865e-52034a989e26"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eaaaaa9f-5c20-4d00-b05f-8028d229ac0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TEMBEXA is an orthopoxvirus nucleotide analog DNA polymerase inhibitor and is indicated for the treatment of human smallpox disease in adult and pediatric patients, including neonates. ( 1.1 ) Limitations of Use: • TEMBEXA is not indicated for the treatment of diseases other than human smallpox disease. ( 1.2 ) • The effectiveness of TEMBEXA for treatment of smallpox disease has not been determined in humans because adequate and well-controlled field trials have not been feasible, and inducing smallpox disease in humans to study the drug’s efficacy is not ethical. ( 1.2 ) • TEMBEXA efficacy may be reduced in immunocompromised patients based on studies in immune deficient animals. ( 1.2 ) uuid:ef1c5651-4f83-4f3d-89b6-cbb8e5bd5db5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64355 biolink:treats MONDO:0005657 PMID:41385096 "[{""id"":""uuid:39a6e552-cede-4729-a5c2-f1bf8bc5c1c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:af8bc7b7-e3a2-45f5-8ed7-9e287189503a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Posaconazole is an azole antifungal indicated as follows: • Posaconazole is indicated for the prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy as follows (1.2) ° Posaconazole delayed-release tablets: Adults and pediatric patients 13 years of age and older. uuid:e5129889-e84f-4c7b-be7e-db55836be8bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64355 biolink:treats MONDO:0002026 PMID:41385096 "[{""id"":""uuid:cb525fa2-8236-49af-b13f-c789d5fd186b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:487f84ef-9354-4b8b-aaec-1f75097304bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Posaconazole is an azole antifungal indicated as follows: • Posaconazole is indicated for the prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy as follows (1.2) ° Posaconazole delayed-release tablets: Adults and pediatric patients 13 years of age and older. uuid:bc666747-0b2a-46bd-aa50-8b0e6aa626d1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64355 biolink:treats MONDO:0013730 PMID:41385096 "[{""id"":""uuid:7bc67e6c-8077-4478-8a3e-64d6e568dc52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:40487fb1-672a-4618-bf45-5ace6279020b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:40339f65-4222-4d9c-9394-4f2bb4893688"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/posaconazole-ahcl""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Posaconazole is an azole antifungal indicated as follows: • Posaconazole is indicated for the prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy as follows (1.2) ° Posaconazole delayed-release tablets: Adults and pediatric patients 13 years of age and older.|[EMA] Noxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in adults (see sections 4.2 and 5.1):- Invasive aspergillosisNoxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections 4.2 and 5.1):- Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;- Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;- Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Noxafil gastro-resistant tablets are also indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections 4.2 and 5.1):- Patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.Please refer to the Summary of Product Characteristics of Noxafil oral suspension for use in oropharyngeal candidiasis. Noxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adults (see sections 4.2 and 5.1):- Invasive aspergillosisNoxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adult and paediatric patients from 2 years of age (see sections 4.2 and 5.1):- Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;- Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;- Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Noxafil concentrate for solution for infusion is also indicated for prophylaxis of invasive fungal infections in the following adult and paediatric patients from 2 years of age (see sections 4.2 and 5.1):- Patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease (GVHD) and who are at high risk of developing invasive fungal infections.Please refer to the Summary of Product Characteristics of Noxafil oral suspension for use in oropharyngeal candidiasis. Noxafil gastro resistant powder and solvent for oral suspension is indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age (see sections 4.2 and 5.1):- Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;- Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;- Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Noxafil gastro-resistant powder and solvent for oral suspension is indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2 years of age:- Patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- Haematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.Please refer to the Summary of Product Characteristics of Noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis.Please refer to the Summary of Product Characteristics of Noxafil oral suspension for use in oropharyngeal candidiasis. Noxafil oral suspension is indicated for use in the treatment of the following fungal infections in adults (see section 5.1):- Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;- Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;- Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products;- Oropharyngeal candidiasis: as first-line therapy in patients who have severe disease or are immunocompromised, in whom response to topical therapy is expected to be poor.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Noxafil oral suspension is also indicated for prophylaxis of invasive fungal infections in the following patients:- Patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.Please refer to the Summary of Product Characteristics of Noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis. uuid:c551ba07-858d-4f41-9b85-d7b50402529a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64355 biolink:treats NCIT:C157387 PMID:41385096 "[{""id"":""uuid:f85cea0f-8624-45a3-a706-21d71ee478ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:106d2900-7a93-4ac5-9698-db9dd92948b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Posaconazole is an azole antifungal indicated as follows: • Posaconazole is indicated for the prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy as follows (1.2) ° Posaconazole delayed-release tablets: Adults and pediatric patients 13 years of age and older. uuid:b8efb881-7149-415b-8c87-9284293d12eb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats MONDO:0006668 PMID:41385096 "[{""id"":""uuid:bb086d0e-9cd0-48b3-944f-5cdeda33bffe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c184b9f3-f359-45fe-bbcf-f0905adcb196"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AzaSite ® is indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following microorganisms: CDC coryneform group G* Haemophilus influenzae Staphylococcus aureus Streptococcus mitis group Streptococcus pneumoniae * Efficacy for this organism was studied in fewer than 10 infections. uuid:04bbcce4-1707-4bde-9cec-988f6ac0f81b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:52717 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:96fb7dfc-c317-4536-8479-d73e8a8b9b77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:144d9cd6-f076-4c35-bb79-53ea78320d1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:bede20c3-9e9f-445d-9392-a95452c0fe42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/bortezomib-hospira""]},{""id"":""uuid:40743ee2-543b-4d3a-815d-0ed0579cebad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bortezomib for injection is a proteasome inhibitor indicated for: treatment of adult patients with multiple myeloma ( 1.1 ) treatment of adult patients with mantle cell lymphoma ( 1.2 )|[EMA] Bortezomib Hospira as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation.Bortezomib Hospira in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.Bortezomib Hospira in combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.Bortezomib Hospira in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.|[PMDA] Drug containing a new active ingredient indicated for treatment of relapsed or refractory multiple myeloma. [Orphan Drug] uuid:048856b2-e99a-44b7-ac40-33161cd80607 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:52717 biolink:treats MONDO:0018876 PMID:41385096 "[{""id"":""uuid:eb852466-f26c-4ee9-ae47-d732eb77500a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3c451731-d7f2-42f3-a71a-06aa95cb2ae9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ad5deb33-d4d6-4740-8a80-440b10b76e2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/bortezomib-hospira""]},{""id"":""uuid:2ea7b38c-6439-41cb-a40b-3c68dc7948ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bortezomib for injection is a proteasome inhibitor indicated for: treatment of adult patients with multiple myeloma ( 1.1 ) treatment of adult patients with mantle cell lymphoma ( 1.2 )|[EMA] Bortezomib Hospira as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for haematopoietic stem cell transplantation.Bortezomib Hospira in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.Bortezomib Hospira in combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with haematopoietic stem cell transplantation.Bortezomib Hospira in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for haematopoietic stem cell transplantation.|[PMDA] A drug with a new additional indication and a new dosage for the treatment of patients with mantle cell lymphoma. [Orphan drug] uuid:7e52aa45-8054-4542-8cf3-60821a815ed6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:53796 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:41644b12-7e97-4bc0-bbe9-e267786ed88a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9109777a-2b6d-417c-8699-c2fd4b8b3db0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CONJUPRI ® is calcium channel blocker and may be used alone or in combination with other antihypertensive agents for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. uuid:928c03ad-d869-47a7-9b5c-8d89f65bf005 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:KE3U2023NP biolink:treats MONDO:0006502 PMID:41385096 "[{""id"":""uuid:93ec23d6-67db-44ed-8b85-667e8f77dc11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fd7c35c2-c819-4539-9f55-8ade4717bfc3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CUROSURF ® (poractant alfa) Intratracheal Suspension is indicated for the rescue treatment of Respiratory Distress Syndrome (RDS) in premature infants. CUROSURF reduces mortality and pneumothoraces associated with RDS. uuid:1796e938-c006-463e-a4f5-adea4d50a334 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:KE3U2023NP biolink:treats HP:0006522 PMID:41385096 "[{""id"":""uuid:ce9631b9-cba0-4398-865d-2749e6b646f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:621f4aee-01af-4b99-b4fa-5d5fe82490ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CUROSURF ® (poractant alfa) Intratracheal Suspension is indicated for the rescue treatment of Respiratory Distress Syndrome (RDS) in premature infants. CUROSURF reduces mortality and pneumothoraces associated with RDS. uuid:fdfd4e01-d733-4025-ab5d-319c5f0b400b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63638 biolink:treats MONDO:0006710 PMID:41385096 "[{""id"":""uuid:d927945f-6118-4dd4-a056-68fff026265c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:36ba1401-89d6-499a-96ee-35c1c59b582a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vigabatrin for oral solution is indicated for the treatment of: Refractory Complex Partial Seizures as adjunctive therapy in patients 2 years of age and older who have responded inadequately to several alternative treatments; vigabatrin for oral solution is not indicated as a first line agent ( 1.1 ) Infantile Spasms - monotherapy in infants 1 month to 2 years of age for whom the potential benefits outweigh the potential risk of vision loss ( 1.2 ) uuid:29673cb0-3c5f-4fad-9af8-542cd35c639b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63638 biolink:treats MONDO:0018097 PMID:41385096 "[{""id"":""uuid:0d575801-849d-48a6-9a8f-48050cad5f1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:95ceb4fd-ba91-48de-8e64-a05eb4e332bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:301e1809-39ec-4cb2-a9d6-9f653f32515f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kigabeq""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vigabatrin for oral solution is indicated for the treatment of: Refractory Complex Partial Seizures as adjunctive therapy in patients 2 years of age and older who have responded inadequately to several alternative treatments; vigabatrin for oral solution is not indicated as a first line agent ( 1.1 ) Infantile Spasms - monotherapy in infants 1 month to 2 years of age for whom the potential benefits outweigh the potential risk of vision loss ( 1.2 )|[EMA] Kigabeq is indicated in infants and children from 1 month to less than 7 years of age for:Treatment in monotherapy of infantile spasms (West's syndrome).Treatment in combination with other antiepileptic medicinal products for patients with resistant partial epilepsy (focal onset seizures) with or without secondary generalisation, that is where all other appropriate medicinal product combinations have proved inadequate or have not been tolerated. uuid:ad56496f-4175-4130-827a-c25cd2331fcc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3654 biolink:treats MONDO:0045048 PMID:41385096 "[{""id"":""uuid:7189de12-b0bf-49d6-aabb-d01c87b5db4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0e680795-4493-473d-9efd-db3cf26ad655"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diuretics such as chlorthalidone are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension. Chlorthalidone is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Chlorthalidone has also been found useful in edema due to various forms of renal dysfunction, such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure.Chlorthalidone has also been found useful in edema due to various forms of renal dysfunction, such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Usage in Pregnancy The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Chlorthalidone is indicated in pregnancy when edema is due to pathologic causes, just as it is in the absence of pregnancy (however, see PRECAUTIONS , below). Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy that is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but that is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort that is not relieved by rest. In these cases, a short course of diuretics may provide relief and be appropriate. uuid:f8eb9625-0b0b-4f6e-adaa-f89c461cadb7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6824 biolink:treats MONDO:0005071 PMID:41385096 "[{""id"":""uuid:cb1aa148-f21d-444e-9e80-a75666e51486"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:69e9e8a4-7045-4a87-8305-6cf7556620c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methenamine mandelate is indicated for the suppression or elimination of bacteriuria associated with pyelonephritis, cystitis, and other chronic urinary tract infections; also those neurologic diseases leading to an infected residual urine. When used as recommended, methenamine mandelate is particularly suitable for long-term therapy because of its safety and because resistance to the nonspecific bactericidal action of formaldehyde does not develop. Pathogens resistant to other antibacterial agents may respond to methenamine mandelate because of the nonspecific effect of formaldehyde formed in an acid urine. Prophylactic Use Rationale: Urine is a good culture medium for many urinary pathogens. Inoculation by a few organisms (relapse or reinfection) may lead to bacteriuria in susceptible individuals. Thus, the rationale of management in recurring urinary tract infection (bacteriuria) is to change the urine from a growth-supporting to a growth-inhibiting medium. There is a growing body of evidence that long-term administration of methenamine mandelate can prevent the recurrence of bacteriuria in patients with chronic pyelonephritis. Therapeutic Use Rationale: Methenamine mandelate helps to sterilize the urine, and in some situations in which underlying pathologic conditions prevent sterilization by any means, it can help to suppress the bacteriuria. Methenamine mandelate should not be used alone for acute infections with parenchymal involvement causing systemic symptoms such as chills and fever. A thorough diagnostic investigation as a part of the overall management of the urinary tract infection should accompany the use of methenamine mandelate. uuid:ea89051f-3371-4f0d-8e1d-95dba244706e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2N4O9L084N biolink:treats HP:0002018 PMID:41385096 "[{""id"":""uuid:8632a143-b2c8-4ce7-b5a4-d4a1b98478fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2d82f882-b7b0-463c-922d-101296718cc6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cesamet capsules are indicated for the treatment of the nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. This restriction is required because a substantial proportion of any group of patients treated with Cesamet can be expected to experience disturbing psychotomimetic reactions not observed with other antiemetic agents. Because of its potential to alter the mental state, Cesamet is intended for use under circumstances that permit close supervision of the patient by a responsible individual particularly during initial use of Cesamet and during dose adjustments. Cesamet contains nabilone, which is controlled in Schedule II of the Controlled Substances Act. Schedule II substances have a high potential for abuse. Prescriptions for Cesamet should be limited to the amount necessary for a single cycle of chemotherapy (i.e., a few days). Cesamet capsules are not intended to be used on as needed basis or as a first antiemetic product prescribed for a patient. As with all controlled drugs, prescribers should monitor patients receiving nabilone for signs of excessive use, abuse and misuse. Patients who may be at increased risk for substance abuse include those with a personal or family history of substance abuse (including drug or alcohol abuse) or mental illness. uuid:30e69a8a-1714-4963-b7fd-680af5141d51 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2N4O9L084N biolink:treats HP:0002013 PMID:41385096 "[{""id"":""uuid:742e5635-c0b2-40bb-908f-a18146a093ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a35c414e-b617-4c8b-a741-cc7d2ebeb6eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cesamet capsules are indicated for the treatment of the nausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments. This restriction is required because a substantial proportion of any group of patients treated with Cesamet can be expected to experience disturbing psychotomimetic reactions not observed with other antiemetic agents. Because of its potential to alter the mental state, Cesamet is intended for use under circumstances that permit close supervision of the patient by a responsible individual particularly during initial use of Cesamet and during dose adjustments. Cesamet contains nabilone, which is controlled in Schedule II of the Controlled Substances Act. Schedule II substances have a high potential for abuse. Prescriptions for Cesamet should be limited to the amount necessary for a single cycle of chemotherapy (i.e., a few days). Cesamet capsules are not intended to be used on as needed basis or as a first antiemetic product prescribed for a patient. As with all controlled drugs, prescribers should monitor patients receiving nabilone for signs of excessive use, abuse and misuse. Patients who may be at increased risk for substance abuse include those with a personal or family history of substance abuse (including drug or alcohol abuse) or mental illness. uuid:dde6e136-9fef-491b-bf4c-76847c0be7ca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63616 biolink:treats MONDO:0005112 PMID:41385096 "[{""id"":""uuid:674d625d-e809-4214-b90a-3f38ae66032c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b25c3807-a0c5-44dd-b47b-69e3939a07e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e0b679a5-2311-4799-b104-22370974a956"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pemetrexed for injection, USP is a folate analog metabolic inhibitor indicated: in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-squamous NSCLC, with no EGFR or ALK genomic tumor aberrations. ( 1.1 ) in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous, non-small cell lung cancer (NSCLC). ( 1.1 ) as a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. ( 1.1 ) as a single agent for the treatment of patients with recurrent, metastatic non-squamous, NSCLC after prior chemotherapy. ( 1.1 ) Limitations of Use : Pemetrexed for injection, USP is not indicated for the treatment of patients with squamous cell, non-small cell lung cancer. ( 1.1 ) initial treatment, in combination with cisplatin, of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery. ( 1.2 )|[EMA] Malignant pleural mesotheliomaPemetrexed Accord in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.Non-small cell lung cancerPemetrexed Accord in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.Pemetrexed Accord is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.Pemetrexed Accord is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. uuid:60909803-45f5-449a-9f55-291bb2b3eebe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:N6OU7HJ70P biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:ed359453-af30-45bf-b074-de2ddfbb90d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:75b52a9d-ebc1-4dfb-9d67-27cd60486926"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Myocardial Imaging: Kit for the Preparation of Technetium Tc99m Sestamibi Injection is a myocardial perfusion agent that is indicated for detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects), in evaluating myocardial function and developing information for use in patient management decisions. Technetium Tc99m Sestamibi evaluation of myocardial ischemia can be accomplished with rest and cardiovascular stress techniques (e.g., exercise or pharmacologic stress in accordance with the pharmacologic stress agent's labeling). It is usually not possible to determine the age of a myocardial infarction or to differentiate a recent myocardial infarction from ischemia. Breast Imaging: Kit for the Preparation of Technetium Tc99m Sestamibi Injection is indicated for planar imaging as a second line diagnostic drug after mammography to assist in the evaluation of breast lesions in patients with an abnormal mammogram or a palpable breast mass. Kit for the Preparation of Technetium Tc99m Sestamibi Injection is not indicated for breast cancer screening, to confirm the presence or absence of malignancy, and it is not an alternative to biopsy. uuid:2bdfa57b-8cab-4be0-8ca3-a1622c112426 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:N6OU7HJ70P biolink:treats MONDO:0024644 PMID:41385096 "[{""id"":""uuid:4199819b-5876-418a-b671-219de53ba2d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d801d691-d9f9-4b02-8b05-5ee6efbbd023"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Myocardial Imaging: Kit for the Preparation of Technetium Tc99m Sestamibi Injection is a myocardial perfusion agent that is indicated for detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects), in evaluating myocardial function and developing information for use in patient management decisions. Technetium Tc99m Sestamibi evaluation of myocardial ischemia can be accomplished with rest and cardiovascular stress techniques (e.g., exercise or pharmacologic stress in accordance with the pharmacologic stress agent's labeling). It is usually not possible to determine the age of a myocardial infarction or to differentiate a recent myocardial infarction from ischemia. Breast Imaging: Kit for the Preparation of Technetium Tc99m Sestamibi Injection is indicated for planar imaging as a second line diagnostic drug after mammography to assist in the evaluation of breast lesions in patients with an abnormal mammogram or a palpable breast mass. Kit for the Preparation of Technetium Tc99m Sestamibi Injection is not indicated for breast cancer screening, to confirm the presence or absence of malignancy, and it is not an alternative to biopsy. uuid:4a912f81-f22c-4605-b146-5e0edbb46e65 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:N6OU7HJ70P biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:40e38e91-5791-4bd9-848b-2b5ac15b3c69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a33ae933-5ba1-437e-815e-f898b90aa9be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Myocardial Imaging: Kit for the Preparation of Technetium Tc99m Sestamibi Injection is a myocardial perfusion agent that is indicated for detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects), in evaluating myocardial function and developing information for use in patient management decisions. Technetium Tc99m Sestamibi evaluation of myocardial ischemia can be accomplished with rest and cardiovascular stress techniques (e.g., exercise or pharmacologic stress in accordance with the pharmacologic stress agent's labeling). It is usually not possible to determine the age of a myocardial infarction or to differentiate a recent myocardial infarction from ischemia. Breast Imaging: Kit for the Preparation of Technetium Tc99m Sestamibi Injection is indicated for planar imaging as a second line diagnostic drug after mammography to assist in the evaluation of breast lesions in patients with an abnormal mammogram or a palpable breast mass. Kit for the Preparation of Technetium Tc99m Sestamibi Injection is not indicated for breast cancer screening, to confirm the presence or absence of malignancy, and it is not an alternative to biopsy. uuid:6efda07f-33e8-4be6-bb53-b49ffd04ad8a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:N6OU7HJ70P biolink:treats NCIT:C159594 PMID:41385096 "[{""id"":""uuid:4ac626db-2cb4-4a42-975a-22c82f31a19d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6838531c-1989-4b1a-bf86-a25127525e0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Myocardial Imaging: Kit for the Preparation of Technetium Tc99m Sestamibi Injection is a myocardial perfusion agent that is indicated for detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects), in evaluating myocardial function and developing information for use in patient management decisions. Technetium Tc99m Sestamibi evaluation of myocardial ischemia can be accomplished with rest and cardiovascular stress techniques (e.g., exercise or pharmacologic stress in accordance with the pharmacologic stress agent's labeling). It is usually not possible to determine the age of a myocardial infarction or to differentiate a recent myocardial infarction from ischemia. Breast Imaging: Kit for the Preparation of Technetium Tc99m Sestamibi Injection is indicated for planar imaging as a second line diagnostic drug after mammography to assist in the evaluation of breast lesions in patients with an abnormal mammogram or a palpable breast mass. Kit for the Preparation of Technetium Tc99m Sestamibi Injection is not indicated for breast cancer screening, to confirm the presence or absence of malignancy, and it is not an alternative to biopsy. uuid:f49cb8d9-b2f6-4643-922f-22398e2959e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:N6OU7HJ70P biolink:treats MONDO:0002657 PMID:41385096 "[{""id"":""uuid:e5994cad-6636-4243-9d0b-83e361f814f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:68af7f57-c770-4406-859d-d8b9061e5387"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Myocardial Imaging: Kit for the Preparation of Technetium Tc99m Sestamibi Injection is a myocardial perfusion agent that is indicated for detecting coronary artery disease by localizing myocardial ischemia (reversible defects) and infarction (non-reversible defects), in evaluating myocardial function and developing information for use in patient management decisions. Technetium Tc99m Sestamibi evaluation of myocardial ischemia can be accomplished with rest and cardiovascular stress techniques (e.g., exercise or pharmacologic stress in accordance with the pharmacologic stress agent's labeling). It is usually not possible to determine the age of a myocardial infarction or to differentiate a recent myocardial infarction from ischemia. Breast Imaging: Kit for the Preparation of Technetium Tc99m Sestamibi Injection is indicated for planar imaging as a second line diagnostic drug after mammography to assist in the evaluation of breast lesions in patients with an abnormal mammogram or a palpable breast mass. Kit for the Preparation of Technetium Tc99m Sestamibi Injection is not indicated for breast cancer screening, to confirm the presence or absence of malignancy, and it is not an alternative to biopsy. uuid:6a68438a-360b-46d8-a419-14a71412d7d7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:49821151 biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:63b2cf5a-9690-4267-88a4-16e55abd6e55"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:70965c31-bc88-471b-bff3-b3b53a380873"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Arformoterol tartrate inhalation solution is a long-acting beta 2 -adrenergic agonist (beta 2 -agonist) indicated for: Long-term, twice daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. (1.1) Important limitations of use: Arformoterol tartrate inhalation solution is not indicated to treat acute deteriorations of chronic obstructive pulmonary disease. (1.2, 5.2) Arformoterol tartrate inhalation solution is not indicated to treat asthma. (1.2) uuid:6fa18353-5eab-4529-8124-68c41fc25250 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:49821151 biolink:treats MONDO:0005607 PMID:41385096 "[{""id"":""uuid:47cf28dc-4017-4cf0-b810-fbd9af8c0bf1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0ca8e1ce-820f-47a2-aa7c-93240f632b38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Arformoterol tartrate inhalation solution is a long-acting beta 2 -adrenergic agonist (beta 2 -agonist) indicated for: Long-term, twice daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. (1.1) Important limitations of use: Arformoterol tartrate inhalation solution is not indicated to treat acute deteriorations of chronic obstructive pulmonary disease. (1.2, 5.2) Arformoterol tartrate inhalation solution is not indicated to treat asthma. (1.2) uuid:9351aef2-8d3d-486d-9340-a43d7e112fd3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:49821151 biolink:treats MONDO:0004849 PMID:41385096 "[{""id"":""uuid:53410965-38e2-43ca-82ac-17675779f483"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f11f19a4-82d0-4015-9661-c6cb08cfc6d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Arformoterol tartrate inhalation solution is a long-acting beta 2 -adrenergic agonist (beta 2 -agonist) indicated for: Long-term, twice daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. (1.1) Important limitations of use: Arformoterol tartrate inhalation solution is not indicated to treat acute deteriorations of chronic obstructive pulmonary disease. (1.2, 5.2) Arformoterol tartrate inhalation solution is not indicated to treat asthma. (1.2) uuid:29a1c47f-ae96-4a3c-ab7a-1f62b4f8a0db biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:34385 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:c3e1d944-4617-429c-bb45-9c82bb9d4863"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0b551ee7-e608-4084-b7c9-a367945b1428"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:79a98fdb-7309-429b-938b-b8bc2dddf92b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/fampridine-accord""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dalfampridine extended-release tablets are indicated as a treatment to improve walking in adult patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed [see Clinical Studies (14) ].|[EMA] Fampridine Accord is indicated for the improvement of walking in adult patients with multiple sclerosis with walking disability (EDSS 4-7). uuid:4a09a061-962b-4dbf-8b6c-0c2687f5b43b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3504 biolink:treats MONDO:0005227 PMID:41385096 "[{""id"":""uuid:c74ec560-255f-4107-8c74-2096ae68ed52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1bbfcd33-df2b-4a68-ba47-43fb83037bbe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefpodoxime proxetil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Recommended dosages, durations of therapy, and applicable patient populations vary among these infections. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute otitis media caused by Streptococcus pneumoniae (excluding penicillin-resistant strains), Streptococcus pyogenes , Haemophilus influenzae (including beta-lactamase-producing strains), or Moraxella (Branhamella) catarrhalis (including beta-lactamase-producing strains). Pharyngitis and/or tonsillitis caused by Streptococcus pyogenes . NOTE: Only penicillin by the intramuscular route of administration has been shown to be effective in the prophylaxis of rheumatic fever. Cefpodoxime proxetil is generally effective in the eradication of streptococci from the oropharynx. However, data establishing the efficacy of cefpodoxime proxetil for the prophylaxis of subsequent rheumatic fever are not available. Community-acquired pneumonia caused by S. pneumoniae or H. Influenzae (including beta-lactamase-producing strains). Acute bacterial exacerbation of chronic bronchitis caused by S. pneumoniae , H. influenzae (non-beta-lactamase-producing strains only), or M. catarrhalis . Data are insufficient at this time to establish efficacy in patients with acute bacterial exacerbations of chronic bronchitis caused by beta-lactamase-producing strains of H. influenzae . Acute, uncomplicated urethral and cervical gonorrhea caused by Neisseria gonorrhoeae (including penicillinase-producing strains). Acute, uncomplicated ano-rectal infections in women due to Neisseria gonorrhoeae (including penicillinase-producing strains). NOTE: The efficacy of cefpodoxime in treating male patients with rectal infections caused by N. gonorrhoeae has not been established. Data do not support the use of cefpodoxime proxetil in the treatment of pharyngeal infections due to N. gonorrhoeae in men or women. Uncomplicated skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains) or Streptococcus pyogenes . Abscesses should be surgically drained as clinically indicated. NOTE: In clinical trials, successful treatment of uncomplicated skin and skin structure infections was dose-related. The effective therapeutic dose for skin infections was higher than those used in other recommended indications. (See DOSAGE AND ADMINISTRATION .) Acute maxillary sinusitis caused by Haemophilus influenzae (including beta-lactamase-producing strains), Streptococcus pneumoniae , and Moraxella catarrhalis . Uncomplicated urinary tract infections (cystitis) caused by Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis , or Staphylococcus saprophyticus . NOTE: In considering the use of cefpodoxime proxetil in the treatment of cystitis, cefpodoxime proxetil’s lower bacterial eradication rates should be weighed against the increased eradication rates and different safety profiles of some other classes of approved agents. (See CLINICAL STUDIES section.) Appropriate specimens for bacteriological examination should be obtained in order to isolate and identify causative organisms and to determine their susceptibility to cefpodoxime. Therapy may be instituted while awaiting the results of these studies. Once these results become available, antimicrobial therapy should be adjusted accordingly. To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefpodoxime proxetil and other antibacterial drugs, cefpodoxime proxetil should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:b0d7c7c8-195b-41db-8228-efaf76cff095 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0008109 PMID:41385096 "[{""id"":""uuid:888c65c0-65fd-4bb8-bd87-3c2db58dc91d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ee2e9597-5eed-4e94-8dc8-10d585e02351"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic states Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic diseases For the palliative management of leukemias and lymphomas. Nervous system Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:219662c2-bd7c-4684-a92a-a42b755542d7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17594 biolink:treats HP:0001003 PMID:41385096 "[{""id"":""uuid:0f5411f0-b366-437b-afc2-5e52ac0735b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:513aea3c-706b-432e-ba6f-f852d84f3f9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE 1.1Indication BLEMISH ERASER is a combination of hydrocortisone (a corticosteroid), hydroquinone (a melanin synthesis inhibitor), and a tretinoin (a retinoid) that is indicated for the gradual bleaching of hyperpigmented skin conditions age and liver spots, freckles, and other unwanted areas of melanin hyperpigmentation, in the presence of measures for sun avoidance, including the use of sunscreen. 1.2 Limitations of Use The safety and efficacy of BLEMISH ERASER in pregnant women and nursing mothers have not been established. uuid:b27336cf-776a-4eab-b906-3db79180b071 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16199 biolink:treats MONDO:0021036 PMID:41385096 "[{""id"":""uuid:4a14c6dd-14bf-492f-ae7f-459638b75ec2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4aebb6af-e4f9-4e1f-8630-ec64b1ef6076"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For debridement and promotion of normal healing of hyperkeratotic surface lesions, particularly where healing is retarded by local infection, necrotic tissue, fibrinous or purulent debris or eshar. Urea is useful for the treatment of hyperkeratotic conditions such as dry, rough skin, dermatitis, psoriasis, xerosis, ichthyosis, eczema, keratosis pilaris, keratosis palmaris, keratoderma, corns and calluses, as well as damaged, ingrown and devitalized nails. uuid:97d947c7-bb95-43cf-a6f4-16cc75bf992d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16199 biolink:treats UMLS:C0856543 PMID:41385096 "[{""id"":""uuid:f558f05b-f095-4b1f-9830-848af16669ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4621e60c-7504-4fc8-9895-dd6548fe4d2b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For debridement and promotion of normal healing of hyperkeratotic surface lesions, particularly where healing is retarded by local infection, necrotic tissue, fibrinous or purulent debris or eshar. Urea is useful for the treatment of hyperkeratotic conditions such as dry, rough skin, dermatitis, psoriasis, xerosis, ichthyosis, eczema, keratosis pilaris, keratosis palmaris, keratoderma, corns and calluses, as well as damaged, ingrown and devitalized nails. uuid:8c8c84b2-815c-40ba-a869-63eec5afbe00 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50378 biolink:treats MONDO:0004741 PMID:41385096 "[{""id"":""uuid:ebd04c22-ffda-4243-87e8-d0ac303ccbc0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9ee6f480-64d0-4224-889a-305ad4d53beb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ORFADIN ® is indicated for the treatment of adult and pediatric patients with hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine. uuid:fa7b2290-4c12-4c9c-a4f4-98cb3d99c13d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:92511 biolink:treats MONDO:0001384 PMID:41385096 "[{""id"":""uuid:23e11680-9c68-41f4-8901-e9e766b70238"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3941be2c-c16b-49f2-818c-804041383bd1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ACUVUE ® Theravision™ with Ketotifen is a daily wear, daily disposable etafilcon A drug-eluting contact lens for prevention ocular itch due to allergic conjunctivitis and correction of refractive ametropia (myopia and hyperopia) in aphakic and/or phakic patients who do not have red eye(s), are suitable for contact lens wear and do not have more than 1 D of astigmatism. The lens contains an H 1 histamine receptor antagonist for the prevention of ocular itch due to allergic conjunctivitis. The prevention of itch has been demonstrated to last through 12 hours in clinical trials; however, the lens may be worn for longer than 12 hours in a single day. uuid:bef58682-580e-4760-8aad-c3034f5e37b4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:92511 biolink:treats MONDO:0004891 PMID:41385096 "[{""id"":""uuid:cab7a9e0-9a95-46ad-9662-f781c9653e5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d23eaf16-8a93-4afa-a14d-0bc62a41122d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ACUVUE ® Theravision™ with Ketotifen is a daily wear, daily disposable etafilcon A drug-eluting contact lens for prevention ocular itch due to allergic conjunctivitis and correction of refractive ametropia (myopia and hyperopia) in aphakic and/or phakic patients who do not have red eye(s), are suitable for contact lens wear and do not have more than 1 D of astigmatism. The lens contains an H 1 histamine receptor antagonist for the prevention of ocular itch due to allergic conjunctivitis. The prevention of itch has been demonstrated to last through 12 hours in clinical trials; however, the lens may be worn for longer than 12 hours in a single day. uuid:266ae299-4949-4d0a-aa2f-2cd59f8d50a3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59594 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:af26ca66-45e5-4292-b613-2b5131ba19db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:56d7578c-7d20-4335-a5f6-081aac7e1c53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] WELCHOL is a bile acid sequestrant indicated as an adjunct to diet and exercise to: reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia ( 1.1 ). reduce LDL-C levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH), unable to reach LDL-C target levels despite an adequate trial of diet and lifestyle modification ( 1.1 ). improve glycemic control in adults with type 2 diabetes mellitus ( 1.2 ). Limitations of Use ( 1.3 ): Do not use for treatment of type 1 diabetes or for diabetic ketoacidosis. Not studied in Fredrickson Type I, III, IV, and V dyslipidemias uuid:9804461a-3278-410e-a4a9-6b24167e7294 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:308714 biolink:treats MONDO:0005982 PMID:41385096 "[{""id"":""uuid:4ca114b8-486d-4743-8e8a-2916cbdae4e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1b35e00d-fc6f-4c4e-9102-7bae0e284448"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clotrimazole and Betamethasone Dipropionate Cream is indicated in patients 17 years and older for the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris and tinea corporis due to Epidermophyton floccosum , Trichophyton mentagrophytes , and Trichophyton rubrum . Effective treatment without the risks associated with topical corticosteroid use may be obtained using a topical antifungal agent that does not contain a corticosteroid, especially for noninflammatory tinea infections. The efficacy of clotrimazole and betamethasone dipropionate cream for the treatment of infections caused by zoophilic dermatophytes (e.g., Microsporum canis ) has not been established. Several cases of treatment failure of clotrimazole and betamethasone dipropionate cream in the treatment of infections caused by Microsporum canis have been reported uuid:f3f2b7a4-531c-4e4b-a8b6-61fcd5e8fdd5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28939 biolink:treats MONDO:0018741 PMID:41385096 "[{""id"":""uuid:4332da21-3f19-4603-84c3-f40e8621e42c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9651fdb1-1668-43ce-9391-f1ae3e5e66a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acetylcysteine Injection is indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in patients with acute ingestion or from repeated supratherapeutic ingestion (RSI). uuid:fc628291-9f85-4931-b481-24abb9572c54 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28939 biolink:treats UMLS:C0160390 PMID:41385096 "[{""id"":""uuid:f399132c-1144-42cd-af9f-520135117c46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:47540908-01da-4355-bdb3-af3d4a96cee1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acetylcysteine Injection is indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen in patients with acute ingestion or from repeated supratherapeutic ingestion (RSI). uuid:5ed482d1-24ab-4c05-8194-712c25db150d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17252 biolink:treats MONDO:0006003 PMID:41385096 "[{""id"":""uuid:24e494cb-7f35-45fd-bd8f-32a90e941e2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fe55cb45-2186-4f1d-9313-3013c8cc4b95"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydroxyprogesterone Caproate Injection, USP is indicated in non-pregnant women: for the treatment of advanced adenocarcinoma of the uterine corpus (Stage III or IV); in the management of amenorrhea (primary and secondary) and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer; as a test for endogenous estrogen production and for the production of secretory endometrium and desquamation. uuid:20ddc659-7d75-4ea2-bac3-f3c5622cda93 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17252 biolink:treats MONDO:0001836 PMID:41385096 "[{""id"":""uuid:132ac0ec-1d95-4180-bd5b-be0c5a3338dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9b33d6ef-9d8f-4f53-a454-e89a3fac8212"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydroxyprogesterone Caproate Injection, USP is indicated in non-pregnant women: for the treatment of advanced adenocarcinoma of the uterine corpus (Stage III or IV); in the management of amenorrhea (primary and secondary) and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer; as a test for endogenous estrogen production and for the production of secretory endometrium and desquamation. uuid:7855202c-7b5a-476b-8293-1ade010fd0df biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17252 biolink:treats UMLS:C3650625 PMID:41385096 "[{""id"":""uuid:fedf0356-f9d5-4eab-9fa1-f9006bf04a0c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4180b1c8-0841-4898-9bfc-ab52f811cbcc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydroxyprogesterone Caproate Injection, USP is indicated in non-pregnant women: for the treatment of advanced adenocarcinoma of the uterine corpus (Stage III or IV); in the management of amenorrhea (primary and secondary) and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer; as a test for endogenous estrogen production and for the production of secretory endometrium and desquamation. uuid:2d8a25a2-8d44-46f7-90d1-ad46e649c91e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17252 biolink:treats MONDO:0002715 PMID:41385096 "[{""id"":""uuid:375961b7-5753-4aad-b343-3e679e4a8dfd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a9e01e2f-cd1a-4255-b950-b76ed884f9ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydroxyprogesterone Caproate Injection, USP is indicated in non-pregnant women: for the treatment of advanced adenocarcinoma of the uterine corpus (Stage III or IV); in the management of amenorrhea (primary and secondary) and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer; as a test for endogenous estrogen production and for the production of secretory endometrium and desquamation. uuid:7e33593f-5497-4b29-9bb8-bcc0b2f10403 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C517983 biolink:treats EFO:0010581 PMID:41385096 "[{""id"":""uuid:f3364b01-888d-44b3-b8fa-5e25b70fdd51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:57c1689a-06a2-451b-9a1b-d04df380eb9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DuoDote is indicated for the treatment of poisoning by organophosphorus nerve agents as well as organophosphorus insecticides in adults and pediatric patients weighing more than 41 kg (90 pounds). uuid:4a05033e-b61e-4cfe-977a-80c6a6c56e9e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3757 biolink:treats UMLS:C0278140 PMID:41385096 "[{""id"":""uuid:57cfa003-23ed-43aa-8a4e-8a951ea4ec96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4ccfd7df-9a52-46b8-b536-044387e2f50d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clonidine Hydrochloride Injection, USP is indicated in combination with opiates for the treatment of severe pain in cancer patients that is not adequately relieved by opioid analgesics alone. Epidural clonidine is more likely to be effective in patients with neuropathic pain than somatic or visceral pain (see CLINICAL PHARMACOLOGY: Clinical Trials ). The safety of this drug product has only been established in a highly selected group of cancer patients, and only after an adequate trial of opioid analgesia. Other use is of unproven safety and is not recommended. In a rare patient, the potential benefits may outweigh the known risks (see WARNINGS ). uuid:6d75df00-9f8a-4c55-9427-307d2e60f59a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6472 biolink:treats MONDO:0005113 PMID:41385096 "[{""id"":""uuid:e7fd05b4-4b6f-4e88-b83a-70e1ed78c03e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:248b940a-f4ed-44c2-99aa-bd47aa90cd1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lincomycin injection is indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of CDAD, as described in the BOXED WARNING , before selecting lincomycin the physician should consider the nature of the infection and the suitability of other alternatives. Indicated surgical procedures should be performed in conjunction with antibacterial therapy. Lincomycin injection may be administered concomitantly with other antimicrobial agents when indicated. Lincomycin is not indicated in the treatment of minor bacterial infections or viral infections. To reduce the development of drug-resistant bacteria and maintain the effectiveness of lincomycin and other antibacterial drugs, lincomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:67ec79bf-8d9a-40db-a5c0-b3fcfb7960ad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6472 biolink:treats MONDO:0005108 PMID:41385096 "[{""id"":""uuid:3b59cf76-6e77-41b0-9107-e96006eafcfb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:def87ca7-7a72-4fbe-b470-f0453e6cb89d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lincomycin injection is indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of CDAD, as described in the BOXED WARNING , before selecting lincomycin the physician should consider the nature of the infection and the suitability of other alternatives. Indicated surgical procedures should be performed in conjunction with antibacterial therapy. Lincomycin injection may be administered concomitantly with other antimicrobial agents when indicated. Lincomycin is not indicated in the treatment of minor bacterial infections or viral infections. To reduce the development of drug-resistant bacteria and maintain the effectiveness of lincomycin and other antibacterial drugs, lincomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:e4187e21-184b-4e4e-9a2e-7a7b4efa86d7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9887103 biolink:treats MONDO:0006497 PMID:41385096 "[{""id"":""uuid:3d3a0576-904b-45a5-b42b-4fee08103465"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eef3c56f-30ca-4890-901e-8c9c621513b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Glycopyrrolate oral solution is indicated to reduce chronic severe drooling in patients aged 3 to 16 years with neurologic conditions associated with problem drooling (e.g., cerebral palsy). uuid:d05deb52-6172-4269-bb21-97014b44c7b1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9887103 biolink:treats HP:0002307 PMID:41385096 "[{""id"":""uuid:7788fdce-cb73-43e3-8a96-ee587494b072"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1b5404aa-5598-4e8f-aac8-01a6576ef8e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Glycopyrrolate oral solution is indicated to reduce chronic severe drooling in patients aged 3 to 16 years with neurologic conditions associated with problem drooling (e.g., cerebral palsy). uuid:98a27e19-11aa-4b2f-94ce-9b233388e895 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63616 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:925b651e-07ad-4f9e-a121-9f92ab214b6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b4ac5b58-6f7e-4d76-809c-faf850abcde4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:328fc8e5-0d45-4556-8804-11776373ff7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:82ca7020-5dda-4ec7-a0a9-eeac21c6cdb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pemetrexed Injection is a folate analog metabolic inhibitor indicated: In combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous, non-small cell lung cancer (NSCLC). ( 1.1 ) As a single agent for the maintenance treatment of patients with locally advanced or metastatic, non -squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. ( 1.1 ) As a single agent for the treatment of patients with recurrent, metastatic non-squamous, NSCLC after prior chemotherapy. ( 1.1 ) Limitations of Use : Pemetrexed Injection is not indicated for the treatment of patients with squamous cell, non-small cell lung cancer. ( 1.1 ) Initial treatment, in combination with cisplatin, of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery. ( 1.2 )|[EMA] Malignant pleural mesotheliomaPemetrexed Accord in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.Non-small cell lung cancerPemetrexed Accord in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.Pemetrexed Accord is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.Pemetrexed Accord is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology.|[PMDA] Drugs with a new additional indication and a new dosage in an additional dosage form (Alimta Injection 100 mg) indicated for the treatment of unresectable advanced or recurrent non-small cell lung cancer. uuid:0dc051eb-068e-4435-9115-9f90f38a7fc7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77776 biolink:treats MONDO:0005984 PMID:41385096 "[{""id"":""uuid:5c13a293-573b-4afe-aad9-e13214a239bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:42dfac9e-b3c4-4b1b-ac38-97de27d9b180"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EXELDERM (sulconazole nitrate, USP) CREAM, 1.0% is an antifungal agent indicated for the treatment of tinea pedis (athlete's foot), tinea cruris, and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagro-phytes, Epidermophyton floccosum, and Microsporum canis,* and for the treatment of tinea versicolor. *Efficacy for this organism in the organ system was studied in fewer than ten infections. uuid:50c97855-1390-4f41-9bec-82a175d92c5f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50223 biolink:treats UMLS:C0278488 PMID:41385096 "[{""id"":""uuid:4c6c54cc-83da-4ca6-98d7-34987d8f6aa3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1b1d3b9b-39d2-4002-ab27-d6d246a71904"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dexrazoxane for injection is indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m 2 and who will continue to receive doxorubicin therapy to maintain tumor control. Do not use with the initiation of doxorubicin therapy [see Warnings and Precautions (5.2) ] . uuid:8de8c781-0e13-4444-9903-424aa0852db3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50223 biolink:treats MONDO:0004994 PMID:41385096 "[{""id"":""uuid:66bb988d-fa47-40a3-b2d3-798c2f2e6a0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b1aa43c5-a663-44ff-a7b9-161a495e98c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dexrazoxane for injection is indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m 2 and who will continue to receive doxorubicin therapy to maintain tumor control. Do not use with the initiation of doxorubicin therapy [see Warnings and Precautions (5.2) ] . uuid:324893c7-575f-4ed1-ac05-6d73ab5c8906 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28001 biolink:treats UMLS:C0340359 PMID:41385096 "[{""id"":""uuid:af933881-0384-4c23-8728-408da76f075b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:995856b6-2be2-4b62-aa98-251650cdb224"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vancomycin hydrochloride for injection, USP is indicated for the treatment of serious or severe infections caused by susceptible strains of methicillin-resistant (β-lactam-resistant) staphylococci. It is indicated for penicillin-allergic patients, for patients who cannot receive or who have failed to respond to other drugs, including the penicillins or cephalosporins, and for infections caused by vancomycin-susceptible organisms that are resistant to other antimicrobial drugs. Vancomycin hydrochloride for injection, USP is indicated for initial therapy when methicillin-resistant staphylococci are suspected, but after susceptibility data are available, therapy should be adjusted accordingly. Vancomycin hydrochloride for injection, USP is effective in the treatment of staphylococcal endocarditis. Its effectiveness has been documented in other infections due to staphylococci, including septicemia, bone infections, lower respiratory tract infections, and skin and skin-structure infections. When staphylococcal infections are localized and purulent, antibiotics are used as adjuncts to appropriate surgical measures. Vancomycin hydrochloride for injection, USP has been reported to be effective alone or in combination with an aminoglycoside for endocarditis caused by S. viridans or S. bovis . For endocarditis caused by enterococci (e.g., E. faecalis ), vancomycin hydrochloride for injection, USP has been reported to be effective only in combination with an aminoglycoside. Vancomycin hydrochloride for injection, USP has been reported to be effective for the treatment of diphtheroid endocarditis. Vancomycin hydrochloride for injection, USP has been used successfully in combination with either rifampin, an aminoglycoside, or both in early-onset prosthetic valve endocarditis caused by S. epidermidis or diphtheroids. Specimens for bacteriologic cultures should be obtained in order to isolate and identify causative organisms and to determine their susceptibilities to vancomycin. To reduce the development of drug-resistant bacteria and maintain the effectiveness of vancomycin hydrochloride for injection, USP and other antibacterial drugs, vancomycin hydrochloride for injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. The parenteral form of vancomycin hydrochloride may be administered orally for treatment of antibiotic-associated pseudomembranous colitis produced by C. difficile and for staphylococcal enterocolitis. Parenteral administration of vancomycin hydrochloride alone is of unproven benefit for these indications. Vancomycin is not effective by the oral route for other types of infections. uuid:d92eed83-f3dc-4685-9b8f-6db72a314fec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:216653 biolink:treats HP:0000505 PMID:41385096 "[{""id"":""uuid:bb182236-c22c-465e-9e36-5e054f67e1fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d11466c0-f009-4f10-b2a3-48d050d3ce61"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Valsartan and hydrochlorothiazide tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including hydrochlorothiazide and the ARB class to which valsartan principally belongs. There are no controlled trials demonstrating risk reduction with valsartan and hydrochlorothiazide tablets, USP. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality have also been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Add-On Therapy Valsartan and hydrochlorothiazide tablets, USP may be used in patients whose blood pressure is not adequately controlled on monotherapy. Replacement Therapy Valsartan and hydrochlorothiazide tablets, USP may be substituted for the titrated components. Initial Therapy Valsartan and hydrochlorothiazide tablets, USP may be used as initial therapy in patients who are likely to need multiple drugs to achieve blood pressure goals. The choice of valsartan and hydrochlorothiazide tablets, USP as initial therapy for hypertension should be based on an assessment of potential benefits and risks. Patients with stage 2 hypertension are at a relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and should be shaped by considerations such as baseline blood pressure, the target goal and the incremental likelihood of achieving goal with a combination compared to monotherapy. Individual blood pressure goals may vary based upon the patient's risk. Data from the high dose multifactorial trial [see Clinical Studies ( 14.1)] provides estimates of the probability of reaching a target blood pressure with valsartan and hydrochlorothiazide tablets, USP compared to valsartan or hydrochlorothiazide monotherapy. The figures below provide estimates of the likelihood of achieving systolic or diastolic blood pressure control with valsartan and hydrochlorothiazide tablets, USP 320/25 mg, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling. The estimated likelihood at the right tail of each curve is less reliable due to small numbers of subjects with high baseline blood pressures. Figure 1: Probability of Achieving Systolic Blood Pressure <140 mmHg at Week 8 Figure 2: Probability of Achieving Diastolic Blood Pressure <90 mmHg at Week 8 Figure 3: Probability of Achieving Systolic Blood Pressure <130 mmHg at Week 8 Figure 4: Probability of Achieving Diastolic Blood Pressure <80 mmHg at Week 8 For example, a patient with a baseline blood pressure of 160/100 mmHg has about a 41% likelihood of achieving a goal of <140 mmHg (systolic) and 60% likelihood of achieving <90 mmHg (diastolic) on valsartan alone and the likelihood of achieving these goals on HCTZ alone is about 50% (systolic) or 57% (diastolic). The likelihood of achieving these goals on valsartan and hydrochlorothiazide tablets, USP rises to about 84% (systolic) or 80% (diastolic). The likelihood of achieving these goals on placebo is about 23% (systolic) or 36% (diastolic). uuid:dbbc8d97-b3a7-4fa4-8c16-018ae89f1f3e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31638 biolink:treats UMLS:C3495917 PMID:41385096 "[{""id"":""uuid:43812eb7-c51a-4d2a-bc72-227d6e437008"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:342755bd-5f55-4f79-a255-336c94941bae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Monotherapy Fulvestrant injection is indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. Combination Therapy Fulvestrant injection is indicated for the treatment of: HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. uuid:a7b00de2-c291-407a-89ea-2f8ff7abc34e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31638 biolink:treats UMLS:C0278488 PMID:41385096 "[{""id"":""uuid:747390a8-acd0-4ab8-8f41-a5ee2039f385"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:083f5d0a-c8a9-4b0e-ba0b-67167023a2e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Monotherapy Fulvestrant injection is indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy, or HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. Combination Therapy Fulvestrant injection is indicated for the treatment of: HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib as initial endocrine based therapy or following disease progression on endocrine therapy. HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. uuid:a9cfe994-fe37-477a-8b49-80f58ff5d24b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:140628 biolink:treats MONDO:0005316 PMID:41385096 "[{""id"":""uuid:e6189279-595f-4306-8e97-b981fc6e06db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:83580328-6cb8-427a-9a58-ad277ae0e766"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SOLOSEC ® is a nitroimidazole antimicrobial indicated for Treatment of bacterial vaginosis in female patients 12 years of age and older. ( 1.1 ) Treatment of trichomoniasis in patients 12 years of age and older. ( 1.2 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of SOLOSEC and other antibacterial drugs, SOLOSEC should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.3 ) uuid:1e4cacbf-794a-4fce-8660-a7b771f49da8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:140628 biolink:treats MONDO:0002154 PMID:41385096 "[{""id"":""uuid:18f48980-5d18-4414-a67c-d59b4d75f3a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:89422d87-7096-4413-b3a9-bfaf439979b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SOLOSEC ® is a nitroimidazole antimicrobial indicated for Treatment of bacterial vaginosis in female patients 12 years of age and older. ( 1.1 ) Treatment of trichomoniasis in patients 12 years of age and older. ( 1.2 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of SOLOSEC and other antibacterial drugs, SOLOSEC should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.3 ) uuid:039b0e5b-9e1f-446b-ba12-998651a64180 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82718 biolink:treats MONDO:0001628 PMID:41385096 "[{""id"":""uuid:de54e7e1-99f5-42fc-93ec-1319e97430e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:54bced9b-56e4-496e-ac33-4ac88bfa725c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:028c8f47-8b97-44b6-af5c-d439413c3e5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] JUBLIA (efinaconazole) topical solution, 10% is an azole antifungal indicated for the topical treatment of onychomycosis of the toenail(s) due to Trichophyton rubrum and Trichophyton mentagrophytes .|[PMDA] A drug with a new active ingredient indicated for the treatment of tinea unguium caused by dermatophyte (trichophyton ). uuid:c0e70f5f-b8c9-485d-a82c-a3690cb994de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82718 biolink:treats UMLS:C5192601 PMID:41385096 "[{""id"":""uuid:aca14287-7a86-4945-96a4-48b353edfd06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6a1c7697-7817-4d06-a465-26b549dd7021"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] JUBLIA (efinaconazole) topical solution, 10% is an azole antifungal indicated for the topical treatment of onychomycosis of the toenail(s) due to Trichophyton rubrum and Trichophyton mentagrophytes . uuid:38d2dd22-24dd-4ac9-b7e7-e7c33b4629d9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:23742 biolink:treats MONDO:0004995 PMID:41385096 "[{""id"":""uuid:19d6f52d-4ad2-4a3f-beb4-42eec2749e15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:82a673b3-2312-4122-ab1a-bebeb9bc56c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] This fixed combination drug is not indicated for the initial therapy of edema or hypertension except in individuals in whom the development of hypokalemia cannot be risked. Triamterene and hydrochlorothiazide capsules, USP are indicated for the treatment of hypertension or edema in patients who develop hypokalemia on hydrochlorothiazide alone. Triamterene and hydrochlorothiazide capsules, USP are also indicated for those patients who require a thiazide diuretic and in whom the development of hypokalemia cannot be risked. Triamterene and hydrochlorothiazide capsules, USP may be used alone or as an adjunct to other antihypertensive drugs, such as beta-blockers. Since triamterene and hydrochlorothiazide capsules, USP may enhance the action of these agents, dosage adjustments may be necessary. Usage in Pregnancy: The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. Edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. Diuretics are indicated in pregnancy when edema is due to pathologic causes, just as they are in the absence of pregnancy. Dependent edema in pregnancy resulting from restriction of venous return by the expanded uterus is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy which is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances this edema may cause extreme discomfort which is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate. uuid:3cd2808b-7d66-4d3f-af23-a9b607150d75 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63916 biolink:treats MONDO:0015924 PMID:41385096 "[{""id"":""uuid:57b14cda-82d6-4162-9339-e91a5f330407"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:06847d4a-f5ea-430c-93fd-18001dd7c82a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:fa5d4b8e-bde6-4c12-a852-f32b8d485e50"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VENTAVIS is a prostacyclin mimetic indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve a composite endpoint consisting of exercise tolerance, symptoms (NYHA Class), and lack of deterioration. Studies establishing effectiveness included predominately patients with NYHA Functional Class III-IV symptoms and etiologies of idiopathic or heritable PAH (65%) or PAH associated with connective tissue diseases (23%). ( 1.1 ).|[PMDA] A drug with a new active ingredient indicated for the treatment of pulmonary arterial hypertension. uuid:055bacf0-d699-43c5-aaf9-082eb5dab5c8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63916 biolink:treats MONDO:0017147 PMID:41385096 "[{""id"":""uuid:bdb0d6e3-3ca7-4ee1-8971-c5a5276200ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:01f69e06-1f75-48c1-9e15-4363aae54317"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VENTAVIS is a prostacyclin mimetic indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve a composite endpoint consisting of exercise tolerance, symptoms (NYHA Class), and lack of deterioration. Studies establishing effectiveness included predominately patients with NYHA Functional Class III-IV symptoms and etiologies of idiopathic or heritable PAH (65%) or PAH associated with connective tissue diseases (23%). ( 1.1 ). uuid:fc57eca7-fd44-4645-9340-88eb293d18eb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63916 biolink:treats MONDO:0017148 PMID:41385096 "[{""id"":""uuid:562a7887-e4f2-4108-b4b5-d4d87d5d9344"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0bdce9a7-816a-4dcd-b035-89462be784b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VENTAVIS is a prostacyclin mimetic indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve a composite endpoint consisting of exercise tolerance, symptoms (NYHA Class), and lack of deterioration. Studies establishing effectiveness included predominately patients with NYHA Functional Class III-IV symptoms and etiologies of idiopathic or heritable PAH (65%) or PAH associated with connective tissue diseases (23%). ( 1.1 ). uuid:379c6297-4da4-4b86-95eb-3b74d6a31ead biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47657 biolink:treats UMLS:C0853854 PMID:41385096 "[{""id"":""uuid:d98c050d-09b0-40f6-96b9-b7299e45fa0f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f3d9c979-427e-4600-9ac6-f5593881cfbf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Roflumilast is indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations. Limitations of Use Roflumilast is not a bronchodilator and is not indicated for the relief of acute bronchospasm. uuid:bce0bfc3-aefc-4fb3-8aab-bfabd87268d3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47657 biolink:treats MONDO:0011751 PMID:41385096 "[{""id"":""uuid:94980b10-e7da-41ff-a786-bdf3954fcd2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1e01e068-94df-4efc-8f2d-e268e54dcabf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Roflumilast is indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations. Limitations of Use Roflumilast is not a bronchodilator and is not indicated for the relief of acute bronchospasm. uuid:c632a449-984c-4ad7-81f6-9d21b4177deb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47657 biolink:treats MONDO:0005607 PMID:41385096 "[{""id"":""uuid:e40181b7-6d4b-4e20-b5ef-06b52c4901a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:8e677951-f6a5-4f95-ad1b-cceefe128fc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e88545ed-b7e4-4c83-9c05-42698ef72d08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/daxas""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Roflumilast is indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations. Limitations of Use Roflumilast is not a bronchodilator and is not indicated for the relief of acute bronchospasm.|[EMA] Daxas is indicated for maintenance treatment of severe chronic obstructive pulmonary disease (COPD) (FEV1 post-bronchodilator less than 50% predicted) associated with chronic bronchitis in adult patients with a history of frequent exacerbations as add-on to bronchodilator treatment., uuid:18ec7b94-656e-486e-91f9-a67dd4aa26df biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47657 biolink:treats UMLS:C0741804 PMID:41385096 "[{""id"":""uuid:99852235-06d2-46a7-adb4-773d46e3dc54"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:55fd74b5-2088-4791-a9b3-10d88c0023da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Roflumilast is indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD associated with chronic bronchitis and a history of exacerbations. Limitations of Use Roflumilast is not a bronchodilator and is not indicated for the relief of acute bronchospasm. uuid:653bbd4f-8d31-4de1-92e4-f4ed42dc1eff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59773 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:a39b2839-84b8-4e7d-970b-04d71c7751f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e551666c-5364-47d0-bf48-ba64c20501d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cromolyn sodium inhalation solution USP is a prophylactic agent indicated in the management of patients with bronchial asthma. In patients whose symptoms are sufficiently frequent to require a continuous program of medication, cromolyn sodium inhalation solution USP is given by inhalation on a regular daily basis (see DOSAGE AND ADMINISTRATION ). The effect of cromolyn sodium is usually evident after several weeks of treatment, although some patients show an almost immediate response. In patients who develop acute bronchoconstriction in response to exposure to exercise, toluene diisocyanate, environmental pollutants, etc., cromolyn sodium should be given shortly before exposure to the precipitating factor (see DOSAGE AND ADMINISTRATION ). uuid:1141b0ca-a4cd-40fe-9a5e-e9891d20f495 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17439 biolink:treats UMLS:C0205707 PMID:41385096 "[{""id"":""uuid:0e55e0f6-0675-45e6-90af-b0b969560dde"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:79a59799-2538-49d4-91aa-d332203c0d87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyanocobalamin is indicated for vitamin B 12 deficiencies due to malabsorption which may be associated with the following conditions: • Addisonian (pernicious) anemia • Gastrointestinal pathology, dysfunction, or surgery, including gluten enteropathy or sprue, small bowel bacteria overgrowth, total or partial gastrectomy • Fish tapeworm infestation • Malignancy of pancreas or bowel • Folic acid deficiency It may be possible to treat the underlying disease by surgical correction of anatomic lesions leading to small bowel bacterial overgrowth, expulsion of fish tapeworm, discontinuation of drugs leading to vitamin malabsorption (see Drug Interactions ), use of a gluten-free diet in nontropical sprue, or administration of antibiotics in tropical sprue. Such measures remove the need for long-term administration of cyanocobalamin. Requirements of vitamin B 12 in excess of normal (due to pregnancy, thyrotoxicosis, hemolytic anemia, hemorrhage, malignancy, hepatic and renal disease) can usually be met with oral supplementation. Cyanocobalamin injection is also suitable for the vitamin B 12 absorption test (Schilling test). uuid:81b1565f-8ea5-4cbf-a15f-e4245b1e1e8d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3515 biolink:treats UMLS:C0036685 PMID:41385096 "[{""id"":""uuid:82b24706-e5cd-4df6-bd88-78fbbc655406"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b15de4f6-0eb4-4a1d-a84d-630240069698"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefuroxime for Injection is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: Lower Respiratory Tract Infections , including pneumonia, caused by Streptococcus pneumoniae , Haemophilus influenzae (including ampicillin-resistant strains), Klebsiella spp., Staphylococcus aureus (penicillinase- and non–penicillinase-producing strains), Streptococcus pyogenes , and Escherichia coli . Urinary Tract Infections caused by Escherichia coli and Klebsiella spp. Skin and Skin­-Structure Infections caused by Staphylococcus aureus (penicillinase- and non–penicillinase-producing strains), Streptococcus pyogenes , Escherichia coli , Klebsiella spp., and Enterobacter spp. Septicemia caused by Staphylococcus aureus (penicillinase- and non–penicillinase-producing strains), Streptococcus pneumoniae , Escherichia coli , Haemophilus influenzae (including ampicillin-resistant strains), and Klebsiella spp. Meningitis caused by Streptococcus pneumoniae , Haemophilus influenzae (including ampicillin-resistant strains), Neisseria meningitidis , and Staphylococcus aureus (penicillinase- and non–penicillinase-producing strains). Gonorrhea: Uncomplicated and disseminated gonococcal infections due to Neisseria gonorrhoeae (penicillinase- and non–penicillinase-producing strains) in both males and females. Bone and Joint Infections caused by Staphylococcus aureus (penicillinase- and non–penicillinase-producing strains). Clinical microbiological studies in skin and skin­-structure infections frequently reveal the growth of susceptible strains of both aerobic and anaerobic organisms. Cefuroxime for Injection has been used successfully in these mixed infections in which several organisms have been isolated. In certain cases of confirmed or suspected gram-positive or gram-negative sepsis or in patients with other serious infections in which the causative organism has not been identified, Cefuroxime for Injection may be used concomitantly with an aminoglycoside (see PRECAUTIONS ). The recommended doses of both antibiotics may be given depending on the severity of the infection and the patient's condition. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefuroxime for Injection and other antibacterial drugs, Cefuroxime for Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:97276347-72a3-4f77-8cc4-7bb81ee848d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29007 biolink:treats UMLS:C4552431 PMID:41385096 "[{""id"":""uuid:e104db89-3ec0-4cb0-9be4-704fd2e0db09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d5fd7343-dd65-4715-a674-c117146a8687"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Before instituting treatment with Ceftriaxone for Injection, USP, appropriate specimens should be obtained for isolation of the causative organism and for determination of its susceptibility to the drug. Therapy may be instituted prior to obtaining results of susceptibility testing. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Ceftriaxone for Injection, USP and other antibacterial drugs, Ceftriaxone for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ceftriaxone for Injection, USP is indicated for the treatment of the following infections when caused by susceptible organisms: LOWER RESPIRATORY TRACT INFECTIONS caused by Streptococcus pneumoniae , Staphylococcus aureus, Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Escherichia coli, Enterobacter aerogenes, Proteus mirabilis or Serratia marcescens . ACUTE BACTERIAL OTITIS MEDIA caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta-lactamase producing strains) or Moraxella catarrhalis (including beta-lactamase producing strains). NOTE: In one study lower clinical cure rates were observed with a single dose of Ceftriaxone compared to 10 days of oral therapy. In a second study comparable cure rates were observed between single dose Ceftriaxone and the comparator. The potentially lower clinical cure rate of ceftriaxone should be balanced against the potential advantages of parenteral therapy (see CLINICAL STUDIES ). SKIN AND SKIN STRUCTURE INFECTIONS caused by Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pyogenes , Viridans group streptococci, Escherichia coli, Enterobacter cloacae, Klebsiella oxytoca, Klebsiella pneumoniae, Proteus mirabilis, Morganella morganii*, Pseudomonas aeruginosa, Serratia marcescens, Acinetobacter calcoaceticus, Bacteroides fragilis* or Peptostreptococcus species. * Efficacy for this organism in this organ system was studied in fewer than ten infections. URINARY TRACT INFECTIONS (complicated and uncomplicated) caused by Escherichia coli, Proteus mirabilis, Proteus vulgaris, Morganella morganii or Klebsiella pneumoniae . UNCOMPLICATED GONORRHEA (cervical/urethral and rectal) caused by Neisseria gonorrhoeae , including both penicillinase- and nonpenicillinase-producing strains, and pharyngeal gonorrhea caused by nonpenicillinase-producing strains of Neisseria gonorrhoeae . PELVIC INFLAMMATORY DISEASE caused by Neisseria gonorrhoeae . Ceftriaxone sodium, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and Chlamydia trachomatis is one of the suspected pathogens, appropriate antichlamydial coverage should be added. BACTERIAL SEPTICEMIA caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Haemophilus influenzae or Klebsiella pneumoniae . BONE AND JOINT INFECTIONS caused by Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae or Enterobacter species. INTRA-ABDOMINAL INFECTIONS caused by Escherichia coli, Klebsiella pneumoniae, Bacteroides fragilis, Clostridium species (Note: most strains of Clostridium difficile are resistant) or Peptostreptococcus species. MENINGITIS caused by Haemophilus influenzae, Neisseria meningitidis or Streptococcus pneumoniae . Ceftriaxone has also been used successfully in a limited number of cases of meningitis and shunt infection caused by Staphylococcus epidermidis* and Escherichia coli* . * Efficacy for this organism in this organ system was studied in fewer than ten infections. SURGICAL PROPHYLAXIS: The preoperative administration of a single 1 g dose of Ceftriaxone may reduce the incidence of postoperative infections in patients undergoing surgical procedures classified as contaminated or potentially contaminated (e.g., vaginal or abdominal hysterectomy or cholecystectomy for chronic calculous cholecystitis in high-risk patients, such as those over 70 years of age, with acute cholecystitis not requiring therapeutic antimicrobials, obstructive jaundice or common duct bile stones) and in surgical patients for whom infection at the operative site would present serious risk (e.g., during coronary artery bypass surgery). Although Ceftriaxone has been shown to have been as effective as cefazolin in the prevention of infection following coronary artery bypass surgery, no placebo-controlled trials have been conducted to evaluate any cephalosporin antibiotic in the prevention of infection following coronary artery bypass surgery. When administered prior to surgical procedures for which it is indicated, a single 1 g dose of Ceftriaxone provides protection from most infections due to susceptible organisms throughout the course of the procedure. uuid:e104ef08-a4e7-4000-8c15-fe3dd40a3683 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:8230 biolink:treats UMLS:C5400441 PMID:41385096 "[{""id"":""uuid:7f90c8f3-36f5-4002-a4b2-dddb970c731d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:21216e7d-8cd2-4f75-9deb-6a4e15d163c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vasopressin Injection, USP is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. uuid:a3393420-db68-4982-ab09-2c1ee4cb41b7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:8230 biolink:treats MONDO:0005468 PMID:41385096 "[{""id"":""uuid:57cf6340-7214-4fba-9add-ff48585d6d4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b88666fc-44ce-40dc-9f0f-7784aeec7958"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vasopressin Injection, USP is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. uuid:8dbf534e-de87-42f3-b12a-f89620bc2a61 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18067 biolink:treats MONDO:0024307 PMID:41385096 "[{""id"":""uuid:f2037458-8d8e-4493-842e-df41f8e8870a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:344933f7-f3a5-4741-a1cd-9aff3b31ac89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Phytonadione injectable emulsion, USP is indicated in the following coagulation disorders which are due to faulty formation of factors II, VII, IX and X when caused by Vitamin K deficiency or interference with Vitamin K activity. Phytonadione injectable emulsion is indicated in­­ anticoagulant-induced prothrombin deficiency caused by coumarin or indanedione derivatives; ­­ prophylaxis and therapy of hemorrhagic disease of the newborn; ­­ hypoprothrombinemia due to antibacterial therapy; hypoprothrombinemia secondary to factors limiting absorption or synthesis of Vitamin K, e.g., obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal resection, cystic fibrosis of the pancreas, and regional enteritis; other drug-induced hypoprothrombinemia where it is definitely shown that the result is due to interference with phytonadione injectable emulsion metabolism, e.g., salicylates. uuid:2d1f6e9b-b211-41a2-967d-3b2d58e8bc24 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0010150 PMID:41385096 "[{""id"":""uuid:bd0df7a8-1957-45da-afb5-5fe445d9ebf7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c68d05d4-dbf2-4593-b6d6-8aa1f703a060"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for Injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin is poorer in patients with previously irradiated head and neck cancer. Lymphomas Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin has also been shown to be useful in the management of: Malignant Pleural Effusion Bleomycin is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:242525d7-9d99-4ad3-9c26-58cc7284627c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0004958 PMID:41385096 "[{""id"":""uuid:8432199d-5c05-4f59-ae7d-f93b3f93efb4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ee20dc6e-8e6f-4743-b4c3-8e1c811d8430"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for Injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin is poorer in patients with previously irradiated head and neck cancer. Lymphomas Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin has also been shown to be useful in the management of: Malignant Pleural Effusion Bleomycin is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:75d92240-c064-4382-9ed7-8aea4c9f7182 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0000500 PMID:41385096 "[{""id"":""uuid:b1a38e8e-32d3-4392-8f70-8e32f0c3c0fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7c39eb95-6dd6-472c-8f69-0dec78d8e38b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for Injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin is poorer in patients with previously irradiated head and neck cancer. Lymphomas Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin has also been shown to be useful in the management of: Malignant Pleural Effusion Bleomycin is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:9b3f3c08-3f19-41fa-8424-c4148e452806 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0006470 PMID:41385096 "[{""id"":""uuid:87e22a17-5858-4a26-86b1-82337de849d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:70c9bbfc-2c6c-4520-b4bf-dc97464ea63f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for Injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin is poorer in patients with previously irradiated head and neck cancer. Lymphomas Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin has also been shown to be useful in the management of: Malignant Pleural Effusion Bleomycin is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:e1632e6b-5c26-49c8-8fb4-aa0cccce759b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0006060 PMID:41385096 "[{""id"":""uuid:cecaa3c5-533c-4348-a2c0-5f5ddd752854"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:966ff753-ffb7-44cc-b424-d4d14e59c210"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for Injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin is poorer in patients with previously irradiated head and neck cancer. Lymphomas Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin has also been shown to be useful in the management of: Malignant Pleural Effusion Bleomycin is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:6fb30264-ee8f-470a-82bd-a19ee13f7a0a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0044704 PMID:41385096 "[{""id"":""uuid:510c33b6-2967-4eee-a990-dd836d334df1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:74e47992-849c-4c6a-87ce-c82d03687ca1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for Injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin is poorer in patients with previously irradiated head and neck cancer. Lymphomas Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin has also been shown to be useful in the management of: Malignant Pleural Effusion Bleomycin is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:d97c6566-8f2e-4a0b-8b27-8ef37a0417f1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0044705 PMID:41385096 "[{""id"":""uuid:ff834f5f-20f1-4787-90fc-363e0ed1a339"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:60b81598-baec-4a01-97f5-d8d7f0526bca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for Injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin is poorer in patients with previously irradiated head and neck cancer. Lymphomas Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin has also been shown to be useful in the management of: Malignant Pleural Effusion Bleomycin is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:5ad22802-1ac0-4632-a714-4c3dd3493370 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0021427 PMID:41385096 "[{""id"":""uuid:8ff97393-bdc9-4f9e-94b5-dc8d77a73a85"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:38b41f6f-1393-4c24-a98c-bda2e0cbae33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for Injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin is poorer in patients with previously irradiated head and neck cancer. Lymphomas Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin has also been shown to be useful in the management of: Malignant Pleural Effusion Bleomycin is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:795cf566-3621-45df-8207-030cfd4a7a77 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0021431 PMID:41385096 "[{""id"":""uuid:92b926e8-8ec0-4200-9ad6-58f4d575f6cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4ff1e943-50d7-459b-a17c-39c4b417d9f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for Injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin is poorer in patients with previously irradiated head and neck cancer. Lymphomas Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin has also been shown to be useful in the management of: Malignant Pleural Effusion Bleomycin is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:5357d2a3-3c01-4132-a7f5-64f7ccca9774 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0002529 PMID:41385096 "[{""id"":""uuid:c028a992-1860-4711-af7b-0339c2363305"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5096b020-5957-4382-89d7-e9c876e7b23c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for Injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin is poorer in patients with previously irradiated head and neck cancer. Lymphomas Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin has also been shown to be useful in the management of: Malignant Pleural Effusion Bleomycin is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:13164f94-1b68-4df9-8809-0e6523b573aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0005595 PMID:41385096 "[{""id"":""uuid:094048bc-78f5-4f8f-9643-22d23e59f84e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0a1bc48d-2a51-40d1-a673-a762467da5b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for Injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin is poorer in patients with previously irradiated head and neck cancer. Lymphomas Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin has also been shown to be useful in the management of: Malignant Pleural Effusion Bleomycin is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:b95b1ecf-9d6f-40d8-b1bb-fb76165d2a17 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0018352 PMID:41385096 "[{""id"":""uuid:39a391be-5fea-4af8-9a6d-817c0e37891e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cf1efc49-c592-4e06-9d82-e67968dbb698"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for Injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin is poorer in patients with previously irradiated head and neck cancer. Lymphomas Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin has also been shown to be useful in the management of: Malignant Pleural Effusion Bleomycin is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:c5b78f50-5e42-4bea-b194-c279574dcb46 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0006143 PMID:41385096 "[{""id"":""uuid:ba4317ce-863a-4a06-aeb6-22a159354035"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4b5c90eb-67fe-405d-b4e8-4d0ed7e76992"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for Injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin is poorer in patients with previously irradiated head and neck cancer. Lymphomas Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin has also been shown to be useful in the management of: Malignant Pleural Effusion Bleomycin is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:58a83911-0c7e-4687-a3a8-ae61554931b1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0024609 PMID:41385096 "[{""id"":""uuid:61c5f0b8-182a-4019-b4c9-40911816945c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9c0270d1-a9d3-4a4a-b3be-0338cf1a87e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for Injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin is poorer in patients with previously irradiated head and neck cancer. Lymphomas Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin has also been shown to be useful in the management of: Malignant Pleural Effusion Bleomycin is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:03e86477-0fd0-4f55-b051-03be021d1704 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0007243 PMID:41385096 "[{""id"":""uuid:a7682388-4c3b-4e97-96cd-2a518bb723f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:adc7b924-90bd-4520-a547-474cb781b41f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for Injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin is poorer in patients with previously irradiated head and neck cancer. Lymphomas Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin has also been shown to be useful in the management of: Malignant Pleural Effusion Bleomycin is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:9255687d-1f05-4e48-8f09-a1379a92c28d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0006446 PMID:41385096 "[{""id"":""uuid:ab92314e-55c9-4300-837d-63e5b6d37094"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:70ddde8c-160b-4645-a089-cec7a75a0867"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for Injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin is poorer in patients with previously irradiated head and neck cancer. Lymphomas Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin has also been shown to be useful in the management of: Malignant Pleural Effusion Bleomycin is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:b6fb38ce-b699-4456-a996-3cd957e63e8d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0003508 PMID:41385096 "[{""id"":""uuid:d4d3bfe9-8734-4e05-9fe9-f0d9267567f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2f797e7d-9653-4b0b-b8c7-e52d58b394b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bleomycin for Injection should be considered a palliative treatment. It has been shown to be useful in the management of the following neoplasms either as a single agent or in proven combinations with other approved chemotherapeutic agents: Squamous Cell Carcinoma Head and neck (including mouth, tongue, tonsil, nasopharynx, oropharynx, sinus, palate, lip, buccal mucosa, gingivae, epiglottis, skin, larynx), penis, cervix, and vulva. The response to bleomycin is poorer in patients with previously irradiated head and neck cancer. Lymphomas Hodgkin's disease, non-Hodgkin's lymphoma. Testicular Carcinoma Embryonal cell, choriocarcinoma, and teratocarcinoma. Bleomycin has also been shown to be useful in the management of: Malignant Pleural Effusion Bleomycin is effective as a sclerosing agent for the treatment of malignant pleural effusion and prevention of recurrent pleural effusions. uuid:11eefd04-18a2-4119-8ea7-3ac34c8efe7e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10119 biolink:treats MONDO:0020575 PMID:41385096 "[{""id"":""uuid:3e4cfea3-a74c-41f1-be01-cbf3035221d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e271e215-0a20-44c3-83f0-3767035a83e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ziprasidone mesylate for injection intramuscular is indicated for acute agitation in schizophrenic patients. When deciding among the alternative treatments available for the condition needing treatment, the prescriber should consider the finding of ziprasidone’s greater capacity to prolong the QT/QTc interval compared to several other antipsychotic drugs [see Warnings and Precautions (5.3) ]. Prolongation of the QTc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia, and sudden death. In many cases this would lead to the conclusion that other drugs should be tried first. Whether ziprasidone will cause torsade de pointes or increase the rate of sudden death is not yet known [see Warnings and Precautions (5.3) ] Acute Treatment of Agitation in Schizophrenia Ziprasidone mesylate for injection intramuscular is indicated for the treatment of acute agitation in schizophrenic adult patients for whom treatment with ziprasidone is appropriate and who need intramuscular antipsychotic medication for rapid control of agitation. Since there is no experience regarding the safety of administering ziprasidone intramuscular to schizophrenic patients already taking oral ziprasidone, the practice of co-administration is not recommended. uuid:2cf51b09-77a4-47b5-9803-f79af42d3150 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1100064 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:eaf19418-ee2b-4717-ad83-f3856610e028"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:61d17e54-cf7d-4cbb-ac08-fe0a3e02e717"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ibuprofen and famotidine tablet, a combination of the NSAID ibuprofen and the histamine H 2 -receptor antagonist famotidine, is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers, which in the clinical trials was defined as a gastric and/or duodenal ulcer, in patients who are taking ibuprofen for those indications. The clinical trials primarily enrolled patients less than 65 years of age without a prior history of gastrointestinal ulcer. Controlled trials do not extend beyond 6 months [see Clinical Studies ( 14 ), Use in Specific Populations ( 8.5 )] . uuid:620d94e7-b5ea-4f59-990c-de86947f6ac4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1100064 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:1aac7cb9-b8e0-448c-a2c2-6703fa859736"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b2d79dbb-2bb1-462a-afdc-62a3e294763a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ibuprofen and famotidine tablet, a combination of the NSAID ibuprofen and the histamine H 2 -receptor antagonist famotidine, is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers, which in the clinical trials was defined as a gastric and/or duodenal ulcer, in patients who are taking ibuprofen for those indications. The clinical trials primarily enrolled patients less than 65 years of age without a prior history of gastrointestinal ulcer. Controlled trials do not extend beyond 6 months [see Clinical Studies ( 14 ), Use in Specific Populations ( 8.5 )] . uuid:30b4e61c-25cb-4413-a8ff-c9a75bbf2caa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1100064 biolink:treats MONDO:0001126 PMID:41385096 "[{""id"":""uuid:9dafd9a9-32f4-40f2-ab60-26a681d86424"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fca9f57e-475d-4404-92f6-7aa558687ee7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ibuprofen and famotidine tablet, a combination of the NSAID ibuprofen and the histamine H 2 -receptor antagonist famotidine, is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers, which in the clinical trials was defined as a gastric and/or duodenal ulcer, in patients who are taking ibuprofen for those indications. The clinical trials primarily enrolled patients less than 65 years of age without a prior history of gastrointestinal ulcer. Controlled trials do not extend beyond 6 months [see Clinical Studies ( 14 ), Use in Specific Populations ( 8.5 )] . uuid:6e399a40-e3ee-47c3-8d7e-ec700f6982e7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1100064 biolink:treats MONDO:0005412 PMID:41385096 "[{""id"":""uuid:f4b32c1f-444e-4d2b-b370-9dac8c36945d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:64deb003-41ea-4306-a841-8bf7828ee69e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ibuprofen and famotidine tablet, a combination of the NSAID ibuprofen and the histamine H 2 -receptor antagonist famotidine, is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers, which in the clinical trials was defined as a gastric and/or duodenal ulcer, in patients who are taking ibuprofen for those indications. The clinical trials primarily enrolled patients less than 65 years of age without a prior history of gastrointestinal ulcer. Controlled trials do not extend beyond 6 months [see Clinical Studies ( 14 ), Use in Specific Populations ( 8.5 )] . uuid:d1deaf39-216a-42f3-a044-3c0b95d57656 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9R3D3Y0UHS biolink:treats MONDO:0007064 PMID:41385096 "[{""id"":""uuid:12dc3b34-ad0f-4ba2-8258-2c27b416f400"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9df3470d-7e8e-4497-ad5e-c570c6056940"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:6c04e86c-2b83-46f3-8894-00ba399efbbb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] REVCOVI is indicated for the treatment of adenosine deaminase severe combined immune deficiency (ADA-SCID) in pediatric and adult patients.|[PMDA] A drug with a new active ingredient indicated for the treatment of adenosine deaminase deficiency. [Orphan drug] uuid:57591840-d72c-47b0-8d5d-33f1d92d3724 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231425 biolink:treats HP:0002902 PMID:41385096 "[{""id"":""uuid:0604f526-cdfe-4c19-a879-27a25de70fbb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f24b9b8b-051f-4c3a-bc3f-15bab7946702"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ab45f9ae-64ba-4406-9e15-94d2edda81cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/jinarc""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tolvaptan tablets are indicated for the treatment of clinically significant hypervolemic and euvolemic hyponatremia (serum sodium <125 mEq/L or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction), including patients with heart failure and Syndrome of Inappropriate Antidiuretic Hormone (SIADH). Limitations of Use: Patients requiring intervention to raise serum sodium urgently to prevent or to treat serious neurological symptoms should not be treated with tolvaptan tablets. It has not been established that raising serum sodium with tolvaptan tablets provide a symptomatic benefit to patients.|[EMA] Tolvaptan is indicated in adults for the treatment of hyponatremia secondary to the syndrome of inappropriate antidiuretic hormone secretion (SIADH). uuid:ae13c24c-dceb-4d53-b5a7-4c489b3866c8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231425 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:98d6c78a-4c54-4429-b2f7-5505ac935a67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:061ed29f-acd4-4a06-b2b3-b9f7a40291a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:eea07347-987b-4228-a119-85e470ac559c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tolvaptan tablets are indicated for the treatment of clinically significant hypervolemic and euvolemic hyponatremia (serum sodium <125 mEq/L or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction), including patients with heart failure and Syndrome of Inappropriate Antidiuretic Hormone (SIADH). Limitations of Use: Patients requiring intervention to raise serum sodium urgently to prevent or to treat serious neurological symptoms should not be treated with tolvaptan tablets. It has not been established that raising serum sodium with tolvaptan tablets provide a symptomatic benefit to patients.|[PMDA] A drug with a new active ingredient indicated for the treatment of fluid retention in heart failure patients who have not responded sufficiently to other diuretics to such as loop diuretics. uuid:9845fecf-6563-4d56-b89f-caa546884244 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231425 biolink:treats MONDO:0006802 PMID:41385096 "[{""id"":""uuid:de492b86-f8ce-458e-84c4-10e9df0cf266"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:23ec2c1f-b054-40cb-846b-226d4d3d89f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:95f99386-b009-4c20-910b-38e5a137f1d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/jinarc""]},{""id"":""uuid:4b17baf1-d225-415a-8f8f-98b8f6224abc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tolvaptan tablets are indicated for the treatment of clinically significant hypervolemic and euvolemic hyponatremia (serum sodium <125 mEq/L or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction), including patients with heart failure and Syndrome of Inappropriate Antidiuretic Hormone (SIADH). Limitations of Use: Patients requiring intervention to raise serum sodium urgently to prevent or to treat serious neurological symptoms should not be treated with tolvaptan tablets. It has not been established that raising serum sodium with tolvaptan tablets provide a symptomatic benefit to patients.|[EMA] Tolvaptan is indicated in adults for the treatment of hyponatremia secondary to the syndrome of inappropriate antidiuretic hormone secretion (SIADH).|[PMDA] Drugs with a new indication and a new dosage for the improvement of hyponatraemia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH). [Orphan drug] uuid:3ac38d6f-9e27-4b4f-b0f8-55847b842efd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4786 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:a3820957-7314-4c61-b048-01e7065dea9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c76815e4-94f7-4c83-bca3-2cebc6c71307"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Enalapril maleate is an angiotensin-converting enzyme inhibitor indicated for: treatment of hypertension in adults and children older than one month, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) treatment of symptomatic heart failure. ( 1.2 ) treatment of asymptomatic left ventricular dysfunction, to decrease the rate of development of overt heart failure and reduce hospitalization for heart failure. ( 1.3 ) uuid:95b80481-d9ae-4043-9359-60fcecf76203 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4786 biolink:treats MONDO:0006652 PMID:41385096 "[{""id"":""uuid:36765d4f-330b-4ae1-a637-fcc06a7a91f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dcaba23f-91c0-4bb7-b1e2-1ed40a212e4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Enalapril maleate is an angiotensin-converting enzyme inhibitor indicated for: treatment of hypertension in adults and children older than one month, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) treatment of symptomatic heart failure. ( 1.2 ) treatment of asymptomatic left ventricular dysfunction, to decrease the rate of development of overt heart failure and reduce hospitalization for heart failure. ( 1.3 ) uuid:38a1211b-37f9-42da-88c2-b56a6fd229f9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:375139 biolink:treats HP:0003418 PMID:41385096 "[{""id"":""uuid:40ccd3bd-deef-499b-a740-eececc8b30f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d5c4ae0b-8b14-4cd3-970a-0c0f2cfe8a3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lidothol Gel is indicated for relief of pain associated with arthritis, backache, cramps, discomfort, neckache, soreness, sprains, strains. It should be applied only to intact skin. uuid:b637e02f-ef3f-497c-84c0-07d50bdedd35 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:375139 biolink:treats MONDO:0008022 PMID:41385096 "[{""id"":""uuid:9baf1cb6-94b9-47cc-b94b-2b2b582eb468"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d46521f9-e0d1-4314-ad55-030a2f1d4eeb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lidothol Gel is indicated for relief of pain associated with arthritis, backache, cramps, discomfort, neckache, soreness, sprains, strains. It should be applied only to intact skin. uuid:119e669f-22a3-4b2d-8d89-0160eba1ec0d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:375139 biolink:treats HP:0030833 PMID:41385096 "[{""id"":""uuid:3bf7424a-1f23-4f65-b1ef-5338c5a89238"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2241cd8b-fe1b-4f7c-b84c-7f19326aacc7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lidothol Gel is indicated for relief of pain associated with arthritis, backache, cramps, discomfort, neckache, soreness, sprains, strains. It should be applied only to intact skin. uuid:22b17484-7a03-4a1b-b3b9-bca364569f53 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:375139 biolink:treats NCIT:C50748 PMID:41385096 "[{""id"":""uuid:a2d637f7-bed7-4fa1-8aee-d3237eda6b37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fa0fbfea-35bb-40f4-8867-155d51c2a986"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lidothol Gel is indicated for relief of pain associated with arthritis, backache, cramps, discomfort, neckache, soreness, sprains, strains. It should be applied only to intact skin. uuid:efee854e-f89e-405d-8fe5-f0d931006625 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16684 biolink:treats MONDO:0000745 PMID:41385096 "[{""id"":""uuid:4fbd3934-271d-403b-bab4-2853f7942b38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:11f97e80-6778-43df-a347-7eed33a39aec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atropine Sulfate Injection, USP, is indicated for temporary blockade of severe or life threatening muscarinic effects, e.g., as an antisialagogue, an antivagal agent, an antidote for organophosphorus or muscarinic mushroom poisoning, and to treat bradyasystolic cardiac arrest. uuid:245e2fd5-7d43-4b7e-b582-325bbe17cf89 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50173 biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:db67e9b0-34c3-4c4e-9f84-5dd81d00cb9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:61efeabf-cab7-406d-a04d-1105c1b31f2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acitretin Capsules are indicated for the treatment of severe psoriasis in adults. Because of significant adverse effects associated with its use, Acitretin Capsules should be prescribed only by those knowledgeable in the systemic use of retinoids. In females of reproductive potential, Acitretin Capsules should be reserved for non-pregnant patients who are unresponsive to other therapies or whose clinical condition contraindicates the use of other treatments (see boxed CONTRAINDICATIONS AND WARNINGS — Acitretin Capsules can cause severe birth defects). Most patients experience relapse of psoriasis after discontinuing therapy. Subsequent courses, when clinically indicated, have produced efficacy results similar to the initial course of therapy. uuid:059707b8-627b-4c89-b0de-845248884ee7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:101278 biolink:treats MONDO:0008685 PMID:41385096 "[{""id"":""uuid:dafa8816-c1ca-459b-a239-e84ca422af3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4af45a1f-38a6-44ce-a4bb-602a0d5df561"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diltiazem hydrochloride injection is indicated for the following: Atrial Fibrillation or Atrial Flutter. Temporary control of rapid ventricular rate in atrial fibrillation or atrial flutter. It should not be used in patients with atrial fibrillation or atrial flutter associated with an accessory bypass tract such as in Wolff-Parkinson-White (WPW) syndrome or short PR syndrome. Paroxysmal Supraventricular Tachycardia. Rapid conversion of paroxysmal supraventricular tachycardias (PSVT) to sinus rhythm. This includes AV nodal reentrant tachycardias and reciprocating tachycardias associated with an extranodal accessory pathway such as the WPW syndrome or short PR syndrome. Unless otherwise contraindicated, appropriate vagal maneuvers should be attempted prior to administration of diltiazem hydrochloride injection. The use of diltiazem hydrochloride injection for control of ventricular response in patients with atrial fibrillation or atrial flutter or conversion to sinus rhythm in patients with PSVT should be undertaken with caution when the patient is compromised hemodynamically or is taking other drugs that decrease any or all of the following: peripheral resistance, myocardial filling, myocardial contractility, or electrical impulse propagation in the myocardium. For either indication and particularly when employing continuous intravenous infusion, the setting should include continuous monitoring of the ECG and frequent measurement of blood pressure. A defibrillator and emergency equipment should be readily available. In domestic controlled trials in patients with atrial fibrillation or atrial flutter, bolus administration of diltiazem hydrochloride injection was effective in reducing heart rate by at least 20% in 95% of patients. Diltiazem hydrochloride injection rarely converts atrial fibrillation or atrial flutter to normal sinus rhythm. Following administration of one or two intravenous bolus doses of diltiazem hydrochloride injection, response usually occurs within 3 minutes and maximal heart rate reduction generally occurs in 2 to 7 minutes. Heart rate reduction may last from 1 to 3 hours. If hypotension occurs, it is generally short-lived, but may last from 1 to 3 hours. A 24-hour continuous infusion of diltiazem hydrochloride injection in the treatment of atrial fibrillation or atrial flutter maintained at least a 20% heart rate reduction during the infusion in 83% of patients. Upon discontinuation of infusion, heart rate reduction may last from 0.5 hours to more than 10 hours (median duration 7 hours). Hypotension, if it occurs, may be similarly persistent. In the controlled clinical trials, 3.2% of patients required some form of intervention (typically, use of intravenous fluids or the Trendelenburg position) for blood pressure support following diltiazem hydrochloride injection. In domestic controlled trials, bolus administration of diltiazem hydrochloride injection was effective in converting PSVT to normal sinus rhythm in 88% of patients within 3 minutes of the first or second bolus dose. Symptoms associated with the arrhythmia were improved in conjunction with decreased heart rate or conversion to normal sinus rhythm following administration of diltiazem hydrochloride injection. uuid:54907f00-e339-4fbf-bcfb-66c27e815607 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:101278 biolink:treats MONDO:0007174 PMID:41385096 "[{""id"":""uuid:cf3b6903-abc3-432f-b02e-27e580d709a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:99aac90d-75a0-4f1a-91d1-31bc1e74c4d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diltiazem hydrochloride injection is indicated for the following: Atrial Fibrillation or Atrial Flutter. Temporary control of rapid ventricular rate in atrial fibrillation or atrial flutter. It should not be used in patients with atrial fibrillation or atrial flutter associated with an accessory bypass tract such as in Wolff-Parkinson-White (WPW) syndrome or short PR syndrome. Paroxysmal Supraventricular Tachycardia. Rapid conversion of paroxysmal supraventricular tachycardias (PSVT) to sinus rhythm. This includes AV nodal reentrant tachycardias and reciprocating tachycardias associated with an extranodal accessory pathway such as the WPW syndrome or short PR syndrome. Unless otherwise contraindicated, appropriate vagal maneuvers should be attempted prior to administration of diltiazem hydrochloride injection. The use of diltiazem hydrochloride injection for control of ventricular response in patients with atrial fibrillation or atrial flutter or conversion to sinus rhythm in patients with PSVT should be undertaken with caution when the patient is compromised hemodynamically or is taking other drugs that decrease any or all of the following: peripheral resistance, myocardial filling, myocardial contractility, or electrical impulse propagation in the myocardium. For either indication and particularly when employing continuous intravenous infusion, the setting should include continuous monitoring of the ECG and frequent measurement of blood pressure. A defibrillator and emergency equipment should be readily available. In domestic controlled trials in patients with atrial fibrillation or atrial flutter, bolus administration of diltiazem hydrochloride injection was effective in reducing heart rate by at least 20% in 95% of patients. Diltiazem hydrochloride injection rarely converts atrial fibrillation or atrial flutter to normal sinus rhythm. Following administration of one or two intravenous bolus doses of diltiazem hydrochloride injection, response usually occurs within 3 minutes and maximal heart rate reduction generally occurs in 2 to 7 minutes. Heart rate reduction may last from 1 to 3 hours. If hypotension occurs, it is generally short-lived, but may last from 1 to 3 hours. A 24-hour continuous infusion of diltiazem hydrochloride injection in the treatment of atrial fibrillation or atrial flutter maintained at least a 20% heart rate reduction during the infusion in 83% of patients. Upon discontinuation of infusion, heart rate reduction may last from 0.5 hours to more than 10 hours (median duration 7 hours). Hypotension, if it occurs, may be similarly persistent. In the controlled clinical trials, 3.2% of patients required some form of intervention (typically, use of intravenous fluids or the Trendelenburg position) for blood pressure support following diltiazem hydrochloride injection. In domestic controlled trials, bolus administration of diltiazem hydrochloride injection was effective in converting PSVT to normal sinus rhythm in 88% of patients within 3 minutes of the first or second bolus dose. Symptoms associated with the arrhythmia were improved in conjunction with decreased heart rate or conversion to normal sinus rhythm following administration of diltiazem hydrochloride injection. uuid:264b6580-b95e-445a-bac4-02aea648e174 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:101278 biolink:treats UMLS:C0039232 PMID:41385096 "[{""id"":""uuid:7447d71b-97ec-407c-8e83-6b051e93b0f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7ffafc7d-0e6b-45d4-ae24-7b0186549bf2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diltiazem hydrochloride injection is indicated for the following: Atrial Fibrillation or Atrial Flutter. Temporary control of rapid ventricular rate in atrial fibrillation or atrial flutter. It should not be used in patients with atrial fibrillation or atrial flutter associated with an accessory bypass tract such as in Wolff-Parkinson-White (WPW) syndrome or short PR syndrome. Paroxysmal Supraventricular Tachycardia. Rapid conversion of paroxysmal supraventricular tachycardias (PSVT) to sinus rhythm. This includes AV nodal reentrant tachycardias and reciprocating tachycardias associated with an extranodal accessory pathway such as the WPW syndrome or short PR syndrome. Unless otherwise contraindicated, appropriate vagal maneuvers should be attempted prior to administration of diltiazem hydrochloride injection. The use of diltiazem hydrochloride injection for control of ventricular response in patients with atrial fibrillation or atrial flutter or conversion to sinus rhythm in patients with PSVT should be undertaken with caution when the patient is compromised hemodynamically or is taking other drugs that decrease any or all of the following: peripheral resistance, myocardial filling, myocardial contractility, or electrical impulse propagation in the myocardium. For either indication and particularly when employing continuous intravenous infusion, the setting should include continuous monitoring of the ECG and frequent measurement of blood pressure. A defibrillator and emergency equipment should be readily available. In domestic controlled trials in patients with atrial fibrillation or atrial flutter, bolus administration of diltiazem hydrochloride injection was effective in reducing heart rate by at least 20% in 95% of patients. Diltiazem hydrochloride injection rarely converts atrial fibrillation or atrial flutter to normal sinus rhythm. Following administration of one or two intravenous bolus doses of diltiazem hydrochloride injection, response usually occurs within 3 minutes and maximal heart rate reduction generally occurs in 2 to 7 minutes. Heart rate reduction may last from 1 to 3 hours. If hypotension occurs, it is generally short-lived, but may last from 1 to 3 hours. A 24-hour continuous infusion of diltiazem hydrochloride injection in the treatment of atrial fibrillation or atrial flutter maintained at least a 20% heart rate reduction during the infusion in 83% of patients. Upon discontinuation of infusion, heart rate reduction may last from 0.5 hours to more than 10 hours (median duration 7 hours). Hypotension, if it occurs, may be similarly persistent. In the controlled clinical trials, 3.2% of patients required some form of intervention (typically, use of intravenous fluids or the Trendelenburg position) for blood pressure support following diltiazem hydrochloride injection. In domestic controlled trials, bolus administration of diltiazem hydrochloride injection was effective in converting PSVT to normal sinus rhythm in 88% of patients within 3 minutes of the first or second bolus dose. Symptoms associated with the arrhythmia were improved in conjunction with decreased heart rate or conversion to normal sinus rhythm following administration of diltiazem hydrochloride injection. uuid:4a56d445-329c-4963-a112-2748bc3fdf95 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:101278 biolink:treats EFO:1001432 PMID:41385096 "[{""id"":""uuid:2816abab-983a-436e-953d-47525b29248d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ba6de74c-645b-48b7-9e6f-03f19b3f3e62"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diltiazem hydrochloride injection is indicated for the following: Atrial Fibrillation or Atrial Flutter. Temporary control of rapid ventricular rate in atrial fibrillation or atrial flutter. It should not be used in patients with atrial fibrillation or atrial flutter associated with an accessory bypass tract such as in Wolff-Parkinson-White (WPW) syndrome or short PR syndrome. Paroxysmal Supraventricular Tachycardia. Rapid conversion of paroxysmal supraventricular tachycardias (PSVT) to sinus rhythm. This includes AV nodal reentrant tachycardias and reciprocating tachycardias associated with an extranodal accessory pathway such as the WPW syndrome or short PR syndrome. Unless otherwise contraindicated, appropriate vagal maneuvers should be attempted prior to administration of diltiazem hydrochloride injection. The use of diltiazem hydrochloride injection for control of ventricular response in patients with atrial fibrillation or atrial flutter or conversion to sinus rhythm in patients with PSVT should be undertaken with caution when the patient is compromised hemodynamically or is taking other drugs that decrease any or all of the following: peripheral resistance, myocardial filling, myocardial contractility, or electrical impulse propagation in the myocardium. For either indication and particularly when employing continuous intravenous infusion, the setting should include continuous monitoring of the ECG and frequent measurement of blood pressure. A defibrillator and emergency equipment should be readily available. In domestic controlled trials in patients with atrial fibrillation or atrial flutter, bolus administration of diltiazem hydrochloride injection was effective in reducing heart rate by at least 20% in 95% of patients. Diltiazem hydrochloride injection rarely converts atrial fibrillation or atrial flutter to normal sinus rhythm. Following administration of one or two intravenous bolus doses of diltiazem hydrochloride injection, response usually occurs within 3 minutes and maximal heart rate reduction generally occurs in 2 to 7 minutes. Heart rate reduction may last from 1 to 3 hours. If hypotension occurs, it is generally short-lived, but may last from 1 to 3 hours. A 24-hour continuous infusion of diltiazem hydrochloride injection in the treatment of atrial fibrillation or atrial flutter maintained at least a 20% heart rate reduction during the infusion in 83% of patients. Upon discontinuation of infusion, heart rate reduction may last from 0.5 hours to more than 10 hours (median duration 7 hours). Hypotension, if it occurs, may be similarly persistent. In the controlled clinical trials, 3.2% of patients required some form of intervention (typically, use of intravenous fluids or the Trendelenburg position) for blood pressure support following diltiazem hydrochloride injection. In domestic controlled trials, bolus administration of diltiazem hydrochloride injection was effective in converting PSVT to normal sinus rhythm in 88% of patients within 3 minutes of the first or second bolus dose. Symptoms associated with the arrhythmia were improved in conjunction with decreased heart rate or conversion to normal sinus rhythm following administration of diltiazem hydrochloride injection. uuid:401bf6e5-8d64-4f72-81cc-e780687e5b96 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9811635 biolink:treats MONDO:0006604 PMID:41385096 "[{""id"":""uuid:0b1c37d3-b1ca-4496-9586-5929da3b24f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:efc6ce63-7cb7-424f-80c3-455092c975c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZYLET ® (loteprednol etabonate and tobramycin ophthalmic suspension), 0.5%/0.3% is a topical anti-infective and corticosteroid combination for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, and where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product (tobramycin) is active against the following common bacterial eye pathogens: Staphylococci, including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin-resistant strains. Streptococci, including some of the Group A-beta-hemolytic species, some nonhemolytic species, and some Streptococcus pneumoniae , Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii , most Proteus vulgaris strains, Haemophilus influenzae , and H. aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus and some Neisseria species. uuid:7cf3f500-8fc9-4d45-883e-744d1b530971 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9811635 biolink:treats MONDO:0033816 PMID:41385096 "[{""id"":""uuid:c310a6c3-cae4-4be9-bc1e-18af2fb036b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5e70ab5e-90ea-4d6b-95a8-6731b0388e90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZYLET ® (loteprednol etabonate and tobramycin ophthalmic suspension), 0.5%/0.3% is a topical anti-infective and corticosteroid combination for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, and where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product (tobramycin) is active against the following common bacterial eye pathogens: Staphylococci, including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin-resistant strains. Streptococci, including some of the Group A-beta-hemolytic species, some nonhemolytic species, and some Streptococcus pneumoniae , Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii , most Proteus vulgaris strains, Haemophilus influenzae , and H. aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus and some Neisseria species. uuid:5f4b657f-2151-4224-8e29-947961623138 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9811635 biolink:treats UMLS:C1275687 PMID:41385096 "[{""id"":""uuid:eb21411a-87dc-430c-be9f-008e48d47fac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d2ef7a5b-8611-4265-9ca0-18770e77b38c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZYLET ® (loteprednol etabonate and tobramycin ophthalmic suspension), 0.5%/0.3% is a topical anti-infective and corticosteroid combination for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, and where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product (tobramycin) is active against the following common bacterial eye pathogens: Staphylococci, including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin-resistant strains. Streptococci, including some of the Group A-beta-hemolytic species, some nonhemolytic species, and some Streptococcus pneumoniae , Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii , most Proteus vulgaris strains, Haemophilus influenzae , and H. aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus and some Neisseria species. uuid:7502d8f2-bc3b-4374-bc1c-b96b13d0bd00 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9811635 biolink:treats MONDO:0006814 PMID:41385096 "[{""id"":""uuid:45156535-9b1e-4813-926b-622743dfe131"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:916a79c8-b44a-4dfd-bcbd-89277f21fcbc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZYLET ® (loteprednol etabonate and tobramycin ophthalmic suspension), 0.5%/0.3% is a topical anti-infective and corticosteroid combination for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, and where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product (tobramycin) is active against the following common bacterial eye pathogens: Staphylococci, including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin-resistant strains. Streptococci, including some of the Group A-beta-hemolytic species, some nonhemolytic species, and some Streptococcus pneumoniae , Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii , most Proteus vulgaris strains, Haemophilus influenzae , and H. aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus and some Neisseria species. uuid:055252b6-fdc0-4ea3-aa6a-a7a3b8d238af biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9811635 biolink:treats UMLS:C0010543 PMID:41385096 "[{""id"":""uuid:cc6162dd-c44e-4243-a126-3e369fc7af6c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2a2c0357-c224-48bf-8e2c-3f9514226f68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZYLET ® (loteprednol etabonate and tobramycin ophthalmic suspension), 0.5%/0.3% is a topical anti-infective and corticosteroid combination for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, and where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product (tobramycin) is active against the following common bacterial eye pathogens: Staphylococci, including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin-resistant strains. Streptococci, including some of the Group A-beta-hemolytic species, some nonhemolytic species, and some Streptococcus pneumoniae , Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii , most Proteus vulgaris strains, Haemophilus influenzae , and H. aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus and some Neisseria species. uuid:091ff72c-caf8-4bf5-bfdb-a3c8cb0b81af biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9811635 biolink:treats UMLS:C0008690 PMID:41385096 "[{""id"":""uuid:afee3d02-a73d-4d00-affc-a7faae6eba1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:94567132-7934-42de-af2c-79404867c33f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZYLET ® (loteprednol etabonate and tobramycin ophthalmic suspension), 0.5%/0.3% is a topical anti-infective and corticosteroid combination for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, and where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product (tobramycin) is active against the following common bacterial eye pathogens: Staphylococci, including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin-resistant strains. Streptococci, including some of the Group A-beta-hemolytic species, some nonhemolytic species, and some Streptococcus pneumoniae , Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii , most Proteus vulgaris strains, Haemophilus influenzae , and H. aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus and some Neisseria species. uuid:e0cdfc28-c3b0-4184-bc2d-5da46e5e3a9e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9811635 biolink:treats UMLS:C0339289 PMID:41385096 "[{""id"":""uuid:53a891b6-c4e1-4128-af99-57922afdbee0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:85cf0635-88c6-415a-82ee-84a86d47f332"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZYLET ® (loteprednol etabonate and tobramycin ophthalmic suspension), 0.5%/0.3% is a topical anti-infective and corticosteroid combination for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists. Ocular steroids are indicated in inflammatory conditions of the palpebral and bulbar conjunctiva, cornea and anterior segment of the globe such as allergic conjunctivitis, acne rosacea, superficial punctate keratitis, herpes zoster keratitis, iritis, cyclitis, and where the inherent risk of steroid use in certain infective conjunctivitides is accepted to obtain a diminution in edema and inflammation. They are also indicated in chronic anterior uveitis and corneal injury from chemical, radiation or thermal burns, or penetration of foreign bodies. The use of a combination drug with an anti-infective component is indicated where the risk of superficial ocular infection is high or where there is an expectation that potentially dangerous numbers of bacteria will be present in the eye. The particular anti-infective drug in this product (tobramycin) is active against the following common bacterial eye pathogens: Staphylococci, including S. aureus and S. epidermidis (coagulase-positive and coagulase-negative), including penicillin-resistant strains. Streptococci, including some of the Group A-beta-hemolytic species, some nonhemolytic species, and some Streptococcus pneumoniae , Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter aerogenes, Proteus mirabilis, Morganella morganii , most Proteus vulgaris strains, Haemophilus influenzae , and H. aegyptius, Moraxella lacunata, Acinetobacter calcoaceticus and some Neisseria species. uuid:f1f03d52-fd83-455b-84d5-4bf9174bd423 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45783 biolink:treats MONDO:0006159 PMID:41385096 "[{""id"":""uuid:583ec127-4f35-4a17-a51d-8365466949d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:433d3157-4051-4749-b39b-440c0b8b5968"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d0e24ba5-db60-4997-a17d-02e6b853d9ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/glivec""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Imatinib mesylate is a kinase inhibitor indicated for the treatment of: Newly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. ( 1.1 ) Patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapy. ( 1.2 ) Adult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL). ( 1.3 ) Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapy. (1.4) Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. ( 1.5 ) Adult patients with aggressive systemic mastocytosis (ASM) without the D816V c-Kit mutation or with c-Kit mutational status unknown. ( 1.6 ) Adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or fluorescence in situ hybridization [FISH] demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1­-PDGFRα fusion kinase negative or unknown. ( 1.7 ) Adult patients with unresectable, recurrent and/or metastatic dermatofibrosarcoma protuberans (DFSP). ( 1.8 ) Patients with Kit (CD117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumors (GIST). (1.9) Adjuvant treatment of adult patients following resection of Kit (CD117) positive GIST. (1.10)|[EMA] Imatinib Teva is indicated for the treatment ofAdult and paediatric patients with newly diagnosed Philadelphia chromosome (bcr‑abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment.Adult and paediatric patients with Ph+ CML in chronic phase after failure of interferon‑alpha therapy, or in accelerated phase or blast crisis.Adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy.Adult patients with relapsed or refractory Ph+ ALL as monotherapy.Adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.Adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFRα rearrangement.The effect of imatinib on the outcome of bone marrow transplantation has not been determined.Imatinib Teva is indicated forthe treatment of adult patients with Kit (CD 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST).the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST. Patients who have a low or very low risk of recurrence should not receive adjuvant treatment.The treatment of adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and/or metastatic DFSP who are not eligible for surgery.In adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in CML, on haematological and cytogenetic response rates in Ph+ ALL, MDS/MPD, on haematological response rates in HES/CEL and on objective response rates in adult patients with unresectable and/or metastatic GIST and DFSP and on recurrence-free survival in adjuvant GIST. The experience with imatinib in patients with MDS/MPD associated with PDGFR gene re-arrangements is very limited (see section 5.1). Except in newly diagnosed chronic phase CML, there are no controlled trials demonstrating a clinical benefit or increased survival for these diseases. uuid:53fbed1b-fd78-4194-aec1-daa03543f6ab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0006604 PMID:41385096 "[{""id"":""uuid:e67ecfa9-24a5-481a-8e85-add7489118ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:209cf3b5-0532-4ea7-8c5f-9410ab56071b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZILXI is indicated for the treatment of inflammatory lesions of rosacea in adults [see Clinical Studies ( 14 )] . Limitations of Use This formulation of minocycline has not been evaluated in the treatment of infections. To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, ZILXI should be used only as indicated [see Warnings and Precautions ( 5.14 )] . uuid:225fb276-3281-4b4f-a618-414aa8bcd357 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16586 biolink:treats MONDO:0005039 PMID:41385096 "[{""id"":""uuid:d2b7b5d1-e70e-4b6b-a5f4-4144e5b31107"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:11a63943-6087-471d-aa56-1a38b20da277"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Aminocaproic acid tablets are useful in enhancing hemostasis when fibrinolysis contributes to bleeding. In life-threatening situations, transfusion of appropriate blood products and other emergency measures may be required. Fibrinolytic bleeding may frequently be associated with surgical complications following heart surgery (with or without cardiac bypass procedures) and portacaval shunt; hematological disorders such as amegakaryocytic thrombocytopenia (accompanying aplastic anemia); acute and life-threatening abruptio placentae; hepatic cirrhosis; and neoplastic disease such as carcinoma of the prostate, lung, stomach, and cervix. Urinary fibrinolysis, usually a normal physiological phenomenon, may contribute to excessive urinary tract fibrinolytic bleeding associated with surgical hematuria (following prostatectomy and nephrectomy) or nonsurgical hematuria (accompanying polycystic or neoplastic diseases of the genitourinary system). (See WARNINGS . ) uuid:9908fe79-7f3f-4e41-95f1-d47c71929ad7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28864 biolink:treats MONDO:0009061 PMID:41385096 "[{""id"":""uuid:ad50ac0c-b692-41e3-8f82-8ce91c94349b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:33276023-bc21-49d3-a1db-77b97dce5f3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:54598da5-609d-44d1-8e9b-3f460aab0200"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vantobra-previously-tobramycin-pari""]},{""id"":""uuid:c9e380b2-20c9-45a4-b161-ca0128a2d1ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tobramycin inhalation solution is indicated for the management of cystic fibrosis in adults and pediatric patients 6 years of age and older with Pseudomonas aeruginosa . Safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with forced expiratory volume in 1 second (FEV 1 ) <25% or >75% predicted, or patients colonized with Burkholderia cepacia [see Clinical Studies ( 14 )].|[EMA] Vantobra is indicated for the management of chronic pulmonary infection due to Pseudomonas aeruginosa in patients aged 6 years and older with cystic fibrosis (CF).Consideration should be given to official guidance on the appropriate use of antibacterial agents.|[PMDA] A drug with a new route of administration indicated for the improvement of symptoms associated with respiratory infection caused by Pseudomonas aeruginosa in cystic fibrosis patients. uuid:91fd3664-e6de-4ff2-b0c8-4504e44c2c73 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28864 biolink:treats UMLS:C0854135 PMID:41385096 "[{""id"":""uuid:33631d90-1072-4118-80a1-e25f75e0d8bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bc443def-2551-4f18-b6be-9fc208d4eb65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:52938a49-925e-4b76-b2f1-1cb2db72ec4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tobramycin inhalation solution is indicated for the management of cystic fibrosis in adults and pediatric patients 6 years of age and older with Pseudomonas aeruginosa . Safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with forced expiratory volume in 1 second (FEV 1 ) <25% or >75% predicted, or patients colonized with Burkholderia cepacia [see Clinical Studies ( 14 )].|[PMDA] A drug with a new route of administration indicated for the improvement of symptoms associated with respiratory infection caused by Pseudomonas aeruginosa in cystic fibrosis patients. uuid:67b0b5ff-1921-4b75-8560-a0ec732753b6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28864 biolink:treats UMLS:C1610617 PMID:41385096 "[{""id"":""uuid:e510af91-7445-4eeb-8741-32870b90a756"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:155eebd7-8b75-46e1-a01c-e2c37bc30abb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tobramycin inhalation solution is indicated for the management of cystic fibrosis in adults and pediatric patients 6 years of age and older with Pseudomonas aeruginosa . Safety and efficacy have not been demonstrated in patients under the age of 6 years, patients with forced expiratory volume in 1 second (FEV 1 ) <25% or >75% predicted, or patients colonized with Burkholderia cepacia [see Clinical Studies ( 14 )]. uuid:37334b85-c668-4751-ba6d-7d6d8e946d27 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45081 biolink:treats MONDO:0019121 PMID:41385096 "[{""id"":""uuid:84576289-9a09-42d6-93a0-f95f3c50c872"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:262d75fb-78da-42e2-a66e-9ef366f6637b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pentam 300 (pentamidine isethionate for injection) is indicated for the treatment of pneumonia due to Pneumocystis carinii . uuid:7b112e9f-0ff0-4de3-99eb-afdd1b4b2abb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:N0A21N6RAU biolink:treats UMLS:C0406317 PMID:41385096 "[{""id"":""uuid:f6b99cae-c0a1-4994-8bd2-ca3f0b1da26a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:dba27cf2-93bd-4725-b445-9e864d4d029e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:65a4fa1c-6e47-40be-b6a0-fc38ad8b6abc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SOTYKTU™ is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. Limitations of Use : SOTYKTU is not recommended for use in combination with other potent immunosuppressants.|[PMDA] A drug with a new active ingredient indicated for the treatment of plaque psoriasis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies. uuid:f253e12f-2215-4645-a7e6-49b2ac101668 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats MONDO:0017767 PMID:41385096 "[{""id"":""uuid:089f6fbe-f6f6-47b7-ba43-ce556743bac1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e1b707f4-b816-4faf-8556-24d410534932"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acute bacterial exacerbations of chronic obstructive pulmonary disease due to Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae. Acute bacterial sinusitis due to Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae . Community-acquired pneumonia due to Chlamydophila pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae or Streptococcus pneumoniae in patients appropriate for oral therapy. NOTE: Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomially acquired infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of Streptococcus pyogenes infection and the prophylaxis of rheumatic fever. Azithromycin tablets USP are often effective in the eradication of susceptible strains of Streptococcus pyogenes from the nasopharynx. Because some strains are resistant to azithromycin tablets USP, susceptibility tests should be performed when patients are treated with azithromycin tablets USP. Data establishing efficacy of azithromycin in subsequent prevention of rheumatic fever are not available. Uncomplicated skin and skin structure infections due to Staphylococcus aureus, Streptococcus pyogenes, or Streptococcus agalactiae. Abscesses usually require surgical drainage. Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae . Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. Azithromycin tablets USP, at the recommended dose, should not be relied upon to treat syphilis. Antimicrobial agents used in high doses for short periods of time to treat non-gonococcal urethritis may mask or delay the symptoms of incubating syphilis. All patients with sexually-transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate cultures for gonorrhea performed at the time of diagnosis. Appropriate antimicrobial therapy and follow-up tests for these diseases should be initiated if infection is confirmed. Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin, USP. Therapy with azithromycin tablets USP may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly. To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin tablets USP and other antibacterial drugs, azithromycin tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:23b47098-7f12-4f58-b72a-041c774860c1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats MONDO:0005227 PMID:41385096 "[{""id"":""uuid:e325b36f-9225-40b4-9d0e-cff492b061a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bc509a17-a35b-43a0-9bae-a29389d3570c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acute bacterial exacerbations of chronic obstructive pulmonary disease due to Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae. Acute bacterial sinusitis due to Haemophilus influenzae, Moraxella catarrhalis or Streptococcus pneumoniae . Community-acquired pneumonia due to Chlamydophila pneumoniae, Haemophilus influenzae, Mycoplasma pneumoniae or Streptococcus pneumoniae in patients appropriate for oral therapy. NOTE: Azithromycin should not be used in patients with pneumonia who are judged to be inappropriate for oral therapy because of moderate to severe illness or risk factors such as any of the following: patients with cystic fibrosis, patients with nosocomially acquired infections, patients with known or suspected bacteremia, patients requiring hospitalization, elderly or debilitated patients, or patients with significant underlying health problems that may compromise their ability to respond to their illness (including immunodeficiency or functional asplenia). Pharyngitis/tonsillitis caused by Streptococcus pyogenes as an alternative to first-line therapy in individuals who cannot use first-line therapy. NOTE: Penicillin by the intramuscular route is the usual drug of choice in the treatment of Streptococcus pyogenes infection and the prophylaxis of rheumatic fever. Azithromycin tablets USP are often effective in the eradication of susceptible strains of Streptococcus pyogenes from the nasopharynx. Because some strains are resistant to azithromycin tablets USP, susceptibility tests should be performed when patients are treated with azithromycin tablets USP. Data establishing efficacy of azithromycin in subsequent prevention of rheumatic fever are not available. Uncomplicated skin and skin structure infections due to Staphylococcus aureus, Streptococcus pyogenes, or Streptococcus agalactiae. Abscesses usually require surgical drainage. Urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae . Genital ulcer disease in men due to Haemophilus ducreyi (chancroid). Due to the small number of women included in clinical trials, the efficacy of azithromycin in the treatment of chancroid in women has not been established. Azithromycin tablets USP, at the recommended dose, should not be relied upon to treat syphilis. Antimicrobial agents used in high doses for short periods of time to treat non-gonococcal urethritis may mask or delay the symptoms of incubating syphilis. All patients with sexually-transmitted urethritis or cervicitis should have a serologic test for syphilis and appropriate cultures for gonorrhea performed at the time of diagnosis. Appropriate antimicrobial therapy and follow-up tests for these diseases should be initiated if infection is confirmed. Appropriate culture and susceptibility tests should be performed before treatment to determine the causative organism and its susceptibility to azithromycin, USP. Therapy with azithromycin tablets USP may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly. To reduce the development of drug-resistant bacteria and maintain the effectiveness of azithromycin tablets USP and other antibacterial drugs, azithromycin tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:23636616-73e8-42be-98dc-780285c578ee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135738 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:cab48375-d623-430b-967a-bafec330d30a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:59c1649d-722d-4f99-bda5-ee9caf017ba0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cleviprex is indicated for the reduction of blood pressure when oral therapy is not feasible or not desirable. uuid:8f54719c-1509-4ca7-b317-374162dd4be5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats MONDO:0008170 PMID:41385096 "[{""id"":""uuid:b09690a4-04cf-4bbd-8075-1eed97e0aea0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6165b7cc-186f-48bd-b58f-7f8a379b6426"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ff33a312-5283-4883-a700-b5723c3c3f18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:20b10d0e-b50b-41db-8941-007fcf49eb45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxorubicin hydrochloride liposome injection is an anthracycline topoisomerase inhibitor indicated for: • Ovarian cancer After failure of platinum-based chemotherapy ( 1.1 ). • AIDS-related Kaposi’s Sarcoma After failure of prior systemic chemotherapy or intolerance to such therapy ( 1.2 ) . • Multiple Myeloma In combination with bortezomib in patients who have not previously received bortezomib and have received at least one prior therapy ( 1.3 ) .|[EMA] Zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. Zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. Zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• Kaposi’s sarcoma in patients with AIDS who have a very damaged immune system. Kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs.Zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. This means that it is similar to a ‘reference medicine’ containing the same active substance called Adriamycin. However, in Zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for Adriamycin.|[PMDA] A drug with a new indication and a new dosage for the treatment of ovarian cancer which has progressed after cancer chemotherapy. [Expedited review] uuid:d3d3e6e5-335e-484a-bc92-bb397571b3d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats MONDO:0005055 PMID:41385096 "[{""id"":""uuid:0dcf8949-9145-40ae-a06a-603d8eec3e67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4e1bf0d8-660d-4144-8fa9-d622e99be943"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:16469c38-49de-4051-a531-718efe81d60e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:aa8c3e48-8a94-4a1a-8ff8-791e835c0634"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxorubicin hydrochloride liposome injection is an anthracycline topoisomerase inhibitor indicated for: • Ovarian cancer After failure of platinum-based chemotherapy ( 1.1 ). • AIDS-related Kaposi’s Sarcoma After failure of prior systemic chemotherapy or intolerance to such therapy ( 1.2 ) . • Multiple Myeloma In combination with bortezomib in patients who have not previously received bortezomib and have received at least one prior therapy ( 1.3 ) .|[EMA] Zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. Zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. Zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• Kaposi’s sarcoma in patients with AIDS who have a very damaged immune system. Kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs.Zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. This means that it is similar to a ‘reference medicine’ containing the same active substance called Adriamycin. However, in Zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for Adriamycin.|[PMDA] Drug with a new indication and dosage for treatment of AIDS-related Kaposi’s sarcoma. [Orphan Drug] uuid:80a2720e-f6bd-44d1-9221-1dfebbb60097 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:520d88eb-fcab-4e74-aee5-15a0bc59e634"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:1d4b1f05-b37e-4f53-a6f5-e255eba6dbc0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:71e5c288-c456-4ec7-8c11-6a3c7e48a9f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxorubicin hydrochloride liposome injection is an anthracycline topoisomerase inhibitor indicated for: • Ovarian cancer After failure of platinum-based chemotherapy ( 1.1 ). • AIDS-related Kaposi’s Sarcoma After failure of prior systemic chemotherapy or intolerance to such therapy ( 1.2 ) . • Multiple Myeloma In combination with bortezomib in patients who have not previously received bortezomib and have received at least one prior therapy ( 1.3 ) .|[EMA] Zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. Zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. Zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• Kaposi’s sarcoma in patients with AIDS who have a very damaged immune system. Kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs.Zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. This means that it is similar to a ‘reference medicine’ containing the same active substance called Adriamycin. However, in Zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for Adriamycin. uuid:0999465f-6e0d-418a-90b9-7212cc678de6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49040 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:276d4028-48f9-4107-80a0-42dc69408849"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c944fec9-7e59-46b1-a8e1-d805ba0b4a5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. 1.1 Primary Hyperlipidemia Monotherapy Ezetimibe Tablets, administered alone, is indicated as adjunctive therapy to diet for the reduction of elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), and non-high-density lipoprotein cholesterol (non-HDL-C) in patients with primary (heterozygous familial and non-familial) hyperlipidemia. Combination Therapy with HMG-CoA Reductase Inhibitors (Statins) Ezetimibe Tablets, administered in combination with a 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor (statin), is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, Apo B, and non-HDL-C in patients with primary (heterozygous familial and non-familial) hyperlipidemia. Combination Therapy with Fenofibrate Ezetimibe Tablets, administered in combination with fenofibrate, is indicated as adjunctive therapy to diet for the reduction of elevated total-C, LDL-C, Apo B, and non-HDL-C in adult patients with mixed hyperlipidemia. 1.2 Homozygous Familial Hypercholesterolemia (HoFH) The combination of Ezetimibe Tablets and atorvastatin or simvastatin is indicated for the reduction of elevated total-C and LDL-C levels in patients with HoFH, as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable. 1.3 Homozygous Sitosterolemia Ezetimibe Tablet is indicated as adjunctive therapy to diet for the reduction of elevated sitosterol and campesterol levels in patients with homozygous familial sitosterolemia. 1.4 Limitations of Use The effect of Ezetimibe Tablets on cardiovascular morbidity and mortality has not been determined. Ezetimibe Tablets has not been studied in Fredrickson Type I, III, IV, and V dyslipidemias. uuid:1e78b9d1-135b-4b84-ae28-6bcd7a604c0e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4450 biolink:treats UMLS:C0018674 PMID:41385096 "[{""id"":""uuid:4cf71383-d117-47a6-b73d-06c3863d32f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:da0e7201-d142-496a-916b-e24936d4c22b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DDAVP Injection is a vasopressin analog used for: Central Diabetes Insipidus - as antidiuretic replacement therapy in the management of central (cranial) diabetes insipidus and for the management of the temporary polyuria and polydipsia following head trauma or surgery in the pituitary region. ( 1.1 ) Hemophilia A- for patients with factor VIII coagulant activity levels greater than 5% to maintain hemostasis during surgical procedures and postoperatively or reduce bleeding with episodes of spontaneous or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. ( 1.2 ) von Willebrand's disease (Type I) - for patients with mild to moderate disease with factor VIII levels greater than 5% to maintain hemostasis during surgical procedures or traumatic injuries such as hemarthroses, intramuscular hematomas, or mucosal bleeding. ( 1.3 ) Limitations of Use DDAVP is ineffective and not indicated for the treatment of nephrogenic diabetes insipidus. ( 1.3 ) von Willebrand's disease (severe Type I) - not indicated for the treatment of patients with severe Type I von Willebrand's disease and when there is evidence of an abnormal molecular form of factor VIII antigen. ( 1.3 ) uuid:8645745f-027c-433a-896a-bd57a6a0fe0d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:66899 biolink:treats MONDO:0005338 PMID:41385096 "[{""id"":""uuid:df363049-2f4d-4787-99aa-bb6fb8d86780"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fb312987-a712-4825-9a46-8795a702a817"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZIOPTAN ® (tafluprost ophthalmic solution) 0.0015% is indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. uuid:3505104d-8cc4-499c-b660-733473517583 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:66899 biolink:treats MONDO:0006875 PMID:41385096 "[{""id"":""uuid:4cf8c378-1aa6-463f-9738-7788d5423ed5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8c6a680b-ed6b-41b1-980a-c2ff5836972d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZIOPTAN ® (tafluprost ophthalmic solution) 0.0015% is indicated for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. uuid:577d9915-1849-4d3b-af12-888e084bb1c7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:177736 biolink:treats UMLS:C4543399 PMID:41385096 "[{""id"":""uuid:1356f97d-913d-4459-8917-f712fe24b1bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3bd7a00e-d493-4ae0-a145-de322935ffa3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Xermelo is indicated for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy. uuid:b178efd3-2a6e-4251-937b-90465d2dc335 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0005244 PMID:41385096 "[{""id"":""uuid:3b9db50d-b9a0-4ca3-9bd1-ba65eda6091e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4e855211-a0c8-45b5-a86e-0269d26293d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Anesthetic for relief of pain at site of injury; relief of musculoskeletal pain and soreness; pain from neuropathy; local medical procedures, injections and vaccines; relief of pruritis, pruritic eczema, abrasions, minor burns, insect bites, pain, soreness and discomfort due to pruritis ani, pruritis vulvae, hemorrhoids, anal fissures and similar conditions of the skin and mucous membranes. uuid:a4addbbc-f991-411a-8151-3fc8e0e68a17 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17026 biolink:treats MONDO:0001836 PMID:41385096 "[{""id"":""uuid:f7d7be34-a59f-4e46-acec-be8bb1572d0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dce28163-40c2-493d-b318-ab6df4a32118"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] This drug is indicated in amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer. uuid:e2e9359a-7cef-4cd0-bccd-8b8f536a4f6f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17026 biolink:treats UMLS:C3650625 PMID:41385096 "[{""id"":""uuid:33f338a5-48a0-498f-a6ea-6d5877066c42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d36a1cf8-600a-4b50-810d-c130aff5b192"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] This drug is indicated in amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer. uuid:bb9cd12d-c8de-47a7-9cb3-b8ca2ef73af6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17026 biolink:treats MONDO:0001664 PMID:41385096 "[{""id"":""uuid:561604e1-a060-4ea3-a8af-a10cba5eff87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:51d0a67f-1e6c-48c7-836f-b348d076e444"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] This drug is indicated in amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer. uuid:d72f840e-de4d-46fb-88a2-08170d2c42cd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17026 biolink:treats MONDO:0002715 PMID:41385096 "[{""id"":""uuid:ac360819-0cb5-4f95-bad2-6f0cf65ef658"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b1c8ba83-bd78-4fb5-9a83-7e75af0954b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] This drug is indicated in amenorrhea and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer. uuid:266e7f96-b70e-440f-82ac-ef9fc2193288 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17905 biolink:treats MONDO:0000496 PMID:41385096 "[{""id"":""uuid:ff579987-2367-47c4-bd16-4b5b021a56aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:21fad20c-0307-435c-ab9b-067bc2abfb95"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mesna Injection is indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis. Limitation of Use : Mesna Injection is not indicated to reduce the risk of hematuria due to other pathological conditions such as thrombocytopenia. uuid:7adf8b18-094c-4961-a40b-a3927d1e0dc7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17905 biolink:treats MONDO:0002049 PMID:41385096 "[{""id"":""uuid:0fee3c8e-f1b9-405f-939c-005ee5211ec3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7ffaa9d2-028e-4cae-8dea-a16489d027e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mesna Injection is indicated as a prophylactic agent in reducing the incidence of ifosfamide-induced hemorrhagic cystitis. Limitation of Use : Mesna Injection is not indicated to reduce the risk of hematuria due to other pathological conditions such as thrombocytopenia. uuid:f5088186-cdd9-4eea-babb-42af78ec91c3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:183909 biolink:treats MONDO:0005393 PMID:41385096 "[{""id"":""uuid:21960d15-592d-481c-afb2-a25f5fb1b941"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f39d72b2-c01c-4689-997d-540f4d40a56f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Colchicine tablets are an alkaloid indicated for: Prophylaxis and treatment of gout flares in adults ( 1.1 ). Familial Mediterranean fever (FMF) in adults and children 4 years or older ( 1.2 ). uuid:afb89132-2e38-49e8-b691-bbe283889a97 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:183909 biolink:treats MONDO:0018088 PMID:41385096 "[{""id"":""uuid:19675fba-394d-4b33-af89-1fcd08a50523"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0c70b3a1-4695-4c44-a4dd-c14345ab992c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Colchicine tablets are an alkaloid indicated for: Prophylaxis and treatment of gout flares in adults ( 1.1 ). Familial Mediterranean fever (FMF) in adults and children 4 years or older ( 1.2 ). uuid:fdd0b55d-864f-491c-82df-79aeba38329b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9241 biolink:treats UMLS:C0341960 PMID:41385096 "[{""id"":""uuid:d07ac0c0-aa85-48c4-9ab3-371ed4bffe4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:82cf598f-666b-4639-b0a8-ca3d7f0cea59"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone tablets are indicated in the management of: Primary hyperaldosteronism for: Establishing the diagnosis of primary hyperaldosteronism by therapeutic trial. Short-term preoperative treatment of patients with primary hyperaldosteronism. Long-term maintenance therapy for patients with discrete aldosterone-producing adrenal adenomas who are judged to be poor operative risks or who decline surgery. Long-term maintenance therapy for patients with bilateral micro or macronodular adrenal hyperplasia (idiopathic hyperaldosteronism). Edematous conditions for patients with: Congestive heart failure: For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures. Spironolactone tablets are also indicated for patients with congestive heart failure taking digitalis when other therapies are considered inappropriate. Cirrhosis of the liver accompanied by edema and/or ascites: Aldosterone levels may be exceptionally high in this condition. Spironolactone tablets are indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. Nephrotic syndrome: For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response. Essential hypertension Spironolactone tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Usually in combination with other drugs, spironolactone tablets are indicated for patients who cannot be treated adequately with other agents or for whom other agents are considered inappropriate. Hypokalemia For the treatment of patients with hypokalemia when other measures are considered inappropriate or inadequate. Spironolactone tablets are also indicated for the prophylaxis of hypokalemia in patients taking digitalis when other measures are considered inadequate or inappropriate. Severe heart failure (NYHA class III – IV) To increase survival, and to reduce the need for hospitalization for heart failure when used in addition to standard therapy. Usage in Pregnancy: The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developing toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Spironolactone tablets are indicated in pregnancy when edema is due to pathologic causes just as it is in the absence of pregnancy (however, see Precautions: Pregnancy). Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is unsupported and unnecessary. There is hypervolemia during normal pregnancy which is not harmful to either the fetus or the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort that is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate. uuid:ad63efa9-b31a-4c24-9df8-276bae70c9e9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:499361 biolink:treats HP:0002017 PMID:41385096 "[{""id"":""uuid:db894518-0817-4edf-baa8-d8cb8edc47d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:656d17ca-4e31-404d-af73-00dd17d06d9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fosaprepitant for injection, in combination with other antiemetic agents, is indicated in adults and pediatric patients 6 months of age and older for the prevention of: • acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. • delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). Limitations of Use • Fosaprepitant for injection has not been studied for the treatment of established nausea and vomiting. uuid:01117346-9ee4-41be-bc1f-6259da538911 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:499361 biolink:treats EFO:0006911 PMID:41385096 "[{""id"":""uuid:695eff27-9a5c-4f72-bb61-7ab6c4527deb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:877530c8-3f13-4a3f-9b41-8f7e97228c7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ee41f2be-21de-4657-8e60-d1adc16ff65c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/emend""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fosaprepitant for injection, in combination with other antiemetic agents, is indicated in adults and pediatric patients 6 months of age and older for the prevention of: • acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. • delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). Limitations of Use • Fosaprepitant for injection has not been studied for the treatment of established nausea and vomiting.|[EMA] Emend 40 mg hard capsules is indicated for the prevention of postoperative nausea and vomiting (PONV) in adults.Emend is also available as 80 mg and 125 mg hard capsules for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and adolescents from the age of 12 (see separate Summary of Product Characteristics).Emend is also available as 165 mg hard capsules for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin based cancer chemotherapy in adults and the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy in adults.Emend is also available as powder for oral suspension for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in children, toddlers and infants from the age of 6 months to less than 12 years.Emend 80 mg, 125 mg, 165 mg hard capsules and Emend powder for oral suspension are given as part of combination therapy. uuid:4a12cbf9-58b4-4112-8c41-e22ba585ae2c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:0b9b74d8-0424-4e80-a5a5-1315f7f602f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c559414b-448b-4c90-8cbc-5046f4488f35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:df25de08-1995-438a-ad63-e4f63527ad4c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0005480 PMID:41385096 "[{""id"":""uuid:9270ecd0-687d-474a-bb8a-76e8f3272c5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fa8f6f53-5f55-475a-bf44-3a5399eec1ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:a6be954a-8b76-4754-b04e-92bfd02e3a66 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0000775 PMID:41385096 "[{""id"":""uuid:473b1ccd-adf4-4a46-9dc7-f2b588ae023a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:256e635c-a89d-4c79-af5e-0f278b2e0fdd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:e98e5916-bc1c-4ae8-aebf-c0c191c8246f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0024332 PMID:41385096 "[{""id"":""uuid:841f5430-5775-4204-a589-b513219c2ead"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2902679f-2c8e-4ac8-932f-c21e9132da82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:ef1db380-75d8-4a16-9e7f-3761aa5e6ec4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:997a4267-16bf-4a2d-ae76-5994629f3e1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ea69c7c7-730f-40fc-a2dd-8cc6a5dc5363"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:a5b34073-3c95-4af6-b8c0-9330e127d966 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0043789 PMID:41385096 "[{""id"":""uuid:65acfc3d-2449-497d-943d-c311153a52e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:66befce8-a573-4980-9cf9-92204a724399"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:f1ee19a6-3eb9-493e-addc-73531b398232 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats UMLS:C0274435 PMID:41385096 "[{""id"":""uuid:764e70f0-351d-4030-9941-68c974a2711b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a3093a16-d8f5-48de-95a7-a8d761e92ad4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:b2accbec-10c9-45ee-a9a0-aa9eea884c42 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0015614 PMID:41385096 "[{""id"":""uuid:11f2cc15-f50c-4e60-8ea2-8ca937b331d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1e0651dd-b4af-4d20-88da-b759e3537f4c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:26e9d1f9-a270-4b02-bc63-cb941362bf72 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0043233 PMID:41385096 "[{""id"":""uuid:5974fa21-8dd8-4d41-aa26-0e5b8ae6c9ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0e5f634e-3fcb-47d8-b574-da9b9cb6d24a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:928b80c6-c95a-4170-8d76-c99a288a97f3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0009691 PMID:41385096 "[{""id"":""uuid:d5285954-2949-433f-803c-67bb340ef076"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b180d6e5-8fd1-4259-af16-324a959ddb61"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:102f21c7-2be3-43e3-997b-b051615fe9aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0006594 PMID:41385096 "[{""id"":""uuid:abb62773-cb73-4f7c-a821-9262a2cffcce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e295698d-21a0-4ed3-ae79-fc6828a655c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:593596b6-2654-4f08-9376-60bc07a590bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0018229 PMID:41385096 "[{""id"":""uuid:58f4390a-581a-4e63-a4b1-81d78efa4ade"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:51532382-ca6a-418c-a7dd-5426532b951e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:b4dd7cf9-06bb-4d8f-aeb1-af1fa9ea7dfd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0018479 PMID:41385096 "[{""id"":""uuid:801d8b15-cf0b-443d-9279-c9089add9fce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:be85f914-92d0-4310-bc0f-c80681f241d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:13b03c44-09cf-4dd2-93e4-1d89d902594b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0043455 PMID:41385096 "[{""id"":""uuid:1d963151-d7b8-4566-852d-df77e3e039fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aa3dd667-fa2e-4769-bad0-9fc1842913df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:6e21f25c-a526-428d-aef2-81fbb9583b85 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0006982 PMID:41385096 "[{""id"":""uuid:6fb70a2f-7602-4a45-b757-193915ab2e53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6e9b3448-c2f0-4cd9-abc2-b234a3f98e87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:fb82f22b-cda9-435c-8789-c70f7cc759fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0000004 PMID:41385096 "[{""id"":""uuid:3a7ab819-4b45-4a70-966b-2f674c26ea19"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:12b61c1d-1810-4a31-86f6-fa3d46b0179e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:61941e30-5633-458d-9d8a-c9d97c4da484 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats UMLS:C0678202 PMID:41385096 "[{""id"":""uuid:68e3c239-bbb8-4566-9da7-481543aa08a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0551ceb9-5529-442b-b8ee-5cd5ceaa082b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:08d2b5c7-3115-42b4-be17-1c5ae2ee2177 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:b39e42d1-c664-4b23-a953-dfb636554c32"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:be653b6f-eecb-410c-8668-7fd3785335d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:b38de7ad-a2fb-4602-8816-025e736646b8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0020108 PMID:41385096 "[{""id"":""uuid:5cbcb812-c0da-4053-bb2f-9636ca527418"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c26b17e0-fd4b-49fd-898e-99337a842880"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:faf1f381-e1e7-47c1-b666-08cd191eda91 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0015253 PMID:41385096 "[{""id"":""uuid:3cbd4e43-f9b7-45c1-adf2-00b75367a927"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6aac7b5e-01a2-48fe-ae30-ffd78eb77b75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:89b1ad2a-3dfb-4f10-a205-f2b4c868d9e2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0001705 PMID:41385096 "[{""id"":""uuid:2c27152a-746d-42aa-877f-8562631ffc1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6512417a-7b41-423e-bab2-fc87499c23d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:6209c55c-786a-42db-83c5-4dad1f101004 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0001198 PMID:41385096 "[{""id"":""uuid:02927836-9714-4c67-927c-3f09083d7115"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6432a09c-910b-4adc-aa4b-c3961e72c224"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:89e759d5-3fe5-4090-b998-40c12bfe296e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0019444 PMID:41385096 "[{""id"":""uuid:dc1f7da0-4af3-4c76-b161-53612c03c62f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1e0d1b88-7545-46f4-8882-40efac06c781"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:d9765da6-aea6-4e6d-bd86-761c673e8249 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0006042 PMID:41385096 "[{""id"":""uuid:d2131d93-bc75-4d91-a281-ff64daffbb1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:97020e5f-1469-4511-82dd-7ba57cdb5a5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:ffac5e5c-c515-4f68-968e-dce8ab825232 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0005059 PMID:41385096 "[{""id"":""uuid:884ff12a-59bc-4a57-8cf9-06eed98dc7d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b8df28a3-feda-4339-be0c-dabb757a5655"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:e178ceeb-e690-4ab6-ac9a-d76100ee70ed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0004095 PMID:41385096 "[{""id"":""uuid:d356e75b-95ec-4cd1-90a3-4b7995bebe6c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f9f19de6-6f24-4062-aeb6-37046f9a488b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:3cdc8d57-f54f-4635-90df-7a7deb5b938b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:6cbcaba9-3149-4e91-ba1d-c2a0528dcbe0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b965f0bf-802f-4a5d-a539-642c5127c636"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:a8ef985a-e5c5-44fe-8e11-12f8c6855912 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0006684 PMID:41385096 "[{""id"":""uuid:b31c1468-125e-4ab2-a2f5-cd09a542e685"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:21095b00-d9d4-443d-baa3-a6d99652e4e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:c3454ce5-a871-4984-bffe-976c5367d909 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0021632 PMID:41385096 "[{""id"":""uuid:690fca77-b65a-4e00-b912-b05e1a9f35a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a762cb71-3b2c-49ab-8748-5fd4e3159f03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:b5d0c923-d915-4923-8b9c-a999720dad3d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:1040026 PMID:41385096 "[{""id"":""uuid:50e07f7c-dd45-4865-ae8f-92703df4077e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:60c81b3f-eb66-4d92-b5f9-a6b8b9818a49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:6f6b68f6-c2d8-48e0-8368-bd3931823aee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0019198 PMID:41385096 "[{""id"":""uuid:6c4c63da-9207-42da-b230-a35fc45cf33f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4700c1b4-cd51-472e-9ab6-b0f14e0efcc1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:3c0f6bc4-5cd9-4bec-b671-7e40dadbe9be biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0008538 PMID:41385096 "[{""id"":""uuid:e56fc7ec-6372-4929-a598-fcbb3268b65e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:911b2216-8a37-43ff-aa21-6cc039af5f8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:2ef6d8f6-84d6-4076-9ca2-c3f94a064688 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0020283 PMID:41385096 "[{""id"":""uuid:92307997-6c0d-4211-aaea-7679443ca881"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6f1c347f-fb33-4dfd-8738-13e742d12d65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:577f4af8-c0f3-4324-ac97-d9b444f0d334 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0018170 PMID:41385096 "[{""id"":""uuid:1547c626-feba-4188-8f75-12150183d4cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ecf665a4-cac6-44f8-9c5f-0737f893e3f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:c69db1e6-8843-46d4-a0b7-18b0e8252032 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0004670 PMID:41385096 "[{""id"":""uuid:04cf0ab6-0e76-41ff-9dc1-b2e1ce08b497"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eb7eb81d-8623-4363-be5f-71f2499ae0b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:4a3a2378-c98b-49d8-94cb-65cbdfa1fab0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0015274 PMID:41385096 "[{""id"":""uuid:2629f402-8bf1-4746-8ea2-aab78e047b2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cb7afb91-4482-454c-87f3-79401923a721"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:1bf8ae77-85aa-4611-b814-e2bbb07e65d4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0006052 PMID:41385096 "[{""id"":""uuid:b2584311-def0-40b9-8307-ca0843496d88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:33d718f0-92d7-4535-a7b4-dd928a1cf215"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:1ef3423d-e9fd-4b19-b25f-ef14b846efdc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0005848 PMID:41385096 "[{""id"":""uuid:4ad7fb3d-74b7-4b6d-97dd-4fab619ff617"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bffc4bee-1122-4f61-ab31-ffca3caf66c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:6bbd66ae-5d53-40fc-997f-0f569a815b27 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0015927 PMID:41385096 "[{""id"":""uuid:e8c18bf7-d4d9-4f36-9593-3ad0a465bbdf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:66365434-6269-45a9-872e-59577146a572"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:20b1a693-d74a-4ee5-8911-d3de04ad80f0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0019338 PMID:41385096 "[{""id"":""uuid:bfa3237c-4bd7-43f6-bf27-4eece7674158"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0db43cd0-abcf-4510-ae55-bb8d25bd27b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:e0571a06-0c2e-40ba-aaa7-32cfaeb3f0d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats UMLS:C0149896 PMID:41385096 "[{""id"":""uuid:2cb9b5fa-a22e-490d-9011-c98cdf795bd0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:babbeccd-912d-4c18-89d0-89be788d0050"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:8a3c8d7f-16bb-4314-9dfd-9fd5ccd34d5c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats UMLS:C5441648 PMID:41385096 "[{""id"":""uuid:7d45a3fc-99dd-418a-95f0-30ae3eb02941"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:df40d80f-ff0b-4702-98fb-4c454c28d404"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:d1e599ec-6a62-4d64-b412-e356ccf28253 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:9172a248-a873-4eb3-854d-5430af2dbd69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1d08de6e-86a5-42b9-9af5-a7d83980d113"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:92c2192d-4de9-424b-ab69-cfd2e05c2690 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:86ccf000-d4a0-43c8-92c9-813ee0ab1fc0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c6b54875-09e5-408e-94c1-270990ce6ff0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:4f323c2e-e4c5-4cdf-a1f0-c33446826ef0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:2aa2a529-5231-48e1-9272-9e79d7523e14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:449e5086-5140-4ad4-8e93-15e26b7564fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:9f403411-163f-4000-a6dd-443428b935cb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0011429 PMID:41385096 "[{""id"":""uuid:1608ce67-7199-4af0-a287-b32749ee54bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c63b73f4-6734-4f55-9b71-cf4a214d50f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:1754c958-3cb1-491e-8535-848c1e19eacd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0016367 PMID:41385096 "[{""id"":""uuid:b6ca5d23-a708-4272-ad21-5af9fdc0690a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d6864f9b-412d-43f1-8c50-78b1875b8f39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:de9c5293-fcda-4c8e-b1df-c53763df795c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0019127 PMID:41385096 "[{""id"":""uuid:aa8584a1-b5f9-4a97-b95f-4ef5b1bd1b64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5a56e6fa-d9dc-4a91-9ede-d6c309fad3ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:6c37f1ad-2200-4b4e-89e4-6932885905b1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0040698 PMID:41385096 "[{""id"":""uuid:79d55e05-a218-4fd9-9abb-71adaf27a216"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:34591692-4de4-484e-8c13-a87f6f2502d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:e1aa11cc-b5f9-456a-ac34-71eedcebaa33 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0004855 PMID:41385096 "[{""id"":""uuid:118bdb11-7afb-4e06-b86d-ee63afdd42b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3b4564c7-14ff-45eb-9fdd-808945d536ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:5a01e2d6-129b-4ee8-b31a-708ead1f575a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0001875 PMID:41385096 "[{""id"":""uuid:005fda80-e6d1-4d8d-9495-5a67d4f311f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ee727973-bc8d-4c62-8319-6d2cd8868859"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:488d0123-dc9c-4049-afc1-e2889f152f06 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:6159f6cd-dad8-4fba-a5ca-a4154174245f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3a09d588-daa3-4dde-b583-8c65c4c8925a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:43298dc6-4081-4279-aef2-82fc844d8770 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0005340 PMID:41385096 "[{""id"":""uuid:f9836a46-d5e9-45ea-8c87-fba250f3e196"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4256327c-034f-4dab-b2f4-d107703c8de7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:fbab4abd-d9e9-4b47-a1b8-dd3feeb8ceaa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0019558 PMID:41385096 "[{""id"":""uuid:490e3b12-26ef-4e7d-a561-4972f23df013"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d81e33a8-510f-41e4-a472-38d79860d99f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:a45a6aa0-25fe-4b4a-8891-06744f2c624f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0005348 PMID:41385096 "[{""id"":""uuid:3cd67c0b-e143-4555-b816-1371d43ef718"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b7938854-2b5e-4515-a2f2-156bae6dedcb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:2bf4d5ba-cd1e-4d92-985e-2ef659cc11ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0006554 PMID:41385096 "[{""id"":""uuid:17871986-30b4-4cad-b41e-660c15235a3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c0634a42-0a65-4626-8b5c-b70c50fca9cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:3e40f74a-3f26-44e7-b786-65f5e4de9afa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0006572 PMID:41385096 "[{""id"":""uuid:9ac4f436-665e-4cab-88ab-0dd782dfd9f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c1b07d78-afed-4924-abca-b53ae60c9e92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:3c1854bf-5fd8-4529-a314-17fa97ee0cd1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0006585 PMID:41385096 "[{""id"":""uuid:612ef622-dce4-4701-bca9-4b6f8b3c27e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a5950a9d-00f2-4661-b329-b89895601403"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:a9807ede-c6c5-4894-a1ca-59fb8359415b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats UMLS:C0392445 PMID:41385096 "[{""id"":""uuid:87f402b1-e549-41e0-bbbd-b5c9af8d7d52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:62edd93c-6c15-478d-aa30-343926f21405"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:76d0cea5-a969-4404-9670-aff2b821daf1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0004874 PMID:41385096 "[{""id"":""uuid:0670423a-1639-4322-97f0-4780254ea752"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d2f25f12-befb-4bb4-a9f1-5a0c88be7b0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:f4c69025-966c-4e5e-bf7f-4616fc21affb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24847774 biolink:treats MONDO:0004795 PMID:41385096 "[{""id"":""uuid:1d465be2-4b26-4860-af2d-c52b21ee5745"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b2a27a9a-dc5e-4d73-bfa3-8cec2ec56d8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of superficial infections of the external auditory canal caused by organisms susceptible to the action of the antimicrobial, complicated by inflammation. uuid:bfe7277c-c5d4-4d58-b435-3b901b130524 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24847774 biolink:treats NCIT:C3137 PMID:41385096 "[{""id"":""uuid:85d1afb8-3f44-4a1e-9306-750b04ddbc38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:86a25fda-8d83-4a0f-a6d4-5eefefcc812f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of superficial infections of the external auditory canal caused by organisms susceptible to the action of the antimicrobial, complicated by inflammation. uuid:0e273c23-8292-4ee0-8cea-f9451fdc4e59 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32588 biolink:treats UMLS:C0151595 PMID:41385096 "[{""id"":""uuid:e4baa906-7020-4ab2-85bd-1a9399c69c5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9e1fb9b3-2061-447e-8924-46ab5e780017"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BECAUSE OF REPORTS OF INTESTINAL AND GASTRIC ULCERATION AND BLEEDING WITH CONTROLLED-RELEASE POTASSIUM CHLORIDE PREPARATIONS, THESE DRUGS SHOULD BE RESERVED FOR THOSE PATIENTS WHO CANNOT TOLERATE OR REFUSE TO TAKE LIQUID OR EFFERVESCENT POTASSIUM PREPARATIONS OR FOR PATIENTS IN WHOM THERE IS A PROBLEM OF COMPLIANCE WITH THESE PREPARATIONS. For the treatment of patients with hypokalemia with or without metabolic alkalosis, in digitalis intoxication, and in patients with hypokalemic familial periodic paralysis. If hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. For the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias. The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern and when low doses of the diuretic are used. Serum potassium should be checked periodically, however, and if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases, and if dose adjustment of the diuretic is ineffective or unwarranted, supplementation with potassium salts may be indicated. uuid:1a72ff07-ffa4-4d3f-8bcf-7b3f16e62759 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32588 biolink:treats MONDO:0008223 PMID:41385096 "[{""id"":""uuid:e831b529-81cc-4c81-9e74-25bfade2c984"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:251ef39d-331f-46ba-b955-c357114b2674"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BECAUSE OF REPORTS OF INTESTINAL AND GASTRIC ULCERATION AND BLEEDING WITH CONTROLLED-RELEASE POTASSIUM CHLORIDE PREPARATIONS, THESE DRUGS SHOULD BE RESERVED FOR THOSE PATIENTS WHO CANNOT TOLERATE OR REFUSE TO TAKE LIQUID OR EFFERVESCENT POTASSIUM PREPARATIONS OR FOR PATIENTS IN WHOM THERE IS A PROBLEM OF COMPLIANCE WITH THESE PREPARATIONS. For the treatment of patients with hypokalemia with or without metabolic alkalosis, in digitalis intoxication, and in patients with hypokalemic familial periodic paralysis. If hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. For the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias. The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern and when low doses of the diuretic are used. Serum potassium should be checked periodically, however, and if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases, and if dose adjustment of the diuretic is ineffective or unwarranted, supplementation with potassium salts may be indicated. uuid:61f17645-ebf3-49fd-86e5-49747ff24a37 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32588 biolink:treats MONDO:0007263 PMID:41385096 "[{""id"":""uuid:46f87a57-cdb4-4779-bf62-5e6393032e32"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ea140535-977a-4f32-b6a0-6ef34d697774"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BECAUSE OF REPORTS OF INTESTINAL AND GASTRIC ULCERATION AND BLEEDING WITH CONTROLLED-RELEASE POTASSIUM CHLORIDE PREPARATIONS, THESE DRUGS SHOULD BE RESERVED FOR THOSE PATIENTS WHO CANNOT TOLERATE OR REFUSE TO TAKE LIQUID OR EFFERVESCENT POTASSIUM PREPARATIONS OR FOR PATIENTS IN WHOM THERE IS A PROBLEM OF COMPLIANCE WITH THESE PREPARATIONS. For the treatment of patients with hypokalemia with or without metabolic alkalosis, in digitalis intoxication, and in patients with hypokalemic familial periodic paralysis. If hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. For the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias. The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern and when low doses of the diuretic are used. Serum potassium should be checked periodically, however, and if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases, and if dose adjustment of the diuretic is ineffective or unwarranted, supplementation with potassium salts may be indicated. uuid:3ef6f770-34cb-418b-bc7e-0a23df0afccc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32588 biolink:treats MONDO:0001134 PMID:41385096 "[{""id"":""uuid:954d14e9-954b-4884-9cbf-cbe99a5fd987"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2ac8635e-e0ce-4fe7-8003-c7a9897cd005"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BECAUSE OF REPORTS OF INTESTINAL AND GASTRIC ULCERATION AND BLEEDING WITH CONTROLLED-RELEASE POTASSIUM CHLORIDE PREPARATIONS, THESE DRUGS SHOULD BE RESERVED FOR THOSE PATIENTS WHO CANNOT TOLERATE OR REFUSE TO TAKE LIQUID OR EFFERVESCENT POTASSIUM PREPARATIONS OR FOR PATIENTS IN WHOM THERE IS A PROBLEM OF COMPLIANCE WITH THESE PREPARATIONS. For the treatment of patients with hypokalemia with or without metabolic alkalosis, in digitalis intoxication, and in patients with hypokalemic familial periodic paralysis. If hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. For the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias. The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern and when low doses of the diuretic are used. Serum potassium should be checked periodically, however, and if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases, and if dose adjustment of the diuretic is ineffective or unwarranted, supplementation with potassium salts may be indicated. uuid:9f24ed18-0253-4a52-8630-e252e338dd28 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72323 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:3cf6374f-37f4-487a-b18a-1f587bac88b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e47e9338-0f1d-418d-a36e-d9e80f44b1cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e18f5f33-d539-4f0d-b7cc-50ac405f63b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:75000157-39c6-400c-a64b-59c580d70c0f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Alogliptin tablets are a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1.1 , 14 ) Important Limitations of Use: Not for treatment of type 1 diabetes or diabetic ketoacidosis. ( 1.1 )|[EMA] Vipidia is indicated in adults aged 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control (see sections 4.4, 4.5 and 5.1 for available data on different combinations).|[PMDA] Drugs with a new active ingredient indicated for the treatment of type 2 diabetes (for use only in patients with inadequate glycemic control by following treatments: Treatment by diet and exercise only In addition to treatment by diet and exercise, treatment by alpha-glucosidase inhibitor). uuid:ca92866e-baab-4df2-be9f-4e83c2e9ffaa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72323 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:6a39bb7e-bade-483b-8648-961dbc7d6922"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f45bc1e4-6a08-4e1a-b1c0-bacc23e0d90f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Alogliptin tablets are a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1.1 , 14 ) Important Limitations of Use: Not for treatment of type 1 diabetes or diabetic ketoacidosis. ( 1.1 ) uuid:565ec8f7-2bdc-4dc9-86e8-c43cc00a6cfe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72323 biolink:treats MONDO:0012819 PMID:41385096 "[{""id"":""uuid:c808d372-4829-4655-8448-433eefb16fac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:70776df0-e84b-404e-a2ce-8b87b641e0fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Alogliptin tablets are a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1.1 , 14 ) Important Limitations of Use: Not for treatment of type 1 diabetes or diabetic ketoacidosis. ( 1.1 ) uuid:e9e05081-509d-4e2c-ac1b-799b918b8219 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5880 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:39c479a5-b0d8-4a5a-91da-540f72235e64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ab079627-b3e5-4bd5-b6ed-543901cbba0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Imipenem and Cilastatin for Injection, USP for intravenous use is a combination of imipenem, a penem antibacterial, and cilastatin, a renal dehydropeptidase inhibitor, indicated for the treatment of the following serious infections caused by designated susceptible bacteria: Lower respiratory tract infections. ( 1.1 ) Urinary tract infections. ( 1.2 ) Intra-abdominal infections. ( 1.3 ) Gynecologic infections. ( 1.4 ) Bacterial septicemia. ( 1.5 ) Bone and joint infections. ( 1.6 ) Skin and skin structure infections. ( 1.7 ) Endocarditis. ( 1.8 ) Limitations of Use : Imipenem and Cilastatin for Injection, USP (I.V.) is not indicated in patients with meningitis because safety and efficacy have not been established ( 1.9 ). Imipenem and Cilastatin for Injection, USP (I.V.) is not recommended in pediatric patients with CNS infections because of the risk of seizures ( 1.9 ). Imipenem and Cilastatin for Injection, USP (I.V.) is not recommended in pediatric patients weighing less than 30 kg with impaired renal function ( 1.9 ). Usage : To reduce the development of drug resistant bacteria and maintain the effectiveness of Imipenem and Cilastatin for Injection, USP (I.V.) and other antibacterial drugs, Imipenem and Cilastatin for Injection, USP (I.V.) should be used only to treat infections that are proven or strongly suspected to be caused by bacteria ( 1.10 ). PUBCHEM.COMPOUND:17756656 uuid:657aec19-9bf3-4f10-a30d-87315a6c3c3e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5880 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:8cda52d3-c2db-446e-a8aa-f8722d0e41ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5ae64145-90e2-4aa0-bd9c-7c0150067ab8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Imipenem and Cilastatin for Injection, USP for intravenous use is a combination of imipenem, a penem antibacterial, and cilastatin, a renal dehydropeptidase inhibitor, indicated for the treatment of the following serious infections caused by designated susceptible bacteria: Lower respiratory tract infections. ( 1.1 ) Urinary tract infections. ( 1.2 ) Intra-abdominal infections. ( 1.3 ) Gynecologic infections. ( 1.4 ) Bacterial septicemia. ( 1.5 ) Bone and joint infections. ( 1.6 ) Skin and skin structure infections. ( 1.7 ) Endocarditis. ( 1.8 ) Limitations of Use : Imipenem and Cilastatin for Injection, USP (I.V.) is not indicated in patients with meningitis because safety and efficacy have not been established ( 1.9 ). Imipenem and Cilastatin for Injection, USP (I.V.) is not recommended in pediatric patients with CNS infections because of the risk of seizures ( 1.9 ). Imipenem and Cilastatin for Injection, USP (I.V.) is not recommended in pediatric patients weighing less than 30 kg with impaired renal function ( 1.9 ). Usage : To reduce the development of drug resistant bacteria and maintain the effectiveness of Imipenem and Cilastatin for Injection, USP (I.V.) and other antibacterial drugs, Imipenem and Cilastatin for Injection, USP (I.V.) should be used only to treat infections that are proven or strongly suspected to be caused by bacteria ( 1.10 ). PUBCHEM.COMPOUND:17756656 uuid:dd865891-1cb5-4271-bedd-28263274d0d0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5880 biolink:treats UMLS:C1112209 PMID:41385096 "[{""id"":""uuid:511a99ab-87b9-4bfa-a806-cd1abccb90de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2648b62a-24d1-4809-aed0-72174067ad54"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Imipenem and Cilastatin for Injection, USP for intravenous use is a combination of imipenem, a penem antibacterial, and cilastatin, a renal dehydropeptidase inhibitor, indicated for the treatment of the following serious infections caused by designated susceptible bacteria: Lower respiratory tract infections. ( 1.1 ) Urinary tract infections. ( 1.2 ) Intra-abdominal infections. ( 1.3 ) Gynecologic infections. ( 1.4 ) Bacterial septicemia. ( 1.5 ) Bone and joint infections. ( 1.6 ) Skin and skin structure infections. ( 1.7 ) Endocarditis. ( 1.8 ) Limitations of Use : Imipenem and Cilastatin for Injection, USP (I.V.) is not indicated in patients with meningitis because safety and efficacy have not been established ( 1.9 ). Imipenem and Cilastatin for Injection, USP (I.V.) is not recommended in pediatric patients with CNS infections because of the risk of seizures ( 1.9 ). Imipenem and Cilastatin for Injection, USP (I.V.) is not recommended in pediatric patients weighing less than 30 kg with impaired renal function ( 1.9 ). Usage : To reduce the development of drug resistant bacteria and maintain the effectiveness of Imipenem and Cilastatin for Injection, USP (I.V.) and other antibacterial drugs, Imipenem and Cilastatin for Injection, USP (I.V.) should be used only to treat infections that are proven or strongly suspected to be caused by bacteria ( 1.10 ). PUBCHEM.COMPOUND:17756656 uuid:7bdfd317-5a17-4eb3-8abd-1c295c31ab5d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5880 biolink:treats UMLS:C0684256 PMID:41385096 "[{""id"":""uuid:2a59555f-0f0b-467a-ab74-bc3b3039353c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c3557df4-0b91-4b97-ad4e-4584a872ec5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Imipenem and Cilastatin for Injection, USP for intravenous use is a combination of imipenem, a penem antibacterial, and cilastatin, a renal dehydropeptidase inhibitor, indicated for the treatment of the following serious infections caused by designated susceptible bacteria: Lower respiratory tract infections. ( 1.1 ) Urinary tract infections. ( 1.2 ) Intra-abdominal infections. ( 1.3 ) Gynecologic infections. ( 1.4 ) Bacterial septicemia. ( 1.5 ) Bone and joint infections. ( 1.6 ) Skin and skin structure infections. ( 1.7 ) Endocarditis. ( 1.8 ) Limitations of Use : Imipenem and Cilastatin for Injection, USP (I.V.) is not indicated in patients with meningitis because safety and efficacy have not been established ( 1.9 ). Imipenem and Cilastatin for Injection, USP (I.V.) is not recommended in pediatric patients with CNS infections because of the risk of seizures ( 1.9 ). Imipenem and Cilastatin for Injection, USP (I.V.) is not recommended in pediatric patients weighing less than 30 kg with impaired renal function ( 1.9 ). Usage : To reduce the development of drug resistant bacteria and maintain the effectiveness of Imipenem and Cilastatin for Injection, USP (I.V.) and other antibacterial drugs, Imipenem and Cilastatin for Injection, USP (I.V.) should be used only to treat infections that are proven or strongly suspected to be caused by bacteria ( 1.10 ). PUBCHEM.COMPOUND:17756656 uuid:046a5bc9-e8e6-4415-bbd2-16c88b9cafa8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5880 biolink:treats UMLS:C0851989 PMID:41385096 "[{""id"":""uuid:832c968f-b64f-4395-8bb8-622a03186360"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:30f78039-aa5f-400a-ae09-81a2e28104e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Imipenem and Cilastatin for Injection, USP for intravenous use is a combination of imipenem, a penem antibacterial, and cilastatin, a renal dehydropeptidase inhibitor, indicated for the treatment of the following serious infections caused by designated susceptible bacteria: Lower respiratory tract infections. ( 1.1 ) Urinary tract infections. ( 1.2 ) Intra-abdominal infections. ( 1.3 ) Gynecologic infections. ( 1.4 ) Bacterial septicemia. ( 1.5 ) Bone and joint infections. ( 1.6 ) Skin and skin structure infections. ( 1.7 ) Endocarditis. ( 1.8 ) Limitations of Use : Imipenem and Cilastatin for Injection, USP (I.V.) is not indicated in patients with meningitis because safety and efficacy have not been established ( 1.9 ). Imipenem and Cilastatin for Injection, USP (I.V.) is not recommended in pediatric patients with CNS infections because of the risk of seizures ( 1.9 ). Imipenem and Cilastatin for Injection, USP (I.V.) is not recommended in pediatric patients weighing less than 30 kg with impaired renal function ( 1.9 ). Usage : To reduce the development of drug resistant bacteria and maintain the effectiveness of Imipenem and Cilastatin for Injection, USP (I.V.) and other antibacterial drugs, Imipenem and Cilastatin for Injection, USP (I.V.) should be used only to treat infections that are proven or strongly suspected to be caused by bacteria ( 1.10 ). PUBCHEM.COMPOUND:17756656 uuid:26c2af1e-0a42-4eae-950d-399d54ed1780 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5880 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:ea90e680-dbd0-4f57-bfdd-674a32b89a47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9f7a68e0-9a42-42cf-8b98-44d21c7841bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Imipenem and Cilastatin for Injection, USP for intravenous use is a combination of imipenem, a penem antibacterial, and cilastatin, a renal dehydropeptidase inhibitor, indicated for the treatment of the following serious infections caused by designated susceptible bacteria: Lower respiratory tract infections. ( 1.1 ) Urinary tract infections. ( 1.2 ) Intra-abdominal infections. ( 1.3 ) Gynecologic infections. ( 1.4 ) Bacterial septicemia. ( 1.5 ) Bone and joint infections. ( 1.6 ) Skin and skin structure infections. ( 1.7 ) Endocarditis. ( 1.8 ) Limitations of Use : Imipenem and Cilastatin for Injection, USP (I.V.) is not indicated in patients with meningitis because safety and efficacy have not been established ( 1.9 ). Imipenem and Cilastatin for Injection, USP (I.V.) is not recommended in pediatric patients with CNS infections because of the risk of seizures ( 1.9 ). Imipenem and Cilastatin for Injection, USP (I.V.) is not recommended in pediatric patients weighing less than 30 kg with impaired renal function ( 1.9 ). Usage : To reduce the development of drug resistant bacteria and maintain the effectiveness of Imipenem and Cilastatin for Injection, USP (I.V.) and other antibacterial drugs, Imipenem and Cilastatin for Injection, USP (I.V.) should be used only to treat infections that are proven or strongly suspected to be caused by bacteria ( 1.10 ). PUBCHEM.COMPOUND:17756656 uuid:40175c59-f095-422f-8bf9-44734b0f0b67 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5880 biolink:treats MONDO:0005025 PMID:41385096 "[{""id"":""uuid:50e7c6f5-b459-47ca-abc7-e35faef63fbe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5848c59d-c2eb-406d-bc5a-544566a9a611"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Imipenem and Cilastatin for Injection, USP for intravenous use is a combination of imipenem, a penem antibacterial, and cilastatin, a renal dehydropeptidase inhibitor, indicated for the treatment of the following serious infections caused by designated susceptible bacteria: Lower respiratory tract infections. ( 1.1 ) Urinary tract infections. ( 1.2 ) Intra-abdominal infections. ( 1.3 ) Gynecologic infections. ( 1.4 ) Bacterial septicemia. ( 1.5 ) Bone and joint infections. ( 1.6 ) Skin and skin structure infections. ( 1.7 ) Endocarditis. ( 1.8 ) Limitations of Use : Imipenem and Cilastatin for Injection, USP (I.V.) is not indicated in patients with meningitis because safety and efficacy have not been established ( 1.9 ). Imipenem and Cilastatin for Injection, USP (I.V.) is not recommended in pediatric patients with CNS infections because of the risk of seizures ( 1.9 ). Imipenem and Cilastatin for Injection, USP (I.V.) is not recommended in pediatric patients weighing less than 30 kg with impaired renal function ( 1.9 ). Usage : To reduce the development of drug resistant bacteria and maintain the effectiveness of Imipenem and Cilastatin for Injection, USP (I.V.) and other antibacterial drugs, Imipenem and Cilastatin for Injection, USP (I.V.) should be used only to treat infections that are proven or strongly suspected to be caused by bacteria ( 1.10 ). PUBCHEM.COMPOUND:17756656 uuid:35c3730a-0a8c-4593-8581-85fa07e41002 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7459 biolink:treats UMLS:C0029104 PMID:41385096 "[{""id"":""uuid:8440c2c9-1bc9-4c28-94d8-d203264dd6da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4a1a97f9-e0a2-4d74-af33-e75da64b5b20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Naloxone HCl Nasal Spray is indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. Naloxone HCl Nasal Spray is intended for immediate administration as emergency therapy in settings where opioids may be present. Naloxone HCl Nasal Spray is not a substitute for emergency medical care. Limitations of Use: Restrict prescription of naloxone hydrochloride nasal spray 2 mg to opioid-dependent patients expected to be at risk for severe opioid withdrawal in situations where there is a low risk for accidental or intentional opioid exposure by household contacts. uuid:e1128132-edc7-478d-a99b-5b4dcc36bbaf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5523 biolink:treats MONDO:0004956 PMID:41385096 "[{""id"":""uuid:90b743c5-3b8c-40b1-8745-a01a1cb1be4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:120246a9-e482-456b-b9fc-66f6081a7ca5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZOLADEX is a Gonadotropin Releasing Hormone (GnRH) agonist indicated for: Use in combination with flutamide for the management of locally confined carcinoma of the prostate ( 1.1 ) Use as palliative treatment of advanced carcinoma of the prostate ( 1.2 ) uuid:5ff58d93-1779-4fe6-bc36-36c45fe3a7a7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3561 biolink:treats UMLS:C0234935 PMID:41385096 "[{""id"":""uuid:e0f7d8ea-4cdb-4635-96c9-9c63b638e25e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1efdd123-5f82-404d-b94f-fe208938890c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] QUZYTTIR™ is indicated for the treatment of acute urticaria in adults and children 6 months of age and older. uuid:03317203-5653-45b4-a3b8-11b979dc403d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135515 biolink:treats MONDO:0004948 PMID:41385096 "[{""id"":""uuid:a2d62cbc-d9a2-4024-abe0-2a570f6abba3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4ba473b3-30b8-4487-b159-ae6f8c21a4bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4b63462c-1673-4a3b-a1e0-e441f5730ae4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TREANDA is an alkylating drug indicated for treatment of patients with: Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established. ( 1.1 ) Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. ( 1.2 )|[PMDA] A drug with a new additional indication, dosage, and dosage form for the treatment of chronic lymphocytic leukemia. [Orphan drug] uuid:42bf265f-e668-4b1e-90e4-76f3f85481a5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135515 biolink:treats MONDO:0017594 PMID:41385096 "[{""id"":""uuid:b5f32036-b9c6-4fd4-9f4f-1005bac6dcbc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4bc04ba8-e9fe-45fa-9091-bd1f047d29c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7c7f5a04-ff34-41d6-b5b6-78ec9ce3cdf8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TREANDA is an alkylating drug indicated for treatment of patients with: Chronic lymphocytic leukemia (CLL). Efficacy relative to first line therapies other than chlorambucil has not been established. ( 1.1 ) Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. ( 1.2 )|[PMDA] A drug with a new active ingredient indicated for the treatment of relapsed or refractory indolent B- cell non-Hodgkin’s lymphoma and mantle cell lymphoma. [Orphan drug] uuid:08c18024-7ca7-41bf-8c57-3d0862b5adf1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:177836 biolink:treats MONDO:0005191 PMID:41385096 "[{""id"":""uuid:d9b31ebc-44ad-405f-adaa-9842e406546c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0f9ddf57-c57b-4028-a3fa-a18c3c32474c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dacarbazine for Injection is indicated in the treatment of metastatic malignant melanoma. In addition, Dacarbazine for Injection is also indicated for Hodgkin’s disease as a second-line therapy when used in combination with other effective agents. uuid:7adaaf40-70f7-468c-9f1c-3217309cdbb0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:177836 biolink:treats MONDO:0009348 PMID:41385096 "[{""id"":""uuid:047dbffd-4da7-42a6-a582-c73b6903e43f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:483a12d0-e6d5-44a5-bc6d-90a73a386a3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dacarbazine for Injection is indicated in the treatment of metastatic malignant melanoma. In addition, Dacarbazine for Injection is also indicated for Hodgkin’s disease as a second-line therapy when used in combination with other effective agents. uuid:3576dfa9-059e-4dfc-b71e-fedb1a42eb92 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2038 biolink:treats MONDO:0018874 PMID:41385096 "[{""id"":""uuid:e31d05b1-4a11-4cdb-896a-cfe5022605cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:91df0ce2-53c1-4dda-a92f-bc72b142f790"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:6c8e7c7e-009f-4841-91fd-706c68f0d848"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/azacitidine-mylan""]},{""id"":""uuid:64a71852-5f62-41b7-8340-7c6f41d1b43f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ONUREG is indicated for continued treatment of adult patients with acute myeloid leukemia who achieved first complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following intensive induction chemotherapy and are not able to complete intensive curative therapy.|[EMA] Azacitidine Mylan is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with:intermediate 2 and high risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS),chronic myelomonocytic leukaemia (CMML) with 10 29% marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (AML) with 20 30% blasts and multi lineage dysplasia, according to World Health Organisation (WHO) classification,AML with > 30% marrow blasts according to the WHO classification.|[PMDA] A drug with a new indication for the treatment of acute myeloid leukemia. [Expedited review] uuid:b828828f-1585-4d69-be74-691ea9244a71 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28939 biolink:treats UMLS:C0572025 PMID:41385096 "[{""id"":""uuid:62e30fe8-3777-40ab-9b7a-f17faf37c239"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ef153084-6c9e-45d2-bf0b-e9a2b2f86e3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Acetylcysteine Injection is an antidote for acetaminophen overdose indicated to prevent or lessen hepatic injury after ingestion of a potentially hepatotoxic quantity of acetaminophen. Overdose incidences are divided into two types; Acute Ingestion or Repeated Supratherapeutic Ingestion (RSI). [see Dosage and Administration ( 2 ) and Acetaminophen Assays – Interpretation and Methodology -(Acute or Repeated Supratherapeutic Ingestion) ( 1.1 , 1.2 )] . On admission for suspected acetaminophen overdose, a serum blood sample should be drawn at least 4 hours after ingestion to determine the acetaminophen level and will serve as a basis for determining the need for treatment with acetylcysteine. If the patient presents after 4 hours post-ingestion, the serum acetaminophen sample should be determined immediately. Acetylcysteine Injection should be administered within 8 hours from acetaminophen ingestion for maximal protection against hepatic injury for patients whose serum acetaminophen levels fall above the ""possible"" toxicity line on the Rumack-Matthew nomogram (line connecting 150 mcg/mL at 4 hours with 37.5 mcg/mL at 12 hours); [see Acetaminophen Assays – Interpretation and Methodology (1.1, 1.2 )] . If the time of ingestion is unknown, or the serum acetaminophen level is not available, cannot be interpreted, or is not available within the 8 hour time interval from acetaminophen ingestion, Acetylcysteine Injection should be administered immediately if 24 hours or less have elapsed from the reported time of ingestion of an overdose of acetaminophen, regardless of the quantity reported to have been ingested. The aspartate aminotransferase (AST, SGOT), alanine aminotranferase (ALT, SGPT), bilirubin, prothrombin time, creatinine, blood urea nitrogen (BUN), blood glucose, and electrolytes also should be determined in order to monitor hepatic and renal function and electrolyte and fluid balance. NOTE: The critical ingestion-treatment interval for maximal protection against severe hepatic injury is between 0 to 8 hours. Efficacy diminishes progressively after 8 hours and treatment initiation between 15 and 24 hours post-ingestion of acetaminophen yields limited efficacy. However, it does not appear to worsen the condition of patients and it should not be withheld, since the reported time of ingestion may not be correct." uuid:8d4d8158-d195-4835-a278-259897e3bc3c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45924 biolink:treats MONDO:0006929 PMID:41385096 "[{""id"":""uuid:f8d56d67-fd94-4afb-9d65-1b4d3972a2da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6f7d5e8a-1e70-406e-9554-1de0fb24a35e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of trimethoprim tablets and other antibacterial drugs, trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. For the treatment of initial episodes of uncomplicated urinary tract infections due to susceptible strains of the following organisms: Escherichia coli , Proteus mirabilis , Klebsiella pneumoniae , Enterobacter species, and coagulase-negative Staphylococcus species, including S. saprophyticus . Cultures and susceptibility tests should be performed to determine the susceptibility of the bacteria to trimethoprim. Therapy may be initiated prior to obtaining the results of these tests. uuid:b6eae0ab-a582-45e9-bda4-12efa640ce28 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45924 biolink:treats MONDO:0030602 PMID:41385096 "[{""id"":""uuid:b4c75647-6e57-403b-b4f2-733e2fc0f9fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:04ec0e7b-385c-467d-a437-289f3a745784"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of trimethoprim tablets and other antibacterial drugs, trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. For the treatment of initial episodes of uncomplicated urinary tract infections due to susceptible strains of the following organisms: Escherichia coli , Proteus mirabilis , Klebsiella pneumoniae , Enterobacter species, and coagulase-negative Staphylococcus species, including S. saprophyticus . Cultures and susceptibility tests should be performed to determine the susceptibility of the bacteria to trimethoprim. Therapy may be initiated prior to obtaining the results of these tests. uuid:67de9a0a-fd5d-4fec-b7b3-f4b046f04864 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17750 biolink:treats MONDO:0009609 PMID:41385096 "[{""id"":""uuid:fbf21cf3-7aaf-43ab-b525-4c9440fd58e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6c1ece2a-a52a-4ef3-b00e-b1dbf6d3d11b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Betaine Anhydrous for Oral Solution is indicated for the treatment of homocystinuria to decrease elevated homocysteine blood concentrations in pediatric and adult patients. Included within the category of homocystinuria are Cystathionine beta-synthase (CBS) deficiency 5,10-methylenetetrahydrofolate reductase (MTHFR) deficiency Cobalamin cofactor metabolism (cbl) defect uuid:88146d93-1c02-4b56-8f4e-101bcd92abee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135876 biolink:treats MONDO:0004703 PMID:41385096 "[{""id"":""uuid:ae9f2627-5268-46a3-b6db-ffce855e1222"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5bd2a156-ae7a-45c9-ad01-c6a749d5de38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Valrubicin intravesical solution is an anthracycline topoisomerase inhibitor indicated for intravesical therapy of BCG-refractory carcinoma in situ (CIS) of the urinary bladder in patients for whom immediate cystectomy would be associated with unacceptable morbidity or mortality. uuid:f5792b13-3db5-4f47-8c24-63fa0c879f95 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2637 biolink:treats UMLS:C0684256 PMID:41385096 "[{""id"":""uuid:b7ed6f5c-3758-49ae-b1fe-78af247fac88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8c3ff2bf-62c4-4636-9ba4-f505cc7f3b11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amikacin Sulfate Injection, USP is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli , species of indole-positive and indole-negative Proteus , Providencia species, Klebsiella-Enterobacter-Serratia species, and Acinetobacter ( Mima-Herellea ) species. Clinical studies have shown Amikacin Sulfate Injection, USP to be effective in bacterial septicemia (including neonatal sepsis); in serious infections of the respiratory tract, bones and joints, central nervous system (including meningitis) and skin and soft tissue; intra-abdominal infections (including peritonitis); and in burns and postoperative infections (including post-vascular surgery). Clinical studies have shown amikacin also to be effective in serious complicated and recurrent urinary tract infections due to those organisms. Aminoglycosides, including Amikacin Sulfate Injection, USP are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Bacteriologic studies should be performed to identify causative organisms and their susceptibilities to amikacin. Amikacin may be considered as initial therapy in suspected Gram-negative infections and therapy may be instituted before obtaining the results of susceptibility testing. Clinical trials demonstrated that amikacin was effective in infections caused by gentamicin and/or tobramycin-resistant strains of Gram-negative organisms, particularly Proteus rettgeri , Providencia stuartii , Serratia marcescens , and Pseudomonas aeruginosa . The decision to continue therapy with the drug should be based on results of the susceptibility tests, the severity of the infection, the response of the patient and the important additional considerations contained in the WARNINGS box above. Amikacin has also been shown to be effective in staphylococci infections and may be considered as initial therapy under certain conditions in the treatment of known or suspected staphylococcal disease such as, severe infections where the causative organism may be either a Gram-negative bacterium or a staphylococcus, infections due to susceptible strains of staphylococci in patients allergic to other antibiotics, and in mixed staphylococci/Gram-negative infections. In certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin-type drug may be indicated because of the possibility of infections due to Gram-positive organisms such as streptococci or pneumococci. To reduce the development of drug-resistant bacteria and maintain the effectiveness of amikacin and other antibacterial drugs, amikacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:eb90bacc-79e0-4354-b775-fba6d1837ddf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2637 biolink:treats MONDO:0700217 PMID:41385096 "[{""id"":""uuid:e4c81fe6-e662-47e1-b495-3ac0274eb234"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e3c5f303-c52e-46a5-a009-ade6e52506ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amikacin Sulfate Injection, USP is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli , species of indole-positive and indole-negative Proteus , Providencia species, Klebsiella-Enterobacter-Serratia species, and Acinetobacter ( Mima-Herellea ) species. Clinical studies have shown Amikacin Sulfate Injection, USP to be effective in bacterial septicemia (including neonatal sepsis); in serious infections of the respiratory tract, bones and joints, central nervous system (including meningitis) and skin and soft tissue; intra-abdominal infections (including peritonitis); and in burns and postoperative infections (including post-vascular surgery). Clinical studies have shown amikacin also to be effective in serious complicated and recurrent urinary tract infections due to those organisms. Aminoglycosides, including Amikacin Sulfate Injection, USP are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Bacteriologic studies should be performed to identify causative organisms and their susceptibilities to amikacin. Amikacin may be considered as initial therapy in suspected Gram-negative infections and therapy may be instituted before obtaining the results of susceptibility testing. Clinical trials demonstrated that amikacin was effective in infections caused by gentamicin and/or tobramycin-resistant strains of Gram-negative organisms, particularly Proteus rettgeri , Providencia stuartii , Serratia marcescens , and Pseudomonas aeruginosa . The decision to continue therapy with the drug should be based on results of the susceptibility tests, the severity of the infection, the response of the patient and the important additional considerations contained in the WARNINGS box above. Amikacin has also been shown to be effective in staphylococci infections and may be considered as initial therapy under certain conditions in the treatment of known or suspected staphylococcal disease such as, severe infections where the causative organism may be either a Gram-negative bacterium or a staphylococcus, infections due to susceptible strains of staphylococci in patients allergic to other antibiotics, and in mixed staphylococci/Gram-negative infections. In certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin-type drug may be indicated because of the possibility of infections due to Gram-positive organisms such as streptococci or pneumococci. To reduce the development of drug-resistant bacteria and maintain the effectiveness of amikacin and other antibacterial drugs, amikacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:4ebcd64d-00fc-40fc-9bab-90a2af9bec26 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2637 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:5bd035d7-04a0-4e5f-9fb3-46541e6347e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:65782fd3-870e-436c-ab6b-b55cfdc2ece5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amikacin Sulfate Injection, USP is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli , species of indole-positive and indole-negative Proteus , Providencia species, Klebsiella-Enterobacter-Serratia species, and Acinetobacter ( Mima-Herellea ) species. Clinical studies have shown Amikacin Sulfate Injection, USP to be effective in bacterial septicemia (including neonatal sepsis); in serious infections of the respiratory tract, bones and joints, central nervous system (including meningitis) and skin and soft tissue; intra-abdominal infections (including peritonitis); and in burns and postoperative infections (including post-vascular surgery). Clinical studies have shown amikacin also to be effective in serious complicated and recurrent urinary tract infections due to those organisms. Aminoglycosides, including Amikacin Sulfate Injection, USP are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Bacteriologic studies should be performed to identify causative organisms and their susceptibilities to amikacin. Amikacin may be considered as initial therapy in suspected Gram-negative infections and therapy may be instituted before obtaining the results of susceptibility testing. Clinical trials demonstrated that amikacin was effective in infections caused by gentamicin and/or tobramycin-resistant strains of Gram-negative organisms, particularly Proteus rettgeri , Providencia stuartii , Serratia marcescens , and Pseudomonas aeruginosa . The decision to continue therapy with the drug should be based on results of the susceptibility tests, the severity of the infection, the response of the patient and the important additional considerations contained in the WARNINGS box above. Amikacin has also been shown to be effective in staphylococci infections and may be considered as initial therapy under certain conditions in the treatment of known or suspected staphylococcal disease such as, severe infections where the causative organism may be either a Gram-negative bacterium or a staphylococcus, infections due to susceptible strains of staphylococci in patients allergic to other antibiotics, and in mixed staphylococci/Gram-negative infections. In certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin-type drug may be indicated because of the possibility of infections due to Gram-positive organisms such as streptococci or pneumococci. To reduce the development of drug-resistant bacteria and maintain the effectiveness of amikacin and other antibacterial drugs, amikacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:a270a1b8-6eb8-4eda-9961-4822e41777f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2637 biolink:treats MONDO:0005246 PMID:41385096 "[{""id"":""uuid:2e791c88-41f7-4e17-b982-b36a7b3b5b74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9e8dc8b4-d0be-4f49-a02f-4929f9ee9e1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amikacin Sulfate Injection, USP is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli , species of indole-positive and indole-negative Proteus , Providencia species, Klebsiella-Enterobacter-Serratia species, and Acinetobacter ( Mima-Herellea ) species. Clinical studies have shown Amikacin Sulfate Injection, USP to be effective in bacterial septicemia (including neonatal sepsis); in serious infections of the respiratory tract, bones and joints, central nervous system (including meningitis) and skin and soft tissue; intra-abdominal infections (including peritonitis); and in burns and postoperative infections (including post-vascular surgery). Clinical studies have shown amikacin also to be effective in serious complicated and recurrent urinary tract infections due to those organisms. Aminoglycosides, including Amikacin Sulfate Injection, USP are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Bacteriologic studies should be performed to identify causative organisms and their susceptibilities to amikacin. Amikacin may be considered as initial therapy in suspected Gram-negative infections and therapy may be instituted before obtaining the results of susceptibility testing. Clinical trials demonstrated that amikacin was effective in infections caused by gentamicin and/or tobramycin-resistant strains of Gram-negative organisms, particularly Proteus rettgeri , Providencia stuartii , Serratia marcescens , and Pseudomonas aeruginosa . The decision to continue therapy with the drug should be based on results of the susceptibility tests, the severity of the infection, the response of the patient and the important additional considerations contained in the WARNINGS box above. Amikacin has also been shown to be effective in staphylococci infections and may be considered as initial therapy under certain conditions in the treatment of known or suspected staphylococcal disease such as, severe infections where the causative organism may be either a Gram-negative bacterium or a staphylococcus, infections due to susceptible strains of staphylococci in patients allergic to other antibiotics, and in mixed staphylococci/Gram-negative infections. In certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin-type drug may be indicated because of the possibility of infections due to Gram-positive organisms such as streptococci or pneumococci. To reduce the development of drug-resistant bacteria and maintain the effectiveness of amikacin and other antibacterial drugs, amikacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:63295412-c7b4-460c-a653-8bef234350fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2637 biolink:treats MONDO:0042485 PMID:41385096 "[{""id"":""uuid:c6b12c34-9e7f-4102-b1c9-c8e7f7dee5b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1a3f0104-18be-4734-89e5-63c0aa3241e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amikacin Sulfate Injection, USP is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli , species of indole-positive and indole-negative Proteus , Providencia species, Klebsiella-Enterobacter-Serratia species, and Acinetobacter ( Mima-Herellea ) species. Clinical studies have shown Amikacin Sulfate Injection, USP to be effective in bacterial septicemia (including neonatal sepsis); in serious infections of the respiratory tract, bones and joints, central nervous system (including meningitis) and skin and soft tissue; intra-abdominal infections (including peritonitis); and in burns and postoperative infections (including post-vascular surgery). Clinical studies have shown amikacin also to be effective in serious complicated and recurrent urinary tract infections due to those organisms. Aminoglycosides, including Amikacin Sulfate Injection, USP are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Bacteriologic studies should be performed to identify causative organisms and their susceptibilities to amikacin. Amikacin may be considered as initial therapy in suspected Gram-negative infections and therapy may be instituted before obtaining the results of susceptibility testing. Clinical trials demonstrated that amikacin was effective in infections caused by gentamicin and/or tobramycin-resistant strains of Gram-negative organisms, particularly Proteus rettgeri , Providencia stuartii , Serratia marcescens , and Pseudomonas aeruginosa . The decision to continue therapy with the drug should be based on results of the susceptibility tests, the severity of the infection, the response of the patient and the important additional considerations contained in the WARNINGS box above. Amikacin has also been shown to be effective in staphylococci infections and may be considered as initial therapy under certain conditions in the treatment of known or suspected staphylococcal disease such as, severe infections where the causative organism may be either a Gram-negative bacterium or a staphylococcus, infections due to susceptible strains of staphylococci in patients allergic to other antibiotics, and in mixed staphylococci/Gram-negative infections. In certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin-type drug may be indicated because of the possibility of infections due to Gram-positive organisms such as streptococci or pneumococci. To reduce the development of drug-resistant bacteria and maintain the effectiveness of amikacin and other antibacterial drugs, amikacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:3b204ca3-4e37-49dc-aa9b-d288a6944e6d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2637 biolink:treats MONDO:0024619 PMID:41385096 "[{""id"":""uuid:35c23291-0e95-4ac5-a391-6545dcc5277f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a266ff35-3a58-4871-9493-638502b01a48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amikacin Sulfate Injection, USP is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli , species of indole-positive and indole-negative Proteus , Providencia species, Klebsiella-Enterobacter-Serratia species, and Acinetobacter ( Mima-Herellea ) species. Clinical studies have shown Amikacin Sulfate Injection, USP to be effective in bacterial septicemia (including neonatal sepsis); in serious infections of the respiratory tract, bones and joints, central nervous system (including meningitis) and skin and soft tissue; intra-abdominal infections (including peritonitis); and in burns and postoperative infections (including post-vascular surgery). Clinical studies have shown amikacin also to be effective in serious complicated and recurrent urinary tract infections due to those organisms. Aminoglycosides, including Amikacin Sulfate Injection, USP are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Bacteriologic studies should be performed to identify causative organisms and their susceptibilities to amikacin. Amikacin may be considered as initial therapy in suspected Gram-negative infections and therapy may be instituted before obtaining the results of susceptibility testing. Clinical trials demonstrated that amikacin was effective in infections caused by gentamicin and/or tobramycin-resistant strains of Gram-negative organisms, particularly Proteus rettgeri , Providencia stuartii , Serratia marcescens , and Pseudomonas aeruginosa . The decision to continue therapy with the drug should be based on results of the susceptibility tests, the severity of the infection, the response of the patient and the important additional considerations contained in the WARNINGS box above. Amikacin has also been shown to be effective in staphylococci infections and may be considered as initial therapy under certain conditions in the treatment of known or suspected staphylococcal disease such as, severe infections where the causative organism may be either a Gram-negative bacterium or a staphylococcus, infections due to susceptible strains of staphylococci in patients allergic to other antibiotics, and in mixed staphylococci/Gram-negative infections. In certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin-type drug may be indicated because of the possibility of infections due to Gram-positive organisms such as streptococci or pneumococci. To reduce the development of drug-resistant bacteria and maintain the effectiveness of amikacin and other antibacterial drugs, amikacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:a6d9fa38-2876-4a96-a5b3-e408b60c2a06 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2637 biolink:treats MONDO:0021108 PMID:41385096 "[{""id"":""uuid:5e930e12-1480-4ec6-8459-b93758cc323f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7b267628-ba75-4dd0-8f21-a3153545176e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amikacin Sulfate Injection, USP is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli , species of indole-positive and indole-negative Proteus , Providencia species, Klebsiella-Enterobacter-Serratia species, and Acinetobacter ( Mima-Herellea ) species. Clinical studies have shown Amikacin Sulfate Injection, USP to be effective in bacterial septicemia (including neonatal sepsis); in serious infections of the respiratory tract, bones and joints, central nervous system (including meningitis) and skin and soft tissue; intra-abdominal infections (including peritonitis); and in burns and postoperative infections (including post-vascular surgery). Clinical studies have shown amikacin also to be effective in serious complicated and recurrent urinary tract infections due to those organisms. Aminoglycosides, including Amikacin Sulfate Injection, USP are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Bacteriologic studies should be performed to identify causative organisms and their susceptibilities to amikacin. Amikacin may be considered as initial therapy in suspected Gram-negative infections and therapy may be instituted before obtaining the results of susceptibility testing. Clinical trials demonstrated that amikacin was effective in infections caused by gentamicin and/or tobramycin-resistant strains of Gram-negative organisms, particularly Proteus rettgeri , Providencia stuartii , Serratia marcescens , and Pseudomonas aeruginosa . The decision to continue therapy with the drug should be based on results of the susceptibility tests, the severity of the infection, the response of the patient and the important additional considerations contained in the WARNINGS box above. Amikacin has also been shown to be effective in staphylococci infections and may be considered as initial therapy under certain conditions in the treatment of known or suspected staphylococcal disease such as, severe infections where the causative organism may be either a Gram-negative bacterium or a staphylococcus, infections due to susceptible strains of staphylococci in patients allergic to other antibiotics, and in mixed staphylococci/Gram-negative infections. In certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin-type drug may be indicated because of the possibility of infections due to Gram-positive organisms such as streptococci or pneumococci. To reduce the development of drug-resistant bacteria and maintain the effectiveness of amikacin and other antibacterial drugs, amikacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:d3a61733-e639-47a2-b0f6-bf76dfb4a8e2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2637 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:80da4bb4-36da-4ab7-b75a-fc48fa1c54e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9a40d010-dbc6-4e9f-b026-5cfe54abe1e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amikacin Sulfate Injection, USP is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli , species of indole-positive and indole-negative Proteus , Providencia species, Klebsiella-Enterobacter-Serratia species, and Acinetobacter ( Mima-Herellea ) species. Clinical studies have shown Amikacin Sulfate Injection, USP to be effective in bacterial septicemia (including neonatal sepsis); in serious infections of the respiratory tract, bones and joints, central nervous system (including meningitis) and skin and soft tissue; intra-abdominal infections (including peritonitis); and in burns and postoperative infections (including post-vascular surgery). Clinical studies have shown amikacin also to be effective in serious complicated and recurrent urinary tract infections due to those organisms. Aminoglycosides, including Amikacin Sulfate Injection, USP are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Bacteriologic studies should be performed to identify causative organisms and their susceptibilities to amikacin. Amikacin may be considered as initial therapy in suspected Gram-negative infections and therapy may be instituted before obtaining the results of susceptibility testing. Clinical trials demonstrated that amikacin was effective in infections caused by gentamicin and/or tobramycin-resistant strains of Gram-negative organisms, particularly Proteus rettgeri , Providencia stuartii , Serratia marcescens , and Pseudomonas aeruginosa . The decision to continue therapy with the drug should be based on results of the susceptibility tests, the severity of the infection, the response of the patient and the important additional considerations contained in the WARNINGS box above. Amikacin has also been shown to be effective in staphylococci infections and may be considered as initial therapy under certain conditions in the treatment of known or suspected staphylococcal disease such as, severe infections where the causative organism may be either a Gram-negative bacterium or a staphylococcus, infections due to susceptible strains of staphylococci in patients allergic to other antibiotics, and in mixed staphylococci/Gram-negative infections. In certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin-type drug may be indicated because of the possibility of infections due to Gram-positive organisms such as streptococci or pneumococci. To reduce the development of drug-resistant bacteria and maintain the effectiveness of amikacin and other antibacterial drugs, amikacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:33a807b8-c1ba-4155-bcf5-0839c352f662 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2637 biolink:treats UMLS:C0149778 PMID:41385096 "[{""id"":""uuid:cf246e85-a1d0-4a32-8129-2d238f44c7d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fc06d868-1936-4f96-843d-28fc61cd25d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amikacin Sulfate Injection, USP is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli , species of indole-positive and indole-negative Proteus , Providencia species, Klebsiella-Enterobacter-Serratia species, and Acinetobacter ( Mima-Herellea ) species. Clinical studies have shown Amikacin Sulfate Injection, USP to be effective in bacterial septicemia (including neonatal sepsis); in serious infections of the respiratory tract, bones and joints, central nervous system (including meningitis) and skin and soft tissue; intra-abdominal infections (including peritonitis); and in burns and postoperative infections (including post-vascular surgery). Clinical studies have shown amikacin also to be effective in serious complicated and recurrent urinary tract infections due to those organisms. Aminoglycosides, including Amikacin Sulfate Injection, USP are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Bacteriologic studies should be performed to identify causative organisms and their susceptibilities to amikacin. Amikacin may be considered as initial therapy in suspected Gram-negative infections and therapy may be instituted before obtaining the results of susceptibility testing. Clinical trials demonstrated that amikacin was effective in infections caused by gentamicin and/or tobramycin-resistant strains of Gram-negative organisms, particularly Proteus rettgeri , Providencia stuartii , Serratia marcescens , and Pseudomonas aeruginosa . The decision to continue therapy with the drug should be based on results of the susceptibility tests, the severity of the infection, the response of the patient and the important additional considerations contained in the WARNINGS box above. Amikacin has also been shown to be effective in staphylococci infections and may be considered as initial therapy under certain conditions in the treatment of known or suspected staphylococcal disease such as, severe infections where the causative organism may be either a Gram-negative bacterium or a staphylococcus, infections due to susceptible strains of staphylococci in patients allergic to other antibiotics, and in mixed staphylococci/Gram-negative infections. In certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin-type drug may be indicated because of the possibility of infections due to Gram-positive organisms such as streptococci or pneumococci. To reduce the development of drug-resistant bacteria and maintain the effectiveness of amikacin and other antibacterial drugs, amikacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:0e7a3378-79a5-46ec-8da2-d5d46b395346 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2637 biolink:treats UMLS:C1112209 PMID:41385096 "[{""id"":""uuid:7311f4d6-a34e-4ed6-a4c5-5babe03f95ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8cd38393-564e-4df5-8bc7-b8306fdd3940"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amikacin Sulfate Injection, USP is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli , species of indole-positive and indole-negative Proteus , Providencia species, Klebsiella-Enterobacter-Serratia species, and Acinetobacter ( Mima-Herellea ) species. Clinical studies have shown Amikacin Sulfate Injection, USP to be effective in bacterial septicemia (including neonatal sepsis); in serious infections of the respiratory tract, bones and joints, central nervous system (including meningitis) and skin and soft tissue; intra-abdominal infections (including peritonitis); and in burns and postoperative infections (including post-vascular surgery). Clinical studies have shown amikacin also to be effective in serious complicated and recurrent urinary tract infections due to those organisms. Aminoglycosides, including Amikacin Sulfate Injection, USP are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Bacteriologic studies should be performed to identify causative organisms and their susceptibilities to amikacin. Amikacin may be considered as initial therapy in suspected Gram-negative infections and therapy may be instituted before obtaining the results of susceptibility testing. Clinical trials demonstrated that amikacin was effective in infections caused by gentamicin and/or tobramycin-resistant strains of Gram-negative organisms, particularly Proteus rettgeri , Providencia stuartii , Serratia marcescens , and Pseudomonas aeruginosa . The decision to continue therapy with the drug should be based on results of the susceptibility tests, the severity of the infection, the response of the patient and the important additional considerations contained in the WARNINGS box above. Amikacin has also been shown to be effective in staphylococci infections and may be considered as initial therapy under certain conditions in the treatment of known or suspected staphylococcal disease such as, severe infections where the causative organism may be either a Gram-negative bacterium or a staphylococcus, infections due to susceptible strains of staphylococci in patients allergic to other antibiotics, and in mixed staphylococci/Gram-negative infections. In certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin-type drug may be indicated because of the possibility of infections due to Gram-positive organisms such as streptococci or pneumococci. To reduce the development of drug-resistant bacteria and maintain the effectiveness of amikacin and other antibacterial drugs, amikacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:c57b23b5-27b4-48b6-929d-622e5fd32eb9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2637 biolink:treats MONDO:0004522 PMID:41385096 "[{""id"":""uuid:67870ad2-5f5f-45c2-a83d-d27d75acbe88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:32e79a83-82fc-413d-8682-6fc2b9ffd96c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amikacin Sulfate Injection, USP is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli , species of indole-positive and indole-negative Proteus , Providencia species, Klebsiella-Enterobacter-Serratia species, and Acinetobacter ( Mima-Herellea ) species. Clinical studies have shown Amikacin Sulfate Injection, USP to be effective in bacterial septicemia (including neonatal sepsis); in serious infections of the respiratory tract, bones and joints, central nervous system (including meningitis) and skin and soft tissue; intra-abdominal infections (including peritonitis); and in burns and postoperative infections (including post-vascular surgery). Clinical studies have shown amikacin also to be effective in serious complicated and recurrent urinary tract infections due to those organisms. Aminoglycosides, including Amikacin Sulfate Injection, USP are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Bacteriologic studies should be performed to identify causative organisms and their susceptibilities to amikacin. Amikacin may be considered as initial therapy in suspected Gram-negative infections and therapy may be instituted before obtaining the results of susceptibility testing. Clinical trials demonstrated that amikacin was effective in infections caused by gentamicin and/or tobramycin-resistant strains of Gram-negative organisms, particularly Proteus rettgeri , Providencia stuartii , Serratia marcescens , and Pseudomonas aeruginosa . The decision to continue therapy with the drug should be based on results of the susceptibility tests, the severity of the infection, the response of the patient and the important additional considerations contained in the WARNINGS box above. Amikacin has also been shown to be effective in staphylococci infections and may be considered as initial therapy under certain conditions in the treatment of known or suspected staphylococcal disease such as, severe infections where the causative organism may be either a Gram-negative bacterium or a staphylococcus, infections due to susceptible strains of staphylococci in patients allergic to other antibiotics, and in mixed staphylococci/Gram-negative infections. In certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin-type drug may be indicated because of the possibility of infections due to Gram-positive organisms such as streptococci or pneumococci. To reduce the development of drug-resistant bacteria and maintain the effectiveness of amikacin and other antibacterial drugs, amikacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:d9017927-1d85-482b-98ff-43fe0b3a4e0d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2637 biolink:treats UMLS:C0548923 PMID:41385096 "[{""id"":""uuid:0a7c4af4-acd0-4d72-b6c1-269ca5efdc30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f73937cf-4a60-4963-9084-4b3e5b90e7b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amikacin Sulfate Injection, USP is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli , species of indole-positive and indole-negative Proteus , Providencia species, Klebsiella-Enterobacter-Serratia species, and Acinetobacter ( Mima-Herellea ) species. Clinical studies have shown Amikacin Sulfate Injection, USP to be effective in bacterial septicemia (including neonatal sepsis); in serious infections of the respiratory tract, bones and joints, central nervous system (including meningitis) and skin and soft tissue; intra-abdominal infections (including peritonitis); and in burns and postoperative infections (including post-vascular surgery). Clinical studies have shown amikacin also to be effective in serious complicated and recurrent urinary tract infections due to those organisms. Aminoglycosides, including Amikacin Sulfate Injection, USP are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Bacteriologic studies should be performed to identify causative organisms and their susceptibilities to amikacin. Amikacin may be considered as initial therapy in suspected Gram-negative infections and therapy may be instituted before obtaining the results of susceptibility testing. Clinical trials demonstrated that amikacin was effective in infections caused by gentamicin and/or tobramycin-resistant strains of Gram-negative organisms, particularly Proteus rettgeri , Providencia stuartii , Serratia marcescens , and Pseudomonas aeruginosa . The decision to continue therapy with the drug should be based on results of the susceptibility tests, the severity of the infection, the response of the patient and the important additional considerations contained in the WARNINGS box above. Amikacin has also been shown to be effective in staphylococci infections and may be considered as initial therapy under certain conditions in the treatment of known or suspected staphylococcal disease such as, severe infections where the causative organism may be either a Gram-negative bacterium or a staphylococcus, infections due to susceptible strains of staphylococci in patients allergic to other antibiotics, and in mixed staphylococci/Gram-negative infections. In certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin-type drug may be indicated because of the possibility of infections due to Gram-positive organisms such as streptococci or pneumococci. To reduce the development of drug-resistant bacteria and maintain the effectiveness of amikacin and other antibacterial drugs, amikacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:f8d705ee-cf41-457a-a06c-d5a85d643454 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2637 biolink:treats MONDO:0021839 PMID:41385096 "[{""id"":""uuid:1dbe8cc0-9dac-4eeb-8162-4fd872b994d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d1dd44d4-ce28-4bb9-8ab8-47889dc7a965"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amikacin Sulfate Injection, USP is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli , species of indole-positive and indole-negative Proteus , Providencia species, Klebsiella-Enterobacter-Serratia species, and Acinetobacter ( Mima-Herellea ) species. Clinical studies have shown Amikacin Sulfate Injection, USP to be effective in bacterial septicemia (including neonatal sepsis); in serious infections of the respiratory tract, bones and joints, central nervous system (including meningitis) and skin and soft tissue; intra-abdominal infections (including peritonitis); and in burns and postoperative infections (including post-vascular surgery). Clinical studies have shown amikacin also to be effective in serious complicated and recurrent urinary tract infections due to those organisms. Aminoglycosides, including Amikacin Sulfate Injection, USP are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Bacteriologic studies should be performed to identify causative organisms and their susceptibilities to amikacin. Amikacin may be considered as initial therapy in suspected Gram-negative infections and therapy may be instituted before obtaining the results of susceptibility testing. Clinical trials demonstrated that amikacin was effective in infections caused by gentamicin and/or tobramycin-resistant strains of Gram-negative organisms, particularly Proteus rettgeri , Providencia stuartii , Serratia marcescens , and Pseudomonas aeruginosa . The decision to continue therapy with the drug should be based on results of the susceptibility tests, the severity of the infection, the response of the patient and the important additional considerations contained in the WARNINGS box above. Amikacin has also been shown to be effective in staphylococci infections and may be considered as initial therapy under certain conditions in the treatment of known or suspected staphylococcal disease such as, severe infections where the causative organism may be either a Gram-negative bacterium or a staphylococcus, infections due to susceptible strains of staphylococci in patients allergic to other antibiotics, and in mixed staphylococci/Gram-negative infections. In certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin-type drug may be indicated because of the possibility of infections due to Gram-positive organisms such as streptococci or pneumococci. To reduce the development of drug-resistant bacteria and maintain the effectiveness of amikacin and other antibacterial drugs, amikacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:4191bcca-b557-4ab2-b6c4-40fd0011532a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2637 biolink:treats MONDO:0043544 PMID:41385096 "[{""id"":""uuid:c939a516-bde5-48da-a2b9-485c10f26286"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:149924bc-91a3-403f-a6cb-90521a61b616"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amikacin Sulfate Injection, USP is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli , species of indole-positive and indole-negative Proteus , Providencia species, Klebsiella-Enterobacter-Serratia species, and Acinetobacter ( Mima-Herellea ) species. Clinical studies have shown Amikacin Sulfate Injection, USP to be effective in bacterial septicemia (including neonatal sepsis); in serious infections of the respiratory tract, bones and joints, central nervous system (including meningitis) and skin and soft tissue; intra-abdominal infections (including peritonitis); and in burns and postoperative infections (including post-vascular surgery). Clinical studies have shown amikacin also to be effective in serious complicated and recurrent urinary tract infections due to those organisms. Aminoglycosides, including Amikacin Sulfate Injection, USP are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Bacteriologic studies should be performed to identify causative organisms and their susceptibilities to amikacin. Amikacin may be considered as initial therapy in suspected Gram-negative infections and therapy may be instituted before obtaining the results of susceptibility testing. Clinical trials demonstrated that amikacin was effective in infections caused by gentamicin and/or tobramycin-resistant strains of Gram-negative organisms, particularly Proteus rettgeri , Providencia stuartii , Serratia marcescens , and Pseudomonas aeruginosa . The decision to continue therapy with the drug should be based on results of the susceptibility tests, the severity of the infection, the response of the patient and the important additional considerations contained in the WARNINGS box above. Amikacin has also been shown to be effective in staphylococci infections and may be considered as initial therapy under certain conditions in the treatment of known or suspected staphylococcal disease such as, severe infections where the causative organism may be either a Gram-negative bacterium or a staphylococcus, infections due to susceptible strains of staphylococci in patients allergic to other antibiotics, and in mixed staphylococci/Gram-negative infections. In certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin-type drug may be indicated because of the possibility of infections due to Gram-positive organisms such as streptococci or pneumococci. To reduce the development of drug-resistant bacteria and maintain the effectiveness of amikacin and other antibacterial drugs, amikacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:169fbfe5-8e01-4b08-960f-740705cc73ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2637 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:c8ec56ac-91cb-4fc4-867e-f710b25d05c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5024bedf-318a-45ef-a3f3-73d6c4f4a9b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amikacin Sulfate Injection, USP is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli , species of indole-positive and indole-negative Proteus , Providencia species, Klebsiella-Enterobacter-Serratia species, and Acinetobacter ( Mima-Herellea ) species. Clinical studies have shown Amikacin Sulfate Injection, USP to be effective in bacterial septicemia (including neonatal sepsis); in serious infections of the respiratory tract, bones and joints, central nervous system (including meningitis) and skin and soft tissue; intra-abdominal infections (including peritonitis); and in burns and postoperative infections (including post-vascular surgery). Clinical studies have shown amikacin also to be effective in serious complicated and recurrent urinary tract infections due to those organisms. Aminoglycosides, including Amikacin Sulfate Injection, USP are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Bacteriologic studies should be performed to identify causative organisms and their susceptibilities to amikacin. Amikacin may be considered as initial therapy in suspected Gram-negative infections and therapy may be instituted before obtaining the results of susceptibility testing. Clinical trials demonstrated that amikacin was effective in infections caused by gentamicin and/or tobramycin-resistant strains of Gram-negative organisms, particularly Proteus rettgeri , Providencia stuartii , Serratia marcescens , and Pseudomonas aeruginosa . The decision to continue therapy with the drug should be based on results of the susceptibility tests, the severity of the infection, the response of the patient and the important additional considerations contained in the WARNINGS box above. Amikacin has also been shown to be effective in staphylococci infections and may be considered as initial therapy under certain conditions in the treatment of known or suspected staphylococcal disease such as, severe infections where the causative organism may be either a Gram-negative bacterium or a staphylococcus, infections due to susceptible strains of staphylococci in patients allergic to other antibiotics, and in mixed staphylococci/Gram-negative infections. In certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin-type drug may be indicated because of the possibility of infections due to Gram-positive organisms such as streptococci or pneumococci. To reduce the development of drug-resistant bacteria and maintain the effectiveness of amikacin and other antibacterial drugs, amikacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:72249376-f41c-473d-a699-1c2f3ab5294a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2637 biolink:treats MONDO:0024313 PMID:41385096 "[{""id"":""uuid:59a518ae-d700-4199-9d43-e305587153e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:25e0bf7a-edaf-45f2-95a3-c9b1ff45b879"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amikacin Sulfate Injection, USP is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli , species of indole-positive and indole-negative Proteus , Providencia species, Klebsiella-Enterobacter-Serratia species, and Acinetobacter ( Mima-Herellea ) species. Clinical studies have shown Amikacin Sulfate Injection, USP to be effective in bacterial septicemia (including neonatal sepsis); in serious infections of the respiratory tract, bones and joints, central nervous system (including meningitis) and skin and soft tissue; intra-abdominal infections (including peritonitis); and in burns and postoperative infections (including post-vascular surgery). Clinical studies have shown amikacin also to be effective in serious complicated and recurrent urinary tract infections due to those organisms. Aminoglycosides, including Amikacin Sulfate Injection, USP are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Bacteriologic studies should be performed to identify causative organisms and their susceptibilities to amikacin. Amikacin may be considered as initial therapy in suspected Gram-negative infections and therapy may be instituted before obtaining the results of susceptibility testing. Clinical trials demonstrated that amikacin was effective in infections caused by gentamicin and/or tobramycin-resistant strains of Gram-negative organisms, particularly Proteus rettgeri , Providencia stuartii , Serratia marcescens , and Pseudomonas aeruginosa . The decision to continue therapy with the drug should be based on results of the susceptibility tests, the severity of the infection, the response of the patient and the important additional considerations contained in the WARNINGS box above. Amikacin has also been shown to be effective in staphylococci infections and may be considered as initial therapy under certain conditions in the treatment of known or suspected staphylococcal disease such as, severe infections where the causative organism may be either a Gram-negative bacterium or a staphylococcus, infections due to susceptible strains of staphylococci in patients allergic to other antibiotics, and in mixed staphylococci/Gram-negative infections. In certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin-type drug may be indicated because of the possibility of infections due to Gram-positive organisms such as streptococci or pneumococci. To reduce the development of drug-resistant bacteria and maintain the effectiveness of amikacin and other antibacterial drugs, amikacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:31f11e6e-dc83-45e6-8d16-a3c4a3db4bb4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2637 biolink:treats MONDO:0100128 PMID:41385096 "[{""id"":""uuid:c61ca98f-5de5-49f6-9e5b-9dfab7ce24b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6bd540d5-9a29-4ec2-b8cf-456efdf35940"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amikacin Sulfate Injection, USP is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli , species of indole-positive and indole-negative Proteus , Providencia species, Klebsiella-Enterobacter-Serratia species, and Acinetobacter ( Mima-Herellea ) species. Clinical studies have shown Amikacin Sulfate Injection, USP to be effective in bacterial septicemia (including neonatal sepsis); in serious infections of the respiratory tract, bones and joints, central nervous system (including meningitis) and skin and soft tissue; intra-abdominal infections (including peritonitis); and in burns and postoperative infections (including post-vascular surgery). Clinical studies have shown amikacin also to be effective in serious complicated and recurrent urinary tract infections due to those organisms. Aminoglycosides, including Amikacin Sulfate Injection, USP are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Bacteriologic studies should be performed to identify causative organisms and their susceptibilities to amikacin. Amikacin may be considered as initial therapy in suspected Gram-negative infections and therapy may be instituted before obtaining the results of susceptibility testing. Clinical trials demonstrated that amikacin was effective in infections caused by gentamicin and/or tobramycin-resistant strains of Gram-negative organisms, particularly Proteus rettgeri , Providencia stuartii , Serratia marcescens , and Pseudomonas aeruginosa . The decision to continue therapy with the drug should be based on results of the susceptibility tests, the severity of the infection, the response of the patient and the important additional considerations contained in the WARNINGS box above. Amikacin has also been shown to be effective in staphylococci infections and may be considered as initial therapy under certain conditions in the treatment of known or suspected staphylococcal disease such as, severe infections where the causative organism may be either a Gram-negative bacterium or a staphylococcus, infections due to susceptible strains of staphylococci in patients allergic to other antibiotics, and in mixed staphylococci/Gram-negative infections. In certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin-type drug may be indicated because of the possibility of infections due to Gram-positive organisms such as streptococci or pneumococci. To reduce the development of drug-resistant bacteria and maintain the effectiveness of amikacin and other antibacterial drugs, amikacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:0843bfcc-0c95-4ee5-a184-099cf7729354 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16347 biolink:treats MONDO:0008919 PMID:41385096 "[{""id"":""uuid:acc0ec7e-cf89-4e32-af28-d5e965ec3575"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1c060d4f-5925-49d7-b60c-ae4179e6f742"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ec1defc6-b66b-4200-acf6-f2a074a9c192"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levocarnitine is indicated in the treatment of primary systemic carnitine deficiency. In the reported cases, the clinical presentation consisted of recurrent episodes of Reye-like encephalopathy, hypoketotic hypoglycemia, and/or cardiomyopathy. Associated symptoms included hypotonia, muscle weakness and failure to thrive. A diagnosis of primary carnitine deficiency requires that serum, red cell and/or tissue carnitine levels be low and that the patient does not have a primary defect in fatty acid or organic acid oxidation (see CLINICAL PHARMACOLOGY ). In some patients, particularly those presenting with cardiomyopathy, carnitine supplementation rapidly alleviated signs and symptoms. Treatment should include, in addition to carnitine, supportive and other therapy as indicated by the condition of the patient. Levocarnitine is also indicated for acute and chronic treatment of patients with an inborn error of metabolism which results in a secondary carnitine deficiency.|[PMDA] Drugs with a new active ingredient indicated for the treatment of carnitine deficiency. uuid:ce021ec0-7c7f-496e-a2f2-ddbbca8ad7b2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16347 biolink:treats HP:0001985 PMID:41385096 "[{""id"":""uuid:da60f5da-c204-41d7-9141-d3201c472dd1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:45131e2e-2fa7-4be8-b7ea-0669b5278713"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levocarnitine is indicated in the treatment of primary systemic carnitine deficiency. In the reported cases, the clinical presentation consisted of recurrent episodes of Reye-like encephalopathy, hypoketotic hypoglycemia, and/or cardiomyopathy. Associated symptoms included hypotonia, muscle weakness and failure to thrive. A diagnosis of primary carnitine deficiency requires that serum, red cell and/or tissue carnitine levels be low and that the patient does not have a primary defect in fatty acid or organic acid oxidation (see CLINICAL PHARMACOLOGY ). In some patients, particularly those presenting with cardiomyopathy, carnitine supplementation rapidly alleviated signs and symptoms. Treatment should include, in addition to carnitine, supportive and other therapy as indicated by the condition of the patient. Levocarnitine is also indicated for acute and chronic treatment of patients with an inborn error of metabolism which results in a secondary carnitine deficiency. uuid:92f00fff-03f9-4d43-bbe4-55b6635e5351 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16347 biolink:treats MONDO:0004994 PMID:41385096 "[{""id"":""uuid:16a20e55-c73d-47be-8bd5-ad3554b7d29b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d51fd84c-4f64-404c-967e-398158b6d6ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levocarnitine is indicated in the treatment of primary systemic carnitine deficiency. In the reported cases, the clinical presentation consisted of recurrent episodes of Reye-like encephalopathy, hypoketotic hypoglycemia, and/or cardiomyopathy. Associated symptoms included hypotonia, muscle weakness and failure to thrive. A diagnosis of primary carnitine deficiency requires that serum, red cell and/or tissue carnitine levels be low and that the patient does not have a primary defect in fatty acid or organic acid oxidation (see CLINICAL PHARMACOLOGY ). In some patients, particularly those presenting with cardiomyopathy, carnitine supplementation rapidly alleviated signs and symptoms. Treatment should include, in addition to carnitine, supportive and other therapy as indicated by the condition of the patient. Levocarnitine is also indicated for acute and chronic treatment of patients with an inborn error of metabolism which results in a secondary carnitine deficiency. uuid:bcaa91d5-3df6-483f-8f4e-eefbc31842f1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0015129 PMID:41385096 "[{""id"":""uuid:f2bf00f4-e5cb-4c9a-9ab7-c3c405eaf249"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9602e108-06ae-4298-bfb4-7d57d153871f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute non-specific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia. 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate anti-tuberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:0c78cee1-f410-48a5-b79b-085ec880cb01 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0043370 PMID:41385096 "[{""id"":""uuid:25db00e4-0e5c-4910-823f-f6fee23031a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:436961f1-f0c9-4425-8638-5a251cebbc33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute non-specific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia. 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate anti-tuberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:8e20d19f-37e6-4fa0-9e3f-f62eaafb54ff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0009197 PMID:41385096 "[{""id"":""uuid:54236202-e6c8-4200-916f-dd991870acaf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bd19c346-34c1-49b6-ac3a-251f6b0ff8ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute non-specific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia. 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate anti-tuberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:b32f8ef1-5b67-4fd2-bee2-3d44a6dc862f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1992683 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:1bc2a648-da2a-4ad6-ac0d-b72b26710d7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4a3159d2-1e9a-416a-889d-bf91c4bf32cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:beb35ce6-e216-43e2-98ba-9106b0c955de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/segluromet""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] SEGLUROMET ® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.|[EMA] Segluromet is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:in patients not adequately controlled on their maximally tolerated dose of metformin alonein patients on their maximally tolerated doses of metformin in addition to other medicinal products for the treatment of diabetesin patients already being treated with the combination of ertugliflozin and metformin as separate tablets. uuid:7fd01f15-fad1-4ee1-b830-0b62d86463a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64317 biolink:treats HP:0031275 PMID:41385096 "[{""id"":""uuid:fa2b9df7-209c-4f9a-9065-6e9bd57f67f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:50170942-2479-459c-b95b-58d1f441e1e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isoproterenol hydrochloride injection is indicated: To improve hemodynamic status in patients in distributive shock and shock due to reduced cardiac output For bronchospasm occurring during anesthesia uuid:de03f389-fd60-46b5-8b46-87598100a206 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:T432289GYZ biolink:treats MONDO:0005647 PMID:41385096 "[{""id"":""uuid:17f45c0c-fe21-46a3-a2b9-c78990b4f058"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2ae36fae-4339-4e89-a739-19744e991b0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Veregen is a topical ointment indicated for the treatment of external genital and perianal warts (Condylomata acuminata) in immunocompetent patients 18 years and older (1.1) . Limitations of Use Safety and effectiveness of Veregen have not been established in immunosuppressed patients, in treatment of external genital and perianal warts beyond 16-weeks, or for multiple treatment courses (1.2) . uuid:2db54cfc-6a20-4126-b6f5-e435c4ca4f4f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841573 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:d7b87745-85d4-43ef-a425-7012bb7af025"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b2fa223c-7520-41c5-91a9-7499371c0bbc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tekturna HCT is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including hydrochlorothiazide (HCTZ). There are no controlled trials demonstrating risk reduction with Tekturna HCT. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality have also been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (e.g., patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. uuid:a883a949-b58a-4207-8f86-b390292df2a9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841573 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:43fc6b82-fa0f-40d4-845f-b32e1ec40e3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:16790e0b-f5f7-43b7-9897-73f94070087a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tekturna HCT is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including hydrochlorothiazide (HCTZ). There are no controlled trials demonstrating risk reduction with Tekturna HCT. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality have also been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (e.g., patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. uuid:d3fad84f-163e-4b31-a68c-b2c89e87e7be biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841573 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:a94bc186-bb37-42df-920e-68c2abfe6ff1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:23cb3568-af29-4c9a-8025-767779b00b2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tekturna HCT is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including hydrochlorothiazide (HCTZ). There are no controlled trials demonstrating risk reduction with Tekturna HCT. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality have also been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (e.g., patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. uuid:368c95d9-343f-481e-80bb-0f7a53c09091 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841573 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:1b569d11-16a4-49c2-a27f-3aaa2fe7d489"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8e02695c-6301-4129-8748-f1d5621521c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tekturna HCT is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including hydrochlorothiazide (HCTZ). There are no controlled trials demonstrating risk reduction with Tekturna HCT. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality have also been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (e.g., patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. uuid:a9477b8f-fde9-4c5a-b1d5-95973a404b2c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24783652 biolink:treats MONDO:0006652 PMID:41385096 "[{""id"":""uuid:fb8128a6-17ed-44fc-88df-b29d3e69cebb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e7101894-3904-401b-bb73-be691f88ee55"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Losartan potassium and hydrochlorothiazide tablet is a combination of losartan, an angiotensin II receptor blocker (ARB) and hydrochlorothiazide, a diuretic indicated for: Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1) Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. ( 1.2 ) uuid:9e12b351-65af-4074-ad96-23c413da50ca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:608828 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:68dfe1b3-55ca-47f0-bfa8-df9474bbccde"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:55258f9b-cecd-4e49-b996-481c9c82c8bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FUZEON ® in combination with other antiretroviral agents is indicated for the treatment of HIV-1 infection in treatment-experienced patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy. uuid:f9407c80-cdeb-421c-b6bf-040e8cd22f68 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB13883 biolink:treats MONDO:0018669 PMID:41385096 "[{""id"":""uuid:e00b2f1b-3ac6-4c42-832c-a85274859364"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:746f6529-72fc-42da-8f13-dc46b5b99fbf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] North American Coral Snake Antivenin (Equine) is indicated only for the treatment of envenomation caused by bites of North American coral snakes - Micrurus (including the eastern and Texas varieties). uuid:bff72aa5-235e-4acd-9327-bcfc99831d3b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2682 biolink:treats MONDO:0002041 PMID:41385096 "[{""id"":""uuid:390d38af-0198-4fd2-92c2-e7c68ebb0ff8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:70426e9e-2312-4fb0-9f6f-a717f0384462"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amphotericin B liposome for injection is indicated for the following: Empirical therapy for presumed fungal infection in febrile, neutropenic patients. Treatment of Cryptococcal Meningitis in HIV-infected patients (see DESCRIPTION OF CLINICAL STUDIES ). Treatment of patients with Aspergillus species, Candida species and/or Cryptococcus species infections (see above for the treatment of Cryptococcal Meningitis) refractory to amphotericin B deoxycholate, or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B deoxycholate. Treatment of visceral leishmaniasis. In immunocompromised patients with visceral leishmaniasis treated with amphotericin B liposome for injection, relapse rates were high following initial clearance of parasites (see DESCRIPTION OF CLINICAL STUDIES ). See DOSAGE AND ADMINISTRATION for recommended doses by indication. uuid:bf525d03-d650-4102-b7aa-4d1ec5ef8d5e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2682 biolink:treats MONDO:0005723 PMID:41385096 "[{""id"":""uuid:cc77b35a-c227-41e6-96f4-17f2fdc1c2a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a33c2c29-202e-4c16-a69f-bd13433c0116"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amphotericin B liposome for injection is indicated for the following: Empirical therapy for presumed fungal infection in febrile, neutropenic patients. Treatment of Cryptococcal Meningitis in HIV-infected patients (see DESCRIPTION OF CLINICAL STUDIES ). Treatment of patients with Aspergillus species, Candida species and/or Cryptococcus species infections (see above for the treatment of Cryptococcal Meningitis) refractory to amphotericin B deoxycholate, or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B deoxycholate. Treatment of visceral leishmaniasis. In immunocompromised patients with visceral leishmaniasis treated with amphotericin B liposome for injection, relapse rates were high following initial clearance of parasites (see DESCRIPTION OF CLINICAL STUDIES ). See DOSAGE AND ADMINISTRATION for recommended doses by indication. uuid:62a11f71-1349-4b70-b402-8aec7624a1b8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2682 biolink:treats MONDO:0002026 PMID:41385096 "[{""id"":""uuid:1f8edc95-125a-414c-8be5-2a0f2b567c5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b3d0a921-d6cb-46ba-870b-4b276a113ee0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1d409bab-5a48-467f-b648-a054f9f1a410"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amphotericin B liposome for injection is indicated for the following: Empirical therapy for presumed fungal infection in febrile, neutropenic patients. Treatment of Cryptococcal Meningitis in HIV-infected patients (see DESCRIPTION OF CLINICAL STUDIES ). Treatment of patients with Aspergillus species, Candida species and/or Cryptococcus species infections (see above for the treatment of Cryptococcal Meningitis) refractory to amphotericin B deoxycholate, or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B deoxycholate. Treatment of visceral leishmaniasis. In immunocompromised patients with visceral leishmaniasis treated with amphotericin B liposome for injection, relapse rates were high following initial clearance of parasites (see DESCRIPTION OF CLINICAL STUDIES ). See DOSAGE AND ADMINISTRATION for recommended doses by indication.|[PMDA] Various infections caused by Aspergillus species, Candida species or Cryptococcus species (drug with a new dosage and dosage form). uuid:aad1ed72-3203-4924-8f68-d8cdc36d80e7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2682 biolink:treats MONDO:0005445 PMID:41385096 "[{""id"":""uuid:6e7173f1-3dea-4abd-9df9-9e9f2aad3838"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f7c039b5-2353-466f-9d26-03383899a114"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1f8563fc-1692-4e11-af96-c13f2d0d3e15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amphotericin B liposome for injection is indicated for the following: Empirical therapy for presumed fungal infection in febrile, neutropenic patients. Treatment of Cryptococcal Meningitis in HIV-infected patients (see DESCRIPTION OF CLINICAL STUDIES ). Treatment of patients with Aspergillus species, Candida species and/or Cryptococcus species infections (see above for the treatment of Cryptococcal Meningitis) refractory to amphotericin B deoxycholate, or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B deoxycholate. Treatment of visceral leishmaniasis. In immunocompromised patients with visceral leishmaniasis treated with amphotericin B liposome for injection, relapse rates were high following initial clearance of parasites (see DESCRIPTION OF CLINICAL STUDIES ). See DOSAGE AND ADMINISTRATION for recommended doses by indication.|[PMDA] A drug with new additional indications and a new dosage for the treatment of fungal infections caused by Mucor species, Absidia species, Rhizopus species, Rhizomucor species, Cladosporium species, Cladophialophora species, Fonsecaea species, Phialophora species, Exophiala species, Coccidioides species, Histoplasma species, and Blastomyces species and visceral leishmaniasis. uuid:2894bd6a-327c-4937-a94d-a5ce794f689a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7565 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:66ec6ab7-f63b-4f58-91ae-1134b424801a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2777a280-3e7d-470b-8009-e7a8b9943261"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] I. Vasospastic Angina Nifedipine extended-release tablets are indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. In those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. Nifedipine extended-release tablets may also be used where the clinical presentation suggests a possible vasospastic component, but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion, or in unstable angina where electrocardiographic findings are compatible with intermittent vasospasm, or when angina is refractory to nitrates and/or adequate doses of beta blockers. II. Chronic Stable Angina (Classical Effort-Associated Angina) Nifedipine extended-release tablets are indicated for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm in patients who remain symptomatic despite adequate doses of beta blockers and/or organic nitrates or who cannot tolerate those agents. In chronic stable angina (effort-associated angina), nifedipine has been effective in controlled trials of up to eight weeks duration in reducing angina frequency and increasing exercise tolerance, but confirmation of sustained effectiveness and evaluation of long-term safety in these patients is incomplete. Controlled studies in small numbers of patients suggest concomitant use of nifedipine and beta-blocking agents may be beneficial in patients with chronic stable angina, but available information is not sufficient to predict with confidence the effects of concurrent treatment, especially in patients with compromised left ventricular function or cardiac conduction abnormalities. When introducing such concomitant therapy, care must be taken to monitor blood pressure closely, since severe hypotension can occur from the combined effects of the drugs (see WARNINGS). III. Hypertension Nifedipine extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including nifedipine extended-release tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Nifedipine extended-release tablets may be used alone or in combination with other antihypertensive agents. uuid:5a930951-a6d9-4379-8399-8cb6a42dcf7d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7565 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:20dd1582-f01c-4f48-ad0f-124dcdb4c3a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b4ef5301-fbcf-4ee0-a185-88b2a9aa5bae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] I. Vasospastic Angina Nifedipine extended-release tablets are indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. In those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. Nifedipine extended-release tablets may also be used where the clinical presentation suggests a possible vasospastic component, but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion, or in unstable angina where electrocardiographic findings are compatible with intermittent vasospasm, or when angina is refractory to nitrates and/or adequate doses of beta blockers. II. Chronic Stable Angina (Classical Effort-Associated Angina) Nifedipine extended-release tablets are indicated for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm in patients who remain symptomatic despite adequate doses of beta blockers and/or organic nitrates or who cannot tolerate those agents. In chronic stable angina (effort-associated angina), nifedipine has been effective in controlled trials of up to eight weeks duration in reducing angina frequency and increasing exercise tolerance, but confirmation of sustained effectiveness and evaluation of long-term safety in these patients is incomplete. Controlled studies in small numbers of patients suggest concomitant use of nifedipine and beta-blocking agents may be beneficial in patients with chronic stable angina, but available information is not sufficient to predict with confidence the effects of concurrent treatment, especially in patients with compromised left ventricular function or cardiac conduction abnormalities. When introducing such concomitant therapy, care must be taken to monitor blood pressure closely, since severe hypotension can occur from the combined effects of the drugs (see WARNINGS). III. Hypertension Nifedipine extended-release tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including nifedipine extended-release tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Nifedipine extended-release tablets may be used alone or in combination with other antihypertensive agents. uuid:351c1be3-7f82-4424-a9ae-2fa5905bc8fc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1304557 biolink:treats MONDO:0024298 PMID:41385096 "[{""id"":""uuid:2bb18e56-6ceb-437c-a400-6d1aaa67f46e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a2aa6320-9d07-446f-aa5c-b205569ef54b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INFUVITE PEDIATRIC is a combination of vitamins indicated for the prevention of vitamin deficiency in pediatric patients up to 11 years of age receiving parenteral nutrition. The physician should not await the development of clinical signs of vitamin deficiency before initiating vitamin therapy. uuid:9c7a08da-8ad3-4a28-ac5a-12ea84f82b99 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:B005P07V07 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:b183f569-a939-4877-9341-d5466aa6641d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b3a32e35-7a3b-4664-978c-eb8107612077"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Neurolite single photon emission computerized tomography (SPECT) is indicated as an adjunct to conventional CT or MRI imaging in the localization of stroke in patients in whom stroke has already been diagnosed. Neurolite is not indicated for assessment of functional viability of brain tissue. Also, Neurolite is not indicated for distinguishing between stroke and other brain lesions. uuid:25f2b57a-0b41-4528-9d42-d110af74623b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32184 biolink:treats UMLS:C0406317 PMID:41385096 "[{""id"":""uuid:ecb09217-347e-4333-b74e-cee624819f21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a5bdffd9-cfa8-43df-8f8e-3efeb9fd9a84"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tazarotene cream 0.1% is a retinoid indicated for the topical treatment of plaque psoriasis. ( 1.1 ) Tazarotene cream 0.1% is indicated for the topical treatment of acne vulgaris. ( 1.2 ) uuid:c078a214-dcd3-44fc-a0eb-d1df24c7fc2a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:478164 biolink:treats UMLS:C4552431 PMID:41385096 "[{""id"":""uuid:ab2433da-bfec-4e36-b7ae-2b12f201fc5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c2233fe6-7987-4e49-a9e4-c38f346f1cca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefepime for Injection is a cephalosporin antibacterial indicated for the treatment of the following infections caused by susceptible strains of the designated microorganisms: Pneumonia. ( 1.1 ) Empiric therapy for febrile neutropenic patients. ( 1.2 ) Uncomplicated and complicated urinary tract infections (including pyelonephritis). ( 1.3 ) Uncomplicated skin and skin structure infections. ( 1.4 ) Complicated intra-abdominal infections (used in combination with metronidazole) in adults. ( 1.5 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Cefepime for Injection and other antibacterial drugs, Cefepime for Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.6 ) uuid:e6942f95-ce43-42ee-8b0e-5791c0b40dc8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15552 biolink:treats MONDO:0015924 PMID:41385096 "[{""id"":""uuid:9de222b3-92a8-4c40-8db5-ac54cd31ad5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0b1a7866-80a5-4bd8-92e6-ca9f565cf590"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:bb609b2f-2fcb-448f-ac03-473ba457e244"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VELETRI is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity. Studies establishing effectiveness included predominantly patients with NYHA Functional Class III–IV symptoms and etiologies of idiopathic or heritable PAH or PAH associated with connective tissue diseases.|[PMDA] Drugs with a new additional pediatric dosage indicated for the treatment of pulmonary arterial hypertension. uuid:444b3520-924c-464f-8eef-1c8ae8cd5004 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15552 biolink:treats MONDO:0017147 PMID:41385096 "[{""id"":""uuid:31094dec-deb3-468e-922a-20aa6ac04377"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ce6e41b0-5ebf-4b30-b78a-151445c406d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VELETRI is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity. Studies establishing effectiveness included predominantly patients with NYHA Functional Class III–IV symptoms and etiologies of idiopathic or heritable PAH or PAH associated with connective tissue diseases. uuid:d82e6272-f4fc-42a5-b483-fa1fa888d638 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15552 biolink:treats MONDO:0017148 PMID:41385096 "[{""id"":""uuid:809cd993-f8a8-4ace-a2b5-9e5dff4ff45b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6bd64b52-e288-4363-956d-65a2606337e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VELETRI is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity. Studies establishing effectiveness included predominantly patients with NYHA Functional Class III–IV symptoms and etiologies of idiopathic or heritable PAH or PAH associated with connective tissue diseases. uuid:fe6c9b50-2800-4268-ba4c-89e78ce4d15c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3654 biolink:treats HP:0000969 PMID:41385096 "[{""id"":""uuid:9a25b40f-4fc3-478c-bbfa-25849b462e97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f06e5d1f-804a-4f79-964d-410a7c58e064"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diuretics such as chlorthalidone are indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effect of other antihypertensive drugs in the more severe forms of hypertension. Chlorthalidone is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Chlorthalidone has also been found useful in edema due to various forms of renal dysfunction, such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Usage in Pregnancy: The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. Edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. Chlorthalidone is indicated in pregnancy when edema is due to pathologic causes, just as it is in the absence of pregnancy (however, see PRECAUTIONS , below). Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy that is harmful to neither the fetus nor the mother (in the absence of cardiovascular disease), but that is associated with edema, including generalized edema, in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort that is not relieved by rest. In these cases, a short course of diuretics may provide relief and be appropriate. uuid:ff80e776-1766-4894-9649-21e020796032 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16899 biolink:treats MONDO:0006684 PMID:41385096 "[{""id"":""uuid:233cd6c5-b313-46ce-83d5-dce149e8f44c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:80835717-ed53-4d61-8464-bb399442ca54"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mannitol Injection is indicated for the reduction of: intracranial pressure and treatment of cerebral edema; elevated intraocular pressure. uuid:7c2edad8-da7e-4b92-aadd-caff1c43b5ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16899 biolink:treats HP:0007906 PMID:41385096 "[{""id"":""uuid:2c023df3-2ddb-4c20-becf-4275ce1963ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:961b9611-3250-4838-a3fb-33a32a371fcd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mannitol Injection is indicated for the reduction of: intracranial pressure and treatment of cerebral edema; elevated intraocular pressure. uuid:56a8e5aa-06a9-4fa2-8e6f-6436b485d69c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:46878853 biolink:treats MONDO:0004982 PMID:41385096 "[{""id"":""uuid:0e1e11b2-0ef4-454d-a459-6f661ae7985d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a0e8eb11-c4f1-4475-81c4-9b7c566a9eb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment of Hypercholesterolemia Fenofibrate capsules are indicated as adjunctive therapy to diet for the reduction of LDL-C, Total-C, Triglycerides and Apo B in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate (see National Cholesterol Education Program [NCEP] Treatment Guidelines, below). Treatment of Hypertriglyceridemia Fenofibrate capsules are also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually reduce fasting triglycerides and eliminate chylomicronemia thereby obviating the need for pharmacologic intervention. Markedly elevated levels of serum triglycerides (e.g., > 2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate therapy on reducing this risk has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV and V hyperlipoproteinemia 2 . The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcoholic intake may be important factors in hypertriglyceridemia and should be addressed prior to any drug therapy. Physical exercise can be an important ancillary measure. Diseases contributory to hyperlipidemia, such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy, like thiazide diuretics and beta-blockers, is sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of the specific etiologic agent may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with non-drug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet (see WARNINGS and PRECAUTIONS ). Fredrickson Classification of Hyperlipoproteinemias Type Lipoprotein Elevated Lipid Elevation Major Minor I (rare) Chylomicrons TG ↑↔C IIa LDL C — IIb LDL, VLDL C TG III (rare) IDL C, TG — IV VLDL TG ↑↔C V (rare) Chylomicrons, VLDL TG ↑↔ C = cholesterol TG = triglycerides LDL = low density lipoprotein VLDL = very low density lipoprotein IDL = intermediate density lipoprotein The NCEP Treatment Guidelines Definite Athlerosclerotic Disease a Two or More Other Risk Factors b LDL-Cholesterol mg/dL (mmol/L) Initiation Level Goal No No ≥ 190 (≥ 4.9) < 160 (< 4.1) No Yes ≥ 160 (≥ 4.1) < 130 (< 3.4) Yes Yes or No ≥ 130 c (≥ 3.4) < 100 (< 2.6) a Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). b Other risk factors for coronary heart disease (CHD) include: age (males: ≥ 45 years; females: ≥ 55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C < 35 mg/dL (< 0.91mmol/L); and diabetes mellitus. Subtract 1 risk factor if HDL-C is ≥ 60 mg/dL (≥ 1.6 mmol/L) c In CHD patients with LDL-C levels 100 to 129 mg/dL, the physician should exercise clinical judgment in deciding whether to initiate drug treatment. uuid:aed5f977-259c-4f22-96d5-35bbfc2b9d43 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17234 biolink:treats MONDO:0004946 PMID:41385096 "[{""id"":""uuid:05c7961b-c979-443b-84a3-7aa4a4273d19"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:15822b10-b460-4cd1-b432-9abf508c0965"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 25% Dextrose Injection is indicated in the treatment of acute symptomatic episodes of hypoglycemia in the neonate or older infant to restore depressed blood glucose levels and control symptoms. Other drugs, such as epinephrine and glucagon, should be considered in patients unresponsive or intolerant to dextrose (glucose). Oral feeding of dextrose may be necessary in infants with frequently recurring hypoglycemic episodes or to prevent recurrences due to hyperinsulinemia. 25% Dextrose Injection also provides a minimal source of carbohydrate calories. uuid:ea2f617a-ed30-406b-a64f-cbd8d1e01987 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28787 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:afdf9ea2-7237-4aef-9cda-ef94660700fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:294119c9-7a0b-44fb-aa33-9e433df7ed25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nitroglycerin in 5% Dextrose Injection is indicated for treatment of peri-operative hypertension; for control of heart failure in the setting of acute myocardial infarction; for treatment of angina pectoris in patients who have not responded to sublingual nitroglycerin and ß-blockers; and for induction of intraoperative hypotension. uuid:16c3a6ae-afd6-4101-929f-dd9ba9ddfcb6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:107736 biolink:treats HP:0002018 PMID:41385096 "[{""id"":""uuid:9a875341-0d48-4046-a72b-6037495c7811"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:58c3a5af-8b9c-40ca-9141-48e241290e65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diabetic Gastroparesis (Diabetic Gastric Stasis) Metoclopramide Injection (metoclopramide hydrochloride, USP) is indicated for the relief of symptoms associated with acute and recurrent diabetic gastric stasis. The Prevention of Nausea and Vomiting Associated with Emetogenic Cancer Chemotherapy Metoclopramide Injection is indicated for the prophylaxis of vomiting associated with emetogenic cancer chemotherapy. The Prevention of Postoperative Nausea and Vomiting Metoclopramide Injection is indicated for the prophylaxis of postoperative nausea and vomiting in those circumstances where nasogastric suction is undesirable. Small Bowel Intubation Metoclopramide Injection may be used to facilitate small bowel intubation in adults and pediatric patients in whom the tube does not pass the pylorus with conventional maneuvers. Radiological Examination Metoclopramide Injection may be used to stimulate gastric emptying and intestinal transit of barium in cases where delayed emptying interferes with radiological examination of the stomach and/or small intestine. uuid:f05baad1-01c0-43d6-b2b6-c6981606b333 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:107736 biolink:treats HP:0002013 PMID:41385096 "[{""id"":""uuid:f2d92e55-a7a6-47a9-9ad9-7e63d8b83b60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9a7497a7-b580-42e4-a880-77bc3f0c62c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diabetic Gastroparesis (Diabetic Gastric Stasis) Metoclopramide Injection (metoclopramide hydrochloride, USP) is indicated for the relief of symptoms associated with acute and recurrent diabetic gastric stasis. The Prevention of Nausea and Vomiting Associated with Emetogenic Cancer Chemotherapy Metoclopramide Injection is indicated for the prophylaxis of vomiting associated with emetogenic cancer chemotherapy. The Prevention of Postoperative Nausea and Vomiting Metoclopramide Injection is indicated for the prophylaxis of postoperative nausea and vomiting in those circumstances where nasogastric suction is undesirable. Small Bowel Intubation Metoclopramide Injection may be used to facilitate small bowel intubation in adults and pediatric patients in whom the tube does not pass the pylorus with conventional maneuvers. Radiological Examination Metoclopramide Injection may be used to stimulate gastric emptying and intestinal transit of barium in cases where delayed emptying interferes with radiological examination of the stomach and/or small intestine. uuid:091cd63c-e8e0-4423-bf6a-68dacc23d729 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7773 biolink:treats EFO:0006911 PMID:41385096 "[{""id"":""uuid:eac188d6-d8b7-4806-aed6-7de005289244"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b9955bbc-30c3-4a64-82fb-fa6784c46522"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Prevention of Nausea and Vomiting Associated with Initial and Repeat Courses of Emetogenic Cancer Chemotherapy Ondansetron injection is indicated for the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin [see CLINICAL STUDIES (14.1)]. Ondansetron is approved for patients aged 6 months and older. 1.2 Prevention of Postoperative Nausea and/or Vomiting Ondansetron injection is indicated for the prevention of postoperative nausea and/or vomiting. As with other antiemetics, routine prophylaxis is not recommended for patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients in whom nausea and/or vomiting must be avoided postoperatively, ondansetron injection is recommended even when the incidence of postoperative nausea and/or vomiting is low. For patients who do not receive prophylactic ondansetron injection and experience nausea and/or vomiting postoperatively, ondansetron injection may be given to prevent further episodes [see CLINICAL STUDIES (14.3)]. Ondansetron is approved for patients aged 1 month and older. uuid:b4ce037b-968e-4f7d-b0d6-fe9facb520b2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27953 biolink:treats UMLS:C0151500 PMID:41385096 "[{""id"":""uuid:3b0904b6-e42e-46d6-886f-787eafb2228e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:67b8849f-580b-4262-a49d-d84d11dd30c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reverse the effect upon the central nervous system, caused by clinical or toxic dosages of drugs capable of producing the anticholinergic syndrome. uuid:515ecc0f-7701-4afb-84e0-cb07533c8c1b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:Q46947FE7K biolink:treats MONDO:0005354 PMID:41385096 "[{""id"":""uuid:44a61a68-2815-4c0b-bc2d-ae0a7eba5423"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:eba2b106-7bb3-425b-882f-b0dd01bf3004"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:6cdba874-d10d-4f66-aafd-58008a3d924b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/pegasys""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] PEGASYS is an inducer of the innate immune response indicated for the treatment of Chronic Hepatitis C (CHC) ( 1.1 ) Adult Patients: In combination therapy with other hepatitis C virus drugs for adults with compensated liver disease. PEGASYS monotherapy is indicated only if patient has contraindication or significant intolerance to other HCV drugs. Pediatric Patients: In combination with ribavirin for pediatric patients 5 years of age and older with compensated liver disease Chronic Hepatitis B (CHB) ( 1.2 ) Adult Patients: Treatment of adults with HBeAg-positive and HBeAg-negative chronic hepatitis B (CHB) infection who have compensated liver disease and evidence of viral replication and liver inflammation Pediatric Patients: Treatment of non-cirrhotic pediatric patients 3 years of age and older with HBeAg-positive CHB and evidence of viral replication and elevations in serum alanine aminotransferase (ALT)|[EMA] Chronic hepatitis B, , Adult patients, , Pegasys is indicated for the treatment of hepatitis B envelope antigen (HBeAg)-positive or HBeAg-negative chronic hepatitis B (CHB) in adult patients with compensated liver disease and evidence of viral replication, increased alanine aminotransferase (ALT) and histologically verified liver inflammation and/or fibrosis (see sections 4.4 and 5.1)., , Paediatric patients 3 years of age and older, , Pegasys is indicated for the treatment of HBeAg-positive CHB in non-cirrhotic children and adolescents 3 years of age and older with evidence of viral replication and persistently elevated serum ALT levels. With respect to the decision to initiate treatment in paediatric patients see sections 4.2, 4.4 and 5.1., , Chronic hepatitis C, , Adult patients, , Pegasys is indicated in combination with other medicinal products, for the treatment of chronic hepatitis C (CHC) in patients with compensated liver disease (see sections 4.2, 4.4 and 5.1)., , For hepatitis C virus (HCV) genotype specific activity, see sections 4.2 and 5.1., , Paediatric patients 5 years of age and older, , Pegasys in combination with ribavirin is indicated for the treatment of CHC in treatment-naïve children and adolescents 5 years of age and older who are positive for serum HCV-RNA., , When deciding to initiate treatment in childhood, it is important to consider growth inhibition induced by combination therapy. The reversibility of growth inhibition is uncertain. The decision to treat should be made on a case by case basis (see section 4.4)., uuid:7e69a2fe-f0a0-4c52-904c-b5b41b9bc75c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:Q46947FE7K biolink:treats MONDO:0005366 PMID:41385096 "[{""id"":""uuid:e71f12fb-8c8d-4227-8b39-04812834b63b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c6954323-00cc-4ff2-905a-6f71753eb0da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:cc6e4eb5-c06a-46d3-87d8-6d2e7e6d6270"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/pegasys""]},{""id"":""uuid:2fb31334-b3ef-4e7b-aaec-aef232e1bd82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PEGASYS is an inducer of the innate immune response indicated for the treatment of Chronic Hepatitis C (CHC) ( 1.1 ) Adult Patients: In combination therapy with other hepatitis C virus drugs for adults with compensated liver disease. PEGASYS monotherapy is indicated only if patient has contraindication or significant intolerance to other HCV drugs. Pediatric Patients: In combination with ribavirin for pediatric patients 5 years of age and older with compensated liver disease Chronic Hepatitis B (CHB) ( 1.2 ) Adult Patients: Treatment of adults with HBeAg-positive and HBeAg-negative chronic hepatitis B (CHB) infection who have compensated liver disease and evidence of viral replication and liver inflammation Pediatric Patients: Treatment of non-cirrhotic pediatric patients 3 years of age and older with HBeAg-positive CHB and evidence of viral replication and elevations in serum alanine aminotransferase (ALT)|[EMA] Chronic hepatitis B, , Adult patients, , Pegasys is indicated for the treatment of hepatitis B envelope antigen (HBeAg)-positive or HBeAg-negative chronic hepatitis B (CHB) in adult patients with compensated liver disease and evidence of viral replication, increased alanine aminotransferase (ALT) and histologically verified liver inflammation and/or fibrosis (see sections 4.4 and 5.1)., , Paediatric patients 3 years of age and older, , Pegasys is indicated for the treatment of HBeAg-positive CHB in non-cirrhotic children and adolescents 3 years of age and older with evidence of viral replication and persistently elevated serum ALT levels. With respect to the decision to initiate treatment in paediatric patients see sections 4.2, 4.4 and 5.1., , Chronic hepatitis C, , Adult patients, , Pegasys is indicated in combination with other medicinal products, for the treatment of chronic hepatitis C (CHC) in patients with compensated liver disease (see sections 4.2, 4.4 and 5.1)., , For hepatitis C virus (HCV) genotype specific activity, see sections 4.2 and 5.1., , Paediatric patients 5 years of age and older, , Pegasys in combination with ribavirin is indicated for the treatment of CHC in treatment-naïve children and adolescents 5 years of age and older who are positive for serum HCV-RNA., , When deciding to initiate treatment in childhood, it is important to consider growth inhibition induced by combination therapy. The reversibility of growth inhibition is uncertain. The decision to treat should be made on a case by case basis (see section 4.4).,|[PMDA] Drugs with a new additional indication and a new dosage for the improvement of viremia in patients with chronic active hepatitis B. [Priority review] uuid:5492c02a-c904-4748-a6d5-fe090ef7ef6c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1540231 biolink:treats HP:0000616 PMID:41385096 "[{""id"":""uuid:d7b875bd-8784-49c1-b3b5-85de087babab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f494d100-498b-4d05-9e6a-23f7e35c97ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Omidria ® is added to an ocular irrigating solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain. uuid:2e1ac28e-d939-4ba3-8ed7-24a4a5086261 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:438HCF2X0M biolink:treats MONDO:0009338 PMID:41385096 "[{""id"":""uuid:62e4c650-7e84-4b70-8ecd-83c401cb876c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2aeb460f-1ddc-4dfc-b134-a99d92434d79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DEFITELIO is indicated for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT). uuid:b75885c0-6485-4923-a77f-45bd815386d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:438HCF2X0M biolink:treats MONDO:0019514 PMID:41385096 "[{""id"":""uuid:06fc623d-1115-47ae-9312-6cf07e6a0362"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8120e616-8dd5-452b-a1b5-1fa5fd86dd14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7abc2bee-b989-41cc-8406-ef976ce93c0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/defitelio""]},{""id"":""uuid:850d0441-3ad8-492a-b2ee-9e3a8d5c1a3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DEFITELIO is indicated for the treatment of adult and pediatric patients with hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), with renal or pulmonary dysfunction following hematopoietic stem-cell transplantation (HSCT).|[EMA] Defitelio is indicated for the treatment of severe hepatic veno-occlusive disease (VOD) also known as sinusoidal obstructive syndrome (SOS) in haematopoietic stem-cell transplantation (HSCT) therapy.It is indicated in adults and in adolescents, children and infants over 1 month of age.|[PMDA] A drug with a new active ingredient indicated for the treatment of sinusoidal obstruction syndrome (SOS) /hepatic veno-occlusive disease (VOD). [Orphan drug] uuid:845fc8ad-4ecd-4da3-9a81-4d74107f7df0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68642 biolink:treats MONDO:0004956 PMID:41385096 "[{""id"":""uuid:a4767049-682f-484a-ba3d-66813fbba6d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:59b43033-591d-45d4-ad7b-451d1730708c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Abiraterone acetate tablets are indicated in combination with prednisone for the treatment of patients with • Metastatic castration-resistant prostate cancer (CRPC) • Metastatic high-risk castration-sensitive prostate cancer (CSPC) uuid:e5f6a300-d958-410b-94b2-ce6d586d90b1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4466 biolink:treats MONDO:0001866 PMID:41385096 "[{""id"":""uuid:d5733737-0899-44fd-9919-29213ab6180c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8b39bfaf-bd50-4390-beb5-34a492394596"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IGALMI is indicated for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. uuid:8426e4f2-baa4-4814-87c3-f5cea39929e5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4466 biolink:treats MONDO:0000693 PMID:41385096 "[{""id"":""uuid:15a0771b-9e55-45f9-a7b8-1365ad7b3256"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:000173fc-6f6f-45ac-b626-3ff615995eb9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IGALMI is indicated for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. uuid:fdd8e555-68d0-43a5-abf9-de7bb64726af biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6717 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:ca328e28-016d-49e6-a2fb-7f71bb9a226a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1a7e212c-2ea4-4e71-8463-adc3f3db0bd6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of mefenamic acid and other treatment options before deciding to use mefenamic acid. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals ( see WARNINGS ). Mefenamic acid is indicated: For relief of mild to moderate pain in patients ≥14 years of age, when therapy will not exceed one week (7 days). For treatment of primary dysmenorrhea. uuid:5d115583-5dd0-4ef5-a73b-940da942c62d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6717 biolink:treats MONDO:1060206 PMID:41385096 "[{""id"":""uuid:e5223c2d-d7a9-4450-b31e-99ff44643aa2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:727d44f7-c520-434d-8020-95f4e4c7eea8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of mefenamic acid and other treatment options before deciding to use mefenamic acid. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals ( see WARNINGS ). Mefenamic acid is indicated: For relief of mild to moderate pain in patients ≥14 years of age, when therapy will not exceed one week (7 days). For treatment of primary dysmenorrhea. UMLS:C0149875 uuid:c2ea30d1-6b1c-463c-b620-2e80793da07a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28001 biolink:treats UMLS:C0235952 PMID:41385096 "[{""id"":""uuid:2ab4d6cc-f3a5-4d9e-b409-e3b2a0ed6d95"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:47d06a36-57be-4a0b-992e-b3021f4c0209"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vancomycin hydrochloride capsule is indicated for the treatment of Clostridioides difficile -associated diarrhea. Vancomycin hydrochloride capsule is also used for the treatment of enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains) in adult and pediatric patients less than 18 years of age. uuid:399bad70-3d2a-4d70-8c45-f1ec4da4412a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28001 biolink:treats MONDO:0009172 PMID:41385096 "[{""id"":""uuid:ea216c9b-003a-468e-aaa7-e388e65ca59a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:df817267-0157-4a8b-9e82-e2a4d591b1a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vancomycin hydrochloride capsule is indicated for the treatment of Clostridioides difficile -associated diarrhea. Vancomycin hydrochloride capsule is also used for the treatment of enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains) in adult and pediatric patients less than 18 years of age. uuid:a4eba218-a05b-4786-a5a6-6fde4b7c24e3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32588 biolink:treats MONDO:0006919 PMID:41385096 "[{""id"":""uuid:5c2db612-4ab0-4032-b069-5953fab32c69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e6c45e15-8a4d-4df9-902c-5672b91d091d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Potassium Chloride for Injection Concentrate USP is indicated in the treatment of potassium deficiency states when oral replacement is not feasible. This is a concentrated solution which is intended for use in a pharmacy admixture service and is restricted to the preparation of admixtures for intravenous infusion. uuid:296cce84-4f48-4de4-bc4d-b7fbaa383d48 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:74T7185BMM biolink:treats MONDO:0035663 PMID:41385096 "[{""id"":""uuid:5583de51-f287-426a-8574-826e41110bc6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d5af2b7e-4c2d-473c-9bbf-b02441fb4844"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:80f71bd1-1295-4135-9fe7-69e375fb961a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/uplizna""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] UPLIZNA is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.|[EMA] Uplizna is indicated as monotherapy for the treatment of adult patients with neuromyelitis optica spectrum disorders (NMOSD) who are anti-aquaporin 4 immunoglobulin G (AQP4-IgG) seropositive (see section 5.1). uuid:eb413d1a-e701-479f-98df-a3a44f7649b5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:74T7185BMM biolink:treats MONDO:0019100 PMID:41385096 "[{""id"":""uuid:830c8c87-86b7-482c-9230-5c3f217d2bbf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2de373c2-cf69-465b-812d-b2614221b733"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0e95825a-e34d-41d8-b29f-3408957d5d26"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] UPLIZNA is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.|[PMDA] A drug with a new active ingredient indicated for the prevention of relapse of neuromyelitis optica spectrum disorder (including neuromyelitis optica). [Orphan drug] uuid:c085d24d-db83-40b8-abb3-278cde3fd020 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5537 biolink:treats UMLS:C0520904 PMID:41385096 "[{""id"":""uuid:d136d293-ed18-404f-b231-6f5cd53fef85"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6750384c-f1bd-4402-b68f-f1b7bb096020"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Granisetron Hydrochloride Injection, USP is a serotonin-3 (5-HT 3 ) receptor antagonist indicated for: The prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. The prevention and treatment of postoperative nausea and vomiting in adults. As with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and/or vomiting must be avoided during the postoperative period, granisetron hydrochloride injection, USP is recommended even where the incidence of postoperative nausea and/or vomiting is low. uuid:b6814698-26d1-421d-85cb-37d88d5794bb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5537 biolink:treats UMLS:C0520905 PMID:41385096 "[{""id"":""uuid:92f358f6-e8d5-4203-99ba-facadc12e8da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ddd87491-3734-400e-88f4-2b04b937c44c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Granisetron Hydrochloride Injection, USP is a serotonin-3 (5-HT 3 ) receptor antagonist indicated for: The prevention of nausea and/or vomiting associated with initial and repeat courses of emetogenic cancer therapy, including high-dose cisplatin. The prevention and treatment of postoperative nausea and vomiting in adults. As with other antiemetics, routine prophylaxis is not recommended in patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and/or vomiting must be avoided during the postoperative period, granisetron hydrochloride injection, USP is recommended even where the incidence of postoperative nausea and/or vomiting is low. uuid:6f9f3170-a0fa-4ccf-8521-af757a289287 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:230846 biolink:treats MONDO:0009861 PMID:41385096 "[{""id"":""uuid:0394ef91-370d-4129-bfe1-90c6e00790f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:28a23950-85b0-4bc1-a445-7d4eb5b3df04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:21850042-359d-49f4-a274-5f144940e15d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/palynziq""]},{""id"":""uuid:26fb1098-0593-46f0-b597-c3bb0dd4555a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Palynziq is indicated to reduce blood phenylalanine concentrations in adult patients with phenylketonuria (PKU) who have uncontrolled blood phenylalanine concentrations greater than 600 micromol/L on existing management.|[EMA] Palynziq is indicated for the treatment of patients with phenylketonuria (PKU) aged 16 years and older who have inadequate blood phenylalanine control (blood phenylalanine levels greater than 600 micromol/l) despite prior management with available treatment options.|[PMDA] Drugs with a new active ingredient indicated for the treatment of phenylketonuria. [Orphan drug] uuid:dfdbcb33-d4e3-4eab-b7d7-c65e581986aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32151 biolink:treats UMLS:C0341736 PMID:41385096 "[{""id"":""uuid:3e071d3b-ede7-4b98-afd7-42aca454cae0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1862464b-5039-43da-823e-f93cf5683f14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VESIcare LS ® is indicated for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients aged 2 years and older. uuid:cfefb1f1-837b-4e72-b3fa-ecc11386744b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:V1N8F1RVVO biolink:treats MONDO:0100187 PMID:41385096 "[{""id"":""uuid:b7725281-41da-431a-bec7-ef06c6a5feba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5342c8c6-4d2e-415d-8d2d-97b0e9f23d08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SYMPROIC is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. uuid:f12234fc-1e8f-4eb9-946a-6d3fcc395764 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:V1N8F1RVVO biolink:treats HP:0012532 PMID:41385096 "[{""id"":""uuid:de3f8c7d-3504-4dc5-8410-f95f348be2cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:987fda31-abbf-4f2a-a8ad-82990f96dbf9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SYMPROIC is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. uuid:4898160e-5377-4045-bdd0-32dc9c8672fb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:V1N8F1RVVO biolink:treats EFO:0801084 PMID:41385096 "[{""id"":""uuid:8d986456-313d-4ca3-a04e-739ce8241817"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f17df138-ad94-4900-8df5-51c7960ec78f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SYMPROIC is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. uuid:cad4dfb7-dac7-42eb-8d66-b269ac20ef8d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27732 biolink:treats MONDO:0043775 PMID:41385096 "[{""id"":""uuid:42b127b2-c92a-4f02-b13c-5fb3a3f37c6d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9a753a03-e94b-4645-94fa-959ad44358a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Caffeine and Sodium Benzoate Injection has been used in conjunction with supportive measure to treat respiratory depression associated with overdosage with CNS depressant drugs (e.g., narcotic analgesics, alcohol). However, because of questionable benefit and transient action, most authorities believe caffeine and other analeptics should not be used in these conditions and recommend other supportive therapy. uuid:ba22736b-5ed5-45e9-9129-7a9bd3364d9e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68855 biolink:treats MONDO:0021095 PMID:41385096 "[{""id"":""uuid:0014c2a0-c223-4116-9afc-881348726385"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:40463bce-8af5-4594-add9-3e0c2376b77d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:71104c72-0ee4-417f-8ccc-c6c1fc7094b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ioflupane I 123 Injection is indicated as an adjunct to other diagnostic evaluations for striatal dopamine transporter visualization using single photon emission computed tomography (SPECT) brain imaging in adult patients with: ● suspected Parkinsonian syndromes (PS) or ● suspected dementia with Lewy bodies (DLB).|[EMA] This medicinal product is for diagnostic use only.Striascan is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum:In adult patients with clinically uncertain parkinsonian syndromes, for example those with early symptoms, in order to help differentiate essential tremor from parkinsonian syndromes related to idiopathic Parkinson’s disease, multiple system atrophy and progressive supranuclear palsy. Striascan is unable to discriminate between Parkinson's disease, multiple system atrophy and progressive supranuclear palsy.In adult patients, to help differentiate probable dementia with Lewy bodies from Alzheimer’s disease. Striascan is unable to discriminate between dementia with Lewy bodies and Parkinson’s disease dementia. uuid:cc63eb88-18c6-46bb-aa0b-6cede90a9f1b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6427 biolink:treats MONDO:0008315 PMID:41385096 "[{""id"":""uuid:063ae5d3-7597-40d5-b60d-997e6a867450"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e51d3f7b-07f6-4bec-beb5-f7bb3661b928"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CAMCEVI is indicated for the treatment of adult patients with advanced prostate cancer. uuid:f787a3ed-6004-4ee4-9158-c4c01a44acdb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28830 biolink:treats MONDO:0004948 PMID:41385096 "[{""id"":""uuid:b0a21559-15ad-4941-b77f-96e93bae9980"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:51162508-6774-4870-b046-44ce93e258ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LEUKERAN (chlorambucil) is indicated in the treatment of chronic lymphatic (lymphocytic) leukemia, malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and Hodgkin’s disease. It is not curative in any of these disorders but may produce clinically useful palliation. uuid:0bf32687-47d6-4545-8f6d-b3c6e74d8fab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28830 biolink:treats MONDO:0004638 PMID:41385096 "[{""id"":""uuid:127484d3-0810-49c8-b3da-69ebd952c6dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a7f49156-9f35-4aa7-b8cd-95ebaef072a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LEUKERAN (chlorambucil) is indicated in the treatment of chronic lymphatic (lymphocytic) leukemia, malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and Hodgkin’s disease. It is not curative in any of these disorders but may produce clinically useful palliation. uuid:8e6142af-aec6-458e-b3fb-36147a6f681b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28830 biolink:treats MONDO:0018906 PMID:41385096 "[{""id"":""uuid:b2df609b-1e18-46ca-a002-ec78c2cd6763"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ad658e1f-4054-49ff-a297-b9f363bd348d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LEUKERAN (chlorambucil) is indicated in the treatment of chronic lymphatic (lymphocytic) leukemia, malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and Hodgkin’s disease. It is not curative in any of these disorders but may produce clinically useful palliation. uuid:abb3ad71-2a65-4663-babc-8c57feee782a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28830 biolink:treats MONDO:0009348 PMID:41385096 "[{""id"":""uuid:888bca02-40ac-40e6-ae13-e1429a7bfc7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b8bf4e8b-8e3b-4b83-b1d0-598fabe08126"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LEUKERAN (chlorambucil) is indicated in the treatment of chronic lymphatic (lymphocytic) leukemia, malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and Hodgkin’s disease. It is not curative in any of these disorders but may produce clinically useful palliation. uuid:20d569f7-7eb6-478c-9413-d9787ae200bb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50275 biolink:treats MONDO:0007186 PMID:41385096 "[{""id"":""uuid:636ce02b-4626-4952-987d-cbacce025d1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0018f9b9-9233-4710-a4ab-c8824fae349f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:89db902d-bacb-472e-acc6-6d878335a45c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Esomeprazole magnesium delayed-release capsules is a proton pump inhibitor (PPI). Esomeprazole magnesium delayed-release capsules is indicated for the: • Short-term treatment in the healing of erosive esophagitis (EE) in adults and pediatric patients 12 years to 17 years of age. ( 1.1 ) • Maintenance of healing of EE in adults. ( 1.2 ) • Short-term treatment of heartburn and other symptoms associated GERD in adults and pediatric patients 12 years to 17 years of age. ( 1.3 ) • Risk reduction of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults at risk for developing gastric ulcers due to age (60 years and older) and/or documented history of gastric ulcers. ( 1.4 ) • Helicobacter pylori eradication in adult patients to reduce the risk of duodenal ulcer recurrence in combination with amoxicillin and clarithromycin. ( 1.5 ) • Long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome in adults. ( 1.6 )|[PMDA] A drug with a new active ingredient indicated for the treatment of gastric ulcer, duodenal ulcer, anastomotic ulcer, reflux esophagitis, non-erosive reflux disease and Zollinger-Ellison syndrome, prevention of recurrence of gastric ulcer or duodenal ulcer in patients treated with nonsteroidal antiinflammatory drugs, and aid to eradication of Helicobacter pylori in patients with gastric ulcer, duodenal ulcer, gastric MALT lymphoma, idiopathic thrombocytopenic purpura, and stomach after endoscopic treatment for early gastric cancer. uuid:5c08539a-e443-4e3f-8011-19c4bfed2183 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50275 biolink:treats MONDO:0006781 PMID:41385096 "[{""id"":""uuid:70c20786-f6eb-4fd7-baef-967e2d88b794"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:62bae756-0f60-435b-8cd5-8dfc6a4ae81d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Esomeprazole magnesium delayed-release capsules is a proton pump inhibitor (PPI). Esomeprazole magnesium delayed-release capsules is indicated for the: • Short-term treatment in the healing of erosive esophagitis (EE) in adults and pediatric patients 12 years to 17 years of age. ( 1.1 ) • Maintenance of healing of EE in adults. ( 1.2 ) • Short-term treatment of heartburn and other symptoms associated GERD in adults and pediatric patients 12 years to 17 years of age. ( 1.3 ) • Risk reduction of nonsteroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer in adults at risk for developing gastric ulcers due to age (60 years and older) and/or documented history of gastric ulcers. ( 1.4 ) • Helicobacter pylori eradication in adult patients to reduce the risk of duodenal ulcer recurrence in combination with amoxicillin and clarithromycin. ( 1.5 ) • Long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome in adults. ( 1.6 ) uuid:252c4ede-65b0-4b38-b5ca-423c8b2a4b2e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3175 biolink:treats MONDO:0006604 PMID:41385096 "[{""id"":""uuid:00398779-ed6b-4a9e-8d51-350d48e55268"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ab959e81-e02c-41e0-94f5-6c909ab7d134"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:fb4e7a91-18eb-42f4-a0d3-e7e806a002de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Brimonidine topical gel, 0.33% is an alpha adrenergic agonist indicated for the topical treatment of persistent (nontransient) erythema of rosacea in adults 18 years of age or older.|[EMA] Mirvaso is indicated for the symptomatic treatment of facial erythema of rosacea in adult patients. uuid:9d0834c9-b075-4310-a575-38bb37503f1b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51230 biolink:treats MONDO:0001335 PMID:41385096 "[{""id"":""uuid:2af9e8ef-1d2a-4c5d-bf4d-69cd61e65d08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b30fca1e-fc56-4f91-8cd7-1724d81843e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bimatoprost ophthalmic solution 0.03% is indicated to treat hypotrichosis of the eyelashes by increasing their growth including length, thickness and darkness. uuid:56ae7e28-62f4-4ff6-853d-dbc55a995960 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9738 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:1511618d-d562-414e-9d65-2aa25c68c402"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:52084af0-6428-4f8d-a397-ba3beb00d9dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Trimipramine Maleate Capsules are indicated for the relief of symptoms of depression. Endogenous depression is more likely to be alleviated than other depressive states. In studies with neurotic outpatients, the drug appeared to be equivalent to amitriptyline in the less-depressed patients but somewhat less effective than amitriptyline in the more severely depressed patients. In hospitalized depressed patients, trimipramine and imipramine were equally effective in relieving depression. uuid:032b8aa6-ff01-4a28-9d7d-5f39b250c2fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9738 biolink:treats MONDO:0012048 PMID:41385096 "[{""id"":""uuid:9997192e-dc1e-4a85-b870-82b53db6cc71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dd166feb-fc35-42ea-810f-7dedc2b7ef09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Trimipramine Maleate Capsules are indicated for the relief of symptoms of depression. Endogenous depression is more likely to be alleviated than other depressive states. In studies with neurotic outpatients, the drug appeared to be equivalent to amitriptyline in the less-depressed patients but somewhat less effective than amitriptyline in the more severely depressed patients. In hospitalized depressed patients, trimipramine and imipramine were equally effective in relieving depression. uuid:6f5e0a80-7271-48b3-918f-f9c5073e109b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8597 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:d55a4cbe-d6bc-4a9f-b029-433dcb810c48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9804b002-6f33-46d9-8b63-f8fc96c13eec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Protriptyline hydrochloride tablets are indicated for the treatment of symptoms of mental depression in patients who are under close medical supervision. Its activating properties make it particularly suitable for withdrawn and anergic patients. uuid:245ad4d2-00b0-49c2-95a8-fcfddd830563 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22652 biolink:treats MONDO:0001356 PMID:41385096 "[{""id"":""uuid:77adccdc-ea70-4c65-b1bb-928bc34acc71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:87b77718-5834-46e6-8ed4-0005ab3c4061"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PureVit DualFe Plus is indicated for the treatment of iron deficiency anemia and folate deficiency as in extended convalescence, menorrhagia, pregnancy, puberty, excessive blood loss and advanced age. Also for treatment of condition in which iron deficiency and vitamin C deficiency occur together, along with a deficient intake or increased need for B-Complex vitamins in chronic and acute illness, as well as cases of metabolic stress, and in convalescence. uuid:4d96877e-ae9f-4403-83f4-2a59304f75fe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22652 biolink:treats MONDO:0001860 PMID:41385096 "[{""id"":""uuid:56ce3b5c-4602-4f1d-a574-4182bee886a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:481a1bb9-9f8d-43a7-a80e-4be4ce4d7500"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PureVit DualFe Plus is indicated for the treatment of iron deficiency anemia and folate deficiency as in extended convalescence, menorrhagia, pregnancy, puberty, excessive blood loss and advanced age. Also for treatment of condition in which iron deficiency and vitamin C deficiency occur together, along with a deficient intake or increased need for B-Complex vitamins in chronic and acute illness, as well as cases of metabolic stress, and in convalescence. uuid:090325da-d21c-4fa1-a084-276613ff25bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22652 biolink:treats MONDO:0009412 PMID:41385096 "[{""id"":""uuid:5cb65de8-692c-4b0a-bbba-5e4d184db96c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e131b3d6-1819-4670-affe-9857d7c46bf3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PureVit DualFe Plus is indicated for the treatment of iron deficiency anemia and folate deficiency as in extended convalescence, menorrhagia, pregnancy, puberty, excessive blood loss and advanced age. Also for treatment of condition in which iron deficiency and vitamin C deficiency occur together, along with a deficient intake or increased need for B-Complex vitamins in chronic and acute illness, as well as cases of metabolic stress, and in convalescence. uuid:981c5f7c-0849-4b4f-9061-2b45a5722ba7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49544 biolink:treats MONDO:0001700 PMID:41385096 "[{""id"":""uuid:f2b0f044-9d64-4fd8-94c8-bb5576991903"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f3d5d9cb-2dfc-4bf2-a513-b949d0ca7bdc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vitrexyl™ is indicated to provide vitamin supplement to men and women. Folic acid is effective in the treatment of megaloblastic anemias due to a deficiency of folic acid (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, pregnancy, infancy, or childhood. uuid:532fd79c-d9c0-40fd-a586-d553bfa45150 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49544 biolink:treats MONDO:0001078 PMID:41385096 "[{""id"":""uuid:2b2fb277-27ef-46c3-bd78-6392afab1838"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9a50cb18-ac81-4e91-ac71-96c48b39fa14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vitrexyl™ is indicated to provide vitamin supplement to men and women. Folic acid is effective in the treatment of megaloblastic anemias due to a deficiency of folic acid (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, pregnancy, infancy, or childhood. uuid:fae454fc-60ce-4a27-8394-2d63db9459e4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49544 biolink:treats MONDO:0005130 PMID:41385096 "[{""id"":""uuid:f13369cf-02a3-4312-b96d-9ad5f33d6c5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:67e7ffc3-f4e9-4502-aed4-6836ac074999"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vitrexyl™ is indicated to provide vitamin supplement to men and women. Folic acid is effective in the treatment of megaloblastic anemias due to a deficiency of folic acid (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, pregnancy, infancy, or childhood. uuid:7ba5aaf6-ab43-4759-883e-7ac88e6b11bd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49544 biolink:treats UMLS:C0271903 PMID:41385096 "[{""id"":""uuid:390a6d32-b40e-4527-8ba7-465a695dea16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:724dcc49-72a7-44ba-a9a5-2464a710b1d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vitrexyl™ is indicated to provide vitamin supplement to men and women. Folic acid is effective in the treatment of megaloblastic anemias due to a deficiency of folic acid (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, pregnancy, infancy, or childhood. uuid:482b1add-71d6-4823-a09d-7fdffcd542a1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49544 biolink:treats MONDO:0009197 PMID:41385096 "[{""id"":""uuid:49302405-9bf7-4031-8032-155a80446291"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:804824a9-d5dc-4d8e-84f4-f3e3be96c546"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vitrexyl™ is indicated to provide vitamin supplement to men and women. Folic acid is effective in the treatment of megaloblastic anemias due to a deficiency of folic acid (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, pregnancy, infancy, or childhood. uuid:6bb6a69a-3a72-4cac-950f-3a8939634d9f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1163417 biolink:treats MONDO:0002406 PMID:41385096 "[{""id"":""uuid:3e099393-5e70-420d-ba3d-bdfed981b7f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e052335a-1cb0-4f58-8533-0ffb730ecd47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The product is used for the anti-inflammatory and anesthetic relief of redness, pain, itching, and discoloration due to inflammation and skin burns. For the relief of redness, pain, itching, discoloration, inflammation and mild skin burns associated with radiation. For use after radiation treatment, cosmetic procedures, sun exposure, and for inflammatory skin conditions. uuid:a55d7b58-dc74-49dd-81dc-54a1ff1f174f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6078 biolink:treats MONDO:0006604 PMID:41385096 "[{""id"":""uuid:dde708ff-db03-458f-b14c-d0b9453854cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e4303d4b-66ff-49ed-bc27-514ab62e8548"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ivermectin cream, 1% is indicated for the treatment of inflammatory lesions of rosacea. uuid:9a5bc10f-2c69-4a6d-80cd-03d852a1c235 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2587738 biolink:treats MONDO:0010811 PMID:41385096 "[{""id"":""uuid:e7a14ca3-eea2-4bfd-b139-7fa3c1fcea3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:635d93ef-6105-40a7-9b9c-59f1ef422aac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENTADFI is indicated to initiate treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) in men with an enlarged prostate for up to 26 weeks. Limitations of Use ENTADFI is not recommended for more than 26 weeks because the incremental benefit of tadalafil decreases from 4 weeks until 26 weeks, and the incremental benefit beyond 26 weeks is unknown [see Clinical Studies ( 14 )] . uuid:b356e971-9811-459f-ae0b-325823fa2639 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:119486 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:5eb6ba27-c1d5-49bf-922d-bb71547618b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:db603721-f33c-46dd-b324-2469707dfc18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Efavirenz tablets in combination with other antiretroviral agents are indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and in pediatric patients at least 3 months old and weighing at least 3.5 kg. uuid:00ddfe33-97a6-42b1-afd7-957be080488c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3387 biolink:treats MONDO:0001866 PMID:41385096 "[{""id"":""uuid:576d06db-862a-4881-be55-a66ba66a8a6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fdda7bc1-46e5-41ad-bd41-3d4991dd3232"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EQUETRO is: A mood stabilizer indicated for the treatment of acute manic or mixed episodes associated with bipolar I disorder ( 1.1 ) Indicated for the treatment of the pain associated with trigeminal neuralgia ( 1.2 ) An anti-epileptic drug (AED) indicated for the treatment of partial seizures with complex symptomatology, generalized tonic-clonic seizures, and mixed seizures ( 1.3 ) uuid:3ed599b8-5ea5-4c29-bfba-49bfffb6c4e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0005246 PMID:41385096 "[{""id"":""uuid:a10cb9a8-ef76-4c8e-bc4a-2871cbbe20bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2ef0d9a8-f028-4505-aa77-87f1bdad4746"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Symptomatic Trichomoniasis Metronidazole tablets USP are indicated for the treatment of T. vaginalis infection in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis Metronidazole tablets USP are indicated in the treatment of asymptomatic T. vaginalis infection in females when the organism is associated with endocervicitis, cervicitis, or cervical erosion. Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. Treatment of Asymptomatic Sexual Partners T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her sexual partner is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the sexual partner should be treated with metronidazole tablets USP in cases of reinfection. Amebiasis Metronidazole tablets USP are indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. In amebic liver abscess, metronidazole tablet therapy does not obviate the need for aspiration or drainage of pus. Anaerobic Bacterial Infections Metronidazole tablets USP are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with metronidazole tablet therapy. In a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole tablets USP. INTRA-ABDOMINAL INFECTIONS, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species including the B. fragilis group (B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus), Clostridium species, Eubacterium species, Peptococcus species, and Peptostreptococcus species. SKIN AND SKIN STRUCTURE INFECTIONS caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus species, Peptostreptococcus species, and Fusobacterium species. GYNECOLOGIC INFECTIONS, including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus species, Peptostreptococcus species, and Fusobacterium species. BACTERIAL SEPTICEMIA caused by Bacteroides species including the B. fragilis group and Clostridium species. BONE AND JOINT INFECTIONS, (as adjunctive therapy), caused by Bacteroides species including the B. fragilis group. CENTRAL NERVOUS SYSTEM (CNS) INFECTIONS, including meningitis and brain abscess, caused by Bacteroides species including the B. fragilis group. LOWER RESPIRATORY TRACT INFECTIONS, including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group. ENDOCARDITIS caused by Bacteroides species including the B. fragilis group. To reduce the development of drug-resistant bacteria and maintain the effectiveness of metronidazole tablets USP and other antibacterial drugs, metronidazole tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:5629a701-4628-4626-b5c4-da936f55f7c0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0042485 PMID:41385096 "[{""id"":""uuid:89eced69-b8c2-4df8-8c7a-bce8fe4c5b89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:31e21560-0e3f-4570-93b9-bd6340516884"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Symptomatic Trichomoniasis Metronidazole tablets USP are indicated for the treatment of T. vaginalis infection in females and males when the presence of the trichomonad has been confirmed by appropriate laboratory procedures (wet smears and/or cultures). Asymptomatic Trichomoniasis Metronidazole tablets USP are indicated in the treatment of asymptomatic T. vaginalis infection in females when the organism is associated with endocervicitis, cervicitis, or cervical erosion. Since there is evidence that presence of the trichomonad can interfere with accurate assessment of abnormal cytological smears, additional smears should be performed after eradication of the parasite. Treatment of Asymptomatic Sexual Partners T. vaginalis infection is a venereal disease. Therefore, asymptomatic sexual partners of treated patients should be treated simultaneously if the organism has been found to be present, in order to prevent reinfection of the partner. The decision as to whether to treat an asymptomatic male partner who has a negative culture or one for whom no culture has been attempted is an individual one. In making this decision, it should be noted that there is evidence that a woman may become reinfected if her sexual partner is not treated. Also, since there can be considerable difficulty in isolating the organism from the asymptomatic male carrier, negative smears and cultures cannot be relied upon in this regard. In any event, the sexual partner should be treated with metronidazole tablets USP in cases of reinfection. Amebiasis Metronidazole tablets USP are indicated in the treatment of acute intestinal amebiasis (amebic dysentery) and amebic liver abscess. In amebic liver abscess, metronidazole tablet therapy does not obviate the need for aspiration or drainage of pus. Anaerobic Bacterial Infections Metronidazole tablets USP are indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with metronidazole tablet therapy. In a mixed aerobic and anaerobic infection, antimicrobials appropriate for the treatment of the aerobic infection should be used in addition to metronidazole tablets USP. INTRA-ABDOMINAL INFECTIONS, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species including the B. fragilis group (B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus), Clostridium species, Eubacterium species, Peptococcus species, and Peptostreptococcus species. SKIN AND SKIN STRUCTURE INFECTIONS caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus species, Peptostreptococcus species, and Fusobacterium species. GYNECOLOGIC INFECTIONS, including endometritis, endomyometritis, tubo-ovarian abscess, and postsurgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus species, Peptostreptococcus species, and Fusobacterium species. BACTERIAL SEPTICEMIA caused by Bacteroides species including the B. fragilis group and Clostridium species. BONE AND JOINT INFECTIONS, (as adjunctive therapy), caused by Bacteroides species including the B. fragilis group. CENTRAL NERVOUS SYSTEM (CNS) INFECTIONS, including meningitis and brain abscess, caused by Bacteroides species including the B. fragilis group. LOWER RESPIRATORY TRACT INFECTIONS, including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group. ENDOCARDITIS caused by Bacteroides species including the B. fragilis group. To reduce the development of drug-resistant bacteria and maintain the effectiveness of metronidazole tablets USP and other antibacterial drugs, metronidazole tablets USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:a61b8901-e0f2-4d71-9cf9-389e674253ca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31932 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:9e1040f3-478d-4faa-88a4-6817210a8e6a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:79bf2702-aa7c-498d-9ae2-01eafad75c81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Olmesartan medoxomil is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. It may be used alone or in combination with other antihypertensive agents. uuid:ef5df8d9-68be-48dd-922d-57774159a901 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31932 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:db812fcf-3a5c-4c49-8707-73388af1b0f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:93090fc4-051b-4a65-9146-745e99617d3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Olmesartan medoxomil is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with olmesartan medoxomil. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. It may be used alone or in combination with other antihypertensive agents. uuid:2094d399-3059-44e3-9060-195116a1591d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40009 biolink:treats MONDO:0018076 PMID:41385096 "[{""id"":""uuid:af5af872-da9b-4a28-b160-ded326d08bac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:03ba8a84-9b37-4f23-822b-332707ca642e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cycloserine is indicated in the treatment of active pulmonary and extrapulmonary tuberculosis (including renal disease) when the causative organisms are susceptible to this drug and when treatment with the primary medications (streptomycin, isoniazid, rifampin, and ethambutol) has proved inadequate. Like all antituberculosis drugs, cycloserine should be administered in conjunction with other effective chemotherapy and not as the sole therapeutic agent. Cycloserine may be effective in the treatment of acute urinary tract infections caused by susceptible strains of gram–positive and gram–negative bacteria, especially Enterobacter spp. and Escherichia coli. It is generally no more and is usually less effective than other antimicrobial agents in the treatment of urinary tract infections caused by bacteria other than mycobacteria. Use of cycloserine in these infections should be considered only when more conventional therapy has failed and when the organism has been demonstrated to be susceptible to the drug. uuid:50b3b83b-05d3-4466-bd57-7544622bc0b2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40009 biolink:treats MONDO:0005240 PMID:41385096 "[{""id"":""uuid:7dce4f5c-5e49-4eaa-bb9b-11c7abb3e543"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1e291699-f6ed-4d7b-809c-f2f66df1da52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cycloserine is indicated in the treatment of active pulmonary and extrapulmonary tuberculosis (including renal disease) when the causative organisms are susceptible to this drug and when treatment with the primary medications (streptomycin, isoniazid, rifampin, and ethambutol) has proved inadequate. Like all antituberculosis drugs, cycloserine should be administered in conjunction with other effective chemotherapy and not as the sole therapeutic agent. Cycloserine may be effective in the treatment of acute urinary tract infections caused by susceptible strains of gram–positive and gram–negative bacteria, especially Enterobacter spp. and Escherichia coli. It is generally no more and is usually less effective than other antimicrobial agents in the treatment of urinary tract infections caused by bacteria other than mycobacteria. Use of cycloserine in these infections should be considered only when more conventional therapy has failed and when the organism has been demonstrated to be susceptible to the drug. uuid:610e31d7-50d9-40ef-8bc1-b12aa881a527 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40009 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:10194e00-49e6-4cfd-afed-2821f339bc00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:48fb6537-0808-42d1-8231-89041282b501"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cycloserine is indicated in the treatment of active pulmonary and extrapulmonary tuberculosis (including renal disease) when the causative organisms are susceptible to this drug and when treatment with the primary medications (streptomycin, isoniazid, rifampin, and ethambutol) has proved inadequate. Like all antituberculosis drugs, cycloserine should be administered in conjunction with other effective chemotherapy and not as the sole therapeutic agent. Cycloserine may be effective in the treatment of acute urinary tract infections caused by susceptible strains of gram–positive and gram–negative bacteria, especially Enterobacter spp. and Escherichia coli. It is generally no more and is usually less effective than other antimicrobial agents in the treatment of urinary tract infections caused by bacteria other than mycobacteria. Use of cycloserine in these infections should be considered only when more conventional therapy has failed and when the organism has been demonstrated to be susceptible to the drug. uuid:57fe5fd7-4a9a-46e9-a675-2742993472cb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:46878853 biolink:treats MONDO:0037748 PMID:41385096 "[{""id"":""uuid:66bdac47-34ce-4b18-91ff-452ab33a19dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:79e760f1-660e-4b42-a912-f477e7d550e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment of Hypercholesterolemia Fenofibrate capsules, USP are indicated as adjunctive therapy to diet for the reduction of LDLC, total-C, Triglycerides and apo B in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Lipid altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate (see National Cholesterol Education Program [NCEP] Treatment Guidelines , below). Treatment of Hypertriglyceridemia Fenofibrate capsules, USP are also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually reduce fasting triglycerides and eliminate chylomicronemia thereby obviating the need for pharmacologic intervention. Markedly elevated levels of serum triglycerides (e.g. > 2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate therapy on reducing this risk has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV and V hyperlipoproteinemia 2 . The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcoholic intake may be important factors in hypertriglyceridemia and should be addressed prior to any drug therapy. Physical exercise can be an important ancillary measure. Diseases contributory to hyperlipidemia, such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy, like thiazide diuretics and beta-blockers, is sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of the specific etiologic agent may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with non-drug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet (See WARNINGS and PRECAUTIONS ). Fredrickson Classification of Hyperlipoproteinemias C = cholesterol TG = triglycerides LDL = low density lipoprotein VLDL = very lot density lipoprotein IDL = intermediate density lipoprotein Lipid Elevation Type Lipoprotein Elevated Major Minor I (rare) IIa IIb III (rare) IV V (rare) Chylomicrons LDL LDL, VLDL IDL VLDL Chylomicrons, VLDL TG C C C, TG TG TG ↑ ↔ C - TG - ↑ ↔ C ↑ ↔ The NCEP Treatment Guidelines Definite Atherosclerotic Two or More Other LDL-Cholesterol mg/dL (mmol/L) Disease Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). Risk Factors Other risk factors for coronary heart disease (CHD) include: age (males: ≥ 45 years; females: ≥ 55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C < 35 mg/dL (< 0.91 mmol/L); and diabetes mellitus. Subtract I risk favor if HDL-C is ≥ 60 mg/dL (≥ 1.6 mmol/L) Initiation Level Goal No No Yes No Yes Yes or No ≥ 190 (≥ 4.9) ≥ 160 (≥ 4.1) ≥ 130 In CHD patients with LDL-C levels 100 to 129 mg/dL, the physician should exercise clinical judgment in deciding whether to initiate drug treatment. (≥ 3.4) < 160 (< 4.1) < 130 (< 3.4) < 100 (< 2.6) uuid:64c2edce-3703-40fb-9446-4ce54428585d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:46878853 biolink:treats MONDO:0005311 PMID:41385096 "[{""id"":""uuid:df2372a5-1d8c-4773-a45c-9731b29586d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e0963499-163b-489e-8936-8e4487267855"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment of Hypercholesterolemia Fenofibrate capsules, USP are indicated as adjunctive therapy to diet for the reduction of LDLC, total-C, Triglycerides and apo B in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Lipid altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate (see National Cholesterol Education Program [NCEP] Treatment Guidelines , below). Treatment of Hypertriglyceridemia Fenofibrate capsules, USP are also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually reduce fasting triglycerides and eliminate chylomicronemia thereby obviating the need for pharmacologic intervention. Markedly elevated levels of serum triglycerides (e.g. > 2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate therapy on reducing this risk has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV and V hyperlipoproteinemia 2 . The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcoholic intake may be important factors in hypertriglyceridemia and should be addressed prior to any drug therapy. Physical exercise can be an important ancillary measure. Diseases contributory to hyperlipidemia, such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy, like thiazide diuretics and beta-blockers, is sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of the specific etiologic agent may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with non-drug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet (See WARNINGS and PRECAUTIONS ). Fredrickson Classification of Hyperlipoproteinemias C = cholesterol TG = triglycerides LDL = low density lipoprotein VLDL = very lot density lipoprotein IDL = intermediate density lipoprotein Lipid Elevation Type Lipoprotein Elevated Major Minor I (rare) IIa IIb III (rare) IV V (rare) Chylomicrons LDL LDL, VLDL IDL VLDL Chylomicrons, VLDL TG C C C, TG TG TG ↑ ↔ C - TG - ↑ ↔ C ↑ ↔ The NCEP Treatment Guidelines Definite Atherosclerotic Two or More Other LDL-Cholesterol mg/dL (mmol/L) Disease Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). Risk Factors Other risk factors for coronary heart disease (CHD) include: age (males: ≥ 45 years; females: ≥ 55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C < 35 mg/dL (< 0.91 mmol/L); and diabetes mellitus. Subtract I risk favor if HDL-C is ≥ 60 mg/dL (≥ 1.6 mmol/L) Initiation Level Goal No No Yes No Yes Yes or No ≥ 190 (≥ 4.9) ≥ 160 (≥ 4.1) ≥ 130 In CHD patients with LDL-C levels 100 to 129 mg/dL, the physician should exercise clinical judgment in deciding whether to initiate drug treatment. (≥ 3.4) < 160 (< 4.1) < 130 (< 3.4) < 100 (< 2.6) uuid:e3c3d722-7d6a-4361-858a-ce60272aeccc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:E3B2GI648A biolink:treats UMLS:C0345468 PMID:41385096 "[{""id"":""uuid:609bb371-0267-43c4-8e72-4cfd2bace7a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:45de6078-33a8-4c8d-bd19-7704295d45bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] • NULOJIX is a selective T cell costimulation blocker indicated for prophylaxis of organ rejection in adult patients receiving a kidney transplant. (1.1) • Use in combination with basiliximab induction, mycophenolate mofetil, and corticosteroids. (1.1) Limitations of Use : • Use only in patients who are EBV seropositive. (1.2 , 4 , 5.1) • Use has not been established for the prophylaxis of organ rejection in transplanted organs other than the kidney. (1.2 , 5.6) uuid:5ddfd16f-c338-46c4-97af-57b65738c6d0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7447 biolink:treats MONDO:0005644 PMID:41385096 "[{""id"":""uuid:0f571de0-085a-4a14-ad4e-b2c9d27b5482"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8a0da922-c42e-4daf-bf62-a167e0af76f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nafcillin is indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. Culture and susceptibility tests should be performed initially to determine the causative organism and its susceptibility to the drug (see CLINICAL PHARMACOLOGY- Susceptibility Test Methods ). Nafcillin should not be used in infections caused by organisms susceptible to penicillin G. If the susceptibility tests indicate that the infection is due to methicillin-resistant Staphylococcus sp., therapy with Nafcillin for Injection, USP should be discontinued and alternative therapy provided. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Nafcillin for Injection, USP and other antibacterial drugs, Nafcillin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:f57167f4-b0ad-41fa-8b20-38b81150c6da biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9241 biolink:treats MONDO:0017871 PMID:41385096 "[{""id"":""uuid:9d33aabb-dd79-47ea-9e7f-aa4473b4715e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:05ef632c-0b2b-4669-954c-a57232b6e91b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone tablets are an aldosterone antagonist indicated for: • The treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure ( 1.1 ). • Use as an add-on therapy for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.2 ). • The management of edema in adult patients who are cirrhotic when edema is not responsive to fluid and sodium restrictions and in the setting of nephrotic syndrome when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics produce an inadequate response ( 1.3 ). • Treatment of primary hyperaldosternism for: ( 1.4 ). • Short-term preoperative treatment • Long-term maintenance for patients with discrete aldosterone-producing adrenal adenomas who are not candidates for surgery and patients with bilateral micro or macronodular adrenal hyperplasia uuid:5f9699dd-9a7c-4f21-a7ea-2b037d93e890 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:50FKX8CB2Y biolink:treats MONDO:0007100 PMID:41385096 "[{""id"":""uuid:8cbbc89f-c696-44f0-8566-cfce8b5e273f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e5a8c54d-545f-4f09-8ac9-fbf54d20a1ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:be1d0c68-9716-4487-825b-4790579b7ff2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:09bf5268-3a15-4957-93aa-6a5ac1cfe18d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ONPATTRO is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.|[EMA] Onpattro is indicated for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.|[PMDA] A drug with a new active ingredient indicated for the treatment of transthyretin familial amyloid polyneuropathy. [Orphan drug] uuid:9811e35a-99c7-434c-8c08-4158528b774c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6970 biolink:treats EFO:1002029 PMID:41385096 "[{""id"":""uuid:5fa6caa6-9141-4044-9635-b800ae60635f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e1985d0f-a753-4cae-9da7-c251a005d23c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SINUVA Sinus Implant is indicated for the treatment of chronic rhinosinusitis with nasal polyps in adult patients ≥18 years of age who have had ethmoid sinus surgery. uuid:44484e42-c58f-4e98-b181-0e43296b0beb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:b83a9555-8e92-4ced-bfc4-e8f472c7953e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5ed56bdb-0cfd-4cbc-a7d2-670b54cd81f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Duloxetine delayed-release capsule is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of the following conditions: Major depressive disorder (MDD) in adults ( 1 ) Generalized anxiety disorder (GAD) in adults and pediatric patients 7 years of age and older ( 1 ) Diabetic peripheral neuropathic Pain (DPNP) in adults ( 1 ) Fibromyalgia (FM) in adults ( 1 ) Chronic musculoskeletal pain in adults ( 1 ) uuid:9d6a514b-670b-4135-8395-c0921adce9c1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0001942 PMID:41385096 "[{""id"":""uuid:8072e1c8-c1e8-429f-9837-e8df2ea1652b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5547eb87-9787-4fde-986f-c061a047c661"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Duloxetine delayed-release capsule is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of the following conditions: Major depressive disorder (MDD) in adults ( 1 ) Generalized anxiety disorder (GAD) in adults and pediatric patients 7 years of age and older ( 1 ) Diabetic peripheral neuropathic Pain (DPNP) in adults ( 1 ) Fibromyalgia (FM) in adults ( 1 ) Chronic musculoskeletal pain in adults ( 1 ) uuid:b3a4af42-d6f4-4cc7-9165-115838672403 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats UMLS:C1963916 PMID:41385096 "[{""id"":""uuid:c6269b6d-759b-4598-b104-64e120c924b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:97755896-75e4-46d4-959a-8b5aac927ef4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Duloxetine delayed-release capsule is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of the following conditions: Major depressive disorder (MDD) in adults ( 1 ) Generalized anxiety disorder (GAD) in adults and pediatric patients 7 years of age and older ( 1 ) Diabetic peripheral neuropathic Pain (DPNP) in adults ( 1 ) Fibromyalgia (FM) in adults ( 1 ) Chronic musculoskeletal pain in adults ( 1 ) uuid:c1ffc06e-c119-48bb-bc94-0a195938b4ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0005546 PMID:41385096 "[{""id"":""uuid:61d24801-0687-4370-9bd7-b55cb5ac80f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c259669c-3324-44bb-8376-d9da0c4b08a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Duloxetine delayed-release capsule is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of the following conditions: Major depressive disorder (MDD) in adults ( 1 ) Generalized anxiety disorder (GAD) in adults and pediatric patients 7 years of age and older ( 1 ) Diabetic peripheral neuropathic Pain (DPNP) in adults ( 1 ) Fibromyalgia (FM) in adults ( 1 ) Chronic musculoskeletal pain in adults ( 1 ) uuid:510c6ad4-f213-43c5-8429-fad53ae44fa5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats UMLS:C0746683 PMID:41385096 "[{""id"":""uuid:2cc51341-e851-4277-b191-adb719e14fd8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:68b06f47-1cfd-4008-8616-f7284b84a6c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Duloxetine delayed-release capsule is a serotonin and norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of the following conditions: Major depressive disorder (MDD) in adults ( 1 ) Generalized anxiety disorder (GAD) in adults and pediatric patients 7 years of age and older ( 1 ) Diabetic peripheral neuropathic Pain (DPNP) in adults ( 1 ) Fibromyalgia (FM) in adults ( 1 ) Chronic musculoskeletal pain in adults ( 1 ) uuid:9435be8a-fc2a-478c-a795-206a3513a504 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6931 biolink:treats MONDO:0002125 PMID:41385096 "[{""id"":""uuid:0c4af349-3410-4b2f-b02d-e9eb7a038144"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9dda20dd-0954-4897-b1c8-d2a85f7d5d59"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b6d69032-7ac9-4de9-807c-389d5bad8925"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SEIZALAM is indicated for the treatment of status epilepticus in adults.|[PMDA] A drug with a new additional indication and a new dosage in an additional dosage form indicated for the treatment of status epilepticus. uuid:f9f70588-cb5f-426d-bf4e-5fc1484d1b23 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6931 biolink:treats MONDO:0005027 PMID:41385096 "[{""id"":""uuid:8d9d015d-0655-4669-b573-619d6cf114cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:fe37cdb3-b460-416d-81c2-f22e6a2a358a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:44238cbd-fa59-4bd5-ba4e-e802d0f7a5f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/buccolam""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] NAYZILAM is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy 12 years of age and older.|[EMA] Treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents (from three months to less than 18 years).Buccolam must only be used by parents / carers where the patient has been diagnosed to have epilepsy.For infants between three and six months of age, treatment should be in a hospital setting where monitoring is possible and resuscitation equipment is available. uuid:2dcc0cf1-6b4b-463e-b0d1-4954a93aeb1b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6931 biolink:treats UMLS:C3203523 PMID:41385096 "[{""id"":""uuid:0463bc07-92fb-474b-bc92-a2b132d3a2ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c723120d-47b2-4ea4-b625-23c2ae8300df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NAYZILAM is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy 12 years of age and older. uuid:dc5dc1d0-67ba-4607-acbb-71b071d8a4a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6472 biolink:treats MONDO:0021680 PMID:41385096 "[{""id"":""uuid:1273cebf-2489-4b2e-bb07-9d72111ab1b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a8dd2055-cedd-47f5-9287-af0dd8cc9f20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lincomycin Injection sterile solution is indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of CDAD, as described in the BOXED WARNING , before selecting lincomycin the physician should consider the nature of the infection and the suitability of other alternatives. Indicated surgical procedures should be performed in conjunction with antibacterial therapy. Lincomycin Injection may be administered concomitantly with other antimicrobial agents when indicated. Lincomycin Injection is not indicated in the treatment of minor bacterial infections or viral infections. To reduce the development of drug-resistant bacteria and maintain the effectiveness of lincomycin injection and other antibacterial drugs, lincomycin injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:19826fa1-ddf5-429f-87ad-a3c0c226990c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6472 biolink:treats MONDO:0005114 PMID:41385096 "[{""id"":""uuid:da78e0ae-1dbd-4bdc-bb4a-e74c8ea3de08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5de5b678-2d75-440b-a528-cbbc666c14de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lincomycin Injection sterile solution is indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of CDAD, as described in the BOXED WARNING , before selecting lincomycin the physician should consider the nature of the infection and the suitability of other alternatives. Indicated surgical procedures should be performed in conjunction with antibacterial therapy. Lincomycin Injection may be administered concomitantly with other antimicrobial agents when indicated. Lincomycin Injection is not indicated in the treatment of minor bacterial infections or viral infections. To reduce the development of drug-resistant bacteria and maintain the effectiveness of lincomycin injection and other antibacterial drugs, lincomycin injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:371f67b4-dd6d-4024-a98a-1993f0af518d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6472 biolink:treats MONDO:0024313 PMID:41385096 "[{""id"":""uuid:b4f5d1cf-4268-499c-bb6d-1104bd1c8ffb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:82bc0b5f-80f1-4001-b0e1-07658cde5269"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lincomycin Injection sterile solution is indicated in the treatment of serious infections due to susceptible strains of streptococci, pneumococci, and staphylococci. Its use should be reserved for penicillin-allergic patients or other patients for whom, in the judgment of the physician, a penicillin is inappropriate. Because of the risk of CDAD, as described in the BOXED WARNING , before selecting lincomycin the physician should consider the nature of the infection and the suitability of other alternatives. Indicated surgical procedures should be performed in conjunction with antibacterial therapy. Lincomycin Injection may be administered concomitantly with other antimicrobial agents when indicated. Lincomycin Injection is not indicated in the treatment of minor bacterial infections or viral infections. To reduce the development of drug-resistant bacteria and maintain the effectiveness of lincomycin injection and other antibacterial drugs, lincomycin injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:bd6ffb56-b0f4-4528-97ff-0af441594f15 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:70707 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:daa1e630-4cc8-4333-867a-f5932f52ddc7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:101b1dc0-7a3d-43f6-80aa-db81a820a0c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vilazodone hydrochloride tablets are indicated for the treatment of major depressive disorder (MDD) in adults [see Clinical Studies (14)]. uuid:154376c5-a94e-4f73-aeb5-e1a36d9c5465 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:11672431 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:4d8290a4-92d4-479c-bb89-496444443525"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b4794b6a-a8ee-48ce-8bed-a82ffbdfe9d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Telmisartan and amlodipine tablets are indicated for the treatment of hypertension, alone or with other antihypertensive agents to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including angiotensin II receptor blockers and dihydropyridine calcium channel blockers. There are no controlled trials demonstrating risk reduction with telmisartan and amlodipine tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Telmisartan and amlodipine tablets may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. Base the choice of telmisartan and amlodipine tablets as initial therapy for hypertension on an assessment of potential benefits and risks including whether the patient is likely to tolerate the starting dose of telmisartan and amlodipine tablets. Patients with moderate or severe hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. Consider the patient’s baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared with monotherapy when deciding whether to use telmisartan and amlodipine tablets as initial therapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from an 8-week, placebo-controlled, multidose, factorial trial provide estimates of the probability of reaching a blood pressure goal with telmisartan and amlodipine tablets compared to telmisartan or amlodipine monotherapy and placebo [see Clinical Studies (14.1)] . The figures below provide estimates of the likelihood of achieving systolic and diastolic blood pressure control with telmisartan and amlodipine 80/10 mg tablets, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling. The estimated likelihood at the right tail of each curve is less reliable due to small numbers of subjects with high baseline blood pressures. The figures above provide an approximation of the likelihood of reaching a targeted blood pressure goal at 8 weeks. For example, a patient with a baseline blood pressure of 160/110 mmHg has about a 16% likelihood of achieving a goal of <140 mmHg (systolic) and 16% likelihood of achieving <90 mmHg (diastolic) on placebo. The likelihood of achieving these same goals on telmisartan is about 46% (systolic) and 26% (diastolic). The likelihood of achieving these same goals on amlodipine is about 69% (systolic) and 22% (diastolic). These likelihoods rise to 79% for systolic and 55% for diastolic with telmisartan and amlodipine tablets. uuid:1d29c170-0f3f-4323-a259-49858269c977 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:11672431 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:ae0e0be3-a7d6-4e61-b3fc-f109f1e6c0d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:be441a12-448c-4216-8611-ba383f2e30ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Telmisartan and amlodipine tablets are indicated for the treatment of hypertension, alone or with other antihypertensive agents to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including angiotensin II receptor blockers and dihydropyridine calcium channel blockers. There are no controlled trials demonstrating risk reduction with telmisartan and amlodipine tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Telmisartan and amlodipine tablets may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. Base the choice of telmisartan and amlodipine tablets as initial therapy for hypertension on an assessment of potential benefits and risks including whether the patient is likely to tolerate the starting dose of telmisartan and amlodipine tablets. Patients with moderate or severe hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. Consider the patient’s baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared with monotherapy when deciding whether to use telmisartan and amlodipine tablets as initial therapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from an 8-week, placebo-controlled, multidose, factorial trial provide estimates of the probability of reaching a blood pressure goal with telmisartan and amlodipine tablets compared to telmisartan or amlodipine monotherapy and placebo [see Clinical Studies (14.1)] . The figures below provide estimates of the likelihood of achieving systolic and diastolic blood pressure control with telmisartan and amlodipine 80/10 mg tablets, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling. The estimated likelihood at the right tail of each curve is less reliable due to small numbers of subjects with high baseline blood pressures. The figures above provide an approximation of the likelihood of reaching a targeted blood pressure goal at 8 weeks. For example, a patient with a baseline blood pressure of 160/110 mmHg has about a 16% likelihood of achieving a goal of <140 mmHg (systolic) and 16% likelihood of achieving <90 mmHg (diastolic) on placebo. The likelihood of achieving these same goals on telmisartan is about 46% (systolic) and 26% (diastolic). The likelihood of achieving these same goals on amlodipine is about 69% (systolic) and 22% (diastolic). These likelihoods rise to 79% for systolic and 55% for diastolic with telmisartan and amlodipine tablets. uuid:fd6a9f2a-6eb2-43fc-907e-56ebe8a62b4c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:11672431 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:0dd4c1d9-9503-4265-92dc-f9e010882616"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:61de784a-f72c-4c80-b58a-9fecc14447b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Telmisartan and amlodipine tablets are indicated for the treatment of hypertension, alone or with other antihypertensive agents to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including angiotensin II receptor blockers and dihydropyridine calcium channel blockers. There are no controlled trials demonstrating risk reduction with telmisartan and amlodipine tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Telmisartan and amlodipine tablets may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. Base the choice of telmisartan and amlodipine tablets as initial therapy for hypertension on an assessment of potential benefits and risks including whether the patient is likely to tolerate the starting dose of telmisartan and amlodipine tablets. Patients with moderate or severe hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. Consider the patient’s baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared with monotherapy when deciding whether to use telmisartan and amlodipine tablets as initial therapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from an 8-week, placebo-controlled, multidose, factorial trial provide estimates of the probability of reaching a blood pressure goal with telmisartan and amlodipine tablets compared to telmisartan or amlodipine monotherapy and placebo [see Clinical Studies (14.1)] . The figures below provide estimates of the likelihood of achieving systolic and diastolic blood pressure control with telmisartan and amlodipine 80/10 mg tablets, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling. The estimated likelihood at the right tail of each curve is less reliable due to small numbers of subjects with high baseline blood pressures. The figures above provide an approximation of the likelihood of reaching a targeted blood pressure goal at 8 weeks. For example, a patient with a baseline blood pressure of 160/110 mmHg has about a 16% likelihood of achieving a goal of <140 mmHg (systolic) and 16% likelihood of achieving <90 mmHg (diastolic) on placebo. The likelihood of achieving these same goals on telmisartan is about 46% (systolic) and 26% (diastolic). The likelihood of achieving these same goals on amlodipine is about 69% (systolic) and 22% (diastolic). These likelihoods rise to 79% for systolic and 55% for diastolic with telmisartan and amlodipine tablets. uuid:2a24f462-cc61-4991-a6b8-4fe54d388c27 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:11672431 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:7146e49a-2e7f-4ef3-a2e2-6af396616e7d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ce1fa449-35e0-4ca1-8a3b-53e17d1d380d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Telmisartan and amlodipine tablets are indicated for the treatment of hypertension, alone or with other antihypertensive agents to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including angiotensin II receptor blockers and dihydropyridine calcium channel blockers. There are no controlled trials demonstrating risk reduction with telmisartan and amlodipine tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Telmisartan and amlodipine tablets may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. Base the choice of telmisartan and amlodipine tablets as initial therapy for hypertension on an assessment of potential benefits and risks including whether the patient is likely to tolerate the starting dose of telmisartan and amlodipine tablets. Patients with moderate or severe hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. Consider the patient’s baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared with monotherapy when deciding whether to use telmisartan and amlodipine tablets as initial therapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from an 8-week, placebo-controlled, multidose, factorial trial provide estimates of the probability of reaching a blood pressure goal with telmisartan and amlodipine tablets compared to telmisartan or amlodipine monotherapy and placebo [see Clinical Studies (14.1)] . The figures below provide estimates of the likelihood of achieving systolic and diastolic blood pressure control with telmisartan and amlodipine 80/10 mg tablets, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling. The estimated likelihood at the right tail of each curve is less reliable due to small numbers of subjects with high baseline blood pressures. The figures above provide an approximation of the likelihood of reaching a targeted blood pressure goal at 8 weeks. For example, a patient with a baseline blood pressure of 160/110 mmHg has about a 16% likelihood of achieving a goal of <140 mmHg (systolic) and 16% likelihood of achieving <90 mmHg (diastolic) on placebo. The likelihood of achieving these same goals on telmisartan is about 46% (systolic) and 26% (diastolic). The likelihood of achieving these same goals on amlodipine is about 69% (systolic) and 22% (diastolic). These likelihoods rise to 79% for systolic and 55% for diastolic with telmisartan and amlodipine tablets. uuid:4ea67c1e-b51c-4ee2-9e83-be9fdc4582de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:11672431 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:fe78cacf-e569-4167-b895-8f0656dbfc21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:191f9b47-8cb3-4bb0-a310-3b2d155d1b92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Telmisartan and amlodipine tablets are indicated for the treatment of hypertension, alone or with other antihypertensive agents to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including angiotensin II receptor blockers and dihydropyridine calcium channel blockers. There are no controlled trials demonstrating risk reduction with telmisartan and amlodipine tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Telmisartan and amlodipine tablets may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. Base the choice of telmisartan and amlodipine tablets as initial therapy for hypertension on an assessment of potential benefits and risks including whether the patient is likely to tolerate the starting dose of telmisartan and amlodipine tablets. Patients with moderate or severe hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. Consider the patient’s baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared with monotherapy when deciding whether to use telmisartan and amlodipine tablets as initial therapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from an 8-week, placebo-controlled, multidose, factorial trial provide estimates of the probability of reaching a blood pressure goal with telmisartan and amlodipine tablets compared to telmisartan or amlodipine monotherapy and placebo [see Clinical Studies (14.1)] . The figures below provide estimates of the likelihood of achieving systolic and diastolic blood pressure control with telmisartan and amlodipine 80/10 mg tablets, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling. The estimated likelihood at the right tail of each curve is less reliable due to small numbers of subjects with high baseline blood pressures. The figures above provide an approximation of the likelihood of reaching a targeted blood pressure goal at 8 weeks. For example, a patient with a baseline blood pressure of 160/110 mmHg has about a 16% likelihood of achieving a goal of <140 mmHg (systolic) and 16% likelihood of achieving <90 mmHg (diastolic) on placebo. The likelihood of achieving these same goals on telmisartan is about 46% (systolic) and 26% (diastolic). The likelihood of achieving these same goals on amlodipine is about 69% (systolic) and 22% (diastolic). These likelihoods rise to 79% for systolic and 55% for diastolic with telmisartan and amlodipine tablets. uuid:47b87cb8-f2c7-4430-b8d2-933272cfd9d3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:11672431 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:d72b48f5-3bd6-41f8-b36f-db74caf912c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2c171ae4-d335-41e0-905f-d674be3d48fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Telmisartan and amlodipine tablets are indicated for the treatment of hypertension, alone or with other antihypertensive agents to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including angiotensin II receptor blockers and dihydropyridine calcium channel blockers. There are no controlled trials demonstrating risk reduction with telmisartan and amlodipine tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Telmisartan and amlodipine tablets may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. Base the choice of telmisartan and amlodipine tablets as initial therapy for hypertension on an assessment of potential benefits and risks including whether the patient is likely to tolerate the starting dose of telmisartan and amlodipine tablets. Patients with moderate or severe hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. Consider the patient’s baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared with monotherapy when deciding whether to use telmisartan and amlodipine tablets as initial therapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from an 8-week, placebo-controlled, multidose, factorial trial provide estimates of the probability of reaching a blood pressure goal with telmisartan and amlodipine tablets compared to telmisartan or amlodipine monotherapy and placebo [see Clinical Studies (14.1)] . The figures below provide estimates of the likelihood of achieving systolic and diastolic blood pressure control with telmisartan and amlodipine 80/10 mg tablets, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling. The estimated likelihood at the right tail of each curve is less reliable due to small numbers of subjects with high baseline blood pressures. The figures above provide an approximation of the likelihood of reaching a targeted blood pressure goal at 8 weeks. For example, a patient with a baseline blood pressure of 160/110 mmHg has about a 16% likelihood of achieving a goal of <140 mmHg (systolic) and 16% likelihood of achieving <90 mmHg (diastolic) on placebo. The likelihood of achieving these same goals on telmisartan is about 46% (systolic) and 26% (diastolic). The likelihood of achieving these same goals on amlodipine is about 69% (systolic) and 22% (diastolic). These likelihoods rise to 79% for systolic and 55% for diastolic with telmisartan and amlodipine tablets. uuid:0e0bc1d4-fd15-47b5-836a-4cc52f9c7e26 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:11672431 biolink:treats MONDO:0001106 PMID:41385096 "[{""id"":""uuid:64c95f8e-69d4-4156-ad61-29176acc917a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4441fb75-a74d-4054-a29a-8e407f999649"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Telmisartan and amlodipine tablets are indicated for the treatment of hypertension, alone or with other antihypertensive agents to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including angiotensin II receptor blockers and dihydropyridine calcium channel blockers. There are no controlled trials demonstrating risk reduction with telmisartan and amlodipine tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Telmisartan and amlodipine tablets may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. Base the choice of telmisartan and amlodipine tablets as initial therapy for hypertension on an assessment of potential benefits and risks including whether the patient is likely to tolerate the starting dose of telmisartan and amlodipine tablets. Patients with moderate or severe hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. Consider the patient’s baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared with monotherapy when deciding whether to use telmisartan and amlodipine tablets as initial therapy. Individual blood pressure goals may vary based upon the patient’s risk. Data from an 8-week, placebo-controlled, multidose, factorial trial provide estimates of the probability of reaching a blood pressure goal with telmisartan and amlodipine tablets compared to telmisartan or amlodipine monotherapy and placebo [see Clinical Studies (14.1)] . The figures below provide estimates of the likelihood of achieving systolic and diastolic blood pressure control with telmisartan and amlodipine 80/10 mg tablets, based upon baseline systolic or diastolic blood pressure. The curve of each treatment group was estimated by logistic regression modeling. The estimated likelihood at the right tail of each curve is less reliable due to small numbers of subjects with high baseline blood pressures. The figures above provide an approximation of the likelihood of reaching a targeted blood pressure goal at 8 weeks. For example, a patient with a baseline blood pressure of 160/110 mmHg has about a 16% likelihood of achieving a goal of <140 mmHg (systolic) and 16% likelihood of achieving <90 mmHg (diastolic) on placebo. The likelihood of achieving these same goals on telmisartan is about 46% (systolic) and 26% (diastolic). The likelihood of achieving these same goals on amlodipine is about 69% (systolic) and 22% (diastolic). These likelihoods rise to 79% for systolic and 55% for diastolic with telmisartan and amlodipine tablets. uuid:acb415cc-4e05-4cb4-9fe8-89f6a6bf8e7a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63607 biolink:treats DOID:50360 PMID:41385096 "[{""id"":""uuid:85428c4a-04eb-4592-8840-0e7ed484ed0f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:becf7157-a14a-47e4-b5d8-bdf99a578204"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Linezolid tablets are indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below. Linezolid tablets are not indicated for the treatment of Gram-negative infections. It is critical that specific Gram-negative therapy be initiated immediately if a concomitant Gram-negative pathogen is documented or suspected [ see Warnings and Precautions (5.4) ]. uuid:fb24c826-7552-4b8a-904b-3fcc21ee4fad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9168 biolink:treats UMLS:C0345468 PMID:41385096 "[{""id"":""uuid:c19115e2-8451-45e7-aacc-3f7ecfaaef78"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:80322cd5-2364-45ed-bfa4-9c8b03ab6dc2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:932f555c-5c39-46a6-8603-07cfdb67b17a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/hyftor""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] • Sirolimus tablet is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in patients aged ≥13 years receiving renal transplants: o Patients at low-to moderate-immunologic risk: Use initially with cyclosporine (CsA) and corticosteroids. CsA withdrawal is recommended 2-4 months after transplantation ( 1.1 ). o Patients at high-immunologic risk: Use in combination with CsA and corticosteroids for the first 12 months following transplantation ( 1.1 ). Safety and efficacy of CsA withdrawal has not been established in high risk patients ( 1.1 , 1.2 , 14.3 ). • Sirolimus tablet is an mTOR inhibitor indicated for the treatment of patients with lymphangioleiomyomatosis ( 1.3 ).|[EMA] Rapamune is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a renal transplant. It is recommended that Rapamune be used initially in combination with ciclosporin microemulsion and corticosteroids for 2 to 3 months. Rapamune may be continued as maintenance therapy with corticosteroids only if ciclosporin microemulsion can be progressively discontinued., , Rapamune is indicated for the treatment of patients with sporadic lymphangioleiomyomatosis with moderate lung disease or declining lung function., uuid:e8ba6c81-df93-4660-a1db-6b2e22e9caab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9168 biolink:treats MONDO:0011705 PMID:41385096 "[{""id"":""uuid:f3c447f3-6a7f-48e9-a116-ae728826a0c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1997e979-c82e-4b2c-ab79-fd45f7dd836c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d4ee04a8-d1ee-4103-8122-a696f2c0f9d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/hyftor""]},{""id"":""uuid:22c09b9d-3b5c-4101-81d1-a84004dc4280"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] • Sirolimus tablet is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in patients aged ≥13 years receiving renal transplants: o Patients at low-to moderate-immunologic risk: Use initially with cyclosporine (CsA) and corticosteroids. CsA withdrawal is recommended 2-4 months after transplantation ( 1.1 ). o Patients at high-immunologic risk: Use in combination with CsA and corticosteroids for the first 12 months following transplantation ( 1.1 ). Safety and efficacy of CsA withdrawal has not been established in high risk patients ( 1.1 , 1.2 , 14.3 ). • Sirolimus tablet is an mTOR inhibitor indicated for the treatment of patients with lymphangioleiomyomatosis ( 1.3 ).|[EMA] Rapamune is indicated for the prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving a renal transplant. It is recommended that Rapamune be used initially in combination with ciclosporin microemulsion and corticosteroids for 2 to 3 months. Rapamune may be continued as maintenance therapy with corticosteroids only if ciclosporin microemulsion can be progressively discontinued., , Rapamune is indicated for the treatment of patients with sporadic lymphangioleiomyomatosis with moderate lung disease or declining lung function.,|[PMDA] A drug with a new active ingredient indicated for the treatment of lymphangioleiomyomatosis. [Orphan drug] uuid:ca7355f2-3dd8-45c0-a0e1-0144c2a656e5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49005 biolink:treats UMLS:C1739382 PMID:41385096 "[{""id"":""uuid:904407ce-ba04-4f2a-8dba-ffdc6ef50f10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:deb0a054-522d-433c-be05-5c0b5bd926f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:290c5a35-76b7-427a-9228-de58553e46fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Deferasirox tablets are an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older. Limitations of Use: The safety and efficacy of deferasirox tablets when administered with other iron chelation therapy have not been established. (1.3)|[PMDA] Drugs in a new dosage form indicated for the treatment of chronic iron overload due to blood transfusions (in patients for whom injection of iron chelating agents is inappropriate). uuid:5ab1c828-59f3-406d-87a5-fa46bfbe22bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49005 biolink:treats UMLS:C0282193 PMID:41385096 "[{""id"":""uuid:fb54a8fa-9d48-4ff1-b597-01ef320243f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:41123704-b255-4bcd-a6cd-a7364fa8e309"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Deferasirox tablets are an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older. Limitations of Use: The safety and efficacy of deferasirox tablets when administered with other iron chelation therapy have not been established. (1.3) uuid:747c06d0-2be8-4249-bc9e-511cfbdad806 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40009 biolink:treats MONDO:0006052 PMID:41385096 "[{""id"":""uuid:c92d59f4-fb21-41a6-b43a-7201ae8366a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5e8271da-ac97-47d5-886e-2c2b04f24df6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cycloserine is indicated in the treatment of active pulmonary and extrapulmonary tuberculosis (including renal disease) when the causative organisms are susceptible to this drug and when treatment with the primary medications (streptomycin, isoniazid, rifampin, and ethambutol) has proved inadequate. Like all antituberculosis drugs, cycloserine should be administered in conjunction with other effective chemotherapy and not as the sole therapeutic agent. Cycloserine may be effective in the treatment of acute urinary tract infections caused by susceptible strains of gram-positive and gram- negative bacteria. Use of cycloserine in these infections should be considered only when more conventional therapy has failed and when the organism has been demonstrated to be susceptible to the drug uuid:46d62d83-55e0-4a22-8b5e-52849fd6f3a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40009 biolink:treats MONDO:0000368 PMID:41385096 "[{""id"":""uuid:2c2aca38-88a7-41a8-8cc1-7c7c506f4557"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:76110234-d587-436a-bb4d-4dbc7df0d9c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cycloserine is indicated in the treatment of active pulmonary and extrapulmonary tuberculosis (including renal disease) when the causative organisms are susceptible to this drug and when treatment with the primary medications (streptomycin, isoniazid, rifampin, and ethambutol) has proved inadequate. Like all antituberculosis drugs, cycloserine should be administered in conjunction with other effective chemotherapy and not as the sole therapeutic agent. Cycloserine may be effective in the treatment of acute urinary tract infections caused by susceptible strains of gram-positive and gram- negative bacteria. Use of cycloserine in these infections should be considered only when more conventional therapy has failed and when the organism has been demonstrated to be susceptible to the drug uuid:5a68f247-cab9-4b16-bfc2-f91bc2fec59b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:B72HH48FLU biolink:treats MONDO:0005011 PMID:41385096 "[{""id"":""uuid:9ff3cd08-9352-47e4-823b-66b1da8fbadd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:12f224bf-8d99-4701-a47f-ca5f1add00cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0192d707-41f1-4ea7-8ff9-81a6173eee05"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zessly""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] RENFLEXIS is a tumor necrosis factor (TNF) blocker indicated for: Crohn's Disease: • reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.1 ) • reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing disease. ( 1.1 ) Pediatric Crohn's Disease: • reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.2 ) Ulcerative Colitis: • reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.3 ) Pediatric Ulcerative Colitis: • reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.4 ) Rheumatoid Arthritis in combination with methotrexate: • reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active disease. ( 1.5 ) Ankylosing Spondylitis: • reducing signs and symptoms in patients with active disease. ( 1.6 ) Psoriatic Arthritis: • reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function. ( 1.7 ) Plaque Psoriasis: • treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. ( 1.8 )|[EMA] Treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis. uuid:079b82c4-7ab8-4ab9-af5f-146a29db602f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:B72HH48FLU biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:cf11b48f-8f59-4411-898e-d0bd255a09f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b9f0866b-e48e-485a-a5fc-cbe68ef4d31e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:35f47970-33cb-4a3a-bdec-8ed772088cc7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zessly""]},{""id"":""uuid:e9a73da3-d44d-40e3-8150-2240452021f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RENFLEXIS is a tumor necrosis factor (TNF) blocker indicated for: Crohn's Disease: • reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.1 ) • reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing disease. ( 1.1 ) Pediatric Crohn's Disease: • reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.2 ) Ulcerative Colitis: • reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.3 ) Pediatric Ulcerative Colitis: • reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.4 ) Rheumatoid Arthritis in combination with methotrexate: • reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active disease. ( 1.5 ) Ankylosing Spondylitis: • reducing signs and symptoms in patients with active disease. ( 1.6 ) Psoriatic Arthritis: • reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function. ( 1.7 ) Plaque Psoriasis: • treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. ( 1.8 )|[EMA] Treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis.|[PMDA] Follow-on biologics indicated for the treatment of rheumatoid arthritis, psoriasis, Crohn’s disease, and ulcerative colitis. uuid:e1e018f8-6df5-4fbc-8b54-9c62121afd79 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:B72HH48FLU biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:9f694487-86b4-4573-8734-99437156ba36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:90498c6e-1c56-403c-8466-fe324e53376b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:255a022b-c474-4842-ab63-b5f65d48e9ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zessly""]},{""id"":""uuid:b2429539-803a-497b-a510-c61577ffda5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RENFLEXIS is a tumor necrosis factor (TNF) blocker indicated for: Crohn's Disease: • reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.1 ) • reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing disease. ( 1.1 ) Pediatric Crohn's Disease: • reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.2 ) Ulcerative Colitis: • reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.3 ) Pediatric Ulcerative Colitis: • reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.4 ) Rheumatoid Arthritis in combination with methotrexate: • reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active disease. ( 1.5 ) Ankylosing Spondylitis: • reducing signs and symptoms in patients with active disease. ( 1.6 ) Psoriatic Arthritis: • reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function. ( 1.7 ) Plaque Psoriasis: • treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. ( 1.8 )|[EMA] Treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis.|[PMDA] Follow-on biologics indicated for the treatment of rheumatoid arthritis, psoriasis, Crohn’s disease, and ulcerative colitis. uuid:e478d126-70ff-45db-9fbf-15bc5530652d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:B72HH48FLU biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:cf237280-5614-45af-905d-985e976ddeca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c3e25305-3aa4-4a74-9e82-57f9da587ef2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b2c33da6-924b-4fb6-a3fe-c06a5ddf02ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zessly""]},{""id"":""uuid:5f56c025-f5a0-4f63-801e-5d60ce9cbdcb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RENFLEXIS is a tumor necrosis factor (TNF) blocker indicated for: Crohn's Disease: • reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.1 ) • reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing disease. ( 1.1 ) Pediatric Crohn's Disease: • reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.2 ) Ulcerative Colitis: • reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.3 ) Pediatric Ulcerative Colitis: • reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.4 ) Rheumatoid Arthritis in combination with methotrexate: • reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active disease. ( 1.5 ) Ankylosing Spondylitis: • reducing signs and symptoms in patients with active disease. ( 1.6 ) Psoriatic Arthritis: • reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function. ( 1.7 ) Plaque Psoriasis: • treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. ( 1.8 )|[EMA] Treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis.|[PMDA] A drug with a new additional indication and a new dosage for the treatment of ankylosing spondylitis in patients who have not responded sufficiently to conventional treatments. [Orphan drug] uuid:03d32223-d47f-4fe5-a3f0-c92069deab89 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:B72HH48FLU biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:c18b5f8f-6979-48d3-ac32-b3d56adab670"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d1c51754-ce50-47a7-a2e4-15f0cda3d13c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4189557d-9efd-4d44-9b70-cd849fc0b975"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zessly""]},{""id"":""uuid:3e2ba58a-a67f-4ee4-8f23-080d00171674"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RENFLEXIS is a tumor necrosis factor (TNF) blocker indicated for: Crohn's Disease: • reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.1 ) • reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing disease. ( 1.1 ) Pediatric Crohn's Disease: • reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.2 ) Ulcerative Colitis: • reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.3 ) Pediatric Ulcerative Colitis: • reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.4 ) Rheumatoid Arthritis in combination with methotrexate: • reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active disease. ( 1.5 ) Ankylosing Spondylitis: • reducing signs and symptoms in patients with active disease. ( 1.6 ) Psoriatic Arthritis: • reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function. ( 1.7 ) Plaque Psoriasis: • treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. ( 1.8 )|[EMA] Treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis.|[PMDA] A drug with a new dosage indicated for plaque psoriasis, psoriatic arthritis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional treatments. uuid:5ce185e2-3dc3-49a1-96fb-3a69573fb23c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:B72HH48FLU biolink:treats UMLS:C0406317 PMID:41385096 "[{""id"":""uuid:6cf5a6ab-7dda-4ca7-ab74-21094005329c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3e8b7d41-4dcf-451e-ae57-f041cd5f85d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:fd12303a-5bfd-4a40-a66b-2998a5997fcc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RENFLEXIS is a tumor necrosis factor (TNF) blocker indicated for: Crohn's Disease: • reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.1 ) • reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing disease. ( 1.1 ) Pediatric Crohn's Disease: • reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.2 ) Ulcerative Colitis: • reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.3 ) Pediatric Ulcerative Colitis: • reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients with moderately to severely active disease who have had an inadequate response to conventional therapy. ( 1.4 ) Rheumatoid Arthritis in combination with methotrexate: • reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active disease. ( 1.5 ) Ankylosing Spondylitis: • reducing signs and symptoms in patients with active disease. ( 1.6 ) Psoriatic Arthritis: • reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function. ( 1.7 ) Plaque Psoriasis: • treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. ( 1.8 )|[PMDA] A drug with a new dosage indicated for plaque psoriasis, psoriatic arthritis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional treatments. uuid:3c83b285-7df9-4dab-9976-698abf46a87d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71193 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:e378be61-bd97-49e1-8967-45e72e5f5afc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:675ec5cd-bb88-4de1-8dde-70cb67c1141e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:28f7780c-b3f1-4e24-b321-1fcdb4de9911"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/saxenda""]},{""id"":""uuid:97c2a3fa-9bbd-4801-ab2b-7593e225dc03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VICTOZA is indicated: • as an adjunct to diet and exercise to improve glycemic control in patients 10 years and older with type 2 diabetes mellitus, • to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease [see Clinical Studies ( 14.3 )] . Limitations of Use : VICTOZA should not be used in patients with type 1 diabetes mellitus. VICTOZA contains liraglutide and should not be coadministered with other liraglutide-containing products.|[EMA] Saxenda is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index (BMI) of• ≥ 30 kg/m² (obese), or• ≥ 27 kg/m² to < 30 kg/m² (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea.Treatment with Saxenda should be discontinued after 12 weeks on the 3.0 mg/day dose if patients have not lost at least 5% of their initial body weight.|[PMDA] A drug with a new active ingredient indicated for the treatment of type 2 diabetes mellitus (for use only in patients who have not responded sufficiently to either [1] diet and exercise therapies alone or [2] sulfonylurea along with diet and exercise therapies). uuid:03038a03-06d7-4461-b67a-4e09e63a779c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71193 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:6fb2aa72-64c1-430d-b0e6-80b8d278780f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c71f3c79-b397-4e87-be04-169a83883dd2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VICTOZA is indicated: • as an adjunct to diet and exercise to improve glycemic control in patients 10 years and older with type 2 diabetes mellitus, • to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease [see Clinical Studies ( 14.3 )] . Limitations of Use : VICTOZA should not be used in patients with type 1 diabetes mellitus. VICTOZA contains liraglutide and should not be coadministered with other liraglutide-containing products. uuid:63e68009-5647-433a-94bf-13c94135312f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71193 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:2b28d248-463c-434e-90ab-17d003c52970"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:99646a74-7c68-464a-ba4d-e4cda041a483"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VICTOZA is indicated: • as an adjunct to diet and exercise to improve glycemic control in patients 10 years and older with type 2 diabetes mellitus, • to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease [see Clinical Studies ( 14.3 )] . Limitations of Use : VICTOZA should not be used in patients with type 1 diabetes mellitus. VICTOZA contains liraglutide and should not be coadministered with other liraglutide-containing products. uuid:55aac164-81aa-41f7-890e-7f6959e93d83 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71193 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:b48a1864-925b-4cef-b760-2804783c361c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fb3907cf-b4ee-44f2-b1d7-4e98a26bd6b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VICTOZA is indicated: • as an adjunct to diet and exercise to improve glycemic control in patients 10 years and older with type 2 diabetes mellitus, • to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease [see Clinical Studies ( 14.3 )] . Limitations of Use : VICTOZA should not be used in patients with type 1 diabetes mellitus. VICTOZA contains liraglutide and should not be coadministered with other liraglutide-containing products. uuid:c23c18b7-5f3b-477a-9bbc-7df3ef0776d3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3207 biolink:treats UMLS:C0741804 PMID:41385096 "[{""id"":""uuid:23195281-4acb-4f90-88a9-fb8eb9ace30e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ebe0d1f9-ffe8-4274-837d-5b37c8dab788"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PULMICORT FLEXHALER is a corticosteroid indicated for: • Maintenance treatment of asthma as prophylactic therapy in adult and pediatric patients six years of age or older ( 1 ) Limitations of Use: Not indicated for the relief of acute bronchospasm ( 1 ) uuid:4efa9446-1daf-47d2-ba35-40c1a806883b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50690 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:94ff0543-5b1b-4972-bd5a-0aeb9c701868"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1ebc2bc0-ae85-49b6-b8a8-5e2a32ef4095"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atorvastatin calcium is indicated: To reduce the risk of. Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD. MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD. Non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in adults with clinically evident CHD. As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in: Adults with primary hyperlipidemia. Adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia. uuid:5b199c11-6438-4f3f-9d6e-8b5ea2bec9a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50690 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:02b2df4b-4895-4361-97d7-7010533ca9f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3d205ce6-6adc-4e2c-8333-e8ead37ea5ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atorvastatin calcium is indicated: To reduce the risk of. Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD. MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD. Non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in adults with clinically evident CHD. As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in: Adults with primary hyperlipidemia. Adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia. Hypertriglyceridemia. uuid:20143f74-5ecf-4c58-bfe9-7503a7b32b9e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C4277251 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:02acf164-ef0a-45c6-80f8-f35e93453839"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:555d80ad-b97c-4bb9-97d5-be240dfcb7b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LANTUS is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. MESH:C000606659 uuid:17fb50ec-313c-4779-ae18-93b5029775d1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68540 biolink:treats MONDO:0005314 PMID:41385096 "[{""id"":""uuid:69db0c9a-f956-459f-97d7-193d9d1c0f1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:24ca9471-03e3-450f-83df-1c4c1320bbda"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7ee73218-8981-4bc5-94f9-83b521a60670"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/aubagio""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Teriflunomide tablets are indicated for the treatment of patients with relapsing forms of multiple sclerosis.|[EMA] AUBAGIO is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (MS) (please refer to section 5.1 for important information on the population for which efficacy has been established). uuid:4f85cf7f-2fe7-42ce-ba67-7ba1d3d15f23 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3640 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:79dc5334-1d0c-4f26-81d6-c957309ebfab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:28981ed8-72c6-4936-b448-168a19952652"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DIURIL is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. DIURIL has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. DIURIL is indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. Use in Pregnancy - Routine use of diuretics during normal pregnancy is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy and there is no satisfactory evidence that they are useful in the treatment of toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Thiazides are indicated in pregnancy when edema is due to pathologic causes, just as they are in the absence of pregnancy (see PRECAUTIONS, Pregnancy ). Dependent edema in pregnancy, resulting from restriction of venous return by the gravid uterus, is properly treated through elevation of the lower extremities and use of support stockings. Use of diuretics to lower intravascular volume in this instance is illogical and unnecessary. During normal pregnancy there is hypervolemia which is not harmful to the fetus or the mother in the absence of cardiovascular disease. However, it may be associated with edema, rarely generalized edema. If such edema causes discomfort, increased recumbency will often provide relief. Rarely this edema may cause extreme discomfort which is not relieved by rest. In these instances, a short course of diuretic therapy may provide relief and be appropriate. uuid:37f89f03-37b2-4b16-b0e1-3f710a160902 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3640 biolink:treats MONDO:0045048 PMID:41385096 "[{""id"":""uuid:9de05e93-67ce-48ca-a32c-3949f4c54b30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f81a1a48-b8ed-4c6d-984b-a99c25462767"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DIURIL is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. DIURIL has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. DIURIL is indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. Use in Pregnancy - Routine use of diuretics during normal pregnancy is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy and there is no satisfactory evidence that they are useful in the treatment of toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Thiazides are indicated in pregnancy when edema is due to pathologic causes, just as they are in the absence of pregnancy (see PRECAUTIONS, Pregnancy ). Dependent edema in pregnancy, resulting from restriction of venous return by the gravid uterus, is properly treated through elevation of the lower extremities and use of support stockings. Use of diuretics to lower intravascular volume in this instance is illogical and unnecessary. During normal pregnancy there is hypervolemia which is not harmful to the fetus or the mother in the absence of cardiovascular disease. However, it may be associated with edema, rarely generalized edema. If such edema causes discomfort, increased recumbency will often provide relief. Rarely this edema may cause extreme discomfort which is not relieved by rest. In these instances, a short course of diuretic therapy may provide relief and be appropriate. uuid:0af12e81-f277-48bb-9c28-9751f3237774 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3640 biolink:treats HP:0000969 PMID:41385096 "[{""id"":""uuid:8b23ce9e-b009-4cd2-8a53-b5bf88bc186b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e0e40317-f373-40e0-9fc6-aef65f54c5cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DIURIL is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. DIURIL has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. DIURIL is indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. Use in Pregnancy - Routine use of diuretics during normal pregnancy is inappropriate and exposes mother and fetus to unnecessary hazard. Diuretics do not prevent development of toxemia of pregnancy and there is no satisfactory evidence that they are useful in the treatment of toxemia. Edema during pregnancy may arise from pathologic causes or from the physiologic and mechanical consequences of pregnancy. Thiazides are indicated in pregnancy when edema is due to pathologic causes, just as they are in the absence of pregnancy (see PRECAUTIONS, Pregnancy ). Dependent edema in pregnancy, resulting from restriction of venous return by the gravid uterus, is properly treated through elevation of the lower extremities and use of support stockings. Use of diuretics to lower intravascular volume in this instance is illogical and unnecessary. During normal pregnancy there is hypervolemia which is not harmful to the fetus or the mother in the absence of cardiovascular disease. However, it may be associated with edema, rarely generalized edema. If such edema causes discomfort, increased recumbency will often provide relief. Rarely this edema may cause extreme discomfort which is not relieved by rest. In these instances, a short course of diuretic therapy may provide relief and be appropriate. uuid:6a0e346e-45aa-4800-a39c-2383d8681fea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41977 biolink:treats MONDO:0018874 PMID:41385096 "[{""id"":""uuid:60d1be8b-1c2f-42c2-a8bb-6c47182477fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6f2df1bc-1794-4202-acc5-0b3f60284beb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Daunorubicin hydrochloride injection in combination with other approved anticancer drugs is indicated for remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults. uuid:52b8a9c8-8ccd-4dac-b2b0-26781f32db76 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41977 biolink:treats MONDO:0004643 PMID:41385096 "[{""id"":""uuid:c4d8379f-98af-425d-9a53-50a19eadad2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e6a7f2a4-5972-4247-a998-1bd38eb31564"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Daunorubicin hydrochloride injection in combination with other approved anticancer drugs is indicated for remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults. uuid:41b6fb42-b0f6-48fd-bd95-8047b35a809a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41977 biolink:treats MONDO:0004600 PMID:41385096 "[{""id"":""uuid:cf900c78-cf5a-4cab-beef-406e7165b7d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1b675f26-8407-45e5-9cb2-c75cedfffd2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Daunorubicin hydrochloride injection in combination with other approved anticancer drugs is indicated for remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults. uuid:3b7f0832-f66b-4b32-9adc-51f5223440bb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41977 biolink:treats MONDO:0017858 PMID:41385096 "[{""id"":""uuid:91442f88-7f76-437b-99af-44e694e472e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d1e1bc6f-3927-47d9-890e-d97033c7698e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Daunorubicin hydrochloride injection in combination with other approved anticancer drugs is indicated for remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults. uuid:15750dfd-7f58-493b-88d0-8f0f78d8e47c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41977 biolink:treats MONDO:0004967 PMID:41385096 "[{""id"":""uuid:25f95464-b752-45c7-ae84-19b91dbde836"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aed4cbf6-17c4-49ef-a86a-7f7c6ec739ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Daunorubicin hydrochloride injection in combination with other approved anticancer drugs is indicated for remission induction in acute nonlymphocytic leukemia (myelogenous, monocytic, erythroid) of adults and for remission induction in acute lymphocytic leukemia of children and adults. uuid:1e867a10-08c3-43c6-ab80-559472dcefb0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68579 biolink:treats MONDO:0004981 PMID:41385096 "[{""id"":""uuid:19f9c930-a6ae-4277-afbc-385e848847ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4d79eccd-55a8-4782-b90b-95f69cc60c88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:59c00480-9a45-4d37-8c58-7581f2c1b6b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/rivaroxaban-accord""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] XARELTO is a factor Xa inhibitor indicated: to reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillation ( 1.1 ) for treatment of deep vein thrombosis (DVT) ( 1.2 ) for treatment of pulmonary embolism (PE) ( 1.3 ) for reduction in the risk of recurrence of DVT or PE ( 1.4 ) for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery ( 1.5 ) for prophylaxis of venous thromboembolism (VTE) in acutely ill medical patients ( 1.6 ) to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) ( 1.7 ) to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD ( 1.8 ) for treatment of VTE and reduction in the risk of recurrent VTE in pediatric patients from birth to less than 18 years ( 1.9 ) for thromboprophylaxis in pediatric patients 2 years and older with congenital heart disease after the Fontan procedure ( 1.10 )|[EMA] Xarelto, co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers.Xarelto, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events.Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.AdultsPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.Paediatric population Treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment.Paediatric population Treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment. uuid:169fe78f-8352-4644-99ba-3823b0b0c18b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68579 biolink:treats HP:0002625 PMID:41385096 "[{""id"":""uuid:acc389b2-335a-4cc3-b2e4-78e86f04d820"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5f6f6774-7992-432c-8445-b052736bcadb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ad168a8a-5e36-4731-8e67-c9ca9c4d75de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/rivaroxaban-accord""]},{""id"":""uuid:4f9de93b-b141-45c8-8742-1d3f9eadc241"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XARELTO is a factor Xa inhibitor indicated: to reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillation ( 1.1 ) for treatment of deep vein thrombosis (DVT) ( 1.2 ) for treatment of pulmonary embolism (PE) ( 1.3 ) for reduction in the risk of recurrence of DVT or PE ( 1.4 ) for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery ( 1.5 ) for prophylaxis of venous thromboembolism (VTE) in acutely ill medical patients ( 1.6 ) to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) ( 1.7 ) to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD ( 1.8 ) for treatment of VTE and reduction in the risk of recurrent VTE in pediatric patients from birth to less than 18 years ( 1.9 ) for thromboprophylaxis in pediatric patients 2 years and older with congenital heart disease after the Fontan procedure ( 1.10 )|[EMA] Xarelto, co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers.Xarelto, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events.Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.AdultsPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.Paediatric population Treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment.Paediatric population Treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.|[PMDA] Drugs with a new additional indication and a new dosage for the treatment and prevention of recurrence of deep vein thrombosis and pulmonary thromboembolism. uuid:1028be6c-db1a-4211-b729-bf67c4851472 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68579 biolink:treats MONDO:0005279 PMID:41385096 "[{""id"":""uuid:4eccddda-680c-4ef6-b95f-811284d88e5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4eaba435-f1c9-4f3f-b94e-8e70c8f03c4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:31ff751c-1cc8-4ff8-a725-78e743421b87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/rivaroxaban-accord""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] XARELTO is a factor Xa inhibitor indicated: to reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillation ( 1.1 ) for treatment of deep vein thrombosis (DVT) ( 1.2 ) for treatment of pulmonary embolism (PE) ( 1.3 ) for reduction in the risk of recurrence of DVT or PE ( 1.4 ) for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery ( 1.5 ) for prophylaxis of venous thromboembolism (VTE) in acutely ill medical patients ( 1.6 ) to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) ( 1.7 ) to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD ( 1.8 ) for treatment of VTE and reduction in the risk of recurrent VTE in pediatric patients from birth to less than 18 years ( 1.9 ) for thromboprophylaxis in pediatric patients 2 years and older with congenital heart disease after the Fontan procedure ( 1.10 )|[EMA] Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients).AdultsPrevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.)Paediatric populationTreatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment.Rivaroxaban Accord, co administered with acetylsalicylic acid (ASA) alone or with ASA plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers (see sections 4.3, 4.4 and 5.1).Rivaroxaban Accord, co administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events.AdultsPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.)Paediatric populationTreatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment. uuid:a75aa941-06aa-415c-9521-495e78f90fb3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68579 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:7a5b1f47-e3c3-40d9-a801-0b7c12573475"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2afb4b9e-322e-4ab7-b740-1494481a6d70"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1fe63b68-15b0-45a1-b0f0-e2f05fdf7b93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/rivaroxaban-accord""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] XARELTO is a factor Xa inhibitor indicated: to reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillation ( 1.1 ) for treatment of deep vein thrombosis (DVT) ( 1.2 ) for treatment of pulmonary embolism (PE) ( 1.3 ) for reduction in the risk of recurrence of DVT or PE ( 1.4 ) for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery ( 1.5 ) for prophylaxis of venous thromboembolism (VTE) in acutely ill medical patients ( 1.6 ) to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) ( 1.7 ) to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD ( 1.8 ) for treatment of VTE and reduction in the risk of recurrent VTE in pediatric patients from birth to less than 18 years ( 1.9 ) for thromboprophylaxis in pediatric patients 2 years and older with congenital heart disease after the Fontan procedure ( 1.10 )|[EMA] Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients).AdultsPrevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.)Paediatric populationTreatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment.Rivaroxaban Accord, co administered with acetylsalicylic acid (ASA) alone or with ASA plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers (see sections 4.3, 4.4 and 5.1).Rivaroxaban Accord, co administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events.AdultsPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.)Paediatric populationTreatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment. uuid:f237d0ea-2411-420b-866a-aff214c178df biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68579 biolink:treats MONDO:0005386 PMID:41385096 "[{""id"":""uuid:9c2b5c10-1db6-4376-b9b2-51b378554ab8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c1b8091c-76a8-45c5-be48-7753ff8c87a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1577de26-2c21-4879-b875-b67b1339cb8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/rivaroxaban-accord""]},{""id"":""uuid:a6abf8f8-2b5d-44bd-b5fa-46e625fca60a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XARELTO is a factor Xa inhibitor indicated: to reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillation ( 1.1 ) for treatment of deep vein thrombosis (DVT) ( 1.2 ) for treatment of pulmonary embolism (PE) ( 1.3 ) for reduction in the risk of recurrence of DVT or PE ( 1.4 ) for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery ( 1.5 ) for prophylaxis of venous thromboembolism (VTE) in acutely ill medical patients ( 1.6 ) to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) ( 1.7 ) to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD ( 1.8 ) for treatment of VTE and reduction in the risk of recurrent VTE in pediatric patients from birth to less than 18 years ( 1.9 ) for thromboprophylaxis in pediatric patients 2 years and older with congenital heart disease after the Fontan procedure ( 1.10 )|[EMA] Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients).AdultsPrevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.)Paediatric populationTreatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment.Rivaroxaban Accord, co administered with acetylsalicylic acid (ASA) alone or with ASA plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers (see sections 4.3, 4.4 and 5.1).Rivaroxaban Accord, co administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events.AdultsPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.)Paediatric populationTreatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.|[PMDA] A drug with a new indication and a new dosage in an additional dosage form for the inhibition of thrombus/embolization formation in patients with peripheral arterial disease after lower extremity revascularization. uuid:e0e73585-f1af-4fb5-956f-8e9fbb7ce71a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68579 biolink:treats MONDO:0005399 PMID:41385096 "[{""id"":""uuid:2bd31960-a32c-4448-869e-d397ae307a58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:731eaaaa-d4b6-463a-a6a3-d1ad7d7ea783"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:37537459-cccd-4763-b78c-8c2c9168a89c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/rivaroxaban-accord""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] XARELTO is a factor Xa inhibitor indicated: to reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillation ( 1.1 ) for treatment of deep vein thrombosis (DVT) ( 1.2 ) for treatment of pulmonary embolism (PE) ( 1.3 ) for reduction in the risk of recurrence of DVT or PE ( 1.4 ) for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery ( 1.5 ) for prophylaxis of venous thromboembolism (VTE) in acutely ill medical patients ( 1.6 ) to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) ( 1.7 ) to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD ( 1.8 ) for treatment of VTE and reduction in the risk of recurrent VTE in pediatric patients from birth to less than 18 years ( 1.9 ) for thromboprophylaxis in pediatric patients 2 years and older with congenital heart disease after the Fontan procedure ( 1.10 )|[EMA] Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients).AdultsPrevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.)Paediatric populationTreatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment.Rivaroxaban Accord, co administered with acetylsalicylic acid (ASA) alone or with ASA plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers (see sections 4.3, 4.4 and 5.1).Rivaroxaban Accord, co administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events.AdultsPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.)Paediatric populationTreatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment. uuid:eb0e7a61-27ec-48be-97d6-0c72ae2d321c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68579 biolink:treats MONDO:0005453 PMID:41385096 "[{""id"":""uuid:4aea52c9-01cb-45c7-9b34-2478c85c0066"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2aefa006-1117-4aab-88f7-70fd8064bcd3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XARELTO is a factor Xa inhibitor indicated: to reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillation ( 1.1 ) for treatment of deep vein thrombosis (DVT) ( 1.2 ) for treatment of pulmonary embolism (PE) ( 1.3 ) for reduction in the risk of recurrence of DVT or PE ( 1.4 ) for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery ( 1.5 ) for prophylaxis of venous thromboembolism (VTE) in acutely ill medical patients ( 1.6 ) to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) ( 1.7 ) to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD ( 1.8 ) for treatment of VTE and reduction in the risk of recurrent VTE in pediatric patients from birth to less than 18 years ( 1.9 ) for thromboprophylaxis in pediatric patients 2 years and older with congenital heart disease after the Fontan procedure ( 1.10 ) uuid:faf72aa1-ba9b-42a5-a3bc-aafa1c4c5659 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9434 biolink:treats MONDO:0006652 PMID:41385096 "[{""id"":""uuid:fd652636-1d60-4200-a352-5718059788d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:93a5144f-113e-4d92-9765-789e271c2aae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Telmisartanis an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. (1.1) • Cardiovascular (CV) risk reduction in patients unable to take ACE inhibitors (1.2) uuid:98cae534-0872-4cf0-82ef-306e36dd715c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134716 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:88ef4c56-7bed-4244-b043-216a3c7d6136"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c1b13b63-6c4f-479c-967c-cd72097b4a4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Brexpiprazole tablets are indicated for: Adjunctive treatment of major depressive disorder (MDD) in adults. Treatment of schizophrenia in adults. uuid:a73766eb-f40e-43d2-a8d5-4d5eb13f0083 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134716 biolink:treats MONDO:0005090 PMID:41385096 "[{""id"":""uuid:aa2646ed-cc23-4373-ad63-116209272c99"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2ecdfdc5-6b9c-4cfc-bf12-c0afc6cc2d80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:671e1492-e642-4b10-9db4-34d544b56bfd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/rxulti""]},{""id"":""uuid:d0e3a1bb-6a9f-4183-aa76-df7a06559356"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Brexpiprazole tablets are indicated for: Adjunctive treatment of major depressive disorder (MDD) in adults. Treatment of schizophrenia in adults.|[EMA] Treatment of schizophrenia.|[PMDA] Drugs with a new active ingredient indicated for the treatment of schizophrenia. uuid:18d29a41-a46a-4231-a3bc-cb3d74448f9d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49668 biolink:treats UMLS:C0278987 PMID:41385096 "[{""id"":""uuid:e4f0c304-1d84-4f99-88fa-1efe6690d49d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b0018d08-8541-4db6-84bf-7d49bf646b2b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gefitinib tablets are indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test [ see Clinical Studies (14) ]. Limitation of Use: Safety and efficacy of gefitinib tablets have not been established in patients with metastatic NSCLC whose tumors have EGFR mutations other than exon 19 deletions or exon 21 (L858R) substitution mutations [ see Clinical Studies (14) ]. uuid:0e277f70-82d1-43ba-8639-dc6d4c2cb74c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49668 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:422fe560-9b90-46c7-b00d-5efc267030f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:22f0122a-6aa6-45a7-8d86-3c2686933602"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f3324568-70e9-4dec-b562-94a41f0eaf38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/gefitinib-mylan""]},{""id"":""uuid:68c966a3-7d97-4a82-831f-e05deb0dea1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gefitinib tablets are indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test [ see Clinical Studies (14) ]. Limitation of Use: Safety and efficacy of gefitinib tablets have not been established in patients with metastatic NSCLC whose tumors have EGFR mutations other than exon 19 deletions or exon 21 (L858R) substitution mutations [ see Clinical Studies (14) ].|[EMA] Gefitinib Mylan is indicated as monotherapy for the treatment of adult patients with locally advanced or metastatic non‑small cell lung cancer (NSCLC) with activating mutations of EGFR‑TK.|[PMDA] A drug with a revised indication for the treatment of unresectable advanced or recurrent non-small cell lung cancer in patients with EGFR gene mutation. uuid:f5a4e94a-107b-48a0-a5d5-475a096afd23 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28864 biolink:treats MONDO:0040732 PMID:41385096 "[{""id"":""uuid:8bda919e-8fa6-4ee2-b2a0-ef88216223e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a4a88d76-3f74-4708-89a6-f94256c78727"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:fc553872-0b4b-430b-a24d-ae470c12e381"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vantobra-previously-tobramycin-pari""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] BETHKIS is indicated for the management of cystic fibrosis patients with Pseudomonas aeruginosa . Safety and efficacy have not been demonstrated in patients under the age of six years, patients with FEV 1 less than 40% or greater than 80% predicted, or patients colonized with Burkholderia cepacia [see Clinical Studies ( 14 )] .|[EMA] Vantobra is indicated for the management of chronic pulmonary infection due to Pseudomonas aeruginosa in patients aged 6 years and older with cystic fibrosis (CF).Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:4b046e89-470d-4b0f-8a51-061c16ce36e7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16382 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:86b07a29-279c-4b22-8037-b1cc885c2fe5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7bf16eee-3d11-4aa4-b077-a8c39ecdb5a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Potassium iodide oral solution, USP is for use as an expectorant in the symptomatic treatment of chronic pulmonary diseases where tenacious mucus complicates the problem, including bronchial asthma, bronchitis and pulmonary emphysema. uuid:4e3bc025-451d-48a6-9192-9969106537e3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16382 biolink:treats MONDO:0003781 PMID:41385096 "[{""id"":""uuid:a2779159-d5e0-4b43-86e7-ad94a8e3d7c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:441a5c24-f383-480f-8732-3f6624ea5d61"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Potassium iodide oral solution, USP is for use as an expectorant in the symptomatic treatment of chronic pulmonary diseases where tenacious mucus complicates the problem, including bronchial asthma, bronchitis and pulmonary emphysema. uuid:4dac6452-4889-493d-bfd5-5d5f524e8880 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16382 biolink:treats MONDO:0004849 PMID:41385096 "[{""id"":""uuid:e1a59b8c-f15b-46d1-b92f-9187e3306c4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e9f5fa70-27ae-4026-bb00-ec9b99f8e77b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Potassium iodide oral solution, USP is for use as an expectorant in the symptomatic treatment of chronic pulmonary diseases where tenacious mucus complicates the problem, including bronchial asthma, bronchitis and pulmonary emphysema. uuid:893169ee-fed8-44b1-85e3-b9c0207e1608 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31348 biolink:treats MONDO:0005575 PMID:41385096 "[{""id"":""uuid:fb5bf240-1ce8-491c-9294-7de069681daf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bbb7f871-32e3-4fa5-8f82-aa3579e94466"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:790ed1cf-34a3-4426-95da-a8ffa906cc7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ecansya""]},{""id"":""uuid:500d2245-3498-4ba6-bb23-7947bea1833b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Capecitabine is a nucleoside metabolic inhibitor indicated for: Colorectal Cancer • adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. (1.1) • perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. (1.1) • treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. (1.1) Breast Cancer • treatment of patients with advanced or metastatic breast cancer as a single agent if an anthracycline-or taxane-containing chemotherapy is not indicated. (1.2) • treatment of patients with advanced or metastatic breast cancer in combination with docetaxel after disease progression on prior anthracycline-containing chemotherapy. (1.2) Gastric, Esophageal, or Gastroesophageal Junction Cancer • treatment of adults with unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer as a component of a combination chemotherapy regimen. (1.3) • treatment of adults with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease as a component of a combination regimen. (1.3) Pancreatic Cancer • adjuvant treatment of adults with pancreatic adenocarcinoma as a component of a combination chemotherapy regimen. (1.4)|[EMA] Capecitabine Medac is indicated for the adjuvant treatment of patients following surgery of stage-III (Dukes’ stage-C) colon cancer.Capecitabine Medac is indicated for the treatment of metastatic colorectal cancer.Capecitabine Medac is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen.Capecitabine Medac in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.Capecitabine Medac is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline-containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.|[PMDA] A drug with a new dosage indicated for the treatment of unresectable or recurrent breast cancer and colorectal cancer. [Public knowledge-based application] uuid:7424ba8f-b601-4395-98bb-be4b92d8748b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31348 biolink:treats MONDO:0006519 PMID:41385096 "[{""id"":""uuid:c7d06848-60ef-4b90-b792-9594c4a4802c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d8b83db1-3cac-4a78-90fc-0873217aa6b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:8d4a66b7-7cf7-4ef2-9541-c2b0effdda9a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Capecitabine is a nucleoside metabolic inhibitor indicated for: Colorectal Cancer • adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. (1.1) • perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. (1.1) • treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. (1.1) Breast Cancer • treatment of patients with advanced or metastatic breast cancer as a single agent if an anthracycline-or taxane-containing chemotherapy is not indicated. (1.2) • treatment of patients with advanced or metastatic breast cancer in combination with docetaxel after disease progression on prior anthracycline-containing chemotherapy. (1.2) Gastric, Esophageal, or Gastroesophageal Junction Cancer • treatment of adults with unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer as a component of a combination chemotherapy regimen. (1.3) • treatment of adults with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease as a component of a combination regimen. (1.3) Pancreatic Cancer • adjuvant treatment of adults with pancreatic adenocarcinoma as a component of a combination chemotherapy regimen. (1.4)|[PMDA] A drug with a new additional indication and a new dosage for adjuvant chemotherapy for rectal cancer. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:6c4a918c-1c08-4fe2-adfe-285ddf5b6b7e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31348 biolink:treats UMLS:C3495917 PMID:41385096 "[{""id"":""uuid:596f0e4d-2ec2-463e-aa28-b6272d09ac6c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e97e0dbc-2b0d-4e11-995e-fceea2806d50"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Capecitabine is a nucleoside metabolic inhibitor indicated for: Colorectal Cancer • adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. (1.1) • perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. (1.1) • treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. (1.1) Breast Cancer • treatment of patients with advanced or metastatic breast cancer as a single agent if an anthracycline-or taxane-containing chemotherapy is not indicated. (1.2) • treatment of patients with advanced or metastatic breast cancer in combination with docetaxel after disease progression on prior anthracycline-containing chemotherapy. (1.2) Gastric, Esophageal, or Gastroesophageal Junction Cancer • treatment of adults with unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer as a component of a combination chemotherapy regimen. (1.3) • treatment of adults with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease as a component of a combination regimen. (1.3) Pancreatic Cancer • adjuvant treatment of adults with pancreatic adenocarcinoma as a component of a combination chemotherapy regimen. (1.4) uuid:ef937d2e-2b6f-4d3c-80f4-d5043c8ab801 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31348 biolink:treats MONDO:0001056 PMID:41385096 "[{""id"":""uuid:a862326d-debf-4649-8058-06ba20a65ad5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5ab4ce8e-de14-42cf-a1f7-da44b27fcf75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:93624c61-aaaa-4fe5-ad77-7bcfa014e61a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ecansya""]},{""id"":""uuid:4d32e412-1d1c-4309-9fb3-3d62e734741b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Capecitabine is a nucleoside metabolic inhibitor indicated for: Colorectal Cancer • adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. (1.1) • perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. (1.1) • treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. (1.1) Breast Cancer • treatment of patients with advanced or metastatic breast cancer as a single agent if an anthracycline-or taxane-containing chemotherapy is not indicated. (1.2) • treatment of patients with advanced or metastatic breast cancer in combination with docetaxel after disease progression on prior anthracycline-containing chemotherapy. (1.2) Gastric, Esophageal, or Gastroesophageal Junction Cancer • treatment of adults with unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer as a component of a combination chemotherapy regimen. (1.3) • treatment of adults with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease as a component of a combination regimen. (1.3) Pancreatic Cancer • adjuvant treatment of adults with pancreatic adenocarcinoma as a component of a combination chemotherapy regimen. (1.4)|[EMA] Ecansya is indicated for the adjuvant treatment of patients following surgery of stage-III (Dukes’ stage-C) colon cancer.Ecansya is indicated for the treatment of metastatic colorectal cancer.Ecansya is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen.Ecansya in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline. Ecansya is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.|[PMDA] A drug with a new additional indication and a new dosage for the treatment of unresectable advanced or recurrent gastric cancer. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:c1f8e3bc-a484-471f-bf46-a84feca3d425 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31348 biolink:treats UMLS:C0278498 PMID:41385096 "[{""id"":""uuid:08d428f7-1ef5-497f-8fbb-edce311687be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c8b321b0-f1ef-4caf-a205-8321d305b4e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Capecitabine is a nucleoside metabolic inhibitor indicated for: Colorectal Cancer • adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. (1.1) • perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. (1.1) • treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. (1.1) Breast Cancer • treatment of patients with advanced or metastatic breast cancer as a single agent if an anthracycline-or taxane-containing chemotherapy is not indicated. (1.2) • treatment of patients with advanced or metastatic breast cancer in combination with docetaxel after disease progression on prior anthracycline-containing chemotherapy. (1.2) Gastric, Esophageal, or Gastroesophageal Junction Cancer • treatment of adults with unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer as a component of a combination chemotherapy regimen. (1.3) • treatment of adults with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease as a component of a combination regimen. (1.3) Pancreatic Cancer • adjuvant treatment of adults with pancreatic adenocarcinoma as a component of a combination chemotherapy regimen. (1.4) uuid:ac2170f3-ef16-4e46-bdd3-c561c694641c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31348 biolink:treats MONDO:0007576 PMID:41385096 "[{""id"":""uuid:f821367d-8586-44db-9611-16d1182063f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:27cf35b6-7fbd-43d4-8370-e8e2aa9b15c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Capecitabine is a nucleoside metabolic inhibitor indicated for: Colorectal Cancer • adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. (1.1) • perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. (1.1) • treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. (1.1) Breast Cancer • treatment of patients with advanced or metastatic breast cancer as a single agent if an anthracycline-or taxane-containing chemotherapy is not indicated. (1.2) • treatment of patients with advanced or metastatic breast cancer in combination with docetaxel after disease progression on prior anthracycline-containing chemotherapy. (1.2) Gastric, Esophageal, or Gastroesophageal Junction Cancer • treatment of adults with unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer as a component of a combination chemotherapy regimen. (1.3) • treatment of adults with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease as a component of a combination regimen. (1.3) Pancreatic Cancer • adjuvant treatment of adults with pancreatic adenocarcinoma as a component of a combination chemotherapy regimen. (1.4) uuid:61accac5-3d28-4651-869c-a57598e2d708 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31348 biolink:treats UMLS:C5400195 PMID:41385096 "[{""id"":""uuid:168c2c70-4437-492b-b380-d0cd5534d7c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e6b38ec5-0009-4b2d-8a5a-1969ba48767c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Capecitabine is a nucleoside metabolic inhibitor indicated for: Colorectal Cancer • adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. (1.1) • perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. (1.1) • treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. (1.1) Breast Cancer • treatment of patients with advanced or metastatic breast cancer as a single agent if an anthracycline-or taxane-containing chemotherapy is not indicated. (1.2) • treatment of patients with advanced or metastatic breast cancer in combination with docetaxel after disease progression on prior anthracycline-containing chemotherapy. (1.2) Gastric, Esophageal, or Gastroesophageal Junction Cancer • treatment of adults with unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer as a component of a combination chemotherapy regimen. (1.3) • treatment of adults with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease as a component of a combination regimen. (1.3) Pancreatic Cancer • adjuvant treatment of adults with pancreatic adenocarcinoma as a component of a combination chemotherapy regimen. (1.4) uuid:834c5cd1-39c6-4c99-b181-590f3d18a14c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31348 biolink:treats MONDO:0003219 PMID:41385096 "[{""id"":""uuid:7eb3c0c8-b57c-49ac-b413-a67037dce5ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c8dcab06-36cc-4158-894a-0b3888fbe980"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Capecitabine is a nucleoside metabolic inhibitor indicated for: Colorectal Cancer • adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. (1.1) • perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. (1.1) • treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. (1.1) Breast Cancer • treatment of patients with advanced or metastatic breast cancer as a single agent if an anthracycline-or taxane-containing chemotherapy is not indicated. (1.2) • treatment of patients with advanced or metastatic breast cancer in combination with docetaxel after disease progression on prior anthracycline-containing chemotherapy. (1.2) Gastric, Esophageal, or Gastroesophageal Junction Cancer • treatment of adults with unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer as a component of a combination chemotherapy regimen. (1.3) • treatment of adults with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease as a component of a combination regimen. (1.3) Pancreatic Cancer • adjuvant treatment of adults with pancreatic adenocarcinoma as a component of a combination chemotherapy regimen. (1.4) uuid:86257c2c-a217-49c4-9567-bcf579ab2392 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31348 biolink:treats MONDO:0006047 PMID:41385096 "[{""id"":""uuid:c14e109e-b1a8-4946-a094-c10b1f3bfb9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7b85af8e-34ca-4848-9718-64da5ace10a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Capecitabine is a nucleoside metabolic inhibitor indicated for: Colorectal Cancer • adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. (1.1) • perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. (1.1) • treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. (1.1) Breast Cancer • treatment of patients with advanced or metastatic breast cancer as a single agent if an anthracycline-or taxane-containing chemotherapy is not indicated. (1.2) • treatment of patients with advanced or metastatic breast cancer in combination with docetaxel after disease progression on prior anthracycline-containing chemotherapy. (1.2) Gastric, Esophageal, or Gastroesophageal Junction Cancer • treatment of adults with unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer as a component of a combination chemotherapy regimen. (1.3) • treatment of adults with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease as a component of a combination regimen. (1.3) Pancreatic Cancer • adjuvant treatment of adults with pancreatic adenocarcinoma as a component of a combination chemotherapy regimen. (1.4) uuid:71af2d0c-3fc5-47e3-9ab7-c0f0ac9adbd0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5108 biolink:treats MONDO:0004795 PMID:41385096 "[{""id"":""uuid:ed5760f9-0b9c-46f9-b6d6-2c8571a62a05"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:df341536-c05f-4ffe-a2ac-21fef0a4c709"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluocinolone acetonide oil, 0.01% is a low to medium potency corticosteroid indicated for the treatment of chronic eczematous external otitis in adults and pediatric patients 2 years and older. uuid:509edabb-22d0-4e5c-b9ce-699610469882 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6933 biolink:treats MONDO:0006875 PMID:41385096 "[{""id"":""uuid:9a9f50cc-ff6d-49ca-876f-6140445442bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0affe30c-07a3-4c24-b799-e89e3f9c7f73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Midodrine hydrochloride tablets, USP are indicated for the treatment of symptomatic orthostatic hypotension (OH). Because midodrine hydrochloride tablets, USP can cause marked elevation of supine blood pressure (BP > 200 mmHg systolic), it should be used in patients whose lives are considerably impaired despite standard clinical care, including non-pharmacologic treatment (such as support stockings), fluid expansion, and lifestyle alterations. The indication is based on midodrine hydrochloride tablets, USP effect on increases in 1-minute standing systolic blood pressure, a surrogate marker considered likely to correspond to a clinical benefit. At present, however, clinical benefits of midodrine hydrochloride tablets, USP principally improved ability to perform life activities, have not been established. Further clinical trials are underway to verify and describe the clinical benefits of midodrine hydrochloride tablets, USP. After initiation of treatment, midodrine hydrochloride tablets, USP should be continued only for patients who report significant symptomatic improvement. uuid:5c79cce1-c4f5-423d-8f87-8231776c635d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7445 biolink:treats MONDO:0019165 PMID:41385096 "[{""id"":""uuid:41be051f-602c-4bd9-9fb6-0a8a741d3e4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d755cd0e-0577-4b5a-8975-4062d8145cb0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] (For Endometriosis, See Reverse Side ) SYNAREL is indicated for treatment of central precocious puberty (CPP) (gonadotropin-dependent precocious puberty) in children of both sexes. The diagnosis of central precocious puberty (CPP) is suspected when premature development of secondary sexual characteristics occurs at or before the age of 8 years in girls and 9 years in boys, and is accompanied by significant advancement of bone age and/or a poor adult height prediction. The diagnosis should be confirmed by pubertal gonadal sex steroid levels and a pubertal LH response to stimulation by native GnRH. Pelvic ultrasound assessment in girls usually reveals enlarged uterus and ovaries, the latter often with multiple cystic formations. Magnetic resonance imaging or CT-scanning of the brain is recommended to detect hypothalamic or pituitary tumors, or anatomical changes associated with increased intracranial pressure. Other causes of sexual precocity, such as congenital adrenal hyperplasia, testotoxicosis, testicular tumors and/or other autonomous feminizing or masculinizing disorders must be excluded by proper clinical hormonal and diagnostic imaging examinations. uuid:80ceaf1f-290e-4ddd-bae6-699e02673140 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7445 biolink:treats MONDO:0018479 PMID:41385096 "[{""id"":""uuid:42038f99-86fe-4ab5-856b-4ff983c09cf7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e0504a95-3d95-4a62-88db-a385f417e75c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] (For Endometriosis, See Reverse Side ) SYNAREL is indicated for treatment of central precocious puberty (CPP) (gonadotropin-dependent precocious puberty) in children of both sexes. The diagnosis of central precocious puberty (CPP) is suspected when premature development of secondary sexual characteristics occurs at or before the age of 8 years in girls and 9 years in boys, and is accompanied by significant advancement of bone age and/or a poor adult height prediction. The diagnosis should be confirmed by pubertal gonadal sex steroid levels and a pubertal LH response to stimulation by native GnRH. Pelvic ultrasound assessment in girls usually reveals enlarged uterus and ovaries, the latter often with multiple cystic formations. Magnetic resonance imaging or CT-scanning of the brain is recommended to detect hypothalamic or pituitary tumors, or anatomical changes associated with increased intracranial pressure. Other causes of sexual precocity, such as congenital adrenal hyperplasia, testotoxicosis, testicular tumors and/or other autonomous feminizing or masculinizing disorders must be excluded by proper clinical hormonal and diagnostic imaging examinations. uuid:5dd6bddc-0003-4f19-9f72-8c377ff77007 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7445 biolink:treats MONDO:0008303 PMID:41385096 "[{""id"":""uuid:bd20aad6-20c6-41cf-b75e-7ce9f5823eae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dd78c8d3-adf6-482a-8290-48a9cc694f4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] (For Endometriosis, See Reverse Side ) SYNAREL is indicated for treatment of central precocious puberty (CPP) (gonadotropin-dependent precocious puberty) in children of both sexes. The diagnosis of central precocious puberty (CPP) is suspected when premature development of secondary sexual characteristics occurs at or before the age of 8 years in girls and 9 years in boys, and is accompanied by significant advancement of bone age and/or a poor adult height prediction. The diagnosis should be confirmed by pubertal gonadal sex steroid levels and a pubertal LH response to stimulation by native GnRH. Pelvic ultrasound assessment in girls usually reveals enlarged uterus and ovaries, the latter often with multiple cystic formations. Magnetic resonance imaging or CT-scanning of the brain is recommended to detect hypothalamic or pituitary tumors, or anatomical changes associated with increased intracranial pressure. Other causes of sexual precocity, such as congenital adrenal hyperplasia, testotoxicosis, testicular tumors and/or other autonomous feminizing or masculinizing disorders must be excluded by proper clinical hormonal and diagnostic imaging examinations. uuid:daaa42a8-707d-4b0e-814d-13b6ed2d3b39 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17823 biolink:treats UMLS:C0406317 PMID:41385096 "[{""id"":""uuid:526c8871-2dad-479f-9918-0c61717601f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d8fcea5c-ce54-4473-bf3c-52425e93d5f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Calcitriol Ointment is a vitamin D analog indicated for the topical treatment of mild to moderate plaque psoriasis in adults and pediatric patients 2 years and older ( 1.1 ) Limitations of Use The safety and effectiveness of Calcitriol Ointment in patients with known or suspected disorders of calcium metabolism have not been evaluated. ( 1.2 ) uuid:7223c740-1313-44e5-9cbc-5a1dd70596e4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63791 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:c5af6e0d-935f-44d2-913a-209aace1475b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4858041b-90b5-4cb9-bc38-f64b3dd1e6e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:dc50d823-b708-4b5f-8741-7db683a7265c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/revlimid""]},{""id"":""uuid:bfecaa6d-f29f-460a-80fd-24ea5d64fa01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lenalidomide is a thalidomide analogue indicated for the treatment of adult patients with: Multiple myeloma (MM), in combination with dexamethasone ( 1.1 ). MM, as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT) ( 1.1 ). Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities ( 1.2 ). Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib ( 1.3 ). Previously treated follicular lymphoma (FL), in combination with a rituximab product ( 1.4 ). Previously treated marginal zone lymphoma (MZL), in combination with a rituximab product ( 1.5 ). Limitations of Use: Lenalidomide capsules are not indicated and are not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.( 1.4 ).|[EMA] Multiple myelomaRevlimid as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.Revlimid as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4.2) is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.Revlimid in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.Myelodysplastic syndromesRevlimid as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.Mantle cell lymphomaRevlimid as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.Follicular lymphomaRevlimid in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 – 3a).|[PMDA] A drug with a new active ingredient indicated for the treatment of relapsed or refractory multiple myeloma. [Orphan drug] uuid:52d36a88-56e5-44c7-9942-2e2f822d56e7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63791 biolink:treats MONDO:0007925 PMID:41385096 "[{""id"":""uuid:69d772b5-0959-4dff-b022-0ecae95b29ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:47550df4-96d9-41ed-84f6-e5b39c23df74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ee97c452-7017-4494-8023-fca3fb8c2d75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lenalidomide is a thalidomide analogue indicated for the treatment of adult patients with: Multiple myeloma (MM), in combination with dexamethasone ( 1.1 ). MM, as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT) ( 1.1 ). Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities ( 1.2 ). Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib ( 1.3 ). Previously treated follicular lymphoma (FL), in combination with a rituximab product ( 1.4 ). Previously treated marginal zone lymphoma (MZL), in combination with a rituximab product ( 1.5 ). Limitations of Use: Lenalidomide capsules are not indicated and are not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.( 1.4 ).|[PMDA] A drug with a new additional indication and a new dosage for the treatment of myelodysplastic syndrome associated with a deletion 5q cytogenetic abnormality. [Orphan drug] uuid:9b4da35d-02c5-4026-8400-55b30859d5f9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63791 biolink:treats MONDO:0018876 PMID:41385096 "[{""id"":""uuid:6031a216-dc80-4228-9a2d-975bf2e7649d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:747e834b-bbf9-4f28-9ac8-2d66a29da7fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e24c349e-72da-4506-bee3-034d4fd043dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/revlimid""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lenalidomide is a thalidomide analogue indicated for the treatment of adult patients with: Multiple myeloma (MM), in combination with dexamethasone ( 1.1 ). MM, as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT) ( 1.1 ). Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities ( 1.2 ). Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib ( 1.3 ). Previously treated follicular lymphoma (FL), in combination with a rituximab product ( 1.4 ). Previously treated marginal zone lymphoma (MZL), in combination with a rituximab product ( 1.5 ). Limitations of Use: Lenalidomide capsules are not indicated and are not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.( 1.4 ).|[EMA] Multiple myelomaRevlimid as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.Revlimid as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4.2) is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.Revlimid in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.Myelodysplastic syndromesRevlimid as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.Mantle cell lymphomaRevlimid as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.Follicular lymphomaRevlimid in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 – 3a). uuid:ab1abd11-656d-4b03-aad3-26fe95cf9db6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63791 biolink:treats MONDO:0018906 PMID:41385096 "[{""id"":""uuid:4853c429-56d9-49ba-b4b6-0d5afb55d76d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ea0c6ab0-2b6c-42dc-ae13-131923b1561a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1b0de25e-e2c9-42f6-80a1-5b2dcdbfe1c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/revlimid""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lenalidomide is a thalidomide analogue indicated for the treatment of adult patients with: Multiple myeloma (MM), in combination with dexamethasone ( 1.1 ). MM, as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT) ( 1.1 ). Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities ( 1.2 ). Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib ( 1.3 ). Previously treated follicular lymphoma (FL), in combination with a rituximab product ( 1.4 ). Previously treated marginal zone lymphoma (MZL), in combination with a rituximab product ( 1.5 ). Limitations of Use: Lenalidomide capsules are not indicated and are not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.( 1.4 ).|[EMA] Multiple myelomaRevlimid as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.Revlimid as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4.2) is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.Revlimid in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.Myelodysplastic syndromesRevlimid as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.Mantle cell lymphomaRevlimid as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.Follicular lymphomaRevlimid in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 – 3a). uuid:e3a4ae37-3dd2-4f70-84b9-65250317fd01 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63791 biolink:treats MONDO:0017604 PMID:41385096 "[{""id"":""uuid:25204f15-d454-4a0f-9d93-af1b6bc4f876"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7120a3be-f4c2-4e1b-aae7-b94a83a72c7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:101adebd-437e-422e-85b0-3f9759415fa9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lenalidomide is a thalidomide analogue indicated for the treatment of adult patients with: Multiple myeloma (MM), in combination with dexamethasone ( 1.1 ). MM, as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT) ( 1.1 ). Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities ( 1.2 ). Mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib ( 1.3 ). Previously treated follicular lymphoma (FL), in combination with a rituximab product ( 1.4 ). Previously treated marginal zone lymphoma (MZL), in combination with a rituximab product ( 1.5 ). Limitations of Use: Lenalidomide capsules are not indicated and are not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials.( 1.4 ).|[PMDA] Drugs with new indications and a new dosage for the treatment of relapsed or refractory follicular lymphoma and marginal zone lymphoma. uuid:a88fb308-2e99-46ec-8647-a418dc820931 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17347 biolink:treats UMLS:C3714660 PMID:41385096 "[{""id"":""uuid:73f7159d-2f03-4d7c-8235-798311991dc2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:74974b3e-97b7-441f-bdd0-9a2624b93e81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Testosterone Topical Solution is indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone. • Primary hypogonadism (congenital or acquired): testicular failure due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter’s syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (FSH, LH) above the normal range. • Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum concentrations but have gonadotropins in the normal or low range. Limitations of use: • Safety and efficacy of Testosterone Topical Solution in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established. • Safety and efficacy of Testosterone Topical Solution in males <18 years old have not been established [ see Use in Specific Populations (8.4) ]. uuid:e9e7d20a-7586-4797-af63-df9bb612899d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10553 biolink:treats MONDO:0005902 PMID:41385096 "[{""id"":""uuid:0ff0ed5d-26eb-4219-b7a9-6bd2079c040d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b5ee6524-70de-4e3d-89a4-c1085c17363b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:41dcf878-06cd-43e8-967c-9f070735072f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/palforzia""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] PALFORZIA is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut. PALFORZIA is approved for use in patients with a confirmed diagnosis of peanut allergy. Initial Dose Escalation may be administered to patients aged 4 through 17 years. Up-Dosing and Maintenance may be continued in patients 4 years of age and older [see Dosage and Administration (2.4) ] . PALFORZIA is to be used in conjunction with a peanut-avoidant diet.|[EMA] Palforzia is indicated for the treatment of patients aged 4 to 17 years with a confirmed diagnosis of peanut allergy. Palforzia may be continued in patients 18 years of age and older.Palforzia should be used in conjunction with a peanut-avoidant diet. DOID:4378 uuid:a08f1c82-5982-4134-98ad-3f8c441db28d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10553 biolink:treats MONDO:0100053 PMID:41385096 "[{""id"":""uuid:7687bf02-baef-4bf6-882e-184119b22d5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:203b4b92-7145-47cb-ae54-d00aa80d7033"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PALFORZIA is an oral immunotherapy indicated for the mitigation of allergic reactions, including anaphylaxis, that may occur with accidental exposure to peanut. PALFORZIA is approved for use in patients with a confirmed diagnosis of peanut allergy. Initial Dose Escalation may be administered to patients aged 4 through 17 years. Up-Dosing and Maintenance may be continued in patients 4 years of age and older [see Dosage and Administration (2.4) ] . PALFORZIA is to be used in conjunction with a peanut-avoidant diet. uuid:b344f4aa-03b9-4e3a-9ca2-1e3a9e32abc9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0004126 PMID:41385096 "[{""id"":""uuid:c4ace837-1e17-4457-a693-eec12f0dcb07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fecb4f22-6c58-4d42-843b-5699ad76bf97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydrocortisone tablets are indicated in the following conditions. 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Non suppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Serum sickness Bronchial asthma Contact dermatitis Atopic dermatitis Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:bb822f6e-9f34-4220-9703-30a0855ea1b1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16899 biolink:treats MONDO:0002492 PMID:41385096 "[{""id"":""uuid:2893b47b-31d0-413f-851b-31bc681e4089"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fa0c219e-9171-4eed-a824-25a4f6ce9d57"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mannitol Injection, USP is indicated for the following therapeutic uses: • The promotion of diuresis, in the prevention and/or treatment of the oliguric phase of acute renal failure before irreversible renal failure becomes established. • The reduction of intracranial pressure and treatment of cerebral edema by reducing brain mass. • The reduction of elevated intraocular pressure when it cannot be lowered by other means. • The promotion of urinary excretion of toxic substances. uuid:d979fae4-2083-466c-914a-d0e676b59733 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9241 biolink:treats MONDO:0003924 PMID:41385096 "[{""id"":""uuid:ab3d6c80-1a8b-4d7e-84c0-4de670ec985d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dc841bd5-a9d9-429e-a9c4-3cb966bfed68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone tablets are an aldosterone antagonist indicated for: • The treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure ( 1.1 ). • Use as an add-on therapy for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.2 ). • The management of edema in adult patients who are cirrhotic when edema is not responsive to fluid and sodium restrictions and in the setting of nephrotic syndrome when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics produce an inadequate response ( 1.3 ). • Treatment of primary hyperaldosternism for: ( 1.4 ). o Short-term preoperative treatment o Long-term maintenance for patients with discrete aldosterone-producing adrenal adenomas who are not candidates for surgery and patients with bilateral micro or macronodular adrenal hyperplasia uuid:baed909f-3668-485a-96d1-c11bd2a9fa17 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31524 biolink:treats UMLS:C1400301 PMID:41385096 "[{""id"":""uuid:14aae865-1daa-4a80-8122-8bacc903f728"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:46f4492a-d0cc-4e0a-afdb-9f7420769e32"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Droxidopa capsules indicated for the treatment of orthostatic dizziness, lightheadedness, or the “feeling that you are about to black out” in adult patients with symptomatic neurogenic orthostatic hypotension (nOH) caused by primary autonomic failure (Parkinson's disease [PD], multiple system atrophy, and pure autonomic failure), dopamine beta-hydroxylase deficiency, and non-diabetic autonomic neuropathy. Effectiveness beyond 2 weeks of treatment has not been established. The continued effectiveness of droxidopa capsules should be assessed periodically. uuid:68e37ec6-bd79-462c-b547-7ed4ff0065a1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C1372952 biolink:treats MONDO:0005700 PMID:41385096 "[{""id"":""uuid:e9bb5f75-b1a9-4095-9b99-2f92d6526a6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9b3c7efb-9b71-4dd4-8e0b-18c7a2e34b0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VARIZIG ® [Varicella Zoster Immune Globulin (Human)] is indicated for post-exposure prophylaxis of varicella in high risk individuals. High risk groups include: immunocompromised children and adults, newborns of mothers with varicella shortly before or after delivery, premature infants, neonates and infants less than one year of age, adults without evidence of immunity, pregnant women. VARIZIG administration is intended to reduce the severity of varicella. Administer VARIZIG as soon as possible following varicella zoster virus (VZV) exposure, ideally within 96 hours for greatest effectiveness. There is no convincing evidence that VARIZIG reduces the incidence of chickenpox infection after exposure to VZV. There is no convincing evidence that established infections with VZV can be modified by VARIZIG administration. There is no indication for the prophylactic use of VARIZIG in immunodeficient children or adults when there is a past history of varicella, unless the patient is undergoing bone marrow transplantation. DRUGBANK:DB11621 uuid:bd0397bb-6198-481f-acc3-a1785b23d59f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats HP:0000958 PMID:41385096 "[{""id"":""uuid:b798bc6b-e97c-4464-bdb7-52fd6e1f6b2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4ff58762-5ab3-4131-9d39-435c2c3d2b4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For debridement and promotion of normal healing of hyperkeratotic surface lesions, particularly where healing is retarded by local infection, necrotic tissue, fibrinous or purulent debris or eshar. Urea is useful for the treatment of hyperkeratotic conditions such as dermatitis, psoriasis, soothes rough and dry skin, xerosis, ichthyosis, eczema, keratosis pilaris, keratosis palmaris, keratoderma, corns and calluses, as well as damaged, ingrown and devitalized nails. uuid:9e696711-4ebc-43d0-b2e5-8708f0607be6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:4bf820b2-88d4-459b-80e8-c4d06fccbb4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5af7f6f7-b94d-4bc9-b162-e8b63b4c73fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For debridement and promotion of normal healing of hyperkeratotic surface lesions, particularly where healing is retarded by local infection, necrotic tissue, fibrinous or purulent debris or eshar. Urea is useful for the treatment of hyperkeratotic conditions such as dermatitis, psoriasis, soothes rough and dry skin, xerosis, ichthyosis, eczema, keratosis pilaris, keratosis palmaris, keratoderma, corns and calluses, as well as damaged, ingrown and devitalized nails. uuid:84cceeb6-9144-47a4-a31a-251f1d301c67 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats MONDO:0019272 PMID:41385096 "[{""id"":""uuid:c06cc0d3-8c5f-495b-9b4c-5edf566a1c7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:94ce6f39-f032-49bc-a621-4bacae713938"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For debridement and promotion of normal healing of hyperkeratotic surface lesions, particularly where healing is retarded by local infection, necrotic tissue, fibrinous or purulent debris or eshar. Urea is useful for the treatment of hyperkeratotic conditions such as dermatitis, psoriasis, soothes rough and dry skin, xerosis, ichthyosis, eczema, keratosis pilaris, keratosis palmaris, keratoderma, corns and calluses, as well as damaged, ingrown and devitalized nails. uuid:184dc8d1-204a-49e9-9bb2-555974f4be4d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats HP:6000789 PMID:41385096 "[{""id"":""uuid:fa3a65e8-c2a7-49e8-ad08-501dfac1ebae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a803c52a-507c-4461-ae13-91b28df9a513"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For debridement and promotion of normal healing of hyperkeratotic surface lesions, particularly where healing is retarded by local infection, necrotic tissue, fibrinous or purulent debris or eshar. Urea is useful for the treatment of hyperkeratotic conditions such as dermatitis, psoriasis, soothes rough and dry skin, xerosis, ichthyosis, eczema, keratosis pilaris, keratosis palmaris, keratoderma, corns and calluses, as well as damaged, ingrown and devitalized nails. uuid:eb1028ad-5d90-4b7c-9f4f-119c58ca6dd8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats MONDO:0007758 PMID:41385096 "[{""id"":""uuid:df3ff574-834e-495d-b98b-b686c2f6e778"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:785e75f2-1f50-4a31-9949-ad08af5427a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For debridement and promotion of normal healing of hyperkeratotic surface lesions, particularly where healing is retarded by local infection, necrotic tissue, fibrinous or purulent debris or eshar. Urea is useful for the treatment of hyperkeratotic conditions such as dermatitis, psoriasis, soothes rough and dry skin, xerosis, ichthyosis, eczema, keratosis pilaris, keratosis palmaris, keratoderma, corns and calluses, as well as damaged, ingrown and devitalized nails. uuid:6501dd50-52a3-4527-921a-4708056860d2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats UMLS:C0406446 PMID:41385096 "[{""id"":""uuid:aa1283d6-bf9a-45cf-943a-647fd030d3a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dd90d11a-0094-40fa-a11c-15c94090380f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For debridement and promotion of normal healing of hyperkeratotic surface lesions, particularly where healing is retarded by local infection, necrotic tissue, fibrinous or purulent debris or eshar. Urea is useful for the treatment of hyperkeratotic conditions such as dermatitis, psoriasis, soothes rough and dry skin, xerosis, ichthyosis, eczema, keratosis pilaris, keratosis palmaris, keratoderma, corns and calluses, as well as damaged, ingrown and devitalized nails. uuid:7f64c8b5-81ca-4c79-ad97-0dbb3247871d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats HP:0012710 PMID:41385096 "[{""id"":""uuid:b7f55101-f728-40a3-b033-78a266d85041"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:90ad42ce-c84a-428b-a69a-03bdb6654ad2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For debridement and promotion of normal healing of hyperkeratotic surface lesions, particularly where healing is retarded by local infection, necrotic tissue, fibrinous or purulent debris or eshar. Urea is useful for the treatment of hyperkeratotic conditions such as dermatitis, psoriasis, soothes rough and dry skin, xerosis, ichthyosis, eczema, keratosis pilaris, keratosis palmaris, keratoderma, corns and calluses, as well as damaged, ingrown and devitalized nails. uuid:fbbc08f4-1ea0-4bf3-91fe-099c3591761a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16914 biolink:treats MONDO:0002884 PMID:41385096 "[{""id"":""uuid:7bb27a96-f32b-445e-b2f9-d4d539ece091"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dcf902b7-4252-4cfb-8742-941ab84c246f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For debridement and promotion of normal healing of hyperkeratotic surface lesions, particularly where healing is retarded by local infection, necrotic tissue, fibrinous or purulent debris or eshar. Urea is useful for the treatment of hyperkeratotic conditions such as dermatitis, psoriasis, soothes rough and dry skin, xerosis, ichthyosis, eczema, keratosis pilaris, keratosis palmaris, keratoderma, corns and calluses, as well as damaged, ingrown and devitalized nails. uuid:4c825b5f-08a7-4bc6-84f3-673995145f63 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7451 biolink:treats UMLS:C5192601 PMID:41385096 "[{""id"":""uuid:2064b984-f7d4-4610-91c0-168b73ef446c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5a8b4f10-a5f8-42d3-8eae-05d2d10ac0ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Naftifine hydrochloride gel USP, 2% is indicated for the treatment of interdigital tinea pedis caused by the organisms Trichophyton rubrum , Trichophyton mentagrophytes , and Epidermophyton floccosum . uuid:02c9ce0b-c956-42c7-b2dd-36974c369a57 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8207 biolink:treats MONDO:0001330 PMID:41385096 "[{""id"":""uuid:e05074c8-4bc3-4f03-b1e0-502feee93d74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ab4b0afb-a174-4be5-980e-154d57128253"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VUITY ® is indicated for the treatment of presbyopia in adults. uuid:3daa646c-721a-4322-abe7-659c3a7f7e98 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16359 biolink:treats MONDO:0019218 PMID:41385096 "[{""id"":""uuid:fc66ea89-e540-484d-8cb6-ba94901c13b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:128f83e6-78ba-4815-89d8-3e7ee0c0bcdc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0db7d3eb-d2f7-49ea-bbd4-6606f44fe272"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CHOLBAM is a bile acid indicated for: Treatment of bile acid synthesis disorders due to single enzyme defects (SEDs). ( 1.1 ) Adjunctive treatment of peroxisomal disorders (PDs) including Zellweger spectrum disorders in patients who exhibit manifestations of liver disease, steatorrhea or complications from decreased fat-soluble vitamin absorption. ( 1.2 ) Limitations of use: The safety and effectiveness of CHOLBAM on extrahepatic manifestations of bile acid synthesis disorders due to SEDs or PDs including Zellweger spectrum disorders have not been established. ( 1.3 ).|[PMDA] A drug with a new active ingredient indicated for the treatment of inborn errors of bile acid metabolism. [Orphan drug] uuid:ad414b8e-7c89-4381-bb8c-1f659254969e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16359 biolink:treats MONDO:0019053 PMID:41385096 "[{""id"":""uuid:a8eb0dfd-7087-4c1d-ac26-3fe0df7aa272"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b0d4bd79-4dd9-49f1-bf9d-162822592bd1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CHOLBAM is a bile acid indicated for: Treatment of bile acid synthesis disorders due to single enzyme defects (SEDs). ( 1.1 ) Adjunctive treatment of peroxisomal disorders (PDs) including Zellweger spectrum disorders in patients who exhibit manifestations of liver disease, steatorrhea or complications from decreased fat-soluble vitamin absorption. ( 1.2 ) Limitations of use: The safety and effectiveness of CHOLBAM on extrahepatic manifestations of bile acid synthesis disorders due to SEDs or PDs including Zellweger spectrum disorders have not been established. ( 1.3 ). uuid:be7e7733-7928-441e-989d-f3ec7d05b9b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16359 biolink:treats MONDO:0019609 PMID:41385096 "[{""id"":""uuid:23268afc-6eda-4714-984e-3689610a4d5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8a04175a-def7-476c-a967-b60e265c37c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CHOLBAM is a bile acid indicated for: Treatment of bile acid synthesis disorders due to single enzyme defects (SEDs). ( 1.1 ) Adjunctive treatment of peroxisomal disorders (PDs) including Zellweger spectrum disorders in patients who exhibit manifestations of liver disease, steatorrhea or complications from decreased fat-soluble vitamin absorption. ( 1.2 ) Limitations of use: The safety and effectiveness of CHOLBAM on extrahepatic manifestations of bile acid synthesis disorders due to SEDs or PDs including Zellweger spectrum disorders have not been established. ( 1.3 ). uuid:af30d288-4a9f-4376-90b3-7f4d0d53f0c3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8805 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:cb6355a8-51f6-4296-b3db-6f2451281655"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:986ec9ea-d884-4b61-b4d1-9fdd631c5705"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Repaglinide tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitation of Use: Repaglinide tablets should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. uuid:4e14bb49-2a33-40d5-9529-94a6d185759a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:74947 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:ba5be155-a4d1-4724-ae54-3c6c663fbd89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:117e1f60-dfaf-4cb5-bc8b-57edbaa5a95c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:89041467-718a-407f-90ee-8be4a1a5b1fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/thalidomide-celgene""]},{""id"":""uuid:0418eedd-034a-4a81-b99f-4111a8d48485"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] • THALOMID in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma (MM). ( 1.1 ) • THALOMID is indicated for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). THALOMID is not indicated as monotherapy for such ENL treatment in the presence of moderate to severe neuritis. THALOMID is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence. ( 1.2 )|[EMA] Thalidomide BMS in combination with melphalan and prednisone as first line treatment of patients with untreated multiple myeloma, aged >/= 65 years or ineligible for high dose chemotherapy.Thalidomide BMS is prescribed and dispensed according to the Thalidomide Celgene Pregnancy Prevention Programme (see section 4.4).|[PMDA] A drug containing a new active ingredient indicated for the treatment of relapsed or refractory multiple myeloma. [Orphan drug] uuid:9c243798-1082-45a2-83d9-5ae0b20fc745 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:74947 biolink:treats UMLS:C0343467 PMID:41385096 "[{""id"":""uuid:f79e853e-2add-438f-9f23-7a6d4af745ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:530c612d-a98c-4e44-a889-8018e9394aae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:393962a3-dcfa-429f-a20d-3c14704cf2ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] • THALOMID in combination with dexamethasone is indicated for the treatment of patients with newly diagnosed multiple myeloma (MM). ( 1.1 ) • THALOMID is indicated for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). THALOMID is not indicated as monotherapy for such ENL treatment in the presence of moderate to severe neuritis. THALOMID is also indicated as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence. ( 1.2 )|[PMDA] Drugs with a new additional indication and a new dosage for the treatment of erythema nodosum leprosum. [Orphan drug] uuid:eb18be35-d301-461d-80b9-76f3b5678699 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60210 biolink:treats MONDO:0009643 PMID:41385096 "[{""id"":""uuid:223c8c9c-daa2-4a8b-a007-ba3249b1d964"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2cf80f7d-3724-4882-8fa9-1250e3eb7b69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1c557176-2cab-412c-9d3c-d86bf33964e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NULIBRY is indicated to reduce the risk of mortality in patients with molybdenum cofactor deficiency (MoCD) Type A.|[EMA] NULIBRY is indicated for the treatment of patients with molybdenum cofactor deficiency (MoCD) Type A. uuid:923ca176-1b3a-4aaf-a88b-135d222a68a8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8768 biolink:treats HP:0005202 PMID:41385096 "[{""id"":""uuid:f71e2890-6f92-4098-a3d4-38eea8aed965"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9f616db6-e8ab-42bc-b65d-4aca54fcb693"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Healing of Erosive or Ulcerative GERD in Adults Rabeprazole sodium delayed-release tablets are indicated for short-term (4 to 8 weeks) treatment in the healing and symptomatic relief of erosive or ulcerative gastroesophageal reflux disease (GERD). For those patients who have not healed after 8 weeks of treatment, an additional 8-week course of rabeprazole sodium delayed-release tablets may be considered. 1.2 Maintenance of Healing of Erosive or Ulcerative GERD in Adults Rabeprazole sodium delayed-release tablets are indicated for maintaining healing and reduction in relapse rates of heartburn symptoms in patients with erosive or ulcerative gastroesophageal reflux disease (GERD Maintenance). Controlled studies do not extend beyond 12 months. 1.3 Treatment of Symptomatic GERD in Adults Rabeprazole sodium delayed-release tablets are indicated for the treatment of daytime and nighttime heartburn and other symptoms associated with GERD in adults for up to 4 weeks. 1.4 Healing of Duodenal Ulcers in Adults Rabeprazole sodium delayed-release tablets are indicated for short-term (up to four weeks) treatment in the healing and symptomatic relief of duodenal ulcers. Most patients heal within four weeks. 1.5 Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence in Adults Rabeprazole sodium delayed-release tablets, in combination with amoxicillin and clarithromycin as a three drug regimen, are indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or history within the past 5 years) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence. In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted [see Clinical Pharmacology (12.2) and the full prescribing information for clarithromycin]. 1.6 Treatment of Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome in Adults Rabeprazole sodium delayed-release tablets are indicated for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome. 1.7 Treatment of Symptomatic GERD in Adolescent Patients 12 Years of Age and Older Rabeprazole sodium delayed-release tablets are indicated for the treatment of symptomatic GERD in adolescents 12 years of age and above for up to 8 weeks. uuid:1007f52a-7722-4b1c-86f2-e460c81e69f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9943 biolink:treats MONDO:0003709 PMID:41385096 "[{""id"":""uuid:6ca6d2fd-0461-4fda-8fa8-9ffeaedc8fe9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dcb2f688-0683-43ed-8e29-4280c71b7849"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Major Depressive Disorder Venlafaxine hydrochloride extended-release capsules, USP are indicated for the treatment of major depressive disorder (MDD). Efficacy was established in three short-term (4, 8, and 12 weeks) and two long-term, maintenance trials. 1.3 Social Anxiety Disorder Venlafaxine hydrochloride extended-release capsules, USP are indicated for the treatment of Social Anxiety Disorder (SAD), also known as social phobia. Efficacy was established in four 12-week and one 26-week, placebo-controlled trials. 1.4 Panic Disorder Venlafaxine hydrochloride extended-release capsules, USP are indicated for the treatment of Panic Disorder (PD), with or without agoraphobia. Efficacy was established in two 12-week placebo-controlled trials. uuid:50edb449-8671-4c9f-97d1-2ee6e3e6f619 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:567361 biolink:treats MONDO:0018935 PMID:41385096 "[{""id"":""uuid:20a7a44d-a68a-4e65-aa69-c63e64007d76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:7f94a92d-6dec-4e67-a627-9f1c354e7b02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:04afb913-646c-4bac-a155-d9688ef35652"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/mavenclad""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cladribine Injection, USP is indicated for the treatment of active Hairy Cell Leukemia as defined by clinically significant anemia, neutropenia, thrombocytopenia or disease-related symptoms.|[EMA] Litak is indicated for the treatment of hairy-cell leukaemia. uuid:e9833b0c-7964-4683-9dce-59c91c1613c7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42068 biolink:treats MONDO:0018874 PMID:41385096 "[{""id"":""uuid:94555b43-c394-489a-9eae-4e15f9295074"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5e55a6ff-a263-4ad9-bebc-adefc9d1d2b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Idarubicin Hydrochloride injection, USP in combination with other approved antileukemic drugs is indicated for the treatment of acute myeloid leukemia (AML) in adults. This includes French-American-British (FAB) classifications M1 through M7. uuid:8e66b836-f59c-4ce9-8a7a-96a3c789f749 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50381 biolink:treats MONDO:0018150 PMID:41385096 "[{""id"":""uuid:48cd24f4-e2dd-4d23-be66-d4e9f935a6d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:faf4d346-6530-4463-97ff-49920fc83f32"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:fb757d92-19de-4d49-ae06-2d7f45a875fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/opfolda""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZAVESCA is a glucosylceramide synthase inhibitor indicated as monotherapy for treatment of adult patients with mild/moderate type 1 Gaucher disease for whom enzyme replacement therapy is not a therapeutic option ( 1.1 ).|[EMA] Miglustat Dipharma is indicated for the oral treatment of adult patients with mild to moderate type 1 Gaucher disease.Miglustat Dipharma may be used only in the treatment of patients for whom enzyme replacement therapy is unsuitable.Miglustat Dipharma is indicated for the treatment of progressive neurological manifestations in adult patients and paediatric patients with Niemann-Pick type C disease. uuid:5c944d0d-e7e4-44d2-bc8b-d46d76291e74 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50381 biolink:treats MONDO:0009265 PMID:41385096 "[{""id"":""uuid:be455903-ec54-4cf9-8875-3ce039ec9d68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fe099482-f132-4f42-921b-44d130ae13be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZAVESCA is a glucosylceramide synthase inhibitor indicated as monotherapy for treatment of adult patients with mild/moderate type 1 Gaucher disease for whom enzyme replacement therapy is not a therapeutic option ( 1.1 ). uuid:7d8806a5-e4d0-488c-8f4d-97c312f7dc15 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15367 biolink:treats MONDO:0012883 PMID:41385096 "[{""id"":""uuid:64849d5b-f643-4b1b-a29c-b0395d1121db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fbebc69c-9ac8-4971-ba9e-f8316480a415"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tretinoin capsules are indicated for the induction of remission in adults and pediatric patients 1 year of age and older with acute promyelocytic leukemia (APL) characterized by the presence of the t(15;17) translocation or PML/RARα gene expression, and who are refractory to or who have relapsed from anthracycline chemotherapy or for whom anthracycline-based chemotherapy is contraindicated. uuid:06777984-6be7-49f2-a923-22d7293254f0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2166086 biolink:treats UMLS:C0406317 PMID:41385096 "[{""id"":""uuid:0ab2617b-6ce0-4096-b470-6da62ffea56d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:226d3168-ca1a-4d4e-a7fe-5b3e8c2259f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DUOBRII ® (halobetasol propionate and tazarotene) Lotion, 0.01%/0.045% is indicated for the topical treatment of plaque psoriasis in adults. uuid:084ae497-f76e-48b6-ac0b-e78b7067834f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4Q52C550XK biolink:treats MONDO:0018906 PMID:41385096 "[{""id"":""uuid:1dd916af-b180-4564-add5-adfbdc29d464"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:fd823f04-76d9-457e-9d2e-4c1691c424a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3790d090-b889-459a-b763-073b0284022e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zevalin""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Zevalin is a CD20-directed radiotherapeutic antibody administered as part of the Zevalin therapeutic regimen indicated for the treatment of adult patients with: relapsed or refractory, low-grade or follicular B-cell non-Hodgkin's lymphoma (NHL) ( 1.1 ). previously untreated follicular NHL who achieve a partial or complete response to first-line chemotherapy ( 1.2 ).|[EMA] Zevalin is indicated in adults.[90Y]-radiolabelled Zevalin is indicated as consolidation therapy after remission induction in previously untreated patients with follicular lymphoma. The benefit of Zevalin following rituximab in combination with chemotherapy has not been established.[90Y]-radiolabelled Zevalin is indicated for the treatment of adult patients with rituximab relapsedorrefractory CD20+ follicular B-cell non-Hodgkin's lymphoma (NHL). uuid:bf558a08-a3ab-429f-863a-fcc2404c4d96 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28364 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:4b20c254-2d43-4636-a23e-bb4f1fb87765"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f6f90730-cf34-4a50-b7cb-fe63b55a6a4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VASCEPA ® (icosapent ethyl) is indicated: as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (≥ 150 mg/dL) and established cardiovascular disease or diabetes mellitus and 2 or more additional risk factors for cardiovascular disease. as an adjunct to diet to reduce TG levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia. Limitations of Use: The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined. uuid:56313628-4c08-4173-9f8b-de81c6abbe53 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28364 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:3047dd62-90f1-4c6e-a18f-64221afb8eaf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:972bb7f6-e076-4b1c-81d6-1a8ab8079271"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VASCEPA ® (icosapent ethyl) is indicated: as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (≥ 150 mg/dL) and established cardiovascular disease or diabetes mellitus and 2 or more additional risk factors for cardiovascular disease. as an adjunct to diet to reduce TG levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia. Limitations of Use: The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined. uuid:e5e05560-e976-411d-8981-34ace0b825a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28364 biolink:treats MONDO:0006805 PMID:41385096 "[{""id"":""uuid:d6231af9-1714-4207-a87a-1e4f135ca5fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aadf6b09-419f-4fb8-85fa-2d9579fc71e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VASCEPA ® (icosapent ethyl) is indicated: as an adjunct to maximally tolerated statin therapy to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina requiring hospitalization in adult patients with elevated triglyceride (TG) levels (≥ 150 mg/dL) and established cardiovascular disease or diabetes mellitus and 2 or more additional risk factors for cardiovascular disease. as an adjunct to diet to reduce TG levels in adult patients with severe (≥ 500 mg/dL) hypertriglyceridemia. Limitations of Use: The effect of VASCEPA on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined. uuid:e6798165-058b-43ad-b2c2-67f5425e7ed8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:581255 biolink:treats MONDO:0004567 PMID:41385096 "[{""id"":""uuid:6bdf9d83-5216-4656-bdb2-a5873b5fe791"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a2c4a9fd-cdd9-48e8-85a0-ff432b602ff3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Plenamine™ 15% is indicated as an amino acid (nitrogen) source in parenteral nutrition regimens. This use is appropriate when the enteral route is inadvisable, inadequate or not possible, as when: — Gastrointestinal absorption is impaired by obstruction, inflammatory disease or its complications, or antineoplastic therapy; — Bowel rest is needed because of gastrointestinal surgery or its complications such as ileus, fistulae or anastomotic leaks; — Tube feeding methods alone cannot provide adequate nutrition. uuid:de7fc937-903b-453c-80da-f88620ccf567 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:581255 biolink:treats UMLS:C0919691 PMID:41385096 "[{""id"":""uuid:377adca8-ee4a-4ff3-920f-73344e4a9b10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:46361800-a315-4647-a1f2-2efc1103f82f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Plenamine™ 15% is indicated as an amino acid (nitrogen) source in parenteral nutrition regimens. This use is appropriate when the enteral route is inadvisable, inadequate or not possible, as when: — Gastrointestinal absorption is impaired by obstruction, inflammatory disease or its complications, or antineoplastic therapy; — Bowel rest is needed because of gastrointestinal surgery or its complications such as ileus, fistulae or anastomotic leaks; — Tube feeding methods alone cannot provide adequate nutrition. uuid:edef263d-7029-48a0-9da2-a92f561e1a4a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2379 biolink:treats HP:0004308 PMID:41385096 "[{""id"":""uuid:fc1f5d8d-9de8-48e2-97e0-1021d5b699d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ab84e368-d491-40c9-92b4-c0d73b7bd789"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypertension Acebutolol HCl capsules are indicated for the management of hypertension in adults. It may be used alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. Ventricular Arrhythmias Acebutolol HCl capsules are indicated in the management of ventricular premature beats; it reduces the total number of premature beats, as well as the number of paired and multiform ventricular ectopic beats, and R-on-T beats. uuid:1692ecb1-445f-404f-a9bb-4dbc288a5ec2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82720 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:76ad2b07-05d9-455f-91eb-8959f25f8d00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e37639d5-b061-40b9-b92c-f4d663ad4020"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:367714f8-2526-4aaa-8d80-fc3beabe2f2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/jardiance""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] JARDIANCE is indicated: to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure. to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease. as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.|[EMA] Type 2 diabetes mellitusJardiance is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered in addition to other medicinal products for the treatment of diabetesFor study results with respect to combinations of therapies, effects on glycaemic control, and cardiovascular and renal events, and the populations studied, see sections 4.4, 4.5 and 5.1. of the annex.Heart failureJardiance is indicated in adults for the treatment of symptomatic chronic heart failure. Chronic kidney diseaseJardiance is indicated in adults for the treatment of chronic kidney disease. uuid:d629c05e-f514-402e-b0fa-1ed46f4726d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82720 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:46908804-e3a4-449f-bbbd-985b84f8e788"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f46e3853-e9bf-48dd-9074-a9c3c57d6094"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:69604f5f-0906-4785-ad6e-06551dac6c02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/jardiance""]},{""id"":""uuid:8de21ae3-82f2-4592-ac39-9aaf3d98cfe1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] JARDIANCE is indicated: to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure. to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease. as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.|[EMA] Type 2 diabetes mellitusJardiance is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered in addition to other medicinal products for the treatment of diabetesFor study results with respect to combinations of therapies, effects on glycaemic control, and cardiovascular and renal events, and the populations studied, see sections 4.4, 4.5 and 5.1. of the annex.Heart failureJardiance is indicated in adults for the treatment of symptomatic chronic heart failure. Chronic kidney diseaseJardiance is indicated in adults for the treatment of chronic kidney disease.|[PMDA] Drugs with a new active ingredient indicated for the treatment of type 2 diabetes mellitus. uuid:4f6d6655-286b-45d9-ac1f-c40f3a032887 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6846 biolink:treats MONDO:0010826 PMID:41385096 "[{""id"":""uuid:aad742e6-f48d-4f7e-9fe6-23fe35ccd2e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cc844a76-6209-4f59-a1fc-f2eb305c0082"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methsuximide is indicated for the control of absence (petit mal) seizures that are refractory to other drugs. uuid:4f153da8-bfa4-42ab-a9a1-513bdfc37c1e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:WTT295HSY5 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:fedce982-41a4-4826-a281-05ad6f4a7af4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:90e38a91-204c-4662-8712-11bd885ce805"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d1181f30-6193-4d1e-813e-02bcca08dd4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/trulicity""]},{""id"":""uuid:5866426a-6378-48c3-8c21-d720edbc77ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRULICITY ® is indicated: As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. To reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.|[EMA] Trulicity is indicated for the treatment of patients 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes.For study results with respect to combinations, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.|[PMDA] A drug with a new active ingredient indicated for the treatment of type 2 diabetes mellitus. uuid:e8c0bda7-7464-428e-a73b-6bd432e54e90 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:WTT295HSY5 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:7c2f4712-a0b7-4323-99b3-0ce67d9b729b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:55d26f29-8628-49f7-bd89-4dd003e15fa5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRULICITY ® is indicated: As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. To reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors. uuid:843ccc3c-db81-4012-82a6-6d2b2d840462 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:WTT295HSY5 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:244bc77c-3360-4240-a0b8-e289ba6d587f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bb5beaa2-bbb5-4a68-8594-aa7197fd9cc4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRULICITY ® is indicated: As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus. To reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors. uuid:31078eab-fd38-4b32-ba33-bcae4616e8b8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0700217 PMID:41385096 "[{""id"":""uuid:7217827c-3377-4351-b073-a1540bf60808"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:05d3b1ab-938a-4728-8908-4bcdb7e98a13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin and other antibacterial drugs, gentamicin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Sulfate Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa , Proteus species (indole-positive and indole-negative), Escherichia coli , Klebsiella-Enterobacter-Serratia species, Citrobacter species, and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown Gentamicin Sulfate Injection, USP to be effective in bacterial neonatal sepsis; bacterial septicemia; and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin sulfate may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection, and the important additional concepts contained in the WARNINGS box. If the causative organisms are resistant to gentamicin, other appropriate therapy should be instituted. In serious infections when the causative organisms are unknown, gentamicin sulfate may be administered as initial therapy in conjunction with a penicillin-type or cephalosporin-type drug before obtaining results of susceptibility testing. If anaerobic organisms are suspected as etiologic agents, consideration should be given to using other suitable antimicrobial therapy in conjunction with gentamicin. Following identification of the organism and its susceptibility, appropriate antibiotic therapy should then be continued. Gentamicin sulfate has been used effectively in combination with carbenicillin for the treatment of life-threatening infections caused by Pseudomonas aeruginosa . It has also been found effective when used in conjunction with a penicillin-type drug for the treatment of endocarditis caused by group D streptococci. Gentamicin Sulfate Injection, USP has also been shown to be effective in the treatment of serious staphylococcal infections. While not the antibiotic of first choice, gentamicin may be considered when penicillins or other less potentially toxic drugs are contraindicated and bacterial susceptibility tests and clinical judgment indicate its use. It may also be considered in mixed infections caused by susceptible strains of staphylococci and gram-negative organisms. In the neonate with suspected bacterial sepsis or staphylococcal pneumonia, a penicillin-type drug is also usually indicated as concomitant therapy with gentamicin. uuid:297bee2c-6a01-4412-9eec-b92ba57adea6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats UMLS:C0684256 PMID:41385096 "[{""id"":""uuid:1e38a9da-82e8-43c5-b665-4d52ca44cc0c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a8ca91bf-bdaa-4a5f-b8d3-6afab0da3e55"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin and other antibacterial drugs, gentamicin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Sulfate Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa , Proteus species (indole-positive and indole-negative), Escherichia coli , Klebsiella-Enterobacter-Serratia species, Citrobacter species, and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown Gentamicin Sulfate Injection, USP to be effective in bacterial neonatal sepsis; bacterial septicemia; and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin sulfate may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection, and the important additional concepts contained in the WARNINGS box. If the causative organisms are resistant to gentamicin, other appropriate therapy should be instituted. In serious infections when the causative organisms are unknown, gentamicin sulfate may be administered as initial therapy in conjunction with a penicillin-type or cephalosporin-type drug before obtaining results of susceptibility testing. If anaerobic organisms are suspected as etiologic agents, consideration should be given to using other suitable antimicrobial therapy in conjunction with gentamicin. Following identification of the organism and its susceptibility, appropriate antibiotic therapy should then be continued. Gentamicin sulfate has been used effectively in combination with carbenicillin for the treatment of life-threatening infections caused by Pseudomonas aeruginosa . It has also been found effective when used in conjunction with a penicillin-type drug for the treatment of endocarditis caused by group D streptococci. Gentamicin Sulfate Injection, USP has also been shown to be effective in the treatment of serious staphylococcal infections. While not the antibiotic of first choice, gentamicin may be considered when penicillins or other less potentially toxic drugs are contraindicated and bacterial susceptibility tests and clinical judgment indicate its use. It may also be considered in mixed infections caused by susceptible strains of staphylococci and gram-negative organisms. In the neonate with suspected bacterial sepsis or staphylococcal pneumonia, a penicillin-type drug is also usually indicated as concomitant therapy with gentamicin. uuid:00f9032e-2af1-4cdd-9253-ae639e41c853 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0021108 PMID:41385096 "[{""id"":""uuid:b591b350-9780-4399-98a7-d94a39bd325b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:942dd97a-693c-4479-8dd5-ba78e305e261"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin and other antibacterial drugs, gentamicin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Sulfate Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa , Proteus species (indole-positive and indole-negative), Escherichia coli , Klebsiella-Enterobacter-Serratia species, Citrobacter species, and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown Gentamicin Sulfate Injection, USP to be effective in bacterial neonatal sepsis; bacterial septicemia; and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin sulfate may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection, and the important additional concepts contained in the WARNINGS box. If the causative organisms are resistant to gentamicin, other appropriate therapy should be instituted. In serious infections when the causative organisms are unknown, gentamicin sulfate may be administered as initial therapy in conjunction with a penicillin-type or cephalosporin-type drug before obtaining results of susceptibility testing. If anaerobic organisms are suspected as etiologic agents, consideration should be given to using other suitable antimicrobial therapy in conjunction with gentamicin. Following identification of the organism and its susceptibility, appropriate antibiotic therapy should then be continued. Gentamicin sulfate has been used effectively in combination with carbenicillin for the treatment of life-threatening infections caused by Pseudomonas aeruginosa . It has also been found effective when used in conjunction with a penicillin-type drug for the treatment of endocarditis caused by group D streptococci. Gentamicin Sulfate Injection, USP has also been shown to be effective in the treatment of serious staphylococcal infections. While not the antibiotic of first choice, gentamicin may be considered when penicillins or other less potentially toxic drugs are contraindicated and bacterial susceptibility tests and clinical judgment indicate its use. It may also be considered in mixed infections caused by susceptible strains of staphylococci and gram-negative organisms. In the neonate with suspected bacterial sepsis or staphylococcal pneumonia, a penicillin-type drug is also usually indicated as concomitant therapy with gentamicin. uuid:abf3a596-8b53-40a5-83f5-85b2f5cd338c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:c6505d8b-2dbf-478a-b071-8197e61a92de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:48523fa9-0dad-4c09-9868-1275032a2863"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin and other antibacterial drugs, gentamicin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Sulfate Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa , Proteus species (indole-positive and indole-negative), Escherichia coli , Klebsiella-Enterobacter-Serratia species, Citrobacter species, and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown Gentamicin Sulfate Injection, USP to be effective in bacterial neonatal sepsis; bacterial septicemia; and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin sulfate may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection, and the important additional concepts contained in the WARNINGS box. If the causative organisms are resistant to gentamicin, other appropriate therapy should be instituted. In serious infections when the causative organisms are unknown, gentamicin sulfate may be administered as initial therapy in conjunction with a penicillin-type or cephalosporin-type drug before obtaining results of susceptibility testing. If anaerobic organisms are suspected as etiologic agents, consideration should be given to using other suitable antimicrobial therapy in conjunction with gentamicin. Following identification of the organism and its susceptibility, appropriate antibiotic therapy should then be continued. Gentamicin sulfate has been used effectively in combination with carbenicillin for the treatment of life-threatening infections caused by Pseudomonas aeruginosa . It has also been found effective when used in conjunction with a penicillin-type drug for the treatment of endocarditis caused by group D streptococci. Gentamicin Sulfate Injection, USP has also been shown to be effective in the treatment of serious staphylococcal infections. While not the antibiotic of first choice, gentamicin may be considered when penicillins or other less potentially toxic drugs are contraindicated and bacterial susceptibility tests and clinical judgment indicate its use. It may also be considered in mixed infections caused by susceptible strains of staphylococci and gram-negative organisms. In the neonate with suspected bacterial sepsis or staphylococcal pneumonia, a penicillin-type drug is also usually indicated as concomitant therapy with gentamicin. uuid:1ecfb5fe-5023-4ecd-a8ed-746bddd7e2b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:33a4f208-4789-489a-9cce-d0f2acc1c102"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cbff076c-289d-46f1-9ae8-29ceb613cf91"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin and other antibacterial drugs, gentamicin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Sulfate Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa , Proteus species (indole-positive and indole-negative), Escherichia coli , Klebsiella-Enterobacter-Serratia species, Citrobacter species, and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown Gentamicin Sulfate Injection, USP to be effective in bacterial neonatal sepsis; bacterial septicemia; and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin sulfate may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection, and the important additional concepts contained in the WARNINGS box. If the causative organisms are resistant to gentamicin, other appropriate therapy should be instituted. In serious infections when the causative organisms are unknown, gentamicin sulfate may be administered as initial therapy in conjunction with a penicillin-type or cephalosporin-type drug before obtaining results of susceptibility testing. If anaerobic organisms are suspected as etiologic agents, consideration should be given to using other suitable antimicrobial therapy in conjunction with gentamicin. Following identification of the organism and its susceptibility, appropriate antibiotic therapy should then be continued. Gentamicin sulfate has been used effectively in combination with carbenicillin for the treatment of life-threatening infections caused by Pseudomonas aeruginosa . It has also been found effective when used in conjunction with a penicillin-type drug for the treatment of endocarditis caused by group D streptococci. Gentamicin Sulfate Injection, USP has also been shown to be effective in the treatment of serious staphylococcal infections. While not the antibiotic of first choice, gentamicin may be considered when penicillins or other less potentially toxic drugs are contraindicated and bacterial susceptibility tests and clinical judgment indicate its use. It may also be considered in mixed infections caused by susceptible strains of staphylococci and gram-negative organisms. In the neonate with suspected bacterial sepsis or staphylococcal pneumonia, a penicillin-type drug is also usually indicated as concomitant therapy with gentamicin. uuid:de832f63-3357-4ab2-91e5-1447b6797fc8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0043424 PMID:41385096 "[{""id"":""uuid:5a1f9a1f-80c5-4803-9884-6f24cb8f092d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:794d8929-6feb-47db-aa22-f38a504b5e63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin and other antibacterial drugs, gentamicin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Sulfate Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa , Proteus species (indole-positive and indole-negative), Escherichia coli , Klebsiella-Enterobacter-Serratia species, Citrobacter species, and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown Gentamicin Sulfate Injection, USP to be effective in bacterial neonatal sepsis; bacterial septicemia; and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin sulfate may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection, and the important additional concepts contained in the WARNINGS box. If the causative organisms are resistant to gentamicin, other appropriate therapy should be instituted. In serious infections when the causative organisms are unknown, gentamicin sulfate may be administered as initial therapy in conjunction with a penicillin-type or cephalosporin-type drug before obtaining results of susceptibility testing. If anaerobic organisms are suspected as etiologic agents, consideration should be given to using other suitable antimicrobial therapy in conjunction with gentamicin. Following identification of the organism and its susceptibility, appropriate antibiotic therapy should then be continued. Gentamicin sulfate has been used effectively in combination with carbenicillin for the treatment of life-threatening infections caused by Pseudomonas aeruginosa . It has also been found effective when used in conjunction with a penicillin-type drug for the treatment of endocarditis caused by group D streptococci. Gentamicin Sulfate Injection, USP has also been shown to be effective in the treatment of serious staphylococcal infections. While not the antibiotic of first choice, gentamicin may be considered when penicillins or other less potentially toxic drugs are contraindicated and bacterial susceptibility tests and clinical judgment indicate its use. It may also be considered in mixed infections caused by susceptible strains of staphylococci and gram-negative organisms. In the neonate with suspected bacterial sepsis or staphylococcal pneumonia, a penicillin-type drug is also usually indicated as concomitant therapy with gentamicin. uuid:b48be97f-dcf1-4144-b689-406431734803 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0004522 PMID:41385096 "[{""id"":""uuid:7ef78634-af3f-44b3-b5ee-206ffea445ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:181e98c1-627d-4d69-81e1-0442b4536d2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:56b73b25-8012-4a8c-8feb-eb7bc10f2357"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin and other antibacterial drugs, gentamicin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Sulfate Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa , Proteus species (indole-positive and indole-negative), Escherichia coli , Klebsiella-Enterobacter-Serratia species, Citrobacter species, and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown Gentamicin Sulfate Injection, USP to be effective in bacterial neonatal sepsis; bacterial septicemia; and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin sulfate may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection, and the important additional concepts contained in the WARNINGS box. If the causative organisms are resistant to gentamicin, other appropriate therapy should be instituted. In serious infections when the causative organisms are unknown, gentamicin sulfate may be administered as initial therapy in conjunction with a penicillin-type or cephalosporin-type drug before obtaining results of susceptibility testing. If anaerobic organisms are suspected as etiologic agents, consideration should be given to using other suitable antimicrobial therapy in conjunction with gentamicin. Following identification of the organism and its susceptibility, appropriate antibiotic therapy should then be continued. Gentamicin sulfate has been used effectively in combination with carbenicillin for the treatment of life-threatening infections caused by Pseudomonas aeruginosa . It has also been found effective when used in conjunction with a penicillin-type drug for the treatment of endocarditis caused by group D streptococci. Gentamicin Sulfate Injection, USP has also been shown to be effective in the treatment of serious staphylococcal infections. While not the antibiotic of first choice, gentamicin may be considered when penicillins or other less potentially toxic drugs are contraindicated and bacterial susceptibility tests and clinical judgment indicate its use. It may also be considered in mixed infections caused by susceptible strains of staphylococci and gram-negative organisms. In the neonate with suspected bacterial sepsis or staphylococcal pneumonia, a penicillin-type drug is also usually indicated as concomitant therapy with gentamicin.|[PMDA] Drugs with a new dosage indicated for the treatment of sepsis, secondary infection of trauma, burn, and surgical wound, pneumonia, cystitis, pyelonephritis, peritonitis, otitis media caused by following applicable microorganisms: Gentamicin-sensitive Staphylococcus, Escherichia coli, Klebsiella, Enterobacter, Serratia, Proteus, Morganella morganii, Providencia, Pseudomonas aeruginosa uuid:d6a961d1-7769-45ab-9c8b-7969a29b49fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0005246 PMID:41385096 "[{""id"":""uuid:68e0282c-1b88-4bf1-a372-9a6bde3a0c5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c4a5b7c1-dd89-48ac-896f-ae054a64da80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin and other antibacterial drugs, gentamicin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Sulfate Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa , Proteus species (indole-positive and indole-negative), Escherichia coli , Klebsiella-Enterobacter-Serratia species, Citrobacter species, and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown Gentamicin Sulfate Injection, USP to be effective in bacterial neonatal sepsis; bacterial septicemia; and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin sulfate may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection, and the important additional concepts contained in the WARNINGS box. If the causative organisms are resistant to gentamicin, other appropriate therapy should be instituted. In serious infections when the causative organisms are unknown, gentamicin sulfate may be administered as initial therapy in conjunction with a penicillin-type or cephalosporin-type drug before obtaining results of susceptibility testing. If anaerobic organisms are suspected as etiologic agents, consideration should be given to using other suitable antimicrobial therapy in conjunction with gentamicin. Following identification of the organism and its susceptibility, appropriate antibiotic therapy should then be continued. Gentamicin sulfate has been used effectively in combination with carbenicillin for the treatment of life-threatening infections caused by Pseudomonas aeruginosa . It has also been found effective when used in conjunction with a penicillin-type drug for the treatment of endocarditis caused by group D streptococci. Gentamicin Sulfate Injection, USP has also been shown to be effective in the treatment of serious staphylococcal infections. While not the antibiotic of first choice, gentamicin may be considered when penicillins or other less potentially toxic drugs are contraindicated and bacterial susceptibility tests and clinical judgment indicate its use. It may also be considered in mixed infections caused by susceptible strains of staphylococci and gram-negative organisms. In the neonate with suspected bacterial sepsis or staphylococcal pneumonia, a penicillin-type drug is also usually indicated as concomitant therapy with gentamicin. uuid:bdfbb8f4-45a8-4ae2-ad1d-d38b919a6554 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats UMLS:C0149778 PMID:41385096 "[{""id"":""uuid:14a29090-4962-42fb-bca9-8b9ed205a266"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9973f7a5-b9fc-439c-86c6-51c8e3be87dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin and other antibacterial drugs, gentamicin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Sulfate Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa , Proteus species (indole-positive and indole-negative), Escherichia coli , Klebsiella-Enterobacter-Serratia species, Citrobacter species, and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown Gentamicin Sulfate Injection, USP to be effective in bacterial neonatal sepsis; bacterial septicemia; and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin sulfate may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection, and the important additional concepts contained in the WARNINGS box. If the causative organisms are resistant to gentamicin, other appropriate therapy should be instituted. In serious infections when the causative organisms are unknown, gentamicin sulfate may be administered as initial therapy in conjunction with a penicillin-type or cephalosporin-type drug before obtaining results of susceptibility testing. If anaerobic organisms are suspected as etiologic agents, consideration should be given to using other suitable antimicrobial therapy in conjunction with gentamicin. Following identification of the organism and its susceptibility, appropriate antibiotic therapy should then be continued. Gentamicin sulfate has been used effectively in combination with carbenicillin for the treatment of life-threatening infections caused by Pseudomonas aeruginosa . It has also been found effective when used in conjunction with a penicillin-type drug for the treatment of endocarditis caused by group D streptococci. Gentamicin Sulfate Injection, USP has also been shown to be effective in the treatment of serious staphylococcal infections. While not the antibiotic of first choice, gentamicin may be considered when penicillins or other less potentially toxic drugs are contraindicated and bacterial susceptibility tests and clinical judgment indicate its use. It may also be considered in mixed infections caused by susceptible strains of staphylococci and gram-negative organisms. In the neonate with suspected bacterial sepsis or staphylococcal pneumonia, a penicillin-type drug is also usually indicated as concomitant therapy with gentamicin. uuid:cb489768-59a8-4c62-b35a-a34392e4eb85 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0005025 PMID:41385096 "[{""id"":""uuid:962d4d8a-7b67-4790-944c-c61cfd4d1f4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ee9bb625-980f-439c-a2ee-2e1ab28d5ba1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin and other antibacterial drugs, gentamicin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Sulfate Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa , Proteus species (indole-positive and indole-negative), Escherichia coli , Klebsiella-Enterobacter-Serratia species, Citrobacter species, and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown Gentamicin Sulfate Injection, USP to be effective in bacterial neonatal sepsis; bacterial septicemia; and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin sulfate may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection, and the important additional concepts contained in the WARNINGS box. If the causative organisms are resistant to gentamicin, other appropriate therapy should be instituted. In serious infections when the causative organisms are unknown, gentamicin sulfate may be administered as initial therapy in conjunction with a penicillin-type or cephalosporin-type drug before obtaining results of susceptibility testing. If anaerobic organisms are suspected as etiologic agents, consideration should be given to using other suitable antimicrobial therapy in conjunction with gentamicin. Following identification of the organism and its susceptibility, appropriate antibiotic therapy should then be continued. Gentamicin sulfate has been used effectively in combination with carbenicillin for the treatment of life-threatening infections caused by Pseudomonas aeruginosa . It has also been found effective when used in conjunction with a penicillin-type drug for the treatment of endocarditis caused by group D streptococci. Gentamicin Sulfate Injection, USP has also been shown to be effective in the treatment of serious staphylococcal infections. While not the antibiotic of first choice, gentamicin may be considered when penicillins or other less potentially toxic drugs are contraindicated and bacterial susceptibility tests and clinical judgment indicate its use. It may also be considered in mixed infections caused by susceptible strains of staphylococci and gram-negative organisms. In the neonate with suspected bacterial sepsis or staphylococcal pneumonia, a penicillin-type drug is also usually indicated as concomitant therapy with gentamicin. uuid:59114286-0593-42d6-b880-001a95ed783d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0005970 PMID:41385096 "[{""id"":""uuid:71405d37-bc09-4923-9b98-bdec997c8840"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:974d0ee7-e1a9-414f-aae2-2dff9eb14494"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin and other antibacterial drugs, gentamicin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Sulfate Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa , Proteus species (indole-positive and indole-negative), Escherichia coli , Klebsiella-Enterobacter-Serratia species, Citrobacter species, and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown Gentamicin Sulfate Injection, USP to be effective in bacterial neonatal sepsis; bacterial septicemia; and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin sulfate may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection, and the important additional concepts contained in the WARNINGS box. If the causative organisms are resistant to gentamicin, other appropriate therapy should be instituted. In serious infections when the causative organisms are unknown, gentamicin sulfate may be administered as initial therapy in conjunction with a penicillin-type or cephalosporin-type drug before obtaining results of susceptibility testing. If anaerobic organisms are suspected as etiologic agents, consideration should be given to using other suitable antimicrobial therapy in conjunction with gentamicin. Following identification of the organism and its susceptibility, appropriate antibiotic therapy should then be continued. Gentamicin sulfate has been used effectively in combination with carbenicillin for the treatment of life-threatening infections caused by Pseudomonas aeruginosa . It has also been found effective when used in conjunction with a penicillin-type drug for the treatment of endocarditis caused by group D streptococci. Gentamicin Sulfate Injection, USP has also been shown to be effective in the treatment of serious staphylococcal infections. While not the antibiotic of first choice, gentamicin may be considered when penicillins or other less potentially toxic drugs are contraindicated and bacterial susceptibility tests and clinical judgment indicate its use. It may also be considered in mixed infections caused by susceptible strains of staphylococci and gram-negative organisms. In the neonate with suspected bacterial sepsis or staphylococcal pneumonia, a penicillin-type drug is also usually indicated as concomitant therapy with gentamicin. uuid:75b28a00-36bf-454c-8712-350627d155c8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8093 biolink:treats MONDO:0001881 PMID:41385096 "[{""id"":""uuid:c45c2e15-dd1b-4da4-90e9-61ca1691e4c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ccd431e7-7c87-4acd-9bac-f5df25ced850"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Phenylephrine hydrochloride injection is an alpha-1 adrenergic receptor agonist indicated for increasing blood pressure in adults with clinically important hypotension resulting primarily from vasodilation, in such settings as septic shock or anesthesia. uuid:30ac9ae8-e219-4ebe-8ed6-5ccb9cefcbe2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:163203584 biolink:treats MONDO:0018754 PMID:41385096 "[{""id"":""uuid:9c92803f-d3c1-4d6e-ad84-a921eeaeaa6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c92f18d5-85d4-4f2b-897a-1b8d52f104f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CYANOKIT is indicated for the treatment of known or suspected cyanide poisoning. uuid:3216ec3e-4dad-4aa8-ac6a-53699a08a9b9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:6473866 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:fb484399-73e8-41b5-9b88-30e256890c66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:001c3bb1-081e-4030-9e6d-83c0a0977f93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tacrolimus Ointment, both 0.03% and 0.1% for adults, and only 0.03% for children aged 2 to 15 years, is indicated as second-line therapy for the short-term and non-continuous chronic treatment of moderate to severe atopic dermatitis in non-immunocompromised adults and children who have failed to respond adequately to other topical prescription treatments for atopic dermatitis, or when those treatments are not advisable. Tacrolimus Ointment is not indicated for children younger than 2 years of age (see boxed WARNING , WARNINGS and PRECAUTIONS: Pediatric Use ). uuid:512ada6a-a885-47b6-9a53-6664ea1d8755 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5147 biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:9ae556e8-1936-4abf-b526-57a49eb3205f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1967f419-f710-4cd0-8aa8-37cac68facf7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PERFOROMIST Inhalation Solution is a long-acting beta 2 -adrenergic agonist (beta 2 -agonist) indicated for: • Long-term, twice daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. ( 1.1 ) Important limitations of use: • PERFOROMIST Inhalation Solution is not indicated to treat acute deteriorations of chronic obstructive pulmonary disease. ( 1.2 , 5.2 ) • PERFOROMIST Inhalation Solution is not indicated to treat asthma. ( 1.2 ) uuid:c79b03dc-362b-4e15-86c0-9f808ed332c0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5147 biolink:treats MONDO:0005607 PMID:41385096 "[{""id"":""uuid:a00bf0c3-055d-4f30-9e66-26d82b01f7a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:56932c20-3b44-4400-a105-cfa273b02a36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:30a5c07e-5a6c-4bed-a334-a42133e1f47b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PERFOROMIST Inhalation Solution is a long-acting beta 2 -adrenergic agonist (beta 2 -agonist) indicated for: • Long-term, twice daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. ( 1.1 ) Important limitations of use: • PERFOROMIST Inhalation Solution is not indicated to treat acute deteriorations of chronic obstructive pulmonary disease. ( 1.2 , 5.2 ) • PERFOROMIST Inhalation Solution is not indicated to treat asthma. ( 1.2 )|[PMDA] Drugs with a new indication and a new dosage for the alleviation of various symptoms due to airway obstructive impairment in chronic obstructive pulmonary diseases (chronic bronchitis and emphysema). uuid:c908ce63-6608-4a9f-ad16-c334af44858d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5147 biolink:treats MONDO:0004849 PMID:41385096 "[{""id"":""uuid:f7e147da-04ee-4783-b8fd-61627fc6b095"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2e75ed0d-06be-4b4e-b5b0-ce94dd04b02c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0baf8a0f-d189-4c5d-80ab-982e72e5a815"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PERFOROMIST Inhalation Solution is a long-acting beta 2 -adrenergic agonist (beta 2 -agonist) indicated for: • Long-term, twice daily (morning and evening) administration in the maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. ( 1.1 ) Important limitations of use: • PERFOROMIST Inhalation Solution is not indicated to treat acute deteriorations of chronic obstructive pulmonary disease. ( 1.2 , 5.2 ) • PERFOROMIST Inhalation Solution is not indicated to treat asthma. ( 1.2 )|[PMDA] Drugs with a new indication and a new dosage for the alleviation of various symptoms due to airway obstructive impairment in chronic obstructive pulmonary diseases (chronic bronchitis and emphysema). uuid:535a9d96-911f-4b8c-a787-8f3edb738c70 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats UMLS:C0278714 PMID:41385096 "[{""id"":""uuid:8ddb9e3d-77ca-4f84-927b-fa44cb7bd0c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6e9c2b36-6c37-4e12-955f-54f82c532a64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxorubicin Hydrochloride Injection is an anthracycline topoisomerase inhibitor indicated: • as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer ( 1.1 ). • for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms' tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma ( 1.2 ). uuid:9cb2851e-e01d-4a99-9d99-4f7112f7a418 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats UMLS:C4722306 PMID:41385096 "[{""id"":""uuid:63bbaf71-16d5-4c22-a517-27934821a258"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5ea42a28-a9db-40e5-abe1-b9a0fedc8a85"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxorubicin Hydrochloride Injection is an anthracycline topoisomerase inhibitor indicated: • as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer ( 1.1 ). • for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms' tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma ( 1.2 ). uuid:0fd543c2-d70a-4931-afb6-631509e9e253 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats UMLS:C4724394 PMID:41385096 "[{""id"":""uuid:20569562-cba5-493d-9f3e-34ee23985e8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:07aac17b-241f-4277-9072-94508466d270"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxorubicin Hydrochloride Injection is an anthracycline topoisomerase inhibitor indicated: • as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer ( 1.1 ). • for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms' tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma ( 1.2 ). uuid:f55a641f-fdc0-4724-aad8-99fc5a74fcce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats UMLS:C0278688 PMID:41385096 "[{""id"":""uuid:8acd3bba-b38a-41f5-9e29-dd7398b2a6d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9067c246-973d-4f33-a1e9-9b96cb2aaa17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxorubicin Hydrochloride Injection is an anthracycline topoisomerase inhibitor indicated: • as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer ( 1.1 ). • for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms' tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma ( 1.2 ). uuid:84e6fb59-9169-46e5-9381-c8840a1c2318 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats UMLS:C4727169 PMID:41385096 "[{""id"":""uuid:0f061cbd-de0c-4b3a-a28b-505897b6da79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cf8dc901-df2a-479c-93ea-b2e221b8e1b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxorubicin Hydrochloride Injection is an anthracycline topoisomerase inhibitor indicated: • as a component of multiagent adjuvant chemotherapy for treatment of women with axillary lymph node involvement following resection of primary breast cancer ( 1.1 ). • for the treatment of: acute lymphoblastic leukemia, acute myeloblastic leukemia, Hodgkin lymphoma, Non-Hodgkin lymphoma, metastatic breast cancer, metastatic Wilms' tumor, metastatic neuroblastoma, metastatic soft tissue sarcoma, metastatic bone sarcomas, metastatic ovarian carcinoma, metastatic transitional cell bladder carcinoma, metastatic thyroid carcinoma, metastatic gastric carcinoma, metastatic bronchogenic carcinoma ( 1.2 ). uuid:ce9167ea-257d-48d7-a692-570efc6f1969 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4027 biolink:treats MONDO:0005059 PMID:41385096 "[{""id"":""uuid:73a29fec-a97e-4694-bfbc-add01bb4dd90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:97766f46-08dd-42d4-bb0e-96eeea7cdd73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclophosphamide is an alkylating drug indicated for treatment of: Malignant Diseases: malignant lymphomas: Hodgkin's disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt's lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma. ( 1.1 ) uuid:dfb59a7e-769c-4e55-9a7f-0e32f179c154 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:17276 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:ce7d9050-f52d-4b5a-b3d4-b4b3ac881f66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2389e341-7847-4f86-b5da-bac074ad94da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone, an ingredient of spironolactone and hydrochlorothiazide tablets, has been shown to be a tumorigen in chronic toxicity studies in rats (see PRECAUTIONS section). Spironolactone and hydrochlorothiazide tablets should be used only in those conditions described below. Unnecessary use of this drug should be avoided. Spironolactone and hydrochlorothiazide tablets are indicated for: Edematous conditions for patients with: Congestive heart failure: • For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures; • The treatment of diuretic-induced hypokalemia in patients with congestive heart failure when other measures are considered inappropriate; • The treatment of patients with congestive heart failure taking digitalis when other therapies are considered inadequate or inappropriate. Cirrhosis of the liver accompanied by edema and/or ascites: • Aldosterone levels may be exceptionally high in this condition. Spironolactone and hydrochlorothiazide tablets are indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. The nephrotic syndrome: • For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response. Essential hypertension: • For patients with essential hypertension in whom other measures are considered inadequate or inappropriate; • In hypertensive patients for the treatment of a diuretic-induced hypokalemia when other measures are considered inappropriate; • Spironolactone and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the classes to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with spironolactone and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. uuid:8516ce44-c1e6-4dde-b0cb-939a77c7430d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:17276 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:04b16165-c845-4b8c-9258-0f89b49e5e9a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0800b566-22ce-44df-9e30-4581b7a42f0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone, an ingredient of spironolactone and hydrochlorothiazide tablets, has been shown to be a tumorigen in chronic toxicity studies in rats (see PRECAUTIONS section). Spironolactone and hydrochlorothiazide tablets should be used only in those conditions described below. Unnecessary use of this drug should be avoided. Spironolactone and hydrochlorothiazide tablets are indicated for: Edematous conditions for patients with: Congestive heart failure: • For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures; • The treatment of diuretic-induced hypokalemia in patients with congestive heart failure when other measures are considered inappropriate; • The treatment of patients with congestive heart failure taking digitalis when other therapies are considered inadequate or inappropriate. Cirrhosis of the liver accompanied by edema and/or ascites: • Aldosterone levels may be exceptionally high in this condition. Spironolactone and hydrochlorothiazide tablets are indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. The nephrotic syndrome: • For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response. Essential hypertension: • For patients with essential hypertension in whom other measures are considered inadequate or inappropriate; • In hypertensive patients for the treatment of a diuretic-induced hypokalemia when other measures are considered inappropriate; • Spironolactone and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the classes to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with spironolactone and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. uuid:3e3656c9-baac-4a58-81c4-d9763fbf21cf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:17276 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:e5afcacb-3095-4000-8a8b-bccd4554d7ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:48613300-1796-4222-bba2-16c32d99b8ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone, an ingredient of spironolactone and hydrochlorothiazide tablets, has been shown to be a tumorigen in chronic toxicity studies in rats (see PRECAUTIONS section). Spironolactone and hydrochlorothiazide tablets should be used only in those conditions described below. Unnecessary use of this drug should be avoided. Spironolactone and hydrochlorothiazide tablets are indicated for: Edematous conditions for patients with: Congestive heart failure: • For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures; • The treatment of diuretic-induced hypokalemia in patients with congestive heart failure when other measures are considered inappropriate; • The treatment of patients with congestive heart failure taking digitalis when other therapies are considered inadequate or inappropriate. Cirrhosis of the liver accompanied by edema and/or ascites: • Aldosterone levels may be exceptionally high in this condition. Spironolactone and hydrochlorothiazide tablets are indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. The nephrotic syndrome: • For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response. Essential hypertension: • For patients with essential hypertension in whom other measures are considered inadequate or inappropriate; • In hypertensive patients for the treatment of a diuretic-induced hypokalemia when other measures are considered inappropriate; • Spironolactone and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the classes to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with spironolactone and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. uuid:92bde709-0f41-4136-9a7c-410fa6611fa9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:17276 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:499a83e7-8156-473c-9c27-642df1c048d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2ec9ffbf-068e-4123-b665-503bf9ae545a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone, an ingredient of spironolactone and hydrochlorothiazide tablets, has been shown to be a tumorigen in chronic toxicity studies in rats (see PRECAUTIONS section). Spironolactone and hydrochlorothiazide tablets should be used only in those conditions described below. Unnecessary use of this drug should be avoided. Spironolactone and hydrochlorothiazide tablets are indicated for: Edematous conditions for patients with: Congestive heart failure: • For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures; • The treatment of diuretic-induced hypokalemia in patients with congestive heart failure when other measures are considered inappropriate; • The treatment of patients with congestive heart failure taking digitalis when other therapies are considered inadequate or inappropriate. Cirrhosis of the liver accompanied by edema and/or ascites: • Aldosterone levels may be exceptionally high in this condition. Spironolactone and hydrochlorothiazide tablets are indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. The nephrotic syndrome: • For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response. Essential hypertension: • For patients with essential hypertension in whom other measures are considered inadequate or inappropriate; • In hypertensive patients for the treatment of a diuretic-induced hypokalemia when other measures are considered inappropriate; • Spironolactone and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the classes to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with spironolactone and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. uuid:e8416c70-a9b9-4082-8d09-1970cf6a6ea5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:17276 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:31e1a36b-8671-4eff-bbd5-37856631b7bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:868b6a45-46f2-431e-aab3-e7c1140b265b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone, an ingredient of spironolactone and hydrochlorothiazide tablets, has been shown to be a tumorigen in chronic toxicity studies in rats (see PRECAUTIONS section). Spironolactone and hydrochlorothiazide tablets should be used only in those conditions described below. Unnecessary use of this drug should be avoided. Spironolactone and hydrochlorothiazide tablets are indicated for: Edematous conditions for patients with: Congestive heart failure: • For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures; • The treatment of diuretic-induced hypokalemia in patients with congestive heart failure when other measures are considered inappropriate; • The treatment of patients with congestive heart failure taking digitalis when other therapies are considered inadequate or inappropriate. Cirrhosis of the liver accompanied by edema and/or ascites: • Aldosterone levels may be exceptionally high in this condition. Spironolactone and hydrochlorothiazide tablets are indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. The nephrotic syndrome: • For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response. Essential hypertension: • For patients with essential hypertension in whom other measures are considered inadequate or inappropriate; • In hypertensive patients for the treatment of a diuretic-induced hypokalemia when other measures are considered inappropriate; • Spironolactone and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the classes to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with spironolactone and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. uuid:498b7abe-1fac-4c2c-b06c-252fc6540011 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:17276 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:3a4ee5d1-0a5d-4536-864f-081cd3c8df4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:80eeaece-1b04-43d6-a46d-70174b42304c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone, an ingredient of spironolactone and hydrochlorothiazide tablets, has been shown to be a tumorigen in chronic toxicity studies in rats (see PRECAUTIONS section). Spironolactone and hydrochlorothiazide tablets should be used only in those conditions described below. Unnecessary use of this drug should be avoided. Spironolactone and hydrochlorothiazide tablets are indicated for: Edematous conditions for patients with: Congestive heart failure: • For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures; • The treatment of diuretic-induced hypokalemia in patients with congestive heart failure when other measures are considered inappropriate; • The treatment of patients with congestive heart failure taking digitalis when other therapies are considered inadequate or inappropriate. Cirrhosis of the liver accompanied by edema and/or ascites: • Aldosterone levels may be exceptionally high in this condition. Spironolactone and hydrochlorothiazide tablets are indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. The nephrotic syndrome: • For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response. Essential hypertension: • For patients with essential hypertension in whom other measures are considered inadequate or inappropriate; • In hypertensive patients for the treatment of a diuretic-induced hypokalemia when other measures are considered inappropriate; • Spironolactone and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the classes to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with spironolactone and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. uuid:b88c3ada-06dc-4d76-8920-5b7834714586 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:17276 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:f8cb2e93-bc57-4cf7-8346-a5531bfcaadd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cb807597-82f5-460a-a84e-835e476a67cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone, an ingredient of spironolactone and hydrochlorothiazide tablets, has been shown to be a tumorigen in chronic toxicity studies in rats (see PRECAUTIONS section). Spironolactone and hydrochlorothiazide tablets should be used only in those conditions described below. Unnecessary use of this drug should be avoided. Spironolactone and hydrochlorothiazide tablets are indicated for: Edematous conditions for patients with: Congestive heart failure: • For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures; • The treatment of diuretic-induced hypokalemia in patients with congestive heart failure when other measures are considered inappropriate; • The treatment of patients with congestive heart failure taking digitalis when other therapies are considered inadequate or inappropriate. Cirrhosis of the liver accompanied by edema and/or ascites: • Aldosterone levels may be exceptionally high in this condition. Spironolactone and hydrochlorothiazide tablets are indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. The nephrotic syndrome: • For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response. Essential hypertension: • For patients with essential hypertension in whom other measures are considered inadequate or inappropriate; • In hypertensive patients for the treatment of a diuretic-induced hypokalemia when other measures are considered inappropriate; • Spironolactone and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the classes to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with spironolactone and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. uuid:666e9e43-8d93-4fb6-8250-42f60408987a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:17276 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:3ba34f40-41c7-4df6-9d81-3f0380bebd9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5d42cf78-fb39-496b-8937-379fe3b28bd4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone, an ingredient of spironolactone and hydrochlorothiazide tablets, has been shown to be a tumorigen in chronic toxicity studies in rats (see PRECAUTIONS section). Spironolactone and hydrochlorothiazide tablets should be used only in those conditions described below. Unnecessary use of this drug should be avoided. Spironolactone and hydrochlorothiazide tablets are indicated for: Edematous conditions for patients with: Congestive heart failure: • For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures; • The treatment of diuretic-induced hypokalemia in patients with congestive heart failure when other measures are considered inappropriate; • The treatment of patients with congestive heart failure taking digitalis when other therapies are considered inadequate or inappropriate. Cirrhosis of the liver accompanied by edema and/or ascites: • Aldosterone levels may be exceptionally high in this condition. Spironolactone and hydrochlorothiazide tablets are indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. The nephrotic syndrome: • For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response. Essential hypertension: • For patients with essential hypertension in whom other measures are considered inadequate or inappropriate; • In hypertensive patients for the treatment of a diuretic-induced hypokalemia when other measures are considered inappropriate; • Spironolactone and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the classes to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with spironolactone and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. uuid:f2c408a9-832d-4ea5-8c38-7ad464d411cf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31711 biolink:treats MONDO:0021042 PMID:41385096 "[{""id"":""uuid:642845e6-5a5d-4b53-8381-dee258c720e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8a379418-12b1-4592-a772-9bb43601e657"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ISOVUE (Iopamidol Injection) is indicated for angiography throughout the cardiovascular system in adults, including cerebral and peripheral arteriography, coronary arteriography and ventriculography, selective visceral arteriography and aortography, peripheral venography (phlebography), and in pediatric patients for angiocardiography; or for intravenous use in adult and pediatric for computed tomographic (CT) imaging of the head and body (see below). CT Head Imaging ISOVUE may be used to refine diagnostic precision in areas of the brain which may not otherwise have been satisfactorily visualized. Tumors ISOVUE may be useful to investigate the presence and extent of certain malignancies such as: gliomas including malignant gliomas, glioblastomas, astrocytomas, oligodendrogliomas and gangliomas, ependymomas, medulloblastomas, meningiomas, neuromas, pinealomas, pituitary adenomas, craniopharyngiomas, germinomas, and metastatic lesions. The usefulness of contrast enhancement for the investigation of the retrobulbar space and in cases of low grade or infiltrative glioma has not been demonstrated. In calcified lesions, there is less likelihood of enhancement. Following therapy, tumors may show decreased or no enhancement. The opacification of the inferior vermis following contrast media administration has resulted in false-positive diagnosis in a number of otherwise normal studies. Nonneoplastic Conditions ISOVUE may be beneficial in the image enhancement of nonneoplastic lesions. Cerebral infarctions of recent onset may be better visualized with contrast enhancement, while some infarctions are obscured if contrast media are used. The use of iodinated contrast media results in contrast enhancement in about 60 percent of cerebral infarctions studied from one to four weeks from the onset of symptoms. Sites of active infection may also be enhanced following contrast media administration. Arteriovenous malformations and aneurysms will show contrast enhancement. For these vascular lesions, the enhancement is probably dependent on the iodine content of the circulating blood pool. Hematomas and intraparenchymal bleeders seldom demonstrate any contrast enhancement. However, in cases of intraparenchymal clot, for which there is no obvious clinical explanation, contrast media administration may be helpful in ruling out the possibility of associated arteriovenous malformation. CT Body Imaging ISOVUE (Iopamidol Injection) may be used for enhancement of computed tomographic images for detection and evaluation of lesions in the liver, pancreas, kidneys, aorta, mediastinum, abdominal cavity, pelvis and retroperitoneal space. Enhancement of computed tomography with ISOVUE may be of benefit in establishing diagnoses of certain lesions in these sites with greater assurance than is possible with CT alone, and in supplying additional features of the lesions (e.g., hepatic abscess delineation prior to percutaneous drainage). In other cases, the contrast agent may allow visualization of lesions not seen with CT alone (e.g. tumor extension), or may help to define suspicious lesions seen with unenhanced CT (e.g., pancreatic cyst). Contrast enhancement appears to be greatest within 60 to 90 seconds after bolus administration of contrast agent. Therefore, utilization of a continuous scanning technique (“dynamic CT scanning”) may improve enhancement and diagnostic assessment of tumor and other lesions such as an abscess, occasionally revealing unsuspected or more extensive disease. For example, a cyst may be distinguished from a vascularized solid lesion when precontrast and enhanced scans are compared; the nonperfused mass shows unchanged x-ray absorption (CT number). A vascularized lesion is characterized by an increase in CT number in the few minutes after a bolus of intravascular contrast agent; it may be malignant, benign, or normal tissue, but would probably not be a cyst, hematoma, or other nonvascular lesion. Because unenhanced scanning may provide adequate diagnostic information in the individual patient, the decision to employ contrast enhancement, which may be associated with risk and increased radiation exposure, should be based upon a careful evaluation of clinical, other radiological, and unenhanced CT findings. uuid:87ad42cd-8215-48f7-92de-95455c287cb5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31711 biolink:treats MONDO:0100342 PMID:41385096 "[{""id"":""uuid:c9bba1b3-73a1-45f0-af96-d8709e6baf5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:27e73220-b593-4cd4-8351-a44558515a1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ISOVUE (Iopamidol Injection) is indicated for angiography throughout the cardiovascular system in adults, including cerebral and peripheral arteriography, coronary arteriography and ventriculography, selective visceral arteriography and aortography, peripheral venography (phlebography), and in pediatric patients for angiocardiography; or for intravenous use in adult and pediatric for computed tomographic (CT) imaging of the head and body (see below). CT Head Imaging ISOVUE may be used to refine diagnostic precision in areas of the brain which may not otherwise have been satisfactorily visualized. Tumors ISOVUE may be useful to investigate the presence and extent of certain malignancies such as: gliomas including malignant gliomas, glioblastomas, astrocytomas, oligodendrogliomas and gangliomas, ependymomas, medulloblastomas, meningiomas, neuromas, pinealomas, pituitary adenomas, craniopharyngiomas, germinomas, and metastatic lesions. The usefulness of contrast enhancement for the investigation of the retrobulbar space and in cases of low grade or infiltrative glioma has not been demonstrated. In calcified lesions, there is less likelihood of enhancement. Following therapy, tumors may show decreased or no enhancement. The opacification of the inferior vermis following contrast media administration has resulted in false-positive diagnosis in a number of otherwise normal studies. Nonneoplastic Conditions ISOVUE may be beneficial in the image enhancement of nonneoplastic lesions. Cerebral infarctions of recent onset may be better visualized with contrast enhancement, while some infarctions are obscured if contrast media are used. The use of iodinated contrast media results in contrast enhancement in about 60 percent of cerebral infarctions studied from one to four weeks from the onset of symptoms. Sites of active infection may also be enhanced following contrast media administration. Arteriovenous malformations and aneurysms will show contrast enhancement. For these vascular lesions, the enhancement is probably dependent on the iodine content of the circulating blood pool. Hematomas and intraparenchymal bleeders seldom demonstrate any contrast enhancement. However, in cases of intraparenchymal clot, for which there is no obvious clinical explanation, contrast media administration may be helpful in ruling out the possibility of associated arteriovenous malformation. CT Body Imaging ISOVUE (Iopamidol Injection) may be used for enhancement of computed tomographic images for detection and evaluation of lesions in the liver, pancreas, kidneys, aorta, mediastinum, abdominal cavity, pelvis and retroperitoneal space. Enhancement of computed tomography with ISOVUE may be of benefit in establishing diagnoses of certain lesions in these sites with greater assurance than is possible with CT alone, and in supplying additional features of the lesions (e.g., hepatic abscess delineation prior to percutaneous drainage). In other cases, the contrast agent may allow visualization of lesions not seen with CT alone (e.g. tumor extension), or may help to define suspicious lesions seen with unenhanced CT (e.g., pancreatic cyst). Contrast enhancement appears to be greatest within 60 to 90 seconds after bolus administration of contrast agent. Therefore, utilization of a continuous scanning technique (“dynamic CT scanning”) may improve enhancement and diagnostic assessment of tumor and other lesions such as an abscess, occasionally revealing unsuspected or more extensive disease. For example, a cyst may be distinguished from a vascularized solid lesion when precontrast and enhanced scans are compared; the nonperfused mass shows unchanged x-ray absorption (CT number). A vascularized lesion is characterized by an increase in CT number in the few minutes after a bolus of intravascular contrast agent; it may be malignant, benign, or normal tissue, but would probably not be a cyst, hematoma, or other nonvascular lesion. Because unenhanced scanning may provide adequate diagnostic information in the individual patient, the decision to employ contrast enhancement, which may be associated with risk and increased radiation exposure, should be based upon a careful evaluation of clinical, other radiological, and unenhanced CT findings. uuid:56beb456-5cf2-4f22-848f-530b43992211 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31711 biolink:treats MONDO:0016682 PMID:41385096 "[{""id"":""uuid:eee17c71-b263-4f8b-99f3-4bb5a93b479e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:213fcf33-2bb8-424f-8f05-f5d2acc048d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ISOVUE (Iopamidol Injection) is indicated for angiography throughout the cardiovascular system in adults, including cerebral and peripheral arteriography, coronary arteriography and ventriculography, selective visceral arteriography and aortography, peripheral venography (phlebography), and in pediatric patients for angiocardiography; or for intravenous use in adult and pediatric for computed tomographic (CT) imaging of the head and body (see below). CT Head Imaging ISOVUE may be used to refine diagnostic precision in areas of the brain which may not otherwise have been satisfactorily visualized. Tumors ISOVUE may be useful to investigate the presence and extent of certain malignancies such as: gliomas including malignant gliomas, glioblastomas, astrocytomas, oligodendrogliomas and gangliomas, ependymomas, medulloblastomas, meningiomas, neuromas, pinealomas, pituitary adenomas, craniopharyngiomas, germinomas, and metastatic lesions. The usefulness of contrast enhancement for the investigation of the retrobulbar space and in cases of low grade or infiltrative glioma has not been demonstrated. In calcified lesions, there is less likelihood of enhancement. Following therapy, tumors may show decreased or no enhancement. The opacification of the inferior vermis following contrast media administration has resulted in false-positive diagnosis in a number of otherwise normal studies. Nonneoplastic Conditions ISOVUE may be beneficial in the image enhancement of nonneoplastic lesions. Cerebral infarctions of recent onset may be better visualized with contrast enhancement, while some infarctions are obscured if contrast media are used. The use of iodinated contrast media results in contrast enhancement in about 60 percent of cerebral infarctions studied from one to four weeks from the onset of symptoms. Sites of active infection may also be enhanced following contrast media administration. Arteriovenous malformations and aneurysms will show contrast enhancement. For these vascular lesions, the enhancement is probably dependent on the iodine content of the circulating blood pool. Hematomas and intraparenchymal bleeders seldom demonstrate any contrast enhancement. However, in cases of intraparenchymal clot, for which there is no obvious clinical explanation, contrast media administration may be helpful in ruling out the possibility of associated arteriovenous malformation. CT Body Imaging ISOVUE (Iopamidol Injection) may be used for enhancement of computed tomographic images for detection and evaluation of lesions in the liver, pancreas, kidneys, aorta, mediastinum, abdominal cavity, pelvis and retroperitoneal space. Enhancement of computed tomography with ISOVUE may be of benefit in establishing diagnoses of certain lesions in these sites with greater assurance than is possible with CT alone, and in supplying additional features of the lesions (e.g., hepatic abscess delineation prior to percutaneous drainage). In other cases, the contrast agent may allow visualization of lesions not seen with CT alone (e.g. tumor extension), or may help to define suspicious lesions seen with unenhanced CT (e.g., pancreatic cyst). Contrast enhancement appears to be greatest within 60 to 90 seconds after bolus administration of contrast agent. Therefore, utilization of a continuous scanning technique (“dynamic CT scanning”) may improve enhancement and diagnostic assessment of tumor and other lesions such as an abscess, occasionally revealing unsuspected or more extensive disease. For example, a cyst may be distinguished from a vascularized solid lesion when precontrast and enhanced scans are compared; the nonperfused mass shows unchanged x-ray absorption (CT number). A vascularized lesion is characterized by an increase in CT number in the few minutes after a bolus of intravascular contrast agent; it may be malignant, benign, or normal tissue, but would probably not be a cyst, hematoma, or other nonvascular lesion. Because unenhanced scanning may provide adequate diagnostic information in the individual patient, the decision to employ contrast enhancement, which may be associated with risk and increased radiation exposure, should be based upon a careful evaluation of clinical, other radiological, and unenhanced CT findings. uuid:fc200150-8258-442d-a4f6-88d1e74016cf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31711 biolink:treats MONDO:0003169 PMID:41385096 "[{""id"":""uuid:7525823c-c6f3-4704-b06d-bcab3391f646"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:25231e18-1b9a-4653-a35d-e5b824dbfc27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ISOVUE (Iopamidol Injection) is indicated for angiography throughout the cardiovascular system in adults, including cerebral and peripheral arteriography, coronary arteriography and ventriculography, selective visceral arteriography and aortography, peripheral venography (phlebography), and in pediatric patients for angiocardiography; or for intravenous use in adult and pediatric for computed tomographic (CT) imaging of the head and body (see below). CT Head Imaging ISOVUE may be used to refine diagnostic precision in areas of the brain which may not otherwise have been satisfactorily visualized. Tumors ISOVUE may be useful to investigate the presence and extent of certain malignancies such as: gliomas including malignant gliomas, glioblastomas, astrocytomas, oligodendrogliomas and gangliomas, ependymomas, medulloblastomas, meningiomas, neuromas, pinealomas, pituitary adenomas, craniopharyngiomas, germinomas, and metastatic lesions. The usefulness of contrast enhancement for the investigation of the retrobulbar space and in cases of low grade or infiltrative glioma has not been demonstrated. In calcified lesions, there is less likelihood of enhancement. Following therapy, tumors may show decreased or no enhancement. The opacification of the inferior vermis following contrast media administration has resulted in false-positive diagnosis in a number of otherwise normal studies. Nonneoplastic Conditions ISOVUE may be beneficial in the image enhancement of nonneoplastic lesions. Cerebral infarctions of recent onset may be better visualized with contrast enhancement, while some infarctions are obscured if contrast media are used. The use of iodinated contrast media results in contrast enhancement in about 60 percent of cerebral infarctions studied from one to four weeks from the onset of symptoms. Sites of active infection may also be enhanced following contrast media administration. Arteriovenous malformations and aneurysms will show contrast enhancement. For these vascular lesions, the enhancement is probably dependent on the iodine content of the circulating blood pool. Hematomas and intraparenchymal bleeders seldom demonstrate any contrast enhancement. However, in cases of intraparenchymal clot, for which there is no obvious clinical explanation, contrast media administration may be helpful in ruling out the possibility of associated arteriovenous malformation. CT Body Imaging ISOVUE (Iopamidol Injection) may be used for enhancement of computed tomographic images for detection and evaluation of lesions in the liver, pancreas, kidneys, aorta, mediastinum, abdominal cavity, pelvis and retroperitoneal space. Enhancement of computed tomography with ISOVUE may be of benefit in establishing diagnoses of certain lesions in these sites with greater assurance than is possible with CT alone, and in supplying additional features of the lesions (e.g., hepatic abscess delineation prior to percutaneous drainage). In other cases, the contrast agent may allow visualization of lesions not seen with CT alone (e.g. tumor extension), or may help to define suspicious lesions seen with unenhanced CT (e.g., pancreatic cyst). Contrast enhancement appears to be greatest within 60 to 90 seconds after bolus administration of contrast agent. Therefore, utilization of a continuous scanning technique (“dynamic CT scanning”) may improve enhancement and diagnostic assessment of tumor and other lesions such as an abscess, occasionally revealing unsuspected or more extensive disease. For example, a cyst may be distinguished from a vascularized solid lesion when precontrast and enhanced scans are compared; the nonperfused mass shows unchanged x-ray absorption (CT number). A vascularized lesion is characterized by an increase in CT number in the few minutes after a bolus of intravascular contrast agent; it may be malignant, benign, or normal tissue, but would probably not be a cyst, hematoma, or other nonvascular lesion. Because unenhanced scanning may provide adequate diagnostic information in the individual patient, the decision to employ contrast enhancement, which may be associated with risk and increased radiation exposure, should be based upon a careful evaluation of clinical, other radiological, and unenhanced CT findings. uuid:6603b96d-2c87-4ba5-a066-19415a91f1b4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31711 biolink:treats MONDO:0016695 PMID:41385096 "[{""id"":""uuid:e9f29aa9-65ac-4500-ab40-1c8bc026e530"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ddcfebf8-3371-4cf6-9c2f-6a31fbde9f0c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ISOVUE (Iopamidol Injection) is indicated for angiography throughout the cardiovascular system in adults, including cerebral and peripheral arteriography, coronary arteriography and ventriculography, selective visceral arteriography and aortography, peripheral venography (phlebography), and in pediatric patients for angiocardiography; or for intravenous use in adult and pediatric for computed tomographic (CT) imaging of the head and body (see below). CT Head Imaging ISOVUE may be used to refine diagnostic precision in areas of the brain which may not otherwise have been satisfactorily visualized. Tumors ISOVUE may be useful to investigate the presence and extent of certain malignancies such as: gliomas including malignant gliomas, glioblastomas, astrocytomas, oligodendrogliomas and gangliomas, ependymomas, medulloblastomas, meningiomas, neuromas, pinealomas, pituitary adenomas, craniopharyngiomas, germinomas, and metastatic lesions. The usefulness of contrast enhancement for the investigation of the retrobulbar space and in cases of low grade or infiltrative glioma has not been demonstrated. In calcified lesions, there is less likelihood of enhancement. Following therapy, tumors may show decreased or no enhancement. The opacification of the inferior vermis following contrast media administration has resulted in false-positive diagnosis in a number of otherwise normal studies. Nonneoplastic Conditions ISOVUE may be beneficial in the image enhancement of nonneoplastic lesions. Cerebral infarctions of recent onset may be better visualized with contrast enhancement, while some infarctions are obscured if contrast media are used. The use of iodinated contrast media results in contrast enhancement in about 60 percent of cerebral infarctions studied from one to four weeks from the onset of symptoms. Sites of active infection may also be enhanced following contrast media administration. Arteriovenous malformations and aneurysms will show contrast enhancement. For these vascular lesions, the enhancement is probably dependent on the iodine content of the circulating blood pool. Hematomas and intraparenchymal bleeders seldom demonstrate any contrast enhancement. However, in cases of intraparenchymal clot, for which there is no obvious clinical explanation, contrast media administration may be helpful in ruling out the possibility of associated arteriovenous malformation. CT Body Imaging ISOVUE (Iopamidol Injection) may be used for enhancement of computed tomographic images for detection and evaluation of lesions in the liver, pancreas, kidneys, aorta, mediastinum, abdominal cavity, pelvis and retroperitoneal space. Enhancement of computed tomography with ISOVUE may be of benefit in establishing diagnoses of certain lesions in these sites with greater assurance than is possible with CT alone, and in supplying additional features of the lesions (e.g., hepatic abscess delineation prior to percutaneous drainage). In other cases, the contrast agent may allow visualization of lesions not seen with CT alone (e.g. tumor extension), or may help to define suspicious lesions seen with unenhanced CT (e.g., pancreatic cyst). Contrast enhancement appears to be greatest within 60 to 90 seconds after bolus administration of contrast agent. Therefore, utilization of a continuous scanning technique (“dynamic CT scanning”) may improve enhancement and diagnostic assessment of tumor and other lesions such as an abscess, occasionally revealing unsuspected or more extensive disease. For example, a cyst may be distinguished from a vascularized solid lesion when precontrast and enhanced scans are compared; the nonperfused mass shows unchanged x-ray absorption (CT number). A vascularized lesion is characterized by an increase in CT number in the few minutes after a bolus of intravascular contrast agent; it may be malignant, benign, or normal tissue, but would probably not be a cyst, hematoma, or other nonvascular lesion. Because unenhanced scanning may provide adequate diagnostic information in the individual patient, the decision to employ contrast enhancement, which may be associated with risk and increased radiation exposure, should be based upon a careful evaluation of clinical, other radiological, and unenhanced CT findings. uuid:1d6b226d-1f69-4b1c-80e6-752831d976f6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31711 biolink:treats MONDO:0016698 PMID:41385096 "[{""id"":""uuid:f50fb72b-6da0-4783-be0d-4932dd3f4b1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:566023a6-d364-4993-80c2-4f107797c9ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ISOVUE (Iopamidol Injection) is indicated for angiography throughout the cardiovascular system in adults, including cerebral and peripheral arteriography, coronary arteriography and ventriculography, selective visceral arteriography and aortography, peripheral venography (phlebography), and in pediatric patients for angiocardiography; or for intravenous use in adult and pediatric for computed tomographic (CT) imaging of the head and body (see below). CT Head Imaging ISOVUE may be used to refine diagnostic precision in areas of the brain which may not otherwise have been satisfactorily visualized. Tumors ISOVUE may be useful to investigate the presence and extent of certain malignancies such as: gliomas including malignant gliomas, glioblastomas, astrocytomas, oligodendrogliomas and gangliomas, ependymomas, medulloblastomas, meningiomas, neuromas, pinealomas, pituitary adenomas, craniopharyngiomas, germinomas, and metastatic lesions. The usefulness of contrast enhancement for the investigation of the retrobulbar space and in cases of low grade or infiltrative glioma has not been demonstrated. In calcified lesions, there is less likelihood of enhancement. Following therapy, tumors may show decreased or no enhancement. The opacification of the inferior vermis following contrast media administration has resulted in false-positive diagnosis in a number of otherwise normal studies. Nonneoplastic Conditions ISOVUE may be beneficial in the image enhancement of nonneoplastic lesions. Cerebral infarctions of recent onset may be better visualized with contrast enhancement, while some infarctions are obscured if contrast media are used. The use of iodinated contrast media results in contrast enhancement in about 60 percent of cerebral infarctions studied from one to four weeks from the onset of symptoms. Sites of active infection may also be enhanced following contrast media administration. Arteriovenous malformations and aneurysms will show contrast enhancement. For these vascular lesions, the enhancement is probably dependent on the iodine content of the circulating blood pool. Hematomas and intraparenchymal bleeders seldom demonstrate any contrast enhancement. However, in cases of intraparenchymal clot, for which there is no obvious clinical explanation, contrast media administration may be helpful in ruling out the possibility of associated arteriovenous malformation. CT Body Imaging ISOVUE (Iopamidol Injection) may be used for enhancement of computed tomographic images for detection and evaluation of lesions in the liver, pancreas, kidneys, aorta, mediastinum, abdominal cavity, pelvis and retroperitoneal space. Enhancement of computed tomography with ISOVUE may be of benefit in establishing diagnoses of certain lesions in these sites with greater assurance than is possible with CT alone, and in supplying additional features of the lesions (e.g., hepatic abscess delineation prior to percutaneous drainage). In other cases, the contrast agent may allow visualization of lesions not seen with CT alone (e.g. tumor extension), or may help to define suspicious lesions seen with unenhanced CT (e.g., pancreatic cyst). Contrast enhancement appears to be greatest within 60 to 90 seconds after bolus administration of contrast agent. Therefore, utilization of a continuous scanning technique (“dynamic CT scanning”) may improve enhancement and diagnostic assessment of tumor and other lesions such as an abscess, occasionally revealing unsuspected or more extensive disease. For example, a cyst may be distinguished from a vascularized solid lesion when precontrast and enhanced scans are compared; the nonperfused mass shows unchanged x-ray absorption (CT number). A vascularized lesion is characterized by an increase in CT number in the few minutes after a bolus of intravascular contrast agent; it may be malignant, benign, or normal tissue, but would probably not be a cyst, hematoma, or other nonvascular lesion. Because unenhanced scanning may provide adequate diagnostic information in the individual patient, the decision to employ contrast enhancement, which may be associated with risk and increased radiation exposure, should be based upon a careful evaluation of clinical, other radiological, and unenhanced CT findings. uuid:05ad3d20-5099-44e1-be1f-b1847c27ed0a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31711 biolink:treats MONDO:0007959 PMID:41385096 "[{""id"":""uuid:07b67af4-b395-4474-8214-8e17203f9c30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7eefc07e-6a9e-42d4-9473-5fef3afa8019"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ISOVUE (Iopamidol Injection) is indicated for angiography throughout the cardiovascular system in adults, including cerebral and peripheral arteriography, coronary arteriography and ventriculography, selective visceral arteriography and aortography, peripheral venography (phlebography), and in pediatric patients for angiocardiography; or for intravenous use in adult and pediatric for computed tomographic (CT) imaging of the head and body (see below). CT Head Imaging ISOVUE may be used to refine diagnostic precision in areas of the brain which may not otherwise have been satisfactorily visualized. Tumors ISOVUE may be useful to investigate the presence and extent of certain malignancies such as: gliomas including malignant gliomas, glioblastomas, astrocytomas, oligodendrogliomas and gangliomas, ependymomas, medulloblastomas, meningiomas, neuromas, pinealomas, pituitary adenomas, craniopharyngiomas, germinomas, and metastatic lesions. The usefulness of contrast enhancement for the investigation of the retrobulbar space and in cases of low grade or infiltrative glioma has not been demonstrated. In calcified lesions, there is less likelihood of enhancement. Following therapy, tumors may show decreased or no enhancement. The opacification of the inferior vermis following contrast media administration has resulted in false-positive diagnosis in a number of otherwise normal studies. Nonneoplastic Conditions ISOVUE may be beneficial in the image enhancement of nonneoplastic lesions. Cerebral infarctions of recent onset may be better visualized with contrast enhancement, while some infarctions are obscured if contrast media are used. The use of iodinated contrast media results in contrast enhancement in about 60 percent of cerebral infarctions studied from one to four weeks from the onset of symptoms. Sites of active infection may also be enhanced following contrast media administration. Arteriovenous malformations and aneurysms will show contrast enhancement. For these vascular lesions, the enhancement is probably dependent on the iodine content of the circulating blood pool. Hematomas and intraparenchymal bleeders seldom demonstrate any contrast enhancement. However, in cases of intraparenchymal clot, for which there is no obvious clinical explanation, contrast media administration may be helpful in ruling out the possibility of associated arteriovenous malformation. CT Body Imaging ISOVUE (Iopamidol Injection) may be used for enhancement of computed tomographic images for detection and evaluation of lesions in the liver, pancreas, kidneys, aorta, mediastinum, abdominal cavity, pelvis and retroperitoneal space. Enhancement of computed tomography with ISOVUE may be of benefit in establishing diagnoses of certain lesions in these sites with greater assurance than is possible with CT alone, and in supplying additional features of the lesions (e.g., hepatic abscess delineation prior to percutaneous drainage). In other cases, the contrast agent may allow visualization of lesions not seen with CT alone (e.g. tumor extension), or may help to define suspicious lesions seen with unenhanced CT (e.g., pancreatic cyst). Contrast enhancement appears to be greatest within 60 to 90 seconds after bolus administration of contrast agent. Therefore, utilization of a continuous scanning technique (“dynamic CT scanning”) may improve enhancement and diagnostic assessment of tumor and other lesions such as an abscess, occasionally revealing unsuspected or more extensive disease. For example, a cyst may be distinguished from a vascularized solid lesion when precontrast and enhanced scans are compared; the nonperfused mass shows unchanged x-ray absorption (CT number). A vascularized lesion is characterized by an increase in CT number in the few minutes after a bolus of intravascular contrast agent; it may be malignant, benign, or normal tissue, but would probably not be a cyst, hematoma, or other nonvascular lesion. Because unenhanced scanning may provide adequate diagnostic information in the individual patient, the decision to employ contrast enhancement, which may be associated with risk and increased radiation exposure, should be based upon a careful evaluation of clinical, other radiological, and unenhanced CT findings. uuid:f968f041-5ba6-44bf-932b-42d453ee7090 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31711 biolink:treats MONDO:0016642 PMID:41385096 "[{""id"":""uuid:9dcee9e4-06ea-40c8-968c-20e54eb54ede"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:05d07eca-b409-4416-8b8a-742100292dac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ISOVUE (Iopamidol Injection) is indicated for angiography throughout the cardiovascular system in adults, including cerebral and peripheral arteriography, coronary arteriography and ventriculography, selective visceral arteriography and aortography, peripheral venography (phlebography), and in pediatric patients for angiocardiography; or for intravenous use in adult and pediatric for computed tomographic (CT) imaging of the head and body (see below). CT Head Imaging ISOVUE may be used to refine diagnostic precision in areas of the brain which may not otherwise have been satisfactorily visualized. Tumors ISOVUE may be useful to investigate the presence and extent of certain malignancies such as: gliomas including malignant gliomas, glioblastomas, astrocytomas, oligodendrogliomas and gangliomas, ependymomas, medulloblastomas, meningiomas, neuromas, pinealomas, pituitary adenomas, craniopharyngiomas, germinomas, and metastatic lesions. The usefulness of contrast enhancement for the investigation of the retrobulbar space and in cases of low grade or infiltrative glioma has not been demonstrated. In calcified lesions, there is less likelihood of enhancement. Following therapy, tumors may show decreased or no enhancement. The opacification of the inferior vermis following contrast media administration has resulted in false-positive diagnosis in a number of otherwise normal studies. Nonneoplastic Conditions ISOVUE may be beneficial in the image enhancement of nonneoplastic lesions. Cerebral infarctions of recent onset may be better visualized with contrast enhancement, while some infarctions are obscured if contrast media are used. The use of iodinated contrast media results in contrast enhancement in about 60 percent of cerebral infarctions studied from one to four weeks from the onset of symptoms. Sites of active infection may also be enhanced following contrast media administration. Arteriovenous malformations and aneurysms will show contrast enhancement. For these vascular lesions, the enhancement is probably dependent on the iodine content of the circulating blood pool. Hematomas and intraparenchymal bleeders seldom demonstrate any contrast enhancement. However, in cases of intraparenchymal clot, for which there is no obvious clinical explanation, contrast media administration may be helpful in ruling out the possibility of associated arteriovenous malformation. CT Body Imaging ISOVUE (Iopamidol Injection) may be used for enhancement of computed tomographic images for detection and evaluation of lesions in the liver, pancreas, kidneys, aorta, mediastinum, abdominal cavity, pelvis and retroperitoneal space. Enhancement of computed tomography with ISOVUE may be of benefit in establishing diagnoses of certain lesions in these sites with greater assurance than is possible with CT alone, and in supplying additional features of the lesions (e.g., hepatic abscess delineation prior to percutaneous drainage). In other cases, the contrast agent may allow visualization of lesions not seen with CT alone (e.g. tumor extension), or may help to define suspicious lesions seen with unenhanced CT (e.g., pancreatic cyst). Contrast enhancement appears to be greatest within 60 to 90 seconds after bolus administration of contrast agent. Therefore, utilization of a continuous scanning technique (“dynamic CT scanning”) may improve enhancement and diagnostic assessment of tumor and other lesions such as an abscess, occasionally revealing unsuspected or more extensive disease. For example, a cyst may be distinguished from a vascularized solid lesion when precontrast and enhanced scans are compared; the nonperfused mass shows unchanged x-ray absorption (CT number). A vascularized lesion is characterized by an increase in CT number in the few minutes after a bolus of intravascular contrast agent; it may be malignant, benign, or normal tissue, but would probably not be a cyst, hematoma, or other nonvascular lesion. Because unenhanced scanning may provide adequate diagnostic information in the individual patient, the decision to employ contrast enhancement, which may be associated with risk and increased radiation exposure, should be based upon a careful evaluation of clinical, other radiological, and unenhanced CT findings. uuid:4b4f9d6e-d2d7-483a-a05d-e59ea172a9a8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31711 biolink:treats MONDO:0002173 PMID:41385096 "[{""id"":""uuid:a08eb69a-545c-4d46-bf95-aee3a4140240"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6bbce391-5ab5-4ec9-8f8e-9a4f704b07a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ISOVUE (Iopamidol Injection) is indicated for angiography throughout the cardiovascular system in adults, including cerebral and peripheral arteriography, coronary arteriography and ventriculography, selective visceral arteriography and aortography, peripheral venography (phlebography), and in pediatric patients for angiocardiography; or for intravenous use in adult and pediatric for computed tomographic (CT) imaging of the head and body (see below). CT Head Imaging ISOVUE may be used to refine diagnostic precision in areas of the brain which may not otherwise have been satisfactorily visualized. Tumors ISOVUE may be useful to investigate the presence and extent of certain malignancies such as: gliomas including malignant gliomas, glioblastomas, astrocytomas, oligodendrogliomas and gangliomas, ependymomas, medulloblastomas, meningiomas, neuromas, pinealomas, pituitary adenomas, craniopharyngiomas, germinomas, and metastatic lesions. The usefulness of contrast enhancement for the investigation of the retrobulbar space and in cases of low grade or infiltrative glioma has not been demonstrated. In calcified lesions, there is less likelihood of enhancement. Following therapy, tumors may show decreased or no enhancement. The opacification of the inferior vermis following contrast media administration has resulted in false-positive diagnosis in a number of otherwise normal studies. Nonneoplastic Conditions ISOVUE may be beneficial in the image enhancement of nonneoplastic lesions. Cerebral infarctions of recent onset may be better visualized with contrast enhancement, while some infarctions are obscured if contrast media are used. The use of iodinated contrast media results in contrast enhancement in about 60 percent of cerebral infarctions studied from one to four weeks from the onset of symptoms. Sites of active infection may also be enhanced following contrast media administration. Arteriovenous malformations and aneurysms will show contrast enhancement. For these vascular lesions, the enhancement is probably dependent on the iodine content of the circulating blood pool. Hematomas and intraparenchymal bleeders seldom demonstrate any contrast enhancement. However, in cases of intraparenchymal clot, for which there is no obvious clinical explanation, contrast media administration may be helpful in ruling out the possibility of associated arteriovenous malformation. CT Body Imaging ISOVUE (Iopamidol Injection) may be used for enhancement of computed tomographic images for detection and evaluation of lesions in the liver, pancreas, kidneys, aorta, mediastinum, abdominal cavity, pelvis and retroperitoneal space. Enhancement of computed tomography with ISOVUE may be of benefit in establishing diagnoses of certain lesions in these sites with greater assurance than is possible with CT alone, and in supplying additional features of the lesions (e.g., hepatic abscess delineation prior to percutaneous drainage). In other cases, the contrast agent may allow visualization of lesions not seen with CT alone (e.g. tumor extension), or may help to define suspicious lesions seen with unenhanced CT (e.g., pancreatic cyst). Contrast enhancement appears to be greatest within 60 to 90 seconds after bolus administration of contrast agent. Therefore, utilization of a continuous scanning technique (“dynamic CT scanning”) may improve enhancement and diagnostic assessment of tumor and other lesions such as an abscess, occasionally revealing unsuspected or more extensive disease. For example, a cyst may be distinguished from a vascularized solid lesion when precontrast and enhanced scans are compared; the nonperfused mass shows unchanged x-ray absorption (CT number). A vascularized lesion is characterized by an increase in CT number in the few minutes after a bolus of intravascular contrast agent; it may be malignant, benign, or normal tissue, but would probably not be a cyst, hematoma, or other nonvascular lesion. Because unenhanced scanning may provide adequate diagnostic information in the individual patient, the decision to employ contrast enhancement, which may be associated with risk and increased radiation exposure, should be based upon a careful evaluation of clinical, other radiological, and unenhanced CT findings. uuid:9034d318-85c9-421d-acd7-5ca23ec1c790 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31711 biolink:treats MONDO:0024890 PMID:41385096 "[{""id"":""uuid:14683f95-fc30-410c-a617-21b9511f4c88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:07ad568d-a894-4a5b-a8ba-7e4634951ae2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ISOVUE (Iopamidol Injection) is indicated for angiography throughout the cardiovascular system in adults, including cerebral and peripheral arteriography, coronary arteriography and ventriculography, selective visceral arteriography and aortography, peripheral venography (phlebography), and in pediatric patients for angiocardiography; or for intravenous use in adult and pediatric for computed tomographic (CT) imaging of the head and body (see below). CT Head Imaging ISOVUE may be used to refine diagnostic precision in areas of the brain which may not otherwise have been satisfactorily visualized. Tumors ISOVUE may be useful to investigate the presence and extent of certain malignancies such as: gliomas including malignant gliomas, glioblastomas, astrocytomas, oligodendrogliomas and gangliomas, ependymomas, medulloblastomas, meningiomas, neuromas, pinealomas, pituitary adenomas, craniopharyngiomas, germinomas, and metastatic lesions. The usefulness of contrast enhancement for the investigation of the retrobulbar space and in cases of low grade or infiltrative glioma has not been demonstrated. In calcified lesions, there is less likelihood of enhancement. Following therapy, tumors may show decreased or no enhancement. The opacification of the inferior vermis following contrast media administration has resulted in false-positive diagnosis in a number of otherwise normal studies. Nonneoplastic Conditions ISOVUE may be beneficial in the image enhancement of nonneoplastic lesions. Cerebral infarctions of recent onset may be better visualized with contrast enhancement, while some infarctions are obscured if contrast media are used. The use of iodinated contrast media results in contrast enhancement in about 60 percent of cerebral infarctions studied from one to four weeks from the onset of symptoms. Sites of active infection may also be enhanced following contrast media administration. Arteriovenous malformations and aneurysms will show contrast enhancement. For these vascular lesions, the enhancement is probably dependent on the iodine content of the circulating blood pool. Hematomas and intraparenchymal bleeders seldom demonstrate any contrast enhancement. However, in cases of intraparenchymal clot, for which there is no obvious clinical explanation, contrast media administration may be helpful in ruling out the possibility of associated arteriovenous malformation. CT Body Imaging ISOVUE (Iopamidol Injection) may be used for enhancement of computed tomographic images for detection and evaluation of lesions in the liver, pancreas, kidneys, aorta, mediastinum, abdominal cavity, pelvis and retroperitoneal space. Enhancement of computed tomography with ISOVUE may be of benefit in establishing diagnoses of certain lesions in these sites with greater assurance than is possible with CT alone, and in supplying additional features of the lesions (e.g., hepatic abscess delineation prior to percutaneous drainage). In other cases, the contrast agent may allow visualization of lesions not seen with CT alone (e.g. tumor extension), or may help to define suspicious lesions seen with unenhanced CT (e.g., pancreatic cyst). Contrast enhancement appears to be greatest within 60 to 90 seconds after bolus administration of contrast agent. Therefore, utilization of a continuous scanning technique (“dynamic CT scanning”) may improve enhancement and diagnostic assessment of tumor and other lesions such as an abscess, occasionally revealing unsuspected or more extensive disease. For example, a cyst may be distinguished from a vascularized solid lesion when precontrast and enhanced scans are compared; the nonperfused mass shows unchanged x-ray absorption (CT number). A vascularized lesion is characterized by an increase in CT number in the few minutes after a bolus of intravascular contrast agent; it may be malignant, benign, or normal tissue, but would probably not be a cyst, hematoma, or other nonvascular lesion. Because unenhanced scanning may provide adequate diagnostic information in the individual patient, the decision to employ contrast enhancement, which may be associated with risk and increased radiation exposure, should be based upon a careful evaluation of clinical, other radiological, and unenhanced CT findings. uuid:c5929171-71fd-4217-ad61-8a3639510d55 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31711 biolink:treats MONDO:0006373 PMID:41385096 "[{""id"":""uuid:a77632b4-2c0f-479e-84ab-ac30961a0e71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c18caf25-abb8-4db9-a6c5-0b5ee844260a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ISOVUE (Iopamidol Injection) is indicated for angiography throughout the cardiovascular system in adults, including cerebral and peripheral arteriography, coronary arteriography and ventriculography, selective visceral arteriography and aortography, peripheral venography (phlebography), and in pediatric patients for angiocardiography; or for intravenous use in adult and pediatric for computed tomographic (CT) imaging of the head and body (see below). CT Head Imaging ISOVUE may be used to refine diagnostic precision in areas of the brain which may not otherwise have been satisfactorily visualized. Tumors ISOVUE may be useful to investigate the presence and extent of certain malignancies such as: gliomas including malignant gliomas, glioblastomas, astrocytomas, oligodendrogliomas and gangliomas, ependymomas, medulloblastomas, meningiomas, neuromas, pinealomas, pituitary adenomas, craniopharyngiomas, germinomas, and metastatic lesions. The usefulness of contrast enhancement for the investigation of the retrobulbar space and in cases of low grade or infiltrative glioma has not been demonstrated. In calcified lesions, there is less likelihood of enhancement. Following therapy, tumors may show decreased or no enhancement. The opacification of the inferior vermis following contrast media administration has resulted in false-positive diagnosis in a number of otherwise normal studies. Nonneoplastic Conditions ISOVUE may be beneficial in the image enhancement of nonneoplastic lesions. Cerebral infarctions of recent onset may be better visualized with contrast enhancement, while some infarctions are obscured if contrast media are used. The use of iodinated contrast media results in contrast enhancement in about 60 percent of cerebral infarctions studied from one to four weeks from the onset of symptoms. Sites of active infection may also be enhanced following contrast media administration. Arteriovenous malformations and aneurysms will show contrast enhancement. For these vascular lesions, the enhancement is probably dependent on the iodine content of the circulating blood pool. Hematomas and intraparenchymal bleeders seldom demonstrate any contrast enhancement. However, in cases of intraparenchymal clot, for which there is no obvious clinical explanation, contrast media administration may be helpful in ruling out the possibility of associated arteriovenous malformation. CT Body Imaging ISOVUE (Iopamidol Injection) may be used for enhancement of computed tomographic images for detection and evaluation of lesions in the liver, pancreas, kidneys, aorta, mediastinum, abdominal cavity, pelvis and retroperitoneal space. Enhancement of computed tomography with ISOVUE may be of benefit in establishing diagnoses of certain lesions in these sites with greater assurance than is possible with CT alone, and in supplying additional features of the lesions (e.g., hepatic abscess delineation prior to percutaneous drainage). In other cases, the contrast agent may allow visualization of lesions not seen with CT alone (e.g. tumor extension), or may help to define suspicious lesions seen with unenhanced CT (e.g., pancreatic cyst). Contrast enhancement appears to be greatest within 60 to 90 seconds after bolus administration of contrast agent. Therefore, utilization of a continuous scanning technique (“dynamic CT scanning”) may improve enhancement and diagnostic assessment of tumor and other lesions such as an abscess, occasionally revealing unsuspected or more extensive disease. For example, a cyst may be distinguished from a vascularized solid lesion when precontrast and enhanced scans are compared; the nonperfused mass shows unchanged x-ray absorption (CT number). A vascularized lesion is characterized by an increase in CT number in the few minutes after a bolus of intravascular contrast agent; it may be malignant, benign, or normal tissue, but would probably not be a cyst, hematoma, or other nonvascular lesion. Because unenhanced scanning may provide adequate diagnostic information in the individual patient, the decision to employ contrast enhancement, which may be associated with risk and increased radiation exposure, should be based upon a careful evaluation of clinical, other radiological, and unenhanced CT findings. uuid:e881148b-9ced-424e-a38f-daec14534067 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31711 biolink:treats MONDO:0002787 PMID:41385096 "[{""id"":""uuid:a5e94e2b-10c4-417d-b720-aa525d00e192"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a0839fc9-7654-404f-830c-c62baa201c14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ISOVUE (Iopamidol Injection) is indicated for angiography throughout the cardiovascular system in adults, including cerebral and peripheral arteriography, coronary arteriography and ventriculography, selective visceral arteriography and aortography, peripheral venography (phlebography), and in pediatric patients for angiocardiography; or for intravenous use in adult and pediatric for computed tomographic (CT) imaging of the head and body (see below). CT Head Imaging ISOVUE may be used to refine diagnostic precision in areas of the brain which may not otherwise have been satisfactorily visualized. Tumors ISOVUE may be useful to investigate the presence and extent of certain malignancies such as: gliomas including malignant gliomas, glioblastomas, astrocytomas, oligodendrogliomas and gangliomas, ependymomas, medulloblastomas, meningiomas, neuromas, pinealomas, pituitary adenomas, craniopharyngiomas, germinomas, and metastatic lesions. The usefulness of contrast enhancement for the investigation of the retrobulbar space and in cases of low grade or infiltrative glioma has not been demonstrated. In calcified lesions, there is less likelihood of enhancement. Following therapy, tumors may show decreased or no enhancement. The opacification of the inferior vermis following contrast media administration has resulted in false-positive diagnosis in a number of otherwise normal studies. Nonneoplastic Conditions ISOVUE may be beneficial in the image enhancement of nonneoplastic lesions. Cerebral infarctions of recent onset may be better visualized with contrast enhancement, while some infarctions are obscured if contrast media are used. The use of iodinated contrast media results in contrast enhancement in about 60 percent of cerebral infarctions studied from one to four weeks from the onset of symptoms. Sites of active infection may also be enhanced following contrast media administration. Arteriovenous malformations and aneurysms will show contrast enhancement. For these vascular lesions, the enhancement is probably dependent on the iodine content of the circulating blood pool. Hematomas and intraparenchymal bleeders seldom demonstrate any contrast enhancement. However, in cases of intraparenchymal clot, for which there is no obvious clinical explanation, contrast media administration may be helpful in ruling out the possibility of associated arteriovenous malformation. CT Body Imaging ISOVUE (Iopamidol Injection) may be used for enhancement of computed tomographic images for detection and evaluation of lesions in the liver, pancreas, kidneys, aorta, mediastinum, abdominal cavity, pelvis and retroperitoneal space. Enhancement of computed tomography with ISOVUE may be of benefit in establishing diagnoses of certain lesions in these sites with greater assurance than is possible with CT alone, and in supplying additional features of the lesions (e.g., hepatic abscess delineation prior to percutaneous drainage). In other cases, the contrast agent may allow visualization of lesions not seen with CT alone (e.g. tumor extension), or may help to define suspicious lesions seen with unenhanced CT (e.g., pancreatic cyst). Contrast enhancement appears to be greatest within 60 to 90 seconds after bolus administration of contrast agent. Therefore, utilization of a continuous scanning technique (“dynamic CT scanning”) may improve enhancement and diagnostic assessment of tumor and other lesions such as an abscess, occasionally revealing unsuspected or more extensive disease. For example, a cyst may be distinguished from a vascularized solid lesion when precontrast and enhanced scans are compared; the nonperfused mass shows unchanged x-ray absorption (CT number). A vascularized lesion is characterized by an increase in CT number in the few minutes after a bolus of intravascular contrast agent; it may be malignant, benign, or normal tissue, but would probably not be a cyst, hematoma, or other nonvascular lesion. Because unenhanced scanning may provide adequate diagnostic information in the individual patient, the decision to employ contrast enhancement, which may be associated with risk and increased radiation exposure, should be based upon a careful evaluation of clinical, other radiological, and unenhanced CT findings. uuid:3958e5d1-ee9d-46a9-b8d1-a01ce647149d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31711 biolink:treats MONDO:0002598 PMID:41385096 "[{""id"":""uuid:9bf462dc-e99b-45f3-be9c-de23fa5040dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:521e6bef-abeb-475c-b86e-e992c2f1e646"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ISOVUE (Iopamidol Injection) is indicated for angiography throughout the cardiovascular system in adults, including cerebral and peripheral arteriography, coronary arteriography and ventriculography, selective visceral arteriography and aortography, peripheral venography (phlebography), and in pediatric patients for angiocardiography; or for intravenous use in adult and pediatric for computed tomographic (CT) imaging of the head and body (see below). CT Head Imaging ISOVUE may be used to refine diagnostic precision in areas of the brain which may not otherwise have been satisfactorily visualized. Tumors ISOVUE may be useful to investigate the presence and extent of certain malignancies such as: gliomas including malignant gliomas, glioblastomas, astrocytomas, oligodendrogliomas and gangliomas, ependymomas, medulloblastomas, meningiomas, neuromas, pinealomas, pituitary adenomas, craniopharyngiomas, germinomas, and metastatic lesions. The usefulness of contrast enhancement for the investigation of the retrobulbar space and in cases of low grade or infiltrative glioma has not been demonstrated. In calcified lesions, there is less likelihood of enhancement. Following therapy, tumors may show decreased or no enhancement. The opacification of the inferior vermis following contrast media administration has resulted in false-positive diagnosis in a number of otherwise normal studies. Nonneoplastic Conditions ISOVUE may be beneficial in the image enhancement of nonneoplastic lesions. Cerebral infarctions of recent onset may be better visualized with contrast enhancement, while some infarctions are obscured if contrast media are used. The use of iodinated contrast media results in contrast enhancement in about 60 percent of cerebral infarctions studied from one to four weeks from the onset of symptoms. Sites of active infection may also be enhanced following contrast media administration. Arteriovenous malformations and aneurysms will show contrast enhancement. For these vascular lesions, the enhancement is probably dependent on the iodine content of the circulating blood pool. Hematomas and intraparenchymal bleeders seldom demonstrate any contrast enhancement. However, in cases of intraparenchymal clot, for which there is no obvious clinical explanation, contrast media administration may be helpful in ruling out the possibility of associated arteriovenous malformation. CT Body Imaging ISOVUE (Iopamidol Injection) may be used for enhancement of computed tomographic images for detection and evaluation of lesions in the liver, pancreas, kidneys, aorta, mediastinum, abdominal cavity, pelvis and retroperitoneal space. Enhancement of computed tomography with ISOVUE may be of benefit in establishing diagnoses of certain lesions in these sites with greater assurance than is possible with CT alone, and in supplying additional features of the lesions (e.g., hepatic abscess delineation prior to percutaneous drainage). In other cases, the contrast agent may allow visualization of lesions not seen with CT alone (e.g. tumor extension), or may help to define suspicious lesions seen with unenhanced CT (e.g., pancreatic cyst). Contrast enhancement appears to be greatest within 60 to 90 seconds after bolus administration of contrast agent. Therefore, utilization of a continuous scanning technique (“dynamic CT scanning”) may improve enhancement and diagnostic assessment of tumor and other lesions such as an abscess, occasionally revealing unsuspected or more extensive disease. For example, a cyst may be distinguished from a vascularized solid lesion when precontrast and enhanced scans are compared; the nonperfused mass shows unchanged x-ray absorption (CT number). A vascularized lesion is characterized by an increase in CT number in the few minutes after a bolus of intravascular contrast agent; it may be malignant, benign, or normal tissue, but would probably not be a cyst, hematoma, or other nonvascular lesion. Because unenhanced scanning may provide adequate diagnostic information in the individual patient, the decision to employ contrast enhancement, which may be associated with risk and increased radiation exposure, should be based upon a careful evaluation of clinical, other radiological, and unenhanced CT findings. uuid:817049fb-b5a9-46c3-8c04-281ccb916b2a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31711 biolink:treats MONDO:0024879 PMID:41385096 "[{""id"":""uuid:e2d08ebc-9585-4738-8741-7d888dd93c28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fb184ab8-a1ab-426c-ac1d-b703d4528608"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ISOVUE (Iopamidol Injection) is indicated for angiography throughout the cardiovascular system in adults, including cerebral and peripheral arteriography, coronary arteriography and ventriculography, selective visceral arteriography and aortography, peripheral venography (phlebography), and in pediatric patients for angiocardiography; or for intravenous use in adult and pediatric for computed tomographic (CT) imaging of the head and body (see below). CT Head Imaging ISOVUE may be used to refine diagnostic precision in areas of the brain which may not otherwise have been satisfactorily visualized. Tumors ISOVUE may be useful to investigate the presence and extent of certain malignancies such as: gliomas including malignant gliomas, glioblastomas, astrocytomas, oligodendrogliomas and gangliomas, ependymomas, medulloblastomas, meningiomas, neuromas, pinealomas, pituitary adenomas, craniopharyngiomas, germinomas, and metastatic lesions. The usefulness of contrast enhancement for the investigation of the retrobulbar space and in cases of low grade or infiltrative glioma has not been demonstrated. In calcified lesions, there is less likelihood of enhancement. Following therapy, tumors may show decreased or no enhancement. The opacification of the inferior vermis following contrast media administration has resulted in false-positive diagnosis in a number of otherwise normal studies. Nonneoplastic Conditions ISOVUE may be beneficial in the image enhancement of nonneoplastic lesions. Cerebral infarctions of recent onset may be better visualized with contrast enhancement, while some infarctions are obscured if contrast media are used. The use of iodinated contrast media results in contrast enhancement in about 60 percent of cerebral infarctions studied from one to four weeks from the onset of symptoms. Sites of active infection may also be enhanced following contrast media administration. Arteriovenous malformations and aneurysms will show contrast enhancement. For these vascular lesions, the enhancement is probably dependent on the iodine content of the circulating blood pool. Hematomas and intraparenchymal bleeders seldom demonstrate any contrast enhancement. However, in cases of intraparenchymal clot, for which there is no obvious clinical explanation, contrast media administration may be helpful in ruling out the possibility of associated arteriovenous malformation. CT Body Imaging ISOVUE (Iopamidol Injection) may be used for enhancement of computed tomographic images for detection and evaluation of lesions in the liver, pancreas, kidneys, aorta, mediastinum, abdominal cavity, pelvis and retroperitoneal space. Enhancement of computed tomography with ISOVUE may be of benefit in establishing diagnoses of certain lesions in these sites with greater assurance than is possible with CT alone, and in supplying additional features of the lesions (e.g., hepatic abscess delineation prior to percutaneous drainage). In other cases, the contrast agent may allow visualization of lesions not seen with CT alone (e.g. tumor extension), or may help to define suspicious lesions seen with unenhanced CT (e.g., pancreatic cyst). Contrast enhancement appears to be greatest within 60 to 90 seconds after bolus administration of contrast agent. Therefore, utilization of a continuous scanning technique (“dynamic CT scanning”) may improve enhancement and diagnostic assessment of tumor and other lesions such as an abscess, occasionally revealing unsuspected or more extensive disease. For example, a cyst may be distinguished from a vascularized solid lesion when precontrast and enhanced scans are compared; the nonperfused mass shows unchanged x-ray absorption (CT number). A vascularized lesion is characterized by an increase in CT number in the few minutes after a bolus of intravascular contrast agent; it may be malignant, benign, or normal tissue, but would probably not be a cyst, hematoma, or other nonvascular lesion. Because unenhanced scanning may provide adequate diagnostic information in the individual patient, the decision to employ contrast enhancement, which may be associated with risk and increased radiation exposure, should be based upon a careful evaluation of clinical, other radiological, and unenhanced CT findings. uuid:a709bdfe-7c7e-4dca-b856-d7178c02ca86 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31711 biolink:treats MONDO:0002679 PMID:41385096 "[{""id"":""uuid:11aa09ba-3c0b-499d-8a29-d29dde5e950f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:81c8e6a4-7d64-4049-8c73-d09917030059"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ISOVUE (Iopamidol Injection) is indicated for angiography throughout the cardiovascular system in adults, including cerebral and peripheral arteriography, coronary arteriography and ventriculography, selective visceral arteriography and aortography, peripheral venography (phlebography), and in pediatric patients for angiocardiography; or for intravenous use in adult and pediatric for computed tomographic (CT) imaging of the head and body (see below). CT Head Imaging ISOVUE may be used to refine diagnostic precision in areas of the brain which may not otherwise have been satisfactorily visualized. Tumors ISOVUE may be useful to investigate the presence and extent of certain malignancies such as: gliomas including malignant gliomas, glioblastomas, astrocytomas, oligodendrogliomas and gangliomas, ependymomas, medulloblastomas, meningiomas, neuromas, pinealomas, pituitary adenomas, craniopharyngiomas, germinomas, and metastatic lesions. The usefulness of contrast enhancement for the investigation of the retrobulbar space and in cases of low grade or infiltrative glioma has not been demonstrated. In calcified lesions, there is less likelihood of enhancement. Following therapy, tumors may show decreased or no enhancement. The opacification of the inferior vermis following contrast media administration has resulted in false-positive diagnosis in a number of otherwise normal studies. Nonneoplastic Conditions ISOVUE may be beneficial in the image enhancement of nonneoplastic lesions. Cerebral infarctions of recent onset may be better visualized with contrast enhancement, while some infarctions are obscured if contrast media are used. The use of iodinated contrast media results in contrast enhancement in about 60 percent of cerebral infarctions studied from one to four weeks from the onset of symptoms. Sites of active infection may also be enhanced following contrast media administration. Arteriovenous malformations and aneurysms will show contrast enhancement. For these vascular lesions, the enhancement is probably dependent on the iodine content of the circulating blood pool. Hematomas and intraparenchymal bleeders seldom demonstrate any contrast enhancement. However, in cases of intraparenchymal clot, for which there is no obvious clinical explanation, contrast media administration may be helpful in ruling out the possibility of associated arteriovenous malformation. CT Body Imaging ISOVUE (Iopamidol Injection) may be used for enhancement of computed tomographic images for detection and evaluation of lesions in the liver, pancreas, kidneys, aorta, mediastinum, abdominal cavity, pelvis and retroperitoneal space. Enhancement of computed tomography with ISOVUE may be of benefit in establishing diagnoses of certain lesions in these sites with greater assurance than is possible with CT alone, and in supplying additional features of the lesions (e.g., hepatic abscess delineation prior to percutaneous drainage). In other cases, the contrast agent may allow visualization of lesions not seen with CT alone (e.g. tumor extension), or may help to define suspicious lesions seen with unenhanced CT (e.g., pancreatic cyst). Contrast enhancement appears to be greatest within 60 to 90 seconds after bolus administration of contrast agent. Therefore, utilization of a continuous scanning technique (“dynamic CT scanning”) may improve enhancement and diagnostic assessment of tumor and other lesions such as an abscess, occasionally revealing unsuspected or more extensive disease. For example, a cyst may be distinguished from a vascularized solid lesion when precontrast and enhanced scans are compared; the nonperfused mass shows unchanged x-ray absorption (CT number). A vascularized lesion is characterized by an increase in CT number in the few minutes after a bolus of intravascular contrast agent; it may be malignant, benign, or normal tissue, but would probably not be a cyst, hematoma, or other nonvascular lesion. Because unenhanced scanning may provide adequate diagnostic information in the individual patient, the decision to employ contrast enhancement, which may be associated with risk and increased radiation exposure, should be based upon a careful evaluation of clinical, other radiological, and unenhanced CT findings. uuid:0ab822ce-7ee5-4942-823d-abe303e014e6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31711 biolink:treats MONDO:0001256 PMID:41385096 "[{""id"":""uuid:e5f0c9bf-abea-4ab7-a636-dc2e091f5284"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d849ba68-cb03-4bd9-baea-c2a923eef18c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ISOVUE (Iopamidol Injection) is indicated for angiography throughout the cardiovascular system in adults, including cerebral and peripheral arteriography, coronary arteriography and ventriculography, selective visceral arteriography and aortography, peripheral venography (phlebography), and in pediatric patients for angiocardiography; or for intravenous use in adult and pediatric for computed tomographic (CT) imaging of the head and body (see below). CT Head Imaging ISOVUE may be used to refine diagnostic precision in areas of the brain which may not otherwise have been satisfactorily visualized. Tumors ISOVUE may be useful to investigate the presence and extent of certain malignancies such as: gliomas including malignant gliomas, glioblastomas, astrocytomas, oligodendrogliomas and gangliomas, ependymomas, medulloblastomas, meningiomas, neuromas, pinealomas, pituitary adenomas, craniopharyngiomas, germinomas, and metastatic lesions. The usefulness of contrast enhancement for the investigation of the retrobulbar space and in cases of low grade or infiltrative glioma has not been demonstrated. In calcified lesions, there is less likelihood of enhancement. Following therapy, tumors may show decreased or no enhancement. The opacification of the inferior vermis following contrast media administration has resulted in false-positive diagnosis in a number of otherwise normal studies. Nonneoplastic Conditions ISOVUE may be beneficial in the image enhancement of nonneoplastic lesions. Cerebral infarctions of recent onset may be better visualized with contrast enhancement, while some infarctions are obscured if contrast media are used. The use of iodinated contrast media results in contrast enhancement in about 60 percent of cerebral infarctions studied from one to four weeks from the onset of symptoms. Sites of active infection may also be enhanced following contrast media administration. Arteriovenous malformations and aneurysms will show contrast enhancement. For these vascular lesions, the enhancement is probably dependent on the iodine content of the circulating blood pool. Hematomas and intraparenchymal bleeders seldom demonstrate any contrast enhancement. However, in cases of intraparenchymal clot, for which there is no obvious clinical explanation, contrast media administration may be helpful in ruling out the possibility of associated arteriovenous malformation. CT Body Imaging ISOVUE (Iopamidol Injection) may be used for enhancement of computed tomographic images for detection and evaluation of lesions in the liver, pancreas, kidneys, aorta, mediastinum, abdominal cavity, pelvis and retroperitoneal space. Enhancement of computed tomography with ISOVUE may be of benefit in establishing diagnoses of certain lesions in these sites with greater assurance than is possible with CT alone, and in supplying additional features of the lesions (e.g., hepatic abscess delineation prior to percutaneous drainage). In other cases, the contrast agent may allow visualization of lesions not seen with CT alone (e.g. tumor extension), or may help to define suspicious lesions seen with unenhanced CT (e.g., pancreatic cyst). Contrast enhancement appears to be greatest within 60 to 90 seconds after bolus administration of contrast agent. Therefore, utilization of a continuous scanning technique (“dynamic CT scanning”) may improve enhancement and diagnostic assessment of tumor and other lesions such as an abscess, occasionally revealing unsuspected or more extensive disease. For example, a cyst may be distinguished from a vascularized solid lesion when precontrast and enhanced scans are compared; the nonperfused mass shows unchanged x-ray absorption (CT number). A vascularized lesion is characterized by an increase in CT number in the few minutes after a bolus of intravascular contrast agent; it may be malignant, benign, or normal tissue, but would probably not be a cyst, hematoma, or other nonvascular lesion. Because unenhanced scanning may provide adequate diagnostic information in the individual patient, the decision to employ contrast enhancement, which may be associated with risk and increased radiation exposure, should be based upon a careful evaluation of clinical, other radiological, and unenhanced CT findings. uuid:83db28a1-c89c-44ca-8687-3147f90b1051 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31711 biolink:treats MONDO:0005385 PMID:41385096 "[{""id"":""uuid:b854a4ab-b905-4453-8cf6-72411b75ad88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aded1a95-8dbe-4e66-b1f6-0855bec3f912"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ISOVUE (Iopamidol Injection) is indicated for angiography throughout the cardiovascular system in adults, including cerebral and peripheral arteriography, coronary arteriography and ventriculography, selective visceral arteriography and aortography, peripheral venography (phlebography), and in pediatric patients for angiocardiography; or for intravenous use in adult and pediatric for computed tomographic (CT) imaging of the head and body (see below). CT Head Imaging ISOVUE may be used to refine diagnostic precision in areas of the brain which may not otherwise have been satisfactorily visualized. Tumors ISOVUE may be useful to investigate the presence and extent of certain malignancies such as: gliomas including malignant gliomas, glioblastomas, astrocytomas, oligodendrogliomas and gangliomas, ependymomas, medulloblastomas, meningiomas, neuromas, pinealomas, pituitary adenomas, craniopharyngiomas, germinomas, and metastatic lesions. The usefulness of contrast enhancement for the investigation of the retrobulbar space and in cases of low grade or infiltrative glioma has not been demonstrated. In calcified lesions, there is less likelihood of enhancement. Following therapy, tumors may show decreased or no enhancement. The opacification of the inferior vermis following contrast media administration has resulted in false-positive diagnosis in a number of otherwise normal studies. Nonneoplastic Conditions ISOVUE may be beneficial in the image enhancement of nonneoplastic lesions. Cerebral infarctions of recent onset may be better visualized with contrast enhancement, while some infarctions are obscured if contrast media are used. The use of iodinated contrast media results in contrast enhancement in about 60 percent of cerebral infarctions studied from one to four weeks from the onset of symptoms. Sites of active infection may also be enhanced following contrast media administration. Arteriovenous malformations and aneurysms will show contrast enhancement. For these vascular lesions, the enhancement is probably dependent on the iodine content of the circulating blood pool. Hematomas and intraparenchymal bleeders seldom demonstrate any contrast enhancement. However, in cases of intraparenchymal clot, for which there is no obvious clinical explanation, contrast media administration may be helpful in ruling out the possibility of associated arteriovenous malformation. CT Body Imaging ISOVUE (Iopamidol Injection) may be used for enhancement of computed tomographic images for detection and evaluation of lesions in the liver, pancreas, kidneys, aorta, mediastinum, abdominal cavity, pelvis and retroperitoneal space. Enhancement of computed tomography with ISOVUE may be of benefit in establishing diagnoses of certain lesions in these sites with greater assurance than is possible with CT alone, and in supplying additional features of the lesions (e.g., hepatic abscess delineation prior to percutaneous drainage). In other cases, the contrast agent may allow visualization of lesions not seen with CT alone (e.g. tumor extension), or may help to define suspicious lesions seen with unenhanced CT (e.g., pancreatic cyst). Contrast enhancement appears to be greatest within 60 to 90 seconds after bolus administration of contrast agent. Therefore, utilization of a continuous scanning technique (“dynamic CT scanning”) may improve enhancement and diagnostic assessment of tumor and other lesions such as an abscess, occasionally revealing unsuspected or more extensive disease. For example, a cyst may be distinguished from a vascularized solid lesion when precontrast and enhanced scans are compared; the nonperfused mass shows unchanged x-ray absorption (CT number). A vascularized lesion is characterized by an increase in CT number in the few minutes after a bolus of intravascular contrast agent; it may be malignant, benign, or normal tissue, but would probably not be a cyst, hematoma, or other nonvascular lesion. Because unenhanced scanning may provide adequate diagnostic information in the individual patient, the decision to employ contrast enhancement, which may be associated with risk and increased radiation exposure, should be based upon a careful evaluation of clinical, other radiological, and unenhanced CT findings. uuid:b7425d3b-9bdd-4f5c-8ed8-36dc296cacab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31711 biolink:treats EFO:0010680 PMID:41385096 "[{""id"":""uuid:13e12f5a-74cc-4554-857a-eb98f3c127c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fdc07670-cea1-4a8a-aafd-cc00a8b8e3df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ISOVUE (Iopamidol Injection) is indicated for angiography throughout the cardiovascular system in adults, including cerebral and peripheral arteriography, coronary arteriography and ventriculography, selective visceral arteriography and aortography, peripheral venography (phlebography), and in pediatric patients for angiocardiography; or for intravenous use in adult and pediatric for computed tomographic (CT) imaging of the head and body (see below). CT Head Imaging ISOVUE may be used to refine diagnostic precision in areas of the brain which may not otherwise have been satisfactorily visualized. Tumors ISOVUE may be useful to investigate the presence and extent of certain malignancies such as: gliomas including malignant gliomas, glioblastomas, astrocytomas, oligodendrogliomas and gangliomas, ependymomas, medulloblastomas, meningiomas, neuromas, pinealomas, pituitary adenomas, craniopharyngiomas, germinomas, and metastatic lesions. The usefulness of contrast enhancement for the investigation of the retrobulbar space and in cases of low grade or infiltrative glioma has not been demonstrated. In calcified lesions, there is less likelihood of enhancement. Following therapy, tumors may show decreased or no enhancement. The opacification of the inferior vermis following contrast media administration has resulted in false-positive diagnosis in a number of otherwise normal studies. Nonneoplastic Conditions ISOVUE may be beneficial in the image enhancement of nonneoplastic lesions. Cerebral infarctions of recent onset may be better visualized with contrast enhancement, while some infarctions are obscured if contrast media are used. The use of iodinated contrast media results in contrast enhancement in about 60 percent of cerebral infarctions studied from one to four weeks from the onset of symptoms. Sites of active infection may also be enhanced following contrast media administration. Arteriovenous malformations and aneurysms will show contrast enhancement. For these vascular lesions, the enhancement is probably dependent on the iodine content of the circulating blood pool. Hematomas and intraparenchymal bleeders seldom demonstrate any contrast enhancement. However, in cases of intraparenchymal clot, for which there is no obvious clinical explanation, contrast media administration may be helpful in ruling out the possibility of associated arteriovenous malformation. CT Body Imaging ISOVUE (Iopamidol Injection) may be used for enhancement of computed tomographic images for detection and evaluation of lesions in the liver, pancreas, kidneys, aorta, mediastinum, abdominal cavity, pelvis and retroperitoneal space. Enhancement of computed tomography with ISOVUE may be of benefit in establishing diagnoses of certain lesions in these sites with greater assurance than is possible with CT alone, and in supplying additional features of the lesions (e.g., hepatic abscess delineation prior to percutaneous drainage). In other cases, the contrast agent may allow visualization of lesions not seen with CT alone (e.g. tumor extension), or may help to define suspicious lesions seen with unenhanced CT (e.g., pancreatic cyst). Contrast enhancement appears to be greatest within 60 to 90 seconds after bolus administration of contrast agent. Therefore, utilization of a continuous scanning technique (“dynamic CT scanning”) may improve enhancement and diagnostic assessment of tumor and other lesions such as an abscess, occasionally revealing unsuspected or more extensive disease. For example, a cyst may be distinguished from a vascularized solid lesion when precontrast and enhanced scans are compared; the nonperfused mass shows unchanged x-ray absorption (CT number). A vascularized lesion is characterized by an increase in CT number in the few minutes after a bolus of intravascular contrast agent; it may be malignant, benign, or normal tissue, but would probably not be a cyst, hematoma, or other nonvascular lesion. Because unenhanced scanning may provide adequate diagnostic information in the individual patient, the decision to employ contrast enhancement, which may be associated with risk and increased radiation exposure, should be based upon a careful evaluation of clinical, other radiological, and unenhanced CT findings. uuid:eecb8ca3-b4d7-4722-adbe-c94d06dfea4a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31711 biolink:treats MONDO:0700051 PMID:41385096 "[{""id"":""uuid:b34df3fd-9860-4c24-9101-70a784251e2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:727bba86-f5fa-4cc8-8854-18c334777aa1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ISOVUE (Iopamidol Injection) is indicated for angiography throughout the cardiovascular system in adults, including cerebral and peripheral arteriography, coronary arteriography and ventriculography, selective visceral arteriography and aortography, peripheral venography (phlebography), and in pediatric patients for angiocardiography; or for intravenous use in adult and pediatric for computed tomographic (CT) imaging of the head and body (see below). CT Head Imaging ISOVUE may be used to refine diagnostic precision in areas of the brain which may not otherwise have been satisfactorily visualized. Tumors ISOVUE may be useful to investigate the presence and extent of certain malignancies such as: gliomas including malignant gliomas, glioblastomas, astrocytomas, oligodendrogliomas and gangliomas, ependymomas, medulloblastomas, meningiomas, neuromas, pinealomas, pituitary adenomas, craniopharyngiomas, germinomas, and metastatic lesions. The usefulness of contrast enhancement for the investigation of the retrobulbar space and in cases of low grade or infiltrative glioma has not been demonstrated. In calcified lesions, there is less likelihood of enhancement. Following therapy, tumors may show decreased or no enhancement. The opacification of the inferior vermis following contrast media administration has resulted in false-positive diagnosis in a number of otherwise normal studies. Nonneoplastic Conditions ISOVUE may be beneficial in the image enhancement of nonneoplastic lesions. Cerebral infarctions of recent onset may be better visualized with contrast enhancement, while some infarctions are obscured if contrast media are used. The use of iodinated contrast media results in contrast enhancement in about 60 percent of cerebral infarctions studied from one to four weeks from the onset of symptoms. Sites of active infection may also be enhanced following contrast media administration. Arteriovenous malformations and aneurysms will show contrast enhancement. For these vascular lesions, the enhancement is probably dependent on the iodine content of the circulating blood pool. Hematomas and intraparenchymal bleeders seldom demonstrate any contrast enhancement. However, in cases of intraparenchymal clot, for which there is no obvious clinical explanation, contrast media administration may be helpful in ruling out the possibility of associated arteriovenous malformation. CT Body Imaging ISOVUE (Iopamidol Injection) may be used for enhancement of computed tomographic images for detection and evaluation of lesions in the liver, pancreas, kidneys, aorta, mediastinum, abdominal cavity, pelvis and retroperitoneal space. Enhancement of computed tomography with ISOVUE may be of benefit in establishing diagnoses of certain lesions in these sites with greater assurance than is possible with CT alone, and in supplying additional features of the lesions (e.g., hepatic abscess delineation prior to percutaneous drainage). In other cases, the contrast agent may allow visualization of lesions not seen with CT alone (e.g. tumor extension), or may help to define suspicious lesions seen with unenhanced CT (e.g., pancreatic cyst). Contrast enhancement appears to be greatest within 60 to 90 seconds after bolus administration of contrast agent. Therefore, utilization of a continuous scanning technique (“dynamic CT scanning”) may improve enhancement and diagnostic assessment of tumor and other lesions such as an abscess, occasionally revealing unsuspected or more extensive disease. For example, a cyst may be distinguished from a vascularized solid lesion when precontrast and enhanced scans are compared; the nonperfused mass shows unchanged x-ray absorption (CT number). A vascularized lesion is characterized by an increase in CT number in the few minutes after a bolus of intravascular contrast agent; it may be malignant, benign, or normal tissue, but would probably not be a cyst, hematoma, or other nonvascular lesion. Because unenhanced scanning may provide adequate diagnostic information in the individual patient, the decision to employ contrast enhancement, which may be associated with risk and increased radiation exposure, should be based upon a careful evaluation of clinical, other radiological, and unenhanced CT findings. uuid:7f52644a-8dd8-4a7d-bd0b-49d204ca5d40 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:133082145 biolink:treats HP:0003124 PMID:41385096 "[{""id"":""uuid:c3ac052e-67da-454b-9a7b-faf14a846fa4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a26892a5-859a-448f-8bee-c47b2477aadc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease in Adults In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In adult patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In adult patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin calcium tablets are indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in adult patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of adult patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of adult patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH) as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in pediatric patients, 10 years to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH) if after an adequate trial of diet therapy the following findings are present: a. LDL-C remains ≥ 190 mg/dL or b. LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin calcium tablets have not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:8d955d3b-f4fb-4a6d-baee-26c5d9f2b85a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:133082145 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:9f3f709f-5cf5-4ca9-85a5-7cb14d05c95f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:30064e33-6e7a-4162-8a41-83b843702f0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease in Adults In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In adult patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In adult patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin calcium tablets are indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in adult patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of adult patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of adult patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH) as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in pediatric patients, 10 years to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH) if after an adequate trial of diet therapy the following findings are present: a. LDL-C remains ≥ 190 mg/dL or b. LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin calcium tablets have not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:ffb003ff-f99f-408e-ba2b-781d42715237 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:133082145 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:6462562e-0841-4c19-862d-990a23c8ccb3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dd2ba808-0f2c-433d-b009-bdadf5dd7bbc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease in Adults In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In adult patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In adult patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin calcium tablets are indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in adult patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of adult patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of adult patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH) as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in pediatric patients, 10 years to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH) if after an adequate trial of diet therapy the following findings are present: a. LDL-C remains ≥ 190 mg/dL or b. LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin calcium tablets have not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:2e770bea-5014-427e-ae00-75f487c5fbed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:133082145 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:60806870-5fce-4784-a127-b49ffd3da543"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b507a879-83bb-4640-8748-3fcc70615ec5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease in Adults In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In adult patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In adult patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin calcium tablets are indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in adult patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of adult patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of adult patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH) as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in pediatric patients, 10 years to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH) if after an adequate trial of diet therapy the following findings are present: a. LDL-C remains ≥ 190 mg/dL or b. LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin calcium tablets have not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:121656df-2e40-4b1e-836e-61b52ac9add1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:133082145 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:c4179b64-1e18-4443-a145-81f117e6f638"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fa14c4a5-ccba-4f27-a7d5-18221a09229c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease in Adults In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In adult patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In adult patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin calcium tablets are indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in adult patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of adult patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of adult patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH) as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in pediatric patients, 10 years to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH) if after an adequate trial of diet therapy the following findings are present: a. LDL-C remains ≥ 190 mg/dL or b. LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin calcium tablets have not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:1a76a876-b3ab-47c4-9cda-45b35536d567 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:133082145 biolink:treats UMLS:C0342879 PMID:41385096 "[{""id"":""uuid:2890dee3-5278-4a09-bb89-b6138c346a43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:74b0edb8-e0f1-4421-93e2-edbba5be529f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease in Adults In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In adult patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In adult patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin calcium tablets are indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in adult patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of adult patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of adult patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH) as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in pediatric patients, 10 years to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH) if after an adequate trial of diet therapy the following findings are present: a. LDL-C remains ≥ 190 mg/dL or b. LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin calcium tablets have not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:0e4c897d-53d0-48f1-bd10-53f0657b10f7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:133082145 biolink:treats UMLS:C0342882 PMID:41385096 "[{""id"":""uuid:527d3c6d-b6b6-4bc6-bb36-b6107caa35e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0ec5f296-9e63-4933-be5c-d694edf539b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease in Adults In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In adult patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In adult patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin calcium tablets are indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in adult patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of adult patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of adult patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH) as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in pediatric patients, 10 years to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH) if after an adequate trial of diet therapy the following findings are present: a. LDL-C remains ≥ 190 mg/dL or b. LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin calcium tablets have not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:ab4cab24-7ca9-40d1-9f7e-0b9c7c252129 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:133082145 biolink:treats HP:0003119 PMID:41385096 "[{""id"":""uuid:30f57235-22f8-40b2-99af-1d7fbef93114"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:71506e0e-b9a6-42d3-8bcc-f7c9fc2a5652"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease in Adults In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In adult patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In adult patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin calcium tablets are indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in adult patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of adult patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of adult patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH) as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in pediatric patients, 10 years to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH) if after an adequate trial of diet therapy the following findings are present: a. LDL-C remains ≥ 190 mg/dL or b. LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin calcium tablets have not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:54aec365-e929-42bf-b868-fefd04a945bd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:133082145 biolink:treats MONDO:0007750 PMID:41385096 "[{""id"":""uuid:5b4f3fef-1526-46ad-bb70-82d33c699164"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5dc824cd-6f83-4cc4-b9fc-8081ee8f4573"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease in Adults In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In adult patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In adult patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin calcium tablets are indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in adult patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of adult patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of adult patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH) as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in pediatric patients, 10 years to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH) if after an adequate trial of diet therapy the following findings are present: a. LDL-C remains ≥ 190 mg/dL or b. LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin calcium tablets have not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:18215f7a-ee38-442c-9c5f-f3aaed76d872 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:133082145 biolink:treats MONDO:0007759 PMID:41385096 "[{""id"":""uuid:63f3faad-4895-4d05-815b-c42203e9b4b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6c2903ad-dc8e-4e2f-b229-b8a90a3ce9fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease in Adults In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In adult patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In adult patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin calcium tablets are indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in adult patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of adult patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of adult patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH) as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in pediatric patients, 10 years to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH) if after an adequate trial of diet therapy the following findings are present: a. LDL-C remains ≥ 190 mg/dL or b. LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin calcium tablets have not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:aa9b82d8-7b93-450b-8778-b51ec04d24e5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:133082145 biolink:treats MONDO:0007788 PMID:41385096 "[{""id"":""uuid:8a2f5d63-b843-4ee2-964b-1f3509857835"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5d71664b-9985-4fd4-9ca0-a73023c443c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease in Adults In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In adult patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In adult patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin calcium tablets are indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in adult patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of adult patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of adult patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH) as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in pediatric patients, 10 years to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH) if after an adequate trial of diet therapy the following findings are present: a. LDL-C remains ≥ 190 mg/dL or b. LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin calcium tablets have not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:338002e7-43fd-47b7-89de-7ae9e31c9c76 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:133082145 biolink:treats MONDO:0018473 PMID:41385096 "[{""id"":""uuid:6ce853ca-275f-42aa-b3c9-469be76380de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5174cd9a-8de9-4715-bc68-979134b3beb7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease in Adults In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In adult patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In adult patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin calcium tablets are indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in adult patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of adult patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of adult patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH) as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in pediatric patients, 10 years to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH) if after an adequate trial of diet therapy the following findings are present: a. LDL-C remains ≥ 190 mg/dL or b. LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin calcium tablets have not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:e6a56b79-ac34-4d5d-a70b-3e7daf13db7e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:133082145 biolink:treats UMLS:C0860248 PMID:41385096 "[{""id"":""uuid:75cdd3a2-0bf2-44fd-8067-54aca643b851"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:10c595d2-34c7-42fd-ad4d-ab4aeaea7ee1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease in Adults In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In adult patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In adult patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin calcium tablets are indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in adult patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of adult patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of adult patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH) as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in pediatric patients, 10 years to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH) if after an adequate trial of diet therapy the following findings are present: a. LDL-C remains ≥ 190 mg/dL or b. LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin calcium tablets have not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:5382d577-705a-465c-89d7-cab9f23de071 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:133082145 biolink:treats MONDO:0018328 PMID:41385096 "[{""id"":""uuid:3767f536-d616-4cd7-908f-b3d6c0c148b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d05e02e3-900a-4d2c-a5e6-e43c4d1ea3e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease in Adults In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In adult patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In adult patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin calcium tablets are indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in adult patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of adult patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of adult patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH) as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in pediatric patients, 10 years to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH) if after an adequate trial of diet therapy the following findings are present: a. LDL-C remains ≥ 190 mg/dL or b. LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin calcium tablets have not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:542b0c4b-7296-4836-a2b3-3dce4d448ec0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:133082145 biolink:treats UMLS:C0856526 PMID:41385096 "[{""id"":""uuid:be81dd38-66c7-4d55-a5c0-edbcc0d0c6a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:04f2734d-4b64-426c-8a05-0dabb4a618ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease in Adults In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In adult patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In adult patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin calcium tablets are indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in adult patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of adult patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of adult patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH) as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in pediatric patients, 10 years to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH) if after an adequate trial of diet therapy the following findings are present: a. LDL-C remains ≥ 190 mg/dL or b. LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin calcium tablets have not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:80a5f530-bb02-43f0-916e-eed6b1e03d07 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:133082145 biolink:treats MONDO:0007762 PMID:41385096 "[{""id"":""uuid:ffd3421e-4cad-4e5b-9597-1bc416575b4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7ea9b29d-1707-4d5e-9f40-359fc90b4e82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is recommended as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. In patients with CHD or multiple risk factors for CHD, atorvastatin calcium tablets can be started simultaneously with diet. 1.1 Prevention of Cardiovascular Disease in Adults In adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low HDL-C, or a family history of early coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke Reduce the risk for revascularization procedures and angina In adult patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension, atorvastatin calcium tablets are indicated to: Reduce the risk of myocardial infarction Reduce the risk of stroke In adult patients with clinically evident coronary heart disease, atorvastatin calcium tablets are indicated to: Reduce the risk of non-fatal myocardial infarction Reduce the risk of fatal and non-fatal stroke Reduce the risk for revascularization procedures Reduce the risk of hospitalization for CHF Reduce the risk of angina 1.2 Hyperlipidemia Atorvastatin calcium tablets are indicated: As an adjunct to diet to reduce elevated total-C, LDL-C, apo B, and TG levels and to increase HDL-C in adult patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson Types IIa and IIb); As an adjunct to diet for the treatment of adult patients with elevated serum TG levels (Fredrickson Type IV); For the treatment of adult patients with primary dysbetalipoproteinemia (Fredrickson Type III) who do not respond adequately to diet; To reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH) as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable; As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in pediatric patients, 10 years to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH) if after an adequate trial of diet therapy the following findings are present: a. LDL-C remains ≥ 190 mg/dL or b. LDL-C remains ≥ 160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the pediatric patient 1.3 Limitations of Use Atorvastatin calcium tablets have not been studied in conditions where the major lipoprotein abnormality is elevation of chylomicrons (Fredrickson Types I and V). uuid:dfc5acb5-050e-4f16-b670-3e9b2861dda4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40303 biolink:treats MONDO:0018473 PMID:41385096 "[{""id"":""uuid:73bf8d93-8a3d-4eca-911a-9764bc4b463d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:610edd48-04a6-41c3-82e4-b08a49e4ecca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lovastatin should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C, lovastatin is indicated to reduce the risk of: Myocardial infarction Unstable angina Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies.) Coronary Heart Disease Lovastatin is indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for artherosclerotic vascular disease due to hypercholesterolemia. Lovastatin is indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin is indicated as an adjunct to diet to reduce total-C, LDL-C and apolipoprotein B levels in adolescent boys and girls who are at least one year post-menarche, 10 to 17 years of age, with heFH if after an adequate trial of diet therapy the following findings are present: LDL-C remains >189 mg/dL or LDL-C remains >160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the adolescent patient General Recommendations Prior to initiating therapy with lovastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total-C, HDL-C, and TG. For patients with TG less than 400 mg/dL (<4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = total-C - [0.2 × (TG) + HDL-C] For TG levels >400 mg/dL (>4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated total-C. In such cases, lovastatin is not indicated. The National Cholesterol Education Program (NCEP) Treatment Guidelines are summarized below: † CHD, coronary heart disease †† Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of <100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgment also may call for deferring drug therapy in this subcategory. ††† Almost all people with 0-1 risk factor have a 10-year risk <10%; thus, 10-year risk assessment in people with 0-1 risk factor is not necessary. NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD † or CHD risk equivalents (10-year risk >20%) <100 ≥100 ≥130 (100-129: drug optional) †† 2+ Risk factors (10 year risk ≤20%) <130 ≥130 10-year risk 10-20%: ≥130 10-year risk <10%: ≥160 0-1 Risk factor ††† <160 ≥160 ≥190 (160-189: LDL-lowering drug optional) 2 Classification of Hyperlipoproteinemias Lipid Elevations Type Lipoproteins elevated major minor I chylomicrons TG ↑→C IIa LDL C -- IIb LDL, VLDL C TG III (rare) IDL C/TG -- IV VLDL TG ↑→C V (rare) chylomicrons, VLDL TG ↑→C IDL = intermediate-density lipoprotein. After the LDL-C goal has been achieved, if the TG is still ≥200 mg/dL, non-HDL-C (total-C minus HDL-C) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is ≥130 mg/dL (see NCEP Guidelines above). Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the total-C be used to monitor therapy. Although lovastatin may be useful to reduce elevated LDL-C levels in patients with combined hypercholesterolemia and hypertriglyceridemia where hypercholesterolemia is the major abnormality (Type IIb hyperlipoproteinemia), it has not been studied in conditions where the major abnormality is elevation of chylomicrons, VLDL or IDL (i.e., hyperlipoproteinemia types I, III, IV, or V). *** The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable <170 <110 Borderline 170-199 110-129 High ≥200 ≥130 Children treated with lovastatin in adolescence should be re-evaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult goals for LDL-C. uuid:a447d4bd-c726-4b47-968f-d3d3997f6208 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40303 biolink:treats MONDO:0007762 PMID:41385096 "[{""id"":""uuid:fad654bf-c377-4feb-86bb-c347b471387c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9e81227a-b35d-4ed5-9c7f-4d75632c3678"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lovastatin should be a component of multiple risk factor intervention in those individuals with dyslipidemia at risk for atherosclerotic vascular disease. Lovastatin should be used in addition to a diet restricted in saturated fat and cholesterol as part of a treatment strategy to lower total-C and LDL-C to target levels when the response to diet and other nonpharmacological measures alone has been inadequate to reduce risk. Primary Prevention of Coronary Heart Disease In individuals without symptomatic cardiovascular disease, average to moderately elevated total-C and LDL-C, and below average HDL-C, lovastatin is indicated to reduce the risk of: Myocardial infarction Unstable angina Coronary revascularization procedures (See CLINICAL PHARMACOLOGY, Clinical Studies.) Coronary Heart Disease Lovastatin is indicated to slow the progression of coronary atherosclerosis in patients with coronary heart disease as part of a treatment strategy to lower total-C and LDL-C to target levels. Hypercholesterolemia Therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for artherosclerotic vascular disease due to hypercholesterolemia. Lovastatin is indicated as an adjunct to diet for the reduction of elevated total-C and LDL-C levels in patients with primary hypercholesterolemia (Types IIa and IIb 2), when the response to diet restricted in saturated fat and cholesterol and to other nonpharmacological measures alone has been inadequate. Adolescent Patients with Heterozygous Familial Hypercholesterolemia Lovastatin is indicated as an adjunct to diet to reduce total-C, LDL-C and apolipoprotein B levels in adolescent boys and girls who are at least one year post-menarche, 10 to 17 years of age, with heFH if after an adequate trial of diet therapy the following findings are present: LDL-C remains >189 mg/dL or LDL-C remains >160 mg/dL and: there is a positive family history of premature cardiovascular disease or two or more other CVD risk factors are present in the adolescent patient General Recommendations Prior to initiating therapy with lovastatin, secondary causes for hypercholesterolemia (e.g., poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinemias, obstructive liver disease, other drug therapy, alcoholism) should be excluded, and a lipid profile performed to measure total-C, HDL-C, and TG. For patients with TG less than 400 mg/dL (<4.5 mmol/L), LDL-C can be estimated using the following equation: LDL-C = total-C - [0.2 × (TG) + HDL-C] For TG levels >400 mg/dL (>4.5 mmol/L), this equation is less accurate and LDL-C concentrations should be determined by ultracentrifugation. In hypertriglyceridemic patients, LDL-C may be low or normal despite elevated total-C. In such cases, lovastatin is not indicated. The National Cholesterol Education Program (NCEP) Treatment Guidelines are summarized below: † CHD, coronary heart disease †† Some authorities recommend use of LDL-lowering drugs in this category if an LDL-C level of <100 mg/dL cannot be achieved by therapeutic lifestyle changes. Others prefer use of drugs that primarily modify triglycerides and HDL-C, e.g., nicotinic acid or fibrate. Clinical judgment also may call for deferring drug therapy in this subcategory. ††† Almost all people with 0-1 risk factor have a 10-year risk <10%; thus, 10-year risk assessment in people with 0-1 risk factor is not necessary. NCEP Treatment Guidelines: LDL-C Goals and Cutpoints for Therapeutic Lifestyle Changes and Drug Therapy in Different Risk Categories Risk Category LDL Goal (mg/dL) LDL Level at Which to Initiate Therapeutic Lifestyle Changes (mg/dL) LDL Level at Which to Consider Drug Therapy (mg/dL) CHD † or CHD risk equivalents (10-year risk >20%) <100 ≥100 ≥130 (100-129: drug optional) †† 2+ Risk factors (10 year risk ≤20%) <130 ≥130 10-year risk 10-20%: ≥130 10-year risk <10%: ≥160 0-1 Risk factor ††† <160 ≥160 ≥190 (160-189: LDL-lowering drug optional) 2 Classification of Hyperlipoproteinemias Lipid Elevations Type Lipoproteins elevated major minor I chylomicrons TG ↑→C IIa LDL C -- IIb LDL, VLDL C TG III (rare) IDL C/TG -- IV VLDL TG ↑→C V (rare) chylomicrons, VLDL TG ↑→C IDL = intermediate-density lipoprotein. After the LDL-C goal has been achieved, if the TG is still ≥200 mg/dL, non-HDL-C (total-C minus HDL-C) becomes a secondary target of therapy. Non-HDL-C goals are set 30 mg/dL higher than LDL-C goals for each risk category. At the time of hospitalization for an acute coronary event, consideration can be given to initiating drug therapy at discharge if the LDL-C is ≥130 mg/dL (see NCEP Guidelines above). Since the goal of treatment is to lower LDL-C, the NCEP recommends that LDL-C levels be used to initiate and assess treatment response. Only if LDL-C levels are not available, should the total-C be used to monitor therapy. Although lovastatin may be useful to reduce elevated LDL-C levels in patients with combined hypercholesterolemia and hypertriglyceridemia where hypercholesterolemia is the major abnormality (Type IIb hyperlipoproteinemia), it has not been studied in conditions where the major abnormality is elevation of chylomicrons, VLDL or IDL (i.e., hyperlipoproteinemia types I, III, IV, or V). *** The NCEP classification of cholesterol levels in pediatric patients with a familial history of hypercholesterolemia or premature cardiovascular disease is summarized below: Category Total-C (mg/dL) LDL-C (mg/dL) Acceptable <170 <110 Borderline 170-199 110-129 High ≥200 ≥130 Children treated with lovastatin in adolescence should be re-evaluated in adulthood and appropriate changes made to their cholesterol-lowering regimen to achieve adult goals for LDL-C. uuid:a8d11120-c13a-426d-acf7-7b6364e70efd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3312 biolink:treats HP:0002901 PMID:41385096 "[{""id"":""uuid:348d33f8-56c3-4c8d-ba5e-e302cc4e3f79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:615925b7-0e44-4937-b570-88a86f29ae0c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 10% Calcium Chloride Injection, USP is indicated for the treatment of hypocalcemia in those conditions requiring a prompt increase in plasma calcium levels. uuid:c70eda38-08ac-4826-883d-2317e3934ce6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46726 biolink:treats MONDO:0001356 PMID:41385096 "[{""id"":""uuid:4b5bed42-0d90-47bb-b732-11da883a56dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:91db1e84-0280-4456-b763-c9543926df9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Feraheme is indicated for the treatment of iron deficiency anemia (IDA) in adult patients: • who have intolerance to oral iron or have had unsatisfactory response to oral iron or • who have chronic kidney disease (CKD). uuid:706d7781-1c5d-4a0f-b142-90bcd25eae6c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46726 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:2afbb6ad-dd7d-4ec2-8783-04cfcbdabf6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dfae9224-1232-474a-ad21-9d8b56be0820"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Feraheme is indicated for the treatment of iron deficiency anemia (IDA) in adult patients: • who have intolerance to oral iron or have had unsatisfactory response to oral iron or • who have chronic kidney disease (CKD). uuid:650efd9c-0441-485a-9d54-6868a34f49bb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63578 biolink:treats MONDO:0005070 PMID:41385096 "[{""id"":""uuid:44bac0aa-07ad-4847-a17e-8ade74488604"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a4099be6-aa27-4599-a746-6a1bd9324949"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ULTRAVIST ® injection is an iodinated contrast agent indicated In Adults • For Computed Tomography (CT) of the head and body (intrathoracic, intra-abdominal and retroperitoneal regions) for the evaluation of neoplastic and non-neoplastic lesions in adults. • The usefulness of contrast enhancement for the investigation of the retrobulbar space and of low grade or infiltrative glioma has not been demonstrated. Pediatric Patients • For Computed Tomography (CT) of the head and body For use only with an automated contrast injection system, contrast management system, or contrast media transfer set approved or cleared for use with this contrast agent in this Imaging Bulk Package. uuid:5e8086b4-8f22-46d2-81b0-ce3a5c44dc09 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63578 biolink:treats MONDO:0021637 PMID:41385096 "[{""id"":""uuid:b9a5458d-3307-423a-ba44-28f6315f47e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:04f0ede6-9d10-4d75-b5f1-8be78b493811"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ULTRAVIST ® injection is an iodinated contrast agent indicated In Adults • For Computed Tomography (CT) of the head and body (intrathoracic, intra-abdominal and retroperitoneal regions) for the evaluation of neoplastic and non-neoplastic lesions in adults. • The usefulness of contrast enhancement for the investigation of the retrobulbar space and of low grade or infiltrative glioma has not been demonstrated. Pediatric Patients • For Computed Tomography (CT) of the head and body For use only with an automated contrast injection system, contrast management system, or contrast media transfer set approved or cleared for use with this contrast agent in this Imaging Bulk Package. uuid:33a3362b-57ac-4b9b-be00-10d40f1cac7a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63578 biolink:treats MONDO:0021042 PMID:41385096 "[{""id"":""uuid:3fca61c8-178a-4d4a-a7ff-f22e8dfc2032"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1136e51f-71be-4bb3-ad27-4ca4d9c8bc41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ULTRAVIST ® injection is an iodinated contrast agent indicated In Adults • For Computed Tomography (CT) of the head and body (intrathoracic, intra-abdominal and retroperitoneal regions) for the evaluation of neoplastic and non-neoplastic lesions in adults. • The usefulness of contrast enhancement for the investigation of the retrobulbar space and of low grade or infiltrative glioma has not been demonstrated. Pediatric Patients • For Computed Tomography (CT) of the head and body For use only with an automated contrast injection system, contrast management system, or contrast media transfer set approved or cleared for use with this contrast agent in this Imaging Bulk Package. uuid:bb1d2620-f944-4a79-9ecd-0afd2b8896e6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB16791 biolink:treats MONDO:0010604 PMID:41385096 "[{""id"":""uuid:4bc37050-24e4-46da-a246-ce5c3ce9d391"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ca3d78e1-c077-4735-bbef-dbe8a908a88b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1b00d059-00a3-43ba-bbef-bc02ac25ff59"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/hemgenix""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] HEMGENIX is an adeno-associated virus vector-based gene therapy indicated for treatment of adults with Hemophilia B (congenital Factor IX deficiency) who: Currently use Factor IX prophylaxis therapy, or Have current or historical life-threatening hemorrhage, or Have repeated, serious spontaneous bleeding episodes.|[EMA] Treatment of severe and moderately severe Haemophilia B (congenital Factor IX deficiency) in adult patients without a history of Factor IX inhibitors. uuid:a9e2948d-6c96-405e-9918-783582883516 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB16791 biolink:treats NCIT:C26791 PMID:41385096 "[{""id"":""uuid:f6d0eee6-4bf1-40b3-a831-2b3a4b17ba06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dca04641-8639-4a8f-8b83-1d50f246c152"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] HEMGENIX is an adeno-associated virus vector-based gene therapy indicated for treatment of adults with Hemophilia B (congenital Factor IX deficiency) who: Currently use Factor IX prophylaxis therapy, or Have current or historical life-threatening hemorrhage, or Have repeated, serious spontaneous bleeding episodes. uuid:1d3695cc-c637-44b0-8263-f36a46bba39a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7454 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:56832394-8d1b-446b-b505-d7b70a6a4969"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:69f09c5b-7683-4423-b973-f0292f386f75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nalbuphine Hydrochloride Injection is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Nalbuphine Hydrochloride Injection can also be used as a supplement to balanced anesthesia, for preoperative and postoperative analgesia, and for obstetrical analgesia during labor and delivery. uuid:3470f78a-0a90-4fc7-bba8-9e908d30625e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7454 biolink:treats NCIT:C92821 PMID:41385096 "[{""id"":""uuid:fa4f87ec-8a38-409f-ae8e-5e3d92537ade"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:51fda415-9069-4acf-8d6d-3931ac3981bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nalbuphine Hydrochloride Injection is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Nalbuphine Hydrochloride Injection can also be used as a supplement to balanced anesthesia, for preoperative and postoperative analgesia, and for obstetrical analgesia during labor and delivery. uuid:334a563b-d706-406c-910a-0a9c3464c425 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:107736 biolink:treats EFO:0004888 PMID:41385096 "[{""id"":""uuid:4e3b35f5-8fab-42a5-bfdc-c30c8f3144dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6534b933-bac3-486b-b36a-acab04dc544f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diabetic Gastroparesis (Diabetic Gastric Stasis) Metoclopramide is indicated for the relief of symptoms associated with acute and recurrent diabetic gastric stasis. The Prevention of Nausea and Vomiting Associated with Emetogenic Cancer Chemotherapy Metoclopramide Injection, USP is indicated for the prophylaxis of vomiting associated with emetogenic cancer chemotherapy. The Prevention of Postoperative Nausea and Vomiting Metoclopramide Injection, USP is indicated for the prophylaxis of postoperative nausea and vomiting in those circumstances where nasogastric suction is undesirable. Small Bowel Intubation Metoclopramide Injection, USP may be used to facilitate small bowel intubation in adults and pediatric patients in whom the tube does not pass the pylorus with conventional maneuvers. Radiological Examination Metoclopramide Injection, USP may be used to stimulate gastric emptying and intestinal transit of barium in cases where delayed emptying interferes with radiological examination of the stomach and/or small intestine. uuid:a4658a44-5ee7-44cd-a25b-bd50f20dbdab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:187893 biolink:treats MONDO:0033613 PMID:41385096 "[{""id"":""uuid:0d18ee3e-3791-487e-8cf8-397fd554374a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8ec3b768-97c4-4e42-9206-fb94f84af8c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Baclofen Injection is indicated for use in the management of severe spasticity. Patients should first respond to a screening dose of intrathecal baclofen prior to consideration for long term infusion via an implantable pump. For spasticity of spinal cord origin, chronic infusion of Baclofen Injection via an implantable pump should be reserved for patients unresponsive to oral baclofen therapy, or those who experience intolerable CNS side effects at effective doses. Patients with spasticity due to traumatic brain injury should wait at least one year after the injury before consideration of long term intrathecal baclofen therapy. Baclofen Injection is intended for use by the intrathecal route in single bolus test doses (via spinal catheter or lumbar puncture) and, for chronic use, only in implantable pumps approved by the FDA specifically for the administration of Baclofen Injection into the intrathecal space. Spasticity of Spinal Cord Origin: Evidence supporting the efficacy of Baclofen Injection was obtained in randomized, controlled investigations that compared the effects of either a single intrathecal dose or a three day intrathecal infusion of Baclofen Injection to placebo in patients with severe spasticity and spasms due to either spinal cord trauma or multiple sclerosis. Baclofen Injection was superior to placebo on both principal outcome measures employed: change from baseline in the Ashworth rating of spasticity and the frequency of spasms. Spasticity of Cerebral Origin: The efficacy of Baclofen Injection was investigated in three controlled clinical trials; two enrolled patients with cerebral palsy and one enrolled patients with spasticity due to previous brain injury. The first study, a randomized controlled cross-over trial of 51 patients with cerebral palsy, provided strong, statistically significant results; Baclofen Injection was superior to placebo in reducing spasticity as measured by the Ashworth Scale. A second cross-over study was conducted in 11 patients with spasticity arising from brain injury. Despite the small sample size, the study yielded a nearly significant test statistic (p= 0.066) and provided directionally favorable results. The last study, however, did not provide data that could be reliably analyzed. Baclofen Injection therapy may be considered an alternative to destructive neurosurgical procedures. Prior to implantation of a device for chronic intrathecal infusion of Baclofen Injection, patients must show a response to Baclofen Injection in a screening trial (see Dosage and Administration). uuid:18d6c2fd-99e4-4b9b-a515-fc59b797fd32 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63611 biolink:treats MONDO:0002885 PMID:41385096 "[{""id"":""uuid:60712e16-0192-4c7b-be79-f3af469c9fcf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cf437a18-3728-4907-be10-452cbbcdf62c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Moxifloxacin ophthalmic solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species Efficacy for this organism was studied in fewer than 10 infections. Micrococcus luteus Staphylococcus aureus Staphylococcus epidermidis Staphylococcus haemolyticus Staphylococcus hominis Staphylococcus warneri Streptococcus pneumoniae Streptococcus viridans group Acinetobacter lwoffii Haemophilus influenza Haemophilus parainfluenzae Chlamydia trachomatis uuid:036d68a7-3fe4-46d3-b73f-2c9d69bdd559 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63611 biolink:treats MONDO:0021679 PMID:41385096 "[{""id"":""uuid:34e08606-112e-47ed-b466-34f47eb017d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:297ea5ee-1b12-41fa-bcdc-ee27d6279c5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Moxifloxacin ophthalmic solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species Efficacy for this organism was studied in fewer than 10 infections. Micrococcus luteus Staphylococcus aureus Staphylococcus epidermidis Staphylococcus haemolyticus Staphylococcus hominis Staphylococcus warneri Streptococcus pneumoniae Streptococcus viridans group Acinetobacter lwoffii Haemophilus influenza Haemophilus parainfluenzae Chlamydia trachomatis uuid:4f183473-46b5-47ea-a7e3-5efdbca0ce0e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63611 biolink:treats MONDO:0024313 PMID:41385096 "[{""id"":""uuid:96e2a4f2-8dd3-49df-9664-2de19f472573"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ea3ac925-3d60-4e8c-8a64-2a595a570890"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Moxifloxacin ophthalmic solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species Efficacy for this organism was studied in fewer than 10 infections. Micrococcus luteus Staphylococcus aureus Staphylococcus epidermidis Staphylococcus haemolyticus Staphylococcus hominis Staphylococcus warneri Streptococcus pneumoniae Streptococcus viridans group Acinetobacter lwoffii Haemophilus influenza Haemophilus parainfluenzae Chlamydia trachomatis uuid:3887d0b0-4ca7-4537-ae4b-cb027acef84c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63611 biolink:treats MONDO:0021680 PMID:41385096 "[{""id"":""uuid:881a1fc9-6af5-43d3-bcb2-b815c716e201"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0473c41b-3347-46b0-a35d-fb17dd4ecb66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Moxifloxacin ophthalmic solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species Efficacy for this organism was studied in fewer than 10 infections. Micrococcus luteus Staphylococcus aureus Staphylococcus epidermidis Staphylococcus haemolyticus Staphylococcus hominis Staphylococcus warneri Streptococcus pneumoniae Streptococcus viridans group Acinetobacter lwoffii Haemophilus influenza Haemophilus parainfluenzae Chlamydia trachomatis uuid:bd27d41d-e1af-457b-a532-04ec6139a351 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63611 biolink:treats MONDO:0006635 PMID:41385096 "[{""id"":""uuid:3118456f-5b8f-427c-ac56-7519fdcfa2da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:29c19567-1b3e-4aaf-8712-8587f6f0daef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Moxifloxacin ophthalmic solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species Efficacy for this organism was studied in fewer than 10 infections. Micrococcus luteus Staphylococcus aureus Staphylococcus epidermidis Staphylococcus haemolyticus Staphylococcus hominis Staphylococcus warneri Streptococcus pneumoniae Streptococcus viridans group Acinetobacter lwoffii Haemophilus influenza Haemophilus parainfluenzae Chlamydia trachomatis uuid:3e151018-b992-47cb-8666-1c7244e43646 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63611 biolink:treats MONDO:0006926 PMID:41385096 "[{""id"":""uuid:dcfde1e0-9ad6-46c6-850d-a6e1bda1fd79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:198bd7ce-95aa-4236-8bac-5249f5ca7e60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Moxifloxacin ophthalmic solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species Efficacy for this organism was studied in fewer than 10 infections. Micrococcus luteus Staphylococcus aureus Staphylococcus epidermidis Staphylococcus haemolyticus Staphylococcus hominis Staphylococcus warneri Streptococcus pneumoniae Streptococcus viridans group Acinetobacter lwoffii Haemophilus influenza Haemophilus parainfluenzae Chlamydia trachomatis uuid:cbcc6f6e-d9b3-40c0-829e-e8ecd063ec1a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63611 biolink:treats MONDO:0021697 PMID:41385096 "[{""id"":""uuid:64509132-39cc-4d07-8eaf-8e1a83b78e12"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cbf91a09-bd7e-4819-82c0-d47f8d1158e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Moxifloxacin ophthalmic solution is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Corynebacterium species Efficacy for this organism was studied in fewer than 10 infections. Micrococcus luteus Staphylococcus aureus Staphylococcus epidermidis Staphylococcus haemolyticus Staphylococcus hominis Staphylococcus warneri Streptococcus pneumoniae Streptococcus viridans group Acinetobacter lwoffii Haemophilus influenza Haemophilus parainfluenzae Chlamydia trachomatis uuid:dab3d58a-2d47-47cb-ab8b-f602f8b22d89 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29108 biolink:treats UMLS:C0270224 PMID:41385096 "[{""id"":""uuid:3b1ec7f4-bc2f-4e83-9d65-127f0bc7aa4c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c6b80848-f2f7-40e5-8122-ec4dabba1e59"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Calcium Chloride Injection, USP, 10% is indicated: In the treatment of hypocalcemia in conditions requiring a prompt increase in plasma calcium levels (e.g., neonatal tetany and tetany due to parathyroid deficiency, vitamin D deficiency and alkalosis) and for prevention of hypocalcemia during exchange transfusions. As adjunctive therapy in the management of acute symptoms in lead colic. In the treatment of magnesium intoxication due to overdosage of magnesium sulfate. In severe hyperkalemia, to combat deleterious effects on electrocardiographic (ECG) function, pending correction of the potassium level in the extracellular fluid. In cardiac resuscitation, particularly after open heart surgery, when epinephrine fails to improve weak or ineffective myocardial contractions. uuid:b347d822-886c-4a4e-bbc1-63e3b13c8edd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29108 biolink:treats MONDO:0001220 PMID:41385096 "[{""id"":""uuid:45ec0fae-5381-41dd-a49f-a1e0f7aa53ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:01097552-90f1-4ace-8740-d5171134d89e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Calcium Chloride Injection, USP, 10% is indicated: In the treatment of hypocalcemia in conditions requiring a prompt increase in plasma calcium levels (e.g., neonatal tetany and tetany due to parathyroid deficiency, vitamin D deficiency and alkalosis) and for prevention of hypocalcemia during exchange transfusions. As adjunctive therapy in the management of acute symptoms in lead colic. In the treatment of magnesium intoxication due to overdosage of magnesium sulfate. In severe hyperkalemia, to combat deleterious effects on electrocardiographic (ECG) function, pending correction of the potassium level in the extracellular fluid. In cardiac resuscitation, particularly after open heart surgery, when epinephrine fails to improve weak or ineffective myocardial contractions. uuid:c8b38dbb-3fc7-44be-b329-4e2ab71d92f7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29108 biolink:treats MONDO:0100471 PMID:41385096 "[{""id"":""uuid:5ed781bc-ef2a-45f4-8428-279b1eb7638b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5730282f-71cc-4838-be43-fc9d2e400014"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Calcium Chloride Injection, USP, 10% is indicated: In the treatment of hypocalcemia in conditions requiring a prompt increase in plasma calcium levels (e.g., neonatal tetany and tetany due to parathyroid deficiency, vitamin D deficiency and alkalosis) and for prevention of hypocalcemia during exchange transfusions. As adjunctive therapy in the management of acute symptoms in lead colic. In the treatment of magnesium intoxication due to overdosage of magnesium sulfate. In severe hyperkalemia, to combat deleterious effects on electrocardiographic (ECG) function, pending correction of the potassium level in the extracellular fluid. In cardiac resuscitation, particularly after open heart surgery, when epinephrine fails to improve weak or ineffective myocardial contractions. uuid:150b2e0a-2348-4fc5-9486-6031ab478aee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29108 biolink:treats HP:0001948 PMID:41385096 "[{""id"":""uuid:1ea08589-e908-4d19-bdde-4d20d671fc22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:efa55908-8e12-4e47-8d69-d316b6455c7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Calcium Chloride Injection, USP, 10% is indicated: In the treatment of hypocalcemia in conditions requiring a prompt increase in plasma calcium levels (e.g., neonatal tetany and tetany due to parathyroid deficiency, vitamin D deficiency and alkalosis) and for prevention of hypocalcemia during exchange transfusions. As adjunctive therapy in the management of acute symptoms in lead colic. In the treatment of magnesium intoxication due to overdosage of magnesium sulfate. In severe hyperkalemia, to combat deleterious effects on electrocardiographic (ECG) function, pending correction of the potassium level in the extracellular fluid. In cardiac resuscitation, particularly after open heart surgery, when epinephrine fails to improve weak or ineffective myocardial contractions. uuid:d6490bea-7853-4c34-8ce5-32c5ef7229b7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29108 biolink:treats MONDO:0018019 PMID:41385096 "[{""id"":""uuid:b79b70c8-7b9f-4314-8963-545f9cd1aadb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:adebb04f-6e49-4492-bb7d-96e3a182f9cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Calcium Chloride Injection, USP, 10% is indicated: In the treatment of hypocalcemia in conditions requiring a prompt increase in plasma calcium levels (e.g., neonatal tetany and tetany due to parathyroid deficiency, vitamin D deficiency and alkalosis) and for prevention of hypocalcemia during exchange transfusions. As adjunctive therapy in the management of acute symptoms in lead colic. In the treatment of magnesium intoxication due to overdosage of magnesium sulfate. In severe hyperkalemia, to combat deleterious effects on electrocardiographic (ECG) function, pending correction of the potassium level in the extracellular fluid. In cardiac resuscitation, particularly after open heart surgery, when epinephrine fails to improve weak or ineffective myocardial contractions. uuid:ee78aa8e-b4ed-4bbd-a955-b1e5bcb961d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29108 biolink:treats HP:0002153 PMID:41385096 "[{""id"":""uuid:084c0e80-5228-4dda-ac4b-7d18406cdbaa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:45a25922-9fa3-4dd4-a27b-092f07a54fd6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Calcium Chloride Injection, USP, 10% is indicated: In the treatment of hypocalcemia in conditions requiring a prompt increase in plasma calcium levels (e.g., neonatal tetany and tetany due to parathyroid deficiency, vitamin D deficiency and alkalosis) and for prevention of hypocalcemia during exchange transfusions. As adjunctive therapy in the management of acute symptoms in lead colic. In the treatment of magnesium intoxication due to overdosage of magnesium sulfate. In severe hyperkalemia, to combat deleterious effects on electrocardiographic (ECG) function, pending correction of the potassium level in the extracellular fluid. In cardiac resuscitation, particularly after open heart surgery, when epinephrine fails to improve weak or ineffective myocardial contractions. uuid:6fdd51d1-149c-4550-bab1-2f0b93894812 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18243 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:1f39b696-5d75-4baf-bfcf-0961d9008d9d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:62e2b9ac-fdf7-431a-a5e2-905f504dc8f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dopamine HCl is indicated for the correction of hemodynamic imbalances present in the shock syndrome due to myocardial infarction, trauma, endotoxic septicemia, open-heart surgery, renal failure, and chronic cardiac decompensation as in congestive failure. Patients most likely to respond adequately to dopamine HCl are those in whom physiological parameters, such as urine flow, myocardial function, and blood pressure, have not undergone profound deterioration. Multiclinic trials indicate that the shorter the time interval between onset of signs and symptoms and initiation of therapy with blood volume correction and dopamine HCl, the better the prognosis. Where appropriate, blood volume restoration with a suitable plasma expander or whole blood should be accomplished prior to administration of dopamine HCl. Poor Perfusion of Vital Organs – Urine flow appears to be one of the better diagnostic signs by which adequacy of vital organ perfusion can be monitored. Nevertheless, the physician should also observe the patient for signs of reversal of confusion or reversal of comatose condition. Loss of pallor, increase in toe temperature, and/or adequacy of nail bed capillary filling may also be used as indices of adequate dosage. Clinical studies have shown that when dopamine HCl is administered before urine flow has diminished to levels of approximately 0.3 mL/minute, prognosis is more favorable. Nevertheless, in a number of oliguric or anuric patients, administration of dopamine HCl has resulted in an increase in urine flow, which in some cases reached normal levels. Dopamine HCl may also increase urine flow in patients whose output is within normal limits and thus may be of value in reducing the degree of pre-existing fluid accumulation. It should be noted that at doses above those optimal for the individual patient, urine flow may decrease, necessitating reduction of dosage. Low Cardiac Output – Increased cardiac output is related to dopamine's direct inotropic effect on the myocardium. Increased cardiac output at low or moderate doses appears to be related to a favorable prognosis. Increase in cardiac output has been associated with either static or decreased systemic vascular resistance (SVR). Static or decreased SVR associated with low or moderate movements in cardiac output is believed to be a reflection of differential effects on specific vascular beds with increased resistance in peripheral beds (e.g., femoral) and concomitant decreases in mesenteric and renal vascular beds. Redistribution of blood flow parallels these changes so that an increase in cardiac output is accompanied by an increase in mesenteric and renal blood flow. In many instances the renal fraction of the total cardiac output has been found to increase. Increase in cardiac output produced by dopamine is not associated with substantial decreases in systemic vascular resistance as may occur with isoproterenol. Hypotension – Hypotension due to inadequate cardiac output can be managed by administration of low to moderate doses of dopamine HCl which have little effect on SVR. At high therapeutic doses, dopamine's alpha-adrenergic activity becomes more prominent and thus may correct hypotension due to diminished SVR. As in the case of other circulatory decompensation states, prognosis is better in patients whose blood pressure and urine flow have not undergone profound deterioration. Therefore, it is suggested that the physician administer dopamine HCl as soon as a definite trend toward decreased systolic and diastolic pressure becomes evident. uuid:ee42139f-b9b5-401a-964a-44a92d855b7e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18243 biolink:treats MONDO:0006893 PMID:41385096 "[{""id"":""uuid:431b632f-0a2b-462e-b61c-ee5730ff1b0f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b677d58d-df67-44c3-a6d4-84d501942222"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dopamine HCl is indicated for the correction of hemodynamic imbalances present in the shock syndrome due to myocardial infarction, trauma, endotoxic septicemia, open-heart surgery, renal failure, and chronic cardiac decompensation as in congestive failure. Patients most likely to respond adequately to dopamine HCl are those in whom physiological parameters, such as urine flow, myocardial function, and blood pressure, have not undergone profound deterioration. Multiclinic trials indicate that the shorter the time interval between onset of signs and symptoms and initiation of therapy with blood volume correction and dopamine HCl, the better the prognosis. Where appropriate, blood volume restoration with a suitable plasma expander or whole blood should be accomplished prior to administration of dopamine HCl. Poor Perfusion of Vital Organs – Urine flow appears to be one of the better diagnostic signs by which adequacy of vital organ perfusion can be monitored. Nevertheless, the physician should also observe the patient for signs of reversal of confusion or reversal of comatose condition. Loss of pallor, increase in toe temperature, and/or adequacy of nail bed capillary filling may also be used as indices of adequate dosage. Clinical studies have shown that when dopamine HCl is administered before urine flow has diminished to levels of approximately 0.3 mL/minute, prognosis is more favorable. Nevertheless, in a number of oliguric or anuric patients, administration of dopamine HCl has resulted in an increase in urine flow, which in some cases reached normal levels. Dopamine HCl may also increase urine flow in patients whose output is within normal limits and thus may be of value in reducing the degree of pre-existing fluid accumulation. It should be noted that at doses above those optimal for the individual patient, urine flow may decrease, necessitating reduction of dosage. Low Cardiac Output – Increased cardiac output is related to dopamine's direct inotropic effect on the myocardium. Increased cardiac output at low or moderate doses appears to be related to a favorable prognosis. Increase in cardiac output has been associated with either static or decreased systemic vascular resistance (SVR). Static or decreased SVR associated with low or moderate movements in cardiac output is believed to be a reflection of differential effects on specific vascular beds with increased resistance in peripheral beds (e.g., femoral) and concomitant decreases in mesenteric and renal vascular beds. Redistribution of blood flow parallels these changes so that an increase in cardiac output is accompanied by an increase in mesenteric and renal blood flow. In many instances the renal fraction of the total cardiac output has been found to increase. Increase in cardiac output produced by dopamine is not associated with substantial decreases in systemic vascular resistance as may occur with isoproterenol. Hypotension – Hypotension due to inadequate cardiac output can be managed by administration of low to moderate doses of dopamine HCl which have little effect on SVR. At high therapeutic doses, dopamine's alpha-adrenergic activity becomes more prominent and thus may correct hypotension due to diminished SVR. As in the case of other circulatory decompensation states, prognosis is better in patients whose blood pressure and urine flow have not undergone profound deterioration. Therefore, it is suggested that the physician administer dopamine HCl as soon as a definite trend toward decreased systolic and diastolic pressure becomes evident. uuid:8b533de1-f4fd-4ffc-b107-bdead9e84ee0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18243 biolink:treats MONDO:0001106 PMID:41385096 "[{""id"":""uuid:1d2e03e8-c0e2-44b0-898e-83feb190c998"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b07b5821-12a6-40c3-ada7-fa02b62f7e8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dopamine HCl is indicated for the correction of hemodynamic imbalances present in the shock syndrome due to myocardial infarction, trauma, endotoxic septicemia, open-heart surgery, renal failure, and chronic cardiac decompensation as in congestive failure. Patients most likely to respond adequately to dopamine HCl are those in whom physiological parameters, such as urine flow, myocardial function, and blood pressure, have not undergone profound deterioration. Multiclinic trials indicate that the shorter the time interval between onset of signs and symptoms and initiation of therapy with blood volume correction and dopamine HCl, the better the prognosis. Where appropriate, blood volume restoration with a suitable plasma expander or whole blood should be accomplished prior to administration of dopamine HCl. Poor Perfusion of Vital Organs – Urine flow appears to be one of the better diagnostic signs by which adequacy of vital organ perfusion can be monitored. Nevertheless, the physician should also observe the patient for signs of reversal of confusion or reversal of comatose condition. Loss of pallor, increase in toe temperature, and/or adequacy of nail bed capillary filling may also be used as indices of adequate dosage. Clinical studies have shown that when dopamine HCl is administered before urine flow has diminished to levels of approximately 0.3 mL/minute, prognosis is more favorable. Nevertheless, in a number of oliguric or anuric patients, administration of dopamine HCl has resulted in an increase in urine flow, which in some cases reached normal levels. Dopamine HCl may also increase urine flow in patients whose output is within normal limits and thus may be of value in reducing the degree of pre-existing fluid accumulation. It should be noted that at doses above those optimal for the individual patient, urine flow may decrease, necessitating reduction of dosage. Low Cardiac Output – Increased cardiac output is related to dopamine's direct inotropic effect on the myocardium. Increased cardiac output at low or moderate doses appears to be related to a favorable prognosis. Increase in cardiac output has been associated with either static or decreased systemic vascular resistance (SVR). Static or decreased SVR associated with low or moderate movements in cardiac output is believed to be a reflection of differential effects on specific vascular beds with increased resistance in peripheral beds (e.g., femoral) and concomitant decreases in mesenteric and renal vascular beds. Redistribution of blood flow parallels these changes so that an increase in cardiac output is accompanied by an increase in mesenteric and renal blood flow. In many instances the renal fraction of the total cardiac output has been found to increase. Increase in cardiac output produced by dopamine is not associated with substantial decreases in systemic vascular resistance as may occur with isoproterenol. Hypotension – Hypotension due to inadequate cardiac output can be managed by administration of low to moderate doses of dopamine HCl which have little effect on SVR. At high therapeutic doses, dopamine's alpha-adrenergic activity becomes more prominent and thus may correct hypotension due to diminished SVR. As in the case of other circulatory decompensation states, prognosis is better in patients whose blood pressure and urine flow have not undergone profound deterioration. Therefore, it is suggested that the physician administer dopamine HCl as soon as a definite trend toward decreased systolic and diastolic pressure becomes evident. uuid:d36feead-d0f3-47a9-b69d-5e22cb141367 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18243 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:2692ac2b-40bc-4a20-acd0-1496a070876f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0f286718-058e-4c18-bbe1-d5c44c2d9bea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dopamine HCl is indicated for the correction of hemodynamic imbalances present in the shock syndrome due to myocardial infarction, trauma, endotoxic septicemia, open-heart surgery, renal failure, and chronic cardiac decompensation as in congestive failure. Patients most likely to respond adequately to dopamine HCl are those in whom physiological parameters, such as urine flow, myocardial function, and blood pressure, have not undergone profound deterioration. Multiclinic trials indicate that the shorter the time interval between onset of signs and symptoms and initiation of therapy with blood volume correction and dopamine HCl, the better the prognosis. Where appropriate, blood volume restoration with a suitable plasma expander or whole blood should be accomplished prior to administration of dopamine HCl. Poor Perfusion of Vital Organs – Urine flow appears to be one of the better diagnostic signs by which adequacy of vital organ perfusion can be monitored. Nevertheless, the physician should also observe the patient for signs of reversal of confusion or reversal of comatose condition. Loss of pallor, increase in toe temperature, and/or adequacy of nail bed capillary filling may also be used as indices of adequate dosage. Clinical studies have shown that when dopamine HCl is administered before urine flow has diminished to levels of approximately 0.3 mL/minute, prognosis is more favorable. Nevertheless, in a number of oliguric or anuric patients, administration of dopamine HCl has resulted in an increase in urine flow, which in some cases reached normal levels. Dopamine HCl may also increase urine flow in patients whose output is within normal limits and thus may be of value in reducing the degree of pre-existing fluid accumulation. It should be noted that at doses above those optimal for the individual patient, urine flow may decrease, necessitating reduction of dosage. Low Cardiac Output – Increased cardiac output is related to dopamine's direct inotropic effect on the myocardium. Increased cardiac output at low or moderate doses appears to be related to a favorable prognosis. Increase in cardiac output has been associated with either static or decreased systemic vascular resistance (SVR). Static or decreased SVR associated with low or moderate movements in cardiac output is believed to be a reflection of differential effects on specific vascular beds with increased resistance in peripheral beds (e.g., femoral) and concomitant decreases in mesenteric and renal vascular beds. Redistribution of blood flow parallels these changes so that an increase in cardiac output is accompanied by an increase in mesenteric and renal blood flow. In many instances the renal fraction of the total cardiac output has been found to increase. Increase in cardiac output produced by dopamine is not associated with substantial decreases in systemic vascular resistance as may occur with isoproterenol. Hypotension – Hypotension due to inadequate cardiac output can be managed by administration of low to moderate doses of dopamine HCl which have little effect on SVR. At high therapeutic doses, dopamine's alpha-adrenergic activity becomes more prominent and thus may correct hypotension due to diminished SVR. As in the case of other circulatory decompensation states, prognosis is better in patients whose blood pressure and urine flow have not undergone profound deterioration. Therefore, it is suggested that the physician administer dopamine HCl as soon as a definite trend toward decreased systolic and diastolic pressure becomes evident. uuid:5faa6490-e7ab-4e49-9bdb-60468ba3f3d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18243 biolink:treats HP:0100520 PMID:41385096 "[{""id"":""uuid:42436d6e-5a49-42a1-8486-d03fe49d8298"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:73de57dd-bf87-4aae-b430-aa392c2d8af5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dopamine HCl is indicated for the correction of hemodynamic imbalances present in the shock syndrome due to myocardial infarction, trauma, endotoxic septicemia, open-heart surgery, renal failure, and chronic cardiac decompensation as in congestive failure. Patients most likely to respond adequately to dopamine HCl are those in whom physiological parameters, such as urine flow, myocardial function, and blood pressure, have not undergone profound deterioration. Multiclinic trials indicate that the shorter the time interval between onset of signs and symptoms and initiation of therapy with blood volume correction and dopamine HCl, the better the prognosis. Where appropriate, blood volume restoration with a suitable plasma expander or whole blood should be accomplished prior to administration of dopamine HCl. Poor Perfusion of Vital Organs – Urine flow appears to be one of the better diagnostic signs by which adequacy of vital organ perfusion can be monitored. Nevertheless, the physician should also observe the patient for signs of reversal of confusion or reversal of comatose condition. Loss of pallor, increase in toe temperature, and/or adequacy of nail bed capillary filling may also be used as indices of adequate dosage. Clinical studies have shown that when dopamine HCl is administered before urine flow has diminished to levels of approximately 0.3 mL/minute, prognosis is more favorable. Nevertheless, in a number of oliguric or anuric patients, administration of dopamine HCl has resulted in an increase in urine flow, which in some cases reached normal levels. Dopamine HCl may also increase urine flow in patients whose output is within normal limits and thus may be of value in reducing the degree of pre-existing fluid accumulation. It should be noted that at doses above those optimal for the individual patient, urine flow may decrease, necessitating reduction of dosage. Low Cardiac Output – Increased cardiac output is related to dopamine's direct inotropic effect on the myocardium. Increased cardiac output at low or moderate doses appears to be related to a favorable prognosis. Increase in cardiac output has been associated with either static or decreased systemic vascular resistance (SVR). Static or decreased SVR associated with low or moderate movements in cardiac output is believed to be a reflection of differential effects on specific vascular beds with increased resistance in peripheral beds (e.g., femoral) and concomitant decreases in mesenteric and renal vascular beds. Redistribution of blood flow parallels these changes so that an increase in cardiac output is accompanied by an increase in mesenteric and renal blood flow. In many instances the renal fraction of the total cardiac output has been found to increase. Increase in cardiac output produced by dopamine is not associated with substantial decreases in systemic vascular resistance as may occur with isoproterenol. Hypotension – Hypotension due to inadequate cardiac output can be managed by administration of low to moderate doses of dopamine HCl which have little effect on SVR. At high therapeutic doses, dopamine's alpha-adrenergic activity becomes more prominent and thus may correct hypotension due to diminished SVR. As in the case of other circulatory decompensation states, prognosis is better in patients whose blood pressure and urine flow have not undergone profound deterioration. Therefore, it is suggested that the physician administer dopamine HCl as soon as a definite trend toward decreased systolic and diastolic pressure becomes evident. uuid:b20bb616-dc0c-4933-b8bd-bf1f1e8e9509 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18243 biolink:treats MONDO:0002476 PMID:41385096 "[{""id"":""uuid:f3ee362d-38e4-4294-908b-932c59578937"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3ad721c4-9039-4407-99cb-1cf3783edcc9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dopamine HCl is indicated for the correction of hemodynamic imbalances present in the shock syndrome due to myocardial infarction, trauma, endotoxic septicemia, open-heart surgery, renal failure, and chronic cardiac decompensation as in congestive failure. Patients most likely to respond adequately to dopamine HCl are those in whom physiological parameters, such as urine flow, myocardial function, and blood pressure, have not undergone profound deterioration. Multiclinic trials indicate that the shorter the time interval between onset of signs and symptoms and initiation of therapy with blood volume correction and dopamine HCl, the better the prognosis. Where appropriate, blood volume restoration with a suitable plasma expander or whole blood should be accomplished prior to administration of dopamine HCl. Poor Perfusion of Vital Organs – Urine flow appears to be one of the better diagnostic signs by which adequacy of vital organ perfusion can be monitored. Nevertheless, the physician should also observe the patient for signs of reversal of confusion or reversal of comatose condition. Loss of pallor, increase in toe temperature, and/or adequacy of nail bed capillary filling may also be used as indices of adequate dosage. Clinical studies have shown that when dopamine HCl is administered before urine flow has diminished to levels of approximately 0.3 mL/minute, prognosis is more favorable. Nevertheless, in a number of oliguric or anuric patients, administration of dopamine HCl has resulted in an increase in urine flow, which in some cases reached normal levels. Dopamine HCl may also increase urine flow in patients whose output is within normal limits and thus may be of value in reducing the degree of pre-existing fluid accumulation. It should be noted that at doses above those optimal for the individual patient, urine flow may decrease, necessitating reduction of dosage. Low Cardiac Output – Increased cardiac output is related to dopamine's direct inotropic effect on the myocardium. Increased cardiac output at low or moderate doses appears to be related to a favorable prognosis. Increase in cardiac output has been associated with either static or decreased systemic vascular resistance (SVR). Static or decreased SVR associated with low or moderate movements in cardiac output is believed to be a reflection of differential effects on specific vascular beds with increased resistance in peripheral beds (e.g., femoral) and concomitant decreases in mesenteric and renal vascular beds. Redistribution of blood flow parallels these changes so that an increase in cardiac output is accompanied by an increase in mesenteric and renal blood flow. In many instances the renal fraction of the total cardiac output has been found to increase. Increase in cardiac output produced by dopamine is not associated with substantial decreases in systemic vascular resistance as may occur with isoproterenol. Hypotension – Hypotension due to inadequate cardiac output can be managed by administration of low to moderate doses of dopamine HCl which have little effect on SVR. At high therapeutic doses, dopamine's alpha-adrenergic activity becomes more prominent and thus may correct hypotension due to diminished SVR. As in the case of other circulatory decompensation states, prognosis is better in patients whose blood pressure and urine flow have not undergone profound deterioration. Therefore, it is suggested that the physician administer dopamine HCl as soon as a definite trend toward decreased systolic and diastolic pressure becomes evident. uuid:7b411af1-89fd-4600-8328-36130ec9e8f2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18243 biolink:treats MONDO:0005468 PMID:41385096 "[{""id"":""uuid:8f672835-c95c-4cfa-b710-6ceada434e69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4c0c9cb5-3da1-4d44-adc9-a03c4327aafa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dopamine HCl is indicated for the correction of hemodynamic imbalances present in the shock syndrome due to myocardial infarction, trauma, endotoxic septicemia, open-heart surgery, renal failure, and chronic cardiac decompensation as in congestive failure. Patients most likely to respond adequately to dopamine HCl are those in whom physiological parameters, such as urine flow, myocardial function, and blood pressure, have not undergone profound deterioration. Multiclinic trials indicate that the shorter the time interval between onset of signs and symptoms and initiation of therapy with blood volume correction and dopamine HCl, the better the prognosis. Where appropriate, blood volume restoration with a suitable plasma expander or whole blood should be accomplished prior to administration of dopamine HCl. Poor Perfusion of Vital Organs – Urine flow appears to be one of the better diagnostic signs by which adequacy of vital organ perfusion can be monitored. Nevertheless, the physician should also observe the patient for signs of reversal of confusion or reversal of comatose condition. Loss of pallor, increase in toe temperature, and/or adequacy of nail bed capillary filling may also be used as indices of adequate dosage. Clinical studies have shown that when dopamine HCl is administered before urine flow has diminished to levels of approximately 0.3 mL/minute, prognosis is more favorable. Nevertheless, in a number of oliguric or anuric patients, administration of dopamine HCl has resulted in an increase in urine flow, which in some cases reached normal levels. Dopamine HCl may also increase urine flow in patients whose output is within normal limits and thus may be of value in reducing the degree of pre-existing fluid accumulation. It should be noted that at doses above those optimal for the individual patient, urine flow may decrease, necessitating reduction of dosage. Low Cardiac Output – Increased cardiac output is related to dopamine's direct inotropic effect on the myocardium. Increased cardiac output at low or moderate doses appears to be related to a favorable prognosis. Increase in cardiac output has been associated with either static or decreased systemic vascular resistance (SVR). Static or decreased SVR associated with low or moderate movements in cardiac output is believed to be a reflection of differential effects on specific vascular beds with increased resistance in peripheral beds (e.g., femoral) and concomitant decreases in mesenteric and renal vascular beds. Redistribution of blood flow parallels these changes so that an increase in cardiac output is accompanied by an increase in mesenteric and renal blood flow. In many instances the renal fraction of the total cardiac output has been found to increase. Increase in cardiac output produced by dopamine is not associated with substantial decreases in systemic vascular resistance as may occur with isoproterenol. Hypotension – Hypotension due to inadequate cardiac output can be managed by administration of low to moderate doses of dopamine HCl which have little effect on SVR. At high therapeutic doses, dopamine's alpha-adrenergic activity becomes more prominent and thus may correct hypotension due to diminished SVR. As in the case of other circulatory decompensation states, prognosis is better in patients whose blood pressure and urine flow have not undergone profound deterioration. Therefore, it is suggested that the physician administer dopamine HCl as soon as a definite trend toward decreased systolic and diastolic pressure becomes evident. uuid:4d337a84-acf8-4b58-b4a2-52d472a769bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:134694335 biolink:treats HP:0002153 PMID:41385096 "[{""id"":""uuid:07d0d2d4-93ef-4d17-91b7-2a39d5e87692"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a4383173-34d8-4c06-97a6-2c0d0a3aedea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LOKELMA is indicated for the treatment of hyperkalemia in adults. Limitation of Use LOKELMA should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action [see Clinical Pharmacology (12.2) and Clinical Studies (14) ] . uuid:94d72da5-8a42-4af1-b9ba-88f5f3c31e78 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:WA16A5Y52X biolink:treats MONDO:0001700 PMID:41385096 "[{""id"":""uuid:b725ffc6-b8ca-4be5-8434-c77ee5e93f1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:82349332-73c1-47f8-a73c-8bc67569846b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levoleucovorin injection is indicated for: rescue after high-dose methotrexate therapy in adult and pediatric patients with osteosarcoma. diminishing the toxicity associated with overdosage of folic acid antagonists or impaired methotrexate elimination in adult and pediatric patients. the treatment of adults with metastatic colorectal cancer in combination with fluorouracil. Limitations of Use: Levoleucovorin injection is not indicated for pernicious anemia and megaloblastic anemia secondary to the lack of vitamin B 12 , because of the risk of progression of neurologic manifestations despite hematologic remission. PUBCHEM.COMPOUND:135465090 uuid:2f39b315-bef7-44bc-8d9e-67f59152f1ab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16347 biolink:treats MONDO:0019052 PMID:41385096 "[{""id"":""uuid:67040a25-4bd0-43bc-a23f-b03e389b37e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bcfda758-9787-4155-80ed-cb275b1b362f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the acute and chronic treatment of patients with an inborn error of metabolism which results in secondary carnitine deficiency. For the prevention and treatment of carnitine deficiency in patients with end stage renal disease who are undergoing dialysis. uuid:e24000f2-9db6-4054-ace9-6ac5a50cf30f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16347 biolink:treats MONDO:0004375 PMID:41385096 "[{""id"":""uuid:b73acea1-0c21-4625-bb64-b2ee800f97f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1093ec4f-ddb8-46d8-8d8e-622a3f2a8035"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the acute and chronic treatment of patients with an inborn error of metabolism which results in secondary carnitine deficiency. For the prevention and treatment of carnitine deficiency in patients with end stage renal disease who are undergoing dialysis. uuid:d479eefa-ee50-4391-9922-af2055eb0298 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:499361 biolink:treats NCIT:C107517 PMID:41385096 "[{""id"":""uuid:6a4f515b-1eb8-4885-b076-e8ad5c9b6928"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b7a90ba0-7696-4cbd-866f-ebc1632a8dc8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fosaprepitant for Injection, in combination with other antiemetic agents, is indicated in adults for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). Limitations of Use Fosaprepitant for Injection has not been studied for the treatment of established nausea and vomiting. uuid:1c103817-f48c-4bcd-947b-5638b71837b2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3240 biolink:treats MONDO:0006014 PMID:41385096 "[{""id"":""uuid:a6b8c0f8-9653-4c20-8de9-d172d079daf0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:48028ecc-829f-451e-9760-6f33e036c347"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] GYNAZOLE • 1 ® Butoconazole Nitrate Vaginal Cream USP, 2% is indicated for the local treatment of vulvovaginal candidiasis (infections caused by Candida ). The diagnosis should be confirmed by KOH smears and/or cultures (see CLINICAL STUDIES ). Note: GYNAZOLE • 1 ® Butoconazole Nitrate Vaginal Cream USP, 2% is safe and effective in non-pregnant women; however, the safety and effectiveness of this product in pregnant women has not been established (see PRECAUTIONS - Pregnancy ). uuid:6d997b54-403b-4fbd-a7b5-a7a4940171c5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:11979316 biolink:treats HP:0100806 PMID:41385096 "[{""id"":""uuid:19b739ed-1d4b-4e63-97f3-11e9e44a3a67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:00f23310-bff8-4b11-99ca-10a297705423"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vasostrict ® is indicated to increase blood pressure in adults with vasodilatory shock (e.g., post-cardiotomy or sepsis) who remain hypotensive despite fluids and catecholamines. uuid:f548e934-82ec-4d14-af5d-fb601ed7c3c0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49662 biolink:treats MONDO:0011827 PMID:41385096 "[{""id"":""uuid:e7502ebc-dff5-4039-9149-4d523e2b73d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c4219765-f4c5-46fd-92d5-094b5d8adde9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Indomethacin for Injection is indicated to close a hemodynamically significant patent ductus arteriosus in premature infants weighing between 500 and 1,750 g when 48 hours usual medical management (e.g., fluid restriction, diuretics, digitalis, respiratory support, etc.) is ineffective. Clear-cut clinical evidence of a hemodynamically significant patent ductus arteriosus should be present, such as respiratory distress, a continuous murmur, a hyperactive precordium, cardiomegaly, or pulmonary plethora on chest x-ray. uuid:5557572d-01aa-4886-b5f7-89cb996deb75 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49662 biolink:treats HP:0002098 PMID:41385096 "[{""id"":""uuid:54ad726a-6ef2-4c1e-a070-c5fbb9ebbd94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6685629f-ab0b-433d-bf82-7c173c35a118"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Indomethacin for Injection is indicated to close a hemodynamically significant patent ductus arteriosus in premature infants weighing between 500 and 1,750 g when 48 hours usual medical management (e.g., fluid restriction, diuretics, digitalis, respiratory support, etc.) is ineffective. Clear-cut clinical evidence of a hemodynamically significant patent ductus arteriosus should be present, such as respiratory distress, a continuous murmur, a hyperactive precordium, cardiomegaly, or pulmonary plethora on chest x-ray. uuid:fa8a546f-7ad2-411d-99ca-0f2d75be9846 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49662 biolink:treats HP:0001640 PMID:41385096 "[{""id"":""uuid:44f92d1d-64e2-4c9d-95cd-ba841156bcc6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c6ca4019-28bc-4c62-bf26-f2ad3d0fb20e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Indomethacin for Injection is indicated to close a hemodynamically significant patent ductus arteriosus in premature infants weighing between 500 and 1,750 g when 48 hours usual medical management (e.g., fluid restriction, diuretics, digitalis, respiratory support, etc.) is ineffective. Clear-cut clinical evidence of a hemodynamically significant patent ductus arteriosus should be present, such as respiratory distress, a continuous murmur, a hyperactive precordium, cardiomegaly, or pulmonary plethora on chest x-ray. uuid:328af576-fd98-4709-9892-7d484942961c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45304 biolink:treats MONDO:0006052 PMID:41385096 "[{""id"":""uuid:04c973a8-d68b-4024-b9e4-8e7ed1e5c7b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:544bfd45-c7e5-4afd-96f6-dbad98ac28aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRIFTIN is a rifamycin antimycobacterial drug indicated in patients 12 years of age and older for the treatment of active pulmonary tuberculosis (TB) caused by Mycobacterium tuberculosis in combination with one or more antituberculosis (anti-TB) drugs to which the isolate is susceptible. ( 1.1 ) PRIFTIN is indicated for the treatment of latent tuberculosis infection (LTBI) caused by M. tuberculosis in combination with isoniazid in patients 2 years of age and older at high risk of progression to TB disease. ( 1.2 ) See Full Prescribing Information for Limitations of Use. ( 1.1 , 1.2 ) uuid:d6e7bbc2-5607-45dd-9b20-f37dd5765268 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45304 biolink:treats MONDO:0040753 PMID:41385096 "[{""id"":""uuid:bfd1980e-e23c-4ffd-a083-5a144185dfe0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8cd5026a-5fe8-43f6-acec-5a715dbe3174"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRIFTIN is a rifamycin antimycobacterial drug indicated in patients 12 years of age and older for the treatment of active pulmonary tuberculosis (TB) caused by Mycobacterium tuberculosis in combination with one or more antituberculosis (anti-TB) drugs to which the isolate is susceptible. ( 1.1 ) PRIFTIN is indicated for the treatment of latent tuberculosis infection (LTBI) caused by M. tuberculosis in combination with isoniazid in patients 2 years of age and older at high risk of progression to TB disease. ( 1.2 ) See Full Prescribing Information for Limitations of Use. ( 1.1 , 1.2 ) uuid:8f7e8123-70a4-4042-9887-7ee3f0ac45db biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8871 biolink:treats MONDO:0004985 PMID:41385096 "[{""id"":""uuid:19466443-de49-4b0c-8320-c89fb0449304"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:afa96c29-f6c4-4425-acd5-0fe89940e957"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Risperidone is an atypical antipsychotic indicated for: Treatment of schizophrenia ( 1.1 ) As monotherapy or adjunctive therapy with lithium or valproate, for the treatment of acute manic or mixed episodes associated with Bipolar Disorder ( 1.2 ) Treatment of irritability associated with autistic disorder ( 1.3 ) uuid:89725a5f-dacc-424e-a660-0f9c1357a8c5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68478 biolink:treats MONDO:0005086 PMID:41385096 "[{""id"":""uuid:66b4c7de-4dd7-4ef1-8ca7-acb2a35f06a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2097f8f7-e380-4df5-8545-819868b9b51a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2ad25689-7e8c-4605-95c4-2461fd9e74c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/votubia""]},{""id"":""uuid:ca0b2477-c1ad-4489-a87c-27832c5096c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Everolimus tablets are a kinase inhibitor indicated for the treatment of: Adults with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. ( 1.3 ) Adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. ( 1.4 ) Everolimus tablets are kinase inhibitors indicated for the treatment of adult and pediatric patients aged 1 year and older with TSC who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected. ( 1.5 )|[EMA] Hormone-receptor-positive advanced breast cancerAfinitor is indicated for the treatment of hormone-receptor-positive, HER2/neu-negative advanced breast cancer, in combination with exemestane, in post-menopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.Neuroendocrine tumours of pancreatic originAfinitor is indicated for the treatment of unresectable or metastatic, well or moderately differentiated neuroendocrine tumours of pancreatic origin in adults with progressive disease.Neuroendocrine tumours of gastrointestinal or lung originAfinitor is indicated for the treatment of unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease.Renal-cell carcinomaAfinitor is indicated for the treatment of patients with advanced renal-cell carcinoma, whose disease has progressed on or after treatment with VEGF-targeted therapy.|[PMDA] A drug with a new additional indication and a new dosage for the treatment of unresectable or metastatic renal cell carcinoma. [Priority review] uuid:a3442d44-1f58-4c00-bb14-52b5d1b296f7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68478 biolink:treats MONDO:0002603 PMID:41385096 "[{""id"":""uuid:775438f0-b2af-436a-95ea-d4c6540ba06a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3b025481-f4a7-4de6-89a9-9016a312ed54"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ad919efd-accd-4050-907e-d4a239b56d33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Everolimus tablets are a kinase inhibitor indicated for the treatment of: Adults with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. ( 1.3 ) Adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. ( 1.4 ) Everolimus tablets are kinase inhibitors indicated for the treatment of adult and pediatric patients aged 1 year and older with TSC who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected. ( 1.5 )|[PMDA] Drugs with new additional indications and a new dosage for the treatment of renal angiomyolipoma associated with tuberous sclerosis complex and subependymal giant cell astrocytoma associated with tuberous sclerosis complex. [Orphan drug] uuid:3626597b-f11e-4e31-a99e-71a84c2ea120 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68478 biolink:treats MONDO:0016693 PMID:41385096 "[{""id"":""uuid:ecc49ab7-0b05-437f-9564-0ae3cbe062b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:dd67c261-dbd8-4409-94e6-f93768accabc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c166450e-0b26-4ed9-9c27-7c9f649afd5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/votubia""]},{""id"":""uuid:da0227f3-6570-4994-9d11-eb6dfe315e5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Everolimus tablets are a kinase inhibitor indicated for the treatment of: Adults with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. ( 1.3 ) Adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. ( 1.4 ) Everolimus tablets are kinase inhibitors indicated for the treatment of adult and pediatric patients aged 1 year and older with TSC who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected. ( 1.5 )|[EMA] Renal angiomyolipoma associated with tuberous sclerosis complex (TSC)Votubia is indicated for the treatment of adult patients with renal angiomyolipoma associated with tuberous sclerosis complex (TSC) who are at risk of complications (based on factors such as tumour size or presence of aneurysm, or presence of multiple or bilateral tumours) but who do not require immediate surgery.The evidence is based on analysis of change in sum of angiomyolipoma volume.Subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC)Votubia is indicated for the treatment of patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC) who require therapeutic intervention but are not amenable to surgery.The evidence is based on analysis of change in SEGA volume. Further clinical benefit, such as improvement in disease‑related symptoms, has not been demonstrated.|[PMDA] Drugs with a new additional indication and a new dosage in an additional dosage form for the treatment of subependymal giant cell astrocytoma associated with tuberous sclerosis complex (currently in the reexamination period). [Orphan drug] uuid:a0a941c7-4745-4031-be2f-0e14e16f20a2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:480999 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:08a58f97-eb87-44a2-8981-cc9baaba7e22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c8cca8a1-ed3f-4052-8be4-7d942b950359"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vinorelbine injection is indicated: In combination with cisplatin for first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) As a single agent for the treatment of patients with metastatic NSCLC uuid:895af4ce-aebc-4887-a750-bd197c7df968 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:480999 biolink:treats UMLS:C0278987 PMID:41385096 "[{""id"":""uuid:0e31128b-35c9-4410-be06-22e67508dc47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2ef11332-e9d2-44a0-a233-3df9cbb4389e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vinorelbine injection is indicated: In combination with cisplatin for first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) As a single agent for the treatment of patients with metastatic NSCLC uuid:926b0e89-60b1-4d89-8e4c-f7fbaafcaf38 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85966 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:fb381428-22bf-4b8e-82b5-46c3b9158828"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:85dfdcfe-97dd-499d-aefc-73a5e5c4ea74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:5d9f8b97-0957-4b1d-a3da-447676d95f7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Corlanor (ivabradine) is a hyperpolarization-activated cyclic nucleotide-gated channel blocker indicated: To reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with reduced left ventricular ejection fraction. ( 1.1 ) For the treatment of stable symptomatic heart failure due to dilated cardiomyopathy in pediatric patients ages 6 months and older. ( 1.2 )|[EMA] Symptomatic treatment of chronic stable angina pectoris Ivabradine is indicated for the symptomatic treatment of chronic stable angina pectoris in coronary artery disease adults with normal sinus rhythm and heart rate ≥ 70 bpm. Ivabradine is indicated:in adults unable to tolerate or with a contra-indication to the use of beta-blockersorin combination with beta-blockers in patients inadequately controlled with an optimal beta-blocker dose. Treatment of chronic heart failure Ivabradine is indicated in chronic heart failure NYHA II to IV class with systolic dysfunction, in patients in sinus rhythm and whose heart rate is ≥ 75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated. uuid:dc177079-5195-48f3-a35f-e7d26bc391b2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85966 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:a162e763-7072-4090-9b87-2f9edaf6057a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d1f49a00-0293-4305-9838-b9b3973c3e8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e619178d-90b2-4664-9279-6cefcdf9bfa2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Corlanor (ivabradine) is a hyperpolarization-activated cyclic nucleotide-gated channel blocker indicated: To reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with reduced left ventricular ejection fraction. ( 1.1 ) For the treatment of stable symptomatic heart failure due to dilated cardiomyopathy in pediatric patients ages 6 months and older. ( 1.2 )|[PMDA] Drugs with a new active ingredient indicated for the treatment of chronic heart failure with sinus rhythm and a resting heart rate of 75 bpm or greater at baseline ( for use only in patients receiving standard treatment of chronic heart failure, including β-blocker). uuid:daff1ee5-3264-4f00-b4e2-5107cf8b5570 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85966 biolink:treats MONDO:0005021 PMID:41385096 "[{""id"":""uuid:1cc3b0cf-ccec-4fbd-9153-10741a14ed5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4c6175bc-4c4a-4d33-b124-bae7ffd2667f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Corlanor (ivabradine) is a hyperpolarization-activated cyclic nucleotide-gated channel blocker indicated: To reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with reduced left ventricular ejection fraction. ( 1.1 ) For the treatment of stable symptomatic heart failure due to dilated cardiomyopathy in pediatric patients ages 6 months and older. ( 1.2 ) uuid:fd5d7df9-4dff-445a-ace7-21fbd264a01e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10127 biolink:treats MONDO:0006710 PMID:41385096 "[{""id"":""uuid:1cd20ba5-7e71-4847-b228-adc086e13c3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:787be187-f244-48b8-aa96-94fadb697048"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZONISADE is indicated as adjunctive therapy for the treatment of partial-onset seizures in adults and pediatric patients 16 years and older. uuid:e494e455-1030-4d0c-a212-529c7c39edb7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31696 biolink:treats MONDO:0002974 PMID:41385096 "[{""id"":""uuid:1c1d5970-0c37-44fb-ae97-0ee732276783"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e8777a89-2392-4963-8c57-792f03da40aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SPY AGENT GREEN is an optical imaging agent indicated for use with a fluorescence imaging device for: Visualization of vessels (micro and macro vasculature), blood flow and tissue perfusion before, during, and after vascular, gastrointestinal, organ transplant, plastic, micro- and reconstructive surgeries including general minimally invasive surgical procedures in adults and pediatric patients one month of age and older. ( 1.1 ) Visualization of extrahepatic biliary ducts in adults and pediatric patients aged 12 years and older. ( 1.2 ) Visualization of lymph nodes and lymphatic vessels during lymphatic mapping in adults with cervical and uterine cancer. ( 1.3 ) Visualization of lymph nodes and lymphatic vessels during lymphatic mapping in adults with breast cancer. ( 1.4 ) uuid:399f8aa0-85ff-4743-ad31-7bee113f8b47 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31696 biolink:treats MONDO:0002715 PMID:41385096 "[{""id"":""uuid:62cd95d9-a046-4fa6-8a5c-ed096224c63c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2c47f5e0-acb0-4bcb-8092-b6ae78474329"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SPY AGENT GREEN is an optical imaging agent indicated for use with a fluorescence imaging device for: Visualization of vessels (micro and macro vasculature), blood flow and tissue perfusion before, during, and after vascular, gastrointestinal, organ transplant, plastic, micro- and reconstructive surgeries including general minimally invasive surgical procedures in adults and pediatric patients one month of age and older. ( 1.1 ) Visualization of extrahepatic biliary ducts in adults and pediatric patients aged 12 years and older. ( 1.2 ) Visualization of lymph nodes and lymphatic vessels during lymphatic mapping in adults with cervical and uterine cancer. ( 1.3 ) Visualization of lymph nodes and lymphatic vessels during lymphatic mapping in adults with breast cancer. ( 1.4 ) uuid:c57f32eb-49da-4f8d-bec1-5b809318ef08 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31696 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:0dd6fdf2-d3fa-4b85-8069-d3592d32040c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:12e7948e-5f1b-4304-9f20-96084901ea08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:52a5f4c3-875b-4bbe-ab70-598d908e35e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SPY AGENT GREEN is an optical imaging agent indicated for use with a fluorescence imaging device for: Visualization of vessels (micro and macro vasculature), blood flow and tissue perfusion before, during, and after vascular, gastrointestinal, organ transplant, plastic, micro- and reconstructive surgeries including general minimally invasive surgical procedures in adults and pediatric patients one month of age and older. ( 1.1 ) Visualization of extrahepatic biliary ducts in adults and pediatric patients aged 12 years and older. ( 1.2 ) Visualization of lymph nodes and lymphatic vessels during lymphatic mapping in adults with cervical and uterine cancer. ( 1.3 ) Visualization of lymph nodes and lymphatic vessels during lymphatic mapping in adults with breast cancer. ( 1.4 )|[PMDA] A drug with a new route of administration, a new indication, and a new dosage for sentinel lymph node mapping in breast cancer and malignant melanoma. [Expedited review] uuid:f4178804-daba-41d4-af88-1f6fd3479e9b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15355 biolink:treats MONDO:0005129 PMID:41385096 "[{""id"":""uuid:f48d3ec0-3dc8-496b-87b1-361faa591626"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9dc04aef-b92c-46f2-83b5-83a3d396d6b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To obtain miosis of the iris in seconds after delivery of the lens in cataract surgery, in penetrating keratoplasty, iridectomy, and other anterior segment surgery where rapid miosis may be required. uuid:165664e3-666e-4a86-b8eb-15a173d3dbf6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:AD4J2O47FQ biolink:treats UMLS:C4728082 PMID:41385096 "[{""id"":""uuid:72d4750b-2588-4a8f-abdf-02269554b6cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dc95dfb6-d114-4e6b-a7c9-d7a3e11fff4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZEGALOGUE ® is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above. uuid:43a666cb-05ff-4ac2-ba3f-a6ef6593c502 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5893 biolink:treats HP:0000969 PMID:41385096 "[{""id"":""uuid:9662d885-09fe-49f4-ab1a-155f8ffc14b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5936270e-624e-4b98-bcc5-6586b5869a7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Indapamide tablets are indicated for the treatment of hypertension, alone or in combination with other antihypertensive drugs. Indapamide tablets are also indicated for the treatment of salt and fluid retention associated with congestive heart failure. Usage in Pregnancy : The routine use of diuretics in an otherwise healthy woman is inappropriate and exposes mother and fetus to unnecessary hazard (see PRECAUTIONS below). Diuretics do not prevent development of toxemia of pregnancy, and there is no satisfactory evidence that they are useful in the treatment of developed toxemia. Edema during pregnancy may arise from pathological causes or from the physiologic and mechanical consequences of pregnancy. Indapamide is indicated in pregnancy when edema is due to pathologic causes, just as it is in the absence of pregnancy (however, see PRECAUTIONS below). Dependent edema in pregnancy, resulting from restriction of venous return by the expanded uterus, is properly treated through elevation of the lower extremities and use of support hose; use of diuretics to lower intravascular volume in this case is illogical and unnecessary. There is hypervolemia during normal pregnancy which is not harmful to either the fetus or the mother (in the absence of cardiovascular disease), but which is associated with edema, including generalized edema in the majority of pregnant women. If this edema produces discomfort, increased recumbency will often provide relief. In rare instances, this edema may cause extreme discomfort which is not relieved by rest. In these cases, a short course of diuretics may provide relief and may be appropriate. uuid:b5b1f1bb-d758-4273-b640-dd16eddfecf5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45863 biolink:treats UMLS:C0278488 PMID:41385096 "[{""id"":""uuid:92826b58-5816-4a5e-b667-5e299ab3c58c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9f5646a9-a04a-44db-8822-dfd60bcecc2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ABRAXANE is a microtubule inhibitor indicated for the treatment of: • Metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. ( 1.1 ) • Locally advanced or metastatic non-small cell lung cancer (NSCLC), as first-line treatment in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy. ( 1.2 ) • Metastatic adenocarcinoma of the pancreas as first-line treatment, in combination with gemcitabine. ( 1.3 ) uuid:abfdada4-1510-4108-9226-9ab9d1ba026b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45863 biolink:treats UMLS:C0278987 PMID:41385096 "[{""id"":""uuid:f2e03a3e-0b3c-48f5-85c2-9b87bf8c3eeb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:966ae740-3f1c-4e4c-bbbf-d91e83348b97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ABRAXANE is a microtubule inhibitor indicated for the treatment of: • Metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. ( 1.1 ) • Locally advanced or metastatic non-small cell lung cancer (NSCLC), as first-line treatment in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy. ( 1.2 ) • Metastatic adenocarcinoma of the pancreas as first-line treatment, in combination with gemcitabine. ( 1.3 ) uuid:13b74702-89ea-4f0f-b177-1efa773ef845 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45863 biolink:treats MONDO:0006047 PMID:41385096 "[{""id"":""uuid:bfb66c7d-743d-410f-b45c-57edced2028a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:751caba5-e57e-44d3-b49f-28b0d717f9d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:eba58767-2ef3-4baf-bf3e-0bdf19cb8015"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/apealea""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ABRAXANE is a microtubule inhibitor indicated for the treatment of: • Metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated. ( 1.1 ) • Locally advanced or metastatic non-small cell lung cancer (NSCLC), as first-line treatment in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy. ( 1.2 ) • Metastatic adenocarcinoma of the pancreas as first-line treatment, in combination with gemcitabine. ( 1.3 )|[EMA] Abraxane monotherapy is indicated for the treatment of metastatic breast cancer in adult patients who have failed first-line treatment for metastatic disease and for whom standard, anthracycline containing therapy is not indicated.Abraxane in combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas.Abraxane in combination with carboplatin is indicated for the first-line treatment of non-small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy. uuid:25fb965d-8920-48ae-aa26-afe979045280 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats MONDO:0006668 PMID:41385096 "[{""id"":""uuid:16cb2e56-d087-491d-8f5d-d86b278a2b53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:14aa7fa7-02e2-4df5-9d55-1d567bd3ec41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CILOXAN ® (ciprofloxacin ophthalmic ointment) 0.3% is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the microorganisms listed below: Gram-Positive: Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Streptococcus Viridans Group Gram-Negative: Haemophilus influenzae uuid:b8853517-edaa-4425-a24d-a593bdb012e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats MONDO:0005545 PMID:41385096 "[{""id"":""uuid:69162deb-e5e6-4d78-b471-9c551bd93ac4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:40d56444-6705-413c-bea4-82a080311a21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CILOXAN ® (ciprofloxacin ophthalmic ointment) 0.3% is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the microorganisms listed below: Gram-Positive: Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Streptococcus Viridans Group Gram-Negative: Haemophilus influenzae uuid:4a3e431d-933e-415b-bbc6-3eb4daaff13a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats MONDO:0005114 PMID:41385096 "[{""id"":""uuid:6ddcdefc-d034-419b-9ebb-4419cbbc0f94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a5d1c9bf-fb8a-4053-bea3-08024519df32"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CILOXAN ® (ciprofloxacin ophthalmic ointment) 0.3% is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the microorganisms listed below: Gram-Positive: Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Streptococcus Viridans Group Gram-Negative: Haemophilus influenzae uuid:d587932c-d09c-4f3f-84e3-2a2c52b37c64 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats UMLS:C1096266 PMID:41385096 "[{""id"":""uuid:225356db-c109-4831-91e1-2162a0f5f217"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:18a27478-53f3-4feb-b2eb-9a43ff8e18c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CILOXAN ® (ciprofloxacin ophthalmic ointment) 0.3% is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the microorganisms listed below: Gram-Positive: Staphylococcus aureus Staphylococcus epidermidis Streptococcus pneumoniae Streptococcus Viridans Group Gram-Negative: Haemophilus influenzae uuid:57d384aa-c1ee-4df2-9e28-df561dc88b8b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29108 biolink:treats HP:0001944 PMID:41385096 "[{""id"":""uuid:aa74c4b5-fd60-4f54-99a5-b611ab03bee8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d97cc2c9-4724-4087-8570-bb32df6ab02a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] This solution is indicated for use in adults and pediatric patients as a source of electrolytes and water for hydration. uuid:b8424e1d-a7dd-4472-ae6b-fc07f464dc24 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3A58010674 biolink:treats UMLS:C0746883 PMID:41385096 "[{""id"":""uuid:325a6fef-7ed5-4c7a-931b-fe9726092113"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d05c3a26-59f1-4bfb-a27f-ed931bf614a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9699840c-8658-400c-9f5e-76613d2cc314"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NYVEPRIA is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia [see Clinical Studies (14) ] .|[PMDA] A drug with a new active ingredient indicated for decreasing the incidence of cancer chemotherapy- induced febrile neutropenia. uuid:fb42456f-8c9f-4583-bc38-fa50fc494ce6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3A58010674 biolink:treats UMLS:C3714514 PMID:41385096 "[{""id"":""uuid:813a9f83-8fc0-4357-946b-4b01b7723401"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:35bc6f68-8ac0-4825-8deb-6509f0562e25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NYVEPRIA is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia [see Clinical Studies (14) ] . uuid:2a00ca31-4651-49fb-8d42-9b20cc29ee39 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63791 biolink:treats MONDO:0004948 PMID:41385096 "[{""id"":""uuid:9e1a14ec-b785-4ad6-ac83-c223a9c3b4c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b81e53ff-054b-4266-a250-47c84e7c7a1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lenalidomide is a thalidomide analogue indicated for the treatment of adult patients with: Multiple myeloma (MM), in combination with dexamethasone ( 1.1 ). MM, as maintenance following autologous hematopoietic stem cell transplantation (auto-HSCT) ( 1.1 ). Transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes (MDS) associated with a deletion 5q abnormality with or without additional cytogenetic abnormalities ( 1.2 ). Limitations of Use: Lenalidomide capsules are not indicated and are not recommended for the treatment of patients with chronic lymphocytic leukemia (CLL) outside of controlled clinical trials ( 1.6 ). uuid:d3b6fa5b-9bd7-435c-9806-031944661c9f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18258 biolink:treats MONDO:0002108 PMID:41385096 "[{""id"":""uuid:05aad35b-dae5-4636-8c5c-dbf7db65a734"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cb72da74-d579-4c12-aad7-2bb5431c60e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Liothyronine sodium tablets are an L-triiodothyronine (T3) indicated for: Hypothyroidism: As replacement in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism ( 1.1 ) Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of well-differentiated thyroid cancer ( 1.2 ) Thyroid Suppression Test: As a diagnostic agent in suppression tests to differentiate suspected mild hyperthyroidism or thyroid gland autonomy ( 1.3 ) Limitations of Use : - Not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients. ( 1 ) - Not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis. ( 1 ) uuid:307a3ca1-f3fb-4c49-b127-7134adb26de6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:30746 biolink:treats MONDO:0004739 PMID:41385096 "[{""id"":""uuid:dfb414cf-ffd4-401b-99c1-fee5a7f02e8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:775b3126-2431-4a84-b217-bdd9a0fc4245"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium phenylacetate and sodium benzoate injection is indicated as adjunctive therapy in pediatric and adult patients for the treatment of acute hyperammonemia and associated encephalopathy in patients with deficiencies in enzymes of the urea cycle. During acute hyperammonemic episodes, arginine supplementation, caloric supplementation, dietary protein restriction, hemodialysis, and other ammonia lowering therapies should be considered [ see Warnings and Precautions (5) ]. uuid:2e459ab0-c034-44fc-8b85-43ef36eac8a5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2637 biolink:treats MONDO:0005113 PMID:41385096 "[{""id"":""uuid:3f1f2e73-2d21-439c-9f7e-4f5183195417"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bdeed975-33d3-4687-b23c-8c613b52036c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amikacin sulfate injection, USP is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli , species of indole-positive and indole-negative Proteus , Providencia species, Klebsiella species, Enterobacter species, Serratia species, and Acinetobacter species. To reduce the development of drug-resistant bacteria and maintain the effectiveness of amikacin and other antibacterial drugs, amikacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:fd48ddf2-cb50-45c2-9e45-07bf0040ba58 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:939U7C91AI biolink:treats MONDO:0021107 PMID:41385096 "[{""id"":""uuid:2e2eb2a1-4fbd-4bbd-a8e2-3a2f715af421"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:62781c84-726c-4d96-bc60-d749129513eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:dd34bb18-3c83-4b11-82a5-6102947291ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SUNOSI is indicated to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA) [see Clinical Studies ( 14 )] . Limitations of Use SUNOSI is not indicated to treat the underlying airway obstruction in OSA. Ensure that the underlying airway obstruction is treated (e.g., with continuous positive airway pressure (CPAP)) for at least one month prior to initiating SUNOSI for excessive daytime sleepiness. Modalities to treat the underlying airway obstruction should be continued during treatment with SUNOSI. SUNOSI is not a substitute for these modalities.|[EMA] Sunosi is indicated to improve wakefulness and reduce excessive daytime sleepiness in adult patients with narcolepsy (with or without cataplexy).Sunosi is indicated to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with obstructive sleep apnoea (OSA) whose EDS has not been satisfactorily treated by primary OSA therapy, such as continuous positive airway pressure (CPAP). uuid:593b39a6-22bc-430c-b8f2-ebf92fe7e967 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:939U7C91AI biolink:treats MONDO:0007147 PMID:41385096 "[{""id"":""uuid:1cd493d6-8b08-44d1-a0ca-067b6ca9e7ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b89bd690-75b7-42b0-b414-e5b8c6539ff1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:33803e05-d40e-4ffc-a933-29ceb885f828"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SUNOSI is indicated to improve wakefulness in adult patients with excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea (OSA) [see Clinical Studies ( 14 )] . Limitations of Use SUNOSI is not indicated to treat the underlying airway obstruction in OSA. Ensure that the underlying airway obstruction is treated (e.g., with continuous positive airway pressure (CPAP)) for at least one month prior to initiating SUNOSI for excessive daytime sleepiness. Modalities to treat the underlying airway obstruction should be continued during treatment with SUNOSI. SUNOSI is not a substitute for these modalities.|[EMA] Sunosi is indicated to improve wakefulness and reduce excessive daytime sleepiness in adult patients with narcolepsy (with or without cataplexy).Sunosi is indicated to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with obstructive sleep apnoea (OSA) whose EDS has not been satisfactorily treated by primary OSA therapy, such as continuous positive airway pressure (CPAP). uuid:0fc028fb-cd8c-4d01-ad09-c5bc6bbd125b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:44476258 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:ce07dcad-81f1-4d65-a4d3-1952a598fed1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a0cc986f-edf0-46d6-8b90-e9489c050c77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tribenzor is indicated for the treatment of hypertension, alone or with other antihypertensive agents, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Tribenzor. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Limitations of Use This fixed combination drug is not indicated for the initial therapy of hypertension . uuid:bcaffe37-ce0c-4ce6-9a0c-6290f967a18d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1162777 biolink:treats MONDO:0006652 PMID:41385096 "[{""id"":""uuid:976aed3f-f2cd-4b69-890c-ac5014e8cff1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f63d06c6-a242-46e1-b670-6f0aaf741725"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BENICAR HCT (olmesartan medoxomil and hydrochlorothiazide) is indicated for the treatment of hypertension, to lower blood pressure. BENICAR HCT is not indicated for the initial therapy of hypertension [see Dosage and Administration (2) ] . Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with BENICAR HCT. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. BENICAR HCT may be used alone, or in combination with other antihypertensive drugs. uuid:e6953806-c592-44b4-9a9c-6ef8557056ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1162777 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:15fa1cce-c12c-4c27-b3d9-795acb2f3a84"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8c5b53ab-0cd1-4bfa-8be2-c9d04aeca143"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BENICAR HCT (olmesartan medoxomil and hydrochlorothiazide) is indicated for the treatment of hypertension, to lower blood pressure. BENICAR HCT is not indicated for the initial therapy of hypertension [see Dosage and Administration (2) ] . Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with BENICAR HCT. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. BENICAR HCT may be used alone, or in combination with other antihypertensive drugs. uuid:075db642-fb48-463a-9e65-68d484b38433 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1162777 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:f725228d-8650-4785-b6f6-9067cb46d406"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0519a267-3ef2-4b34-b36f-7ed7f30f0bc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BENICAR HCT (olmesartan medoxomil and hydrochlorothiazide) is indicated for the treatment of hypertension, to lower blood pressure. BENICAR HCT is not indicated for the initial therapy of hypertension [see Dosage and Administration (2) ] . Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with BENICAR HCT. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. BENICAR HCT may be used alone, or in combination with other antihypertensive drugs. uuid:04a53593-9059-4690-8edf-b22ac18841fa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:189563 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:9ea40266-6064-45b4-87e0-c98c7dc490a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e40bf8f5-caf0-4cad-8129-977825d4c882"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nebivolol tablets are a beta-adrenergic blocking agent indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) uuid:8b317af2-668c-4197-a246-cf3eba69544f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2S713A4VP3 biolink:treats MONDO:0005647 PMID:41385096 "[{""id"":""uuid:9f1b18f8-99b9-4f6d-8675-1a29f15677e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cd643c84-88e0-4568-b1d0-9d6efd7b2d96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Podocon-25® (25% podophyllin in benzoin tincture) is indicated for the removal of soft genital (venereal) warts (condylomata acuminata) (4) . uuid:55872235-39f2-461e-844f-c6ce3d40f06c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:93635 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:8f6083da-9917-424a-9943-ecf2c561fa98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:022dc875-4e90-4a8e-b90f-7f0a6ad429eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Marplan is indicated for the treatment of depression. Because of its potentially serious side effects, Marplan is not an antidepressant of first choice in the treatment of newly diagnosed depressed patients. The efficacy of Marplan in the treatment of depression was established in 6-week controlled trials of depressed outpatients. These patients had symptoms that corresponded to the DSM-IV category of major depressive disorder; however, they often also had signs and symptoms of anxiety (anxious mood, panic, and/or phobic symptoms) ( see CLINICAL PHARMACOLOGY ). A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. The antidepressant effectiveness of Marplan in hospitalized depressed patients, or in endogenomorphically retarded and delusionally depressed patients, has not been adequately studied. The effectiveness of Marplan in long-term use, that is, for more than 6 weeks, has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use Marplan for extended periods should periodically evaluate the long-term usefulness of the drug for the individual patient. uuid:0cd7c0d0-ac32-49b5-9178-11da6b2ed346 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0005688 PMID:41385096 "[{""id"":""uuid:88a5197e-d37c-4a48-9326-70396e902473"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4bb7c509-2425-43ca-af68-565842c9b0e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae, Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp . ) Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci. Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli, Klebsiella, etc. Other infections caused by susceptible gram-negative organisms such as E. coli, Enterobacter aerogenes, Shigella sp ., Acinetobacter sp ., Klebsiella sp. , and Bacteroides sp. In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: Syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent's infection caused by Fusobacterium fusiforme , Infections caused by Neisseria gonorrhoeae , Anthrax caused by Bacillus anthracis , Infections due to Listeria monocytogenes , Actinomycosis caused by Actinomyces species, Infections due to Clostridium species. uuid:f6b3adae-260a-408a-aea6-734b26b560a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0005828 PMID:41385096 "[{""id"":""uuid:3867199d-048a-412c-a1cd-85d2a58485e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0dfc69b3-ba44-4ef6-90f6-354bba8f3e54"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae, Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp . ) Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci. Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli, Klebsiella, etc. Other infections caused by susceptible gram-negative organisms such as E. coli, Enterobacter aerogenes, Shigella sp ., Acinetobacter sp ., Klebsiella sp. , and Bacteroides sp. In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: Syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent's infection caused by Fusobacterium fusiforme , Infections caused by Neisseria gonorrhoeae , Anthrax caused by Bacillus anthracis , Infections due to Listeria monocytogenes , Actinomycosis caused by Actinomyces species, Infections due to Clostridium species. uuid:8dcdc072-70e4-41c2-9e62-786c8b5a8a68 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0024388 PMID:41385096 "[{""id"":""uuid:2abd3831-25b8-4008-aaba-48ba3d39375d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:add1db91-0a50-416e-b9f2-3447178dd1ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae, Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp . ) Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci. Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli, Klebsiella, etc. Other infections caused by susceptible gram-negative organisms such as E. coli, Enterobacter aerogenes, Shigella sp ., Acinetobacter sp ., Klebsiella sp. , and Bacteroides sp. In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: Syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent's infection caused by Fusobacterium fusiforme , Infections caused by Neisseria gonorrhoeae , Anthrax caused by Bacillus anthracis , Infections due to Listeria monocytogenes , Actinomycosis caused by Actinomyces species, Infections due to Clostridium species. uuid:d853d096-1cd8-42cf-ac13-d1d170ae97ab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0021680 PMID:41385096 "[{""id"":""uuid:70852fba-3b46-4928-a55f-1972ef746ef7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4ffcd9a4-ae95-4f8c-8764-2b375192d79d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes, Streptococcus pneumoniae, Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp . ) Skin and soft tissue infections caused by Streptococcus pyogenes, Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci. Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli, Klebsiella, etc. Other infections caused by susceptible gram-negative organisms such as E. coli, Enterobacter aerogenes, Shigella sp ., Acinetobacter sp ., Klebsiella sp. , and Bacteroides sp. In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: Syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent's infection caused by Fusobacterium fusiforme , Infections caused by Neisseria gonorrhoeae , Anthrax caused by Bacillus anthracis , Infections due to Listeria monocytogenes , Actinomycosis caused by Actinomyces species, Infections due to Clostridium species. uuid:f210d066-9438-47be-8704-45dc9b92d949 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16794 biolink:treats EFO:0004888 PMID:41385096 "[{""id"":""uuid:8287904b-19fc-4f66-8c5d-71db203c52d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6ee61fc7-6971-40bc-8101-6a1f1965e4b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Scopolamine transdermal system is indicated in adults for the prevention of: • nausea and vomiting associated with motion sickness. • post-operative nausea and vomiting (PONV) associated with recovery from anesthesia and/or opiate analgesia and surgery. uuid:4c5b88a2-ef5b-4d67-a6a6-ff8864a76e6e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:700516 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:8fc8a227-017a-4d3c-b135-0bb3c92bbbca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:20558000-bda2-4184-9c71-8c451af5b191"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] JANUMET is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use JANUMET should not be used in patients with type 1 diabetes mellitus. JANUMET has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using JANUMET. [See Warnings and Precautions (5.2) .] uuid:c33702a1-80d9-4624-81f6-57946d66ba3b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:700516 biolink:treats MONDO:0004982 PMID:41385096 "[{""id"":""uuid:0069e665-d190-4d63-b681-77cd1cd59d18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:19e0bdf9-e4e9-4e05-a84d-ca4ded19643a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] JANUMET is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use JANUMET should not be used in patients with type 1 diabetes mellitus. JANUMET has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using JANUMET. [See Warnings and Precautions (5.2) .] uuid:744d4e57-7d16-4604-ac7e-53dea8fdc973 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7478 biolink:treats MONDO:0005475 PMID:41385096 "[{""id"":""uuid:52fc0cf7-2a52-456d-bbc8-05b531e62533"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4a7be5cb-6e2e-4bce-ba9d-6ceec0ae5ffa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Naratriptan is indicated for the acute treatment of migraine attacks with or without aura in adults. Limitations of Use: • Use only if a clear diagnosis of migraine has been established. If a patient has no response to the first migraine attack treated with naratriptan, reconsider the diagnosis of migraine before naratriptan is administered to treat any subsequent attacks. • Naratriptan is not indicated for the prevention of migraine attacks. • Safety and effectiveness of naratriptan have not been established for cluster headache. uuid:4ed2d4ec-90bf-4c12-81c6-1d8aba23a0e9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7478 biolink:treats MONDO:0100431 PMID:41385096 "[{""id"":""uuid:c386781f-1244-4d05-b7a9-f6be310f49fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7a6f6072-5191-46fc-ba4a-ee63d6b52566"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Naratriptan is indicated for the acute treatment of migraine attacks with or without aura in adults. Limitations of Use: • Use only if a clear diagnosis of migraine has been established. If a patient has no response to the first migraine attack treated with naratriptan, reconsider the diagnosis of migraine before naratriptan is administered to treat any subsequent attacks. • Naratriptan is not indicated for the prevention of migraine attacks. • Safety and effectiveness of naratriptan have not been established for cluster headache. uuid:85b13d4d-221b-4f44-abff-e405e46fef58 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7478 biolink:treats MONDO:0005277 PMID:41385096 "[{""id"":""uuid:2480efad-8d30-4429-b843-f4e0253c55e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f0489d79-f53c-4b85-aac7-52cda1557a48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:508848fe-321c-4e5d-be9b-9c3afa806cd8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Naratriptan is indicated for the acute treatment of migraine attacks with or without aura in adults. Limitations of Use: • Use only if a clear diagnosis of migraine has been established. If a patient has no response to the first migraine attack treated with naratriptan, reconsider the diagnosis of migraine before naratriptan is administered to treat any subsequent attacks. • Naratriptan is not indicated for the prevention of migraine attacks. • Safety and effectiveness of naratriptan have not been established for cluster headache.|[PMDA] A drug containing a new active ingredient indicated for the treatment of migraine. uuid:62ca9d2f-97b9-4b60-82a4-38b655a19bc0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:194135 biolink:treats MONDO:0002345 PMID:41385096 "[{""id"":""uuid:8bbf1bab-aac2-47d8-b526-dc0f1cfb7492"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:52f838fc-c4bc-4a0c-a878-e1cc29f3a7bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of ofloxacin tablets, USP and other antibacterial drugs, ofloxacin tablets, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Ofloxacin tablets, USP are indicated for the treatment of adults with mild to moderate infections (unless otherwise indicated) caused by susceptible strains of the designated microorganisms in the infections listed below. Please see DOSAGE AND ADMINISTRATION for specific recommendations. Acute Bacterial Exacerbations of Chronic Bronchitis (ABECB) due to Haemophilus influenzae or Streptococcus pneumoniae . Because fluoroquinolones, including ofloxacin, have been associated with serious adverse reactions (see Warnings ), - and for some patients ABECB is self-limiting, reserve ofloxacin for treatment of ABECB in patients who have no alternative treatment options . Community-Acquired Pneumonia due to Haemophilus influenzae or Streptococcus pneumoniae . Uncomplicated Skin and Skin Structure Infections due to methicillin-susceptible Staphylococcus aureus, Streptococcus pyogenes, or Proteus mirabilis. Acute, Uncomplicated Urethral and Cervical Gonorrhea due to Neisseria gonorrhoeae (see WARNINGS ). Nongonococcal Urethritis and Cervicitis due to Chlamydia trachomatis (see WARNINGS ). Mixed Infections of the Urethra and Cervix due to Chlamydia trachomatis and Neisseria gonorrhoeae (see WARNINGS ). Acute Pelvic Inflammatory Disease (including severe infection) due to Chlamydia trachomatis and/or Neisseria gonorrhoeae (see WARNINGS ). NOTE: If anaerobic microorganisms are suspected of contributing to the infection, appropriate therapy for anaerobic pathogens should be administered. Uncomplicated Cystitis due to Citrobacter diversus, Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, or Pseudomonas aeruginosa. Because fluoroquinolones, including ofloxacin, have been associated with serious adverse reactions (see WARNINGS ), and for some patients uncomplicated cystitis is self-limiting, reserve ofloxacin for treatment of uncomplicated cystitis in patients who have no alternative treatment options. Complicated Urinary Tract Infections due to Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Citrobacter diversus, = Although treatment of infections due to this organism in this organ system demonstrated a clinically significant outcome, efficacy was studied in fewer than 10 patients. or Pseudomonas aeruginosa. Prostatitis due to Escherichia coli. Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to ofloxacin, USP. Therapy with ofloxacin, USP may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued. As with other drugs in this class, some strains of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with ofloxacin, USP. Culture and susceptibility testing performed periodically during therapy will provide information not only on the therapeutic effect of the antimicrobial agent but also on the possible emergence of bacterial resistance. uuid:05f28045-08e1-4ed9-a962-e0fea84fba71 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:616538 biolink:treats MONDO:0800501 PMID:41385096 "[{""id"":""uuid:4d68211c-e3da-4a31-a1c3-332a4f4451f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3ec39cca-7e08-4624-89cc-d5d55a134503"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZEGERID for oral suspension and ZEGERID capsules are indicated in adults for the : • short-term treatment of active duodenal ulcer. Most patients heal within four weeks. Some patients may require an additional four weeks of therapy. • short-term treatment (4 to 8 weeks) of active benign gastric ulcer. • treatment of heartburn and other symptoms associated with GERD for up to 4 weeks. • short-term treatment (4 to 8 weeks) of EE due to acid-mediated GERD which has been diagnosed by endoscopy in adults. • The efficacy of ZEGERID used for longer than 8 weeks in patients with EE has not been established. If a patient does not respond to 8 weeks of treatment, an additional 4 weeks of treatment may be given. If there is recurrence of EE or GERD symptoms (e.g., heartburn), additional 4 to 8-week courses of ZEGERID may be considered. • maintenance of healing of EE due to acid-mediated GERD. Controlled studies do not extend beyond 12 months. ZEGERID for oral suspension is indicated in adults for the : • reduction of risk of upper GI bleeding in critically ill adult patients. uuid:58a0f571-0804-4c11-8d5d-d3d80767d034 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6633 biolink:treats UMLS:C0332687 PMID:41385096 "[{""id"":""uuid:17e63c6a-99e1-4ef5-af65-c260c258e4ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3681873b-62aa-4900-a27b-454bd917f06d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SULFAMYLON Cream is a topical agent indicated for adjunctive therapy of patients with second- and third-degree burns. uuid:f4217ebe-a59d-478d-a1cf-19cea3c9ebad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6633 biolink:treats UMLS:C0433445 PMID:41385096 "[{""id"":""uuid:368d5b5d-4e07-426d-a671-dd78f21fa40d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7bb414df-ba88-4949-8a65-5a7fa721c2fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SULFAMYLON Cream is a topical agent indicated for adjunctive therapy of patients with second- and third-degree burns. uuid:672de1e3-d695-45f9-be92-253680f24971 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:SXA7YP6EKX biolink:treats MONDO:0010679 PMID:41385096 "[{""id"":""uuid:2056179f-89e4-44ef-aba0-40c137e67507"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6d560704-36f6-4cc0-9b07-45a61df70730"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:73795667-de54-457b-acb6-24255fbd73a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VILTEPSO is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VILTEPSO [see Clinical Studies ( 14 )]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.|[PMDA] A drug with a new active ingredient indicated for the treatment of Duchenne muscular dystrophy (DMD) with a confirmed deficiency of the dystrophin gene amenable to exon 53 skipping therapy. [SAKIGAKE designation] [Conditional early approval] [Orphan drug] uuid:bbb1d17d-d040-4fd0-a27a-d2b4d1dfa531 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133023 biolink:treats MONDO:0006733 PMID:41385096 "[{""id"":""uuid:a54e74fd-4f01-49c4-99a1-85580413533e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d9ae4d49-6e80-49b4-aedd-33ada01627b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Xiidra ® (lifitegrast ophthalmic solution) 5% is indicated for the treatment of the signs and symptoms of dry eye disease (DED). uuid:0683c6bf-f5eb-4cae-ae10-192657a600fb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:11979316 biolink:treats MONDO:0005468 PMID:41385096 "[{""id"":""uuid:e1714cc9-f2f7-4781-902f-9d9294ea6162"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c10bf272-5f42-4f43-9343-1c297b57f39c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vasopressin injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines. uuid:40ff84ed-0d62-4361-850e-8d1f9b7cae33 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71272 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:2e6ace40-6c4e-47b3-bdb0-fe7333fbc632"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:07191eca-679c-48f1-b933-2e11eb688ee1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2f810696-e422-459a-8e8a-cd31c96d73de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Saxagliptin tablets are a dipeptidyl peptidase-4 (DPP4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1.1 , 14 ) Limitation of use: • Not used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis. ( 1.2 )|[PMDA] Drugs with a new active ingredient indicated for the treatment of type 2 diabetes mellitus. uuid:e8e3aaca-c3df-48c0-8676-3999900c0a05 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71272 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:5c5d26a4-3048-45b4-b59e-597fd90addbe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2f8d9cc9-7707-4916-b5de-715e2778b1af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Saxagliptin tablets are a dipeptidyl peptidase-4 (DPP4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1.1 , 14 ) Limitation of use: • Not used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis. ( 1.2 ) uuid:642a294f-dcea-4442-87f1-98979412b175 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71272 biolink:treats MONDO:0012819 PMID:41385096 "[{""id"":""uuid:b54a9cf2-888e-4f8d-b3f0-9cde57c53994"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2fc0fa5e-7d4f-4e17-95a8-e7e708765842"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Saxagliptin tablets are a dipeptidyl peptidase-4 (DPP4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1.1 , 14 ) Limitation of use: • Not used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis. ( 1.2 ) uuid:5109c3e4-9420-4626-9f76-3ace2d288a6d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29036 biolink:treats HP:0011967 PMID:41385096 "[{""id"":""uuid:ba91caf3-0245-4d39-b8dc-999be7f18aa2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:91a685a3-6ca1-42d5-a4a0-8747640da708"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cupric Chloride Injection, USP 0.4 mg/mL is indicated for use as a supplement to intravenous solutions given for total parenteral nutrition (TPN). Administration helps to maintain copper serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms. uuid:9a2dc3f2-2dde-4b77-9b27-091209d37a17 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18067 biolink:treats MONDO:0001244 PMID:41385096 "[{""id"":""uuid:29924521-6914-4e5e-a72c-40023236bc4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aca74af1-5b6f-4292-adb6-72f21abaa40f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Phytonadione is indicated for the treatment of adults with the following coagulation disorders which are due to faulty formation of factors II, VII, IX and X when caused by vitamin K deficiency or interference with vitamin K activity. • anticoagulant-induced hypoprothrombinemia caused by coumarin or indanedione derivatives; • hypoprothrombinemia secondary to antibacterial therapy; • hypoprothrombinemia secondary to factors limiting absorpsion or synthesis of vitamin K, e.g., obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal resection, cystic fibrosis of the pancrease, and regional enteritis; • Other drug-induced hypoprothrombinemia where it is definitely shown that the result is due to interference with vitamin K metabolism, e.g., salicylates. uuid:5fe3cb92-c311-440a-808b-ffd84d95173b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18067 biolink:treats MONDO:0009061 PMID:41385096 "[{""id"":""uuid:668ca464-3965-415d-aabf-19ec9728ba4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:43f6d9c8-c7ab-469a-b4f0-39fea0f16798"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Phytonadione is indicated for the treatment of adults with the following coagulation disorders which are due to faulty formation of factors II, VII, IX and X when caused by vitamin K deficiency or interference with vitamin K activity. • anticoagulant-induced hypoprothrombinemia caused by coumarin or indanedione derivatives; • hypoprothrombinemia secondary to antibacterial therapy; • hypoprothrombinemia secondary to factors limiting absorpsion or synthesis of vitamin K, e.g., obstructive jaundice, biliary fistula, sprue, ulcerative colitis, celiac disease, intestinal resection, cystic fibrosis of the pancrease, and regional enteritis; • Other drug-induced hypoprothrombinemia where it is definitely shown that the result is due to interference with vitamin K metabolism, e.g., salicylates. uuid:3368f1e1-1c4a-44d1-a8a8-6be1a4e10640 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:L0HR9A577V biolink:treats UMLS:C5577628 PMID:41385096 "[{""id"":""uuid:4e918871-b1ce-4e62-b928-56da6bcc118d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ecbe56c6-7d90-420b-9db0-f8a1d247621a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ELREXFIO is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. This indication is approved under accelerated approval based on response rate and durability of response [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). uuid:23b680de-0a88-47a5-9a61-39be8012b193 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:L0HR9A577V biolink:treats UMLS:C4551538 PMID:41385096 "[{""id"":""uuid:60f57463-09e5-4413-a37a-38007f7d6cdd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ee8c0d9c-cce2-47f0-9742-ed95e3b63c3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ELREXFIO is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. This indication is approved under accelerated approval based on response rate and durability of response [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). uuid:ef141518-96b2-4dd5-97af-ab2fff400769 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32229 biolink:treats EFO:0010826 PMID:41385096 "[{""id"":""uuid:c8231ce6-8b5c-4922-ba0b-b575c4610a57"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:839c9dd5-8c2a-47f0-aa4d-b756aec4e012"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tiopronin delayed-release tablets are indicated, in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation in adults and pediatric patients 9 years of age and older with severe homozygous cystinuria, who are not responsive to these measures alone. Additional pediatric use information is approved for Mission Pharmacal Company’s THIOLA EC (tiopronin) delayed-release tablets. However, due to Mission Pharmacal Company’s marketing exclusivity rights, this drug product is not labeled with that information. uuid:865bdd5f-5d97-45e1-ab07-92bbc502c52c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32229 biolink:treats MONDO:0009067 PMID:41385096 "[{""id"":""uuid:95d5c041-7d24-402c-a073-64acc7d2cadc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ef274754-5dcc-4682-be18-daa92bf7b455"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tiopronin delayed-release tablets are indicated, in combination with high fluid intake, alkali, and diet modification, for the prevention of cystine stone formation in adults and pediatric patients 9 years of age and older with severe homozygous cystinuria, who are not responsive to these measures alone. Additional pediatric use information is approved for Mission Pharmacal Company’s THIOLA EC (tiopronin) delayed-release tablets. However, due to Mission Pharmacal Company’s marketing exclusivity rights, this drug product is not labeled with that information. uuid:7cf42a34-b48e-47fa-b9f2-2a2b9405ae4e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB09422 biolink:treats UMLS:C0854100 PMID:41385096 "[{""id"":""uuid:f90bd003-ca43-4dcc-91bc-8b846e103600"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4edfd1b2-f5ab-48ad-8d04-f91613e50cd1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KABIVEN is indicated as a source of calories, protein, electrolytes and essential fatty acids for adult patients requiring parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. KABIVEN may be used to prevent essential fatty acid deficiency or treat negative nitrogen balance in adult patients. Limitations of Use: KABIVEN is not recommended for use in pediatric patients under the age of 2 years, including preterm infants because the fixed content of the formulation does not meet the nutritional requirements of this age group [see Warnings and Precautions ( 5.1 ) and Use in Specific Populations ( 8.4 )] . uuid:5e816d4c-29f6-45af-a66e-cdfd9408e1ef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17076 biolink:treats MONDO:0018076 PMID:41385096 "[{""id"":""uuid:24bff12e-bdd3-4f37-9649-69cb90873201"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1720f126-9630-435c-8f9f-3dffa535a775"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Streptomycin is indicated for the treatment of individuals with moderate to severe infections caused by susceptibile strains of microorganisms in the specific conditions listed below: Mycobacterium tuberculosis: The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Center for Disease Control recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH or rifampin resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. In the past when the national rate of primary drug resistance to isoniazid was known to be less than 4% and was either stable or declining, therapy with two and three drug regimens was considered adequate. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered. Streptomycin is also indicated for therapy of tuberculosis when one or more of the above drugs is contraindicated because of toxicity or intolerance. The management of tuberculosis has become more complex as a consequence of increasing rates of drug resistance and concomitant HIV infection. Additional consultation from experts in the treatment of tuberculosis may be desirable in those settings. Non-tuberculosis infections: The use of streptomycin should be limited to the treatment of infections caused by bacteria which have been shown to be susceptible to the antibacterial effects of streptomycin and which are not amenable to therapy with less potentially toxic agents. Yersinia pestis (plague), Francisella tularensis (tularemia), Brucella , Calymmatobacterium granulomatis (donovanosis, granuloma inguinale), H. ducreyi (chancroid), H. influenzae (in respiratory, endocardial, and meningeal infections-concomitantly with another antibacterial agent), K. pneumoniae pneumonia (concomitantly with another antibacterial agent), E.coli, Proteus, A. aerogenes, K. pneumoniae, and Enterococcus faecalis in urinary tract infections, Streptococcus viridans , Enterococcus faecalis (in endocardial infections - concomitantly with penicillin), Gram-negative bacillary bacteremia (concomitantly with another antibacterial agent). To reduce the development of drug-resistant bacteria and maintain the effectiveness of streptomycin and other antibacterial drugs, streptomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:cc352a83-71bf-4402-9f26-b124c9c7f4bb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17076 biolink:treats MONDO:0019095 PMID:41385096 "[{""id"":""uuid:0e740482-006d-4115-bac3-b2a397e655a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:694f3041-c3b9-4e26-accb-0154e8281c46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Streptomycin is indicated for the treatment of individuals with moderate to severe infections caused by susceptibile strains of microorganisms in the specific conditions listed below: Mycobacterium tuberculosis: The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Center for Disease Control recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH or rifampin resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. In the past when the national rate of primary drug resistance to isoniazid was known to be less than 4% and was either stable or declining, therapy with two and three drug regimens was considered adequate. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered. Streptomycin is also indicated for therapy of tuberculosis when one or more of the above drugs is contraindicated because of toxicity or intolerance. The management of tuberculosis has become more complex as a consequence of increasing rates of drug resistance and concomitant HIV infection. Additional consultation from experts in the treatment of tuberculosis may be desirable in those settings. Non-tuberculosis infections: The use of streptomycin should be limited to the treatment of infections caused by bacteria which have been shown to be susceptible to the antibacterial effects of streptomycin and which are not amenable to therapy with less potentially toxic agents. Yersinia pestis (plague), Francisella tularensis (tularemia), Brucella , Calymmatobacterium granulomatis (donovanosis, granuloma inguinale), H. ducreyi (chancroid), H. influenzae (in respiratory, endocardial, and meningeal infections-concomitantly with another antibacterial agent), K. pneumoniae pneumonia (concomitantly with another antibacterial agent), E.coli, Proteus, A. aerogenes, K. pneumoniae, and Enterococcus faecalis in urinary tract infections, Streptococcus viridans , Enterococcus faecalis (in endocardial infections - concomitantly with penicillin), Gram-negative bacillary bacteremia (concomitantly with another antibacterial agent). To reduce the development of drug-resistant bacteria and maintain the effectiveness of streptomycin and other antibacterial drugs, streptomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:c7dac55c-ae8e-4a6c-bca9-e1ba14dd1c28 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17076 biolink:treats MONDO:0018077 PMID:41385096 "[{""id"":""uuid:9e3483f7-8b67-432a-b60a-11f780971252"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:781792ad-d6be-456c-be13-dfb3f3dda170"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Streptomycin is indicated for the treatment of individuals with moderate to severe infections caused by susceptibile strains of microorganisms in the specific conditions listed below: Mycobacterium tuberculosis: The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Center for Disease Control recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH or rifampin resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. In the past when the national rate of primary drug resistance to isoniazid was known to be less than 4% and was either stable or declining, therapy with two and three drug regimens was considered adequate. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered. Streptomycin is also indicated for therapy of tuberculosis when one or more of the above drugs is contraindicated because of toxicity or intolerance. The management of tuberculosis has become more complex as a consequence of increasing rates of drug resistance and concomitant HIV infection. Additional consultation from experts in the treatment of tuberculosis may be desirable in those settings. Non-tuberculosis infections: The use of streptomycin should be limited to the treatment of infections caused by bacteria which have been shown to be susceptible to the antibacterial effects of streptomycin and which are not amenable to therapy with less potentially toxic agents. Yersinia pestis (plague), Francisella tularensis (tularemia), Brucella , Calymmatobacterium granulomatis (donovanosis, granuloma inguinale), H. ducreyi (chancroid), H. influenzae (in respiratory, endocardial, and meningeal infections-concomitantly with another antibacterial agent), K. pneumoniae pneumonia (concomitantly with another antibacterial agent), E.coli, Proteus, A. aerogenes, K. pneumoniae, and Enterococcus faecalis in urinary tract infections, Streptococcus viridans , Enterococcus faecalis (in endocardial infections - concomitantly with penicillin), Gram-negative bacillary bacteremia (concomitantly with another antibacterial agent). To reduce the development of drug-resistant bacteria and maintain the effectiveness of streptomycin and other antibacterial drugs, streptomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:a76002b1-0a33-49a7-9bc5-fa1805aae5d4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17076 biolink:treats MONDO:0005683 PMID:41385096 "[{""id"":""uuid:9289b061-49aa-440f-94ab-4b6ff2b2aa5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0c5b1420-1c2e-47ee-abd3-ddcf5e932014"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Streptomycin is indicated for the treatment of individuals with moderate to severe infections caused by susceptibile strains of microorganisms in the specific conditions listed below: Mycobacterium tuberculosis: The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Center for Disease Control recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH or rifampin resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. In the past when the national rate of primary drug resistance to isoniazid was known to be less than 4% and was either stable or declining, therapy with two and three drug regimens was considered adequate. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered. Streptomycin is also indicated for therapy of tuberculosis when one or more of the above drugs is contraindicated because of toxicity or intolerance. The management of tuberculosis has become more complex as a consequence of increasing rates of drug resistance and concomitant HIV infection. Additional consultation from experts in the treatment of tuberculosis may be desirable in those settings. Non-tuberculosis infections: The use of streptomycin should be limited to the treatment of infections caused by bacteria which have been shown to be susceptible to the antibacterial effects of streptomycin and which are not amenable to therapy with less potentially toxic agents. Yersinia pestis (plague), Francisella tularensis (tularemia), Brucella , Calymmatobacterium granulomatis (donovanosis, granuloma inguinale), H. ducreyi (chancroid), H. influenzae (in respiratory, endocardial, and meningeal infections-concomitantly with another antibacterial agent), K. pneumoniae pneumonia (concomitantly with another antibacterial agent), E.coli, Proteus, A. aerogenes, K. pneumoniae, and Enterococcus faecalis in urinary tract infections, Streptococcus viridans , Enterococcus faecalis (in endocardial infections - concomitantly with penicillin), Gram-negative bacillary bacteremia (concomitantly with another antibacterial agent). To reduce the development of drug-resistant bacteria and maintain the effectiveness of streptomycin and other antibacterial drugs, streptomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:a1a1a391-2dd4-43d0-b8dd-000df439015d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17076 biolink:treats MONDO:0005777 PMID:41385096 "[{""id"":""uuid:bfbea3c2-323e-4bad-afa0-438a1db33c21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bc2a5077-0fb4-4e0c-ab00-1dbfa3d61185"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Streptomycin is indicated for the treatment of individuals with moderate to severe infections caused by susceptibile strains of microorganisms in the specific conditions listed below: Mycobacterium tuberculosis: The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Center for Disease Control recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH or rifampin resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. In the past when the national rate of primary drug resistance to isoniazid was known to be less than 4% and was either stable or declining, therapy with two and three drug regimens was considered adequate. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered. Streptomycin is also indicated for therapy of tuberculosis when one or more of the above drugs is contraindicated because of toxicity or intolerance. The management of tuberculosis has become more complex as a consequence of increasing rates of drug resistance and concomitant HIV infection. Additional consultation from experts in the treatment of tuberculosis may be desirable in those settings. Non-tuberculosis infections: The use of streptomycin should be limited to the treatment of infections caused by bacteria which have been shown to be susceptible to the antibacterial effects of streptomycin and which are not amenable to therapy with less potentially toxic agents. Yersinia pestis (plague), Francisella tularensis (tularemia), Brucella , Calymmatobacterium granulomatis (donovanosis, granuloma inguinale), H. ducreyi (chancroid), H. influenzae (in respiratory, endocardial, and meningeal infections-concomitantly with another antibacterial agent), K. pneumoniae pneumonia (concomitantly with another antibacterial agent), E.coli, Proteus, A. aerogenes, K. pneumoniae, and Enterococcus faecalis in urinary tract infections, Streptococcus viridans , Enterococcus faecalis (in endocardial infections - concomitantly with penicillin), Gram-negative bacillary bacteremia (concomitantly with another antibacterial agent). To reduce the development of drug-resistant bacteria and maintain the effectiveness of streptomycin and other antibacterial drugs, streptomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:c2a5e620-1e14-401c-8f55-7fb3194d12d2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17076 biolink:treats MONDO:0001797 PMID:41385096 "[{""id"":""uuid:e79569eb-703d-4aa0-94dd-ba9094ce4ac0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3949c902-ed38-471d-b95c-db661c11362c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Streptomycin is indicated for the treatment of individuals with moderate to severe infections caused by susceptibile strains of microorganisms in the specific conditions listed below: Mycobacterium tuberculosis: The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Center for Disease Control recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH or rifampin resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. In the past when the national rate of primary drug resistance to isoniazid was known to be less than 4% and was either stable or declining, therapy with two and three drug regimens was considered adequate. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered. Streptomycin is also indicated for therapy of tuberculosis when one or more of the above drugs is contraindicated because of toxicity or intolerance. The management of tuberculosis has become more complex as a consequence of increasing rates of drug resistance and concomitant HIV infection. Additional consultation from experts in the treatment of tuberculosis may be desirable in those settings. Non-tuberculosis infections: The use of streptomycin should be limited to the treatment of infections caused by bacteria which have been shown to be susceptible to the antibacterial effects of streptomycin and which are not amenable to therapy with less potentially toxic agents. Yersinia pestis (plague), Francisella tularensis (tularemia), Brucella , Calymmatobacterium granulomatis (donovanosis, granuloma inguinale), H. ducreyi (chancroid), H. influenzae (in respiratory, endocardial, and meningeal infections-concomitantly with another antibacterial agent), K. pneumoniae pneumonia (concomitantly with another antibacterial agent), E.coli, Proteus, A. aerogenes, K. pneumoniae, and Enterococcus faecalis in urinary tract infections, Streptococcus viridans , Enterococcus faecalis (in endocardial infections - concomitantly with penicillin), Gram-negative bacillary bacteremia (concomitantly with another antibacterial agent). To reduce the development of drug-resistant bacteria and maintain the effectiveness of streptomycin and other antibacterial drugs, streptomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:d4fd4cbd-f76d-4d7a-bab5-1c790edb97d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17076 biolink:treats HP:0005376 PMID:41385096 "[{""id"":""uuid:55892e57-0016-42a2-baa2-03ae7c379bac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a99f6f8e-ef37-4d3f-a247-85eefb78e3ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Streptomycin is indicated for the treatment of individuals with moderate to severe infections caused by susceptibile strains of microorganisms in the specific conditions listed below: Mycobacterium tuberculosis: The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Center for Disease Control recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH or rifampin resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. In the past when the national rate of primary drug resistance to isoniazid was known to be less than 4% and was either stable or declining, therapy with two and three drug regimens was considered adequate. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered. Streptomycin is also indicated for therapy of tuberculosis when one or more of the above drugs is contraindicated because of toxicity or intolerance. The management of tuberculosis has become more complex as a consequence of increasing rates of drug resistance and concomitant HIV infection. Additional consultation from experts in the treatment of tuberculosis may be desirable in those settings. Non-tuberculosis infections: The use of streptomycin should be limited to the treatment of infections caused by bacteria which have been shown to be susceptible to the antibacterial effects of streptomycin and which are not amenable to therapy with less potentially toxic agents. Yersinia pestis (plague), Francisella tularensis (tularemia), Brucella , Calymmatobacterium granulomatis (donovanosis, granuloma inguinale), H. ducreyi (chancroid), H. influenzae (in respiratory, endocardial, and meningeal infections-concomitantly with another antibacterial agent), K. pneumoniae pneumonia (concomitantly with another antibacterial agent), E.coli, Proteus, A. aerogenes, K. pneumoniae, and Enterococcus faecalis in urinary tract infections, Streptococcus viridans , Enterococcus faecalis (in endocardial infections - concomitantly with penicillin), Gram-negative bacillary bacteremia (concomitantly with another antibacterial agent). To reduce the development of drug-resistant bacteria and maintain the effectiveness of streptomycin and other antibacterial drugs, streptomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:b1616133-4c6c-4ac1-a587-2f7f3d4f130d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17076 biolink:treats MONDO:0030602 PMID:41385096 "[{""id"":""uuid:4b29cce9-210c-4e16-9852-a74f199b789f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:62a3d92f-dd2e-4057-8d7d-74f67ebd4e3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Streptomycin is indicated for the treatment of individuals with moderate to severe infections caused by susceptibile strains of microorganisms in the specific conditions listed below: Mycobacterium tuberculosis: The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Center for Disease Control recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH or rifampin resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. In the past when the national rate of primary drug resistance to isoniazid was known to be less than 4% and was either stable or declining, therapy with two and three drug regimens was considered adequate. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered. Streptomycin is also indicated for therapy of tuberculosis when one or more of the above drugs is contraindicated because of toxicity or intolerance. The management of tuberculosis has become more complex as a consequence of increasing rates of drug resistance and concomitant HIV infection. Additional consultation from experts in the treatment of tuberculosis may be desirable in those settings. Non-tuberculosis infections: The use of streptomycin should be limited to the treatment of infections caused by bacteria which have been shown to be susceptible to the antibacterial effects of streptomycin and which are not amenable to therapy with less potentially toxic agents. Yersinia pestis (plague), Francisella tularensis (tularemia), Brucella , Calymmatobacterium granulomatis (donovanosis, granuloma inguinale), H. ducreyi (chancroid), H. influenzae (in respiratory, endocardial, and meningeal infections-concomitantly with another antibacterial agent), K. pneumoniae pneumonia (concomitantly with another antibacterial agent), E.coli, Proteus, A. aerogenes, K. pneumoniae, and Enterococcus faecalis in urinary tract infections, Streptococcus viridans , Enterococcus faecalis (in endocardial infections - concomitantly with penicillin), Gram-negative bacillary bacteremia (concomitantly with another antibacterial agent). To reduce the development of drug-resistant bacteria and maintain the effectiveness of streptomycin and other antibacterial drugs, streptomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:2321d9f7-86c3-4f0c-be0d-3b0b79b3627f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17076 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:2c6f5e82-ce46-45d8-8c1a-7060b8db5665"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4b1bcf66-a9f3-48c7-8a1d-4a7a29e0eef9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Streptomycin is indicated for the treatment of individuals with moderate to severe infections caused by susceptibile strains of microorganisms in the specific conditions listed below: Mycobacterium tuberculosis: The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Center for Disease Control recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH or rifampin resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. In the past when the national rate of primary drug resistance to isoniazid was known to be less than 4% and was either stable or declining, therapy with two and three drug regimens was considered adequate. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered. Streptomycin is also indicated for therapy of tuberculosis when one or more of the above drugs is contraindicated because of toxicity or intolerance. The management of tuberculosis has become more complex as a consequence of increasing rates of drug resistance and concomitant HIV infection. Additional consultation from experts in the treatment of tuberculosis may be desirable in those settings. Non-tuberculosis infections: The use of streptomycin should be limited to the treatment of infections caused by bacteria which have been shown to be susceptible to the antibacterial effects of streptomycin and which are not amenable to therapy with less potentially toxic agents. Yersinia pestis (plague), Francisella tularensis (tularemia), Brucella , Calymmatobacterium granulomatis (donovanosis, granuloma inguinale), H. ducreyi (chancroid), H. influenzae (in respiratory, endocardial, and meningeal infections-concomitantly with another antibacterial agent), K. pneumoniae pneumonia (concomitantly with another antibacterial agent), E.coli, Proteus, A. aerogenes, K. pneumoniae, and Enterococcus faecalis in urinary tract infections, Streptococcus viridans , Enterococcus faecalis (in endocardial infections - concomitantly with penicillin), Gram-negative bacillary bacteremia (concomitantly with another antibacterial agent). To reduce the development of drug-resistant bacteria and maintain the effectiveness of streptomycin and other antibacterial drugs, streptomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:ef7cb424-28d2-429f-b828-8ec4a72a0290 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17076 biolink:treats UMLS:C0744471 PMID:41385096 "[{""id"":""uuid:bd618266-686f-4920-89e9-372213fc56b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cc82f473-cbce-47a0-ba75-17a02af4755e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Streptomycin is indicated for the treatment of individuals with moderate to severe infections caused by susceptibile strains of microorganisms in the specific conditions listed below: Mycobacterium tuberculosis: The Advisory Council for the Elimination of Tuberculosis, the American Thoracic Society, and the Center for Disease Control recommend that either streptomycin or ethambutol be added as a fourth drug in a regimen containing isoniazid (INH), rifampin and pyrazinamide for initial treatment of tuberculosis unless the likelihood of INH or rifampin resistance is very low. The need for a fourth drug should be reassessed when the results of susceptibility testing are known. In the past when the national rate of primary drug resistance to isoniazid was known to be less than 4% and was either stable or declining, therapy with two and three drug regimens was considered adequate. If community rates of INH resistance are currently less than 4%, an initial treatment regimen with less than four drugs may be considered. Streptomycin is also indicated for therapy of tuberculosis when one or more of the above drugs is contraindicated because of toxicity or intolerance. The management of tuberculosis has become more complex as a consequence of increasing rates of drug resistance and concomitant HIV infection. Additional consultation from experts in the treatment of tuberculosis may be desirable in those settings. Non-tuberculosis infections: The use of streptomycin should be limited to the treatment of infections caused by bacteria which have been shown to be susceptible to the antibacterial effects of streptomycin and which are not amenable to therapy with less potentially toxic agents. Yersinia pestis (plague), Francisella tularensis (tularemia), Brucella , Calymmatobacterium granulomatis (donovanosis, granuloma inguinale), H. ducreyi (chancroid), H. influenzae (in respiratory, endocardial, and meningeal infections-concomitantly with another antibacterial agent), K. pneumoniae pneumonia (concomitantly with another antibacterial agent), E.coli, Proteus, A. aerogenes, K. pneumoniae, and Enterococcus faecalis in urinary tract infections, Streptococcus viridans , Enterococcus faecalis (in endocardial infections - concomitantly with penicillin), Gram-negative bacillary bacteremia (concomitantly with another antibacterial agent). To reduce the development of drug-resistant bacteria and maintain the effectiveness of streptomycin and other antibacterial drugs, streptomycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:55fa99cb-ef84-42b6-a9d1-abebd8095127 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:O43472U9X8 biolink:treats MONDO:0004948 PMID:41385096 "[{""id"":""uuid:acd18383-ea9a-4c7c-9807-e175f8f6eba4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:06ae6bdc-1b40-4b6b-80f8-a6d400b39729"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1e9ca55e-bba4-4240-832b-922661e4b105"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/gazyvaro""]},{""id"":""uuid:664f53a8-1a94-4a0b-bf38-8234ef683381"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] GAZYVA is a CD20-directed cytolytic antibody indicated: in combination with chlorambucil, for the treatment of patients with previously untreated chronic lymphocytic leukemia. ( 1 , 14 ) in combination with bendamustine followed by GAZYVA monotherapy, for the treatment of patients with follicular lymphoma who relapsed after, or are refractory to, a rituximab-containing regimen. ( 1 , 14 ) in combination with chemotherapy followed by GAZYVA monotherapy in patients achieving at least a partial remission, for the treatment of adult patients with previously untreated stage II bulky, III or IV follicular lymphoma. ( 1 , 14 )|[EMA] Chronic Lymphocytic Leukaemia (CLL)Gazyvaro in combination with chlorambucil is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) and with comorbidities making them unsuitable for full-dose fludarabine based therapy (see section 5.1).Follicular Lymphoma (FL)Gazyvaro in combination with chemotherapy, followed by Gazyvaro maintenance therapy in patients achieving a response, is indicated for the treatment of patients with previously untreated advanced follicular lymphoma.Gazyvaro in combination with bendamustine followed by Gazyvaro maintenance is indicated for the treatment of patients with follicular lymphoma (FL) who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen.|[PMDA] A drug with a new indication and a new dosage for the treatment of CD20-positive chronic lymphocytic leukemia (including small lymphocytic lymphoma). uuid:a01977af-59df-4a50-9298-45a25ba93ddd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:O43472U9X8 biolink:treats MONDO:0018906 PMID:41385096 "[{""id"":""uuid:b580ca2e-f332-44d4-87a4-2fe15a5e4a9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7c9a1fdb-2544-4767-9f85-ab7630595b4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7782d737-494f-41a8-ae96-72578013c94f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/gazyvaro""]},{""id"":""uuid:fb36806a-62ce-43a0-a6d5-30a10d028772"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] GAZYVA is a CD20-directed cytolytic antibody indicated: in combination with chlorambucil, for the treatment of patients with previously untreated chronic lymphocytic leukemia. ( 1 , 14 ) in combination with bendamustine followed by GAZYVA monotherapy, for the treatment of patients with follicular lymphoma who relapsed after, or are refractory to, a rituximab-containing regimen. ( 1 , 14 ) in combination with chemotherapy followed by GAZYVA monotherapy in patients achieving at least a partial remission, for the treatment of adult patients with previously untreated stage II bulky, III or IV follicular lymphoma. ( 1 , 14 )|[EMA] Chronic Lymphocytic Leukaemia (CLL)Gazyvaro in combination with chlorambucil is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) and with comorbidities making them unsuitable for full-dose fludarabine based therapy (see section 5.1).Follicular Lymphoma (FL)Gazyvaro in combination with chemotherapy, followed by Gazyvaro maintenance therapy in patients achieving a response, is indicated for the treatment of patients with previously untreated advanced follicular lymphoma.Gazyvaro in combination with bendamustine followed by Gazyvaro maintenance is indicated for the treatment of patients with follicular lymphoma (FL) who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen.|[PMDA] A drug with a new active ingredient indicated for the treatment of CD20-positive follicular lymphoma. uuid:e2c14997-a988-4b50-9b44-8a7fe8332a06 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7478 biolink:treats MONDO:0043537 PMID:41385096 "[{""id"":""uuid:e8035f80-87cb-4b6d-a05a-88d011decc78"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6baaf25d-817d-45bb-b62e-ba7f927414ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Naratriptan tablets are indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use: Use only if a clear diagnosis of migraine has been established. If a patient has no response to the first migraine attack treated with naratriptan tablets reconsider the diagnosis of migraine before naratriptan tablets are administered to treat any subsequent attacks. Naratriptan tablets are not indicated for the prevention of migraine attacks. Safety and effectiveness of naratriptan tablets have not been established for cluster headache. uuid:9fa6a73c-dceb-46a2-a90a-34dfad95d747 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9241 biolink:treats MONDO:0006652 PMID:41385096 "[{""id"":""uuid:d3e6df5d-5ec4-4617-bf21-834a7e131964"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:50ddd6ff-fe1f-43ee-a88d-2120ff9dd44d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone is an aldosterone antagonist indicated for: The treatment of NYHA Class III-IV heart failure and reduced ejection fraction to increase survival, manage edema, and to reduce the need for hospitalization for heart failure (1.1) . Use as an add-on therapy for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions (1.2) . The management of edema in adult patients who are cirrhotic when edema is not responsive to fluid and sodium restrictions and in the setting of nephrotic syndrome when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics produce an inadequate response (1.3) . Treatment of primary hyperaldosternism for: (1.4) Short-term preoperative treatment Long-term maintenance for patients with discrete aldosterone-producing adrenal adenomas who are not candidates for surgery and patients with bilateral micro or macronodular adrenal hyperplasia uuid:9353fe27-6b32-4697-b03b-a25f083ba8f2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135925 biolink:treats MONDO:0007743 PMID:41385096 "[{""id"":""uuid:376e6a63-2ee1-4a1a-88a6-0308e31967c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d8a5dd81-4dfb-42c5-a1bd-2cc91d1014c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lisdexamfetamine dimesylate capsules are indicated for the treatment of: Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older [see Clinical Studies (14.1)] Moderate to severe binge eating disorder (BED) in adults [see Clinical Studies (14.2)]. Limitations of Use: Pediatric patients with ADHD younger than 6 years of age experienced more long-term weight loss than patients 6 years and older [see Use in Specific Populations (8.4)]. Lisdexamfetamine dimesylate capsules are not indicated or recommended for weight loss. Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. The safety and effectiveness of lisdexamfetamine dimesylate capsules for the treatment of obesity have not been established [see Warnings and Precautions (5.2)]. uuid:d6940509-1a8e-46d3-b8f2-77ff731b1ada biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135925 biolink:treats MONDO:0005582 PMID:41385096 "[{""id"":""uuid:f8dd1062-6f4c-4aa1-915f-bbbe291f6194"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:22359c57-4042-45a6-9201-0e0e926fb21b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lisdexamfetamine dimesylate capsules are indicated for the treatment of: Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older [see Clinical Studies (14.1)] Moderate to severe binge eating disorder (BED) in adults [see Clinical Studies (14.2)]. Limitations of Use: Pediatric patients with ADHD younger than 6 years of age experienced more long-term weight loss than patients 6 years and older [see Use in Specific Populations (8.4)]. Lisdexamfetamine dimesylate capsules are not indicated or recommended for weight loss. Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. The safety and effectiveness of lisdexamfetamine dimesylate capsules for the treatment of obesity have not been established [see Warnings and Precautions (5.2)]. uuid:c3dbb7e3-e590-470b-ac77-15baf599f748 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1375946 biolink:treats MONDO:0006791 PMID:41385096 "[{""id"":""uuid:80a43b7f-6e00-45f1-a078-a2bc446f0d60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b1058bdf-392e-4917-9570-535c637d7b4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxylamine succinate and pyridoxine hydrochloride delayed-release tablets are indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management. Limitations of Use Doxylamine succinate and pyridoxine hydrochloride delayed-release tablet has not been studied in women with hyperemesis gravidarum. uuid:58d67088-567d-4c7b-99c3-3522786ce08b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135925 biolink:treats MONDO:0005302 PMID:41385096 "[{""id"":""uuid:a7b4da49-ca01-42d0-8682-c73f31f8563d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1b6323e9-98f3-4143-abdd-292ffd6e047a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b7a5d5a2-c725-4083-9712-3f5b8f28d9a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lisdexamfetamine dimesylate chewable tablets are indicated for the treatment of: Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older [see Clinical Studies (14.1)] Moderate to severe binge eating disorder (BED) in adults [see Clinical Studies (14.2)]. Limitations of Use: Pediatric patients with ADHD younger than 6 years of age experienced more long-term weight loss than patients 6 years and older [see Use in Specific Populations (8.4)]. Lisdexamfetamine dimesylate are not indicated or recommended for weight loss. Use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. The safety and effectiveness of lisdexamfetamine dimesylate for the treatment of obesity have not been established [see Warnings and Precautions (5.2)]|[PMDA] Drugs with a new active ingredient indicated for the treatment of pediatric attention deficit/hyperactivity disorder (AD/HD). uuid:9e051bba-80c0-4acd-8cf8-0765e5414f28 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6942 biolink:treats MONDO:0006846 PMID:41385096 "[{""id"":""uuid:4a2d5c9f-538f-4966-b4d8-dd333a4ec8cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f4e1e903-d849-43a2-a22e-895bcc3a4f1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Because of the potential for serious adverse effects, minoxidil tablets are indicated only in the treatment of hypertension that is symptomatic or associated with target organ damage and is not manageable with maximum therapeutic doses of a diuretic plus two other antihypertensive drugs. At the present time use in milder degrees of hypertension is not recommended because the benefit-risk relationship in such patients has not been defined. Minoxidil reduced supine diastolic blood pressure by 20 mmHg or to 90 mmHg or less in approximately 75% of patients, most of who had hypertension that could not be controlled by other drugs. uuid:4c553f4d-b2a2-45d4-ab85-bdae82582cfe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17996 biolink:treats MONDO:0003019 PMID:41385096 "[{""id"":""uuid:856d48c3-6be7-4ece-8fbe-ef2fb9c5d2d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0f44fdd4-cd7a-44e2-968c-7a88500285c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Potassium Chloride is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient. uuid:857ed8f3-d842-40c9-9133-cc38de469859 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17996 biolink:treats HP:0200114 PMID:41385096 "[{""id"":""uuid:42192b4f-e172-4dc1-9b49-404cf5468774"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bda9517b-873c-40f4-add6-97ddfa2132ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Potassium Chloride is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient. uuid:e3e5cac8-6bd4-4b3b-a77b-3ba54ca82f9c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:38545 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:0e794b68-7829-454b-b020-8658b2c2d9fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c39f2fd6-8bf0-4d74-aee1-752854a332e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Rosuvastatin tablets are indicated: To reduce the risk of stroke, myocardial infarction, and arterial revascularization procedures in adults without established coronary heart disease who are at increased risk of cardiovascular (CV) disease based on age, hsCRP ≥2 mg/L, and at least one additional CV risk factor. As an adjunct to diet to: o Reduce LDL-C in adults with primary hyperlipidemia. o Reduce low-density lipoprotein cholesterol (LDL-C) and slow the progression of atherosclerosis in adults. o Reduce LDL-C in adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 7 years and older with homozygous familial hypercholesterolemia (HoFH). As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia. o Hypertriglyceridemia. uuid:d44566ce-1454-4d6d-ba0e-c38e3d233762 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:38545 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:8c64180d-44b1-4439-9911-bd6080dcd8f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c9a9f90e-55f0-4c52-9620-0d16874328b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Rosuvastatin tablets are indicated: To reduce the risk of stroke, myocardial infarction, and arterial revascularization procedures in adults without established coronary heart disease who are at increased risk of cardiovascular (CV) disease based on age, hsCRP ≥2 mg/L, and at least one additional CV risk factor. As an adjunct to diet to: o Reduce LDL-C in adults with primary hyperlipidemia. o Reduce low-density lipoprotein cholesterol (LDL-C) and slow the progression of atherosclerosis in adults. o Reduce LDL-C in adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 7 years and older with homozygous familial hypercholesterolemia (HoFH). As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia. o Hypertriglyceridemia. uuid:e43c24b5-1c1c-4b34-9f2c-8aed8e18b0a8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6076 biolink:treats UMLS:C0919659 PMID:41385096 "[{""id"":""uuid:66f84a0f-e475-4ac5-bf76-70d55fc35152"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:969a8f42-6df8-4908-9b30-71f19fecc95b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3e59f48e-c817-477c-bfd2-abb931c90309"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Itraconazole oral solution is indicated for the treatment of oropharyngeal and esophageal candidiasis. (See CLINICAL PHARMACOLOGY: Special Populations , WARNINGS , and ADVERSE REACTIONS: Post-marketing Experience for more information .)|[PMDA] Addition of a new dosage form and dosage for treatment of oropharyngeal candidiasis and oesophageal candidiasis. uuid:201b2d42-8e8f-44c1-8a07-4a5d5ceffbdf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6076 biolink:treats MONDO:0001648 PMID:41385096 "[{""id"":""uuid:8216743d-507b-491c-a504-fc621212db70"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:04049732-4165-4b5f-b78a-4859784030a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9d349145-3869-4b71-a801-5e8ce829156e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Itraconazole oral solution is indicated for the treatment of oropharyngeal and esophageal candidiasis. (See CLINICAL PHARMACOLOGY: Special Populations , WARNINGS , and ADVERSE REACTIONS: Post-marketing Experience for more information .)|[PMDA] Addition of a new dosage form and dosage for treatment of oropharyngeal candidiasis and oesophageal candidiasis. uuid:930c90e8-d510-4ecd-a7e8-5f73a0f3ae63 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0024313 PMID:41385096 "[{""id"":""uuid:de84b2d7-b246-4fab-b5f0-6b131f4d9b56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:70a20673-c008-4413-a3b1-f26c8a334801"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin injection and other antibacterial drugs, gentamicin injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin injection is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa, Proteus species (indole-positive and indole-negative), Escherichia coli, Klebsiella-Enterobacter- Serratia species, Citrobacter species and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown gentamicin injection to be effective in bacterial neonatal sepsis; bacterial septicemia and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin injection may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection and the important additional concepts contained in the BOXED WARNINGS . If the causative organisms are resistant to gentamicin, other appropriate therapy should be instituted. In serious infections when the causative organisms are unknown, gentamicin injection may be administered as initial therapy in conjunction with a penicillin-type or cephalosporin-type drug before obtaining results of susceptibility testing. If anaerobic organisms are suspected as etiologic agents, consideration should be given to using other suitable antimicrobial therapy in conjunction with gentamicin. Following identification of the organism and its susceptibility, appropriate antibiotic therapy should then be continued. Gentamicin injection has been used effectively in combination with carbenicillin for the treatment of life-threatening infections caused by Pseudomonas aeruginosa. It has also been found effective when used in conjunction with a penicillin-type drug for treatment of endocarditis caused by group D streptococci. Gentamicin injection has also been shown to be effective in the treatment of serious staphylococcal infections. While not the antibiotic of first choice, gentamicin injection may be considered when penicillins or other less potentially toxic drugs are contraindicated and bacterial susceptibility tests and clinical judgment indicate its use. It may also be considered in mixed infections caused by susceptible strains of staphylococci and gram-negative organisms. In the neonate with suspected bacterial sepsis or staphylococcal pneumonia, a penicillin- type drug is also usually indicated as concomitant therapy with gentamicin. uuid:92a21763-fce3-4c31-a200-066ccfe83df0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats DOID:50360 PMID:41385096 "[{""id"":""uuid:bbc91669-5b68-4d37-994d-f24f4775e58b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8ea5fbd3-2ccc-464a-b9c3-58946a1663c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin injection and other antibacterial drugs, gentamicin injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin injection is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa, Proteus species (indole-positive and indole-negative), Escherichia coli, Klebsiella-Enterobacter- Serratia species, Citrobacter species and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown gentamicin injection to be effective in bacterial neonatal sepsis; bacterial septicemia and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin injection may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection and the important additional concepts contained in the BOXED WARNINGS . If the causative organisms are resistant to gentamicin, other appropriate therapy should be instituted. In serious infections when the causative organisms are unknown, gentamicin injection may be administered as initial therapy in conjunction with a penicillin-type or cephalosporin-type drug before obtaining results of susceptibility testing. If anaerobic organisms are suspected as etiologic agents, consideration should be given to using other suitable antimicrobial therapy in conjunction with gentamicin. Following identification of the organism and its susceptibility, appropriate antibiotic therapy should then be continued. Gentamicin injection has been used effectively in combination with carbenicillin for the treatment of life-threatening infections caused by Pseudomonas aeruginosa. It has also been found effective when used in conjunction with a penicillin-type drug for treatment of endocarditis caused by group D streptococci. Gentamicin injection has also been shown to be effective in the treatment of serious staphylococcal infections. While not the antibiotic of first choice, gentamicin injection may be considered when penicillins or other less potentially toxic drugs are contraindicated and bacterial susceptibility tests and clinical judgment indicate its use. It may also be considered in mixed infections caused by susceptible strains of staphylococci and gram-negative organisms. In the neonate with suspected bacterial sepsis or staphylococcal pneumonia, a penicillin- type drug is also usually indicated as concomitant therapy with gentamicin. uuid:28cbdf39-6fae-4a7a-859c-c1d74e66e6be biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60311 biolink:treats MONDO:0006982 PMID:41385096 "[{""id"":""uuid:ccbbb4e2-327a-4e6d-8e38-064e3c8cf26d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9960e761-6ee8-46f2-8f8d-aee329eef1f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Armour® Thyroid tablets are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS ). 2. As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto’s), multinodular goiter, and in the management of thyroid cancer. CONTRAINDICATIONS Thyroid hormone preparations are generally contraindicated in patients with diagnosed but as yet uncorrected adrenal cortical insufficiency, untreated thyrotoxicosis, and apparent hypersensitivity to any of their active or extraneous constituents. There is no well-documented evidence from the literature, however, of true allergic or idiosyncratic reactions to thyroid hormone. PUBCHEM.COMPOUND:53462828 uuid:cfc62024-2050-4a99-b909-f06821d47d6c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60311 biolink:treats MONDO:0000004 PMID:41385096 "[{""id"":""uuid:812e8fcf-efd7-49dc-b543-6cb800ec8a92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8e624c0f-9aac-4cdd-9028-e3c1ee1bd294"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Armour® Thyroid tablets are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS ). 2. As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto’s), multinodular goiter, and in the management of thyroid cancer. CONTRAINDICATIONS Thyroid hormone preparations are generally contraindicated in patients with diagnosed but as yet uncorrected adrenal cortical insufficiency, untreated thyrotoxicosis, and apparent hypersensitivity to any of their active or extraneous constituents. There is no well-documented evidence from the literature, however, of true allergic or idiosyncratic reactions to thyroid hormone. PUBCHEM.COMPOUND:53462828 uuid:86e4f7f9-3e2d-4866-ad00-6df1c5cb1812 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60311 biolink:treats MONDO:0010138 PMID:41385096 "[{""id"":""uuid:7635867f-feb9-4aa4-bfcd-24c73f47874e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a598a1ff-f1c1-498a-bedd-df44a6eddb91"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Armour® Thyroid tablets are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS ). 2. As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto’s), multinodular goiter, and in the management of thyroid cancer. CONTRAINDICATIONS Thyroid hormone preparations are generally contraindicated in patients with diagnosed but as yet uncorrected adrenal cortical insufficiency, untreated thyrotoxicosis, and apparent hypersensitivity to any of their active or extraneous constituents. There is no well-documented evidence from the literature, however, of true allergic or idiosyncratic reactions to thyroid hormone. PUBCHEM.COMPOUND:53462828 uuid:9980e7c1-9e1c-4d41-ac3c-303abdaba1f6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50861 biolink:treats MONDO:0015924 PMID:41385096 "[{""id"":""uuid:291b8499-3a10-426b-804a-76cf9ae92a88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:56eb58c8-8670-4e7a-845e-2c0d387739ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:49fd1b40-be16-4890-95e3-e771402948a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treprostinil injection is a prostacyclin mimetic indicated for: • Treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%). ( 1.1 ) • Patients who require transition from epoprostenol, to reduce the rate of clinical deterioration. The risks and benefits of each drug should be carefully considered prior to transition. ( 1.2 )|[PMDA] A drug with a new route of administration indicated for the treatment of pulmonary arterial hypertension. uuid:fe5b96ed-5957-4da2-8dff-947011b3b5e9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50861 biolink:treats MONDO:0017147 PMID:41385096 "[{""id"":""uuid:467f7a55-11a8-4690-852a-496f039ecbb6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c8173efd-0e2f-4e8c-bdaf-2b66005104bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treprostinil injection is a prostacyclin mimetic indicated for: • Treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%). ( 1.1 ) • Patients who require transition from epoprostenol, to reduce the rate of clinical deterioration. The risks and benefits of each drug should be carefully considered prior to transition. ( 1.2 ) uuid:9494c4df-140f-429a-8564-2f41ef2c6648 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50861 biolink:treats MONDO:0017148 PMID:41385096 "[{""id"":""uuid:60c0de59-2306-48b5-bc97-946fdae00790"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ccf0aa9c-3ee1-4f27-817b-b9d857f38eb8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treprostinil injection is a prostacyclin mimetic indicated for: • Treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%). ( 1.1 ) • Patients who require transition from epoprostenol, to reduce the rate of clinical deterioration. The risks and benefits of each drug should be carefully considered prior to transition. ( 1.2 ) uuid:da7ce958-95fe-4d14-b9ce-b2753d1fbbd7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3181 biolink:treats MONDO:0019933 PMID:41385096 "[{""id"":""uuid:d64e0c19-e28b-4717-94bb-d52a6b32f280"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:34f5d51e-1d79-4095-950a-04b4a9d7ddab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Hyperprolactinemia-Associated Dysfunctions Bromocriptine mesylate capsules are indicated for the treatment of dysfunctions associated with hyperprolactinemia including amenorrhea with or without galactorrhea, infertility or hypogonadism. Bromocriptine treatment is indicated in patients with prolactin-secreting adenomas, which may be the basic underlying endocrinopathy contributing to the above clinical presentations. Reduction in tumor size has been demonstrated in both male and female patients with macroadenomas. In cases where adenectomy is elected, a course of bromocriptine mesylate capsule therapy may be used to reduce the tumor mass prior to surgery. Acromegaly Bromocriptine mesylate capsule therapy is indicated in the treatment of acromegaly. Bromocriptine mesylate capsule therapy, alone or as adjunctive therapy with pituitary irradiation or surgery, reduces serum growth hormone by 50% or more in approximately ½ of patients treated, although not usually to normal levels. Since the effects of external pituitary radiation may not become maximal for several years, adjunctive therapy with bromocriptine mesylate capsule offers potential benefit before the effects of irradiation are manifested. Parkinson's Disease Bromocriptine mesylate capsules are indicated in the treatment of the signs and symptoms of idiopathic or postencephalitic Parkinson's disease. As adjunctive treatment to levodopa (alone or with a peripheral decarboxylase inhibitor), bromocriptine mesylate capsule therapy may provide additional therapeutic benefits in those patients who are currently maintained on optimal dosages of levodopa, those who are beginning to deteriorate (develop tolerance) to levodopa therapy, and those who are experiencing ""end of dose failure"" on levodopa therapy. Bromocriptine mesylate capsule therapy may permit a reduction of the maintenance dose of levodopa and, thus may ameliorate the occurrence and/or severity of adverse reactions associated with long-term levodopa therapy such as abnormal involuntary movements (e.g., dyskinesias) and the marked swings in motor function (""on-off"" phenomenon). Continued efficacy of bromocriptine mesylate capsule therapy during treatment of more than 2 years has not been established. Data are insufficient to evaluate potential benefit from treating newly diagnosed Parkinson's disease with bromocriptine mesylate capsules. Studies have shown, however, significantly more adverse reactions (notably nausea, hallucinations, confusion and hypotension) in bromocriptine-treated patients than in levodopa/carbidopa-treated patients. Patients unresponsive to levodopa are poor candidates for bromocriptine mesylate capsule therapy." uuid:20f0a3fa-fdcd-46bd-a48c-b58460ae5d89 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3181 biolink:treats MONDO:0005180 PMID:41385096 "[{""id"":""uuid:2e72a84d-b937-4bdb-aceb-9468920c8e5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e4c26abe-76b6-4ca6-ae72-4d6dd09fbfc9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Hyperprolactinemia-Associated Dysfunctions Bromocriptine mesylate capsules are indicated for the treatment of dysfunctions associated with hyperprolactinemia including amenorrhea with or without galactorrhea, infertility or hypogonadism. Bromocriptine treatment is indicated in patients with prolactin-secreting adenomas, which may be the basic underlying endocrinopathy contributing to the above clinical presentations. Reduction in tumor size has been demonstrated in both male and female patients with macroadenomas. In cases where adenectomy is elected, a course of bromocriptine mesylate capsule therapy may be used to reduce the tumor mass prior to surgery. Acromegaly Bromocriptine mesylate capsule therapy is indicated in the treatment of acromegaly. Bromocriptine mesylate capsule therapy, alone or as adjunctive therapy with pituitary irradiation or surgery, reduces serum growth hormone by 50% or more in approximately ½ of patients treated, although not usually to normal levels. Since the effects of external pituitary radiation may not become maximal for several years, adjunctive therapy with bromocriptine mesylate capsule offers potential benefit before the effects of irradiation are manifested. Parkinson's Disease Bromocriptine mesylate capsules are indicated in the treatment of the signs and symptoms of idiopathic or postencephalitic Parkinson's disease. As adjunctive treatment to levodopa (alone or with a peripheral decarboxylase inhibitor), bromocriptine mesylate capsule therapy may provide additional therapeutic benefits in those patients who are currently maintained on optimal dosages of levodopa, those who are beginning to deteriorate (develop tolerance) to levodopa therapy, and those who are experiencing ""end of dose failure"" on levodopa therapy. Bromocriptine mesylate capsule therapy may permit a reduction of the maintenance dose of levodopa and, thus may ameliorate the occurrence and/or severity of adverse reactions associated with long-term levodopa therapy such as abnormal involuntary movements (e.g., dyskinesias) and the marked swings in motor function (""on-off"" phenomenon). Continued efficacy of bromocriptine mesylate capsule therapy during treatment of more than 2 years has not been established. Data are insufficient to evaluate potential benefit from treating newly diagnosed Parkinson's disease with bromocriptine mesylate capsules. Studies have shown, however, significantly more adverse reactions (notably nausea, hallucinations, confusion and hypotension) in bromocriptine-treated patients than in levodopa/carbidopa-treated patients. Patients unresponsive to levodopa are poor candidates for bromocriptine mesylate capsule therapy." uuid:f33bce68-19ef-4fbe-85ae-233aa5f29b4f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:284780 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:c21b32e7-5a06-49a6-b7b1-b0448f4ea84c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9452f798-6d39-4b3d-9dcd-00e4c56fe6ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Telmisartan and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the classes to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with telmisartan and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy [see Clinical Studies (14)]. Telmisartan and hydrochlorothiazide tablets are not indicated for initial therapy for the treatment of hypertension [see Dosage and Administration (2.1)]. Telmisartan and hydrochlorothiazide tablets may be used alone or in combination with other antihypertensive agents. uuid:1b221fb4-435b-4422-80ec-d6d7c699eb09 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:284780 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:cede872c-f9f3-41e3-8f92-b82f44cac682"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fda0bc04-5e92-4cc3-86ef-3b2509c3bebe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Telmisartan and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the classes to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with telmisartan and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy [see Clinical Studies (14)]. Telmisartan and hydrochlorothiazide tablets are not indicated for initial therapy for the treatment of hypertension [see Dosage and Administration (2.1)]. Telmisartan and hydrochlorothiazide tablets may be used alone or in combination with other antihypertensive agents. uuid:71dd13fc-1dbd-4e19-83f1-f1f999c8bed0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:284780 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:e70e0520-4993-47d4-95f3-b5df70b3ec33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:daec28fe-c5ec-443e-8951-9b7054a6fc54"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Telmisartan and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the classes to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with telmisartan and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy [see Clinical Studies (14)]. Telmisartan and hydrochlorothiazide tablets are not indicated for initial therapy for the treatment of hypertension [see Dosage and Administration (2.1)]. Telmisartan and hydrochlorothiazide tablets may be used alone or in combination with other antihypertensive agents. uuid:cf9fc314-81c3-4f3a-b794-2197ad08b890 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:284780 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:1c0f3c72-ebb3-4bff-86dd-2831beee175d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e0f1a906-bea3-4434-a08c-ea0321c53d15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Telmisartan and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the classes to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with telmisartan and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy [see Clinical Studies (14)]. Telmisartan and hydrochlorothiazide tablets are not indicated for initial therapy for the treatment of hypertension [see Dosage and Administration (2.1)]. Telmisartan and hydrochlorothiazide tablets may be used alone or in combination with other antihypertensive agents. uuid:14417c49-48e9-4262-8ea4-1da930268dcf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16094 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:7f529e3f-738d-437e-870c-164be6917708"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4b2718f6-5b8b-4c28-b9b3-9eb0925d395a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] This product is indicated for use in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis. uuid:a437f3b5-23d1-4b4c-855e-15410d7c911b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16094 biolink:treats MONDO:0006604 PMID:41385096 "[{""id"":""uuid:e76104f8-6836-4ee7-a601-599221fa2b01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c9993d77-d482-4ac7-b642-017265eb9b15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] This product is indicated for use in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis. uuid:aecccd2b-4385-4b87-851f-f4bf21fc335c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16094 biolink:treats MONDO:0006608 PMID:41385096 "[{""id"":""uuid:9b6c6f94-2b49-48ed-b485-f495c5e95567"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a2610a5d-2112-4906-80a7-c0257274bd53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] This product is indicated for use in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis. uuid:64114b3d-90e4-47b6-a430-59847751eb4a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0006050 biolink:treats UMLS:C1996997 PMID:41385096 "[{""id"":""uuid:9dbb5055-6d8d-4cd5-847b-b7958390d6df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ba9b135f-4f12-4527-b43c-dd5fd63db524"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DYSPORT is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for: The treatment of cervical dystonia in adults ( 1.1 ) The temporary improvement in the appearance of moderate to severe glabellar lines associated with procerus and corrugator muscle activity in adults < 65 years of age ( 1.2 ) The treatment of spasticity in patients 2 years of age and older ( 1.3 ) DRUGBANK:DB00083 uuid:5a90d881-77e5-40f6-9aca-4246fa04e110 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0006050 biolink:treats HP:0001257 PMID:41385096 "[{""id"":""uuid:d780fa29-2b3b-4405-b2a6-8b44d59fae88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5da40860-f2ac-44fb-8a22-ed02f550df3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:8f98bc91-270d-4b84-ac73-0dd14a0f35b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DYSPORT is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for: The treatment of cervical dystonia in adults ( 1.1 ) The temporary improvement in the appearance of moderate to severe glabellar lines associated with procerus and corrugator muscle activity in adults < 65 years of age ( 1.2 ) The treatment of spasticity in patients 2 years of age and older ( 1.3 )|[PMDA] Drugs with new additional indications and new dosages for the treatment of upper and lower limb spasticity. DRUGBANK:DB00083 uuid:1968e8d3-27e6-4cc7-90c4-b9c72de367b4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:FYS6T7F842 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:489514ab-e91e-4073-b1eb-050ba41c022c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e6f4855c-9c72-44ed-ad08-d2e3425523ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c10c342e-0d4d-4d99-99f2-a6b75134e526"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/hulio""]},{""id"":""uuid:2c473928-ca81-4ad7-b88e-0810d3674fa6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] HADLIMA is a tumor necrosis factor (TNF) blocker indicated for • Rheumatoid Arthritis (RA) ( 1.1 ): reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA. • Juvenile Idiopathic Arthritis (JIA) ( 1.2 ): reducing signs and symptoms of moderately to severely active polyarticular JIA in patients 2 years of age and older. • Psoriatic Arthritis (PsA) ( 1.3 ) : reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active PsA. • Ankylosing Spondylitis (AS) ( 1.4 ): reducing signs and symptoms in adult patients with active AS. • Crohn’s Disease (CD) ( 1.5 ): treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. • Ulcerative Colitis (UC) ( 1.6 ): treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use : Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. • Plaque Psoriasis (Ps) ( 1.7 ): treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. • Hidradenitis Suppurativa (HS) ( 1.8 ): treatment of moderate to severe hidradenitis suppurativa in adult patients. • Uveitis (UV) ( 1.9 ): treatment of non-infectious intermediate, posterior, and panuveitis in adult patients.|[EMA] Rheumatoid arthritisYuflyma in combination with methotrexate, is indicated for:- the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate.- the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.Yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.Adalimumab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate.Juvenile idiopathic arthritisPolyarticular juvenile idiopathic arthritisYuflyma in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5.1). Adalimumab has not been studied in patients aged less than 2 years.Enthesitis-related arthritisYuflyma is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5.1).Axial spondyloarthritisAnkylosing spondylitis (AS)Yuflyma is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.Axial spondyloarthritis without radiographic evidence of ASYuflyma is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated CRP and/or MRI, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs).Psoriatic arthritisYuflyma is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate.Adalimumab has been shown to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease (see section 5.1) and to improve physical function.PsoriasisYuflyma is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy.Paediatric plaque psoriasisYuflyma is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies.Hidradenitis suppurativa (HS)Yuflyma is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic HS therapy (see sections 5.1 and 5.2).Crohn’s diseaseYuflyma is indicated for treatment of moderately to severely active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.Paediatric Crohn's diseaseYuflyma is indicated for the treatment of moderately to severely active Crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies.Ulcerative colitisYuflyma is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.Paediatric ulcerative colitisYuflyma is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.UveitisYuflyma is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid- sparing, or in whom corticosteroid treatment is inappropriate.Paediatric uveitisYuflyma is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.|[PMDA] A drug containing a new active ingredient indicated for the treatment of rheumatoid arthritis (for use only when conventional therapies are not sufficiently effective). uuid:b777bdb9-cf81-4dea-bca6-86620d956613 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:FYS6T7F842 biolink:treats MONDO:0011429 PMID:41385096 "[{""id"":""uuid:32ae3ba0-f01f-4f97-8e50-b89078ef7079"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:21e1bf9f-bca2-4670-b974-0718999535bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4282b778-53ed-4c27-a571-06da79e22a6d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/hulio""]},{""id"":""uuid:4ee1f796-709a-48c6-934a-e0dbf3b4345a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] HADLIMA is a tumor necrosis factor (TNF) blocker indicated for • Rheumatoid Arthritis (RA) ( 1.1 ): reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA. • Juvenile Idiopathic Arthritis (JIA) ( 1.2 ): reducing signs and symptoms of moderately to severely active polyarticular JIA in patients 2 years of age and older. • Psoriatic Arthritis (PsA) ( 1.3 ) : reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active PsA. • Ankylosing Spondylitis (AS) ( 1.4 ): reducing signs and symptoms in adult patients with active AS. • Crohn’s Disease (CD) ( 1.5 ): treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. • Ulcerative Colitis (UC) ( 1.6 ): treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use : Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. • Plaque Psoriasis (Ps) ( 1.7 ): treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. • Hidradenitis Suppurativa (HS) ( 1.8 ): treatment of moderate to severe hidradenitis suppurativa in adult patients. • Uveitis (UV) ( 1.9 ): treatment of non-infectious intermediate, posterior, and panuveitis in adult patients.|[EMA] Rheumatoid arthritisYuflyma in combination with methotrexate, is indicated for:- the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate.- the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.Yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.Adalimumab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate.Juvenile idiopathic arthritisPolyarticular juvenile idiopathic arthritisYuflyma in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5.1). Adalimumab has not been studied in patients aged less than 2 years.Enthesitis-related arthritisYuflyma is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5.1).Axial spondyloarthritisAnkylosing spondylitis (AS)Yuflyma is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.Axial spondyloarthritis without radiographic evidence of ASYuflyma is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated CRP and/or MRI, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs).Psoriatic arthritisYuflyma is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate.Adalimumab has been shown to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease (see section 5.1) and to improve physical function.PsoriasisYuflyma is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy.Paediatric plaque psoriasisYuflyma is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies.Hidradenitis suppurativa (HS)Yuflyma is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic HS therapy (see sections 5.1 and 5.2).Crohn’s diseaseYuflyma is indicated for treatment of moderately to severely active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.Paediatric Crohn's diseaseYuflyma is indicated for the treatment of moderately to severely active Crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies.Ulcerative colitisYuflyma is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.Paediatric ulcerative colitisYuflyma is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.UveitisYuflyma is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid- sparing, or in whom corticosteroid treatment is inappropriate.Paediatric uveitisYuflyma is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.|[PMDA] Drugs with a new additional indication, a new dosage, and an additional dosage form for the treatment of polyarticular-course juvenile idiopathic arthritis (for use only in patients who have not sufficiently responded to conventional treatments). uuid:c7e068a7-49e1-47fa-954e-a243496ee281 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:FYS6T7F842 biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:4ac83eab-444c-467f-a06f-14b431fca5c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:612f20d9-9ee4-4138-804f-8c0cba1de75d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:dd6ad479-bff1-4d00-af0b-3f1fc18faf69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/hulio""]},{""id"":""uuid:44d4a915-0224-477e-97c5-8c4bc509c23e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] HADLIMA is a tumor necrosis factor (TNF) blocker indicated for • Rheumatoid Arthritis (RA) ( 1.1 ): reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA. • Juvenile Idiopathic Arthritis (JIA) ( 1.2 ): reducing signs and symptoms of moderately to severely active polyarticular JIA in patients 2 years of age and older. • Psoriatic Arthritis (PsA) ( 1.3 ) : reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active PsA. • Ankylosing Spondylitis (AS) ( 1.4 ): reducing signs and symptoms in adult patients with active AS. • Crohn’s Disease (CD) ( 1.5 ): treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. • Ulcerative Colitis (UC) ( 1.6 ): treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use : Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. • Plaque Psoriasis (Ps) ( 1.7 ): treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. • Hidradenitis Suppurativa (HS) ( 1.8 ): treatment of moderate to severe hidradenitis suppurativa in adult patients. • Uveitis (UV) ( 1.9 ): treatment of non-infectious intermediate, posterior, and panuveitis in adult patients.|[EMA] Rheumatoid arthritisYuflyma in combination with methotrexate, is indicated for:- the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate.- the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.Yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.Adalimumab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate.Juvenile idiopathic arthritisPolyarticular juvenile idiopathic arthritisYuflyma in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5.1). Adalimumab has not been studied in patients aged less than 2 years.Enthesitis-related arthritisYuflyma is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5.1).Axial spondyloarthritisAnkylosing spondylitis (AS)Yuflyma is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.Axial spondyloarthritis without radiographic evidence of ASYuflyma is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated CRP and/or MRI, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs).Psoriatic arthritisYuflyma is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate.Adalimumab has been shown to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease (see section 5.1) and to improve physical function.PsoriasisYuflyma is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy.Paediatric plaque psoriasisYuflyma is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies.Hidradenitis suppurativa (HS)Yuflyma is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic HS therapy (see sections 5.1 and 5.2).Crohn’s diseaseYuflyma is indicated for treatment of moderately to severely active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.Paediatric Crohn's diseaseYuflyma is indicated for the treatment of moderately to severely active Crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies.Ulcerative colitisYuflyma is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.Paediatric ulcerative colitisYuflyma is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.UveitisYuflyma is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid- sparing, or in whom corticosteroid treatment is inappropriate.Paediatric uveitisYuflyma is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.|[PMDA] Follow-on biologics indicated for the treatment of rheumatoid arthritis (including the prevention of structural joint damage), and the treatment of the following diseases in patients who have not responded sufficiently to conventional treatments; polyarticular- course juvenile idiopathic arthritis, plaque psoriasis, psoriatic arthritis, pustular psoriasis, ankylosing spondylitis and intestinal Behcet’s disease; and the remission induction therapy and maintenance therapy for moderate to severe active Crohn's disease (for use only in patients who have not sufficiently responded to conventional therapies). uuid:85e819e2-744f-4515-bff5-e13e51d6af15 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:FYS6T7F842 biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:76b6bc25-97fe-419f-959a-96944634faea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:535393ce-b3ea-4d26-8b79-f735ae0c85e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:90d1e1b4-439f-412c-a8fd-c831b5e2554c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/hulio""]},{""id"":""uuid:d9f28335-81b8-4e26-9a65-7dbbb4294d27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] HADLIMA is a tumor necrosis factor (TNF) blocker indicated for • Rheumatoid Arthritis (RA) ( 1.1 ): reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA. • Juvenile Idiopathic Arthritis (JIA) ( 1.2 ): reducing signs and symptoms of moderately to severely active polyarticular JIA in patients 2 years of age and older. • Psoriatic Arthritis (PsA) ( 1.3 ) : reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active PsA. • Ankylosing Spondylitis (AS) ( 1.4 ): reducing signs and symptoms in adult patients with active AS. • Crohn’s Disease (CD) ( 1.5 ): treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. • Ulcerative Colitis (UC) ( 1.6 ): treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use : Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. • Plaque Psoriasis (Ps) ( 1.7 ): treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. • Hidradenitis Suppurativa (HS) ( 1.8 ): treatment of moderate to severe hidradenitis suppurativa in adult patients. • Uveitis (UV) ( 1.9 ): treatment of non-infectious intermediate, posterior, and panuveitis in adult patients.|[EMA] Rheumatoid arthritisYuflyma in combination with methotrexate, is indicated for:- the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate.- the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.Yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.Adalimumab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate.Juvenile idiopathic arthritisPolyarticular juvenile idiopathic arthritisYuflyma in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5.1). Adalimumab has not been studied in patients aged less than 2 years.Enthesitis-related arthritisYuflyma is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5.1).Axial spondyloarthritisAnkylosing spondylitis (AS)Yuflyma is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.Axial spondyloarthritis without radiographic evidence of ASYuflyma is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated CRP and/or MRI, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs).Psoriatic arthritisYuflyma is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate.Adalimumab has been shown to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease (see section 5.1) and to improve physical function.PsoriasisYuflyma is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy.Paediatric plaque psoriasisYuflyma is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies.Hidradenitis suppurativa (HS)Yuflyma is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic HS therapy (see sections 5.1 and 5.2).Crohn’s diseaseYuflyma is indicated for treatment of moderately to severely active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.Paediatric Crohn's diseaseYuflyma is indicated for the treatment of moderately to severely active Crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies.Ulcerative colitisYuflyma is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.Paediatric ulcerative colitisYuflyma is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.UveitisYuflyma is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid- sparing, or in whom corticosteroid treatment is inappropriate.Paediatric uveitisYuflyma is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.|[PMDA] Follow-on biologics indicated for the treatment of rheumatoid arthritis (including the prevention of structural joint damage), and the treatment of the following diseases in patients who have not responded sufficiently to conventional treatments; polyarticular- course juvenile idiopathic arthritis, plaque psoriasis, psoriatic arthritis, pustular psoriasis, ankylosing spondylitis and intestinal Behcet’s disease; and the remission induction therapy and maintenance therapy for moderate to severe active Crohn's disease (for use only in patients who have not sufficiently responded to conventional therapies). uuid:c7adfa41-bfae-4b72-bc8c-a52a35d6c69e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:FYS6T7F842 biolink:treats MONDO:0005011 PMID:41385096 "[{""id"":""uuid:83ec47dc-d2c2-4874-ad0e-6ac63cc1403b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d7a9fd3f-53bc-466e-b1d9-3c97fb79af74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:df4f2c6f-96cb-48da-a5e9-f2b53133d342"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/hulio""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] HADLIMA is a tumor necrosis factor (TNF) blocker indicated for • Rheumatoid Arthritis (RA) ( 1.1 ): reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA. • Juvenile Idiopathic Arthritis (JIA) ( 1.2 ): reducing signs and symptoms of moderately to severely active polyarticular JIA in patients 2 years of age and older. • Psoriatic Arthritis (PsA) ( 1.3 ) : reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active PsA. • Ankylosing Spondylitis (AS) ( 1.4 ): reducing signs and symptoms in adult patients with active AS. • Crohn’s Disease (CD) ( 1.5 ): treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. • Ulcerative Colitis (UC) ( 1.6 ): treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use : Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. • Plaque Psoriasis (Ps) ( 1.7 ): treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. • Hidradenitis Suppurativa (HS) ( 1.8 ): treatment of moderate to severe hidradenitis suppurativa in adult patients. • Uveitis (UV) ( 1.9 ): treatment of non-infectious intermediate, posterior, and panuveitis in adult patients.|[EMA] Rheumatoid arthritisYuflyma in combination with methotrexate, is indicated for:- the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate.- the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.Yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.Adalimumab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate.Juvenile idiopathic arthritisPolyarticular juvenile idiopathic arthritisYuflyma in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5.1). Adalimumab has not been studied in patients aged less than 2 years.Enthesitis-related arthritisYuflyma is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5.1).Axial spondyloarthritisAnkylosing spondylitis (AS)Yuflyma is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.Axial spondyloarthritis without radiographic evidence of ASYuflyma is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated CRP and/or MRI, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs).Psoriatic arthritisYuflyma is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate.Adalimumab has been shown to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease (see section 5.1) and to improve physical function.PsoriasisYuflyma is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy.Paediatric plaque psoriasisYuflyma is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies.Hidradenitis suppurativa (HS)Yuflyma is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic HS therapy (see sections 5.1 and 5.2).Crohn’s diseaseYuflyma is indicated for treatment of moderately to severely active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.Paediatric Crohn's diseaseYuflyma is indicated for the treatment of moderately to severely active Crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies.Ulcerative colitisYuflyma is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.Paediatric ulcerative colitisYuflyma is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.UveitisYuflyma is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid- sparing, or in whom corticosteroid treatment is inappropriate.Paediatric uveitisYuflyma is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate. uuid:e8146f8a-6b29-4bb2-8eaf-93ea2550664e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:FYS6T7F842 biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:a49d2cb6-7f0d-47e1-ab1d-9c1946df3d6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e9d14a31-58fc-43cd-a3d7-14c48bb4858c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:53adaad6-934b-4359-ac24-746b2cb4d567"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/hulio""]},{""id"":""uuid:6cb20834-1840-47da-b623-9e1c9af51249"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] HADLIMA is a tumor necrosis factor (TNF) blocker indicated for • Rheumatoid Arthritis (RA) ( 1.1 ): reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA. • Juvenile Idiopathic Arthritis (JIA) ( 1.2 ): reducing signs and symptoms of moderately to severely active polyarticular JIA in patients 2 years of age and older. • Psoriatic Arthritis (PsA) ( 1.3 ) : reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active PsA. • Ankylosing Spondylitis (AS) ( 1.4 ): reducing signs and symptoms in adult patients with active AS. • Crohn’s Disease (CD) ( 1.5 ): treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. • Ulcerative Colitis (UC) ( 1.6 ): treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use : Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. • Plaque Psoriasis (Ps) ( 1.7 ): treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. • Hidradenitis Suppurativa (HS) ( 1.8 ): treatment of moderate to severe hidradenitis suppurativa in adult patients. • Uveitis (UV) ( 1.9 ): treatment of non-infectious intermediate, posterior, and panuveitis in adult patients.|[EMA] Rheumatoid arthritisYuflyma in combination with methotrexate, is indicated for:- the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate.- the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.Yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.Adalimumab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate.Juvenile idiopathic arthritisPolyarticular juvenile idiopathic arthritisYuflyma in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5.1). Adalimumab has not been studied in patients aged less than 2 years.Enthesitis-related arthritisYuflyma is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5.1).Axial spondyloarthritisAnkylosing spondylitis (AS)Yuflyma is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.Axial spondyloarthritis without radiographic evidence of ASYuflyma is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated CRP and/or MRI, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs).Psoriatic arthritisYuflyma is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate.Adalimumab has been shown to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease (see section 5.1) and to improve physical function.PsoriasisYuflyma is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy.Paediatric plaque psoriasisYuflyma is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies.Hidradenitis suppurativa (HS)Yuflyma is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic HS therapy (see sections 5.1 and 5.2).Crohn’s diseaseYuflyma is indicated for treatment of moderately to severely active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.Paediatric Crohn's diseaseYuflyma is indicated for the treatment of moderately to severely active Crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies.Ulcerative colitisYuflyma is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.Paediatric ulcerative colitisYuflyma is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.UveitisYuflyma is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid- sparing, or in whom corticosteroid treatment is inappropriate.Paediatric uveitisYuflyma is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.|[PMDA] Follow-on biologics indicated for the treatment of rheumatoid arthritis (including the prevention of structural joint damage), and the treatment of the following diseases in patients who have not responded sufficiently to conventional treatments; polyarticular- course juvenile idiopathic arthritis, plaque psoriasis, psoriatic arthritis, pustular psoriasis, ankylosing spondylitis and intestinal Behçet's disease; the remission induction therapy and maintenance therapy for moderate to severe active Crohn's disease, and treatment of moderate to severe ulcerative colitis. uuid:8437fec3-3d94-4953-bb20-dbae2938d4ad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:FYS6T7F842 biolink:treats UMLS:C0406317 PMID:41385096 "[{""id"":""uuid:2f571564-f865-4fbb-992e-2a0ff05e96da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:60fd8ea6-e5ab-4e4e-837a-d0538c887870"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7f8175cd-442f-47f4-a199-09d5c05380ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] HADLIMA is a tumor necrosis factor (TNF) blocker indicated for • Rheumatoid Arthritis (RA) ( 1.1 ): reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA. • Juvenile Idiopathic Arthritis (JIA) ( 1.2 ): reducing signs and symptoms of moderately to severely active polyarticular JIA in patients 2 years of age and older. • Psoriatic Arthritis (PsA) ( 1.3 ) : reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active PsA. • Ankylosing Spondylitis (AS) ( 1.4 ): reducing signs and symptoms in adult patients with active AS. • Crohn’s Disease (CD) ( 1.5 ): treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. • Ulcerative Colitis (UC) ( 1.6 ): treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use : Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. • Plaque Psoriasis (Ps) ( 1.7 ): treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. • Hidradenitis Suppurativa (HS) ( 1.8 ): treatment of moderate to severe hidradenitis suppurativa in adult patients. • Uveitis (UV) ( 1.9 ): treatment of non-infectious intermediate, posterior, and panuveitis in adult patients.|[PMDA] Follow-on biologics indicated for the treatment of rheumatoid arthritis (including the prevention of structural joint damage), and the treatment of the following diseases in patients who have not responded sufficiently to conventional treatments; polyarticular- course juvenile idiopathic arthritis, plaque psoriasis, psoriatic arthritis, pustular psoriasis, ankylosing spondylitis and intestinal Behcet’s disease; and the remission induction therapy and maintenance therapy for moderate to severe active Crohn's disease (for use only in patients who have not sufficiently responded to conventional therapies). uuid:06c0942c-7d0d-4531-8329-7b09e9665bf7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:FYS6T7F842 biolink:treats MONDO:0006559 PMID:41385096 "[{""id"":""uuid:55fce9a3-579c-43c0-bd39-cf2d961178a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:82a83979-7894-4e16-9d7d-e21c0c5917b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f8e45913-00e2-4b8c-a3ca-93b2cea17476"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/hulio""]},{""id"":""uuid:428a245c-6e9f-4399-b29e-5464a518806b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] HADLIMA is a tumor necrosis factor (TNF) blocker indicated for • Rheumatoid Arthritis (RA) ( 1.1 ): reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA. • Juvenile Idiopathic Arthritis (JIA) ( 1.2 ): reducing signs and symptoms of moderately to severely active polyarticular JIA in patients 2 years of age and older. • Psoriatic Arthritis (PsA) ( 1.3 ) : reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active PsA. • Ankylosing Spondylitis (AS) ( 1.4 ): reducing signs and symptoms in adult patients with active AS. • Crohn’s Disease (CD) ( 1.5 ): treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. • Ulcerative Colitis (UC) ( 1.6 ): treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use : Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. • Plaque Psoriasis (Ps) ( 1.7 ): treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. • Hidradenitis Suppurativa (HS) ( 1.8 ): treatment of moderate to severe hidradenitis suppurativa in adult patients. • Uveitis (UV) ( 1.9 ): treatment of non-infectious intermediate, posterior, and panuveitis in adult patients.|[EMA] Rheumatoid arthritisYuflyma in combination with methotrexate, is indicated for:- the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate.- the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.Yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.Adalimumab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate.Juvenile idiopathic arthritisPolyarticular juvenile idiopathic arthritisYuflyma in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5.1). Adalimumab has not been studied in patients aged less than 2 years.Enthesitis-related arthritisYuflyma is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5.1).Axial spondyloarthritisAnkylosing spondylitis (AS)Yuflyma is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.Axial spondyloarthritis without radiographic evidence of ASYuflyma is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated CRP and/or MRI, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs).Psoriatic arthritisYuflyma is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate.Adalimumab has been shown to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease (see section 5.1) and to improve physical function.PsoriasisYuflyma is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy.Paediatric plaque psoriasisYuflyma is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies.Hidradenitis suppurativa (HS)Yuflyma is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic HS therapy (see sections 5.1 and 5.2).Crohn’s diseaseYuflyma is indicated for treatment of moderately to severely active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.Paediatric Crohn's diseaseYuflyma is indicated for the treatment of moderately to severely active Crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies.Ulcerative colitisYuflyma is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.Paediatric ulcerative colitisYuflyma is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.UveitisYuflyma is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid- sparing, or in whom corticosteroid treatment is inappropriate.Paediatric uveitisYuflyma is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.|[PMDA] Drugs with a new dosage indicated for the treatment of hidradenitis suppurativa. [Orphan drug] uuid:df98b007-414b-463e-a0d5-4cb9e136fee3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:FYS6T7F842 biolink:treats MONDO:0020283 PMID:41385096 "[{""id"":""uuid:d43d157e-1742-4f68-9e8d-5882aa105775"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0be95da2-940e-42ec-b658-9cf023e9c959"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2c553792-19a9-4eba-912b-f5afc21ac7c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/hulio""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] HADLIMA is a tumor necrosis factor (TNF) blocker indicated for • Rheumatoid Arthritis (RA) ( 1.1 ): reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active RA. • Juvenile Idiopathic Arthritis (JIA) ( 1.2 ): reducing signs and symptoms of moderately to severely active polyarticular JIA in patients 2 years of age and older. • Psoriatic Arthritis (PsA) ( 1.3 ) : reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active PsA. • Ankylosing Spondylitis (AS) ( 1.4 ): reducing signs and symptoms in adult patients with active AS. • Crohn’s Disease (CD) ( 1.5 ): treatment of moderately to severely active Crohn’s disease in adults and pediatric patients 6 years of age and older. • Ulcerative Colitis (UC) ( 1.6 ): treatment of moderately to severely active ulcerative colitis in adult patients. Limitations of Use : Effectiveness has not been established in patients who have lost response to or were intolerant to TNF blockers. • Plaque Psoriasis (Ps) ( 1.7 ): treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy, and when other systemic therapies are medically less appropriate. • Hidradenitis Suppurativa (HS) ( 1.8 ): treatment of moderate to severe hidradenitis suppurativa in adult patients. • Uveitis (UV) ( 1.9 ): treatment of non-infectious intermediate, posterior, and panuveitis in adult patients.|[EMA] Rheumatoid arthritisYuflyma in combination with methotrexate, is indicated for:- the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate.- the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.Yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.Adalimumab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate.Juvenile idiopathic arthritisPolyarticular juvenile idiopathic arthritisYuflyma in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5.1). Adalimumab has not been studied in patients aged less than 2 years.Enthesitis-related arthritisYuflyma is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5.1).Axial spondyloarthritisAnkylosing spondylitis (AS)Yuflyma is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.Axial spondyloarthritis without radiographic evidence of ASYuflyma is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated CRP and/or MRI, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs).Psoriatic arthritisYuflyma is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate.Adalimumab has been shown to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease (see section 5.1) and to improve physical function.PsoriasisYuflyma is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy.Paediatric plaque psoriasisYuflyma is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies.Hidradenitis suppurativa (HS)Yuflyma is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic HS therapy (see sections 5.1 and 5.2).Crohn’s diseaseYuflyma is indicated for treatment of moderately to severely active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.Paediatric Crohn's diseaseYuflyma is indicated for the treatment of moderately to severely active Crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies.Ulcerative colitisYuflyma is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.Paediatric ulcerative colitisYuflyma is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.UveitisYuflyma is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid- sparing, or in whom corticosteroid treatment is inappropriate.Paediatric uveitisYuflyma is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate. uuid:b8ce5fbe-1f9c-4b53-88ab-c178759bc30b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:125354 biolink:treats MONDO:0018908 PMID:41385096 "[{""id"":""uuid:816f8b4e-63c0-413a-b759-ff9ef5b700b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dbb7c4b0-7c42-45ed-b360-e488d10580aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mozobil is indicated in combination with filgrastim to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma (NHL) or multiple myeloma (MM). uuid:734322d3-6800-4d32-b042-f5f9b988289c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:125354 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:91291e38-f379-48ae-b1bd-f725bbfa722f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:991c6e72-b105-4d9d-bc24-c72b80b727c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:6d0e6d4f-aa47-4d27-b774-b440b4ffc952"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/mozobil""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mozobil is indicated in combination with filgrastim to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma (NHL) or multiple myeloma (MM).|[EMA] Mozobil is indicated in combination with granulocyte-colony-stimulating factor to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma and multiple myeloma whose cells mobilise poorly., uuid:1378069e-273a-4811-8c37-114859764eef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:G0G0H52U6K biolink:treats MONDO:0005338 PMID:41385096 "[{""id"":""uuid:6d95a629-6ae7-4ce3-8008-0fffccd72d72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9065d914-9207-4249-bb55-c6b1ae02ff77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Omlonti (omidenepag isopropyl ophthalmic solution) 0.002%, is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. uuid:6232e4ed-a140-45e7-bbf0-83a781f61a94 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:G0G0H52U6K biolink:treats MONDO:0006875 PMID:41385096 "[{""id"":""uuid:09a0d4a7-4b06-45d7-b5cb-d563024022ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9d2e6f93-c243-48f2-8b56-1d9d6fd3f5d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Omlonti (omidenepag isopropyl ophthalmic solution) 0.002%, is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. uuid:0b5aede8-42cc-4330-b242-e0d41954f52e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4735 biolink:treats UMLS:C0572061 PMID:41385096 "[{""id"":""uuid:b70cecda-fd54-436f-a681-b415727e77b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eb550ce5-9026-4c4b-b5c4-ddb01ce65229"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NARCAN Nasal Spray is indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. NARCAN Nasal Spray is intended for immediate administration as emergency therapy in settings where opioids may be present. NARCAN Nasal Spray is not a substitute for emergency medical care. Limitations of Use: Restrict prescription of NARCAN Nasal Spray 2 mg to opioid-dependent patients expected to be at risk for severe opioid withdrawal in situations where there is a low risk for accidental or intentional opioid exposure by household contacts. uuid:b8a70c0e-dfa3-4c77-8561-f17ea476d2bb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4735 biolink:treats UMLS:C0029104 PMID:41385096 "[{""id"":""uuid:3706720b-c3bd-4e40-8ac7-ae2796cd1bf9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a87ddab7-ce11-420f-8d7d-87cf2c7d02be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NARCAN Nasal Spray is indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. NARCAN Nasal Spray is intended for immediate administration as emergency therapy in settings where opioids may be present. NARCAN Nasal Spray is not a substitute for emergency medical care. Limitations of Use: Restrict prescription of NARCAN Nasal Spray 2 mg to opioid-dependent patients expected to be at risk for severe opioid withdrawal in situations where there is a low risk for accidental or intentional opioid exposure by household contacts. uuid:d59b9602-ae59-4434-8ba3-39c9a4388f8a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72564 biolink:treats UMLS:C5239366 PMID:41385096 "[{""id"":""uuid:2c664aee-c196-438c-8e55-f87e92aad188"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b1cfc6a8-c5de-4433-969b-80ee3897e357"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Temozolomide is an alkylating drug indicated for the treatment of adults with: • Newly diagnosed glioblastoma concomitantly with radiotherapy and then as maintenance treatment. (1.1) • Anaplastic astrocytoma. (1.2) o Adjuvant treatment of adults with newly diagnosed anaplastic astrocytoma. (1.2) o Treatment of adults with refractory anaplastic astrocytoma. (1.2) uuid:3f97ac5c-fd56-4716-ac46-37ffd952affd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9620 biolink:treats MONDO:0005984 PMID:41385096 "[{""id"":""uuid:c69ef4cc-fa8e-4c52-b7c7-bd578e954694"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:524a80aa-912f-4e65-a8eb-13e9666c9dd6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mycozyl AL™ is effective in the treatment of most skin infections such as athlete's foot (tinea pedis) and ringworm (tinea corporis). Mycozyl AL™ has been designed to reach skin areas around and under the nails while it relives burning, cracking, scaling and discomfort which accompany these conditions. Mycozyl AL™ is an antifungal that works by preventing and eliminating the growth of fungus on fingers, toes and around the nails. It eliminates and helps stop the spread of fungal infections on cuticles around nail edges and under the nail tips where reachable with applicator brush. Mycozyl AL™ cures and prevents fungal infections from coming back with daily use. uuid:acdb4ab3-eadb-4ddc-8b9d-7d03501b57ac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9620 biolink:treats MONDO:0001461 PMID:41385096 "[{""id"":""uuid:fc35d4e5-013b-48d3-b5bc-bac693364210"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d5ed98aa-6510-4d29-9803-201f6b48d13f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mycozyl AL™ is effective in the treatment of most skin infections such as athlete's foot (tinea pedis) and ringworm (tinea corporis). Mycozyl AL™ has been designed to reach skin areas around and under the nails while it relives burning, cracking, scaling and discomfort which accompany these conditions. Mycozyl AL™ is an antifungal that works by preventing and eliminating the growth of fungus on fingers, toes and around the nails. It eliminates and helps stop the spread of fungal infections on cuticles around nail edges and under the nail tips where reachable with applicator brush. Mycozyl AL™ cures and prevents fungal infections from coming back with daily use. uuid:37fef7e0-657d-4958-a1fe-76bd8730731e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9620 biolink:treats MONDO:0002041 PMID:41385096 "[{""id"":""uuid:a05d1054-f7f2-48c8-a625-6a826006a40b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:24484b09-4a46-4e90-8e7e-9b8f22aa64bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mycozyl AL™ is effective in the treatment of most skin infections such as athlete's foot (tinea pedis) and ringworm (tinea corporis). Mycozyl AL™ has been designed to reach skin areas around and under the nails while it relives burning, cracking, scaling and discomfort which accompany these conditions. Mycozyl AL™ is an antifungal that works by preventing and eliminating the growth of fungus on fingers, toes and around the nails. It eliminates and helps stop the spread of fungal infections on cuticles around nail edges and under the nail tips where reachable with applicator brush. Mycozyl AL™ cures and prevents fungal infections from coming back with daily use. uuid:618b6cfd-d842-42b0-b6df-75c734a3d347 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27899 biolink:treats MONDO:0004829 PMID:41385096 "[{""id"":""uuid:b6792c6d-4bae-45cb-8470-62e73381a903"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e925d820-a36e-41d4-b007-894367261f56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cisplatin Injection is indicated as therapy to be employed as follows: Metastatic Testicular Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. Metastatic Ovarian Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of cisplatin and cyclophosphamide. Cisplatin Injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received Cisplatin Injection therapy. Advanced Bladder Cancer Cisplatin Injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy. uuid:99271085-c908-4893-ad6a-57040d68fbfd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27899 biolink:treats MONDO:0005611 PMID:41385096 "[{""id"":""uuid:195aca31-e5c4-4a75-bb06-6d0f2e984961"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:59be3a21-e246-4839-9103-1c4e1f2fda05"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cisplatin Injection is indicated as therapy to be employed as follows: Metastatic Testicular Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic testicular tumors who have already received appropriate surgical and/or radiotherapeutic procedures. Metastatic Ovarian Tumors In established combination therapy with other approved chemotherapeutic agents in patients with metastatic ovarian tumors who have already received appropriate surgical and/or radiotherapeutic procedures. An established combination consists of cisplatin and cyclophosphamide. Cisplatin Injection, as a single agent, is indicated as secondary therapy in patients with metastatic ovarian tumors refractory to standard chemotherapy who have not previously received Cisplatin Injection therapy. Advanced Bladder Cancer Cisplatin Injection is indicated as a single agent for patients with transitional cell bladder cancer which is no longer amenable to local treatments, such as surgery and/or radiotherapy. uuid:d467c098-6d2a-48b6-adc1-2e639b64e96c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:73274 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:785c3b46-6f5e-47a0-9f95-2f36125bd559"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9f5ad736-f96b-4edf-bedf-6ead6eb4afa2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f4bf6adf-e40b-43de-86d8-6bef266c4734"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/invokana""]},{""id"":""uuid:8cb555c6-665a-4e74-b82d-7cd094688d8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INVOKANA (canagliflozin) is indicated: as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. to reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction and nonfatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease (CVD). to reduce the risk of end-stage kidney disease (ESKD), doubling of serum creatinine, cardiovascular (CV) death, and hospitalization for heart failure in adults with type 2 diabetes mellitus and diabetic nephropathy with albuminuria greater than 300 mg/day.|[EMA] Invokana is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise:as monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes.For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4.4, 4.5 and 5.1.|[PMDA] A drug with a new active ingredient indicated for the treatment of type 2 diabetes mellitus. uuid:f4f39fac-5f11-40ca-a84f-b008b23acb1b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:73274 biolink:treats MONDO:0004995 PMID:41385096 "[{""id"":""uuid:e2d2aa18-f3da-4239-b685-87737f3b4bcd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:65de4809-1ffd-4b12-a684-f8dc5a08d6b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INVOKANA (canagliflozin) is indicated: as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. to reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction and nonfatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease (CVD). to reduce the risk of end-stage kidney disease (ESKD), doubling of serum creatinine, cardiovascular (CV) death, and hospitalization for heart failure in adults with type 2 diabetes mellitus and diabetic nephropathy with albuminuria greater than 300 mg/day. uuid:1dc14c4d-38c9-4701-b09d-1e894f8630ff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:73274 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:1b78bca2-d4c3-49dd-acbf-eee2772634b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3c4007e9-7802-468c-99c7-fdcf43776758"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INVOKANA (canagliflozin) is indicated: as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. to reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction and nonfatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease (CVD). to reduce the risk of end-stage kidney disease (ESKD), doubling of serum creatinine, cardiovascular (CV) death, and hospitalization for heart failure in adults with type 2 diabetes mellitus and diabetic nephropathy with albuminuria greater than 300 mg/day. uuid:17d508e7-f6c4-4ab4-9811-72c7f71e0bff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:73274 biolink:treats MONDO:0004375 PMID:41385096 "[{""id"":""uuid:54a521d8-7a04-4222-93e2-7600f53361bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6117cc98-5c14-4c39-9cd6-f04f88856e90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INVOKANA (canagliflozin) is indicated: as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. to reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction and nonfatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease (CVD). to reduce the risk of end-stage kidney disease (ESKD), doubling of serum creatinine, cardiovascular (CV) death, and hospitalization for heart failure in adults with type 2 diabetes mellitus and diabetic nephropathy with albuminuria greater than 300 mg/day. uuid:f5cdcadb-4259-44c1-ad19-5a64ab5bbcdd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:73274 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:e3fbd982-f802-4532-be82-b67de31a656a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bd01da2e-3db5-47b8-8ffb-b03c7aa5ab45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INVOKANA (canagliflozin) is indicated: as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. to reduce the risk of major adverse cardiovascular events (cardiovascular death, nonfatal myocardial infarction and nonfatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease (CVD). to reduce the risk of end-stage kidney disease (ESKD), doubling of serum creatinine, cardiovascular (CV) death, and hospitalization for heart failure in adults with type 2 diabetes mellitus and diabetic nephropathy with albuminuria greater than 300 mg/day. uuid:df7e42e9-4279-4185-b1fc-2f6ac3cef765 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0017767 PMID:41385096 "[{""id"":""uuid:58399bb7-a409-4214-9318-7c9fe674b3e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f3540e00-146b-4803-9d77-858469ea2aeb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bicillin L-A and other antibacterial drugs, Bicillin L-A should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Intramuscular penicillin G benzathine is indicated in the treatment of infections due to penicillin-G-sensitive microorganisms that are susceptible to the low and very prolonged serum levels common to this particular dosage form. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. The following infections will usually respond to adequate dosage of intramuscular penicillin G benzathine: Mild-to-moderate infections of the upper-respiratory tract due to susceptible streptococci. Venereal infections —Syphilis, yaws, bejel, and pinta. Medical Conditions in which Penicillin G Benzathine Therapy is indicated as Prophylaxis: Rheumatic fever and/or chorea —Prophylaxis with penicillin G benzathine has proven effective in preventing recurrence of these conditions. It has also been used as follow-up prophylactic therapy for rheumatic heart disease and acute glomerulonephritis. CHEBI:18208 uuid:93514c89-7874-4091-b88b-2ff415545eea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0001595 PMID:41385096 "[{""id"":""uuid:70b6adf2-6242-4d54-9918-8298b34c6d3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:904f9fca-cf7d-456f-bc1d-0673c3f9a2fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bicillin L-A and other antibacterial drugs, Bicillin L-A should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Intramuscular penicillin G benzathine is indicated in the treatment of infections due to penicillin-G-sensitive microorganisms that are susceptible to the low and very prolonged serum levels common to this particular dosage form. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. The following infections will usually respond to adequate dosage of intramuscular penicillin G benzathine: Mild-to-moderate infections of the upper-respiratory tract due to susceptible streptococci. Venereal infections —Syphilis, yaws, bejel, and pinta. Medical Conditions in which Penicillin G Benzathine Therapy is indicated as Prophylaxis: Rheumatic fever and/or chorea —Prophylaxis with penicillin G benzathine has proven effective in preventing recurrence of these conditions. It has also been used as follow-up prophylactic therapy for rheumatic heart disease and acute glomerulonephritis. CHEBI:18208 uuid:e97df9a2-deef-4a7a-8a33-14c424aeb259 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0006955 PMID:41385096 "[{""id"":""uuid:f94ccdb9-21b6-4e61-a519-c2f270021385"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cdc5f495-a448-43ca-94fc-fa0f68972f46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bicillin L-A and other antibacterial drugs, Bicillin L-A should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Intramuscular penicillin G benzathine is indicated in the treatment of infections due to penicillin-G-sensitive microorganisms that are susceptible to the low and very prolonged serum levels common to this particular dosage form. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. The following infections will usually respond to adequate dosage of intramuscular penicillin G benzathine: Mild-to-moderate infections of the upper-respiratory tract due to susceptible streptococci. Venereal infections —Syphilis, yaws, bejel, and pinta. Medical Conditions in which Penicillin G Benzathine Therapy is indicated as Prophylaxis: Rheumatic fever and/or chorea —Prophylaxis with penicillin G benzathine has proven effective in preventing recurrence of these conditions. It has also been used as follow-up prophylactic therapy for rheumatic heart disease and acute glomerulonephritis. CHEBI:18208 uuid:bcfce5f1-d6df-4eb8-ae39-a489026d5d24 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats UMLS:C0156221 PMID:41385096 "[{""id"":""uuid:64539adb-d151-4806-b4aa-ae447fad663a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:41594d0e-0ca1-4762-97e9-2a993cc3e3d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bicillin L-A and other antibacterial drugs, Bicillin L-A should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Intramuscular penicillin G benzathine is indicated in the treatment of infections due to penicillin-G-sensitive microorganisms that are susceptible to the low and very prolonged serum levels common to this particular dosage form. Therapy should be guided by bacteriological studies (including sensitivity tests) and by clinical response. The following infections will usually respond to adequate dosage of intramuscular penicillin G benzathine: Mild-to-moderate infections of the upper-respiratory tract due to susceptible streptococci. Venereal infections —Syphilis, yaws, bejel, and pinta. Medical Conditions in which Penicillin G Benzathine Therapy is indicated as Prophylaxis: Rheumatic fever and/or chorea —Prophylaxis with penicillin G benzathine has proven effective in preventing recurrence of these conditions. It has also been used as follow-up prophylactic therapy for rheumatic heart disease and acute glomerulonephritis. CHEBI:18208 uuid:52ff7954-1333-483e-8db4-58157b60f78f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3696 biolink:treats MONDO:0043424 PMID:41385096 "[{""id"":""uuid:35c536f8-b4cc-42d4-8a15-abd7ea7a490d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bb748a34-deac-4db7-9b33-b3094cb1b07e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cidofovir injection is indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). THE SAFETY AND EFFICACY OF CIDOFOVIR INJECTION HAVE NOT BEEN ESTABLISHED FOR TREATMENT OF OTHER CMV INFECTIONS (SUCH AS PNEUMONITIS OR GASTROENTERITIS), CONGENITAL OR NEONATAL CMV DISEASE, OR CMV DISEASE IN NON-HIV-INFECTED INDIVIDUALS. DESCRIPTION OF CLINICAL TRIALS Three phase II/III controlled trials of cidofovir injection have been conducted in HIV-infected patients with CMV retinitis. Delayed Versus Immediate Therapy (Study 105) In stage 1 of this open-label trial, conducted by the Studies of the Ocular Complications of AIDS (SOCA) Clinical Research Group, 29 previously untreated patients with peripheral CMV retinitis were randomized to either immediate treatment with cidofovir injection (5 mg/kg once a week for 2 weeks, then 3 mg/kg every other week) or to have cidofovir injection delayed until progression of CMV retinitis 13 . In stage 2 of this trial, an additional 35 previously untreated patients with peripheral CMV retinitis were randomized to either immediate treatment with cidofovir injection (5 mg/kg once a week for 2 weeks, then 5 mg/kg every other week), immediate treatment with cidofovir injection (5 mg/kg once a week for 2 weeks, then 3 mg/kg every other week), or to have cidofovir injection delayed until progression of CMV retinitis. Of the 64 patients in this study, 12 were randomized to 5 mg/kg maintenance therapy, 26 to 3 mg/kg maintenance therapy, and 26 to delayed therapy. Of the 12 patients enrolled in the 5 mg/kg maintenance group, 5 patients progressed, 5 patients discontinued therapy and 2 patients had no progression at study completion. Based on masked readings of retinal photographs, the median [95% confidence interval (CI)] time to retinitis progression was not reached (25, not reached) for the 5 mg/kg maintenance group. Median (95% CI) time to the alternative endpoint of retinitis progression or study drug discontinuation was 44 days (24, 207) for the 5 mg/kg maintenance group. Patients receiving 5 mg/kg maintenance had delayed time to retinitis progression compared to patients receiving 3 mg/kg maintenance or deferred therapy. Delayed Versus Immediate Therapy (Study 106) In an open-label trial, 48 previously untreated patients with peripheral CMV retinitis were randomized to either immediate treatment with cidofovir injection (5 mg/kg once a week for 2 weeks, then 5 mg/kg every other week), or to have cidofovir injection delayed until progression of CMV retinitis 14 . Patient baseline characteristics and disposition are shown in Table 3. Of 25 and 23 patients in the immediate and delayed groups respectively, 23 and 21 were evaluable for retinitis progression as determined by retinal photography. Based on masked readings of retinal photographs, the median [95% confidence interval (CI)] times to retinitis progression were 120 days (40, 134) and 22 days (10, 27) for the immediate and delayed therapy groups, respectively. This difference was statistically significant. However, because of the limited number of patients remaining on treatment over time (3 of 25 patients received cidofovir injection for 120 days or longer), the median time to progression for the immediate therapy group was difficult to precisely estimate. Median (95% CI) times to the alternative endpoint of retinitis progression or study drug discontinuation (including adverse events, withdrawn consent, and systemic CMV disease) were 52 days (37, 85) and 22 days (13, 27) for the immediate and delayed therapy groups, respectively. This difference was statistically significant. Time to progression estimates from this study may not be directly comparable to estimates reported for other therapies. Table 3. Patient Characteristics and Disposition (Study 106) * One patient died 2 weeks after withdrawing consent. † Two patients on immediate therapy were diagnosed with CMV disease and discontinued from study. One patient on delayed therapy was diagnosed with CMV gastrointestinal disease. ‡ CMV retinitis progression not confirmed by retinal photography. Immediate Therapy (n = 25) Delayed Therapy (n = 23) Baseline Characteristics Age (years) 38 38 Sex (M/F) 24/1 22/1 Median CD4 Cell Count 6 9 Endpoints CMV Retinitis Progression 10 18 Discontinued Due to Adverse Event 6 0 Withdrew Consent 3 * 1 Discontinued Due to Intercurrent Illness 2 † 1 † Discontinued Based on Ophthalmological Examination 1 ‡ 1 ‡ No Progression at Study Completion 1 0 Not Evaluable at Baseline 2 2 Dose-response study of cidofovir injection (Study 107) In an open-label trial, 100 patients with relapsing CMV retinitis were randomized to receive 5 mg/kg once a week for 2 weeks and then either 5 mg/kg (n = 49) or 3 mg/kg (n = 51) every other week. Enrolled patients had been diagnosed with CMV retinitis an average of 390 days prior to randomization and had received a median of 3.8 prior courses of systemic CMV therapy. Eighty four of the 100 patients were considered evaluable for progression by serial retinal photographs (43 randomized to 5 mg/kg and 41 randomized to 3 mg/kg). Twenty-six and 21 patients discontinued therapy due to either an adverse event, intercurrent illness, excluded medication, or withdrawn consent in the 5 mg/kg and 3 mg/kg groups, respectively. Thirty-eight of the 100 randomized patients had progressed according to masked assessment of serial retinal photographs (13 randomized to 5 mg/kg and 25 randomized to 3 mg/kg). Using retinal photographs, the median (95% CI) times to retinitis progression for the 5 mg/kg and 3 mg/kg groups were 115 days (70, not reached) and 49 days (35, 52), respectively. This difference was statistically significant. Similar to Study 106, the median time to retinitis progression for the 5 mg/kg group was difficult to precisely estimate due to the limited number of patients remaining on treatment over time (4 of the 49 patients in the 5 mg/kg group were treated for 115 days or longer). Median (95% CI) times to the alternative endpoint of retinitis progression or study drug discontinuation were 49 days (38, 63) and 35 days (27, 39) for the 5 mg/kg and 3 mg/kg groups, respectively. This difference was statistically significant. uuid:fb26f88e-26db-4ac2-8b00-547dab6f0780 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3696 biolink:treats MONDO:0005132 PMID:41385096 "[{""id"":""uuid:8d8a7c29-7d4f-4d3a-bcdc-78f55f639776"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:41c19658-ce06-4ebc-8e42-3619c19541fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cidofovir injection is indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). THE SAFETY AND EFFICACY OF CIDOFOVIR INJECTION HAVE NOT BEEN ESTABLISHED FOR TREATMENT OF OTHER CMV INFECTIONS (SUCH AS PNEUMONITIS OR GASTROENTERITIS), CONGENITAL OR NEONATAL CMV DISEASE, OR CMV DISEASE IN NON-HIV-INFECTED INDIVIDUALS. DESCRIPTION OF CLINICAL TRIALS Three phase II/III controlled trials of cidofovir injection have been conducted in HIV-infected patients with CMV retinitis. Delayed Versus Immediate Therapy (Study 105) In stage 1 of this open-label trial, conducted by the Studies of the Ocular Complications of AIDS (SOCA) Clinical Research Group, 29 previously untreated patients with peripheral CMV retinitis were randomized to either immediate treatment with cidofovir injection (5 mg/kg once a week for 2 weeks, then 3 mg/kg every other week) or to have cidofovir injection delayed until progression of CMV retinitis 13 . In stage 2 of this trial, an additional 35 previously untreated patients with peripheral CMV retinitis were randomized to either immediate treatment with cidofovir injection (5 mg/kg once a week for 2 weeks, then 5 mg/kg every other week), immediate treatment with cidofovir injection (5 mg/kg once a week for 2 weeks, then 3 mg/kg every other week), or to have cidofovir injection delayed until progression of CMV retinitis. Of the 64 patients in this study, 12 were randomized to 5 mg/kg maintenance therapy, 26 to 3 mg/kg maintenance therapy, and 26 to delayed therapy. Of the 12 patients enrolled in the 5 mg/kg maintenance group, 5 patients progressed, 5 patients discontinued therapy and 2 patients had no progression at study completion. Based on masked readings of retinal photographs, the median [95% confidence interval (CI)] time to retinitis progression was not reached (25, not reached) for the 5 mg/kg maintenance group. Median (95% CI) time to the alternative endpoint of retinitis progression or study drug discontinuation was 44 days (24, 207) for the 5 mg/kg maintenance group. Patients receiving 5 mg/kg maintenance had delayed time to retinitis progression compared to patients receiving 3 mg/kg maintenance or deferred therapy. Delayed Versus Immediate Therapy (Study 106) In an open-label trial, 48 previously untreated patients with peripheral CMV retinitis were randomized to either immediate treatment with cidofovir injection (5 mg/kg once a week for 2 weeks, then 5 mg/kg every other week), or to have cidofovir injection delayed until progression of CMV retinitis 14 . Patient baseline characteristics and disposition are shown in Table 3. Of 25 and 23 patients in the immediate and delayed groups respectively, 23 and 21 were evaluable for retinitis progression as determined by retinal photography. Based on masked readings of retinal photographs, the median [95% confidence interval (CI)] times to retinitis progression were 120 days (40, 134) and 22 days (10, 27) for the immediate and delayed therapy groups, respectively. This difference was statistically significant. However, because of the limited number of patients remaining on treatment over time (3 of 25 patients received cidofovir injection for 120 days or longer), the median time to progression for the immediate therapy group was difficult to precisely estimate. Median (95% CI) times to the alternative endpoint of retinitis progression or study drug discontinuation (including adverse events, withdrawn consent, and systemic CMV disease) were 52 days (37, 85) and 22 days (13, 27) for the immediate and delayed therapy groups, respectively. This difference was statistically significant. Time to progression estimates from this study may not be directly comparable to estimates reported for other therapies. Table 3. Patient Characteristics and Disposition (Study 106) * One patient died 2 weeks after withdrawing consent. † Two patients on immediate therapy were diagnosed with CMV disease and discontinued from study. One patient on delayed therapy was diagnosed with CMV gastrointestinal disease. ‡ CMV retinitis progression not confirmed by retinal photography. Immediate Therapy (n = 25) Delayed Therapy (n = 23) Baseline Characteristics Age (years) 38 38 Sex (M/F) 24/1 22/1 Median CD4 Cell Count 6 9 Endpoints CMV Retinitis Progression 10 18 Discontinued Due to Adverse Event 6 0 Withdrew Consent 3 * 1 Discontinued Due to Intercurrent Illness 2 † 1 † Discontinued Based on Ophthalmological Examination 1 ‡ 1 ‡ No Progression at Study Completion 1 0 Not Evaluable at Baseline 2 2 Dose-response study of cidofovir injection (Study 107) In an open-label trial, 100 patients with relapsing CMV retinitis were randomized to receive 5 mg/kg once a week for 2 weeks and then either 5 mg/kg (n = 49) or 3 mg/kg (n = 51) every other week. Enrolled patients had been diagnosed with CMV retinitis an average of 390 days prior to randomization and had received a median of 3.8 prior courses of systemic CMV therapy. Eighty four of the 100 patients were considered evaluable for progression by serial retinal photographs (43 randomized to 5 mg/kg and 41 randomized to 3 mg/kg). Twenty-six and 21 patients discontinued therapy due to either an adverse event, intercurrent illness, excluded medication, or withdrawn consent in the 5 mg/kg and 3 mg/kg groups, respectively. Thirty-eight of the 100 randomized patients had progressed according to masked assessment of serial retinal photographs (13 randomized to 5 mg/kg and 25 randomized to 3 mg/kg). Using retinal photographs, the median (95% CI) times to retinitis progression for the 5 mg/kg and 3 mg/kg groups were 115 days (70, not reached) and 49 days (35, 52), respectively. This difference was statistically significant. Similar to Study 106, the median time to retinitis progression for the 5 mg/kg group was difficult to precisely estimate due to the limited number of patients remaining on treatment over time (4 of the 49 patients in the 5 mg/kg group were treated for 115 days or longer). Median (95% CI) times to the alternative endpoint of retinitis progression or study drug discontinuation were 49 days (38, 63) and 35 days (27, 39) for the 5 mg/kg and 3 mg/kg groups, respectively. This difference was statistically significant. uuid:96679b04-3515-4b1a-b6d9-fc36defabb93 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3A58010674 biolink:treats UMLS:C4509926 PMID:41385096 "[{""id"":""uuid:b031f7f6-cf29-4620-b8a9-8455bfaf8a53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6fd18400-9715-4b3d-b83c-728b397ca844"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Stimufend is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. ( 1.1 ) Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Subsyndrome of Acute Radiation Syndrome). ( 1.2 ) Limitations of Use Stimufend is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation. uuid:ca17caeb-ad1a-46cb-a81f-5f153557a42b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4469 biolink:treats MONDO:0005485 PMID:41385096 "[{""id"":""uuid:699883e0-5aed-4fc1-afeb-5ec8a6159eb3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0f3db86b-017b-43dd-a221-ccba895e7f2d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DEXEDRINE is indicated in: Narcolepsy Attention Deficit Disorder with Hyperactivity As an integral part of a total treatment program that typically includes other measures (psychological, educational, social) for patients (ages 6 years to 16 years) with this syndrome. A diagnosis of Attention Deficit Hyperactivity Disorder (ADHD; DSM-IV) implies the presence of the hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. The symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in 2 or more settings, e.g., school (or work) and at home. The symptoms must not be better accounted for by another mental disorder. For the Inattentive Type, at least 6 of the following symptoms must have persisted for at least 6 months: lack of attention to details/careless mistakes; lack of sustained attention; poor listener; failure to follow through on tasks; poor organization; avoids tasks requiring sustained mental effort; loses things; easily distracted; forgetful. For the Hyperactive-Impulsive Type, at least 6 of the following symptoms must have persisted for at least 6 months: fidgeting/squirming; leaving seat; inappropriate running/climbing; difficulty with quiet activities; “on the go”; excessive talking; blurting answers; can't wait turn; intrusive. The Combined Type requires both inattentive and hyperactive-impulsive criteria to be met. Special Diagnostic Considerations Specific etiology of this syndrome is unknown, and there is no single diagnostic test. Adequate diagnosis requires the use of medical and special psychological, educational, and social resources. Learning may or may not be impaired. The diagnosis must be based upon a complete history and evaluation of the patient and not solely on the presences of the required number of DSM-IV characteristics. Need for Comprehensive Treatment Program DEXEDRINE is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, social) for patients with this syndrome. Drug treatment may not be indicated for all patients with this syndrome. Stimulants are not intended for use in patients who exhibit symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis. Appropriate educational placement is essential and psychosocial intervention is often helpful. When remedial measures alone are insufficient, the decision to prescribe stimulant medication will depend upon the physician’s assessment of the chronicity and severity of the patient’s symptoms. uuid:52ec812a-58fe-4500-b5e7-aa1210d08066 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17347 biolink:treats UMLS:C0432476 PMID:41385096 "[{""id"":""uuid:ad342e04-e60e-4459-af75-a4a516d2fa88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e0b20459-cb5a-4848-86cf-c03a74da7759"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KYZATREX™ is indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired): testicular failure due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (folliclestimulating hormone (FSH), luteinizing hormone (LH)) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low serum testosterone concentrations but have gonadotropins in the normal or low range. uuid:cd7fff50-2032-47f2-b045-a065a6cadcdb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:30746 biolink:treats HP:0001987 PMID:41385096 "[{""id"":""uuid:a92b6bd3-679c-4d72-a2c4-212f4bc60ffb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:896fba63-473f-4f54-8a59-c0ca512b10f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Phenylacetate and Sodium Benzoate Injection is a nitrogen binding agent indicated as adjunctive therapy for the treatment of acute hyperammonemia and associated encephalopathy in paediatric and adult patients with deficiencies in enzymes of the urea cycle. ( 1 ) uuid:340ecab0-8f63-46b6-9846-6a8837875231 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1368383 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:54c1c489-82a9-44fc-b327-9442cf8cd8eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6b6489fb-ad57-4315-8ae8-83e0ce5fa571"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ae9a1545-0cf7-4dfb-bd9d-54a4105ac896"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Alogliptin and metformin HCl tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.|[PMDA] A new combination drug indicated for the treatment of type 2 diabetes mellitus (only when a concomitant use of alogliptin benzoate with metformin hydrochloride is deemed appropriate). uuid:168d962f-78b3-46f6-8d7a-2ac2fcfad0fe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:122361353 biolink:treats MONDO:0018076 PMID:41385096 "[{""id"":""uuid:3864079b-967e-4685-b68b-04eab7162837"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:24e35ad0-68fa-42b0-abe3-3e03beb0afd5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cosyntropin for Injection is intended for use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency. Because of its rapid effect on the adrenal cortex it may be utilized to perform a 30-minute test of adrenal function (plasma cortisol response) as an office or outpatient procedure, using only 2 venipunctures (see DOSAGE AND ADMINISTRATION section). Severe hypofunction of the pituitary - adrenal axis is usually associated with subnormal plasma cortisol values but a low basal level is not per se evidence of adrenal insufficiency and does not suffice to make the diagnosis. Many patients with proven insufficiency will have normal basal levels and will develop signs of insufficiency only when stressed. For this reason a criterion which should be used in establishing the diagnosis is the failure to respond to adequate corticotropin stimulation. When presumptive adrenal insufficiency is diagnosed by a subnormal Cosyntropin for Injection test, further studies are indicated to determine if it is primary or secondary. Primary adrenal insufficiency (Addison's disease) is the result of an intrinsic disease process, such as tuberculosis within the gland. The production of adrenocortical hormones is deficient despite high ACTH levels (feedback mechanism). Secondary or relative insufficiency arises as the result of defective production of ACTH leading in turn to disuse atrophy of the adrenal cortex. It is commonly seen, for example, as result of corticosteroid therapy, Sheehan's syndrome and pituitary tumors or ablation. The differentiation of both types is based on the premise that a primarily defective gland cannot be stimulated by ACTH whereas a secondarily defective gland is potentially functional and will respond to adequate stimulation with ACTH. Patients selected for further study as the result of a subnormal Cosyntropin for Injection test should be given a 3 or 4 day course of treatment with Repository Corticotropin Injection USP and then retested. Suggested doses are 40 USP units twice daily for 4 days or 60 USP units twice daily for 3 days. Under these conditions little or no increase in plasma cortisol levels will be seen in Addison's disease whereas higher or even normal levels will be seen in cases with secondary adrenal insufficiency. uuid:73dc7b1d-e610-4e2e-9da7-8d29998dbc2b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:122361353 biolink:treats MONDO:0019618 PMID:41385096 "[{""id"":""uuid:7e0fed28-d087-4149-acc7-0f71f065aaed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8b99b8d4-29e2-4ce5-9494-044dc66fac24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cosyntropin for Injection is intended for use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency. Because of its rapid effect on the adrenal cortex it may be utilized to perform a 30-minute test of adrenal function (plasma cortisol response) as an office or outpatient procedure, using only 2 venipunctures (see DOSAGE AND ADMINISTRATION section). Severe hypofunction of the pituitary - adrenal axis is usually associated with subnormal plasma cortisol values but a low basal level is not per se evidence of adrenal insufficiency and does not suffice to make the diagnosis. Many patients with proven insufficiency will have normal basal levels and will develop signs of insufficiency only when stressed. For this reason a criterion which should be used in establishing the diagnosis is the failure to respond to adequate corticotropin stimulation. When presumptive adrenal insufficiency is diagnosed by a subnormal Cosyntropin for Injection test, further studies are indicated to determine if it is primary or secondary. Primary adrenal insufficiency (Addison's disease) is the result of an intrinsic disease process, such as tuberculosis within the gland. The production of adrenocortical hormones is deficient despite high ACTH levels (feedback mechanism). Secondary or relative insufficiency arises as the result of defective production of ACTH leading in turn to disuse atrophy of the adrenal cortex. It is commonly seen, for example, as result of corticosteroid therapy, Sheehan's syndrome and pituitary tumors or ablation. The differentiation of both types is based on the premise that a primarily defective gland cannot be stimulated by ACTH whereas a secondarily defective gland is potentially functional and will respond to adequate stimulation with ACTH. Patients selected for further study as the result of a subnormal Cosyntropin for Injection test should be given a 3 or 4 day course of treatment with Repository Corticotropin Injection USP and then retested. Suggested doses are 40 USP units twice daily for 4 days or 60 USP units twice daily for 3 days. Under these conditions little or no increase in plasma cortisol levels will be seen in Addison's disease whereas higher or even normal levels will be seen in cases with secondary adrenal insufficiency. uuid:0f23f76a-0397-4e06-9653-94ba6737daa3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:122361353 biolink:treats MONDO:0017611 PMID:41385096 "[{""id"":""uuid:7eadd6a9-ceaf-45f8-b70b-1ae6f344d309"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5191538d-8773-41fe-a1a8-a95b42bcd28a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cosyntropin for Injection is intended for use as a diagnostic agent in the screening of patients presumed to have adrenocortical insufficiency. Because of its rapid effect on the adrenal cortex it may be utilized to perform a 30-minute test of adrenal function (plasma cortisol response) as an office or outpatient procedure, using only 2 venipunctures (see DOSAGE AND ADMINISTRATION section). Severe hypofunction of the pituitary - adrenal axis is usually associated with subnormal plasma cortisol values but a low basal level is not per se evidence of adrenal insufficiency and does not suffice to make the diagnosis. Many patients with proven insufficiency will have normal basal levels and will develop signs of insufficiency only when stressed. For this reason a criterion which should be used in establishing the diagnosis is the failure to respond to adequate corticotropin stimulation. When presumptive adrenal insufficiency is diagnosed by a subnormal Cosyntropin for Injection test, further studies are indicated to determine if it is primary or secondary. Primary adrenal insufficiency (Addison's disease) is the result of an intrinsic disease process, such as tuberculosis within the gland. The production of adrenocortical hormones is deficient despite high ACTH levels (feedback mechanism). Secondary or relative insufficiency arises as the result of defective production of ACTH leading in turn to disuse atrophy of the adrenal cortex. It is commonly seen, for example, as result of corticosteroid therapy, Sheehan's syndrome and pituitary tumors or ablation. The differentiation of both types is based on the premise that a primarily defective gland cannot be stimulated by ACTH whereas a secondarily defective gland is potentially functional and will respond to adequate stimulation with ACTH. Patients selected for further study as the result of a subnormal Cosyntropin for Injection test should be given a 3 or 4 day course of treatment with Repository Corticotropin Injection USP and then retested. Suggested doses are 40 USP units twice daily for 4 days or 60 USP units twice daily for 3 days. Under these conditions little or no increase in plasma cortisol levels will be seen in Addison's disease whereas higher or even normal levels will be seen in cases with secondary adrenal insufficiency. uuid:21d375b5-4853-4691-8e67-ee7f0ba13ace biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3423 biolink:treats MONDO:0018177 PMID:41385096 "[{""id"":""uuid:67deca9e-8053-40df-a69e-547feb902db8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:84691865-b37c-4720-b245-5575f3d4ca68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:8508c16a-4c33-4e62-a3a2-b0d90c0201cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/carmustine-medac-previously-carmustine-obvius""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carmustine for injection is indicated as palliative therapy as a single agent or in established combination therapy in the following: - Brain tumors glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors. - Multiple myeloma in combination with prednisone. - Relapsed or refractory Hodgkin's lymphoma in combination with other approved drugs. - Relapsed or refractory Non-Hodgkin's lymphomas in combination with other approved drugs.|[EMA] Carmustine is indicated n adults in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery):, , , Brain tumours (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases, Secondary therapy in non-Hodgkin’s lymphoma and Hodgkin’s disease, as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (HPCT) in malignant haematological diseases (Hodgkin’s disease / Non-hodgkin’s lymphoma)., , uuid:48c4726c-b89e-4456-a76b-75cdacde138a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3423 biolink:treats MONDO:0003153 PMID:41385096 "[{""id"":""uuid:2c1e53d9-cbc1-4d86-8c78-2a5e968f1a68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0f888953-72b5-44fb-9b67-569e16fb7817"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carmustine for injection is indicated as palliative therapy as a single agent or in established combination therapy in the following: - Brain tumors glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors. - Multiple myeloma in combination with prednisone. - Relapsed or refractory Hodgkin's lymphoma in combination with other approved drugs. - Relapsed or refractory Non-Hodgkin's lymphomas in combination with other approved drugs. uuid:41f2582c-5858-4af8-90d2-85ee9b7bfc35 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3423 biolink:treats MONDO:0007959 PMID:41385096 "[{""id"":""uuid:0e336c31-b4c3-4ef2-9612-ae8369c810ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:60bfab98-1b55-492b-953b-921e7ea1199b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:17481326-2b3e-496e-8a9f-aaffbeaf9acc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/carmustine-medac-previously-carmustine-obvius""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carmustine for injection is indicated as palliative therapy as a single agent or in established combination therapy in the following: - Brain tumors glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors. - Multiple myeloma in combination with prednisone. - Relapsed or refractory Hodgkin's lymphoma in combination with other approved drugs. - Relapsed or refractory Non-Hodgkin's lymphomas in combination with other approved drugs.|[EMA] Carmustine is indicated n adults in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery):, , , Brain tumours (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases, Secondary therapy in non-Hodgkin’s lymphoma and Hodgkin’s disease, as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (HPCT) in malignant haematological diseases (Hodgkin’s disease / Non-hodgkin’s lymphoma)., , uuid:3ee6b238-f302-443e-81d4-e9c0790a84ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3423 biolink:treats MONDO:0019781 PMID:41385096 "[{""id"":""uuid:06a4a61b-83e5-42c7-8c82-62e1efa30c16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:38ea9d00-c4a8-48ad-a2c8-bcd63d7b606c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:684c0231-5402-4651-8abb-02f7f9189ff6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/carmustine-medac-previously-carmustine-obvius""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carmustine for injection is indicated as palliative therapy as a single agent or in established combination therapy in the following: - Brain tumors glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors. - Multiple myeloma in combination with prednisone. - Relapsed or refractory Hodgkin's lymphoma in combination with other approved drugs. - Relapsed or refractory Non-Hodgkin's lymphomas in combination with other approved drugs.|[EMA] Carmustine is indicated n adults in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery):, , , Brain tumours (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases, Secondary therapy in non-Hodgkin’s lymphoma and Hodgkin’s disease, as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (HPCT) in malignant haematological diseases (Hodgkin’s disease / Non-hodgkin’s lymphoma)., , uuid:12eb6731-2644-4b35-81cc-010084c8c803 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3423 biolink:treats MONDO:0016698 PMID:41385096 "[{""id"":""uuid:55aed5c9-b0ce-4168-b43b-18df0d1796f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:03721c78-8edc-4482-95bc-e6cd26d48a0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0985df9a-5f4c-42ee-91a8-4e5e74a79e89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/carmustine-medac-previously-carmustine-obvius""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carmustine for injection is indicated as palliative therapy as a single agent or in established combination therapy in the following: - Brain tumors glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors. - Multiple myeloma in combination with prednisone. - Relapsed or refractory Hodgkin's lymphoma in combination with other approved drugs. - Relapsed or refractory Non-Hodgkin's lymphomas in combination with other approved drugs.|[EMA] Carmustine is indicated n adults in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery):, , , Brain tumours (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases, Secondary therapy in non-Hodgkin’s lymphoma and Hodgkin’s disease, as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (HPCT) in malignant haematological diseases (Hodgkin’s disease / Non-hodgkin’s lymphoma)., , uuid:83b6fd29-e0f7-49a8-a6bf-7bd5d4f54292 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3423 biolink:treats MONDO:1040026 PMID:41385096 "[{""id"":""uuid:6c5a80e6-3305-4e5f-9467-51d9a4cb22cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c8a07e9d-8ce1-40c2-9a70-9fac4330196e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d7eb5868-ea04-435c-ab91-03c93c2fc8b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/carmustine-medac-previously-carmustine-obvius""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carmustine for injection is indicated as palliative therapy as a single agent or in established combination therapy in the following: - Brain tumors glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors. - Multiple myeloma in combination with prednisone. - Relapsed or refractory Hodgkin's lymphoma in combination with other approved drugs. - Relapsed or refractory Non-Hodgkin's lymphomas in combination with other approved drugs.|[EMA] Carmustine is indicated n adults in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery):, , , Brain tumours (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases, Secondary therapy in non-Hodgkin’s lymphoma and Hodgkin’s disease, as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (HPCT) in malignant haematological diseases (Hodgkin’s disease / Non-hodgkin’s lymphoma)., , uuid:3e234bed-1992-4976-9907-f888edc3c76e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3423 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:e890d547-56b3-455a-8d3a-634db27d87ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a12b86e4-183a-4548-a55d-810db7545b2b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carmustine for injection is indicated as palliative therapy as a single agent or in established combination therapy in the following: - Brain tumors glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors. - Multiple myeloma in combination with prednisone. - Relapsed or refractory Hodgkin's lymphoma in combination with other approved drugs. - Relapsed or refractory Non-Hodgkin's lymphomas in combination with other approved drugs. uuid:3ced262b-00f7-4536-85b2-c44b28e9c223 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3423 biolink:treats MONDO:0009348 PMID:41385096 "[{""id"":""uuid:d3a39fb2-6e34-4145-a006-d3bf18da7bb4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7ff74918-b7cc-44f4-84e3-085a520c2c7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carmustine for injection is indicated as palliative therapy as a single agent or in established combination therapy in the following: - Brain tumors glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, and metastatic brain tumors. - Multiple myeloma in combination with prednisone. - Relapsed or refractory Hodgkin's lymphoma in combination with other approved drugs. - Relapsed or refractory Non-Hodgkin's lymphomas in combination with other approved drugs. uuid:181cdf38-4e67-46a2-b522-5dff2e7ba458 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32954 biolink:treats HP:0002902 PMID:41385096 "[{""id"":""uuid:6ffb0bad-1d3d-4e95-9908-924e6ec2e12e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6d8168d3-6d78-4513-a5a9-cbd2e07a5320"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Acetate Injection, USP is indicated as a source of sodium for addition to large volume intravenous fluids to prevent or correct hyponatremia in patients with restricted or no oral intake. It is also useful as an additive for preparing specific intravenous fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions. uuid:6abacdaf-b078-4d5e-b3f8-c1b6df6fc4b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:44149770 biolink:treats MONDO:0005393 PMID:41385096 "[{""id"":""uuid:010a6960-a450-4078-a584-04a0da89ad0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fe8affa2-ffc2-4a21-9d77-ee0bd15a2f61"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of chronic gouty arthritis when complicated by frequent, recurrent acute attacks of gout. uuid:a43a4627-6e83-4224-8b35-3da1826de790 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18258 biolink:treats MONDO:1010100 PMID:41385096 "[{""id"":""uuid:51cd3a64-5b9e-49bc-a472-fdad86d04f97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c1116ae4-7968-410c-947b-74213932b2e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Liothyronine sodium injection (T 3 ) is indicated in the treatment of myxedema coma/precoma. Liothyronine sodium injection (T 3 ) can be used in patients allergic to desiccated thyroid or thyroid extract derived from pork or beef. UMLS:C0238298 uuid:bcb29d7d-377c-4179-b971-a17dd1cadc31 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75984 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:7d3e8b74-9922-4ecb-b3ae-f6a8a227edfc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e771a967-5a9c-4f08-91fc-d12f5633680d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In patients without structural heart disease, flecainide is indicated for the prevention of - paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms - paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms. Flecainide is also indicated for the prevention of - documented ventricular arrhythmias, such as sustained ventricular tachycardia ( sustained VT), that in the judgment of the physician, are life-threatening. Use of flecainide for the treatment of sustained VT, like other antiarrhythmics, should be initiated in the hospital. The use of flecainide is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. Because of the proarrhythmic effects of flecainide, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks. Flecainide should not be used in patients with recent myocardial infarction (see Boxed WARNINGS ). Use of flecainide in chronic atrial fibrillation has not been adequately studied and is not recommended (see Boxed WARNINGS ). As is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of flecainide favorably affects survival or the incidence of sudden death. uuid:4a8890e0-bee3-40ab-9dfa-8137070a5d3a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75984 biolink:treats HP:0004754 PMID:41385096 "[{""id"":""uuid:fa537cec-db54-48fb-8b6c-35f803a85d15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:76f8a99a-14b0-443f-aab0-fcbc744e86ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In patients without structural heart disease, flecainide is indicated for the prevention of - paroxysmal supraventricular tachycardias (PSVT), including atrioventricular nodal reentrant tachycardia, atrioventricular reentrant tachycardia and other supraventricular tachycardias of unspecified mechanism associated with disabling symptoms - paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms. Flecainide is also indicated for the prevention of - documented ventricular arrhythmias, such as sustained ventricular tachycardia ( sustained VT), that in the judgment of the physician, are life-threatening. Use of flecainide for the treatment of sustained VT, like other antiarrhythmics, should be initiated in the hospital. The use of flecainide is not recommended in patients with less severe ventricular arrhythmias even if the patients are symptomatic. Because of the proarrhythmic effects of flecainide, its use should be reserved for patients in whom, in the opinion of the physician, the benefits of treatment outweigh the risks. Flecainide should not be used in patients with recent myocardial infarction (see Boxed WARNINGS ). Use of flecainide in chronic atrial fibrillation has not been adequately studied and is not recommended (see Boxed WARNINGS ). As is the case for other antiarrhythmic agents, there is no evidence from controlled trials that the use of flecainide favorably affects survival or the incidence of sudden death. uuid:abb39117-0e95-40e1-9868-059435132a1b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135935 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:5a4bbb68-0c09-4837-969c-8caad71efad4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:05cea4a6-e29b-4e07-b928-fc660a61fcf6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NUCYNTA ER (tapentadol) is indicated for the management of: pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate neuropathic pain associated with diabetic peripheral neuropathy (DPN) severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. uuid:be3bd325-b855-42ff-b265-d423a2a1e156 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135935 biolink:treats MONDO:0001583 PMID:41385096 "[{""id"":""uuid:121f87bb-92c9-4ff2-8945-f30dd5cd0ec2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:89963a70-4999-45e4-b63f-331fcabd67fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NUCYNTA ER (tapentadol) is indicated for the management of: pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate neuropathic pain associated with diabetic peripheral neuropathy (DPN) severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. uuid:ed803d1d-b68e-41aa-a0ef-cc44c7860d40 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135935 biolink:treats UMLS:C0278140 PMID:41385096 "[{""id"":""uuid:43303949-3163-42cc-9966-6e862375492a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2b2b910c-13e2-4ce9-aa91-38f9152cfcca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NUCYNTA (tapentadol) tablets are indicated for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate in adults. uuid:1892843b-284c-41dc-bfb5-88a995bf9258 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:722125 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:1e4e15bb-7661-4bb3-8d81-b6a5794206c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:195114ff-e862-4fd7-805a-4c5cf992e869"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amlodipine and valsartan tablets are a combination tablet of amlodipine, a dihydropyridine calcium channel blocker (DHP CCB), and valsartan, an angiotensin II receptor blocker (ARB). Amlodipine and valsartan tablets are indicated for the treatment of hypertension, to lower blood pressure: In patients not adequately controlled on monotherapy ( 1 ) As initial therapy in patients likely to need multiple drugs to achieve their blood pressure goals ( 1 ) Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. uuid:93ab36a4-fbb0-4c2f-bfc6-d05abf066da5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2566414 biolink:treats MONDO:0005114 PMID:41385096 "[{""id"":""uuid:af297230-0459-4436-8c10-69583b8f5fd8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:52519567-56ea-4014-8e09-96a85d3108ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0051a610-ebdf-41b3-84d1-1a59d07b74fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In children 6 weeks through 5 years of age (prior to the 6 th birthday), Prevnar 13 is indicated for: active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F. ( 1.1 ) active immunization for the prevention of otitis media caused by S. pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F. No otitis media efficacy data are available for serotypes 1, 3, 5, 6A, 7F, and 19A. ( 1.1 ) In children 6 years through 17 years of age (prior to the 18 th birthday), Prevnar 13 is indicated for: active immunization for the prevention of invasive disease caused by S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F. ( 1.2 ) In adults 18 years of age and older, Prevnar 13 is indicated for: active immunization for the prevention of pneumonia and invasive disease caused by S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F. ( 1.3 ) Limitations of Prevnar 13 Use and Effectiveness Prevnar 13 does not protect against disease caused by S. pneumoniae serotypes that are not in the vaccine. ( 1.4 )|[PMDA] A drug with a new active ingredient indicated for the prophylaxis of pneumococcal disease (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F) in the elderly or in adults who are considered to be at a high risk of pneumococcal disease. uuid:067828ca-a5dc-4418-96a3-78493f17f6d9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2566414 biolink:treats MONDO:0005441 PMID:41385096 "[{""id"":""uuid:f7866fc1-f5d4-41c6-98a9-b5fff307c6cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2e09d354-f8be-474c-904b-bd625179b129"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In children 6 weeks through 5 years of age (prior to the 6 th birthday), Prevnar 13 is indicated for: active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F. ( 1.1 ) active immunization for the prevention of otitis media caused by S. pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F. No otitis media efficacy data are available for serotypes 1, 3, 5, 6A, 7F, and 19A. ( 1.1 ) In children 6 years through 17 years of age (prior to the 18 th birthday), Prevnar 13 is indicated for: active immunization for the prevention of invasive disease caused by S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F. ( 1.2 ) In adults 18 years of age and older, Prevnar 13 is indicated for: active immunization for the prevention of pneumonia and invasive disease caused by S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F. ( 1.3 ) Limitations of Prevnar 13 Use and Effectiveness Prevnar 13 does not protect against disease caused by S. pneumoniae serotypes that are not in the vaccine. ( 1.4 ) uuid:928af439-ad4f-40a8-8a96-1d83288f2d6d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2566414 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:f33e61c6-65a3-49e4-8e1e-e9e3a277b7ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eaad89ef-566d-4671-b48a-1a592dfebc2b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] In children 6 weeks through 5 years of age (prior to the 6 th birthday), Prevnar 13 is indicated for: active immunization for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F. ( 1.1 ) active immunization for the prevention of otitis media caused by S. pneumoniae serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F. No otitis media efficacy data are available for serotypes 1, 3, 5, 6A, 7F, and 19A. ( 1.1 ) In children 6 years through 17 years of age (prior to the 18 th birthday), Prevnar 13 is indicated for: active immunization for the prevention of invasive disease caused by S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F. ( 1.2 ) In adults 18 years of age and older, Prevnar 13 is indicated for: active immunization for the prevention of pneumonia and invasive disease caused by S. pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F. ( 1.3 ) Limitations of Prevnar 13 Use and Effectiveness Prevnar 13 does not protect against disease caused by S. pneumoniae serotypes that are not in the vaccine. ( 1.4 ) uuid:c6f4513e-b5ee-4c3f-8c22-fca42375882f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:11679580 biolink:treats UMLS:C0426732 PMID:41385096 "[{""id"":""uuid:133180a6-9390-4377-909a-91a209b283ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8969c23c-2f54-4872-adcd-dd4a89bca7cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dutasteride and tamsulosin hydrochloride capsules are a combination of dutasteride, a 5-alpha-reductase inhibitor, and tamsulosin, an alpha-adrenergic antagonist, indicated for the treatment of symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate. ( 1.1 ) Limitations of Use: Dutasteride-containing products, including dutasteride and tamsulosin hydrochloride capsules, are not approved for the prevention of prostate cancer. ( 1.2 ) uuid:ca0754b6-3daa-453a-b10b-edc892a085ad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3638 biolink:treats UMLS:C5554310 PMID:41385096 "[{""id"":""uuid:41b10067-3fa3-4b04-8c64-b4af72995b80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8c2793ff-fd16-4e02-b63e-8f1b0a56f1ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chloroquine phosphate tablets are indicated for the: Treatment of uncomplicated malaria due to susceptible strains of P. falciparum, P.malariae, P. ovale , and P.vivax. Prophylaxis of malaria in geographic areas where resistance to chloroquine is not present. Treatment of extraintestinal amebiasis. Chloroquine phosphate tablets do not prevent relapses in patients with vivax or ovale malaria because it is not effective against exoerythrocytic forms of the parasites. Limitations of Use in Malaria: Do not use chloroquine phosphate tablets for the treatment of complicated malaria (high-grade parasitemia and/or complications e.g., cerebral malaria or acute renal failure). Do not use chloroquine phosphate tablets for malaria prophylaxis in areas where chloroquine resistance occurs, Resistance to chloroquine phosphate tablets are widespread in P. falciparum, and is reported in P.vivax (see WARNINGS ). Concomitant therapy with an 8-aminoquinoline drug is necessary for treatment of the hypnozoite liver stage forms of P.vivax and P.ovale (see DOSAGE AND ADMINISTRATION ). uuid:a956ffd9-c70a-4352-a30a-8d5aea1cd366 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3638 biolink:treats MONDO:0005644 PMID:41385096 "[{""id"":""uuid:da2cfead-2c03-4fcd-9003-413db941856d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:03652011-5145-43ac-a932-d80f40423e6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chloroquine phosphate tablets are indicated for the: Treatment of uncomplicated malaria due to susceptible strains of P. falciparum, P.malariae, P. ovale , and P.vivax. Prophylaxis of malaria in geographic areas where resistance to chloroquine is not present. Treatment of extraintestinal amebiasis. Chloroquine phosphate tablets do not prevent relapses in patients with vivax or ovale malaria because it is not effective against exoerythrocytic forms of the parasites. Limitations of Use in Malaria: Do not use chloroquine phosphate tablets for the treatment of complicated malaria (high-grade parasitemia and/or complications e.g., cerebral malaria or acute renal failure). Do not use chloroquine phosphate tablets for malaria prophylaxis in areas where chloroquine resistance occurs, Resistance to chloroquine phosphate tablets are widespread in P. falciparum, and is reported in P.vivax (see WARNINGS ). Concomitant therapy with an 8-aminoquinoline drug is necessary for treatment of the hypnozoite liver stage forms of P.vivax and P.ovale (see DOSAGE AND ADMINISTRATION ). uuid:ab71bbf0-b2b2-4836-a66c-99ce62bb3c7b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3638 biolink:treats MONDO:0005921 PMID:41385096 "[{""id"":""uuid:7045ec09-2b9e-4c49-95df-0dd59316f656"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fbe15d63-5d7c-4b64-aa36-2457be5a3887"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chloroquine phosphate tablets are indicated for the: Treatment of uncomplicated malaria due to susceptible strains of P. falciparum, P.malariae, P. ovale , and P.vivax. Prophylaxis of malaria in geographic areas where resistance to chloroquine is not present. Treatment of extraintestinal amebiasis. Chloroquine phosphate tablets do not prevent relapses in patients with vivax or ovale malaria because it is not effective against exoerythrocytic forms of the parasites. Limitations of Use in Malaria: Do not use chloroquine phosphate tablets for the treatment of complicated malaria (high-grade parasitemia and/or complications e.g., cerebral malaria or acute renal failure). Do not use chloroquine phosphate tablets for malaria prophylaxis in areas where chloroquine resistance occurs, Resistance to chloroquine phosphate tablets are widespread in P. falciparum, and is reported in P.vivax (see WARNINGS ). Concomitant therapy with an 8-aminoquinoline drug is necessary for treatment of the hypnozoite liver stage forms of P.vivax and P.ovale (see DOSAGE AND ADMINISTRATION ). uuid:0c3a5b10-8c83-4380-a43b-838bde020d2c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3638 biolink:treats MONDO:0001601 PMID:41385096 "[{""id"":""uuid:2d4c724e-2160-47fe-b881-bd0b4420ec8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4072135e-95c2-4340-9441-8043e529114c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chloroquine phosphate tablets are indicated for the: Treatment of uncomplicated malaria due to susceptible strains of P. falciparum, P.malariae, P. ovale , and P.vivax. Prophylaxis of malaria in geographic areas where resistance to chloroquine is not present. Treatment of extraintestinal amebiasis. Chloroquine phosphate tablets do not prevent relapses in patients with vivax or ovale malaria because it is not effective against exoerythrocytic forms of the parasites. Limitations of Use in Malaria: Do not use chloroquine phosphate tablets for the treatment of complicated malaria (high-grade parasitemia and/or complications e.g., cerebral malaria or acute renal failure). Do not use chloroquine phosphate tablets for malaria prophylaxis in areas where chloroquine resistance occurs, Resistance to chloroquine phosphate tablets are widespread in P. falciparum, and is reported in P.vivax (see WARNINGS ). Concomitant therapy with an 8-aminoquinoline drug is necessary for treatment of the hypnozoite liver stage forms of P.vivax and P.ovale (see DOSAGE AND ADMINISTRATION ). uuid:0f237d8a-7869-4f76-8189-dbb5e5f81992 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3638 biolink:treats UMLS:C2747816 PMID:41385096 "[{""id"":""uuid:fda2371a-f0ea-4c3e-8716-4000f70e4645"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6541269b-607f-4c8e-8de5-b17f579d7506"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chloroquine phosphate tablets are indicated for the: Treatment of uncomplicated malaria due to susceptible strains of P. falciparum, P.malariae, P. ovale , and P.vivax. Prophylaxis of malaria in geographic areas where resistance to chloroquine is not present. Treatment of extraintestinal amebiasis. Chloroquine phosphate tablets do not prevent relapses in patients with vivax or ovale malaria because it is not effective against exoerythrocytic forms of the parasites. Limitations of Use in Malaria: Do not use chloroquine phosphate tablets for the treatment of complicated malaria (high-grade parasitemia and/or complications e.g., cerebral malaria or acute renal failure). Do not use chloroquine phosphate tablets for malaria prophylaxis in areas where chloroquine resistance occurs, Resistance to chloroquine phosphate tablets are widespread in P. falciparum, and is reported in P.vivax (see WARNINGS ). Concomitant therapy with an 8-aminoquinoline drug is necessary for treatment of the hypnozoite liver stage forms of P.vivax and P.ovale (see DOSAGE AND ADMINISTRATION ). uuid:c8bcda31-063d-4891-92ea-bdebeecc4b5f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3638 biolink:treats MONDO:0005625 PMID:41385096 "[{""id"":""uuid:75de62f9-5765-4eff-b71d-66c0902d4316"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:022c4392-7f28-4774-bb75-4c2fbe344b03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chloroquine phosphate tablets are indicated for the: Treatment of uncomplicated malaria due to susceptible strains of P. falciparum, P.malariae, P. ovale , and P.vivax. Prophylaxis of malaria in geographic areas where resistance to chloroquine is not present. Treatment of extraintestinal amebiasis. Chloroquine phosphate tablets do not prevent relapses in patients with vivax or ovale malaria because it is not effective against exoerythrocytic forms of the parasites. Limitations of Use in Malaria: Do not use chloroquine phosphate tablets for the treatment of complicated malaria (high-grade parasitemia and/or complications e.g., cerebral malaria or acute renal failure). Do not use chloroquine phosphate tablets for malaria prophylaxis in areas where chloroquine resistance occurs, Resistance to chloroquine phosphate tablets are widespread in P. falciparum, and is reported in P.vivax (see WARNINGS ). Concomitant therapy with an 8-aminoquinoline drug is necessary for treatment of the hypnozoite liver stage forms of P.vivax and P.ovale (see DOSAGE AND ADMINISTRATION ). uuid:715b6e4e-0f67-4245-ac89-d3a4517c1654 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3638 biolink:treats MONDO:0002492 PMID:41385096 "[{""id"":""uuid:4c00673c-fe79-4c00-909f-d37ce7c3f413"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a866c8d7-0006-4157-a91c-5077e814089c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chloroquine phosphate tablets are indicated for the: Treatment of uncomplicated malaria due to susceptible strains of P. falciparum, P.malariae, P. ovale , and P.vivax. Prophylaxis of malaria in geographic areas where resistance to chloroquine is not present. Treatment of extraintestinal amebiasis. Chloroquine phosphate tablets do not prevent relapses in patients with vivax or ovale malaria because it is not effective against exoerythrocytic forms of the parasites. Limitations of Use in Malaria: Do not use chloroquine phosphate tablets for the treatment of complicated malaria (high-grade parasitemia and/or complications e.g., cerebral malaria or acute renal failure). Do not use chloroquine phosphate tablets for malaria prophylaxis in areas where chloroquine resistance occurs, Resistance to chloroquine phosphate tablets are widespread in P. falciparum, and is reported in P.vivax (see WARNINGS ). Concomitant therapy with an 8-aminoquinoline drug is necessary for treatment of the hypnozoite liver stage forms of P.vivax and P.ovale (see DOSAGE AND ADMINISTRATION ). uuid:80ca1ef7-a60b-4a21-8f94-b62ad73a163c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:91820600 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:f70d30c3-8fa2-4002-bcbf-8a8122edb9a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8ad51ed3-77b5-4680-95a4-f752eb95b907"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Efavirenz, lamivudine and tenofovir disoproxil fumarate tablets are indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adult and pediatric patients weighing at least 40 kg. uuid:bb62bfbf-49bc-46c7-85c9-fe69ba10f1b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28241 biolink:treats MONDO:0004781 PMID:41385096 "[{""id"":""uuid:109db079-9dcd-4400-8acd-2d3ec6db8b1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:74273fef-20ca-4072-b7b6-b66eed43f4e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Papaverine is recommended in various conditions accompanied by spasm of smooth muscle, such as vascular spasm associated with acute myocardial infarction (coronary occlusion), angina pectoris, peripheral and pulmonary embolism, peripheral vascular disease in which there is a vasospastic element, or certain cerebral angiospastic states; and visceral spasm, as in ureteral, biliary, or gastrointestinal colic. uuid:96d60e60-2b2b-41cd-a2c4-b89895456c2f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28241 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:70960e1c-b5f3-45ad-9401-8e645b19c69c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c465b8c2-e797-4cbb-98c0-c6f1104b95a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Papaverine is recommended in various conditions accompanied by spasm of smooth muscle, such as vascular spasm associated with acute myocardial infarction (coronary occlusion), angina pectoris, peripheral and pulmonary embolism, peripheral vascular disease in which there is a vasospastic element, or certain cerebral angiospastic states; and visceral spasm, as in ureteral, biliary, or gastrointestinal colic. uuid:abf08b45-4c8b-4910-9571-52c1a17b0a43 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28241 biolink:treats UMLS:C0856049 PMID:41385096 "[{""id"":""uuid:4cca2d2d-b85e-44af-9d09-a464a582241c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4452bdee-dc0d-4345-bb2e-849bb7fc0bdc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Papaverine is recommended in various conditions accompanied by spasm of smooth muscle, such as vascular spasm associated with acute myocardial infarction (coronary occlusion), angina pectoris, peripheral and pulmonary embolism, peripheral vascular disease in which there is a vasospastic element, or certain cerebral angiospastic states; and visceral spasm, as in ureteral, biliary, or gastrointestinal colic. uuid:52656837-1f08-4cad-949b-192426f6dbf5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28241 biolink:treats MONDO:0005279 PMID:41385096 "[{""id"":""uuid:e482c474-83ed-4056-941e-7caf884642c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2814c1ba-472f-4211-8d86-654282a082c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Papaverine is recommended in various conditions accompanied by spasm of smooth muscle, such as vascular spasm associated with acute myocardial infarction (coronary occlusion), angina pectoris, peripheral and pulmonary embolism, peripheral vascular disease in which there is a vasospastic element, or certain cerebral angiospastic states; and visceral spasm, as in ureteral, biliary, or gastrointestinal colic. uuid:d16ad25e-55f2-48cd-b21e-b687bcc0ab71 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28241 biolink:treats MONDO:0005294 PMID:41385096 "[{""id"":""uuid:c108285b-4952-4918-8d70-4a12a8b6805c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0801b682-8f49-4852-bb52-9b196a039997"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Papaverine is recommended in various conditions accompanied by spasm of smooth muscle, such as vascular spasm associated with acute myocardial infarction (coronary occlusion), angina pectoris, peripheral and pulmonary embolism, peripheral vascular disease in which there is a vasospastic element, or certain cerebral angiospastic states; and visceral spasm, as in ureteral, biliary, or gastrointestinal colic. uuid:cd918bb4-48d5-4ff4-b19c-94a82bf24280 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28241 biolink:treats UMLS:C0265110 PMID:41385096 "[{""id"":""uuid:937fea2a-2bb1-4a68-a08e-dbb78064a6c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:895deb6e-cdff-4d10-ab7e-c62e978b6fec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Papaverine is recommended in various conditions accompanied by spasm of smooth muscle, such as vascular spasm associated with acute myocardial infarction (coronary occlusion), angina pectoris, peripheral and pulmonary embolism, peripheral vascular disease in which there is a vasospastic element, or certain cerebral angiospastic states; and visceral spasm, as in ureteral, biliary, or gastrointestinal colic. uuid:cf6b418d-dc59-4f2d-8dc5-0df1d707554f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28241 biolink:treats MONDO:0007009 PMID:41385096 "[{""id"":""uuid:85435f5d-0bf9-4ba3-b7fb-7e93153824fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1a42af73-661f-4499-8c4c-edb2fdab2ab7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Papaverine is recommended in various conditions accompanied by spasm of smooth muscle, such as vascular spasm associated with acute myocardial infarction (coronary occlusion), angina pectoris, peripheral and pulmonary embolism, peripheral vascular disease in which there is a vasospastic element, or certain cerebral angiospastic states; and visceral spasm, as in ureteral, biliary, or gastrointestinal colic. uuid:c596c5e8-ae2b-43c3-a297-f5219d0b3abc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28241 biolink:treats UMLS:C0151824 PMID:41385096 "[{""id"":""uuid:7eb30c57-2c15-4c03-be04-c6a304c7eb72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:65763db4-a8b1-4ef0-89e9-68d6d0d2a519"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Papaverine is recommended in various conditions accompanied by spasm of smooth muscle, such as vascular spasm associated with acute myocardial infarction (coronary occlusion), angina pectoris, peripheral and pulmonary embolism, peripheral vascular disease in which there is a vasospastic element, or certain cerebral angiospastic states; and visceral spasm, as in ureteral, biliary, or gastrointestinal colic. uuid:c994f4aa-46bc-4d92-b2d9-49be64736cb6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28241 biolink:treats HP:0011848 PMID:41385096 "[{""id"":""uuid:8ea2dfe1-a99c-4133-8b0f-3aab43506b69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ba1d0749-bad5-4c3f-aa1a-a17d4b7ab75a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Papaverine is recommended in various conditions accompanied by spasm of smooth muscle, such as vascular spasm associated with acute myocardial infarction (coronary occlusion), angina pectoris, peripheral and pulmonary embolism, peripheral vascular disease in which there is a vasospastic element, or certain cerebral angiospastic states; and visceral spasm, as in ureteral, biliary, or gastrointestinal colic. uuid:8492e8b9-f249-4016-9306-50dbce5c360c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:167574 biolink:treats MONDO:0004995 PMID:41385096 "[{""id"":""uuid:993f029f-7e02-4e57-9e15-21646ef181d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:afe904d8-81fe-4d76-9367-de0776b4ed25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OZEMPIC is indicated: • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. • to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease. Limitations of Use • OZEMPIC has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis [see Warnings and Precautions ( 5.2 )] . • OZEMPIC is not indicated for use in patients with type 1 diabetes mellitus. uuid:77d8db69-20e1-45d8-a6b3-261b314808e2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:167574 biolink:treats MONDO:0004982 PMID:41385096 "[{""id"":""uuid:0ff0e4de-2db3-4db4-87bd-1f8ce8738839"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:504257b2-245c-4bbf-845a-ed0a12bfce7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OZEMPIC is indicated: • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. • to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease. Limitations of Use • OZEMPIC has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis [see Warnings and Precautions ( 5.2 )] . • OZEMPIC is not indicated for use in patients with type 1 diabetes mellitus. uuid:9dc84733-03a7-465a-b2a4-31d3174a4505 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:404930 biolink:treats MONDO:0005545 PMID:41385096 "[{""id"":""uuid:507f6ca8-07a2-4bf0-aebc-0d55ce310a3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bc340680-5780-43eb-9ef0-37567800dfa4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension USP is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the specific conditions listed below: Acute Otitis Externa (AOE) in pediatric (age 6 months and older), adult and elderly patients due to Staphylococcus aureus and Pseudomonas aeruginosa . uuid:ffc6054d-ea2e-4d85-a57d-ccad55290bc0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:404930 biolink:treats UMLS:C0854135 PMID:41385096 "[{""id"":""uuid:eb8450f3-746c-4c58-bc7f-bcb654f8278a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7ad14dd4-d86e-4630-b8b8-3414fae24941"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension USP is indicated for the treatment of infections caused by susceptible isolates of the designated microorganisms in the specific conditions listed below: Acute Otitis Externa (AOE) in pediatric (age 6 months and older), adult and elderly patients due to Staphylococcus aureus and Pseudomonas aeruginosa . uuid:1ea2463e-8958-4c46-9a06-92404fd74106 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3082 biolink:treats MONDO:0100470 PMID:41385096 "[{""id"":""uuid:970fa748-7294-46ec-82ff-c751b92ff0b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:56b066a4-68e3-4288-a558-4d05989c8a49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Betaxolol Hydrochloride Ophthalmic Solution has been shown to be effective in lowering intraocular pressure and is indicated in the treatment of ocular hypertension and chronic open-angle glaucoma. It may be used alone or in combination with other anti-glaucoma drugs. In clinical studies, Betaxolol Hydrochloride Ophthalmic Solution was safely used to lower intraocular pressure in 47 patients with both glaucoma and reactive airway disease who were followed for a mean period of 15 months. However, caution should be used in treating patients with severe reactive airway disease or a history of asthma. uuid:954cb83c-0159-42d5-a7a6-64aa59ab0dc0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2682 biolink:treats MONDO:0016426 PMID:41385096 "[{""id"":""uuid:840daf65-b9ee-4ef1-91ab-ee1225e41369"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:020a97bb-e2fb-4039-b7bd-46d353173f85"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ABELCET ® is indicated for the treatment of invasive fungal infections in patients who are refractory to or intolerant of conventional amphotericin B therapy. This is based on open-label treatment of patients judged by their physicians to be intolerant to or failing conventional amphotericin B therapy (See DESCRIPTION OF CLINICAL STUDIES). DESCRIPTION OF CLINICAL STUDIES Fungal Infections Data from 473 patients were pooled from three open-label studies in which ABELCET ® was provided for the treatment of patients with invasive fungal infections who were judged by their physicians to be refractory to or intolerant of conventional amphotericin B, or who had preexisting nephrotoxicity. Results of these studies demonstrated effectiveness of ABELCET ® in the treatment of invasive fungal infections as a second line therapy. Patients were defined by their individual physician as being refractory to or failing conventional amphotericin B therapy based on overall clinical judgement after receiving a minimum total dose of 500 mg of amphotericin B. Nephrotoxicity was defined as a serum creatinine that had increased to >2.5 mg/dL in adults and >1.5 mg/dL in pediatric patients, or a creatinine clearance of <25 mL/min while receiving conventional amphotericin B therapy. Of the 473 patients, four were enrolled more than once; each enrollment contributed separately to the denominator. The median age was 39 years (range of <1 to 93 years); 307 patients were male and 166 female. Patients were Caucasian (381, 81%), African-American (41, 9%), Hispanic (27, 6%), Asian (10, 2%), and various other races (14, 3%). The median baseline neutrophil count was 4,000 PMN/mm3; of these, 101 (21%) had a baseline neutrophil count <500/mm 3 . Two-hundred eighty-two patients of the 473 patients were considered evaluable for response to therapy; the other 191 patients were excluded on the basis of unconfirmed diagnosis, confounding factors, concomitant systemic antifungal therapy, or receiving 4 doses or less of ABELCET ® . For evaluable patients, the following fungal infections were treated (n=282): aspergillosis (n=111), candidiasis (n=87), zygomycosis (n=25), cryptococcosis (n=16), and fusariosis (n=11). There were fewer than 10 evaluable patients for each of several other fungal species treated. For each type of fungal infection listed above there were some patients successfully treated. However, in the absence of controlled studies it is unknown how response would have compared to either continuing conventional amphotericin B therapy or the use of alternative antifungal agents. Renal Function: Patients with aspergillosis who initiated treatment with ABELCET ® when serum creatinine was above 2.5 mg/dL experienced a decline in serum creatinine during treatment (Figure 1). Serum creatinine levels were also lower during treatment with ABELCET ® when compared to the serum creatinine levels of patients treated with conventional amphotericin B in a retrospective historical control study. Meaningful statistical testing of the differences between these two groups is precluded since these data were obtained from two separate studies. [ ]= Number of patients at each time point. Note: These curves do not represent the clinical course of a given patient, but that of an open-label cohort of patients. [ ]= Number of patients at each time point. Note: These curves do not represent the clinical course of a given patient, but that of an open-label cohort of patients. In a randomized study of ABELCET ® for the treatment of invasive candidiasis in patients with normal baseline renal function, the incidence of nephrotoxicity was significantly less for ABELCET ® at a dose of 5 mg/kg/day than for conventional amphotericin B at a dose of 0.7 mg/kg/day. Despite generally less nephrotoxicity of ABELCET ® observed at a dose of 5 mg/kg/day compared with conventional amphotericin B therapy at a dose range of 0.6-1 mg/kg/day, dose-limiting renal toxicity may still be observed with ABELCET ® . Renal toxicity of doses greater than 5 mg/kg/day of ABELCET ® has not been formally studied. uuid:97e19737-15b3-4dfb-aa6f-8c67ea537f2b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2682 biolink:treats HP:0020101 PMID:41385096 "[{""id"":""uuid:c71df937-a81c-457d-8836-f16552522061"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2065e9bf-96bc-48b5-bc41-63c436e2edcb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ABELCET ® is indicated for the treatment of invasive fungal infections in patients who are refractory to or intolerant of conventional amphotericin B therapy. This is based on open-label treatment of patients judged by their physicians to be intolerant to or failing conventional amphotericin B therapy (See DESCRIPTION OF CLINICAL STUDIES). DESCRIPTION OF CLINICAL STUDIES Fungal Infections Data from 473 patients were pooled from three open-label studies in which ABELCET ® was provided for the treatment of patients with invasive fungal infections who were judged by their physicians to be refractory to or intolerant of conventional amphotericin B, or who had preexisting nephrotoxicity. Results of these studies demonstrated effectiveness of ABELCET ® in the treatment of invasive fungal infections as a second line therapy. Patients were defined by their individual physician as being refractory to or failing conventional amphotericin B therapy based on overall clinical judgement after receiving a minimum total dose of 500 mg of amphotericin B. Nephrotoxicity was defined as a serum creatinine that had increased to >2.5 mg/dL in adults and >1.5 mg/dL in pediatric patients, or a creatinine clearance of <25 mL/min while receiving conventional amphotericin B therapy. Of the 473 patients, four were enrolled more than once; each enrollment contributed separately to the denominator. The median age was 39 years (range of <1 to 93 years); 307 patients were male and 166 female. Patients were Caucasian (381, 81%), African-American (41, 9%), Hispanic (27, 6%), Asian (10, 2%), and various other races (14, 3%). The median baseline neutrophil count was 4,000 PMN/mm3; of these, 101 (21%) had a baseline neutrophil count <500/mm 3 . Two-hundred eighty-two patients of the 473 patients were considered evaluable for response to therapy; the other 191 patients were excluded on the basis of unconfirmed diagnosis, confounding factors, concomitant systemic antifungal therapy, or receiving 4 doses or less of ABELCET ® . For evaluable patients, the following fungal infections were treated (n=282): aspergillosis (n=111), candidiasis (n=87), zygomycosis (n=25), cryptococcosis (n=16), and fusariosis (n=11). There were fewer than 10 evaluable patients for each of several other fungal species treated. For each type of fungal infection listed above there were some patients successfully treated. However, in the absence of controlled studies it is unknown how response would have compared to either continuing conventional amphotericin B therapy or the use of alternative antifungal agents. Renal Function: Patients with aspergillosis who initiated treatment with ABELCET ® when serum creatinine was above 2.5 mg/dL experienced a decline in serum creatinine during treatment (Figure 1). Serum creatinine levels were also lower during treatment with ABELCET ® when compared to the serum creatinine levels of patients treated with conventional amphotericin B in a retrospective historical control study. Meaningful statistical testing of the differences between these two groups is precluded since these data were obtained from two separate studies. [ ]= Number of patients at each time point. Note: These curves do not represent the clinical course of a given patient, but that of an open-label cohort of patients. [ ]= Number of patients at each time point. Note: These curves do not represent the clinical course of a given patient, but that of an open-label cohort of patients. In a randomized study of ABELCET ® for the treatment of invasive candidiasis in patients with normal baseline renal function, the incidence of nephrotoxicity was significantly less for ABELCET ® at a dose of 5 mg/kg/day than for conventional amphotericin B at a dose of 0.7 mg/kg/day. Despite generally less nephrotoxicity of ABELCET ® observed at a dose of 5 mg/kg/day compared with conventional amphotericin B therapy at a dose range of 0.6-1 mg/kg/day, dose-limiting renal toxicity may still be observed with ABELCET ® . Renal toxicity of doses greater than 5 mg/kg/day of ABELCET ® has not been formally studied. uuid:fd2a1d0f-4813-42c4-9297-d9b08f274461 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27796 biolink:treats MONDO:0005942 PMID:41385096 "[{""id"":""uuid:d7f76da4-309d-4c43-94c0-2bc9687beaff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:57f951c6-4137-4a38-8c90-c3148b657689"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Trimethobenzamide hydrochloride capsules are indicated in adults for the treatment of postoperative nausea and vomiting and for nausea associated with gastroenteritis. Limitation of Use: Trimethobenzamide hydrochloride capsules are not recommended for use in pediatric patients due to the risk of extrapyramidal signs and symptoms and other serious central nervous system (CNS) effects, and the risk of exacerbation of the underlying disease in pediatric patients with Reye’s syndrome or other hepatic impairment. uuid:1410028f-7926-4d85-8ca9-5274a99bd6eb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1157355 biolink:treats MONDO:0005298 PMID:41385096 "[{""id"":""uuid:4ea66682-7fe8-4eec-a7a9-d3b246672454"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:907d5435-0577-4769-b8ac-5a62aac23d97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Norethindrone acetate and Ethinyl estradiol tablets are an estrogen plus progestin indicated in a woman with a uterus for: Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause ( 1.1 ) Prevention of Postmenopausal Osteoporosis ( 1.2 ) uuid:61a9a26a-4d98-42fb-a670-25f10c880b01 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71013 biolink:treats MONDO:0005027 PMID:41385096 "[{""id"":""uuid:30187d64-6d63-4351-a450-8e3b3d86d716"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2ae4ae74-7f4d-4b6a-8705-86c543152050"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f1683776-5be2-4f21-9c6d-1052fe2485bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FYCOMPA, a non-competitive AMPA glutamate receptor antagonist, is indicated for: Treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 4 years of age and older ( 1.1 ) Adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older ( 1.2 )|[PMDA] Drugs with a new active ingredient indicated for use as an adjunctive therapy with other antiepileptic drugs to treat partial seizures (including secondary generalized seizures) and tonic-clonic seizures in patients with epilepsy who have not responded sufficiently to other antiepileptic drugs. uuid:e6fdc4fa-af19-4237-9e10-7d957f4e62ea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71013 biolink:treats MONDO:0006710 PMID:41385096 "[{""id"":""uuid:9145caf9-4c19-4ae3-b04f-c44450338b9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1d5eb0d1-45d0-4a4f-a407-b69db7112580"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FYCOMPA, a non-competitive AMPA glutamate receptor antagonist, is indicated for: Treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 4 years of age and older ( 1.1 ) Adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older ( 1.2 ) uuid:76c812f4-f46d-4d1c-8fb7-03cf792560e4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71013 biolink:treats MONDO:0005754 PMID:41385096 "[{""id"":""uuid:233c8283-3c28-4891-9db3-44892ae42baf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6434ca1b-37f4-4851-bfc8-c1e642d85427"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:cc8e10f5-7744-4eba-8919-0483a5547de7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/fycompa""]},{""id"":""uuid:768af3cb-c087-4512-a79a-22772888640d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FYCOMPA, a non-competitive AMPA glutamate receptor antagonist, is indicated for: Treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy 4 years of age and older ( 1.1 ) Adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients with epilepsy 12 years of age and older ( 1.2 )|[EMA] Fycompa is indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in adult and adolescent patients from 12 years of age with epilepsy.Fycompa is indicated for the adjunctive treatment of primary generalised tonic-clonic seizures in adult and adolescent patients from 12 years of age with idiopathic generalised epilepsy.|[PMDA] Drugs with a new active ingredient indicated for use as an adjunctive therapy with other antiepileptic drugs to treat partial seizures (including secondary generalized seizures) and tonic-clonic seizures in patients with epilepsy who have not responded sufficiently to other antiepileptic drugs. uuid:739da954-012b-479a-9667-1e15f52a5871 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:70746 biolink:treats HP:0001907 PMID:41385096 "[{""id"":""uuid:0e4f8409-41b5-48f2-a11f-dd8f754a9f82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:62010b9e-bca2-419f-b014-9f1ebc37803e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRADAXA Oral Pellets are a direct thrombin inhibitor indicated: For the treatment of venous thromboembolic events (VTE) in pediatric patients aged 3 months to less than 12 years of age who have been treated with a parenteral anticoagulant for at least 5 days ( 1.1 ) To reduce the risk of recurrence of VTE in pediatric patients aged 3 months to less than 12 years of age who have been previously treated ( 1.2 ) uuid:15b5925e-0717-4440-949f-68b88ab4de57 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31941 biolink:treats UMLS:C0278480 PMID:41385096 "[{""id"":""uuid:f63b9e0c-0d61-48aa-8f8b-f11bdb3b520e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:176c7b2c-a8e7-46c2-a048-1bbe1facf860"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxaliplatin injection is a platinum-based drug used in combination with infusional fluorouracil/leucovorin, which is indicated for: adjuvant treatment of Stage III colon cancer in patients who have undergone complete resection of the primary tumor. ( 1 ) treatment of advanced colorectal cancer. ( 1 ) uuid:620a5a32-035d-45ec-b3a5-29d3d13b25a0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31941 biolink:treats EFO:1001480 PMID:41385096 "[{""id"":""uuid:3760f973-2337-4444-88af-becf666cd88e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ede9aa1d-234c-4bf6-b2ea-b06c0b1c9d02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxaliplatin injection is a platinum-based drug used in combination with infusional fluorouracil/leucovorin, which is indicated for: adjuvant treatment of Stage III colon cancer in patients who have undergone complete resection of the primary tumor. ( 1 ) treatment of advanced colorectal cancer. ( 1 ) uuid:75d178aa-6ba7-4605-8bfc-b573f5a0470b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:600520 biolink:treats MONDO:0044070 PMID:41385096 "[{""id"":""uuid:8de49a94-223e-44a6-a64e-1c3af0d8af59"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8d65fb1b-1c75-4bcf-b6f4-640e7ccac923"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Micafungin for Injection is indicated for: Treatment of Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses in adult and pediatric patients 4 months of age and older [see Clinical Studies (14.1) and Use in Specific Populations (8.4) ]. Treatment of Esophageal Candidiasis in adult and pediatric patients 4 months of age and older [see Clinical Studies (14.2) ]. Prophylaxis of Candida Infections in adult and pediatric patients 4 months of age and older undergoing hematopoietic stem cell transplantation [see Clinical Studies (14.3) ]. uuid:8c6cf054-fa60-4edc-a2e3-1ee1b9d74cc9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:600520 biolink:treats UMLS:C0343884 PMID:41385096 "[{""id"":""uuid:f922ece9-e3fe-44dd-8cd7-ccee13dfc229"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:33fab09c-5355-44da-b872-a5dd6e287372"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Micafungin for Injection is indicated for: Treatment of Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses in adult and pediatric patients 4 months of age and older [see Clinical Studies (14.1) and Use in Specific Populations (8.4) ]. Treatment of Esophageal Candidiasis in adult and pediatric patients 4 months of age and older [see Clinical Studies (14.2) ]. Prophylaxis of Candida Infections in adult and pediatric patients 4 months of age and older undergoing hematopoietic stem cell transplantation [see Clinical Studies (14.3) ]. uuid:12cbe437-9e13-4a60-94db-63166e07c244 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:600520 biolink:treats MONDO:0005227 PMID:41385096 "[{""id"":""uuid:2b0b4e61-b192-4f79-bb90-ce101cf59b7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6b41358c-b6a0-4ed5-9f79-97a539a99f17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Micafungin for Injection is indicated for: Treatment of Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses in adult and pediatric patients 4 months of age and older [see Clinical Studies (14.1) and Use in Specific Populations (8.4) ]. Treatment of Esophageal Candidiasis in adult and pediatric patients 4 months of age and older [see Clinical Studies (14.2) ]. Prophylaxis of Candida Infections in adult and pediatric patients 4 months of age and older undergoing hematopoietic stem cell transplantation [see Clinical Studies (14.3) ]. uuid:7749e2d5-3c0f-46f1-b2f0-e06696554826 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:600520 biolink:treats MONDO:0001648 PMID:41385096 "[{""id"":""uuid:a22d0d2f-b1ad-4116-9860-609eb340e474"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0e17e262-2da0-4c44-9fba-3c4c57ecc725"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:74871770-82c3-4e97-a9d5-ff822de0999e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/mycamine""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Micafungin for Injection is indicated for: Treatment of Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses in adult and pediatric patients 4 months of age and older [see Clinical Studies (14.1) and Use in Specific Populations (8.4) ]. Treatment of Esophageal Candidiasis in adult and pediatric patients 4 months of age and older [see Clinical Studies (14.2) ]. Prophylaxis of Candida Infections in adult and pediatric patients 4 months of age and older undergoing hematopoietic stem cell transplantation [see Clinical Studies (14.3) ].|[EMA] Mycamine is indicated for:Adults, adolescents ≥ 16 years of age and elderlytreatment of invasive candidiasis;treatment of oesophageal candidiasis in patients for whom intravenous therapy is appropriate;prophylaxis of Candida infection in patients undergoing allogeneic haematopoietic stem-cell transplantation or patients who are expected to have neutropenia (absolute neutrophil count < 500 cells/µl) for 10 or more days.Children (including neonates) and adolescents < 16 years of agetreatment of invasive candidiasis.prophylaxis of Candida infection in patients undergoing allogeneic haematopoietic stem-cell transplantation or patients who are expected to have neutropenia (absolute neutrophil count < 500 cells/µl) for 10 or more days.The decision to use Mycamine should take into account a potential risk for the development of liver tumours. Mycamine should therefore only be used if other antifungals are not appropriate. uuid:a04217df-82bb-445f-9701-5c92ea6dbddb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:600520 biolink:treats MONDO:0002026 PMID:41385096 "[{""id"":""uuid:b5aa082d-27bb-43c4-83da-ac71910af7f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a23b2323-6caa-4071-ac60-2c78bc43fc36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:5201b6d5-ae9d-4eaf-8d3d-2456d491fc12"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/mycamine""]},{""id"":""uuid:d6c848da-5da1-44ff-bcff-d0e50beff872"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Micafungin for Injection is indicated for: Treatment of Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses in adult and pediatric patients 4 months of age and older [see Clinical Studies (14.1) and Use in Specific Populations (8.4) ]. Treatment of Esophageal Candidiasis in adult and pediatric patients 4 months of age and older [see Clinical Studies (14.2) ]. Prophylaxis of Candida Infections in adult and pediatric patients 4 months of age and older undergoing hematopoietic stem cell transplantation [see Clinical Studies (14.3) ].|[EMA] Mycamine is indicated for:Adults, adolescents ≥ 16 years of age and elderlytreatment of invasive candidiasis;treatment of oesophageal candidiasis in patients for whom intravenous therapy is appropriate;prophylaxis of Candida infection in patients undergoing allogeneic haematopoietic stem-cell transplantation or patients who are expected to have neutropenia (absolute neutrophil count < 500 cells/µl) for 10 or more days.Children (including neonates) and adolescents < 16 years of agetreatment of invasive candidiasis.prophylaxis of Candida infection in patients undergoing allogeneic haematopoietic stem-cell transplantation or patients who are expected to have neutropenia (absolute neutrophil count < 500 cells/µl) for 10 or more days.The decision to use Mycamine should take into account a potential risk for the development of liver tumours. Mycamine should therefore only be used if other antifungals are not appropriate.|[PMDA] Drugs with a new indication and dosage for prophylaxis of aspergillosis and candidiasis in hematopoietic stem cell transplant patients. uuid:f20fc052-4000-4cd8-82d2-99d86808d434 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:142406 biolink:treats HP:0012532 PMID:41385096 "[{""id"":""uuid:be666cdf-431c-430d-b4c2-28d7c1eb823d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:89685806-6e96-4abb-99a7-e7e692c8b7be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRIALT (ziconotide) solution, intrathecal infusion is indicated for the management of severe chronic pain in adult patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies, or intrathecal morphine. uuid:e649f722-2885-4fac-a2b8-8b3488f18cbb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135939 biolink:treats MONDO:0005754 PMID:41385096 "[{""id"":""uuid:7ef2341d-e3de-4edb-98b0-7ef378f204c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:72efc6a4-2909-4572-b51f-eac601d1e02d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ffe30477-ef92-4a3f-8010-ef43b2c132b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vimpat""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lacosamide tablets are indicated for: • Treatment of partial-onset seizures in patients 4 years of age and older (1.1) • Adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older (1.2)|[EMA] Lacosamide Adroiq is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy.Lacosamide Adroiq is indicated as adjunctive therapyin the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy.in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy. uuid:89ad6bab-8ee1-4fc1-a360-4aa6cf9d2b40 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:87016 biolink:treats MONDO:0006710 PMID:41385096 "[{""id"":""uuid:29d67ab9-a4d2-4db8-b4b1-b80086ead591"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:767eaede-d079-43ab-8a32-bd70991bec23"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] APTIOM is indicated for the treatment of partial-onset seizures in patients 4 years of age and older. uuid:9d2c389f-ccf2-42b1-b1bd-2ce5fa4fc902 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71229 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:4cdc77b4-98a4-4701-b81e-b5d8cc55cfc1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:64a47838-3515-42e4-b11d-fd58aa3ce62e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VIBATIV is a lipoglycopeptide antibacterial drug indicated for the treatment of the following infections in adult patients caused by designated susceptible bacteria: Complicated skin and skin structure infections (cSSSI) ( 1.1 ) Hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Staphylococcus aureus . VIBATIV should be reserved for use when alternative treatments are not suitable. ( 1.2 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of VIBATIV and other antibacterial drugs VIBATIV should only be used to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. uuid:90af409f-335c-4ac0-bf4d-73039d06cdc3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71229 biolink:treats MONDO:0004652 PMID:41385096 "[{""id"":""uuid:a51bb80f-2d4c-48ab-94ec-d1ca60755039"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4c1b9860-957f-4e99-a043-98d094689f83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VIBATIV is a lipoglycopeptide antibacterial drug indicated for the treatment of the following infections in adult patients caused by designated susceptible bacteria: Complicated skin and skin structure infections (cSSSI) ( 1.1 ) Hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP) caused by susceptible isolates of Staphylococcus aureus . VIBATIV should be reserved for use when alternative treatments are not suitable. ( 1.2 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of VIBATIV and other antibacterial drugs VIBATIV should only be used to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. uuid:05fa7c48-595d-4064-bd57-448759351df9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1552339 biolink:treats HP:0002018 PMID:41385096 "[{""id"":""uuid:e42049fa-7eb7-44df-9d97-b6cfcb02e7ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8b774e48-cbe4-46eb-a9ac-b41a5cc2d089"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AKYNZEO capsules is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. AKYNZEO capsules is a combination of palonosetron and netupitant: palonosetron prevents nausea and vomiting during the acute phase and netupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy. AKYNZEO for injection and AKYNZEO injection are indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. AKYNZEO for injection is a combination of palonosetron and fosnetupitant, a prodrug of netupitant: palonosetron prevents nausea and vomiting during the acute phase and fosnetupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy. Limitations of Use AKYNZEO for injection and AKYNZEO injection have not been studied for the prevention of nausea and vomiting associated with anthracycline plus cyclophosphamide chemotherapy. uuid:5ffdf639-34a0-4d4a-bd9d-098792dcf1d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1552339 biolink:treats HP:0002013 PMID:41385096 "[{""id"":""uuid:8e489db0-32c4-4c44-94d3-7f1009868a3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b9c34d35-d4d4-43e4-9041-0c8f0b530479"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AKYNZEO capsules is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. AKYNZEO capsules is a combination of palonosetron and netupitant: palonosetron prevents nausea and vomiting during the acute phase and netupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy. AKYNZEO for injection and AKYNZEO injection are indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. AKYNZEO for injection is a combination of palonosetron and fosnetupitant, a prodrug of netupitant: palonosetron prevents nausea and vomiting during the acute phase and fosnetupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy. Limitations of Use AKYNZEO for injection and AKYNZEO injection have not been studied for the prevention of nausea and vomiting associated with anthracycline plus cyclophosphamide chemotherapy. uuid:e9abc8ac-00b9-4e08-9b5f-38e1f646551e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7507 biolink:treats MONDO:0001548 PMID:41385096 "[{""id"":""uuid:63f5d698-0220-44f0-a818-70332239091d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c85a2713-1d00-4609-8e4c-97ad36372975"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of neomycin sulfate tablets and other antibacterial drugs, neomycin sulfate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Suppression of Intestinal Bacteria Neomycin sulfate tablets are indicated as adjunctive therapy as part of a regimen for the suppression of the normal bacterial flora of the bowel, e.g., preoperative preparation of the bowel. It is given concomitantly with erythromycin enteric-coated base (see DOSAGE AND ADMINISTRATION ). Hepatic Coma (Portal-Systemic Encephalopathy) Neomycin sulfate has been shown to be effective adjunctive therapy in hepatic coma by reduction of the ammonia-forming bacteria in the intestinal tract. The subsequent reduction in blood ammonia has resulted in neurologic improvement. uuid:c9749b03-2550-4dcb-9a75-7e1bb4cae35f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7507 biolink:treats MONDO:0001711 PMID:41385096 "[{""id"":""uuid:61aed7ac-8e51-4fe0-9165-15a7b17dc84a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:86a817b7-3a9e-4930-8a25-99ec2d209884"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of neomycin sulfate tablets and other antibacterial drugs, neomycin sulfate tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Suppression of Intestinal Bacteria Neomycin sulfate tablets are indicated as adjunctive therapy as part of a regimen for the suppression of the normal bacterial flora of the bowel, e.g., preoperative preparation of the bowel. It is given concomitantly with erythromycin enteric-coated base (see DOSAGE AND ADMINISTRATION ). Hepatic Coma (Portal-Systemic Encephalopathy) Neomycin sulfate has been shown to be effective adjunctive therapy in hepatic coma by reduction of the ammonia-forming bacteria in the intestinal tract. The subsequent reduction in blood ammonia has resulted in neurologic improvement. uuid:263b2bea-c41a-4598-a6fa-edb78f515acc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6427 biolink:treats MONDO:0019165 PMID:41385096 "[{""id"":""uuid:81fb458d-8e53-4f03-8025-1ddfb62b5753"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c094e909-a419-466a-9851-5d5af9eec92b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FENSOLVI is indicated for the treatment of pediatric patients 2 years of age and older with central precocious puberty (CPP). uuid:a45d5599-3abe-4ac4-a574-6251ed8d05cc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7627 biolink:treats HP:0000869 PMID:41385096 "[{""id"":""uuid:b4451790-bae9-442f-94be-d2affa4dbe9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:83916cf1-5fd2-4bb6-b6f1-a50ef7d819d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Norethindrone acetate tablets are indicated for the treatment of secondary amenorrhea, endometriosis, and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer. Norethindrone acetate tablets are not intended, recommended or approved to be used with concomitant estrogen therapy in postmenopausal women for endometrial protection. uuid:73ece744-489b-43dd-a525-1c29af0deba1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7627 biolink:treats MONDO:0005133 PMID:41385096 "[{""id"":""uuid:a8053c65-88b5-4c10-b5a9-53797d30101c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f343af9c-67f5-420d-b646-704ddc3265d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Norethindrone acetate tablets are indicated for the treatment of secondary amenorrhea, endometriosis, and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer. Norethindrone acetate tablets are not intended, recommended or approved to be used with concomitant estrogen therapy in postmenopausal women for endometrial protection. uuid:178606bb-03b8-4317-ab7b-682aea7a8586 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7627 biolink:treats UMLS:C3650625 PMID:41385096 "[{""id"":""uuid:bf463f22-c1d2-4ff5-a32e-2b8ba4bf4ff9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:521ff475-9834-4eee-aa66-c5f3c8769cc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Norethindrone acetate tablets are indicated for the treatment of secondary amenorrhea, endometriosis, and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer. Norethindrone acetate tablets are not intended, recommended or approved to be used with concomitant estrogen therapy in postmenopausal women for endometrial protection. uuid:1b47d7e9-a045-4f37-ab5c-36154265b667 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7627 biolink:treats MONDO:0002715 PMID:41385096 "[{""id"":""uuid:9236d081-5bd8-4977-b485-e6e0de78d9d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dcb991b2-cd32-41c4-87a9-56978a51a0d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Norethindrone acetate tablets are indicated for the treatment of secondary amenorrhea, endometriosis, and abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology, such as submucous fibroids or uterine cancer. Norethindrone acetate tablets are not intended, recommended or approved to be used with concomitant estrogen therapy in postmenopausal women for endometrial protection. uuid:a2b6b50c-ddc5-460e-9cf0-bde3a1b661f1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29034 biolink:treats UMLS:C0240066 PMID:41385096 "[{""id"":""uuid:2ac45918-abdb-4028-8a05-4272c7b86a7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:807a2017-78bb-4552-81b9-596e77ab1692"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ACCRUFER is indicated for the treatment of iron deficiency in adults. uuid:5bf5e807-44a3-462f-9daf-14a368e9ddc4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2205092 biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:b6c645f5-c0fc-4dff-82f2-8d16ff39dda8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:cc375900-812e-438a-8fb4-8742bb8dc708"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:5f7c3ef5-ade2-4239-9d4c-c53de50eb017"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/brimica-genuair""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] DUAKLIR PRESSAIR is a combination of aclidinium bromide (an anticholinergic) and formoterol fumarate (a LABA) indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Limitations of Use: DUAKLIR PRESSAIR is not indicated for the relief of acute bronchospasm or for the treatment of asthma [see Warnings and Precautions ( 5.1 , 5.4 )] .|[EMA] Brimica Genuair is indicated as a maintenance bronchodilator treatment for airflow obstruction and relief of symptoms in adult patients with chronic obstructive pulmonary disease (COPD). uuid:8fc7b464-378d-4840-8bc0-2ce2f0cf8d57 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2205092 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:03dbde1c-f905-4469-b96c-6371ec459b14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ef553511-c9ed-4167-a4f9-97c18d7a85d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DUAKLIR PRESSAIR is a combination of aclidinium bromide (an anticholinergic) and formoterol fumarate (a LABA) indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Limitations of Use: DUAKLIR PRESSAIR is not indicated for the relief of acute bronchospasm or for the treatment of asthma [see Warnings and Precautions ( 5.1 , 5.4 )] . uuid:9d3ad96d-3ab5-4b42-9678-33af8c94bc4e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1040052 biolink:treats HP:0002193 PMID:41385096 "[{""id"":""uuid:877ed086-071f-4e06-a5f1-85c7df76ed13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:820ea53a-7e53-4a6b-89c7-c97209e99084"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NUEDEXTA is indicated for the treatment of pseudobulbar affect (PBA). PBA occurs secondary to a variety of otherwise unrelated neurologic conditions, and is characterized by involuntary, sudden, and frequent episodes of laughing and/or crying. PBA episodes typically occur out of proportion or incongruent to the underlying emotional state. PBA is a specific condition, distinct from other types of emotional lability that may occur in patients with neurological disease or injury. uuid:c404f329-9019-4be1-8183-bce6ab75a41e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:65346 biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:438351f4-b11b-4340-956f-5c12da96440d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:08a9f777-c0a5-4420-98cb-1d4258104567"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:dff58ab8-48b7-4e45-b14d-66fb927ff272"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/eklira-genuair""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] TUDORZA® PRESSAIR® (aclidinium bromide inhalation powder) is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).|[EMA] Eklira Genuair is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). uuid:1bee1d32-31f9-4435-9454-1bd45fc84a1c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:65346 biolink:treats MONDO:0011751 PMID:41385096 "[{""id"":""uuid:3dd0f9f1-9f7a-4f13-9ce2-47ae0dea59a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4be6ae80-8901-4b76-842c-1ffadec026dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TUDORZA® PRESSAIR® (aclidinium bromide inhalation powder) is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). uuid:2b95454a-7c6d-4577-9cd5-64cdeae96970 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:30769 biolink:treats MONDO:0000440 PMID:41385096 "[{""id"":""uuid:fae731c6-9930-4282-9af7-ae123041444b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:37db4c2e-56a5-4947-ba17-48bfe01ced38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ORACIT ® is indicated for the treatment of metabolic acidosis. This solution is also useful in conditions where long term maintenance of alkaline urine is needed (e.g. uric acid and cystine calculi of the urinary tract). ORACIT ® is also effective in treatment for acidosis of certain renal tubular disorders. uuid:2067a705-cf60-4368-bcf4-d487fc25eca1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PVI5M0M1GW biolink:treats UMLS:C0746883 PMID:41385096 "[{""id"":""uuid:bc5cc49c-7182-49ea-8b61-a77cd1501666"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2597aaca-4a22-4234-8e34-79471e872387"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] GRANIX is indicated to reduce the duration of severe neutropenia in adult and pediatric patients 1 month and older with non-myeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia. uuid:88c14c46-4ad8-444e-af82-82d4ba2a1a99 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2671296 biolink:treats MONDO:0002040 PMID:41385096 "[{""id"":""uuid:b9e518ae-febd-47e0-b7a2-f1f0946eb493"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2beb0c73-17cd-4eae-b2e5-e3680d730a55"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mycozyl HC ™ is indicated for treatment of fungal infection of the skin, skin around the nail, and for the relief of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. uuid:c7fcc919-28f9-4cec-90b8-d1517f639f6b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:1B56C968OA biolink:treats MONDO:0004601 PMID:41385096 "[{""id"":""uuid:39d9fffe-2e85-40af-9552-3b49a315cabc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6d073260-1fd7-4a89-853e-4db3dbf8824b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] REGRANEX is indicated for the treatment of lower extremity diabetic neuropathic ulcers that extend into the subcutaneous tissue or beyond and have an adequate blood supply, when used as an adjunct to, and not a substitute for, good ulcer care practices including initial sharp debridement, pressure relief and infection control. Limitations of Use : The efficacy of REGRANEX has not been established for the treatment of pressure ulcers and venous stasis ulcers [ see Clinical Studies (14.2) ] and has not been evaluated for the treatment of diabetic neuropathic ulcers that do not extend through the dermis into subcutaneous tissue [Stage I or II, International Association of Enterostomal Therapy (IAET) staging classification] or ischemic diabetic ulcers. The effects of becaplermin on exposed joints, tendons, ligaments, and bone have not been established in humans [ see Nonclinical Toxicology (13.2) ] . REGRANEX is not intended to be used in wounds that close by primary intention. uuid:91596c04-c262-41c9-b31e-06446bac2efb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:1B56C968OA biolink:treats MONDO:0004646 PMID:41385096 "[{""id"":""uuid:61077e5d-89d6-4d8c-adc1-6350a8d5eaaa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:14605c0a-fa84-420d-9403-62609002816d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] REGRANEX is indicated for the treatment of lower extremity diabetic neuropathic ulcers that extend into the subcutaneous tissue or beyond and have an adequate blood supply, when used as an adjunct to, and not a substitute for, good ulcer care practices including initial sharp debridement, pressure relief and infection control. Limitations of Use : The efficacy of REGRANEX has not been established for the treatment of pressure ulcers and venous stasis ulcers [ see Clinical Studies (14.2) ] and has not been evaluated for the treatment of diabetic neuropathic ulcers that do not extend through the dermis into subcutaneous tissue [Stage I or II, International Association of Enterostomal Therapy (IAET) staging classification] or ischemic diabetic ulcers. The effects of becaplermin on exposed joints, tendons, ligaments, and bone have not been established in humans [ see Nonclinical Toxicology (13.2) ] . REGRANEX is not intended to be used in wounds that close by primary intention. uuid:d9e477ae-6c7a-4f50-8813-30d99355d4c8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:1B56C968OA biolink:treats UMLS:C0042344 PMID:41385096 "[{""id"":""uuid:4d3d81c0-01a8-4e86-86a1-c59080a9967d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eff2e281-a10a-49de-b5ab-9e7a9c206356"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] REGRANEX is indicated for the treatment of lower extremity diabetic neuropathic ulcers that extend into the subcutaneous tissue or beyond and have an adequate blood supply, when used as an adjunct to, and not a substitute for, good ulcer care practices including initial sharp debridement, pressure relief and infection control. Limitations of Use : The efficacy of REGRANEX has not been established for the treatment of pressure ulcers and venous stasis ulcers [ see Clinical Studies (14.2) ] and has not been evaluated for the treatment of diabetic neuropathic ulcers that do not extend through the dermis into subcutaneous tissue [Stage I or II, International Association of Enterostomal Therapy (IAET) staging classification] or ischemic diabetic ulcers. The effects of becaplermin on exposed joints, tendons, ligaments, and bone have not been established in humans [ see Nonclinical Toxicology (13.2) ] . REGRANEX is not intended to be used in wounds that close by primary intention. uuid:faf590f9-bb37-42bf-afaa-52b945177bb0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85078 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:93bc5596-5747-4f82-8be9-e6e1b98e4bb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:20727d05-38cb-4615-be3c-96f3ef3b6371"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:cb04038d-5090-47e9-972a-79e4ce397d20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:81fa33e3-2fb5-460b-b06d-56d4b361cc54"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FARXIGA (dapagliflozin) is indicated: • To reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression. • To reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure. • To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk factors. • As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use • FARXIGA is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus [see Warnings and Precautions (5.1) ] . • FARXIGA is not recommended for use to improve glycemic control in adults with type 2 diabetes mellitus with an eGFR less than 45 mL/min/1.73 m 2 . FARXIGA is likely to be ineffective in this setting based upon its mechanism of action. • FARXIGA is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of immunosuppressive therapy for kidney disease. FARXIGA is not expected to be effective in these populations.|[EMA] Type 2 diabetes mellitusForxiga is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance.in addition to other medicinal products for the treatment of type 2 diabetes.For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4.4, 4.5 and 5.1.Heart failureForxiga is indicated in adults for the treatment of symptomatic chronic heart failure.Chronic kidney diseaseForxiga is indicated in adults for the treatment of chronic kidney disease.|[PMDA] Drugs with a new indication for the treatment of chronic kidney disease. [Priority review] uuid:15d15205-05dc-4b34-b64c-ea8aa080a973 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85078 biolink:treats MONDO:0004375 PMID:41385096 "[{""id"":""uuid:94f73366-9b67-4569-84b0-7c740f15b85f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6685bf3a-0dd9-491a-9ec1-8ed124ba07d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FARXIGA (dapagliflozin) is indicated: • To reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression. • To reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure. • To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk factors. • As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use • FARXIGA is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus [see Warnings and Precautions (5.1) ] . • FARXIGA is not recommended for use to improve glycemic control in adults with type 2 diabetes mellitus with an eGFR less than 45 mL/min/1.73 m 2 . FARXIGA is likely to be ineffective in this setting based upon its mechanism of action. • FARXIGA is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of immunosuppressive therapy for kidney disease. FARXIGA is not expected to be effective in these populations. uuid:b6c9b486-15fd-47c5-a29e-9a9aad7bb8e1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85078 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:1b4b46be-59cc-497c-a348-6373029d08af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:08787c4c-f78e-4daa-a8dd-9db47aa61cbc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:bff9d540-b288-476b-b43c-f9240bc2d4a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FARXIGA (dapagliflozin) is indicated: • To reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression. • To reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure. • To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk factors. • As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use • FARXIGA is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus [see Warnings and Precautions (5.1) ] . • FARXIGA is not recommended for use to improve glycemic control in adults with type 2 diabetes mellitus with an eGFR less than 45 mL/min/1.73 m 2 . FARXIGA is likely to be ineffective in this setting based upon its mechanism of action. • FARXIGA is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of immunosuppressive therapy for kidney disease. FARXIGA is not expected to be effective in these populations.|[EMA] Type 2 diabetes mellitusForxiga is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance.in addition to other medicinal products for the treatment of type 2 diabetes.For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4.4, 4.5 and 5.1.Heart failureForxiga is indicated in adults for the treatment of symptomatic chronic heart failure.Chronic kidney diseaseForxiga is indicated in adults for the treatment of chronic kidney disease. uuid:94db2f3b-49d5-48fc-90b2-24315f59e021 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85078 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:bcc590f4-5d29-4df7-a8e7-a913eea1c18d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:98f101fc-e9a2-4ccc-bac9-21e1e255ee0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:62037de9-7abd-436b-bbc5-7b0ac4ee0a5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:077d3294-2739-43c6-bdee-a9b10026e90b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FARXIGA (dapagliflozin) is indicated: • To reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression. • To reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure. • To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk factors. • As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use • FARXIGA is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus [see Warnings and Precautions (5.1) ] . • FARXIGA is not recommended for use to improve glycemic control in adults with type 2 diabetes mellitus with an eGFR less than 45 mL/min/1.73 m 2 . FARXIGA is likely to be ineffective in this setting based upon its mechanism of action. • FARXIGA is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of immunosuppressive therapy for kidney disease. FARXIGA is not expected to be effective in these populations.|[EMA] Type 2 diabetes mellitusForxiga is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance.in addition to other medicinal products for the treatment of type 2 diabetes.For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4.4, 4.5 and 5.1.Heart failureForxiga is indicated in adults for the treatment of symptomatic chronic heart failure.Chronic kidney diseaseForxiga is indicated in adults for the treatment of chronic kidney disease.|[PMDA] Drugs with a new active ingredient indicated for the treatment of type 2 diabetes mellitus. uuid:3c022010-5972-41a9-ba48-2ee773c61759 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85078 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:f995050b-5227-4bf5-8faf-ebd373918b63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:06c4dd1a-6dcc-44f3-bd8b-a52e671f4d1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2c4dc135-a57b-4144-8e38-40973b1f7e1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FARXIGA (dapagliflozin) is indicated: • To reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression. • To reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure. • To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk factors. • As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use • FARXIGA is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus [see Warnings and Precautions (5.1) ] . • FARXIGA is not recommended for use to improve glycemic control in adults with type 2 diabetes mellitus with an eGFR less than 45 mL/min/1.73 m 2 . FARXIGA is likely to be ineffective in this setting based upon its mechanism of action. • FARXIGA is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of immunosuppressive therapy for kidney disease. FARXIGA is not expected to be effective in these populations.|[PMDA] Drugs with a new additional indication and a new dosage for the treatment of type 1 diabetes mellitus. uuid:85d947f8-00b7-4cbb-886a-14c77cc04781 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85078 biolink:treats MONDO:0020642 PMID:41385096 "[{""id"":""uuid:4afcb4ec-749b-4a4d-8f5a-1561f002cdbf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:26c1a20d-5180-478f-a134-77aaeec31b4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FARXIGA (dapagliflozin) is indicated: • To reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with chronic kidney disease at risk of progression. • To reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure. • To reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk factors. • As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use • FARXIGA is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus [see Warnings and Precautions (5.1) ] . • FARXIGA is not recommended for use to improve glycemic control in adults with type 2 diabetes mellitus with an eGFR less than 45 mL/min/1.73 m 2 . FARXIGA is likely to be ineffective in this setting based upon its mechanism of action. • FARXIGA is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of immunosuppressive therapy for kidney disease. FARXIGA is not expected to be effective in these populations. uuid:0292fb4d-6e74-4ae5-b091-5c0050c7cf08 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50305 biolink:treats UMLS:C0343730 PMID:41385096 "[{""id"":""uuid:52fdad17-c415-4ad6-a69c-8c10d6fe33d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a3cdbbff-7ea5-4a03-8181-f0cd8a91d47a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Podofilox gel is indicated for the topical treatment of anogenital warts (external genital warts and perianal warts). This product is not indicated in the treatment of mucous membrane warts (see PRECAUTIONS ). Diagnosis Although anogenital warts have a characteristic appearance, histopathologic confirmation should be obtained if there is any doubt of the diagnosis. Differentiating warts from squamous cell carcinoma and ""Bowenoid papulosis"" is of particular concern. Squamous cell carcinoma may also be associated with human papillomavirus which should not be treated with podofilox gel." uuid:14c3bea0-941f-409b-8797-8407646bb08c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50305 biolink:treats MONDO:0005096 PMID:41385096 "[{""id"":""uuid:422e9e9b-e4f5-4550-85dd-426e1fe0f1cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:35952d46-4393-47c9-833b-e1f00a0a61b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Podofilox gel is indicated for the topical treatment of anogenital warts (external genital warts and perianal warts). This product is not indicated in the treatment of mucous membrane warts (see PRECAUTIONS ). Diagnosis Although anogenital warts have a characteristic appearance, histopathologic confirmation should be obtained if there is any doubt of the diagnosis. Differentiating warts from squamous cell carcinoma and ""Bowenoid papulosis"" is of particular concern. Squamous cell carcinoma may also be associated with human papillomavirus which should not be treated with podofilox gel." uuid:fb8c0a8b-5a9c-4baf-92c7-643abddcd9d9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50305 biolink:treats MONDO:0022022 PMID:41385096 "[{""id"":""uuid:b2d89c4e-7759-4067-91f0-54301782053e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6923aa19-7cb2-4876-9f0b-b44d9b393b0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Podofilox gel is indicated for the topical treatment of anogenital warts (external genital warts and perianal warts). This product is not indicated in the treatment of mucous membrane warts (see PRECAUTIONS ). Diagnosis Although anogenital warts have a characteristic appearance, histopathologic confirmation should be obtained if there is any doubt of the diagnosis. Differentiating warts from squamous cell carcinoma and ""Bowenoid papulosis"" is of particular concern. Squamous cell carcinoma may also be associated with human papillomavirus which should not be treated with podofilox gel." uuid:0661e2c6-6525-4e6b-aa23-8781ca94f6e5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1155433 biolink:treats MONDO:0005578 PMID:41385096 "[{""id"":""uuid:1ed96269-3b2b-403a-8a9b-04168844ad68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ef36fe99-0e4c-4478-8a66-b845b966783e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Trubrexa TM Transdermal Patch is indicated in adults over the age of 12 years old for the treatment of acute and chronic pain in muscles and joints associated with muscle soreness, strains, sprains, arthritis, simple backache, muscle stiffness, and more. uuid:7b0ca226-3499-4997-b434-ef08efedf539 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4682 biolink:treats HP:0002018 PMID:41385096 "[{""id"":""uuid:afa27925-e960-40fe-ae84-297525480930"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f8634277-88c3-47ef-a026-01aa2e454465"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ANZEMET Tablets are indicated for the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy, including initial and repeat courses in adults and children 2 years and older. uuid:1ca42056-0038-462e-ac2a-da3f32f5ace4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4682 biolink:treats HP:0002013 PMID:41385096 "[{""id"":""uuid:be0e58b2-45fe-4485-a10d-1f06be34a828"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:467b1d5c-c694-4ddc-ab90-e5081e13fd58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ANZEMET Tablets are indicated for the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy, including initial and repeat courses in adults and children 2 years and older. uuid:2f608962-88fa-48c7-81d1-5dcd9ea378ef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:848151 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:f4227c89-c98f-4056-984e-f425969334b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ed61c838-ec48-49b2-a233-827c7bf09de2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amlodipine, valsartan and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including amlodipine, hydrochlorothiazide, and the ARB class to which valsartan principally belongs. There are no controlled trials demonstrating risk reduction with amlodipine, valsartan and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (e.g., patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Limitation of Use Amlodipine, valsartan and hydrochlorothiazide tablets are not indicated for the initial therapy of hypertension [ see Dosage and Administration ( 2 ) ]. uuid:cd142498-0e31-4a0f-bb57-8c9d9cfaecb7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:848151 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:71a2ccd1-79cf-47ff-b40e-aa6145a64a32"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:df491eea-3890-4f2c-8643-ff605e590cfa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amlodipine, valsartan and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including amlodipine, hydrochlorothiazide, and the ARB class to which valsartan principally belongs. There are no controlled trials demonstrating risk reduction with amlodipine, valsartan and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (e.g., patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Limitation of Use Amlodipine, valsartan and hydrochlorothiazide tablets are not indicated for the initial therapy of hypertension [ see Dosage and Administration ( 2 ) ]. uuid:5f99a1bf-a612-4671-8cdc-45379b1ad054 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:848151 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:d200703d-5f73-4c9f-916a-27051d9eee7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d0c79ea1-9048-4e06-b76c-937678cfe26b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amlodipine, valsartan and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including amlodipine, hydrochlorothiazide, and the ARB class to which valsartan principally belongs. There are no controlled trials demonstrating risk reduction with amlodipine, valsartan and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (e.g., patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Limitation of Use Amlodipine, valsartan and hydrochlorothiazide tablets are not indicated for the initial therapy of hypertension [ see Dosage and Administration ( 2 ) ]. uuid:14e196fc-091d-4b16-8761-7087aef4f79d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:848151 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:fc87cb25-e87f-4bd1-8970-d82de632f91c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:652aea55-d91e-49b1-8206-3188dbf0a9f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amlodipine, valsartan and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including amlodipine, hydrochlorothiazide, and the ARB class to which valsartan principally belongs. There are no controlled trials demonstrating risk reduction with amlodipine, valsartan and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (e.g., patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Limitation of Use Amlodipine, valsartan and hydrochlorothiazide tablets are not indicated for the initial therapy of hypertension [ see Dosage and Administration ( 2 ) ]. uuid:3d3da2a9-3943-4834-a6b3-9855cd921745 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2BT4C47RUI biolink:treats MONDO:0056806 PMID:41385096 "[{""id"":""uuid:a7cfba24-c61a-4d65-af21-a91b573ff404"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a9835dbb-71fb-4a1a-8f74-2752cf41cb41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PORTRAZZA™ is an epidermal growth factor receptor (EGFR) antagonist indicated, in combination with gemcitabine and cisplatin, for first-line treatment of patients with metastatic squamous non-small cell lung cancer. ( 1.1 ) Limitation of Use: PORTRAZZA is not indicated for treatment of non-squamous non-small cell lung cancer. ( 1.2 , 5.6 , 14.2 ) uuid:dcb29801-ba6f-4e05-92a2-42ef841a67c6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:11672431 biolink:treats MONDO:0006652 PMID:41385096 "[{""id"":""uuid:0f12f8bf-0d9a-4a81-837c-76bdc36abb43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:40d33efd-be47-446c-8f38-cb696edebe90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Telmisartan and amlodipine tablet is an angiotensin II receptor blocker (ARB) and a dihydropyridine calcium channel blocker (DHP-CCB) combination product indicated for the treatment of hypertension alone or with other antihypertensive agents to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1 ) Telmisartan and amlodipine tablets are indicated as initial therapy in patients likely to need multiple antihypertensive agents to achieve their blood pressure goals ( 1 ) uuid:1a6500fb-64d7-4bfb-9dbf-1afb1926facc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49575 biolink:treats MONDO:0005027 PMID:41385096 "[{""id"":""uuid:7bd91ea2-3456-4be7-aa53-9f28a3cec711"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:81fdf9c3-87f1-4f6d-ba0f-75b553fb274d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diazepam rectal gel is intended for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy 2 years of age and older. uuid:b4c1c78b-a4eb-46f4-b60b-7350fe97c345 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49575 biolink:treats UMLS:C3203523 PMID:41385096 "[{""id"":""uuid:70e1c59d-ca58-428e-8cde-07b20d34686f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1f114a36-7705-4630-abd1-650232fb38db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diazepam rectal gel is intended for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy 2 years of age and older. uuid:222aeaec-f763-4637-a4a0-f66b4f1d113b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6965 biolink:treats MONDO:0005090 PMID:41385096 "[{""id"":""uuid:b53308b1-8717-41ef-aeeb-a9c93df062be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ad3fcaca-2250-434f-a18f-d4f637e5b3da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Molindone Hydrochloride Tablets, USP are indicated for the management of schizophrenia. The efficacy of Molindone Hydrochloride Tablets, USP in schizophrenia was established in clinical studies which enrolled newly hospitalized and chronically hospitalized, acutely ill, schizophrenic patients as subjects. uuid:fd22bdbf-43ab-49b6-9af4-cb429ddb4f98 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9328 biolink:treats MONDO:0001797 PMID:41385096 "[{""id"":""uuid:59466c62-d076-44ff-a4b0-4ee0266e61aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d998ac93-c6b2-442c-aa59-6798c2a2fcb6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] sulfADIAZINE Tablets, USP are indicated in the following conditions: Chancroid Trachoma Inclusion conjunctivitis Nocardiosis Urinary tract infections (primarily pyelonephritis, pyelitis and cystitis) in the absence of obstructive uropathy or foreign bodies, when these infections are caused by susceptible strains of the following organisms: Esch erichia coli, Klebsiella species, Enterobacter species, Staphylococcus aureus, Proteus mirabilis and P. vulgaris . Sulfadiazine should be used for urinary tract infections only after use of more soluble sulfonamides has been unsuccessful. Toxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome, as adjunctive therapy with pyrimethamine. Malaria due to chloroquine-resistant strains of Plasmodium falciparum , when used as adjunctive therapy. Prophylaxis of meningococcal meningitis when sulfonamide-sensitive group A strains are known to prevail in family groups or larger closed populations (the prophylactic usefulness of sulfonamides when group B or C infections are prevalent is not proved and may be harmful in closed population groups). Meningococcal meningitis, when the organism has been demonstrated to be susceptible. Acute otitis media due to Haemophilus influenzae, when used concomitantly with adequate doses of penicilin. Prophylaxis against recurrences of rheumatic fever, as an alternative to penicillin. H. influenzae meningitis, as adjunctive therapy with parental streptomycin. IMPORTANT NOTES In vitro sulfonamide susceptibility tests are not always reliable. The test must be carefully coordinated with bacteriologic and clinical response. When the patient is already taking sulfonamides, follow-up cultures should have aminobenzoic acid added to the culture media. Currently, the increasing frequency of resistant organisms limits the usefulness of antibacterial agents, including the sulfonamides, especially in the treatment of recurrent and complicated urinary tract infections. Wide variation in blood levels may result with identical doses. Blood levels should be measured in patients receiving sulfonamides for serious infections. Free sulfonamide blood levels of 5 mg to 15 mg per 100 mL may be considered therapeutically effective for most infections and blood levels of 12 mg to 15 mg per 100 mL may be considered optimal for serious infections. Twenty mg per 100 mL should be the maximum total sulfonamide level, since adverse reactions occur more frequently above this level. uuid:32ce8d51-2186-4f49-a965-0b505c6bc906 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9328 biolink:treats MONDO:0001249 PMID:41385096 "[{""id"":""uuid:1254e5fb-2731-458f-8388-e28968081f35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:26134c75-1d5f-4ab5-ae64-c33ea1c009c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] sulfADIAZINE Tablets, USP are indicated in the following conditions: Chancroid Trachoma Inclusion conjunctivitis Nocardiosis Urinary tract infections (primarily pyelonephritis, pyelitis and cystitis) in the absence of obstructive uropathy or foreign bodies, when these infections are caused by susceptible strains of the following organisms: Esch erichia coli, Klebsiella species, Enterobacter species, Staphylococcus aureus, Proteus mirabilis and P. vulgaris . Sulfadiazine should be used for urinary tract infections only after use of more soluble sulfonamides has been unsuccessful. Toxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome, as adjunctive therapy with pyrimethamine. Malaria due to chloroquine-resistant strains of Plasmodium falciparum , when used as adjunctive therapy. Prophylaxis of meningococcal meningitis when sulfonamide-sensitive group A strains are known to prevail in family groups or larger closed populations (the prophylactic usefulness of sulfonamides when group B or C infections are prevalent is not proved and may be harmful in closed population groups). Meningococcal meningitis, when the organism has been demonstrated to be susceptible. Acute otitis media due to Haemophilus influenzae, when used concomitantly with adequate doses of penicilin. Prophylaxis against recurrences of rheumatic fever, as an alternative to penicillin. H. influenzae meningitis, as adjunctive therapy with parental streptomycin. IMPORTANT NOTES In vitro sulfonamide susceptibility tests are not always reliable. The test must be carefully coordinated with bacteriologic and clinical response. When the patient is already taking sulfonamides, follow-up cultures should have aminobenzoic acid added to the culture media. Currently, the increasing frequency of resistant organisms limits the usefulness of antibacterial agents, including the sulfonamides, especially in the treatment of recurrent and complicated urinary tract infections. Wide variation in blood levels may result with identical doses. Blood levels should be measured in patients receiving sulfonamides for serious infections. Free sulfonamide blood levels of 5 mg to 15 mg per 100 mL may be considered therapeutically effective for most infections and blood levels of 12 mg to 15 mg per 100 mL may be considered optimal for serious infections. Twenty mg per 100 mL should be the maximum total sulfonamide level, since adverse reactions occur more frequently above this level. uuid:8bc6e0fa-aede-4e91-ad1b-2e00a87a075e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9328 biolink:treats MONDO:0005808 PMID:41385096 "[{""id"":""uuid:088d445a-1e81-4a49-9518-9356f88d6e09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4d135ad7-8c2c-4904-9093-dfe845db2b8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] sulfADIAZINE Tablets, USP are indicated in the following conditions: Chancroid Trachoma Inclusion conjunctivitis Nocardiosis Urinary tract infections (primarily pyelonephritis, pyelitis and cystitis) in the absence of obstructive uropathy or foreign bodies, when these infections are caused by susceptible strains of the following organisms: Esch erichia coli, Klebsiella species, Enterobacter species, Staphylococcus aureus, Proteus mirabilis and P. vulgaris . Sulfadiazine should be used for urinary tract infections only after use of more soluble sulfonamides has been unsuccessful. Toxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome, as adjunctive therapy with pyrimethamine. Malaria due to chloroquine-resistant strains of Plasmodium falciparum , when used as adjunctive therapy. Prophylaxis of meningococcal meningitis when sulfonamide-sensitive group A strains are known to prevail in family groups or larger closed populations (the prophylactic usefulness of sulfonamides when group B or C infections are prevalent is not proved and may be harmful in closed population groups). Meningococcal meningitis, when the organism has been demonstrated to be susceptible. Acute otitis media due to Haemophilus influenzae, when used concomitantly with adequate doses of penicilin. Prophylaxis against recurrences of rheumatic fever, as an alternative to penicillin. H. influenzae meningitis, as adjunctive therapy with parental streptomycin. IMPORTANT NOTES In vitro sulfonamide susceptibility tests are not always reliable. The test must be carefully coordinated with bacteriologic and clinical response. When the patient is already taking sulfonamides, follow-up cultures should have aminobenzoic acid added to the culture media. Currently, the increasing frequency of resistant organisms limits the usefulness of antibacterial agents, including the sulfonamides, especially in the treatment of recurrent and complicated urinary tract infections. Wide variation in blood levels may result with identical doses. Blood levels should be measured in patients receiving sulfonamides for serious infections. Free sulfonamide blood levels of 5 mg to 15 mg per 100 mL may be considered therapeutically effective for most infections and blood levels of 12 mg to 15 mg per 100 mL may be considered optimal for serious infections. Twenty mg per 100 mL should be the maximum total sulfonamide level, since adverse reactions occur more frequently above this level. uuid:7e3b444c-4d41-4ae4-ab7c-35adba424d5b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9328 biolink:treats MONDO:0017776 PMID:41385096 "[{""id"":""uuid:349694e6-6c56-4238-acfb-8a0abc3a906f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7a434649-a5e6-411a-bfbb-20b48da33162"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] sulfADIAZINE Tablets, USP are indicated in the following conditions: Chancroid Trachoma Inclusion conjunctivitis Nocardiosis Urinary tract infections (primarily pyelonephritis, pyelitis and cystitis) in the absence of obstructive uropathy or foreign bodies, when these infections are caused by susceptible strains of the following organisms: Esch erichia coli, Klebsiella species, Enterobacter species, Staphylococcus aureus, Proteus mirabilis and P. vulgaris . Sulfadiazine should be used for urinary tract infections only after use of more soluble sulfonamides has been unsuccessful. Toxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome, as adjunctive therapy with pyrimethamine. Malaria due to chloroquine-resistant strains of Plasmodium falciparum , when used as adjunctive therapy. Prophylaxis of meningococcal meningitis when sulfonamide-sensitive group A strains are known to prevail in family groups or larger closed populations (the prophylactic usefulness of sulfonamides when group B or C infections are prevalent is not proved and may be harmful in closed population groups). Meningococcal meningitis, when the organism has been demonstrated to be susceptible. Acute otitis media due to Haemophilus influenzae, when used concomitantly with adequate doses of penicilin. Prophylaxis against recurrences of rheumatic fever, as an alternative to penicillin. H. influenzae meningitis, as adjunctive therapy with parental streptomycin. IMPORTANT NOTES In vitro sulfonamide susceptibility tests are not always reliable. The test must be carefully coordinated with bacteriologic and clinical response. When the patient is already taking sulfonamides, follow-up cultures should have aminobenzoic acid added to the culture media. Currently, the increasing frequency of resistant organisms limits the usefulness of antibacterial agents, including the sulfonamides, especially in the treatment of recurrent and complicated urinary tract infections. Wide variation in blood levels may result with identical doses. Blood levels should be measured in patients receiving sulfonamides for serious infections. Free sulfonamide blood levels of 5 mg to 15 mg per 100 mL may be considered therapeutically effective for most infections and blood levels of 12 mg to 15 mg per 100 mL may be considered optimal for serious infections. Twenty mg per 100 mL should be the maximum total sulfonamide level, since adverse reactions occur more frequently above this level. uuid:930b6557-5d3b-4f12-8830-f77355b7f7da biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9328 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:1f4756e6-7c9b-41f6-ac2e-110b3403286e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:930e61c9-261f-43d1-9d48-9786299dad07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] sulfADIAZINE Tablets, USP are indicated in the following conditions: Chancroid Trachoma Inclusion conjunctivitis Nocardiosis Urinary tract infections (primarily pyelonephritis, pyelitis and cystitis) in the absence of obstructive uropathy or foreign bodies, when these infections are caused by susceptible strains of the following organisms: Esch erichia coli, Klebsiella species, Enterobacter species, Staphylococcus aureus, Proteus mirabilis and P. vulgaris . Sulfadiazine should be used for urinary tract infections only after use of more soluble sulfonamides has been unsuccessful. Toxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome, as adjunctive therapy with pyrimethamine. Malaria due to chloroquine-resistant strains of Plasmodium falciparum , when used as adjunctive therapy. Prophylaxis of meningococcal meningitis when sulfonamide-sensitive group A strains are known to prevail in family groups or larger closed populations (the prophylactic usefulness of sulfonamides when group B or C infections are prevalent is not proved and may be harmful in closed population groups). Meningococcal meningitis, when the organism has been demonstrated to be susceptible. Acute otitis media due to Haemophilus influenzae, when used concomitantly with adequate doses of penicilin. Prophylaxis against recurrences of rheumatic fever, as an alternative to penicillin. H. influenzae meningitis, as adjunctive therapy with parental streptomycin. IMPORTANT NOTES In vitro sulfonamide susceptibility tests are not always reliable. The test must be carefully coordinated with bacteriologic and clinical response. When the patient is already taking sulfonamides, follow-up cultures should have aminobenzoic acid added to the culture media. Currently, the increasing frequency of resistant organisms limits the usefulness of antibacterial agents, including the sulfonamides, especially in the treatment of recurrent and complicated urinary tract infections. Wide variation in blood levels may result with identical doses. Blood levels should be measured in patients receiving sulfonamides for serious infections. Free sulfonamide blood levels of 5 mg to 15 mg per 100 mL may be considered therapeutically effective for most infections and blood levels of 12 mg to 15 mg per 100 mL may be considered optimal for serious infections. Twenty mg per 100 mL should be the maximum total sulfonamide level, since adverse reactions occur more frequently above this level. uuid:7ad674d5-5e5e-4c35-ab61-73b86e3c48d3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9328 biolink:treats MONDO:0006939 PMID:41385096 "[{""id"":""uuid:d875b50d-928e-436a-870a-32b38492cb43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9d60b2f5-0dc8-424f-b8b6-174c7f056968"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] sulfADIAZINE Tablets, USP are indicated in the following conditions: Chancroid Trachoma Inclusion conjunctivitis Nocardiosis Urinary tract infections (primarily pyelonephritis, pyelitis and cystitis) in the absence of obstructive uropathy or foreign bodies, when these infections are caused by susceptible strains of the following organisms: Esch erichia coli, Klebsiella species, Enterobacter species, Staphylococcus aureus, Proteus mirabilis and P. vulgaris . Sulfadiazine should be used for urinary tract infections only after use of more soluble sulfonamides has been unsuccessful. Toxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome, as adjunctive therapy with pyrimethamine. Malaria due to chloroquine-resistant strains of Plasmodium falciparum , when used as adjunctive therapy. Prophylaxis of meningococcal meningitis when sulfonamide-sensitive group A strains are known to prevail in family groups or larger closed populations (the prophylactic usefulness of sulfonamides when group B or C infections are prevalent is not proved and may be harmful in closed population groups). Meningococcal meningitis, when the organism has been demonstrated to be susceptible. Acute otitis media due to Haemophilus influenzae, when used concomitantly with adequate doses of penicilin. Prophylaxis against recurrences of rheumatic fever, as an alternative to penicillin. H. influenzae meningitis, as adjunctive therapy with parental streptomycin. IMPORTANT NOTES In vitro sulfonamide susceptibility tests are not always reliable. The test must be carefully coordinated with bacteriologic and clinical response. When the patient is already taking sulfonamides, follow-up cultures should have aminobenzoic acid added to the culture media. Currently, the increasing frequency of resistant organisms limits the usefulness of antibacterial agents, including the sulfonamides, especially in the treatment of recurrent and complicated urinary tract infections. Wide variation in blood levels may result with identical doses. Blood levels should be measured in patients receiving sulfonamides for serious infections. Free sulfonamide blood levels of 5 mg to 15 mg per 100 mL may be considered therapeutically effective for most infections and blood levels of 12 mg to 15 mg per 100 mL may be considered optimal for serious infections. Twenty mg per 100 mL should be the maximum total sulfonamide level, since adverse reactions occur more frequently above this level. uuid:14b44066-dafc-4cd7-899a-c09ba27d2adb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9328 biolink:treats MONDO:0006938 PMID:41385096 "[{""id"":""uuid:659271d8-52a9-4fb4-bda5-465c0e7c497c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:04c5237e-8239-4aec-9908-eac0a1a81c70"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] sulfADIAZINE Tablets, USP are indicated in the following conditions: Chancroid Trachoma Inclusion conjunctivitis Nocardiosis Urinary tract infections (primarily pyelonephritis, pyelitis and cystitis) in the absence of obstructive uropathy or foreign bodies, when these infections are caused by susceptible strains of the following organisms: Esch erichia coli, Klebsiella species, Enterobacter species, Staphylococcus aureus, Proteus mirabilis and P. vulgaris . Sulfadiazine should be used for urinary tract infections only after use of more soluble sulfonamides has been unsuccessful. Toxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome, as adjunctive therapy with pyrimethamine. Malaria due to chloroquine-resistant strains of Plasmodium falciparum , when used as adjunctive therapy. Prophylaxis of meningococcal meningitis when sulfonamide-sensitive group A strains are known to prevail in family groups or larger closed populations (the prophylactic usefulness of sulfonamides when group B or C infections are prevalent is not proved and may be harmful in closed population groups). Meningococcal meningitis, when the organism has been demonstrated to be susceptible. Acute otitis media due to Haemophilus influenzae, when used concomitantly with adequate doses of penicilin. Prophylaxis against recurrences of rheumatic fever, as an alternative to penicillin. H. influenzae meningitis, as adjunctive therapy with parental streptomycin. IMPORTANT NOTES In vitro sulfonamide susceptibility tests are not always reliable. The test must be carefully coordinated with bacteriologic and clinical response. When the patient is already taking sulfonamides, follow-up cultures should have aminobenzoic acid added to the culture media. Currently, the increasing frequency of resistant organisms limits the usefulness of antibacterial agents, including the sulfonamides, especially in the treatment of recurrent and complicated urinary tract infections. Wide variation in blood levels may result with identical doses. Blood levels should be measured in patients receiving sulfonamides for serious infections. Free sulfonamide blood levels of 5 mg to 15 mg per 100 mL may be considered therapeutically effective for most infections and blood levels of 12 mg to 15 mg per 100 mL may be considered optimal for serious infections. Twenty mg per 100 mL should be the maximum total sulfonamide level, since adverse reactions occur more frequently above this level. uuid:ee825ed3-e88e-4d42-bba4-87a58a9ceb86 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9328 biolink:treats MONDO:0006032 PMID:41385096 "[{""id"":""uuid:85a8fff8-0edc-476e-b75f-13786a4c47ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3c33a56f-888f-43d1-9641-7a8da9df77de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] sulfADIAZINE Tablets, USP are indicated in the following conditions: Chancroid Trachoma Inclusion conjunctivitis Nocardiosis Urinary tract infections (primarily pyelonephritis, pyelitis and cystitis) in the absence of obstructive uropathy or foreign bodies, when these infections are caused by susceptible strains of the following organisms: Esch erichia coli, Klebsiella species, Enterobacter species, Staphylococcus aureus, Proteus mirabilis and P. vulgaris . Sulfadiazine should be used for urinary tract infections only after use of more soluble sulfonamides has been unsuccessful. Toxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome, as adjunctive therapy with pyrimethamine. Malaria due to chloroquine-resistant strains of Plasmodium falciparum , when used as adjunctive therapy. Prophylaxis of meningococcal meningitis when sulfonamide-sensitive group A strains are known to prevail in family groups or larger closed populations (the prophylactic usefulness of sulfonamides when group B or C infections are prevalent is not proved and may be harmful in closed population groups). Meningococcal meningitis, when the organism has been demonstrated to be susceptible. Acute otitis media due to Haemophilus influenzae, when used concomitantly with adequate doses of penicilin. Prophylaxis against recurrences of rheumatic fever, as an alternative to penicillin. H. influenzae meningitis, as adjunctive therapy with parental streptomycin. IMPORTANT NOTES In vitro sulfonamide susceptibility tests are not always reliable. The test must be carefully coordinated with bacteriologic and clinical response. When the patient is already taking sulfonamides, follow-up cultures should have aminobenzoic acid added to the culture media. Currently, the increasing frequency of resistant organisms limits the usefulness of antibacterial agents, including the sulfonamides, especially in the treatment of recurrent and complicated urinary tract infections. Wide variation in blood levels may result with identical doses. Blood levels should be measured in patients receiving sulfonamides for serious infections. Free sulfonamide blood levels of 5 mg to 15 mg per 100 mL may be considered therapeutically effective for most infections and blood levels of 12 mg to 15 mg per 100 mL may be considered optimal for serious infections. Twenty mg per 100 mL should be the maximum total sulfonamide level, since adverse reactions occur more frequently above this level. uuid:c532f50d-8eca-4472-8c92-1d743ef57842 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9328 biolink:treats MONDO:0005697 PMID:41385096 "[{""id"":""uuid:51c3525e-517f-428d-813b-c619166b779d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6b1b14de-d680-401a-9deb-08ff2f49a129"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] sulfADIAZINE Tablets, USP are indicated in the following conditions: Chancroid Trachoma Inclusion conjunctivitis Nocardiosis Urinary tract infections (primarily pyelonephritis, pyelitis and cystitis) in the absence of obstructive uropathy or foreign bodies, when these infections are caused by susceptible strains of the following organisms: Esch erichia coli, Klebsiella species, Enterobacter species, Staphylococcus aureus, Proteus mirabilis and P. vulgaris . Sulfadiazine should be used for urinary tract infections only after use of more soluble sulfonamides has been unsuccessful. Toxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome, as adjunctive therapy with pyrimethamine. Malaria due to chloroquine-resistant strains of Plasmodium falciparum , when used as adjunctive therapy. Prophylaxis of meningococcal meningitis when sulfonamide-sensitive group A strains are known to prevail in family groups or larger closed populations (the prophylactic usefulness of sulfonamides when group B or C infections are prevalent is not proved and may be harmful in closed population groups). Meningococcal meningitis, when the organism has been demonstrated to be susceptible. Acute otitis media due to Haemophilus influenzae, when used concomitantly with adequate doses of penicilin. Prophylaxis against recurrences of rheumatic fever, as an alternative to penicillin. H. influenzae meningitis, as adjunctive therapy with parental streptomycin. IMPORTANT NOTES In vitro sulfonamide susceptibility tests are not always reliable. The test must be carefully coordinated with bacteriologic and clinical response. When the patient is already taking sulfonamides, follow-up cultures should have aminobenzoic acid added to the culture media. Currently, the increasing frequency of resistant organisms limits the usefulness of antibacterial agents, including the sulfonamides, especially in the treatment of recurrent and complicated urinary tract infections. Wide variation in blood levels may result with identical doses. Blood levels should be measured in patients receiving sulfonamides for serious infections. Free sulfonamide blood levels of 5 mg to 15 mg per 100 mL may be considered therapeutically effective for most infections and blood levels of 12 mg to 15 mg per 100 mL may be considered optimal for serious infections. Twenty mg per 100 mL should be the maximum total sulfonamide level, since adverse reactions occur more frequently above this level. uuid:53c492ef-5840-49ea-ac73-68de98a98791 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9328 biolink:treats MONDO:0012268 PMID:41385096 "[{""id"":""uuid:5d38da2c-7b6c-4f12-8e51-1ea39548d5dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:42c0c5bc-8bbb-41f9-b0c2-f73759b3d7bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] sulfADIAZINE Tablets, USP are indicated in the following conditions: Chancroid Trachoma Inclusion conjunctivitis Nocardiosis Urinary tract infections (primarily pyelonephritis, pyelitis and cystitis) in the absence of obstructive uropathy or foreign bodies, when these infections are caused by susceptible strains of the following organisms: Esch erichia coli, Klebsiella species, Enterobacter species, Staphylococcus aureus, Proteus mirabilis and P. vulgaris . Sulfadiazine should be used for urinary tract infections only after use of more soluble sulfonamides has been unsuccessful. Toxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome, as adjunctive therapy with pyrimethamine. Malaria due to chloroquine-resistant strains of Plasmodium falciparum , when used as adjunctive therapy. Prophylaxis of meningococcal meningitis when sulfonamide-sensitive group A strains are known to prevail in family groups or larger closed populations (the prophylactic usefulness of sulfonamides when group B or C infections are prevalent is not proved and may be harmful in closed population groups). Meningococcal meningitis, when the organism has been demonstrated to be susceptible. Acute otitis media due to Haemophilus influenzae, when used concomitantly with adequate doses of penicilin. Prophylaxis against recurrences of rheumatic fever, as an alternative to penicillin. H. influenzae meningitis, as adjunctive therapy with parental streptomycin. IMPORTANT NOTES In vitro sulfonamide susceptibility tests are not always reliable. The test must be carefully coordinated with bacteriologic and clinical response. When the patient is already taking sulfonamides, follow-up cultures should have aminobenzoic acid added to the culture media. Currently, the increasing frequency of resistant organisms limits the usefulness of antibacterial agents, including the sulfonamides, especially in the treatment of recurrent and complicated urinary tract infections. Wide variation in blood levels may result with identical doses. Blood levels should be measured in patients receiving sulfonamides for serious infections. Free sulfonamide blood levels of 5 mg to 15 mg per 100 mL may be considered therapeutically effective for most infections and blood levels of 12 mg to 15 mg per 100 mL may be considered optimal for serious infections. Twenty mg per 100 mL should be the maximum total sulfonamide level, since adverse reactions occur more frequently above this level. uuid:cc122270-026e-4fcf-afe4-179c0be41e40 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9328 biolink:treats MONDO:0005136 PMID:41385096 "[{""id"":""uuid:ffbbd16d-0b76-4aa9-91ea-e3dc4589e217"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d23f3d32-5211-4e3f-92c6-b693ee214d11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] sulfADIAZINE Tablets, USP are indicated in the following conditions: Chancroid Trachoma Inclusion conjunctivitis Nocardiosis Urinary tract infections (primarily pyelonephritis, pyelitis and cystitis) in the absence of obstructive uropathy or foreign bodies, when these infections are caused by susceptible strains of the following organisms: Esch erichia coli, Klebsiella species, Enterobacter species, Staphylococcus aureus, Proteus mirabilis and P. vulgaris . Sulfadiazine should be used for urinary tract infections only after use of more soluble sulfonamides has been unsuccessful. Toxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome, as adjunctive therapy with pyrimethamine. Malaria due to chloroquine-resistant strains of Plasmodium falciparum , when used as adjunctive therapy. Prophylaxis of meningococcal meningitis when sulfonamide-sensitive group A strains are known to prevail in family groups or larger closed populations (the prophylactic usefulness of sulfonamides when group B or C infections are prevalent is not proved and may be harmful in closed population groups). Meningococcal meningitis, when the organism has been demonstrated to be susceptible. Acute otitis media due to Haemophilus influenzae, when used concomitantly with adequate doses of penicilin. Prophylaxis against recurrences of rheumatic fever, as an alternative to penicillin. H. influenzae meningitis, as adjunctive therapy with parental streptomycin. IMPORTANT NOTES In vitro sulfonamide susceptibility tests are not always reliable. The test must be carefully coordinated with bacteriologic and clinical response. When the patient is already taking sulfonamides, follow-up cultures should have aminobenzoic acid added to the culture media. Currently, the increasing frequency of resistant organisms limits the usefulness of antibacterial agents, including the sulfonamides, especially in the treatment of recurrent and complicated urinary tract infections. Wide variation in blood levels may result with identical doses. Blood levels should be measured in patients receiving sulfonamides for serious infections. Free sulfonamide blood levels of 5 mg to 15 mg per 100 mL may be considered therapeutically effective for most infections and blood levels of 12 mg to 15 mg per 100 mL may be considered optimal for serious infections. Twenty mg per 100 mL should be the maximum total sulfonamide level, since adverse reactions occur more frequently above this level. uuid:b0046f60-a7d8-416a-8afa-0b3c8b575730 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9328 biolink:treats MONDO:0018059 PMID:41385096 "[{""id"":""uuid:baa8af29-0cb0-4707-b9dd-c218067587af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3a0816c8-e63c-4a93-ba8e-9e82b733917e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] sulfADIAZINE Tablets, USP are indicated in the following conditions: Chancroid Trachoma Inclusion conjunctivitis Nocardiosis Urinary tract infections (primarily pyelonephritis, pyelitis and cystitis) in the absence of obstructive uropathy or foreign bodies, when these infections are caused by susceptible strains of the following organisms: Esch erichia coli, Klebsiella species, Enterobacter species, Staphylococcus aureus, Proteus mirabilis and P. vulgaris . Sulfadiazine should be used for urinary tract infections only after use of more soluble sulfonamides has been unsuccessful. Toxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome, as adjunctive therapy with pyrimethamine. Malaria due to chloroquine-resistant strains of Plasmodium falciparum , when used as adjunctive therapy. Prophylaxis of meningococcal meningitis when sulfonamide-sensitive group A strains are known to prevail in family groups or larger closed populations (the prophylactic usefulness of sulfonamides when group B or C infections are prevalent is not proved and may be harmful in closed population groups). Meningococcal meningitis, when the organism has been demonstrated to be susceptible. Acute otitis media due to Haemophilus influenzae, when used concomitantly with adequate doses of penicilin. Prophylaxis against recurrences of rheumatic fever, as an alternative to penicillin. H. influenzae meningitis, as adjunctive therapy with parental streptomycin. IMPORTANT NOTES In vitro sulfonamide susceptibility tests are not always reliable. The test must be carefully coordinated with bacteriologic and clinical response. When the patient is already taking sulfonamides, follow-up cultures should have aminobenzoic acid added to the culture media. Currently, the increasing frequency of resistant organisms limits the usefulness of antibacterial agents, including the sulfonamides, especially in the treatment of recurrent and complicated urinary tract infections. Wide variation in blood levels may result with identical doses. Blood levels should be measured in patients receiving sulfonamides for serious infections. Free sulfonamide blood levels of 5 mg to 15 mg per 100 mL may be considered therapeutically effective for most infections and blood levels of 12 mg to 15 mg per 100 mL may be considered optimal for serious infections. Twenty mg per 100 mL should be the maximum total sulfonamide level, since adverse reactions occur more frequently above this level. uuid:1d797288-1423-4b2b-a577-fe40f3bb72bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9328 biolink:treats HP:0000371 PMID:41385096 "[{""id"":""uuid:1d8ee431-bd17-4000-8eb0-e7104c6cf954"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:85a0d9da-ebd7-479a-b2a1-6c732076b3ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] sulfADIAZINE Tablets, USP are indicated in the following conditions: Chancroid Trachoma Inclusion conjunctivitis Nocardiosis Urinary tract infections (primarily pyelonephritis, pyelitis and cystitis) in the absence of obstructive uropathy or foreign bodies, when these infections are caused by susceptible strains of the following organisms: Esch erichia coli, Klebsiella species, Enterobacter species, Staphylococcus aureus, Proteus mirabilis and P. vulgaris . Sulfadiazine should be used for urinary tract infections only after use of more soluble sulfonamides has been unsuccessful. Toxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome, as adjunctive therapy with pyrimethamine. Malaria due to chloroquine-resistant strains of Plasmodium falciparum , when used as adjunctive therapy. Prophylaxis of meningococcal meningitis when sulfonamide-sensitive group A strains are known to prevail in family groups or larger closed populations (the prophylactic usefulness of sulfonamides when group B or C infections are prevalent is not proved and may be harmful in closed population groups). Meningococcal meningitis, when the organism has been demonstrated to be susceptible. Acute otitis media due to Haemophilus influenzae, when used concomitantly with adequate doses of penicilin. Prophylaxis against recurrences of rheumatic fever, as an alternative to penicillin. H. influenzae meningitis, as adjunctive therapy with parental streptomycin. IMPORTANT NOTES In vitro sulfonamide susceptibility tests are not always reliable. The test must be carefully coordinated with bacteriologic and clinical response. When the patient is already taking sulfonamides, follow-up cultures should have aminobenzoic acid added to the culture media. Currently, the increasing frequency of resistant organisms limits the usefulness of antibacterial agents, including the sulfonamides, especially in the treatment of recurrent and complicated urinary tract infections. Wide variation in blood levels may result with identical doses. Blood levels should be measured in patients receiving sulfonamides for serious infections. Free sulfonamide blood levels of 5 mg to 15 mg per 100 mL may be considered therapeutically effective for most infections and blood levels of 12 mg to 15 mg per 100 mL may be considered optimal for serious infections. Twenty mg per 100 mL should be the maximum total sulfonamide level, since adverse reactions occur more frequently above this level. uuid:16611f31-ddbd-4f67-b463-aa4bd30110da biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9328 biolink:treats MONDO:0017767 PMID:41385096 "[{""id"":""uuid:2c35f624-c6c8-4f4c-ac8d-0b1d9f664c32"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:be917ab2-cc02-412c-a132-6b2521e5e69d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] sulfADIAZINE Tablets, USP are indicated in the following conditions: Chancroid Trachoma Inclusion conjunctivitis Nocardiosis Urinary tract infections (primarily pyelonephritis, pyelitis and cystitis) in the absence of obstructive uropathy or foreign bodies, when these infections are caused by susceptible strains of the following organisms: Esch erichia coli, Klebsiella species, Enterobacter species, Staphylococcus aureus, Proteus mirabilis and P. vulgaris . Sulfadiazine should be used for urinary tract infections only after use of more soluble sulfonamides has been unsuccessful. Toxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome, as adjunctive therapy with pyrimethamine. Malaria due to chloroquine-resistant strains of Plasmodium falciparum , when used as adjunctive therapy. Prophylaxis of meningococcal meningitis when sulfonamide-sensitive group A strains are known to prevail in family groups or larger closed populations (the prophylactic usefulness of sulfonamides when group B or C infections are prevalent is not proved and may be harmful in closed population groups). Meningococcal meningitis, when the organism has been demonstrated to be susceptible. Acute otitis media due to Haemophilus influenzae, when used concomitantly with adequate doses of penicilin. Prophylaxis against recurrences of rheumatic fever, as an alternative to penicillin. H. influenzae meningitis, as adjunctive therapy with parental streptomycin. IMPORTANT NOTES In vitro sulfonamide susceptibility tests are not always reliable. The test must be carefully coordinated with bacteriologic and clinical response. When the patient is already taking sulfonamides, follow-up cultures should have aminobenzoic acid added to the culture media. Currently, the increasing frequency of resistant organisms limits the usefulness of antibacterial agents, including the sulfonamides, especially in the treatment of recurrent and complicated urinary tract infections. Wide variation in blood levels may result with identical doses. Blood levels should be measured in patients receiving sulfonamides for serious infections. Free sulfonamide blood levels of 5 mg to 15 mg per 100 mL may be considered therapeutically effective for most infections and blood levels of 12 mg to 15 mg per 100 mL may be considered optimal for serious infections. Twenty mg per 100 mL should be the maximum total sulfonamide level, since adverse reactions occur more frequently above this level. uuid:b5ad5015-3600-4635-8963-365a7e463f92 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9328 biolink:treats MONDO:0000889 PMID:41385096 "[{""id"":""uuid:f1f04257-1e77-4b65-9788-7ddd20a50caf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7c88938a-da6e-4506-b2f4-92df618f01b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] sulfADIAZINE Tablets, USP are indicated in the following conditions: Chancroid Trachoma Inclusion conjunctivitis Nocardiosis Urinary tract infections (primarily pyelonephritis, pyelitis and cystitis) in the absence of obstructive uropathy or foreign bodies, when these infections are caused by susceptible strains of the following organisms: Esch erichia coli, Klebsiella species, Enterobacter species, Staphylococcus aureus, Proteus mirabilis and P. vulgaris . Sulfadiazine should be used for urinary tract infections only after use of more soluble sulfonamides has been unsuccessful. Toxoplasmosis encephalitis in patients with and without acquired immunodeficiency syndrome, as adjunctive therapy with pyrimethamine. Malaria due to chloroquine-resistant strains of Plasmodium falciparum , when used as adjunctive therapy. Prophylaxis of meningococcal meningitis when sulfonamide-sensitive group A strains are known to prevail in family groups or larger closed populations (the prophylactic usefulness of sulfonamides when group B or C infections are prevalent is not proved and may be harmful in closed population groups). Meningococcal meningitis, when the organism has been demonstrated to be susceptible. Acute otitis media due to Haemophilus influenzae, when used concomitantly with adequate doses of penicilin. Prophylaxis against recurrences of rheumatic fever, as an alternative to penicillin. H. influenzae meningitis, as adjunctive therapy with parental streptomycin. IMPORTANT NOTES In vitro sulfonamide susceptibility tests are not always reliable. The test must be carefully coordinated with bacteriologic and clinical response. When the patient is already taking sulfonamides, follow-up cultures should have aminobenzoic acid added to the culture media. Currently, the increasing frequency of resistant organisms limits the usefulness of antibacterial agents, including the sulfonamides, especially in the treatment of recurrent and complicated urinary tract infections. Wide variation in blood levels may result with identical doses. Blood levels should be measured in patients receiving sulfonamides for serious infections. Free sulfonamide blood levels of 5 mg to 15 mg per 100 mL may be considered therapeutically effective for most infections and blood levels of 12 mg to 15 mg per 100 mL may be considered optimal for serious infections. Twenty mg per 100 mL should be the maximum total sulfonamide level, since adverse reactions occur more frequently above this level. uuid:8542dcc2-cead-449c-afd0-90e17a789099 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9316 biolink:treats NCIT:C27003 PMID:41385096 "[{""id"":""uuid:811df566-c8ce-4824-9d14-5a80957465eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:92c6bddd-a69c-49b5-be70-dfd9c2c83dec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c806b413-6301-4213-ac9f-27bddde07657"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DSUVIA is indicated for use in adults in a certified medically supervised healthcare setting, such as hospitals, surgical centers, and emergency departments, for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use: Not for home use or for use in children. Discontinue treatment with DSUVIA before patients leave the certified medically supervised healthcare setting. Not for use for more than 72 hours. The use of DSUVIA beyond 72 hours has not been studied. Only to be administered by a healthcare provider. Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration [see Warnings and Precautions ( 5.3 )] , reserve DSUVIA for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or opioid combination products): - Have not been tolerated, or are not expected to be tolerated, - Have not provided adequate analgesia, or are not expected to provide adequate analgesia.|[EMA] Dzuveo is indicated for the management of acute moderate to severe pain in adult patients. uuid:daeec15f-c7c1-4278-b813-3b1c9f3225b6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:5Q6TZN2HNM biolink:treats MONDO:0019623 PMID:41385096 "[{""id"":""uuid:923287c7-f322-4ded-a282-cebf72858a7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c12a0614-8f5d-40ec-aeca-63e828b59762"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KALBITOR ® (ecallantide) is indicated for treatment of acute attacks of hereditary angioedema (HAE) in patients 12 years of age and older. uuid:5b233dcf-19d4-4781-af44-d7760758f90d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:5Q6TZN2HNM biolink:treats MONDO:0012526 PMID:41385096 "[{""id"":""uuid:6873afd0-3363-4444-8b22-094c359de8bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:99fe88d4-8e82-492c-b740-aa08ea90d03c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KALBITOR ® (ecallantide) is indicated for treatment of acute attacks of hereditary angioedema (HAE) in patients 12 years of age and older. uuid:86a1126d-e4ef-4c55-9427-ea4db834651a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135935 biolink:treats MONDO:0018362 PMID:41385096 "[{""id"":""uuid:e472745d-4e73-433f-9a01-c7fff179e116"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:703c559a-cfb7-4259-9767-52dd373f8830"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NUCYNTA ER (tapentadol) is indicated for the management of: Severe and persistent pain in adults that requires an extended treatment period with a daily opioid analgesic and for which alternative treatment options are inadequate. Severe and persistent neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults that requires an extended treatment period with a daily opioid analgesic and for which alternative treatment options are inadequate. uuid:78567759-8989-44aa-a161-59bdf7be60e3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0005580 PMID:41385096 "[{""id"":""uuid:330b914e-bdd4-4002-8bc2-043a2d4defd3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fc802942-4226-4793-9e94-18bee6111fc6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Palliation and treatment adjutant to surgery and radiation therapy of the following neoplasms: Squamous cell carcinoma of the skin, head and neck, and esophagus (primary indication). Squamous cell carcinoma of the larynx, penis and uterine cervix. Squamous cell carcinoma of the bronchus (response infrequent). Ch0riocarcinoma and embryonal cell carcinoma of the testis. Advanced Hodgkin’s disease and Other lymphomas. Mycosis fungoides. Note . Use of bleomycin after radiation therapy is less successful than use before radiation therapy. Bleomycin is bone marrow sparing and may be used when other cytotoxic agents are contraindicated. uuid:d515f398-5988-4406-949b-fb296752ad35 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0004430 PMID:41385096 "[{""id"":""uuid:a10f4fd0-0d98-4c64-938d-fc7f6d0a05f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6cbf56c4-c2d3-429c-840a-afe34c4ff2d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Palliation and treatment adjutant to surgery and radiation therapy of the following neoplasms: Squamous cell carcinoma of the skin, head and neck, and esophagus (primary indication). Squamous cell carcinoma of the larynx, penis and uterine cervix. Squamous cell carcinoma of the bronchus (response infrequent). Ch0riocarcinoma and embryonal cell carcinoma of the testis. Advanced Hodgkin’s disease and Other lymphomas. Mycosis fungoides. Note . Use of bleomycin after radiation therapy is less successful than use before radiation therapy. Bleomycin is bone marrow sparing and may be used when other cytotoxic agents are contraindicated. uuid:9f89ebdd-04c8-4cb0-a92a-39cf13d3098d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0005097 PMID:41385096 "[{""id"":""uuid:361cb5d8-0427-44a3-845e-75b5f7f57b2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:228ebe07-7cf5-48d1-9764-e71a15f6e4de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Palliation and treatment adjutant to surgery and radiation therapy of the following neoplasms: Squamous cell carcinoma of the skin, head and neck, and esophagus (primary indication). Squamous cell carcinoma of the larynx, penis and uterine cervix. Squamous cell carcinoma of the bronchus (response infrequent). Ch0riocarcinoma and embryonal cell carcinoma of the testis. Advanced Hodgkin’s disease and Other lymphomas. Mycosis fungoides. Note . Use of bleomycin after radiation therapy is less successful than use before radiation therapy. Bleomycin is bone marrow sparing and may be used when other cytotoxic agents are contraindicated. uuid:0439ae48-2fdf-426f-b976-723bfd026164 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0005062 PMID:41385096 "[{""id"":""uuid:5576d4d0-92b8-472d-9103-94553e5d4a9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8abfb19d-8a86-4584-a880-a0874ea7adf5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Palliation and treatment adjutant to surgery and radiation therapy of the following neoplasms: Squamous cell carcinoma of the skin, head and neck, and esophagus (primary indication). Squamous cell carcinoma of the larynx, penis and uterine cervix. Squamous cell carcinoma of the bronchus (response infrequent). Ch0riocarcinoma and embryonal cell carcinoma of the testis. Advanced Hodgkin’s disease and Other lymphomas. Mycosis fungoides. Note . Use of bleomycin after radiation therapy is less successful than use before radiation therapy. Bleomycin is bone marrow sparing and may be used when other cytotoxic agents are contraindicated. uuid:9cbbb009-c1e2-45a5-ae2b-7ac24aeb9afd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0009691 PMID:41385096 "[{""id"":""uuid:60246c71-ecd1-459c-b59d-99f46ccdcc23"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2a1845c9-466e-4f58-8c41-6f128be98471"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Palliation and treatment adjutant to surgery and radiation therapy of the following neoplasms: Squamous cell carcinoma of the skin, head and neck, and esophagus (primary indication). Squamous cell carcinoma of the larynx, penis and uterine cervix. Squamous cell carcinoma of the bronchus (response infrequent). Ch0riocarcinoma and embryonal cell carcinoma of the testis. Advanced Hodgkin’s disease and Other lymphomas. Mycosis fungoides. Note . Use of bleomycin after radiation therapy is less successful than use before radiation therapy. Bleomycin is bone marrow sparing and may be used when other cytotoxic agents are contraindicated. uuid:af95375d-dfa8-4357-85f7-077ad8d840d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42355 biolink:treats MONDO:0021697 PMID:41385096 "[{""id"":""uuid:bcbf403e-5433-489b-b050-ec8235ce14b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8bbff596-5351-4a49-ac31-b51610a96e52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin tablets and other antibacterial drugs, erythromycin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Erythromycin tablets are indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in the diseases listed below: Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes ; Streptococcus pneumoniae ; Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H. influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information.) Lower respiratory tract infections of mild to moderate severity caused by Streptococcus pyogenes or Streptococcus pneumoniae . Listeriosis caused by Listeria monocytogenes . Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes or Staphylococcus aureus (resistant staphylococci may emerge during treatment). Pertussis (whooping cough) caused by Bordetella pertussis . Erythromycin is effective in eliminating the organism from the nasopharynx of infected individuals, rendering them noninfectious. Some clinical studies suggest that erythromycin may be helpful in the prophylaxis of pertussis in exposed susceptible individuals. Diphtheria: Infections due to Corynebacterium diphtheriae , as an adjunct to antitoxin, to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum . Intestinal amebiasis caused by Entamoeba histolytica (oral erythromycins only). Extraenteric amebiasis requires treatment with other agents. Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae : Erythrocin™ Lactobionate-I.V. (erythromycin lactobionate for injection, USP) followed by erythromycin base orally, as an alternative drug in treatment of acute pelvic inflammatory disease caused by N. gonorrhoeae in female patients with a history of sensitivity to penicillin. Patients should have a serologic test for syphilis before receiving erythromycin as treatment of gonorrhea and a follow-up serologic test for syphilis after 3 months. Erythromycins are indicated for treatment of the following infections caused by Chlamydia trachomatis : conjunctivitis of the newborn, pneumonia of infancy, and urogenital infections during pregnancy. When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of uncomplicated urethral, endocervical, or rectal infections in adults due to Chlamydia trachomatis. 3 When tetracyclines are contraindicated or not tolerated, erythromycin is indicated for the treatment of nongonococcal urethritis caused by Ureaplasma urealyticum. 3 Primary syphilis caused by Treponema pallidum . Erythromycin (oral forms only) is an alternative choice of treatment for primary syphilis in patients allergic to the penicillins. In treatment of primary syphilis, spinal fluid should be examined before treatment and as part of the follow-up after therapy. Legionnaires' Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires' Disease. Prophylaxis Prevention of Initial Attacks of Rheumatic Fever Penicillin is considered by the American Heart Association to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of Streptococcus pyogenes infections of the upper respiratory tract e.g., tonsillitis, or pharyngitis). 1 Erythromycin is indicated for the treatment of penicillin-allergic patients. The therapeutic dose should be administered for ten days. Prevention of Recurrent Attacks of Rheumatic Fever Penicillin or sulfonamides are considered by the American Heart Association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. In patients who are allergic to penicillin and sulfonamides, oral erythromycin is recommended by the American Heart Association in the long-term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever). 1 uuid:8c16d3c8-007e-402c-8097-804e66d81e18 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3ZO554A4Q8 biolink:treats MONDO:0011382 PMID:41385096 "[{""id"":""uuid:45851573-f64f-4aaa-b43e-2c3951832bc6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:821674a9-60b6-4849-b7c5-a9ab064eb496"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9aa61f2f-b045-4601-95c0-89c1cbaaa5e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/oxbryta""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] OXBRYTA is indicated for the treatment of sickle cell disease (SCD) in adults and pediatric patients 4 years of age and older. This indication is approved under accelerated approval based on increase in hemoglobin (Hb) [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).|[EMA] Oxbryta is indicated for the treatment of haemolytic anaemia due to sickle cell disease (SCD) in adults and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide. uuid:c5d7af5b-fa8d-4a68-81e4-e39c040b9a52 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5296 biolink:treats MONDO:0015629 PMID:41385096 "[{""id"":""uuid:a9abd4d4-29c9-45b0-b9c4-8c1685daaeeb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a177ed3f-d63c-447b-a02b-8151c7c1f8c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gemfibrozil tablets, USP are indicated as adjunctive therapy to diet for: 1. Treatment of adult patients with very high elevations of serum triglyceride levels (Types IV and V hyperlipidemia) who present a risk of pancreatitis and who do not respond adequately to a determined dietary effort to control them. Patients who present such risk typically have serum triglycerides over 2000 mg/dL and have elevations of VLDL-cholesterol as well as fasting chylomicrons (Type V hyperlipidemia). Subjects who consistently have total serum or plasma triglycerides below 1000 mg/dL are unlikely to present a risk of pancreatitis. Gemfibrozil therapy may be considered for those subjects with triglyceride elevations between 1000 and 2000 mg/dL who have a history of pancreatitis or of recurrent abdominal pain typical of pancreatitis. It is recognized that some Type IV patients with triglycerides under 1000 mg/dL may, through dietary or alcoholic indiscretion, convert to a Type V pattern with massive triglyceride elevations accompanying fasting chylomicronemia, but the influence of gemfibrozil therapy on the risk of pancreatitis in such situations has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV, and V hyperlipoproteinemia. 2. Reducing the risk of developing coronary heart disease only in Type IIb patients without history of or symptoms of existing coronary heart disease who have had an inadequate response to weight loss, dietary therapy, exercise, and other pharmacologic agents (such as bile acid sequestrants and nicotinic acid, known to reduce LDL- and raise HDL-cholesterol) and who have the following triad of lipid abnormalities: low HDL-cholesterol levels in addition to elevated LDL-cholesterol and elevated triglycerides (see WARNINGS , PRECAUTIONS , and CLINICAL PHARMACOLOGY ). The National Cholesterol Education Program has defined a serum HDL-cholesterol value that is consistently below 35 mg/dL as constituting an independent risk factor for coronary heart disease. Patients with significantly elevated triglycerides should be closely observed when treated with gemfibrozil. In some patients with high triglyceride levels, treatment with gemfibrozil is associated with a significant increase in LDL-cholesterol. BECAUSE OF POTENTIAL TOXICITY SUCH AS MALIGNANCY, GALLBLADDER DISEASE, ABDOMINAL PAIN LEADING TO APPENDECTOMY AND OTHER ABDOMINAL SURGERIES, AN INCREASED INCIDENCE IN NON-CORONARY MORTALITY, AND THE 44% RELATIVE INCREASE DURING THE TRIAL PERIOD IN AGE-ADJUSTED ALL-CAUSE MORTALITY SEEN WITH THE CHEMICALLY AND PHARMACOLOGICALLY RELATED DRUG, CLOFIBRATE, THE POTENTIAL BENEFIT OF GEMFIBROZIL IN TREATING TYPE IIA PATIENTS WITH ELEVATIONS OF LDL-CHOLESTEROL ONLY IS NOT LIKELY TO OUTWEIGH THE RISKS. GEMFIBROZIL IS ALSO NOT INDICATED FOR THE TREATMENT OF PATIENTS WITH LOW HDL-CHOLESTEROL AS THEIR ONLY LIPID ABNORMALITY. In a subgroup analysis of patients in the Helsinki Heart Study with above-median HDL-cholesterol values at baseline (greater than 46.4 mg/dL), the incidence of serious coronary events was similar for gemfibrozil and placebo subgroups (see Table I). The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcohol intake may be important factors in hypertriglyceridemia and should be managed prior to any drug therapy. Physical exercise can be an important ancillary measure, and has been associated with rises in HDL-cholesterol. Diseases contributory to hyperlipidemia such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy is sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of estrogen therapy may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with nondrug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet. uuid:1f023488-366d-4651-83c0-9775f640bf10 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:91495 biolink:treats MONDO:0024332 PMID:41385096 "[{""id"":""uuid:71013ff4-59cb-49bc-b0bb-c299a67ef7a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cfcf7a43-975a-4e09-9339-66b88c54001f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ipratropium Bromide Nasal Solution 0.03% is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis in adults and children age 6 years and older. Ipratropium Bromide Nasal Solution 0.03% does not relieve nasal congestion, sneezing, or postnasal drip associated with allergic or nonallergic perennial rhinitis. uuid:fe3d1783-d0c1-4bf3-aeaa-48b751f90703 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:91495 biolink:treats MONDO:0004514 PMID:41385096 "[{""id"":""uuid:7a98ceb7-d6c5-4f3a-8379-292c0fb873f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:21994d02-b85f-4d9c-8bab-25c56bb41231"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ipratropium Bromide Nasal Solution 0.03% is indicated for the symptomatic relief of rhinorrhea associated with allergic and nonallergic perennial rhinitis in adults and children age 6 years and older. Ipratropium Bromide Nasal Solution 0.03% does not relieve nasal congestion, sneezing, or postnasal drip associated with allergic or nonallergic perennial rhinitis. uuid:53072ffe-a799-4929-9e79-df8103e90f9b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7852 biolink:treats MONDO:0005530 PMID:41385096 "[{""id"":""uuid:a473bc67-a0e2-4fc7-a4cc-cea60fc73431"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cf8d8070-3965-44f9-873f-70735c538261"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OXYCODONE HCl EXTENDED-RELEASE TABLETS are indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate in: Adults; and Opioid-tolerant pediatric patients 11 years of age and older who are already receiving and tolerate a minimum daily opioid dose of at least 20 mg oxycodone orally or its equivalent. Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations [see Warnings and Precautions (5.1) ] , reserve OXYCODONE HCl EXTENDED-RELEASE TABLETS for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. OXYCODONE HCl EXTENDED-RELEASE TABLETS are not indicated as an as-needed (prn) analgesic. uuid:bd514145-f2c8-4e02-96ca-6535f2a3c403 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7852 biolink:treats MONDO:0001225 PMID:41385096 "[{""id"":""uuid:de585bd6-e245-4431-803b-6cd0d6a52865"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8fb0fbff-ed27-41b7-860a-91f4aef94860"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OXYCODONE HCl EXTENDED-RELEASE TABLETS are indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate in: Adults; and Opioid-tolerant pediatric patients 11 years of age and older who are already receiving and tolerate a minimum daily opioid dose of at least 20 mg oxycodone orally or its equivalent. Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations [see Warnings and Precautions (5.1) ] , reserve OXYCODONE HCl EXTENDED-RELEASE TABLETS for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. OXYCODONE HCl EXTENDED-RELEASE TABLETS are not indicated as an as-needed (prn) analgesic. uuid:8e599dae-81fa-4bb2-8d1a-4f04358f9020 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7852 biolink:treats UMLS:C0572061 PMID:41385096 "[{""id"":""uuid:c6511033-a29e-4a4a-901b-c9c5fe8686cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b628f836-0f7b-449b-95c7-a4a3ed6c0c3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OXYCODONE HCl EXTENDED-RELEASE TABLETS are indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate in: Adults; and Opioid-tolerant pediatric patients 11 years of age and older who are already receiving and tolerate a minimum daily opioid dose of at least 20 mg oxycodone orally or its equivalent. Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations [see Warnings and Precautions (5.1) ] , reserve OXYCODONE HCl EXTENDED-RELEASE TABLETS for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. OXYCODONE HCl EXTENDED-RELEASE TABLETS are not indicated as an as-needed (prn) analgesic. uuid:f7db1c36-3d9b-481a-b291-a360f14cf11a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4027 biolink:treats MONDO:0018874 PMID:41385096 "[{""id"":""uuid:b8f0e0c7-12e1-4f71-a3a3-638650198531"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:02a7803d-3cdf-49e5-8c6f-882306234914"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Malignant Diseases Cyclophosphamide Injection is indicated for the treatment of adult and pediatric patients with: malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin's disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt's lymphoma multiple myeloma leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration) mycosis fungoides (advanced disease) neuroblastoma (disseminated disease) adenocarcinoma of the ovary retinoblastoma carcinoma of the breast Cyclophosphamide, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. uuid:a70b2072-1750-49b9-9a8c-16a286aa5251 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4027 biolink:treats MONDO:0004600 PMID:41385096 "[{""id"":""uuid:3e6a0f60-bba9-4127-bbe1-c7360eaafd33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fba5233d-9cb3-45b4-ad9e-8a5a98b0ba9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Malignant Diseases Cyclophosphamide Injection is indicated for the treatment of adult and pediatric patients with: malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin's disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitt's lymphoma multiple myeloma leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration) mycosis fungoides (advanced disease) neuroblastoma (disseminated disease) adenocarcinoma of the ovary retinoblastoma carcinoma of the breast Cyclophosphamide, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. uuid:12533dc1-762e-42d8-b9a1-f82ca9de076b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:76511460 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:848a0960-1cc1-4556-9ca4-bccf237392fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:66fa6633-3ac1-435a-a572-17fbbcb283df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PREZCOBIX is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection in treatment-naïve and treatment-experienced adults and pediatric patients weighing at least 40 kg with no darunavir resistance-associated substitutions (V11I, V32I, L33F, I47V, I50V, I54L, I54M, T74P, L76V, I84V, L89V). uuid:e2f70752-ff14-4a72-b61a-1f25b36970bc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63612 biolink:treats MONDO:0003537 PMID:41385096 "[{""id"":""uuid:5c2d3c27-7414-4e5d-903a-207169946d58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5625d673-bcf6-43d2-b7f1-1e258b7e8f68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a2c4e2ce-d4ec-4b42-a61a-323b13249c8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/atriance""]},{""id"":""uuid:02e89490-4f51-4513-b04e-8adbddf139c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nelarabine Injection is indicated for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least 2 chemotherapy regimens.|[EMA] Nelarabine is indicated for the treatment of patients with T-cell acute lymphoblastic leukaemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens., , Due to the small patient populations in these disease settings, the information to support these indications is based on limited data.,|[PMDA] A drug containing a new active ingredient indicated for the treatment of relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. [Orphan drug] uuid:3f09ada3-6410-4017-8809-7eb317664d97 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:913P6LK81M biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:c8150b06-26a2-4157-a714-686801c1ec4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9d48dd06-54a0-40a8-8ca9-53c18e7a61b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PIFELTRO ® is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg: with no prior antiretroviral treatment history; OR to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to doravirine [see Clinical Studies (14) ] . uuid:0d220d44-98dc-4641-b092-a5a490972de0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134991 biolink:treats MONDO:0005277 PMID:41385096 "[{""id"":""uuid:28729ac5-c90a-42c4-9d7f-8c8ed37fbeb6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f23cb01c-8b47-41f0-92ef-46165802b1f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Frovatriptan succinate tablets are indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use • Use only if a clear diagnosis of migraine has been established. If a patient has no response for the first migraine attack treated with frovatriptan succinate tablets, reconsider the diagnosis of migraine before frovatriptan succinate tablets are administered to treat any subsequent attacks. • Frovatriptan succinate tablets are not indicated for the prevention of migraine attacks. • Safety and effectiveness of frovatriptan succinate tablets have not been established for cluster headache. uuid:738376b8-9d6a-4a0d-9293-30d31e683cc5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5134 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:e8818442-f500-4d43-8693-7f76d6a951b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:00d7f4dc-5b8c-4924-9dcc-6e8d81c7df4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluticasone propionate lotion is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of atopic dermatitis in patients 3 months of age or older. uuid:1603af74-d78a-4f41-be78-24fc58447036 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64355 biolink:treats MONDO:0000240 PMID:41385096 "[{""id"":""uuid:bcfaf23e-d8c1-4f3c-8c5c-752297d0298c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a6d1ebdc-dfd0-470d-91e6-1d2d0f2ca2bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:41797356-83e1-40a3-ba53-859d09131f7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/posaconazole-ahcl""]},{""id"":""uuid:039331d1-5cc3-4743-b834-39e48af50ecf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Posaconazole is an azole antifungal indicated as follows: Posaconazole injection is indicated for the treatment of invasive aspergillosis in adults and pediatric patients 13 years of age and older. ( 1.1 ) Posaconazole is indicated for the prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy as follows: ( 1.2 ) Posaconazole injection: adults and pediatric patients 2 years of age and older|[EMA] Posaconazole AHCL oral suspension is indicated for use in the treatment of the following fungal infections in adults:Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.Oropharyngeal candidiasis: as first-line therapy in patients who have severe disease or are immunocompromised, in whom response to topical therapy is expected to be poor.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Posaconazole AHCL oral suspension is also indicated for prophylaxis of invasive fungal infections in the following patients:Patients receiving remission-induction chemotherapy for acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.|[PMDA] Drugs with a new indication for the treatment of invasive aspergillosis. uuid:cc2752a2-555c-48e4-bd80-6b764b2e2702 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3216 biolink:treats MONDO:0018362 PMID:41385096 "[{""id"":""uuid:9145f5c3-c5d5-4983-9b75-c60d52b4b234"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b20d9c38-170b-4ba7-8f17-7061cf076d23"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BELBUCA is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic and for which alternative treatment options are inadequate. uuid:4573eda3-bc7e-430a-a4b6-2d1119f4a04e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29103 biolink:treats MONDO:0005020 PMID:41385096 "[{""id"":""uuid:c9312241-e74b-4ee8-8846-c070819cfb43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:843e4195-3059-4e87-9038-0daba438f9b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BECAUSE OF REPORTS OF INTESTINAL AND GASTRIC ULCERATION AND BLEEDING WITH CONTROLLED-RELEASE POTASSIUM CHLORIDE PREPARATIONS, THESE DRUGS SHOULD BE RESERVED FOR THOSE PATIENTS WHO CANNOT TOLERATE OR REFUSE TO TAKE LIQUID OR EFFERVESCENT POTASSIUM PREPARATIONS OR FOR PATIENTS IN WHOM THERE IS A PROBLEM OF COMPLIANCE WITH THESE PREPARATIONS. 1. For the treatment of patients with hypokalemia with or without metabolic alkalosis, in digitalis intoxication, and in patients with hypokalemic familial periodic paralysis. If hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. 2. For the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias. The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern and when low doses of the diuretic are used. Serum potassium should be checked periodically, however, and if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases, and if dose adjustment of the diuretic is ineffective or unwarranted, supplementation with potassium salts may be indicated. uuid:dd8f0189-4afc-4470-90bb-3a1544378a95 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29103 biolink:treats MONDO:0001126 PMID:41385096 "[{""id"":""uuid:4078a3dd-0cd8-48e2-8ff8-5933a998d68c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0e4aecfd-054f-4c6c-b502-2c0ec49635b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BECAUSE OF REPORTS OF INTESTINAL AND GASTRIC ULCERATION AND BLEEDING WITH CONTROLLED-RELEASE POTASSIUM CHLORIDE PREPARATIONS, THESE DRUGS SHOULD BE RESERVED FOR THOSE PATIENTS WHO CANNOT TOLERATE OR REFUSE TO TAKE LIQUID OR EFFERVESCENT POTASSIUM PREPARATIONS OR FOR PATIENTS IN WHOM THERE IS A PROBLEM OF COMPLIANCE WITH THESE PREPARATIONS. 1. For the treatment of patients with hypokalemia with or without metabolic alkalosis, in digitalis intoxication, and in patients with hypokalemic familial periodic paralysis. If hypokalemia is the result of diuretic therapy, consideration should be given to the use of a lower dose of diuretic, which may be sufficient without leading to hypokalemia. 2. For the prevention of hypokalemia in patients who would be at particular risk if hypokalemia were to develop, e.g., digitalized patients or patients with significant cardiac arrhythmias. The use of potassium salts in patients receiving diuretics for uncomplicated essential hypertension is often unnecessary when such patients have a normal dietary pattern and when low doses of the diuretic are used. Serum potassium should be checked periodically, however, and if hypokalemia occurs, dietary supplementation with potassium-containing foods may be adequate to control milder cases. In more severe cases, and if dose adjustment of the diuretic is ineffective or unwarranted, supplementation with potassium salts may be indicated. uuid:c05c2ca5-c5b7-4c2a-9a83-9a11f96aef36 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31348 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:6bdd62b4-e9e7-4149-affb-3187ded6629e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:91ebf6f6-b8e1-46a6-b074-33a9747cdd77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:51e7337b-a4a1-4eb2-8055-b442ed498e7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ecansya""]},{""id"":""uuid:46791e2f-b8ba-48c8-b527-3a0e7f1019fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Capecitabine is a nucleoside metabolic inhibitor indicated for: Colorectal Cancer adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. ( 1.1 ) perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. ( 1.1 ) treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. ( 1.1 ) Breast Cancer treatment of patients with advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated. ( 1.2 ) treatment of patients with advanced or metastatic breast cancer in combination with docetaxel after disease progression on prior anthracycline-containing chemotherapy.( 1.2 ) Gastric, Esophageal, or Gastroesophageal Junction Cancer treatment of adults with unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer as a component of a combination chemotherapy regimen. ( 1.3 ) treatment of adults with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease as a component of a combination regimen. ( 1.3 ) Pancreatic Cancer adjuvant treatment of adults with pancreatic adenocarcinoma as a component of a combination chemotherapy regimen. ( 1.4 )|[EMA] Capecitabine Medac is indicated for the adjuvant treatment of patients following surgery of stage-III (Dukes’ stage-C) colon cancer.Capecitabine Medac is indicated for the treatment of metastatic colorectal cancer.Capecitabine Medac is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen.Capecitabine Medac in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.Capecitabine Medac is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline-containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.|[PMDA] A drug with a new dosage indicated for the treatment of unresectable or recurrent breast cancer and colorectal cancer. [Public knowledge-based application] uuid:082e15d7-5ab4-4580-be9e-dea324147dc8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31348 biolink:treats MONDO:0850129 PMID:41385096 "[{""id"":""uuid:02140586-be28-47a3-8154-9973a3b3ace4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a8da1b80-579c-4763-872c-6b30bb0c41a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Capecitabine is a nucleoside metabolic inhibitor indicated for: Colorectal Cancer adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. ( 1.1 ) perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. ( 1.1 ) treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. ( 1.1 ) Breast Cancer treatment of patients with advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated. ( 1.2 ) treatment of patients with advanced or metastatic breast cancer in combination with docetaxel after disease progression on prior anthracycline-containing chemotherapy.( 1.2 ) Gastric, Esophageal, or Gastroesophageal Junction Cancer treatment of adults with unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer as a component of a combination chemotherapy regimen. ( 1.3 ) treatment of adults with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease as a component of a combination regimen. ( 1.3 ) Pancreatic Cancer adjuvant treatment of adults with pancreatic adenocarcinoma as a component of a combination chemotherapy regimen. ( 1.4 ) uuid:408479b6-5405-4fb8-a6e3-7523f63dda9e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31348 biolink:treats MONDO:0021040 PMID:41385096 "[{""id"":""uuid:22b30bb7-589b-4e7f-bd7c-5c0825692e84"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:18969a63-8d50-4bbe-b094-0d6c51e0b6c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Capecitabine is a nucleoside metabolic inhibitor indicated for: Colorectal Cancer adjuvant treatment of patients with Stage III colon cancer as a single agent or as a component of a combination chemotherapy regimen. ( 1.1 ) perioperative treatment of adults with locally advanced rectal cancer as a component of chemoradiotherapy. ( 1.1 ) treatment of patients with unresectable or metastatic colorectal cancer as a single agent or as a component of a combination chemotherapy regimen. ( 1.1 ) Breast Cancer treatment of patients with advanced or metastatic breast cancer as a single agent if an anthracycline- or taxane-containing chemotherapy is not indicated. ( 1.2 ) treatment of patients with advanced or metastatic breast cancer in combination with docetaxel after disease progression on prior anthracycline-containing chemotherapy.( 1.2 ) Gastric, Esophageal, or Gastroesophageal Junction Cancer treatment of adults with unresectable or metastatic gastric, esophageal, or gastroesophageal junction cancer as a component of a combination chemotherapy regimen. ( 1.3 ) treatment of adults with HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma who have not received prior treatment for metastatic disease as a component of a combination regimen. ( 1.3 ) Pancreatic Cancer adjuvant treatment of adults with pancreatic adenocarcinoma as a component of a combination chemotherapy regimen. ( 1.4 ) uuid:22b68bcb-5b49-4a70-b322-0140c34eec8d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:209807 biolink:treats UMLS:C1112209 PMID:41385096 "[{""id"":""uuid:af1905b9-238a-49e9-811f-d3af5b9e44db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9a17c09c-703a-44eb-a61d-b96800bc253d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefoxitin for Injection, USP is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections, including pneumonia and lung abscess, caused by Streptococcus pneumoniae , other streptococci (excluding enterococci, e.g., Enterococcus faecalis [formerly Streptococcus faecalis ]), Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli , Klebsiella species, Haemophilus influenzae, and Bacteroides species. (2) Urinary tract infections caused by Escherichia coli , Klebsiella species, Proteus mirabilis , Morganella morganii , Proteus vulgaris and Providencia species (including P. rettgeri ). (3) Intra-abdominal infections, including peritonitis and intra-abdominal abscess, caused by Escherichia coli , Klebsiella species, Bacteroides species including Bacteroides fragilis , and Clostridium species. (4) Gynecological infections, including endometritis, pelvic cellulitis, and pelvic inflammatory disease caused by Escherichia coli , Neisseria gonorrhoeae (including penicillinase-producing strains), Bacteroides species including B. fragilis , Clostridium species, Peptococcus niger , Peptostreptococcus species, and Streptococcus agalactiae . Cefoxitin for Injection, USP, like cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when Cefoxitin for Injection, USP is used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (5) Septicemia caused by Streptococcus pneumoniae , Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli , Klebsiella species, and Bacteroides species including B. fragilis. (6) Bone and joint infections caused by Staphylococcus aureus (including Penicillinase-producing strains). (7) Skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains), Staphylococcus epidermidis , Streptococcus pyogenes and other streptococci (excluding enterococci e.g., Enterococcus faecalis [formerly Streptococcus faecalis ]), Escherichia coli , Proteus mirabilis , Klebsiella species, Bacteroides species including B. fragilis , Clostridium species, Peptococcus niger , and Peptostreptococcus species. Appropriate culture and susceptibility studies should be performed to determine the susceptibility of the causative organisms to Cefoxitin for Injection, USP. Therapy may be started while awaiting the results of these studies. In randomized comparative studies, Cefoxitin for Injection, USP and cephalothin were comparably safe and effective in the management of infections caused by gram-positive cocci and gram-negative rods susceptible to the cephalosporins. Cefoxitin for Injection, USP has a high degree of stability in the presence of bacterial beta-lactamases, both penicillinases and cephalosporinases. Many infections caused by aerobic and anaerobic gram-negative bacteria resistant to some cephalosporins respond to Cefoxitin for Injection, USP. Similarly, many infections caused by aerobic and anaerobic bacteria resistant to some penicillin antibiotics (ampicillin, carbenicillin, penicillin G) respond to treatment with Cefoxitin for Injection, USP. Many infections caused by mixtures of susceptible aerobic and anaerobic bacteria respond to treatment with Cefoxitin for Injection, USP. uuid:462c0fe6-7baa-48a9-ac1d-007b19844bad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:209807 biolink:treats UMLS:C1262234 PMID:41385096 "[{""id"":""uuid:d57d38cd-8aba-4998-885c-a1217b2883c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:16feeb04-972d-44a1-ba5e-12151ac4c516"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefoxitin for Injection, USP is indicated for the treatment of serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections, including pneumonia and lung abscess, caused by Streptococcus pneumoniae , other streptococci (excluding enterococci, e.g., Enterococcus faecalis [formerly Streptococcus faecalis ]), Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli , Klebsiella species, Haemophilus influenzae, and Bacteroides species. (2) Urinary tract infections caused by Escherichia coli , Klebsiella species, Proteus mirabilis , Morganella morganii , Proteus vulgaris and Providencia species (including P. rettgeri ). (3) Intra-abdominal infections, including peritonitis and intra-abdominal abscess, caused by Escherichia coli , Klebsiella species, Bacteroides species including Bacteroides fragilis , and Clostridium species. (4) Gynecological infections, including endometritis, pelvic cellulitis, and pelvic inflammatory disease caused by Escherichia coli , Neisseria gonorrhoeae (including penicillinase-producing strains), Bacteroides species including B. fragilis , Clostridium species, Peptococcus niger , Peptostreptococcus species, and Streptococcus agalactiae . Cefoxitin for Injection, USP, like cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when Cefoxitin for Injection, USP is used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (5) Septicemia caused by Streptococcus pneumoniae , Staphylococcus aureus (including penicillinase-producing strains), Escherichia coli , Klebsiella species, and Bacteroides species including B. fragilis. (6) Bone and joint infections caused by Staphylococcus aureus (including Penicillinase-producing strains). (7) Skin and skin structure infections caused by Staphylococcus aureus (including penicillinase-producing strains), Staphylococcus epidermidis , Streptococcus pyogenes and other streptococci (excluding enterococci e.g., Enterococcus faecalis [formerly Streptococcus faecalis ]), Escherichia coli , Proteus mirabilis , Klebsiella species, Bacteroides species including B. fragilis , Clostridium species, Peptococcus niger , and Peptostreptococcus species. Appropriate culture and susceptibility studies should be performed to determine the susceptibility of the causative organisms to Cefoxitin for Injection, USP. Therapy may be started while awaiting the results of these studies. In randomized comparative studies, Cefoxitin for Injection, USP and cephalothin were comparably safe and effective in the management of infections caused by gram-positive cocci and gram-negative rods susceptible to the cephalosporins. Cefoxitin for Injection, USP has a high degree of stability in the presence of bacterial beta-lactamases, both penicillinases and cephalosporinases. Many infections caused by aerobic and anaerobic gram-negative bacteria resistant to some cephalosporins respond to Cefoxitin for Injection, USP. Similarly, many infections caused by aerobic and anaerobic bacteria resistant to some penicillin antibiotics (ampicillin, carbenicillin, penicillin G) respond to treatment with Cefoxitin for Injection, USP. Many infections caused by mixtures of susceptible aerobic and anaerobic bacteria respond to treatment with Cefoxitin for Injection, USP. uuid:fa63b05e-85ab-4433-a3ec-34123818658c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5855 biolink:treats MONDO:0011827 PMID:41385096 "[{""id"":""uuid:fee6b0c0-bc22-4406-baa2-404683598d73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2dca5fa7-bf52-4bb1-9ae8-abcca53599a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f9f5f0b8-2bc8-478c-89c7-1ae7d5511e5d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/pedea""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ibuprofen Lysine is indicated to close a clinically significant patent ductus arteriosus (PDA) in premature infants weighing between 500 and 1500 g, who are no more than 32 weeks gestational age when usual medical management (e.g., fluid restriction, diuretics, respiratory support, etc.) is ineffective. The clinical trial was conducted among infants with an asymptomatic PDA. However, the consequences beyond 8 weeks after treatment have not been evaluated; therefore, treatment should be reserved for infants with clear evidence of a clinically significant PDA.|[EMA] Treatment of a haemodynamically significant patent ductus arteriosus in preterm newborn infants less than 34 weeks of gestational age. uuid:3e0feeb5-a884-4905-8176-ee289fecc3d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68556 biolink:treats MONDO:0019623 PMID:41385096 "[{""id"":""uuid:a59602e5-99e0-446f-982b-9f90e98d4279"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0e88ef3c-f804-4d7b-a4bc-25410219ddd7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:472e383c-5d17-4265-8715-d49a3752b4e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/firazyr""]},{""id"":""uuid:1718594a-9ffc-4095-8a97-24ae54f8fdde"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Icatibant injection is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.|[EMA] Firazyr is indicated for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults (with C1-esterase-inhibitor deficiency).|[PMDA] A drug with a new active ingredient indicated for the treatment of acute attacks of hereditary angioedema. [Orphan drug] uuid:2c646d21-7ade-40d8-9d06-a00fd936e7f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68556 biolink:treats MONDO:0012526 PMID:41385096 "[{""id"":""uuid:37623174-ee7c-4cfa-8056-23fa38baa4de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b9417617-f8bc-4aad-a12c-79969ec2908b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Icatibant injection is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older. uuid:8ae557a3-3586-4102-ade9-b6e75058ea46 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4464 biolink:treats MONDO:0024332 PMID:41385096 "[{""id"":""uuid:0b4a5462-2294-4a82-8d15-5da62ab907fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4f79c57e-4c0e-4be2-8e38-2c99a3a26d8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema Amelioration of allergic reactions to blood or plasma Dermographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. uuid:ca7dc2f5-ae18-4e6a-9700-2f4f77bcb5f5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4464 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:defe1fa2-6693-4593-b20e-2eed6a0e8795"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c47fa7e4-033d-4a23-bfba-cf5155128b4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema Amelioration of allergic reactions to blood or plasma Dermographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. uuid:f5dc2c54-e59f-4416-a470-dd0b5ef46002 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4464 biolink:treats MONDO:0006004 PMID:41385096 "[{""id"":""uuid:8ea99fb0-2eda-491a-8630-b2953fbcc01e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fb0f19e7-845b-4a4b-8f95-35309e1bbd60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema Amelioration of allergic reactions to blood or plasma Dermographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. uuid:16ba9654-9e59-4d16-bcf7-8d86c2687a67 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4464 biolink:treats MONDO:0005492 PMID:41385096 "[{""id"":""uuid:892a74c2-be2a-41b2-a84c-7d3dafa6852e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:42024845-2ac2-4bf5-ab97-225acff65c2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema Amelioration of allergic reactions to blood or plasma Dermographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. uuid:f0002cd1-24c1-4899-a873-121924c8e4e1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4464 biolink:treats MONDO:0010481 PMID:41385096 "[{""id"":""uuid:98ceafe7-653b-4e90-890d-93c984e9fdb7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:48e6d60c-97c9-43d7-b8bf-19147441a378"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema Amelioration of allergic reactions to blood or plasma Dermographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. uuid:36fcb4d7-0336-41b2-aca7-1cb7219dcb3b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4464 biolink:treats MONDO:0100053 PMID:41385096 "[{""id"":""uuid:2609dc43-65af-4d2f-b621-d35bfeaad4c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:18bf34ac-387b-4ecd-85de-09715ae4a1a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema Amelioration of allergic reactions to blood or plasma Dermographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. uuid:b778e02b-f0c6-4a14-9076-716e41d7ca52 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4464 biolink:treats MONDO:0007448 PMID:41385096 "[{""id"":""uuid:aa374b4c-186f-4f59-a642-86aa61760c5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:46674416-7541-434a-a16e-4cb3cac91dce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Perennial and seasonal allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema Amelioration of allergic reactions to blood or plasma Dermographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. uuid:77bfcb09-5127-404b-9dfc-050ea1736445 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:WA16A5Y52X biolink:treats UMLS:C0573830 PMID:41385096 "[{""id"":""uuid:c9291841-b6ae-4eb0-a0d0-d36f301f851e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6c3795bb-4d0c-4057-b5ac-8d428b7a77d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levoleucovorin Injection is indicated for: rescue after high-dose methotrexate therapy in adult and pediatric patients with osteosarcoma. diminishing the toxicity associated with overdosage of folic acid antagonists or impaired methotrexate elimination in adult and pediatric patients. the treatment of adults with metastatic colorectal cancer in combination with fluorouracil. Limitations of Use Levoleucovorin Injection is not indicated for pernicious anemia and megaloblastic anemia secondary to the lack of vitamin B 12 , because of the risk of progression of neurologic manifestations despite hematologic remission. PUBCHEM.COMPOUND:135465090 uuid:31ea6457-347e-4aba-a44e-e8c7efc34261 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16469 biolink:treats UMLS:C3671918 PMID:41385096 "[{""id"":""uuid:9435769c-df44-4ac1-bb63-6f66c935115c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e17a5919-db5b-4bb9-86aa-a8588fed4bd4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b28ec63b-eef1-424c-b4d6-70bcfaa319e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Estradiol tablets are indicated in the: Treatment of moderate to severe vasomotor symptoms associated with the menopause. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. Treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. Treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). Prevention of osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate. (See CLINICAL PHARMACOLOGY , Clinical Studies. ) The mainstays for decreasing the risk of postmenopausal osteoporosis are weight bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 1500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400 to 800 IU/day may also be required to ensure adequate daily intake in postmenopausal women.|[PMDA] A drug with a new additional indication and new dosages for the treatment of hypoestrogenism caused by hypogonadism, gonadectomy or primary ovarian insufficiency. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:189e6c00-13b1-4e33-ab3f-65139f4fcbf3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16469 biolink:treats MONDO:0002146 PMID:41385096 "[{""id"":""uuid:8207857f-80f2-4b0c-a220-c9254c3fe10b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:80958444-e9bd-45bf-8406-caf23946867f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2923f5e5-8488-4d9f-b205-f04f194b81b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Estradiol tablets are indicated in the: Treatment of moderate to severe vasomotor symptoms associated with the menopause. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure. Treatment of breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. Treatment of advanced androgen-dependent carcinoma of the prostate (for palliation only). Prevention of osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and for whom non-estrogen medications are not considered to be appropriate. (See CLINICAL PHARMACOLOGY , Clinical Studies. ) The mainstays for decreasing the risk of postmenopausal osteoporosis are weight bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 1500 mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400 to 800 IU/day may also be required to ensure adequate daily intake in postmenopausal women.|[PMDA] A drug with a new additional indication and new dosages for the treatment of hypoestrogenism caused by hypogonadism, gonadectomy or primary ovarian insufficiency. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:7dfa2432-c690-4a6a-87a3-d492cbed332d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3398 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:bec800d5-43a3-4327-9e48-0bb4bd3b5101"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fbc83721-f387-4c06-a1e9-4195810b9f2b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carbinoxamine maleate is effective for the symptomatic treatment of: Seasonal and perennial allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Dermatographism. As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. Amelioration of the severity of allergic reactions to blood or plasma. uuid:8d57aa8d-a34e-4678-99ea-8c195b335afa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3398 biolink:treats MONDO:0024332 PMID:41385096 "[{""id"":""uuid:4b4dca15-f16a-492a-9342-ec0a574a0008"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:507623e0-23b2-440c-9fae-2ce33e4dbe5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carbinoxamine maleate is effective for the symptomatic treatment of: Seasonal and perennial allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Dermatographism. As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. Amelioration of the severity of allergic reactions to blood or plasma. uuid:67c86fdf-77c9-4f79-bd27-d7530d3c7ef6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3398 biolink:treats MONDO:0006004 PMID:41385096 "[{""id"":""uuid:c444e18a-6063-440a-a900-17d038b8617d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:92863c9d-8bf1-4273-918a-b3c905f5c264"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carbinoxamine maleate is effective for the symptomatic treatment of: Seasonal and perennial allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Dermatographism. As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. Amelioration of the severity of allergic reactions to blood or plasma. uuid:86806d1d-540d-4344-adde-e250b4aafd80 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3398 biolink:treats MONDO:0005492 PMID:41385096 "[{""id"":""uuid:1525ccc0-7996-4b96-b534-b03416187322"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dc6f5323-146a-44ff-ad22-da977af2ba32"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carbinoxamine maleate is effective for the symptomatic treatment of: Seasonal and perennial allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Dermatographism. As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. Amelioration of the severity of allergic reactions to blood or plasma. uuid:3527b4ec-df25-49e6-89bb-88b0e9d81150 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3398 biolink:treats MONDO:0010481 PMID:41385096 "[{""id"":""uuid:c485d55d-9550-49f8-a383-a6b902247dbc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8fa3649b-a38c-4709-88e3-1d50d21df856"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carbinoxamine maleate is effective for the symptomatic treatment of: Seasonal and perennial allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Dermatographism. As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. Amelioration of the severity of allergic reactions to blood or plasma. uuid:6060996f-271b-45bb-98e2-ff685ad29e02 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3398 biolink:treats MONDO:0007448 PMID:41385096 "[{""id"":""uuid:938a0cdd-5e44-480a-8de9-c25f7e3c0436"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:efef1999-0b11-49c9-a8d5-7c8427cae380"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carbinoxamine maleate is effective for the symptomatic treatment of: Seasonal and perennial allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Dermatographism. As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. Amelioration of the severity of allergic reactions to blood or plasma. uuid:6b73a28f-62e7-49e9-b6ea-b8810cb80517 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3398 biolink:treats MONDO:0100053 PMID:41385096 "[{""id"":""uuid:a4cbbc61-63ec-4879-bda6-5848c0a4aabd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a7b39cf3-8ad0-4ce6-b4bd-58129e5faf02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carbinoxamine maleate is effective for the symptomatic treatment of: Seasonal and perennial allergic rhinitis. Vasomotor rhinitis. Allergic conjunctivitis due to inhalant allergens and foods. Mild, uncomplicated allergic skin manifestations of urticaria and angioedema. Dermatographism. As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled. Amelioration of the severity of allergic reactions to blood or plasma. uuid:8acd794c-2b14-4cce-bbd5-a87c17fee0c1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:91583 biolink:treats MONDO:0015254 PMID:41385096 "[{""id"":""uuid:719ec7e5-d345-4cb9-b529-1ff8f637678d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:05a6ed7f-310b-4d90-91a0-4b91ab54b107"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Biltricide is indicated in patients aged 1 year and older for the treatment of the following infections: • Schistosomiasis due to all species of schistosoma (for example, Schistosoma mekongi, Schistosoma japonicum, Schistosoma mansoni and Schistosoma hematobium ), and • Clonorchiasis and Opisthorchiasis due to the liver flukes, Clonorchis sinensis/Opisthorchis viverrini (approval of this indication was based on studies in which the two species were not differentiated) uuid:69ff275d-35e9-4a6e-914c-503d20a0c58e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3A58010674 biolink:treats MONDO:0004992 PMID:41385096 "[{""id"":""uuid:7ec95484-da07-44f0-95f9-965e7cf5f210"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aabb5ac6-b9d2-4549-aeac-5c2fe67ae21a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fulphila is a leukocyte growth factor indicated to • Decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. ( 1.1 ) Limitations of Use Fulphila is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation. uuid:5781aaf5-32fe-4b1f-9830-8acde8672366 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32229 biolink:treats MONDO:0024647 PMID:41385096 "[{""id"":""uuid:42691841-6068-44ae-b908-9c7b6bf5882b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2b7a3dc6-a026-4414-8088-a25c093cb51a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] THIOLA ® is indicated for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria with urinary cystine greater than 500 mg/day, who are resistant to treatment with conservative measures of high fluid intake, alkali and diet modification, or who have adverse reactions to d-penicillamine. Cystine stones typically occur in approximately 10,000 persons in the United States who are homozygous for cystinuria. These persons excrete abnormal amounts of cystine in urine of over 250 mg/g creatinine, as well as excessive amounts of other dibasic amino acids (lysine, arginine and ornithine). In addition, they show varying intestinal transport defects for these same amino acids. The stone formation is the result of poor aqueous solubility of cystine. Since there are no known inhibitors of the crystallization of cystine, the stone formation is determined primarily by the urinary supersaturation of cystine. Thus, cystine stones could theoretically form whenever urinary cystine concentration exceeds the solubility limit. Cystine solubility in urine is pH-dependent, and ranges from 170-300 mg/liter at pH 5, 190-400 mg/liter at pH 7 and 220-500 mg/liter at pH 7.5. The goal of therapy is to reduce urinary cystine concentration below its solubility limit. It may be accomplished by dietary means aimed at reducing cystine synthesis and by a high fluid intake in order to increase urine volume and thereby lower cystine concentration. Unfortunately, the above conservative measures alone may be ineffective in controlling cystine stone formation in some homozygous patients with severe cystinuria (urinary cystine exceeding 500 mg/day). In such patients, d-penicillamine has been used as an additional therapy. Like THIOLA ™ , dpenicillamine undergoes thiol-disulfide exchange with cystine, thereby lowering the amount of sparingly soluble cystine in urine. However, d-penicillamine treatment is frequently accompanied by adverse reactions, such as dermatologic complications, hypersensitivity reactions, hematologic abnormalities and renal disturbances. THIOLA ® may have a particular therapeutic role in such patients. uuid:8fb301a1-3bf0-4d7b-9e2b-b8d7839ce696 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27777 biolink:treats MONDO:0006030 PMID:41385096 "[{""id"":""uuid:463f74e8-4999-4a0c-b673-09a0bef1c00e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:15005b1b-0d81-45bf-a8a2-1fd1d1eef2fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acetohydroxamic acid is indicated as adjunctive therapy in patients with chronic urea-splitting urinary infection. AHA is intended to decrease urinary ammonia and alkalinity, but it should not be used in lieu of curative surgical treatment (for patients with stones) or antimicrobial treatment. Long-term treatment with AHA may be warranted to maintain urease inhibition as long as urea-splitting infection is present. Experience with AHA does not go beyond 7 years. A patient package insert should be distributed to each patient who receives AHA. uuid:83ed4f8e-2ca1-471d-8c34-b4cc5b0f7bbc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68642 biolink:treats MONDO:0850353 PMID:41385096 "[{""id"":""uuid:c2bff203-2706-44c0-9954-d0088b195f0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:014074ac-1d43-496b-8cb9-5de205067cca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Abiraterone acetate tablets are indicated in combination with prednisone for the treatment of patients with Metastatic castration-resistant prostate cancer (CRPC) uuid:626db403-bec0-46ee-b685-ddad0cec51fe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51066 biolink:treats MONDO:0005338 PMID:41385096 "[{""id"":""uuid:9fc8fa66-c6bc-4664-a308-64ebb9c6b749"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:211f3553-a927-41a5-8758-7f7bfff6a255"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dapiprazole hydrochloride ophthalmic solution is indicated in the treatment of iatrogenically induced mydriasis produced by adrenergic (phenylephrine) or parasympatholytic (tropicamide) agents. Dapiprazole hydrochloride ophthalmic solution is not indicated for the reduction of intraocular pressure or in the treatment of open angle glaucoma. uuid:702220b0-ebca-4e9a-8140-346c7c728826 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42944 biolink:treats MONDO:0001627 PMID:41385096 "[{""id"":""uuid:e468e55a-016a-4b50-bc88-6236a0b76637"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e300423b-500e-461b-8ee1-0e0e192f2c8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Galantamine is indicated for the treatment of mild to moderate dementia of the Alzheimer’s type. uuid:c7eed24f-ba0a-4ebc-a45e-ca4d115557d8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6923 biolink:treats UMLS:C0919659 PMID:41385096 "[{""id"":""uuid:2027aab9-19f8-471c-aee0-293bb9d39f4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:98ef74b2-f755-453c-974d-bc9e58b896c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b6c4193e-c18f-4f67-99d6-9843c3d76937"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ORAVIG is indicated for the local treatment of oropharyngeal candidiasis (OPC) in adults.|[PMDA] A drug in a new dosage form indicated for the treatment of oropharyngeal candidiasis caused by Candida . uuid:bf33617c-8f5c-49ca-bdc1-ab090f646951 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6923 biolink:treats MONDO:0009769 PMID:41385096 "[{""id"":""uuid:7faaa552-92cb-41f2-8ea3-8882ea4df23f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:983d97c0-dd21-482d-bf6e-f0b77d403695"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ORAVIG is indicated for the local treatment of oropharyngeal candidiasis (OPC) in adults. uuid:0c43bf82-edd5-400e-be0e-1b07468ab96b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:135659058 biolink:treats MONDO:0024613 PMID:41385096 "[{""id"":""uuid:a263aecd-754a-4ccd-9ca4-6f0b91ab3e29"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ce212fb4-834f-4677-a446-ba1843d625f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Olanzapine and fluoxetine capsules are indicated for the treatment of: Acute depressive episodes in Bipolar I Disorder [see Clinical Studies (14.1) ]. Treatment resistant depression (Major Depressive Disorder in patient who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode) [see Clinical Studies (14.2) ]. uuid:3b2eab41-f0d1-44ea-80e2-bd410bb7b642 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:135659058 biolink:treats UMLS:C2063866 PMID:41385096 "[{""id"":""uuid:c27fb3ba-b4a4-4c6a-903c-227c56396fcf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:76cc12a7-6820-49fc-909e-d02b0df3f975"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Olanzapine and fluoxetine capsules are indicated for the treatment of: Acute depressive episodes in Bipolar I Disorder [see Clinical Studies (14.1) ]. Treatment resistant depression (Major Depressive Disorder in patient who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode) [see Clinical Studies (14.2) ]. uuid:d8fca6a4-90fd-4e22-b0d5-1b75ba649b0b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:135659058 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:c199b795-7964-40d7-bf13-ed507923cee8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3a7e84f3-6a20-4b0b-a382-1f4d1a4f7030"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Olanzapine and fluoxetine capsules are indicated for the treatment of: Acute depressive episodes in Bipolar I Disorder [see Clinical Studies (14.1) ]. Treatment resistant depression (Major Depressive Disorder in patient who do not respond to 2 separate trials of different antidepressants of adequate dose and duration in the current episode) [see Clinical Studies (14.2) ]. uuid:cbdb16a4-f1b0-41cd-bfe0-86d2459eb5e2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135598 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:a57a44fa-8765-4980-94cb-bdff5590d3f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e5195ca8-cfc1-480e-b003-84fde558dd53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MYOVIEW is a kit for the preparation of technetium Tc99m tetrofosmin for injection. Technetium Tc99m tetrofosmin injection is a radioactive diagnostic agent indicated for the following: Myocardial perfusion imaging under rest and/or exercise or pharmacologic stress conditions to delineate regions of reversible myocardial ischemia or infarcted myocardium in patients with known or suspected coronary artery disease ( 1.1 ) Assessment of left ventricular function (left ventricular ejection fraction and wall motion) in patients with known or suspected heart disease ( 1.2 ) uuid:974e70e2-d268-43c7-a7cc-5142050005eb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135598 biolink:treats MONDO:0005267 PMID:41385096 "[{""id"":""uuid:3401a47d-8270-4181-ba7e-58d7aba94904"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:be8a0277-a717-4084-bbd0-eff78965167b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MYOVIEW is a kit for the preparation of technetium Tc99m tetrofosmin for injection. Technetium Tc99m tetrofosmin injection is a radioactive diagnostic agent indicated for the following: Myocardial perfusion imaging under rest and/or exercise or pharmacologic stress conditions to delineate regions of reversible myocardial ischemia or infarcted myocardium in patients with known or suspected coronary artery disease ( 1.1 ) Assessment of left ventricular function (left ventricular ejection fraction and wall motion) in patients with known or suspected heart disease ( 1.2 ) uuid:c2040f9f-9f8f-44e6-a761-d794f18d374b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:105013 biolink:treats MONDO:0005227 PMID:41385096 "[{""id"":""uuid:0e3053fe-ecc2-4f2d-a7b9-bfe03c3bcb06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:67f0fd77-8854-4e91-8f21-98d976c8dec5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Indium In 111 Oxyquinoline Solution is indicated for radiolabeling autologous leukocytes. Indium In 111 oxyquinoline labeled leukocytes may be used as an adjunct in the detection of inflammatory processes to which leukocytes migrate, such as those associated with abscesses or other infection, following reinjection and detection by appropriate imaging procedures. The degree of accuracy may vary with labeling techniques and with the size, location and nature of the inflammatory process. Indium In 111 oxyquinoline labeled leukocyte imaging is not the preferred technique for the initial evaluation of patients with a high clinical probability of an abscess in a known location. Ultrasound or computed tomography may provide a better anatomical delineation of the infectious process and information may be obtained more quickly than with labeled leukocytes. If localization by these techniques is successful, labeled leukocytes should not be used as a confirmatory procedure. If localization or diagnosis by these methods fails or is ambiguous, indium In 111 oxyquinoline labeled leukocyte imaging may be appropriate. uuid:13cef1b5-f2d7-4659-85d1-d7d4b1cb646e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:105013 biolink:treats UMLS:C3714514 PMID:41385096 "[{""id"":""uuid:ca724c5d-e5e2-436f-9d36-95d878330a8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bc1673ec-73bd-4536-8ebe-c489dafcd0b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Indium In 111 Oxyquinoline Solution is indicated for radiolabeling autologous leukocytes. Indium In 111 oxyquinoline labeled leukocytes may be used as an adjunct in the detection of inflammatory processes to which leukocytes migrate, such as those associated with abscesses or other infection, following reinjection and detection by appropriate imaging procedures. The degree of accuracy may vary with labeling techniques and with the size, location and nature of the inflammatory process. Indium In 111 oxyquinoline labeled leukocyte imaging is not the preferred technique for the initial evaluation of patients with a high clinical probability of an abscess in a known location. Ultrasound or computed tomography may provide a better anatomical delineation of the infectious process and information may be obtained more quickly than with labeled leukocytes. If localization by these techniques is successful, labeled leukocytes should not be used as a confirmatory procedure. If localization or diagnosis by these methods fails or is ambiguous, indium In 111 oxyquinoline labeled leukocyte imaging may be appropriate. uuid:7991b163-51b7-45de-a4d4-b1c704296c72 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4027 biolink:treats MONDO:0006835 PMID:41385096 "[{""id"":""uuid:a372f266-bb06-4670-be70-5460d74e7eea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f3be86cd-8547-4c2b-a167-3d72878389ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclophosphamide is an alkylating drug indicated for treatment of: Malignant Diseases : malignant lymphomas: Hodgkin’s disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt’s lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma ( 1.1 ) Minimal Change Nephrotic Syndrome in Pediatric Patients : biopsy proven minimal change nephrotic syndrome in pediatric patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy ( 1.2 ) Limitations of Use: The safety and effectiveness for the treatment of nephrotic syndrome in adults or other renal disease has not been established. uuid:ac291941-d25a-4cf6-a739-bc95d0e2fd31 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1043298 biolink:treats MONDO:0006873 PMID:41385096 "[{""id"":""uuid:8e3dc0a1-b482-4c5a-a13a-cc391d53f8de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:783073c3-065f-467a-954f-8ae82fb5d345"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS: PNV-DHA is a multivitamin/multimineral nutritional supplement indicated for use in the dietary management of patients with nutritional deficiencies or are in need of nutritional supplementation. uuid:4259a983-8450-4202-ad3e-21df549d9445 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71260 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:bffb8913-e617-4a21-af33-b058f3eb1011"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d4804c36-4edd-4feb-91a8-6c99e6109380"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pitavastatin tablets are indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in: Adult with primary hyperlipidemia. Adults with heterozygous familial hypercholesterolemia (HeFH). Pediatric use information is approved for Kowa Co Ltd’s LIVALO (pitavastatin) tablets. However, due to Kowa Co Ltd’s marketing exclusivity rights, this drug product is not labeled with that information. uuid:2a1327a2-7222-412b-9ed4-30ad47057731 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71260 biolink:treats UMLS:C0342882 PMID:41385096 "[{""id"":""uuid:d6aae612-4351-448d-a5d9-939ed711c410"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:67b69ac2-7e6d-4418-ac9b-10c324c846dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pitavastatin tablets are indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in: Adult with primary hyperlipidemia. Adults with heterozygous familial hypercholesterolemia (HeFH). Pediatric use information is approved for Kowa Co Ltd’s LIVALO (pitavastatin) tablets. However, due to Kowa Co Ltd’s marketing exclusivity rights, this drug product is not labeled with that information. uuid:7f519ca9-15e9-4877-bfaf-b119bea27157 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3242 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:a470f90d-bb69-4cd8-858a-3e762c1aacae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8cd40e8e-33b7-45d0-998f-ba8a9fc52243"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Butorphanol tartrate nasal spray is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use : Because of the risks of addiction, abuse, and misuse, with opioids, which can occur at any dosage or duration [see WARNINGS ] reserve butorphanol tartrate nasal spray for use in patients for whom alternative treatment options (e.g., non-opioid analgesics): Have not been tolerated or are not expected to be tolerated, Have not provided adequate analgesia or are not expected to provide adequate analgesia Butorphanol tartrate nasal spray should not be used for an extended period of time unless the pain remains severe enough to require an opioid analgesic and for which alternative treatment options continue to be inadequate. uuid:aa539253-49ef-4a89-bdca-9c4846598f29 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1153890 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:693cf3ab-8000-443f-8d33-11da12d40fd0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2e11f4ae-ba5a-4bab-8303-b7ab8c0bb0f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TUXARIN ER is indicated for the temporary relief of cough and upper respiratory symptoms associated with allergy or the common cold in patients 18 years of age and older. uuid:17d61f61-8ec9-4b07-8b75-106dd4b990fa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50692 biolink:treats MONDO:0018912 PMID:41385096 "[{""id"":""uuid:d67f0f8d-8c3b-47de-aef0-697fcb886f7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6728900f-2d13-4846-a174-7c6453f3ccbd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mifepristone is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. LIMITATIONS OF USE: Mifepristone tablets should not be used in the treatment of patients with type 2 diabetes unless it is secondary to Cushing’s syndrome. uuid:ad549087-9bc8-4907-abab-10181057513c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50692 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:af9beb1a-1d60-4ea0-babb-7da6215d79b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:593ee7e4-568b-4439-989e-fee6fce3583f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mifepristone is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. LIMITATIONS OF USE: Mifepristone tablets should not be used in the treatment of patients with type 2 diabetes unless it is secondary to Cushing’s syndrome. uuid:f853d424-7e0e-4766-9976-fb5276d776dc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50692 biolink:treats MONDO:0001076 PMID:41385096 "[{""id"":""uuid:e4af5512-ac3b-41fc-9bb4-b448f643164a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1764b812-b358-4c53-a8de-23a31ded6016"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mifepristone is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. LIMITATIONS OF USE: Mifepristone tablets should not be used in the treatment of patients with type 2 diabetes unless it is secondary to Cushing’s syndrome. uuid:6ff911d7-b264-47c9-b273-f8a2cd598e68 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1164653 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:a1ae0b2c-2632-469d-b04c-1a841efc9d59"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7241cfb7-f9c4-4801-ba16-a753b9cb24a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] UrNeva Capsules is indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures. uuid:979f7c47-3692-4823-9542-fb90afad0682 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:284780 biolink:treats MONDO:0006652 PMID:41385096 "[{""id"":""uuid:b22ea7fa-29a5-4da1-965d-356b24c2c902"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c3246984-0c1e-4bdc-9205-a7aa48ffa311"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Telmisartan and hydrochlorothiazide tablets are combination of an angiotensin II receptor blocker (ARB) and a thiazide diuretic indicated for the treatment of hypertension, alone or with other antihypertensive agents, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1 ) Telmisartan and hydrochlorothiazide tablets are not indicated for initial therapy ( 1 ) uuid:d064feef-9814-4553-9931-9cf3f49391b8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6717 biolink:treats HP:0100607 PMID:41385096 "[{""id"":""uuid:288fd36f-50a2-4e86-bd06-cc520a8fe977"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:02eab753-98ee-4c79-8c6f-b3734008f354"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of mefenamic acid capsules and other treatment options before deciding to use mefenamic acid capsules. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ; Gastrointestinal Bleeding, Ulceration, and Perforation ). Mefenamic acid capsules are indicated: For relief of mild to moderate pain in patients ≥14 years of age, when therapy will not exceed one week (7 days). For treatment of primary dysmenorrhea. uuid:039bfd88-8672-43ae-bd9b-ee7314492d17 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:372890 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:2c1332fa-df10-4ad6-8fb3-8af66febae98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7f0dd56b-4b23-4152-b9d2-d35370452de3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metoprolol tartrate and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Metoprolol tartrate and hydrochlorothiazide tablets may be administered with other antihypertensive agents. Limitation of Use Metoprolol tartrate and hydrochlorothiazide tablets are not indicated for initial therapy of hypertension. If the fixed combination represents the dose titrated to the individual patient’s needs, therapy with the fixed combination may be more convenient than with the separate components. uuid:57f12129-fb9f-4dca-899a-963df33c3350 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:372890 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:783a039f-081a-41fb-a48a-20519d5e84e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:01de58bc-bdfe-4547-8a05-0a106b0c2ec5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metoprolol tartrate and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Metoprolol tartrate and hydrochlorothiazide tablets may be administered with other antihypertensive agents. Limitation of Use Metoprolol tartrate and hydrochlorothiazide tablets are not indicated for initial therapy of hypertension. If the fixed combination represents the dose titrated to the individual patient’s needs, therapy with the fixed combination may be more convenient than with the separate components. uuid:435b26aa-44d5-451c-ab0e-64cc5dcdd03e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:372890 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:9b758ecc-2274-4b96-beb5-353e5b55ea0c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:76b04e86-b227-4a38-ae9e-31a090b4ef84"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metoprolol tartrate and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Metoprolol tartrate and hydrochlorothiazide tablets may be administered with other antihypertensive agents. Limitation of Use Metoprolol tartrate and hydrochlorothiazide tablets are not indicated for initial therapy of hypertension. If the fixed combination represents the dose titrated to the individual patient’s needs, therapy with the fixed combination may be more convenient than with the separate components. uuid:af523e73-cfad-4e8c-991d-27f7415ac5ae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:372890 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:7ada312b-e60c-4d33-9c9b-25b18c83b131"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8338fc98-4eca-462c-88d3-6e8d65151ec7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metoprolol tartrate and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Metoprolol tartrate and hydrochlorothiazide tablets may be administered with other antihypertensive agents. Limitation of Use Metoprolol tartrate and hydrochlorothiazide tablets are not indicated for initial therapy of hypertension. If the fixed combination represents the dose titrated to the individual patient’s needs, therapy with the fixed combination may be more convenient than with the separate components. uuid:626bd3d7-a14b-4d1c-a604-d3f571b4175a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:372890 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:986b15d3-05dd-4f72-882f-d9bf7686a0a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d9025c72-8b98-4692-ab4a-00ef0e9fe757"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metoprolol tartrate and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Metoprolol tartrate and hydrochlorothiazide tablets may be administered with other antihypertensive agents. Limitation of Use Metoprolol tartrate and hydrochlorothiazide tablets are not indicated for initial therapy of hypertension. If the fixed combination represents the dose titrated to the individual patient’s needs, therapy with the fixed combination may be more convenient than with the separate components. uuid:a228b9a1-14a7-4704-923c-58e073042ace biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:372890 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:31afccf1-7dae-4375-85c1-17a3da4d0d35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2dd88afc-575a-41d3-9d0b-1175e61187b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metoprolol tartrate and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Metoprolol tartrate and hydrochlorothiazide tablets may be administered with other antihypertensive agents. Limitation of Use Metoprolol tartrate and hydrochlorothiazide tablets are not indicated for initial therapy of hypertension. If the fixed combination represents the dose titrated to the individual patient’s needs, therapy with the fixed combination may be more convenient than with the separate components. uuid:a8829e6c-4e55-4012-a7f2-c8d557e061c3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:372890 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:187bd628-89be-4ec5-847c-64f677dfab21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:719920b5-283b-4b69-a312-4b9d59ce2562"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metoprolol tartrate and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including metoprolol. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Metoprolol tartrate and hydrochlorothiazide tablets may be administered with other antihypertensive agents. Limitation of Use Metoprolol tartrate and hydrochlorothiazide tablets are not indicated for initial therapy of hypertension. If the fixed combination represents the dose titrated to the individual patient’s needs, therapy with the fixed combination may be more convenient than with the separate components. uuid:08d5d25e-1138-4095-9cb1-83f132491027 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16899 biolink:treats MONDO:0009061 PMID:41385096 "[{""id"":""uuid:0fe61638-9bfa-4893-978e-8f1ff7908a2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:45f0b24f-f305-4c62-ac36-28f5ee189a47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2bd0ce0d-f902-468f-bb00-5fd38c2cec76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/bronchitol""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] BRONCHITOL is indicated as add-on maintenance therapy to improve pulmonary function in adult patients 18 years and older with Cystic Fibrosis. Use BRONCHITOL only for adults who have passed the BRONCHITOL Tolerance Test [see Dosage and Administration ( 2.1 )].|[EMA] Bronchitol is indicated for the treatment of cystic fibrosis (CF) in adults aged 18 years and above as an add-on therapy to best standard of care. uuid:96e89253-651a-45ab-b1cc-776324581fdd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:0DE9724IHC biolink:treats UMLS:C0573789 PMID:41385096 "[{""id"":""uuid:2231071e-a449-4c05-8b9e-185ee90a9faa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c48b3f13-adc5-4bb7-85f0-41362412974d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Protamine Sulfate Injection, USP is indicated in the treatment of heparin overdosage. uuid:a8dda96a-820f-4c24-9ebc-e014d2030e69 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68610 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:1e5c4956-e5f5-44e7-9fd0-076cbd761820"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:41ae41db-a8de-43f2-82a9-9ed19ccaf51b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ac38a587-c9eb-4b2c-9f2a-3fe492738c2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/trajenta""]},{""id"":""uuid:bb8655a2-a443-47fd-b0fb-96026d3f9695"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRADJENTA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus .|[EMA] Trajenta is indicated in the treatment of type 2 diabetes mellitus to improve glycaemic control in adults:as monotherapyin patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to intolerance, or contraindicated due to renal impairment.as combination therapyin combination with metformin when diet and exercise plus metformin alone do not provide adequate glycaemic control.in combination with a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do not provide adequate glycaemic control.in combination with insulin with or without metformin, when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.|[PMDA] A drug with a new active ingredient indicated for the treatment of type 2 diabetes mellitus (for use only in patients who have not responded sufficiently to diet and exercise therapies alone). uuid:c00cd440-2acb-45e9-b473-dc1d102efd26 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135686 biolink:treats UMLS:C0400877 PMID:41385096 "[{""id"":""uuid:e817ea00-9053-4323-8a2d-799debf565a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a832539b-da10-47da-b0a3-4cee90d3d51c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Alvimopan capsules are indicated to accelerate the time to upper and lower gastrointestinal recovery following surgeries that include partial bowel resection with primary anastomosis. uuid:42a17d0d-0eef-480d-a306-d650b7f37b70 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5856 biolink:treats MONDO:0004981 PMID:41385096 "[{""id"":""uuid:e31c3707-d380-4ddc-8791-49fa37170662"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:018a57f6-05bb-4cc3-805b-a9932a9004cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CORVERT Injection is indicated for the rapid conversion of atrial fibrillation or atrial flutter of recent onset to sinus rhythm. Patients with atrial arrhythmias of longer duration are less likely to respond to CORVERT. The effectiveness of ibutilide has not been determined in patients with arrhythmias of more than 90 days in duration. uuid:15530716-f4bf-4768-8940-e1eb86c520bb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5856 biolink:treats MONDO:0005310 PMID:41385096 "[{""id"":""uuid:106ec962-f7e4-4cd0-885a-922d5a2e5125"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6fbc5807-8a00-45f3-8fff-40ae63ca5e06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CORVERT Injection is indicated for the rapid conversion of atrial fibrillation or atrial flutter of recent onset to sinus rhythm. Patients with atrial arrhythmias of longer duration are less likely to respond to CORVERT. The effectiveness of ibutilide has not been determined in patients with arrhythmias of more than 90 days in duration. uuid:fc3fe2be-ef55-4996-90db-2a940bbd8d00 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:0IEO0F56LV biolink:treats MONDO:0007100 PMID:41385096 "[{""id"":""uuid:c653c348-a04e-46f4-b73a-4fcf114bde1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:34c3ea00-70df-4198-9d07-9217367bf915"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:eb52ba92-6595-4bc0-8c92-93215b209745"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TEGSEDI is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.|[EMA] Treatment of stage 1 or Stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR). uuid:6de2815e-d557-4e63-9f26-44d16248a82e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18243 biolink:treats HP:0031273 PMID:41385096 "[{""id"":""uuid:81c939ea-bbc7-4fbd-838d-819a2dd8a55d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cf434e67-a7d2-4274-9566-5b1e4d4b71bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dopamine Hydrochloride in 5% Dextrose Injection, USP is indicated for the correction of hemodynamic imbalances present in shock due to myocardial infarction, trauma, endotoxic septicemia, open heart surgery, renal failure and chronic cardiac decompensation as in refractory congestive failure. When indicated, restoration of circulatory volume should be instituted or completed with a suitable plasma expander or whole blood, prior to administration of dopamine hydrochloride. Patients most likely to respond to dopamine are those whose physiological parameters (such as urine flow, myocardial function and blood pressure) have not undergone extreme deterioration. Reports indicate that the shorter the time between onset of signs and symptoms and initiation of therapy with volume restoration and dopamine, the better the prognosis. Poor Perfusion of Vital Organs: Although urine flow is apparently one of the better diagnostic signs for monitoring vital organ perfusion, the physician also should observe the patient for signs of reversal of mental confusion or coma. Loss of pallor, increase in toe temperature or adequacy of nail bed capillary filling also may be observed as indices of adequate dosage. Reported studies indicate that when dopamine is administered before urine flow has decreased to approximately 0.3 mL/minute prognosis is more favorable. However, it has been observed that in some oliguric or anuric patients, administration of the drug has produced an increase in urine flow which may reach normal levels. The drug also may increase urine flow in patients whose output is within normal limits and thus may help in reducing the degree of pre-existing fluid accumulation. Conversely, at higher than optimal doses for a given patient, urinary flow may decrease, requiring a reduction of dosage. Concomitant administration of dopamine and diuretic agents may produce an additive or potentiating effect. Low Cardiac Output: Dopamine's direct inotropic effect on the myocardium which increases cardiac output at low or moderate doses is related to a favorable prognosis. Increased output has been associated with unchanged or decreased systemic vascular resistance (SVR). The association of static or decreased SVR with low or moderate increases in cardiac output is regarded as a reflection of differential effects on specific vascular beds, with increased resistance in peripheral beds (e.g., femoral), and concurrent decreases in mesenteric and renal vascular beds. Redistribution of blood flow parallels these changes so that an increase in cardiac output is accompanied by an increase in mesenteric and renal blood flow. In many instances the renal fraction of the total cardiac output has been found to increase. Increase in cardiac output produced by dopamine is not associated with substantial decreases in systemic vascular resistance as may occur with isoproterenol. Hypotension: Low to moderate doses of dopamine, which have little effect on SVR, can be used to manage hypotension due to inadequate cardiac output. At high therapeutic doses, dopamine's α-adrenergic action becomes more prominent and thus may correct hypotension due to diminished SVR. As in other circulatory decompensation states, prognosis is better in patients whose blood pressure and urine flow have not undergone extreme deterioration. Therefore, it is suggested the physician administer dopamine as soon as a definite trend toward decreased systolic and diastolic pressure becomes apparent. uuid:29a661be-397e-4a62-a37b-7119268d9610 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18243 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:ec8df6d9-e0f6-44a1-b6fb-d642b27eeded"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6942df58-3eb4-413e-8e7a-45223d184355"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dopamine Hydrochloride in 5% Dextrose Injection, USP is indicated for the correction of hemodynamic imbalances present in shock due to myocardial infarction, trauma, endotoxic septicemia, open heart surgery, renal failure and chronic cardiac decompensation as in refractory congestive failure. When indicated, restoration of circulatory volume should be instituted or completed with a suitable plasma expander or whole blood, prior to administration of dopamine hydrochloride. Patients most likely to respond to dopamine are those whose physiological parameters (such as urine flow, myocardial function and blood pressure) have not undergone extreme deterioration. Reports indicate that the shorter the time between onset of signs and symptoms and initiation of therapy with volume restoration and dopamine, the better the prognosis. Poor Perfusion of Vital Organs: Although urine flow is apparently one of the better diagnostic signs for monitoring vital organ perfusion, the physician also should observe the patient for signs of reversal of mental confusion or coma. Loss of pallor, increase in toe temperature or adequacy of nail bed capillary filling also may be observed as indices of adequate dosage. Reported studies indicate that when dopamine is administered before urine flow has decreased to approximately 0.3 mL/minute prognosis is more favorable. However, it has been observed that in some oliguric or anuric patients, administration of the drug has produced an increase in urine flow which may reach normal levels. The drug also may increase urine flow in patients whose output is within normal limits and thus may help in reducing the degree of pre-existing fluid accumulation. Conversely, at higher than optimal doses for a given patient, urinary flow may decrease, requiring a reduction of dosage. Concomitant administration of dopamine and diuretic agents may produce an additive or potentiating effect. Low Cardiac Output: Dopamine's direct inotropic effect on the myocardium which increases cardiac output at low or moderate doses is related to a favorable prognosis. Increased output has been associated with unchanged or decreased systemic vascular resistance (SVR). The association of static or decreased SVR with low or moderate increases in cardiac output is regarded as a reflection of differential effects on specific vascular beds, with increased resistance in peripheral beds (e.g., femoral), and concurrent decreases in mesenteric and renal vascular beds. Redistribution of blood flow parallels these changes so that an increase in cardiac output is accompanied by an increase in mesenteric and renal blood flow. In many instances the renal fraction of the total cardiac output has been found to increase. Increase in cardiac output produced by dopamine is not associated with substantial decreases in systemic vascular resistance as may occur with isoproterenol. Hypotension: Low to moderate doses of dopamine, which have little effect on SVR, can be used to manage hypotension due to inadequate cardiac output. At high therapeutic doses, dopamine's α-adrenergic action becomes more prominent and thus may correct hypotension due to diminished SVR. As in other circulatory decompensation states, prognosis is better in patients whose blood pressure and urine flow have not undergone extreme deterioration. Therefore, it is suggested the physician administer dopamine as soon as a definite trend toward decreased systolic and diastolic pressure becomes apparent. uuid:a2856a31-f107-4049-a9f0-39fee2da7b13 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18243 biolink:treats HP:0001259 PMID:41385096 "[{""id"":""uuid:3da0c0ba-b0a2-4132-9eaf-9864c4181d91"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5de971d0-8791-4cc2-87a0-ac4b283ea459"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dopamine Hydrochloride in 5% Dextrose Injection, USP is indicated for the correction of hemodynamic imbalances present in shock due to myocardial infarction, trauma, endotoxic septicemia, open heart surgery, renal failure and chronic cardiac decompensation as in refractory congestive failure. When indicated, restoration of circulatory volume should be instituted or completed with a suitable plasma expander or whole blood, prior to administration of dopamine hydrochloride. Patients most likely to respond to dopamine are those whose physiological parameters (such as urine flow, myocardial function and blood pressure) have not undergone extreme deterioration. Reports indicate that the shorter the time between onset of signs and symptoms and initiation of therapy with volume restoration and dopamine, the better the prognosis. Poor Perfusion of Vital Organs: Although urine flow is apparently one of the better diagnostic signs for monitoring vital organ perfusion, the physician also should observe the patient for signs of reversal of mental confusion or coma. Loss of pallor, increase in toe temperature or adequacy of nail bed capillary filling also may be observed as indices of adequate dosage. Reported studies indicate that when dopamine is administered before urine flow has decreased to approximately 0.3 mL/minute prognosis is more favorable. However, it has been observed that in some oliguric or anuric patients, administration of the drug has produced an increase in urine flow which may reach normal levels. The drug also may increase urine flow in patients whose output is within normal limits and thus may help in reducing the degree of pre-existing fluid accumulation. Conversely, at higher than optimal doses for a given patient, urinary flow may decrease, requiring a reduction of dosage. Concomitant administration of dopamine and diuretic agents may produce an additive or potentiating effect. Low Cardiac Output: Dopamine's direct inotropic effect on the myocardium which increases cardiac output at low or moderate doses is related to a favorable prognosis. Increased output has been associated with unchanged or decreased systemic vascular resistance (SVR). The association of static or decreased SVR with low or moderate increases in cardiac output is regarded as a reflection of differential effects on specific vascular beds, with increased resistance in peripheral beds (e.g., femoral), and concurrent decreases in mesenteric and renal vascular beds. Redistribution of blood flow parallels these changes so that an increase in cardiac output is accompanied by an increase in mesenteric and renal blood flow. In many instances the renal fraction of the total cardiac output has been found to increase. Increase in cardiac output produced by dopamine is not associated with substantial decreases in systemic vascular resistance as may occur with isoproterenol. Hypotension: Low to moderate doses of dopamine, which have little effect on SVR, can be used to manage hypotension due to inadequate cardiac output. At high therapeutic doses, dopamine's α-adrenergic action becomes more prominent and thus may correct hypotension due to diminished SVR. As in other circulatory decompensation states, prognosis is better in patients whose blood pressure and urine flow have not undergone extreme deterioration. Therefore, it is suggested the physician administer dopamine as soon as a definite trend toward decreased systolic and diastolic pressure becomes apparent. uuid:73c0240e-10a5-4f42-9ea5-37889ac6e121 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28304 biolink:treats MONDO:0005399 PMID:41385096 "[{""id"":""uuid:f9ed84ef-b31e-4095-92b6-b987b103577b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:98a0eb95-d432-4aeb-8406-575330ea2e9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Heparin sodium is indicated for: Prophylaxis and treatment of venous thromboembolism and pulmonary embolism; Atrial fibrillation with embolization; Treatment of acute and chronic consumptive coagulopathies (disseminated intravascular coagulation); Prevention of clotting in arterial and cardiac surgery; Prophylaxis and treatment of peripheral arterial embolism; Anticoagulant use in blood transfusions, extracorporeal circulation, and dialysis procedures. uuid:93416996-d638-423f-a3e6-6bb4d7d3f898 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16709 biolink:treats MONDO:0004574 PMID:41385096 "[{""id"":""uuid:59a5705c-1b35-4d70-a83a-11ecb9a8df0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:07b905af-e96a-4925-9f4e-3fce9be3cff1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pyridoxine Hydrochloride Injection is effective for the treatment of pyridoxine deficiency as seen in the following: Inadequate dietary intake. Drug-induced deficiency, as from isoniazid (INH) or oral contraceptives. Inborn errors of metabolism, e.g., vitamin B6 dependent convulsions or vitamin B6 responsive anemia. The parenteral route is indicated when oral administration is not feasible as in anorexia, nausea and vomiting, and preoperative and postoperative conditions. It is also indicated when gastrointestinal absorption is impaired. uuid:ed454def-9efb-44e6-ad05-927124118c1d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16709 biolink:treats MONDO:0015005 PMID:41385096 "[{""id"":""uuid:b3a4bc24-4389-4db3-afb2-70294cabf65b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:026a1e1b-e0b7-4288-bce6-ee7870f8f4e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pyridoxine Hydrochloride Injection is effective for the treatment of pyridoxine deficiency as seen in the following: Inadequate dietary intake. Drug-induced deficiency, as from isoniazid (INH) or oral contraceptives. Inborn errors of metabolism, e.g., vitamin B6 dependent convulsions or vitamin B6 responsive anemia. The parenteral route is indicated when oral administration is not feasible as in anorexia, nausea and vomiting, and preoperative and postoperative conditions. It is also indicated when gastrointestinal absorption is impaired. uuid:2a7bf29a-b80c-490f-b7e6-75e6edb5a784 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16709 biolink:treats MONDO:0005351 PMID:41385096 "[{""id"":""uuid:29a6cba1-a294-4d86-9e24-45e038547e99"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:13a775c7-3e7a-46ff-9cb9-b8c193bb91d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pyridoxine Hydrochloride Injection is effective for the treatment of pyridoxine deficiency as seen in the following: Inadequate dietary intake. Drug-induced deficiency, as from isoniazid (INH) or oral contraceptives. Inborn errors of metabolism, e.g., vitamin B6 dependent convulsions or vitamin B6 responsive anemia. The parenteral route is indicated when oral administration is not feasible as in anorexia, nausea and vomiting, and preoperative and postoperative conditions. It is also indicated when gastrointestinal absorption is impaired. uuid:9d67e4ed-a7aa-4725-a546-df9ae92d27d3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16709 biolink:treats HP:0002017 PMID:41385096 "[{""id"":""uuid:1c7d00c8-d279-4014-b44d-1f8b5fd414d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9f72a874-528f-456b-afdd-27e6803e4ecd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pyridoxine Hydrochloride Injection is effective for the treatment of pyridoxine deficiency as seen in the following: Inadequate dietary intake. Drug-induced deficiency, as from isoniazid (INH) or oral contraceptives. Inborn errors of metabolism, e.g., vitamin B6 dependent convulsions or vitamin B6 responsive anemia. The parenteral route is indicated when oral administration is not feasible as in anorexia, nausea and vomiting, and preoperative and postoperative conditions. It is also indicated when gastrointestinal absorption is impaired. uuid:49042114-e926-4875-8d8d-fb95f6fb2d88 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5134 biolink:treats MONDO:0005093 PMID:41385096 "[{""id"":""uuid:3b9f8006-e31d-4d41-95db-980b94073d12"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5c2f60e8-8de3-4198-b5b4-6d43f9abbf22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluticasone propionate ointment is a corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in adult patients. uuid:a426e20b-baa2-47c3-a68b-4ab2f9b91a2e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229226 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:95a29c17-cb6f-4396-89a8-a5c4a0480fe5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:02324e13-19eb-4b24-a456-894143526a87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INPEFA is indicated to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with: heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors uuid:0869f0be-573e-4f34-bcab-f19a444209d9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229226 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:2e042f51-fa76-4988-9583-05df0517bd90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:385e3533-3591-4679-a5fc-b20025453ce9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INPEFA is indicated to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with: heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors uuid:61e129c8-a3e3-4ea3-b86b-339d44e792f1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229226 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:3856552f-ac4e-4606-9811-0a4b3ef9a0e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cd4f5699-ed92-466d-8d56-30c741124079"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INPEFA is indicated to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with: heart failure or type 2 diabetes mellitus, chronic kidney disease, and other cardiovascular risk factors uuid:41bc3e50-2311-450b-bb2f-867a7c529948 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2038 biolink:treats MONDO:0011908 PMID:41385096 "[{""id"":""uuid:93c8446f-5978-4a47-9e48-0502d9b8eafa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:71952aa6-81fb-493c-a3a3-b5c2b957ee89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VIDAZA is a nucleoside metabolic inhibitor indicated for the treatment of: • Adult patients with the following FAB myelodysplastic syndrome (MDS) subtypes: Refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) (if accompanied by neutropenia or thrombocytopenia or requiring transfusions), refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL). ( 1.1 ) • Pediatric patients aged 1 month and older with newly diagnosed Juvenile Myelomonocytic Leukemia (JMML). ( 1.2 ) uuid:28213d18-4abe-46fc-adad-efd4904e0ad2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71028 biolink:treats MONDO:0009377 PMID:41385096 "[{""id"":""uuid:403c3faf-8ced-4433-9c5c-a2acf2cb2b1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:233ec19a-2bd4-453e-b0f5-776811eead60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:48fecc0c-9f76-4f0f-b71b-4d738f39298b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/carbaglu""]},{""id"":""uuid:e9f6fca6-deb5-4fbf-9657-38a5140dce72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CARBAGLU is a carbamoyl phosphate synthetase 1 (CPS 1) activator indicated in pediatric and adult patients as: Adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. ( 1.1 ) Maintenance therapy for the treatment of chronic hyperammonemia due to NAGS deficiency. ( 1.1 ) Adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to propionic acidemia (PA) or methylmalonic acidemia (MMA). ( 1.2 )|[EMA] Carbaglu is indicated in treatment of:hyperammonaemia due to N-acetylglutamate-synthase primary deficiency;hyperammonaemia due to isovaleric acidaemia;hyperammonaemia due to methymalonic acidaemia;hyperammonaemia due to propionic acidaemia.|[PMDA] A drug with a new active ingredient indicated for the treatment of hyperammonemia due to N- acetylglutamate synthetase deficiency, isovaleric acidemia, methylmalonic acidemia, and propionic acidemia. [Orphan drug] uuid:3f3a92f8-5f2c-4589-a0dc-d8010d3c57c4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71028 biolink:treats HP:0001987 PMID:41385096 "[{""id"":""uuid:eff6d1d4-aab4-45c4-aa93-9f9ad8053fdf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b108c6a1-729e-4a84-a445-1a8c7d67afb3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CARBAGLU is a carbamoyl phosphate synthetase 1 (CPS 1) activator indicated in pediatric and adult patients as: Adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. ( 1.1 ) Maintenance therapy for the treatment of chronic hyperammonemia due to NAGS deficiency. ( 1.1 ) Adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to propionic acidemia (PA) or methylmalonic acidemia (MMA). ( 1.2 ) uuid:0f2d5def-54eb-4e03-b0ba-199315ae588f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71028 biolink:treats MONDO:0011628 PMID:41385096 "[{""id"":""uuid:f0c4a30d-4c7a-4428-8e1b-f5ca51877670"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:25cf7e81-c117-41d4-a635-266954484972"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:07dcb99e-ab4b-494a-a8f0-11d177c58ad3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CARBAGLU is a carbamoyl phosphate synthetase 1 (CPS 1) activator indicated in pediatric and adult patients as: Adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. ( 1.1 ) Maintenance therapy for the treatment of chronic hyperammonemia due to NAGS deficiency. ( 1.1 ) Adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to propionic acidemia (PA) or methylmalonic acidemia (MMA). ( 1.2 )|[PMDA] A drug with a new active ingredient indicated for the treatment of hyperammonemia due to N- acetylglutamate synthetase deficiency, isovaleric acidemia, methylmalonic acidemia, and propionic acidemia. [Orphan drug] uuid:152b988e-95f9-4aca-bf06-f863c53bf5c2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71028 biolink:treats MONDO:0002012 PMID:41385096 "[{""id"":""uuid:2bc9ae2c-270e-4aed-ab75-7e8b1fab3ffd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f5444fe6-a375-4607-bedb-10ed4344646b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:38153503-1eb2-4699-ad77-5aaff482133b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CARBAGLU is a carbamoyl phosphate synthetase 1 (CPS 1) activator indicated in pediatric and adult patients as: Adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. ( 1.1 ) Maintenance therapy for the treatment of chronic hyperammonemia due to NAGS deficiency. ( 1.1 ) Adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to propionic acidemia (PA) or methylmalonic acidemia (MMA). ( 1.2 )|[PMDA] A drug with a new active ingredient indicated for the treatment of hyperammonemia due to N- acetylglutamate synthetase deficiency, isovaleric acidemia, methylmalonic acidemia, and propionic acidemia. [Orphan drug] uuid:b393aaa1-fd98-4aa5-adde-67a6b6e08765 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68845 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:3aaa3755-9c9d-408d-b4f4-d49750aa5e63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d6f9d526-bce8-4d89-a06b-0bb95c49d731"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Edarbi is indicated for the treatment of hypertension in adults, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Edarbi. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Edarbi may be used alone or in combination with other antihypertensive agents. uuid:0c6e96c9-7a7d-4e09-918b-9666bd25ff45 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68845 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:8e75dd7b-ef4a-436e-bbd6-e84319ae558a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cec6d794-c08f-422d-b566-de3476a117c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Edarbi is indicated for the treatment of hypertension in adults, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Edarbi. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Edarbi may be used alone or in combination with other antihypertensive agents. uuid:b5fb1852-2cb5-4d7d-839d-fedefa73ddd6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68845 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:1d45d08d-4012-440c-9121-2fd88c31bb69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6e28b3a6-04eb-46f7-8002-fa8a7012ee8e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Edarbi is indicated for the treatment of hypertension in adults, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Edarbi. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Edarbi may be used alone or in combination with other antihypertensive agents. uuid:266858d8-0427-459e-a4e2-e2d4aebc400e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68845 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:2d5c3a6f-3281-4e91-8d82-f2ea1f3ceabe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8644b38d-c00d-4070-809d-df5f45587433"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Edarbi is indicated for the treatment of hypertension in adults, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Edarbi. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Edarbi may be used alone or in combination with other antihypertensive agents. uuid:4017d6cd-a9ba-41f0-99a6-28472f169eb6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68845 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:e930a515-0b5b-4777-9d98-d59ac2306f76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:638b4836-5c03-480f-ad5b-adbd35aa0f3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Edarbi is indicated for the treatment of hypertension in adults, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Edarbi. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Edarbi may be used alone or in combination with other antihypertensive agents. uuid:ec669344-6052-4d0f-bbe5-ac3f1b274f68 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68845 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:bcb126f9-9002-4516-84d4-9a5c8bd48e77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9b180661-c214-467d-bdfd-89d92799f136"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Edarbi is indicated for the treatment of hypertension in adults, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Edarbi. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Edarbi may be used alone or in combination with other antihypertensive agents. uuid:558f5c7b-5cfe-4ae0-95e4-236c09e38e6f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68845 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:10eb3de4-2649-4aae-91a3-edde462a8ef3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:85678052-3d93-4649-9c40-2510f38a9f0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Edarbi is indicated for the treatment of hypertension in adults, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Edarbi. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Edarbi may be used alone or in combination with other antihypertensive agents. uuid:756f17a0-343a-479a-b801-d668a10ff011 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68845 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:40c857d6-9a09-40a7-ab4f-0d1b411dee15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1c58d312-e574-4d11-a6e2-ac95874561b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Edarbi is indicated for the treatment of hypertension in adults, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with Edarbi. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Edarbi may be used alone or in combination with other antihypertensive agents. uuid:e08f6563-341f-4954-9d7a-b1f8d1e6c77b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1163417 biolink:treats MONDO:0004872 PMID:41385096 "[{""id"":""uuid:56d3cde5-314f-46cb-a24a-61a5a72dad1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f88a01c1-6488-4044-a065-77efae9fcd89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Product is used for the anti-inflammatory and anesthetic relief of itching, pain, soreness and discomfort due to hemorrhoids, anal fissures, pruritus ani and similar conditions of the anal area. uuid:58df2e3b-86d1-4a0b-b328-c8fb68abf9a2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1163417 biolink:treats HP:0012390 PMID:41385096 "[{""id"":""uuid:6a09b75f-0819-4746-bfef-d65ff9b6d517"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:183dc577-b1ae-44a3-8d1a-f62d1f30d2d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Product is used for the anti-inflammatory and anesthetic relief of itching, pain, soreness and discomfort due to hemorrhoids, anal fissures, pruritus ani and similar conditions of the anal area. uuid:d56b7c1c-284c-4620-9e15-2c5bde21a2cf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1163417 biolink:treats UMLS:C0033775 PMID:41385096 "[{""id"":""uuid:e945692a-97c6-4e87-8a4c-a3319cc915d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:053fe340-a114-4ecf-83b0-40080eeceefe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Product is used for the anti-inflammatory and anesthetic relief of itching, pain, soreness and discomfort due to hemorrhoids, anal fissures, pruritus ani and similar conditions of the anal area. uuid:c4ad1dc2-15cc-48a8-bc5c-4ff5c6ce6c22 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3312 biolink:treats HP:0002153 PMID:41385096 "[{""id"":""uuid:6f735924-524d-4e43-9b0b-87c87da93608"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:13e52cc7-8b36-4259-8e1d-e7e9f55c3322"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 10% Calcium Chloride Injection, USP is indicated (1) for the treatment of hypocalcemia in those conditions requiring a prompt increase in blood plasma calcium levels, (2) in the treatment of magnesium intoxication due to overdosage of magnesium sulfate and (3) to combat the deleterious effects of hyperkalemia as measured by electrocardiographic (ECG), pending correction of the increased potassium level in the extracellular fluid. 10% Calcium Chloride Injection, USP also may be used in cardiac resuscitation when weak or inadequate contractions return following defibrillation or when epinephrine injection has failed to strengthen myocardial contractions. uuid:ada713cc-d685-48f8-a7e8-ca355b0fb360 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1154831 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:ccf0a8ce-d317-49fd-94ec-043a6ff651f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2fda6572-0fd7-48e3-8656-5c5431ecb140"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Promethazine VC with Codeine Oral Solution is indicated for the temporary relief of coughs and upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold in patients 18 years of age and older. Important Limitations of Use • Not indicated for pediatric patients under 18 years of age [see Use in Specific Populations (8.4)]. • Contraindicated in pediatric patients under 12 years of age [see Contraindications (4) and Use in Specific Populations (8.4)]. • Contraindicated in pediatric patients 12 to 18 years of age after tonsillectomy or adenoidectomy [see Contraindications (4) and Use in Specific Populations (8.4)]. • Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see Warnings and Precautions (5.1)], reserve Promethazine VC with Codeine Oral Solution for use in adult patients for whom the benefits of cough suppression are expected to outweigh the risks,and in whom an adequate assessment of the etiology of the cough has been made. uuid:3332cfd5-e221-471b-b845-963ad47da8a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1154831 biolink:treats MONDO:0005709 PMID:41385096 "[{""id"":""uuid:05807adc-f816-4a3c-a8c0-1da3f9c46508"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:02ab24fb-37ea-4f39-a095-e4a327dbf37b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Promethazine VC with Codeine Oral Solution is indicated for the temporary relief of coughs and upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold in patients 18 years of age and older. Important Limitations of Use • Not indicated for pediatric patients under 18 years of age [see Use in Specific Populations (8.4)]. • Contraindicated in pediatric patients under 12 years of age [see Contraindications (4) and Use in Specific Populations (8.4)]. • Contraindicated in pediatric patients 12 to 18 years of age after tonsillectomy or adenoidectomy [see Contraindications (4) and Use in Specific Populations (8.4)]. • Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see Warnings and Precautions (5.1)], reserve Promethazine VC with Codeine Oral Solution for use in adult patients for whom the benefits of cough suppression are expected to outweigh the risks,and in whom an adequate assessment of the etiology of the cough has been made. uuid:039e5ed0-20a0-4de6-8198-82d80b05a48c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1163417 biolink:treats HP:0000989 PMID:41385096 "[{""id"":""uuid:38b19f3d-5fbc-4e7b-8418-e2da81ab44f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d61c1f85-0cea-4db9-9e56-518b2c8868be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Product is used for the anti-inflammatory and anesthetic relief of pruritus, pruritic eczemas, abrasions, minor burns, insect bites, pain, soreness and discomfort due to pruritus ani, pruritus vulvae, hemorrhoids, anal fissures and similar conditions of the skin and mucous membranes. uuid:df1840f6-8eda-4241-8a8f-458596f99c08 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1163417 biolink:treats UMLS:C0332686 PMID:41385096 "[{""id"":""uuid:84b3f00e-41ba-4736-a0b8-f812eb8bc370"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e5773093-6f74-4af7-9ee5-9b63ca568db2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Product is used for the anti-inflammatory and anesthetic relief of pruritus, pruritic eczemas, abrasions, minor burns, insect bites, pain, soreness and discomfort due to pruritus ani, pruritus vulvae, hemorrhoids, anal fissures and similar conditions of the skin and mucous membranes. uuid:9d53905f-6d56-4359-a2e8-f7ebd80bca50 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1163417 biolink:treats UMLS:C0021564 PMID:41385096 "[{""id"":""uuid:6e90487f-02ba-4fd8-b91d-90b79bc33a8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2e09a89e-a1ff-4d27-80f0-da68a2c6499a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Product is used for the anti-inflammatory and anesthetic relief of pruritus, pruritic eczemas, abrasions, minor burns, insect bites, pain, soreness and discomfort due to pruritus ani, pruritus vulvae, hemorrhoids, anal fissures and similar conditions of the skin and mucous membranes. uuid:66fcbd3a-0296-48ca-8c2d-a282bf149d83 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1163417 biolink:treats HP:0032004 PMID:41385096 "[{""id"":""uuid:1c5df5e8-b384-4483-b515-a1d607c4e6c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dafef4ed-eab2-450b-aa5b-d6b2f7889023"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Product is used for the anti-inflammatory and anesthetic relief of pruritus, pruritic eczemas, abrasions, minor burns, insect bites, pain, soreness and discomfort due to pruritus ani, pruritus vulvae, hemorrhoids, anal fissures and similar conditions of the skin and mucous membranes. uuid:414c79e2-3355-44ab-ba78-53c325879255 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71193 biolink:treats MONDO:0011122 PMID:41385096 "[{""id"":""uuid:3cac965c-f570-489b-8e6d-0d58bd3ded89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b7719205-3b4b-4313-a698-9750504da521"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:fd32ce65-3392-4064-94c1-4a1244418c8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/saxenda""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] SAXENDA is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in: • Adult patients with an initial body mass index (BMI) of [see Dosage and Administration ( 2.1 )] : ▪ 30 kg/m 2 or greater (obese), or ▪ 27 kg/m 2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia) • Pediatric patients aged 12 years and older with: ▪ body weight above 60 kg and ▪ an initial BMI corresponding to 30 kg/m 2 or greater for adults (obese) by international cut-offs (Cole Criteria, Table 2) [see Dosage and Administration ( 2.1 )] Limitations of Use ▪ SAXENDA contains liraglutide and should not be coadministered with other liraglutide-containing products or with any other GLP-1 receptor agonist. ▪ The safety and effectiveness of SAXENDA in pediatric patients with type 2 diabetes have not been established. ▪ The safety and effectiveness of SAXENDA in combination with other products intended for weight loss, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established.|[EMA] Saxenda is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index (BMI) of• ≥ 30 kg/m² (obese), or• ≥ 27 kg/m² to < 30 kg/m² (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea.Treatment with Saxenda should be discontinued after 12 weeks on the 3.0 mg/day dose if patients have not lost at least 5% of their initial body weight. uuid:e4397c0c-d93e-402d-b4d8-7780eef58eab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71193 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:fb940fa8-8f1e-4ead-9119-cca995577d45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:85a72895-5fb4-4602-be48-83b589ca65fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SAXENDA is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in: • Adult patients with an initial body mass index (BMI) of [see Dosage and Administration ( 2.1 )] : ▪ 30 kg/m 2 or greater (obese), or ▪ 27 kg/m 2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia) • Pediatric patients aged 12 years and older with: ▪ body weight above 60 kg and ▪ an initial BMI corresponding to 30 kg/m 2 or greater for adults (obese) by international cut-offs (Cole Criteria, Table 2) [see Dosage and Administration ( 2.1 )] Limitations of Use ▪ SAXENDA contains liraglutide and should not be coadministered with other liraglutide-containing products or with any other GLP-1 receptor agonist. ▪ The safety and effectiveness of SAXENDA in pediatric patients with type 2 diabetes have not been established. ▪ The safety and effectiveness of SAXENDA in combination with other products intended for weight loss, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established. uuid:e252812c-46cd-446f-82ae-05a9347012c5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71193 biolink:treats HP:0003119 PMID:41385096 "[{""id"":""uuid:5feaa2c5-2412-4dd4-88b9-123f9c643516"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:3e33420d-31cd-4d45-becb-a28056c77603"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b25ecd1d-7e8d-4095-b47a-7bc3347fed3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/saxenda""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] SAXENDA is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in: • Adult patients with an initial body mass index (BMI) of [see Dosage and Administration ( 2.1 )] : ▪ 30 kg/m 2 or greater (obese), or ▪ 27 kg/m 2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia) • Pediatric patients aged 12 years and older with: ▪ body weight above 60 kg and ▪ an initial BMI corresponding to 30 kg/m 2 or greater for adults (obese) by international cut-offs (Cole Criteria, Table 2) [see Dosage and Administration ( 2.1 )] Limitations of Use ▪ SAXENDA contains liraglutide and should not be coadministered with other liraglutide-containing products or with any other GLP-1 receptor agonist. ▪ The safety and effectiveness of SAXENDA in pediatric patients with type 2 diabetes have not been established. ▪ The safety and effectiveness of SAXENDA in combination with other products intended for weight loss, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established.|[EMA] Saxenda is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index (BMI) of• ≥ 30 kg/m² (obese), or• ≥ 27 kg/m² to < 30 kg/m² (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea.Treatment with Saxenda should be discontinued after 12 weeks on the 3.0 mg/day dose if patients have not lost at least 5% of their initial body weight. uuid:bf25d0a5-7499-43d5-bdbd-d4f29fff5a46 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB09106 biolink:treats HP:0011106 PMID:41385096 "[{""id"":""uuid:d5b46f0a-3064-4e0e-b292-b8d54b8f1fa2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7ffff9b5-7d61-4e9a-80c5-7cb126da380d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 6% Hetastarch in 0.9% Sodium Chloride Injection is indicated in the treatment of hypovolemia when plasma volume expansion is desired. It is not a substitute for blood or plasma. The adjunctive use of 6% Hetastarch in 0.9% Sodium Chloride Injection in leukapheresis has also been shown to be safe and efficacious in improving the harvesting and increasing the yield of granulocytes by centrifugal means. uuid:e96b84b0-bd18-4cf1-8c99-45babcaaf31d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63635 biolink:treats MONDO:0000878 PMID:41385096 "[{""id"":""uuid:a234c519-9154-400a-8236-eeca0f70ef97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:63fa68fb-c049-44c0-a3dd-df2b8bdf4417"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Valganciclovir hydrochloride is a deoxynucleoside analogue cytomegalovirus (CMV) DNA polymerase inhibitor indicated for: Adult Patients (1.1) • Treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). • Prevention of CMV disease in kidney, heart, and kidney-pancreas transplant patients at high risk. Pediatric Patients (1.2) • Prevention of CMV disease in kidney and heart transplant patients at high risk. uuid:88d4920d-269f-4b00-b8e1-a1e5a53a3e56 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63635 biolink:treats MONDO:0012268 PMID:41385096 "[{""id"":""uuid:710ec8d5-833b-4503-b8f0-2068117c8728"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2da7c4d0-ebdc-4e3a-ad66-cf9df4b9e67c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0c1b681a-ccd2-468d-9549-84a6a84b2a93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Valganciclovir hydrochloride is a deoxynucleoside analogue cytomegalovirus (CMV) DNA polymerase inhibitor indicated for: Adult Patients (1.1) • Treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). • Prevention of CMV disease in kidney, heart, and kidney-pancreas transplant patients at high risk. Pediatric Patients (1.2) • Prevention of CMV disease in kidney and heart transplant patients at high risk.|[PMDA] A drug containing a new active ingredient, L- valine ester of ganciclovir, with indications for treatment of retinitis caused by cytomegalovirus in patients with acquired immune deficiency syndrome (AIDS) and dosage regimen. uuid:5fac99ee-19a8-4a6a-aed0-4220cce28d01 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63635 biolink:treats MONDO:0005132 PMID:41385096 "[{""id"":""uuid:b1813c22-8763-4174-a36d-d9f3ccf94709"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:78e17014-184f-4d0a-84fc-d56bf55b2547"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:8275ba90-2cc4-4168-916a-03d10add6334"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Valganciclovir hydrochloride is a deoxynucleoside analogue cytomegalovirus (CMV) DNA polymerase inhibitor indicated for: Adult Patients (1.1) • Treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). • Prevention of CMV disease in kidney, heart, and kidney-pancreas transplant patients at high risk. Pediatric Patients (1.2) • Prevention of CMV disease in kidney and heart transplant patients at high risk.|[PMDA] A drug with a new additional indication and a new dosage for the prevention of cytomegalovirus disease in organ transplant patients (excluding hematopoietic stem cell transplantation). [Public knowledge-based application after PAFSC's preliminary assessment] uuid:3a82218f-854d-4299-8221-98117c16b609 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1422082 biolink:treats HP:0003124 PMID:41385096 "[{""id"":""uuid:b1e42a10-bb5c-4eaf-a641-fc13c236e00c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:666c527d-ca22-455a-a162-5939ed76ca3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d51071ab-ffdc-4efc-8282-e1fd6f181740"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate.|[PMDA] New combination drugs indicated for the treatment of hypercholesterolemia and familial hypercholesterolemia. uuid:f7f9082f-419d-4626-82ff-67f59bdc7f48 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1422082 biolink:treats MONDO:0005311 PMID:41385096 "[{""id"":""uuid:c58d8b25-0039-45c6-a0cc-de102e530df8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:df91cb3e-0bad-43a0-8234-db27712ba924"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. Drug therapy is indicated as an adjunct to diet when the response to a diet restricted in saturated fat and cholesterol and other nonpharmacologic measures alone has been inadequate. uuid:2322e741-9aa7-4c23-864a-b2bcffcfd182 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0017767 PMID:41385096 "[{""id"":""uuid:8ecfb1b7-1d4f-47e1-99a0-03164602a081"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d1dd25ba-42b4-4f92-ab30-84d4b988ec6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Doxycycline for Injection, USP and other antibacterial drugs, Doxycycline for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline for Injection, USP is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever, and the typhus group, Q fever, rickettsial pox and tick fevers). Mycoplasma pneumoniae (PPLO, Eaton Agent). Agents of psittacosis and ornithosis. Agents of lymphogranuloma venereum and granuloma inguinale. The spirochetal agent of relapsing fever (Borrelia recurrentis). The following gram-negative microorganisms: Haemophilus ducreyi (chancroid). Yersinia pestis (formerly Pasteurella pestis) and Francisella tularensis (formerly Pasteurella tularensis). Bartonella bacilliformis. Bacteroides species. Vibrio cholerae (formerly Vibrio comma) and Campylobacter fetus (formerly Vibrio fetus). Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes (formerly Aerobacter aerogenes). Shigella species. Acinetobacter species (formerly Mima species and Herellea species). Haemophilus influenzae (respiratory infections). Klebsiella species (respiratory and urinary infections). Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Enterococcus faecalis (formerly Streptococcus faecalis) have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Streptococcus pneumoniae (formerly Diplococcus pneumoniae). Staphylococcus aureus, respiratory, skin and soft tissue infections. Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections. Anthrax due to Bacillus anthracis, including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of infections due to: Neisseria gonorrhoeae and N. meningitidis. Treponema pallidum and Treponema pertenue (syphilis and yaws). Listeria monocytogenes. Clostridium species. Fusobacterium fusiforme (Vincent's infection). Actinomyces species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. Doxycycline is indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. uuid:76887d51-3e3c-4802-b567-58fcd6d99c58 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135961 biolink:treats MONDO:0008315 PMID:41385096 "[{""id"":""uuid:23d4ea46-c57c-4b6f-a14f-12a619763de6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0c464e96-a44a-4574-a52e-45969de6dcb7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:67c3fa3c-461e-4714-99fc-69e7368e26fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:365f3b5c-0991-49cd-842d-f9a1885ed828"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FIRMAGON ® is indicated for treatment of patients with advanced prostate cancer.|[EMA] Degarelix Accord is a gonadotrophin releasing hormone (GnRH) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer.for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.|[PMDA] Drugs with a new active ingredient indicated for the treatment of prostate cancer. uuid:1051aef4-ae5e-40d6-bb42-9ae34c2baf17 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1235141 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:340386b1-45bd-47bf-93c8-cbaae2d7dafe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c4f0c8f1-fb46-4ba0-8e56-976de715deff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Edarbyclor is indicated for the treatment of hypertension, to lower blood pressure. Edarbyclor may be used in patients whose blood pressure is not adequately controlled on monotherapy. Edarbyclor may be used as initial therapy if a patient is likely to need multiple drugs to achieve blood pressure goals. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including thiazide-like diuretics such as chlorthalidone and ARBs such as azilsartan medoxomil. There are no controlled trials demonstrating risk reduction with Edarbyclor. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management of high blood pressure, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients; however, the blood pressure effect of Edarbyclor in blacks is similar to that in non-blacks. Many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. The choice of Edarbyclor as initial therapy for hypertension should be based on an assessment of potential benefits and risks including whether the patient is likely to tolerate the starting dose of Edarbyclor. Patients with moderate-to-severe hypertension are at a relatively high risk of cardiovascular events (e.g., stroke, heart attack, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. Consider the patient's baseline blood pressure, target goal and the incremental likelihood of achieving the goal with a combination product, such as Edarbyclor, versus a monotherapy product when deciding upon initial therapy. Individual blood pressure goals may vary based on the patient's risk. Data from an 8-week, active-controlled, factorial trial provide estimates of the probability of reaching a target blood pressure with Edarbyclor compared with azilsartan medoxomil or chlorthalidone monotherapy [see Clinical Studies (14) ] . Figures 1.a-1.d provide estimates of the likelihood of achieving target clinic systolic and diastolic blood pressure control with Edarbyclor 40/25 mg tablets after 8 weeks, based on baseline systolic or diastolic blood pressure. The curve for each treatment group was estimated by logistic regression modeling and is more variable at the tails. Figure 1.a Probability of Achieving Systolic Blood Pressure <140 mmHg at Week 8 Figure 1.b Probability of Achieving Systolic Blood Pressure <130 mmHg at Week 8 Figure 1.c Probability of Achieving Diastolic Blood Pressure <90 mmHg at Week 8 Figure 1.d Probability of Achieving Diastolic Blood Pressure <80 mmHg at Week 8 For example, a patient with a baseline blood pressure of 170/105 mm Hg has approximately a 48% likelihood of achieving a goal of <140 mm Hg (systolic) and 48% likelihood of achieving <90 mm Hg (diastolic) on azilsartan medoxomil 80 mg. The likelihood of achieving these same goals on chlorthalidone 25 mg is approximately 51% (systolic) and 40% (diastolic). These likelihoods rise to 85% (systolic) and 85% (diastolic) with Edarbyclor 40/25 mg. uuid:e42aa13c-0710-41b2-a358-1d957f605d59 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1235141 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:8e39a3f1-243d-4e11-86b2-3661a9157176"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:10a879d2-4239-4823-83ad-96adbb4a0a30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Edarbyclor is indicated for the treatment of hypertension, to lower blood pressure. Edarbyclor may be used in patients whose blood pressure is not adequately controlled on monotherapy. Edarbyclor may be used as initial therapy if a patient is likely to need multiple drugs to achieve blood pressure goals. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including thiazide-like diuretics such as chlorthalidone and ARBs such as azilsartan medoxomil. There are no controlled trials demonstrating risk reduction with Edarbyclor. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management of high blood pressure, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients; however, the blood pressure effect of Edarbyclor in blacks is similar to that in non-blacks. Many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. The choice of Edarbyclor as initial therapy for hypertension should be based on an assessment of potential benefits and risks including whether the patient is likely to tolerate the starting dose of Edarbyclor. Patients with moderate-to-severe hypertension are at a relatively high risk of cardiovascular events (e.g., stroke, heart attack, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. Consider the patient's baseline blood pressure, target goal and the incremental likelihood of achieving the goal with a combination product, such as Edarbyclor, versus a monotherapy product when deciding upon initial therapy. Individual blood pressure goals may vary based on the patient's risk. Data from an 8-week, active-controlled, factorial trial provide estimates of the probability of reaching a target blood pressure with Edarbyclor compared with azilsartan medoxomil or chlorthalidone monotherapy [see Clinical Studies (14) ] . Figures 1.a-1.d provide estimates of the likelihood of achieving target clinic systolic and diastolic blood pressure control with Edarbyclor 40/25 mg tablets after 8 weeks, based on baseline systolic or diastolic blood pressure. The curve for each treatment group was estimated by logistic regression modeling and is more variable at the tails. Figure 1.a Probability of Achieving Systolic Blood Pressure <140 mmHg at Week 8 Figure 1.b Probability of Achieving Systolic Blood Pressure <130 mmHg at Week 8 Figure 1.c Probability of Achieving Diastolic Blood Pressure <90 mmHg at Week 8 Figure 1.d Probability of Achieving Diastolic Blood Pressure <80 mmHg at Week 8 For example, a patient with a baseline blood pressure of 170/105 mm Hg has approximately a 48% likelihood of achieving a goal of <140 mm Hg (systolic) and 48% likelihood of achieving <90 mm Hg (diastolic) on azilsartan medoxomil 80 mg. The likelihood of achieving these same goals on chlorthalidone 25 mg is approximately 51% (systolic) and 40% (diastolic). These likelihoods rise to 85% (systolic) and 85% (diastolic) with Edarbyclor 40/25 mg. uuid:96433d20-c14a-489d-8b07-2cb13d69ec5d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1235141 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:1e2f1f51-34ab-40b0-b499-a0495ade4beb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:66849866-a85a-4440-bb1f-141adf8664f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Edarbyclor is indicated for the treatment of hypertension, to lower blood pressure. Edarbyclor may be used in patients whose blood pressure is not adequately controlled on monotherapy. Edarbyclor may be used as initial therapy if a patient is likely to need multiple drugs to achieve blood pressure goals. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including thiazide-like diuretics such as chlorthalidone and ARBs such as azilsartan medoxomil. There are no controlled trials demonstrating risk reduction with Edarbyclor. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management of high blood pressure, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients; however, the blood pressure effect of Edarbyclor in blacks is similar to that in non-blacks. Many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. The choice of Edarbyclor as initial therapy for hypertension should be based on an assessment of potential benefits and risks including whether the patient is likely to tolerate the starting dose of Edarbyclor. Patients with moderate-to-severe hypertension are at a relatively high risk of cardiovascular events (e.g., stroke, heart attack, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. Consider the patient's baseline blood pressure, target goal and the incremental likelihood of achieving the goal with a combination product, such as Edarbyclor, versus a monotherapy product when deciding upon initial therapy. Individual blood pressure goals may vary based on the patient's risk. Data from an 8-week, active-controlled, factorial trial provide estimates of the probability of reaching a target blood pressure with Edarbyclor compared with azilsartan medoxomil or chlorthalidone monotherapy [see Clinical Studies (14) ] . Figures 1.a-1.d provide estimates of the likelihood of achieving target clinic systolic and diastolic blood pressure control with Edarbyclor 40/25 mg tablets after 8 weeks, based on baseline systolic or diastolic blood pressure. The curve for each treatment group was estimated by logistic regression modeling and is more variable at the tails. Figure 1.a Probability of Achieving Systolic Blood Pressure <140 mmHg at Week 8 Figure 1.b Probability of Achieving Systolic Blood Pressure <130 mmHg at Week 8 Figure 1.c Probability of Achieving Diastolic Blood Pressure <90 mmHg at Week 8 Figure 1.d Probability of Achieving Diastolic Blood Pressure <80 mmHg at Week 8 For example, a patient with a baseline blood pressure of 170/105 mm Hg has approximately a 48% likelihood of achieving a goal of <140 mm Hg (systolic) and 48% likelihood of achieving <90 mm Hg (diastolic) on azilsartan medoxomil 80 mg. The likelihood of achieving these same goals on chlorthalidone 25 mg is approximately 51% (systolic) and 40% (diastolic). These likelihoods rise to 85% (systolic) and 85% (diastolic) with Edarbyclor 40/25 mg. uuid:bf4e34e2-c9e5-485a-8ad2-c6b03ac34db8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1235141 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:a51aee99-0ddc-4e02-8a8f-627ab202f8a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:47a60ab1-db54-4a3f-a464-ea1b658f77e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Edarbyclor is indicated for the treatment of hypertension, to lower blood pressure. Edarbyclor may be used in patients whose blood pressure is not adequately controlled on monotherapy. Edarbyclor may be used as initial therapy if a patient is likely to need multiple drugs to achieve blood pressure goals. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including thiazide-like diuretics such as chlorthalidone and ARBs such as azilsartan medoxomil. There are no controlled trials demonstrating risk reduction with Edarbyclor. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management of high blood pressure, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients; however, the blood pressure effect of Edarbyclor in blacks is similar to that in non-blacks. Many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. The choice of Edarbyclor as initial therapy for hypertension should be based on an assessment of potential benefits and risks including whether the patient is likely to tolerate the starting dose of Edarbyclor. Patients with moderate-to-severe hypertension are at a relatively high risk of cardiovascular events (e.g., stroke, heart attack, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. Consider the patient's baseline blood pressure, target goal and the incremental likelihood of achieving the goal with a combination product, such as Edarbyclor, versus a monotherapy product when deciding upon initial therapy. Individual blood pressure goals may vary based on the patient's risk. Data from an 8-week, active-controlled, factorial trial provide estimates of the probability of reaching a target blood pressure with Edarbyclor compared with azilsartan medoxomil or chlorthalidone monotherapy [see Clinical Studies (14) ] . Figures 1.a-1.d provide estimates of the likelihood of achieving target clinic systolic and diastolic blood pressure control with Edarbyclor 40/25 mg tablets after 8 weeks, based on baseline systolic or diastolic blood pressure. The curve for each treatment group was estimated by logistic regression modeling and is more variable at the tails. Figure 1.a Probability of Achieving Systolic Blood Pressure <140 mmHg at Week 8 Figure 1.b Probability of Achieving Systolic Blood Pressure <130 mmHg at Week 8 Figure 1.c Probability of Achieving Diastolic Blood Pressure <90 mmHg at Week 8 Figure 1.d Probability of Achieving Diastolic Blood Pressure <80 mmHg at Week 8 For example, a patient with a baseline blood pressure of 170/105 mm Hg has approximately a 48% likelihood of achieving a goal of <140 mm Hg (systolic) and 48% likelihood of achieving <90 mm Hg (diastolic) on azilsartan medoxomil 80 mg. The likelihood of achieving these same goals on chlorthalidone 25 mg is approximately 51% (systolic) and 40% (diastolic). These likelihoods rise to 85% (systolic) and 85% (diastolic) with Edarbyclor 40/25 mg. uuid:bc3fdeaa-466b-4198-a187-ac9738fb7af7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1235141 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:f79c51dd-aef6-4009-8d55-d396ce52bf8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0e02ae40-9075-4cd0-b7d5-390c9fdd47be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Edarbyclor is indicated for the treatment of hypertension, to lower blood pressure. Edarbyclor may be used in patients whose blood pressure is not adequately controlled on monotherapy. Edarbyclor may be used as initial therapy if a patient is likely to need multiple drugs to achieve blood pressure goals. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including thiazide-like diuretics such as chlorthalidone and ARBs such as azilsartan medoxomil. There are no controlled trials demonstrating risk reduction with Edarbyclor. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management of high blood pressure, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients; however, the blood pressure effect of Edarbyclor in blacks is similar to that in non-blacks. Many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. The choice of Edarbyclor as initial therapy for hypertension should be based on an assessment of potential benefits and risks including whether the patient is likely to tolerate the starting dose of Edarbyclor. Patients with moderate-to-severe hypertension are at a relatively high risk of cardiovascular events (e.g., stroke, heart attack, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. Consider the patient's baseline blood pressure, target goal and the incremental likelihood of achieving the goal with a combination product, such as Edarbyclor, versus a monotherapy product when deciding upon initial therapy. Individual blood pressure goals may vary based on the patient's risk. Data from an 8-week, active-controlled, factorial trial provide estimates of the probability of reaching a target blood pressure with Edarbyclor compared with azilsartan medoxomil or chlorthalidone monotherapy [see Clinical Studies (14) ] . Figures 1.a-1.d provide estimates of the likelihood of achieving target clinic systolic and diastolic blood pressure control with Edarbyclor 40/25 mg tablets after 8 weeks, based on baseline systolic or diastolic blood pressure. The curve for each treatment group was estimated by logistic regression modeling and is more variable at the tails. Figure 1.a Probability of Achieving Systolic Blood Pressure <140 mmHg at Week 8 Figure 1.b Probability of Achieving Systolic Blood Pressure <130 mmHg at Week 8 Figure 1.c Probability of Achieving Diastolic Blood Pressure <90 mmHg at Week 8 Figure 1.d Probability of Achieving Diastolic Blood Pressure <80 mmHg at Week 8 For example, a patient with a baseline blood pressure of 170/105 mm Hg has approximately a 48% likelihood of achieving a goal of <140 mm Hg (systolic) and 48% likelihood of achieving <90 mm Hg (diastolic) on azilsartan medoxomil 80 mg. The likelihood of achieving these same goals on chlorthalidone 25 mg is approximately 51% (systolic) and 40% (diastolic). These likelihoods rise to 85% (systolic) and 85% (diastolic) with Edarbyclor 40/25 mg. uuid:4601737a-6c38-4e5b-909f-6ef1bbf3967e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1235141 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:7d3d5ac8-a080-44e1-a3ba-037d3be9f3a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:df4b317c-ab1e-4a6d-b0fd-b84e893946ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Edarbyclor is indicated for the treatment of hypertension, to lower blood pressure. Edarbyclor may be used in patients whose blood pressure is not adequately controlled on monotherapy. Edarbyclor may be used as initial therapy if a patient is likely to need multiple drugs to achieve blood pressure goals. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including thiazide-like diuretics such as chlorthalidone and ARBs such as azilsartan medoxomil. There are no controlled trials demonstrating risk reduction with Edarbyclor. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management of high blood pressure, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients; however, the blood pressure effect of Edarbyclor in blacks is similar to that in non-blacks. Many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. The choice of Edarbyclor as initial therapy for hypertension should be based on an assessment of potential benefits and risks including whether the patient is likely to tolerate the starting dose of Edarbyclor. Patients with moderate-to-severe hypertension are at a relatively high risk of cardiovascular events (e.g., stroke, heart attack, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. Consider the patient's baseline blood pressure, target goal and the incremental likelihood of achieving the goal with a combination product, such as Edarbyclor, versus a monotherapy product when deciding upon initial therapy. Individual blood pressure goals may vary based on the patient's risk. Data from an 8-week, active-controlled, factorial trial provide estimates of the probability of reaching a target blood pressure with Edarbyclor compared with azilsartan medoxomil or chlorthalidone monotherapy [see Clinical Studies (14) ] . Figures 1.a-1.d provide estimates of the likelihood of achieving target clinic systolic and diastolic blood pressure control with Edarbyclor 40/25 mg tablets after 8 weeks, based on baseline systolic or diastolic blood pressure. The curve for each treatment group was estimated by logistic regression modeling and is more variable at the tails. Figure 1.a Probability of Achieving Systolic Blood Pressure <140 mmHg at Week 8 Figure 1.b Probability of Achieving Systolic Blood Pressure <130 mmHg at Week 8 Figure 1.c Probability of Achieving Diastolic Blood Pressure <90 mmHg at Week 8 Figure 1.d Probability of Achieving Diastolic Blood Pressure <80 mmHg at Week 8 For example, a patient with a baseline blood pressure of 170/105 mm Hg has approximately a 48% likelihood of achieving a goal of <140 mm Hg (systolic) and 48% likelihood of achieving <90 mm Hg (diastolic) on azilsartan medoxomil 80 mg. The likelihood of achieving these same goals on chlorthalidone 25 mg is approximately 51% (systolic) and 40% (diastolic). These likelihoods rise to 85% (systolic) and 85% (diastolic) with Edarbyclor 40/25 mg. uuid:08d0c495-8539-48c9-9bfa-322e0ec29146 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1235141 biolink:treats MONDO:0001106 PMID:41385096 "[{""id"":""uuid:c321f9ce-2602-461d-81a0-13ea78224683"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5d81a1f5-cf18-4a2b-ab77-c65d0f6f1994"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Edarbyclor is indicated for the treatment of hypertension, to lower blood pressure. Edarbyclor may be used in patients whose blood pressure is not adequately controlled on monotherapy. Edarbyclor may be used as initial therapy if a patient is likely to need multiple drugs to achieve blood pressure goals. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including thiazide-like diuretics such as chlorthalidone and ARBs such as azilsartan medoxomil. There are no controlled trials demonstrating risk reduction with Edarbyclor. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management of high blood pressure, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients; however, the blood pressure effect of Edarbyclor in blacks is similar to that in non-blacks. Many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. The choice of Edarbyclor as initial therapy for hypertension should be based on an assessment of potential benefits and risks including whether the patient is likely to tolerate the starting dose of Edarbyclor. Patients with moderate-to-severe hypertension are at a relatively high risk of cardiovascular events (e.g., stroke, heart attack, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. Consider the patient's baseline blood pressure, target goal and the incremental likelihood of achieving the goal with a combination product, such as Edarbyclor, versus a monotherapy product when deciding upon initial therapy. Individual blood pressure goals may vary based on the patient's risk. Data from an 8-week, active-controlled, factorial trial provide estimates of the probability of reaching a target blood pressure with Edarbyclor compared with azilsartan medoxomil or chlorthalidone monotherapy [see Clinical Studies (14) ] . Figures 1.a-1.d provide estimates of the likelihood of achieving target clinic systolic and diastolic blood pressure control with Edarbyclor 40/25 mg tablets after 8 weeks, based on baseline systolic or diastolic blood pressure. The curve for each treatment group was estimated by logistic regression modeling and is more variable at the tails. Figure 1.a Probability of Achieving Systolic Blood Pressure <140 mmHg at Week 8 Figure 1.b Probability of Achieving Systolic Blood Pressure <130 mmHg at Week 8 Figure 1.c Probability of Achieving Diastolic Blood Pressure <90 mmHg at Week 8 Figure 1.d Probability of Achieving Diastolic Blood Pressure <80 mmHg at Week 8 For example, a patient with a baseline blood pressure of 170/105 mm Hg has approximately a 48% likelihood of achieving a goal of <140 mm Hg (systolic) and 48% likelihood of achieving <90 mm Hg (diastolic) on azilsartan medoxomil 80 mg. The likelihood of achieving these same goals on chlorthalidone 25 mg is approximately 51% (systolic) and 40% (diastolic). These likelihoods rise to 85% (systolic) and 85% (diastolic) with Edarbyclor 40/25 mg. uuid:8c5e6e45-a000-41b7-a873-fe0dc921679f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22652 biolink:treats MONDO:0002280 PMID:41385096 "[{""id"":""uuid:54dc4b5f-44f6-4ba1-b27a-b86f5ab76fe4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1cec93a2-839e-4179-a499-79da3a6f30c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of anemia due to lack of iron and low folate as in menorrhagia, pregnancy, puberty, excessive blood loss, and advanced age. Also for treatment of conditions where iron and vitamin C deficiency occur together, along with a poor intake or increased need for B-complex vitamins in chronic and acute illness, as well as cases of metabolic stress, and in periods of extended recovery. uuid:99ed6396-663e-41bd-bee8-b277b61e6e26 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17561 biolink:treats UMLS:C5707743 PMID:41385096 "[{""id"":""uuid:290ce9ef-71d7-4de0-8904-2746216ff3f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c29c7aef-26fe-45ba-aa4f-21c17339a756"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ELCYS ® is indicated for use as an additive to amino acid solutions to meet the nutritional requirements of newborn infants requiring total parenteral nutrition (TPN); and of adult and pediatric patients with severe liver disease who may have impaired enzymatic processes and require TPN. It can also be added to amino acid solutions to provide a more complete profile of amino acids for protein synthesis. uuid:14324dd0-b47f-433d-a4f3-2a8db03696de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6444 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:bf55575c-8cc7-4891-ad76-abcc76436728"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ad0f5980-e5cc-45aa-a926-37a5b4d48a4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levorphanol tartrate tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse, with opioids, which can occur at any dosage or duration [see WARNINGS ] , reserve levorphanol tartrate tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics]: • Have not been tolerated or are not expected to be tolerated, • Have not provided adequate analgesia or are not expected to provide adequate analgesia Levorphanol tartrate tablets should not be used for an extended period of time unless the pain remains severe enough to require an opioid analgesic and for which alternative treatment options continue to be inadequate. uuid:19c1da69-b9a0-4c44-974a-80a120df7176 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17439 biolink:treats MONDO:0011786 PMID:41385096 "[{""id"":""uuid:417032e1-24ec-41d8-b23d-7656f16c3a50"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:903e8052-4794-4ef9-9129-92051b18ae90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyanocobalamin Nasal Spray is indicated for: Vitamin B12 maintenance therapy in adult patients with pernicious anemia who are in remission following intramuscular vitamin B12 therapy and who have no nervous system involvement Treatment of adult patients with dietary, drug-induced, or malabsorption-related vitamin B12 deficiency not due to pernicious anemia Prevention of vitamin B12 deficiency in adult patients with vitamin B12 requirements in excess of normal Limitations of Use: Cyanocobalamin Nasal Spray should not be used for the vitamin B12 absorption test (Schilling test). In patients with correctible or temporary causes of vitamin B12 deficiency, the benefit of continued long term use of Cyanocobalamin Nasal Spray following adequate correction of vitamin B12 deficiency and underlying disease has not been established. The effectiveness of Cyanocobalamin Nasal Spray in patients with active symptoms of nasal congestion, allergic rhinitis or upper respiratory infection has not been determined. Treatment with Cyanocobalamin Nasal Spray should be deferred until symptoms have subsided. uuid:64b74b6a-35ba-4727-ab67-c2145a995b14 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17439 biolink:treats UMLS:C0041912 PMID:41385096 "[{""id"":""uuid:0bb0d18d-37a1-40e8-a1c8-c28d327aa6fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:01b04ab1-53f2-42fa-a996-0d28775c7055"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyanocobalamin Nasal Spray is indicated for: Vitamin B12 maintenance therapy in adult patients with pernicious anemia who are in remission following intramuscular vitamin B12 therapy and who have no nervous system involvement Treatment of adult patients with dietary, drug-induced, or malabsorption-related vitamin B12 deficiency not due to pernicious anemia Prevention of vitamin B12 deficiency in adult patients with vitamin B12 requirements in excess of normal Limitations of Use: Cyanocobalamin Nasal Spray should not be used for the vitamin B12 absorption test (Schilling test). In patients with correctible or temporary causes of vitamin B12 deficiency, the benefit of continued long term use of Cyanocobalamin Nasal Spray following adequate correction of vitamin B12 deficiency and underlying disease has not been established. The effectiveness of Cyanocobalamin Nasal Spray in patients with active symptoms of nasal congestion, allergic rhinitis or upper respiratory infection has not been determined. Treatment with Cyanocobalamin Nasal Spray should be deferred until symptoms have subsided. uuid:dc56685e-e482-4f76-9105-abd16acba08d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0015129 PMID:41385096 "[{""id"":""uuid:70e32893-85a4-49f0-ad20-08f67032ea51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8beecda8-42e8-4018-84dc-bfecc224f9f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PEDIAPRED ​® is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under “Allergic States”), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren’s syndrome, relapsing polychondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). uuid:639ac042-3a43-4612-ba22-ad94259c9b43 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0043370 PMID:41385096 "[{""id"":""uuid:d8fff4c1-1e90-443e-8d57-7e3cc142e0cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:280e655f-bf7e-4792-9193-91fbf1de6603"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PEDIAPRED ​® is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under “Allergic States”), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti-PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren’s syndrome, relapsing polychondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). uuid:4dba39e0-8f3d-4fd1-a772-a1671398fa30 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8389 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:c4886ba0-ce9c-4494-bb08-45ee1c34bf7c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8a86305a-1536-41e6-88da-61d908ea0b8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PREMARIN is a mixture of estrogens indicated for: • Treatment of Moderate to Severe Vasomotor Symptoms due to Menopause ( 1.1 ) • Treatment of Moderate to Severe Vulvar and Vaginal Atrophy due to Menopause ( 1.2 ) • Treatment of Hypoestrogenism due to Hypogonadism, Castration or Primary Ovarian Failure ( 1.3 ) • Treatment of Breast Cancer (for Palliation Only) in Appropriately Selected Women and Men with Metastatic Disease ( 1.4 ) • Treatment of Advanced Androgen-Dependent Carcinoma of the Prostate (for Palliation Only) ( 1.5 ) • Prevention of Postmenopausal Osteoporosis ( 1.6 ) uuid:4dfae377-34a6-4173-b05a-36dbebc1ba19 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49040 biolink:treats UMLS:C0342882 PMID:41385096 "[{""id"":""uuid:94b11423-2277-49a7-9c3d-09620071fab6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9817ce11-9c8b-4b32-9eb3-6e5d1912d9f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ezetimibe tablets are indicated: • In combination with a statin, or alone when additional low-density lipoprotein cholesterol (LDL-C) lowering therapy is not possible, as an adjunct to diet to reduce elevated LDL-C in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH). • In combination with a statin as an adjunct to diet to reduce elevated LDL-C in pediatric patients 10 years of age and older with HeFH. • In combination with fenofibrate as an adjunct to diet to reduce elevated LDL-C in adults with mixed hyperlipidemia. • In combination with a statin, and other LDL-C lowering therapies, to reduce elevated LDL-C levels in adults and in pediatric patients 10 years of age and older with homozygous familial hypercholesterolemia (HoFH). • As an adjunct to diet for the reduction of elevated sitosterol and campesterol levels in adults and in pediatric patients 9 years of age and older with homozygous familial sitosterolemia. When ezetimibe tablets are used in combination with a statin, fenofibrate, or other LDL-C lowering therapies, refer to the Prescribing Information of these products for information on the safe and effective use. uuid:ef3e88a9-e6b6-4fe5-96cc-d31eaa72c0d3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63580 biolink:treats MONDO:0012143 PMID:41385096 "[{""id"":""uuid:0a96e4d2-92c0-4a52-bdf9-e68e551606ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ec349ea0-a14c-452c-a0b7-cc6766f454f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ribavirin capsules are a nucleoside analogue indicated in combination with interferon alfa-2b (pegylated and nonpegylated) for the treatment of Chronic Hepatitis C (CHC) in patients 3 years of age or older with compensated liver disease. ( 1.1 ) Patients with the following characteristics are less likely to benefit from re-treatment after failing a course of therapy: previous nonresponse, previous pegylated interferon treatment, significant bridging fibrosis or cirrhosis, and genotype 1 infection. uuid:2e13bfd7-fa5c-401b-b7cf-b5d1d836bfcd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1165654 biolink:treats MONDO:0001358 PMID:41385096 "[{""id"":""uuid:8d476534-b254-4f77-bc65-07e950d692be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8fb1ca8c-e452-4561-8f90-b1b7986e0428"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AIRDUO ® RESPICLICK ® is indicated for the treatment of asthma in adult and pediatric patients aged 12 years and older. AIRDUO RESPICLICK should be used for patients not adequately controlled on a long term asthma control medication such as an inhaled corticosteroid or whose disease warrants initiation of treatment with both an inhaled corticosteroid and long acting beta 2 -adrenergic agonist (LABA). Limitations of Use : AIRDUO RESPICLICK is not indicated for the relief of acute bronchospasm. uuid:bed89968-5b6d-48df-a7b5-57acfa3c43ad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63580 biolink:treats MONDO:0043479 PMID:41385096 "[{""id"":""uuid:1182fb7c-2d8b-4ecb-988d-e3e503beab17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d0bda93d-f199-427a-8057-1eab2ab6248b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ribavirin tablets in combination with PEGASYS ® (peginterferon alfa-2a) are indicated for the treatment of patients 5 years of age and older with chronic hepatitis C (CHC) virus infection who have compensated liver disease and have not been previously treated with interferon alpha. The following points should be considered when initiating ribavirin tablets combination therapy with PEGASYS ® : This indication is based on clinical trials of combination therapy in patients with CHC and compensated liver disease, some of whom had histological evidence of cirrhosis (Child-Pugh class A), and in adult patients with clinically stable HIV disease and CD4 count greater than 100 cells/mm 3 . This indication is based on achieving undetectable HCV RNA after treatment for 24 or 48 weeks, based on HCV genotype, and maintaining a Sustained Virologic Response (SVR) 24 weeks after the last dose. Safety and efficacy data are not available for treatment longer than 48 weeks. The safety and efficacy of ribavirin tablets and PEGASYS ® therapy have not been established in liver or other organ transplant recipients, patients with decompensated liver disease, or previous non-responders to interferon therapy. The safety and efficacy of ribavirin tablets therapy for the treatment of adenovirus, RSV, parainfluenza or influenza infections have not been established. Ribavirin tablets should not be used for these indications. Ribavirin for inhalation has a separate package insert, which should be consulted if ribavirin inhalation therapy is being considered. uuid:88a32a85-e0b4-4b72-ba17-456bee0eee4c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63580 biolink:treats UMLS:C0302507 PMID:41385096 "[{""id"":""uuid:211413bf-3425-4a9d-87e0-eeaca4024c31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8968619e-9c27-46c0-9fa3-da10d4c5df77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ribavirin tablets in combination with PEGASYS ® (peginterferon alfa-2a) are indicated for the treatment of patients 5 years of age and older with chronic hepatitis C (CHC) virus infection who have compensated liver disease and have not been previously treated with interferon alpha. The following points should be considered when initiating ribavirin tablets combination therapy with PEGASYS ® : This indication is based on clinical trials of combination therapy in patients with CHC and compensated liver disease, some of whom had histological evidence of cirrhosis (Child-Pugh class A), and in adult patients with clinically stable HIV disease and CD4 count greater than 100 cells/mm 3 . This indication is based on achieving undetectable HCV RNA after treatment for 24 or 48 weeks, based on HCV genotype, and maintaining a Sustained Virologic Response (SVR) 24 weeks after the last dose. Safety and efficacy data are not available for treatment longer than 48 weeks. The safety and efficacy of ribavirin tablets and PEGASYS ® therapy have not been established in liver or other organ transplant recipients, patients with decompensated liver disease, or previous non-responders to interferon therapy. The safety and efficacy of ribavirin tablets therapy for the treatment of adenovirus, RSV, parainfluenza or influenza infections have not been established. Ribavirin tablets should not be used for these indications. Ribavirin for inhalation has a separate package insert, which should be consulted if ribavirin inhalation therapy is being considered. uuid:e7fe19c8-73cf-4947-8f6f-75c385ef9c43 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63580 biolink:treats MONDO:0005812 PMID:41385096 "[{""id"":""uuid:127c3167-c306-42a5-985f-0c739bafdacd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:31573ad9-19e5-429a-a30b-28f5c3f43dfb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ribavirin tablets in combination with PEGASYS ® (peginterferon alfa-2a) are indicated for the treatment of patients 5 years of age and older with chronic hepatitis C (CHC) virus infection who have compensated liver disease and have not been previously treated with interferon alpha. The following points should be considered when initiating ribavirin tablets combination therapy with PEGASYS ® : This indication is based on clinical trials of combination therapy in patients with CHC and compensated liver disease, some of whom had histological evidence of cirrhosis (Child-Pugh class A), and in adult patients with clinically stable HIV disease and CD4 count greater than 100 cells/mm 3 . This indication is based on achieving undetectable HCV RNA after treatment for 24 or 48 weeks, based on HCV genotype, and maintaining a Sustained Virologic Response (SVR) 24 weeks after the last dose. Safety and efficacy data are not available for treatment longer than 48 weeks. The safety and efficacy of ribavirin tablets and PEGASYS ® therapy have not been established in liver or other organ transplant recipients, patients with decompensated liver disease, or previous non-responders to interferon therapy. The safety and efficacy of ribavirin tablets therapy for the treatment of adenovirus, RSV, parainfluenza or influenza infections have not been established. Ribavirin tablets should not be used for these indications. Ribavirin for inhalation has a separate package insert, which should be consulted if ribavirin inhalation therapy is being considered. uuid:7c89c306-cecc-48ab-9505-a41faf7a7c54 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229661 biolink:treats MONDO:0100339 PMID:41385096 "[{""id"":""uuid:4cd68ea9-ac15-4128-87f6-ce9334ce31be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cff5bb10-e47f-4056-bea6-f7d924a6f3fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SKYCLARYS is indicated for the treatment of Friedreich's ataxia in adults and adolescents aged 16 years and older. uuid:62255f25-316d-4f79-973f-5adad0c8501b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PY79D6C8RX biolink:treats MONDO:0001673 PMID:41385096 "[{""id"":""uuid:905a88b3-ae5e-49b9-909b-b977901cce6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:44202e3b-017c-44e3-b529-4ece6892ba28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MYTESI is indicated for symptomatic relief of non-infectious diarrhea in adult patients with HIV/AIDS on anti-retroviral therapy. uuid:fe1d941c-8e71-49db-a0e2-495efb6b9706 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1165654 biolink:treats UMLS:C0741804 PMID:41385096 "[{""id"":""uuid:e417907a-86e6-40cf-8196-05e10de56375"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:841e83bd-7dd5-42c6-8fb0-f08ae38f8f68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler (FS MDPI) is indicated for the treatment of asthma in adult and pediatric patients aged 12 years and older. Fluticasone Propionate/Salmeterol MDPI should be used for patients not adequately controlled on a long term asthma control medication such as an inhaled corticosteroid or whose disease warrants initiation of treatment with both an inhaled corticosteroid and long acting beta 2 -adrenergic agonist (LABA). Limitations of Use : Fluticasone Propionate/Salmeterol MDPI is not indicated for the relief of acute bronchospasm. uuid:daa53797-d609-4cad-b855-f849b5903aff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71028 biolink:treats HP:0008281 PMID:41385096 "[{""id"":""uuid:9a32b058-458a-4a62-bc43-124af7e30007"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:43ec6672-6e76-4822-8f80-f5fbf6451008"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carglumic acid tablets for oral suspension is a carbamoyl phosphate synthetase 1 (CPS 1) activator indicated in pediatric and adult patients as: Adjunctive therapy to standard of care for the treatment of acute hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. (1.1) Maintenance therapy for the treatment of chronic hyperammonemia due to NAGS deficiency. (1.1) uuid:63031930-0810-4ea7-bcca-0535f176bd4b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1090966 biolink:treats MONDO:0006873 PMID:41385096 "[{""id"":""uuid:ebe582ae-dabf-4902-bd1b-dd370717b33b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5c62c611-5ca3-4d40-b3a2-879499af8634"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Supplementation of the diet with fluoride and ten essential vitamins. Multivitamin with 1.0 mg Fluoride Chewable Tablets provide fluoride in tablet form for children 6-16 years of age in areas where the water fluoride level is less than 0.3 ppm. Multivitamin with 0.5 mg Fluoride Chewable Tablet s provide fluoride in tablet form for children 4-6 years of age where the water fluoride level is less than 0.3 ppm, and for children 6 years of age and above where the drinking water contains 0.3 through 0.6 ppm of fluoride. Multivitamin with 0.25 mg Fluoride Chewable Tablets provide fluoride in tablet form for children 4-6 years of age where the drinking water contains 0.3 through 0.6 ppm of fluoride. Multivitamin with Fluoride Chewable Tablets supply significant amounts of vitamins A, C, D, E, thiamine, riboflavin, niacin, vitamin B6, vitamin B12, and folate to supplement the diet, and to help assure that nutritional deficiencies of these vitamins will not develop. Thus, in a single easy-to-use preparation, children obtain ten essential vitamins and the important mineral, fluoride. Supplementation of the diet with fluoride for caries prophylaxis. The American Academy of Pediatrics recommends that children up to age 16, in areas where drinking water contains less than optimal levels of fluoride, receive daily fluoride supplementation. Children using Multivitamin with Fluoride Chewable Tablets regularly should receive semiannual dental examinations. The regular brushing of teeth and attention to good oral hygiene practices are also essential. Multivitamin with Fluoride Chewable tablets are prescription product for the clinical dietary management of metabolic processes of caries prophylaxis and provides supplementation of the diet with ten essential vitamins. uuid:53ec1a28-735e-44c8-84cf-797f5aecba8f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135990 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:3201c356-8861-46e3-83b0-489116c3748e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b98bfc76-9278-45ca-8106-088cf4a51e05"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EXXUA is indicated for the treatment of major depressive disorder (MDD) in adults. uuid:989bc5ae-9e7d-43c9-8e1b-aada97c5ae83 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63115 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:740b27ef-32b2-4e5c-a37d-edcedb952e0f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:dcc6c0db-0ad8-4227-95dc-f3098e91d73f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:883b94bb-305e-4ead-8c8a-965bcdbc0551"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fingolimod capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older.|[PMDA] Drugs with a new active ingredient indicated for the prevention of relapse and for delaying the accumulation of physical disability in multiple sclerosis. [Orphan drug] uuid:6affe948-6f8f-496b-b679-9a3bd5ecd95d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63115 biolink:treats UMLS:C2921627 PMID:41385096 "[{""id"":""uuid:54e2aabd-2017-4e64-b5c0-b5fbb8888fbd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2cf01036-655f-4ebe-aa6e-fbded286078f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fingolimod capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older. uuid:0b8579c5-56c5-445f-9c7c-eafb60676012 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63115 biolink:treats MONDO:0000450 PMID:41385096 "[{""id"":""uuid:85f54b1a-baaa-417b-9c98-4387361ba29c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dc2e5886-d8d0-4a55-936d-ffc29fa98050"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fingolimod capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older. uuid:c1808450-baa7-44bc-a0d8-d6e2c25af1be biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6775 biolink:treats MONDO:0021736 PMID:41385096 "[{""id"":""uuid:6ba9a51b-ea30-4f09-8322-847705886d24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0b875e33-1453-4de8-b5d3-7636b5355410"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mesalamine Rectal Suspension Enema is indicated for the treatment of active mild to moderate distal ulcerative colitis, proctosigmoiditis or proctitis in adults. uuid:e30e4005-3368-489a-8a7f-980891220a38 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6775 biolink:treats MONDO:0005538 PMID:41385096 "[{""id"":""uuid:9548772d-11bc-4d65-911b-43bd348824d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cef06921-bb76-43be-b04d-5fc11481f4c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mesalamine Rectal Suspension Enema is indicated for the treatment of active mild to moderate distal ulcerative colitis, proctosigmoiditis or proctitis in adults. uuid:10d3fa69-597d-4cc6-9453-33d6d72c9c9f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:55346 biolink:treats MONDO:0044070 PMID:41385096 "[{""id"":""uuid:7558c86c-2440-4276-88aa-55ca3e87eead"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:43b7ef18-1c7e-414b-a980-c6ce375389f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ERAXIS is an echinocandin antifungal indicated for the treatment of the following infections: • Candidemia and other forms of Candida infections (intra-abdominal abscess and peritonitis) in adults and pediatric patients (1 month of age and older) ( 1.1 ) • Esophageal candidiasis in adults ( 1.2 ) Limitations of use • ERAXIS has not been studied in adult and pediatric patients with endocarditis, osteomyelitis, and meningitis due to Candida or in sufficient numbers of neutropenic patients. The dosage of ERAXIS for the treatment of Candida dissemination into the CNS and the eye has not been established. ( 1.3 , 5.3 , 8.4 ) • ERAXIS is associated with high relapse rates in esophageal candidiasis. ( 1.3 , 14.2 ) uuid:2997b583-1a45-4a31-b017-51b3c5c536ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:55346 biolink:treats MONDO:0002026 PMID:41385096 "[{""id"":""uuid:08513186-510b-49b7-8846-ce588995b862"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f607ff31-9aed-4ad8-9f99-987d1c7b6d57"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ERAXIS is an echinocandin antifungal indicated for the treatment of the following infections: • Candidemia and other forms of Candida infections (intra-abdominal abscess and peritonitis) in adults and pediatric patients (1 month of age and older) ( 1.1 ) • Esophageal candidiasis in adults ( 1.2 ) Limitations of use • ERAXIS has not been studied in adult and pediatric patients with endocarditis, osteomyelitis, and meningitis due to Candida or in sufficient numbers of neutropenic patients. The dosage of ERAXIS for the treatment of Candida dissemination into the CNS and the eye has not been established. ( 1.3 , 5.3 , 8.4 ) • ERAXIS is associated with high relapse rates in esophageal candidiasis. ( 1.3 , 14.2 ) uuid:e78cdf3c-7e98-4b25-beb5-a73e986a6317 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:55346 biolink:treats MONDO:0001648 PMID:41385096 "[{""id"":""uuid:5402c9f1-16aa-4e21-9d99-1f63f4d83415"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3ab37d92-5afc-4e87-836f-f5228be3e108"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ERAXIS is an echinocandin antifungal indicated for the treatment of the following infections: • Candidemia and other forms of Candida infections (intra-abdominal abscess and peritonitis) in adults and pediatric patients (1 month of age and older) ( 1.1 ) • Esophageal candidiasis in adults ( 1.2 ) Limitations of use • ERAXIS has not been studied in adult and pediatric patients with endocarditis, osteomyelitis, and meningitis due to Candida or in sufficient numbers of neutropenic patients. The dosage of ERAXIS for the treatment of Candida dissemination into the CNS and the eye has not been established. ( 1.3 , 5.3 , 8.4 ) • ERAXIS is associated with high relapse rates in esophageal candidiasis. ( 1.3 , 14.2 ) uuid:211a2ff9-d43c-4629-8a3d-1245e79276f1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71219 biolink:treats MONDO:0005086 PMID:41385096 "[{""id"":""uuid:ef8f836c-b83d-46ee-9e57-34cfa801500d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4b5d0ab7-5127-4fea-8cae-a5286e85c97b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7ad56b65-8289-4430-9cb5-cfc9993b6bc0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/votrient""]},{""id"":""uuid:fa59a99c-8444-428f-9906-afed3623f433"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pazopanib tablets are kinase inhibitor indicated for the treatment of adults with: • advanced renal cell carcinoma (RCC). (1.1) • advanced soft tissue sarcoma (STS) who have received prior chemotherapy. (1.2) Limitations of Use : The efficacy of pazopanib tablets for the treatment of patients with adipocytic soft tissue sarcoma or gastrointestinal stromal tumors has not been demonstrated.|[EMA] Renal-cell carcinoma (RCC)Votrient is indicated in adults for the first-line treatment of advanced renal-cell carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease.Soft-tissue sarcoma (STS)Votrient is indicated for the treatment of adult patients with selective subtypes of advanced soft-tissue sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo)adjuvant therapy.Efficacy and safety have only been established in certain STS histological tumour subtypes.|[PMDA] A drug with a new additional indication for the treatment of unresectable or metastatic renal cell carcinoma. uuid:d93929be-c119-4bd3-9c7c-3459a4e92bd9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71219 biolink:treats MONDO:0018078 PMID:41385096 "[{""id"":""uuid:ea36686f-860b-44f8-b277-c43747e102d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9d23878d-e7b9-48f5-b2f9-ea122daea699"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ce72e7cd-4fbe-4384-b3a3-fe06f1c2dbf1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/votrient""]},{""id"":""uuid:19330cf3-79c1-4042-b2da-40089a48604b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pazopanib tablets are kinase inhibitor indicated for the treatment of adults with: • advanced renal cell carcinoma (RCC). (1.1) • advanced soft tissue sarcoma (STS) who have received prior chemotherapy. (1.2) Limitations of Use : The efficacy of pazopanib tablets for the treatment of patients with adipocytic soft tissue sarcoma or gastrointestinal stromal tumors has not been demonstrated.|[EMA] Renal-cell carcinoma (RCC)Votrient is indicated in adults for the first-line treatment of advanced renal-cell carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease.Soft-tissue sarcoma (STS)Votrient is indicated for the treatment of adult patients with selective subtypes of advanced soft-tissue sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo)adjuvant therapy.Efficacy and safety have only been established in certain STS histological tumour subtypes.|[PMDA] A drug with a new active ingredient indicated for the treatment of soft tissue sarcoma. [Orphan drug] uuid:2f083eab-7ed9-47bb-8540-3c05141dfe8d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6754 biolink:treats NCIT:C27003 PMID:41385096 "[{""id"":""uuid:850bcb41-b5a3-4bd4-8da5-c2bab0b65fc8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1ac4c8c7-6f79-4444-aa9f-afb61c46933b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Meperidine hydrochloride tablets are indicated for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. uuid:4c26c2a0-d53d-4101-a96c-44c78541898a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6754 biolink:treats UMLS:C0278140 PMID:41385096 "[{""id"":""uuid:d57a8935-bbda-4e6f-a7cc-616e17a1ddc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:396e0a76-bd0a-422d-a824-10a986bd8c6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Meperidine hydrochloride tablets are indicated for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. uuid:ec5ff04d-dfae-4712-85b7-e912cdc26711 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134689 biolink:treats MONDO:0008170 PMID:41385096 "[{""id"":""uuid:ecf1b11c-fe21-46a7-8daf-4f268a506333"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9e80e1c1-dfa2-482c-8297-c6ff8f2ea5ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a891dd84-aa2b-4623-8723-94a1cf4dfdd4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: Ovarian cancer for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)- associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. ( 1.1 ) Prostate cancer for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for RUBRACA. ( 1.2 , 2.1 ) This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. ( 1.2 )|[EMA] Rubraca is indicated as monotherapy for the maintenance treatment of adult patients with advanced (FIGO Stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.Rubraca is indicated as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy. uuid:2be5e99a-a633-4e2f-ad71-868faec3551a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134689 biolink:treats MONDO:0002158 PMID:41385096 "[{""id"":""uuid:b55887f3-db15-448f-8834-7e092dab6b3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:558933c3-65b9-4754-afce-4d2e6c7d2017"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:25e9a6df-8997-4722-8355-892942f71a0f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: Ovarian cancer for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)- associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. ( 1.1 ) Prostate cancer for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for RUBRACA. ( 1.2 , 2.1 ) This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. ( 1.2 )|[EMA] Rubraca is indicated as monotherapy for the maintenance treatment of adult patients with advanced (FIGO Stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.Rubraca is indicated as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy. uuid:4757244b-d286-4f87-9cd7-7eb03e64c44c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134689 biolink:treats MONDO:0015686 PMID:41385096 "[{""id"":""uuid:581bbb63-3a9e-4fff-b361-36876454336a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:cc9185a0-50d4-451b-88c9-921d81222dbe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d80fc290-6ac4-4445-97bb-d9d24300a756"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: Ovarian cancer for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)- associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. ( 1.1 ) Prostate cancer for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for RUBRACA. ( 1.2 , 2.1 ) This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. ( 1.2 )|[EMA] Rubraca is indicated as monotherapy for the maintenance treatment of adult patients with advanced (FIGO Stages III and IV) high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.Rubraca is indicated as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy. uuid:cb9d8eb8-ae2e-4286-9d4c-92c8a7904792 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134689 biolink:treats MONDO:0004956 PMID:41385096 "[{""id"":""uuid:5dbdc8a3-cf8f-4f44-94d6-e0646670d30a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0d0985eb-3c3b-4f9e-af4d-d9d16baeb6b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RUBRACA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: Ovarian cancer for the maintenance treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)- associated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. ( 1.1 ) Prostate cancer for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for RUBRACA. ( 1.2 , 2.1 ) This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. ( 1.2 ) uuid:50d8496d-e8f1-4b1c-997f-54821e86fe1d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:30769 biolink:treats MONDO:0004828 PMID:41385096 "[{""id"":""uuid:ec821373-1228-4feb-943b-b74ac60c40fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8bdf4799-0dd0-4e34-a408-facec000f90a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oral Citrate Solution is indicated for the treatment of metabolic acidosis. This solution is also useful in conditions where long-term maintenance of alkaline urine is needed (e.g. uric acid and cystine calculi of the urinary tract). Oral Citrate Solution is also effective in treatment for acidosis of certain renal tubular disorders. uuid:4b8f8764-d18e-492d-b216-f6bb4a6f1c50 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats UMLS:C0274435 PMID:41385096 "[{""id"":""uuid:34fd303b-8c7c-4216-8e49-b2f9a6dd4406"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1196c627-c88e-4742-9477-a498f6aa4c6c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramusculat use of SOLU-CORTEF Sterile Powder is indicated as follows: Allergic states Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus. uuid:ee0c57b1-5e39-49d1-8585-7634c695ea99 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0015129 PMID:41385096 "[{""id"":""uuid:dc9d68a7-b882-477f-afb0-37c276ce22c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5de32d2d-d9ed-4584-8a46-a9a1f00a165c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramusculat use of SOLU-CORTEF Sterile Powder is indicated as follows: Allergic states Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus. uuid:420543e9-8c61-425e-8bfa-596302fb3813 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0043370 PMID:41385096 "[{""id"":""uuid:95d7705e-061a-4ba1-a2a8-131fe51bf3ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:23058d50-4ac0-4b1e-bcdf-55ca085a9667"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramusculat use of SOLU-CORTEF Sterile Powder is indicated as follows: Allergic states Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus. uuid:5772fa2a-b381-42d7-8a8b-30f1049ffa70 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0001705 PMID:41385096 "[{""id"":""uuid:fadfcb40-28d5-48a0-a012-061dd098d272"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:88f3c062-f4a5-481c-9ef2-f3b98f1aad9a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramusculat use of SOLU-CORTEF Sterile Powder is indicated as follows: Allergic states Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus. uuid:ddb210bb-f7f7-4271-90cb-3ec8fd1a058e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0006684 PMID:41385096 "[{""id"":""uuid:0a54e35e-9374-405f-a47b-3be742adb0fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:174d1921-ef7c-41e1-b201-1119c3af546d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramusculat use of SOLU-CORTEF Sterile Powder is indicated as follows: Allergic states Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus. uuid:4bd1e2fc-cfdb-4891-871f-e13338aae0e9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0020283 PMID:41385096 "[{""id"":""uuid:de46758a-6b8e-4ac7-9337-ae3d6aa5935c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dd6581d3-8e07-4991-8d59-bfae9175655e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramusculat use of SOLU-CORTEF Sterile Powder is indicated as follows: Allergic states Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus. uuid:e6f786da-7fd3-411a-b489-70d419f888a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0008109 PMID:41385096 "[{""id"":""uuid:0fd7374f-d7d9-40f0-a795-dc05e82ec8c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3f763352-689c-4be6-87bf-312bf11b21f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramusculat use of SOLU-CORTEF Sterile Powder is indicated as follows: Allergic states Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus. uuid:2567bbcc-354a-40c6-9875-eb850e9b75f7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0018170 PMID:41385096 "[{""id"":""uuid:ab8682d7-ba12-401d-b84c-8f2a0938d7b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a505aa22-ecee-4651-adb8-7a81996e14ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramusculat use of SOLU-CORTEF Sterile Powder is indicated as follows: Allergic states Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus. uuid:e41cb450-db23-4d21-8c4e-cde0d58e6001 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0005556 PMID:41385096 "[{""id"":""uuid:db773150-bb96-4684-a074-9353a3d7d1e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b839f73d-e0a7-40cb-87f7-942c996993b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramusculat use of SOLU-CORTEF Sterile Powder is indicated as follows: Allergic states Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus. uuid:75b872bd-fd44-4e6d-b52a-7cbb6b310f7c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0015927 PMID:41385096 "[{""id"":""uuid:b47125ff-2606-4c8e-b378-84221598703b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:87f99226-044e-4bae-939b-e93cd913fabb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramusculat use of SOLU-CORTEF Sterile Powder is indicated as follows: Allergic states Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus. uuid:c17ec313-7f2e-483c-ac87-63338b397b6e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0008538 PMID:41385096 "[{""id"":""uuid:6a875818-5168-4ffb-a299-1b4fe092eb60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3da75ac1-5720-47d4-99ae-c029710fcad5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramusculat use of SOLU-CORTEF Sterile Powder is indicated as follows: Allergic states Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus. uuid:cdf962ad-4419-49e5-9021-37e7cd0d5bae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1165173 biolink:treats MONDO:0018555 PMID:41385096 "[{""id"":""uuid:c7f3484d-8f6e-4ff0-bd82-a71d3f066e07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4196b7a6-cb9b-4979-8578-860f72b16329"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CombiPatch is indicated in a woman with a uterus for: Treatment of moderate to severe vasomotor symptoms due to menopause. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Treatment of hypoestrogenism due to hypogonadism, castration, or primary ovarian failure. uuid:b352a089-3c18-429a-a795-d21ea7c2de9b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1165173 biolink:treats MONDO:0005387 PMID:41385096 "[{""id"":""uuid:591396e3-379f-4ee0-a0e1-fc1b16c0fbf5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f24fc4c3-26f4-4c3b-8a5e-5b0bcddf8eae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CombiPatch is indicated in a woman with a uterus for: Treatment of moderate to severe vasomotor symptoms due to menopause. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. Treatment of hypoestrogenism due to hypogonadism, castration, or primary ovarian failure. uuid:5539439b-d628-4949-b4ce-4ec4dfed52ab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28787 biolink:treats UMLS:C0349071 PMID:41385096 "[{""id"":""uuid:8bfb2724-d0d1-459a-8e0d-349991a33a06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:24771fc9-de34-472f-a35d-b99d55ac781b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nitroglycerin ointment 0.4% is indicated for the treatment of moderate to severe pain associated with chronic anal fissure. uuid:2edac1c1-3606-41f6-ab64-4294d00d82a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2675584 biolink:treats MONDO:0006543 PMID:41385096 "[{""id"":""uuid:c6e993b4-8fc9-4609-a256-63173b118481"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:35f29382-ce6c-4c72-8021-7fbad1e5d5d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FILSUVEZ is indicated for the treatment of wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in adult and pediatric patients 6 months of age and older. uuid:a6561e18-56b3-4056-a09c-60e89165e1d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2675584 biolink:treats MONDO:0017612 PMID:41385096 "[{""id"":""uuid:77d515d6-d7ec-44ae-b94e-86c1dcf3608e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:653fe11e-851f-4340-9917-ba6ef5963868"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FILSUVEZ is indicated for the treatment of wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in adult and pediatric patients 6 months of age and older. uuid:25ad4689-111e-4b14-a816-872081434eb1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB09381 biolink:treats UMLS:C5442256 PMID:41385096 "[{""id"":""uuid:597aa201-6633-470c-af2f-e6fdd61b357b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:66bfc316-137a-4980-b7c6-81faef534614"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Menest is indicated in the: 1. Treatment of moderate to severe vasomotor symptoms associated with the menopause. 2. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. 3. Female hypogonadism. 4. Female castration. 5. Primary ovarian failure. 6. Breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. 7. Prostatic carcinoma - palliative therapy of advanced disease. uuid:2bbb7b96-b5cd-4518-b537-bf38349089c4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB09381 biolink:treats MONDO:0001932 PMID:41385096 "[{""id"":""uuid:7614d579-8a2f-42f9-8bd3-7394c55335ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4f57d07d-d4cf-401c-8409-4cfe517afbae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Menest is indicated in the: 1. Treatment of moderate to severe vasomotor symptoms associated with the menopause. 2. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered. 3. Female hypogonadism. 4. Female castration. 5. Primary ovarian failure. 6. Breast cancer (for palliation only) in appropriately selected women and men with metastatic disease. 7. Prostatic carcinoma - palliative therapy of advanced disease. DOID:14275 uuid:b49195c5-64d5-4874-949a-d71781fce3c0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:53394049 biolink:treats MONDO:0005338 PMID:41385096 "[{""id"":""uuid:0da01fdd-d81e-4a27-9b25-612de94dd45e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e7e09c6d-290d-4919-ab06-f89857391ce2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VYZULTA ® (latanoprostene bunod ophthalmic solution) 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. uuid:f6f88f90-bdc6-4abb-8599-d200df029f0d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:53394049 biolink:treats MONDO:0006875 PMID:41385096 "[{""id"":""uuid:66740e30-93bf-43f3-b197-10d6f15b638a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:539eae1d-ae2e-4043-bb3e-789017fc5247"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VYZULTA ® (latanoprostene bunod ophthalmic solution) 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. uuid:d0f16878-2f7b-452f-a5d1-8db7b9152a07 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51450 biolink:treats MONDO:0015924 PMID:41385096 "[{""id"":""uuid:9d964d72-4dbd-4757-a359-cb02f0253560"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:36152a4a-91e3-4f06-ba3c-7e1da405bcfe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b3c171af-5cf7-447c-bcd6-653a32cb97b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9eb24d0f-bc61-4e54-82e2-2d3fd98695f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bosentan tablets are indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1): in adults to improve exercise ability and to decrease clinical worsening. Studies establishing effectiveness included predominantly patients with WHO Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (60%), PAH associated with connective tissue diseases (21%), and PAH associated with congenital heart disease with left-to-right shunts (18%) [see Clinical Studies ( 14.1 )] .|[EMA] Treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity and symptoms in patients with WHO functional class III.Efficacy has been shown in:, , , Primary (idiopathic and familial) PAH;, PAH secondary to scleroderma without significant interstitial pulmonary disease;, PAH associated with congenital systemic-to-pulmonary shunts and Eisenmenger's physiology., , , Some improvements have also been shown in patients with PAH WHO functional class II., , Tracleer is also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease.,|[PMDA] A drug with a new indication and a new dosage in a new additional dosage form indicated for the treatment of pulmonary arterial hypertension. [Orphan drug] uuid:4580fcdc-6fd3-404b-9418-8eed53dfb9d4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51450 biolink:treats MONDO:0017147 PMID:41385096 "[{""id"":""uuid:73d444d2-9244-44c8-9427-0e6d0d424250"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a9575264-43ae-4d44-b831-44004285baa7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bosentan tablets are indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1): in adults to improve exercise ability and to decrease clinical worsening. Studies establishing effectiveness included predominantly patients with WHO Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (60%), PAH associated with connective tissue diseases (21%), and PAH associated with congenital heart disease with left-to-right shunts (18%) [see Clinical Studies ( 14.1 )] . uuid:315977d6-7baa-4ae0-a2cf-05cb11963daf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51450 biolink:treats MONDO:0017148 PMID:41385096 "[{""id"":""uuid:55a84228-338b-41c6-91fc-0ea6e95086bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:26879d6a-88b5-4ff2-a18c-34472938ecbe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bosentan tablets are indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1): in adults to improve exercise ability and to decrease clinical worsening. Studies establishing effectiveness included predominantly patients with WHO Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (60%), PAH associated with connective tissue diseases (21%), and PAH associated with congenital heart disease with left-to-right shunts (18%) [see Clinical Studies ( 14.1 )] . uuid:14e4f4eb-16df-4aa1-99e0-7b971f32e6eb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:465284 biolink:treats MONDO:0015288 PMID:41385096 "[{""id"":""uuid:573f5201-3f62-4d3b-8d13-aa83a1dfa6b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a362f2eb-2194-49ad-80a1-dd1b17f77ad5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZIRGAN ® (ganciclovir ophthalmic gel) 0.15% is indicated for the treatment of acute herpetic keratitis (dendritic ulcers). uuid:3a5834ce-9db8-48a1-a378-426d171ee780 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:465284 biolink:treats UMLS:C0333303 PMID:41385096 "[{""id"":""uuid:8c1fce5c-16dc-4113-ba2a-042a6b1b3d44"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cbcaf220-a20a-434d-b811-f4a45bd15180"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZIRGAN ® (ganciclovir ophthalmic gel) 0.15% is indicated for the treatment of acute herpetic keratitis (dendritic ulcers). uuid:cb841425-6f01-4dc1-945c-ba25747d0b88 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15544 biolink:treats NCIT:C55615 PMID:41385096 "[{""id"":""uuid:d5bf9bae-b533-4178-b981-ba487fe998e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1ea9abf2-9236-456c-9eec-eb0453ec44ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CAVERJECT IMPULSE is a prostaglandin E1 agonist indicated • For the treatment of erectile dysfunction ( 1.1 ) • As an adjunct to other diagnostic tests in the diagnosis of erectile dysfunction ( 1.2 ). uuid:3cc9ce11-7b51-4249-baf4-5ca92a3b18f0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:S866O45PIG biolink:treats MONDO:0006502 PMID:41385096 "[{""id"":""uuid:09e1e935-6ef3-480d-96fe-1b3595ac21c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:43f5c03a-d592-4ec6-ac52-6d2d43df0a3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SURVANTA is indicated for prevention and treatment (“rescue”) of Respiratory Distress Syndrome (RDS) (hyaline membrane disease) in premature infants. uuid:eb15b6da-9819-4af6-811e-37f1cd8d2c78 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:S866O45PIG biolink:treats MONDO:0700081 PMID:41385096 "[{""id"":""uuid:6f2fe3dd-d0d2-4f80-81f8-bd0b7ce5a145"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9535b693-4b94-4058-bddb-96fa03e499da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SURVANTA is indicated for prevention and treatment (“rescue”) of Respiratory Distress Syndrome (RDS) (hyaline membrane disease) in premature infants. uuid:e39df058-fbed-4953-adf0-deb47adbccaa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1945037 biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:3c308f32-3964-4013-a309-279ce23e64e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:55871156-6298-4041-b206-89e6d4b4456a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f12d7b0b-4b17-4ba7-9843-db3884af4917"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/trelegy-ellipta""]},{""id"":""uuid:e3ff38a2-64c1-45e7-9302-afb46672abc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRELEGY ELLIPTA is a combination of fluticasone furoate, an inhaled corticosteroid (ICS); umeclidinium, an anticholinergic; and vilanterol, a long-acting beta 2 -adrenergic agonist (LABA), indicated for: • the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). ( 1.1 ) • the maintenance treatment of asthma in patients aged 18 years and older. ( 1.2 ) Limitations of Use: Not indicated for relief of acute bronchospasm. ( 1.3 , 5.2 )|[EMA] Trelegy Ellipta is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist.|[PMDA] New combination drugs indicated for the relief of symptoms in patients with chronic obstructive pulmonary disease (chronic bronchitis, emphysema) (who require a combination therapy with an inhaled corticosteroid, a long-acting inhaled anticholinergic agent and a long-acting beta-2 agonist). uuid:bc757797-e00c-4c1d-b86c-b7ddbd0894fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1945037 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:531c8b51-479d-4f04-a025-8600e6f05efd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eb6562ad-9ea3-461a-af98-54a18835e37f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRELEGY ELLIPTA is a combination of fluticasone furoate, an inhaled corticosteroid (ICS); umeclidinium, an anticholinergic; and vilanterol, a long-acting beta 2 -adrenergic agonist (LABA), indicated for: • the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). ( 1.1 ) • the maintenance treatment of asthma in patients aged 18 years and older. ( 1.2 ) Limitations of Use: Not indicated for relief of acute bronchospasm. ( 1.3 , 5.2 ) uuid:3cb6ff62-54e9-4f3a-aab6-f783502d2d42 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6520 biolink:treats MONDO:0021211 PMID:41385096 "[{""id"":""uuid:1b6fc1b9-5d74-4bbb-940d-37f40024b2e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2efd7801-aecc-4d7b-a99e-e0f5ac9614e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gleostine is an alkylating drug indicated for the treatment of patients with: Brain tumors, primary and metastatic, following appropriate surgical and/or radiotherapeutic procedures. ( 1 ) Hodgkin's lymphoma in combination with other chemotherapies, following disease progression with initial chemotherapy. ( 1 ) uuid:ae4b4be2-42cc-4bd8-81c2-892b3b052a1d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6520 biolink:treats MONDO:0009348 PMID:41385096 "[{""id"":""uuid:49a45d62-dcd6-4df2-873a-e18f24724899"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4cff3d8f-bfb5-4c79-8d01-ea1162016b91"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gleostine is an alkylating drug indicated for the treatment of patients with: Brain tumors, primary and metastatic, following appropriate surgical and/or radiotherapeutic procedures. ( 1 ) Hodgkin's lymphoma in combination with other chemotherapies, following disease progression with initial chemotherapy. ( 1 ) uuid:5a7deca2-908b-4569-95db-0f2d66af6eaa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0005556 PMID:41385096 "[{""id"":""uuid:0235bfac-2f89-445b-93a8-36abd0bf61c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:06167497-17c8-454a-91fa-ca81e4c9f450"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, and serum sickness. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, and severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; may be used in conjunction with synthetic mineralocorticoid analogs where applicable; in infancy mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, and nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults, pure red cell aplasia, and selected cases of secondary thrombocytopenia. Miscellaneous Diagnostic testing of adrenocortical hyperfunction, trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For the palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis, cerebral edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce a diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute rheumatic carditis, ankylosing spondylitis, psoriatic arthritis, rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low- dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. uuid:93a077ca-9a9a-447e-9c05-721e5bb94fd0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:681K1JDI8M biolink:treats MONDO:0010602 PMID:41385096 "[{""id"":""uuid:036014bd-6e2d-4148-b929-fd9b43cbb8bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5a0751b2-5598-47ab-b87b-f6d5bbe21bac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e1120706-fe23-40db-87ef-2dff1ad9bcc4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/roctavian-0""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ROCTAVIAN is an adeno-associated virus vector-based gene therapy indicated for the treatment of adults with severe hemophilia A (congenital factor VIII deficiency with factor VIII activity < 1 IU/dL) without antibodies to adeno-associated virus serotype 5 (AAV5) detected by an FDA-approved test.|[EMA] Treatment of severe haemophilia A (congenital factor VIII deficiency) in adult patients without a history of factor VIII inhibitors and without detectable antibodies to adeno-associated virus serotype 5 (AAV5). uuid:f0c0b3df-e72f-48ce-a01e-8f5614dbac04 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2596777 biolink:treats MONDO:0005105 PMID:41385096 "[{""id"":""uuid:a9975467-f340-41fd-bf84-07ea6bc6b535"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:68d5c937-b294-43d4-9d5e-3f7d9df0cc5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:28f779d0-c77b-41ce-b1f8-c34a74ee6e2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OPDUALAG™ is indicated for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma.|[EMA] Opdualag is indicated for the first line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell PD L1 expression < 1%. uuid:82df40b1-667c-4fe0-8fb6-e153b7b5eaf7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31638 biolink:treats MONDO:0000618 PMID:41385096 "[{""id"":""uuid:1156a0ef-0610-4875-87c3-e3aaedc3ed94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8ad44315-b74b-4521-abb8-6b8056552cb5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fulvestrant Injection is an estrogen receptor antagonist indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy. ( 1 ) HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. ( 1 ) uuid:aff0fb01-3496-4096-a55e-074f4d350b0b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31638 biolink:treats MONDO:0006512 PMID:41385096 "[{""id"":""uuid:46633998-0955-49b7-a1e6-1a7020eb6d2d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5dcb42e1-15b9-42c9-9b86-58d2c58e437a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fulvestrant Injection is an estrogen receptor antagonist indicated for the treatment of: Hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in postmenopausal women not previously treated with endocrine therapy. ( 1 ) HR-positive advanced breast cancer in postmenopausal women with disease progression following endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in postmenopausal women in combination with ribociclib, as initial endocrine based therapy or following disease progression on endocrine therapy. ( 1 ) HR-positive, HER2-negative advanced or metastatic breast cancer in combination with palbociclib or abemaciclib in women with disease progression after endocrine therapy. ( 1 ) uuid:f1bbfa69-7873-465e-9b4c-0efc1b9fa58b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82752 biolink:treats MONDO:0009265 PMID:41385096 "[{""id"":""uuid:f363e4e2-7977-478d-a54a-70a8c0cf18b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:01141bc1-cfdc-4e22-885f-82c76a91f031"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:373561e3-3b39-4e0e-be91-6e9173297610"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cerdelga""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] CERDELGA is indicated for the long-term treatment of adult patients with Gaucher disease type 1 (GD1) who are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) as detected by an FDA-cleared test [see Dosage and Administration (2.1) ] .|[EMA] Cerdelga is indicated for the long-term treatment of adult patients with Gaucher disease type 1 (GD1), who are CYP2D6 poor metabolisers (PMs), intermediate metabolisers (IMs) or extensive metabolisers (EMs). uuid:7d13e970-4b4d-483d-8f8a-311731bd98f2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47426 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:efdea29e-5816-42df-afe1-0d1ef00091a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:975e8b81-d230-4a46-8b0a-8a645225f39d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Furosemide Injection is a loop diuretic indicated for: The treatment of edema associated with heart failure, cirrhosis of the liver, and renal disease ( 1.1 ) Acute pulmonary edema as adjunctive therapy ( 1.2 ) uuid:1894db19-6699-4aa1-b1d5-9a4d902aaa82 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:601027 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:e7d1c48d-d2f3-4902-8f29-0e3b6c11c7f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:de83ac6f-74f4-4e6a-8d24-df1c0085cf36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tekturna is a renin inhibitor (RI) indicated for the treatment of hypertension in adults and in pediatric patients weighing 50 kg or greater who are at least 6 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) uuid:15702929-7957-43b1-b52c-0926bf74fe6c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:601027 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:b676bd5a-cf35-4018-9675-e316ff43d724"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c90ecb1d-dd3f-43b1-92e2-111c1c850235"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tekturna is a renin inhibitor (RI) indicated for the treatment of hypertension in adults and in pediatric patients weighing 50 kg or greater who are at least 6 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. ( 1.1 ) uuid:3109d0b6-2d60-458c-bae2-b0c344ad48f6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17234 biolink:treats HP:0001944 PMID:41385096 "[{""id"":""uuid:45c6bc72-f65a-451a-899f-48d53e48e85f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bede792b-2141-49ea-9816-263527ad14c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] These intravenous solutions are indicated for use in adults and pediatric patients as sources of calories and water for hydration. uuid:41a4afe2-3aa8-48e0-ad63-dbea704d0c57 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1939325 biolink:treats MONDO:0005354 PMID:41385096 "[{""id"":""uuid:27df1e05-5463-4724-8149-41dc03be1dd7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f62c671b-b888-43ac-8e88-d13aa69a1d2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VOSEVI is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) infection without cirrhosis or with compensated cirrhosis (Child-Pugh A) who have [see Dosage and Administration (2.2) and Clinical Studies (14) ]: genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an HCV regimen containing an NS5A inhibitor. genotype 1a or 3 infection and have previously been treated with an HCV regimen containing sofosbuvir without an NS5A inhibitor. Additional benefit of VOSEVI over sofosbuvir/velpatasvir was not shown in adults with genotype 1b, 2, 4, 5, or 6 infection previously treated with sofosbuvir without an NS5A inhibitor. uuid:f6093b18-8a8e-4ffe-b11f-bff62379ffad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0003634 PMID:41385096 "[{""id"":""uuid:8d172564-870e-4a8d-b14a-6340ab46bc4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d0813e72-af89-4d6d-976e-4f748620954f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisolone Oral Solution USP is indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice: synthetic analogs may be used in conjunction with mineralocorticoids where applicable: in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and Iridocyclitis 7. Respiratory Disorders Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. In addition to the above indications, Prednisolone Oral Solution USP is indicated for systemic dermatomyositis (polymyositis). uuid:04a58150-5684-4398-9df1-af5b425cb761 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:UT99UG9QJX biolink:treats UMLS:C0746883 PMID:41385096 "[{""id"":""uuid:90f9ee18-1acd-4888-9d0e-540fa0e6ed86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e47e47d1-d7ca-4dc8-a9a0-750686a9d4b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Rolvedon is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia. Limitations of Use Rolvedon is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation. uuid:5d4a6435-bf88-4e49-9700-fb7924bcaa66 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:UT99UG9QJX biolink:treats UMLS:C3714514 PMID:41385096 "[{""id"":""uuid:c0214267-f8a7-4eb0-b6d3-966728f16022"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b52e3a8a-ac30-4d96-a325-e9321386e549"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Rolvedon is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with clinically significant incidence of febrile neutropenia. Limitations of Use Rolvedon is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation. uuid:02e769d6-301f-419f-8ffb-261edaadc3f6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0004874 PMID:41385096 "[{""id"":""uuid:e9c06a08-3e25-4b2a-97ba-59273b74b5ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2538115a-2afb-4fb7-96ec-aa6a5f65f954"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A. FOR INTRAMUSCULAR ADMINISTRATION When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of Methylprednisolone acetate Sterile Aqueous Suspension is indicated as follows: Allergic States: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic Diseases: Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases: For palliative management of leukemias and lymphomas. Nervous System: Cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases: Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. B. FOR INTRA-ARTICULAR OR SOFT TISSUE ADMINISTRATION (See WARNINGS ) Methylprednisolone acetate injectable suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. C. FOR INTRALESIONAL ADMINISTRATION Methylprednisolone acetate injectable suspension is indicated for intralesional use in alopecia areata, discoid lupus erythematosus, keloids, localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques, necrobiosis lipoidica diabeticorum. Methylprednisolone acetate injectable suspension also may be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:80906c3e-53e2-4d2e-a9fa-d93def5fa26c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8081 biolink:treats MONDO:0008233 PMID:41385096 "[{""id"":""uuid:73e7d7fd-2e56-4b4e-a657-2701ba0d92a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4c4c3727-a4af-4a36-8116-077486a4cf75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Phentolamine Mesylate for Injection is indicated for the prevention or control of hypertensive episodes that may occur in a patient with pheochromocytoma as a result of stress or manipulation during preoperative preparation and surgical excision. Phentolamine Mesylate for Injection is indicated for the prevention or treatment of dermal necrosis and sloughing following intravenous administration or extravasation of norepinephrine. Phentolamine Mesylate for Injection is also indicated for the diagnosis of pheochromocytoma by the phentolamine blocking test. uuid:11e7198f-64b1-48d7-a106-272befcf557e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17051 biolink:treats MONDO:0006873 PMID:41385096 "[{""id"":""uuid:60bc89cc-2ae1-487b-ab55-82b66e6e6347"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:21cd6d51-6e97-4a28-8572-efdabf43ef9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Supplementation of the diet with ten essential vitamins. Supplementation of the diet with fluoride for caries prophylaxis. Contraindications : This product is contraindicated in patients with a known hypersensitivity to any of the ingredients. The American Academy of Pediatrics recommends that children up to the age 16, in areas where drinking water contains less than optimal levels of fluoride, receive daily fluoride supplementation. Davimet™ with Flouride 0.75 mg Chewable Multivitamin provide 0.75 mg fluoride in tablet form for children 6-16 years of age in areas where the drinking water fluoride level is less than 0.3 ppm. Davimet™ with Flouride 0.75 mg Chewable Multivitamin supply significant amounts of Vitamins A, C, D, E, thiamine, riboflavin, niacin, vitamin B6, vitamin B12, and folate to supplement the diet, and to help assure that nutritional deficiencies of these vitamins will not develop. Thus, in a single easy-to-use preparation, children obtain ten essential vitamins and the important mineral, fluoride. Children using Davimet™ with Flouride 0.75 mg Chewable Multivitamin regularly should receive semiannual dental examinations. The regular brushing of teeth and attention to good oral hygiene practices are also essential. Davimet™ with Flouride 0.75 mg Chewable Multivitamin is a prescription product for the clinical dietary management of the metabolic processes of caries prophylaxis and provides supplementation of the diet with ten essential vitamins. uuid:14a6a2cc-34b5-4c87-84db-c016040d2085 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:132041 biolink:treats MONDO:0021661 PMID:41385096 "[{""id"":""uuid:7a637d9e-1847-45ef-a53f-44af1178ff8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:51b74e6c-ebd7-4002-8889-5f4a1365be68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Perindopril erbumine tablets are indicated for the treatment of patients with essential hypertension. (1.1) Perindopril erbumine tablets are indicated for treatment of patients with stable coronary artery disease to reduce the risk of cardiovascular mortality or nonfatal myocardial infarction. (1.2) uuid:634eff2e-962c-420c-aa4c-2e4cd545ddbb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:499361 biolink:treats EFO:0004888 PMID:41385096 "[{""id"":""uuid:5150adf4-c7da-4d9a-8646-fee8e6142e9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:740b9b0a-9bcb-44f4-93b6-fb73f559e17e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] APONVIE is indicated for the prevention of postoperative nausea and vomiting (PONV) in adults. uuid:a9df8da3-75fb-4e79-a8d5-32ff465fc094 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45081 biolink:treats MONDO:0005055 PMID:41385096 "[{""id"":""uuid:9c34de8a-276f-4167-be9e-f80cb14be297"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d357d90a-c9f5-4269-af20-6b7f3adec2d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pentamidine Isethionate is indicated for the prevention of Pneumocystis jiroveci pneumonia (PJP) in high-risk, HIV-infected patients defined by one or both of the following criteria: i. a history of one or more episodes of PJP ii. a peripheral CD4+ (T4 helper/inducer) lymphocyte count less than or equal to 200/mm 3 . These indications are based on the results of an 18-month randomized, dose-response trial in high risk HIV-infected patients and on existing epidemiological data from natural history studies. The patient population of the controlled trial consisted of 408 patients, 237 of whom had a history of one or more episodes of PJP. The remaining patients without a history of PJP included 55 patients with Kaposi’s sarcoma and 116 patients with other AIDS diagnoses, ARC or asymptomatic HIV infection. Patients were randomly assigned to receive Pentamidine isethionate via the Respirgard ® II nebulizer at one of the following three doses: 30 mg every two weeks (n=135), 150 mg every two weeks (n=134) or 300 mg every four weeks (n=139). The results of the trial demonstrated a significant protective effect (p<0.01) against PJP with the 300 mg every four week dosage regimen compared to the 30 mg every two week dosage regimen. The 300 mg dose regimen reduced the risk of developing PJP by 50 to 70% compared to the 30 mg regimen. A total of 293 patients (72% of all patients) also received zidovudine at sometime during the trial. The analysis of the data demonstrated the efficacy of the 300 mg dose even after adjusting for the effect of zidovudine. The results of the trial further demonstrate that the dose and frequency of dosing are important to the efficacy of Pentamidine Isethionate prophylaxis in that multiple analyses consistently demonstrated a trend toward greater efficacy with 300 mg every four weeks as compared to 150 mg every two weeks. No dose-response was observed for reduction in overall mortality; however, mortality from PJP was low in all three dosage groups. uuid:555c2e0f-51e7-4d1a-bbdc-8363bd9786a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:80343 biolink:treats NCIT:C118469 PMID:41385096 "[{""id"":""uuid:45fa90b4-f233-44bf-a8b3-df9985d1588e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5a278c45-63b2-4f1e-9eb1-842a77a19d4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:15e83608-f173-4c50-93ac-f6bc0082b837"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/increlex""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] INCRELEX (mecasermin) injection is indicated for the treatment of growth failure in pediatric patients 2 years of age and older with severe primary IGF-1 deficiency or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH. ( 1 ) Limitations of use: INCRELEX is not a substitute to GH for approved GH indications.|[EMA] For the long-term treatment of growth failure in children and adolescents with severe primary insulin-like-growth-factor-1 deficiency (primary IGFD).Severe primary IGFD is defined by:height standard deviation score ≤ -3.0 and;basal insulin-like growth factor-1 (IGF-1) levels below the 2.5th percentile for age and gender and;growth hormone (GH) sufficiency;exclusion of secondary forms of IGF-1 deficiency, such as malnutrition, hypothyroidism, or chronic treatment with pharmacologic doses of anti-inflammatory steroids.Severe primary IGFD includes patients with mutations in the GH receptor (GHR), post-GHR signalling pathway, and IGF-1 gene defects; they are not GH deficient, and therefore, they cannot be expected to respond adequately to exogenous GH treatment. It is recommended to confirm the diagnosis by conducting an IGF-1 generation test. uuid:d8c19db7-5a1e-4c99-adfa-92714d14f5f2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:0JJ21K6L2I biolink:treats MONDO:0032586 PMID:41385096 "[{""id"":""uuid:e64afcc5-a8ad-4ff0-a1dc-9d6c8b4e43fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:65aaba5e-d78e-437d-b1ee-55b5b79471d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VEOPOZ is indicated for the treatment of adult and pediatric patients 1 year of age and older with CD55-deficient protein-losing enteropathy (PLE), also known as CHAPLE disease. uuid:41002c12-4ea1-4669-8d77-b31a9c17bb02 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:207a6673-5333-46dd-9246-2fd6a6e41d92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:631093b1-36a4-4625-9c6f-da73c2bc9a50"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDERAL XL is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including beta-blockers. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mm Hg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. uuid:ac83940a-4a5f-45b7-a94e-b42171636a59 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:ec58f348-f728-4eb3-b14d-9a7ec37fb62c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:71f405e0-da05-40ca-8598-9b12faa23b0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDERAL XL is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including beta-blockers. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mm Hg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. uuid:f420994f-492a-40d1-a826-f304c65eb31c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:04429963-9e7f-4b1c-b7ee-6d8c6a93686f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:165d458c-397a-4e8a-8588-b62822ca9454"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDERAL XL is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including beta-blockers. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mm Hg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. uuid:a500ee3c-3981-49a1-8181-973fb2f8a247 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:0b9de16b-6708-4244-a9e2-1f73a9aceaa0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:660e3e3b-d7db-418c-bae2-f940e4b176f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDERAL XL is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including beta-blockers. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mm Hg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. uuid:30c711e6-6bf5-4143-bc03-872fba589db5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:1e290498-eb95-4e2b-95d4-dd4816d7db11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1286ffd2-fa30-4f03-b711-8737e0d0d7fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDERAL XL is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including beta-blockers. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mm Hg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. uuid:2c8c4668-9608-4860-899c-18e76bd3cb16 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:94807 biolink:treats MONDO:0001103 PMID:41385096 "[{""id"":""uuid:b7a440f6-9ed8-48b5-bb05-b3f3081da1d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7636cbea-f265-409a-a700-c8cc22ef3d89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diarrhea caused by Giardia lamblia or Cryptosporidium parvum: ALINIA for Oral Suspension (patients 1 year of age and older) and ALINIA Tablets (patients 12 years and older) are indicated for the treatment of diarrhea caused by Giardia lamblia or Cryptosporidium parvum . Limitations of Use ALINIA for Oral Suspension and ALINIA Tablets have not been shown to be effective for the treatment of diarrhea caused by Cryptosporidium parvum in HIV-infected or immunodeficient patients [ see Clinical Studies (14.2) ] uuid:488b5178-d54c-4c23-aab6-f912bbee34ac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:94807 biolink:treats MONDO:0015474 PMID:41385096 "[{""id"":""uuid:7b048e78-bfc2-4930-b642-a0d4ad3b2c1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:09ad6640-3eab-40ce-900a-ebbc1e47fcab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diarrhea caused by Giardia lamblia or Cryptosporidium parvum: ALINIA for Oral Suspension (patients 1 year of age and older) and ALINIA Tablets (patients 12 years and older) are indicated for the treatment of diarrhea caused by Giardia lamblia or Cryptosporidium parvum . Limitations of Use ALINIA for Oral Suspension and ALINIA Tablets have not been shown to be effective for the treatment of diarrhea caused by Cryptosporidium parvum in HIV-infected or immunodeficient patients [ see Clinical Studies (14.2) ] uuid:6c3339fd-633c-45a9-9043-b09d6122a994 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2637 biolink:treats MONDO:0018602 PMID:41385096 "[{""id"":""uuid:9183edfa-7f47-4440-882a-5cc312617408"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c217cbd4-b951-49bf-9b1c-1f2ea914d37d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amikacin Sulfate Injection is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli , species of indole-positive and indole-negative Proteus , Providencia species, Klebsiella-Enterobacter-Serratia species, and Acinetobacter ( Mima-Herellea ) species. Clinical studies have shown Amikacin Sulfate Injection to be effective in bacterial septicemia (including neonatal sepsis); in serious infections of the respiratory tract, bones and joints, central nervous system (including meningitis) and skin and soft tissue; intra-abdominal infections (including peritonitis); and in burns and post-operative infections (including post-vascular surgery). Clinical studies have shown amikacin also to be effective in serious complicated and recurrent urinary tract infections due to these organisms. Aminoglycosides, including Amikacin Sulfate Injection are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Bacteriologic studies should be performed to identify causative organisms and their susceptibilities to amikacin. Amikacin may be considered as initial therapy in suspected Gram-negative infections and therapy may be instituted before obtaining the results of susceptibility testing. Clinical trials demonstrated that amikacin was effective in infections caused by gentamicin and/or tobramycin-resistant strains of Gram-negative organisms, particularly Proteus rettgeri , Providencia stuartii , Serratia marcescens , and Pseudomonas aeruginosa . The decision to continue therapy with the drug should be based on results of the susceptibility tests, the severity of the infection, the response of the patient and the important additional considerations contained in the WARNINGS box above. Amikacin has also been shown to be effective in staphylococcal infections and may be considered as initial therapy under certain conditions in the treatment of known or suspected staphylococcal disease such as, severe infections where the causative organism may be either a Gram-negative bacterium or a staphylococcus, infections due to susceptible strains of staphylococci in patients allergic to other antibiotics, and in mixed staphylococci/Gram-negative infections. In certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin-type drug may be indicated because of the possibility of infections due to Gram-positive organisms such as streptococci or pneumococci. To reduce the development of drug-resistant bacteria and maintain the effectiveness of amikacin and other antibacterial drugs, amikacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:79354bf9-10fc-43e1-b6cd-2b8abf3b64d4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2637 biolink:treats HP:0000010 PMID:41385096 "[{""id"":""uuid:ee53665e-b3f3-4010-a1f8-8deb0f39dfd0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1c3eb98a-e7ca-459c-bd0d-4606b18b27fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amikacin Sulfate Injection is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli , species of indole-positive and indole-negative Proteus , Providencia species, Klebsiella-Enterobacter-Serratia species, and Acinetobacter ( Mima-Herellea ) species. Clinical studies have shown Amikacin Sulfate Injection to be effective in bacterial septicemia (including neonatal sepsis); in serious infections of the respiratory tract, bones and joints, central nervous system (including meningitis) and skin and soft tissue; intra-abdominal infections (including peritonitis); and in burns and post-operative infections (including post-vascular surgery). Clinical studies have shown amikacin also to be effective in serious complicated and recurrent urinary tract infections due to these organisms. Aminoglycosides, including Amikacin Sulfate Injection are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Bacteriologic studies should be performed to identify causative organisms and their susceptibilities to amikacin. Amikacin may be considered as initial therapy in suspected Gram-negative infections and therapy may be instituted before obtaining the results of susceptibility testing. Clinical trials demonstrated that amikacin was effective in infections caused by gentamicin and/or tobramycin-resistant strains of Gram-negative organisms, particularly Proteus rettgeri , Providencia stuartii , Serratia marcescens , and Pseudomonas aeruginosa . The decision to continue therapy with the drug should be based on results of the susceptibility tests, the severity of the infection, the response of the patient and the important additional considerations contained in the WARNINGS box above. Amikacin has also been shown to be effective in staphylococcal infections and may be considered as initial therapy under certain conditions in the treatment of known or suspected staphylococcal disease such as, severe infections where the causative organism may be either a Gram-negative bacterium or a staphylococcus, infections due to susceptible strains of staphylococci in patients allergic to other antibiotics, and in mixed staphylococci/Gram-negative infections. In certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin-type drug may be indicated because of the possibility of infections due to Gram-positive organisms such as streptococci or pneumococci. To reduce the development of drug-resistant bacteria and maintain the effectiveness of amikacin and other antibacterial drugs, amikacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:50ab4037-2f30-4020-a97d-31671af13a44 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1153736 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:2a17bd5f-2cf0-4865-bcf8-dd1fac901368"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:04329ac1-4113-4fdb-af03-9025989c3131"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydrocodone Bitartrate and Aspirin Tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse, with opioids, which can occur at any dosage or duration, reserve Hydrocodone Bitartrate and Aspirin Tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics): have not been tolerated or are not expected to be tolerated. have not provided adequate analgesia or are not expected to provide adequate analgesia. Hydrocodone Bitartrate and Aspirin Tablets should not be used for extended period of time unless the pain remains severe enough to require an opioid analgesic and for which alternative treatment options continue to be inadequate. uuid:98168a29-95fc-478b-8896-bfd30b4591f3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0024388 PMID:41385096 "[{""id"":""uuid:d1385c3d-e448-44cb-9c78-1e83c07ab06c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ac77c9f3-00c4-4d2f-99f1-f25b42746ea5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Metronidazole Injection and other antibacterial drugs, Metronidazole Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment of Anaerobic Infections Metronidazole Injection is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with Metronidazole Injection therapy. In a mixed aerobic and anaerobic infection, antibiotics appropriate for the treatment of the aerobic infection should be used in addition to Metronidazole Injection. Metronidazole Injection is effective in Bacteroides fragilis infections resistant to clindamycin, chloramphenicol, and penicillin. Intra-Abdominal Infections, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species including the B. fragilis group (B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus), Clostridium species, Eubacterium species, Peptococcus species, and Peptostreptococcus species. Skin and Skin Structure Infections caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus species, Peptostreptococcus species, and Fusobacterium species. Gynecologic Infections, including endometritis, endomyometritis, tubo-ovarian abscess, and post-surgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus species, and Peptostreptococcus species. Bacterial Septicemia caused by Bacteroides species including the B. fragilis group and Clostridium species. Bone and Joint Infections, as adjunctive therapy, caused by Bacteroides species including the B. fragilis group. Central Nervous System (CNS) Infections, including meningitis and brain abscess, caused by Bacteroides species including the B. fragilis group. Lower Respiratory Tract Infections, including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group. Endocarditis caused by Bacteroides species including the B. fragilis group. Prophylaxis The prophylactic administration of Metronidazole Injection preoperatively, intraoperatively, and postoperatively may reduce the incidence of postoperative infection in patients undergoing elective colorectal surgery which is classified as contaminated or potentially contaminated. Prophylactic use of Metronidazole Injection should be discontinued within 12 hours after surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism(s) so that appropriate therapy may be given (see DOSAGE AND ADMINISTRATION). To reduce the development of drug-resistant bacteria and maintain the effectiveness of metronidazole and other antibacterial drugs, metronidazole should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antimicrobial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:1939009a-c4bf-4e2c-a2c5-0f215ada7853 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0006671 PMID:41385096 "[{""id"":""uuid:d5fb35ea-753d-47aa-8552-58f400c776ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c813a915-3275-461c-b150-bce5869c6f33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Metronidazole Injection and other antibacterial drugs, Metronidazole Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment of Anaerobic Infections Metronidazole Injection is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with Metronidazole Injection therapy. In a mixed aerobic and anaerobic infection, antibiotics appropriate for the treatment of the aerobic infection should be used in addition to Metronidazole Injection. Metronidazole Injection is effective in Bacteroides fragilis infections resistant to clindamycin, chloramphenicol, and penicillin. Intra-Abdominal Infections, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species including the B. fragilis group (B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus), Clostridium species, Eubacterium species, Peptococcus species, and Peptostreptococcus species. Skin and Skin Structure Infections caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus species, Peptostreptococcus species, and Fusobacterium species. Gynecologic Infections, including endometritis, endomyometritis, tubo-ovarian abscess, and post-surgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus species, and Peptostreptococcus species. Bacterial Septicemia caused by Bacteroides species including the B. fragilis group and Clostridium species. Bone and Joint Infections, as adjunctive therapy, caused by Bacteroides species including the B. fragilis group. Central Nervous System (CNS) Infections, including meningitis and brain abscess, caused by Bacteroides species including the B. fragilis group. Lower Respiratory Tract Infections, including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group. Endocarditis caused by Bacteroides species including the B. fragilis group. Prophylaxis The prophylactic administration of Metronidazole Injection preoperatively, intraoperatively, and postoperatively may reduce the incidence of postoperative infection in patients undergoing elective colorectal surgery which is classified as contaminated or potentially contaminated. Prophylactic use of Metronidazole Injection should be discontinued within 12 hours after surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism(s) so that appropriate therapy may be given (see DOSAGE AND ADMINISTRATION). To reduce the development of drug-resistant bacteria and maintain the effectiveness of metronidazole and other antibacterial drugs, metronidazole should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antimicrobial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:834f821f-9f86-4b93-8292-dabcffb67f4b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats UMLS:C0392618 PMID:41385096 "[{""id"":""uuid:8ed888c9-5a5e-4741-bf5e-0a692aa19e0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9c804d39-d795-4eef-bd44-1d10363c68d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Metronidazole Injection and other antibacterial drugs, Metronidazole Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Treatment of Anaerobic Infections Metronidazole Injection is indicated in the treatment of serious infections caused by susceptible anaerobic bacteria. Indicated surgical procedures should be performed in conjunction with Metronidazole Injection therapy. In a mixed aerobic and anaerobic infection, antibiotics appropriate for the treatment of the aerobic infection should be used in addition to Metronidazole Injection. Metronidazole Injection is effective in Bacteroides fragilis infections resistant to clindamycin, chloramphenicol, and penicillin. Intra-Abdominal Infections, including peritonitis, intra-abdominal abscess, and liver abscess, caused by Bacteroides species including the B. fragilis group (B. fragilis, B. distasonis, B. ovatus, B. thetaiotaomicron, B. vulgatus), Clostridium species, Eubacterium species, Peptococcus species, and Peptostreptococcus species. Skin and Skin Structure Infections caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus species, Peptostreptococcus species, and Fusobacterium species. Gynecologic Infections, including endometritis, endomyometritis, tubo-ovarian abscess, and post-surgical vaginal cuff infection, caused by Bacteroides species including the B. fragilis group, Clostridium species, Peptococcus species, and Peptostreptococcus species. Bacterial Septicemia caused by Bacteroides species including the B. fragilis group and Clostridium species. Bone and Joint Infections, as adjunctive therapy, caused by Bacteroides species including the B. fragilis group. Central Nervous System (CNS) Infections, including meningitis and brain abscess, caused by Bacteroides species including the B. fragilis group. Lower Respiratory Tract Infections, including pneumonia, empyema, and lung abscess, caused by Bacteroides species including the B. fragilis group. Endocarditis caused by Bacteroides species including the B. fragilis group. Prophylaxis The prophylactic administration of Metronidazole Injection preoperatively, intraoperatively, and postoperatively may reduce the incidence of postoperative infection in patients undergoing elective colorectal surgery which is classified as contaminated or potentially contaminated. Prophylactic use of Metronidazole Injection should be discontinued within 12 hours after surgery. If there are signs of infection, specimens for cultures should be obtained for the identification of the causative organism(s) so that appropriate therapy may be given (see DOSAGE AND ADMINISTRATION). To reduce the development of drug-resistant bacteria and maintain the effectiveness of metronidazole and other antibacterial drugs, metronidazole should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antimicrobial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:c389ae1e-9695-47d5-a644-444611425df3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31547 biolink:treats MONDO:0006652 PMID:41385096 "[{""id"":""uuid:8dbe80d1-2c14-4cac-809d-923f942109fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:22aecf27-5acd-424f-9a31-45f3cad9d79d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Eplerenone Tablets are an aldosterone antagonist indicated for: the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.2 ). uuid:d7e4f9fe-6162-46d3-a0f3-0a8eb9762227 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68478 biolink:treats UMLS:C0345468 PMID:41385096 "[{""id"":""uuid:9f6fc2ec-4f25-4b48-8dd4-6e2c8c7884c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d1ee663f-2e69-4e5d-b9c2-ffed9ea841b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:41aa53dd-acfc-4736-83fa-5e763f65d09b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Everolimus is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult patients: Kidney Transplant : at low-moderate immunologic risk. Use in combination with basiliximab, cyclosporine (reduced doses) and corticosteroids. ( 1.1 ) Liver Transplant : Administer no earlier than 30 days post transplant. Use in combination with tacrolimus (reduced doses) and corticosteroids. ( 1.2 , 5.5 ) Limitations of Use ( 1.3 ) Safety and efficacy have not been established in the following: Kidney transplant patients at high immunologic risk ( 1.3 ) Recipients of transplanted organs other than kidney or liver ( 1.3 , 5.7 ) Pediatric patients (less than 18 years) ( 1.3 )|[PMDA] Drugs containing a new active ingredient indicated for the prophylaxis of organ rejection in cardiac transplant. [Priority Review] uuid:2549ebd2-9154-4c33-94da-c7849158b33f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24755620 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:5bbabf59-914a-4cc5-af6f-00de5d11a7e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eaea99ed-105c-4e49-a42e-4dfefbd9a93a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENTRESTO is indicated: to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. ( 1.1 ) for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. ENTRESTO reduces NT-proBNP and is expected to improve cardiovascular outcomes. ( 1.2 ) uuid:b37d23c8-113b-4573-a00a-34843afee223 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24755620 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:2e4c3519-a50d-4323-865e-f5c879041f30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:996ee2ec-e0dd-4e8f-aa0a-1cbddec39748"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENTRESTO is indicated: to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. ( 1.1 ) for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. ENTRESTO reduces NT-proBNP and is expected to improve cardiovascular outcomes. ( 1.2 ) uuid:685ad15f-79b1-4fcf-a360-be7db7ccabe2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24755620 biolink:treats MONDO:0005254 PMID:41385096 "[{""id"":""uuid:b8427383-f3c1-42f1-8961-32272738bb31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8319708d-b662-4855-982b-911ebd6f3519"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENTRESTO is indicated: to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. ( 1.1 ) for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. ENTRESTO reduces NT-proBNP and is expected to improve cardiovascular outcomes. ( 1.2 ) uuid:023dd55f-c31c-4334-b946-119eb0d72ad1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5856 biolink:treats MONDO:0020575 PMID:41385096 "[{""id"":""uuid:63d387a1-b811-4554-b686-e6f68cfeeaba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:71cd5709-dba6-4b8b-b9ba-8f1fbe4821a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ibutilide fumarate injection is indicated for the rapid conversion of atrial fibrillation or atrial flutter of recent onset to sinus rhythm. Patients with atrial arrhythmias of longer duration are less likely to respond to ibutilide fumarate. The effectiveness of ibutilide has not been determined in patients with arrhythmias of more than 90 days in duration. LIFE-THREATENING ARRHYTHMIAS—APPROPRIATE TREATMENT ENVIRONMENT Ibutilide fumarate can cause potentially fatal arrhythmias, particularly sustained polymorphic ventricular tachycardia, usually in association with QT prolongation (torsades de pointes), but sometimes without documented QT prolongation. In registration studies, these arrhythmias, which require cardioversion, occurred in 1.7% of treated patients during, or within a number of hours of, use of Ibutilide fumarate. These arrhythmias can be reversed if treated promptly (see WARNINGS, Proarrhythmia ). It is essential that Ibutilide fumarate be administered in a setting of continuous ECG monitoring and by personnel trained in identification and treatment of acute ventricular arrhythmias, particularly polymorphic ventricular tachycardia. Patients with atrial fibrillation of more than 2 to 3 days’ duration must be adequately anticoagulated, generally for at least 2 weeks. CHOICE OF PATIENTS Patients with chronic atrial fibrillation have a strong tendency to revert after conversion to sinus rhythm (see CLINICAL STUDIES ) and treatments to maintain sinus rhythm carry risks. Patients to be treated with Ibutilide fumarate , therefore, should be carefully selected such that the expected benefits of maintaining sinus rhythm outweigh the immediate risks of Ibutilide fumarate , and the risks of maintenance therapy, and are likely to offer an advantage compared with alternative management. uuid:532aed87-d861-4062-8037-b9256b5856c7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16467 biolink:treats MONDO:0019591 PMID:41385096 "[{""id"":""uuid:82f234a6-ac58-45a7-b9be-935768f5f755"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cf98ce4f-6d5e-4609-89eb-1e748c0ff37f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] R-Gene ® 10 is indicated as an intravenous stimulant to the pituitary for the release of human growth hormone in patients where the measurement of pituitary reserve for HGH can be of diagnostic usefulness. It can be used as a diagnostic aid in such conditions as panhypopituitarism, pituitary dwarfism, chromophobe adenoma, postsurgical craniopharyngioma, hypophysectomy, pituitary trauma, acromegaly, gigantism and problems of growth and stature. If the insulin hypoglycemia test has indicated a deficiency of pituitary reserve for HGH, a test with R-Gene ® 10 is advisable to confirm the negative response. This can be done after a waiting period of one day. As patients may not respond to R-Gene ® 10 (Arginine Hydrochloride Injection, USP) during the first test, the unresponsive patient should be tested again to confirm the negative result. A second test can be performed after a waiting period of one day. Some patients who respond to R-Gene ® 10 do not respond to insulin and vice versa. The rate of false positive responses for R-Gene ® 10 is approximately 32%, and the rate of false negatives is approximately 27%. uuid:ba46d282-de84-4190-8cae-952db0658060 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16467 biolink:treats MONDO:0008250 PMID:41385096 "[{""id"":""uuid:dd67cdf8-40b2-4868-96d7-ff6a5d80d630"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ef89ac07-2553-450a-ab76-6c8e9c77f202"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] R-Gene ® 10 is indicated as an intravenous stimulant to the pituitary for the release of human growth hormone in patients where the measurement of pituitary reserve for HGH can be of diagnostic usefulness. It can be used as a diagnostic aid in such conditions as panhypopituitarism, pituitary dwarfism, chromophobe adenoma, postsurgical craniopharyngioma, hypophysectomy, pituitary trauma, acromegaly, gigantism and problems of growth and stature. If the insulin hypoglycemia test has indicated a deficiency of pituitary reserve for HGH, a test with R-Gene ® 10 is advisable to confirm the negative response. This can be done after a waiting period of one day. As patients may not respond to R-Gene ® 10 (Arginine Hydrochloride Injection, USP) during the first test, the unresponsive patient should be tested again to confirm the negative result. A second test can be performed after a waiting period of one day. Some patients who respond to R-Gene ® 10 do not respond to insulin and vice versa. The rate of false positive responses for R-Gene ® 10 is approximately 32%, and the rate of false negatives is approximately 27%. uuid:3c166a47-9322-447c-9ad9-487a85f940a7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16467 biolink:treats MONDO:0006701 PMID:41385096 "[{""id"":""uuid:5496ca0a-dcd0-4225-970c-762458fa6a94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4493f94f-98db-41ec-bfbe-ae894ac5ec5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] R-Gene ® 10 is indicated as an intravenous stimulant to the pituitary for the release of human growth hormone in patients where the measurement of pituitary reserve for HGH can be of diagnostic usefulness. It can be used as a diagnostic aid in such conditions as panhypopituitarism, pituitary dwarfism, chromophobe adenoma, postsurgical craniopharyngioma, hypophysectomy, pituitary trauma, acromegaly, gigantism and problems of growth and stature. If the insulin hypoglycemia test has indicated a deficiency of pituitary reserve for HGH, a test with R-Gene ® 10 is advisable to confirm the negative response. This can be done after a waiting period of one day. As patients may not respond to R-Gene ® 10 (Arginine Hydrochloride Injection, USP) during the first test, the unresponsive patient should be tested again to confirm the negative result. A second test can be performed after a waiting period of one day. Some patients who respond to R-Gene ® 10 do not respond to insulin and vice versa. The rate of false positive responses for R-Gene ® 10 is approximately 32%, and the rate of false negatives is approximately 27%. uuid:3421f39d-a6ed-49e6-bbae-637c4f3b66d8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16467 biolink:treats MONDO:0019933 PMID:41385096 "[{""id"":""uuid:aca95b7d-9990-4bff-81cd-9b32382c8fb2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:34373c82-65fd-4cac-8ee6-fafa2214e1ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] R-Gene ® 10 is indicated as an intravenous stimulant to the pituitary for the release of human growth hormone in patients where the measurement of pituitary reserve for HGH can be of diagnostic usefulness. It can be used as a diagnostic aid in such conditions as panhypopituitarism, pituitary dwarfism, chromophobe adenoma, postsurgical craniopharyngioma, hypophysectomy, pituitary trauma, acromegaly, gigantism and problems of growth and stature. If the insulin hypoglycemia test has indicated a deficiency of pituitary reserve for HGH, a test with R-Gene ® 10 is advisable to confirm the negative response. This can be done after a waiting period of one day. As patients may not respond to R-Gene ® 10 (Arginine Hydrochloride Injection, USP) during the first test, the unresponsive patient should be tested again to confirm the negative result. A second test can be performed after a waiting period of one day. Some patients who respond to R-Gene ® 10 do not respond to insulin and vice versa. The rate of false positive responses for R-Gene ® 10 is approximately 32%, and the rate of false negatives is approximately 27%. uuid:e4507e04-925f-4d59-80aa-da6fd133359a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16467 biolink:treats MONDO:0020479 PMID:41385096 "[{""id"":""uuid:1ce588b8-e513-4021-b277-1267477ead05"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ca5c0507-70d6-45d2-a8ae-a1a901f14507"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] R-Gene ® 10 is indicated as an intravenous stimulant to the pituitary for the release of human growth hormone in patients where the measurement of pituitary reserve for HGH can be of diagnostic usefulness. It can be used as a diagnostic aid in such conditions as panhypopituitarism, pituitary dwarfism, chromophobe adenoma, postsurgical craniopharyngioma, hypophysectomy, pituitary trauma, acromegaly, gigantism and problems of growth and stature. If the insulin hypoglycemia test has indicated a deficiency of pituitary reserve for HGH, a test with R-Gene ® 10 is advisable to confirm the negative response. This can be done after a waiting period of one day. As patients may not respond to R-Gene ® 10 (Arginine Hydrochloride Injection, USP) during the first test, the unresponsive patient should be tested again to confirm the negative result. A second test can be performed after a waiting period of one day. Some patients who respond to R-Gene ® 10 do not respond to insulin and vice versa. The rate of false positive responses for R-Gene ® 10 is approximately 32%, and the rate of false negatives is approximately 27%. uuid:52eef96a-219c-439e-ae54-c9ba0ca9d722 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:94187 biolink:treats MONDO:0010679 PMID:41385096 "[{""id"":""uuid:55bb22f1-b990-48bc-88f6-671253f4efa5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7bb0df36-34a8-469a-8d6c-dd7861df04e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DUVYZAT is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 6 years of age and older. uuid:03948b1a-9c79-45cd-9f8c-a591ebc7f1b2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PP0SHH6V16 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:3a54f3b4-52f7-4903-91aa-b4d187f45d17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f14edbb0-3d7a-48a7-bf59-0b19df4a87a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRALUENT ® is indicated: To reduce the risk of myocardial infarction, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease . As an adjunct to diet, alone or in combination with other low density lipoprotein cholesterol (LDL-C)-lowering therapies, in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce LDL-C. As an adjunct to other LDL-C-lowering therapies in adult patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C. As an adjunct to diet and other LDL-C-lowering therapies in pediatric patients aged 8 years and older with HeFH to reduce LDL-C. uuid:33555a69-cbb1-4b03-bae2-6731c2d35401 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PP0SHH6V16 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:d4c12f2f-0e76-410d-b949-5af55b89f8a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bf342230-4271-44f4-b1e3-159d40d83f42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRALUENT ® is indicated: To reduce the risk of myocardial infarction, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease . As an adjunct to diet, alone or in combination with other low density lipoprotein cholesterol (LDL-C)-lowering therapies, in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce LDL-C. As an adjunct to other LDL-C-lowering therapies in adult patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C. As an adjunct to diet and other LDL-C-lowering therapies in pediatric patients aged 8 years and older with HeFH to reduce LDL-C. uuid:79cada97-7dab-4cf0-b610-2e1d01624f81 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PP0SHH6V16 biolink:treats MONDO:0006805 PMID:41385096 "[{""id"":""uuid:be8405a4-2e0d-49e3-a1cc-d4d102601a30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4d87d627-36b6-47c7-bda1-46a17e5cf6fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRALUENT ® is indicated: To reduce the risk of myocardial infarction, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease . As an adjunct to diet, alone or in combination with other low density lipoprotein cholesterol (LDL-C)-lowering therapies, in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce LDL-C. As an adjunct to other LDL-C-lowering therapies in adult patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C. As an adjunct to diet and other LDL-C-lowering therapies in pediatric patients aged 8 years and older with HeFH to reduce LDL-C. uuid:62c34281-95cb-43cf-8a6d-7571a63282f9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PP0SHH6V16 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:3febb3cc-3295-45d8-bbc2-d73aa9f3dcef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:12f14dbe-3f39-45e2-8238-8949a82c7c8e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRALUENT ® is indicated: To reduce the risk of myocardial infarction, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease . As an adjunct to diet, alone or in combination with other low density lipoprotein cholesterol (LDL-C)-lowering therapies, in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce LDL-C. As an adjunct to other LDL-C-lowering therapies in adult patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C. As an adjunct to diet and other LDL-C-lowering therapies in pediatric patients aged 8 years and older with HeFH to reduce LDL-C. uuid:1761807e-6dc2-4a12-8982-7c7a2dae3b15 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PP0SHH6V16 biolink:treats UMLS:C0342882 PMID:41385096 "[{""id"":""uuid:606afc47-eab9-4ab2-82b5-e36e8fb8f94a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:01be9da5-1f72-4433-af3c-5fcbdc2435de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRALUENT ® is indicated: To reduce the risk of myocardial infarction, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease . As an adjunct to diet, alone or in combination with other low density lipoprotein cholesterol (LDL-C)-lowering therapies, in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce LDL-C. As an adjunct to other LDL-C-lowering therapies in adult patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C. As an adjunct to diet and other LDL-C-lowering therapies in pediatric patients aged 8 years and older with HeFH to reduce LDL-C. uuid:b9c1fd57-4d9a-470c-898e-0e14cd1dabe4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PP0SHH6V16 biolink:treats MONDO:0018328 PMID:41385096 "[{""id"":""uuid:bbefbed3-5dfc-4899-86d3-ce52df36f522"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3dfaf25b-35d6-4553-8242-61f300e6de4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRALUENT ® is indicated: To reduce the risk of myocardial infarction, stroke, and unstable angina requiring hospitalization in adults with established cardiovascular disease . As an adjunct to diet, alone or in combination with other low density lipoprotein cholesterol (LDL-C)-lowering therapies, in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce LDL-C. As an adjunct to other LDL-C-lowering therapies in adult patients with homozygous familial hypercholesterolemia (HoFH) to reduce LDL-C. As an adjunct to diet and other LDL-C-lowering therapies in pediatric patients aged 8 years and older with HeFH to reduce LDL-C. uuid:a24571b0-5b22-45db-b25e-a475e2b39105 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47097 biolink:treats MONDO:0008310 PMID:41385096 "[{""id"":""uuid:db4bdb96-5ba2-4045-b745-80ee23e0103c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a49e65a7-d259-4ed1-a717-c125c0e3f6fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:8f20c3e9-9a41-4575-9123-f7c12ad99a9a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zokinvy""]},{""id"":""uuid:d3c8f1bf-3421-426f-bd6c-a871916aedfd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZOKINVY is indicated in patients 12 months of age and older with a body surface area (BSA) of 0.39 m 2 and above: To reduce the risk of mortality in Hutchinson-Gilford Progeria Syndrome (HGPS) For the treatment of processing-deficient Progeroid Laminopathies with either: Heterozygous LMNA mutation with progerin-like protein accumulation Homozygous or compound heterozygous ZMPSTE24 mutations Limitations of Use ZOKINVY is not indicated for other Progeroid Syndromes or processing-proficient Progeroid Laminopathies. Based upon its mechanism of action, ZOKINVY would not be expected to be effective in these populations.|[EMA] Zokinvy is indicated for the treatment of patients 12 months of age and older with a genetically confirmed diagnosis of Hutchinson-Gilford progeria syndrome or a processing-deficient progeroid laminopathy associated with either a heterozygous LMNA mutation with progerin-like protein accumulation or a homozygous or compound heterozygous ZMPSTE24 mutation.|[PMDA] Drugs with a new active ingredient indicated for the treatment of Hutchinson-Gilford Progeria syndrome and processing-deficient progeroid laminopathies. [Orphan drug] uuid:efab4983-0c6a-48ee-b436-a4606ea12845 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47097 biolink:treats MONDO:0021106 PMID:41385096 "[{""id"":""uuid:82496e86-aec6-4a3e-9dc1-574819c945f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ad6abf91-5488-49c7-9dea-93e7b9bddd87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:6c6cc1fb-a629-4559-9244-a992943cbd7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zokinvy""]},{""id"":""uuid:12196cec-8eac-4e2c-a346-5da48e1a1e06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZOKINVY is indicated in patients 12 months of age and older with a body surface area (BSA) of 0.39 m 2 and above: To reduce the risk of mortality in Hutchinson-Gilford Progeria Syndrome (HGPS) For the treatment of processing-deficient Progeroid Laminopathies with either: Heterozygous LMNA mutation with progerin-like protein accumulation Homozygous or compound heterozygous ZMPSTE24 mutations Limitations of Use ZOKINVY is not indicated for other Progeroid Syndromes or processing-proficient Progeroid Laminopathies. Based upon its mechanism of action, ZOKINVY would not be expected to be effective in these populations.|[EMA] Zokinvy is indicated for the treatment of patients 12 months of age and older with a genetically confirmed diagnosis of Hutchinson-Gilford progeria syndrome or a processing-deficient progeroid laminopathy associated with either a heterozygous LMNA mutation with progerin-like protein accumulation or a homozygous or compound heterozygous ZMPSTE24 mutation.|[PMDA] Drugs with a new active ingredient indicated for the treatment of Hutchinson-Gilford Progeria syndrome and processing-deficient progeroid laminopathies. [Orphan drug] uuid:25274aaa-83a9-49ac-aeea-46863d587691 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7IK8Z952OK biolink:treats UMLS:C0267509 PMID:41385096 "[{""id"":""uuid:555d0909-3baa-4892-a49c-602d10ff9c6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9b75f886-7cb3-4b90-827d-83e69136dfbd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRULANCE is indicated in adults for the treatment of: chronic idiopathic constipation (CIC). irritable bowel syndrome with constipation (IBS-C). uuid:e74c2d9b-8d80-4a77-a73c-dc79a8d2c791 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7IK8Z952OK biolink:treats MONDO:0005052 PMID:41385096 "[{""id"":""uuid:9c53e4a9-84fa-4eb4-bbd0-7c1dc122c843"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fb4681a1-51a6-451e-a343-d4779d13cdb0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRULANCE is indicated in adults for the treatment of: chronic idiopathic constipation (CIC). irritable bowel syndrome with constipation (IBS-C). uuid:2502c8d5-41e1-45c1-a4ee-45d0e222a5ab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68558 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:04ecf67a-ed89-4ae0-b33c-b71169ee1cfd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:3afbf8df-787b-4af3-9e12-4c2c14082bf9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:18fe2027-3f41-4ce1-8ad0-df2421add3d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/brilique""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] BRILINTA is a P2Y 12 platelet inhibitor indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. BRILINTA also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS. (1.1) to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events. While use is not limited to this setting, the efficacy of BRILINTA was established in a population with type 2 diabetes mellitus (T2DM). (1.2) to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA). (1.3)|[EMA] Brilique, co administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients withacute coronary syndromes (ACS) ora history of myocardial infarction (MI) and a high risk of developing an atherothrombotic eventBrilique, co-administered with acetyl salicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with a history of myocardial infarction (MI occurred at least one year ago) and a high risk of developing an atherothrombotic event. uuid:8b9712f0-7004-4162-8b45-da304adea7e6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68558 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:986822db-97a6-44f4-bda5-8aaa172a06df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:74fd4870-4dc9-4290-90cc-c6ba8d482ea9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BRILINTA is a P2Y 12 platelet inhibitor indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. BRILINTA also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS. (1.1) to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events. While use is not limited to this setting, the efficacy of BRILINTA was established in a population with type 2 diabetes mellitus (T2DM). (1.2) to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA). (1.3) uuid:dd798d9d-e936-424c-9c69-bc0be363b8ee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68558 biolink:treats MONDO:0005542 PMID:41385096 "[{""id"":""uuid:a1e0b8f8-a580-4fea-9281-f9004fea083e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ee9ff03d-02dd-4eee-91fd-f1cd626ea277"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:aa1c9c8e-c850-4d57-9934-b346700405e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/brilique""]},{""id"":""uuid:2874e77c-2257-4983-a75d-2b6d6aa15d0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BRILINTA is a P2Y 12 platelet inhibitor indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. BRILINTA also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS. (1.1) to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events. While use is not limited to this setting, the efficacy of BRILINTA was established in a population with type 2 diabetes mellitus (T2DM). (1.2) to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA). (1.3)|[EMA] Brilique, co administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients withacute coronary syndromes (ACS) ora history of myocardial infarction (MI) and a high risk of developing an atherothrombotic eventBrilique, co-administered with acetyl salicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with a history of myocardial infarction (MI occurred at least one year ago) and a high risk of developing an atherothrombotic event.|[PMDA] Drugs with a new active ingredient indicated for the treatment of: Old myocardial infarction at especially high risk of developing atherothrombosis with at least one of the following risk factors: age of 65 years or older, with diabetes mellitus requiring drug therapy, history of two or more episodes of myocardial infarction, angiography- confirmed multivessel coronary artery disease, or non-end-stage chronic renal dysfunction. Acute coronary syndrome (unstable angina, non-ST-segment elevation myocardial infarction, and ST-segment elevation myocardial infarction) for which percutaneous coronary intervention (PCI) is indicated. (provided that dual antiplatelet therapy including aspirin is appropriate but the administration of other antiplatelet drugs in combination with aspirin is not suitable for the patient.) uuid:6419200c-3d7b-459a-a688-89f8849a2a5b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68558 biolink:treats UMLS:C3897493 PMID:41385096 "[{""id"":""uuid:e44eb396-58aa-439f-9b64-3a8271c65eed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c72e8525-0502-4e3b-8852-8d9fef78cde4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BRILINTA is a P2Y 12 platelet inhibitor indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. BRILINTA also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS. (1.1) to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events. While use is not limited to this setting, the efficacy of BRILINTA was established in a population with type 2 diabetes mellitus (T2DM). (1.2) to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA). (1.3) uuid:18702c18-93d6-480f-bc54-86ce41ec19d7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68558 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:f4164108-deaf-45c9-9020-0cf9a23549d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:43d2b5b1-06a1-403d-99db-1bd63a906996"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BRILINTA is a P2Y 12 platelet inhibitor indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. BRILINTA also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS. (1.1) to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events. While use is not limited to this setting, the efficacy of BRILINTA was established in a population with type 2 diabetes mellitus (T2DM). (1.2) to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA). (1.3) uuid:44b27f46-2c8c-4d76-8ae5-1af005e5ee9b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68558 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:4886fce7-17f4-470f-bc5e-a27f255e88fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ff5da58a-7a60-494b-a85f-624579bef688"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BRILINTA is a P2Y 12 platelet inhibitor indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. BRILINTA also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS. (1.1) to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events. While use is not limited to this setting, the efficacy of BRILINTA was established in a population with type 2 diabetes mellitus (T2DM). (1.2) to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA). (1.3) uuid:89188a2f-7714-4c81-9330-5947f2b4084e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68558 biolink:treats HP:0002140 PMID:41385096 "[{""id"":""uuid:8c1b63c7-d53a-4201-92fd-357e9e1a30f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4480198b-1e5e-48c4-b590-5ef2d73743c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BRILINTA is a P2Y 12 platelet inhibitor indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. BRILINTA also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS. (1.1) to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events. While use is not limited to this setting, the efficacy of BRILINTA was established in a population with type 2 diabetes mellitus (T2DM). (1.2) to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA). (1.3) uuid:7c48e08d-525e-4e69-a6d1-b778d2fcaeb1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68558 biolink:treats MONDO:0005264 PMID:41385096 "[{""id"":""uuid:9f36471b-b415-47aa-aecf-9b7d83f28325"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5b922622-a9fe-42dc-9724-438c3e822c1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BRILINTA is a P2Y 12 platelet inhibitor indicated to reduce the risk of cardiovascular (CV) death, myocardial infarction (MI), and stroke in patients with acute coronary syndrome (ACS) or a history of MI. For at least the first 12 months following ACS, it is superior to clopidogrel. BRILINTA also reduces the risk of stent thrombosis in patients who have been stented for treatment of ACS. (1.1) to reduce the risk of a first MI or stroke in patients with coronary artery disease (CAD) at high risk for such events. While use is not limited to this setting, the efficacy of BRILINTA was established in a population with type 2 diabetes mellitus (T2DM). (1.2) to reduce the risk of stroke in patients with acute ischemic stroke (NIH Stroke Scale score ≤5) or high-risk transient ischemic attack (TIA). (1.3) uuid:60953850-a55a-449f-8a16-aab8d9e6e7bc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6344 biolink:treats MONDO:0006846 PMID:41385096 "[{""id"":""uuid:ea9516a1-0986-4b4b-afe8-f8d7e59ee063"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a048eb92-64df-442b-a120-62d02df654bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Labetalol HCl Injection is indicated in severe hypertension, to lower blood pressure. uuid:acc2c989-5d45-4f7f-9268-d438eb6cd89e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4514 biolink:treats MONDO:0004880 PMID:41385096 "[{""id"":""uuid:44a645cd-8080-4abc-bc0d-ebdee37a6e88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6c2ff9c3-ed3b-4b67-a112-231ee28d9d42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dicyclomine Hydrochloride Injection, USP is indicated for the treatment of patients with functional bowel/irritable bowel syndrome. uuid:fbd68eca-a5d8-4957-a77b-83aa9a04c4df biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5790 biolink:treats MONDO:0004992 PMID:41385096 "[{""id"":""uuid:333f8cb4-ddf3-4f1c-bda1-bd2870e87e20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:757eb1fd-7d70-4459-b7c0-fa6b690a4ad0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydromorphone Hydrochloride Injection is indicated for the relief of moderate to severe pain such as that due to: surgery, cancer, trauma (soft tissue and bone), biliary colic, myocardial infarction, burns, renal colic. uuid:d5cbfda4-23a8-4fae-ae5f-a34a13678df1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5790 biolink:treats UMLS:C0151824 PMID:41385096 "[{""id"":""uuid:56d65acb-872a-48b8-839c-d5461291e136"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:97ea62d6-62b0-4463-8005-de124ed2b84c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydromorphone Hydrochloride Injection is indicated for the relief of moderate to severe pain such as that due to: surgery, cancer, trauma (soft tissue and bone), biliary colic, myocardial infarction, burns, renal colic. uuid:03e7efe6-6201-48b0-8620-5901b1106e4f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5790 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:35ee9b28-24ba-43d0-b988-107e447c8aec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:81a25485-e5d7-4ad2-af79-fe3baadb2a70"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydromorphone Hydrochloride Injection is indicated for the relief of moderate to severe pain such as that due to: surgery, cancer, trauma (soft tissue and bone), biliary colic, myocardial infarction, burns, renal colic. uuid:a2e267ed-dd42-45f7-b971-ecfd1e4340a0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5790 biolink:treats EFO:1001412 PMID:41385096 "[{""id"":""uuid:eb70f6db-848f-4f16-ae28-47da2a889df2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:502d0df1-1f03-4a78-ac99-8186ee22f50e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydromorphone Hydrochloride Injection is indicated for the relief of moderate to severe pain such as that due to: surgery, cancer, trauma (soft tissue and bone), biliary colic, myocardial infarction, burns, renal colic. uuid:b6f871b1-5628-4c86-9010-92f577138662 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:681848 biolink:treats MONDO:0043775 PMID:41385096 "[{""id"":""uuid:b0eccc5f-e058-413a-9710-3d302bd70965"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:762951e4-69f2-40b8-8ee1-101f63c7f5a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When the possibility of airway obstruction and/or hypoxia have been eliminated, doxapram may be used to stimulate respiration in patients with drug-induced postanesthesia respiratory depression or apnea other than that due to muscle relaxant drugs. To pharmacologically stimulate deep breathing in the postoperative patient. (A quantitative method of assessing oxygenation, such as pulse oximetry, is recommended.) uuid:c9b51c88-ac1d-4733-9fb2-9d4e73de5e79 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:681848 biolink:treats HP:0002104 PMID:41385096 "[{""id"":""uuid:122468d1-7f63-4de8-997a-321f26b4858c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4e043425-1339-442c-b0fe-6c43b90e8773"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When the possibility of airway obstruction and/or hypoxia have been eliminated, doxapram may be used to stimulate respiration in patients with drug-induced postanesthesia respiratory depression or apnea other than that due to muscle relaxant drugs. To pharmacologically stimulate deep breathing in the postoperative patient. (A quantitative method of assessing oxygenation, such as pulse oximetry, is recommended.) uuid:5d20f137-fbfe-405b-8a81-af886ca8e668 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17303 biolink:treats MONDO:0024317 PMID:41385096 "[{""id"":""uuid:18535898-de20-4e0e-ad6c-9a6b389aaa8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:64ea718c-c010-4eb4-81e0-7abdcf6aeb5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INFUMORPH is for use in continuous microinfusion devices and indicated only for intrathecal or epidural infusion in the management of intractable chronic pain severe enough to require an opioid analgesic and for which less invasive means of controlling pain are inadequate. Limitations of Use Not for single-dose intravenous, intramuscular, or subcutaneous administration due to the risk of overdose. Not for single-dose neuraxial injection because INFUMORPH is too concentrated for accurate delivery of the smaller doses used in this setting. INFUMORPH should not be used for an extended period of time unless the pain remains severe enough to require an opioid analgesic and for which alternative treatment options continue to be inadequate. uuid:1a5b584e-a6c6-462b-97a4-4073ccd38323 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63625 biolink:treats MONDO:0005344 PMID:41385096 "[{""id"":""uuid:7bf66dd0-52bb-446f-8b7f-09de8b3854f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3e07b55f-1a0d-46c4-b93c-ad79e1916c23"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VEMLIDY is indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults and pediatric patients 6 years of age and older and weighing at least 25 kg with compensated liver disease [see Clinical Studies (14) ] . uuid:2dd4c413-8f87-47e5-9fc5-a6b5851ae467 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8069 biolink:treats UMLS:C0700613 PMID:41385096 "[{""id"":""uuid:45e05449-1a9f-43f0-883f-0c27fb0ed14b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:30fc5a79-88fc-45c1-91f4-4f50ab0dad5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sedative. Sedation is obtainable within an hour, and in adequate dosage, the duration of action is more than six hours. Included in the more common conditions in which the sedative action of this class of drugs is desired are anxiety-tension states, hyperthyroidism, essential hypertension, nausea and vomiting of functional origin, motion sickness, acute labyrinthitis, pylorospasm in infants, chorea and cardiac failure. Phenobarbital is also a useful adjunct in treatment of hemorrhage from the respiratory or gastrointestinal tract. Phenobarbital controls anxiety, decreases muscular activity and lessens nervous excitability in hyperthyroid patients. However, thyrotoxic individuals occasionally react poorly to barbiturates. Hypnotic, for the short-term treatment of insomnia, since it appears to lose its effectiveness for sleep induction and sleep maintenance after 2 weeks (see CLINICAL PHARMACOLOGY ). Preanesthetic. Long-term anticonvulsant, (phenobarbital, mephobarbital and metharbital) for the treatment of generalized tonic-clonic and cortical focal seizures. And, in the emergency control of certain acute convulsive episodes, e.g., those associated with status epilepticus, cholera, eclampsia, cerebral hemorrhage, meningitis, tetanus, and toxic reactions to strychnine or local anesthetics. Phenobarbital sodium may be administered intramuscularly or intravenously as an anticonvulsant for emergency use. When administered intravenously, it may require 15 or more minutes before reaching peak concentrations in the brain. Therefore, injecting phenobarbital sodium until the convulsions stop may cause the brain level to exceed that required to control the convulsions and lead to severe barbiturate-induced depression. Phenobarbital is indicated in pediatric patients as an anticonvulsant and as a sedative, including its preoperative and postoperative use. uuid:76ffa390-cdd8-4850-9ab4-03a5cc4bc88b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8069 biolink:treats MONDO:0004425 PMID:41385096 "[{""id"":""uuid:4853731c-6484-47f5-9ccc-db5670005064"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6c68db3c-6479-4725-b87f-270ba4fce0d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sedative. Sedation is obtainable within an hour, and in adequate dosage, the duration of action is more than six hours. Included in the more common conditions in which the sedative action of this class of drugs is desired are anxiety-tension states, hyperthyroidism, essential hypertension, nausea and vomiting of functional origin, motion sickness, acute labyrinthitis, pylorospasm in infants, chorea and cardiac failure. Phenobarbital is also a useful adjunct in treatment of hemorrhage from the respiratory or gastrointestinal tract. Phenobarbital controls anxiety, decreases muscular activity and lessens nervous excitability in hyperthyroid patients. However, thyrotoxic individuals occasionally react poorly to barbiturates. Hypnotic, for the short-term treatment of insomnia, since it appears to lose its effectiveness for sleep induction and sleep maintenance after 2 weeks (see CLINICAL PHARMACOLOGY ). Preanesthetic. Long-term anticonvulsant, (phenobarbital, mephobarbital and metharbital) for the treatment of generalized tonic-clonic and cortical focal seizures. And, in the emergency control of certain acute convulsive episodes, e.g., those associated with status epilepticus, cholera, eclampsia, cerebral hemorrhage, meningitis, tetanus, and toxic reactions to strychnine or local anesthetics. Phenobarbital sodium may be administered intramuscularly or intravenously as an anticonvulsant for emergency use. When administered intravenously, it may require 15 or more minutes before reaching peak concentrations in the brain. Therefore, injecting phenobarbital sodium until the convulsions stop may cause the brain level to exceed that required to control the convulsions and lead to severe barbiturate-induced depression. Phenobarbital is indicated in pediatric patients as an anticonvulsant and as a sedative, including its preoperative and postoperative use. uuid:f8d558de-cbe6-4083-aa03-a902c1975f34 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8069 biolink:treats MONDO:0001134 PMID:41385096 "[{""id"":""uuid:2421a933-94e8-43fa-809e-a68dab223d7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f2deb20c-4d8c-4c7d-af69-3412f5410448"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sedative. Sedation is obtainable within an hour, and in adequate dosage, the duration of action is more than six hours. Included in the more common conditions in which the sedative action of this class of drugs is desired are anxiety-tension states, hyperthyroidism, essential hypertension, nausea and vomiting of functional origin, motion sickness, acute labyrinthitis, pylorospasm in infants, chorea and cardiac failure. Phenobarbital is also a useful adjunct in treatment of hemorrhage from the respiratory or gastrointestinal tract. Phenobarbital controls anxiety, decreases muscular activity and lessens nervous excitability in hyperthyroid patients. However, thyrotoxic individuals occasionally react poorly to barbiturates. Hypnotic, for the short-term treatment of insomnia, since it appears to lose its effectiveness for sleep induction and sleep maintenance after 2 weeks (see CLINICAL PHARMACOLOGY ). Preanesthetic. Long-term anticonvulsant, (phenobarbital, mephobarbital and metharbital) for the treatment of generalized tonic-clonic and cortical focal seizures. And, in the emergency control of certain acute convulsive episodes, e.g., those associated with status epilepticus, cholera, eclampsia, cerebral hemorrhage, meningitis, tetanus, and toxic reactions to strychnine or local anesthetics. Phenobarbital sodium may be administered intramuscularly or intravenously as an anticonvulsant for emergency use. When administered intravenously, it may require 15 or more minutes before reaching peak concentrations in the brain. Therefore, injecting phenobarbital sodium until the convulsions stop may cause the brain level to exceed that required to control the convulsions and lead to severe barbiturate-induced depression. Phenobarbital is indicated in pediatric patients as an anticonvulsant and as a sedative, including its preoperative and postoperative use. uuid:aae03af6-7452-4a19-ac00-24d20d7b0a0d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8069 biolink:treats MONDO:0001318 PMID:41385096 "[{""id"":""uuid:6420cf41-0576-4021-99e4-6eb055392bd2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f0f8846f-5d54-4d2c-879e-29ea20d73adf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sedative. Sedation is obtainable within an hour, and in adequate dosage, the duration of action is more than six hours. Included in the more common conditions in which the sedative action of this class of drugs is desired are anxiety-tension states, hyperthyroidism, essential hypertension, nausea and vomiting of functional origin, motion sickness, acute labyrinthitis, pylorospasm in infants, chorea and cardiac failure. Phenobarbital is also a useful adjunct in treatment of hemorrhage from the respiratory or gastrointestinal tract. Phenobarbital controls anxiety, decreases muscular activity and lessens nervous excitability in hyperthyroid patients. However, thyrotoxic individuals occasionally react poorly to barbiturates. Hypnotic, for the short-term treatment of insomnia, since it appears to lose its effectiveness for sleep induction and sleep maintenance after 2 weeks (see CLINICAL PHARMACOLOGY ). Preanesthetic. Long-term anticonvulsant, (phenobarbital, mephobarbital and metharbital) for the treatment of generalized tonic-clonic and cortical focal seizures. And, in the emergency control of certain acute convulsive episodes, e.g., those associated with status epilepticus, cholera, eclampsia, cerebral hemorrhage, meningitis, tetanus, and toxic reactions to strychnine or local anesthetics. Phenobarbital sodium may be administered intramuscularly or intravenously as an anticonvulsant for emergency use. When administered intravenously, it may require 15 or more minutes before reaching peak concentrations in the brain. Therefore, injecting phenobarbital sodium until the convulsions stop may cause the brain level to exceed that required to control the convulsions and lead to severe barbiturate-induced depression. Phenobarbital is indicated in pediatric patients as an anticonvulsant and as a sedative, including its preoperative and postoperative use. uuid:969f6608-a3e7-4511-9b0d-2e8413c4d9f9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8069 biolink:treats MONDO:0008015 PMID:41385096 "[{""id"":""uuid:13aeb3c9-b489-4569-bb8b-fe1b20b4654b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3d97a006-4877-48a1-84ba-249147cc8aff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sedative. Sedation is obtainable within an hour, and in adequate dosage, the duration of action is more than six hours. Included in the more common conditions in which the sedative action of this class of drugs is desired are anxiety-tension states, hyperthyroidism, essential hypertension, nausea and vomiting of functional origin, motion sickness, acute labyrinthitis, pylorospasm in infants, chorea and cardiac failure. Phenobarbital is also a useful adjunct in treatment of hemorrhage from the respiratory or gastrointestinal tract. Phenobarbital controls anxiety, decreases muscular activity and lessens nervous excitability in hyperthyroid patients. However, thyrotoxic individuals occasionally react poorly to barbiturates. Hypnotic, for the short-term treatment of insomnia, since it appears to lose its effectiveness for sleep induction and sleep maintenance after 2 weeks (see CLINICAL PHARMACOLOGY ). Preanesthetic. Long-term anticonvulsant, (phenobarbital, mephobarbital and metharbital) for the treatment of generalized tonic-clonic and cortical focal seizures. And, in the emergency control of certain acute convulsive episodes, e.g., those associated with status epilepticus, cholera, eclampsia, cerebral hemorrhage, meningitis, tetanus, and toxic reactions to strychnine or local anesthetics. Phenobarbital sodium may be administered intramuscularly or intravenously as an anticonvulsant for emergency use. When administered intravenously, it may require 15 or more minutes before reaching peak concentrations in the brain. Therefore, injecting phenobarbital sodium until the convulsions stop may cause the brain level to exceed that required to control the convulsions and lead to severe barbiturate-induced depression. Phenobarbital is indicated in pediatric patients as an anticonvulsant and as a sedative, including its preoperative and postoperative use. uuid:9bfa1c28-0abb-4d9d-8416-d5c8a0218c92 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8069 biolink:treats UMLS:C3536631 PMID:41385096 "[{""id"":""uuid:ef476acd-d510-4839-ab3f-c6b7da8b11e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e1c69616-d3fc-4577-ab13-ce933b965850"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sedative. Sedation is obtainable within an hour, and in adequate dosage, the duration of action is more than six hours. Included in the more common conditions in which the sedative action of this class of drugs is desired are anxiety-tension states, hyperthyroidism, essential hypertension, nausea and vomiting of functional origin, motion sickness, acute labyrinthitis, pylorospasm in infants, chorea and cardiac failure. Phenobarbital is also a useful adjunct in treatment of hemorrhage from the respiratory or gastrointestinal tract. Phenobarbital controls anxiety, decreases muscular activity and lessens nervous excitability in hyperthyroid patients. However, thyrotoxic individuals occasionally react poorly to barbiturates. Hypnotic, for the short-term treatment of insomnia, since it appears to lose its effectiveness for sleep induction and sleep maintenance after 2 weeks (see CLINICAL PHARMACOLOGY ). Preanesthetic. Long-term anticonvulsant, (phenobarbital, mephobarbital and metharbital) for the treatment of generalized tonic-clonic and cortical focal seizures. And, in the emergency control of certain acute convulsive episodes, e.g., those associated with status epilepticus, cholera, eclampsia, cerebral hemorrhage, meningitis, tetanus, and toxic reactions to strychnine or local anesthetics. Phenobarbital sodium may be administered intramuscularly or intravenously as an anticonvulsant for emergency use. When administered intravenously, it may require 15 or more minutes before reaching peak concentrations in the brain. Therefore, injecting phenobarbital sodium until the convulsions stop may cause the brain level to exceed that required to control the convulsions and lead to severe barbiturate-induced depression. Phenobarbital is indicated in pediatric patients as an anticonvulsant and as a sedative, including its preoperative and postoperative use. uuid:06bf57d8-d762-4b26-ba4d-4343ecbe4a29 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8069 biolink:treats MONDO:0001428 PMID:41385096 "[{""id"":""uuid:c0b7f661-521f-4065-8193-b6dfbfab3b58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f276e9df-dfda-4a49-be2f-089611cd0e5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sedative. Sedation is obtainable within an hour, and in adequate dosage, the duration of action is more than six hours. Included in the more common conditions in which the sedative action of this class of drugs is desired are anxiety-tension states, hyperthyroidism, essential hypertension, nausea and vomiting of functional origin, motion sickness, acute labyrinthitis, pylorospasm in infants, chorea and cardiac failure. Phenobarbital is also a useful adjunct in treatment of hemorrhage from the respiratory or gastrointestinal tract. Phenobarbital controls anxiety, decreases muscular activity and lessens nervous excitability in hyperthyroid patients. However, thyrotoxic individuals occasionally react poorly to barbiturates. Hypnotic, for the short-term treatment of insomnia, since it appears to lose its effectiveness for sleep induction and sleep maintenance after 2 weeks (see CLINICAL PHARMACOLOGY ). Preanesthetic. Long-term anticonvulsant, (phenobarbital, mephobarbital and metharbital) for the treatment of generalized tonic-clonic and cortical focal seizures. And, in the emergency control of certain acute convulsive episodes, e.g., those associated with status epilepticus, cholera, eclampsia, cerebral hemorrhage, meningitis, tetanus, and toxic reactions to strychnine or local anesthetics. Phenobarbital sodium may be administered intramuscularly or intravenously as an anticonvulsant for emergency use. When administered intravenously, it may require 15 or more minutes before reaching peak concentrations in the brain. Therefore, injecting phenobarbital sodium until the convulsions stop may cause the brain level to exceed that required to control the convulsions and lead to severe barbiturate-induced depression. Phenobarbital is indicated in pediatric patients as an anticonvulsant and as a sedative, including its preoperative and postoperative use. uuid:e01a0b1c-c47e-4b9a-a72b-1d6d53cdeee5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8069 biolink:treats MONDO:0001595 PMID:41385096 "[{""id"":""uuid:e8c8d8c0-ce29-44c8-a92a-792f38adece2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bb999dc2-8c08-41f1-913b-3d1e02809da2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sedative. Sedation is obtainable within an hour, and in adequate dosage, the duration of action is more than six hours. Included in the more common conditions in which the sedative action of this class of drugs is desired are anxiety-tension states, hyperthyroidism, essential hypertension, nausea and vomiting of functional origin, motion sickness, acute labyrinthitis, pylorospasm in infants, chorea and cardiac failure. Phenobarbital is also a useful adjunct in treatment of hemorrhage from the respiratory or gastrointestinal tract. Phenobarbital controls anxiety, decreases muscular activity and lessens nervous excitability in hyperthyroid patients. However, thyrotoxic individuals occasionally react poorly to barbiturates. Hypnotic, for the short-term treatment of insomnia, since it appears to lose its effectiveness for sleep induction and sleep maintenance after 2 weeks (see CLINICAL PHARMACOLOGY ). Preanesthetic. Long-term anticonvulsant, (phenobarbital, mephobarbital and metharbital) for the treatment of generalized tonic-clonic and cortical focal seizures. And, in the emergency control of certain acute convulsive episodes, e.g., those associated with status epilepticus, cholera, eclampsia, cerebral hemorrhage, meningitis, tetanus, and toxic reactions to strychnine or local anesthetics. Phenobarbital sodium may be administered intramuscularly or intravenously as an anticonvulsant for emergency use. When administered intravenously, it may require 15 or more minutes before reaching peak concentrations in the brain. Therefore, injecting phenobarbital sodium until the convulsions stop may cause the brain level to exceed that required to control the convulsions and lead to severe barbiturate-induced depression. Phenobarbital is indicated in pediatric patients as an anticonvulsant and as a sedative, including its preoperative and postoperative use. uuid:cbc944b0-954b-4203-ab9f-e232030d6aae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8069 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:dfa5cc19-138c-487a-a781-f8a876a65539"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:80ead275-4eb9-4c5c-8f96-94dd2da5ac6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sedative. Sedation is obtainable within an hour, and in adequate dosage, the duration of action is more than six hours. Included in the more common conditions in which the sedative action of this class of drugs is desired are anxiety-tension states, hyperthyroidism, essential hypertension, nausea and vomiting of functional origin, motion sickness, acute labyrinthitis, pylorospasm in infants, chorea and cardiac failure. Phenobarbital is also a useful adjunct in treatment of hemorrhage from the respiratory or gastrointestinal tract. Phenobarbital controls anxiety, decreases muscular activity and lessens nervous excitability in hyperthyroid patients. However, thyrotoxic individuals occasionally react poorly to barbiturates. Hypnotic, for the short-term treatment of insomnia, since it appears to lose its effectiveness for sleep induction and sleep maintenance after 2 weeks (see CLINICAL PHARMACOLOGY ). Preanesthetic. Long-term anticonvulsant, (phenobarbital, mephobarbital and metharbital) for the treatment of generalized tonic-clonic and cortical focal seizures. And, in the emergency control of certain acute convulsive episodes, e.g., those associated with status epilepticus, cholera, eclampsia, cerebral hemorrhage, meningitis, tetanus, and toxic reactions to strychnine or local anesthetics. Phenobarbital sodium may be administered intramuscularly or intravenously as an anticonvulsant for emergency use. When administered intravenously, it may require 15 or more minutes before reaching peak concentrations in the brain. Therefore, injecting phenobarbital sodium until the convulsions stop may cause the brain level to exceed that required to control the convulsions and lead to severe barbiturate-induced depression. Phenobarbital is indicated in pediatric patients as an anticonvulsant and as a sedative, including its preoperative and postoperative use. uuid:40522d58-8b77-4be8-8dc8-b16d47351792 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8069 biolink:treats MONDO:0013600 PMID:41385096 "[{""id"":""uuid:279b0a5f-590b-48d7-bd10-4bf67ffc9497"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:921e276e-9e47-41e2-8d1d-cc5a3e1b3bb2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sedative. Sedation is obtainable within an hour, and in adequate dosage, the duration of action is more than six hours. Included in the more common conditions in which the sedative action of this class of drugs is desired are anxiety-tension states, hyperthyroidism, essential hypertension, nausea and vomiting of functional origin, motion sickness, acute labyrinthitis, pylorospasm in infants, chorea and cardiac failure. Phenobarbital is also a useful adjunct in treatment of hemorrhage from the respiratory or gastrointestinal tract. Phenobarbital controls anxiety, decreases muscular activity and lessens nervous excitability in hyperthyroid patients. However, thyrotoxic individuals occasionally react poorly to barbiturates. Hypnotic, for the short-term treatment of insomnia, since it appears to lose its effectiveness for sleep induction and sleep maintenance after 2 weeks (see CLINICAL PHARMACOLOGY ). Preanesthetic. Long-term anticonvulsant, (phenobarbital, mephobarbital and metharbital) for the treatment of generalized tonic-clonic and cortical focal seizures. And, in the emergency control of certain acute convulsive episodes, e.g., those associated with status epilepticus, cholera, eclampsia, cerebral hemorrhage, meningitis, tetanus, and toxic reactions to strychnine or local anesthetics. Phenobarbital sodium may be administered intramuscularly or intravenously as an anticonvulsant for emergency use. When administered intravenously, it may require 15 or more minutes before reaching peak concentrations in the brain. Therefore, injecting phenobarbital sodium until the convulsions stop may cause the brain level to exceed that required to control the convulsions and lead to severe barbiturate-induced depression. Phenobarbital is indicated in pediatric patients as an anticonvulsant and as a sedative, including its preoperative and postoperative use. uuid:52964f74-3acc-4338-bdf1-4c74bd47498c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8069 biolink:treats MONDO:0002125 PMID:41385096 "[{""id"":""uuid:73c88c22-eba9-4058-a85b-664f5df88d9d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c331e828-9a47-4ca2-a73d-707a08a035c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sedative. Sedation is obtainable within an hour, and in adequate dosage, the duration of action is more than six hours. Included in the more common conditions in which the sedative action of this class of drugs is desired are anxiety-tension states, hyperthyroidism, essential hypertension, nausea and vomiting of functional origin, motion sickness, acute labyrinthitis, pylorospasm in infants, chorea and cardiac failure. Phenobarbital is also a useful adjunct in treatment of hemorrhage from the respiratory or gastrointestinal tract. Phenobarbital controls anxiety, decreases muscular activity and lessens nervous excitability in hyperthyroid patients. However, thyrotoxic individuals occasionally react poorly to barbiturates. Hypnotic, for the short-term treatment of insomnia, since it appears to lose its effectiveness for sleep induction and sleep maintenance after 2 weeks (see CLINICAL PHARMACOLOGY ). Preanesthetic. Long-term anticonvulsant, (phenobarbital, mephobarbital and metharbital) for the treatment of generalized tonic-clonic and cortical focal seizures. And, in the emergency control of certain acute convulsive episodes, e.g., those associated with status epilepticus, cholera, eclampsia, cerebral hemorrhage, meningitis, tetanus, and toxic reactions to strychnine or local anesthetics. Phenobarbital sodium may be administered intramuscularly or intravenously as an anticonvulsant for emergency use. When administered intravenously, it may require 15 or more minutes before reaching peak concentrations in the brain. Therefore, injecting phenobarbital sodium until the convulsions stop may cause the brain level to exceed that required to control the convulsions and lead to severe barbiturate-induced depression. Phenobarbital is indicated in pediatric patients as an anticonvulsant and as a sedative, including its preoperative and postoperative use. uuid:0e93d2dd-fbe4-4a48-bfe7-744a2a28c523 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8069 biolink:treats MONDO:0015766 PMID:41385096 "[{""id"":""uuid:4ff4a584-7623-4180-8e69-667ebc82e759"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a23f8715-0cfa-4a0d-9085-6ad1f7a69df2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sedative. Sedation is obtainable within an hour, and in adequate dosage, the duration of action is more than six hours. Included in the more common conditions in which the sedative action of this class of drugs is desired are anxiety-tension states, hyperthyroidism, essential hypertension, nausea and vomiting of functional origin, motion sickness, acute labyrinthitis, pylorospasm in infants, chorea and cardiac failure. Phenobarbital is also a useful adjunct in treatment of hemorrhage from the respiratory or gastrointestinal tract. Phenobarbital controls anxiety, decreases muscular activity and lessens nervous excitability in hyperthyroid patients. However, thyrotoxic individuals occasionally react poorly to barbiturates. Hypnotic, for the short-term treatment of insomnia, since it appears to lose its effectiveness for sleep induction and sleep maintenance after 2 weeks (see CLINICAL PHARMACOLOGY ). Preanesthetic. Long-term anticonvulsant, (phenobarbital, mephobarbital and metharbital) for the treatment of generalized tonic-clonic and cortical focal seizures. And, in the emergency control of certain acute convulsive episodes, e.g., those associated with status epilepticus, cholera, eclampsia, cerebral hemorrhage, meningitis, tetanus, and toxic reactions to strychnine or local anesthetics. Phenobarbital sodium may be administered intramuscularly or intravenously as an anticonvulsant for emergency use. When administered intravenously, it may require 15 or more minutes before reaching peak concentrations in the brain. Therefore, injecting phenobarbital sodium until the convulsions stop may cause the brain level to exceed that required to control the convulsions and lead to severe barbiturate-induced depression. Phenobarbital is indicated in pediatric patients as an anticonvulsant and as a sedative, including its preoperative and postoperative use. uuid:6dab1eef-96c5-40e2-aece-d75592dfb566 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8069 biolink:treats MONDO:0001754 PMID:41385096 "[{""id"":""uuid:ae9c334c-4217-4841-9660-0b7b4e3ff06e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a4619347-61c8-4316-b0e3-0ea093f2b236"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sedative. Sedation is obtainable within an hour, and in adequate dosage, the duration of action is more than six hours. Included in the more common conditions in which the sedative action of this class of drugs is desired are anxiety-tension states, hyperthyroidism, essential hypertension, nausea and vomiting of functional origin, motion sickness, acute labyrinthitis, pylorospasm in infants, chorea and cardiac failure. Phenobarbital is also a useful adjunct in treatment of hemorrhage from the respiratory or gastrointestinal tract. Phenobarbital controls anxiety, decreases muscular activity and lessens nervous excitability in hyperthyroid patients. However, thyrotoxic individuals occasionally react poorly to barbiturates. Hypnotic, for the short-term treatment of insomnia, since it appears to lose its effectiveness for sleep induction and sleep maintenance after 2 weeks (see CLINICAL PHARMACOLOGY ). Preanesthetic. Long-term anticonvulsant, (phenobarbital, mephobarbital and metharbital) for the treatment of generalized tonic-clonic and cortical focal seizures. And, in the emergency control of certain acute convulsive episodes, e.g., those associated with status epilepticus, cholera, eclampsia, cerebral hemorrhage, meningitis, tetanus, and toxic reactions to strychnine or local anesthetics. Phenobarbital sodium may be administered intramuscularly or intravenously as an anticonvulsant for emergency use. When administered intravenously, it may require 15 or more minutes before reaching peak concentrations in the brain. Therefore, injecting phenobarbital sodium until the convulsions stop may cause the brain level to exceed that required to control the convulsions and lead to severe barbiturate-induced depression. Phenobarbital is indicated in pediatric patients as an anticonvulsant and as a sedative, including its preoperative and postoperative use. uuid:2c281b0a-2c8e-4e10-ae17-00bc64bef48a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8069 biolink:treats MONDO:0013792 PMID:41385096 "[{""id"":""uuid:ba08c317-b1c2-4a00-a1e2-41df61e8f18a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2790dc87-3e7b-447a-ae1d-20dd8123582c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sedative. Sedation is obtainable within an hour, and in adequate dosage, the duration of action is more than six hours. Included in the more common conditions in which the sedative action of this class of drugs is desired are anxiety-tension states, hyperthyroidism, essential hypertension, nausea and vomiting of functional origin, motion sickness, acute labyrinthitis, pylorospasm in infants, chorea and cardiac failure. Phenobarbital is also a useful adjunct in treatment of hemorrhage from the respiratory or gastrointestinal tract. Phenobarbital controls anxiety, decreases muscular activity and lessens nervous excitability in hyperthyroid patients. However, thyrotoxic individuals occasionally react poorly to barbiturates. Hypnotic, for the short-term treatment of insomnia, since it appears to lose its effectiveness for sleep induction and sleep maintenance after 2 weeks (see CLINICAL PHARMACOLOGY ). Preanesthetic. Long-term anticonvulsant, (phenobarbital, mephobarbital and metharbital) for the treatment of generalized tonic-clonic and cortical focal seizures. And, in the emergency control of certain acute convulsive episodes, e.g., those associated with status epilepticus, cholera, eclampsia, cerebral hemorrhage, meningitis, tetanus, and toxic reactions to strychnine or local anesthetics. Phenobarbital sodium may be administered intramuscularly or intravenously as an anticonvulsant for emergency use. When administered intravenously, it may require 15 or more minutes before reaching peak concentrations in the brain. Therefore, injecting phenobarbital sodium until the convulsions stop may cause the brain level to exceed that required to control the convulsions and lead to severe barbiturate-induced depression. Phenobarbital is indicated in pediatric patients as an anticonvulsant and as a sedative, including its preoperative and postoperative use. uuid:0cf8da8c-5c4e-4d11-a86c-fca913da84cf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8069 biolink:treats MONDO:0021108 PMID:41385096 "[{""id"":""uuid:8cd136be-eb81-451b-92ee-ce9a8277f114"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2241d505-24df-44c0-bccb-d51b161ea029"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sedative. Sedation is obtainable within an hour, and in adequate dosage, the duration of action is more than six hours. Included in the more common conditions in which the sedative action of this class of drugs is desired are anxiety-tension states, hyperthyroidism, essential hypertension, nausea and vomiting of functional origin, motion sickness, acute labyrinthitis, pylorospasm in infants, chorea and cardiac failure. Phenobarbital is also a useful adjunct in treatment of hemorrhage from the respiratory or gastrointestinal tract. Phenobarbital controls anxiety, decreases muscular activity and lessens nervous excitability in hyperthyroid patients. However, thyrotoxic individuals occasionally react poorly to barbiturates. Hypnotic, for the short-term treatment of insomnia, since it appears to lose its effectiveness for sleep induction and sleep maintenance after 2 weeks (see CLINICAL PHARMACOLOGY ). Preanesthetic. Long-term anticonvulsant, (phenobarbital, mephobarbital and metharbital) for the treatment of generalized tonic-clonic and cortical focal seizures. And, in the emergency control of certain acute convulsive episodes, e.g., those associated with status epilepticus, cholera, eclampsia, cerebral hemorrhage, meningitis, tetanus, and toxic reactions to strychnine or local anesthetics. Phenobarbital sodium may be administered intramuscularly or intravenously as an anticonvulsant for emergency use. When administered intravenously, it may require 15 or more minutes before reaching peak concentrations in the brain. Therefore, injecting phenobarbital sodium until the convulsions stop may cause the brain level to exceed that required to control the convulsions and lead to severe barbiturate-induced depression. Phenobarbital is indicated in pediatric patients as an anticonvulsant and as a sedative, including its preoperative and postoperative use. uuid:8eca2a43-5b0e-44f3-9675-0b0911cd4207 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8069 biolink:treats MONDO:0005526 PMID:41385096 "[{""id"":""uuid:7f6f2d09-adca-4a34-b8c3-2243dca8b19e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:843671a0-f8d7-47f4-8d15-a8ee8e8fea52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sedative. Sedation is obtainable within an hour, and in adequate dosage, the duration of action is more than six hours. Included in the more common conditions in which the sedative action of this class of drugs is desired are anxiety-tension states, hyperthyroidism, essential hypertension, nausea and vomiting of functional origin, motion sickness, acute labyrinthitis, pylorospasm in infants, chorea and cardiac failure. Phenobarbital is also a useful adjunct in treatment of hemorrhage from the respiratory or gastrointestinal tract. Phenobarbital controls anxiety, decreases muscular activity and lessens nervous excitability in hyperthyroid patients. However, thyrotoxic individuals occasionally react poorly to barbiturates. Hypnotic, for the short-term treatment of insomnia, since it appears to lose its effectiveness for sleep induction and sleep maintenance after 2 weeks (see CLINICAL PHARMACOLOGY ). Preanesthetic. Long-term anticonvulsant, (phenobarbital, mephobarbital and metharbital) for the treatment of generalized tonic-clonic and cortical focal seizures. And, in the emergency control of certain acute convulsive episodes, e.g., those associated with status epilepticus, cholera, eclampsia, cerebral hemorrhage, meningitis, tetanus, and toxic reactions to strychnine or local anesthetics. Phenobarbital sodium may be administered intramuscularly or intravenously as an anticonvulsant for emergency use. When administered intravenously, it may require 15 or more minutes before reaching peak concentrations in the brain. Therefore, injecting phenobarbital sodium until the convulsions stop may cause the brain level to exceed that required to control the convulsions and lead to severe barbiturate-induced depression. Phenobarbital is indicated in pediatric patients as an anticonvulsant and as a sedative, including its preoperative and postoperative use. uuid:0a08439e-5398-488a-9ca7-3dc4403968a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135515 biolink:treats MONDO:0018908 PMID:41385096 "[{""id"":""uuid:39bb20fa-a30a-4076-87cb-39c9059b2f0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:819dc492-7edf-4337-acb5-ee3c0f3f6f94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:09d62094-93d8-4dec-bf51-21110fd97e73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Non-Hodgkin Lymphoma (NHL) Bendamustine hydrochloride injection is indicated for the treatment of adult patients with indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.|[PMDA] A drug with a new dosage indicated for the treatment of low-grade B-cell non-Hodgkin’s lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia, and relapsed or refractory diffuse large B-cell lymphoma. uuid:51afa2f6-4a3e-44b7-a790-08258835f1e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:N824AOU5XV biolink:treats MONDO:0019933 PMID:41385096 "[{""id"":""uuid:f804cd07-d9ae-4ee6-9d62-1752f1696f81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f013cfeb-0298-4fd5-aabf-82d854ebe9b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:fc3e6838-92e9-4f46-8c18-05a35bb886d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/somavert""]},{""id"":""uuid:4f9ed34e-b296-431a-98ab-b21d6d8dc7aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SOMAVERT is indicated for the treatment of acromegaly in patients who have had an inadequate response to surgery or radiation therapy, or for whom these therapies are not appropriate. The goal of treatment is to normalize serum insulin-like growth factor-1 (IGF-1) levels.|[EMA] Treatment of adult patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalize IGF-I concentrations or was not tolerated.Treatment of adult patients with acromegaly who have had an inadequate response to surgery and/or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalize IGF -I concentrations or was not tolerated.|[PMDA] Drugs with a new active ingredient used to treat excessive secretion of IGF-I (somatomedin C) and other related symptoms in patients with acromegaly (used in cases where other surgical and pharmaceutical therapies are not sufficiently effective or practicable.) [Orphan Drug] uuid:2a2adfa4-6044-4ba6-b069-7ebd09024ac1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats MONDO:0024643 PMID:41385096 "[{""id"":""uuid:3309902a-fe20-42b7-8647-3be1a4a06cb4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0f333cf6-92b1-496a-a143-f4832d1fa19c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cardiomyopathy: Myocardial damage, including acute left ventricular failure can occur with doxorubicin. The risk of cardiomyopathy is proportional to the cumulative exposure with incidences from 1% to 20% for cumulative doses from 300 mg/m 2 to 500 mg/m 2 when doxorubicin is administered every 3 weeks. The risk of cardiomyopathy is further increased with concomitant cardiotoxic therapy. Assess LVEF before and regularly during and after treatment with doxorubicin [see Warnings and Precautions ( 5.1 )]. Secondary Malignancies: Secondary acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) occur at a higher incidence in patients treated with anthracyclines, including doxorubicin [see Warnings and Precautions ( 5.2 )]. Extravasation and Tissue Necrosis: Extravasation of doxorubicin can result in severe local tissue injury and necrosis requiring wide excision of the affected area and skin grafting.Immediately terminate the drug, and apply ice to the affected area [see Warnings and Precautions ( 5.3 )]. Severe myelosuppression resulting in serious infection, septic shock, requirement for transfusions, hospitalization, and death may occur [see Warnings and Precautions ( 5.4 )]. uuid:827ce6f9-4093-4063-88fa-bb67dc6ead7f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats UMLS:C1306063 PMID:41385096 "[{""id"":""uuid:3243b57b-bd42-4089-8ad7-3d729f2be8a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:666dbcbc-72c0-4c83-af64-24d0d94f1fd2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cardiomyopathy: Myocardial damage, including acute left ventricular failure can occur with doxorubicin. The risk of cardiomyopathy is proportional to the cumulative exposure with incidences from 1% to 20% for cumulative doses from 300 mg/m 2 to 500 mg/m 2 when doxorubicin is administered every 3 weeks. The risk of cardiomyopathy is further increased with concomitant cardiotoxic therapy. Assess LVEF before and regularly during and after treatment with doxorubicin [see Warnings and Precautions ( 5.1 )]. Secondary Malignancies: Secondary acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) occur at a higher incidence in patients treated with anthracyclines, including doxorubicin [see Warnings and Precautions ( 5.2 )]. Extravasation and Tissue Necrosis: Extravasation of doxorubicin can result in severe local tissue injury and necrosis requiring wide excision of the affected area and skin grafting.Immediately terminate the drug, and apply ice to the affected area [see Warnings and Precautions ( 5.3 )]. Severe myelosuppression resulting in serious infection, septic shock, requirement for transfusions, hospitalization, and death may occur [see Warnings and Precautions ( 5.4 )]. uuid:2ab8867b-88dd-4ee9-87a8-35e9710042a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats MONDO:0019457 PMID:41385096 "[{""id"":""uuid:d354a7db-0d02-4829-9da4-898ae33690a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0d3923da-9ad5-4139-a233-5cedd29bf1de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cardiomyopathy: Myocardial damage, including acute left ventricular failure can occur with doxorubicin. The risk of cardiomyopathy is proportional to the cumulative exposure with incidences from 1% to 20% for cumulative doses from 300 mg/m 2 to 500 mg/m 2 when doxorubicin is administered every 3 weeks. The risk of cardiomyopathy is further increased with concomitant cardiotoxic therapy. Assess LVEF before and regularly during and after treatment with doxorubicin [see Warnings and Precautions ( 5.1 )]. Secondary Malignancies: Secondary acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) occur at a higher incidence in patients treated with anthracyclines, including doxorubicin [see Warnings and Precautions ( 5.2 )]. Extravasation and Tissue Necrosis: Extravasation of doxorubicin can result in severe local tissue injury and necrosis requiring wide excision of the affected area and skin grafting.Immediately terminate the drug, and apply ice to the affected area [see Warnings and Precautions ( 5.3 )]. Severe myelosuppression resulting in serious infection, septic shock, requirement for transfusions, hospitalization, and death may occur [see Warnings and Precautions ( 5.4 )]. uuid:59dc94fe-d6f7-4604-b991-1d5e78441e9f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats MONDO:0018881 PMID:41385096 "[{""id"":""uuid:e6a418da-e29e-44f6-a4e4-8e2e598c45a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9fd8928f-1c0b-4a1d-bf5a-7471653653e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cardiomyopathy: Myocardial damage, including acute left ventricular failure can occur with doxorubicin. The risk of cardiomyopathy is proportional to the cumulative exposure with incidences from 1% to 20% for cumulative doses from 300 mg/m 2 to 500 mg/m 2 when doxorubicin is administered every 3 weeks. The risk of cardiomyopathy is further increased with concomitant cardiotoxic therapy. Assess LVEF before and regularly during and after treatment with doxorubicin [see Warnings and Precautions ( 5.1 )]. Secondary Malignancies: Secondary acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) occur at a higher incidence in patients treated with anthracyclines, including doxorubicin [see Warnings and Precautions ( 5.2 )]. Extravasation and Tissue Necrosis: Extravasation of doxorubicin can result in severe local tissue injury and necrosis requiring wide excision of the affected area and skin grafting.Immediately terminate the drug, and apply ice to the affected area [see Warnings and Precautions ( 5.3 )]. Severe myelosuppression resulting in serious infection, septic shock, requirement for transfusions, hospitalization, and death may occur [see Warnings and Precautions ( 5.4 )]. uuid:c418ba64-45e5-4af1-a25d-a221b71a4a4a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats EFO:0009426 PMID:41385096 "[{""id"":""uuid:96c90b42-4054-417d-bd44-8feb07862cf8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6f5a7be8-67cc-4a5b-83ea-6e1e2722a5ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cardiomyopathy: Myocardial damage, including acute left ventricular failure can occur with doxorubicin. The risk of cardiomyopathy is proportional to the cumulative exposure with incidences from 1% to 20% for cumulative doses from 300 mg/m 2 to 500 mg/m 2 when doxorubicin is administered every 3 weeks. The risk of cardiomyopathy is further increased with concomitant cardiotoxic therapy. Assess LVEF before and regularly during and after treatment with doxorubicin [see Warnings and Precautions ( 5.1 )]. Secondary Malignancies: Secondary acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) occur at a higher incidence in patients treated with anthracyclines, including doxorubicin [see Warnings and Precautions ( 5.2 )]. Extravasation and Tissue Necrosis: Extravasation of doxorubicin can result in severe local tissue injury and necrosis requiring wide excision of the affected area and skin grafting.Immediately terminate the drug, and apply ice to the affected area [see Warnings and Precautions ( 5.3 )]. Severe myelosuppression resulting in serious infection, septic shock, requirement for transfusions, hospitalization, and death may occur [see Warnings and Precautions ( 5.4 )]. uuid:b4c5fe5d-ba49-4304-bd71-c800d8e4dbff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats MONDO:0001881 PMID:41385096 "[{""id"":""uuid:dbc6ec5d-0aca-465a-8413-0308eff2b175"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b91a7da6-b63e-4be0-82c9-ef60163136f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cardiomyopathy: Myocardial damage, including acute left ventricular failure can occur with doxorubicin. The risk of cardiomyopathy is proportional to the cumulative exposure with incidences from 1% to 20% for cumulative doses from 300 mg/m 2 to 500 mg/m 2 when doxorubicin is administered every 3 weeks. The risk of cardiomyopathy is further increased with concomitant cardiotoxic therapy. Assess LVEF before and regularly during and after treatment with doxorubicin [see Warnings and Precautions ( 5.1 )]. Secondary Malignancies: Secondary acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) occur at a higher incidence in patients treated with anthracyclines, including doxorubicin [see Warnings and Precautions ( 5.2 )]. Extravasation and Tissue Necrosis: Extravasation of doxorubicin can result in severe local tissue injury and necrosis requiring wide excision of the affected area and skin grafting.Immediately terminate the drug, and apply ice to the affected area [see Warnings and Precautions ( 5.3 )]. Severe myelosuppression resulting in serious infection, septic shock, requirement for transfusions, hospitalization, and death may occur [see Warnings and Precautions ( 5.4 )]. uuid:a8ede7d9-b3f0-41d9-b022-7d4d2f01dae0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3242 biolink:treats NCIT:C92821 PMID:41385096 "[{""id"":""uuid:890910a6-b385-4d7d-a01f-876f3ba0b7a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3f389cbe-42cc-47a5-86c6-f833347c0d08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Butorphanol Tartrate Injection is indicated: as a preoperative or pre-anesthetic medication as a supplement to balanced anesthesia for the relief of pain during labor, and for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses [see WARNINGS ], reserve Butorphanol Tartrate Injection for use in patients for whom alternative treatment options [e.g. non-opioid analgesics] Have not been tolerated, or are not expected to be tolerated Have not provided adequate analgesia, or are not expected to provide adequate analgesia uuid:98ae5f40-670f-40f7-bd52-2155187e3ec9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:204928 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:cfe97196-0a67-4adf-aca1-57aefb0bc628"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:26611e2c-e459-490c-9008-20d8dacdd971"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cefotaxime for Injection, USP is indicated for the treatment of patients with serious infections caused by susceptible strains of the designated microorganisms in the diseases listed below. (1) Lower respiratory tract infections, including pneumonia, caused by Streptococcus pneumoniae (formerly Diplococcus pneumoniae ), Streptococcus pyogenes* (Group A streptococci) and other streptococci (excluding enterococci, e.g., Enterococcus faecalis ), Staphylococcus aureus (penicillinase and non-penicillinase producing), Escherichia coli , Klebsiella species, Haemophilus influenzae (including ampicillin resistant strains), Haemophilus parainfluenzae , Proteus mirabilis , Serratia marcescens* , Enterobacter species, indole positive Proteus and Pseudomonas species (including P. aeruginosa ). (2) Genitourinary infections . Urinary tract infections caused by Enterococcus species, Staphylococcus epidermidis , Staphylococcus aureus* , (penicillinase and non-penicillinase producing), Citrobacter species, Enterobacter species, Escherichia coli , Klebsiella species, Proteus mirabilis , Proteus vulgaris* , Providencia stuartii , Morganella morganii* , Providencia rettgeri* , Serratia marcescens and Pseudomonas species (including P. aeruginosa ). Also, uncomplicated gonorrhea (cervical/urethral and rectal) caused by Neisseria gonorrhoeae , including penicillinase producing strains. (3) Gynecologic infections, including pelvic inflammatory disease, endometritis and pelvic cellulitis caused by Staphylococcus epidermidis , Streptococcus species, Enterococcus species, Enterobacter species*, Klebsiella species*, Escherichia coli , Proteus mirabilis , Bacteroides species (including Bacteroides fragilis* ), Clostridium species, and anaerobic cocci (including Peptostreptococcus species and Peptococcus species) and Fusobacterium species (including F. nucleatum* ). Cefotaxime for Injection, USP, like other cephalosporins, has no activity against Chlamydia trachomatis . Therefore, when cephalosporins are used in the treatment of patients with pelvic inflammatory disease and C. trachomatis is one of the suspected pathogens, appropriate anti-chlamydial coverage should be added. (4) Bacteremia/Septicemia caused by Escherichia coli , Klebsiella species, and Serratia marcescens , Staphylococcus aureus and Streptococcus species (including S. pneumoniae ). (5) Skin and skin structure infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing), Staphylococcus epidermidis , Streptococcus pyogenes (Group A streptococci) and other streptococci, Enterococcus species, Acinetobacter species*, Escherichia coli , Citrobacter species (including C. freundii* ), Enterobacter species, Klebsiella species, Proteus mirabilis , Proteus vulgaris* , Morganella morganii , Providencia rettgeri* , Pseudomonas species, Serratia marcescens , Bacteroides species, and anaerobic cocci (including Peptostreptococcus* species and Peptococcus species). (6) Intra-abdominal infections including peritonitis caused by Streptococcus species*, Escherichia coli , Klebsiella species, Bacteroides species, and anaerobic cocci (including Peptostreptococcus* species and Peptococcus* species) Proteus mirabilis* , and Clostridium species*. (7) Bone and/or joint infections caused by Staphylococcus aureus (penicillinase and non-penicillinase producing strains), Streptococcus species (including S. pyogenes* ), Pseudomonas species (including P. aeruginosa* ), and Proteus mirabilis* . (8) Central nervous system infections, e.g., meningitis and ventriculitis, caused by Neisseria meningitidis , Haemophilus influenzae , Streptococcus pneumoniae , Klebsiella pneumoniae* and Escherichia coli* . (*) Efficacy for this organism, in this organ system, has been studied in fewer than 10 infections. Although many strains of enterococci (e.g., S. faecalis ) and Pseudomonas species are resistant to cefotaxime sodium in vitro , Cefotaxime for Injection, USP has been used successfully in treating patients with infections caused by susceptible organisms. Specimens for bacteriologic culture should be obtained prior to therapy in order to isolate and identify causative organisms and to determine their susceptibilities to cefotaxime. Therapy may be instituted before results of susceptibility studies are known; however, once these results become available, the antibiotic treatment should be adjusted accordingly. In certain cases of confirmed or suspected gram-positive or gram-negative sepsis or in patients with other serious infections in which the causative organism has not been identified, Cefotaxime for Injection, USP may be used concomitantly with an aminoglycoside. The dosage recommended in the labeling of both antibiotics may be given and depends on the severity of the infection and the patient's condition. Renal function should be carefully monitored, especially if higher dosages of the aminoglycosides are to be administered or if therapy is prolonged, because of the potential nephrotoxicity and ototoxicity of aminoglycoside antibiotics. It is possible that nephrotoxicity may be potentiated if Cefotaxime for Injection, USP is used concomitantly with an aminoglycoside. uuid:e25082eb-35bc-4661-848c-0fbe7bbd0007 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63587 biolink:treats UMLS:C0278488 PMID:41385096 "[{""id"":""uuid:a5716674-0169-4acc-a262-3d47f9fb3e79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:84f8efc3-5ff3-41a9-b01a-ac6e3cfddcc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Eribulin mesylate injection is a microtubule inhibitor indicated for the treatment of patients with: Metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting. ( 1.1 ) Unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen. ( 1.2 ) uuid:c3ce5e42-e9a7-4ce9-8d28-839fe85a732f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63587 biolink:treats UMLS:C4331476 PMID:41385096 "[{""id"":""uuid:582d8bd8-368b-4b85-a342-5ee8bb352e98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6791062d-7a71-44fd-beff-0fdfab61adba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Eribulin mesylate injection is a microtubule inhibitor indicated for the treatment of patients with: Metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting. ( 1.1 ) Unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen. ( 1.2 ) uuid:b8aaf2a8-585b-420b-a1d6-a399abec6b6c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63587 biolink:treats UMLS:C0855059 PMID:41385096 "[{""id"":""uuid:39fe9048-2cba-49f6-82ec-51a75b1a69ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2864feae-50bd-43b1-8556-e43f8878a5bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Eribulin mesylate injection is a microtubule inhibitor indicated for the treatment of patients with: Metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting. ( 1.1 ) Unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen. ( 1.2 ) uuid:195c5e35-79e5-46df-8af0-a370808795fc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59297 biolink:treats MONDO:0000775 PMID:41385096 "[{""id"":""uuid:81f35e1c-0e00-4b1c-a5a7-fffbecdd9711"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6c5049aa-4dc3-45d6-843a-ec80c3b75f82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRE-PEN is indicated for the assessment of sensitization to penicillin (benzylpenicillin or penicillin G) in patients suspected to have clinical penicillin hypersensitivity. A negative skin test to PRE-PEN is associated with an incidence of immediate allergic reactions of less than 5% after the administration of therapeutic penicillin, whereas the incidence may be more than 50% in a history-positive patient with a positive skin test to PRE-PEN. These allergic reactions are predominantly dermatologic. Whether a negative skin test to PRE-PEN predicts a lower risk of anaphylaxis is not established. Similarly, when deciding the risk of proposed penicillin treatment, there are not enough data at present to permit relative weighing in individual cases of a history of clinical penicillin hypersensitivity as compared to positive skin tests to PRE-PEN and/or minor penicillin determinants. uuid:3f3f9ddb-5eda-4f69-9f3a-518afd6b5b6a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59297 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:ea1b3d9f-1493-4415-8088-f73da63e36e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:559c79cf-c10a-45a5-8435-ee4cd9e9297b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRE-PEN is indicated for the assessment of sensitization to penicillin (benzylpenicillin or penicillin G) in patients suspected to have clinical penicillin hypersensitivity. A negative skin test to PRE-PEN is associated with an incidence of immediate allergic reactions of less than 5% after the administration of therapeutic penicillin, whereas the incidence may be more than 50% in a history-positive patient with a positive skin test to PRE-PEN. These allergic reactions are predominantly dermatologic. Whether a negative skin test to PRE-PEN predicts a lower risk of anaphylaxis is not established. Similarly, when deciding the risk of proposed penicillin treatment, there are not enough data at present to permit relative weighing in individual cases of a history of clinical penicillin hypersensitivity as compared to positive skin tests to PRE-PEN and/or minor penicillin determinants. uuid:e76066b1-3dbf-471f-be43-71329672eda6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59297 biolink:treats MONDO:0100053 PMID:41385096 "[{""id"":""uuid:03fbb791-14d3-4b55-8e9b-9665a8cbbe46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5a1487fd-1329-4116-a4d2-0ad38c4610e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRE-PEN is indicated for the assessment of sensitization to penicillin (benzylpenicillin or penicillin G) in patients suspected to have clinical penicillin hypersensitivity. A negative skin test to PRE-PEN is associated with an incidence of immediate allergic reactions of less than 5% after the administration of therapeutic penicillin, whereas the incidence may be more than 50% in a history-positive patient with a positive skin test to PRE-PEN. These allergic reactions are predominantly dermatologic. Whether a negative skin test to PRE-PEN predicts a lower risk of anaphylaxis is not established. Similarly, when deciding the risk of proposed penicillin treatment, there are not enough data at present to permit relative weighing in individual cases of a history of clinical penicillin hypersensitivity as compared to positive skin tests to PRE-PEN and/or minor penicillin determinants. uuid:6d895053-5407-4aa2-a42f-192aef19b737 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:167309 biolink:treats MONDO:0018362 PMID:41385096 "[{""id"":""uuid:c888fc61-d213-4cb4-ad7a-008a57114ad2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:189f5bc4-d047-4294-8a5c-637629d3f347"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methadone hydrochloride tablets are indicated for the: 1. Management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic and for which alternative treatment options are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration [see Warnings and Precautions (5.1)] , reserve methadone hydrochloride tablets for use in patients for whom alternative analgesic treatment options (e.g., non-opioid analgesics or opioid combination products) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. Methadone hydrochloride tablets are not indicated as an as-needed (prn) analgesic. 2. Detoxification treatment of opioid addiction (heroin or other morphine-like drugs). 3. Maintenance treatment of opioid addiction (heroin or other morphine-like drugs), in conjunction with appropriate social and medical services. Limitations of Use Methadone products used for the treatment of opioid addiction in detoxification or maintenance programs are subject to the conditions for distribution and use required under 42 CFR 8.12 [see Dosage and Administration (2.1)]. uuid:bd738a44-2393-45c9-8b17-306bf2904a40 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63577 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:c04733fe-84c1-479f-9cb2-0cc46fac90e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:75f4f538-6d69-4d02-adac-49f9b734c0f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:60edca43-ecb9-4833-b2ee-5aba204667d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lamivudine-teva-pharma-bv""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lamivudine oral solution is a nucleoside analogue indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. Limitations of Use: The dosage of this product is for HIV-1 and not for HBV.|[EMA] Lamivudine Teva Pharma B.V. is indicated as part of antiretroviral combination therapy for the treatment of human-immunodeficiency-virus (HIV)-infected adults and children. uuid:6d16d998-5cc8-44cb-86f0-173323aea192 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135905 biolink:treats MONDO:0001382 PMID:41385096 "[{""id"":""uuid:a068ceaa-63b3-44d2-811b-7ea84b1225d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:51d8edaa-6942-4895-8472-e76e35a10fe0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TERLIVAZ is indicated to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function. uuid:887a4870-688f-4655-bea4-035b7b9160f7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31439 biolink:treats MONDO:0004525 PMID:41385096 "[{""id"":""uuid:08ee0366-2d5a-4cb0-bb29-1cc45d51050a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e354710f-e26b-4e59-a503-0e6257939d51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CROTAN ™ (crotamiton USP 10%) is a scabicidal and antipruritic agent as a lotion for topical use only. Crotamiton is a colorless to slightly yellowish oil, having a faint amine-like odor. It is miscible with alcohol and with methanol. Crotamiton is a mixture of the cis and trans isomers. Its molecular weight is 203. 28. Crotamiton is N-ethyl-N(o-methyl-phenyl) 2-butenamide and its structural formula is: CROTAN lotion contains crotamiton USP 10% (100mg/ml) in a creamy lotion base containing purified water, light mineral oil, propylene glycol, cetearyl alcohol (and) cetearth-20, cetyl alcohol, lanolin, benzyl alcohol, carbomer 971P, sodium hydroxide with citric acid (for pH adjustment). uuid:4ade2676-d388-469d-befe-966c9e4c88b4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31439 biolink:treats HP:0000989 PMID:41385096 "[{""id"":""uuid:200717c5-1f98-4e00-a09c-eb4850da2fe3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:972924ed-5b5c-494a-bafe-6379f200a280"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CROTAN ™ (crotamiton USP 10%) is a scabicidal and antipruritic agent as a lotion for topical use only. Crotamiton is a colorless to slightly yellowish oil, having a faint amine-like odor. It is miscible with alcohol and with methanol. Crotamiton is a mixture of the cis and trans isomers. Its molecular weight is 203. 28. Crotamiton is N-ethyl-N(o-methyl-phenyl) 2-butenamide and its structural formula is: CROTAN lotion contains crotamiton USP 10% (100mg/ml) in a creamy lotion base containing purified water, light mineral oil, propylene glycol, cetearyl alcohol (and) cetearth-20, cetyl alcohol, lanolin, benzyl alcohol, carbomer 971P, sodium hydroxide with citric acid (for pH adjustment). uuid:ae460ebe-a382-4510-9e66-e05a446b89ae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2665904 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:8ab1b63c-9d6c-475f-96bd-ff80f2c34888"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7e29cae3-365c-4d03-9a2a-6748fe583644"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AIRSUPRA is indicated for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in patients with asthma 18 years of age and older. uuid:e0c451f2-d957-4b97-b860-b034baef4c0f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2665904 biolink:treats HP:4000007 PMID:41385096 "[{""id"":""uuid:877e79bd-c7fd-49e5-b5cb-5afabd5ff60f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9a176031-742e-4067-9d09-9375d6be6646"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AIRSUPRA is indicated for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of exacerbations in patients with asthma 18 years of age and older. uuid:272c1009-f006-4901-8cc0-f25e86c7f134 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51450 biolink:treats UMLS:C3697119 PMID:41385096 "[{""id"":""uuid:9aeceb85-92d0-423a-9cd4-de9695835767"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e13fd239-e2cf-4440-a5b9-b76a331189cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bosentan tablets are indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1): in adults to improve exercise ability and to decrease clinical worsening. Studies establishing effectiveness included predominantly patients with WHO Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (60%), PAH associated with connective tissue diseases (21%), and PAH associated with congenital heart disease with left-to-right shunts (18%) [see Clinical Studies (14.1) ] . in pediatric patients aged 3 years and older with idiopathic or congenital PAH to improve pulmonary vascular resistance (PVR), which is expected to result in an improvement in exercise ability. uuid:765389cd-4c01-4223-a37b-a33986a5f364 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:5Z9SP3X666 biolink:treats MONDO:0001516 PMID:41385096 "[{""id"":""uuid:d879e55a-a549-4267-94bc-d0635310421a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7ff9b92d-744b-4ad0-8454-5d1dfe155987"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3623d27c-086a-4d79-b7b1-7312b690a6f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SPINRAZA is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.|[PMDA] A drug with a new indication for the treatment of spinal muscular atrophy without any clinical manifestations that is predicted to develop with genetic test. [Orphan drug] uuid:65486858-fcd9-4e74-a8ae-bed2e80fb360 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:5Z9SP3X666 biolink:treats MONDO:0019079 PMID:41385096 "[{""id"":""uuid:fa3e24cc-55a7-4546-b959-02fe709952a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:191c3caa-2088-4a58-a6f8-1e9439c00bc4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9e3f45bf-4f4b-4a57-9b2d-399707f84832"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SPINRAZA is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.|[EMA] Spinraza is indicated for the treatment of 5q Spinal Muscular Atrophy. uuid:c4de4b5e-a8ad-408f-8d3f-8b2a298cba06 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5739 biolink:treats MONDO:0019165 PMID:41385096 "[{""id"":""uuid:c4505b0e-12b8-43b8-b46c-8f16dba67a65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a433c31b-31cf-445c-b90d-70f1b0c2a863"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SUPPRELIN LA (histrelin acetate) subcutaneous implant is indicated for the treatment of children with central precocious puberty (CPP). Children with CPP (neurogenic or idiopathic) have an early onset of secondary sexual characteristics (earlier than 8 years of age in females and 9 years of age in males). They also show a significantly advanced bone age that can result in diminished adult height attainment. Prior to initiation of treatment a clinical diagnosis of CPP should be confirmed by measurement of blood concentrations of total sex steroids, luteinizing hormone (LH) and follicle stimulating hormone (FSH) following stimulation with a GnRH analog, and assessment of bone age versus chronological age. Baseline evaluations should include height and weight measurements, diagnostic imaging of the brain (to rule out intracranial tumor), pelvic/testicular/adrenal ultrasound (to rule out steroid secreting tumors), human chorionic gonadotropin levels (to rule out a chorionic gonadotropin secreting tumor), and adrenal steroids to exclude congenital adrenal hyperplasia. uuid:8461112b-96e1-48f9-8196-86f89079cb69 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5739 biolink:treats MONDO:0015713 PMID:41385096 "[{""id"":""uuid:f0878d04-efef-4dc0-97ac-801614cad063"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0f083de6-5ef4-44a7-9915-74b4703a4d57"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SUPPRELIN LA (histrelin acetate) subcutaneous implant is indicated for the treatment of children with central precocious puberty (CPP). Children with CPP (neurogenic or idiopathic) have an early onset of secondary sexual characteristics (earlier than 8 years of age in females and 9 years of age in males). They also show a significantly advanced bone age that can result in diminished adult height attainment. Prior to initiation of treatment a clinical diagnosis of CPP should be confirmed by measurement of blood concentrations of total sex steroids, luteinizing hormone (LH) and follicle stimulating hormone (FSH) following stimulation with a GnRH analog, and assessment of bone age versus chronological age. Baseline evaluations should include height and weight measurements, diagnostic imaging of the brain (to rule out intracranial tumor), pelvic/testicular/adrenal ultrasound (to rule out steroid secreting tumors), human chorionic gonadotropin levels (to rule out a chorionic gonadotropin secreting tumor), and adrenal steroids to exclude congenital adrenal hyperplasia. uuid:698556c9-a895-4a50-a74b-df37d18fe43c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5739 biolink:treats MONDO:0021211 PMID:41385096 "[{""id"":""uuid:d7d15ca7-47cc-4403-90b0-eebb04a24d3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5cf02b97-efe0-4c47-b14c-bca9214d84f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SUPPRELIN LA (histrelin acetate) subcutaneous implant is indicated for the treatment of children with central precocious puberty (CPP). Children with CPP (neurogenic or idiopathic) have an early onset of secondary sexual characteristics (earlier than 8 years of age in females and 9 years of age in males). They also show a significantly advanced bone age that can result in diminished adult height attainment. Prior to initiation of treatment a clinical diagnosis of CPP should be confirmed by measurement of blood concentrations of total sex steroids, luteinizing hormone (LH) and follicle stimulating hormone (FSH) following stimulation with a GnRH analog, and assessment of bone age versus chronological age. Baseline evaluations should include height and weight measurements, diagnostic imaging of the brain (to rule out intracranial tumor), pelvic/testicular/adrenal ultrasound (to rule out steroid secreting tumors), human chorionic gonadotropin levels (to rule out a chorionic gonadotropin secreting tumor), and adrenal steroids to exclude congenital adrenal hyperplasia. uuid:23d720ab-1117-4e31-a3d3-db58d9bb88ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5739 biolink:treats MONDO:0018479 PMID:41385096 "[{""id"":""uuid:fcc83f31-6f6d-4b6b-b8ac-99a955858cb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9dd83fd8-a926-4466-9b3d-0ee59e2c86a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SUPPRELIN LA (histrelin acetate) subcutaneous implant is indicated for the treatment of children with central precocious puberty (CPP). Children with CPP (neurogenic or idiopathic) have an early onset of secondary sexual characteristics (earlier than 8 years of age in females and 9 years of age in males). They also show a significantly advanced bone age that can result in diminished adult height attainment. Prior to initiation of treatment a clinical diagnosis of CPP should be confirmed by measurement of blood concentrations of total sex steroids, luteinizing hormone (LH) and follicle stimulating hormone (FSH) following stimulation with a GnRH analog, and assessment of bone age versus chronological age. Baseline evaluations should include height and weight measurements, diagnostic imaging of the brain (to rule out intracranial tumor), pelvic/testicular/adrenal ultrasound (to rule out steroid secreting tumors), human chorionic gonadotropin levels (to rule out a chorionic gonadotropin secreting tumor), and adrenal steroids to exclude congenital adrenal hyperplasia. uuid:f8801f99-365b-4b93-b041-0fc943e269f0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:167574 biolink:treats MONDO:0011122 PMID:41385096 "[{""id"":""uuid:99ef4c0f-8aef-4d4f-8dfe-47fd84fd8374"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d84e854a-400f-49f0-8ed9-0e5e37e60d23"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ff30644c-c630-4068-b354-5eafdebdef8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/wegovy""]},{""id"":""uuid:13ca2de3-89ef-4296-be07-5d40a2090c2d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] WEGOVY is indicated in combination with a reduced calorie diet and increased physical activity: • to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight. • to reduce excess body weight and maintain weight reduction long term in: o Adults and pediatric patients aged 12 years and older with obesity o Adults with overweight in the presence of at least one weight-related comorbid condition. Limitations of Use • WEGOVY contains semaglutide. Coadministration with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended.|[EMA] Wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial Body Mass Index (BMI) of- ≥30 kg/m² (obesity), or- ≥27 kg/m² to|[PMDA] Drugs with a new indication, a new dosage and other characteristics for the treatment of obesity. Drugs with a new indication and a new dosage in an additional dosage form for the treatment of obesity. For use only in patients with any of hypertension, hyperlipidemia or type 2 diabetes mellitus who have not responded sufficiently to diet therapy and exercise therapy, and meet the following conditions: BMI of 27 kg/m2 or greater in the presence of at least two obesity-related comorbidities or BMI of 35 kg/m2 or greater uuid:9d342a99-8611-4898-948c-a44a9f80c7a9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:167574 biolink:treats EFO:0005935 PMID:41385096 "[{""id"":""uuid:0a9cce32-2659-44bb-8d00-c5b7d499cebd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6438dcac-8a83-4c27-ab9b-ccd69d92d7a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] WEGOVY is indicated in combination with a reduced calorie diet and increased physical activity: • to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight. • to reduce excess body weight and maintain weight reduction long term in: o Adults and pediatric patients aged 12 years and older with obesity o Adults with overweight in the presence of at least one weight-related comorbid condition. Limitations of Use • WEGOVY contains semaglutide. Coadministration with other semaglutide-containing products or with any other GLP-1 receptor agonist is not recommended. uuid:3c7fc64c-b1bd-4b71-bb66-8a52e6bbdf2b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1999667 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:dc1d8f7a-bb79-45a0-bd10-661583802b41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3cdb1ba5-c498-4649-8b17-76b88d097d8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BIKTARVY is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients weighing at least 14 kg: who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no known or suspected substitutions associated with resistance to bictegravir or tenofovir. uuid:9426a004-79aa-4ec5-a9cb-6512055a459f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4B93MGE4AL biolink:treats MONDO:0003210 PMID:41385096 "[{""id"":""uuid:ba5fc80e-562a-4c84-9d8b-d51b838249ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c007d783-b25f-4741-b87e-f01a9d951f4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LYTGOBI is indicated for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements [see Dosage and Administration (2.1) ] . This indication is approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies (14.1) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). uuid:37186d7b-2066-4dee-9688-be3a39008be1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:476348 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:ebc69340-dc74-4f1a-b3b8-2ccfedb3d9d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:63c12458-c6c1-4034-8632-f770765d0d3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ezetimibe and Simvastatin Tablets Ezetimibe and Simvastatin Tablets are a combination of simvastatin and ezetimibe indicated: • As an adjunct to diet to reduce elevated low density lipoprotein cholesterol (LDL-C): o In adults with primary hyperlipidemia. o In adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to other LDL-C-lowering therapies to reduce elevated LDL-C in adults with homozygous familial hypercholesterolemia (HoFH). Simvastatin Simvastatin, when used as a component of ezetimibe and simvastatin tablets, is indicated to reduce the risk of total mortality by reducing risk of coronary heart disease death, non-fatal myocardial infarction and stroke, and the need for coronary and non-coronary revascularization procedures in adults with established coronary heart disease, cerebrovascular disease, peripheral vascular disease, and/or diabetes, who are at high risk of coronary heart disease events. uuid:81932a70-6537-40cf-adf0-2681060e40af biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:476348 biolink:treats UMLS:C0342882 PMID:41385096 "[{""id"":""uuid:b09d1da5-b2ab-4b19-8819-09850a7912a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:62b92d4b-7d3d-49cb-bd15-95f4a7de27d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ezetimibe and Simvastatin Tablets Ezetimibe and Simvastatin Tablets are a combination of simvastatin and ezetimibe indicated: • As an adjunct to diet to reduce elevated low density lipoprotein cholesterol (LDL-C): o In adults with primary hyperlipidemia. o In adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to other LDL-C-lowering therapies to reduce elevated LDL-C in adults with homozygous familial hypercholesterolemia (HoFH). Simvastatin Simvastatin, when used as a component of ezetimibe and simvastatin tablets, is indicated to reduce the risk of total mortality by reducing risk of coronary heart disease death, non-fatal myocardial infarction and stroke, and the need for coronary and non-coronary revascularization procedures in adults with established coronary heart disease, cerebrovascular disease, peripheral vascular disease, and/or diabetes, who are at high risk of coronary heart disease events. uuid:543a4fc7-57ee-4381-a96a-42b56c8690e1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:476348 biolink:treats MONDO:0018328 PMID:41385096 "[{""id"":""uuid:4d56714a-5c47-4ced-94b6-4bec37638ecc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9037bf7e-80df-47d0-8a15-fae048e2b445"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ezetimibe and Simvastatin Tablets Ezetimibe and Simvastatin Tablets are a combination of simvastatin and ezetimibe indicated: • As an adjunct to diet to reduce elevated low density lipoprotein cholesterol (LDL-C): o In adults with primary hyperlipidemia. o In adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to other LDL-C-lowering therapies to reduce elevated LDL-C in adults with homozygous familial hypercholesterolemia (HoFH). Simvastatin Simvastatin, when used as a component of ezetimibe and simvastatin tablets, is indicated to reduce the risk of total mortality by reducing risk of coronary heart disease death, non-fatal myocardial infarction and stroke, and the need for coronary and non-coronary revascularization procedures in adults with established coronary heart disease, cerebrovascular disease, peripheral vascular disease, and/or diabetes, who are at high risk of coronary heart disease events. uuid:cc8e6752-e3d8-4258-85b0-b5bccac6f6e2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:476348 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:0e4e5e8b-9136-402d-88ad-8517ae8e14ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5d7baf28-af2e-4dc8-91cc-b70effb988ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ezetimibe and Simvastatin Tablets Ezetimibe and Simvastatin Tablets are a combination of simvastatin and ezetimibe indicated: • As an adjunct to diet to reduce elevated low density lipoprotein cholesterol (LDL-C): o In adults with primary hyperlipidemia. o In adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to other LDL-C-lowering therapies to reduce elevated LDL-C in adults with homozygous familial hypercholesterolemia (HoFH). Simvastatin Simvastatin, when used as a component of ezetimibe and simvastatin tablets, is indicated to reduce the risk of total mortality by reducing risk of coronary heart disease death, non-fatal myocardial infarction and stroke, and the need for coronary and non-coronary revascularization procedures in adults with established coronary heart disease, cerebrovascular disease, peripheral vascular disease, and/or diabetes, who are at high risk of coronary heart disease events. uuid:cfaee8a8-01fc-4406-908e-a9033601a6a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:476348 biolink:treats MONDO:0011057 PMID:41385096 "[{""id"":""uuid:58d8b7be-aff6-4090-ab61-ca11e1304519"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e644fab9-ac7c-4faf-9dc0-d756260d922c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ezetimibe and Simvastatin Tablets Ezetimibe and Simvastatin Tablets are a combination of simvastatin and ezetimibe indicated: • As an adjunct to diet to reduce elevated low density lipoprotein cholesterol (LDL-C): o In adults with primary hyperlipidemia. o In adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to other LDL-C-lowering therapies to reduce elevated LDL-C in adults with homozygous familial hypercholesterolemia (HoFH). Simvastatin Simvastatin, when used as a component of ezetimibe and simvastatin tablets, is indicated to reduce the risk of total mortality by reducing risk of coronary heart disease death, non-fatal myocardial infarction and stroke, and the need for coronary and non-coronary revascularization procedures in adults with established coronary heart disease, cerebrovascular disease, peripheral vascular disease, and/or diabetes, who are at high risk of coronary heart disease events. uuid:626feca4-4933-4325-b7a1-a5855a76f01f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:476348 biolink:treats MONDO:0005294 PMID:41385096 "[{""id"":""uuid:58267fe1-d723-4555-9ad0-8ae8850b887b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c1450a2b-383e-4840-bda4-e1c56ff4a556"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ezetimibe and Simvastatin Tablets Ezetimibe and Simvastatin Tablets are a combination of simvastatin and ezetimibe indicated: • As an adjunct to diet to reduce elevated low density lipoprotein cholesterol (LDL-C): o In adults with primary hyperlipidemia. o In adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to other LDL-C-lowering therapies to reduce elevated LDL-C in adults with homozygous familial hypercholesterolemia (HoFH). Simvastatin Simvastatin, when used as a component of ezetimibe and simvastatin tablets, is indicated to reduce the risk of total mortality by reducing risk of coronary heart disease death, non-fatal myocardial infarction and stroke, and the need for coronary and non-coronary revascularization procedures in adults with established coronary heart disease, cerebrovascular disease, peripheral vascular disease, and/or diabetes, who are at high risk of coronary heart disease events. uuid:db624f16-20af-407b-8f5a-c40107b11ca5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:476348 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:09ea13f4-1644-474b-a634-b59525c077a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9f84a769-40e9-44b3-964e-7e05b21547b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ezetimibe and Simvastatin Tablets Ezetimibe and Simvastatin Tablets are a combination of simvastatin and ezetimibe indicated: • As an adjunct to diet to reduce elevated low density lipoprotein cholesterol (LDL-C): o In adults with primary hyperlipidemia. o In adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH). • As an adjunct to other LDL-C-lowering therapies to reduce elevated LDL-C in adults with homozygous familial hypercholesterolemia (HoFH). Simvastatin Simvastatin, when used as a component of ezetimibe and simvastatin tablets, is indicated to reduce the risk of total mortality by reducing risk of coronary heart disease death, non-fatal myocardial infarction and stroke, and the need for coronary and non-coronary revascularization procedures in adults with established coronary heart disease, cerebrovascular disease, peripheral vascular disease, and/or diabetes, who are at high risk of coronary heart disease events. uuid:b7858dfd-5a05-49b8-8ab4-3ebd821c5bc2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28445 biolink:treats MONDO:0010643 PMID:41385096 "[{""id"":""uuid:287e1002-d137-4c06-baa6-d31f80fab6ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:53d37180-92a4-4689-bff5-95ed8ad0aec5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vincristine Sulfate Injection is indicated in acute leukemia. Vincristine Sulfate Injection has also been shown to be useful in combination with other oncolytic agents in Hodgkin's disease, non–Hodgkin's malignant lymphomas, rhabdomyosarcoma, neuroblastoma, and Wilms' tumor. uuid:56be79b4-5617-4740-ab35-bc566a5f6da8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28445 biolink:treats MONDO:0009348 PMID:41385096 "[{""id"":""uuid:e5e0b52e-c8c8-4fa6-8529-ff0a5e54f6df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7611dc4c-a1e1-4ebf-afba-a2907d627ff3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vincristine Sulfate Injection is indicated in acute leukemia. Vincristine Sulfate Injection has also been shown to be useful in combination with other oncolytic agents in Hodgkin's disease, non–Hodgkin's malignant lymphomas, rhabdomyosarcoma, neuroblastoma, and Wilms' tumor. uuid:abdee81d-3777-4726-9358-3e60d608e480 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28445 biolink:treats MONDO:0005062 PMID:41385096 "[{""id"":""uuid:81d2c2ce-ace4-450e-b668-8491fab26c1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f2caedfa-fe72-431d-864c-725cc8553535"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vincristine Sulfate Injection is indicated in acute leukemia. Vincristine Sulfate Injection has also been shown to be useful in combination with other oncolytic agents in Hodgkin's disease, non–Hodgkin's malignant lymphomas, rhabdomyosarcoma, neuroblastoma, and Wilms' tumor. uuid:8af1b252-6cea-4b0e-b35a-e3788a53ce51 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28445 biolink:treats MONDO:0005212 PMID:41385096 "[{""id"":""uuid:4bcb9917-cbe2-4cdf-9968-48b73ceecc78"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8ee8cc63-33f1-4ab2-941f-aee4c43d6045"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vincristine Sulfate Injection is indicated in acute leukemia. Vincristine Sulfate Injection has also been shown to be useful in combination with other oncolytic agents in Hodgkin's disease, non–Hodgkin's malignant lymphomas, rhabdomyosarcoma, neuroblastoma, and Wilms' tumor. uuid:cd70185e-3f1e-4f8c-95c8-e502c76f4d7c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28445 biolink:treats MONDO:0005072 PMID:41385096 "[{""id"":""uuid:c15084ad-3836-4755-bb1b-b1517a97e8c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cb281588-b26a-43a4-a20c-790ad2c76d96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vincristine Sulfate Injection is indicated in acute leukemia. Vincristine Sulfate Injection has also been shown to be useful in combination with other oncolytic agents in Hodgkin's disease, non–Hodgkin's malignant lymphomas, rhabdomyosarcoma, neuroblastoma, and Wilms' tumor. uuid:399c66e6-ff23-44d6-94c1-91b69a76475b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28445 biolink:treats MONDO:0006058 PMID:41385096 "[{""id"":""uuid:ee3001e1-6b80-4c28-b5bb-8a0fa0209fe8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:12458257-1c6e-4629-adb3-345ec0f01ef5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vincristine Sulfate Injection is indicated in acute leukemia. Vincristine Sulfate Injection has also been shown to be useful in combination with other oncolytic agents in Hodgkin's disease, non–Hodgkin's malignant lymphomas, rhabdomyosarcoma, neuroblastoma, and Wilms' tumor. uuid:3fa160d6-9c9d-4f54-add2-9f37d4fef041 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151539 biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:90575871-7376-46e1-a5e4-a62cfa90afaf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9cac7f99-93c6-40ff-a711-01e0db78fc4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] COMBIVENT RESPIMAT is a combination of ipratropium bromide (an anticholinergic agent) and albuterol sulfate (a beta 2 -adrenergic agonist) indicated for use in patients with chronic obstructive pulmonary disease (COPD) on a regular aerosol bronchodilator who continue to have evidence of bronchospasm and who require a second bronchodilator. uuid:e183d1b8-5f37-4906-87d2-bd3481a126e2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:136040 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:8b36a1a3-c7ba-4e46-b593-46752d3194c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:11133d71-ba90-434f-a9df-91f45aa40efb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FETZIMA ® is indicated for the treatment of major depressive disorder (MDD) in adults [see Clinical Studies ( 14 )]. Limitation of Use: FETZIMA is not approved for the management of fibromyalgia. The efficacy and safety of FETZIMA for the management of fibromyalgia have not been established. uuid:e4d7f771-3b1b-46e2-b477-bb9524e2076c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:136040 biolink:treats MONDO:0005546 PMID:41385096 "[{""id"":""uuid:27a989ed-9cea-4d07-adbd-fd675386ae74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d220c783-912d-40ab-8a7b-a2b2bce3e20f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FETZIMA ® is indicated for the treatment of major depressive disorder (MDD) in adults [see Clinical Studies ( 14 )]. Limitation of Use: FETZIMA is not approved for the management of fibromyalgia. The efficacy and safety of FETZIMA for the management of fibromyalgia have not been established. uuid:1c474e91-1db7-4cc2-b9be-b57a0eaa97c3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7496 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:a1b61506-667d-4e89-ae15-0884a9587258"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9e73b099-a6c8-46c3-af61-a6b6b290f044"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VIRACEPT in combination with other antiretroviral agents is indicated for the treatment of HIV-1 infection. uuid:0a446730-3024-49b2-b6c0-0d9f99e01e15 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5864 biolink:treats MONDO:0003120 PMID:41385096 "[{""id"":""uuid:35b3c354-55a7-4649-a5f6-b56059e0227f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4a0ee390-b6b7-45fb-85cf-ef2c47ee6efe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ifosfamide Injection is indicated for use in combination with certain other approved antineoplastic agentsfor third-line chemotherapy of germ cell testicular cancer. It should be used in combination with mesna for prophylaxis of hemorrhagic cystitis. uuid:4b154226-b3a0-479d-934e-ac34b778762d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5864 biolink:treats MONDO:0000496 PMID:41385096 "[{""id"":""uuid:77f7590d-098d-4362-bc02-36ec41bb9186"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0f2083cc-e868-4288-98a8-2f25d40ce534"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ifosfamide Injection is indicated for use in combination with certain other approved antineoplastic agentsfor third-line chemotherapy of germ cell testicular cancer. It should be used in combination with mesna for prophylaxis of hemorrhagic cystitis. uuid:ac041d0d-6a0d-42d7-9a3d-be9be73ec93f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17549 biolink:treats MONDO:0021042 PMID:41385096 "[{""id"":""uuid:a9ac26c0-d1ba-41e2-93fa-fe4ae8d4cdad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:83f797f5-2cec-4465-8d3f-06312c054d8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gleolan is indicated in patients with glioma [suspected World Health Organization (WHO) Grades III or IV on preoperative imaging] as an adjunct for the visualization of malignant tissue during surgery. uuid:4d9796a6-3d95-47d5-8d8c-cb64aed60dab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB09100 biolink:treats MONDO:0006982 PMID:41385096 "[{""id"":""uuid:1eaa4c01-0009-4bf3-9682-f321c47a1641"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6ef6f2a0-00c8-4f84-b055-fe875cd6f43a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Armour Thyroid (thyroid tablets, USP) are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS ). 2. As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto’s), multinodular goiter, and in the management of thyroid cancer. uuid:62ddb6b5-3c37-4196-98a2-4b52f2f59c32 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:NQX9KB6PCL biolink:treats MONDO:0008250 PMID:41385096 "[{""id"":""uuid:a27557bf-2203-44b8-ad6d-790120b45569"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:1871fad4-d7bc-4263-b05a-6d85320dffc9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2d569c65-a230-48fc-bb2a-136575dda87e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/omnitrope""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZOMACTON is a recombinant human growth hormone indicated for: Pediatric: Treatment of pediatric patients with growth failure due to inadequate secretion of endogenous growth hormone (GH), short stature associated with Turner syndrome, idiopathic short stature (ISS), short stature or growth failure in short stature homeobox-containing gene (SHOX) deficiency, and short stature born small for gestational age (SGA) with no catch-up growth by 2 years to 4 years. ( 1.1 ) Adult: Replacement of endogenous GH in adults with GH deficiency ( 1.2 )|[EMA] Infants, children and adolescentsGrowth disturbance due to insufficient secretion of growth hormone (GH).Growth disturbance associated with Turner syndrome.Growth disturbance associated with chronic renal insufficiency.Growth disturbance (current height standard-deviation score (SDS) < -2.5 and parental adjusted SDS < -1) in short children / adolescents born small for gestational age (SGA), with a birth weight and / or length below -2 standard deviations (SDs), who failed to show catch-up growth (height velocity (HV) SDS < 0 during the last year) by four years of age or later.Prader-Willi syndrome (PWS), for improvement of growth and body composition. The diagnosis of PWS should be confirmed by appropriate genetic testing.AdultsReplacement therapy in adults with pronounced growth hormone deficiency. Patients with severe growth hormone deficiency in adulthood are defined as patients with known hypothalamic pituitary pathology and at least one known deficiency of a pituitary hormone not being prolactin. These patients should undergo a single dynamic test in order to diagnose or exclude a growth hormone deficiency. In patients with childhood-onset isolated GH deficiency (no evidence of hypothalamic-pituitary disease or cranial irradiation), two dynamic tests should be recommended, except for those having low insulin-like-growth-factor-I (IGF-I) concentrations (SDS < -2) who may be considered for one test. The cut-off point of the dynamic test should be strict. uuid:ce5fe763-8f3f-483f-88af-13353641821b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:NQX9KB6PCL biolink:treats UMLS:C1740819 PMID:41385096 "[{""id"":""uuid:0fe6e76c-dfe6-4677-bd46-89c0c4c6f8c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b8a5987c-8383-4a80-844e-7c35eadf2e30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZOMACTON is a recombinant human growth hormone indicated for: Pediatric: Treatment of pediatric patients with growth failure due to inadequate secretion of endogenous growth hormone (GH), short stature associated with Turner syndrome, idiopathic short stature (ISS), short stature or growth failure in short stature homeobox-containing gene (SHOX) deficiency, and short stature born small for gestational age (SGA) with no catch-up growth by 2 years to 4 years. ( 1.1 ) Adult: Replacement of endogenous GH in adults with GH deficiency ( 1.2 ) uuid:7a9088f6-c6d6-4a68-a894-732dc6ff2129 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:NQX9KB6PCL biolink:treats MONDO:0010367 PMID:41385096 "[{""id"":""uuid:3354b3d9-2762-4806-9366-a737a6c75f9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9ea896e8-82f7-40ac-825e-f3037e53694a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a5f9ba6f-d7ff-4bbc-a682-88b918359d80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/omnitrope""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZOMACTON is a recombinant human growth hormone indicated for: Pediatric: Treatment of pediatric patients with growth failure due to inadequate secretion of endogenous growth hormone (GH), short stature associated with Turner syndrome, idiopathic short stature (ISS), short stature or growth failure in short stature homeobox-containing gene (SHOX) deficiency, and short stature born small for gestational age (SGA) with no catch-up growth by 2 years to 4 years. ( 1.1 ) Adult: Replacement of endogenous GH in adults with GH deficiency ( 1.2 )|[EMA] Infants, children and adolescentsGrowth disturbance due to insufficient secretion of growth hormone (GH).Growth disturbance associated with Turner syndrome.Growth disturbance associated with chronic renal insufficiency.Growth disturbance (current height standard-deviation score (SDS) < -2.5 and parental adjusted SDS < -1) in short children / adolescents born small for gestational age (SGA), with a birth weight and / or length below -2 standard deviations (SDs), who failed to show catch-up growth (height velocity (HV) SDS < 0 during the last year) by four years of age or later.Prader-Willi syndrome (PWS), for improvement of growth and body composition. The diagnosis of PWS should be confirmed by appropriate genetic testing.AdultsReplacement therapy in adults with pronounced growth hormone deficiency. Patients with severe growth hormone deficiency in adulthood are defined as patients with known hypothalamic pituitary pathology and at least one known deficiency of a pituitary hormone not being prolactin. These patients should undergo a single dynamic test in order to diagnose or exclude a growth hormone deficiency. In patients with childhood-onset isolated GH deficiency (no evidence of hypothalamic-pituitary disease or cranial irradiation), two dynamic tests should be recommended, except for those having low insulin-like-growth-factor-I (IGF-I) concentrations (SDS < -2) who may be considered for one test. The cut-off point of the dynamic test should be strict. uuid:47e13ae1-7c23-4206-b460-62222e748d5f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:38940 biolink:treats MONDO:0005086 PMID:41385096 "[{""id"":""uuid:128c9baf-20fd-4065-8b4e-b3adc935e7eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a1d450b7-a7ae-474a-abd2-822c7e99320c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2956959c-0e0b-411d-b779-424af471a5eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/sunitinib-accord""]},{""id"":""uuid:adb6d23b-6555-435f-8935-b61041ab9f61"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sunitinib malate capsules are a kinase inhibitor indicated for: • treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. ( 1.1 ) • treatment of adult patients with advanced renal cell carcinoma (RCC). ( 1.2 ) • adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy. ( 1.3 ) • treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic disease. ( 1.4 )|[EMA] Gastrointestinal stromal tumour (GIST)Sunitinib Accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST) in adults after failure of imatinib treatment due to resistance or intolerance.Metastatic renal cell carcinoma (MRCC)Sunitinib Accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (MRCC) in adults.Pancreatic neuroendocrine tumours (pNET)Sunitinib Accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pNET) with disease progression in adults.|[PMDA] A drug containing a new active ingredient indicated for the treatment of imatinib-resistant gastrointestinal stromal tumors, and unresectable or metastatic renal cell carcinomas. [Priority review] uuid:eb581b81-e3ac-4c69-8185-ba255435cc71 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:38940 biolink:treats MONDO:0005815 PMID:41385096 "[{""id"":""uuid:a580fdce-8251-4b87-863a-2216c38838ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e965e201-0c85-47a7-b468-e75932b305e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e5a2ee8b-c664-44bd-acff-e44986020d88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/sunitinib-accord""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sunitinib malate capsules are a kinase inhibitor indicated for: • treatment of adult patients with gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate. ( 1.1 ) • treatment of adult patients with advanced renal cell carcinoma (RCC). ( 1.2 ) • adjuvant treatment of adult patients at high risk of recurrent RCC following nephrectomy. ( 1.3 ) • treatment of progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in adult patients with unresectable locally advanced or metastatic disease. ( 1.4 )|[EMA] Gastrointestinal stromal tumour (GIST)Sunitinib Accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST) in adults after failure of imatinib treatment due to resistance or intolerance.Metastatic renal cell carcinoma (MRCC)Sunitinib Accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (MRCC) in adults.Pancreatic neuroendocrine tumours (pNET)Sunitinib Accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pNET) with disease progression in adults. uuid:1fb3e0df-70ad-47fe-9cb9-87fc044d4b5b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31530 biolink:treats MONDO:0004976 PMID:41385096 "[{""id"":""uuid:22033dbe-734e-41ab-8192-c5f4a41dc839"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8a657543-132a-4ef1-aa72-ee9f2e8d50b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:28c2cb58-f345-4762-ad67-7766906b2703"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Edaravone injection is indicated for the treatment of amyotrophic lateral sclerosis (ALS).|[PMDA] A drug with a new route of administration indicated for delaying the functional disorder in patients with amyotrophic lateral sclerosis (ALS). uuid:2ac1d8ac-be03-417f-b48c-556f7fe2b36f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31530 biolink:treats MONDO:0008781 PMID:41385096 "[{""id"":""uuid:fe9573fd-05a7-472d-a905-f7132d805d25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b753dfae-81c3-44b6-946c-914a7c895240"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Edaravone injection is indicated for the treatment of amyotrophic lateral sclerosis (ALS). uuid:b551b074-50c9-42ed-a87e-13d8627d555c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4FI88BTT8M biolink:treats MONDO:0009348 PMID:41385096 "[{""id"":""uuid:398fd84d-bc10-4110-b0c2-83f6289c0469"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ff5ded53-3ff0-4c96-9463-0df99442bac7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gallium Citrate Ga 67 Injection may be useful to demonstrate the presence and extent of Hodgkin's disease, lymphoma, and bronchogenic carcinoma. Positive gallium Ga-67 uptake in the absence of prior symptoms warrants follow-up as an indication of a potential disease state. Gallium Citrate Ga 67 Injection may be useful as an aid in detecting some acute inflammatory lesions. uuid:c0ed0d71-6003-4bf9-886d-e359931fc034 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4FI88BTT8M biolink:treats MONDO:0005062 PMID:41385096 "[{""id"":""uuid:d200cc17-f568-43b2-8539-a00b96f05e0c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:30f6d987-babc-4841-ab32-b75ede5c549c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gallium Citrate Ga 67 Injection may be useful to demonstrate the presence and extent of Hodgkin's disease, lymphoma, and bronchogenic carcinoma. Positive gallium Ga-67 uptake in the absence of prior symptoms warrants follow-up as an indication of a potential disease state. Gallium Citrate Ga 67 Injection may be useful as an aid in detecting some acute inflammatory lesions. uuid:84295e82-0c31-4a1b-84f6-5a364e892d3e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4FI88BTT8M biolink:treats MONDO:0002806 PMID:41385096 "[{""id"":""uuid:8a96bbfe-67db-42f6-b975-0d0dda31feb3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d3f5b9bb-28db-43af-b2b7-5fb858ba00aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gallium Citrate Ga 67 Injection may be useful to demonstrate the presence and extent of Hodgkin's disease, lymphoma, and bronchogenic carcinoma. Positive gallium Ga-67 uptake in the absence of prior symptoms warrants follow-up as an indication of a potential disease state. Gallium Citrate Ga 67 Injection may be useful as an aid in detecting some acute inflammatory lesions. uuid:f2c97138-821f-4d06-b9ca-438777f39180 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:26710 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:b76881a1-385a-4464-ab80-640a8d3e79e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cd715331-f64c-4f6a-afe6-ceeeebd4fe3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] These intravenous solutions are indicated for use in adults and pediatric patients as sources of electrolytes and water for hydration. 3% and 5% Sodium Chloride Injections USP are of particular value in severe salt depletion when rapid electrolyte restoration is of paramount importance. The low salt syndrome may occur in the presence of heart failure, renal impairment, during surgery, and postoperatively. In these conditions, chloride loss frequently exceeds sodium loss. These hypertonic sodium chloride solutions are also indicated for the following clinical conditions. Hyponatremia and hypochloremia due to electrolyte and fluid loss replaced with sodium-free fluids. Drastic dilution of extracellular body fluid following excessive water intake sometimes resulting from multiple enemas or perfusion of irrigating fluids into open venous sinuses during transurethral prostatic resections. Emergency treatment of severe salt depletion due to excess sweating, vomiting, diarrhea and other conditions. uuid:05c7e7de-8f70-458b-ad7b-2a5ad930b8d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:26710 biolink:treats MONDO:0001343 PMID:41385096 "[{""id"":""uuid:0849ae23-c8a3-41c8-a9d1-a145efdf03eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b13485ea-b6b9-413c-98d0-3a20c290734b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] These intravenous solutions are indicated for use in adults and pediatric patients as sources of electrolytes and water for hydration. 3% and 5% Sodium Chloride Injections USP are of particular value in severe salt depletion when rapid electrolyte restoration is of paramount importance. The low salt syndrome may occur in the presence of heart failure, renal impairment, during surgery, and postoperatively. In these conditions, chloride loss frequently exceeds sodium loss. These hypertonic sodium chloride solutions are also indicated for the following clinical conditions. Hyponatremia and hypochloremia due to electrolyte and fluid loss replaced with sodium-free fluids. Drastic dilution of extracellular body fluid following excessive water intake sometimes resulting from multiple enemas or perfusion of irrigating fluids into open venous sinuses during transurethral prostatic resections. Emergency treatment of severe salt depletion due to excess sweating, vomiting, diarrhea and other conditions. uuid:9ef1be1e-3a85-469a-b4d1-70b0c89e115e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:26710 biolink:treats HP:0003113 PMID:41385096 "[{""id"":""uuid:5b56bf01-62c9-42f9-a0e4-cfac6883d7cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:69d765d2-38cf-4215-8fc4-c8b745185818"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] These intravenous solutions are indicated for use in adults and pediatric patients as sources of electrolytes and water for hydration. 3% and 5% Sodium Chloride Injections USP are of particular value in severe salt depletion when rapid electrolyte restoration is of paramount importance. The low salt syndrome may occur in the presence of heart failure, renal impairment, during surgery, and postoperatively. In these conditions, chloride loss frequently exceeds sodium loss. These hypertonic sodium chloride solutions are also indicated for the following clinical conditions. Hyponatremia and hypochloremia due to electrolyte and fluid loss replaced with sodium-free fluids. Drastic dilution of extracellular body fluid following excessive water intake sometimes resulting from multiple enemas or perfusion of irrigating fluids into open venous sinuses during transurethral prostatic resections. Emergency treatment of severe salt depletion due to excess sweating, vomiting, diarrhea and other conditions. uuid:999e9e49-9030-41ab-81e0-b06e83351dab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:78540 biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:da1f362c-346d-41e0-b979-207f78032f1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:130b8812-1a64-4030-bd61-0d307f9018de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:21de8207-913a-43ef-a795-f63a301e54e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/otezla""]},{""id"":""uuid:aad07ce5-d434-433e-9e84-81c738408813"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OTEZLA, an inhibitor of phosphodiesterase 4 (PDE4), is indicated for the treatment of: Adult patients with active psoriatic arthritis ( 1.1 ) Adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy ( 1.2 ) Pediatric patients 6 years of age and older and weighing at least 20 kg with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy ( 1.2 ) Adult patients with oral ulcers associated with Behçet's Disease ( 1.3 )|[EMA] Psoriatic arthritisOtezla, alone or in combination with Disease Modifying Antirheumatic Drugs (DMARDs), is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy.PsoriasisOtezla is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen and ultraviolet-A light (PUVA).|[PMDA] Drugs with a new active ingredient indicated for the treatment of plaque psoriasis in patients who have not responded sufficiently to topical therapy or psoriatic arthritis. uuid:85b12c0f-5393-4c6b-b336-665ec3e93daa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:78540 biolink:treats UMLS:C0406317 PMID:41385096 "[{""id"":""uuid:e85cd40d-2273-48da-9bb8-c57a527c8ede"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c6d9a44e-26d5-4a68-acc9-2452b9f1d622"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b54bc0f0-9f22-4694-a169-769b01ddbc63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OTEZLA, an inhibitor of phosphodiesterase 4 (PDE4), is indicated for the treatment of: Adult patients with active psoriatic arthritis ( 1.1 ) Adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy ( 1.2 ) Pediatric patients 6 years of age and older and weighing at least 20 kg with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy ( 1.2 ) Adult patients with oral ulcers associated with Behçet's Disease ( 1.3 )|[PMDA] Drugs with a new active ingredient indicated for the treatment of plaque psoriasis in patients who have not responded sufficiently to topical therapy or psoriatic arthritis. uuid:0a1c3c56-137f-4433-be2e-40e0b6636c3f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:78540 biolink:treats MONDO:0007191 PMID:41385096 "[{""id"":""uuid:4540e376-6705-4963-b4eb-5f29073a49e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5dd9d7f9-ea85-4ce4-ba90-454b9ff0a4e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:acb4945f-3d5c-4b21-a9aa-02fe005c9251"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OTEZLA, an inhibitor of phosphodiesterase 4 (PDE4), is indicated for the treatment of: Adult patients with active psoriatic arthritis ( 1.1 ) Adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy ( 1.2 ) Pediatric patients 6 years of age and older and weighing at least 20 kg with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy ( 1.2 ) Adult patients with oral ulcers associated with Behçet's Disease ( 1.3 )|[PMDA] Drugs with a new indication for the treatment of oral ulcer associated with Behcet’s disease in patients who have not responded sufficiently to local treatment. uuid:848224a5-cd88-4ee0-8bf0-d95ad6a2dc93 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64355 biolink:treats MONDO:0020546 PMID:41385096 "[{""id"":""uuid:7a2cc9c5-26f6-493e-a707-e7917776eccd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c1174d3a-0336-4874-af92-6d161c82e136"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Posaconazole delayed-release tablets is an azole antifungal agent indicated for: prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as HSCT recipients with GVHD or those with hematologic malignancies with prolonged neutropenia from chemotherapy. (1.1) uuid:7e4692a4-b83c-4917-a087-d39ce0b1798b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:ROV204583W biolink:treats MONDO:0002520 PMID:41385096 "[{""id"":""uuid:8cf1f876-69ca-4f45-b020-cafded1962fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:458bd89f-4c27-4281-9d1d-e5bde4b3647b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:fca18ca5-208e-480f-9bd0-36d3b03ed126"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/givlaari""]},{""id"":""uuid:e43ac06d-e53b-45c3-81c8-6e9396eb0ba3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] GIVLAARI is indicated for the treatment of adults with acute hepatic porphyria (AHP).|[EMA] Treatment of acute hepatic porphyria (AHP) in adults and adolescents aged 12 years and older.|[PMDA] A drug with a new active ingredient indicated for the treatment of acute hepatic porphyria. [Orphan drug] uuid:45cb151f-68f9-4a0d-a35d-092211339963 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:ROV204583W biolink:treats MONDO:0013564 PMID:41385096 "[{""id"":""uuid:6a9c3089-95ea-4d8e-ba08-671c5abd508a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f40d6839-dd10-4ab8-83d6-16a8314141fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] GIVLAARI is indicated for the treatment of adults with acute hepatic porphyria (AHP). uuid:9dfb4d13-4a82-447a-bf44-228a4ae305d8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:GNWE7KJ995 biolink:treats MONDO:0018922 PMID:41385096 "[{""id"":""uuid:bd22e301-de0d-4f6b-a988-689abcaa6f4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6cb7e590-f706-4e36-bbd5-f551e059f27c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:db5e633d-4ff0-4492-b15e-18d84d9c0f35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/enjaymo""]},{""id"":""uuid:66d58917-5a50-45d9-9ca5-865f4e63b2d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENJAYMO is a classical complement inhibitor indicated for the treatment of hemolysis in adults with cold agglutinin disease (CAD). ( 1 )|[EMA] Enjaymo is indicated for the treatment of haemolytic anaemia in adult patients with cold agglutinin disease (CAD).|[PMDA] A drug with a new active ingredient indicated for the treatment of cold agglutinin disease. [Orphan drug] uuid:a8f66f66-d2df-4758-a49b-294127a9f9b2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:GNWE7KJ995 biolink:treats UMLS:C0019054 PMID:41385096 "[{""id"":""uuid:0822dcef-e890-4aae-8890-c2c4c120c5f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d4e4a3f5-8705-4845-b3c1-e7ac47ae7886"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENJAYMO is a classical complement inhibitor indicated for the treatment of hemolysis in adults with cold agglutinin disease (CAD). ( 1 ) uuid:2b8c9727-4a75-4799-a16f-6fd12e732a0d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63633 biolink:treats MONDO:0019165 PMID:41385096 "[{""id"":""uuid:024c970d-944c-4cb8-b7b3-c2e5a59714da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:660e2de3-3a6d-4c8a-a886-604f3ad04b2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRIPTODUR is indicated for the treatment of pediatric patients 2 years of age and older with central precocious puberty (CPP). uuid:e4630edd-428f-4cef-841b-58676028b1b2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18145 biolink:treats MONDO:0005276 PMID:41385096 "[{""id"":""uuid:d601c03d-02b6-4b7c-b079-dd1b9fbdb622"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5798ae32-ac01-471b-b829-2cf80c3c08ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Supplementation of the diet with ten essential vitamins. Supplementation of the diet with fluoride for caries prophylaxis. Multivitamin with Fluoride 1.0 mg Chewable Tablets provide 1.0 mg fluoride in tablet form for children 6-16 years of age in areas where the water fluoride level is less than 0.3 ppm. Multivitamin with Fluoride 1.0 mg Chewable Tablets supply significant amounts of Vitamins A, C, D, E, thiamine, riboflavin, niacin, vitamin B6, vitamin B12, and folate to supplement the diet, and to help assure that nutritional deficiencies of these vitamins will not develop. Thus, in a single easy-to-use preparation, children obtain ten essential vitamins and the important mineral, fluoride. The American Academy of Pediatrics recommends that children up to age 16, in areas where drinking water contains less than optimal levels of fluoride, receive daily fluoride supplements. Children using Multivitamin with Fluoride 1.0 mg Chewable Tablets regularly should receive semiannual dental examinations. The regular brushing of teeth and attention to good oral hygiene practices are also essential. Multivitamin with Fluoride Chewable Tablets is a prescription product for the clinical dietary management of the metabolic processes of caries prophylaxis and provides supplementation of the diet with ten essential vitamins. uuid:d3c9141f-c3bd-4a57-9ecf-d92d956434ab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17051 biolink:treats MONDO:0007016 PMID:41385096 "[{""id"":""uuid:75b7059b-be7e-4c63-bb1d-6b16f309a05e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5761f9f1-a328-4958-a7ef-89f3a6e05a1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Supplementation of the diet with vitamins A, C and D. Tri-Vite Drops with Fluoride 0.5 mg also provides fluoride for caries prophylaxis. The American Academy of Pediatrics recommend that infants and young children 6 months to 3 years of age, in areas where the drinking water contains less than 0.3 ppm of fluoride, and children 3-6 years of age, in areas where the drinking water contains 0.3 through 0.6 ppm of fluoride, receive 0.5 mg of supplemental fluoride daily which is provided in a dose of 1 mL of Tri-Vite Drops with Fluoride 0.5 mg (See Dosage and Administration ). Tri-Vite Drops with Fluoride 0.5 mg supply significant amounts of vitamins A, C and D to supplement the diet, and to help assure that nutritional deficiencies of these vitamins will not develop. Thus, in a single easy-to-use preparation, children obtain essential vitamins and fluoride. uuid:d8c3cb45-6264-42c1-a89f-a7e574896da2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17051 biolink:treats MONDO:0009412 PMID:41385096 "[{""id"":""uuid:3fa7c68f-7eee-415e-85ab-075abbb6da0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aacf7af5-2210-40ad-97e1-0d0d6ca2f1eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Supplementation of the diet with vitamins A, C and D. Tri-Vite Drops with Fluoride 0.5 mg also provides fluoride for caries prophylaxis. The American Academy of Pediatrics recommend that infants and young children 6 months to 3 years of age, in areas where the drinking water contains less than 0.3 ppm of fluoride, and children 3-6 years of age, in areas where the drinking water contains 0.3 through 0.6 ppm of fluoride, receive 0.5 mg of supplemental fluoride daily which is provided in a dose of 1 mL of Tri-Vite Drops with Fluoride 0.5 mg (See Dosage and Administration ). Tri-Vite Drops with Fluoride 0.5 mg supply significant amounts of vitamins A, C and D to supplement the diet, and to help assure that nutritional deficiencies of these vitamins will not develop. Thus, in a single easy-to-use preparation, children obtain essential vitamins and fluoride. uuid:6ddc89b9-cef2-490f-b223-7323f4706b3b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17051 biolink:treats MONDO:0100471 PMID:41385096 "[{""id"":""uuid:0d831331-db98-4192-9583-4c08fdbc3e44"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:66713d53-f8f8-4dfe-b7a4-2b45cd1f0c14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Supplementation of the diet with vitamins A, C and D. Tri-Vite Drops with Fluoride 0.5 mg also provides fluoride for caries prophylaxis. The American Academy of Pediatrics recommend that infants and young children 6 months to 3 years of age, in areas where the drinking water contains less than 0.3 ppm of fluoride, and children 3-6 years of age, in areas where the drinking water contains 0.3 through 0.6 ppm of fluoride, receive 0.5 mg of supplemental fluoride daily which is provided in a dose of 1 mL of Tri-Vite Drops with Fluoride 0.5 mg (See Dosage and Administration ). Tri-Vite Drops with Fluoride 0.5 mg supply significant amounts of vitamins A, C and D to supplement the diet, and to help assure that nutritional deficiencies of these vitamins will not develop. Thus, in a single easy-to-use preparation, children obtain essential vitamins and fluoride. uuid:1f517609-e58b-476b-8c7b-ee36863622dc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17996 biolink:treats MONDO:0015129 PMID:41385096 "[{""id"":""uuid:326f478d-ed3e-4fdc-8b28-56a67e3390f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c486c05a-52db-4b10-8bb1-39b0758eafac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Chloride Injection, USP, 23.4%, is indicated as an additive in parenteral fluid therapy for use in patients who have special problems of sodium electrolyte intake or excretion. It is intended to meet the specific requirements of the patient with unusual fluid and electrolyte needs. After available clinical and laboratory information is considered and correlated, the appropriate number of milliequivalents of sodium chloride required can be withdrawn from Sodium Chloride Injection, USP, 23.4% and diluted for use. Sodium Chloride Injection is indicated for the treatment of sodium, chloride and water deficiencies that commonly occur in many diseases. Isotonic Sodium Chloride Injection should be limited to cases in which the chloride loss is greater than the sodium loss, as in vomiting from pyloric obstruction, or in which the loss is about equal, as in vomiting from duodenal, jejunal or ileal obstruction and in the replacement of aspirated gastrointestinal fluids. The toxic symptoms that follow various forms of intestinal obstruction are accompanied by a marked reduction of blood chloride and often sodium chloride has a lifesaving effect. Symptoms of sodium chloride deficiency are very similar to those of Addison’s disease and large doses of sodium chloride will produce temporary alleviation of the symptoms. Other disorders in which sodium chloride is therapeutically useful include extensive burns, failure of gastric secretion and postoperative intestinal paralysis. uuid:7a3e308d-9e4f-47e1-923c-98c2569d53e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17996 biolink:treats UMLS:C0856633 PMID:41385096 "[{""id"":""uuid:fb8295af-68ef-4a7b-a7d6-20566179e4ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e7b5a639-e29b-4d73-968d-ec6de93f09be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Chloride Injection, USP, 23.4%, is indicated as an additive in parenteral fluid therapy for use in patients who have special problems of sodium electrolyte intake or excretion. It is intended to meet the specific requirements of the patient with unusual fluid and electrolyte needs. After available clinical and laboratory information is considered and correlated, the appropriate number of milliequivalents of sodium chloride required can be withdrawn from Sodium Chloride Injection, USP, 23.4% and diluted for use. Sodium Chloride Injection is indicated for the treatment of sodium, chloride and water deficiencies that commonly occur in many diseases. Isotonic Sodium Chloride Injection should be limited to cases in which the chloride loss is greater than the sodium loss, as in vomiting from pyloric obstruction, or in which the loss is about equal, as in vomiting from duodenal, jejunal or ileal obstruction and in the replacement of aspirated gastrointestinal fluids. The toxic symptoms that follow various forms of intestinal obstruction are accompanied by a marked reduction of blood chloride and often sodium chloride has a lifesaving effect. Symptoms of sodium chloride deficiency are very similar to those of Addison’s disease and large doses of sodium chloride will produce temporary alleviation of the symptoms. Other disorders in which sodium chloride is therapeutically useful include extensive burns, failure of gastric secretion and postoperative intestinal paralysis. uuid:40756435-f6ba-4f65-aa23-875f4af2eb78 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17996 biolink:treats MONDO:0004565 PMID:41385096 "[{""id"":""uuid:f78cfb05-03ae-48fc-b133-a0c0ee49a532"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:56a57283-b1a6-4317-a445-4cfe14192315"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Chloride Injection, USP, 23.4%, is indicated as an additive in parenteral fluid therapy for use in patients who have special problems of sodium electrolyte intake or excretion. It is intended to meet the specific requirements of the patient with unusual fluid and electrolyte needs. After available clinical and laboratory information is considered and correlated, the appropriate number of milliequivalents of sodium chloride required can be withdrawn from Sodium Chloride Injection, USP, 23.4% and diluted for use. Sodium Chloride Injection is indicated for the treatment of sodium, chloride and water deficiencies that commonly occur in many diseases. Isotonic Sodium Chloride Injection should be limited to cases in which the chloride loss is greater than the sodium loss, as in vomiting from pyloric obstruction, or in which the loss is about equal, as in vomiting from duodenal, jejunal or ileal obstruction and in the replacement of aspirated gastrointestinal fluids. The toxic symptoms that follow various forms of intestinal obstruction are accompanied by a marked reduction of blood chloride and often sodium chloride has a lifesaving effect. Symptoms of sodium chloride deficiency are very similar to those of Addison’s disease and large doses of sodium chloride will produce temporary alleviation of the symptoms. Other disorders in which sodium chloride is therapeutically useful include extensive burns, failure of gastric secretion and postoperative intestinal paralysis. uuid:50512cab-169a-4d7c-8c2a-079bd0240a0c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17996 biolink:treats MONDO:0004568 PMID:41385096 "[{""id"":""uuid:a7d951b5-c067-4bb3-857e-a11a4da6e68c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:605516f4-0ff7-45f5-a016-02dab7bdea90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Chloride Injection, USP, 23.4%, is indicated as an additive in parenteral fluid therapy for use in patients who have special problems of sodium electrolyte intake or excretion. It is intended to meet the specific requirements of the patient with unusual fluid and electrolyte needs. After available clinical and laboratory information is considered and correlated, the appropriate number of milliequivalents of sodium chloride required can be withdrawn from Sodium Chloride Injection, USP, 23.4% and diluted for use. Sodium Chloride Injection is indicated for the treatment of sodium, chloride and water deficiencies that commonly occur in many diseases. Isotonic Sodium Chloride Injection should be limited to cases in which the chloride loss is greater than the sodium loss, as in vomiting from pyloric obstruction, or in which the loss is about equal, as in vomiting from duodenal, jejunal or ileal obstruction and in the replacement of aspirated gastrointestinal fluids. The toxic symptoms that follow various forms of intestinal obstruction are accompanied by a marked reduction of blood chloride and often sodium chloride has a lifesaving effect. Symptoms of sodium chloride deficiency are very similar to those of Addison’s disease and large doses of sodium chloride will produce temporary alleviation of the symptoms. Other disorders in which sodium chloride is therapeutically useful include extensive burns, failure of gastric secretion and postoperative intestinal paralysis. uuid:00a82048-f897-48b9-bd85-cfae4eb9abce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17996 biolink:treats UMLS:C1971019 PMID:41385096 "[{""id"":""uuid:8a1604a5-37ba-4204-a0df-84610b0d2438"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c184457b-b66c-4c36-a27f-4131dcbe4e7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Chloride Injection, USP, 23.4%, is indicated as an additive in parenteral fluid therapy for use in patients who have special problems of sodium electrolyte intake or excretion. It is intended to meet the specific requirements of the patient with unusual fluid and electrolyte needs. After available clinical and laboratory information is considered and correlated, the appropriate number of milliequivalents of sodium chloride required can be withdrawn from Sodium Chloride Injection, USP, 23.4% and diluted for use. Sodium Chloride Injection is indicated for the treatment of sodium, chloride and water deficiencies that commonly occur in many diseases. Isotonic Sodium Chloride Injection should be limited to cases in which the chloride loss is greater than the sodium loss, as in vomiting from pyloric obstruction, or in which the loss is about equal, as in vomiting from duodenal, jejunal or ileal obstruction and in the replacement of aspirated gastrointestinal fluids. The toxic symptoms that follow various forms of intestinal obstruction are accompanied by a marked reduction of blood chloride and often sodium chloride has a lifesaving effect. Symptoms of sodium chloride deficiency are very similar to those of Addison’s disease and large doses of sodium chloride will produce temporary alleviation of the symptoms. Other disorders in which sodium chloride is therapeutically useful include extensive burns, failure of gastric secretion and postoperative intestinal paralysis. uuid:251152f9-2d2b-4e90-a056-7a4ea8029626 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17996 biolink:treats UMLS:C0342921 PMID:41385096 "[{""id"":""uuid:3db16998-1ccf-4b9d-a6e1-978f3d9d4b23"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a6110967-d427-463d-976d-39cb2869324b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Chloride Injection, USP, 23.4%, is indicated as an additive in parenteral fluid therapy for use in patients who have special problems of sodium electrolyte intake or excretion. It is intended to meet the specific requirements of the patient with unusual fluid and electrolyte needs. After available clinical and laboratory information is considered and correlated, the appropriate number of milliequivalents of sodium chloride required can be withdrawn from Sodium Chloride Injection, USP, 23.4% and diluted for use. Sodium Chloride Injection is indicated for the treatment of sodium, chloride and water deficiencies that commonly occur in many diseases. Isotonic Sodium Chloride Injection should be limited to cases in which the chloride loss is greater than the sodium loss, as in vomiting from pyloric obstruction, or in which the loss is about equal, as in vomiting from duodenal, jejunal or ileal obstruction and in the replacement of aspirated gastrointestinal fluids. The toxic symptoms that follow various forms of intestinal obstruction are accompanied by a marked reduction of blood chloride and often sodium chloride has a lifesaving effect. Symptoms of sodium chloride deficiency are very similar to those of Addison’s disease and large doses of sodium chloride will produce temporary alleviation of the symptoms. Other disorders in which sodium chloride is therapeutically useful include extensive burns, failure of gastric secretion and postoperative intestinal paralysis. uuid:c1aeaa54-2991-49e5-85b9-555a71633b17 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2591804 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:5f62810d-8cbf-454a-9780-37c77979c57e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:06933ccd-658a-4920-92ae-89646d8d681b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RYALTRIS is indicated for the treatment of symptoms of seasonal allergic rhinitis in adult and pediatric patients 12 years of age and older. uuid:8f0f1252-84dd-45a7-af10-ed8935848741 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18145 biolink:treats MONDO:0007016 PMID:41385096 "[{""id"":""uuid:1644905b-48f6-4477-b6c1-e5947a1c629a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f3b56754-af4c-4eb5-8adc-048d43dfbec7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Supplementation of the diet with ten essential vitamins. Supplementation of the diet with fluoride for caries prophylaxis. M ultivitamin with Fluoride 0.5 mg Chewable Tablets provide 0.5 mg fluoride in tablet form for children 4-6 years of age in areas where the drinking water fluoride level is less than 0.3 ppm, and for children 6 years of age and above where the drinking water contains 0.3 through 0.6 ppm of fluoride. Multivitamin with Fluoride 0.5 mg Chewable Tablets supply significant amounts of Vitamins A, C, D, E, thiamine, riboflavin, niacin, vitamin B6, vitamin B12, and folate to supplement the diet, and to help assure that nutritional deficiencies of these vitamins will not develop. Thus, in a single easy-to-use preparation, children obtain ten essential vitamins and the important mineral, fluoride. The American Academy of Pediatrics recommends that children up to age 16, in areas where drinking water contains less than optimal levels of fluoride, receive daily fluoride supplements. Children using Multivitamin with Fluoride 0 . 5 mg Chewable Tablets regularly should receive semiannual dental examinations. The regular brushing of teeth and attention to good oral hygiene practices are also essential. Multivitamin with Fluoride Chewable Tablets is a prescription product for the clinical dietary management of the metabolic processes of caries prophylaxis and provides supplementation of the diet with ten essential vitamins. uuid:c2c40ada-1981-411b-94eb-cf478485d111 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18145 biolink:treats MONDO:0009412 PMID:41385096 "[{""id"":""uuid:794e1bb2-13ee-4d95-99a5-a3dfcbd0d6d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:80d7d3ae-53a7-4b8b-a49e-45aafc0afaf9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Supplementation of the diet with ten essential vitamins. Supplementation of the diet with fluoride for caries prophylaxis. M ultivitamin with Fluoride 0.5 mg Chewable Tablets provide 0.5 mg fluoride in tablet form for children 4-6 years of age in areas where the drinking water fluoride level is less than 0.3 ppm, and for children 6 years of age and above where the drinking water contains 0.3 through 0.6 ppm of fluoride. Multivitamin with Fluoride 0.5 mg Chewable Tablets supply significant amounts of Vitamins A, C, D, E, thiamine, riboflavin, niacin, vitamin B6, vitamin B12, and folate to supplement the diet, and to help assure that nutritional deficiencies of these vitamins will not develop. Thus, in a single easy-to-use preparation, children obtain ten essential vitamins and the important mineral, fluoride. The American Academy of Pediatrics recommends that children up to age 16, in areas where drinking water contains less than optimal levels of fluoride, receive daily fluoride supplements. Children using Multivitamin with Fluoride 0 . 5 mg Chewable Tablets regularly should receive semiannual dental examinations. The regular brushing of teeth and attention to good oral hygiene practices are also essential. Multivitamin with Fluoride Chewable Tablets is a prescription product for the clinical dietary management of the metabolic processes of caries prophylaxis and provides supplementation of the diet with ten essential vitamins. uuid:6c5248c2-a0f6-4782-8309-89a69c848c13 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18145 biolink:treats MONDO:0100471 PMID:41385096 "[{""id"":""uuid:99a1a5a6-8785-4dbb-b0e2-a3a29a1d44d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e321cad5-cfa3-4050-aba2-40a0758cd71b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Supplementation of the diet with ten essential vitamins. Supplementation of the diet with fluoride for caries prophylaxis. M ultivitamin with Fluoride 0.5 mg Chewable Tablets provide 0.5 mg fluoride in tablet form for children 4-6 years of age in areas where the drinking water fluoride level is less than 0.3 ppm, and for children 6 years of age and above where the drinking water contains 0.3 through 0.6 ppm of fluoride. Multivitamin with Fluoride 0.5 mg Chewable Tablets supply significant amounts of Vitamins A, C, D, E, thiamine, riboflavin, niacin, vitamin B6, vitamin B12, and folate to supplement the diet, and to help assure that nutritional deficiencies of these vitamins will not develop. Thus, in a single easy-to-use preparation, children obtain ten essential vitamins and the important mineral, fluoride. The American Academy of Pediatrics recommends that children up to age 16, in areas where drinking water contains less than optimal levels of fluoride, receive daily fluoride supplements. Children using Multivitamin with Fluoride 0 . 5 mg Chewable Tablets regularly should receive semiannual dental examinations. The regular brushing of teeth and attention to good oral hygiene practices are also essential. Multivitamin with Fluoride Chewable Tablets is a prescription product for the clinical dietary management of the metabolic processes of caries prophylaxis and provides supplementation of the diet with ten essential vitamins. uuid:248a59b3-2599-4382-9b83-ec4a7e30c8b5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18145 biolink:treats MONDO:0042976 PMID:41385096 "[{""id"":""uuid:6d36177f-352f-403c-9388-0affa1a47532"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2f0d2b1c-91c7-44b5-ab06-3864467c2190"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Supplementation of the diet with ten essential vitamins. Supplementation of the diet with fluoride for caries prophylaxis. M ultivitamin with Fluoride 0.5 mg Chewable Tablets provide 0.5 mg fluoride in tablet form for children 4-6 years of age in areas where the drinking water fluoride level is less than 0.3 ppm, and for children 6 years of age and above where the drinking water contains 0.3 through 0.6 ppm of fluoride. Multivitamin with Fluoride 0.5 mg Chewable Tablets supply significant amounts of Vitamins A, C, D, E, thiamine, riboflavin, niacin, vitamin B6, vitamin B12, and folate to supplement the diet, and to help assure that nutritional deficiencies of these vitamins will not develop. Thus, in a single easy-to-use preparation, children obtain ten essential vitamins and the important mineral, fluoride. The American Academy of Pediatrics recommends that children up to age 16, in areas where drinking water contains less than optimal levels of fluoride, receive daily fluoride supplements. Children using Multivitamin with Fluoride 0 . 5 mg Chewable Tablets regularly should receive semiannual dental examinations. The regular brushing of teeth and attention to good oral hygiene practices are also essential. Multivitamin with Fluoride Chewable Tablets is a prescription product for the clinical dietary management of the metabolic processes of caries prophylaxis and provides supplementation of the diet with ten essential vitamins. uuid:91b54ffc-647f-4ffa-b2f8-b702e34e3962 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18145 biolink:treats MONDO:0004573 PMID:41385096 "[{""id"":""uuid:65790531-92b8-4402-8e24-c648629ac55c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9a9aa05e-a504-4bc4-97e6-3e8100abc244"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Supplementation of the diet with ten essential vitamins. Supplementation of the diet with fluoride for caries prophylaxis. M ultivitamin with Fluoride 0.5 mg Chewable Tablets provide 0.5 mg fluoride in tablet form for children 4-6 years of age in areas where the drinking water fluoride level is less than 0.3 ppm, and for children 6 years of age and above where the drinking water contains 0.3 through 0.6 ppm of fluoride. Multivitamin with Fluoride 0.5 mg Chewable Tablets supply significant amounts of Vitamins A, C, D, E, thiamine, riboflavin, niacin, vitamin B6, vitamin B12, and folate to supplement the diet, and to help assure that nutritional deficiencies of these vitamins will not develop. Thus, in a single easy-to-use preparation, children obtain ten essential vitamins and the important mineral, fluoride. The American Academy of Pediatrics recommends that children up to age 16, in areas where drinking water contains less than optimal levels of fluoride, receive daily fluoride supplements. Children using Multivitamin with Fluoride 0 . 5 mg Chewable Tablets regularly should receive semiannual dental examinations. The regular brushing of teeth and attention to good oral hygiene practices are also essential. Multivitamin with Fluoride Chewable Tablets is a prescription product for the clinical dietary management of the metabolic processes of caries prophylaxis and provides supplementation of the diet with ten essential vitamins. uuid:33b1034d-3e7c-499f-b6d8-da508ca1deb6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18145 biolink:treats MONDO:0019975 PMID:41385096 "[{""id"":""uuid:fa6f8c28-a777-4d7d-b7ef-b444dcf037f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cfe812f2-c2d9-490e-a8e6-bea603ccc472"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Supplementation of the diet with ten essential vitamins. Supplementation of the diet with fluoride for caries prophylaxis. M ultivitamin with Fluoride 0.5 mg Chewable Tablets provide 0.5 mg fluoride in tablet form for children 4-6 years of age in areas where the drinking water fluoride level is less than 0.3 ppm, and for children 6 years of age and above where the drinking water contains 0.3 through 0.6 ppm of fluoride. Multivitamin with Fluoride 0.5 mg Chewable Tablets supply significant amounts of Vitamins A, C, D, E, thiamine, riboflavin, niacin, vitamin B6, vitamin B12, and folate to supplement the diet, and to help assure that nutritional deficiencies of these vitamins will not develop. Thus, in a single easy-to-use preparation, children obtain ten essential vitamins and the important mineral, fluoride. The American Academy of Pediatrics recommends that children up to age 16, in areas where drinking water contains less than optimal levels of fluoride, receive daily fluoride supplements. Children using Multivitamin with Fluoride 0 . 5 mg Chewable Tablets regularly should receive semiannual dental examinations. The regular brushing of teeth and attention to good oral hygiene practices are also essential. Multivitamin with Fluoride Chewable Tablets is a prescription product for the clinical dietary management of the metabolic processes of caries prophylaxis and provides supplementation of the diet with ten essential vitamins. uuid:8da49cb1-e1dd-428d-97fd-ff7ad0195ade biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18145 biolink:treats MONDO:0004574 PMID:41385096 "[{""id"":""uuid:b0fa4d4c-7cc3-4b8f-8624-f1bde8522399"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1ce80be3-7a07-4098-b5a0-0e692142c135"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Supplementation of the diet with ten essential vitamins. Supplementation of the diet with fluoride for caries prophylaxis. M ultivitamin with Fluoride 0.5 mg Chewable Tablets provide 0.5 mg fluoride in tablet form for children 4-6 years of age in areas where the drinking water fluoride level is less than 0.3 ppm, and for children 6 years of age and above where the drinking water contains 0.3 through 0.6 ppm of fluoride. Multivitamin with Fluoride 0.5 mg Chewable Tablets supply significant amounts of Vitamins A, C, D, E, thiamine, riboflavin, niacin, vitamin B6, vitamin B12, and folate to supplement the diet, and to help assure that nutritional deficiencies of these vitamins will not develop. Thus, in a single easy-to-use preparation, children obtain ten essential vitamins and the important mineral, fluoride. The American Academy of Pediatrics recommends that children up to age 16, in areas where drinking water contains less than optimal levels of fluoride, receive daily fluoride supplements. Children using Multivitamin with Fluoride 0 . 5 mg Chewable Tablets regularly should receive semiannual dental examinations. The regular brushing of teeth and attention to good oral hygiene practices are also essential. Multivitamin with Fluoride Chewable Tablets is a prescription product for the clinical dietary management of the metabolic processes of caries prophylaxis and provides supplementation of the diet with ten essential vitamins. uuid:0064e39b-4e43-4ed2-88c8-a35e7918b88a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18145 biolink:treats MONDO:0020696 PMID:41385096 "[{""id"":""uuid:b14c1613-d941-4978-8b46-8e922de0d91b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:89710672-35ea-4f12-a3f9-11f66be6bc3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Supplementation of the diet with ten essential vitamins. Supplementation of the diet with fluoride for caries prophylaxis. M ultivitamin with Fluoride 0.5 mg Chewable Tablets provide 0.5 mg fluoride in tablet form for children 4-6 years of age in areas where the drinking water fluoride level is less than 0.3 ppm, and for children 6 years of age and above where the drinking water contains 0.3 through 0.6 ppm of fluoride. Multivitamin with Fluoride 0.5 mg Chewable Tablets supply significant amounts of Vitamins A, C, D, E, thiamine, riboflavin, niacin, vitamin B6, vitamin B12, and folate to supplement the diet, and to help assure that nutritional deficiencies of these vitamins will not develop. Thus, in a single easy-to-use preparation, children obtain ten essential vitamins and the important mineral, fluoride. The American Academy of Pediatrics recommends that children up to age 16, in areas where drinking water contains less than optimal levels of fluoride, receive daily fluoride supplements. Children using Multivitamin with Fluoride 0 . 5 mg Chewable Tablets regularly should receive semiannual dental examinations. The regular brushing of teeth and attention to good oral hygiene practices are also essential. Multivitamin with Fluoride Chewable Tablets is a prescription product for the clinical dietary management of the metabolic processes of caries prophylaxis and provides supplementation of the diet with ten essential vitamins. uuid:5b5b5c0a-da36-4a02-ad39-e388928c1f14 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18145 biolink:treats MONDO:0001860 PMID:41385096 "[{""id"":""uuid:5484d455-68e0-4c35-a157-4880d2da8d91"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:437015bd-b3c8-4501-9e70-90a46fceb9cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Supplementation of the diet with ten essential vitamins. Supplementation of the diet with fluoride for caries prophylaxis. M ultivitamin with Fluoride 0.5 mg Chewable Tablets provide 0.5 mg fluoride in tablet form for children 4-6 years of age in areas where the drinking water fluoride level is less than 0.3 ppm, and for children 6 years of age and above where the drinking water contains 0.3 through 0.6 ppm of fluoride. Multivitamin with Fluoride 0.5 mg Chewable Tablets supply significant amounts of Vitamins A, C, D, E, thiamine, riboflavin, niacin, vitamin B6, vitamin B12, and folate to supplement the diet, and to help assure that nutritional deficiencies of these vitamins will not develop. Thus, in a single easy-to-use preparation, children obtain ten essential vitamins and the important mineral, fluoride. The American Academy of Pediatrics recommends that children up to age 16, in areas where drinking water contains less than optimal levels of fluoride, receive daily fluoride supplements. Children using Multivitamin with Fluoride 0 . 5 mg Chewable Tablets regularly should receive semiannual dental examinations. The regular brushing of teeth and attention to good oral hygiene practices are also essential. Multivitamin with Fluoride Chewable Tablets is a prescription product for the clinical dietary management of the metabolic processes of caries prophylaxis and provides supplementation of the diet with ten essential vitamins. uuid:d12baaff-387b-405e-aeb3-4ffa1e15fc7d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:RWM8CCW8GP biolink:treats MONDO:0005369 PMID:41385096 "[{""id"":""uuid:95360936-6e06-4a78-b7e6-8b8caf47db37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:43418b05-15ed-4792-ac8e-5f275913a84f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Octreotide Acetate Injection is a somatostatin analogue indicated: Acromegaly : To reduce blood levels of growth hormone (GH) and insulin growth factor-1 (IGF-1; somatomedin C) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses. ( 1.1 ) Carcinoid Tumors : For the symptomatic treatment of patients with metastatic carcinoid tumors where it suppresses or inhibits the severe diarrhea and flushing episodes associated with the disease. ( 1.2 ) Vasoactive Intestinal Peptide Tumors (VIPomas) : For the treatment of profuse watery diarrhea associated with VIP-secreting tumors. ( 1.3 ) Limitations of Use Improvement in clinical signs and symptoms, or reduction in tumor size or rate of growth, were not shown in clinical trials performed with Octreotide Acetate Injection; these trials were not optimally designed to detect such effects. ( 1.4 ) uuid:ad7fd9d3-0b40-4e2e-b53b-3a1b64349562 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4885 biolink:treats MONDO:0018076 PMID:41385096 "[{""id"":""uuid:6a376c2b-73b7-4b2c-b115-39004d34a158"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9d054d8d-23b2-4185-9091-8ab854d15103"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Trecator is primarily indicated for the treatment of active tuberculosis in patients with M. tuberculosis resistant to isoniazid or rifampin, or when there is intolerance on the part of the patient to other drugs. Its use alone in the treatment of tuberculosis results in the rapid development of resistance. It is essential, therefore, to give a suitable companion drug or drugs, the choice being based on the results of susceptibility tests. If the susceptibility tests indicate that the patient's organism is resistant to one of the first-line anti-tuberculosis drugs (i.e., isoniazid or rifampin) yet susceptible to ethionamide, ethionamide should be accompanied by at least one drug to which the M. tuberculosis isolate is known to be susceptible. 3 If the tuberculosis is resistant to both isoniazid and rifampin, yet susceptible to ethionamide, ethionamide should be accompanied by at least two other drugs to which the M. tuberculosis isolate is known to be susceptible. 3 To reduce the development of drug-resistant bacteria and maintain the effectiveness of Trecator and other antibacterial drugs, Trecator should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Patient nonadherence to prescribed treatment can result in treatment failure and in the development of drug-resistant tuberculosis, which can be life-threatening and lead to other serious health risks. It is, therefore, essential that patients adhere to the drug regimen for the full duration of treatment. Directly observed therapy is recommended for all patients receiving treatment for tuberculosis. Patients in whom drug-resistant M. tuberculosis organisms are isolated should be managed in consultation with an expert in the treatment of drug-resistant tuberculosis. uuid:12362fe8-7011-4b98-9568-61dd3203abdf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4885 biolink:treats MONDO:0005861 PMID:41385096 "[{""id"":""uuid:eb5cfeb0-902a-413e-9f8f-74a45b56c01e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5f036900-aa13-4f9b-82e2-eaa57f886ca0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Trecator is primarily indicated for the treatment of active tuberculosis in patients with M. tuberculosis resistant to isoniazid or rifampin, or when there is intolerance on the part of the patient to other drugs. Its use alone in the treatment of tuberculosis results in the rapid development of resistance. It is essential, therefore, to give a suitable companion drug or drugs, the choice being based on the results of susceptibility tests. If the susceptibility tests indicate that the patient's organism is resistant to one of the first-line anti-tuberculosis drugs (i.e., isoniazid or rifampin) yet susceptible to ethionamide, ethionamide should be accompanied by at least one drug to which the M. tuberculosis isolate is known to be susceptible. 3 If the tuberculosis is resistant to both isoniazid and rifampin, yet susceptible to ethionamide, ethionamide should be accompanied by at least two other drugs to which the M. tuberculosis isolate is known to be susceptible. 3 To reduce the development of drug-resistant bacteria and maintain the effectiveness of Trecator and other antibacterial drugs, Trecator should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Patient nonadherence to prescribed treatment can result in treatment failure and in the development of drug-resistant tuberculosis, which can be life-threatening and lead to other serious health risks. It is, therefore, essential that patients adhere to the drug regimen for the full duration of treatment. Directly observed therapy is recommended for all patients receiving treatment for tuberculosis. Patients in whom drug-resistant M. tuberculosis organisms are isolated should be managed in consultation with an expert in the treatment of drug-resistant tuberculosis. uuid:d972ec13-dbf8-4008-b27c-eabc22f67dc7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3A189DH42V biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:c82c279c-2618-4400-95fa-14edddd895ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:715d1bc5-7223-4a46-94d2-d3339ef69456"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LEMTRADA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Because of its safety profile, the use of LEMTRADA should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS [see Warnings and Precautions (5) ] . uuid:97c4c9e1-e57e-42cd-9199-b95a86ea570f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3A189DH42V biolink:treats MONDO:0000450 PMID:41385096 "[{""id"":""uuid:3a8abfcd-699b-4351-b011-5fd66829d2da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a02999d8-34ce-4fb6-abf1-8e2fb1cb1c12"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LEMTRADA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Because of its safety profile, the use of LEMTRADA should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS [see Warnings and Precautions (5) ] . uuid:aa266a7b-ac81-44ee-bfa2-899db338fa3f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:18680304 biolink:treats MONDO:0007476 PMID:41385096 "[{""id"":""uuid:738f6015-bbe5-4eae-b871-3e5de09794a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:19c73246-3d7a-448f-abf0-d1d866217c77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XIAFLEX is indicated for the treatment of adult patients with Dupuytren’s contracture with a palpable cord. XIAFLEX is indicated for the treatment of adult men with Peyronie’s disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy. uuid:c197837a-a7d6-4b84-a79d-1a89f7e76ab6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:18680304 biolink:treats MONDO:0008231 PMID:41385096 "[{""id"":""uuid:d77c70cb-15c6-49a3-b542-0eecd2804cdd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:052f9e86-85ba-493e-870f-af2fade34480"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XIAFLEX is indicated for the treatment of adult patients with Dupuytren’s contracture with a palpable cord. XIAFLEX is indicated for the treatment of adult men with Peyronie’s disease with a palpable plaque and curvature deformity of at least 30 degrees at the start of therapy. uuid:aa8ccb22-583d-4fc8-a018-6919176a6dea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:567361 biolink:treats MONDO:0005314 PMID:41385096 "[{""id"":""uuid:d2f32f1f-0407-4c3f-81de-d4274852c075"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3842f0f1-e07e-43a2-9dbc-67126b87f6f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MAVENCLAD is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Because of its safety profile, use of MAVENCLAD is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, an alternate drug indicated for the treatment of MS [see Warnings and Precautions (5) ]. uuid:7af082d8-f2cb-40c1-98a5-f72656f3ad81 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:567361 biolink:treats MONDO:0000450 PMID:41385096 "[{""id"":""uuid:802972a0-fa91-4b42-b4ff-a8be32352df8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:783a7758-f011-4486-afa2-b7d7ddbcaed4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MAVENCLAD is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include relapsing-remitting disease and active secondary progressive disease, in adults. Because of its safety profile, use of MAVENCLAD is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, an alternate drug indicated for the treatment of MS [see Warnings and Precautions (5) ]. uuid:191d4a0c-e156-40e6-accb-d52b411c353c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0100128 PMID:41385096 "[{""id"":""uuid:c25c8e0f-f856-4f34-bbbe-9af9294963a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:661714fb-2f38-4bac-adb7-cf53ba778882"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin and other antibacterial drugs, gentamicin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Sulfate Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa, Proteus species (indole-positive and indole-negative), Escherichia coli, Klebsiella-Enterobacter-Serratia species, Citrobacter species, and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown Gentamicin Sulfate Injection, USP to be effective in bacterial neonatal sepsis; bacterial septicemia; and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin sulfate may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection, and the important additional concepts contained in the WARNINGS BOX. If the causative organisms are resistant to gentamicin, other appropriate therapy should be instituted. In serious infections when the causative organisms are unknown, gentamicin sulfate may be administered as initial therapy in conjunction with a penicillin-type or cephalosporin-type drug before obtaining results of susceptibility testing. If anaerobic organisms are suspected as etiologic agents, consideration should be given to using other suitable antimicrobial therapy in conjunction with gentamicin. Following identification of the organism and its susceptibility, appropriate antibiotic therapy should then be continued. Gentamicin sulfate has been used effectively in combination with carbenicillin for the treatment of life-threatening infections caused by Pseudomonas aeruginosa. It has also been found effective when used in conjunction with a penicillin-type drug for the treatment of endocarditis caused by group D streptococci. Gentamicin Sulfate Injection, USP has also been shown to be effective in the treatment of serious staphylococcal infections. While not the antibiotic of first choice, gentamicin may be considered when penicillins or other less potentially toxic drugs are contraindicated and bacterial susceptibility tests and clinical judgment indicate its use. It may also be considered in mixed infections caused by susceptible strains of staphylococci and gram-negative organisms. In the neonate with suspected bacterial sepsis or staphylococcal pneumonia, a penicillin-type drug is also usually indicated as concomitant therapy with gentamicin. uuid:d5034576-6b52-44bf-ba71-2fec18b3d982 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5818 biolink:treats HP:0000713 PMID:41385096 "[{""id"":""uuid:f9a6a564-8c59-4c95-8044-234f1dc59b7c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a4c6614d-74ed-4020-a1da-5d71557bd306"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The total management of anxiety, tension, and psychomotor agitation in conditions of emotional stress requires in most instances a combined approach of psychotherapy and chemotherapy. Hydroxyzine has been found to be particularly useful for this latter phase of therapy in its ability to render the disturbed patient more amenable to psychotherapy in long term treatment of the psychoneurotic and psychotic, although it should not be used as the sole treatment of psychosis or of clearly demonstrated cases of depression. Hydroxyzine is also useful in alleviating the manifestations of anxiety and tension as in the preparation for dental procedures and in acute emotional problems. It has also been recommended for the management of anxiety associated with organic disturbances and as adjunctive therapy in alcoholism and allergic conditions with strong emotional overlay, such as in asthma, chronic urticaria, and pruritus. Hydroxyzine hydrochloride intramuscular solution is useful in treating the following types of patients when intramuscular administration is indicated: 1. The acutely disturbed or hysterical patient. 2. The acute or chronic alcoholic with anxiety withdrawal symptoms or delirium tremens. 3. As pre-and postoperative and pre- and postpartum adjunctive medication to permit reduction in narcotic dosage, allay anxiety and control emesis. Hydroxyzine hydrochloride has also demonstrated effectiveness in controlling nausea and vomiting, excluding nausea and vomiting of pregnancy. (See CONTRAINDICATIONS). In prepartum states, the reduction in narcotic requirement effected by hydroxyzine is of particular benefit to both mother and neonate. Hydroxyzine benefits the cardiac patient by its ability to allay the associated anxiety and apprehension attendant to certain types of heart disease. Hydroxyzine is not known to interfere with the action of digitalis in any way and may be used concurrently with this agent. The effectiveness of hydroxyzine in long term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient. uuid:62077dad-a9ae-41eb-8cd9-04606c1b00a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5818 biolink:treats UMLS:C0086209 PMID:41385096 "[{""id"":""uuid:d8617a9c-ee82-48c1-bd8e-47fb63529692"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7b7ce4a9-c776-4c66-a81e-63285d215032"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The total management of anxiety, tension, and psychomotor agitation in conditions of emotional stress requires in most instances a combined approach of psychotherapy and chemotherapy. Hydroxyzine has been found to be particularly useful for this latter phase of therapy in its ability to render the disturbed patient more amenable to psychotherapy in long term treatment of the psychoneurotic and psychotic, although it should not be used as the sole treatment of psychosis or of clearly demonstrated cases of depression. Hydroxyzine is also useful in alleviating the manifestations of anxiety and tension as in the preparation for dental procedures and in acute emotional problems. It has also been recommended for the management of anxiety associated with organic disturbances and as adjunctive therapy in alcoholism and allergic conditions with strong emotional overlay, such as in asthma, chronic urticaria, and pruritus. Hydroxyzine hydrochloride intramuscular solution is useful in treating the following types of patients when intramuscular administration is indicated: 1. The acutely disturbed or hysterical patient. 2. The acute or chronic alcoholic with anxiety withdrawal symptoms or delirium tremens. 3. As pre-and postoperative and pre- and postpartum adjunctive medication to permit reduction in narcotic dosage, allay anxiety and control emesis. Hydroxyzine hydrochloride has also demonstrated effectiveness in controlling nausea and vomiting, excluding nausea and vomiting of pregnancy. (See CONTRAINDICATIONS). In prepartum states, the reduction in narcotic requirement effected by hydroxyzine is of particular benefit to both mother and neonate. Hydroxyzine benefits the cardiac patient by its ability to allay the associated anxiety and apprehension attendant to certain types of heart disease. Hydroxyzine is not known to interfere with the action of digitalis in any way and may be used concurrently with this agent. The effectiveness of hydroxyzine in long term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient. uuid:03736160-a828-4225-8b23-d4ab7f11ef2f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5818 biolink:treats MONDO:0005379 PMID:41385096 "[{""id"":""uuid:298b159d-fddf-4bbb-8c5f-a5fb154fb991"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d7d2c96d-525e-493a-93e3-a1c400ffcc13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The total management of anxiety, tension, and psychomotor agitation in conditions of emotional stress requires in most instances a combined approach of psychotherapy and chemotherapy. Hydroxyzine has been found to be particularly useful for this latter phase of therapy in its ability to render the disturbed patient more amenable to psychotherapy in long term treatment of the psychoneurotic and psychotic, although it should not be used as the sole treatment of psychosis or of clearly demonstrated cases of depression. Hydroxyzine is also useful in alleviating the manifestations of anxiety and tension as in the preparation for dental procedures and in acute emotional problems. It has also been recommended for the management of anxiety associated with organic disturbances and as adjunctive therapy in alcoholism and allergic conditions with strong emotional overlay, such as in asthma, chronic urticaria, and pruritus. Hydroxyzine hydrochloride intramuscular solution is useful in treating the following types of patients when intramuscular administration is indicated: 1. The acutely disturbed or hysterical patient. 2. The acute or chronic alcoholic with anxiety withdrawal symptoms or delirium tremens. 3. As pre-and postoperative and pre- and postpartum adjunctive medication to permit reduction in narcotic dosage, allay anxiety and control emesis. Hydroxyzine hydrochloride has also demonstrated effectiveness in controlling nausea and vomiting, excluding nausea and vomiting of pregnancy. (See CONTRAINDICATIONS). In prepartum states, the reduction in narcotic requirement effected by hydroxyzine is of particular benefit to both mother and neonate. Hydroxyzine benefits the cardiac patient by its ability to allay the associated anxiety and apprehension attendant to certain types of heart disease. Hydroxyzine is not known to interfere with the action of digitalis in any way and may be used concurrently with this agent. The effectiveness of hydroxyzine in long term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient. uuid:90a144a0-83ca-45dc-8787-b6003a989d5d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5818 biolink:treats MONDO:0005485 PMID:41385096 "[{""id"":""uuid:08979e19-7397-426d-b3a7-156f7f525ccd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aa480231-13ff-45b0-ad53-8d426bd60ee7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The total management of anxiety, tension, and psychomotor agitation in conditions of emotional stress requires in most instances a combined approach of psychotherapy and chemotherapy. Hydroxyzine has been found to be particularly useful for this latter phase of therapy in its ability to render the disturbed patient more amenable to psychotherapy in long term treatment of the psychoneurotic and psychotic, although it should not be used as the sole treatment of psychosis or of clearly demonstrated cases of depression. Hydroxyzine is also useful in alleviating the manifestations of anxiety and tension as in the preparation for dental procedures and in acute emotional problems. It has also been recommended for the management of anxiety associated with organic disturbances and as adjunctive therapy in alcoholism and allergic conditions with strong emotional overlay, such as in asthma, chronic urticaria, and pruritus. Hydroxyzine hydrochloride intramuscular solution is useful in treating the following types of patients when intramuscular administration is indicated: 1. The acutely disturbed or hysterical patient. 2. The acute or chronic alcoholic with anxiety withdrawal symptoms or delirium tremens. 3. As pre-and postoperative and pre- and postpartum adjunctive medication to permit reduction in narcotic dosage, allay anxiety and control emesis. Hydroxyzine hydrochloride has also demonstrated effectiveness in controlling nausea and vomiting, excluding nausea and vomiting of pregnancy. (See CONTRAINDICATIONS). In prepartum states, the reduction in narcotic requirement effected by hydroxyzine is of particular benefit to both mother and neonate. Hydroxyzine benefits the cardiac patient by its ability to allay the associated anxiety and apprehension attendant to certain types of heart disease. Hydroxyzine is not known to interfere with the action of digitalis in any way and may be used concurrently with this agent. The effectiveness of hydroxyzine in long term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient. uuid:08e67be5-654b-4e27-9be5-4054deabb59e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5818 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:dc1ee6fa-42d9-4222-9d77-016fc74eaaa3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a397ca66-9baf-482f-9ebf-3343f617d22d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The total management of anxiety, tension, and psychomotor agitation in conditions of emotional stress requires in most instances a combined approach of psychotherapy and chemotherapy. Hydroxyzine has been found to be particularly useful for this latter phase of therapy in its ability to render the disturbed patient more amenable to psychotherapy in long term treatment of the psychoneurotic and psychotic, although it should not be used as the sole treatment of psychosis or of clearly demonstrated cases of depression. Hydroxyzine is also useful in alleviating the manifestations of anxiety and tension as in the preparation for dental procedures and in acute emotional problems. It has also been recommended for the management of anxiety associated with organic disturbances and as adjunctive therapy in alcoholism and allergic conditions with strong emotional overlay, such as in asthma, chronic urticaria, and pruritus. Hydroxyzine hydrochloride intramuscular solution is useful in treating the following types of patients when intramuscular administration is indicated: 1. The acutely disturbed or hysterical patient. 2. The acute or chronic alcoholic with anxiety withdrawal symptoms or delirium tremens. 3. As pre-and postoperative and pre- and postpartum adjunctive medication to permit reduction in narcotic dosage, allay anxiety and control emesis. Hydroxyzine hydrochloride has also demonstrated effectiveness in controlling nausea and vomiting, excluding nausea and vomiting of pregnancy. (See CONTRAINDICATIONS). In prepartum states, the reduction in narcotic requirement effected by hydroxyzine is of particular benefit to both mother and neonate. Hydroxyzine benefits the cardiac patient by its ability to allay the associated anxiety and apprehension attendant to certain types of heart disease. Hydroxyzine is not known to interfere with the action of digitalis in any way and may be used concurrently with this agent. The effectiveness of hydroxyzine in long term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient. uuid:9959d3b7-91d1-4362-a0ce-48746c75dded biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5818 biolink:treats UMLS:C0236748 PMID:41385096 "[{""id"":""uuid:65b99c14-8d9d-4efe-a6e5-f34609997067"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b7de52bb-fcfc-4ac3-8e29-56a8f9a4a7a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The total management of anxiety, tension, and psychomotor agitation in conditions of emotional stress requires in most instances a combined approach of psychotherapy and chemotherapy. Hydroxyzine has been found to be particularly useful for this latter phase of therapy in its ability to render the disturbed patient more amenable to psychotherapy in long term treatment of the psychoneurotic and psychotic, although it should not be used as the sole treatment of psychosis or of clearly demonstrated cases of depression. Hydroxyzine is also useful in alleviating the manifestations of anxiety and tension as in the preparation for dental procedures and in acute emotional problems. It has also been recommended for the management of anxiety associated with organic disturbances and as adjunctive therapy in alcoholism and allergic conditions with strong emotional overlay, such as in asthma, chronic urticaria, and pruritus. Hydroxyzine hydrochloride intramuscular solution is useful in treating the following types of patients when intramuscular administration is indicated: 1. The acutely disturbed or hysterical patient. 2. The acute or chronic alcoholic with anxiety withdrawal symptoms or delirium tremens. 3. As pre-and postoperative and pre- and postpartum adjunctive medication to permit reduction in narcotic dosage, allay anxiety and control emesis. Hydroxyzine hydrochloride has also demonstrated effectiveness in controlling nausea and vomiting, excluding nausea and vomiting of pregnancy. (See CONTRAINDICATIONS). In prepartum states, the reduction in narcotic requirement effected by hydroxyzine is of particular benefit to both mother and neonate. Hydroxyzine benefits the cardiac patient by its ability to allay the associated anxiety and apprehension attendant to certain types of heart disease. Hydroxyzine is not known to interfere with the action of digitalis in any way and may be used concurrently with this agent. The effectiveness of hydroxyzine in long term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient. uuid:aa57b471-aa10-4828-b670-64fe81b1c33f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5818 biolink:treats MONDO:0007079 PMID:41385096 "[{""id"":""uuid:ac7be90d-587b-44a7-817d-a2089fd54929"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f00f0788-daa4-4199-931c-472aa97204d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The total management of anxiety, tension, and psychomotor agitation in conditions of emotional stress requires in most instances a combined approach of psychotherapy and chemotherapy. Hydroxyzine has been found to be particularly useful for this latter phase of therapy in its ability to render the disturbed patient more amenable to psychotherapy in long term treatment of the psychoneurotic and psychotic, although it should not be used as the sole treatment of psychosis or of clearly demonstrated cases of depression. Hydroxyzine is also useful in alleviating the manifestations of anxiety and tension as in the preparation for dental procedures and in acute emotional problems. It has also been recommended for the management of anxiety associated with organic disturbances and as adjunctive therapy in alcoholism and allergic conditions with strong emotional overlay, such as in asthma, chronic urticaria, and pruritus. Hydroxyzine hydrochloride intramuscular solution is useful in treating the following types of patients when intramuscular administration is indicated: 1. The acutely disturbed or hysterical patient. 2. The acute or chronic alcoholic with anxiety withdrawal symptoms or delirium tremens. 3. As pre-and postoperative and pre- and postpartum adjunctive medication to permit reduction in narcotic dosage, allay anxiety and control emesis. Hydroxyzine hydrochloride has also demonstrated effectiveness in controlling nausea and vomiting, excluding nausea and vomiting of pregnancy. (See CONTRAINDICATIONS). In prepartum states, the reduction in narcotic requirement effected by hydroxyzine is of particular benefit to both mother and neonate. Hydroxyzine benefits the cardiac patient by its ability to allay the associated anxiety and apprehension attendant to certain types of heart disease. Hydroxyzine is not known to interfere with the action of digitalis in any way and may be used concurrently with this agent. The effectiveness of hydroxyzine in long term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient. uuid:8d86b16c-a5e1-4c04-b423-6a5240d96a2d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5818 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:f34d1f79-8bb0-407c-b8d8-74c5982a1212"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6ecb5fe3-9c4e-4c5f-ab54-4c4c82852c62"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The total management of anxiety, tension, and psychomotor agitation in conditions of emotional stress requires in most instances a combined approach of psychotherapy and chemotherapy. Hydroxyzine has been found to be particularly useful for this latter phase of therapy in its ability to render the disturbed patient more amenable to psychotherapy in long term treatment of the psychoneurotic and psychotic, although it should not be used as the sole treatment of psychosis or of clearly demonstrated cases of depression. Hydroxyzine is also useful in alleviating the manifestations of anxiety and tension as in the preparation for dental procedures and in acute emotional problems. It has also been recommended for the management of anxiety associated with organic disturbances and as adjunctive therapy in alcoholism and allergic conditions with strong emotional overlay, such as in asthma, chronic urticaria, and pruritus. Hydroxyzine hydrochloride intramuscular solution is useful in treating the following types of patients when intramuscular administration is indicated: 1. The acutely disturbed or hysterical patient. 2. The acute or chronic alcoholic with anxiety withdrawal symptoms or delirium tremens. 3. As pre-and postoperative and pre- and postpartum adjunctive medication to permit reduction in narcotic dosage, allay anxiety and control emesis. Hydroxyzine hydrochloride has also demonstrated effectiveness in controlling nausea and vomiting, excluding nausea and vomiting of pregnancy. (See CONTRAINDICATIONS). In prepartum states, the reduction in narcotic requirement effected by hydroxyzine is of particular benefit to both mother and neonate. Hydroxyzine benefits the cardiac patient by its ability to allay the associated anxiety and apprehension attendant to certain types of heart disease. Hydroxyzine is not known to interfere with the action of digitalis in any way and may be used concurrently with this agent. The effectiveness of hydroxyzine in long term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient. uuid:ede87ecc-7158-4818-9424-63e825ee6295 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5818 biolink:treats UMLS:C0020701 PMID:41385096 "[{""id"":""uuid:5d0260f6-d83d-49b2-b0ee-11ef3521a157"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:192507a4-45f3-499d-bdd7-f842ec928940"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The total management of anxiety, tension, and psychomotor agitation in conditions of emotional stress requires in most instances a combined approach of psychotherapy and chemotherapy. Hydroxyzine has been found to be particularly useful for this latter phase of therapy in its ability to render the disturbed patient more amenable to psychotherapy in long term treatment of the psychoneurotic and psychotic, although it should not be used as the sole treatment of psychosis or of clearly demonstrated cases of depression. Hydroxyzine is also useful in alleviating the manifestations of anxiety and tension as in the preparation for dental procedures and in acute emotional problems. It has also been recommended for the management of anxiety associated with organic disturbances and as adjunctive therapy in alcoholism and allergic conditions with strong emotional overlay, such as in asthma, chronic urticaria, and pruritus. Hydroxyzine hydrochloride intramuscular solution is useful in treating the following types of patients when intramuscular administration is indicated: 1. The acutely disturbed or hysterical patient. 2. The acute or chronic alcoholic with anxiety withdrawal symptoms or delirium tremens. 3. As pre-and postoperative and pre- and postpartum adjunctive medication to permit reduction in narcotic dosage, allay anxiety and control emesis. Hydroxyzine hydrochloride has also demonstrated effectiveness in controlling nausea and vomiting, excluding nausea and vomiting of pregnancy. (See CONTRAINDICATIONS). In prepartum states, the reduction in narcotic requirement effected by hydroxyzine is of particular benefit to both mother and neonate. Hydroxyzine benefits the cardiac patient by its ability to allay the associated anxiety and apprehension attendant to certain types of heart disease. Hydroxyzine is not known to interfere with the action of digitalis in any way and may be used concurrently with this agent. The effectiveness of hydroxyzine in long term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient. uuid:cb4d07e3-e359-4ea7-86d3-c827c68b40c0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5818 biolink:treats MONDO:0005567 PMID:41385096 "[{""id"":""uuid:2bf6179a-852f-455c-ad49-edb676b1edb6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b4cfba5a-6155-4e12-aa41-93b2e2a19b0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The total management of anxiety, tension, and psychomotor agitation in conditions of emotional stress requires in most instances a combined approach of psychotherapy and chemotherapy. Hydroxyzine has been found to be particularly useful for this latter phase of therapy in its ability to render the disturbed patient more amenable to psychotherapy in long term treatment of the psychoneurotic and psychotic, although it should not be used as the sole treatment of psychosis or of clearly demonstrated cases of depression. Hydroxyzine is also useful in alleviating the manifestations of anxiety and tension as in the preparation for dental procedures and in acute emotional problems. It has also been recommended for the management of anxiety associated with organic disturbances and as adjunctive therapy in alcoholism and allergic conditions with strong emotional overlay, such as in asthma, chronic urticaria, and pruritus. Hydroxyzine hydrochloride intramuscular solution is useful in treating the following types of patients when intramuscular administration is indicated: 1. The acutely disturbed or hysterical patient. 2. The acute or chronic alcoholic with anxiety withdrawal symptoms or delirium tremens. 3. As pre-and postoperative and pre- and postpartum adjunctive medication to permit reduction in narcotic dosage, allay anxiety and control emesis. Hydroxyzine hydrochloride has also demonstrated effectiveness in controlling nausea and vomiting, excluding nausea and vomiting of pregnancy. (See CONTRAINDICATIONS). In prepartum states, the reduction in narcotic requirement effected by hydroxyzine is of particular benefit to both mother and neonate. Hydroxyzine benefits the cardiac patient by its ability to allay the associated anxiety and apprehension attendant to certain types of heart disease. Hydroxyzine is not known to interfere with the action of digitalis in any way and may be used concurrently with this agent. The effectiveness of hydroxyzine in long term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient. uuid:ea4db544-f6e1-481e-99c4-44133c0c8ef4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5818 biolink:treats MONDO:0006642 PMID:41385096 "[{""id"":""uuid:d4dbe26f-3d14-4e9a-8aca-1c5886c7c9f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:968d0ca2-3607-43c4-ba4e-87b17cb87302"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The total management of anxiety, tension, and psychomotor agitation in conditions of emotional stress requires in most instances a combined approach of psychotherapy and chemotherapy. Hydroxyzine has been found to be particularly useful for this latter phase of therapy in its ability to render the disturbed patient more amenable to psychotherapy in long term treatment of the psychoneurotic and psychotic, although it should not be used as the sole treatment of psychosis or of clearly demonstrated cases of depression. Hydroxyzine is also useful in alleviating the manifestations of anxiety and tension as in the preparation for dental procedures and in acute emotional problems. It has also been recommended for the management of anxiety associated with organic disturbances and as adjunctive therapy in alcoholism and allergic conditions with strong emotional overlay, such as in asthma, chronic urticaria, and pruritus. Hydroxyzine hydrochloride intramuscular solution is useful in treating the following types of patients when intramuscular administration is indicated: 1. The acutely disturbed or hysterical patient. 2. The acute or chronic alcoholic with anxiety withdrawal symptoms or delirium tremens. 3. As pre-and postoperative and pre- and postpartum adjunctive medication to permit reduction in narcotic dosage, allay anxiety and control emesis. Hydroxyzine hydrochloride has also demonstrated effectiveness in controlling nausea and vomiting, excluding nausea and vomiting of pregnancy. (See CONTRAINDICATIONS). In prepartum states, the reduction in narcotic requirement effected by hydroxyzine is of particular benefit to both mother and neonate. Hydroxyzine benefits the cardiac patient by its ability to allay the associated anxiety and apprehension attendant to certain types of heart disease. Hydroxyzine is not known to interfere with the action of digitalis in any way and may be used concurrently with this agent. The effectiveness of hydroxyzine in long term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient. uuid:6703acb3-1e8c-4a37-a314-6c41c1416773 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5818 biolink:treats HP:0002018 PMID:41385096 "[{""id"":""uuid:8f2f803d-e15f-41e3-96d6-8c9200a65e6c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c5feac01-4a43-4068-a1e1-29efc0108aa2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The total management of anxiety, tension, and psychomotor agitation in conditions of emotional stress requires in most instances a combined approach of psychotherapy and chemotherapy. Hydroxyzine has been found to be particularly useful for this latter phase of therapy in its ability to render the disturbed patient more amenable to psychotherapy in long term treatment of the psychoneurotic and psychotic, although it should not be used as the sole treatment of psychosis or of clearly demonstrated cases of depression. Hydroxyzine is also useful in alleviating the manifestations of anxiety and tension as in the preparation for dental procedures and in acute emotional problems. It has also been recommended for the management of anxiety associated with organic disturbances and as adjunctive therapy in alcoholism and allergic conditions with strong emotional overlay, such as in asthma, chronic urticaria, and pruritus. Hydroxyzine hydrochloride intramuscular solution is useful in treating the following types of patients when intramuscular administration is indicated: 1. The acutely disturbed or hysterical patient. 2. The acute or chronic alcoholic with anxiety withdrawal symptoms or delirium tremens. 3. As pre-and postoperative and pre- and postpartum adjunctive medication to permit reduction in narcotic dosage, allay anxiety and control emesis. Hydroxyzine hydrochloride has also demonstrated effectiveness in controlling nausea and vomiting, excluding nausea and vomiting of pregnancy. (See CONTRAINDICATIONS). In prepartum states, the reduction in narcotic requirement effected by hydroxyzine is of particular benefit to both mother and neonate. Hydroxyzine benefits the cardiac patient by its ability to allay the associated anxiety and apprehension attendant to certain types of heart disease. Hydroxyzine is not known to interfere with the action of digitalis in any way and may be used concurrently with this agent. The effectiveness of hydroxyzine in long term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient. uuid:67aa758a-237e-4ed6-af7f-cf699425a035 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5818 biolink:treats HP:0002013 PMID:41385096 "[{""id"":""uuid:de80c867-58b0-410b-b330-d74060237f3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cc42a51a-ba40-4e92-8c75-811f81cf114d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The total management of anxiety, tension, and psychomotor agitation in conditions of emotional stress requires in most instances a combined approach of psychotherapy and chemotherapy. Hydroxyzine has been found to be particularly useful for this latter phase of therapy in its ability to render the disturbed patient more amenable to psychotherapy in long term treatment of the psychoneurotic and psychotic, although it should not be used as the sole treatment of psychosis or of clearly demonstrated cases of depression. Hydroxyzine is also useful in alleviating the manifestations of anxiety and tension as in the preparation for dental procedures and in acute emotional problems. It has also been recommended for the management of anxiety associated with organic disturbances and as adjunctive therapy in alcoholism and allergic conditions with strong emotional overlay, such as in asthma, chronic urticaria, and pruritus. Hydroxyzine hydrochloride intramuscular solution is useful in treating the following types of patients when intramuscular administration is indicated: 1. The acutely disturbed or hysterical patient. 2. The acute or chronic alcoholic with anxiety withdrawal symptoms or delirium tremens. 3. As pre-and postoperative and pre- and postpartum adjunctive medication to permit reduction in narcotic dosage, allay anxiety and control emesis. Hydroxyzine hydrochloride has also demonstrated effectiveness in controlling nausea and vomiting, excluding nausea and vomiting of pregnancy. (See CONTRAINDICATIONS). In prepartum states, the reduction in narcotic requirement effected by hydroxyzine is of particular benefit to both mother and neonate. Hydroxyzine benefits the cardiac patient by its ability to allay the associated anxiety and apprehension attendant to certain types of heart disease. Hydroxyzine is not known to interfere with the action of digitalis in any way and may be used concurrently with this agent. The effectiveness of hydroxyzine in long term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient. uuid:01507727-fd48-4677-9222-c5e9664eb49a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5818 biolink:treats MONDO:0005267 PMID:41385096 "[{""id"":""uuid:f67f5266-3175-4f85-9500-9a8da8ad0da2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c176df76-a28e-4858-ada2-3829b32af705"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The total management of anxiety, tension, and psychomotor agitation in conditions of emotional stress requires in most instances a combined approach of psychotherapy and chemotherapy. Hydroxyzine has been found to be particularly useful for this latter phase of therapy in its ability to render the disturbed patient more amenable to psychotherapy in long term treatment of the psychoneurotic and psychotic, although it should not be used as the sole treatment of psychosis or of clearly demonstrated cases of depression. Hydroxyzine is also useful in alleviating the manifestations of anxiety and tension as in the preparation for dental procedures and in acute emotional problems. It has also been recommended for the management of anxiety associated with organic disturbances and as adjunctive therapy in alcoholism and allergic conditions with strong emotional overlay, such as in asthma, chronic urticaria, and pruritus. Hydroxyzine hydrochloride intramuscular solution is useful in treating the following types of patients when intramuscular administration is indicated: 1. The acutely disturbed or hysterical patient. 2. The acute or chronic alcoholic with anxiety withdrawal symptoms or delirium tremens. 3. As pre-and postoperative and pre- and postpartum adjunctive medication to permit reduction in narcotic dosage, allay anxiety and control emesis. Hydroxyzine hydrochloride has also demonstrated effectiveness in controlling nausea and vomiting, excluding nausea and vomiting of pregnancy. (See CONTRAINDICATIONS). In prepartum states, the reduction in narcotic requirement effected by hydroxyzine is of particular benefit to both mother and neonate. Hydroxyzine benefits the cardiac patient by its ability to allay the associated anxiety and apprehension attendant to certain types of heart disease. Hydroxyzine is not known to interfere with the action of digitalis in any way and may be used concurrently with this agent. The effectiveness of hydroxyzine in long term use, that is, more than 4 months, has not been assessed by systematic clinical studies. The physician should reassess periodically the usefulness of the drug for the individual patient. uuid:b0080dae-da36-4502-aa9b-6a49b20a64a5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5103 biolink:treats MONDO:0002125 PMID:41385096 "[{""id"":""uuid:948bdcb3-1f98-4cfb-a890-d24794f2ddae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:47dddfbe-2e59-4512-a00f-b4e8f408d47b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Adult Patients: Flumazenil injection is indicated for the complete or partial reversal of the sedative effects of benzodiazepines in cases where general anesthesia has been induced and/or maintained with benzodiazepines, where sedation has been produced with benzodiazepines for diagnostic and therapeutic procedures, and for the management of benzodiazepine overdose. Pediatric Patients (aged 1 to 17): Flumazenil injection is indicated for the reversal of conscious sedation induced with benzodiazepines (see PRECAUTIONS: PEDIATRIC USE). CLOSE CONTRAINDICATIONS Flumazenil injection is contraindicated: •in patients with a known hypersensitivity to flumazenil or benzodiazepines. •in patients who have been given a benzodiazepine for control of a potentially life-threatening condition (e.g., control of intracranial pressure or status epilepticus). •in patients who are showing signs of serious cyclic antidepressant overdose (see WARNINGS). uuid:0b7050a3-c99f-486b-947e-987cac60b0b0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9843669 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:258e591d-b722-4b1b-98d7-ac983e23fda5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1db2ad04-7e5b-4fd0-ad33-a9d9499d9aa6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Isosorbide dinitrate and hydralazine hydrochloride tablets are a combination of isosorbide dinitrate, a nitrate vasodilator, and hydralazine hydrochloride, an arteriolar vasodilator, indicated for: the treatment of heart failure as an adjunct therapy to standard therapy in self-identified black patients to improve survival, prolong time to hospitalization for heart failure and to improve patient-reported functional status ( 1.1 ) Limitations of use: There is little experience in patients with NYHA class IV heart failure ( 1.2 ) uuid:b6c743ee-b6d4-4e31-836e-c08788cc3b31 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:AQK7UBA1LS biolink:treats MONDO:0016486 PMID:41385096 "[{""id"":""uuid:44c9c396-ffe0-4b36-bffd-c04c6ab62786"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:65003263-8251-45c0-9c48-171e938b6f19"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] REBLOZYL is an erythroid maturation agent indicated for the treatment of: • Anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions ( 1.1 ). • Anemia without previous erythropoiesis stimulating agent use (ESA-naïve) in adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) who may require regular red blood cell (RBC) transfusions ( 1.2 ). • Anemia failing an erythropoiesis stimulating agent and requiring 2 or more RBC units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) ( 1.3 ). • Limitations of Use: REBLOZYL is not indicated for use as a substitute for RBC transfusions in patients who require immediate correction of anemia ( 1.4 ). uuid:a0c9c0fe-1e52-41d4-99a9-7453f852b25f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:AQK7UBA1LS biolink:treats MONDO:0019157 PMID:41385096 "[{""id"":""uuid:1b7c3ff4-d092-428b-91c8-a3feb13d154d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:58ab220a-f511-4cb4-850f-137c285bfba5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b0c7021c-77ff-4e84-81ed-eb2726cd33e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/reblozyl""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] REBLOZYL is an erythroid maturation agent indicated for the treatment of: • Anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions ( 1.1 ). • Anemia without previous erythropoiesis stimulating agent use (ESA-naïve) in adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) who may require regular red blood cell (RBC) transfusions ( 1.2 ). • Anemia failing an erythropoiesis stimulating agent and requiring 2 or more RBC units over 8 weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts (MDS-RS) or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) ( 1.3 ). • Limitations of Use: REBLOZYL is not indicated for use as a substitute for RBC transfusions in patients who require immediate correction of anemia ( 1.4 ).|[EMA] Reblozyl is indicated for the treatment of adult patients with transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy (see section 5.1).Reblozyl is indicated in adults for the treatment of anaemia associated with transfusion dependent and non transfusion dependent beta thalassaemia (see section 5.1). uuid:5bbbb72f-9c7b-4d47-a056-f97bc6d4e147 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:122361353 biolink:treats MONDO:0000004 PMID:41385096 "[{""id"":""uuid:3e8b6663-57f9-48c8-9cd0-84881ae3c658"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4a6f1b24-73eb-44c6-9f23-88998e9ae937"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cosyntropin for injection is indicated, in combination with other diagnostic tests, for use as a diagnostic agent in the screening of adrenocortical insufficiency in adults and pediatric patients. uuid:4b2f8d4a-f24c-4e38-87dd-aeb1288da8e7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6367 biolink:treats MONDO:0004985 PMID:41385096 "[{""id"":""uuid:f57e7f1d-14d3-4dc0-abd3-6512c914e38e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9d20245f-dd0f-4048-abcd-f3616ba70814"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:997aec2a-e506-4019-ac4b-20abf5ca8d17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lamotrigine tablet is indicated for: Epilepsy—adjunctive therapy in patients aged 2 years and older: partial-onset seizures. primary generalized tonic-clonic seizures. generalized seizures of Lennox-Gastaut syndrome. ( 1.1 ) Epilepsy—monotherapy in patients aged 16 years and older: Conversion to monotherapy in patients with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single antiepileptic drug. ( 1.1 ) Bipolar disorder : Maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes in patients treated for acute mood episodes with standard therapy. ( 1.2 ) Limitations of Use: Treatment of acute manic or mixed episodes is not recommended. Effectiveness of lamotrigine tablets in the acute treatment of mood episodes has not been established.|[PMDA] Drugs with a new additional indication and a new dosage for the prevention of recurrence/relapse of mood episodes in patients with bipolar disorder. uuid:74bd8d43-56b3-4a52-959f-ba44bf5f364e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90227 biolink:treats MONDO:0003304 PMID:41385096 "[{""id"":""uuid:dfda58ad-6547-4843-9fbf-e7024464eeb3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:14f75c76-229f-4d1f-b31c-a0e379d830ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:85cd18ed-e028-4260-8950-b7741f29359a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f5c72ed5-a921-40c5-b7fa-d8b5080d1e23"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KOSELUGO is indicated for the treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN).|[EMA] Koselugo as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in paediatric patients with neurofibromatosis type 1 (NF1) aged 3 years and above|[PMDA] Drugs with a new active ingredient indicated for the treatment of plexiform neurofibroma in patients with neurofibromatosis type 1. [Orphan drug] uuid:74ac91e3-77fd-4da0-98ab-071b56262e16 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:30769 biolink:treats HP:0001996 PMID:41385096 "[{""id"":""uuid:124e8f42-ad88-4795-b510-28d54f6899fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:42587078-6895-488f-ad4a-d855f2191a82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium citrate and citric acid oral solution, is an effective alkalinizing agent. It is useful in those conditions where long-term maintenance of an alkaline urine is desirable, and is of value in the alleviation of chronic metabolic acidosis, such as results from chronic renal insufficiency or the syndrome of renal tubular acidosis, especially when the administration of potassium salts is undesirable or contraindicated. This product is also useful for buffering and neutralizing gastric hydrochloric acid quickly and effectively. Sodium citrate and citric acid oral solution is concentrated, and when administered after meals and before bedtime, allows one to maintain an alkaline urinary pH around the clock, usually without the necessity of a 2 A.M. dose. This product alkalinizes the urine without producing a systemic alkalosis in the recommended dosage. This product is highly palatable, pleasant tasting, and tolerable, even when administered for long periods. uuid:692ed6f6-3db3-45d4-b359-0e42a21c5ae4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:30769 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:1d7b7e7f-66a9-46d4-b647-df1f0c88ddb5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e299375f-096a-4802-9c56-c92f151d00c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium citrate and citric acid oral solution, is an effective alkalinizing agent. It is useful in those conditions where long-term maintenance of an alkaline urine is desirable, and is of value in the alleviation of chronic metabolic acidosis, such as results from chronic renal insufficiency or the syndrome of renal tubular acidosis, especially when the administration of potassium salts is undesirable or contraindicated. This product is also useful for buffering and neutralizing gastric hydrochloric acid quickly and effectively. Sodium citrate and citric acid oral solution is concentrated, and when administered after meals and before bedtime, allows one to maintain an alkaline urinary pH around the clock, usually without the necessity of a 2 A.M. dose. This product alkalinizes the urine without producing a systemic alkalosis in the recommended dosage. This product is highly palatable, pleasant tasting, and tolerable, even when administered for long periods. uuid:d5ad80f4-aa82-4063-9d08-4cebd52890a2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1163417 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:4350fc89-14aa-49c9-97ca-7f5240a38075"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a44ce2e7-dbd8-427d-8db4-cb4a6be385bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the temporary relief of pain and itching associated with minor burns, sunburns or minor skin irritations or hemorrhoids and itching associated with inflammation, and rashes due to eczema. uuid:ebf4f8e1-50c4-4b32-a475-dfa0d63cad9e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1163417 biolink:treats MONDO:0005326 PMID:41385096 "[{""id"":""uuid:47ce502f-a0f5-49db-a358-0c6917484a1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0cc543f9-565d-4334-8fde-c45c3ba7efe6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the temporary relief of pain and itching associated with minor burns, sunburns or minor skin irritations or hemorrhoids and itching associated with inflammation, and rashes due to eczema. uuid:187240be-ffd5-448d-8e82-85c43f3643d0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:AL3L5D17Y7 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:856abb4d-0426-4d13-b3cf-b9a3adfea029"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5bf0a104-2282-4cfd-b27b-935befe41327"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LUMISIGHT is indicated for fluorescence imaging in adults with breast cancer as an adjunct for the intraoperative detection of cancerous tissue within the resection cavity following removal of the primary specimen during lumpectomy surgery. uuid:94b87af6-c6dc-4c10-9325-16c89a722033 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3398 biolink:treats MONDO:0100177 PMID:41385096 "[{""id"":""uuid:df86f83b-c1a8-47af-90c3-0314168d15ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d91495c8-9f81-48d8-b959-b4be790e310a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carbinoxamine Maleate extended-release oral suspension is indicated for adults and pediatric patients 2 years of age and older for the symptomatic treatment of: Seasonal and perennial allergic rhinitis Vasomotor rhinitis Allergic conjunctivitis due to inhalant allergens and foods Mild, uncomplicated allergic skin manifestations of urticaria and angioedema Dermatographism As therapy for anaphylactic reactions adjunctive to epinephrine and other standard measures after the acute manifestations have been controlled Amelioration of the severity of allergic reactions to blood or plasma uuid:619e493a-6b57-4b93-bc87-40e941dfa055 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:4ea28c28-b4b1-4df9-85e7-02f4f917223f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d6b59d0b-8051-4f4e-ad41-95bbe2256365"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a09e3499-c236-4e68-accb-96c3f015a97f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] HEMADY is indicated in combination with other anti-myeloma products for the treatment of adults with multiple myeloma (MM).|[PMDA] A drug with a new additional indication and a new dosage for the treatment of multiple myeloma. [Expedited review] uuid:daa576b5-8f15-4b87-a42d-7e1dcddfc180 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0009685 PMID:41385096 "[{""id"":""uuid:92af5cf1-95e7-4817-8fe9-44fac101837d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a1e195c1-23c2-4e40-a99a-187e7b7b7226"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] HEMADY is indicated in combination with other anti-myeloma products for the treatment of adults with multiple myeloma (MM). uuid:9afecff0-3b04-4695-8cfc-d84b45a686a3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6427 biolink:treats UMLS:C5553997 PMID:41385096 "[{""id"":""uuid:775e86b6-51c9-42ac-95f2-9f608d687880"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:111d7154-4e25-43bc-9535-b39a31de9617"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LUPRON DEPOT 7.5 mg for 1-month administration, 22.5 mg for 3-month administration, 30 mg for 4-month administration, and 45 mg for 6-month administration (leuprolide acetate) are indicated for the treatment of advanced prostate cancer. uuid:70410ee2-d70d-4422-9d60-e891d0de6354 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6QVL057INT biolink:treats UMLS:C4087141 PMID:41385096 "[{""id"":""uuid:8cfb1728-09f5-4c3e-9f82-831311b05a3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:666a4f37-7af4-46a4-b86c-200e5f70c1dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LIBTAYO is a programmed death receptor-1 (PD-1) blocking antibody indicated: Cutaneous Squamous Cell Carcinoma (CSCC) for the treatment of patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation. ( 1.1 ) Basal Cell Carcinoma (BCC) for the treatment of patients with locally advanced or metastatic BCC (laBCC or mBCC) who have been previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate. ( 1.2 ) Non-Small Cell Lung Cancer (NSCLC) in combination with platinum-based chemotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations and is: locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or metastatic. ( 1.3 ) as single agent for the first-line treatment of adult patients with NSCLC whose tumors have high PD-L1 expression [Tumor Proportion Score (TPS) ≥ 50%] as determined by an FDA-approved test, with no EGFR, ALK or ROS1 aberrations, and is: locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or metastatic. ( 1.3 , 2.1 ) uuid:753ac9ee-8790-401c-8bb4-9a2bc8db4f89 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6QVL057INT biolink:treats UMLS:C5556695 PMID:41385096 "[{""id"":""uuid:31a15e8f-aba8-4c76-ba3a-8f5147da0b7d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:810529b5-3ce0-40d1-b5e4-067405965f02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LIBTAYO is a programmed death receptor-1 (PD-1) blocking antibody indicated: Cutaneous Squamous Cell Carcinoma (CSCC) for the treatment of patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation. ( 1.1 ) Basal Cell Carcinoma (BCC) for the treatment of patients with locally advanced or metastatic BCC (laBCC or mBCC) who have been previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate. ( 1.2 ) Non-Small Cell Lung Cancer (NSCLC) in combination with platinum-based chemotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations and is: locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or metastatic. ( 1.3 ) as single agent for the first-line treatment of adult patients with NSCLC whose tumors have high PD-L1 expression [Tumor Proportion Score (TPS) ≥ 50%] as determined by an FDA-approved test, with no EGFR, ALK or ROS1 aberrations, and is: locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or metastatic. ( 1.3 , 2.1 ) uuid:0153bbfc-b525-448f-8275-86bb2ed68d67 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6QVL057INT biolink:treats MONDO:0020804 PMID:41385096 "[{""id"":""uuid:f73802a8-8747-4856-82b8-8250fa359988"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:080049bc-6b58-466a-a3a8-b285e589c0b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:eb9a5a51-b3be-43b9-b116-5324cbafefd6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/libtayo""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] LIBTAYO is a programmed death receptor-1 (PD-1) blocking antibody indicated: Cutaneous Squamous Cell Carcinoma (CSCC) for the treatment of patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation. ( 1.1 ) Basal Cell Carcinoma (BCC) for the treatment of patients with locally advanced or metastatic BCC (laBCC or mBCC) who have been previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate. ( 1.2 ) Non-Small Cell Lung Cancer (NSCLC) in combination with platinum-based chemotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations and is: locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or metastatic. ( 1.3 ) as single agent for the first-line treatment of adult patients with NSCLC whose tumors have high PD-L1 expression [Tumor Proportion Score (TPS) ≥ 50%] as determined by an FDA-approved test, with no EGFR, ALK or ROS1 aberrations, and is: locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or metastatic. ( 1.3 , 2.1 )|[EMA] Cutaneous Squamous Cell CarcinomaLibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mCSCC or laCSCC) who are not candidates for curative surgery or curative radiation.Basal Cell CarcinomaLibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (laBCC or mBCC) who have progressed on or are intolerant to a hedgehog pathway inhibitor (HHI).Non-Small Cell Lung CancerLibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 (in ≥ 50% tumour cells), with no EGFR, ALK or ROS1 aberrations, who have:locally advanced NSCLC who are not candidates for definitive chemoradiation, ormetastatic NSCLC.Libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with NSCLC expressing PD-L1 (in ≥ 1% of tumour cells), with no EGFR, ALK or ROS1 aberrations, who have:locally advanced NSCLC who are not candidates for definitive chemoradiation, ormetastatic NSCLC.Cervical CancerLibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy. uuid:7813a54a-5db3-4703-b10e-1681627ef444 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6QVL057INT biolink:treats UMLS:C4745056 PMID:41385096 "[{""id"":""uuid:f1904b08-f649-4450-87a0-bc2e174d1b95"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e37629e4-89e8-4335-a425-af7f4b07a8d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LIBTAYO is a programmed death receptor-1 (PD-1) blocking antibody indicated: Cutaneous Squamous Cell Carcinoma (CSCC) for the treatment of patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation. ( 1.1 ) Basal Cell Carcinoma (BCC) for the treatment of patients with locally advanced or metastatic BCC (laBCC or mBCC) who have been previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate. ( 1.2 ) Non-Small Cell Lung Cancer (NSCLC) in combination with platinum-based chemotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations and is: locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or metastatic. ( 1.3 ) as single agent for the first-line treatment of adult patients with NSCLC whose tumors have high PD-L1 expression [Tumor Proportion Score (TPS) ≥ 50%] as determined by an FDA-approved test, with no EGFR, ALK or ROS1 aberrations, and is: locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or metastatic. ( 1.3 , 2.1 ) uuid:93ab4b96-32ff-4cf3-9288-62bf197aa125 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6QVL057INT biolink:treats UMLS:C1304306 PMID:41385096 "[{""id"":""uuid:e2afffd6-7042-42a7-a3d2-028fd772587c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3346ce7c-14af-4a4c-b68c-f3c2738f0009"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LIBTAYO is a programmed death receptor-1 (PD-1) blocking antibody indicated: Cutaneous Squamous Cell Carcinoma (CSCC) for the treatment of patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation. ( 1.1 ) Basal Cell Carcinoma (BCC) for the treatment of patients with locally advanced or metastatic BCC (laBCC or mBCC) who have been previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate. ( 1.2 ) Non-Small Cell Lung Cancer (NSCLC) in combination with platinum-based chemotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations and is: locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or metastatic. ( 1.3 ) as single agent for the first-line treatment of adult patients with NSCLC whose tumors have high PD-L1 expression [Tumor Proportion Score (TPS) ≥ 50%] as determined by an FDA-approved test, with no EGFR, ALK or ROS1 aberrations, and is: locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or metastatic. ( 1.3 , 2.1 ) uuid:094bf808-6260-454b-ad09-e59569ade636 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6QVL057INT biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:4f5f271c-848d-414c-8d93-04fa8f6f023f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:cabe4422-1bfb-4aa0-8593-d89551459594"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:dcad2427-4327-4bbe-bf72-5b3a6d5b7be3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/libtayo""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] LIBTAYO is a programmed death receptor-1 (PD-1) blocking antibody indicated: Cutaneous Squamous Cell Carcinoma (CSCC) for the treatment of patients with metastatic cutaneous squamous cell carcinoma (mCSCC) or locally advanced CSCC (laCSCC) who are not candidates for curative surgery or curative radiation. ( 1.1 ) Basal Cell Carcinoma (BCC) for the treatment of patients with locally advanced or metastatic BCC (laBCC or mBCC) who have been previously treated with a hedgehog pathway inhibitor or for whom a hedgehog pathway inhibitor is not appropriate. ( 1.2 ) Non-Small Cell Lung Cancer (NSCLC) in combination with platinum-based chemotherapy for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) with no EGFR, ALK or ROS1 aberrations and is: locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or metastatic. ( 1.3 ) as single agent for the first-line treatment of adult patients with NSCLC whose tumors have high PD-L1 expression [Tumor Proportion Score (TPS) ≥ 50%] as determined by an FDA-approved test, with no EGFR, ALK or ROS1 aberrations, and is: locally advanced where patients are not candidates for surgical resection or definitive chemoradiation or metastatic. ( 1.3 , 2.1 )|[EMA] Cutaneous Squamous Cell CarcinomaLibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mCSCC or laCSCC) who are not candidates for curative surgery or curative radiation.Basal Cell CarcinomaLibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (laBCC or mBCC) who have progressed on or are intolerant to a hedgehog pathway inhibitor (HHI).Non-Small Cell Lung CancerLibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 (in ≥ 50% tumour cells), with no EGFR, ALK or ROS1 aberrations, who have:locally advanced NSCLC who are not candidates for definitive chemoradiation, ormetastatic NSCLC.Libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with NSCLC expressing PD-L1 (in ≥ 1% of tumour cells), with no EGFR, ALK or ROS1 aberrations, who have:locally advanced NSCLC who are not candidates for definitive chemoradiation, ormetastatic NSCLC.Cervical CancerLibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy. uuid:5190f257-3343-483a-8f44-8449c5450aec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:94435 biolink:treats MONDO:0100135 PMID:41385096 "[{""id"":""uuid:68a2291b-3411-4b6a-b3d5-cd98b8d30ea4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4eec7a5e-0538-4b4c-bda1-bc8e748be652"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9e997403-2a04-4bc5-aed0-96dd1ff93282"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/diacomit""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] DIACOMIT is indicated for the treatment of seizures associated with Dravet syndrome (DS) in patients taking clobazam who are 6 months of age and older and weighing 7 kg or more. There are no clinical data to support the use of DIACOMIT as monotherapy in Dravet syndrome.|[EMA] Diacomit is indicated for use in conjunction with clobazam and valproate as adjunctive therapy of refractory generalized tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy (SMEI, Dravet's syndrome) whose seizures are not adequately controlled with clobazam and valproate. uuid:fda5912d-c2d7-4e98-b6d7-d9c1feb6de52 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9RV78Q2002 biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:990f8e61-77a0-47d2-a0f1-dbe810999d08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bd64ef18-f54a-433d-a7ad-ad7c8f456112"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2f590c3e-0ce4-4cb7-baaf-e4650fcaf7af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/entyvio""]},{""id"":""uuid:693359bf-d6ba-4c1d-b6ae-12da6e6dd800"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENTYVIO is indicated in adults for the treatment of: moderately to severely active ulcerative colitis (UC). moderately to severely active Crohn's disease (CD).|[EMA] Ulcerative colitisEntyvio is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor alpha (TNFα) antagonist.Crohn’s diseaseEntyvio is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor alpha (TNFα) antagonist.PouchitisEntyvio is indicated for the treatment of adult patients with moderately to severely active chronic pouchitis, who have undergone proctocolectomy and ileal pouch anal anastomosis for ulcerative colitis, and have had an inadequate response with or lost response to antibiotic therapy.|[PMDA] A drug with a new active ingredient indicated for the treatment and maintenance therapy of moderate to severe ulcerative colitis (for use only in patients who have not sufficiently responded to conventional treatments). uuid:80bfba90-819b-4baa-9671-0c642f4f4fd7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9RV78Q2002 biolink:treats MONDO:0005011 PMID:41385096 "[{""id"":""uuid:dbdf8bbc-2739-4eca-9a16-45308c26f436"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6ae2e2ca-00c9-4689-b6f7-c7abb3e92303"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:84e78bd1-0925-4984-8541-d7debf984697"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/entyvio""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENTYVIO is indicated in adults for the treatment of: moderately to severely active ulcerative colitis (UC). moderately to severely active Crohn's disease (CD).|[EMA] Ulcerative colitisEntyvio is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor alpha (TNFα) antagonist.Crohn’s diseaseEntyvio is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor alpha (TNFα) antagonist.PouchitisEntyvio is indicated for the treatment of adult patients with moderately to severely active chronic pouchitis, who have undergone proctocolectomy and ileal pouch anal anastomosis for ulcerative colitis, and have had an inadequate response with or lost response to antibiotic therapy. uuid:e6035221-019f-45b1-b3c7-c7a2eac81df8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60311 biolink:treats MONDO:0005397 PMID:41385096 "[{""id"":""uuid:dcae4b1f-7074-4373-abdb-0e9be75b3e1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a59f6879-bd86-4eff-a0b5-67c22c781a4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thyroid Tablets are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (see WARNINGS ). 2. As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto’s), multinodular goiter, and in the management of thyroid cancer. PUBCHEM.COMPOUND:53462828 uuid:32b879d2-a07f-4613-9539-5f924a0d9c1a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:36161 biolink:treats MONDO:0008294 PMID:41385096 "[{""id"":""uuid:b9ff7185-2963-4c09-851f-1c8a832df1a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:228fc55f-c06c-432b-aee1-f7a4e8b2fdfa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:10ce4854-fcf8-4568-b1bf-30a586bdb12c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PANHEMATIN is a hemin for injection indicated for the amelioration of recurrent attacks of acute intermittent porphyria temporally related to the menstrual cycle in susceptible women, after initial carbohydrate therapy is known or suspected to be inadequate. Limitations of Use • Before administering PANHEMATIN, consider an appropriate period of carbohydrate loading (i.e., 400 g glucose/day for 1 to 2 days) [See Dosage and Administration ( 2.1 )] . • Attacks of porphyria may progress to a point where irreversible neuronal damage has occurred. PANHEMATIN therapy is intended to prevent an attack from reaching the critical stage of neuronal degeneration. PANHEMATIN is not effective in repairing neuronal damage.|[PMDA] A drug with a new active ingredient indicated for the improvement of symptoms of acute attack in patients with acute porphyria. [Orphan drug] uuid:d9904d5a-4bc9-4846-868e-96f551a23dc4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2J3H5C81A5 biolink:treats MONDO:0005388 PMID:41385096 "[{""id"":""uuid:499c987a-d6bb-41bb-a539-d612723f442a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d25f033a-f9cb-4916-b92e-5bd760ce39c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IQIRVO is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have had an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA. This indication is approved under accelerated approval based on reduction of alkaline phosphatase (ALP) [see Clinical Studies (14) ] . Improvement in survival or prevention of liver decompensation events have not been demonstrated. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). uuid:44bd19bc-c255-4362-beeb-fe643036a813 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2J3H5C81A5 biolink:treats MONDO:0007193 PMID:41385096 "[{""id"":""uuid:e9bfa865-914f-436e-ac4b-22e8b3077e4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:439fb4f8-77cf-49dd-be18-5bd94cd66dae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IQIRVO is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have had an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA. This indication is approved under accelerated approval based on reduction of alkaline phosphatase (ALP) [see Clinical Studies (14) ] . Improvement in survival or prevention of liver decompensation events have not been demonstrated. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). uuid:3894c6ce-74cb-4dcd-8639-3b8235c97449 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats UMLS:C0554628 PMID:41385096 "[{""id"":""uuid:93415ea9-c75d-4b63-b428-15bd7594f843"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d555bef3-2807-433b-aeed-75c0ea730680"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lentocilin S is indicated for the treatment of the following infections in adults and children: - Upper respiratory tract infections, namely group A streptococcal infections - Primary and secondary syphilis - Latent syphilis - Tertiary syphilis (in adults) - Congenital syphilis (in children) - Yaws - Bejel - Pinta Lentocilin S is also indicated prophylactically in the following situations: - Rheumatic fever - Diphtheria (including elimination of the asymptomatic carrier state) Consideration should be given to official guidelines for appropriate use of antimicrobial agents. CHEBI:18208 uuid:a5c8c785-0a49-4a7b-8ca1-39b3f4a021bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0002896 PMID:41385096 "[{""id"":""uuid:8b0729ef-eca1-437c-8567-f0ffb6247e9a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8b6c65e8-86b4-45b7-a68b-451ccc27e3e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lentocilin S is indicated for the treatment of the following infections in adults and children: - Upper respiratory tract infections, namely group A streptococcal infections - Primary and secondary syphilis - Latent syphilis - Tertiary syphilis (in adults) - Congenital syphilis (in children) - Yaws - Bejel - Pinta Lentocilin S is also indicated prophylactically in the following situations: - Rheumatic fever - Diphtheria (including elimination of the asymptomatic carrier state) Consideration should be given to official guidelines for appropriate use of antimicrobial agents. CHEBI:18208 uuid:5e088acf-71bc-49cc-98d5-bde3827f36fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0002897 PMID:41385096 "[{""id"":""uuid:210fde8e-a676-4bd9-994e-ec638f8fc2e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bea74773-ed61-4c95-9c3e-be5b595f68d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lentocilin S is indicated for the treatment of the following infections in adults and children: - Upper respiratory tract infections, namely group A streptococcal infections - Primary and secondary syphilis - Latent syphilis - Tertiary syphilis (in adults) - Congenital syphilis (in children) - Yaws - Bejel - Pinta Lentocilin S is also indicated prophylactically in the following situations: - Rheumatic fever - Diphtheria (including elimination of the asymptomatic carrier state) Consideration should be given to official guidelines for appropriate use of antimicrobial agents. CHEBI:18208 uuid:0d13bc27-e99c-4851-8bad-d4b8a31c6d6b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0005822 PMID:41385096 "[{""id"":""uuid:64f8176c-c7b4-4294-a56e-293f31099614"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bd2e2e84-737f-4937-a22d-2189f2466beb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lentocilin S is indicated for the treatment of the following infections in adults and children: - Upper respiratory tract infections, namely group A streptococcal infections - Primary and secondary syphilis - Latent syphilis - Tertiary syphilis (in adults) - Congenital syphilis (in children) - Yaws - Bejel - Pinta Lentocilin S is also indicated prophylactically in the following situations: - Rheumatic fever - Diphtheria (including elimination of the asymptomatic carrier state) Consideration should be given to official guidelines for appropriate use of antimicrobial agents. CHEBI:18208 uuid:93e6b1e5-754d-48fd-9a5c-bb1dfcef5c0c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0004497 PMID:41385096 "[{""id"":""uuid:1b61a4c6-41f8-46f9-8166-eee71fca04ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5d2793b2-d344-4b86-b8ac-ca627483a5ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lentocilin S is indicated for the treatment of the following infections in adults and children: - Upper respiratory tract infections, namely group A streptococcal infections - Primary and secondary syphilis - Latent syphilis - Tertiary syphilis (in adults) - Congenital syphilis (in children) - Yaws - Bejel - Pinta Lentocilin S is also indicated prophylactically in the following situations: - Rheumatic fever - Diphtheria (including elimination of the asymptomatic carrier state) Consideration should be given to official guidelines for appropriate use of antimicrobial agents. CHEBI:18208 uuid:14366549-497e-4ca6-89fa-9f9b9d1cbfff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0005714 PMID:41385096 "[{""id"":""uuid:625d885a-8cb1-4df7-97c4-62ffd56f4f8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ff1c6711-99d3-45d4-b403-624386b39ca6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lentocilin S is indicated for the treatment of the following infections in adults and children: - Upper respiratory tract infections, namely group A streptococcal infections - Primary and secondary syphilis - Latent syphilis - Tertiary syphilis (in adults) - Congenital syphilis (in children) - Yaws - Bejel - Pinta Lentocilin S is also indicated prophylactically in the following situations: - Rheumatic fever - Diphtheria (including elimination of the asymptomatic carrier state) Consideration should be given to official guidelines for appropriate use of antimicrobial agents. CHEBI:18208 uuid:4017552e-a194-42d3-ad2d-3ce1a7bf5092 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:LR3UXN0193 biolink:treats MONDO:0020725 PMID:41385096 "[{""id"":""uuid:7a025462-84ef-4b40-8632-6641b31547ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f67e9796-7621-439b-a363-010b1f0f9e0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:8ff51fbc-d06d-47bf-9259-fde061536c95"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/mircera""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mircera is an erythropoiesis-stimulating agent (ESA) indicated for the treatment of anemia associated with chronic kidney disease (CKD) in: • adult patients on dialysis and adult patients not on dialysis ( 1.1 ). • pediatric patients 3 months to 17 years of age on dialysis or not on dialysis who are converting from another ESA after their hemoglobin level was stabilized with an ESA ( 1.1 ). Limitations of Use Mircera is not indicated and is not recommended for use: • In the treatment of anemia due to cancer chemotherapy ( 5.2 ). • As a substitute for RBC transfusions in patients who require immediate correction of anemia ( 12.2 ). Mircera has not been shown to improve quality of life, fatigue, or patient well-being.|[EMA] Treatment of symptomatic anaemia associated with chronic kidney disease (CKD) in adult patients (see section 5.1).Treatment of symptomatic anaemia associated with chronic kidney disease (CKD) in paediatric patients from 3 months to less than 18 years of age who are converting from another erythropoiesis stimulating agent (ESA) after their haemoglobin level was stabilised with the previous ESA (see section 5.1). uuid:3cb070c9-3403-404c-b485-d5dc42c73687 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:F60NE4XB53 biolink:treats MONDO:0018881 PMID:41385096 "[{""id"":""uuid:af759e9c-582b-4aa6-b58f-0ac55eee12a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0d3d2b27-d90f-4bae-ae3e-6f2301f6822e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RYTELO is indicated for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA). uuid:046989e6-fb0b-4bc9-9c12-0982c7a62eb8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18243 biolink:treats HP:0031275 PMID:41385096 "[{""id"":""uuid:8e71b102-4f08-487c-a62b-e6b61918b2b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ff4e1dc0-c734-44b1-af99-8abaeb0f6794"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dopamine HCl Injection is indicated to improve hemodynamic status in patients in distributive shock or shock due to reduced cardiac output. uuid:354aef65-2a1d-468a-b8dc-57524776e866 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0021632 PMID:41385096 "[{""id"":""uuid:f83ab079-28bb-425c-b42e-5ee0bbe5d390"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fd699190-57eb-440f-9bea-7013ea6fffba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, and the strength, dosage form and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of methylprednisolone sodium succinate for injection, USP is indicated as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases : For the palliative management of leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases : Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus. uuid:8370c74d-afa6-49b2-b0ad-1fd86ee9fda8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:1040026 PMID:41385096 "[{""id"":""uuid:ee346444-8949-4b59-b3f9-e5a6b67f21e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:195f8b34-0e08-4ace-84fb-c4313a8dad38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, and the strength, dosage form and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of methylprednisolone sodium succinate for injection, USP is indicated as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases : For the palliative management of leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases : Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus. uuid:3eef2ada-1943-45de-8857-3462e0acf261 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3207 biolink:treats MONDO:0005342 PMID:41385096 "[{""id"":""uuid:6edf86c3-7f23-4f36-adf7-dce6bd6e756c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ddce62ac-04f4-4f16-a1d0-5c52f2a9c9c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ebcfcbf1-4ded-48a9-8923-56b44fced320"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TARPEYO is indicated to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression.|[EMA] Kinpeygo is indicated for the treatment of primary immunoglobulin A (IgA) nephropathy (IgAN) in adults at risk of rapid disease progression with a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/gram. uuid:5c37a114-4ae7-4721-995d-0295598344fa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3207 biolink:treats MONDO:0008072 PMID:41385096 "[{""id"":""uuid:4bda8a3b-b3c4-4428-9d77-4468c879a6c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:692a8c90-5863-4eaf-bd4e-9c1fd4b04009"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TARPEYO is indicated to reduce the loss of kidney function in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression. uuid:ee7ecabc-01bb-4609-91d8-ff79ec819096 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:54681908 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:fe20bc12-980a-49f2-a6ae-9b48f0468274"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:32273566-56b4-4e86-b6bb-9e19abd137b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SEYSARA ® (sarecycline) tablet, is indicated for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older. Limitations of Use Efficacy of SEYSARA beyond 12 weeks and safety beyond 12 months have not been established. SEYSARA has not been evaluated in the treatment of infections [see Clinical Studies ( 14 )] . To reduce the development of drug-resistant bacteria as well as to maintain the effectiveness of other antibacterial drugs, SEYSARA should be used only as indicated [see Warnings and Precautions ( 5.6 )] . uuid:9fcec4fa-e458-465c-a13a-a29db3cc51d4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:17276 biolink:treats MONDO:0003019 PMID:41385096 "[{""id"":""uuid:6d697a2c-7e08-48d3-8715-31e62fbc2141"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9973f3ea-b88c-4252-9e4a-dd243fe1d3d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone, an ingredient of spironolactone and hydrochlorothiazide tablets, has been shown to be a tumorigen in chronic toxicity studies in rats (see PRECAUTIONS section). Spironolactone and hydrochlorothiazide tablets should be used only in those conditions described below. Unnecessary use of this drug should be avoided. Spironolactone and hydrochlorothiazide tablets are indicated for: Edematous conditions for patients with: Congestive heart failure: For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures; The treatment of diuretic-induced hypokalemia in patients with congestive heart failure when other measures are considered inappropriate; The treatment of patients with congestive heart failure taking digitalis when other therapies are considered inadequate or inappropriate. Cirrhosis of the liver accompanied by edema and/or ascites: Aldosterone levels may be exceptionally high in this condition. Spironolactone and hydrochlorothiazide tablets are indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. The nephrotic syndrome: For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response. Essential hypertension: For patients with essential hypertension in whom other measures are considered inadequate or inappropriate; In hypertensive patients for the treatment of a diuretic-induced hypokalemia when other measures are considered inappropriate; Spironolactone and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the classes to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with spironolactone and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. uuid:0e8934cb-8c00-470b-a1ae-9c8faf54ed37 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3219 biolink:treats MONDO:0008575 PMID:41385096 "[{""id"":""uuid:be78bce5-95de-402f-8e02-0310d009bee0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:92cbeebb-f0c1-4d27-8242-b019a4cfd76d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bupropion Hydrochloride Extended-Release Tablets (SR) are indicated as an aid to smoking cessation treatment. uuid:4afb07e5-bcd5-49a8-8435-d16e8b5647f7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18145 biolink:treats MONDO:0024298 PMID:41385096 "[{""id"":""uuid:700fb53e-6d8a-4ca5-a4ad-f64ad0228dc9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:283ff1a0-8613-424a-b3c4-17d77fba097b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Supplementation of the diet with ten essential vitamins. Supplementation of the diet with fluoride for caries prophylaxis. Multivitamin with Fluoride 0.25 mg Chewable Tablets provide 0.25 mg fluoride in tablet form for children 4-6years of age in areas where the drinking water contains 0.3 through 0.6 ppm of fluoride. Multivitamin with Fluoride 0.25 mg Chewable Tablets supply significant amounts of Vitamins A, C, D, E, thiamine, riboflavin, niacin, vitamin B6, vitamin B12, and folate to supplement the diet, and to help assure that nutritional deficiencies of these vitamins will not develop. Thus, in a single easy-to-use preparation, children obtain ten essential vitamins and the important mineral, fluoride. The American Academy of Pediatrics recommends that children up to age 16, in areas where drinking water contains less than optimal levels of fluoride, receive daily fluoride supplements. Children using Multivitamin with Fluoride 0 . 25 mg Chewable Tablets regularly should receive semiannual dental examinations. The regular brushing of teeth and attention to good oral hygiene practices are also essential. Multivitamin with Fluoride Chewable Tablets is a prescription product for the clinical dietary management of the metabolic processes of caries prophylaxis and provides supplementation of the diet with ten essential vitamins. uuid:4fb5d956-1b10-4eec-aebf-e47629f14e8c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229230 biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:12ec0663-e395-441b-a637-8ae55607326b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:146ff022-1e9f-46fa-b3a3-1963a449ff49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VELSIPITY is indicated for the treatment of moderately to severely active ulcerative colitis (UC) in adults. uuid:8f5d76dd-d9e4-4366-9241-7e5a84999973 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:129073603 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:12388b54-d161-4ce8-9846-5883014be440"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2682664f-f2be-4a61-84c8-a3b07ee392c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c8c0b8e5-d8b9-4b63-86c5-d6c8422549f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/gavreto""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] GAVRETO is a kinase inhibitor indicated for treatment of: Adult patients with metastatic rearranged during transfection (RET ) fusion-positive non-small cell lung cancer as detected by an FDA approved test (NSCLC). ( 1.1 ) Adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). ( 1.2 )|[EMA] Gavreto is indicated as monotherapy for the treatment of adult patients with rearranged during transfection (RET) fusion-positive advanced non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitor. uuid:30546e23-9880-4789-86e2-5e45af2ee1a1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:129073603 biolink:treats MONDO:0002108 PMID:41385096 "[{""id"":""uuid:c65126f8-e8a4-4a9a-b385-c7574bb5b845"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ade042e3-d098-48f6-9682-61f442eec1f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] GAVRETO is a kinase inhibitor indicated for treatment of: Adult patients with metastatic rearranged during transfection (RET ) fusion-positive non-small cell lung cancer as detected by an FDA approved test (NSCLC). ( 1.1 ) Adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). ( 1.2 ) uuid:1eca7f75-050d-4da1-bf71-02d2a36c3bb3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71193 biolink:treats MONDO:0004995 PMID:41385096 "[{""id"":""uuid:0b8d37d1-4e65-41a2-9791-1dc68e12f687"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8de190ff-1294-4cf0-976c-3830643d728a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Liraglutide is indicated: • as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus, • to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease. Limitations of Use : Liraglutide should not be used in patients with type 1 diabetes mellitus. Liraglutide contains liraglutide and should not be coadministered with other liraglutide-containing products. uuid:c1000601-4b6d-461f-aff2-0879e75b3b42 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135720 biolink:treats MONDO:0010679 PMID:41385096 "[{""id"":""uuid:60e50770-bece-4822-9193-8b1426beea46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:22aec04c-d6c2-4687-8254-75f73f993068"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Deflazacort tablets are indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older. Additional pediatric use information is approved for PTC Therapeutics, Inc.'s Emflaza TM (deflazacort) tablets. However, due to PTC Therapeutics, Inc.'s marketing exclusivity rights, this drug product is not labeled with that information . uuid:4635f46f-850f-4752-80eb-ded1c404900d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135948 biolink:treats MONDO:0018556 PMID:41385096 "[{""id"":""uuid:253c3d0d-eb94-4d89-b50b-d1bf5ffd666b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:99983a11-d84d-4b24-b4a8-4d06f7a43210"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4ca0651b-9c29-428f-9124-9a3f2c3f2fff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/firdapse""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] FIRDAPSE ® is indicated for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults and pediatric patients 6 years of age and older.|[EMA] Symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adults. uuid:784d4af2-293a-4db2-8267-ea2c326800ff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2359277 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:203ee96f-4de2-480c-b2d2-cd8ee89bdff8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5e4d3631-0a61-462a-b38b-82c2a6423c86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRIJARDY XR is a combination of empagliflozin, linagliptin, and metformin hydrochloride (HCl) indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus . Empagliflozin is indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease [see Clinical Studies (14.2) ] . uuid:ff69d495-37e9-4f33-bbe6-d931c3f2af2f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2359277 biolink:treats MONDO:0004995 PMID:41385096 "[{""id"":""uuid:bbacbaf5-cd01-437a-a5a6-f9ba764976d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eaee4464-97f4-4e09-9f64-32e40eb838e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRIJARDY XR is a combination of empagliflozin, linagliptin, and metformin hydrochloride (HCl) indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus . Empagliflozin is indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease [see Clinical Studies (14.2) ] . uuid:9765d864-04df-437f-901a-c04f458494ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:1351PE5UGS biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:52e34f7b-bebc-4e5a-82f5-3fbe82cf7b4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:edb69583-c43a-456c-a5bc-f27494732907"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:87cbd4fb-f7d6-4ea3-b48d-add3507fda2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/empliciti""]},{""id"":""uuid:9c28eb80-ca0f-4d72-87dd-97b1f527ae5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] • EMPLICITI is indicated in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one to three prior therapies. • EMPLICITI is indicated in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.|[EMA] Empliciti is indicated in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in adult patients who have received at least one prior therapy (see sections 4.2 and 5.1).|[PMDA] Drugs with a new active ingredient indicated for the treatment of relapsed or refractory multiple myeloma. [Orphan drug] uuid:03a2d879-a860-42bd-a8f3-98c64ec8fa8e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C4534619 biolink:treats MONDO:0005326 PMID:41385096 "[{""id"":""uuid:60ab3955-2614-47bb-8561-56a71da92b51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:935bbb5b-060c-43ae-8ed2-438610c18297"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] helps prevent sunburn if used as directed with other sun protection measures (see Directions ), decreases the risk of skin cancer and early skin aging caused by the sun uuid:1452b5a7-16a9-4796-8f6b-c0f30c71a5a1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0005631 PMID:41385096 "[{""id"":""uuid:d3c786ce-32ec-48e6-9104-7d2e9a2a6a41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f0e26107-3ebb-496b-b9db-979e6d8df75e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy Penicillin G Potassium for Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Potassium for Injection, USP may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below; however, once these results become available, appropriate therapy should be continued. Clinical Indication Infecting Organism Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C,H,G,L and M, Streptococcus pneumoniae and Staphylococcus species (non-penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico-facial disease and thoracic and abdominal disease) Actinomyces israelii Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopathiae Fusospirochetosis (severe infections of the oropharynx [Vincent’s], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococcal meningitis and / or septicemia Neisseria meningitidis Gram-negative bacillary infections (bacteremias) Penicillin G is not the drug of choice in the treatment of gram-negative bacillary infections . Gram -negative bacillary organisms (i.e. Enterobacteriaceae) To reduce the development of drug-resistant bacteria and maintain effectiveness of Penicillin G Potassium for Injection, USP and other antibacterial drugs, Penicillin G Potassium for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. CHEBI:18208 uuid:85725c19-6611-4ad7-aadc-e9a8a4e2efb8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats UMLS:C0039978 PMID:41385096 "[{""id"":""uuid:c74ad6aa-2f73-4420-99b4-7ad35883a84c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d3f2d862-46e4-451f-9f1b-ef33ba64bc38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy Penicillin G Potassium for Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Potassium for Injection, USP may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below; however, once these results become available, appropriate therapy should be continued. Clinical Indication Infecting Organism Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C,H,G,L and M, Streptococcus pneumoniae and Staphylococcus species (non-penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico-facial disease and thoracic and abdominal disease) Actinomyces israelii Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopathiae Fusospirochetosis (severe infections of the oropharynx [Vincent’s], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococcal meningitis and / or septicemia Neisseria meningitidis Gram-negative bacillary infections (bacteremias) Penicillin G is not the drug of choice in the treatment of gram-negative bacillary infections . Gram -negative bacillary organisms (i.e. Enterobacteriaceae) To reduce the development of drug-resistant bacteria and maintain effectiveness of Penicillin G Potassium for Injection, USP and other antibacterial drugs, Penicillin G Potassium for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. CHEBI:18208 uuid:ba79ad50-5219-4333-833f-870a18726d97 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0006865 PMID:41385096 "[{""id"":""uuid:cb5703c6-83a8-48a2-86de-383003752335"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8f60b7b4-921b-4950-98fe-cee65975de6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy Penicillin G Potassium for Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Potassium for Injection, USP may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below; however, once these results become available, appropriate therapy should be continued. Clinical Indication Infecting Organism Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C,H,G,L and M, Streptococcus pneumoniae and Staphylococcus species (non-penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico-facial disease and thoracic and abdominal disease) Actinomyces israelii Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopathiae Fusospirochetosis (severe infections of the oropharynx [Vincent’s], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococcal meningitis and / or septicemia Neisseria meningitidis Gram-negative bacillary infections (bacteremias) Penicillin G is not the drug of choice in the treatment of gram-negative bacillary infections . Gram -negative bacillary organisms (i.e. Enterobacteriaceae) To reduce the development of drug-resistant bacteria and maintain effectiveness of Penicillin G Potassium for Injection, USP and other antibacterial drugs, Penicillin G Potassium for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. CHEBI:18208 uuid:25d1e7ed-0f0c-48bc-908a-133eebea8262 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17334 biolink:treats MONDO:0004944 PMID:41385096 "[{""id"":""uuid:890214ea-2d30-4d3e-b65a-6ddd07d65a0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d7324fd1-6419-4c09-ac9c-414bd82b518b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapy Penicillin G Potassium for Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the designated microorganisms in the conditions listed below. Appropriate culture and susceptibility tests should be done before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to penicillin G. Therapy with Penicillin G Potassium for Injection, USP may be initiated before results of such tests are known when there is reason to believe the infection may involve any of the organisms listed below; however, once these results become available, appropriate therapy should be continued. Clinical Indication Infecting Organism Septicemia, empyema, pneumonia, pericarditis, endocarditis, meningitis Streptococcus pyogenes (group A β-hemolytic streptococcus), other β-hemolytic streptococci including groups C,H,G,L and M, Streptococcus pneumoniae and Staphylococcus species (non-penicillinase producing strains) Anthrax Bacillus anthracis Actinomycosis (cervico-facial disease and thoracic and abdominal disease) Actinomyces israelii Botulism (adjunctive therapy to antitoxin), gas gangrene, and tetanus (adjunctive therapy to human tetanus immune globulin) Clostridium species Diphtheria (adjunctive therapy to antitoxin and prevention of the carrier state) Corynebacterium diphtheriae Erysipelothrix endocarditis Erysipelothrix rhusiopathiae Fusospirochetosis (severe infections of the oropharynx [Vincent’s], lower respiratory tract and genital area) Fusobacterium species and spirochetes Listeria infections including meningitis and endocarditis Listeria monocytogenes Pasteurella infections including bacteremia and meningitis Pasteurella multocida Haverhill fever Streptobacillus moniliformis Rat bite fever Spirillum minus or Streptobacillus moniliformis Disseminated gonococcal infections Neisseria gonorrhoeae (penicillin-susceptible) Syphilis (congenital and neurosyphilis) Treponema pallidum Meningococcal meningitis and / or septicemia Neisseria meningitidis Gram-negative bacillary infections (bacteremias) Penicillin G is not the drug of choice in the treatment of gram-negative bacillary infections . Gram -negative bacillary organisms (i.e. Enterobacteriaceae) To reduce the development of drug-resistant bacteria and maintain effectiveness of Penicillin G Potassium for Injection, USP and other antibacterial drugs, Penicillin G Potassium for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. CHEBI:18208 uuid:9a35b864-9410-4834-85e4-43257461a680 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:GK1LYB375A biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:1f047d72-5eb5-4f3f-af55-3198211b33f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9715528f-4c03-4a8b-bd21-fb9861c0e13c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:90f4590b-8618-40b6-96dc-0b106569352a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/adtralza""]},{""id"":""uuid:c79f2b35-54b2-42b8-8e55-77b6e8256175"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ADBRY is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and pediatric patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. ADBRY can be used with or without topical corticosteroids.|[EMA] Adtralza is indicated for the treatment of moderate to severe atopic dermatitis in adult and adolescent patients 12 years and older who are candidates for systemic therapy.|[PMDA] A drug with a new active ingredient indicated for the treatment of atopic dermatitis in patients who have not responded sufficiently to conventional treatments. uuid:f5f78920-abfb-4cd8-a9a8-1aa4b242619d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1158330 biolink:treats HP:0000132 PMID:41385096 "[{""id"":""uuid:92bfdc2e-4dac-4982-9d8c-44466a111d35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fce37476-6fa3-4b71-83d8-44e469d699a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] • Natazia is a combination of dienogest , a progestin, and estradiol valerate, an estrogen, indicated for use by females of reproductive potential to prevent pregnancy. ( 1 ) • The efficacy of Natazia in females of reproductive potential with a body mass index (BMI) of >30 kg/m 2 has not been evaluated. ( 1 , 8.8 ) • Treatment of heavy menstrual bleeding in females of reproductive potential without organic pathology who choose to use an oral contraceptive as their method of contraception. ( 1.2 ) uuid:ae5e42f7-a711-42ad-8480-7a23b0c0418a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5418336 biolink:treats MONDO:0100244 PMID:41385096 "[{""id"":""uuid:51d13ef5-fd50-4406-a588-5ba6647960ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fcf3034e-50d2-499d-a68c-fc997a0b6ed7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c07da14d-b49a-4ede-b928-f295d07b43af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PIASKY is indicated for the treatment of adult and pediatric patients 13 years and older with paroxysmal nocturnal hemoglobinuria (PNH) and body weight of at least 40 kg.|[PMDA] A drug with a new active ingredient indicated for the treatment of paroxysmal nocturnal haemoglobinuria. DRUGBANK:DB16128 uuid:f7b058d7-a770-4886-b4ef-4a01f5210550 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9H414A99MD biolink:treats UMLS:C5444038 PMID:41385096 "[{""id"":""uuid:54c13ef4-2565-4531-84e0-ebbb09230c55"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:65fb7192-13d3-4c3e-a8d1-077c6025db99"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Xofigo is indicated for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease. uuid:c159bf2d-6d71-4452-9ebd-1071be9e732f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:188153 biolink:treats HP:0012204 PMID:41385096 "[{""id"":""uuid:be200d62-3f1a-4614-a8e5-4d8a78b2d395"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:057e1965-a810-41c2-8722-c70a331e4a42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VIVJOA ® is an azole antifungal indicated to reduce the incidence of recurrent vulvovaginal candidiasis (RVVC) in females with a history of RVVC who are NOT of reproductive potential. ( 1 ) uuid:e873ba5b-4c4a-4ce2-ad65-05d9ec6c212c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135752 biolink:treats MONDO:0005921 PMID:41385096 "[{""id"":""uuid:9f121eaa-116e-4bf6-a491-40fe20a6b001"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2a848360-3eef-4690-be4e-5919a4360245"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KRINTAFEL is indicated for the radical cure (prevention of relapse) of Plasmodium vivax malaria in patients aged 16 years and older who are receiving chloroquine therapy for acute P. vivax infection [see Dosage and Administration ( 2.2 )] . Limitations of Use • KRINTAFEL is NOT indicated for the treatment of acute P. vivax malaria. • Concomitant use of KRINTAFEL with antimalarials other than chloroquine is not recommended because of the risk of recurrence of P. vivax malaria [see Warnings and Precautions ( 5.6 )] . uuid:79f7b253-2849-4e35-bbe2-4ba077126773 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4W3KFI3TN3 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:0f22e491-7136-4f88-a63e-b62c788e37d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:fe17aeed-5529-4aa3-8101-94f63b59a97b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e38c579c-1052-4917-9be9-60ed93b44352"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/talvey""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] TALVEY is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody. This indication is approved under accelerated approval based on response rate and durability of response [see Clinical Studies (14) ]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).|[EMA] Talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti CD38 antibody and have demonstrated disease progression on the last therapy., uuid:1bf1839b-eaf2-40c2-a57e-62a6a0946103 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90217 biolink:treats MONDO:0018874 PMID:41385096 "[{""id"":""uuid:31c055b7-13f7-45c0-b7d6-9e94bcf03b36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:582944b0-182e-4fd0-9a6c-f8698b0dcc7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:fa2799e1-7b04-4f80-87fa-14ca6746a3c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1f2ab395-089d-4faa-b88a-e18c4a2628fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VANFLYTA is indicated in combination with standard cytarabine and anthracycline induction and cytarabine consolidation, and as maintenance monotherapy following consolidation chemotherapy, for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) that is FLT3 internal tandem duplication (ITD)-positive as detected by an FDA-approved test [see Dosage and Administration (2.1) and Clinical Studies (14) ] .|[EMA] Vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by Vanflyta single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (AML) that is FLT3-ITD positive.|[PMDA] Drugs with a new indication and a new dosage for the treatment of newly diagnosed FLT3-ITD mutation-positive acute myeloid leukemia. [Orphan drug] uuid:bdbe2b85-b09d-4f17-8644-264f1cbd3286 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:94686 biolink:treats MONDO:0011122 PMID:41385096 "[{""id"":""uuid:5ef25849-85b7-40c4-9643-bf252765e4c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5e1f1af5-589e-4ae1-9582-b9bc408ce86d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c4199f2d-17df-46ac-8b0d-7f20f1f76adc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/alli""]}]" infores:medic knowledge_assertion text_mining_agent "[FDA] XENICAL is indicated for obesity management including weight loss and weight maintenance when used in conjunction with a reduced-calorie diet. XENICAL is also indicated to reduce the risk for weight regain after prior weight loss. XENICAL is indicated for obese patients with an initial body mass index (BMI) ≥30 kg/m 2 or ≥27 kg/m 2 in the presence of other risk factors (e.g., hypertension, diabetes, dyslipidemia). Table 1 illustrates body mass index (BMI) according to a variety of weights and heights. The BMI is calculated by dividing weight in kilograms by height in meters squared. For example, a person who weighs 180 lbs and is 5 ' 5 "" would have a BMI of 30. Table 1 Body Mass Index (BMI), kg/m 2 Conversion Factors: Weight in lbs ÷ 2.2 = weight in kilograms (kg) Height in inches × 0.0254 = height in meters (m) 1 foot = 12 inches|[EMA] Alli is indicated for weight loss in adults who are overweight (body mass index, BMI, ≥ 28 kg/m2) and should be taken in conjunction with a mildly hypocaloric, lower-fat diet." uuid:c9a772d2-0a2b-4239-a1cc-dd8870600299 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:94686 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:61a58873-b923-4cde-b289-74207c538fd7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b11bf7e4-e270-46c1-8056-fee81493b3cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] XENICAL is indicated for obesity management including weight loss and weight maintenance when used in conjunction with a reduced-calorie diet. XENICAL is also indicated to reduce the risk for weight regain after prior weight loss. XENICAL is indicated for obese patients with an initial body mass index (BMI) ≥30 kg/m 2 or ≥27 kg/m 2 in the presence of other risk factors (e.g., hypertension, diabetes, dyslipidemia). Table 1 illustrates body mass index (BMI) according to a variety of weights and heights. The BMI is calculated by dividing weight in kilograms by height in meters squared. For example, a person who weighs 180 lbs and is 5 ' 5 "" would have a BMI of 30. Table 1 Body Mass Index (BMI), kg/m 2 Conversion Factors: Weight in lbs ÷ 2.2 = weight in kilograms (kg) Height in inches × 0.0254 = height in meters (m) 1 foot = 12 inches" uuid:e7804bca-cd60-4753-9076-720d0c790c49 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:94686 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:da90f5d0-8659-40da-9905-7855bd37bab2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:efe2d0d8-0e17-4dbf-9e12-7be4e6515b5d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] XENICAL is indicated for obesity management including weight loss and weight maintenance when used in conjunction with a reduced-calorie diet. XENICAL is also indicated to reduce the risk for weight regain after prior weight loss. XENICAL is indicated for obese patients with an initial body mass index (BMI) ≥30 kg/m 2 or ≥27 kg/m 2 in the presence of other risk factors (e.g., hypertension, diabetes, dyslipidemia). Table 1 illustrates body mass index (BMI) according to a variety of weights and heights. The BMI is calculated by dividing weight in kilograms by height in meters squared. For example, a person who weighs 180 lbs and is 5 ' 5 "" would have a BMI of 30. Table 1 Body Mass Index (BMI), kg/m 2 Conversion Factors: Weight in lbs ÷ 2.2 = weight in kilograms (kg) Height in inches × 0.0254 = height in meters (m) 1 foot = 12 inches" uuid:86e49fd2-700b-4116-9540-2fa3c4ae2697 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:94686 biolink:treats HP:0003119 PMID:41385096 "[{""id"":""uuid:f0cc36d8-eaa5-4fa2-9f64-3943f92c093c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bd066004-a318-45ee-9dad-e67003869710"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] XENICAL is indicated for obesity management including weight loss and weight maintenance when used in conjunction with a reduced-calorie diet. XENICAL is also indicated to reduce the risk for weight regain after prior weight loss. XENICAL is indicated for obese patients with an initial body mass index (BMI) ≥30 kg/m 2 or ≥27 kg/m 2 in the presence of other risk factors (e.g., hypertension, diabetes, dyslipidemia). Table 1 illustrates body mass index (BMI) according to a variety of weights and heights. The BMI is calculated by dividing weight in kilograms by height in meters squared. For example, a person who weighs 180 lbs and is 5 ' 5 "" would have a BMI of 30. Table 1 Body Mass Index (BMI), kg/m 2 Conversion Factors: Weight in lbs ÷ 2.2 = weight in kilograms (kg) Height in inches × 0.0254 = height in meters (m) 1 foot = 12 inches" uuid:de4587cc-36d0-4004-b5a4-f6190c18f063 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8M7V7Q6537 biolink:treats MONDO:0010526 PMID:41385096 "[{""id"":""uuid:87c87486-e099-4daa-9017-ecb83b1e5a2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:cb0cafe3-b456-4492-92c2-dd6a965085aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a4599948-1fcd-48ee-b2cd-116259e48d0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/elfabrio""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ELFABRIO is indicated for the treatment of adults with confirmed Fabry disease.|[EMA] Elfabrio is indicated for long-term enzyme replacement therapy in adult patients with a confirmed diagnosis of Fabry disease (deficiency of alpha-galactosidase). uuid:f43b4d7c-f39a-471c-84d1-0edb8e370b28 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90844 biolink:treats MONDO:0015924 PMID:41385096 "[{""id"":""uuid:7464fa0b-7da7-4195-90a6-7659601a96f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a8741811-3efb-4bc4-8b9c-417d40758b2d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0c96498d-0613-4f76-83b4-15ce71613f3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/uptravi""]},{""id"":""uuid:42f6af5f-b57b-4fb1-9b39-92d027ace511"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] UPTRAVI is a prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH. ( 1.1 )|[EMA] Uptravi is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II–III, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies., , Efficacy has been shown in a PAH population including idiopathic and heritable PAH, PAH associated with connective tissue disorders, and PAH associated with corrected simple congenital heart disease.,|[PMDA] Drugs with a new active ingredient indicated for the treatment of pulmonary arterial hypertension. [Orphan drug] uuid:9b1f7196-aebe-46f6-9087-288959dc9369 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9934746 biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:e070d049-977a-4c81-a40c-a76cdb949b20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a59183ab-fca5-42fc-adec-82be76c8c6b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OHTUVAYRE is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients. uuid:3bf23abc-d6b0-4378-9ed1-cb0571120b4b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9934746 biolink:treats MONDO:0011751 PMID:41385096 "[{""id"":""uuid:aa8fe708-4c5c-411e-8e3e-b6fdb26e00c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:776a9af0-e7d6-49c7-802c-b3903a90a002"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OHTUVAYRE is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adult patients. uuid:a452dba5-dd74-42b1-899c-12349b6f5d19 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59560 biolink:treats MONDO:0016543 PMID:41385096 "[{""id"":""uuid:510fb48f-1af0-4128-a8c3-697d6778a23a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9b2ecf03-c133-432a-bcdb-5b878bce5064"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sapropterin dihydrochloride powder for oral solution is indicated to reduce blood phenylalanine (Phe) levels in adult and pediatric patients one month of age and older with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin-(BH4-) responsive Phenylketonuria (PKU). Sapropterin dihydrochloride powder for oral solution is to be used in conjunction with a Phe-restricted diet. uuid:b6e1927d-6a50-40f2-9e5a-9df39597d53a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59560 biolink:treats MONDO:0009861 PMID:41385096 "[{""id"":""uuid:f4b87dc5-731f-41a1-a076-2e87668de946"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3a6d3bbd-d7fb-4e6c-9829-1ce4ebd870c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sapropterin dihydrochloride powder for oral solution is indicated to reduce blood phenylalanine (Phe) levels in adult and pediatric patients one month of age and older with hyperphenylalaninemia (HPA) due to tetrahydrobiopterin-(BH4-) responsive Phenylketonuria (PKU). Sapropterin dihydrochloride powder for oral solution is to be used in conjunction with a Phe-restricted diet. uuid:46b67752-98a3-4b3a-9fda-e1dbb7d8f651 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68551 biolink:treats MONDO:0005052 PMID:41385096 "[{""id"":""uuid:86b355d8-5767-48cd-8c9e-69f7472a6794"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f6d7cfc8-1c10-4664-98a9-05ae37922d42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LINZESS is indicated for the treatment of: • irritable bowel syndrome with constipation (IBS-C) in adults • chronic idiopathic constipation (CIC) in adults • functional constipation (FC) in pediatric patients 6 to 17 years of age uuid:0fb3d199-4fec-42fc-952b-026d271cb56a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68551 biolink:treats UMLS:C0267509 PMID:41385096 "[{""id"":""uuid:ae401537-b801-40e6-93b9-244778260304"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:73b3355a-fab0-45e6-85cd-602699a9d6c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LINZESS is indicated for the treatment of: • irritable bowel syndrome with constipation (IBS-C) in adults • chronic idiopathic constipation (CIC) in adults • functional constipation (FC) in pediatric patients 6 to 17 years of age uuid:5e0f601b-34b1-4216-b879-67abc0ca58b9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68551 biolink:treats UMLS:C0401146 PMID:41385096 "[{""id"":""uuid:b49b7cf6-cee6-4e2f-ae23-8328beebc196"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:be2c2e99-091f-43cf-ab97-f9f92bf613dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LINZESS is indicated for the treatment of: • irritable bowel syndrome with constipation (IBS-C) in adults • chronic idiopathic constipation (CIC) in adults • functional constipation (FC) in pediatric patients 6 to 17 years of age uuid:10f985ae-d752-40c7-8f03-05dec191caee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1546884 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:36b0c780-ef96-430a-92ce-0c0fae8b22cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c6ac5b00-4d07-45b8-bfca-f02cdbcf4145"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRIUMEQ and TRIUMEQ PD are indicated for the treatment of HIV-1 infection in adults and in pediatric patients aged at least 3 months and weighing at least 6 kg. Limitations of Use: TRIUMEQ and TRIUMEQ PD alone are not recommended in patients with resistance‑associated integrase substitutions or clinically suspected integrase strand transfer inhibitor (INSTI) resistance because the dose of dolutegravir in TRIUMEQ and TRIUMEQ PD is insufficient in these subpopulations. See full prescribing information for TIVICAY (dolutegravir). uuid:1c5da6f6-dddd-43f8-9603-540f46b8a8f5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63036 biolink:treats MONDO:0000313 PMID:41385096 "[{""id"":""uuid:47ac4498-3422-4260-baa2-94d4abb381e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:43caf205-afc8-4105-93af-48369b1f5bb7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Potassium phosphates injection is indicated as a source of phosphorus: in intravenous fluids to correct hypophosphatemia in adults and pediatric patients when oral or enteral replacement is not possible, insufficient or contraindicated. for parenteral nutrition in adults and pediatric patients when oral or enteral nutrition is not possible, insufficient or contraindicated. uuid:ac11f765-81e7-4371-9bbc-ee3be15c1a32 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18050 biolink:treats MONDO:0011382 PMID:41385096 "[{""id"":""uuid:5e13797b-e7e2-474b-a86e-9fa7045c6e59"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:254379d8-72ba-4a1d-aab9-51b537f4219f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] L-glutamine is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older. uuid:dda2ad09-7be4-448e-b272-3e1968e4118c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50663 biolink:treats UMLS:C0276353 PMID:41385096 "[{""id"":""uuid:2eb16b9f-4ee6-4433-a6d3-5a73e9890ef7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:beb0ede0-120c-4560-8c73-7bf39a26ca1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RELENZA, an influenza virus neuraminidase inhibitor (NAI), is indicated for: Treatment of acute, uncomplicated influenza type A and B infections in patients aged 7 years and older who have been symptomatic for no more than 2 days. ( 1.1 ) Prophylaxis of influenza in patients aged 5 years and older. ( 1.2 ) Important Limitations of Use: Not recommended for treatment or prophylaxis of influenza in: • Individuals with underlying airways disease. ( 5.1 ) Not proven effective for: • Treatment in individuals with underlying airways disease. ( 1.3 ) • Prophylaxis in nursing home residents. ( 1.3 ) Not a substitute for annual influenza vaccination. ( 1.3 ) Consider available information on influenza drug susceptibility patterns and treatment effects when deciding whether to use RELENZA. ( 1.3 ) uuid:2c5c762f-8192-4ce1-a80d-ce54c9efae6c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1734632 biolink:treats MONDO:0005354 PMID:41385096 "[{""id"":""uuid:4c16fb3f-8c72-42df-89a2-730cd078d5c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:54478ce7-99c4-48df-ac34-e740bc9ac5db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:af288da8-f58c-47d9-a72d-5a5e6e77877a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zepatier""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZEPATIER ® is indicated for the treatment of chronic hepatitis C virus (HCV) genotype 1 or 4 infection in adult and pediatric patients 12 years of age and older or weighing at least 30 kg. ZEPATIER is indicated for use with ribavirin in certain patient populations [see Dosage and Administration (2.2) ] .|[EMA] ZEPATIER is indicated for the treatment of chronic hepatitis C (CHC) in adult and paediatric patients 12 years of age and older who weigh at least 30 kg (see sections 4.2, 4.4 and 5.1).For hepatitis C virus (HCV) genotype-specific activity see sections 4.4 and 5.1. uuid:ac58a043-0f27-4d9c-9b86-c91910fa5cad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5237999 biolink:treats MONDO:0004975 PMID:41385096 "[{""id"":""uuid:442e90d8-0ec8-4789-947b-353d6017af80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4ad3fdff-c1d3-45c6-9765-d3d5c975cb08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KISUNLA TM is indicated for the treatment of Alzheimer's disease. Treatment with KISUNLA should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in the clinical trials. DRUGBANK:DB16647 uuid:d16814b8-6e31-4660-a9c4-99ecc35746d2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5237999 biolink:treats EFO:0007982 PMID:41385096 "[{""id"":""uuid:49f34ab2-3e29-4ce5-9680-83cee50cc130"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3bffcc2b-6563-4291-9717-a88cce5e1b04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KISUNLA TM is indicated for the treatment of Alzheimer's disease. Treatment with KISUNLA should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in the clinical trials. DRUGBANK:DB16647 uuid:133cd068-edf0-4645-a8da-872220d787db biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5237999 biolink:treats UMLS:C3494623 PMID:41385096 "[{""id"":""uuid:6c9f3839-eca6-457b-b847-89f82ec55a27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c742ac56-d39d-4454-87ec-62b6c7d3188a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KISUNLA TM is indicated for the treatment of Alzheimer's disease. Treatment with KISUNLA should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in the clinical trials. DRUGBANK:DB16647 uuid:660cba4a-5e6c-42b5-8f42-307b0d173cbb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1602106 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:97beb5ee-7a32-4b0d-b4d9-752f5f8e93bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bb25107a-9270-4ec6-8ab2-2117201b5091"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b57feb09-c7eb-4aef-b77e-59e15011e05f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/glyxambi""]},{""id"":""uuid:8d8ce14b-6835-46f2-80bd-29bab891bf90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] GLYXAMBI is a combination of empagliflozin and linagliptin indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus . Empagliflozin is indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease [see Clinical Studies (14.2) ] .|[EMA] Glyxambi, fixed dose combination of empagliflozin and linagliptin, is indicated in adults aged 18 years and older with type 2 diabetes mellitus:to improve glycaemic control when metformin and/or sulphonylurea (SU) and one of the monocomponents of Glyxambi do not provide adequate glycaemic control;when already being treated with the free combination of empagliflozin and linagliptin.|[PMDA] New combination drugs indicated for the treatment of type 2 diabetes mellitus (only when a concomitant use of empagliflozin with linagliptin is deemed appropriate). uuid:56d0a237-2ec1-4683-97d9-f9d6e6d2ed64 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1602106 biolink:treats MONDO:0004995 PMID:41385096 "[{""id"":""uuid:d799bbaa-cc24-4c78-9c93-c0c5a2cc6629"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:109f694c-12a3-44c8-9353-4f09b3b7d91d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] GLYXAMBI is a combination of empagliflozin and linagliptin indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus . Empagliflozin is indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease [see Clinical Studies (14.2) ] . uuid:00d47949-aeab-49f6-8b76-876081f9d708 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DE2O63YV8R biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:1d81f20a-5353-4b38-b41a-2966e2e72484"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:459cf467-cd27-40e5-8d56-496e07dbf51f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c7e29e77-d33a-4456-9fb4-768685abe828"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kerendia""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Kerendia is indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D).|[EMA] Kerendia is indicated for the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults. uuid:12543ce2-09de-48ec-9f15-1060fd71da54 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DE2O63YV8R biolink:treats MONDO:0004375 PMID:41385096 "[{""id"":""uuid:d1cdec8d-1d8c-42bd-a339-5a1c38ecbda7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7a3d7675-1637-49ec-b7f3-46e8354db4c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Kerendia is indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D). uuid:82bd83f9-26ec-4e96-9da3-b32322afb3fb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DE2O63YV8R biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:fb213e41-6dc5-46d4-b8ae-d8dbdb4626c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:118f14f8-4306-41ef-991f-d99842eff465"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:885bd7b4-640e-490d-bfb7-898d7507a91e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kerendia""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Kerendia is indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D).|[EMA] Kerendia is indicated for the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults. uuid:9aa6d45c-6330-4077-9a17-ecc5507526e2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DE2O63YV8R biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:85439852-2207-443c-9f1a-5906d637fd8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f9027fda-7645-4739-b5e1-e670dbadbd2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Kerendia is indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D). uuid:dcabaa7d-d531-488d-8329-be069fb06534 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DE2O63YV8R biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:60c3b24f-b0fc-4269-8b98-259546c131c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b2ed5502-a0f8-432e-90f8-6040b39e7e51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Kerendia is indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adult patients with chronic kidney disease (CKD) associated with type 2 diabetes (T2D). uuid:2ad5e1f0-3048-4bfa-b4e8-fe8b7eb877c1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27470 biolink:treats MONDO:0008228 PMID:41385096 "[{""id"":""uuid:29c8f66d-875f-4359-b8b9-ed90e6b552a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0e112b65-cf11-492d-a8e2-b705ca7d22aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Biopar TM delta -FORTE is specifically indicated as a primary and adjunctive treatment in pernicious anemia patients having idiosyncrasy or sensitivity to parenteral administration - or when parental therapy is refused; uuid:3cd0d62c-e727-45b6-818c-8c49ea402a40 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C4687660 biolink:treats MONDO:0008433 PMID:41385096 "[{""id"":""uuid:7ca99c05-fe92-4e0a-bb08-c5c95fb8e872"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:987ac038-5378-4dc5-af6e-c6fea171dc49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IMDELLTRA is indicated for the treatment of adult patients with extensive stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy. This indication is approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). DRUGBANK:DB17256 uuid:68f61e87-ca86-4236-8e39-e34dfeafd85c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3766 biolink:treats MONDO:0005414 PMID:41385096 "[{""id"":""uuid:57b4db6b-a960-4e69-913d-da82eac3c697"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:23b56b89-836f-42b1-80dd-99c255ea3bca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clozapine is an atypical antipsychotic indicated for: Treatment-resistant schizophrenia. Efficacy was established in an active-controlled study. ( 1.1 , 14.1 ) Reducing suicidal behavior in patients with schizophrenia or schizoaffective disorder. Efficacy was established in an active-controlled study. ( 1.2 , 14.2 ) uuid:fef8050c-e62c-40aa-8ab8-6ec6c77c483f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:83353 biolink:treats MONDO:0010526 PMID:41385096 "[{""id"":""uuid:939dd452-c34a-40a0-bacf-e0cd1a1c676a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:37106c51-9bb1-4f45-aef7-bd73329f8698"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:83dc8623-6ab4-4649-b234-28b1c231be67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/fabrazyme""]},{""id"":""uuid:298e48e7-f69a-439d-8304-81ad462d886a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FABRAZYME ® is indicated for the treatment of adult and pediatric patients 2 years of age and older with confirmed Fabry disease.|[EMA] Fabrazyme is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease (α-galactosidase-A deficiency).|[PMDA] Follow-on biologics indicated for the treatment of Fabry disease. uuid:87c0a72f-bba3-430b-9438-1eec5d165c52 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133021 biolink:treats MONDO:0004948 PMID:41385096 "[{""id"":""uuid:761c61df-0114-4ede-80f6-b2bcf04450df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cdc0f412-35f5-46a8-a061-5567b20a499d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:951636e0-c0dd-4f72-b7b3-b59862f98aa7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/venclyxto""]},{""id"":""uuid:d9a8ab5e-48c6-4536-bb02-c51c12f694f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VENCLEXTA is a BCL-2 inhibitor indicated: For the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). ( 1.1 ) In combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. ( 1.2 )|[EMA] Venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) (see section 5.1).Venclyxto in combination with rituximab is indicated for the treatment of adult patients with CLL who have received at least one prior therapy.Venclyxto monotherapy is indicated for the treatment of CLL:- in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B cell receptor pathway inhibitor, or- in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor.Venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy.|[PMDA] Drugs with a new active ingredient indicated for the treatment of relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. uuid:3b54c371-2f1f-4bcc-9254-098ede8393ad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133021 biolink:treats MONDO:0003864 PMID:41385096 "[{""id"":""uuid:33e0a4f6-ddd5-4bbb-a07c-c477c093a501"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:588fbdfe-05ae-456c-9e7a-e0c3265b07e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:55f12f7b-03ff-4bb2-b405-141d4d88f74d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VENCLEXTA is a BCL-2 inhibitor indicated: For the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). ( 1.1 ) In combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. ( 1.2 )|[PMDA] Drugs with a new active ingredient indicated for the treatment of relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. uuid:95a24b0c-d74d-4a08-8049-9118b8fd5b21 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133021 biolink:treats MONDO:0018874 PMID:41385096 "[{""id"":""uuid:83d402ff-959f-4c3f-9a8c-17252278eeb0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b5c075f0-538b-48ad-accf-8437630aa335"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:faf45765-875d-428b-8f2c-9634c2dc3f0f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/venclyxto""]},{""id"":""uuid:9e362e7a-8a39-4dbf-b12a-3090b6cf3573"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VENCLEXTA is a BCL-2 inhibitor indicated: For the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). ( 1.1 ) In combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy. ( 1.2 )|[EMA] Venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) (see section 5.1).Venclyxto in combination with rituximab is indicated for the treatment of adult patients with CLL who have received at least one prior therapy.Venclyxto monotherapy is indicated for the treatment of CLL:- in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B cell receptor pathway inhibitor, or- in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor.Venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy.|[PMDA] Drugs with a new indication and a new dosage for the treatment of acute myeloid leukemia. [Orphan drug] uuid:b4ee59d6-58a3-4cde-9a38-8d4211e19f49 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:F925RR824R biolink:treats MONDO:0004651 PMID:41385096 "[{""id"":""uuid:3cff3ff8-6786-40de-a174-97d897a34dd9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8c2c8194-1a55-47d3-8074-de5059049f3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TPOXX is an inhibitor of the orthopoxvirus VP37 envelope wrapping protein and is indicated for the treatment of human smallpox disease in adults and pediatric patients weighing at least 3 kg. ( 1.1 ) Limitations of Use: The effectiveness of TPOXX for treatment of smallpox disease has not been determined in humans because adequate and well-controlled field trials have not been feasible, and inducing smallpox disease in humans to study the drug’s efficacy is not ethical. ( 1.2 ) TPOXX efficacy may be reduced in immunocompromised patients based on studies demonstrating reduced efficacy in immunocompromised animal models. ( 1.2 ) uuid:49f505a9-246b-40ea-96b1-df440c4c6e2d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:Z633861EIM biolink:treats MONDO:0018570 PMID:41385096 "[{""id"":""uuid:d475da7a-ddf8-4313-8ff3-6a9178aadd41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e90ff25e-d9dc-4a6b-995c-45abc67ce558"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:096020f7-25fd-45c4-bb14-04b31d2ac88a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/strensiq""]},{""id"":""uuid:e590785a-8471-4a55-b911-3664f5ac84e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] STRENSIQ ® is indicated for the treatment of patients with perinatal/infantile- and juvenile-onset hypophosphatasia (HPP).|[EMA] Strensiq is indicated for long-term enzyme replacement therapy in patients with paediatric-onset hypophosphatasia to treat the bone manifestations of the disease.|[PMDA] Drugs with a new active ingredient indicated for the treatment of hypophosphatasia. [Orphan drug] uuid:4bbace9b-f85a-4a72-8df9-8ed29b870258 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:Z633861EIM biolink:treats MONDO:0016605 PMID:41385096 "[{""id"":""uuid:702c76c0-e849-4a11-99ea-58774674d6d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:68e6b099-2349-491c-9c67-3006575d713a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] STRENSIQ ® is indicated for the treatment of patients with perinatal/infantile- and juvenile-onset hypophosphatasia (HPP). uuid:2020647e-b6f8-4e2e-b03c-dd9a32f20133 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229658 biolink:treats MONDO:0006733 PMID:41385096 "[{""id"":""uuid:1bce7144-a748-47c7-9f3d-89ee3bb59fea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fb2ffa7f-c8b2-4381-834a-23abc538aabf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MIEBO ® (perfluorohexyloctane ophthalmic solution) is indicated for the treatment of the signs and symptoms of dry eye disease (DED). uuid:159c104f-7d26-4824-ad67-4b2f6a5a19fe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:K4YTU42T8G biolink:treats MONDO:0800449 PMID:41385096 "[{""id"":""uuid:e067d2a7-68a0-4f94-939d-0c6eb05b0f76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3e3ef0b8-5145-4bcc-b1aa-e73f3a1f9c5d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:102b104e-3c77-433b-b8a6-0a10b4fd10d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kanuma""]},{""id"":""uuid:3f3beda9-0124-4ab3-9092-c35e2254ff79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KANUMA ® is indicated for the treatment of patients with a diagnosis of Lysosomal Acid Lipase (LAL) deficiency.|[EMA] Kanuma is indicated for long-term enzyme replacement therapy (ERT) in patients of all ages with lysosomal acid lipase (LAL) deficiency.|[PMDA] A drug with a new active ingredient indicated for the treatment of lysosomal acid lipase deficiency. [Orphan drug] uuid:9d1d5080-0505-4d03-acb2-8aaee3b131e3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72312 biolink:treats MONDO:0019933 PMID:41385096 "[{""id"":""uuid:52bb354a-1bac-429f-9939-5e7910f4b2be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a457aca6-b312-43db-bcfb-4fc8ad229b30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:8f59f8d6-c9e7-4e19-8f89-be546f3c1cf2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/signifor""]},{""id"":""uuid:72d21f27-9be8-4d0e-8bb8-d2273e983a38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SIGNIFOR LAR is a somatostatin analog indicated for the treatment of: Patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. ( 1.1 ) Patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative. ( 1.2 )|[EMA] Signifor is indicated for the treatment of adult patients with Cushing’s disease for whom surgery is not an option or for whom surgery has failed.Signifor is indicated for the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with another somatostatin analogue.|[PMDA] Drugs with a new active ingredient indicated for the improvement of hypersecretion of growth hormone and IGF-I (somatomedin-C) and related symptoms in acromegaly and pituitary gigantism (when surgical therapies are not sufficiently effective or are difficult to perform). uuid:cd534f62-147e-4e54-82f6-2a95a9f0febf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72312 biolink:treats MONDO:0009050 PMID:41385096 "[{""id"":""uuid:8b0d6256-bd03-4b69-89ea-e91498edf12d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5d7fbc2d-3a01-48a4-b3bf-7ed61723c9d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:60a05164-17ea-41ee-8482-f6661f630d6c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/signifor""]},{""id"":""uuid:0f62956d-79e5-4ccf-9e02-7b872f37a34e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SIGNIFOR LAR is a somatostatin analog indicated for the treatment of: Patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. ( 1.1 ) Patients with Cushing's disease for whom pituitary surgery is not an option or has not been curative. ( 1.2 )|[EMA] Signifor is indicated for the treatment of adult patients with Cushing’s disease for whom surgery is not an option or for whom surgery has failed.Signifor is indicated for the treatment of adult patients with acromegaly for whom surgery is not an option or has not been curative and who are inadequately controlled on treatment with another somatostatin analogue.|[PMDA] Drugs with a new additional indication and a new dosage and in additional dosage forms indicated for the treatment of Cushing’s disease (when surgical therapies are not sufficiently effective or are difficult to perform). [Orphan drug] uuid:f3d403e7-14a3-4350-ae6c-938f6ede45c7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63616 biolink:treats UMLS:C0278987 PMID:41385096 "[{""id"":""uuid:3d67db12-43b7-4b23-8b32-e8f1dff952e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e12e9381-a946-43a4-95ab-cf0f3c05b8e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pemetrexed for injection is a folate analog metabolic inhibitor indicated: in combination with pembrolizumab and platinum chemotherapy, for the initial treatment of patients with metastatic non-small cell lung cancer (NSCLC), with no EGFR or ALK genomic tumor aberrations. ( 1.1 ) in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous NSCLC. ( 1.1 ) as a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. ( 1.1 ) as a single agent for the treatment of patients with recurrent, metastatic non-squamous, NSCLC after prior chemotherapy. ( 1.1 ) Limitations of Use: Pemetrexed for injection is not indicated for the treatment of patients with squamous cell, non-small cell lung cancer. ( 1.1 ) initial treatment, in combination with cisplatin, of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery. ( 1.2 ) uuid:c5f269ed-1bc7-42fd-bfd2-c0854c2809e3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4495 biolink:treats MONDO:0004946 PMID:41385096 "[{""id"":""uuid:c14ff472-426f-43b1-b6ff-46fe6c6e11ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2fbc7983-b079-4a8a-aad4-aab55cd42d00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROGLYCEM is indicated for the management of hypoglycemia due to hyperinsulinism associated with the following conditions: Adults: Inoperable islet cell adenoma or carcinoma, or extrapancreatic malignancy. Infants and children: Leucine sensitivity, islet cell hyperplasia, nesidioblastosis, extrapancreatic malignancy, islet cell adenoma, or adenomatosis. PROGLYCEM may be used preoperatively as a temporary measure, and postoperatively, if hypoglycemia persists. PROGLYCEM should be used only after a diagnosis of hypoglycemia due to one of the above conditions has been definitely established. When other specific medical therapy or surgical management either has been unsuccessful or is not feasible, treatment with PROGLYCEM should be considered. uuid:fb33a422-df8d-4c45-94de-11c1df85554d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4495 biolink:treats MONDO:0002177 PMID:41385096 "[{""id"":""uuid:483f51d4-537e-452c-977a-db275e54d83f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:94b6ae17-d047-483e-86fa-322e55b5afb8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROGLYCEM is indicated for the management of hypoglycemia due to hyperinsulinism associated with the following conditions: Adults: Inoperable islet cell adenoma or carcinoma, or extrapancreatic malignancy. Infants and children: Leucine sensitivity, islet cell hyperplasia, nesidioblastosis, extrapancreatic malignancy, islet cell adenoma, or adenomatosis. PROGLYCEM may be used preoperatively as a temporary measure, and postoperatively, if hypoglycemia persists. PROGLYCEM should be used only after a diagnosis of hypoglycemia due to one of the above conditions has been definitely established. When other specific medical therapy or surgical management either has been unsuccessful or is not feasible, treatment with PROGLYCEM should be considered. uuid:a894507e-3321-4621-aae9-0c83b516629b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4495 biolink:treats MONDO:0005815 PMID:41385096 "[{""id"":""uuid:f7184f6f-ed95-45e1-b162-6976c0bebabf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5bb78eab-5302-4ce8-9db6-516d0160c9d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROGLYCEM is indicated for the management of hypoglycemia due to hyperinsulinism associated with the following conditions: Adults: Inoperable islet cell adenoma or carcinoma, or extrapancreatic malignancy. Infants and children: Leucine sensitivity, islet cell hyperplasia, nesidioblastosis, extrapancreatic malignancy, islet cell adenoma, or adenomatosis. PROGLYCEM may be used preoperatively as a temporary measure, and postoperatively, if hypoglycemia persists. PROGLYCEM should be used only after a diagnosis of hypoglycemia due to one of the above conditions has been definitely established. When other specific medical therapy or surgical management either has been unsuccessful or is not feasible, treatment with PROGLYCEM should be considered. uuid:e2293769-f66f-4b83-b2e3-4ce0d2a6f53d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4495 biolink:treats MONDO:0004993 PMID:41385096 "[{""id"":""uuid:b3880eb4-d80d-4a3d-965f-9ecfc4afd4c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fbee7b0e-2f55-4af0-84e5-24bc372b8cc0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROGLYCEM is indicated for the management of hypoglycemia due to hyperinsulinism associated with the following conditions: Adults: Inoperable islet cell adenoma or carcinoma, or extrapancreatic malignancy. Infants and children: Leucine sensitivity, islet cell hyperplasia, nesidioblastosis, extrapancreatic malignancy, islet cell adenoma, or adenomatosis. PROGLYCEM may be used preoperatively as a temporary measure, and postoperatively, if hypoglycemia persists. PROGLYCEM should be used only after a diagnosis of hypoglycemia due to one of the above conditions has been definitely established. When other specific medical therapy or surgical management either has been unsuccessful or is not feasible, treatment with PROGLYCEM should be considered. uuid:724acbcd-7720-47bf-9702-bad95e67930e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4495 biolink:treats HP:0004510 PMID:41385096 "[{""id"":""uuid:3eff67f7-8c28-42b8-b4ea-8deb18192797"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:19290f78-3989-4557-9819-f13c1ef9697c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROGLYCEM is indicated for the management of hypoglycemia due to hyperinsulinism associated with the following conditions: Adults: Inoperable islet cell adenoma or carcinoma, or extrapancreatic malignancy. Infants and children: Leucine sensitivity, islet cell hyperplasia, nesidioblastosis, extrapancreatic malignancy, islet cell adenoma, or adenomatosis. PROGLYCEM may be used preoperatively as a temporary measure, and postoperatively, if hypoglycemia persists. PROGLYCEM should be used only after a diagnosis of hypoglycemia due to one of the above conditions has been definitely established. When other specific medical therapy or surgical management either has been unsuccessful or is not feasible, treatment with PROGLYCEM should be considered. uuid:f69457d5-fc90-47d9-959d-b8c61ce45cf2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4495 biolink:treats MONDO:0019010 PMID:41385096 "[{""id"":""uuid:ebe23e1f-8dcf-4205-818b-7bdde84b0c34"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:60fb5adb-d2ae-4a13-8c3d-2453d1189f0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROGLYCEM is indicated for the management of hypoglycemia due to hyperinsulinism associated with the following conditions: Adults: Inoperable islet cell adenoma or carcinoma, or extrapancreatic malignancy. Infants and children: Leucine sensitivity, islet cell hyperplasia, nesidioblastosis, extrapancreatic malignancy, islet cell adenoma, or adenomatosis. PROGLYCEM may be used preoperatively as a temporary measure, and postoperatively, if hypoglycemia persists. PROGLYCEM should be used only after a diagnosis of hypoglycemia due to one of the above conditions has been definitely established. When other specific medical therapy or surgical management either has been unsuccessful or is not feasible, treatment with PROGLYCEM should be considered. uuid:43c6a1f9-f0bd-4758-9410-0cf844609f0c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C000632565 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:70531a9e-12c4-4e9a-943a-1b70200ad45c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:22010e63-745d-417a-a5fc-2d8621f3b1dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SYMTUZA is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and pediatric patients weighing at least 40 kg: who have no prior antiretroviral treatment history or who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least 6 months and have no known substitutions associated with resistance to darunavir or tenofovir. uuid:cdd0a504-7b1a-45ef-a20f-cf0e9e97c5a7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6443 biolink:treats HP:0000132 PMID:41385096 "[{""id"":""uuid:01c3ee0d-cdc7-44b2-9bf7-c219e37156d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c3f8e481-9a1f-488a-b350-0ddbdb59b4ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:890406ae-224a-424f-81ef-008b1853647f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mirena is a progestin-containing intrauterine system (IUS) indicated for: • Prevention of pregnancy for up to 8 years ( 1.1 ) • Treatment of heavy menstrual bleeding for women who choose to use intrauterine contraception as their method of contraception for up to 5 years. ( 1.2 )|[PMDA] A drug with a new additional indication for the treatment of hypermenorrhea. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:11d94cfc-d812-450e-b87f-9220a4395a06 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:66876 biolink:treats NCIT:C55615 PMID:41385096 "[{""id"":""uuid:4179ae30-addd-47ac-ae2b-9fbcb9ea0ecf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:72518a42-8529-40fc-9d9e-a35cdc147a1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] STENDRA is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction in adult males. uuid:d22adacb-ce09-490f-bb95-16be2595757c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2556795 biolink:treats MONDO:0007886 PMID:41385096 "[{""id"":""uuid:81d1b998-9b9a-491b-891b-17ceef53845a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:433dbf88-2dff-42bf-bc27-14330d8f2e1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MYFEMBREE is a combination of relugolix, a gonadotropin-releasing hormone (GnRH) receptor antagonist, estradiol, an estrogen, and norethindrone acetate, a progestin, indicated in premenopausal women for the: management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids). ( 1.1 , 14.1 ) management of moderate to severe pain associated with endometriosis. ( 1.2 , 14.2 ) Limitations of Use Use of MYFEMBREE should be limited to 24 months due to the risk of continued bone loss which may not be reversible. ( 1.3 , 5.2 , 6 ) uuid:fd38353c-502a-49ee-a303-28ff01f8ad1f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2556795 biolink:treats MONDO:0005133 PMID:41385096 "[{""id"":""uuid:fb4a1f5c-5b74-420f-a1df-f77fa2dede42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:45482ec4-42f6-4e13-ab2d-a43321954c02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MYFEMBREE is a combination of relugolix, a gonadotropin-releasing hormone (GnRH) receptor antagonist, estradiol, an estrogen, and norethindrone acetate, a progestin, indicated in premenopausal women for the: management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids). ( 1.1 , 14.1 ) management of moderate to severe pain associated with endometriosis. ( 1.2 , 14.2 ) Limitations of Use Use of MYFEMBREE should be limited to 24 months due to the risk of continued bone loss which may not be reversible. ( 1.3 , 5.2 , 6 ) uuid:1d74600b-3870-46dc-9c2a-d31711e75010 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2668 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:a134ac2b-7d25-47ea-a233-59e4083d6bc7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:47980892-181b-4b88-b896-1a883279b1b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amlodipine besylate tablets is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including Amlodipine besylate tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Amlodipine besylate tablets may be used alone or in combination with other antihypertensive agents. uuid:878b5048-f002-4c4a-816f-32e9e83d2e14 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2668 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:a1f1e218-4c8b-4758-831e-3cac7b4b875e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ac7481ad-65c4-4357-9fd4-4dd41b10b2f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amlodipine besylate tablets is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including Amlodipine besylate tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Amlodipine besylate tablets may be used alone or in combination with other antihypertensive agents. uuid:e1ced120-aab6-4c20-80c8-a19c3d4ac7a1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:705860 biolink:treats HP:0005202 PMID:41385096 "[{""id"":""uuid:ed136a07-1a96-4465-aef3-1106be5eb37a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7ffacc00-7446-4de4-85de-548aad1887d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bismuth Subcitrate Potassium, Metronidazole and Tetracycline Hydrochloride Capsules is a combination of metronidazole, a nitroimidazole antimicrobial, tetracycline,- a tetracycline class antimicrobial and bismuth subcitrate potassium, indicated for use, in combination with omeprazole, for the treatment of patients with Helicobacter pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate H. pylori. ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bismuth Subcitrate Potassium, Metronidazole and Tetracycline Hydrochloride Capsules and other antibacterial drugs, Bismuth Subcitrate Potassium, Metronidazole and Tetracycline Hydrochloride Capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.2 ) uuid:49bf715b-dc6e-45f0-bef6-db8298750ec1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:705860 biolink:treats MONDO:0005412 PMID:41385096 "[{""id"":""uuid:e47956e3-33cc-4923-af04-57a20b191043"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:271242b3-1b2a-4451-aa0a-9e22fd49e6b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bismuth Subcitrate Potassium, Metronidazole and Tetracycline Hydrochloride Capsules is a combination of metronidazole, a nitroimidazole antimicrobial, tetracycline,- a tetracycline class antimicrobial and bismuth subcitrate potassium, indicated for use, in combination with omeprazole, for the treatment of patients with Helicobacter pylori infection and duodenal ulcer disease (active or history of within the past 5 years) to eradicate H. pylori. ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Bismuth Subcitrate Potassium, Metronidazole and Tetracycline Hydrochloride Capsules and other antibacterial drugs, Bismuth Subcitrate Potassium, Metronidazole and Tetracycline Hydrochloride Capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.2 ) uuid:64e87711-a8df-4da4-9539-6be11b1a0f78 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9XZ8H6N6OH biolink:treats MONDO:0006733 PMID:41385096 "[{""id"":""uuid:8bf6e803-234a-492d-95dc-37a884dd84eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fcfcd111-21ae-4c08-b318-d8310e464a7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LACRISERT is indicated in patients with moderate to severe dry eye syndromes, including keratoconjunctivitis sicca. LACRISERT is indicated especially in patients who remain symptomatic after an adequate trial of therapy with artificial tear solutions. LACRISERT is also indicated for patients with: Exposure keratitis Decreased corneal sensitivity Recurrent corneal erosions uuid:420c9b17-4c30-4f47-9faf-976842d1ecb6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9XZ8H6N6OH biolink:treats MONDO:0004794 PMID:41385096 "[{""id"":""uuid:13dba704-3c1b-411c-92d6-8375d37521c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:21b17575-61d2-4297-a33e-666a9afa5d97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LACRISERT is indicated in patients with moderate to severe dry eye syndromes, including keratoconjunctivitis sicca. LACRISERT is indicated especially in patients who remain symptomatic after an adequate trial of therapy with artificial tear solutions. LACRISERT is also indicated for patients with: Exposure keratitis Decreased corneal sensitivity Recurrent corneal erosions uuid:d4e2f403-0a07-45e9-b236-4263da57f086 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9XZ8H6N6OH biolink:treats HP:0012155 PMID:41385096 "[{""id"":""uuid:6a075fd3-8815-45cc-89e9-47345edec92f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2de104da-1132-4f97-bd09-08a2ed46520d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LACRISERT is indicated in patients with moderate to severe dry eye syndromes, including keratoconjunctivitis sicca. LACRISERT is indicated especially in patients who remain symptomatic after an adequate trial of therapy with artificial tear solutions. LACRISERT is also indicated for patients with: Exposure keratitis Decreased corneal sensitivity Recurrent corneal erosions uuid:3417798c-868a-4a06-b056-d305ae1b34dc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9XZ8H6N6OH biolink:treats HP:0000495 PMID:41385096 "[{""id"":""uuid:7b84e476-1995-4c24-8e8b-8458f895a471"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6b6c0279-8051-4343-9d6e-1e174eae9aad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LACRISERT is indicated in patients with moderate to severe dry eye syndromes, including keratoconjunctivitis sicca. LACRISERT is indicated especially in patients who remain symptomatic after an adequate trial of therapy with artificial tear solutions. LACRISERT is also indicated for patients with: Exposure keratitis Decreased corneal sensitivity Recurrent corneal erosions uuid:22e39ac4-6da5-40e2-bee3-ba8f5d804ac5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6754 biolink:treats HP:0012532 PMID:41385096 "[{""id"":""uuid:89cf7682-92f9-47f4-a9e3-4733083aaa79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e4693476-2904-4399-a8de-34e1ce2f09f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Meperidine Hydrochloride Tablets and Oral Solution are indicated for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration [see Warnings and Precautions ( 5.2 )] , reserve Meperidine Hydrochloride Tablets and Oral Solution for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products] : • Have not been tolerated or are not expected to be tolerated, • Have not provided adequate analgesia or are not expected to provide adequate analgesia. Meperidine Hydrochloride Tablets or Oral Solution should not be used for an extended period of time unless the pain remains severe enough to require an opioid analgesic and for which alternative treatment options continue to be inadequate. Meperidine Hydrochloride Tablets or Oral Solution should not be used for the treatment of chronic pain. Use of Meperidine Hydrochloride Tablets or Oral Solution for an extended period of time may increase the risk of toxicity (e.g. seizures) from the accumulation of the meperidine metabolite, normeperidine . uuid:de96a612-2ea6-4b07-ad3c-fdce491e7935 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PQX0D8J21J biolink:treats MONDO:0005627 PMID:41385096 "[{""id"":""uuid:eea3ccd8-3956-43d7-8221-585be64cccd5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9ec68d97-8f9f-4829-a181-98c2b8dd1afe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f0391cda-12ef-48ee-b993-9e7de70685d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ERBITUX ® is an epidermal growth factor receptor (EGFR) antagonist indicated for treatment of: Head and Neck Cancer Locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy. ( 1.1 , 14.1 ) Recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck in combination with platinum-based therapy with fluorouracil. ( 1.1 , 14.1 ) Recurrent or metastatic squamous cell carcinoma of the head and neck progressing after platinum-based therapy. ( 1.1 , 14.1 ) Colorectal Cancer K-Ras wild-type, EGFR-expressing, metastatic colorectal cancer as determined by an FDA-approved test in combination with FOLFIRI for first-line treatment, in combination with irinotecan in patients who are refractory to irinotecan-based chemotherapy, as a single-agent in patients who have failed oxaliplatin- and irinotecan-based chemotherapy or who are intolerant to irinotecan. ( 1.2 , 5.7 , 12.1 , 14.2 ) Limitations of Use: ERBITUX is not indicated for treatment of Ras-mutant colorectal cancer or when the results of the Ras mutation tests are unknown. ( 5.7 ) BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC) in combination with encorafenib, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy. ( 1.3 )|[PMDA] A drug with a new additional dosage indicated for the treatment of unresectable, advanced or recurrent colon or rectal cancer with wild-type RAS and head and neck cancer. [Public knowledge-based application] uuid:f78d0455-7cd8-4bb9-934b-a3c5052b8d1c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PQX0D8J21J biolink:treats MONDO:0010150 PMID:41385096 "[{""id"":""uuid:4a86125d-e5e5-4fc7-891c-5fa0a0636dc8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:3449a23d-c323-42c9-bb7f-de8f2082b222"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:6b42058d-2fa4-4f3f-8505-c236235b40b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/erbitux""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ERBITUX ® is an epidermal growth factor receptor (EGFR) antagonist indicated for treatment of: Head and Neck Cancer Locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy. ( 1.1 , 14.1 ) Recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck in combination with platinum-based therapy with fluorouracil. ( 1.1 , 14.1 ) Recurrent or metastatic squamous cell carcinoma of the head and neck progressing after platinum-based therapy. ( 1.1 , 14.1 ) Colorectal Cancer K-Ras wild-type, EGFR-expressing, metastatic colorectal cancer as determined by an FDA-approved test in combination with FOLFIRI for first-line treatment, in combination with irinotecan in patients who are refractory to irinotecan-based chemotherapy, as a single-agent in patients who have failed oxaliplatin- and irinotecan-based chemotherapy or who are intolerant to irinotecan. ( 1.2 , 5.7 , 12.1 , 14.2 ) Limitations of Use: ERBITUX is not indicated for treatment of Ras-mutant colorectal cancer or when the results of the Ras mutation tests are unknown. ( 5.7 ) BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC) in combination with encorafenib, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy. ( 1.3 )|[EMA] Erbitux is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer:in combination with irinotecan-based chemotherapy;in first-line in combination with FOLFOX;as a single agent in patients who have failed oxaliplatin- and irinotecan-based therapy and who are intolerant to irinotecan.For details, see section 5.1.Erbitux is indicated for the treatment of patients with squamous cell cancer of the head and neck:in combination with radiation therapy for locally advanced disease;in combination with platinum-based chemotherapy for recurrent and/or metastatic disease. uuid:476f6e4f-46ae-4dcc-98f9-39293d077031 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PQX0D8J21J biolink:treats MONDO:0005575 PMID:41385096 "[{""id"":""uuid:00e76f68-ca5e-41ab-af7f-fd6cb812f00b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:30fbd94b-fa46-4216-85ff-92dffde53a04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ERBITUX ® is an epidermal growth factor receptor (EGFR) antagonist indicated for treatment of: Head and Neck Cancer Locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy. ( 1.1 , 14.1 ) Recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck in combination with platinum-based therapy with fluorouracil. ( 1.1 , 14.1 ) Recurrent or metastatic squamous cell carcinoma of the head and neck progressing after platinum-based therapy. ( 1.1 , 14.1 ) Colorectal Cancer K-Ras wild-type, EGFR-expressing, metastatic colorectal cancer as determined by an FDA-approved test in combination with FOLFIRI for first-line treatment, in combination with irinotecan in patients who are refractory to irinotecan-based chemotherapy, as a single-agent in patients who have failed oxaliplatin- and irinotecan-based chemotherapy or who are intolerant to irinotecan. ( 1.2 , 5.7 , 12.1 , 14.2 ) Limitations of Use: ERBITUX is not indicated for treatment of Ras-mutant colorectal cancer or when the results of the Ras mutation tests are unknown. ( 5.7 ) BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC) in combination with encorafenib, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy. ( 1.3 ) uuid:393b0dc5-738f-49c2-923a-56969e65eb33 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PQX0D8J21J biolink:treats EFO:1001480 PMID:41385096 "[{""id"":""uuid:b9fa9b88-9207-495f-a085-5c75103cb9c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:81a54083-72a0-4232-8a81-c5d8e326b645"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ERBITUX ® is an epidermal growth factor receptor (EGFR) antagonist indicated for treatment of: Head and Neck Cancer Locally or regionally advanced squamous cell carcinoma of the head and neck in combination with radiation therapy. ( 1.1 , 14.1 ) Recurrent locoregional disease or metastatic squamous cell carcinoma of the head and neck in combination with platinum-based therapy with fluorouracil. ( 1.1 , 14.1 ) Recurrent or metastatic squamous cell carcinoma of the head and neck progressing after platinum-based therapy. ( 1.1 , 14.1 ) Colorectal Cancer K-Ras wild-type, EGFR-expressing, metastatic colorectal cancer as determined by an FDA-approved test in combination with FOLFIRI for first-line treatment, in combination with irinotecan in patients who are refractory to irinotecan-based chemotherapy, as a single-agent in patients who have failed oxaliplatin- and irinotecan-based chemotherapy or who are intolerant to irinotecan. ( 1.2 , 5.7 , 12.1 , 14.2 ) Limitations of Use: ERBITUX is not indicated for treatment of Ras-mutant colorectal cancer or when the results of the Ras mutation tests are unknown. ( 5.7 ) BRAF V600E Mutation-Positive Metastatic Colorectal Cancer (CRC) in combination with encorafenib, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy. ( 1.3 ) uuid:38cde101-f0f5-4262-ba72-e90810d3f49e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats MONDO:0005545 PMID:41385096 "[{""id"":""uuid:935c7855-b606-4f66-b76e-344da003983a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6a556e80-9195-4415-994a-1ce96e68ab22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AzaSite ® is indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following microorganisms: CDC coryneform group G Efficacy for this organism was studied in fewer than 10 infections. Haemophilus influenzae Staphylococcus aureus Streptococcus mitis group Streptococcus pneumoniae uuid:d93f796b-5b88-4507-a047-9d725c4e85af biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats MONDO:0005114 PMID:41385096 "[{""id"":""uuid:a279e887-4da6-4db2-ad88-63379c127212"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0aa4da32-521e-445d-baa4-cc8e33c4c51d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AzaSite ® is indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following microorganisms: CDC coryneform group G Efficacy for this organism was studied in fewer than 10 infections. Haemophilus influenzae Staphylococcus aureus Streptococcus mitis group Streptococcus pneumoniae uuid:a7967b01-4719-43cb-92eb-6d5801a8937c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:136048 biolink:treats UMLS:C0267055 PMID:41385096 "[{""id"":""uuid:7021f5b9-cead-4f85-93ce-b44114779462"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7cbf67ba-d5dd-4b2c-8d8b-5472f312d9ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VOQUEZNA is indicated: for healing of all grades of erosive esophagitis and relief of heartburn associated with erosive esophagitis in adults. to maintain healing of all grades of erosive esophagitis and relief of heartburn associated with erosive esophagitis in adults. for the relief of heartburn associated with non-erosive gastroesophageal reflux disease in adults. in combination with amoxicillin and clarithromycin for the treatment of Helicobacter pylori ( H. pylori ) infection in adults. in combination with amoxicillin for the treatment of H. pylori infection in adults. uuid:95c9a499-bf8e-4726-8a5c-dbe93400e566 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:136048 biolink:treats HP:0005202 PMID:41385096 "[{""id"":""uuid:e0207b0f-c81f-4b7f-ac1c-d5f10b56bda1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a6239b74-b91c-44ac-a32d-8d18b8659c03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VOQUEZNA is indicated: for healing of all grades of erosive esophagitis and relief of heartburn associated with erosive esophagitis in adults. to maintain healing of all grades of erosive esophagitis and relief of heartburn associated with erosive esophagitis in adults. for the relief of heartburn associated with non-erosive gastroesophageal reflux disease in adults. in combination with amoxicillin and clarithromycin for the treatment of Helicobacter pylori ( H. pylori ) infection in adults. in combination with amoxicillin for the treatment of H. pylori infection in adults. uuid:3995f7c8-0c39-4163-99cf-22e4f87523ea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6129 biolink:treats NCIT:C3137 PMID:41385096 "[{""id"":""uuid:36ad24ea-2517-4ecf-a8a6-9eb3546283cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a32ce817-5f3c-45f9-8182-c4ccbb14dc29"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ACUVAIL ® is indicated for the treatment of pain and inflammation following cataract surgery. uuid:2a2bb5a4-a5b3-4327-93ee-87ca48841520 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:GDW7M2P1IS biolink:treats MONDO:0002049 PMID:41385096 "[{""id"":""uuid:321d3ed9-4530-49f5-bd5c-f31aded855b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:638c4dbd-eb98-4a45-a2eb-bec504e1b31c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:976cec75-b412-4e0e-8fa8-3a38af52ef1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DOPTELET is a thrombopoietin receptor agonist indicated for the treatment of: Thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure. ( 1.1 ) Thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. ( 1.2 )|[PMDA] A drug with a new active ingredient indicated for the improvement of thrombocytopenia in patients with chronic liver disease for whom an elective invasive procedure is planned. uuid:878b8ae8-cd2b-47f4-8260-5a29e80e5982 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:GDW7M2P1IS biolink:treats MONDO:0019098 PMID:41385096 "[{""id"":""uuid:c01bf68e-b954-46d9-9982-b0f4cd1cb047"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:51adab90-e505-4f82-bccb-1f6f97253bbe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DOPTELET is a thrombopoietin receptor agonist indicated for the treatment of: Thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo a procedure. ( 1.1 ) Thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. ( 1.2 ) uuid:941c59c9-dd4e-499c-9a89-ce422a02704c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:192617 biolink:treats MONDO:0003471 PMID:41385096 "[{""id"":""uuid:e530d1ff-c382-4023-9424-5687a0aa38ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:13394ba5-e668-4a18-95c3-ec5a9a7ba297"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XEGLYZE is indicated for the topical treatment of head lice infestation in patients 6 months of age and older. XEGLYZE should be used in the context of an overall lice management program: Wash (with hot water) or dry-clean all recently worn clothing, hats, used bedding and towels Wash personal care items such as combs, brushes, and hair clips in hot water Use a fine-tooth comb or special nit comb to remove dead lice and nits uuid:cb19a3dc-5f97-4893-9e79-812c76176612 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:ZJ0EKR6M10 biolink:treats MONDO:0019496 PMID:41385096 "[{""id"":""uuid:366a5c06-5e90-4f3b-9b9e-07aa3e9144d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2432dfd8-2848-4f13-9c93-c0cdc016e488"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NETSPOT, after radiolabeling with gallium-68, is indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult and pediatric patients. uuid:a098bfd2-66df-4a81-abb9-786e730b8f6a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:0P70AR5BYB biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:f81c3689-942d-4833-9eef-4dc05c63c7c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:cea6b0ab-36f9-4560-9fa6-dae8c51e04b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f391dd6b-24c3-4fe5-b906-63d272a8dd69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kapruvia""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] KORSUVA is indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis (HD). Limitation of Use Korsuva has not been studied in patients on peritoneal dialysis and is not recommended for use in this population.|[EMA] Kapruvia is indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on haemodialysis (see section 5.1). uuid:c41d96b3-73ec-4b4b-a1c3-1b5ca81d56ac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72292 biolink:treats MONDO:0006052 PMID:41385096 "[{""id"":""uuid:658f6f67-b428-4cb7-aa88-b6fe8c8c0ba9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6dc670c8-b08a-4574-bbcc-128334aaf44b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SIRTURO is a diarylquinoline antimycobacterial drug indicated as part of combination therapy in the treatment of adult and pediatric patients (5 years and older and weighing at least 15 kg) with pulmonary tuberculosis (TB) due to Mycobacterium tuberculosis resistant to at least rifampin and isoniazid. uuid:6a8b3eae-9072-4464-8e5f-bfc0f59e3d55 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5118 biolink:treats MONDO:0024613 PMID:41385096 "[{""id"":""uuid:83d056ed-74d4-4755-b839-959f043518d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c4c9afb9-8b3d-4d23-a749-d64f4c2d2b10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluoxetine is a selective serotonin reuptake inhibitor indicated for: Acute and maintenance treatment of Major Depressive Disorder (MDD) ( 1 ) Acute and maintenance treatment of Obsessive Compulsive Disorder (OCD) ( 1 ) Acute and maintenance treatment of Bulimia Nervosa ( 1 ) Acute treatment of Panic Disorder, with or without agoraphobia ( 1 ) Fluoxetine capsules and olanzapine in combination for treatment of: Acute Depressive Episodes Associated with Bipolar I Disorder ( 1 ) Treatment Resistant Depression ( 1 ) uuid:3873e0fe-a901-494a-a5f3-b6a7546bfc6f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:QEN1X95CIX biolink:treats UMLS:C1112459 PMID:41385096 "[{""id"":""uuid:483e674b-46c7-4136-aa0c-a5d26f16b571"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4e92f6a2-2bc2-4932-8f41-ab9991178d47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IMJUDO is a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blocking antibody indicated: • in combination with durvalumab, for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC). ( 1.1 ) • in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. ( 1.2 ) uuid:d4ba7bdc-4e01-4419-a89f-49de940c6aa7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:QEN1X95CIX biolink:treats UMLS:C0278987 PMID:41385096 "[{""id"":""uuid:0c95e010-c751-478c-a519-2682be8e05c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:91ae6c0f-cbe7-48c3-b484-0024c8e60502"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IMJUDO is a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blocking antibody indicated: • in combination with durvalumab, for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC). ( 1.1 ) • in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations. ( 1.2 ) uuid:a7d2f749-9a60-4424-8a23-0ba1b4c38a5b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:1864 biolink:treats MONDO:0005062 PMID:41385096 "[{""id"":""uuid:27115be0-428b-4f49-9e78-4a684a381e5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1acb8e15-c1fd-4f98-97d9-005adc2d4987"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Malignant Diseases Cyclophosphamide Injection is indicated for the treatment of adult and pediatric patients with: malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin's disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma Burkitt's lymphoma multiple myeloma leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration) mycosis fungoides (advanced disease) neuroblastoma (disseminated disease) adenocarcinoma of the ovary retinoblastoma carcinoma of the breast Cyclophosphamide Injection, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. uuid:bf2e74de-a8eb-465b-8baa-21fb38b9f9b2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:1864 biolink:treats MONDO:0009348 PMID:41385096 "[{""id"":""uuid:97816113-715b-4ee2-b3b0-4543fa5b3596"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2be920cc-974f-48cf-8c0d-3cfe33b566a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Malignant Diseases Cyclophosphamide Injection is indicated for the treatment of adult and pediatric patients with: malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin's disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma Burkitt's lymphoma multiple myeloma leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration) mycosis fungoides (advanced disease) neuroblastoma (disseminated disease) adenocarcinoma of the ovary retinoblastoma carcinoma of the breast Cyclophosphamide Injection, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. uuid:9e378e94-c78c-4a8e-9558-c64574d2aac1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:1864 biolink:treats MONDO:0003864 PMID:41385096 "[{""id"":""uuid:949a067a-cce8-4e45-a25f-0b5aa379d8f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1fc26dad-6737-4ff9-ac8d-b685380c847f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Malignant Diseases Cyclophosphamide Injection is indicated for the treatment of adult and pediatric patients with: malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin's disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma Burkitt's lymphoma multiple myeloma leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration) mycosis fungoides (advanced disease) neuroblastoma (disseminated disease) adenocarcinoma of the ovary retinoblastoma carcinoma of the breast Cyclophosphamide Injection, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. uuid:c68cf184-5b56-4adb-a6b8-305143e2b998 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:1864 biolink:treats MONDO:0004633 PMID:41385096 "[{""id"":""uuid:c8b5a0e4-6b17-40f4-8377-22d22440dbd2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4608c333-51da-4195-839c-48d2a187edaf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Malignant Diseases Cyclophosphamide Injection is indicated for the treatment of adult and pediatric patients with: malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin's disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma Burkitt's lymphoma multiple myeloma leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration) mycosis fungoides (advanced disease) neuroblastoma (disseminated disease) adenocarcinoma of the ovary retinoblastoma carcinoma of the breast Cyclophosphamide Injection, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. uuid:e94adf0d-596d-497a-87d8-38dcfc1b1009 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:1864 biolink:treats MONDO:0004604 PMID:41385096 "[{""id"":""uuid:7c5305d0-6d58-4fbe-bc24-e1dd1013d574"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:881ac480-eaaf-449b-bbab-1049efed9d8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Malignant Diseases Cyclophosphamide Injection is indicated for the treatment of adult and pediatric patients with: malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin's disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma Burkitt's lymphoma multiple myeloma leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration) mycosis fungoides (advanced disease) neuroblastoma (disseminated disease) adenocarcinoma of the ovary retinoblastoma carcinoma of the breast Cyclophosphamide Injection, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. uuid:73997367-9ba5-41bf-ba2e-f8cb73e1863b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:1864 biolink:treats MONDO:0006150 PMID:41385096 "[{""id"":""uuid:754e471b-2352-4b14-b228-aabab9b69f97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:df221aaf-1fdb-49d3-b6a0-747b2d9ea88e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Malignant Diseases Cyclophosphamide Injection is indicated for the treatment of adult and pediatric patients with: malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin's disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma Burkitt's lymphoma multiple myeloma leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration) mycosis fungoides (advanced disease) neuroblastoma (disseminated disease) adenocarcinoma of the ovary retinoblastoma carcinoma of the breast Cyclophosphamide Injection, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. uuid:4f7307b5-efa5-4780-8a6f-92bb4998161c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:1864 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:a0ab457d-88b0-488f-abd8-15d5bf9bcb27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:38b3e399-eea4-4a5d-9cd8-18157c9fa827"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Malignant Diseases Cyclophosphamide Injection is indicated for the treatment of adult and pediatric patients with: malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin's disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma Burkitt's lymphoma multiple myeloma leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration) mycosis fungoides (advanced disease) neuroblastoma (disseminated disease) adenocarcinoma of the ovary retinoblastoma carcinoma of the breast Cyclophosphamide Injection, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. uuid:5da045db-56b7-4dec-9c41-c7a13096e893 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:1864 biolink:treats MONDO:0004948 PMID:41385096 "[{""id"":""uuid:534675de-8627-466e-b886-b5c8e5e895bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:494c7639-6aba-4399-94ad-26b10231ccd6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Malignant Diseases Cyclophosphamide Injection is indicated for the treatment of adult and pediatric patients with: malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin's disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma Burkitt's lymphoma multiple myeloma leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration) mycosis fungoides (advanced disease) neuroblastoma (disseminated disease) adenocarcinoma of the ovary retinoblastoma carcinoma of the breast Cyclophosphamide Injection, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. uuid:d6b38942-26f2-4779-8923-a1ed3909a8a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:1864 biolink:treats MONDO:0011996 PMID:41385096 "[{""id"":""uuid:c14b9144-10dc-414d-9f3c-953dc68bbe55"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f07c7c4c-bf6d-4097-a97d-e72bc35735f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Malignant Diseases Cyclophosphamide Injection is indicated for the treatment of adult and pediatric patients with: malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin's disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma Burkitt's lymphoma multiple myeloma leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration) mycosis fungoides (advanced disease) neuroblastoma (disseminated disease) adenocarcinoma of the ovary retinoblastoma carcinoma of the breast Cyclophosphamide Injection, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. uuid:fc8448c6-9884-4077-ae0a-0bb7967101ce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:1864 biolink:treats MONDO:0018871 PMID:41385096 "[{""id"":""uuid:9d5b7067-0b5b-4939-8ad7-87fc441269ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4600a3d1-4d1e-4116-88db-064c72a0fe74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Malignant Diseases Cyclophosphamide Injection is indicated for the treatment of adult and pediatric patients with: malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin's disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma Burkitt's lymphoma multiple myeloma leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration) mycosis fungoides (advanced disease) neuroblastoma (disseminated disease) adenocarcinoma of the ovary retinoblastoma carcinoma of the breast Cyclophosphamide Injection, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. uuid:14369fe9-833d-4325-8509-a0d64eaba1b2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:1864 biolink:treats MONDO:0004967 PMID:41385096 "[{""id"":""uuid:001e98a5-bc76-4fd5-8e26-bdef51658d75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:673baa46-e432-45ee-8a3c-a735e56329e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Malignant Diseases Cyclophosphamide Injection is indicated for the treatment of adult and pediatric patients with: malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin's disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma Burkitt's lymphoma multiple myeloma leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration) mycosis fungoides (advanced disease) neuroblastoma (disseminated disease) adenocarcinoma of the ovary retinoblastoma carcinoma of the breast Cyclophosphamide Injection, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. uuid:55a6cf8c-68c3-40cf-a4ae-3057b9ed5c75 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:1864 biolink:treats MONDO:0009691 PMID:41385096 "[{""id"":""uuid:01e559d9-6513-4c33-8b7d-0db9e3b84e17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e24fc079-4986-453c-9600-4bb1de310807"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Malignant Diseases Cyclophosphamide Injection is indicated for the treatment of adult and pediatric patients with: malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin's disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma Burkitt's lymphoma multiple myeloma leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration) mycosis fungoides (advanced disease) neuroblastoma (disseminated disease) adenocarcinoma of the ovary retinoblastoma carcinoma of the breast Cyclophosphamide Injection, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. uuid:89e6424c-016b-4111-b674-5875da8ed40a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:1864 biolink:treats MONDO:0005072 PMID:41385096 "[{""id"":""uuid:46dbd627-079e-4101-81e6-22feca24303f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7003eaaa-31dc-4933-8428-7455cfcc316b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Malignant Diseases Cyclophosphamide Injection is indicated for the treatment of adult and pediatric patients with: malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin's disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma Burkitt's lymphoma multiple myeloma leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration) mycosis fungoides (advanced disease) neuroblastoma (disseminated disease) adenocarcinoma of the ovary retinoblastoma carcinoma of the breast Cyclophosphamide Injection, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. uuid:e7b3ef7f-0e47-4ccd-84d6-c5bf394d6d71 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:1864 biolink:treats MONDO:0002752 PMID:41385096 "[{""id"":""uuid:50644e9f-81cf-46ab-9f75-341bbad76c87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6be0fbf0-7afd-4819-b477-8c76ddc9cbba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Malignant Diseases Cyclophosphamide Injection is indicated for the treatment of adult and pediatric patients with: malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin's disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma Burkitt's lymphoma multiple myeloma leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration) mycosis fungoides (advanced disease) neuroblastoma (disseminated disease) adenocarcinoma of the ovary retinoblastoma carcinoma of the breast Cyclophosphamide Injection, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. uuid:0cd4be30-387c-4d25-b28a-b0db11a4c691 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:1864 biolink:treats MONDO:0008380 PMID:41385096 "[{""id"":""uuid:716d1b47-60aa-4c2b-9dd6-4e1a03b8a707"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2cf33189-d804-4d1e-ab60-7de2cb83e1f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Malignant Diseases Cyclophosphamide Injection is indicated for the treatment of adult and pediatric patients with: malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin's disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma Burkitt's lymphoma multiple myeloma leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration) mycosis fungoides (advanced disease) neuroblastoma (disseminated disease) adenocarcinoma of the ovary retinoblastoma carcinoma of the breast Cyclophosphamide Injection, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. uuid:a8cf716e-2f58-4a2d-968e-8c88a2eeaa4c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:1864 biolink:treats MONDO:0004989 PMID:41385096 "[{""id"":""uuid:7885836c-9830-424b-8a4d-d3528d78ec93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4aa40e8b-bea3-43d7-8e2e-f121a9e832f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Malignant Diseases Cyclophosphamide Injection is indicated for the treatment of adult and pediatric patients with: malignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkin's disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma Burkitt's lymphoma multiple myeloma leukemias: chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide given during remission is effective in prolonging its duration) mycosis fungoides (advanced disease) neuroblastoma (disseminated disease) adenocarcinoma of the ovary retinoblastoma carcinoma of the breast Cyclophosphamide Injection, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs. uuid:f3fe5641-a16b-4283-968d-986bd2a8c142 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71260 biolink:treats HP:0003119 PMID:41385096 "[{""id"":""uuid:c16b9061-d344-4292-ad34-f217fec7af9a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:14dc9cc0-b524-4245-a251-e1da56c3141e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pitavastatin is indicated as an adjunctive therapy to diet in: Adult patients with primary hyperlipidemia or mixed dyslipidemia to reduce elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C). Limitations of Use The effect of pitavastatin on cardiovascular morbidity and mortality has not been determined. Pediatric use information is approved for Kowa Co Ltd's LIVALO (pitavastatin) tablets. However, due to Kowa Co Ltd's marketing exclusivity rights, this drug product is not labeled with that information. uuid:1e3f94d3-c07b-450c-913e-2c2ad44e3ba8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229213 biolink:treats UMLS:C0278488 PMID:41385096 "[{""id"":""uuid:44178665-1e55-49a2-85ff-c95bb2f9147d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0d516fbf-d5c8-47c1-ae28-7819934c26c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ORSERDU is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)‑negative, ESR1 -mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. uuid:937ff5a0-6450-4bc8-bd43-10337abfb2eb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:36791 biolink:treats MONDO:0002050 PMID:41385096 "[{""id"":""uuid:5d453998-4c8a-4ead-b9e4-6412a7a560d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4f0a81e0-7532-42ed-9623-fb1ef9b8b16e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:857ed941-393c-4c34-a4e6-2915dc9be39c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Escitalopram tablet, is indicated for the acute and maintenance treatment of major depressive disorder in adults and in adolescents 12 to 17 years of age [ see Clinical Studies ( 14.1 ) ]. A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation.|[PMDA] A drug with a new active ingredient indicated for the treatment of depression. uuid:65f811cf-c4b6-4be5-b585-82f12c73815a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:36791 biolink:treats MONDO:0013600 PMID:41385096 "[{""id"":""uuid:8aba618a-6df8-4aee-8a6b-8d9af61caf5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f24239e6-642d-4578-af6f-b05ef5479f5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Escitalopram tablet, is indicated for the acute and maintenance treatment of major depressive disorder in adults and in adolescents 12 to 17 years of age [ see Clinical Studies ( 14.1 ) ]. A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. uuid:0e9da973-a0aa-489d-87e8-7975cc1d2d50 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:36791 biolink:treats MONDO:0005466 PMID:41385096 "[{""id"":""uuid:2a4c36f1-f330-46ed-b47e-22773d5947b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:375820d0-c9e2-468e-9aeb-04783249234d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Escitalopram tablet, is indicated for the acute and maintenance treatment of major depressive disorder in adults and in adolescents 12 to 17 years of age [ see Clinical Studies ( 14.1 ) ]. A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. uuid:b256c4ce-32da-47a9-8f77-6d49d44a5548 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:36791 biolink:treats NCIT:C143864 PMID:41385096 "[{""id"":""uuid:b9d9ea55-57c6-4fd7-be0a-21778d96ab9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:433f6a61-c89b-4e54-8fe9-c7e9492b44ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Escitalopram tablet, is indicated for the acute and maintenance treatment of major depressive disorder in adults and in adolescents 12 to 17 years of age [ see Clinical Studies ( 14.1 ) ]. A major depressive episode (DSM-IV) implies a prominent and relatively persistent (nearly every day for at least 2 weeks) depressed or dysphoric mood that usually interferes with daily functioning, and includes at least five of the following nine symptoms: depressed mood, loss of interest in usual activities, significant change in weight and/or appetite, insomnia or hypersomnia, psychomotor agitation or retardation, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, a suicide attempt or suicidal ideation. uuid:54f040fd-ec10-4722-a4ed-51b3d625039a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:131169 biolink:treats MONDO:0004948 PMID:41385096 "[{""id"":""uuid:c2f2aee5-ff3b-4540-8cd0-b7c8116e1846"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:dd6a3e61-e778-47e7-88ae-d2b931de80d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b2c277d5-395c-4fb0-95c4-0d40bdc5e0a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/copiktra""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] COPIKTRA is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) after at least two prior therapies. Limitations of Use : COPIKTRA is not indicated or recommended for the treatment of any patients with CLL or SLL as initial or second line treatment due to an increased risk of treatment-related mortality.|[EMA] Copiktra monotherapy is indicated for the treatment of adult patients with: Relapsed or refractory chronic lymphocytic leukaemia (CLL) after at least two prior therapies. Follicular lymphoma (FL) that is refractory to at least two prior systemic therapies. uuid:52084774-848d-43d6-9bdd-086b10fcf7fc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10023 biolink:treats MONDO:0002026 PMID:41385096 "[{""id"":""uuid:77744132-2ffc-41d6-abb5-7311356c2e03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1320eb73-f2d1-47c1-9d25-108dd647fde3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Voriconazole tablets are an azole antifungal indicated for the treatment of adults and pediatric patients aged 12 to 14 years weighing greater than or equal to 50 kg and those aged 15 years and older regardless of body weight with: • Invasive aspergillosis ( 1.1 ) • Candidemia in non-neutropenics and other deep tissue Candida infections ( 1.2 ) • Esophageal candidiasis ( 1.3 ) • Serious fungal infections caused by Scedosporium apiospermum and Fusarium species including Fusarium solani , in patients intolerant of, or refractory to, other therapy ( 1.4 ) uuid:17058ee6-04f6-4e04-98ef-bcbb6f3188ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:X8R2D92QP1 biolink:treats MONDO:0008769 PMID:41385096 "[{""id"":""uuid:8bfe380b-f55c-4de8-b37e-df2f1fddf416"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1751c0f7-8da4-499c-bf48-b680093e70bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ff9f8922-9acf-454c-a18b-852005b50002"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/brineura""]},{""id"":""uuid:31d08789-583e-4b4e-b4e4-a267bed7b1d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BRINEURA is indicated to slow the loss of ambulation in pediatric patients with neuronal ceroid lipofuscinosis type 2 (CLN2 disease), also known as tripeptidyl peptidase 1 (TPP1) deficiency.|[EMA] Brineura is indicated for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency,|[PMDA] A drug with a new active ingredient indicated for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2). [Orphan drug] uuid:ed13ddc2-1e96-4a12-9295-61081359619f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:600520 biolink:treats MONDO:0005025 PMID:41385096 "[{""id"":""uuid:32fea7ef-7fa2-424c-95b4-e351fcf379b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:204c7f64-589a-4e0c-a59c-987f723c899b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Micafungin for Injection, USP is indicated for: Treatment of Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses in adult and pediatric patients 4 months of age and older [see Clinical Studies (14.1) and Use in Specific Populations (8.4 )]. Treatment of Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses without meningoencephalitis and/or ocular dissemination in pediatric patients younger than 4 months of age [see Use in Specific Populations (8.4) ]. Treatment of Esophageal Candidiasis in adult and pediatric patients 4 months of age and older [see Clinical Studies (14.2 )]. Prophylaxis of Candida Infections in adult and pediatric patients 4 months of age and older undergoing hematopoietic stem cell transplantation [see Clinical Studies (14.3 )]. Limitations of Use The safety and effectiveness of Micafungin for Injection, USP have not been established for the treatment of candidemia with meningoencephalitis and/or ocular dissemination in pediatric patients younger than 4 months of age as a higher dose may be needed [see Use in Specific Populations (8.4) ] Micafungin for Injection, USP has not been adequately studied in patients with endocarditis, osteomyelitis and meningoencephalitis due to Candida. The efficacy of Micafungin for Injection, USP against infections caused by fungi other than Candida has not been established. uuid:afd9037e-d243-4db8-a670-0c74555277d8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:600520 biolink:treats MONDO:0005246 PMID:41385096 "[{""id"":""uuid:f002ea99-5a9d-404e-812c-63f5d217f90d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:59fc5e49-cffc-4abe-88be-cc8c1c9d41e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Micafungin for Injection, USP is indicated for: Treatment of Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses in adult and pediatric patients 4 months of age and older [see Clinical Studies (14.1) and Use in Specific Populations (8.4 )]. Treatment of Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses without meningoencephalitis and/or ocular dissemination in pediatric patients younger than 4 months of age [see Use in Specific Populations (8.4) ]. Treatment of Esophageal Candidiasis in adult and pediatric patients 4 months of age and older [see Clinical Studies (14.2 )]. Prophylaxis of Candida Infections in adult and pediatric patients 4 months of age and older undergoing hematopoietic stem cell transplantation [see Clinical Studies (14.3 )]. Limitations of Use The safety and effectiveness of Micafungin for Injection, USP have not been established for the treatment of candidemia with meningoencephalitis and/or ocular dissemination in pediatric patients younger than 4 months of age as a higher dose may be needed [see Use in Specific Populations (8.4) ] Micafungin for Injection, USP has not been adequately studied in patients with endocarditis, osteomyelitis and meningoencephalitis due to Candida. The efficacy of Micafungin for Injection, USP against infections caused by fungi other than Candida has not been established. uuid:3b751b1e-2610-4cbe-8992-bc28d39e97b2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:600520 biolink:treats MONDO:0005845 PMID:41385096 "[{""id"":""uuid:9a30e9e0-97c5-4a55-b5e3-773f3cb362ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fe84a4c6-62cb-4354-8e8e-d9ce24f4c4f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Micafungin for Injection, USP is indicated for: Treatment of Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses in adult and pediatric patients 4 months of age and older [see Clinical Studies (14.1) and Use in Specific Populations (8.4 )]. Treatment of Candidemia, Acute Disseminated Candidiasis, Candida Peritonitis and Abscesses without meningoencephalitis and/or ocular dissemination in pediatric patients younger than 4 months of age [see Use in Specific Populations (8.4) ]. Treatment of Esophageal Candidiasis in adult and pediatric patients 4 months of age and older [see Clinical Studies (14.2 )]. Prophylaxis of Candida Infections in adult and pediatric patients 4 months of age and older undergoing hematopoietic stem cell transplantation [see Clinical Studies (14.3 )]. Limitations of Use The safety and effectiveness of Micafungin for Injection, USP have not been established for the treatment of candidemia with meningoencephalitis and/or ocular dissemination in pediatric patients younger than 4 months of age as a higher dose may be needed [see Use in Specific Populations (8.4) ] Micafungin for Injection, USP has not been adequately studied in patients with endocarditis, osteomyelitis and meningoencephalitis due to Candida. The efficacy of Micafungin for Injection, USP against infections caused by fungi other than Candida has not been established. uuid:842148e7-ede8-4aa1-a56f-113070e9afa3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2375135 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:394ab5e0-caf1-4378-8a38-a2f86d8edb92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f88d842a-8daf-4627-a131-6a609df0ffe0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DARZALEX FASPRO is a combination of daratumumab, a CD38-directed cytolytic antibody, and hyaluronidase, an endoglycosidase, indicated for the treatment of adult patients with: multiple myeloma in combination with bortezomib, lenalidomide, and dexamethasone for induction and consolidation in newly diagnosed patients who are eligible for autologous stem cell transplant multiple myeloma in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant multiple myeloma in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy multiple myeloma in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant multiple myeloma in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy multiple myeloma in combination with pomalidomide and dexamethasone in patients who have received at least one prior line of therapy including lenalidomide and a proteasome inhibitor multiple myeloma in combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy multiple myeloma as monotherapy, in patients who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent light chain (AL) amyloidosis in combination with bortezomib, cyclophosphamide and dexamethasone in newly diagnosed patients. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s) ( 1.2 ) Limitations of Use: DARZALEX FASPRO is not indicated and is not recommended for the treatment of patients with light chain (AL) amyloidosis who have NYHA Class IIIB or Class IV cardiac disease or Mayo Stage IIIB outside of controlled clinical trials ( 1.2 ) uuid:7761fcf2-6bc0-460c-a07d-095d80f2c9d3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2375135 biolink:treats MONDO:0019438 PMID:41385096 "[{""id"":""uuid:f5045503-caa3-4330-bbd6-d565fbd226b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:63686742-2279-4079-a1ca-76832a504446"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DARZALEX FASPRO is a combination of daratumumab, a CD38-directed cytolytic antibody, and hyaluronidase, an endoglycosidase, indicated for the treatment of adult patients with: multiple myeloma in combination with bortezomib, lenalidomide, and dexamethasone for induction and consolidation in newly diagnosed patients who are eligible for autologous stem cell transplant multiple myeloma in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant multiple myeloma in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy multiple myeloma in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant multiple myeloma in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy multiple myeloma in combination with pomalidomide and dexamethasone in patients who have received at least one prior line of therapy including lenalidomide and a proteasome inhibitor multiple myeloma in combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy multiple myeloma as monotherapy, in patients who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent light chain (AL) amyloidosis in combination with bortezomib, cyclophosphamide and dexamethasone in newly diagnosed patients. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s) ( 1.2 ) Limitations of Use: DARZALEX FASPRO is not indicated and is not recommended for the treatment of patients with light chain (AL) amyloidosis who have NYHA Class IIIB or Class IV cardiac disease or Mayo Stage IIIB outside of controlled clinical trials ( 1.2 ) uuid:fac226ec-f2b8-4096-94c7-da28550bcf6d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:D6OMY2L0WA biolink:treats MONDO:0018905 PMID:41385096 "[{""id"":""uuid:b3868f89-6792-4324-aeee-a898a36dc3b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:930233de-d567-4a53-991b-9661a3efa30e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:bc40ba96-4340-4e82-b164-1a038311a316"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tepkinly""]},{""id"":""uuid:dd0bdf01-f19e-4dfd-bcf2-3c43e5566884"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EPKINLY is a bispecific CD20-directed CD3 T-cell engager indicated for the treatment of: Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy. ( 1.1 ) Follicular Lymphoma adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. ( 1.2 ) These indications are approved under accelerated approval based on response rate and durability of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).|[EMA] Tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.|[PMDA] Drugs with a new active ingredient indicated for the treatment of relapsed or refractory large B-cell lymphoma (diffuse large B-cell lymphoma, high- grade B-cell lymphoma, and primary mediastinal large B-cell lymphoma) or relapsed or refractory follicular lymphoma. uuid:b2922bfe-9349-40fa-a23f-65f943210a16 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:D6OMY2L0WA biolink:treats MONDO:0000901 PMID:41385096 "[{""id"":""uuid:c5d219bd-e6df-4f3a-b41d-f30001ecb3b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:66b85306-abad-4da5-bb83-18969de2f7ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f28bfc38-1ea6-4edb-bb35-49c74eeeecfd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EPKINLY is a bispecific CD20-directed CD3 T-cell engager indicated for the treatment of: Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy. ( 1.1 ) Follicular Lymphoma adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. ( 1.2 ) These indications are approved under accelerated approval based on response rate and durability of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).|[PMDA] Drugs with a new active ingredient indicated for the treatment of relapsed or refractory large B-cell lymphoma (diffuse large B-cell lymphoma, high- grade B-cell lymphoma, and primary mediastinal large B-cell lymphoma) or relapsed or refractory follicular lymphoma. uuid:298dbcd6-8076-4892-afa6-e6b1e8299d4a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:D6OMY2L0WA biolink:treats MONDO:0018906 PMID:41385096 "[{""id"":""uuid:0e2114f2-1c1d-420a-852c-b9b4ec51e536"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0b71fe9e-412f-4948-994c-3f50f10b157d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:fa3d1061-ede8-4017-8bd8-87997753bf00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EPKINLY is a bispecific CD20-directed CD3 T-cell engager indicated for the treatment of: Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after two or more lines of systemic therapy. ( 1.1 ) Follicular Lymphoma adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. ( 1.2 ) These indications are approved under accelerated approval based on response rate and durability of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).|[PMDA] Drugs with a new active ingredient indicated for the treatment of relapsed or refractory large B-cell lymphoma (diffuse large B-cell lymphoma, high- grade B-cell lymphoma, and primary mediastinal large B-cell lymphoma) or relapsed or refractory follicular lymphoma. uuid:b3125c69-b019-4949-9cdf-7c5261055b82 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:370642 biolink:treats HP:0030858 PMID:41385096 "[{""id"":""uuid:633ccdda-f749-4281-ad32-7c488be23311"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f501ac9f-4909-4d90-9fb0-3f3bff2f925b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydrocodone Bitartrate and Acetaminophen Oral Solution is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses [see WARNINGS ], reserve Hydrocodone Bitartrate and Acetaminophen Oral Solution for use in patients for whom alternative treatment options (e.g., non-opioid analgesics): have not been tolerated, or are not expected to be tolerated have not provided adequate analgesia, or are not expected to provide adequate analgesia uuid:62b673fb-ad0e-4e1f-8352-2f01505d5457 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:370642 biolink:treats MONDO:0002491 PMID:41385096 "[{""id"":""uuid:cb7f84df-8660-4264-9386-a5f836a1b55f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:48cb7d23-fa6e-422d-bca9-e65672093102"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydrocodone Bitartrate and Acetaminophen Oral Solution is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses [see WARNINGS ], reserve Hydrocodone Bitartrate and Acetaminophen Oral Solution for use in patients for whom alternative treatment options (e.g., non-opioid analgesics): have not been tolerated, or are not expected to be tolerated have not provided adequate analgesia, or are not expected to provide adequate analgesia uuid:e8ab73e6-fce1-4e6e-b177-91947126d248 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:370642 biolink:treats EFO:0011049 PMID:41385096 "[{""id"":""uuid:86a7dcd4-f361-4322-95bc-4a5b0a9e7a9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0043450d-7610-4155-8909-0dd5810752b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydrocodone Bitartrate and Acetaminophen Oral Solution is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses [see WARNINGS ], reserve Hydrocodone Bitartrate and Acetaminophen Oral Solution for use in patients for whom alternative treatment options (e.g., non-opioid analgesics): have not been tolerated, or are not expected to be tolerated have not provided adequate analgesia, or are not expected to provide adequate analgesia uuid:5588ef70-6f8c-4345-b062-4b1df515ef0e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3374 biolink:treats MONDO:0041052 PMID:41385096 "[{""id"":""uuid:7f464152-abea-4e00-9365-53e54165a1b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f9cc477e-add3-43d5-a993-b9c296a7ebac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] QUTENZA is indicated in adults for the treatment of neuropathic pain associated with postherpetic neuralgia (PHN) and for neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet. uuid:c5ea8367-5537-4470-a4b3-f75bf007ff7c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3374 biolink:treats UMLS:C0740447 PMID:41385096 "[{""id"":""uuid:5121d278-e93a-4ab2-a3eb-0d7af065edad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7ac2934a-fc41-45f2-b7ef-a91aef99d021"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] QUTENZA is indicated in adults for the treatment of neuropathic pain associated with postherpetic neuralgia (PHN) and for neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet. uuid:b7290d8f-a63d-4e00-90a5-caacbd3950d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229657 biolink:treats UMLS:C5780078 PMID:41385096 "[{""id"":""uuid:48ab554f-09f1-4f74-9d2c-a83e2d571c7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d9aaf9e5-63e1-4ee6-bfab-67f187d8aeb6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XDEMVY is indicated for the treatment of Demodex blepharitis. uuid:ed0cdb4f-7c53-4da6-b920-4e24900ff080 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47657 biolink:treats UMLS:C0406317 PMID:41385096 "[{""id"":""uuid:f04ed842-d10c-4b0a-aa6d-490ab718e91b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6293290a-4813-4955-bbb6-baf5710b2fea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZORYVE cream is a phosphodiesterase 4 inhibitor: ZORYVE cream, 0.3%, is indicated for the topical treatment of plaque psoriasis, including intertriginous areas, in adult and pediatric patients 6 years of age and older. ( 1.1 ) ZORYVE cream, 0.15%, is indicated for the topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 6 years of age and older. ( 1.2 ) uuid:5ce0b4ee-01a2-4813-b8fb-56baf560e613 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47657 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:897250a1-a73e-477f-843e-33d53686fc38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a8738506-06ec-4f67-a7eb-301edcd5f403"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZORYVE cream is a phosphodiesterase 4 inhibitor: ZORYVE cream, 0.3%, is indicated for the topical treatment of plaque psoriasis, including intertriginous areas, in adult and pediatric patients 6 years of age and older. ( 1.1 ) ZORYVE cream, 0.15%, is indicated for the topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 6 years of age and older. ( 1.2 ) uuid:95671061-dadb-415b-85c9-844e981fe8b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0009850 PMID:41385096 "[{""id"":""uuid:5347166d-bf41-4fc8-99af-b55bd123f735"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:044ed66c-f3eb-4660-90ab-bb60cc4e332b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ARESTIN is indicated as an adjunct to scaling and root planing procedures for reduction of pocket depth in patients with adult periodontitis. ARESTIN may be used as part of a periodontal maintenance program which includes good oral hygiene and scaling and root planing. uuid:f89b3502-802b-46b0-9afe-34b552218fa1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:11476297 biolink:treats MONDO:0005388 PMID:41385096 "[{""id"":""uuid:c3991446-7512-48f7-a9ba-d1f8a4b828ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:beb979f3-9366-4644-8979-41010333ba22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LIVDELZI is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have had an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA. This indication is approved under accelerated approval based on a reduction of alkaline phosphatase (ALP) [see Clinical Studies (14) ] . Improvement in survival or prevention of liver decompensation events have not been demonstrated. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). uuid:a9d69c89-3089-440f-aa96-e558701da8c3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:11476297 biolink:treats MONDO:0007193 PMID:41385096 "[{""id"":""uuid:519f6288-04e6-485c-b996-869a16b227b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f229434a-7f4b-4424-bcae-8209cdd5de54"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LIVDELZI is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have had an inadequate response to UDCA, or as monotherapy in patients unable to tolerate UDCA. This indication is approved under accelerated approval based on a reduction of alkaline phosphatase (ALP) [see Clinical Studies (14) ] . Improvement in survival or prevention of liver decompensation events have not been demonstrated. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). uuid:69accf7f-1a5d-447c-a3d5-4d49051bdcd2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:136034 biolink:treats MONDO:0001676 PMID:41385096 "[{""id"":""uuid:d8bc9a6a-e5f1-4e91-84bf-d3059ac7fb04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:02e95e7e-317a-4eb6-b1b6-3b13cb926153"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:eee8dcc9-734e-4e48-8808-4e309beee390"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/scenesse""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] SCENESSE ® is indicated to increase pain free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP).|[EMA] Prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). uuid:0e60f06f-0b3d-4f50-ae8d-fc23245e069c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8A7F670F2Y biolink:treats MONDO:0009114 PMID:41385096 "[{""id"":""uuid:709c8512-e706-44ac-a052-cc7893b24f15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:79bea81c-a8a8-4630-8f80-307dfb27cb96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sucraid ® (sacrosidase) Oral Solution is indicated for the treatment of sucrase deficiency, which is part of congenital sucrase-isomaltase deficiency (CSID), in adult and pediatric patients 5 months of age and older. uuid:dedf38e6-3e7b-468e-b7eb-21501f66d530 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16724 biolink:treats HP:0001262 PMID:41385096 "[{""id"":""uuid:33e98c27-6dfe-474d-823b-cf07570899a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:54940e89-f712-4204-a5e2-e0529d3fbd1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Xyrem is indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy. uuid:3f43a27f-535f-497f-a034-35e12e930282 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16724 biolink:treats MONDO:0021107 PMID:41385096 "[{""id"":""uuid:e31e1fca-3836-4a86-ae9d-565aceee5bb9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:63802898-fdf6-4514-824c-78ba0d2c5649"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Xyrem is indicated for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy. uuid:fa9da2f3-a468-4be7-8b7c-7104c58953ab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44423 biolink:treats MONDO:0011382 PMID:41385096 "[{""id"":""uuid:68482ba7-7a60-47dd-925a-03b17dad135d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:7f3aea8f-eccf-46ec-a0af-80b6a1b75ad3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f2febf24-d98b-4dd4-a982-27f1e9720b2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/siklos""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] DROXIA is indicated to reduce the frequency of painful crises and to reduce the need for blood transfusions in patients with sickle cell anemia with recurrent moderate to severe painful crises.|[EMA] Prevention of vaso-occlusive complications of sickle cell disease in patients over 2 years of age uuid:fe1aa8b7-3fef-4a09-8b70-4e6d390d0b56 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44423 biolink:treats MONDO:0018820 PMID:41385096 "[{""id"":""uuid:5cc25d7c-b3ab-415e-bc69-4901e3091cd3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3d47391a-04d5-4368-b033-b6ed0ac89538"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DROXIA is indicated to reduce the frequency of painful crises and to reduce the need for blood transfusions in patients with sickle cell anemia with recurrent moderate to severe painful crises. uuid:fb650c42-5eb7-4edb-a6a6-3b0a51c2829a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135922 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:b9f09007-9771-426f-9e3b-190bb43010f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:35188be1-75f6-4ddc-872a-5ba1423945ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SYMLIN is indicated as an adjunctive treatment in patients with type 1 or type 2 diabetes who use mealtime insulin therapy and who have failed to achieve desired glucose control despite optimal insulin therapy. uuid:084c2a02-c3b8-4375-958d-f97d9e4718f6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135922 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:25f206ce-41a7-4fa6-9ad2-bc947f2beb85"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:277ebc3b-0efe-440f-a877-fb3b69bc2261"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SYMLIN is indicated as an adjunctive treatment in patients with type 1 or type 2 diabetes who use mealtime insulin therapy and who have failed to achieve desired glucose control despite optimal insulin therapy. uuid:a297ca76-5036-4804-a783-541da4fb97c9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231598 biolink:treats MONDO:0017387 PMID:41385096 "[{""id"":""uuid:a8a4b142-83a6-4538-bdee-d1e7f3b051f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:242af051-f336-422d-84de-6bccefaf0dd1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TAZVERIK is a methyltransferase inhibitor indicated for the treatment of: Adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. ( 1.1 ) Adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies. ( 1.2 ) Adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options. ( 1.2 ) These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). uuid:69905840-e081-4eef-9575-9da4730890bb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231598 biolink:treats MONDO:0018906 PMID:41385096 "[{""id"":""uuid:50fcfe6d-4260-476c-9e0f-d02a9b550541"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e3f0f096-e9ec-4ad2-b8bb-8f751c5fec2b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3abc3670-a968-406d-8fda-65a751b1d25d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TAZVERIK is a methyltransferase inhibitor indicated for the treatment of: Adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection. ( 1.1 ) Adult patients with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies. ( 1.2 ) Adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options. ( 1.2 ) These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).|[PMDA] A drug with a new active ingredient indicated for the treatment of relapsed or refractory EZH 2 gene mutation-positive follicular lymphoma (for use only if refractory or intolerant to standard therapies). uuid:4d8a8432-3304-4740-850e-fa436e7c3857 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2645243 biolink:treats MONDO:0004956 PMID:41385096 "[{""id"":""uuid:f05a5b84-fdc1-4643-978c-a5489b4567bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e842da9d-de40-41bd-bb0e-be4adf2f9b97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AKEEGA with prednisone is indicated for the treatment of adult patients with deleterious or suspected deleterious BRCA -mutated ( BRCA m) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved test for AKEEGA [see Dosage and Administration (2.1) ] . uuid:8181bad0-f7ee-4fbd-9793-efb0f81a1fe4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:65349 biolink:treats EFO:0006865 PMID:41385096 "[{""id"":""uuid:7cd9b1cc-ce8f-4496-948b-35eb9f1514f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0be325e4-c83c-4a63-8bcd-815e2df8bfdd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:fb4e1193-8bb1-41ff-94cb-676601aa08d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MYRBETRIQ is a beta-3 adrenergic agonist indicated for the treatment of: • Overactive bladder (OAB) in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency, either alone or in combination with the muscarinic antagonist solifenacin succinate. ( 1.1 ) • Neurogenic detrusor overactivity (NDO) in pediatric patients aged 3 years and older and weighing 35 kg or more. ( 1.2 ) MYRBETRIQ Granules is a beta-3 adrenergic agonist indicated for the treatment of NDO in pediatric patients aged 3 years and older. ( 1.2 )|[PMDA] Drugs with a new active ingredient indicated for the treatment of urinary urgency, urinary frequency, and urge urinary incontinence associated with overactive bladder. uuid:bc657f0e-7b7f-4b9a-a8ff-7e97803f6129 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:65349 biolink:treats UMLS:C0341736 PMID:41385096 "[{""id"":""uuid:cbcda292-14f9-4143-b70b-d77ccda67ef4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:49e11f27-9c8a-4ce4-92ac-eaa4c299cb76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MYRBETRIQ is a beta-3 adrenergic agonist indicated for the treatment of: • Overactive bladder (OAB) in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency, either alone or in combination with the muscarinic antagonist solifenacin succinate. ( 1.1 ) • Neurogenic detrusor overactivity (NDO) in pediatric patients aged 3 years and older and weighing 35 kg or more. ( 1.2 ) MYRBETRIQ Granules is a beta-3 adrenergic agonist indicated for the treatment of NDO in pediatric patients aged 3 years and older. ( 1.2 ) uuid:4ae1427e-715f-41d0-87c2-f1ee9931b6c5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3D089V7L0K biolink:treats MONDO:0006698 PMID:41385096 "[{""id"":""uuid:2ea55057-c3d0-48e4-8272-3196ced07f5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ecac03bd-8132-4fee-95f4-f1e8b9e29c02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ursodiol Capsules are indicated for patients with radiolucent, noncalcified gallbladder stones < 20 mm in greatest diameter in whom elective cholecystectomy would be undertaken except for the presence of increased surgical risk due to systemic disease, advanced age, idiosyncratic reaction to general anesthesia, or for those patients who refuse surgery. Safety of use of ursodiol capsules beyond 24 months is not established. Ursodiol capsules are indicated for the prevention of gallstone formation in obese patients experiencing rapid weight loss. uuid:a189269a-1686-4b94-8c2c-8210575a106c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3D089V7L0K biolink:treats MONDO:0012672 PMID:41385096 "[{""id"":""uuid:56abdbaa-8b40-4887-ad13-30fe6f4f87a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:034faabd-d866-4ed5-96fa-a4c2e065d34e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ursodiol Capsules are indicated for patients with radiolucent, noncalcified gallbladder stones < 20 mm in greatest diameter in whom elective cholecystectomy would be undertaken except for the presence of increased surgical risk due to systemic disease, advanced age, idiosyncratic reaction to general anesthesia, or for those patients who refuse surgery. Safety of use of ursodiol capsules beyond 24 months is not established. Ursodiol capsules are indicated for the prevention of gallstone formation in obese patients experiencing rapid weight loss. uuid:30341e07-0f62-479e-bfd7-0021af4c80f6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5938 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:f54b4220-39b6-43bf-a79d-16eee96f5f84"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:8a6e332c-36bc-4872-aff6-21f3f9088702"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:fcdcc3e4-7569-47c7-9df0-1c2d0b3e6fa3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/betaferon""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] BETASERON is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.|[EMA] Betaferon is indicated for the treatment ofpatients with a single demyelinating event with an active inflammatory process, if it is severe enough to warrant treatment with intravenous corticosteroids, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis;patients with relapsing-remitting multiple sclerosis and two or more relapses within the last two years;patients with secondary progressive multiple sclerosis with active disease, evidenced by relapses. uuid:61ca37e3-90a2-4998-978f-e54a448d93b7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5938 biolink:treats UMLS:C2921627 PMID:41385096 "[{""id"":""uuid:723d7e58-eb69-469a-a618-1620dcbbfb2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e544aa2d-3bdd-48b3-83a9-9b5b68f6a9a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BETASERON is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. uuid:b0c6778f-32b4-4609-9b77-230d60490da3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5938 biolink:treats MONDO:0000450 PMID:41385096 "[{""id"":""uuid:1618b5e9-4bef-4f86-82d0-256836a894de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d019e8ab-89c4-4a3b-8f58-66847fcff9a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:8ac02123-8d41-452f-82b3-1499c38508fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/betaferon""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] BETASERON is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.|[EMA] Betaferon is indicated for the treatment ofpatients with a single demyelinating event with an active inflammatory process, if it is severe enough to warrant treatment with intravenous corticosteroids, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis;patients with relapsing-remitting multiple sclerosis and two or more relapses within the last two years;patients with secondary progressive multiple sclerosis with active disease, evidenced by relapses. uuid:8e13019b-db70-4104-b9e6-52319d1938e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75722 biolink:treats MONDO:0018362 PMID:41385096 "[{""id"":""uuid:bb689053-b4e2-4a8a-8adf-f57caa51032b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:26203b54-c9c7-4a47-afc2-fbe22f06fb94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tramadol hydrochloride extended-release tablet is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic and for which alternative treatment options are inadequate. Limitations of Use • Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosages or duration, and because of the greater risks of overdose and death with extended-release opioid formulations [see Warnings and Precautions ( 5.1 )] , reserve tramadol hydrochloride extended-release tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. • Tramadol hydrochloride extended-release tablet is not indicated as an as-needed (prn) analgesic. uuid:5f7d2b53-3e8b-4e91-98b1-897166b6e1aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51368 biolink:treats MONDO:0005567 PMID:41385096 "[{""id"":""uuid:126dce4a-8869-4cc8-b87e-8bf48a97243e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:667da9ff-e6c9-4158-966c-c809541a74bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lofexidine tablets are indicated for mitigation of opioid withdrawal symptoms to facilitate abrupt opioid discontinuation in adults. uuid:198559eb-d02f-440d-969c-fe7792a07831 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:38RL9AE51Q biolink:treats MONDO:0005556 PMID:41385096 "[{""id"":""uuid:3a22425a-c254-4f8f-be01-b56a1fe9a6f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4fc345a1-423b-4fc9-bec1-623dc60c59c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SAPHNELO (anifrolumab-fnia) is indicated for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE), who are receiving standard therapy [see Clinical Studies (14) ] . Limitations of Use The efficacy of SAPHNELO has not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus. Use of SAPHNELO is not recommended in these situations. uuid:15f658af-6063-4184-8ddd-8ee7874cc641 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:38RL9AE51Q biolink:treats MONDO:0043985 PMID:41385096 "[{""id"":""uuid:6d0bd9b6-c184-4ed0-986f-24831710bffd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a3726851-d94d-41c3-afff-f5f1d556cd0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SAPHNELO (anifrolumab-fnia) is indicated for the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE), who are receiving standard therapy [see Clinical Studies (14) ] . Limitations of Use The efficacy of SAPHNELO has not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus. Use of SAPHNELO is not recommended in these situations. uuid:2b27619c-d682-4d0c-8ee3-d8ed11eb126b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8382 biolink:treats MONDO:0005062 PMID:41385096 "[{""id"":""uuid:836076cf-e830-4f13-ac85-d4e80c6a5afd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b35c6f0f-cbaf-4ca3-bb4c-f68dd61d9f7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PredniSONE Tablets are indicated in the following conditions: Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer ​Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis Respiratory Diseases Symptomatic sarcoidosis Loeffler's syndrome not manageable by other means Berylliosis Aspiration pneumonitis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:85a64aba-3f05-4065-acb2-88abc2b92b1b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27882 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:d4e03c39-a1e8-474f-a11d-c728b8fa9674"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6b28fbc6-a228-40c9-9fc8-0edfa74f145a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LODOCO is indicated to reduce the risk of myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death in adult patients with established atherosclerotic disease or with multiple risk factors for cardiovascular disease. uuid:d44c4dbf-110f-4675-b6cf-7e1511cc0bfe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27882 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:fce7f188-994e-45c8-aa1b-3fc27d18e3f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:458874bb-cd49-4a30-9558-70df6f228e60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LODOCO is indicated to reduce the risk of myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death in adult patients with established atherosclerotic disease or with multiple risk factors for cardiovascular disease. uuid:b58643c6-b21b-4967-b578-85d21687a36d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27882 biolink:treats MONDO:0005311 PMID:41385096 "[{""id"":""uuid:3597f4d8-8966-4a4f-8adb-df7c8e7073d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e715c246-0ee9-4c47-9c23-a025826e2011"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LODOCO is indicated to reduce the risk of myocardial infarction (MI), stroke, coronary revascularization, and cardiovascular death in adult patients with established atherosclerotic disease or with multiple risk factors for cardiovascular disease. uuid:fe85ca3f-7e30-40c9-b016-44a1f26d93d2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44185 biolink:treats MONDO:0018944 PMID:41385096 "[{""id"":""uuid:eb144b0a-456e-48c4-b22e-56974ff3ea4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9897200e-aba9-48a4-9912-e937c20f97f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methotrexate Injection is a folate analog metabolic inhibitor indicated for: • The following neoplastic diseases for the: o Treatment of adult and pediatric patients with acute lymphoblastic leukemia as part of a combination chemotherapy regimen ( 1.1 ) o Prophylaxis and treatment of adult and pediatric patients with meningeal leukemia ( 1.2 ) o Treatment of adult and pediatric patients with non-Hodgkin lymphoma ( 1.3 ) o Treatment of adult and pediatric patients with osteosarcoma as part of a combination chemotherapy regimen ( 1.4 ) o Treatment of adults with breast cancer as part of a combination chemotherapy regimen ( 1.5 ) o Treatment of adults with squamous cell carcinoma of the head and neck as single-agent ( 1.6 ) o Treatment of adults with gestational trophoblastic neoplasia as part of a combination chemotherapy regimen ( 1.7 ) • Treatment of adults with rheumatoid arthritis (RA). ( 1.8 ) • Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA). ( 1.9 ) • Treatment of adults with severe psoriasis. ( 1.10 ) uuid:5029e4cd-712e-4674-a7d0-bf69d999c7fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50275 biolink:treats UMLS:C0341164 PMID:41385096 "[{""id"":""uuid:0175d671-811f-495e-aecd-2db62d531395"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8caafa3f-74c5-48cd-ada1-548d43d53aa0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Esomeprazole sodium for injection is a proton pump inhibitor (PPI) indicated for the: Short-term treatment of Gastroesophageal Reflux Disease (GERD) with erosive esophagitis (EE) in adults and pediatric patients 1 month to 17 years of age, as an alternative to oral therapy when oral esomeprazole is not possible or appropriate. ( 1.1 ) Risk reduction of rebleeding of gastric or duodenal ulcers following therapeutic endoscopy for acute bleeding gastric or duodenal ulcers in adults. ( 1.2 ) uuid:b4228fa1-b914-4299-8a64-93694ef54539 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50275 biolink:treats UMLS:C0155992 PMID:41385096 "[{""id"":""uuid:1b5c30d9-d2a7-4f78-9148-0c82627ffa61"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:59bd3059-22ae-4053-8fae-a7da1f1e424d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Esomeprazole sodium for injection is a proton pump inhibitor (PPI) indicated for the: Short-term treatment of Gastroesophageal Reflux Disease (GERD) with erosive esophagitis (EE) in adults and pediatric patients 1 month to 17 years of age, as an alternative to oral therapy when oral esomeprazole is not possible or appropriate. ( 1.1 ) Risk reduction of rebleeding of gastric or duodenal ulcers following therapeutic endoscopy for acute bleeding gastric or duodenal ulcers in adults. ( 1.2 ) uuid:2ee33ce7-3a59-4230-ab27-f7cfcaa01e78 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:T4H8FMA7IM biolink:treats MONDO:0019754 PMID:41385096 "[{""id"":""uuid:17fa8096-f5c4-4a0b-b1df-5020e33237a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:1a8cab78-9af6-45a9-8942-0f3a9ad6ad65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f9c12749-c91f-48d8-86f2-2580d218d83d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/sylvant""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] SYLVANT is indicated for the treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.|[EMA] Sylvant is indicated for the treatment of adult patients with multicentric Castleman’s disease (MCD who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative., uuid:f9f59305-2bdc-47fa-8295-0d937199a88a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:T4H8FMA7IM biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:7f745e7d-b7ff-4363-87ac-eac7284f799f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dbef771b-18a3-44f0-b800-3e42b5249c8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SYLVANT is indicated for the treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. uuid:e500b17d-f767-48d5-8d00-4ff10c41d087 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:T4H8FMA7IM biolink:treats MONDO:0005187 PMID:41385096 "[{""id"":""uuid:13a3bfc3-31e1-490c-8c52-1adcf325440f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b2eee9d1-9764-42db-8724-175bd7a9f537"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SYLVANT is indicated for the treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. uuid:cf4b3408-98f6-4954-b727-fde5697b50d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64355 biolink:treats UMLS:C0919659 PMID:41385096 "[{""id"":""uuid:015960fd-185d-4c98-8872-b85d72ad5184"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f16476b9-e191-4961-b00b-7ecd8ef34a45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Posaconazole is an azole antifungal indicated as follows: Posaconazole delayed-release tablets are indicated for the treatment of invasive aspergillosis in adults and pediatric patients 13 years of age and older. ( 1.1 ) Posaconazole is indicated for the prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy as follows: ( 1.2 ) Posaconazole delayed-release tablets: adults and pediatric patients 2 years of age and older who weigh greater than 40 kg Posaconazole oral suspension: adults and pediatric patients 13 years of age and older Posaconazole oral suspension is indicated for the treatment of oropharyngeal candidiasis (OPC), including OPC refractory (rOPC) to itraconazole and/or fluconazole in adult and pediatric patients aged 13 years and older. ( 1.3 ) uuid:796a4b2a-4b20-4a53-8847-73a7e45977e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:SQ8A3S5101 biolink:treats MONDO:0002049 PMID:41385096 "[{""id"":""uuid:6bc9d255-53ac-4407-9c8a-e85e80a9d830"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d203030e-3b5f-470d-ad4b-0a2c2a3cd4cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TAVALISSE is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. uuid:eba14ae8-2fdb-4b83-a5b5-22acc0e09ecd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:SQ8A3S5101 biolink:treats MONDO:0019098 PMID:41385096 "[{""id"":""uuid:92d7ee2c-d643-44ee-9690-9c61c71fdded"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a1bd5a4e-ea16-4985-89c6-2c72ce26f434"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b491ee4d-0202-4636-afd5-3c92c50ee7cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ad303a01-7984-49b0-8661-a2307afda9d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TAVALISSE is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.|[EMA] Tavlesse is indicated for the treatment of chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments.|[PMDA] Drugs with a new active ingredient indicated for the treatment of chronic idiopathic thrombocytopenic purpura. [Orphan drug] uuid:1eb38c53-6d4c-429b-900c-60aa310ac724 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:B72HH48FLU biolink:treats UMLS:C2931173 PMID:41385096 "[{""id"":""uuid:334ab72b-0679-4323-b64c-8ae635677683"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:338b1e5f-7eb5-4f43-af6f-b031ea0f6bbd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INFLECTRA is a tumor necrosis factor (TNF) blocker indicated for: Crohn's Disease ( 1.1 ): • reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. • reducing the number of draining enterocutaneous and rectovaginal fistulas and maintaining fistula closure in adult patients with fistulizing disease. Pediatric Crohn's Disease ( 1.2 ): • reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who have had an inadequate response to conventional therapy. Ulcerative Colitis ( 1.3 ): • reducing signs and symptoms, inducing and maintaining clinical remission and mucosal healing, and eliminating corticosteroid use in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy. Pediatric Ulcerative Colitis ( 1.4 ): • reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active disease who have had an inadequate response to conventional therapy. Rheumatoid Arthritis ( 1.5 ) in combination with methotrexate: • reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active disease. Ankylosing Spondylitis ( 1.6 ): • reducing signs and symptoms in adult patients with active disease. Psoriatic Arthritis ( 1.7 ): • reducing signs and symptoms of active arthritis, inhibiting the progression of structural damage, and improving physical function in adult patients. Plaque Psoriasis ( 1.8 ): • treatment of adult patients with chronic severe (i.e., extensive and/or disabling) plaque psoriasis who are candidates for systemic therapy and when other systemic therapies are medically less appropriate. uuid:64ee3c3a-9a38-4e91-917b-5ccb5d973e69 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:404914 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:2617f736-403d-45cb-8598-c893469deedf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:50ee1ce2-b7f0-44b1-b3b3-dcf6bf112a96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amlodipine and atorvastatin tablets are indicated in patients for whom treatment with both amlodipine and atorvastatin is appropriate. Amlodipine Hypertension Amlodipine is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Amlodipine may be used alone or in combination with other antihypertensive agents. Coronary Artery Disease (CAD) Chronic Stable Angina Amlodipine is indicated for the symptomatic treatment of chronic stable angina. Amlodipine may be used alone or in combination with other antianginal agents. Vasospastic Angina (Prinzmetal’s or Variant Angina) Amlodipine is indicated for the treatment of confirmed or suspected vasospastic angina. Amlodipine may be used as monotherapy or in combination with other antianginal agents. Angiographically Documented CAD In patients with recently documented CAD by angiography and without heart failure or an ejection fraction < 40%, amlodipine is indicated to reduce the risk of hospitalization for angina and to reduce the risk of a coronary revascularization procedure. Atorvastatin Atorvastatin is indicated: To reduce the risk of: Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD Non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in adults with clinically evident CHD As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in:Adults with primary hyperlipidemia.Adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH).As an adjunct to other LDL-C lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia Hypertriglyceridemia uuid:e5e1733b-f6b4-46c1-8bf4-c9b38ec5be55 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:404914 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:03e2f41e-bf60-4a4c-8f40-87f61991d580"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:80369724-07cb-480d-b5db-c88e41587c65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amlodipine and atorvastatin tablets are indicated in patients for whom treatment with both amlodipine and atorvastatin is appropriate. Amlodipine Hypertension Amlodipine is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Amlodipine may be used alone or in combination with other antihypertensive agents. Coronary Artery Disease (CAD) Chronic Stable Angina Amlodipine is indicated for the symptomatic treatment of chronic stable angina. Amlodipine may be used alone or in combination with other antianginal agents. Vasospastic Angina (Prinzmetal’s or Variant Angina) Amlodipine is indicated for the treatment of confirmed or suspected vasospastic angina. Amlodipine may be used as monotherapy or in combination with other antianginal agents. Angiographically Documented CAD In patients with recently documented CAD by angiography and without heart failure or an ejection fraction < 40%, amlodipine is indicated to reduce the risk of hospitalization for angina and to reduce the risk of a coronary revascularization procedure. Atorvastatin Atorvastatin is indicated: To reduce the risk of: Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD Non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in adults with clinically evident CHD As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in:Adults with primary hyperlipidemia.Adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH).As an adjunct to other LDL-C lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia Hypertriglyceridemia uuid:a0db5f21-6fc8-4d53-a1e2-8f97850562eb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:404914 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:009d389b-42ed-4b72-bfcf-135e6d163906"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eb1ce6c9-53f2-4f60-8574-1c9a1ecf67bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amlodipine and atorvastatin tablets are indicated in patients for whom treatment with both amlodipine and atorvastatin is appropriate. Amlodipine Hypertension Amlodipine is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Amlodipine may be used alone or in combination with other antihypertensive agents. Coronary Artery Disease (CAD) Chronic Stable Angina Amlodipine is indicated for the symptomatic treatment of chronic stable angina. Amlodipine may be used alone or in combination with other antianginal agents. Vasospastic Angina (Prinzmetal’s or Variant Angina) Amlodipine is indicated for the treatment of confirmed or suspected vasospastic angina. Amlodipine may be used as monotherapy or in combination with other antianginal agents. Angiographically Documented CAD In patients with recently documented CAD by angiography and without heart failure or an ejection fraction < 40%, amlodipine is indicated to reduce the risk of hospitalization for angina and to reduce the risk of a coronary revascularization procedure. Atorvastatin Atorvastatin is indicated: To reduce the risk of: Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD Non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in adults with clinically evident CHD As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in:Adults with primary hyperlipidemia.Adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH).As an adjunct to other LDL-C lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia Hypertriglyceridemia uuid:a8fd5c06-9576-4570-afba-c58a8f79980a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:404914 biolink:treats UMLS:C0342882 PMID:41385096 "[{""id"":""uuid:e061ada3-afda-40a9-b80a-52904ff56bf8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:39c17136-d71c-471a-97b1-ea48cf64cbec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amlodipine and atorvastatin tablets are indicated in patients for whom treatment with both amlodipine and atorvastatin is appropriate. Amlodipine Hypertension Amlodipine is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including amlodipine. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Amlodipine may be used alone or in combination with other antihypertensive agents. Coronary Artery Disease (CAD) Chronic Stable Angina Amlodipine is indicated for the symptomatic treatment of chronic stable angina. Amlodipine may be used alone or in combination with other antianginal agents. Vasospastic Angina (Prinzmetal’s or Variant Angina) Amlodipine is indicated for the treatment of confirmed or suspected vasospastic angina. Amlodipine may be used as monotherapy or in combination with other antianginal agents. Angiographically Documented CAD In patients with recently documented CAD by angiography and without heart failure or an ejection fraction < 40%, amlodipine is indicated to reduce the risk of hospitalization for angina and to reduce the risk of a coronary revascularization procedure. Atorvastatin Atorvastatin is indicated: To reduce the risk of: Myocardial infarction (MI), stroke, revascularization procedures, and angina in adults with multiple risk factors for coronary heart disease (CHD) but without clinically evident CHD MI and stroke in adults with type 2 diabetes mellitus with multiple risk factors for CHD but without clinically evident CHD Non-fatal MI, fatal and non-fatal stroke, revascularization procedures, hospitalization for congestive heart failure, and angina in adults with clinically evident CHD As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in:Adults with primary hyperlipidemia.Adults and pediatric patients aged 10 years and older with heterozygous familial hypercholesterolemia (HeFH).As an adjunct to other LDL-C lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH). As an adjunct to diet for the treatment of adults with: Primary dysbetalipoproteinemia Hypertriglyceridemia uuid:55648fd5-e5ec-4e85-b78f-bf362a433d33 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37943 biolink:treats UMLS:C0275518 PMID:41385096 "[{""id"":""uuid:ae9d05fe-a9bf-476b-902e-efb777a27920"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:43eaacf6-ecc5-4ce8-a426-edd8b116e91e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Colistimethate for Injection, USP is indicated for the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli. It is particularly indicated when the infection is caused by sensitive strains of Pseudomonas aeruginosa . This antibiotic is not indicated for infections due to Proteus or Neisseria . Colistimethate for Injection, USP has proven clinically effective in treatment of infections due to the following gram-negative organisms: Enterobacter aerogenes, Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa. Colistimethate for Injection, USP may be used to initiate therapy in serious infections that are suspected to be due to gram-negative organisms and in the treatment of infections due to susceptible gram-negative pathogenic bacilli. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Colistimethate for Injection, USP and other antibacterial drugs, Colistimethate for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:5ec4317a-657f-467a-a402-9fbba400e3b4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C4547518 biolink:treats MONDO:0010122 PMID:41385096 "[{""id"":""uuid:a7745851-60ce-44cc-a401-5162b0c6a7a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c7b06dee-b738-4f19-a210-6c7268239269"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9294b041-28ac-4073-bec7-02f53f57939d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ADZYNMA (ADAMTS13, recombinant-krhn) is a human recombinant “A disintegrin and metalloproteinase with thrombospondin motifs 13” (rADAMTS13) indicated for prophylactic or on demand enzyme replacement therapy (ERT) in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP) [see Use in Specific Populations (8.4) , Clinical Studies (14) ].|[PMDA] A drug with a new active ingredient indicated for the treatment of congenital thrombotic thrombocytopenic purpura. [Orphan drug] DRUGBANK:DB15164 uuid:01cdd0c4-9415-46e5-bc71-679d4e9a1c94 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:65349 biolink:treats HP:0100515 PMID:41385096 "[{""id"":""uuid:d36d4253-bac7-4de9-a146-0429ea11b315"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:182d4613-4c39-4fa3-85ab-b066f5f6185b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:209851c5-2423-4ab7-a17a-d1bfa05973e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mirabegron extended-release tablets are beta-3 adrenergic agonist indicated for the treatment of: Overactive bladder (OAB) in adult patients with symptoms of urge urinary incontinence, urgency, and urinary frequency. ( 1.1 )|[PMDA] Drugs with a new active ingredient indicated for the treatment of urinary urgency, urinary frequency, and urge urinary incontinence associated with overactive bladder. uuid:a04e1c30-1ac5-4e42-8488-8717985c2e93 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB16802 biolink:treats MONDO:0010679 PMID:41385096 "[{""id"":""uuid:3f4c8a7e-825b-4bed-97e3-c1e0cfcbbcb4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:52d8a627-5a01-4e37-b4a4-1043a3580a00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ELEVIDYS is indicated for the treatment of Duchenne muscular dystrophy (DMD) in individuals at least 4 years of age: For patients who are ambulatory and have a confirmed mutation in the DMD gene [see Clinical Pharmacology ( 12.2 ), Clinical Studies ( 14 ) ] For patients who are non-ambulatory and have a confirmed mutation in the DMD gene. The DMD indication in non-ambulatory patients is approved under accelerated approval based on expression of ELEVIDYS micro-dystrophin (noted hereafter as “micro-dystrophin”) in skeletal muscle. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). [see Clinical Pharmacology ( 12.2 )]. uuid:11cc10e2-372e-4df6-b533-c612e5ad2f99 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB11597 biolink:treats MONDO:0008558 PMID:41385096 "[{""id"":""uuid:90c6079f-09dc-4953-a35d-ff415d1fdb05"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6871477e-3dcd-4f58-82c1-6bbf815cae88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] WinRho ® SDF is a Rh o (D) Immune Globulin Intravenous (Human) (anti-D) product that is indicated for the treatment of ITP in Rh o (D)-positive patients and for the suppression of Rh isoimmunization in non-sensitized Rh o (D)-negative patients. uuid:83ec44f7-c260-4972-85f8-a337c11b2420 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB11597 biolink:treats MONDO:0006953 PMID:41385096 "[{""id"":""uuid:a8b9b59b-fb56-4666-a3a8-de935b1a04ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:93ffb724-fdc6-4a36-801a-133355262f0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] WinRho ® SDF is a Rh o (D) Immune Globulin Intravenous (Human) (anti-D) product that is indicated for the treatment of ITP in Rh o (D)-positive patients and for the suppression of Rh isoimmunization in non-sensitized Rh o (D)-negative patients. uuid:5dd00214-6479-470e-9cf9-fc704ac86a53 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0040732 PMID:41385096 "[{""id"":""uuid:9bc7271b-1576-40a2-b7de-d2d3e57cc9d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3274b825-47a8-4e57-b695-f60237e65454"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin and other antibacterial drugs, gentamicin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Sulfate Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa , Proteus species (indole-positive and indole-negative), Escherichia coli , Klebsiella-Enterobacter-Serratia species, Citrobacter species, and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown Gentamicin Sulfate Injection, USP to be effective in bacterial neonatal sepsis; bacterial septicemia; and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin sulfate may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection, and the important additional concepts contained in the WARNINGS box . If the causative organisms are resistant to gentamicin, other appropriate therapy should be instituted. In serious infections when the causative organisms are unknown, gentamicin sulfate may be administered as initial therapy in conjunction with a penicillin-type or cephalosporin-type drug before obtaining results of susceptibility testing. If anaerobic organisms are suspected as etiologic agents, consideration should be given to using other suitable antimicrobial therapy in conjunction with gentamicin. Following identification of the organism and its susceptibility, appropriate antibiotic therapy should then be continued. Gentamicin sulfate has been used effectively in combination with carbenicillin for the treatment of life-threatening infections caused by Pseudomonas aeruginosa . It has also been found effective when used in conjunction with a penicillin-type drug for the treatment of endocarditis caused by group D streptococci. Gentamicin Sulfate Injection, USP has also been shown to be effective in the treatment of serious staphylococcal infections. While not the antibiotic of first choice, gentamicin may be considered when penicillins or other less potentially toxic drugs are contraindicated and bacterial susceptibility tests and clinical judgment indicate its use. It may also be considered in mixed infections caused by susceptible strains of staphylococci and gram-negative organisms. In the neonate with suspected bacterial sepsis or staphylococcal pneumonia, a penicillin-type drug is also usually indicated as concomitant therapy with gentamicin. uuid:409232ca-b000-46c7-a682-ad17b1e15b81 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0006929 PMID:41385096 "[{""id"":""uuid:92202ebd-d223-47b9-9a7a-bcfe34d08382"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:11c38115-e2cb-477f-a4af-a5923dbcdcc8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin and other antibacterial drugs, gentamicin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Sulfate Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa , Proteus species (indole-positive and indole-negative), Escherichia coli , Klebsiella-Enterobacter-Serratia species, Citrobacter species, and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown Gentamicin Sulfate Injection, USP to be effective in bacterial neonatal sepsis; bacterial septicemia; and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin sulfate may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection, and the important additional concepts contained in the WARNINGS box . If the causative organisms are resistant to gentamicin, other appropriate therapy should be instituted. In serious infections when the causative organisms are unknown, gentamicin sulfate may be administered as initial therapy in conjunction with a penicillin-type or cephalosporin-type drug before obtaining results of susceptibility testing. If anaerobic organisms are suspected as etiologic agents, consideration should be given to using other suitable antimicrobial therapy in conjunction with gentamicin. Following identification of the organism and its susceptibility, appropriate antibiotic therapy should then be continued. Gentamicin sulfate has been used effectively in combination with carbenicillin for the treatment of life-threatening infections caused by Pseudomonas aeruginosa . It has also been found effective when used in conjunction with a penicillin-type drug for the treatment of endocarditis caused by group D streptococci. Gentamicin Sulfate Injection, USP has also been shown to be effective in the treatment of serious staphylococcal infections. While not the antibiotic of first choice, gentamicin may be considered when penicillins or other less potentially toxic drugs are contraindicated and bacterial susceptibility tests and clinical judgment indicate its use. It may also be considered in mixed infections caused by susceptible strains of staphylococci and gram-negative organisms. In the neonate with suspected bacterial sepsis or staphylococcal pneumonia, a penicillin-type drug is also usually indicated as concomitant therapy with gentamicin. uuid:00970d35-87c3-4049-8b4e-17131114d9b6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0020920 PMID:41385096 "[{""id"":""uuid:6771cde0-db28-4782-9a52-480163b44ea9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:016d65e4-71af-4957-beb1-04fb5e123e99"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin and other antibacterial drugs, gentamicin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Sulfate Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa , Proteus species (indole-positive and indole-negative), Escherichia coli , Klebsiella-Enterobacter-Serratia species, Citrobacter species, and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown Gentamicin Sulfate Injection, USP to be effective in bacterial neonatal sepsis; bacterial septicemia; and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin sulfate may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection, and the important additional concepts contained in the WARNINGS box . If the causative organisms are resistant to gentamicin, other appropriate therapy should be instituted. In serious infections when the causative organisms are unknown, gentamicin sulfate may be administered as initial therapy in conjunction with a penicillin-type or cephalosporin-type drug before obtaining results of susceptibility testing. If anaerobic organisms are suspected as etiologic agents, consideration should be given to using other suitable antimicrobial therapy in conjunction with gentamicin. Following identification of the organism and its susceptibility, appropriate antibiotic therapy should then be continued. Gentamicin sulfate has been used effectively in combination with carbenicillin for the treatment of life-threatening infections caused by Pseudomonas aeruginosa . It has also been found effective when used in conjunction with a penicillin-type drug for the treatment of endocarditis caused by group D streptococci. Gentamicin Sulfate Injection, USP has also been shown to be effective in the treatment of serious staphylococcal infections. While not the antibiotic of first choice, gentamicin may be considered when penicillins or other less potentially toxic drugs are contraindicated and bacterial susceptibility tests and clinical judgment indicate its use. It may also be considered in mixed infections caused by susceptible strains of staphylococci and gram-negative organisms. In the neonate with suspected bacterial sepsis or staphylococcal pneumonia, a penicillin-type drug is also usually indicated as concomitant therapy with gentamicin. uuid:a9d56ad5-21e3-4c2d-ae32-b85a7128ae9e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0030603 PMID:41385096 "[{""id"":""uuid:3d0c14c5-b35f-48d8-8239-8c8813327850"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b0ed39b7-ff94-4d32-86f0-f97cf46eb135"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin and other antibacterial drugs, gentamicin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Sulfate Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa , Proteus species (indole-positive and indole-negative), Escherichia coli , Klebsiella-Enterobacter-Serratia species, Citrobacter species, and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown Gentamicin Sulfate Injection, USP to be effective in bacterial neonatal sepsis; bacterial septicemia; and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin sulfate may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection, and the important additional concepts contained in the WARNINGS box . If the causative organisms are resistant to gentamicin, other appropriate therapy should be instituted. In serious infections when the causative organisms are unknown, gentamicin sulfate may be administered as initial therapy in conjunction with a penicillin-type or cephalosporin-type drug before obtaining results of susceptibility testing. If anaerobic organisms are suspected as etiologic agents, consideration should be given to using other suitable antimicrobial therapy in conjunction with gentamicin. Following identification of the organism and its susceptibility, appropriate antibiotic therapy should then be continued. Gentamicin sulfate has been used effectively in combination with carbenicillin for the treatment of life-threatening infections caused by Pseudomonas aeruginosa . It has also been found effective when used in conjunction with a penicillin-type drug for the treatment of endocarditis caused by group D streptococci. Gentamicin Sulfate Injection, USP has also been shown to be effective in the treatment of serious staphylococcal infections. While not the antibiotic of first choice, gentamicin may be considered when penicillins or other less potentially toxic drugs are contraindicated and bacterial susceptibility tests and clinical judgment indicate its use. It may also be considered in mixed infections caused by susceptible strains of staphylococci and gram-negative organisms. In the neonate with suspected bacterial sepsis or staphylococcal pneumonia, a penicillin-type drug is also usually indicated as concomitant therapy with gentamicin. uuid:12931b0b-f33f-4a6b-90d0-172769ee3055 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0005545 PMID:41385096 "[{""id"":""uuid:708c8219-4869-45e0-acb6-85a73d19120a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:da45ffd7-2574-43f9-8255-6ff41f0f3f6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of gentamicin and other antibacterial drugs, gentamicin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Sulfate Injection, USP is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa , Proteus species (indole-positive and indole-negative), Escherichia coli , Klebsiella-Enterobacter-Serratia species, Citrobacter species, and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown Gentamicin Sulfate Injection, USP to be effective in bacterial neonatal sepsis; bacterial septicemia; and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin sulfate may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection, and the important additional concepts contained in the WARNINGS box . If the causative organisms are resistant to gentamicin, other appropriate therapy should be instituted. In serious infections when the causative organisms are unknown, gentamicin sulfate may be administered as initial therapy in conjunction with a penicillin-type or cephalosporin-type drug before obtaining results of susceptibility testing. If anaerobic organisms are suspected as etiologic agents, consideration should be given to using other suitable antimicrobial therapy in conjunction with gentamicin. Following identification of the organism and its susceptibility, appropriate antibiotic therapy should then be continued. Gentamicin sulfate has been used effectively in combination with carbenicillin for the treatment of life-threatening infections caused by Pseudomonas aeruginosa . It has also been found effective when used in conjunction with a penicillin-type drug for the treatment of endocarditis caused by group D streptococci. Gentamicin Sulfate Injection, USP has also been shown to be effective in the treatment of serious staphylococcal infections. While not the antibiotic of first choice, gentamicin may be considered when penicillins or other less potentially toxic drugs are contraindicated and bacterial susceptibility tests and clinical judgment indicate its use. It may also be considered in mixed infections caused by susceptible strains of staphylococci and gram-negative organisms. In the neonate with suspected bacterial sepsis or staphylococcal pneumonia, a penicillin-type drug is also usually indicated as concomitant therapy with gentamicin. uuid:aa4c5f13-01f0-451b-bfda-7ccc81bf58b7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:Z80293URPV biolink:treats MONDO:0005314 PMID:41385096 "[{""id"":""uuid:41eb9dc5-8e14-4ff7-b172-61fe5edd15e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b6a7c48f-e2c0-41b9-97d0-1aaf7c4b1c02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZEPOSIA is indicated for the treatment of: • relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. • moderately to severely active ulcerative colitis (UC) in adults. uuid:02fc0f41-f63b-467e-8ceb-dab878672149 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:Z80293URPV biolink:treats UMLS:C2921627 PMID:41385096 "[{""id"":""uuid:9c0b27c8-4483-41a8-82cd-c02b71d7394a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:17ddc691-46d9-441c-a863-1f9c0b44c961"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZEPOSIA is indicated for the treatment of: • relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. • moderately to severely active ulcerative colitis (UC) in adults. uuid:77d5ed97-79be-4f5f-9312-90dd67891e01 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:Z80293URPV biolink:treats MONDO:0000450 PMID:41385096 "[{""id"":""uuid:bdd59572-6573-4a1c-a15c-a05fe6bfa377"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:62f591c9-fa08-4080-bfe5-f60b60ec5b42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZEPOSIA is indicated for the treatment of: • relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. • moderately to severely active ulcerative colitis (UC) in adults. uuid:372d5f89-3864-4037-81bb-69a4327d3694 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:Z80293URPV biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:cba560e0-0b03-4b43-9678-d8d8a6665b7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8e0197bf-bba9-4593-a2d7-4a120f33e795"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZEPOSIA is indicated for the treatment of: • relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. • moderately to severely active ulcerative colitis (UC) in adults. uuid:41e74802-c620-45f0-89fb-d09616354f42 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:129011819 biolink:treats MONDO:0005382 PMID:41385096 "[{""id"":""uuid:9755a752-deeb-4de0-a2b7-b30283672319"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3a8ef5be-eace-478b-bb0f-321e0e67142c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Miacalcin synthetic injection is a calcitonin, indicated for the following conditions: • Treatment of symptomatic Paget’s disease of bone when alternative treatments are not suitable ( 1.1 ) • Treatment of hypercalcemia ( 1.2 ) • Treatment of postmenopausal osteoporosis when alternative treatments are not suitable. Fracture reduction efficacy has not been demonstrated ( 1.3 ) Limitations of Use: • Due to the possible association between malignancy and calcitonin salmon use, the need for continued therapy should be re-evaluated on a periodic basis ( 1.4 , 5.3 ) uuid:c3824dae-a73b-4959-bdff-2cc2ad851bdd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:129011819 biolink:treats MONDO:0001566 PMID:41385096 "[{""id"":""uuid:46d25581-8b15-44db-afb5-d1bad4d327c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:93a00c73-7b61-40d0-90f7-a575b0f1788b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Miacalcin synthetic injection is a calcitonin, indicated for the following conditions: • Treatment of symptomatic Paget’s disease of bone when alternative treatments are not suitable ( 1.1 ) • Treatment of hypercalcemia ( 1.2 ) • Treatment of postmenopausal osteoporosis when alternative treatments are not suitable. Fracture reduction efficacy has not been demonstrated ( 1.3 ) Limitations of Use: • Due to the possible association between malignancy and calcitonin salmon use, the need for continued therapy should be re-evaluated on a periodic basis ( 1.4 , 5.3 ) uuid:0fce669c-b927-4d4e-a9ae-d82799bef0af biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4753 biolink:treats HP:0007906 PMID:41385096 "[{""id"":""uuid:7571668b-a387-49c5-881a-4480bcc48c23"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ee1af596-61f7-4a8d-ad70-71ffaa477dca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Echothiophate iodide for ophthalmic solution is indicated for the reduction of elevated IOP. uuid:23924244-5935-48ed-acfe-de1cc3998631 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4495 biolink:treats MONDO:0005893 PMID:41385096 "[{""id"":""uuid:287f877d-68ed-41a5-996e-2b722fe6351e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7d918dd0-da48-4fef-8636-8b17a178bad3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Diazoxide oral suspension is indicated for the management of hypoglycemia due to hyperinsulinism associated with the following conditions: Adults: Inoperable islet cell adenoma or carcinoma, or extrapancreatic malignancy. Infants and children: Leucine sensitivity, islet cell hyperplasia, nesidioblastosis, extrapancreatic malignancy, islet cell adenoma, or adenomatosis. Diazoxide oral suspension may be used preoperatively as a temporary measure, and postoperatively, if hypoglycemia persists. Diazoxide oral suspension should be used only after a diagnosis of hypoglycemia due to one of the above conditions has been definitely established. When other specific medical therapy or surgical management either has been unsuccessful or is not feasible, treatment with diazoxide oral suspension should be considered. uuid:24094147-04e6-4e13-8b98-04a4003bd527 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49701 biolink:treats MONDO:0004375 PMID:41385096 "[{""id"":""uuid:9ce65595-a09d-49d4-a106-59be8fb20072"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0607a422-f827-43d7-b5fb-5cfa991679a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LANTHANUM CARBONATE is a phosphate binder indicated to reduce serum phosphate in patients with end-stage renal disease (ESRD). Management of elevated serum phosphorus levels in patients with ESRD usually includes all of the following: reduction in dietary intake of phosphate, removal of phosphate by dialysis, and reduction of intestinal phosphate absorption with phosphate binders. uuid:350338c2-9731-4d2f-b563-5e5332aa8164 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49701 biolink:treats MONDO:0000328 PMID:41385096 "[{""id"":""uuid:caf22911-8c64-4bc5-b80b-a355a41435eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:49ec207d-fa77-4aad-8ecf-a77e18b0c45a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LANTHANUM CARBONATE is a phosphate binder indicated to reduce serum phosphate in patients with end-stage renal disease (ESRD). Management of elevated serum phosphorus levels in patients with ESRD usually includes all of the following: reduction in dietary intake of phosphate, removal of phosphate by dialysis, and reduction of intestinal phosphate absorption with phosphate binders. uuid:50749105-360e-4e19-97fd-8b4da08ce6ef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1368399 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:7d143b14-cd7d-4416-972b-05b0cbbd6447"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3b719dec-4bc6-4fe1-8f78-e755f92e9eab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:53412cb2-aa5b-4e4a-bb89-1b17bee7201f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/incresync""]},{""id"":""uuid:e6497fcf-e419-4c49-86aa-bbc1e800e60e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Alogliptin and pioglitazone tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus .|[EMA] Incresync is indicated as a second- or third-line treatment in adult patients aged 18 years and older with type-2 diabetes mellitus:, , , as an adjunct to diet and exercise to improve glycaemic control in adult patients (particularly overweight patients) inadequately controlled on pioglitazone alone, and for whom metformin is inappropriate due to contraindications or intolerance;, in combination with metformin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in adult patients (particularly overweight patients) inadequately controlled on their maximal tolerated dose of metformin and pioglitazone., , , In addition, Incresync can be used to replace separate tablets of alogliptin and pioglitazone in those adult patients aged 18 years and older with type-2 diabetes mellitus already being treated with this combination., , After initiation of therapy with Incresync, patients should be reviewed after three to six months to assess adequacy of response to treatment (e.g. reduction in HbA1c). In patients who fail to show an adequate response, Incresync should be discontinued. In light of potential risks with prolonged pioglitazone therapy, prescribers should confirm at subsequent routine reviews that the benefit of Incresync is maintained (see section 4.4).,|[PMDA] New combination drugs indicated for the treatment of type 2 diabetes mellitus. uuid:3f2009ea-a509-45aa-91ad-3ca9623863f3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7852 biolink:treats UMLS:C0278140 PMID:41385096 "[{""id"":""uuid:b9ab35cb-44d9-4a29-b5ed-5fad1f27d026"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:025d5f95-cd9d-4d5f-834c-5f06646ac561"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ROXYBOND is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. uuid:0b901491-5223-4f31-aa8f-0748972a6ac0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22652 biolink:treats MONDO:0001700 PMID:41385096 "[{""id"":""uuid:5c483027-ee3d-45c6-8440-ad0b4503f442"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cf48ee83-94d6-49f7-bb2d-3f4b673c269e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dexatran™ is indicated to provide dietary management for men and women. Folic acid is effective in the treatment of megaloblastic anemias due to a deficiency of folic acid (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, pregnancy, infancy, or childhood. uuid:111a7d83-4e1f-4c31-867a-2b2d7f07a427 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22652 biolink:treats UMLS:C0271903 PMID:41385096 "[{""id"":""uuid:1a100906-00dc-46ec-a7a4-ac58d4fcdb65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8c6e6da3-0e3e-48db-89f0-6e542f57a173"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dexatran™ is indicated to provide dietary management for men and women. Folic acid is effective in the treatment of megaloblastic anemias due to a deficiency of folic acid (as may be seen in tropical or nontropical sprue) and in anemias of nutritional origin, pregnancy, infancy, or childhood. uuid:5136f8bf-4806-4bce-a969-b9b8d92057dc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:0J8RN2W0HK biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:98a8e66c-19f9-485f-8516-2a225e568d2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:25f388ec-b369-4ae7-aa69-1d9515873fe6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AKLIEF Cream is a retinoid indicated for the topical treatment of acne vulgaris in patients 9 years of age and older. uuid:1a2ccedb-5a5a-470d-8006-e3037710ca35 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C4753601 biolink:treats MONDO:0020511 PMID:41385096 "[{""id"":""uuid:6b31d8f9-1f32-4bc4-a12f-98f80d43f5a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:be61bf69-9da7-4f8c-8d8a-a5fab51f45b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ef690750-c0f7-47c6-84cc-1e9884f91aa7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/besponsa""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] BESPONSA is indicated for the treatment of relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients 1 year and older .|[EMA] Besponsa is indicated as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL). Adult patients with Philadelphia chromosome positive (Ph+) relapsed or refractory B cell precursor ALL should have failed treatment with at least 1 tyrosine kinase inhibitor (TKI). uuid:76b0439b-1498-4882-ba23-160c41b1b33b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C4753601 biolink:treats MONDO:0004967 PMID:41385096 "[{""id"":""uuid:cd7f6a02-c47d-4e2f-a702-de5c3ec4648a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1a05b82b-bb5c-43ba-bdd4-b98968037614"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BESPONSA is indicated for the treatment of relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients 1 year and older . uuid:b8ea3feb-2686-4441-9b26-12c669a64066 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:AHU547PI9H biolink:treats MONDO:0001356 PMID:41385096 "[{""id"":""uuid:6152d2d3-405c-44a9-ac2b-edd0825e03fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f4b057ee-1893-4ab1-9471-1b1cdce7e060"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Monoferric is indicated for the treatment of iron deficiency anemia (IDA) in adult patients: who have intolerance to oral iron or have had unsatisfactory response to oral iron who have non-hemodialysis dependent chronic kidney disease (NDD-CKD) uuid:5f74bc30-458a-4cd8-b879-1c2c6f162b99 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:AHU547PI9H biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:92c3d605-4efd-4d43-9c67-b54dc519c28b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1bed01d5-c4ff-493d-a1bd-cbd148278ca6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Monoferric is indicated for the treatment of iron deficiency anemia (IDA) in adult patients: who have intolerance to oral iron or have had unsatisfactory response to oral iron who have non-hemodialysis dependent chronic kidney disease (NDD-CKD) uuid:dddd7ce3-64e1-451e-9b1b-ee0eb3e0bc81 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2611258 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:76c05665-a7ee-42e6-bf53-68b76c6dc45c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aeee6139-cc7d-4e07-8fe5-54d73e1bfa8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AUVELITY is indicated for the treatment of major depressive disorder (MDD) in adults. uuid:93d6c00c-1c22-45bf-8dce-43e41d8728dd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:145430 biolink:treats MONDO:0018874 PMID:41385096 "[{""id"":""uuid:aa5f1848-9a36-453c-b374-3b200fbf3969"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:07551968-0c9f-4eec-ab52-105f42a1701f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:6c1324af-61f3-42c5-97e0-0de75f9c1c3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tibsovo-0""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test with: Newly Diagnosed Acute Myeloid Leukemia (AML) In combination with azacitidine or as monotherapy for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy ( 1.1 ). Relapsed or refractory AML For the treatment of adult patients with relapsed or refractory AML ( 1.2 ). Relapsed or refractory Myelodysplastic Syndromes (MDS) For the treatment of adult patients with relapsed or refractory myelodysplastic syndromes ( 1.3 ). Locally Advanced or Metastatic Cholangiocarcinoma For the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma who have been previously treated ( 1.4 ).|[EMA] Tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy (see section 5.1).Tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy. uuid:1e8239c6-33b9-45cd-8218-46650ea342a0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:145430 biolink:treats MONDO:0018881 PMID:41385096 "[{""id"":""uuid:b6f79cdd-7887-4990-a733-2610accecba1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cff57f03-861b-419f-b1a0-ccd2c2c705af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test with: Newly Diagnosed Acute Myeloid Leukemia (AML) In combination with azacitidine or as monotherapy for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy ( 1.1 ). Relapsed or refractory AML For the treatment of adult patients with relapsed or refractory AML ( 1.2 ). Relapsed or refractory Myelodysplastic Syndromes (MDS) For the treatment of adult patients with relapsed or refractory myelodysplastic syndromes ( 1.3 ). Locally Advanced or Metastatic Cholangiocarcinoma For the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma who have been previously treated ( 1.4 ). uuid:0f16dbfb-d26e-41ba-9c71-5a637636e035 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:145430 biolink:treats MONDO:0019087 PMID:41385096 "[{""id"":""uuid:bc462cd5-fbc0-4944-9a01-7c0d71cd7bcf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:291264a0-f9b0-4b3e-bdd5-e9383ba108f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:8d441757-c623-422a-85b9-9d5db444f479"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tibsovo-0""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] TIBSOVO is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test with: Newly Diagnosed Acute Myeloid Leukemia (AML) In combination with azacitidine or as monotherapy for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy ( 1.1 ). Relapsed or refractory AML For the treatment of adult patients with relapsed or refractory AML ( 1.2 ). Relapsed or refractory Myelodysplastic Syndromes (MDS) For the treatment of adult patients with relapsed or refractory myelodysplastic syndromes ( 1.3 ). Locally Advanced or Metastatic Cholangiocarcinoma For the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma who have been previously treated ( 1.4 ).|[EMA] Tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) with an isocitrate dehydrogenase-1 (IDH1) R132 mutation who are not eligible to receive standard induction chemotherapy (see section 5.1).Tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation who were previously treated by at least one prior line of systemic therapy. uuid:17ef2d52-eaa4-4f68-a159-7a39fbb4ad6b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:54736666 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:c31e8426-14ac-4c67-aba5-2351db71553e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:71afbf71-06a5-4a97-ad4e-c6657cf6e8cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DOVATO is indicated as a complete regimen for the treatment of HIV-1 infection in adults and adolescents 12 years of age and older and weighing at least 25 kg with no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of DOVATO. uuid:96f440ea-6982-42dd-9a2e-372cff74b090 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:46878853 biolink:treats MONDO:0018637 PMID:41385096 "[{""id"":""uuid:27948198-7958-4ed6-95f6-73ed864e26ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4d404848-900b-4e80-b6b4-af0864adc3e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Treatment of Hypercholesterolemia Fenofibrate capsules are indicated as adjunctive therapy to diet for the reduction of LDL-C, Total-C, Triglycerides and apo B in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate (see National Cholesterol Education Program [NCEP] Treatment Guidelines, below). Treatment of Hypertriglyceridemia Fenofibrate capsules are also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually reduce fasting triglycerides and eliminate chylomicronemia thereby obviating the need for pharmacologic intervention. Markedly elevated levels of serum triglycerides (e.g. > 2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate therapy on reducing this risk has not been adequately studied. Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV and V hyperlipoproteinemia 2 . The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcoholic intake may be important factors in hypertriglyceridemia and should be addressed prior to any drug therapy. Physical exercise can be an important ancillary measure. Diseases contributory to hyperlipidemia, such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy, like thiazide diuretics and beta-blockers, is sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of the specific etiologic agent may obviate the need for specific drug therapy of hypertriglyceridemia. The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with non-drug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet (see WARNINGS and PRECAUTIONS ). Fredrickson Classification of Hyperlipoproteinemias Lipid Elevation Type Lipoprotein Elevated Major Minor I (rare) Chylomicrons TG ↑↔C IIa LDL C — IIb LDL, VLDL C TG III (rare) IDL C, TG — IV VLDL TG ↑↔C V (rare) Chylomicrons, VLDL TG ↑↔ C = cholesterol TG = triglycerides LDL = low density lipoprotein VLDL = very low density lipoprotein IDL = intermediate density lipoprotein The NCEP Treatment Guidelines Definite Athlerosclerotic Disease a Two or More Other Risk Factors b LDL-Cholesterol mg/dL (mmol/L) Initiation Level Goal No No ≥ 190 (≥ 4.9) < 160 (< 4.1) No Yes ≥ 160 (≥ 4.1) < 130 (< 3.4) Yes Yes or No ≥ 130 c (≥ 3.4) < 100 (< 2.6) a Coronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease). b Other risk factors for coronary heart disease (CHD) include: age (males: ≥ 4 5 years; females: ≥ 55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL- C <35 mg/dL (<0.91mmol/L); and diabetes mellitus. Subtract 1 risk factor if HDL-C is ≥ 60 mg/dL (≥1.6 mmol/L) c In CHD patients with LDL-C levels 100 to 129 mg/dL, the physician should exercise clinical judgment in deciding whether to initiate drug treatment. uuid:bebe5b1b-05b2-45e0-b7c2-2c33c30892b1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135901 biolink:treats MONDO:0019933 PMID:41385096 "[{""id"":""uuid:a8e4ff9c-644a-49a8-8f70-171f7588a7cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e7ae0f61-ffa4-42bc-ad60-2277a34904f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:5b2dc1f6-15da-426d-94e0-eb12473ab271"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lanreotide Injection is a somatostatin analog indicated for: the long-term treatment of acromegalic patients who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy. ( 1.1 ) the treatment of adult patients with unresectable, well- or moderately- differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival. ( 1.2 ) the treatment of adults with carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analog rescue therapy. ( 1.3 )|[PMDA] Drugs with a new active ingredient for the improvement of hypersecretion of growth hormone and IGF-I (somatomedin-C) and related symptoms in acromegaly and pituitary gigantism (when surgical therapies are not sufficiently effective or are difficult to perform). uuid:e6a32fb6-1736-463f-b884-ba140e0f64cb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135901 biolink:treats MONDO:0024503 PMID:41385096 "[{""id"":""uuid:21c94955-15b2-4067-8a93-5765987b269b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f1d0d092-1c45-4eea-93b5-6621843a2a2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9290373d-3480-4769-95fb-7ded8a24fe09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lanreotide Injection is a somatostatin analog indicated for: the long-term treatment of acromegalic patients who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy. ( 1.1 ) the treatment of adult patients with unresectable, well- or moderately- differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival. ( 1.2 ) the treatment of adults with carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analog rescue therapy. ( 1.3 )|[PMDA] A drug with a new additional indication and a new dosage indicated for the treatment of neuroendocrine tumors of the pancreas and gastrointestinal tract. uuid:67fc70bc-f923-41cb-9426-cfc7e9538a11 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135901 biolink:treats MONDO:0100347 PMID:41385096 "[{""id"":""uuid:2282c097-d192-4129-ace9-73392305cd92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9767ab02-7991-442b-84b1-a8ae89e08379"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lanreotide Injection is a somatostatin analog indicated for: the long-term treatment of acromegalic patients who have had an inadequate response to or cannot be treated with surgery and/or radiotherapy. ( 1.1 ) the treatment of adult patients with unresectable, well- or moderately- differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival. ( 1.2 ) the treatment of adults with carcinoid syndrome; when used, it reduces the frequency of short-acting somatostatin analog rescue therapy. ( 1.3 ) uuid:2fb9edbb-a2a9-4cd4-9a07-4a31aa4060ab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71417 biolink:treats MONDO:0009348 PMID:41385096 "[{""id"":""uuid:1ca2815b-966c-47f2-a3d0-e741fbb4e596"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4a602e5e-6996-4e13-8f2a-9de38a153047"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Matulane is indicated for use in combination with other anticancer drugs for the treatment of Stage III and IV Hodgkin's disease. Matulane is used as part of the MOPP (nitrogen mustard, vincristine, procarbazine, prednisone) regimen. uuid:b2a79eeb-1486-4e69-87a1-4c47aa5499e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17347 biolink:treats MONDO:0002146 PMID:41385096 "[{""id"":""uuid:d6a6ce56-0880-4c97-a3f8-10e96d39462d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9c806bee-b896-4d76-93f4-d635d3507351"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Testosterone implants are pellets containing 100mg of the active ingredient testosterone. These implants are used in hormone replacement therapy in men. Testosterone is a natural male hormone, known as an androgen, which controls normal sexual development in men. Testosterone implants are used in testosterone replacement therapy in men with low or no natural testosterone (a condition known as hypogonadism). uuid:dc3128e9-3503-467e-ae9e-b75325518915 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4031 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:8c8492b7-46ee-4018-a246-57b71dc30aa3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d1d9b290-fca9-499e-ae6a-14b7d0c0091a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Kidney, Liver, and Heart Transplantation Cyclosporine capsules (modified) is indicated for the prophylaxis of organ rejection in kidney, liver, and heart allogeneic transplants. Cyclosporine capsules (modified) has been used in combination with azathioprine and corticosteroids. Rheumatoid Arthritis Cyclosporine capsules (modified) is indicated for the treatment of patients with severe active, rheumatoid arthritis where the disease has not adequately responded to methotrexate. Cyclosporine capsules (modified) can be used in combination with methotrexate in rheumatoid arthritis patients who do not respond adequately to methotrexate alone. Psoriasis Cyclosporine capsules (modified) is indicated for the treatment of adult, nonimmunocompromised patients with severe (i.e., extensive and/or disabling), recalcitrant, plaque psoriasis who have failed to respond to at least one systemic therapy (e.g., PUVA, retinoids, or methotrexate) or in patients for whom other systemic therapies are contraindicated or cannot be tolerated. While rebound rarely occurs, most patients will experience relapse with cyclosporine capsules (modified) as with other therapies upon cessation of treatment. uuid:848df4fb-63d0-4ca2-8178-ed9078d701dc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4031 biolink:treats UMLS:C0406317 PMID:41385096 "[{""id"":""uuid:8aefea61-1a08-45d0-a799-2faa9cb3d2de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:60515bd6-a91a-487e-9499-1d982e5bcf92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Kidney, Liver, and Heart Transplantation Cyclosporine capsules (modified) is indicated for the prophylaxis of organ rejection in kidney, liver, and heart allogeneic transplants. Cyclosporine capsules (modified) has been used in combination with azathioprine and corticosteroids. Rheumatoid Arthritis Cyclosporine capsules (modified) is indicated for the treatment of patients with severe active, rheumatoid arthritis where the disease has not adequately responded to methotrexate. Cyclosporine capsules (modified) can be used in combination with methotrexate in rheumatoid arthritis patients who do not respond adequately to methotrexate alone. Psoriasis Cyclosporine capsules (modified) is indicated for the treatment of adult, nonimmunocompromised patients with severe (i.e., extensive and/or disabling), recalcitrant, plaque psoriasis who have failed to respond to at least one systemic therapy (e.g., PUVA, retinoids, or methotrexate) or in patients for whom other systemic therapies are contraindicated or cannot be tolerated. While rebound rarely occurs, most patients will experience relapse with cyclosporine capsules (modified) as with other therapies upon cessation of treatment. uuid:8761ed60-6d64-44ee-9efc-bd0b4d1912e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:825fe4d0-87c0-43f9-b8f1-86f2f8d3e0da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:19e1fd8a-27cb-4d8d-84be-fb8494ac598a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisolone Sodium Phosphate Oral Solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under “Allergic States”), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti- PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren’s syndrome, relapsing polychondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); Trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). uuid:40dab491-7ab1-4009-b536-3ed1d27f1f70 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0018076 PMID:41385096 "[{""id"":""uuid:a08f0ddf-1960-44e9-9eda-cf08c4df953e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7df1ea11-ae2e-46d1-a88e-b4687ccbb481"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prednisolone Sodium Phosphate Oral Solution is indicated in the following conditions: 1. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in adult and pediatric populations with: seasonal or perennial allergic rhinitis; asthma; contact dermatitis; atopic dermatitis; serum sickness; drug hypersensitivity reactions. 2. Dermatologic Diseases Pemphigus; bullous dermatitis herpetiformis; severe erythema multiforme (Stevens-Johnson syndrome); exfoliative erythroderma; mycosis fungoides. 3. Edematous States To induce diuresis or remission of proteinuria in nephrotic syndrome in adults with lupus erythematosus and in adults and pediatric populations, with idiopathic nephrotic syndrome, without uremia. 4. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance); congenital adrenal hyperplasia; hypercalcemia associated with cancer; nonsuppurative thyroiditis. 5. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: ulcerative colitis; regional enteritis. 6. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults; selected cases of secondary thrombocytopenia; acquired (autoimmune) hemolytic anemia; pure red cell aplasia; Diamond-Blackfan anemia. 7. Neoplastic Diseases For the treatment of acute leukemia and aggressive lymphomas in adults and children. 8. Nervous System Acute exacerbations of multiple sclerosis. 9. Ophthalmic Diseases Uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids; temporal arteritis; sympathetic ophthalmia. 10. Respiratory Diseases Symptomatic sarcoidosis; idiopathic eosinophilic pneumonias; fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy; asthma (as distinct from allergic asthma listed above under “Allergic States”), hypersensitivity pneumonitis, idiopathic pulmonary fibrosis, acute exacerbations of chronic obstructive pulmonary disease (COPD), and Pneumocystis carinii pneumonia (PCP) associated with hypoxemia occurring in an HIV (+) individual who is also under treatment with appropriate anti- PCP antibiotics. Studies support the efficacy of systemic corticosteroids for the treatment of these conditions: allergic bronchopulmonary aspergillosis, idiopathic bronchiolitis obliterans with organizing pneumonia. 11. Rheumatic Disorders As adjunctive therapy for short term administration (to tide the patient over an acute episode or exacerbation) in: psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low dose maintenance therapy); ankylosing spondylitis; acute and subacute bursitis; acute nonspecific tenosynovitis; acute gouty arthritis; epicondylitis. For the treatment of systemic lupus erythematosus, dermatomyositis (polymyositis), polymyalgia rheumatica, Sjogren’s syndrome, relapsing polychondritis, and certain cases of vasculitis. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block, tuberculosis with enlarged mediastinal lymph nodes causing respiratory difficulty, and tuberculosis with pleural or pericardial effusion (appropriate antituberculous chemotherapy must be used concurrently when treating any tuberculosis complications); Trichinosis with neurologic or myocardial involvement; acute or chronic solid organ rejection (with or without other agents). uuid:8eabd715-1dd8-4220-b137-87291c8c8d97 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8212 biolink:treats MONDO:0007661 PMID:41385096 "[{""id"":""uuid:320920f7-9109-4829-9131-9f7d127a6f04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:09221197-3621-4d3c-9d66-c8b2e0da4373"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pimozide tablets, USP are indicated for the suppression of motor and phonic tics in patients with Tourette’s Disorder who have failed to respond satisfactorily to standard treatment. Pimozide Tablets, USP are not intended as a treatment of first choice nor is it intended for the treatment of tics that are merely annoying or cosmetically troublesome. Pimozide Tablets, USP should be reserved for use in Tourette’s Disorder patients whose development and/or daily life function is severely compromised by the presence of motor and phonic tics. Evidence supporting approval of pimozide tablets, USP for use in Tourette’s Disorder was obtained in two controlled clinical investigations which enrolled patients between the ages of 8 and 53 years. Most subjects in the two trials were 12 or older. uuid:22cfce21-7d30-425d-96bb-611916d9315d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:VL756B1K0U biolink:treats MONDO:0005338 PMID:41385096 "[{""id"":""uuid:d1f8177a-2c91-41a6-8aad-2b6af192560b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fb425609-0043-46ce-afcf-919ef78d7d1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RHOPRESSA is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. uuid:94a1d318-a0e4-40ea-b4c8-8da6a333ab31 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:VL756B1K0U biolink:treats MONDO:0006875 PMID:41385096 "[{""id"":""uuid:c419c78f-9bba-4ec5-bf6e-3c99dbc68038"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:58e5eb44-69fa-4deb-84bb-67dd8b05377c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RHOPRESSA is indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. uuid:4e03c571-2abc-4305-b571-03578602c389 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4356 biolink:treats MONDO:0859316 PMID:41385096 "[{""id"":""uuid:753a5072-a77a-452c-9952-23a3a521433a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1643a779-e00e-4a16-be52-b9f554232692"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Deferoxamine mesylate for injection is an iron-chelating agent indicated: Limitations of Use Deferoxamine mesylate for injection is not indicated for the treatment of primary hemochromatosis (since phlebotomy is the method of choice for removing excess iron in this disorder). As an adjunct to standard measures for the treatment of acute iron intoxication. ( 1.1 ) For the treatment of transfusional iron overload in patients with chronic anemia. ( 1.2 ) Limitations of Use Deferoxamine mesylate for injection is not indicated for the treatment of primary hemochromatosis (since phlebotomy is the method of choice for removing excess iron in this disorder). uuid:143ff9fe-be27-4432-be04-5e722a4554a2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4356 biolink:treats UMLS:C0581384 PMID:41385096 "[{""id"":""uuid:d963f054-8f46-4fda-939f-d6c52975bcfd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c2a11f6e-da80-4bf8-a0a9-f990b3f150f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Deferoxamine mesylate for injection is an iron-chelating agent indicated: Limitations of Use Deferoxamine mesylate for injection is not indicated for the treatment of primary hemochromatosis (since phlebotomy is the method of choice for removing excess iron in this disorder). As an adjunct to standard measures for the treatment of acute iron intoxication. ( 1.1 ) For the treatment of transfusional iron overload in patients with chronic anemia. ( 1.2 ) Limitations of Use Deferoxamine mesylate for injection is not indicated for the treatment of primary hemochromatosis (since phlebotomy is the method of choice for removing excess iron in this disorder). uuid:807fcf62-1392-4577-943c-93d46f29fb05 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63623 biolink:treats MONDO:0018019 PMID:41385096 "[{""id"":""uuid:d4d5772a-6713-4a52-b730-e8c8ba60d5c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:da41babc-785d-4948-8a72-c0223b974409"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CHEMET is indicated for the treatment of lead poisoning in pediatric patients aged 1 year and older with blood lead levels above 45 mcg/dL. uuid:9e3c3dc1-d5a8-4ea4-9dc8-e559d1d951d2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27834 biolink:treats MONDO:0018935 PMID:41385096 "[{""id"":""uuid:737290f0-c5b1-46d7-b845-459e196a20d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1a9df288-e31e-475d-b1ed-260d74caf7f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NIPENT is indicated as single-agent treatment for both untreated and alpha-interferon-refractory hairy cell leukemia patients with active disease as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms. uuid:f1139cc2-3ad1-44ae-a96b-3ef57013f500 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27834 biolink:treats MONDO:0002280 PMID:41385096 "[{""id"":""uuid:3a5897e8-ba1f-4823-b4a1-905d72ed509c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4a59fae1-8811-4b2e-84e3-a1337bed5f04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NIPENT is indicated as single-agent treatment for both untreated and alpha-interferon-refractory hairy cell leukemia patients with active disease as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms. uuid:482448ba-cfdb-42c1-bae7-9bdbf77407ae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27834 biolink:treats MONDO:0001475 PMID:41385096 "[{""id"":""uuid:3ba67340-44ba-4ee5-8922-22a0f08ddded"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:014b87dc-f4ce-4b11-88c0-0de65cb30bc1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NIPENT is indicated as single-agent treatment for both untreated and alpha-interferon-refractory hairy cell leukemia patients with active disease as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms. uuid:d0e3a16c-deb8-4b2b-a624-b1c348038886 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27834 biolink:treats MONDO:0002049 PMID:41385096 "[{""id"":""uuid:48533734-7608-4dac-a2f6-2deed3e22796"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:20136e34-8f65-491e-88fd-779826481bfc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NIPENT is indicated as single-agent treatment for both untreated and alpha-interferon-refractory hairy cell leukemia patients with active disease as defined by clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms. uuid:ab047d59-d601-4241-aac0-e3654cb6476b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8069 biolink:treats MONDO:0016027 PMID:41385096 "[{""id"":""uuid:caa7ad93-cafd-4579-820d-217453947eb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:93a3928f-d485-4604-b322-d64402b31aab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SEZABY is indicated for the treatment of neonatal seizures in term and preterm infants. uuid:a2eada95-99b2-4a51-ac45-a7007a4d0179 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:52CMI0WC3Y biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:e806a03c-6154-4cd8-940c-ef6d0e42145e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7a891b41-4ffe-49d7-a878-5ce3a612a622"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:76f29952-1bc3-4868-affa-2ba913821860"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tecentriq""]},{""id"":""uuid:adb52e1e-6849-4759-8dc1-728dbb5ecd00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TECENTRIQ HYBREZA is a combination of atezolizumab, a programmed death-ligand 1 (PD-L1) blocking antibody, and hyaluronidase, an endoglycosidase indicated: Non-Small Cell Lung Cancer (NSCLC) as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage II to IIIA NSCLC whose tumors have PD-L1 expression on ≥ 1% of tumor cells, as determined by an FDA-approved test. ( 1.2 , 2.1 ) for the first-line treatment of adult patients with metastatic NSCLC whose tumors have high PD-L1 expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 10% of the tumor area [IC ≥ 10%]), as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. ( 1.2 , 2.1 ) in combination with bevacizumab, paclitaxel, and carboplatin, for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with paclitaxel protein-bound and carboplatin for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) for the treatment of adult patients with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for NSCLC harboring these aberrations prior to receiving TECENTRIQ HYBREZA. ( 1.2 ) Small Cell Lung Cancer (SCLC) ( 1.3 ) in combination with carboplatin and etoposide, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). ( 1.3 ) Hepatocellular Carcinoma (HCC) ( 1.4 ) in combination with bevacizumab for the treatment of adult patients with unresectable or metastatic HCC who have not received prior systemic therapy. ( 1.4 ) Melanoma ( 1.5 ) in combination with cobimetinib and vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma as determined by an FDA-approved test. ( 1.5 , 2.1 ) Alveolar Soft Part Sarcoma (ASPS) (1.6) for the treatment of adult patients with unresectable or metastatic ASPS. (1.6)|[EMA] Urothelial carcinomaTecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression ≥ 5% (see section 5.1).Non-small cell lung cancer Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (NSCLC). In patients with EGFR mutant or ALK-positive NSCLC, Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5.1).Tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous NSCLC who do not have EGFR mutant or ALK positive NSCLC (see section 5.1).Tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PD-L1 expression ≥ 50% tumour cells (TC) or ≥ 10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC (see section 5.1).Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR mutant or ALK positive NSCLC should also have received targeted therapies before receiving Tecentriq (see section 5.1).Small cell lung cancerTecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) (see section 5.1).Hepatocellular carcinomaTecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy (see section 5.1).Urothelial carcinomaTecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression ≥ 5% (see section 5.1).Non-small cell lung cancerTecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PD-L1 expression ≥ 50% tumour cells (TC) or ≥ 10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC (see section 5.1).Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR mutant or ALK positive NSCLC should also have received targeted therapies before receiving Tecentriq (see section 5.1).Triple-negative breast cancerTecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.|[PMDA] A drug with a new active ingredient indicated for the treatment of unresectable advanced or recurrent non-small-cell lung cancer. uuid:687ea605-320f-495e-ad64-607a924d8eab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:52CMI0WC3Y biolink:treats MONDO:0008433 PMID:41385096 "[{""id"":""uuid:319ad522-8161-4b89-8c71-03d529d8367c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cbff7e5c-d403-4cb1-8021-d0e3f32bb338"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c1bed086-6dd4-40c7-a64a-9caaf310dfd9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tecentriq""]},{""id"":""uuid:2988a6a0-ba21-45ce-ae20-e6ceef679f89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TECENTRIQ HYBREZA is a combination of atezolizumab, a programmed death-ligand 1 (PD-L1) blocking antibody, and hyaluronidase, an endoglycosidase indicated: Non-Small Cell Lung Cancer (NSCLC) as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage II to IIIA NSCLC whose tumors have PD-L1 expression on ≥ 1% of tumor cells, as determined by an FDA-approved test. ( 1.2 , 2.1 ) for the first-line treatment of adult patients with metastatic NSCLC whose tumors have high PD-L1 expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 10% of the tumor area [IC ≥ 10%]), as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. ( 1.2 , 2.1 ) in combination with bevacizumab, paclitaxel, and carboplatin, for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with paclitaxel protein-bound and carboplatin for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) for the treatment of adult patients with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for NSCLC harboring these aberrations prior to receiving TECENTRIQ HYBREZA. ( 1.2 ) Small Cell Lung Cancer (SCLC) ( 1.3 ) in combination with carboplatin and etoposide, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). ( 1.3 ) Hepatocellular Carcinoma (HCC) ( 1.4 ) in combination with bevacizumab for the treatment of adult patients with unresectable or metastatic HCC who have not received prior systemic therapy. ( 1.4 ) Melanoma ( 1.5 ) in combination with cobimetinib and vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma as determined by an FDA-approved test. ( 1.5 , 2.1 ) Alveolar Soft Part Sarcoma (ASPS) (1.6) for the treatment of adult patients with unresectable or metastatic ASPS. (1.6)|[EMA] Urothelial carcinomaTecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression ≥ 5% (see section 5.1).Non-small cell lung cancer Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (NSCLC). In patients with EGFR mutant or ALK-positive NSCLC, Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5.1).Tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous NSCLC who do not have EGFR mutant or ALK positive NSCLC (see section 5.1).Tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PD-L1 expression ≥ 50% tumour cells (TC) or ≥ 10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC (see section 5.1).Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR mutant or ALK positive NSCLC should also have received targeted therapies before receiving Tecentriq (see section 5.1).Small cell lung cancerTecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) (see section 5.1).Hepatocellular carcinomaTecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy (see section 5.1).Urothelial carcinomaTecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression ≥ 5% (see section 5.1).Non-small cell lung cancerTecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PD-L1 expression ≥ 50% tumour cells (TC) or ≥ 10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC (see section 5.1).Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR mutant or ALK positive NSCLC should also have received targeted therapies before receiving Tecentriq (see section 5.1).Triple-negative breast cancerTecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.|[PMDA] A drug with a new indication and a new dosage for the treatment of extensive-stage small-cell lung cancer. [Orphan drug] uuid:6c9ee77c-004b-46b9-9334-ca1a37342fc8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:52CMI0WC3Y biolink:treats MONDO:0007256 PMID:41385096 "[{""id"":""uuid:8e9fa710-9ddf-4a9c-8eb6-881f107c4a03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:daa364be-0315-45e0-ab98-fbc440022fc3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0fd5cbd6-479d-42e4-a873-134e8da84e9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tecentriq""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] TECENTRIQ HYBREZA is a combination of atezolizumab, a programmed death-ligand 1 (PD-L1) blocking antibody, and hyaluronidase, an endoglycosidase indicated: Non-Small Cell Lung Cancer (NSCLC) as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage II to IIIA NSCLC whose tumors have PD-L1 expression on ≥ 1% of tumor cells, as determined by an FDA-approved test. ( 1.2 , 2.1 ) for the first-line treatment of adult patients with metastatic NSCLC whose tumors have high PD-L1 expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 10% of the tumor area [IC ≥ 10%]), as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. ( 1.2 , 2.1 ) in combination with bevacizumab, paclitaxel, and carboplatin, for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with paclitaxel protein-bound and carboplatin for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) for the treatment of adult patients with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for NSCLC harboring these aberrations prior to receiving TECENTRIQ HYBREZA. ( 1.2 ) Small Cell Lung Cancer (SCLC) ( 1.3 ) in combination with carboplatin and etoposide, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). ( 1.3 ) Hepatocellular Carcinoma (HCC) ( 1.4 ) in combination with bevacizumab for the treatment of adult patients with unresectable or metastatic HCC who have not received prior systemic therapy. ( 1.4 ) Melanoma ( 1.5 ) in combination with cobimetinib and vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma as determined by an FDA-approved test. ( 1.5 , 2.1 ) Alveolar Soft Part Sarcoma (ASPS) (1.6) for the treatment of adult patients with unresectable or metastatic ASPS. (1.6)|[EMA] Urothelial carcinomaTecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression ≥ 5% (see section 5.1).Non-small cell lung cancer Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (NSCLC). In patients with EGFR mutant or ALK-positive NSCLC, Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5.1).Tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous NSCLC who do not have EGFR mutant or ALK positive NSCLC (see section 5.1).Tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PD-L1 expression ≥ 50% tumour cells (TC) or ≥ 10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC (see section 5.1).Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR mutant or ALK positive NSCLC should also have received targeted therapies before receiving Tecentriq (see section 5.1).Small cell lung cancerTecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) (see section 5.1).Hepatocellular carcinomaTecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy (see section 5.1).Urothelial carcinomaTecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression ≥ 5% (see section 5.1).Non-small cell lung cancerTecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PD-L1 expression ≥ 50% tumour cells (TC) or ≥ 10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC (see section 5.1).Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR mutant or ALK positive NSCLC should also have received targeted therapies before receiving Tecentriq (see section 5.1).Triple-negative breast cancerTecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease. uuid:f2ea8017-fed0-4c50-917f-d56d9d6bc741 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:52CMI0WC3Y biolink:treats MONDO:0005105 PMID:41385096 "[{""id"":""uuid:c4eb88b8-4379-4d3b-a108-5ab8df1e1ad2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ccb307bb-af36-4c76-93a9-26910bee3f24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TECENTRIQ HYBREZA is a combination of atezolizumab, a programmed death-ligand 1 (PD-L1) blocking antibody, and hyaluronidase, an endoglycosidase indicated: Non-Small Cell Lung Cancer (NSCLC) as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage II to IIIA NSCLC whose tumors have PD-L1 expression on ≥ 1% of tumor cells, as determined by an FDA-approved test. ( 1.2 , 2.1 ) for the first-line treatment of adult patients with metastatic NSCLC whose tumors have high PD-L1 expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 10% of the tumor area [IC ≥ 10%]), as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. ( 1.2 , 2.1 ) in combination with bevacizumab, paclitaxel, and carboplatin, for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with paclitaxel protein-bound and carboplatin for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) for the treatment of adult patients with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for NSCLC harboring these aberrations prior to receiving TECENTRIQ HYBREZA. ( 1.2 ) Small Cell Lung Cancer (SCLC) ( 1.3 ) in combination with carboplatin and etoposide, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). ( 1.3 ) Hepatocellular Carcinoma (HCC) ( 1.4 ) in combination with bevacizumab for the treatment of adult patients with unresectable or metastatic HCC who have not received prior systemic therapy. ( 1.4 ) Melanoma ( 1.5 ) in combination with cobimetinib and vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma as determined by an FDA-approved test. ( 1.5 , 2.1 ) Alveolar Soft Part Sarcoma (ASPS) (1.6) for the treatment of adult patients with unresectable or metastatic ASPS. (1.6) uuid:bfd4613c-f87c-4080-b274-5cd49b0084b7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:52CMI0WC3Y biolink:treats MONDO:0005191 PMID:41385096 "[{""id"":""uuid:7066f119-3a82-4f0b-8aaf-45f9a0a3b3cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9546a709-a697-4e2f-bea2-c71abfc15c23"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TECENTRIQ HYBREZA is a combination of atezolizumab, a programmed death-ligand 1 (PD-L1) blocking antibody, and hyaluronidase, an endoglycosidase indicated: Non-Small Cell Lung Cancer (NSCLC) as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage II to IIIA NSCLC whose tumors have PD-L1 expression on ≥ 1% of tumor cells, as determined by an FDA-approved test. ( 1.2 , 2.1 ) for the first-line treatment of adult patients with metastatic NSCLC whose tumors have high PD-L1 expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 10% of the tumor area [IC ≥ 10%]), as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. ( 1.2 , 2.1 ) in combination with bevacizumab, paclitaxel, and carboplatin, for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with paclitaxel protein-bound and carboplatin for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) for the treatment of adult patients with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for NSCLC harboring these aberrations prior to receiving TECENTRIQ HYBREZA. ( 1.2 ) Small Cell Lung Cancer (SCLC) ( 1.3 ) in combination with carboplatin and etoposide, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). ( 1.3 ) Hepatocellular Carcinoma (HCC) ( 1.4 ) in combination with bevacizumab for the treatment of adult patients with unresectable or metastatic HCC who have not received prior systemic therapy. ( 1.4 ) Melanoma ( 1.5 ) in combination with cobimetinib and vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma as determined by an FDA-approved test. ( 1.5 , 2.1 ) Alveolar Soft Part Sarcoma (ASPS) (1.6) for the treatment of adult patients with unresectable or metastatic ASPS. (1.6) uuid:a4983b6c-8e63-411d-b2e0-e70cd873467d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:52CMI0WC3Y biolink:treats MONDO:0011655 PMID:41385096 "[{""id"":""uuid:b07e4087-dabc-41c0-baa3-c5ea2df1c912"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8ec3136b-9aee-4067-808b-b29bce3ee6fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TECENTRIQ HYBREZA is a combination of atezolizumab, a programmed death-ligand 1 (PD-L1) blocking antibody, and hyaluronidase, an endoglycosidase indicated: Non-Small Cell Lung Cancer (NSCLC) as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage II to IIIA NSCLC whose tumors have PD-L1 expression on ≥ 1% of tumor cells, as determined by an FDA-approved test. ( 1.2 , 2.1 ) for the first-line treatment of adult patients with metastatic NSCLC whose tumors have high PD-L1 expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 10% of the tumor area [IC ≥ 10%]), as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. ( 1.2 , 2.1 ) in combination with bevacizumab, paclitaxel, and carboplatin, for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with paclitaxel protein-bound and carboplatin for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) for the treatment of adult patients with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for NSCLC harboring these aberrations prior to receiving TECENTRIQ HYBREZA. ( 1.2 ) Small Cell Lung Cancer (SCLC) ( 1.3 ) in combination with carboplatin and etoposide, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). ( 1.3 ) Hepatocellular Carcinoma (HCC) ( 1.4 ) in combination with bevacizumab for the treatment of adult patients with unresectable or metastatic HCC who have not received prior systemic therapy. ( 1.4 ) Melanoma ( 1.5 ) in combination with cobimetinib and vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma as determined by an FDA-approved test. ( 1.5 , 2.1 ) Alveolar Soft Part Sarcoma (ASPS) (1.6) for the treatment of adult patients with unresectable or metastatic ASPS. (1.6) uuid:7a68e064-1efb-42aa-8e50-1a68d505277f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:C3VX249T6L biolink:treats MONDO:0100244 PMID:41385096 "[{""id"":""uuid:897bc6a1-4bd8-4761-b6b7-064a4fc8c177"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:35c4a82c-5390-4265-af3d-ed1dc9e0ac7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:464b73c7-2902-4c96-981d-124fa934adea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ultomiris""]},{""id"":""uuid:eed83c95-c636-4fe1-bfc2-a8144d60b738"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ULTOMIRIS is a complement inhibitor indicated for: the treatment of adult and pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria (PNH). ( 1.1 ) the treatment of adult and pediatric patients one month of age and older with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA). ( 1.2 ) Limitations of Use: ULTOMIRIS is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS). the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive. ( 1.3 ) the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody-positive. ( 1.4 )|[EMA] Paroxysmal nocturnal haemoglobinuria (PNH)Ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with PNH:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity.- in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5.1).Atypical haemolytic uremic syndrome (aHUS)Ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with aHUS who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5.1).Generalized myasthenia gravis (gMG)Ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gMG who are anti-acetylcholine receptor (AChR) antibody-positive.Neuromyelitis Optica Spectrum Disorder (NMOSD)Ultomiris is indicated in the treatment of adult patients with NMOSD who are anti-aquaporin 4 (AQP4) antibody-positive (see section 5.1).Ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity.- in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months.Ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (aHUS) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.|[PMDA] A drug with a new active ingredient indicated for the treatment of paroxysmal nocturnal hemoglobinuria. [Orphan drug] uuid:a8ca85f0-37d8-4ad5-9851-9bc038a2b92e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:C3VX249T6L biolink:treats MONDO:0016244 PMID:41385096 "[{""id"":""uuid:18e61185-4796-4c0d-b72c-d60aded444bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:be3e6b01-8445-4841-9c34-c3e5a65afc82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:111a3b13-9111-4595-9278-585497286007"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ultomiris""]},{""id"":""uuid:e781c58b-b7d9-4e58-bae8-271e4381f768"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ULTOMIRIS is a complement inhibitor indicated for: the treatment of adult and pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria (PNH). ( 1.1 ) the treatment of adult and pediatric patients one month of age and older with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA). ( 1.2 ) Limitations of Use: ULTOMIRIS is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS). the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive. ( 1.3 ) the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody-positive. ( 1.4 )|[EMA] Paroxysmal nocturnal haemoglobinuria (PNH)Ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with PNH:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity.- in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5.1).Atypical haemolytic uremic syndrome (aHUS)Ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with aHUS who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5.1).Generalized myasthenia gravis (gMG)Ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gMG who are anti-acetylcholine receptor (AChR) antibody-positive.Neuromyelitis Optica Spectrum Disorder (NMOSD)Ultomiris is indicated in the treatment of adult patients with NMOSD who are anti-aquaporin 4 (AQP4) antibody-positive (see section 5.1).Ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity.- in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months.Ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (aHUS) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.|[PMDA] A drug with a new indication and a new dosage for the treatment of atypical hemolytic uremic syndrome (aHUS). uuid:8c472aa1-6c6b-4051-ad61-1fa820a7216d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:C3VX249T6L biolink:treats MONDO:0009688 PMID:41385096 "[{""id"":""uuid:ed6ec6d6-7372-4f82-a991-e9bd356f3a4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:38e64af1-236d-4875-93bc-1708b812d6e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b05d8407-1860-405b-9268-fcd1f11e8f16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ultomiris""]},{""id"":""uuid:4bb31660-4f40-4d58-9949-453026ebdc37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ULTOMIRIS is a complement inhibitor indicated for: the treatment of adult and pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria (PNH). ( 1.1 ) the treatment of adult and pediatric patients one month of age and older with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA). ( 1.2 ) Limitations of Use: ULTOMIRIS is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS). the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive. ( 1.3 ) the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody-positive. ( 1.4 )|[EMA] Paroxysmal nocturnal haemoglobinuria (PNH)Ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with PNH:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity.- in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5.1).Atypical haemolytic uremic syndrome (aHUS)Ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with aHUS who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5.1).Generalized myasthenia gravis (gMG)Ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gMG who are anti-acetylcholine receptor (AChR) antibody-positive.Neuromyelitis Optica Spectrum Disorder (NMOSD)Ultomiris is indicated in the treatment of adult patients with NMOSD who are anti-aquaporin 4 (AQP4) antibody-positive (see section 5.1).Ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity.- in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months.Ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (aHUS) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.|[PMDA] Drugs with a new indication for the treatment of generalized myasthenia gravis (for use only in patients whose symptoms cannot be sufficiently controlled with high-dose intravenous immunoglobulin therapy or plasmapheresis). uuid:d937f668-4852-4e66-baf6-de358681214d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:C3VX249T6L biolink:treats MONDO:0035663 PMID:41385096 "[{""id"":""uuid:fb2c2d1e-9e13-4657-8f75-93bf87aa9558"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:00db157b-7f34-42ab-92b4-51b144843652"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:29134388-cf00-4d2b-b076-dedce96c0cfe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ultomiris""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ULTOMIRIS is a complement inhibitor indicated for: the treatment of adult and pediatric patients one month of age and older with paroxysmal nocturnal hemoglobinuria (PNH). ( 1.1 ) the treatment of adult and pediatric patients one month of age and older with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy (TMA). ( 1.2 ) Limitations of Use: ULTOMIRIS is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS). the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive. ( 1.3 ) the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody-positive. ( 1.4 )|[EMA] Paroxysmal nocturnal haemoglobinuria (PNH)Ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with PNH:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity.- in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5.1).Atypical haemolytic uremic syndrome (aHUS)Ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with aHUS who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5.1).Generalized myasthenia gravis (gMG)Ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gMG who are anti-acetylcholine receptor (AChR) antibody-positive.Neuromyelitis Optica Spectrum Disorder (NMOSD)Ultomiris is indicated in the treatment of adult patients with NMOSD who are anti-aquaporin 4 (AQP4) antibody-positive (see section 5.1).Ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity.- in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months.Ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (aHUS) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab. uuid:d03569da-a472-4ff1-a1f4-13d768685205 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:70BSQ12069 biolink:treats MONDO:0005090 PMID:41385096 "[{""id"":""uuid:5d91a9c8-0499-419a-a275-a392e377ede9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:543e4b05-1ea2-4fe1-9995-87dbdc655466"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CAPLYTA is indicated for the treatment of: Schizophrenia in adults [see Clinical Studies (14.1) ] . Depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults, as monotherapy and as adjunctive therapy with lithium or valproate [see Clinical Studies (14.2) ] . uuid:35f2f8c3-cfc6-4929-aab8-e5f9418350fb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:70BSQ12069 biolink:treats MONDO:0024613 PMID:41385096 "[{""id"":""uuid:f0a50ba5-70fb-4748-847b-65e6a9aded3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:59ef3927-f3ff-4b2a-8643-46724cabc2c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CAPLYTA is indicated for the treatment of: Schizophrenia in adults [see Clinical Studies (14.1) ] . Depressive episodes associated with bipolar I or II disorder (bipolar depression) in adults, as monotherapy and as adjunctive therapy with lithium or valproate [see Clinical Studies (14.2) ] . uuid:cc3e7c1e-bfab-46af-86cd-5293ea6cceb2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16469 biolink:treats MONDO:0006491 PMID:41385096 "[{""id"":""uuid:c8f9ab75-f61f-43c1-a044-81e462f69ff8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:066b9538-8698-487d-af15-cab58b08be9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Estradiol is indicated in the treatment of: 1. Estrogen deficiency in Hysterectomized Women. (There is no evidence that estrogens are effective for nervous symptoms or depression which might occur during menopause, and they should not be used to treat these conditions.) 2. Atrophic vaginitis. 3. Kraurosis vulvae. 4. Female hypogonadism. 5. Female castration. 6. Primary ovarian failure. 7. Breast cancer (for palliation only) in approximately selected women and men with metastatic disease. 8. Postpartum breast engorgement - Although estrogens have been widely used for the prevention of postpatum breast engorgement, controlled studies have demonstrated that the incidence of significant painful engorgement in patients not receiving such hormonal therapy is low and usually responsive to appropriate analgesic or other supportive therapy. Consequently, the benefit to be derived from estrogen therapy for this indication must be carefully weighed against the potential increased risk or puerperal thromboembolism associated with the use of large doses of estrogen. 20,22 ESTRADIOL HAS NOT BEEN SHOWN TO BE EFFECTIVE FOR ANY PURPOSE DURING PREGNANCY AND ITS USE MAY CAUSE SEVERE HARM TO THE FETUS (SEE BOXED WARNING). uuid:fe6f5b85-d423-48f1-8b83-2ab576c73f78 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16469 biolink:treats HP:0000134 PMID:41385096 "[{""id"":""uuid:931f087f-16f9-4c8d-996e-5897620d56ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7d1f9b4b-82ab-4abb-b0e3-cd2ea44b72ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Estradiol is indicated in the treatment of: 1. Estrogen deficiency in Hysterectomized Women. (There is no evidence that estrogens are effective for nervous symptoms or depression which might occur during menopause, and they should not be used to treat these conditions.) 2. Atrophic vaginitis. 3. Kraurosis vulvae. 4. Female hypogonadism. 5. Female castration. 6. Primary ovarian failure. 7. Breast cancer (for palliation only) in approximately selected women and men with metastatic disease. 8. Postpartum breast engorgement - Although estrogens have been widely used for the prevention of postpatum breast engorgement, controlled studies have demonstrated that the incidence of significant painful engorgement in patients not receiving such hormonal therapy is low and usually responsive to appropriate analgesic or other supportive therapy. Consequently, the benefit to be derived from estrogen therapy for this indication must be carefully weighed against the potential increased risk or puerperal thromboembolism associated with the use of large doses of estrogen. 20,22 ESTRADIOL HAS NOT BEEN SHOWN TO BE EFFECTIVE FOR ANY PURPOSE DURING PREGNANCY AND ITS USE MAY CAUSE SEVERE HARM TO THE FETUS (SEE BOXED WARNING). uuid:236e2fe5-63dd-430b-893b-733e94f1c799 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16469 biolink:treats NCIT:C92746 PMID:41385096 "[{""id"":""uuid:18fd2842-1909-4c53-a8e9-a5c133e4c2ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:60f2ab8e-de6e-4343-94af-cb9bc689c19b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Estradiol is indicated in the treatment of: 1. Estrogen deficiency in Hysterectomized Women. (There is no evidence that estrogens are effective for nervous symptoms or depression which might occur during menopause, and they should not be used to treat these conditions.) 2. Atrophic vaginitis. 3. Kraurosis vulvae. 4. Female hypogonadism. 5. Female castration. 6. Primary ovarian failure. 7. Breast cancer (for palliation only) in approximately selected women and men with metastatic disease. 8. Postpartum breast engorgement - Although estrogens have been widely used for the prevention of postpatum breast engorgement, controlled studies have demonstrated that the incidence of significant painful engorgement in patients not receiving such hormonal therapy is low and usually responsive to appropriate analgesic or other supportive therapy. Consequently, the benefit to be derived from estrogen therapy for this indication must be carefully weighed against the potential increased risk or puerperal thromboembolism associated with the use of large doses of estrogen. 20,22 ESTRADIOL HAS NOT BEEN SHOWN TO BE EFFECTIVE FOR ANY PURPOSE DURING PREGNANCY AND ITS USE MAY CAUSE SEVERE HARM TO THE FETUS (SEE BOXED WARNING). uuid:13eb5fea-1cf4-4d34-a984-633244c31ee4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68478 biolink:treats MONDO:0700079 PMID:41385096 "[{""id"":""uuid:01e1e8d5-5150-4858-baf6-4e8a14c3aab4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f31e5b2a-66c1-4127-81ad-baa8c0c0b4cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Everolimus tablets are kinase inhibitor indicated for the treatment of: Postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole. ( 1.1 ) Adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. ( 1.4 ) Everolimus tablets are kinase inhibitors indicated for the treatment of adult and pediatric patients aged 1 year and older with TSC who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected. ( 1.5 ) uuid:ed74f84c-99ae-4f2d-bceb-0062e16f6452 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72305 biolink:treats MONDO:0015183 PMID:41385096 "[{""id"":""uuid:4de05493-b532-40dd-9489-27f6fd3f25de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b02766a5-7c94-43d9-9ca2-915d05b19569"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d533b0a0-b6b3-4a1d-863d-8b8832e439e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/revestive""]},{""id"":""uuid:cb2d2c69-ea84-4329-ab99-4a80c2567b58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] GATTEX ® is indicated for the treatment of adults and pediatric patients 1 year of age and older with Short Bowel Syndrome (SBS) who are dependent on parenteral support .|[EMA] Revestive is indicated for the treatment of patients aged 1 year and above with Short Bowel Syndrome (SBS). Patients should be stable following a period of intestinal adaptation after surgery.Revestive is indicated for the treatment of patients aged 1 year and above with Short Bowel Syndrome. Patients should be stable following a period of intestinal adaptation after surgery.|[PMDA] A drug with a new active ingredient indicated for the treatment of short bowel syndrome. [Orphan drug] uuid:3e2e76b1-983f-4977-b05f-fcbeb276dbd0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:1864 biolink:treats MONDO:0005059 PMID:41385096 "[{""id"":""uuid:c1e5b199-478b-48ce-819e-56a339be5209"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2398bbd6-20da-4e29-ade4-977bad0eff23"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclophosphamide is an alkylating drug indicated for treatment of adults and pediatric patients with: Malignant Diseases: malignant lymphomas: Hodgkin's disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt's lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma. ( 1.1 ) uuid:d095bfce-6fb2-419e-b80f-bf6654aad103 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:61390 biolink:treats UMLS:C0278987 PMID:41385096 "[{""id"":""uuid:cfd9e3db-068a-4cc6-9f17-a4acbf770376"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c303202d-2651-470e-91c1-f34aa00ce7ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] GILOTRIF is a kinase inhibitor indicated for: First-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test ( 1.1 ) Limitations of Use : Safety and efficacy of GILOTRIF were not established in patients whose tumors have resistant EGFR mutations ( 1.1 ) Treatment of patients with metastatic, squamous NSCLC progressing after platinum-based chemotherapy ( 1.2 ) uuid:c4c954d3-8b69-4b60-9a0d-73ac8feee579 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:61390 biolink:treats MONDO:0056806 PMID:41385096 "[{""id"":""uuid:1d80259d-23fb-4331-a6a5-0bbb1c3abd39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:94686ef7-6ba6-4bc4-8ee6-ae9635cb615d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] GILOTRIF is a kinase inhibitor indicated for: First-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test ( 1.1 ) Limitations of Use : Safety and efficacy of GILOTRIF were not established in patients whose tumors have resistant EGFR mutations ( 1.1 ) Treatment of patients with metastatic, squamous NSCLC progressing after platinum-based chemotherapy ( 1.2 ) uuid:b1fd6d24-3139-4014-ae46-04936bce479e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56842108 biolink:treats MONDO:0011122 PMID:41385096 "[{""id"":""uuid:98d626cc-225c-487d-a9bd-982431d69cc8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9c7b6ca5-361b-45b2-81ae-b290a3ccdb79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] QSYMIA is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in: Adults and pediatric patients aged 12 years and older with obesity Adults with overweight in the presence of at least one weight-related comorbid condition uuid:30b4dd10-90cc-4a69-9f40-8eb3b58c1bc2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56842108 biolink:treats EFO:0005935 PMID:41385096 "[{""id"":""uuid:07a1da2d-98e9-49ef-a9f2-199a700b5e0c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:42cb8ba1-45be-4bbe-b569-98a89683a2aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] QSYMIA is indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in: Adults and pediatric patients aged 12 years and older with obesity Adults with overweight in the presence of at least one weight-related comorbid condition uuid:c8cad2fd-c91a-4702-922b-f1dcd831d0c9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50841 biolink:treats MONDO:0001866 PMID:41385096 "[{""id"":""uuid:d15c62a4-35d9-4b25-a50c-cf33e8d28dcb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:89b3ec9b-be20-43db-84cf-3c535660aca5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ADASUVE is indicated for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults [see Clinical Studies (14) ] . uuid:7ad1e365-833d-4084-b3a3-a838c0e0c05f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:Q85FFY6179 biolink:treats MONDO:0018982 PMID:41385096 "[{""id"":""uuid:f3c0e51e-4e12-489e-b186-e4e1f7318730"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:32786d90-3795-4cad-82e4-da45d3a00261"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MIPLYFFA is indicated for use in combination with miglustat for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adult and pediatric patients 2 years of age and older. uuid:fc4a7b8a-c208-4ce5-abba-5a2b70857fc8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63623 biolink:treats MONDO:0005240 PMID:41385096 "[{""id"":""uuid:f9b100ad-47e3-4fa2-bd88-1063bf31e951"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aadb1b01-a4dc-4bee-8fe5-d26333825b0f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NEPHROSCAN, after radiolabeling with technetium Tc 99m, is indicated for use as an aid in the scintigraphic evaluation of renal parenchymal disorders in adult and pediatric patients including term neonates. uuid:2d6bb91d-0731-4a83-9931-4c44ff443408 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats UMLS:C3824874 PMID:41385096 "[{""id"":""uuid:18231962-3884-45ad-954f-739efac632c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:40fa24ed-3789-475b-9b46-b04ff08cd9ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Minocycline hydrochloride capsules are indicated in the treatment of the following infections due to susceptible strains of the designated microorganisms: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae. Lymphogranuloma venereum caused by Chlamydia trachomatis. Psittacosis (Ornithosis) due to Chlamydophila psittaci. Trachoma caused by Chlamydia trachomatis, although the infectious agent is not always eliminated, as judged by immunofluorescence . Inclusion conjunctivitis caused by Chlamydia trachomatis. Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis. Chancroid caused by Haemophilus ducreyi. Plague due to Yersinia pestis. Tularemia due to Francisella tularensis. Cholera caused by Vibrio cholerae. Campylobacter fetus infections caused by Campylobacter fetus. Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis. Granuloma inguinale caused by Klebsiella granulomatis. Minocycline is indicated for the treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Klebsiella aerogenes Shigella species. Acinetobacter species. Respiratory tract infections caused by Haemophilus influenzae. Respiratory tract and urinary tract infections caused by Klebsiella species. Minocycline hydrochloride capsules are indicated for the treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus. (NOTE: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection). When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Uncomplicated urethritis in men due to Neisseria gonorrhoeae and for the treatment of other gonococcal infections. Infections in women caused by Neisseria gonorrhoeae. Syphilis caused by Treponema pallidum subspecies pallidum. Yaws caused by Treponema pallidum subspecies pertenue. Listeriosis due to Listeria monocytogenes. Anthrax due to Bacillus anthracis. Vincent’s infection caused by Fusobacterium fusiforme. Actinomycosis caused by Actinomyces israelii. Infections caused by Clostridium species . In acute intestinal amebiasis, minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. Oral minocycline is indicated in the treatment of asymptomatic carriers of Neisseria meningitidis to eliminate meningococci from the nasopharynx. In order to preserve the usefulness of minocycline in the treatment of asymptomatic meningococcal carriers, diagnostic laboratory procedures, including serotyping and susceptibility testing, should be performed to establish the carrier state and the correct treatment. It is recommended that the prophylactic use of minocycline be reserved for situations in which the risk of meningococcal meningitis is high. Oral minocycline is not indicated for the treatment of meningococcal infection. Although no controlled clinical efficacy studies have been conducted, limited clinical data show that oral minocycline hydrochloride has been used successfully in the treatment of infections caused by Mycobacterium marinum. To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:8f440e42-0b41-4278-b04a-1f8e9a3f49d7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0005340 PMID:41385096 "[{""id"":""uuid:e5bed19f-6acf-40d2-a4b5-7d233979b17f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c6cc2a72-c71a-4d6c-acf2-ba7bcad5d7f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A. For Intramuscular Administration When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of methylprednisolone acetate injectable suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic ophthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. B. For Intra-articular Or Soft Tissue Administration ( See WARNINGS ) Methylprednisolone acetate injectable suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. C. For Intralesional Administration Methylprednisolone acetate injectable suspension is indicated for intralesional use in alopecia areata, discoid lupus erythematosus; keloids, localized hypertrophic, infiltrated inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis) and psoriatic plaques; necrobiosis lipoidica diabeticorum. Methylprednisolone acetate injectable suspension also may be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:f04affc0-1473-405a-84a6-b9da2f49e164 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0019558 PMID:41385096 "[{""id"":""uuid:a76f981f-4cb7-424f-9c1c-2d281881647b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7dea189b-8931-4faf-ad45-84af158b83d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A. For Intramuscular Administration When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of methylprednisolone acetate injectable suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic ophthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. B. For Intra-articular Or Soft Tissue Administration ( See WARNINGS ) Methylprednisolone acetate injectable suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. C. For Intralesional Administration Methylprednisolone acetate injectable suspension is indicated for intralesional use in alopecia areata, discoid lupus erythematosus; keloids, localized hypertrophic, infiltrated inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis) and psoriatic plaques; necrobiosis lipoidica diabeticorum. Methylprednisolone acetate injectable suspension also may be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:25e7deb9-a917-4fcf-8ad4-bd7fa2427a3e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0005348 PMID:41385096 "[{""id"":""uuid:457c88c6-5174-44ed-9c48-07b359b2f5f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1a0e1fe1-e88e-42b5-8286-fd6602a2ae49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A. For Intramuscular Administration When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of methylprednisolone acetate injectable suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic ophthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. B. For Intra-articular Or Soft Tissue Administration ( See WARNINGS ) Methylprednisolone acetate injectable suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. C. For Intralesional Administration Methylprednisolone acetate injectable suspension is indicated for intralesional use in alopecia areata, discoid lupus erythematosus; keloids, localized hypertrophic, infiltrated inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis) and psoriatic plaques; necrobiosis lipoidica diabeticorum. Methylprednisolone acetate injectable suspension also may be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:70d611fb-7a5b-49f4-9f6d-353279b2be64 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0006554 PMID:41385096 "[{""id"":""uuid:77c8bdb6-eafa-41a4-bff3-781bc11e40a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:839e6ac5-b374-4d04-b993-27147e8b70e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A. For Intramuscular Administration When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of methylprednisolone acetate injectable suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic ophthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. B. For Intra-articular Or Soft Tissue Administration ( See WARNINGS ) Methylprednisolone acetate injectable suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. C. For Intralesional Administration Methylprednisolone acetate injectable suspension is indicated for intralesional use in alopecia areata, discoid lupus erythematosus; keloids, localized hypertrophic, infiltrated inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis) and psoriatic plaques; necrobiosis lipoidica diabeticorum. Methylprednisolone acetate injectable suspension also may be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:e0ff0bb6-6e3d-44db-ab61-16589e6087a2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0006572 PMID:41385096 "[{""id"":""uuid:7346184d-b8b5-48eb-ba37-17a931067210"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:53d8f6fe-b639-456a-ac80-b41841d3b144"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A. For Intramuscular Administration When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of methylprednisolone acetate injectable suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic ophthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. B. For Intra-articular Or Soft Tissue Administration ( See WARNINGS ) Methylprednisolone acetate injectable suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. C. For Intralesional Administration Methylprednisolone acetate injectable suspension is indicated for intralesional use in alopecia areata, discoid lupus erythematosus; keloids, localized hypertrophic, infiltrated inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis) and psoriatic plaques; necrobiosis lipoidica diabeticorum. Methylprednisolone acetate injectable suspension also may be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:6f70a0d9-1b0b-4ddd-b39c-f467736a30fe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0006585 PMID:41385096 "[{""id"":""uuid:88db7461-a02d-489f-ad71-267fb5e0e09d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fafdfbcf-e820-49e0-82d9-07cc03fa595a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A. For Intramuscular Administration When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of methylprednisolone acetate injectable suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic ophthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. B. For Intra-articular Or Soft Tissue Administration ( See WARNINGS ) Methylprednisolone acetate injectable suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. C. For Intralesional Administration Methylprednisolone acetate injectable suspension is indicated for intralesional use in alopecia areata, discoid lupus erythematosus; keloids, localized hypertrophic, infiltrated inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis) and psoriatic plaques; necrobiosis lipoidica diabeticorum. Methylprednisolone acetate injectable suspension also may be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:d4dc7d3c-e117-4110-905e-67733dcdea8e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats UMLS:C0392445 PMID:41385096 "[{""id"":""uuid:f983dcd5-98a5-45c7-af31-0992ad9d9601"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:714e86a0-8d33-4098-9585-12839b360e6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] A. For Intramuscular Administration When oral therapy is not feasible and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intramuscular use of methylprednisolone acetate injectable suspension is indicated as follows: Allergic States : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic Diseases : Bullous dermatitis herpetiformis, exfoliative dermatitis, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportive thyroiditis. Gastrointestinal Diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic Disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond Blackfan anemia), pure red cell aplasia, select cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic Diseases : For palliative management of: leukemias and lymphomas. Nervous System : Cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases : Sympathetic ophthalmia, temporal arteritis, uveitis, ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome, or that due to lupus erythematosus. Respiratory Diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. B. For Intra-articular Or Soft Tissue Administration ( See WARNINGS ) Methylprednisolone acetate injectable suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. C. For Intralesional Administration Methylprednisolone acetate injectable suspension is indicated for intralesional use in alopecia areata, discoid lupus erythematosus; keloids, localized hypertrophic, infiltrated inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis) and psoriatic plaques; necrobiosis lipoidica diabeticorum. Methylprednisolone acetate injectable suspension also may be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:3e4bc496-7170-4b7a-9a4a-d53f19d7af7b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0019801 PMID:41385096 "[{""id"":""uuid:8ee29f44-0d3a-4c9b-b982-ab3ffa2e6a46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ad374592-79d8-425f-9d2c-f0cb252782a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:4804f7a0-eb4e-4a40-9699-847142a848e4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats UMLS:C1290158 PMID:41385096 "[{""id"":""uuid:b827eff7-b08a-43cc-8e6d-2b65e3331fa3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:faf62122-6729-45b8-8851-88772f52e523"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:e08683f5-1fd7-4ec0-bb36-69e00a3e89d9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0006545 PMID:41385096 "[{""id"":""uuid:41d19d60-520b-483e-b62a-e4b7640a30c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7b2ac7a4-bb60-4b9b-b31b-679d44dae1ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:202741e9-48c5-4201-89a3-18c6420d3b0a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0006608 PMID:41385096 "[{""id"":""uuid:be0572e7-820d-42c7-be8b-c71a5a3a5444"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fefb5895-37ff-4219-a31f-8a6ad9f9670e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:4a8a7318-5273-4f6b-a0ab-e2485a2db1b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:68078982-5267-48d6-bd47-841f522b4718"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2bc8b080-c270-41a6-b83b-d317395188d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:0ad6beed-6bbe-463f-95f7-5d0e2ca1b999 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats UMLS:C0274440 PMID:41385096 "[{""id"":""uuid:f26b2418-2cb2-4cd0-b8d0-ade17b98af01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ec84505d-120c-4e87-8411-0aa4f03bcc3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:a96e0715-fb64-40a2-9294-1e676e13dc4e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0005883 PMID:41385096 "[{""id"":""uuid:bc4daf6d-1f53-4849-ad20-37d8d92252d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0e32ad62-26fc-4f95-88ec-d842329da90b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:1c0ebb0a-93eb-40b0-8498-1b7880a3e6fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0006814 PMID:41385096 "[{""id"":""uuid:88c30aed-aebc-4d08-8e84-d6b41f14344e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:45ec37f7-4a27-4f80-ae7c-d41c0cd29c4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:e76c6d61-a736-4a8e-b8cd-2e73755c3338 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0004773 PMID:41385096 "[{""id"":""uuid:b24f5bf6-1689-4081-8415-84dd605f0aed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:367e3613-0329-4bb6-86ad-9ccd7183f2ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:7e58c5f0-cc95-4f78-9bc2-49db3e989977 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0004674 PMID:41385096 "[{""id"":""uuid:dbfd53c9-bf7e-45d9-aae6-56ea69a1f21b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:47d9aa97-9e97-452f-9bec-3d77d66fe55e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:9b290b87-4bdc-499b-82e1-a9845bd4b70b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0006918 PMID:41385096 "[{""id"":""uuid:dbf44a36-bb29-495d-b4d7-28bdfd20a0f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4bfd99e9-0f56-4332-93e8-ed8e7e749f57"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:6b3bc72c-496e-41bb-9e78-c3a724d471e3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0001280 PMID:41385096 "[{""id"":""uuid:da59b314-1a7a-4dbd-8a39-bdbf9852027f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:efd7ac40-faf6-4b25-a871-b3d56c383c92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:0e8689e6-9db8-4b62-bd56-c94b7868fb43 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0005885 PMID:41385096 "[{""id"":""uuid:80200d67-b4f5-4b62-a710-8c09f96a4202"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d0c35cd8-23b3-4556-a16e-012948dcdbeb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:d4aa334f-c57e-4e9e-90ba-adcb1a9ffb57 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0006651 PMID:41385096 "[{""id"":""uuid:08234c55-c163-4aa8-84ff-de90c4c0b4b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bb218031-ee2c-4a03-99ca-353cd02edfac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:581e60c7-6acd-42f6-87e4-c06186cc41af biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0003085 PMID:41385096 "[{""id"":""uuid:c684c77b-ac7a-470f-a157-8beb5277f760"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7b430ffa-f90a-47bb-a729-9f02305f7680"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:2990845e-50c7-4ce3-ab2f-55060c6f0f06 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0001034 PMID:41385096 "[{""id"":""uuid:a8560793-d25e-4c66-8c66-593d3789f10e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:35584d9e-cdb4-49d1-bc0c-5882af93e8c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:9f83d8af-3d36-40f1-b0a0-bd7d2e426177 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0002572 PMID:41385096 "[{""id"":""uuid:fea4135e-c939-4635-9484-dbb850110bdb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:809f6e2b-ec49-4235-b29a-23fd257d905d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:60a73f62-f71f-4efb-b70a-46441a9b4f4f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats UMLS:C0002879 PMID:41385096 "[{""id"":""uuid:a31c99e3-414f-4a18-9287-21f82401bbe7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:14c92704-2623-44c3-b539-f6095f5293be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:6928810b-17d4-4bdc-b210-cec01bcc2a94 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0019098 PMID:41385096 "[{""id"":""uuid:d1c1edfa-ccf8-4774-b0e8-4d7f7b5e4db2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bebc476d-c125-4fd6-ba37-4607f327984b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:643f28e2-0f86-4bc0-b25c-208772c93a21 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0002280 PMID:41385096 "[{""id"":""uuid:5b834923-74d4-4891-9b04-6eb1880a12f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:053ab1cf-c0a4-49d0-a882-97d77914523d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:20e0a8f7-d781-4665-a8e9-d0ce5acbd7c0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats HP:0001908 PMID:41385096 "[{""id"":""uuid:125c161c-6fdd-4671-b90e-5b932f43a2de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:989ee682-d77e-4282-a3cf-503cb4369eae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:93465282-0f78-4f72-a078-4bf8fcfc865a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0004355 PMID:41385096 "[{""id"":""uuid:df497677-f016-4834-a58a-06875d3466fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:575a0c32-4f38-46ab-a8cc-7025f9472a97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:4e52c63f-eed0-41e1-9295-38803435e395 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0005377 PMID:41385096 "[{""id"":""uuid:484cd12a-a423-4f23-b48d-d3df76ab2449"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:38b942ec-20c1-4684-bc73-536dffafc7ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:34cd331f-c699-4d26-adc0-335d3305f16d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0006640 PMID:41385096 "[{""id"":""uuid:e23136c6-c015-4ea3-9c76-1aeeec26e223"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:723ae4dd-3d48-4f22-85a4-0c08a1ec654f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] By intravenous or intramuscular injection when oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance). Acute adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; mineralocorticoid supplementation may be necessary, particularly when synthetic analogs are used). Preoperatively, and in the event of serious trauma or illness, in patients with known adrenal insufficiency or when adrenocortical reserve is doubtful. Shock unresponsive to conventional therapy if adrenocortical insufficiency exists or is suspected. Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Post-traumatic osteoarthritis Synovitis of osteoarthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Acute and subacute bursitis Epicondylitis Acute nonspecific tenosynovitis Acute gouty arthritis Psoriatic arthritis Ankylosing spondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Bullous dermatitis herpetiformis Severe seborrheic dermatitis Severe psoriasis Mycosis fungoides 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Urticarial transfusion reactions Acute noninfectious laryngeal edema (epinephrine is the drug of first choice). 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye, such as: Herpes zoster ophthalmicus Iritis, iridocyclitis Chorioretinitis Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia Anterior segment inflammation Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers 7. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis (systemic therapy) Regional enteritis (systemic therapy) 8. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy. Loeffler’s syndrome not manageable by other means. Aspiration pneumonitis 9. Hematologic Disorders Acquired (autoimmune) hemolytic anemia. Idiopathic thrombocytopenic purpura in adults (IV only; IM administration is contraindicated). Secondary thrombocytopenia in adults Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 10. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 11. Edematous States To induce diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. 13. Diagnostic testing of adrenocortical hyperfunction. 14. Cerebral Edema associated with primary or metastatic brain tumor, craniotomy, or head injury. Use in cerebral edema is not a substitute for careful neurosurgical evaluation and definitive management such as neurosurgery or other specific therapy. uuid:30443616-8fb7-48d6-a79d-20712f820357 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0000004 PMID:41385096 "[{""id"":""uuid:775d9f47-ba55-471b-a3bb-33d2ac7da218"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c12a228e-74cb-4ff2-911b-8e445be886cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:1ffeebc9-c406-4314-9cad-d3c6b0ae3c5e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:b7685075-0908-4155-a905-63c0e8ab0519"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d05464d5-3b8c-442b-91de-2f0ceebfdae6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:cb8433de-ba52-4015-af7b-fd3b2c530c0f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0021632 PMID:41385096 "[{""id"":""uuid:b4c708a9-1098-4fb8-b925-a3394e268a65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eea1f6d1-a0bc-49f0-9c86-284d3178205f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:9f1c3c1c-b68d-427d-a66d-995c1ba38479 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:1040026 PMID:41385096 "[{""id"":""uuid:7ac40a54-4499-49cd-8eaf-af2a3951f2c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:87c64817-9945-468b-8c4d-9f62244b766a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:2c810ec5-f9f2-42fc-9aa4-3746f0a46604 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0004670 PMID:41385096 "[{""id"":""uuid:b2d5bb08-6700-4631-9de4-b14c06b79abd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:36208438-77da-4874-bc93-1dbf3f11fa85"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:c003d1f8-0326-48fc-ab84-3d551a2f5472 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0004874 PMID:41385096 "[{""id"":""uuid:d137090b-4251-44f8-8137-702d11beef24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:307547c1-f11d-4d1a-9890-06e32bf36741"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, the intramuscular use of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. Synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. The intra-articular or soft tissue administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. The intralesional administration of Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). uuid:959021f6-ff55-4c96-ae97-16b5143ef5dd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats NCIT:C27003 PMID:41385096 "[{""id"":""uuid:e347ffb0-fb3b-4f68-b045-fbc55eaec098"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6e3a7f9c-6e03-45d3-86ef-69a5fee18a52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of ketorolac tromethamine and other treatment options before deciding to use ketorolac. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Acute Pain in Adult Patients Ketorolac tromethamine is indicated for the short-term (≤5 days) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting. Therapy should always be initiated with intravenous or intramuscular dosing of ketorolac tromethamine, and oral ketorolac tromethamine is to be used only as continuation treatment, if necessary. The total combined duration of use of ketorolac tromethamine injection and oral ketorolac tromethamine is not to exceed 5 days of use because of the potential of increasing the frequency and severity of adverse reactions associated with the recommended doses (see WARNINGS , PRECAUTIONS , DOSAGE AND ADMINISTRATION , and ADVERSE REACTIONS ). Patients should be switched to alternative analgesics as soon as possible, but ketorolac tromethamine therapy is not to exceed 5 days. uuid:1c40166a-283c-4a71-8d76-9b42500268b1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats NCIT:C34887 PMID:41385096 "[{""id"":""uuid:6a84f24f-5fbf-4e13-b87e-e69cbe886610"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dd61a26c-2e39-4894-823a-3452758416e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of ketorolac tromethamine and other treatment options before deciding to use ketorolac. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Acute Pain in Adult Patients Ketorolac tromethamine is indicated for the short-term (≤5 days) management of moderately severe acute pain that requires analgesia at the opioid level, usually in a postoperative setting. Therapy should always be initiated with intravenous or intramuscular dosing of ketorolac tromethamine, and oral ketorolac tromethamine is to be used only as continuation treatment, if necessary. The total combined duration of use of ketorolac tromethamine injection and oral ketorolac tromethamine is not to exceed 5 days of use because of the potential of increasing the frequency and severity of adverse reactions associated with the recommended doses (see WARNINGS , PRECAUTIONS , DOSAGE AND ADMINISTRATION , and ADVERSE REACTIONS ). Patients should be switched to alternative analgesics as soon as possible, but ketorolac tromethamine therapy is not to exceed 5 days. uuid:77b907c1-2f6a-49eb-8747-519781543597 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37804 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:d377e8fb-1fd6-40c8-985d-54b2a46d105c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3869fc2a-c4c0-418e-980c-0d80562b701c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thallous Chloride Tl 201 Injection is a diagnostic radiopharmaceutical indicated for Myocardial perfusion imaging with planar scintigraphy or single-photon emission computed tomography (SPECT) for the diagnosis of coronary artery disease by localization of: Non-reversible defects (myocardial infarction) which may have prognostic value regarding survival. Reversible defects (myocardial ischemia) when used in conjunction with exercise or pharmacologic stress. Localization of sites of parathyroid hyperactivity pre- and post-operatively in patients with elevated serum calcium and parathyroid hormone levels. uuid:3e78097d-bdf2-4fd3-ae5b-5956360bbdb6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37804 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:4b203adb-458f-4986-a155-c7c365ecec9a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a1fb89fc-4ad3-4fb6-9b70-5b23a8401b3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thallous Chloride Tl 201 Injection is a diagnostic radiopharmaceutical indicated for Myocardial perfusion imaging with planar scintigraphy or single-photon emission computed tomography (SPECT) for the diagnosis of coronary artery disease by localization of: Non-reversible defects (myocardial infarction) which may have prognostic value regarding survival. Reversible defects (myocardial ischemia) when used in conjunction with exercise or pharmacologic stress. Localization of sites of parathyroid hyperactivity pre- and post-operatively in patients with elevated serum calcium and parathyroid hormone levels. uuid:cd7e7b34-0d32-4a77-ba14-6f9a2a2f5331 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37804 biolink:treats MONDO:0024644 PMID:41385096 "[{""id"":""uuid:66ec0283-68ea-4c2d-85cc-bac82cb05159"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:87310796-babd-4453-a85b-8f6f1a6a079e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thallous Chloride Tl 201 Injection is a diagnostic radiopharmaceutical indicated for Myocardial perfusion imaging with planar scintigraphy or single-photon emission computed tomography (SPECT) for the diagnosis of coronary artery disease by localization of: Non-reversible defects (myocardial infarction) which may have prognostic value regarding survival. Reversible defects (myocardial ischemia) when used in conjunction with exercise or pharmacologic stress. Localization of sites of parathyroid hyperactivity pre- and post-operatively in patients with elevated serum calcium and parathyroid hormone levels. uuid:759d181e-1051-41c8-8625-18418c80fb85 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37804 biolink:treats MONDO:0001741 PMID:41385096 "[{""id"":""uuid:3eb9ae05-41fa-4797-a027-270580f1ec33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d2de63e1-fef5-4b02-b099-fc7f3d3c4f11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thallous Chloride Tl 201 Injection is a diagnostic radiopharmaceutical indicated for Myocardial perfusion imaging with planar scintigraphy or single-photon emission computed tomography (SPECT) for the diagnosis of coronary artery disease by localization of: Non-reversible defects (myocardial infarction) which may have prognostic value regarding survival. Reversible defects (myocardial ischemia) when used in conjunction with exercise or pharmacologic stress. Localization of sites of parathyroid hyperactivity pre- and post-operatively in patients with elevated serum calcium and parathyroid hormone levels. uuid:1c04c745-049e-478e-bf42-ed643891f983 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1942744 biolink:treats MONDO:0019457 PMID:41385096 "[{""id"":""uuid:d4acdd07-9521-4d3d-a843-09d8f5d60eac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a6417271-0feb-4df8-b1e0-ba3fcc618649"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:00e5d672-dbab-4719-ba86-b0941fb04a0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vyxeos-liposomal""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] VYXEOS is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.|[EMA] Vyxeos liposomal is indicated for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC). uuid:a482fb5d-8eab-48db-b995-fad2b3dcd426 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1942744 biolink:treats MONDO:0019456 PMID:41385096 "[{""id"":""uuid:caf1f442-ae04-42a7-a5b7-194dab7109d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:840908d0-efa0-4af0-87ca-28d5d757cc0c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1f63634c-4b1f-41dc-b9d3-84acea917231"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vyxeos-liposomal""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] VYXEOS is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.|[EMA] Vyxeos liposomal is indicated for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC). uuid:604b5606-0e41-460f-9d41-c27ed4b50d07 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:30830 biolink:treats HP:0001262 PMID:41385096 "[{""id"":""uuid:c7226c1a-6f41-4ea8-ab39-1be8a6c5990c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a3959a8f-fad4-492f-870d-3b058be6a930"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XYWAV is a central nervous system depressant indicated for the treatment of: • Cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy ( 1.1 ). • Idiopathic Hypersomnia (IH) in adults ( 1.2 ). uuid:c7e94fe2-3f1b-4155-9b11-735782fa67cf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:30830 biolink:treats MONDO:0021107 PMID:41385096 "[{""id"":""uuid:fb81d14f-c97b-465d-b625-012782f40ed8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c788ba2d-4cfa-44d0-8622-8102aeb536b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XYWAV is a central nervous system depressant indicated for the treatment of: • Cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy ( 1.1 ). • Idiopathic Hypersomnia (IH) in adults ( 1.2 ). uuid:cfc41e20-c1be-4529-8e4b-f5e9f48aa454 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:30830 biolink:treats MONDO:0018044 PMID:41385096 "[{""id"":""uuid:9f70aaea-5854-425a-9a8f-829667746983"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0bd1f30d-8ff8-47f5-866c-2c5cf324dfa2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XYWAV is a central nervous system depressant indicated for the treatment of: • Cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy ( 1.1 ). • Idiopathic Hypersomnia (IH) in adults ( 1.2 ). uuid:f7babf4e-664d-44aa-a87a-a88ff2d12721 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32660 biolink:treats MONDO:0004967 PMID:41385096 "[{""id"":""uuid:a07aa012-288d-4803-9423-fb148066ba2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b1579ecb-4312-4b7e-900a-aadbfaf6dea6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:048aade9-1b22-4392-899c-ac9e8f1f2a52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/spectrila""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] RYLAZE is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli -derived asparaginase.|[EMA] Spectrila is indicated as a component of antineoplastic combination therapy for the treatment of acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years and adults. uuid:8aee8d3d-4467-4c87-aee1-e5f89d596f4f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32660 biolink:treats MONDO:0000873 PMID:41385096 "[{""id"":""uuid:9b3b3bdc-c55e-4aee-b285-9268754e70db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:476998a7-e5c7-4b2f-a9f7-7e7570823d18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:32bedd05-6093-4726-b327-288d16e0b215"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/enrylaze""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] RYLAZE is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli -derived asparaginase.|[EMA] Enrylaze is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma (LBL) in adult and paediatric patients (1 month and older) who developed hypersensitivity or silent inactivation to E. coli-derived asparaginase. uuid:42f821f9-6316-4030-9207-b171b930b659 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:WP58SVM6R4 biolink:treats MONDO:0011758 PMID:41385096 "[{""id"":""uuid:b7157060-45ae-4d87-8382-6e85fe2104d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:316b3f8c-41b9-4672-a241-c1dbc272c2ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ALDURAZYME ® is indicated for the treatment of: adult and pediatric patients with Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I) and patients with the Scheie form of MPS I who have moderate to severe symptoms. uuid:bd04fcbb-043c-4e21-ac96-8fa4bff1e11e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:WP58SVM6R4 biolink:treats MONDO:0011759 PMID:41385096 "[{""id"":""uuid:1bc592bb-449c-406b-a610-b0763e3cade2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7979c03a-d31e-4523-afdc-9f37e6a4d317"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ALDURAZYME ® is indicated for the treatment of: adult and pediatric patients with Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I) and patients with the Scheie form of MPS I who have moderate to severe symptoms. uuid:e421433b-fa83-48c7-a2f5-302fab1fc79b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:WP58SVM6R4 biolink:treats MONDO:0011760 PMID:41385096 "[{""id"":""uuid:6ca4546a-4e99-4591-b57c-558501e9d6b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0bb14de8-d86b-42d4-be06-64acf286cc25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ALDURAZYME ® is indicated for the treatment of: adult and pediatric patients with Hurler and Hurler-Scheie forms of Mucopolysaccharidosis I (MPS I) and patients with the Scheie form of MPS I who have moderate to severe symptoms. uuid:5cf579cd-5e29-4300-b87c-9b2e4ac8b44e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats MONDO:0001051 PMID:41385096 "[{""id"":""uuid:b2a2e479-1060-47bd-889b-4519f56c01ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d48220c6-df67-4948-be10-9c2af36ae634"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CETRAXAL is a quinolone antimicrobial indicated for the treatment of acute otitis externa due to susceptible isolates of Pseudomonas aeruginosa or Staphylococcus aureus. uuid:727887c7-6569-423c-b0ac-5a1a0c1db46e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:T9FVH03HMZ biolink:treats MONDO:0004967 PMID:41385096 "[{""id"":""uuid:cac48481-bd9f-409b-baca-50736cfb811b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:96a83423-f416-4b34-80b4-d0bfeeba7372"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ASPARLAS is an asparagine specific enzyme indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in pediatric and young adult patients age 1 month to 21 years. ( 1.1 ) uuid:c09cca0a-7f15-4f6b-af20-a432b81ce498 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1291856 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:7be8e249-6806-4d3a-b741-73f59a19d988"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:24abee4f-3a42-4e4c-aa5a-b3b1d918e5f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azelastine hydrochloride and fluticasone propionate nasal spray is indicated for the relief of symptoms of seasonal allergic rhinitis in adult and pediatric patients 6 years of age and older. uuid:8496b1f2-c810-4042-814b-f04361110a93 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3S252O2Z4X biolink:treats MONDO:0015541 PMID:41385096 "[{""id"":""uuid:d1b5a30f-b021-468c-9eae-6f8e9ae8b30d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1d8a993e-b9f2-4589-97df-458592f2cc5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] GAMIFANT is indicated for the treatment of adult and pediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy. uuid:588c002f-7a92-45b5-9445-f6c734cf731b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3S252O2Z4X biolink:treats MONDO:0015540 PMID:41385096 "[{""id"":""uuid:2bb3ae91-d81d-45c8-8fab-3f6f73ea9931"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d8f56d26-cc5f-46ea-9cc8-d60afdff9451"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] GAMIFANT is indicated for the treatment of adult and pediatric (newborn and older) patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy. uuid:68334b1e-220e-4663-a6b8-f7487f35b998 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats UMLS:C0854135 PMID:41385096 "[{""id"":""uuid:19a3b28d-1e18-4b42-b657-fd267a13e234"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8880623f-98c1-4397-a2d7-f261dd06cf8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ciprofloxacin Otic Solution is a quinolone antimicrobial indicated for the treatment of acute otitis externa due to susceptible isolates of Pseudomonas aeruginosa or Staphylococcus aureus . uuid:0504bde1-f7c7-46d7-8ef7-064c71045e81 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:145536 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:987e7753-4e93-4904-844e-924492ed0a4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:94437f96-3955-434f-b08c-766772378989"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] APHEXDA is indicated in combination with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma. uuid:d4cd663d-4ec7-425e-8f8c-13850997bbce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3638 biolink:treats MONDO:0005136 PMID:41385096 "[{""id"":""uuid:7de1c540-6a03-406e-9528-f972aab86de5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5439d0db-d42f-4cbc-9d75-742bb9c53d51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chloroquine phosphate tablets are indicated for the: Treatment of uncomplicated malaria due to susceptible strains of P. falciparum, P. malariae, P. ovale, and P. vivax . Prophylaxis of malaria in geographic areas where resistance to chloroquine is not present. Treatment of extraintestinal amebiasis. Chloroquine phosphate tablets do not prevent relapses in patients with vivax or ovale malaria because it is not effective against exoerythrocytic forms of the parasites. Limitations of Use in Malaria: Do not use Chloroquine phosphate tablets for the treatment of complicated malaria (high-grade parasitemia and/or complications e.g., cerebral malaria or acute renal failure). Do not use Chloroquine phosphate tablets for malaria prophylaxis in areas where chloroquine resistance occurs, Resistance to Chloroquine phosphate tablets is widespread in P. falciparum , and is reported in P. vivax (see WARNINGS ). Concomitant therapy with an 8-aminoquinoline drug is necessary for treatment of the hypnozoite liver stage forms of P. vivax and P. ovale (see DOSAGE AND ADMINISTRATION ). uuid:2e4e4dc2-ab12-47e8-908f-3315bf6a16a2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32130 biolink:treats UMLS:C0043255 PMID:41385096 "[{""id"":""uuid:a3c105c9-2d0f-4953-a0b4-93d321a3d6b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b60bd97e-cb68-4d81-aaea-dd13f0b4dd1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] On the skin, applications of silver nitrate are recommended for cauterization of wounds and sluggish ulcers, also for removal of granulation tissue and warts. On mucous membranes, silver nitrate may be applied to small ulcers and aphthae in the mouth resulting from injury or stomatitis, to infected tonsils, to rectal fissures and fistulae, and to vaginal or cervical ulcerations or erosions. Epistaxis may be controlled by direct application to the site of hemorrhage within the nostrils. uuid:4af85818-8745-4dee-a7d3-48788ce5f3f7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32130 biolink:treats MONDO:0005318 PMID:41385096 "[{""id"":""uuid:0a9fc7b1-6d79-4ee7-b9f4-1586bf474092"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:81bc51e8-3406-4b9e-92d4-556a618b1c1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] On the skin, applications of silver nitrate are recommended for cauterization of wounds and sluggish ulcers, also for removal of granulation tissue and warts. On mucous membranes, silver nitrate may be applied to small ulcers and aphthae in the mouth resulting from injury or stomatitis, to infected tonsils, to rectal fissures and fistulae, and to vaginal or cervical ulcerations or erosions. Epistaxis may be controlled by direct application to the site of hemorrhage within the nostrils. uuid:b90890ac-008b-419e-9c78-fd7506aba2e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32130 biolink:treats MONDO:0004842 PMID:41385096 "[{""id"":""uuid:b2da0d62-30f5-4ccc-9c7f-2f3fec28fe21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1596b9ca-2d88-44ae-866e-17398df74156"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] On the skin, applications of silver nitrate are recommended for cauterization of wounds and sluggish ulcers, also for removal of granulation tissue and warts. On mucous membranes, silver nitrate may be applied to small ulcers and aphthae in the mouth resulting from injury or stomatitis, to infected tonsils, to rectal fissures and fistulae, and to vaginal or cervical ulcerations or erosions. Epistaxis may be controlled by direct application to the site of hemorrhage within the nostrils. uuid:697efe8d-4e02-4734-a66c-6d209c3bdc33 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32130 biolink:treats MONDO:0001039 PMID:41385096 "[{""id"":""uuid:a94fbb5f-6cab-4f41-bba0-913578f1da0c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:957d9a3b-226d-4085-9cf1-672883a9066d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] On the skin, applications of silver nitrate are recommended for cauterization of wounds and sluggish ulcers, also for removal of granulation tissue and warts. On mucous membranes, silver nitrate may be applied to small ulcers and aphthae in the mouth resulting from injury or stomatitis, to infected tonsils, to rectal fissures and fistulae, and to vaginal or cervical ulcerations or erosions. Epistaxis may be controlled by direct application to the site of hemorrhage within the nostrils. uuid:cb05ebdb-8a3b-4058-9204-0d1177a8efa1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32130 biolink:treats HP:0100590 PMID:41385096 "[{""id"":""uuid:79cea703-7046-43f0-9f5b-b9a6131a3190"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:08b1d0f9-8a11-4a36-aa4a-144863251807"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] On the skin, applications of silver nitrate are recommended for cauterization of wounds and sluggish ulcers, also for removal of granulation tissue and warts. On mucous membranes, silver nitrate may be applied to small ulcers and aphthae in the mouth resulting from injury or stomatitis, to infected tonsils, to rectal fissures and fistulae, and to vaginal or cervical ulcerations or erosions. Epistaxis may be controlled by direct application to the site of hemorrhage within the nostrils. uuid:2ef94269-4473-4e67-8f3e-7b1af5501d2e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32130 biolink:treats UMLS:C0566951 PMID:41385096 "[{""id"":""uuid:0c7275fb-c077-413b-85a5-45cc891434c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8a9f7fd4-778e-458e-81de-cb6e7e3acdc3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] On the skin, applications of silver nitrate are recommended for cauterization of wounds and sluggish ulcers, also for removal of granulation tissue and warts. On mucous membranes, silver nitrate may be applied to small ulcers and aphthae in the mouth resulting from injury or stomatitis, to infected tonsils, to rectal fissures and fistulae, and to vaginal or cervical ulcerations or erosions. Epistaxis may be controlled by direct application to the site of hemorrhage within the nostrils. uuid:e265bc1a-3fae-4792-9dff-fd1b4807da70 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32130 biolink:treats MONDO:0006696 PMID:41385096 "[{""id"":""uuid:af4a026f-70a9-43a2-80f4-bfe7a6f3eb1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0463404b-fa60-46f7-8282-33b41b0edf0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] On the skin, applications of silver nitrate are recommended for cauterization of wounds and sluggish ulcers, also for removal of granulation tissue and warts. On mucous membranes, silver nitrate may be applied to small ulcers and aphthae in the mouth resulting from injury or stomatitis, to infected tonsils, to rectal fissures and fistulae, and to vaginal or cervical ulcerations or erosions. Epistaxis may be controlled by direct application to the site of hemorrhage within the nostrils. uuid:b2a2b8a9-ffc9-4c24-ad2b-6838080332c3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32130 biolink:treats MONDO:0001433 PMID:41385096 "[{""id"":""uuid:05c00063-feb5-436b-b32b-591422be53f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1062ef42-9148-49a4-9417-f2788581e722"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] On the skin, applications of silver nitrate are recommended for cauterization of wounds and sluggish ulcers, also for removal of granulation tissue and warts. On mucous membranes, silver nitrate may be applied to small ulcers and aphthae in the mouth resulting from injury or stomatitis, to infected tonsils, to rectal fissures and fistulae, and to vaginal or cervical ulcerations or erosions. Epistaxis may be controlled by direct application to the site of hemorrhage within the nostrils. uuid:60442458-3573-49d2-9bf8-7271564bdd76 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32130 biolink:treats HP:0000421 PMID:41385096 "[{""id"":""uuid:e406369e-1b47-4831-8ae5-f7010115d632"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:568b8cdc-c437-461f-b5e1-9388d5373fe3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] On the skin, applications of silver nitrate are recommended for cauterization of wounds and sluggish ulcers, also for removal of granulation tissue and warts. On mucous membranes, silver nitrate may be applied to small ulcers and aphthae in the mouth resulting from injury or stomatitis, to infected tonsils, to rectal fissures and fistulae, and to vaginal or cervical ulcerations or erosions. Epistaxis may be controlled by direct application to the site of hemorrhage within the nostrils. uuid:966a30e4-e8bb-48ec-b288-ee6b44ea3e91 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:D7RD81HE4W biolink:treats NCIT:C97128 PMID:41385096 "[{""id"":""uuid:10b218ae-30d2-4785-9b13-28888ff20c59"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:02a0e306-f2da-4887-9f50-66068ac9ed48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] THYMOGLOBULIN is indicated for the prophylaxis and treatment of acute rejection in patients receiving a kidney transplant. THYMOGLOBULIN is to be used in conjunction with concomitant immunosuppression. uuid:f1ba78ba-fa59-4a06-accc-da1a51ed2d28 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134718 biolink:treats MONDO:0005180 PMID:41385096 "[{""id"":""uuid:eb8f9ad2-7d77-4ea8-9d08-a77b60d2c7f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:081a66cc-7fef-4659-a637-c5835e48fdc4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f9a1f19f-50e7-48f5-83ee-f7bbe394adef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9afb74cd-7668-4dd5-b34d-c4172af90191"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] XADAGO is indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease (PD) experiencing ""off"" episodes.|[EMA] Xadago is indicated for the treatment of adult patients with idiopathic Parkinson’s disease (PD) as add-on therapy to a stable dose of Levodopa (L-dopa) alone or in combination with other PD medicinal products in mid-to late-stage fluctuating patients.|[PMDA] A drug with a new active ingredient indicated for the improvement of wearing-off phenomenon in patients with Parkinson’s disease under the treatment with levodopa-containing preparations." uuid:1253d9a4-f796-4a32-ad83-49d8d6ffc804 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46859 biolink:treats MONDO:0008638 PMID:41385096 "[{""id"":""uuid:31e2f088-a250-4687-9a52-579e68bbb929"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b7c27569-26bf-4a40-932a-69a6df73b19d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d7254486-ea38-4e9f-a5e6-bc8eb4b1ebf8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VARITHENA (polidocanol injectable foam) is indicated for the treatment of incompetent great saphenous veins, accessory saphenous veins, and visible varicosities of the great saphenous vein (GSV) system above and below the knee. VARITHENA improves the symptoms of superficial venous incompetence and the appearance of visible varicosities.|[PMDA] Drugs with a new route of administration, used as a sclerosant to treat primary varicose veins of the lower extremity (excluding the varicosity of the main stem of the saphenous vein). uuid:9af88d86-dc12-4c56-ab4d-af1207ac1882 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46859 biolink:treats MONDO:0000945 PMID:41385096 "[{""id"":""uuid:a3905ef4-9774-4d28-b945-6d0068124378"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9091e024-ab19-4dc2-97d1-2bacc9eb0ade"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VARITHENA (polidocanol injectable foam) is indicated for the treatment of incompetent great saphenous veins, accessory saphenous veins, and visible varicosities of the great saphenous vein (GSV) system above and below the knee. VARITHENA improves the symptoms of superficial venous incompetence and the appearance of visible varicosities. uuid:ca07aab6-9195-4e35-9aeb-13f94d06b826 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8694 biolink:treats MONDO:0013600 PMID:41385096 "[{""id"":""uuid:2978010f-6244-4569-a78c-ba889a2af650"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:55241f2a-bacf-4ec0-b4b2-b2c3a5c5b5ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Quazepam Tablets are indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. The effectiveness of Quazepam Tablets has been established in placebo-controlled clinical studies of 5 nights duration in acute and chronic insomnia. The sustained effectiveness of Quazepam Tablets has been established in chronic insomnia in a sleep lab (polysomnographic) study of 28 nights duration. Because insomnia is often transient and intermittent, the prolonged administration of Quazepam Tablets is generally not necessary or recommended. Since insomnia may be a symptom of several other disorders, the possibility that the complaint may be related to a condition for which there is a more specific treatment should be considered. uuid:4fb32933-a48d-4541-8d2a-a90e44f8e766 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8694 biolink:treats UMLS:C4546137 PMID:41385096 "[{""id"":""uuid:5528f76b-99ac-422a-90ed-31094de0faf0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ffe91735-9ef1-492b-8db9-d4f087c6b792"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Quazepam Tablets are indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. The effectiveness of Quazepam Tablets has been established in placebo-controlled clinical studies of 5 nights duration in acute and chronic insomnia. The sustained effectiveness of Quazepam Tablets has been established in chronic insomnia in a sleep lab (polysomnographic) study of 28 nights duration. Because insomnia is often transient and intermittent, the prolonged administration of Quazepam Tablets is generally not necessary or recommended. Since insomnia may be a symptom of several other disorders, the possibility that the complaint may be related to a condition for which there is a more specific treatment should be considered. uuid:5664d65f-8bfa-4c34-a99b-746c00059815 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8694 biolink:treats UMLS:C0751249 PMID:41385096 "[{""id"":""uuid:5ff24e3a-169e-4ee9-8160-59826e871288"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7219949d-8e45-4d3a-b468-71fc03907d64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Quazepam Tablets are indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. The effectiveness of Quazepam Tablets has been established in placebo-controlled clinical studies of 5 nights duration in acute and chronic insomnia. The sustained effectiveness of Quazepam Tablets has been established in chronic insomnia in a sleep lab (polysomnographic) study of 28 nights duration. Because insomnia is often transient and intermittent, the prolonged administration of Quazepam Tablets is generally not necessary or recommended. Since insomnia may be a symptom of several other disorders, the possibility that the complaint may be related to a condition for which there is a more specific treatment should be considered. uuid:80fb9905-cdcc-4243-bd91-be0a5067cfec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:21904A5386 biolink:treats MONDO:0004652 PMID:41385096 "[{""id"":""uuid:76e83f47-f9a3-487c-a00e-5828e6a58058"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f06b6452-82a4-46f3-bf93-e8808b8e62dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XENLETA is a pleuromutilin antibacterial indicated for the treatment of adults with community-acquired bacterial pneumonia (CABP) caused by susceptible microorganisms. ( 1.1 ) To reduce the development of drug resistant bacteria and maintain the effectiveness of XENLETA and other antibacterial drugs, XENLETA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.2 ) uuid:a8934e00-90e9-4533-9bfb-4ccc6dd37c4a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22652 biolink:treats HP:0000978 PMID:41385096 "[{""id"":""uuid:a86aa727-b527-446c-a458-0989c6648980"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0b95be7a-afeb-4860-bb5c-be9109830ac8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bruselix™ Bruising Tablets are formulated to provide nutritional support during the body’s natural recovery process. They may be helpful for individuals experiencing bruising due to minor injuries, surgical procedures, or sensitive skin. The formula contains antioxidants, enzymes, and natural extracts that are traditionally used to support overall skin health and recovery. uuid:0a57eb04-d8e9-4232-a428-920fd750c6e1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:LMQ24G57E9 biolink:treats MONDO:0013600 PMID:41385096 "[{""id"":""uuid:a117d3fe-0e37-41d9-89b4-40ddca47415c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c1395585-5f69-4e18-8e8f-1e4a4893ced1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d4fa0d04-f7d1-4841-84fb-505071814ed6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] QUVIVIQ is indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance [see Clinical Studies (14.1) ] .|[EMA] Quviviq is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning. uuid:6fad2c44-1b5c-4e5d-98b1-da35cdedbba8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2386036 biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:1c25caaf-b332-4520-8d6a-14a07edbc1cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:59125205-f2c0-4070-9e78-8df770b22aaf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ca866fe1-3c1a-48f7-a310-1306bdb57ee8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/trixeo-aerosphere""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] BREZTRI AEROSPHERE is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Limitations of Use: BREZTRI AEROSPHERE is not indicated for the relief of acute bronchospasm or for the treatment of asthma [see Warnings and Precautions (5.1 , 5.2) ] .|[EMA] Trixeo Aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long acting beta2 agonist or combination of a long-acting beta2 agonist and a long acting muscarinic antagonist. uuid:f1c611c0-ad9a-476c-beba-5569a6f07120 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2386036 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:b4795e41-0c74-49fc-938f-59cdca49b17e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:32e1d93a-2ced-4c10-953e-aacb7a839d79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BREZTRI AEROSPHERE is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Limitations of Use: BREZTRI AEROSPHERE is not indicated for the relief of acute bronchospasm or for the treatment of asthma [see Warnings and Precautions (5.1 , 5.2) ] . uuid:7a3cd74b-4d2a-4f59-9d09-31be5c4aeed1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:177453 biolink:treats MONDO:0005133 PMID:41385096 "[{""id"":""uuid:2017366f-effb-4daf-b970-86aec0984021"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0237ff92-1678-4434-aa61-2f1b92b0f994"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ORILISSA is indicated for the management of moderate to severe pain associated with endometriosis. Limitation s of Use: Limit the duration of use based on the dose and coexisting condition (see Table 1 ) [see D osage and Administration ( 2.1 ) and Warnings and Precautions ( 5.1 ) ] . uuid:ea21cadc-b3e9-4da0-af2b-75449b76b1a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:ZJ0EKR6M10 biolink:treats MONDO:0008315 PMID:41385096 "[{""id"":""uuid:2501a135-4356-4613-bcda-afa9056f496d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:af7b2253-34b7-4c13-9740-49616b797484"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a5172f93-f5c7-4df5-bc19-7c3a37f8d612"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/locametz""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gallium Ga 68 Gozeotide Injection is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy. with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.|[EMA] This medicinal product is for diagnostic use only. Locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (PSMA) positive lesions with positron emission tomography (PET) in adults with prostate cancer (PCa) in the following clinical settings:Primary staging of patients with high risk PCa prior to primary curative therapy,Suspected PCa recurrence in patients with increasing levels of serum prostate specific antigen (PSA) after primary curative therapy,Identification of patients with PSMA positive progressive metastatic castration resistant prostate cancer (mCRPC) for whom PSMA targeted therapy is indicated (see section 4.4). uuid:189e03ee-45ec-4f65-b580-d6766232bf7b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47426 biolink:treats MONDO:0006932 PMID:41385096 "[{""id"":""uuid:483c562b-35d2-40d8-a7da-70ed21ab950b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cf27de4c-9380-4e26-ae3f-9efeb310efec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FUROSEMIDE INJECTION is a loop diuretic indicated for: • The treatment of edema associated with heart failure, cirrhosis of the liver, and renal disease ( 1.1 ) • Acute pulmonary edema as adjunctive therapy ( 1.2 ) uuid:518d1734-2ff1-47cd-b3f6-85f6649ef71e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10125 biolink:treats UMLS:C0393759 PMID:41385096 "[{""id"":""uuid:85bc677c-1134-4390-82bc-24606fd39f49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c8aa30cf-4661-4f60-891b-83273f07328a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Zolpidem Tartrate Capsules are indicated for the short-term treatment of transient insomnia characterized by difficulties with sleep initiation in adults younger than 65 years of age [see Dosage and Administration ( 2.1 ) and Clinical Studies ( 14 )] . uuid:42abed11-546a-4563-a225-8966f9ef6b4e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:F7BD3Z4X8L biolink:treats MONDO:0008170 PMID:41385096 "[{""id"":""uuid:e244e27d-4221-4bb9-8ce7-6c41a96bbf12"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:49f2287b-b39e-440d-809d-8c9fc95403d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CYTALUX is indicated as an adjunct for intraoperative identification of: Malignant lesions in adult patients with ovarian cancer. Malignant and non-malignant pulmonary lesions in adult patients with known or suspected cancer in the lung. uuid:d2f721bb-ebd2-455a-956d-b0f7952e2399 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:QQA9MLH692 biolink:treats MONDO:0000901 PMID:41385096 "[{""id"":""uuid:ced3f1b6-ac46-4da8-b263-03e5cb11aafe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a973ca78-3cdf-43fb-ba9e-823e7c9fa623"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:bcdeeca9-a067-477b-bd3d-d18cf08bb000"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/minjuvi""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] MONJUVI, in combination with lenalidomide, is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT). This indication is approved under accelerated approval based on overall response rate [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).|[EMA] Minjuvi is indicated in combination with lenalidomide followed by Minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplant (ASCT). uuid:ca9b33ca-98f8-4000-a098-c8db6395f486 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:QQA9MLH692 biolink:treats MONDO:0018905 PMID:41385096 "[{""id"":""uuid:28ec0082-b200-4e6b-a64a-b18314e66d06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1a5137e6-d0db-4fe1-ae5d-3808fa69c992"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MONJUVI, in combination with lenalidomide, is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT). This indication is approved under accelerated approval based on overall response rate [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). uuid:5b3748a8-ef03-4e11-902e-9db86429945a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6801 biolink:treats MONDO:0012819 PMID:41385096 "[{""id"":""uuid:0d37bb20-adf4-4288-a537-9d195db41aaa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e5ef341b-68ab-4f9a-a4d7-2e75af077bf8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metformin hydrochloride extended-release tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Important Limitations of Use Metformin hydrochloride extended-release tablets should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings. uuid:86b09799-88aa-4948-9384-fec68920b2c8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0024619 PMID:41385096 "[{""id"":""uuid:0e76810f-c67d-49f9-b57b-87a77b5ad828"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1672680a-5592-421a-8763-a49699683549"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Gentamicin Injection, USP and other antibacterial drugs, Gentamicin Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Gentamicin Injection is indicated in the treatment of serious infections caused by susceptible strains of the following microorganisms: Pseudomonas aeruginosa, Proteus species (indole-positive and indole-negative), Escherichia coli, Klebsiella-Enterobacter-Serratia species, Citrobacter species, and Staphylococcus species (coagulase-positive and coagulase-negative). Clinical studies have shown Gentamicin Injection to be effective in bacterial neonatal sepsis; bacterial septicemia; and serious bacterial infections of the central nervous system (meningitis), urinary tract, respiratory tract, gastrointestinal tract (including peritonitis), skin, bone and soft tissue (including burns). Aminoglycosides, including gentamicin, are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are susceptible to these antibiotics and are not susceptible to antibiotics having less potential for toxicity. Specimens for bacterial culture should be obtained to isolate and identify causative organisms and to determine their susceptibility to gentamicin. Gentamicin may be considered as initial therapy in suspected or confirmed gram-negative infections, and therapy may be instituted before obtaining results of susceptibility testing. The decision to continue therapy with this drug should be based on the results of susceptibility tests, the severity of the infection, and the important additional concepts contained in the WARNINGS box above. If the causative organisms are resistant to gentamicin, other appropriate therapy should be instituted. In serious infections when the causative organisms are unknown, gentamicin may be administered as initial therapy in conjunction with a penicillin-type or cephalosporin type drug before obtaining results of susceptibility testing. If anaerobic organisms are suspected as etiologic agents, consideration should be given to using other suitable antimicrobial therapy in conjunction with gentamicin. Following identification of the organism and its susceptibility, appropriate antibiotic therapy should then be continued. Gentamicin has been used effectively in combination with carbenicillin for the treatment of life-threatening infections caused by Pseudomonas aeruginosa. It has also been found effective when used in conjunction with a penicillin-type drug for the treatment of endocarditis caused by group D streptococci. Gentamicin Injection has also been shown to be effective in the treatment of serious staphylococcal infections. While not the antibiotic of first choice, gentamicin may be considered when penicillins or other less potentially toxic drugs are contraindicated and bacterial susceptibility tests and clinical judgment indicate its use. It may also be considered in mixed infections caused by susceptible strains of staphylococci and gram-negative organisms. In the neonate with suspected bacterial sepsis or staphylococcal pneumonia, a penicillin-type drug is also usually indicated as concomitant therapy with gentamicin. uuid:1ac08223-f5fe-4f0b-9a86-573cc0c191db biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1158563 biolink:treats MONDO:0005709 PMID:41385096 "[{""id"":""uuid:120600f3-84af-4518-8a12-e2bb5e6690ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8f7601ee-4158-4c07-8ecf-9eaeb0dcd5db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OBREDON is indicated for the symptomatic relief of cough and to loosen mucus associated with the common cold in patients 18 years of age and older. Important Limitations of Use Not indicated for pediatric patients under 18 years of age [ see Use in Specific Populations ( 8.4 ) ]. Contraindicated in pediatric patients less than 6 years of age [ see Contraindications ( 4 ) ] Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, reserve OBREDON for use in adult patients for whom the benefits of cough suppression are expected to outweigh the risks, and in whom an adequate assessment of the etiology of the cough has been made. uuid:ee459a99-1955-4684-8190-e79a17dba44e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:205919 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:78471ca9-ce70-4e71-9b4d-7d0de236e363"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fb9a5a8d-f1af-4da1-80b0-867cfcd34272"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clobetasol Propionate Ophthalmic Suspension 0.05% is indicated for the treatment of post-operative inflammation and pain following ocular surgery. uuid:7d862908-c3cf-4014-9821-a1c2e14961d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:474180 biolink:treats UMLS:C0746883 PMID:41385096 "[{""id"":""uuid:dfc0c31d-5c17-4acb-838d-32de440a6b82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:21c1385c-e457-4cdf-82dd-fdc7d6238163"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f0c41666-b2f2-4e5b-9703-608c85f252e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CANCIDAS is an echinocandin antifungal indicated in adults and pediatric patients (3 months of age and older) for: Empirical therapy for presumed fungal infections in febrile, neutropenic patients. ( 1 ) Treatment of candidemia and the following Candida infections: intra-abdominal abscesses, peritonitis and pleural space infections. ( 1 ) Treatment of esophageal candidiasis. ( 1 ) Treatment of invasive aspergillosis in patients who are refractory to or intolerant of other therapies. ( 1 )|[PMDA] Drugs with a new active ingredient indicated for the treatment of febrile neutropenia suspected of a fungal infection and fungal infections due to Candida or Aspergillus (esophageal candidiasis, invasive candidiasis, aspergillosis). uuid:dd7460d4-8b96-4ae6-9221-e39646fa891f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27504 biolink:treats MONDO:0020654 PMID:41385096 "[{""id"":""uuid:db8d3ddf-6e4c-4817-b818-7af473053977"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e7a1c710-0468-4903-93a2-0ce3d36f38a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] JELMYTO ® is indicated for the treatment of adult patients with low-grade Upper Tract Urothelial Cancer (LG-UTUC). uuid:5c278e39-ba0c-4aa6-b58c-f755dfb8da2f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats MONDO:0000922 PMID:41385096 "[{""id"":""uuid:6dd41ae9-0a5b-4fa1-aa75-627bc509145a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:de407cd3-4f35-4d01-a1f0-451fe5fd724e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b259215f-15f4-4b44-a9e6-fb949d649d6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Azithromycin for Injection, USP is indicated for the treatment of patients with infections caused by susceptible strains of the designated microorganisms in the conditions listed below. As recommended dosages, durations of therapy, and applicable patient populations vary among these infections, please see DOSAGE AND ADMINISTRATION for dosing recommendations. Community-acquired pneumonia due to Chlamydia pneumoniae, Haemophilus influenzae, Legionella pneumophila, Moraxella catarrhalis, Mycoplasma pneumoniae, Staphylococcus aureus, or Streptococcus pneumoniae in patients who require initial intravenous therapy. Pelvic inflammatory disease due to Chlamydia trachomatis, Neisseria gonorrhoeae, or Mycoplasma hominis in patients who require initial intravenous therapy. If anaerobic microorganisms are suspected of contributing to the infection, an antimicrobial agent with anaerobic activity should be administered in combination with Azithromycin for Injection, USP. Azithromycin for Injection, USP should be followed by azithromycin by the oral route as required (see DOSAGE AND ADMINISTRATION ). Appropriate culture and susceptibility tests should be performed before treatment to determine the causative microorganism and its susceptibility to azithromycin. Therapy with azithromycin may be initiated before results of these tests are known; once the results become available, antimicrobial therapy should be adjusted accordingly. To reduce the development of drug-resistant bacteria and maintain the effectiveness of Azithromycin for Injection, USP and other antibacterial drugs, Azithromycin for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.|[PMDA] Drugs with a new additional indication and a new dosage for the treatment of pelvic inflammatory diseases. uuid:905130f2-df34-4c2d-a5c4-a11bc772d1f1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29101 biolink:treats MONDO:0000440 PMID:41385096 "[{""id"":""uuid:914058a7-3af0-4fd9-b466-1fad6b1aee36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:96cb782a-744b-4779-9796-7974f49789e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial – e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:02d86299-879d-4c72-a32a-bd79e590b602 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29101 biolink:treats MONDO:0001106 PMID:41385096 "[{""id"":""uuid:86cfae62-6218-4e06-96ea-989124a698bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:99ec3b9b-f520-4e46-a8e6-23553aa1cf9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial – e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:f738652a-8571-42d2-86e8-cd1b9eddfdea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29101 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:c55b90f3-fb85-4872-818d-5aff1a6f07dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c995cdf5-32d6-4ade-a29d-3a8d63983759"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial – e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:77236e37-efba-4572-8d62-bd702617c924 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29101 biolink:treats HP:0031273 PMID:41385096 "[{""id"":""uuid:2183d76b-3c72-4dcd-b18e-109fda7f8c39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2cc7b4d1-241f-4946-9f6e-cdef49bf2aef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial – e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:850a5b08-ef64-4759-a3c2-70f65df5ac10 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29101 biolink:treats UMLS:C3472181 PMID:41385096 "[{""id"":""uuid:d91773cc-ff01-4e26-a018-82f4e70100ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2bdf8b06-9a93-4a36-be0f-7f7f14526e2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial – e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:bc4029fc-368c-40b2-a1d4-8b15f769a862 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29101 biolink:treats MONDO:0000745 PMID:41385096 "[{""id"":""uuid:ff705350-68c5-4a9d-b855-617b1a108d6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ec9e655c-6d79-4e3c-9de9-cdae0696930e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial – e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:3836f134-541b-4fa0-bd44-478b21323c5d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29101 biolink:treats MONDO:0006040 PMID:41385096 "[{""id"":""uuid:771e9ba2-e17b-4dba-bf6d-5251ac351b22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7ba62dc3-e0a1-458a-89dd-0c5393e10f3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial – e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:94ce37bd-bf4c-48db-a25c-b68dc1ba900e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29101 biolink:treats EFO:0009574 PMID:41385096 "[{""id"":""uuid:7b621f38-272f-4c7e-a8c8-0f507f389e84"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d60ea6a4-72fa-4ae1-9732-4e40741ee7a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial – e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:ac1b31b9-da7e-4e09-a9a9-97685f23eadc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29101 biolink:treats UMLS:C0161558 PMID:41385096 "[{""id"":""uuid:f5a755bd-4df3-428e-ae7a-47d60f6753d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ca637022-5e58-4819-ac7c-a37bc8ce985d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial – e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:8d0db174-a211-48dd-a9d9-bce336c0cf61 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29101 biolink:treats UMLS:C0161544 PMID:41385096 "[{""id"":""uuid:a516291a-746b-424f-ae75-c8ab3c028158"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:acb46e99-65c4-47a1-9193-58279c8ea6ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial – e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:141e223a-9d93-478e-add3-cad2308f6ceb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29101 biolink:treats UMLS:C0161680 PMID:41385096 "[{""id"":""uuid:d3046576-c2ce-433a-8f27-a8562084d8a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6818336b-8e36-4d34-96f5-378facd43422"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial – e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:f30456e4-64a3-4708-8592-04f886e8364f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29101 biolink:treats UMLS:C0235575 PMID:41385096 "[{""id"":""uuid:ff18b9a6-5ce0-4195-9c6e-efef6b307797"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ad4f89ba-e348-4058-b3f9-45ebeddcc83c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial – e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:211e7f9e-f163-4c96-b682-4d06a8f14f17 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29101 biolink:treats UMLS:C1443924 PMID:41385096 "[{""id"":""uuid:7b4d7fb7-e897-4289-b4c6-e6311d41b105"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7b93ba11-f3f2-46bd-b393-b84fe0c432f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial – e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:6fff1da5-3a32-4851-ba64-13332a2f9bc7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29101 biolink:treats MONDO:0012819 PMID:41385096 "[{""id"":""uuid:52679fa9-f87d-46cf-a52d-36dcdf0219af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:efa129d5-4ac8-455a-957e-351ad15d4659"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO 2 content is crucial – e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. uuid:95170424-b351-42ae-8ee7-d1b467292923 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:71492GE1FX biolink:treats UMLS:C0581126 PMID:41385096 "[{""id"":""uuid:a52e2956-9924-480e-82e6-e8aee42b4a2d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:96a27654-ca44-48c1-8ac7-3d98ef9b240d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FASENRA is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody (IgG1, kappa) indicated for: • add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma, and with an eosinophilic phenotype. (1.1) • treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). (1.2) Limitations of Use: Not for relief of acute bronchospasm or status asthmaticus. (1.1) uuid:34b2be3f-4628-4b60-8ba0-514d3abcf4c0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:71492GE1FX biolink:treats MONDO:0015943 PMID:41385096 "[{""id"":""uuid:333e03b8-e9da-4f2c-b2e3-97db2c99906b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ed61396b-77c7-4ad1-8830-6edd0d77d0c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FASENRA is an interleukin-5 receptor alpha-directed cytolytic monoclonal antibody (IgG1, kappa) indicated for: • add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma, and with an eosinophilic phenotype. (1.1) • treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). (1.2) Limitations of Use: Not for relief of acute bronchospasm or status asthmaticus. (1.1) uuid:fd801d08-06b3-4a34-aa25-377f25905e37 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0030602 PMID:41385096 "[{""id"":""uuid:ba1b4abf-0669-4d17-aeb7-63006257adaf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2cce993a-ef55-4555-9643-3d4a99e633b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline for injection and other antibacterial drugs, doxycycline for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever, and the typhus group, Q fever, rickettsialpox and tick fevers). Mycoplasma pneumoniae (PPLO, Eaton Agent). Agents of psittacosis and ornithosis. Agents of lymphogranuloma venereum and granuloma inguinale. The spirochetal agent of relapsing fever (Borrelia recurrentis). The following gram-negative microorganisms: Haemophilus ducreyi (chancroid), Yersinia pestis Francisella tularensis, Bartonella bacilliformis, Bacteroides species, Vibrio cholerae and Campylobacte fetus, Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli, Enterobacter aerogenes, Shigella species, Acinetobacter species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Streptococcus pneumoniae, Staphylococcus aureus, respiratory skin and soft tissue infections. Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections. Anthrax due to Bacillus anthracis, including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of infections due to: Neisseria gonorrhoeae and N. meningitidis, Treponema pallidum and Treponema pallidum subspecies pertenue (syphilis and yaws), Listeria monocytogenes, Clostridium species, Fusobacterium fusiforme (Vincent’s infection), Actinomyces species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. Doxycycline is indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. uuid:a29466d4-147f-4d4c-bd9d-19fc890ac915 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats MONDO:0004989 PMID:41385096 "[{""id"":""uuid:8ed9f882-ba22-4c59-b74a-874fc2cef02d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6754e53f-8c7f-4cef-9eab-b8153c8ca3b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxorubicin Hydrochloride Injection, USP has been used successfully to produce regression in disseminated neoplastic conditions such as acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms' tumor, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, Hodgkin's disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types. Doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer. uuid:99538ebb-7609-467f-8ea9-f47aa63e5017 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats MONDO:0005062 PMID:41385096 "[{""id"":""uuid:df8cb71a-6ed5-417c-bc03-f08dea156fb7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8b73fa4f-41e8-47a3-aed3-d757efc9c9cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:dd6a4a37-d6b2-455e-8b0e-2201b03a9b3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Doxorubicin Hydrochloride Injection, USP has been used successfully to produce regression in disseminated neoplastic conditions such as acute lymphoblastic leukemia, acute myeloblastic leukemia, Wilms' tumor, neuroblastoma, soft tissue and bone sarcomas, breast carcinoma, ovarian carcinoma, transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, Hodgkin's disease, malignant lymphoma and bronchogenic carcinoma in which the small cell histologic type is the most responsive compared to other cell types. Doxorubicin is also indicated for use as a component of adjuvant therapy in women with evidence of axillary lymph node involvement following resection of primary breast cancer.|[PMDA] Drugs with a revised indication and a new dosage for the relief of symptoms of malignant lymphoma. [Expedited review] uuid:37911b79-ff76-4945-b08a-2cea3197a401 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:119915 biolink:treats HP:0030858 PMID:41385096 "[{""id"":""uuid:11902b7d-a8f9-4e8d-b6f2-372fbec22fc7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f1f87f37-7853-42bf-b47e-aefd1187fb2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fentanyl transdermal system is indicated for the management of severe and persistent pain in opioid tolerant patients, that requires an extended treatment period with a daily opioid analgesic and for which alternative treatment options are inadequate. Patients considered opioid-tolerant are those who are taking, for one week or longer, at least 60 mg morphine per day, 25 mcg transdermal fentanyl per hour, 30 mg oral oxycodone per day, 8 mg oral hydromorphone per day, 25 mg oral oxymorphone per day, 60 mg oral hydrocodone per day, or an equianalgesic dose of another opioid. Limitations of Use: • Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration, and because of the greater risks of overdose and death with extended-release/long-acting opioid formulations [see Warnings and Precautions (5.1) ] , reserve fentanyl transdermal system for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated or would be otherwise inadequate to provide sufficient management of pain. • Fentanyl transdermal system is not indicated as an as-needed (prn) analgesic. uuid:67f5bf0e-cbcc-4072-bc15-f6384406ce81 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:119915 biolink:treats MONDO:0002491 PMID:41385096 "[{""id"":""uuid:8fda485d-bed0-4e73-9c82-e5d0616c88d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4f391b02-77d5-439d-9649-c092a99d7cbf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fentanyl transdermal system is indicated for the management of severe and persistent pain in opioid tolerant patients, that requires an extended treatment period with a daily opioid analgesic and for which alternative treatment options are inadequate. Patients considered opioid-tolerant are those who are taking, for one week or longer, at least 60 mg morphine per day, 25 mcg transdermal fentanyl per hour, 30 mg oral oxycodone per day, 8 mg oral hydromorphone per day, 25 mg oral oxymorphone per day, 60 mg oral hydrocodone per day, or an equianalgesic dose of another opioid. Limitations of Use: • Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration, and because of the greater risks of overdose and death with extended-release/long-acting opioid formulations [see Warnings and Precautions (5.1) ] , reserve fentanyl transdermal system for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated or would be otherwise inadequate to provide sufficient management of pain. • Fentanyl transdermal system is not indicated as an as-needed (prn) analgesic. uuid:dec02746-fb42-4b05-9b40-13b0d0c774ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:119915 biolink:treats EFO:0011049 PMID:41385096 "[{""id"":""uuid:bd450815-071b-485d-8413-cccd57d9d994"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6724fea3-7e6f-4873-81d5-b9f6045be28b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fentanyl transdermal system is indicated for the management of severe and persistent pain in opioid tolerant patients, that requires an extended treatment period with a daily opioid analgesic and for which alternative treatment options are inadequate. Patients considered opioid-tolerant are those who are taking, for one week or longer, at least 60 mg morphine per day, 25 mcg transdermal fentanyl per hour, 30 mg oral oxycodone per day, 8 mg oral hydromorphone per day, 25 mg oral oxymorphone per day, 60 mg oral hydrocodone per day, or an equianalgesic dose of another opioid. Limitations of Use: • Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration, and because of the greater risks of overdose and death with extended-release/long-acting opioid formulations [see Warnings and Precautions (5.1) ] , reserve fentanyl transdermal system for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated or would be otherwise inadequate to provide sufficient management of pain. • Fentanyl transdermal system is not indicated as an as-needed (prn) analgesic. uuid:5fcc31e9-28d0-4ef1-83f2-3bc06f8a9a2f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:119915 biolink:treats EFO:0020911 PMID:41385096 "[{""id"":""uuid:014cba60-b72d-420b-b592-96fb28986d19"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ecb7e284-7949-432a-b7c0-7453b61ef766"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fentanyl transdermal system is indicated for the management of severe and persistent pain in opioid tolerant patients, that requires an extended treatment period with a daily opioid analgesic and for which alternative treatment options are inadequate. Patients considered opioid-tolerant are those who are taking, for one week or longer, at least 60 mg morphine per day, 25 mcg transdermal fentanyl per hour, 30 mg oral oxycodone per day, 8 mg oral hydromorphone per day, 25 mg oral oxymorphone per day, 60 mg oral hydrocodone per day, or an equianalgesic dose of another opioid. Limitations of Use: • Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration, and because of the greater risks of overdose and death with extended-release/long-acting opioid formulations [see Warnings and Precautions (5.1) ] , reserve fentanyl transdermal system for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated or would be otherwise inadequate to provide sufficient management of pain. • Fentanyl transdermal system is not indicated as an as-needed (prn) analgesic. uuid:3000b987-25da-4418-9b0d-100759fd0d55 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:5284632 biolink:treats MONDO:0005090 PMID:41385096 "[{""id"":""uuid:68f36e43-0129-4648-a82b-41d3425c6294"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8010f507-94b8-40fa-8e56-98923da4a57c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] COBENFY is indicated for the treatment of schizophrenia in adults. uuid:dce5a87f-f022-44e1-9757-5ed9087371a9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135983 biolink:treats MONDO:0001220 PMID:41385096 "[{""id"":""uuid:b725ed52-d5ea-40d4-aa17-04d2a081aca4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0e5eedad-1784-404c-b27c-6877faeae726"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] YORVIPATH is indicated for the treatment of hypoparathyroidism in adults. uuid:a18ac876-370c-4c97-b64a-dfc5302bfb66 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50729 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:43f62545-9b4e-44a9-9ff5-25ac68f1fd2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:76d82ca4-ea06-47f1-9f84-2eccae8ef304"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mitoxantrone Injection, USP is indicated for reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly abnormal between relapses). Mitoxantrone Injection, USP is not indicated in the treatment of patients with primary progressive multiple sclerosis. The clinical patterns of multiple sclerosis in the studies were characterized as follows: secondary progressive and progressive relapsing disease were characterized by gradual increasing disability with or without superimposed clinical relapses, and worsening relapsing-remitting disease was characterized by clinical relapses resulting in a step-wise worsening of disability. Mitoxantrone Injection, USP in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer. Mitoxantrone Injection, USP in combination with other approved drug(s) is indicated in the initial therapy of acute nonlymphocytic leukemia (ANLL) in adults. This category includes myelogenous, promyelocytic, monocytic, and erythroid acute leukemias. uuid:6b63e5c4-13e9-4898-9e8a-b2ab5146d044 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50729 biolink:treats MONDO:0000450 PMID:41385096 "[{""id"":""uuid:576ec578-95b0-4726-ab1c-36fbe0906dd2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:009f0ed5-8305-4d36-af06-20cd1ed236fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mitoxantrone Injection, USP is indicated for reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly abnormal between relapses). Mitoxantrone Injection, USP is not indicated in the treatment of patients with primary progressive multiple sclerosis. The clinical patterns of multiple sclerosis in the studies were characterized as follows: secondary progressive and progressive relapsing disease were characterized by gradual increasing disability with or without superimposed clinical relapses, and worsening relapsing-remitting disease was characterized by clinical relapses resulting in a step-wise worsening of disability. Mitoxantrone Injection, USP in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer. Mitoxantrone Injection, USP in combination with other approved drug(s) is indicated in the initial therapy of acute nonlymphocytic leukemia (ANLL) in adults. This category includes myelogenous, promyelocytic, monocytic, and erythroid acute leukemias. uuid:ff6a4432-d32f-41c2-b369-4e700cdeade0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50729 biolink:treats MONDO:0000452 PMID:41385096 "[{""id"":""uuid:de336c52-0d3b-4aea-a0ee-91c5a57589a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6e3e85d0-8eff-4ff2-8e46-c276ab3a7a17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mitoxantrone Injection, USP is indicated for reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly abnormal between relapses). Mitoxantrone Injection, USP is not indicated in the treatment of patients with primary progressive multiple sclerosis. The clinical patterns of multiple sclerosis in the studies were characterized as follows: secondary progressive and progressive relapsing disease were characterized by gradual increasing disability with or without superimposed clinical relapses, and worsening relapsing-remitting disease was characterized by clinical relapses resulting in a step-wise worsening of disability. Mitoxantrone Injection, USP in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer. Mitoxantrone Injection, USP in combination with other approved drug(s) is indicated in the initial therapy of acute nonlymphocytic leukemia (ANLL) in adults. This category includes myelogenous, promyelocytic, monocytic, and erythroid acute leukemias. uuid:cd648a2a-30c1-479e-9b01-6525c5dd11ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50729 biolink:treats MONDO:0005314 PMID:41385096 "[{""id"":""uuid:904b20ff-760a-4b5f-a795-ae9d3acd9b0f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:086137df-6bf8-4d99-84e4-f82715b1ad38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mitoxantrone Injection, USP is indicated for reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly abnormal between relapses). Mitoxantrone Injection, USP is not indicated in the treatment of patients with primary progressive multiple sclerosis. The clinical patterns of multiple sclerosis in the studies were characterized as follows: secondary progressive and progressive relapsing disease were characterized by gradual increasing disability with or without superimposed clinical relapses, and worsening relapsing-remitting disease was characterized by clinical relapses resulting in a step-wise worsening of disability. Mitoxantrone Injection, USP in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer. Mitoxantrone Injection, USP in combination with other approved drug(s) is indicated in the initial therapy of acute nonlymphocytic leukemia (ANLL) in adults. This category includes myelogenous, promyelocytic, monocytic, and erythroid acute leukemias. uuid:34956457-ed47-4279-b642-618001d454bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50729 biolink:treats MONDO:0004956 PMID:41385096 "[{""id"":""uuid:801fba2f-3748-42dd-ae6d-43e3368c22ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:813b9aaa-ff6c-4d07-94a4-5d1004b00447"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mitoxantrone Injection, USP is indicated for reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly abnormal between relapses). Mitoxantrone Injection, USP is not indicated in the treatment of patients with primary progressive multiple sclerosis. The clinical patterns of multiple sclerosis in the studies were characterized as follows: secondary progressive and progressive relapsing disease were characterized by gradual increasing disability with or without superimposed clinical relapses, and worsening relapsing-remitting disease was characterized by clinical relapses resulting in a step-wise worsening of disability. Mitoxantrone Injection, USP in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer. Mitoxantrone Injection, USP in combination with other approved drug(s) is indicated in the initial therapy of acute nonlymphocytic leukemia (ANLL) in adults. This category includes myelogenous, promyelocytic, monocytic, and erythroid acute leukemias. uuid:5bbd49bc-1b4a-4480-9c87-7d005d0c1a2a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50729 biolink:treats MONDO:0018874 PMID:41385096 "[{""id"":""uuid:19e2d471-0c58-4ab4-9f6a-7dd8ed1c5f8e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3e24401e-c0c8-479e-9830-cc3a7c9fa6fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mitoxantrone Injection, USP is indicated for reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly abnormal between relapses). Mitoxantrone Injection, USP is not indicated in the treatment of patients with primary progressive multiple sclerosis. The clinical patterns of multiple sclerosis in the studies were characterized as follows: secondary progressive and progressive relapsing disease were characterized by gradual increasing disability with or without superimposed clinical relapses, and worsening relapsing-remitting disease was characterized by clinical relapses resulting in a step-wise worsening of disability. Mitoxantrone Injection, USP in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer. Mitoxantrone Injection, USP in combination with other approved drug(s) is indicated in the initial therapy of acute nonlymphocytic leukemia (ANLL) in adults. This category includes myelogenous, promyelocytic, monocytic, and erythroid acute leukemias. uuid:68cba07e-b486-4511-beee-f299d654578f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50729 biolink:treats MONDO:0012883 PMID:41385096 "[{""id"":""uuid:09b6db22-c021-4554-ae0d-677104495d04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:45a21577-846e-474e-bd72-74df5af54de0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mitoxantrone Injection, USP is indicated for reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly abnormal between relapses). Mitoxantrone Injection, USP is not indicated in the treatment of patients with primary progressive multiple sclerosis. The clinical patterns of multiple sclerosis in the studies were characterized as follows: secondary progressive and progressive relapsing disease were characterized by gradual increasing disability with or without superimposed clinical relapses, and worsening relapsing-remitting disease was characterized by clinical relapses resulting in a step-wise worsening of disability. Mitoxantrone Injection, USP in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer. Mitoxantrone Injection, USP in combination with other approved drug(s) is indicated in the initial therapy of acute nonlymphocytic leukemia (ANLL) in adults. This category includes myelogenous, promyelocytic, monocytic, and erythroid acute leukemias. uuid:1b5a2065-6368-462c-af91-50b688aeb53a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50729 biolink:treats MONDO:0007896 PMID:41385096 "[{""id"":""uuid:827bebf3-dfb5-4d1c-9565-b7fd80168060"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:faa1206e-b84d-4437-99fc-3c6ef8409ad0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mitoxantrone Injection, USP is indicated for reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly abnormal between relapses). Mitoxantrone Injection, USP is not indicated in the treatment of patients with primary progressive multiple sclerosis. The clinical patterns of multiple sclerosis in the studies were characterized as follows: secondary progressive and progressive relapsing disease were characterized by gradual increasing disability with or without superimposed clinical relapses, and worsening relapsing-remitting disease was characterized by clinical relapses resulting in a step-wise worsening of disability. Mitoxantrone Injection, USP in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer. Mitoxantrone Injection, USP in combination with other approved drug(s) is indicated in the initial therapy of acute nonlymphocytic leukemia (ANLL) in adults. This category includes myelogenous, promyelocytic, monocytic, and erythroid acute leukemias. uuid:be432259-b1fe-4070-a0d9-ff7361b2f97a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50729 biolink:treats MONDO:0017858 PMID:41385096 "[{""id"":""uuid:152f6066-c44c-4962-8fee-a9d73ef4ffe3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:69300d65-a498-4c36-90dc-523e89c3d1f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mitoxantrone Injection, USP is indicated for reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly abnormal between relapses). Mitoxantrone Injection, USP is not indicated in the treatment of patients with primary progressive multiple sclerosis. The clinical patterns of multiple sclerosis in the studies were characterized as follows: secondary progressive and progressive relapsing disease were characterized by gradual increasing disability with or without superimposed clinical relapses, and worsening relapsing-remitting disease was characterized by clinical relapses resulting in a step-wise worsening of disability. Mitoxantrone Injection, USP in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer. Mitoxantrone Injection, USP in combination with other approved drug(s) is indicated in the initial therapy of acute nonlymphocytic leukemia (ANLL) in adults. This category includes myelogenous, promyelocytic, monocytic, and erythroid acute leukemias. uuid:54de0580-7ece-4757-94e5-9aaf16d6fc2d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45081 biolink:treats MONDO:0012268 PMID:41385096 "[{""id"":""uuid:2a63cf61-27ca-43ca-bac8-b979c02035fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2beb45b4-6a7a-48b7-a136-97e81d38460c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NebuPent is indicated for the prevention of Pneumocystis jiroveci pneumonia (PJP) in high-risk, HIV-infected patients defined by one or both of the following criteria: i. a history of one or more episodes of PJP ii. a peripheral CD4+ (T4 helper/inducer) lymphocyte count less than or equal to 200/mm 3 . These indications are based on the results of an 18-month randomized, dose-response trial in high risk HIV-infected patients and on existing epidemiological data from natural history studies. The patient population of the controlled trial consisted of 408 patients, 237 of whom had a history of one or more episodes of PJP. The remaining patients without a history of PJP included 55 patients with Kaposi’s sarcoma and 116 patients with other AIDS diagnoses, ARC or asymptomatic HIV infection. Patients were randomly assigned to receive NebuPent via the Respirgard ® II nebulizer at one of the following three doses: 30 mg every two weeks (n=135), 150 mg every two weeks (n=134) or 300 mg every four weeks (n=139). The results of the trial demonstrated a significant protective effect (p<0.01) against PJP with the 300 mg every four week dosage regimen compared to the 30 mg every two week dosage regimen. The 300 mg dose regimen reduced the risk of developing PJP by 50 to 70% compared to the 30 mg regimen. A total of 293 patients (72% of all patients) also received zidovudine at sometime during the trial. The analysis of the data demonstrated the efficacy of the 300 mg dose even after adjusting for the effect of zidovudine. The results of the trial further demonstrate that the dose and frequency of dosing are important to the efficacy of NebuPent prophylaxis in that multiple analyses consistently demonstrated a trend toward greater efficacy with 300 mg every four weeks as compared to 150 mg every two weeks. No dose-response was observed for reduction in overall mortality; however, mortality from PJP was low in all three dosage groups. uuid:650f2782-7924-4929-ae12-fe7e1d8a03e7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1043561 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:9bd30ac0-a668-4dff-9501-bdf7edd415e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:fb9fc1c7-dc8b-4d21-b9c0-0dada0a1054f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1ead55f1-8efb-4afa-bd8b-11422cdad43a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/komboglyze""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] KOMBIGLYZE XR is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [ see Clinical Studies (14) ].|[EMA] Komboglyze is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients aged 18 years and older with type-2 diabetes mellitus inadequately controlled on their maximally tolerated dose of metformin alone or those already being treated with the combination of saxagliptin and metformin as separate tablets.Komboglyze is also indicated in combination with insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in adult patients aged 18 years and older with type-2 diabetes mellitus when insulin and metformin alone do not provide adequate glycaemic control. uuid:27860026-43c2-4e94-adf6-d088de9322e9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:1864 biolink:treats MONDO:0006835 PMID:41385096 "[{""id"":""uuid:042dd1ce-2115-41a5-9eed-a667485446c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2e49ef7e-2702-4cd3-b5c8-1822fb73418b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclophosphamide is an alkylating drug indicated for treatment of: Malignant Diseases: malignant lymphomas: Hodgkin's disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt's lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma ( 1.1 ) Minimal Change Nephrotic Syndrome in Pediatric Patients: biopsy proven minimal change nephrotic syndrome patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy ( 1.2 ) Limitations of Use: The safety and effectiveness for the treatment of nephrotic syndrome in adults or other renal disease has not been established. uuid:413d11e2-e4ff-4d6b-aeb5-5aa91fc52d71 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75179 biolink:treats MONDO:0004768 PMID:41385096 "[{""id"":""uuid:db4bfdbc-f4cd-4fa9-a585-1bf059e89859"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bbb20491-4be8-4015-9704-e3ae2da25a36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE: Trifluridine Ophthalmic Solution is indicated for the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus, types 1 and 2. uuid:af59d54f-d703-4474-b9b2-595526cbcd85 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75179 biolink:treats MONDO:0015289 PMID:41385096 "[{""id"":""uuid:b61cf98b-26a5-4079-859f-4d44b79cca79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d701a114-e698-4390-afb6-8ae45157bcd9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS AND USAGE: Trifluridine Ophthalmic Solution is indicated for the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus, types 1 and 2. uuid:77a85330-bb6d-49ef-8775-806de8f61ce1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:166177295 biolink:treats MONDO:0005180 PMID:41385096 "[{""id"":""uuid:f62ac384-b264-4140-8909-a45e3edaf6f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a7ab75c8-6216-4048-bcb4-c28548dcd02d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VYALEV is indicated for the treatment of motor fluctuations in adults with advanced Parkinson’s disease (PD). uuid:927a4939-0152-48e5-8618-44be5624ef19 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1999667 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:78af3735-1dc8-4ef3-b811-68e21693e72d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b10a9d7b-85d6-400d-b02c-a21de87f13ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BIKTARVY is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in: adults and pediatric patients weighing at least 14 kg: who have no antiretroviral treatment history or to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no known or suspected substitutions associated with resistance to bictegravir or tenofovir [see Dosage and Administration (2.4) , and Use in Specific Populations (8.1) ]. uuid:78d9597e-4311-41e1-b56e-6f4f88262717 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229680 biolink:treats MONDO:0044070 PMID:41385096 "[{""id"":""uuid:458c8b92-5e85-40d6-b5d5-37d10d6c0d1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:720bec1b-2fe4-4fe3-b929-38bd90f260cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] REZZAYO is an echinocandin antifungal indicated in patients 18 years of age or older who have limited or no alternative options for the treatment of candidemia and invasive candidiasis. Approval of this indication is based on limited clinical safety and efficacy data for REZZAYO. ( 1 , 12.4 , 14 ) Limitations of Use REZZAYO has not been studied in patients with endocarditis, osteomyelitis, and meningitis due to Candida. ( 1 ) uuid:6198c5ea-3442-4473-a413-980d93a843fc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229680 biolink:treats MONDO:0044067 PMID:41385096 "[{""id"":""uuid:1556fae6-4a07-4bbf-8aef-51532987804e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:13ec56ea-b653-4abd-865c-f605af85d7c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] REZZAYO is an echinocandin antifungal indicated in patients 18 years of age or older who have limited or no alternative options for the treatment of candidemia and invasive candidiasis. Approval of this indication is based on limited clinical safety and efficacy data for REZZAYO. ( 1 , 12.4 , 14 ) Limitations of Use REZZAYO has not been studied in patients with endocarditis, osteomyelitis, and meningitis due to Candida. ( 1 ) uuid:a706237e-eb35-46be-af3d-ea45566d52bd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229680 biolink:treats MONDO:0000565 PMID:41385096 "[{""id"":""uuid:9e1f52b6-ca68-41a9-9642-b880a1ff1a60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d41cb544-d2d2-4ddd-9938-94e8a937e718"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] REZZAYO is an echinocandin antifungal indicated in patients 18 years of age or older who have limited or no alternative options for the treatment of candidemia and invasive candidiasis. Approval of this indication is based on limited clinical safety and efficacy data for REZZAYO. ( 1 , 12.4 , 14 ) Limitations of Use REZZAYO has not been studied in patients with endocarditis, osteomyelitis, and meningitis due to Candida. ( 1 ) uuid:a09ddc33-38f8-4ddc-8d96-dc5fa8b7d02c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229680 biolink:treats MONDO:0006764 PMID:41385096 "[{""id"":""uuid:3d051ae6-d95b-47be-8517-de515272f657"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:321fc410-f2b1-4bae-94f1-936617ba8ff3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] REZZAYO is an echinocandin antifungal indicated in patients 18 years of age or older who have limited or no alternative options for the treatment of candidemia and invasive candidiasis. Approval of this indication is based on limited clinical safety and efficacy data for REZZAYO. ( 1 , 12.4 , 14 ) Limitations of Use REZZAYO has not been studied in patients with endocarditis, osteomyelitis, and meningitis due to Candida. ( 1 ) uuid:5779ed04-ffa7-4cc1-8836-d144cf140a5d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7565 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:34c64b1b-546d-4b8f-8568-3974d78dfa6c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:949bae5f-5af3-40c9-a08a-cc2bd5be2d39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] I. Vasospastic Angina Nifedipine Extended-release Tablet is indicated for the management of vasospastic angina confirmed by any of the following criteria: 1) classical pattern of angina at rest accompanied by ST segment elevation, 2) angina or coronary artery spasm provoked by ergonovine, or 3) angiographically demonstrated coronary artery spasm. In those patients who have had angiography, the presence of significant fixed obstructive disease is not incompatible with the diagnosis of vasospastic angina, provided that the above criteria are satisfied. Nifedipine Extended-release Tablet may also be used where the clinical presentation suggests a possible vasospastic component but where vasospasm has not been confirmed, e.g., where pain has a variable threshold on exertion or in unstable angina where electrocardiographic findings are compatible with intermittent vasospasm, or when angina is refractory to nitrates and/or adequate doses of beta-blockers. II. Chronic Stable Angina (Classical Effort-Associated Angina) Nifedipine Extended-release Tablet is indicated for the management of chronic stable angina (effort-associated angina) without evidence of vasospasm in patients who remain symptomatic despite adequate doses of beta-blockers and/or organic nitrates or who cannot tolerate those agents. In chronic stable angina (effort-associated angina) nifedipine has been effective in controlled trials of up to eight weeks duration in reducing angina frequency and increasing exercise tolerance, but confirmation of sustained effectiveness and evaluation of long-term safety in these patients is incomplete. Controlled studies in small numbers of patients suggest concomitant use of nifedipine and beta-blocking agents may be beneficial in patients with chronic stable angina, but available information is not sufficient to predict with confidence the effects of concurrent treatment, especially in patients with compromised left ventricular function or cardiac conduction abnormalities. When introducing such concomitant therapy, care must be taken to monitor blood pressure closely since severe hypotension can occur from the combined effects of the drugs (see WARNINGS .) III. Hypertension Nifedipine Extended-release Tablet is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents. Nifedipine Extended-release Tablet is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including Nifedipine Extended-release Tablet. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Nifedipine Extended-release Tablet may be used alone or in combination with other antihypertensive agents. uuid:7c067859-c5f3-47e3-8d60-c5a442c2d268 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18332 biolink:treats UMLS:C0271795 PMID:41385096 "[{""id"":""uuid:8e2721ae-3c07-4b3f-950e-bba9104f3bfc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7123f54a-5bf2-4934-8449-98cb87dbb2c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TIROSINT-SOL is L-thyroxine (T4) indicated in adult and pediatric patients, including neonates, for: Hypothyroidism - As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism ( 1 ) Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression - As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer ( 1 ) Limitations of Use Not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients ( 1 ) Not indicated for treatment of transient hypothyroidism during the recovery phase of subacute thyroiditis ( 1 ) uuid:62f0b137-0216-4030-9fe4-883015c667e4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:36572 biolink:treats MONDO:0017639 PMID:41385096 "[{""id"":""uuid:20444d46-f935-4e32-a590-114e898862c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e5119c0f-90d5-46cf-b313-a1a99f9f19cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RYTARY is indicated for the treatment of Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. uuid:584ec4ac-22a0-406c-8645-1652e29d56d4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:36572 biolink:treats MONDO:0017638 PMID:41385096 "[{""id"":""uuid:0470e519-a940-4234-8a3d-72e177001c3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0d199f14-63fd-43db-8b10-82db360b218e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RYTARY is indicated for the treatment of Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. uuid:6092bb56-d877-4e06-b093-c0bc45793c42 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3638 biolink:treats MONDO:0005920 PMID:41385096 "[{""id"":""uuid:c5f229ce-f5e4-49e8-90ac-dc3b1d74cfd5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:edde7833-d259-4a29-88ed-49d64c9c1631"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chloroquine phosphate tablets are indicated for the: Treatment of uncomplicated malaria due to susceptible strains of P. falciparum, P.malariae, P. ovale, and P.vivax . Prophylaxis of malaria in geographic areas where resistance to chloroquine is not present. Treatment of extraintestinal amebiasis. Chloroquine phosphate tablets do not prevent relapses in patients with vivax or ovale malaria because it is not effective against exoerythrocytic forms of the parasites. Limitations of Use in Malaria: Do not use chloroquine phosphate tablets for the treatment of complicated malaria (high-grade parasitemia and/or complications e.g., cerebral malaria or acute renal failure). Do not use chloroquine phosphate tablets for malaria prophylaxis in areas where chloroquine resistance occurs, Resistance to chloroquine phosphate tablets is widespread in P. falciparum, and is reported in P.vivax (see WARNINGS ). Concomitant therapy with an 8-aminoquinoline drug is necessary for treatment of the hypnozoite liver stage forms of P.vivax and P.ovale (see DOSAGE AND ADMINISTRATION ). uuid:a9fa674d-a8c3-4c0f-8283-f4cbfc814b7e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3181 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:955342d7-4f37-413d-ac84-a238a46aa0cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c5583ff6-7c35-4a74-8ab6-17aadc2abd9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CYCLOSET is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. uuid:8d126c64-f09f-410b-a45a-58bdc90784c8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16094 biolink:treats MONDO:0001874 PMID:41385096 "[{""id"":""uuid:b33e079d-9977-422d-a234-79e067ba85fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9d87cd1c-2e5f-41fe-8c63-d4b056897c40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PEDMARK is indicated to reduce the risk of ototoxicity associated with cisplatin in pediatric patients 1 month of age and older with localized, non-metastatic solid tumors. uuid:7025db6c-0324-486e-9333-495a8bf39a31 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9168 biolink:treats MONDO:0006359 PMID:41385096 "[{""id"":""uuid:5c01633e-7a0d-4080-bea4-c27d9d9184ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2a4f2a66-174e-44b5-8f0d-0ac863aafea5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FYARRO ™ is indicated for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). uuid:94f375c9-648b-4c2c-9c4e-957a535b4e9c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:232810 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:c611debb-1122-4d58-a26a-143dc71f084b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:604a5a87-9df1-42f2-8a29-ef35d979007e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e2aea632-e356-4c4a-ac5a-a01276b96f1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/alunbrig""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ALUNBRIG is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test [see Dosage and Administration (2.1) ] .|[EMA] Alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)‑positive advanced non‑small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.Alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase ALKpositive advanced NSCLC previously treated with crizotinib. UNII:HYW8DB273J uuid:2c5f0984-cb89-471c-859f-89526d1e6b3d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5959 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:e1c7971b-79ad-4734-b775-4f2ef9311b5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0f332732-aea4-4828-a803-9d426b8b01f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4249825a-962d-45b2-93ac-fd4988b1ca96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/irbesartan-teva""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Irbesartan tablets are an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. (1.1) Treatment of diabetic nephropathy in hypertensive patients with type 2 diabetes, an elevated serum creatinine, and proteinuria. (1.2)|[EMA] Treatment of essential hypertension.Treatment of renal disease in patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive medicinal product regimen. uuid:7a563494-c0d6-4075-a097-791d5bd6bf56 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:P76B05O5V6 biolink:treats MONDO:0008315 PMID:41385096 "[{""id"":""uuid:b0525685-8852-40ae-a50b-503b4fa07225"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:99120680-6a1f-4f69-8f53-40f2897347ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ORGOVYX is indicated for the treatment of adult patients with advanced prostate cancer. uuid:a3794c78-623e-4987-b278-0e7ac2be44f7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2637040 biolink:treats HP:0001662 PMID:41385096 "[{""id"":""uuid:c16e1b84-733a-46fd-a405-0bc5566414fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6475dd52-a548-434e-9677-da164c9f3e7d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PREVDUO ® , a fixed dose combination of cholinesterase inhibitor and antimuscarinic agent, is indicated in patients age two years and above for the reversal of the effects of nondepolarizing neuromuscular blocking agents (NMBA) after surgery, while decreasing the peripheral muscarinic effects (e.g., bradycardia and excessive secretions) associated with cholinesterase inhibition following NMBA reversal administration. uuid:5d06ec71-3686-471e-a4af-4da549c69e93 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:98DE7VN88D biolink:treats MONDO:0005140 PMID:41385096 "[{""id"":""uuid:0f075c43-6f16-4a21-8e05-4a9f3d03ac93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:134cf9c0-34f4-4d25-a291-81626fda5115"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ELAHERE ® is indicated for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Select patients for therapy based on an FDA-approved test [see Dosage and Administration ( 2.1 )] . uuid:be712733-63a2-498a-8302-1b0bca5f28a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:98DE7VN88D biolink:treats MONDO:0002158 PMID:41385096 "[{""id"":""uuid:be2ee123-67cf-4035-8e9f-28837813370a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5f5a30bf-71ef-4a9a-9287-b4919e7db736"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ELAHERE ® is indicated for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Select patients for therapy based on an FDA-approved test [see Dosage and Administration ( 2.1 )] . uuid:133b3840-5bb2-48e0-b59f-87f0ab71ed18 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:98DE7VN88D biolink:treats MONDO:0015686 PMID:41385096 "[{""id"":""uuid:b718a834-72c6-42d7-95dd-4427450f03d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b5925da7-1a5a-4e55-a530-f01d1337171b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ELAHERE ® is indicated for the treatment of adult patients with folate receptor-alpha (FRα) positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens. Select patients for therapy based on an FDA-approved test [see Dosage and Administration ( 2.1 )] . uuid:af2fd734-906d-455e-bb5c-73855f3ec835 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0006050 biolink:treats EFO:0006865 PMID:41385096 "[{""id"":""uuid:ad3f67b5-d22e-4a2d-a79b-26820ae1d8d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d9c75e9e-c74c-4595-907c-f520090b7997"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BOTOX is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for: Treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency, in adults who have an inadequate response to or are intolerant of an anticholinergic medication ( 1.1 ) Treatment of urinary incontinence due to detrusor overactivity associated with a neurologic condition [e.g., spinal cord injury (SCI), multiple sclerosis (MS)] in adults who have an inadequate response to or are intolerant of an anticholinergic medication ( 1.1 ) Treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 5 years of age and older who have an inadequate response to or are intolerant of anticholinergic medication. ( 1.2 ) Prophylaxis of headaches in adult patients with chronic migraine (≥15 days per month with headache lasting 4 hours a day or longer) ( 1.3 ) Treatment of spasticity in patients 2 years of age and older ( 1.4 ) Treatment of cervical dystonia in adult patients, to reduce the severity of abnormal head position and neck pain ( 1.5 ) Treatment of severe axillary hyperhidrosis that is inadequately managed by topical agents in adult patients ( 1.6 ) Treatment of blepharospasm associated with dystonia in patients 12 years of age and older ( 1.7 ) Treatment of strabismus in patients 12 years of age and older ( 1.7 ) Limitations of Use Safety and effectiveness of BOTOX have not been established for: Prophylaxis of episodic migraine (14 headache days or fewer per month) ( 1.3 ) Treatment of hyperhidrosis in body areas other than axillary ( 1.6 ) DRUGBANK:DB00083 uuid:22aae4a0-ae46-410d-85c5-f8adc8666046 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0006050 biolink:treats MONDO:0043797 PMID:41385096 "[{""id"":""uuid:3446263a-68b5-4ebb-86b0-b64bf86f46c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bb735b96-1246-4cad-ac01-f00eca45587b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BOTOX is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for: Treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency, in adults who have an inadequate response to or are intolerant of an anticholinergic medication ( 1.1 ) Treatment of urinary incontinence due to detrusor overactivity associated with a neurologic condition [e.g., spinal cord injury (SCI), multiple sclerosis (MS)] in adults who have an inadequate response to or are intolerant of an anticholinergic medication ( 1.1 ) Treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 5 years of age and older who have an inadequate response to or are intolerant of anticholinergic medication. ( 1.2 ) Prophylaxis of headaches in adult patients with chronic migraine (≥15 days per month with headache lasting 4 hours a day or longer) ( 1.3 ) Treatment of spasticity in patients 2 years of age and older ( 1.4 ) Treatment of cervical dystonia in adult patients, to reduce the severity of abnormal head position and neck pain ( 1.5 ) Treatment of severe axillary hyperhidrosis that is inadequately managed by topical agents in adult patients ( 1.6 ) Treatment of blepharospasm associated with dystonia in patients 12 years of age and older ( 1.7 ) Treatment of strabismus in patients 12 years of age and older ( 1.7 ) Limitations of Use Safety and effectiveness of BOTOX have not been established for: Prophylaxis of episodic migraine (14 headache days or fewer per month) ( 1.3 ) Treatment of hyperhidrosis in body areas other than axillary ( 1.6 ) DRUGBANK:DB00083 uuid:0151a60f-c755-48e1-89d1-f8acd563a1c1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0006050 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:0f34d51b-3df5-4955-bc7d-046c7ba14738"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b7e4f8c9-bdfc-4aae-b948-2fc11fe36c8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BOTOX is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for: Treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency, in adults who have an inadequate response to or are intolerant of an anticholinergic medication ( 1.1 ) Treatment of urinary incontinence due to detrusor overactivity associated with a neurologic condition [e.g., spinal cord injury (SCI), multiple sclerosis (MS)] in adults who have an inadequate response to or are intolerant of an anticholinergic medication ( 1.1 ) Treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 5 years of age and older who have an inadequate response to or are intolerant of anticholinergic medication. ( 1.2 ) Prophylaxis of headaches in adult patients with chronic migraine (≥15 days per month with headache lasting 4 hours a day or longer) ( 1.3 ) Treatment of spasticity in patients 2 years of age and older ( 1.4 ) Treatment of cervical dystonia in adult patients, to reduce the severity of abnormal head position and neck pain ( 1.5 ) Treatment of severe axillary hyperhidrosis that is inadequately managed by topical agents in adult patients ( 1.6 ) Treatment of blepharospasm associated with dystonia in patients 12 years of age and older ( 1.7 ) Treatment of strabismus in patients 12 years of age and older ( 1.7 ) Limitations of Use Safety and effectiveness of BOTOX have not been established for: Prophylaxis of episodic migraine (14 headache days or fewer per month) ( 1.3 ) Treatment of hyperhidrosis in body areas other than axillary ( 1.6 ) DRUGBANK:DB00083 uuid:185a6a39-0689-47ba-b121-061148028676 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0006050 biolink:treats UMLS:C0341736 PMID:41385096 "[{""id"":""uuid:e12be21b-ad62-4543-88fc-5a97b148ecba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ff49c483-b51e-4de7-957c-1b3f1fb85b5d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BOTOX is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for: Treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency, in adults who have an inadequate response to or are intolerant of an anticholinergic medication ( 1.1 ) Treatment of urinary incontinence due to detrusor overactivity associated with a neurologic condition [e.g., spinal cord injury (SCI), multiple sclerosis (MS)] in adults who have an inadequate response to or are intolerant of an anticholinergic medication ( 1.1 ) Treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 5 years of age and older who have an inadequate response to or are intolerant of anticholinergic medication. ( 1.2 ) Prophylaxis of headaches in adult patients with chronic migraine (≥15 days per month with headache lasting 4 hours a day or longer) ( 1.3 ) Treatment of spasticity in patients 2 years of age and older ( 1.4 ) Treatment of cervical dystonia in adult patients, to reduce the severity of abnormal head position and neck pain ( 1.5 ) Treatment of severe axillary hyperhidrosis that is inadequately managed by topical agents in adult patients ( 1.6 ) Treatment of blepharospasm associated with dystonia in patients 12 years of age and older ( 1.7 ) Treatment of strabismus in patients 12 years of age and older ( 1.7 ) Limitations of Use Safety and effectiveness of BOTOX have not been established for: Prophylaxis of episodic migraine (14 headache days or fewer per month) ( 1.3 ) Treatment of hyperhidrosis in body areas other than axillary ( 1.6 ) DRUGBANK:DB00083 uuid:4a68da57-e0ff-436e-a9e0-20c7c6ac3422 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0006050 biolink:treats HP:0000975 PMID:41385096 "[{""id"":""uuid:8c91598f-8515-4bfc-98d9-1493f5e8ce6c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:93e220cd-d9ad-4e24-8f3d-e21a152027ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:253533df-1be4-4443-8781-304482b52c81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BOTOX is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for: Treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency, in adults who have an inadequate response to or are intolerant of an anticholinergic medication ( 1.1 ) Treatment of urinary incontinence due to detrusor overactivity associated with a neurologic condition [e.g., spinal cord injury (SCI), multiple sclerosis (MS)] in adults who have an inadequate response to or are intolerant of an anticholinergic medication ( 1.1 ) Treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 5 years of age and older who have an inadequate response to or are intolerant of anticholinergic medication. ( 1.2 ) Prophylaxis of headaches in adult patients with chronic migraine (≥15 days per month with headache lasting 4 hours a day or longer) ( 1.3 ) Treatment of spasticity in patients 2 years of age and older ( 1.4 ) Treatment of cervical dystonia in adult patients, to reduce the severity of abnormal head position and neck pain ( 1.5 ) Treatment of severe axillary hyperhidrosis that is inadequately managed by topical agents in adult patients ( 1.6 ) Treatment of blepharospasm associated with dystonia in patients 12 years of age and older ( 1.7 ) Treatment of strabismus in patients 12 years of age and older ( 1.7 ) Limitations of Use Safety and effectiveness of BOTOX have not been established for: Prophylaxis of episodic migraine (14 headache days or fewer per month) ( 1.3 ) Treatment of hyperhidrosis in body areas other than axillary ( 1.6 )|[PMDA] Drugs with a new route of administration and an additional indication for the treatment of severe primary axillary hyperhidrosis. DRUGBANK:DB00083 uuid:b34d75f3-3a7f-4c40-9994-efa8f8d2599a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0006050 biolink:treats MONDO:0019772 PMID:41385096 "[{""id"":""uuid:5d76ea04-941b-4bf8-a0a5-f870cc6b1e49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d4d2f36a-b4b5-41b9-bdaf-43500f8fb399"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BOTOX is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for: Treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency, in adults who have an inadequate response to or are intolerant of an anticholinergic medication ( 1.1 ) Treatment of urinary incontinence due to detrusor overactivity associated with a neurologic condition [e.g., spinal cord injury (SCI), multiple sclerosis (MS)] in adults who have an inadequate response to or are intolerant of an anticholinergic medication ( 1.1 ) Treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 5 years of age and older who have an inadequate response to or are intolerant of anticholinergic medication. ( 1.2 ) Prophylaxis of headaches in adult patients with chronic migraine (≥15 days per month with headache lasting 4 hours a day or longer) ( 1.3 ) Treatment of spasticity in patients 2 years of age and older ( 1.4 ) Treatment of cervical dystonia in adult patients, to reduce the severity of abnormal head position and neck pain ( 1.5 ) Treatment of severe axillary hyperhidrosis that is inadequately managed by topical agents in adult patients ( 1.6 ) Treatment of blepharospasm associated with dystonia in patients 12 years of age and older ( 1.7 ) Treatment of strabismus in patients 12 years of age and older ( 1.7 ) Limitations of Use Safety and effectiveness of BOTOX have not been established for: Prophylaxis of episodic migraine (14 headache days or fewer per month) ( 1.3 ) Treatment of hyperhidrosis in body areas other than axillary ( 1.6 ) DRUGBANK:DB00083 uuid:d9a4aba9-66c2-4265-8ea3-5bb85e2c6436 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0006050 biolink:treats MONDO:0003432 PMID:41385096 "[{""id"":""uuid:2d44a398-9159-413e-afc5-154537004e26"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:42eac727-9e6c-4811-bf18-0965480b8eba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3b5cd65a-d72e-4479-8b7b-e968bb7ca168"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BOTOX is an acetylcholine release inhibitor and a neuromuscular blocking agent indicated for: Treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency, in adults who have an inadequate response to or are intolerant of an anticholinergic medication ( 1.1 ) Treatment of urinary incontinence due to detrusor overactivity associated with a neurologic condition [e.g., spinal cord injury (SCI), multiple sclerosis (MS)] in adults who have an inadequate response to or are intolerant of an anticholinergic medication ( 1.1 ) Treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 5 years of age and older who have an inadequate response to or are intolerant of anticholinergic medication. ( 1.2 ) Prophylaxis of headaches in adult patients with chronic migraine (≥15 days per month with headache lasting 4 hours a day or longer) ( 1.3 ) Treatment of spasticity in patients 2 years of age and older ( 1.4 ) Treatment of cervical dystonia in adult patients, to reduce the severity of abnormal head position and neck pain ( 1.5 ) Treatment of severe axillary hyperhidrosis that is inadequately managed by topical agents in adult patients ( 1.6 ) Treatment of blepharospasm associated with dystonia in patients 12 years of age and older ( 1.7 ) Treatment of strabismus in patients 12 years of age and older ( 1.7 ) Limitations of Use Safety and effectiveness of BOTOX have not been established for: Prophylaxis of episodic migraine (14 headache days or fewer per month) ( 1.3 ) Treatment of hyperhidrosis in body areas other than axillary ( 1.6 )|[PMDA] Drugs with a new additional indication and a new dosage for the treatment of strabismus. DRUGBANK:DB00083 uuid:1c6016b4-4b59-4398-9174-db06a2a65a85 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB17381 biolink:treats MONDO:0004200 PMID:41385096 "[{""id"":""uuid:9085df2f-6408-456d-a011-045c230430ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0e35d17f-a253-43ce-8bf2-4747bd358daa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ADSTILADRIN ® is indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-Muscle Invasive Bladder Cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. uuid:9b862710-6f26-4258-8c72-4174b4f016ca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB17381 biolink:treats MONDO:0004641 PMID:41385096 "[{""id"":""uuid:3f20f479-40c2-44f9-aef0-1c0284b28a89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cf88b801-7be4-4225-bac1-cee666ab00aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ADSTILADRIN ® is indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-Muscle Invasive Bladder Cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. uuid:fdec53fe-eb88-4d4f-b370-4f52c97095ab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C2826078 biolink:treats MONDO:0009212 PMID:41385096 "[{""id"":""uuid:45408852-a5fa-4296-bb54-22de3ab7185d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a6bf68db-d3a6-4031-ae00-90368eae39fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c12a2c22-215c-4ad5-b148-c1dfe0ae5fc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/coagadex""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] COAGADEX, Coagulation Factor X (Human), is a plasma-derived human blood coagulation Factor indicated in adults and children with hereditary Factor X deficiency for: Routine prophylaxis to reduce the frequency of bleeding episodes On-demand treatment and control of bleeding episodes Perioperative management of bleeding in patients with mild, moderate, and severe hereditary Factor X deficiency|[EMA] Coagadex is indicated for the treatment and prophylaxis of bleeding episodes and for perioperative management in patients with hereditary factor X deficiency. Coagadex is indicated in all age groups. DRUGBANK:DB13148 uuid:c70a3c2e-120a-4324-b197-36bb29d1a40b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C2826078 biolink:treats MONDO:0002243 PMID:41385096 "[{""id"":""uuid:d7f4d04c-feed-4a95-90bc-c0869255e309"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:344ddf01-fc57-4795-9e28-0ffff138635e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] COAGADEX, Coagulation Factor X (Human), is a plasma-derived human blood coagulation Factor indicated in adults and children with hereditary Factor X deficiency for: Routine prophylaxis to reduce the frequency of bleeding episodes On-demand treatment and control of bleeding episodes Perioperative management of bleeding in patients with mild, moderate, and severe hereditary Factor X deficiency DRUGBANK:DB13148 uuid:c2551e94-d1f6-435e-b5ef-c47b448dad25 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50924 biolink:treats UMLS:C1112459 PMID:41385096 "[{""id"":""uuid:23a3798f-58cb-4cbd-8365-46c700c085e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:41a8b0e6-e69e-4f93-82d7-8977e84195a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sorafenib tablets are a kinase inhibitor indicated for the treatment of • Unresectable hepatocellular carcinoma ( 1.1 ) • Advanced renal cell carcinoma ( 1.2 ) • Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) refractory to radioactive iodine treatment ( 1.3 ) uuid:34e4d492-d2c6-4199-bd6a-3e9fdd954bc9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50924 biolink:treats UMLS:C4727069 PMID:41385096 "[{""id"":""uuid:26cf99d5-a407-46e8-aa5f-b9715eb24a86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2070150e-493c-4397-ab09-a0065007478c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sorafenib tablets are a kinase inhibitor indicated for the treatment of • Unresectable hepatocellular carcinoma ( 1.1 ) • Advanced renal cell carcinoma ( 1.2 ) • Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) refractory to radioactive iodine treatment ( 1.3 ) uuid:d14d2e29-a8f2-4bee-8549-063f60186064 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50924 biolink:treats MONDO:0015447 PMID:41385096 "[{""id"":""uuid:82348b4e-8590-4dc6-bcd4-1eb6a6e676d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:27797975-958d-476e-a031-272b5097d56b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:886025d4-801e-4abb-af28-8a17877171ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/nexavar""]},{""id"":""uuid:d6de7cb0-5e3b-4b8a-b9f5-8687c5ebacba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sorafenib tablets are a kinase inhibitor indicated for the treatment of • Unresectable hepatocellular carcinoma ( 1.1 ) • Advanced renal cell carcinoma ( 1.2 ) • Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) refractory to radioactive iodine treatment ( 1.3 )|[EMA] Hepatocellular carcinomaNexavar is indicated for the treatment of hepatocellular carcinoma.Renal cell carcinomaNexavar is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.Differentiated thyroid carcinomaNexavar is indicated for the treatment of patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma, refractory to radioactive iodine.|[PMDA] A drug with a new additional indication for the treatment of unresectable differentiated thyroid carcinoma. [Orphan drug] uuid:170f46cd-98e2-420b-bc5f-67ce4d6c796a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7488 biolink:treats MONDO:0020944 PMID:41385096 "[{""id"":""uuid:b7a7ee2f-cc04-4f66-ae35-8d87b6d1a529"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c4902fea-cd6e-4c5f-aab6-d4d0c26c0735"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NATACYN™ (natamycin ophthalmic suspension) 5% is indicated for the treatment of fungal blepharitis, conjunctivitis, and keratitis caused by susceptible organisms including Fusarium solani keratitis. As in other forms of suppurative keratitis, initial and sustained therapy of fungal keratitis should be determined by the clinical diagnosis, laboratory diagnosis by smear and culture of corneal scrapings and drug response. Whenever possible the in vitro activity of natamycin against the responsible fungus should be determined. The effectiveness of natamycin as a single agent in fungal endophthalmitis has not been established. uuid:b34eb646-78d3-48b2-9862-b517ad884369 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7488 biolink:treats MONDO:0003799 PMID:41385096 "[{""id"":""uuid:81a8b434-2566-4124-a9d9-c47b5b61082f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:83e30557-9a28-4998-a767-3cbd705c45a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NATACYN™ (natamycin ophthalmic suspension) 5% is indicated for the treatment of fungal blepharitis, conjunctivitis, and keratitis caused by susceptible organisms including Fusarium solani keratitis. As in other forms of suppurative keratitis, initial and sustained therapy of fungal keratitis should be determined by the clinical diagnosis, laboratory diagnosis by smear and culture of corneal scrapings and drug response. Whenever possible the in vitro activity of natamycin against the responsible fungus should be determined. The effectiveness of natamycin as a single agent in fungal endophthalmitis has not been established. uuid:5efe0d87-9b63-4c8e-8db7-d3a4180e68bd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7488 biolink:treats MONDO:0003085 PMID:41385096 "[{""id"":""uuid:f2f796bd-6efa-4322-803d-841a8377d7e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0df0ad02-60b0-498e-afd5-ea0e53d13c05"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NATACYN™ (natamycin ophthalmic suspension) 5% is indicated for the treatment of fungal blepharitis, conjunctivitis, and keratitis caused by susceptible organisms including Fusarium solani keratitis. As in other forms of suppurative keratitis, initial and sustained therapy of fungal keratitis should be determined by the clinical diagnosis, laboratory diagnosis by smear and culture of corneal scrapings and drug response. Whenever possible the in vitro activity of natamycin against the responsible fungus should be determined. The effectiveness of natamycin as a single agent in fungal endophthalmitis has not been established. uuid:6be4c550-a19e-4cba-a3f9-c7aa8c51fdd7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7488 biolink:treats MONDO:0033821 PMID:41385096 "[{""id"":""uuid:f6ae2a0a-31cf-4a93-9847-dd9185c7609a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1df3eed8-bee9-45b2-86f4-179d03230cb6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NATACYN™ (natamycin ophthalmic suspension) 5% is indicated for the treatment of fungal blepharitis, conjunctivitis, and keratitis caused by susceptible organisms including Fusarium solani keratitis. As in other forms of suppurative keratitis, initial and sustained therapy of fungal keratitis should be determined by the clinical diagnosis, laboratory diagnosis by smear and culture of corneal scrapings and drug response. Whenever possible the in vitro activity of natamycin against the responsible fungus should be determined. The effectiveness of natamycin as a single agent in fungal endophthalmitis has not been established. uuid:b50b264a-16b7-4257-a658-6a0871de0165 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7488 biolink:treats UMLS:C1532533 PMID:41385096 "[{""id"":""uuid:0045136e-f75d-4006-bdb0-db8ec1e662a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c8a81981-632f-49d7-9a13-dbfdb3921360"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NATACYN™ (natamycin ophthalmic suspension) 5% is indicated for the treatment of fungal blepharitis, conjunctivitis, and keratitis caused by susceptible organisms including Fusarium solani keratitis. As in other forms of suppurative keratitis, initial and sustained therapy of fungal keratitis should be determined by the clinical diagnosis, laboratory diagnosis by smear and culture of corneal scrapings and drug response. Whenever possible the in vitro activity of natamycin against the responsible fungus should be determined. The effectiveness of natamycin as a single agent in fungal endophthalmitis has not been established. uuid:ee705e6f-29a9-4c18-9d3b-7f11f48f049d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:88SH1NBL2B biolink:treats MONDO:0019623 PMID:41385096 "[{""id"":""uuid:69d9c1d1-be47-41b1-a24b-444295725d1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ecc3dc8c-f614-417b-a5ea-bb0bf8b436ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0cf64099-8aaf-4558-b126-f173f5966206"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ORLADEYO ® is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years of age and older.|[PMDA] A drug with a new active ingredient indicated for the prophylaxis of acute attacks of hereditary angioedema. [SAKIGAKE review, orphan drug] uuid:38fbdf02-c336-4f9c-8aaa-ab1040f64b24 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:88SH1NBL2B biolink:treats MONDO:0012526 PMID:41385096 "[{""id"":""uuid:d2af539e-b73e-4fb0-bc71-f8c0ee41def5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a00632dd-f57b-46d3-b579-df9ad19cd523"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ORLADEYO ® is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adults and pediatric patients 12 years of age and older. uuid:6de7cae7-781c-4ebe-a108-feca368dca82 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63584 biolink:treats MONDO:0004956 PMID:41385096 "[{""id"":""uuid:af0817ee-6f9b-4c3f-a7ac-41cc5fc5ba34"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d3afaa94-c12e-43ac-9528-b9bd2e9902f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2b28415e-8ab5-4a60-a2b6-b97c301218f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cabazitaxel-accord""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cabazitaxel Injection is indicated in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing treatment regimen.|[EMA] Jevtana in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen. uuid:5c790804-cf50-4519-8e63-0d61fd2f9b4e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63916 biolink:treats UMLS:C0016736 PMID:41385096 "[{""id"":""uuid:23a2a373-b95f-42e2-ac3d-c6a5277ee97c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7ecff08d-689c-4220-9efa-aa88911762a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AURLUMYN is a prostacyclin mimetic indicated for the treatment of severe frostbite in adults to reduce the risk of digit amputations. Effectiveness was established in young, healthy adults who suffered frostbite at high altitudes ( 1.1 ). uuid:ffa49a47-0664-450a-bf28-a669f187c179 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:233412 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:0b090023-4d85-405a-abde-e18c8d090ea1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4d5a911f-1b0a-49a6-80a5-1bf2f1b48375"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:fb5dff4f-063d-40d2-ad01-3e522993841d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ponvory""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] PONVORY is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.|[EMA] Ponvory is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features. PUBCHEM.COMPOUND:11363176 uuid:4eb8c991-edb7-41e7-b2c6-4c6db0b34535 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:233412 biolink:treats UMLS:C2921627 PMID:41385096 "[{""id"":""uuid:a520d49d-6629-44d5-8ba3-f903520e6fcb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:45fb5307-c222-4b9c-a62d-b2dd8ff24441"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PONVORY is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. PUBCHEM.COMPOUND:11363176 uuid:e17187ec-0b45-4894-8158-cd3faf1ec4c9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:233412 biolink:treats MONDO:0000450 PMID:41385096 "[{""id"":""uuid:4a3f81a7-2245-4dfd-9681-9f74a048d139"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ebde11f6-2559-4589-8e34-4808595822db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PONVORY is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. PUBCHEM.COMPOUND:11363176 uuid:7e4ff6e0-a1da-4d73-948c-2aff7dba5e23 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PVI5M0M1GW biolink:treats MONDO:0033938 PMID:41385096 "[{""id"":""uuid:8fcb424a-053d-4628-b77f-364f1ff7d92e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d8681c0c-b2c2-4800-9d88-73bc7addeb16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZARXIO is a leukocyte growth factor indicated to • Decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies receiving myelosuppressive anti‑cancer drugs associated with a significant incidence of severe neutropenia with fever ( 1.1 ) • Reduce the time to neutrophil recovery and the duration of fever, following induction or consolidation chemotherapy treatment of patients with acute myeloid leukemia (AML) ( 1.2 ) • Reduce the duration of neutropenia and neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients with nonmyeloid malignancies undergoing myeloablative chemotherapy followed by bone marrow transplantation (BMT) ( 1.3 ) • Mobilize autologous hematopoietic progenitor cells into the peripheral blood for collection by leukapheresis ( 1.4 ) • Reduce the incidence and duration of sequelae of severe neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in symptomatic patients with congenital neutropenia‚ cyclic neutropenia‚ or idiopathic neutropenia ( 1.5 ) • Increase survival in patients acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome) ( 1.6 ) uuid:db702572-dcbf-4fba-b63a-3d676eb6e416 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5134 biolink:treats EFO:1002029 PMID:41385096 "[{""id"":""uuid:eea791c2-0ed4-493e-8369-10f1b0a4b3c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bde21acf-0341-4ac0-b328-b6c1c0d2c05a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XHANCE is a corticosteroid indicated for the treatment of: • Chronic rhinosinusitis with nasal polyps (CRSwNP) in adults. ( 1.1 ) • Chronic rhinosinusitis without nasal polyps (CRSsNP) in adults. ( 1.2 ) uuid:34b00bb4-530d-4fae-b6da-d50516816567 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5134 biolink:treats EFO:1002030 PMID:41385096 "[{""id"":""uuid:1606b210-bf63-436b-b324-0ac5ef3f9afb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a3a65934-126c-4f98-973e-82ad5b4042c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XHANCE is a corticosteroid indicated for the treatment of: • Chronic rhinosinusitis with nasal polyps (CRSwNP) in adults. ( 1.1 ) • Chronic rhinosinusitis without nasal polyps (CRSsNP) in adults. ( 1.2 ) uuid:6db78a6d-d75f-408b-b2b7-9815eaa74817 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24755620 biolink:treats MONDO:0006993 PMID:41385096 "[{""id"":""uuid:40ca7c8d-c044-42e8-b859-5e420a07522a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cc225a07-cdfe-4b8e-8dfd-ef4e98aca22f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sacubitril and valsartan tablet is a combination of sacubitril, a neprilisin inhibitor, and valsartan, an angiotensin II receptor blocker, and is indicated: • to reduce the risk of cardiovascular death and hospitalization for heart failure in adult patients with chronic heart failure. Benefits are most clearly evident in patients with left ventricular ejection fraction (LVEF) below normal. ( 1.1 ) • for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. Sacubitril and valsartan tablet reduce NT-proBNP and is expected to improve cardiovascular outcomes. ( 1.2 ) uuid:a942725d-d646-4a35-b17a-8d058f215aac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134892 biolink:treats MONDO:0004986 PMID:41385096 "[{""id"":""uuid:48f49ef4-f1a2-4923-92cb-e491ebd70edb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:518ee445-fb87-4c7e-9419-dcbdbde0cd98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cysview is indicated for use in the cystoscopic detection of carcinoma of the bladder, including carcinoma in situ (CIS), among patients suspected or known to have lesion(s) on the basis of a prior cystoscopy, or in patients undergoing surveillance cystoscopy for carcinoma of the bladder. Cysview is used with the Karl Storz D-Light C Photodynamic Diagnostic (PDD) system to perform Blue Light Cystoscopy (BLC ® ) as an adjunct to the white light cystoscopy. uuid:4340d12c-d54a-408e-b207-e30bf7d5c01b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134892 biolink:treats MONDO:0004641 PMID:41385096 "[{""id"":""uuid:a41bcf17-0716-4bb1-a96a-3574153c3894"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:31d12179-4060-4a9d-b01f-12f9de77d4df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cysview is indicated for use in the cystoscopic detection of carcinoma of the bladder, including carcinoma in situ (CIS), among patients suspected or known to have lesion(s) on the basis of a prior cystoscopy, or in patients undergoing surveillance cystoscopy for carcinoma of the bladder. Cysview is used with the Karl Storz D-Light C Photodynamic Diagnostic (PDD) system to perform Blue Light Cystoscopy (BLC ® ) as an adjunct to the white light cystoscopy. uuid:57d920c7-1652-4533-9fe0-73c519cc0fbc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:310870 biolink:treats HP:0032004 PMID:41385096 "[{""id"":""uuid:5540aeda-0272-49dc-909e-e69e73140a5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0f6a73ad-9e13-4d8a-8c5f-e181a0544843"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: “Possibly” Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation. uuid:714b84f4-f2bc-44a1-98f6-7a8f46f3dd46 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:310870 biolink:treats UMLS:C0451941 PMID:41385096 "[{""id"":""uuid:9a8a5986-3b3f-44db-9bc6-8b4dec089478"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1431a1bc-dfb4-4c40-a72e-9f8725c8a9dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: “Possibly” Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation. uuid:e6980995-fea3-4adb-927a-ff1fc646408e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:310870 biolink:treats UMLS:C0033775 PMID:41385096 "[{""id"":""uuid:0f6c67d5-569e-4cab-ab08-e377b1dd8a40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:21100e99-5ebf-4cc3-a4de-5409b5919483"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: “Possibly” Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); moniliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation. uuid:cbe2ea11-21af-40d2-8787-3503499b2f04 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats UMLS:C0343886 PMID:41385096 "[{""id"":""uuid:c7b75bf6-9b04-4abc-ae1e-e88faac29148"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f2e365f4-c84e-4758-a335-f1244e16dea6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Based on a review of a related drug by the National Research Council and subsequent FDA classification for that drug, the indications are as follows: “Possibly” Effective: Contact or atopic dermatitis; impetiginized eczema; nummular eczema; endogenous chronic infectious dermatitis; stasis dermatitis; pyoderma; nuchal eczema and chronic eczematoid otitis externa; acne urticata; localized or disseminated neurodermatitis; lichen simplex chronicus; anogenital pruritus (vulvae, scroti, ani); folliculitis; bacterial dermatoses; mycotic dermatoses such as tinea (capitis, cruris, corporis, pedis); monliasis; intertrigo. Final classification of the less-than-effective indications requires further investigation. uuid:ec672b3b-1e38-4349-8fec-fbbedadc07f5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:A92JFM5XNU biolink:treats MONDO:0006014 PMID:41385096 "[{""id"":""uuid:e924c217-2e7f-4417-8574-da2facf0c9b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:acb14ac0-7774-4014-936e-ea09d7fd5803"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BREXAFEMME is a triterpenoid antifungal indicated in adult and post-menarchal pediatric females for: Treatment of vulvovaginal candidiasis (VVC). ( 1.1 ) Reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC) ( 1.1 ) uuid:639fce3d-1538-4358-8f44-469bdec8919d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:A92JFM5XNU biolink:treats HP:0012204 PMID:41385096 "[{""id"":""uuid:31f9614e-8306-4711-b155-99cb24bdeeb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cda68618-80f1-4380-8016-586bd89c11ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BREXAFEMME is a triterpenoid antifungal indicated in adult and post-menarchal pediatric females for: Treatment of vulvovaginal candidiasis (VVC). ( 1.1 ) Reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC) ( 1.1 ) uuid:2e30a9cd-2657-4fdd-aac1-71f3e5b476d2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:T41737F88A biolink:treats MONDO:0002974 PMID:41385096 "[{""id"":""uuid:c76a3be0-dd45-497d-b04f-920425745927"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f50adb40-b5db-47ea-a4cc-1331372d928d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TIVDAK ® is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. uuid:4f4eb5de-7863-47bb-98c2-1656f470dcd6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:G9WJT6RD29 biolink:treats MONDO:0020720 PMID:41385096 "[{""id"":""uuid:55e2f632-0858-4c17-b8a7-b32ae58d9403"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e451ba58-3efa-4f65-b8f3-d863ca68baec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CRYSVITA is a fibroblast growth factor 23 (FGF23) blocking antibody indicated for: The treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 6 months of age and older. ( 1.1 ) The treatment of FGF23-related hypophosphatemia in tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized in adult and pediatric patients 2 years of age and older. ( 1.2 ) uuid:556ee217-e864-46bf-b482-1e26863f1108 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:G9WJT6RD29 biolink:treats MONDO:0018124 PMID:41385096 "[{""id"":""uuid:233b9dff-8b3e-47f6-8e4f-2e2eec920b40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:83c58ddc-609d-41df-89c5-045fb391f7c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:5634e2d7-6011-4396-b02b-dad87a5fd842"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/crysvita""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] CRYSVITA is a fibroblast growth factor 23 (FGF23) blocking antibody indicated for: The treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 6 months of age and older. ( 1.1 ) The treatment of FGF23-related hypophosphatemia in tumor-induced osteomalacia (TIO) associated with phosphaturic mesenchymal tumors that cannot be curatively resected or localized in adult and pediatric patients 2 years of age and older. ( 1.2 )|[EMA] Crysvita is indicated for the treatment of X-linked hypophosphataemia, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults.Crysvita is indicated for the treatment of FGF23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults. uuid:df103103-9deb-4c76-a8e9-3ce380fa971a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76018 biolink:treats MONDO:0013024 PMID:41385096 "[{""id"":""uuid:678917ce-30ca-4a06-bbcc-760d96d1feb2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d0d1291b-407b-4569-a8e3-7b09069405ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b778b164-09ec-473b-a83c-07a0dc3ef140"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/adempas""]},{""id"":""uuid:e32faa03-e1c9-4251-aa93-a80c091e548e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Adempas is a soluble guanylate cyclase (sGC) stimulator indicated for the treatment of adults with: • Persistent/recurrent Chronic Thromboembolic Pulmonary Hypertension (CTEPH) (WHO Group 4) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO functional class. ( 1.1 ) • Pulmonary Arterial Hypertension (PAH) (WHO Group 1) to improve exercise capacity, improve WHO functional class and to delay clinical worsening. ( 1.2 )|[EMA] Chronic thromboembolic pulmonary hypertension (CTEPH)Adempas is indicated for the treatment of adult patients with WHO Functional Class (FC) II to III withinoperable CTEPH,persistent or recurrent CTEPH after surgical treatment,to improve exercise capacity.Pulmonary arterial hypertension (PAH)AdultsAdempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (PAH) with WHO Functional Class (FC) II to III to improve exercise capacity.Efficacy has been shown in a PAH population including aetiologies of idiopathic or heritable PAH or PAH associated with connective tissue disease.PaediatricsAdempas is indicated for the treatment of PAH in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with WHO Functional Class (FC) II to III in combination with endothelin receptor antagonists.|[PMDA] Drugs with a new active ingredient indicated for the treatment of persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) after surgical treatment or inoperable CTEPH. [Orphan drug] uuid:abf9039a-bb48-49d9-9ad3-c2936fb2e2b6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76018 biolink:treats MONDO:0015924 PMID:41385096 "[{""id"":""uuid:19b0aa9d-15e5-43e6-8633-04f823d8eb18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7a577b6e-cbce-4941-ac04-ac43a1ebee53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e2b33bab-a597-42b9-8cfb-cdf53c7cdbfb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/adempas""]},{""id"":""uuid:4939e5a9-b9e9-4f7a-83d5-9bd4c60a4892"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Adempas is a soluble guanylate cyclase (sGC) stimulator indicated for the treatment of adults with: • Persistent/recurrent Chronic Thromboembolic Pulmonary Hypertension (CTEPH) (WHO Group 4) after surgical treatment or inoperable CTEPH to improve exercise capacity and WHO functional class. ( 1.1 ) • Pulmonary Arterial Hypertension (PAH) (WHO Group 1) to improve exercise capacity, improve WHO functional class and to delay clinical worsening. ( 1.2 )|[EMA] Chronic thromboembolic pulmonary hypertension (CTEPH)Adempas is indicated for the treatment of adult patients with WHO Functional Class (FC) II to III withinoperable CTEPH,persistent or recurrent CTEPH after surgical treatment,to improve exercise capacity.Pulmonary arterial hypertension (PAH)AdultsAdempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (PAH) with WHO Functional Class (FC) II to III to improve exercise capacity.Efficacy has been shown in a PAH population including aetiologies of idiopathic or heritable PAH or PAH associated with connective tissue disease.PaediatricsAdempas is indicated for the treatment of PAH in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with WHO Functional Class (FC) II to III in combination with endothelin receptor antagonists.|[PMDA] Drugs with a new additional indication for the treatment of pulmonary arterial hypertension. uuid:0a433637-b764-4a31-8881-a53a992b28ac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2184139 biolink:treats MONDO:0004652 PMID:41385096 "[{""id"":""uuid:655e34e3-c711-45c1-9b5b-b86dc10e5823"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c1b4f128-935c-48ad-8027-813ca676fd3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RECARBRIO is a combination of imipenem, a penem antibacterial, cilastatin, a renal dehydropeptidase inhibitor, and relebactam, a beta-lactamase inhibitor, indicated in patients 18 years of age and older for the treatment of the following infections caused by susceptible gram-negative microorganisms: Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP). ( 1.1 ) Complicated urinary tract infections, including pyelonephritis (cUTI) in patients who have limited or no alternative treatment options. ( 1.2 ) Complicated intra-abdominal infections (cIAI) in patients who have limited or no alternative treatment options. ( 1.3 ) Approval of the cUTI and cIAI indications is based on limited clinical safety and efficacy data for RECARBRIO. ( 1.2 , 1.3 , 14 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of RECARBRIO and other antibacterial drugs, RECARBRIO should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.3 ) uuid:a1d354aa-c307-40e8-b5e0-e7885ed65b5e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2184139 biolink:treats MONDO:0006939 PMID:41385096 "[{""id"":""uuid:48d5a74a-24d6-431a-a696-d8ffb53e6299"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:322d838b-7255-4126-b8a1-8bfcd6556c7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RECARBRIO is a combination of imipenem, a penem antibacterial, cilastatin, a renal dehydropeptidase inhibitor, and relebactam, a beta-lactamase inhibitor, indicated in patients 18 years of age and older for the treatment of the following infections caused by susceptible gram-negative microorganisms: Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP). ( 1.1 ) Complicated urinary tract infections, including pyelonephritis (cUTI) in patients who have limited or no alternative treatment options. ( 1.2 ) Complicated intra-abdominal infections (cIAI) in patients who have limited or no alternative treatment options. ( 1.3 ) Approval of the cUTI and cIAI indications is based on limited clinical safety and efficacy data for RECARBRIO. ( 1.2 , 1.3 , 14 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of RECARBRIO and other antibacterial drugs, RECARBRIO should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.3 ) uuid:82fa2e3e-14aa-4f82-8610-f977606af009 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2184139 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:4eb2efb1-bc54-493d-88ec-5e2557041ab8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a1c8ab71-0d54-4325-81b0-860cc6f11fdd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RECARBRIO is a combination of imipenem, a penem antibacterial, cilastatin, a renal dehydropeptidase inhibitor, and relebactam, a beta-lactamase inhibitor, indicated in patients 18 years of age and older for the treatment of the following infections caused by susceptible gram-negative microorganisms: Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP). ( 1.1 ) Complicated urinary tract infections, including pyelonephritis (cUTI) in patients who have limited or no alternative treatment options. ( 1.2 ) Complicated intra-abdominal infections (cIAI) in patients who have limited or no alternative treatment options. ( 1.3 ) Approval of the cUTI and cIAI indications is based on limited clinical safety and efficacy data for RECARBRIO. ( 1.2 , 1.3 , 14 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of RECARBRIO and other antibacterial drugs, RECARBRIO should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.3 ) uuid:c71c33c9-4985-443f-81d4-20503eeaa9d2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2R27AB6766 biolink:treats MONDO:0019740 PMID:41385096 "[{""id"":""uuid:c50c8c1f-3e3a-48ae-ac96-00a2bda16737"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:81c7802f-d61f-422c-91ba-f21e55ccc895"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:35d8832f-c9ed-4e3b-a938-e448b50abf31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cablivi""]},{""id"":""uuid:a2c1ce95-204a-4760-9b8e-2c88f3075dfd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CABLIVI is indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.|[EMA] Cablivi is indicated for the treatment of adults experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), in conjunction with plasma exchange and immunosuppression.|[PMDA] A drug with a new active ingredient indicated for the treatment of acquired thrombotic thrombocytopenic purpura. [Orphan drug] uuid:a9d7294f-425e-4853-b2f1-937e1faf5e60 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats MONDO:0011191 PMID:41385096 "[{""id"":""uuid:98aa3dea-7654-4172-b9b3-df5319b2634a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:aa80c31d-fdb0-466b-92c2-90e28e422b83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:bd76c40c-06c2-4ee1-8a12-f2c7c942f14a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] HEMANGEOL oral solution contains the beta-adrenergic blocker propranolol hydrochloride and is indicated for the treatment of proliferating infantile hemangioma requiring systemic therapy.|[PMDA] A drug with a new indication in a new dosage form indicated for the treatment of infantile hemangioma. [Orphan drug] uuid:1103e1a8-fb68-48fa-9bd9-9f2af21b8048 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6ZA31Y954Z biolink:treats UMLS:C0406317 PMID:41385096 "[{""id"":""uuid:90b1f425-8de5-44f2-9cf1-f1591da5c324"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ed1dbc38-8b63-438d-bdc0-bdd990c04246"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d0cc0392-ea71-430f-82d4-5cc01bd25e03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SILIQ ® (brodalumab) is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies.|[PMDA] A drug with a new active ingredient indicated for the treatment of plaque psoriasis, psoriatic arthritis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies. uuid:9124cd28-2f23-40f2-958b-9a4de329fc08 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29101 biolink:treats MONDO:0006022 PMID:41385096 "[{""id"":""uuid:0739f76d-5ecb-45dd-87af-d91049c5f9d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:77b7ecd7-d2ad-43c6-8ee2-efe4174e864d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ionosol MB and 5% Dextrose Injection is indicated for intravenous administration to infants for treatment of dehydration, acidosis, diarrhea, and burns, but only after administration of an initial priming solution: 15 mL of 5% dextrose and 0.45% Sodium Chloride Injection/kg of body weight. In adults, Ionosol MB and 5% Dextrose Injection is indicated postoperatively for intravenous fluid and electrolyte maintenance therapy, with a small amount of carbohydrate calories for reducing catabolism of endogenous protein reserves. uuid:2e9da50d-73cc-4ad2-9a3a-bc85c27a5402 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29101 biolink:treats MONDO:0001673 PMID:41385096 "[{""id"":""uuid:2e3e7099-a48d-4283-a2c5-833787609925"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:497b83b3-aab4-4225-bc15-aaf4ae2e17ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ionosol MB and 5% Dextrose Injection is indicated for intravenous administration to infants for treatment of dehydration, acidosis, diarrhea, and burns, but only after administration of an initial priming solution: 15 mL of 5% dextrose and 0.45% Sodium Chloride Injection/kg of body weight. In adults, Ionosol MB and 5% Dextrose Injection is indicated postoperatively for intravenous fluid and electrolyte maintenance therapy, with a small amount of carbohydrate calories for reducing catabolism of endogenous protein reserves. uuid:1ef68688-01ab-4ca6-af38-3d79bf1fdb4d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231702 biolink:treats MONDO:0005173 PMID:41385096 "[{""id"":""uuid:9f4ffec8-061c-494e-a1db-a1e6cb21de17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c53fbaaf-1dbf-4c0a-bd31-15738b0152b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:eb3018b2-ec3a-4483-be82-4b94be3e751f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/klisyri""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] KLISYRI is indicated for the topical field treatment of actinic keratosis on the face or scalp.|[EMA] Klisyri is indicated for the field treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis (Olsen grade 1) of the face or scalp in adults. uuid:f37bdbcf-6345-4a05-9216-6df2604f66b1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:76037163 biolink:treats MONDO:0004975 PMID:41385096 "[{""id"":""uuid:954ce500-484c-42fd-8a49-ea237ceb7508"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5544ee1f-69e2-401e-a4b5-c2865fdd98e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NAMZARIC is indicated for the treatment of moderate to severe dementia of the Alzheimer’s type in patients stabilized on 10 mg of donepezil hydrochloride once daily. uuid:b85d497f-b8d1-4c33-92f0-de804b37a0b6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29101 biolink:treats MONDO:0006844 PMID:41385096 "[{""id"":""uuid:1ad5c455-563e-4886-af79-28b9784ef383"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1a1484a8-4af1-41b4-9136-cce0c5ee8771"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Normosol-M and 5% Dextrose Injection (Multiple Electrolytes and 5% Dextrose Injection Type 1, USP) is indicated for parenteral maintenance of routine daily fluid and electrolyte requirements with minimal carbohydrate calories from dextrose. Magnesium in the formula may help to prevent iatrogenic magnesium deficiency in patients receiving prolonged parenteral therapy. uuid:ca170336-f11f-4426-bdc4-1b81167f4ae1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64355 biolink:treats MONDO:0005886 PMID:41385096 "[{""id"":""uuid:ebb322e2-0636-4e92-81ac-32330a604b7c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:83ca1b81-4b4f-4359-ba27-c207292f21fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:fdfa74dd-e7d6-4fa7-87b9-1b3df64c8735"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/posaconazole-ahcl""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Noxafil is an azole antifungal indicated as follows: Noxafil injection and Noxafil delayed-release tablets are indicated for the treatment of invasive aspergillosis in adults and pediatric patients 13 years of age and older. ( 1.1 ) Noxafil is indicated for the prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these infections due to being severely immunocompromised, such as hematopoietic stem cell transplant (HSCT) recipients with graft-versus-host disease (GVHD) or those with hematologic malignancies with prolonged neutropenia from chemotherapy as follows: ( 1.2 ) Noxafil injection: adults and pediatric patients 2 years of age and older Noxafil delayed-release tablets: adults and pediatric patients 2 years of age and older who weigh greater than 40 kg Noxafil oral suspension: adults and pediatric patients 13 years of age and older Noxafil PowderMix for delayed-release oral suspension: pediatric patients 2 years of age and older who weigh 40 kg or less Noxafil oral suspension is indicated for the treatment of oropharyngeal candidiasis (OPC), including OPC refractory (rOPC) to itraconazole and/or fluconazole in adult and pediatric patients aged 13 years and older. ( 1.3 )|[EMA] Posaconazole AHCL oral suspension is indicated for use in the treatment of the following fungal infections in adults:Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.Oropharyngeal candidiasis: as first-line therapy in patients who have severe disease or are immunocompromised, in whom response to topical therapy is expected to be poor.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Posaconazole AHCL oral suspension is also indicated for prophylaxis of invasive fungal infections in the following patients:Patients receiving remission-induction chemotherapy for acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections. uuid:4c3f2fba-dc4a-405d-97ec-0ab92da02970 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27953 biolink:treats UMLS:C0001969 PMID:41385096 "[{""id"":""uuid:4eef9be2-ef84-4459-ba63-79a56f21b3a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3d760646-d701-4043-aa1a-9ffe7ec56e8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ANTICHOLIUM ® is indicated for: 1. the use as an antidote and/or antagonist in case of intoxication with and/or overdose of: alcohol tropane alkaloids (hyoscyamine, atropine, scopolamine, as e.g. in brugmansia, datura, atropa belladonna) amanita pantherina and amanita muscaria tricyclic antidepressants (amitriptyline, imipramine, trimipramine, clomipramine, doxepine) antiemetics/antihistamines (phenothiazine, thioridazine, chlorpromazine, promethazine, diphenhydramine, dimenhydrinate) neuroleptic drugs (especially butyrophenones) benzodiazepines tolterodine, oxybutynine amantadine, diphenhydramine baclofen 4-hydroxybutyric acid (GHB) inhalation anesthetics ketamine 3-quinuclidinyl benzilate 2. the treatment of postoperative disorders: Central anticholinergic syndrome (CAS) Delayed postoperative awakening Shivering uuid:e8504f74-e9ca-4ad8-ac52-39de0c310da2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27953 biolink:treats UMLS:C0275249 PMID:41385096 "[{""id"":""uuid:7168d95e-1f01-494a-98dc-89b5cf4bf9ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:197f7a73-16ee-4537-8ba3-7ca633b7ed37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ANTICHOLIUM ® is indicated for: 1. the use as an antidote and/or antagonist in case of intoxication with and/or overdose of: alcohol tropane alkaloids (hyoscyamine, atropine, scopolamine, as e.g. in brugmansia, datura, atropa belladonna) amanita pantherina and amanita muscaria tricyclic antidepressants (amitriptyline, imipramine, trimipramine, clomipramine, doxepine) antiemetics/antihistamines (phenothiazine, thioridazine, chlorpromazine, promethazine, diphenhydramine, dimenhydrinate) neuroleptic drugs (especially butyrophenones) benzodiazepines tolterodine, oxybutynine amantadine, diphenhydramine baclofen 4-hydroxybutyric acid (GHB) inhalation anesthetics ketamine 3-quinuclidinyl benzilate 2. the treatment of postoperative disorders: Central anticholinergic syndrome (CAS) Delayed postoperative awakening Shivering uuid:2d30ad92-91a9-43d7-9e14-49f89f3d51cf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27953 biolink:treats UMLS:C0275193 PMID:41385096 "[{""id"":""uuid:94720d53-212a-4f4b-ab97-48b5d1917499"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:901e37ea-44d9-4701-8a2a-a1f6e729cc09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ANTICHOLIUM ® is indicated for: 1. the use as an antidote and/or antagonist in case of intoxication with and/or overdose of: alcohol tropane alkaloids (hyoscyamine, atropine, scopolamine, as e.g. in brugmansia, datura, atropa belladonna) amanita pantherina and amanita muscaria tricyclic antidepressants (amitriptyline, imipramine, trimipramine, clomipramine, doxepine) antiemetics/antihistamines (phenothiazine, thioridazine, chlorpromazine, promethazine, diphenhydramine, dimenhydrinate) neuroleptic drugs (especially butyrophenones) benzodiazepines tolterodine, oxybutynine amantadine, diphenhydramine baclofen 4-hydroxybutyric acid (GHB) inhalation anesthetics ketamine 3-quinuclidinyl benzilate 2. the treatment of postoperative disorders: Central anticholinergic syndrome (CAS) Delayed postoperative awakening Shivering uuid:248508d0-329d-4c19-ab29-342e17df5e3c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27953 biolink:treats UMLS:C0413031 PMID:41385096 "[{""id"":""uuid:7f463700-ac04-4f5a-bde9-7b4e13bc506b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a3a70f1a-16b3-41d1-80d3-6f966ef8c7ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ANTICHOLIUM ® is indicated for: 1. the use as an antidote and/or antagonist in case of intoxication with and/or overdose of: alcohol tropane alkaloids (hyoscyamine, atropine, scopolamine, as e.g. in brugmansia, datura, atropa belladonna) amanita pantherina and amanita muscaria tricyclic antidepressants (amitriptyline, imipramine, trimipramine, clomipramine, doxepine) antiemetics/antihistamines (phenothiazine, thioridazine, chlorpromazine, promethazine, diphenhydramine, dimenhydrinate) neuroleptic drugs (especially butyrophenones) benzodiazepines tolterodine, oxybutynine amantadine, diphenhydramine baclofen 4-hydroxybutyric acid (GHB) inhalation anesthetics ketamine 3-quinuclidinyl benzilate 2. the treatment of postoperative disorders: Central anticholinergic syndrome (CAS) Delayed postoperative awakening Shivering uuid:f9741c7b-5412-4c5f-a251-fb39dd1ba01a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27953 biolink:treats UMLS:C0413030 PMID:41385096 "[{""id"":""uuid:ef5b2070-3ecf-4dd3-9960-243469543560"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:99a0d766-2c6e-4b2d-9765-d6a9e98aee11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ANTICHOLIUM ® is indicated for: 1. the use as an antidote and/or antagonist in case of intoxication with and/or overdose of: alcohol tropane alkaloids (hyoscyamine, atropine, scopolamine, as e.g. in brugmansia, datura, atropa belladonna) amanita pantherina and amanita muscaria tricyclic antidepressants (amitriptyline, imipramine, trimipramine, clomipramine, doxepine) antiemetics/antihistamines (phenothiazine, thioridazine, chlorpromazine, promethazine, diphenhydramine, dimenhydrinate) neuroleptic drugs (especially butyrophenones) benzodiazepines tolterodine, oxybutynine amantadine, diphenhydramine baclofen 4-hydroxybutyric acid (GHB) inhalation anesthetics ketamine 3-quinuclidinyl benzilate 2. the treatment of postoperative disorders: Central anticholinergic syndrome (CAS) Delayed postoperative awakening Shivering uuid:f587ee3c-fc47-46ff-8baf-d80f5aefd84f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27953 biolink:treats MONDO:0018547 PMID:41385096 "[{""id"":""uuid:b6bc460c-3340-4b74-8fd6-a908a6ecf30a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dc5b6116-c44f-4d88-8798-2bbfc477d4d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ANTICHOLIUM ® is indicated for: 1. the use as an antidote and/or antagonist in case of intoxication with and/or overdose of: alcohol tropane alkaloids (hyoscyamine, atropine, scopolamine, as e.g. in brugmansia, datura, atropa belladonna) amanita pantherina and amanita muscaria tricyclic antidepressants (amitriptyline, imipramine, trimipramine, clomipramine, doxepine) antiemetics/antihistamines (phenothiazine, thioridazine, chlorpromazine, promethazine, diphenhydramine, dimenhydrinate) neuroleptic drugs (especially butyrophenones) benzodiazepines tolterodine, oxybutynine amantadine, diphenhydramine baclofen 4-hydroxybutyric acid (GHB) inhalation anesthetics ketamine 3-quinuclidinyl benzilate 2. the treatment of postoperative disorders: Central anticholinergic syndrome (CAS) Delayed postoperative awakening Shivering uuid:025cf46b-ffb4-431b-b8ad-fd643d9604a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27953 biolink:treats UMLS:C0572718 PMID:41385096 "[{""id"":""uuid:0b8e52a6-8289-464d-b3fe-8176e35b6424"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aad74551-3821-4a29-a9c4-cf3996e49756"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ANTICHOLIUM ® is indicated for: 1. the use as an antidote and/or antagonist in case of intoxication with and/or overdose of: alcohol tropane alkaloids (hyoscyamine, atropine, scopolamine, as e.g. in brugmansia, datura, atropa belladonna) amanita pantherina and amanita muscaria tricyclic antidepressants (amitriptyline, imipramine, trimipramine, clomipramine, doxepine) antiemetics/antihistamines (phenothiazine, thioridazine, chlorpromazine, promethazine, diphenhydramine, dimenhydrinate) neuroleptic drugs (especially butyrophenones) benzodiazepines tolterodine, oxybutynine amantadine, diphenhydramine baclofen 4-hydroxybutyric acid (GHB) inhalation anesthetics ketamine 3-quinuclidinyl benzilate 2. the treatment of postoperative disorders: Central anticholinergic syndrome (CAS) Delayed postoperative awakening Shivering uuid:f9234682-2ceb-446b-b487-34e869cee158 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27953 biolink:treats UMLS:C0568195 PMID:41385096 "[{""id"":""uuid:3437cca7-2e83-4ee9-b2fd-fa78cab47c33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fbf9891e-331c-45f3-8697-a4222518108b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ANTICHOLIUM ® is indicated for: 1. the use as an antidote and/or antagonist in case of intoxication with and/or overdose of: alcohol tropane alkaloids (hyoscyamine, atropine, scopolamine, as e.g. in brugmansia, datura, atropa belladonna) amanita pantherina and amanita muscaria tricyclic antidepressants (amitriptyline, imipramine, trimipramine, clomipramine, doxepine) antiemetics/antihistamines (phenothiazine, thioridazine, chlorpromazine, promethazine, diphenhydramine, dimenhydrinate) neuroleptic drugs (especially butyrophenones) benzodiazepines tolterodine, oxybutynine amantadine, diphenhydramine baclofen 4-hydroxybutyric acid (GHB) inhalation anesthetics ketamine 3-quinuclidinyl benzilate 2. the treatment of postoperative disorders: Central anticholinergic syndrome (CAS) Delayed postoperative awakening Shivering uuid:3fae4013-e2c2-4c30-8dac-54eadb7412b8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27953 biolink:treats UMLS:C0572305 PMID:41385096 "[{""id"":""uuid:5f6765d2-46d3-4399-891f-687db3bf258a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b9e79545-8cb6-4ca3-abf0-299a36a525f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ANTICHOLIUM ® is indicated for: 1. the use as an antidote and/or antagonist in case of intoxication with and/or overdose of: alcohol tropane alkaloids (hyoscyamine, atropine, scopolamine, as e.g. in brugmansia, datura, atropa belladonna) amanita pantherina and amanita muscaria tricyclic antidepressants (amitriptyline, imipramine, trimipramine, clomipramine, doxepine) antiemetics/antihistamines (phenothiazine, thioridazine, chlorpromazine, promethazine, diphenhydramine, dimenhydrinate) neuroleptic drugs (especially butyrophenones) benzodiazepines tolterodine, oxybutynine amantadine, diphenhydramine baclofen 4-hydroxybutyric acid (GHB) inhalation anesthetics ketamine 3-quinuclidinyl benzilate 2. the treatment of postoperative disorders: Central anticholinergic syndrome (CAS) Delayed postoperative awakening Shivering uuid:c5e73e44-6ed7-4d03-8db8-e3ab82465466 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27953 biolink:treats UMLS:C0274565 PMID:41385096 "[{""id"":""uuid:ce1e2b9f-3fdf-4045-aa6b-444cbd749301"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:36a16279-c3d8-4ec8-873a-1a40a31bdb02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ANTICHOLIUM ® is indicated for: 1. the use as an antidote and/or antagonist in case of intoxication with and/or overdose of: alcohol tropane alkaloids (hyoscyamine, atropine, scopolamine, as e.g. in brugmansia, datura, atropa belladonna) amanita pantherina and amanita muscaria tricyclic antidepressants (amitriptyline, imipramine, trimipramine, clomipramine, doxepine) antiemetics/antihistamines (phenothiazine, thioridazine, chlorpromazine, promethazine, diphenhydramine, dimenhydrinate) neuroleptic drugs (especially butyrophenones) benzodiazepines tolterodine, oxybutynine amantadine, diphenhydramine baclofen 4-hydroxybutyric acid (GHB) inhalation anesthetics ketamine 3-quinuclidinyl benzilate 2. the treatment of postoperative disorders: Central anticholinergic syndrome (CAS) Delayed postoperative awakening Shivering uuid:bb6cce8d-3779-4478-afa9-52378d1ebd3c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27953 biolink:treats UMLS:C0274967 PMID:41385096 "[{""id"":""uuid:045d289c-6ec8-4a20-bfa7-00b143484cd9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:af637880-2413-48a3-80c4-6615ff575aa6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ANTICHOLIUM ® is indicated for: 1. the use as an antidote and/or antagonist in case of intoxication with and/or overdose of: alcohol tropane alkaloids (hyoscyamine, atropine, scopolamine, as e.g. in brugmansia, datura, atropa belladonna) amanita pantherina and amanita muscaria tricyclic antidepressants (amitriptyline, imipramine, trimipramine, clomipramine, doxepine) antiemetics/antihistamines (phenothiazine, thioridazine, chlorpromazine, promethazine, diphenhydramine, dimenhydrinate) neuroleptic drugs (especially butyrophenones) benzodiazepines tolterodine, oxybutynine amantadine, diphenhydramine baclofen 4-hydroxybutyric acid (GHB) inhalation anesthetics ketamine 3-quinuclidinyl benzilate 2. the treatment of postoperative disorders: Central anticholinergic syndrome (CAS) Delayed postoperative awakening Shivering uuid:62b0d0eb-4358-45a5-bb95-7f609d9bba9e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27953 biolink:treats UMLS:C0568550 PMID:41385096 "[{""id"":""uuid:ffac6446-e769-42ff-be21-9e5d7a824c94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:785d5d55-c77e-4d57-829e-d172b660e48f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ANTICHOLIUM ® is indicated for: 1. the use as an antidote and/or antagonist in case of intoxication with and/or overdose of: alcohol tropane alkaloids (hyoscyamine, atropine, scopolamine, as e.g. in brugmansia, datura, atropa belladonna) amanita pantherina and amanita muscaria tricyclic antidepressants (amitriptyline, imipramine, trimipramine, clomipramine, doxepine) antiemetics/antihistamines (phenothiazine, thioridazine, chlorpromazine, promethazine, diphenhydramine, dimenhydrinate) neuroleptic drugs (especially butyrophenones) benzodiazepines tolterodine, oxybutynine amantadine, diphenhydramine baclofen 4-hydroxybutyric acid (GHB) inhalation anesthetics ketamine 3-quinuclidinyl benzilate 2. the treatment of postoperative disorders: Central anticholinergic syndrome (CAS) Delayed postoperative awakening Shivering uuid:4949cb4f-8803-4f0f-b264-ffb0680ce65f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27953 biolink:treats UMLS:C0344133 PMID:41385096 "[{""id"":""uuid:232093be-de23-4c1b-ab31-026283003053"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:080d237a-afed-4032-bd48-efc7fc99747f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ANTICHOLIUM ® is indicated for: 1. the use as an antidote and/or antagonist in case of intoxication with and/or overdose of: alcohol tropane alkaloids (hyoscyamine, atropine, scopolamine, as e.g. in brugmansia, datura, atropa belladonna) amanita pantherina and amanita muscaria tricyclic antidepressants (amitriptyline, imipramine, trimipramine, clomipramine, doxepine) antiemetics/antihistamines (phenothiazine, thioridazine, chlorpromazine, promethazine, diphenhydramine, dimenhydrinate) neuroleptic drugs (especially butyrophenones) benzodiazepines tolterodine, oxybutynine amantadine, diphenhydramine baclofen 4-hydroxybutyric acid (GHB) inhalation anesthetics ketamine 3-quinuclidinyl benzilate 2. the treatment of postoperative disorders: Central anticholinergic syndrome (CAS) Delayed postoperative awakening Shivering uuid:eda1b33c-2588-4dcb-b0ac-cf8834acceea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27953 biolink:treats UMLS:C4076763 PMID:41385096 "[{""id"":""uuid:20b4b8a2-8bfe-4436-b765-56cceedf257c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9d20e160-d7e0-4cce-b93d-781953e040fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ANTICHOLIUM ® is indicated for: 1. the use as an antidote and/or antagonist in case of intoxication with and/or overdose of: alcohol tropane alkaloids (hyoscyamine, atropine, scopolamine, as e.g. in brugmansia, datura, atropa belladonna) amanita pantherina and amanita muscaria tricyclic antidepressants (amitriptyline, imipramine, trimipramine, clomipramine, doxepine) antiemetics/antihistamines (phenothiazine, thioridazine, chlorpromazine, promethazine, diphenhydramine, dimenhydrinate) neuroleptic drugs (especially butyrophenones) benzodiazepines tolterodine, oxybutynine amantadine, diphenhydramine baclofen 4-hydroxybutyric acid (GHB) inhalation anesthetics ketamine 3-quinuclidinyl benzilate 2. the treatment of postoperative disorders: Central anticholinergic syndrome (CAS) Delayed postoperative awakening Shivering uuid:7f3604ea-0c7e-4f37-a794-5351c5eae875 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27953 biolink:treats UMLS:C4511354 PMID:41385096 "[{""id"":""uuid:8aa54887-6a3e-4e08-b053-25186cdf347e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:39a2d5c9-e7f7-4afd-a559-6b8b951ea78d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ANTICHOLIUM ® is indicated for: 1. the use as an antidote and/or antagonist in case of intoxication with and/or overdose of: alcohol tropane alkaloids (hyoscyamine, atropine, scopolamine, as e.g. in brugmansia, datura, atropa belladonna) amanita pantherina and amanita muscaria tricyclic antidepressants (amitriptyline, imipramine, trimipramine, clomipramine, doxepine) antiemetics/antihistamines (phenothiazine, thioridazine, chlorpromazine, promethazine, diphenhydramine, dimenhydrinate) neuroleptic drugs (especially butyrophenones) benzodiazepines tolterodine, oxybutynine amantadine, diphenhydramine baclofen 4-hydroxybutyric acid (GHB) inhalation anesthetics ketamine 3-quinuclidinyl benzilate 2. the treatment of postoperative disorders: Central anticholinergic syndrome (CAS) Delayed postoperative awakening Shivering uuid:08f5c35a-c7bb-4923-8efa-1459980f9d34 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27953 biolink:treats UMLS:C0520757 PMID:41385096 "[{""id"":""uuid:e49cbae6-fb9a-4433-9ff2-c2a536b33cb5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:af2ea2b7-e874-4c3f-a03e-a55b229c6833"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ANTICHOLIUM ® is indicated for: 1. the use as an antidote and/or antagonist in case of intoxication with and/or overdose of: alcohol tropane alkaloids (hyoscyamine, atropine, scopolamine, as e.g. in brugmansia, datura, atropa belladonna) amanita pantherina and amanita muscaria tricyclic antidepressants (amitriptyline, imipramine, trimipramine, clomipramine, doxepine) antiemetics/antihistamines (phenothiazine, thioridazine, chlorpromazine, promethazine, diphenhydramine, dimenhydrinate) neuroleptic drugs (especially butyrophenones) benzodiazepines tolterodine, oxybutynine amantadine, diphenhydramine baclofen 4-hydroxybutyric acid (GHB) inhalation anesthetics ketamine 3-quinuclidinyl benzilate 2. the treatment of postoperative disorders: Central anticholinergic syndrome (CAS) Delayed postoperative awakening Shivering uuid:35a6c75e-920d-446a-8a0c-b68b6ab91134 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27953 biolink:treats HP:0025144 PMID:41385096 "[{""id"":""uuid:a59e4228-fc4a-4018-999b-7f490e14cc88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8be09e8c-f24d-42b3-b814-0cffa9fd4f16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ANTICHOLIUM ® is indicated for: 1. the use as an antidote and/or antagonist in case of intoxication with and/or overdose of: alcohol tropane alkaloids (hyoscyamine, atropine, scopolamine, as e.g. in brugmansia, datura, atropa belladonna) amanita pantherina and amanita muscaria tricyclic antidepressants (amitriptyline, imipramine, trimipramine, clomipramine, doxepine) antiemetics/antihistamines (phenothiazine, thioridazine, chlorpromazine, promethazine, diphenhydramine, dimenhydrinate) neuroleptic drugs (especially butyrophenones) benzodiazepines tolterodine, oxybutynine amantadine, diphenhydramine baclofen 4-hydroxybutyric acid (GHB) inhalation anesthetics ketamine 3-quinuclidinyl benzilate 2. the treatment of postoperative disorders: Central anticholinergic syndrome (CAS) Delayed postoperative awakening Shivering uuid:b4b74da7-0d8b-4f31-a1c9-cfcf8d9fa813 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:43602 biolink:treats MONDO:0005388 PMID:41385096 "[{""id"":""uuid:cbca1f4e-d1a1-4a59-9fc5-25336848d371"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a2c20728-b71d-48fa-a959-6d67efdbe175"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:42284c33-5443-47b5-8011-012c8169c1e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ocaliva""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] OCALIVA ® is indicated for the treatment of adult patients with primary biliary cholangitis (PBC) without cirrhosis or with compensated cirrhosis who do not have evidence of portal hypertension, either in combination with ursodeoxycholic acid (UDCA) with an inadequate response to UDCA or as monotherapy in patients unable to tolerate UDCA. This indication is approved under accelerated approval based on a reduction in alkaline phosphatase (ALP) [see Clinical Studies (14) ] . An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.|[EMA] Ocaliva is indicated for the treatment of primary biliary cholangitis (also known as primary biliary cirrhosis) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. uuid:60e0b021-9d8d-4601-baae-e27754a9dfb3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:43602 biolink:treats MONDO:0007193 PMID:41385096 "[{""id"":""uuid:60b364fd-30ce-4261-8437-b4c9ef402b5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f8c1e893-2ad6-453e-8567-1bf2dcab8a41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OCALIVA ® is indicated for the treatment of adult patients with primary biliary cholangitis (PBC) without cirrhosis or with compensated cirrhosis who do not have evidence of portal hypertension, either in combination with ursodeoxycholic acid (UDCA) with an inadequate response to UDCA or as monotherapy in patients unable to tolerate UDCA. This indication is approved under accelerated approval based on a reduction in alkaline phosphatase (ALP) [see Clinical Studies (14) ] . An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. uuid:5f1a07fd-3fd0-404c-8df1-720fb9f28b6f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1861726 biolink:treats MONDO:1010182 PMID:41385096 "[{""id"":""uuid:41e72e39-ee30-442d-8570-9359d9c8a312"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2c916c32-a92f-40df-9f23-1caa3de81fc3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Beyaz is a combination of drospirenone, a progestin and ethinyl estradiol, an estrogen containing a folate, indicated for use by females of reproductive potential to: • Prevent pregnancy. ( 1.1 ) • Treat symptoms of premenstrual dysphoric disorder (PMDD) for females of reproductive potential who choose to use an oral contraceptive for contraception. ( 1.2 ) • Treat moderate acne for females of reproductive potential at least 14 years old only if the patient desires an oral contraceptive for birth control. ( 1.3 ) • Raise folate levels in females of reproductive potential who choose to use an oral contraceptive for contraception. ( 1.4 ) UMLS:C0520676 uuid:a84855f1-b306-46a6-a31f-82284d044447 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1861726 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:37e79e89-4287-43fe-a52a-86176ad7b3d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e80fecde-7b42-4e91-9799-e8b5711d37a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Beyaz is a combination of drospirenone, a progestin and ethinyl estradiol, an estrogen containing a folate, indicated for use by females of reproductive potential to: • Prevent pregnancy. ( 1.1 ) • Treat symptoms of premenstrual dysphoric disorder (PMDD) for females of reproductive potential who choose to use an oral contraceptive for contraception. ( 1.2 ) • Treat moderate acne for females of reproductive potential at least 14 years old only if the patient desires an oral contraceptive for birth control. ( 1.3 ) • Raise folate levels in females of reproductive potential who choose to use an oral contraceptive for contraception. ( 1.4 ) uuid:777cc856-45c1-4d8e-935f-8a5359a13d24 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2S9ZZM9Q9V biolink:treats EFO:1001480 PMID:41385096 "[{""id"":""uuid:b7254175-3dfe-46df-9dec-5216017a97db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:21bbb9c9-7451-4e19-8c1f-09cec2b023df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MVASI is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment. ( 1.1 ) Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. ( 1.1 ) Limitations of Use : MVASI is not indicated for adjuvant treatment of colon cancer. ( 1.1 ) Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment. ( 1.2 ) Recurrent glioblastoma in adults. ( 1.3 ) Metastatic renal cell carcinoma in combination with interferon-alfa. ( 1.4 ) Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan. ( 1.5 ) Epithelial ovarian, fallopian tube, or primary peritoneal cancer: in combination with carboplatin and paclitaxel, followed by MVASI as a single agent, for stage III or IV disease following initial surgical resection ( 1.6 ) in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens ( 1.6 ) in combination with carboplatin and paclitaxel or carboplatin and gemcitabine, followed by MVASI as a single agent, for platinum-sensitive recurrent disease ( 1.6 ) uuid:3adec648-73af-4f1b-a221-529a1d228ccb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2S9ZZM9Q9V biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:4a48ed71-8d2a-4851-b655-440d385fa9cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4b85fcc5-6bc4-4f33-998a-c44621409615"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ee999973-f63e-41fb-a6a1-5b24164d7c88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/abevmy""]},{""id"":""uuid:10d33c35-32ff-4b14-87a7-84455f88ef44"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MVASI is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment. ( 1.1 ) Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. ( 1.1 ) Limitations of Use : MVASI is not indicated for adjuvant treatment of colon cancer. ( 1.1 ) Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment. ( 1.2 ) Recurrent glioblastoma in adults. ( 1.3 ) Metastatic renal cell carcinoma in combination with interferon-alfa. ( 1.4 ) Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan. ( 1.5 ) Epithelial ovarian, fallopian tube, or primary peritoneal cancer: in combination with carboplatin and paclitaxel, followed by MVASI as a single agent, for stage III or IV disease following initial surgical resection ( 1.6 ) in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens ( 1.6 ) in combination with carboplatin and paclitaxel or carboplatin and gemcitabine, followed by MVASI as a single agent, for platinum-sensitive recurrent disease ( 1.6 )|[EMA] Abevmy in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum.Abevmy in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 (HER2) status, please refer to section 5.1.Abevmy in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. Patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with Abevmy in combination with capecitabine. For further information as to HER2 status, please refer to section 5.1.Abevmy, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology.Abevmy, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations (see section 5.1).Abevmy in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer.Abevmy, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics [FIGO] stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5.1).Abevmy, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents.Abevmy in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents (see section 5.1).Abevmy, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.1).|[PMDA] Follow-on biologics indicated for the treatment of unresectable advanced or recurrent colon or rectal cancer and unresectable advanced or recurrent non-squamous non-small cell lung cancer. uuid:e75a8e59-c997-43a8-8dc6-191ea520d2c8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2S9ZZM9Q9V biolink:treats UMLS:C4288305 PMID:41385096 "[{""id"":""uuid:bf746f90-5b83-441b-82db-7fdcf66ea59b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:73ba72b0-5256-4c0f-9d22-81570766d5f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MVASI is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment. ( 1.1 ) Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. ( 1.1 ) Limitations of Use : MVASI is not indicated for adjuvant treatment of colon cancer. ( 1.1 ) Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment. ( 1.2 ) Recurrent glioblastoma in adults. ( 1.3 ) Metastatic renal cell carcinoma in combination with interferon-alfa. ( 1.4 ) Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan. ( 1.5 ) Epithelial ovarian, fallopian tube, or primary peritoneal cancer: in combination with carboplatin and paclitaxel, followed by MVASI as a single agent, for stage III or IV disease following initial surgical resection ( 1.6 ) in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens ( 1.6 ) in combination with carboplatin and paclitaxel or carboplatin and gemcitabine, followed by MVASI as a single agent, for platinum-sensitive recurrent disease ( 1.6 ) uuid:dc3af46b-3a3e-4789-913a-4978cdcd1cb4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2S9ZZM9Q9V biolink:treats UMLS:C4721698 PMID:41385096 "[{""id"":""uuid:43dcebaa-2894-439b-945c-840466d47d3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b928a2a7-9b0c-402d-b3a1-525b3a0b77b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MVASI is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment. ( 1.1 ) Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. ( 1.1 ) Limitations of Use : MVASI is not indicated for adjuvant treatment of colon cancer. ( 1.1 ) Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment. ( 1.2 ) Recurrent glioblastoma in adults. ( 1.3 ) Metastatic renal cell carcinoma in combination with interferon-alfa. ( 1.4 ) Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan. ( 1.5 ) Epithelial ovarian, fallopian tube, or primary peritoneal cancer: in combination with carboplatin and paclitaxel, followed by MVASI as a single agent, for stage III or IV disease following initial surgical resection ( 1.6 ) in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens ( 1.6 ) in combination with carboplatin and paclitaxel or carboplatin and gemcitabine, followed by MVASI as a single agent, for platinum-sensitive recurrent disease ( 1.6 ) uuid:cc101096-bd75-4eb8-ba08-f2bbd1319a89 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2S9ZZM9Q9V biolink:treats MONDO:0002974 PMID:41385096 "[{""id"":""uuid:b6893695-1223-4746-9193-bf0e4e735508"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3c2b7bbd-a594-40d8-989b-cdf72600ec55"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:21871e7e-9696-4ab4-9072-533c088ee7af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MVASI is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment. ( 1.1 ) Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. ( 1.1 ) Limitations of Use : MVASI is not indicated for adjuvant treatment of colon cancer. ( 1.1 ) Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment. ( 1.2 ) Recurrent glioblastoma in adults. ( 1.3 ) Metastatic renal cell carcinoma in combination with interferon-alfa. ( 1.4 ) Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan. ( 1.5 ) Epithelial ovarian, fallopian tube, or primary peritoneal cancer: in combination with carboplatin and paclitaxel, followed by MVASI as a single agent, for stage III or IV disease following initial surgical resection ( 1.6 ) in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens ( 1.6 ) in combination with carboplatin and paclitaxel or carboplatin and gemcitabine, followed by MVASI as a single agent, for platinum-sensitive recurrent disease ( 1.6 )|[PMDA] Drugs with a new additional indication for the treatment of advanced or recurrent cervical cancer. [Orphan drug] uuid:6109f670-0439-4db7-90f5-bba92cbc7c31 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2S9ZZM9Q9V biolink:treats MONDO:0005140 PMID:41385096 "[{""id"":""uuid:4f8552a7-4903-4336-a908-43b01b298a3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:fa91f06c-55e2-499b-8720-6c5901848ae7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:07880efa-881d-4a5a-98be-eb3067de53e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/abevmy""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] MVASI is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment. ( 1.1 ) Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. ( 1.1 ) Limitations of Use : MVASI is not indicated for adjuvant treatment of colon cancer. ( 1.1 ) Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment. ( 1.2 ) Recurrent glioblastoma in adults. ( 1.3 ) Metastatic renal cell carcinoma in combination with interferon-alfa. ( 1.4 ) Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan. ( 1.5 ) Epithelial ovarian, fallopian tube, or primary peritoneal cancer: in combination with carboplatin and paclitaxel, followed by MVASI as a single agent, for stage III or IV disease following initial surgical resection ( 1.6 ) in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens ( 1.6 ) in combination with carboplatin and paclitaxel or carboplatin and gemcitabine, followed by MVASI as a single agent, for platinum-sensitive recurrent disease ( 1.6 )|[EMA] Mvasi in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum.Mvasi in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 (HER2) status, please refer to section 5.1.Mvasi, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology.Mvasi in combination with interferon alfa-2a is indicated for first-line treatment of adult patients with advanced and/or metastatic renal cell cancer.Mvasi, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO) stages IIIB, IIIC and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer.Mvasi, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents.Mvasi in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents.Mvasi, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix. uuid:83c1e033-bb34-4197-9cbc-21aac0af3f8d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2S9ZZM9Q9V biolink:treats MONDO:0002158 PMID:41385096 "[{""id"":""uuid:3dd23cea-6c1e-464d-b5cf-38c0fa88cc76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:3c28a6c5-af87-4d58-a80a-569032e69f50"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:caf96ec3-9ea7-4e19-ba24-2718d97a49fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/abevmy""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] MVASI is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment. ( 1.1 ) Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. ( 1.1 ) Limitations of Use : MVASI is not indicated for adjuvant treatment of colon cancer. ( 1.1 ) Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment. ( 1.2 ) Recurrent glioblastoma in adults. ( 1.3 ) Metastatic renal cell carcinoma in combination with interferon-alfa. ( 1.4 ) Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan. ( 1.5 ) Epithelial ovarian, fallopian tube, or primary peritoneal cancer: in combination with carboplatin and paclitaxel, followed by MVASI as a single agent, for stage III or IV disease following initial surgical resection ( 1.6 ) in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens ( 1.6 ) in combination with carboplatin and paclitaxel or carboplatin and gemcitabine, followed by MVASI as a single agent, for platinum-sensitive recurrent disease ( 1.6 )|[EMA] Mvasi in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum.Mvasi in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 (HER2) status, please refer to section 5.1.Mvasi, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology.Mvasi in combination with interferon alfa-2a is indicated for first-line treatment of adult patients with advanced and/or metastatic renal cell cancer.Mvasi, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO) stages IIIB, IIIC and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer.Mvasi, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents.Mvasi in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents.Mvasi, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix. uuid:19eaf3e0-f209-431b-baeb-007268029db5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2S9ZZM9Q9V biolink:treats MONDO:0015686 PMID:41385096 "[{""id"":""uuid:c8fd837e-4563-4e02-b11c-0cc104f58a8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:be33a274-c2cc-4fd4-9058-90fff30ae3bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e5fe5053-29e0-41b2-a6ec-d4d83724c1a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/abevmy""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] MVASI is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment. ( 1.1 ) Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. ( 1.1 ) Limitations of Use : MVASI is not indicated for adjuvant treatment of colon cancer. ( 1.1 ) Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment. ( 1.2 ) Recurrent glioblastoma in adults. ( 1.3 ) Metastatic renal cell carcinoma in combination with interferon-alfa. ( 1.4 ) Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan. ( 1.5 ) Epithelial ovarian, fallopian tube, or primary peritoneal cancer: in combination with carboplatin and paclitaxel, followed by MVASI as a single agent, for stage III or IV disease following initial surgical resection ( 1.6 ) in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens ( 1.6 ) in combination with carboplatin and paclitaxel or carboplatin and gemcitabine, followed by MVASI as a single agent, for platinum-sensitive recurrent disease ( 1.6 )|[EMA] Mvasi in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum.Mvasi in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 (HER2) status, please refer to section 5.1.Mvasi, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology.Mvasi in combination with interferon alfa-2a is indicated for first-line treatment of adult patients with advanced and/or metastatic renal cell cancer.Mvasi, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO) stages IIIB, IIIC and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer.Mvasi, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents.Mvasi in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents.Mvasi, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix. uuid:b6c0643c-6cf5-44b3-ba47-02f4f540785c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PUE0TO3XDR biolink:treats MONDO:0006805 PMID:41385096 "[{""id"":""uuid:0bdb2343-1d40-406f-98aa-7bfef1f13d54"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fa9df4a9-69f5-4a05-9738-3d7083961e00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FRAGMIN is a low molecular weight heparin (LMWH) indicated for • Prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction ( 1.1 ) • Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery or medical patients with severely restricted mobility during acute illness ( 1.2 ) • Extended treatment of symptomatic venous thromboembolism (VTE) to reduce the recurrence in adult patients with cancer. In these patients, the FRAGMIN therapy begins with the initial VTE treatment and continues for six months ( 1.3 ) • Treatment of symptomatic venous thromboembolism (VTE) to reduce the recurrence in pediatric patients from birth (gestational age at least 35 weeks) ( 1.4 ) • Limitations of Use FRAGMIN is not indicated for the acute treatment of VTE ( 1.5 ) uuid:aa9735af-9114-4383-b541-4c3168f033ac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PUE0TO3XDR biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:2d238979-14fc-40ea-898e-755f0b38b124"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2908c824-c87f-4edd-8e06-58e8374a925d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FRAGMIN is a low molecular weight heparin (LMWH) indicated for • Prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction ( 1.1 ) • Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery or medical patients with severely restricted mobility during acute illness ( 1.2 ) • Extended treatment of symptomatic venous thromboembolism (VTE) to reduce the recurrence in adult patients with cancer. In these patients, the FRAGMIN therapy begins with the initial VTE treatment and continues for six months ( 1.3 ) • Treatment of symptomatic venous thromboembolism (VTE) to reduce the recurrence in pediatric patients from birth (gestational age at least 35 weeks) ( 1.4 ) • Limitations of Use FRAGMIN is not indicated for the acute treatment of VTE ( 1.5 ) uuid:26309c24-1f4a-4054-8594-892fbcb5be90 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PUE0TO3XDR biolink:treats HP:0002625 PMID:41385096 "[{""id"":""uuid:6bd24407-d2b6-417d-940f-412af95ee7f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:24ec9b85-ceee-4e6d-9060-10d8aa12760b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FRAGMIN is a low molecular weight heparin (LMWH) indicated for • Prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction ( 1.1 ) • Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery or medical patients with severely restricted mobility during acute illness ( 1.2 ) • Extended treatment of symptomatic venous thromboembolism (VTE) to reduce the recurrence in adult patients with cancer. In these patients, the FRAGMIN therapy begins with the initial VTE treatment and continues for six months ( 1.3 ) • Treatment of symptomatic venous thromboembolism (VTE) to reduce the recurrence in pediatric patients from birth (gestational age at least 35 weeks) ( 1.4 ) • Limitations of Use FRAGMIN is not indicated for the acute treatment of VTE ( 1.5 ) uuid:56a906b7-0854-4329-ae45-562b0ad7827a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PUE0TO3XDR biolink:treats MONDO:0005399 PMID:41385096 "[{""id"":""uuid:3eba7628-10cd-4fbe-b786-fae3f37ca795"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b710ff6d-8bcd-46d6-8177-a0cdc49fb45f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FRAGMIN is a low molecular weight heparin (LMWH) indicated for • Prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction ( 1.1 ) • Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery or medical patients with severely restricted mobility during acute illness ( 1.2 ) • Extended treatment of symptomatic venous thromboembolism (VTE) to reduce the recurrence in adult patients with cancer. In these patients, the FRAGMIN therapy begins with the initial VTE treatment and continues for six months ( 1.3 ) • Treatment of symptomatic venous thromboembolism (VTE) to reduce the recurrence in pediatric patients from birth (gestational age at least 35 weeks) ( 1.4 ) • Limitations of Use FRAGMIN is not indicated for the acute treatment of VTE ( 1.5 ) uuid:df83aa3a-a794-4534-9372-393003ec157b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2565805 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:bed7d5a1-7f3b-4741-8c96-73b66f0f75f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:56f15a4c-3fbc-45cf-b7ad-11d2e46a125f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TWYNEO is indicated for the topical treatment of acne vulgaris in adults and pediatric patients 9 years of age and older. uuid:1f93b75e-2ca3-4b30-bf1e-9441b048ae36 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:232556 biolink:treats MONDO:0040679 PMID:41385096 "[{""id"":""uuid:6cdfd004-76df-4ac0-a47c-68c156207f22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:80810d3e-6506-4c07-b767-62df67fc3d49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BALVERSA is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Select patients for therapy based on an FDA-approved companion diagnostic for BALVERSA [see Dosage and Administration (2.1) and Clinical Studies (14.1) ] . uuid:7ea38492-2511-495c-ab8c-e71cf0d7d594 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:232556 biolink:treats UMLS:C4288754 PMID:41385096 "[{""id"":""uuid:6355eac6-6e74-44d6-afb8-c96ad883223a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ffa90bd7-a794-4c74-bb37-fb9312443c4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BALVERSA is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (mUC) with susceptible FGFR3 genetic alterations whose disease has progressed on or after at least one line of prior systemic therapy. Select patients for therapy based on an FDA-approved companion diagnostic for BALVERSA [see Dosage and Administration (2.1) and Clinical Studies (14.1) ] . uuid:e78340a2-f4e3-43b9-95c6-8d5207c2cc85 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82405 biolink:treats MONDO:0006604 PMID:41385096 "[{""id"":""uuid:d1200f22-ee10-41d5-8cbb-1725ee5154e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a2d43f4a-41fd-40c9-b77f-f76cc541e368"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EPSOLAY is indicated for the treatment of inflammatory lesions of rosacea in adults. uuid:d661edba-5fda-410c-aa54-74e124200493 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1597612 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:3e6e1354-aa9d-4641-a45c-8067d9cee8c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4dee67d4-a0cd-4aed-a92f-b25eb3b95728"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZERBAXA (ceftolozane and tazobactam) is a combination of ceftolozane, a cephalosporin antibacterial, and tazobactam, a beta-lactamase inhibitor, indicated for the treatment of the following infections caused by designated susceptible microorganisms: Complicated Intra-abdominal Infections (cIAI), used in combination with metronidazole, in adult and pediatric patients (birth to less than 18 years old). ( 1.1 ) Complicated Urinary Tract Infections (cUTI), Including Pyelonephritis, in adult and pediatric patients (birth to less than 18 years old). ( 1.2 ) Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP), in adult patients 18 years and older. ( 1.3 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZERBAXA and other antibacterial drugs, ZERBAXA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.4 ) uuid:f802f6f5-22fd-4a1c-86bf-4db7c0044d83 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1597612 biolink:treats MONDO:0006939 PMID:41385096 "[{""id"":""uuid:67b178ed-b407-47db-baf6-9024ace70e9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:40e2959d-7fa2-40a8-b2de-c5d72bbd213d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:baf3ebc6-5362-41f0-b2c8-555f1b871f35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZERBAXA (ceftolozane and tazobactam) is a combination of ceftolozane, a cephalosporin antibacterial, and tazobactam, a beta-lactamase inhibitor, indicated for the treatment of the following infections caused by designated susceptible microorganisms: Complicated Intra-abdominal Infections (cIAI), used in combination with metronidazole, in adult and pediatric patients (birth to less than 18 years old). ( 1.1 ) Complicated Urinary Tract Infections (cUTI), Including Pyelonephritis, in adult and pediatric patients (birth to less than 18 years old). ( 1.2 ) Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP), in adult patients 18 years and older. ( 1.3 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZERBAXA and other antibacterial drugs, ZERBAXA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.4 )|[PMDA] A new combination drug with new active ingredients indicated for the treatment of cystitis, pyelonephritis, peritonitis, intra-abdominal abscess, cholecystitis, and liver abscess caused by Zerbaxa- sensitive Streptococcus spp., Escherichia coli , Citrobacter spp., Klebsiella spp., Enterobacter spp., Proteus spp., or Pseudomonas aeruginosa . uuid:474b1775-81eb-4405-a000-b0bb0d29804c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1597612 biolink:treats MONDO:0004652 PMID:41385096 "[{""id"":""uuid:6c35e071-85b7-4109-933c-f1bb8513781e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c83df526-e6e9-4cfc-83f7-6491b42661a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZERBAXA (ceftolozane and tazobactam) is a combination of ceftolozane, a cephalosporin antibacterial, and tazobactam, a beta-lactamase inhibitor, indicated for the treatment of the following infections caused by designated susceptible microorganisms: Complicated Intra-abdominal Infections (cIAI), used in combination with metronidazole, in adult and pediatric patients (birth to less than 18 years old). ( 1.1 ) Complicated Urinary Tract Infections (cUTI), Including Pyelonephritis, in adult and pediatric patients (birth to less than 18 years old). ( 1.2 ) Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP), in adult patients 18 years and older. ( 1.3 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZERBAXA and other antibacterial drugs, ZERBAXA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.4 ) uuid:459d9300-8e48-46f0-ad44-65996e5a70fa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8JXN261VVA biolink:treats MONDO:0015459 PMID:41385096 "[{""id"":""uuid:464e8b67-ebdf-4ed3-a260-efb461cf2e75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:912d6789-fb10-4182-9053-ace07afc5441"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LOQTORZI is a programmed death receptor-1 (PD-1)- blocking antibody indicated: in combination with cisplatin and gemcitabine, for first-line treatment of adults with metastatic or with recurrent locally advanced nasopharyngeal carcinoma (NPC) ( 1.1 ) as a single agent for the treatment of adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy ( 1.2 ) uuid:f11e22c2-6107-4427-85ef-0af42dbee93b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8JXN261VVA biolink:treats MONDO:0024879 PMID:41385096 "[{""id"":""uuid:92f13167-3e78-42b6-96df-cfa0f93329f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4646b0f4-2d86-4596-9b6f-63e99728be97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LOQTORZI is a programmed death receptor-1 (PD-1)- blocking antibody indicated: in combination with cisplatin and gemcitabine, for first-line treatment of adults with metastatic or with recurrent locally advanced nasopharyngeal carcinoma (NPC) ( 1.1 ) as a single agent for the treatment of adults with recurrent unresectable or metastatic NPC with disease progression on or after a platinum-containing chemotherapy ( 1.2 ) uuid:32e5fea1-ce0c-4574-b444-61fd81fad645 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7457 biolink:treats UMLS:C0151559 PMID:41385096 "[{""id"":""uuid:e9788758-f154-41db-9860-a495eab24ad3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c66fa457-f854-4c7e-ac9f-d25f09af01e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OPVEE nasal spray is indicated for the emergency treatment of known or suspected overdose induced by natural or synthetic opioids in adults and pediatric patients aged 12 years and older, as manifested by respiratory and/or central nervous system depression. OPVEE nasal spray is intended for immediate administration as emergency therapy in settings where opioids may be present. OPVEE nasal spray is not a substitute for emergency medical care. uuid:3b899684-5824-4cf9-861b-5aa7f60a25ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1163417 biolink:treats MONDO:0005093 PMID:41385096 "[{""id"":""uuid:ae9e8590-27a8-406d-9f07-0bdeb4acad7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d76c2462-0b72-46d8-a0a7-0c7089e622a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the temporary relief of pain and itching associated with minor burns, sunburns, minor skin irritations or hemmorhoids and itching associated with inflammation, and rashes due to eczema. uuid:e5589e89-24e4-4b2a-a54c-89e254a24429 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:66880 biolink:treats MONDO:0004975 PMID:41385096 "[{""id"":""uuid:adbfbb29-fc2b-4a96-a316-74543e6ea5ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b487a8bb-0b97-41a3-a40f-6f2b124a87ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:733697e4-e991-4c8d-8cc1-aeadd69f5815"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:bac92776-df36-4083-9e10-003dd2b5e67a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amyvid is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease (AD) and other causes of cognitive decline. A negative Amyvid scan indicates sparse to no neuritic plaques and is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition; a negative scan result reduces the likelihood that a patient's cognitive impairment is due to AD. A positive Amyvid scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with AD, but may also be present in patients with other types of neurologic conditions as well as older people with normal cognition. Amyvid is an adjunct to other diagnostic evaluations.|[EMA] This medicinal product is for diagnostic use only.Amyvid is a radiopharmaceutical indicated for Positron Emission Tomography (PET) imaging of β-amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive impairment. Amyvid should be used in conjunction with a clinical evaluation.A negative scan indicates sparse or no plaques, which is not consistent with a diagnosis of AD.|[PMDA] A drug with a new active ingredient indicated for visualization of beta‑amyloid plaques in the brain of patients with cognitive impairment suspected to be Alzheimer's disease. uuid:97591c0e-7243-4bb6-b474-4347743fc949 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:66880 biolink:treats MONDO:0850292 PMID:41385096 "[{""id"":""uuid:86e0c322-2bee-40ca-aa6d-dceec780c96e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d3e1e38d-ec06-4cb5-956c-7ceac70eea15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amyvid is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease (AD) and other causes of cognitive decline. A negative Amyvid scan indicates sparse to no neuritic plaques and is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition; a negative scan result reduces the likelihood that a patient's cognitive impairment is due to AD. A positive Amyvid scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with AD, but may also be present in patients with other types of neurologic conditions as well as older people with normal cognition. Amyvid is an adjunct to other diagnostic evaluations. uuid:8d0d031f-e873-46ed-b195-f3f4bf3b4aaa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17824 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:7216ac3b-8517-4639-90aa-4e98794987a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:63ec541a-74a7-4235-8529-81069fcff3c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AVONEX is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. uuid:4c9ad4e4-b460-4714-a9af-b46c41457d1d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17824 biolink:treats UMLS:C2921627 PMID:41385096 "[{""id"":""uuid:0cef36a1-553f-4097-a8c7-276a4deaf6a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:83a2edf0-de92-4311-926b-6e2a8febcef8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AVONEX is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. uuid:751e1f38-d297-4547-a0cc-102f9581e033 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17824 biolink:treats MONDO:0000450 PMID:41385096 "[{""id"":""uuid:d957648f-7645-4ac8-ace9-ad5a48ac8fd9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f515eb82-f950-448c-a25b-c09bb05f950c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AVONEX is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. uuid:a573e2a0-5409-4664-82e9-f787b9fa76c3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9013DUQ28K biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:856aa471-ad7f-4909-b895-599fb3c1e38c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:43be82ec-4639-4293-8959-f1a3464f89ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:992794bd-863e-4db5-9a3a-f0133ed7f991"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kineret""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] KINERET is an interleukin-1 receptor antagonist indicated for: Rheumatoid Arthritis (RA) Reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis, in patients 18 years of age or older who have failed 1 or more disease modifying antirheumatic drugs (DMARDs) ( 1.1 ) Cryopyrin-Associated Periodic Syndromes (CAPS) Treatment of Neonatal-Onset Multisystem Inflammatory Disease (NOMID) ( 1.2 ) Deficiency of Interleukin-1 Receptor Antagonist (DIRA) Treatment of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) ( 1.3 )|[EMA] Rheumatoid Arthritis (RA)Kineret is indicated in adults for the treatment of the signs and symptoms of RA in combination with methotrexate, with an inadequate response to methotrexate alone.COVID-19Kineret is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adult patients with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) who are at risk of progressing to severe respiratory failure determined by plasma concentration of soluble urokinase plasminogen activator receptor (suPAR) ≥ 6 ng/ml.Periodic fever syndromesKineret is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above:Cryopyrin-Associated Periodic Syndromes (CAPS)Kineret is indicated for the treatment of CAPS, including:Neonatal-Onset Multisystem Inflammatory Disease (NOMID) / Chronic Infantile Neurological, Cutaneous, Articular Syndrome (CINCA)Muckle-Wells Syndrome (MWS)Familial Cold Autoinflammatory Syndrome (FCAS)Familial Mediterranean Fever (FMF)Kineret is indicated for the treatment of Familial Mediterranean Fever (FMF). Kineret should be given in combination with colchicine, if appropriate.Still’s DiseaseKineret is indicated in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above for the treatment of Still’s disease, including Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still’s Disease (AOSD), with active systemic features of moderate to high disease activity, or in patients with continued disease activity after treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or glucocorticoids.Kineret can be given as monotherapy or in combination with other anti-inflammatory drugs and disease-modifying antirheumatic drugs (DMARDs). uuid:30533693-4d1d-4be5-88bb-2407945058fb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9013DUQ28K biolink:treats MONDO:0011776 PMID:41385096 "[{""id"":""uuid:988d78aa-a131-4e89-a30f-d4cbba110d3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f77dab7b-bf04-4e3d-a336-2d40bf4eff92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:48168cb5-6833-4dd4-ba2a-2ba04c8dc26a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kineret""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] KINERET is an interleukin-1 receptor antagonist indicated for: Rheumatoid Arthritis (RA) Reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis, in patients 18 years of age or older who have failed 1 or more disease modifying antirheumatic drugs (DMARDs) ( 1.1 ) Cryopyrin-Associated Periodic Syndromes (CAPS) Treatment of Neonatal-Onset Multisystem Inflammatory Disease (NOMID) ( 1.2 ) Deficiency of Interleukin-1 Receptor Antagonist (DIRA) Treatment of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) ( 1.3 )|[EMA] Rheumatoid Arthritis (RA)Kineret is indicated in adults for the treatment of the signs and symptoms of RA in combination with methotrexate, with an inadequate response to methotrexate alone.COVID-19Kineret is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adult patients with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) who are at risk of progressing to severe respiratory failure determined by plasma concentration of soluble urokinase plasminogen activator receptor (suPAR) ≥ 6 ng/ml.Periodic fever syndromesKineret is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above:Cryopyrin-Associated Periodic Syndromes (CAPS)Kineret is indicated for the treatment of CAPS, including:Neonatal-Onset Multisystem Inflammatory Disease (NOMID) / Chronic Infantile Neurological, Cutaneous, Articular Syndrome (CINCA)Muckle-Wells Syndrome (MWS)Familial Cold Autoinflammatory Syndrome (FCAS)Familial Mediterranean Fever (FMF)Kineret is indicated for the treatment of Familial Mediterranean Fever (FMF). Kineret should be given in combination with colchicine, if appropriate.Still’s DiseaseKineret is indicated in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above for the treatment of Still’s disease, including Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still’s Disease (AOSD), with active systemic features of moderate to high disease activity, or in patients with continued disease activity after treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or glucocorticoids.Kineret can be given as monotherapy or in combination with other anti-inflammatory drugs and disease-modifying antirheumatic drugs (DMARDs). uuid:afd87e5f-10ba-4b8b-b780-44601892e263 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:I8309403R0 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:27c633cd-ed6b-4a57-9375-520bd8dfb6e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3a27ae49-26da-41f1-bbde-e44a5df2d145"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PLEGRIDY is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. uuid:6ffdbc63-61c6-407f-ad0e-9ab646125526 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:I8309403R0 biolink:treats UMLS:C2921627 PMID:41385096 "[{""id"":""uuid:215cffd7-80de-4d59-b0d6-c871ac9e15a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ab35a83e-7d4b-4dc6-9ad9-859744331bcf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PLEGRIDY is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. uuid:161493ee-31b8-4898-a0c8-fed17ef3f962 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:I8309403R0 biolink:treats MONDO:0000450 PMID:41385096 "[{""id"":""uuid:366f9ffe-5e21-4944-a4f7-fb5b2cc60103"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c07ca6d6-f6f4-4dac-9c1c-48605edf3b5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PLEGRIDY is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. uuid:3bbfbd65-1318-4c04-80d5-8c5f67ee3a6b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:142432 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:2f4d9ddf-ad64-4f41-b446-9c3e1476f7f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:22e759b5-8ac7-4c3e-a96a-7b20cc56f00a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d1b544ea-e808-468a-9d60-2b3542574999"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/verquvo""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] VERQUVO ® is indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45% [see Clinical Studies (14) ] .|[EMA] Treatment of symptomatic chronic heart failure uuid:c758997c-330c-4460-88c2-7985fbc7466b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1925495 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:439a0e49-d920-4cb3-a0f1-dd9e0154aa19"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ffbed1ec-9df1-4f51-8da6-c5138dbc13b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:cfaba318-e0ca-496c-b0a3-ac79449e9290"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/qtern""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] QTERN is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use QTERN is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus [ see WARNINGS AND PRECAUTIONS (5.1) ].|[EMA] Qtern, fixed dose combination of saxagliptin and dapagliflozin, is indicated in adults aged 18 years and older with type 2 diabetes mellitus:to improve glycaemic control when metformin and/or sulphonylurea (SU) and one of the monocomponents of Qtern do not provide adequate glycaemic control,when already being treated with the free combination of dapagliflozin and saxagliptin.(See sections 4.2, 4.4, 4.5 and 5.1 for available data on combinations studied.) uuid:74033185-1124-491a-bd8b-66dd84b81dfe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1925495 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:7bc2b1cc-9546-4081-a5e7-b0a4fe54df0c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9619b1e2-7551-4037-a4d2-f69b84ef29d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] QTERN is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use QTERN is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus [ see WARNINGS AND PRECAUTIONS (5.1) ]. uuid:94211011-90fe-4d6c-96a6-15f5094f3280 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:138865 biolink:treats MONDO:8000006 PMID:41385096 "[{""id"":""uuid:607dfd8d-b583-4744-ab54-08d67985ac33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:26dee40f-c1de-4645-8e80-0eb20c3d8005"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XOLREMDI is indicated in patients 12 years of age and older with WHIM syndrome (warts, hypogammaglobulinemia, infections and myelokathexis) to increase the number of circulating mature neutrophils and lympocytes. uuid:a132c35b-062e-4ed2-a75a-a35c732d5d61 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2NU6F9601K biolink:treats MONDO:0004976 PMID:41385096 "[{""id"":""uuid:67a2f346-5e5b-4a5a-9e08-242433aa7060"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3ad7901f-a585-4fb7-91fa-b5bc9ea9bf28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] QALSODY is indicated for the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 ( SOD1 ) gene. This indication is approved under accelerated approval based on reduction in plasma neurofilament light chain (NfL) observed in patients treated with QALSODY [see Clinical Studies ( 14 )] . Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trial(s). uuid:121dcba6-54c2-4c3d-b104-2d3c45729376 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2NU6F9601K biolink:treats MONDO:0008781 PMID:41385096 "[{""id"":""uuid:721afc24-0111-4d59-86f0-2189b23765d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2ec73a1a-1de9-4731-9b4d-f72873752231"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] QALSODY is indicated for the treatment of amyotrophic lateral sclerosis (ALS) in adults who have a mutation in the superoxide dismutase 1 ( SOD1 ) gene. This indication is approved under accelerated approval based on reduction in plasma neurofilament light chain (NfL) observed in patients treated with QALSODY [see Clinical Studies ( 14 )] . Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trial(s). uuid:28716196-d283-4ad8-8b9f-b1946e3c54f3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4A2Y23XK11 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:b88232a7-3ab6-41dd-9051-127fd86cf766"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d52bcd62-1fa6-489c-9a81-9f2d22861528"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LAZCLUZE, in combination with amivantamab, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test [see Dosage and Administration (2.1) ] . uuid:877f60b8-6f77-400a-8936-f84d284462a2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4A2Y23XK11 biolink:treats UMLS:C0278987 PMID:41385096 "[{""id"":""uuid:99af03b7-dfd0-43fd-b79e-e7394276575f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:07400741-2d14-4e84-8559-f810f5539ef7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LAZCLUZE, in combination with amivantamab, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test [see Dosage and Administration (2.1) ] . uuid:490f9a36-42b5-4ff0-ab52-64809b5ad6ca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1790637 biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:b6dfe8b6-5408-422c-8d95-3b582c466b3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a7f7491a-061a-4c05-a66b-2dff289ad8ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:6f25d426-1436-4c01-a158-44559a43766c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/bevespi-aerosphere""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] BEVESPI AEROSPHERE is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Limitations of Use: BEVESPI AEROSPHERE is not indicated for the relief of acute bronchospasm or for the treatment of asthma [see Warnings and Precautions ( 5.1 , 5.2 )] .|[EMA] Bevespi Aerosphere is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). uuid:2251d39a-d8a2-4803-ac73-d842e1d021e5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1790637 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:ea2cc6e3-a185-46fb-b4fe-d91ebcbace0c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:56c7fe1f-9ce8-47d0-805a-605b25d05003"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BEVESPI AEROSPHERE is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Limitations of Use: BEVESPI AEROSPHERE is not indicated for the relief of acute bronchospasm or for the treatment of asthma [see Warnings and Precautions ( 5.1 , 5.2 )] . uuid:ec24dacb-970e-440a-8f50-9b9904c2096f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133326 biolink:treats HP:0002043 PMID:41385096 "[{""id"":""uuid:8908c340-fc2e-4d7d-ba38-2547a5d38fcb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:08199880-94b6-4247-977d-abdb6374ce72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] E-Z-DISK is indicated for use in radiography of the esophagus, for detection of esophageal strictures. uuid:515593bc-d5c6-4d4a-9afc-61222f600b93 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:228302 biolink:treats MONDO:0000594 PMID:41385096 "[{""id"":""uuid:bf5d9eb5-8ef3-4203-821f-c38bf24e3759"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3f7af60f-bbfd-4fa8-b25e-710f941df67f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZURZUVAE is indicated for the treatment of postpartum depression (PPD) in adults. uuid:9231a43a-b414-4bcd-b6e6-3f3e8c22c350 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7NL2E3F6K3 biolink:treats MONDO:0010602 PMID:41385096 "[{""id"":""uuid:75847d18-cbad-4fcc-82a2-2b4efe42572c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bcd4c8b8-72cd-409a-8f43-8ff5387c9b2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1044e213-104c-41d5-a38c-1c80d0afc61d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/hemlibra""]},{""id"":""uuid:262c9dba-a494-4bd9-9cda-62e6ae2ded45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] HEMLIBRA is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients ages newborn and older with hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors.|[EMA] Hemlibra is indicated for routine prophylaxis of bleeding episodes in patients with haemophilia A (congenital factor VIII deficiency):with factor VIII inhibitorswithout factor VIII inhibitors who have:severe disease (FVIII < 1%)moderate disease (FVIII ≥ 1% and ≤ 5%) with severe bleeding phenotype.Hemlibra can be used in all age groups.|[PMDA] Drugs with a new active ingredient indicated for the control of bleeding tendency in patients with congenital blood coagulation factor VIII deficiency with blood coagulation factor VIII inhibitors. [Orphan drug] uuid:14370099-74a8-4e46-9edd-4e50ddc5d01c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:513P80B4YJ biolink:treats MONDO:0020333 PMID:41385096 "[{""id"":""uuid:36ed18fa-4754-4da4-807d-019fcf90df94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:437d2c41-7aa7-41da-859f-3f2f39a25217"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AYVAKIT is a kinase inhibitor indicated for: Gastrointestinal Stromal Tumor (GIST) the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations. ( 1.1 , 2.2 ) Advanced Systemic Mastocytosis (AdvSM) the treatment of adult patients with AdvSM. AdvSM includes patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL). ( 1.2 ) Limitations of Use: AYVAKIT is not recommended for the treatment of patients with AdvSM with platelet counts of less than 50 × 10 9 /L ( 1.2 ) Indolent Systemic Mastocytosis (ISM) the treatment of adult patients with ISM. ( 1.3 ) Limitations of Use: AYVAKIT is not recommended for the treatment of patients with ISM with platelet counts of less than 50 × 10 9 /L ( 1.2 ) uuid:26e9a8c6-39ad-4019-af2a-6e47082a3083 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:513P80B4YJ biolink:treats MONDO:0020332 PMID:41385096 "[{""id"":""uuid:3a10375e-0ecd-4805-a488-4d5cd60b2ce2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bbaa6839-102a-4848-a502-87943394a576"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AYVAKIT is a kinase inhibitor indicated for: Gastrointestinal Stromal Tumor (GIST) the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations. ( 1.1 , 2.2 ) Advanced Systemic Mastocytosis (AdvSM) the treatment of adult patients with AdvSM. AdvSM includes patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL). ( 1.2 ) Limitations of Use: AYVAKIT is not recommended for the treatment of patients with AdvSM with platelet counts of less than 50 × 10 9 /L ( 1.2 ) Indolent Systemic Mastocytosis (ISM) the treatment of adult patients with ISM. ( 1.3 ) Limitations of Use: AYVAKIT is not recommended for the treatment of patients with ISM with platelet counts of less than 50 × 10 9 /L ( 1.2 ) uuid:ad9fee66-85bd-4d51-b5e0-5306a6c0a811 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:513P80B4YJ biolink:treats MONDO:0020334 PMID:41385096 "[{""id"":""uuid:6ed5dce4-1ab9-4fbd-a65c-fb667f6288d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e992494a-9924-4921-bf16-fb4307f6df6c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AYVAKIT is a kinase inhibitor indicated for: Gastrointestinal Stromal Tumor (GIST) the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations. ( 1.1 , 2.2 ) Advanced Systemic Mastocytosis (AdvSM) the treatment of adult patients with AdvSM. AdvSM includes patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL). ( 1.2 ) Limitations of Use: AYVAKIT is not recommended for the treatment of patients with AdvSM with platelet counts of less than 50 × 10 9 /L ( 1.2 ) Indolent Systemic Mastocytosis (ISM) the treatment of adult patients with ISM. ( 1.3 ) Limitations of Use: AYVAKIT is not recommended for the treatment of patients with ISM with platelet counts of less than 50 × 10 9 /L ( 1.2 ) uuid:13f2f5eb-7c74-4a86-979f-a88a9f650ec7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:513P80B4YJ biolink:treats MONDO:0020331 PMID:41385096 "[{""id"":""uuid:a6167972-161e-420f-88a8-9a572899ff74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:38a3eb35-a6a1-4d68-9190-7ab7820cbd77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AYVAKIT is a kinase inhibitor indicated for: Gastrointestinal Stromal Tumor (GIST) the treatment of adults with unresectable or metastatic GIST harboring a platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation, including PDGFRA D842V mutations. ( 1.1 , 2.2 ) Advanced Systemic Mastocytosis (AdvSM) the treatment of adult patients with AdvSM. AdvSM includes patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL). ( 1.2 ) Limitations of Use: AYVAKIT is not recommended for the treatment of patients with AdvSM with platelet counts of less than 50 × 10 9 /L ( 1.2 ) Indolent Systemic Mastocytosis (ISM) the treatment of adult patients with ISM. ( 1.3 ) Limitations of Use: AYVAKIT is not recommended for the treatment of patients with ISM with platelet counts of less than 50 × 10 9 /L ( 1.2 ) uuid:a3f70ffa-6744-4776-b94d-51e1f0ee9f91 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10343 biolink:treats MONDO:0004703 PMID:41385096 "[{""id"":""uuid:52fad707-9560-4cb4-9559-4d6803f56d9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7221830e-77a1-41cd-991b-f3144ae31f4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9917977d-e463-45ee-a266-88eb1c0d70e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TICE ® BCG is indicated for: the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder the prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR) Limitations of Use: TICE BCG is not recommended for stage TaG1 papillary tumors, unless they are judged to be at high risk of tumor recurrence. TICE BCG is not indicated for papillary tumors of stages higher than T1.|[PMDA] A drug with a new additional dosage indicated for the treatment of superficial bladder cancer and carcinoma in situ of bladder. uuid:1f4ce60b-d248-474f-96a3-46b8bb1bb5bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10343 biolink:treats MONDO:0006509 PMID:41385096 "[{""id"":""uuid:e232a708-b701-4d48-9f01-eb4408c2800c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9cba247a-2440-4c97-96cc-be294ad86126"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TICE ® BCG is indicated for: the treatment and prophylaxis of carcinoma in situ (CIS) of the urinary bladder the prophylaxis of primary or recurrent stage Ta and/or T1 papillary tumors following transurethral resection (TUR) Limitations of Use: TICE BCG is not recommended for stage TaG1 papillary tumors, unless they are judged to be at high risk of tumor recurrence. TICE BCG is not indicated for papillary tumors of stages higher than T1. uuid:0b8de19e-784a-40bf-9ec8-6b9e83bb17e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5280 biolink:treats UMLS:C1096572 PMID:41385096 "[{""id"":""uuid:b7dfa3dd-590d-499b-b897-b707c592d1cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6f63878d-ba75-45af-a4eb-88742c66d2b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZYMAXID ® is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Aerobic gram-positive bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus mitis group * Streptococcus oralis * Streptococcus pneumoniae Aerobic gram-negative bacteria: Haemophilus influenzae *Efficacy for these organisms were studied in fewer than 10 infections . uuid:a2dc7e07-155d-4bc5-be76-21b60e2e7a67 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5280 biolink:treats MONDO:0021680 PMID:41385096 "[{""id"":""uuid:8e176db8-4fc6-40a0-bbdf-7b1ea6c854e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:07930312-e2a3-485e-8470-347b73f9bdaa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZYMAXID ® is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Aerobic gram-positive bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus mitis group * Streptococcus oralis * Streptococcus pneumoniae Aerobic gram-negative bacteria: Haemophilus influenzae *Efficacy for these organisms were studied in fewer than 10 infections . uuid:85079c7f-4366-47ab-a85e-33e2ea9914e2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5280 biolink:treats UMLS:C0348321 PMID:41385096 "[{""id"":""uuid:ade56488-b91f-4023-a3d8-f83d0e0aaa1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f3450b58-a7b5-46e4-8495-c7b97c93bccb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZYMAXID ® is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Aerobic gram-positive bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus mitis group * Streptococcus oralis * Streptococcus pneumoniae Aerobic gram-negative bacteria: Haemophilus influenzae *Efficacy for these organisms were studied in fewer than 10 infections . uuid:9e771a27-c371-41f1-818d-fa90350ccef3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82717 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:c5525308-c74f-4ff7-9bf3-82a057d2c607"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b0f6ff83-b0f9-48ee-912a-d2e17da38391"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3c3f8247-1160-479f-b0a3-d1e222724bbe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/sivextro""]},{""id"":""uuid:7e283bff-c62b-4e32-9118-392036c2555a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SIVEXTRO is an oxazolidinone antibacterial indicated in adult and pediatric patients 12 years of age and older for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria. ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of SIVEXTRO and other antibacterial drugs, SIVEXTRO should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.|[EMA] Sivextro is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults and adolescents 12 years of age and older.|[PMDA] Drugs with a new active ingredient indicated for the treatment of bacterial skin infections mainly involving the dermis and/or subcutaneous tissues, secondary bacterial infections of pre-existing skin ulcers and/or erosion, and secondary bacterial infections of trauma, burn, and surgical wounds. uuid:2d3d400f-09b1-4a37-a1f3-9639b351bf97 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82717 biolink:treats UMLS:C4552483 PMID:41385096 "[{""id"":""uuid:06e67a9e-dc08-47d2-a5f9-ce8c3307e596"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:97d4638a-cebe-4b2d-a64d-5b8f85591cc6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SIVEXTRO is an oxazolidinone antibacterial indicated in adult and pediatric patients 12 years of age and older for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria. ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of SIVEXTRO and other antibacterial drugs, SIVEXTRO should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. uuid:9ccbf8f0-fa27-4dc5-b0d6-35a44aef3ea0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:NQX9KB6PCL biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:b73d0bb8-4aab-42e8-b487-94db8e57c939"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:069cbf7c-00ba-4a92-baee-c978d772f0ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:6da02647-88a0-4f96-9c88-213390d4d3dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/omnitrope""]},{""id"":""uuid:7c34ab8a-a20c-4721-a57c-6904d6b513e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nutropin AQ is a recombinant human growth hormone indicated for: Pediatric Patients : Treatment of children with growth failure due to growth hormone deficiency (GHD), idiopathic short stature (ISS), Turner syndrome (TS), and chronic kidney disease (CKD) up to the time of renal transplantation ( 1.1 ). Adult Patients: Treatment of adults with either childhood-onset or adult-onset GHD ( 1.2 ).|[EMA] Infants, children and adolescentsGrowth disturbance due to insufficient secretion of growth hormone (GH).Growth disturbance associated with Turner syndrome.Growth disturbance associated with chronic renal insufficiency.Growth disturbance (current height standard-deviation score (SDS) < -2.5 and parental adjusted SDS < -1) in short children / adolescents born small for gestational age (SGA), with a birth weight and / or length below -2 standard deviations (SDs), who failed to show catch-up growth (height velocity (HV) SDS < 0 during the last year) by four years of age or later.Prader-Willi syndrome (PWS), for improvement of growth and body composition. The diagnosis of PWS should be confirmed by appropriate genetic testing.AdultsReplacement therapy in adults with pronounced growth hormone deficiency. Patients with severe growth hormone deficiency in adulthood are defined as patients with known hypothalamic pituitary pathology and at least one known deficiency of a pituitary hormone not being prolactin. These patients should undergo a single dynamic test in order to diagnose or exclude a growth hormone deficiency. In patients with childhood-onset isolated GH deficiency (no evidence of hypothalamic-pituitary disease or cranial irradiation), two dynamic tests should be recommended, except for those having low insulin-like-growth-factor-I (IGF-I) concentrations (SDS < -2) who may be considered for one test. The cut-off point of the dynamic test should be strict.|[PMDA] Follow-on biologics indicated for the treatment of growth disturbance due to growth hormone deficiency before epiphyseal closure and growth disturbance associated with Turner syndrome or chronic renal insufficiency before epiphyseal closure. uuid:d315928d-5474-4b86-8d08-ea181646f820 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:52CMI0WC3Y biolink:treats UMLS:C0278987 PMID:41385096 "[{""id"":""uuid:21d00837-3083-43d1-ad53-a7f8a5ab0fc9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ab528b55-850a-4dd5-a07a-4499edbb793d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated: Non-Small Cell Lung Cancer (NSCLC) as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage II to IIIA NSCLC whose tumors have PD-L1 expression on ≥ 1% of tumor cells, as determined by an FDA-approved test. ( 1.1 , 14.1 ) for the first-line treatment of adult patients with metastatic NSCLC whose tumors have high PD-L1 expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 10% of the tumor area [IC ≥ 10%] ), as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. ( 1.1 ) in combination with bevacizumab, paclitaxel, and carboplatin, for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations. ( 1.1 ) in combination with paclitaxel protein-bound and carboplatin for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations ( 1.1 ) for the treatment of adult patients with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for NSCLC harboring these aberrations prior to receiving TECENTRIQ. ( 1.1 ) Small Cell Lung Cancer (SCLC) in combination with carboplatin and etoposide, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). ( 1.2 ) Hepatocellular Carcinoma (HCC) in combination with bevacizumab for the treatment of adult patients with unresectable or metastatic HCC who have not received prior systemic therapy. ( 1.3 ) Melanoma in combination with cobimetinib and vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma. ( 1.4 ) Alveolar Soft Part Sarcoma (ASPS) for the treatment of adult and pediatric patients 2 years of age and older with unresectable or metastatic ASPS. ( 1.5 ) uuid:b1a0c657-db3b-466d-b5c5-ac3a0565bd24 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:52CMI0WC3Y biolink:treats UMLS:C0744869 PMID:41385096 "[{""id"":""uuid:12371bc1-ab4f-41cc-9b10-d9d8d97ab262"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e7e85702-1c1d-4447-a740-09b7943c1952"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TECENTRIQ is a programmed death-ligand 1 (PD-L1) blocking antibody indicated: Non-Small Cell Lung Cancer (NSCLC) as adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage II to IIIA NSCLC whose tumors have PD-L1 expression on ≥ 1% of tumor cells, as determined by an FDA-approved test. ( 1.1 , 14.1 ) for the first-line treatment of adult patients with metastatic NSCLC whose tumors have high PD-L1 expression (PD-L1 stained ≥ 50% of tumor cells [TC ≥ 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 10% of the tumor area [IC ≥ 10%] ), as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. ( 1.1 ) in combination with bevacizumab, paclitaxel, and carboplatin, for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations. ( 1.1 ) in combination with paclitaxel protein-bound and carboplatin for the first-line treatment of adult patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations ( 1.1 ) for the treatment of adult patients with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for NSCLC harboring these aberrations prior to receiving TECENTRIQ. ( 1.1 ) Small Cell Lung Cancer (SCLC) in combination with carboplatin and etoposide, for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). ( 1.2 ) Hepatocellular Carcinoma (HCC) in combination with bevacizumab for the treatment of adult patients with unresectable or metastatic HCC who have not received prior systemic therapy. ( 1.3 ) Melanoma in combination with cobimetinib and vemurafenib for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma. ( 1.4 ) Alveolar Soft Part Sarcoma (ASPS) for the treatment of adult and pediatric patients 2 years of age and older with unresectable or metastatic ASPS. ( 1.5 ) uuid:286b36b7-c88c-412b-9881-d36efba6f962 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:81570 biolink:treats MONDO:0011122 PMID:41385096 "[{""id"":""uuid:10fa5db2-5144-4304-9cf2-db3f4eaf1b14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:20efe712-470d-4710-b538-54ddb5d80295"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] HCG HAS NOT BEEN DEMONSTRATED TO BE EFFECTIVE ADJUNCTIVE THERAPY IN THE TREATMENT OF OBESITY. THERE IS NO SUBSTANTIAL EVIDENCE THAT IT INCREASES WEIGHT LOSS BEYOND THAT RESULTING FROM CALORIC RESTRICTION, THAT IT CAUSES A MORE ATTRACTIVE OR ""NORMAL"" DISTRIBUTION OF FAT, OR THAT IT DECREASES THE HUNGER AND DISCOMFORT ASSOCIATED WITH CALORIE-RESTRICTED DIETS. Prepubertal cryptorchidism not due to anatomic obstruction. In general, HCG is thought to induce testicular descent in situations when descent would have occurred at puberty. HCG thus may help to predict whether or not orchiopexy will be needed in the future. Although, in some cases, descent following HCG administration is permanent, in most cases the response is temporary. Therapy is usually instituted between the ages of 4 and 9. Selected cases of hypogonadotropic hypogonadism (hypogonadism secondary to a pituitary deficiency) in males. Induction of ovulation and pregnancy in the anovulatory, infertile woman in whom the cause of anovulation is secondary and not due to primary ovarian failure, and who has been appropriately pretreated with human menotropins." uuid:f0626112-9e75-4704-a90c-2d8a15997fe8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:81570 biolink:treats MONDO:0009047 PMID:41385096 "[{""id"":""uuid:3e12db7f-a0d4-474e-a57c-011c52cd30ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:541481d0-c0d4-410c-bb66-13a06b4bf5e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] HCG HAS NOT BEEN DEMONSTRATED TO BE EFFECTIVE ADJUNCTIVE THERAPY IN THE TREATMENT OF OBESITY. THERE IS NO SUBSTANTIAL EVIDENCE THAT IT INCREASES WEIGHT LOSS BEYOND THAT RESULTING FROM CALORIC RESTRICTION, THAT IT CAUSES A MORE ATTRACTIVE OR ""NORMAL"" DISTRIBUTION OF FAT, OR THAT IT DECREASES THE HUNGER AND DISCOMFORT ASSOCIATED WITH CALORIE-RESTRICTED DIETS. Prepubertal cryptorchidism not due to anatomic obstruction. In general, HCG is thought to induce testicular descent in situations when descent would have occurred at puberty. HCG thus may help to predict whether or not orchiopexy will be needed in the future. Although, in some cases, descent following HCG administration is permanent, in most cases the response is temporary. Therapy is usually instituted between the ages of 4 and 9. Selected cases of hypogonadotropic hypogonadism (hypogonadism secondary to a pituitary deficiency) in males. Induction of ovulation and pregnancy in the anovulatory, infertile woman in whom the cause of anovulation is secondary and not due to primary ovarian failure, and who has been appropriately pretreated with human menotropins." uuid:089c46e4-1515-4b01-94b6-e694d3b07cf9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:81570 biolink:treats MONDO:0018555 PMID:41385096 "[{""id"":""uuid:1a1fc970-2f6c-4d41-94db-aecb81403081"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d6486c2c-d6e8-423d-af27-7af966bea552"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] HCG HAS NOT BEEN DEMONSTRATED TO BE EFFECTIVE ADJUNCTIVE THERAPY IN THE TREATMENT OF OBESITY. THERE IS NO SUBSTANTIAL EVIDENCE THAT IT INCREASES WEIGHT LOSS BEYOND THAT RESULTING FROM CALORIC RESTRICTION, THAT IT CAUSES A MORE ATTRACTIVE OR ""NORMAL"" DISTRIBUTION OF FAT, OR THAT IT DECREASES THE HUNGER AND DISCOMFORT ASSOCIATED WITH CALORIE-RESTRICTED DIETS. Prepubertal cryptorchidism not due to anatomic obstruction. In general, HCG is thought to induce testicular descent in situations when descent would have occurred at puberty. HCG thus may help to predict whether or not orchiopexy will be needed in the future. Although, in some cases, descent following HCG administration is permanent, in most cases the response is temporary. Therapy is usually instituted between the ages of 4 and 9. Selected cases of hypogonadotropic hypogonadism (hypogonadism secondary to a pituitary deficiency) in males. Induction of ovulation and pregnancy in the anovulatory, infertile woman in whom the cause of anovulation is secondary and not due to primary ovarian failure, and who has been appropriately pretreated with human menotropins." uuid:89a6a3a5-ad7a-4c62-961f-611b13a178b8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:81570 biolink:treats MONDO:0002775 PMID:41385096 "[{""id"":""uuid:1ec4fd66-498a-4b20-b3f9-ebf997e9e18f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:18f5dc59-8d99-4baa-819d-dc9dc8ab0638"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] HCG HAS NOT BEEN DEMONSTRATED TO BE EFFECTIVE ADJUNCTIVE THERAPY IN THE TREATMENT OF OBESITY. THERE IS NO SUBSTANTIAL EVIDENCE THAT IT INCREASES WEIGHT LOSS BEYOND THAT RESULTING FROM CALORIC RESTRICTION, THAT IT CAUSES A MORE ATTRACTIVE OR ""NORMAL"" DISTRIBUTION OF FAT, OR THAT IT DECREASES THE HUNGER AND DISCOMFORT ASSOCIATED WITH CALORIE-RESTRICTED DIETS. Prepubertal cryptorchidism not due to anatomic obstruction. In general, HCG is thought to induce testicular descent in situations when descent would have occurred at puberty. HCG thus may help to predict whether or not orchiopexy will be needed in the future. Although, in some cases, descent following HCG administration is permanent, in most cases the response is temporary. Therapy is usually instituted between the ages of 4 and 9. Selected cases of hypogonadotropic hypogonadism (hypogonadism secondary to a pituitary deficiency) in males. Induction of ovulation and pregnancy in the anovulatory, infertile woman in whom the cause of anovulation is secondary and not due to primary ovarian failure, and who has been appropriately pretreated with human menotropins." uuid:2cb20a5b-bcae-4c54-814e-1014da9e7e17 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:81570 biolink:treats MONDO:0005047 PMID:41385096 "[{""id"":""uuid:29a09238-e7f8-468e-bdec-58b224fac051"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2853d4a7-a6db-4b58-adca-5ad335283068"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] HCG HAS NOT BEEN DEMONSTRATED TO BE EFFECTIVE ADJUNCTIVE THERAPY IN THE TREATMENT OF OBESITY. THERE IS NO SUBSTANTIAL EVIDENCE THAT IT INCREASES WEIGHT LOSS BEYOND THAT RESULTING FROM CALORIC RESTRICTION, THAT IT CAUSES A MORE ATTRACTIVE OR ""NORMAL"" DISTRIBUTION OF FAT, OR THAT IT DECREASES THE HUNGER AND DISCOMFORT ASSOCIATED WITH CALORIE-RESTRICTED DIETS. Prepubertal cryptorchidism not due to anatomic obstruction. In general, HCG is thought to induce testicular descent in situations when descent would have occurred at puberty. HCG thus may help to predict whether or not orchiopexy will be needed in the future. Although, in some cases, descent following HCG administration is permanent, in most cases the response is temporary. Therapy is usually instituted between the ages of 4 and 9. Selected cases of hypogonadotropic hypogonadism (hypogonadism secondary to a pituitary deficiency) in males. Induction of ovulation and pregnancy in the anovulatory, infertile woman in whom the cause of anovulation is secondary and not due to primary ovarian failure, and who has been appropriately pretreated with human menotropins." uuid:a560db67-08c2-40c8-91c2-71131de556f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63637 biolink:treats MONDO:0005105 PMID:41385096 "[{""id"":""uuid:19fa2eab-8768-414f-a1b4-5d887f88cd7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:22dc3a4d-a7ea-4a06-8f68-bee8526be7da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:5268a91b-a6d3-499b-b01b-9d1f673d4960"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zelboraf""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZELBORAF ® is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test. ( 1.1 , 2.1 ) ZELBORAF ® is indicated for the treatment of patients with Erdheim- Chester Disease with BRAF V600 mutation. ( 1.2 , 2.1 ) Limitation of Use: ZELBORAF is not indicated for treatment of patients with wild-type BRAF melanoma ( 2.1 , 5.2 )|[EMA] Vemurafenib is indicated in monotherapy for the treatment of adult patients with BRAF-V600-mutation-positive unresectable or metastatic melanoma., uuid:2333f842-6139-45f7-b508-29c99d4c01ef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28925 biolink:treats MONDO:0009691 PMID:41385096 "[{""id"":""uuid:9e5cc3f2-16a1-4d95-9f1a-1223066ab7c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:796c0c2c-d122-4f62-b24c-fe269f37d1ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c8d0ca33-ad8a-4f3e-87ae-5d9501375940"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ledaga""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] VALCHLOR is indicated for the topical treatment of Stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma in patients who have received prior skin-directed therapy.|[EMA] Ledaga is indicated for the topical treatment of mycosis fungoides-type cutaneous T-cell lymphoma (MF-type CTCL) in adult patients. uuid:364cfacc-9866-4785-aa5e-50cfe75b8244 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:ZJ0EKR6M10 biolink:treats UMLS:C0027627 PMID:41385096 "[{""id"":""uuid:b380a395-6953-458a-a1d0-1a90446eb0fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d6ee659e-4548-42b2-9299-299540618bb9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gallium Ga 68 Gozetotide Injection is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy. with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level. uuid:04848a9d-c545-4219-b693-9215943d2ad3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2P471X1Z11 biolink:treats MONDO:0850282 PMID:41385096 "[{""id"":""uuid:393abad5-d634-4d66-956e-e5bea5775cc1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b8846695-b9c2-445a-a08e-1284029549b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XOLAIR is an anti-IgE antibody indicated for: Moderate to severe persistent asthma in adults and pediatric patients 6 years of age and older with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms that are inadequately controlled with inhaled corticosteroids ( 1.1 ) Chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients 18 years of age and older with inadequate response to nasal corticosteroids, as add-on maintenance treatment ( 1.2 ) IgE-mediated food allergy in adult and pediatric patients aged 1 year and older for the reduction of allergic reactions (Type I), including anaphylaxis, that may occur with accidental exposure to one or more foods. To be used in conjunction with food allergen avoidance ( 1.3 ) Chronic spontaneous urticaria (CSU) in adults and adolescents 12 years of age and older who remain symptomatic despite H1 antihistamine treatment ( 1.4 ) Limitations of Use : Not indicated for acute bronchospasm or status asthmaticus. ( 1.1 , 5.3 ) Not indicated for the emergency treatment of allergic reactions, including anaphylaxis ( 1.3 ) Not indicated for other forms of urticaria. ( 1.4 ) uuid:7c353f51-a333-480c-bf11-6648241acacd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2P471X1Z11 biolink:treats EFO:1002029 PMID:41385096 "[{""id"":""uuid:21e9114b-45f5-4df5-b738-9ce60f383866"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:850053e6-7279-47dd-8b44-a70919cb0497"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XOLAIR is an anti-IgE antibody indicated for: Moderate to severe persistent asthma in adults and pediatric patients 6 years of age and older with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms that are inadequately controlled with inhaled corticosteroids ( 1.1 ) Chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients 18 years of age and older with inadequate response to nasal corticosteroids, as add-on maintenance treatment ( 1.2 ) IgE-mediated food allergy in adult and pediatric patients aged 1 year and older for the reduction of allergic reactions (Type I), including anaphylaxis, that may occur with accidental exposure to one or more foods. To be used in conjunction with food allergen avoidance ( 1.3 ) Chronic spontaneous urticaria (CSU) in adults and adolescents 12 years of age and older who remain symptomatic despite H1 antihistamine treatment ( 1.4 ) Limitations of Use : Not indicated for acute bronchospasm or status asthmaticus. ( 1.1 , 5.3 ) Not indicated for the emergency treatment of allergic reactions, including anaphylaxis ( 1.3 ) Not indicated for other forms of urticaria. ( 1.4 ) uuid:de3cb05d-973c-4c26-866b-cc9995f5a094 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2P471X1Z11 biolink:treats MONDO:0700226 PMID:41385096 "[{""id"":""uuid:d138a141-e5c7-4710-be12-fff6490653cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b81018b4-c2d4-4488-8853-89658039f82c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XOLAIR is an anti-IgE antibody indicated for: Moderate to severe persistent asthma in adults and pediatric patients 6 years of age and older with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms that are inadequately controlled with inhaled corticosteroids ( 1.1 ) Chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients 18 years of age and older with inadequate response to nasal corticosteroids, as add-on maintenance treatment ( 1.2 ) IgE-mediated food allergy in adult and pediatric patients aged 1 year and older for the reduction of allergic reactions (Type I), including anaphylaxis, that may occur with accidental exposure to one or more foods. To be used in conjunction with food allergen avoidance ( 1.3 ) Chronic spontaneous urticaria (CSU) in adults and adolescents 12 years of age and older who remain symptomatic despite H1 antihistamine treatment ( 1.4 ) Limitations of Use : Not indicated for acute bronchospasm or status asthmaticus. ( 1.1 , 5.3 ) Not indicated for the emergency treatment of allergic reactions, including anaphylaxis ( 1.3 ) Not indicated for other forms of urticaria. ( 1.4 ) uuid:b77a7175-ccf5-49e2-bcc0-0c680db53aaa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2P471X1Z11 biolink:treats MONDO:0044212 PMID:41385096 "[{""id"":""uuid:cfe5df22-adeb-45df-97c9-95561450fcc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:45e7d8a4-15a3-4040-8087-baf7116b38cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:80259c22-9603-45df-b665-201c313a2779"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XOLAIR is an anti-IgE antibody indicated for: Moderate to severe persistent asthma in adults and pediatric patients 6 years of age and older with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms that are inadequately controlled with inhaled corticosteroids ( 1.1 ) Chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients 18 years of age and older with inadequate response to nasal corticosteroids, as add-on maintenance treatment ( 1.2 ) IgE-mediated food allergy in adult and pediatric patients aged 1 year and older for the reduction of allergic reactions (Type I), including anaphylaxis, that may occur with accidental exposure to one or more foods. To be used in conjunction with food allergen avoidance ( 1.3 ) Chronic spontaneous urticaria (CSU) in adults and adolescents 12 years of age and older who remain symptomatic despite H1 antihistamine treatment ( 1.4 ) Limitations of Use : Not indicated for acute bronchospasm or status asthmaticus. ( 1.1 , 5.3 ) Not indicated for the emergency treatment of allergic reactions, including anaphylaxis ( 1.3 ) Not indicated for other forms of urticaria. ( 1.4 )|[PMDA] Drugs with a new additional indication and a new dosage for the treatment of chronic idiopathic urticaria (for use only in patients who have not responded sufficiently to conventional therapies). uuid:47d1e2e6-7306-4945-86a6-99c3c7bc3524 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C4331966 biolink:treats MONDO:0003060 PMID:41385096 "[{""id"":""uuid:43dbd05e-9fe6-48a9-b834-6298d30e3f7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4318f677-a559-4e7e-bf3d-68ed0eb01900"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZIIHERA is indicated for the treatment of adults with previously treated, unresectable or metastatic HER2-positive (IHC 3+) biliary tract cancer (BTC), as detected by an FDA-approved test [see Dosage and Administration ( 2.1 )]. This indication is approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies ( 14 )] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). DRUGBANK:DB15471 uuid:48d5e656-9a1b-47c6-b5cb-228d376eae32 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90851 biolink:treats MONDO:0005105 PMID:41385096 "[{""id"":""uuid:db4ca088-da76-4b5a-b790-78ae5cdaf0d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:04d617fc-9c28-42d4-8b6c-887537cf6b7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:14afb07b-8fbd-4660-a774-bcda3851f58e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] COTELLIC ® is a kinase inhibitor indicated: For the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib. ( 1.1 , 14.1 ) As a single agent for the treatment of adult patients with histiocytic neoplasms. ( 1.2 , 14.2 )|[EMA] Cotellic is indicated for use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation. uuid:eaf0fdbe-21e4-490c-83a8-d23aba25a2f9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90851 biolink:treats MONDO:0006247 PMID:41385096 "[{""id"":""uuid:6c35bcfb-3f39-4013-bdda-b546821237ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f14626e8-eb4d-4830-879c-c0f656334601"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] COTELLIC ® is a kinase inhibitor indicated: For the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib. ( 1.1 , 14.1 ) As a single agent for the treatment of adult patients with histiocytic neoplasms. ( 1.2 , 14.2 ) uuid:732dbe61-8b42-4130-8d6f-283be71def7a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42355 biolink:treats MONDO:0008647 PMID:41385096 "[{""id"":""uuid:d457d30e-2387-4331-9dcf-b337b49dbf74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:87a1c8f1-18e5-460c-88b8-11efff26e21f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Erythromycin lactobionate for injection, USP is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the diseases listed below when oral administration is not possible or when the severity of the infection requires immediate high serum levels of erythromycin. Intravenous therapy should be replaced by oral administration at the appropriate time. Upper respiratory tract infections of mild to moderate degree caused by Streptococcus pyogenes (Group A beta-hemolytic streptococci); Streptococcus pneumoniae (Diplococcus pneumoniae); Haemophilus influenzae (when used concomitantly with adequate doses of sulfonamides, since many strains of H . influenzae are not susceptible to the erythromycin concentrations ordinarily achieved). (See appropriate sulfonamide labeling for prescribing information). Lower respiratory tract infections of mild to moderate severity caused by Streptococcus pyogenes (Group A beta-hemolytic streptococci); Streptococcus pneumoniae (Diplococcus pneumoniae). Respiratory tract infections due to Mycoplasma pneumoniae . Skin and skin structure infections of mild to moderate severity caused by Streptococcus pyogenes and Staphylococcus aureus (resistant staphylococci may emerge during treatment). Diphtheria: As an adjunct to antitoxin infections due to Corynebacterium diphtheriae to prevent establishment of carriers and to eradicate the organism in carriers. Erythrasma: In the treatment of infections due to Corynebacterium minutissimum . Acute pelvic inflammatory disease caused by Neisseria gonorrhoeae : Erythromycin lactobionate for injection, USP followed by erythromycin stearate or erythromycin base orally, as an alternative drug in treatment of acute pelvic inflammatory disease caused by N . gonorrhoeae in female patients with a history of sensitivity to penicillin. Before treatment of gonorrhea, patients who are suspected of also having syphilis should have a microscopic examination for T . pallidum (by immunofluorescence or darkfield) before receiving erythromycin and monthly serologic tests for a minimum of 4 months thereafter. Legionnaires’ Disease caused by Legionella pneumophila . Although no controlled clinical efficacy studies have been conducted, in vitro and limited preliminary clinical data suggest that erythromycin may be effective in treating Legionnaires’ Disease. Prevention of Initial Attacks of Rheumatic Fever Penicillin is considered by the American Heart Association to be the drug of choice in the prevention of initial attacks of rheumatic fever (treatment of Group A beta-hemolytic streptococcal infections of the upper respiratory tract e.g., tonsillitis, or pharyngitis).1 Erythromycin is indicated for the treatment of penicillin-allergic patients. The therapeutic dose should be administered for ten days. Prevention of Recurrent Attacks of Rheumatic Fever Penicillin or sulfonamides are considered by the American Heart Association to be the drugs of choice in the prevention of recurrent attacks of rheumatic fever. In patients who are allergic to penicillin and sulfonamides, oral erythromycin is recommended by the American Heart Association in the long-term prophylaxis of streptococcal pharyngitis (for the prevention of recurrent attacks of rheumatic fever). 1 Prevention of Bacterial Endocarditis Although no controlled clinical efficacy trials have been conducted, oral erythromycin has been recommended by the American Heart Association for prevention of bacterial endocarditis in penicillin- allergic patients with prosthetic cardiac valves, most congenital cardiac malformations, surgically constructed systemic pulmonary shunts, rheumatic or other acquired valvular dysfunction, idiopathic hypertrophic subaortic stenosis (IHSS), previous history of bacterial endocarditis and mitral valve prolapse with insufficiency when they undergo dental procedures and surgical procedures of the upper respiratory tract. 2 To reduce the development of drug-resistant bacteria and maintain the effectiveness of erythromycin and other antibacterial drugs, erythromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:8a878fc6-6849-4f48-a0bf-e37dafb56355 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:195558 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:532f878d-c5d0-4581-8b0b-fcb692dc345f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:74c443f7-4179-4653-819d-7357507ca564"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0ad0d28c-d772-4ea6-a17e-35ee2a22f4ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/rozlytrek""]},{""id"":""uuid:cb42ab56-1ed2-4c94-aa3d-75f530881910"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ROZLYTREK is a kinase inhibitor indicated for the treatment of: Adult patients with ROS1- positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. ( 1.1 ) Adult and pediatric patients older than 1 month of age with solid tumors that: have a neurotrophic tyrosine receptor kinase ( NTRK) gene fusion, as detected by an FDA-approved test without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. ( 1.2 )|[EMA] Rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior NTRK inhibitorwho have no satisfactory treatment options.Rozlytrek as monotherapy is indicated for the treatment of adult patients with ROS1 positive, advanced non small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors.|[PMDA] Drugs with a new indication and a new dosage for the treatment of ROS1 fusion gene-positive unresectable advanced or recurrent non-small-cell lung cancer. uuid:a11c0731-1613-4af1-8879-db652694032e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:195558 biolink:treats UMLS:C4728198 PMID:41385096 "[{""id"":""uuid:85c75a46-0a0e-4528-a1af-71d1851811f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:faf20cc2-7053-4f7f-9295-7eabb46b129a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ROZLYTREK is a kinase inhibitor indicated for the treatment of: Adult patients with ROS1- positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. ( 1.1 ) Adult and pediatric patients older than 1 month of age with solid tumors that: have a neurotrophic tyrosine receptor kinase ( NTRK) gene fusion, as detected by an FDA-approved test without a known acquired resistance mutation, are metastatic or where surgical resection is likely to result in severe morbidity, and have progressed following treatment or have no satisfactory alternative therapy. This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. ( 1.2 ) uuid:8e7ca468-0c1f-4c2a-bc7e-572dc53ed9be biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229217 biolink:treats MONDO:0005031 PMID:41385096 "[{""id"":""uuid:11b55497-9076-4941-ab3f-0babfd7a4bfc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:37acc963-0ea5-4adc-89e6-d02fcb103b09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OGSIVEO is indicated for adult patients with progressing desmoid tumors who require systemic treatment. uuid:3495db36-cd4d-4cf8-bca6-9d8e850fd549 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:70718 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:86f6f173-c097-4e38-8aa5-c4c40417157f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4f1a6223-4d9a-472f-803f-65caf94e628d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Teflaro is a cephalosporin antibacterial indicated in adult and pediatric patients for the treatment of the following infection caused by designated susceptible bacteria: Acute bacterial skin and skin structure infections (ABSSSI) in adult and pediatric patients (at least 34 weeks gestational age and 12 days postnatal age) ( 1.1 ) Community-acquired bacterial pneumonia (CABP) in adult and pediatric patients 2 months of age and older ( 1.2 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Teflaro and other antibacterial drugs, Teflaro should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.3 ) uuid:1efe722a-bb1a-434f-a93c-60b1ca699711 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:70718 biolink:treats MONDO:0004652 PMID:41385096 "[{""id"":""uuid:6dc2fc9e-1d22-49e9-b943-2333ea6b42b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dec17bef-d6eb-432f-a877-846885a9e6dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Teflaro is a cephalosporin antibacterial indicated in adult and pediatric patients for the treatment of the following infection caused by designated susceptible bacteria: Acute bacterial skin and skin structure infections (ABSSSI) in adult and pediatric patients (at least 34 weeks gestational age and 12 days postnatal age) ( 1.1 ) Community-acquired bacterial pneumonia (CABP) in adult and pediatric patients 2 months of age and older ( 1.2 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Teflaro and other antibacterial drugs, Teflaro should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.3 ) uuid:94a9f050-796b-48cb-b985-b709cfe4ae52 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:A10SJL62JY biolink:treats MONDO:0005314 PMID:41385096 "[{""id"":""uuid:fad8b2c6-c21a-47ed-a82e-300ffdbc23bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:bd2738c0-d80d-4fab-bbae-6c11cd97aaf6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:21dcb3ca-5eb4-4851-92cc-04170c064133"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ocrevus""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] OCREVUS is indicated for the treatment of: Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults Primary progressive MS, in adults|[EMA] Treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.Treatment of adult patients with early primary progressive multiple sclerosis (PPMS) in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity. uuid:96b0767f-74eb-401f-937a-c8711ecfb3b9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:A10SJL62JY biolink:treats UMLS:C2921627 PMID:41385096 "[{""id"":""uuid:901076e9-d569-4233-8926-d7b2db9f967b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bf40cb3a-5ea7-49da-9f50-9233edb34617"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OCREVUS is indicated for the treatment of: Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults Primary progressive MS, in adults uuid:f607b436-8479-4bb0-957e-ada1309acb0a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:A10SJL62JY biolink:treats MONDO:0000450 PMID:41385096 "[{""id"":""uuid:718cae30-3265-4823-96f3-2ee29bc801f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:29c391cc-e1bd-45e2-bc27-afebd42ed305"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OCREVUS is indicated for the treatment of: Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults Primary progressive MS, in adults uuid:a4c122d7-142a-47f8-8cd4-f83bc28dd0fe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:A10SJL62JY biolink:treats MONDO:0000451 PMID:41385096 "[{""id"":""uuid:59524d25-8463-45cb-b3e4-32693e21bd1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:63673560-9da6-4b29-bca9-f12a296452c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:55aff341-1b0c-435c-9455-1cc7600473e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ocrevus""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] OCREVUS is indicated for the treatment of: Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults Primary progressive MS, in adults|[EMA] Treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.Treatment of adult patients with early primary progressive multiple sclerosis (PPMS) in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity. uuid:de1b0452-73ca-476e-a697-6bba19557078 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16000 biolink:treats MONDO:0021645 PMID:41385096 "[{""id"":""uuid:5ddfc34c-0356-4778-bbd1-8c5678d6b8f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:897444bd-b26a-44fa-886f-6d613dbeb22e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ETHAMOLIN Injection is indicated for the treatment of patients with esophageal varices that have recently bled, to prevent rebleeding. ETHAMOLIN is not indicated for the treatment of patients with esophageal varices that have not bled. There is no evidence that treatment of this population decreases the likelihood of bleeding. Sclerotherapy with ETHAMOLIN has no beneficial effect upon portal hypertension, the cause of esophageal varices, so that recanalization and collateralization may occur, necessitating reinjection. uuid:a0d29497-7c9f-44c7-b53c-07174be90e71 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16000 biolink:treats MONDO:0001221 PMID:41385096 "[{""id"":""uuid:57649683-2395-474e-8427-f45d14442836"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:35b8e888-93b6-4724-90d8-8c763d68f8a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ETHAMOLIN Injection is indicated for the treatment of patients with esophageal varices that have recently bled, to prevent rebleeding. ETHAMOLIN is not indicated for the treatment of patients with esophageal varices that have not bled. There is no evidence that treatment of this population decreases the likelihood of bleeding. Sclerotherapy with ETHAMOLIN has no beneficial effect upon portal hypertension, the cause of esophageal varices, so that recanalization and collateralization may occur, necessitating reinjection. uuid:ee93fa66-e932-4612-aa80-fff5bdb65955 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2719 biolink:treats MONDO:0001881 PMID:41385096 "[{""id"":""uuid:634ff838-3720-446e-a65d-c7a297eadf03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:38508e56-8191-4dec-962f-d8e9b3d1afcf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] GIAPREZA increases blood pressure in adults with septic or other distributive shock [see Clinical Studies (14)] . uuid:699489ce-81b3-438b-be0a-79211be12ec0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2719 biolink:treats HP:0031275 PMID:41385096 "[{""id"":""uuid:eb5d23f1-33ca-4bdc-8ff7-f67761aac6a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:090962f7-dcb1-49fb-b0b5-16ded147de8e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:76b80807-d3da-42c3-9030-f51a73a60ba3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] GIAPREZA increases blood pressure in adults with septic or other distributive shock [see Clinical Studies (14)] .|[EMA] Giapreza is indicated for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies. uuid:10af48dd-b51d-4baf-8b33-4174ca7341e4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:I031V2H011 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:c053789f-00d0-4a5f-9f74-b3dbe9ceea06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:87e91856-35cf-46c4-bc76-f24a33b58f8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:26b0ee9d-dcdd-489f-9b28-e3f3a68107fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/roactemra""]},{""id"":""uuid:9c6fbbdb-47ba-4674-a5a4-d8febe18aa89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ACTEMRA ® (tocilizumab) is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of: Rheumatoid Arthritis (RA) ( 1.1 ) Adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). Giant Cell Arteritis (GCA) ( 1.2 ) Adult patients with giant cell arteritis. Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) ( 1.3 ) Slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) Polyarticular Juvenile Idiopathic Arthritis (PJIA) ( 1.4 ) Patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis. Systemic Juvenile Idiopathic Arthritis (SJIA) ( 1.5 ) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis. Cytokine Release Syndrome (CRS) ( 1.6 ) Adults and pediatric patients 2 years of age and older with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome. Coronavirus Disease 2019 (COVID-19) ( 1.7 ) Hospitalized adult patients with coronavirus disease 2019 (COVID-19) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).|[EMA] RoActemra, in combination with methotrexate (MTX), is indicated forthe treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with MTX.the treatment of moderate to severe active RA in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists.In these patients, RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.RoActemra has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function when given in combination with methotrexate.RoActemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients 1 year of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids. RoActemra can be given as monotherapy (in case of intolerance to MTX or where treatment with MTX is inappropriate) or in combination with MTX.RoActemra in combination with methotrexate (MTX) is indicated for the treatment of juvenile idiopathic polyarthritis (pJIA; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with MTX. RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.RoActemra is indicated for the treatment of Giant Cell Arteritis (GCA) in adult patients.RoActemra, in combination with methotrexate (MTX), is indicated for:the treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with MTX.the treatment of moderate to severe active RA in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists.In these patients, RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate. RoActemra has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function when given in combination with methotrexate.RoActemra is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.RoActemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients 2 years of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids. RoActemra can be given as monotherapy (in case of intolerance to MTX or where treatment with MTX is inappropriate) or in combination with MTX.RoActemra in combination with methotrexate (MTX) is indicated for the treatment of juvenile idiopathic polyarthritis (pJIA; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with MTX. RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.RoActemra is indicated for the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and paediatric patients 2 years of age and older.RoActemra, in combination with methotrexate (MTX), is indicated for:the treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with MTX.the treatment of moderate to severe active RA in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists.In these patients, RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate. RoActemra has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function when given in combination with methotrexate.RoActemra is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.RoActemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients 2 years of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids. RoActemra can be given as monotherapy (in case of intolerance to MTX or where treatment with MTX is inappropriate) or in combination with MTX.RoActemra in combination with methotrexate (MTX) is indicated for the treatment of juvenile idiopathic polyarthritis (pJIA; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with MTX. RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.RoActemra is indicated for the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and paediatric patients 2 years of age and older.|[PMDA] Drugs with a new route of administration indicated for the treatment of rheumatoid arthritis (including prevention of structural joint damage) in patients who have not sufficiently responded to conventional treatments. uuid:365ecc93-9eec-443a-a5df-9198c48c20c4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:I031V2H011 biolink:treats MONDO:0008538 PMID:41385096 "[{""id"":""uuid:7e4ec867-7a72-45c8-b833-b82fd5c66647"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:36fa2876-5eb8-467d-90d4-51fdeaa1619c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:dbd08aaf-720b-4455-928e-97a679e8c3fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/roactemra""]},{""id"":""uuid:84200b65-f2c9-4776-8c9c-fca351f77131"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ACTEMRA ® (tocilizumab) is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of: Rheumatoid Arthritis (RA) ( 1.1 ) Adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). Giant Cell Arteritis (GCA) ( 1.2 ) Adult patients with giant cell arteritis. Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) ( 1.3 ) Slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) Polyarticular Juvenile Idiopathic Arthritis (PJIA) ( 1.4 ) Patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis. Systemic Juvenile Idiopathic Arthritis (SJIA) ( 1.5 ) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis. Cytokine Release Syndrome (CRS) ( 1.6 ) Adults and pediatric patients 2 years of age and older with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome. Coronavirus Disease 2019 (COVID-19) ( 1.7 ) Hospitalized adult patients with coronavirus disease 2019 (COVID-19) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).|[EMA] RoActemra, in combination with methotrexate (MTX), is indicated forthe treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with MTX.the treatment of moderate to severe active RA in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists.In these patients, RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.RoActemra has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function when given in combination with methotrexate.RoActemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients 1 year of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids. RoActemra can be given as monotherapy (in case of intolerance to MTX or where treatment with MTX is inappropriate) or in combination with MTX.RoActemra in combination with methotrexate (MTX) is indicated for the treatment of juvenile idiopathic polyarthritis (pJIA; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with MTX. RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.RoActemra is indicated for the treatment of Giant Cell Arteritis (GCA) in adult patients.RoActemra, in combination with methotrexate (MTX), is indicated for:the treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with MTX.the treatment of moderate to severe active RA in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists.In these patients, RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate. RoActemra has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function when given in combination with methotrexate.RoActemra is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.RoActemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients 2 years of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids. RoActemra can be given as monotherapy (in case of intolerance to MTX or where treatment with MTX is inappropriate) or in combination with MTX.RoActemra in combination with methotrexate (MTX) is indicated for the treatment of juvenile idiopathic polyarthritis (pJIA; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with MTX. RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.RoActemra is indicated for the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and paediatric patients 2 years of age and older.RoActemra, in combination with methotrexate (MTX), is indicated for:the treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with MTX.the treatment of moderate to severe active RA in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists.In these patients, RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate. RoActemra has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function when given in combination with methotrexate.RoActemra is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.RoActemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients 2 years of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids. RoActemra can be given as monotherapy (in case of intolerance to MTX or where treatment with MTX is inappropriate) or in combination with MTX.RoActemra in combination with methotrexate (MTX) is indicated for the treatment of juvenile idiopathic polyarthritis (pJIA; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with MTX. RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.RoActemra is indicated for the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and paediatric patients 2 years of age and older.|[PMDA] Drugs with new additional indications and a new dosage for the treatment of Takayasu arteritis and giant cell arteritis in patients who have not responded sufficiently to conventional treatments. [Orphan drug] uuid:598a09ce-de0e-4891-8415-657142f21ff8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:I031V2H011 biolink:treats MONDO:0002047 PMID:41385096 "[{""id"":""uuid:60e61ec5-bdf8-4c0a-91eb-516d8cd7ca8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1be86277-cb0e-4c8b-a252-cfcbab842e23"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ACTEMRA ® (tocilizumab) is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of: Rheumatoid Arthritis (RA) ( 1.1 ) Adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). Giant Cell Arteritis (GCA) ( 1.2 ) Adult patients with giant cell arteritis. Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) ( 1.3 ) Slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) Polyarticular Juvenile Idiopathic Arthritis (PJIA) ( 1.4 ) Patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis. Systemic Juvenile Idiopathic Arthritis (SJIA) ( 1.5 ) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis. Cytokine Release Syndrome (CRS) ( 1.6 ) Adults and pediatric patients 2 years of age and older with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome. Coronavirus Disease 2019 (COVID-19) ( 1.7 ) Hospitalized adult patients with coronavirus disease 2019 (COVID-19) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO). uuid:479a45c8-6332-4548-8a69-6b7c442ccd3b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:I031V2H011 biolink:treats MONDO:0018456 PMID:41385096 "[{""id"":""uuid:b0216a6a-1524-45d5-b127-d2201be2f8d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f1c002f9-9320-4be0-a74c-4bae415fe1cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:793f7103-ffea-4dae-912d-7b9eb28f1657"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/roactemra""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ACTEMRA ® (tocilizumab) is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of: Rheumatoid Arthritis (RA) ( 1.1 ) Adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). Giant Cell Arteritis (GCA) ( 1.2 ) Adult patients with giant cell arteritis. Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) ( 1.3 ) Slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) Polyarticular Juvenile Idiopathic Arthritis (PJIA) ( 1.4 ) Patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis. Systemic Juvenile Idiopathic Arthritis (SJIA) ( 1.5 ) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis. Cytokine Release Syndrome (CRS) ( 1.6 ) Adults and pediatric patients 2 years of age and older with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome. Coronavirus Disease 2019 (COVID-19) ( 1.7 ) Hospitalized adult patients with coronavirus disease 2019 (COVID-19) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).|[EMA] RoActemra, in combination with methotrexate (MTX), is indicated forthe treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with MTX.the treatment of moderate to severe active RA in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists.In these patients, RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.RoActemra has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function when given in combination with methotrexate.RoActemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients 1 year of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids. RoActemra can be given as monotherapy (in case of intolerance to MTX or where treatment with MTX is inappropriate) or in combination with MTX.RoActemra in combination with methotrexate (MTX) is indicated for the treatment of juvenile idiopathic polyarthritis (pJIA; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with MTX. RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.RoActemra is indicated for the treatment of Giant Cell Arteritis (GCA) in adult patients.RoActemra, in combination with methotrexate (MTX), is indicated for:the treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with MTX.the treatment of moderate to severe active RA in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists.In these patients, RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate. RoActemra has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function when given in combination with methotrexate.RoActemra is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.RoActemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients 2 years of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids. RoActemra can be given as monotherapy (in case of intolerance to MTX or where treatment with MTX is inappropriate) or in combination with MTX.RoActemra in combination with methotrexate (MTX) is indicated for the treatment of juvenile idiopathic polyarthritis (pJIA; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with MTX. RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.RoActemra is indicated for the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and paediatric patients 2 years of age and older.RoActemra, in combination with methotrexate (MTX), is indicated for:the treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with MTX.the treatment of moderate to severe active RA in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists.In these patients, RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate. RoActemra has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function when given in combination with methotrexate.RoActemra is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.RoActemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients 2 years of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids. RoActemra can be given as monotherapy (in case of intolerance to MTX or where treatment with MTX is inappropriate) or in combination with MTX.RoActemra in combination with methotrexate (MTX) is indicated for the treatment of juvenile idiopathic polyarthritis (pJIA; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with MTX. RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.RoActemra is indicated for the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and paediatric patients 2 years of age and older. uuid:0754985e-2108-4c15-9461-837c927a0644 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:I031V2H011 biolink:treats MONDO:0019434 PMID:41385096 "[{""id"":""uuid:77c1ae57-ced3-49d6-a651-cfe9ee7bb53f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ead17ed8-b398-4725-86ef-6cf9c5928736"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3e74bacf-b98a-4319-8d9e-fcacd2fc3ae1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/roactemra""]},{""id"":""uuid:e1eda6f4-2521-43d4-8bd9-c164e303fbab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ACTEMRA ® (tocilizumab) is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of: Rheumatoid Arthritis (RA) ( 1.1 ) Adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). Giant Cell Arteritis (GCA) ( 1.2 ) Adult patients with giant cell arteritis. Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) ( 1.3 ) Slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) Polyarticular Juvenile Idiopathic Arthritis (PJIA) ( 1.4 ) Patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis. Systemic Juvenile Idiopathic Arthritis (SJIA) ( 1.5 ) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis. Cytokine Release Syndrome (CRS) ( 1.6 ) Adults and pediatric patients 2 years of age and older with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome. Coronavirus Disease 2019 (COVID-19) ( 1.7 ) Hospitalized adult patients with coronavirus disease 2019 (COVID-19) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).|[EMA] RoActemra, in combination with methotrexate (MTX), is indicated forthe treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with MTX.the treatment of moderate to severe active RA in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists.In these patients, RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.RoActemra has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function when given in combination with methotrexate.RoActemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients 1 year of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids. RoActemra can be given as monotherapy (in case of intolerance to MTX or where treatment with MTX is inappropriate) or in combination with MTX.RoActemra in combination with methotrexate (MTX) is indicated for the treatment of juvenile idiopathic polyarthritis (pJIA; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with MTX. RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.RoActemra is indicated for the treatment of Giant Cell Arteritis (GCA) in adult patients.RoActemra, in combination with methotrexate (MTX), is indicated for:the treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with MTX.the treatment of moderate to severe active RA in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists.In these patients, RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate. RoActemra has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function when given in combination with methotrexate.RoActemra is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.RoActemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients 2 years of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids. RoActemra can be given as monotherapy (in case of intolerance to MTX or where treatment with MTX is inappropriate) or in combination with MTX.RoActemra in combination with methotrexate (MTX) is indicated for the treatment of juvenile idiopathic polyarthritis (pJIA; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with MTX. RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.RoActemra is indicated for the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and paediatric patients 2 years of age and older.RoActemra, in combination with methotrexate (MTX), is indicated for:the treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with MTX.the treatment of moderate to severe active RA in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists.In these patients, RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate. RoActemra has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function when given in combination with methotrexate.RoActemra is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.RoActemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients 2 years of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids. RoActemra can be given as monotherapy (in case of intolerance to MTX or where treatment with MTX is inappropriate) or in combination with MTX.RoActemra in combination with methotrexate (MTX) is indicated for the treatment of juvenile idiopathic polyarthritis (pJIA; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with MTX. RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.RoActemra is indicated for the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and paediatric patients 2 years of age and older.|[PMDA] Drugs with a new indication and a new dosage in a new dosage form for the treatment of rheumatoid arthritis (including prevention of structural damage of joint) that cannot be treated sufficiently with conventional therapies, active juvenile idiopathic arthritis in multiple joints, and systemic juvenile idiopathic arthritis. [Priority review] [Expedited review] uuid:ea9c0141-a2a1-4b28-a9d4-166dff96aff4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:I031V2H011 biolink:treats MONDO:0600008 PMID:41385096 "[{""id"":""uuid:a0b153c8-50cb-424b-84da-929c0c10987a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8d9d69f8-8a6b-4285-b1da-684121682dc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:05213ae0-6d3a-4c25-a1e6-f14c6ececbf7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/roactemra""]},{""id"":""uuid:bc7b169c-029d-4849-ac61-c6bdfe0707c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ACTEMRA ® (tocilizumab) is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of: Rheumatoid Arthritis (RA) ( 1.1 ) Adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). Giant Cell Arteritis (GCA) ( 1.2 ) Adult patients with giant cell arteritis. Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) ( 1.3 ) Slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) Polyarticular Juvenile Idiopathic Arthritis (PJIA) ( 1.4 ) Patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis. Systemic Juvenile Idiopathic Arthritis (SJIA) ( 1.5 ) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis. Cytokine Release Syndrome (CRS) ( 1.6 ) Adults and pediatric patients 2 years of age and older with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome. Coronavirus Disease 2019 (COVID-19) ( 1.7 ) Hospitalized adult patients with coronavirus disease 2019 (COVID-19) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).|[EMA] RoActemra, in combination with methotrexate (MTX), is indicated forthe treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with MTX.the treatment of moderate to severe active RA in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists.In these patients, RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.RoActemra has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function when given in combination with methotrexate.RoActemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients 1 year of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids. RoActemra can be given as monotherapy (in case of intolerance to MTX or where treatment with MTX is inappropriate) or in combination with MTX.RoActemra in combination with methotrexate (MTX) is indicated for the treatment of juvenile idiopathic polyarthritis (pJIA; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with MTX. RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.RoActemra is indicated for the treatment of Giant Cell Arteritis (GCA) in adult patients.RoActemra, in combination with methotrexate (MTX), is indicated for:the treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with MTX.the treatment of moderate to severe active RA in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists.In these patients, RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate. RoActemra has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function when given in combination with methotrexate.RoActemra is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.RoActemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients 2 years of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids. RoActemra can be given as monotherapy (in case of intolerance to MTX or where treatment with MTX is inappropriate) or in combination with MTX.RoActemra in combination with methotrexate (MTX) is indicated for the treatment of juvenile idiopathic polyarthritis (pJIA; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with MTX. RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.RoActemra is indicated for the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and paediatric patients 2 years of age and older.RoActemra, in combination with methotrexate (MTX), is indicated for:the treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with MTX.the treatment of moderate to severe active RA in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists.In these patients, RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate. RoActemra has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function when given in combination with methotrexate.RoActemra is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.RoActemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients 2 years of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids. RoActemra can be given as monotherapy (in case of intolerance to MTX or where treatment with MTX is inappropriate) or in combination with MTX.RoActemra in combination with methotrexate (MTX) is indicated for the treatment of juvenile idiopathic polyarthritis (pJIA; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with MTX. RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.RoActemra is indicated for the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and paediatric patients 2 years of age and older.|[PMDA] Drugs with a new indication for the treatment of cytokine release syndrome induced by the treatment for malignant tumor. uuid:cd264932-70d2-4396-a750-c8ee7a304334 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:I031V2H011 biolink:treats MONDO:0100096 PMID:41385096 "[{""id"":""uuid:d91ceb00-39d8-4550-b5e7-696525162cf6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9a2e1af8-657e-4940-8898-a00714bdab21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f0456b0d-fed8-45d5-8a2b-56c12cc78e19"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/roactemra""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ACTEMRA ® (tocilizumab) is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of: Rheumatoid Arthritis (RA) ( 1.1 ) Adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more Disease-Modifying Anti-Rheumatic Drugs (DMARDs). Giant Cell Arteritis (GCA) ( 1.2 ) Adult patients with giant cell arteritis. Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD) ( 1.3 ) Slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) Polyarticular Juvenile Idiopathic Arthritis (PJIA) ( 1.4 ) Patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis. Systemic Juvenile Idiopathic Arthritis (SJIA) ( 1.5 ) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis. Cytokine Release Syndrome (CRS) ( 1.6 ) Adults and pediatric patients 2 years of age and older with chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome. Coronavirus Disease 2019 (COVID-19) ( 1.7 ) Hospitalized adult patients with coronavirus disease 2019 (COVID-19) who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).|[EMA] RoActemra, in combination with methotrexate (MTX), is indicated forthe treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with MTX.the treatment of moderate to severe active RA in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists.In these patients, RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.RoActemra has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function when given in combination with methotrexate.RoActemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients 1 year of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids. RoActemra can be given as monotherapy (in case of intolerance to MTX or where treatment with MTX is inappropriate) or in combination with MTX.RoActemra in combination with methotrexate (MTX) is indicated for the treatment of juvenile idiopathic polyarthritis (pJIA; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with MTX. RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.RoActemra is indicated for the treatment of Giant Cell Arteritis (GCA) in adult patients.RoActemra, in combination with methotrexate (MTX), is indicated for:the treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with MTX.the treatment of moderate to severe active RA in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists.In these patients, RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate. RoActemra has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function when given in combination with methotrexate.RoActemra is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.RoActemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients 2 years of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids. RoActemra can be given as monotherapy (in case of intolerance to MTX or where treatment with MTX is inappropriate) or in combination with MTX.RoActemra in combination with methotrexate (MTX) is indicated for the treatment of juvenile idiopathic polyarthritis (pJIA; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with MTX. RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.RoActemra is indicated for the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and paediatric patients 2 years of age and older.RoActemra, in combination with methotrexate (MTX), is indicated for:the treatment of severe, active and progressive rheumatoid arthritis (RA) in adults not previously treated with MTX.the treatment of moderate to severe active RA in adult patients who have either responded inadequately to, or who were intolerant to, previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) or tumour necrosis factor (TNF) antagonists.In these patients, RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate. RoActemra has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function when given in combination with methotrexate.RoActemra is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation.RoActemra is indicated for the treatment of active systemic juvenile idiopathic arthritis (sJIA) in patients 2 years of age and older, who have responded inadequately to previous therapy with NSAIDs and systemic corticosteroids. RoActemra can be given as monotherapy (in case of intolerance to MTX or where treatment with MTX is inappropriate) or in combination with MTX.RoActemra in combination with methotrexate (MTX) is indicated for the treatment of juvenile idiopathic polyarthritis (pJIA; rheumatoid factor positive or negative and extended oligoarthritis) in patients 2 years of age and older, who have responded inadequately to previous therapy with MTX. RoActemra can be given as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.RoActemra is indicated for the treatment of chimeric antigen receptor (CAR) T cell-induced severe or life-threatening cytokine release syndrome (CRS) in adults and paediatric patients 2 years of age and older. uuid:290b372c-30b1-4e56-9a4e-aae05c2466ce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231350 biolink:treats MONDO:0009692 PMID:41385096 "[{""id"":""uuid:52bc6146-3fca-4dfb-9c05-16f636940f00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a293b0e3-b1f6-421f-9628-12484fa2c3a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VONJO is indicated for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF) with a platelet count below 50 × 10 9 /L. This indication is approved under accelerated approval based on spleen volume reduction [see Clinical Studies (14.2)] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). uuid:22e81012-1f43-4af2-9a15-c47d7af1c16b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64213 biolink:treats MONDO:0005855 PMID:41385096 "[{""id"":""uuid:7d194f01-f33f-4b4c-bf28-14633ee6a10b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:af8f6bec-2cf4-4311-a3c9-daf3ab6b6a3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] YCANTH is indicated for the topical treatment of molluscum contagiosum in adult and pediatric patients 2 years of age and older. uuid:dd62eae5-c067-4a4f-9bb1-3df21337e553 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1090966 biolink:treats MONDO:0001356 PMID:41385096 "[{""id"":""uuid:44d7c74b-bb6f-4848-a4d3-7bba30325f72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3fb09fc7-d0db-41f2-ad00-459a42aec182"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Davimet™ with Iron Multivitamin Chewable Tablets are indicated for the treatment of iron deficiency anemia and folate deficiency, commonly seen in conditionssuch as extended convalescence, menorrhagia, pregnancy, puberty, excessive blood loss, and advanced age. They are also indicated for condition in which irondeficiency and vitamin C deficiency occur together, along with a deficient intake or increased need for B-Complex vitamins in chronic and acute illness, as well as casesof metabolic stress, and in convalescence. uuid:20376345-74fb-4ad6-8fb7-e81a90e4c6a5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82975 biolink:treats MONDO:0100187 PMID:41385096 "[{""id"":""uuid:c0c87f2e-1ff8-4da1-a3c9-797fde83016d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:8f14dec2-5d81-4348-b408-67d309978136"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1c3d63d6-a779-488e-b938-2778dbc7ca9a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MOVANTIK ® is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation.|[EMA] Treatment of opioid-induced constipation (OIC) in adult patients who have had an inadequate response to laxative(s). uuid:0f46df11-947e-42fb-ae07-f12cab69d4b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82975 biolink:treats HP:0012532 PMID:41385096 "[{""id"":""uuid:8df058f3-5ffc-4532-a657-67602c6795ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6d8c9e56-5ef3-4906-9fce-169704bac683"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MOVANTIK ® is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. uuid:a4318759-a366-4e77-a1d6-4eb9a8d9b22f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82975 biolink:treats EFO:0801084 PMID:41385096 "[{""id"":""uuid:93bc631c-52cb-49eb-a76f-1b87a1e700df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2f8de6ac-49b1-4ab1-ae8c-83c95ae85d54"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MOVANTIK ® is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. uuid:5ab4c1ca-8efb-41b7-8e6f-58f6f6c60a50 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:54534MX6Z9 biolink:treats UMLS:C5577628 PMID:41385096 "[{""id"":""uuid:f8e44bb8-c591-4338-af52-2bb762e6c65b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4a4dd628-2c93-4387-a116-7d5cdd6e8a1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TECVAYLI is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody. This indication is approved under accelerated approval based on response rate [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). uuid:709fe00e-384f-47ca-a94b-4874d1ab7787 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:54534MX6Z9 biolink:treats UMLS:C4551538 PMID:41385096 "[{""id"":""uuid:5a3105c9-9454-4689-a3bc-9ef7d8acbf41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ea500753-1e81-4aea-8b8c-7fadf12c7e8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TECVAYLI is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody. This indication is approved under accelerated approval based on response rate [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). uuid:2bec96a6-08c2-4b19-897b-1a26d30c768f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4H5YMK1H2E biolink:treats EFO:0009130 PMID:41385096 "[{""id"":""uuid:df271950-2feb-481f-83bf-3d350af39633"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:190124d3-fec1-4497-833d-98ce5e9d2b87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2c024639-1480-4a08-be54-adfa089cbc18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZINPLAVA™ is indicated to reduce recurrence of Clostridioides difficile infection (CDI) in adults and pediatric patients 1 year of age and older who are receiving antibacterial drug treatment for CDI and are at a high risk for CDI recurrence.|[PMDA] A drug with a new active ingredient indicated for the prevention of recurrent Clostridium difficile infection. uuid:9467d610-17b6-479a-ac72-17c3d11d2b7c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4H5YMK1H2E biolink:treats MONDO:0019846 PMID:41385096 "[{""id"":""uuid:a01c8c6b-0f32-4a6f-9893-9a2092346d33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:391c8225-f870-4fe9-997d-6346fdb1e738"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZINPLAVA™ is indicated to reduce recurrence of Clostridioides difficile infection (CDI) in adults and pediatric patients 1 year of age and older who are receiving antibacterial drug treatment for CDI and are at a high risk for CDI recurrence. uuid:7d167a28-a54e-43ff-a849-48f066b48bdb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45716 biolink:treats MONDO:0015758 PMID:41385096 "[{""id"":""uuid:4619587b-6793-48ce-9425-8397190e73e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:de004435-363a-4b56-8637-9786bb16ac69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f4d94684-dbf5-4bf6-a993-27a0ba2c1296"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZOLINZA ® is indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma who have progressive, persistent or recurrent disease on or following two systemic therapies.|[PMDA] A drug with a new active ingredient indicated for the treatment of cutaneous T-cell lymphoma. uuid:a4b4238a-a524-47ab-b469-b5e844d34a9f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4724 biolink:treats HP:0000155 PMID:41385096 "[{""id"":""uuid:5e9e7469-aa5e-4eac-8349-b66aad3a189f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dae9b1df-385d-4a60-8ead-3a57aa68a9a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dyclonine HCl Topical Solution, USP is indicated for anesthetizing accessible mucous membranes (e.g., the mouth, pharynx, larynx, trachea, esophagus, and urethra) prior to various endoscopic procedures. Dyclonine HCl Topical Solution, USP, 0.5% topical anesthetic may also be used to block the gag reflex, to relieve the pain of oral ulcers or stomatitis and to relieve pain associated with ano-genital lesions. uuid:c226108c-a493-4816-8395-9ae6f60b46ac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4724 biolink:treats MONDO:0004842 PMID:41385096 "[{""id"":""uuid:9d2a50b1-92fe-4c87-8f49-5da419dfeff7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:20517f5c-e3d8-44e5-99fc-95d4f9a39641"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dyclonine HCl Topical Solution, USP is indicated for anesthetizing accessible mucous membranes (e.g., the mouth, pharynx, larynx, trachea, esophagus, and urethra) prior to various endoscopic procedures. Dyclonine HCl Topical Solution, USP, 0.5% topical anesthetic may also be used to block the gag reflex, to relieve the pain of oral ulcers or stomatitis and to relieve pain associated with ano-genital lesions. uuid:e8169f19-921b-4725-b995-c3b54c4a1c42 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4724 biolink:treats MONDO:0005647 PMID:41385096 "[{""id"":""uuid:4a030cda-13d6-449f-92aa-8e10200f0ae4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6b944abc-8ab0-4c97-ba9e-17a3b2c9da6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dyclonine HCl Topical Solution, USP is indicated for anesthetizing accessible mucous membranes (e.g., the mouth, pharynx, larynx, trachea, esophagus, and urethra) prior to various endoscopic procedures. Dyclonine HCl Topical Solution, USP, 0.5% topical anesthetic may also be used to block the gag reflex, to relieve the pain of oral ulcers or stomatitis and to relieve pain associated with ano-genital lesions. uuid:933b22b6-cc52-46e1-85c8-a43ecd08dc32 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:52172 biolink:treats MONDO:0011996 PMID:41385096 "[{""id"":""uuid:d6ba6513-d08d-4d6a-a1c2-f884802322f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9aff5965-104a-403d-9947-3920180bdc72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b2aa2b10-b2f1-4be1-84e9-c705f9f0a049"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tasigna""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] DANZITEN is a kinase inhibitor indicated for the treatment of: • Adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. ( 1.1 ) • Adult patients with chronic phase (CP) and accelerated phase (AP) Ph+ CML resistant to or intolerant to prior therapy that included imatinib. ( 1.2 )|[EMA] Tasigna is indicated for the treatment of:adult and paediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia (CML) in the chronic phase,paediatric patients with Philadelphia chromosome positive CML in chronic phase with resistance or intolerance to prior therapy including imatinib.Tasigna is indicated for the treatment of:adult and paediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia (CML) in the chronic phase,adult patients with chronic phase and accelerated phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib. Efficacy data in patients with CML in blast crisis are not available,paediatric patients with chronic phase Philadelphia chromosome positive CML with resistance or intolerance to prior therapy including imatinib. uuid:6803dec4-2225-4af3-bb52-e18e029470a3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:52172 biolink:treats MONDO:0021367 PMID:41385096 "[{""id"":""uuid:7ce9e956-c107-461b-920f-ed278eaf08ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:272fcca9-3a37-4344-93e8-f203e8d63f22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DANZITEN is a kinase inhibitor indicated for the treatment of: • Adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase. ( 1.1 ) • Adult patients with chronic phase (CP) and accelerated phase (AP) Ph+ CML resistant to or intolerant to prior therapy that included imatinib. ( 1.2 ) uuid:19b1415b-4622-4979-aef1-017d41d18ef8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:375139 biolink:treats NCIT:C50743 PMID:41385096 "[{""id"":""uuid:01f21f0a-c5dd-42db-93fc-15b3a3b692c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b0de4631-2f18-4bad-94b4-a33ea09c3356"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the temporary relief of pain and itching associated with minor burns, sunburn, minor cuts, scrapes, insect bites, and minor skin irritation. This formulation can be used to assist patients in the treatment of mild to moderate acute or chronic aches or pain. Muscle or joint pain can be due to musculoligamentous strains, simple backache, tendonitis, osteoarthritis, rheumatoid arthritis, peripheral neuropathies such as diabetic neuropathy or post herpetic neuralgia, and other complex regional pains. If consulted by your physician, it may be used for other conditions as well. If consulted by your physician, it may be used for other conditions as well. uuid:c8421588-5a53-4a5d-8f96-0a72997bfe27 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:375139 biolink:treats UMLS:C0080194 PMID:41385096 "[{""id"":""uuid:10c9e409-da83-4c33-b708-2104297d3789"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2356114c-7a1f-44e7-90e2-d718876cca07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the temporary relief of pain and itching associated with minor burns, sunburn, minor cuts, scrapes, insect bites, and minor skin irritation. This formulation can be used to assist patients in the treatment of mild to moderate acute or chronic aches or pain. Muscle or joint pain can be due to musculoligamentous strains, simple backache, tendonitis, osteoarthritis, rheumatoid arthritis, peripheral neuropathies such as diabetic neuropathy or post herpetic neuralgia, and other complex regional pains. If consulted by your physician, it may be used for other conditions as well. If consulted by your physician, it may be used for other conditions as well. uuid:aa7ef18b-21ff-45f2-afc8-c0bc38b54e9e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:375139 biolink:treats MONDO:0002321 PMID:41385096 "[{""id"":""uuid:48ed20b8-4564-4028-928f-2ab3ea4f38b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:92b400d4-6599-49f7-9a28-1891ade15a7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the temporary relief of pain and itching associated with minor burns, sunburn, minor cuts, scrapes, insect bites, and minor skin irritation. This formulation can be used to assist patients in the treatment of mild to moderate acute or chronic aches or pain. Muscle or joint pain can be due to musculoligamentous strains, simple backache, tendonitis, osteoarthritis, rheumatoid arthritis, peripheral neuropathies such as diabetic neuropathy or post herpetic neuralgia, and other complex regional pains. If consulted by your physician, it may be used for other conditions as well. If consulted by your physician, it may be used for other conditions as well. uuid:cfb6219e-54c2-4eeb-a07e-225571839ca2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:S51J6N56M7 biolink:treats MONDO:0012084 PMID:41385096 "[{""id"":""uuid:711d7906-2c6f-4d2c-8c75-4bfef3db9426"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:577b445f-4e39-4599-a245-c4a773d1b270"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:491f71b7-e501-482e-ab28-341418ce2bce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/upstaza""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEBILIDI (eladocagene exuparvovec-tneq) is an adeno-associated virus (AAV) vector-based gene therapy indicated for the treatment of adult and pediatric patients with aromatic L-amino acid decarboxylase (AADC) deficiency. This indication is approved under accelerated approval based on the change from baseline in gross motor milestone achievement at 48 weeks post treatment [see Clinical Studies ( 14 )] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial.|[EMA] Upstaza is indicated for the treatment of patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic L amino acid decarboxylase (AADC) deficiency with a severe phenotype (see section 5.1). uuid:9a14dff3-58ac-4160-8b0b-895cb330aa1f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3756 biolink:treats MONDO:0010826 PMID:41385096 "[{""id"":""uuid:226da882-86d3-4285-8eae-b8cd90a94893"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:547d7e84-24fa-4a3f-b49f-d2055609735e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Klonopin is useful alone or as an adjunct in the treatment of the Lennox-Gastaut syndrome (petit mal variant), akinetic, and myoclonic seizures. In patients with absence seizures (petit mal) who have failed to respond to succinimides, Klonopin may be useful. Some loss of effect may occur during the course of clonazepam treatment (see PRECAUTIONS: Loss of Effect ). uuid:688a8399-016a-4125-8627-3aaa64d9fde3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2DJ8R0NT7K biolink:treats MONDO:0018912 PMID:41385096 "[{""id"":""uuid:1fa8f778-57d3-4f24-874d-e8f274e3073f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3d805caf-0f77-4bee-9ae9-127077542ba2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RECORLEV is indicated for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative. Limitations of Use RECORLEV is not approved for the treatment of fungal infections. The safety and effectiveness of RECORLEV for the treatment of fungal infections have not been established. uuid:c8c423d3-9690-43ba-9938-c10853b8c839 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2DJ8R0NT7K biolink:treats MONDO:0002041 PMID:41385096 "[{""id"":""uuid:bfa4c063-8695-4814-80df-596f8dcfa300"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:de590726-715a-41c7-a912-a29dc8682190"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RECORLEV is indicated for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome for whom surgery is not an option or has not been curative. Limitations of Use RECORLEV is not approved for the treatment of fungal infections. The safety and effectiveness of RECORLEV for the treatment of fungal infections have not been established. uuid:15aec38b-6a4f-4ae2-a678-0ab51a11bbff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5108 biolink:treats MONDO:0020283 PMID:41385096 "[{""id"":""uuid:cd62ccdf-c9e1-4fea-8673-e5253dc9ba71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1fbfd37a-b34a-4f7d-a033-f4b1739fc1a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] YUTIQ ® (fluocinolone acetonide intravitreal implant) 0.18 mg is indicated for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. uuid:f42cbc75-a5a1-4e0d-bbb7-754f6b2b483b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:KG6VO684Z6 biolink:treats MONDO:0018905 PMID:41385096 "[{""id"":""uuid:f73057c6-5433-43e6-808d-ae52d2c3784d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f9b2f866-6f6f-4793-9f7d-d22e9aff9d26"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7a5258d5-cb82-41eb-924e-845d5d742b1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/polivy""]},{""id"":""uuid:3df8db83-0784-4667-a315-69846da68dfb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] POLIVY is a CD79b-directed antibody and microtubule inhibitor conjugate indicated: in combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index score of 2 or greater. ( 1.1 ) in combination with bendamustine and a rituximab product for the treatment of adult patients with relapsed or refractory DLBCL, NOS, after at least two prior therapies. ( 1.2 )|[EMA] Polivy in combination with bendamustine and rituximab is indicated for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant.Polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) is indicated for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL).|[PMDA] Drugs with a new indication and a new dosage for the treatment of diffuse large B-cell lymphoma. [Orphan drug] uuid:bdb645e0-04f7-4716-bee3-c38d46806e4a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:KG6VO684Z6 biolink:treats MONDO:0044889 PMID:41385096 "[{""id"":""uuid:2999d28f-ffb8-4df0-ae26-6d8d0ea24f2d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6cee598f-7435-4abb-ab80-65b89395976a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] POLIVY is a CD79b-directed antibody and microtubule inhibitor conjugate indicated: in combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index score of 2 or greater. ( 1.1 ) in combination with bendamustine and a rituximab product for the treatment of adult patients with relapsed or refractory DLBCL, NOS, after at least two prior therapies. ( 1.2 ) uuid:06b1de06-404e-49fc-9bef-005e9e3dbe06 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:KG6VO684Z6 biolink:treats MONDO:0000901 PMID:41385096 "[{""id"":""uuid:d249af08-2757-42ff-8293-cd44dd60b54e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:38ab8061-1ee1-498c-b6f9-77a73e6cf997"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:29692705-45a3-465a-a4b3-906660a89aca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/polivy""]},{""id"":""uuid:6c468013-9fec-492a-8636-d5be0e8d22b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] POLIVY is a CD79b-directed antibody and microtubule inhibitor conjugate indicated: in combination with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for the treatment of adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index score of 2 or greater. ( 1.1 ) in combination with bendamustine and a rituximab product for the treatment of adult patients with relapsed or refractory DLBCL, NOS, after at least two prior therapies. ( 1.2 )|[EMA] Polivy in combination with bendamustine and rituximab is indicated for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who are not candidates for haematopoietic stem cell transplant.Polivy in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) is indicated for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma (DLBCL).|[PMDA] Drugs with a new active ingredient indicated for the treatment of relapsed or refractory diffuse large B-cell lymphoma. [Orphan drug] uuid:03dfbf66-5d97-479d-8d48-a913104bfe15 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2382602 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:f420d29c-968a-4e56-b8cb-19f21c580f0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:70f162d9-eb42-42dd-9ce1-8a0c452d3aa7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c017f0cc-6959-4013-933b-6dd956039949"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PHESGO is a combination of pertuzumab and trastuzumab, HER2/neu receptor antagonists, and hyaluronidase, an endoglycosidase, indicated for: Use in combination with chemotherapy as: neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. ( 1.1 ) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence ( 1.1 ) Use in combination with docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. ( 1.2 )|[PMDA] New combination drugs with a new active ingredient indicated for the treatment of HER2- positive breast cancer and unresectable advanced or recurrent HER2-positive colon or rectal cancer that has progressed after cancer chemotherapy. uuid:402a02a4-b56e-4bac-af19-dec907502ffa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2382602 biolink:treats UMLS:C0278488 PMID:41385096 "[{""id"":""uuid:5e4341b2-02a1-4940-b173-1a4816d071b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2256f8ef-db65-4674-ace1-2a5994166698"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PHESGO is a combination of pertuzumab and trastuzumab, HER2/neu receptor antagonists, and hyaluronidase, an endoglycosidase, indicated for: Use in combination with chemotherapy as: neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. ( 1.1 ) adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence ( 1.1 ) Use in combination with docetaxel for treatment of patients with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. ( 1.2 ) uuid:59d8c693-c4a5-46ce-a6cd-9804690cc707 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90933 biolink:treats MONDO:0005090 PMID:41385096 "[{""id"":""uuid:da60e946-abe6-43b6-b45e-9493c5dd67f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:11fb0948-a6a0-4305-b654-b12f87a2eabd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:432d25ff-53aa-4380-9ae6-ddc1b9fc7473"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VRAYLAR ® is indicated for: Treatment of schizophrenia in adults [see Clinical Studies ( 14.1 )] Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults [see Clinical Studies ( 14.2 )] Treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adults [see Clinical Studies ( 14.3 )] Adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults [see Clinical Studies ( 14.4 )]|[EMA] Reagila is indicated for the treatment of schizophrenia in adult patients. uuid:dfddca85-3403-4af9-bdf5-fdf1a21db43d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90933 biolink:treats MONDO:0001866 PMID:41385096 "[{""id"":""uuid:ebb04a2e-87af-480d-9f68-3154f364b80f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:05c24752-aa84-4e60-9e0c-cedece902804"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VRAYLAR ® is indicated for: Treatment of schizophrenia in adults [see Clinical Studies ( 14.1 )] Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults [see Clinical Studies ( 14.2 )] Treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adults [see Clinical Studies ( 14.3 )] Adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults [see Clinical Studies ( 14.4 )] uuid:75d44a1b-2fea-4334-b87f-fd94ec4771b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90933 biolink:treats MONDO:0024613 PMID:41385096 "[{""id"":""uuid:eb206771-95d9-4856-9f37-9c017c7d1b63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3f536175-4f87-4ddf-88ec-ffca81a01b8e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VRAYLAR ® is indicated for: Treatment of schizophrenia in adults [see Clinical Studies ( 14.1 )] Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults [see Clinical Studies ( 14.2 )] Treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adults [see Clinical Studies ( 14.3 )] Adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults [see Clinical Studies ( 14.4 )] uuid:ab236ab0-b230-4b53-b060-0e523be838a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90933 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:9f592112-15e0-4be7-83b2-d21f00192a6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4ff29b8f-ad14-4b07-a050-255cc6805fd8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VRAYLAR ® is indicated for: Treatment of schizophrenia in adults [see Clinical Studies ( 14.1 )] Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults [see Clinical Studies ( 14.2 )] Treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adults [see Clinical Studies ( 14.3 )] Adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults [see Clinical Studies ( 14.4 )] uuid:93ac70da-b38b-4ca5-9c47-f86bde866a95 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:95341 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:8e3b78f8-e509-436c-a4ca-19cf2850e1f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f5f63d5c-7366-4e05-995a-bbe054607160"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e495b605-aafb-45b8-acac-88459bf8a2d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/olumiant""]},{""id"":""uuid:c15567fb-9081-4338-90ae-8b45336a6901"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OLUMIANT ® is a Janus kinase (JAK) inhibitor indicated for: the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF blockers. ( 1.1 ) Limitations of Use : Not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.1 ) the treatment of COVID-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or ECMO. ( 1.2 ) the treatment of adult patients with severe alopecia areata. ( 1.3 ) Limitations of Use : Not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants. ( 1.3 )|[EMA] Rheumatoid arthritisBaricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (DMARDs). Olumiant may be used as monotherapy or in combination with methotrexate.Atopic DermatitisOlumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy.Alopecia areataBaricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5.1).Juvenile idiopathic arthritisBaricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic DMARDs:- Polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [RF+] or negative [RF-], extended oligoarticular),- Enthesitis related arthritis, and- Juvenile psoriatic arthritis.Baricitinib may be used as monotherapy or in combination with methotrexate.|[PMDA] Drugs with a new active ingredient indicated for the treatment of rheumatoid arthritis (including prevention of structural joint damage) in patients who have not responded sufficiently to conventional treatments. uuid:3a2a35b0-fa3c-4015-bcf7-49b76175a2e1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:95341 biolink:treats MONDO:0100096 PMID:41385096 "[{""id"":""uuid:35b926ad-a84c-4ec5-852e-ad427488af07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8f43a7d2-0e2a-445a-b0df-45cff9963bee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OLUMIANT ® is a Janus kinase (JAK) inhibitor indicated for: the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF blockers. ( 1.1 ) Limitations of Use : Not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.1 ) the treatment of COVID-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or ECMO. ( 1.2 ) the treatment of adult patients with severe alopecia areata. ( 1.3 ) Limitations of Use : Not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants. ( 1.3 ) uuid:19292342-f32c-4bd8-b3e5-ef93bf091d55 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:95341 biolink:treats MONDO:0005340 PMID:41385096 "[{""id"":""uuid:4001e120-3904-4135-8111-2bbe151d4c0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:eeb5b6c1-0506-43b7-91b6-3fb4f82397af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3b61d707-493f-4c4e-bb17-d6635fd345f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/olumiant""]},{""id"":""uuid:8dbe57fc-1a9b-4be6-9112-85d538d30198"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OLUMIANT ® is a Janus kinase (JAK) inhibitor indicated for: the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF blockers. ( 1.1 ) Limitations of Use : Not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.1 ) the treatment of COVID-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or ECMO. ( 1.2 ) the treatment of adult patients with severe alopecia areata. ( 1.3 ) Limitations of Use : Not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants. ( 1.3 )|[EMA] Rheumatoid arthritisBaricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (DMARDs). Olumiant may be used as monotherapy or in combination with methotrexate.Atopic DermatitisOlumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy.Alopecia areataBaricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5.1).Juvenile idiopathic arthritisBaricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic DMARDs:- Polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [RF+] or negative [RF-], extended oligoarticular),- Enthesitis related arthritis, and- Juvenile psoriatic arthritis.Baricitinib may be used as monotherapy or in combination with methotrexate.|[PMDA] Drugs with a new indication and a new dosage for the treatment of alopecia areata (for use only in patients with intractable and extensive alopecia areata). uuid:ca51c5b5-943d-48b9-b737-6e38b79958f5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50861 biolink:treats UMLS:C3697982 PMID:41385096 "[{""id"":""uuid:3afa856a-2d1e-4806-8081-9a00baa6bcf6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fd1263df-ee13-46da-bb3e-ecf3ff863d35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Orenitram is a prostacyclin mimetic indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1): To delay disease progression and to improve exercise capacity. The studies that established effectiveness included predominately patients with WHO functional class II-III symptoms and etiologies of idiopathic or heritable PAH (66%) or PAH associated with connective tissue disease (26%). ( 1.1 ) uuid:d657d7d2-9f81-4a9b-a38b-cb62cc16e50b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:953A26OA1Y biolink:treats MONDO:0009061 PMID:41385096 "[{""id"":""uuid:3a93081e-b99e-4667-a41e-cc4c4c4cd232"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a9f4400e-acce-40b8-9f6d-eaabc01ba778"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:5f518ba6-5aee-48e5-be0e-949f67f609ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PULMOZYME ® is indicated, in conjunction with standard therapies, for the management of pediatric and adult patients with cystic fibrosis (CF) to improve pulmonary function. In CF patients with an FVC ≥ 40% of predicted, daily administration of PULMOZYME has also been shown to reduce the risk of respiratory tract infections requiring parenteral antibiotics.|[PMDA] A drug with a new active ingredient indicated for the improvement of lung function in patients with cystic fibrosis. [Orphan drug] uuid:380b500d-4fac-4f5b-b18c-c2bedde2467d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:953A26OA1Y biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:fb09463c-cef7-413d-b3de-2019230841b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9e0d5ed7-0f33-44f0-9bd0-6ecf47abec90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PULMOZYME ® is indicated, in conjunction with standard therapies, for the management of pediatric and adult patients with cystic fibrosis (CF) to improve pulmonary function. In CF patients with an FVC ≥ 40% of predicted, daily administration of PULMOZYME has also been shown to reduce the risk of respiratory tract infections requiring parenteral antibiotics. uuid:0edc82e2-682e-40f3-b60c-0364df08ad89 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229220 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:1fcebf12-3016-4d61-aa3c-f17852f5b624"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:991c940c-b2e6-451c-9ac1-fd6a52a36237"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AUGTYRO is a kinase inhibitor indicated for the treatment of • adult patients with locally advanced or metastatic ROS1- positive non-small cell lung cancer (NSCLC). ( 1.1 ) • adult and pediatric patients 12 years of age and older with solid tumors that: • have a neurotrophic tyrosine receptor kinase ( NTRK ) gene fusion and • are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity. • have progressed following treatment or have no satisfactory alternative therapy. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. ( 1.2 ) uuid:22859d16-f466-4df4-bc2e-b46e59c36e5f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229220 biolink:treats UMLS:C0280100 PMID:41385096 "[{""id"":""uuid:f5c758a7-4d50-4979-8c00-2eec45c0d54f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:89516946-149e-4db4-8102-eff2b878bcb9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AUGTYRO is a kinase inhibitor indicated for the treatment of • adult patients with locally advanced or metastatic ROS1- positive non-small cell lung cancer (NSCLC). ( 1.1 ) • adult and pediatric patients 12 years of age and older with solid tumors that: • have a neurotrophic tyrosine receptor kinase ( NTRK ) gene fusion and • are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity. • have progressed following treatment or have no satisfactory alternative therapy. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. ( 1.2 ) uuid:d14e34ba-e1c4-4f9f-a257-c0c785ed62ee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6427 biolink:treats MONDO:0005133 PMID:41385096 "[{""id"":""uuid:06483286-d732-45e7-9767-6a253162f261"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f8a602b8-c6b7-468b-9b76-545d2185b268"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LUPRON DEPOT 3.75 mg is a gonadotropin-releasing hormone (GnRH) agonist indicated for: Endometriosis Management of endometriosis, including pain relief and reduction of endometriotic lesions. ( 1.1 ) In combination with a norethindrone acetate for initial management of the painful symptoms of endometriosis and for management of recurrence of symptoms. ( 1.1 ) Limitations of Use: The total duration of therapy with LUPRON DEPOT 3.75 mg plus add-back therapy should not exceed 12 months due to concerns about adverse impact on bone mineral density. ( 1.1 , 2.1 , 5.1 ) Uterine Leiomyomata (Fibroids) Concomitant use with iron therapy for preoperative hematologic improvement of women with anemia caused by fibroids for whom three months of hormonal suppression is deemed necessary. ( 1.2 ) Limitations of Use: LUPRON DEPOT 3.75 mg is not indicated for combination use with norethindrone acetate add-back therapy for the preoperative hematologic improvement of women with anemia caused by heavy menstrual bleeding due to fibroids. ( 1.2 ) uuid:f67ec006-6929-4aff-88d2-602d593e5ed6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:LDJ89SS0YG biolink:treats UMLS:C1335723 PMID:41385096 "[{""id"":""uuid:a19731ab-6178-4454-9e74-2615cc9f0d4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3b5589da-cd76-4ebe-a260-26b4108e4a96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LUNSUMIO is a bispecific CD20-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1.1 ) uuid:0a59cccd-56a8-4657-84af-c5b619fcacb4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2283226 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:a2725734-2228-4108-8218-fff0e7799081"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1d7255b7-7985-4ee6-8a78-15dcffa46d75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NEXLIZET, a combination of bempedoic acid and ezetimibe, is indicated: As an adjunct to diet, alone or in combination with other low-density lipoprotein cholesterol (LDL-C) lowering therapies, to reduce LDL-C in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH). The bempedoic acid component of NEXLIZET is indicated: To reduce the risk of myocardial infarction and coronary revascularization in adults who are unable to take recommended statin therapy (including those not taking a statin) with: established cardiovascular disease (CVD), or a high risk for a CVD event but without established CVD. uuid:828b7859-d680-497a-9c89-e97743736921 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2283226 biolink:treats UMLS:C0342882 PMID:41385096 "[{""id"":""uuid:261e1e8f-3360-4af9-a22f-7b8b87d42d0f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9bf9b24b-17c2-4166-b07d-4f1e2b1308c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NEXLIZET, a combination of bempedoic acid and ezetimibe, is indicated: As an adjunct to diet, alone or in combination with other low-density lipoprotein cholesterol (LDL-C) lowering therapies, to reduce LDL-C in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH). The bempedoic acid component of NEXLIZET is indicated: To reduce the risk of myocardial infarction and coronary revascularization in adults who are unable to take recommended statin therapy (including those not taking a statin) with: established cardiovascular disease (CVD), or a high risk for a CVD event but without established CVD. uuid:9f2cdefd-6f07-4887-afc9-0a40ebdff16b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2283226 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:286a950d-11dd-4031-aac1-e1533ef0ad1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1b236cdc-c999-4582-b16a-7643fa51a2b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NEXLIZET, a combination of bempedoic acid and ezetimibe, is indicated: As an adjunct to diet, alone or in combination with other low-density lipoprotein cholesterol (LDL-C) lowering therapies, to reduce LDL-C in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH). The bempedoic acid component of NEXLIZET is indicated: To reduce the risk of myocardial infarction and coronary revascularization in adults who are unable to take recommended statin therapy (including those not taking a statin) with: established cardiovascular disease (CVD), or a high risk for a CVD event but without established CVD. uuid:f3bfb227-390a-4f68-af17-046691903590 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2283226 biolink:treats MONDO:0004995 PMID:41385096 "[{""id"":""uuid:79fbce62-6abf-401f-905b-f11a791e62ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9b8eb9fd-4d5d-4673-a337-18671cf0a17b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NEXLIZET, a combination of bempedoic acid and ezetimibe, is indicated: As an adjunct to diet, alone or in combination with other low-density lipoprotein cholesterol (LDL-C) lowering therapies, to reduce LDL-C in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH). The bempedoic acid component of NEXLIZET is indicated: To reduce the risk of myocardial infarction and coronary revascularization in adults who are unable to take recommended statin therapy (including those not taking a statin) with: established cardiovascular disease (CVD), or a high risk for a CVD event but without established CVD. uuid:90e56c49-30dd-4b65-b6dd-95418c72f3fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:149601 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:15a6c6a7-9dc3-483d-b78d-3284f7e0c998"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:543c557a-8f3a-4de4-8bff-23089cde6bb2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NEXLETOL is indicated: To reduce the risk of myocardial infarction and coronary revascularization in adults who are unable to take recommended statin therapy (including those not taking a statin) with: established cardiovascular disease (CVD), or a high risk for a CVD event but without established CVD. As an adjunct to diet, in combination with other low-density lipoprotein cholesterol (LDL-C) lowering therapies, or alone when concomitant LDL-C lowering therapy is not possible, to reduce LDL-C in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH). uuid:59338932-d578-4ea1-b9f1-4052028f449c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:149601 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:d753bc7d-fc4a-4c59-95cc-d68a05cfdae8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d733cda3-6e4f-44f7-b7a4-e6985a961fa1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NEXLETOL is indicated: To reduce the risk of myocardial infarction and coronary revascularization in adults who are unable to take recommended statin therapy (including those not taking a statin) with: established cardiovascular disease (CVD), or a high risk for a CVD event but without established CVD. As an adjunct to diet, in combination with other low-density lipoprotein cholesterol (LDL-C) lowering therapies, or alone when concomitant LDL-C lowering therapy is not possible, to reduce LDL-C in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH). uuid:729d1cc7-97e9-41bc-aa18-252ff98d51f6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:149601 biolink:treats UMLS:C0342882 PMID:41385096 "[{""id"":""uuid:ad0e91fc-8377-4398-8ccf-33ef8a5623c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2666c992-9f64-4f71-98da-4ee77d412871"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NEXLETOL is indicated: To reduce the risk of myocardial infarction and coronary revascularization in adults who are unable to take recommended statin therapy (including those not taking a statin) with: established cardiovascular disease (CVD), or a high risk for a CVD event but without established CVD. As an adjunct to diet, in combination with other low-density lipoprotein cholesterol (LDL-C) lowering therapies, or alone when concomitant LDL-C lowering therapy is not possible, to reduce LDL-C in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH). uuid:da24d142-8802-452d-9e0a-8255ce657b34 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0005972 PMID:41385096 "[{""id"":""uuid:67844326-dff2-4cc7-9aea-9cc3057cd6f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:12169c94-92e8-4efa-b247-635d3c7f8fa5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline for injection and other antibacterial drugs, doxycycline for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers). Mycoplasma pneumoniae (PPLO, Eaton Agent). Agents of psittacosis and ornithosis. Agents of lymphogranuloma venereum and granuloma inguinale. The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram-negative microorganisms: Haemophilus ducreyi (chancroid) Yersinia pestis Francisella tularensis Bartonella bacilliformis Bacteroides species Vibrio cholerae and Campylobacte fetus Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli Enterobacter aerogenes Shigella species Acinetobacter species Haemophilus influenzae (respiratory infections) Klebsiella species (respiratory and urinary infections) Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Streptococcus pneumoniae Staphylococcus aureus , respiratory, skin and soft tissue infections. Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections. Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of infections due to: Neisseria gonorrhoeae and N. meningitidis Treponema pallidum and Treponema pallidum subspecies pertenue (syphilis and yaws) Listeria monocytogenes Clostridium species Fusobacterium fusiforme (Vincent’s infection) Actinomyces species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. Doxycycline is indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. uuid:5d660024-c0db-456e-b37e-43fa144fcc93 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16480 biolink:treats UMLS:C3805211 PMID:41385096 "[{""id"":""uuid:33c866c7-7bc7-4187-9af3-a728630188a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:50a23cc0-296d-4b70-b252-6b7a1c026bd4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:093480e8-3555-46e1-b15d-ad6e6ded93f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] GENOSYL ® is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents.|[PMDA] A drug containing a new active ingredient indicated for the treatment of hypoxic respiratory failure (HRF) with concurrent pulmonary hypertension in neonates. [Orphan drug] uuid:7817adb7-5d90-4bc8-9ec5-86e715bbeda3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16480 biolink:treats MONDO:0005149 PMID:41385096 "[{""id"":""uuid:51248ab2-13eb-4fc4-8703-8fe3e9384765"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c119c2f0-72dc-4922-b985-b8c87fe8e5d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:be2251e1-aa83-4a4a-aa69-b9436fdb80fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f39973cd-b43e-41b3-a571-92670f2341fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] GENOSYL ® is indicated to improve oxygenation and reduce the need for extracorporeal membrane oxygenation in term and near-term (>34 weeks gestation) neonates with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in conjunction with ventilatory support and other appropriate agents.|[EMA] INOmax, in conjunction with ventilatory support and other appropriate active substances, is indicated:for the treatment of newborn infants ≥34 weeks gestation with hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension, in order to improve oxygenation and to reduce the need for extracorporeal membrane oxygenation;as part of the treatment of peri- and post-operative pulmonary hypertension in adults and newborn infants, infants and toddlers, children and adolescents, ages 0-17 years in conjunction to heart surgery, in order to selectively decrease pulmonary arterial pressure and improve right ventricular function and oxygenation.|[PMDA] A drug containing a new active ingredient indicated for the treatment of hypoxic respiratory failure (HRF) with concurrent pulmonary hypertension in neonates. [Orphan drug] uuid:3c37871c-22dd-49f1-adb0-319509cd4df5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4SED7F4BSG biolink:treats MONDO:0009290 PMID:41385096 "[{""id"":""uuid:f6a509f8-c23c-41f2-8bb0-96b99a5214be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:41890350-b92b-4730-ad35-52cb30847f50"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:47420d83-1ace-455a-b817-3036d4276260"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/pombiliti""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] POMBILITI is indicated, in combination with Opfolda, for the treatment of adult patients with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency) weighing ≥40 kg and who are not improving on their current enzyme replacement therapy (ERT).|[EMA] Pombiliti (cipaglucosidase alfa) is a long-term enzyme replacement therapy used in combination with the enzyme stabiliser miglustat for the treatment of adults with late-onset Pompe disease (acid α-glucosidase [GAA] deficiency). uuid:9d93c88d-5424-4e31-9c5d-29708cc8b03b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50381 biolink:treats MONDO:0009290 PMID:41385096 "[{""id"":""uuid:72de58bc-75ed-4792-8795-a78f154cdfb8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:dfc94c8e-5589-4e47-bd81-b6d3c11f0d6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:04c7071e-c1ce-4a36-afed-78f905a37d5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/opfolda""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] OPFOLDA is indicated, in combination with Pombiliti, for the treatment of adult patients with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency) weighing ≥40 kg and who are not improving on their current enzyme replacement therapy (ERT).|[EMA] Opfolda (miglustat) is an enzyme stabiliser of cipaglucosidase alfa long-term enzyme replacement therapy in adults with late-onset Pompe disease (acid α- glucosidase [GAA] deficiency). uuid:7a8c8cbf-aad9-4791-b728-6b36af9e1662 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71219 biolink:treats UMLS:C4727069 PMID:41385096 "[{""id"":""uuid:b828ed98-baf6-49f4-be90-4e4e02b3dc07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3db24d0f-7452-4903-ad88-7a4c50e200d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pazopanib tablets are a kinase inhibitor indicated for the treatment of adults with: Advanced renal cell carcinoma (RCC). ( 1.1 ) Advanced soft tissue sarcoma (STS) who have received prior chemotherapy. ( 1.2 ) Limitations of Use : The efficacy of pazopanib tablets for the treatment of patients with adipocytic soft tissue sarcoma or gastrointestinal stromal tumors has not been demonstrated. uuid:20f289e1-ca95-4d99-afc6-fee28822258f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71219 biolink:treats UMLS:C5206410 PMID:41385096 "[{""id"":""uuid:d755d2de-1b1a-4132-a3b5-016a413111d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:236f710e-63b4-4a10-b5f9-3ca4dfb684ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Pazopanib tablets are a kinase inhibitor indicated for the treatment of adults with: Advanced renal cell carcinoma (RCC). ( 1.1 ) Advanced soft tissue sarcoma (STS) who have received prior chemotherapy. ( 1.2 ) Limitations of Use : The efficacy of pazopanib tablets for the treatment of patients with adipocytic soft tissue sarcoma or gastrointestinal stromal tumors has not been demonstrated. uuid:1b7ac840-7943-4908-bfc5-c6e67f0a4879 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3423 biolink:treats MONDO:0100342 PMID:41385096 "[{""id"":""uuid:46063798-6ff8-45bc-ab7f-261b1faff29e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0f40a309-52fb-455e-b2cd-dfd0d87bcf04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:750c369e-abb1-4132-9bbd-59e263dbf9c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] GLIADEL Wafer is indicated for the treatment of patients with: newly-diagnosed high-grade glioma as an adjunct to surgery and radiation, and recurrent glioblastoma as an adjunct to surgery.|[PMDA] A drug with a new active ingredient indicated for the treatment of malignant glioma. [Orphan drug] uuid:2b67f3f2-c0b3-4398-9f4d-51d654d147fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C1589331 biolink:treats MONDO:0015804 PMID:41385096 "[{""id"":""uuid:cd2e6422-636f-42da-afd9-723297811146"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cf34c4b1-4250-4719-8bfd-c33a96bf7187"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BabyBIG ® , Botulism Immune Globulin Intravenous (Human), is indicated for the treatment of infant botulism caused by toxin type A or B in patients below one year of age. DRUGBANK:DB14115 uuid:f9e68651-9bc9-4a48-bdbb-18fb6fb346ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C1589331 biolink:treats MONDO:0005498 PMID:41385096 "[{""id"":""uuid:f2a41e45-0c87-4eea-a936-02380f0abf59"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:091ba68f-5836-429e-b754-251fd9e67a9d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BabyBIG ® , Botulism Immune Globulin Intravenous (Human), is indicated for the treatment of infant botulism caused by toxin type A or B in patients below one year of age. DRUGBANK:DB14115 uuid:30e503e6-78fc-4572-9bc1-c040814a7f0c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7573 biolink:treats MONDO:0008315 PMID:41385096 "[{""id"":""uuid:7b17efa3-5b8e-44ac-bfb3-82c424df2ad7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:69b61556-b9c9-4486-b58f-5a75bf59df25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NILANDRON tablets are indicated for use in combination with surgical castration for the treatment of metastatic prostate cancer (Stage D 2 ). For maximum benefit, NILANDRON treatment must begin on the same day as or on the day after surgical castration. uuid:15073089-3e5f-4880-8d51-521b06ee6d7c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231416 biolink:treats UMLS:C0312854 PMID:41385096 "[{""id"":""uuid:48350a04-1d15-4614-9a66-37b52c05e17a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e498fbf0-46a9-443a-b8d7-c41f80c60c0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VOYDEYA is indicated as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH). uuid:a2023124-3f92-4f6d-810c-4aaaf34919c3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231416 biolink:treats MONDO:0100244 PMID:41385096 "[{""id"":""uuid:01568097-f513-458c-a074-f1ed46c282cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:77db2615-d69e-4846-a9c3-3235e05f5f87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1b8653f9-0b74-45ff-83df-43f8252da93c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VOYDEYA is indicated as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria (PNH).|[PMDA] A drug with a new active ingredient indicated for the treatment of paroxysmal nocturnal haemoglobinuria. [Orphan drug] uuid:da242744-2b91-4109-8bb6-903373dea607 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:66903 biolink:treats UMLS:C1304306 PMID:41385096 "[{""id"":""uuid:4e34f008-c7f1-418e-8123-ceea8a1cbec5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:62076f3b-36f2-4664-8cd0-0b2b3a4db0f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ERIVEDGE is indicated for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery and who are not candidates for radiation. uuid:13730336-07b0-45dc-b403-e56d93df3198 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:66903 biolink:treats UMLS:C4745056 PMID:41385096 "[{""id"":""uuid:f5919207-b678-4fd5-b6bb-096a6db695ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4c30b7e5-f826-4ba6-aa3f-c44234436a0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ERIVEDGE is indicated for the treatment of adults with metastatic basal cell carcinoma, or with locally advanced basal cell carcinoma that has recurred following surgery or who are not candidates for surgery and who are not candidates for radiation. uuid:23f5c3b3-2478-4ea2-be98-3a9313ce3d0f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7566 biolink:treats MONDO:0001444 PMID:41385096 "[{""id"":""uuid:7431a076-203f-42af-b75d-0a2983b42220"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eb88fb46-1980-472b-bb58-66fbd2e2f5a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LAMPIT is indicated in pediatric patients (birth to less than 18 years of age and weighing at least 2.5 kg) for the treatment of Chagas disease (American Trypanosomiasis) caused by Trypanosoma cruzi [see Clinical Studies ( 14 )]. uuid:9e1fd47a-eccd-4ac4-9a66-7c9ec108f79b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:23HYE36B0I biolink:treats MONDO:0009265 PMID:41385096 "[{""id"":""uuid:efb35951-99bc-4a09-97ac-b07ee4c8614c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:62aa8cdc-cd5d-4774-b951-66bdc2263cf9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0b30efa4-68e1-4678-9b95-4bc1395771c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vpriv""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] VPRIV is indicated for long-term enzyme replacement therapy (ERT) for patients with type 1 Gaucher disease.|[EMA] Vpriv is indicated for long-term enzyme-replacement therapy (ERT) in patients with type-1 Gaucher disease. uuid:6361241d-122a-4ca7-8831-66ef53b0bb91 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:59UA429E5G biolink:treats MONDO:0009661 PMID:41385096 "[{""id"":""uuid:225e6d10-7f7c-4717-acb3-8eea396ce90b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e45461c2-9b66-4ba1-9fe1-6194145a61a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e6743699-8d1e-44dc-8f5d-1d8d484e11a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/naglazyme""]},{""id"":""uuid:c933367e-d616-49ca-9910-43f64c6b053a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NAGLAZYME is indicated for patients with Mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome). NAGLAZYME has been shown to improve walking and stair-climbing capacity.|[EMA] Naglazyme is indicated for long-term enzyme-replacement therapy in patients with a confirmed diagnosis of mucopolysaccharidosis VI (MPS VI; N-acetylgalactosamine-4-sulfatase deficiency; Maroteaux-Lamy syndrome) (see section 5.1)., , As for all lysosomal genetic disorders, it is of primary importance, especially in severe forms, to initiate treatment as early as possible, before appearance of non-reversible clinical manifestations of the disease., , A key issue is to treat young patients aged|[PMDA] A drug containing a new active ingredient indicated for the treatment of mucopolysaccharidosis VI. [Orphan drug] uuid:fb3f1fc0-9683-41a6-947a-f1826ac43f23 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8ZHS5657EH biolink:treats MONDO:0019467 PMID:41385096 "[{""id"":""uuid:360ec70b-9ee8-47a4-a95e-b9f89357280d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0f6602ae-b441-4f72-8415-fc0c0796b526"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:6e191636-c51f-4b89-9b37-8c4d789a7a3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/elzonris""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ELZONRIS is indicated for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults and in pediatric patients 2 years and older.|[EMA] Elzonris is indicated as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). uuid:bf021f67-03e8-4ead-b054-4984c49ae98d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:NQX9KB6PCL biolink:treats MONDO:0000050 PMID:41385096 "[{""id"":""uuid:d8c8206e-4c31-4abe-90d9-ad0d46b8587f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:59141883-09e8-4a42-afff-7c7b15102e71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:cdde2095-1f00-4a81-89f7-e63895539b5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/omnitrope""]},{""id"":""uuid:caf4b4e2-5e03-4acf-9efd-0aba54f569f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] HUMATROPE is a recombinant human growth hormone indicated for: Pediatric Patients: growth failure due to inadequate secretion of endogenous growth hormone (GH); short stature associated with Turner syndrome; Idiopathic Short Stature (ISS), height standard deviation score (SDS) <-2.25, and associated with growth rates unlikely to permit attainment of adult height in the normal range; short stature or growth failure in short stature homeobox-containing gene (SHOX) deficiency; short stature born small for gestational age (SGA) with no catch-up growth by 2 years to 4 years of age. ( 1.1 ) Adult Patients: replacement of endogenous GH in adults with GH deficiency. ( 1.2 )|[EMA] Long-term treatment of children with growth failure due to inadequate endogenous growth hormone secretion.Long-term treatment of growth failure associated with Turner syndrome.Treatment of prepubertal children with growth failure associated with chronic renal insufficiency up to the time of renal transplantation.Replacement of endogenous growth hormone in adults with growth hormone deficiency of either childhood or adult-onset etiology. Growth hormone deficiency should be confirmed appropriately prior to treatment.|[PMDA] Follow-on biologics indicated for the treatment of growth disturbance due to growth hormone deficiency before epiphyseal closure and growth disturbance associated with Turner syndrome or chronic renal insufficiency before epiphyseal closure. uuid:d103d59b-fafe-4472-bcaf-f401ef6b37c2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:5TAA004E22 biolink:treats MONDO:0018874 PMID:41385096 "[{""id"":""uuid:4a4e6521-b08a-4e37-a98c-5820c33496a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e64fbb35-36df-4dd1-9c1b-c90c4afe2556"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LEUKINE is a leukocyte growth factor indicated: To shorten time to neutrophil recovery and to reduce the incidence of severe and life-threatening infections and infections resulting in death following induction chemotherapy in adult patients 55 years and older with acute myeloid leukemia (AML). ( 1.1 ) For the mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis and autologous transplantation in adult patients. ( 1.2 ) For the acceleration of myeloid reconstitution following autologous bone marrow or peripheral blood progenitor cell transplantation in adult and pediatric patients 2 years of age and older. ( 1.3 ) For the acceleration of myeloid reconstitution following allogeneic bone marrow transplantation in adult and pediatric patients 2 years of age and older. ( 1.4 ) For treatment of delayed neutrophil recovery or graft failure after autologous or allogeneic bone marrow transplantation in adult and pediatric patients 2 years of age and older. ( 1.5 ) To increase survival in adult and pediatric patients from birth to 17 years of age acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS]). ( 1.6 ) uuid:25700505-516d-4fc6-a1ef-fb70483459d9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:5TAA004E22 biolink:treats MONDO:0033938 PMID:41385096 "[{""id"":""uuid:7f29e8dc-0b79-4cfa-acc3-f299ce1bd44f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f256c7b3-f367-4d93-9f00-ad7dda1274bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LEUKINE is a leukocyte growth factor indicated: To shorten time to neutrophil recovery and to reduce the incidence of severe and life-threatening infections and infections resulting in death following induction chemotherapy in adult patients 55 years and older with acute myeloid leukemia (AML). ( 1.1 ) For the mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis and autologous transplantation in adult patients. ( 1.2 ) For the acceleration of myeloid reconstitution following autologous bone marrow or peripheral blood progenitor cell transplantation in adult and pediatric patients 2 years of age and older. ( 1.3 ) For the acceleration of myeloid reconstitution following allogeneic bone marrow transplantation in adult and pediatric patients 2 years of age and older. ( 1.4 ) For treatment of delayed neutrophil recovery or graft failure after autologous or allogeneic bone marrow transplantation in adult and pediatric patients 2 years of age and older. ( 1.5 ) To increase survival in adult and pediatric patients from birth to 17 years of age acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS]). ( 1.6 ) uuid:65a27599-a538-47e9-973d-aab82f30aa86 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:5TAA004E22 biolink:treats UMLS:C1262018 PMID:41385096 "[{""id"":""uuid:b55ebec8-609f-40a9-80c8-b509e1d3c0d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ab23d765-c8e0-42dc-8ca4-460464ca9676"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LEUKINE is a leukocyte growth factor indicated: To shorten time to neutrophil recovery and to reduce the incidence of severe and life-threatening infections and infections resulting in death following induction chemotherapy in adult patients 55 years and older with acute myeloid leukemia (AML). ( 1.1 ) For the mobilization of hematopoietic progenitor cells into peripheral blood for collection by leukapheresis and autologous transplantation in adult patients. ( 1.2 ) For the acceleration of myeloid reconstitution following autologous bone marrow or peripheral blood progenitor cell transplantation in adult and pediatric patients 2 years of age and older. ( 1.3 ) For the acceleration of myeloid reconstitution following allogeneic bone marrow transplantation in adult and pediatric patients 2 years of age and older. ( 1.4 ) For treatment of delayed neutrophil recovery or graft failure after autologous or allogeneic bone marrow transplantation in adult and pediatric patients 2 years of age and older. ( 1.5 ) To increase survival in adult and pediatric patients from birth to 17 years of age acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [H-ARS]). ( 1.6 ) uuid:d961c217-2177-45fe-89fd-5e359c05c9cd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:ODJ69JZG85 biolink:treats MONDO:0009659 PMID:41385096 "[{""id"":""uuid:112e65c7-3c69-4b51-9f56-1d2bfea1966c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6d307a6d-3446-4868-83fa-5000e63831fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:08a40563-33f4-44dc-a015-40db7dc22b8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b93d5827-2c8b-4385-afa1-8e84f929c6ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vimizim (elosulfase alfa) is indicated for patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome).|[EMA] Vimizim is indicated for the treatment of mucopolysaccharidosis, type IVA (Morquio A Syndrome, MPS IVA) in patients of all ages.|[PMDA] A drug with a new active ingredient indicated for the treatment of mucopolysaccharidosis type IVA. [Orphan drug] uuid:3b5e0240-cd69-4122-9d78-1a4a4430e03a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:ODJ69JZG85 biolink:treats MONDO:0018938 PMID:41385096 "[{""id"":""uuid:8aae2fb3-9c96-4d03-93c7-2041b7fceefa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ab129618-a1b9-4cce-99fd-dc45ee0f55f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vimizim (elosulfase alfa) is indicated for patients with Mucopolysaccharidosis type IVA (MPS IVA; Morquio A syndrome). uuid:3feddc74-cff3-4d74-a053-aa9b71198c41 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3A189DH42V biolink:treats MONDO:0004948 PMID:41385096 "[{""id"":""uuid:e15b2cad-6f3b-467e-8184-25bd82939cee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:889556db-edf9-4730-9675-03125e1726ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CAMPATH is indicated as a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL). uuid:1845895d-db24-483e-87e2-0afb1ab0b151 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB17278 biolink:treats MONDO:0024503 PMID:41385096 "[{""id"":""uuid:67db09ea-3ac2-429b-ad14-7ce5a7732d73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:02fb40cc-c279-4b68-81bf-4a410954eed0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LUTATHERA is indicated for the treatment of adult and pediatric patients 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors. uuid:256f1c3b-a332-4720-9945-697f9689f64c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB17278 biolink:treats MONDO:0018510 PMID:41385096 "[{""id"":""uuid:4cd41931-4368-441b-a5be-fac22fd1b43b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0723523d-a862-4900-a7fc-6c7664c34f80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LUTATHERA is indicated for the treatment of adult and pediatric patients 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors. uuid:620775d8-5f95-491e-8a81-30e033e3d3b6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB17278 biolink:treats MONDO:0003646 PMID:41385096 "[{""id"":""uuid:b572d7d3-73b8-42ee-b7d2-306038011dfd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:576ebaeb-476a-466f-98dd-24fb7ef284fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LUTATHERA is indicated for the treatment of adult and pediatric patients 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors. uuid:21b8d7f3-db75-4bb5-9e63-26c3aab8cc50 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:44476258 biolink:treats MONDO:0006652 PMID:41385096 "[{""id"":""uuid:678e9615-f284-4305-b53c-43de3950ad42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f760e8b8-3797-46ea-8faa-b36a03c94afa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets are a combination of olmesartan medoximil, an angiotensin II receptor blocker, amlodipine, a dihydropyridine calcium channel blocker, and hydrochlorothiazide, a thiazide diuretic indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions ( 1 ). Limitations of Use Olmesartan medoxomil, amlodipine and hydrochlorothiazide tablets is not indicated for initial therapy ( 1 ). uuid:ebde945b-894e-4034-8c5b-1547bbe5abfa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17234 biolink:treats UMLS:C0854100 PMID:41385096 "[{""id"":""uuid:3dc97664-9065-49c0-9a3c-8dc7aa3fea7c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d748a65b-ee06-471b-8014-a61bcbc5bc7c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 70% Dextrose Injection USP is indicated as a caloric component in a parenteral nutrition regimen. 70% Dextrose Injection USP is used with an appropriate protein (nitrogen) source in the prevention of nitrogen loss or in the treatment of negative nitrogen balance in patients where: (1) the alimentary tract cannot or should not be used, (2) gastrointestinal absorption of protein is impaired, or (3) metabolic requirements for protein are substantially increased, as with extensive burns. uuid:cc4461a6-5e37-4b9a-bff9-e0c4d015af83 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135983 biolink:treats MONDO:0005298 PMID:41385096 "[{""id"":""uuid:37ae7d83-091a-43d3-9dcc-5b118d1d4295"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:34d93e0b-e704-4bb7-af1b-68eede5f1a3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:04ea2052-57e7-4091-bb4a-7e7d8600b54b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kauliv""]},{""id"":""uuid:87fce03d-cdb3-4fd5-a652-ea03e60493d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FORTEO is indicated: For the treatment of postmenopausal women with osteoporosis at high risk for fracture (defined herein as having a history of osteoporotic fracture or multiple risk factors for fracture) or who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, FORTEO reduces the risk of vertebral and nonvertebral fractures. To increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy. For the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy (daily dosage equivalent to 5 mg or greater of prednisone) at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy.|[EMA] Kauliv is indicated in adults., , Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5.1). In postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated., , Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.1).,|[PMDA] A drug with a new dosage in an additional dosage form indicated for the treatment of osteoporosis with a high risk of fracture. uuid:f89bf326-96f2-4808-b525-235709a13796 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135983 biolink:treats UMLS:C0521170 PMID:41385096 "[{""id"":""uuid:3aaaab94-7300-443d-9bbc-c3e3a59547a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6f9acd7f-bd3d-4758-95b7-0589734ad1c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FORTEO is indicated: For the treatment of postmenopausal women with osteoporosis at high risk for fracture (defined herein as having a history of osteoporotic fracture or multiple risk factors for fracture) or who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, FORTEO reduces the risk of vertebral and nonvertebral fractures. To increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy. For the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy (daily dosage equivalent to 5 mg or greater of prednisone) at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy. uuid:ba89c931-098f-47a5-b7ac-a179b64508fe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135983 biolink:treats UMLS:C0410438 PMID:41385096 "[{""id"":""uuid:afaf8a1b-16b4-41ba-93aa-902438d0801a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eb0a5552-dae2-4420-8e25-a66f523c3a3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FORTEO is indicated: For the treatment of postmenopausal women with osteoporosis at high risk for fracture (defined herein as having a history of osteoporotic fracture or multiple risk factors for fracture) or who have failed or are intolerant to other available osteoporosis therapy. In postmenopausal women with osteoporosis, FORTEO reduces the risk of vertebral and nonvertebral fractures. To increase bone mass in men with primary or hypogonadal osteoporosis at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy. For the treatment of men and women with osteoporosis associated with sustained systemic glucocorticoid therapy (daily dosage equivalent to 5 mg or greater of prednisone) at high risk for fracture or who have failed or are intolerant to other available osteoporosis therapy. uuid:af94c258-23c3-4215-950e-cb3e2a8cc581 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5118 biolink:treats MONDO:1010182 PMID:41385096 "[{""id"":""uuid:735fffff-df81-4c7f-a29e-bf4dbdc0cf0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7523db3d-2a41-4594-8a7c-da93f6e1ada7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fluoxetine tablets, USP are selective serotonin reuptake inhibitor (SSRI) indicated for the treatment of Premenstrual Dysphoric Disorder (PMDD) ( 1.1 ) UMLS:C0520676 uuid:bfd4e095-bd43-43f3-aa22-2a48b84319f3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1157512 biolink:treats MONDO:0005277 PMID:41385096 "[{""id"":""uuid:50497268-53a1-40ff-add1-0980e4a971de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:566a0306-a1df-4eb7-9126-9e8c48182933"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sumatriptan and naproxen sodium tablets are indicated for the acute treatment of migraine with or without aura in adults and pediatric patients 12 years of age and older. Limitations of Use: Use only if a clear diagnosis of migraine headache has been established. If a patient has no response to the first migraine attack treated with sumatriptan and naproxen sodium tablets, reconsider the diagnosis of migraine before sumatriptan and naproxen sodium tablets are administered to treat any subsequent attacks. Sumatriptan and naproxen sodium tablets are not indicated for the prevention of migraine attacks. Safety and effectiveness of sumatriptan and naproxen sodium tablets have not been established for cluster headache. uuid:833d0f13-f5a1-43db-b6b0-c8941316e7f9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9829639 biolink:treats EFO:1001480 PMID:41385096 "[{""id"":""uuid:5d8f8c17-79e3-4d16-aeb4-844f9dec8ad6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d21c7962-d50b-4631-b881-3aea27dde566"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LONSURF is a combination of trifluridine, a nucleoside metabolic inhibitor, and tipiracil, a thymidine phosphorylase inhibitor, indicated for the treatment of adult patients with: metastatic colorectal cancer as a single agent or in combination with bevacizumab who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy. ( 1.1 ) metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy. ( 1.2 ) uuid:653ed42f-4110-4989-ab44-4f58c938c310 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9829639 biolink:treats UMLS:C3160888 PMID:41385096 "[{""id"":""uuid:aaeeed33-c262-4cd9-9ebf-a5e0eb71747e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6cec7fd3-3ea8-4f88-81f0-0ca951d6c3b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LONSURF is a combination of trifluridine, a nucleoside metabolic inhibitor, and tipiracil, a thymidine phosphorylase inhibitor, indicated for the treatment of adult patients with: metastatic colorectal cancer as a single agent or in combination with bevacizumab who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy. ( 1.1 ) metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy. ( 1.2 ) uuid:8d36b69b-419d-4771-b869-673441b9e556 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9829639 biolink:treats UMLS:C4725845 PMID:41385096 "[{""id"":""uuid:5a5ba027-a2ed-4d5c-b226-a49ea7fd62da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:14db3b73-6d0b-4bda-96a1-a715c11014ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LONSURF is a combination of trifluridine, a nucleoside metabolic inhibitor, and tipiracil, a thymidine phosphorylase inhibitor, indicated for the treatment of adult patients with: metastatic colorectal cancer as a single agent or in combination with bevacizumab who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy. ( 1.1 ) metastatic gastric or gastroesophageal junction adenocarcinoma previously treated with at least two prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy. ( 1.2 ) uuid:55ff4d8c-96e6-44b2-bf12-c1f47c30b06e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9754 biolink:treats MONDO:0000440 PMID:41385096 "[{""id"":""uuid:eee63d3f-be43-4c9f-9233-bbd311ca174c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:25d7887e-42aa-4c5f-af76-5bc1838096e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tham Solution (tromethamine injection) is indicated for the prevention and correction of metabolic acidosis. In the following conditions it may help to sustain vital functions and thus provide time for treatment of the primary disease: Metabolic Acidosis Associated with Cardiac Bypass Surgery. Tham Solution has been found to be primarily beneficial in correcting metabolic acidosis which may occur during or immediately following cardiac bypass surgical procedures. Correction of Acidity of ACD Blood in Cardiac Bypass Surgery. It is well known that ACD blood is acidic and becomes more acidic on storage. Tromethamine effectively corrects this acidity. Tham Solution may be added directly to the blood used to prime the pump-oxygenator. When ACD blood is brought to a normal pH range the patient is spared an initial acid load. Additional tromethamine may be indicated during cardiac bypass surgery should metabolic acidosis appear. Metabolic Acidosis Associated with Cardiac Arrest. Acidosis is nearly always one of the consequences of cardiac arrest and, in some instances, may even be a causative factor in arrest. It is important therefore, that the correction of acidosis should be started promptly with other resuscitative efforts. By correcting acidosis, Tham Solution (tromethamine injection) has caused the arrested heart to respond to resuscitative efforts after standard methods alone had failed. In these cases, tromethamine was given intraventricularly. It is to be noted, however, that such precariously ill patients often have died subsequently of causes unrelated to the administration of tromethamine. With administration by the peripheral venous route, metabolic acidosis has been corrected in a majority of patients. The success in reinstitution of cardiac rhythm by this means probably has not been of the same order of magnitude as with the intraventricular route. uuid:03e773a6-6720-4bbd-8220-9fa1e3f8209b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9754 biolink:treats MONDO:0006022 PMID:41385096 "[{""id"":""uuid:5a0783d2-2968-4cce-9e0f-fd900da1376b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:15f0ce0a-ef79-447e-b2dd-5017e145889b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tham Solution (tromethamine injection) is indicated for the prevention and correction of metabolic acidosis. In the following conditions it may help to sustain vital functions and thus provide time for treatment of the primary disease: Metabolic Acidosis Associated with Cardiac Bypass Surgery. Tham Solution has been found to be primarily beneficial in correcting metabolic acidosis which may occur during or immediately following cardiac bypass surgical procedures. Correction of Acidity of ACD Blood in Cardiac Bypass Surgery. It is well known that ACD blood is acidic and becomes more acidic on storage. Tromethamine effectively corrects this acidity. Tham Solution may be added directly to the blood used to prime the pump-oxygenator. When ACD blood is brought to a normal pH range the patient is spared an initial acid load. Additional tromethamine may be indicated during cardiac bypass surgery should metabolic acidosis appear. Metabolic Acidosis Associated with Cardiac Arrest. Acidosis is nearly always one of the consequences of cardiac arrest and, in some instances, may even be a causative factor in arrest. It is important therefore, that the correction of acidosis should be started promptly with other resuscitative efforts. By correcting acidosis, Tham Solution (tromethamine injection) has caused the arrested heart to respond to resuscitative efforts after standard methods alone had failed. In these cases, tromethamine was given intraventricularly. It is to be noted, however, that such precariously ill patients often have died subsequently of causes unrelated to the administration of tromethamine. With administration by the peripheral venous route, metabolic acidosis has been corrected in a majority of patients. The success in reinstitution of cardiac rhythm by this means probably has not been of the same order of magnitude as with the intraventricular route. uuid:57ecab4a-98f7-4ccd-bd7a-6fdb2049f61d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9754 biolink:treats MONDO:0000745 PMID:41385096 "[{""id"":""uuid:1d362475-47fd-4106-b223-9b6590aeeae7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:98f57510-e95e-40da-a4d3-4366571ae466"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tham Solution (tromethamine injection) is indicated for the prevention and correction of metabolic acidosis. In the following conditions it may help to sustain vital functions and thus provide time for treatment of the primary disease: Metabolic Acidosis Associated with Cardiac Bypass Surgery. Tham Solution has been found to be primarily beneficial in correcting metabolic acidosis which may occur during or immediately following cardiac bypass surgical procedures. Correction of Acidity of ACD Blood in Cardiac Bypass Surgery. It is well known that ACD blood is acidic and becomes more acidic on storage. Tromethamine effectively corrects this acidity. Tham Solution may be added directly to the blood used to prime the pump-oxygenator. When ACD blood is brought to a normal pH range the patient is spared an initial acid load. Additional tromethamine may be indicated during cardiac bypass surgery should metabolic acidosis appear. Metabolic Acidosis Associated with Cardiac Arrest. Acidosis is nearly always one of the consequences of cardiac arrest and, in some instances, may even be a causative factor in arrest. It is important therefore, that the correction of acidosis should be started promptly with other resuscitative efforts. By correcting acidosis, Tham Solution (tromethamine injection) has caused the arrested heart to respond to resuscitative efforts after standard methods alone had failed. In these cases, tromethamine was given intraventricularly. It is to be noted, however, that such precariously ill patients often have died subsequently of causes unrelated to the administration of tromethamine. With administration by the peripheral venous route, metabolic acidosis has been corrected in a majority of patients. The success in reinstitution of cardiac rhythm by this means probably has not been of the same order of magnitude as with the intraventricular route. uuid:4f796983-0a92-45e3-b790-eda5ba20386c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:205919 biolink:treats MONDO:0005093 PMID:41385096 "[{""id"":""uuid:cb25c389-1157-48fa-8c57-29e0fa1bc4d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:76ec8973-f74c-40b6-87a5-1cddcab0a529"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tovet Foam is indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 12 years and older. uuid:5a4acc96-6a78-4366-be75-8373a72f91cc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135920 biolink:treats UMLS:C0341736 PMID:41385096 "[{""id"":""uuid:8224ec63-c318-41e1-8c33-4f2016eb3ab4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:40f41546-68b5-4b26-8764-d8ac61bd6499"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Toviaz is indicated for the treatment of: • Overactive bladder (OAB) in adults with symptoms of urge urinary incontinence, urgency, and frequency. ( 1.1 ) • Neurogenic detrusor overactivity (NDO) in pediatric patients 6 years of age and older and weighing greater than 25 kg. ( 1.2 ) uuid:c8cbf697-c832-4fc8-82a6-a455c05d7475 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29108 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:ec6dcb5a-d6fb-42a8-97cd-a15c0a361fe4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6b8eb498-612c-4984-9b8b-0988f5b52e22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELFLEX® is indicated in the treatment of chronic kidney failure in patients being maintained on peritoneal dialysis. uuid:100d31de-1114-4ba3-a093-a969a9ad5f16 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2562180 biolink:treats MONDO:0005302 PMID:41385096 "[{""id"":""uuid:b240353c-5066-43b9-8eac-f90ba3ff1cbd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aab9c12b-5639-4883-937c-ff0dfc68b456"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dexmethylphenidate hydrochloride tablets are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) [see Clinical Studies (14)] . uuid:c8b457a3-e0b0-4b77-bf2d-e545990e8e17 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135957 biolink:treats MONDO:0005556 PMID:41385096 "[{""id"":""uuid:e2184ca6-4770-4622-ac89-8dc9e1268a34"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:eb50df91-867d-4d4b-aa59-53acefe76ab3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f760773e-8860-4cbc-9cfc-06a9f2156387"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lupkynis""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] LUPKYNIS is indicated in combination with a background immunosuppressive therapy regimen [see Clinical Studies ( 14 )] for the treatment of adult patients with active lupus nephritis (LN). Limitations of Use: Safety and efficacy of LUPKYNIS have not been established in combination with cyclophosphamide. Use of LUPKYNIS is not recommended in this situation.|[EMA] Lupkynis is indicated in combination with mycophenolate mofetil for the treatment of adult patients with active class III, IV or V (including mixed class III/V and IV/V) lupus nephritis (LN). uuid:3fd8645f-de5f-4568-b37e-8548466968a0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135957 biolink:treats MONDO:0002486 PMID:41385096 "[{""id"":""uuid:fa366c0d-1438-436f-98af-626a262a4698"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:29e141c9-ca06-4486-8341-ff76b90a6d7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LUPKYNIS is indicated in combination with a background immunosuppressive therapy regimen [see Clinical Studies ( 14 )] for the treatment of adult patients with active lupus nephritis (LN). Limitations of Use: Safety and efficacy of LUPKYNIS have not been established in combination with cyclophosphamide. Use of LUPKYNIS is not recommended in this situation. uuid:32c9a6f6-e1ef-48b2-80c6-337e126d053c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:39112 biolink:treats MONDO:0011996 PMID:41385096 "[{""id"":""uuid:114a4842-b2f2-49a5-8e3c-3eb7ae2e4672"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3b038917-1252-4ac7-b7c9-41113faa9529"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0ffc7f95-8a01-41b7-bbd8-1b3fcd462ef3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f4e9d61f-b66e-434c-94f0-ab65493768fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BOSULIF is indicated for the treatment of: • Adult and pediatric patients 1 year of age and older with chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML), newly-diagnosed or resistant or intolerant to prior therapy [see Clinical Studies ( 14.1 , 14.2 , 14.3 )] . • Adult patients with accelerated phase (AP), or blast phase (BP) Ph+ CML with resistance or intolerance to prior therapy [see Clinical Studies (14.2) ] .|[EMA] Bosulif is indicated for the treatment of adult patients with:newly‑diagnosed chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukaemia (Ph+ CML).CP, accelerated phase (AP), and blast phase (BP) Ph+ CML previously treated with one or more tyrosine kinase inhibitor(s) [TKI(s)] and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options.|[PMDA] A drug with a new active ingredient indicated for the treatment of chronic myelogenous leukemia with resistance or intolerance to prior drug therapies. [Orphan drug] uuid:64e52257-7ce7-4ad0-a16b-207742e8ac27 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:39112 biolink:treats MONDO:0021367 PMID:41385096 "[{""id"":""uuid:62cdda3b-6f94-4b0f-be92-149cf405cef8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:3874b86f-82f0-4ff0-92b7-2ddf55f33dec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:815c8885-548f-49c7-b596-d1f6ca2d2c5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BOSULIF is indicated for the treatment of: • Adult and pediatric patients 1 year of age and older with chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML), newly-diagnosed or resistant or intolerant to prior therapy [see Clinical Studies ( 14.1 , 14.2 , 14.3 )] . • Adult patients with accelerated phase (AP), or blast phase (BP) Ph+ CML with resistance or intolerance to prior therapy [see Clinical Studies (14.2) ] .|[EMA] Bosulif is indicated for the treatment of adult patients with:newly‑diagnosed chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukaemia (Ph+ CML).CP, accelerated phase (AP), and blast phase (BP) Ph+ CML previously treated with one or more tyrosine kinase inhibitor(s) [TKI(s)] and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options. uuid:f14dc356-cc1b-492f-a088-808128e35d7d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:39112 biolink:treats MONDO:0006115 PMID:41385096 "[{""id"":""uuid:881736aa-e969-4a13-b205-4cbefca39a81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:313c6567-802d-45bb-866c-51dbbe64a91a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2d2555b6-f3d8-475b-a928-463b9cc20fc7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BOSULIF is indicated for the treatment of: • Adult and pediatric patients 1 year of age and older with chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML), newly-diagnosed or resistant or intolerant to prior therapy [see Clinical Studies ( 14.1 , 14.2 , 14.3 )] . • Adult patients with accelerated phase (AP), or blast phase (BP) Ph+ CML with resistance or intolerance to prior therapy [see Clinical Studies (14.2) ] .|[EMA] Bosulif is indicated for the treatment of adult patients with:newly‑diagnosed chronic phase (CP) Philadelphia chromosome-positive chronic myelogenous leukaemia (Ph+ CML).CP, accelerated phase (AP), and blast phase (BP) Ph+ CML previously treated with one or more tyrosine kinase inhibitor(s) [TKI(s)] and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options. uuid:313fb965-47ae-4c5c-9dfa-b79fe3c92f05 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:760I9WM792 biolink:treats MONDO:0005475 PMID:41385096 "[{""id"":""uuid:493e10e7-d5d2-49aa-9dbb-9f9bff385b94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1bc3b316-a4f1-4cad-849d-054f5e8cbb9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] REYVOW ® is indicated for the acute treatment of migraine with or without aura in adults. uuid:206803dc-25b2-43e0-a201-84c4e54c244c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:760I9WM792 biolink:treats MONDO:0100431 PMID:41385096 "[{""id"":""uuid:890194cb-961b-4231-b401-7bb31bc95f97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3fdf4a61-3b72-4d2a-b4f5-a6965b8ac842"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] REYVOW ® is indicated for the acute treatment of migraine with or without aura in adults. uuid:7a7f2822-f33f-495d-887f-70087426bf64 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:174856 biolink:treats MONDO:0005984 PMID:41385096 "[{""id"":""uuid:00f6cefb-e4b8-4484-a740-bdef5a0390fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8851801c-a03e-4de2-981d-c5917d1f7440"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clotrimazole and betamethasone dipropionate cream is a combination of an azole antifungal and corticosteroid and is indicated for the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris, and tinea corporis due to Epidermophyton floccosum, Trichophyton mentagrophytes, and Trichophyton rubrum in patients 17 years and older. uuid:697a1eb1-13f5-44eb-b0f9-bde3588498d1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:174856 biolink:treats MONDO:0001405 PMID:41385096 "[{""id"":""uuid:5df97732-5dac-4547-91c7-c1cd2de27fd9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:12ea6c69-8598-4bb0-8122-23acdb99ae0f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clotrimazole and betamethasone dipropionate cream is a combination of an azole antifungal and corticosteroid and is indicated for the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris, and tinea corporis due to Epidermophyton floccosum, Trichophyton mentagrophytes, and Trichophyton rubrum in patients 17 years and older. uuid:bbf433e2-d4ea-4521-916f-583732eabd39 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:174856 biolink:treats MONDO:0001461 PMID:41385096 "[{""id"":""uuid:63c2dcd2-c975-4039-af62-84bdc4012072"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:285971e5-6fcf-4e99-96b7-e8b323223cbe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clotrimazole and betamethasone dipropionate cream is a combination of an azole antifungal and corticosteroid and is indicated for the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris, and tinea corporis due to Epidermophyton floccosum, Trichophyton mentagrophytes, and Trichophyton rubrum in patients 17 years and older. uuid:a8fb8165-bce9-4c71-959e-4ab4ccd8a519 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:O880NM097T biolink:treats MONDO:0012105 PMID:41385096 "[{""id"":""uuid:8d225aed-7149-4208-a667-7ea5bcdddeb3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:131996ab-c820-4c87-a2ee-99d43fc18a01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4e65b1c9-c6d4-4cbf-b997-079bdedd2cbd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tavneos""]},{""id"":""uuid:fb7d27bc-9394-4940-b0c3-9ec2d1f91ee2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TAVNEOS is indicated as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]) in combination with standard therapy including glucocorticoids. TAVNEOS does not eliminate glucocorticoid use.|[EMA] Tavneos, in combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA).|[PMDA] A drug with a new active ingredient indicated for the treatment of microscopic polyangiitis and granulomatosis with polyangiitis. [Orphan drug] uuid:3a050e49-a437-46e3-a467-f59ed00b17fb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:O880NM097T biolink:treats MONDO:0019124 PMID:41385096 "[{""id"":""uuid:26c4295f-e9fc-4966-b50c-eb13806f3af0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8ccff75f-c647-4807-aeab-a55a0733d5c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:6e2aaebd-d60e-4075-bab8-0bb3ac2cdf47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tavneos""]},{""id"":""uuid:1c76b545-9c1b-4937-a368-5b1ee19a4179"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TAVNEOS is indicated as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (granulomatosis with polyangiitis [GPA] and microscopic polyangiitis [MPA]) in combination with standard therapy including glucocorticoids. TAVNEOS does not eliminate glucocorticoid use.|[EMA] Tavneos, in combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA).|[PMDA] A drug with a new active ingredient indicated for the treatment of microscopic polyangiitis and granulomatosis with polyangiitis. [Orphan drug] uuid:12d2da3c-1a63-48e3-a2ad-58a4e31534d2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats MONDO:0005277 PMID:41385096 "[{""id"":""uuid:39ce2d0e-58dd-48ff-88e7-fc3b4ccd79d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7a685848-64e1-41fe-b870-3614072a2577"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CAMBIA is indicated for the acute treatment of migraine attacks with or without aura in adults (18 years of age or older). Limitations of Use: CAMBIA is not indicated for the prophylactic therapy of migraine. The safety and effectiveness of CAMBIA have not been established for cluster headache, which is present in an older, predominantly male population. uuid:499c02a2-1c01-4c88-890a-1c85171bef3c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:216989 biolink:treats NCIT:C3837 PMID:41385096 "[{""id"":""uuid:a7fee986-282e-483f-819b-92d4f9924a90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:63932250-e0c4-4c1e-a1c5-45217a31128d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Esterified Estrogens and Methyltestosterone Full and Half-Strength Tablets are indicated in the: • Treatment of moderate to severe vasomotor symptoms associated with the menopause in those patients not improved by estrogens alone. (There is no evidence that estrogens are effective for nervous symptoms or depression without associated vasomotor symptoms, and they should not be used to treat such conditions.) • Esterified Estrogens and Methyltestosterone Full and Half-Strength Tablets have not been shown to be effective for any purpose during pregnancy and its use may cause severe harm to the fetus. uuid:a86aadb8-9402-47c2-8d7f-4a3b066ef77b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:216989 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:8dab8b3f-9189-410c-b3cf-22e13f636c23"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b2c2936d-b367-4ac0-b6cc-1bef6296fac8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Esterified Estrogens and Methyltestosterone Full and Half-Strength Tablets are indicated in the: • Treatment of moderate to severe vasomotor symptoms associated with the menopause in those patients not improved by estrogens alone. (There is no evidence that estrogens are effective for nervous symptoms or depression without associated vasomotor symptoms, and they should not be used to treat such conditions.) • Esterified Estrogens and Methyltestosterone Full and Half-Strength Tablets have not been shown to be effective for any purpose during pregnancy and its use may cause severe harm to the fetus. uuid:74d3ff4b-5ee2-47fa-9f65-ad8386976cf6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17141 biolink:treats MONDO:0100151 PMID:41385096 "[{""id"":""uuid:8b7d6545-da53-4b79-bbbb-ba991218eab1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:212003ea-4aa8-49f2-86b5-212cd7cd1d54"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:444a1abc-3226-445c-8f28-a3e4d5437c42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c920c79d-2597-46ad-b329-ef08762811c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CYSTAGON ® is indicated for the management of nephropathic cystinosis in children and adults.|[EMA] Procysbi is indicated for the treatment of proven nephropathic cystinosis. Cysteamine reduces cystine accumulation in some cells (e.g. leukocytes, muscle and liver cells) of nephropathic cystinosis patients and, when treatment is started early, it delays the development of renal failure.|[PMDA] Drugs with a new active ingredient indicated for the treatment of nephropathic cystinosis. [Orphan drug] uuid:9cc78c08-4a4a-47a2-9d14-5238ce6c30b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15765 biolink:treats MONDO:0005180 PMID:41385096 "[{""id"":""uuid:535f7c89-1482-4c57-b7e6-7d3a0e87d732"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2897ab82-458a-4e89-9e7b-75e85b3f30de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7ab87911-f7bb-4cc7-83ae-fa808e1dde58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/inbrija""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] INBRIJA is indicated for the intermittent treatment of OFF episodes in patients with Parkinson's disease treated with carbidopa/levodopa.|[EMA] Inbrija is indicated for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor. uuid:b2fbcaaa-446b-4980-896c-429696ece58f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15765 biolink:treats UMLS:C5681154 PMID:41385096 "[{""id"":""uuid:40fa2625-80b3-4d44-a1b0-02d6fcca99a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0bb4dd88-1e4b-435b-8f51-f8e01fb075e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:cb95a4e9-efdb-448c-839b-9c5fe4b81343"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/inbrija""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] INBRIJA is indicated for the intermittent treatment of OFF episodes in patients with Parkinson's disease treated with carbidopa/levodopa.|[EMA] Inbrija is indicated for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor. uuid:0e3ca48b-f3dd-4a08-b098-bde21c7790aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7D0YB67S97 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:84755152-d0dc-4e5b-a6a1-54726af166bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ac1865e0-dd8d-41f9-8948-bee4561b08bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:897645d4-7990-4bb5-b6e7-c4f565377e1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/orencia""]},{""id"":""uuid:228c7b82-11ec-42f2-b38b-abedd1c076c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ORENCIA is a selective T cell costimulation modulator indicated for: • the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). (1.1) • the treatment of patients 2 years of age and older with moderately to severely active polyarticular juvenile idiopathic arthritis (pJIA). (1.2) • the treatment of patients 2 years of age and older with active psoriatic arthritis (PsA). (1.3) • the prophylaxis of acute graft versus host disease (aGVHD), in combination with a calcineurin inhibitor and methotrexate, in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated donor. (1.4) Limitations of Use: Concomitant use of ORENCIA with other immunosuppressives [e.g., biologic disease-modifying antirheumatic drugs (bDMARDS), Janus kinase (JAK) inhibitors] is not recommended ( 1.5 , 5.1) .|[EMA] Rheumatoid arthritisOrencia, in combination with methotrexate, is indicated for:the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who responded inadequately to previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) including methotrexate (MTX) or a tumour necrosis factor (TNF)-alpha inhibitor.the treatment of highly active and progressive disease in adult patients with rheumatoid arthritis not previously treated with methotrexate.A reduction in the progression of joint damage and improvement of physical function have been demonstrated during combination treatment with abatacept and methotrexate.Psoriatic arthritisOrencia, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients when the response to previous DMARD therapy including MTX has been inadequate, and for whom additional systemic therapy for psoriatic skin lesions is not required. Polyarticular juvenile idiopathic arthritisOrencia in combination with methotrexate is indicated for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis (pJIA) in paediatric patients 2 years of age and older who have had an inadequate response to previous DMARD therapy.Orencia can be given as monotherapy in case of intolerance to methotrexate or when treatment with methotrexate is inappropriate.|[PMDA] A drug with a new route of administration and a new dosage in a new dosage form indicated for the treatment of rheumatoid arthritis in patients who have not responded sufficiently to conventional treatments. uuid:19f30776-ca23-43e3-96fe-8db4a3466c71 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7D0YB67S97 biolink:treats MONDO:0018456 PMID:41385096 "[{""id"":""uuid:5c3e85be-24bc-4c68-a4e7-c316d78a2c39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:8a986ad4-77c2-4aed-a567-2f551baea43d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:089858cd-b880-4d9d-abf0-09b84fde9d0c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/orencia""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ORENCIA is a selective T cell costimulation modulator indicated for: • the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). (1.1) • the treatment of patients 2 years of age and older with moderately to severely active polyarticular juvenile idiopathic arthritis (pJIA). (1.2) • the treatment of patients 2 years of age and older with active psoriatic arthritis (PsA). (1.3) • the prophylaxis of acute graft versus host disease (aGVHD), in combination with a calcineurin inhibitor and methotrexate, in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated donor. (1.4) Limitations of Use: Concomitant use of ORENCIA with other immunosuppressives [e.g., biologic disease-modifying antirheumatic drugs (bDMARDS), Janus kinase (JAK) inhibitors] is not recommended ( 1.5 , 5.1) .|[EMA] Rheumatoid arthritisOrencia, in combination with methotrexate, is indicated for:the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who responded inadequately to previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) including methotrexate (MTX) or a tumour necrosis factor (TNF)-alpha inhibitor.the treatment of highly active and progressive disease in adult patients with rheumatoid arthritis not previously treated with methotrexate.A reduction in the progression of joint damage and improvement of physical function have been demonstrated during combination treatment with abatacept and methotrexate.Psoriatic arthritisOrencia, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients when the response to previous DMARD therapy including MTX has been inadequate, and for whom additional systemic therapy for psoriatic skin lesions is not required. Polyarticular juvenile idiopathic arthritisOrencia in combination with methotrexate is indicated for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis (pJIA) in paediatric patients 2 years of age and older who have had an inadequate response to previous DMARD therapy.Orencia can be given as monotherapy in case of intolerance to methotrexate or when treatment with methotrexate is inappropriate. uuid:d321799b-2bd8-480b-94cc-75eaed49a6f7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7D0YB67S97 biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:5bf0e563-bd4b-457a-b47e-54c8d343587b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e55e4fc0-72ba-41f9-afdc-9b99671e6265"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:02b08652-8e7c-4d8d-a025-1b25548758c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/orencia""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ORENCIA is a selective T cell costimulation modulator indicated for: • the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). (1.1) • the treatment of patients 2 years of age and older with moderately to severely active polyarticular juvenile idiopathic arthritis (pJIA). (1.2) • the treatment of patients 2 years of age and older with active psoriatic arthritis (PsA). (1.3) • the prophylaxis of acute graft versus host disease (aGVHD), in combination with a calcineurin inhibitor and methotrexate, in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated donor. (1.4) Limitations of Use: Concomitant use of ORENCIA with other immunosuppressives [e.g., biologic disease-modifying antirheumatic drugs (bDMARDS), Janus kinase (JAK) inhibitors] is not recommended ( 1.5 , 5.1) .|[EMA] Rheumatoid arthritisOrencia, in combination with methotrexate, is indicated for:the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who responded inadequately to previous therapy with one or more disease-modifying anti-rheumatic drugs (DMARDs) including methotrexate (MTX) or a tumour necrosis factor (TNF)-alpha inhibitor.the treatment of highly active and progressive disease in adult patients with rheumatoid arthritis not previously treated with methotrexate.A reduction in the progression of joint damage and improvement of physical function have been demonstrated during combination treatment with abatacept and methotrexate.Psoriatic arthritisOrencia, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients when the response to previous DMARD therapy including MTX has been inadequate, and for whom additional systemic therapy for psoriatic skin lesions is not required. Polyarticular juvenile idiopathic arthritisOrencia in combination with methotrexate is indicated for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis (pJIA) in paediatric patients 2 years of age and older who have had an inadequate response to previous DMARD therapy.Orencia can be given as monotherapy in case of intolerance to methotrexate or when treatment with methotrexate is inappropriate. uuid:ef38ce18-2ae3-4e9a-b7bf-920555b20a93 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7D0YB67S97 biolink:treats MONDO:0020546 PMID:41385096 "[{""id"":""uuid:480573ea-b51d-4f53-b0c8-0335f87fa91b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6296596a-a4d5-4d16-8a8f-eeefd3a2a050"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ORENCIA is a selective T cell costimulation modulator indicated for: • the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). (1.1) • the treatment of patients 2 years of age and older with moderately to severely active polyarticular juvenile idiopathic arthritis (pJIA). (1.2) • the treatment of patients 2 years of age and older with active psoriatic arthritis (PsA). (1.3) • the prophylaxis of acute graft versus host disease (aGVHD), in combination with a calcineurin inhibitor and methotrexate, in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation (HSCT) from a matched or 1 allele-mismatched unrelated donor. (1.4) Limitations of Use: Concomitant use of ORENCIA with other immunosuppressives [e.g., biologic disease-modifying antirheumatic drugs (bDMARDS), Janus kinase (JAK) inhibitors] is not recommended ( 1.5 , 5.1) . uuid:77837b6b-4604-4c57-92c9-3d02977a32f7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7SE5582Q2P biolink:treats MONDO:0007037 PMID:41385096 "[{""id"":""uuid:8c8bcd96-f668-4721-83d3-abb721119035"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:580209c4-59d6-4d79-a598-f8925b0d4d2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:226515b8-4430-498a-ba4a-039d53d2e783"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/voxzogo""]},{""id"":""uuid:044d4b84-002f-470f-b89f-699f7980f08d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VOXZOGO is indicated to increase linear growth in pediatric patients with achondroplasia with open epiphyses. This indication is approved under accelerated approval based on an improvement in annualized growth velocity [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).|[EMA] Voxzogo is indicated for the treatment of achondroplasia in patients 4 months of age and older whose epiphyses are not closed. The diagnosis of achondroplasia should be confirmed by appropriate genetic testing.|[PMDA] Drugs with a new active ingredient indicated for the treatment of achondroplasia prior to epiphyseal closure. [Orphan drug] uuid:fea88a3b-93b6-48b3-b46b-39b8e971810e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:87PZU03K0K biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:bd2b8dd0-87b8-4551-91e6-8f53b4870627"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3b5ff7b4-403e-4180-9687-de7a616b53f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Velphoro is indicated for the control of serum phosphorus levels in adults and pediatric patients 9 years of age and older with chronic kidney disease (CKD) on dialysis. uuid:c91527b8-17db-4f24-8ead-d88ce39e78cf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:73B0K5S26A biolink:treats MONDO:0005556 PMID:41385096 "[{""id"":""uuid:508ba0a1-4d34-4be1-b618-812daf2e9001"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e87ce0d6-e8a6-4192-94df-b5e32a72b2cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:6c77d8af-3c63-41c4-ba22-f901f32fd608"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/benlysta""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] BENLYSTA (belimumab) is indicated for the treatment of: • patients 5 years of age and older with active systemic lupus erythematosus (SLE) who are receiving standard therapy, and • patients 5 years of age and older with active lupus nephritis who are receiving standard therapy. Limitations of Use The efficacy of BENLYSTA has not been evaluated in patients with severe active central nervous system (CNS) lupus. Use of BENLYSTA is not recommended in this situation.|[EMA] Benlysta is indicated as add-on therapy in patients aged 5 years and older with active, autoantibody positive systemic lupus erythematosus (SLE) with a high degree of disease activity (e.g., positive anti dsDNA and low complement) despite standard therapy.Benlysta is indicated in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis. uuid:1b28396f-43e5-4c8d-ab18-e91fbf6f6a80 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:84050 biolink:treats MONDO:0005060 PMID:41385096 "[{""id"":""uuid:c2bff5a5-145e-49e5-9e42-da0e4f4fbef2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e618b04b-06a5-4aeb-9f4c-1ae399e8c761"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:64b9c3be-e0cf-41d3-93f0-1e20dee8edab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/yondelis""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] YONDELIS ® is indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen [see Clinical Studies (14) ] .|[EMA] Yondelis is indicated for the treatment of patients with advanced soft-tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. Efficacy data are based mainly on liposarcoma and leiomyosarcoma patients.Yondelis in combination with pegylated liposomal doxorubicin (PLD) is indicated for the treatment of patients with relapsed platinum-sensitive ovarian cancer. uuid:73432512-0857-448c-b18b-abac12e01ede biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:84050 biolink:treats MONDO:0005058 PMID:41385096 "[{""id"":""uuid:66f0a8a9-bdb4-4408-bb1f-ec75231d1337"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:804fac99-873b-44d4-935b-cb2bec0a2ca7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9b44a908-393e-44d2-9c5a-6a2e78235481"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/yondelis""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] YONDELIS ® is indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen [see Clinical Studies (14) ] .|[EMA] Yondelis is indicated for the treatment of patients with advanced soft-tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. Efficacy data are based mainly on liposarcoma and leiomyosarcoma patients.Yondelis in combination with pegylated liposomal doxorubicin (PLD) is indicated for the treatment of patients with relapsed platinum-sensitive ovarian cancer. uuid:7afb27c5-4244-477d-a897-2d47f95c79d2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18358 biolink:treats MONDO:0015758 PMID:41385096 "[{""id"":""uuid:88b3c06f-a49e-4676-8116-c9ec7a4e8529"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b6a63262-f457-4a7a-8a61-86fa23e1d849"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] UVADEX ® (methoxsalen) Sterile Solution is indicated for extracorporeal administration with the THERAKOS ® CELLEX ® Photopheresis System in the palliative treatment of the skin manifestations of Cutaneous T-Cell Lymphoma (CTCL) that is unresponsive to other forms of treatment. uuid:3a1516eb-4969-47fe-92bf-ea44a8e26f63 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8680B21W73 biolink:treats UMLS:C1720505 PMID:41385096 "[{""id"":""uuid:fbfed8e8-da9d-4179-99ad-8f1d0325cc8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b32341c5-586d-4cd5-a086-c41f7ad5cf1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MACRILEN is indicated for the diagnosis of adult growth hormone deficiency (AGHD). uuid:90ec78d2-0f3f-46b0-95da-055c9038ab99 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63577 biolink:treats MONDO:0100192 PMID:41385096 "[{""id"":""uuid:2b43913f-f585-4cc6-9ffa-f2fca9855afd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b69a723d-423c-429b-9dfb-dced217ad68d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lamivudine tablets (HBV) are indicated for the treatment of chronic hepatitis B virus (HBV) infection associated with evidence of hepatitis B viral replication and active liver inflammation [see Clinical Studies ( 14.1 , 14.2 )]. The following points should be considered when initiating therapy with Lamivudine tablets (HBV): • Due to high rates of resistance development in treated patients, initiation of treatment with Lamivudine tablets (HBV) should only be considered when the use of an alternative antiviral agent with a higher genetic barrier to resistance is not available or appropriate. • Lamivudine tablets (HBV) have not been evaluated in patients co-infected with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis delta virus. • Lamivudine tablets (HBV) have not been evaluated in liver transplant recipients or in patients with chronic hepatitis B virus infection with decompensated liver disease. uuid:9b4198c2-4863-4f67-9937-6c0efe0bc199 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:BTY153760O biolink:treats UMLS:C0406317 PMID:41385096 "[{""id"":""uuid:03f2e291-3061-4401-8f27-08b5cfc12e39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:50bfd9fb-05e5-47b6-a858-6dcab2d7c88d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:408c15e2-ce41-42c2-8b45-1399af0025b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TALTZ ® is a humanized interleukin-17A antagonist indicated for the treatment of: patients aged 6 years or older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. ( 1.1 ) adults with active psoriatic arthritis. ( 1.2 ) adults with active ankylosing spondylitis. ( 1.3 ) adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation. ( 1.4 )|[PMDA] Drugs with a new active ingredient indicated for the treatment of plaque psoriasis, psoriatic arthritis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies. uuid:536511f2-ad10-4010-9bfd-5f613ce5ba81 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:BTY153760O biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:a5242b58-f81d-417c-ad77-c43185442999"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:761319ee-db5b-4870-8703-b74b2f516171"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:05685d39-3d90-4ecd-becb-5b8c6d40ea2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/taltz""]},{""id"":""uuid:aa23ffbf-9047-4ab5-928d-b3f7b3adf466"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TALTZ ® is a humanized interleukin-17A antagonist indicated for the treatment of: patients aged 6 years or older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. ( 1.1 ) adults with active psoriatic arthritis. ( 1.2 ) adults with active ankylosing spondylitis. ( 1.3 ) adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation. ( 1.4 )|[EMA] Plaque psoriasisTaltz is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.Psoriatic arthritisTaltz, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drug (DMARD) therapies.|[PMDA] Drugs with a new active ingredient indicated for the treatment of plaque psoriasis, psoriatic arthritis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies. uuid:7f93c5db-b1f1-4d88-9f97-0a33739d1492 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:BTY153760O biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:8a315b77-54a4-4d5f-84f9-360fbd81ae35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e6701c71-9602-4d92-beb6-dd73732e8ee9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9197a4c2-8948-43a6-9f42-9d956a6bdf72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TALTZ ® is a humanized interleukin-17A antagonist indicated for the treatment of: patients aged 6 years or older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. ( 1.1 ) adults with active psoriatic arthritis. ( 1.2 ) adults with active ankylosing spondylitis. ( 1.3 ) adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation. ( 1.4 )|[PMDA] Drugs with a new additional indication and a new dosage for the treatment of ankylosing spondylitis in patients who have not responded sufficiently to conventional treatments. uuid:b564532e-44fe-4129-9dab-d6932df45d8c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:BTY153760O biolink:treats UMLS:C3203547 PMID:41385096 "[{""id"":""uuid:f83f2d45-b401-49b1-ac26-2fffc7585189"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:148fb069-43b7-478d-8e1c-87edcd65cdbc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:959b0c80-5f29-45cb-bb86-8ef153322083"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TALTZ ® is a humanized interleukin-17A antagonist indicated for the treatment of: patients aged 6 years or older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. ( 1.1 ) adults with active psoriatic arthritis. ( 1.2 ) adults with active ankylosing spondylitis. ( 1.3 ) adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation. ( 1.4 )|[PMDA] Drugs with a new indication and a new dosage for the treatment of non-radiographic axial spondyloarthritis in patients who have not responded sufficiently to conventional treatments. uuid:f9dd5fea-f71f-4af6-868c-36e94507819c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:78543 biolink:treats MONDO:0011996 PMID:41385096 "[{""id"":""uuid:ed86b70b-efea-4fd3-8b19-9b2734a04535"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f5ebd167-041e-4ad6-9961-e2ea6afde9ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3bcec514-edfb-4b37-afce-18a0261366b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/iclusig""]},{""id"":""uuid:876e4d5b-2e06-4797-b463-189275e4f949"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ICLUSIG is indicated for the treatment of adult patients with: Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Newly diagnosed Ph+ ALL in combination with chemotherapy. This indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete remission (CR) at the end of induction [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). As monotherapy in Ph+ ALL for whom no other kinase inhibitors are indicated or T315I-positive Ph+ ALL. Chronic Myeloid Leukemia (CML) Chronic phase (CP) CML with resistance or intolerance to at least two prior kinase inhibitors. Accelerated phase (AP) or blast phase (BP) CML for whom no other kinase inhibitors are indicated. T315I-positive CML (chronic phase, accelerated phase, or blast phase).|[EMA] Iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (CML) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutationPhiladelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the T315I mutation.See sections 4.2 Assessment of cardiovascular status prior to start of therapy and 4.4 situations where an alternative treatment may be considered.|[PMDA] A drug with a new active ingredient indicated for the treatment of chronic myelogenous leukemia with resistance or intolerance to prior drug therapies, and recurrent or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. [Orphan drug] uuid:a88eff74-d8f4-4349-b9d2-e309a3ac97ce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63626 biolink:treats MONDO:0006573 PMID:41385096 "[{""id"":""uuid:094e6c1f-792b-4a63-880b-1c4604acec80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:888eb922-00b3-43de-af5a-449dfb9de49d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EGRIFTA SV is indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy. Limitations of Use: Long-term cardiovascular safety of EGRIFTA SV has not been established. Consider risk/benefit of continuation of treatment in patients who have not had a reduction in visceral adipose tissue. EGRIFTA SV is not indicated for weight loss management as it has a weight neutral effect. There are no data to support improved compliance with anti-retroviral therapies in HIV-positive patients taking EGRIFTA SV. uuid:20eba19e-66ee-40ea-8e49-3823a8849fb0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0006050 biolink:treats HP:0006986 PMID:41385096 "[{""id"":""uuid:51b8a5fc-0104-4cdd-8930-5fe3b8a79b52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:041523d7-64c9-46fd-8043-bc1fed7ce940"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XEOMIN is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the treatment or improvement of: Chronic sialorrhea in patients 2 years of age and older ( 1.1 ) Upper limb spasticity in adults ( 1.2 ) Upper limb spasticity in pediatric patients 2 to 17 years of age, excluding spasticity caused by cerebral palsy ( 1.2 ) Cervical dystonia in adults ( 1.3 ) Blepharospasm in adults ( 1.4 ) the appearance of upper facial lines in adults: moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity ( 1.5 ) moderate to severe horizontal forehead lines associated with frontalis muscle activity ( 1.5 ) moderate to severe lateral canthal lines associated with orbicularis oculi muscle activity ( 1.5 ) DRUGBANK:DB00083 uuid:a31df77a-cd15-4f11-a45d-6ccd63c78b37 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0006050 biolink:treats MONDO:0011728 PMID:41385096 "[{""id"":""uuid:50862d17-3433-4c7f-b923-34453d91870c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6352a286-e338-4fa8-b818-fe3ac0b86a30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XEOMIN is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the treatment or improvement of: Chronic sialorrhea in patients 2 years of age and older ( 1.1 ) Upper limb spasticity in adults ( 1.2 ) Upper limb spasticity in pediatric patients 2 to 17 years of age, excluding spasticity caused by cerebral palsy ( 1.2 ) Cervical dystonia in adults ( 1.3 ) Blepharospasm in adults ( 1.4 ) the appearance of upper facial lines in adults: moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity ( 1.5 ) moderate to severe horizontal forehead lines associated with frontalis muscle activity ( 1.5 ) moderate to severe lateral canthal lines associated with orbicularis oculi muscle activity ( 1.5 ) DRUGBANK:DB00083 uuid:67cd4c59-f68c-4ddd-8914-4a8de56799fb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1655924 biolink:treats MONDO:0009061 PMID:41385096 "[{""id"":""uuid:a03c8fe6-f81f-467d-ae34-91cfdeefb0e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ae61c194-8c88-4d30-92fd-ed4b40f9dbbe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ORKAMBI is indicated for the treatment of cystic fibrosis (CF) in patients aged 1 year and older who are homozygous for the F508del mutation in the CFTR gene. If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of the F508del mutation on both alleles of the CFTR gene. uuid:1793f6a4-17d2-4120-91ed-7b15362ce6e2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:QMS40680K6 biolink:treats MONDO:0005588 PMID:41385096 "[{""id"":""uuid:83cedb23-c0fd-402a-bcb3-4fccb373b2a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a63fb533-23f2-4c32-87da-b2f50f5014e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Kepivance is a mucocutaneous epithelial human growth factor indicated to decrease the incidence and duration of severe oral mucositis in patients with hematologic malignancies receiving myelotoxic therapy in the setting of autologous hematopoietic stem cell support. Kepivance is indicated as supportive care for preparative regimens predicted to result in ≥ WHO Grade 3 mucositis in the majority of patients. ( 1.1 ) Limitations of Use The safety and efficacy of Kepivance have not been established in patients with non-hematologic malignancies ( 1.2 , 5.1 ) Kepivance was not effective in decreasing the incidence of severe mucositis in patients with hematologic malignancies receiving myelotoxic therapy in the setting of allogeneic hematopoietic stem cell support. ( 1.2 , 14.3 ) Kepivance is not recommended for use with melphalan 200 mg/m 2 as a conditioning regimen ( 14.2 ). uuid:58631022-2ca9-452b-b5d3-aa09c24c0019 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:QMS40680K6 biolink:treats NCIT:C157387 PMID:41385096 "[{""id"":""uuid:0929c788-6432-400b-805b-5c4d80027636"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2589e9c1-d306-4000-89c0-e3905802d937"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Kepivance is a mucocutaneous epithelial human growth factor indicated to decrease the incidence and duration of severe oral mucositis in patients with hematologic malignancies receiving myelotoxic therapy in the setting of autologous hematopoietic stem cell support. Kepivance is indicated as supportive care for preparative regimens predicted to result in ≥ WHO Grade 3 mucositis in the majority of patients. ( 1.1 ) Limitations of Use The safety and efficacy of Kepivance have not been established in patients with non-hematologic malignancies ( 1.2 , 5.1 ) Kepivance was not effective in decreasing the incidence of severe mucositis in patients with hematologic malignancies receiving myelotoxic therapy in the setting of allogeneic hematopoietic stem cell support. ( 1.2 , 14.3 ) Kepivance is not recommended for use with melphalan 200 mg/m 2 as a conditioning regimen ( 14.2 ). uuid:5ef67d6c-1e3e-44a6-a53a-c5c78e263bb4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:I60W9520VV biolink:treats UMLS:C5438213 PMID:41385096 "[{""id"":""uuid:f9f79b9f-bfdb-48ad-85bb-5101538925d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:910c2061-a3d8-44ad-8e78-c94ac6fac4bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VAFSEO is indicated for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months. Limitations of Use VAFSEO has not been shown to improve quality of life, fatigue, or patient well-being. VAFSEO is not indicated for use: As a substitute for red blood cell transfusions in patients who require immediate correction of anemia In patients with anemia due to CKD not on dialysis [see Warnings and Precautions ( 5.6 )] . uuid:b9722114-b84e-41ea-a0e2-1562c655450f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:I60W9520VV biolink:treats MONDO:0002280 PMID:41385096 "[{""id"":""uuid:17e49d26-792a-49a6-8bdb-2fd2aadf9966"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:46e98466-a1e5-493b-bdab-31cd21db2e6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:21b182c6-b6c6-444c-b226-f5c3a9e49aab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vafseo""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] VAFSEO is indicated for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months. Limitations of Use VAFSEO has not been shown to improve quality of life, fatigue, or patient well-being. VAFSEO is not indicated for use: As a substitute for red blood cell transfusions in patients who require immediate correction of anemia In patients with anemia due to CKD not on dialysis [see Warnings and Precautions ( 5.6 )] .|[EMA] Vafseo is indicated for the treatment of symptomatic anaemia associated with chronic kidney disease (CKD) in adults on chronic maintenance dialysis. uuid:91c34ab8-4e37-4d3b-a332-459c97899294 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:T1JP1KYU9O biolink:treats MONDO:0004975 PMID:41385096 "[{""id"":""uuid:5cdb8021-044f-410a-8700-187079a13fd1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:18db82c1-1c50-4039-b25a-e3e82ab96e26"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TAUVID is indicated for use with positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD). uuid:8ad428bd-c43f-4743-adff-2b487547c7e6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:T1JP1KYU9O biolink:treats HP:0100543 PMID:41385096 "[{""id"":""uuid:99b951ba-ffb2-4492-aef1-7e175e255cbc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5d279c03-e06e-45d9-a097-8b093a1e5f6d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TAUVID is indicated for use with positron emission tomography (PET) imaging of the brain to estimate the density and distribution of aggregated tau neurofibrillary tangles (NFTs) in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD). uuid:a19c03d4-fcb0-45fe-beff-037fb713e0c7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50861 biolink:treats MONDO:0002429 PMID:41385096 "[{""id"":""uuid:88a9d25a-aafa-4b69-8f62-46e90517c2c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4aa08689-93d5-4941-ab5f-47348c8f0b17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tyvaso is a prostacyclin mimetic indicated for the treatment of: Pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability. Studies establishing effectiveness predominately included patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%). ( 1.1 ) Pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability. The study establishing effectiveness predominately included patients with etiologies of idiopathic interstitial pneumonia (IIP) (45%) inclusive of idiopathic pulmonary fibrosis (IPF), combined pulmonary fibrosis and emphysema (CPFE) (25%), and WHO Group 3 connective tissue disease (22%). ( 1.2 ) uuid:0a5e0878-99f6-4ec9-963d-de9767725ab9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50861 biolink:treats MONDO:0002771 PMID:41385096 "[{""id"":""uuid:7dfb675b-ac42-4ca0-98ce-e193ae03014f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:76641bc8-6948-4d39-ac36-c3a0f87ad2d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tyvaso is a prostacyclin mimetic indicated for the treatment of: Pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability. Studies establishing effectiveness predominately included patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%). ( 1.1 ) Pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability. The study establishing effectiveness predominately included patients with etiologies of idiopathic interstitial pneumonia (IIP) (45%) inclusive of idiopathic pulmonary fibrosis (IPF), combined pulmonary fibrosis and emphysema (CPFE) (25%), and WHO Group 3 connective tissue disease (22%). ( 1.2 ) uuid:6514de62-ff1c-4fe4-b18c-f0e30dd116bc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50861 biolink:treats MONDO:0017591 PMID:41385096 "[{""id"":""uuid:e5e75f4b-c1a8-474f-b82e-3ef6824aad13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ea598f30-4051-442a-b4ce-d4268b610405"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tyvaso is a prostacyclin mimetic indicated for the treatment of: Pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability. Studies establishing effectiveness predominately included patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%). ( 1.1 ) Pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability. The study establishing effectiveness predominately included patients with etiologies of idiopathic interstitial pneumonia (IIP) (45%) inclusive of idiopathic pulmonary fibrosis (IPF), combined pulmonary fibrosis and emphysema (CPFE) (25%), and WHO Group 3 connective tissue disease (22%). ( 1.2 ) uuid:c8fc4a5f-708e-4919-b413-13dc1374cbb0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50861 biolink:treats MONDO:0003900 PMID:41385096 "[{""id"":""uuid:93dc398e-2bb6-4cb1-ae39-ebf91e152a82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:79fba2ae-ad51-4fe7-a0b4-1e37c37938ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Tyvaso is a prostacyclin mimetic indicated for the treatment of: Pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability. Studies establishing effectiveness predominately included patients with NYHA Functional Class III symptoms and etiologies of idiopathic or heritable PAH (56%) or PAH associated with connective tissue diseases (33%). ( 1.1 ) Pulmonary hypertension associated with interstitial lung disease (PH-ILD; WHO Group 3) to improve exercise ability. The study establishing effectiveness predominately included patients with etiologies of idiopathic interstitial pneumonia (IIP) (45%) inclusive of idiopathic pulmonary fibrosis (IPF), combined pulmonary fibrosis and emphysema (CPFE) (25%), and WHO Group 3 connective tissue disease (22%). ( 1.2 ) uuid:1db83241-70ba-4b10-918c-2ee899152390 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7SQY4ZUD30 biolink:treats MONDO:0005072 PMID:41385096 "[{""id"":""uuid:b0820498-3e0d-4beb-afe1-5ea97ad6b88c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ef464351-fd56-41c8-be4c-cbabc4ddd93f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a26e3261-a200-4f0f-9355-b2da33f34b10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Unituxin (dinutuximab) is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy [see Clinical Studies (14) ].|[PMDA] A drug with a new active ingredient indicated for the treatment of neuroblastoma following high- dose chemotherapy. [Orphan drug] uuid:89a8e55b-427b-49e1-8557-b6314ca81e6a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22652 biolink:treats MONDO:0020696 PMID:41385096 "[{""id"":""uuid:c128ed9b-477b-4736-a0b5-5e563512e05c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8005ae48-af31-4048-8ca1-4b1f3a1ba5c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PaxLyte is indicated in the TREATMENT of vitamin deficiency – specifically vitamin B 12 deficiency, and the PREVENTION of vitamin B 12 -cofactor deficiency, l-methylfolate. uuid:068861ee-c4f0-4589-850b-4e369e30d047 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82699 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:a29a29a8-d376-4910-a1ef-21e8572d5636"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:99f99b94-eb4a-4833-8d94-401ceae6d525"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ecf15d08-02a5-4293-be7c-62665c374ed1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ORBACTIV is a lipoglycopeptide antibacterial drug indicated for the treatment of adult patients with acute bacterial skin and skin structure infections caused or suspected to be caused by susceptible isolates of designated Gram-positive microorganisms. ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of ORBACTIV and other antibacterial drugs, ORBACTIV should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.2 )|[EMA] Tenkasi is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults and paediatric patients aged 3 months and older (see sections 4.2, 4.4 and 5.1).Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:35ddf755-ab45-4389-919a-e7290496f622 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB17743 biolink:treats EFO:0009130 PMID:41385096 "[{""id"":""uuid:6dc95763-4f00-485b-a57f-59b2d05b0ed6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0bb74145-1347-4440-b025-52d30b6afcd7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] REBYOTA is indicated for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older following antibiotic treatment for recurrent CDI. uuid:ed0d7686-c6f6-4713-945d-c0c3b36eed71 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB17743 biolink:treats UMLS:C5230640 PMID:41385096 "[{""id"":""uuid:116fd3e0-4c01-4bce-a691-d37ac551eb23"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:25d07dcb-d220-4706-9fc5-07357962006c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] REBYOTA is indicated for the prevention of recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older following antibiotic treatment for recurrent CDI. uuid:5d649240-0902-4005-a662-a016229baeb3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31485 biolink:treats NCIT:C3137 PMID:41385096 "[{""id"":""uuid:9597fe92-8684-4253-b1ce-0e4bff20ab9a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:24aa6ea5-06ff-4097-8f76-7f1da1cd374a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Difluprednate ophthalmic emulsion is a topical corticosteroid that is indicated for: The treatment of inflammation and pain associated with ocular surgery. ( 1.1 ) The treatment of endogenous anterior uveitis. ( 1.2 ) uuid:ebaf2ab6-3aeb-44bc-865d-0b38a5ec785e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31485 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:ee467595-6943-47d9-947b-a7e13227ada3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:da1fae0b-37d7-4c7a-9427-e0c0897ed9b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Difluprednate ophthalmic emulsion is a topical corticosteroid that is indicated for: The treatment of inflammation and pain associated with ocular surgery. ( 1.1 ) The treatment of endogenous anterior uveitis. ( 1.2 ) uuid:3e214fb5-a037-4ce8-b802-9f139118ccfc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2670458 biolink:treats MONDO:0043544 PMID:41385096 "[{""id"":""uuid:dd761121-eaec-44be-bd5f-32229fad6712"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d242cf06-3e9c-40f6-be85-4e62f5b9004e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LIMITED POPULATION: DEFENCATH ® is indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients [see Clinical Studies (14) ]. Limitations of Use The safety and effectiveness of DEFENCATH have not been established for use in populations other than adult patients with kidney failure receiving chronic HD through a CVC. uuid:7bc3f190-1f28-4411-95a9-38fa7df42a8e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2670458 biolink:treats MONDO:0001106 PMID:41385096 "[{""id"":""uuid:b9e3419d-d99c-447e-9257-2079b0852b73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:97c6092f-8020-4a96-a7f8-8e8350c2fc03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LIMITED POPULATION: DEFENCATH ® is indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients [see Clinical Studies (14) ]. Limitations of Use The safety and effectiveness of DEFENCATH have not been established for use in populations other than adult patients with kidney failure receiving chronic HD through a CVC. uuid:9ef2be9a-4d1c-45a8-a83d-db725aea9757 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16301 biolink:treats MONDO:0018754 PMID:41385096 "[{""id"":""uuid:e78f3a24-bb51-4da1-b80e-df8999e9c839"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:43d2793c-c00e-4aae-9c71-d68191b96cee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Nitrite Injection, an antidote, is indicated for sequential use with sodium thiosulfate for the treatment of acute cyanide poisoning that is judged to be serious or life-threatening. When the diagnosis of cyanide poisoning is uncertain, the potentially life-threatening risks associated with Sodium Nitrite Injection should be carefully weighed against the potential benefits, especially if the patient is not in extremis. uuid:8b4b874d-654d-4b8a-b0e5-4764d7461841 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16094 biolink:treats MONDO:0018754 PMID:41385096 "[{""id"":""uuid:ea88075d-bc34-4161-83d6-c488b99080d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1a2d2db2-48df-4b7d-b72f-87ad50889060"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sodium Thiosulfate Injection is indicated for sequential use with sodium nitrite for the treatment of acute cyanide poisoning that is judged to be serious or life-threatening. When the diagnosis of cyanide poisoning is uncertain, the potential risks associated with Sodium Thiosulfate Injection should be carefully weighed against the potential benefits, especially if the patient is not in extremis. uuid:59158759-92a7-4856-acde-b460c7910d86 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135552 biolink:treats UMLS:C0267509 PMID:41385096 "[{""id"":""uuid:c6ca3025-2fa5-4a45-ae07-d57ac51758d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a05ec0cb-a9cf-4d49-8a65-2328d4b34b2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prucalopride tablet is indicated for the treatment of chronic idiopathic constipation (CIC) in adults. uuid:8c991c66-c6b1-4ca4-aea0-5e374a7f3faa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135552 biolink:treats MONDO:0956989 PMID:41385096 "[{""id"":""uuid:875945df-de49-43c8-b764-e0b4693e8a6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9126fb89-0388-4bc5-ab9d-e5ce1d1ac982"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Prucalopride tablet is indicated for the treatment of chronic idiopathic constipation (CIC) in adults. uuid:195f63e4-d10c-4903-a572-34456b355fe7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17439 biolink:treats MONDO:0007705 PMID:41385096 "[{""id"":""uuid:6893c101-a4be-4195-9dc9-6ef8f7d5ce3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:49d64d84-6a7f-4ac4-a59e-bcaf1ae7831c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of all anemias responsive to oral iron therapy, such as hypochromic anemia associated with pregnancy, chronic or acute blood loss, dietary restriction, metabolic disease and post-surgical convalescence. uuid:b188e2cd-3e59-4a23-80a3-691e5a877c99 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17439 biolink:treats MONDO:0001357 PMID:41385096 "[{""id"":""uuid:46ef1201-45df-4f25-acf9-c43e26142e90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:709b3863-0773-4ae6-9673-0fa536ee3878"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the treatment of all anemias responsive to oral iron therapy, such as hypochromic anemia associated with pregnancy, chronic or acute blood loss, dietary restriction, metabolic disease and post-surgical convalescence. uuid:666cbb1c-b756-4f01-81f1-fb42ba867b73 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6D848RA61B biolink:treats MONDO:0008250 PMID:41385096 "[{""id"":""uuid:ca2f5102-e5bf-4fcc-bd03-4b6d1d029b52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:3e451a33-4407-4ded-8d9e-332473a19875"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b84f4341-cf08-4228-b265-2ba06154998f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ngenla""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] NGENLA is indicated for the treatment of pediatric patients aged 3 years and older who have growth failure due to an inadequate secretion of endogenous growth hormone.|[EMA] Indicated for the long-term treatment of paediatric patients with growth disturbance due to insufficient secretion of growth hormone uuid:32f44997-f7a5-41f0-b9ea-77dbb1731b7e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1487516 biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:e9881c56-a708-42db-bd6e-5ae8e82b4801"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a4e8845a-5a8e-4739-bbdd-ec1b606d8957"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c44fb3df-5f50-4960-8009-614017f6d7fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/anoro-ellipta""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ANORO ELLIPTA is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Limitations of Use ANORO ELLIPTA is NOT indicated for the relief of acute bronchospasm or for the treatment of asthma. The safety and effectiveness of ANORO ELLIPTA in asthma have not been established.|[EMA] Anoro Ellipta is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). uuid:f26938ec-0dd0-4199-a54b-3a9e72e61904 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1487516 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:3c0cd751-6987-47c7-b40f-69051c2504a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aaff2c4a-b4cf-4016-9e89-9f6f75bab2aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ANORO ELLIPTA is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Limitations of Use ANORO ELLIPTA is NOT indicated for the relief of acute bronchospasm or for the treatment of asthma. The safety and effectiveness of ANORO ELLIPTA in asthma have not been established. uuid:77cb634f-0116-4731-b9e8-94cb771cc461 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0007256 PMID:41385096 "[{""id"":""uuid:1119c901-0dd2-49c5-993e-b8cc0b03e9c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:77e8304a-dcd2-4141-919a-a1250b08e0dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lipiodol is an oil-based radio-opaque contrast agent indicated for: hysterosalpingography in adults lymphography in adult and pediatric patients selective hepatic intra-arterial use for imaging tumors in adults with known hepatocellular carcinoma (HCC) uuid:cbb39154-e0f0-4e6f-b353-8b6250346f57 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1545147 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:700ba6f5-a100-4726-b66a-417728bb1d33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0a74dc86-06c5-4de1-af15-05b8b5bd97a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7294dc6c-b766-4176-8938-b53a1455762c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vokanamet""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] INVOKAMET and INVOKAMET XR are a combination of canagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, and metformin hydrochloride (HCl), a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus ( 1 ). Canagliflozin Canagliflozin, when used as a component of INVOKAMET or INVOKAMET XR is indicated in adults with type 2 diabetes mellitus to reduce the risk of: Major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease ( 1 ). End-stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in adults with type 2 diabetes mellitus and diabetic nephropathy with albuminuria ( 1 ). Limitations of Use: Not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus ( 1 ).|[EMA] Vokanamet is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:in patients not adequately controlled on their maximally tolerated doses of metformin alonein patients on their maximally tolerated doses of metformin along with other glucose lowering medicinal products including insulin, when these do not provide adequate glycaemic control.in patients already being treated with the combination of canagliflozin and metformin as separate tabletsFor study results with respect to combination of therapies, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1. uuid:7ab09458-1bc8-4300-b4aa-081b07279467 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1545147 biolink:treats MONDO:0004995 PMID:41385096 "[{""id"":""uuid:52518eb8-c37b-427c-a448-b0fc0e6d1111"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5af472a4-7b4f-4043-a36f-79ad349416cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INVOKAMET and INVOKAMET XR are a combination of canagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, and metformin hydrochloride (HCl), a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus ( 1 ). Canagliflozin Canagliflozin, when used as a component of INVOKAMET or INVOKAMET XR is indicated in adults with type 2 diabetes mellitus to reduce the risk of: Major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease ( 1 ). End-stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in adults with type 2 diabetes mellitus and diabetic nephropathy with albuminuria ( 1 ). Limitations of Use: Not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus ( 1 ). uuid:c8e2cea9-51b1-4fc6-bbdf-2b9b8beeab4b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1545147 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:5e63993d-0669-4c42-8c5f-dfae0280ebe7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cf1c75f5-979f-45da-8b33-0a8bfd9d5474"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INVOKAMET and INVOKAMET XR are a combination of canagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, and metformin hydrochloride (HCl), a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus ( 1 ). Canagliflozin Canagliflozin, when used as a component of INVOKAMET or INVOKAMET XR is indicated in adults with type 2 diabetes mellitus to reduce the risk of: Major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease ( 1 ). End-stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in adults with type 2 diabetes mellitus and diabetic nephropathy with albuminuria ( 1 ). Limitations of Use: Not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus ( 1 ). uuid:55a472eb-00bb-4bc5-8d6d-f003dd480eb5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1545147 biolink:treats MONDO:0004375 PMID:41385096 "[{""id"":""uuid:e497e320-74b6-433f-a91d-f97917b01d90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f86aa2b5-0f12-41b3-a5e7-3ea947100866"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INVOKAMET and INVOKAMET XR are a combination of canagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, and metformin hydrochloride (HCl), a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus ( 1 ). Canagliflozin Canagliflozin, when used as a component of INVOKAMET or INVOKAMET XR is indicated in adults with type 2 diabetes mellitus to reduce the risk of: Major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease ( 1 ). End-stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in adults with type 2 diabetes mellitus and diabetic nephropathy with albuminuria ( 1 ). Limitations of Use: Not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus ( 1 ). uuid:0068713f-3421-429d-b74b-cd3ba18219de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1545147 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:989c2658-73cb-405c-a7a4-d03512cadadf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ca54960c-a699-48dc-86cb-38b8daebbbc1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INVOKAMET and INVOKAMET XR are a combination of canagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, and metformin hydrochloride (HCl), a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus ( 1 ). Canagliflozin Canagliflozin, when used as a component of INVOKAMET or INVOKAMET XR is indicated in adults with type 2 diabetes mellitus to reduce the risk of: Major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease ( 1 ). End-stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in adults with type 2 diabetes mellitus and diabetic nephropathy with albuminuria ( 1 ). Limitations of Use: Not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus ( 1 ). uuid:aaf949e7-195f-4253-9bcd-e2511965dc16 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1545147 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:5cc0b960-d5f2-4523-9095-02a25402963a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a3192741-f730-44e8-aa4f-f98f935fb6ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INVOKAMET and INVOKAMET XR are a combination of canagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor, and metformin hydrochloride (HCl), a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus ( 1 ). Canagliflozin Canagliflozin, when used as a component of INVOKAMET or INVOKAMET XR is indicated in adults with type 2 diabetes mellitus to reduce the risk of: Major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease ( 1 ). End-stage kidney disease, doubling of serum creatinine, cardiovascular death, and hospitalization for heart failure in adults with type 2 diabetes mellitus and diabetic nephropathy with albuminuria ( 1 ). Limitations of Use: Not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus ( 1 ). uuid:ed2d825e-fe46-49fd-9098-bfbeee8baee3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:66910 biolink:treats MONDO:0005086 PMID:41385096 "[{""id"":""uuid:9f0a736f-b06c-44ed-899f-c5767ae2f59f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7241e8db-f52b-4040-bac0-08a79d0db897"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:23ab9168-730c-4c01-998b-f4c4103b7444"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/inlyta""]},{""id"":""uuid:effb6c5c-acad-4623-bcbe-487d4f60c554"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INLYTA is a kinase inhibitor indicated: • in combination with avelumab, for the first-line treatment of patients with advanced renal cell carcinoma (RCC). ( 1.1 ) • in combination with pembrolizumab, for the first-line treatment of patients with advanced RCC. ( 1.1 ) • as a single agent, for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy. ( 1.2 )|[EMA] Inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine.|[PMDA] Drugs with a new active ingredient indicated for the treatment of unresectable or metastatic renal cell carcinoma. uuid:5b5dcc2c-f769-4c8e-9eaa-53505c806d07 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:66910 biolink:treats UMLS:C4727069 PMID:41385096 "[{""id"":""uuid:eb6d46d6-049a-4be8-91d3-f3175422d143"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a546f556-5300-4b4a-b8e1-3e38f063e0c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INLYTA is a kinase inhibitor indicated: • in combination with avelumab, for the first-line treatment of patients with advanced renal cell carcinoma (RCC). ( 1.1 ) • in combination with pembrolizumab, for the first-line treatment of patients with advanced RCC. ( 1.1 ) • as a single agent, for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy. ( 1.2 ) uuid:79199404-469b-4f19-8fb8-aec696221e99 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5881776 biolink:treats EFO:1001480 PMID:41385096 "[{""id"":""uuid:0bdbed7d-e15c-4fa6-8ecf-b86d78a9ecf4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ac67e0d8-2605-49d8-86f4-0d9f906d6530"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Avzivi is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil­based chemotherapy for first- or second-line treatment. ( 1.1 ) Metastatic colorectal cancer, in combination with fluoropyrimidine­ irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. ( 1.1 ) Limitations of Use : Avzivi is not indicated for adjuvant treatment of colon cancer. ( 1.1 ) Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment. ( 1.2 ) Recurrent glioblastoma in adults. ( 1.3 ) Metastatic renal cell carcinoma in combination with interferon alfa. ( 1.4 ) Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan. ( 1.5 ) Epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens. ( 1.6 ) uuid:6817f921-449f-4f22-a95a-80e824e8f3d8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5881776 biolink:treats MONDO:0021063 PMID:41385096 "[{""id"":""uuid:8768bcad-d368-4afe-bc88-9f612ad44a7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0d470fc0-06f1-48a7-89d5-fcdca6ac2111"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Avzivi is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil­based chemotherapy for first- or second-line treatment. ( 1.1 ) Metastatic colorectal cancer, in combination with fluoropyrimidine­ irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. ( 1.1 ) Limitations of Use : Avzivi is not indicated for adjuvant treatment of colon cancer. ( 1.1 ) Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment. ( 1.2 ) Recurrent glioblastoma in adults. ( 1.3 ) Metastatic renal cell carcinoma in combination with interferon alfa. ( 1.4 ) Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan. ( 1.5 ) Epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens. ( 1.6 ) uuid:b5b306c4-0ecb-4014-8878-88fdade5ef71 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5881776 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:39ae259d-0373-4ec3-b521-e82e24359053"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:15234f3b-2780-4244-9641-9a6c75cc1218"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Avzivi is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil­based chemotherapy for first- or second-line treatment. ( 1.1 ) Metastatic colorectal cancer, in combination with fluoropyrimidine­ irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. ( 1.1 ) Limitations of Use : Avzivi is not indicated for adjuvant treatment of colon cancer. ( 1.1 ) Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment. ( 1.2 ) Recurrent glioblastoma in adults. ( 1.3 ) Metastatic renal cell carcinoma in combination with interferon alfa. ( 1.4 ) Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan. ( 1.5 ) Epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens. ( 1.6 ) uuid:20934dc6-b6a2-4158-8922-7334c0b12941 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5881776 biolink:treats UMLS:C4288305 PMID:41385096 "[{""id"":""uuid:6dc55b55-1184-4692-b0e1-08b15259d0cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fc932bb8-6fae-46b6-9368-967342551aee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Avzivi is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil­based chemotherapy for first- or second-line treatment. ( 1.1 ) Metastatic colorectal cancer, in combination with fluoropyrimidine­ irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. ( 1.1 ) Limitations of Use : Avzivi is not indicated for adjuvant treatment of colon cancer. ( 1.1 ) Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment. ( 1.2 ) Recurrent glioblastoma in adults. ( 1.3 ) Metastatic renal cell carcinoma in combination with interferon alfa. ( 1.4 ) Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan. ( 1.5 ) Epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens. ( 1.6 ) uuid:7de79fab-90a7-4cdc-9e1e-88798dd97479 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5881776 biolink:treats UMLS:C4721698 PMID:41385096 "[{""id"":""uuid:f1c85133-d9c0-44d9-b634-52d17720ae70"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8a4c6060-5266-4e14-87ab-e5634de892d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Avzivi is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil­based chemotherapy for first- or second-line treatment. ( 1.1 ) Metastatic colorectal cancer, in combination with fluoropyrimidine­ irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. ( 1.1 ) Limitations of Use : Avzivi is not indicated for adjuvant treatment of colon cancer. ( 1.1 ) Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment. ( 1.2 ) Recurrent glioblastoma in adults. ( 1.3 ) Metastatic renal cell carcinoma in combination with interferon alfa. ( 1.4 ) Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan. ( 1.5 ) Epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens. ( 1.6 ) uuid:03adb5d9-f2db-4a0c-a849-9987b579e72b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5881776 biolink:treats MONDO:0002974 PMID:41385096 "[{""id"":""uuid:c8e0fbcc-c3f3-4377-a2d6-2f86d230364a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9bf624e4-77eb-42c3-9f37-418bd7f7f913"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Avzivi is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil­based chemotherapy for first- or second-line treatment. ( 1.1 ) Metastatic colorectal cancer, in combination with fluoropyrimidine­ irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. ( 1.1 ) Limitations of Use : Avzivi is not indicated for adjuvant treatment of colon cancer. ( 1.1 ) Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment. ( 1.2 ) Recurrent glioblastoma in adults. ( 1.3 ) Metastatic renal cell carcinoma in combination with interferon alfa. ( 1.4 ) Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan. ( 1.5 ) Epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens. ( 1.6 ) uuid:76d66f6c-b263-4614-9dae-2deda1f0d163 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5881776 biolink:treats UMLS:C0278579 PMID:41385096 "[{""id"":""uuid:5f2b3b81-6dd2-41a9-aecc-921977006c95"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a0fd123b-b798-491b-9ae2-71bf5da0ef55"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Avzivi is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil­based chemotherapy for first- or second-line treatment. ( 1.1 ) Metastatic colorectal cancer, in combination with fluoropyrimidine­ irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. ( 1.1 ) Limitations of Use : Avzivi is not indicated for adjuvant treatment of colon cancer. ( 1.1 ) Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment. ( 1.2 ) Recurrent glioblastoma in adults. ( 1.3 ) Metastatic renal cell carcinoma in combination with interferon alfa. ( 1.4 ) Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan. ( 1.5 ) Epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens. ( 1.6 ) uuid:7c5fa5db-b278-4ce5-ae32-d93a38c95b5e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5881776 biolink:treats MONDO:0005140 PMID:41385096 "[{""id"":""uuid:9b7a0e48-6bf3-4d67-bbe6-cc20649b7885"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:adff3720-95d8-4a45-b41d-bd6361278a0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Avzivi is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil­based chemotherapy for first- or second-line treatment. ( 1.1 ) Metastatic colorectal cancer, in combination with fluoropyrimidine­ irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. ( 1.1 ) Limitations of Use : Avzivi is not indicated for adjuvant treatment of colon cancer. ( 1.1 ) Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment. ( 1.2 ) Recurrent glioblastoma in adults. ( 1.3 ) Metastatic renal cell carcinoma in combination with interferon alfa. ( 1.4 ) Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan. ( 1.5 ) Epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens. ( 1.6 ) uuid:7318eec7-0102-4f0e-a36a-fffdf9be7649 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5881776 biolink:treats MONDO:0002158 PMID:41385096 "[{""id"":""uuid:a3314b59-4e12-4a3f-be5b-64b816e044de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9183aa21-f763-4f6e-9a45-96c6c1fc4f8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Avzivi is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil­based chemotherapy for first- or second-line treatment. ( 1.1 ) Metastatic colorectal cancer, in combination with fluoropyrimidine­ irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. ( 1.1 ) Limitations of Use : Avzivi is not indicated for adjuvant treatment of colon cancer. ( 1.1 ) Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment. ( 1.2 ) Recurrent glioblastoma in adults. ( 1.3 ) Metastatic renal cell carcinoma in combination with interferon alfa. ( 1.4 ) Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan. ( 1.5 ) Epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens. ( 1.6 ) uuid:4582d348-0c3b-4c4d-8388-d17233598d24 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5881776 biolink:treats MONDO:0015686 PMID:41385096 "[{""id"":""uuid:7ae9eb92-407b-403d-b403-a53df3d8b15f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f51f5f16-8a05-4c40-840c-d347c1b83eda"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Avzivi is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil­based chemotherapy for first- or second-line treatment. ( 1.1 ) Metastatic colorectal cancer, in combination with fluoropyrimidine­ irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. ( 1.1 ) Limitations of Use : Avzivi is not indicated for adjuvant treatment of colon cancer. ( 1.1 ) Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment. ( 1.2 ) Recurrent glioblastoma in adults. ( 1.3 ) Metastatic renal cell carcinoma in combination with interferon alfa. ( 1.4 ) Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan. ( 1.5 ) Epithelial ovarian, fallopian tube, or primary peritoneal cancer in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens. ( 1.6 ) uuid:26440c9b-9051-4c7a-9f87-be90ca7b3545 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49603 biolink:treats UMLS:C3495917 PMID:41385096 "[{""id"":""uuid:1614f265-d906-44c6-b2c6-83dd02f59755"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0134f299-df6e-4529-b31d-e6ba5ec2e802"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lapatinib tablets are indicated in combination with: capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy, including an anthracycline, a taxane, and trastuzumab. Limitations of Use : Patients should have disease progression on trastuzumab prior to initiation of treatment with lapatinib tablets in combination with capecitabine. letrozole for the treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. Lapatinib tablets in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer. uuid:8e41d31b-52c5-4e1a-87d9-ef1e7c2c40ea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49603 biolink:treats UMLS:C0278488 PMID:41385096 "[{""id"":""uuid:514ca0fe-abf3-4b65-b5d1-580c45c0de22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:34f30f8c-2ec6-4301-8e26-550650ccd869"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lapatinib tablets are indicated in combination with: capecitabine for the treatment of patients with advanced or metastatic breast cancer whose tumors overexpress human epidermal growth factor receptor 2 (HER2) and who have received prior therapy, including an anthracycline, a taxane, and trastuzumab. Limitations of Use : Patients should have disease progression on trastuzumab prior to initiation of treatment with lapatinib tablets in combination with capecitabine. letrozole for the treatment of postmenopausal women with hormone receptor-positive metastatic breast cancer that overexpresses the HER2 receptor for whom hormonal therapy is indicated. Lapatinib tablets in combination with an aromatase inhibitor has not been compared to a trastuzumab-containing chemotherapy regimen for the treatment of metastatic breast cancer. uuid:2ccf4b28-3083-439f-804e-556eca4532c5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:LT369U66CE biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:1038de67-4434-48f4-ba91-ed4fae41095d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fa8e262b-61e7-4250-b2a0-5c9f126e8e68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TROGARZO, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 infection failing their current antiretroviral regimen. uuid:9dca2973-370e-4ff0-b7f1-81419bcebe5e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:Q6U6J48BWY biolink:treats MONDO:0009265 PMID:41385096 "[{""id"":""uuid:c03d450c-dd17-4145-9472-ff3654c1cfea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:36774250-090f-4495-a4d6-207032a5119c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cerezyme is indicated for treatment of adults and pediatric patients 2 years of age and older with Type 1 Gaucher disease that results in one or more of the following conditions: anemia thrombocytopenia bone disease hepatomegaly or splenomegaly uuid:ed1f175d-97d2-4253-be61-7e73ddbcbb2c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:Q6U6J48BWY biolink:treats MONDO:0002280 PMID:41385096 "[{""id"":""uuid:272c252a-299e-4368-a4a1-e305a8164eb4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a589d89a-e5be-4ea6-801f-3291f1db2233"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9dfaf78f-2917-42ff-a173-9ee4b785828b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cerezyme""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cerezyme is indicated for treatment of adults and pediatric patients 2 years of age and older with Type 1 Gaucher disease that results in one or more of the following conditions: anemia thrombocytopenia bone disease hepatomegaly or splenomegaly|[EMA] Cerezyme (imiglucerase) is indicated for use as longterm enzyme replacement therapy in patients with a confirmed diagnosis of non-neuronopathic (Type 1) or chronic neuronopathic (Type 3) Gaucher disease who exhibit clinically significant nonneurological manifestations of the disease. The non-neurological manifestations of Gaucher disease include one or more of the following conditions:anaemia after exclusion of other causes, such as iron deficiencyThrombocytopeniaBone disease after exclusion of other causes such as Vitamin D deficiencyhepatomegaly or splenomegaly uuid:c61c37ca-0b97-462c-aa95-55de5227e53d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:Q6U6J48BWY biolink:treats MONDO:0002049 PMID:41385096 "[{""id"":""uuid:9077775d-f34a-4ec9-8c59-8f89a89d071e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:70b9eb06-587e-4e8e-b75c-b385b5b27c90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d5d52a00-f3d8-4468-a92d-ca2ab7e26e1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cerezyme""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cerezyme is indicated for treatment of adults and pediatric patients 2 years of age and older with Type 1 Gaucher disease that results in one or more of the following conditions: anemia thrombocytopenia bone disease hepatomegaly or splenomegaly|[EMA] Cerezyme (imiglucerase) is indicated for use as longterm enzyme replacement therapy in patients with a confirmed diagnosis of non-neuronopathic (Type 1) or chronic neuronopathic (Type 3) Gaucher disease who exhibit clinically significant nonneurological manifestations of the disease. The non-neurological manifestations of Gaucher disease include one or more of the following conditions:anaemia after exclusion of other causes, such as iron deficiencyThrombocytopeniaBone disease after exclusion of other causes such as Vitamin D deficiencyhepatomegaly or splenomegaly uuid:3eec00eb-fe1c-4fe8-996c-e760bb441871 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:Q6U6J48BWY biolink:treats MONDO:0005381 PMID:41385096 "[{""id"":""uuid:588e1a5f-f608-4661-aeb1-9425517fb411"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a539e61c-0d0a-41ea-929a-0c0178de10a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ce764900-6780-4f21-be0a-cf4be15ea76e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cerezyme""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cerezyme is indicated for treatment of adults and pediatric patients 2 years of age and older with Type 1 Gaucher disease that results in one or more of the following conditions: anemia thrombocytopenia bone disease hepatomegaly or splenomegaly|[EMA] Cerezyme (imiglucerase) is indicated for use as longterm enzyme replacement therapy in patients with a confirmed diagnosis of non-neuronopathic (Type 1) or chronic neuronopathic (Type 3) Gaucher disease who exhibit clinically significant nonneurological manifestations of the disease. The non-neurological manifestations of Gaucher disease include one or more of the following conditions:anaemia after exclusion of other causes, such as iron deficiencyThrombocytopeniaBone disease after exclusion of other causes such as Vitamin D deficiencyhepatomegaly or splenomegaly uuid:af5aed11-63e3-4115-80bb-f600c3b7c218 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:Q6U6J48BWY biolink:treats HP:0002240 PMID:41385096 "[{""id"":""uuid:8d7bc0c6-3155-4121-9d0c-b4395dc928e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:df855e13-8262-4a11-ae15-9766a6fba644"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:13444fb6-5ed4-4648-afce-c375bed928b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cerezyme""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cerezyme is indicated for treatment of adults and pediatric patients 2 years of age and older with Type 1 Gaucher disease that results in one or more of the following conditions: anemia thrombocytopenia bone disease hepatomegaly or splenomegaly|[EMA] Cerezyme (imiglucerase) is indicated for use as longterm enzyme replacement therapy in patients with a confirmed diagnosis of non-neuronopathic (Type 1) or chronic neuronopathic (Type 3) Gaucher disease who exhibit clinically significant nonneurological manifestations of the disease. The non-neurological manifestations of Gaucher disease include one or more of the following conditions:anaemia after exclusion of other causes, such as iron deficiencyThrombocytopeniaBone disease after exclusion of other causes such as Vitamin D deficiencyhepatomegaly or splenomegaly uuid:61e21e76-fcb2-49a6-aa1f-0991cae6ec57 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:Q6U6J48BWY biolink:treats HP:0001744 PMID:41385096 "[{""id"":""uuid:7858f2ad-3b71-43c6-bfc2-41461f381742"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b94d2cc8-a6fb-4a4e-bec6-7fe43cc4285c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cerezyme is indicated for treatment of adults and pediatric patients 2 years of age and older with Type 1 Gaucher disease that results in one or more of the following conditions: anemia thrombocytopenia bone disease hepatomegaly or splenomegaly uuid:f586118c-89ea-4e4c-849f-62914cdce2dc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats UMLS:C3824874 PMID:41385096 "[{""id"":""uuid:b6ca8e61-baba-48d5-b572-525f3b31d14d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:97ebb428-cd51-4beb-a1c8-6e3a351dbb74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline for injection and other antibacterial drugs, doxycycline for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever, and the typhus group, Q fever, rickettsialpox and tick fevers). Mycoplasma pneumoniae (PPLO, Eaton Agent). Agents of psittacosis and ornithosis. Agents of lymphogranuloma venereum and granuloma inguinale. The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram-negative microorganisms: Haemophilus ducreyi ( chancroid ), Yersinia pestis Francisella tularensis, Bartonella bacilliformis, Bacteroides species, Vibrio cholerae and Campylobacte fetus, Brucella species ( in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli, Enterobacter aerogenes, Shigella species, Acinetobacter species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Streptococcus pneumoniae, Staphylococcus aureus , respiratory skin and soft tissue infections. Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections. Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of infections due to: Neisseria gonorrhoeae and N. meningitidis, Treponema pallidum and Treponema pallidum subspecie s pertenue (syphilis and yaws), Listeria monocytogenes, Clostridium species, Fusobacterium fusiforme (Vincent's infection), Actinomyces species . In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. Doxycycline is indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. uuid:c20f9e07-5aa1-4e9f-a38a-6f873461730c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats UMLS:C0948205 PMID:41385096 "[{""id"":""uuid:97e8be5e-67e9-4a2b-86a8-ed632d5efee5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9b2e8620-9fd8-4a71-bf2a-3e56afdd91ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline for injection and other antibacterial drugs, doxycycline for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever, and the typhus group, Q fever, rickettsialpox and tick fevers). Mycoplasma pneumoniae (PPLO, Eaton Agent). Agents of psittacosis and ornithosis. Agents of lymphogranuloma venereum and granuloma inguinale. The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram-negative microorganisms: Haemophilus ducreyi ( chancroid ), Yersinia pestis Francisella tularensis, Bartonella bacilliformis, Bacteroides species, Vibrio cholerae and Campylobacte fetus, Brucella species ( in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli, Enterobacter aerogenes, Shigella species, Acinetobacter species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Streptococcus pneumoniae, Staphylococcus aureus , respiratory skin and soft tissue infections. Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections. Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of infections due to: Neisseria gonorrhoeae and N. meningitidis, Treponema pallidum and Treponema pallidum subspecie s pertenue (syphilis and yaws), Listeria monocytogenes, Clostridium species, Fusobacterium fusiforme (Vincent's infection), Actinomyces species . In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. Doxycycline is indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. uuid:459537b0-4eb0-4376-a1a8-8b29b22cd5c1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0005247 PMID:41385096 "[{""id"":""uuid:2bd27dc3-9d53-40da-ac58-472a80abb586"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:59a236d6-eb3c-4976-8938-88ef6378b9b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline for injection and other antibacterial drugs, doxycycline for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever, and the typhus group, Q fever, rickettsialpox and tick fevers). Mycoplasma pneumoniae (PPLO, Eaton Agent). Agents of psittacosis and ornithosis. Agents of lymphogranuloma venereum and granuloma inguinale. The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram-negative microorganisms: Haemophilus ducreyi ( chancroid ), Yersinia pestis Francisella tularensis, Bartonella bacilliformis, Bacteroides species, Vibrio cholerae and Campylobacte fetus, Brucella species ( in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli, Enterobacter aerogenes, Shigella species, Acinetobacter species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Streptococcus pneumoniae, Staphylococcus aureus , respiratory skin and soft tissue infections. Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections. Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of infections due to: Neisseria gonorrhoeae and N. meningitidis, Treponema pallidum and Treponema pallidum subspecie s pertenue (syphilis and yaws), Listeria monocytogenes, Clostridium species, Fusobacterium fusiforme (Vincent's infection), Actinomyces species . In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. Doxycycline is indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. uuid:910eb8db-538a-415f-b80c-c8c5b93ab476 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats UMLS:C0554628 PMID:41385096 "[{""id"":""uuid:9694da2d-839b-4413-b5da-435572c4417e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:59f34cb6-3728-4181-bcf6-17e332775fb4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline for injection and other antibacterial drugs, doxycycline for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever, and the typhus group, Q fever, rickettsialpox and tick fevers). Mycoplasma pneumoniae (PPLO, Eaton Agent). Agents of psittacosis and ornithosis. Agents of lymphogranuloma venereum and granuloma inguinale. The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram-negative microorganisms: Haemophilus ducreyi ( chancroid ), Yersinia pestis Francisella tularensis, Bartonella bacilliformis, Bacteroides species, Vibrio cholerae and Campylobacte fetus, Brucella species ( in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli, Enterobacter aerogenes, Shigella species, Acinetobacter species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Streptococcus pneumoniae, Staphylococcus aureus , respiratory skin and soft tissue infections. Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections. Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of infections due to: Neisseria gonorrhoeae and N. meningitidis, Treponema pallidum and Treponema pallidum subspecie s pertenue (syphilis and yaws), Listeria monocytogenes, Clostridium species, Fusobacterium fusiforme (Vincent's infection), Actinomyces species . In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. Doxycycline is indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. uuid:c3835240-e3c6-462f-9075-820bac9df02d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats UMLS:C1739131 PMID:41385096 "[{""id"":""uuid:4e948f38-f8a2-436e-8c15-79342b3690be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a07baa2e-9372-4729-b9bf-bc5b4d8af27c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain effectiveness of doxycycline for injection and other antibacterial drugs, doxycycline for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever, and the typhus group, Q fever, rickettsialpox and tick fevers). Mycoplasma pneumoniae (PPLO, Eaton Agent). Agents of psittacosis and ornithosis. Agents of lymphogranuloma venereum and granuloma inguinale. The spirochetal agent of relapsing fever ( Borrelia recurrentis ). The following gram-negative microorganisms: Haemophilus ducreyi ( chancroid ), Yersinia pestis Francisella tularensis, Bartonella bacilliformis, Bacteroides species, Vibrio cholerae and Campylobacte fetus, Brucella species ( in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli, Enterobacter aerogenes, Shigella species, Acinetobacter species, Haemophilus influenzae (respiratory infections), Klebsiella species (respiratory and urinary infections). Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Streptococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Streptococcus pneumoniae, Staphylococcus aureus , respiratory skin and soft tissue infections. Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections. Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of infections due to: Neisseria gonorrhoeae and N. meningitidis, Treponema pallidum and Treponema pallidum subspecie s pertenue (syphilis and yaws), Listeria monocytogenes, Clostridium species, Fusobacterium fusiforme (Vincent's infection), Actinomyces species . In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. Doxycycline is indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. uuid:e880bf4d-dc6d-4e7f-aded-2dbeb7dd2740 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0003634 PMID:41385096 "[{""id"":""uuid:a54ef461-943e-49b3-8e1d-f405dfb1dbf5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0177ecbe-a212-471e-ace0-982dc95d5678"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler's syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:2d3ae816-7c31-424e-b830-caa34635248e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0007008 PMID:41385096 "[{""id"":""uuid:e919efb0-450d-4b66-8a48-be93a2e39ae2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:84a7a6b6-eb7a-4d14-aa59-8dc68ad7a2ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone Tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis Epicondylitis Acute gouty arthritis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler's syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. 11.Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:853bdcb3-9d1f-47df-aa18-a394be499a7e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90863 biolink:treats MONDO:0020804 PMID:41385096 "[{""id"":""uuid:1fba8e4b-d92a-4c4d-81f1-9a41983b21c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:df36937e-b712-41bc-9d87-129cbd3adec1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ODOMZO (sonidegib) is indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. uuid:e5555f65-a37d-4225-a921-aa597d0a1157 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90863 biolink:treats UMLS:C4745056 PMID:41385096 "[{""id"":""uuid:dd7d32ac-40f6-47a1-abd3-9abbc9109166"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f0dfca86-c5a4-42f9-908e-6b5a01f01424"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ODOMZO (sonidegib) is indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) that has recurred following surgery or radiation therapy, or those who are not candidates for surgery or radiation therapy. uuid:ca967fdd-318a-4ce4-82a9-6e80557a74d7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:78538 biolink:treats MONDO:0018018 PMID:41385096 "[{""id"":""uuid:7b61a697-dab8-449a-ad1c-deff427e950d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6575a549-26b4-4315-8c88-c4e35e715183"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization. uuid:c0b58da3-2415-4a37-971b-d96736620035 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:78538 biolink:treats MONDO:0971008 PMID:41385096 "[{""id"":""uuid:f6191ebd-43c5-4a60-b636-b55b22545f7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cee28528-a8de-4eb9-a77d-b0415b5489e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VYNDAQEL and VYNDAMAX are indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization. uuid:62f42fec-2553-4380-9e2f-ea677233fd6a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:CEGM9YBNGD biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:05c0ea98-7ccf-4c36-879e-91f881776df4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:dc731d4c-e56e-49ec-8836-51002128c68f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2f2ef1eb-499e-42c0-95a6-cd3aeffadda3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/retsevmo""]},{""id"":""uuid:e60116e4-3a54-40d4-812d-d56ff8b42f2d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RETEVMO ® is a kinase inhibitor indicated for the treatment of: Adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved test ( 1.1 ) Adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy ( 1.2 ) Adult and pediatric patients 2 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, as detected by an FDA-approved test, who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate) ( 1.3 ) Adult and pediatric patients 2 years of age and older with locally advanced or metastatic solid tumors with a RET gene fusion, as detected by an FDA-approved test, that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options 1 ( 1.4 ) 1 This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).|[EMA] Retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced RET-mutant medullary thyroid cancer (MTC)advanced RET fusion-positive non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitoradvanced RET fusion-positive thyroid cancer who require systematic therapy following prior treatment|[PMDA] Drugs with a new active ingredient indicated for the treatment of RET fusion gene-positive unresectable advanced or recurrent non-small cell lung cancer. [Orphan drug] uuid:0cc25e5a-8e39-433d-808a-0734a173ba31 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:CEGM9YBNGD biolink:treats MONDO:0015277 PMID:41385096 "[{""id"":""uuid:cb4d9d7a-a9f3-438a-9981-900c687a58d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a36a90b2-9443-4d52-a743-6e8116ca9c5d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:475e5516-3443-451e-835a-fc092710f1e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/retsevmo""]},{""id"":""uuid:0612e369-db43-4833-a695-fa61de069bb4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RETEVMO ® is a kinase inhibitor indicated for the treatment of: Adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved test ( 1.1 ) Adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy ( 1.2 ) Adult and pediatric patients 2 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, as detected by an FDA-approved test, who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate) ( 1.3 ) Adult and pediatric patients 2 years of age and older with locally advanced or metastatic solid tumors with a RET gene fusion, as detected by an FDA-approved test, that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options 1 ( 1.4 ) 1 This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).|[EMA] Retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced RET-mutant medullary thyroid cancer (MTC)advanced RET fusion-positive non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitoradvanced RET fusion-positive thyroid cancer who require systematic therapy following prior treatment|[PMDA] Drugs with a new indication and a new dosage for the treatment of RET fusion gene-positive unresectable thyroid cancer and RET gene mutation-positive unresectable medullary thyroid cancer. [Orphan drug] uuid:939f92c9-0a1e-4fb2-8a3b-a4cca3a13c4a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:CEGM9YBNGD biolink:treats MONDO:0002108 PMID:41385096 "[{""id"":""uuid:c07e797d-5f12-4858-a966-d7e97c4aadd2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:72925531-4f5d-465b-8161-a5912739b4cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:32668585-9f53-4499-bbba-661bd013292f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/retsevmo""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] RETEVMO ® is a kinase inhibitor indicated for the treatment of: Adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved test ( 1.1 ) Adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy ( 1.2 ) Adult and pediatric patients 2 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, as detected by an FDA-approved test, who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate) ( 1.3 ) Adult and pediatric patients 2 years of age and older with locally advanced or metastatic solid tumors with a RET gene fusion, as detected by an FDA-approved test, that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options 1 ( 1.4 ) 1 This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).|[EMA] Retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced RET-mutant medullary thyroid cancer (MTC)advanced RET fusion-positive non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitoradvanced RET fusion-positive thyroid cancer who require systematic therapy following prior treatment uuid:c2080bb5-acc1-487c-9638-6ed6c4537582 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:CEGM9YBNGD biolink:treats UMLS:C0280100 PMID:41385096 "[{""id"":""uuid:f4a94b5f-30c8-46a7-b53c-99791eed4e35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:81b0f971-5fcc-4639-978f-aecd96f80ed1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RETEVMO ® is a kinase inhibitor indicated for the treatment of: Adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a rearranged during transfection (RET) gene fusion, as detected by an FDA-approved test ( 1.1 ) Adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy ( 1.2 ) Adult and pediatric patients 2 years of age and older with advanced or metastatic thyroid cancer with a RET gene fusion, as detected by an FDA-approved test, who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate) ( 1.3 ) Adult and pediatric patients 2 years of age and older with locally advanced or metastatic solid tumors with a RET gene fusion, as detected by an FDA-approved test, that have progressed on or following prior systemic treatment or who have no satisfactory alternative treatment options 1 ( 1.4 ) 1 This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s). uuid:ae26d484-0704-49a6-8239-acb16f79dbfa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:XN7MM8XG2M biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:5ce42661-6ebe-4718-8329-6bd17498a93b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a3e12ba2-4a5a-43a2-a04e-e9bbd8df934d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] WINLEVI (clascoterone) cream is an androgen receptor inhibitor indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. uuid:83038268-5af3-400d-be2c-a51b3ef00200 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60311 biolink:treats MONDO:0005420 PMID:41385096 "[{""id"":""uuid:eb5c2fe6-7e66-4557-b8cc-c19dd731c1f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ea8bc84a-5174-43d9-b535-bba9633dc90b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thyroid Tablets, USP are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS ). 2. As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto’s), multinodular goiter, and in the management of thyroid cancer. uuid:0edae189-7f38-42ed-a814-657583b38950 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60311 biolink:treats MONDO:0018612 PMID:41385096 "[{""id"":""uuid:cfdda824-5a8b-43db-9bbd-62f2ddab7616"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:220dbe62-eed3-45fc-a343-c9e4bed08368"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thyroid Tablets, USP are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS ). 2. As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto’s), multinodular goiter, and in the management of thyroid cancer. uuid:20d0498d-d351-44f0-9ed3-9701af53de2d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60311 biolink:treats MONDO:0009718 PMID:41385096 "[{""id"":""uuid:d9eef699-9f94-46f3-806b-e0a874dde4de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a394a05a-fc6d-4f43-8faf-8b2effc70bbc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thyroid Tablets, USP are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS ). 2. As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto’s), multinodular goiter, and in the management of thyroid cancer. uuid:985bbf0d-9ead-4e4f-9c97-a1a303239033 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60311 biolink:treats MONDO:0001658 PMID:41385096 "[{""id"":""uuid:de8dc251-4fe5-4e8a-a24a-45a8888128e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d6a5df0a-e822-4185-8bff-f3bf8e2d3b72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thyroid Tablets, USP are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS ). 2. As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto’s), multinodular goiter, and in the management of thyroid cancer. uuid:2aabbfb0-f2a4-40c3-b480-3d8970458227 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60311 biolink:treats HP:0025388 PMID:41385096 "[{""id"":""uuid:7c54ed66-b152-46d7-b40f-1bc5b7c8358a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:47ad6f0a-4dc6-4856-bb44-5fd6afbf0000"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thyroid Tablets, USP are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS ). 2. As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto’s), multinodular goiter, and in the management of thyroid cancer. uuid:9e05f4c5-a843-441f-a7b0-f4a02b8f556a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60311 biolink:treats MONDO:0006982 PMID:41385096 "[{""id"":""uuid:19f91077-bc66-4376-9c08-c6fc7856968f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:05fa36e1-bb2d-40b0-9754-d364edb7dc1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thyroid Tablets, USP are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS ). 2. As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto’s), multinodular goiter, and in the management of thyroid cancer. uuid:04ba5049-368d-4beb-a32a-8b5094bbbe48 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60311 biolink:treats MONDO:0007699 PMID:41385096 "[{""id"":""uuid:3e43979c-2509-428b-8aaf-466a57c27dbc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:36edaa48-f178-4c0c-b00c-e8ba41e95cec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thyroid Tablets, USP are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS ). 2. As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto’s), multinodular goiter, and in the management of thyroid cancer. uuid:78a2873b-cc08-4fa7-b2b1-55178c72fdbe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60311 biolink:treats MONDO:0000334 PMID:41385096 "[{""id"":""uuid:e60975ee-5bfd-4571-ad53-3ac1fed3ed8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6d1b72b7-d098-49e9-8bcb-08386bc99062"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thyroid Tablets, USP are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS ). 2. As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto’s), multinodular goiter, and in the management of thyroid cancer. uuid:3535a647-b5ce-49f2-8052-51252b18decb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60311 biolink:treats MONDO:0002108 PMID:41385096 "[{""id"":""uuid:6a4310a5-f2b3-4241-9cb8-7b8f3ffad9df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9bacae19-b2d9-4d0f-8a54-4927733dc313"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Thyroid Tablets, USP are indicated: 1. As replacement or supplemental therapy in patients with hypothyroidism of any etiology, except transient hypothyroidism during the recovery phase of subacute thyroiditis. This category includes cretinism, myxedema, and ordinary hypothyroidism in patients of any age (children, adults, the elderly), or state (including pregnancy); primary hypothyroidism resulting from functional deficiency, primary atrophy, partial or total absence of thyroid gland, or the effects of surgery, radiation, or drugs, with or without the presence of goiter; and secondary (pituitary), or tertiary (hypothalamic) hypothyroidism (See WARNINGS ). 2. As pituitary TSH suppressants, in the treatment or prevention of various types of euthyroid goiters, including thyroid nodules, subacute or chronic lymphocytic thyroiditis (Hashimoto’s), multinodular goiter, and in the management of thyroid cancer. uuid:5f68a44f-3abf-4afe-b49c-760afd03ef43 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2118728 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:8cb9c284-82fb-4db4-a467-220e1b8b4139"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9d72c57a-e1c3-4c7a-99af-212fa3c6f086"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] APADAZ is indicated for the short-term (no more than 14 days) management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration [see Warnings and Precautions ( 5.1 ) ] reserve APADAZ for use in patients for whom alternative treatment options [e.g., non-opioid analgesics]: Have not been tolerated or are not expected to be tolerated, Have not provided adequate analgesia or are not expected to provide adequate analgesia. APADAZ should not be used for an extended period of time unless the pain remains severe enough to require an opioid analgesic and for which alternative treatment options continue to be inadequate. uuid:567fb995-8cd9-4301-958d-2fc72e46d686 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29034 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:6125e829-ea90-42c6-9533-a9b1a2d49894"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:186b6689-fcb0-42cb-88fb-e84e715485d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Injectafer is indicated for the treatment of: • iron deficiency anemia (IDA) in: adult and pediatric patients 1 year of age and older who have either intolerance or an unsatisfactory response to oral iron. adult patients who have non-dialysis dependent chronic kidney disease. • iron deficiency in adult patients with heart failure and New York Heart Association class II/III to improve exercise capacity. uuid:f3fe4f91-4731-4355-a73c-ea97725ac8e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2S9ZZM9Q9V biolink:treats UMLS:C0278579 PMID:41385096 "[{""id"":""uuid:f3f7b119-9771-4b44-b70f-8a23497648f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9adfe821-40d4-449d-855c-5161b8e414c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Avastin is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment. ( 1.1 ) Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. ( 1.1 ) Limitations of Use : Avastin is not indicated for adjuvant treatment of colon cancer. ( 1.1 ) Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment. ( 1.2 ) Recurrent glioblastoma in adults. ( 1.3 ) Metastatic renal cell carcinoma in combination with interferon alfa. ( 1.4 ) Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan. ( 1.5 ) Epithelial ovarian, fallopian tube, or primary peritoneal cancer: in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, for stage III or IV disease following initial surgical resection ( 1.6 ) in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens ( 1.6 ) in combination with carboplatin and paclitaxel or carboplatin and gemcitabine, followed by Avastin as a single agent, for platinum-sensitive recurrent disease ( 1.6 ) Hepatocellular Carcinoma (HCC) in combination with atezolizumab for the treatment of patients with unresectable or metastatic HCC who have not received prior systemic therapy ( 1.7 ) uuid:a13aa637-8241-42c8-b02c-42910628981f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2S9ZZM9Q9V biolink:treats MONDO:0007256 PMID:41385096 "[{""id"":""uuid:9abb63d7-4e44-4316-bb75-4f50c6082ee5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cd4a1529-4149-460d-8427-da07d1eb6a06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e4547f9a-0d34-4695-bebb-133b6659294b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Avastin is a vascular endothelial growth factor inhibitor indicated for the treatment of: Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment. ( 1.1 ) Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. ( 1.1 ) Limitations of Use : Avastin is not indicated for adjuvant treatment of colon cancer. ( 1.1 ) Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment. ( 1.2 ) Recurrent glioblastoma in adults. ( 1.3 ) Metastatic renal cell carcinoma in combination with interferon alfa. ( 1.4 ) Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin, or paclitaxel and topotecan. ( 1.5 ) Epithelial ovarian, fallopian tube, or primary peritoneal cancer: in combination with carboplatin and paclitaxel, followed by Avastin as a single agent, for stage III or IV disease following initial surgical resection ( 1.6 ) in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens ( 1.6 ) in combination with carboplatin and paclitaxel or carboplatin and gemcitabine, followed by Avastin as a single agent, for platinum-sensitive recurrent disease ( 1.6 ) Hepatocellular Carcinoma (HCC) in combination with atezolizumab for the treatment of patients with unresectable or metastatic HCC who have not received prior systemic therapy ( 1.7 )|[PMDA] Drugs with a new indication and a new dosage for the treatment of unresectable hepatocellular carcinoma. [Priority review] uuid:fdc2934e-83a7-4fe0-a391-57974506277d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63616 biolink:treats UMLS:C5770027 PMID:41385096 "[{""id"":""uuid:9cb3297b-6010-4387-a05c-2106fd0e697d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e3cc0a05-88ad-4ddc-801b-ea82898538f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AXTLE is a folate analog metabolic inhibitor indicated: in combination with cisplatin for the initial treatment of patients with locally advanced or metastatic, non-squamous NSCLC. ( 1.1 ) as a single agent for the maintenance treatment of patients with locally advanced or metastatic, non-squamous NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. ( 1.1 ) as a single agent for the treatment of patients with recurrent, metastatic non-squamous, NSCLC after prior chemotherapy. ( 1.1 ) Limitations of Use: AXTLE is not indicated for the treatment of patients with squamous cell, non-small cell lung cancer. ( 1.1 ) initial treatment, in combination with cisplatin, of patients with malignant pleural mesothelioma whose disease is unresectable or who are otherwise not candidates for curative surgery. ( 1.2 ) uuid:1946c41e-4b43-48d5-b22b-f36b7b71f4e7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4F4X42SYQ6 biolink:treats MONDO:0018908 PMID:41385096 "[{""id"":""uuid:9cae000b-e507-48c6-8b5c-cf7d9225b541"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:12af9ec6-85e9-4ed7-a9bb-0b1e28da4d14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:66146410-a693-4b09-9091-6f5e869529b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/riximyo""]},{""id"":""uuid:890b0260-2bd7-49b4-b6c0-1e163ce8f138"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RITUXAN is a CD20-directed cytolytic antibody indicated for the treatment of: Adult patients with Non-Hodgkin's Lymphoma (NHL) ( 1.1 ). Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a single agent. Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy. Previously untreated diffuse large B-cell, CD20-positive NHL in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (CHOP) or other anthracycline-based chemotherapy regimens. Pediatric patients aged 6 months and older with mature B-cell NHL and mature B-cell acute leukemia (B-AL) ( 1.1 ) Previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL) in combination with chemotherapy. Adult patients with Chronic Lymphocytic Leukemia (CLL) ( 1.2 ). Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC). Rheumatoid Arthritis (RA) in combination with methotrexate in adult patients with moderately-to severely-active RA who have inadequate response to one or more TNF antagonist therapies ( 1.3 ). Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA) in adult and pediatric patients 2 years of age and older in combination with glucocorticoids ( 1.4 ). Moderate to severe Pemphigus Vulgaris (PV) in adult patients ( 1.5 ).|[EMA] Riximyo is indicated in adults for the following indications:Non-Hodgkin’s lymphoma (NHL)Riximyo is indicated for the treatment of previously untreated adult patients with stage III-IV follicular lymphoma in combination with chemotherapy.Riximyo maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy.Riximyo monotherapy is indicated for treatment of adult patients with stage III-IV follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy.Riximyo is indicated for the treatment of adult patients with CD20 positive diffuse large B cell non-Hodgkin’s lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.Riximyo in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ≥ 6 months to < 18 years old) with previously untreated advanced stage CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL)/Burkitt leukaemia (mature B-cell acute leukaemia) (BAL) or Burkitt-like lymphoma (BLL).Chronic lymphocytic leukaemia (CLL)Riximyo in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. Only limited data are available on efficacy and safety for patients previously treated with monoclonal antibodies including rituximab or patients refractory to previous rituximab plus chemotherapy.See section 5.1 for further information.Rheumatoid arthritisRiximyo in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (DMARD) including one or more tumour necrosis factor (TNF) inhibitor therapies.Rituximab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate.Granulomatosis with polyangiitis and microscopic polyangiitisRiximyo, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (Wegener’s) (GPA) and microscopic polyangiitis (MPA).Riximyo, in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged ≥ 2 to < 18 years old) with severe, active GPA (Wegener’s) and MPA.Pemphigus vulgarisRiximyo is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (PV).|[PMDA] Follow-on biologics indicated for the treatment of CD20-positive B-cell non-Hodgkin's lymphoma, CD20-positive B-cell lymphoproliferative disorder associated with immunosuppression, Wegener's granulomatosis, and microscopic polyangiitis. uuid:b79c688f-c9b6-4a7b-b6de-39b125bf78cf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4F4X42SYQ6 biolink:treats MONDO:0018906 PMID:41385096 "[{""id"":""uuid:9e8aaeea-d91a-4530-b24e-5bc174076ea3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d2f04941-0159-4cf7-a66f-8a0a8651db9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:342cec0c-2f17-4830-a2db-e41095d4785a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/riximyo""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] RITUXAN is a CD20-directed cytolytic antibody indicated for the treatment of: Adult patients with Non-Hodgkin's Lymphoma (NHL) ( 1.1 ). Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a single agent. Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy. Previously untreated diffuse large B-cell, CD20-positive NHL in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (CHOP) or other anthracycline-based chemotherapy regimens. Pediatric patients aged 6 months and older with mature B-cell NHL and mature B-cell acute leukemia (B-AL) ( 1.1 ) Previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL) in combination with chemotherapy. Adult patients with Chronic Lymphocytic Leukemia (CLL) ( 1.2 ). Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC). Rheumatoid Arthritis (RA) in combination with methotrexate in adult patients with moderately-to severely-active RA who have inadequate response to one or more TNF antagonist therapies ( 1.3 ). Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA) in adult and pediatric patients 2 years of age and older in combination with glucocorticoids ( 1.4 ). Moderate to severe Pemphigus Vulgaris (PV) in adult patients ( 1.5 ).|[EMA] Riximyo is indicated in adults for the following indications:Non-Hodgkin’s lymphoma (NHL)Riximyo is indicated for the treatment of previously untreated adult patients with stage III-IV follicular lymphoma in combination with chemotherapy.Riximyo maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy.Riximyo monotherapy is indicated for treatment of adult patients with stage III-IV follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy.Riximyo is indicated for the treatment of adult patients with CD20 positive diffuse large B cell non-Hodgkin’s lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.Riximyo in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ≥ 6 months to < 18 years old) with previously untreated advanced stage CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL)/Burkitt leukaemia (mature B-cell acute leukaemia) (BAL) or Burkitt-like lymphoma (BLL).Chronic lymphocytic leukaemia (CLL)Riximyo in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. Only limited data are available on efficacy and safety for patients previously treated with monoclonal antibodies including rituximab or patients refractory to previous rituximab plus chemotherapy.See section 5.1 for further information.Rheumatoid arthritisRiximyo in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (DMARD) including one or more tumour necrosis factor (TNF) inhibitor therapies.Rituximab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate.Granulomatosis with polyangiitis and microscopic polyangiitisRiximyo, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (Wegener’s) (GPA) and microscopic polyangiitis (MPA).Riximyo, in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged ≥ 2 to < 18 years old) with severe, active GPA (Wegener’s) and MPA.Pemphigus vulgarisRiximyo is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (PV). uuid:a375ce5f-31a9-4938-b115-67a918bcf66d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4F4X42SYQ6 biolink:treats MONDO:0018905 PMID:41385096 "[{""id"":""uuid:6ac27bb3-bc22-4772-9d4c-07fa4dc04651"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c4d64d47-be66-438d-aa2c-1796e427c94e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:43adfaba-3f8a-4e87-bf55-ce489e935eff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/riximyo""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] RITUXAN is a CD20-directed cytolytic antibody indicated for the treatment of: Adult patients with Non-Hodgkin's Lymphoma (NHL) ( 1.1 ). Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a single agent. Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy. Previously untreated diffuse large B-cell, CD20-positive NHL in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (CHOP) or other anthracycline-based chemotherapy regimens. Pediatric patients aged 6 months and older with mature B-cell NHL and mature B-cell acute leukemia (B-AL) ( 1.1 ) Previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL) in combination with chemotherapy. Adult patients with Chronic Lymphocytic Leukemia (CLL) ( 1.2 ). Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC). Rheumatoid Arthritis (RA) in combination with methotrexate in adult patients with moderately-to severely-active RA who have inadequate response to one or more TNF antagonist therapies ( 1.3 ). Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA) in adult and pediatric patients 2 years of age and older in combination with glucocorticoids ( 1.4 ). Moderate to severe Pemphigus Vulgaris (PV) in adult patients ( 1.5 ).|[EMA] Riximyo is indicated in adults for the following indications:Non-Hodgkin’s lymphoma (NHL)Riximyo is indicated for the treatment of previously untreated adult patients with stage III-IV follicular lymphoma in combination with chemotherapy.Riximyo maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy.Riximyo monotherapy is indicated for treatment of adult patients with stage III-IV follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy.Riximyo is indicated for the treatment of adult patients with CD20 positive diffuse large B cell non-Hodgkin’s lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.Riximyo in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ≥ 6 months to < 18 years old) with previously untreated advanced stage CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL)/Burkitt leukaemia (mature B-cell acute leukaemia) (BAL) or Burkitt-like lymphoma (BLL).Chronic lymphocytic leukaemia (CLL)Riximyo in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. Only limited data are available on efficacy and safety for patients previously treated with monoclonal antibodies including rituximab or patients refractory to previous rituximab plus chemotherapy.See section 5.1 for further information.Rheumatoid arthritisRiximyo in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (DMARD) including one or more tumour necrosis factor (TNF) inhibitor therapies.Rituximab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate.Granulomatosis with polyangiitis and microscopic polyangiitisRiximyo, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (Wegener’s) (GPA) and microscopic polyangiitis (MPA).Riximyo, in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged ≥ 2 to < 18 years old) with severe, active GPA (Wegener’s) and MPA.Pemphigus vulgarisRiximyo is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (PV). uuid:9db00698-4829-41b1-8de9-b467097309cc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4F4X42SYQ6 biolink:treats MONDO:0004949 PMID:41385096 "[{""id"":""uuid:a570bc8b-e39c-4648-ad1f-a71f367a8a31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:802ce9c7-730f-41ef-a243-078a1e0f3178"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RITUXAN is a CD20-directed cytolytic antibody indicated for the treatment of: Adult patients with Non-Hodgkin's Lymphoma (NHL) ( 1.1 ). Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a single agent. Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy. Previously untreated diffuse large B-cell, CD20-positive NHL in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (CHOP) or other anthracycline-based chemotherapy regimens. Pediatric patients aged 6 months and older with mature B-cell NHL and mature B-cell acute leukemia (B-AL) ( 1.1 ) Previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL) in combination with chemotherapy. Adult patients with Chronic Lymphocytic Leukemia (CLL) ( 1.2 ). Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC). Rheumatoid Arthritis (RA) in combination with methotrexate in adult patients with moderately-to severely-active RA who have inadequate response to one or more TNF antagonist therapies ( 1.3 ). Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA) in adult and pediatric patients 2 years of age and older in combination with glucocorticoids ( 1.4 ). Moderate to severe Pemphigus Vulgaris (PV) in adult patients ( 1.5 ). uuid:37d9f9e9-8474-4fb4-8adb-138f1f826a56 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4F4X42SYQ6 biolink:treats MONDO:0004947 PMID:41385096 "[{""id"":""uuid:a7cfaa59-4687-49ae-b7c2-3da6403c8436"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e24cc703-e4f4-404f-810f-3a9c2fc5a781"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RITUXAN is a CD20-directed cytolytic antibody indicated for the treatment of: Adult patients with Non-Hodgkin's Lymphoma (NHL) ( 1.1 ). Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a single agent. Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy. Previously untreated diffuse large B-cell, CD20-positive NHL in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (CHOP) or other anthracycline-based chemotherapy regimens. Pediatric patients aged 6 months and older with mature B-cell NHL and mature B-cell acute leukemia (B-AL) ( 1.1 ) Previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL) in combination with chemotherapy. Adult patients with Chronic Lymphocytic Leukemia (CLL) ( 1.2 ). Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC). Rheumatoid Arthritis (RA) in combination with methotrexate in adult patients with moderately-to severely-active RA who have inadequate response to one or more TNF antagonist therapies ( 1.3 ). Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA) in adult and pediatric patients 2 years of age and older in combination with glucocorticoids ( 1.4 ). Moderate to severe Pemphigus Vulgaris (PV) in adult patients ( 1.5 ). uuid:ab78b8cd-1896-49d3-8663-0c5b8ec51683 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4F4X42SYQ6 biolink:treats MONDO:0007243 PMID:41385096 "[{""id"":""uuid:afbfad82-7014-4306-afdf-6e0c79216d5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ba3b0be4-1053-41c3-bf95-0a3c1660574a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7143c763-cbd5-4b19-87c5-9e6f794039a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/riximyo""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] RITUXAN is a CD20-directed cytolytic antibody indicated for the treatment of: Adult patients with Non-Hodgkin's Lymphoma (NHL) ( 1.1 ). Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a single agent. Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy. Previously untreated diffuse large B-cell, CD20-positive NHL in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (CHOP) or other anthracycline-based chemotherapy regimens. Pediatric patients aged 6 months and older with mature B-cell NHL and mature B-cell acute leukemia (B-AL) ( 1.1 ) Previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL) in combination with chemotherapy. Adult patients with Chronic Lymphocytic Leukemia (CLL) ( 1.2 ). Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC). Rheumatoid Arthritis (RA) in combination with methotrexate in adult patients with moderately-to severely-active RA who have inadequate response to one or more TNF antagonist therapies ( 1.3 ). Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA) in adult and pediatric patients 2 years of age and older in combination with glucocorticoids ( 1.4 ). Moderate to severe Pemphigus Vulgaris (PV) in adult patients ( 1.5 ).|[EMA] Riximyo is indicated in adults for the following indications:Non-Hodgkin’s lymphoma (NHL)Riximyo is indicated for the treatment of previously untreated adult patients with stage III-IV follicular lymphoma in combination with chemotherapy.Riximyo maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy.Riximyo monotherapy is indicated for treatment of adult patients with stage III-IV follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy.Riximyo is indicated for the treatment of adult patients with CD20 positive diffuse large B cell non-Hodgkin’s lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.Riximyo in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ≥ 6 months to < 18 years old) with previously untreated advanced stage CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL)/Burkitt leukaemia (mature B-cell acute leukaemia) (BAL) or Burkitt-like lymphoma (BLL).Chronic lymphocytic leukaemia (CLL)Riximyo in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. Only limited data are available on efficacy and safety for patients previously treated with monoclonal antibodies including rituximab or patients refractory to previous rituximab plus chemotherapy.See section 5.1 for further information.Rheumatoid arthritisRiximyo in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (DMARD) including one or more tumour necrosis factor (TNF) inhibitor therapies.Rituximab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate.Granulomatosis with polyangiitis and microscopic polyangiitisRiximyo, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (Wegener’s) (GPA) and microscopic polyangiitis (MPA).Riximyo, in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged ≥ 2 to < 18 years old) with severe, active GPA (Wegener’s) and MPA.Pemphigus vulgarisRiximyo is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (PV). uuid:2c6c8341-f0c1-4b60-898b-eeda254a5ce5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4F4X42SYQ6 biolink:treats MONDO:0004948 PMID:41385096 "[{""id"":""uuid:8c955129-fdcf-484f-a8dd-a54137368bf9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cfa342a6-cadd-4b76-bf4f-a52102f69b9a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:afa86ec1-6aae-4169-adc6-4162baca01c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/riximyo""]},{""id"":""uuid:50c64eeb-b0d6-4641-aad7-3de79784e2ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RITUXAN is a CD20-directed cytolytic antibody indicated for the treatment of: Adult patients with Non-Hodgkin's Lymphoma (NHL) ( 1.1 ). Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a single agent. Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy. Previously untreated diffuse large B-cell, CD20-positive NHL in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (CHOP) or other anthracycline-based chemotherapy regimens. Pediatric patients aged 6 months and older with mature B-cell NHL and mature B-cell acute leukemia (B-AL) ( 1.1 ) Previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL) in combination with chemotherapy. Adult patients with Chronic Lymphocytic Leukemia (CLL) ( 1.2 ). Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC). Rheumatoid Arthritis (RA) in combination with methotrexate in adult patients with moderately-to severely-active RA who have inadequate response to one or more TNF antagonist therapies ( 1.3 ). Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA) in adult and pediatric patients 2 years of age and older in combination with glucocorticoids ( 1.4 ). Moderate to severe Pemphigus Vulgaris (PV) in adult patients ( 1.5 ).|[EMA] Riximyo is indicated in adults for the following indications:Non-Hodgkin’s lymphoma (NHL)Riximyo is indicated for the treatment of previously untreated adult patients with stage III-IV follicular lymphoma in combination with chemotherapy.Riximyo maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy.Riximyo monotherapy is indicated for treatment of adult patients with stage III-IV follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy.Riximyo is indicated for the treatment of adult patients with CD20 positive diffuse large B cell non-Hodgkin’s lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.Riximyo in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ≥ 6 months to < 18 years old) with previously untreated advanced stage CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL)/Burkitt leukaemia (mature B-cell acute leukaemia) (BAL) or Burkitt-like lymphoma (BLL).Chronic lymphocytic leukaemia (CLL)Riximyo in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. Only limited data are available on efficacy and safety for patients previously treated with monoclonal antibodies including rituximab or patients refractory to previous rituximab plus chemotherapy.See section 5.1 for further information.Rheumatoid arthritisRiximyo in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (DMARD) including one or more tumour necrosis factor (TNF) inhibitor therapies.Rituximab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate.Granulomatosis with polyangiitis and microscopic polyangiitisRiximyo, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (Wegener’s) (GPA) and microscopic polyangiitis (MPA).Riximyo, in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged ≥ 2 to < 18 years old) with severe, active GPA (Wegener’s) and MPA.Pemphigus vulgarisRiximyo is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (PV).|[PMDA] Drugs with a new additional indication and a new dosage for the treatment of CD20-positive chronic lymphocytic leukemia. [Orphan drug] uuid:9e29ac75-de9c-41be-ae39-fa581ef2c84d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4F4X42SYQ6 biolink:treats UMLS:C0861880 PMID:41385096 "[{""id"":""uuid:008c1c96-1887-4992-842b-d6108c12254e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d82aece1-7daf-49e3-a1b9-2965a94dae75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RITUXAN is a CD20-directed cytolytic antibody indicated for the treatment of: Adult patients with Non-Hodgkin's Lymphoma (NHL) ( 1.1 ). Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a single agent. Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy. Previously untreated diffuse large B-cell, CD20-positive NHL in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (CHOP) or other anthracycline-based chemotherapy regimens. Pediatric patients aged 6 months and older with mature B-cell NHL and mature B-cell acute leukemia (B-AL) ( 1.1 ) Previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL) in combination with chemotherapy. Adult patients with Chronic Lymphocytic Leukemia (CLL) ( 1.2 ). Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC). Rheumatoid Arthritis (RA) in combination with methotrexate in adult patients with moderately-to severely-active RA who have inadequate response to one or more TNF antagonist therapies ( 1.3 ). Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA) in adult and pediatric patients 2 years of age and older in combination with glucocorticoids ( 1.4 ). Moderate to severe Pemphigus Vulgaris (PV) in adult patients ( 1.5 ). uuid:f5412180-b604-4bd0-90d9-6be5978b4497 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4F4X42SYQ6 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:a376e3f2-2dce-4de4-b4a3-4829146b90f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:8ae2efb0-10d4-4f18-8c45-38ccacd4ea14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:6ed8c11b-4df6-42f5-b14c-eb67af796841"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/riximyo""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] RITUXAN is a CD20-directed cytolytic antibody indicated for the treatment of: Adult patients with Non-Hodgkin's Lymphoma (NHL) ( 1.1 ). Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a single agent. Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy. Previously untreated diffuse large B-cell, CD20-positive NHL in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (CHOP) or other anthracycline-based chemotherapy regimens. Pediatric patients aged 6 months and older with mature B-cell NHL and mature B-cell acute leukemia (B-AL) ( 1.1 ) Previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL) in combination with chemotherapy. Adult patients with Chronic Lymphocytic Leukemia (CLL) ( 1.2 ). Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC). Rheumatoid Arthritis (RA) in combination with methotrexate in adult patients with moderately-to severely-active RA who have inadequate response to one or more TNF antagonist therapies ( 1.3 ). Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA) in adult and pediatric patients 2 years of age and older in combination with glucocorticoids ( 1.4 ). Moderate to severe Pemphigus Vulgaris (PV) in adult patients ( 1.5 ).|[EMA] Riximyo is indicated in adults for the following indications:Non-Hodgkin’s lymphoma (NHL)Riximyo is indicated for the treatment of previously untreated adult patients with stage III-IV follicular lymphoma in combination with chemotherapy.Riximyo maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy.Riximyo monotherapy is indicated for treatment of adult patients with stage III-IV follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy.Riximyo is indicated for the treatment of adult patients with CD20 positive diffuse large B cell non-Hodgkin’s lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.Riximyo in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ≥ 6 months to < 18 years old) with previously untreated advanced stage CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL)/Burkitt leukaemia (mature B-cell acute leukaemia) (BAL) or Burkitt-like lymphoma (BLL).Chronic lymphocytic leukaemia (CLL)Riximyo in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. Only limited data are available on efficacy and safety for patients previously treated with monoclonal antibodies including rituximab or patients refractory to previous rituximab plus chemotherapy.See section 5.1 for further information.Rheumatoid arthritisRiximyo in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (DMARD) including one or more tumour necrosis factor (TNF) inhibitor therapies.Rituximab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate.Granulomatosis with polyangiitis and microscopic polyangiitisRiximyo, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (Wegener’s) (GPA) and microscopic polyangiitis (MPA).Riximyo, in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged ≥ 2 to < 18 years old) with severe, active GPA (Wegener’s) and MPA.Pemphigus vulgarisRiximyo is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (PV). uuid:41f0d8d2-fc79-4ac3-baa7-fc7446e9a155 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4F4X42SYQ6 biolink:treats MONDO:0012105 PMID:41385096 "[{""id"":""uuid:0c7fcf49-cc57-402b-bffc-802aa4ae1302"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:410f5739-eb09-4e10-98d6-41a15b111499"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0169b5f0-990d-4257-8aed-eaa7b2e7673d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/riximyo""]},{""id"":""uuid:99f85aee-2cc4-4369-8c8f-0d851369cbc3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RITUXAN is a CD20-directed cytolytic antibody indicated for the treatment of: Adult patients with Non-Hodgkin's Lymphoma (NHL) ( 1.1 ). Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a single agent. Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy. Previously untreated diffuse large B-cell, CD20-positive NHL in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (CHOP) or other anthracycline-based chemotherapy regimens. Pediatric patients aged 6 months and older with mature B-cell NHL and mature B-cell acute leukemia (B-AL) ( 1.1 ) Previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL) in combination with chemotherapy. Adult patients with Chronic Lymphocytic Leukemia (CLL) ( 1.2 ). Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC). Rheumatoid Arthritis (RA) in combination with methotrexate in adult patients with moderately-to severely-active RA who have inadequate response to one or more TNF antagonist therapies ( 1.3 ). Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA) in adult and pediatric patients 2 years of age and older in combination with glucocorticoids ( 1.4 ). Moderate to severe Pemphigus Vulgaris (PV) in adult patients ( 1.5 ).|[EMA] Riximyo is indicated in adults for the following indications:Non-Hodgkin’s lymphoma (NHL)Riximyo is indicated for the treatment of previously untreated adult patients with stage III-IV follicular lymphoma in combination with chemotherapy.Riximyo maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy.Riximyo monotherapy is indicated for treatment of adult patients with stage III-IV follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy.Riximyo is indicated for the treatment of adult patients with CD20 positive diffuse large B cell non-Hodgkin’s lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.Riximyo in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ≥ 6 months to < 18 years old) with previously untreated advanced stage CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL)/Burkitt leukaemia (mature B-cell acute leukaemia) (BAL) or Burkitt-like lymphoma (BLL).Chronic lymphocytic leukaemia (CLL)Riximyo in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. Only limited data are available on efficacy and safety for patients previously treated with monoclonal antibodies including rituximab or patients refractory to previous rituximab plus chemotherapy.See section 5.1 for further information.Rheumatoid arthritisRiximyo in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (DMARD) including one or more tumour necrosis factor (TNF) inhibitor therapies.Rituximab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate.Granulomatosis with polyangiitis and microscopic polyangiitisRiximyo, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (Wegener’s) (GPA) and microscopic polyangiitis (MPA).Riximyo, in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged ≥ 2 to < 18 years old) with severe, active GPA (Wegener’s) and MPA.Pemphigus vulgarisRiximyo is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (PV).|[PMDA] Follow-on biologics indicated for the treatment of CD20-positive B-cell non-Hodgkin's lymphoma, CD20-positive B-cell lymphoproliferative disorder associated with immunosuppression, Wegener's granulomatosis, and microscopic polyangiitis. uuid:e77b2038-738f-4d41-b1bf-3cbab1da556a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4F4X42SYQ6 biolink:treats MONDO:0019124 PMID:41385096 "[{""id"":""uuid:ae484a5e-dafb-424f-a7a0-100697a609e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d18eca5f-e46e-41a6-88b3-4400fdfcfba2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9e91a180-f421-44ca-9278-1e8d6374f427"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/riximyo""]},{""id"":""uuid:fcea5401-d09d-4b9b-ae9a-b0f25af980e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RITUXAN is a CD20-directed cytolytic antibody indicated for the treatment of: Adult patients with Non-Hodgkin's Lymphoma (NHL) ( 1.1 ). Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a single agent. Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy. Previously untreated diffuse large B-cell, CD20-positive NHL in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (CHOP) or other anthracycline-based chemotherapy regimens. Pediatric patients aged 6 months and older with mature B-cell NHL and mature B-cell acute leukemia (B-AL) ( 1.1 ) Previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL) in combination with chemotherapy. Adult patients with Chronic Lymphocytic Leukemia (CLL) ( 1.2 ). Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC). Rheumatoid Arthritis (RA) in combination with methotrexate in adult patients with moderately-to severely-active RA who have inadequate response to one or more TNF antagonist therapies ( 1.3 ). Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA) in adult and pediatric patients 2 years of age and older in combination with glucocorticoids ( 1.4 ). Moderate to severe Pemphigus Vulgaris (PV) in adult patients ( 1.5 ).|[EMA] Riximyo is indicated in adults for the following indications:Non-Hodgkin’s lymphoma (NHL)Riximyo is indicated for the treatment of previously untreated adult patients with stage III-IV follicular lymphoma in combination with chemotherapy.Riximyo maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy.Riximyo monotherapy is indicated for treatment of adult patients with stage III-IV follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy.Riximyo is indicated for the treatment of adult patients with CD20 positive diffuse large B cell non-Hodgkin’s lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.Riximyo in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ≥ 6 months to < 18 years old) with previously untreated advanced stage CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL)/Burkitt leukaemia (mature B-cell acute leukaemia) (BAL) or Burkitt-like lymphoma (BLL).Chronic lymphocytic leukaemia (CLL)Riximyo in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. Only limited data are available on efficacy and safety for patients previously treated with monoclonal antibodies including rituximab or patients refractory to previous rituximab plus chemotherapy.See section 5.1 for further information.Rheumatoid arthritisRiximyo in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (DMARD) including one or more tumour necrosis factor (TNF) inhibitor therapies.Rituximab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate.Granulomatosis with polyangiitis and microscopic polyangiitisRiximyo, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (Wegener’s) (GPA) and microscopic polyangiitis (MPA).Riximyo, in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged ≥ 2 to < 18 years old) with severe, active GPA (Wegener’s) and MPA.Pemphigus vulgarisRiximyo is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (PV).|[PMDA] Follow-on biologics indicated for the treatment of CD20-positive B-cell non-Hodgkin's lymphoma, CD20-positive B-cell lymphoproliferative disorder associated with immunosuppression, Wegener's granulomatosis, and microscopic polyangiitis. uuid:03523bc5-283c-456e-9ec1-e11fa476eabf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4F4X42SYQ6 biolink:treats MONDO:0008219 PMID:41385096 "[{""id"":""uuid:8efef277-543f-491d-ab8c-48a20a237f92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bb4cd17b-482b-4188-813c-23ca7c1f5084"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:953ba932-98ea-4a28-890b-eabc06a8a902"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/riximyo""]},{""id"":""uuid:ee58beb3-4674-4535-80cd-41efda0943f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RITUXAN is a CD20-directed cytolytic antibody indicated for the treatment of: Adult patients with Non-Hodgkin's Lymphoma (NHL) ( 1.1 ). Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a single agent. Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy. Previously untreated diffuse large B-cell, CD20-positive NHL in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (CHOP) or other anthracycline-based chemotherapy regimens. Pediatric patients aged 6 months and older with mature B-cell NHL and mature B-cell acute leukemia (B-AL) ( 1.1 ) Previously untreated, advanced stage, CD20-positive, diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL), Burkitt-like lymphoma (BLL) or mature B-cell acute leukemia (B-AL) in combination with chemotherapy. Adult patients with Chronic Lymphocytic Leukemia (CLL) ( 1.2 ). Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC). Rheumatoid Arthritis (RA) in combination with methotrexate in adult patients with moderately-to severely-active RA who have inadequate response to one or more TNF antagonist therapies ( 1.3 ). Granulomatosis with Polyangiitis (GPA) (Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA) in adult and pediatric patients 2 years of age and older in combination with glucocorticoids ( 1.4 ). Moderate to severe Pemphigus Vulgaris (PV) in adult patients ( 1.5 ).|[EMA] Riximyo is indicated in adults for the following indications:Non-Hodgkin’s lymphoma (NHL)Riximyo is indicated for the treatment of previously untreated adult patients with stage III-IV follicular lymphoma in combination with chemotherapy.Riximyo maintenance therapy is indicated for the treatment of adult follicular lymphoma patients responding to induction therapy.Riximyo monotherapy is indicated for treatment of adult patients with stage III-IV follicular lymphoma who are chemoresistant or are in their second or subsequent relapse after chemotherapy.Riximyo is indicated for the treatment of adult patients with CD20 positive diffuse large B cell non-Hodgkin’s lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.Riximyo in combination with chemotherapy is indicated for the treatment of paediatric patients (aged ≥ 6 months to < 18 years old) with previously untreated advanced stage CD20 positive diffuse large B-cell lymphoma (DLBCL), Burkitt lymphoma (BL)/Burkitt leukaemia (mature B-cell acute leukaemia) (BAL) or Burkitt-like lymphoma (BLL).Chronic lymphocytic leukaemia (CLL)Riximyo in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. Only limited data are available on efficacy and safety for patients previously treated with monoclonal antibodies including rituximab or patients refractory to previous rituximab plus chemotherapy.See section 5.1 for further information.Rheumatoid arthritisRiximyo in combination with methotrexate is indicated for the treatment of adult patients with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying anti-rheumatic drugs (DMARD) including one or more tumour necrosis factor (TNF) inhibitor therapies.Rituximab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate.Granulomatosis with polyangiitis and microscopic polyangiitisRiximyo, in combination with glucocorticoids, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (Wegener’s) (GPA) and microscopic polyangiitis (MPA).Riximyo, in combination with glucocorticoids, is indicated for the induction of remission in paediatric patients (aged ≥ 2 to < 18 years old) with severe, active GPA (Wegener’s) and MPA.Pemphigus vulgarisRiximyo is indicated for the treatment of patients with moderate to severe pemphigus vulgaris (PV).|[PMDA] Drugs with a new indication and a new dosage for the treatment of refractory pemphigus vulgaris and pemphigus foliaceus. [Orphan drug] uuid:19d91ed3-402e-4e6a-a1e9-31b09336ee19 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:143117 biolink:treats UMLS:C0278987 PMID:41385096 "[{""id"":""uuid:4216cc50-3fed-4e72-a5cb-06df4f7cb89b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9115629e-baca-4723-9222-56daade8b2a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LORBRENA ® is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. uuid:72ef2f13-c43f-45b3-b6e9-1f8d4b085a16 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64310 biolink:treats UMLS:C0278987 PMID:41385096 "[{""id"":""uuid:01e419b7-7a48-4e2f-9680-9cb88a8d5d65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9f850ccb-c84e-4901-be93-360ed6e8205c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XALKORI is a kinase inhibitor indicated for the treatment of • adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive as detected by an FDA-approved test. ( 1.1 , 2.1 ) • pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. ( 1.2 , 2.3 ) o Limitations of Use: The safety and efficacy of XALKORI have not been established in older adults with relapsed or refractory, systemic ALK-positive ALCL. • adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT) that is ALK-positive. ( 1.3 , 2.3 ) uuid:e9e5325e-7250-4224-b1ce-57935e65057b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64310 biolink:treats UMLS:C1336548 PMID:41385096 "[{""id"":""uuid:0c82ce1d-0b0e-41c4-9332-ed968beab93c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a9112e89-8c19-48a7-bddd-2c669cfe4953"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XALKORI is a kinase inhibitor indicated for the treatment of • adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive as detected by an FDA-approved test. ( 1.1 , 2.1 ) • pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. ( 1.2 , 2.3 ) o Limitations of Use: The safety and efficacy of XALKORI have not been established in older adults with relapsed or refractory, systemic ALK-positive ALCL. • adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT) that is ALK-positive. ( 1.3 , 2.3 ) uuid:9b4ea0cd-0333-4827-b4d6-5acc29d05252 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64310 biolink:treats MONDO:0015798 PMID:41385096 "[{""id"":""uuid:442749d3-063f-44f7-9e83-fe89e87f6f66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d9b8cc02-1a0c-4bc2-b6a5-01a0c900860d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XALKORI is a kinase inhibitor indicated for the treatment of • adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive as detected by an FDA-approved test. ( 1.1 , 2.1 ) • pediatric patients 1 year of age and older and young adults with relapsed or refractory, systemic anaplastic large cell lymphoma (ALCL) that is ALK-positive. ( 1.2 , 2.3 ) o Limitations of Use: The safety and efficacy of XALKORI have not been established in older adults with relapsed or refractory, systemic ALK-positive ALCL. • adult and pediatric patients 1 year of age and older with unresectable, recurrent, or refractory inflammatory myofibroblastic tumor (IMT) that is ALK-positive. ( 1.3 , 2.3 ) uuid:28684758-8125-4228-8cfa-7f3328f49aa4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:Q4K217VGA9 biolink:treats MONDO:0006502 PMID:41385096 "[{""id"":""uuid:93220408-24ec-4f2d-b6de-11a04dfa9519"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7b2177f4-e68c-4ec7-9fd1-e40400469279"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INFASURF is indicated: to reduce the risk of respiratory distress syndrome (RDS) in preterm neonates <29 weeks of gestational age at risk for RDS. for the rescue treatment of RDS in preterm neonates ≤72 hours of age with RDS who require endotracheal intubation. uuid:fff5e6ab-1fc8-4264-b149-085623c9ebba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:Q4K217VGA9 biolink:treats MONDO:0009971 PMID:41385096 "[{""id"":""uuid:4de85847-3e05-4c1d-b1e8-073046dab3f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:881b7a31-85c6-457a-95f9-fd08928a396f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INFASURF is indicated: to reduce the risk of respiratory distress syndrome (RDS) in preterm neonates <29 weeks of gestational age at risk for RDS. for the rescue treatment of RDS in preterm neonates ≤72 hours of age with RDS who require endotracheal intubation. uuid:e9290d82-c65b-4855-b947-f66708b7e37d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0982025 biolink:treats MONDO:0010602 PMID:41385096 "[{""id"":""uuid:b0d5a8b5-77c3-4175-afab-020522d00002"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a40b4aa0-c938-4a58-a21c-7e7f3d374701"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c2fcb6bf-4920-4f10-971f-1edc53e047b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FEIBA is an Anti-Inhibitor Coagulant Complex indicated for use in hemophilia A and B patients with inhibitors for: Control and prevention of bleeding episodes Perioperative management Routine prophylaxis to prevent or reduce the frequency of bleeding episodes. FEIBA is not indicated for the treatment of bleeding episodes resulting from coagulation factor deficiencies in the absence of inhibitors to coagulation factor VIII or coagulation factor IX.|[PMDA] Drugs with a revised indication and a new dosage for inhibition of bleeding tendency by promoting the blood coagulation in the plasma in patients with inhibitors to blood coagulation factor VIII or factor IX. DRUGBANK:DB13151 uuid:9eb2da16-8b66-4c68-ad80-27cafd4d074d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0982025 biolink:treats MONDO:0010604 PMID:41385096 "[{""id"":""uuid:872479ff-7ea3-4a3c-8974-fa5e7b6dce90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4245266f-d15b-452f-afc4-7561d8d9ce92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1dbb9ad7-dd76-4e71-9950-e55893c77666"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FEIBA is an Anti-Inhibitor Coagulant Complex indicated for use in hemophilia A and B patients with inhibitors for: Control and prevention of bleeding episodes Perioperative management Routine prophylaxis to prevent or reduce the frequency of bleeding episodes. FEIBA is not indicated for the treatment of bleeding episodes resulting from coagulation factor deficiencies in the absence of inhibitors to coagulation factor VIII or coagulation factor IX.|[PMDA] Drugs with a revised indication and a new dosage for inhibition of bleeding tendency by promoting the blood coagulation in the plasma in patients with inhibitors to blood coagulation factor VIII or factor IX. DRUGBANK:DB13151 uuid:36615e7e-d1ac-4a37-a998-e43992924f22 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0009197 PMID:41385096 "[{""id"":""uuid:e899ebd1-0739-4ff4-a275-166b7191c13a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bcb6fd86-a25a-413d-b857-ba6caac43e18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylprednisolone tablets are indicated in the following conditions: Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Synovitis of osteoarthritis Acute nonspecific tenosynovitis Post-traumatic osteoarthritis Psoriatic arthritis EpicondylitisAcute gouty arthritis Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis Dermatologic Diseases Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Severe seborrheic dermatitis Exfoliative dermatitis Mycosis fungoides Pemphigus Severe psoriasis Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Drug hypersensitivity reactions Serum sickness Contact dermatitis Bronchial asthma Atopic dermatitis Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Keratitis Optic neuritis Allergic conjunctivitis Chorioretinitis Iritis and iridocyclitis Respiratory Diseases Symptomatic sarcoidosis Berylliosis Loeffler's syndrome not manageable by other means Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis Nervous System Acute exacerbations of multiple sclerosis Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Trichinosis with neurologic or myocardial involvement. uuid:44295f08-412d-43d4-b197-84b432e3425b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134677 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:3caa3788-374b-4847-b50a-eff5f019c678"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e7bf2abc-728e-4941-b0a4-45c610a5db53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EUCRISA is indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 3 months of age and older. uuid:eec4eedb-d73a-43d4-a73d-fc4c88bbe432 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:681848 biolink:treats UMLS:C0865850 PMID:41385096 "[{""id"":""uuid:7c83c522-046d-428d-800c-2c0ced04f301"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d9b994cf-f137-4eae-9b22-c92ba345503f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Postanesthesia When the possibility of airway obstruction and/or hypoxia have been eliminated, doxapram may be used to stimulate respiration in patients with drug-induced postanesthesia respiratory depression or apnea other than that due to muscle relaxant drugs. To pharmacologically stimulate deep breathing in the postoperative patient. (A quantitative method of assessing oxygenation, such as pulse oximetry, is recommended.) Drug-Induced Central Nervous System Depression Exercising care to prevent vomiting and aspiration, doxapram may be used to stimulate respiration, hasten arousal, and to encourage the return of laryngopharyngeal reflexes in patients with mild to moderate respiratory and CNS depression due to drug overdosage. Chronic Pulmonary Disease Associated with Acute Hypercapnia Doxapram is indicated as a temporary measure in hospitalized patients with acute respiratory insufficiency superimposed on chronic obstructive pulmonary disease. Its use should be for a short period of time (see DOSAGE & ADMINISTRATION ) as an aid in the prevention of elevation of arterial CO2 tension during the administration of oxygen. It should not be used in conjunction with mechanical ventilation. uuid:6a5c3ec3-a2d0-497c-86d0-d1558e5fcb0c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:681848 biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:48524168-4d14-4fcb-99c8-d6d8464abd1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cbfd0b19-5855-428b-96ce-0722da56db27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Postanesthesia When the possibility of airway obstruction and/or hypoxia have been eliminated, doxapram may be used to stimulate respiration in patients with drug-induced postanesthesia respiratory depression or apnea other than that due to muscle relaxant drugs. To pharmacologically stimulate deep breathing in the postoperative patient. (A quantitative method of assessing oxygenation, such as pulse oximetry, is recommended.) Drug-Induced Central Nervous System Depression Exercising care to prevent vomiting and aspiration, doxapram may be used to stimulate respiration, hasten arousal, and to encourage the return of laryngopharyngeal reflexes in patients with mild to moderate respiratory and CNS depression due to drug overdosage. Chronic Pulmonary Disease Associated with Acute Hypercapnia Doxapram is indicated as a temporary measure in hospitalized patients with acute respiratory insufficiency superimposed on chronic obstructive pulmonary disease. Its use should be for a short period of time (see DOSAGE & ADMINISTRATION ) as an aid in the prevention of elevation of arterial CO2 tension during the administration of oxygen. It should not be used in conjunction with mechanical ventilation. uuid:abdd738e-a92e-4d5d-ad5a-2df87cb86746 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:681848 biolink:treats HP:0012416 PMID:41385096 "[{""id"":""uuid:0de00d9e-bbac-4432-90f4-da3b03b7d095"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d94ccf13-879e-4565-96b7-573c50986844"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Postanesthesia When the possibility of airway obstruction and/or hypoxia have been eliminated, doxapram may be used to stimulate respiration in patients with drug-induced postanesthesia respiratory depression or apnea other than that due to muscle relaxant drugs. To pharmacologically stimulate deep breathing in the postoperative patient. (A quantitative method of assessing oxygenation, such as pulse oximetry, is recommended.) Drug-Induced Central Nervous System Depression Exercising care to prevent vomiting and aspiration, doxapram may be used to stimulate respiration, hasten arousal, and to encourage the return of laryngopharyngeal reflexes in patients with mild to moderate respiratory and CNS depression due to drug overdosage. Chronic Pulmonary Disease Associated with Acute Hypercapnia Doxapram is indicated as a temporary measure in hospitalized patients with acute respiratory insufficiency superimposed on chronic obstructive pulmonary disease. Its use should be for a short period of time (see DOSAGE & ADMINISTRATION ) as an aid in the prevention of elevation of arterial CO2 tension during the administration of oxygen. It should not be used in conjunction with mechanical ventilation. uuid:6bca94cd-bee7-4eab-8b07-807bf82a0e2b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7903 biolink:treats MONDO:0005382 PMID:41385096 "[{""id"":""uuid:b4922081-309b-4803-aeca-a5dbb4b02e77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b76b5e54-6856-41ca-b6bd-b9e2717a9499"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypercalcemia of Malignancy Pamidronate disodium, in conjunction with adequate hydration, is indicated for the treatment of moderate or severe hypercalcemia associated with malignancy, with or without bone metastases. Patients who have either epidermoid or non-epidermoid tumors respond to treatment with pamidronate disodium. Vigorous saline hydration, an integral part of hypercalcemia therapy, should be initiated promptly and an attempt should be made to restore the urine output to about 2 L/day throughout treatment. Mild or asymptomatic hypercalcemia may be treated with conservative measures (i.e., saline hydration, with or without loop diuretics). Patients should be hydrated adequately throughout the treatment, but overhydration, especially in those patients who have cardiac failure, must be avoided. Diuretic therapy should not be employed prior to correction of hypovolemia. The safety and efficacy of pamidronate disodium in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions has not been established. Paget’s Disease Pamidronate disodium is indicated for the treatment of patients with moderate to severe Paget’s disease of bone. The effectiveness of pamidronate disodium was demonstrated primarily in patients with serum alkaline phosphatase ≥ 3 times the upper limit of normal. Pamidronate disodium therapy in patients with Paget’s disease has been effective in reducing serum alkaline phosphatase and urinary hydroxyproline levels by ≥ 50% in at least 50% of patients, and by ≥ 30% in at least 80% of patients. Pamidronate disodium therapy has also been effective in reducing these biochemical markers in patients with Paget’s disease who failed to respond, or no longer responded to other treatments. Osteolytic Bone Metastases of Breast Cancer and Osteolytic Lesions of Multiple Myeloma Pamidronate disodium is indicated, in conjunction with standard antineoplastic therapy, for the treatment of osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma. The pamidronate disodium treatment effect appeared to be smaller in the study of breast cancer patients receiving hormonal therapy than in the study of those receiving chemotherapy, however, overall evidence of clinical benefit has been demonstrated (see CLINICAL PHARMACOLOGY , Osteolytic Bone Metastases of Breast Cancer and Osteolytic Lesions of Multiple Myeloma, Clinical Trials section). uuid:882992aa-3d36-4a59-9e66-e7355d992669 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7903 biolink:treats UMLS:C3898069 PMID:41385096 "[{""id"":""uuid:2dd51454-cfc7-4158-aeb4-8219aa6ff937"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:31b6d83f-5dd7-4a25-88dd-a7992e1067a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hypercalcemia of Malignancy Pamidronate disodium, in conjunction with adequate hydration, is indicated for the treatment of moderate or severe hypercalcemia associated with malignancy, with or without bone metastases. Patients who have either epidermoid or non-epidermoid tumors respond to treatment with pamidronate disodium. Vigorous saline hydration, an integral part of hypercalcemia therapy, should be initiated promptly and an attempt should be made to restore the urine output to about 2 L/day throughout treatment. Mild or asymptomatic hypercalcemia may be treated with conservative measures (i.e., saline hydration, with or without loop diuretics). Patients should be hydrated adequately throughout the treatment, but overhydration, especially in those patients who have cardiac failure, must be avoided. Diuretic therapy should not be employed prior to correction of hypovolemia. The safety and efficacy of pamidronate disodium in the treatment of hypercalcemia associated with hyperparathyroidism or with other non-tumor-related conditions has not been established. Paget’s Disease Pamidronate disodium is indicated for the treatment of patients with moderate to severe Paget’s disease of bone. The effectiveness of pamidronate disodium was demonstrated primarily in patients with serum alkaline phosphatase ≥ 3 times the upper limit of normal. Pamidronate disodium therapy in patients with Paget’s disease has been effective in reducing serum alkaline phosphatase and urinary hydroxyproline levels by ≥ 50% in at least 50% of patients, and by ≥ 30% in at least 80% of patients. Pamidronate disodium therapy has also been effective in reducing these biochemical markers in patients with Paget’s disease who failed to respond, or no longer responded to other treatments. Osteolytic Bone Metastases of Breast Cancer and Osteolytic Lesions of Multiple Myeloma Pamidronate disodium is indicated, in conjunction with standard antineoplastic therapy, for the treatment of osteolytic bone metastases of breast cancer and osteolytic lesions of multiple myeloma. The pamidronate disodium treatment effect appeared to be smaller in the study of breast cancer patients receiving hormonal therapy than in the study of those receiving chemotherapy, however, overall evidence of clinical benefit has been demonstrated (see CLINICAL PHARMACOLOGY , Osteolytic Bone Metastases of Breast Cancer and Osteolytic Lesions of Multiple Myeloma, Clinical Trials section). uuid:2ffef045-5785-42ca-908b-502c2987bd64 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0001658 PMID:41385096 "[{""id"":""uuid:5098dbea-3669-4b97-8616-b6852ecb391e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9480c36c-fc3a-4823-93a6-2f0501c62e24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Strong Iodine Solution, containing 5 percent of iodine and 10 percent of potassium iodide, is employed in the prophylaxis of simple and colloid goiters and in the treatment of exophthalmic goiter. It can be used alone as a preoperative preparation but is now most commonly used concomitantly with propylthiouracil and other antithyroid drugs. When used with these drugs, Strong Iodine Solution produces involution of the hyperplastic gland thus making a less triable and vascular gland for thyroidectomy. In addition, it has an additive antithyroid action that helps make the patient enthyroid faster than if the antithyroid drugs were used alone. uuid:e044b8ba-67f7-4684-b295-91437865a4b0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0006869 PMID:41385096 "[{""id"":""uuid:befe8848-7215-4a20-86e9-bc32c6217dc3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f1990237-3dca-4da4-a175-ccf4aa67acac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Strong Iodine Solution, containing 5 percent of iodine and 10 percent of potassium iodide, is employed in the prophylaxis of simple and colloid goiters and in the treatment of exophthalmic goiter. It can be used alone as a preoperative preparation but is now most commonly used concomitantly with propylthiouracil and other antithyroid drugs. When used with these drugs, Strong Iodine Solution produces involution of the hyperplastic gland thus making a less triable and vascular gland for thyroidectomy. In addition, it has an additive antithyroid action that helps make the patient enthyroid faster than if the antithyroid drugs were used alone. uuid:3e1acbad-5fe7-44c7-aaad-295887bdacad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17606 biolink:treats MONDO:0005364 PMID:41385096 "[{""id"":""uuid:9c99afd3-20d3-42b1-bf58-9efb6eeb7698"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:39b4d6ed-2195-49a1-88d7-80ad97341812"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Strong Iodine Solution, containing 5 percent of iodine and 10 percent of potassium iodide, is employed in the prophylaxis of simple and colloid goiters and in the treatment of exophthalmic goiter. It can be used alone as a preoperative preparation but is now most commonly used concomitantly with propylthiouracil and other antithyroid drugs. When used with these drugs, Strong Iodine Solution produces involution of the hyperplastic gland thus making a less triable and vascular gland for thyroidectomy. In addition, it has an additive antithyroid action that helps make the patient enthyroid faster than if the antithyroid drugs were used alone. uuid:477e3e28-27b8-4182-a3ef-89d834bf4ef0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:AIW6036FAS biolink:treats MONDO:0010679 PMID:41385096 "[{""id"":""uuid:2ca6cee7-111f-4ecd-9d24-c1d61d9f4d39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f79c0eb1-ee12-495d-9d7e-2f9223e20e94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EXONDYS 51 is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. This indication is approved under accelerated approval based on an increase in dystrophin in skeletal muscle observed in some patients treated with EXONDYS 51 [see Clinical Studies ( 14 )] . Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials. uuid:895c92a6-27ef-4e8e-9281-2ffcfa0388db biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5959 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:b30a0629-4283-4c14-b6d6-1e593de4400a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d08f4cdd-7c9f-45c7-8123-e955aadd1060"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hypertension Irbesartan tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Irbesartan tablets may be used alone or in combination with other antihypertensive agents. 1.2 Nephropathy in Type 2 Diabetic Patients Irbesartan tablets are indicated for the treatment of diabetic nephropathy in patients with type 2 diabetes and hypertension, an elevated serum creatinine, and proteinuria (>300 mg/day). In this population, irbesartan reduces the rate of progression of nephropathy as measured by the occurrence of doubling of serum creatinine or end-stage renal disease (need for dialysis or renal transplantation) [see Clinical Studies (14.2)]. uuid:c082dbec-d9e5-42a2-b4d3-79c96fb6b1e9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5959 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:986bdaca-88db-42e5-b9a8-e76dc0da0916"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6f11cd17-cf94-4b4c-9e99-5bf33507b919"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hypertension Irbesartan tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Irbesartan tablets may be used alone or in combination with other antihypertensive agents. 1.2 Nephropathy in Type 2 Diabetic Patients Irbesartan tablets are indicated for the treatment of diabetic nephropathy in patients with type 2 diabetes and hypertension, an elevated serum creatinine, and proteinuria (>300 mg/day). In this population, irbesartan reduces the rate of progression of nephropathy as measured by the occurrence of doubling of serum creatinine or end-stage renal disease (need for dialysis or renal transplantation) [see Clinical Studies (14.2)]. uuid:0a605d9e-07a6-454e-8278-449eb08a9a5c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5959 biolink:treats MONDO:0004375 PMID:41385096 "[{""id"":""uuid:f7935579-6371-46bd-82f6-588e740341c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9bd2fc50-724d-461f-bbbe-300b9a27e784"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hypertension Irbesartan tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Irbesartan tablets may be used alone or in combination with other antihypertensive agents. 1.2 Nephropathy in Type 2 Diabetic Patients Irbesartan tablets are indicated for the treatment of diabetic nephropathy in patients with type 2 diabetes and hypertension, an elevated serum creatinine, and proteinuria (>300 mg/day). In this population, irbesartan reduces the rate of progression of nephropathy as measured by the occurrence of doubling of serum creatinine or end-stage renal disease (need for dialysis or renal transplantation) [see Clinical Studies (14.2)]. uuid:a346c557-abff-4dfc-9186-7b548070b351 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17933 biolink:treats MONDO:0006964 PMID:41385096 "[{""id"":""uuid:3d0ee88d-1a69-420e-b682-fe6e7c371294"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:46c3a8bf-7377-424a-ad3b-b2f1a5a98390"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RAYALDEE is a vitamin D 3 analog indicated for the treatment of secondary hyperparathyroidism in adult patients with stage 3 or 4 chronic kidney disease and serum total 25-hydroxyvitamin D levels less than 30 ng/mL. Limitations of Use RAYALDEE is not indicated for the treatment of secondary hyperparathyroidism in patients with stage 5 chronic kidney disease or in patients with end-stage renal disease on dialysis. uuid:f5371d91-0f35-40a5-bab3-369a2b6b9342 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17933 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:8fb44ced-6069-4c99-9d32-7a13be511fd5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:22bb69c1-5fd5-4ea1-98ee-7d1c5de2b824"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RAYALDEE is a vitamin D 3 analog indicated for the treatment of secondary hyperparathyroidism in adult patients with stage 3 or 4 chronic kidney disease and serum total 25-hydroxyvitamin D levels less than 30 ng/mL. Limitations of Use RAYALDEE is not indicated for the treatment of secondary hyperparathyroidism in patients with stage 5 chronic kidney disease or in patients with end-stage renal disease on dialysis. uuid:be5069d7-e09e-4a83-a61f-75ffa99088cc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90959 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:b497f741-1c11-4e2b-904b-87396522359f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9a7add42-e4ae-4712-b5e6-4a7dfcdddaf7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f499459c-5b1d-471f-bf2d-13149dfbebf5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SPIRIVA RESPIMAT is an anticholinergic indicated for: The long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), and for reducing COPD exacerbations ( 1.1 ) The long-term, once-daily, maintenance treatment of asthma in patients 6 years of age and older ( 1.2 ) Limitation of Use: Not indicated for relief of acute bronchospasm ( 1.1 , 1.2 , 5.1 )|[PMDA] Drugs with a new additional indication, dosage, and dosage form for the relief of symptoms secondary to airway obstructive disorders in mild to moderate persistent bronchial asthma. uuid:05cc956f-1b22-4d5f-adf3-a96032647e6e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90959 biolink:treats UMLS:C0853854 PMID:41385096 "[{""id"":""uuid:3b3d135d-c451-4061-9efe-09babe67c954"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4602589a-3855-4581-91a6-43ef336556b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SPIRIVA RESPIMAT is an anticholinergic indicated for: The long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), and for reducing COPD exacerbations ( 1.1 ) The long-term, once-daily, maintenance treatment of asthma in patients 6 years of age and older ( 1.2 ) Limitation of Use: Not indicated for relief of acute bronchospasm ( 1.1 , 1.2 , 5.1 ) uuid:448ac78f-5344-41ae-9825-c0c07666a75e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:132268 biolink:treats UMLS:C0278987 PMID:41385096 "[{""id"":""uuid:791907e1-17c7-45d3-9af9-a7e5e55f127f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dc9bfa49-5730-4785-8452-20517d377e8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VIZIMPRO is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test [see Dosage and Administration (2.1) ] . uuid:4f188fb8-0ecd-4984-b364-31c38d6fa55c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:132268 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:b2868e01-4f9f-4f20-abfb-e4398823ef0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:adbd6cfe-ed1b-415e-86cd-ddb3486a06c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:37427849-b399-4500-8d16-b4685ccf9ee8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:40cb1529-0160-444e-a724-6b106b977062"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VIZIMPRO is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test [see Dosage and Administration (2.1) ] .|[EMA] Vizimpro, as monotherapy, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutations.|[PMDA] Drugs with a new active ingredient indicated for the treatment of inoperable or recurrent non-small cell lung cancer with EGFR gene mutation. [Priority review] uuid:a095e54a-0aa6-465a-8624-2f6a5f27f89a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1992822 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:a0028a2d-d7b7-44e2-a260-f6b807a81129"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:588c3044-8645-4dd8-a18b-989aead18f42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d5323567-9863-4766-8026-64b8ca0f4758"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/steglujan""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] STEGLUJAN ® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use Not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus [see Warnings and Precautions (5.1) ]. Has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using STEGLUJAN [see Warnings and Precautions (5.2) ] .|[EMA] Steglujan is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:when metformin and/or a sulphonylurea (SU) and one of the monocomponents of Steglujan do not provide adequate glycaemic control.in patients already being treated with the combination of ertugliflozin and sitagliptin as separate tablets. uuid:1b74f3d5-4425-454e-90f8-ab4a8784d16a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1992822 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:ed26651b-d497-430e-93c6-77491b85c632"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3c5724c2-a3d5-48df-967d-1397b5ac7112"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] STEGLUJAN ® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use Not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus [see Warnings and Precautions (5.1) ]. Has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using STEGLUJAN [see Warnings and Precautions (5.2) ] . uuid:0e58699a-c063-4051-8934-26c18251de23 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1992822 biolink:treats MONDO:0004982 PMID:41385096 "[{""id"":""uuid:b016d4e6-af03-406b-b533-3529c47e7ff0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a1d9a210-ac57-480e-a1d2-18acd84d4ba2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] STEGLUJAN ® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use Not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus [see Warnings and Precautions (5.1) ]. Has not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using STEGLUJAN [see Warnings and Precautions (5.2) ] . uuid:92f59c26-0afa-4636-bece-7c966ebe0942 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:581255 biolink:treats UMLS:C0854100 PMID:41385096 "[{""id"":""uuid:3d1ba072-0a42-4ab8-929d-ae72d118bfbd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bcdfd5b9-7a6c-4cff-a3e1-1d774841ce98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROSOL is indicated as a source of amino acids for patients requiring parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. PROSOL may be used to treat negative nitrogen balance in patients. uuid:67c09512-a9dd-449e-a8fa-10fe0efdff44 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:MCN858TCP0 biolink:treats NCIT:C27003 PMID:41385096 "[{""id"":""uuid:10ec869c-086c-439b-88ab-b6a0cce8afb4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a3fdbc70-6f60-4fd0-85d0-a3b95f43fccd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OLINVYK is indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration [see Warnings and Precautions ( 5.1 )] , reserve OLINVYK for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]: Have not been tolerated, or are not expected to be tolerated Have not provided adequate analgesia, or are not expected to provide adequate analgesia. The cumulative total daily dose should not exceed 27 mg, as total daily doses greater than 27 mg may increase the risk for QTc interval prolongation [see Warnings and Precautions ( 5.5 ] . uuid:aa7c286f-bbc8-42de-a4d4-89c0d38b47dc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DTI67O9503 biolink:treats MONDO:0009290 PMID:41385096 "[{""id"":""uuid:dcef3167-05a1-484f-ae04-1e7b41e38b6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d289c5a8-338f-4088-b7d1-0003c3101ac6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2242e3c0-8ae7-4b46-bfc3-9c56e1721c91"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/myozyme""]},{""id"":""uuid:db96105c-eba4-4437-be90-95aa6810b847"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LUMIZYME ® is a hydrolytic lysosomal glycogen-specific enzyme indicated for patients with Pompe disease (acid α-glucosidase [GAA] deficiency).|[EMA] Myozyme is indicated for long-term enzyme-replacement therapy (ERT) in patients with a confirmed diagnosis of Pompe disease (acid-α-glucosidase deficiency).In patients with late-onset Pompe disease the evidence of efficacy is limited.|[PMDA] A drug containing a new active ingredient indicated for the treatment of type 2 glycogenosis. [Orphan drug] uuid:0b588a73-a247-4e9e-9e23-4dc27570b0a2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:188719 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:f3ef2814-c3ef-4d6f-a7d9-1df4b6b4bccc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:343d710f-7552-48c1-b9c7-e79d9ff1e887"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a0fc2be8-d587-44b5-9e23-bb81ceaf1ca7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] STEGLATRO ® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.|[EMA] Steglatro is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:as monotherapy in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications.in addition to other medicinal products for the treatment of diabetes. uuid:688cfc8b-e5a0-4366-ad32-64f1be320f3e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1591939 biolink:treats MONDO:0005354 PMID:41385096 "[{""id"":""uuid:4e53c65f-0e0a-4e45-af27-bccd6c7106cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1bda78e1-e185-41d4-a61d-218fd78205eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:20e06188-fd22-4694-a1ba-fa49cb1c6a74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] HARVONI is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) [see Dosage and Administration (2.2 and 2.3) and Clinical Studies (14) ] : genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis genotype 1 infection with decompensated cirrhosis, for use in combination with ribavirin genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis, for use in combination with ribavirin|[PMDA] A new combination drug with new active ingredients indicated for the improvement of viremia in patients with chronic hepatitis C or compensated cirrhosis type C in serogroup 1 (genotype 1). [Priority review] uuid:ecb164da-b7b0-4eac-90d0-e21bf9fff9af biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:794PGL549S biolink:treats MONDO:0016595 PMID:41385096 "[{""id"":""uuid:61f1fdc8-fc48-41e8-bcab-66f1cb0108c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:55a33cb8-3dfe-4713-9035-b7032eb2eeee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Raxibacumab is indicated for the treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs, and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate. ( 1.1 ) Limitations of Use: The effectiveness of raxibacumab is based solely on efficacy studies in animal models of inhalational anthrax. ( 1.2 , 14.1 ) There have been no studies of raxibacumab in the pediatric population. Dosing in pediatric patients was derived using an extrapolation approach. ( 1.2 , 8.4 ) Raxibacumab does not cross the blood-brain barrier and does not prevent or treat meningitis. Raxibacumab should be used in combination with appropriate antibacterial drugs. ( 1.2 ) uuid:85704b7d-4553-4a0c-a887-6ed899df5f37 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:794PGL549S biolink:treats MONDO:0021108 PMID:41385096 "[{""id"":""uuid:c975ff87-f82e-43af-bffe-1d5cedbf3f11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:98c40505-63c5-466a-bdff-9b1f6cfb68ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Raxibacumab is indicated for the treatment of adult and pediatric patients with inhalational anthrax due to Bacillus anthracis in combination with appropriate antibacterial drugs, and for prophylaxis of inhalational anthrax when alternative therapies are not available or are not appropriate. ( 1.1 ) Limitations of Use: The effectiveness of raxibacumab is based solely on efficacy studies in animal models of inhalational anthrax. ( 1.2 , 14.1 ) There have been no studies of raxibacumab in the pediatric population. Dosing in pediatric patients was derived using an extrapolation approach. ( 1.2 , 8.4 ) Raxibacumab does not cross the blood-brain barrier and does not prevent or treat meningitis. Raxibacumab should be used in combination with appropriate antibacterial drugs. ( 1.2 ) uuid:dd57165a-0aed-4022-bd2d-2b5802605067 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB17831 biolink:treats MONDO:0006543 PMID:41385096 "[{""id"":""uuid:0c748c6e-8d0e-4e8b-83be-9b9dd6a1901a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f05a449d-45d5-4d7b-844f-7a9c85347089"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VYJUVEK is indicated for the treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene. uuid:86978fa2-3171-48a3-8a6c-549de98ef3bb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135752 biolink:treats MONDO:0005136 PMID:41385096 "[{""id"":""uuid:58313fd8-3c09-463f-9560-b96a2e2128e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f3086343-7cc1-4eee-b932-477699056f16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ARAKODA is indicated for the prophylaxis of malaria in patients aged 18 years and older. uuid:5043b934-727a-439c-adae-b464db5296ae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82700 biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:152ac31c-d299-4ac5-8b2b-cb851cf26cc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e8260cfe-b637-45b4-aa0a-591640881d36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] STRIVERDI RESPIMAT Inhalation Spray is a long-acting beta 2 -adrenergic agonist (LABA) indicated for: The long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. ( 1.1 ) Important limitations: STRIVERDI RESPIMAT is NOT indicated to treat acute deterioration of COPD. ( 1.2 ) STRIVERDI RESPIMAT is NOT indicated to treat asthma. ( 1.2 ) uuid:bf172fb4-77f3-4fbb-ac90-b5dde17f77f0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82700 biolink:treats MONDO:0005607 PMID:41385096 "[{""id"":""uuid:149389fb-b67f-441a-bb59-759a526ca5bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:46e5f6ff-1ade-432a-82a2-05c81c65c87b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] STRIVERDI RESPIMAT Inhalation Spray is a long-acting beta 2 -adrenergic agonist (LABA) indicated for: The long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. ( 1.1 ) Important limitations: STRIVERDI RESPIMAT is NOT indicated to treat acute deterioration of COPD. ( 1.2 ) STRIVERDI RESPIMAT is NOT indicated to treat asthma. ( 1.2 ) uuid:a4f086a7-773d-4571-bcc0-23d5660130c4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82700 biolink:treats MONDO:0004849 PMID:41385096 "[{""id"":""uuid:c0a1f8c3-19f4-492f-a494-146fb4df033a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1a148e3a-27bf-485c-a0d8-3a0e137b8860"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] STRIVERDI RESPIMAT Inhalation Spray is a long-acting beta 2 -adrenergic agonist (LABA) indicated for: The long-term, once-daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. ( 1.1 ) Important limitations: STRIVERDI RESPIMAT is NOT indicated to treat acute deterioration of COPD. ( 1.2 ) STRIVERDI RESPIMAT is NOT indicated to treat asthma. ( 1.2 ) uuid:1cafbd1e-6c54-4942-aa9f-b6b0f07bef72 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:T8B2ORP1DW biolink:treats MONDO:0018328 PMID:41385096 "[{""id"":""uuid:41a69b40-2d17-49b4-8944-8eb375906334"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:610e7c2c-f6b7-4e35-98fb-0b3a456d08f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a2f87349-decb-4c94-9383-f4ad7d343b25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/evkeeza""]},{""id"":""uuid:85cd72c2-fa5c-4726-8b35-daf1314d9709"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EVKEEZA is indicated as an adjunct to other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and pediatric patients, aged 5 years and older, with homozygous familial hypercholesterolemia (HoFH).|[EMA] Evkeeza is indicated as an adjunct to diet and other low-density lipoprotein-cholesterol (LDL-C) lowering therapies for the treatment of adult and adolescent patients aged 12 years and older with homozygous familial hypercholesterolaemia (HoFH).|[PMDA] A drug with a new active ingredient indicated for the treatment of homozygous familial hypercholesterolemia. [Orphan drug] uuid:081ea7e5-ba60-458a-b542-af28ac1f8d10 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40303 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:b18ab2ce-d8f8-420a-b218-1019bc8519e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d024c31e-e359-4e1e-8a71-6d16b2cb0a3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Altoprev is indicated: • To reduce the risk of myocardial infarction, unstable angina, and coronary revascularization procedures in adults at high risk for coronary heart disease. • As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) and slow the progression of coronary atherosclerosis in adults with coronary heart disease. • As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH). uuid:c6f7b634-cfb1-46ad-b3ca-5481f9015425 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB11294 biolink:treats MONDO:0005706 PMID:41385096 "[{""id"":""uuid:c48b5940-fef3-4bb2-bd2b-77dbe8577e49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:04f40672-4658-492d-97dd-b395bdbb43ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spherusol ® is a skin test antigen indicated for the detection of delayed-type hypersensitivity to Coccidioides immitis in individuals with a history of pulmonary coccidioidomycosis. Spherusol ® is approved for use in individuals 18-64 years of age. The use of Spherusol ® to detect delayed-type hypersensitivity responses in a general population with unknown exposure to C. immitis has not been evaluated. Persons with acute or disseminated coccidioidomycosis may not develop a delayed-type hypersensitivity response to Spherusol ® . Persons with immunodeficiency and a history of coccidioidomycosis may not develop a delayed-type hypersensitivity response to Spherusol ® . uuid:39858f97-a700-4caa-a184-c1b277f84494 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB11294 biolink:treats UMLS:C3840167 PMID:41385096 "[{""id"":""uuid:5edeadb9-aaf0-4e84-ad5e-99d3e4a773fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:33a0fbd0-e0ee-4ef0-8b24-c02c840b15ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spherusol ® is a skin test antigen indicated for the detection of delayed-type hypersensitivity to Coccidioides immitis in individuals with a history of pulmonary coccidioidomycosis. Spherusol ® is approved for use in individuals 18-64 years of age. The use of Spherusol ® to detect delayed-type hypersensitivity responses in a general population with unknown exposure to C. immitis has not been evaluated. Persons with acute or disseminated coccidioidomycosis may not develop a delayed-type hypersensitivity response to Spherusol ® . Persons with immunodeficiency and a history of coccidioidomycosis may not develop a delayed-type hypersensitivity response to Spherusol ® . uuid:e2375071-ce4b-47fc-9294-121bb5f79ea2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB11294 biolink:treats UMLS:C0276667 PMID:41385096 "[{""id"":""uuid:55eae38a-de75-4c76-823b-047984e9561b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:664efb94-0409-4a61-8a0d-3b105d3a0c95"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spherusol ® is a skin test antigen indicated for the detection of delayed-type hypersensitivity to Coccidioides immitis in individuals with a history of pulmonary coccidioidomycosis. Spherusol ® is approved for use in individuals 18-64 years of age. The use of Spherusol ® to detect delayed-type hypersensitivity responses in a general population with unknown exposure to C. immitis has not been evaluated. Persons with acute or disseminated coccidioidomycosis may not develop a delayed-type hypersensitivity response to Spherusol ® . Persons with immunodeficiency and a history of coccidioidomycosis may not develop a delayed-type hypersensitivity response to Spherusol ® . uuid:cbf996b9-3d29-4c1d-b010-9af87e156a9a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85980 biolink:treats UMLS:C0348898 PMID:41385096 "[{""id"":""uuid:fd7b995b-3516-42ff-89d0-6bdb189b954e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c825d56e-d1c9-4530-9b11-8c6ebb871199"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VIBERZI is indicated in adults for the treatment of irritable bowel syndrome with diarrhea (IBS-D). uuid:1b9b65c2-1d8c-4034-a975-f0670aa0717b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:372452 biolink:treats NCIT:C27003 PMID:41385096 "[{""id"":""uuid:f2f99b93-3346-4a31-9f62-c174907ba8b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8b4dd4f9-ec50-426f-9c83-8e134e385cfb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] COMBOGESIC is indicated in adults for the short-term management of mild to moderate acute pain. uuid:0dffa078-a244-4046-bb9e-d06c4d8d1565 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:581255 biolink:treats UMLS:C0856633 PMID:41385096 "[{""id"":""uuid:291bb2bb-51c2-416f-9cbf-0991262fd42e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e254ec35-2737-4ea0-a3a1-53ebbadebd36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 15% CLINISOL - sulfite-free (Amino Acid) Injection Pharmacy Bulk Package is indicated as an adjunct in the offsetting of nitrogen loss or in the treatment of negative nitrogen balance in patients where: (1) the alimentary tract cannot or should not be used, (2) gastrointestinal absorption of protein is impaired, or (3) metabolic requirements for protein are substantially increased, as with extensive burns. uuid:641785e8-30b6-4bdf-a74f-05c62b66ddbc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7XZ4062R17 biolink:treats MONDO:0009662 PMID:41385096 "[{""id"":""uuid:30d7bf9a-434b-46a7-bd1d-2c17457c6d6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:68c5cbad-aea9-44d6-9444-0bc9ef085c58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:119710e2-beb1-43e6-8f8e-4f513cf5e728"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/mepsevii""]},{""id"":""uuid:88eb9c33-90c9-4d87-9021-fa9fb3232d9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MEPSEVII is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII (MPS VII, Sly syndrome). Limitations of Use The effect of MEPSEVII on the central nervous system manifestations of MPS VII has not been determined.|[EMA] Mepsevii is indicated for the treatment of non-neurological manifestations of Mucopolysaccharidosis VII (MPS VII; Sly syndrome).|[PMDA] A drug with a new active ingredient indicated for the treatment of mucopolysaccharidosis type VII. [Orphan drug] uuid:a69477d1-35c9-4217-9824-befc46d3778c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6710 biolink:treats MONDO:0011429 PMID:41385096 "[{""id"":""uuid:c3768f76-1946-4ee7-b65d-f6486b7fcf1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e6fdcb78-c6ee-4061-838f-f59c1ae81816"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of meclofenamate sodium capsules and other treatment options before deciding to use meclofenamate sodium capsules. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Meclofenamate sodium capsules are indicated: • For reduction of fever in adults • For relief of mild to moderate pain in adults • For relief of signs and symptoms of juvenile arthritis. • For relief of the signs and symptoms of rheumatoid arthritis • For relief of the signs and symptoms of osteoarthritis. • For treatment of primary dysmenorrhea. • For acute or long-term use in the relief of signs and symptoms of the following: 1. Ankylosing spondylitis 2. Acute painful shoulder (Acute subacromial bursitis/supraspinatus tendinitis) 3. Acute gouty arthritis Meclofenamate sodium capsules are also indicated for the treatment of idiopathic heavy menstrual blood loss (see CLINICAL PHARMACOLOGY and PRECAUTIONS ). As with all nonsteroidal anti-inflammatory drugs, selection of meclofenamate sodium capsules require a careful assessment of the benefit/risk ratio (see WARNINGS , PRECAUTIONS and ADVERSE REACTIONS ). Meclofenamate sodium capsules are not recommended in children because adequate studies to demonstrate safety and efficacy have not been carried out. uuid:7c5f97c7-8853-4495-a000-bf6255d6407d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6710 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:2636999e-b27b-4d50-ae1d-20f143698828"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3317ab40-bf03-4190-b15d-f5cd0ca7fbbe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of meclofenamate sodium capsules and other treatment options before deciding to use meclofenamate sodium capsules. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Meclofenamate sodium capsules are indicated: • For reduction of fever in adults • For relief of mild to moderate pain in adults • For relief of signs and symptoms of juvenile arthritis. • For relief of the signs and symptoms of rheumatoid arthritis • For relief of the signs and symptoms of osteoarthritis. • For treatment of primary dysmenorrhea. • For acute or long-term use in the relief of signs and symptoms of the following: 1. Ankylosing spondylitis 2. Acute painful shoulder (Acute subacromial bursitis/supraspinatus tendinitis) 3. Acute gouty arthritis Meclofenamate sodium capsules are also indicated for the treatment of idiopathic heavy menstrual blood loss (see CLINICAL PHARMACOLOGY and PRECAUTIONS ). As with all nonsteroidal anti-inflammatory drugs, selection of meclofenamate sodium capsules require a careful assessment of the benefit/risk ratio (see WARNINGS , PRECAUTIONS and ADVERSE REACTIONS ). Meclofenamate sodium capsules are not recommended in children because adequate studies to demonstrate safety and efficacy have not been carried out. uuid:22719e86-abc4-477b-ba31-c76ee9bac46e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6710 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:d41bc234-4724-4f6d-9505-5c7741a29c7d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6f386ce2-d5ab-45a0-86d6-116c30fbb871"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of meclofenamate sodium capsules and other treatment options before deciding to use meclofenamate sodium capsules. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Meclofenamate sodium capsules are indicated: • For reduction of fever in adults • For relief of mild to moderate pain in adults • For relief of signs and symptoms of juvenile arthritis. • For relief of the signs and symptoms of rheumatoid arthritis • For relief of the signs and symptoms of osteoarthritis. • For treatment of primary dysmenorrhea. • For acute or long-term use in the relief of signs and symptoms of the following: 1. Ankylosing spondylitis 2. Acute painful shoulder (Acute subacromial bursitis/supraspinatus tendinitis) 3. Acute gouty arthritis Meclofenamate sodium capsules are also indicated for the treatment of idiopathic heavy menstrual blood loss (see CLINICAL PHARMACOLOGY and PRECAUTIONS ). As with all nonsteroidal anti-inflammatory drugs, selection of meclofenamate sodium capsules require a careful assessment of the benefit/risk ratio (see WARNINGS , PRECAUTIONS and ADVERSE REACTIONS ). Meclofenamate sodium capsules are not recommended in children because adequate studies to demonstrate safety and efficacy have not been carried out. uuid:cc4f52c7-af2b-4306-9108-e981aa9b6689 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6710 biolink:treats MONDO:1060206 PMID:41385096 "[{""id"":""uuid:96cbbe18-5685-44f5-bad6-00f4856c7d20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d54d56b2-1649-4cf1-8ade-ef3ceefcbc62"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of meclofenamate sodium capsules and other treatment options before deciding to use meclofenamate sodium capsules. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Meclofenamate sodium capsules are indicated: • For reduction of fever in adults • For relief of mild to moderate pain in adults • For relief of signs and symptoms of juvenile arthritis. • For relief of the signs and symptoms of rheumatoid arthritis • For relief of the signs and symptoms of osteoarthritis. • For treatment of primary dysmenorrhea. • For acute or long-term use in the relief of signs and symptoms of the following: 1. Ankylosing spondylitis 2. Acute painful shoulder (Acute subacromial bursitis/supraspinatus tendinitis) 3. Acute gouty arthritis Meclofenamate sodium capsules are also indicated for the treatment of idiopathic heavy menstrual blood loss (see CLINICAL PHARMACOLOGY and PRECAUTIONS ). As with all nonsteroidal anti-inflammatory drugs, selection of meclofenamate sodium capsules require a careful assessment of the benefit/risk ratio (see WARNINGS , PRECAUTIONS and ADVERSE REACTIONS ). Meclofenamate sodium capsules are not recommended in children because adequate studies to demonstrate safety and efficacy have not been carried out. UMLS:C0149875 uuid:4894d07d-75fd-4749-a094-aa19a06fd5ed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6710 biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:0cc4c305-c5cc-4beb-b8d1-b975c27fd53c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fbf794d6-941a-4591-82b0-3761f6948e9d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of meclofenamate sodium capsules and other treatment options before deciding to use meclofenamate sodium capsules. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Meclofenamate sodium capsules are indicated: • For reduction of fever in adults • For relief of mild to moderate pain in adults • For relief of signs and symptoms of juvenile arthritis. • For relief of the signs and symptoms of rheumatoid arthritis • For relief of the signs and symptoms of osteoarthritis. • For treatment of primary dysmenorrhea. • For acute or long-term use in the relief of signs and symptoms of the following: 1. Ankylosing spondylitis 2. Acute painful shoulder (Acute subacromial bursitis/supraspinatus tendinitis) 3. Acute gouty arthritis Meclofenamate sodium capsules are also indicated for the treatment of idiopathic heavy menstrual blood loss (see CLINICAL PHARMACOLOGY and PRECAUTIONS ). As with all nonsteroidal anti-inflammatory drugs, selection of meclofenamate sodium capsules require a careful assessment of the benefit/risk ratio (see WARNINGS , PRECAUTIONS and ADVERSE REACTIONS ). Meclofenamate sodium capsules are not recommended in children because adequate studies to demonstrate safety and efficacy have not been carried out. uuid:f19fb99a-9b7c-4110-8812-43a24a02af25 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6710 biolink:treats UMLS:C0149896 PMID:41385096 "[{""id"":""uuid:2a8f19a9-0b35-4b20-b819-bd91d85375e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3c26302e-7e1c-4a5b-8223-67ce6caba64c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of meclofenamate sodium capsules and other treatment options before deciding to use meclofenamate sodium capsules. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Meclofenamate sodium capsules are indicated: • For reduction of fever in adults • For relief of mild to moderate pain in adults • For relief of signs and symptoms of juvenile arthritis. • For relief of the signs and symptoms of rheumatoid arthritis • For relief of the signs and symptoms of osteoarthritis. • For treatment of primary dysmenorrhea. • For acute or long-term use in the relief of signs and symptoms of the following: 1. Ankylosing spondylitis 2. Acute painful shoulder (Acute subacromial bursitis/supraspinatus tendinitis) 3. Acute gouty arthritis Meclofenamate sodium capsules are also indicated for the treatment of idiopathic heavy menstrual blood loss (see CLINICAL PHARMACOLOGY and PRECAUTIONS ). As with all nonsteroidal anti-inflammatory drugs, selection of meclofenamate sodium capsules require a careful assessment of the benefit/risk ratio (see WARNINGS , PRECAUTIONS and ADVERSE REACTIONS ). Meclofenamate sodium capsules are not recommended in children because adequate studies to demonstrate safety and efficacy have not been carried out. uuid:8a561dba-9c7b-4afb-9833-f4fdadb0a941 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6710 biolink:treats HP:0000132 PMID:41385096 "[{""id"":""uuid:74298dd6-b006-401b-aba9-2d34b787bebe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:97008dca-b90e-42d0-a394-7f706ea02f10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of meclofenamate sodium capsules and other treatment options before deciding to use meclofenamate sodium capsules. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see WARNINGS ). Meclofenamate sodium capsules are indicated: • For reduction of fever in adults • For relief of mild to moderate pain in adults • For relief of signs and symptoms of juvenile arthritis. • For relief of the signs and symptoms of rheumatoid arthritis • For relief of the signs and symptoms of osteoarthritis. • For treatment of primary dysmenorrhea. • For acute or long-term use in the relief of signs and symptoms of the following: 1. Ankylosing spondylitis 2. Acute painful shoulder (Acute subacromial bursitis/supraspinatus tendinitis) 3. Acute gouty arthritis Meclofenamate sodium capsules are also indicated for the treatment of idiopathic heavy menstrual blood loss (see CLINICAL PHARMACOLOGY and PRECAUTIONS ). As with all nonsteroidal anti-inflammatory drugs, selection of meclofenamate sodium capsules require a careful assessment of the benefit/risk ratio (see WARNINGS , PRECAUTIONS and ADVERSE REACTIONS ). Meclofenamate sodium capsules are not recommended in children because adequate studies to demonstrate safety and efficacy have not been carried out. uuid:a5c8467e-9ed7-4249-bbfe-4fba59bddefd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46859 biolink:treats MONDO:0001576 PMID:41385096 "[{""id"":""uuid:a740d788-d478-46d6-ae62-e6697bbea390"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:77015aa8-be4d-41a4-9ebe-5c0f3c2ccead"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Asclera ® (polidocanol) is indicated to sclerose uncomplicated spider veins (varicose veins ≤1 mm in diameter) and uncomplicated reticular veins (varicose veins 1 to 3 mm in diameter) in the lower extremity. Asclera has not been studied in varicose veins more than 3 mm in diameter. uuid:f7ec15c2-0ef8-439c-af6a-d9bdc92af55d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46859 biolink:treats UMLS:C5906718 PMID:41385096 "[{""id"":""uuid:736a233a-5675-4690-8da3-55ed4c795eb2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2c914137-46d1-47a0-8ce0-8aee140e813b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Asclera ® (polidocanol) is indicated to sclerose uncomplicated spider veins (varicose veins ≤1 mm in diameter) and uncomplicated reticular veins (varicose veins 1 to 3 mm in diameter) in the lower extremity. Asclera has not been studied in varicose veins more than 3 mm in diameter. uuid:a0e08d41-8e0f-43d0-815f-618eb4eef76f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49618 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:f5477b50-762d-4a51-a1b3-6abb29faf45f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:68f1c7c0-dd9d-48dc-8ecd-bd7a1e9014a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gadobutrol injection is a gadolinium-based contrast agent indicated for use with magnetic resonance imaging (MRI): To detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system in adult and pediatric patients, including term neonates ( 1.1 ) To assess the presence and extent of malignant breast disease in adult patients ( 1.2 ) To evaluate known or suspected supra-aortic or renal artery disease in adult and pediatric patients, including term neonates ( 1.3 ) To assess myocardial perfusion (stress, rest) and late gadolinium enhancement in adult patients with known or suspected coronary artery disease (CAD). ( 1.4 ). uuid:31b89b45-4263-4fed-8e72-7634861a79c1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49618 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:ed2b2afe-524e-4a3e-80c2-abbce2906a80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2ce49f1d-6622-4944-8be8-a3609c9f91e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Gadobutrol injection is a gadolinium-based contrast agent indicated for use with magnetic resonance imaging (MRI): To detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system in adult and pediatric patients, including term neonates ( 1.1 ) To assess the presence and extent of malignant breast disease in adult patients ( 1.2 ) To evaluate known or suspected supra-aortic or renal artery disease in adult and pediatric patients, including term neonates ( 1.3 ) To assess myocardial perfusion (stress, rest) and late gadolinium enhancement in adult patients with known or suspected coronary artery disease (CAD). ( 1.4 ). uuid:923ade0e-dcbc-40ca-9343-e3b38b976973 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:233309 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:a6f10444-977b-41ef-bc48-e8aefe2d4f70"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:daf205a3-096c-4182-92a5-2613fd4ec843"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KRAZATI is an inhibitor of the RAS GTPase family indicated for: Non-small cell lung cancer (NSCLC)* • As a single agent, for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC, as determined by an FDA-approved test, who have received at least one prior systemic therapy. ( 1.1 ) Colorectal cancer (CRC)* • In combination with cetuximab, for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic CRC, as determined by an FDA-approved test, who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. ( 1.2 ) *These indications are approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR). Continued approval for these indications may be contingent upon verification and description of a clinical benefit in confirmatory trials. ( 1.1 , 1.2 ) UNII:8EOO6HQF8Y uuid:4512d132-588c-4934-9fe7-6e975daadf4a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:233309 biolink:treats MONDO:0005575 PMID:41385096 "[{""id"":""uuid:6396eaa9-b1b6-4c0e-b44f-009a8ef49749"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dac149ca-11a5-49d3-a02c-d33a18218eeb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KRAZATI is an inhibitor of the RAS GTPase family indicated for: Non-small cell lung cancer (NSCLC)* • As a single agent, for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC, as determined by an FDA-approved test, who have received at least one prior systemic therapy. ( 1.1 ) Colorectal cancer (CRC)* • In combination with cetuximab, for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic CRC, as determined by an FDA-approved test, who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. ( 1.2 ) *These indications are approved under accelerated approval based on objective response rate (ORR) and duration of response (DOR). Continued approval for these indications may be contingent upon verification and description of a clinical benefit in confirmatory trials. ( 1.1 , 1.2 ) UNII:8EOO6HQF8Y uuid:1adc364f-9ed4-4aae-8ec2-8a69e3270ffb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72291 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:759dbc51-6018-4f5f-b0d4-6d48623da3f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e66e1e89-4503-49d9-8fa8-545be13da91d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TYBOST is a CYP3A inhibitor indicated to increase systemic exposure of atazanavir or darunavir (once daily dosing regimen) in combination with other antiretroviral agents in the treatment of HIV-1 infection in adults and in pediatric patients: weighing at least 35 kg coadministered with atazanavir or weighing at least 40 kg coadministered with darunavir. ( 1.1 ) Limitations of Use : TYBOST is not interchangeable with ritonavir to increase systemic exposure of darunavir 600 mg twice daily, fosamprenavir, saquinavir, or tipranavir due to lack of exposure data. The use of TYBOST is not recommended with darunavir 600 mg twice daily, fosamprenavir, saquinavir, or tipranavir. ( 1.2 , 5.4 ) Complex or unknown mechanisms of drug interactions preclude extrapolation of ritonavir drug interactions to certain TYBOST interactions. TYBOST and ritonavir when administered with either atazanavir or darunavir may result in different drug interactions when used with concomitant medications. ( 1.2 , 5.3 , 7 , 12.3 ) uuid:7321d450-7da3-4b06-abfa-b8ca74e61372 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:140296 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:9beb3dc3-7621-4c1e-8b98-eadda9b04db8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8a61aa70-dc68-4ea0-affc-058faa350320"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ACCUPRIL is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with ACCUPRIL. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. ACCUPRIL may be used alone or in combination with thiazide diuretics . uuid:db2fcbad-42ce-4538-b3d1-a8cb9188b698 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:145373 biolink:treats MONDO:0002522 PMID:41385096 "[{""id"":""uuid:09f13f51-b48f-490b-ac7e-3eb667bac8e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a972f762-3d88-420b-8a8a-c4441afc530d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TURALIO is indicated for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery. uuid:1233c4f4-b42f-4f68-8264-b150f9485311 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:145373 biolink:treats MONDO:0010108 PMID:41385096 "[{""id"":""uuid:bdccc119-e675-4820-86a6-8fb78b4c7154"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0d8b6a30-109f-4479-bd9c-a8ab58c9d352"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TURALIO is indicated for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitations and not amenable to improvement with surgery. uuid:90f69a53-b035-4480-aacc-307a7484e8cd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:FU77B4U5Z0 biolink:treats UMLS:C0406317 PMID:41385096 "[{""id"":""uuid:20095957-1b9e-45ce-80c7-94d82d77c9e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2cc8ecbc-2b69-428d-8f67-884184e90428"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7573c093-1692-4464-8765-0fa3cfe46820"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OTULFI is a human interleukin-12 and -23 antagonist indicated for the treatment of: Adult patients with: moderate to severe plaque psoriasis (PsO) who are candidates for phototherapy or systemic therapy. ( 1.1 ) active psoriatic arthritis (PsA) . ( 1.2 ) moderately to severely active Crohn's disease (CD) . ( 1.3 ) moderately to severely active ulcerative colitis. ( 1.4 ) Pediatric patients 6 years and older with: moderate to severe plaque psoriasis , who are candidates for phototherapy or systemic therapy. ( 1.1 ) active psoriatic arthritis (PsA) . ( 1.2 )|[PMDA] A biosimilar indicated for the treatment of the following disease in patients who have not sufficiently responded to conventional therapies: plaque psoriasis and psoriatic arthritis uuid:226d3cc4-6632-4a95-837d-ab63141cec7f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:FU77B4U5Z0 biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:24e17f95-8ed9-4fe1-871f-6a7b8f9fc7c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:361c44ff-41a8-4bf3-9c3e-5fb9b3803249"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b482d37d-44ee-41f5-b1cf-08ca48d4c824"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/stelara""]},{""id"":""uuid:5277f041-4354-40cf-b001-9bbc26c0e68a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OTULFI is a human interleukin-12 and -23 antagonist indicated for the treatment of: Adult patients with: moderate to severe plaque psoriasis (PsO) who are candidates for phototherapy or systemic therapy. ( 1.1 ) active psoriatic arthritis (PsA) . ( 1.2 ) moderately to severely active Crohn's disease (CD) . ( 1.3 ) moderately to severely active ulcerative colitis. ( 1.4 ) Pediatric patients 6 years and older with: moderate to severe plaque psoriasis , who are candidates for phototherapy or systemic therapy. ( 1.1 ) active psoriatic arthritis (PsA) . ( 1.2 )|[EMA] Crohn’s DiseaseStelara is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNFα antagonist or have medical contraindications to such therapies.Ulcerative colitisSTELARA is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies.Plaque psoriasisStelara is indicated for the treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and psoralen ultraviolet A.Paediatric plaque psoriasisStelara is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescent patients from the age of 6 years and older, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.Psoriatic arthritisStelara, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous non-biological disease-modifying antirheumatic drug (DMARD) therapy has been inadequate.|[PMDA] A biosimilar indicated for the treatment of the following disease in patients who have not sufficiently responded to conventional therapies: plaque psoriasis and psoriatic arthritis uuid:5493c669-515f-4b8b-8380-e4da6255ce91 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:FU77B4U5Z0 biolink:treats MONDO:0005011 PMID:41385096 "[{""id"":""uuid:73cef0a3-7e4f-47a6-a4ac-264da3583ab2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:116ab6c2-9984-43c7-a7a6-161b3a2baac7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:23baec44-6fef-4b6d-b631-a9bbfdd1fb11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/stelara""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] OTULFI is a human interleukin-12 and -23 antagonist indicated for the treatment of: Adult patients with: moderate to severe plaque psoriasis (PsO) who are candidates for phototherapy or systemic therapy. ( 1.1 ) active psoriatic arthritis (PsA) . ( 1.2 ) moderately to severely active Crohn's disease (CD) . ( 1.3 ) moderately to severely active ulcerative colitis. ( 1.4 ) Pediatric patients 6 years and older with: moderate to severe plaque psoriasis , who are candidates for phototherapy or systemic therapy. ( 1.1 ) active psoriatic arthritis (PsA) . ( 1.2 )|[EMA] Crohn’s DiseaseStelara is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNFα antagonist or have medical contraindications to such therapies.Ulcerative colitisSTELARA is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies.Plaque psoriasisStelara is indicated for the treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and psoralen ultraviolet A.Paediatric plaque psoriasisStelara is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescent patients from the age of 6 years and older, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.Psoriatic arthritisStelara, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous non-biological disease-modifying antirheumatic drug (DMARD) therapy has been inadequate. uuid:5e65816a-8e75-463e-b599-d9b5b4825362 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:FU77B4U5Z0 biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:ac9afb57-646f-4534-b2ab-483d39a3bedb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f516ae5f-b0b0-4ebe-a2e6-9ca0de260367"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c32c0d90-6fac-4f57-9ac4-2fca3f99e32d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/stelara""]},{""id"":""uuid:a0126003-69f5-4ff9-bd27-6f4198ce5ff1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OTULFI is a human interleukin-12 and -23 antagonist indicated for the treatment of: Adult patients with: moderate to severe plaque psoriasis (PsO) who are candidates for phototherapy or systemic therapy. ( 1.1 ) active psoriatic arthritis (PsA) . ( 1.2 ) moderately to severely active Crohn's disease (CD) . ( 1.3 ) moderately to severely active ulcerative colitis. ( 1.4 ) Pediatric patients 6 years and older with: moderate to severe plaque psoriasis , who are candidates for phototherapy or systemic therapy. ( 1.1 ) active psoriatic arthritis (PsA) . ( 1.2 )|[EMA] Crohn’s DiseaseStelara is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNFα antagonist or have medical contraindications to such therapies.Ulcerative colitisSTELARA is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies.Plaque psoriasisStelara is indicated for the treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and psoralen ultraviolet A.Paediatric plaque psoriasisStelara is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescent patients from the age of 6 years and older, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.Psoriatic arthritisStelara, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous non-biological disease-modifying antirheumatic drug (DMARD) therapy has been inadequate.|[PMDA] A drug with a new indication for the remission induction therapy of moderate to severe ulcerative colitis (for use only in patients who have not sufficiently responded to conventional treatments). A drug with a new indication for the maintenance therapy of moderate to severe ulcerative colitis (for use only in patients who have not sufficiently responded to conventional treatments). uuid:24905f39-f5cc-482e-a3c6-1280c58df0c9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9637 biolink:treats HP:0000969 PMID:41385096 "[{""id"":""uuid:1b258787-ce40-48c7-a574-e18d341a561a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d49100f1-a6dd-4c1e-9364-9b0c205e2387"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Edema Torsemide tablets are indicated for the treatment of edema associated with heart failure, renal disease or hepatic disease. 1.2 Hypertension Torsemide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with torsemide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. The antihypertensive effects of torsemide tablets are on the average greater in black patients than in nonblack patients [see Clinical Pharmacology (12.2)]. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Torsemide tablets can be used alone or in combination with other antihypertensive agents. uuid:b5e05135-787f-4cb5-a522-f1740bb5ae54 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9637 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:9d0f0d0c-bc51-46d9-85eb-a8dbe2441fcf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:72b4bd34-03ba-48ba-bbd8-4fefc767f4f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Edema Torsemide tablets are indicated for the treatment of edema associated with heart failure, renal disease or hepatic disease. 1.2 Hypertension Torsemide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with torsemide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. The antihypertensive effects of torsemide tablets are on the average greater in black patients than in nonblack patients [see Clinical Pharmacology (12.2)]. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Torsemide tablets can be used alone or in combination with other antihypertensive agents. uuid:f3905c7c-026b-443a-93ea-347bd16c2d27 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9637 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:8c98798b-7d62-47e6-8f9a-e8088516e286"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8324a076-f888-4476-ae54-cb33e29e9449"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Edema Torsemide tablets are indicated for the treatment of edema associated with heart failure, renal disease or hepatic disease. 1.2 Hypertension Torsemide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with torsemide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. The antihypertensive effects of torsemide tablets are on the average greater in black patients than in nonblack patients [see Clinical Pharmacology (12.2)]. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Torsemide tablets can be used alone or in combination with other antihypertensive agents. uuid:64e52165-0fbf-4ff3-84f1-ed690483888a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9637 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:89fe785f-30b6-4307-8057-b60081b358b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c628f05a-1898-48e6-ba33-30612904fe0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Edema Torsemide tablets are indicated for the treatment of edema associated with heart failure, renal disease or hepatic disease. 1.2 Hypertension Torsemide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with torsemide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. The antihypertensive effects of torsemide tablets are on the average greater in black patients than in nonblack patients [see Clinical Pharmacology (12.2)]. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Torsemide tablets can be used alone or in combination with other antihypertensive agents. uuid:1abfcb7b-952c-4c7f-baa1-48bb8354c99d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9637 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:70dff755-b16b-4a7d-a5f1-cb79e96c575b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2b0cd17e-0576-4be6-afe5-c7c363015ee2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Edema Torsemide tablets are indicated for the treatment of edema associated with heart failure, renal disease or hepatic disease. 1.2 Hypertension Torsemide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with torsemide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. The antihypertensive effects of torsemide tablets are on the average greater in black patients than in nonblack patients [see Clinical Pharmacology (12.2)]. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Torsemide tablets can be used alone or in combination with other antihypertensive agents. uuid:d981c7cb-ddc9-466f-9dab-14e085ca46f2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6722 biolink:treats UMLS:C0278802 PMID:41385096 "[{""id"":""uuid:b497d8d0-1ef7-4f3c-a62a-b98c1a82fd70"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c813554e-e94f-4bc1-b20b-436001d4a933"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Megestrol Acetate Tablets are indicated for the palliative treatment of advanced carcinoma of the breast or endometrium (i.e., recurrent, inoperable, or metastatic disease). It should not be used in lieu of currently accepted procedures such as surgery, radiation, or chemotherapy. uuid:37d04aa4-e1ac-43ce-9fc2-8c3222ccdb1b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6722 biolink:treats UMLS:C0813148 PMID:41385096 "[{""id"":""uuid:57a66ece-af4e-49c2-8244-e91675e2c8d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ef8475f3-fe74-4c24-9b4f-26dcda11aa76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Megestrol Acetate Tablets are indicated for the palliative treatment of advanced carcinoma of the breast or endometrium (i.e., recurrent, inoperable, or metastatic disease). It should not be used in lieu of currently accepted procedures such as surgery, radiation, or chemotherapy. uuid:5d3ecc42-ed5b-4443-8bd7-65e449ee9e17 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:36704 biolink:treats MONDO:0002954 PMID:41385096 "[{""id"":""uuid:3d3a2e5a-315f-40de-a571-2b343d70b776"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:77e0a55c-1534-48d1-a312-079da0c080c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d0409f26-c7c4-4697-a00b-1d8b962e9aab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zyclara""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Actinic Keratosis Imiquimod Cream is indicated for the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults. 1.2 Superficial Basal Cell Carcinoma Imiquimod Cream is indicated for the topical treatment of biopsy-confirmed, primary superficial basal cell carcinoma (sBCC) in immunocompetent adults, with a maximum tumor diameter of 2.0 cm, located on the trunk (excluding anogenital skin), neck, or extremities (excluding hands and feet), only when surgical methods are medically less appropriate and patient follow-up can be reasonably assured. The histological diagnosis of superficial basal cell carcinoma should be established prior to treatment, since safety and efficacy of Imiquimod Cream have not been established for other types of basal cell carcinomas, including nodular and morpheaform (fibrosing or sclerosing) types. 1.3 External Genital Warts Imiquimod Cream is indicated for the treatment of external genital and perianal warts/condyloma acuminata in patients 12 years old and older. 1.4 Limitations of Use Imiquimod cream has been evaluated in children ages 2 to 12 years with molluscum contagiosum and these studies failed to demonstrate efficacy. [see USE IN SPECIFIC POPULATIONS (8.4)]. 1.5 Unevaluated Populations The safety and efficacy of Imiquimod Cream in immunosuppressed patients have not been established. Imiquimod Cream should be used with caution in patients with pre-existing autoimmune conditions. The efficacy and safety of Imiquimod Cream have not been established for patients with Basal Cell Nevus Syndrome or Xeroderma Pigmentosum.|[EMA] Imiquimod cream is indicated for the topical treatment of :External genital and perianal warts (condylomata acuminata) in adults.Small superficial basal cell carcinomas (sBCCs) in adults.Clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses (AKs) on the face or scalp in immunocompetent adult patients when size or number of lesions limit the efficacy and/or acceptability of cryotherapy and other topical treatment options are contraindicated or less appropriate. uuid:abca5a98-6e6f-413b-b7b5-fb854e47d3de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4708 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:0dddb07b-e833-413f-b839-f9c7bb212ca6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:33b98092-f38f-4077-88d9-0def312c0bb2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Benign Prostatic Hyperplasia (BPH) Doxazosin tablets, USP are indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension Doxazosin tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Doxazosin tablets, USP may be used alone or in combination with other antihypertensives. uuid:06b8fc6f-6a73-4b85-8489-39ea750539b0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4708 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:c7997c03-cfef-4c9e-99e2-586981d84742"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2111f2d4-dc10-4045-9314-1fb26e1a9da3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Benign Prostatic Hyperplasia (BPH) Doxazosin tablets, USP are indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension Doxazosin tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Doxazosin tablets, USP may be used alone or in combination with other antihypertensives. uuid:8887252d-34ea-42db-833f-f22452b77500 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4708 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:a88c1c4c-75df-4594-824a-ae5f18c19108"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:02ce07ca-5f44-4918-bfca-02c7e6ee8756"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Benign Prostatic Hyperplasia (BPH) Doxazosin tablets, USP are indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension Doxazosin tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Doxazosin tablets, USP may be used alone or in combination with other antihypertensives. uuid:1d5be83c-bdf0-4d9a-bc7b-33b5361a974b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4708 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:35405f0d-d109-4007-9e1d-8338b3a65a5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:96589b77-bff4-47c0-a50f-9d4e84e5a595"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Benign Prostatic Hyperplasia (BPH) Doxazosin tablets, USP are indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension Doxazosin tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Doxazosin tablets, USP may be used alone or in combination with other antihypertensives. uuid:bad817a6-3a57-4381-ac33-a9cb6dc36b3c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4708 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:d55e76a0-c84e-4a82-9bd1-e4f9c1cdb195"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:27561286-0c20-4747-827f-fffd66eb8ce4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Benign Prostatic Hyperplasia (BPH) Doxazosin tablets, USP are indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension Doxazosin tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Doxazosin tablets, USP may be used alone or in combination with other antihypertensives. uuid:db0a7752-a69b-4e88-94f7-8c3af1c4533c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4708 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:fce07869-9a29-4585-b865-bd0e968b7b69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:af41ff5a-8b9f-4446-af62-52c3e15ac0c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Benign Prostatic Hyperplasia (BPH) Doxazosin tablets, USP are indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension Doxazosin tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Doxazosin tablets, USP may be used alone or in combination with other antihypertensives. uuid:e4e30718-fcb8-4248-9965-f899466f95e3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4708 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:8b13cf95-4929-4429-9995-2b95455b6e10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:126122ca-4eff-4b9d-9884-d373f1cbd1d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Benign Prostatic Hyperplasia (BPH) Doxazosin tablets, USP are indicated for the treatment of the signs and symptoms of BPH. 1.2 Hypertension Doxazosin tablets, USP are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including this drug. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Doxazosin tablets, USP may be used alone or in combination with other antihypertensives. uuid:6b0cb71e-9074-4191-bb17-68c168e8a261 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1152283 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:54bc8409-9ffd-4d2b-b729-943f27db74ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a4a0778f-1d54-43b2-982a-f72ff2086171"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hypertension Amlodipine besylate tablets is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including Amlodipine besylate tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Amlodipine besylate tablets may be used alone or in combination with other antihypertensive agents. 1.2 Coronary Artery Disease (CAD) Chronic Stable Angina Amlodipine besylate tablets is indicated for the symptomatic treatment of chronic stable angina. Amlodipine besylate tablets may be used alone or in combination with other antianginal agents. Vasospastic Angina (Prinzmetal’s or Variant Angina) Amlodipine besylate tablets is indicated for the treatment of confirmed or suspected vasospastic angina. Amlodipine besylate tablets may be used as monotherapy or in combination with other antianginal agents. Angiographically Documented CAD In patients with recently documented CAD by angiography and without heart failure or an ejection fraction <40%, Amlodipine besylate tablets is indicated to reduce the risk of hospitalization for angina and to reduce the risk of a coronary revascularization procedure. uuid:22c472e6-6f7d-42e4-818c-0946a4b6b72e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1152283 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:d812d738-409a-496d-a667-eeac90501717"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9a075f30-4b42-4ba1-8a59-dd4db06d0bf5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hypertension Amlodipine besylate tablets is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including Amlodipine besylate tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Amlodipine besylate tablets may be used alone or in combination with other antihypertensive agents. 1.2 Coronary Artery Disease (CAD) Chronic Stable Angina Amlodipine besylate tablets is indicated for the symptomatic treatment of chronic stable angina. Amlodipine besylate tablets may be used alone or in combination with other antianginal agents. Vasospastic Angina (Prinzmetal’s or Variant Angina) Amlodipine besylate tablets is indicated for the treatment of confirmed or suspected vasospastic angina. Amlodipine besylate tablets may be used as monotherapy or in combination with other antianginal agents. Angiographically Documented CAD In patients with recently documented CAD by angiography and without heart failure or an ejection fraction <40%, Amlodipine besylate tablets is indicated to reduce the risk of hospitalization for angina and to reduce the risk of a coronary revascularization procedure. uuid:ce98f656-64b3-49d0-b2b7-6e0388d78017 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1152283 biolink:treats MONDO:0006021 PMID:41385096 "[{""id"":""uuid:b7332539-dc5a-4e65-93ba-cd8fbb5753a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a7cc1864-e66b-4510-bf40-76ac6959f6ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hypertension Amlodipine besylate tablets is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including Amlodipine besylate tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Amlodipine besylate tablets may be used alone or in combination with other antihypertensive agents. 1.2 Coronary Artery Disease (CAD) Chronic Stable Angina Amlodipine besylate tablets is indicated for the symptomatic treatment of chronic stable angina. Amlodipine besylate tablets may be used alone or in combination with other antianginal agents. Vasospastic Angina (Prinzmetal’s or Variant Angina) Amlodipine besylate tablets is indicated for the treatment of confirmed or suspected vasospastic angina. Amlodipine besylate tablets may be used as monotherapy or in combination with other antianginal agents. Angiographically Documented CAD In patients with recently documented CAD by angiography and without heart failure or an ejection fraction <40%, Amlodipine besylate tablets is indicated to reduce the risk of hospitalization for angina and to reduce the risk of a coronary revascularization procedure. uuid:c0f8f4e2-fa35-4de7-8f45-33436fedd5c5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4031 biolink:treats MONDO:0019085 PMID:41385096 "[{""id"":""uuid:f69d14c5-ce69-4fc0-8be5-179310f1ee50"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:60202a81-c661-416f-9e2f-d0ef3c86fc61"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a99ca840-95b2-46b7-8b79-006eac27dab7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/verkazia""]},{""id"":""uuid:dd9d03a9-f86e-4813-8d74-b7575c718e79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Verkazia ophthalmic emulsion is indicated for the treatment of vernal keratoconjunctivitis (VKC) in children and adults.|[EMA] Treatment of severe vernal keratoconjunctivitis (VKC) in children from 4 years of age and adolescents.|[PMDA] Eye drops indicated for the treatment of spring catarrh (where treatment with anti-allergic agents is inadequate) [Orphan drug] uuid:80dfbb01-31ce-4d5b-95f3-cad0175ee468 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:145428 biolink:treats MONDO:0018874 PMID:41385096 "[{""id"":""uuid:932f0449-00b1-4650-9975-b294c3c40867"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e8003933-2725-45aa-9afc-1dd4b645a0a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:507242fc-cf02-4697-b512-7cecace36e92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DAURISMO is indicated, in combination with low-dose cytarabine, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are ≥75 years old or who have comorbidities that preclude use of intensive induction chemotherapy.|[EMA] Daurismo is indicated, in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (AML) in adult patients who are not candidates for standard induction chemotherapy. uuid:6673251b-920e-44e4-9939-37001f46cdce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50729 biolink:treats MONDO:0000451 PMID:41385096 "[{""id"":""uuid:4da02ef1-6635-4a12-8504-3a603c31e446"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ba06c25b-27d8-4879-a5d4-ebf14b6b4cbf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mitoxantrone is indicated for reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly abnormal between relapses). Mitoxantrone is not indicated in the treatment of patients with primary progressive multiple sclerosis. The clinical patterns of multiple sclerosis in the studies were characterized as follows: secondary progressive and progressive relapsing disease were characterized by gradual increasing disability with or without superimposed clinical relapses, and worsening relapsing-remitting disease was characterized by clinical relapses resulting in a step-wise worsening of disability. Mitoxantrone in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer. Mitoxantrone in combination with other approved drug(s) is indicated in the initial therapy of acute nonlymphocytic leukemia (ANLL) in adults. This category includes myelogenous, promyelocytic, monocytic, and erythroid acute leukemias. uuid:ba7884ea-65e4-48a2-a8de-7eb24471d9e2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64312 biolink:treats UMLS:C3494871 PMID:41385096 "[{""id"":""uuid:cee4a31c-8302-4919-8ca6-463813dc614a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6e59dd71-1f81-473f-aa9c-bae1139ed9ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Memantine hydrochloride tablets, USP are indicated for the treatment of moderate to severe dementia of the Alzheimer's type. uuid:926078ef-42e7-4d28-ad31-66d8ff0cc42d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64312 biolink:treats UMLS:C3494652 PMID:41385096 "[{""id"":""uuid:18030192-9e34-41cb-8a9a-85eac0f27a9a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ebc3c340-d850-4c3a-83d7-b2b954db139c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Memantine hydrochloride tablets, USP are indicated for the treatment of moderate to severe dementia of the Alzheimer's type. uuid:560b34ff-5182-40cd-9bd9-98ed5eb82df0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1162127 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:08815ec2-3f4b-4e4d-a70f-20f542a66878"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:21a0f0e4-d140-45db-b378-baa0e7266dba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hypertension Losartan potassium and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in Black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients [see Clinical Studies (14) and Dosage and Administration (2.1)]. Losartan potassium and hydrochlorothiazide tablets may be administered with other antihypertensive agents. 1.2 Hypertensive Patients with Left Ventricular Hypertrophy Losartan potassium and hydrochlorothiazide tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients. [See Use in Specific Populations (8.6), Clinical Pharmacology (12.3), and Dosage and Administration (2.2).] uuid:a8b61c53-9a00-4ef0-90df-0a12e4721ecb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1162127 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:9b086dd3-edaa-40dc-afeb-28e81a156fb5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2dfe1082-ade2-4421-997d-8b8bf4f9e307"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hypertension Losartan potassium and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in Black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients [see Clinical Studies (14) and Dosage and Administration (2.1)]. Losartan potassium and hydrochlorothiazide tablets may be administered with other antihypertensive agents. 1.2 Hypertensive Patients with Left Ventricular Hypertrophy Losartan potassium and hydrochlorothiazide tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients. [See Use in Specific Populations (8.6), Clinical Pharmacology (12.3), and Dosage and Administration (2.2).] uuid:28a05616-9be5-4dbe-a62f-992db63ab306 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1162127 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:818881db-8813-4b50-b4f1-08b1cf7a1978"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a9684538-2d6a-46eb-9bf1-113b9e0f2974"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hypertension Losartan potassium and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in Black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients [see Clinical Studies (14) and Dosage and Administration (2.1)]. Losartan potassium and hydrochlorothiazide tablets may be administered with other antihypertensive agents. 1.2 Hypertensive Patients with Left Ventricular Hypertrophy Losartan potassium and hydrochlorothiazide tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients. [See Use in Specific Populations (8.6), Clinical Pharmacology (12.3), and Dosage and Administration (2.2).] uuid:1dd90e0e-8988-4b4c-8160-58b43e4abc33 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1162127 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:8bc6038e-eb8d-4b44-82d2-57ba362c4cfb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2fe7cfca-5358-4d46-8dee-f6e598dd3e47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hypertension Losartan potassium and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in Black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients [see Clinical Studies (14) and Dosage and Administration (2.1)]. Losartan potassium and hydrochlorothiazide tablets may be administered with other antihypertensive agents. 1.2 Hypertensive Patients with Left Ventricular Hypertrophy Losartan potassium and hydrochlorothiazide tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients. [See Use in Specific Populations (8.6), Clinical Pharmacology (12.3), and Dosage and Administration (2.2).] uuid:e1fcfe78-3676-4c9e-8735-abd4a1a6e443 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1162127 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:bd7d3d10-5db7-4f9d-a908-af4bb9b3c6a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fa14f2ff-9acc-4e91-a010-6906db678aa2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hypertension Losartan potassium and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in Black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients [see Clinical Studies (14) and Dosage and Administration (2.1)]. Losartan potassium and hydrochlorothiazide tablets may be administered with other antihypertensive agents. 1.2 Hypertensive Patients with Left Ventricular Hypertrophy Losartan potassium and hydrochlorothiazide tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients. [See Use in Specific Populations (8.6), Clinical Pharmacology (12.3), and Dosage and Administration (2.2).] uuid:5508eb83-f595-4f9e-bd03-8a71ff1a62be biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1162127 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:9bd6a013-1f52-44c6-bb04-bcadfd12e7ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0e35af96-fe77-4cb7-8525-e25757ccfe29"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.1 Hypertension Losartan potassium and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan and hydrochlorothiazide. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in Black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. This fixed dose combination is not indicated for initial therapy of hypertension, except when the hypertension is severe enough that the value of achieving prompt blood pressure control exceeds the risk of initiating combination therapy in these patients [see Clinical Studies (14) and Dosage and Administration (2.1)]. Losartan potassium and hydrochlorothiazide tablets may be administered with other antihypertensive agents. 1.2 Hypertensive Patients with Left Ventricular Hypertrophy Losartan potassium and hydrochlorothiazide tablets are indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients. [See Use in Specific Populations (8.6), Clinical Pharmacology (12.3), and Dosage and Administration (2.2).] uuid:864c90d2-95d7-45ae-a67b-84ec959530bb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:379056 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:c8afabe7-b8b2-490d-acfd-5f4d804273b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a36ce2e6-3c2e-430b-bb00-716642a0cf35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:63918185-3a88-4fa2-b1cc-8c58aede8dbe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NOVOLOG is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.|[PMDA] New combination drugs indicated for the treatment of diabetes mellitus in cases where insulin therapy is indicated. uuid:9e617914-b09c-4ff0-bc49-d8233e54ff26 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:RWM8CCW8GP biolink:treats MONDO:0001673 PMID:41385096 "[{""id"":""uuid:92142c96-1601-40f7-b2fb-d896763bf107"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a8fba3cc-d7b9-4045-9e3a-045bc3816154"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sandostatin Injection is a somatostatin analogue indicated: Acromegaly : To reduce blood levels of growth hormone (GH) and insulin growth factor-1 (IGF-1; somatomedin C) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation, and bromocriptine mesylate at maximally tolerated doses. ( 1.1 ) Carcinoid Tumors : For the symptomatic treatment of patients with metastatic carcinoid tumors where it suppresses or inhibits the severe diarrhea and flushing episodes associated with the disease. ( 1.2 ) Vasoactive Intestinal Peptide Tumors (VIPomas) : For the treatment of profuse watery diarrhea associated with VIP-secreting tumors. ( 1.3 ) Limitations of Use Improvement in clinical signs and symptoms, or reduction in tumor size or rate of growth, were not shown in clinical trials performed with Sandostatin Injection; these trials were not optimally designed to detect such effects. ( 1.4 ) uuid:ff4e3538-1ad9-46bb-8930-f196bf0ec06f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:AE72RB1W1X biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:df3e119c-8154-4f26-9e2d-fbe0ec31fbcc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:06793245-241b-49c0-a204-84e3ae44c005"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BIZENGRI® is a bispecific HER2- and HER3-directed antibody indicated for the treatment of: Adults with advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) harboring a neuregulin 1 ( NRG1 ) gene fusion with disease progression on or after prior systemic therapy.* ( 1.1 ) Adults with advanced, unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 ( NRG1 ) gene fusion with disease progression on or after prior systemic therapy.* ( 1.2 ) *This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). uuid:8a34db3d-2951-426e-afce-98f329817d1d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:AE72RB1W1X biolink:treats MONDO:0006047 PMID:41385096 "[{""id"":""uuid:485dbeb7-69e6-4bc7-be84-ff646c9167c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:09d086b9-3d8a-4c45-9d8f-10bc62b80eec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BIZENGRI® is a bispecific HER2- and HER3-directed antibody indicated for the treatment of: Adults with advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) harboring a neuregulin 1 ( NRG1 ) gene fusion with disease progression on or after prior systemic therapy.* ( 1.1 ) Adults with advanced, unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 ( NRG1 ) gene fusion with disease progression on or after prior systemic therapy.* ( 1.2 ) *This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). uuid:43d885e8-345a-430c-8a23-1b7e9a66acb1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:17276 biolink:treats HP:0000969 PMID:41385096 "[{""id"":""uuid:da2ee3c4-e671-4026-a3b9-e0bbe7cf7735"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:200ed7fa-6f89-4e21-b64e-a19475dc3ad1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone, an ingredient of spironolactone and hydrochlorothiazide tablets, has been shown to be a tumorigen in chronic toxicity studies in rats (see Precautions section). Spironolactone and hydrochlorothiazide tablets should be used only in those conditions described below. Unnecessary use of this drug should be avoided. Spironolactone and hydrochlorothiazide tablets are indicated for: Edematous conditions for patients with: Congestive heart failure: • For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures; • The treatment of diuretic-induced hypokalemia in patients with congestive heart failure when other measures are considered inappropriate; • The treatment of patients with congestive heart failure taking digitalis when other therapies are considered inadequate or inappropriate. Cirrhosis of the liver accompanied by edema and/or ascites: • Aldosterone levels may be exceptionally high in this condition. Spironolactone and hydrochlorothiazide tablets are indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. The nephrotic syndrome: • For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response. Essential hypertension: • For patients with essential hypertension in whom other measures are considered inadequate or inappropriate; • In hypertensive patients for the treatment of a diuretic-induced hypokalemia when other measures are considered inappropriate; • Spironolactone and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the classes to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with spironolactone and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. uuid:852d6d20-3c95-4c66-8bba-b6fb8942e4e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:17276 biolink:treats UMLS:C4722157 PMID:41385096 "[{""id"":""uuid:3eb55dd6-37c5-4cb1-89a0-abd3ace0ea3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a75dc7ee-2dde-439d-b8d6-a13d94006b9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Spironolactone, an ingredient of spironolactone and hydrochlorothiazide tablets, has been shown to be a tumorigen in chronic toxicity studies in rats (see Precautions section). Spironolactone and hydrochlorothiazide tablets should be used only in those conditions described below. Unnecessary use of this drug should be avoided. Spironolactone and hydrochlorothiazide tablets are indicated for: Edematous conditions for patients with: Congestive heart failure: • For the management of edema and sodium retention when the patient is only partially responsive to, or is intolerant of, other therapeutic measures; • The treatment of diuretic-induced hypokalemia in patients with congestive heart failure when other measures are considered inappropriate; • The treatment of patients with congestive heart failure taking digitalis when other therapies are considered inadequate or inappropriate. Cirrhosis of the liver accompanied by edema and/or ascites: • Aldosterone levels may be exceptionally high in this condition. Spironolactone and hydrochlorothiazide tablets are indicated for maintenance therapy together with bed rest and the restriction of fluid and sodium. The nephrotic syndrome: • For nephrotic patients when treatment of the underlying disease, restriction of fluid and sodium intake, and the use of other diuretics do not provide an adequate response. Essential hypertension: • For patients with essential hypertension in whom other measures are considered inadequate or inappropriate; • In hypertensive patients for the treatment of a diuretic-induced hypokalemia when other measures are considered inappropriate; • Spironolactone and hydrochlorothiazide tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes, including the classes to which this drug principally belongs. There are no controlled trials demonstrating risk reduction with spironolactone and hydrochlorothiazide tablets. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. uuid:3e462635-db45-48b9-a7e6-fa33cd0ed73a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1592709 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:55800ddf-5ac9-4f27-bfa5-be38bca628ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a9d302b1-5654-444c-938f-cf4f884ea502"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XIGDUO XR is a combination of dapagliflozin and metformin hydrochloride (HCl) extended-release, indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. Dapagliflozin, when used as a component of XIGDUO XR, is indicated in adults with type 2 diabetes mellitus to reduce the risk of: • Sustained eGFR decline, end‑stage kidney disease, cardiovascular death, and hospitalization for heart failure in patients with chronic kidney disease at risk of progression. • Cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in patients with heart failure. • Hospitalization for heart failure in patients with type 2 diabetes mellitus and either established cardiovascular disease (CVD) or multiple cardiovascular (CV) risk factors. Limitations of Use • XIGDUO XR is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus [see Warnings and Precautions (5.2) ] . • Because of the metformin HCl component, the use of XIGDUO XR is limited to patients with type 2 diabetes mellitus for all indications. • XIGDUO XR is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of immunosuppressive therapy for kidney disease. XIGDUO XR is not expected to be effective in these populations. uuid:8de28abe-700b-4f27-af6a-aef565ceb462 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1592709 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:17b244e5-1033-4780-a318-3d7c6bdc2849"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2570724b-3c0e-409c-bde0-0212cd0602b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XIGDUO XR is a combination of dapagliflozin and metformin hydrochloride (HCl) extended-release, indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. Dapagliflozin, when used as a component of XIGDUO XR, is indicated in adults with type 2 diabetes mellitus to reduce the risk of: • Sustained eGFR decline, end‑stage kidney disease, cardiovascular death, and hospitalization for heart failure in patients with chronic kidney disease at risk of progression. • Cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in patients with heart failure. • Hospitalization for heart failure in patients with type 2 diabetes mellitus and either established cardiovascular disease (CVD) or multiple cardiovascular (CV) risk factors. Limitations of Use • XIGDUO XR is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus [see Warnings and Precautions (5.2) ] . • Because of the metformin HCl component, the use of XIGDUO XR is limited to patients with type 2 diabetes mellitus for all indications. • XIGDUO XR is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of immunosuppressive therapy for kidney disease. XIGDUO XR is not expected to be effective in these populations. uuid:dd19cbfd-300e-43cf-94e9-d50804e27436 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1592709 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:795ae6b4-5086-457e-b436-1335eee2679d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2bd4ddad-5cb4-4846-b47d-14f95a7b2237"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XIGDUO XR is a combination of dapagliflozin and metformin hydrochloride (HCl) extended-release, indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. Dapagliflozin, when used as a component of XIGDUO XR, is indicated in adults with type 2 diabetes mellitus to reduce the risk of: • Sustained eGFR decline, end‑stage kidney disease, cardiovascular death, and hospitalization for heart failure in patients with chronic kidney disease at risk of progression. • Cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in patients with heart failure. • Hospitalization for heart failure in patients with type 2 diabetes mellitus and either established cardiovascular disease (CVD) or multiple cardiovascular (CV) risk factors. Limitations of Use • XIGDUO XR is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus [see Warnings and Precautions (5.2) ] . • Because of the metformin HCl component, the use of XIGDUO XR is limited to patients with type 2 diabetes mellitus for all indications. • XIGDUO XR is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of immunosuppressive therapy for kidney disease. XIGDUO XR is not expected to be effective in these populations. uuid:12495032-f0e6-4a59-9451-a2e18f5fa586 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1592709 biolink:treats MONDO:0004375 PMID:41385096 "[{""id"":""uuid:34b4e14f-08aa-4926-a3be-88e67f989622"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:76ac6ada-c27b-42a8-9009-dcad25f86df5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XIGDUO XR is a combination of dapagliflozin and metformin hydrochloride (HCl) extended-release, indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. Dapagliflozin, when used as a component of XIGDUO XR, is indicated in adults with type 2 diabetes mellitus to reduce the risk of: • Sustained eGFR decline, end‑stage kidney disease, cardiovascular death, and hospitalization for heart failure in patients with chronic kidney disease at risk of progression. • Cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in patients with heart failure. • Hospitalization for heart failure in patients with type 2 diabetes mellitus and either established cardiovascular disease (CVD) or multiple cardiovascular (CV) risk factors. Limitations of Use • XIGDUO XR is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus [see Warnings and Precautions (5.2) ] . • Because of the metformin HCl component, the use of XIGDUO XR is limited to patients with type 2 diabetes mellitus for all indications. • XIGDUO XR is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of immunosuppressive therapy for kidney disease. XIGDUO XR is not expected to be effective in these populations. uuid:4525decd-4750-4854-ae7b-2018b1bcda72 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1592709 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:3ca20ca4-192a-4a88-8e79-bc8f4a765d65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f89ab6b2-a68d-4593-9a78-a69d3e39e2cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XIGDUO XR is a combination of dapagliflozin and metformin hydrochloride (HCl) extended-release, indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. Dapagliflozin, when used as a component of XIGDUO XR, is indicated in adults with type 2 diabetes mellitus to reduce the risk of: • Sustained eGFR decline, end‑stage kidney disease, cardiovascular death, and hospitalization for heart failure in patients with chronic kidney disease at risk of progression. • Cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in patients with heart failure. • Hospitalization for heart failure in patients with type 2 diabetes mellitus and either established cardiovascular disease (CVD) or multiple cardiovascular (CV) risk factors. Limitations of Use • XIGDUO XR is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus [see Warnings and Precautions (5.2) ] . • Because of the metformin HCl component, the use of XIGDUO XR is limited to patients with type 2 diabetes mellitus for all indications. • XIGDUO XR is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of immunosuppressive therapy for kidney disease. XIGDUO XR is not expected to be effective in these populations. uuid:25282322-4268-4356-adb4-a7fda8d7fc13 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1592709 biolink:treats MONDO:0020642 PMID:41385096 "[{""id"":""uuid:814f47de-3e82-4f7e-a3e0-1a6447a88ca7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aab0ae93-5539-4fc5-abef-ff975aa1b9bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XIGDUO XR is a combination of dapagliflozin and metformin hydrochloride (HCl) extended-release, indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. Dapagliflozin, when used as a component of XIGDUO XR, is indicated in adults with type 2 diabetes mellitus to reduce the risk of: • Sustained eGFR decline, end‑stage kidney disease, cardiovascular death, and hospitalization for heart failure in patients with chronic kidney disease at risk of progression. • Cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in patients with heart failure. • Hospitalization for heart failure in patients with type 2 diabetes mellitus and either established cardiovascular disease (CVD) or multiple cardiovascular (CV) risk factors. Limitations of Use • XIGDUO XR is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus [see Warnings and Precautions (5.2) ] . • Because of the metformin HCl component, the use of XIGDUO XR is limited to patients with type 2 diabetes mellitus for all indications. • XIGDUO XR is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of immunosuppressive therapy for kidney disease. XIGDUO XR is not expected to be effective in these populations. uuid:1aa69c51-2456-47f8-a25a-dd0e044355c8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:L4C1UY2NYH biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:1a1cf827-beb4-465c-af17-f6d3cefdf2c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:82066217-5116-4f81-9701-96d3a0f7a3ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ITOVEBI, in combination with palbociclib and fulvestrant, is indicated for the treatment of adults with endocrine-resistant, PIK3CA -mutated, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy [see Clinical Studies (14.1) ] . uuid:b669ca06-a192-4ee0-a1c6-a16110358aa8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2S9ZZM9Q9V biolink:treats MONDO:0018177 PMID:41385096 "[{""id"":""uuid:8f5cde86-1b42-4b88-8fbf-3bdf8fa5781f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f22eded5-92ec-48ef-a89a-73b63e0b5425"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZIRABEV is a vascular endothelial growth factor inhibitor indicated for the treatment of: • Metastatic colorectal cancer, in combination with intravenous fluorouracil-based chemotherapy for first- or second-line treatment. ( 1.1 ) • Metastatic colorectal cancer, in combination with fluoropyrimidine-irinotecan- or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab product-containing regimen. ( 1.1 ) Limitations of Use : ZIRABEV is not indicated for adjuvant treatment of colon cancer. ( 1.1 ) • Unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer, in combination with carboplatin and paclitaxel for first-line treatment. ( 1.2 ) • Recurrent glioblastoma in adults. ( 1.3 ) • Metastatic renal cell carcinoma in combination with interferon alfa. ( 1.4 ) • Persistent, recurrent, or metastatic cervical cancer, in combination with paclitaxel and cisplatin or paclitaxel and topotecan. ( 1.5 ) • Epithelial ovarian, fallopian tube, or primary peritoneal cancer: o in combination with carboplatin and paclitaxel, followed by ZIRABEV as a single agent, for stage III or IV disease following initial surgical resection. ( 1.6 ) o in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens. ( 1.6 ) o in combination with carboplatin and paclitaxel or carboplatin and gemcitabine, followed by ZIRABEV as a single agent, for platinum-sensitive recurrent disease. ( 1.6 ) uuid:e6f82da8-2ec9-4016-8ea2-5f2cfc6e3096 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17786 biolink:treats MONDO:0018982 PMID:41385096 "[{""id"":""uuid:3c317e74-bce4-4ea3-b831-ceabb80affe0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0681ec08-a89a-47a7-b3cd-264a75b8715c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AQNEURSA™ is indicated for the treatment of neurological manifestations of Niemann-Pick disease type C (NPC) in adults and pediatric patients weighing ≥15 kg. uuid:05937fbe-8bce-4528-ad6d-e9da0e34fa6c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:145372 biolink:treats MONDO:0018874 PMID:41385096 "[{""id"":""uuid:c8bd96b9-49a0-47d7-bdde-9de07cd313c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:3dab1553-ab4a-4bb7-b450-25c713f733a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4be47aa1-13cd-4801-ae1c-4c5c54e65ec9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XOSPATA is a kinase inhibitor indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test. ( 1.1 )|[EMA] Xospata is indicated as monotherapy for the treatment of adult patients who have relapsed or refractory acute myeloid leukaemia (AML) with a FLT3 mutation., uuid:21c4f33e-056c-4dc0-8ed1-3c44838b311b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:67101 biolink:treats UMLS:C0278493 PMID:41385096 "[{""id"":""uuid:99af316f-d25d-4c65-90b4-4d9509a38bb9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:67d80d38-3470-4953-805e-5ef7ce3872c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CERIANNA is indicated for use with positron emission tomography (PET) imaging for the detection of estrogen receptor (ER)-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer. uuid:e63b0928-b6d4-457c-bdb2-096abec5eb80 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:67101 biolink:treats UMLS:C0278488 PMID:41385096 "[{""id"":""uuid:bc5ac9bc-8b2b-4d93-96c7-0d39864400d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b1ce15f6-1f35-485e-b323-d3f373c5ed34"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CERIANNA is indicated for use with positron emission tomography (PET) imaging for the detection of estrogen receptor (ER)-positive lesions as an adjunct to biopsy in patients with recurrent or metastatic breast cancer. uuid:4e7fd0af-bc3c-4c54-b3e0-b128da0af32a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:145994 biolink:treats MONDO:0100096 PMID:41385096 "[{""id"":""uuid:5c843d9d-c9f1-48cc-8191-c935d08d1424"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:412e8095-e1ca-4269-97de-b4e53d5e6fee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c53ec109-39d1-461b-ac6a-6f2c8876233a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/veklury""]},{""id"":""uuid:f8a6f29b-5412-48b3-b163-925a57f936ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VEKLURY is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults and pediatric patients (birth to less than 18 years of age weighing at least 1.5 kg) who are [see Clinical Studies (14) ] : Hospitalized, or Not hospitalized and have mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19, including hospitalization or death.|[EMA] Veklury is indicated for the treatment of coronavirus disease 2019 (COVID 19) in:adults and paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment)adults and paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19|[PMDA] Drugs with a new active ingredient indicated for the treatment of disease caused by SARS-CoV-2 infection (COVID-19). [Drug pertaining to Special Approval for Emergency] uuid:ecca0a28-f121-4e0b-8cf6-755e0614a698 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:0R4NLX88O4 biolink:treats MONDO:0009265 PMID:41385096 "[{""id"":""uuid:6e8c4e00-065f-4365-91a3-ad7b6d3989e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b2d858a7-ce4e-4bdc-ae1d-165a85a24399"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ELELYSO is indicated for the treatment of patients 4 years of age and older with a confirmed diagnosis of Type 1 Gaucher disease. uuid:682a631f-34c1-481d-b5de-7baa53604551 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68478 biolink:treats MONDO:0005815 PMID:41385096 "[{""id"":""uuid:32c10dc5-6b68-455d-bec6-10077de27c0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:795951cf-6eb6-4bb1-9d27-c4b1adafc55f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Everolimus tablets are a kinase inhibitor indicated for the treatment of: Postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole. ( 1.1 ) Adults with progressive neuroendocrine tumors of pancreatic origin (PNET) and adults with progressive, well-differentiated, non-functional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin that are unresectable, locally advanced or metastatic. Limitations of Use: Everolimus tablets are not indicated for the treatment of patients with functional carcinoid tumors. ( 1.2 ) Adults with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. ( 1.3 ) Adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. ( 1.4 ) Everolimus tablets and everolimus tablets for oral suspension are kinase inhibitors indicated for the treatment of adult and pediatric patients aged 1 year and older with TSC who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected. ( 1.5 ) uuid:b79043e5-4992-4bff-a78b-7178b2796d5d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68478 biolink:treats MONDO:0024503 PMID:41385096 "[{""id"":""uuid:eef68a56-4899-4cd9-a31c-10be18b5d1f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b27aca41-c56a-4903-8618-35bdc11ad616"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Everolimus tablets are a kinase inhibitor indicated for the treatment of: Postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole. ( 1.1 ) Adults with progressive neuroendocrine tumors of pancreatic origin (PNET) and adults with progressive, well-differentiated, non-functional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin that are unresectable, locally advanced or metastatic. Limitations of Use: Everolimus tablets are not indicated for the treatment of patients with functional carcinoid tumors. ( 1.2 ) Adults with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. ( 1.3 ) Adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. ( 1.4 ) Everolimus tablets and everolimus tablets for oral suspension are kinase inhibitors indicated for the treatment of adult and pediatric patients aged 1 year and older with TSC who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected. ( 1.5 ) uuid:31403976-084b-48ba-9358-efe443ba5606 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68478 biolink:treats MONDO:0005454 PMID:41385096 "[{""id"":""uuid:d8ce2463-8786-4924-8dea-5f8aa6a1cd25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d5565c89-f0c3-4988-816d-4d9e3f4f5165"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2bb69f53-cf30-4485-aceb-5aa263a1c17c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/votubia""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Everolimus tablets are a kinase inhibitor indicated for the treatment of: Postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole. ( 1.1 ) Adults with progressive neuroendocrine tumors of pancreatic origin (PNET) and adults with progressive, well-differentiated, non-functional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin that are unresectable, locally advanced or metastatic. Limitations of Use: Everolimus tablets are not indicated for the treatment of patients with functional carcinoid tumors. ( 1.2 ) Adults with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. ( 1.3 ) Adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. ( 1.4 ) Everolimus tablets and everolimus tablets for oral suspension are kinase inhibitors indicated for the treatment of adult and pediatric patients aged 1 year and older with TSC who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected. ( 1.5 )|[EMA] Hormone-receptor-positive advanced breast cancerAfinitor is indicated for the treatment of hormone-receptor-positive, HER2/neu-negative advanced breast cancer, in combination with exemestane, in post-menopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.Neuroendocrine tumours of pancreatic originAfinitor is indicated for the treatment of unresectable or metastatic, well or moderately differentiated neuroendocrine tumours of pancreatic origin in adults with progressive disease.Neuroendocrine tumours of gastrointestinal or lung originAfinitor is indicated for the treatment of unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease.Renal-cell carcinomaAfinitor is indicated for the treatment of patients with advanced renal-cell carcinoma, whose disease has progressed on or after treatment with VEGF-targeted therapy. uuid:8cf37f48-4e06-4ab3-940c-aec97f123196 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68478 biolink:treats UMLS:C4727069 PMID:41385096 "[{""id"":""uuid:f9753648-a93c-49f1-85e6-d763dd00551c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:98792dc8-992a-4f8c-99c1-3b5551e7205b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Everolimus tablets are a kinase inhibitor indicated for the treatment of: Postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole. ( 1.1 ) Adults with progressive neuroendocrine tumors of pancreatic origin (PNET) and adults with progressive, well-differentiated, non-functional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin that are unresectable, locally advanced or metastatic. Limitations of Use: Everolimus tablets are not indicated for the treatment of patients with functional carcinoid tumors. ( 1.2 ) Adults with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. ( 1.3 ) Adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. ( 1.4 ) Everolimus tablets and everolimus tablets for oral suspension are kinase inhibitors indicated for the treatment of adult and pediatric patients aged 1 year and older with TSC who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected. ( 1.5 ) uuid:1bbd2a5e-3a75-4e30-a7bd-d373dffdd329 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:145374 biolink:treats MONDO:0018874 PMID:41385096 "[{""id"":""uuid:ea9fe40e-40ac-47e9-b6df-fb68e9a65c39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:07aa4b95-6add-46b7-acdd-9bb8cd8f364e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IDHIFA is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test ( 1.1 ). uuid:3eaff778-bd39-4637-8e76-e303464bb094 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:145374 biolink:treats UMLS:C4528668 PMID:41385096 "[{""id"":""uuid:624f1ce4-128d-498e-8343-b2095800dd73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:52e6f487-a9a9-484b-8896-eab61703feb9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IDHIFA is an isocitrate dehydrogenase-2 inhibitor indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an FDA-approved test ( 1.1 ). uuid:5a6cbef3-5b60-42fc-8471-58ba41339a76 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:R96Z451BMC biolink:treats MONDO:0020547 PMID:41385096 "[{""id"":""uuid:4c5df5c7-9dcf-439e-863a-c42376b03862"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c80ef5a9-22da-4f13-8902-46baa35cded6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NIKTIMVO is indicated for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg. uuid:d5e0a266-8eab-449b-a465-91f4339974fe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:R96Z451BMC biolink:treats UMLS:C3539781 PMID:41385096 "[{""id"":""uuid:2173df2e-f003-4706-b720-e8a1057f2203"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:624815ec-c3ae-4376-a603-827bc01bbe82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NIKTIMVO is indicated for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients weighing at least 40 kg. uuid:30193b8e-db74-4a67-b5d7-3d9503215b62 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:178199 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:8a380ce9-9dfd-4180-b880-bb4ecb096cbd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:367370c8-ff3b-4be2-9032-01723a0c1d15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:74533280-d4ab-4c3a-9197-97155a944274"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lumykras""]},{""id"":""uuid:05580ca7-3027-456f-ac4f-040bb7d7ba9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LUMAKRAS is an inhibitor of the RAS GTPase family indicated for: KRAS G12C-mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) As a single agent, for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC, as determined by an FDA-approved test, who have received at least one prior systemic therapy. ( 1.1 ) This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1.1 ) KRAS G12C-mutated Metastatic Colorectal Cancer (mCRC) In combination with panitumumab, for the treatment of adult patients with KRAS G12C-mutated mCRC as determined by an FDA approved-test, who have received prior fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy. ( 1.2 )|[EMA] Lumykras as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and who have progressed after at least one prior line of systemic therapy.|[PMDA] A drug with a new active ingredient indicated for the treatment of unresectable advanced or recurrent KRAS G12C mutation-positive non-small cell lung cancer that has progressed after cancer chemotherapy. [Orphan drug] uuid:d948fa75-9e44-40ff-aa29-e2f48218cd5f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:178199 biolink:treats EFO:1001480 PMID:41385096 "[{""id"":""uuid:47d07314-8da2-4e0a-a7f3-69c932828ee8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1968655b-8e8e-4abd-bc29-af171480134f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LUMAKRAS is an inhibitor of the RAS GTPase family indicated for: KRAS G12C-mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) As a single agent, for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC, as determined by an FDA-approved test, who have received at least one prior systemic therapy. ( 1.1 ) This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1.1 ) KRAS G12C-mutated Metastatic Colorectal Cancer (mCRC) In combination with panitumumab, for the treatment of adult patients with KRAS G12C-mutated mCRC as determined by an FDA approved-test, who have received prior fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy. ( 1.2 ) uuid:0839760e-0244-4e7e-a106-d54f3fab4a57 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:167707 biolink:treats MONDO:0018876 PMID:41385096 "[{""id"":""uuid:7ce23e36-a266-46d2-b9e6-f7d6ece7e552"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fdc20543-1e84-4f9f-8ff5-00a403906c2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CALQUENCE is a kinase inhibitor indicated: • In combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation (HSCT). ( 1.1 ) • For the treatment of adult patients with MCL who have received at least one prior therapy. ( 1.2 ) • For the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). (1.3) uuid:86ef5a8d-3417-4c1e-9e41-f02d9c32ea7b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:167707 biolink:treats MONDO:0004948 PMID:41385096 "[{""id"":""uuid:67efbc29-9049-4ab4-9880-fcbfca276a88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6209ba4b-bd61-4ec5-baf2-a8b6421c85ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2886e3be-38ea-4dcd-85cc-5bea36b64b00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/calquence""]},{""id"":""uuid:f892e04f-96c7-4439-b8f1-88b6408af8a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CALQUENCE is a kinase inhibitor indicated: • In combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation (HSCT). ( 1.1 ) • For the treatment of adult patients with MCL who have received at least one prior therapy. ( 1.2 ) • For the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). (1.3)|[EMA] Calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL).Calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy.|[PMDA] A drug with a new active ingredient indicated for the treatment of relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. uuid:edae598e-f913-4659-a509-253f55a70add biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:167707 biolink:treats MONDO:0003864 PMID:41385096 "[{""id"":""uuid:684a42af-8083-4b02-94eb-dd91f35bb347"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7ec14de0-22da-4356-bb63-183f3b37d278"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:29c55115-aaf8-4d4d-bc9f-86f0d6cea991"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CALQUENCE is a kinase inhibitor indicated: • In combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation (HSCT). ( 1.1 ) • For the treatment of adult patients with MCL who have received at least one prior therapy. ( 1.2 ) • For the treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). (1.3)|[PMDA] A drug with a new active ingredient indicated for the treatment of relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. uuid:b00a7a40-e79f-4797-9e91-06e75395b0c7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:43830 biolink:treats UMLS:C0271905 PMID:41385096 "[{""id"":""uuid:7632f0b0-d7dd-4c46-b5af-044182270389"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f66eddeb-fecc-476b-a47e-99391689c0a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methylene blue injection is indicated for the treatment of pediatric and adult patients with acquired methemoglobinemia. uuid:ed0e86bb-ec85-4b16-8a2f-2441e8986ce2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44241 biolink:treats MONDO:0000004 PMID:41385096 "[{""id"":""uuid:519e93d7-433a-4054-8990-1c36fa6c3e75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1ef78a97-39c0-4590-9dd2-a545c06f079e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Metopirone is indicated, in combination with other diagnostic tests, for the diagnosis of adrenal insufficiency in adult and pediatric patients. uuid:9bc838e4-6be9-4546-8be4-3ffcf182ce57 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:40237 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:40e97e6e-2caf-4ce8-9a8f-62df667f6702"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c9e1c02c-5050-4f1d-87c6-e813d54a2309"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sitagliptin Tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use Sitagliptin Tablets is not recommended in patients with type 1 diabetes mellitus. Sitagliptin Tablets have not been studied in patients with a history of pancreatitis. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using Sitagliptin Tablets. [see Warnings and Precautions (5.1) ]. uuid:85c673b3-fd4d-4d57-85e4-66a429a0a268 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:12PYH0FTU9 biolink:treats MONDO:0004975 PMID:41385096 "[{""id"":""uuid:04ec3474-fd3e-4826-a772-d10b7250dc3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b5b82db4-4cb7-4e1d-9d3a-cfd8a8de8fea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:6825d45e-6386-4e9a-ad41-27b023682c6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LEQEMBI is indicated for the treatment of Alzheimer’s disease. Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.|[PMDA] Drugs with a new active ingredient indicated for slowing the progression of mild cognitive impairment and mild dementia due to Alzheimer’s disease. [Priority review] uuid:bf5faa48-0bd2-4792-acd6-18bf94b22b35 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:12PYH0FTU9 biolink:treats EFO:0007982 PMID:41385096 "[{""id"":""uuid:68fdb7fc-66db-4ff2-b326-91768a3a4bd3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a2e97a56-b28f-482d-b90e-7d679b92bec3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:064b7dd2-0420-4a46-84da-b3f7ed3435db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LEQEMBI is indicated for the treatment of Alzheimer’s disease. Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.|[PMDA] Drugs with a new active ingredient indicated for slowing the progression of mild cognitive impairment and mild dementia due to Alzheimer’s disease. [Priority review] uuid:fadedd9c-299f-4143-81e0-c655221dfcf1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:12PYH0FTU9 biolink:treats UMLS:C3494623 PMID:41385096 "[{""id"":""uuid:eb4bd413-d9ab-4672-8d4b-df51ded24788"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c645fa04-9b3d-42f2-bb5b-896d39e3ffdf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LEQEMBI is indicated for the treatment of Alzheimer’s disease. Treatment with LEQEMBI should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials. uuid:748f307d-717b-4496-860a-ea0b7e2b1f81 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:61033 biolink:treats MONDO:0005399 PMID:41385096 "[{""id"":""uuid:797bdf20-5ec2-4451-b863-1c93b854a880"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d73ce2c5-fd5c-475e-befe-c21e8f14b6b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e6241e9c-8389-4833-80e6-2f6760bf8d55"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/arixtra""]},{""id"":""uuid:71c39c09-97a6-4ef3-b52f-f9554d051a20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ARIXTRA is a Factor Xa inhibitor (anticoagulant) indicated for: • Prophylaxis of deep vein thrombosis (DVT) in adult patients undergoing hip fracture surgery (including extended prophylaxis), hip replacement surgery, knee replacement surgery, or abdominal surgery. ( 1.1 ) • Treatment of DVT or acute pulmonary embolism (PE) in adult patients when administered in conjunction with warfarin sodium. ( 1.2 , 1.3 ) • Treatment of venous thromboembolism (VTE) in pediatric patients aged 1 year or older weighing at least 10 kg. ( 1.4 )|[EMA] 1.5-mg/0.3-ml and 2.5-mg/0.5-ml solution for injectionPrevention of venous thromboembolic events (VTE) in adults undergoing major orthopaedic surgery of the lower limbs such as hip fracture, major knee surgery or hip-replacement surgery.Prevention of VTE in adults undergoing abdominal surgery who are judged to be at high risk of thromboembolic complications, such as patients undergoing abdominal cancer surgery.Prevention of VTE in adult medical patients who are judged to be at high risk for VTE and who are immobilised due to acute illness such as cardiac insufficiency and / or acute respiratory disorders, and / or acute infectious or inflammatory disease.Treatment of adults with acute symptomatic spontaneous superficial-vein thrombosis of the lower limbs without concomitant deep-vein thrombosis.2.5-mg/0.5-ml solution for injectionTreatment of unstable angina or non-ST-segment-elevation myocardial infarction (UA/NSTEMI) in adult patients for whom urgent (< 120 mins) invasive management (PCI) is not indicated.infarction (STEMI) in adult patients who are managed with thrombolytics or who initially are to receive no other form of reperfusion therapy.5-mg/0.4-ml, 7.5-mg/0.6-ml and 10-mg/0.8-ml solution for injectionTreatment of adults with acute deep-vein thrombosis (DVT) and treatment of acute pulmonary embolism (PE), except in haemodynamically unstable patients or patients who require thrombolysis or pulmonary embolectomy.|[PMDA] Drugs containing a new active ingredient indicated for the prevention of venous thromboembolism in high-risk patients who have undergone lower-extremity orthopedic surgery. [Priority review] uuid:99334e47-93e0-4ca0-a964-1ce375b0ba55 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:94405 biolink:treats MONDO:0005302 PMID:41385096 "[{""id"":""uuid:28355a1d-bfa9-49e4-aba8-96db47fa51dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:11684d05-681c-43d4-a63e-355c6dada6c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Qelbree is indicated for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older. uuid:065707e4-83b1-4ad2-9476-fdc23ac375bc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:N3858377KC biolink:treats MONDO:0019496 PMID:41385096 "[{""id"":""uuid:997c8611-f029-4bf8-b94b-4e3231ccb5db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:19929fdc-9458-4c3f-a78f-ac7b1aeea9a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Detectnet is indicated for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult patients. uuid:1563c00f-5979-46a0-90da-224ae8eb6a36 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6076 biolink:treats UMLS:C0348805 PMID:41385096 "[{""id"":""uuid:9105137f-d871-4789-b5b3-07a008fb12f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4d8d4bda-c364-4025-8223-f3901e7a0ac4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Itraconazole capsules are indicated for the treatment of the following fungal infections in immunocompromised and non-immunocompromised patients: 1. Blastomycosis, pulmonary and extrapulmonary 2. Histoplasmosis, including chronic cavitary pulmonary disease and disseminated, non-meningeal histoplasmosis, and 3. Aspergillosis, pulmonary and extrapulmonary, in patients who are intolerant of or who are refractory to amphotericin B therapy. Specimens for fungal cultures and other relevant laboratory studies (wet mount, histopathology, serology) should be obtained before therapy to isolate and identify causative organisms. Therapy may be instituted before the results of the cultures and other laboratory studies are known; however, once these results become available, antiinfective therapy should be adjusted accordingly. Itraconazole capsules are also indicated for the treatment of the following fungal infections in non-immunocompromised patients: 1. Onychomycosis of the toenail, with or without fingernail involvement, due to dermatophytes (tinea unguium), and 2. Onychomycosis of the fingernail due to dermatophytes (tinea unguium). Prior to initiating treatment, appropriate nail specimens for laboratory testing (KOH preparation, fungal culture, or nail biopsy) should be obtained to confirm the diagnosis of onychomycosis. (See CLINICAL PHARMACOLOGY: Special Populations, CONTRAINDICATIONS, WARNINGS, and ADVERSE REACTIONS: Postmarketing Experience for more information.) Description of Clinical Studies: Blastomycosis: Analyses were conducted on data from two open-label, non-concurrently controlled studies (N=73 combined) in patients with normal or abnormal immune status. The median dose was 200 mg/day. A response for most signs and symptoms was observed within the first 2 weeks, and all signs and symptoms cleared between 3 and 6 months. Results of these two studies demonstrated substantial evidence of the effectiveness of itraconazole for the treatment of blastomycosis compared with the natural history of untreated cases. Histoplasmosis: Analyses were conducted on data from two open-label, non-concurrently controlled studies (N=34 combined) in patients with normal or abnormal immune status (not including HIV-infected patients). The median dose was 200 mg/day. A response for most signs and symptoms was observed within the first 2 weeks, and all signs and symptoms cleared between 3 and 12 months. Results of these two studies demonstrated substantial evidence of the effectiveness of itraconazole for the treatment of histoplasmosis, compared with the natural history of untreated cases. Histoplasmosis in HIV-infected patients: Data from a small number of HIV-infected patients suggested that the response rate of histoplasmosis in HIV-infected patients is similar to that of non-HIV-infected patients. The clinical course of histoplasmosis in HIV-infected patients is more severe and usually requires maintenance therapy to prevent relapse. Aspergillosis: Analyses were conducted on data from an open-label, “single-patient-use” protocol designed to make itraconazole available in the U.S. for patients who either failed or were intolerant of amphotericin B therapy (N=190). The findings were corroborated by two smaller open-label studies (N=31 combined) in the same patient population. Most adult patients were treated with a daily dose of 200 to 400 mg, with a median duration of 3 months. Results of these studies demonstrated substantial evidence of effectiveness of itraconazole as a second-line therapy for the treatment of aspergillosis compared with the natural history of the disease in patients who either failed or were intolerant of amphotericin B therapy. Onychomycosis of the toenail: Analyses were conducted on data from three double-blind, placebo-controlled studies (N=214 total; 110 given itraconazole capsules) in which patients with onychomycosis of the toenails received 200 mg of itraconazole capsules once daily for 12 consecutive weeks. Results of these studies demonstrated mycologic cure, defined as simultaneous occurrence of negative KOH plus negative culture, in 54% of patients. Thirty-five percent (35%) of patients were considered an overall success (mycologic cure plus clear or minimal nail involvement with significantly decreased signs) and 14% of patients demonstrated mycologic cure plus clinical cure (clearance of all signs, with or without residual nail deformity). The mean time to overall success was approximately 10 months. Twenty-one percent (21%) of the overall success group had a relapse (worsening of the global score or conversion of KOH or culture from negative to positive). Onychomycosis of the fingernail: Analyses were conducted on data from a double-blind, placebo-controlled study (N=73 total; 37 given itraconazole capsules) in which patients with onychomycosis of the fingernails received a 1-week course of 200 mg of itraconazole capsules b.i.d., followed by a 3-week period without itraconazole, which was followed by a second 1-week course of 200 mg of itraconazole capsules b.i.d. Results demonstrated mycologic cure in 61% of patients. Fifty-six percent (56%) of patients were considered an overall success and 47% of patients demonstrated mycologic cure plus clinical cure. The mean time to overall success was approximately 5 months. None of the patients who achieved overall success relapsed. uuid:465c5284-96d6-47c8-a3d2-1cbd9b735f2c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:139399801 biolink:treats MONDO:0009061 PMID:41385096 "[{""id"":""uuid:8ffcd3a5-4c3e-4139-b6a4-4b7c2185d983"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:055034d7-d0af-4a42-8335-8414ca5a122d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ALYFTREK is indicated for the treatment of cystic fibrosis (CF) in patients 6 years of age and older who have at least one F508del mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator ( CFTR ) gene (see Table 5 ) [see Clinical Pharmacology (12.1) ]. If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to confirm the presence of at least one indicated mutation. uuid:0bcf4508-7b23-4e91-bf4c-a749533e313b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72317 biolink:treats MONDO:0015277 PMID:41385096 "[{""id"":""uuid:0c506e0b-23d2-4022-913f-75924cedd299"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0d9e74f3-9ba1-4fc7-8bb0-6139b13dc2c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a4835a55-326f-4598-a958-d5dd50f17243"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cometriq""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] COMETRIQ is indicated for the treatment of patients with progressive, metastatic medullary thyroid cancer (MTC).|[EMA] Treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma. uuid:5bf86135-b3eb-4901-8c7a-b7548d8dc45d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5778 biolink:treats MONDO:0005240 PMID:41385096 "[{""id"":""uuid:edc4023d-426f-4c90-893f-88d8b30592a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:08f11abf-e2f2-481d-a28c-6b1fec8ae84c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INZIRQO™ (hydrochlorothiazide) is a thiazide diuretic indicated for: The treatment of hypertension in adult and pediatric patients alone or in combination with other antihypertensive agents, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarction (1.1). The treatment of edema associated with congestive heart failure, hepatic cirrhosis and renal disease including the nephrotic syndrome in adult and pediatric patients. (1.2). uuid:5416533e-83aa-4067-b5cd-bae5797ada2e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3207 biolink:treats MONDO:0005361 PMID:41385096 "[{""id"":""uuid:aa24304f-9bfb-4d66-a8f6-f44236f2e5c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:8d3b911d-95fd-4365-9fd3-d96c2706bad1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1dd324aa-ed45-43da-a69f-d1244253513d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EOHILIA ™ is indicated for 12 weeks of treatment in adult and pediatric patients 11 years of age and older with eosinophilic esophagitis (EoE). Limitations of Use EOHILIA has not been shown to be safe and effective for the treatment of EoE for longer than 12 weeks [see Dosage and Administration (2.1) , Clinical Studies (14) ].|[EMA] Jorveza is indicated for the treatment of eosinophilic esophagitis (EoE) in adults (older than 18 years of age). uuid:f387ae4e-2b99-4607-b2bc-112c7f698abf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1799208 biolink:treats MONDO:0005354 PMID:41385096 "[{""id"":""uuid:aac9a921-430e-4813-bbc1-bb9d8fa3e923"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1f9c326f-217d-4ece-a814-7f822c4ff09b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1e971375-822c-4af9-aa78-41c6e4123261"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/epclusa""]},{""id"":""uuid:bab54855-cb29-4b7c-95d1-a100b494c742"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EPCLUSA is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection [see Dosage and Administration (2.2 , 2.3 , 2.4) and Clinical Studies (14) ] : without cirrhosis or with compensated cirrhosis with decompensated cirrhosis for use in combination with ribavirin.|[EMA] Epclusa is indicated for the treatment of chronic hepatitis C virus (HCV) infection in patients 3 years of age and older (see sections 4.2, 4.4 and 5.1).|[PMDA] A drug with a new indication and a new dosage for the improvement of viremia in patients with chronic hepatitis C or compensated cirrhosis type C who are naïve or have not previously been treated. uuid:b90d18ef-e1a3-48ef-b69d-6f08fbd9c8ce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:1FQ2RY5YHH biolink:treats HP:0002153 PMID:41385096 "[{""id"":""uuid:513d178f-9c2f-4e94-9b97-50f80b233128"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c2f04b53-883f-42f7-8661-a0f373aa3b3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:affefccf-e6fa-4dfe-a77f-a55ac53a3204"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Veltassa is indicated for the treatment of hyperkalemia in adults and pediatric patients ages 12 years and older. Limitation of Use: Veltassa should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action [see Clinical Pharmacology (12.2) ] .|[EMA] Veltassa is indicated for the treatment of hyperkalaemia in adults. uuid:798cf177-d61f-4a8a-906c-fdd9e0f26142 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68602 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:a9c60fbe-be8b-4c48-bf6f-33dfbc9b9215"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d9fc2a61-99f2-481e-abb1-cd83e6872943"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EDURANT and EDURANT PED are a human immunodeficiency virus type 1 (HIV-1) specific, non-nucleoside reverse transcriptase inhibitor (NNRTI) indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in treatment-naïve patients 2 years of age and older and weighing at least 14 kg with HIV-1 RNA less than or equal to 100,000 copies/mL. ( 1.1 ). Limitations of Use: More EDURANT treated subjects with HIV-1 RNA greater than 100,000 copies/mL at the start of therapy experienced virologic failure (HIV-1 RNA ≥50 copies/mL) compared to EDURANT treated subjects with HIV-1 RNA less than or equal to 100,000 copies/mL. ( 1.1 , 14 ) EDURANT is indicated in combination with VOCABRIA (cabotegravir), for short-term treatment of HIV-1 infection in adults and adolescents 12 years and older and weighing at least 35 kg who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable regimen with no history of treatment failure and with no known or suspected resistance to either cabotegravir or rilpivirine. ( 1.2 ) uuid:ce77da34-6357-489f-9da1-f958c82a53d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2003249 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:08b76db5-e6b5-4d2b-86c3-4a0bac9b351a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:90086c5c-f49f-4dcf-828d-4ce689b3027b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CIMDUO ® (lamivudine and tenofovir disoproxil fumarate) is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adult and pediatric patients weighing at least 35 kg. uuid:0936bd4c-deef-4506-8d94-7bce016a5355 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:167574 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:2a7e2e9a-a91d-4155-9a02-08d853dc9daa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b177cc09-0ace-4f49-8cef-cf983be01fc8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OZEMPIC is indicated: • as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. • to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease. • to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease . uuid:9d09b271-1f31-4a9c-8698-15c41b069f3f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9086 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:896e0f85-1137-4d9f-8c09-4ed6dc841211"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8627c035-937e-43de-b232-eee7e2e336cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EMSAM (selegiline transdermal system) is a monoamine oxidase inhibitor (MAOI) indicated for the treatment of adults with major depressive disorder (MDD) [see Clinical Studies (14) ] . uuid:c7e4af95-5c91-4300-bf95-b93188f1eac4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:233446 biolink:treats NCIT:C27003 PMID:41385096 "[{""id"":""uuid:57e283c9-83c7-4097-a8ff-ba7a6dd4eec0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:343326b1-068f-4f54-b9f5-35cda533d731"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] JOURNAVX is indicated for the treatment of moderate to severe acute pain in adults. PUBCHEM.COMPOUND:156445116 uuid:f4d95fe5-dabb-42a3-9933-9d3acf50c625 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:78432 biolink:treats UMLS:C0278987 PMID:41385096 "[{""id"":""uuid:bc5479f4-06a2-46a6-833f-fce2e98de64b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a5126c90-e4f1-4ae5-bc57-4c32d22ce67c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZYKADIA ® is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test [see Dosage and Administration (2.1)] . uuid:5cdd0c12-89fb-41c1-baf9-c8716e4e90cf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:JD24M53P9U biolink:treats UMLS:C0701836 PMID:41385096 "[{""id"":""uuid:3a9d6ba7-9fc8-48d9-b32c-b0f94f573aa0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cbbf073b-82a0-4fbd-bece-0756235c8845"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NEXOBRID is indicated for eschar removal in adults and pediatric patients with deep partial thickness (DPT) and/or full thickness (FT) thermal burns. Limitations of Use The safety and effectiveness of NEXOBRID have not been established for treatment of: Chemical or electrical burns Burns on the face, perineum, or genitalia Burns on the feet of patients with diabetes mellitus or on the feet of patients with occlusive vascular disease Circumferential burns Burns in patients with significant cardiopulmonary disease, including inhalation injury NEXOBRID is not recommended for: Wounds contaminated with radioactive and other hazardous substances to avoid unforeseeable reactions with the product and an increased risk of spreading the noxious substance. Treatment of burn wounds where medical devices (e.g., implants, pacemakers, shunts) or vital structures (e.g., large vessels) could become exposed during eschar removal. uuid:15eec681-1000-43ea-b831-0be15713a68a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:VRN8S9CW5V biolink:treats MONDO:0001577 PMID:41385096 "[{""id"":""uuid:39bea68b-00fc-466b-bd14-07901e5afdad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d6a557eb-f1f3-4645-aed7-b404dfdb2619"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1132ff7a-81b0-4df0-bc1a-1a1642262e6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/beyfortus""]},{""id"":""uuid:cfbfce16-ae4c-4daa-8917-4086b32bac78"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BEYFORTUS is indicated for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in: • Neonates and infants born during or entering their first RSV season. • Children up to 24 months of age who remain vulnerable to severe RSV disease through their second RSV season.|[EMA] Beyfortus is indicated for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in neonates and infants during their first RSV season.Beyfortus should be used in accordance with official recommendations.|[PMDA] Drugs with a new active ingredient indicated for as follows: The prevention of lower respiratory tract disease caused by respiratory syncytial (RS) virus infection in neonates, infants and children at risk of serious RS virus infection entering their first or second RS virus season after birth. The prophylaxis of lower respiratory tract disease caused by RS virus infection in all neonates and infants other than those described in Item 1 entering their first RS virus season after birth. uuid:2cfe1053-ee64-43a5-a364-41177062d567 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:91820600 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:adddce69-f575-48ee-8645-ed57ba75d57a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f3875184-e277-47dd-81e0-985d0fd16f4c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SYMFI ® (efavirenz, lamivudine and tenofovir disoproxil fumarate) is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adult and pediatric patients weighing at least 40 kg. uuid:e0dfd2b3-2e75-4ca1-a6a3-df7f0392f458 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:B6E7K36KT8 biolink:treats MONDO:0015290 PMID:41385096 "[{""id"":""uuid:67656767-2f86-4c31-8f3e-e6eac4754819"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b0d610c8-8d6e-45e2-b1ef-c22a02604f5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d0659bb7-14c2-43e0-8fd6-56099dee90dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OXERVATE ® (cenegermin-bkbj) ophthalmic solution 0.002% is indicated for the treatment of neurotrophic keratitis.|[EMA] Treatment of moderate (persistent epithelial defect) or severe (corneal ulcer) neurotrophic keratitis in adults uuid:1f5b95b7-da84-438b-98f5-7761825fe9e3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229648 biolink:treats MONDO:0004956 PMID:41385096 "[{""id"":""uuid:af1545e6-0ece-4d59-9636-34b16295ebc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fdb736be-6edf-48eb-8559-afd6fcd0eb08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] POSLUMA is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy. with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level. uuid:e08dfb94-71d5-4365-a3b5-15422cdb5d2f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229648 biolink:treats MONDO:0008315 PMID:41385096 "[{""id"":""uuid:b8d57535-e189-4864-846d-132c2ffdcc1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:73b10a64-ad1d-4ae3-8d48-66838cdcf5ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] POSLUMA is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy. with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level. uuid:f53cb85e-5cb4-40bd-b96f-95a4ad350cb7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:TG8IQ19NG2 biolink:treats MONDO:0005737 PMID:41385096 "[{""id"":""uuid:e9968518-e597-47ae-ab86-3601b3d0bd78"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ee58abaf-e7a8-42d9-bc3d-ad4867197f13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EBANGA is indicated for the treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection [see Dosage and Administration (2.2) and Clinical Studies (14) ] . uuid:b68006b4-a370-43d5-adb6-18e7ebae6b83 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:0UB3OA67O7 biolink:treats MONDO:0010602 PMID:41385096 "[{""id"":""uuid:ba3e02c5-0fc1-4d59-83a0-921417f12c20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:64430b18-3d8c-41b7-8efb-a7aef9907ce5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] HYMPAVZI is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with: • hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors, or • hemophilia B (congenital factor IX deficiency) without factor IX inhibitors. uuid:646fcc3e-e777-438e-9d4b-b06d07980899 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:0UB3OA67O7 biolink:treats MONDO:0010604 PMID:41385096 "[{""id"":""uuid:97427bb2-24d8-4ce5-9186-ae53d85b9dff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c922061a-4051-4f2a-8129-b5922a6252be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] HYMPAVZI is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with: • hemophilia A (congenital factor VIII deficiency) without factor VIII inhibitors, or • hemophilia B (congenital factor IX deficiency) without factor IX inhibitors. uuid:51c334aa-682f-4b4b-a6fc-36495da9be81 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:U59UGK3IPC biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:30cb191e-56a7-49ce-b5bf-8ce5b58e2ff4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:38766cdc-6cd4-4579-a3d4-f70e6fb4c251"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BRIUMVI is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. uuid:16aebe77-adce-401b-a44b-2f45a653e98e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:U59UGK3IPC biolink:treats UMLS:C2921627 PMID:41385096 "[{""id"":""uuid:a9ed4671-9aa1-4741-b5fd-4c92e03ea396"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7d777c2d-81bd-480b-bf18-1e69c8c589bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BRIUMVI is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. uuid:bcd12eee-0e87-45de-a262-b90ba301a818 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:U59UGK3IPC biolink:treats MONDO:0000450 PMID:41385096 "[{""id"":""uuid:d9794d1a-0310-4bb1-9586-444b40088cff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fd23a310-0915-49d8-aa3e-643a58d7def0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BRIUMVI is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. uuid:cce75c16-2de1-4948-8ae2-497975a40578 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:183811 biolink:treats MONDO:0017137 PMID:41385096 "[{""id"":""uuid:3eb51148-9fcb-43f0-acd9-3df6e0b0998d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3461d728-b58f-4eb0-a29a-915027c66e55"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Moxidectin Tablets are indicated for the treatment of onchocerciasis due to Onchocerca volvulus in adult and pediatric patients aged 4 years and older and weighing at least 13 kg [see Clinical Studies ( 14 )] . Limitations of Use: Moxidectin Tablets does not kill adult Onchocerca volvulus (O. volvulus) parasites . Follow-up evaluation is advised. The safety and efficacy of repeat administration of Moxidectin Tablets in patients with O . volvulus has not been studied. uuid:8e16c69b-2a37-41d2-9cd2-1fa586872b8f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:43830 biolink:treats MONDO:0018740 PMID:41385096 "[{""id"":""uuid:b6db741e-6a89-467f-8cd6-600095310bee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c1e7a7b5-5a60-49b8-9355-5086b8797ea3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Drug-induced methemoglobinemia uuid:319793bf-958f-49d7-89f9-648cf8bd4357 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:34969 biolink:treats MONDO:0060783 PMID:41385096 "[{""id"":""uuid:3993ea8d-6fa6-474c-b463-da1a9b484e67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:07e0e38f-5cf3-4732-896b-7623614140cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CRENESSITY is indicated as adjunctive treatment to glucocorticoid replacement to control androgens in adults and pediatric patients 4 years of age and older with classic congenital adrenal hyperplasia (CAH) . uuid:a28f6d55-3742-4c8e-8c8d-366d21a28e96 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:34969 biolink:treats MONDO:0018479 PMID:41385096 "[{""id"":""uuid:cc270475-7bcb-45cb-9e07-1fd246a8c62a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7eeac5ed-f739-4a4c-af69-dcefe134fcc7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CRENESSITY is indicated as adjunctive treatment to glucocorticoid replacement to control androgens in adults and pediatric patients 4 years of age and older with classic congenital adrenal hyperplasia (CAH) . uuid:e604721c-54a5-42d6-b3f4-c068db652cd5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76016 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:9fe3975c-a6e3-4354-ad08-a83870422e1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:44ec657e-6cc5-418d-8513-7b3264de2ff6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRINTELLIX is indicated for the treatment of major depressive disorder (MDD) in adults. uuid:bcfa5dc7-0f59-4460-8260-a53f404b2bcc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:65370 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:6d6a67f3-e94c-4545-b38d-78fba95bd36b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:df3dc89e-5028-4062-b402-39a7669ade45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0f4a93e8-64c2-42e0-9d82-93343201ea28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Glatopa is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.|[PMDA] A drug with a new active ingredient indicated for the prevention of relapse in multiple sclerosis. [Orphan drug] uuid:aec267d1-62e6-48c0-a5c3-461135668709 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:65370 biolink:treats UMLS:C2921627 PMID:41385096 "[{""id"":""uuid:cf4e7fed-e9be-4740-9ee4-73fcae0ff3ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:67c47b07-2159-4542-b50f-65b81b1a3b27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Glatopa is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. uuid:012da5e9-0c87-4f01-b2b8-cc73dc1bdc6c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:65370 biolink:treats MONDO:0000450 PMID:41385096 "[{""id"":""uuid:14e32816-4f3b-44f5-a6c6-d92360cf7a99"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bfe9f37b-40b4-4aa4-a846-d5a506269b80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Glatopa is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. uuid:e3b58396-3d5d-4b60-93f9-2353a7d38a44 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17824 biolink:treats MONDO:0001516 PMID:41385096 "[{""id"":""uuid:d35170e4-9b7a-47d5-ba6c-5959bbfbf439"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:946f6d2f-1dbb-4f54-b54f-981b71b5ed5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZOLGENSMA is an adeno-associated virus (AAV) vector-based gene therapy indicated for the treatment of pediatric patients less than 2 years of age with spinal muscular atrophy (SMA) with bi-allelic mutations in the survival motor neuron 1 (SMN1) gene. Limitations of Use The safety and effectiveness of repeat administration of ZOLGENSMA have not been evaluated [see Adverse Reactions ( 6.2 )] . The use of ZOLGENSMA in patients with advanced SMA (e.g., complete paralysis of limbs, permanent ventilator-dependence) has not been evaluated [see Clinical Studies ( 14 )] . uuid:2f4e38bf-73d4-452a-a760-1c9a9761ab79 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:G2AE2VE07O biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:03f129c3-db88-4257-923b-9068954ad901"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ce5234f6-2a9b-4907-9b32-4e0945f46f39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] YUPELRI is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). uuid:72e10562-db1c-49d4-ade6-22acd4221296 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:G2AE2VE07O biolink:treats MONDO:0011751 PMID:41385096 "[{""id"":""uuid:5100796d-5784-42c6-acfb-17837b54a956"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:630d966c-50cf-4faf-a717-9da547d139fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] YUPELRI is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). uuid:855855ea-fd0a-4713-a031-4047dd012cc3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16899 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:888374c8-7f5e-430b-94e3-dab0d8e9dca5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2ba567c9-cc4f-4e8a-bc34-347a7c273da6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ARIDOL is indicated for the assessment of bronchial hyperresponsiveness in adult and pediatric patients 6 years of age or older who do not have clinically apparent asthma. Limitations of Use: ARIDOL is not a standalone test or a screening test for asthma. Bronchial challenge testing with ARIDOL should be used only as part of a physician's overall assessment of asthma. uuid:8b32f8e6-f2d5-4f03-8759-aa07bc407a4e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8FOJ430U94 biolink:treats MONDO:0008250 PMID:41385096 "[{""id"":""uuid:fcaa5c18-089f-4f2e-a699-956a06c232d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e393c92e-71ad-4132-b78a-0cb5e47ea2b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:62e9fb71-e989-4e18-ba1c-a0d5d9f4cb07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/sogroya""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] SOGROYA is indicated for the: • Treatment of pediatric patients aged 2.5 years and older who have growth failure due to inadequate secretion of endogenous growth hormone (GH). • Replacement of endogenous GH in adults with growth hormone deficiency (GHD).|[EMA] Sogroya is indicated for the replacement of endogenous growth hormone (GH) in children aged 3 years and above, and adolescents with growth failure due to growth hormone deficiency (paediatric GHD), and in adults with growth hormone deficiency (adult GHD). uuid:d6c4c514-2211-411b-a8bb-f0de4d0187fc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:165363555 biolink:treats MONDO:0009061 PMID:41385096 "[{""id"":""uuid:0e483b64-cb48-4bcc-9f91-4f820bff4cc8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d4999816-32be-47eb-8391-19d6c5bfaa08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRIKAFTA is indicated for the treatment of cystic fibrosis (CF) in patients aged 2 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator ( CFTR ) gene or a mutation in the CFTR gene that is responsive based on clinical and/or in vitro data (see Table 6 ) [see Clinical Pharmacology (12.1) ] . If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to confirm the presence of at least one indicated mutation [see Clinical Pharmacology (12.1) ] . uuid:421efe79-8fc7-4745-a0e0-35088ff9374f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7XL5ISS668 biolink:treats MONDO:0004665 PMID:41385096 "[{""id"":""uuid:dff42d4e-c991-4e2c-8291-3b395bd70b50"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c5df11b1-64b2-4b33-84a9-a9951b12f4fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ADCETRIS is a CD30-directed antibody and microtubule inhibitor conjugate indicated for treatment of: • Adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vinblastine, and dacarbazine ( 1.1 ). • Pediatric patients 2 years and older with previously untreated high risk classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide ( 1.2 ). • Adult patients with classical Hodgkin lymphoma (cHL) at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation ( 1.3 ). • Adult patients with classical Hodgkin lymphoma (cHL) after failure of auto-HSCT or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates ( 1.4 ). • Adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified (NOS), in combination with cyclophosphamide, doxorubicin, and prednisone ( 1.5 ). • Adult patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen ( 1.6 ). • Adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy ( 1.7 ). • Adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) NOS, DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are not eligible for auto-HSCT or CAR T-cell therapy, in combination with lenalidomide and a rituximab product ( 1.8 ). uuid:53f7b769-91e5-4318-b1d0-6342e2006658 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7XL5ISS668 biolink:treats UMLS:C1336548 PMID:41385096 "[{""id"":""uuid:3e6926a5-7b06-417e-b6f6-0c23fe5e8a57"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dafdb6ff-e437-4241-94f1-e4c36dd3102c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ADCETRIS is a CD30-directed antibody and microtubule inhibitor conjugate indicated for treatment of: • Adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vinblastine, and dacarbazine ( 1.1 ). • Pediatric patients 2 years and older with previously untreated high risk classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide ( 1.2 ). • Adult patients with classical Hodgkin lymphoma (cHL) at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation ( 1.3 ). • Adult patients with classical Hodgkin lymphoma (cHL) after failure of auto-HSCT or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates ( 1.4 ). • Adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified (NOS), in combination with cyclophosphamide, doxorubicin, and prednisone ( 1.5 ). • Adult patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen ( 1.6 ). • Adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy ( 1.7 ). • Adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) NOS, DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are not eligible for auto-HSCT or CAR T-cell therapy, in combination with lenalidomide and a rituximab product ( 1.8 ). uuid:3cb9d158-989f-4355-bf4e-0df65fca367a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7XL5ISS668 biolink:treats MONDO:0004977 PMID:41385096 "[{""id"":""uuid:d2b5e89c-7a10-4fb8-909c-095a06197782"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ec3dd3e7-9f47-4065-aa63-12c58e68d5af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ADCETRIS is a CD30-directed antibody and microtubule inhibitor conjugate indicated for treatment of: • Adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vinblastine, and dacarbazine ( 1.1 ). • Pediatric patients 2 years and older with previously untreated high risk classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide ( 1.2 ). • Adult patients with classical Hodgkin lymphoma (cHL) at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation ( 1.3 ). • Adult patients with classical Hodgkin lymphoma (cHL) after failure of auto-HSCT or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates ( 1.4 ). • Adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified (NOS), in combination with cyclophosphamide, doxorubicin, and prednisone ( 1.5 ). • Adult patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen ( 1.6 ). • Adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy ( 1.7 ). • Adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) NOS, DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are not eligible for auto-HSCT or CAR T-cell therapy, in combination with lenalidomide and a rituximab product ( 1.8 ). uuid:986c829d-6af6-47c3-a4fc-4957cf9dff80 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7XL5ISS668 biolink:treats MONDO:0004964 PMID:41385096 "[{""id"":""uuid:2ff40b3e-799e-4dc8-ae96-5b49103b3a42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5f35b664-d4ec-45e6-931b-7bffec632fcb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ADCETRIS is a CD30-directed antibody and microtubule inhibitor conjugate indicated for treatment of: • Adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vinblastine, and dacarbazine ( 1.1 ). • Pediatric patients 2 years and older with previously untreated high risk classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide ( 1.2 ). • Adult patients with classical Hodgkin lymphoma (cHL) at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation ( 1.3 ). • Adult patients with classical Hodgkin lymphoma (cHL) after failure of auto-HSCT or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates ( 1.4 ). • Adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified (NOS), in combination with cyclophosphamide, doxorubicin, and prednisone ( 1.5 ). • Adult patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen ( 1.6 ). • Adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy ( 1.7 ). • Adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) NOS, DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are not eligible for auto-HSCT or CAR T-cell therapy, in combination with lenalidomide and a rituximab product ( 1.8 ). uuid:4140ced0-2876-4b3b-8c1f-e4c41dc9c434 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7XL5ISS668 biolink:treats MONDO:0017598 PMID:41385096 "[{""id"":""uuid:6ba0165d-9e7b-426b-868c-2f0f964fd102"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:34f012b9-3b74-46ce-9376-53b3c94d6e26"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:8dd6c8ad-edce-4613-91da-d8aba79b2b1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ADCETRIS is a CD30-directed antibody and microtubule inhibitor conjugate indicated for treatment of: • Adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vinblastine, and dacarbazine ( 1.1 ). • Pediatric patients 2 years and older with previously untreated high risk classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide ( 1.2 ). • Adult patients with classical Hodgkin lymphoma (cHL) at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation ( 1.3 ). • Adult patients with classical Hodgkin lymphoma (cHL) after failure of auto-HSCT or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates ( 1.4 ). • Adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified (NOS), in combination with cyclophosphamide, doxorubicin, and prednisone ( 1.5 ). • Adult patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen ( 1.6 ). • Adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy ( 1.7 ). • Adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) NOS, DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are not eligible for auto-HSCT or CAR T-cell therapy, in combination with lenalidomide and a rituximab product ( 1.8 ).|[PMDA] A drug with a new indication and a new dosage for the treatment of relapsed or refractory CD30- positive cutaneous T-cell lymphoma. uuid:0c8711c2-0c37-4c8b-895f-4f628d6dda2e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7XL5ISS668 biolink:treats MONDO:0009691 PMID:41385096 "[{""id"":""uuid:6df96732-bd95-43a8-a533-d1ba8cde9c00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:572c6cee-a0d2-418b-9d31-b71ac4d0c4ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ADCETRIS is a CD30-directed antibody and microtubule inhibitor conjugate indicated for treatment of: • Adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vinblastine, and dacarbazine ( 1.1 ). • Pediatric patients 2 years and older with previously untreated high risk classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide ( 1.2 ). • Adult patients with classical Hodgkin lymphoma (cHL) at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation ( 1.3 ). • Adult patients with classical Hodgkin lymphoma (cHL) after failure of auto-HSCT or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates ( 1.4 ). • Adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified (NOS), in combination with cyclophosphamide, doxorubicin, and prednisone ( 1.5 ). • Adult patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen ( 1.6 ). • Adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy ( 1.7 ). • Adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) NOS, DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are not eligible for auto-HSCT or CAR T-cell therapy, in combination with lenalidomide and a rituximab product ( 1.8 ). uuid:11b406b1-5f26-4e55-bcd6-575118d5731a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7XL5ISS668 biolink:treats MONDO:0018905 PMID:41385096 "[{""id"":""uuid:89f576ab-4cbc-4679-8aa6-ed49cdb906a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cc9f33bb-8bec-4dab-ac47-0f6591d0803f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ADCETRIS is a CD30-directed antibody and microtubule inhibitor conjugate indicated for treatment of: • Adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vinblastine, and dacarbazine ( 1.1 ). • Pediatric patients 2 years and older with previously untreated high risk classical Hodgkin lymphoma (cHL), in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide ( 1.2 ). • Adult patients with classical Hodgkin lymphoma (cHL) at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation ( 1.3 ). • Adult patients with classical Hodgkin lymphoma (cHL) after failure of auto-HSCT or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates ( 1.4 ). • Adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL) or other CD30-expressing peripheral T-cell lymphomas (PTCL), including angioimmunoblastic T-cell lymphoma and PTCL not otherwise specified (NOS), in combination with cyclophosphamide, doxorubicin, and prednisone ( 1.5 ). • Adult patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen ( 1.6 ). • Adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy ( 1.7 ). • Adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) NOS, DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are not eligible for auto-HSCT or CAR T-cell therapy, in combination with lenalidomide and a rituximab product ( 1.8 ). uuid:994fa0e4-ee3d-4be2-8c65-c2e6baab92c2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:5SML1T733B biolink:treats MONDO:0010096 PMID:41385096 "[{""id"":""uuid:09475a1a-27a7-4c03-a243-5146629ff17a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:93604ff7-895e-4eed-a1c8-095502a24e64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INGREZZA and INGREZZA SPRINKLE are indicated for the treatment of adults with: - tardive dyskinesia [see Clinical Studies ( 14.1 )] . - chorea associated with Huntington’s disease [see Clinical Studies ( 14.2 )] . uuid:ad8aeb63-5001-40b7-b3d6-f6ffa548ca7d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:5SML1T733B biolink:treats MONDO:0007739 PMID:41385096 "[{""id"":""uuid:663f5fca-5448-40c4-a89e-7a19de2e309b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a9b268df-87c4-4510-8c2c-21f93dd854fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INGREZZA and INGREZZA SPRINKLE are indicated for the treatment of adults with: - tardive dyskinesia [see Clinical Studies ( 14.1 )] . - chorea associated with Huntington’s disease [see Clinical Studies ( 14.2 )] . uuid:81cbd7c5-be12-46f5-9848-1e9393dc4ffa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60773 biolink:treats MONDO:0007576 PMID:41385096 "[{""id"":""uuid:eaf54a18-77a0-499f-ab58-d038f9c41e8e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d797597a-734f-4764-9b45-3dc90d7c0417"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PHOTOFRIN is a photoactivated radical generator indicated for: Esophageal Cancer ( 1.1 ) Palliation of patients with completely obstructing esophageal cancer, or of patients with partially obstructing esophageal cancer who, in the opinion of their physician, cannot be satisfactorily treated with Nd:YAG laser therapy Endobronchial Cancer ( 1.2 ) Treatment of microinvasive endobronchial non-small-cell lung cancer (NSCLC) in patients for whom surgery and radiotherapy are not indicated Reduction of obstruction and palliation of symptoms in patients with completely or partially obstructing endobronchial NSCLC High-Grade Dysplasia in Barrett’s Esophagus ( 1.3 ) Ablation of high-grade dysplasia (HGD) in Barrett’s esophagus (BE) patients who do not undergo esophagectomy uuid:a83b3402-e51e-4e5a-ae1c-0a60a2d88ad0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60773 biolink:treats MONDO:0008903 PMID:41385096 "[{""id"":""uuid:c347dc7b-e17d-47af-9697-839e884bc361"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6c57ddc3-10de-4b50-a7c1-9ff25b750441"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PHOTOFRIN is a photoactivated radical generator indicated for: Esophageal Cancer ( 1.1 ) Palliation of patients with completely obstructing esophageal cancer, or of patients with partially obstructing esophageal cancer who, in the opinion of their physician, cannot be satisfactorily treated with Nd:YAG laser therapy Endobronchial Cancer ( 1.2 ) Treatment of microinvasive endobronchial non-small-cell lung cancer (NSCLC) in patients for whom surgery and radiotherapy are not indicated Reduction of obstruction and palliation of symptoms in patients with completely or partially obstructing endobronchial NSCLC High-Grade Dysplasia in Barrett’s Esophagus ( 1.3 ) Ablation of high-grade dysplasia (HGD) in Barrett’s esophagus (BE) patients who do not undergo esophagectomy uuid:ba364dd6-c915-48c7-b523-2d1573f09887 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60773 biolink:treats UMLS:C1334003 PMID:41385096 "[{""id"":""uuid:ec01fd20-16a2-4aec-8a57-7e47a6d21308"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:812819ee-eb55-434c-9f9e-e13909f8d90a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PHOTOFRIN is a photoactivated radical generator indicated for: Esophageal Cancer ( 1.1 ) Palliation of patients with completely obstructing esophageal cancer, or of patients with partially obstructing esophageal cancer who, in the opinion of their physician, cannot be satisfactorily treated with Nd:YAG laser therapy Endobronchial Cancer ( 1.2 ) Treatment of microinvasive endobronchial non-small-cell lung cancer (NSCLC) in patients for whom surgery and radiotherapy are not indicated Reduction of obstruction and palliation of symptoms in patients with completely or partially obstructing endobronchial NSCLC High-Grade Dysplasia in Barrett’s Esophagus ( 1.3 ) Ablation of high-grade dysplasia (HGD) in Barrett’s esophagus (BE) patients who do not undergo esophagectomy uuid:48b51193-da2e-4d81-9b4d-03f6a71b2bdd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16704 biolink:treats MONDO:0009797 PMID:41385096 "[{""id"":""uuid:cc08a019-0415-4531-b273-8d6bf528bf0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8aab0150-2a99-43bf-b8ac-92a806ab6782"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XURIDEN ® is indicated in adult and pediatric patients for the treatment of hereditary orotic aciduria. uuid:800666b4-f0e0-4abe-831c-6f0bdb91a5ee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:XOI2Q0ZF7G biolink:treats MONDO:0004975 PMID:41385096 "[{""id"":""uuid:43271af4-772d-44fb-944d-8414de69d19e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7247bb70-47d9-4fd2-913c-b2deef5e3783"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZUNVEYL is indicated for the treatment of mild to moderate dementia of the Alzheimer's type in adults. uuid:58b81f23-8138-41aa-9c40-4931c73ad229 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63622 biolink:treats MONDO:0000190 PMID:41385096 "[{""id"":""uuid:c407e128-d1d3-49c3-b799-2075a91b6398"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7f73f40a-c10e-43eb-aa0f-1dc67bbe0719"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Sotalol hydrochloride tablets are an antiarrhythmic indicated for: • the treatment of life-threatening ventricular arrhythmias ( Error! Hyperlink reference not valid. ) • the maintenance of normal sinus rhythm in patients with atrial fibrillation or flutter (AFIB/AFL) ( Error! Hyperlink reference not valid. ) Limitations of Use • Sotalol hydrochloride tablets have not been shown to enhance survival in patients with life-threatening ventricular arrhythmias ( Error! Hyperlink reference not valid. ) • Avoid use in patients with minimally symptomatic or easily reversible AFIB/AFL ( Error! Hyperlink reference not valid. ) uuid:ef2b48a7-51dc-45e8-b333-e130031248f5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59771 biolink:treats MONDO:0008015 PMID:41385096 "[{""id"":""uuid:b3c94486-3a12-44ba-b74a-19de3acb6135"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:36445220-7565-4b20-a46d-99e91f0cf269"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dimenhydrinate Injection, USP is indicated for the prevention and treatment of nausea, vomiting, or vertigo of motion sickness. uuid:2f604e9b-15bb-40c3-934e-6d93e11dfbf5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59771 biolink:treats HP:0002018 PMID:41385096 "[{""id"":""uuid:36a5f9b4-ff83-406c-99c1-62c2bb95b44a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:529ab2b3-07a8-4b26-8b1e-181efd2068c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dimenhydrinate Injection, USP is indicated for the prevention and treatment of nausea, vomiting, or vertigo of motion sickness. uuid:c33866d9-f25f-4f53-afd0-b4afaa50afd9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59771 biolink:treats HP:0002013 PMID:41385096 "[{""id"":""uuid:1e329962-b2ea-4940-bb8c-4307e91940c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8819af78-5ec2-484d-bd01-f460eb5207ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dimenhydrinate Injection, USP is indicated for the prevention and treatment of nausea, vomiting, or vertigo of motion sickness. uuid:4ecf2f89-4a2e-49be-9f21-cc3ebaaf892a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59771 biolink:treats MONDO:0004900 PMID:41385096 "[{""id"":""uuid:d4c29748-98bb-47e2-ae78-9cfdedb0a639"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dbe93e1b-6107-4f95-8973-b9c4d5003be8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dimenhydrinate Injection, USP is indicated for the prevention and treatment of nausea, vomiting, or vertigo of motion sickness. uuid:dec9b860-bc4a-43f2-9368-d753e9a49d34 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PX9FTM69BF biolink:treats MONDO:0002522 PMID:41385096 "[{""id"":""uuid:33acd019-ebf7-4123-a5ca-75d0064c1087"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:30f42476-34d9-422c-87f2-7d77a727ae25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ROMVIMZA is indicated for treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity. uuid:13289772-f194-42d9-89ed-c14d33643853 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PX9FTM69BF biolink:treats MONDO:0010108 PMID:41385096 "[{""id"":""uuid:7766c014-415a-4a90-aa1c-8e03398bb09a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:75067330-d742-4d53-959c-f3e1cb33fda5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ROMVIMZA is indicated for treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity. uuid:fbbccceb-ae78-437c-b640-12598e1faea2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:Y64GQ0KC0A biolink:treats MONDO:0001509 PMID:41385096 "[{""id"":""uuid:4caa84f3-e3a6-44eb-a16a-0c95291beac0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0fa37e92-fdcf-49cd-878f-70d3312d4164"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TEPEZZA is indicated for the treatment of Thyroid Eye Disease regardless of Thyroid Eye Disease activity or duration. uuid:30ccf0d0-ab04-45d6-a0ab-805ce37a592c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:83766 biolink:treats MONDO:0008170 PMID:41385096 "[{""id"":""uuid:369d84d7-6677-48ec-bd89-f6125559d307"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ad22911b-f52e-4ed0-ac20-622185992192"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f53fbe94-b907-4375-985f-e2db5003534f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza""]},{""id"":""uuid:0dda91ea-f5b3-40c9-8a7c-581e5619e6a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: Ovarian cancer • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA -mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.1 , 2.1 ) • in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either: • a deleterious or suspected deleterious BRCA mutation, and/or • genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.2 , 2.1 ) • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.3 , 2.1 ) Breast cancer • for the adjuvant treatment of adult patients with deleterious or suspected deleterious g BRCA m human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.4 , 2.1 ) • for the treatment of adult patients with deleterious or suspected deleterious gBRCA m, HER2-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.5 , 2.1 ) Pancreatic cancer • for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCA m metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.6 , 2.1 ) Prostate cancer • for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.7 , 2.1 ) • in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA -mutated ( BRCA m) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.8 , 2.1 )|[EMA] Ovarian cancerLynparza is indicated as monotherapy for the:maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.Lynparza in combination with bevacizumab is indicated for the:maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability (see section 5.1).Breast cancerLynparza is indicated as:monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy (see sections 4.2 and 5.1).monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2 negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments (see section 5.1). Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy.Adenocarcinoma of the pancreasLynparza is indicated as:monotherapy for the maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen.Prostate cancerLynparza is indicated as:monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mCRPC in whom chemotherapy is not clinically indicated (see section 5.1).|[PMDA] Drugs with new indications and new dosage for the maintenance treatment of homologous recombination deficiency (HRD)-positive ovarian cancer in patients who have received first chemotherapy including treatment with bevacizumab and the treatment of metastatic, BRCA mutation-positive, castration-resistant prostate cancer. uuid:f7e223c5-64dd-4127-85aa-31fb88a7387b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:83766 biolink:treats MONDO:0002158 PMID:41385096 "[{""id"":""uuid:c6f94db4-1fde-409a-b968-68bee9bed513"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:61145f30-05c2-4d45-a927-7a29784a411c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d8fb3c19-da8d-46fd-8c55-67ec32a12560"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: Ovarian cancer • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA -mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.1 , 2.1 ) • in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either: • a deleterious or suspected deleterious BRCA mutation, and/or • genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.2 , 2.1 ) • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.3 , 2.1 ) Breast cancer • for the adjuvant treatment of adult patients with deleterious or suspected deleterious g BRCA m human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.4 , 2.1 ) • for the treatment of adult patients with deleterious or suspected deleterious gBRCA m, HER2-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.5 , 2.1 ) Pancreatic cancer • for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCA m metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.6 , 2.1 ) Prostate cancer • for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.7 , 2.1 ) • in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA -mutated ( BRCA m) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.8 , 2.1 )|[EMA] Ovarian cancerLynparza is indicated as monotherapy for the:maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.Lynparza in combination with bevacizumab is indicated for the:maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability (see section 5.1).Breast cancerLynparza is indicated as:monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy (see sections 4.2 and 5.1).monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2 negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments (see section 5.1). Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy.Adenocarcinoma of the pancreasLynparza is indicated as:monotherapy for the maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen.Prostate cancerLynparza is indicated as:monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mCRPC in whom chemotherapy is not clinically indicated (see section 5.1). uuid:62397697-fe1b-4382-926f-aa1e22473069 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:83766 biolink:treats MONDO:0015686 PMID:41385096 "[{""id"":""uuid:2b5a9a6a-469f-4953-b685-72da6f1cf246"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:992a6a82-7c89-43d4-be71-98437201eaf2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:efcf3866-4e7b-4de9-b520-9a0f4b2b2741"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: Ovarian cancer • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA -mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.1 , 2.1 ) • in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either: • a deleterious or suspected deleterious BRCA mutation, and/or • genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.2 , 2.1 ) • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.3 , 2.1 ) Breast cancer • for the adjuvant treatment of adult patients with deleterious or suspected deleterious g BRCA m human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.4 , 2.1 ) • for the treatment of adult patients with deleterious or suspected deleterious gBRCA m, HER2-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.5 , 2.1 ) Pancreatic cancer • for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCA m metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.6 , 2.1 ) Prostate cancer • for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.7 , 2.1 ) • in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA -mutated ( BRCA m) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.8 , 2.1 )|[EMA] Ovarian cancerLynparza is indicated as monotherapy for the:maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.Lynparza in combination with bevacizumab is indicated for the:maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability (see section 5.1).Breast cancerLynparza is indicated as:monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy (see sections 4.2 and 5.1).monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2 negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments (see section 5.1). Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy.Adenocarcinoma of the pancreasLynparza is indicated as:monotherapy for the maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen.Prostate cancerLynparza is indicated as:monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mCRPC in whom chemotherapy is not clinically indicated (see section 5.1). uuid:c5b1c9e1-e488-4cfc-bf19-42d9ced92c41 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:83766 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:655cea12-6266-4ea4-a8fb-0899100bc246"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c5d21a8b-29b9-4d0f-a670-87a08be43dd8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:22d06d2b-d897-47bd-9a47-fa48f5853969"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza""]},{""id"":""uuid:d8664169-4a54-4dd6-a7b0-bb8de26f2eb3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: Ovarian cancer • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA -mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.1 , 2.1 ) • in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either: • a deleterious or suspected deleterious BRCA mutation, and/or • genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.2 , 2.1 ) • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.3 , 2.1 ) Breast cancer • for the adjuvant treatment of adult patients with deleterious or suspected deleterious g BRCA m human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.4 , 2.1 ) • for the treatment of adult patients with deleterious or suspected deleterious gBRCA m, HER2-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.5 , 2.1 ) Pancreatic cancer • for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCA m metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.6 , 2.1 ) Prostate cancer • for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.7 , 2.1 ) • in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA -mutated ( BRCA m) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.8 , 2.1 )|[EMA] Ovarian cancerLynparza is indicated as monotherapy for the:maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.Lynparza in combination with bevacizumab is indicated for the:maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability (see section 5.1).Breast cancerLynparza is indicated as:monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy (see sections 4.2 and 5.1).monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2 negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments (see section 5.1). Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy.Adenocarcinoma of the pancreasLynparza is indicated as:monotherapy for the maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen.Prostate cancerLynparza is indicated as:monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mCRPC in whom chemotherapy is not clinically indicated (see section 5.1).|[PMDA] Drugs with a new indication and a new dosage for the postoperative adjuvant treatment of BRCA mutation- positive and HER2-negative breast cancer with a high risk of recurrence. [Orphan drug] uuid:0a2e8ea9-9479-4cb6-8e7c-cbc5fa0592da biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:83766 biolink:treats MONDO:0021040 PMID:41385096 "[{""id"":""uuid:201a54ea-5280-45e0-bb8c-927746393f82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:233a430c-47d9-476a-9d38-58d14769bffe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: Ovarian cancer • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA -mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.1 , 2.1 ) • in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either: • a deleterious or suspected deleterious BRCA mutation, and/or • genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.2 , 2.1 ) • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.3 , 2.1 ) Breast cancer • for the adjuvant treatment of adult patients with deleterious or suspected deleterious g BRCA m human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.4 , 2.1 ) • for the treatment of adult patients with deleterious or suspected deleterious gBRCA m, HER2-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.5 , 2.1 ) Pancreatic cancer • for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCA m metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.6 , 2.1 ) Prostate cancer • for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.7 , 2.1 ) • in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA -mutated ( BRCA m) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.8 , 2.1 ) uuid:63c8a668-427f-4b9e-82bf-db30cef5373c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:83766 biolink:treats UMLS:C0861727 PMID:41385096 "[{""id"":""uuid:2180ba45-8ea7-4a9a-b9d7-ff5e62d25239"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0e69848c-a268-433c-a11e-6a21ce025490"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: Ovarian cancer • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA -mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.1 , 2.1 ) • in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either: • a deleterious or suspected deleterious BRCA mutation, and/or • genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.2 , 2.1 ) • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.3 , 2.1 ) Breast cancer • for the adjuvant treatment of adult patients with deleterious or suspected deleterious g BRCA m human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.4 , 2.1 ) • for the treatment of adult patients with deleterious or suspected deleterious gBRCA m, HER2-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.5 , 2.1 ) Pancreatic cancer • for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCA m metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.6 , 2.1 ) Prostate cancer • for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.7 , 2.1 ) • in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA -mutated ( BRCA m) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.8 , 2.1 ) uuid:f9c78cbe-db12-434d-a50c-1bbef305eea6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:83766 biolink:treats MONDO:0008315 PMID:41385096 "[{""id"":""uuid:3380b665-5817-4173-875d-e1f0a4c8dea5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b4cef59a-82a7-4ef1-a388-128cd1f4ea0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:dece8f60-2235-4545-a142-0253ddaca105"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza""]},{""id"":""uuid:4802b1e9-7cee-4ffb-acb7-247bc01f618f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: Ovarian cancer • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA -mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.1 , 2.1 ) • in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either: • a deleterious or suspected deleterious BRCA mutation, and/or • genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.2 , 2.1 ) • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.3 , 2.1 ) Breast cancer • for the adjuvant treatment of adult patients with deleterious or suspected deleterious g BRCA m human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.4 , 2.1 ) • for the treatment of adult patients with deleterious or suspected deleterious gBRCA m, HER2-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.5 , 2.1 ) Pancreatic cancer • for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCA m metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.6 , 2.1 ) Prostate cancer • for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.7 , 2.1 ) • in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA -mutated ( BRCA m) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.8 , 2.1 )|[EMA] Ovarian cancerLynparza is indicated as monotherapy for the:maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.Lynparza in combination with bevacizumab is indicated for the:maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability (see section 5.1).Breast cancerLynparza is indicated as:monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy (see sections 4.2 and 5.1).monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2 negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments (see section 5.1). Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy.Adenocarcinoma of the pancreasLynparza is indicated as:monotherapy for the maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen.Prostate cancerLynparza is indicated as:monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mCRPC in whom chemotherapy is not clinically indicated (see section 5.1).|[PMDA] Drugs with new indications and new dosage for the maintenance treatment of homologous recombination deficiency (HRD)-positive ovarian cancer in patients who have received first chemotherapy including treatment with bevacizumab and the treatment of metastatic, BRCA mutation-positive, castration-resistant prostate cancer. uuid:8e676f8f-c278-493c-bc14-5aed4b9d119d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:83766 biolink:treats MONDO:0004956 PMID:41385096 "[{""id"":""uuid:8642980d-e7a6-412f-91fe-80b67b700999"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f0c2f4f5-3584-4d75-8d47-dc78312030b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:84e2f741-071e-4867-8921-3bd44b29999a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: Ovarian cancer • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA -mutated advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.1 , 2.1 ) • in combination with bevacizumab for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status defined by either: • a deleterious or suspected deleterious BRCA mutation, and/or • genomic instability. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.2 , 2.1 ) • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.3 , 2.1 ) Breast cancer • for the adjuvant treatment of adult patients with deleterious or suspected deleterious g BRCA m human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.4 , 2.1 ) • for the treatment of adult patients with deleterious or suspected deleterious gBRCA m, HER2-negative metastatic breast cancer who have been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.5 , 2.1 ) Pancreatic cancer • for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCA m metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.6 , 2.1 ) Prostate cancer • for the treatment of adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.7 , 2.1 ) • in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA -mutated ( BRCA m) metastatic castration-resistant prostate cancer (mCRPC). Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza. ( 1.8 , 2.1 )|[PMDA] Drugs with a new dosage indicated for the treatment of BRCA mutation-positive, metastatic castration-resistant prostate cancer. uuid:55307c3c-6a82-4bc5-beb4-d2da5c19544f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:93752 biolink:treats UMLS:C3495917 PMID:41385096 "[{""id"":""uuid:c7b7c603-8305-4d74-9684-2ab75a7b7c9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:741d584b-927c-4f4d-b3ae-e17794080c8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PIQRAY is indicated in combination with fulvestrant for the treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen. uuid:93cfca69-0d8c-4528-b21f-c4963381ac55 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:93752 biolink:treats UMLS:C0278488 PMID:41385096 "[{""id"":""uuid:fbfb8b47-185d-4ed9-b971-f65c742b6f1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2b03930d-718d-4b49-8dea-59e9cf56d202"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PIQRAY is indicated in combination with fulvestrant for the treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer as detected by an FDA-approved test following progression on or after an endocrine-based regimen. uuid:6da9e64a-f32e-40d2-8eeb-5cca04240c19 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82701 biolink:treats MONDO:0004948 PMID:41385096 "[{""id"":""uuid:220cf9ed-74e1-487d-855d-0e8c054e4897"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:3db18792-55e3-426a-861f-dcf58dbcdbf3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:dd974f74-8488-4d8f-958d-7515c62496bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zydelig""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Zydelig is indicated, in combination with rituximab, for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL) for whom rituximab alone would be considered appropriate therapy due to other co-morbidities.|[EMA] Zydelig is indicated in combination with an anti‑CD20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (CLL):who have received at least one prior therapy, oras first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies.Zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (FL) that is refractory to two prior lines of treatment. uuid:9178e6c5-d5dd-4a4c-9c9f-6e093232b8f2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82701 biolink:treats UMLS:C0861880 PMID:41385096 "[{""id"":""uuid:0ee5eeed-dd51-4c1a-b850-63897bf35811"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:52b8c0a1-09ab-44c5-abd7-563209897086"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Zydelig is indicated, in combination with rituximab, for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL) for whom rituximab alone would be considered appropriate therapy due to other co-morbidities. uuid:7b403c91-b8a8-452a-a7a7-70d6a0653e92 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:78323835 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:c72d744d-d015-4d7f-a7f8-533faa26e2ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fceacc80-b40e-4542-ad82-cbd35d221485"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:27af2db3-4a57-4573-8614-896555a878f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cibinqo""]},{""id"":""uuid:be8b242a-b564-4558-9be0-0a85a3f79837"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CIBINQO is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.|[EMA] Cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults who are candidates for systemic therapy.|[PMDA] Drugs with a new active ingredient indicated for the treatment of atopic dermatitis in patients who have not responded sufficiently to conventional treatments. uuid:47345fae-796e-40da-8194-4592bc504fde biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229222 biolink:treats UMLS:C3495949 PMID:41385096 "[{""id"":""uuid:22c3ecc0-bf50-49e5-bde6-2315084cb3ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6d78392d-db16-482a-81c6-2591253340b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRUQAP, in combination with fulvestrant, is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN -alteration as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. uuid:334a04a7-33e3-44d8-96bc-319ecaffe802 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229222 biolink:treats UMLS:C0278488 PMID:41385096 "[{""id"":""uuid:3d9ef699-1f88-430c-9f6d-feee15136ad6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:406bbe9b-e6fe-4aee-9660-0eecd5722975"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRUQAP, in combination with fulvestrant, is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN -alteration as detected by an FDA-approved test following progression on at least one endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy. uuid:27a95f84-cdbc-4ec6-9a07-c2837d9abea6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63605 biolink:treats UMLS:C0278488 PMID:41385096 "[{""id"":""uuid:8eab0887-c2df-4b7a-8f63-0882389240b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b2a98d2b-cbb9-4b8c-9f6f-c31fc7018244"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IXEMPRA is indicated in combination with capecitabine for the treatment of patients with metastatic or locally advanced breast cancer resistant to treatment with an anthracycline and a taxane, or whose cancer is taxane resistant and for whom further anthracycline therapy is contraindicated. Anthracycline resistance is defined as progression while on therapy or within 6 months in the adjuvant setting or 3 months in the metastatic setting. Taxane resistance is defined as progression while on therapy or within 12 months in the adjuvant setting or 4 months in the metastatic setting [see Clinical Studies ( 14 )]. IXEMPRA is indicated as a single agent for the treatment of patients with metastatic or locally advanced breast cancer whose tumors are resistant or refractory to anthracyclines, taxanes, and capecitabine [see Clinical Studies ( 14 )]. uuid:2d22df0f-4fb9-470e-96f7-1fac785d47d7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63605 biolink:treats UMLS:C3495949 PMID:41385096 "[{""id"":""uuid:0615fc06-3692-41cf-88b8-3a789f5dc2c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d4d302d5-631f-4e9e-bf9b-60b5d139efdf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IXEMPRA is indicated in combination with capecitabine for the treatment of patients with metastatic or locally advanced breast cancer resistant to treatment with an anthracycline and a taxane, or whose cancer is taxane resistant and for whom further anthracycline therapy is contraindicated. Anthracycline resistance is defined as progression while on therapy or within 6 months in the adjuvant setting or 3 months in the metastatic setting. Taxane resistance is defined as progression while on therapy or within 12 months in the adjuvant setting or 4 months in the metastatic setting [see Clinical Studies ( 14 )]. IXEMPRA is indicated as a single agent for the treatment of patients with metastatic or locally advanced breast cancer whose tumors are resistant or refractory to anthracyclines, taxanes, and capecitabine [see Clinical Studies ( 14 )]. uuid:c0c44966-f590-4d3c-87b2-5d683140d075 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4031 biolink:treats UMLS:C0400968 PMID:41385096 "[{""id"":""uuid:ddc2c2b3-1ccf-46ea-9af8-ba23aa8c6351"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:577ba5f9-a241-4493-9de4-ca264ac8e32b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Cyclosporine capsules, USP MODIFIED are indicated for the prophylaxis of organ rejection in kidney, liver, and heart allogeneic transplants. Cyclosporine capsules, USP MODIFIED have been used in combination with azathioprine and corticosteroids. uuid:c4e89cfd-18e4-46f3-85ac-6113fd8d2498 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1999385 biolink:treats MONDO:0009061 PMID:41385096 "[{""id"":""uuid:1a9f9e2f-a70d-4412-8609-5aa429940bde"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ce46ba15-6a36-43c2-a310-439be82838ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:575a2775-90dc-4d40-ba4a-ea521fd96caa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/symkevi""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] SYMDEKO is indicated for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who are homozygous for the F508del mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator ( CFTR ) gene that is responsive to tezacaftor/ivacaftor based on in vitro data and/or clinical evidence [see Clinical Pharmacology (12.1) and Clinical Studies (14) ] . If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of a CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use.|[EMA] Symkevi is indicated in a combination regimen with ivacaftor tablets for the treatment of patients with cystic fibrosis (CF) aged 6 years and older who are homozygous for the F508del mutation or who are heterozygous for the F508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: P67L, R117C, L206W, R352Q, A455E, D579G, 711+3A→G, S945L, S977F, R1070W, D1152H, 2789+5G→A, 3272 26A→G, and 3849+10kbC→T. uuid:47141517-b997-4d44-9c3c-6e75db292b32 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64318 biolink:treats MONDO:0005277 PMID:41385096 "[{""id"":""uuid:9769c5bc-ce20-482f-9753-6d6ad44d2fa1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c1cd1311-2d28-484a-88c0-32e72902b142"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Ergomar ® is indicated as therapy to abort or prevent vascular headache, e.g., migraine, migraine variants or so-called ""histaminic cephalalgia""." uuid:b2a50c27-02b3-42a1-b2fe-c68079e4b6cb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64318 biolink:treats MONDO:0043537 PMID:41385096 "[{""id"":""uuid:5a36ae35-dfda-4b3a-840f-916f2857cdff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b76b4f18-850e-4562-beeb-d31911e7ea4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Ergomar ® is indicated as therapy to abort or prevent vascular headache, e.g., migraine, migraine variants or so-called ""histaminic cephalalgia""." uuid:a531cc1f-6a5d-49d1-a763-245d5db5d1af biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DEW6X41BEK biolink:treats UMLS:C0406317 PMID:41385096 "[{""id"":""uuid:c845af10-be1f-41cd-a6a3-adb8e774243b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8a6aeddd-b065-48f8-9a3b-c04327391a17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2f518e64-49c9-4f24-b3da-bcf52ec14db9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ILUMYA ® is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.|[PMDA] A drug with a new active ingredient indicated for the treatment of plaque psoriasis in patients who have not responded sufficiently to conventional therapies. uuid:17a81653-2699-4be9-85ea-cb42807b6970 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:0JSR7Z0NB6 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:b3f98f51-f686-4bbb-af82-5d135188ef8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:fac6f455-688f-4013-b429-3ff34fb282bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:afe197f5-b31d-4d2a-bce7-c1418e6f3830"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/rybrevant""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] RYBREVANT is a bispecific EGF receptor-directed and MET receptor-directed antibody indicated: in combination with lazertinib for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test. ( 1 , 2.2 ) in combination with carboplatin and pemetrexed for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R substitution mutations, whose disease has progressed on or after treatment with an EGFR tyrosine kinase inhibitor. ( 1 , 2.2 ) in combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test. ( 1 , 2.2 ) as a single agent for the treatment of adult patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy. ( 1 , 2.2 )|[EMA] Rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) Exon 20 insertion mutations, after failure of platinum-based chemotherapy. uuid:7f4b4067-aac8-4289-80d5-dfc9b666ba85 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8354 biolink:treats MONDO:0029000 PMID:41385096 "[{""id"":""uuid:eda98ca4-e818-4938-8c94-8b3e215730fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:946c30f4-0949-487d-b099-cb4eaa4044b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROTOPAM Chloride is indicated as an antidote: 1. In the treatment of poisoning due to those pesticides and chemicals (e.g., nerve agents) of the organophosphate class which have anticholinesterase activity and 2. In the control of overdosage by anticholinesterase drugs used in the treatment of myasthenia gravis. The principal indications for the use of PROTOPAM Chloride are muscle weakness and respiratory depression. In severe poisoning, respiratory depression may be due to muscle weakness. uuid:b20b7c30-b13d-40a7-86f8-24c0a24bde39 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8354 biolink:treats MONDO:0009688 PMID:41385096 "[{""id"":""uuid:182c04a1-6d4b-4150-a909-06ac84f8fa7c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:992c1ffe-f6ed-482e-990d-1ec17028e6dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROTOPAM Chloride is indicated as an antidote: 1. In the treatment of poisoning due to those pesticides and chemicals (e.g., nerve agents) of the organophosphate class which have anticholinesterase activity and 2. In the control of overdosage by anticholinesterase drugs used in the treatment of myasthenia gravis. The principal indications for the use of PROTOPAM Chloride are muscle weakness and respiratory depression. In severe poisoning, respiratory depression may be due to muscle weakness. uuid:bb1dbceb-52ee-45a7-bbf6-53c74b0fb997 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8354 biolink:treats HP:0001324 PMID:41385096 "[{""id"":""uuid:afd0e30c-51b9-4575-b9ac-148398203f20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7e3de398-eb10-444d-a661-ab87a6e1c24f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROTOPAM Chloride is indicated as an antidote: 1. In the treatment of poisoning due to those pesticides and chemicals (e.g., nerve agents) of the organophosphate class which have anticholinesterase activity and 2. In the control of overdosage by anticholinesterase drugs used in the treatment of myasthenia gravis. The principal indications for the use of PROTOPAM Chloride are muscle weakness and respiratory depression. In severe poisoning, respiratory depression may be due to muscle weakness. uuid:807a4b99-7c41-4518-90d9-82241aa635aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8354 biolink:treats MONDO:0043775 PMID:41385096 "[{""id"":""uuid:c9a554b5-8252-42b4-8ba2-ae24b55d6c95"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f9bdbe35-cd24-428a-8db3-29c7876bc260"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROTOPAM Chloride is indicated as an antidote: 1. In the treatment of poisoning due to those pesticides and chemicals (e.g., nerve agents) of the organophosphate class which have anticholinesterase activity and 2. In the control of overdosage by anticholinesterase drugs used in the treatment of myasthenia gravis. The principal indications for the use of PROTOPAM Chloride are muscle weakness and respiratory depression. In severe poisoning, respiratory depression may be due to muscle weakness. uuid:41b18768-b10b-4e00-bb16-fa6268cdda3d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231087 biolink:treats MONDO:0008433 PMID:41385096 "[{""id"":""uuid:c9802148-e16c-449a-a472-5cd5cd113f8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:871bc51b-5ff4-48fd-b818-6fb745db55d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] COSELA is indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer (ES-SCLC). uuid:51778eb5-2da6-4a25-87a5-9c3abacaef13 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82721 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:b05a9490-41d3-4f9d-8940-64f07b0d4bbf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4116099b-d0db-4951-a522-ffa7d551c61d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:93bf1663-c76f-4832-9089-650c41cef896"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DALVANCE is a lipoglycopeptide antibacterial indicated for the treatment of adult and pediatric patients with acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible strains of Gram-positive microorganisms. ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of DALVANCE and other antibacterial drugs, DALVANCE should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.2 )|[EMA] Treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults. uuid:fe7fbf15-8843-4dc7-a25b-ada353cf8dc2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82721 biolink:treats UMLS:C4552483 PMID:41385096 "[{""id"":""uuid:058d032a-3fde-4a3e-9296-92c4b95ca72b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:bf326b6f-0526-49b3-8974-b64a83a0fd36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:79ffd9f6-b338-4e25-a774-bdbf8495dece"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DALVANCE is a lipoglycopeptide antibacterial indicated for the treatment of adult and pediatric patients with acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible strains of Gram-positive microorganisms. ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of DALVANCE and other antibacterial drugs, DALVANCE should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.2 )|[EMA] Treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults. uuid:3bf6a8ec-9964-4c3c-b18b-842863001174 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90943 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:e19b72f8-70e5-48bb-8570-fbc88540817e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f0240ea7-3559-45ce-970a-1d580b93230e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:919dcc67-cb17-409f-8669-10708b3b3b14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:81ae36a1-8264-4da7-b456-0e924e738887"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TAGRISSO is a kinase inhibitor indicated for: • adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. ( 1.1 , 2.2 ) • the treatment of adult patients with locally advanced, unresectable (stage III) NSCLC whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. ( 1.2 , 2.2 ) • the first-line treatment of adult patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. ( 1.3 , 2.2 ) • in combination with pemetrexed and platinum-based chemotherapy, the first-line treatment of adult patients with locally advanced or metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. ( 1.4 , 2.2 ) • the treatment of adult patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, whose disease has progressed on or after EGFR TKI therapy. ( 1.5 , 2.2 )|[EMA] TAGRISSO as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations- the first-line treatment of adult patients NSCLC with activating EGFR mutations.- the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC.TAGRISSO as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.- the first-line treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR mutations.- the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC.|[PMDA] Drugs with a new active ingredient indicated for the treatment of inoperable or recurrent epidermal growth factor receptor (EGFR) T790M mutation- positive non-small-cell lung cancer with resistance to EGFR tyrosine kinase inhibitors. uuid:a3d6bd96-a1c8-4f06-bcb8-89aa2dfb619c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90943 biolink:treats UMLS:C0278987 PMID:41385096 "[{""id"":""uuid:17c21d73-edd3-472b-b5e2-c7c9ad2b203b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d58458bc-c4d7-4010-a759-b61f3a147eca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TAGRISSO is a kinase inhibitor indicated for: • adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. ( 1.1 , 2.2 ) • the treatment of adult patients with locally advanced, unresectable (stage III) NSCLC whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. ( 1.2 , 2.2 ) • the first-line treatment of adult patients with metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. ( 1.3 , 2.2 ) • in combination with pemetrexed and platinum-based chemotherapy, the first-line treatment of adult patients with locally advanced or metastatic NSCLC whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. ( 1.4 , 2.2 ) • the treatment of adult patients with metastatic EGFR T790M mutation-positive NSCLC, as detected by an FDA-approved test, whose disease has progressed on or after EGFR TKI therapy. ( 1.5 , 2.2 ) uuid:c99a9416-8c72-44ff-a008-84920800d1f0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:RE0V0T1ES0 biolink:treats MONDO:0007027 PMID:41385096 "[{""id"":""uuid:fc104a03-a998-4c9e-85a3-927ac3695d32"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8982ba3b-5df7-4c44-ac59-42a02ed145d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] REZDIFFRA is indicated in conjunction with diet and exercise for the treatment of adults with noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis). This indication is approved under accelerated approval based on improvement of NASH and fibrosis [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. Limitations of Use Avoid use of REZDIFFRA in patients with decompensated cirrhosis [see Use in Specific Populations (8.7) , Clinical Pharmacology (12.3) ] . uuid:0698eb15-f39e-4185-ba11-11c25847be68 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:RE0V0T1ES0 biolink:treats UMLS:C1619727 PMID:41385096 "[{""id"":""uuid:3d33c355-7209-48ef-be01-fd9f7af8252e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cdfb6a29-41a6-4317-8673-2a774459a885"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] REZDIFFRA is indicated in conjunction with diet and exercise for the treatment of adults with noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced liver fibrosis (consistent with stages F2 to F3 fibrosis). This indication is approved under accelerated approval based on improvement of NASH and fibrosis [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. Limitations of Use Avoid use of REZDIFFRA in patients with decompensated cirrhosis [see Use in Specific Populations (8.7) , Clinical Pharmacology (12.3) ] . uuid:d5c3e82d-03e3-44d3-b96a-b9aeae45be64 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:A3ULP0F556 biolink:treats MONDO:0100244 PMID:41385096 "[{""id"":""uuid:16a59ca8-f591-4ca8-bcce-271bfc11db99"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f9d269c0-0b4e-46f5-8dd7-358144e63ef0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b1a08cfa-9679-4c3e-af66-1a08c0cf3077"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/soliris""]},{""id"":""uuid:b11e9c6e-129a-4c09-89fd-7e01f17e17a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BKEMV is a complement inhibitor indicated for: The treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. ( 1.1 ) The treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy. ( 1.2 ) Limitation of Use BKEMV is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS). The treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AchR) antibody positive. ( 1.3 )|[EMA] Soliris is indicated in adults and children for the treatment of:Paroxysmal nocturnal haemoglobinuria (PNH).Evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history (see section 5.1). Atypical haemolytic uremic syndrome (aHUS).Soliris is indicated in adults for the treatment of:Refractory generalized myasthenia gravis (gMG) in patients who are anti-acetylcholine receptor (AChR) antibody-positive (see section 5.1).Neuromyelitis optica spectrum disorder (NMOSD) in patients who are anti-aquaporin-4 (AQP4) antibody-positive with a relapsing course of the disease.|[PMDA] A drug with a new active ingredient indicated to reduce hemolysis in patients with paroxysmal nocturnal hemoglobinuria. [Orphan drug] uuid:92dc411b-b6bd-4dfb-bc3b-74e09fe14f1b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:A3ULP0F556 biolink:treats MONDO:0016244 PMID:41385096 "[{""id"":""uuid:9c4fa0fa-470c-4dd4-a656-e53f5aa2683e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:38147d15-ec17-40db-8352-fb6019f67424"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d793dc39-6cde-4e2d-9b19-deb6b7940cf7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/soliris""]},{""id"":""uuid:fff36b18-02f7-4fa3-9fe7-ec25f8620f3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BKEMV is a complement inhibitor indicated for: The treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. ( 1.1 ) The treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy. ( 1.2 ) Limitation of Use BKEMV is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS). The treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AchR) antibody positive. ( 1.3 )|[EMA] Soliris is indicated in adults and children for the treatment of:Paroxysmal nocturnal haemoglobinuria (PNH).Evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history (see section 5.1). Atypical haemolytic uremic syndrome (aHUS).Soliris is indicated in adults for the treatment of:Refractory generalized myasthenia gravis (gMG) in patients who are anti-acetylcholine receptor (AChR) antibody-positive (see section 5.1).Neuromyelitis optica spectrum disorder (NMOSD) in patients who are anti-aquaporin-4 (AQP4) antibody-positive with a relapsing course of the disease.|[PMDA] A drug with a new additional indication and a new dosage for the treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy. uuid:8230921e-d7fb-425a-b42b-1b6802caa8d9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:A3ULP0F556 biolink:treats MONDO:0009688 PMID:41385096 "[{""id"":""uuid:2b4d08f5-f28a-41f0-8e9f-0d9a8d843931"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6dccd853-936f-4027-ac2d-bf5f22670068"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:477a1d07-6f6c-459a-9801-373251474063"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/soliris""]},{""id"":""uuid:421176f0-39ec-4a95-8c99-b7278333fdcc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BKEMV is a complement inhibitor indicated for: The treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. ( 1.1 ) The treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy. ( 1.2 ) Limitation of Use BKEMV is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS). The treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AchR) antibody positive. ( 1.3 )|[EMA] Soliris is indicated in adults and children for the treatment of:Paroxysmal nocturnal haemoglobinuria (PNH).Evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history (see section 5.1). Atypical haemolytic uremic syndrome (aHUS).Soliris is indicated in adults for the treatment of:Refractory generalized myasthenia gravis (gMG) in patients who are anti-acetylcholine receptor (AChR) antibody-positive (see section 5.1).Neuromyelitis optica spectrum disorder (NMOSD) in patients who are anti-aquaporin-4 (AQP4) antibody-positive with a relapsing course of the disease.|[PMDA] A drug with a new additional pediatric dosage indicated for the treatment of generalized myasthenia gravis (for use only in patients whose symptoms cannot be sufficiently controlled with high-dose intravenous immunoglobulin therapy or plasmapheresis). [Orphan drug] uuid:ecb9d863-a63d-47bd-b8c4-bff5787492d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45367 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:c4f8b4ce-3e77-40c6-93c4-dd9db7de2b43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0d48a655-bfda-4bfe-9fc0-232207d55aa6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Rifabutin capsules USP are indicated for the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection. uuid:9ac91b61-df02-41ac-82b0-c59c8a26d7cd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4735 biolink:treats MONDO:0018019 PMID:41385096 "[{""id"":""uuid:03959991-21c4-4d73-8269-fa9a429f1de5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0b5e287a-1151-42f4-87dc-3081acf56693"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Edetate calcium disodium is indicated for the reduction of blood levels and depot stores of lead in lead poisoning (acute and chronic) and lead encephalopathy, in both pediatric populations and adults. Chelation therapy should not replace effective measures to eliminate or reduce further exposure to lead. uuid:12d3a328-72a8-4546-a02a-7d7ae5a2e424 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4735 biolink:treats UMLS:C0338472 PMID:41385096 "[{""id"":""uuid:3365f606-f80d-4de3-8994-586e6d7cd81c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c3537dc6-0e3b-494f-acd1-701aed8e6c8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Edetate calcium disodium is indicated for the reduction of blood levels and depot stores of lead in lead poisoning (acute and chronic) and lead encephalopathy, in both pediatric populations and adults. Chelation therapy should not replace effective measures to eliminate or reduce further exposure to lead. uuid:afee96c8-823b-4fb6-8a9f-cd4cb19e2b2f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:25E79B5CTM biolink:treats MONDO:0015758 PMID:41385096 "[{""id"":""uuid:03bad62a-d1db-4e23-830a-93d1cfb59499"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2a4d718d-728a-45c3-8c53-c46f011dfbd8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LYMPHIR is indicated for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. uuid:27bde598-2380-4912-9980-1c1bf5cc15ff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:25E79B5CTM biolink:treats MONDO:0009691 PMID:41385096 "[{""id"":""uuid:d599d630-2f3f-4d1c-ab01-898978bea518"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:20b26d06-22b8-4c7a-854f-60a972a8cfb2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LYMPHIR is indicated for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. uuid:69b441fb-f781-4c8c-90fb-d124507740d9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5547273 biolink:treats MONDO:0005011 PMID:41385096 "[{""id"":""uuid:d7af68ea-5b8b-413d-b9e7-d46883723800"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0f569091-a809-4421-ad50-1a855f6866f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CIMZIA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy ( 1.1 ) Treatment of adults with moderately to severely active rheumatoid arthritis ( 1.2 ) Treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older ( 1.3 ) Treatment of adult patients with active psoriatic arthritis. ( 1.4 ) Treatment of adults with active ankylosing spondylitis ( 1.5 ) Treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation ( 1.6 ) Treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy ( 1.7 ) uuid:ee7103b7-3c26-4f17-8aca-2ef77f0614fe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5547273 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:749e6914-6567-44a5-91d7-fd33b945ccdc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:87e2b936-88b0-4e6f-896a-dc257d48b845"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CIMZIA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy ( 1.1 ) Treatment of adults with moderately to severely active rheumatoid arthritis ( 1.2 ) Treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older ( 1.3 ) Treatment of adult patients with active psoriatic arthritis. ( 1.4 ) Treatment of adults with active ankylosing spondylitis ( 1.5 ) Treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation ( 1.6 ) Treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy ( 1.7 ) uuid:038b39dc-2fc4-44d8-bcec-3bdd1d16ffe5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5547273 biolink:treats MONDO:0018456 PMID:41385096 "[{""id"":""uuid:21cdf76c-13f9-476f-8d53-04d6dbbf4354"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:19bf03cd-d3cc-43cb-b6ac-cfea6b7b3e04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CIMZIA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy ( 1.1 ) Treatment of adults with moderately to severely active rheumatoid arthritis ( 1.2 ) Treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older ( 1.3 ) Treatment of adult patients with active psoriatic arthritis. ( 1.4 ) Treatment of adults with active ankylosing spondylitis ( 1.5 ) Treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation ( 1.6 ) Treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy ( 1.7 ) uuid:a654404b-d5ed-4678-b0e9-bd609c6ca32d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5547273 biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:0c9152e0-9896-4516-98a8-29f123f22857"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4fe31c8e-aa64-41f5-aa6f-601f5f292c24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CIMZIA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy ( 1.1 ) Treatment of adults with moderately to severely active rheumatoid arthritis ( 1.2 ) Treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older ( 1.3 ) Treatment of adult patients with active psoriatic arthritis. ( 1.4 ) Treatment of adults with active ankylosing spondylitis ( 1.5 ) Treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation ( 1.6 ) Treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy ( 1.7 ) uuid:a2832015-ba08-42ba-91d0-2fcdb950c647 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5547273 biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:9f7eac5d-980f-48b4-b788-5ad850ebd66e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d74d9729-a5ff-4d9a-a3bb-866c3c81cb34"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CIMZIA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy ( 1.1 ) Treatment of adults with moderately to severely active rheumatoid arthritis ( 1.2 ) Treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older ( 1.3 ) Treatment of adult patients with active psoriatic arthritis. ( 1.4 ) Treatment of adults with active ankylosing spondylitis ( 1.5 ) Treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation ( 1.6 ) Treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy ( 1.7 ) uuid:fe768066-c3b0-4ecf-b613-d9c52f9e71aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5547273 biolink:treats UMLS:C3203547 PMID:41385096 "[{""id"":""uuid:1e3281fd-478b-4746-83cb-1df0a55f0017"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8a24cbe6-bd25-4480-96e2-923ecc316d1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CIMZIA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy ( 1.1 ) Treatment of adults with moderately to severely active rheumatoid arthritis ( 1.2 ) Treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older ( 1.3 ) Treatment of adult patients with active psoriatic arthritis. ( 1.4 ) Treatment of adults with active ankylosing spondylitis ( 1.5 ) Treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation ( 1.6 ) Treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy ( 1.7 ) uuid:120c5bd6-bb35-47ea-9957-63bf6d9bdf2b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5547273 biolink:treats UMLS:C0406317 PMID:41385096 "[{""id"":""uuid:5beb2e36-9c50-41c2-9c62-432ea2ad29a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1a03f4c8-9991-463a-afa6-83b4ad865029"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CIMZIA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy ( 1.1 ) Treatment of adults with moderately to severely active rheumatoid arthritis ( 1.2 ) Treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older ( 1.3 ) Treatment of adult patients with active psoriatic arthritis. ( 1.4 ) Treatment of adults with active ankylosing spondylitis ( 1.5 ) Treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation ( 1.6 ) Treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy ( 1.7 ) uuid:b8a166cf-cef4-4ba3-9773-0132f04999a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:0K5743G68X biolink:treats MONDO:0013600 PMID:41385096 "[{""id"":""uuid:44b959ef-e493-4f8d-8c33-6866959808e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0c71d26d-2e23-449e-947a-8e2a8cc8fc15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:40d3cf54-5bb3-4568-b2dd-c59288fd1806"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DAYVIGO is indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance [see Clinical Studies ( 14.1 )] .|[PMDA] Drugs with a new active ingredient indicated for the treatment of insomnia. uuid:00967013-2d91-4545-bc43-5d48036ef6e9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:230905 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:100d9c0e-30a0-4d98-b51d-0cc9e9018049"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b2e52306-7459-4ecb-a1da-233d4203a3c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KISQALI is a kinase inhibitor indicated: in combination with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence. ( 1 ) for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer in combination with: an aromatase inhibitor as initial endocrine-based therapy; or fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy. ( 1 ) uuid:52f45c6b-8cff-4f75-9602-df8ee4246ea5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:230905 biolink:treats UMLS:C3495917 PMID:41385096 "[{""id"":""uuid:b638b17f-ad19-433d-82b8-7c5a87998fe7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3c66734b-0161-4280-b2b6-39029ac123fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KISQALI is a kinase inhibitor indicated: in combination with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence. ( 1 ) for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer in combination with: an aromatase inhibitor as initial endocrine-based therapy; or fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy. ( 1 ) uuid:23b579aa-287f-42d1-9173-9ddcc4d2b67c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:230905 biolink:treats UMLS:C0278488 PMID:41385096 "[{""id"":""uuid:208f019c-ca05-4e83-8254-719f67a773c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b0c97185-2c6e-4640-9254-5fd7232162db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KISQALI is a kinase inhibitor indicated: in combination with an aromatase inhibitor for the adjuvant treatment of adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative stage II and III early breast cancer at high risk of recurrence. ( 1 ) for the treatment of adults with HR-positive, HER2-negative advanced or metastatic breast cancer in combination with: an aromatase inhibitor as initial endocrine-based therapy; or fulvestrant as initial endocrine-based therapy or following disease progression on endocrine therapy. ( 1 ) uuid:3fe52d9b-98d4-4d5f-a44f-8515a11db421 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27363 biolink:treats MONDO:0010200 PMID:41385096 "[{""id"":""uuid:6c784561-1f36-47f9-90d7-53f14a929317"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4d2d1b14-d96f-4575-951d-efaa3a8010e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:55457de7-c29e-4e7e-8309-755c0a0850ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/wilzin""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Zinc acetate therapy is indicated for maintenance treatment of patients with Wilson’s disease who have been initially treated with a chelating agent (See PRECAUTIONS: Monitoring Patients ).|[EMA] Treatment of Wilson's disease. uuid:3a6b0f9a-8dda-40e8-a840-f20d1e867139 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1651267 biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:8c817557-cd25-450f-af1c-597ed4f16ab3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7f18d956-e7f8-468f-b2df-f5903e26047a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] STIOLTO RESPIMAT is a combination of tiotropium bromide, an anticholinergic and olodaterol, a long-acting beta 2 -adrenergic agonist (LABA) indicated for the long-term, once-daily maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). ( 1.1 ) Important limitations: STIOLTO RESPIMAT is NOT indicated to treat acute deterioration of COPD. ( 1.1 ) STIOLTO RESPIMAT is NOT indicated to treat asthma. ( 1.1 ) uuid:d6e0a6ef-a591-4855-ab18-42af9b649ffb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1651267 biolink:treats MONDO:0011751 PMID:41385096 "[{""id"":""uuid:22f1db6a-2b2a-4852-bd35-b5317d1e2cdc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5173ce72-94b2-4c5f-9da2-e5e741814e63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] STIOLTO RESPIMAT is a combination of tiotropium bromide, an anticholinergic and olodaterol, a long-acting beta 2 -adrenergic agonist (LABA) indicated for the long-term, once-daily maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). ( 1.1 ) Important limitations: STIOLTO RESPIMAT is NOT indicated to treat acute deterioration of COPD. ( 1.1 ) STIOLTO RESPIMAT is NOT indicated to treat asthma. ( 1.1 ) uuid:985d9f65-1c77-4e21-8091-b594ff9d8649 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1651267 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:5a4a382c-2b7f-4b0b-ada9-dc22bb191447"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:10f9ab88-5837-49d0-bbc1-de87bed4a30c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] STIOLTO RESPIMAT is a combination of tiotropium bromide, an anticholinergic and olodaterol, a long-acting beta 2 -adrenergic agonist (LABA) indicated for the long-term, once-daily maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). ( 1.1 ) Important limitations: STIOLTO RESPIMAT is NOT indicated to treat acute deterioration of COPD. ( 1.1 ) STIOLTO RESPIMAT is NOT indicated to treat asthma. ( 1.1 ) uuid:d364af5d-4085-4749-bfe3-7cce8b09bb5a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5971 biolink:treats UMLS:C0861727 PMID:41385096 "[{""id"":""uuid:111759b4-0d5b-446b-bc0e-f3a068de2126"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d0dc21ed-8f94-4314-9e66-ff235616aede"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ONIVYDE is indicated, in combination with oxaliplatin, fluorouracil and leucovorin for the first-line treatment of adult patients with metastatic pancreatic adenocarcinoma. ONIVYDE is indicated, in combination with fluorouracil and leucovorin, for the treatment of adult patients with metastatic pancreatic adenocarcinoma after disease progression following gemcitabine-based therapy. Limitations of Use: ONIVYDE is not indicated as a single agent for the treatment of patients with metastatic pancreatic adenocarcinoma. [see Clinical Studies (14) ] . uuid:a3eb06c6-a981-45eb-a535-1d90bfea381b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6D5766Q4OP biolink:treats MONDO:0100464 PMID:41385096 "[{""id"":""uuid:a50234c5-042e-45a0-8f7f-a7e1b8173eb5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a5d91a50-4378-4230-bc53-e87bfe5f7c2b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:efcca01c-5fb3-4ba0-adc1-ec6c5516dbec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/xenpozyme""]},{""id"":""uuid:704e39e6-3e7e-4005-aad5-b9c9ef440025"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XENPOZYME is indicated for treatment of non–central nervous system manifestations of acid sphingomyelinase deficiency (ASMD) in adult and pediatric patients.|[EMA] Xenpozyme is indicated as an enzyme replacement therapy for the treatment of non-Central Nervous System (CNS) manifestations of Acid Sphingomyelinase Deficiency (ASMD) in paediatric and adult patients with type A/B or type B.|[PMDA] A drug with a new active ingredient indicated for the treatment of acid sphingomyelinase deficiency. [SAKIGAKE designation, orphan drug] uuid:bb2a4456-e86e-4444-b01a-17de3dbf2dc8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45951 biolink:treats UMLS:C0235136 PMID:41385096 "[{""id"":""uuid:9dc5d98f-303c-4e20-85a1-9eeae84747f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3d1dd4f5-f593-4948-bd92-11f3366a9aa4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] For the management of schizophrenia. Trifluoperazine hydrochloride tablets, USP are effective for the short-term treatment of generalized non-psychotic anxiety. However, trifluoperazine hydrochloride tablets are not the first drug to be used in therapy for most patients with non-psychotic anxiety because certain risks associated with its use are not shared by common alternative treatments (i.e., benzodiazepines). When used in the treatment of non-psychotic anxiety, trifluoperazine hydrochloride tablets should not be administered at doses of more than 6 mg per day or for longer than 12 weeks because the use of trifluoperazine hydrochloride tablets at higher doses or for longer intervals may cause persistent tardive dyskinesia that may prove irreversible (see WARNINGS ). The effectiveness of trifluoperazine hydrochloride tablets as a treatment for non-psychotic anxiety was established in a 4-week clinical multicenter study of outpatients with generalized anxiety disorder (DSM-III). This evidence does not predict that trifluoperazine hydrochloride tablets will be useful in patients with other non-psychotic conditions in which anxiety, or signs that mimic anxiety, are found (i.e., physical illness, organic mental conditions, agitated depression, character pathologies, etc.). Trifluoperazine hydrochloride tablets have not been shown effective in the management of behavioral complications in patients with mental retardation. uuid:b0769c48-f6cc-41de-830e-eed73e9011a2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71200 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:1210682e-ba37-4776-8b5b-63ed1e50691e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9e5cc6af-e81f-431b-ae0b-2c9587842e90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1a15fe6e-88d7-43cf-adb1-15dac9037444"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XELJANZ/XELJANZ XR/XELJANZ Oral Solution is a Janus kinase (JAK) inhibitor indicated for: • Rheumatoid Arthritis : XELJANZ/XELJANZ XR is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers. o Limitations of Use: Use of XELJANZ/XELJANZ XR in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine is not recommended. ( 1.1 ) • Psoriatic Arthritis : XELJANZ/XELJANZ XR is indicated for the treatment of adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. o Limitations of Use: Use of XELJANZ/XELJANZ XR in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine is not recommended. ( 1.2 ) • Ankylosing Spondylitis : XELJANZ/XELJANZ XR is indicated for the treatment of adult patients with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers. o Limitations of Use: Use of XELJANZ/XELJANZ XR in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine is not recommended. ( 1.3 ) • Ulcerative Colitis : XELJANZ/XELJANZ XR is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC), who have had an inadequate response or intolerance to one or more TNF blockers. o Limitations of Use: Use of XELJANZ/XELJANZ XR in combination with biological therapies for UC or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended. ( 1.4 ) • Polyarticular Course Juvenile Idiopathic Arthritis : XELJANZ/XELJANZ Oral Solution is indicated for the treatment of active polyarticular course juvenile idiopathic arthritis (pcJIA) in patients 2 years of age and older who have had an inadequate response or intolerance to one or more TNF blockers. o Limitations of Use: Use of XELJANZ/XELJANZ Oral Solution in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine is not recommended. ( 1.5 )|[PMDA] A drug with a new active ingredient for the treatment of rheumatoid arthritis in patients who have not sufficiently responded to conventional treatments. uuid:b8110e04-c8bd-486c-8806-a33b8303eef6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71200 biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:e21363b7-a2e0-4b61-a3b5-373b5915ee73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b87430b7-6d5c-48cc-8a47-af01506cd264"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XELJANZ/XELJANZ XR/XELJANZ Oral Solution is a Janus kinase (JAK) inhibitor indicated for: • Rheumatoid Arthritis : XELJANZ/XELJANZ XR is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers. o Limitations of Use: Use of XELJANZ/XELJANZ XR in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine is not recommended. ( 1.1 ) • Psoriatic Arthritis : XELJANZ/XELJANZ XR is indicated for the treatment of adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. o Limitations of Use: Use of XELJANZ/XELJANZ XR in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine is not recommended. ( 1.2 ) • Ankylosing Spondylitis : XELJANZ/XELJANZ XR is indicated for the treatment of adult patients with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers. o Limitations of Use: Use of XELJANZ/XELJANZ XR in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine is not recommended. ( 1.3 ) • Ulcerative Colitis : XELJANZ/XELJANZ XR is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC), who have had an inadequate response or intolerance to one or more TNF blockers. o Limitations of Use: Use of XELJANZ/XELJANZ XR in combination with biological therapies for UC or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended. ( 1.4 ) • Polyarticular Course Juvenile Idiopathic Arthritis : XELJANZ/XELJANZ Oral Solution is indicated for the treatment of active polyarticular course juvenile idiopathic arthritis (pcJIA) in patients 2 years of age and older who have had an inadequate response or intolerance to one or more TNF blockers. o Limitations of Use: Use of XELJANZ/XELJANZ Oral Solution in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine is not recommended. ( 1.5 ) uuid:32d779a5-6e8f-495f-9801-10034470428c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71200 biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:9748d348-ba73-48e2-aa68-9b3bc436a27a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aebdc8ea-a108-48d9-92fa-323226840b20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XELJANZ/XELJANZ XR/XELJANZ Oral Solution is a Janus kinase (JAK) inhibitor indicated for: • Rheumatoid Arthritis : XELJANZ/XELJANZ XR is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers. o Limitations of Use: Use of XELJANZ/XELJANZ XR in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine is not recommended. ( 1.1 ) • Psoriatic Arthritis : XELJANZ/XELJANZ XR is indicated for the treatment of adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. o Limitations of Use: Use of XELJANZ/XELJANZ XR in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine is not recommended. ( 1.2 ) • Ankylosing Spondylitis : XELJANZ/XELJANZ XR is indicated for the treatment of adult patients with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers. o Limitations of Use: Use of XELJANZ/XELJANZ XR in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine is not recommended. ( 1.3 ) • Ulcerative Colitis : XELJANZ/XELJANZ XR is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC), who have had an inadequate response or intolerance to one or more TNF blockers. o Limitations of Use: Use of XELJANZ/XELJANZ XR in combination with biological therapies for UC or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended. ( 1.4 ) • Polyarticular Course Juvenile Idiopathic Arthritis : XELJANZ/XELJANZ Oral Solution is indicated for the treatment of active polyarticular course juvenile idiopathic arthritis (pcJIA) in patients 2 years of age and older who have had an inadequate response or intolerance to one or more TNF blockers. o Limitations of Use: Use of XELJANZ/XELJANZ Oral Solution in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine is not recommended. ( 1.5 ) uuid:96e044c8-1346-4dcc-9530-707e3d0e0f5b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71200 biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:00f53f98-5dc2-4af9-abc6-1c55573700e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:68439dcd-c9ad-48a5-aefd-d264e66ba191"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:6575157d-9b7a-47b8-a6aa-f73bbe0cfd2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XELJANZ/XELJANZ XR/XELJANZ Oral Solution is a Janus kinase (JAK) inhibitor indicated for: • Rheumatoid Arthritis : XELJANZ/XELJANZ XR is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers. o Limitations of Use: Use of XELJANZ/XELJANZ XR in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine is not recommended. ( 1.1 ) • Psoriatic Arthritis : XELJANZ/XELJANZ XR is indicated for the treatment of adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. o Limitations of Use: Use of XELJANZ/XELJANZ XR in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine is not recommended. ( 1.2 ) • Ankylosing Spondylitis : XELJANZ/XELJANZ XR is indicated for the treatment of adult patients with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers. o Limitations of Use: Use of XELJANZ/XELJANZ XR in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine is not recommended. ( 1.3 ) • Ulcerative Colitis : XELJANZ/XELJANZ XR is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC), who have had an inadequate response or intolerance to one or more TNF blockers. o Limitations of Use: Use of XELJANZ/XELJANZ XR in combination with biological therapies for UC or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended. ( 1.4 ) • Polyarticular Course Juvenile Idiopathic Arthritis : XELJANZ/XELJANZ Oral Solution is indicated for the treatment of active polyarticular course juvenile idiopathic arthritis (pcJIA) in patients 2 years of age and older who have had an inadequate response or intolerance to one or more TNF blockers. o Limitations of Use: Use of XELJANZ/XELJANZ Oral Solution in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine is not recommended. ( 1.5 )|[PMDA] A drug with a new additional indication and a new dosage for the remission induction and maintenance therapy of moderate to severe ulcerative colitis (for use only in patients who have not sufficiently responded to conventional treatments). uuid:197df988-904e-44b5-b2b5-4548d008a101 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71200 biolink:treats MONDO:0018456 PMID:41385096 "[{""id"":""uuid:f2fc20fc-0ddd-424b-9557-03916bbeabd5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d15da9fe-59c0-4dff-a328-bccd614adfd2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XELJANZ/XELJANZ XR/XELJANZ Oral Solution is a Janus kinase (JAK) inhibitor indicated for: • Rheumatoid Arthritis : XELJANZ/XELJANZ XR is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers. o Limitations of Use: Use of XELJANZ/XELJANZ XR in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine is not recommended. ( 1.1 ) • Psoriatic Arthritis : XELJANZ/XELJANZ XR is indicated for the treatment of adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. o Limitations of Use: Use of XELJANZ/XELJANZ XR in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine is not recommended. ( 1.2 ) • Ankylosing Spondylitis : XELJANZ/XELJANZ XR is indicated for the treatment of adult patients with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers. o Limitations of Use: Use of XELJANZ/XELJANZ XR in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine is not recommended. ( 1.3 ) • Ulcerative Colitis : XELJANZ/XELJANZ XR is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC), who have had an inadequate response or intolerance to one or more TNF blockers. o Limitations of Use: Use of XELJANZ/XELJANZ XR in combination with biological therapies for UC or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended. ( 1.4 ) • Polyarticular Course Juvenile Idiopathic Arthritis : XELJANZ/XELJANZ Oral Solution is indicated for the treatment of active polyarticular course juvenile idiopathic arthritis (pcJIA) in patients 2 years of age and older who have had an inadequate response or intolerance to one or more TNF blockers. o Limitations of Use: Use of XELJANZ/XELJANZ Oral Solution in combination with biologic DMARDs or potent immunosuppressants such as azathioprine and cyclosporine is not recommended. ( 1.5 ) uuid:d9d79840-bbbd-4cd5-86c9-3b524da5a70c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:94759 biolink:treats MONDO:0004668 PMID:41385096 "[{""id"":""uuid:523558a7-5fc8-4750-9002-705026cdfb38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a47852ca-30fd-4b7c-9832-8749be640dbd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EGATEN ® is indicated for the treatment of fascioliasis in patients 6 years of age and older. uuid:495e5b4e-3291-457b-af95-99b264d8145a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133833 biolink:treats MONDO:0001444 PMID:41385096 "[{""id"":""uuid:9edce865-cb07-4705-a626-7fc47a1bc613"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e5e69558-633f-4a6c-b65a-2e68a6139960"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Benznidazole Tablets are indicated in pediatric patients 2 to 12 years of age for the treatment of Chagas disease (American trypanosomiasis) caused by Trypanosoma cruzi . This indication is approved under accelerated approval based on the number of treated patients who became Immunoglobulin G (IgG) antibody negative against the recombinant antigens of T. cruzi [see Clinical Studies ( 14 )] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. uuid:28c52832-2ba1-44b6-a003-eac7731601c6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3934EF02T7 biolink:treats MONDO:0008315 PMID:41385096 "[{""id"":""uuid:04e345cd-7645-4c5a-84c6-31d844d19e9d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:237aee88-0076-43e1-ae2f-9d4a0d7ea97e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:df29e42d-4636-4b5a-be71-cc0d902ff69b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PYLARIFY is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy. with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level.|[EMA] This medicinal product is for diagnostic use only.Pylclari is indicated for the detection of prostate-specific membrane antigen (PSMA) positive lesions with positron emission tomography (PET) in adults with prostate cancer (PCa) in the following clinical settings:Primary staging of patients with high-risk PCa prior to initial curative therapy,To localize recurrence of PCa in patients with a suspected recurrence based on increasing serum prostate-specific antigen (PSA) levels after primary treatment with curative intent.Pylclari is indicated for use with positron emission tomography (PET). uuid:325e4c90-a584-410c-96f0-0c039b1e521a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3892 biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:74a6e4f2-8749-4934-9cc3-352eaf8ae76c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8f225419-c2da-4872-bd38-d4b4672a72b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Purified Cortrophin Gel is indicated in the following disorders: 1. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Ankylosing spondylitis. Acute gouty arthritis. 2. Collagen diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Systemic dermatomyositis (polymyositis). 3. Dermatologic diseases: Severe erythema multiforme (Stevens-Johnson syndrome). Severe psoriasis. 4. Allergic states: Atopic dermatitis Serum sickness. 5. Ophthalmic diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis. Keratitis. Iritis and iridocyclitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Chorioretinitis. Anterior segment inflammation. 6. Respiratory diseases: Symptomatic sarcoidosis. 7. Edematous states: To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus. 8. Nervous system: Acute exacerbations of multiple sclerosis. uuid:4a5986ec-0e3b-401d-83bc-4dba9a65ce8b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3892 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:e5d58f10-f784-4936-b84d-2deff0a7c483"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:684338a3-6c50-4cf5-97c9-1bd0f11f3010"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Purified Cortrophin Gel is indicated in the following disorders: 1. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Ankylosing spondylitis. Acute gouty arthritis. 2. Collagen diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Systemic dermatomyositis (polymyositis). 3. Dermatologic diseases: Severe erythema multiforme (Stevens-Johnson syndrome). Severe psoriasis. 4. Allergic states: Atopic dermatitis Serum sickness. 5. Ophthalmic diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis. Keratitis. Iritis and iridocyclitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Chorioretinitis. Anterior segment inflammation. 6. Respiratory diseases: Symptomatic sarcoidosis. 7. Edematous states: To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus. 8. Nervous system: Acute exacerbations of multiple sclerosis. uuid:8c7815e3-95e0-43f4-bbc3-28c1a2220c14 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3892 biolink:treats MONDO:0011429 PMID:41385096 "[{""id"":""uuid:098558aa-f6d2-45c8-9586-7b534fa63a3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c24d727a-e535-41ab-8b95-01c003d2c435"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Purified Cortrophin Gel is indicated in the following disorders: 1. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Ankylosing spondylitis. Acute gouty arthritis. 2. Collagen diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Systemic dermatomyositis (polymyositis). 3. Dermatologic diseases: Severe erythema multiforme (Stevens-Johnson syndrome). Severe psoriasis. 4. Allergic states: Atopic dermatitis Serum sickness. 5. Ophthalmic diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis. Keratitis. Iritis and iridocyclitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Chorioretinitis. Anterior segment inflammation. 6. Respiratory diseases: Symptomatic sarcoidosis. 7. Edematous states: To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus. 8. Nervous system: Acute exacerbations of multiple sclerosis. uuid:c1cca079-1142-4bac-87b4-0ec5ca1f0493 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3892 biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:b6b99004-e871-4700-a0a1-526b40e1f753"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:999cee8b-d0ef-4951-8cab-789d197fae33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Purified Cortrophin Gel is indicated in the following disorders: 1. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Ankylosing spondylitis. Acute gouty arthritis. 2. Collagen diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Systemic dermatomyositis (polymyositis). 3. Dermatologic diseases: Severe erythema multiforme (Stevens-Johnson syndrome). Severe psoriasis. 4. Allergic states: Atopic dermatitis Serum sickness. 5. Ophthalmic diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis. Keratitis. Iritis and iridocyclitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Chorioretinitis. Anterior segment inflammation. 6. Respiratory diseases: Symptomatic sarcoidosis. 7. Edematous states: To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus. 8. Nervous system: Acute exacerbations of multiple sclerosis. uuid:e839dbb0-3031-42d4-acf9-dab8eaf8e46c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3892 biolink:treats UMLS:C0149896 PMID:41385096 "[{""id"":""uuid:c69cf359-5151-487c-a993-da513c2ad083"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f45fa98b-5554-4814-9700-50b9881d146b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Purified Cortrophin Gel is indicated in the following disorders: 1. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Ankylosing spondylitis. Acute gouty arthritis. 2. Collagen diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Systemic dermatomyositis (polymyositis). 3. Dermatologic diseases: Severe erythema multiforme (Stevens-Johnson syndrome). Severe psoriasis. 4. Allergic states: Atopic dermatitis Serum sickness. 5. Ophthalmic diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis. Keratitis. Iritis and iridocyclitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Chorioretinitis. Anterior segment inflammation. 6. Respiratory diseases: Symptomatic sarcoidosis. 7. Edematous states: To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus. 8. Nervous system: Acute exacerbations of multiple sclerosis. uuid:2826ddb5-87a2-4bd7-9898-c5858b8924c2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3892 biolink:treats MONDO:0016367 PMID:41385096 "[{""id"":""uuid:91fe4a82-75e8-47fc-a0e9-7a9d9aa0644a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:78d4b4b6-ab36-4f72-ab89-c72146dd3e30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Purified Cortrophin Gel is indicated in the following disorders: 1. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Ankylosing spondylitis. Acute gouty arthritis. 2. Collagen diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Systemic dermatomyositis (polymyositis). 3. Dermatologic diseases: Severe erythema multiforme (Stevens-Johnson syndrome). Severe psoriasis. 4. Allergic states: Atopic dermatitis Serum sickness. 5. Ophthalmic diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis. Keratitis. Iritis and iridocyclitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Chorioretinitis. Anterior segment inflammation. 6. Respiratory diseases: Symptomatic sarcoidosis. 7. Edematous states: To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus. 8. Nervous system: Acute exacerbations of multiple sclerosis. uuid:f5217401-6555-4e7b-8a5b-11e141c77329 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3892 biolink:treats MONDO:0019127 PMID:41385096 "[{""id"":""uuid:d6d33c97-ec19-4e2e-9d81-d94ed511b837"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:371a7a04-7007-4c8a-a907-2e84f7e50630"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Purified Cortrophin Gel is indicated in the following disorders: 1. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Ankylosing spondylitis. Acute gouty arthritis. 2. Collagen diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Systemic dermatomyositis (polymyositis). 3. Dermatologic diseases: Severe erythema multiforme (Stevens-Johnson syndrome). Severe psoriasis. 4. Allergic states: Atopic dermatitis Serum sickness. 5. Ophthalmic diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis. Keratitis. Iritis and iridocyclitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Chorioretinitis. Anterior segment inflammation. 6. Respiratory diseases: Symptomatic sarcoidosis. 7. Edematous states: To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus. 8. Nervous system: Acute exacerbations of multiple sclerosis. uuid:cc735f55-4500-4ab9-949e-a7be25d9b9f3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3892 biolink:treats MONDO:0006545 PMID:41385096 "[{""id"":""uuid:44207513-e07f-4fb9-878b-dc7dd1a4e68c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a9c2e414-cb4f-44fc-9647-a048f8d9d50e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Purified Cortrophin Gel is indicated in the following disorders: 1. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Ankylosing spondylitis. Acute gouty arthritis. 2. Collagen diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Systemic dermatomyositis (polymyositis). 3. Dermatologic diseases: Severe erythema multiforme (Stevens-Johnson syndrome). Severe psoriasis. 4. Allergic states: Atopic dermatitis Serum sickness. 5. Ophthalmic diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis. Keratitis. Iritis and iridocyclitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Chorioretinitis. Anterior segment inflammation. 6. Respiratory diseases: Symptomatic sarcoidosis. 7. Edematous states: To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus. 8. Nervous system: Acute exacerbations of multiple sclerosis. uuid:ef614608-96ca-49c0-a482-b1519cf3357d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3892 biolink:treats MONDO:0018229 PMID:41385096 "[{""id"":""uuid:2299b582-0cb1-4586-b2e2-345b682957a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:35503677-e81b-496b-9104-ea593e37bd84"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Purified Cortrophin Gel is indicated in the following disorders: 1. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Ankylosing spondylitis. Acute gouty arthritis. 2. Collagen diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Systemic dermatomyositis (polymyositis). 3. Dermatologic diseases: Severe erythema multiforme (Stevens-Johnson syndrome). Severe psoriasis. 4. Allergic states: Atopic dermatitis Serum sickness. 5. Ophthalmic diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis. Keratitis. Iritis and iridocyclitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Chorioretinitis. Anterior segment inflammation. 6. Respiratory diseases: Symptomatic sarcoidosis. 7. Edematous states: To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus. 8. Nervous system: Acute exacerbations of multiple sclerosis. uuid:3ded3206-40c2-4646-a1d6-d77a6cbec073 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3892 biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:1fef4c43-a22d-44a8-a43d-c866d0045a0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1d004c2c-33c9-4c50-a3cf-a6dcad9e26a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Purified Cortrophin Gel is indicated in the following disorders: 1. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Ankylosing spondylitis. Acute gouty arthritis. 2. Collagen diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Systemic dermatomyositis (polymyositis). 3. Dermatologic diseases: Severe erythema multiforme (Stevens-Johnson syndrome). Severe psoriasis. 4. Allergic states: Atopic dermatitis Serum sickness. 5. Ophthalmic diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis. Keratitis. Iritis and iridocyclitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Chorioretinitis. Anterior segment inflammation. 6. Respiratory diseases: Symptomatic sarcoidosis. 7. Edematous states: To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus. 8. Nervous system: Acute exacerbations of multiple sclerosis. uuid:ab885def-16a5-4f69-998f-7c3e5079e3c3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3892 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:7b0409a0-b9f3-47ed-b8da-6b8a07b92ec0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:076b0a63-388c-4d0e-a252-5de93a2c2a9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Purified Cortrophin Gel is indicated in the following disorders: 1. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Ankylosing spondylitis. Acute gouty arthritis. 2. Collagen diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Systemic dermatomyositis (polymyositis). 3. Dermatologic diseases: Severe erythema multiforme (Stevens-Johnson syndrome). Severe psoriasis. 4. Allergic states: Atopic dermatitis Serum sickness. 5. Ophthalmic diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis. Keratitis. Iritis and iridocyclitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Chorioretinitis. Anterior segment inflammation. 6. Respiratory diseases: Symptomatic sarcoidosis. 7. Edematous states: To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus. 8. Nervous system: Acute exacerbations of multiple sclerosis. uuid:e81b26ee-219f-4f51-a925-f7d81707e0e2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3892 biolink:treats MONDO:0043789 PMID:41385096 "[{""id"":""uuid:6e820852-c436-448c-aa83-35a866b4b6f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3398be56-8619-4479-9dc7-afb3f85f6bae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Purified Cortrophin Gel is indicated in the following disorders: 1. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Ankylosing spondylitis. Acute gouty arthritis. 2. Collagen diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Systemic dermatomyositis (polymyositis). 3. Dermatologic diseases: Severe erythema multiforme (Stevens-Johnson syndrome). Severe psoriasis. 4. Allergic states: Atopic dermatitis Serum sickness. 5. Ophthalmic diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis. Keratitis. Iritis and iridocyclitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Chorioretinitis. Anterior segment inflammation. 6. Respiratory diseases: Symptomatic sarcoidosis. 7. Edematous states: To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus. 8. Nervous system: Acute exacerbations of multiple sclerosis. uuid:f0e419ef-e46e-431f-bfd3-539ccdfc5dbb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3892 biolink:treats MONDO:0003085 PMID:41385096 "[{""id"":""uuid:254200ae-c2ef-4c97-960b-9a2496a8eb5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:38a7a37e-b326-46e5-9f5c-371eb6cb2234"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Purified Cortrophin Gel is indicated in the following disorders: 1. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Ankylosing spondylitis. Acute gouty arthritis. 2. Collagen diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Systemic dermatomyositis (polymyositis). 3. Dermatologic diseases: Severe erythema multiforme (Stevens-Johnson syndrome). Severe psoriasis. 4. Allergic states: Atopic dermatitis Serum sickness. 5. Ophthalmic diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis. Keratitis. Iritis and iridocyclitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Chorioretinitis. Anterior segment inflammation. 6. Respiratory diseases: Symptomatic sarcoidosis. 7. Edematous states: To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus. 8. Nervous system: Acute exacerbations of multiple sclerosis. uuid:641e01e4-5c34-434e-98cb-33ee0588e756 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3892 biolink:treats MONDO:0004773 PMID:41385096 "[{""id"":""uuid:c9b480d3-6161-4767-a715-ccb2b0741d36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1c4988f2-e06e-4d22-9f8c-8fe802b06433"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Purified Cortrophin Gel is indicated in the following disorders: 1. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Ankylosing spondylitis. Acute gouty arthritis. 2. Collagen diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Systemic dermatomyositis (polymyositis). 3. Dermatologic diseases: Severe erythema multiforme (Stevens-Johnson syndrome). Severe psoriasis. 4. Allergic states: Atopic dermatitis Serum sickness. 5. Ophthalmic diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis. Keratitis. Iritis and iridocyclitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Chorioretinitis. Anterior segment inflammation. 6. Respiratory diseases: Symptomatic sarcoidosis. 7. Edematous states: To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus. 8. Nervous system: Acute exacerbations of multiple sclerosis. uuid:fd38be6c-62ed-4b9c-8c75-7d9161522b7b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3892 biolink:treats MONDO:0006918 PMID:41385096 "[{""id"":""uuid:0f657ea8-d484-4220-a36e-eebc3f6ac309"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:45e0f7b5-22ca-4ff3-ba38-7e71b7c3065f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Purified Cortrophin Gel is indicated in the following disorders: 1. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Ankylosing spondylitis. Acute gouty arthritis. 2. Collagen diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Systemic dermatomyositis (polymyositis). 3. Dermatologic diseases: Severe erythema multiforme (Stevens-Johnson syndrome). Severe psoriasis. 4. Allergic states: Atopic dermatitis Serum sickness. 5. Ophthalmic diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis. Keratitis. Iritis and iridocyclitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Chorioretinitis. Anterior segment inflammation. 6. Respiratory diseases: Symptomatic sarcoidosis. 7. Edematous states: To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus. 8. Nervous system: Acute exacerbations of multiple sclerosis. uuid:ddf52118-c768-40ba-a334-646fbdb5c3b8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3892 biolink:treats MONDO:0001280 PMID:41385096 "[{""id"":""uuid:5b457386-9ea8-41b4-8c2e-008119f0df6c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fd231c65-b696-4402-aabd-3dce67a6d4ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Purified Cortrophin Gel is indicated in the following disorders: 1. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Ankylosing spondylitis. Acute gouty arthritis. 2. Collagen diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Systemic dermatomyositis (polymyositis). 3. Dermatologic diseases: Severe erythema multiforme (Stevens-Johnson syndrome). Severe psoriasis. 4. Allergic states: Atopic dermatitis Serum sickness. 5. Ophthalmic diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis. Keratitis. Iritis and iridocyclitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Chorioretinitis. Anterior segment inflammation. 6. Respiratory diseases: Symptomatic sarcoidosis. 7. Edematous states: To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus. 8. Nervous system: Acute exacerbations of multiple sclerosis. uuid:0a8e2510-b7fc-4dbd-b0b5-e716ce3adb18 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3892 biolink:treats MONDO:0005885 PMID:41385096 "[{""id"":""uuid:3c74c047-21e9-4e9b-8655-3ced5f89c26a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6103849e-e008-4224-96b4-f2f5895c9705"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Purified Cortrophin Gel is indicated in the following disorders: 1. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Ankylosing spondylitis. Acute gouty arthritis. 2. Collagen diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Systemic dermatomyositis (polymyositis). 3. Dermatologic diseases: Severe erythema multiforme (Stevens-Johnson syndrome). Severe psoriasis. 4. Allergic states: Atopic dermatitis Serum sickness. 5. Ophthalmic diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis. Keratitis. Iritis and iridocyclitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Chorioretinitis. Anterior segment inflammation. 6. Respiratory diseases: Symptomatic sarcoidosis. 7. Edematous states: To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus. 8. Nervous system: Acute exacerbations of multiple sclerosis. uuid:8c457071-2599-4d20-9d8f-93c56398eefc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3892 biolink:treats MONDO:0004674 PMID:41385096 "[{""id"":""uuid:ba6600cc-ff39-434a-b122-3229bc7f2766"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f9ceb964-e37a-467e-a793-337aea6cdedd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Purified Cortrophin Gel is indicated in the following disorders: 1. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Ankylosing spondylitis. Acute gouty arthritis. 2. Collagen diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Systemic dermatomyositis (polymyositis). 3. Dermatologic diseases: Severe erythema multiforme (Stevens-Johnson syndrome). Severe psoriasis. 4. Allergic states: Atopic dermatitis Serum sickness. 5. Ophthalmic diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis. Keratitis. Iritis and iridocyclitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Chorioretinitis. Anterior segment inflammation. 6. Respiratory diseases: Symptomatic sarcoidosis. 7. Edematous states: To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus. 8. Nervous system: Acute exacerbations of multiple sclerosis. uuid:6fbb1097-869c-490e-bc45-f73ef090f86a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3892 biolink:treats MONDO:0006651 PMID:41385096 "[{""id"":""uuid:27063649-3b82-4aef-a337-abb46ceec665"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a3933d2c-4286-4fc8-8018-3c1f3ea8aa10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Purified Cortrophin Gel is indicated in the following disorders: 1. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Ankylosing spondylitis. Acute gouty arthritis. 2. Collagen diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Systemic dermatomyositis (polymyositis). 3. Dermatologic diseases: Severe erythema multiforme (Stevens-Johnson syndrome). Severe psoriasis. 4. Allergic states: Atopic dermatitis Serum sickness. 5. Ophthalmic diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis. Keratitis. Iritis and iridocyclitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Chorioretinitis. Anterior segment inflammation. 6. Respiratory diseases: Symptomatic sarcoidosis. 7. Edematous states: To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus. 8. Nervous system: Acute exacerbations of multiple sclerosis. uuid:fabcf60f-d7d6-4463-8a02-406e47e81fab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3892 biolink:treats MONDO:0019338 PMID:41385096 "[{""id"":""uuid:88ef0b24-41bd-4515-b9d9-054197e9f8db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:918f35d4-48e9-47e3-9a54-1060af514653"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Purified Cortrophin Gel is indicated in the following disorders: 1. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Ankylosing spondylitis. Acute gouty arthritis. 2. Collagen diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Systemic dermatomyositis (polymyositis). 3. Dermatologic diseases: Severe erythema multiforme (Stevens-Johnson syndrome). Severe psoriasis. 4. Allergic states: Atopic dermatitis Serum sickness. 5. Ophthalmic diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis. Keratitis. Iritis and iridocyclitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Chorioretinitis. Anterior segment inflammation. 6. Respiratory diseases: Symptomatic sarcoidosis. 7. Edematous states: To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus. 8. Nervous system: Acute exacerbations of multiple sclerosis. uuid:d29425da-2189-4575-8432-92521e9bf8eb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3892 biolink:treats MONDO:0005377 PMID:41385096 "[{""id"":""uuid:f6a95489-665d-46f2-aea9-35ae9381a468"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8aba4759-59ff-4af7-8730-976199e4eadc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Purified Cortrophin Gel is indicated in the following disorders: 1. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Ankylosing spondylitis. Acute gouty arthritis. 2. Collagen diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Systemic dermatomyositis (polymyositis). 3. Dermatologic diseases: Severe erythema multiforme (Stevens-Johnson syndrome). Severe psoriasis. 4. Allergic states: Atopic dermatitis Serum sickness. 5. Ophthalmic diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis. Keratitis. Iritis and iridocyclitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Chorioretinitis. Anterior segment inflammation. 6. Respiratory diseases: Symptomatic sarcoidosis. 7. Edematous states: To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus. 8. Nervous system: Acute exacerbations of multiple sclerosis. uuid:182d28fd-fa41-4ed9-b2a7-c02607eec883 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3892 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:2bb66231-4393-4434-af4d-f3d142ff3c24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9bc1a725-1fbf-428e-9e1f-cc6f73cdc74f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Purified Cortrophin Gel is indicated in the following disorders: 1. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis. Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). Ankylosing spondylitis. Acute gouty arthritis. 2. Collagen diseases: During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus. Systemic dermatomyositis (polymyositis). 3. Dermatologic diseases: Severe erythema multiforme (Stevens-Johnson syndrome). Severe psoriasis. 4. Allergic states: Atopic dermatitis Serum sickness. 5. Ophthalmic diseases: Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic conjunctivitis. Keratitis. Iritis and iridocyclitis. Diffuse posterior uveitis and choroiditis. Optic neuritis. Chorioretinitis. Anterior segment inflammation. 6. Respiratory diseases: Symptomatic sarcoidosis. 7. Edematous states: To induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus. 8. Nervous system: Acute exacerbations of multiple sclerosis. uuid:87db1528-6b4f-455a-bd10-e79d8b2a3986 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76612 biolink:treats MONDO:0004948 PMID:41385096 "[{""id"":""uuid:7d6b9f8b-eaa4-485f-81dc-d3d6b550dac3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d721a321-4b11-49d4-a753-a4a79e4e725d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e276a6b8-a086-48ac-b118-4ea5b26264a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/imbruvica""]},{""id"":""uuid:f8fd225e-ffb1-491f-856b-76c32e19dd7c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IMBRUVICA is a kinase inhibitor indicated for the treatment of: Adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) ( 1.1 ). Adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion ( 1.2 ). Adult patients with Waldenström’s macroglobulinemia (WM) ( 1.3 ). Adult and pediatric patients age 1 year and older with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy ( 1.4 ).|[EMA] IMBRUVICA as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).IMBRUVICA as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) (see section 5.1).IMBRUVICA as a single agent or in combination with bendamustine and rituximab (BR) is indicated for the treatment of adult patients with CLL who have received at least one prior therapy.IMBRUVICA as a single agent is indicated for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. IMBRUVICA in combination with rituximab is indicated for the treatment of adult patients with WM.|[PMDA] A drug with a new active ingredient indicated for the treatment of relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. uuid:90d9fe88-f9cf-4825-b29f-dd19e73d9b17 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76612 biolink:treats MONDO:0003864 PMID:41385096 "[{""id"":""uuid:0e158729-e95b-4bda-abfa-87b565ca259f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:75e3c186-1f59-4dde-8701-1a28b2aa7210"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:cfa5587c-7846-413d-ba29-fd6e0df23cf4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IMBRUVICA is a kinase inhibitor indicated for the treatment of: Adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) ( 1.1 ). Adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion ( 1.2 ). Adult patients with Waldenström’s macroglobulinemia (WM) ( 1.3 ). Adult and pediatric patients age 1 year and older with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy ( 1.4 ).|[PMDA] A drug with a new active ingredient indicated for the treatment of relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. uuid:c20ac59f-5299-4b25-beff-87ffc67de029 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76612 biolink:treats MONDO:0100280 PMID:41385096 "[{""id"":""uuid:aeabc3f4-cc72-4ed5-abc6-88ecc8261abe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:dfa822a6-f97a-45aa-84b3-1aaf6b48f9b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:97e5c536-fb23-4bc8-8dd8-e99972c27582"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/imbruvica""]},{""id"":""uuid:393e71b8-f95f-40c5-b6da-a1b82552b997"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IMBRUVICA is a kinase inhibitor indicated for the treatment of: Adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) ( 1.1 ). Adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion ( 1.2 ). Adult patients with Waldenström’s macroglobulinemia (WM) ( 1.3 ). Adult and pediatric patients age 1 year and older with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy ( 1.4 ).|[EMA] IMBRUVICA as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).IMBRUVICA as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) (see section 5.1).IMBRUVICA as a single agent or in combination with bendamustine and rituximab (BR) is indicated for the treatment of adult patients with CLL who have received at least one prior therapy.IMBRUVICA as a single agent is indicated for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. IMBRUVICA in combination with rituximab is indicated for the treatment of adult patients with WM.|[PMDA] A drug with new indications for the treatment of Waldenström's macroglobulinemia and lymphoplasmacytic lymphoma. [Orphan drug] uuid:af63036f-396f-4b0e-9585-657c79df9289 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76612 biolink:treats MONDO:0020547 PMID:41385096 "[{""id"":""uuid:65989c4b-05a0-423e-9cfc-7c768f6738ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d0e7b9c5-254d-48f6-b552-9d6e7ab31e81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:11ca471c-760c-4631-807d-dada44d3a690"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IMBRUVICA is a kinase inhibitor indicated for the treatment of: Adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) ( 1.1 ). Adult patients with chronic lymphocytic leukemia (CLL)/Small lymphocytic lymphoma (SLL) with 17p deletion ( 1.2 ). Adult patients with Waldenström’s macroglobulinemia (WM) ( 1.3 ). Adult and pediatric patients age 1 year and older with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy ( 1.4 ).|[PMDA] A drug with a new indication and a new dosage for the treatment of chronic graft-versus-host disease after hematopoietic stem cell transplantation (for use when steroid drugs are not sufficiently effective). [Orphan drug] uuid:a708f1a3-02ca-42ba-b0ba-e5ef3c8a4597 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229221 biolink:treats EFO:1001480 PMID:41385096 "[{""id"":""uuid:2544d505-110c-4b45-b9fd-82176d061a6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d08f3de1-cd67-426a-8a94-338d10e9f268"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FRUZAQLA is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with fluoropyrimidine‑, oxaliplatin‑, and irinotecan‑based chemotherapy, an anti‑VEGF therapy, and, if RAS wild‑type and medically appropriate, an anti-EGFR therapy. uuid:ce72b384-1b73-4418-bc8b-10362a32ba98 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68647 biolink:treats EFO:1001480 PMID:41385096 "[{""id"":""uuid:94998fd3-8459-43ba-9e62-fb22a54db6e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0f5ba485-9d58-4fa2-9eb9-648e18c77a3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] STIVARGA is a kinase inhibitor indicated for the treatment of patients with: • Metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type, an anti-EGFR therapy. ( 1.1 ) • Locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. ( 1.2 ) • Hepatocellular carcinoma (HCC) who have been previously treated with sorafenib ( 1.3 ) uuid:ee89be2a-0e65-4d80-bed3-2b1a8de2e561 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68647 biolink:treats MONDO:0007256 PMID:41385096 "[{""id"":""uuid:a51302f5-d326-4472-8b53-1c2526b2d4cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:043f7701-5bea-4302-ab95-b7875048bc2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:95db4781-74d4-4518-8f9d-eab561e57e2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/stivarga""]},{""id"":""uuid:a82a3ea3-6edb-4295-97db-619658af5c15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] STIVARGA is a kinase inhibitor indicated for the treatment of patients with: • Metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if RAS wild-type, an anti-EGFR therapy. ( 1.1 ) • Locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate. ( 1.2 ) • Hepatocellular carcinoma (HCC) who have been previously treated with sorafenib ( 1.3 )|[EMA] Stivarga is indicated as monotherapy for the treatment of adult patients with:metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies - these include fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy;unresectable or metastatic gastrointestinal stromal tumors (GIST) who progressed on or are intolerant to prior treatment with imatinib and sunitinib;hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.|[PMDA] A drug with a new additional indication for the treatment of unresectable hepatocellular carcinoma which has progressed after cancer chemotherapy. [Priority review] uuid:581c3bb7-5531-4972-9782-cb58389ab759 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:233362 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:becdda12-b339-49bb-a95c-d747b7baeae3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b5149154-1a03-413b-b6b5-a643b4f222c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:83b22105-7fbd-42e9-82b9-782724a55369"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/verzenios""]},{""id"":""uuid:9099b9f0-c4e2-4f9c-9ef0-f6f6fe287df7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VERZENIO ® is a kinase inhibitor indicated: in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence. ( 1.1 , 14.1 ) in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. ( 1.2 ) in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. ( 1.2 ) as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting. ( 1.2 )|[EMA] Early Breast CancerVerzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative, node positive early breast cancer at high risk of recurrence (see section 5.1).In pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.Advanced or Metastatic Breast CancerVerzenios is indicated for the treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.In pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist.|[PMDA] Drugs with a new active ingredient indicated for the treatment of hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)- negative inoperable or recurrent breast cancer. UNII:60UAB198HK uuid:448f8fe8-db2c-496d-b600-12f3ee658bf1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:233362 biolink:treats UMLS:C3495917 PMID:41385096 "[{""id"":""uuid:e934cd77-2b93-4cc6-8eea-fb806b7cbc99"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:22c94c7c-a372-4658-b09c-40354f6fd066"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VERZENIO ® is a kinase inhibitor indicated: in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence. ( 1.1 , 14.1 ) in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. ( 1.2 ) in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. ( 1.2 ) as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting. ( 1.2 ) UNII:60UAB198HK uuid:18cf337e-3fda-4bd4-ae9a-3cd43619735d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:233362 biolink:treats UMLS:C0278488 PMID:41385096 "[{""id"":""uuid:263708d1-7271-472a-99a4-3072ed0c103f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cac3a732-0277-4eed-a6bf-5e0b74741b4c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VERZENIO ® is a kinase inhibitor indicated: in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence. ( 1.1 , 14.1 ) in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. ( 1.2 ) in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy. ( 1.2 ) as monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting. ( 1.2 ) UNII:60UAB198HK uuid:e56c5aa1-012d-4d70-86bc-d2fe9940613a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PTB4X93HE1 biolink:treats MONDO:0005132 PMID:41385096 "[{""id"":""uuid:e40efc72-c9c5-4ddb-b7d4-a2f8fc41695b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:1fc8654b-99eb-48d3-b709-6395f19947cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:fa72c794-864b-4a25-a6e6-a10ebfe5aa7c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/livtencity""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] LIVTENCITY is indicated for the treatment of adults and pediatric patients (12 years of age and older and weighing at least 35 kg) with post-transplant cytomegalovirus (CMV) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet [see Use in Specific Populations (8.4) and Clinical Studies (14) ] .|[EMA] LIVTENCITY is indicated for the treatment of cytomegalovirus (CMV) infection and/or disease that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet in adult patients who have undergone a haematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT).Consideration should be given to official guidance on the appropriate use of antiviral agents. uuid:4b03a462-f84c-4715-85a5-8a22c71c6659 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49375 biolink:treats MONDO:0024685 PMID:41385096 "[{""id"":""uuid:baafd212-faae-43a9-8024-1decc3c82f96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:259defd5-102f-4f48-ac86-7c3027e90086"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dasatinib tablets are indicated for the treatment of adult patients with • newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase. • chronic, accelerated, or myeloid or lymphoid blast phase Ph+ CML with resistance or intolerance to prior therapy including imatinib. • Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to prior therapy. Dasatinib tablets are indicated for the treatment of pediatric patients 1 year of age and older with • Ph+ CML in chronic phase. • newly diagnosed Ph+ ALL in combination with chemotherapy. uuid:bff32448-96e4-432c-a5fd-78e2cb264278 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:84500 biolink:treats MONDO:0006733 PMID:41385096 "[{""id"":""uuid:f4447161-c110-47b7-8d51-fd15e91e2e40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cd39f4fe-ac03-48f5-9fa4-46a14bb1fda9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TYRVAYA (varenicline solution) nasal spray is indicated for the treatment of the signs and symptoms of dry eye disease. uuid:1516f06f-4c29-40bb-84d1-74a53ffd6476 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:A3ULP0F556 biolink:treats MONDO:0035663 PMID:41385096 "[{""id"":""uuid:37fd4201-421e-4de8-a285-af304936dccd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:40a41613-5f2b-44c2-bb3f-3133c3417691"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:dd9ec661-95f2-4216-b3c3-04fe2cf6c587"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/soliris""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] SOLIRIS is a complement inhibitor indicated for: the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis. ( 1.1 ) the treatment of patients with atypical hemolytic uremic syndrome (aHUS) to inhibit complement-mediated thrombotic microangiopathy. ( 1.2 ) Limitation of Use SOLIRIS is not indicated for the treatment of patients with Shiga toxin E. coli related hemolytic uremic syndrome (STEC-HUS). the treatment of generalized myasthenia gravis (gMG) in adult and pediatric patients six years of age and older who are anti-acetylcholine receptor (AChR) antibody positive. ( 1.3 ) the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. ( 1.4 )|[EMA] Soliris is indicated in adults and children for the treatment of:Paroxysmal nocturnal haemoglobinuria (PNH).Evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history (see section 5.1). Atypical haemolytic uremic syndrome (aHUS).Soliris is indicated in adults for the treatment of:Refractory generalized myasthenia gravis (gMG) in patients who are anti-acetylcholine receptor (AChR) antibody-positive (see section 5.1).Neuromyelitis optica spectrum disorder (NMOSD) in patients who are anti-aquaporin-4 (AQP4) antibody-positive with a relapsing course of the disease. uuid:772c2e07-d722-4725-9619-54aca3579cd5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2372V1TKXK biolink:treats MONDO:0019623 PMID:41385096 "[{""id"":""uuid:196fe075-cbdb-4456-86f9-8a292c2b6cfb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6610e6b5-9344-458e-b915-3be3b9b7b99e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1c936908-82ad-406c-a4c4-5ea6a3f68e94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/takhzyro""]},{""id"":""uuid:c8a07c03-c045-45c3-ae07-6bdd2977e99d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TAKHZYRO ® is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 2 years and older.|[EMA] TAKHZYRO is indicated for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 2 years and older.|[PMDA] A drug with a new active ingredient indicated for the prophylaxis of acute attacks of hereditary angioedema. [Orphan drug] uuid:c726973d-7dbf-4063-a14b-8ddc9de21fa7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2372V1TKXK biolink:treats MONDO:0012526 PMID:41385096 "[{""id"":""uuid:876ec534-0563-4b64-92ea-97d3254f92af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1edea88a-fbba-46b9-82a3-bd5f0d2146bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TAKHZYRO ® is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 2 years and older. uuid:47c5d10f-986e-4359-a8e9-87d26d713ac4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22652 biolink:treats MONDO:0010525 PMID:41385096 "[{""id"":""uuid:4420b4aa-f8dd-4959-9d8a-b9cf0ea43fc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a46cf175-744e-44e7-988e-7b1d1ca7ba5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Accentrate® PNV (Folate/Omega-3/Iron) (6 mg-210 mg-10 mg) is a Prescription Prenatal Multivitamin Tablet and combination Omega-3 Softgel/Mineral Capsule indicated for preventing neural tube defects and use in improving the nutritional status of women prior to conception, throughout pregnancy, and in the postnatal period for both lactating and nonlactating mothers. uuid:0a308390-fbdd-4e24-8fb1-f213bc825d09 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229225 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:2380098f-a9d7-4d2e-bbca-21022e504bed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5282665e-bdb2-4ae4-8424-0cf45855c564"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bexagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use Bexagliflozin is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus. [see Warnings and Precautions ( 5.1 )] . uuid:c347ee71-44c6-4134-9738-d5308b8e0765 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229225 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:7406093f-b8f1-499d-8588-73b4a03598fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:881c0e20-ca80-42c4-afbb-693de8c0d6ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Bexagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use Bexagliflozin is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus. [see Warnings and Precautions ( 5.1 )] . uuid:25752917-3822-4f73-9b19-388ad5c4e340 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8K80YB5GMG biolink:treats MONDO:0016168 PMID:41385096 "[{""id"":""uuid:2d314b9d-d86d-4bb7-9fe3-9f7750315014"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5646ea35-28bf-4077-af6f-312ce2027631"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ARCALYST (rilonacept) is an interleukin-1 blocker indicated for: Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS), and Muckle-Wells Syndrome (MWS) in adults and children 12 years and older ( 1.1 , 14.1 ) Maintenance of remission of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) in adults and pediatric patients weighing 10 kg or more ( 1.2 , 14.2 ) Treatment of recurrent pericarditis (RP) and reduction in risk of recurrence in adults and children 12 years and older ( 1.3 , 14.3 ) uuid:de1c3895-5b17-40db-9c2e-99e0f9620590 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8K80YB5GMG biolink:treats MONDO:0018768 PMID:41385096 "[{""id"":""uuid:912025c4-682b-466a-a283-a8bc104b0007"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7c2d3c92-b9b0-4b22-9aff-5c477219034b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ARCALYST (rilonacept) is an interleukin-1 blocker indicated for: Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS), and Muckle-Wells Syndrome (MWS) in adults and children 12 years and older ( 1.1 , 14.1 ) Maintenance of remission of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) in adults and pediatric patients weighing 10 kg or more ( 1.2 , 14.2 ) Treatment of recurrent pericarditis (RP) and reduction in risk of recurrence in adults and children 12 years and older ( 1.3 , 14.3 ) uuid:1aaa5a32-a4ff-4355-8868-fed758e34faf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8K80YB5GMG biolink:treats UMLS:C5577988 PMID:41385096 "[{""id"":""uuid:9513fddf-8c9e-490d-bdc7-d0d243780101"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a0efc0f3-0130-462b-8a6d-8c786ab5e800"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ARCALYST (rilonacept) is an interleukin-1 blocker indicated for: Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS), and Muckle-Wells Syndrome (MWS) in adults and children 12 years and older ( 1.1 , 14.1 ) Maintenance of remission of Deficiency of Interleukin-1 Receptor Antagonist (DIRA) in adults and pediatric patients weighing 10 kg or more ( 1.2 , 14.2 ) Treatment of recurrent pericarditis (RP) and reduction in risk of recurrence in adults and children 12 years and older ( 1.3 , 14.3 ) uuid:6eca58b5-0c01-4a1d-8d8c-1b232e5c1000 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47426 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:3f2bdab3-e07a-4949-985b-9605bede44bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:af10b428-5900-4a24-b1fb-58b08102c8f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FUROSCIX is indicated for the treatment of edema in adult patients with chronic heart failure or chronic kidney disease (CKD), including the nephrotic syndrome. uuid:d4af0e90-dedf-4546-9444-8b04f7ef3af8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:TT0V5JLG5B biolink:treats HP:0031609 PMID:41385096 "[{""id"":""uuid:8b0237d9-d815-4f8e-87e0-c8ff1de79628"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3c069f91-16fd-4c70-b708-a99f42940daf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IZERVAY ™ is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). uuid:84bed074-3a17-4633-a280-fbdf1566ed57 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:TT0V5JLG5B biolink:treats MONDO:0005150 PMID:41385096 "[{""id"":""uuid:8d9a7ef5-a4f6-4c86-8047-c324fee37611"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fe49665a-8315-457e-a3f2-0520ea4a7544"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IZERVAY ™ is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). uuid:4f5b047f-92ae-4d0a-bfa8-4f8486e14ccc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2570392 biolink:treats MONDO:0005090 PMID:41385096 "[{""id"":""uuid:e33cc3ed-d6c3-48b1-bc77-9946df6dae8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:73c9b947-662d-4aa2-918b-c917a59b0405"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LYBALVI is indicated for the treatment of: Schizophrenia in adults Bipolar I disorder in adults Acute treatment of manic or mixed episodes as monotherapy and as adjunct to lithium or valproate Maintenance monotherapy treatment uuid:b5e527fd-e727-469b-ad70-a9a5701c62e1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2570392 biolink:treats MONDO:0001866 PMID:41385096 "[{""id"":""uuid:7dc876bc-7389-4cbf-8a30-96ddd75bad0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:12da7e87-4045-46a7-ab1b-534a01f24ef3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LYBALVI is indicated for the treatment of: Schizophrenia in adults Bipolar I disorder in adults Acute treatment of manic or mixed episodes as monotherapy and as adjunct to lithium or valproate Maintenance monotherapy treatment uuid:a5b8eb14-8cfd-4fe3-b008-5f59c1efb201 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2570392 biolink:treats MONDO:0024612 PMID:41385096 "[{""id"":""uuid:1aba07de-86ee-4ee5-aaee-2a1001d158c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bbb21a4b-2490-470f-a5e0-234a9f1bd81d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LYBALVI is indicated for the treatment of: Schizophrenia in adults Bipolar I disorder in adults Acute treatment of manic or mixed episodes as monotherapy and as adjunct to lithium or valproate Maintenance monotherapy treatment uuid:6a6758eb-4f47-4bf1-acfe-c08e7a56f464 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229659 biolink:treats MONDO:0009688 PMID:41385096 "[{""id"":""uuid:67de4acc-fc27-44f3-b667-0cae2b945f3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:301056d3-032b-4ce5-bce4-794d521b3580"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:42586a2a-de92-4735-bd3b-27d9865a66f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZILBRYSQ is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.|[PMDA] Drugs with a new active ingredient indicated for the treatment of generalized myasthenia gravis (for use only in patients who have not sufficiently responded to steroids or other immunosuppressants). uuid:712fb792-2fec-403d-ab01-941a389fcee2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50848 biolink:treats MONDO:0006733 PMID:41385096 "[{""id"":""uuid:42e55174-1010-41fe-9b2e-14951f1e9b1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:17a986b5-789d-4ce0-916f-401062eecb9d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EYSUVIS is a corticosteroid indicated for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease. uuid:4ed19008-faaa-4089-ada2-d87d392053a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9961469 biolink:treats MONDO:0005338 PMID:41385096 "[{""id"":""uuid:9a75779e-662b-4a74-a460-1396e01ef3cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6d6896ea-ff2e-41da-9f7b-d0226d4e3bf4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SIMBRINZA (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2% is a fixed combination of a carbonic anhydrase inhibitor and an alpha 2 adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. uuid:d507568f-eb6b-4b2c-b45d-770255358b2c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9961469 biolink:treats MONDO:0006875 PMID:41385096 "[{""id"":""uuid:7df65315-ca27-49f1-92f0-7899e306f6d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bd67e2ab-31d8-46c4-9b5c-5b7daee5cb0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SIMBRINZA (brinzolamide/brimonidine tartrate ophthalmic suspension) 1%/0.2% is a fixed combination of a carbonic anhydrase inhibitor and an alpha 2 adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. uuid:a16023ef-773a-4d42-b2fc-e3b13daf059a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18358 biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:3c1b5ac1-9b0d-463d-8ff9-5f1170d4b93f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:97e578ca-e424-4627-9b40-5861f3a55005"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Photochemotherapy (Methoxsalen with long wave UVA radiation) is indicated for the symptomatic control of severe, recalcitrant, disabling psoriasis not adequately responsive to other forms of therapy and when the diagnosis has been supported by biopsy. Methoxsalen is intended to be administered only in conjunction with a schedule of controlled doses of long wave ultraviolet radiation. uuid:7109ee39-7ea0-4a7a-a499-c4f6c97d45ef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231601 biolink:treats MONDO:0003219 PMID:41385096 "[{""id"":""uuid:ad9de197-7aa5-4400-b5a9-3e52f5b143ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:04f32d19-ec38-415c-8adf-b0a2879d24c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ontruzant is a HER2/neu receptor antagonist indicated in adults for: The treatment of HER2-overexpressing breast cancer. ( 1.1 , 1.2 ) The treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. ( 1.3 ) Select patients for therapy based on an FDA-approved companion diagnostic for a trastuzumab product ( 1 , 2.2 ). uuid:8f04551c-046b-4b5d-939d-8b9e29e94343 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229223 biolink:treats MONDO:0020725 PMID:41385096 "[{""id"":""uuid:14a72c26-877c-46a6-b6f0-2a8e9deb12cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5f617136-45a9-4e47-85d7-047bbc426457"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] JESDUVROQ is indicated for the treatment of anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least four months. Limitations of Use JESDUVROQ has not been shown to improve quality of life, fatigue, or patient well-being. JESDUVROQ is not indicated for use: • As a substitute for red blood cell transfusions in patients who require immediate correction of anemia. • For treatment of anemia of chronic kidney disease in patients who are not on dialysis. uuid:d3bc6575-d126-46a6-94a3-6a81e6d2eace biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229764 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:5767da6d-a312-4a14-9699-0c75a495de28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6953ade0-ff5a-422b-a7bd-b1b9b2b83f54"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b77b4a51-5b0b-4b42-84bb-7eb0a0f9a323"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/nexpovio""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] XPOVIO is a nuclear export inhibitor indicated: In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy ( 1.1 ). In combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody ( 1.1 ). For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s) ( 1.2 ).|[EMA] NEXPOVIO is indicatedin combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy. uuid:a1fa07c8-0a10-432e-a4bf-49e02c5abe4e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229764 biolink:treats MONDO:0000901 PMID:41385096 "[{""id"":""uuid:54f5a074-8e0e-492a-b2d0-78852edb0f19"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:559b3349-de52-42ac-bd32-a8531dfe9d03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XPOVIO is a nuclear export inhibitor indicated: In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy ( 1.1 ). In combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody ( 1.1 ). For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s) ( 1.2 ). uuid:c874f0c6-84df-409b-8173-2a2a638956a0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229764 biolink:treats MONDO:0018908 PMID:41385096 "[{""id"":""uuid:d06f69ec-a78c-4550-b95f-276e8d859b22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:97863fc2-d34e-4e85-8179-42498ed650f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XPOVIO is a nuclear export inhibitor indicated: In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy ( 1.1 ). In combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody ( 1.1 ). For the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least 2 lines of systemic therapy. This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s) ( 1.2 ). uuid:84ed0084-da76-4783-8ac2-f12d327a63a5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:033072U4MZ biolink:treats MONDO:0010679 PMID:41385096 "[{""id"":""uuid:622135e4-bc72-4339-93ef-299f8151ab66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9e66be10-440c-4332-9e8f-4003efee2cf2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VYONDYS 53 is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VYONDYS 53 [see Clinical Studies ( 14 )] . Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials. uuid:8fe2ef36-4405-4184-a016-d9cbf727e857 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:161680 biolink:treats MONDO:0009061 PMID:41385096 "[{""id"":""uuid:0fa1f5c2-deb6-4bee-9cfc-14db1936f429"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:66a9cba9-9fa4-4815-a5ba-84116bb03d95"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CAYSTON ® is indicated to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa . Safety and effectiveness have not been established in pediatric patients below the age of 7 years, patients with FEV 1 <25% or >75% predicted, or patients colonized with Burkholderia cepacia [see Clinical Studies (14) ]. To reduce the development of drug-resistant bacteria and maintain the effectiveness of CAYSTON and other antibacterial drugs, CAYSTON should be used only to treat patients with CF known to have Pseudomonas aeruginosa in the lungs. uuid:173c516c-f4d3-4c27-953f-0e1064b4417e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:161680 biolink:treats UMLS:C0854135 PMID:41385096 "[{""id"":""uuid:b12b9183-8bb6-4ebc-b556-039afe99419d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:90c4c012-7ff5-4a37-bc5c-77d6e96ff9d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CAYSTON ® is indicated to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa . Safety and effectiveness have not been established in pediatric patients below the age of 7 years, patients with FEV 1 <25% or >75% predicted, or patients colonized with Burkholderia cepacia [see Clinical Studies (14) ]. To reduce the development of drug-resistant bacteria and maintain the effectiveness of CAYSTON and other antibacterial drugs, CAYSTON should be used only to treat patients with CF known to have Pseudomonas aeruginosa in the lungs. uuid:29d64c04-81a1-4ec2-a341-e04d0f13975d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29101 biolink:treats HP:0001892 PMID:41385096 "[{""id"":""uuid:276283ce-b0fe-4f2b-ada0-5e96552ce2a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4a560145-4eb2-4b7c-b0fa-000f0101d710"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] REGIOCIT (sodium chloride and sodium citrate) solution is indicated for use as replacement solution for regional citrate anticoagulation (RCA) of the extracorporeal circuit in patients treated with continuous renal replacement therapy (CRRT), particularly when systemic anticoagulation with heparin is contraindicated, e.g., in patients with increased bleeding risks. REGIOCIT should be administered only under the supervision of a physician experienced in the use of CRRT. Pediatrics Pediatrics (<18 years of age): No data are available to Health Canada; therefore, Health Canada has not authorized an indication for pediatric use. Geriatrics Geriatrics (> 65 years of age): Evidence from clinical studies and experience suggests that use in the geriatric population is not associated with differences in safety or effectiveness. uuid:f82b427b-47ea-491a-98c6-28ed5120b819 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6709 biolink:treats MONDO:0002643 PMID:41385096 "[{""id"":""uuid:f0f12b82-4a23-4389-ba3c-3aa8891a78b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b3a36447-b7e1-4f10-a1ae-1eca22b6f910"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Meclizine hydrochloride tablet is indicated for the treatment of vertigo associated with diseases affecting the vestibular system in adults. uuid:e19d544b-f8fb-44a6-8b78-9ad861ff0c4e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229212 biolink:treats MONDO:0004948 PMID:41385096 "[{""id"":""uuid:7334d303-0428-4009-ac1d-14fddeae9bc8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:78fca43f-fbe0-4b0a-a753-3063c35e712e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] JAYPIRCA ® is a kinase inhibitor indicated for the treatment of Adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor. ( 1.1 ). This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor. ( 1.2 ). This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. uuid:d6ed886b-3dfb-402b-8fce-a28aa4298ae7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229212 biolink:treats MONDO:0003864 PMID:41385096 "[{""id"":""uuid:16db9b82-9cf4-4763-b26e-1400d7fd3ce7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:016d9dc4-bb6d-4fde-8d34-1b122ebbf778"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] JAYPIRCA ® is a kinase inhibitor indicated for the treatment of Adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor. ( 1.1 ). This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor. ( 1.2 ). This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. uuid:b434e85a-3dbf-4339-a346-d49f5497b91c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8CQO07490I biolink:treats MONDO:0010679 PMID:41385096 "[{""id"":""uuid:5d457e67-5147-403b-b6d0-7324851ee506"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8282f3fc-c67f-42fc-919e-01348341c83d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AMONDYS 45 is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with AMONDYS 45 [see Clinical Studies ( 14 )] . Continued approval for this indication may be contingent upon verification of a clinical benefit in confirmatory trials. uuid:b71fb76b-3293-4ca8-a06f-1691caa17de3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229233 biolink:treats MONDO:0005340 PMID:41385096 "[{""id"":""uuid:87dc2cb4-6394-478b-b3d4-d134051a1d59"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8f5f4eaf-05fa-47fe-bb81-047d9139a104"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:950b0423-9741-4e14-bb72-bb0e81a3b42b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:606f99d6-f921-496e-a709-647128e2fc81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LITFULO is a kinase inhibitor indicated for the treatment of severe alopecia areata in adults and adolescents 12 years and older. Limitations of Use : Not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants.|[EMA] Litfulo is indicated for the treatment of severe alopecia areata in adults and adolescents 12 years of age and older.|[PMDA] A drug with a new active ingredient indicated for the treatment of alopecia areata (for use only in patients with intractable and extensive alopecia areata). uuid:a6829666-41d9-4a05-a755-ba01ea528525 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:BT2LV86QKA biolink:treats MONDO:0007739 PMID:41385096 "[{""id"":""uuid:013269dd-96e0-44db-b045-a4c530dff012"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ebc8081f-353a-4c38-ae05-ee1fa028f7af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AUSTEDO XR ® and AUSTEDO ® are indicated in adults for the treatment of: chorea associated with Huntington’s disease [see Clinical Studies ( 14.1 )] tardive dyskinesia [see Clinical Studies ( 14.2 )] uuid:aca24c16-ef75-4271-86ab-63a67b3544f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:BT2LV86QKA biolink:treats MONDO:0010096 PMID:41385096 "[{""id"":""uuid:714a8baf-9a98-4b9c-bc2c-fbc2d2eabe38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:26ad6608-e887-4f09-8e80-100fa64684c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AUSTEDO XR ® and AUSTEDO ® are indicated in adults for the treatment of: chorea associated with Huntington’s disease [see Clinical Studies ( 14.1 )] tardive dyskinesia [see Clinical Studies ( 14.2 )] uuid:4de29aa6-638f-452e-b67e-2eb633393aea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2119698 biolink:treats MONDO:0005338 PMID:41385096 "[{""id"":""uuid:36a7b44a-4184-4950-a8c8-f76457cd9f22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9dc5418a-228b-4370-b9a9-e11a6e89b8aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7d2df1a7-072a-4738-8785-9c1ffcce3e7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ROCKLATAN is a fixed dose combination of a Rho kinase inhibitor and a prostaglandin F 2α analogue indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.|[EMA] Roclanda is indicated for the reduction of elevated intraocular pressure (IOP) in adult patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil provides insufficient IOP reduction. uuid:5d16dbdc-8ae5-4897-a9cf-baa55da568b0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2119698 biolink:treats MONDO:0006875 PMID:41385096 "[{""id"":""uuid:f5957609-164a-4561-9917-fd302e0f865c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:84ca4c5f-bafc-4c97-a162-8c3d9719925d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ec8e85bb-7085-41a3-a284-e3f6e9a2108d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ROCKLATAN is a fixed dose combination of a Rho kinase inhibitor and a prostaglandin F 2α analogue indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.|[EMA] Roclanda is indicated for the reduction of elevated intraocular pressure (IOP) in adult patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil provides insufficient IOP reduction. uuid:602c8ceb-d0ea-4920-ac28-7ec4167e959d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0001947 PMID:41385096 "[{""id"":""uuid:913d88c1-7508-426a-9703-66cf314d9cd1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9b6fb711-6b9b-47f6-9b7f-233214d6e9c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of SOLU-MEDROL Sterile Powder is indicated as follows: Allergic states: Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic diseases: Bullous dermatitis herpetiformis, exfoliiative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsupportable thyroiditis. Gastrointestinal diseases: To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hemotologic disorders: Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous: Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases: For the palliative management of leukemias and lymphomas. Nervous System: Acute exacerbations of multiple sclerosis; cerebral adema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases: Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases: To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases: Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders: As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus. uuid:a126a0da-5bc3-4a4b-94ef-2f714fc2359d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:76RS4S2ET1 biolink:treats MONDO:0001516 PMID:41385096 "[{""id"":""uuid:6e0b9680-e43d-4031-9a0e-65320c9bd77a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:486828d6-eced-4278-8eff-db75e870aedc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f2278783-307f-488a-bd8d-7bf5fede8fe8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/evrysdi""]},{""id"":""uuid:1b0cfea1-5763-4bda-86ba-41085ee83787"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EVRYSDI is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients.|[EMA] Evrysdi is indicated for the treatment of 5q spinal muscular atrophy (SMA) in patients with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies.|[PMDA] A drug with a new active ingredient indicated for the treatment of spinal muscular atrophy. [Orphan drug] uuid:6cf1ace0-9a9a-428b-992b-d78ac3ee52f7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:76RS4S2ET1 biolink:treats MONDO:0019079 PMID:41385096 "[{""id"":""uuid:01638a55-b7ef-4091-98ed-291bc39f80bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bfe7ce2f-2af7-4605-a406-066eb311069f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EVRYSDI is indicated for the treatment of spinal muscular atrophy (SMA) in pediatric and adult patients. uuid:c4b5d702-ca9f-4106-8ded-0a18b027afb5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3746 biolink:treats MONDO:0024389 PMID:41385096 "[{""id"":""uuid:ac6df145-2f3d-4ed9-9df8-91951bea1604"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c89af471-a41b-4d31-a891-66fff5003e5d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clindamycin Phosphate in Sodium Chloride Injection contains clindamycin, a lincosamide antibacterial indicated for the treatment of the following in adult and pediatric patients for whom appropriate dosing with this formulation can be achieved: • Serious infections caused by susceptible anaerobic bacteria ( 1.1 ) • Infections Due to Susceptible Isolates of Streptococci, Pneumococci and Staphylococci. ( 1.2 ) • Lower Respiratory Tract Infections. ( 1.3 ) • Skin and Skin Structure Infections. ( 1.4 ) • Gynecological Infections. ( 1.5 ) • Intra-abdominal Infections. ( 1.6 ) • Septicemia. ( 1.7 ) • Bone and Joint Infections. ( 1.8 ) Limitation of use Since clindamycin does not diffuse adequately into the cerebrospinal fluid, Clindamycin Phosphate in Sodium Chloride Injection should not be used in the treatment of meningitis ( 1.9 ) Usage To reduce the development of drug-resistant bacteria and maintain the effectiveness of Clindamycin Phosphate in Sodium Chloride Injection and other antibacterial drugs, Clindamycin Phosphate in Sodium Chloride Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.10 ) uuid:c4b60015-ce5a-43b3-a507-bfb0562704df biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:188559 biolink:treats MONDO:0007606 PMID:41385096 "[{""id"":""uuid:d95c970a-c459-4a78-89cf-64d51f12e907"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a4535381-2db9-4d45-a260-f9d067b95c87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SOHONOS is indicated for the reduction in volume of new heterotopic ossification in adults and pediatric patients aged 8 years and older for females and 10 years and older for males with fibrodysplasia ossificans progressiva (FOP). uuid:1a408f57-779e-48b0-b261-27a9707624ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:188559 biolink:treats HP:0011986 PMID:41385096 "[{""id"":""uuid:1b07b86e-b1b3-46a9-b71e-42c3c144f220"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9dbb3be1-1f03-4f85-af55-f4d2c2792939"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SOHONOS is indicated for the reduction in volume of new heterotopic ossification in adults and pediatric patients aged 8 years and older for females and 10 years and older for males with fibrodysplasia ossificans progressiva (FOP). uuid:7e1dcb4a-7d90-40fd-9c54-df739ca245e7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:145371 biolink:treats MONDO:0005105 PMID:41385096 "[{""id"":""uuid:3ba61a8c-a45f-44c0-afab-3102706039ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a98a08cd-31f1-4d3c-8c62-bf1d1f38f586"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f6037e00-1211-4da8-91da-63971f964918"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/mektovi""]},{""id"":""uuid:c06ac2d1-e599-4c87-be87-d7e8405eb1ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MEKTOVI is a kinase inhibitor indicated: • in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. ( 1.1 , 2.1 ) • in combination with encorafenib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test. ( 1.2 , 2.1 )|[EMA] Binimetinib in combination with encorafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.|[PMDA] A drug with a new active ingredient indicated for the treatment of unresectable melanoma with BRAF gene mutation. [Orphan drug] uuid:1c6db7ac-0b4a-4526-a572-1685ea22ab32 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:145371 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:ee605aec-2161-4b61-ada2-f54a239b691b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:41651907-47ad-49ed-8ced-49b52df39134"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MEKTOVI is a kinase inhibitor indicated: • in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. ( 1.1 , 2.1 ) • in combination with encorafenib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test. ( 1.2 , 2.1 ) uuid:80971a16-8baf-4ec2-9063-4a6a54743e6e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1664312 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:bac6fa7f-f303-4b5d-9919-8c6fe00050be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a940d4ca-f951-42cd-b0ee-11393559ed2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3df02624-2f6b-49ce-b826-b4c60e3bd8e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/synjardy""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] SYNJARDY SYNJARDY is a combination of empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor and metformin hydrochloride (HCl) immediate-release, a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. SYNJARDY XR SYNJARDY XR is a combination of empagliflozin, a SGLT2 inhibitor and metformin HCl extended-release, a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus . Empagliflozin Empagliflozin, when used as a component of SYNJARDY or SYNJARDY XR, is indicated in adults with type 2 diabetes mellitus to reduce the risk of: Cardiovascular (CV) death in adults with established CV disease. ( 1 ) CV death and hospitalization for heart failure in adults with heart failure. ( 1 ) Sustained decline in eGFR, end-stage kidney disease, CV death, and hospitalization in adults with chronic kidney disease at risk of progression. ( 1 ) Limitations of Use : Not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus. It may increase the risk of diabetic ketoacidosis in these patients. ( 1 ) Because of the metformin HCl component, the use of SYNJARDY or SYNJARDY XR is limited to patients with type 2 diabetes mellitus for all indications. ( 1 ) Empagliflozin, when used as a component of SYNJARDY or SYNJARDY XR, is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of intravenous immunosuppressive therapy or greater than 45 mg of prednisone or equivalent for kidney disease. Empagliflozin is not expected to be effective in these populations. ( 1 )|[EMA] Synjardy is indicated in adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control:in patients inadequately controlled on their maximally tolerated dose of metformin alone;in patients inadequately controlled with metformin in combination with other glucose-lowering medicinal products, including insulin;in patients already being treated with the combination of empagliflozin and metformin as separate tablets. uuid:32da2359-e869-4394-991d-3ec17043a3a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1664312 biolink:treats MONDO:0004995 PMID:41385096 "[{""id"":""uuid:afd9456a-8a35-4d2e-9d3f-1a3f1de6586d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:245fd480-ee23-4a6d-9530-f01a66a27ea0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SYNJARDY SYNJARDY is a combination of empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor and metformin hydrochloride (HCl) immediate-release, a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. SYNJARDY XR SYNJARDY XR is a combination of empagliflozin, a SGLT2 inhibitor and metformin HCl extended-release, a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus . Empagliflozin Empagliflozin, when used as a component of SYNJARDY or SYNJARDY XR, is indicated in adults with type 2 diabetes mellitus to reduce the risk of: Cardiovascular (CV) death in adults with established CV disease. ( 1 ) CV death and hospitalization for heart failure in adults with heart failure. ( 1 ) Sustained decline in eGFR, end-stage kidney disease, CV death, and hospitalization in adults with chronic kidney disease at risk of progression. ( 1 ) Limitations of Use : Not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus. It may increase the risk of diabetic ketoacidosis in these patients. ( 1 ) Because of the metformin HCl component, the use of SYNJARDY or SYNJARDY XR is limited to patients with type 2 diabetes mellitus for all indications. ( 1 ) Empagliflozin, when used as a component of SYNJARDY or SYNJARDY XR, is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of intravenous immunosuppressive therapy or greater than 45 mg of prednisone or equivalent for kidney disease. Empagliflozin is not expected to be effective in these populations. ( 1 ) uuid:02a7abd5-72b1-453f-8333-b1ee0ed02efb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1664312 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:73ad6e91-37fa-43f6-9637-784250c3d1b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9c5a33dd-2e50-4a4b-8959-116d7d3758ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SYNJARDY SYNJARDY is a combination of empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor and metformin hydrochloride (HCl) immediate-release, a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. SYNJARDY XR SYNJARDY XR is a combination of empagliflozin, a SGLT2 inhibitor and metformin HCl extended-release, a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus . Empagliflozin Empagliflozin, when used as a component of SYNJARDY or SYNJARDY XR, is indicated in adults with type 2 diabetes mellitus to reduce the risk of: Cardiovascular (CV) death in adults with established CV disease. ( 1 ) CV death and hospitalization for heart failure in adults with heart failure. ( 1 ) Sustained decline in eGFR, end-stage kidney disease, CV death, and hospitalization in adults with chronic kidney disease at risk of progression. ( 1 ) Limitations of Use : Not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus. It may increase the risk of diabetic ketoacidosis in these patients. ( 1 ) Because of the metformin HCl component, the use of SYNJARDY or SYNJARDY XR is limited to patients with type 2 diabetes mellitus for all indications. ( 1 ) Empagliflozin, when used as a component of SYNJARDY or SYNJARDY XR, is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of intravenous immunosuppressive therapy or greater than 45 mg of prednisone or equivalent for kidney disease. Empagliflozin is not expected to be effective in these populations. ( 1 ) uuid:3ad8a9be-d0ab-411e-9957-c792cd5f4d6f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1664312 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:5d2673b4-24f5-4aa2-bfab-ef13b4f28b3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e7958aee-19b3-4951-9949-06e7efbf8e3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SYNJARDY SYNJARDY is a combination of empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor and metformin hydrochloride (HCl) immediate-release, a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. SYNJARDY XR SYNJARDY XR is a combination of empagliflozin, a SGLT2 inhibitor and metformin HCl extended-release, a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus . Empagliflozin Empagliflozin, when used as a component of SYNJARDY or SYNJARDY XR, is indicated in adults with type 2 diabetes mellitus to reduce the risk of: Cardiovascular (CV) death in adults with established CV disease. ( 1 ) CV death and hospitalization for heart failure in adults with heart failure. ( 1 ) Sustained decline in eGFR, end-stage kidney disease, CV death, and hospitalization in adults with chronic kidney disease at risk of progression. ( 1 ) Limitations of Use : Not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus. It may increase the risk of diabetic ketoacidosis in these patients. ( 1 ) Because of the metformin HCl component, the use of SYNJARDY or SYNJARDY XR is limited to patients with type 2 diabetes mellitus for all indications. ( 1 ) Empagliflozin, when used as a component of SYNJARDY or SYNJARDY XR, is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of intravenous immunosuppressive therapy or greater than 45 mg of prednisone or equivalent for kidney disease. Empagliflozin is not expected to be effective in these populations. ( 1 ) uuid:f653f224-de9f-4552-a5fe-3471bb91b5d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1664312 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:43c399df-d80e-473c-a326-9d945bcdd542"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5a567fe4-f3dd-4412-84b5-939ca8a8e3d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SYNJARDY SYNJARDY is a combination of empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor and metformin hydrochloride (HCl) immediate-release, a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. SYNJARDY XR SYNJARDY XR is a combination of empagliflozin, a SGLT2 inhibitor and metformin HCl extended-release, a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus . Empagliflozin Empagliflozin, when used as a component of SYNJARDY or SYNJARDY XR, is indicated in adults with type 2 diabetes mellitus to reduce the risk of: Cardiovascular (CV) death in adults with established CV disease. ( 1 ) CV death and hospitalization for heart failure in adults with heart failure. ( 1 ) Sustained decline in eGFR, end-stage kidney disease, CV death, and hospitalization in adults with chronic kidney disease at risk of progression. ( 1 ) Limitations of Use : Not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus. It may increase the risk of diabetic ketoacidosis in these patients. ( 1 ) Because of the metformin HCl component, the use of SYNJARDY or SYNJARDY XR is limited to patients with type 2 diabetes mellitus for all indications. ( 1 ) Empagliflozin, when used as a component of SYNJARDY or SYNJARDY XR, is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of intravenous immunosuppressive therapy or greater than 45 mg of prednisone or equivalent for kidney disease. Empagliflozin is not expected to be effective in these populations. ( 1 ) uuid:dcceadd7-0a7d-42e5-a2e9-8161f2c82d17 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1664312 biolink:treats MONDO:0012819 PMID:41385096 "[{""id"":""uuid:32d03c0e-8229-4046-9c69-41f669e81712"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:691f1c34-b2f4-41e1-8b03-c979973289d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SYNJARDY SYNJARDY is a combination of empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor and metformin hydrochloride (HCl) immediate-release, a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. SYNJARDY XR SYNJARDY XR is a combination of empagliflozin, a SGLT2 inhibitor and metformin HCl extended-release, a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus . Empagliflozin Empagliflozin, when used as a component of SYNJARDY or SYNJARDY XR, is indicated in adults with type 2 diabetes mellitus to reduce the risk of: Cardiovascular (CV) death in adults with established CV disease. ( 1 ) CV death and hospitalization for heart failure in adults with heart failure. ( 1 ) Sustained decline in eGFR, end-stage kidney disease, CV death, and hospitalization in adults with chronic kidney disease at risk of progression. ( 1 ) Limitations of Use : Not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus. It may increase the risk of diabetic ketoacidosis in these patients. ( 1 ) Because of the metformin HCl component, the use of SYNJARDY or SYNJARDY XR is limited to patients with type 2 diabetes mellitus for all indications. ( 1 ) Empagliflozin, when used as a component of SYNJARDY or SYNJARDY XR, is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of intravenous immunosuppressive therapy or greater than 45 mg of prednisone or equivalent for kidney disease. Empagliflozin is not expected to be effective in these populations. ( 1 ) uuid:92f1fa77-e812-46e3-8efd-e5e3a794d1aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1664312 biolink:treats MONDO:0020642 PMID:41385096 "[{""id"":""uuid:7c85dcf4-fe97-4668-9d7f-19df20f3f0fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7609e3f5-6bb0-415b-b80c-c0164b825e17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SYNJARDY SYNJARDY is a combination of empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor and metformin hydrochloride (HCl) immediate-release, a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus. SYNJARDY XR SYNJARDY XR is a combination of empagliflozin, a SGLT2 inhibitor and metformin HCl extended-release, a biguanide, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus . Empagliflozin Empagliflozin, when used as a component of SYNJARDY or SYNJARDY XR, is indicated in adults with type 2 diabetes mellitus to reduce the risk of: Cardiovascular (CV) death in adults with established CV disease. ( 1 ) CV death and hospitalization for heart failure in adults with heart failure. ( 1 ) Sustained decline in eGFR, end-stage kidney disease, CV death, and hospitalization in adults with chronic kidney disease at risk of progression. ( 1 ) Limitations of Use : Not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus. It may increase the risk of diabetic ketoacidosis in these patients. ( 1 ) Because of the metformin HCl component, the use of SYNJARDY or SYNJARDY XR is limited to patients with type 2 diabetes mellitus for all indications. ( 1 ) Empagliflozin, when used as a component of SYNJARDY or SYNJARDY XR, is not recommended for the treatment of chronic kidney disease in patients with polycystic kidney disease or patients requiring or with a recent history of intravenous immunosuppressive therapy or greater than 45 mg of prednisone or equivalent for kidney disease. Empagliflozin is not expected to be effective in these populations. ( 1 ) uuid:a97950ed-4060-4fb6-961e-bfc6cc6bdea5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229652 biolink:treats MONDO:0100244 PMID:41385096 "[{""id"":""uuid:1bd7fec1-0d4f-43a4-a56e-98b694c0ddb4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:74c6d54d-855e-4bfb-ae0a-8ce0aa39b736"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FABHALTA is a complement factor B inhibitor, indicated for: the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH). ( 1.1 ) the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥ 1.5 g/g. ( 1.2 ) This indication is approved under accelerated approval based on reduction of proteinuria. It has not been established whether FABHALTA slows kidney function decline in patients with IgAN. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial. the treatment of adults with complement 3 glomerulopathy (C3G), to reduce proteinuria. ( 1.3 ) uuid:9e966c8f-9787-406a-991e-ebc19bc61ef8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229652 biolink:treats MONDO:0005342 PMID:41385096 "[{""id"":""uuid:c47a2f22-49f6-4acf-80c3-e1e10c332615"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ec291de4-63a7-4179-8f1a-8d2e4742c382"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FABHALTA is a complement factor B inhibitor, indicated for: the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH). ( 1.1 ) the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥ 1.5 g/g. ( 1.2 ) This indication is approved under accelerated approval based on reduction of proteinuria. It has not been established whether FABHALTA slows kidney function decline in patients with IgAN. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial. the treatment of adults with complement 3 glomerulopathy (C3G), to reduce proteinuria. ( 1.3 ) uuid:13b32037-8a77-42a1-8d36-bcf7e721a080 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3JB47N2Q2P biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:ea97dc23-9fc5-4200-ad37-06d36ca51681"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:93c9df4c-51c4-4b81-8343-74ed4d874e96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:5177e742-2155-4596-a910-07541ba7b618"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TYSABRI is an integrin receptor antagonist indicated for treatment of: Multiple Sclerosis (MS) TYSABRI is indicated as monotherapy for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. TYSABRI increases the risk of PML [See Warnings and Precautions ( 5.1 ) ]. When initiating and continuing treatment with TYSABRI, physicians should consider whether the expected benefit of TYSABRI is sufficient to offset this risk. ( 1.1 ) Crohn's Disease (CD) TYSABRI is indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active Crohn's disease with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional CD therapies and inhibitors of TNF-α. ( 1.2 ) Important Limitations: In CD, TYSABRI should not be used in combination with immunosuppressants or inhibitors of TNF-α. ( 1.2 )|[PMDA] A drug with a new active ingredient indicated for the prevention of relapse and for delaying the accumulation of physical disability in multiple sclerosis. [Orphan drug] uuid:13869ce9-0219-4848-9cd1-f16045333723 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3JB47N2Q2P biolink:treats UMLS:C2921627 PMID:41385096 "[{""id"":""uuid:89f67772-03b3-494e-a2c8-258c3757e396"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b4d5ab8c-3aa1-449a-b9a7-3dd0f612a012"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TYSABRI is an integrin receptor antagonist indicated for treatment of: Multiple Sclerosis (MS) TYSABRI is indicated as monotherapy for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. TYSABRI increases the risk of PML [See Warnings and Precautions ( 5.1 ) ]. When initiating and continuing treatment with TYSABRI, physicians should consider whether the expected benefit of TYSABRI is sufficient to offset this risk. ( 1.1 ) Crohn's Disease (CD) TYSABRI is indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active Crohn's disease with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional CD therapies and inhibitors of TNF-α. ( 1.2 ) Important Limitations: In CD, TYSABRI should not be used in combination with immunosuppressants or inhibitors of TNF-α. ( 1.2 ) uuid:46e65a3a-6afe-42b7-b179-7bc27a479574 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3JB47N2Q2P biolink:treats MONDO:0000450 PMID:41385096 "[{""id"":""uuid:fe36f525-b967-444d-a825-c6a8052a5ded"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2ed926a5-c496-419f-8202-71a701720e8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TYSABRI is an integrin receptor antagonist indicated for treatment of: Multiple Sclerosis (MS) TYSABRI is indicated as monotherapy for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. TYSABRI increases the risk of PML [See Warnings and Precautions ( 5.1 ) ]. When initiating and continuing treatment with TYSABRI, physicians should consider whether the expected benefit of TYSABRI is sufficient to offset this risk. ( 1.1 ) Crohn's Disease (CD) TYSABRI is indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active Crohn's disease with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional CD therapies and inhibitors of TNF-α. ( 1.2 ) Important Limitations: In CD, TYSABRI should not be used in combination with immunosuppressants or inhibitors of TNF-α. ( 1.2 ) uuid:dfec7bf8-0b35-4cdf-adc1-17d2e4f7a59a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3JB47N2Q2P biolink:treats MONDO:0005011 PMID:41385096 "[{""id"":""uuid:b8f0f355-1c22-4be5-aeac-47ce60905295"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9e32511f-6195-476e-bd5c-2a5198f45f29"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TYSABRI is an integrin receptor antagonist indicated for treatment of: Multiple Sclerosis (MS) TYSABRI is indicated as monotherapy for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. TYSABRI increases the risk of PML [See Warnings and Precautions ( 5.1 ) ]. When initiating and continuing treatment with TYSABRI, physicians should consider whether the expected benefit of TYSABRI is sufficient to offset this risk. ( 1.1 ) Crohn's Disease (CD) TYSABRI is indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active Crohn's disease with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional CD therapies and inhibitors of TNF-α. ( 1.2 ) Important Limitations: In CD, TYSABRI should not be used in combination with immunosuppressants or inhibitors of TNF-α. ( 1.2 ) uuid:e4d88221-d5ea-48c6-b07c-7d903a39ff66 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82698 biolink:treats MONDO:0013600 PMID:41385096 "[{""id"":""uuid:5ee8977e-8f62-4086-a6c4-b5023efcd00b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:da5671cc-2c5b-4e97-b26d-29dc3543ffbf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b7147b51-9b35-4bc0-9cf9-17b35efd92b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BELSOMRA ® (suvorexant) is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.|[PMDA] Drugs with a new active ingredient indicated for the treatment of insomnia. uuid:a031e9ba-4014-4960-8355-82fb2fae1802 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEMBL.COMPOUND:CHEMBL2108334 biolink:treats MONDO:0010602 PMID:41385096 "[{""id"":""uuid:69d62a76-49f9-4c00-958b-d1c61b65a33c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:231a4301-05d8-4b4e-95d9-bfcebb889788"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SEVENFACT [coagulation factor VIIa (recombinant)-jncw] is indicated for the treatment and control of bleeding episodes occurring in adults and adolescents (12 years of age and older) with hemophilia A or B with inhibitors. Limitation of Use: SEVENFACT is not indicated for the treatment of patients with congenital Factor VII deficiency. uuid:61558213-9dd1-4737-b408-f2ad880c2168 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEMBL.COMPOUND:CHEMBL2108334 biolink:treats MONDO:0010604 PMID:41385096 "[{""id"":""uuid:0f33f241-6496-48b8-bae3-51722aa42add"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:88162db1-adfd-4ed8-a157-f13729e6f2f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SEVENFACT [coagulation factor VIIa (recombinant)-jncw] is indicated for the treatment and control of bleeding episodes occurring in adults and adolescents (12 years of age and older) with hemophilia A or B with inhibitors. Limitation of Use: SEVENFACT is not indicated for the treatment of patients with congenital Factor VII deficiency. uuid:24a887db-f692-4e0e-b87d-a8d4fc2e5468 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEMBL.COMPOUND:CHEMBL2108334 biolink:treats MONDO:0009211 PMID:41385096 "[{""id"":""uuid:7dce824c-ad42-4843-828d-ded213a1f4bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5c5bd01c-cbdc-4eb6-9d52-94334a60ccab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d4f8e32b-c7d8-424f-b4e7-fefafc67eddb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SEVENFACT [coagulation factor VIIa (recombinant)-jncw] is indicated for the treatment and control of bleeding episodes occurring in adults and adolescents (12 years of age and older) with hemophilia A or B with inhibitors. Limitation of Use: SEVENFACT is not indicated for the treatment of patients with congenital Factor VII deficiency.|[PMDA] Drugs with a new additional indication and a new dosage for inhibition of bleeding tendency in patients with congenital factor VII deficiency. uuid:3a55b7fc-341b-4adf-a7cd-c3cc7c633f23 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:J3LVA7RZT2 biolink:treats UMLS:C5231121 PMID:41385096 "[{""id"":""uuid:447ee197-fbe5-4fdd-9cbb-428f0114736c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9bf236f0-ab4a-4672-ad3a-73bf853e3115"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENCELTO is indicated for the treatment of adults with idiopathic macular telangiectasia type 2 (MacTel). uuid:ea6698dc-0b6f-4706-a7e4-17099a8a95ed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5108 biolink:treats MONDO:0004728 PMID:41385096 "[{""id"":""uuid:abf3ab49-8275-4c82-b939-e86dd37a3d5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:28e84f07-a96e-475f-bb18-a4805411f4a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ILUVIEN is a corticosteroid indicated for: the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure. (1.1) the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. (1.2) uuid:7877140f-fe89-4387-beae-d042ef4cffb7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41948 biolink:treats MONDO:0005072 PMID:41385096 "[{""id"":""uuid:c94746ad-1201-4f20-a3e9-36826290d500"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b2c6de99-6d37-4cb8-b8dd-fa4f3801bc8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IWILFIN (eflornithine) is indicated to reduce the risk of relapse in adult and pediatric patients with high-risk neuroblastoma (HRNB) who have demonstrated at least a partial response to prior multiagent, multimodality therapy including anti-GD2 immunotherapy. uuid:e6b5fc40-5f5a-4cdb-97a2-3aac4849007b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2637 biolink:treats MONDO:0005866 PMID:41385096 "[{""id"":""uuid:647cc67b-3c6a-4dfb-8ad9-1417c2039407"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9e146394-f5f0-422a-90ba-05567f7f906a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:07971a43-5b5c-4525-8e1f-caaf6ac41b64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:71e8dd54-0cda-478e-ba42-49167e284f56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LIMITED POPULATION: ARIKAYCE ® is indicated in adults, who have limited or no alternative treatment options, for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen in patients who do not achieve negative sputum cultures after a minimum of 6 consecutive months of a multidrug background regimen therapy. As only limited clinical safety and effectiveness data for ARIKAYCE are currently available, reserve ARIKAYCE for use in adults who have limited or no alternative treatment options . This drug is indicated for use in a limited and specific population of patients. This indication is approved under accelerated approval based on achieving sputum culture conversion (defined as 3 consecutive negative monthly sputum cultures) by Month 6. Clinical benefit has not yet been established [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials .|[EMA] Arikayce liposomal is indicated for the treatment of non-tuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium Complex (MAC) in adults with limited treatment options who do not have cystic fibrosis.|[PMDA] A drug with a new route of administration indicated for the treatment of nontuberculous mycobacterial pulmonary disease caused by amikacin-sensitive Mycobacterium avium complex (MAC). uuid:ce4d136e-12e8-4e14-ac08-7a0ad347363e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DVF0PR037D biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:a44397e2-eda3-46d9-9380-1317db9872d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:22ac2d0e-c55f-44fd-be2f-5988e36392cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BLUJEPA is a triazaacenaphthylene bacterial type II topoisomerase inhibitor indicated for the treatment of female adult and pediatric patients 12 years of age and older weighing at least 40 kilograms (kg) with uncomplicated urinary tract infections (uUTI) caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii complex , Staphylococcus saprophyticus, and Enterococcus faecalis . ( 1.1 ) Usage to Reduce Development of Drug-Resistant Bacteria To reduce the development of drug-resistant bacteria and maintain the effectiveness of BLUJEPA and other antibacterial drugs, BLUJEPA should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. ( 1.2 ) uuid:a8521d7b-f835-49e6-9081-2860c12d6d10 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DVF0PR037D biolink:treats MONDO:0020920 PMID:41385096 "[{""id"":""uuid:df313964-d2cf-420c-90f7-2436edb80413"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9e1a9818-fc25-4912-a84c-51aac7a48a99"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BLUJEPA is a triazaacenaphthylene bacterial type II topoisomerase inhibitor indicated for the treatment of female adult and pediatric patients 12 years of age and older weighing at least 40 kilograms (kg) with uncomplicated urinary tract infections (uUTI) caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii complex , Staphylococcus saprophyticus, and Enterococcus faecalis . ( 1.1 ) Usage to Reduce Development of Drug-Resistant Bacteria To reduce the development of drug-resistant bacteria and maintain the effectiveness of BLUJEPA and other antibacterial drugs, BLUJEPA should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. ( 1.2 ) uuid:3175bf8a-48d1-478f-9c92-f02e64825e6b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DVF0PR037D biolink:treats UMLS:C0948802 PMID:41385096 "[{""id"":""uuid:adadb8f7-71fb-49db-8142-5cb82c7870f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:976d086d-6a6b-4c34-ba2b-243fa02358fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BLUJEPA is a triazaacenaphthylene bacterial type II topoisomerase inhibitor indicated for the treatment of female adult and pediatric patients 12 years of age and older weighing at least 40 kilograms (kg) with uncomplicated urinary tract infections (uUTI) caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii complex , Staphylococcus saprophyticus, and Enterococcus faecalis . ( 1.1 ) Usage to Reduce Development of Drug-Resistant Bacteria To reduce the development of drug-resistant bacteria and maintain the effectiveness of BLUJEPA and other antibacterial drugs, BLUJEPA should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. ( 1.2 ) uuid:f861d9e7-5c09-476c-8d03-0ae5fefe2a18 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DVF0PR037D biolink:treats UMLS:C1142267 PMID:41385096 "[{""id"":""uuid:9ed17ff7-acbc-41d1-9be4-4aa459759571"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bfc55340-cc12-4369-a049-f2c822675b9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BLUJEPA is a triazaacenaphthylene bacterial type II topoisomerase inhibitor indicated for the treatment of female adult and pediatric patients 12 years of age and older weighing at least 40 kilograms (kg) with uncomplicated urinary tract infections (uUTI) caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii complex , Staphylococcus saprophyticus, and Enterococcus faecalis . ( 1.1 ) Usage to Reduce Development of Drug-Resistant Bacteria To reduce the development of drug-resistant bacteria and maintain the effectiveness of BLUJEPA and other antibacterial drugs, BLUJEPA should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. ( 1.2 ) uuid:afd7ceeb-6928-4f3a-81e6-d58b74eca09d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DVF0PR037D biolink:treats MONDO:0005121 PMID:41385096 "[{""id"":""uuid:f83ec052-f0f5-42ae-8280-1e55bd809547"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eb279fe2-6f92-4e38-982a-c88a909941a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BLUJEPA is a triazaacenaphthylene bacterial type II topoisomerase inhibitor indicated for the treatment of female adult and pediatric patients 12 years of age and older weighing at least 40 kilograms (kg) with uncomplicated urinary tract infections (uUTI) caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii complex , Staphylococcus saprophyticus, and Enterococcus faecalis . ( 1.1 ) Usage to Reduce Development of Drug-Resistant Bacteria To reduce the development of drug-resistant bacteria and maintain the effectiveness of BLUJEPA and other antibacterial drugs, BLUJEPA should be used only to treat infections that are proven or strongly suspected to be caused by bacteria. ( 1.2 ) uuid:e72c44bf-3b23-47b6-bf31-db295126a7b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2636536 biolink:treats EFO:0009130 PMID:41385096 "[{""id"":""uuid:2cd29ba9-e6e5-44d8-a39f-a9355da6605b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:adeb87e4-d0b6-4289-b16b-01a4351f77c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VOWST is indicated to prevent the recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older following antibacterial treatment for recurrent CDI (rCDI). uuid:2e6e45af-82e9-4ef1-87aa-95a037486be8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2636536 biolink:treats UMLS:C5230640 PMID:41385096 "[{""id"":""uuid:48e3f7c2-4839-4f07-a5a8-8bea57cc6be7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:be9a8522-f015-4438-ab8d-48a5a79a520e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VOWST is indicated to prevent the recurrence of Clostridioides difficile infection (CDI) in individuals 18 years of age and older following antibacterial treatment for recurrent CDI (rCDI). uuid:2a661101-44e1-48c1-92b7-f308c2e2ad31 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63633 biolink:treats MONDO:0008315 PMID:41385096 "[{""id"":""uuid:6b5565bf-17d4-4361-9893-15b5412c700d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:43da15b1-e871-43af-80c5-954397611514"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRELSTAR is indicated for the treatment of advanced prostate cancer [ see Clinical Studies (14) ]. uuid:32ddfa79-1d8c-41e1-a8aa-e54ae2a6136f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:176844 biolink:treats MONDO:0018364 PMID:41385096 "[{""id"":""uuid:662e30fb-d57c-4ddf-8003-f5f775156049"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a170bc5d-2c93-4bcb-bf8a-e17e07159207"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZEJULA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: • for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy. ( 1.1 ) • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA -mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for ZEJULA ( 1.2 , 2.1 ) uuid:45a3196e-09a4-4526-be90-a5b0b2111782 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:176844 biolink:treats MONDO:0002158 PMID:41385096 "[{""id"":""uuid:0b23a858-8dc3-437f-902a-344b34e77335"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a8b5f17d-64ea-476a-a66a-c2fa79086fd3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:72a1b7a8-83a6-4a54-b475-6939093cc357"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZEJULA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: • for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy. ( 1.1 ) • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA -mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for ZEJULA ( 1.2 , 2.1 )|[EMA] Zejula is indicated:, , , as monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy., as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy., , uuid:578ae0a3-1c28-4aaf-94a6-023b74da479d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:176844 biolink:treats MONDO:0015686 PMID:41385096 "[{""id"":""uuid:d9f900ac-1df5-4050-b830-a6f45df84d32"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c47994b0-abaa-4f21-904b-813b03487e4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0a32a518-f34e-4535-81f5-78b67902a519"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZEJULA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: • for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy. ( 1.1 ) • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA -mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for ZEJULA ( 1.2 , 2.1 )|[EMA] Zejula is indicated:, , , as monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy., as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy., , uuid:45279289-cc20-4515-bc11-dcce3b763510 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:176844 biolink:treats UMLS:C3897738 PMID:41385096 "[{""id"":""uuid:13a15427-5c78-4996-b3e8-c544440739c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b7e1a7ae-7419-4d88-94db-5474b64529bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZEJULA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: • for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy. ( 1.1 ) • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA -mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for ZEJULA ( 1.2 , 2.1 ) uuid:88b271ee-3681-4065-a917-042edb3364d3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:176844 biolink:treats UMLS:C3897731 PMID:41385096 "[{""id"":""uuid:f52e2b94-c864-4828-9a3d-19d5f8e2a217"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0b7e1dc3-eceb-45ea-82ff-0cd50fc071dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZEJULA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated: • for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy. ( 1.1 ) • for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA -mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for ZEJULA ( 1.2 , 2.1 ) uuid:2b36bc07-260f-4891-b90e-39cbd6e60065 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2W150K0UUC biolink:treats MONDO:0015762 PMID:41385096 "[{""id"":""uuid:6f42205b-b5c3-4652-b8b1-5365721eb768"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:342e69ad-a234-4c2f-8320-39527e81fe7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:11cacdf6-ee67-436b-9a5e-5841df201b14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/bylvay""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] BYLVAY is an ileal bile acid transporter (IBAT) inhibitor indicated for: Progressive Familial Intrahepatic Cholestasis (PFIC) the treatment of pruritus in patients 3 months of age and older with progressive familial intrahepatic cholestasis (PFIC). ( 1.1 ) Limitation of Use : BYLVAY may not be effective in a subgroup of PFIC type 2 patients with specific ABCB11 variants resulting in non-functional or complete absence of the bile salt export pump protein. ( 1.1 , 12.5 , 14 ) Alagille Syndrome (ALGS) the treatment of cholestatic pruritus in patients 12 months of age and older with Alagille syndrome (ALGS). ( 1.2 )|[EMA] Bylvay is indicated for the treatment of progressive familial intrahepatic cholestasis (PFIC) in patients aged 6 months or older (see sections 4.4 and 5.1). uuid:5319d437-b9bb-4202-b5ef-2943f635e6dc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2W150K0UUC biolink:treats HP:0000989 PMID:41385096 "[{""id"":""uuid:a114c4e5-bec0-4c63-8ba0-dc5c6e0774ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c80d7168-4289-45ee-bb34-4b5c4420e2f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BYLVAY is an ileal bile acid transporter (IBAT) inhibitor indicated for: Progressive Familial Intrahepatic Cholestasis (PFIC) the treatment of pruritus in patients 3 months of age and older with progressive familial intrahepatic cholestasis (PFIC). ( 1.1 ) Limitation of Use : BYLVAY may not be effective in a subgroup of PFIC type 2 patients with specific ABCB11 variants resulting in non-functional or complete absence of the bile salt export pump protein. ( 1.1 , 12.5 , 14 ) Alagille Syndrome (ALGS) the treatment of cholestatic pruritus in patients 12 months of age and older with Alagille syndrome (ALGS). ( 1.2 ) uuid:4cbf0d3a-e4ae-45e0-8122-620fb060d341 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2W150K0UUC biolink:treats MONDO:0007318 PMID:41385096 "[{""id"":""uuid:d6078875-2d9d-4cf0-a99e-724c8d84be0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9e1a16aa-5c4e-4fe8-a44b-8313b050734c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BYLVAY is an ileal bile acid transporter (IBAT) inhibitor indicated for: Progressive Familial Intrahepatic Cholestasis (PFIC) the treatment of pruritus in patients 3 months of age and older with progressive familial intrahepatic cholestasis (PFIC). ( 1.1 ) Limitation of Use : BYLVAY may not be effective in a subgroup of PFIC type 2 patients with specific ABCB11 variants resulting in non-functional or complete absence of the bile salt export pump protein. ( 1.1 , 12.5 , 14 ) Alagille Syndrome (ALGS) the treatment of cholestatic pruritus in patients 12 months of age and older with Alagille syndrome (ALGS). ( 1.2 ) uuid:f1d2931d-84b6-41fe-8726-8dc1fbd42c09 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2W150K0UUC biolink:treats UMLS:C1535964 PMID:41385096 "[{""id"":""uuid:d68121ae-e85e-425e-bad5-c949b8a7c21b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:148fb0dd-0b89-4d7f-9917-e5145d330728"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BYLVAY is an ileal bile acid transporter (IBAT) inhibitor indicated for: Progressive Familial Intrahepatic Cholestasis (PFIC) the treatment of pruritus in patients 3 months of age and older with progressive familial intrahepatic cholestasis (PFIC). ( 1.1 ) Limitation of Use : BYLVAY may not be effective in a subgroup of PFIC type 2 patients with specific ABCB11 variants resulting in non-functional or complete absence of the bile salt export pump protein. ( 1.1 , 12.5 , 14 ) Alagille Syndrome (ALGS) the treatment of cholestatic pruritus in patients 12 months of age and older with Alagille syndrome (ALGS). ( 1.2 ) uuid:c7687322-f312-4912-bcd0-dcea0b6f6189 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:15C2VL427D biolink:treats MONDO:0005417 PMID:41385096 "[{""id"":""uuid:c0ba109c-ae55-41fc-b2c1-6e3ceb583d94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e4f72ca0-00e3-4a39-8797-cc9d2bdbab55"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:21ea968d-9efa-4458-8401-0e37e6cf6935"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/yesafili""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1 INDICATIONS AND USAGE AHZANTIVE is indicated for the treatment of: 1.1 Neovascular (Wet) Age-Related Macular Degeneration (AMD) 1.2 Macular Edema Following Retinal Vein Occlusion (RVO) 1.3 Diabetic Macular Edema (DME) 1.4 Diabetic Retinopathy (DR)|[EMA] Yesafili is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (AMD) (see section 5.1),visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) (see section 5.1),visual impairment due to diabetic macular oedema (DME) (see section 5.1),visual impairment due to myopic choroidal neovascularisation (myopic CNV) (see section 5.1). uuid:5eaa4c90-2b25-40b2-a5db-007752cebfbf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:15C2VL427D biolink:treats MONDO:0041093 PMID:41385096 "[{""id"":""uuid:d4e06378-ab08-48f3-ba74-89a93850e28e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:18f63cce-3a5b-4990-a976-943dfc419a18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4cf03d70-7ed8-4b7d-9b62-38df097cbc4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1 INDICATIONS AND USAGE AHZANTIVE is indicated for the treatment of: 1.1 Neovascular (Wet) Age-Related Macular Degeneration (AMD) 1.2 Macular Edema Following Retinal Vein Occlusion (RVO) 1.3 Diabetic Macular Edema (DME) 1.4 Diabetic Retinopathy (DR)|[PMDA] Drugs with a revised indication for the treatment of macular edema following retinal vein occlusion. uuid:f9f16009-4d76-44f1-827f-1331bbc9268a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:15C2VL427D biolink:treats MONDO:0004728 PMID:41385096 "[{""id"":""uuid:48d5dee9-f3e2-4d6a-9be2-8cec0a9a3021"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4f24cc24-8d16-4ea6-b4f7-48854035fceb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4bd3fcf3-d22a-4989-a031-6e6d60d14e37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/yesafili""]},{""id"":""uuid:93adf229-6c9d-4005-9158-29f709461e8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1 INDICATIONS AND USAGE AHZANTIVE is indicated for the treatment of: 1.1 Neovascular (Wet) Age-Related Macular Degeneration (AMD) 1.2 Macular Edema Following Retinal Vein Occlusion (RVO) 1.3 Diabetic Macular Edema (DME) 1.4 Diabetic Retinopathy (DR)|[EMA] Yesafili is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (AMD) (see section 5.1),visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) (see section 5.1),visual impairment due to diabetic macular oedema (DME) (see section 5.1),visual impairment due to myopic choroidal neovascularisation (myopic CNV) (see section 5.1).|[PMDA] A drug in a new dosage form indicated for the treatment of age-related macular degeneration associated with subfoveal choroidal neovascularization and diabetic macular edema. uuid:940c1c6a-7b6c-41df-a9b2-907a3c48dd0f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:15C2VL427D biolink:treats MONDO:0005266 PMID:41385096 "[{""id"":""uuid:f4e9cf6a-de4c-4fe7-8f7b-e35b85207b9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8853cef0-cb07-47b9-874c-bb4880207c7c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1 INDICATIONS AND USAGE AHZANTIVE is indicated for the treatment of: 1.1 Neovascular (Wet) Age-Related Macular Degeneration (AMD) 1.2 Macular Edema Following Retinal Vein Occlusion (RVO) 1.3 Diabetic Macular Edema (DME) 1.4 Diabetic Retinopathy (DR) uuid:4862db87-305c-4435-865d-97ded1ec2175 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:88249 biolink:treats MONDO:0003304 PMID:41385096 "[{""id"":""uuid:650d5053-792e-4082-8a0b-7d3426c32acb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1fe6da0d-ced9-496c-826b-5afa78f622ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] GOMEKLI is indicated for the treatment of adult and pediatric patients 2 years of age and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection [see Clinical Studies (14) ]. uuid:d4f17068-172a-4fe0-b776-ef14115db265 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134699 biolink:treats MONDO:0005180 PMID:41385096 "[{""id"":""uuid:102fd951-dd54-4180-926a-136b1a495b4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:de31f913-492b-4023-b6b1-76cdae3bc388"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7c8b490e-eeea-42d0-a93c-c987bbef825e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ontilyv""]},{""id"":""uuid:3a228586-925f-4073-a4cb-4b3c7e050de1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ONGENTYS is indicated as adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease (PD) experiencing “off” episodes.|[EMA] Ontilyv is indicated as adjunctive therapy to preparations of levodopa/ DOPA decarboxylase inhibitors (DDCI) in adult patients with Parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.|[PMDA] A drug with a new active ingredient indicated for the improvement of wearing-off phenomenon in patients with Parkinson’s disease in combination with levodopa/carbidopa or levodopa/benserazide hydrochloride. uuid:f12330a3-d491-4aeb-9467-4f27a58c78d4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:127780 biolink:treats MONDO:0043905 PMID:41385096 "[{""id"":""uuid:760ecc27-0174-4096-a33c-0d97940ed83f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ffd33224-4f2b-440b-a68d-146fb38d5ca2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Foscarnet sodium injection is indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). Combination therapy with foscarnet sodium and ganciclovir is indicated for patients who have relapsed after monotherapy with either drug. SAFETY AND EFFICACY OF FOSCARNET SODIUM INJETION HAVE NOT BEEN ESTABLISHED FOR TREATMENT OF OTHER CMV INFECTIONS (e.g., PNEUMONITIS, GASTROENTERITIS); CONGENITAL OR NEONATAL CMV DISEASE; OR NONIMMUNOCOMPROMISED INDIVIDUALS. uuid:fbc498a0-9d9a-4f2b-b834-b0ce89594d9b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:127780 biolink:treats MONDO:0002269 PMID:41385096 "[{""id"":""uuid:1d998353-8f0d-4c0e-9e13-97aeea473fc1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bd719e08-1e69-4ba4-8d7b-8f636a2d7eec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Foscarnet sodium injection is indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). Combination therapy with foscarnet sodium and ganciclovir is indicated for patients who have relapsed after monotherapy with either drug. SAFETY AND EFFICACY OF FOSCARNET SODIUM INJETION HAVE NOT BEEN ESTABLISHED FOR TREATMENT OF OTHER CMV INFECTIONS (e.g., PNEUMONITIS, GASTROENTERITIS); CONGENITAL OR NEONATAL CMV DISEASE; OR NONIMMUNOCOMPROMISED INDIVIDUALS. uuid:83aaa0a5-c9ca-4164-a978-8d26ffd29fc9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:127780 biolink:treats MONDO:0017409 PMID:41385096 "[{""id"":""uuid:40846d40-f791-4a13-a85e-5694798b99b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:682ce4ce-c6e2-4a66-a172-d699eb7e34c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Foscarnet sodium injection is indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). Combination therapy with foscarnet sodium and ganciclovir is indicated for patients who have relapsed after monotherapy with either drug. SAFETY AND EFFICACY OF FOSCARNET SODIUM INJETION HAVE NOT BEEN ESTABLISHED FOR TREATMENT OF OTHER CMV INFECTIONS (e.g., PNEUMONITIS, GASTROENTERITIS); CONGENITAL OR NEONATAL CMV DISEASE; OR NONIMMUNOCOMPROMISED INDIVIDUALS. uuid:fbb44895-cd79-4b31-a5d2-c07f28d42b59 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:127780 biolink:treats MONDO:0005132 PMID:41385096 "[{""id"":""uuid:b9ce336b-8dfd-4d3c-a6ad-4e16717bdc96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fefd2207-9c46-43ec-bad3-68482eccd160"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ad8df7d9-6569-4398-9ea9-e8cef6140b1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Foscarnet sodium injection is indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). Combination therapy with foscarnet sodium and ganciclovir is indicated for patients who have relapsed after monotherapy with either drug. SAFETY AND EFFICACY OF FOSCARNET SODIUM INJETION HAVE NOT BEEN ESTABLISHED FOR TREATMENT OF OTHER CMV INFECTIONS (e.g., PNEUMONITIS, GASTROENTERITIS); CONGENITAL OR NEONATAL CMV DISEASE; OR NONIMMUNOCOMPROMISED INDIVIDUALS.|[PMDA] A drug with new additional indications and a new dosage for the treatment of cytomegalovirus viremia and cytomegalovirus infection in patients undergoing hematopoietic stem cell transplantation. uuid:1bed2a5b-3a66-4c8d-8407-f861ea3129ce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:119058042 biolink:treats MONDO:0010602 PMID:41385096 "[{""id"":""uuid:559f2e18-be68-4bfb-9728-7548b81614c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7b8c07ef-5484-4139-acce-603455b6ef95"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] QFITLIA is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients aged 12 years and older with hemophilia A or B with or without factor VIII or IX inhibitors. uuid:c17b1809-5ffa-4368-b5bc-c1b0cb96cf4e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:119058042 biolink:treats MONDO:0010604 PMID:41385096 "[{""id"":""uuid:798ccda6-bacc-44ec-9be8-fbdbdaceb1c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aad7a02e-edbb-44f4-a023-8c64bb23939e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] QFITLIA is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients aged 12 years and older with hemophilia A or B with or without factor VIII or IX inhibitors. uuid:30ebee68-bc91-41fd-af39-2f71d7615a5c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1989496 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:b6e10697-4b6e-40e4-aefe-8c4aa5249ec4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:38e14ffe-72f9-48d6-a818-d709cdac0cf0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] JULUCA is indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies/mL) on a stable antiretroviral regimen for at least 6 months with no history of treatment failure and no known substitutions associated with resistance to the individual components of JULUCA. uuid:7b16bdf0-910f-48eb-bd95-3bbfe221af5d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:GB4I2JI8UI biolink:treats MONDO:0007100 PMID:41385096 "[{""id"":""uuid:1da594e5-6791-4a67-b766-7ad86fdc1620"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3446edf5-6774-4388-84b1-8be6a3f1cf9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:454ad9b5-1867-4427-bbdb-53563c7cd9ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c52dbc32-f526-407a-b92f-69d63b93d792"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AMVUTTRA is a transthyretin-directed small interfering RNA indicated for the treatment of: the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults ( 1.1 ) the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits ( 1.2 )|[EMA] Treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.|[PMDA] A drug with a new active ingredient indicated for the treatment of transthyretin familial amyloid polyneuropathy. [Orphan drug] uuid:4cefe639-6d29-45b9-b183-ebdfd78e22bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:GB4I2JI8UI biolink:treats MONDO:0018018 PMID:41385096 "[{""id"":""uuid:bef1476c-5e56-495c-8b90-fdadae039891"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:968d1686-41b6-40ae-b3a8-18591f3c1dec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AMVUTTRA is a transthyretin-directed small interfering RNA indicated for the treatment of: the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults ( 1.1 ) the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits ( 1.2 ) uuid:5abe67ed-6c89-4972-a504-66265b66f99e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:GB4I2JI8UI biolink:treats MONDO:0971008 PMID:41385096 "[{""id"":""uuid:bbd9210e-7b08-457c-baf0-1299902dad63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d7e7375a-ba60-48c3-a819-9f073952126c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AMVUTTRA is a transthyretin-directed small interfering RNA indicated for the treatment of: the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults ( 1.1 ) the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits ( 1.2 ) uuid:229d7cd2-7fb7-4dbc-83e7-95e67053c5cf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:GB4I2JI8UI biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:10cdf3ec-f47b-41af-aa86-df22d8fb9e22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1bfeb496-5d9f-4b0f-8a93-7bb0f3548591"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AMVUTTRA is a transthyretin-directed small interfering RNA indicated for the treatment of: the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults ( 1.1 ) the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits ( 1.2 ) uuid:abd17859-e1e9-42bf-84ba-b07569fdfbc5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:G6UF363ECX biolink:treats MONDO:0004956 PMID:41385096 "[{""id"":""uuid:5e1a0836-1224-461e-9727-ca4abee1af17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:71a7d17e-c0e3-45b0-b9ab-813dae38fa19"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:46702c38-4c88-481f-80e5-62fc2cccba0f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PLUVICTO is indicated for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor pathway inhibitor (ARPI) therapy, and are considered appropriate to delay taxane-based chemotherapy, or have received prior taxane-based chemotherapy.|[EMA] Pluvicto in combination with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with AR pathway inhibition and taxane based chemotherapy. uuid:6d27e363-1087-48ab-9ccc-a206d4f80fc7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231693 biolink:treats UMLS:C0278987 PMID:41385096 "[{""id"":""uuid:a62f70ff-74ee-4b69-bcec-3b3a9b4f8d8e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c76abc68-e93d-41c0-94d7-e2aba4dc368a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TABRECTA is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test. uuid:317ccbb3-f3f4-4dc4-a491-ca546832dee9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231693 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:2b43ffd6-37ae-460c-800a-627398ce8ff5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d40a6368-28d4-40e7-b391-6ecf8d5935f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TABRECTA is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test. uuid:efab3772-f0f0-4b9a-81a2-b646a6272a75 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37924 biolink:treats MONDO:0018477 PMID:41385096 "[{""id"":""uuid:b80a8ef4-0fbe-4aca-aa28-f8cecc04bfc9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:103cbed1-fb52-4275-8338-ce445fd33557"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Atazanavir capsules are indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and in pediatric patients 6 years and older weighing at least 15 kg. Limitations of Use: Atazanavir capsules are not recommended for use in pediatric patients below the age of 3 months due to the risk of kernicterus [see Use in Specific Populations ( 8.4 )] . Use of atazanavir capsules with ritonavir in treatment-experienced patients should be guided by the number of baseline primary protease inhibitor resistance substitutions [see Microbiology ( 12.4 )] . uuid:6e2d68ac-c9ad-4b4a-9e0d-c2fd954836d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16755 biolink:treats MONDO:0008948 PMID:41385096 "[{""id"":""uuid:b9b33e41-ec57-4a0d-a15a-7e06dabe5c20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:19038386-0160-4ad3-b6fb-268d0e1c2d7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:88067919-d0ee-40fe-a588-831e8d971878"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/chenodeoxycholic-acid-leadiant""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] CTEXLI is indicated for the treatment of cerebrotendinous xanthomatosis (CTX) in adults.|[EMA] Chenodeoxycholic acid is indicated for the treatment of inborn errors of primary bile acid synthesis due to sterol 27 hydroxylase deficiency (presenting as cerebrotendinous xanthomatosis (CTX)) in infants, children and adolescents aged 1 month to 18 years and adults. uuid:5862ec8f-58df-4285-96af-29ee3efa781c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:ZJ0EKR6M10 biolink:treats MONDO:0008315 PMID:41385096 "[{""id"":""uuid:b7a29651-fd46-479b-bce7-12cfcfc89de3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0e331a58-0cb6-4088-9069-38f20e65678f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LOCAMETZ, after radiolabeling with gallium-68, is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA)-positive lesions in men with prostate cancer: with suspected metastasis who are candidates for initial definitive therapy. with suspected recurrence based on elevated serum prostate-specific antigen (PSA) level. for selection of patients who are indicated for PSMA-directed therapy as described in the prescribing information of the therapeutic products. PUBCHEM.COMPOUND:91800164 uuid:d6f1c5d3-467a-411d-8825-373a0b1ec676 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17996 biolink:treats UMLS:C1112600 PMID:41385096 "[{""id"":""uuid:49208192-d038-481c-b3af-766fe4198d94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a1e4b22e-189d-4d97-b2b4-ee684de1f77a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Therapeutic indications TURKFLEKS 0.9% ISOTONIC SODIUM CHLORIDE is indicated for: - Treatment of isotonic extracellular dehydration - Treatment of sodium depletion - As diluent of compatible drugs for parenteral administration. uuid:452a42d3-b209-4d22-9a07-45ab15deba84 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C4753359 biolink:treats MONDO:0018874 PMID:41385096 "[{""id"":""uuid:ed8c3088-3677-4150-bfcc-b9907efd546b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:93d6f301-f263-4e15-bb48-731c23002038"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MYLOTARG is a CD33-directed antibody and cytotoxic drug conjugate indicated for: • treatment of newly-diagnosed CD33-positive acute myeloid leukemia (AML) in adults and pediatric patients 1 month and older ( 1.1 ). • treatment of relapsed or refractory CD33-positive AML in adults and pediatric patients 2 years and older ( 1.2 ). uuid:58661ac3-aa5a-4310-813f-ee30fa45a884 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:Z7HVY03PHP biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:d998031d-fad4-4a4c-a11e-fb6f655d9f05"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:094c327d-b997-4a80-b1d2-e2aa0dd00cb0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:5897b3c2-c981-411f-80c1-5d2bb3324351"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/omvoh""]},{""id"":""uuid:1ca6df36-09cb-4df0-b057-8dbcbe4231ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OMVOH is indicated for the treatment of: moderately to severely active ulcerative colitis in adults. moderately to severely active Crohn's disease in adults.|[EMA] Omvoh is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic treatment.|[PMDA] A drug with a new active ingredient indicated for the remission induction therapy of moderate to severe ulcerative colitis (for use only in patients who have not sufficiently responded to conventional treatments). (3) Drugs with a new active ingredient indicated for the maintenance therapy of moderate to severe ulcerative colitis (for use only in patients who have not sufficiently responded to conventional treatments). uuid:f0292bde-0ac8-463e-ba4a-2776129d88e6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:Z7HVY03PHP biolink:treats MONDO:0005011 PMID:41385096 "[{""id"":""uuid:75d13e82-5cc3-47d9-bad3-2711d64c0427"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8ecd2287-a40b-486a-bfb4-ca3b4632f8fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OMVOH is indicated for the treatment of: moderately to severely active ulcerative colitis in adults. moderately to severely active Crohn's disease in adults. uuid:aa519c59-0ccc-4984-9229-b5517bc337d7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:156963654 biolink:treats UMLS:C0278488 PMID:41385096 "[{""id"":""uuid:b850d272-a77a-44d6-bdcc-c1df9b39a9a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:becda54d-ecfa-47c1-a78e-6b34cb55b513"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRODELVY is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with: Locally Advanced or Metastatic Breast Cancer Unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease. ( 1.1 , 14.1 ) Unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. ( 1.1 , 14.2 ) uuid:2b72a33f-f6fe-46ca-9644-b1376bc7567e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:156963654 biolink:treats MONDO:0005494 PMID:41385096 "[{""id"":""uuid:175d2c02-cb71-4215-b302-80f530d89382"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cfe6713a-bb21-40bc-97ac-78982ef6c2af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRODELVY is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with: Locally Advanced or Metastatic Breast Cancer Unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease. ( 1.1 , 14.1 ) Unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. ( 1.1 , 14.2 ) uuid:9369dc72-224f-470e-a34a-2580b5d9f509 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:156963654 biolink:treats MONDO:0700079 PMID:41385096 "[{""id"":""uuid:9a5740c4-ae45-4bd7-8d21-f77adfb74413"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:43f2c43e-8905-4730-b12a-85e9a1735803"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRODELVY is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of adult patients with: Locally Advanced or Metastatic Breast Cancer Unresectable locally advanced or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease. ( 1.1 , 14.1 ) Unresectable locally advanced or metastatic hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH–) breast cancer who have received endocrine-based therapy and at least two additional systemic therapies in the metastatic setting. ( 1.1 , 14.2 ) uuid:ca1803d5-64d6-4802-beba-3302bf12d84d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135923 biolink:treats MONDO:0010526 PMID:41385096 "[{""id"":""uuid:0110b80e-322f-40f4-9841-dedd018ba366"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b676d943-901d-4c7b-8b6a-22da6d2a552b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:385f228e-7a24-42ca-8b14-35f213afe45b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f01f0a94-7096-46ba-82f1-9b8b57fab066"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] GALAFOLD is indicated for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene ( GLA ) variant based on in vitro assay data [see Dosage and Administration (2.1) and Clinical Pharmacology (12.1) ] . This indication is approved under accelerated approval based on reduction in kidney interstitial capillary cell globotriaosylceramide (KIC GL-3) substrate [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.|[EMA] Galafold is indicated for long-term treatment of adults and adolescents aged 16 years and older with a confirmed diagnosis of Fabry disease (α-galactosidase A deficiency) and who have an amenable mutation.|[PMDA] A drug with a new active ingredient indicated for the treatment of Fabry disease in patients with GLA mutations categorized as amenable to treatment with migalastat. [Orphan drug] uuid:7677fc55-5181-4a53-a0bb-0bb839f244b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:65173 biolink:treats MONDO:0005478 PMID:41385096 "[{""id"":""uuid:e0f38f6e-b368-4156-8da1-eeebf0886328"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c82bde8b-4937-46b6-8e05-35f687dd18b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Iloperidone tablets are indicated for the treatment of schizophrenia in adults. When deciding among the alternative treatments available for this condition, the prescriber should consider the finding that iloperidone tablets are associated with prolongation of the QTc interval [see Warnings and Precautions (5.3) ] . Prolongation of the QTc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia which can result in sudden death. In many cases this would lead to the conclusion that other drugs should be tried first. Whether iloperidone tablets will cause torsade de pointes or increase the rate of sudden death is not yet known. Patients must be titrated to an effective dose of iloperidone tablets. Thus, control of symptoms may be delayed during the first 1 to 2 weeks of treatment compared to some other antipsychotic drugs that do not require a similar titration. Prescribers should be mindful of this delay when selecting an antipsychotic drug for the treatment of schizophrenia [see Dosage and Administration (2.1) and Clinical Studies (14) ] . uuid:f6387f99-4093-45e1-ba46-f8be11bafdd6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:65173 biolink:treats MONDO:0005477 PMID:41385096 "[{""id"":""uuid:471d22ef-b51d-4d55-998b-cbdb0cc5463b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8f3adfe0-ac89-4c70-9bbe-95857af89df1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Iloperidone tablets are indicated for the treatment of schizophrenia in adults. When deciding among the alternative treatments available for this condition, the prescriber should consider the finding that iloperidone tablets are associated with prolongation of the QTc interval [see Warnings and Precautions (5.3) ] . Prolongation of the QTc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia which can result in sudden death. In many cases this would lead to the conclusion that other drugs should be tried first. Whether iloperidone tablets will cause torsade de pointes or increase the rate of sudden death is not yet known. Patients must be titrated to an effective dose of iloperidone tablets. Thus, control of symptoms may be delayed during the first 1 to 2 weeks of treatment compared to some other antipsychotic drugs that do not require a similar titration. Prescribers should be mindful of this delay when selecting an antipsychotic drug for the treatment of schizophrenia [see Dosage and Administration (2.1) and Clinical Studies (14) ] . uuid:9993ebbf-aa99-4738-9c7e-b73132f14c30 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8202AY8I7H biolink:treats MONDO:0005277 PMID:41385096 "[{""id"":""uuid:556613bf-a709-45d8-81eb-905aaca26fe1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6e01e704-2323-4b4b-a3e9-3670a1c780fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:21895ed9-1ba4-48b5-a9b7-a2698d7fefdd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vyepti""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] VYEPTI is indicated for the preventive treatment of migraine in adults.|[EMA] Vyepti is indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month. uuid:704bace5-dde1-419b-a238-445879e6477c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17347 biolink:treats MONDO:0006908 PMID:41385096 "[{""id"":""uuid:34b55089-5351-4ed7-aa58-8cb41a0615de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:81db13a4-943f-45ca-94ce-b21f8bf357ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XYOSTED (testosterone enanthate) injection is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. Primary hypogonadism (congenital or acquired): testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum concentrations but have gonadotropins in the normal or low range. Limitations of Use: Safety and efficacy of XYOSTED in men with “age-related hypogonadism” has not been established. Safety and efficacy of XYOSTED in males less than 18 years old have not been established [see Use in Specific Populations ( 8.4 )] . uuid:03b48b52-b9ff-4f1e-a68d-a9c87b06c419 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17347 biolink:treats MONDO:0002150 PMID:41385096 "[{""id"":""uuid:8cb96c8f-f4cb-4989-a1b0-d0bb12cb3091"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c9b2b1ef-1c3b-4e14-a616-76a879bf667a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XYOSTED (testosterone enanthate) injection is an androgen indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency or absence of endogenous testosterone. Primary hypogonadism (congenital or acquired): testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter's syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range. Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum concentrations but have gonadotropins in the normal or low range. Limitations of Use: Safety and efficacy of XYOSTED in men with “age-related hypogonadism” has not been established. Safety and efficacy of XYOSTED in males less than 18 years old have not been established [see Use in Specific Populations ( 8.4 )] . uuid:e1c9f17e-9d84-4522-8f00-4bdc31578cb1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:76511460 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:3b7e0ae3-13d3-4a55-9ec5-8b0fb5933017"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:46734520-5513-416a-bc5c-031d581c70c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PREZCOBIX is indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) in treatment-naïve and treatment-experienced adults and pediatric patients weighing at least 25 kg with no darunavir resistance-associated substitutions (V11I, V32I, L33F, I47V, I50V, I54L, I54M, T74P, L76V, I84V, L89V). uuid:34266770-2530-4ab2-984e-bff668a3a236 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:1383NM3Q0H biolink:treats MONDO:0005475 PMID:41385096 "[{""id"":""uuid:e10b5f22-1495-4ca6-8b22-ffa9f4ae58e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3043b44c-a280-4fe1-bc5d-263e897200c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NURTEC ODT is a calcitonin gene-related peptide receptor antagonist indicated for the: • acute treatment of migraine with or without aura in adults ( 1.1 ) • preventive treatment of episodic migraine in adults ( 1.2 ) uuid:71221dd5-fec0-4a41-a367-f8925dab68c9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:1383NM3Q0H biolink:treats MONDO:0100431 PMID:41385096 "[{""id"":""uuid:13b5a17d-c33d-4de4-b90b-90bbd0c0cbcf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9411b596-f379-459d-a03d-6e04ac04ea49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NURTEC ODT is a calcitonin gene-related peptide receptor antagonist indicated for the: • acute treatment of migraine with or without aura in adults ( 1.1 ) • preventive treatment of episodic migraine in adults ( 1.2 ) uuid:7d0dfd94-c835-4696-ac03-433fff234c19 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:1383NM3Q0H biolink:treats UMLS:C4760993 PMID:41385096 "[{""id"":""uuid:aa9dc277-c390-4247-9550-7a941a2fcf22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b4b4989a-b1da-42f2-b68e-79fb71df71ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NURTEC ODT is a calcitonin gene-related peptide receptor antagonist indicated for the: • acute treatment of migraine with or without aura in adults ( 1.1 ) • preventive treatment of episodic migraine in adults ( 1.2 ) uuid:c5e37853-ff6a-4215-826f-5bee099d75e4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68534 biolink:treats MONDO:0004956 PMID:41385096 "[{""id"":""uuid:d9103163-e8a0-4ff3-8b17-f1369f52f706"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:13b6e3c6-75a2-4167-93d1-cc9a5b25d999"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:98506d33-621d-4af9-bd1a-d0365394bf5d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/xtandi""]},{""id"":""uuid:98b1afbf-e6b9-4160-9130-debc492ce359"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XTANDI ® is indicated for the treatment of patients with: • castration-resistant prostate cancer (CRPC) • metastatic castration-sensitive prostate cancer (mCSPC) • non‑metastatic castration‑sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk for metastasis (high-risk BCR)|[EMA] Xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (see section 5.1).the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (CRPC) (see section 5.1).the treatment of adult men with metastatic CRPC who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5.1).the treatment of adult men with metastatic CRPC whose disease has progressed on or after docetaxel therapy.|[PMDA] Drugs with a new indication for the treatment of metastatic prostate cancer. uuid:5c594bed-7229-4ad5-a8ed-f54bdb6611f6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68534 biolink:treats MONDO:0008315 PMID:41385096 "[{""id"":""uuid:a7515e10-dce9-4a55-9167-c615345b43e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c55bb9ed-d482-4845-a4c6-251e106633ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XTANDI ® is indicated for the treatment of patients with: • castration-resistant prostate cancer (CRPC) • metastatic castration-sensitive prostate cancer (mCSPC) • non‑metastatic castration‑sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk for metastasis (high-risk BCR) uuid:479be450-bf50-4681-8d28-d4f35f4383a2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:81569 biolink:treats MONDO:0005047 PMID:41385096 "[{""id"":""uuid:4711bfef-1b6d-4ebe-a178-1e00402e49b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:02ff23ea-6b8f-4e4b-9db2-25cf0b5147f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] GONAL-f ® RFF Redi-ject ® is a prefilled gonadotropin-containing auto-injection device indicated for: Induction of ovulation and pregnancy in oligo-anovulatory women in whom the cause of infertility is functional and not due to primary ovarian failure ( 1.1 ) Development of multiple follicles in ovulatory women as part of an Assisted Reproductive Technology (ART) cycle ( 1.2 ) uuid:f34d0df1-f870-4180-b4d7-2b721fdd3a15 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:I5I8VB78VT biolink:treats MONDO:0005277 PMID:41385096 "[{""id"":""uuid:fe78ff2e-232a-47ec-ad74-06ad72c5d6d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3e8cc560-630a-4261-a95b-b17d11dd3ac4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:54f437f3-d966-48fb-9237-c42c07a8e135"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/aimovig""]},{""id"":""uuid:fcb2dd29-8b18-49f9-8188-c93f99e4a382"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AIMOVIG is indicated for the preventive treatment of migraine in adults.|[EMA] Aimovig is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month when initiating treatment with Aimovig.|[PMDA] A drug with a new active ingredient indicated for the prevention of migraine attacks. uuid:165e27b4-970e-4b24-a07b-dd8c10deeb0a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4T36H88UA7 biolink:treats MONDO:0004956 PMID:41385096 "[{""id"":""uuid:ec796866-775e-499b-9cf7-75790ad10081"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ef96bc00-4eba-4876-85e1-95c19096f81e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:687b740e-8c2f-4b5d-8ec9-ac30fdebe566"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/erleada""]},{""id"":""uuid:0cbbb9cc-97a2-43db-8051-26134474b095"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ERLEADA is indicated for the treatment of patients with Metastatic castration-sensitive prostate cancer (mCSPC) Non-metastatic castration-resistant prostate cancer (nmCRPC)|[EMA] Erleada is indicated:in adult men for the treatment of non metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.in adult men for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT).|[PMDA] A drug with a new indication for the treatment of metastatic prostate cancer. uuid:77331d69-cb32-45e3-81ad-846652702104 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:BDT58WJ9WE biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:36692165-ff99-4273-95f0-e867e8b53846"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1b32ee68-8c32-4c33-86fa-2fd47118f28c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SUNLENCA, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 whose current antiretroviral regimen is failing due to resistance, intolerance, or safety considerations. uuid:cad64730-e391-4792-a6a5-41945da78ef5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:142418 biolink:treats EFO:0006865 PMID:41385096 "[{""id"":""uuid:2e56f96a-f595-4017-902e-529dc4dbe697"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d19d598d-5205-4357-9cb1-7028e6b7af59"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e4bc46fb-00da-44a8-a94c-b92be1b464ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] GEMTESA is a beta-3 adrenergic agonist indicated for the treatment of: overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults. ( 1.1 ) overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adult males on pharmacological therapy for benign prostatic hyperplasia (BPH). ( 1.2 )|[PMDA] A drug with a new active ingredient indicated for the treatment of urinary urgency, urinary frequency, and urge urinary incontinence associated with overactive bladder. uuid:eb391ca1-4dfc-4a7a-9b3e-01d644c3e2d1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:142418 biolink:treats MONDO:0010811 PMID:41385096 "[{""id"":""uuid:6891daa7-28e7-4ad7-abda-5bdab3f9baa6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:efa6126f-f7fa-45a8-9e6c-a785b00e0597"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] GEMTESA is a beta-3 adrenergic agonist indicated for the treatment of: overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults. ( 1.1 ) overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adult males on pharmacological therapy for benign prostatic hyperplasia (BPH). ( 1.2 ) uuid:5a6d4e7b-be23-4df6-9d2c-0c23ffdbd60b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:69478 biolink:treats MONDO:0100135 PMID:41385096 "[{""id"":""uuid:239082e4-2fda-4bb6-b0ff-6301c5a242cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e1f5159f-7c9d-4054-ae01-7794b6f087b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:bbf9c765-db58-4143-8f12-777cf60eaaf7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/epidyolex""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] EPIDIOLEX is indicated for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC) in patients 1 year of age and older.|[EMA] Epidyolex is indicated for use as adjunctive therapy of seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome (DS), in conjunction with clobazam, for patients 2 years of age and older. uuid:c2d676a7-4e85-4030-8f38-ceb8a01539f7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50694 biolink:treats MONDO:0021108 PMID:41385096 "[{""id"":""uuid:50d824ac-3a65-4e6c-a570-1c43247e835c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5d2b1358-4890-47c9-bc68-3dcd048c43f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MINOCIN ® Intravenous is indicated in the treatment of the following infections due to susceptible isolates of the designated bacteria: Rocky Mountain spotted fever, typhus fever and the typhus group, Q fever, rickettsialpox and tick fevers caused by rickettsiae. Respiratory tract infections caused by Mycoplasma pneumoniae . Lymphogranuloma venereum caused by Chlamydia trachomatis . Psittacosis (Ornithosis) due to Chlamydophila psittaci . Trachoma caused by Chlamydia trachomatis , although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis caused by Chlamydia trachomatis . Nongonococcal urethritis, endocervical, or rectal infections in adults caused by Ureaplasma urealyticum or Chlamydia trachomatis. Relapsing fever due to Borrelia recurrentis . Plague due to Yersinia pestis . Tularemia due to Francisella tularensis . Cholera caused by Vibrio cholerae . Campylobacter fetus infections caused by Campylobacter fetus . Brucellosis due to Brucella species (in conjunction with streptomycin). Bartonellosis due to Bartonella bacilliformis . Granuloma inguinale caused by Klebsiella granulomatis . Minocycline is indicated for the treatment of infections caused by the following Gram-negative bacteria when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli . Enterobacter aerogenes . Shigella species . Acinetobacter species . Respiratory tract infections caused by Haemophilus influenzae . Respiratory tract and urinary tract infections caused by Klebsiella species . MINOCIN ® Intravenous is indicated for the treatment of infections caused by the following Gram-positive bacteria when bacteriologic testing indicates appropriate susceptibility to the drug: Upper respiratory tract infections caused by Streptococcus pneumoniae. Skin and skin structure infections caused by Staphylococcus aureus (Note: Minocycline is not the drug of choice in the treatment of any type of staphylococcal infection.) When penicillin is contraindicated, minocycline is an alternative drug in the treatment of the following infections: Meningitis due to Neisseria meningitidis . Syphilis caused by Treponema pallidum subspecies pallidum . Yaws caused by Treponema pallidum subspecies pertenue . Listeriosis due to Listeria monocytogenes . Anthrax due to Bacillus anthracis . Vincent's infection caused by Fusobacterium fusiforme. Actinomycosis caused by Actinomyces israelii . Infections caused by Clostridium species . In acute intestinal amebiasis , minocycline may be a useful adjunct to amebicides. In severe acne , minocycline may be useful adjunctive therapy. To reduce the development of drug-resistant bacteria and maintain the effectiveness of MINOCIN ® (minocycline) for Injection and other antibacterial drugs, MINOCIN ® (minocycline) for Injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:0b01931f-5619-4a0f-b2f9-1b95eff8adac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:647208 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:cf85f085-6dcd-4c25-a40a-c52aa31acf09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:51a0c85b-53fe-4e79-92b6-e1cfaa5b7f4c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DUETACT is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are already treated with a thiazolidinedione and sulfonylurea or who have inadequate glycemic control on a thiazolidinedione alone or a sulfonylurea alone [see Clinical Studies ( 14 )] . Important Limitations of Use Pioglitazone exerts its antihyperglycemic effect only in the presence of endogenous insulin. DUETACT should not be used to treat type 1 diabetes or diabetic ketoacidosis, as it would not be effective in these settings. Use caution in patients with liver disease [see Warnings and Precautions ( 5.5 )] . uuid:ade5390e-8fe3-48ea-a5d5-03d651408dbb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:647208 biolink:treats MONDO:0012819 PMID:41385096 "[{""id"":""uuid:21eb59d4-1689-49db-909f-20d402b7249b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a6ab23db-e4e2-4dd4-b393-a91a7907ba6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DUETACT is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus who are already treated with a thiazolidinedione and sulfonylurea or who have inadequate glycemic control on a thiazolidinedione alone or a sulfonylurea alone [see Clinical Studies ( 14 )] . Important Limitations of Use Pioglitazone exerts its antihyperglycemic effect only in the presence of endogenous insulin. DUETACT should not be used to treat type 1 diabetes or diabetic ketoacidosis, as it would not be effective in these settings. Use caution in patients with liver disease [see Warnings and Precautions ( 5.5 )] . uuid:78a9702f-bf73-4b5d-be60-068358bef844 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:92043599 biolink:treats UMLS:C5438213 PMID:41385096 "[{""id"":""uuid:85ec50e5-2ced-41d3-9700-f1eb93cef72b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3e17da68-cd2c-450c-b1c3-201dc0eb6f63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROCRIT is an erythropoiesis-stimulating agent (ESA) indicated for: Treatment of anemia due to Chronic Kidney Disease (CKD) in patients on dialysis and not on dialysis ( 1.1 ). Zidovudine in patients with Human Immunodeficiency Virus (HIV) infection ( 1.2 ). The effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy ( 1.3 ). Reduction of allogeneic red blood cell (RBC) transfusions in patients undergoing elective, noncardiac, nonvascular surgery ( 1.4 ). Limitations of Use PROCRIT has not been shown to improve quality of life, fatigue, or patient well-being ( 1.5 ). PROCRIT is not indicated for use: In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy ( 1.5 ). In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure ( 1.5 ). In patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion ( 1.5 ). In patients scheduled for surgery who are willing to donate autologous blood ( 1.5 ). In patients undergoing cardiac or vascular surgery ( 1.5 ). As a substitute for RBC transfusions in patients who require immediate correction of anemia ( 1.5 ). uuid:2d5226bb-cc79-421f-ad43-2200495c0e0f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:92043599 biolink:treats UMLS:C0343751 PMID:41385096 "[{""id"":""uuid:7c73826b-a14e-4a4d-88ad-67cf00bfa95a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4b1f7e38-21e9-4adf-91a3-bf5026f2c165"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROCRIT is an erythropoiesis-stimulating agent (ESA) indicated for: Treatment of anemia due to Chronic Kidney Disease (CKD) in patients on dialysis and not on dialysis ( 1.1 ). Zidovudine in patients with Human Immunodeficiency Virus (HIV) infection ( 1.2 ). The effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy ( 1.3 ). Reduction of allogeneic red blood cell (RBC) transfusions in patients undergoing elective, noncardiac, nonvascular surgery ( 1.4 ). Limitations of Use PROCRIT has not been shown to improve quality of life, fatigue, or patient well-being ( 1.5 ). PROCRIT is not indicated for use: In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy ( 1.5 ). In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure ( 1.5 ). In patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion ( 1.5 ). In patients scheduled for surgery who are willing to donate autologous blood ( 1.5 ). In patients undergoing cardiac or vascular surgery ( 1.5 ). As a substitute for RBC transfusions in patients who require immediate correction of anemia ( 1.5 ). uuid:f8a7bc03-340b-425f-8814-82ca9f74b0cc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:92043599 biolink:treats MONDO:0002280 PMID:41385096 "[{""id"":""uuid:4dcf99fb-337e-4f62-b487-923c790ab11b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:1217141a-c006-4552-9a93-e37fbf636a3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3f743c39-77c1-4f0e-92f4-b3a1098d6a2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/epoetin-alfa-hexal""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROCRIT is an erythropoiesis-stimulating agent (ESA) indicated for: Treatment of anemia due to Chronic Kidney Disease (CKD) in patients on dialysis and not on dialysis ( 1.1 ). Zidovudine in patients with Human Immunodeficiency Virus (HIV) infection ( 1.2 ). The effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy ( 1.3 ). Reduction of allogeneic red blood cell (RBC) transfusions in patients undergoing elective, noncardiac, nonvascular surgery ( 1.4 ). Limitations of Use PROCRIT has not been shown to improve quality of life, fatigue, or patient well-being ( 1.5 ). PROCRIT is not indicated for use: In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy ( 1.5 ). In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure ( 1.5 ). In patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion ( 1.5 ). In patients scheduled for surgery who are willing to donate autologous blood ( 1.5 ). In patients undergoing cardiac or vascular surgery ( 1.5 ). As a substitute for RBC transfusions in patients who require immediate correction of anemia ( 1.5 ).|[EMA] Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult and paediatric patients:, , , treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis;, Treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis., , , Treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre-existing anaemia at the start of chemotherapy)., uuid:4790c81b-ca6c-4022-8028-bfc84049aa37 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4495 biolink:treats HP:0002591 PMID:41385096 "[{""id"":""uuid:54f8e3af-4aad-4c98-882f-7006aabe43e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f7d81f68-b8e1-489d-94df-ffd1d26b892c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VYKAT XR is indicated for the treatment of hyperphagia in adults and pediatric patients 4 years of age and older with Prader-Willi syndrome (PWS). uuid:c5b5b0e0-d4a9-45a5-a4f2-647d3a08288e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:789Q85GA8P biolink:treats MONDO:0016686 PMID:41385096 "[{""id"":""uuid:ddb1f5ea-0922-44df-9114-234c32c27126"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f661d759-1aa8-45c7-a6f9-217f86eb536a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VORANIGO is indicated for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) or isocitrate dehydrogenase-2 (IDH2) mutation, as detected by an FDA-approved test, following surgery including biopsy, sub-total resection, or gross total resection [see Dosage and Administration (2.1) , Clinical Pharmacology (12.1) and Clinical Studies (14) ] . uuid:b83a8d4f-6acf-4d27-907c-15bd7720ff93 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:789Q85GA8P biolink:treats MONDO:0016695 PMID:41385096 "[{""id"":""uuid:2ea12742-361b-441e-ab4a-63bec2e2e7c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cb321dbf-dc2d-469a-a7e1-63992be4b199"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VORANIGO is indicated for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) or isocitrate dehydrogenase-2 (IDH2) mutation, as detected by an FDA-approved test, following surgery including biopsy, sub-total resection, or gross total resection [see Dosage and Administration (2.1) , Clinical Pharmacology (12.1) and Clinical Studies (14) ] . uuid:2a86a2a9-7437-4d92-8d23-d50e3e8fe8f6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:090IP5RV8F biolink:treats MONDO:0004652 PMID:41385096 "[{""id"":""uuid:032b9cae-033c-4222-9d41-10caae5ac136"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:424aee89-8b42-48d6-a6d8-0af5a7edd784"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NUZYRA is a tetracycline class antibacterial indicated for the treatment of adult patients with the following infections caused by susceptible microorganisms ( 1 ): Community-acquired bacterial pneumonia (CABP) ( 1.1 ) Acute bacterial skin and skin structure infections (ABSSSI) ( 1.2 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of NUZYRA and other antibacterial drugs, NUZYRA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.3 ) uuid:e1108a21-77b9-4678-a6d2-756957d5f59c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:090IP5RV8F biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:3f09c1c8-f8e4-491b-9ee6-265d1d5d5f0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:97333cee-eaa3-4b19-be99-2af632d089bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NUZYRA is a tetracycline class antibacterial indicated for the treatment of adult patients with the following infections caused by susceptible microorganisms ( 1 ): Community-acquired bacterial pneumonia (CABP) ( 1.1 ) Acute bacterial skin and skin structure infections (ABSSSI) ( 1.2 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of NUZYRA and other antibacterial drugs, NUZYRA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.3 ) uuid:ea480e9d-80ce-4b55-b5bd-13af311fefbf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:28X28X9OKV biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:5161277f-fd63-4c24-99d0-dd63780877a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5349e846-fd99-4d8f-ba26-36aa63f16504"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d345d325-d7dc-42d4-997d-04e53bea4082"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/imfinzi""]},{""id"":""uuid:cae5e9cc-7173-4026-b8c8-6c9a7eb9a4e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IMFINZI is a programmed death-ligand 1 (PD-L1) blocking antibody indicated: • in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by IMFINZI continued as a single agent as adjuvant treatment after surgery, for the treatment of adult patients with resectable (tumors ≥ 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. ( 1.1 ) • as a single agent, for the treatment of adult patients with unresectable, Stage III NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. ( 1.1 ) • in combination with tremelimumab-actl and platinum-based chemotherapy, for the treatment of adult patients with metastatic NSCLC with no sensitizing EGFR mutations or ALK genomic tumor aberrations. ( 1.1 ) • as a single agent, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. ( 1.2 ) • in combination with etoposide and either carboplatin or cisplatin, as first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). ( 1.2 ) • in combination with gemcitabine and cisplatin, as treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC). ( 1.3 ) • in combination with tremelimumab-actl, for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC). ( 1.4 ) • in combination with carboplatin and paclitaxel followed by IMFINZI as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR) as determined by an FDA-approved test. ( 1.5 , 2.1 ) • in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent IMFINZI as adjuvant treatment following radical cystectomy, for the treatment of adult patients with muscle invasive bladder cancer (MIBC). ( 1.6 )|[EMA] Non-Small Cell Lung Cancer (NSCLC)IMFINZI as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5.1).IMFINZI in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic NSCLC with no sensitising EGFR mutations or ALK positive mutations.Small Cell Lung Cancer (SCLC)IMFINZI in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC).Biliary Tract Cancer (BTC)IMFINZI in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (BTC).Hepatocellular Carcinoma (HCC)IMFINZI in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC).|[PMDA] Drugs with a new active ingredient indicated for the maintenance treatment of locally-advanced, unresectable non-small cell lung cancer following definitive chemoradiation therapy. uuid:b0146cc2-7651-4eb3-9183-12e5ad617020 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:28X28X9OKV biolink:treats MONDO:0008433 PMID:41385096 "[{""id"":""uuid:e80d1a9a-a007-4a1f-8b90-893f99d6f52b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:429cd9b2-4785-4caa-8f05-677d1d6db4fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:58d0dc3b-d676-4b1c-871e-86ee10170d21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/imfinzi""]},{""id"":""uuid:216702f8-ff64-4eb8-ab09-3da62390aeca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IMFINZI is a programmed death-ligand 1 (PD-L1) blocking antibody indicated: • in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by IMFINZI continued as a single agent as adjuvant treatment after surgery, for the treatment of adult patients with resectable (tumors ≥ 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. ( 1.1 ) • as a single agent, for the treatment of adult patients with unresectable, Stage III NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. ( 1.1 ) • in combination with tremelimumab-actl and platinum-based chemotherapy, for the treatment of adult patients with metastatic NSCLC with no sensitizing EGFR mutations or ALK genomic tumor aberrations. ( 1.1 ) • as a single agent, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. ( 1.2 ) • in combination with etoposide and either carboplatin or cisplatin, as first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). ( 1.2 ) • in combination with gemcitabine and cisplatin, as treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC). ( 1.3 ) • in combination with tremelimumab-actl, for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC). ( 1.4 ) • in combination with carboplatin and paclitaxel followed by IMFINZI as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR) as determined by an FDA-approved test. ( 1.5 , 2.1 ) • in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent IMFINZI as adjuvant treatment following radical cystectomy, for the treatment of adult patients with muscle invasive bladder cancer (MIBC). ( 1.6 )|[EMA] Non-Small Cell Lung Cancer (NSCLC)IMFINZI as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5.1).IMFINZI in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic NSCLC with no sensitising EGFR mutations or ALK positive mutations.Small Cell Lung Cancer (SCLC)IMFINZI in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC).Biliary Tract Cancer (BTC)IMFINZI in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (BTC).Hepatocellular Carcinoma (HCC)IMFINZI in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC).|[PMDA] Drugs with a new indication and a new dosage for the treatment of extensive-stage small-cell lung cancer. uuid:67ab2fbb-4054-48b2-a4f2-fbe69783c320 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:28X28X9OKV biolink:treats MONDO:0003060 PMID:41385096 "[{""id"":""uuid:2faf5ee7-c582-4dcd-9a4d-1824a3e32d52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0547b659-95b7-469a-99fb-cba79d708921"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:04ee7ca6-0d31-42fd-99f0-402c2ae725e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/imfinzi""]},{""id"":""uuid:ac43b3d0-c32b-403c-9d58-65ced81eeb81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IMFINZI is a programmed death-ligand 1 (PD-L1) blocking antibody indicated: • in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by IMFINZI continued as a single agent as adjuvant treatment after surgery, for the treatment of adult patients with resectable (tumors ≥ 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. ( 1.1 ) • as a single agent, for the treatment of adult patients with unresectable, Stage III NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. ( 1.1 ) • in combination with tremelimumab-actl and platinum-based chemotherapy, for the treatment of adult patients with metastatic NSCLC with no sensitizing EGFR mutations or ALK genomic tumor aberrations. ( 1.1 ) • as a single agent, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. ( 1.2 ) • in combination with etoposide and either carboplatin or cisplatin, as first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). ( 1.2 ) • in combination with gemcitabine and cisplatin, as treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC). ( 1.3 ) • in combination with tremelimumab-actl, for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC). ( 1.4 ) • in combination with carboplatin and paclitaxel followed by IMFINZI as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR) as determined by an FDA-approved test. ( 1.5 , 2.1 ) • in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent IMFINZI as adjuvant treatment following radical cystectomy, for the treatment of adult patients with muscle invasive bladder cancer (MIBC). ( 1.6 )|[EMA] Non-Small Cell Lung Cancer (NSCLC)IMFINZI as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5.1).IMFINZI in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic NSCLC with no sensitising EGFR mutations or ALK positive mutations.Small Cell Lung Cancer (SCLC)IMFINZI in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC).Biliary Tract Cancer (BTC)IMFINZI in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (BTC).Hepatocellular Carcinoma (HCC)IMFINZI in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC).|[PMDA] Drugs with a new indication and a new dosage for the treatment of unresectable biliary tract cancer. [Orphan drug] uuid:64f1fa34-c405-4e3d-92c0-1da03788826f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:28X28X9OKV biolink:treats MONDO:0007256 PMID:41385096 "[{""id"":""uuid:c8f3f2e4-bf92-4860-be52-9bfd7aba99b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e0911789-7005-44b9-83ee-d0971469172d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:eec2e4cf-1cc7-4bc2-8f7e-011456e62560"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/imfinzi""]},{""id"":""uuid:0012ccb9-a5c8-4a7a-b293-b9cf33917362"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IMFINZI is a programmed death-ligand 1 (PD-L1) blocking antibody indicated: • in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by IMFINZI continued as a single agent as adjuvant treatment after surgery, for the treatment of adult patients with resectable (tumors ≥ 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. ( 1.1 ) • as a single agent, for the treatment of adult patients with unresectable, Stage III NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. ( 1.1 ) • in combination with tremelimumab-actl and platinum-based chemotherapy, for the treatment of adult patients with metastatic NSCLC with no sensitizing EGFR mutations or ALK genomic tumor aberrations. ( 1.1 ) • as a single agent, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. ( 1.2 ) • in combination with etoposide and either carboplatin or cisplatin, as first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). ( 1.2 ) • in combination with gemcitabine and cisplatin, as treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC). ( 1.3 ) • in combination with tremelimumab-actl, for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC). ( 1.4 ) • in combination with carboplatin and paclitaxel followed by IMFINZI as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR) as determined by an FDA-approved test. ( 1.5 , 2.1 ) • in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent IMFINZI as adjuvant treatment following radical cystectomy, for the treatment of adult patients with muscle invasive bladder cancer (MIBC). ( 1.6 )|[EMA] Non-Small Cell Lung Cancer (NSCLC)IMFINZI as monotherapy is indicated for the treatment of locally advanced, unresectable non small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 on ≥ 1% of tumour cells and whose disease has not progressed following platinum based chemoradiation therapy (see section 5.1).IMFINZI in combination with tremelimumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic NSCLC with no sensitising EGFR mutations or ALK positive mutations.Small Cell Lung Cancer (SCLC)IMFINZI in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC).Biliary Tract Cancer (BTC)IMFINZI in combination with gemcitabine and cisplatin is indicated for the first line treatment of adults with unresectable or metastatic biliary tract cancer (BTC).Hepatocellular Carcinoma (HCC)IMFINZI in combination with tremelimumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC).|[PMDA] (1) Drugs with a new indication and a new dosage for the treatment of unresectable advanced or recurrent non-small-cell lung cancer. (2) Drugs with a new indication and a new dosage for the treatment of unresectable hepatocellular carcinoma. uuid:1a6e9e15-7dc8-4ca1-a048-3fa5b7d6e83b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:28X28X9OKV biolink:treats MONDO:0011962 PMID:41385096 "[{""id"":""uuid:7700788f-6db5-43d7-959d-785a510814d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e56d58b4-3381-40cb-a389-91527dd65b75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IMFINZI is a programmed death-ligand 1 (PD-L1) blocking antibody indicated: • in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by IMFINZI continued as a single agent as adjuvant treatment after surgery, for the treatment of adult patients with resectable (tumors ≥ 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. ( 1.1 ) • as a single agent, for the treatment of adult patients with unresectable, Stage III NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. ( 1.1 ) • in combination with tremelimumab-actl and platinum-based chemotherapy, for the treatment of adult patients with metastatic NSCLC with no sensitizing EGFR mutations or ALK genomic tumor aberrations. ( 1.1 ) • as a single agent, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. ( 1.2 ) • in combination with etoposide and either carboplatin or cisplatin, as first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). ( 1.2 ) • in combination with gemcitabine and cisplatin, as treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC). ( 1.3 ) • in combination with tremelimumab-actl, for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC). ( 1.4 ) • in combination with carboplatin and paclitaxel followed by IMFINZI as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR) as determined by an FDA-approved test. ( 1.5 , 2.1 ) • in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent IMFINZI as adjuvant treatment following radical cystectomy, for the treatment of adult patients with muscle invasive bladder cancer (MIBC). ( 1.6 ) uuid:6520319b-26e7-4426-b37d-ce5988ba647b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:28X28X9OKV biolink:treats MONDO:0003890 PMID:41385096 "[{""id"":""uuid:837d86d3-414e-4c27-9455-de424ccf2fcf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c7bd5014-eeb9-47e2-9f34-1c6911008363"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IMFINZI is a programmed death-ligand 1 (PD-L1) blocking antibody indicated: • in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by IMFINZI continued as a single agent as adjuvant treatment after surgery, for the treatment of adult patients with resectable (tumors ≥ 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. ( 1.1 ) • as a single agent, for the treatment of adult patients with unresectable, Stage III NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. ( 1.1 ) • in combination with tremelimumab-actl and platinum-based chemotherapy, for the treatment of adult patients with metastatic NSCLC with no sensitizing EGFR mutations or ALK genomic tumor aberrations. ( 1.1 ) • as a single agent, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. ( 1.2 ) • in combination with etoposide and either carboplatin or cisplatin, as first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). ( 1.2 ) • in combination with gemcitabine and cisplatin, as treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC). ( 1.3 ) • in combination with tremelimumab-actl, for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC). ( 1.4 ) • in combination with carboplatin and paclitaxel followed by IMFINZI as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR) as determined by an FDA-approved test. ( 1.5 , 2.1 ) • in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent IMFINZI as adjuvant treatment following radical cystectomy, for the treatment of adult patients with muscle invasive bladder cancer (MIBC). ( 1.6 ) uuid:938dac49-58e0-40ab-b23e-5e3a4276e625 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7852 biolink:treats HP:0030858 PMID:41385096 "[{""id"":""uuid:3c34972a-b118-459b-82ec-0a4794f979ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:686529c3-d0b9-4daa-a5aa-bf86dcb4e614"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxycodone hydrochloride tablets are an opioid agonist indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. ( 1) Limitations of Use ( 1) Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, reserve oxycodone hydrochloride tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or non-opioid combination products): Have not been tolerated, or are not expected to be tolerated, Have not provided adequate analgesia or are not expected to provide adequate analgesia. Oxycodone hydrochloride tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see Warnings and Precautions (5.1) ] , reserve oxycodone hydrochloride tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or opioid combination products): Have not been tolerated or are not expected to be tolerated, Have not provided adequate analgesia or are not expected to provide adequate analgesia. uuid:7855b213-99d6-4192-90fd-0768a94cbcfc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7852 biolink:treats MONDO:0002491 PMID:41385096 "[{""id"":""uuid:f56c0acf-4661-4c95-aa21-b5cf6e9a28e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a367af27-3031-424d-b71d-a4310fcf12e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxycodone hydrochloride tablets are an opioid agonist indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. ( 1) Limitations of Use ( 1) Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, reserve oxycodone hydrochloride tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or non-opioid combination products): Have not been tolerated, or are not expected to be tolerated, Have not provided adequate analgesia or are not expected to provide adequate analgesia. Oxycodone hydrochloride tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see Warnings and Precautions (5.1) ] , reserve oxycodone hydrochloride tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or opioid combination products): Have not been tolerated or are not expected to be tolerated, Have not provided adequate analgesia or are not expected to provide adequate analgesia. uuid:a2a4ca0c-c40c-4e08-bfed-31ff5d7965b9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7852 biolink:treats EFO:0011049 PMID:41385096 "[{""id"":""uuid:8e6b03e9-d4ef-4902-8f63-0615e9682f77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5967a34b-f262-438d-9dda-09a22358d7a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Oxycodone hydrochloride tablets are an opioid agonist indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. ( 1) Limitations of Use ( 1) Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, reserve oxycodone hydrochloride tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or non-opioid combination products): Have not been tolerated, or are not expected to be tolerated, Have not provided adequate analgesia or are not expected to provide adequate analgesia. Oxycodone hydrochloride tablets are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Limitations of Use Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses [see Warnings and Precautions (5.1) ] , reserve oxycodone hydrochloride tablets for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or opioid combination products): Have not been tolerated or are not expected to be tolerated, Have not provided adequate analgesia or are not expected to provide adequate analgesia. uuid:cc594f4e-e181-4004-a52a-28bb7c761dc0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB17635 biolink:treats MONDO:0009823 PMID:41385096 "[{""id"":""uuid:59dfee17-8b7e-43ed-929a-0408503e00be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4f88a56d-8218-45c4-9488-d924a72fb504"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RIVFLOZA is indicated to lower urinary oxalate levels in children 2 years of age and older and adults with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function, e.g., eGFR ≥30 mL/min/1.73 m 2 [see Clinical Pharmacology (‎ 12.3 )], Clinical Studies (‎ 14.1 )]. uuid:fae84f09-5cee-408e-816f-9a792de37e25 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB17635 biolink:treats MONDO:0024685 PMID:41385096 "[{""id"":""uuid:5a844e49-6910-4c1b-8081-3547e3d159d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:261da720-7f30-49a2-8dc9-54d6656ab8ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RIVFLOZA is indicated to lower urinary oxalate levels in children 2 years of age and older and adults with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function, e.g., eGFR ≥30 mL/min/1.73 m 2 [see Clinical Pharmacology (‎ 12.3 )], Clinical Studies (‎ 14.1 )]. uuid:7e17f5b6-52cd-484d-8e01-fb9b69a194ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9334 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:45c25296-e1ad-48cc-937f-54419c166431"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c42cda04-2c0b-4949-bdcf-e07747cadd9a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AZULFIDINE EN-tabs Tablets are indicated: • in the treatment of mild to moderate ulcerative colitis, and as adjunctive therapy in severe ulcerative colitis; • for the prolongation of the remission period between acute attacks of ulcerative colitis; • in the treatment of patients with rheumatoid arthritis who have responded inadequately to salicylates or other nonsteroidal anti-inflammatory drugs (e.g., an insufficient therapeutic response to, or intolerance of, an adequate trial of full doses of one or more nonsteroidal anti-inflammatory drugs); and • in the treatment of pediatric patients with polyarticular-course 1 juvenile rheumatoid arthritis who have responded inadequately to salicylates or other nonsteroidal anti-inflammatory drugs. AZULFIDINE EN-tabs is particularly indicated in patients with ulcerative colitis who cannot take uncoated sulfasalazine tablets because of gastrointestinal intolerance, and in whom there is evidence that this intolerance is not primarily the result of high blood levels of sulfapyridine and its metabolites, e.g., patients experiencing nausea and vomiting with the first few doses of the drug, or patients in whom a reduction in dosage does not alleviate the adverse gastrointestinal effects. In patients with rheumatoid arthritis or juvenile rheumatoid arthritis, rest and physiotherapy as indicated should be continued. Unlike anti-inflammatory drugs, AZULFIDINE EN-tabs does not produce an immediate response. Concurrent treatment with analgesics and/or nonsteroidal anti-inflammatory drugs is recommended at least until the effect of AZULFIDINE EN-tabs is apparent. uuid:a3e03038-e042-4f36-a055-6b4af7222153 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9334 biolink:treats MONDO:0011429 PMID:41385096 "[{""id"":""uuid:bfa99aa6-d2cb-432e-8a75-afea7ed8e602"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:28190e16-d36c-4f5e-b820-e479102d0e39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AZULFIDINE EN-tabs Tablets are indicated: • in the treatment of mild to moderate ulcerative colitis, and as adjunctive therapy in severe ulcerative colitis; • for the prolongation of the remission period between acute attacks of ulcerative colitis; • in the treatment of patients with rheumatoid arthritis who have responded inadequately to salicylates or other nonsteroidal anti-inflammatory drugs (e.g., an insufficient therapeutic response to, or intolerance of, an adequate trial of full doses of one or more nonsteroidal anti-inflammatory drugs); and • in the treatment of pediatric patients with polyarticular-course 1 juvenile rheumatoid arthritis who have responded inadequately to salicylates or other nonsteroidal anti-inflammatory drugs. AZULFIDINE EN-tabs is particularly indicated in patients with ulcerative colitis who cannot take uncoated sulfasalazine tablets because of gastrointestinal intolerance, and in whom there is evidence that this intolerance is not primarily the result of high blood levels of sulfapyridine and its metabolites, e.g., patients experiencing nausea and vomiting with the first few doses of the drug, or patients in whom a reduction in dosage does not alleviate the adverse gastrointestinal effects. In patients with rheumatoid arthritis or juvenile rheumatoid arthritis, rest and physiotherapy as indicated should be continued. Unlike anti-inflammatory drugs, AZULFIDINE EN-tabs does not produce an immediate response. Concurrent treatment with analgesics and/or nonsteroidal anti-inflammatory drugs is recommended at least until the effect of AZULFIDINE EN-tabs is apparent. uuid:413a9ec4-3629-460c-bde7-8c410ed1b973 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17303 biolink:treats MONDO:0018362 PMID:41385096 "[{""id"":""uuid:a82d21a4-53ce-4d7c-a3ab-a1ed4ec17c25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:98be878f-ab4a-4da7-bafb-491bcb3d5922"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MS CONTIN is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic and for which alternative treatment options are inadequate. uuid:1891d2d2-b001-4237-a76e-863944759a73 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18243 biolink:treats MONDO:0006652 PMID:41385096 "[{""id"":""uuid:722a9cfa-d7d1-419c-81bd-03f7576512a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:63892b5b-72b9-4bb9-994b-d24fdfb03cc6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Dopamine hydrochloride is indicated for the correction of hemodynamic imbalances present in the shock syndrome due to myocardial infarctions, trauma, endotoxic septicemia, open heart surgery, renal failure and chronic cardiac decompensation as in congestive failure. Where appropriate, restoration of blood volume with a suitable plasma expander or whole blood should be instituted or completed prior to administration of dopamine hydrochloride. Patients most likely to respond adequately to dopamine hydrochloride are those in whom physiological parameters, such as urine flow, myocardial function and blood pressure have not undergone profound deterioration. Reports indicate that the shorter the time interval between onset of signs and symptoms and initiation of therapy with volume correction and dopamine hydrochloride, the better the prognosis. uuid:5a2bdb88-ba69-401d-a600-8f4f1db4f1d1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2XOI31YC4N biolink:treats MONDO:0006052 PMID:41385096 "[{""id"":""uuid:29db0bcb-234a-4473-9185-f127c0a2386b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b99ed2df-3f4a-4b35-bb29-38dc94f8e171"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Limited Population: Pretomanid Tablet is indicated, as part of a combination regimen with bedaquiline and linezolid for the treatment of adults with pulmonary tuberculosis (TB) resistant to isoniazid, rifamycins, a fluoroquinolone and a second line injectable antibacterial drug OR adults with pulmonary TB resistant to isoniazid and rifampin, who are treatment-intolerant or nonresponsive to standard therapy. Approval of this indication is based on limited clinical safety and efficacy data. This drug is indicated for use in a limited and specific population of patients. Limitations of Use: • Pretomanid Tablets are not indicated in patients with: o Drug-sensitive (DS) TB o Latent infection due to Mycobacterium tuberculosis o Extra-pulmonary infection due to Mycobacterium tuberculosis o TB resistant to isoniazid and rifampin who are responsive to standard therapy and not treatment-intolerant o TB with known resistance to any component of the combination • Safety and effectiveness of Pretomanid Tablets have not been established for its use in combination with drugs other than bedaquiline and linezolid as part of the recommended dosing regimen [see Dosage and Administration (2.2) ] . uuid:d6350ef0-5b42-45ab-8c6c-38fc555a08b0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2XOI31YC4N biolink:treats MONDO:0100479 PMID:41385096 "[{""id"":""uuid:b0360be4-24c6-4ef0-afdc-f1b98a280aed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4f1b7659-0bdf-4fb8-8d1b-fd04620ec6a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Limited Population: Pretomanid Tablet is indicated, as part of a combination regimen with bedaquiline and linezolid for the treatment of adults with pulmonary tuberculosis (TB) resistant to isoniazid, rifamycins, a fluoroquinolone and a second line injectable antibacterial drug OR adults with pulmonary TB resistant to isoniazid and rifampin, who are treatment-intolerant or nonresponsive to standard therapy. Approval of this indication is based on limited clinical safety and efficacy data. This drug is indicated for use in a limited and specific population of patients. Limitations of Use: • Pretomanid Tablets are not indicated in patients with: o Drug-sensitive (DS) TB o Latent infection due to Mycobacterium tuberculosis o Extra-pulmonary infection due to Mycobacterium tuberculosis o TB resistant to isoniazid and rifampin who are responsive to standard therapy and not treatment-intolerant o TB with known resistance to any component of the combination • Safety and effectiveness of Pretomanid Tablets have not been established for its use in combination with drugs other than bedaquiline and linezolid as part of the recommended dosing regimen [see Dosage and Administration (2.2) ] . uuid:ef230350-536e-4ca5-919f-79485dc7d45e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2XOI31YC4N biolink:treats MONDO:0100482 PMID:41385096 "[{""id"":""uuid:578ee594-1d86-48ea-ac63-3e1363a0b692"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:242d862a-4d27-4535-9aa8-4c5799cf21dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:15e20937-44bf-492a-8ef7-75fc3b4963b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/dovprela-previously-pretomanid-fgk""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Limited Population: Pretomanid Tablet is indicated, as part of a combination regimen with bedaquiline and linezolid for the treatment of adults with pulmonary tuberculosis (TB) resistant to isoniazid, rifamycins, a fluoroquinolone and a second line injectable antibacterial drug OR adults with pulmonary TB resistant to isoniazid and rifampin, who are treatment-intolerant or nonresponsive to standard therapy. Approval of this indication is based on limited clinical safety and efficacy data. This drug is indicated for use in a limited and specific population of patients. Limitations of Use: • Pretomanid Tablets are not indicated in patients with: o Drug-sensitive (DS) TB o Latent infection due to Mycobacterium tuberculosis o Extra-pulmonary infection due to Mycobacterium tuberculosis o TB resistant to isoniazid and rifampin who are responsive to standard therapy and not treatment-intolerant o TB with known resistance to any component of the combination • Safety and effectiveness of Pretomanid Tablets have not been established for its use in combination with drugs other than bedaquiline and linezolid as part of the recommended dosing regimen [see Dosage and Administration (2.2) ] .|[EMA] Dovprela is indicated in combination with bedaquiline and linezolid, in adults, for the treatment of pulmonary extensively drug resistant (XDR), or treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB).Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:1ffd7789-5912-4a1d-8a72-b9235c1ba22d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2XOI31YC4N biolink:treats MONDO:0005861 PMID:41385096 "[{""id"":""uuid:7ac37938-f825-4cd6-8be7-30028a9636b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f899c270-df2c-47f2-ad25-a806acd414a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d68a050e-9d47-4cc7-ae72-b0224483e6e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/dovprela-previously-pretomanid-fgk""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Limited Population: Pretomanid Tablet is indicated, as part of a combination regimen with bedaquiline and linezolid for the treatment of adults with pulmonary tuberculosis (TB) resistant to isoniazid, rifamycins, a fluoroquinolone and a second line injectable antibacterial drug OR adults with pulmonary TB resistant to isoniazid and rifampin, who are treatment-intolerant or nonresponsive to standard therapy. Approval of this indication is based on limited clinical safety and efficacy data. This drug is indicated for use in a limited and specific population of patients. Limitations of Use: • Pretomanid Tablets are not indicated in patients with: o Drug-sensitive (DS) TB o Latent infection due to Mycobacterium tuberculosis o Extra-pulmonary infection due to Mycobacterium tuberculosis o TB resistant to isoniazid and rifampin who are responsive to standard therapy and not treatment-intolerant o TB with known resistance to any component of the combination • Safety and effectiveness of Pretomanid Tablets have not been established for its use in combination with drugs other than bedaquiline and linezolid as part of the recommended dosing regimen [see Dosage and Administration (2.2) ] .|[EMA] Dovprela is indicated in combination with bedaquiline and linezolid, in adults, for the treatment of pulmonary extensively drug resistant (XDR), or treatment-intolerant or nonresponsive multidrug-resistant (MDR) tuberculosis (TB).Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:a0a11135-1824-4719-ab06-fc152502ca66 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2XOI31YC4N biolink:treats MONDO:0040753 PMID:41385096 "[{""id"":""uuid:c0660825-9cb8-4cbb-90b8-4f38acbe7ce2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c9ebb51b-ba31-4836-8783-ab6aa3ead1bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Limited Population: Pretomanid Tablet is indicated, as part of a combination regimen with bedaquiline and linezolid for the treatment of adults with pulmonary tuberculosis (TB) resistant to isoniazid, rifamycins, a fluoroquinolone and a second line injectable antibacterial drug OR adults with pulmonary TB resistant to isoniazid and rifampin, who are treatment-intolerant or nonresponsive to standard therapy. Approval of this indication is based on limited clinical safety and efficacy data. This drug is indicated for use in a limited and specific population of patients. Limitations of Use: • Pretomanid Tablets are not indicated in patients with: o Drug-sensitive (DS) TB o Latent infection due to Mycobacterium tuberculosis o Extra-pulmonary infection due to Mycobacterium tuberculosis o TB resistant to isoniazid and rifampin who are responsive to standard therapy and not treatment-intolerant o TB with known resistance to any component of the combination • Safety and effectiveness of Pretomanid Tablets have not been established for its use in combination with drugs other than bedaquiline and linezolid as part of the recommended dosing regimen [see Dosage and Administration (2.2) ] . uuid:9b58428a-be6c-45b6-84c4-579a7a4077da biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2XOI31YC4N biolink:treats MONDO:0018076 PMID:41385096 "[{""id"":""uuid:780d97cb-658f-406e-82cc-abdffac43020"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:40495121-025d-4fee-91f7-9d84fb782131"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Limited Population: Pretomanid Tablet is indicated, as part of a combination regimen with bedaquiline and linezolid for the treatment of adults with pulmonary tuberculosis (TB) resistant to isoniazid, rifamycins, a fluoroquinolone and a second line injectable antibacterial drug OR adults with pulmonary TB resistant to isoniazid and rifampin, who are treatment-intolerant or nonresponsive to standard therapy. Approval of this indication is based on limited clinical safety and efficacy data. This drug is indicated for use in a limited and specific population of patients. Limitations of Use: • Pretomanid Tablets are not indicated in patients with: o Drug-sensitive (DS) TB o Latent infection due to Mycobacterium tuberculosis o Extra-pulmonary infection due to Mycobacterium tuberculosis o TB resistant to isoniazid and rifampin who are responsive to standard therapy and not treatment-intolerant o TB with known resistance to any component of the combination • Safety and effectiveness of Pretomanid Tablets have not been established for its use in combination with drugs other than bedaquiline and linezolid as part of the recommended dosing regimen [see Dosage and Administration (2.2) ] . uuid:d9307460-9a5e-4b99-8c1d-cce59d50f40e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82720 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:9b6342f1-5387-4480-b619-44d857a02ce6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:da19e1f0-eed6-43cd-ac95-763a0098cd34"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f755a8ac-9aa9-4829-b9f9-b0d91363774a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/jardiance""]},{""id"":""uuid:512b863c-e77b-4432-badf-791c98c86194"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] JARDIANCE is indicated: to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure. to reduce the risk of sustained decline in eGFR, end-stage kidney disease, cardiovascular death, and hospitalization in adults with chronic kidney disease at risk of progression. to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease. as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus.|[EMA] Type 2 diabetes mellitusJardiance is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered in addition to other medicinal products for the treatment of diabetesFor study results with respect to combinations of therapies, effects on glycaemic control, and cardiovascular and renal events, and the populations studied, see sections 4.4, 4.5 and 5.1. of the annex.Heart failureJardiance is indicated in adults for the treatment of symptomatic chronic heart failure. Chronic kidney diseaseJardiance is indicated in adults for the treatment of chronic kidney disease.|[PMDA] A drug with a new indication and a new dosage for the treatment of chronic kidney disease. uuid:74de8d8e-12ea-46ac-9df2-9aca25d3ea57 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:580134 biolink:treats UMLS:C0240066 PMID:41385096 "[{""id"":""uuid:1fd8317f-d6fa-42d3-86b7-b9002216a13d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a56d983f-7fc6-4804-b1a0-00e8811324c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATIONS: Chromagen™ is a multivitamin/multimineral dietary supplement indicated for use in improving the nutritional status of patients with iron deficiency. uuid:4258b462-ba1b-4821-b2e1-96e033d30eb8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:AG9MHG098Z biolink:treats MONDO:0018876 PMID:41385096 "[{""id"":""uuid:2e35ad7d-40ef-4648-91cd-7d3b33a650ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f3c464d0-11f2-4414-a72d-9f54353b19bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BRUKINSA is a kinase inhibitor indicated for the treatment of adult patients with: Mantle cell lymphoma (MCL) who have received at least one prior therapy. ( 1.1 ) This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Waldenström's macroglobulinemia (WM). ( 1.2 ) Relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti–CD20-based regimen. ( 1.3 ) This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). ( 1.4 ) Relapsed or refractory follicular lymphoma (FL), in combination with obinutuzumab, after two or more lines of systemic therapy. ( 1.5 ) This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. uuid:2fc8bc1f-179e-44be-80b5-e476298317a1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:AG9MHG098Z biolink:treats MONDO:0100280 PMID:41385096 "[{""id"":""uuid:ae519b8b-c546-4946-9bed-1e7ec3488bea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:63671fd4-975b-4c30-b3d2-4e5f7eee95de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:27ec4435-59e5-4c70-b645-b52e1c610a15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/brukinsa""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] BRUKINSA is a kinase inhibitor indicated for the treatment of adult patients with: Mantle cell lymphoma (MCL) who have received at least one prior therapy. ( 1.1 ) This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Waldenström's macroglobulinemia (WM). ( 1.2 ) Relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti–CD20-based regimen. ( 1.3 ) This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). ( 1.4 ) Relapsed or refractory follicular lymphoma (FL), in combination with obinutuzumab, after two or more lines of systemic therapy. ( 1.5 ) This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.|[EMA] Brukinsa as monotherapy is indicated for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.Brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy.Brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL). uuid:2e235a5c-e53b-4f0e-af6c-89982f2b97b4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:AG9MHG098Z biolink:treats MONDO:0017604 PMID:41385096 "[{""id"":""uuid:e73ee05e-16b7-4399-85de-c0668a012300"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2855bc78-3d61-4eb2-8b33-b5014992a0a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a259c0a3-b021-4c86-9a5d-976f1c4d70a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/brukinsa""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] BRUKINSA is a kinase inhibitor indicated for the treatment of adult patients with: Mantle cell lymphoma (MCL) who have received at least one prior therapy. ( 1.1 ) This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Waldenström's macroglobulinemia (WM). ( 1.2 ) Relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti–CD20-based regimen. ( 1.3 ) This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). ( 1.4 ) Relapsed or refractory follicular lymphoma (FL), in combination with obinutuzumab, after two or more lines of systemic therapy. ( 1.5 ) This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.|[EMA] Brukinsa as monotherapy is indicated for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.Brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy.Brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL). uuid:5440d9c4-dea3-411a-b5c9-9b429db4b349 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:AG9MHG098Z biolink:treats MONDO:0004948 PMID:41385096 "[{""id"":""uuid:73e3d149-0ca4-44ee-9e0d-3cf288dbdb3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3959122b-d30e-4afb-a94b-0eaa9e24418d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BRUKINSA is a kinase inhibitor indicated for the treatment of adult patients with: Mantle cell lymphoma (MCL) who have received at least one prior therapy. ( 1.1 ) This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Waldenström's macroglobulinemia (WM). ( 1.2 ) Relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti–CD20-based regimen. ( 1.3 ) This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). ( 1.4 ) Relapsed or refractory follicular lymphoma (FL), in combination with obinutuzumab, after two or more lines of systemic therapy. ( 1.5 ) This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. uuid:b8a84974-363f-4605-ab93-bc97a238e6b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:AG9MHG098Z biolink:treats MONDO:0003864 PMID:41385096 "[{""id"":""uuid:a540f45a-0958-429e-91e6-8e55398562cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:99e6423a-4062-4f38-b575-2e96abd85d7c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:835c4077-2080-4bd7-a002-2a04842c614b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/brukinsa""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] BRUKINSA is a kinase inhibitor indicated for the treatment of adult patients with: Mantle cell lymphoma (MCL) who have received at least one prior therapy. ( 1.1 ) This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Waldenström's macroglobulinemia (WM). ( 1.2 ) Relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti–CD20-based regimen. ( 1.3 ) This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). ( 1.4 ) Relapsed or refractory follicular lymphoma (FL), in combination with obinutuzumab, after two or more lines of systemic therapy. ( 1.5 ) This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.|[EMA] Brukinsa as monotherapy is indicated for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.Brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (MZL) who have received at least one prior anti-CD20-based therapy.Brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (CLL). uuid:46b286a5-6f86-42a8-be1d-df1796371a59 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:AG9MHG098Z biolink:treats MONDO:0018906 PMID:41385096 "[{""id"":""uuid:dd6ffef8-d041-4db1-b475-f8055d694958"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2c57f6b3-be11-4521-9ea0-6110df1170e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BRUKINSA is a kinase inhibitor indicated for the treatment of adult patients with: Mantle cell lymphoma (MCL) who have received at least one prior therapy. ( 1.1 ) This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Waldenström's macroglobulinemia (WM). ( 1.2 ) Relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti–CD20-based regimen. ( 1.3 ) This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). ( 1.4 ) Relapsed or refractory follicular lymphoma (FL), in combination with obinutuzumab, after two or more lines of systemic therapy. ( 1.5 ) This indication is approved under accelerated approval based on response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. uuid:0deffc29-bdf3-4b8b-a810-d3440ebeb123 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:AVK0I6HY2U biolink:treats MONDO:0005298 PMID:41385096 "[{""id"":""uuid:8c018d36-abfa-4d38-9a82-cf50e1a3f41a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a76af7b8-4e13-4194-b3c3-3a48031a3138"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:5589ccff-6d72-4802-bb4e-ed3d7e402ca3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/eladynos""]},{""id"":""uuid:d133b8fe-37f7-4745-a915-b39023e09538"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TYMLOS is a human parathyroid hormone related peptide [PTHrP(1-34)] analog indicated for the: Treatment of postmenopausal women with osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy. ( 1.1 ) Treatment to increase bone density in men with osteoporosis at high risk for fracture or patients who have failed or are intolerant to other available osteoporosis therapy. ( 1.2 )|[EMA] Treatment of osteoporosis in postmenopausal women at increased risk of fracture.|[PMDA] A drug with a new active ingredient indicated for the treatment of osteoporosis with a high risk of fracture. uuid:a0600eed-9b4a-4ebd-9599-347b08f1e6a8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:370572 biolink:treats MONDO:0011918 PMID:41385096 "[{""id"":""uuid:b24c601c-9787-4fe0-93a9-d14b5ff12d1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ca9ff84c-f40f-48c9-a3ae-2ae38ba5fd47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Perphenazine and amitriptyline hydrochloride tablets are recommended for treatment of (1) patients with moderate to severe anxiety and/or agitation and depressed mood, (2) patients with depression in whom anxiety and/or agitation are severe, and (3) patients with depression and anxiety in association with chronic physical disease. In many of these patients, anxiety masks the depressive state so that, although therapy with a tranquilizer appears to be indicated, the administration of a tranquilizer alone will not be adequate. Schizophrenic patients who have associated depressive symptoms should be considered for therapy with perphenazine and amitriptyline hydrochloride tablets. uuid:3d22223f-c2ba-4bf2-816c-e6c7cf7a058c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:370572 biolink:treats HP:0000713 PMID:41385096 "[{""id"":""uuid:ede3af40-78f1-4b63-b543-a6e36bc798dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3418262a-1d5c-4b67-8aea-4bb45c7697df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Perphenazine and amitriptyline hydrochloride tablets are recommended for treatment of (1) patients with moderate to severe anxiety and/or agitation and depressed mood, (2) patients with depression in whom anxiety and/or agitation are severe, and (3) patients with depression and anxiety in association with chronic physical disease. In many of these patients, anxiety masks the depressive state so that, although therapy with a tranquilizer appears to be indicated, the administration of a tranquilizer alone will not be adequate. Schizophrenic patients who have associated depressive symptoms should be considered for therapy with perphenazine and amitriptyline hydrochloride tablets. uuid:7ee8144a-f299-4cc3-9e91-0199382da52a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:370572 biolink:treats MONDO:0002050 PMID:41385096 "[{""id"":""uuid:50232390-cb4d-400b-8981-b77b6f8e97ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2777daad-c8e6-43a9-b06a-cf8a65b9a8f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Perphenazine and amitriptyline hydrochloride tablets are recommended for treatment of (1) patients with moderate to severe anxiety and/or agitation and depressed mood, (2) patients with depression in whom anxiety and/or agitation are severe, and (3) patients with depression and anxiety in association with chronic physical disease. In many of these patients, anxiety masks the depressive state so that, although therapy with a tranquilizer appears to be indicated, the administration of a tranquilizer alone will not be adequate. Schizophrenic patients who have associated depressive symptoms should be considered for therapy with perphenazine and amitriptyline hydrochloride tablets. uuid:3f97ebf5-e268-4333-ab87-272fb9d10167 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:370572 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:6581755f-b36f-47f6-8d58-cca2d526df2d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0ba14719-71b5-40c5-9576-58557e43bdcc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Perphenazine and amitriptyline hydrochloride tablets are recommended for treatment of (1) patients with moderate to severe anxiety and/or agitation and depressed mood, (2) patients with depression in whom anxiety and/or agitation are severe, and (3) patients with depression and anxiety in association with chronic physical disease. In many of these patients, anxiety masks the depressive state so that, although therapy with a tranquilizer appears to be indicated, the administration of a tranquilizer alone will not be adequate. Schizophrenic patients who have associated depressive symptoms should be considered for therapy with perphenazine and amitriptyline hydrochloride tablets. uuid:845dca87-26f1-420e-ba03-addc1e08a5a0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:370572 biolink:treats MONDO:0005090 PMID:41385096 "[{""id"":""uuid:4e8410b4-1566-4ecc-a290-d652c141c256"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c3d6e700-1ef1-427c-ae08-2dcea71bc716"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Perphenazine and amitriptyline hydrochloride tablets are recommended for treatment of (1) patients with moderate to severe anxiety and/or agitation and depressed mood, (2) patients with depression in whom anxiety and/or agitation are severe, and (3) patients with depression and anxiety in association with chronic physical disease. In many of these patients, anxiety masks the depressive state so that, although therapy with a tranquilizer appears to be indicated, the administration of a tranquilizer alone will not be adequate. Schizophrenic patients who have associated depressive symptoms should be considered for therapy with perphenazine and amitriptyline hydrochloride tablets. uuid:c50d7b60-7797-499e-8cd2-6dc2ddb95d09 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75998 biolink:treats MONDO:0005105 PMID:41385096 "[{""id"":""uuid:dd305d48-a5d6-4c1a-8c0b-60e4d7f9f13c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:1e795e74-d80c-4006-817d-59c64d0a42de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:40b572af-22f2-4538-9b92-995ed4e521ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/mekinist""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] MEKINIST is a kinase inhibitor indicated as a single agent for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. ( 1.1 , 2.1 ) MEKINIST is indicated, in combination with dabrafenib, for: the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. ( 1.1 , 2.1 ) the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection. ( 1.2 , 2.1 ) the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test. ( 1.3 , 2.1 ) the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an FDA-approved test, and with no satisfactory locoregional treatment options. ( 1.4 , 2.1 ) the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1.5 , 2.1 ) the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. ( 1.6 , 2.1 ) Limitations of Use : MEKINIST is not indicated for treatment of patients with colorectal cancer because of known intrinsic resistance to BRAF inhibition. ( 1.7 , 12.1 )|[EMA] MelanomaTrametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation (see sections 4.4 and 5.1).Trametinib monotherapy has not demonstrated clinical activity in patients who have progressed on a prior BRAF inhibitor therapy (see section 5.1).Adjuvant treatment of melanomaTrametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection.Non-small cell lung cancer (NSCLC)Trametinib in combination with dabrafenib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation. uuid:a6fcbf81-9628-4575-a7b5-8c7424b0d93e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75998 biolink:treats MONDO:0005191 PMID:41385096 "[{""id"":""uuid:aea87bf2-e9ab-4047-944a-04a3a7352e91"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b4b1ed6b-18a8-4a68-8845-527e5d262a7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MEKINIST is a kinase inhibitor indicated as a single agent for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. ( 1.1 , 2.1 ) MEKINIST is indicated, in combination with dabrafenib, for: the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. ( 1.1 , 2.1 ) the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection. ( 1.2 , 2.1 ) the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test. ( 1.3 , 2.1 ) the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an FDA-approved test, and with no satisfactory locoregional treatment options. ( 1.4 , 2.1 ) the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1.5 , 2.1 ) the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. ( 1.6 , 2.1 ) Limitations of Use : MEKINIST is not indicated for treatment of patients with colorectal cancer because of known intrinsic resistance to BRAF inhibition. ( 1.7 , 12.1 ) uuid:49a31713-ed24-40da-afcc-be622f202644 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75998 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:0ff76628-6d05-44b4-a89d-c1be6a97e83d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e4317969-892c-4a2d-900a-1422f22ef222"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:fd4d93d6-8ee1-4d46-b3f8-b67696fdae27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/mekinist""]},{""id"":""uuid:13d20536-e1d0-4141-b8cd-97bb7981348a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MEKINIST is a kinase inhibitor indicated as a single agent for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. ( 1.1 , 2.1 ) MEKINIST is indicated, in combination with dabrafenib, for: the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. ( 1.1 , 2.1 ) the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection. ( 1.2 , 2.1 ) the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test. ( 1.3 , 2.1 ) the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an FDA-approved test, and with no satisfactory locoregional treatment options. ( 1.4 , 2.1 ) the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1.5 , 2.1 ) the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. ( 1.6 , 2.1 ) Limitations of Use : MEKINIST is not indicated for treatment of patients with colorectal cancer because of known intrinsic resistance to BRAF inhibition. ( 1.7 , 12.1 )|[EMA] MelanomaTrametinib as monotherapy or in combination with dabrafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation (see sections 4.4 and 5.1).Trametinib monotherapy has not demonstrated clinical activity in patients who have progressed on a prior BRAF inhibitor therapy (see section 5.1).Adjuvant treatment of melanomaTrametinib in combination with dabrafenib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection.Non-small cell lung cancer (NSCLC)Trametinib in combination with dabrafenib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation.|[PMDA] Drugs with a new additional indication for the treatment of unresectable advanced or recurrent BRAF mutation-positive non-small-cell lung cancer. [Orphan drug] uuid:41b38064-6f21-4920-beff-65bd4ad57641 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75998 biolink:treats MONDO:0006468 PMID:41385096 "[{""id"":""uuid:075e3a71-6487-47e2-b685-565b53ecc078"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ea9762bc-9323-4cfd-ae63-bd83c1199fc4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MEKINIST is a kinase inhibitor indicated as a single agent for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. ( 1.1 , 2.1 ) MEKINIST is indicated, in combination with dabrafenib, for: the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. ( 1.1 , 2.1 ) the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection. ( 1.2 , 2.1 ) the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test. ( 1.3 , 2.1 ) the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an FDA-approved test, and with no satisfactory locoregional treatment options. ( 1.4 , 2.1 ) the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1.5 , 2.1 ) the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. ( 1.6 , 2.1 ) Limitations of Use : MEKINIST is not indicated for treatment of patients with colorectal cancer because of known intrinsic resistance to BRAF inhibition. ( 1.7 , 12.1 ) uuid:dcf27bd5-5084-4c40-a418-b777664a7cf1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75998 biolink:treats MONDO:0024879 PMID:41385096 "[{""id"":""uuid:1e5d9850-32f7-44d4-9225-f9e510891c6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0bcd9f01-2a1f-4d89-89a1-46e420aa2688"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MEKINIST is a kinase inhibitor indicated as a single agent for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. ( 1.1 , 2.1 ) MEKINIST is indicated, in combination with dabrafenib, for: the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. ( 1.1 , 2.1 ) the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection. ( 1.2 , 2.1 ) the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test. ( 1.3 , 2.1 ) the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an FDA-approved test, and with no satisfactory locoregional treatment options. ( 1.4 , 2.1 ) the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1.5 , 2.1 ) the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. ( 1.6 , 2.1 ) Limitations of Use : MEKINIST is not indicated for treatment of patients with colorectal cancer because of known intrinsic resistance to BRAF inhibition. ( 1.7 , 12.1 ) uuid:9511a9ec-fa8e-4a35-ad52-5d0df40a4d68 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75998 biolink:treats MONDO:0021042 PMID:41385096 "[{""id"":""uuid:cc8075bc-4ead-4d66-85eb-466a2000623e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d1102618-0654-4847-822b-331fa6e1f144"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MEKINIST is a kinase inhibitor indicated as a single agent for the treatment of BRAF-inhibitor treatment-naïve patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. ( 1.1 , 2.1 ) MEKINIST is indicated, in combination with dabrafenib, for: the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. ( 1.1 , 2.1 ) the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection. ( 1.2 , 2.1 ) the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test. ( 1.3 , 2.1 ) the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an FDA-approved test, and with no satisfactory locoregional treatment options. ( 1.4 , 2.1 ) the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1.5 , 2.1 ) the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. ( 1.6 , 2.1 ) Limitations of Use : MEKINIST is not indicated for treatment of patients with colorectal cancer because of known intrinsic resistance to BRAF inhibition. ( 1.7 , 12.1 ) uuid:5895d12a-7b27-4e54-a948-0d1ef75f870f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:RZT8C352O1 biolink:treats MONDO:0009823 PMID:41385096 "[{""id"":""uuid:46e67f4d-6bcf-429b-a85c-8aa1e95d99cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f6ea8359-f75a-48f4-8eca-c9d7f84dd55b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3dd2c5f5-e1fe-4ab5-8e8d-35633a67166d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OXLUMO is indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary and plasma oxalate levels in pediatric and adult patients [see Clinical Pharmacology (12.1) , Clinical Studies (14.1 , 14.2 , 14.3) ] .|[EMA] Treatment of primary hyperoxaluria type 1 (PH1) in all age groups. uuid:892db85c-ed08-47b0-8640-843d0fcdb506 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:RZT8C352O1 biolink:treats MONDO:0024685 PMID:41385096 "[{""id"":""uuid:8cedc28a-d6d9-4dc2-bae1-95e034b3eb17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c587e499-1ac2-441b-a120-1e94a5c7a631"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OXLUMO is indicated for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary and plasma oxalate levels in pediatric and adult patients [see Clinical Pharmacology (12.1) , Clinical Studies (14.1 , 14.2 , 14.3) ] . uuid:75346e8a-715a-40f3-a532-66876f3e74a1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76607 biolink:treats MONDO:0015924 PMID:41385096 "[{""id"":""uuid:df01c9bc-66b1-46b7-9bcd-b2e49b0509a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:45f35544-4cc3-490a-9e5b-beaff8e293ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d53152d8-2454-4989-a40f-40186d828cfd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/opsumit""]},{""id"":""uuid:3bddbe5e-0607-4808-ab5c-90238424961e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OPSUMIT is an endothelin receptor antagonist (ERA) indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) in adults to reduce the risks of disease progression and hospitalization for PAH ( 1.1 ).|[EMA] Opsumit, as monotherapy or in combination, is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III.Efficacy has been shown in a PAH population including idiopathic and heritable PAH, PAH associated with connective tissue disorders, and PAH associated with corrected simple congenital heart disease.|[PMDA] A drug with a new active ingredient indicated for the treatment of pulmonary arterial hypertension. uuid:c2870258-3947-4457-b1a4-5888357695f9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:WGD229O42W biolink:treats MONDO:0041656 PMID:41385096 "[{""id"":""uuid:ef437357-9005-41d7-8f8c-10ab6525ba19"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e8e93aa3-70dc-4339-a7a8-b61305b83e85"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TNKase ® is indicated to reduce the risk of death associated with acute ST elevation myocardial infarction (STEMI). uuid:140317bf-1772-4193-8ea4-ac0e5717b9a2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135913 biolink:treats MONDO:0001684 PMID:41385096 "[{""id"":""uuid:b2d04000-12d7-4eca-9ef8-35bb11fe7e14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3a32d779-a752-476e-a944-6c18e26cc5f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ChiRhoStim ® is indicated for the stimulation of: pancreatic secretions, including bicarbonate, to aid in the diagnosis of pancreatic exocrine dysfunction. gastrin secretion to aid in the diagnosis of gastrinoma, and pancreatic secretions to facilitate the identification of the ampulla of Vater and accessory papilla during endoscopic retrograde cholangiopancreatography (ERCP). uuid:861fe10c-0a6b-4a48-8b31-72cf2ddd5ecb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135913 biolink:treats MONDO:0003523 PMID:41385096 "[{""id"":""uuid:d02d4864-2e22-43ae-8578-d9d7dadecd8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a1a3d4dd-271c-4d43-830b-4d8d606c1534"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ChiRhoStim ® is indicated for the stimulation of: pancreatic secretions, including bicarbonate, to aid in the diagnosis of pancreatic exocrine dysfunction. gastrin secretion to aid in the diagnosis of gastrinoma, and pancreatic secretions to facilitate the identification of the ampulla of Vater and accessory papilla during endoscopic retrograde cholangiopancreatography (ERCP). uuid:8fcd3001-98c0-47e6-be4f-59e6b9685a35 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:132233 biolink:treats MONDO:0005302 PMID:41385096 "[{""id"":""uuid:2008a51d-4c2d-46a3-9864-cfb641b90ec2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:64cda7c1-a87b-45c6-9c47-3e39e91adb3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ADZENYS XR-ODT is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older [see Clinical Studies (14) ]. uuid:749f377e-209b-4040-b5b9-f9b1e69a21f9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:WGD229O42W biolink:treats HP:0002140 PMID:41385096 "[{""id"":""uuid:7ea8e362-0b57-40fc-b42b-383797e03646"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e9f36fbc-1331-47b8-8b31-76b1938577dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TNKase is a tissue plasminogen activator (tPA) indicated: for the treatment of acute ischemic stroke (AIS) in adults. ( 1.1 ) to reduce the risk of death associated with acute ST elevation myocardial infarction (STEMI) in adults. ( 1.2 ) uuid:967f9ec7-f14d-4d06-8771-4c205298a657 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75045 biolink:treats UMLS:C4725093 PMID:41385096 "[{""id"":""uuid:1cbfaf6f-3f4c-4884-a7e5-40ce91a63109"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:286da5c4-83e9-438e-a05f-a89329046eaa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TAFINLAR is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test. ( 1.1 , 2.1 ) TAFINLAR is indicated, in combination with trametinib , for: the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. ( 1.2 , 2.1 ) the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection. ( 1.3 , 2.1 ) the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test. ( 1.4 , 2.1 ) the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an FDA-approved test, and with no satisfactory locoregional treatment options. ( 1.5 , 2.1 ) the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DoR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1.6 , 2.1 ) the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. ( 1.7 , 2.1 ) Limitations of Use : TAFINLAR is not indicated for treatment of patients with colorectal cancer because of known intrinsic resistance to BRAF inhibition. ( 1.8 , 12.1 ) TAFINLAR is not indicated for treatment of patients with wild-type BRAF solid tumors. ( 5.2 ) uuid:181ce7e3-0780-415c-8402-22c9ea8bcfac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75045 biolink:treats MONDO:0005191 PMID:41385096 "[{""id"":""uuid:c0e69757-261c-49cc-bff7-5229cd0ebea3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:68e0f091-ce96-4fc9-8308-d07071d16538"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TAFINLAR is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test. ( 1.1 , 2.1 ) TAFINLAR is indicated, in combination with trametinib , for: the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. ( 1.2 , 2.1 ) the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection. ( 1.3 , 2.1 ) the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test. ( 1.4 , 2.1 ) the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an FDA-approved test, and with no satisfactory locoregional treatment options. ( 1.5 , 2.1 ) the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DoR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1.6 , 2.1 ) the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. ( 1.7 , 2.1 ) Limitations of Use : TAFINLAR is not indicated for treatment of patients with colorectal cancer because of known intrinsic resistance to BRAF inhibition. ( 1.8 , 12.1 ) TAFINLAR is not indicated for treatment of patients with wild-type BRAF solid tumors. ( 5.2 ) uuid:fc854faf-507d-44bf-a011-e4f0dd80f465 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75045 biolink:treats MONDO:0005438 PMID:41385096 "[{""id"":""uuid:42123c9f-5afa-4ac5-8dd1-008a5cfea2d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8c129e51-d929-4b0d-a096-03ddaa8edb08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TAFINLAR is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test. ( 1.1 , 2.1 ) TAFINLAR is indicated, in combination with trametinib , for: the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. ( 1.2 , 2.1 ) the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection. ( 1.3 , 2.1 ) the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test. ( 1.4 , 2.1 ) the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an FDA-approved test, and with no satisfactory locoregional treatment options. ( 1.5 , 2.1 ) the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DoR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1.6 , 2.1 ) the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. ( 1.7 , 2.1 ) Limitations of Use : TAFINLAR is not indicated for treatment of patients with colorectal cancer because of known intrinsic resistance to BRAF inhibition. ( 1.8 , 12.1 ) TAFINLAR is not indicated for treatment of patients with wild-type BRAF solid tumors. ( 5.2 ) uuid:bd220ab5-75c6-4c0f-ab75-4bba50c11b8f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75045 biolink:treats UMLS:C0278987 PMID:41385096 "[{""id"":""uuid:07555f0b-fa8f-473c-8f78-a8b8d99430c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:887cebdd-6d28-4f3a-be3b-5386ebe470a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TAFINLAR is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test. ( 1.1 , 2.1 ) TAFINLAR is indicated, in combination with trametinib , for: the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. ( 1.2 , 2.1 ) the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection. ( 1.3 , 2.1 ) the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test. ( 1.4 , 2.1 ) the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an FDA-approved test, and with no satisfactory locoregional treatment options. ( 1.5 , 2.1 ) the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DoR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1.6 , 2.1 ) the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. ( 1.7 , 2.1 ) Limitations of Use : TAFINLAR is not indicated for treatment of patients with colorectal cancer because of known intrinsic resistance to BRAF inhibition. ( 1.8 , 12.1 ) TAFINLAR is not indicated for treatment of patients with wild-type BRAF solid tumors. ( 5.2 ) uuid:a8f42ca6-3fe9-42f2-9d98-cdc64e3358f3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75045 biolink:treats MONDO:0006468 PMID:41385096 "[{""id"":""uuid:d3a1adf7-31f8-4116-853c-5e6cf57a5426"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c09274e9-9964-461b-87e1-390b1045e79c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TAFINLAR is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test. ( 1.1 , 2.1 ) TAFINLAR is indicated, in combination with trametinib , for: the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. ( 1.2 , 2.1 ) the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection. ( 1.3 , 2.1 ) the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test. ( 1.4 , 2.1 ) the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an FDA-approved test, and with no satisfactory locoregional treatment options. ( 1.5 , 2.1 ) the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DoR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1.6 , 2.1 ) the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. ( 1.7 , 2.1 ) Limitations of Use : TAFINLAR is not indicated for treatment of patients with colorectal cancer because of known intrinsic resistance to BRAF inhibition. ( 1.8 , 12.1 ) TAFINLAR is not indicated for treatment of patients with wild-type BRAF solid tumors. ( 5.2 ) uuid:6d09091d-31d4-41a6-b497-b556b40155af biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75045 biolink:treats MONDO:0024879 PMID:41385096 "[{""id"":""uuid:59f938f7-4251-425e-8081-5435f82a6f66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7fc472ea-e78c-4174-8528-6e2e56bf619a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TAFINLAR is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test. ( 1.1 , 2.1 ) TAFINLAR is indicated, in combination with trametinib , for: the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. ( 1.2 , 2.1 ) the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection. ( 1.3 , 2.1 ) the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test. ( 1.4 , 2.1 ) the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an FDA-approved test, and with no satisfactory locoregional treatment options. ( 1.5 , 2.1 ) the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DoR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1.6 , 2.1 ) the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. ( 1.7 , 2.1 ) Limitations of Use : TAFINLAR is not indicated for treatment of patients with colorectal cancer because of known intrinsic resistance to BRAF inhibition. ( 1.8 , 12.1 ) TAFINLAR is not indicated for treatment of patients with wild-type BRAF solid tumors. ( 5.2 ) uuid:0fe9975d-8a80-42da-aef8-ef9918e47b35 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75045 biolink:treats MONDO:0021042 PMID:41385096 "[{""id"":""uuid:67730bff-f8a7-46be-9d17-7506fe2e9f5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:648fe53e-01ef-48f1-a1f5-fe78c5b48e6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TAFINLAR is a kinase inhibitor indicated as a single agent for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E mutation as detected by an FDA-approved test. ( 1.1 , 2.1 ) TAFINLAR is indicated, in combination with trametinib , for: the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test. ( 1.2 , 2.1 ) the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection. ( 1.3 , 2.1 ) the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test. ( 1.4 , 2.1 ) the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an FDA-approved test, and with no satisfactory locoregional treatment options. ( 1.5 , 2.1 ) the treatment of adult and pediatric patients 1 year of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DoR). Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1.6 , 2.1 ) the treatment of pediatric patients 1 year of age and older with low-grade glioma (LGG) with a BRAF V600E mutation who require systemic therapy. ( 1.7 , 2.1 ) Limitations of Use : TAFINLAR is not indicated for treatment of patients with colorectal cancer because of known intrinsic resistance to BRAF inhibition. ( 1.8 , 12.1 ) TAFINLAR is not indicated for treatment of patients with wild-type BRAF solid tumors. ( 5.2 ) uuid:828c972c-62ab-452c-a1fc-6f479107eabe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2677762 biolink:treats MONDO:0015924 PMID:41385096 "[{""id"":""uuid:5692d883-4222-43f1-8579-11042feb0911"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:87707c0e-2e0c-4342-964e-c3ad83deffe1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OPSYNVI is a combination of macitentan, an endothelin receptor antagonist (ERA), and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor, indicated for chronic treatment of pulmonary arterial hypertension (PAH, WHO Group I) in adult patients of WHO functional class (FC) II–III. ( 1.1 ) Individually, macitentan reduces the risk of clinical worsening events and hospitalization, and tadalafil improves exercise ability. ( 1.1 , 14 ) uuid:7fea948b-b8e3-49d3-93b4-03d2b630cec9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:961YV2O515 biolink:treats MONDO:0009688 PMID:41385096 "[{""id"":""uuid:fe155f78-c220-4003-ae6d-8e9d45fd6c11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b917efad-35f0-4434-897b-31f0dd643c10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:01d44d71-c309-40df-8c81-c50906727e76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vyvgart""]},{""id"":""uuid:a54f17be-e78c-4803-898b-6846d1fde275"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VYVGART is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.|[EMA] Vyvgart is indicated as an add on to standard therapy for the treatment of adult patients with generalised myasthenia gravis (gMG) who are anti acetylcholine receptor (AChR) antibody positive.|[PMDA] A drug with a new active ingredient indicated for the treatment of generalized myasthenia gravis (for use only in patients who have not sufficiently responded to steroids or other immunosuppressants). [Orphan drug] uuid:6378613a-897a-4c60-9215-d3f5f7a7e958 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:228304 biolink:treats MONDO:0010679 PMID:41385096 "[{""id"":""uuid:6eb89498-f185-472d-88b2-6ee4520b93ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:426b8225-9a10-4d5c-b52c-cd3a36fa5b8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AGAMREE is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older. uuid:4fce07a0-ac62-43f2-8c9a-f467ba2eec36 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:140407 biolink:treats MONDO:0005545 PMID:41385096 "[{""id"":""uuid:5f3202fb-c596-4087-b42d-5c29ee5d8568"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bb000fed-c38f-4f8e-81f3-3e03eab0f813"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZEVTERA is a cephalosporin antibacterial indicated for the treatment of: Adult patients with Staphylococcus aureus bloodstream infections (bacteremia) (SAB), including those with right-sided infective endocarditis ( 1.1 ), Adult patients with acute bacterial skin and skin structure infections (ABSSSI) ( 1.2 ), and Adult and pediatric patients (3 months to less than 18 years old) with community-acquired bacterial pneumonia (CABP) ( 1.3 ). To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZEVTERA and other antibacterial drugs, ZEVTERA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria ( 1.4 ). uuid:772b9c77-b3bd-465f-889a-2dcd09310fda biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:140407 biolink:treats MONDO:0005229 PMID:41385096 "[{""id"":""uuid:6affd020-4f50-4792-8583-9438a69de45b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:abe5004b-1c75-456e-b002-dc96cc479347"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZEVTERA is a cephalosporin antibacterial indicated for the treatment of: Adult patients with Staphylococcus aureus bloodstream infections (bacteremia) (SAB), including those with right-sided infective endocarditis ( 1.1 ), Adult patients with acute bacterial skin and skin structure infections (ABSSSI) ( 1.2 ), and Adult and pediatric patients (3 months to less than 18 years old) with community-acquired bacterial pneumonia (CABP) ( 1.3 ). To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZEVTERA and other antibacterial drugs, ZEVTERA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria ( 1.4 ). uuid:76dfd9b6-87b3-4051-a6fb-cbc20be1fe1a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:140407 biolink:treats MONDO:0000565 PMID:41385096 "[{""id"":""uuid:cb0a7f68-07b0-481e-979f-bef4ca836984"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e82de23f-c764-48d9-ad97-759338a31340"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZEVTERA is a cephalosporin antibacterial indicated for the treatment of: Adult patients with Staphylococcus aureus bloodstream infections (bacteremia) (SAB), including those with right-sided infective endocarditis ( 1.1 ), Adult patients with acute bacterial skin and skin structure infections (ABSSSI) ( 1.2 ), and Adult and pediatric patients (3 months to less than 18 years old) with community-acquired bacterial pneumonia (CABP) ( 1.3 ). To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZEVTERA and other antibacterial drugs, ZEVTERA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria ( 1.4 ). uuid:67cac05b-566d-4ed3-a2eb-cf7602457bbc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:140407 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:11699b64-e23e-47a8-823e-daca454d854b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:89fec8fd-86d7-48aa-9b1b-e6d98e58f752"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZEVTERA is a cephalosporin antibacterial indicated for the treatment of: Adult patients with Staphylococcus aureus bloodstream infections (bacteremia) (SAB), including those with right-sided infective endocarditis ( 1.1 ), Adult patients with acute bacterial skin and skin structure infections (ABSSSI) ( 1.2 ), and Adult and pediatric patients (3 months to less than 18 years old) with community-acquired bacterial pneumonia (CABP) ( 1.3 ). To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZEVTERA and other antibacterial drugs, ZEVTERA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria ( 1.4 ). uuid:bc403efb-b89c-4582-acdb-5c1edabf12c6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:140407 biolink:treats MONDO:0004652 PMID:41385096 "[{""id"":""uuid:74b26e2f-22a5-428f-beb5-14264a033ca8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:01ded481-cd6e-4b4b-9cb1-427ca57d9f96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZEVTERA is a cephalosporin antibacterial indicated for the treatment of: Adult patients with Staphylococcus aureus bloodstream infections (bacteremia) (SAB), including those with right-sided infective endocarditis ( 1.1 ), Adult patients with acute bacterial skin and skin structure infections (ABSSSI) ( 1.2 ), and Adult and pediatric patients (3 months to less than 18 years old) with community-acquired bacterial pneumonia (CABP) ( 1.3 ). To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZEVTERA and other antibacterial drugs, ZEVTERA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria ( 1.4 ). uuid:e0396c49-9f58-4b8b-9e9b-ee18a41cc1eb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:XII270YC6M biolink:treats UMLS:C3854623 PMID:41385096 "[{""id"":""uuid:fec2e605-2250-4c09-9dd1-55fe588abd70"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0d78c811-b204-44d0-b5bf-8234c7a97829"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nabi-HB, Hepatitis B Immune Globulin (Human), is indicated for treatment of acute exposure to blood containing HBsAg, perinatal exposure of infants born to HBsAg-positive mothers, sexual exposure to HBsAg-positive persons and household exposure to persons with acute HBV infec- tion in the following settings: Acute Exposure to Blood Containing HBsAg: Following either parenteral exposure (needlestick, bite, sharps), direct mucous membrane contact (accidental splash), or oral ingestion (pipetting accident), involving HBsAg-positive materials such as blood, plasma, or serum. Perinatal Exposure of Infants Born to HBsAg-positive Mothers: Infants born to mothers positive for HBsAg with or without HBeAg 12 . Sexual Exposure to HBsAg-positive Persons: Sexual partners of HBsAg-positive persons. Household Exposure to Persons with Acute HBV Infection: Infants less than 12 months old whose mother or primary caregiver is positive for HBsAg. Other household contacts with an identifiable blood exposure to the index patient. Nabi-HB is indicated for intramuscular use only. uuid:b5bed9aa-2270-4cd7-9402-48e0737b0043 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4Z63YK6E0E biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:6440f218-598f-4f0a-9b29-5aa47cb5da4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9be0d26b-99d2-4655-9da7-33dea728a2bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3ec0e0bb-3c41-4b46-b5de-d834a94a01c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/darzalex""]},{""id"":""uuid:20f2c617-c403-42d7-a000-f21130eae74c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DARZALEX is indicated for the treatment of adult patients with multiple myeloma: in combination with lenalidomide and dexamethasone in newly diagnosed patients who are ineligible for autologous stem cell transplant and in patients with relapsed or refractory multiple myeloma who have received at least one prior therapy. in combination with bortezomib, melphalan and prednisone in newly diagnosed patients who are ineligible for autologous stem cell transplant. in combination with bortezomib, thalidomide, and dexamethasone in newly diagnosed patients who are eligible for autologous stem cell transplant. in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy. in combination with carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma who have received one to three prior lines of therapy. in combination with pomalidomide and dexamethasone in patients who have received at least two prior therapies including lenalidomide and a proteasome inhibitor. as monotherapy, in patients who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an immunomodulatory agent or who are double-refractory to a PI and an immunomodulatory agent.|[EMA] Multiple MyelomaDarzalex is indicated: in combination with lenalidomide and dexamethasone or with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy (see section 5.1).as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.AL AmyloidosisDARZALEX is indicated in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of adult patients with newly diagnosed systemic light chain (AL) amyloidosis.|[PMDA] Drugs with a new active ingredient indicated for the treatment of relapsed or refractory multiple myeloma. [Orphan drug] uuid:30e53264-05ca-47aa-9b6f-8ccea8d6f893 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76609 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:4f17e344-6496-4c9c-9963-2bfdca3b4a51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:810c5f35-64b5-4949-9ce5-72b1556abf81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRYVIO, in combination with other antihypertensive drugs, is indicated for the treatment of hypertension, to lower blood pressure (BP) in adult patients who are not adequately controlled on other drugs. Lowering BP reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. There are no controlled trials demonstrating reduction of risk of these events with TRYVIO. Control of high BP should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve BP goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is BP reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher BPs, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from BP reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower BP goal. uuid:e7aba7e7-7338-4e60-a5f0-e570d3aca162 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76609 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:e441033e-91dc-44b0-938c-b1b472d94b48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:98b67d94-006c-40ea-a304-3b96abbf86fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRYVIO, in combination with other antihypertensive drugs, is indicated for the treatment of hypertension, to lower blood pressure (BP) in adult patients who are not adequately controlled on other drugs. Lowering BP reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. There are no controlled trials demonstrating reduction of risk of these events with TRYVIO. Control of high BP should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve BP goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is BP reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher BPs, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from BP reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower BP goal. uuid:e796ee25-0666-4722-9c2e-2800570c19a0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76609 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:294c5a8d-0815-42e9-97c2-cb76da05997a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:53d4824c-6204-44db-83b8-c753136d93f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRYVIO, in combination with other antihypertensive drugs, is indicated for the treatment of hypertension, to lower blood pressure (BP) in adult patients who are not adequately controlled on other drugs. Lowering BP reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. There are no controlled trials demonstrating reduction of risk of these events with TRYVIO. Control of high BP should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve BP goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is BP reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher BPs, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from BP reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower BP goal. uuid:e2d63cf6-f0fa-4d03-8e93-8c8557f45367 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76609 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:bf0c7a0f-b1ad-47b2-9777-cb54307b41d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d63df52e-794b-4e70-aeb1-dbf040890e7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRYVIO, in combination with other antihypertensive drugs, is indicated for the treatment of hypertension, to lower blood pressure (BP) in adult patients who are not adequately controlled on other drugs. Lowering BP reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. There are no controlled trials demonstrating reduction of risk of these events with TRYVIO. Control of high BP should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve BP goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is BP reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher BPs, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from BP reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower BP goal. uuid:db7698d0-b054-4621-b8de-4aa52bc8cdfe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76609 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:4858bb28-e30a-44d3-b385-5cee0b079379"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b3f356a2-7c0f-4419-bdb1-a0d52678c932"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRYVIO, in combination with other antihypertensive drugs, is indicated for the treatment of hypertension, to lower blood pressure (BP) in adult patients who are not adequately controlled on other drugs. Lowering BP reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes. There are no controlled trials demonstrating reduction of risk of these events with TRYVIO. Control of high BP should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve BP goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is BP reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher BPs, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from BP reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower BP goal. uuid:d842fc89-cd21-4659-bf89-0fb4990ce607 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1945215 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:f15b820a-102a-4c1b-80dd-60c6d5630cc9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d29d1671-f357-4e30-8591-ab272a7d28ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:02f9f1ee-98f9-423e-8995-fa6cf096eb27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vaborem""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] VABOMERE (meropenem and vaborbactam) is a combination of meropenem, a penem antibacterial, and vaborbactam, a beta-lactamase inhibitor, indicated for the treatment of patients 18 years and older with complicated urinary tract infections (cUTI) including pyelonephritis caused by designated susceptible bacteria. ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of VABOMERE and other antibacterial drugs, VABOMERE should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.2 )|[EMA] Vaborem is indicated for the treatment of the following infections in adults:Complicated urinary tract infection (cUTI), including pyelonephritisComplicated intra-abdominal infection (cIAI)Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP).Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.Vaborem is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options.Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:386837fa-757f-42d4-b512-595fb689fcfb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1945215 biolink:treats MONDO:0006939 PMID:41385096 "[{""id"":""uuid:07824b85-59ba-4cff-b331-2959f6c2611b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f082748b-268c-4c2d-a9f0-57c16f99e4d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:773d3afd-6134-4427-bc7e-3e9387d156ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vaborem""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] VABOMERE (meropenem and vaborbactam) is a combination of meropenem, a penem antibacterial, and vaborbactam, a beta-lactamase inhibitor, indicated for the treatment of patients 18 years and older with complicated urinary tract infections (cUTI) including pyelonephritis caused by designated susceptible bacteria. ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of VABOMERE and other antibacterial drugs, VABOMERE should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.2 )|[EMA] Vaborem is indicated for the treatment of the following infections in adults:Complicated urinary tract infection (cUTI), including pyelonephritisComplicated intra-abdominal infection (cIAI)Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP).Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.Vaborem is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options.Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:0cca47b0-7eb8-41bc-872f-f649c130d02b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8L7891MRB6 biolink:treats MONDO:0005105 PMID:41385096 "[{""id"":""uuid:d13499f4-3d7d-4dc7-8e20-20b705b2d50c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7c381bd1-af3d-4d2f-90d4-d2fcac9aeb17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:22091ee8-5083-4b1a-97d3-0ebaad30d74f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/braftovi""]},{""id"":""uuid:7bce1181-bd0a-4324-841f-8b7e00cd13af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BRAFTOVI is a kinase inhibitor indicated: Melanoma • in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. ( 1.1 , 2.1 ) Colorectal Cancer (CRC) • in combination with cetuximab and mFOLFOX6, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA‑approved test. ( 1.2 , 2.1 ) This indication is approved under accelerated approval based on response rate and durability of response [see Clinical Studies (14.2) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). • in combination with cetuximab, for the treatment of adult patients with metastatic CRC with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy. ( 1.2 , 2.1 ) Non-Small Cell Lung Cancer (NSCLC) • in combination with binimetinib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test. ( 1.3 , 2.1 ) Limitations of Use BRAFTOVI is not indicated for treatment of patients with wild-type BRAF melanoma, wild-type BRAF CRC, or wild-type BRAF NSCLC. ( 1.4 , 5.2 )|[EMA] Encorafenib is indicated:in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutationin combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, who have received prior systemic therapy|[PMDA] A drug with a new active ingredient indicated for the treatment of unresectable melanoma with BRAF gene mutation. [Orphan drug] uuid:d5db4c08-a296-4843-9b43-59037025a1ef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8L7891MRB6 biolink:treats MONDO:0005191 PMID:41385096 "[{""id"":""uuid:a630ed08-b4b6-450f-af45-9e232c2fe112"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:912284ad-7bf0-4373-82fe-494db0d3b865"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BRAFTOVI is a kinase inhibitor indicated: Melanoma • in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. ( 1.1 , 2.1 ) Colorectal Cancer (CRC) • in combination with cetuximab and mFOLFOX6, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA‑approved test. ( 1.2 , 2.1 ) This indication is approved under accelerated approval based on response rate and durability of response [see Clinical Studies (14.2) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). • in combination with cetuximab, for the treatment of adult patients with metastatic CRC with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy. ( 1.2 , 2.1 ) Non-Small Cell Lung Cancer (NSCLC) • in combination with binimetinib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test. ( 1.3 , 2.1 ) Limitations of Use BRAFTOVI is not indicated for treatment of patients with wild-type BRAF melanoma, wild-type BRAF CRC, or wild-type BRAF NSCLC. ( 1.4 , 5.2 ) uuid:6a89daef-bbec-45e6-a3e0-8435624addbb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8L7891MRB6 biolink:treats MONDO:0005575 PMID:41385096 "[{""id"":""uuid:c5ded070-2621-49ed-83c2-ef8e08987eb5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:10f27d95-012f-4117-a6f3-fd5eb2f30ba0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:fa81d9e9-340b-4885-b2da-1d3f00c33013"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/braftovi""]},{""id"":""uuid:67b9ad2f-b426-46a6-ba9e-8394b6ce453e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BRAFTOVI is a kinase inhibitor indicated: Melanoma • in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. ( 1.1 , 2.1 ) Colorectal Cancer (CRC) • in combination with cetuximab and mFOLFOX6, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA‑approved test. ( 1.2 , 2.1 ) This indication is approved under accelerated approval based on response rate and durability of response [see Clinical Studies (14.2) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). • in combination with cetuximab, for the treatment of adult patients with metastatic CRC with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy. ( 1.2 , 2.1 ) Non-Small Cell Lung Cancer (NSCLC) • in combination with binimetinib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test. ( 1.3 , 2.1 ) Limitations of Use BRAFTOVI is not indicated for treatment of patients with wild-type BRAF melanoma, wild-type BRAF CRC, or wild-type BRAF NSCLC. ( 1.4 , 5.2 )|[EMA] Encorafenib is indicated:in combination with binimetinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutationin combination with cetuximab, for the treatment of adult patients with metastatic colorectal cancer (CRC) with a BRAF V600E mutation, who have received prior systemic therapy|[PMDA] Drugs with a new indication and a new dosage for the treatment of unresectable, advanced or recurrent BRAF mutation-positive colorectal cancer that has progressed after cancer chemotherapy. [Priority review] uuid:2716b493-ff17-4f1f-9691-1bbb542aef19 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8L7891MRB6 biolink:treats EFO:1001480 PMID:41385096 "[{""id"":""uuid:c84ad34d-29ea-4e3f-a525-4ce72de1cae1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c6aa133f-5345-474e-b4c6-7144a67a0cd0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BRAFTOVI is a kinase inhibitor indicated: Melanoma • in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. ( 1.1 , 2.1 ) Colorectal Cancer (CRC) • in combination with cetuximab and mFOLFOX6, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA‑approved test. ( 1.2 , 2.1 ) This indication is approved under accelerated approval based on response rate and durability of response [see Clinical Studies (14.2) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). • in combination with cetuximab, for the treatment of adult patients with metastatic CRC with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy. ( 1.2 , 2.1 ) Non-Small Cell Lung Cancer (NSCLC) • in combination with binimetinib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test. ( 1.3 , 2.1 ) Limitations of Use BRAFTOVI is not indicated for treatment of patients with wild-type BRAF melanoma, wild-type BRAF CRC, or wild-type BRAF NSCLC. ( 1.4 , 5.2 ) uuid:b0d382fe-b51e-40ca-96c7-cc0582a7001f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8L7891MRB6 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:f1b45160-707b-4644-9d3a-889c07fa9540"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7a91edc6-eb56-4ddf-9cf4-7e0c362a1115"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BRAFTOVI is a kinase inhibitor indicated: Melanoma • in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. ( 1.1 , 2.1 ) Colorectal Cancer (CRC) • in combination with cetuximab and mFOLFOX6, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA‑approved test. ( 1.2 , 2.1 ) This indication is approved under accelerated approval based on response rate and durability of response [see Clinical Studies (14.2) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). • in combination with cetuximab, for the treatment of adult patients with metastatic CRC with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy. ( 1.2 , 2.1 ) Non-Small Cell Lung Cancer (NSCLC) • in combination with binimetinib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test. ( 1.3 , 2.1 ) Limitations of Use BRAFTOVI is not indicated for treatment of patients with wild-type BRAF melanoma, wild-type BRAF CRC, or wild-type BRAF NSCLC. ( 1.4 , 5.2 ) uuid:f2e29a93-eefd-4c83-b300-5ea41941ea34 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8L7891MRB6 biolink:treats UMLS:C0278987 PMID:41385096 "[{""id"":""uuid:6e8fd6fe-281c-4090-9a99-48cdae3fefc4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:36d2697a-f831-49c2-9eea-c6396eab060e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BRAFTOVI is a kinase inhibitor indicated: Melanoma • in combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. ( 1.1 , 2.1 ) Colorectal Cancer (CRC) • in combination with cetuximab and mFOLFOX6, for the treatment of patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, as detected by an FDA‑approved test. ( 1.2 , 2.1 ) This indication is approved under accelerated approval based on response rate and durability of response [see Clinical Studies (14.2) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). • in combination with cetuximab, for the treatment of adult patients with metastatic CRC with a BRAF V600E mutation, as detected by an FDA-approved test, after prior therapy. ( 1.2 , 2.1 ) Non-Small Cell Lung Cancer (NSCLC) • in combination with binimetinib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test. ( 1.3 , 2.1 ) Limitations of Use BRAFTOVI is not indicated for treatment of patients with wild-type BRAF melanoma, wild-type BRAF CRC, or wild-type BRAF NSCLC. ( 1.4 , 5.2 ) uuid:770c6060-4ecd-47db-a876-a55917725d88 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:5W8JGG2651 biolink:treats MONDO:0010674 PMID:41385096 "[{""id"":""uuid:eaae59eb-bc2b-4b75-bdbf-2cd919f1d8b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5d6d9def-06ea-473a-baf3-59923776e641"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:07389427-2cbf-4a24-ac7c-7cc968fbcfea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/elaprase""]},{""id"":""uuid:7f19b7cc-8cf9-4cad-bf36-b0248fb9cfe9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ELAPRASE is indicated for patients with Hunter syndrome (Mucopolysaccharidosis II, MPS II). ELAPRASE has been shown to improve walking capacity in patients 5 years and older. In patients 16 months to 5 years of age, no data are available to demonstrate improvement in disease-related symptoms or long term clinical outcome; however, treatment with ELAPRASE has reduced spleen volume similarly to that of adults and children 5 years of age and older. The safety and efficacy of ELAPRASE have not been established in pediatric patients less than 16 months of age [see Use in Specific Populations (8.4) ].|[EMA] Elaprase is indicated for the long-term treatment of patients with Hunter syndrome (mucopolysaccharidosis II, MPS II). Heterozygous females were not studied in the clinical trials.|[PMDA] A drug with a new active ingredient indicated for the treatment of mucopolysaccharidosis type II. [Orphan drug] uuid:398e4381-b58e-47c8-b260-0648e802e590 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:07730V90L6 biolink:treats MONDO:0005105 PMID:41385096 "[{""id"":""uuid:27577c79-159b-43ad-8e38-873d5314aaa4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c45d897d-eed5-4a05-845a-65f44702adfb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:940728b1-1eb0-42ba-a996-4382e217385a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/imlygic""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] IMLYGIC is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery. Limitations of use : IMLYGIC has not been shown to improve overall survival or have an effect on visceral metastases.|[EMA] Imlygic is indicated for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic (Stage IIIB, IIIC and IVM1a) with no bone, brain, lung or other visceral disease. uuid:7a6a1b77-c629-4040-bbf2-711e3df73a41 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:961YV2O515 biolink:treats MONDO:0006702 PMID:41385096 "[{""id"":""uuid:12764094-3e51-4cda-bed9-38c81f8338b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:abc7c938-2b14-482d-9ec5-ab051ffda4d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VYVGART HYTRULO is indicated for the treatment of adult patients with: generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive chronic inflammatory demyelinating polyneuropathy (CIDP) uuid:72e8d3a1-7dd9-480c-9b3e-f4beda06fbfe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:74T7185BMM biolink:treats MONDO:0017287 PMID:41385096 "[{""id"":""uuid:f93f2e55-ac29-47b7-9527-f4a5e1047d27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:facd3219-8190-4463-8add-28bb975a5d5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] UPLIZNA is a CD19-directed cytolytic antibody indicated for: The treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. ( 1.1 ) The treatment of Immunoglobulin G4-related disease (IgG4-RD) in adult patients. ( 1.2 ) uuid:a31961d3-870e-47e9-9f08-0d1698ead238 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229643 biolink:treats MONDO:0005475 PMID:41385096 "[{""id"":""uuid:1835fe4d-4c1e-4c1d-bcdd-8fe3f013180a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a8f2db0f-305c-4037-8ddf-2bd0352858a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZAVZPRET is indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use ZAVZPRET is not indicated for the preventive treatment of migraine. uuid:94828c65-8c1d-40d9-8efb-40f24e33d5eb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229643 biolink:treats MONDO:0100431 PMID:41385096 "[{""id"":""uuid:5f071475-c8c5-47dd-8d46-4ddfe9eb1b80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0b74e299-730a-4c3a-a5da-24ed98372158"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZAVZPRET is indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use ZAVZPRET is not indicated for the preventive treatment of migraine. uuid:3bafbaf9-ab0e-4ecc-afab-d04d02d918e4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:D99YVK4L0X biolink:treats UMLS:C5237824 PMID:41385096 "[{""id"":""uuid:b2fd3d61-524a-4b54-86c6-d20a306f92c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:59f928bd-ec68-4d95-8b1c-ae271ee379e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CYRAMZA ® is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated: as a single agent or in combination with paclitaxel, for treatment of adults with advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy. ( 1.1 ) in combination with erlotinib, for first-line treatment of adults with metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations. ( 1.2 ) in combination with docetaxel, for treatment of adults with metastatic non-small cell lung cancer with disease progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving CYRAMZA. ( 1.2 ) in combination with FOLFIRI, for the treatment of adults with metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. ( 1.3 ) as a single agent, for the treatment of adults with hepatocellular carcinoma in patients who have an alpha fetoprotein of ≥400 ng/mL and have been treated with sorafenib. ( 1.4 ) uuid:b57a1fc3-806e-40d1-a843-8f2161384b82 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:D99YVK4L0X biolink:treats UMLS:C3160888 PMID:41385096 "[{""id"":""uuid:fc168e23-b019-4ee3-872f-ea0ef26b8e53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:23db9ec3-2191-4714-aaed-12c225af949a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CYRAMZA ® is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated: as a single agent or in combination with paclitaxel, for treatment of adults with advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy. ( 1.1 ) in combination with erlotinib, for first-line treatment of adults with metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations. ( 1.2 ) in combination with docetaxel, for treatment of adults with metastatic non-small cell lung cancer with disease progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving CYRAMZA. ( 1.2 ) in combination with FOLFIRI, for the treatment of adults with metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. ( 1.3 ) as a single agent, for the treatment of adults with hepatocellular carcinoma in patients who have an alpha fetoprotein of ≥400 ng/mL and have been treated with sorafenib. ( 1.4 ) uuid:ea743ebc-ebf3-4146-9ba3-f150b833aea2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:D99YVK4L0X biolink:treats MONDO:0003219 PMID:41385096 "[{""id"":""uuid:631b840a-737d-45b0-a029-36007cb70620"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2f062450-a84b-427b-9fe8-375953eb60c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:6aa6c1f4-dd70-48bf-8db1-76094d102632"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cyramza""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] CYRAMZA ® is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated: as a single agent or in combination with paclitaxel, for treatment of adults with advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy. ( 1.1 ) in combination with erlotinib, for first-line treatment of adults with metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations. ( 1.2 ) in combination with docetaxel, for treatment of adults with metastatic non-small cell lung cancer with disease progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving CYRAMZA. ( 1.2 ) in combination with FOLFIRI, for the treatment of adults with metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. ( 1.3 ) as a single agent, for the treatment of adults with hepatocellular carcinoma in patients who have an alpha fetoprotein of ≥400 ng/mL and have been treated with sorafenib. ( 1.4 )|[EMA] Gastric cancerCyramza in combination with paclitaxel is indicated for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy.Cyramza monotherapy is indicated for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy, for whom treatment in combination with paclitaxel is not appropriate.Colorectal cancerCyramza, in combination with FOLFIRI (irinotecan, folinic acid, and 5‑fluorouracil), is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin and a fluoropyrimidine.Non-small cell lung cancerCyramza in combination with docetaxel is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with disease progression after platinum-based chemotherapy.Hepatocellular carcinomaCyramza monotherapy is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have a serum alpha fetoprotein (AFP) of ≥ 400 ng/ml and who have been previously treated with sorafenib. uuid:7c2b45f8-fed8-4099-a29c-e9b26f237888 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:D99YVK4L0X biolink:treats UMLS:C0278987 PMID:41385096 "[{""id"":""uuid:3edcb9cc-1899-497d-a4f4-d0074e766104"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a3ff4d57-deba-41cb-9e14-5ddf534b56d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CYRAMZA ® is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated: as a single agent or in combination with paclitaxel, for treatment of adults with advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy. ( 1.1 ) in combination with erlotinib, for first-line treatment of adults with metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations. ( 1.2 ) in combination with docetaxel, for treatment of adults with metastatic non-small cell lung cancer with disease progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving CYRAMZA. ( 1.2 ) in combination with FOLFIRI, for the treatment of adults with metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. ( 1.3 ) as a single agent, for the treatment of adults with hepatocellular carcinoma in patients who have an alpha fetoprotein of ≥400 ng/mL and have been treated with sorafenib. ( 1.4 ) uuid:a1cccdc5-239a-4c1d-8e0d-7e7a2cdcc4f5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:D99YVK4L0X biolink:treats EFO:1001480 PMID:41385096 "[{""id"":""uuid:c0206504-0b2d-4118-b030-341629aec655"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e1da339f-1bc5-4121-a27a-1aa0467fcd72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CYRAMZA ® is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated: as a single agent or in combination with paclitaxel, for treatment of adults with advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy. ( 1.1 ) in combination with erlotinib, for first-line treatment of adults with metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations. ( 1.2 ) in combination with docetaxel, for treatment of adults with metastatic non-small cell lung cancer with disease progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving CYRAMZA. ( 1.2 ) in combination with FOLFIRI, for the treatment of adults with metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. ( 1.3 ) as a single agent, for the treatment of adults with hepatocellular carcinoma in patients who have an alpha fetoprotein of ≥400 ng/mL and have been treated with sorafenib. ( 1.4 ) uuid:819ad42f-6fea-4227-ba25-b696dc9d6b90 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:D99YVK4L0X biolink:treats MONDO:0007256 PMID:41385096 "[{""id"":""uuid:a805fb57-4817-4a48-bb2f-d1a9ca0b6a67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ad74ce84-02e8-499c-b72f-d536582e59d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:eb4fd02d-48e8-4922-a5e0-d3e7d5b5b089"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cyramza""]},{""id"":""uuid:1b7648f2-4575-4b4d-ae93-e49039093dcf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CYRAMZA ® is a human vascular endothelial growth factor receptor 2 (VEGFR2) antagonist indicated: as a single agent or in combination with paclitaxel, for treatment of adults with advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy. ( 1.1 ) in combination with erlotinib, for first-line treatment of adults with metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations. ( 1.2 ) in combination with docetaxel, for treatment of adults with metastatic non-small cell lung cancer with disease progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving CYRAMZA. ( 1.2 ) in combination with FOLFIRI, for the treatment of adults with metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. ( 1.3 ) as a single agent, for the treatment of adults with hepatocellular carcinoma in patients who have an alpha fetoprotein of ≥400 ng/mL and have been treated with sorafenib. ( 1.4 )|[EMA] Gastric cancerCyramza in combination with paclitaxel is indicated for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy.Cyramza monotherapy is indicated for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy, for whom treatment in combination with paclitaxel is not appropriate.Colorectal cancerCyramza, in combination with FOLFIRI (irinotecan, folinic acid, and 5‑fluorouracil), is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin and a fluoropyrimidine.Non-small cell lung cancerCyramza in combination with docetaxel is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with disease progression after platinum-based chemotherapy.Hepatocellular carcinomaCyramza monotherapy is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have a serum alpha fetoprotein (AFP) of ≥ 400 ng/ml and who have been previously treated with sorafenib.|[PMDA] Drugs with a new dosage indicated for the treatment of unresectable advanced or recurrent non-small cell lung cancer. Drugs with a new dosage indicated for the treatment of unresectable advanced or recurrent gastric cancer, unresectable advanced or recurrent colon or rectal cancer, unresectable advanced or recurrent non-small cell lung cancer, and unresectable hepatocellular carcinoma whose serum AFP level is greater than 400 ng/mL and conditions have progressed after cancer chemotherapy. uuid:29390ddb-1d90-4587-8c99-a718ac2b05a5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5790 biolink:treats MONDO:0005530 PMID:41385096 "[{""id"":""uuid:06098ec7-8886-446a-a921-4597d89246a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:588fead0-74bc-4d3d-8ff7-a4e074b4b69c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydromorphone Hydrochloride Injection is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Hydromorphone Hydrochloride Injection [high potency formulation (HPF)] is indicated for use in opioid-tolerant patients who require higher doses of opioids for the management of pain severe enough to require an opioid analgesic and for which alternate treatments are inadequate. Patients considered opioid tolerant are those who are taking for one week or longer, around-the-clock medicine consisting of at least 60 mg oral morphine per day, or at least 25 mcg transdermal fentanyl per hour, or at least 30 mg oral oxycodone per day, or at least 8 g oral hydromorphone per day, or at least 25 mg oral oxymorphone per day, or at least 60 mg oral hydrocodone per day, or an equianalgesic dose of another opioid for one week or longer. Patients must remain on around-the-clock opioids while administering Hydromorphone Hydrochloride Injection (HPF). Limitations of Use: Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration [see Warnings and Precautions ( 5.2 )] , reserve Hydromorphone Hydrochloride Injection and Hydromorphone Hydrochloride Injection [high potency formulation (HPF)] for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or opioid combination products): • Have not been tolerated or are not expected to be tolerated, • Have not provided adequate analgesia or are not expected to provide adequate analgesia. Hydromorphone Hydrochloride Injection or Hydromorphone Hydrochloride Injection (HPF) should not be used for an extended period of time unless the pain remains severe enough to require an opioid analgesic and for which alternative treatment options continue to be inadequate. uuid:a84389b4-7b7f-4990-af67-3259a946a7fe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5790 biolink:treats MONDO:0001225 PMID:41385096 "[{""id"":""uuid:1ac51929-7446-43d3-a662-7b43a33129ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4960df9d-1383-4fec-92ec-f6fe970f34e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Hydromorphone Hydrochloride Injection is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. Hydromorphone Hydrochloride Injection [high potency formulation (HPF)] is indicated for use in opioid-tolerant patients who require higher doses of opioids for the management of pain severe enough to require an opioid analgesic and for which alternate treatments are inadequate. Patients considered opioid tolerant are those who are taking for one week or longer, around-the-clock medicine consisting of at least 60 mg oral morphine per day, or at least 25 mcg transdermal fentanyl per hour, or at least 30 mg oral oxycodone per day, or at least 8 g oral hydromorphone per day, or at least 25 mg oral oxymorphone per day, or at least 60 mg oral hydrocodone per day, or an equianalgesic dose of another opioid for one week or longer. Patients must remain on around-the-clock opioids while administering Hydromorphone Hydrochloride Injection (HPF). Limitations of Use: Because of the risks of addiction, abuse, and misuse with opioids, which can occur at any dosage or duration [see Warnings and Precautions ( 5.2 )] , reserve Hydromorphone Hydrochloride Injection and Hydromorphone Hydrochloride Injection [high potency formulation (HPF)] for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or opioid combination products): • Have not been tolerated or are not expected to be tolerated, • Have not provided adequate analgesia or are not expected to provide adequate analgesia. Hydromorphone Hydrochloride Injection or Hydromorphone Hydrochloride Injection (HPF) should not be used for an extended period of time unless the pain remains severe enough to require an opioid analgesic and for which alternative treatment options continue to be inadequate. uuid:bd5e800b-5cd0-4af0-85ae-a2aa2618de9e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5000 biolink:treats MONDO:0100135 PMID:41385096 "[{""id"":""uuid:d8949256-a57f-4656-98ad-85eb718ef817"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8256509e-b7c9-499b-8a65-908accae49de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ba863ec3-58cc-4929-8779-c03fcf7256ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d5c560d3-e776-4316-87db-26ad25d7e90c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FINTEPLA is indicated for the treatment of seizures associated with Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) in patients 2 years of age and older.|[EMA] Treatment of seizures associated with Dravet syndrome as an add-on therapy to other antiepileptic medicines for patients 2 years of age and older.Fintepla is indicated for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome as an add-on therapy to other anti-epileptic medicines for patients 2 years of age and older.|[PMDA] A drug with a new active ingredient indicated for use as an adjunctive therapy with other antiepileptic drugs to treat epileptic seizures in patients with Dravet syndrome who have not responded sufficiently to other antiepileptic drugs. [Orphan drug] uuid:ea2112e7-22af-468b-82cd-6f580303409a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:172944 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:db4cd1dd-9925-4ba5-a5c3-f5241e04e6f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4b2c4c91-41de-4457-8547-e7792b81aba5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] APRETUDE is indicated for pre‑exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents weighing at least 35 kg who are at risk for HIV-1 acquisition. Individuals must have a negative HIV-1 test prior to initiating APRETUDE (with or without an oral lead-in with oral cabotegravir) for HIV-1 PrEP [see Dosage and Administration ( 2.2 , 2.4 ), Contraindications ( 4 ), Warnings and Precautions ( 5.1 )] . uuid:e0b1d1d5-02fc-47ae-aa82-31f46fe2af2d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3VHF2ZD92J biolink:treats MONDO:0005298 PMID:41385096 "[{""id"":""uuid:1d41e2bc-0ab9-4998-bcc0-7a95f987f3be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5ebf4fd9-1b26-4b46-8646-b46eb6dab5a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9bd88073-ee85-47c3-9bc0-ba5f6dd56c9d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/evenity""]},{""id"":""uuid:7218cbc0-212f-4a8c-aeb3-5d700acb66e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EVENITY is a sclerostin inhibitor indicated for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. ( 1 ) Limitations of Use: Limit duration of use to 12 monthly doses. If osteoporosis therapy remains warranted, continued therapy with an anti-resorptive agent should be considered. ( 1.2 )|[EMA] Evenity is indicated in treatment of severe osteoporosis in postmenopausal women at high risk of fracture.|[PMDA] A drug with a new active ingredient indicated for the treatment of osteoporosis with a high risk of fracture. uuid:2c8906e3-bb12-4a2e-b7b1-2d91f88954d7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3VHF2ZD92J biolink:treats UMLS:C0521170 PMID:41385096 "[{""id"":""uuid:b7720851-d040-49e9-a72c-37d048e4e120"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1b24acef-1b41-4434-81f5-647eb5617452"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EVENITY is a sclerostin inhibitor indicated for the treatment of osteoporosis in postmenopausal women at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy. ( 1 ) Limitations of Use: Limit duration of use to 12 monthly doses. If osteoporosis therapy remains warranted, continued therapy with an anti-resorptive agent should be considered. ( 1.2 ) uuid:b5f9fdf0-3a02-4cb0-9c5e-a5e2f1bb0c0c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9445 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:57ac5d6e-a52e-4301-bef8-102ea390cbfb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:240bd13e-534a-422b-8183-38c8bf34497b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TEZRULY TM (terazosin) is an alpha-1 adrenoceptor antagonist indicated for: The treatment of signs and symptoms of benign prostatic hyperplasia (BPH) (1.1) The treatment of hypertension alone or with other antihypertensive agents, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarction. (1.2) uuid:99316ceb-fed0-4f47-a5b1-327f793e659c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9445 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:1aa1d0cd-2bd4-43fe-a900-97422dd9bdd9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:10d47cff-948d-4882-915f-380e13d869b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TEZRULY TM (terazosin) is an alpha-1 adrenoceptor antagonist indicated for: The treatment of signs and symptoms of benign prostatic hyperplasia (BPH) (1.1) The treatment of hypertension alone or with other antihypertensive agents, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarction. (1.2) uuid:35dad5b9-8cf6-4a35-9741-58ffb9c25e9e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats HP:0100533 PMID:41385096 "[{""id"":""uuid:c1845275-d0e9-4386-8e3f-653b188431e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:00679df7-5ad0-4279-9aed-f8d9fc8f0b07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DEXTENZA ® is a corticosteroid indicated for: The treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients. ( 1.1 ). The treatment of ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged 2 years and older. The use of DEXTENZA is not recommended for the treatment of ocular itching associated with allergic conjunctivitis in pediatric patients who require sedation for the insertion procedure. ( 1.2 ). uuid:8dadd0af-29db-4c3b-ba8b-cda492519904 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:194ec29e-b45a-43e9-91f2-4ecb47c99954"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6ea82551-5148-41d2-8784-5d94618f48b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DEXTENZA ® is a corticosteroid indicated for: The treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients. ( 1.1 ). The treatment of ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged 2 years and older. The use of DEXTENZA is not recommended for the treatment of ocular itching associated with allergic conjunctivitis in pediatric patients who require sedation for the insertion procedure. ( 1.2 ). uuid:fd163305-aef9-4606-8ce1-55d22b9e7ce3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats HP:0033841 PMID:41385096 "[{""id"":""uuid:6cfc3aa7-3b0f-4b69-9b61-05067815839c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:05e5b809-9a7a-4247-9281-cbeaf6c8d5d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DEXTENZA ® is a corticosteroid indicated for: The treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients. ( 1.1 ). The treatment of ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged 2 years and older. The use of DEXTENZA is not recommended for the treatment of ocular itching associated with allergic conjunctivitis in pediatric patients who require sedation for the insertion procedure. ( 1.2 ). uuid:1d38f4d0-2822-4060-b71b-8618cf284ef6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:VY5YX2TQ1F biolink:treats UMLS:C0278987 PMID:41385096 "[{""id"":""uuid:dfdfca37-d72a-4608-adb8-63c371643674"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:46c5968e-c6e5-4b34-9644-cee337d7de79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TEPMETKO is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring mesenchymal-epithelial transition ( MET ) exon 14 skipping alterations. uuid:23356737-a9a9-4d3f-b091-bb325ecc6e24 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27504 biolink:treats MONDO:0005041 PMID:41385096 "[{""id"":""uuid:6f903830-896e-45fd-931b-1b590fcd1208"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:90e9ca31-0a78-405b-a0a7-91f16608a7c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:11832990-1a77-48b6-aaa9-d0c88af6a5f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Mitosol ® is an antimetabolite indicated for use as an adjunct to ab externo glaucoma surgery.|[PMDA] A drug with a new route of administration indicated for an adjunct to incisional glaucoma surgery. uuid:58401aa2-eb8e-4700-9d50-c6637987c1c7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29101 biolink:treats UMLS:C0342579 PMID:41385096 "[{""id"":""uuid:969f492f-373b-4298-bccc-ba1182ed6a49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:211e202d-d977-40df-ad68-6b74de99958b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRISMASOL and PHOXILLUM solutions are indicated in pediatric and adult patients for use as a replacement solution in Continuous Renal Replacement Therapy (CRRT) to replace plasma volume removed by ultrafiltration and to correct electrolyte and acid-base imbalances. They may also be used in case of drug poisoning when CRRT is used to remove dialyzable substances. uuid:f1e869a3-fb15-4fda-92fd-2ba5f0f08e54 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29101 biolink:treats HP:0004360 PMID:41385096 "[{""id"":""uuid:a8b79eeb-3cda-4340-9408-aca55aa32ba4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:76ef0c7b-d650-4386-b55a-254d8260751c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRISMASOL and PHOXILLUM solutions are indicated in pediatric and adult patients for use as a replacement solution in Continuous Renal Replacement Therapy (CRRT) to replace plasma volume removed by ultrafiltration and to correct electrolyte and acid-base imbalances. They may also be used in case of drug poisoning when CRRT is used to remove dialyzable substances. uuid:073499a3-b7b7-4b65-ab9c-398502378435 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29101 biolink:treats UMLS:C0013221 PMID:41385096 "[{""id"":""uuid:d7263712-0799-4707-8442-c1bdeb807bbb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4427e43d-467d-4e63-8dfb-c21dd4630f3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PRISMASOL and PHOXILLUM solutions are indicated in pediatric and adult patients for use as a replacement solution in Continuous Renal Replacement Therapy (CRRT) to replace plasma volume removed by ultrafiltration and to correct electrolyte and acid-base imbalances. They may also be used in case of drug poisoning when CRRT is used to remove dialyzable substances. uuid:1a015c9e-2899-4bd6-8056-21b5009a1195 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3756 biolink:treats HP:0025269 PMID:41385096 "[{""id"":""uuid:f09be655-0420-4227-a583-21b66e164b9d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0f957bc8-ece1-48b5-92b5-0714f1bf67d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Seizure Disorders: ; Clonazepam tablets are useful alone or as an adjunct in the treatment of the Lennox-Gastaut syndrome (petit mal variant), akinetic, and myoclonic seizures. In patients with absence seizures (petit mal) who have failed to respond to succinimides, clonazepam tablets may be useful. Some loss of effect may occur during the course of clonazepam treatment (see; PRECAUTIONS : Loss of Effect ). Panic Disorder:; Clonazepam tablets are indicated for the treatment of panic disorder, with or without agoraphobia, as defined in DSM-V. Panic disorder is characterized by the occurrence of unexpected panic attacks and associated concern about having additional attacks, worry about the implications or consequences of the attacks, and/or a significant change in behavior related to the attacks. The efficacy of clonazepam tablets was established in two 6- to 9-week trials in panic disorder patients whose diagnoses corresponded to the DSM-IIIR category of panic disorder (see; CLINICAL PHARMACOLOGY: ;Clinical Trials ). Panic disorder (DSM-V) is characterized by recurrent unexpected panic attacks, i.e., a discrete period of intense fear or discomfort in which four (or more) of the following symptoms develop abruptly and reach a peak within 10 minutes: (1) palpitations, pounding heart or accelerated heart rate; (2) sweating; (3) trembling or shaking; (4) sensations of shortness of breath or smothering; (5) feeling of choking; (6) chest pain or discomfort; (7) nausea or abdominal distress; (8) feeling dizzy, unsteady, lightheaded or faint; (9) derealization (feelings of unreality) or depersonalization (being detached from oneself); (10) fear of losing control; (11) fear of dying; (12) paresthesias (numbness or tingling sensations); (13) chills or hot flushes. The effectiveness of clonazepam tablets in long-term use, that is, for more than 9 weeks, has not been systematically studied in controlled clinical trials. The physician who elects to use clonazepam tablets for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual patient (see; DOSAGE AND ADMINISTRATION ). uuid:7be0148b-8dba-440d-b1ab-994cf52c8c75 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229526 biolink:treats MONDO:0005342 PMID:41385096 "[{""id"":""uuid:cfa6f91c-822c-4a05-addc-fd3122620dc2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a663dbc5-9507-4e12-9fd7-7b267efef3f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FILSPARI is indicated to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression. uuid:b17445ae-0e90-48df-bf24-0d02290066c0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229526 biolink:treats MONDO:0008072 PMID:41385096 "[{""id"":""uuid:054f825f-3480-47a3-9747-a4db11265d80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:147d924b-8f35-4d20-b82b-397ded1fe779"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FILSPARI is indicated to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression. uuid:2852e6b9-ffbd-4e4c-9f32-93444fa78cf2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:92043599 biolink:treats MONDO:0020725 PMID:41385096 "[{""id"":""uuid:7673b348-5c09-4cb8-b2cd-cd8acbcb8ed0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:28b60c67-c8f6-4e13-9763-749a9ece9fc6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:948ac962-da98-4f38-8135-7a64e334f6fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/epoetin-alfa-hexal""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Epogen is an erythropoiesis-stimulating agent (ESA) indicated for: Treatment of anemia due to: - Chronic Kidney Disease (CKD) in patients on dialysis and not on dialysis ( 1.1 ). - Zidovudine in patients with Human Immunodeficiency Virus (HIV) infection ( 1.2 ). - The effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy ( 1.3 ). Reduction of allogeneic red blood cell (RBC) transfusions in patients undergoing elective, noncardiac, nonvascular surgery ( 1.4 ). Limitations of Use Epogen has not been shown to improve quality of life, fatigue, or patient well-being ( 1.5 ). Epogen is not indicated for use: In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy ( 1.5 ). In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure ( 1.5 ). In patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion ( 1.5 ). In patients scheduled for surgery who are willing to donate autologous blood ( 1.5 ). In patients undergoing cardiac or vascular surgery ( 1.5 ). As a substitute for RBC transfusions in patients who require immediate correction of anemia ( 1.5 ).|[EMA] Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult and paediatric patients:, , , treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis;, treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis;, Treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre-existing anaemia at the start of chemotherapy)., , uuid:271d7290-b035-45aa-a733-4053edbbb960 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:V78M04F0XC biolink:treats MONDO:0007318 PMID:41385096 "[{""id"":""uuid:c8dd22d4-862e-4659-92f0-cc026b06eb31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:8b981441-0fca-4c12-986d-526fbf660232"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:dfb68916-fb10-45de-aa54-bb639d88fc0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/livmarli""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] LIVMARLI is an ileal bile acid transporter (IBAT) inhibitor indicated for: • the treatment of cholestatic pruritus in patients 3 months of age and older with Alagille syndrome (ALGS). ( 1.1 ) • the treatment of cholestatic pruritus in patients 12 months of age and older with progressive familial intrahepatic cholestasis (PFIC). ( 1.2 ) o Limitations of Use: LIVMARLI is not recommended in a subgroup of PFIC type 2 patients with specific ABCB11 variants resulting in non-functional or complete absence of bile salt export pump (BSEP) protein. ( 14.2 )|[EMA] Livmarli is indicated for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) 2 months of age and older. uuid:5d99ed1d-252b-4f24-8e5c-7e4f8954ef9e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:V78M04F0XC biolink:treats MONDO:0015762 PMID:41385096 "[{""id"":""uuid:1319a56c-c333-4a61-a122-9a8a8eb50a6a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:03ad144d-b0ef-415d-bf12-b95a91d1a6ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LIVMARLI is an ileal bile acid transporter (IBAT) inhibitor indicated for: • the treatment of cholestatic pruritus in patients 3 months of age and older with Alagille syndrome (ALGS). ( 1.1 ) • the treatment of cholestatic pruritus in patients 12 months of age and older with progressive familial intrahepatic cholestasis (PFIC). ( 1.2 ) o Limitations of Use: LIVMARLI is not recommended in a subgroup of PFIC type 2 patients with specific ABCB11 variants resulting in non-functional or complete absence of bile salt export pump (BSEP) protein. ( 14.2 ) uuid:f4d8bdc7-e339-45ee-a174-7e772385e48e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:LZ0M43NNF2 biolink:treats MONDO:0010643 PMID:41385096 "[{""id"":""uuid:13e7eaed-8ac6-4626-bb10-13d7ead11816"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4cab9fb4-1b10-42e3-9550-69cccaa4aefc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] REVUFORJ is a menin inhibitor indicated for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients 1 year and older. ( 1 ) uuid:17b5b7b5-dbea-41ad-ac41-0ec76581b543 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:LZ0M43NNF2 biolink:treats UMLS:C4725027 PMID:41385096 "[{""id"":""uuid:72f14abf-470d-47e5-9cf1-a204a5032213"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b581d11c-75b3-4ccb-ae06-1cee887b0f00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] REVUFORJ is a menin inhibitor indicated for the treatment of relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (KMT2A) translocation in adult and pediatric patients 1 year and older. ( 1 ) uuid:1eae6d81-7211-49b9-bc88-d1397a26c77b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85993 biolink:treats UMLS:C3495917 PMID:41385096 "[{""id"":""uuid:33079d80-98c9-40ec-8f46-529dd332e678"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e638b216-e1ca-488d-9155-d56aba6c3950"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IBRANCE is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: • an aromatase inhibitor as initial endocrine-based therapy; or • fulvestrant in patients with disease progression following endocrine therapy. uuid:dc7a7448-0632-4cb8-98e9-8cae18285389 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85993 biolink:treats UMLS:C0278488 PMID:41385096 "[{""id"":""uuid:06124dc6-9be7-4eb8-a9ca-c6ca90eafeb3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d0de17f5-93b5-46c8-818f-9582df036a00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IBRANCE is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: • an aromatase inhibitor as initial endocrine-based therapy; or • fulvestrant in patients with disease progression following endocrine therapy. uuid:812ebe2c-ab26-40ff-9bf0-08d38b56f622 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2668195 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:1f139178-64c7-45e5-aae1-94fac3e62580"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:667be1cf-c71e-42cc-9008-5947076ae03d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:180d67a2-0c59-4e18-a692-5ae05fe3d0b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CABTREO is indicated for the topical treatment of acne vulgaris in adult and pediatric patients 12 years of age and older.|[PMDA] A new combination drug with a new active ingredient indicated for the treatment of acne vulgaris. uuid:4d18b933-2d30-42c0-bf58-6e4a7657606f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68579 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:4cc0cd1d-7e3f-496d-bf2b-228c8918d3fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:304e9a5f-3ffe-47b7-9d17-11f4dcbb802d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e1f83f8f-ba0d-4f20-bbd6-b73be142bbeb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/rivaroxaban-accord""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Rivaroxaban tablets are a factor Xa inhibitor indicated: to reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillation ( 1.1 ) for treatment of deep vein thrombosis (DVT) ( 1.2 ) for treatment of pulmonary embolism (PE) ( 1.3 ) for reduction in the risk of recurrence of DVT or PE ( 1.4 ) for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery ( 1.5 ) for prophylaxis of venous thromboembolism (VTE) in acutely ill medical patients ( 1.6 ) to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) ( 1.7 ) to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD ( 1.8 ) for treatment of VTE and reduction in the risk of recurrent VTE in pediatric patients from birth to less than 18 years ( 1.9 ) for thromboprophylaxis in pediatric patients 2 years and older with congenital heart disease after the Fontan procedure ( 1.10 )|[EMA] Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients).AdultsPrevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.)Paediatric populationTreatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment.Rivaroxaban Accord, co administered with acetylsalicylic acid (ASA) alone or with ASA plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers (see sections 4.3, 4.4 and 5.1).Rivaroxaban Accord, co administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events.AdultsPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.)Paediatric populationTreatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment. uuid:fd8491da-2cae-4c71-bef3-e93e8196c65f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68579 biolink:treats UMLS:C5400523 PMID:41385096 "[{""id"":""uuid:de82f6bb-373c-4372-a918-1437bc97adbc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bc51f90d-08d4-4918-80a5-56f26bf42d37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:459b6ef0-2d72-4554-b5f5-86d5009ec7d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Rivaroxaban tablets are a factor Xa inhibitor indicated: to reduce risk of stroke and systemic embolism in nonvalvular atrial fibrillation ( 1.1 ) for treatment of deep vein thrombosis (DVT) ( 1.2 ) for treatment of pulmonary embolism (PE) ( 1.3 ) for reduction in the risk of recurrence of DVT or PE ( 1.4 ) for the prophylaxis of DVT, which may lead to PE in patients undergoing knee or hip replacement surgery ( 1.5 ) for prophylaxis of venous thromboembolism (VTE) in acutely ill medical patients ( 1.6 ) to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) ( 1.7 ) to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD ( 1.8 ) for treatment of VTE and reduction in the risk of recurrent VTE in pediatric patients from birth to less than 18 years ( 1.9 ) for thromboprophylaxis in pediatric patients 2 years and older with congenital heart disease after the Fontan procedure ( 1.10 )|[PMDA] Drugs with a new active ingredient indicated for the prevention of ischemic stroke and systemic embolism in patients with nonvalvular atrial fibrillation. uuid:ce3a3c41-175b-40b5-88a6-faae5f069071 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75283 biolink:treats MONDO:0005445 PMID:41385096 "[{""id"":""uuid:eef7dadc-ebf8-4143-ae21-babafb2f9fa0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b21d30b1-b91c-4896-a94f-cf0b66a1d779"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IMPAVIDO (miltefosine) capsules are indicated in adults and pediatric patients 12 years of age and older weighing greater than or equal to 30 kg (66 lbs) for the treatment of: • Visceral leishmaniasis caused by Leishmania donovani [see Clinical Trials ( 14.1 )] . • Cutaneous leishmaniasis caused by Leishmania braziliensis , Leishmania guyanensis, and Leishmania panamensis [see Clinical Trials ( 14.2 )] . • Mucosal leishmaniasis caused by Leishmania braziliensis [see Clinical Trials ( 14.3 )] . Limitations of Use: • Leishmania species studied in clinical trials evaluating IMPAVIDO were based on epidemiologic data [see Clinical Trials ( 14.1 , 14.2 )] . • There may be geographic variation in clinical response of the same Leishmania species to IMPAVIDO [see Clinical Trials ( 14.1 , 14.2 )] . • The efficacy of IMPAVIDO in the treatment of other Leishmania species has not been evaluated. uuid:ea6d7c12-43ca-48f8-9064-d503a06384c8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75283 biolink:treats MONDO:0005446 PMID:41385096 "[{""id"":""uuid:e7554bf5-b5d3-421c-9117-d45535fa995b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:03e7c9ab-c158-4dc6-b7cd-1eb79e93d767"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IMPAVIDO (miltefosine) capsules are indicated in adults and pediatric patients 12 years of age and older weighing greater than or equal to 30 kg (66 lbs) for the treatment of: • Visceral leishmaniasis caused by Leishmania donovani [see Clinical Trials ( 14.1 )] . • Cutaneous leishmaniasis caused by Leishmania braziliensis , Leishmania guyanensis, and Leishmania panamensis [see Clinical Trials ( 14.2 )] . • Mucosal leishmaniasis caused by Leishmania braziliensis [see Clinical Trials ( 14.3 )] . Limitations of Use: • Leishmania species studied in clinical trials evaluating IMPAVIDO were based on epidemiologic data [see Clinical Trials ( 14.1 , 14.2 )] . • There may be geographic variation in clinical response of the same Leishmania species to IMPAVIDO [see Clinical Trials ( 14.1 , 14.2 )] . • The efficacy of IMPAVIDO in the treatment of other Leishmania species has not been evaluated. uuid:a37d77b0-e7ba-4210-9f1b-3f9c2873dc3f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:N7V53U4U4T biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:b9bcf63c-5954-408e-ae6c-0a11dd213000"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:29930096-2e66-46ee-bdd7-89cf56f9313e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:003010cb-b207-4457-901a-5179d579fd54"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BAXDELA is a fluoroquinolone antibacterial indicated for the treatment of adults with the following infections caused by designated susceptible bacteria: Acute Bacterial Skin and Skin Structure Infections (ABSSSI) ( 1.1 ) Community-Acquired Bacterial Pneumonia (CABP) ( 1.2 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of BAXDELA and other antibacterial drugs, BAXDELA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.3 )|[EMA] Quofenix is indicated for the treatment of the following infections in adults:acute bacterial skin and skin structure infections (ABSSSI),community-acquired pneumonia (CAP), when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of these infections (see sections 4.4 and 5.1).Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:3a98fcf9-1bf2-44a2-a0ad-05fbd2bbfcf4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:N7V53U4U4T biolink:treats MONDO:0004652 PMID:41385096 "[{""id"":""uuid:7330fb96-d2ff-4f73-9cda-6b8ef303e403"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a8d19e2c-9676-4050-b883-18739ccf53aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BAXDELA is a fluoroquinolone antibacterial indicated for the treatment of adults with the following infections caused by designated susceptible bacteria: Acute Bacterial Skin and Skin Structure Infections (ABSSSI) ( 1.1 ) Community-Acquired Bacterial Pneumonia (CABP) ( 1.2 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of BAXDELA and other antibacterial drugs, BAXDELA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.3 ) uuid:56b0a136-60ef-4cbf-b1a2-105b0e45e8fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82720 biolink:treats MONDO:0012819 PMID:41385096 "[{""id"":""uuid:f7c8f3ce-2c00-4608-896a-6f3e5e7bf508"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:52f9f9fd-23a2-4564-be79-a60ab86acf44"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] JARDIANCE is indicated: as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and established cardiovascular disease. Limitations of Use JARDIANCE is not recommended for patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. uuid:3d6ab76a-d52d-4f34-a578-3649227961ad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:91X1KLU43E biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:30fbea3f-eee7-431f-963b-15bbbcaaeeb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e6127c6b-a7ec-4c5e-bcd4-d8f7a591e57e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1ed27af6-aa51-463d-ab7e-d260de18ff4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/simponi""]},{""id"":""uuid:0407adf2-0ded-4f43-b547-5cb0fa783e2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SIMPONI ARIA is a tumor necrosis factor (TNF) blocker indicated for the treatment of: Adult patients with moderately to severely active Rheumatoid Arthritis (RA) in combination with methotrexate ( 1.1 ) Active Psoriatic Arthritis (PsA) in patients 2 years of age and older ( 1.2 ) Adult patients with active Ankylosing Spondylitis (AS) ( 1.3 ) Active polyarticular Juvenile Idiopathic Arthritis (pJIA) in patients 2 years of age and older ( 1.4 )|[EMA] Rheumatoid arthritis (RA)Simponi, in combination with methotrexate (MTX), is indicated for:the treatment of moderate to severe, active rheumatoid arthritis in adults when the response to disease modifying anti rheumatic drug (DMARD) therapy including MTX has been inadequate.the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with MTX.Simponi, in combination with MTX, has been shown to reduce the rate of progression of joint damage as measured by X ray and to improve physical function.For information regarding the polyarticular juvenile idiopathic arthritis indication, please see the Simponi 50 mg SmPC.Psoriatic arthritis (PsA)Simponi, alone or in combination with MTX, is indicated for the treatment of active and progressive psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate. Simponi has been shown to reduce the rate of progression of peripheral joint damage as measured by X ray in patients with polyarticular symmetrical subtypes of the disease (see section 5.1) and to improve physical function.Axial spondyloarthritisAnkylosing spondylitis (AS)Simponi is indicated for the treatment of severe, active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.Non radiographic axial spondyloarthritis (nr Axial SpA)Simponi is indicated for the treatment of adults with severe, active non radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).Ulcerative colitis (UC)Simponi is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6 mercaptopurine (6 MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.Juvenile idiopathic arthritisPolyarticular juvenile idiopathic arthritis (pJIA)Simponi in combination with methotrexate (MTX) is indicated for the treatment of polyarticular juvenile idiopathic arthritis in children 2 years of age and older, who have responded inadequately to previous therapy with MTX.Rheumatoid arthritis (RA)Simponi, in combination with methotrexate (MTX), is indicated for:the treatment of moderate to severe, active rheumatoid arthritis in adults when the response to disease modifying anti rheumatic drug (DMARD) therapy including MTX has been inadequate.the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with MTX.Simponi, in combination with MTX, has been shown to reduce the rate of progression of joint damage as measured by X ray and to improve physical function.Juvenile idiopathic arthritisPolyarticular juvenile idiopathic arthritis (pJIA)Simponi in combination with MTX is indicated for the treatment of polyarticular juvenile idiopathic arthritis in children 2 years of age and older, who have responded inadequately to previous therapy with MTX.Psoriatic arthritis (PsA)Simponi, alone or in combination with MTX, is indicated for the treatment of active and progressive psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate. Simponi has been shown to reduce the rate of progression of peripheral joint damage as measured by X ray in patients with polyarticular symmetrical subtypes of the disease (see section 5.1) and to improve physical function.Axial spondyloarthritisAnkylosing spondylitis (AS)Simponi is indicated for the treatment of severe, active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.Non radiographic axial spondyloarthritis (nr Axial SpA)Simponi is indicated for the treatment of adults with severe, active non radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).Ulcerative colitis (UC)Simponi is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6 mercaptopurine (6 MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.|[PMDA] A drug with a new active ingredient indicated for the treatment of rheumatoid arthritis (including prevention of structural joint damage) in patients who have not sufficiently responded to conventional treatments. uuid:e24a90a4-76a7-4321-b35d-b4598ad8053a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:91X1KLU43E biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:df84ce7c-75ef-4c23-971d-c9bb73f79371"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f4d2052b-a26f-4bc1-a7fc-a34f5297ad25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f34302c3-fc87-4c41-85d4-894588949427"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/simponi""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] SIMPONI ARIA is a tumor necrosis factor (TNF) blocker indicated for the treatment of: Adult patients with moderately to severely active Rheumatoid Arthritis (RA) in combination with methotrexate ( 1.1 ) Active Psoriatic Arthritis (PsA) in patients 2 years of age and older ( 1.2 ) Adult patients with active Ankylosing Spondylitis (AS) ( 1.3 ) Active polyarticular Juvenile Idiopathic Arthritis (pJIA) in patients 2 years of age and older ( 1.4 )|[EMA] Rheumatoid arthritis (RA)Simponi, in combination with methotrexate (MTX), is indicated for:the treatment of moderate to severe, active rheumatoid arthritis in adults when the response to disease modifying anti rheumatic drug (DMARD) therapy including MTX has been inadequate.the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with MTX.Simponi, in combination with MTX, has been shown to reduce the rate of progression of joint damage as measured by X ray and to improve physical function.For information regarding the polyarticular juvenile idiopathic arthritis indication, please see the Simponi 50 mg SmPC.Psoriatic arthritis (PsA)Simponi, alone or in combination with MTX, is indicated for the treatment of active and progressive psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate. Simponi has been shown to reduce the rate of progression of peripheral joint damage as measured by X ray in patients with polyarticular symmetrical subtypes of the disease (see section 5.1) and to improve physical function.Axial spondyloarthritisAnkylosing spondylitis (AS)Simponi is indicated for the treatment of severe, active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.Non radiographic axial spondyloarthritis (nr Axial SpA)Simponi is indicated for the treatment of adults with severe, active non radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).Ulcerative colitis (UC)Simponi is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6 mercaptopurine (6 MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.Juvenile idiopathic arthritisPolyarticular juvenile idiopathic arthritis (pJIA)Simponi in combination with methotrexate (MTX) is indicated for the treatment of polyarticular juvenile idiopathic arthritis in children 2 years of age and older, who have responded inadequately to previous therapy with MTX.Rheumatoid arthritis (RA)Simponi, in combination with methotrexate (MTX), is indicated for:the treatment of moderate to severe, active rheumatoid arthritis in adults when the response to disease modifying anti rheumatic drug (DMARD) therapy including MTX has been inadequate.the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with MTX.Simponi, in combination with MTX, has been shown to reduce the rate of progression of joint damage as measured by X ray and to improve physical function.Juvenile idiopathic arthritisPolyarticular juvenile idiopathic arthritis (pJIA)Simponi in combination with MTX is indicated for the treatment of polyarticular juvenile idiopathic arthritis in children 2 years of age and older, who have responded inadequately to previous therapy with MTX.Psoriatic arthritis (PsA)Simponi, alone or in combination with MTX, is indicated for the treatment of active and progressive psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate. Simponi has been shown to reduce the rate of progression of peripheral joint damage as measured by X ray in patients with polyarticular symmetrical subtypes of the disease (see section 5.1) and to improve physical function.Axial spondyloarthritisAnkylosing spondylitis (AS)Simponi is indicated for the treatment of severe, active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.Non radiographic axial spondyloarthritis (nr Axial SpA)Simponi is indicated for the treatment of adults with severe, active non radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).Ulcerative colitis (UC)Simponi is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6 mercaptopurine (6 MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies. uuid:e195e755-743d-40e2-a363-d2fff4ebae75 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:91X1KLU43E biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:85542895-ff04-427c-8fc5-04ed25bcc7a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b882b62c-6911-41a8-b535-ac6e5983ce4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f36d6180-27d7-4a6e-a06c-517fbcfa0099"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/simponi""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] SIMPONI ARIA is a tumor necrosis factor (TNF) blocker indicated for the treatment of: Adult patients with moderately to severely active Rheumatoid Arthritis (RA) in combination with methotrexate ( 1.1 ) Active Psoriatic Arthritis (PsA) in patients 2 years of age and older ( 1.2 ) Adult patients with active Ankylosing Spondylitis (AS) ( 1.3 ) Active polyarticular Juvenile Idiopathic Arthritis (pJIA) in patients 2 years of age and older ( 1.4 )|[EMA] Rheumatoid arthritis (RA)Simponi, in combination with methotrexate (MTX), is indicated for:the treatment of moderate to severe, active rheumatoid arthritis in adults when the response to disease modifying anti rheumatic drug (DMARD) therapy including MTX has been inadequate.the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with MTX.Simponi, in combination with MTX, has been shown to reduce the rate of progression of joint damage as measured by X ray and to improve physical function.For information regarding the polyarticular juvenile idiopathic arthritis indication, please see the Simponi 50 mg SmPC.Psoriatic arthritis (PsA)Simponi, alone or in combination with MTX, is indicated for the treatment of active and progressive psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate. Simponi has been shown to reduce the rate of progression of peripheral joint damage as measured by X ray in patients with polyarticular symmetrical subtypes of the disease (see section 5.1) and to improve physical function.Axial spondyloarthritisAnkylosing spondylitis (AS)Simponi is indicated for the treatment of severe, active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.Non radiographic axial spondyloarthritis (nr Axial SpA)Simponi is indicated for the treatment of adults with severe, active non radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).Ulcerative colitis (UC)Simponi is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6 mercaptopurine (6 MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.Juvenile idiopathic arthritisPolyarticular juvenile idiopathic arthritis (pJIA)Simponi in combination with methotrexate (MTX) is indicated for the treatment of polyarticular juvenile idiopathic arthritis in children 2 years of age and older, who have responded inadequately to previous therapy with MTX.Rheumatoid arthritis (RA)Simponi, in combination with methotrexate (MTX), is indicated for:the treatment of moderate to severe, active rheumatoid arthritis in adults when the response to disease modifying anti rheumatic drug (DMARD) therapy including MTX has been inadequate.the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with MTX.Simponi, in combination with MTX, has been shown to reduce the rate of progression of joint damage as measured by X ray and to improve physical function.Juvenile idiopathic arthritisPolyarticular juvenile idiopathic arthritis (pJIA)Simponi in combination with MTX is indicated for the treatment of polyarticular juvenile idiopathic arthritis in children 2 years of age and older, who have responded inadequately to previous therapy with MTX.Psoriatic arthritis (PsA)Simponi, alone or in combination with MTX, is indicated for the treatment of active and progressive psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate. Simponi has been shown to reduce the rate of progression of peripheral joint damage as measured by X ray in patients with polyarticular symmetrical subtypes of the disease (see section 5.1) and to improve physical function.Axial spondyloarthritisAnkylosing spondylitis (AS)Simponi is indicated for the treatment of severe, active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.Non radiographic axial spondyloarthritis (nr Axial SpA)Simponi is indicated for the treatment of adults with severe, active non radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).Ulcerative colitis (UC)Simponi is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6 mercaptopurine (6 MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies. uuid:cc93a30a-13a5-4fd5-865c-3b695eaacf20 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:91X1KLU43E biolink:treats MONDO:0018456 PMID:41385096 "[{""id"":""uuid:9a706555-607a-455a-9046-0c61c1aaf82f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:452e8ce4-690e-4dd8-9823-be3defe61c89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:6a8a85aa-d910-4908-b0f1-f7158351bc48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/simponi""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] SIMPONI ARIA is a tumor necrosis factor (TNF) blocker indicated for the treatment of: Adult patients with moderately to severely active Rheumatoid Arthritis (RA) in combination with methotrexate ( 1.1 ) Active Psoriatic Arthritis (PsA) in patients 2 years of age and older ( 1.2 ) Adult patients with active Ankylosing Spondylitis (AS) ( 1.3 ) Active polyarticular Juvenile Idiopathic Arthritis (pJIA) in patients 2 years of age and older ( 1.4 )|[EMA] Rheumatoid arthritis (RA)Simponi, in combination with methotrexate (MTX), is indicated for:the treatment of moderate to severe, active rheumatoid arthritis in adults when the response to disease modifying anti rheumatic drug (DMARD) therapy including MTX has been inadequate.the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with MTX.Simponi, in combination with MTX, has been shown to reduce the rate of progression of joint damage as measured by X ray and to improve physical function.For information regarding the polyarticular juvenile idiopathic arthritis indication, please see the Simponi 50 mg SmPC.Psoriatic arthritis (PsA)Simponi, alone or in combination with MTX, is indicated for the treatment of active and progressive psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate. Simponi has been shown to reduce the rate of progression of peripheral joint damage as measured by X ray in patients with polyarticular symmetrical subtypes of the disease (see section 5.1) and to improve physical function.Axial spondyloarthritisAnkylosing spondylitis (AS)Simponi is indicated for the treatment of severe, active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.Non radiographic axial spondyloarthritis (nr Axial SpA)Simponi is indicated for the treatment of adults with severe, active non radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).Ulcerative colitis (UC)Simponi is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6 mercaptopurine (6 MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.Juvenile idiopathic arthritisPolyarticular juvenile idiopathic arthritis (pJIA)Simponi in combination with methotrexate (MTX) is indicated for the treatment of polyarticular juvenile idiopathic arthritis in children 2 years of age and older, who have responded inadequately to previous therapy with MTX.Rheumatoid arthritis (RA)Simponi, in combination with methotrexate (MTX), is indicated for:the treatment of moderate to severe, active rheumatoid arthritis in adults when the response to disease modifying anti rheumatic drug (DMARD) therapy including MTX has been inadequate.the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with MTX.Simponi, in combination with MTX, has been shown to reduce the rate of progression of joint damage as measured by X ray and to improve physical function.Juvenile idiopathic arthritisPolyarticular juvenile idiopathic arthritis (pJIA)Simponi in combination with MTX is indicated for the treatment of polyarticular juvenile idiopathic arthritis in children 2 years of age and older, who have responded inadequately to previous therapy with MTX.Psoriatic arthritis (PsA)Simponi, alone or in combination with MTX, is indicated for the treatment of active and progressive psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate. Simponi has been shown to reduce the rate of progression of peripheral joint damage as measured by X ray in patients with polyarticular symmetrical subtypes of the disease (see section 5.1) and to improve physical function.Axial spondyloarthritisAnkylosing spondylitis (AS)Simponi is indicated for the treatment of severe, active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.Non radiographic axial spondyloarthritis (nr Axial SpA)Simponi is indicated for the treatment of adults with severe, active non radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).Ulcerative colitis (UC)Simponi is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6 mercaptopurine (6 MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies. uuid:76d83e3d-d66d-48c3-afdf-6d228dab83b5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17824 biolink:treats MONDO:0020546 PMID:41385096 "[{""id"":""uuid:f7efd2a3-4305-4cc9-bed5-88b77926c515"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:861c9c34-1847-45db-900b-0cf5cae7851b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RYONCIL is indicated for the treatment of steroid refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months of age and older. uuid:b9c68fa2-6357-41ef-be70-227b169e3965 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:79033 biolink:treats MONDO:0004975 PMID:41385096 "[{""id"":""uuid:1e157154-6472-4f7c-aaf0-5dda82018f7c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:cb935287-77bb-436e-94f3-b6b55ac67e41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a01e95ba-0b19-426f-8317-10e27b07860d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Neuraceq is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s Disease (AD) and other causes of cognitive decline. A negative Neuraceq scan indicates sparse to no amyloid neuritic plaques and is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition; a negative scan result reduces the likelihood that a patient’s cognitive impairment is due to AD. A positive Neuraceq scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with AD, but may also be present in patients with other types of neurologic conditions as well as older people with normal cognition. Neuraceq is an adjunct to other diagnostic evaluations. Limitations of Use • A positive Neuraceq scan does not establish the diagnosis of AD or any other cognitive disorder. • Safety and effectiveness of Neuraceq have not been established for: o Predicting development of dementia or other neurologic conditions; o Monitoring responses to therapies.|[EMA] This medicinal product is for diagnostic use only.Neuraceq is a radiopharmaceutical indicated for Positron Emission Tomography (PET) imaging of β amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive impairment. Neuraceq should be used in conjunction with a clinical evaluation.A negative scan indicates sparse or no plaques, which is not consistent with a diagnosis of AD. uuid:a315bfb0-3f18-4887-894c-c046460ec436 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:79033 biolink:treats MONDO:0002039 PMID:41385096 "[{""id"":""uuid:c136ba21-7936-49df-8daf-f1ab14ba4c03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9c25e0f9-1c2d-45e9-879f-bf822c1d5a28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3d7d75f8-6480-4ae5-ad25-2a89f4ff709f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Neuraceq is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer’s Disease (AD) and other causes of cognitive decline. A negative Neuraceq scan indicates sparse to no amyloid neuritic plaques and is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition; a negative scan result reduces the likelihood that a patient’s cognitive impairment is due to AD. A positive Neuraceq scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with AD, but may also be present in patients with other types of neurologic conditions as well as older people with normal cognition. Neuraceq is an adjunct to other diagnostic evaluations. Limitations of Use • A positive Neuraceq scan does not establish the diagnosis of AD or any other cognitive disorder. • Safety and effectiveness of Neuraceq have not been established for: o Predicting development of dementia or other neurologic conditions; o Monitoring responses to therapies.|[EMA] This medicinal product is for diagnostic use only.Neuraceq is a radiopharmaceutical indicated for Positron Emission Tomography (PET) imaging of β amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive impairment. Neuraceq should be used in conjunction with a clinical evaluation.A negative scan indicates sparse or no plaques, which is not consistent with a diagnosis of AD. uuid:a7bba9b7-0922-4d77-bb76-c21171560dad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27375 biolink:treats MONDO:0009348 PMID:41385096 "[{""id"":""uuid:5af079ff-d7d1-4eb6-b949-ab7dca1527c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4e91f4cf-32b3-47aa-bcbe-d22246d2874d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vinblastine Sulfate Injection is indicated in the palliative treatment of the following: I. Frequently Responsive Malignancies • Generalized Hodgkin’s disease (Stages III and IV, Ann Arbor modification of Rye staging system) • Lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated) • Histiocytic lymphoma • Mycosis fungoides (advanced stages) • Advanced carcinoma of the testis • Kaposi’s sarcoma • Letterer-Siwe disease (histiocytosis X) II. Less Frequently Responsive Malignancies • Choriocarcinoma resistant to other chemotherapeutic agents • Carcinoma of the breast, unresponsive to appropriate endocrine surgery and hormonal therapy Current principles of chemotherapy for many types of cancer include the concurrent administration of several antineoplastic agents. For enhanced therapeutic effect without additive toxicity, agents with different dose-limiting clinical toxicities and different mechanisms of action are generally selected. Therefore, although vinblastine sulfate is effective as a single agent in the aforementioned indications, it is usually administered in combination with other antineoplastic drugs. Such combination therapy produces a greater percentage of response than does a single-agent regimen. These principles have been applied, for example, in the chemotherapy of Hodgkin’s disease. uuid:74065b2e-316a-45f1-acab-7425651ce230 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27375 biolink:treats MONDO:0003864 PMID:41385096 "[{""id"":""uuid:62c4b03d-b07a-461d-ba90-82ddc7c65f3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9edde40c-86d2-4008-a35a-4d0e8d89187b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vinblastine Sulfate Injection is indicated in the palliative treatment of the following: I. Frequently Responsive Malignancies • Generalized Hodgkin’s disease (Stages III and IV, Ann Arbor modification of Rye staging system) • Lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated) • Histiocytic lymphoma • Mycosis fungoides (advanced stages) • Advanced carcinoma of the testis • Kaposi’s sarcoma • Letterer-Siwe disease (histiocytosis X) II. Less Frequently Responsive Malignancies • Choriocarcinoma resistant to other chemotherapeutic agents • Carcinoma of the breast, unresponsive to appropriate endocrine surgery and hormonal therapy Current principles of chemotherapy for many types of cancer include the concurrent administration of several antineoplastic agents. For enhanced therapeutic effect without additive toxicity, agents with different dose-limiting clinical toxicities and different mechanisms of action are generally selected. Therefore, although vinblastine sulfate is effective as a single agent in the aforementioned indications, it is usually administered in combination with other antineoplastic drugs. Such combination therapy produces a greater percentage of response than does a single-agent regimen. These principles have been applied, for example, in the chemotherapy of Hodgkin’s disease. uuid:4a9754de-4584-41d5-a7a1-fea5080d1e44 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27375 biolink:treats MONDO:0004604 PMID:41385096 "[{""id"":""uuid:180ea4e8-0584-4525-9adc-463606d9552d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:860f1e94-2709-4ca3-bace-d0fe0d725b40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vinblastine Sulfate Injection is indicated in the palliative treatment of the following: I. Frequently Responsive Malignancies • Generalized Hodgkin’s disease (Stages III and IV, Ann Arbor modification of Rye staging system) • Lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated) • Histiocytic lymphoma • Mycosis fungoides (advanced stages) • Advanced carcinoma of the testis • Kaposi’s sarcoma • Letterer-Siwe disease (histiocytosis X) II. Less Frequently Responsive Malignancies • Choriocarcinoma resistant to other chemotherapeutic agents • Carcinoma of the breast, unresponsive to appropriate endocrine surgery and hormonal therapy Current principles of chemotherapy for many types of cancer include the concurrent administration of several antineoplastic agents. For enhanced therapeutic effect without additive toxicity, agents with different dose-limiting clinical toxicities and different mechanisms of action are generally selected. Therefore, although vinblastine sulfate is effective as a single agent in the aforementioned indications, it is usually administered in combination with other antineoplastic drugs. Such combination therapy produces a greater percentage of response than does a single-agent regimen. These principles have been applied, for example, in the chemotherapy of Hodgkin’s disease. uuid:d5337b19-8f5b-4b47-bb77-dc34bafa849d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27375 biolink:treats MONDO:0009691 PMID:41385096 "[{""id"":""uuid:4166e8b3-6daa-4417-8f00-b7c1a7833bee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d7c3bc2e-11a8-428f-aa18-ef0ddc3625b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vinblastine Sulfate Injection is indicated in the palliative treatment of the following: I. Frequently Responsive Malignancies • Generalized Hodgkin’s disease (Stages III and IV, Ann Arbor modification of Rye staging system) • Lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated) • Histiocytic lymphoma • Mycosis fungoides (advanced stages) • Advanced carcinoma of the testis • Kaposi’s sarcoma • Letterer-Siwe disease (histiocytosis X) II. Less Frequently Responsive Malignancies • Choriocarcinoma resistant to other chemotherapeutic agents • Carcinoma of the breast, unresponsive to appropriate endocrine surgery and hormonal therapy Current principles of chemotherapy for many types of cancer include the concurrent administration of several antineoplastic agents. For enhanced therapeutic effect without additive toxicity, agents with different dose-limiting clinical toxicities and different mechanisms of action are generally selected. Therefore, although vinblastine sulfate is effective as a single agent in the aforementioned indications, it is usually administered in combination with other antineoplastic drugs. Such combination therapy produces a greater percentage of response than does a single-agent regimen. These principles have been applied, for example, in the chemotherapy of Hodgkin’s disease. uuid:4af80299-e86f-4536-b4c7-e90bd64460d9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27375 biolink:treats MONDO:0006446 PMID:41385096 "[{""id"":""uuid:4ed98e7f-f4f7-48c1-8e77-321ea4b368ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fe930da2-dde0-404f-9f55-2fd3b6327b71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vinblastine Sulfate Injection is indicated in the palliative treatment of the following: I. Frequently Responsive Malignancies • Generalized Hodgkin’s disease (Stages III and IV, Ann Arbor modification of Rye staging system) • Lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated) • Histiocytic lymphoma • Mycosis fungoides (advanced stages) • Advanced carcinoma of the testis • Kaposi’s sarcoma • Letterer-Siwe disease (histiocytosis X) II. Less Frequently Responsive Malignancies • Choriocarcinoma resistant to other chemotherapeutic agents • Carcinoma of the breast, unresponsive to appropriate endocrine surgery and hormonal therapy Current principles of chemotherapy for many types of cancer include the concurrent administration of several antineoplastic agents. For enhanced therapeutic effect without additive toxicity, agents with different dose-limiting clinical toxicities and different mechanisms of action are generally selected. Therefore, although vinblastine sulfate is effective as a single agent in the aforementioned indications, it is usually administered in combination with other antineoplastic drugs. Such combination therapy produces a greater percentage of response than does a single-agent regimen. These principles have been applied, for example, in the chemotherapy of Hodgkin’s disease. uuid:daad4fd6-0de2-4293-9976-52e4da046d5c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27375 biolink:treats MONDO:0005055 PMID:41385096 "[{""id"":""uuid:44ff8b30-31a5-4afd-b523-da5103b8666f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4e42510c-3155-4b7f-93f5-7fd32f0b97a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vinblastine Sulfate Injection is indicated in the palliative treatment of the following: I. Frequently Responsive Malignancies • Generalized Hodgkin’s disease (Stages III and IV, Ann Arbor modification of Rye staging system) • Lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated) • Histiocytic lymphoma • Mycosis fungoides (advanced stages) • Advanced carcinoma of the testis • Kaposi’s sarcoma • Letterer-Siwe disease (histiocytosis X) II. Less Frequently Responsive Malignancies • Choriocarcinoma resistant to other chemotherapeutic agents • Carcinoma of the breast, unresponsive to appropriate endocrine surgery and hormonal therapy Current principles of chemotherapy for many types of cancer include the concurrent administration of several antineoplastic agents. For enhanced therapeutic effect without additive toxicity, agents with different dose-limiting clinical toxicities and different mechanisms of action are generally selected. Therefore, although vinblastine sulfate is effective as a single agent in the aforementioned indications, it is usually administered in combination with other antineoplastic drugs. Such combination therapy produces a greater percentage of response than does a single-agent regimen. These principles have been applied, for example, in the chemotherapy of Hodgkin’s disease. uuid:8f4c8939-fef4-4fca-88d8-41ba4d89267a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27375 biolink:treats MONDO:0005207 PMID:41385096 "[{""id"":""uuid:caddb3a1-8812-46a4-82ad-435e6899acf2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bdf10de8-27f3-4d4a-ab0e-d83b156a63bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vinblastine Sulfate Injection is indicated in the palliative treatment of the following: I. Frequently Responsive Malignancies • Generalized Hodgkin’s disease (Stages III and IV, Ann Arbor modification of Rye staging system) • Lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated) • Histiocytic lymphoma • Mycosis fungoides (advanced stages) • Advanced carcinoma of the testis • Kaposi’s sarcoma • Letterer-Siwe disease (histiocytosis X) II. Less Frequently Responsive Malignancies • Choriocarcinoma resistant to other chemotherapeutic agents • Carcinoma of the breast, unresponsive to appropriate endocrine surgery and hormonal therapy Current principles of chemotherapy for many types of cancer include the concurrent administration of several antineoplastic agents. For enhanced therapeutic effect without additive toxicity, agents with different dose-limiting clinical toxicities and different mechanisms of action are generally selected. Therefore, although vinblastine sulfate is effective as a single agent in the aforementioned indications, it is usually administered in combination with other antineoplastic drugs. Such combination therapy produces a greater percentage of response than does a single-agent regimen. These principles have been applied, for example, in the chemotherapy of Hodgkin’s disease. uuid:fa889cc9-c2ae-4125-8965-f450dbdb9906 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27375 biolink:treats MONDO:0004989 PMID:41385096 "[{""id"":""uuid:48544373-69ff-4f50-8842-3c6f7e714bea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ceb22fcc-ca72-4d1b-9d74-b0ad504deb77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vinblastine Sulfate Injection is indicated in the palliative treatment of the following: I. Frequently Responsive Malignancies • Generalized Hodgkin’s disease (Stages III and IV, Ann Arbor modification of Rye staging system) • Lymphocytic lymphoma (nodular and diffuse, poorly and well differentiated) • Histiocytic lymphoma • Mycosis fungoides (advanced stages) • Advanced carcinoma of the testis • Kaposi’s sarcoma • Letterer-Siwe disease (histiocytosis X) II. Less Frequently Responsive Malignancies • Choriocarcinoma resistant to other chemotherapeutic agents • Carcinoma of the breast, unresponsive to appropriate endocrine surgery and hormonal therapy Current principles of chemotherapy for many types of cancer include the concurrent administration of several antineoplastic agents. For enhanced therapeutic effect without additive toxicity, agents with different dose-limiting clinical toxicities and different mechanisms of action are generally selected. Therefore, although vinblastine sulfate is effective as a single agent in the aforementioned indications, it is usually administered in combination with other antineoplastic drugs. Such combination therapy produces a greater percentage of response than does a single-agent regimen. These principles have been applied, for example, in the chemotherapy of Hodgkin’s disease. uuid:7bf62f13-6993-47fc-ad61-f97c402df3c4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:91X1KLU43E biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:19e5ead6-bb79-42d4-b4f0-88da8e16d42f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:87653620-3490-45a3-8e0f-3d4fa47372bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e423357e-5de3-46a0-8856-2c3d06687c3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/simponi""]},{""id"":""uuid:90a1c8f2-131d-43b8-bb71-89f8b697aef8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SIMPONI is a tumor necrosis factor (TNF) blocker indicated for the treatment of adult patients with: Moderately to severely active rheumatoid arthritis (RA) in combination with methotrexate ( 1.1 ) Active psoriatic arthritis (PsA) alone, or in combination with methotrexate ( 1.2 ) Active ankylosing spondylitis (AS) ( 1.3 ) Moderate to severe Ulcerative colitis (UC) with an inadequate response or intolerant to prior treatment or requiring continuous steroid therapy ( 1.4 ) inducing and maintaining clinical response improving endoscopic appearance of the mucosa during induction inducing clinical remission achieving and sustaining clinical remission in induction responders|[EMA] Rheumatoid arthritis (RA)Simponi, in combination with methotrexate (MTX), is indicated for:the treatment of moderate to severe, active rheumatoid arthritis in adults when the response to disease modifying anti rheumatic drug (DMARD) therapy including MTX has been inadequate.the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with MTX.Simponi, in combination with MTX, has been shown to reduce the rate of progression of joint damage as measured by X ray and to improve physical function.For information regarding the polyarticular juvenile idiopathic arthritis indication, please see the Simponi 50 mg SmPC.Psoriatic arthritis (PsA)Simponi, alone or in combination with MTX, is indicated for the treatment of active and progressive psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate. Simponi has been shown to reduce the rate of progression of peripheral joint damage as measured by X ray in patients with polyarticular symmetrical subtypes of the disease (see section 5.1) and to improve physical function.Axial spondyloarthritisAnkylosing spondylitis (AS)Simponi is indicated for the treatment of severe, active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.Non radiographic axial spondyloarthritis (nr Axial SpA)Simponi is indicated for the treatment of adults with severe, active non radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).Ulcerative colitis (UC)Simponi is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6 mercaptopurine (6 MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.Juvenile idiopathic arthritisPolyarticular juvenile idiopathic arthritis (pJIA)Simponi in combination with methotrexate (MTX) is indicated for the treatment of polyarticular juvenile idiopathic arthritis in children 2 years of age and older, who have responded inadequately to previous therapy with MTX.Rheumatoid arthritis (RA)Simponi, in combination with methotrexate (MTX), is indicated for:the treatment of moderate to severe, active rheumatoid arthritis in adults when the response to disease modifying anti rheumatic drug (DMARD) therapy including MTX has been inadequate.the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with MTX.Simponi, in combination with MTX, has been shown to reduce the rate of progression of joint damage as measured by X ray and to improve physical function.Juvenile idiopathic arthritisPolyarticular juvenile idiopathic arthritis (pJIA)Simponi in combination with MTX is indicated for the treatment of polyarticular juvenile idiopathic arthritis in children 2 years of age and older, who have responded inadequately to previous therapy with MTX.Psoriatic arthritis (PsA)Simponi, alone or in combination with MTX, is indicated for the treatment of active and progressive psoriatic arthritis in adult patients when the response to previous DMARD therapy has been inadequate. Simponi has been shown to reduce the rate of progression of peripheral joint damage as measured by X ray in patients with polyarticular symmetrical subtypes of the disease (see section 5.1) and to improve physical function.Axial spondyloarthritisAnkylosing spondylitis (AS)Simponi is indicated for the treatment of severe, active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.Non radiographic axial spondyloarthritis (nr Axial SpA)Simponi is indicated for the treatment of adults with severe, active non radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).Ulcerative colitis (UC)Simponi is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6 mercaptopurine (6 MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.|[PMDA] Drugs with a new additional indication and a new dosage, in a new additional dosage form for improvement and maintenance of moderate to severe ulcerative colitis (for use only in patients who have not responded sufficiently to conventional treatments). uuid:3e3f3aaa-10d1-4523-a665-9d2ccf34ba6a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:834YJF89WO biolink:treats MONDO:0020547 PMID:41385096 "[{""id"":""uuid:98a6fcdb-06c2-435a-9ebf-6309e44e7c67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3187c298-e1f9-4bb1-acc8-10aa8c83a590"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:74387af3-3225-48d0-9ad2-3019d04f84db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] REZUROCK is indicated for the treatment of adult and pediatric patients 12 years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy.|[PMDA] A drug with a new active ingredient indicated for the treatment of chronic graft-versus-host disease after hematopoietic stem cell transplantation (for use when steroid drugs are not sufficiently effective). [Orphan drug] uuid:2a2955ed-6866-481b-9c43-44a3052df322 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:SMA5ZS5B22 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:8868db95-9b94-4235-b7b8-e0414772ca10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ca88fd98-f21b-4a7a-8fd2-29445861c387"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENSACOVE is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK-inhibitor. uuid:cbb6f7b1-a705-4449-8d6e-9e1fbb2f598e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:91407 biolink:treats MONDO:0009692 PMID:41385096 "[{""id"":""uuid:73f205ec-ad74-420e-8396-9bbf8b15bf7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6c0b3ee0-5f50-4cd6-b6ff-be8522a2fb1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OJJAARA is indicated for the treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [post-polycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia. uuid:9c1a3c09-9b3d-48a2-8a57-07f27009f3ac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:91407 biolink:treats MONDO:0004463 PMID:41385096 "[{""id"":""uuid:24dc4b75-e36f-4f36-bbb8-384d0d085931"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:04e60bf2-f185-45a1-b7f5-670df1bae8e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OJJAARA is indicated for the treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [post-polycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia. uuid:ff72b710-e9b3-4316-a04c-2d8d80e72a4b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:91407 biolink:treats UMLS:C0242006 PMID:41385096 "[{""id"":""uuid:effe4825-8109-4734-a41f-222d08d73ce9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cbc57a0a-00e5-4ee2-9c60-e3278bf7c0b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OJJAARA is indicated for the treatment of intermediate or high-risk myelofibrosis (MF), including primary MF or secondary MF [post-polycythemia vera (PV) and post-essential thrombocythemia (ET)], in adults with anemia. uuid:bc2a008c-0690-45a6-a64f-1189bbed004d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C4723695 biolink:treats MONDO:0015459 PMID:41385096 "[{""id"":""uuid:cc1168d6-06f9-4d7a-a286-00da476b9b61"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9c53e6df-fe83-4b9f-8e27-5802b02e3948"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Penpulimab-kcqx is a programmed death receptor-1 (PD-1)-blocking antibody indicated: in combination with either cisplatin or carboplatin and gemcitabine for the first-line treatment of adults with recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC) ( 1.1 ) as a single agent for the treatment of adults with metastatic non-keratinizing NPC with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy. ( 1.2 ) DRUGBANK:DB16747 uuid:0e5a99da-eb75-47fb-bef7-39e481b55d70 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C4723695 biolink:treats MONDO:0024879 PMID:41385096 "[{""id"":""uuid:1cbef310-0072-4602-a8be-3172d9a2598c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6412478a-d8a0-4e3a-a3e3-a902dc537806"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Penpulimab-kcqx is a programmed death receptor-1 (PD-1)-blocking antibody indicated: in combination with either cisplatin or carboplatin and gemcitabine for the first-line treatment of adults with recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC) ( 1.1 ) as a single agent for the treatment of adults with metastatic non-keratinizing NPC with disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy. ( 1.2 ) DRUGBANK:DB16747 uuid:a54ff221-0adc-457e-80b4-080bf05c5007 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:5YL4IQ1078 biolink:treats MONDO:0018912 PMID:41385096 "[{""id"":""uuid:087415f3-d3f8-46e0-a6c3-b57542d7d500"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2161bf3a-6b3e-4744-bca3-646090d64b4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:fd8a2cdd-48fd-4866-bc1f-5fbf9b42f3fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1b256aac-e3e2-4b1e-9667-601757b49e70"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ISTURISA is indicated for the treatment of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative.|[EMA] Isturisa is indicated for the treatment of endogenous Cushing’s syndrome in adults.|[PMDA] Drugs with a new active ingredient indicated for the treatment of Cushing's syndrome (when surgical therapies are not sufficiently effective or are difficult to be performed). uuid:48af9a40-d2e4-4e2c-a1fb-33785a815232 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4RA0KN46E0 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:2896453e-da0e-46fd-9b25-a33c28508994"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b838b92e-e9a8-4187-a8e2-e57646aeddf8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:31d134fc-9cb7-466b-b8a6-42fd0bb4b67c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/rinvoq""]},{""id"":""uuid:3202b335-24ed-4c4d-ae62-f92634a6f6aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RINVOQ/RINVOQ LQ is a Janus kinase (JAK) inhibitor. RINVOQ is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.1 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.1 ) RINVOQ/RINVOQ LQ is indicated for the treatment of adults and pediatric patients 2 years of age and older with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.2 ) Limitation s of Use RINVOQ/RINVOQ LQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.2 ) RINVOQ is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies are inadvisable. ( 1.3 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants. ( 1.3 ) RINVOQ is indicated for the treatment of adults with moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.4 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for ulcerative colitis, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.4 ) RINVOQ is indicated for the treatment of adults with moderately to severely active Crohn’s disease who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.5 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for Crohn’s disease, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.5 ) RINVOQ is indicated for the treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.6 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.6 ) RINVOQ is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation who have had an inadequate response or intolerance to TNF blocker therapy. ( 1.7 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.7 ) RINVOQ/RINVOQ LQ is indicated for the treatment of patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.8 ) Limitations of Use RINVOQ/RINVOQ LQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.8 ) RINVOQ is indicated for the treatment of adults with giant cell arteritis ( 1.9 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.9 )|[EMA] Rheumatoid arthritisRINVOQ is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). RINVOQ may be used as monotherapy or in combination with methotrexate.Psoriatic arthritisRINVOQ is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate.Axial spondyloarthritisNon-radiographic axial spondyloarthritis (nr-axSpA)RINVOQ is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).Ankylosing spondylitis (AS, radiographic axial spondyloarthritis)RINVOQ is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy.Atopic dermatitisRINVOQ is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.Ulcerative colitisRINVOQ is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. Crohn’s diseaseRINVOQ is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.|[PMDA] Drugs with a new active ingredient indicated for the treatment of rheumatoid arthritis (including the prevention of structural joint damage) in patients who have not responded sufficiently to conventional treatments. uuid:5b8c1ef9-a844-47af-b55d-358e19ddbd7b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4RA0KN46E0 biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:ce0c49e1-64ad-4006-a56a-1cb65073f87b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:78ae02fe-7e1b-4336-a2bc-19ee7817e3c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:63fa4330-0101-423f-b861-c665d10b457d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/rinvoq""]},{""id"":""uuid:0ac4d6cf-c9a5-4f0a-9ecc-e1b580a69644"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RINVOQ/RINVOQ LQ is a Janus kinase (JAK) inhibitor. RINVOQ is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.1 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.1 ) RINVOQ/RINVOQ LQ is indicated for the treatment of adults and pediatric patients 2 years of age and older with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.2 ) Limitation s of Use RINVOQ/RINVOQ LQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.2 ) RINVOQ is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies are inadvisable. ( 1.3 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants. ( 1.3 ) RINVOQ is indicated for the treatment of adults with moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.4 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for ulcerative colitis, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.4 ) RINVOQ is indicated for the treatment of adults with moderately to severely active Crohn’s disease who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.5 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for Crohn’s disease, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.5 ) RINVOQ is indicated for the treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.6 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.6 ) RINVOQ is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation who have had an inadequate response or intolerance to TNF blocker therapy. ( 1.7 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.7 ) RINVOQ/RINVOQ LQ is indicated for the treatment of patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.8 ) Limitations of Use RINVOQ/RINVOQ LQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.8 ) RINVOQ is indicated for the treatment of adults with giant cell arteritis ( 1.9 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.9 )|[EMA] Rheumatoid arthritisRINVOQ is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). RINVOQ may be used as monotherapy or in combination with methotrexate.Psoriatic arthritisRINVOQ is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate.Axial spondyloarthritisNon-radiographic axial spondyloarthritis (nr-axSpA)RINVOQ is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).Ankylosing spondylitis (AS, radiographic axial spondyloarthritis)RINVOQ is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy.Atopic dermatitisRINVOQ is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.Ulcerative colitisRINVOQ is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. Crohn’s diseaseRINVOQ is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.|[PMDA] Drugs with a new indication and a new dosage for the treatment of psoriatic arthritis in patients who have not responded sufficiently to conventional therapies. uuid:99b0cbc4-5001-41be-b50c-0be077ff8ff4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4RA0KN46E0 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:ec113674-a3a2-4c48-9da4-d5bb1bf05ade"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d6370d87-91d6-4f41-8a5f-e7480785a08c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:12a84d9c-4e99-4eab-9b7a-0a24ea688afc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/rinvoq""]},{""id"":""uuid:51972db6-9939-4122-8fef-d487005916c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RINVOQ/RINVOQ LQ is a Janus kinase (JAK) inhibitor. RINVOQ is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.1 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.1 ) RINVOQ/RINVOQ LQ is indicated for the treatment of adults and pediatric patients 2 years of age and older with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.2 ) Limitation s of Use RINVOQ/RINVOQ LQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.2 ) RINVOQ is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies are inadvisable. ( 1.3 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants. ( 1.3 ) RINVOQ is indicated for the treatment of adults with moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.4 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for ulcerative colitis, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.4 ) RINVOQ is indicated for the treatment of adults with moderately to severely active Crohn’s disease who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.5 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for Crohn’s disease, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.5 ) RINVOQ is indicated for the treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.6 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.6 ) RINVOQ is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation who have had an inadequate response or intolerance to TNF blocker therapy. ( 1.7 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.7 ) RINVOQ/RINVOQ LQ is indicated for the treatment of patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.8 ) Limitations of Use RINVOQ/RINVOQ LQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.8 ) RINVOQ is indicated for the treatment of adults with giant cell arteritis ( 1.9 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.9 )|[EMA] Rheumatoid arthritisRINVOQ is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). RINVOQ may be used as monotherapy or in combination with methotrexate.Psoriatic arthritisRINVOQ is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate.Axial spondyloarthritisNon-radiographic axial spondyloarthritis (nr-axSpA)RINVOQ is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).Ankylosing spondylitis (AS, radiographic axial spondyloarthritis)RINVOQ is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy.Atopic dermatitisRINVOQ is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.Ulcerative colitisRINVOQ is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. Crohn’s diseaseRINVOQ is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.|[PMDA] A drug in an additional dosage form indicated for the treatment of atopic dermatitis in patients who have not responded sufficiently to conventional treatments. uuid:a9c179e4-2290-416f-85fb-c66f10cb1f0e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4RA0KN46E0 biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:bd0d04f3-dd35-491f-96af-182e1f64fb5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1ee21578-a0d7-4429-9766-06c0993c4ddf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:86cf6e99-9e42-47aa-b671-923d72737796"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/rinvoq""]},{""id"":""uuid:df54f32c-cca9-4f52-a9bb-51aee1a53bfb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RINVOQ/RINVOQ LQ is a Janus kinase (JAK) inhibitor. RINVOQ is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.1 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.1 ) RINVOQ/RINVOQ LQ is indicated for the treatment of adults and pediatric patients 2 years of age and older with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.2 ) Limitation s of Use RINVOQ/RINVOQ LQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.2 ) RINVOQ is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies are inadvisable. ( 1.3 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants. ( 1.3 ) RINVOQ is indicated for the treatment of adults with moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.4 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for ulcerative colitis, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.4 ) RINVOQ is indicated for the treatment of adults with moderately to severely active Crohn’s disease who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.5 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for Crohn’s disease, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.5 ) RINVOQ is indicated for the treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.6 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.6 ) RINVOQ is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation who have had an inadequate response or intolerance to TNF blocker therapy. ( 1.7 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.7 ) RINVOQ/RINVOQ LQ is indicated for the treatment of patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.8 ) Limitations of Use RINVOQ/RINVOQ LQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.8 ) RINVOQ is indicated for the treatment of adults with giant cell arteritis ( 1.9 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.9 )|[EMA] Rheumatoid arthritisRINVOQ is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). RINVOQ may be used as monotherapy or in combination with methotrexate.Psoriatic arthritisRINVOQ is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate.Axial spondyloarthritisNon-radiographic axial spondyloarthritis (nr-axSpA)RINVOQ is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).Ankylosing spondylitis (AS, radiographic axial spondyloarthritis)RINVOQ is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy.Atopic dermatitisRINVOQ is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.Ulcerative colitisRINVOQ is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. Crohn’s diseaseRINVOQ is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.|[PMDA] (1) (2) (3) Drugs with a new indication and a new dosage for the remission induction and maintenance therapy of moderate to severe ulcerative colitis (for use only in patients who have not sufficiently responded to conventional treatments). (4) A drug with a new indication and a new dosage in an additional dosage form for the remission induction therapy of moderate to severe ulcerative colitis (for use only in patients who have not sufficiently responded to conventional treatments). uuid:50ee779b-ce03-4340-8e41-559fa84ee015 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4RA0KN46E0 biolink:treats MONDO:0005011 PMID:41385096 "[{""id"":""uuid:d1acbaa0-b32b-4517-bf98-db124d177127"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2f3a2361-b4ef-4c01-b243-5126d3746212"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:afa175e5-5541-479d-b35b-b5c195457be7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/rinvoq""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] RINVOQ/RINVOQ LQ is a Janus kinase (JAK) inhibitor. RINVOQ is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.1 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.1 ) RINVOQ/RINVOQ LQ is indicated for the treatment of adults and pediatric patients 2 years of age and older with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.2 ) Limitation s of Use RINVOQ/RINVOQ LQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.2 ) RINVOQ is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies are inadvisable. ( 1.3 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants. ( 1.3 ) RINVOQ is indicated for the treatment of adults with moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.4 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for ulcerative colitis, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.4 ) RINVOQ is indicated for the treatment of adults with moderately to severely active Crohn’s disease who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.5 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for Crohn’s disease, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.5 ) RINVOQ is indicated for the treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.6 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.6 ) RINVOQ is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation who have had an inadequate response or intolerance to TNF blocker therapy. ( 1.7 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.7 ) RINVOQ/RINVOQ LQ is indicated for the treatment of patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.8 ) Limitations of Use RINVOQ/RINVOQ LQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.8 ) RINVOQ is indicated for the treatment of adults with giant cell arteritis ( 1.9 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.9 )|[EMA] Rheumatoid arthritisRINVOQ is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). RINVOQ may be used as monotherapy or in combination with methotrexate.Psoriatic arthritisRINVOQ is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate.Axial spondyloarthritisNon-radiographic axial spondyloarthritis (nr-axSpA)RINVOQ is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).Ankylosing spondylitis (AS, radiographic axial spondyloarthritis)RINVOQ is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy.Atopic dermatitisRINVOQ is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.Ulcerative colitisRINVOQ is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. Crohn’s diseaseRINVOQ is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. uuid:fee268da-8d49-4118-91e4-dbe6e5268a79 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4RA0KN46E0 biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:a9b80423-2f9a-4449-9506-b2f67ad08873"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e583956b-7064-4707-8ea5-7299da605658"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:26f1db7b-e1d9-49d0-bae4-1691eb7574cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/rinvoq""]},{""id"":""uuid:a5c8b23c-f000-4194-8000-93c7969b1d95"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RINVOQ/RINVOQ LQ is a Janus kinase (JAK) inhibitor. RINVOQ is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.1 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.1 ) RINVOQ/RINVOQ LQ is indicated for the treatment of adults and pediatric patients 2 years of age and older with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.2 ) Limitation s of Use RINVOQ/RINVOQ LQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.2 ) RINVOQ is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies are inadvisable. ( 1.3 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants. ( 1.3 ) RINVOQ is indicated for the treatment of adults with moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.4 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for ulcerative colitis, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.4 ) RINVOQ is indicated for the treatment of adults with moderately to severely active Crohn’s disease who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.5 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for Crohn’s disease, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.5 ) RINVOQ is indicated for the treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.6 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.6 ) RINVOQ is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation who have had an inadequate response or intolerance to TNF blocker therapy. ( 1.7 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.7 ) RINVOQ/RINVOQ LQ is indicated for the treatment of patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.8 ) Limitations of Use RINVOQ/RINVOQ LQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.8 ) RINVOQ is indicated for the treatment of adults with giant cell arteritis ( 1.9 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.9 )|[EMA] Rheumatoid arthritisRINVOQ is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). RINVOQ may be used as monotherapy or in combination with methotrexate.Psoriatic arthritisRINVOQ is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. RINVOQ may be used as monotherapy or in combination with methotrexate.Axial spondyloarthritisNon-radiographic axial spondyloarthritis (nr-axSpA)RINVOQ is indicated for the treatment of active non-radiographic axial spondyloarthritis in adult patients with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI), who have responded inadequately to nonsteroidal anti-inflammatory drugs (NSAIDs).Ankylosing spondylitis (AS, radiographic axial spondyloarthritis)RINVOQ is indicated for the treatment of active ankylosing spondylitis in adult patients who have responded inadequately to conventional therapy.Atopic dermatitisRINVOQ is indicated for the treatment of moderate to severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.Ulcerative colitisRINVOQ is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent. Crohn’s diseaseRINVOQ is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.|[PMDA] Drugs with a new indication and a new dosage for the treatment of ankylosing spondylitis in patients who have not responded sufficiently to conventional treatments. uuid:d8884e84-bc3e-41d2-907f-1dd61f7af3e2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4RA0KN46E0 biolink:treats UMLS:C3203547 PMID:41385096 "[{""id"":""uuid:44c5ace3-8e2b-47e3-b2c8-d923dd67ddc1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8163ffe7-137c-4088-a155-e1703eaad267"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d648df2f-115a-4aec-8203-a49b10ccaa13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RINVOQ/RINVOQ LQ is a Janus kinase (JAK) inhibitor. RINVOQ is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.1 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.1 ) RINVOQ/RINVOQ LQ is indicated for the treatment of adults and pediatric patients 2 years of age and older with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.2 ) Limitation s of Use RINVOQ/RINVOQ LQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.2 ) RINVOQ is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies are inadvisable. ( 1.3 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants. ( 1.3 ) RINVOQ is indicated for the treatment of adults with moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.4 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for ulcerative colitis, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.4 ) RINVOQ is indicated for the treatment of adults with moderately to severely active Crohn’s disease who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.5 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for Crohn’s disease, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.5 ) RINVOQ is indicated for the treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.6 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.6 ) RINVOQ is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation who have had an inadequate response or intolerance to TNF blocker therapy. ( 1.7 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.7 ) RINVOQ/RINVOQ LQ is indicated for the treatment of patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.8 ) Limitations of Use RINVOQ/RINVOQ LQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.8 ) RINVOQ is indicated for the treatment of adults with giant cell arteritis ( 1.9 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.9 )|[PMDA] Drugs with a new indication and a new dosage for the treatment of non-radiographic axial spondyloarthritis in patients who have not responded sufficiently to conventional treatments. uuid:54e2a910-68e0-46df-92b3-7957f7e2c33a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4RA0KN46E0 biolink:treats MONDO:0018456 PMID:41385096 "[{""id"":""uuid:b6a59dfd-90ac-45b1-b02e-fdacf1d7fa37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c660eb82-c6ed-4a65-ab99-bf4b2a01d32b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RINVOQ/RINVOQ LQ is a Janus kinase (JAK) inhibitor. RINVOQ is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.1 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.1 ) RINVOQ/RINVOQ LQ is indicated for the treatment of adults and pediatric patients 2 years of age and older with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.2 ) Limitation s of Use RINVOQ/RINVOQ LQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.2 ) RINVOQ is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies are inadvisable. ( 1.3 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants. ( 1.3 ) RINVOQ is indicated for the treatment of adults with moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.4 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for ulcerative colitis, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.4 ) RINVOQ is indicated for the treatment of adults with moderately to severely active Crohn’s disease who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.5 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for Crohn’s disease, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.5 ) RINVOQ is indicated for the treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.6 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.6 ) RINVOQ is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation who have had an inadequate response or intolerance to TNF blocker therapy. ( 1.7 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.7 ) RINVOQ/RINVOQ LQ is indicated for the treatment of patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.8 ) Limitations of Use RINVOQ/RINVOQ LQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.8 ) RINVOQ is indicated for the treatment of adults with giant cell arteritis ( 1.9 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.9 ) uuid:676c1447-212b-446b-b697-dafe6de27eaf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4RA0KN46E0 biolink:treats MONDO:0008538 PMID:41385096 "[{""id"":""uuid:075eacd1-8192-4eef-9ddc-7787d49b9baa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a0379c1b-56d7-42a8-8911-b0bbf1cba5a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RINVOQ/RINVOQ LQ is a Janus kinase (JAK) inhibitor. RINVOQ is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.1 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.1 ) RINVOQ/RINVOQ LQ is indicated for the treatment of adults and pediatric patients 2 years of age and older with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.2 ) Limitation s of Use RINVOQ/RINVOQ LQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.2 ) RINVOQ is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies are inadvisable. ( 1.3 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or with other immunosuppressants. ( 1.3 ) RINVOQ is indicated for the treatment of adults with moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.4 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for ulcerative colitis, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.4 ) RINVOQ is indicated for the treatment of adults with moderately to severely active Crohn’s disease who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.5 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biological therapies for Crohn’s disease, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.5 ) RINVOQ is indicated for the treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.6 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.6 ) RINVOQ is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation who have had an inadequate response or intolerance to TNF blocker therapy. ( 1.7 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.7 ) RINVOQ/RINVOQ LQ is indicated for the treatment of patients 2 years of age and older with active polyarticular juvenile idiopathic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. ( 1.8 ) Limitations of Use RINVOQ/RINVOQ LQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.8 ) RINVOQ is indicated for the treatment of adults with giant cell arteritis ( 1.9 ) Limitations of Use RINVOQ is not recommended for use in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine. ( 1.9 ) uuid:bfac8e48-f700-4fef-9420-3d2e139e778b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3757 biolink:treats MONDO:0007743 PMID:41385096 "[{""id"":""uuid:d3f3ea68-9016-41d7-9fbf-db2a1b6f4291"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4bc6e869-e6c9-48b0-8e1b-3fcd779effc2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ONYDA XR is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) as monotherapy and as adjunctive therapy to central nervous system (CNS) stimulant medications in pediatric patients 6 years of age and older [see Clinical Studies ( 14 )]. uuid:999bd973-3808-47a4-973a-be13a81c5f2b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:21K6M2I7AG biolink:treats MONDO:0018305 PMID:41385096 "[{""id"":""uuid:7f04854d-cfe5-4230-9d88-4fcfa238581b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:83f24c92-cf69-4f4b-bb50-ce68400166f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ACTIMMUNE is indicated for reducing the frequency and severity of serious infections associated with Chronic Granulomatous Disease (CGD). ACTIMMUNE is indicated for delaying time to disease progression in patients with severe, malignant osteopetrosis (SMO). uuid:ec37d5d9-f04c-416a-823a-e740ae192c0f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:21K6M2I7AG biolink:treats MONDO:0019026 PMID:41385096 "[{""id"":""uuid:184eff91-63d2-42cb-8053-f536e664bf60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:889d6793-0637-469d-bee1-a2324ed31a58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ACTIMMUNE is indicated for reducing the frequency and severity of serious infections associated with Chronic Granulomatous Disease (CGD). ACTIMMUNE is indicated for delaying time to disease progression in patients with severe, malignant osteopetrosis (SMO). uuid:752d4ffc-3588-4200-bc1a-90affd34eeee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:QX45B99R3J biolink:treats MONDO:0005045 PMID:41385096 "[{""id"":""uuid:6c48fc38-253d-42c1-8570-001fdee522e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:3e2142bb-4684-49ff-b1fe-fe2f5e53749d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:75ec0519-10ba-41fd-a1de-6f0d4629699b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/camzyos""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] CAMZYOS ® is indicated for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (HCM) to improve functional capacity and symptoms.|[EMA] Treatment of symptomatic obstructive hypertrophic cardiomyopathy. uuid:cf89ae04-4b60-4719-9162-6370e291bc8d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats HP:0100607 PMID:41385096 "[{""id"":""uuid:81679435-76d2-45d8-b2bd-22d095d2c403"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4db17fcc-6e5c-442c-949b-eb3808d9862a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Carefully consider the potential benefits and risks of diclofenac potassium tablets and other treatment options before deciding to use diclofenac potassium tablets. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see ). Diclofenac potassium tablets are indicated: • for treatment of primary dysmenorrhea • for relief of mild to moderate pain • for relief of the signs and symptoms of osteoarthritis • for relief of the signs and symptoms of rheumatoid arthritis uuid:35f6a5c7-2678-40dd-8531-1b40427421e4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:50605O2ZNS biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:48d41c64-ef1a-4075-85da-18ee0882a4b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d090dff5-5c4f-476c-a557-f21fcd0ffd1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f9bcaafa-3be9-4c2a-b2e7-be3cf99c3c01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XPHOZAH is indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.|[PMDA] Drugs with a new active ingredient indicated for the improvement of hyperphosphatemia in patients with chronic kidney disease on dialysis. uuid:654c4899-3f82-4793-8236-967106fd694c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3614 biolink:treats HP:0032674 PMID:41385096 "[{""id"":""uuid:37469e7b-5d7f-4adc-93db-5737e4a0ded1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6d7df37e-7ec7-4df4-a1e0-2e97e17bc458"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] healthcare personnel handwash: helps reduce bacteria that potentially can cause disease skin wound and general skin cleansing uuid:e537c620-1581-4371-88e8-647b247f4ae1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85979 biolink:treats MONDO:0000240 PMID:41385096 "[{""id"":""uuid:25a9e3fb-50bc-4afb-add7-069c282a0b05"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:aa13c749-0868-4438-b0b9-fd32014842c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:91d7b181-ab72-42d7-90a7-09f24863e8a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cresemba""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] CRESEMBA ® is an azole antifungal indicated for the treatment of: Invasive aspergillosis ( 1.1 ) and Invasive mucormycosis ( 1.2 ) as follows: • CRESEMBA for injection : adults and pediatric patients 1 year of age and older • CRESEMBA capsules : adults and pediatric patients 6 years of age and older who weigh 16 kilograms (kg) and greater|[EMA] Cresemba is indicated in adults for the treatment of:invasive aspergillosismucormycosis in patients for whom amphotericin B is inappropriateConsideration should be given to official guidance on the appropriate use of antifungal agents. uuid:03852198-f9ea-4d77-be04-ce2b53179d24 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85979 biolink:treats MONDO:0019136 PMID:41385096 "[{""id"":""uuid:736f8d47-4db3-4935-90fb-2974c4051cd0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f7a01a3b-fac8-434e-91ad-20d9c1e1523f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CRESEMBA ® is an azole antifungal indicated for the treatment of: Invasive aspergillosis ( 1.1 ) and Invasive mucormycosis ( 1.2 ) as follows: • CRESEMBA for injection : adults and pediatric patients 1 year of age and older • CRESEMBA capsules : adults and pediatric patients 6 years of age and older who weigh 16 kilograms (kg) and greater uuid:30d5121e-acc8-42c7-ae95-232fb25dc9bc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17141 biolink:treats MONDO:0016239 PMID:41385096 "[{""id"":""uuid:d657f490-e62c-422f-bb71-be4d7e0931c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cf0cfa29-e571-49a4-91d7-f98ba1fb15d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e818619a-8cb7-479e-84ad-6dd6f28e5cc1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9c3d7520-40c3-40f8-b3d2-ded37b724b29"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CYSTARAN ® is a cystine-depleting agent indicated for the treatment of corneal cystine crystal accumulation in patients with cystinosis.|[EMA] Cystadrops is indicated for the treatment of corneal cystine crystal deposits in adults and children from 2 years of age with cystinosis.|[PMDA] A drug with a new active ingredient indicated for the reduction of corneal cystine crystals in patients with cystinosis. [Orphan drug] uuid:e0f7634c-2230-4d1a-a41f-8a632e110580 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1603837 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:5f77dd5f-4bd5-4eb7-b413-1f63811c6465"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d847ca87-266c-4285-8f32-f9d333c18c38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AVYCAZ is a combination of ceftazidime, a cephalosporin, and avibactam, a beta-lactamase inhibitor, indicated for the treatment of the following infections caused by designated susceptible Gram-negative microorganisms in adult and pediatric patients (at least 31 weeks gestational age): Complicated Intra-abdominal Infections (cIAI), used in combination with metronidazole ( 1.1 ) Complicated Urinary Tract Infections (cUTI), including Pyelonephritis ( 1.2 ) Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP) ( 1.3 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of AVYCAZ and other antibacterial drugs, AVYCAZ should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.4 ) uuid:adda39a7-d722-48f1-88ae-1df1e5b26746 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1603837 biolink:treats MONDO:0006939 PMID:41385096 "[{""id"":""uuid:98e0c0be-0e3a-4d0a-9b79-217f8d62a898"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d550647f-9269-47af-bb2e-2c4c8f3a8e6c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2a51fef4-2b24-4407-9566-dff85f27ffe5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zavicefta""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] AVYCAZ is a combination of ceftazidime, a cephalosporin, and avibactam, a beta-lactamase inhibitor, indicated for the treatment of the following infections caused by designated susceptible Gram-negative microorganisms in adult and pediatric patients (at least 31 weeks gestational age): Complicated Intra-abdominal Infections (cIAI), used in combination with metronidazole ( 1.1 ) Complicated Urinary Tract Infections (cUTI), including Pyelonephritis ( 1.2 ) Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP) ( 1.3 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of AVYCAZ and other antibacterial drugs, AVYCAZ should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.4 )|[EMA] Zavicefta is indicated in adults and paediatric patients aged 3 months and older for the treatment of the following infections:Complicated intra-abdominal infection (cIAI)Complicated urinary tract infection (cUTI), including pyelonephritisHospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP)Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.Zavicefta is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adults and paediatric patients aged 3 months and older with limited treatment options.Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:54f3055e-a88b-4d59-b2d3-c6506d0ff79e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1603837 biolink:treats MONDO:0004652 PMID:41385096 "[{""id"":""uuid:080e39af-60e6-4b33-991a-a277e79998e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:22de700a-1d06-4c53-8e53-43cf1cda8f05"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AVYCAZ is a combination of ceftazidime, a cephalosporin, and avibactam, a beta-lactamase inhibitor, indicated for the treatment of the following infections caused by designated susceptible Gram-negative microorganisms in adult and pediatric patients (at least 31 weeks gestational age): Complicated Intra-abdominal Infections (cIAI), used in combination with metronidazole ( 1.1 ) Complicated Urinary Tract Infections (cUTI), including Pyelonephritis ( 1.2 ) Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP) ( 1.3 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of AVYCAZ and other antibacterial drugs, AVYCAZ should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. ( 1.4 ) uuid:9a043cdd-203d-4117-ad03-6fd83d64cde1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72296 biolink:treats MONDO:0005399 PMID:41385096 "[{""id"":""uuid:ccaa45a7-d436-469a-b8f2-edb64a03d2e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:760208e2-adda-453c-ba2b-8511010c4a4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:8c9c33cf-e33c-4cc9-a52b-40c30e6d3abf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/eliquis""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ELIQUIS is a factor Xa inhibitor indicated: • to reduce the risk of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation. (1.1) • for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in adult patients who have undergone hip or knee replacement surgery. (1.2) • for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE in adult patients following initial therapy. (1.3 , 1.4 , 1.5) • Treatment of venous thromboembolism (VTE) and reduction in the risk of recurrent VTE in pediatric patients from birth and older after at least 5 days of initial anticoagulant treatment. (1.6)|[EMA] For Eliquis 2.5 mg film-coated tablets:Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery.Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II).Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients).For Eliquis 5 mg film-coated tablets:Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II).Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients). uuid:e8106863-1eba-4c4e-bdac-84b872640e8b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6954 biolink:treats MONDO:0008734 PMID:41385096 "[{""id"":""uuid:ec8c55be-712d-4eba-95ec-e1a971f0f5aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c94fef4a-18eb-48b5-8ee2-a84615d1b3d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LYSODREN is indicated for the treatment of patients with inoperable, functional or nonfunctional, adrenocortical carcinoma (ACC). uuid:349f90fb-95ee-4d2b-81fb-72328f4a743e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6954 biolink:treats MONDO:0008808 PMID:41385096 "[{""id"":""uuid:99dc5473-7b63-4cf7-92b9-66ff4c3bf46f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:905fb3f9-68ce-4235-bec5-6c4031978241"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LYSODREN is indicated for the treatment of patients with inoperable, functional or nonfunctional, adrenocortical carcinoma (ACC). uuid:add2c332-3bb5-4628-a675-3c0dda8b6247 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:2877953 biolink:treats MONDO:0015924 PMID:41385096 "[{""id"":""uuid:5b1811db-2c49-486d-be7c-f19d7369ad09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5afd3a31-4d19-44ce-9c7b-103556ee47c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] WINREVAIR™ is indicated for the treatment of adults with pulmonary arterial hypertension (PAH, World Health Organization [WHO] Group 1) to increase exercise capacity, improve WHO functional class (FC), and reduce the risk of clinical worsening events. uuid:fc4fb125-4c0d-43cb-ab5e-7a3728bf2b21 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42797 biolink:treats MONDO:0005391 PMID:41385096 "[{""id"":""uuid:4dc0cc33-281b-4691-9c46-a1d3bdc07801"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7f932b93-749d-4d92-8832-abd9f25b9356"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:6dd8bc9a-fe59-4d47-92c6-e52c22e07c2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] HORIZANT is indicated for: treatment of moderate-to-severe primary Restless Legs Syndrome (RLS) in adults. ( 1.1 ) management of postherpetic neuralgia (PHN) in adults. ( 1.2 )|[PMDA] A drug with a new active ingredient indicated for the treatment of moderate to severe idiopathic restless legs syndrome. uuid:0a50df6d-b5ff-4579-85e2-d39360666257 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:306ERL82IR biolink:treats MONDO:0005459 PMID:41385096 "[{""id"":""uuid:f8c7fb20-71d6-475b-be1e-feb77d6202cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:93f4db41-11a0-44f7-bd98-4beaf921ea3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Fexinidazole Tablets are indicated for the treatment of both the first-stage (hemolymphatic) and second-stage (meningoencephalitic) human African trypanosomiasis (HAT) due to Trypanosoma brucei gambiense in patients 6 years of age and older and weighing at least 20 kg. uuid:857b0121-421f-43dc-a123-ba226e2c890a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB16257 biolink:treats MONDO:0009688 PMID:41385096 "[{""id"":""uuid:c50073ba-5985-46c7-987c-51d7d3e6e9e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b6380c7e-102e-4fed-a832-46b385a8236b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IMAAVY is indicated for the treatment of generalized myasthenia gravis (gMG) in adult and pediatric patients 12 years of age and older who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive. uuid:b074f8c8-3708-41f4-8c2e-cb6679eaed65 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB00028 biolink:treats MONDO:0003778 PMID:41385096 "[{""id"":""uuid:c27e8d1a-0d9f-4674-a313-dd78ca23af96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4e18c395-ec4f-47cb-8720-a4e8009cb03b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BIVIGAM is an Immune Globulin Intravenous (Human), 10% Liquid, indicated for the treatment of adults and pediatric patients 2 years of age and older with primary humoral immunodeficiency (PI). [1] uuid:3798da90-82ce-402f-88ce-54c34699c451 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB00028 biolink:treats MONDO:0001902 PMID:41385096 "[{""id"":""uuid:51504bb8-30ab-4e10-9e2a-3fe42f4ad8c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5782abf1-7a84-4bdb-8b0a-50b2110b1d05"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ASCENIV (immune globulin intravenous, human – slra) is a 10% immune globulin liquid for intravenous injection, indicated for the treatment of primary humoral immunodeficiency (PI) in adults and adolescents (12 to 17 years of age). PI includes, but is not limited to, the humoral immune defect in congenital agammaglobulinemia, common variable immunodeficiency (CVID), X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies (SCID). uuid:e279a210-625a-461f-8650-6c52338cad32 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB00028 biolink:treats MONDO:0015517 PMID:41385096 "[{""id"":""uuid:31bc2f0c-cbad-40bd-bb2e-2eca237666ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:eaddb119-1844-470c-a6ee-e9d55991a083"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ASCENIV (immune globulin intravenous, human – slra) is a 10% immune globulin liquid for intravenous injection, indicated for the treatment of primary humoral immunodeficiency (PI) in adults and adolescents (12 to 17 years of age). PI includes, but is not limited to, the humoral immune defect in congenital agammaglobulinemia, common variable immunodeficiency (CVID), X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies (SCID). uuid:c3b6c934-7490-45fa-a3aa-4953a0ade089 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB00028 biolink:treats MONDO:0010421 PMID:41385096 "[{""id"":""uuid:da78f897-5714-4fd0-a7f2-f7517cf51249"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0c1003b0-551b-43c8-8d0b-3ba9bfe3289b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ASCENIV (immune globulin intravenous, human – slra) is a 10% immune globulin liquid for intravenous injection, indicated for the treatment of primary humoral immunodeficiency (PI) in adults and adolescents (12 to 17 years of age). PI includes, but is not limited to, the humoral immune defect in congenital agammaglobulinemia, common variable immunodeficiency (CVID), X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies (SCID). uuid:bcca5894-7fbf-4f88-8250-c261bbaad4db biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB00028 biolink:treats MONDO:0015974 PMID:41385096 "[{""id"":""uuid:2fdd4504-1347-4fda-9e11-4055243fec11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1cec4120-188c-4d14-9141-b516bf277e7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ASCENIV (immune globulin intravenous, human – slra) is a 10% immune globulin liquid for intravenous injection, indicated for the treatment of primary humoral immunodeficiency (PI) in adults and adolescents (12 to 17 years of age). PI includes, but is not limited to, the humoral immune defect in congenital agammaglobulinemia, common variable immunodeficiency (CVID), X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies (SCID). uuid:2d4b8513-4d4d-44e3-8da2-ae9f27967168 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85993 biolink:treats MONDO:0000618 PMID:41385096 "[{""id"":""uuid:9f7469f0-2395-4eea-b5ab-f343288b7b84"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:67697be5-e86c-4fa8-935c-8dc374f9fb0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:fc0d2640-8478-429a-8321-71dcb55350bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ibrance""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] IBRANCE is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with: • an aromatase inhibitor as initial endocrine-based therapy; or • fulvestrant in patients with disease progression following endocrine therapy. IBRANCE is indicated in combination with inavolisib and fulvestrant for the treatment of adult patients with endocrine-resistant, PIK3CA -mutated, HR-positive, HER2-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy.|[EMA] Ibrance is indicated for the treatment of hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer:in combination with an aromatase inhibitor;in combination with fulvestrant in women who have received prior endocrine therapy.In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone releasing hormone (LHRH) agonist. uuid:70b2a71d-a98d-40e6-ba5f-82bb8499e5a1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:GN465U8B72 biolink:treats MONDO:0026045 PMID:41385096 "[{""id"":""uuid:4338b1d9-66ad-493d-b1ac-59f7a0d2f407"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8bab8400-dde5-4f75-bc93-14d2701d0df0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1e8272bc-f035-43a7-b76e-95f7d12c05f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NEMLUVIO is indicated for the treatment of adults with prurigo nodularis.|[PMDA] A drug with a new indication and a new dosage for the treatment of prurigo nodularis in patients who have not responded sufficiently to conventional treatments, and a new additional pediatric dosage in an additional dosage form, indicated for the treatment of pruritus associated with atopic dermatitis in patients who have not responded sufficiently to conventional treatments. uuid:38cde5f9-9ae7-4d9a-a6f2-16fce96bf2c6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:N658GY6L3E biolink:treats MONDO:0006486 PMID:41385096 "[{""id"":""uuid:49e54db5-ca6b-440d-a47c-98669ba197a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:49fe4acf-dad3-4f35-919f-b9338080b478"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c5f97b0e-0c9b-4ea7-95d0-440fa901b532"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kimmtrak""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] KIMMTRAK is indicated for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.|[EMA] Kimmtrak is indicated as monotherapy for the treatment of human leukocyte antigen (HLA)-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. uuid:67f2fe94-7a03-4e4d-b0d7-ca4ebd0d70f6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:N658GY6L3E biolink:treats UMLS:C4725091 PMID:41385096 "[{""id"":""uuid:b54dc76e-54c9-4673-8cc8-6b78efce383a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:87e758ab-4924-43c7-802c-96c5b052cdc6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KIMMTRAK is indicated for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma. uuid:4473d2a0-52bc-40e9-829d-9b6528307bd3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:P7186074QC biolink:treats MONDO:0009688 PMID:41385096 "[{""id"":""uuid:d240c359-6673-44cc-8e93-754cb488e045"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d01d915b-d783-42a8-981f-cec2fd8ea310"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1499a4f4-bac5-44f4-8af2-285218a990b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RYSTIGGO is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive.|[PMDA] A drug with a new active ingredient indicated for the treatment of generalized myasthenia gravis (for use only in patients who have not sufficiently responded to steroids or other immunosuppressants). [Orphan drug] uuid:c9724dc8-a9c5-4a11-9ab2-e5e161b41aef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231425 biolink:treats MONDO:0004691 PMID:41385096 "[{""id"":""uuid:aa1fc08a-03f4-46b4-916b-d75064f8edea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:993c43e5-52c6-4503-b549-b70691c7b5de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2dabb9e9-f159-416a-a665-7698d7082ff0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/jinarc""]},{""id"":""uuid:d11eb259-55a5-4ed9-a799-6ddbc5ec179d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] JYNARQUE is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD).|[EMA] Jinarc is indicated to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with CKD stage 1 to 3 at initiation of treatment with evidence of rapidly progressing disease.|[PMDA] Drugs with a new additional indication and a new dosage, and a drug with a newly-added dosage form indicated for inhibiting the progression of autosomal dominant polycystic kidney disease in patients whose kidney volume already have increased and enlarged at a rapid rate. [Orphan drug] uuid:cdeb283f-e0c8-4dff-bb0d-534acefb51ac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85966 biolink:treats MONDO:0006993 PMID:41385096 "[{""id"":""uuid:1676ff82-bd78-44d4-a070-4f140af7391f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d368169d-bbfc-4fdb-b086-58fa7d444f25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Ivabradine tablets are a hyperpolarization-activated cyclic nucleotide-gated channel blocker indicated: To reduce the risk of hospitalization for worsening heart failure in adult patients with stable, symptomatic chronic heart failure with reduced left ventricular ejection fraction. ( 1.1 ) uuid:c93abed4-4a69-4ebc-9729-2eef06d21a43 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:OP35X9610Y biolink:treats MONDO:0008250 PMID:41385096 "[{""id"":""uuid:1a0e77c3-2a21-485b-ad29-fec991d76735"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:dc648ef2-6344-4f16-876d-714e7774cc11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9c0284d3-ada4-4c3c-b7c2-a59795aa530a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/skytrofa-previously-lonapegsomatropin-ascendis-pharma""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] SKYTROFA (lonapegsomatropin-tcgd) is a human growth hormone indicated for the treatment of pediatric patients 1 year and older who weigh at least 11.5 kg and have growth failure due to inadequate secretion of endogenous growth hormone (GH).|[EMA] Growth failure in children and adolescents aged from 3 years up to 18 years due to insufficient endogenous growth hormone secretion (growth hormone deficiency [GHD]), uuid:3e3ff8de-84db-4ce2-b6f4-7100f17942e6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:80343 biolink:treats MONDO:0000050 PMID:41385096 "[{""id"":""uuid:494dda24-b1b2-4bd7-b65a-53a83cef9431"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:04c32d4b-8784-4d02-9dbe-7d717e981545"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Severe Primary IGF-1 Deficiency (Primary IGFD) INCRELEX is indicated for the treatment of growth failure in pediatric patients 2 years of age and older with: severe primary IGF-1 deficiency or growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH. Severe Primary IGF-1 deficiency (IGFD) is defined by: height standard deviation score ≤ –3.0 and basal IGF-1 standard deviation score ≤ –3.0 and normal or elevated growth hormone (GH). uuid:a9be55cc-a4ac-4b0d-a0a5-81c4467e0801 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:YI437801BE biolink:treats MONDO:0009691 PMID:41385096 "[{""id"":""uuid:443ed732-3f73-4f09-a5e0-f0a871a5a21d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:7a879d42-dad4-41ed-b486-a698b5c1aa77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:478f51d5-b98d-4a4f-b1af-d5d02678abb3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/poteligeo""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] POTELIGEO is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy.|[EMA] Poteligeo is indicated for the treatment of adult patients with mycosis fungoides (MF) or Sézary syndrome (SS) who have received at least one prior systemic therapy. uuid:0119d634-3eac-409f-9d50-5b90ed72d44a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:YI437801BE biolink:treats MONDO:0017844 PMID:41385096 "[{""id"":""uuid:60557d2b-bcd4-41b7-8f96-63cfe52947e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e05ce507-7efb-4b2b-bcfc-23a4bf52dc8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] POTELIGEO is indicated for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy. uuid:455eaf70-beab-439b-a953-84b46da7d2e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:S4M959U2IJ biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:b4e3076d-269f-4624-a5a9-baf926b235ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7e800cf9-6f8f-4638-93f7-ff137e3e38ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TZIELD is indicated to delay the onset of Stage 3 type 1 diabetes in adults and pediatric patients 8 years of age and older with Stage 2 type 1 diabetes [see Dosage and Administration ( 2.1 )] . uuid:cf7c72f7-3037-406a-a0b9-e00716212f19 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:K16AIQ8CTM biolink:treats UMLS:C0278488 PMID:41385096 "[{""id"":""uuid:9f6f777b-ab89-4273-88e6-8ab4c4bc4788"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:19e6ccee-4640-4c8f-a245-dd6086111ab8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PERJETA is a HER2/neu receptor antagonist indicated for: Use in combination with trastuzumab and docetaxel for treatment of adults with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. ( 1.1 ) Use in combination with trastuzumab and chemotherapy as neoadjuvant treatment of adults with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. ( 1.2 , 2.2 , 14.2 ) adjuvant treatment of adults with HER2-positive early breast cancer at high risk of recurrence ( 1.2 , 2.2 , 14.3 ) uuid:d75aaa22-3011-4c00-8566-d33b9cca6f5e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:K16AIQ8CTM biolink:treats MONDO:0006804 PMID:41385096 "[{""id"":""uuid:189caeed-2362-476d-99e1-118734a89530"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:35219426-b8ad-4272-8a80-087bbbea8ea7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b5ac66c1-8f1f-49f6-bc3c-7a6fbb3db589"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/perjeta""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] PERJETA is a HER2/neu receptor antagonist indicated for: Use in combination with trastuzumab and docetaxel for treatment of adults with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. ( 1.1 ) Use in combination with trastuzumab and chemotherapy as neoadjuvant treatment of adults with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. ( 1.2 , 2.2 , 14.2 ) adjuvant treatment of adults with HER2-positive early breast cancer at high risk of recurrence ( 1.2 , 2.2 , 14.3 )|[EMA] Metastatic Breast Cancer:Perjeta is indicated for use in combination with trastuzumab and docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.Neoadjuvant Treatment of Breast Cancer:Perjeta is indicated for use in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence. uuid:812f4de4-b604-4ae5-9780-ce3cb0978568 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:K16AIQ8CTM biolink:treats UMLS:C2986665 PMID:41385096 "[{""id"":""uuid:af6d8869-febc-49db-a38f-0b57ec78d3e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6f8baafb-3d18-41c6-bb1d-dc2bc2573ff0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PERJETA is a HER2/neu receptor antagonist indicated for: Use in combination with trastuzumab and docetaxel for treatment of adults with HER2-positive metastatic breast cancer (MBC) who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease. ( 1.1 ) Use in combination with trastuzumab and chemotherapy as neoadjuvant treatment of adults with HER2-positive, locally advanced, inflammatory, or early stage breast cancer (either greater than 2 cm in diameter or node positive) as part of a complete treatment regimen for early breast cancer. ( 1.2 , 2.2 , 14.2 ) adjuvant treatment of adults with HER2-positive early breast cancer at high risk of recurrence ( 1.2 , 2.2 , 14.3 ) uuid:0b1c786e-f041-438d-ba71-e55b29c7bb5e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:TO3JYR3BOU biolink:treats HP:0031609 PMID:41385096 "[{""id"":""uuid:037abd39-009b-43c9-83d5-dcd1a70d9e0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9f1a8210-13ce-4ace-ae83-a7ff8487dfa7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SYFOVRE is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). uuid:acaae6db-bbef-4933-a159-580ca80c1605 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:TO3JYR3BOU biolink:treats MONDO:0005150 PMID:41385096 "[{""id"":""uuid:25df0689-0e74-4580-bb93-8825f8d745a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:52f673bf-9142-46fb-9cda-679400179e48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SYFOVRE is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). uuid:d8b5ef91-2b43-4594-ba9b-7b7085f08bf7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72690 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:95af93ef-db76-4d99-aaf9-d31acec1b185"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9123d2fc-37b8-41fb-bd85-9e1411dd0dc1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1e2f6c94-1d3c-44bd-8a9b-acff65f7dc3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/imnovid""]},{""id"":""uuid:1bd18f66-0766-452e-a3e2-8c285e75c89c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] POMALYST is a thalidomide analogue indicated for the treatment of adult patients: • in combination with dexamethasone, for patients with multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy ( 1.1 ). • with AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART) or in patients with KS who are HIV-negative. This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s) ( 1.2 ).|[EMA] Imnovid in combination with bortezomib and dexamethasone is indicated in the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide.Imnovid in combination with dexamethasone is indicated in the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior treatment regimens, including both lenalidomide and bortezomib, and have demonstrated disease progression on the last therapy.|[PMDA] Drugs with a new active ingredient indicated for the treatment of relapsed or refractory multiple myeloma. [Orphan drug] uuid:96e06178-5279-4e60-bce7-ae17d9a257a1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72690 biolink:treats MONDO:0005055 PMID:41385096 "[{""id"":""uuid:bbb0038c-7769-4695-80db-0bf32ebf1438"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8422bfd0-ff77-486f-8ea7-167d0add035a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] POMALYST is a thalidomide analogue indicated for the treatment of adult patients: • in combination with dexamethasone, for patients with multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or within 60 days of completion of the last therapy ( 1.1 ). • with AIDS-related Kaposi sarcoma (KS) after failure of highly active antiretroviral therapy (HAART) or in patients with KS who are HIV-negative. This indication is approved under accelerated approval based on overall response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s) ( 1.2 ). uuid:e29cab3c-3122-4c99-b9b2-9758588b0f5a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:1RXS4UE564 biolink:treats HP:0002140 PMID:41385096 "[{""id"":""uuid:03484bd8-a3c7-4f27-bc09-cc7ecd78b256"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:31c16acb-e1ef-4bf0-aebc-eab7be7dffc9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Activase is a tissue plasminogen activator (tPA) indicated for the treatment of: Acute Ischemic Stroke (AIS). ( 1.1 ) Acute Myocardial Infarction (AMI) to reduce mortality and incidence of heart failure. ( 1.2 ) Limitation of Use in AMI: the risk of stroke may be greater than the benefit in patients at low risk of death from cardiac causes. ( 1.2 ) Acute Massive Pulmonary Embolism (PE) for lysis. ( 1.3 ) uuid:fb893946-e534-4c0e-84ef-491685f71bb1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:1RXS4UE564 biolink:treats MONDO:0004781 PMID:41385096 "[{""id"":""uuid:c65b79eb-b70c-49f2-88da-3183477317a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fea6d919-48b3-4e03-b6db-94325facfff5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Activase is a tissue plasminogen activator (tPA) indicated for the treatment of: Acute Ischemic Stroke (AIS). ( 1.1 ) Acute Myocardial Infarction (AMI) to reduce mortality and incidence of heart failure. ( 1.2 ) Limitation of Use in AMI: the risk of stroke may be greater than the benefit in patients at low risk of death from cardiac causes. ( 1.2 ) Acute Massive Pulmonary Embolism (PE) for lysis. ( 1.3 ) uuid:53edbade-e144-45fe-9f9c-ffc7ff9497a1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:1RXS4UE564 biolink:treats UMLS:C0340535 PMID:41385096 "[{""id"":""uuid:7dede626-28f8-4fb1-84c0-242e1b61f78c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:258e9abf-29f0-410a-9229-a4eff1b93eec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Activase is a tissue plasminogen activator (tPA) indicated for the treatment of: Acute Ischemic Stroke (AIS). ( 1.1 ) Acute Myocardial Infarction (AMI) to reduce mortality and incidence of heart failure. ( 1.2 ) Limitation of Use in AMI: the risk of stroke may be greater than the benefit in patients at low risk of death from cardiac causes. ( 1.2 ) Acute Massive Pulmonary Embolism (PE) for lysis. ( 1.3 ) uuid:920cc59e-daa7-4978-8539-80836fdbcb2e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4FR53SIF3A biolink:treats MONDO:0004967 PMID:41385096 "[{""id"":""uuid:86218114-827b-4cd8-8b91-0b7db4aea21b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:aa324a7b-1b13-4a40-b697-c958a5666f00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ea93deb9-cfbf-4607-9fa8-f425c5b53b8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BLINCYTO is a bispecific CD19-directed CD3 T-cell engager indicated for the treatment of adult and pediatric patients one month and older with: CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%. ( 1.1 ) Relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL). ( 1.2 ) CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy. ( 1.3 )|[PMDA] A drug with a new active ingredient indicated for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia. [Orphan drug] uuid:ced3b927-8357-456e-a0a1-19fd80f65daf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4FR53SIF3A biolink:treats MONDO:0020511 PMID:41385096 "[{""id"":""uuid:4f2abfca-6898-4f3a-8f38-6b04b8948d63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:671b1bbe-6863-40d2-bcc5-75074edeb498"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:dea9ff1f-5579-488c-8379-28ba14483a95"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/blincyto""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] BLINCYTO is a bispecific CD19-directed CD3 T-cell engager indicated for the treatment of adult and pediatric patients one month and older with: CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%. ( 1.1 ) Relapsed or refractory CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL). ( 1.2 ) CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy. ( 1.3 )|[EMA] Blincyto is indicated as monotherapy for the treatment of adults with CD19 positive relapsed or refractory B precursor acute lymphoblastic leukaemia (ALL). Patients with Philadelphia chromosome positive B-precursor ALL should have failed treatment with at least 2 tyrosine kinase inhibitors (TKIs) and have no alternative treatment options., , Blincyto is indicated as monotherapy for the treatment of adults with Philadelphia chromosome negative CD19 positive B-precursor ALL in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%., , Blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with Philadelphia chromosome negative CD19 positive B precursor ALL which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation., , Blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed Philadelphia chromosome negative CD19 positive B-precursor ALL as part of the consolidation therapy (see section 4.2)., uuid:8ab07849-d5c9-4c95-ac1b-928009c18dac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:0KVO411B3N biolink:treats MONDO:0005580 PMID:41385096 "[{""id"":""uuid:0b7718cd-3486-40b5-b9d7-8440d90e1c5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:09ef2c5a-85f7-46dc-b4e7-db1717b992a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7033f0a1-d7f0-460c-87e3-b415e420dbf3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tevimbra""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] TEVIMBRA is a programmed death receptor-1 (PD-1)-blocking antibody indicated for: Esophageal Cancer in combination with platinum-containing chemotherapy for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1). ( 1.1 ) as a single agent in adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor. ( 1.1 ) Gastric Cancer in combination with platinum and fluoropyrimidine-based chemotherapy in adults for the first line treatment of unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 (≥1). ( 1.2 )|[EMA] Oesophageal squamous cell carcinoma (OSCC) Tevimbra as monotherapy is indicated for the treatment of adult patients with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma after prior platinum-based chemotherapy. uuid:171e3a65-749e-4503-89f2-872fd658dbaa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:0KVO411B3N biolink:treats MONDO:0001056 PMID:41385096 "[{""id"":""uuid:b47fdcf3-349f-430d-900d-a9b3582a0c4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9d3e1ef0-a49b-4fab-9ea3-59396a8e4d33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TEVIMBRA is a programmed death receptor-1 (PD-1)-blocking antibody indicated for: Esophageal Cancer in combination with platinum-containing chemotherapy for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1). ( 1.1 ) as a single agent in adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor. ( 1.1 ) Gastric Cancer in combination with platinum and fluoropyrimidine-based chemotherapy in adults for the first line treatment of unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 (≥1). ( 1.2 ) uuid:84df0351-fe46-4900-afe7-159bf1d173dc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:0KVO411B3N biolink:treats MONDO:0003219 PMID:41385096 "[{""id"":""uuid:3455a9e4-720a-4c2c-8915-2b42facae07a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:45555ff4-fffb-4a4d-804b-1539642d7bb5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TEVIMBRA is a programmed death receptor-1 (PD-1)-blocking antibody indicated for: Esophageal Cancer in combination with platinum-containing chemotherapy for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1). ( 1.1 ) as a single agent in adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor. ( 1.1 ) Gastric Cancer in combination with platinum and fluoropyrimidine-based chemotherapy in adults for the first line treatment of unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 (≥1). ( 1.2 ) uuid:f8947e9b-d829-48e3-9506-a36f9edba95e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB18728 biolink:treats MONDO:0018637 PMID:41385096 "[{""id"":""uuid:1607c5cd-c21b-4719-91eb-0c0384f4221c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:03167895-7739-4068-8274-085bec9f4a79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRYNGOLZA is indicated as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS). uuid:18538749-1193-4ae8-a74f-2934ea0bc9e6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:65173 biolink:treats MONDO:0001866 PMID:41385096 "[{""id"":""uuid:b19ac1f3-36a9-4cf5-9bbb-e372dede20e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:307b1151-f9d2-4a2c-8cc5-0fb3e943b752"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FANAPT ® is indicated for: Treatment of schizophrenia in adults [see Clinical Studies (14.1) ]. Acute treatment of manic or mixed episodes associated with bipolar I disorder in adults [see Clinical Studies (14.2) ] . uuid:86143237-ad7f-4bd4-b4e6-2aa144030880 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85010 biolink:treats MONDO:0002048 PMID:41385096 "[{""id"":""uuid:1c80347e-7151-490f-8d13-33d1281e0a52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9291aeb8-d8d3-4c8e-91b5-e59356fc52b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Eltrombopag for oral suspension is a thrombopoietin receptor agonist indicated: • for the treatment of thrombocytopenia in adult and pediatric patients 1 year and older with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Eltrombopag for oral suspension should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding. ( 1.1 ) • for the treatment of thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy. Eltrombopag for oral suspension should be used only in patients with chronic hepatitis C whose degree of thrombocytopenia prevents the initiation of interferon-based therapy or limits the ability to maintain interferon-based therapy. ( 1.2 ) • for the treatment of patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy. ( 1.3 ) Limitations of Use: • Eltrombopag for oral suspension is not indicated for the treatment of patients with myelodysplastic syndrome (MDS). ( 1.4 ) • Safety and efficacy have not been established in combination with direct-acting antiviral agents used without interferon for treatment of chronic hepatitis C infection. ( 1.4 ) uuid:fce893a4-9184-4794-843b-7d7612996fdf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85010 biolink:treats MONDO:0005354 PMID:41385096 "[{""id"":""uuid:6030bf24-c4c6-4972-97a5-e5dbb722f966"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c43c9c9d-efda-440e-b6be-777cf02cb6e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ddc3129a-c500-4d5f-95e5-3f9d1a0b11b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/revolade""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] Eltrombopag for oral suspension is a thrombopoietin receptor agonist indicated: • for the treatment of thrombocytopenia in adult and pediatric patients 1 year and older with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Eltrombopag for oral suspension should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding. ( 1.1 ) • for the treatment of thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy. Eltrombopag for oral suspension should be used only in patients with chronic hepatitis C whose degree of thrombocytopenia prevents the initiation of interferon-based therapy or limits the ability to maintain interferon-based therapy. ( 1.2 ) • for the treatment of patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy. ( 1.3 ) Limitations of Use: • Eltrombopag for oral suspension is not indicated for the treatment of patients with myelodysplastic syndrome (MDS). ( 1.4 ) • Safety and efficacy have not been established in combination with direct-acting antiviral agents used without interferon for treatment of chronic hepatitis C infection. ( 1.4 )|[EMA] Revolade is indicated for the treatment of adult patients with primary immune thrombocytopenia (ITP) who are refractory to other treatments (e.g. corticosteroids, immunoglobulins) (see sections 4.2 and 5.1).Revolade is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (ITP) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e.g. corticosteroids, immunoglobulins) (see sections 4.2 and 5.1).Revolade is indicated in adult patients with chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy (see sections 4.4 and 5.1).Revolade is indicated in adult patients with acquired severe aplastic anaemia (SAA) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation (see section 5.1). uuid:9e9d44d1-6c3b-4aff-a774-1060c06e5abb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85010 biolink:treats UMLS:C1883018 PMID:41385096 "[{""id"":""uuid:45a56129-4475-4ed8-b05a-c494226fe308"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4978bd66-a349-4955-8bf1-959abf192237"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Eltrombopag for oral suspension is a thrombopoietin receptor agonist indicated: • for the treatment of thrombocytopenia in adult and pediatric patients 1 year and older with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Eltrombopag for oral suspension should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding. ( 1.1 ) • for the treatment of thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy. Eltrombopag for oral suspension should be used only in patients with chronic hepatitis C whose degree of thrombocytopenia prevents the initiation of interferon-based therapy or limits the ability to maintain interferon-based therapy. ( 1.2 ) • for the treatment of patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy. ( 1.3 ) Limitations of Use: • Eltrombopag for oral suspension is not indicated for the treatment of patients with myelodysplastic syndrome (MDS). ( 1.4 ) • Safety and efficacy have not been established in combination with direct-acting antiviral agents used without interferon for treatment of chronic hepatitis C infection. ( 1.4 ) uuid:407006dd-b6d7-4c7b-a3a0-3231b055a9a0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85010 biolink:treats MONDO:0002049 PMID:41385096 "[{""id"":""uuid:1cbe2e77-5ad6-41aa-aca0-9e79c5147bd3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1f4410b9-95b9-48e3-a664-883aeffb2132"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Eltrombopag for oral suspension is a thrombopoietin receptor agonist indicated: • for the treatment of thrombocytopenia in adult and pediatric patients 1 year and older with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Eltrombopag for oral suspension should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding. ( 1.1 ) • for the treatment of thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy. Eltrombopag for oral suspension should be used only in patients with chronic hepatitis C whose degree of thrombocytopenia prevents the initiation of interferon-based therapy or limits the ability to maintain interferon-based therapy. ( 1.2 ) • for the treatment of patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy. ( 1.3 ) Limitations of Use: • Eltrombopag for oral suspension is not indicated for the treatment of patients with myelodysplastic syndrome (MDS). ( 1.4 ) • Safety and efficacy have not been established in combination with direct-acting antiviral agents used without interferon for treatment of chronic hepatitis C infection. ( 1.4 ) uuid:b54ef5b4-309c-4937-b982-d5c1afe0f5e1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60799 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:4d6e555e-bc00-4a95-a210-fb738b58e10a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:93e3f3f3-ff34-4114-a02e-484c0a252ae9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:38bf7a63-a19a-46b1-b365-f4a9eea08364"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SPRAVATO is indicated for the treatment of: Treatment-resistant depression (TRD) in adults as monotherapy or in conjunction with an oral antidepressant Depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior in conjunction with an oral antidepressant|[EMA] Spravato, in combination with a SSRI or SNRI, is indicated for adults with treatment-resistant Major Depressive Disorder, who have not responded to at least two different treatments with antidepressants in the current moderate to severe depressive episode. uuid:e39800b3-f35d-45e4-b5ba-7adb548946b2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8310 biolink:treats MONDO:0040732 PMID:41385096 "[{""id"":""uuid:c301a48a-4ac8-4c2b-aeef-2049cbc9c7a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e809c094-9e14-42e7-8129-85e6ec1bb4e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acute Infections Caused by Susceptible Strains of Pseudomonas aeruginosa . Polymyxin B sulfate is a drug of choice in the treatment of infections of the urinary tract, meninges, and bloodstream caused by susceptible strains of Ps. aeruginosa. It may also be used topically and subconjunctivally in the treatment of infections of the eye caused by susceptible strains of Ps. aeruginosa . It may be indicated in serious infections caused by susceptible strains of the following organisms, when less potentially toxic drugs are ineffective or contraindicated: H. influenzae , specifically meningeal infections. Escherichia coli , specifically urinary tract infections. Aerobacter aerogenes , specifically bacteremia. Klebsiella pneumoniae , specifically bacteremia. NOTE: IN MENINGEAL INFECTIONS, POLYMYXIN B SULFATE SHOULD BE ADMINISTERED ONLY BY THE INTRATHECAL ROUTE. To reduce the development of drug-resistant bacteria and maintain the effectiveness of polymyxin B and other antibacterial drugs, polymyxin B should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:96fe3a84-84ae-4977-b708-b6ec0d51270d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8310 biolink:treats MONDO:0000889 PMID:41385096 "[{""id"":""uuid:bd915bdb-137c-451c-b3f1-74e8a64f6aa9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:16c49002-3803-42de-b686-d4b08da69c8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acute Infections Caused by Susceptible Strains of Pseudomonas aeruginosa . Polymyxin B sulfate is a drug of choice in the treatment of infections of the urinary tract, meninges, and bloodstream caused by susceptible strains of Ps. aeruginosa. It may also be used topically and subconjunctivally in the treatment of infections of the eye caused by susceptible strains of Ps. aeruginosa . It may be indicated in serious infections caused by susceptible strains of the following organisms, when less potentially toxic drugs are ineffective or contraindicated: H. influenzae , specifically meningeal infections. Escherichia coli , specifically urinary tract infections. Aerobacter aerogenes , specifically bacteremia. Klebsiella pneumoniae , specifically bacteremia. NOTE: IN MENINGEAL INFECTIONS, POLYMYXIN B SULFATE SHOULD BE ADMINISTERED ONLY BY THE INTRATHECAL ROUTE. To reduce the development of drug-resistant bacteria and maintain the effectiveness of polymyxin B and other antibacterial drugs, polymyxin B should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:849a6298-f799-4631-b110-edda0ef06994 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85010 biolink:treats MONDO:0019098 PMID:41385096 "[{""id"":""uuid:c6e7072b-664d-44dd-91ff-927e58eb8882"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:203e5ce5-ce1f-42ff-98fa-fc7772ee4049"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:db34e821-e72f-4e90-97d3-db15a7bf7950"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Eltrombopag tablet is a thrombopoietin receptor agonist indicated: • for the treatment of thrombocytopenia in adult and pediatric patients 1 year and older with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. Eltrombopag tablets should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding. (1.1) • for the treatment of thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy. Eltrombopag tablets should be used only in patients with chronic hepatitis C whose degree of thrombocytopenia prevents the initiation of interferon-based therapy or limits the ability to maintain interferon-based therapy. (1.2) • for the treatment of patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy. (1.3) Limitations of Use: • Eltrombopag tablets are not indicated for the treatment of patients with myelodysplastic syndrome (MDS). (1.4) • Safety and efficacy have not been established in combination with direct-acting antiviral agents used without interferon for treatment of chronic hepatitis C infection. (1.4)|[PMDA] Drugs with a new active ingredient indicated for the treatment of chronic idiopathic thrombocytopenic purpura. [Orphan drug] uuid:5a9d5384-7892-473f-b5e3-1610ae9a0a72 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22652 biolink:treats MONDO:0001357 PMID:41385096 "[{""id"":""uuid:57d862e7-8558-4487-bd92-9c73f3694961"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:efd8a400-2339-4238-8f40-a0edade2e8b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INDICATION AND USAGE: IROSPAN 24/6 is indicated for the treatment of all anemias that are responsive to oral iron therapy. These include: hypochromic anemia associated with pregnancy, chronic and/or acute blood loss, metabolic disease, post-surgical convalescence, and dietary needs. uuid:4b18f4c3-4ed3-4ebd-9299-a8ee91ed1219 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:08GY9K1EUO biolink:treats MONDO:0005059 PMID:41385096 "[{""id"":""uuid:a73295e7-1076-4e41-8bac-f69003b485ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2f823bfd-e9e6-49cc-a856-3c9e62bf7ef5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Elitek is indicated for the initial management of plasma uric acid levels in pediatric and adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anticancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid. uuid:3fcfee34-12f1-462e-b1b0-a7a02c78056c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:08GY9K1EUO biolink:treats MONDO:0005062 PMID:41385096 "[{""id"":""uuid:3e2b89ba-8c7c-4a6a-84cb-af6dc393c60b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:952d52cb-9d8b-4b6a-ba41-9e1a7aa18a32"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Elitek is indicated for the initial management of plasma uric acid levels in pediatric and adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anticancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid. uuid:f754c4fb-68b4-4fd3-8389-ce3286a2a26d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:08GY9K1EUO biolink:treats MONDO:0004992 PMID:41385096 "[{""id"":""uuid:9bc85418-adb1-45dd-8abd-e001bd12009e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1dc10984-2c42-409f-9fd9-2bb9882aca48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Elitek is indicated for the initial management of plasma uric acid levels in pediatric and adult patients with leukemia, lymphoma, and solid tumor malignancies who are receiving anticancer therapy expected to result in tumor lysis and subsequent elevation of plasma uric acid. uuid:a660495f-147c-4087-bad3-728ea0571daa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68478 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:e795b308-8fa7-4109-b5ad-b232edbde15a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:29c819bc-23ed-42d2-9969-aa9da2659120"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:6c79d041-d106-4de0-9801-b302c87d8519"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/votubia""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] AFINITOR is a kinase inhibitor indicated for the treatment of: Postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole. ( 1.1 ) Adults with progressive neuroendocrine tumors of pancreatic origin (PNET) and adults with progressive, well-differentiated, non-functional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin that are unresectable, locally advanced or metastatic. Limitations of Use: AFINITOR is not indicated for the treatment of patients with functional carcinoid tumors. ( 1.2 ) Adults with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. ( 1.3 ) Adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. ( 1.4 ) AFINITOR and AFINITOR DISPERZ are kinase inhibitors indicated for the treatment of adult and pediatric patients aged 1 year and older with TSC who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected. ( 1.5 ) AFINITOR DISPERZ is a kinase inhibitor indicated for the adjunctive treatment of adult and pediatric patients aged 2 years and older with TSC-associated partial-onset seizures. ( 1.6 )|[EMA] Hormone-receptor-positive advanced breast cancerAfinitor is indicated for the treatment of hormone-receptor-positive, HER2/neu-negative advanced breast cancer, in combination with exemestane, in post-menopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.Neuroendocrine tumours of pancreatic originAfinitor is indicated for the treatment of unresectable or metastatic, well or moderately differentiated neuroendocrine tumours of pancreatic origin in adults with progressive disease.Neuroendocrine tumours of gastrointestinal or lung originAfinitor is indicated for the treatment of unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease.Renal-cell carcinomaAfinitor is indicated for the treatment of patients with advanced renal-cell carcinoma, whose disease has progressed on or after treatment with VEGF-targeted therapy. uuid:aa8ae890-843a-442e-ab84-6c0aebadf3b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2CN60TN6ZS biolink:treats MONDO:0008433 PMID:41385096 "[{""id"":""uuid:0b1278d2-5c01-46f7-a1fe-cd515b1ba18c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fa6ce498-bfe1-4ca2-b5b2-e4b87acf5bce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZEPZELCA is indicated for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy. This indication is approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). uuid:758c4dbe-626b-40a7-a0d7-c5bbf5270f37 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2CN60TN6ZS biolink:treats UMLS:C5706270 PMID:41385096 "[{""id"":""uuid:4e7c1a9b-3f5e-4db1-b006-262bfd2bbcce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:24822035-e69c-4322-82e6-23a598babf66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZEPZELCA is indicated for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy. This indication is approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). uuid:3d0b0507-df42-4463-b193-33ccb0349cb4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:YB18NF020M biolink:treats MONDO:0035663 PMID:41385096 "[{""id"":""uuid:04db73d6-eb50-4eb3-b40f-24c6fb0a368a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:31aafdb9-dcbe-43f2-ace5-a4c853e3a121"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9ace6692-6392-4be6-aa52-f371194ddd4c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/enspryng""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENSPRYNG is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.|[EMA] Satralizumab (Enspryng) is indicated as a monotherapy or in combination with immunosuppressive therapy (IST) for the treatment of neuromyelitis optica spectrum disorders (NMOSD) in adult and adolescent patients from 12 years of age who are anti-aquaporin-4 IgG (AQP4-IgG) seropositive. uuid:cf84a6cf-0d94-4abb-9ec2-abaa52231401 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:YB18NF020M biolink:treats MONDO:0019100 PMID:41385096 "[{""id"":""uuid:90fe3fff-8726-4223-94a4-14d5e7975c47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3e2ae1e8-8a80-4ee6-b8b3-b4eae6251296"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:dd727711-0d4d-45bd-8809-799e3fcf5478"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENSPRYNG is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive.|[PMDA] A drug with a new active ingredient indicated for the prevention of relapse of neuromyelitis optica spectrum disorder (including neuromyelitis optica). [Orphan drug] uuid:b6ea5df2-b00c-40cf-8061-075284a9a13f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:VY9C88C2NV biolink:treats MONDO:0018018 PMID:41385096 "[{""id"":""uuid:a7a065fa-dc12-4d2a-a8a0-9e52eee56ecb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a7b7d6da-accd-4ddb-b754-769ce18d4617"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ATTRUBY is indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization. uuid:33084af7-7329-4149-bb3a-8f28d5af629d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:VY9C88C2NV biolink:treats MONDO:0019441 PMID:41385096 "[{""id"":""uuid:bb5cef91-aa0e-4f27-8de5-389a53cc4e28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d8afb795-6988-4260-83c9-82bcf30ee20d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ATTRUBY is indicated for the treatment of the cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular death and cardiovascular-related hospitalization. uuid:3baa10b8-8072-4685-8c4a-42f0289a5d8c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:167672 biolink:treats MONDO:0859591 PMID:41385096 "[{""id"":""uuid:23460d59-d7b4-47a8-af7a-adb0048e9fe5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c7c8a38a-c613-47d2-b562-669a35e1f0e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OJEMDA is indicated for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. This indication is approved under accelerated approval based on response rate and duration of response [see Clinical Studies (14) ]. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). uuid:ea575e94-1427-4933-9b6d-524a17c4cc12 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:68603V9EAF biolink:treats MONDO:0010602 PMID:41385096 "[{""id"":""uuid:c47b529d-e437-4050-a649-f580cfcb753f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4fa86347-29f6-41ec-9f61-edccbca8bcf8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Alhemo is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with: • hemophilia A (congenital factor VIII deficiency) with FVIII inhibitors • hemophilia B (congenital factor IX deficiency) with FIX inhibitors uuid:edd638cf-8f00-4cd9-84eb-e2ace823d327 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:68603V9EAF biolink:treats MONDO:0010604 PMID:41385096 "[{""id"":""uuid:addca6f1-9c6c-4647-ab09-64d32a94f123"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0671b337-bbfa-443f-b187-e5502c351b53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Alhemo is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with: • hemophilia A (congenital factor VIII deficiency) with FVIII inhibitors • hemophilia B (congenital factor IX deficiency) with FIX inhibitors uuid:ec2e5c62-aef7-449d-b48d-bd7bce865cb9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:0T4IMT8S5Z biolink:treats MONDO:0018874 PMID:41385096 "[{""id"":""uuid:87c50de8-591b-4d1e-9786-e9c9a993ae69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3d360852-dfc6-44bf-99da-e9ef0541fde4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Relapsed or Refractory Acute Myeloid Leukemia REZLIDHIA is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test [see Dosage and Administration ( 2.1 ), Clinical Pharmacology ( 12.1 ), and Clinical Studies ( 14.1 )] . uuid:6822818c-f72e-40be-99c5-85439f0cf380 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:0T4IMT8S5Z biolink:treats UMLS:C4528668 PMID:41385096 "[{""id"":""uuid:5afed95a-e011-429d-89cf-71606486dfda"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c874b586-a3bf-49c9-adfe-0176dbace44e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Relapsed or Refractory Acute Myeloid Leukemia REZLIDHIA is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test [see Dosage and Administration ( 2.1 ), Clinical Pharmacology ( 12.1 ), and Clinical Studies ( 14.1 )] . uuid:d26f897c-de77-4573-9714-76dd8e733abe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0005114 PMID:41385096 "[{""id"":""uuid:546e692e-a021-4376-86f4-96e7aa7b613a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8cc991df-9bfb-4ae3-8b42-a1166476151f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes , Shigella sp. , Acinetobacter sp. , Klebsiella sp. , and Bacteroides sp . In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: Syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , Infections caused by Neisseria gonorrhoeae , Anthrax caused by Bacillus anthracis , Infections due to Listeria monocytogenes , Actinomycosis caused by Actinomyces species, Infections due to Clostridium species. uuid:1588c162-a30a-467d-a57e-8d434d560070 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0006926 PMID:41385096 "[{""id"":""uuid:ed2e1b2e-fdd2-4077-b035-9a872376d7df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cd2dbef4-1d46-41e2-a5b6-0b12bde48147"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes , Shigella sp. , Acinetobacter sp. , Klebsiella sp. , and Bacteroides sp . In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: Syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , Infections caused by Neisseria gonorrhoeae , Anthrax caused by Bacillus anthracis , Infections due to Listeria monocytogenes , Actinomycosis caused by Actinomyces species, Infections due to Clostridium species. uuid:c60c07eb-2f48-4a8b-b892-c0edea989c4d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats UMLS:C3824874 PMID:41385096 "[{""id"":""uuid:c30c40d2-5bef-47c0-a0c6-c0b3c0d973bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:109730c5-d7ff-4a84-87ce-a5df617307a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes , Shigella sp. , Acinetobacter sp. , Klebsiella sp. , and Bacteroides sp . In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: Syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , Infections caused by Neisseria gonorrhoeae , Anthrax caused by Bacillus anthracis , Infections due to Listeria monocytogenes , Actinomycosis caused by Actinomyces species, Infections due to Clostridium species. uuid:ebb80bcd-151e-4725-9f67-87a74bb19c3d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0030603 PMID:41385096 "[{""id"":""uuid:81e7d5c2-cfce-4909-80d8-95f19b004835"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:128d0d17-42d8-49d7-b755-d8912849764e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes , Shigella sp. , Acinetobacter sp. , Klebsiella sp. , and Bacteroides sp . In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: Syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , Infections caused by Neisseria gonorrhoeae , Anthrax caused by Bacillus anthracis , Infections due to Listeria monocytogenes , Actinomycosis caused by Actinomyces species, Infections due to Clostridium species. uuid:7c974036-2816-47c5-a99c-caafeab4af9e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0005545 PMID:41385096 "[{""id"":""uuid:e2e2d1bb-c335-4f25-9f0d-1272834e947b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d679d435-dee4-44c8-a6b4-c04ce4b02267"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes , Shigella sp. , Acinetobacter sp. , Klebsiella sp. , and Bacteroides sp . In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: Syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , Infections caused by Neisseria gonorrhoeae , Anthrax caused by Bacillus anthracis , Infections due to Listeria monocytogenes , Actinomycosis caused by Actinomyces species, Infections due to Clostridium species. uuid:d96b390a-901d-4b7a-affd-fd8168ef936b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0006956 PMID:41385096 "[{""id"":""uuid:b925a375-ed61-4454-9cd1-760d2b8ad3e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a1f58dff-36f8-42f2-b5a3-99a1c73ac8a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes , Shigella sp. , Acinetobacter sp. , Klebsiella sp. , and Bacteroides sp . In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: Syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , Infections caused by Neisseria gonorrhoeae , Anthrax caused by Bacillus anthracis , Infections due to Listeria monocytogenes , Actinomycosis caused by Actinomyces species, Infections due to Clostridium species. uuid:03efdd02-cc8c-48c4-b975-8aea8fc0cf81 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0021697 PMID:41385096 "[{""id"":""uuid:2a3c65b2-f157-4734-803b-2cbabf5e95a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fc78f665-9c34-475b-8dce-dc5bac0a8822"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes , Shigella sp. , Acinetobacter sp. , Klebsiella sp. , and Bacteroides sp . In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: Syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , Infections caused by Neisseria gonorrhoeae , Anthrax caused by Bacillus anthracis , Infections due to Listeria monocytogenes , Actinomycosis caused by Actinomyces species, Infections due to Clostridium species. uuid:711111d1-8227-425c-a5c7-bb7d03fb9072 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0006681 PMID:41385096 "[{""id"":""uuid:a2533f9d-6561-47dc-9c75-c0d7262a588b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f304f08e-e2e7-48cb-8e5f-f22872d91ce5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes , Shigella sp. , Acinetobacter sp. , Klebsiella sp. , and Bacteroides sp . In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: Syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , Infections caused by Neisseria gonorrhoeae , Anthrax caused by Bacillus anthracis , Infections due to Listeria monocytogenes , Actinomycosis caused by Actinomyces species, Infections due to Clostridium species. uuid:ba18b590-378d-4f16-8254-6dc35c7ef3cc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0018984 PMID:41385096 "[{""id"":""uuid:e54beae4-3182-4d45-a9b1-6a52941c42ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dc9643eb-bf7c-4a3d-8dd9-68a2a42cc826"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes , Shigella sp. , Acinetobacter sp. , Klebsiella sp. , and Bacteroides sp . In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: Syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , Infections caused by Neisseria gonorrhoeae , Anthrax caused by Bacillus anthracis , Infections due to Listeria monocytogenes , Actinomycosis caused by Actinomyces species, Infections due to Clostridium species. uuid:a7b5c3ed-1826-495c-8161-b2584ffd1d4d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0019095 PMID:41385096 "[{""id"":""uuid:2c8a56a4-c714-488f-99ee-c5cb011e8680"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c3871093-c222-44a3-9cf4-d94d62d837cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes , Shigella sp. , Acinetobacter sp. , Klebsiella sp. , and Bacteroides sp . In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: Syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , Infections caused by Neisseria gonorrhoeae , Anthrax caused by Bacillus anthracis , Infections due to Listeria monocytogenes , Actinomycosis caused by Actinomyces species, Infections due to Clostridium species. uuid:4a942dfc-daa7-45e1-94d8-02cca0585fea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0020920 PMID:41385096 "[{""id"":""uuid:d6fad770-63e8-4311-800e-9f4a5df2f836"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:78c72efb-f0ee-442a-ac66-17f4637f39d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes , Shigella sp. , Acinetobacter sp. , Klebsiella sp. , and Bacteroides sp . In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: Syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , Infections caused by Neisseria gonorrhoeae , Anthrax caused by Bacillus anthracis , Infections due to Listeria monocytogenes , Actinomycosis caused by Actinomyces species, Infections due to Clostridium species. uuid:40922ef3-318f-475c-bbbf-794e41fad895 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0019345 PMID:41385096 "[{""id"":""uuid:9f15a955-ecd5-404a-b86b-d9a93912dc49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9504449a-3675-4b72-b94e-fb730bfbb884"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes , Shigella sp. , Acinetobacter sp. , Klebsiella sp. , and Bacteroides sp . In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: Syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , Infections caused by Neisseria gonorrhoeae , Anthrax caused by Bacillus anthracis , Infections due to Listeria monocytogenes , Actinomycosis caused by Actinomyces species, Infections due to Clostridium species. uuid:bde3749d-9b09-4fc2-8224-aa711ae41eeb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0006635 PMID:41385096 "[{""id"":""uuid:b690502a-897c-45f9-8f86-5ea58beb100e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ecc2776d-254a-4c5c-af5b-eb7a9d371cac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes , Shigella sp. , Acinetobacter sp. , Klebsiella sp. , and Bacteroides sp . In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: Syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , Infections caused by Neisseria gonorrhoeae , Anthrax caused by Bacillus anthracis , Infections due to Listeria monocytogenes , Actinomycosis caused by Actinomyces species, Infections due to Clostridium species. uuid:e257867d-8273-41bb-9f53-aa1dc69ca9ab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0006671 PMID:41385096 "[{""id"":""uuid:f31e5a7c-dfaf-430c-8be3-78ac06039dc4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1c996e27-f3aa-4d7b-82a3-6082213b1705"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes , Shigella sp. , Acinetobacter sp. , Klebsiella sp. , and Bacteroides sp . In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: Syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , Infections caused by Neisseria gonorrhoeae , Anthrax caused by Bacillus anthracis , Infections due to Listeria monocytogenes , Actinomycosis caused by Actinomyces species, Infections due to Clostridium species. uuid:094e8d05-3562-4447-af59-2511f7efd9e2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0015306 PMID:41385096 "[{""id"":""uuid:99f5b436-2332-4375-ad90-afd179d400a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cd7d7a9d-4935-4008-a563-c5f5093aa9c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes , Shigella sp. , Acinetobacter sp. , Klebsiella sp. , and Bacteroides sp . In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: Syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , Infections caused by Neisseria gonorrhoeae , Anthrax caused by Bacillus anthracis , Infections due to Listeria monocytogenes , Actinomycosis caused by Actinomyces species, Infections due to Clostridium species. uuid:d4b2a003-83f5-4752-8c94-4ecaa9e3ef57 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27902 biolink:treats MONDO:0001719 PMID:41385096 "[{""id"":""uuid:082d38e3-2b10-48eb-91d3-57561da95d71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:578ad2ff-38c5-4ef9-a5df-0e31ae1cbfd6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of tetracycline hydrochloride and other antibacterial drugs, tetracycline hydrochloride should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Tetracycline is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below: Upper respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae and Hemophilus influenzae . Note: Tetracycline should not be used for streptococcal disease unless the organism has been demonstrated to be susceptible. Lower respiratory tract infections caused by Streptococcus pyogenes , Streptococcus pneumoniae , Mycoplasma pneumoniae (Eaton agent, and Klebsiella sp. ) Skin and soft tissue infections caused by Streptococcus pyogenes , Staphylococcus aureaus . (Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections.) Infections caused by rickettsia including Rocky Mountain spotted fever, typhus group infections, Q fever, rickettsialpox. Psittacosis caused by Chlamydophila psittaci . Infections caused by Chlamydia trachomatis such as uncomplicated urethral, endocervical or rectal infections, inclusion conjunctivitis, trachoma, and lymphogranuloma venereum. Granuloma inquinale caused by Klebsiella granulomatis . Relapsing fever caused by Borrelia sp. Bartonellosis caused by Bartonella bacilliformis . Chancroid caused by Hemophilus ducreyi . Tularemia caused by Francisella tularensis . Plaque caused by Yersinia pestis . Cholera caused by Vibrio cholerae . Brucellosis caused by Brucella species (tetracycline may be used in conjunction with an aminoglycoside). Infections due to Campylobacter fetus . As adjunctive therapy in intestinal amebiasis caused by Entamoeba histolytica . Urinary tract infections caused by susceptible strains of Escherichia coli , Klebsiella , etc. Other infections caused by susceptible gram-negative organisms such as E. coli , Enterobacter aerogenes , Shigella sp. , Acinetobacter sp. , Klebsiella sp. , and Bacteroides sp . In severe acne, adjunctive therapy with tetracycline may be useful. When penicillin is contraindicated, tetracyclines are alternative drugs in the treatment of the following infections: Syphilis and yaws caused by Treponema pallidum and pertenue , respectively, Vincent’s infection caused by Fusobacterium fusiforme , Infections caused by Neisseria gonorrhoeae , Anthrax caused by Bacillus anthracis , Infections due to Listeria monocytogenes , Actinomycosis caused by Actinomyces species, Infections due to Clostridium species. uuid:2799fe85-ab39-489d-a211-a07220053ced biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:976X9VXC3Z biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:028d1551-30c7-4f77-a0c2-b7f1616d2927"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8b834783-5b84-49f2-875f-2031144d5e77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EMRELIS is indicated for the treatment of adult patients with locally advanced or metastatic, non-squamous non-small cell lung cancer (NSCLC) with high c-Met protein overexpression [≥50% of tumor cells with strong (3+) staining], as determined by an FDA-approved test [see Dosage and Administration ( 2.1 )] , who have received a prior systemic therapy . This indication is approved under accelerated approval based on overall response rate (ORR) and duration of response (DOR) [see Clinical Studies ( 14 )] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). uuid:ac563dbf-dd00-4617-bf7c-fadb7146f419 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:089658A12D biolink:treats UMLS:C0406317 PMID:41385096 "[{""id"":""uuid:f0865694-7b6a-477e-bfd0-248bd6627c2d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:41984f1c-bf18-441f-9248-80bf4a4d0e66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:43da1c59-ca3a-42b6-8f46-73b2005169fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TREMFYA is an interleukin-23 antagonist indicated for the treatment of adult patients with: moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy ( 1.1 ) active psoriatic arthritis ( 1.2 ) moderately to severely active ulcerative colitis ( 1.3 ) moderately to severely active Crohn’s disease ( 1.4 )|[PMDA] A drug with a new active ingredient indicated for the treatment of plaque psoriasis, psoriatic arthritis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies. uuid:6cdd905b-35d5-4ead-bc69-06ae135cef53 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:089658A12D biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:a9a7c861-9957-40ff-be24-d1567435c0cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b2dc5470-46f9-4bde-9dd4-616b1ede44e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:98b40b2e-c4e4-4cbb-8581-616015a39381"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tremfya""]},{""id"":""uuid:7a8f3b5f-f2d4-4ac5-b19f-faac76102e2b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TREMFYA is an interleukin-23 antagonist indicated for the treatment of adult patients with: moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy ( 1.1 ) active psoriatic arthritis ( 1.2 ) moderately to severely active ulcerative colitis ( 1.3 ) moderately to severely active Crohn’s disease ( 1.4 )|[EMA] Plaque psoriasis, , Tremfya is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy., , Psoriatic arthritis, , Tremfya, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy (see section 5.1).,|[PMDA] A drug with a new active ingredient indicated for the treatment of plaque psoriasis, psoriatic arthritis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies. uuid:c7921a07-1177-48a8-bc69-d3e22183b59b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:089658A12D biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:48e0195a-95dc-459e-be2b-680e25ec94ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3119b3b4-3b0b-43f5-a7ea-4dda172e822d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TREMFYA is an interleukin-23 antagonist indicated for the treatment of adult patients with: moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy ( 1.1 ) active psoriatic arthritis ( 1.2 ) moderately to severely active ulcerative colitis ( 1.3 ) moderately to severely active Crohn’s disease ( 1.4 ) uuid:9d864055-9d6a-4e49-8e31-491eb69eec47 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:089658A12D biolink:treats MONDO:0005011 PMID:41385096 "[{""id"":""uuid:3248be06-db3a-4aad-8ec7-4383aaaf96d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:05b852b9-bd58-49c3-ab7b-45ec58a4de61"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TREMFYA is an interleukin-23 antagonist indicated for the treatment of adult patients with: moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy ( 1.1 ) active psoriatic arthritis ( 1.2 ) moderately to severely active ulcerative colitis ( 1.3 ) moderately to severely active Crohn’s disease ( 1.4 ) uuid:2530d8dd-20ff-41ba-90f5-a700312e5eb2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135809 biolink:treats MONDO:0004981 PMID:41385096 "[{""id"":""uuid:f456887c-b2a6-4222-98a6-92fd7e2de346"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1fca0a3e-db80-405e-9530-5aadc228338b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d85a34fe-af60-42f1-bde6-d1e5c97471bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RAPIBLYK is indicated for the short-term reduction of ventricular rate in adults with supraventricular tachycardia including atrial fibrillation and atrial flutter.|[PMDA] A drug with a new additional indication and a new dosage for the treatment of tachyarrhythmia including atrial fibrillation/flutter in patients with low cardiac function. uuid:6de8c7e3-34ed-4aa2-9046-bcc940076bbf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135809 biolink:treats MONDO:0005310 PMID:41385096 "[{""id"":""uuid:68fc6ceb-bbf9-43e9-b608-30105d9e4a78"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:37635e22-ce56-444a-b5d8-1397c5fb8d36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0a334b4e-7df0-41f3-a5de-3ac96d384330"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RAPIBLYK is indicated for the short-term reduction of ventricular rate in adults with supraventricular tachycardia including atrial fibrillation and atrial flutter.|[PMDA] A drug with a new additional indication and a new dosage for the treatment of tachyarrhythmia including atrial fibrillation/flutter in patients with low cardiac function. uuid:9220f412-696c-41a8-8dfb-c7cc21ceb776 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135809 biolink:treats HP:0004755 PMID:41385096 "[{""id"":""uuid:e835a2f7-c533-4c11-a844-89dfbad3b68e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d2231a7b-fbc5-4b85-afff-d69a32f55d08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7e6e0bb6-774f-495d-b222-f9a52852554d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RAPIBLYK is indicated for the short-term reduction of ventricular rate in adults with supraventricular tachycardia including atrial fibrillation and atrial flutter.|[PMDA] Drugs with a new indication and a new additional pediatric dosage for the treatment of the following tachyarrhythmia in patients with low cardiac function: supraventricular tachycardia, atrial fibrillation, and atrial flutter. uuid:99a80459-eff0-497a-8884-2a96d689a104 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1424887 biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:67006ad8-288a-458e-ba0f-2797382eba51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9f066d33-4071-4a86-a7f9-cc60af090622"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1ed81884-74f4-4081-a108-b142fa6a7c1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/relvar-ellipta""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] BREO ELLIPTA is a combination of fluticasone furoate, a corticosteroid, and vilanterol, a long-acting beta 2 -adrenergic agonist (LABA), indicated for: • the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). ( 1.1 ) • the maintenance treatment of asthma in patients aged 5 years and older. ( 1.2 ) Limitations of Use: Not indicated for relief of acute bronchospasm. ( 1.3 , 5.2 )|[EMA] Asthma indication:Relvar Ellipta is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older, where use of a combination product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate:patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short acting beta2-agonists.patients already adequately controlled on both inhaled corticosteroid and long-acting beta2-agonist.COPD indication:Relvar Ellipta is indicated for the symptomatic treatment of adults with COPD with a FEV1 uuid:02e7b18c-1874-4085-b8db-37d7343596d9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1424887 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:2d9f2531-b23f-48f7-902a-792845e9fc32"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4ab23692-00f2-4ad8-8144-b652dc3787d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e3cfa208-318e-46f5-9f2f-2b2acfe27e03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/relvar-ellipta""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] BREO ELLIPTA is a combination of fluticasone furoate, a corticosteroid, and vilanterol, a long-acting beta 2 -adrenergic agonist (LABA), indicated for: • the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). ( 1.1 ) • the maintenance treatment of asthma in patients aged 5 years and older. ( 1.2 ) Limitations of Use: Not indicated for relief of acute bronchospasm. ( 1.3 , 5.2 )|[EMA] Asthma indication:Relvar Ellipta is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older, where use of a combination product (long-acting beta2-agonist and inhaled corticosteroid) is appropriate:patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short acting beta2-agonists.patients already adequately controlled on both inhaled corticosteroid and long-acting beta2-agonist.COPD indication:Relvar Ellipta is indicated for the symptomatic treatment of adults with COPD with a FEV1 uuid:119be9af-5431-4879-aab9-b2b590b096c3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:177658 biolink:treats MONDO:0010396 PMID:41385096 "[{""id"":""uuid:fcc50ac6-c13c-4856-9f55-d2466424c91c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5038126c-7dff-4803-8824-c711ececa828"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZTALMY is indicated for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 years of age and older. uuid:695f235b-743e-45ed-ba88-c53c57003499 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28876 biolink:treats MONDO:0006486 PMID:41385096 "[{""id"":""uuid:397a8dff-31b4-4e46-b071-3344770cde41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:02904a2c-2e35-47c8-addd-efdab5942809"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] HEPZATO for injection, as a component of the HEPZATO KIT, is indicated as a liver-directed treatment for adult patients with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation. uuid:885b5969-d98c-43d9-9f0d-fcfd046b7e8b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28876 biolink:treats UMLS:C0153690 PMID:41385096 "[{""id"":""uuid:1687aa1b-d3fc-4449-9c99-ea06e852755d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:17d8926e-7d00-4be3-8d56-64a68d6e266c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] HEPZATO for injection, as a component of the HEPZATO KIT, is indicated as a liver-directed treatment for adult patients with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation. uuid:629db7e3-1923-450c-969f-c333111339f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28876 biolink:treats MONDO:0005438 PMID:41385096 "[{""id"":""uuid:6838fd4c-cd13-47a4-8bcf-8d38434cbc35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fd85719b-79bc-4bfc-899b-0074028c3286"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] HEPZATO for injection, as a component of the HEPZATO KIT, is indicated as a liver-directed treatment for adult patients with uveal melanoma with unresectable hepatic metastases affecting less than 50% of the liver and no extrahepatic disease or extrahepatic disease limited to the bone, lymph nodes, subcutaneous tissues, or lung that is amenable to resection or radiation. uuid:15894cf0-63c2-4ac2-a0b5-8c9b2ab7069b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:5384HK7574 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:72707d5e-1bb7-4c6e-92f9-690b400589da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a30105b7-319f-422b-943e-04dbc220c802"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:03f362bb-fabc-4301-a86a-3cfaffce021f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ogivri""]},{""id"":""uuid:d8918ad1-ca57-4e0c-b11b-409511a348ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of: adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH positive) breast cancer who have received a prior anti-HER2-based regimen either: in the metastatic setting, or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy. ( 1.1 ) adult patients with unresectable or metastatic Hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, as determined by an FDA-approved test, that has progressed on one or more endocrine therapies in the metastatic setting. (1.2) HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer, as determined by an FDA-approved test, who have received a prior chemotherapy in the metastatic setting; or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy. ( 1.2 ) adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy.* ( 1.3 ) adult patients with locally advanced or metastatic HER2-positive (IHC 3+ or IHC 2+/ISH positive) gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen. ( 1.4 ) adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options.* ( 1.5 ) * These indications are approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. ( 14.3 , 14.5 )|[EMA] Breast cancerMetastatic breast cancerOgivri is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC):as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. Prior chemotherapy must have included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. Hormone receptor positive patients must also have failed hormonal therapy, unless patients are unsuitable for these treatmentsin combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitablein combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic diseasein combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab.Early breast cancer Ogivri is indicated for the treatment of adult patients with HER2 positive early breast cancer (EBC):following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable)following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxelin combination with adjuvant chemotherapy consisting of docetaxel and carboplatin.in combination with neoadjuvant chemotherapy followed by adjuvant Ogivri therapy, for locally advanced (including inflammatory) disease or tumours > 2 cm in diameter.Ogivri should only be used in patients with metastatic or EBC whose tumours have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.Metastatic gastric cancerOgivri in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of adult patients with HER2 positive metastatic adenocarcinoma of the stomach or gastroesophageal junction who have not received prior anti-cancer treatment for their metastatic disease.Ogivri should only be used in patients with metastatic gastric cancer (MGC) whose tumours have HER2 overexpression as defined by IHC2+ and a confirmatory SISH or FISH result, or by an IHC 3+ result. Accurate and validated assay methods should be used.|[PMDA] A drug with a new indication for the treatment of unresectable or recurrent HER2-low breast cancer in patients who have previously been treated with chemotherapy. [Priority review] uuid:8d859b2d-926e-4547-9a25-de74e3bb1ff6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:5384HK7574 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:add17a70-38a3-4050-b463-37c1e94a78ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:abfb44e4-a3f2-443a-bebf-0da28a0890e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c94ff591-cc23-4268-a498-f2f64cae904c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/enhertu""]},{""id"":""uuid:8e8ca999-f21e-4faf-a529-ada4cd88c0ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of: adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH positive) breast cancer who have received a prior anti-HER2-based regimen either: in the metastatic setting, or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy. ( 1.1 ) adult patients with unresectable or metastatic Hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, as determined by an FDA-approved test, that has progressed on one or more endocrine therapies in the metastatic setting. (1.2) HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer, as determined by an FDA-approved test, who have received a prior chemotherapy in the metastatic setting; or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy. ( 1.2 ) adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy.* ( 1.3 ) adult patients with locally advanced or metastatic HER2-positive (IHC 3+ or IHC 2+/ISH positive) gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen. ( 1.4 ) adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options.* ( 1.5 ) * These indications are approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. ( 14.3 , 14.5 )|[EMA] Breast cancerHER2-positive breast cancerEnhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens.HER2-low breast cancerEnhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4.2).Non-small cell lung cancer (NSCLC)Enhertu as monotherapy is indicated for the treatment of adult patients with advanced NSCLC whose tumours have an activating HER2 (ERBB2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy.Gastric cancerEnhertu as monotherapy is indicated for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.|[PMDA] A drug with a new indication for the treatment of unresectable advanced or recurrent HER2 (ERBB2 ) mutation-positive non-small cell lung cancer that has progressed after cancer chemotherapy. [Orphan drug] uuid:0064c3cc-d990-41fa-b8d1-61b41e94e6dd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:5384HK7574 biolink:treats MONDO:0003219 PMID:41385096 "[{""id"":""uuid:fdcbb06d-848e-4941-8c92-6fb5bb938977"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0eaad4bd-4e41-4dcb-af51-60d91c052247"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d84ce205-3b30-4858-97a8-b64d43371a83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/enhertu""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENHERTU is a HER2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of: adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH positive) breast cancer who have received a prior anti-HER2-based regimen either: in the metastatic setting, or in the neoadjuvant or adjuvant setting and have developed disease recurrence during or within six months of completing therapy. ( 1.1 ) adult patients with unresectable or metastatic Hormone receptor (HR)-positive, HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, as determined by an FDA-approved test, that has progressed on one or more endocrine therapies in the metastatic setting. (1.2) HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer, as determined by an FDA-approved test, who have received a prior chemotherapy in the metastatic setting; or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy. ( 1.2 ) adult patients with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumors have activating HER2 (ERBB2) mutations, as detected by an FDA-approved test, and who have received a prior systemic therapy.* ( 1.3 ) adult patients with locally advanced or metastatic HER2-positive (IHC 3+ or IHC 2+/ISH positive) gastric or gastroesophageal junction adenocarcinoma who have received a prior trastuzumab-based regimen. ( 1.4 ) adult patients with unresectable or metastatic HER2-positive (IHC 3+) solid tumors who have received prior systemic treatment and have no satisfactory alternative treatment options.* ( 1.5 ) * These indications are approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. ( 14.3 , 14.5 )|[EMA] Breast cancerHER2-positive breast cancerEnhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens.HER2-low breast cancerEnhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4.2).Non-small cell lung cancer (NSCLC)Enhertu as monotherapy is indicated for the treatment of adult patients with advanced NSCLC whose tumours have an activating HER2 (ERBB2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy.Gastric cancerEnhertu as monotherapy is indicated for the treatment of adult patients with advanced HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen. uuid:21abe127-0c2b-46cb-a5c7-2c36c73d376c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7K28NB895L biolink:treats MONDO:0008667 PMID:41385096 "[{""id"":""uuid:461f08fa-6f2c-481d-8a35-293163dfeb12"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d5cdf5de-08bd-4441-b056-c7ca078a0c79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] WELIREG is a hypoxia-inducible factor inhibitor indicated: von Hippel-Lindau (VHL) disease for treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery. ( 1.1 ) Advanced Renal Cell Carcinoma (RCC) for treatment of adult patients with advanced renal cell carcinoma (RCC) with a clear cell component following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI). ( 1.2 ) Pheochromocytoma or Paraganglioma (PPGL) for treatment of adult and pediatric patients 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL). ( 1.3 ) uuid:44d2c877-d3a7-4f1e-aaa2-106a33a34356 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7K28NB895L biolink:treats MONDO:0005086 PMID:41385096 "[{""id"":""uuid:ceead273-8558-4d22-8227-4dd5fd9b8647"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:372bd35d-8bd2-4436-b868-88ec01f576a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] WELIREG is a hypoxia-inducible factor inhibitor indicated: von Hippel-Lindau (VHL) disease for treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery. ( 1.1 ) Advanced Renal Cell Carcinoma (RCC) for treatment of adult patients with advanced renal cell carcinoma (RCC) with a clear cell component following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI). ( 1.2 ) Pheochromocytoma or Paraganglioma (PPGL) for treatment of adult and pediatric patients 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL). ( 1.3 ) uuid:06784d6c-4496-4d7f-b93d-fa775d2d50ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7K28NB895L biolink:treats MONDO:0000628 PMID:41385096 "[{""id"":""uuid:e40a0869-7b42-4c98-a62d-1740a0888f91"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:46e3e251-cbca-4f8e-8ad0-538d343f861d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] WELIREG is a hypoxia-inducible factor inhibitor indicated: von Hippel-Lindau (VHL) disease for treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery. ( 1.1 ) Advanced Renal Cell Carcinoma (RCC) for treatment of adult patients with advanced renal cell carcinoma (RCC) with a clear cell component following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI). ( 1.2 ) Pheochromocytoma or Paraganglioma (PPGL) for treatment of adult and pediatric patients 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL). ( 1.3 ) uuid:af5f9073-81b1-45a8-92c5-ed4294de5209 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7K28NB895L biolink:treats MONDO:0005815 PMID:41385096 "[{""id"":""uuid:142091d9-6506-4bc8-9741-d848dd0328cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:72ce01d5-bc60-4f99-8a99-cba2277938e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] WELIREG is a hypoxia-inducible factor inhibitor indicated: von Hippel-Lindau (VHL) disease for treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery. ( 1.1 ) Advanced Renal Cell Carcinoma (RCC) for treatment of adult patients with advanced renal cell carcinoma (RCC) with a clear cell component following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI). ( 1.2 ) Pheochromocytoma or Paraganglioma (PPGL) for treatment of adult and pediatric patients 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL). ( 1.3 ) uuid:fcb1b454-f61c-4a13-a9e3-809547dcf111 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7K28NB895L biolink:treats MONDO:0008233 PMID:41385096 "[{""id"":""uuid:ca662056-4b51-4cd5-a19a-bd82703d802d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:348660d8-6c6d-4367-95cb-c5a4ddaab1d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] WELIREG is a hypoxia-inducible factor inhibitor indicated: von Hippel-Lindau (VHL) disease for treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery. ( 1.1 ) Advanced Renal Cell Carcinoma (RCC) for treatment of adult patients with advanced renal cell carcinoma (RCC) with a clear cell component following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI). ( 1.2 ) Pheochromocytoma or Paraganglioma (PPGL) for treatment of adult and pediatric patients 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL). ( 1.3 ) uuid:8c0e466a-59fb-4205-9a08-acb7914ea3a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7K28NB895L biolink:treats MONDO:0000448 PMID:41385096 "[{""id"":""uuid:372774eb-7826-4dc1-a087-9c37d7a5efb4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e381798c-ddfd-4229-94d7-e2587dbb3674"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] WELIREG is a hypoxia-inducible factor inhibitor indicated: von Hippel-Lindau (VHL) disease for treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery. ( 1.1 ) Advanced Renal Cell Carcinoma (RCC) for treatment of adult patients with advanced renal cell carcinoma (RCC) with a clear cell component following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI). ( 1.2 ) Pheochromocytoma or Paraganglioma (PPGL) for treatment of adult and pediatric patients 12 years and older with locally advanced, unresectable, or metastatic pheochromocytoma or paraganglioma (PPGL). ( 1.3 ) uuid:53d4ca8b-e77e-4bab-b718-8c5d675f6ab1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:163341910 biolink:treats UMLS:C0278488 PMID:41385096 "[{""id"":""uuid:b90661a0-8592-4882-9ef2-3dd25deee1c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:48db3dfa-e953-4547-8823-e411d9dd849a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KADCYLA is a HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for: the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: received prior therapy for metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy. ( 1.1 ) the adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment. ( 1.2 ) Select patients for therapy based on an FDA-approved companion diagnostic for KADCYLA [see Dosage and Administration (2.1) ] uuid:6ebdc1c3-49b2-4979-809e-f9ced5e89722 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:163341910 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:9f481ab6-9c97-4fb8-8ad5-62ffd9570441"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:afe9fe31-1b91-4e5d-882d-dd34164a8aad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KADCYLA is a HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for: the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: received prior therapy for metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy. ( 1.1 ) the adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment. ( 1.2 ) Select patients for therapy based on an FDA-approved companion diagnostic for KADCYLA [see Dosage and Administration (2.1) ] uuid:8e48256b-f2db-410e-a4e8-6c75bd9a4d83 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9K8GNJ2874 biolink:treats MONDO:0005072 PMID:41385096 "[{""id"":""uuid:25bda8a0-c6d6-4cb6-9176-7f08fbbd7dde"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:61bb20de-951b-4153-a082-7f04201d8fce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DANYELZA is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy. This indication is approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). uuid:a8c2fc27-180f-46d2-adf1-0cf31e4a8996 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9K8GNJ2874 biolink:treats UMLS:C0278695 PMID:41385096 "[{""id"":""uuid:205cf4b4-ea59-4e88-83cd-1154c2b078cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f2e1639a-fb73-40e1-a343-7919c8ebd308"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DANYELZA is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy. This indication is approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). uuid:84759557-4757-4155-81fa-4f46ad2a6ffc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9K8GNJ2874 biolink:treats UMLS:C4525059 PMID:41385096 "[{""id"":""uuid:43f09ac7-fe6f-4a49-9788-a3d6322552ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0c034fe3-a4a6-4ffc-b00f-a516d9e6f012"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DANYELZA is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of pediatric patients 1 year of age and older and adult patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who have demonstrated a partial response, minor response, or stable disease to prior therapy. This indication is approved under accelerated approval based on overall response rate and duration of response [see Clinical Studies (14) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). uuid:4736d542-34db-415b-9fac-e3049fde97c9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats HP:0003326 PMID:41385096 "[{""id"":""uuid:6afa5bbb-c19f-439b-9d3f-f03683faad8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2b62877e-d917-4ab4-85fa-1c6708f95c76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Xiclofen TM Ointment is indicated in adults over the age of 12 years old for the treatment of signs and symptoms of osteoarthritis of the joints, and of acute and chronic pain in muscles and joints associated with muscle soreness, strains, sprains, arthritis, simple backache, muscle stiffness, and more. uuid:b35cd8a5-fd6f-41ec-842d-1b730f51aa10 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats MONDO:0005578 PMID:41385096 "[{""id"":""uuid:452be084-a9df-4bbf-9620-5f1ee5c09d6c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2035fbd2-405b-4c6b-aad3-5408a4840058"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Xiclofen TM Ointment is indicated in adults over the age of 12 years old for the treatment of signs and symptoms of osteoarthritis of the joints, and of acute and chronic pain in muscles and joints associated with muscle soreness, strains, sprains, arthritis, simple backache, muscle stiffness, and more. uuid:35e3493b-d429-49b6-a880-92968bf50641 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats HP:0003552 PMID:41385096 "[{""id"":""uuid:e0fe3d98-8850-4d25-bf8c-2e4a9c115af6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:db6b0233-bd7c-4d24-b6b9-43dc536f9d7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Xiclofen TM Ointment is indicated in adults over the age of 12 years old for the treatment of signs and symptoms of osteoarthritis of the joints, and of acute and chronic pain in muscles and joints associated with muscle soreness, strains, sprains, arthritis, simple backache, muscle stiffness, and more. uuid:1d41cd96-f0b4-4c3e-bd71-82488c9cf0bd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats HP:0020165 PMID:41385096 "[{""id"":""uuid:9e33c2a9-4498-4c67-9156-8b7d7c1b34f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:158ee7b7-c533-4236-9d22-2bdf828fde47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OZURDEX ® is a corticosteroid indicated for: The treatment of macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO) ( 1.1 ) The treatment of non-infectious uveitis affecting the posterior segment of the eye ( 1.2 ) The treatment of diabetic macular edema ( 1.3 ) uuid:8759986a-336f-4a69-b955-f1825c2d4012 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0002303 PMID:41385096 "[{""id"":""uuid:c5a1b4b6-3be6-4b13-b2c6-8b888b54f8ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4bd8f17c-d934-4219-a66f-fda297340474"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OZURDEX ® is a corticosteroid indicated for: The treatment of macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO) ( 1.1 ) The treatment of non-infectious uveitis affecting the posterior segment of the eye ( 1.2 ) The treatment of diabetic macular edema ( 1.3 ) uuid:d022e947-7533-4a45-93bc-293897bf3c15 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0041093 PMID:41385096 "[{""id"":""uuid:3623dcf8-3474-4971-a7ae-ce56d5a47e2b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:95c39614-d93d-4e0e-892f-b2ae7d225286"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OZURDEX ® is a corticosteroid indicated for: The treatment of macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO) ( 1.1 ) The treatment of non-infectious uveitis affecting the posterior segment of the eye ( 1.2 ) The treatment of diabetic macular edema ( 1.3 ) uuid:b25a3d21-8588-420d-8000-2a42e375aa4a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0004728 PMID:41385096 "[{""id"":""uuid:c1f55d97-8ded-482d-b3ce-250caf86fbe2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:002ad42a-1c59-4311-8fd5-79235de375e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OZURDEX ® is a corticosteroid indicated for: The treatment of macular edema following branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO) ( 1.1 ) The treatment of non-infectious uveitis affecting the posterior segment of the eye ( 1.2 ) The treatment of diabetic macular edema ( 1.3 ) uuid:405c6e67-7091-48a5-8c78-772fff2fe5d9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:N7T15V1FUY biolink:treats MONDO:0012335 PMID:41385096 "[{""id"":""uuid:970c18ee-5724-457f-90eb-3b59da3b74b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6134cd40-8f97-4b46-baa7-fc374dfb3dba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:5124be54-07e9-47a7-99d8-8eafeddc2488"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/imcivree""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] IMCIVREE is indicated to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 2 years and older with syndromic or monogenic obesity due to: Bardet-Biedl syndrome (BBS) [see Dosage and Administration ( 2.1 )] Pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS) [see Dosage and Administration ( 2.1 )]. Limitations of Use: IMCIVREE is not indicated for the treatment of patients with the following conditions as IMCIVREE would not be expected to be effective: Obesity due to suspected POMC, PCSK1, or LEPR deficiency with POMC , PCSK1 , or LEPR variants classified as benign or likely benign Other types of obesity not related to BBS or POMC, PCSK1, or LEPR deficiency, including obesity associated with other genetic syndromes and general (polygenic) obesity|[EMA] Imcivree is indicated for the treatment of obesity and the control of hunger associated with genetically confirmed Bardet Biedl syndrome (BBS), loss-of-function biallelic pro-opiomelanocortin (POMC), including PCSK1, deficiency or biallelic leptin receptor (LEPR) deficiency in adults and children 6 years of age and above. uuid:bc0c0a42-f38e-4e4d-a1fe-dc8f94241bed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:N7T15V1FUY biolink:treats MONDO:0010961 PMID:41385096 "[{""id"":""uuid:a3473579-c88b-4ec6-af17-b45c437764ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:89062b53-e2f6-4883-9406-915d77848a22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c3b4e7ee-c37d-4a5e-9a28-de4ff42ba16f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/imcivree""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] IMCIVREE is indicated to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 2 years and older with syndromic or monogenic obesity due to: Bardet-Biedl syndrome (BBS) [see Dosage and Administration ( 2.1 )] Pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS) [see Dosage and Administration ( 2.1 )]. Limitations of Use: IMCIVREE is not indicated for the treatment of patients with the following conditions as IMCIVREE would not be expected to be effective: Obesity due to suspected POMC, PCSK1, or LEPR deficiency with POMC , PCSK1 , or LEPR variants classified as benign or likely benign Other types of obesity not related to BBS or POMC, PCSK1, or LEPR deficiency, including obesity associated with other genetic syndromes and general (polygenic) obesity|[EMA] Imcivree is indicated for the treatment of obesity and the control of hunger associated with genetically confirmed Bardet Biedl syndrome (BBS), loss-of-function biallelic pro-opiomelanocortin (POMC), including PCSK1, deficiency or biallelic leptin receptor (LEPR) deficiency in adults and children 6 years of age and above. uuid:e72a1c45-1391-48f7-8e4d-5847eecc8f01 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:N7T15V1FUY biolink:treats MONDO:0013992 PMID:41385096 "[{""id"":""uuid:a54e3a4a-3a90-4cd9-9317-d96c240f2887"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:422c3954-08e3-4b06-9534-786688b5f1c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:62c17191-1a3c-48d8-bc00-d69dad50d25a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/imcivree""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] IMCIVREE is indicated to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 2 years and older with syndromic or monogenic obesity due to: Bardet-Biedl syndrome (BBS) [see Dosage and Administration ( 2.1 )] Pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS) [see Dosage and Administration ( 2.1 )]. Limitations of Use: IMCIVREE is not indicated for the treatment of patients with the following conditions as IMCIVREE would not be expected to be effective: Obesity due to suspected POMC, PCSK1, or LEPR deficiency with POMC , PCSK1 , or LEPR variants classified as benign or likely benign Other types of obesity not related to BBS or POMC, PCSK1, or LEPR deficiency, including obesity associated with other genetic syndromes and general (polygenic) obesity|[EMA] Imcivree is indicated for the treatment of obesity and the control of hunger associated with genetically confirmed Bardet Biedl syndrome (BBS), loss-of-function biallelic pro-opiomelanocortin (POMC), including PCSK1, deficiency or biallelic leptin receptor (LEPR) deficiency in adults and children 6 years of age and above. uuid:9aa8d355-2465-49bf-83ba-d0d0264834bd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:N7T15V1FUY biolink:treats MONDO:0011122 PMID:41385096 "[{""id"":""uuid:a153b4ed-b4a5-44a8-a969-aea1ee034e17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d259d5aa-66f7-432f-8920-d4c70aaa9959"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7ccee839-1fc4-47c8-8958-9566546ca7dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/imcivree""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] IMCIVREE is indicated to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 2 years and older with syndromic or monogenic obesity due to: Bardet-Biedl syndrome (BBS) [see Dosage and Administration ( 2.1 )] Pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS) [see Dosage and Administration ( 2.1 )]. Limitations of Use: IMCIVREE is not indicated for the treatment of patients with the following conditions as IMCIVREE would not be expected to be effective: Obesity due to suspected POMC, PCSK1, or LEPR deficiency with POMC , PCSK1 , or LEPR variants classified as benign or likely benign Other types of obesity not related to BBS or POMC, PCSK1, or LEPR deficiency, including obesity associated with other genetic syndromes and general (polygenic) obesity|[EMA] Imcivree is indicated for the treatment of obesity and the control of hunger associated with genetically confirmed Bardet Biedl syndrome (BBS), loss-of-function biallelic pro-opiomelanocortin (POMC), including PCSK1, deficiency or biallelic leptin receptor (LEPR) deficiency in adults and children 6 years of age and above. uuid:6a18076e-0f4b-4150-9b3e-62376558cfaf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:NU90V55F8I biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:1d960121-b3ca-4837-ac66-9f9d04038ade"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:86cc0339-4e98-4a7b-9607-071c30611eb2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:32d83558-1513-4e77-a6f9-40b1c328fc34"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kevzara""]},{""id"":""uuid:48ad0681-7bb5-4be6-a787-5423125715ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEVZARA ® is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of: adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs). ( 1.1 ) adult patients with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper. ( 1.2 ) patients who weigh 63 kg or greater with active polyarticular juvenile idiopathic arthritis (pJIA). ( 1.3 )|[EMA] Kevzara in combination with methotrexate (MTX) is indicated for the treatment of moderately to severely active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (DMARDs). Kevzara can be given as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate.|[PMDA] Drugs with a new active ingredient indicated for the treatment of rheumatoid arthritis in patients who have not responded sufficiently to conventional treatments. uuid:2bed8991-2424-444b-9de8-b8c99e3ebb1a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:NU90V55F8I biolink:treats MONDO:0019735 PMID:41385096 "[{""id"":""uuid:19a53133-8520-45f2-a0b0-126479af46ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:83870e48-5a62-491b-a5e3-49448ff21e7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEVZARA ® is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of: adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs). ( 1.1 ) adult patients with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper. ( 1.2 ) patients who weigh 63 kg or greater with active polyarticular juvenile idiopathic arthritis (pJIA). ( 1.3 ) uuid:78e707b5-1225-4c90-843f-1422f4ca2b0c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:NU90V55F8I biolink:treats MONDO:0018456 PMID:41385096 "[{""id"":""uuid:da8cc556-029f-4ccd-b85d-5592abd76e33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b1cc9497-6801-467c-a252-b57a10ee8c84"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEVZARA ® is an interleukin-6 (IL-6) receptor antagonist indicated for treatment of: adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs). ( 1.1 ) adult patients with polymyalgia rheumatica (PMR) who have had an inadequate response to corticosteroids or who cannot tolerate corticosteroid taper. ( 1.2 ) patients who weigh 63 kg or greater with active polyarticular juvenile idiopathic arthritis (pJIA). ( 1.3 ) uuid:31c9df5e-2f54-4790-89e3-2f5bd0216a29 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6344 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:6e7fc213-849e-4c1e-9261-a54e22b0b2ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2e599a50-b409-4588-9e9c-c7ac6155026c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Labetalol Hydrochloride is indicated in the management of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including beta adrenergic blockers. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Labetalol Hydrochloride Tablets, USP may be used alone or in combination with other antihypertensive agents, especially thiazide and loop diuretics. uuid:04673835-d46c-4e93-bf4e-cf5044e80060 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6344 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:b6e73db0-e0d4-470d-b19a-df2d1fd60621"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:59704e36-7b1b-443e-8219-98918b6850bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Labetalol Hydrochloride is indicated in the management of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including beta adrenergic blockers. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Labetalol Hydrochloride Tablets, USP may be used alone or in combination with other antihypertensive agents, especially thiazide and loop diuretics. uuid:b29916dc-6a3b-4a9c-9a36-6e75e624d645 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6344 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:5994a070-5851-4bd2-8b12-119c8824fccd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5e66ae77-4c65-4a8c-8f7a-70e154a65879"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Labetalol Hydrochloride is indicated in the management of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including beta adrenergic blockers. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Labetalol Hydrochloride Tablets, USP may be used alone or in combination with other antihypertensive agents, especially thiazide and loop diuretics. uuid:b9947b25-db13-44e3-973d-1727fe3e68c6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6344 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:0bb5daac-d8b9-4a06-a487-f4f48ff8dc1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:67dc38d1-c964-4530-9879-601fd0f2ce1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Labetalol Hydrochloride is indicated in the management of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including beta adrenergic blockers. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Labetalol Hydrochloride Tablets, USP may be used alone or in combination with other antihypertensive agents, especially thiazide and loop diuretics. uuid:d708c377-0c31-41bf-9d4f-659a859948d9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6344 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:3bbc7caf-a882-4c4e-86a0-d2f515a063b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:34524528-255f-45eb-ab71-c4e9621c244e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Labetalol Hydrochloride is indicated in the management of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including beta adrenergic blockers. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Labetalol Hydrochloride Tablets, USP may be used alone or in combination with other antihypertensive agents, especially thiazide and loop diuretics. uuid:ae533466-1c08-4adb-9af2-0137ebb488eb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6344 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:e78a6973-e595-46d5-8e1c-b369f0e86d44"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a1efb24d-b3c8-4422-b78a-30259eedace6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Labetalol Hydrochloride is indicated in the management of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including beta adrenergic blockers. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Labetalol Hydrochloride Tablets, USP may be used alone or in combination with other antihypertensive agents, especially thiazide and loop diuretics. uuid:8921e402-f89c-4074-856b-5f95717ead8a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6344 biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:6cd9ddac-061b-4120-8dfb-94e9a906dc1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2f804f02-6b27-4655-9544-8fc1a84da0ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Labetalol Hydrochloride is indicated in the management of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including beta adrenergic blockers. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly. Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal. Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. Labetalol Hydrochloride Tablets, USP may be used alone or in combination with other antihypertensive agents, especially thiazide and loop diuretics. uuid:d8337976-8605-4cb3-9b68-3096b6530bd6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6809 biolink:treats MONDO:0007743 PMID:41385096 "[{""id"":""uuid:1892ebd3-a7ec-4e01-9926-945ec47ebc16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6456ae86-afe8-469c-9194-20ec5db42872"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Methamphetamine hydrochloride tablets are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in pediatric patients 6 years of age and older. uuid:c69b9520-8c21-47ba-b826-836a7a5f0263 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134726 biolink:treats MONDO:0005180 PMID:41385096 "[{""id"":""uuid:5040e6e6-ef45-4319-9b65-509f8bdb6465"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:aece0012-0874-41d9-95ec-c4082282ec49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:32808c45-209e-4e92-a6cc-ddc5ff705e0c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] NOURIANZ is indicated as adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson's disease (PD) experiencing ""off"" episodes.|[PMDA] A drug with a new active ingredient indicated for the improvement of wearing-off phenomenon in patients with Parkinson's disease on treatment with levodopa-containing products." uuid:5413d10c-da4c-4f44-b022-55cb76c9fd32 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:343262 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:7c80bee4-51d2-4ce2-907d-fe70267dbfad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4565ddcb-a98b-4866-acfa-38e79b823bfd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] HUMALOG is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. uuid:841598ec-eb1b-4098-be6f-910bec3bfd96 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85164 biolink:treats MONDO:0002771 PMID:41385096 "[{""id"":""uuid:22d828b8-ff25-4adc-9305-b2661d76bbe1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e820f1b1-0ef7-4dce-b26d-d1171af54eda"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:40ce348f-72a9-4d14-9c3b-151b017aa687"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OFEV is a kinase inhibitor indicated in adults for: Treatment of idiopathic pulmonary fibrosis (IPF) ( 1.1 ) Treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype ( 1.2 ) Slowing the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) ( 1.3 )|[PMDA] Drugs with a new active ingredient indicated for the treatment of idiopathic pulmonary fibrosis. [Orphan drug] uuid:464967cf-d87e-4ad3-a471-22d28af887ae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85164 biolink:treats MONDO:0002047 PMID:41385096 "[{""id"":""uuid:b2680297-8b90-43b0-9b2f-de7fec86b215"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f5554079-7508-4cb7-83ea-cf48fafbbe95"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b01807dd-ee0d-4814-8c9d-0a39a63b2c17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OFEV is a kinase inhibitor indicated in adults for: Treatment of idiopathic pulmonary fibrosis (IPF) ( 1.1 ) Treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype ( 1.2 ) Slowing the rate of decline in pulmonary function in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) ( 1.3 )|[PMDA] Drugs with a new additional indication for the treatment of systemic sclerosis associated interstitial lung disease. [Orphan drug] uuid:44b1912d-057c-444d-9f9b-49032258b179 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49960 biolink:treats MONDO:0015277 PMID:41385096 "[{""id"":""uuid:a8b03bb0-44a9-4914-9b50-e6bc8af3be38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e42fcafd-b629-4342-8369-5504529a143a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2bc43a0a-b6b8-4a34-958c-77e26418a85d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/caprelsa""]},{""id"":""uuid:cf674195-1be7-49d9-9119-86ea614b5180"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CAPRELSA is indicated for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. Use CAPRELSA in patients with indolent, asymptomatic or slowly progressing disease only after careful consideration of the treatment related risks of CAPRELSA.|[EMA] Caprelsa is indicated for the treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease.Caprelsa is indicated in adults, children and adolescents aged 5 years and older.For patients in whom re-arranged-during-transfection(RET) mutation is not known or is negative, a possible lower benefit should be taken into account before individual treatment decision.|[PMDA] A drug with a new active ingredient indicated for the treatment of unresectable medullary thyroid cancer. [Orphan drug] uuid:6109a753-119b-4cad-af0f-d789cedefd62 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:15C2VL427D biolink:treats EFO:1001480 PMID:41385096 "[{""id"":""uuid:8a44eea0-67a8-4276-a03d-0232e2a7f37b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5564a788-158f-487e-972b-1ec638a82e71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZALTRAP, in combination with fluorouracil, leucovorin, irinotecan-(FOLFIRI), is indicated for the treatment of patients with metastatic colorectal cancer (mCRC) that is resistant to or has progressed following an oxaliplatin-containing regimen. uuid:aa54b38c-adc5-4ae4-a704-eaf5edcb0e05 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1601650 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:3a506141-a08d-4307-98a7-73315a8a1c52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9ed470cb-f0ff-43f3-a6be-daf529e6e283"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EVOTAZ is a two-drug combination of atazanavir, a human immunodeficiency virus (HIV-1) protease inhibitor, and cobicistat, a CYP3A inhibitor indicated for use in combination with other antiretroviral agents for the treatment of HIV‑1 infection in adults and pediatric patients weighing at least 35 kg. (1) Limitations of Use Use of EVOTAZ in treatment-experienced patients should be guided by the number of baseline primary protease inhibitor resistance substitutions. (1) uuid:0051e91c-54de-4d93-a2a5-1fdb4fd70e26 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:LKC0U3A8NJ biolink:treats MONDO:0004995 PMID:41385096 "[{""id"":""uuid:d2a3a11b-6425-4119-87cc-8166c396e99b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e7682b8e-4d17-4362-a0a2-60d48d59c1a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] REPATHA is indicated: To reduce the risk of major adverse cardiovascular (CV) events (CV death, myocardial infarction, stroke, unstable angina requiring hospitalization, or coronary revascularization) in adults with established cardiovascular disease As an adjunct to diet, alone or in combination with other low-density lipoprotein cholesterol (LDL-C)-lowering therapies, in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce LDL-C As an adjunct to diet and other LDL-C-lowering therapies in pediatric patients aged 10 years and older with HeFH, to reduce LDL-C As an adjunct to other LDL-C-lowering therapies in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH), to reduce LDL-C uuid:6f7939eb-5a09-42d9-b0ac-f04bdd7f8864 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:LKC0U3A8NJ biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:6f6a3ddd-2a9d-4022-bf4c-9d5e79458df5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8f9fe065-4f99-4477-944c-5713c53e7e2b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] REPATHA is indicated: To reduce the risk of major adverse cardiovascular (CV) events (CV death, myocardial infarction, stroke, unstable angina requiring hospitalization, or coronary revascularization) in adults with established cardiovascular disease As an adjunct to diet, alone or in combination with other low-density lipoprotein cholesterol (LDL-C)-lowering therapies, in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce LDL-C As an adjunct to diet and other LDL-C-lowering therapies in pediatric patients aged 10 years and older with HeFH, to reduce LDL-C As an adjunct to other LDL-C-lowering therapies in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH), to reduce LDL-C uuid:e0472ccc-5f39-4f46-bf94-11cd4aac7b59 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:LKC0U3A8NJ biolink:treats UMLS:C0342882 PMID:41385096 "[{""id"":""uuid:0ed973b3-90f0-46e3-abb7-5168be0cb5f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c7c9707b-4dd0-4166-b254-f33e8640211b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] REPATHA is indicated: To reduce the risk of major adverse cardiovascular (CV) events (CV death, myocardial infarction, stroke, unstable angina requiring hospitalization, or coronary revascularization) in adults with established cardiovascular disease As an adjunct to diet, alone or in combination with other low-density lipoprotein cholesterol (LDL-C)-lowering therapies, in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce LDL-C As an adjunct to diet and other LDL-C-lowering therapies in pediatric patients aged 10 years and older with HeFH, to reduce LDL-C As an adjunct to other LDL-C-lowering therapies in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH), to reduce LDL-C uuid:23c0890d-3109-471e-86eb-b3b99a357676 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:LKC0U3A8NJ biolink:treats MONDO:0018328 PMID:41385096 "[{""id"":""uuid:5ca1a0a8-ed1e-45d8-bd42-4e22d37c077a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:59693d7f-32cc-40c1-89f3-b4734ccf6bc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:906f58f9-e07a-47d4-87fe-bc5120be4d99"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/repatha""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] REPATHA is indicated: To reduce the risk of major adverse cardiovascular (CV) events (CV death, myocardial infarction, stroke, unstable angina requiring hospitalization, or coronary revascularization) in adults with established cardiovascular disease As an adjunct to diet, alone or in combination with other low-density lipoprotein cholesterol (LDL-C)-lowering therapies, in adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce LDL-C As an adjunct to diet and other LDL-C-lowering therapies in pediatric patients aged 10 years and older with HeFH, to reduce LDL-C As an adjunct to other LDL-C-lowering therapies in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH), to reduce LDL-C|[EMA] Hypercholesterolaemia and mixed dyslipidaemiaRepatha is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin or statin with other lipid lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin or,alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.Homozygous familial hypercholesterolaemiaRepatha is indicated in adults and adolescents aged 12 years and over with homozygous familial hypercholesterolaemia in combination with other lipid-lowering therapies.Established atherosclerotic cardiovascular diseaseRepatha is indicated in adults with established atherosclerotic cardiovascular disease (myocardial infarction, stroke or peripheral arterial disease) to reduce cardiovascular risk by lowering LDL-C levels, as an adjunct to correction of other risk factors:in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies or,alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.For study results with respect to effects on LDL-C, cardiovascular events and populations studied see section 5.1. uuid:e9e63ce4-536d-4ca0-80b7-596258b87a41 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:91327 biolink:treats MONDO:0005086 PMID:41385096 "[{""id"":""uuid:c31aa50b-8ab7-4835-a7b8-07a08c9797a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c494c5f4-a946-4d4d-87ed-96fa12f13a60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FOTIVDA is indicated for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. uuid:5fc3282f-352f-4abb-8022-82cd1aeea44f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:91408 biolink:treats MONDO:0009692 PMID:41385096 "[{""id"":""uuid:8bb388b1-9813-465f-b2cd-74ce522e1c73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d44e3247-78e8-4ecd-b898-c9b6455cbc04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e031e0ee-16b9-4165-bdc2-f7bca32cbb04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INREBIC ® is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF).|[EMA] Inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are Janus Associated Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib. uuid:fb6ecd49-4bff-43d5-981c-2cad29a2bf74 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:GE2T1418SV biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:57f5da71-3f8a-4428-84ee-8fb691c1b2d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:8f12e937-2dcc-4715-a1fc-193fa9f49d55"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:8cdce1d6-85d3-4e5f-af06-dee215f157d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INCRUSE ELLIPTA is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).|[EMA] Rolufta is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD)., uuid:3be2bdfe-5c7a-48b2-aac8-224c3ef41cc8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:GE2T1418SV biolink:treats MONDO:0011751 PMID:41385096 "[{""id"":""uuid:8d89e069-c455-445a-99cf-78297b7f5136"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bd1f9b79-e91b-4e09-bff4-ce01937c2fd7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] INCRUSE ELLIPTA is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). uuid:45416c7d-65d3-4916-987e-1100aa11a4e3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68554 biolink:treats MONDO:0000984 PMID:41385096 "[{""id"":""uuid:7386a1d0-1b91-4d05-8d9f-2950db4dc381"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4e00d814-9f50-4292-8716-5fa7faceba27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FERRIPROX Oral Solution is indicated for the treatment of transfusional iron overload in adult and pediatric patients 3 years of age and older with thalassemia syndromes, sickle cell disease or other anemias. uuid:5875c013-b9aa-41b7-adeb-570266fef9f9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68554 biolink:treats MONDO:0011382 PMID:41385096 "[{""id"":""uuid:79063978-5b95-4e02-8a36-465bab53df31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:393a6f09-71b1-4642-80b0-13020b995ded"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FERRIPROX Oral Solution is indicated for the treatment of transfusional iron overload in adult and pediatric patients 3 years of age and older with thalassemia syndromes, sickle cell disease or other anemias. uuid:cc9fbe87-2b22-47a1-8193-1f3d12813cd0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:194186 biolink:treats MONDO:0011122 PMID:41385096 "[{""id"":""uuid:4fcd16ec-421d-463d-a458-5c595b863c10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bcdc5017-7435-4621-b6c7-5b948f16e492"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZEPBOUND ® is indicated in combination with a reduced-calorie diet and increased physical activity: to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity. uuid:cca0a2ef-050a-4b09-8760-e8454e553964 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:194186 biolink:treats MONDO:0007147 PMID:41385096 "[{""id"":""uuid:3339121c-6468-471d-86a2-18f27e099328"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3d16c098-81d0-4b0f-b239-6bbff3f11fa2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZEPBOUND ® is indicated in combination with a reduced-calorie diet and increased physical activity: to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. to treat moderate to severe obstructive sleep apnea (OSA) in adults with obesity. uuid:9eba1000-be10-4a2e-ab08-bb8a427011ef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:26271 biolink:treats UMLS:C0854100 PMID:41385096 "[{""id"":""uuid:0b3b47ac-8a08-4849-85d9-235138ae103a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9c95101e-54d5-43cc-958b-d6195f80b18f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CLINIMIX is indicated as a source of calories and protein for patients requiring parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. CLINIMIX may be used to treat negative nitrogen balance in patients. uuid:efda354c-8011-4fda-bacd-22af241afd18 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47657 biolink:treats MONDO:0006608 PMID:41385096 "[{""id"":""uuid:1161abae-d5c0-47a7-a7b3-b8c046d25602"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b65a2db4-12ad-481e-b649-de968a3c1965"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ZORYVE topical foam, 0.3%, is a phosphodiesterase 4 inhibitor indicated for the treatment of seborrheic dermatitis in adult and pediatric patients 9 years of age and older. ( 1.1 ) plaque psoriasis of the scalp and body in adult and pediatric patients 12 years of age and older. ( 1.2 ) uuid:6b971ee4-2d64-48e4-afb7-c7351221586f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15854 biolink:treats MONDO:0005136 PMID:41385096 "[{""id"":""uuid:bcbc5f6e-135f-4270-99f7-f1a69db0c5cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7d46db8f-55a4-4ff9-af70-0a6434c95b7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Quinine sulfate capsule USP is a cinchona alkaloid indicated for treatment of uncomplicated Plasmodium falciparum malaria ( 1 ). uuid:057cf289-3178-46e6-bc24-3fb9a56b958d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:QI30938BMS biolink:treats MONDO:0004781 PMID:41385096 "[{""id"":""uuid:a91e7890-19d0-48d0-82b5-fbdc5d6e165e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4731ed2a-9937-4251-972b-ca765f96ec1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Technetium Tc 99m Pyrophosphate Injection is a skeletal imaging agent used to demonstrate areas of altered osteogenesis, and a cardiac imaging agent used as an adjunct in the diagnosis of acute myocardial infarction. As an adjunct in the diagnosis of confirmed myocardial infarction (ECG and serum enzymes positive), the incidence of false negative images has been found to be 6%. False negative images can also occur if made too early in the evolutionary phase of the infarct or too late in the resolution phase. In a limited study involving 22 patients in whom the ECG was positive and serum enzymes questionable or negative, but in whom the final diagnosis of acute myocardial infarction was made, the incidence of false negative images was 23%. The incidence of false positive images has been found to be 7 to 9%. False positive images have been reported following coronary by-pass graft surgery, in unstable angina pectoris, old myocardial infarcts and in cardiac contusions. Technescan PYP is a blood pool imaging agent which may be used for gated blood pool imaging and for the detection of sites of gastrointestinal bleeding. When administered intravenously 15 to 30 minutes prior to intravenous administration of sodium pertechnetate Tc 99m for in vivo red blood cell labeling, approximately 75% of the injected activity remains in the blood pool. The modified in vivo/in vitro red blood cell labeling method may also be used for blood pool imaging. uuid:9086bdff-ab81-41f7-83a1-45e4c4e7cdeb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:QI30938BMS biolink:treats MONDO:0006805 PMID:41385096 "[{""id"":""uuid:d79c8b04-8eb2-40ec-9859-9a5ff9b965c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fb003f20-a8d1-4f1f-be02-20f36c60a600"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Technetium Tc 99m Pyrophosphate Injection is a skeletal imaging agent used to demonstrate areas of altered osteogenesis, and a cardiac imaging agent used as an adjunct in the diagnosis of acute myocardial infarction. As an adjunct in the diagnosis of confirmed myocardial infarction (ECG and serum enzymes positive), the incidence of false negative images has been found to be 6%. False negative images can also occur if made too early in the evolutionary phase of the infarct or too late in the resolution phase. In a limited study involving 22 patients in whom the ECG was positive and serum enzymes questionable or negative, but in whom the final diagnosis of acute myocardial infarction was made, the incidence of false negative images was 23%. The incidence of false positive images has been found to be 7 to 9%. False positive images have been reported following coronary by-pass graft surgery, in unstable angina pectoris, old myocardial infarcts and in cardiac contusions. Technescan PYP is a blood pool imaging agent which may be used for gated blood pool imaging and for the detection of sites of gastrointestinal bleeding. When administered intravenously 15 to 30 minutes prior to intravenous administration of sodium pertechnetate Tc 99m for in vivo red blood cell labeling, approximately 75% of the injected activity remains in the blood pool. The modified in vivo/in vitro red blood cell labeling method may also be used for blood pool imaging. uuid:d759e4a9-e624-4ed6-ab3e-a2cdb2d7ccd7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:QI30938BMS biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:6462003b-997e-4179-a20c-2afedc0d5414"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:48070766-2563-4aed-823e-0906361bbdec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Technetium Tc 99m Pyrophosphate Injection is a skeletal imaging agent used to demonstrate areas of altered osteogenesis, and a cardiac imaging agent used as an adjunct in the diagnosis of acute myocardial infarction. As an adjunct in the diagnosis of confirmed myocardial infarction (ECG and serum enzymes positive), the incidence of false negative images has been found to be 6%. False negative images can also occur if made too early in the evolutionary phase of the infarct or too late in the resolution phase. In a limited study involving 22 patients in whom the ECG was positive and serum enzymes questionable or negative, but in whom the final diagnosis of acute myocardial infarction was made, the incidence of false negative images was 23%. The incidence of false positive images has been found to be 7 to 9%. False positive images have been reported following coronary by-pass graft surgery, in unstable angina pectoris, old myocardial infarcts and in cardiac contusions. Technescan PYP is a blood pool imaging agent which may be used for gated blood pool imaging and for the detection of sites of gastrointestinal bleeding. When administered intravenously 15 to 30 minutes prior to intravenous administration of sodium pertechnetate Tc 99m for in vivo red blood cell labeling, approximately 75% of the injected activity remains in the blood pool. The modified in vivo/in vitro red blood cell labeling method may also be used for blood pool imaging. uuid:8c5a377f-4723-4b2b-b7ee-e303118d519b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:QI30938BMS biolink:treats UMLS:C0273112 PMID:41385096 "[{""id"":""uuid:be01c65f-7370-47c8-b5e9-6234e9694301"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ebe58a79-c686-4daa-a60a-59165c56406c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Technetium Tc 99m Pyrophosphate Injection is a skeletal imaging agent used to demonstrate areas of altered osteogenesis, and a cardiac imaging agent used as an adjunct in the diagnosis of acute myocardial infarction. As an adjunct in the diagnosis of confirmed myocardial infarction (ECG and serum enzymes positive), the incidence of false negative images has been found to be 6%. False negative images can also occur if made too early in the evolutionary phase of the infarct or too late in the resolution phase. In a limited study involving 22 patients in whom the ECG was positive and serum enzymes questionable or negative, but in whom the final diagnosis of acute myocardial infarction was made, the incidence of false negative images was 23%. The incidence of false positive images has been found to be 7 to 9%. False positive images have been reported following coronary by-pass graft surgery, in unstable angina pectoris, old myocardial infarcts and in cardiac contusions. Technescan PYP is a blood pool imaging agent which may be used for gated blood pool imaging and for the detection of sites of gastrointestinal bleeding. When administered intravenously 15 to 30 minutes prior to intravenous administration of sodium pertechnetate Tc 99m for in vivo red blood cell labeling, approximately 75% of the injected activity remains in the blood pool. The modified in vivo/in vitro red blood cell labeling method may also be used for blood pool imaging. uuid:24930243-c1b3-400e-a7a2-eeb5bc237269 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2WTV10SIKH biolink:treats MONDO:0003664 PMID:41385096 "[{""id"":""uuid:5d732764-f04e-46fa-a555-eea150e33ddd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d88e5504-63fa-4d01-a63f-fee2dcd1c2b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PYRUKYND is indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency. uuid:bb470685-bf00-4b4e-b8b6-0a8de1639875 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2WTV10SIKH biolink:treats MONDO:0009950 PMID:41385096 "[{""id"":""uuid:787dd41a-8bdb-4daa-8924-1a607c5c0fd8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f561e506-3259-4a12-a14f-0cc135aafdf0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:72410c8d-9259-4778-af13-f9c1e9a62f06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PYRUKYND is indicated for the treatment of hemolytic anemia in adults with pyruvate kinase (PK) deficiency.|[EMA] Pyrukynd is indicated for the treatment of pyruvate kinase deficiency (PK deficiency) in adult patients (see section 4.4). uuid:958e99aa-60aa-45eb-ad9c-a2a1a5406299 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90841 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:ba793b49-8f14-4de2-b42c-e1d5f48e1da3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8a64a248-9548-4583-8be1-4d26d1f38060"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KENGREAL is indicated as an adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y 12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor [see Clinical Studies ( 14.1 )]. uuid:52cc17bd-21a6-4a7b-a95a-c3292689c5f4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90841 biolink:treats UMLS:C3897493 PMID:41385096 "[{""id"":""uuid:1ecb110a-9ed2-4543-9a00-1d1f49447bcc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ecd34c6e-cee4-4bce-9a90-7bd58f7b3913"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KENGREAL is indicated as an adjunct to percutaneous coronary intervention (PCI) to reduce the risk of periprocedural myocardial infarction (MI), repeat coronary revascularization, and stent thrombosis (ST) in patients who have not been treated with a P2Y 12 platelet inhibitor and are not being given a glycoprotein IIb/IIIa inhibitor [see Clinical Studies ( 14.1 )]. uuid:564af876-5cee-4a65-a371-c426dfe4bb62 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90942 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:1fbd4e9a-4954-40a1-be6c-d7a7b77c4a47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:23e16801-7090-4cd1-ac25-d2f82600d2cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:333f08e8-e735-436f-b9fe-21e08bb9e840"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NINLARO is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.|[PMDA] Drugs with a new active ingredient indicated for the treatment of relapsed or refractory multiple myeloma. [Orphan drug] uuid:57297441-c866-4fa1-aabf-a54d52e17d16 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:140376 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:7282613d-c74a-413e-b6be-5fbcfe0f65a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2d3d31a8-08ab-4b2d-848c-f1bfad412240"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FETROJA is a cephalosporin antibacterial indicated in patients 18 years of age or older for the treatment of the following infections caused by susceptible Gram-negative microorganisms: Complicated Urinary Tract Infections (cUTI), including Pyelonephritis ( 1.1 ) Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP) ( 1.2 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of FETROJA and other antibacterial drugs, FETROJA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.3 ) uuid:d0d29c61-3848-49c2-b2fd-6a9e64c459b9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:140376 biolink:treats MONDO:0006939 PMID:41385096 "[{""id"":""uuid:932eac93-fb56-4074-8e16-218c8b5ba45c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e8b4a4fa-c190-460a-9716-3b3b47a589b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FETROJA is a cephalosporin antibacterial indicated in patients 18 years of age or older for the treatment of the following infections caused by susceptible Gram-negative microorganisms: Complicated Urinary Tract Infections (cUTI), including Pyelonephritis ( 1.1 ) Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP) ( 1.2 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of FETROJA and other antibacterial drugs, FETROJA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.3 ) uuid:3897ea49-dbdd-4897-8ecb-27e30f567b6f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:140376 biolink:treats MONDO:0004652 PMID:41385096 "[{""id"":""uuid:db4392b7-c81e-49bc-a94e-131dcb933232"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bfc58117-29b9-4f24-aae6-7c94f129b252"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FETROJA is a cephalosporin antibacterial indicated in patients 18 years of age or older for the treatment of the following infections caused by susceptible Gram-negative microorganisms: Complicated Urinary Tract Infections (cUTI), including Pyelonephritis ( 1.1 ) Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia (HABP/VABP) ( 1.2 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of FETROJA and other antibacterial drugs, FETROJA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.3 ) uuid:f33da447-1cb5-43d4-aa32-efd66642a6e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8389 biolink:treats UMLS:C3650625 PMID:41385096 "[{""id"":""uuid:5417df19-97e0-49ed-a7a2-346c926900c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d159d2bc-0c4a-4e0d-bf64-4186c882c819"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Premarin Intravenous (conjugated estrogens, USP) for injection is indicated in the treatment of abnormal uterine bleeding due to hormonal imbalance in the absence of organic pathology. Premarin Intravenous is indicated for short-term use only, to provide a rapid and temporary increase in estrogen levels. uuid:f91f8511-f105-4e1c-82fa-36bcea19b450 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51208 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:23b24b64-3756-4568-8710-1fc551143524"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7ea73e20-a4be-418d-92ac-9fa149958d8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PIVYA is a penicillin class antibacterial indicated for the treatment of female patients 18 years of age and older with uncomplicated urinary tract infections (uUTI) caused by susceptible isolates of Escherichia coli, Proteus mirabilis and Staphylococcus saprophyticus . ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of PIVYA and other antibacterial drugs, PIVYA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.2 ) uuid:c36b8640-3d35-495b-a4c2-4a5c8db5a554 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51208 biolink:treats MONDO:0020920 PMID:41385096 "[{""id"":""uuid:68b0c813-cd97-47f8-bec0-6a9dc69e7116"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c76a4755-0136-456c-a433-20f0d414582b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PIVYA is a penicillin class antibacterial indicated for the treatment of female patients 18 years of age and older with uncomplicated urinary tract infections (uUTI) caused by susceptible isolates of Escherichia coli, Proteus mirabilis and Staphylococcus saprophyticus . ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of PIVYA and other antibacterial drugs, PIVYA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.2 ) uuid:3f4ba4e6-3add-4a09-b1a2-40d4fe81fed9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51208 biolink:treats MONDO:0006929 PMID:41385096 "[{""id"":""uuid:d92a163b-58bf-4bb3-8ce7-57c523ef0a4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d45933bc-b80c-4a40-a5ec-6538956c6b0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PIVYA is a penicillin class antibacterial indicated for the treatment of female patients 18 years of age and older with uncomplicated urinary tract infections (uUTI) caused by susceptible isolates of Escherichia coli, Proteus mirabilis and Staphylococcus saprophyticus . ( 1.1 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of PIVYA and other antibacterial drugs, PIVYA should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.2 ) uuid:5770722f-9c29-40b4-864c-ab248b0e4d1c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5931 biolink:treats MONDO:0012819 PMID:41385096 "[{""id"":""uuid:df4a118e-0fff-4194-8ab1-0da586ee3187"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ae8cbd81-7620-4560-8159-9297866efd43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AFREZZA ® is a rapid acting inhaled human insulin indicated to improve glycemic control in adult patients with diabetes mellitus. Limitations of Use: AFREZZA is not recommended for the treatment of diabetic ketoacidosis [see Warning and Precautions ( 5.6 )] . The safety and effectiveness of AFREZZA in patients who smoke have not been established. The use of AFREZZA is not recommended in patients who smoke or who have recently stopped smoking. uuid:564346b1-330b-4deb-9445-2230d55a2a99 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3892 biolink:treats MONDO:0018097 PMID:41385096 "[{""id"":""uuid:3f49e571-b2e2-4cb5-a60f-fc4c255e9197"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9be7e295-188b-4aa7-9b59-a3d5c1ffaf0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acthar Gel is indicated as monotherapy for the treatment of infantile spasms in infants and children under 2 years of age. ( 1.1 ) Acthar Gel is indicated for the treatment of exacerbations of multiple sclerosis in adults. ( 1.2 ) Acthar Gel may be used for the following disorders and diseases: rheumatic ( 1.3 ); collagen ( 1.4 ); dermatologic ( 1.5 ); allergic states ( 1.6 ); ophthalmic ( 1.7 ); respiratory ( 1.8 ); and edematous state. ( 1.9 ) uuid:f71aa4cb-7f97-4557-97e9-8c86304d66d7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3892 biolink:treats MONDO:0005554 PMID:41385096 "[{""id"":""uuid:cb1e05b9-482c-4ce8-ad8a-04bb82a23e99"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:927986f3-e34c-4d60-9417-4af16b7198de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acthar Gel is indicated as monotherapy for the treatment of infantile spasms in infants and children under 2 years of age. ( 1.1 ) Acthar Gel is indicated for the treatment of exacerbations of multiple sclerosis in adults. ( 1.2 ) Acthar Gel may be used for the following disorders and diseases: rheumatic ( 1.3 ); collagen ( 1.4 ); dermatologic ( 1.5 ); allergic states ( 1.6 ); ophthalmic ( 1.7 ); respiratory ( 1.8 ); and edematous state. ( 1.9 ) uuid:6ba387eb-06bc-418f-8f06-989a099fe554 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3892 biolink:treats MONDO:0005093 PMID:41385096 "[{""id"":""uuid:061e4390-24a9-406f-baa4-96c9d42373af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b27a1467-7c68-46e4-9673-ac98fd6aa912"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acthar Gel is indicated as monotherapy for the treatment of infantile spasms in infants and children under 2 years of age. ( 1.1 ) Acthar Gel is indicated for the treatment of exacerbations of multiple sclerosis in adults. ( 1.2 ) Acthar Gel may be used for the following disorders and diseases: rheumatic ( 1.3 ); collagen ( 1.4 ); dermatologic ( 1.5 ); allergic states ( 1.6 ); ophthalmic ( 1.7 ); respiratory ( 1.8 ); and edematous state. ( 1.9 ) uuid:10828759-21f3-4587-837e-b7468d8b3e18 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3892 biolink:treats MONDO:0005271 PMID:41385096 "[{""id"":""uuid:d19236d0-6b91-4b15-9b09-f91821022d5d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:76092c57-ceff-4a88-9e53-f549ec563b05"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acthar Gel is indicated as monotherapy for the treatment of infantile spasms in infants and children under 2 years of age. ( 1.1 ) Acthar Gel is indicated for the treatment of exacerbations of multiple sclerosis in adults. ( 1.2 ) Acthar Gel may be used for the following disorders and diseases: rheumatic ( 1.3 ); collagen ( 1.4 ); dermatologic ( 1.5 ); allergic states ( 1.6 ); ophthalmic ( 1.7 ); respiratory ( 1.8 ); and edematous state. ( 1.9 ) uuid:eefe7e60-2037-4fdd-a5f1-ded296878e62 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3892 biolink:treats MONDO:0005328 PMID:41385096 "[{""id"":""uuid:393c0585-fb7f-4316-bcb9-e601020188f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cbcc7b61-84c1-4aab-8519-ab65fd9be335"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acthar Gel is indicated as monotherapy for the treatment of infantile spasms in infants and children under 2 years of age. ( 1.1 ) Acthar Gel is indicated for the treatment of exacerbations of multiple sclerosis in adults. ( 1.2 ) Acthar Gel may be used for the following disorders and diseases: rheumatic ( 1.3 ); collagen ( 1.4 ); dermatologic ( 1.5 ); allergic states ( 1.6 ); ophthalmic ( 1.7 ); respiratory ( 1.8 ); and edematous state. ( 1.9 ) uuid:0b84d175-63d5-4457-abef-8dd2465f0497 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3892 biolink:treats MONDO:0005087 PMID:41385096 "[{""id"":""uuid:34ea4bea-d5dc-48d5-9814-48c308be3b1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5d17c340-dd8c-48d0-8a63-257dd3ddda1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Acthar Gel is indicated as monotherapy for the treatment of infantile spasms in infants and children under 2 years of age. ( 1.1 ) Acthar Gel is indicated for the treatment of exacerbations of multiple sclerosis in adults. ( 1.2 ) Acthar Gel may be used for the following disorders and diseases: rheumatic ( 1.3 ); collagen ( 1.4 ); dermatologic ( 1.5 ); allergic states ( 1.6 ); ophthalmic ( 1.7 ); respiratory ( 1.8 ); and edematous state. ( 1.9 ) uuid:0cea4d97-bf31-4c03-afc4-533f3fac89d1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:ZL1R02VT79 biolink:treats MONDO:0005417 PMID:41385096 "[{""id"":""uuid:8a741310-10d2-4c6e-96c2-51ea33b8234e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:79d8e461-e2cf-482f-aa34-6598dda9c8ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7fdb7ce0-5632-4357-a926-27e2bc461865"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ranivisio""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] SUSVIMO (ranibizumab injection) is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with: Neovascular (wet) Age-related Macular Degeneration (AMD) who have previously responded to at least two intravitreal injections of a VEGF inhibitor ( 1.1 ). Diabetic Macular Edema (DME) who have previously responded to at least two intravitreal injections of a VEGF inhibitor ( 1.2 ). Diabetic Retinopathy (DR) who have previously responded to at least two intravitreal injections of a VEGF inhibitor ( 1.3 ).|[EMA] Ranivisio is indicated in adults for:• The treatment of neovascular (wet) age-related macular degeneration (AMD)• The treatment of visual impairment due to diabetic macular oedema (DME)• The treatment of proliferative diabetic retinopathy (PDR)• The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)• The treatment of visual impairment due to choroidal neovascularisation (CNV) uuid:8bc9fdf5-4d18-4cea-8dae-b2907d09060a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:ZL1R02VT79 biolink:treats MONDO:0004728 PMID:41385096 "[{""id"":""uuid:53952ceb-9858-4011-954f-65ccd0eba353"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3643b08f-95f3-47bb-a1d2-b98887232f19"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7582a02e-8db7-4167-977b-890ad6a4034c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ranivisio""]},{""id"":""uuid:9a18591e-5bae-443d-9027-b43931daeb92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SUSVIMO (ranibizumab injection) is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with: Neovascular (wet) Age-related Macular Degeneration (AMD) who have previously responded to at least two intravitreal injections of a VEGF inhibitor ( 1.1 ). Diabetic Macular Edema (DME) who have previously responded to at least two intravitreal injections of a VEGF inhibitor ( 1.2 ). Diabetic Retinopathy (DR) who have previously responded to at least two intravitreal injections of a VEGF inhibitor ( 1.3 ).|[EMA] Ranivisio is indicated in adults for:• The treatment of neovascular (wet) age-related macular degeneration (AMD)• The treatment of visual impairment due to diabetic macular oedema (DME)• The treatment of proliferative diabetic retinopathy (PDR)• The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)• The treatment of visual impairment due to choroidal neovascularisation (CNV)|[PMDA] A drug with a new additional indication for the treatment of diabetic macular edema. uuid:b7243209-d3d5-4e56-8f46-8cedc0264920 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:ZL1R02VT79 biolink:treats MONDO:0005266 PMID:41385096 "[{""id"":""uuid:6f01dc89-9061-44cb-8da6-085a7e4714bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0a873df3-2ae5-4723-8178-273fba47752f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SUSVIMO (ranibizumab injection) is a vascular endothelial growth factor (VEGF) inhibitor indicated for the treatment of patients with: Neovascular (wet) Age-related Macular Degeneration (AMD) who have previously responded to at least two intravitreal injections of a VEGF inhibitor ( 1.1 ). Diabetic Macular Edema (DME) who have previously responded to at least two intravitreal injections of a VEGF inhibitor ( 1.2 ). Diabetic Retinopathy (DR) who have previously responded to at least two intravitreal injections of a VEGF inhibitor ( 1.3 ). uuid:ea4a3253-8ad1-4ffa-813c-d19e5b0a73cc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4EQZ6YO2HI biolink:treats MONDO:0005298 PMID:41385096 "[{""id"":""uuid:a1822174-d656-47ed-8711-ff3c80a80d14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b54c2420-5d15-4d5a-b8c8-d442592ecac6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:6bd5a435-5ab5-48aa-bcda-06a9df307335"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/prolia""]},{""id"":""uuid:02b843a4-9c45-444c-b3ce-ce5dcc711ccb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Jubbonti is a RANK ligand (RANKL) inhibitor indicated for treatment: • of postmenopausal women with osteoporosis at high risk for fracture. ( 1.1 ) • to increase bone mass in men with osteoporosis at high risk for fracture. ( 1.2 ) • of glucocorticoid-induced osteoporosis in men and women at high risk for fracture. ( 1.3 ) • to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer. ( 1.4 ) • to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer. ( 1.5 )|[EMA] Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. In postmenopausal women Prolia significantly reduces the risk of vertebral, non vertebral and hip fractures.Treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures. In men with prostate cancer receiving hormone ablation, Prolia significantly reduces the risk of vertebral fractures.|[PMDA] A drug with a new indication and a new dosage for the treatment of osteoporosis. uuid:82b5512e-304a-4e9e-ab33-427daf7eebf5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4EQZ6YO2HI biolink:treats MONDO:0024651 PMID:41385096 "[{""id"":""uuid:fdf1537b-8c48-4380-a58d-6dada26cf847"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3267f7ec-8358-49cd-96d4-2c641cbb11de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Jubbonti is a RANK ligand (RANKL) inhibitor indicated for treatment: • of postmenopausal women with osteoporosis at high risk for fracture. ( 1.1 ) • to increase bone mass in men with osteoporosis at high risk for fracture. ( 1.2 ) • of glucocorticoid-induced osteoporosis in men and women at high risk for fracture. ( 1.3 ) • to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer. ( 1.4 ) • to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer. ( 1.5 ) uuid:c6b11081-5868-427b-9f90-eb5dc39a81e3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4EQZ6YO2HI biolink:treats MONDO:0008315 PMID:41385096 "[{""id"":""uuid:e03237e0-0c00-444d-bebf-2011eb2e97c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1deee6b0-5a53-4a29-a282-a5101c908830"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Jubbonti is a RANK ligand (RANKL) inhibitor indicated for treatment: • of postmenopausal women with osteoporosis at high risk for fracture. ( 1.1 ) • to increase bone mass in men with osteoporosis at high risk for fracture. ( 1.2 ) • of glucocorticoid-induced osteoporosis in men and women at high risk for fracture. ( 1.3 ) • to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer. ( 1.4 ) • to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer. ( 1.5 ) uuid:9d5e6b7f-4a9c-4b84-8fca-0a85d2f4f143 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4EQZ6YO2HI biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:2873e5c0-d105-4d66-a412-b3eb1d9b0c93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a7b8a630-8945-4ac8-be24-58e7c7bc889a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Jubbonti is a RANK ligand (RANKL) inhibitor indicated for treatment: • of postmenopausal women with osteoporosis at high risk for fracture. ( 1.1 ) • to increase bone mass in men with osteoporosis at high risk for fracture. ( 1.2 ) • of glucocorticoid-induced osteoporosis in men and women at high risk for fracture. ( 1.3 ) • to increase bone mass in men at high risk for fracture receiving androgen deprivation therapy for nonmetastatic prostate cancer. ( 1.4 ) • to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer. ( 1.5 ) uuid:701ab5fc-5534-4880-9df0-a7f1ebc77562 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4EQZ6YO2HI biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:2627b975-04cb-40b2-9957-32b5d00016f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c242fca9-0a9a-4bc4-85f9-9a87e99231eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:db46c19d-a250-4fa6-a298-9fbe00e146ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Wyost is a RANK ligand (RANKL) inhibitor indicated for: • Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. ( 1.1 ) • Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity. ( 1.2 , 14.3 ) • Treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy. ( 1.3 )|[PMDA] A drug with a new active ingredient indicated for the treatment of bone lesions due to multiple myeloma and bone lesions due to bone metastasis of solid tumor. uuid:37f12e1f-496c-44ac-838d-717c955eb143 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4EQZ6YO2HI biolink:treats UMLS:C0153690 PMID:41385096 "[{""id"":""uuid:ecae4927-3fce-4654-8551-780e58e1c962"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c0004d28-4347-4434-b3f4-7bceb18da1d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b6b8bb4c-8044-4b11-b761-f90a4e502779"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Wyost is a RANK ligand (RANKL) inhibitor indicated for: • Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. ( 1.1 ) • Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity. ( 1.2 , 14.3 ) • Treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy. ( 1.3 )|[PMDA] A drug with a new active ingredient indicated for the treatment of bone lesions due to multiple myeloma and bone lesions due to bone metastasis of solid tumor. uuid:0f4d925c-ff0d-4cfb-b914-18db25b09b8a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4EQZ6YO2HI biolink:treats MONDO:0005674 PMID:41385096 "[{""id"":""uuid:456030ba-9e69-42d8-befa-5c74c5455b12"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:24d60f4d-7bc8-4e43-8793-0c49eb3b6835"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c0eb7256-ba3b-4af2-a9ce-3ad302fa3f30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/prolia""]},{""id"":""uuid:f1b61ade-ea5b-4f6c-a620-159011d8ffeb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Wyost is a RANK ligand (RANKL) inhibitor indicated for: • Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. ( 1.1 ) • Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity. ( 1.2 , 14.3 ) • Treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy. ( 1.3 )|[EMA] Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone (see section 5.1).Treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity.|[PMDA] A drug with a new additional indication and a new dosage for the treatment of giant cell tumor of bone. [Orphan drug] uuid:3c8b44c5-3397-438c-944f-9f9d0baa151f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4EQZ6YO2HI biolink:treats MONDO:0043455 PMID:41385096 "[{""id"":""uuid:e1b3aa9b-f88b-49aa-85bf-1ded280e3eee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ba1e4638-4ea8-43c1-90fe-008a2a1b1dcd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Wyost is a RANK ligand (RANKL) inhibitor indicated for: • Prevention of skeletal-related events in patients with multiple myeloma and in patients with bone metastases from solid tumors. ( 1.1 ) • Treatment of adults and skeletally mature adolescents with giant cell tumor of bone that is unresectable or where surgical resection is likely to result in severe morbidity. ( 1.2 , 14.3 ) • Treatment of hypercalcemia of malignancy refractory to bisphosphonate therapy. ( 1.3 ) uuid:1b0fd58f-191c-4261-a7d1-6fa1779f04f3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17234 biolink:treats HP:0002013 PMID:41385096 "[{""id"":""uuid:7f83d791-08ef-4e63-8a75-a5f9eb9926c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f664b543-72d4-4512-9dbf-1c581c8623c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] (1) Energy and fluid supplementation;It is used for underfeeding or massive fluid loss caused by various reasons (such as vomiting, diarrhea, etc.), total intravenous nutrition, and starvation ketosis. (2) Drug diluents. uuid:a96bd006-85cf-47c7-95ee-5c72cb28cdde biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17234 biolink:treats MONDO:0001673 PMID:41385096 "[{""id"":""uuid:cb9a4b96-629b-4a8b-9fad-52ffaea240ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d7a4952f-1744-4d50-8816-cde84098fc75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] (1) Energy and fluid supplementation;It is used for underfeeding or massive fluid loss caused by various reasons (such as vomiting, diarrhea, etc.), total intravenous nutrition, and starvation ketosis. (2) Drug diluents. uuid:2c6f02ae-962e-4efb-9564-d12494ee3f0f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:L7451S9126 biolink:treats MONDO:0011382 PMID:41385096 "[{""id"":""uuid:309ef512-f128-43bb-96eb-bd02866f5fb2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d71b33b8-eb3e-4bab-8255-54a089e74ee7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ADAKVEO ® is indicated to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease. uuid:95faf645-01e5-4ff3-b98b-007af611596d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:L7451S9126 biolink:treats UMLS:C0750151 PMID:41385096 "[{""id"":""uuid:f2d6b942-cc76-44eb-8053-7215d9f4a5fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:81a45639-aeb8-4aa2-b771-32c019471724"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ADAKVEO ® is indicated to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged 16 years and older with sickle cell disease. uuid:2a21c701-e14d-4d6b-ba2f-21bc74f433b2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10385 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:377ef301-dd08-4649-aac2-23baa4aa02df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:67b16428-4aa1-4099-9e2f-7071eae8bf46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Studies have shown that properly performed an interpreted skin tests with ragweed pollen extract are useful in the diagnosis of allergy to ragweed pollen 7, 8, 20, 21 . Immunotherapy with the appropriate dosage of short ragweed pollen extract is effective in reducing symptoms of hay fever and asthma resulting from exposure to short ragweed pollen (9, 10, 11), and it is believed to be effective with extract of giant ragweed, although carefully controlled studies are unavailable. However, clinical observations and known cross reactivity between short and giant ragweed pollens have led to the practice of using a mixture of the two species for skin testing and treatment 22, 23, 24, 25, 26, 27 . This form of treatment is recommended for patients who cannot avoid exposure to pollen and who do not obtain satisfactory relief of symptoms from other medications, such as antihistamines. Immunologic changes resulting from treatment with short ragweed pollen extract are believed to include: The induction of specific anti-ragweed IgG antibodies commonly referred to as ""blocking antibodies"" 12, 13 . A decrease in the elevation of ragweed specific IgE during and immediately following the ragweed pollen season 14 . A reduction of circulating anti-ragweed IgE after long-term immunotherapy 15 . A decrease in skin reactivity to the extract 16 and a decrease in leukocyte sensitivity to histamine release 17 after long-term immunotherapy." uuid:76bd40ba-5068-4eaf-a9f3-c011d91d12b1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:50605O2ZNS biolink:treats MONDO:0005052 PMID:41385096 "[{""id"":""uuid:645f1c59-f171-41c4-aed5-944dc7f31f1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c96e7dd9-7cf4-44bf-9667-3d9b0058b8f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IBSRELA is indicated for treatment of irritable bowel syndrome with constipation (IBS-C) in adults. uuid:5d6aeb03-4ad1-43dd-90fb-06162de49d82 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:55KHL3P693 biolink:treats MONDO:0005277 PMID:41385096 "[{""id"":""uuid:3da25cb2-800d-4f80-a08e-d03cb5842648"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:45951890-c2ec-4341-997b-0b404418297f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ef19a1c9-9e02-43c3-a44e-8dcbd97608aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/emgality""]},{""id"":""uuid:e2e73dc6-a954-4637-a653-a48e2f185382"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EMGALITY ® is a calcitonin-gene related peptide antagonist indicated in adults for the: preventive treatment of migraine. ( 1.1 ) treatment of episodic cluster headache. ( 1.2 )|[EMA] Emgality is indicated for the prophylaxis of migraine in adults who have at least 4 migraine days per month.|[PMDA] Drugs with a new active ingredient indicated for the prevention of migraine attacks. uuid:88546f2d-dd5a-4407-9fb5-27a67d9ae652 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:55KHL3P693 biolink:treats UMLS:C0393739 PMID:41385096 "[{""id"":""uuid:a763d59f-b175-4921-a69e-e8113d10992c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:73d58206-8adc-4804-b4df-915b92d22c23"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EMGALITY ® is a calcitonin-gene related peptide antagonist indicated in adults for the: preventive treatment of migraine. ( 1.1 ) treatment of episodic cluster headache. ( 1.2 ) uuid:e757f709-72c7-490e-adc1-e096ec1d8a9d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229599 biolink:treats MONDO:0010726 PMID:41385096 "[{""id"":""uuid:912a466e-6443-4789-9793-c83142171cad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:219a0f5a-10ad-45d6-a7b3-63ae678e03fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DAYBUE is indicated for the treatment of Rett syndrome in adults and pediatric patients 2 years of age and older. uuid:d7a8198e-1583-48dd-94d9-d8243737bcfe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27436 biolink:treats MONDO:0008573 PMID:41385096 "[{""id"":""uuid:1ef02566-0891-44cc-8af9-bc194e9a97d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5d536678-ba2f-493c-ae06-bd5d770e83de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1. Males Androgens are indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenita or acquired) — Testicular failure due to cryptohidism, bilateral torsion, orchitis, vanishing testis syndrome, or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired) — Gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. (Appropriate adrenal cortical and thyroid hormone replacement therapy are still necessary, however, and are actually of primary importance.) If the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sexual characteristics. Prolonged androgen treatment will be required to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty. Safety and efficacy of methyltestosterone in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established. Androgens may be used to stimulate puberty in carefully selected males with clearly delayed puberty. These patients usually have a familial pattern of delayed puberty that is not secondary to a pathological disorder; puberty is expected to occur spontaneously at a relatively late date. Brief treatment with conservative doses may occasionally be justified in these patients if they do not respond to psychological support. The potential adverse effect on bone maturation should be discussed with the patient and parents prior to androgen administration. An X-ray of the hand and wrist to determine bone age should be obtained every 6 months to assess the effect of treatment on the epiphyseal centers (see WARNINGS ). 2. Females Androgens may be used secondarily in women with advancing inoperable metastatic (skeletal) mammary cancer who are 1 to 5 years postmenopausal. Primary goals of therapy in these women include ablation of the ovaries. Other methods of counteracting estrogen activity are adrenalectomy, hypophysectomy, and/or antiestrogen therapy. This treatment has also been used in premenopausal women with breast cancer who have benefitted from oophorectomy and are considered to have a hormone-responsive tumor. Judgment concerning androgen therapy should be made by an oncologist with expertise in this field. uuid:c3326bf9-10b3-45d8-8472-b42c9dcd3927 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:U9JLP7V031 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:7f1d2644-df30-4c8f-bc3a-9ece72e03529"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:17b0da17-c329-47e7-8429-65cbddb49bbd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f189ed0e-05fe-4fbc-a3ad-42b37ab33592"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ebglyss""]},{""id"":""uuid:377f875e-e005-42d5-a032-a510a88fa52c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EBGLYSS is indicated for the treatment of adults and pediatric patients 12 years of age and older who weigh at least 40 kg with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. EBGLYSS can be used with or without topical corticosteroids.|[EMA] Ebglyss is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy.|[PMDA] Drugs with a new active ingredient indicated for the treatment of atopic dermatitis in patients who have not responded sufficiently to conventional treatments. uuid:a43047d0-7fcc-45bb-86a3-19b3fd395aef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27436 biolink:treats MONDO:0002146 PMID:41385096 "[{""id"":""uuid:0fba0402-0c93-4086-ad9b-6237490c86b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4204548e-cde4-49bc-b39e-cc368bb6d857"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Androgens are indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) — testicular failure due to cryptorchidism, bilateral torsions, orchitis, vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired) — gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary hypothalamic injury from tumors, trauma, or radiation. (Appropriate adrenal cortical and thyroid hormone replacement therapy are still necessary, however, and are actually of primary importance.) If the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sexual characteristics. Prolonged androgen treatment will be required to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty. Safety and efficacy of methyltestosterone in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established. Androgens may be used to stimulate puberty in carefully selected males with clearly delayed puberty. These patients usually have a familial pattern of delayed puberty that is not secondary to a pathological disorder; puberty is expected to occur spontaneously at a relatively late date. Brief treatment with conservative doses may occasionally be justified in these patients if they do not respond to psychological support. The potential adverse effect on bone maturation should be discussed with the patient and parents prior to androgen administration. An X-ray of the hand and wrist to determine bone age should be obtained every 6 months to assess the effect of treatment on the epiphyseal centers (see WARNINGS ). uuid:a243bccb-58e6-46b7-97f9-b8f0662a1925 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27436 biolink:treats UMLS:C1963961 PMID:41385096 "[{""id"":""uuid:7023aea0-4a92-43b1-b9da-7df0176caa8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7e187306-4123-4b93-84bf-e8196a967cf0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Androgens are indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone: Primary hypogonadism (congenital or acquired) — testicular failure due to cryptorchidism, bilateral torsions, orchitis, vanishing testis syndrome; or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired) — gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary hypothalamic injury from tumors, trauma, or radiation. (Appropriate adrenal cortical and thyroid hormone replacement therapy are still necessary, however, and are actually of primary importance.) If the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sexual characteristics. Prolonged androgen treatment will be required to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty. Safety and efficacy of methyltestosterone in men with “age-related hypogonadism” (also referred to as “late-onset hypogonadism”) have not been established. Androgens may be used to stimulate puberty in carefully selected males with clearly delayed puberty. These patients usually have a familial pattern of delayed puberty that is not secondary to a pathological disorder; puberty is expected to occur spontaneously at a relatively late date. Brief treatment with conservative doses may occasionally be justified in these patients if they do not respond to psychological support. The potential adverse effect on bone maturation should be discussed with the patient and parents prior to androgen administration. An X-ray of the hand and wrist to determine bone age should be obtained every 6 months to assess the effect of treatment on the epiphyseal centers (see WARNINGS ). uuid:b7c9c7b3-3b4a-4364-bc43-214f1c002957 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10499 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:58ca7acb-cd45-4661-b343-d35ea5c68c09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0646077b-dd8c-4050-8122-15ae6a5eaf9d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Studies have shown that skin tests with cat extract are useful in the diagnosis of cat allergy. As a rule, persons with cat allergy have positive skin reactions when tested with cat extract, and non-allergic individuals rarely react (7, 8, 9). However, the relationship between a positive skin test and the appearance of clinical symptoms after exposure to a cat is not absolute, i.e., some skin-test positive persons do not experience allergic symptoms after exposure (10). Failure to experience symptoms may be dose related, since it is known that cats vary significantly in the amount of Fel d1 they produce (11). The efficacy of cat extract immunotherapy in the treatment of bronchial asthma has been shown in two studies (12, 13) A reduction in bronchial sensitivity was observed in five patients with cat allergy, whereas no reduction was observed in placebo treated, cat-allergic patients. uuid:49cdeb31-db0e-49e9-8ca0-cf96e14e2b56 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:66901 biolink:treats MONDO:0009061 PMID:41385096 "[{""id"":""uuid:c1342fbb-7526-4f2e-8ac3-c9c6834e7144"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0fc573aa-1b38-4332-8387-aae1fd3d879a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0ddb1568-9b4f-4cc2-b319-29ae8b8bbea4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kalydeco""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] KALYDECO is indicated for the treatment of cystic fibrosis (CF) in patients aged 1 month and older who have at least one mutation in the CFTR gene that is responsive to ivacaftor potentiation based on clinical and/or in vitro assay data [see Clinical Pharmacology (12.1) and Clinical Studies (14) ] . If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of a CFTR mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use.|[EMA] Kalydeco tablets are indicated:As monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (CF) who have an R117H CFTR mutation or one of the following gating (class III) mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R (see sections 4.4 and 5.1).In a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (CF) who are homozygous for the F508del mutation or who are heterozygous for the F508del mutation and have one of the following mutations in the CFTR gene: P67L, R117C, L206W, R352Q, A455E, D579G, 711+3A→G, S945L, S977F, R1070W, D1152H, 2789+5G→A, 3272 26A→G, and 3849+10kbC→T.In a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (CF) who have at least one F508del mutation in the CFTR gene (see section 5.1).Kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (CF) who have an R117H CFTR mutation or one of the following gating (class III) mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R (see sections 4.4 and 5.1).In a combination regimen with ivacaftor/tezacaftor/elexacaftor for the treatment of cystic fibrosis (CF) in paediatric patients aged 2 to less than 6 years who have at least one F508del mutation in the CFTR gene. uuid:b5b9b5a8-2070-475c-a2f0-d69b0a55d975 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10400 biolink:treats UMLS:C4087338 PMID:41385096 "[{""id"":""uuid:093d1287-3873-4fba-a928-2b8012dedb7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e8373325-56a6-428e-a69a-170f559dbba4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Standardized mite extract is indicated for use in the diagnosis of patients with a history of allergy to mites or house dust and for the treatment of patients with a history of mite allergy who have established sensitivity to mites by diagnostic skin testing. The use of mite extract for the above purposes should be made only by physicians with special familiarity and knowledge of allergy as described in a standard allergy textbook (10). uuid:17b035af-cbd5-4c58-91ad-1ad826de7bed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85994 biolink:treats MONDO:0015447 PMID:41385096 "[{""id"":""uuid:a0815477-7063-4de2-813b-36a3fe58f5a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2511d900-7d34-4bb5-8486-e5541521d349"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:35b386a9-2a3a-4436-8e19-3aacea54b255"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LENVIMA is a kinase inhibitor that is indicated: Differentiated Thyroid Cancer (DTC) For the treatment of adult patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC). ( 1.1 ) Renal Cell Carcinoma (RCC) In combination with pembrolizumab, for the first line treatment of adult patients with advanced renal cell carcinoma (RCC). ( 1.2 ) In combination with everolimus, for the treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior anti-angiogenic therapy. ( 1.2 ) Hepatocellular Carcinoma (HCC) For the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). ( 1.3 ) Endometrial Carcinoma (EC) In combination with pembrolizumab, for the treatment of patients with advanced endometrial carcinoma (EC) that is mismatch repair proficient (pMMR) or not microsatellite instability-high (MSI-H), as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.4 , 2.1 )|[EMA] Lenvima is indicated as monotherapy for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI).Lenvima is indicated as monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systemic therapy. uuid:40e74558-988b-4806-8ffa-088b0aec9901 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85994 biolink:treats MONDO:0005086 PMID:41385096 "[{""id"":""uuid:eeec8958-056a-4856-87e3-55bc19cf897e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:85d63d57-c04e-484f-997a-e298b9efc68d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4db0d369-61b7-41ef-bc42-5bf7fd71c8d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a12b32ab-2c95-4156-8435-4e5c7e8902d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LENVIMA is a kinase inhibitor that is indicated: Differentiated Thyroid Cancer (DTC) For the treatment of adult patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC). ( 1.1 ) Renal Cell Carcinoma (RCC) In combination with pembrolizumab, for the first line treatment of adult patients with advanced renal cell carcinoma (RCC). ( 1.2 ) In combination with everolimus, for the treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior anti-angiogenic therapy. ( 1.2 ) Hepatocellular Carcinoma (HCC) For the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). ( 1.3 ) Endometrial Carcinoma (EC) In combination with pembrolizumab, for the treatment of patients with advanced endometrial carcinoma (EC) that is mismatch repair proficient (pMMR) or not microsatellite instability-high (MSI-H), as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.4 , 2.1 )|[EMA] Kisplyx is indicated for the treatment of adults with advanced renal cell carcinoma (RCC):in combination with pembrolizumab, as first-line treatment (see section 5.1).in combination with everolimus, following one prior vascular endothelial growth factor (VEGF)-targeted therapy.|[PMDA] Drugs with a new indication and a new dosage for the treatment of unresectable or metastatic renal cell carcinoma. uuid:213a196c-30a1-471f-905c-fb2e6eefc97a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85994 biolink:treats MONDO:0007256 PMID:41385096 "[{""id"":""uuid:24b6383e-dc17-4fbf-86cf-17aa9900f5a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:db171e87-d7fa-44ee-a291-959cfb81f9f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:cedf11c5-6d8c-44e4-bcae-dd8d104422d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c0044b4a-603d-46e2-8df5-5f87f91596de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LENVIMA is a kinase inhibitor that is indicated: Differentiated Thyroid Cancer (DTC) For the treatment of adult patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC). ( 1.1 ) Renal Cell Carcinoma (RCC) In combination with pembrolizumab, for the first line treatment of adult patients with advanced renal cell carcinoma (RCC). ( 1.2 ) In combination with everolimus, for the treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior anti-angiogenic therapy. ( 1.2 ) Hepatocellular Carcinoma (HCC) For the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). ( 1.3 ) Endometrial Carcinoma (EC) In combination with pembrolizumab, for the treatment of patients with advanced endometrial carcinoma (EC) that is mismatch repair proficient (pMMR) or not microsatellite instability-high (MSI-H), as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.4 , 2.1 )|[EMA] Lenvima is indicated as monotherapy for the treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI).Lenvima is indicated as monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systemic therapy.|[PMDA] A drug with a new additional indication and a new dosage indicated for the treatment of unresectable hepatic cell carcinoma. uuid:2f4eed5e-1a45-4289-8064-e8af657c2bff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85994 biolink:treats MONDO:0002447 PMID:41385096 "[{""id"":""uuid:9fcf3fa4-c637-4258-8cc6-98ed6c254e58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:276b65de-e8f3-4750-8844-e0e27c8f059f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:cf0bcd5a-0bda-438c-bcdd-863b228c2f80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LENVIMA is a kinase inhibitor that is indicated: Differentiated Thyroid Cancer (DTC) For the treatment of adult patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC). ( 1.1 ) Renal Cell Carcinoma (RCC) In combination with pembrolizumab, for the first line treatment of adult patients with advanced renal cell carcinoma (RCC). ( 1.2 ) In combination with everolimus, for the treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior anti-angiogenic therapy. ( 1.2 ) Hepatocellular Carcinoma (HCC) For the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). ( 1.3 ) Endometrial Carcinoma (EC) In combination with pembrolizumab, for the treatment of patients with advanced endometrial carcinoma (EC) that is mismatch repair proficient (pMMR) or not microsatellite instability-high (MSI-H), as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.4 , 2.1 )|[PMDA] Drugs with a new indication and a new dosage for the treatment of unresectable advanced or recurrent endometrial carcinoma that has progressed after cancer chemotherapy. [Orphan drug] uuid:7dc0d546-1ba0-40b8-b6b7-cd0444f4cbbe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8060 biolink:treats MONDO:0001485 PMID:41385096 "[{""id"":""uuid:f79c7756-a116-4293-98e3-79770e2c8703"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:064b7f82-2be6-4009-adef-ee3fa0b1e759"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Phenelzine sulfate has been found to be effective in depressed patients clinically characterized as ""atypical,"" ""nonendogenous,"" or ""neurotic."" These patients often have mixed anxiety and depression and phobic or hypochondriacal features. There is less conclusive evidence of its usefulness with severely depressed patients with endogenous features. Phenelzine sulfate should rarely be the first antidepressant drug used. Rather, it is more suitable for use with patients who have failed to respond to the drugs more commonly used for these conditions." uuid:bba30589-8ea1-4ac1-adc6-b8508114ca50 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8060 biolink:treats MONDO:0024614 PMID:41385096 "[{""id"":""uuid:41253c8c-aaa5-49f8-9724-5a18287b6430"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6a0524ee-d038-4445-98fb-dfd0d0e8fbbe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] Phenelzine sulfate has been found to be effective in depressed patients clinically characterized as ""atypical,"" ""nonendogenous,"" or ""neurotic."" These patients often have mixed anxiety and depression and phobic or hypochondriacal features. There is less conclusive evidence of its usefulness with severely depressed patients with endogenous features. Phenelzine sulfate should rarely be the first antidepressant drug used. Rather, it is more suitable for use with patients who have failed to respond to the drugs more commonly used for these conditions." uuid:b36ea85e-b57c-4e8e-8dd8-f11579aed62b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6T8C155666 biolink:treats MONDO:0005105 PMID:41385096 "[{""id"":""uuid:f2280d25-be30-435d-b39a-b94ac8bd874b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3fe63d67-531b-42cb-a426-c2192ac5b7d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:cea7508e-dd2e-4012-90d3-bfcb66e7f229"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/yervoy""]},{""id"":""uuid:5fcdf760-1ee5-4a32-9c78-7f73defad386"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for: Melanoma • Treatment of unresectable or metastatic melanoma in adults and pediatric patients 12 years and older as a single agent or in combination with nivolumab. (1.1) • Adjuvant treatment of adult patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy. (1.2) Renal Cell Carcinoma (RCC) • Treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma, as first-line treatment in combination with nivolumab. (1.3) Colorectal Cancer • Treatment of adults and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with nivolumab. (1.4) Hepatocellular Carcinoma • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) as first-line treatment in combination with nivolumab. ( 1.5 ) • in combination with nivolumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. (1.5) Non-Small Cell Lung Cancer (NSCLC) • Treatment of adult patients with metastatic non-small cell lung cancer expressing PD-L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with nivolumab. (1.6) • Treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy. (1.6) Malignant Pleural Mesothelioma • Treatment of adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with nivolumab. (1.7) Esophageal Cancer • Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab whose tumors express PD-L1 (≥1). (1.8)|[EMA] MelanomaYERVOY as monotherapy or combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older (see section 4.4). YERVOY in combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults.Relative to nivolumab monotherapy, an increase in progression-free survival (PFS) and overall survival (OS) for the combination of nivolumab with ipilimumab is established only in patients with low tumour PD-L1 expression (see sections 4.4 and 5.1).Renal cell carcinoma (RCC)YERVOY in combination with nivolumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (see section 5.1).Non-small cell lung cancer (NSCLC)YERVOY in combination with nivolumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising EGFR mutation or ALK translocation.Malignant pleural mesothelioma (MPM)YERVOY in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma.Mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC)YERVOY in combination with nivolumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy (see section 5.1).Oesophageal squamous cell carcinoma (OSCC)YERVOY in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression ≥ 1%.|[PMDA] A drug with a new active ingredient indicated for the treatment of unresectable melanoma. [Orphan drug] uuid:f8153206-06b1-4513-a60b-fb17ad743109 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6T8C155666 biolink:treats MONDO:0005191 PMID:41385096 "[{""id"":""uuid:57f401ba-722d-40b6-90e9-2ca3cc226268"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3d9d990f-7ee7-4e84-9ce2-6bd85c9c6f8e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for: Melanoma • Treatment of unresectable or metastatic melanoma in adults and pediatric patients 12 years and older as a single agent or in combination with nivolumab. (1.1) • Adjuvant treatment of adult patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy. (1.2) Renal Cell Carcinoma (RCC) • Treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma, as first-line treatment in combination with nivolumab. (1.3) Colorectal Cancer • Treatment of adults and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with nivolumab. (1.4) Hepatocellular Carcinoma • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) as first-line treatment in combination with nivolumab. ( 1.5 ) • in combination with nivolumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. (1.5) Non-Small Cell Lung Cancer (NSCLC) • Treatment of adult patients with metastatic non-small cell lung cancer expressing PD-L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with nivolumab. (1.6) • Treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy. (1.6) Malignant Pleural Mesothelioma • Treatment of adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with nivolumab. (1.7) Esophageal Cancer • Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab whose tumors express PD-L1 (≥1). (1.8) uuid:1b922a19-147a-49d8-befc-8a9532ec601d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6T8C155666 biolink:treats MONDO:0005012 PMID:41385096 "[{""id"":""uuid:201c9494-e9c6-4e94-9d6d-252bf3cd4326"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9d153fb7-72bb-4947-9366-803de65f0e18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for: Melanoma • Treatment of unresectable or metastatic melanoma in adults and pediatric patients 12 years and older as a single agent or in combination with nivolumab. (1.1) • Adjuvant treatment of adult patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy. (1.2) Renal Cell Carcinoma (RCC) • Treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma, as first-line treatment in combination with nivolumab. (1.3) Colorectal Cancer • Treatment of adults and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with nivolumab. (1.4) Hepatocellular Carcinoma • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) as first-line treatment in combination with nivolumab. ( 1.5 ) • in combination with nivolumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. (1.5) Non-Small Cell Lung Cancer (NSCLC) • Treatment of adult patients with metastatic non-small cell lung cancer expressing PD-L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with nivolumab. (1.6) • Treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy. (1.6) Malignant Pleural Mesothelioma • Treatment of adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with nivolumab. (1.7) Esophageal Cancer • Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab whose tumors express PD-L1 (≥1). (1.8) uuid:b6e92808-83d1-4481-8190-c2f027197270 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6T8C155666 biolink:treats MONDO:0005086 PMID:41385096 "[{""id"":""uuid:8af68504-6aa3-4c00-ad45-fcfc97448c2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:73c531da-0ef8-4dfd-b0eb-e5724c70fbc1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f8194881-e0a4-4f19-9ac4-e2b1fdb8a22f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/yervoy""]},{""id"":""uuid:6ff7642c-b8ac-48f8-8ab7-78d5ed72e449"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for: Melanoma • Treatment of unresectable or metastatic melanoma in adults and pediatric patients 12 years and older as a single agent or in combination with nivolumab. (1.1) • Adjuvant treatment of adult patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy. (1.2) Renal Cell Carcinoma (RCC) • Treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma, as first-line treatment in combination with nivolumab. (1.3) Colorectal Cancer • Treatment of adults and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with nivolumab. (1.4) Hepatocellular Carcinoma • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) as first-line treatment in combination with nivolumab. ( 1.5 ) • in combination with nivolumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. (1.5) Non-Small Cell Lung Cancer (NSCLC) • Treatment of adult patients with metastatic non-small cell lung cancer expressing PD-L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with nivolumab. (1.6) • Treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy. (1.6) Malignant Pleural Mesothelioma • Treatment of adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with nivolumab. (1.7) Esophageal Cancer • Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab whose tumors express PD-L1 (≥1). (1.8)|[EMA] MelanomaYERVOY as monotherapy or combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older (see section 4.4). YERVOY in combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults.Relative to nivolumab monotherapy, an increase in progression-free survival (PFS) and overall survival (OS) for the combination of nivolumab with ipilimumab is established only in patients with low tumour PD-L1 expression (see sections 4.4 and 5.1).Renal cell carcinoma (RCC)YERVOY in combination with nivolumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (see section 5.1).Non-small cell lung cancer (NSCLC)YERVOY in combination with nivolumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising EGFR mutation or ALK translocation.Malignant pleural mesothelioma (MPM)YERVOY in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma.Mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC)YERVOY in combination with nivolumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy (see section 5.1).Oesophageal squamous cell carcinoma (OSCC)YERVOY in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression ≥ 1%.|[PMDA] A drug with a new indication and a new dosage for the treatment of unresectable or metastatic renal cell carcinoma. [Priority review] uuid:2f36f70b-ffc1-4978-a7b5-4251321da5e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6T8C155666 biolink:treats UMLS:C4727069 PMID:41385096 "[{""id"":""uuid:c6e593f6-4100-4284-8f6f-4cf3e14e3f95"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d5e93973-f24c-4ba5-baad-994bb949fa7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for: Melanoma • Treatment of unresectable or metastatic melanoma in adults and pediatric patients 12 years and older as a single agent or in combination with nivolumab. (1.1) • Adjuvant treatment of adult patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy. (1.2) Renal Cell Carcinoma (RCC) • Treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma, as first-line treatment in combination with nivolumab. (1.3) Colorectal Cancer • Treatment of adults and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with nivolumab. (1.4) Hepatocellular Carcinoma • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) as first-line treatment in combination with nivolumab. ( 1.5 ) • in combination with nivolumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. (1.5) Non-Small Cell Lung Cancer (NSCLC) • Treatment of adult patients with metastatic non-small cell lung cancer expressing PD-L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with nivolumab. (1.6) • Treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy. (1.6) Malignant Pleural Mesothelioma • Treatment of adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with nivolumab. (1.7) Esophageal Cancer • Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab whose tumors express PD-L1 (≥1). (1.8) uuid:a593282b-d7bf-4cf7-b502-3c8b107150df biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6T8C155666 biolink:treats MONDO:0005575 PMID:41385096 "[{""id"":""uuid:4999259d-508d-4e80-82e0-269577728f7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:15a993c0-8421-4979-9f7f-477d17ad7e73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ed59a433-2edf-42db-aa16-7a3b08b33c8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/yervoy""]},{""id"":""uuid:7652bda0-b74f-4ca1-ac1a-2d4e9800244c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for: Melanoma • Treatment of unresectable or metastatic melanoma in adults and pediatric patients 12 years and older as a single agent or in combination with nivolumab. (1.1) • Adjuvant treatment of adult patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy. (1.2) Renal Cell Carcinoma (RCC) • Treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma, as first-line treatment in combination with nivolumab. (1.3) Colorectal Cancer • Treatment of adults and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with nivolumab. (1.4) Hepatocellular Carcinoma • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) as first-line treatment in combination with nivolumab. ( 1.5 ) • in combination with nivolumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. (1.5) Non-Small Cell Lung Cancer (NSCLC) • Treatment of adult patients with metastatic non-small cell lung cancer expressing PD-L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with nivolumab. (1.6) • Treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy. (1.6) Malignant Pleural Mesothelioma • Treatment of adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with nivolumab. (1.7) Esophageal Cancer • Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab whose tumors express PD-L1 (≥1). (1.8)|[EMA] MelanomaYERVOY as monotherapy or combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older (see section 4.4). YERVOY in combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults.Relative to nivolumab monotherapy, an increase in progression-free survival (PFS) and overall survival (OS) for the combination of nivolumab with ipilimumab is established only in patients with low tumour PD-L1 expression (see sections 4.4 and 5.1).Renal cell carcinoma (RCC)YERVOY in combination with nivolumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (see section 5.1).Non-small cell lung cancer (NSCLC)YERVOY in combination with nivolumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising EGFR mutation or ALK translocation.Malignant pleural mesothelioma (MPM)YERVOY in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma.Mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC)YERVOY in combination with nivolumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy (see section 5.1).Oesophageal squamous cell carcinoma (OSCC)YERVOY in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression ≥ 1%.|[PMDA] A drug with a new indication for the treatment of unresectable advanced or recurrent microsatellite instability-high (MSI-High) colorectal cancer that has progressed after cancer chemotherapy. uuid:d78dc9ee-3921-41df-9f3e-34fdad5f8baa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6T8C155666 biolink:treats UMLS:C4544822 PMID:41385096 "[{""id"":""uuid:a8702d20-e33f-48ad-a77c-5ffe3146b6ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:964e3760-302b-4451-8f14-edc9e9c09164"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for: Melanoma • Treatment of unresectable or metastatic melanoma in adults and pediatric patients 12 years and older as a single agent or in combination with nivolumab. (1.1) • Adjuvant treatment of adult patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy. (1.2) Renal Cell Carcinoma (RCC) • Treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma, as first-line treatment in combination with nivolumab. (1.3) Colorectal Cancer • Treatment of adults and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with nivolumab. (1.4) Hepatocellular Carcinoma • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) as first-line treatment in combination with nivolumab. ( 1.5 ) • in combination with nivolumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. (1.5) Non-Small Cell Lung Cancer (NSCLC) • Treatment of adult patients with metastatic non-small cell lung cancer expressing PD-L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with nivolumab. (1.6) • Treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy. (1.6) Malignant Pleural Mesothelioma • Treatment of adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with nivolumab. (1.7) Esophageal Cancer • Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab whose tumors express PD-L1 (≥1). (1.8) uuid:ea674ce6-bb56-4a2c-97f9-2591e768ab51 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6T8C155666 biolink:treats MONDO:0007256 PMID:41385096 "[{""id"":""uuid:45ea9094-a929-4b7e-b2c4-4b622a76cf5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5cc51431-e2c8-46c6-a100-7259b45b1a32"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for: Melanoma • Treatment of unresectable or metastatic melanoma in adults and pediatric patients 12 years and older as a single agent or in combination with nivolumab. (1.1) • Adjuvant treatment of adult patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy. (1.2) Renal Cell Carcinoma (RCC) • Treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma, as first-line treatment in combination with nivolumab. (1.3) Colorectal Cancer • Treatment of adults and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with nivolumab. (1.4) Hepatocellular Carcinoma • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) as first-line treatment in combination with nivolumab. ( 1.5 ) • in combination with nivolumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. (1.5) Non-Small Cell Lung Cancer (NSCLC) • Treatment of adult patients with metastatic non-small cell lung cancer expressing PD-L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with nivolumab. (1.6) • Treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy. (1.6) Malignant Pleural Mesothelioma • Treatment of adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with nivolumab. (1.7) Esophageal Cancer • Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab whose tumors express PD-L1 (≥1). (1.8) uuid:bc2a9f0c-ef92-4b6c-9f34-d1620a2c5c90 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6T8C155666 biolink:treats UMLS:C0744869 PMID:41385096 "[{""id"":""uuid:88a3a33a-6547-4ae6-8af8-be113a5bdd7d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ee551a72-28ee-40b2-9136-7fca4e1677b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for: Melanoma • Treatment of unresectable or metastatic melanoma in adults and pediatric patients 12 years and older as a single agent or in combination with nivolumab. (1.1) • Adjuvant treatment of adult patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy. (1.2) Renal Cell Carcinoma (RCC) • Treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma, as first-line treatment in combination with nivolumab. (1.3) Colorectal Cancer • Treatment of adults and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with nivolumab. (1.4) Hepatocellular Carcinoma • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) as first-line treatment in combination with nivolumab. ( 1.5 ) • in combination with nivolumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. (1.5) Non-Small Cell Lung Cancer (NSCLC) • Treatment of adult patients with metastatic non-small cell lung cancer expressing PD-L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with nivolumab. (1.6) • Treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy. (1.6) Malignant Pleural Mesothelioma • Treatment of adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with nivolumab. (1.7) Esophageal Cancer • Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab whose tumors express PD-L1 (≥1). (1.8) uuid:4d78d4df-2ba3-4ef3-932b-7f373a267443 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6T8C155666 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:e3b039db-1014-459c-871e-e019076fe134"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5564925c-1baa-46c2-92a5-40315b6c9d16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b766881f-e665-4b6b-adfd-c6881181e7ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/yervoy""]},{""id"":""uuid:80a4ca7b-0302-4cb4-a395-984e221eb03e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for: Melanoma • Treatment of unresectable or metastatic melanoma in adults and pediatric patients 12 years and older as a single agent or in combination with nivolumab. (1.1) • Adjuvant treatment of adult patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy. (1.2) Renal Cell Carcinoma (RCC) • Treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma, as first-line treatment in combination with nivolumab. (1.3) Colorectal Cancer • Treatment of adults and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with nivolumab. (1.4) Hepatocellular Carcinoma • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) as first-line treatment in combination with nivolumab. ( 1.5 ) • in combination with nivolumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. (1.5) Non-Small Cell Lung Cancer (NSCLC) • Treatment of adult patients with metastatic non-small cell lung cancer expressing PD-L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with nivolumab. (1.6) • Treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy. (1.6) Malignant Pleural Mesothelioma • Treatment of adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with nivolumab. (1.7) Esophageal Cancer • Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab whose tumors express PD-L1 (≥1). (1.8)|[EMA] MelanomaYERVOY as monotherapy or combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older (see section 4.4). YERVOY in combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults.Relative to nivolumab monotherapy, an increase in progression-free survival (PFS) and overall survival (OS) for the combination of nivolumab with ipilimumab is established only in patients with low tumour PD-L1 expression (see sections 4.4 and 5.1).Renal cell carcinoma (RCC)YERVOY in combination with nivolumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (see section 5.1).Non-small cell lung cancer (NSCLC)YERVOY in combination with nivolumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising EGFR mutation or ALK translocation.Malignant pleural mesothelioma (MPM)YERVOY in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma.Mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC)YERVOY in combination with nivolumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy (see section 5.1).Oesophageal squamous cell carcinoma (OSCC)YERVOY in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression ≥ 1%.|[PMDA] A drug with a new indication and a new dosage for the treatment of unresectable advanced or recurrent non- small cell lung cancer. uuid:d8bd8783-a8fc-4660-bfc3-5d69e145e658 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6T8C155666 biolink:treats UMLS:C0278987 PMID:41385096 "[{""id"":""uuid:e395e7b5-21d2-4aa8-a5dc-fb3de4d42a45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6c3a45a2-4f8f-4c9d-a732-29df42a6a287"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for: Melanoma • Treatment of unresectable or metastatic melanoma in adults and pediatric patients 12 years and older as a single agent or in combination with nivolumab. (1.1) • Adjuvant treatment of adult patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy. (1.2) Renal Cell Carcinoma (RCC) • Treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma, as first-line treatment in combination with nivolumab. (1.3) Colorectal Cancer • Treatment of adults and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with nivolumab. (1.4) Hepatocellular Carcinoma • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) as first-line treatment in combination with nivolumab. ( 1.5 ) • in combination with nivolumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. (1.5) Non-Small Cell Lung Cancer (NSCLC) • Treatment of adult patients with metastatic non-small cell lung cancer expressing PD-L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with nivolumab. (1.6) • Treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy. (1.6) Malignant Pleural Mesothelioma • Treatment of adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with nivolumab. (1.7) Esophageal Cancer • Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab whose tumors express PD-L1 (≥1). (1.8) uuid:e30fdbd6-f0c6-4d14-b56a-df6c9985c68c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6T8C155666 biolink:treats UMLS:C0278517 PMID:41385096 "[{""id"":""uuid:e43e1290-e613-4d44-a667-b3162bebac66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7c505b67-6450-45da-bcb2-d053bfbf231f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for: Melanoma • Treatment of unresectable or metastatic melanoma in adults and pediatric patients 12 years and older as a single agent or in combination with nivolumab. (1.1) • Adjuvant treatment of adult patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy. (1.2) Renal Cell Carcinoma (RCC) • Treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma, as first-line treatment in combination with nivolumab. (1.3) Colorectal Cancer • Treatment of adults and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with nivolumab. (1.4) Hepatocellular Carcinoma • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) as first-line treatment in combination with nivolumab. ( 1.5 ) • in combination with nivolumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. (1.5) Non-Small Cell Lung Cancer (NSCLC) • Treatment of adult patients with metastatic non-small cell lung cancer expressing PD-L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with nivolumab. (1.6) • Treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy. (1.6) Malignant Pleural Mesothelioma • Treatment of adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with nivolumab. (1.7) Esophageal Cancer • Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab whose tumors express PD-L1 (≥1). (1.8) uuid:14e458ed-b721-469b-bd96-bb651fdcd2bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6T8C155666 biolink:treats MONDO:0005112 PMID:41385096 "[{""id"":""uuid:8e7abae8-ff9a-4f05-b855-ad3371d5b6d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2f5070e1-0811-4c25-bc1d-7068c35fd1a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:726171a0-3442-4c10-b13a-4bdd6b02dece"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/yervoy""]},{""id"":""uuid:da758f8f-4592-4587-b8a4-7e3932f12308"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for: Melanoma • Treatment of unresectable or metastatic melanoma in adults and pediatric patients 12 years and older as a single agent or in combination with nivolumab. (1.1) • Adjuvant treatment of adult patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy. (1.2) Renal Cell Carcinoma (RCC) • Treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma, as first-line treatment in combination with nivolumab. (1.3) Colorectal Cancer • Treatment of adults and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with nivolumab. (1.4) Hepatocellular Carcinoma • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) as first-line treatment in combination with nivolumab. ( 1.5 ) • in combination with nivolumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. (1.5) Non-Small Cell Lung Cancer (NSCLC) • Treatment of adult patients with metastatic non-small cell lung cancer expressing PD-L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with nivolumab. (1.6) • Treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy. (1.6) Malignant Pleural Mesothelioma • Treatment of adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with nivolumab. (1.7) Esophageal Cancer • Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab whose tumors express PD-L1 (≥1). (1.8)|[EMA] MelanomaYERVOY as monotherapy or combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older (see section 4.4). YERVOY in combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults.Relative to nivolumab monotherapy, an increase in progression-free survival (PFS) and overall survival (OS) for the combination of nivolumab with ipilimumab is established only in patients with low tumour PD-L1 expression (see sections 4.4 and 5.1).Renal cell carcinoma (RCC)YERVOY in combination with nivolumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (see section 5.1).Non-small cell lung cancer (NSCLC)YERVOY in combination with nivolumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising EGFR mutation or ALK translocation.Malignant pleural mesothelioma (MPM)YERVOY in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma.Mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC)YERVOY in combination with nivolumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy (see section 5.1).Oesophageal squamous cell carcinoma (OSCC)YERVOY in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression ≥ 1%.|[PMDA] A drug with a new indication and a new dosage for the treatment of unresectable advanced or recurrent malignant pleural mesothelioma. [Orphan drug] uuid:01829545-2eb8-4eb6-9a70-1c4758274e88 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6T8C155666 biolink:treats MONDO:0005580 PMID:41385096 "[{""id"":""uuid:6a784559-4ac2-4f2b-9e0f-e1e1cefe6ecc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:61dc1ec6-7813-4799-91dd-ae769ade0bcd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3c818560-29de-4b0d-92f4-32ef9174afd7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/yervoy""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for: Melanoma • Treatment of unresectable or metastatic melanoma in adults and pediatric patients 12 years and older as a single agent or in combination with nivolumab. (1.1) • Adjuvant treatment of adult patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy. (1.2) Renal Cell Carcinoma (RCC) • Treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma, as first-line treatment in combination with nivolumab. (1.3) Colorectal Cancer • Treatment of adults and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with nivolumab. (1.4) Hepatocellular Carcinoma • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) as first-line treatment in combination with nivolumab. ( 1.5 ) • in combination with nivolumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. (1.5) Non-Small Cell Lung Cancer (NSCLC) • Treatment of adult patients with metastatic non-small cell lung cancer expressing PD-L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with nivolumab. (1.6) • Treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy. (1.6) Malignant Pleural Mesothelioma • Treatment of adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with nivolumab. (1.7) Esophageal Cancer • Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab whose tumors express PD-L1 (≥1). (1.8)|[EMA] MelanomaYERVOY as monotherapy or combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older (see section 4.4). YERVOY in combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults.Relative to nivolumab monotherapy, an increase in progression-free survival (PFS) and overall survival (OS) for the combination of nivolumab with ipilimumab is established only in patients with low tumour PD-L1 expression (see sections 4.4 and 5.1).Renal cell carcinoma (RCC)YERVOY in combination with nivolumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (see section 5.1).Non-small cell lung cancer (NSCLC)YERVOY in combination with nivolumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising EGFR mutation or ALK translocation.Malignant pleural mesothelioma (MPM)YERVOY in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma.Mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal cancer (CRC)YERVOY in combination with nivolumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy (see section 5.1).Oesophageal squamous cell carcinoma (OSCC)YERVOY in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell PD-L1 expression ≥ 1%. uuid:7bdb027f-14b3-45e6-934e-35aefb115a80 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6T8C155666 biolink:treats UMLS:C1142025 PMID:41385096 "[{""id"":""uuid:9fb28e18-6a7d-4311-aaf2-3f89a61ce8fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4b290fad-4083-4d46-b802-2a0e783379e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] YERVOY is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for: Melanoma • Treatment of unresectable or metastatic melanoma in adults and pediatric patients 12 years and older as a single agent or in combination with nivolumab. (1.1) • Adjuvant treatment of adult patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy. (1.2) Renal Cell Carcinoma (RCC) • Treatment of adult patients with intermediate or poor risk advanced renal cell carcinoma, as first-line treatment in combination with nivolumab. (1.3) Colorectal Cancer • Treatment of adults and pediatric patients 12 years and older with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with nivolumab. (1.4) Hepatocellular Carcinoma • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) as first-line treatment in combination with nivolumab. ( 1.5 ) • in combination with nivolumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. (1.5) Non-Small Cell Lung Cancer (NSCLC) • Treatment of adult patients with metastatic non-small cell lung cancer expressing PD-L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with nivolumab. (1.6) • Treatment of adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with nivolumab and 2 cycles of platinum-doublet chemotherapy. (1.6) Malignant Pleural Mesothelioma • Treatment of adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with nivolumab. (1.7) Esophageal Cancer • Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab whose tumors express PD-L1 (≥1). (1.8) uuid:472b7b45-1d4b-449f-971f-89a54ffd5e8a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:P85X70RZWS biolink:treats MONDO:0006710 PMID:41385096 "[{""id"":""uuid:ba1ed590-7543-4c76-b2d2-f2971c06e916"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:21752d67-d5a3-4c1b-9acf-a5a82c9624be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XCOPRI is indicated for the treatment of partial-onset seizures in adult patients. uuid:3ef72a31-4f72-4cb2-8dbf-9413131b7186 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PF8K38CG54 biolink:treats MONDO:0005277 PMID:41385096 "[{""id"":""uuid:a0cc2da8-dbdd-48f6-b5ac-dec0488ceddf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:458ad522-d1c7-4b61-96a1-c96fc6e4cf44"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:df9087d2-dd59-4281-b17e-c7a3ac086a79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ajovy""]},{""id"":""uuid:deb9db2f-e6df-4db8-b7db-38f376a402a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] AJOVY is indicated for the preventive treatment of migraine in adults.|[EMA] Ajovy is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month.|[PMDA] A drug with a new active ingredient indicated for the prevention of migraine attacks. uuid:f3c9ce01-21f2-44a8-9e68-4d7a795eeaf7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68554 biolink:treats MONDO:0018881 PMID:41385096 "[{""id"":""uuid:ab8fd197-a277-4829-ae4e-8b3d493911c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:047e5af8-8b35-4ffb-a1b3-d5251584c180"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Deferiprone tablets are indicated for the treatment of transfusional iron overload in adult patients with thalassemia syndromes when current chelation therapy is inadequate. Limitations of Use: • Safety and effectiveness have not been established for the treatment of transfusional iron overload in patients with myelodysplastic syndrome or in patients with Diamond Blackfan anemia. Pediatric use information is approved for Chiesi USA, Inc.’s FERRIPROX ® (deferiprone) tablets. However, due to Chiesi USA, Inc.’s marketing exclusivity rights, this drug product is not labeled with that information. uuid:7bbb1ef9-1790-4f32-873a-12ffd2546adb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68554 biolink:treats MONDO:0015253 PMID:41385096 "[{""id"":""uuid:d6e8fed6-ce75-4f5b-a8fa-494d81332877"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f0716b68-58a0-4f8e-9094-7b96681b840c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Deferiprone tablets are indicated for the treatment of transfusional iron overload in adult patients with thalassemia syndromes when current chelation therapy is inadequate. Limitations of Use: • Safety and effectiveness have not been established for the treatment of transfusional iron overload in patients with myelodysplastic syndrome or in patients with Diamond Blackfan anemia. Pediatric use information is approved for Chiesi USA, Inc.’s FERRIPROX ® (deferiprone) tablets. However, due to Chiesi USA, Inc.’s marketing exclusivity rights, this drug product is not labeled with that information. uuid:5806b342-fdd2-4cdc-a321-de5353560556 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:31YO63LBSN biolink:treats MONDO:0005105 PMID:41385096 "[{""id"":""uuid:8f162b31-9757-4525-b3f0-919df02f83c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6ab72384-5018-4110-8161-4885ac8aee43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7e7fd6e7-b7b7-4d03-951a-352460e93578"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of: Melanoma • adult and pediatric (12 years and older) patients with unresectable or metastatic melanoma, as a single agent or in combination with ipilimumab. (1.1) • for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma. (1.2) Non-Small Cell Lung Cancer (NSCLC) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer in the neoadjuvant setting, in combination with platinum-doublet chemotherapy. (1.3) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer and no known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by single-agent OPDIVO as adjuvant treatment after surgery. (1.4) • adult patients with metastatic non-small cell lung cancer expressing PD‑L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with ipilimumab. (1.5) • adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy. (1.5) • adult patients with metastatic non-small cell lung cancer and progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. (1.5) Malignant Pleural Mesothelioma • adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with ipilimumab. (1.6) Renal Cell Carcinoma (RCC) • adult patients with intermediate or poor risk advanced renal cell carcinoma, as a first-line treatment in combination with ipilimumab. (1.7) • adult patients with advanced renal cell carcinoma, as a first-line treatment in combination with cabozantinib. (1.7) • adult patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy. (1.7) Classical Hodgkin Lymphoma (cHL) • adult patients with classical Hodgkin lymphoma that has relapsed or progressed after a : (1.8) • autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or • 3 or more lines of systemic therapy that includes autologous HSCT. Squamous Cell Carcinoma of the Head and Neck (SCCHN) • adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after a platinum-based therapy. (1.9) Urothelial Carcinoma • adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC. (1.10) • adult patients with unresectable or metastatic urothelial carcinoma, as first-line treatment in combination with cisplatin and gemcitabine. (1.10) • adult patients with locally advanced or metastatic urothelial carcinoma who: • have disease progression during or following platinum-containing chemotherapy. • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. (1.10) Colorectal Cancer • adult and pediatric (12 years and older) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with ipilimumab. (1.11) • adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. ( 1.11 ) Hepatocellular Carcinoma (HCC) • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC), as a first-line treatment in combination with ipilimumab. (1.12) • in combination with ipilimumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. ( 1.12 ) Esophageal Cancer • adult patients with completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease, who have received neoadjuvant chemoradiotherapy (CRT). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with fluoropyrimidine- and platinum‑containing chemotherapy whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with ipilimumab whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy. (1.13) Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma • adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma whose tumors express PD-L1 (≥1) in combination with fluoropyrimidine- and platinum-containing chemotherapy. (1.14) a This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.|[PMDA] A drug with new indications and a new dosage in an additional dosage form for the treatment of unresectable or recurrent malignant pleural mesothelioma and melanoma that have progressed after chemotherapy. [Orphan drug] A drug with a new dosage in an additional dosage form indicated for the treatment of melanoma, unresectable or recurrent non-small cell lung cancer, unresectable or metastatic renal cell carcinoma, relapsed or refractory classical Hodgkin lymphoma, recurrent or metastatic head and neck cancer, unresectable or recurrent gastric cancer that has progressed after chemotherapy, and (3) unresectable or metastatic renal cell carcinoma. [(3) Priority review] uuid:35bf5382-adc0-4703-9037-e725d6496843 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:31YO63LBSN biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:ef255a0f-4355-4ee6-926d-ad1b6b0aea4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f8d7fd6d-4782-48d3-a454-064ec5180b01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:eead8c44-c155-4adc-bae5-c8a4c2f69008"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of: Melanoma • adult and pediatric (12 years and older) patients with unresectable or metastatic melanoma, as a single agent or in combination with ipilimumab. (1.1) • for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma. (1.2) Non-Small Cell Lung Cancer (NSCLC) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer in the neoadjuvant setting, in combination with platinum-doublet chemotherapy. (1.3) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer and no known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by single-agent OPDIVO as adjuvant treatment after surgery. (1.4) • adult patients with metastatic non-small cell lung cancer expressing PD‑L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with ipilimumab. (1.5) • adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy. (1.5) • adult patients with metastatic non-small cell lung cancer and progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. (1.5) Malignant Pleural Mesothelioma • adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with ipilimumab. (1.6) Renal Cell Carcinoma (RCC) • adult patients with intermediate or poor risk advanced renal cell carcinoma, as a first-line treatment in combination with ipilimumab. (1.7) • adult patients with advanced renal cell carcinoma, as a first-line treatment in combination with cabozantinib. (1.7) • adult patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy. (1.7) Classical Hodgkin Lymphoma (cHL) • adult patients with classical Hodgkin lymphoma that has relapsed or progressed after a : (1.8) • autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or • 3 or more lines of systemic therapy that includes autologous HSCT. Squamous Cell Carcinoma of the Head and Neck (SCCHN) • adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after a platinum-based therapy. (1.9) Urothelial Carcinoma • adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC. (1.10) • adult patients with unresectable or metastatic urothelial carcinoma, as first-line treatment in combination with cisplatin and gemcitabine. (1.10) • adult patients with locally advanced or metastatic urothelial carcinoma who: • have disease progression during or following platinum-containing chemotherapy. • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. (1.10) Colorectal Cancer • adult and pediatric (12 years and older) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with ipilimumab. (1.11) • adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. ( 1.11 ) Hepatocellular Carcinoma (HCC) • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC), as a first-line treatment in combination with ipilimumab. (1.12) • in combination with ipilimumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. ( 1.12 ) Esophageal Cancer • adult patients with completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease, who have received neoadjuvant chemoradiotherapy (CRT). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with fluoropyrimidine- and platinum‑containing chemotherapy whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with ipilimumab whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy. (1.13) Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma • adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma whose tumors express PD-L1 (≥1) in combination with fluoropyrimidine- and platinum-containing chemotherapy. (1.14) a This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.|[PMDA] A drug with new indications and a new dosage in an additional dosage form for the treatment of unresectable or recurrent malignant pleural mesothelioma and melanoma that have progressed after chemotherapy. [Orphan drug] A drug with a new dosage in an additional dosage form indicated for the treatment of melanoma, unresectable or recurrent non-small cell lung cancer, unresectable or metastatic renal cell carcinoma, relapsed or refractory classical Hodgkin lymphoma, recurrent or metastatic head and neck cancer, unresectable or recurrent gastric cancer that has progressed after chemotherapy, and (3) unresectable or metastatic renal cell carcinoma. [(3) Priority review] uuid:449db79b-0ddd-48b7-a459-2b5a3dfc75af biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:31YO63LBSN biolink:treats MONDO:0005112 PMID:41385096 "[{""id"":""uuid:28ff6ed0-51da-4d77-a3f9-d4a8b877a65e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d8bb878e-ce57-442b-b9cd-20fa306b8825"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:98260957-c4ee-40be-8abe-6a4b9882d949"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of: Melanoma • adult and pediatric (12 years and older) patients with unresectable or metastatic melanoma, as a single agent or in combination with ipilimumab. (1.1) • for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma. (1.2) Non-Small Cell Lung Cancer (NSCLC) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer in the neoadjuvant setting, in combination with platinum-doublet chemotherapy. (1.3) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer and no known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by single-agent OPDIVO as adjuvant treatment after surgery. (1.4) • adult patients with metastatic non-small cell lung cancer expressing PD‑L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with ipilimumab. (1.5) • adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy. (1.5) • adult patients with metastatic non-small cell lung cancer and progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. (1.5) Malignant Pleural Mesothelioma • adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with ipilimumab. (1.6) Renal Cell Carcinoma (RCC) • adult patients with intermediate or poor risk advanced renal cell carcinoma, as a first-line treatment in combination with ipilimumab. (1.7) • adult patients with advanced renal cell carcinoma, as a first-line treatment in combination with cabozantinib. (1.7) • adult patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy. (1.7) Classical Hodgkin Lymphoma (cHL) • adult patients with classical Hodgkin lymphoma that has relapsed or progressed after a : (1.8) • autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or • 3 or more lines of systemic therapy that includes autologous HSCT. Squamous Cell Carcinoma of the Head and Neck (SCCHN) • adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after a platinum-based therapy. (1.9) Urothelial Carcinoma • adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC. (1.10) • adult patients with unresectable or metastatic urothelial carcinoma, as first-line treatment in combination with cisplatin and gemcitabine. (1.10) • adult patients with locally advanced or metastatic urothelial carcinoma who: • have disease progression during or following platinum-containing chemotherapy. • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. (1.10) Colorectal Cancer • adult and pediatric (12 years and older) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with ipilimumab. (1.11) • adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. ( 1.11 ) Hepatocellular Carcinoma (HCC) • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC), as a first-line treatment in combination with ipilimumab. (1.12) • in combination with ipilimumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. ( 1.12 ) Esophageal Cancer • adult patients with completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease, who have received neoadjuvant chemoradiotherapy (CRT). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with fluoropyrimidine- and platinum‑containing chemotherapy whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with ipilimumab whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy. (1.13) Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma • adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma whose tumors express PD-L1 (≥1) in combination with fluoropyrimidine- and platinum-containing chemotherapy. (1.14) a This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.|[PMDA] A drug with new indications and a new dosage in an additional dosage form for the treatment of unresectable or recurrent malignant pleural mesothelioma and melanoma that have progressed after chemotherapy. [Orphan drug] A drug with a new dosage in an additional dosage form indicated for the treatment of melanoma, unresectable or recurrent non-small cell lung cancer, unresectable or metastatic renal cell carcinoma, relapsed or refractory classical Hodgkin lymphoma, recurrent or metastatic head and neck cancer, unresectable or recurrent gastric cancer that has progressed after chemotherapy, and (3) unresectable or metastatic renal cell carcinoma. [(3) Priority review] uuid:9fee0806-277b-4b8a-9fe2-325f535317d7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:31YO63LBSN biolink:treats MONDO:0005086 PMID:41385096 "[{""id"":""uuid:e1c50da6-f1aa-444f-b893-eed0a5c5d3c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2060cc83-0f63-43bf-8080-722070ef9e01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9d9b8d7a-1c6c-4615-83bf-6a9ed0a61b02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of: Melanoma • adult and pediatric (12 years and older) patients with unresectable or metastatic melanoma, as a single agent or in combination with ipilimumab. (1.1) • for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma. (1.2) Non-Small Cell Lung Cancer (NSCLC) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer in the neoadjuvant setting, in combination with platinum-doublet chemotherapy. (1.3) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer and no known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by single-agent OPDIVO as adjuvant treatment after surgery. (1.4) • adult patients with metastatic non-small cell lung cancer expressing PD‑L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with ipilimumab. (1.5) • adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy. (1.5) • adult patients with metastatic non-small cell lung cancer and progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. (1.5) Malignant Pleural Mesothelioma • adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with ipilimumab. (1.6) Renal Cell Carcinoma (RCC) • adult patients with intermediate or poor risk advanced renal cell carcinoma, as a first-line treatment in combination with ipilimumab. (1.7) • adult patients with advanced renal cell carcinoma, as a first-line treatment in combination with cabozantinib. (1.7) • adult patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy. (1.7) Classical Hodgkin Lymphoma (cHL) • adult patients with classical Hodgkin lymphoma that has relapsed or progressed after a : (1.8) • autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or • 3 or more lines of systemic therapy that includes autologous HSCT. Squamous Cell Carcinoma of the Head and Neck (SCCHN) • adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after a platinum-based therapy. (1.9) Urothelial Carcinoma • adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC. (1.10) • adult patients with unresectable or metastatic urothelial carcinoma, as first-line treatment in combination with cisplatin and gemcitabine. (1.10) • adult patients with locally advanced or metastatic urothelial carcinoma who: • have disease progression during or following platinum-containing chemotherapy. • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. (1.10) Colorectal Cancer • adult and pediatric (12 years and older) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with ipilimumab. (1.11) • adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. ( 1.11 ) Hepatocellular Carcinoma (HCC) • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC), as a first-line treatment in combination with ipilimumab. (1.12) • in combination with ipilimumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. ( 1.12 ) Esophageal Cancer • adult patients with completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease, who have received neoadjuvant chemoradiotherapy (CRT). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with fluoropyrimidine- and platinum‑containing chemotherapy whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with ipilimumab whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy. (1.13) Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma • adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma whose tumors express PD-L1 (≥1) in combination with fluoropyrimidine- and platinum-containing chemotherapy. (1.14) a This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.|[PMDA] A drug with new indications and a new dosage in an additional dosage form for the treatment of unresectable or recurrent malignant pleural mesothelioma and melanoma that have progressed after chemotherapy. [Orphan drug] A drug with a new dosage in an additional dosage form indicated for the treatment of melanoma, unresectable or recurrent non-small cell lung cancer, unresectable or metastatic renal cell carcinoma, relapsed or refractory classical Hodgkin lymphoma, recurrent or metastatic head and neck cancer, unresectable or recurrent gastric cancer that has progressed after chemotherapy, and (3) unresectable or metastatic renal cell carcinoma. [(3) Priority review] uuid:3329a4b5-3a66-4201-850b-cdb08df95cec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:31YO63LBSN biolink:treats MONDO:0004665 PMID:41385096 "[{""id"":""uuid:9c9d4131-6722-409a-9a6f-f38dcb9470bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:455ac7cb-2e01-4030-ae63-23e3cdca9476"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d69a2817-63c1-4076-993e-7cb489fa291b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of: Melanoma • adult and pediatric (12 years and older) patients with unresectable or metastatic melanoma, as a single agent or in combination with ipilimumab. (1.1) • for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma. (1.2) Non-Small Cell Lung Cancer (NSCLC) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer in the neoadjuvant setting, in combination with platinum-doublet chemotherapy. (1.3) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer and no known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by single-agent OPDIVO as adjuvant treatment after surgery. (1.4) • adult patients with metastatic non-small cell lung cancer expressing PD‑L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with ipilimumab. (1.5) • adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy. (1.5) • adult patients with metastatic non-small cell lung cancer and progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. (1.5) Malignant Pleural Mesothelioma • adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with ipilimumab. (1.6) Renal Cell Carcinoma (RCC) • adult patients with intermediate or poor risk advanced renal cell carcinoma, as a first-line treatment in combination with ipilimumab. (1.7) • adult patients with advanced renal cell carcinoma, as a first-line treatment in combination with cabozantinib. (1.7) • adult patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy. (1.7) Classical Hodgkin Lymphoma (cHL) • adult patients with classical Hodgkin lymphoma that has relapsed or progressed after a : (1.8) • autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or • 3 or more lines of systemic therapy that includes autologous HSCT. Squamous Cell Carcinoma of the Head and Neck (SCCHN) • adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after a platinum-based therapy. (1.9) Urothelial Carcinoma • adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC. (1.10) • adult patients with unresectable or metastatic urothelial carcinoma, as first-line treatment in combination with cisplatin and gemcitabine. (1.10) • adult patients with locally advanced or metastatic urothelial carcinoma who: • have disease progression during or following platinum-containing chemotherapy. • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. (1.10) Colorectal Cancer • adult and pediatric (12 years and older) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with ipilimumab. (1.11) • adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. ( 1.11 ) Hepatocellular Carcinoma (HCC) • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC), as a first-line treatment in combination with ipilimumab. (1.12) • in combination with ipilimumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. ( 1.12 ) Esophageal Cancer • adult patients with completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease, who have received neoadjuvant chemoradiotherapy (CRT). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with fluoropyrimidine- and platinum‑containing chemotherapy whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with ipilimumab whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy. (1.13) Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma • adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma whose tumors express PD-L1 (≥1) in combination with fluoropyrimidine- and platinum-containing chemotherapy. (1.14) a This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.|[PMDA] A drug with new indications and a new dosage in an additional dosage form for the treatment of unresectable or recurrent malignant pleural mesothelioma and melanoma that have progressed after chemotherapy. [Orphan drug] A drug with a new dosage in an additional dosage form indicated for the treatment of melanoma, unresectable or recurrent non-small cell lung cancer, unresectable or metastatic renal cell carcinoma, relapsed or refractory classical Hodgkin lymphoma, recurrent or metastatic head and neck cancer, unresectable or recurrent gastric cancer that has progressed after chemotherapy, and (3) unresectable or metastatic renal cell carcinoma. [(3) Priority review] uuid:241b2848-9dd5-4f78-a2ae-bfd85223fec1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:31YO63LBSN biolink:treats MONDO:0010150 PMID:41385096 "[{""id"":""uuid:3c5ca170-2be3-4d70-a708-9b3e8429db15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4124e2f2-69fb-4cb1-8e3e-d5b9786c7e4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of: Melanoma • adult and pediatric (12 years and older) patients with unresectable or metastatic melanoma, as a single agent or in combination with ipilimumab. (1.1) • for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma. (1.2) Non-Small Cell Lung Cancer (NSCLC) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer in the neoadjuvant setting, in combination with platinum-doublet chemotherapy. (1.3) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer and no known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by single-agent OPDIVO as adjuvant treatment after surgery. (1.4) • adult patients with metastatic non-small cell lung cancer expressing PD‑L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with ipilimumab. (1.5) • adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy. (1.5) • adult patients with metastatic non-small cell lung cancer and progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. (1.5) Malignant Pleural Mesothelioma • adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with ipilimumab. (1.6) Renal Cell Carcinoma (RCC) • adult patients with intermediate or poor risk advanced renal cell carcinoma, as a first-line treatment in combination with ipilimumab. (1.7) • adult patients with advanced renal cell carcinoma, as a first-line treatment in combination with cabozantinib. (1.7) • adult patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy. (1.7) Classical Hodgkin Lymphoma (cHL) • adult patients with classical Hodgkin lymphoma that has relapsed or progressed after a : (1.8) • autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or • 3 or more lines of systemic therapy that includes autologous HSCT. Squamous Cell Carcinoma of the Head and Neck (SCCHN) • adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after a platinum-based therapy. (1.9) Urothelial Carcinoma • adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC. (1.10) • adult patients with unresectable or metastatic urothelial carcinoma, as first-line treatment in combination with cisplatin and gemcitabine. (1.10) • adult patients with locally advanced or metastatic urothelial carcinoma who: • have disease progression during or following platinum-containing chemotherapy. • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. (1.10) Colorectal Cancer • adult and pediatric (12 years and older) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with ipilimumab. (1.11) • adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. ( 1.11 ) Hepatocellular Carcinoma (HCC) • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC), as a first-line treatment in combination with ipilimumab. (1.12) • in combination with ipilimumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. ( 1.12 ) Esophageal Cancer • adult patients with completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease, who have received neoadjuvant chemoradiotherapy (CRT). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with fluoropyrimidine- and platinum‑containing chemotherapy whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with ipilimumab whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy. (1.13) Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma • adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma whose tumors express PD-L1 (≥1) in combination with fluoropyrimidine- and platinum-containing chemotherapy. (1.14) a This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. uuid:8ec5d674-6883-4a22-9203-045ceaef1862 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:31YO63LBSN biolink:treats MONDO:0040679 PMID:41385096 "[{""id"":""uuid:9020f8c8-09cf-4bef-9f3c-9f0857ed1858"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6e456429-d19e-43b5-a8dd-806256ed60d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:34c5cda4-c70c-4995-b362-9a607829d09e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of: Melanoma • adult and pediatric (12 years and older) patients with unresectable or metastatic melanoma, as a single agent or in combination with ipilimumab. (1.1) • for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma. (1.2) Non-Small Cell Lung Cancer (NSCLC) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer in the neoadjuvant setting, in combination with platinum-doublet chemotherapy. (1.3) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer and no known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by single-agent OPDIVO as adjuvant treatment after surgery. (1.4) • adult patients with metastatic non-small cell lung cancer expressing PD‑L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with ipilimumab. (1.5) • adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy. (1.5) • adult patients with metastatic non-small cell lung cancer and progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. (1.5) Malignant Pleural Mesothelioma • adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with ipilimumab. (1.6) Renal Cell Carcinoma (RCC) • adult patients with intermediate or poor risk advanced renal cell carcinoma, as a first-line treatment in combination with ipilimumab. (1.7) • adult patients with advanced renal cell carcinoma, as a first-line treatment in combination with cabozantinib. (1.7) • adult patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy. (1.7) Classical Hodgkin Lymphoma (cHL) • adult patients with classical Hodgkin lymphoma that has relapsed or progressed after a : (1.8) • autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or • 3 or more lines of systemic therapy that includes autologous HSCT. Squamous Cell Carcinoma of the Head and Neck (SCCHN) • adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after a platinum-based therapy. (1.9) Urothelial Carcinoma • adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC. (1.10) • adult patients with unresectable or metastatic urothelial carcinoma, as first-line treatment in combination with cisplatin and gemcitabine. (1.10) • adult patients with locally advanced or metastatic urothelial carcinoma who: • have disease progression during or following platinum-containing chemotherapy. • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. (1.10) Colorectal Cancer • adult and pediatric (12 years and older) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with ipilimumab. (1.11) • adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. ( 1.11 ) Hepatocellular Carcinoma (HCC) • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC), as a first-line treatment in combination with ipilimumab. (1.12) • in combination with ipilimumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. ( 1.12 ) Esophageal Cancer • adult patients with completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease, who have received neoadjuvant chemoradiotherapy (CRT). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with fluoropyrimidine- and platinum‑containing chemotherapy whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with ipilimumab whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy. (1.13) Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma • adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma whose tumors express PD-L1 (≥1) in combination with fluoropyrimidine- and platinum-containing chemotherapy. (1.14) a This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.|[PMDA] Drugs with a new indication and a new dosage for the postoperative adjuvant therapy for urothelial carcinoma. uuid:076fe772-2d39-4316-9ec6-108e34558187 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:31YO63LBSN biolink:treats MONDO:0005575 PMID:41385096 "[{""id"":""uuid:9cf6a69a-88df-4145-859f-9ae09c1efda2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:99980f55-2f03-478d-bef1-3d85d90d034f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:34296f7b-b033-402b-b370-69930ddc3cb6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of: Melanoma • adult and pediatric (12 years and older) patients with unresectable or metastatic melanoma, as a single agent or in combination with ipilimumab. (1.1) • for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma. (1.2) Non-Small Cell Lung Cancer (NSCLC) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer in the neoadjuvant setting, in combination with platinum-doublet chemotherapy. (1.3) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer and no known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by single-agent OPDIVO as adjuvant treatment after surgery. (1.4) • adult patients with metastatic non-small cell lung cancer expressing PD‑L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with ipilimumab. (1.5) • adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy. (1.5) • adult patients with metastatic non-small cell lung cancer and progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. (1.5) Malignant Pleural Mesothelioma • adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with ipilimumab. (1.6) Renal Cell Carcinoma (RCC) • adult patients with intermediate or poor risk advanced renal cell carcinoma, as a first-line treatment in combination with ipilimumab. (1.7) • adult patients with advanced renal cell carcinoma, as a first-line treatment in combination with cabozantinib. (1.7) • adult patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy. (1.7) Classical Hodgkin Lymphoma (cHL) • adult patients with classical Hodgkin lymphoma that has relapsed or progressed after a : (1.8) • autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or • 3 or more lines of systemic therapy that includes autologous HSCT. Squamous Cell Carcinoma of the Head and Neck (SCCHN) • adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after a platinum-based therapy. (1.9) Urothelial Carcinoma • adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC. (1.10) • adult patients with unresectable or metastatic urothelial carcinoma, as first-line treatment in combination with cisplatin and gemcitabine. (1.10) • adult patients with locally advanced or metastatic urothelial carcinoma who: • have disease progression during or following platinum-containing chemotherapy. • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. (1.10) Colorectal Cancer • adult and pediatric (12 years and older) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with ipilimumab. (1.11) • adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. ( 1.11 ) Hepatocellular Carcinoma (HCC) • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC), as a first-line treatment in combination with ipilimumab. (1.12) • in combination with ipilimumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. ( 1.12 ) Esophageal Cancer • adult patients with completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease, who have received neoadjuvant chemoradiotherapy (CRT). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with fluoropyrimidine- and platinum‑containing chemotherapy whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with ipilimumab whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy. (1.13) Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma • adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma whose tumors express PD-L1 (≥1) in combination with fluoropyrimidine- and platinum-containing chemotherapy. (1.14) a This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.|[PMDA] Drugs with a new dosage for the treatment of unresectable advanced or recurrent microsatellite instability-high (MSI-High) colorectal cancer that has progressed after cancer chemotherapy. Drugs with a new dosage for the treatment of melanoma, unresectable advanced or recurrent non- small cell lung cancer, unresectable or metastatic renal cell carcinoma, relapsed or refractory classical Hodgkin lymphoma, recurrent or metastatic head and neck cancer, unresectable advanced or recurrent gastric cancer that has progressed after cancer chemotherapy, unresectable advanced or recurrent malignant pleural mesothelioma that have progressed after cancer chemotherapy, unresectable advanced or recurrent microsatellite instability-high (MSI-High) colorectal cancer that has progressed after cancer chemotherapy, and unresectable advanced or recurrent esophageal cancer that has progressed after cancer chemotherapy. uuid:17640a42-b651-4da0-a48d-a166db172c58 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:31YO63LBSN biolink:treats MONDO:0007256 PMID:41385096 "[{""id"":""uuid:0583931a-6444-497b-86b8-dd96ebcf9d34"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:78cec6b6-cc9c-4e51-af7a-c331ce3034e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of: Melanoma • adult and pediatric (12 years and older) patients with unresectable or metastatic melanoma, as a single agent or in combination with ipilimumab. (1.1) • for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma. (1.2) Non-Small Cell Lung Cancer (NSCLC) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer in the neoadjuvant setting, in combination with platinum-doublet chemotherapy. (1.3) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer and no known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by single-agent OPDIVO as adjuvant treatment after surgery. (1.4) • adult patients with metastatic non-small cell lung cancer expressing PD‑L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with ipilimumab. (1.5) • adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy. (1.5) • adult patients with metastatic non-small cell lung cancer and progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. (1.5) Malignant Pleural Mesothelioma • adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with ipilimumab. (1.6) Renal Cell Carcinoma (RCC) • adult patients with intermediate or poor risk advanced renal cell carcinoma, as a first-line treatment in combination with ipilimumab. (1.7) • adult patients with advanced renal cell carcinoma, as a first-line treatment in combination with cabozantinib. (1.7) • adult patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy. (1.7) Classical Hodgkin Lymphoma (cHL) • adult patients with classical Hodgkin lymphoma that has relapsed or progressed after a : (1.8) • autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or • 3 or more lines of systemic therapy that includes autologous HSCT. Squamous Cell Carcinoma of the Head and Neck (SCCHN) • adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after a platinum-based therapy. (1.9) Urothelial Carcinoma • adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC. (1.10) • adult patients with unresectable or metastatic urothelial carcinoma, as first-line treatment in combination with cisplatin and gemcitabine. (1.10) • adult patients with locally advanced or metastatic urothelial carcinoma who: • have disease progression during or following platinum-containing chemotherapy. • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. (1.10) Colorectal Cancer • adult and pediatric (12 years and older) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with ipilimumab. (1.11) • adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. ( 1.11 ) Hepatocellular Carcinoma (HCC) • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC), as a first-line treatment in combination with ipilimumab. (1.12) • in combination with ipilimumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. ( 1.12 ) Esophageal Cancer • adult patients with completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease, who have received neoadjuvant chemoradiotherapy (CRT). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with fluoropyrimidine- and platinum‑containing chemotherapy whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with ipilimumab whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy. (1.13) Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma • adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma whose tumors express PD-L1 (≥1) in combination with fluoropyrimidine- and platinum-containing chemotherapy. (1.14) a This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. uuid:9344e901-2403-463f-9606-dc40f9f3320f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:31YO63LBSN biolink:treats MONDO:0007576 PMID:41385096 "[{""id"":""uuid:3d381faf-40c5-43b4-b451-55688f9aed05"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:511b2ec3-83f9-4ddb-b765-07bb74949549"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:eebe2fb7-aebc-464d-b77e-5584ed2468b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of: Melanoma • adult and pediatric (12 years and older) patients with unresectable or metastatic melanoma, as a single agent or in combination with ipilimumab. (1.1) • for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma. (1.2) Non-Small Cell Lung Cancer (NSCLC) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer in the neoadjuvant setting, in combination with platinum-doublet chemotherapy. (1.3) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer and no known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by single-agent OPDIVO as adjuvant treatment after surgery. (1.4) • adult patients with metastatic non-small cell lung cancer expressing PD‑L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with ipilimumab. (1.5) • adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy. (1.5) • adult patients with metastatic non-small cell lung cancer and progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. (1.5) Malignant Pleural Mesothelioma • adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with ipilimumab. (1.6) Renal Cell Carcinoma (RCC) • adult patients with intermediate or poor risk advanced renal cell carcinoma, as a first-line treatment in combination with ipilimumab. (1.7) • adult patients with advanced renal cell carcinoma, as a first-line treatment in combination with cabozantinib. (1.7) • adult patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy. (1.7) Classical Hodgkin Lymphoma (cHL) • adult patients with classical Hodgkin lymphoma that has relapsed or progressed after a : (1.8) • autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or • 3 or more lines of systemic therapy that includes autologous HSCT. Squamous Cell Carcinoma of the Head and Neck (SCCHN) • adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after a platinum-based therapy. (1.9) Urothelial Carcinoma • adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC. (1.10) • adult patients with unresectable or metastatic urothelial carcinoma, as first-line treatment in combination with cisplatin and gemcitabine. (1.10) • adult patients with locally advanced or metastatic urothelial carcinoma who: • have disease progression during or following platinum-containing chemotherapy. • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. (1.10) Colorectal Cancer • adult and pediatric (12 years and older) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with ipilimumab. (1.11) • adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. ( 1.11 ) Hepatocellular Carcinoma (HCC) • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC), as a first-line treatment in combination with ipilimumab. (1.12) • in combination with ipilimumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. ( 1.12 ) Esophageal Cancer • adult patients with completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease, who have received neoadjuvant chemoradiotherapy (CRT). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with fluoropyrimidine- and platinum‑containing chemotherapy whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with ipilimumab whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy. (1.13) Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma • adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma whose tumors express PD-L1 (≥1) in combination with fluoropyrimidine- and platinum-containing chemotherapy. (1.14) a This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.|[PMDA] Drugs with a new dosage for the treatment of unresectable advanced or recurrent microsatellite instability-high (MSI-High) colorectal cancer that has progressed after cancer chemotherapy. Drugs with a new dosage for the treatment of melanoma, unresectable advanced or recurrent non- small cell lung cancer, unresectable or metastatic renal cell carcinoma, relapsed or refractory classical Hodgkin lymphoma, recurrent or metastatic head and neck cancer, unresectable advanced or recurrent gastric cancer that has progressed after cancer chemotherapy, unresectable advanced or recurrent malignant pleural mesothelioma that have progressed after cancer chemotherapy, unresectable advanced or recurrent microsatellite instability-high (MSI-High) colorectal cancer that has progressed after cancer chemotherapy, and unresectable advanced or recurrent esophageal cancer that has progressed after cancer chemotherapy. uuid:97d47cb6-0a9f-4a86-a8bd-107c45c8f928 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:31YO63LBSN biolink:treats UMLS:C5400195 PMID:41385096 "[{""id"":""uuid:d365a55e-1870-4381-83f2-6c2d8be5e158"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8baea95e-cdf0-41be-8df3-80b4adc197ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of: Melanoma • adult and pediatric (12 years and older) patients with unresectable or metastatic melanoma, as a single agent or in combination with ipilimumab. (1.1) • for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma. (1.2) Non-Small Cell Lung Cancer (NSCLC) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer in the neoadjuvant setting, in combination with platinum-doublet chemotherapy. (1.3) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer and no known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by single-agent OPDIVO as adjuvant treatment after surgery. (1.4) • adult patients with metastatic non-small cell lung cancer expressing PD‑L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with ipilimumab. (1.5) • adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy. (1.5) • adult patients with metastatic non-small cell lung cancer and progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. (1.5) Malignant Pleural Mesothelioma • adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with ipilimumab. (1.6) Renal Cell Carcinoma (RCC) • adult patients with intermediate or poor risk advanced renal cell carcinoma, as a first-line treatment in combination with ipilimumab. (1.7) • adult patients with advanced renal cell carcinoma, as a first-line treatment in combination with cabozantinib. (1.7) • adult patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy. (1.7) Classical Hodgkin Lymphoma (cHL) • adult patients with classical Hodgkin lymphoma that has relapsed or progressed after a : (1.8) • autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or • 3 or more lines of systemic therapy that includes autologous HSCT. Squamous Cell Carcinoma of the Head and Neck (SCCHN) • adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after a platinum-based therapy. (1.9) Urothelial Carcinoma • adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC. (1.10) • adult patients with unresectable or metastatic urothelial carcinoma, as first-line treatment in combination with cisplatin and gemcitabine. (1.10) • adult patients with locally advanced or metastatic urothelial carcinoma who: • have disease progression during or following platinum-containing chemotherapy. • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. (1.10) Colorectal Cancer • adult and pediatric (12 years and older) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with ipilimumab. (1.11) • adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. ( 1.11 ) Hepatocellular Carcinoma (HCC) • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC), as a first-line treatment in combination with ipilimumab. (1.12) • in combination with ipilimumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. ( 1.12 ) Esophageal Cancer • adult patients with completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease, who have received neoadjuvant chemoradiotherapy (CRT). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with fluoropyrimidine- and platinum‑containing chemotherapy whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with ipilimumab whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy. (1.13) Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma • adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma whose tumors express PD-L1 (≥1) in combination with fluoropyrimidine- and platinum-containing chemotherapy. (1.14) a This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. uuid:3a413f7d-c395-474e-911b-6f21001f18e6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:31YO63LBSN biolink:treats MONDO:0005028 PMID:41385096 "[{""id"":""uuid:af26dd18-ef07-4fa9-b200-1f49e1ef9f59"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7a47cc80-0546-4769-b9f4-a7f7ee8bc275"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of: Melanoma • adult and pediatric (12 years and older) patients with unresectable or metastatic melanoma, as a single agent or in combination with ipilimumab. (1.1) • for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma. (1.2) Non-Small Cell Lung Cancer (NSCLC) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer in the neoadjuvant setting, in combination with platinum-doublet chemotherapy. (1.3) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer and no known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by single-agent OPDIVO as adjuvant treatment after surgery. (1.4) • adult patients with metastatic non-small cell lung cancer expressing PD‑L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with ipilimumab. (1.5) • adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy. (1.5) • adult patients with metastatic non-small cell lung cancer and progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. (1.5) Malignant Pleural Mesothelioma • adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with ipilimumab. (1.6) Renal Cell Carcinoma (RCC) • adult patients with intermediate or poor risk advanced renal cell carcinoma, as a first-line treatment in combination with ipilimumab. (1.7) • adult patients with advanced renal cell carcinoma, as a first-line treatment in combination with cabozantinib. (1.7) • adult patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy. (1.7) Classical Hodgkin Lymphoma (cHL) • adult patients with classical Hodgkin lymphoma that has relapsed or progressed after a : (1.8) • autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or • 3 or more lines of systemic therapy that includes autologous HSCT. Squamous Cell Carcinoma of the Head and Neck (SCCHN) • adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after a platinum-based therapy. (1.9) Urothelial Carcinoma • adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC. (1.10) • adult patients with unresectable or metastatic urothelial carcinoma, as first-line treatment in combination with cisplatin and gemcitabine. (1.10) • adult patients with locally advanced or metastatic urothelial carcinoma who: • have disease progression during or following platinum-containing chemotherapy. • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. (1.10) Colorectal Cancer • adult and pediatric (12 years and older) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with ipilimumab. (1.11) • adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. ( 1.11 ) Hepatocellular Carcinoma (HCC) • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC), as a first-line treatment in combination with ipilimumab. (1.12) • in combination with ipilimumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. ( 1.12 ) Esophageal Cancer • adult patients with completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease, who have received neoadjuvant chemoradiotherapy (CRT). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with fluoropyrimidine- and platinum‑containing chemotherapy whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with ipilimumab whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy. (1.13) Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma • adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma whose tumors express PD-L1 (≥1) in combination with fluoropyrimidine- and platinum-containing chemotherapy. (1.14) a This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. uuid:1c6d3ace-159e-464b-888f-72edb0907c31 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:31YO63LBSN biolink:treats MONDO:0001056 PMID:41385096 "[{""id"":""uuid:3ecfbcb2-8113-4d7a-891c-0aa94d2599fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:387b1d5d-0a10-4a8a-b9ab-57a31681a824"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1939bca3-b364-4721-a5f9-f9ef5bf8cca6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OPDIVO is a programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of: Melanoma • adult and pediatric (12 years and older) patients with unresectable or metastatic melanoma, as a single agent or in combination with ipilimumab. (1.1) • for the adjuvant treatment of adult and pediatric patients 12 years and older with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma. (1.2) Non-Small Cell Lung Cancer (NSCLC) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer in the neoadjuvant setting, in combination with platinum-doublet chemotherapy. (1.3) • adult patients with resectable (tumors ≥4 cm or node positive) non-small cell lung cancer and no known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by single-agent OPDIVO as adjuvant treatment after surgery. (1.4) • adult patients with metastatic non-small cell lung cancer expressing PD‑L1 (≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, as first-line treatment in combination with ipilimumab. (1.5) • adult patients with metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations as first-line treatment, in combination with ipilimumab and 2 cycles of platinum-doublet chemotherapy. (1.5) • adult patients with metastatic non-small cell lung cancer and progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO. (1.5) Malignant Pleural Mesothelioma • adult patients with unresectable malignant pleural mesothelioma, as first-line treatment in combination with ipilimumab. (1.6) Renal Cell Carcinoma (RCC) • adult patients with intermediate or poor risk advanced renal cell carcinoma, as a first-line treatment in combination with ipilimumab. (1.7) • adult patients with advanced renal cell carcinoma, as a first-line treatment in combination with cabozantinib. (1.7) • adult patients with advanced renal cell carcinoma who have received prior anti-angiogenic therapy. (1.7) Classical Hodgkin Lymphoma (cHL) • adult patients with classical Hodgkin lymphoma that has relapsed or progressed after a : (1.8) • autologous hematopoietic stem cell transplantation (HSCT) and brentuximab vedotin, or • 3 or more lines of systemic therapy that includes autologous HSCT. Squamous Cell Carcinoma of the Head and Neck (SCCHN) • adult patients with recurrent or metastatic squamous cell carcinoma of the head and neck with disease progression on or after a platinum-based therapy. (1.9) Urothelial Carcinoma • adjuvant treatment of adult patients with urothelial carcinoma (UC) who are at high risk of recurrence after undergoing radical resection of UC. (1.10) • adult patients with unresectable or metastatic urothelial carcinoma, as first-line treatment in combination with cisplatin and gemcitabine. (1.10) • adult patients with locally advanced or metastatic urothelial carcinoma who: • have disease progression during or following platinum-containing chemotherapy. • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. (1.10) Colorectal Cancer • adult and pediatric (12 years and older) patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer (CRC) in combination with ipilimumab. (1.11) • adult and pediatric (12 years and older) patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan. ( 1.11 ) Hepatocellular Carcinoma (HCC) • adult patients with unresectable or metastatic hepatocellular carcinoma (HCC), as a first-line treatment in combination with ipilimumab. (1.12) • in combination with ipilimumab in adult patients with unresectable or metastatic HCC who have been previously treated with sorafenib. ( 1.12 ) Esophageal Cancer • adult patients with completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease, who have received neoadjuvant chemoradiotherapy (CRT). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with fluoropyrimidine- and platinum‑containing chemotherapy whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma as first-line treatment in combination with ipilimumab whose tumors express PD-L1 (≥1). (1.13) • adult patients with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC) after prior fluoropyrimidine- and platinum-based chemotherapy. (1.13) Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma • adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma whose tumors express PD-L1 (≥1) in combination with fluoropyrimidine- and platinum-containing chemotherapy. (1.14) a This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.|[PMDA] A drug with new indications and a new dosage in an additional dosage form for the treatment of unresectable or recurrent malignant pleural mesothelioma and melanoma that have progressed after chemotherapy. [Orphan drug] A drug with a new dosage in an additional dosage form indicated for the treatment of melanoma, unresectable or recurrent non-small cell lung cancer, unresectable or metastatic renal cell carcinoma, relapsed or refractory classical Hodgkin lymphoma, recurrent or metastatic head and neck cancer, unresectable or recurrent gastric cancer that has progressed after chemotherapy, and (3) unresectable or metastatic renal cell carcinoma. [(3) Priority review] uuid:5c88604b-10fb-4896-9f77-d6ac04452052 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:TY3V24C029 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:d9ecb154-46dd-4e11-9dcc-0b35b1ed40a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0f91c6a7-0ea0-4ad4-90a0-e555305b1f31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FLYRCADO is indicated for positron emission tomography (PET) myocardial perfusion imaging (MPI) under rest or stress (pharmacologic or exercise) in adult patients with known or suspected coronary artery disease (CAD) to evaluate for myocardial ischemia and infarction. ( 1 ) uuid:fddd90b2-8248-4bc1-ad40-dddfe2952de8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:TY3V24C029 biolink:treats MONDO:0024644 PMID:41385096 "[{""id"":""uuid:6382c65f-7d78-4133-897d-b3333262d41f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c79ce99e-0a8f-4183-a4ce-649e957955a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FLYRCADO is indicated for positron emission tomography (PET) myocardial perfusion imaging (MPI) under rest or stress (pharmacologic or exercise) in adult patients with known or suspected coronary artery disease (CAD) to evaluate for myocardial ischemia and infarction. ( 1 ) uuid:a75fff57-e754-405e-a72a-ec784d8141d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:TY3V24C029 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:87e70fc4-aa4d-47e1-8779-eda269b5246f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:345a6ced-737b-45fb-8a66-36df5872ba10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] FLYRCADO is indicated for positron emission tomography (PET) myocardial perfusion imaging (MPI) under rest or stress (pharmacologic or exercise) in adult patients with known or suspected coronary artery disease (CAD) to evaluate for myocardial ischemia and infarction. ( 1 ) uuid:c7ad41d0-3d99-4b3e-bc8d-feda7f5cc94c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:EO144CP0X9 biolink:treats MONDO:0009290 PMID:41385096 "[{""id"":""uuid:be5637a7-6652-413b-9c58-e0bb9537ab74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:52fb2093-f3dc-4c2b-9998-00063bdfe828"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:dd063610-b9ba-4a7d-bafa-9a14849ea460"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/nexviadyme""]},{""id"":""uuid:77292824-b5a1-40a9-875c-ad475743cbd7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NEXVIAZYME is indicated for the treatment of patients 1 year of age and older with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency).|[EMA] Nexviadyme (avalglucosidase alfa) is indicated for long-term enzyme replacement therapy for the treatment of patients with Pompe disease (acid α-glucosidase deficiency).|[PMDA] A drug with a new active ingredient indicated for the treatment of Pompe disease. [Orphan drug] uuid:027c07bc-f9df-4b58-bc4e-a096f8a790a8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17347 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:6c65226b-cdc4-4954-a7f4-cd0dbe5c3567"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7e662fd4-bd3e-4bec-aa44-9a003732950a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Males Testosterone enanthate injection is indicated for replacement therapy in conditions associated with a deficiency or absence of endogenous testosterone. Primary hypogonadism (congenital or acquired) – Testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, or orchidectomy. Hypogonadotropic hypogonadism (congenital or acquired) – Gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. (Appropriate adrenal cortical and thyroid hormone replacement therapy are still necessary, however, and are actually of primary importance.) If the above conditions occur prior to puberty, androgen replacement therapy will be needed during the adolescent years for development of secondary sexual characteristics. Prolonged androgen treatment will be required to maintain sexual characteristics in these and other males who develop testosterone deficiency after puberty. Safety and efficacy of testosterone enanthate injection in men with age-related hypogonadism have not been established. Delayed puberty – Testosterone enanthate injection may be used to stimulate puberty in carefully selected males with clearly delayed puberty. These patients usually have a familial pattern of delayed puberty that is not secondary to a pathological disorder; puberty is expected to occur spontaneously at a relatively late date. Brief treatment with conservative doses may occasionally be justified in these patients if they do not respond to psychological support. The potential adverse effect on bone maturation should be discussed with the patient and parents prior to androgen administration. An X-ray of the hand and wrist to determine bone age should be obtained every six months to assess the effect of treatment on the epiphyseal centers (see WARNINGS ). Females Metastatic mammary cancer – Testosterone enanthate injection may be used secondarily in women with advancing inoperable metastatic (skeletal) mammary cancer who are one to five years postmenopausal. Primary goals of therapy in these women include ablation of the ovaries. Other methods of counteracting estrogen activity are adrenalectomy, hypophysectomy, and/or antiestrogen therapy. This treatment has also been used in premenopausal women with breast cancer who have benefited from oophorectomy and are considered to have a hormone-responsive tumor. Judgment concerning androgen therapy should be made by an oncologist with expertise in this field. uuid:be7d7daf-c19d-45dc-9841-8cdf1d889a96 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135810 biolink:treats MONDO:0005342 PMID:41385096 "[{""id"":""uuid:f43cb1cc-49a3-4587-9f8e-5713b598e2e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1b3baa33-eaf1-4149-bd1e-064ef4557f2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VANRAFIA is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥ 1.5 g/g. This indication is approved under accelerated approval based on a reduction of proteinuria [see Clinical Studies (14.1)] . It has not been established whether VANRAFIA slows kidney function decline in patients with IgAN. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial. uuid:ebab8479-75b1-4279-9f5a-285c3da13414 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135810 biolink:treats MONDO:0008072 PMID:41385096 "[{""id"":""uuid:f9ded79e-c286-4699-9c99-48e385761820"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:99e8d9e0-645e-4218-9af9-435a805b5b84"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VANRAFIA is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression, generally a urine protein-to-creatinine ratio (UPCR) ≥ 1.5 g/g. This indication is approved under accelerated approval based on a reduction of proteinuria [see Clinical Studies (14.1)] . It has not been established whether VANRAFIA slows kidney function decline in patients with IgAN. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial. uuid:b20ee391-0fc4-41e7-8f76-1ecf6a904bb2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29108 biolink:treats MONDO:0002492 PMID:41385096 "[{""id"":""uuid:a1218bc4-00ca-4564-9997-3f5cf2798fb0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:940de41f-c294-4720-984b-473447956699"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DIANEAL peritoneal dialysis solutions are indicated for patients in acute or chronic renal failure. uuid:8f4753e0-3de4-4008-85c9-6f7cd3db5cc3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0000004 PMID:41385096 "[{""id"":""uuid:493a9d7e-47e0-47d2-b008-11ad3aa373ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7d5f3cec-e9ff-41a8-9ba9-cc328ea7d3e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:b263d0b8-9efa-4f83-8d93-63b85203260e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0018479 PMID:41385096 "[{""id"":""uuid:a5167124-5d58-49c3-b26b-9e458a9b6472"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c25e0cd4-facd-423f-9206-839ce50c3949"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:036bf620-9734-42e6-9a42-0f8c151af4c2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0006982 PMID:41385096 "[{""id"":""uuid:2b3eda12-893c-4f5c-8adc-397e803be466"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a36b6563-b445-4e8c-8a6a-f1ddd5ed4809"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:8503fdc5-c479-4bce-acac-78b1d4654dd7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0043455 PMID:41385096 "[{""id"":""uuid:f0c7ebbb-a99a-4afc-abca-671b759af85e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cc434a55-f0b8-4936-888e-d91d9028ef6d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:4db9ad43-f15c-41d4-95da-b485b4447736 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:65709987-de24-4872-b3a7-3520ee9c17fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e1375780-2860-48c6-8946-ddf07d235782"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:b9e3408d-9de1-4e42-85df-b9962b06812c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:01de7e81-a846-4b83-a64a-8e9b0dff4e6a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:df6d400b-7748-4fd7-9ad5-02b63dc62a35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:fa307636-0264-4123-80dc-29f2a55b52c9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0011429 PMID:41385096 "[{""id"":""uuid:32f4cc85-d94f-4623-ae13-dbc7b9ce3043"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6c6a9f59-cf59-4c7b-8af9-93a53c97dfae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:b1febcf1-be7c-44d5-a78b-5af7c5ce3cb9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:a78703d5-0396-4541-90be-68acfa015dbb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2a5599a8-6a71-4f1d-bc02-96049abdc078"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:a9ac13c6-5c8e-4b38-9d80-ed45de70539a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats UMLS:C1290158 PMID:41385096 "[{""id"":""uuid:f8042838-ab8c-4013-b9e3-2425582d0c79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7b93c643-aea6-41ec-bd1e-d26515daacb6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:7fd5ee87-36ba-47f0-bd2a-d7a8038757a9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0040698 PMID:41385096 "[{""id"":""uuid:c9545712-ff7b-45d9-bee0-edf8d68ee7da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:18b84ef6-83c4-4aa5-bdcb-c3a1ef3f23bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:f0d29adc-1de5-4217-8e0f-fed55369db7c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0004855 PMID:41385096 "[{""id"":""uuid:3a8e495b-0cad-4982-9f7b-718322f5e021"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a479ff5c-f4f9-447c-98b1-f81c32860184"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:cc8abc80-0e4d-4edb-9b04-59a56289c407 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats UMLS:C0149896 PMID:41385096 "[{""id"":""uuid:69e7cf0d-9ea1-4da0-8653-34de615c535e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4a60600c-67e1-4d61-aa63-66d9b00aa0a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:dee3ea9a-491c-48e3-8038-f3cb2e394fb7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:f83a07dd-217c-40dd-96d6-e9cdf14fb8d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9be285c4-78b8-479e-a754-fa43473fe005"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:06a1869d-aabb-432b-8a38-6ad9f23d1294 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0001875 PMID:41385096 "[{""id"":""uuid:cf89fb1d-b486-4993-91ec-9be99555310b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5223bc1e-6ce7-466c-afdc-72e818c1b345"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:43eba1dc-0ad3-4703-94ba-7b7ed4405e03 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats UMLS:C5441648 PMID:41385096 "[{""id"":""uuid:f2d0f930-5607-4e00-a5a4-250d7d9eb1d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:20ac2d7f-3e61-4862-b01e-8231a4cdd3ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:4078efe7-43d4-4afe-9a53-bdab633131c4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0016367 PMID:41385096 "[{""id"":""uuid:19b884f0-c32b-43df-8858-a905eb9b8c37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4daa917c-b9bd-4bc4-a0c3-4229032af770"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:d62d0714-d6db-47fd-a922-48c3c1806d2b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0019127 PMID:41385096 "[{""id"":""uuid:bf1529d6-29c7-4b9a-bfc6-2c185004d171"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f793c276-6777-47a2-91f6-78cfb6afbdcf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:2fec3114-5f86-4c27-9753-3dae9c6df4d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0006594 PMID:41385096 "[{""id"":""uuid:a38d41ce-fc0f-4211-be99-0e4e1a1b213c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:417296f9-0e20-4066-8474-d0a56be2ac5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:3261fc5d-7a6f-4567-b19c-e47c1f052ebb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0015614 PMID:41385096 "[{""id"":""uuid:c2f0d505-bb2d-427c-a787-4dd2fa1c80bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cfe267a0-7b91-4c51-bffe-0fcf4374be2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:f01fbc5a-1160-4401-a7ee-48e32f5f5b5a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0006545 PMID:41385096 "[{""id"":""uuid:7cddf367-a32b-41c8-a9aa-be22907dd72b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:703730ce-299c-4f39-8c0f-f5bfde6ca7b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:5f351f7f-09fc-4da0-b364-09b682810b38 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0018229 PMID:41385096 "[{""id"":""uuid:888bff5e-fd45-4cfa-87d4-8fdd2e90408a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2f0abd39-da6c-4c6f-af0b-c242716b9655"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:d9bf1fda-4533-43a9-8804-395b1656ff68 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0043233 PMID:41385096 "[{""id"":""uuid:e482f919-90cc-4370-83cf-e22f5ab03717"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cb50e331-0495-4ddd-a2b4-9610dbb389fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:e03bcdfd-2ce4-468e-8483-7e85024a943a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0009691 PMID:41385096 "[{""id"":""uuid:cfa0db42-6fc4-4746-83c7-fa4166ec1461"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:46a75e5f-82da-49bf-8328-51adbe0e6f86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:fb4c9298-4d0c-4104-8d0a-028e33e5a8a8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:c6855624-654c-4ec1-b54b-f37cdb344906"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:af625cb4-5ea9-4263-b505-7dfe7424ff52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:7ab300a8-19bd-4bd7-a215-12f24573e6ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0006608 PMID:41385096 "[{""id"":""uuid:29ff2e12-79fe-4844-ad67-06b144c836ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a277d022-3931-4b65-a6e7-d82b3b57401c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:ed17b699-ada9-4dd0-9f4d-cd68ffe10bda biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:74289549-1861-4f4d-b70a-cbfb3724043b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:39532aec-34a1-4a33-b387-10f50a0c4388"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:2963d49d-57d7-4050-926e-1d17e4e0fe87 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0024332 PMID:41385096 "[{""id"":""uuid:74b865b2-7fc2-4a32-a065-d0301cc71db7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:223c5a89-8990-405b-b268-5fbf129c682a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:19b3dd65-e0c3-48bd-a1a3-6a680ef90a8c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:56bd4c5a-344e-4d64-827e-328f9fa4f603"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0db05906-1558-4ede-bf7e-bbb7fd60c285"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:05d5cf7f-3dbb-47f8-9921-246d9f9ee003 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0005480 PMID:41385096 "[{""id"":""uuid:ce087203-0775-48a8-b345-f317b91e4f76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ed0f432c-61a4-47f7-93fb-8952d3088377"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:757221d9-ff96-4394-8f05-0be629509384 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:c8588d00-df2a-4d18-bb2e-76259c41592d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fcdf50a0-a65c-47e1-880f-5669d1a969b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:d60dc199-a218-4da4-8cca-6154089dd176 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0043789 PMID:41385096 "[{""id"":""uuid:422e73a8-f25d-44b7-8e3f-3abd16d059a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:45c2138f-d4eb-4647-92b0-d86a4b0d2a31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:2ec86511-1477-40ad-8b59-8766d99be1aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0000775 PMID:41385096 "[{""id"":""uuid:d54d82dd-6ceb-4b6a-83d7-657929041bda"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d7ac3acb-e6a2-4d1e-ba7f-bcc43c1bcb94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:c37e8517-4d30-49ec-9fe2-494d6cf5a19a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0003085 PMID:41385096 "[{""id"":""uuid:6d75a594-d026-4842-bee7-5d9bb3bc0f34"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d34f6fb6-4744-4737-8813-0965b06b2d26"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:04b9e9ab-1b40-4393-9e09-2281308daca7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0001034 PMID:41385096 "[{""id"":""uuid:636ffa6d-d7bf-40c3-b5a9-19056460b3d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fb0a971b-38bd-4ca2-a522-a13cb9569a06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:33a948a3-e159-4f5e-a659-e96db9cf6323 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0005883 PMID:41385096 "[{""id"":""uuid:14c3a39a-f4a8-4a68-8570-e753e99e1fa1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:188b0897-9286-484d-bc0d-e0e5a60922a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:b080452f-f97f-488d-8fa7-0b49e3fbe9c9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0006814 PMID:41385096 "[{""id"":""uuid:3f51517e-da47-4b3a-9eff-4b0730e4c6de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:07771e8a-f36f-46dd-9149-f4f5d87f2984"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:43eecc4a-4cee-4a62-a8d8-7ce270113171 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0004773 PMID:41385096 "[{""id"":""uuid:549a50a0-b32e-4eaf-a8b6-c22fee1451dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fb185b8f-c681-460d-8500-c1aa4676eab9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:8563f4e8-9840-4d9c-ae83-ee2ce02ffe38 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0004674 PMID:41385096 "[{""id"":""uuid:c5918925-b4c5-4d6f-8811-0fcd45e66c8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b81337f0-e42e-487d-bdc7-b6e8efbc69c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:c1ba7064-02d9-4c85-8ef2-ef0500e6eb76 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0006651 PMID:41385096 "[{""id"":""uuid:f0ea620f-c60c-4bfb-ab88-1d9d059f43ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:066566eb-77a0-4ce1-b5b3-0b98c2c89f3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:70a4f850-2837-43a8-9b5b-5fb3fa5d21f5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0006918 PMID:41385096 "[{""id"":""uuid:20fbaedb-8126-4e1f-8ca7-a162e76bb9d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b6157045-5991-4072-9f3b-3f7192139271"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:172bd8c0-4265-40f7-863c-694ac37d1ce5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0001280 PMID:41385096 "[{""id"":""uuid:12a8af37-0988-4e76-93f9-7bb6490f552f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0983beb4-08b5-49b5-bacc-61f83a7fa210"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:d87258e5-a4dd-4aaa-9576-0cd3315356cf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0005885 PMID:41385096 "[{""id"":""uuid:77140e0c-b001-4130-bbcd-3a8b93dd9068"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:885d4c67-43c2-4a0c-8568-61db7ca7f9cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:62ca64a4-0f10-4015-8a05-8f5ad1e77885 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0019198 PMID:41385096 "[{""id"":""uuid:ce0f07c1-5e73-4a45-8776-7b6eb93a1ca3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a050eeb9-62cf-47b1-98d6-08b31bc2981a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:c37b3312-e096-446e-883a-e5c124822bda biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0019338 PMID:41385096 "[{""id"":""uuid:f7f2d218-2e71-4f27-b1c4-db1e22a4b530"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e8a35c58-0fab-449f-9a33-0ef4def5e762"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:1adfc1d8-1c37-4b0f-8133-6262d95a37ae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0015274 PMID:41385096 "[{""id"":""uuid:23f75c67-93d2-4af8-8310-9d493ad33baf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:15e077ea-889c-481e-abd9-859e8ab79a89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:c02197a2-183a-4ad0-8202-9715e4b0e239 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0006052 PMID:41385096 "[{""id"":""uuid:c77e7392-b2b0-44a7-9ee2-32ee392ab757"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:75257054-a880-4319-b7c5-7aad1ad3f855"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:584c5271-ed37-4c0c-b0ab-5de0658e6d5d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0005848 PMID:41385096 "[{""id"":""uuid:9b0dbea7-2390-43b3-bf81-f70c38e2a777"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e06a204a-3a3f-424b-a57a-648e5a0e096b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:b7576b2d-cbda-437b-9ee7-473391d9fe61 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0002572 PMID:41385096 "[{""id"":""uuid:ec1f0dda-146a-417b-a968-467868c0cffd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9b65c131-fe7f-4922-9c97-7d24175ba5a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:dfa8a3c6-c8d2-4fc3-864f-05c3048311fb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0019098 PMID:41385096 "[{""id"":""uuid:b222a44e-4d22-4166-8ed2-c5a5a6556de2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:26e5b75c-80ac-4406-9154-c3b89810a863"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:509fc5d3-5ade-4202-bfc5-534701ff714e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0001198 PMID:41385096 "[{""id"":""uuid:3920174b-e8c1-4d71-80fa-c161a798d791"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:850736ee-2b37-4479-88ea-8419a218a3c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:d74bba3e-7dfe-4e34-8d1c-9fa9aef1ddfa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats UMLS:C0002879 PMID:41385096 "[{""id"":""uuid:1869a97a-2527-4ef9-907c-f2932f9f1687"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ddb44532-fcb4-44f8-8635-3f29118ed81e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:9d8803ac-cd95-4eac-b836-c202d86a33a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0020108 PMID:41385096 "[{""id"":""uuid:eed4dd99-5c26-4f49-aa06-51190e415631"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6455dcbc-fd1c-482d-b9c5-9ce4698003dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:194c5884-dc9d-4e5c-884e-914e24657c59 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0002280 PMID:41385096 "[{""id"":""uuid:109bcc72-4c52-452e-a52f-3c7137acf8d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3d6d0406-e790-41fa-9084-12d51b47a11c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:4421b680-db2b-452c-9f04-2038e43bd224 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0015253 PMID:41385096 "[{""id"":""uuid:c3d2d381-8263-4818-b1b2-cff377c6856b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c1aea7d4-9ade-4b81-a39e-7c1eea51227a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:0baaaa60-dbe1-4ef7-8b3f-57b4f16e6c06 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0005059 PMID:41385096 "[{""id"":""uuid:ec8165f0-fff9-41e8-9082-4ac9ca46bb60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:10f3423b-8eff-4b44-a381-14b6089b3c67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:83262465-023f-47f1-a8b5-f632967be1e5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0004095 PMID:41385096 "[{""id"":""uuid:57c8b1ff-8707-4179-bbf3-5cac66975d24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d40c3b92-fceb-422a-bc5d-27b68f15daca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:d6deb46a-44b8-4e29-91f5-7f6c421dc9a2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0004355 PMID:41385096 "[{""id"":""uuid:1228e0bc-1d38-4eae-9f6e-d988b9a31290"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:51bdfb87-7d08-4b3d-8a2b-d28a5b36f09f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:44c396cc-9615-4352-93a7-bd14a301b285 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0005377 PMID:41385096 "[{""id"":""uuid:d0aa3630-361f-4962-a843-f3fdb6307192"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9ba2752f-e07c-414c-982e-0048d4c51fb6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:f94149bd-df04-4bcb-9887-6b05e148203c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:bfab066c-f59b-450a-9b51-43c6054f8fb9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:74cef009-3924-4e84-81ff-1ac2b038d444"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:681f7756-122d-4765-9725-9445c684d6e3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats UMLS:C0678202 PMID:41385096 "[{""id"":""uuid:38732603-443d-439c-aadf-492087057878"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:70ab1710-0dad-4586-a4be-685d93cffbb3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:5977170e-4b6e-4e59-add8-3da41b85414e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0006042 PMID:41385096 "[{""id"":""uuid:418d2540-d260-431f-a217-3270746787ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8aa01a49-0e05-40de-b891-96f2fc87fdb2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:7f114fd4-922c-4abd-ad80-6f2dbd90c476 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16962 biolink:treats MONDO:0019444 PMID:41385096 "[{""id"":""uuid:71dfe120-f510-4b61-9830-cb640394deac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7e424e6f-9241-4d1c-ab1d-6caa85065021"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] When oral therapy is not feasible: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance). Congenital adrenal hyperplasia Nonsuppurative thyroiditis Hypercalcemia associated with cancer 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3. Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Acute rheumatic carditis Systemic dermatomyositis (polymyositis) 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6. Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa, such as: Allergic conjunctivitis Keratitis Allergic corneal marginal ulcers Herpes zoster ophthalmicus Iritis and iridocyclitis Chorioretinitis Anterior segment inflammation Diffuse posterior uveitis and choroiditis Optic neuritis Sympathetic ophthalmia 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculosis chemotherapy Aspiration pneumonitis 8. Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus 11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement uuid:32fcd3b5-4d92-4c0c-9f94-6d4d2480406e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0001719 PMID:41385096 "[{""id"":""uuid:c4625f7d-c8f2-44cc-9f3f-edbafaec0f26"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c6e0e969-ceb1-4094-9aa5-ed11c64313c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Doxycycline for Injection, USP and other antibacterial drugs, Doxycycline for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline for Injection, USP is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever, and the typhus group, Q fever, rickettsial pox and tick fevers). Mycoplasma pneumoniae (PPLO, Eaton Agent). Agents of psittacosis and ornithosis. Agents of lymphogranuloma venereum and granuloma inguinale. The spirochetal agent of relapsing fever (Borrelia recurrentis) . The following gram-negative microorganisms: Haemophilus ducreyi (chancroid). Yersinia pestis and Francisella tularensis . Bartonella bacilliformis . Bacteroides species. Vibrio cholerae and Campylobacter fetus . Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes . Shigella species. Acinetobacter species. Haemophilus influenzae (respiratory infections). Klebsiella species (respiratory and urinary infections). Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Enterococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Streptococcus pneumoniae . Staphylococcus aureus , respiratory, skin and soft tissue infections. Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections. Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of infections due to: Neisseria gonorrhoeae and N. meningitidis . Treponema pallidum and Treponema pallidum subspecies pertenue (syphilis and yaws). Listeria monocytogenes . Clostridium species. Fusobacterium fusiforme (Vincent's infection). Actinomyces species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. Doxycycline is indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. uuid:c8a5fa31-6988-4b75-8cc4-300a9de30eb2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50845 biolink:treats MONDO:0005373 PMID:41385096 "[{""id"":""uuid:eeccbd83-42d6-450d-9c9d-7e08b29bd0a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5ab3c416-bb94-4def-bf7b-c9fe81415010"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] To reduce the development of drug-resistant bacteria and maintain the effectiveness of Doxycycline for Injection, USP and other antibacterial drugs, Doxycycline for Injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Doxycycline for Injection, USP is indicated in infections caused by the following microorganisms: Rickettsiae (Rocky Mountain spotted fever, typhus fever, and the typhus group, Q fever, rickettsial pox and tick fevers). Mycoplasma pneumoniae (PPLO, Eaton Agent). Agents of psittacosis and ornithosis. Agents of lymphogranuloma venereum and granuloma inguinale. The spirochetal agent of relapsing fever (Borrelia recurrentis) . The following gram-negative microorganisms: Haemophilus ducreyi (chancroid). Yersinia pestis and Francisella tularensis . Bartonella bacilliformis . Bacteroides species. Vibrio cholerae and Campylobacter fetus . Brucella species (in conjunction with streptomycin). Because many strains of the following groups of microorganisms have been shown to be resistant to tetracyclines, culture and susceptibility testing are recommended. Doxycycline is indicated for treatment of infections caused by the following gram-negative microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Escherichia coli. Enterobacter aerogenes . Shigella species. Acinetobacter species. Haemophilus influenzae (respiratory infections). Klebsiella species (respiratory and urinary infections). Doxycycline is indicated for treatment of infections caused by the following gram-positive microorganisms when bacteriologic testing indicates appropriate susceptibility to the drug: Streptococcus species: Up to 44 percent of strains of Streptococcus pyogenes and 74 percent of Enterococcus faecalis have been found to be resistant to tetracycline drugs. Therefore, tetracyclines should not be used for streptococcal disease unless the organism has been demonstrated to be sensitive. For upper respiratory infections due to group A beta-hemolytic streptococci, penicillin is the usual drug of choice, including prophylaxis of rheumatic fever. Streptococcus pneumoniae . Staphylococcus aureus , respiratory, skin and soft tissue infections. Tetracyclines are not the drugs of choice in the treatment of any type of staphylococcal infections. Anthrax due to Bacillus anthracis , including inhalational anthrax (post-exposure): to reduce the incidence or progression of disease following exposure to aerosolized Bacillus anthracis . When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of infections due to: Neisseria gonorrhoeae and N. meningitidis . Treponema pallidum and Treponema pallidum subspecies pertenue (syphilis and yaws). Listeria monocytogenes . Clostridium species. Fusobacterium fusiforme (Vincent's infection). Actinomyces species. In acute intestinal amebiasis, doxycycline may be a useful adjunct to amebicides. Doxycycline is indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. uuid:0000ea25-e470-4890-ad36-47e6eb3abec8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64045 biolink:treats EFO:0004888 PMID:41385096 "[{""id"":""uuid:4f0e1dc2-d72b-4fe9-b3f6-7bc67ec01365"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a0035a7e-cabc-4c14-b4af-958118f86501"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BARHEMSYS ® is indicated in adults for: prevention of postoperative nausea and vomiting (PONV), either alone or in combination with an antiemetic of a different class. treatment of PONV in patients who have received antiemetic prophylaxis with an agent of a different class or have not received prophylaxis. uuid:ed1c6ead-338b-46d7-b277-57802963b1c9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:P0GVQ9A4S5 biolink:treats MONDO:0011962 PMID:41385096 "[{""id"":""uuid:f94b82b3-9511-48a9-ad72-db55e0ee0608"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:334c109a-b0a5-416e-a38c-2bd8358cf9b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1a10388d-cec6-473a-bb64-6a7f322efe55"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/jemperli""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] JEMPERLI is a programmed death receptor-1 (PD-1)–blocking antibody indicated: Endometrial Cancer • in combination with carboplatin and paclitaxel, followed by JEMPERLI as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer (EC). ( 1.1 ) • as a single agent for the treatment of adult patients with mismatch repair deficient (dMMR) recurrent or advanced EC, as determined by an FDA-approved test, that has progressed on or following prior treatment with a platinum-containing regimen in any setting and are not candidates for curative surgery or radiation. ( 1.1 , 2.1 ) Mismatch Repair Deficient Recurrent or Advanced Solid Tumors • as a single agent for the treatment of adult patients with dMMR recurrent or advanced solid tumors, as determined by an FDA-approved test, that have progressed on or following prior treatment and who have no satisfactory alternative treatment options. 1 ( 1.2 , 2.1 ) 1 This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). ( 1.2 )|[EMA] Jemparli is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI H) recurrent or advanced endometrial cancer (EC) that has progressed on or following prior treatment with a platinum-containing regimen. uuid:24697e6a-5340-4891-85b0-13b77383e2e1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:43830 biolink:treats MONDO:0001117 PMID:41385096 "[{""id"":""uuid:b3044ef2-dcf5-4b1f-affe-0952a84eae07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f58fff3d-ce4e-415b-9403-e13a91c5e510"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d14a4ba0-ffe0-4bb9-857b-76ed86c5e896"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lumeblue""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROVAYBLUE is indicated for the treatment of pediatric and adult patients with acquired methemoglobinemia.|[EMA] Acute symptomatic treatment of medicinal and chemical products- induced methaemoglobinaemia.Methylthioninium chloride Proveblue is indicated in adults, children and adolescents (aged 0 to 17 years old). uuid:a7b70fb8-6c2a-4698-9ff0-8844a6ae9fda biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4B6J53W8N3 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:4ca79320-50f4-4952-98c0-3c5cb5d7286f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3f89efd3-c21b-4e7b-8130-7b7d814c685f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RUKOBIA, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen due to resistance, intolerance, or safety considerations [see Clinical Studies ( 14 )]. uuid:9b693b95-bc9b-41ba-96d8-ccb03d57b144 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:139589551 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:075f99ff-3c99-4cdf-a72b-876355486e17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0bc837ef-a9fd-4386-901d-8c06f4932937"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:5d813a45-4381-492c-a2b6-1a0a206cfb9a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] APIDRA is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.|[EMA] Treatment of adults, adolescents and children, six years or older with diabetes mellitus, where treatment with insulin is required. uuid:bbfa8318-1613-4921-aa4d-cf19d636a1e4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229649 biolink:treats MONDO:0014222 PMID:41385096 "[{""id"":""uuid:bc96721c-5f60-4be3-9641-a8d72456acd5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:60ed9c3a-ce3e-4e64-bfa6-5a99fe694337"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] JOENJA is indicated for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older. uuid:05e30095-e147-4e0c-81e7-bb7eae7b94c3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229649 biolink:treats MONDO:0018338 PMID:41385096 "[{""id"":""uuid:15f7aeac-195e-4c58-ac0b-32166d83b8b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:009d97f0-e20f-4c05-ac60-8604f697c009"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] JOENJA is indicated for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older. uuid:830c2546-0c50-4b11-a63d-0eeddce75e9a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C4294565 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:0ecfbdcd-ad96-4294-96e0-79ce4ef57229"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1a59e2b4-755b-45f8-83b1-750d4c69c570"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a1bdff42-6d2a-408b-944a-0662ccd4e073"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XULTOPHY 100/3.6 is a combination of insulin degludec and liraglutide and is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use: • XULTOPHY 100/3.6 contains liraglutide. Coadministration with any other product containing liraglutide or another glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended [ see Warnings and Precautions ( 5.5 ) ]. • XULTOPHY 100/3.6 is not recommended for the treatment of diabetic ketoacidosis. • XULTOPHY 100/3.6 has not been studied in combination with prandial insulin.|[PMDA] A new combination drug indicated for the treatment of type 2 diabetes mellitus in cases where insulin therapy is indicated. MESH:C000629636 uuid:7e2d6434-8fe9-456c-b440-c9f4fe74798e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C4294565 biolink:treats MONDO:0012819 PMID:41385096 "[{""id"":""uuid:435bf131-5f51-4521-bafb-f5ca7ac8394f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:49e2a310-9bc2-471c-9166-89b9b18861c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XULTOPHY 100/3.6 is a combination of insulin degludec and liraglutide and is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use: • XULTOPHY 100/3.6 contains liraglutide. Coadministration with any other product containing liraglutide or another glucagon-like peptide-1 (GLP-1) receptor agonist is not recommended [ see Warnings and Precautions ( 5.5 ) ]. • XULTOPHY 100/3.6 is not recommended for the treatment of diabetic ketoacidosis. • XULTOPHY 100/3.6 has not been studied in combination with prandial insulin. MESH:C000629636 uuid:a29e6c1d-5ca4-48b0-870c-35b2c75e2ad5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:379014 biolink:treats MONDO:0004872 PMID:41385096 "[{""id"":""uuid:c7d5b919-18a4-4e44-bb6b-196ccfbe5cb8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7625e914-cf0b-4d04-90d0-91bc06735946"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Product is used for the anti-inflammatory and anesthetic relief of itching, pain, soreness and discomfort due to hemorrhoids, anal fissures, pruritus ani and similar conditions of the anal area. uuid:f11050c4-8d48-4f4a-b036-beabc27641cd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:379014 biolink:treats HP:0012390 PMID:41385096 "[{""id"":""uuid:a40c2421-f07e-4395-ad44-8499fbf3f316"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:88e05beb-58db-4203-bf3b-eb689790bb0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Product is used for the anti-inflammatory and anesthetic relief of itching, pain, soreness and discomfort due to hemorrhoids, anal fissures, pruritus ani and similar conditions of the anal area. uuid:16072dde-46bd-49bb-a8b2-82415918140a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:379014 biolink:treats UMLS:C0033775 PMID:41385096 "[{""id"":""uuid:4b6f7116-5ffb-4a75-8556-f48fc83a0a7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5f2264d6-4db1-403c-8c24-2272bb44b9bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Product is used for the anti-inflammatory and anesthetic relief of itching, pain, soreness and discomfort due to hemorrhoids, anal fissures, pruritus ani and similar conditions of the anal area. uuid:f1074a31-5239-4299-8cd4-94a405606d5a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:5IB2J79MCX biolink:treats MONDO:0100491 PMID:41385096 "[{""id"":""uuid:2def2105-e0fa-4f72-adb5-c561ced0c41e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:16cf22ce-f404-480b-a40b-d25845164e7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3fa4f4a7-4449-48e0-a6d6-8cd493f3500b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/spevigo""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] SPEVIGO is indicated for the treatment of generalized pustular psoriasis (GPP) in adults and pediatric patients 12 years of age and older and weighing at least 40 kg.|[EMA] Spevigo is indicated for the treatment of flares in adult patients with generalised pustular psoriasis (GPP) as monotherapy. uuid:3c3d8c8f-dc0a-4f30-9503-7088688f69c2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1858992 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:23a2c0eb-fe5d-45b0-855a-1ce3849e9a2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2d670b37-45ab-448c-84fa-77261bb12c8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:cb859df4-5382-4af2-a198-465c68f433df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/suliqua""]},{""id"":""uuid:856d56be-447a-4f61-a814-068cc46a5544"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SOLIQUA 100/33 is a combination of insulin glargine and lixisenatide and is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.|[EMA] Suliqua is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus to improve glycaemic control as an adjunct to diet and exercise in addition to metformin with or without SGLT-2 inhibitors.,|[PMDA] A new combination drug indicated for the treatment of type 2 diabetes mellitus in cases where insulin therapy is indicated. uuid:96b10c72-0353-4132-b5b4-be9352c4070a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2P6O7CFW5K biolink:treats MONDO:0017713 PMID:41385096 "[{""id"":""uuid:f4e125cb-c760-4a0c-813b-6f8d2c7e477d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a6545052-6dc0-44dd-a8bd-f4781759570b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DOJOLVI is indicated as a source of calories and fatty acids for the treatment of adult and pediatric patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAOD). uuid:d629ca4e-c56a-4471-b039-cfe331471922 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17141 biolink:treats MONDO:0009064 PMID:41385096 "[{""id"":""uuid:c6362aa1-19b7-4327-a291-b3bc9ff9dda9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:61edf09e-c716-4172-abaf-16cf6c757d32"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] CYSTADROPS is a cystine-depleting agent indicated for the treatment of corneal cystine crystal deposits in adults and children with cystinosis. uuid:df957d3c-d222-4a08-9cb3-a0c9185841c6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:370571 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:80228925-2d23-40a0-89e7-15d24ca7a8fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6053a1cc-aa50-4b78-b77f-2b79f9c906f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chlordiazepoxide and amitriptyline hydrochloride tablets are indicated for the treatment of patients with moderate to severe depression associated with moderate to severe anxiety. The therapeutic response to chlordiazepoxide and amitriptyline hydrochloride tablet occurs earlier and with fewer treatment failures than when either amitriptyline or chlordiazepoxide is used alone. Symptoms likely to respond in the first week of treatment include: insomnia, feelings of guilt or worthlessness, agitation, psychic and somatic anxiety, suicidal ideation and anorexia. uuid:14742277-b811-4347-ae4e-927cbfe5480e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:370571 biolink:treats MONDO:0011918 PMID:41385096 "[{""id"":""uuid:72cb3a14-7e40-4592-91bd-a4e4c6913ae1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:aec2752b-47b3-4b10-92b7-a669e5527b9d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chlordiazepoxide and amitriptyline hydrochloride tablets are indicated for the treatment of patients with moderate to severe depression associated with moderate to severe anxiety. The therapeutic response to chlordiazepoxide and amitriptyline hydrochloride tablet occurs earlier and with fewer treatment failures than when either amitriptyline or chlordiazepoxide is used alone. Symptoms likely to respond in the first week of treatment include: insomnia, feelings of guilt or worthlessness, agitation, psychic and somatic anxiety, suicidal ideation and anorexia. uuid:f88c0094-9b66-46d0-9655-f7dcae2f9575 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:370571 biolink:treats MONDO:0013600 PMID:41385096 "[{""id"":""uuid:e1594c5e-3696-4ff7-b670-c8f0905db8b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f9d8de8f-c5a6-4915-ad46-413e0c8d52ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chlordiazepoxide and amitriptyline hydrochloride tablets are indicated for the treatment of patients with moderate to severe depression associated with moderate to severe anxiety. The therapeutic response to chlordiazepoxide and amitriptyline hydrochloride tablet occurs earlier and with fewer treatment failures than when either amitriptyline or chlordiazepoxide is used alone. Symptoms likely to respond in the first week of treatment include: insomnia, feelings of guilt or worthlessness, agitation, psychic and somatic anxiety, suicidal ideation and anorexia. uuid:f1878f4a-8395-40fa-9370-2dd7c7c1dac8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:370571 biolink:treats MONDO:0005351 PMID:41385096 "[{""id"":""uuid:9165d3a1-c8b7-4ec4-bbb9-867f71d894a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1a86491e-019e-47d3-82b2-5a781e65c571"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chlordiazepoxide and amitriptyline hydrochloride tablets are indicated for the treatment of patients with moderate to severe depression associated with moderate to severe anxiety. The therapeutic response to chlordiazepoxide and amitriptyline hydrochloride tablet occurs earlier and with fewer treatment failures than when either amitriptyline or chlordiazepoxide is used alone. Symptoms likely to respond in the first week of treatment include: insomnia, feelings of guilt or worthlessness, agitation, psychic and somatic anxiety, suicidal ideation and anorexia. uuid:2f53e504-6dae-4cce-bf10-416ba20c3c2b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:136007 biolink:treats MONDO:0100187 PMID:41385096 "[{""id"":""uuid:3839f0ff-6c26-4002-897e-8dc03faf5c4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9069fdfd-6680-4113-8f08-7e7c51816b45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:5afc83e2-6750-4d2d-b492-2d7247023fb8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/relistor""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] RELISTOR is an opioid antagonist. RELISTOR tablets and RELISTOR injection are indicated for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g., weekly) opioid dosage escalation. ( 1.1 ) RELISTOR injection is indicated for the treatment of OIC in adults with advanced illness or pain caused by active cancer who require opioid dosage escalation for palliative care. ( 1.2 )|[EMA] Treatment of opioid-induced constipation in advanced-illness patients who are receiving palliative care when response to usual laxative therapy has not been sufficient. uuid:2d819e68-22e4-4e97-8199-5d757bfea489 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:194186 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:6ab8fe66-5cf5-48d4-8879-937d9020bb45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:041b1e00-e6a4-4e33-8457-46af1279b0cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:998452a2-79e3-4c00-b818-d4a22f343497"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/mounjaro""]},{""id"":""uuid:84538bde-7596-480f-8b39-df86bb109476"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MOUNJARO ® is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.|[EMA] Mounjaro is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance or contraindications- in addition to other medicinal products for the treatment of diabetes.For study results with respect to combinations, effects on glycaemic control and the populations studied, see sections 4.4, 4.5 and 5.1.|[PMDA] Drugs with a new active ingredient indicated for the treatment of type 2 diabetes mellitus. uuid:d0fdf03a-fd59-46f2-86cd-ad284df103db biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB18704 biolink:treats UMLS:C0746883 PMID:41385096 "[{""id"":""uuid:bb9fae20-5b78-44ff-8e7a-2dda3e7037f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:cfabed57-270f-4744-897a-cf58e74f0645"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RYZNEUTA is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. Limitations of Use RYZNEUTA is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation. uuid:0269944d-7060-4fbb-a8bc-f496e3c11f18 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:1L7BVT4Z4Z biolink:treats MONDO:0006733 PMID:41385096 "[{""id"":""uuid:56f7577c-a62e-4559-a455-2a8627212db5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2ab4097f-26a4-435a-a011-febb9b74051d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRYPTYR is indicated for the treatment of the signs and symptoms of dry eye disease. uuid:ebbd171b-aba9-43da-96a7-177ebbd39dbe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1940699 biolink:treats MONDO:0005231 PMID:41385096 "[{""id"":""uuid:07ee5233-a97b-4eb7-bba5-0fd71607aa24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6a2f3970-ffea-4b8f-82d4-1d11111613b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MAVYRET is indicated for the treatment of adult and pediatric patients 3 years and older with acute or chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A). MAVYRET is indicated for the treatment of adult and pediatric patients 3 years and older with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor (PI), but not both [see Dosage and Administration ( 2.2 ) and Clinical Studies ( 14 )]. uuid:5e9c6aee-796f-48f6-ad12-1d5719259666 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:ZJ0EKR6M10 biolink:treats UMLS:C0027627 PMID:41385096 "[{""id"":""uuid:61bfc89f-fc18-4445-8a2e-44d8093c22ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1b841e44-2c3f-4092-a1a1-70b4916784b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ILLUCCIX, after radiolabeling with Ga 68, is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: With suspected metastasis who are candidates for initial definitive therapy. With suspected recurrence based on elevated serum prostate-specific antigen (PSA) level. For selection of patients who are indicated for PSMA-directed therapy as described in the prescribing information of the therapeutic products. PUBCHEM.COMPOUND:91800164 uuid:be1d78f9-3605-4eb6-81f7-87ed4f56bb0e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:ZJ0EKR6M10 biolink:treats UMLS:C2825055 PMID:41385096 "[{""id"":""uuid:96eba030-c302-4a0c-8a69-7b7dcf7412a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9f9d34c9-104c-4cca-973d-6cf93cb90014"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ILLUCCIX, after radiolabeling with Ga 68, is indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer: With suspected metastasis who are candidates for initial definitive therapy. With suspected recurrence based on elevated serum prostate-specific antigen (PSA) level. For selection of patients who are indicated for PSMA-directed therapy as described in the prescribing information of the therapeutic products. PUBCHEM.COMPOUND:91800164 uuid:05d5242e-7f71-4101-b4d6-849573db1d79 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3766 biolink:treats MONDO:0001475 PMID:41385096 "[{""id"":""uuid:8e42bd2e-b32e-4398-88e9-edf07893a556"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f5fa561c-f31e-485f-9142-f7813ae2ec8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clozapine orally disintegrating tablets (Clozapine ODT) is an atypical antipsychotic indicated for: Treatment of severely ill patients with schizophrenia who fail to respond adequately to standard antipsychotic treatment. Because of the risks of severe neutropenia and of seizure associated with its use, Clozapine ODT should be used only in patients who have failed to respond adequately to standard antipsychotic treatment ( 1.1 ) Reducing the risk of recurrent suicidal behavior in patients with schizophrenia or schizoaffective disorder who are judged to be at chronic risk for re-experiencing suicidal behavior ( 1.2 ) uuid:68007d32-8960-4050-8e08-cec699d53721 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5908975 biolink:treats MONDO:0100096 PMID:41385096 "[{""id"":""uuid:dce1f832-ab32-4fed-b08a-e37a1b1772c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:495e3c44-b16e-4fba-8fd9-9c1113e22af8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the unapproved product PEMGARDA (pemivibart) for the pre-exposure prophylaxis of coronavirus disease 2019 (COVID-19) in adults and adolescents (12 years of age and older weighing at least 40 kg): Who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2 and Who have moderate-to-severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments and are unlikely to mount an adequate response to COVID-19 vaccination. Medical conditions or treatments that may result in moderate to severe immune compromise and an inadequate immune response to COVID-19 vaccination include: Active treatment for solid tumor and hematologic malignancies Hematologic malignancies associated with poor responses to COVID-19 vaccines regardless of current treatment status (e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia) Receipt of solid-organ transplant or an islet transplant and taking immunosuppressive therapy Receipt of chimeric antigen receptor (CAR)-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppressive therapy) Moderate or severe primary immunodeficiency (e.g., common variable immunodeficiency disease, severe combined immunodeficiency, DiGeorge syndrome, Wiskott-Aldrich syndrome) Advanced or untreated HIV infection (people with HIV and CD4 cell counts <200/mm 3 , history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV) Active treatment with high-dose corticosteroids (i.e., ≥20 mg prednisone or equivalent per day when administered for ≥2 weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, and biologic agents that are immunosuppressive or immunomodulatory (e.g., B-cell depleting agents) Limitations of Authorized Use PEMGARDA is not authorized for use: For treatment of COVID-19, or For post-exposure prophylaxis of COVID-19 in individuals who have been exposed to someone infected with SARS-CoV-2. Pre-exposure prophylaxis with PEMGARDA is not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended. Individuals for whom COVID-19 vaccination is recommended, including individuals with moderate-to-severe immune compromise who may derive benefit from COVID-19 vaccination, should receive COVID‑19 vaccination. In individuals who have recently received a COVID-19 vaccine, PEMGARDA should be administered at least 2 weeks after vaccination. PEMGARDA may only be prescribed for an individual patient by physicians, advanced practice registered nurses, and physician assistants that are licensed or authorized under State law to prescribe drugs. PEMGARDA has been authorized by FDA for the emergency use described above. PEMGARDA is not FDA-approved for any use, including use for pre-exposure prophylaxis of COVID-19. PEMGARDA is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of PEMGARDA under section 564(b)(1) of the FD&C Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. Justification for Emergency Use of Drugs During the COVID‑19 Pandemic: There is currently an outbreak of coronavirus disease 2019 (COVID‑19) caused by SARS‑CoV‑2, a novel coronavirus. The Secretary of the U.S. Department of Health and Human Services (HHS) has: Determined that there is a public health emergency, or significant potential for a public health emergency [1] . Declared that circumstances exist justifying the authorization of emergency use of drugs and biological products for the prevention or treatment of COVID-19 [2] . An EUA is an FDA authorization for the emergency use of an unapproved product or unapproved use of an approved product (i.e., drug, biological product, or device) in the United States under certain circumstances including, but not limited to, when the Secretary of HHS declares that there is a public health emergency that affects the national security or the health and security of United States citizens living abroad, and that involves biological agent(s) or a disease or condition that may be attributable to such agent(s). Criteria for issuing an EUA include: The biological agent(s) can cause a serious or life-threatening disease or condition. Based on the totality of the available scientific evidence (including data from adequate and well controlled clinical trials, if available), it is reasonable to believe that: the product may be effective in diagnosing, treating, or preventing the serious or life-threatening disease or condition; and the known and potential benefits of the product - when used to diagnose, prevent, or treat such disease or condition - outweigh the known and potential risks of the product, taking into consideration the material threat posed by the biological agent(s). There is no adequate, approved, and available alternative to the product for diagnosing, preventing, or treating the serious or life-threatening disease or condition. Information Regarding Available Alternatives for the EUA Authorized Use There are no adequate, approved, and available alternatives to PEMGARDA for the pre-exposure prophylaxis of COVID-19 in individuals who are unlikely to mount an adequate immune response to COVID-19 vaccination. For information on clinical studies of PEMGARDA and other therapies for the pre-exposure prophylaxis of COVID-19, see www.clinicaltrials.gov . DRUGBANK:DB18720 uuid:2e969fcc-8c41-4c11-98f6-7789349b91f3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5908975 biolink:treats UMLS:C0280100 PMID:41385096 "[{""id"":""uuid:b6f2515b-f97c-4f33-a8bd-228d560ce6e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:96c6bfc2-5b42-4b8b-ba86-082ee05d2e3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the unapproved product PEMGARDA (pemivibart) for the pre-exposure prophylaxis of coronavirus disease 2019 (COVID-19) in adults and adolescents (12 years of age and older weighing at least 40 kg): Who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2 and Who have moderate-to-severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments and are unlikely to mount an adequate response to COVID-19 vaccination. Medical conditions or treatments that may result in moderate to severe immune compromise and an inadequate immune response to COVID-19 vaccination include: Active treatment for solid tumor and hematologic malignancies Hematologic malignancies associated with poor responses to COVID-19 vaccines regardless of current treatment status (e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia) Receipt of solid-organ transplant or an islet transplant and taking immunosuppressive therapy Receipt of chimeric antigen receptor (CAR)-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppressive therapy) Moderate or severe primary immunodeficiency (e.g., common variable immunodeficiency disease, severe combined immunodeficiency, DiGeorge syndrome, Wiskott-Aldrich syndrome) Advanced or untreated HIV infection (people with HIV and CD4 cell counts <200/mm 3 , history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV) Active treatment with high-dose corticosteroids (i.e., ≥20 mg prednisone or equivalent per day when administered for ≥2 weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, and biologic agents that are immunosuppressive or immunomodulatory (e.g., B-cell depleting agents) Limitations of Authorized Use PEMGARDA is not authorized for use: For treatment of COVID-19, or For post-exposure prophylaxis of COVID-19 in individuals who have been exposed to someone infected with SARS-CoV-2. Pre-exposure prophylaxis with PEMGARDA is not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended. Individuals for whom COVID-19 vaccination is recommended, including individuals with moderate-to-severe immune compromise who may derive benefit from COVID-19 vaccination, should receive COVID‑19 vaccination. In individuals who have recently received a COVID-19 vaccine, PEMGARDA should be administered at least 2 weeks after vaccination. PEMGARDA may only be prescribed for an individual patient by physicians, advanced practice registered nurses, and physician assistants that are licensed or authorized under State law to prescribe drugs. PEMGARDA has been authorized by FDA for the emergency use described above. PEMGARDA is not FDA-approved for any use, including use for pre-exposure prophylaxis of COVID-19. PEMGARDA is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of PEMGARDA under section 564(b)(1) of the FD&C Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. Justification for Emergency Use of Drugs During the COVID‑19 Pandemic: There is currently an outbreak of coronavirus disease 2019 (COVID‑19) caused by SARS‑CoV‑2, a novel coronavirus. The Secretary of the U.S. Department of Health and Human Services (HHS) has: Determined that there is a public health emergency, or significant potential for a public health emergency [1] . Declared that circumstances exist justifying the authorization of emergency use of drugs and biological products for the prevention or treatment of COVID-19 [2] . An EUA is an FDA authorization for the emergency use of an unapproved product or unapproved use of an approved product (i.e., drug, biological product, or device) in the United States under certain circumstances including, but not limited to, when the Secretary of HHS declares that there is a public health emergency that affects the national security or the health and security of United States citizens living abroad, and that involves biological agent(s) or a disease or condition that may be attributable to such agent(s). Criteria for issuing an EUA include: The biological agent(s) can cause a serious or life-threatening disease or condition. Based on the totality of the available scientific evidence (including data from adequate and well controlled clinical trials, if available), it is reasonable to believe that: the product may be effective in diagnosing, treating, or preventing the serious or life-threatening disease or condition; and the known and potential benefits of the product - when used to diagnose, prevent, or treat such disease or condition - outweigh the known and potential risks of the product, taking into consideration the material threat posed by the biological agent(s). There is no adequate, approved, and available alternative to the product for diagnosing, preventing, or treating the serious or life-threatening disease or condition. Information Regarding Available Alternatives for the EUA Authorized Use There are no adequate, approved, and available alternatives to PEMGARDA for the pre-exposure prophylaxis of COVID-19 in individuals who are unlikely to mount an adequate immune response to COVID-19 vaccination. For information on clinical studies of PEMGARDA and other therapies for the pre-exposure prophylaxis of COVID-19, see www.clinicaltrials.gov . DRUGBANK:DB18720 uuid:7bc2197a-acd3-44cd-9d55-6c5bc46260b8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5908975 biolink:treats NCIT:C157387 PMID:41385096 "[{""id"":""uuid:192ff606-e8f4-422b-8f03-da071adffd71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d1fbada3-0848-44d7-ad80-b2d73b6b3dff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the unapproved product PEMGARDA (pemivibart) for the pre-exposure prophylaxis of coronavirus disease 2019 (COVID-19) in adults and adolescents (12 years of age and older weighing at least 40 kg): Who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2 and Who have moderate-to-severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments and are unlikely to mount an adequate response to COVID-19 vaccination. Medical conditions or treatments that may result in moderate to severe immune compromise and an inadequate immune response to COVID-19 vaccination include: Active treatment for solid tumor and hematologic malignancies Hematologic malignancies associated with poor responses to COVID-19 vaccines regardless of current treatment status (e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia) Receipt of solid-organ transplant or an islet transplant and taking immunosuppressive therapy Receipt of chimeric antigen receptor (CAR)-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppressive therapy) Moderate or severe primary immunodeficiency (e.g., common variable immunodeficiency disease, severe combined immunodeficiency, DiGeorge syndrome, Wiskott-Aldrich syndrome) Advanced or untreated HIV infection (people with HIV and CD4 cell counts <200/mm 3 , history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV) Active treatment with high-dose corticosteroids (i.e., ≥20 mg prednisone or equivalent per day when administered for ≥2 weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, and biologic agents that are immunosuppressive or immunomodulatory (e.g., B-cell depleting agents) Limitations of Authorized Use PEMGARDA is not authorized for use: For treatment of COVID-19, or For post-exposure prophylaxis of COVID-19 in individuals who have been exposed to someone infected with SARS-CoV-2. Pre-exposure prophylaxis with PEMGARDA is not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended. Individuals for whom COVID-19 vaccination is recommended, including individuals with moderate-to-severe immune compromise who may derive benefit from COVID-19 vaccination, should receive COVID‑19 vaccination. In individuals who have recently received a COVID-19 vaccine, PEMGARDA should be administered at least 2 weeks after vaccination. PEMGARDA may only be prescribed for an individual patient by physicians, advanced practice registered nurses, and physician assistants that are licensed or authorized under State law to prescribe drugs. PEMGARDA has been authorized by FDA for the emergency use described above. PEMGARDA is not FDA-approved for any use, including use for pre-exposure prophylaxis of COVID-19. PEMGARDA is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of PEMGARDA under section 564(b)(1) of the FD&C Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. Justification for Emergency Use of Drugs During the COVID‑19 Pandemic: There is currently an outbreak of coronavirus disease 2019 (COVID‑19) caused by SARS‑CoV‑2, a novel coronavirus. The Secretary of the U.S. Department of Health and Human Services (HHS) has: Determined that there is a public health emergency, or significant potential for a public health emergency [1] . Declared that circumstances exist justifying the authorization of emergency use of drugs and biological products for the prevention or treatment of COVID-19 [2] . An EUA is an FDA authorization for the emergency use of an unapproved product or unapproved use of an approved product (i.e., drug, biological product, or device) in the United States under certain circumstances including, but not limited to, when the Secretary of HHS declares that there is a public health emergency that affects the national security or the health and security of United States citizens living abroad, and that involves biological agent(s) or a disease or condition that may be attributable to such agent(s). Criteria for issuing an EUA include: The biological agent(s) can cause a serious or life-threatening disease or condition. Based on the totality of the available scientific evidence (including data from adequate and well controlled clinical trials, if available), it is reasonable to believe that: the product may be effective in diagnosing, treating, or preventing the serious or life-threatening disease or condition; and the known and potential benefits of the product - when used to diagnose, prevent, or treat such disease or condition - outweigh the known and potential risks of the product, taking into consideration the material threat posed by the biological agent(s). There is no adequate, approved, and available alternative to the product for diagnosing, preventing, or treating the serious or life-threatening disease or condition. Information Regarding Available Alternatives for the EUA Authorized Use There are no adequate, approved, and available alternatives to PEMGARDA for the pre-exposure prophylaxis of COVID-19 in individuals who are unlikely to mount an adequate immune response to COVID-19 vaccination. For information on clinical studies of PEMGARDA and other therapies for the pre-exposure prophylaxis of COVID-19, see www.clinicaltrials.gov . DRUGBANK:DB18720 uuid:f9da26b0-63d3-4dd9-ac62-3f8ec2b68f50 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5908975 biolink:treats MONDO:0004948 PMID:41385096 "[{""id"":""uuid:640601c7-2dc9-42d5-8cf4-270fff30ddbb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d076824b-fe3d-4cb6-a376-87fdbe13a4ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the unapproved product PEMGARDA (pemivibart) for the pre-exposure prophylaxis of coronavirus disease 2019 (COVID-19) in adults and adolescents (12 years of age and older weighing at least 40 kg): Who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2 and Who have moderate-to-severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments and are unlikely to mount an adequate response to COVID-19 vaccination. Medical conditions or treatments that may result in moderate to severe immune compromise and an inadequate immune response to COVID-19 vaccination include: Active treatment for solid tumor and hematologic malignancies Hematologic malignancies associated with poor responses to COVID-19 vaccines regardless of current treatment status (e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia) Receipt of solid-organ transplant or an islet transplant and taking immunosuppressive therapy Receipt of chimeric antigen receptor (CAR)-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppressive therapy) Moderate or severe primary immunodeficiency (e.g., common variable immunodeficiency disease, severe combined immunodeficiency, DiGeorge syndrome, Wiskott-Aldrich syndrome) Advanced or untreated HIV infection (people with HIV and CD4 cell counts <200/mm 3 , history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV) Active treatment with high-dose corticosteroids (i.e., ≥20 mg prednisone or equivalent per day when administered for ≥2 weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, and biologic agents that are immunosuppressive or immunomodulatory (e.g., B-cell depleting agents) Limitations of Authorized Use PEMGARDA is not authorized for use: For treatment of COVID-19, or For post-exposure prophylaxis of COVID-19 in individuals who have been exposed to someone infected with SARS-CoV-2. Pre-exposure prophylaxis with PEMGARDA is not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended. Individuals for whom COVID-19 vaccination is recommended, including individuals with moderate-to-severe immune compromise who may derive benefit from COVID-19 vaccination, should receive COVID‑19 vaccination. In individuals who have recently received a COVID-19 vaccine, PEMGARDA should be administered at least 2 weeks after vaccination. PEMGARDA may only be prescribed for an individual patient by physicians, advanced practice registered nurses, and physician assistants that are licensed or authorized under State law to prescribe drugs. PEMGARDA has been authorized by FDA for the emergency use described above. PEMGARDA is not FDA-approved for any use, including use for pre-exposure prophylaxis of COVID-19. PEMGARDA is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of PEMGARDA under section 564(b)(1) of the FD&C Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. Justification for Emergency Use of Drugs During the COVID‑19 Pandemic: There is currently an outbreak of coronavirus disease 2019 (COVID‑19) caused by SARS‑CoV‑2, a novel coronavirus. The Secretary of the U.S. Department of Health and Human Services (HHS) has: Determined that there is a public health emergency, or significant potential for a public health emergency [1] . Declared that circumstances exist justifying the authorization of emergency use of drugs and biological products for the prevention or treatment of COVID-19 [2] . An EUA is an FDA authorization for the emergency use of an unapproved product or unapproved use of an approved product (i.e., drug, biological product, or device) in the United States under certain circumstances including, but not limited to, when the Secretary of HHS declares that there is a public health emergency that affects the national security or the health and security of United States citizens living abroad, and that involves biological agent(s) or a disease or condition that may be attributable to such agent(s). Criteria for issuing an EUA include: The biological agent(s) can cause a serious or life-threatening disease or condition. Based on the totality of the available scientific evidence (including data from adequate and well controlled clinical trials, if available), it is reasonable to believe that: the product may be effective in diagnosing, treating, or preventing the serious or life-threatening disease or condition; and the known and potential benefits of the product - when used to diagnose, prevent, or treat such disease or condition - outweigh the known and potential risks of the product, taking into consideration the material threat posed by the biological agent(s). There is no adequate, approved, and available alternative to the product for diagnosing, preventing, or treating the serious or life-threatening disease or condition. Information Regarding Available Alternatives for the EUA Authorized Use There are no adequate, approved, and available alternatives to PEMGARDA for the pre-exposure prophylaxis of COVID-19 in individuals who are unlikely to mount an adequate immune response to COVID-19 vaccination. For information on clinical studies of PEMGARDA and other therapies for the pre-exposure prophylaxis of COVID-19, see www.clinicaltrials.gov . DRUGBANK:DB18720 uuid:a5887550-a573-4e84-8ec8-e1c0265e870e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5908975 biolink:treats MONDO:0018908 PMID:41385096 "[{""id"":""uuid:c726d90c-ccaf-4ef1-9da3-76b1dd0808c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e2299656-bfa3-4ea3-9b10-687309c5e183"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the unapproved product PEMGARDA (pemivibart) for the pre-exposure prophylaxis of coronavirus disease 2019 (COVID-19) in adults and adolescents (12 years of age and older weighing at least 40 kg): Who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2 and Who have moderate-to-severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments and are unlikely to mount an adequate response to COVID-19 vaccination. Medical conditions or treatments that may result in moderate to severe immune compromise and an inadequate immune response to COVID-19 vaccination include: Active treatment for solid tumor and hematologic malignancies Hematologic malignancies associated with poor responses to COVID-19 vaccines regardless of current treatment status (e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia) Receipt of solid-organ transplant or an islet transplant and taking immunosuppressive therapy Receipt of chimeric antigen receptor (CAR)-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppressive therapy) Moderate or severe primary immunodeficiency (e.g., common variable immunodeficiency disease, severe combined immunodeficiency, DiGeorge syndrome, Wiskott-Aldrich syndrome) Advanced or untreated HIV infection (people with HIV and CD4 cell counts <200/mm 3 , history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV) Active treatment with high-dose corticosteroids (i.e., ≥20 mg prednisone or equivalent per day when administered for ≥2 weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, and biologic agents that are immunosuppressive or immunomodulatory (e.g., B-cell depleting agents) Limitations of Authorized Use PEMGARDA is not authorized for use: For treatment of COVID-19, or For post-exposure prophylaxis of COVID-19 in individuals who have been exposed to someone infected with SARS-CoV-2. Pre-exposure prophylaxis with PEMGARDA is not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended. Individuals for whom COVID-19 vaccination is recommended, including individuals with moderate-to-severe immune compromise who may derive benefit from COVID-19 vaccination, should receive COVID‑19 vaccination. In individuals who have recently received a COVID-19 vaccine, PEMGARDA should be administered at least 2 weeks after vaccination. PEMGARDA may only be prescribed for an individual patient by physicians, advanced practice registered nurses, and physician assistants that are licensed or authorized under State law to prescribe drugs. PEMGARDA has been authorized by FDA for the emergency use described above. PEMGARDA is not FDA-approved for any use, including use for pre-exposure prophylaxis of COVID-19. PEMGARDA is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of PEMGARDA under section 564(b)(1) of the FD&C Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. Justification for Emergency Use of Drugs During the COVID‑19 Pandemic: There is currently an outbreak of coronavirus disease 2019 (COVID‑19) caused by SARS‑CoV‑2, a novel coronavirus. The Secretary of the U.S. Department of Health and Human Services (HHS) has: Determined that there is a public health emergency, or significant potential for a public health emergency [1] . Declared that circumstances exist justifying the authorization of emergency use of drugs and biological products for the prevention or treatment of COVID-19 [2] . An EUA is an FDA authorization for the emergency use of an unapproved product or unapproved use of an approved product (i.e., drug, biological product, or device) in the United States under certain circumstances including, but not limited to, when the Secretary of HHS declares that there is a public health emergency that affects the national security or the health and security of United States citizens living abroad, and that involves biological agent(s) or a disease or condition that may be attributable to such agent(s). Criteria for issuing an EUA include: The biological agent(s) can cause a serious or life-threatening disease or condition. Based on the totality of the available scientific evidence (including data from adequate and well controlled clinical trials, if available), it is reasonable to believe that: the product may be effective in diagnosing, treating, or preventing the serious or life-threatening disease or condition; and the known and potential benefits of the product - when used to diagnose, prevent, or treat such disease or condition - outweigh the known and potential risks of the product, taking into consideration the material threat posed by the biological agent(s). There is no adequate, approved, and available alternative to the product for diagnosing, preventing, or treating the serious or life-threatening disease or condition. Information Regarding Available Alternatives for the EUA Authorized Use There are no adequate, approved, and available alternatives to PEMGARDA for the pre-exposure prophylaxis of COVID-19 in individuals who are unlikely to mount an adequate immune response to COVID-19 vaccination. For information on clinical studies of PEMGARDA and other therapies for the pre-exposure prophylaxis of COVID-19, see www.clinicaltrials.gov . DRUGBANK:DB18720 uuid:2eec8f3a-3451-45d1-9509-a518d46ee90e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5908975 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:d7345297-2c59-4c83-911a-2085a46fc234"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e2573368-f672-408a-b323-c8cfb8e1b1e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the unapproved product PEMGARDA (pemivibart) for the pre-exposure prophylaxis of coronavirus disease 2019 (COVID-19) in adults and adolescents (12 years of age and older weighing at least 40 kg): Who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2 and Who have moderate-to-severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments and are unlikely to mount an adequate response to COVID-19 vaccination. Medical conditions or treatments that may result in moderate to severe immune compromise and an inadequate immune response to COVID-19 vaccination include: Active treatment for solid tumor and hematologic malignancies Hematologic malignancies associated with poor responses to COVID-19 vaccines regardless of current treatment status (e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia) Receipt of solid-organ transplant or an islet transplant and taking immunosuppressive therapy Receipt of chimeric antigen receptor (CAR)-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppressive therapy) Moderate or severe primary immunodeficiency (e.g., common variable immunodeficiency disease, severe combined immunodeficiency, DiGeorge syndrome, Wiskott-Aldrich syndrome) Advanced or untreated HIV infection (people with HIV and CD4 cell counts <200/mm 3 , history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV) Active treatment with high-dose corticosteroids (i.e., ≥20 mg prednisone or equivalent per day when administered for ≥2 weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, and biologic agents that are immunosuppressive or immunomodulatory (e.g., B-cell depleting agents) Limitations of Authorized Use PEMGARDA is not authorized for use: For treatment of COVID-19, or For post-exposure prophylaxis of COVID-19 in individuals who have been exposed to someone infected with SARS-CoV-2. Pre-exposure prophylaxis with PEMGARDA is not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended. Individuals for whom COVID-19 vaccination is recommended, including individuals with moderate-to-severe immune compromise who may derive benefit from COVID-19 vaccination, should receive COVID‑19 vaccination. In individuals who have recently received a COVID-19 vaccine, PEMGARDA should be administered at least 2 weeks after vaccination. PEMGARDA may only be prescribed for an individual patient by physicians, advanced practice registered nurses, and physician assistants that are licensed or authorized under State law to prescribe drugs. PEMGARDA has been authorized by FDA for the emergency use described above. PEMGARDA is not FDA-approved for any use, including use for pre-exposure prophylaxis of COVID-19. PEMGARDA is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of PEMGARDA under section 564(b)(1) of the FD&C Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. Justification for Emergency Use of Drugs During the COVID‑19 Pandemic: There is currently an outbreak of coronavirus disease 2019 (COVID‑19) caused by SARS‑CoV‑2, a novel coronavirus. The Secretary of the U.S. Department of Health and Human Services (HHS) has: Determined that there is a public health emergency, or significant potential for a public health emergency [1] . Declared that circumstances exist justifying the authorization of emergency use of drugs and biological products for the prevention or treatment of COVID-19 [2] . An EUA is an FDA authorization for the emergency use of an unapproved product or unapproved use of an approved product (i.e., drug, biological product, or device) in the United States under certain circumstances including, but not limited to, when the Secretary of HHS declares that there is a public health emergency that affects the national security or the health and security of United States citizens living abroad, and that involves biological agent(s) or a disease or condition that may be attributable to such agent(s). Criteria for issuing an EUA include: The biological agent(s) can cause a serious or life-threatening disease or condition. Based on the totality of the available scientific evidence (including data from adequate and well controlled clinical trials, if available), it is reasonable to believe that: the product may be effective in diagnosing, treating, or preventing the serious or life-threatening disease or condition; and the known and potential benefits of the product - when used to diagnose, prevent, or treat such disease or condition - outweigh the known and potential risks of the product, taking into consideration the material threat posed by the biological agent(s). There is no adequate, approved, and available alternative to the product for diagnosing, preventing, or treating the serious or life-threatening disease or condition. Information Regarding Available Alternatives for the EUA Authorized Use There are no adequate, approved, and available alternatives to PEMGARDA for the pre-exposure prophylaxis of COVID-19 in individuals who are unlikely to mount an adequate immune response to COVID-19 vaccination. For information on clinical studies of PEMGARDA and other therapies for the pre-exposure prophylaxis of COVID-19, see www.clinicaltrials.gov . DRUGBANK:DB18720 uuid:ce2a7636-16a3-4938-975a-2adcd99a5f07 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5908975 biolink:treats MONDO:0010643 PMID:41385096 "[{""id"":""uuid:bce991fe-b30a-4cfa-bc6f-25ddd1b6c52d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:5c4f3cd5-2d0b-4819-9b47-e641f69e4b6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the unapproved product PEMGARDA (pemivibart) for the pre-exposure prophylaxis of coronavirus disease 2019 (COVID-19) in adults and adolescents (12 years of age and older weighing at least 40 kg): Who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2 and Who have moderate-to-severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments and are unlikely to mount an adequate response to COVID-19 vaccination. Medical conditions or treatments that may result in moderate to severe immune compromise and an inadequate immune response to COVID-19 vaccination include: Active treatment for solid tumor and hematologic malignancies Hematologic malignancies associated with poor responses to COVID-19 vaccines regardless of current treatment status (e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia) Receipt of solid-organ transplant or an islet transplant and taking immunosuppressive therapy Receipt of chimeric antigen receptor (CAR)-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppressive therapy) Moderate or severe primary immunodeficiency (e.g., common variable immunodeficiency disease, severe combined immunodeficiency, DiGeorge syndrome, Wiskott-Aldrich syndrome) Advanced or untreated HIV infection (people with HIV and CD4 cell counts <200/mm 3 , history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV) Active treatment with high-dose corticosteroids (i.e., ≥20 mg prednisone or equivalent per day when administered for ≥2 weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, and biologic agents that are immunosuppressive or immunomodulatory (e.g., B-cell depleting agents) Limitations of Authorized Use PEMGARDA is not authorized for use: For treatment of COVID-19, or For post-exposure prophylaxis of COVID-19 in individuals who have been exposed to someone infected with SARS-CoV-2. Pre-exposure prophylaxis with PEMGARDA is not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended. Individuals for whom COVID-19 vaccination is recommended, including individuals with moderate-to-severe immune compromise who may derive benefit from COVID-19 vaccination, should receive COVID‑19 vaccination. In individuals who have recently received a COVID-19 vaccine, PEMGARDA should be administered at least 2 weeks after vaccination. PEMGARDA may only be prescribed for an individual patient by physicians, advanced practice registered nurses, and physician assistants that are licensed or authorized under State law to prescribe drugs. PEMGARDA has been authorized by FDA for the emergency use described above. PEMGARDA is not FDA-approved for any use, including use for pre-exposure prophylaxis of COVID-19. PEMGARDA is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of PEMGARDA under section 564(b)(1) of the FD&C Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. Justification for Emergency Use of Drugs During the COVID‑19 Pandemic: There is currently an outbreak of coronavirus disease 2019 (COVID‑19) caused by SARS‑CoV‑2, a novel coronavirus. The Secretary of the U.S. Department of Health and Human Services (HHS) has: Determined that there is a public health emergency, or significant potential for a public health emergency [1] . Declared that circumstances exist justifying the authorization of emergency use of drugs and biological products for the prevention or treatment of COVID-19 [2] . An EUA is an FDA authorization for the emergency use of an unapproved product or unapproved use of an approved product (i.e., drug, biological product, or device) in the United States under certain circumstances including, but not limited to, when the Secretary of HHS declares that there is a public health emergency that affects the national security or the health and security of United States citizens living abroad, and that involves biological agent(s) or a disease or condition that may be attributable to such agent(s). Criteria for issuing an EUA include: The biological agent(s) can cause a serious or life-threatening disease or condition. Based on the totality of the available scientific evidence (including data from adequate and well controlled clinical trials, if available), it is reasonable to believe that: the product may be effective in diagnosing, treating, or preventing the serious or life-threatening disease or condition; and the known and potential benefits of the product - when used to diagnose, prevent, or treat such disease or condition - outweigh the known and potential risks of the product, taking into consideration the material threat posed by the biological agent(s). There is no adequate, approved, and available alternative to the product for diagnosing, preventing, or treating the serious or life-threatening disease or condition. Information Regarding Available Alternatives for the EUA Authorized Use There are no adequate, approved, and available alternatives to PEMGARDA for the pre-exposure prophylaxis of COVID-19 in individuals who are unlikely to mount an adequate immune response to COVID-19 vaccination. For information on clinical studies of PEMGARDA and other therapies for the pre-exposure prophylaxis of COVID-19, see www.clinicaltrials.gov . DRUGBANK:DB18720 uuid:692af35f-b4f4-4722-a8bb-667da0f7ad83 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5908975 biolink:treats MONDO:0003778 PMID:41385096 "[{""id"":""uuid:8ff0b957-8267-4a39-86fa-7534dd2537e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:774765b8-faaf-41fa-ad3c-8a891b50782f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the unapproved product PEMGARDA (pemivibart) for the pre-exposure prophylaxis of coronavirus disease 2019 (COVID-19) in adults and adolescents (12 years of age and older weighing at least 40 kg): Who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2 and Who have moderate-to-severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments and are unlikely to mount an adequate response to COVID-19 vaccination. Medical conditions or treatments that may result in moderate to severe immune compromise and an inadequate immune response to COVID-19 vaccination include: Active treatment for solid tumor and hematologic malignancies Hematologic malignancies associated with poor responses to COVID-19 vaccines regardless of current treatment status (e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia) Receipt of solid-organ transplant or an islet transplant and taking immunosuppressive therapy Receipt of chimeric antigen receptor (CAR)-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppressive therapy) Moderate or severe primary immunodeficiency (e.g., common variable immunodeficiency disease, severe combined immunodeficiency, DiGeorge syndrome, Wiskott-Aldrich syndrome) Advanced or untreated HIV infection (people with HIV and CD4 cell counts <200/mm 3 , history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV) Active treatment with high-dose corticosteroids (i.e., ≥20 mg prednisone or equivalent per day when administered for ≥2 weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, and biologic agents that are immunosuppressive or immunomodulatory (e.g., B-cell depleting agents) Limitations of Authorized Use PEMGARDA is not authorized for use: For treatment of COVID-19, or For post-exposure prophylaxis of COVID-19 in individuals who have been exposed to someone infected with SARS-CoV-2. Pre-exposure prophylaxis with PEMGARDA is not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended. Individuals for whom COVID-19 vaccination is recommended, including individuals with moderate-to-severe immune compromise who may derive benefit from COVID-19 vaccination, should receive COVID‑19 vaccination. In individuals who have recently received a COVID-19 vaccine, PEMGARDA should be administered at least 2 weeks after vaccination. PEMGARDA may only be prescribed for an individual patient by physicians, advanced practice registered nurses, and physician assistants that are licensed or authorized under State law to prescribe drugs. PEMGARDA has been authorized by FDA for the emergency use described above. PEMGARDA is not FDA-approved for any use, including use for pre-exposure prophylaxis of COVID-19. PEMGARDA is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of PEMGARDA under section 564(b)(1) of the FD&C Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. Justification for Emergency Use of Drugs During the COVID‑19 Pandemic: There is currently an outbreak of coronavirus disease 2019 (COVID‑19) caused by SARS‑CoV‑2, a novel coronavirus. The Secretary of the U.S. Department of Health and Human Services (HHS) has: Determined that there is a public health emergency, or significant potential for a public health emergency [1] . Declared that circumstances exist justifying the authorization of emergency use of drugs and biological products for the prevention or treatment of COVID-19 [2] . An EUA is an FDA authorization for the emergency use of an unapproved product or unapproved use of an approved product (i.e., drug, biological product, or device) in the United States under certain circumstances including, but not limited to, when the Secretary of HHS declares that there is a public health emergency that affects the national security or the health and security of United States citizens living abroad, and that involves biological agent(s) or a disease or condition that may be attributable to such agent(s). Criteria for issuing an EUA include: The biological agent(s) can cause a serious or life-threatening disease or condition. Based on the totality of the available scientific evidence (including data from adequate and well controlled clinical trials, if available), it is reasonable to believe that: the product may be effective in diagnosing, treating, or preventing the serious or life-threatening disease or condition; and the known and potential benefits of the product - when used to diagnose, prevent, or treat such disease or condition - outweigh the known and potential risks of the product, taking into consideration the material threat posed by the biological agent(s). There is no adequate, approved, and available alternative to the product for diagnosing, preventing, or treating the serious or life-threatening disease or condition. Information Regarding Available Alternatives for the EUA Authorized Use There are no adequate, approved, and available alternatives to PEMGARDA for the pre-exposure prophylaxis of COVID-19 in individuals who are unlikely to mount an adequate immune response to COVID-19 vaccination. For information on clinical studies of PEMGARDA and other therapies for the pre-exposure prophylaxis of COVID-19, see www.clinicaltrials.gov . DRUGBANK:DB18720 uuid:893c9a95-fdd8-488f-a1bf-2a808b25c710 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5908975 biolink:treats MONDO:0015517 PMID:41385096 "[{""id"":""uuid:0407a290-0eb8-404b-a64d-72b6eff30b47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:510184c8-76b8-4661-9368-189c6ac527f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the unapproved product PEMGARDA (pemivibart) for the pre-exposure prophylaxis of coronavirus disease 2019 (COVID-19) in adults and adolescents (12 years of age and older weighing at least 40 kg): Who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2 and Who have moderate-to-severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments and are unlikely to mount an adequate response to COVID-19 vaccination. Medical conditions or treatments that may result in moderate to severe immune compromise and an inadequate immune response to COVID-19 vaccination include: Active treatment for solid tumor and hematologic malignancies Hematologic malignancies associated with poor responses to COVID-19 vaccines regardless of current treatment status (e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia) Receipt of solid-organ transplant or an islet transplant and taking immunosuppressive therapy Receipt of chimeric antigen receptor (CAR)-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppressive therapy) Moderate or severe primary immunodeficiency (e.g., common variable immunodeficiency disease, severe combined immunodeficiency, DiGeorge syndrome, Wiskott-Aldrich syndrome) Advanced or untreated HIV infection (people with HIV and CD4 cell counts <200/mm 3 , history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV) Active treatment with high-dose corticosteroids (i.e., ≥20 mg prednisone or equivalent per day when administered for ≥2 weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, and biologic agents that are immunosuppressive or immunomodulatory (e.g., B-cell depleting agents) Limitations of Authorized Use PEMGARDA is not authorized for use: For treatment of COVID-19, or For post-exposure prophylaxis of COVID-19 in individuals who have been exposed to someone infected with SARS-CoV-2. Pre-exposure prophylaxis with PEMGARDA is not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended. Individuals for whom COVID-19 vaccination is recommended, including individuals with moderate-to-severe immune compromise who may derive benefit from COVID-19 vaccination, should receive COVID‑19 vaccination. In individuals who have recently received a COVID-19 vaccine, PEMGARDA should be administered at least 2 weeks after vaccination. PEMGARDA may only be prescribed for an individual patient by physicians, advanced practice registered nurses, and physician assistants that are licensed or authorized under State law to prescribe drugs. PEMGARDA has been authorized by FDA for the emergency use described above. PEMGARDA is not FDA-approved for any use, including use for pre-exposure prophylaxis of COVID-19. PEMGARDA is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of PEMGARDA under section 564(b)(1) of the FD&C Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. Justification for Emergency Use of Drugs During the COVID‑19 Pandemic: There is currently an outbreak of coronavirus disease 2019 (COVID‑19) caused by SARS‑CoV‑2, a novel coronavirus. The Secretary of the U.S. Department of Health and Human Services (HHS) has: Determined that there is a public health emergency, or significant potential for a public health emergency [1] . Declared that circumstances exist justifying the authorization of emergency use of drugs and biological products for the prevention or treatment of COVID-19 [2] . An EUA is an FDA authorization for the emergency use of an unapproved product or unapproved use of an approved product (i.e., drug, biological product, or device) in the United States under certain circumstances including, but not limited to, when the Secretary of HHS declares that there is a public health emergency that affects the national security or the health and security of United States citizens living abroad, and that involves biological agent(s) or a disease or condition that may be attributable to such agent(s). Criteria for issuing an EUA include: The biological agent(s) can cause a serious or life-threatening disease or condition. Based on the totality of the available scientific evidence (including data from adequate and well controlled clinical trials, if available), it is reasonable to believe that: the product may be effective in diagnosing, treating, or preventing the serious or life-threatening disease or condition; and the known and potential benefits of the product - when used to diagnose, prevent, or treat such disease or condition - outweigh the known and potential risks of the product, taking into consideration the material threat posed by the biological agent(s). There is no adequate, approved, and available alternative to the product for diagnosing, preventing, or treating the serious or life-threatening disease or condition. Information Regarding Available Alternatives for the EUA Authorized Use There are no adequate, approved, and available alternatives to PEMGARDA for the pre-exposure prophylaxis of COVID-19 in individuals who are unlikely to mount an adequate immune response to COVID-19 vaccination. For information on clinical studies of PEMGARDA and other therapies for the pre-exposure prophylaxis of COVID-19, see www.clinicaltrials.gov . DRUGBANK:DB18720 uuid:f79bb0b2-99be-44c8-bd5d-ecb59942d022 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5908975 biolink:treats MONDO:0015974 PMID:41385096 "[{""id"":""uuid:c9d1288e-a1b8-479e-b9e3-3f81ec1e9bf5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a8a69109-b3b9-4b06-ba99-f31f2648c5c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the unapproved product PEMGARDA (pemivibart) for the pre-exposure prophylaxis of coronavirus disease 2019 (COVID-19) in adults and adolescents (12 years of age and older weighing at least 40 kg): Who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2 and Who have moderate-to-severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments and are unlikely to mount an adequate response to COVID-19 vaccination. Medical conditions or treatments that may result in moderate to severe immune compromise and an inadequate immune response to COVID-19 vaccination include: Active treatment for solid tumor and hematologic malignancies Hematologic malignancies associated with poor responses to COVID-19 vaccines regardless of current treatment status (e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia) Receipt of solid-organ transplant or an islet transplant and taking immunosuppressive therapy Receipt of chimeric antigen receptor (CAR)-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppressive therapy) Moderate or severe primary immunodeficiency (e.g., common variable immunodeficiency disease, severe combined immunodeficiency, DiGeorge syndrome, Wiskott-Aldrich syndrome) Advanced or untreated HIV infection (people with HIV and CD4 cell counts <200/mm 3 , history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV) Active treatment with high-dose corticosteroids (i.e., ≥20 mg prednisone or equivalent per day when administered for ≥2 weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, and biologic agents that are immunosuppressive or immunomodulatory (e.g., B-cell depleting agents) Limitations of Authorized Use PEMGARDA is not authorized for use: For treatment of COVID-19, or For post-exposure prophylaxis of COVID-19 in individuals who have been exposed to someone infected with SARS-CoV-2. Pre-exposure prophylaxis with PEMGARDA is not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended. Individuals for whom COVID-19 vaccination is recommended, including individuals with moderate-to-severe immune compromise who may derive benefit from COVID-19 vaccination, should receive COVID‑19 vaccination. In individuals who have recently received a COVID-19 vaccine, PEMGARDA should be administered at least 2 weeks after vaccination. PEMGARDA may only be prescribed for an individual patient by physicians, advanced practice registered nurses, and physician assistants that are licensed or authorized under State law to prescribe drugs. PEMGARDA has been authorized by FDA for the emergency use described above. PEMGARDA is not FDA-approved for any use, including use for pre-exposure prophylaxis of COVID-19. PEMGARDA is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of PEMGARDA under section 564(b)(1) of the FD&C Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. Justification for Emergency Use of Drugs During the COVID‑19 Pandemic: There is currently an outbreak of coronavirus disease 2019 (COVID‑19) caused by SARS‑CoV‑2, a novel coronavirus. The Secretary of the U.S. Department of Health and Human Services (HHS) has: Determined that there is a public health emergency, or significant potential for a public health emergency [1] . Declared that circumstances exist justifying the authorization of emergency use of drugs and biological products for the prevention or treatment of COVID-19 [2] . An EUA is an FDA authorization for the emergency use of an unapproved product or unapproved use of an approved product (i.e., drug, biological product, or device) in the United States under certain circumstances including, but not limited to, when the Secretary of HHS declares that there is a public health emergency that affects the national security or the health and security of United States citizens living abroad, and that involves biological agent(s) or a disease or condition that may be attributable to such agent(s). Criteria for issuing an EUA include: The biological agent(s) can cause a serious or life-threatening disease or condition. Based on the totality of the available scientific evidence (including data from adequate and well controlled clinical trials, if available), it is reasonable to believe that: the product may be effective in diagnosing, treating, or preventing the serious or life-threatening disease or condition; and the known and potential benefits of the product - when used to diagnose, prevent, or treat such disease or condition - outweigh the known and potential risks of the product, taking into consideration the material threat posed by the biological agent(s). There is no adequate, approved, and available alternative to the product for diagnosing, preventing, or treating the serious or life-threatening disease or condition. Information Regarding Available Alternatives for the EUA Authorized Use There are no adequate, approved, and available alternatives to PEMGARDA for the pre-exposure prophylaxis of COVID-19 in individuals who are unlikely to mount an adequate immune response to COVID-19 vaccination. For information on clinical studies of PEMGARDA and other therapies for the pre-exposure prophylaxis of COVID-19, see www.clinicaltrials.gov . DRUGBANK:DB18720 uuid:b4276048-6dbf-4e5f-a795-3169fad95185 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5908975 biolink:treats MONDO:0008564 PMID:41385096 "[{""id"":""uuid:53ad7624-0836-429e-bed8-3accea5f677d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2515d394-3b8a-40a4-a452-285195436e5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the unapproved product PEMGARDA (pemivibart) for the pre-exposure prophylaxis of coronavirus disease 2019 (COVID-19) in adults and adolescents (12 years of age and older weighing at least 40 kg): Who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2 and Who have moderate-to-severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments and are unlikely to mount an adequate response to COVID-19 vaccination. Medical conditions or treatments that may result in moderate to severe immune compromise and an inadequate immune response to COVID-19 vaccination include: Active treatment for solid tumor and hematologic malignancies Hematologic malignancies associated with poor responses to COVID-19 vaccines regardless of current treatment status (e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia) Receipt of solid-organ transplant or an islet transplant and taking immunosuppressive therapy Receipt of chimeric antigen receptor (CAR)-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppressive therapy) Moderate or severe primary immunodeficiency (e.g., common variable immunodeficiency disease, severe combined immunodeficiency, DiGeorge syndrome, Wiskott-Aldrich syndrome) Advanced or untreated HIV infection (people with HIV and CD4 cell counts <200/mm 3 , history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV) Active treatment with high-dose corticosteroids (i.e., ≥20 mg prednisone or equivalent per day when administered for ≥2 weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, and biologic agents that are immunosuppressive or immunomodulatory (e.g., B-cell depleting agents) Limitations of Authorized Use PEMGARDA is not authorized for use: For treatment of COVID-19, or For post-exposure prophylaxis of COVID-19 in individuals who have been exposed to someone infected with SARS-CoV-2. Pre-exposure prophylaxis with PEMGARDA is not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended. Individuals for whom COVID-19 vaccination is recommended, including individuals with moderate-to-severe immune compromise who may derive benefit from COVID-19 vaccination, should receive COVID‑19 vaccination. In individuals who have recently received a COVID-19 vaccine, PEMGARDA should be administered at least 2 weeks after vaccination. PEMGARDA may only be prescribed for an individual patient by physicians, advanced practice registered nurses, and physician assistants that are licensed or authorized under State law to prescribe drugs. PEMGARDA has been authorized by FDA for the emergency use described above. PEMGARDA is not FDA-approved for any use, including use for pre-exposure prophylaxis of COVID-19. PEMGARDA is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of PEMGARDA under section 564(b)(1) of the FD&C Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. Justification for Emergency Use of Drugs During the COVID‑19 Pandemic: There is currently an outbreak of coronavirus disease 2019 (COVID‑19) caused by SARS‑CoV‑2, a novel coronavirus. The Secretary of the U.S. Department of Health and Human Services (HHS) has: Determined that there is a public health emergency, or significant potential for a public health emergency [1] . Declared that circumstances exist justifying the authorization of emergency use of drugs and biological products for the prevention or treatment of COVID-19 [2] . An EUA is an FDA authorization for the emergency use of an unapproved product or unapproved use of an approved product (i.e., drug, biological product, or device) in the United States under certain circumstances including, but not limited to, when the Secretary of HHS declares that there is a public health emergency that affects the national security or the health and security of United States citizens living abroad, and that involves biological agent(s) or a disease or condition that may be attributable to such agent(s). Criteria for issuing an EUA include: The biological agent(s) can cause a serious or life-threatening disease or condition. Based on the totality of the available scientific evidence (including data from adequate and well controlled clinical trials, if available), it is reasonable to believe that: the product may be effective in diagnosing, treating, or preventing the serious or life-threatening disease or condition; and the known and potential benefits of the product - when used to diagnose, prevent, or treat such disease or condition - outweigh the known and potential risks of the product, taking into consideration the material threat posed by the biological agent(s). There is no adequate, approved, and available alternative to the product for diagnosing, preventing, or treating the serious or life-threatening disease or condition. Information Regarding Available Alternatives for the EUA Authorized Use There are no adequate, approved, and available alternatives to PEMGARDA for the pre-exposure prophylaxis of COVID-19 in individuals who are unlikely to mount an adequate immune response to COVID-19 vaccination. For information on clinical studies of PEMGARDA and other therapies for the pre-exposure prophylaxis of COVID-19, see www.clinicaltrials.gov . DRUGBANK:DB18720 uuid:7c388314-b1ab-4da9-a0e6-a74568e7828f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5908975 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:2182cf9d-a468-43f5-a673-bc1a8bf63db8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3fdae76e-1359-40bf-87c4-7a1edea81209"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the unapproved product PEMGARDA (pemivibart) for the pre-exposure prophylaxis of coronavirus disease 2019 (COVID-19) in adults and adolescents (12 years of age and older weighing at least 40 kg): Who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2 and Who have moderate-to-severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments and are unlikely to mount an adequate response to COVID-19 vaccination. Medical conditions or treatments that may result in moderate to severe immune compromise and an inadequate immune response to COVID-19 vaccination include: Active treatment for solid tumor and hematologic malignancies Hematologic malignancies associated with poor responses to COVID-19 vaccines regardless of current treatment status (e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia) Receipt of solid-organ transplant or an islet transplant and taking immunosuppressive therapy Receipt of chimeric antigen receptor (CAR)-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppressive therapy) Moderate or severe primary immunodeficiency (e.g., common variable immunodeficiency disease, severe combined immunodeficiency, DiGeorge syndrome, Wiskott-Aldrich syndrome) Advanced or untreated HIV infection (people with HIV and CD4 cell counts <200/mm 3 , history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV) Active treatment with high-dose corticosteroids (i.e., ≥20 mg prednisone or equivalent per day when administered for ≥2 weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, and biologic agents that are immunosuppressive or immunomodulatory (e.g., B-cell depleting agents) Limitations of Authorized Use PEMGARDA is not authorized for use: For treatment of COVID-19, or For post-exposure prophylaxis of COVID-19 in individuals who have been exposed to someone infected with SARS-CoV-2. Pre-exposure prophylaxis with PEMGARDA is not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended. Individuals for whom COVID-19 vaccination is recommended, including individuals with moderate-to-severe immune compromise who may derive benefit from COVID-19 vaccination, should receive COVID‑19 vaccination. In individuals who have recently received a COVID-19 vaccine, PEMGARDA should be administered at least 2 weeks after vaccination. PEMGARDA may only be prescribed for an individual patient by physicians, advanced practice registered nurses, and physician assistants that are licensed or authorized under State law to prescribe drugs. PEMGARDA has been authorized by FDA for the emergency use described above. PEMGARDA is not FDA-approved for any use, including use for pre-exposure prophylaxis of COVID-19. PEMGARDA is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of PEMGARDA under section 564(b)(1) of the FD&C Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. Justification for Emergency Use of Drugs During the COVID‑19 Pandemic: There is currently an outbreak of coronavirus disease 2019 (COVID‑19) caused by SARS‑CoV‑2, a novel coronavirus. The Secretary of the U.S. Department of Health and Human Services (HHS) has: Determined that there is a public health emergency, or significant potential for a public health emergency [1] . Declared that circumstances exist justifying the authorization of emergency use of drugs and biological products for the prevention or treatment of COVID-19 [2] . An EUA is an FDA authorization for the emergency use of an unapproved product or unapproved use of an approved product (i.e., drug, biological product, or device) in the United States under certain circumstances including, but not limited to, when the Secretary of HHS declares that there is a public health emergency that affects the national security or the health and security of United States citizens living abroad, and that involves biological agent(s) or a disease or condition that may be attributable to such agent(s). Criteria for issuing an EUA include: The biological agent(s) can cause a serious or life-threatening disease or condition. Based on the totality of the available scientific evidence (including data from adequate and well controlled clinical trials, if available), it is reasonable to believe that: the product may be effective in diagnosing, treating, or preventing the serious or life-threatening disease or condition; and the known and potential benefits of the product - when used to diagnose, prevent, or treat such disease or condition - outweigh the known and potential risks of the product, taking into consideration the material threat posed by the biological agent(s). There is no adequate, approved, and available alternative to the product for diagnosing, preventing, or treating the serious or life-threatening disease or condition. Information Regarding Available Alternatives for the EUA Authorized Use There are no adequate, approved, and available alternatives to PEMGARDA for the pre-exposure prophylaxis of COVID-19 in individuals who are unlikely to mount an adequate immune response to COVID-19 vaccination. For information on clinical studies of PEMGARDA and other therapies for the pre-exposure prophylaxis of COVID-19, see www.clinicaltrials.gov . DRUGBANK:DB18720 uuid:374ca739-f64b-4f00-882e-3d4fabe098c8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5908975 biolink:treats UMLS:C0740830 PMID:41385096 "[{""id"":""uuid:847deddd-1ab6-426f-9bfb-5401c7282502"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6910955d-c942-4f13-b26d-0ccd552efb98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for the emergency use of the unapproved product PEMGARDA (pemivibart) for the pre-exposure prophylaxis of coronavirus disease 2019 (COVID-19) in adults and adolescents (12 years of age and older weighing at least 40 kg): Who are not currently infected with SARS-CoV-2 and who have not had a known recent exposure to an individual infected with SARS-CoV-2 and Who have moderate-to-severe immune compromise due to a medical condition or receipt of immunosuppressive medications or treatments and are unlikely to mount an adequate response to COVID-19 vaccination. Medical conditions or treatments that may result in moderate to severe immune compromise and an inadequate immune response to COVID-19 vaccination include: Active treatment for solid tumor and hematologic malignancies Hematologic malignancies associated with poor responses to COVID-19 vaccines regardless of current treatment status (e.g., chronic lymphocytic leukemia, non-Hodgkin lymphoma, multiple myeloma, acute leukemia) Receipt of solid-organ transplant or an islet transplant and taking immunosuppressive therapy Receipt of chimeric antigen receptor (CAR)-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppressive therapy) Moderate or severe primary immunodeficiency (e.g., common variable immunodeficiency disease, severe combined immunodeficiency, DiGeorge syndrome, Wiskott-Aldrich syndrome) Advanced or untreated HIV infection (people with HIV and CD4 cell counts <200/mm 3 , history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV) Active treatment with high-dose corticosteroids (i.e., ≥20 mg prednisone or equivalent per day when administered for ≥2 weeks), alkylating agents, antimetabolites, transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, and biologic agents that are immunosuppressive or immunomodulatory (e.g., B-cell depleting agents) Limitations of Authorized Use PEMGARDA is not authorized for use: For treatment of COVID-19, or For post-exposure prophylaxis of COVID-19 in individuals who have been exposed to someone infected with SARS-CoV-2. Pre-exposure prophylaxis with PEMGARDA is not a substitute for vaccination in individuals for whom COVID-19 vaccination is recommended. Individuals for whom COVID-19 vaccination is recommended, including individuals with moderate-to-severe immune compromise who may derive benefit from COVID-19 vaccination, should receive COVID‑19 vaccination. In individuals who have recently received a COVID-19 vaccine, PEMGARDA should be administered at least 2 weeks after vaccination. PEMGARDA may only be prescribed for an individual patient by physicians, advanced practice registered nurses, and physician assistants that are licensed or authorized under State law to prescribe drugs. PEMGARDA has been authorized by FDA for the emergency use described above. PEMGARDA is not FDA-approved for any use, including use for pre-exposure prophylaxis of COVID-19. PEMGARDA is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of PEMGARDA under section 564(b)(1) of the FD&C Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner. Justification for Emergency Use of Drugs During the COVID‑19 Pandemic: There is currently an outbreak of coronavirus disease 2019 (COVID‑19) caused by SARS‑CoV‑2, a novel coronavirus. The Secretary of the U.S. Department of Health and Human Services (HHS) has: Determined that there is a public health emergency, or significant potential for a public health emergency [1] . Declared that circumstances exist justifying the authorization of emergency use of drugs and biological products for the prevention or treatment of COVID-19 [2] . An EUA is an FDA authorization for the emergency use of an unapproved product or unapproved use of an approved product (i.e., drug, biological product, or device) in the United States under certain circumstances including, but not limited to, when the Secretary of HHS declares that there is a public health emergency that affects the national security or the health and security of United States citizens living abroad, and that involves biological agent(s) or a disease or condition that may be attributable to such agent(s). Criteria for issuing an EUA include: The biological agent(s) can cause a serious or life-threatening disease or condition. Based on the totality of the available scientific evidence (including data from adequate and well controlled clinical trials, if available), it is reasonable to believe that: the product may be effective in diagnosing, treating, or preventing the serious or life-threatening disease or condition; and the known and potential benefits of the product - when used to diagnose, prevent, or treat such disease or condition - outweigh the known and potential risks of the product, taking into consideration the material threat posed by the biological agent(s). There is no adequate, approved, and available alternative to the product for diagnosing, preventing, or treating the serious or life-threatening disease or condition. Information Regarding Available Alternatives for the EUA Authorized Use There are no adequate, approved, and available alternatives to PEMGARDA for the pre-exposure prophylaxis of COVID-19 in individuals who are unlikely to mount an adequate immune response to COVID-19 vaccination. For information on clinical studies of PEMGARDA and other therapies for the pre-exposure prophylaxis of COVID-19, see www.clinicaltrials.gov . DRUGBANK:DB18720 uuid:7c69c534-4068-4794-9bfc-bacc47ae9c5a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:X05U0N2RCO biolink:treats MONDO:0004956 PMID:41385096 "[{""id"":""uuid:d7178503-9ecb-4f8e-a3bd-44a2221ec17a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f2fff709-76e5-406e-b01e-ed0dcff118cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3f21de50-05d4-459c-a9c1-04b7436608c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/nubeqa""]},{""id"":""uuid:ec7095fe-8e67-4fb3-8a35-8942a0b6299c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NUBEQA is an androgen receptor inhibitor indicated for the treatment of adult patients with: non-metastatic castration-resistant prostate cancer (nmCRPC). ( 1 ) metastatic castration-sensitive prostate cancer (mCSPC). ( 1 ) metastatic castration-sensitive prostate cancer (mCSPC) in combination with docetaxel. ( 1 )|[EMA] NUBEQA is indicated for the treatment of adult men with- non metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease (see section 5.1).- metastatic hormone sensitive prostate cancer (mHSPC) in combination with docetaxel and androgen deprivation therapy (see section 5.1).|[PMDA] A drug with a new indication and a new dosage for the treatment of metastatic prostate cancer. uuid:c3da86d8-30ff-49c1-9f98-2d7ab2729552 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:09495UIM6V biolink:treats UMLS:C0406317 PMID:41385096 "[{""id"":""uuid:2e859559-848d-443e-af36-24f8caaae0b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1cc643f5-29f2-44e0-a9b2-c1209406f122"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:036c47ad-6190-4f85-a184-562dbff908b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BIMZELX is a humanized interleukin-17A and F antagonist indicated for the treatment of: Moderate to severe plaque psoriasis (PSO) in adults who are candidates for systemic therapy or phototherapy. ( 1.1 ) Adults with active psoriatic arthritis (PsA) . ( 1.2 ) Adults with active non-radiographic axial spondyloarthritis ( nr-axSpA ) with objective signs of inflammation. ( 1.3 ) Adults with active ankylosing spondylitis ( AS ). ( 1.4 ) Adults with moderate to severe hidradenitis suppurativa (HS) . ( 1.5 )|[PMDA] Drugs with a new active ingredient indicated for the treatment of plaque psoriasis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies. uuid:4f1c0d47-64d3-44bb-a5bb-60b37c6d090e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:09495UIM6V biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:51fd2b09-8c2d-456e-bd7d-651bf4685785"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:236a8433-7e07-487a-997c-067bf65b09ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:452ae83b-655e-41c0-b652-abb2f511503d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/bimzelx""]},{""id"":""uuid:e45afdf8-03c8-4b3b-8b1d-69c965ae291c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BIMZELX is a humanized interleukin-17A and F antagonist indicated for the treatment of: Moderate to severe plaque psoriasis (PSO) in adults who are candidates for systemic therapy or phototherapy. ( 1.1 ) Adults with active psoriatic arthritis (PsA) . ( 1.2 ) Adults with active non-radiographic axial spondyloarthritis ( nr-axSpA ) with objective signs of inflammation. ( 1.3 ) Adults with active ankylosing spondylitis ( AS ). ( 1.4 ) Adults with moderate to severe hidradenitis suppurativa (HS) . ( 1.5 )|[EMA] Plaque psoriasisBimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.Psoriatic arthritisBimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).Axial spondyloarthritisNon-radiographic axial spondyloarthritis (nr-axSpA)Bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs).Ankylosing spondylitis (AS, radiographic axial spondyloarthritis)Bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.|[PMDA] Drugs with a new indication and a new dosage for the treatment of psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis in patients who have not sufficiently responded to conventional treatments. uuid:a71689c4-f4cc-47d1-9903-1eb9b9e63931 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:09495UIM6V biolink:treats UMLS:C3203547 PMID:41385096 "[{""id"":""uuid:c8779af3-9b38-4214-ac57-f40d71c1e6c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:14885d28-d374-447a-ac27-a82897906eda"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:723b33bd-657a-49a3-8fef-50669f0e9fbc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BIMZELX is a humanized interleukin-17A and F antagonist indicated for the treatment of: Moderate to severe plaque psoriasis (PSO) in adults who are candidates for systemic therapy or phototherapy. ( 1.1 ) Adults with active psoriatic arthritis (PsA) . ( 1.2 ) Adults with active non-radiographic axial spondyloarthritis ( nr-axSpA ) with objective signs of inflammation. ( 1.3 ) Adults with active ankylosing spondylitis ( AS ). ( 1.4 ) Adults with moderate to severe hidradenitis suppurativa (HS) . ( 1.5 )|[PMDA] Drugs with a new indication and a new dosage for the treatment of psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis in patients who have not sufficiently responded to conventional treatments. uuid:12b340a0-bbd3-4ba2-9dc4-682adad65bd0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:09495UIM6V biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:f24f5019-f6ee-4a49-a064-67745dc4bf50"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:82dc1d66-06a4-48f4-a85e-c2549df3757d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:04c88e8b-c5f7-4ef4-895b-31c1fb4af8a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/bimzelx""]},{""id"":""uuid:c895e6f3-218c-4226-b7b1-d4a0c4a21428"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BIMZELX is a humanized interleukin-17A and F antagonist indicated for the treatment of: Moderate to severe plaque psoriasis (PSO) in adults who are candidates for systemic therapy or phototherapy. ( 1.1 ) Adults with active psoriatic arthritis (PsA) . ( 1.2 ) Adults with active non-radiographic axial spondyloarthritis ( nr-axSpA ) with objective signs of inflammation. ( 1.3 ) Adults with active ankylosing spondylitis ( AS ). ( 1.4 ) Adults with moderate to severe hidradenitis suppurativa (HS) . ( 1.5 )|[EMA] Plaque psoriasisBimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.Psoriatic arthritisBimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).Axial spondyloarthritisNon-radiographic axial spondyloarthritis (nr-axSpA)Bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs).Ankylosing spondylitis (AS, radiographic axial spondyloarthritis)Bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy.|[PMDA] Drugs with a new indication and a new dosage for the treatment of psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis in patients who have not sufficiently responded to conventional treatments. uuid:9c727dca-a7ca-4870-b612-647842d2691f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:09495UIM6V biolink:treats MONDO:0006559 PMID:41385096 "[{""id"":""uuid:f6e79a17-749e-4048-b3b9-b647c6d747e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:50de14fc-5868-48fa-b2f0-ec6b2588d09c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BIMZELX is a humanized interleukin-17A and F antagonist indicated for the treatment of: Moderate to severe plaque psoriasis (PSO) in adults who are candidates for systemic therapy or phototherapy. ( 1.1 ) Adults with active psoriatic arthritis (PsA) . ( 1.2 ) Adults with active non-radiographic axial spondyloarthritis ( nr-axSpA ) with objective signs of inflammation. ( 1.3 ) Adults with active ankylosing spondylitis ( AS ). ( 1.4 ) Adults with moderate to severe hidradenitis suppurativa (HS) . ( 1.5 ) uuid:b22efb68-3d0f-4bbb-9190-0c7ea816d2be biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133013 biolink:treats MONDO:0006710 PMID:41385096 "[{""id"":""uuid:0191d559-66d0-4d83-ab7a-21b894f4c43a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d04a10a2-133a-44e9-bfab-30f8d600f9a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BRIVIACT is indicated for the treatment of partial-onset seizures in patients 1 month of age and older. uuid:ed3bc646-f320-4547-980d-0fc4b72b522a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28887 biolink:treats MONDO:0004948 PMID:41385096 "[{""id"":""uuid:06a78c4b-b79e-40cc-bd27-501dee245251"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ba288ca7-e252-4dac-8459-c24a367e37ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ae2b34b3-114d-4e9a-963d-15fb08605ebd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chronic Lymphocytic Leukemia (CLL) ARZERRA (ofatumumab) is indicated: in combination with chlorambucil, for the treatment of previously untreated patients with CLL for whom fludarabine-based therapy is considered inappropriate [see Clinical Studies (14.1)] in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed CLL [see Clinical Studies (14.2)] for extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL [see Clinical Studies (14.3)] for the treatment of patients with CLL refractory to fludarabine and alemtuzumab [see Clinical Studies (14.4)]|[PMDA] Drugs with a new active ingredient indicated for the treatment of relapsed or refractory CD20- positive chronic lymphocytic leukemia. [Orphan drug] uuid:a560dc84-044a-4227-ab01-f8b9633ac978 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28887 biolink:treats UMLS:C0854802 PMID:41385096 "[{""id"":""uuid:aabb0810-6409-4af4-9a57-13f9bc397ef5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:fc7dafba-a8d6-41e7-9acd-70dd49d4dd31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Chronic Lymphocytic Leukemia (CLL) ARZERRA (ofatumumab) is indicated: in combination with chlorambucil, for the treatment of previously untreated patients with CLL for whom fludarabine-based therapy is considered inappropriate [see Clinical Studies (14.1)] in combination with fludarabine and cyclophosphamide for the treatment of patients with relapsed CLL [see Clinical Studies (14.2)] for extended treatment of patients who are in complete or partial response after at least two lines of therapy for recurrent or progressive CLL [see Clinical Studies (14.3)] for the treatment of patients with CLL refractory to fludarabine and alemtuzumab [see Clinical Studies (14.4)] uuid:c4ea4a02-0f73-44be-8b61-0d1323b221ff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63577 biolink:treats MONDO:0005231 PMID:41385096 "[{""id"":""uuid:f450ba42-8b96-4485-8866-fc39b030581d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6b635f37-cde5-43e7-a737-eed308b474ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Lamivudine tablets (HBV) are indicated for the treatment of chronic hepatitis B virus (HBV) infection associated with evidence of hepatitis B viral replication and active liver inflammation [ see Clinical Studies ( 14.1 , 14.2 ) ]. The following points should be considered when initiating therapy with lamivudine tablets (HBV): Due to high rates of resistance development in treated patients, initiation of treatment with lamivudine tablets (HBV) should only be considered when the use of an alternative antiviral agent with a higher genetic barrier to resistance is not available or appropriate. Lamivudine tablets (HBV) have not been evaluated in patients co-infected with human immunodeficiency virus (HIV), hepatitis C virus (HCV), or hepatitis delta virus. Lamivudine tablets (HBV) have not been evaluated in liver transplant recipients or in patients with chronic hepatitis B virus infection with decompensated liver disease. uuid:886575e9-c77b-4cad-9af7-9ce6114aa603 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:196955 biolink:treats MONDO:0005277 PMID:41385096 "[{""id"":""uuid:76b639b3-4977-48e3-a9f9-4e93819e517a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e59292b6-c0d7-49fa-9391-ec9d892f7473"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:75cd6672-1bf0-446c-8047-ab824c705cac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/aquipta""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] QULIPTA is indicated for the preventive treatment of migraine in adults.|[EMA] Aquipta is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month uuid:01c86c7c-8ced-432b-abf3-816b84e6605d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:TO3JYR3BOU biolink:treats MONDO:0100244 PMID:41385096 "[{""id"":""uuid:9e6c12d4-b8e1-4898-819a-9910810235c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:25743554-06d1-4c34-a352-06deec35f70c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:acfe11ae-f2d0-41a5-98e6-3fb26df67259"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/aspaveli""]},{""id"":""uuid:6f91819d-54a2-4a3b-8fc4-45ada69fb00e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] EMPAVELI ® is indicated for the treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH).|[EMA] Aspaveli is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (PNH) who are anaemic after treatment with a C5 inhibitor for at least 3 months.|[PMDA] A drug with a new active ingredient indicated for the treatment of paroxysmal nocturnal haemoglobinuria. uuid:eacea815-1395-48a3-babd-33ae45404528 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:91083 biolink:treats MONDO:0002048 PMID:41385096 "[{""id"":""uuid:08bf3b27-533a-4841-bdf7-8c9bfefc7bf6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d5749834-08d6-4f44-8869-9c9420dfc21f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nplate is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in: Adult patients with immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. ( 1.1 ) Pediatric patients 1 year of age and older with ITP for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. ( 1.1 ) Nplate is indicated to increase survival in adults and in pediatric patients (including term neonates) acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [HS-ARS]). ( 1.2 ) Limitations of Use: Nplate is not indicated for the treatment of thrombocytopenia due to myelodysplastic syndrome (MDS) or any cause of thrombocytopenia other than ITP. Nplate should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increases the risk for bleeding. Nplate should not be used in an attempt to normalize platelet counts. ( 1 ) uuid:2d91b1de-5d1c-4310-b891-e2a0f3f52f08 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:91083 biolink:treats MONDO:0033938 PMID:41385096 "[{""id"":""uuid:bb397735-64e6-47ff-845d-26a48ddded48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:de751e35-33a8-4b86-a0c2-32488cb9d1b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nplate is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in: Adult patients with immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. ( 1.1 ) Pediatric patients 1 year of age and older with ITP for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. ( 1.1 ) Nplate is indicated to increase survival in adults and in pediatric patients (including term neonates) acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [HS-ARS]). ( 1.2 ) Limitations of Use: Nplate is not indicated for the treatment of thrombocytopenia due to myelodysplastic syndrome (MDS) or any cause of thrombocytopenia other than ITP. Nplate should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increases the risk for bleeding. Nplate should not be used in an attempt to normalize platelet counts. ( 1 ) uuid:64b8da61-4fea-47b6-b229-e78e0ee5015c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:91083 biolink:treats MONDO:0002049 PMID:41385096 "[{""id"":""uuid:7cc704a7-9608-415c-a0c9-1bdfb28dd3f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:69dda111-176e-491b-992d-7aa0b97bd925"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Nplate is a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in: Adult patients with immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. ( 1.1 ) Pediatric patients 1 year of age and older with ITP for at least 6 months who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. ( 1.1 ) Nplate is indicated to increase survival in adults and in pediatric patients (including term neonates) acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of Acute Radiation Syndrome [HS-ARS]). ( 1.2 ) Limitations of Use: Nplate is not indicated for the treatment of thrombocytopenia due to myelodysplastic syndrome (MDS) or any cause of thrombocytopenia other than ITP. Nplate should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increases the risk for bleeding. Nplate should not be used in an attempt to normalize platelet counts. ( 1 ) uuid:3bd9cb44-46f8-4ee5-83f0-2b7d1eacb643 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB16199 biolink:treats MONDO:0007100 PMID:41385096 "[{""id"":""uuid:f856a153-70dc-4deb-bf09-0893fb33a651"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d0b94d09-d011-4709-8794-350c108dfcac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] WAINUA is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. uuid:1cf213c1-e6de-42a4-a89a-5451e334dffd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:AD0O8X2QJR biolink:treats MONDO:0005475 PMID:41385096 "[{""id"":""uuid:180ffb39-01f9-4d8f-bca2-24f5689828ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:029b9145-e904-4a43-b89b-94434371218d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] UBRELVY is indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use UBRELVY is not indicated for the preventive treatment of migraine. uuid:095ec6b9-2bae-4920-85d0-373fa9006b5f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:AD0O8X2QJR biolink:treats MONDO:0100431 PMID:41385096 "[{""id"":""uuid:092718b3-764a-4c30-a144-ef03afd8777b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:05192235-e73d-4533-82d4-b38bc3a338ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] UBRELVY is indicated for the acute treatment of migraine with or without aura in adults. Limitations of Use UBRELVY is not indicated for the preventive treatment of migraine. uuid:b9fd1f64-8ee7-495a-ae6e-59781e026c8b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6KLL51GNBG biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:46b3d7f8-3e33-4ac3-a467-29b3c4e73be7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7cc8708d-50dd-467e-9abc-f25db5f67d40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] IBTROZI ™ (taletrectinib) is indicated for the treatment of adult patients with locally advanced or metastatic ROS1 -positive non-small cell lung cancer (NSCLC) [see Dosage and Administration ( 2.1 )] . uuid:9523b489-90ef-4029-a693-45542b9a0111 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:KXG2PJ551I biolink:treats MONDO:0019210 PMID:41385096 "[{""id"":""uuid:64493b22-bed8-4208-8fee-00704b1af759"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:daf9cd49-6ccb-4336-adc2-d9160416842f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:400307a8-f093-40aa-80c8-bb8b09ff0480"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/bavencio""]},{""id"":""uuid:08255c70-126a-452a-9567-f0baa8e2da93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BAVENCIO is a programmed death ligand-1 (PD-L1) blocking antibody indicated for: Merkel Cell Carcinoma (MCC) Adults and pediatric patients 12 years and older with metastatic MCC. ( 1.1 , 14.1 ) Urothelial Carcinoma (UC) Maintenance treatment of patients with locally advanced or metastatic UC that has not progressed with first-line platinum-containing chemotherapy. ( 1.2 , 14.2 ) Patients with locally advanced or metastatic UC who: Have disease progression during or following platinum-containing chemotherapy. ( 1.2 , 14.2 ) Have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. ( 1.2 , 14.2 ) Renal Cell Carcinoma (RCC) First-line treatment, in combination with axitinib, of patients with advanced RCC. ( 1.3 , 14.3 )|[EMA] Bavencio is indicated as monotherapy for the treatment of adult patients with metastatic Merkel cell carcinoma (MCC).Bavencio in combination with axitinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC).Bavencio is indicated as monotherapy for the first‑line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are progression-free following platinum‑based chemotherapy.|[PMDA] A drug with a new active ingredient indicated for the treatment of unresectable Merkel cell carcinoma. [Orphan drug] uuid:02c91aa4-b518-4895-b305-160fadda89db biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:KXG2PJ551I biolink:treats MONDO:0040679 PMID:41385096 "[{""id"":""uuid:9cf51db4-7583-425c-a742-1c3f4b027b82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0999aadb-9027-4f25-af36-06796a498889"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7a7b2cb5-a8ee-47f1-8fe0-bd16135e4a47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/bavencio""]},{""id"":""uuid:f71c6a2a-8249-45ef-8d48-87fe196fb22b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BAVENCIO is a programmed death ligand-1 (PD-L1) blocking antibody indicated for: Merkel Cell Carcinoma (MCC) Adults and pediatric patients 12 years and older with metastatic MCC. ( 1.1 , 14.1 ) Urothelial Carcinoma (UC) Maintenance treatment of patients with locally advanced or metastatic UC that has not progressed with first-line platinum-containing chemotherapy. ( 1.2 , 14.2 ) Patients with locally advanced or metastatic UC who: Have disease progression during or following platinum-containing chemotherapy. ( 1.2 , 14.2 ) Have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. ( 1.2 , 14.2 ) Renal Cell Carcinoma (RCC) First-line treatment, in combination with axitinib, of patients with advanced RCC. ( 1.3 , 14.3 )|[EMA] Bavencio is indicated as monotherapy for the treatment of adult patients with metastatic Merkel cell carcinoma (MCC).Bavencio in combination with axitinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC).Bavencio is indicated as monotherapy for the first‑line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are progression-free following platinum‑based chemotherapy.|[PMDA] A drug with a new indication for the maintenance therapy of unresectable urothelial carcinoma in patients who have received chemotherapy. [Priority review] uuid:3f142a1e-82c6-41b6-a729-0e370d812015 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:KXG2PJ551I biolink:treats MONDO:0005086 PMID:41385096 "[{""id"":""uuid:904fa91a-7102-4884-b976-21de3256754e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1b5cc676-672c-40d5-9d1c-25be7dfe08d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e05ff242-30b6-449b-9b4e-8991200f47ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/bavencio""]},{""id"":""uuid:52ab9d1e-3db9-4fb8-917e-52a3ae0f2a38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] BAVENCIO is a programmed death ligand-1 (PD-L1) blocking antibody indicated for: Merkel Cell Carcinoma (MCC) Adults and pediatric patients 12 years and older with metastatic MCC. ( 1.1 , 14.1 ) Urothelial Carcinoma (UC) Maintenance treatment of patients with locally advanced or metastatic UC that has not progressed with first-line platinum-containing chemotherapy. ( 1.2 , 14.2 ) Patients with locally advanced or metastatic UC who: Have disease progression during or following platinum-containing chemotherapy. ( 1.2 , 14.2 ) Have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. ( 1.2 , 14.2 ) Renal Cell Carcinoma (RCC) First-line treatment, in combination with axitinib, of patients with advanced RCC. ( 1.3 , 14.3 )|[EMA] Bavencio is indicated as monotherapy for the treatment of adult patients with metastatic Merkel cell carcinoma (MCC).Bavencio in combination with axitinib is indicated for the first-line treatment of adult patients with advanced renal cell carcinoma (RCC).Bavencio is indicated as monotherapy for the first‑line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are progression-free following platinum‑based chemotherapy.|[PMDA] A drug with a new indication and a new dosage for the treatment of unresectable or metastatic renal cell carcinoma. uuid:aafd224c-4c43-40a3-94d4-bf6ad8b434bc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85010 biolink:treats MONDO:0018881 PMID:41385096 "[{""id"":""uuid:fb46c2c4-af0c-4299-ad4e-b826dd8354d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:92f6831a-f343-4d60-ac1e-c5b5079a1b75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PROMACTA is a thrombopoietin receptor agonist indicated: for the treatment of thrombocytopenia in adult and pediatric patients 1 year and older with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. PROMACTA should be used only in patients with ITP whose degree of thrombocytopenia and clinical condition increase the risk for bleeding. ( 1.1 ) for the treatment of thrombocytopenia in patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy. PROMACTA should be used only in patients with chronic hepatitis C whose degree of thrombocytopenia prevents the initiation of interferon-based therapy or limits the ability to maintain interferon-based therapy. ( 1.2 ) in combination with standard immunosuppressive therapy for the first-line treatment of adult and pediatric patients 2 years and older with severe aplastic anemia. ( 1.3 ) for the treatment of patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy. ( 1.3 ) Limitations of Use: PROMACTA is not indicated for the treatment of patients with myelodysplastic syndrome (MDS). ( 1.4 ) Safety and efficacy have not been established in combination with direct-acting antiviral agents used without interferon for treatment of chronic hepatitis C infection. ( 1.4 ) uuid:a2a0e9fb-cde0-4055-83bb-e12bd7e181cf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:31YO63LBSN biolink:treats MONDO:0005580 PMID:41385096 "[{""id"":""uuid:ef441fc5-15d9-4184-b58c-c5a1f1bbeb66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9915b2cf-ed8e-47e4-b5ab-95c2095abb23"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] OPDIVO QVANTIG is a combination of nivolumab, a programmed death receptor-1 (PD-1)-blocking antibody, and hyaluronidase, an endoglycosidase, indicated for the treatment of: Renal Cell Carcinoma (RCC) • adult patients with intermediate or poor risk advanced RCC, as a first-line treatment following combination treatment with intravenous nivolumab and ipilimumab. (1.1) • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of renal cell carcinoma. • adult patients with advanced RCC, as a first-line treatment in combination with cabozantinib. (1.1) • adult patients with advanced RCC who have received prior anti-angiogenic therapy. ( 1.1 ) Melanoma • adult patients with unresectable or metastatic melanoma. (1.2) • adult patients with unresectable or metastatic melanoma following combination treatment with intravenous nivolumab and ipilimumab. (1.2) • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of unresectable or metastatic melanoma. • for the adjuvant treatment of adult patients with completely resected Stage IIB, Stage IIC, Stage III, or Stage IV melanoma. (1.3) Non-Small Cell Lung Cancer (NSCLC) • adult patients with resectable (tumors ≥4 cm or node positive) NSCLC in the neoadjuvant setting, in combination with platinum-doublet chemotherapy. (1.4) • adult patients with resectable (tumors ≥4 cm or node positive) NSCLC and no known EGFR mutations or ALK rearrangements, for neoadjuvant treatment, in combination with platinum-doublet chemotherapy, followed by OPDIVO QVANTIG monotherapy as adjuvant treatment after surgery. (1.5) • adult patients with metastatic NSCLC and progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving OPDIVO QVANTIG. (1.6) • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of metastatic NSCLC. Squamous Cell Carcinoma of the Head and Neck (SCCHN) • adult patients with recurrent or metastatic SCCHN with disease progression on or after a platinum-based therapy. (1.7) Urothelial Carcinoma (UC) • adjuvant treatment of adult patients with UC who are at high risk of recurrence after undergoing radical resection of UC. (1.8) • adult patients with unresectable or metastatic urothelial carcinoma, as first-line treatment in combination with cisplatin and gemcitabine. (1.8) • adult patients with locally advanced or metastatic UC who: • have disease progression during or following platinum-containing chemotherapy. • have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. (1.8) Colorectal Cancer • adult patients with MSI-H or dMMR metastatic CRC that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan, as monotherapy or as monotherapy following combination treatment with intravenous nivolumab and ipilimumab. a (1.9) • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of MSI-H or dMMR metastatic CRC. Hepatocellular Carcinoma (HCC) • adult patients with HCC previously treated with sorafenib and following combination treatment with intravenous nivolumab and ipilimumab. a (1.10) • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of HCC. Esophageal Cancer • adult patients with completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease, who have received neoadjuvant chemoradiotherapy (CRT). (1.11) • adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) as first-line treatment in combination with fluoropyrimidine- and platinum-containing chemotherapy whose tumors express PD-L1 (≥1). (1.11) • Limitations of Use: OPDIVO QVANTIG is not indicated in combination with ipilimumab for the treatment of patients with unresectable advanced or metastatic ESCC. • adult patients with unresectable advanced, recurrent or metastatic ESCC after prior fluoropyrimidine- and platinum-based chemotherapy. (1.11) Gastric Cancer, Gastroesophageal Junction Cancer, and Esophageal Adenocarcinoma • adult patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma whose tumors express PD-L1 (≥1) in combination with fluoropyrimidine- and platinum-containing chemotherapy. (1.12) a This indication is approved under accelerated approval based on overall response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. uuid:023cb9ec-34a0-442a-936b-da15f4f0938d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4F4X42SYQ6 biolink:treats MONDO:0017594 PMID:41385096 "[{""id"":""uuid:ced00fa3-ae54-4252-aa9a-ddce31656e1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9853be66-545d-4de1-843f-510f2fd73a06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TRUXIMA (rituximab-abbs) is a CD20-directed cytolytic antibody indicated for the treatment of adult patients with: Non-Hodgkin's Lymphoma (NHL) ( 1.1 ). Relapsed or refractory, low grade or follicular, CD20-positive B-cell NHL as a single agent. Previously untreated follicular, CD20-positive, B-cell NHL in combination with first line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy. Non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy. Previously untreated diffuse large B-cell, CD20-positive NHL in combination with (cyclophosphamide, doxorubicin, vincristine, and prednisone) (CHOP) or other anthracycline-based chemotherapy regimens. Chronic Lymphocytic Leukemia (CLL) ( 1.2 ). Previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide (FC). Rheumatoid Arthritis (RA) in combination with methotrexate in adult patients with moderately-to severely-active RA who have inadequate response to one or more TNF antagonist therapies ( 1.3 ). Granulomatosis with Polyangiitis (GPA) (Wegener’s Granulomatosis) and Microscopic Polyangiitis (MPA) in adult patients in combination with glucocorticoids ( 1.4 ). Moderate to severe Pemphigus Vulgaris (PV) in adult patients ( 1.5 ) uuid:fc531f4d-850a-4cc8-b1c6-448b6254df33 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63628 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:eb412191-0edb-4e91-b2db-c9b09ad7e5d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7155f434-2c4f-4b9f-86fd-60505b2de775"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] APTIVUS, co-administered with ritonavir, is indicated for combination antiretroviral treatment of HIV-1 infected adults and pediatric patients weighing 36 kg or higher who are treatment-experienced and infected with HIV-1 strains resistant to more than one protease inhibitor (PI) [see Use in Specific Populations (8.4) ] . This indication is based on analyses of plasma HIV-1 RNA levels in two controlled studies of APTIVUS/ritonavir of 48 weeks duration in treatment-experienced adults and one open-label 48-week study in pediatric patients. The adult studies were conducted in clinically advanced, 3-class antiretroviral (NRTI, NNRTI, PI) treatment-experienced adults with evidence of HIV-1 replication despite ongoing antiretroviral therapy. The following points should be considered when initiating therapy with APTIVUS/ritonavir: The use of APTIVUS/ritonavir in treatment-naïve patients is not recommended [ see Warnings and Precautions (5.2) ]. The use of other active agents with APTIVUS/ritonavir is associated with a greater likelihood of treatment response [ see Microbiology (12.4) and Clinical Studies (14) ]. Genotypic or phenotypic testing and/or treatment history should guide the use of APTIVUS/ritonavir [ see Microbiology (12.4) ]. The number of baseline primary protease inhibitor mutations affects the virologic response to APTIVUS/ritonavir [ see Microbiology (12.4) ]. Use caution when prescribing APTIVUS/ritonavir to patients with elevated transaminases, hepatitis B or C co-infection or patients with mild hepatic impairment [ see Warnings and Precautions (5.2) ]. Liver function tests should be performed at initiation of therapy with APTIVUS/ritonavir and monitored frequently throughout the duration of treatment [ see Warnings and Precautions (5.2) ]. The drug-drug interaction potential of APTIVUS/ritonavir when co-administered with other drugs must be considered prior to and during APTIVUS/ritonavir use [ see Contraindications (4) and Drug Interactions (7) ]. Use caution when prescribing APTIVUS/ritonavir in patients who may be at risk for increased bleeding or who are receiving medications known to increase the risk of bleeding [ see Warnings and Precautions (5.5) ]. There are no study results demonstrating the effect of APTIVUS/ritonavir on clinical progression of HIV-1. uuid:412fd259-ae85-4a35-8869-2328008b48af biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63628 biolink:treats MONDO:0005344 PMID:41385096 "[{""id"":""uuid:eda22d01-a170-498d-a3b9-d19440197612"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ddde164d-20c8-4394-9424-c6cb221d5983"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] APTIVUS, co-administered with ritonavir, is indicated for combination antiretroviral treatment of HIV-1 infected adults and pediatric patients weighing 36 kg or higher who are treatment-experienced and infected with HIV-1 strains resistant to more than one protease inhibitor (PI) [see Use in Specific Populations (8.4) ] . This indication is based on analyses of plasma HIV-1 RNA levels in two controlled studies of APTIVUS/ritonavir of 48 weeks duration in treatment-experienced adults and one open-label 48-week study in pediatric patients. The adult studies were conducted in clinically advanced, 3-class antiretroviral (NRTI, NNRTI, PI) treatment-experienced adults with evidence of HIV-1 replication despite ongoing antiretroviral therapy. The following points should be considered when initiating therapy with APTIVUS/ritonavir: The use of APTIVUS/ritonavir in treatment-naïve patients is not recommended [ see Warnings and Precautions (5.2) ]. The use of other active agents with APTIVUS/ritonavir is associated with a greater likelihood of treatment response [ see Microbiology (12.4) and Clinical Studies (14) ]. Genotypic or phenotypic testing and/or treatment history should guide the use of APTIVUS/ritonavir [ see Microbiology (12.4) ]. The number of baseline primary protease inhibitor mutations affects the virologic response to APTIVUS/ritonavir [ see Microbiology (12.4) ]. Use caution when prescribing APTIVUS/ritonavir to patients with elevated transaminases, hepatitis B or C co-infection or patients with mild hepatic impairment [ see Warnings and Precautions (5.2) ]. Liver function tests should be performed at initiation of therapy with APTIVUS/ritonavir and monitored frequently throughout the duration of treatment [ see Warnings and Precautions (5.2) ]. The drug-drug interaction potential of APTIVUS/ritonavir when co-administered with other drugs must be considered prior to and during APTIVUS/ritonavir use [ see Contraindications (4) and Drug Interactions (7) ]. Use caution when prescribing APTIVUS/ritonavir in patients who may be at risk for increased bleeding or who are receiving medications known to increase the risk of bleeding [ see Warnings and Precautions (5.5) ]. There are no study results demonstrating the effect of APTIVUS/ritonavir on clinical progression of HIV-1. uuid:60ddd2a2-7368-4ac3-9ed9-cadb1006938f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63628 biolink:treats MONDO:0005231 PMID:41385096 "[{""id"":""uuid:a4af0132-8cfb-4132-9f04-6390e81b4497"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:70839008-9b64-4e76-a815-8fc7b266860c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] APTIVUS, co-administered with ritonavir, is indicated for combination antiretroviral treatment of HIV-1 infected adults and pediatric patients weighing 36 kg or higher who are treatment-experienced and infected with HIV-1 strains resistant to more than one protease inhibitor (PI) [see Use in Specific Populations (8.4) ] . This indication is based on analyses of plasma HIV-1 RNA levels in two controlled studies of APTIVUS/ritonavir of 48 weeks duration in treatment-experienced adults and one open-label 48-week study in pediatric patients. The adult studies were conducted in clinically advanced, 3-class antiretroviral (NRTI, NNRTI, PI) treatment-experienced adults with evidence of HIV-1 replication despite ongoing antiretroviral therapy. The following points should be considered when initiating therapy with APTIVUS/ritonavir: The use of APTIVUS/ritonavir in treatment-naïve patients is not recommended [ see Warnings and Precautions (5.2) ]. The use of other active agents with APTIVUS/ritonavir is associated with a greater likelihood of treatment response [ see Microbiology (12.4) and Clinical Studies (14) ]. Genotypic or phenotypic testing and/or treatment history should guide the use of APTIVUS/ritonavir [ see Microbiology (12.4) ]. The number of baseline primary protease inhibitor mutations affects the virologic response to APTIVUS/ritonavir [ see Microbiology (12.4) ]. Use caution when prescribing APTIVUS/ritonavir to patients with elevated transaminases, hepatitis B or C co-infection or patients with mild hepatic impairment [ see Warnings and Precautions (5.2) ]. Liver function tests should be performed at initiation of therapy with APTIVUS/ritonavir and monitored frequently throughout the duration of treatment [ see Warnings and Precautions (5.2) ]. The drug-drug interaction potential of APTIVUS/ritonavir when co-administered with other drugs must be considered prior to and during APTIVUS/ritonavir use [ see Contraindications (4) and Drug Interactions (7) ]. Use caution when prescribing APTIVUS/ritonavir in patients who may be at risk for increased bleeding or who are receiving medications known to increase the risk of bleeding [ see Warnings and Precautions (5.5) ]. There are no study results demonstrating the effect of APTIVUS/ritonavir on clinical progression of HIV-1. uuid:8fe6ed94-ddd1-443e-a66c-f755cd2bde04 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6970 biolink:treats MONDO:0001358 PMID:41385096 "[{""id"":""uuid:ce510c98-7c2c-4797-bbe2-38e1d1592dbc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:decb84f2-d149-40a5-ab92-e40c65a45197"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ASMANEX HFA is a corticosteroid indicated for: Maintenance treatment of asthma as prophylactic therapy in patients 5 years of age and older. ( 1.1 ) Important limitations: Not indicated for the relief of acute bronchospasm. ( 1.1 ) uuid:962a8461-6300-422e-8fc6-9e00008b3269 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63452 biolink:treats MONDO:0018874 PMID:41385096 "[{""id"":""uuid:e4c62fa5-46c1-4e13-9f41-690d5b25e854"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:8933cf0d-2818-49f5-8426-c81511d90eb6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e4175204-f085-43cd-999c-d14c5c8f6b8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/rydapt""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] RYDAPT is a kinase inhibitor indicated for the treatment of adult patients with: Newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. ( 1.1 ) Limitations of Use: RYDAPT is not indicated as a single-agent induction therapy for the treatment of patients with AML. Aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL). ( 1.2 )|[EMA] Rydapt is indicated:in combination with standard daunorubicin and cytarabine induction and high dose cytarabine consolidation chemotherapy, and for patients in complete response followed by Rydapt single agent maintenance therapy, for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation positive (see section 4.2);as monotherapy for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated haematological neoplasm (SM AHN), or mast cell leukaemia (MCL). uuid:3eaa86cc-a43d-468b-b4f1-4ddbacc2949c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63452 biolink:treats MONDO:0020333 PMID:41385096 "[{""id"":""uuid:146d2bcd-e4b8-4223-83dd-81e86b4205cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d79b6e9e-3ad9-4bc7-82d5-015005a68803"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2c83647a-48ca-4db6-a014-d54b7289fb8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/rydapt""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] RYDAPT is a kinase inhibitor indicated for the treatment of adult patients with: Newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. ( 1.1 ) Limitations of Use: RYDAPT is not indicated as a single-agent induction therapy for the treatment of patients with AML. Aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL). ( 1.2 )|[EMA] Rydapt is indicated:in combination with standard daunorubicin and cytarabine induction and high dose cytarabine consolidation chemotherapy, and for patients in complete response followed by Rydapt single agent maintenance therapy, for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation positive (see section 4.2);as monotherapy for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated haematological neoplasm (SM AHN), or mast cell leukaemia (MCL). uuid:bf48172c-b8a2-4235-a111-10bb585b5f01 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63452 biolink:treats MONDO:0020332 PMID:41385096 "[{""id"":""uuid:f66b00d6-a21f-4724-8edf-ed843a260c3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:33761292-ca6c-4113-986d-50d34158a50d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2786e879-c513-4bd8-a421-3f4d6d7bdf1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/rydapt""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] RYDAPT is a kinase inhibitor indicated for the treatment of adult patients with: Newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. ( 1.1 ) Limitations of Use: RYDAPT is not indicated as a single-agent induction therapy for the treatment of patients with AML. Aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL). ( 1.2 )|[EMA] Rydapt is indicated:in combination with standard daunorubicin and cytarabine induction and high dose cytarabine consolidation chemotherapy, and for patients in complete response followed by Rydapt single agent maintenance therapy, for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation positive (see section 4.2);as monotherapy for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated haematological neoplasm (SM AHN), or mast cell leukaemia (MCL). uuid:82717f06-cd03-46aa-89b4-ec0cde3f9f7d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63452 biolink:treats MONDO:0020334 PMID:41385096 "[{""id"":""uuid:b4f92fda-2167-4bd6-b9b1-b059b7474bb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:45882fe1-ff77-41ac-8201-75dcb4fce03c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a658dd8e-8825-41c4-9f41-f0ce975e27cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/rydapt""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] RYDAPT is a kinase inhibitor indicated for the treatment of adult patients with: Newly diagnosed acute myeloid leukemia (AML) that is FLT3 mutation-positive as detected by an FDA-approved test, in combination with standard cytarabine and daunorubicin induction and cytarabine consolidation. ( 1.1 ) Limitations of Use: RYDAPT is not indicated as a single-agent induction therapy for the treatment of patients with AML. Aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated hematological neoplasm (SM-AHN), or mast cell leukemia (MCL). ( 1.2 )|[EMA] Rydapt is indicated:in combination with standard daunorubicin and cytarabine induction and high dose cytarabine consolidation chemotherapy, and for patients in complete response followed by Rydapt single agent maintenance therapy, for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation positive (see section 4.2);as monotherapy for the treatment of adult patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with associated haematological neoplasm (SM AHN), or mast cell leukaemia (MCL). uuid:449f3a4f-0c52-4dc4-861c-93079d99fa3e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:06P3KLK2J8 biolink:treats MONDO:0000901 PMID:41385096 "[{""id"":""uuid:ac46cdfd-e658-4a7b-8c5e-1ba23217bf3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ede01a67-9d9b-4469-83e2-248618f76a73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] COLUMVI is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate and durability of response [see Clinical Studies (14.1) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s). uuid:7a6724f7-0a66-48f5-aacd-01e030b686a9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:06P3KLK2J8 biolink:treats MONDO:0018905 PMID:41385096 "[{""id"":""uuid:c22ab051-69e9-47bc-90fa-6cecb941c7a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:cb172c61-8067-4f94-bec0-c7791eadc4f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:66dbf52a-ea0c-423e-a5c2-40997a474290"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/columvi""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] COLUMVI is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS) or large B-cell lymphoma (LBCL) arising from follicular lymphoma, after two or more lines of systemic therapy. This indication is approved under accelerated approval based on response rate and durability of response [see Clinical Studies (14.1) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).|[EMA] Columvi as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL), after two or more lines of systemic therapy. uuid:95b25bdd-2d13-45b3-8c91-1af42a939d55 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:RR6P8L282I biolink:treats UMLS:C2921627 PMID:41385096 "[{""id"":""uuid:b2bd148f-32ed-4611-a69c-60519e0dd1ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c7f35a69-cc2c-4641-88fa-7f8b94a7318f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MAYZENT is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. uuid:8ffa84f8-d2ff-4927-b069-24af1d6d48a1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:RR6P8L282I biolink:treats MONDO:0000450 PMID:41385096 "[{""id"":""uuid:72b2ccfc-b650-4983-89d0-5556777e339a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2f1df5d9-f70f-4680-b971-211830820f82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:029b68e8-2629-4487-b85a-142cbe507fd3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MAYZENT is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.|[EMA] Mayzent is indicated for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity. uuid:a3609fff-4182-4871-957e-c9d38d57f6f9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:RR6P8L282I biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:b31f4cd0-1037-4d10-b711-bf252675a306"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:56eac4ee-10a5-4cba-98a6-2032d91b9181"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ad16e1a0-91d3-4a50-b012-75cefee55970"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] MAYZENT is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.|[EMA] Mayzent is indicated for the treatment of adult patients with secondary progressive multiple sclerosis (SPMS) with active disease evidenced by relapses or imaging features of inflammatory activity. uuid:1711e69e-b3ec-412c-b556-9d0455f97c4c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:RJ1IW3B4QX biolink:treats UMLS:C0581126 PMID:41385096 "[{""id"":""uuid:90b231dd-82b2-40bb-bfe4-1147587225fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9122140e-435b-4a7c-a807-5953cc34212e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TEZSPIRE is indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma. Limitations of Use: TEZSPIRE is not indicated for the relief of acute bronchospasm or status asthmaticus. uuid:2132770d-4e8b-4c54-91ed-93a707394e82 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:RJ1IW3B4QX biolink:treats UMLS:C0741804 PMID:41385096 "[{""id"":""uuid:cde90105-d949-457f-b9fd-f94c376ed6de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:177c2b60-99b3-4daf-8707-54180ec3d0a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] TEZSPIRE is indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma. Limitations of Use: TEZSPIRE is not indicated for the relief of acute bronchospasm or status asthmaticus. uuid:00c96255-664c-44c9-9b5b-e72124e4bc72 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:RJ1IW3B4QX biolink:treats MONDO:0004766 PMID:41385096 "[{""id"":""uuid:9814c688-d3e8-4122-b27e-8e553c904e4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b441c493-941d-4745-95f4-56a55162e747"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c29ac0e2-9289-4866-835f-044ce2e110b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tezspire""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] TEZSPIRE is indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma. Limitations of Use: TEZSPIRE is not indicated for the relief of acute bronchospasm or status asthmaticus.|[EMA] Tezspire is indicated as an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma who are inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment. uuid:c8b78bb9-5123-4933-84e3-ae2fe19ee49a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:93752 biolink:treats MONDO:1040002 PMID:41385096 "[{""id"":""uuid:dc18d189-4ad7-4e0b-90b9-497cb2c4d824"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:521ecbd7-d098-4aed-bd2b-64a7b8cfe4d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:8290e800-3872-4ac1-89c3-f5d896dd647d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/piqray""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] VIJOICE is indicated for the treatment of adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CA-Related Overgrowth Spectrum (PROS) who require systemic therapy. This indication is approved under accelerated approval based on response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).|[EMA] Piqray is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as monotherapy (see section 5.1). uuid:779ef789-5c0c-4dee-ba82-0ad955b6a347 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28887 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:b7a71104-a295-4ef6-b4b5-52a56e382739"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3820a165-e116-43ef-acd8-f8ee56b16a1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:83dc0431-a74d-44a5-bafb-ad05bbc68106"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KESIMPTA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.|[PMDA] A drug with a new route of administration and new indications for the prevention of relapse and for delaying the accumulation of physical disability in relapsing- remitting multiple sclerosis (RRMS) and active secondary progressive multiple sclerosis (active SPMS). [Orphan drug] uuid:193632f7-6dba-4dc5-8957-71d3633a4834 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28887 biolink:treats UMLS:C2921627 PMID:41385096 "[{""id"":""uuid:56259852-c78f-418b-b990-254e60491481"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:34349803-4278-4aed-af4a-e7ba5d00692b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KESIMPTA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. uuid:7165adef-3b09-41a3-b212-a6fa690d148b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28887 biolink:treats MONDO:0000450 PMID:41385096 "[{""id"":""uuid:075cc577-6c12-4bea-8cde-78c004bf7f6d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:27033cfc-8a7f-4ed5-a7f0-417108d25268"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:46b5b992-10e0-487b-8d84-6ec9744d49fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KESIMPTA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.|[PMDA] A drug with a new route of administration and new indications for the prevention of relapse and for delaying the accumulation of physical disability in relapsing- remitting multiple sclerosis (RRMS) and active secondary progressive multiple sclerosis (active SPMS). [Orphan drug] uuid:8b0d468b-073b-4855-98e5-f5762436ab90 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:176399 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:1f62af1a-e0d8-466f-9ee5-c3018616f03e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:39e44a94-534b-480a-be99-04425200de91"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LEQVIO ® is indicated as an adjunct to diet and statin therapy for the treatment of adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce low-density lipoprotein cholesterol (LDL-C). uuid:334c337b-2da3-40a8-8e27-a4d91df35302 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:176399 biolink:treats UMLS:C0342882 PMID:41385096 "[{""id"":""uuid:ea668693-2967-4c34-8280-7f829e4d4fd4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9707fcf0-7b04-4206-bf9d-10e418708191"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LEQVIO ® is indicated as an adjunct to diet and statin therapy for the treatment of adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH), to reduce low-density lipoprotein cholesterol (LDL-C). uuid:5457bb08-156c-4c0d-8aee-89890a9695b0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:37CQ2C7X93 biolink:treats MONDO:0016168 PMID:41385096 "[{""id"":""uuid:2d6641a0-6e54-4da4-b2ee-bd1ee8fccb7d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b4ea3526-19d5-46bf-bce6-ed345781fe4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:75a76517-1689-4328-bcee-b320efc25fb4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ilaris""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ILARIS is an interleukin-1β blocker indicated for the treatment of: • Periodic Fever Syndromes ( 1.1 ): - Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and children 4 years of age and older, including: ◾ Familial Cold Auto-inflammatory Syndrome (FCAS) ◾ Muckle-Wells Syndrome (MWS) - Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients - Hyperimmunoglobulin D Syndrome (HIDS)/ Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients - Familial Mediterranean Fever (FMF) in adult and pediatric patients • Active Still’s Disease, including Adult-Onset Still’s Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients 2 years of age and older ( 1.2 ) • Gout flares in adults in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate ( 1.3 )|[EMA] Periodic fever syndromesIlaris is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older:Cryopyrin-associated periodic syndromesIlaris is indicated for the treatment of cryopyrin-associated periodic syndromes (CAPS) including:Muckle-Wells syndrome (MWS),Neonatal-onset multisystem inflammatory disease (NOMID) / chronic infantile neurological, cutaneous, articular syndrome (CINCA),Severe forms of familial cold autoinflammatory syndrome (FCAS) / familial cold urticaria (FCU) presenting with signs and symptoms beyond cold-induced urticarial skin rash.Tumour necrosis factor receptor associated periodic syndrome (TRAPS)Ilaris is indicated for the treatment of tumour necrosis factor (TNF) receptor associated periodic syndrome (TRAPS).Hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD)Ilaris is indicated for the treatment of hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD).Familial Mediterranean fever (FMF)Ilaris is indicated for the treatment of Familial Mediterranean Fever (FMF). Ilaris should be given in combination with colchicine, if appropriate.Ilaris is also indicated for the treatment of:Still’s diseaseIlaris is indicated for the treatment of active Still’s disease including adult-onset Still’s disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids. Ilaris can be given as monotherapy or in combination with methotrexate.Gouty arthritisIlaris is indicated for the symptomatic treatment of adult patients with frequent gouty arthritis attacks (at least 3 attacks in the previous 12 months) in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate. uuid:946136f8-e58e-4494-9f80-ea93aff2a781 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:37CQ2C7X93 biolink:treats MONDO:0018768 PMID:41385096 "[{""id"":""uuid:8a25225e-b838-4e60-8904-43b2f15d104c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:706d00d3-8d10-443d-8c54-4f7bde6d8b7d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c1ec35ec-e7a2-4d27-92eb-04be6bf688b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ilaris""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ILARIS is an interleukin-1β blocker indicated for the treatment of: • Periodic Fever Syndromes ( 1.1 ): - Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and children 4 years of age and older, including: ◾ Familial Cold Auto-inflammatory Syndrome (FCAS) ◾ Muckle-Wells Syndrome (MWS) - Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients - Hyperimmunoglobulin D Syndrome (HIDS)/ Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients - Familial Mediterranean Fever (FMF) in adult and pediatric patients • Active Still’s Disease, including Adult-Onset Still’s Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients 2 years of age and older ( 1.2 ) • Gout flares in adults in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate ( 1.3 )|[EMA] Periodic fever syndromesIlaris is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older:Cryopyrin-associated periodic syndromesIlaris is indicated for the treatment of cryopyrin-associated periodic syndromes (CAPS) including:Muckle-Wells syndrome (MWS),Neonatal-onset multisystem inflammatory disease (NOMID) / chronic infantile neurological, cutaneous, articular syndrome (CINCA),Severe forms of familial cold autoinflammatory syndrome (FCAS) / familial cold urticaria (FCU) presenting with signs and symptoms beyond cold-induced urticarial skin rash.Tumour necrosis factor receptor associated periodic syndrome (TRAPS)Ilaris is indicated for the treatment of tumour necrosis factor (TNF) receptor associated periodic syndrome (TRAPS).Hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD)Ilaris is indicated for the treatment of hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD).Familial Mediterranean fever (FMF)Ilaris is indicated for the treatment of Familial Mediterranean Fever (FMF). Ilaris should be given in combination with colchicine, if appropriate.Ilaris is also indicated for the treatment of:Still’s diseaseIlaris is indicated for the treatment of active Still’s disease including adult-onset Still’s disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids. Ilaris can be given as monotherapy or in combination with methotrexate.Gouty arthritisIlaris is indicated for the symptomatic treatment of adult patients with frequent gouty arthritis attacks (at least 3 attacks in the previous 12 months) in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate. uuid:4a1bdefe-b0e3-4157-a6aa-a50be80a73b2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:37CQ2C7X93 biolink:treats MONDO:0007727 PMID:41385096 "[{""id"":""uuid:b47420ca-f048-490d-9d92-a394364302d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f52d7764-aa4f-40c8-9ca3-e855f4c3063a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:bee04857-592b-4ea3-80c9-97835e2bc93f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ILARIS is an interleukin-1β blocker indicated for the treatment of: • Periodic Fever Syndromes ( 1.1 ): - Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and children 4 years of age and older, including: ◾ Familial Cold Auto-inflammatory Syndrome (FCAS) ◾ Muckle-Wells Syndrome (MWS) - Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients - Hyperimmunoglobulin D Syndrome (HIDS)/ Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients - Familial Mediterranean Fever (FMF) in adult and pediatric patients • Active Still’s Disease, including Adult-Onset Still’s Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients 2 years of age and older ( 1.2 ) • Gout flares in adults in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate ( 1.3 )|[PMDA] A drug with a new active ingredient indicated for the treatment of cryopyrin-associated periodic syndrome. [Orphan drug] uuid:04f7040f-d145-4791-84e9-8f6f1203af47 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:37CQ2C7X93 biolink:treats MONDO:0009849 PMID:41385096 "[{""id"":""uuid:c61fdfd6-35da-44cd-92ad-275d461dc4c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:291927b2-d2cd-4226-8532-0c7f58b5c409"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ef80076e-2365-4a7d-87b5-7fbebe91e454"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ilaris""]},{""id"":""uuid:201a5bea-0c82-4640-b246-f16279d5514b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ILARIS is an interleukin-1β blocker indicated for the treatment of: • Periodic Fever Syndromes ( 1.1 ): - Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and children 4 years of age and older, including: ◾ Familial Cold Auto-inflammatory Syndrome (FCAS) ◾ Muckle-Wells Syndrome (MWS) - Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients - Hyperimmunoglobulin D Syndrome (HIDS)/ Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients - Familial Mediterranean Fever (FMF) in adult and pediatric patients • Active Still’s Disease, including Adult-Onset Still’s Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients 2 years of age and older ( 1.2 ) • Gout flares in adults in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate ( 1.3 )|[EMA] Periodic fever syndromesIlaris is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older:Cryopyrin-associated periodic syndromesIlaris is indicated for the treatment of cryopyrin-associated periodic syndromes (CAPS) including:Muckle-Wells syndrome (MWS),Neonatal-onset multisystem inflammatory disease (NOMID) / chronic infantile neurological, cutaneous, articular syndrome (CINCA),Severe forms of familial cold autoinflammatory syndrome (FCAS) / familial cold urticaria (FCU) presenting with signs and symptoms beyond cold-induced urticarial skin rash.Tumour necrosis factor receptor associated periodic syndrome (TRAPS)Ilaris is indicated for the treatment of tumour necrosis factor (TNF) receptor associated periodic syndrome (TRAPS).Hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD)Ilaris is indicated for the treatment of hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD).Familial Mediterranean fever (FMF)Ilaris is indicated for the treatment of Familial Mediterranean Fever (FMF). Ilaris should be given in combination with colchicine, if appropriate.Ilaris is also indicated for the treatment of:Still’s diseaseIlaris is indicated for the treatment of active Still’s disease including adult-onset Still’s disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids. Ilaris can be given as monotherapy or in combination with methotrexate.Gouty arthritisIlaris is indicated for the symptomatic treatment of adult patients with frequent gouty arthritis attacks (at least 3 attacks in the previous 12 months) in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate.|[PMDA] A drug with new additional indications and a new dosage for the treatment of patients with familial Mediterranean fever who have not responded sufficiently to conventional therapies, TNF receptor-associated periodic syndrome, or hyper IgD syndrome (mevalonate kinase deficiency). [Orphan drug] uuid:d060bc10-0d2a-4afa-bbb3-cb2dc6cb3fda biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:37CQ2C7X93 biolink:treats MONDO:0017708 PMID:41385096 "[{""id"":""uuid:81c75766-af7d-4d4c-8267-6700b347d169"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:03075150-901f-4593-8717-9726e1f8dcb8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4ac6e22f-42c4-4862-a7c7-65596ae94ee5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ilaris""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ILARIS is an interleukin-1β blocker indicated for the treatment of: • Periodic Fever Syndromes ( 1.1 ): - Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and children 4 years of age and older, including: ◾ Familial Cold Auto-inflammatory Syndrome (FCAS) ◾ Muckle-Wells Syndrome (MWS) - Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients - Hyperimmunoglobulin D Syndrome (HIDS)/ Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients - Familial Mediterranean Fever (FMF) in adult and pediatric patients • Active Still’s Disease, including Adult-Onset Still’s Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients 2 years of age and older ( 1.2 ) • Gout flares in adults in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate ( 1.3 )|[EMA] Periodic fever syndromesIlaris is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older:Cryopyrin-associated periodic syndromesIlaris is indicated for the treatment of cryopyrin-associated periodic syndromes (CAPS) including:Muckle-Wells syndrome (MWS),Neonatal-onset multisystem inflammatory disease (NOMID) / chronic infantile neurological, cutaneous, articular syndrome (CINCA),Severe forms of familial cold autoinflammatory syndrome (FCAS) / familial cold urticaria (FCU) presenting with signs and symptoms beyond cold-induced urticarial skin rash.Tumour necrosis factor receptor associated periodic syndrome (TRAPS)Ilaris is indicated for the treatment of tumour necrosis factor (TNF) receptor associated periodic syndrome (TRAPS).Hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD)Ilaris is indicated for the treatment of hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD).Familial Mediterranean fever (FMF)Ilaris is indicated for the treatment of Familial Mediterranean Fever (FMF). Ilaris should be given in combination with colchicine, if appropriate.Ilaris is also indicated for the treatment of:Still’s diseaseIlaris is indicated for the treatment of active Still’s disease including adult-onset Still’s disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids. Ilaris can be given as monotherapy or in combination with methotrexate.Gouty arthritisIlaris is indicated for the symptomatic treatment of adult patients with frequent gouty arthritis attacks (at least 3 attacks in the previous 12 months) in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate. uuid:42e93e28-f2b1-42de-962f-ef7192bf93fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:37CQ2C7X93 biolink:treats MONDO:0018088 PMID:41385096 "[{""id"":""uuid:b54e16c8-edb8-44a3-ba2f-8743fa109111"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:daa4a8ea-3a44-449a-a2fd-a53e2dbd0f60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:0dee58a2-1ed6-429d-b06a-ccaf53bd9562"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ilaris""]},{""id"":""uuid:5ce633a7-3c39-4a74-9dc9-dcbf535ae2b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ILARIS is an interleukin-1β blocker indicated for the treatment of: • Periodic Fever Syndromes ( 1.1 ): - Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and children 4 years of age and older, including: ◾ Familial Cold Auto-inflammatory Syndrome (FCAS) ◾ Muckle-Wells Syndrome (MWS) - Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients - Hyperimmunoglobulin D Syndrome (HIDS)/ Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients - Familial Mediterranean Fever (FMF) in adult and pediatric patients • Active Still’s Disease, including Adult-Onset Still’s Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients 2 years of age and older ( 1.2 ) • Gout flares in adults in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate ( 1.3 )|[EMA] Periodic fever syndromesIlaris is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older:Cryopyrin-associated periodic syndromesIlaris is indicated for the treatment of cryopyrin-associated periodic syndromes (CAPS) including:Muckle-Wells syndrome (MWS),Neonatal-onset multisystem inflammatory disease (NOMID) / chronic infantile neurological, cutaneous, articular syndrome (CINCA),Severe forms of familial cold autoinflammatory syndrome (FCAS) / familial cold urticaria (FCU) presenting with signs and symptoms beyond cold-induced urticarial skin rash.Tumour necrosis factor receptor associated periodic syndrome (TRAPS)Ilaris is indicated for the treatment of tumour necrosis factor (TNF) receptor associated periodic syndrome (TRAPS).Hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD)Ilaris is indicated for the treatment of hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD).Familial Mediterranean fever (FMF)Ilaris is indicated for the treatment of Familial Mediterranean Fever (FMF). Ilaris should be given in combination with colchicine, if appropriate.Ilaris is also indicated for the treatment of:Still’s diseaseIlaris is indicated for the treatment of active Still’s disease including adult-onset Still’s disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids. Ilaris can be given as monotherapy or in combination with methotrexate.Gouty arthritisIlaris is indicated for the symptomatic treatment of adult patients with frequent gouty arthritis attacks (at least 3 attacks in the previous 12 months) in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate.|[PMDA] A drug with new additional indications and a new dosage for the treatment of patients with familial Mediterranean fever who have not responded sufficiently to conventional therapies, TNF receptor-associated periodic syndrome, or hyper IgD syndrome (mevalonate kinase deficiency). [Orphan drug] uuid:fbec46fa-6bfc-4665-8691-f4046b86fedb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:37CQ2C7X93 biolink:treats MONDO:0019355 PMID:41385096 "[{""id"":""uuid:d491682a-06a1-4fdb-912f-959446832b9d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:598e7c05-bceb-4a46-b054-3003199310ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3c7c78c4-bc50-4999-a8b9-dece2a306b98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ilaris""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ILARIS is an interleukin-1β blocker indicated for the treatment of: • Periodic Fever Syndromes ( 1.1 ): - Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and children 4 years of age and older, including: ◾ Familial Cold Auto-inflammatory Syndrome (FCAS) ◾ Muckle-Wells Syndrome (MWS) - Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients - Hyperimmunoglobulin D Syndrome (HIDS)/ Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients - Familial Mediterranean Fever (FMF) in adult and pediatric patients • Active Still’s Disease, including Adult-Onset Still’s Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients 2 years of age and older ( 1.2 ) • Gout flares in adults in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate ( 1.3 )|[EMA] Periodic fever syndromesIlaris is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older:Cryopyrin-associated periodic syndromesIlaris is indicated for the treatment of cryopyrin-associated periodic syndromes (CAPS) including:Muckle-Wells syndrome (MWS),Neonatal-onset multisystem inflammatory disease (NOMID) / chronic infantile neurological, cutaneous, articular syndrome (CINCA),Severe forms of familial cold autoinflammatory syndrome (FCAS) / familial cold urticaria (FCU) presenting with signs and symptoms beyond cold-induced urticarial skin rash.Tumour necrosis factor receptor associated periodic syndrome (TRAPS)Ilaris is indicated for the treatment of tumour necrosis factor (TNF) receptor associated periodic syndrome (TRAPS).Hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD)Ilaris is indicated for the treatment of hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD).Familial Mediterranean fever (FMF)Ilaris is indicated for the treatment of Familial Mediterranean Fever (FMF). Ilaris should be given in combination with colchicine, if appropriate.Ilaris is also indicated for the treatment of:Still’s diseaseIlaris is indicated for the treatment of active Still’s disease including adult-onset Still’s disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids. Ilaris can be given as monotherapy or in combination with methotrexate.Gouty arthritisIlaris is indicated for the symptomatic treatment of adult patients with frequent gouty arthritis attacks (at least 3 attacks in the previous 12 months) in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate. uuid:c7b85b4b-bdae-4dbb-b3dd-21e1febe14f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:37CQ2C7X93 biolink:treats MONDO:0019434 PMID:41385096 "[{""id"":""uuid:2eb0b28a-b1fd-460f-a365-c8a1c6a6d49f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:08a00807-d218-46e6-8945-51826b0315f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3eb55020-ac3a-4462-ba17-05147e5df713"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ilaris""]},{""id"":""uuid:f65fb2f8-8388-4fc6-8fdf-c049d2655e96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ILARIS is an interleukin-1β blocker indicated for the treatment of: • Periodic Fever Syndromes ( 1.1 ): - Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and children 4 years of age and older, including: ◾ Familial Cold Auto-inflammatory Syndrome (FCAS) ◾ Muckle-Wells Syndrome (MWS) - Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients - Hyperimmunoglobulin D Syndrome (HIDS)/ Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients - Familial Mediterranean Fever (FMF) in adult and pediatric patients • Active Still’s Disease, including Adult-Onset Still’s Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients 2 years of age and older ( 1.2 ) • Gout flares in adults in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate ( 1.3 )|[EMA] Periodic fever syndromesIlaris is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older:Cryopyrin-associated periodic syndromesIlaris is indicated for the treatment of cryopyrin-associated periodic syndromes (CAPS) including:Muckle-Wells syndrome (MWS),Neonatal-onset multisystem inflammatory disease (NOMID) / chronic infantile neurological, cutaneous, articular syndrome (CINCA),Severe forms of familial cold autoinflammatory syndrome (FCAS) / familial cold urticaria (FCU) presenting with signs and symptoms beyond cold-induced urticarial skin rash.Tumour necrosis factor receptor associated periodic syndrome (TRAPS)Ilaris is indicated for the treatment of tumour necrosis factor (TNF) receptor associated periodic syndrome (TRAPS).Hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD)Ilaris is indicated for the treatment of hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD).Familial Mediterranean fever (FMF)Ilaris is indicated for the treatment of Familial Mediterranean Fever (FMF). Ilaris should be given in combination with colchicine, if appropriate.Ilaris is also indicated for the treatment of:Still’s diseaseIlaris is indicated for the treatment of active Still’s disease including adult-onset Still’s disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids. Ilaris can be given as monotherapy or in combination with methotrexate.Gouty arthritisIlaris is indicated for the symptomatic treatment of adult patients with frequent gouty arthritis attacks (at least 3 attacks in the previous 12 months) in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate.|[PMDA] Drugs with a new additional indication and a new dosage for the treatment of systemic juvenile idiopathic arthritis in patients who have not responded sufficiently to conventional treatments. [Orphan drug] uuid:8e4e50de-a809-4ee1-9b6e-dcc82c8072cd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:37CQ2C7X93 biolink:treats MONDO:0005393 PMID:41385096 "[{""id"":""uuid:80eded4a-64d9-4c04-91c6-6ed43962f806"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b9949020-047b-4c81-9d01-15f9de4ffc1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:63f6e457-792b-4c33-b6ff-a103c0986403"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ilaris""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] ILARIS is an interleukin-1β blocker indicated for the treatment of: • Periodic Fever Syndromes ( 1.1 ): - Cryopyrin-Associated Periodic Syndromes (CAPS), in adults and children 4 years of age and older, including: ◾ Familial Cold Auto-inflammatory Syndrome (FCAS) ◾ Muckle-Wells Syndrome (MWS) - Tumor Necrosis Factor Receptor Associated Periodic Syndrome (TRAPS) in adult and pediatric patients - Hyperimmunoglobulin D Syndrome (HIDS)/ Mevalonate Kinase Deficiency (MKD) in adult and pediatric patients - Familial Mediterranean Fever (FMF) in adult and pediatric patients • Active Still’s Disease, including Adult-Onset Still’s Disease (AOSD) and Systemic Juvenile Idiopathic Arthritis (SJIA) in patients 2 years of age and older ( 1.2 ) • Gout flares in adults in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate ( 1.3 )|[EMA] Periodic fever syndromesIlaris is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older:Cryopyrin-associated periodic syndromesIlaris is indicated for the treatment of cryopyrin-associated periodic syndromes (CAPS) including:Muckle-Wells syndrome (MWS),Neonatal-onset multisystem inflammatory disease (NOMID) / chronic infantile neurological, cutaneous, articular syndrome (CINCA),Severe forms of familial cold autoinflammatory syndrome (FCAS) / familial cold urticaria (FCU) presenting with signs and symptoms beyond cold-induced urticarial skin rash.Tumour necrosis factor receptor associated periodic syndrome (TRAPS)Ilaris is indicated for the treatment of tumour necrosis factor (TNF) receptor associated periodic syndrome (TRAPS).Hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD)Ilaris is indicated for the treatment of hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD).Familial Mediterranean fever (FMF)Ilaris is indicated for the treatment of Familial Mediterranean Fever (FMF). Ilaris should be given in combination with colchicine, if appropriate.Ilaris is also indicated for the treatment of:Still’s diseaseIlaris is indicated for the treatment of active Still’s disease including adult-onset Still’s disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids. Ilaris can be given as monotherapy or in combination with methotrexate.Gouty arthritisIlaris is indicated for the symptomatic treatment of adult patients with frequent gouty arthritis attacks (at least 3 attacks in the previous 12 months) in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate. uuid:297edd7b-7799-4ccf-9233-a10280554706 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134709 biolink:treats MONDO:0021107 PMID:41385096 "[{""id"":""uuid:4ea4d3d3-a287-465d-93bd-d33e8041cb67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0486309b-f991-41bb-ac00-1c2e02b012ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e38707fe-5a4b-4649-ae4a-768f9de5ddf0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ozawade""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] WAKIX is indicated for the: treatment of excessive daytime sleepiness (EDS) or cataplexy in adult patients with narcolepsy. treatment of excessive daytime sleepiness (EDS) in pediatric patients 6 years of age and older with narcolepsy.|[EMA] Wakix is indicated in adults, adolescents and children from the age of 6 years for the treatment of narcolepsy with or without cataplexy (see also section 5.1). uuid:a61006b3-5ff3-414d-8f08-05a56aa1d592 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:998040 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:485049e3-7681-4f30-a8a4-3142634c333b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6cd3a582-fd51-4c21-9c90-e29cfdbb01c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DULERA is a combination product containing a corticosteroid and a long-acting beta 2 -adrenergic agonist (LABA) indicated for: Treatment of asthma in patients 5 years of age and older. ( 1.1 ) Important Limitation of Use: Not indicated for the relief of acute bronchospasm. ( 1.1 ) uuid:70f37fd4-dec1-4aa3-b746-528c4afe5b6c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:998040 biolink:treats UMLS:C0741804 PMID:41385096 "[{""id"":""uuid:80eafa13-947e-4cd3-95f1-95c6cde464fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b3a1f6ef-8f93-4ec1-9862-919a0f8e12d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DULERA is a combination product containing a corticosteroid and a long-acting beta 2 -adrenergic agonist (LABA) indicated for: Treatment of asthma in patients 5 years of age and older. ( 1.1 ) Important Limitation of Use: Not indicated for the relief of acute bronchospasm. ( 1.1 ) uuid:dcb372d1-2da1-447c-84e7-5d3e7198939e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76611 biolink:treats MONDO:0004975 PMID:41385096 "[{""id"":""uuid:2f36acd6-bcea-4204-a821-c46346559f25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:21beb792-8df1-4e4d-aa55-d1998b1268ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:35cc2ca6-0ef2-40da-abf1-7812fa27d26c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a03c03bb-cea6-456b-b931-5447693746b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vizamyl is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease (AD) and other causes of cognitive decline. A negative Vizamyl scan indicates sparse to no neuritic plaques and is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition; a negative scan result reduces the likelihood that a patient's cognitive impairment is due to AD. A positive Vizamyl scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with AD, but may also be present in patients with other types of neurologic conditions as well as in older people with normal cognition. Vizamyl is an adjunct to other diagnostic evaluations. Limitations of Use: A positive Vizamyl scan does not establish a diagnosis of AD or other cognitive disorder. Safety and effectiveness of Vizamyl have not been established for: Predicting development of dementia or other neurologic condition. Monitoring responses to therapies.|[EMA] This medicinal product is for diagnostic use only.Vizamyl is a radiopharmaceutical medicinal product indicated for Positron Emission Tomography (PET) imaging of β amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive impairment. Vizamyl should be used in conjunction with a clinical evaluation.A negative scan indicates sparse or no plaques, which is not consistent with a diagnosis of AD.|[PMDA] A drug with a new active ingredient indicated for visualization of beta‑amyloid plaques in the brains of patients with cognitive impairment suspected to be Alzheimer's disease. uuid:0380e08c-f56d-4bab-b04a-d1b8d6903f46 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76611 biolink:treats MONDO:0850292 PMID:41385096 "[{""id"":""uuid:98f818a6-602e-4f48-a6e9-c092e1aacb75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:553ffe8f-e35e-4b0e-8591-007de204e498"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vizamyl is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease (AD) and other causes of cognitive decline. A negative Vizamyl scan indicates sparse to no neuritic plaques and is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition; a negative scan result reduces the likelihood that a patient's cognitive impairment is due to AD. A positive Vizamyl scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with AD, but may also be present in patients with other types of neurologic conditions as well as in older people with normal cognition. Vizamyl is an adjunct to other diagnostic evaluations. Limitations of Use: A positive Vizamyl scan does not establish a diagnosis of AD or other cognitive disorder. Safety and effectiveness of Vizamyl have not been established for: Predicting development of dementia or other neurologic condition. Monitoring responses to therapies. uuid:f12d3608-0a43-4d9c-abf1-923cf195d583 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76611 biolink:treats MONDO:0001627 PMID:41385096 "[{""id"":""uuid:076ea0a4-c56a-405a-86aa-930941c78880"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:121084d0-d103-4bed-a50b-6d9f54929862"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vizamyl is indicated for Positron Emission Tomography (PET) imaging of the brain to estimate β-amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's Disease (AD) and other causes of cognitive decline. A negative Vizamyl scan indicates sparse to no neuritic plaques and is inconsistent with a neuropathological diagnosis of AD at the time of image acquisition; a negative scan result reduces the likelihood that a patient's cognitive impairment is due to AD. A positive Vizamyl scan indicates moderate to frequent amyloid neuritic plaques; neuropathological examination has shown this amount of amyloid neuritic plaque is present in patients with AD, but may also be present in patients with other types of neurologic conditions as well as in older people with normal cognition. Vizamyl is an adjunct to other diagnostic evaluations. Limitations of Use: A positive Vizamyl scan does not establish a diagnosis of AD or other cognitive disorder. Safety and effectiveness of Vizamyl have not been established for: Predicting development of dementia or other neurologic condition. Monitoring responses to therapies. uuid:d8b5520c-336c-4d1c-a8f6-1e74ca50b81d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:C5U34S9XFV biolink:treats MONDO:0011996 PMID:41385096 "[{""id"":""uuid:f2dc959e-3db0-43e4-85c1-357ef0dd9dcc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:449a37a2-6a1a-4dac-9e9c-c74ef1ec71bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:6fd635af-d230-4136-9d85-9ea8010fdf2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:9ee2ba1a-701d-47a1-b987-489c58a0bbc9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SCEMBLIX is indicated for the treatment of adult patients with: Newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP). This indication is approved under accelerated approval based on major molecular response rate [see Clinical Studies (14.1)] . Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s). Previously treated Ph+ CML in CP. Ph+ CML in CP with the T315I mutation.|[EMA] Scemblix is indicated for the treatment of adult patients with Philadelphia chromosome positive chronic myeloid leukaemia in chronic phase (Ph+ CML CP) previously treated with two or more tyrosine kinase inhibitors (see section 5.1).|[PMDA] Drugs with a new active ingredient indicated for the treatment of chronic myelogenous leukemia with resistance or intolerance to prior drug therapies. [Orphan drug] uuid:78904e0e-3948-4b58-b190-7f99a6074234 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49005 biolink:treats MONDO:0016487 PMID:41385096 "[{""id"":""uuid:e23909a0-e720-406f-88c5-4b32da089b38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2b46e581-635e-465a-8460-a0d7d44a5ec0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] JADENU is an iron chelator indicated for the treatment of chronic iron overload due to blood transfusions in patients 2 years of age and older. ( 1.1 ) JADENU is indicated for the treatment of chronic iron overload in patients 10 years of age and older with non-transfusion-dependent thalassemia (NTDT) syndromes, and with a liver iron (Fe) concentration (LIC) of at least 5 mg Fe per gram of dry weight (Fe/g dw) and a serum ferritin greater than 300 mcg/L. ( 1.2 ) Limitations of Use: The safety and efficacy of JADENU when administered with other iron chelation therapy have not been established. ( 1.3 ) uuid:ef37b64c-7979-4292-8425-d501af0b9162 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2682 biolink:treats MONDO:0000256 PMID:41385096 "[{""id"":""uuid:f3a76ab5-de79-49db-8e2b-e424cffb0d01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0b81d2ed-ecea-48a6-a3f3-0240daecd2c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amphotericin B liposome for injection is indicated for the following: Empirical therapy for presumed fungal infection in febrile, neutropenic patients. Treatment of Cryptococcal Meningitis in HIV-infected patients (see DESCRIPTION OF CLINICAL STUDIES ). Treatment of patients with Aspergillus species, Candida species and/or Cryptococcus species infections (see above for the treatment of Cryptococcal Meningitis) refractory to amphotericin B deoxycholate, or in patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B deoxycholate. Treatment of visceral leishmaniasis. In immunocompromised patients with visceral leishmaniasis treated with amphotericin B liposome for injection, relapse rates were high following initial clearance of parasites (see DESCRIPTION OF CLINICAL STUDIES ). See DOSAGE AND ADMINISTRATION for recommended doses by indication. DESCRIPTION OF CLINICAL STUDIES Eleven clinical studies supporting the efficacy and safety of amphotericin B liposome for injection were conducted. This clinical program included both controlled and uncontrolled studies. These studies, which involved 2,171 patients, included patients with confirmed systemic mycoses, empirical therapy, and visceral leishmaniasis. Nineteen hundred and forty-six (1946) episodes were evaluable for efficacy, of which 1,280 (302 pediatric and 978 adults) were treated with amphotericin B liposome for injection. Three controlled empirical therapy trials compared the efficacy and safety of amphotericin B liposome for injection to amphotericin B. One of these studies was conducted in a pediatric population, one in adults, and a third in patients aged 2 years or more. In addition, a controlled empirical therapy trial comparing the safety of amphotericin B liposome for injection to Abelcet ® (amphotericin B lipid complex) was conducted in patients aged 2 years or more. One controlled trial compared the efficacy and safety of amphotericin B liposome for injection to amphotericin B in HIV patients with cryptococcal meningitis. One compassionate use study enrolled patients who had failed amphotericin B deoxycholate therapy or who were unable to receive amphotericin B deoxycholate because of renal insufficiency. uuid:0d175fc1-f412-4448-a4fe-da363ea976bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4735 biolink:treats MONDO:0001358 PMID:41385096 "[{""id"":""uuid:4729a0a0-8356-4c5b-86f1-f5195e14fc69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:47f88916-2cc5-4316-8e8f-8fe3e4329aff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levalbuterol Inhalation Solution, USP is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. uuid:e8160bed-5d17-4c5d-9f18-d6d664393e14 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4735 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:378bcc30-d76f-4f85-b94d-66ed17bc8c77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:bdd55bd6-d9a7-45dc-975a-7c6030887a88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Levalbuterol Inhalation Solution, USP is indicated for the treatment or prevention of bronchospasm in adults, adolescents, and children 6 years of age and older with reversible obstructive airway disease. uuid:7bc0d3a1-7867-488a-9a77-df9db54f71d3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:TF5MPQ8WGY biolink:treats MONDO:0005036 PMID:41385096 "[{""id"":""uuid:3aabd338-9401-4f32-a4cf-f8a500a9ed9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:519bb6ff-2c64-48a1-a165-2b05e6de9e00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VYLOY, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)‑negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are claudin (CLDN) 18.2 positive as determined by an FDA-approved test [see Dosage and Administration ( 2.1 ) and Clinical Studies ( 14 )]. uuid:ed0d4943-b128-48d9-9b18-e3513beebe14 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:TF5MPQ8WGY biolink:treats MONDO:0003219 PMID:41385096 "[{""id"":""uuid:2717b432-717f-4912-8fb0-94dfde5afd30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:98441f20-a101-4657-ac3a-845dfff48be7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] VYLOY, in combination with fluoropyrimidine- and platinum-containing chemotherapy, is indicated for the first-line treatment of adults with locally advanced unresectable or metastatic human epidermal growth factor receptor 2 (HER2)‑negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors are claudin (CLDN) 18.2 positive as determined by an FDA-approved test [see Dosage and Administration ( 2.1 ) and Clinical Studies ( 14 )]. uuid:2c285637-4114-4b8b-b376-156f81f3aebe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5238067 biolink:treats MONDO:0019623 PMID:41385096 "[{""id"":""uuid:ebb51584-5aef-453c-8f5b-f86661896c8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:acb7b91b-8f78-4b51-a905-82e0963c560a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ANDEMBRY is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older. DRUGBANK:DB15629 uuid:944653eb-0bf7-4276-ab0c-d32909032ec3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5238067 biolink:treats MONDO:0012526 PMID:41385096 "[{""id"":""uuid:f13b8348-7268-4946-8641-d29208aaeb2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1127ec1f-e0ae-41bf-9278-c0b020140bc4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ANDEMBRY is indicated for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older. DRUGBANK:DB15629 uuid:a2ea6a0a-cff7-481c-aafd-a5246938897b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1591939 biolink:treats MONDO:0005231 PMID:41385096 "[{""id"":""uuid:474f8ae0-7cef-4f8d-8a21-4b483b10b668"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:256c3bf4-18ed-4665-a164-8223e55a9e04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] HARVONI is a fixed-dose combination of ledipasvir, a hepatitis C virus (HCV) NS5A inhibitor, and sofosbuvir, an HCV nucleotide analog NS5B polymerase inhibitor, and is indicated for the treatment of chronic hepatitis C virus (HCV) in: Adults with genotype 1, 4, 5, or 6 infection without cirrhosis or with compensated cirrhosis Adults with genotype 1 infection with decompensated cirrhosis, in combination with ribavirin Adults with genotype 1 or 4 infection who are liver transplant recipients without cirrhosis or with compensated cirrhosis, in combination with ribavirin Pediatric patients 12 years of age and older or weighing at least 35 kg with genotype 1, 4, 5, or 6 without cirrhosis or with compensated cirrhosis. ( 1 ) uuid:20a030da-c716-4707-b885-9a03a4a231fc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134716 biolink:treats MONDO:0004975 PMID:41385096 "[{""id"":""uuid:6025cba4-5ca8-4355-b86b-47303fa0cf01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:c64904d8-a578-40e5-ae34-abc18ad4953b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[FDA] REXULTI is indicated for: Adjunctive treatment to antidepressants for major depressive disorder (MDD) in adults Treatment of schizophrenia in adults and pediatric patients ages 13 years and older Treatment of agitation associated with dementia due to Alzheimer's disease Limitations of Use: REXULTI is not indicated as an as needed (""prn"") treatment for agitation associated with dementia due to Alzheimer's disease [see Clinical Studies (14.3) ] ." uuid:44ea8b1c-453b-41dc-8739-7a1607aaa2e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DPT0O3T46P biolink:treats MONDO:0005105 PMID:41385096 "[{""id"":""uuid:c7658613-155d-4899-9080-1c0af56cc3a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b018890b-edf6-4fda-b298-ba31e09aa569"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:20002885-fcb1-4727-8227-a24e7f596c80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated: Melanoma for the treatment of patients with unresectable or metastatic melanoma. ( 1.1 ) for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection. ( 1.1 ) Non-Small Cell Lung Cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC. ( 1.2 ) as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic. ( 1.2 , 2.1 ) as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. ( 1.2 , 2.1 ) for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.2 ) as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC. ( 1.2 ) Malignant Pleural Mesothelioma (MPM) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic MPM. ( 1.3 ) Head and Neck Squamous Cell Cancer (HNSCC) for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent. ( 1.4 ) in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC. ( 1.4 ) as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test. ( 1.4 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. ( 1.4 ) Classical Hodgkin Lymphoma (cHL) for the treatment of adult patients with relapsed or refractory cHL. ( 1.5 ) for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy. ( 1.5 ) Primary Mediastinal Large B-Cell Lymphoma (PMBCL) for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therapy. ( 1.6 ) Limitations of Use : KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy. Urothelial Cancer in combination with enfortumab vedotin, for the treatment of adult patients with locally advanced or metastatic urothelial cancer. ( 1.7 ) as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: are not eligible for any platinum-containing chemotherapy, or who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. ( 1.7 ) as a single agent for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. ( 1.7 ) Microsatellite Instability-High or Mismatch Repair Deficient Cancer for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. ( 1.8 , 2.1 ) Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC) for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-approved test. ( 1.9 , 2.1 ) Gastric Cancer in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) Esophageal Cancer for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either: in combination with platinum- and fluoropyrimidine-based chemotherapy for patients whose tumors express PD-L1 (CPS ≥1), or as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-approved test. ( 1.11 , 2.1 ) Cervical Cancer in combination with chemoradiotherapy, for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, with or without extension to pelvic sidewall, or hydronephrosis/non-functioning kidney, or spread to adjacent pelvic organs (FIGO 2014 Stage III-IVA). ( 1.12 ) in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) Hepatocellular Carcinoma (HCC) for the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen. ( 1.13 ) Biliary Tract Cancer (BTC) in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. ( 1.14 ) Merkel Cell Carcinoma (MCC) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma. ( 1.15 ) Renal Cell Carcinoma (RCC) in combination with axitinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. ( 1.16 ) Endometrial Carcinoma in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. ( 1.17 ) in combination with lenvatinib, for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) as a single agent, for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) Tumor Mutational Burden-High (TMB-H) Cancer for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. 1 ( 1.18 , 2.1 ) Limitations of Use : The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established. Cutaneous Squamous Cell Carcinoma (cSCC) for the treatment of patients with recurrent or metastatic cSCC or locally advanced cSCC that is not curable by surgery or radiation. ( 1.19 ) Triple-Negative Breast Cancer (TNBC) for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.20 ) in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA approved test. ( 1.20 , 2.1 ) Adult Classical Hodgkin Lymphoma and Adult Primary Mediastinal Large B-Cell Lymphoma: Additional Dosing Regimen of 400 mg Every 6 Weeks for use at an additional recommended dosage of 400 mg every 6 weeks for Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma in adults. 2 ( 1.21 , 2.2 ) 1 This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. 2 This indication is approved under accelerated approval based on pharmacokinetic data, the relationship of exposure to efficacy, and the relationship of exposure to safety. Continued approval for this dosing may be contingent upon verification and description of clinical benefit in the confirmatory trials.|[PMDA] Drugs with new indications and a new dosage for the treatment of: advanced or recurrent microsatellite instability- high (MSI-High) solid tumors that have progressed after cancer chemotherapy (for use only if refractory or intolerant to standard therapies), melanoma, and unresectable advanced or recurrent non-small cell lung cancer. [(1) Conditional early approval, (2) Orphan drug, (3) Priority review] uuid:e788598c-a038-457f-8c0b-4bb51364c562 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DPT0O3T46P biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:7e9ae2c5-ae06-4b97-9865-f344d9d79dc6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cb9ac737-d702-40a6-b5e5-224ccfeae4ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1f06a3ed-d7c3-4cc5-9911-da726250dcdf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated: Melanoma for the treatment of patients with unresectable or metastatic melanoma. ( 1.1 ) for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection. ( 1.1 ) Non-Small Cell Lung Cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC. ( 1.2 ) as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic. ( 1.2 , 2.1 ) as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. ( 1.2 , 2.1 ) for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.2 ) as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC. ( 1.2 ) Malignant Pleural Mesothelioma (MPM) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic MPM. ( 1.3 ) Head and Neck Squamous Cell Cancer (HNSCC) for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent. ( 1.4 ) in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC. ( 1.4 ) as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test. ( 1.4 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. ( 1.4 ) Classical Hodgkin Lymphoma (cHL) for the treatment of adult patients with relapsed or refractory cHL. ( 1.5 ) for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy. ( 1.5 ) Primary Mediastinal Large B-Cell Lymphoma (PMBCL) for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therapy. ( 1.6 ) Limitations of Use : KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy. Urothelial Cancer in combination with enfortumab vedotin, for the treatment of adult patients with locally advanced or metastatic urothelial cancer. ( 1.7 ) as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: are not eligible for any platinum-containing chemotherapy, or who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. ( 1.7 ) as a single agent for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. ( 1.7 ) Microsatellite Instability-High or Mismatch Repair Deficient Cancer for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. ( 1.8 , 2.1 ) Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC) for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-approved test. ( 1.9 , 2.1 ) Gastric Cancer in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) Esophageal Cancer for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either: in combination with platinum- and fluoropyrimidine-based chemotherapy for patients whose tumors express PD-L1 (CPS ≥1), or as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-approved test. ( 1.11 , 2.1 ) Cervical Cancer in combination with chemoradiotherapy, for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, with or without extension to pelvic sidewall, or hydronephrosis/non-functioning kidney, or spread to adjacent pelvic organs (FIGO 2014 Stage III-IVA). ( 1.12 ) in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) Hepatocellular Carcinoma (HCC) for the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen. ( 1.13 ) Biliary Tract Cancer (BTC) in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. ( 1.14 ) Merkel Cell Carcinoma (MCC) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma. ( 1.15 ) Renal Cell Carcinoma (RCC) in combination with axitinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. ( 1.16 ) Endometrial Carcinoma in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. ( 1.17 ) in combination with lenvatinib, for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) as a single agent, for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) Tumor Mutational Burden-High (TMB-H) Cancer for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. 1 ( 1.18 , 2.1 ) Limitations of Use : The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established. Cutaneous Squamous Cell Carcinoma (cSCC) for the treatment of patients with recurrent or metastatic cSCC or locally advanced cSCC that is not curable by surgery or radiation. ( 1.19 ) Triple-Negative Breast Cancer (TNBC) for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.20 ) in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA approved test. ( 1.20 , 2.1 ) Adult Classical Hodgkin Lymphoma and Adult Primary Mediastinal Large B-Cell Lymphoma: Additional Dosing Regimen of 400 mg Every 6 Weeks for use at an additional recommended dosage of 400 mg every 6 weeks for Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma in adults. 2 ( 1.21 , 2.2 ) 1 This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. 2 This indication is approved under accelerated approval based on pharmacokinetic data, the relationship of exposure to efficacy, and the relationship of exposure to safety. Continued approval for this dosing may be contingent upon verification and description of clinical benefit in the confirmatory trials.|[PMDA] Drugs with a new additional indication and a new dosage for the treatment of patients with PD-L1- positive, unresectable, recurrent or advanced non- small cell lung cancer. uuid:46b57245-9f75-4546-b52e-c3f0c6175876 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DPT0O3T46P biolink:treats MONDO:0005112 PMID:41385096 "[{""id"":""uuid:730e0f07-f87c-4bbc-92e9-1cfdb9153eb3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:309b162c-a0e4-4ed2-bdcd-ff4dd2560738"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated: Melanoma for the treatment of patients with unresectable or metastatic melanoma. ( 1.1 ) for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection. ( 1.1 ) Non-Small Cell Lung Cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC. ( 1.2 ) as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic. ( 1.2 , 2.1 ) as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. ( 1.2 , 2.1 ) for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.2 ) as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC. ( 1.2 ) Malignant Pleural Mesothelioma (MPM) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic MPM. ( 1.3 ) Head and Neck Squamous Cell Cancer (HNSCC) for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent. ( 1.4 ) in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC. ( 1.4 ) as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test. ( 1.4 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. ( 1.4 ) Classical Hodgkin Lymphoma (cHL) for the treatment of adult patients with relapsed or refractory cHL. ( 1.5 ) for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy. ( 1.5 ) Primary Mediastinal Large B-Cell Lymphoma (PMBCL) for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therapy. ( 1.6 ) Limitations of Use : KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy. Urothelial Cancer in combination with enfortumab vedotin, for the treatment of adult patients with locally advanced or metastatic urothelial cancer. ( 1.7 ) as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: are not eligible for any platinum-containing chemotherapy, or who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. ( 1.7 ) as a single agent for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. ( 1.7 ) Microsatellite Instability-High or Mismatch Repair Deficient Cancer for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. ( 1.8 , 2.1 ) Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC) for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-approved test. ( 1.9 , 2.1 ) Gastric Cancer in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) Esophageal Cancer for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either: in combination with platinum- and fluoropyrimidine-based chemotherapy for patients whose tumors express PD-L1 (CPS ≥1), or as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-approved test. ( 1.11 , 2.1 ) Cervical Cancer in combination with chemoradiotherapy, for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, with or without extension to pelvic sidewall, or hydronephrosis/non-functioning kidney, or spread to adjacent pelvic organs (FIGO 2014 Stage III-IVA). ( 1.12 ) in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) Hepatocellular Carcinoma (HCC) for the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen. ( 1.13 ) Biliary Tract Cancer (BTC) in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. ( 1.14 ) Merkel Cell Carcinoma (MCC) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma. ( 1.15 ) Renal Cell Carcinoma (RCC) in combination with axitinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. ( 1.16 ) Endometrial Carcinoma in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. ( 1.17 ) in combination with lenvatinib, for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) as a single agent, for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) Tumor Mutational Burden-High (TMB-H) Cancer for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. 1 ( 1.18 , 2.1 ) Limitations of Use : The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established. Cutaneous Squamous Cell Carcinoma (cSCC) for the treatment of patients with recurrent or metastatic cSCC or locally advanced cSCC that is not curable by surgery or radiation. ( 1.19 ) Triple-Negative Breast Cancer (TNBC) for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.20 ) in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA approved test. ( 1.20 , 2.1 ) Adult Classical Hodgkin Lymphoma and Adult Primary Mediastinal Large B-Cell Lymphoma: Additional Dosing Regimen of 400 mg Every 6 Weeks for use at an additional recommended dosage of 400 mg every 6 weeks for Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma in adults. 2 ( 1.21 , 2.2 ) 1 This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. 2 This indication is approved under accelerated approval based on pharmacokinetic data, the relationship of exposure to efficacy, and the relationship of exposure to safety. Continued approval for this dosing may be contingent upon verification and description of clinical benefit in the confirmatory trials. uuid:8aad2ad4-fef4-4e4a-b966-fad0af664bd1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DPT0O3T46P biolink:treats MONDO:0010150 PMID:41385096 "[{""id"":""uuid:ab21fa54-6ee2-4458-8664-779565f27438"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:201c57c3-62e1-4b82-b216-15847a7e5bba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated: Melanoma for the treatment of patients with unresectable or metastatic melanoma. ( 1.1 ) for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection. ( 1.1 ) Non-Small Cell Lung Cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC. ( 1.2 ) as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic. ( 1.2 , 2.1 ) as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. ( 1.2 , 2.1 ) for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.2 ) as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC. ( 1.2 ) Malignant Pleural Mesothelioma (MPM) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic MPM. ( 1.3 ) Head and Neck Squamous Cell Cancer (HNSCC) for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent. ( 1.4 ) in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC. ( 1.4 ) as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test. ( 1.4 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. ( 1.4 ) Classical Hodgkin Lymphoma (cHL) for the treatment of adult patients with relapsed or refractory cHL. ( 1.5 ) for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy. ( 1.5 ) Primary Mediastinal Large B-Cell Lymphoma (PMBCL) for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therapy. ( 1.6 ) Limitations of Use : KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy. Urothelial Cancer in combination with enfortumab vedotin, for the treatment of adult patients with locally advanced or metastatic urothelial cancer. ( 1.7 ) as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: are not eligible for any platinum-containing chemotherapy, or who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. ( 1.7 ) as a single agent for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. ( 1.7 ) Microsatellite Instability-High or Mismatch Repair Deficient Cancer for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. ( 1.8 , 2.1 ) Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC) for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-approved test. ( 1.9 , 2.1 ) Gastric Cancer in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) Esophageal Cancer for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either: in combination with platinum- and fluoropyrimidine-based chemotherapy for patients whose tumors express PD-L1 (CPS ≥1), or as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-approved test. ( 1.11 , 2.1 ) Cervical Cancer in combination with chemoradiotherapy, for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, with or without extension to pelvic sidewall, or hydronephrosis/non-functioning kidney, or spread to adjacent pelvic organs (FIGO 2014 Stage III-IVA). ( 1.12 ) in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) Hepatocellular Carcinoma (HCC) for the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen. ( 1.13 ) Biliary Tract Cancer (BTC) in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. ( 1.14 ) Merkel Cell Carcinoma (MCC) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma. ( 1.15 ) Renal Cell Carcinoma (RCC) in combination with axitinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. ( 1.16 ) Endometrial Carcinoma in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. ( 1.17 ) in combination with lenvatinib, for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) as a single agent, for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) Tumor Mutational Burden-High (TMB-H) Cancer for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. 1 ( 1.18 , 2.1 ) Limitations of Use : The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established. Cutaneous Squamous Cell Carcinoma (cSCC) for the treatment of patients with recurrent or metastatic cSCC or locally advanced cSCC that is not curable by surgery or radiation. ( 1.19 ) Triple-Negative Breast Cancer (TNBC) for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.20 ) in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA approved test. ( 1.20 , 2.1 ) Adult Classical Hodgkin Lymphoma and Adult Primary Mediastinal Large B-Cell Lymphoma: Additional Dosing Regimen of 400 mg Every 6 Weeks for use at an additional recommended dosage of 400 mg every 6 weeks for Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma in adults. 2 ( 1.21 , 2.2 ) 1 This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. 2 This indication is approved under accelerated approval based on pharmacokinetic data, the relationship of exposure to efficacy, and the relationship of exposure to safety. Continued approval for this dosing may be contingent upon verification and description of clinical benefit in the confirmatory trials. uuid:ad6d0975-a8f5-4a69-9871-bd5e443a9dfa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DPT0O3T46P biolink:treats MONDO:0004665 PMID:41385096 "[{""id"":""uuid:4777eafd-d724-4ec8-8606-eadcadc41eb0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:47a5a8b4-2d93-430b-9f68-5d5499422436"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated: Melanoma for the treatment of patients with unresectable or metastatic melanoma. ( 1.1 ) for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection. ( 1.1 ) Non-Small Cell Lung Cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC. ( 1.2 ) as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic. ( 1.2 , 2.1 ) as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. ( 1.2 , 2.1 ) for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.2 ) as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC. ( 1.2 ) Malignant Pleural Mesothelioma (MPM) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic MPM. ( 1.3 ) Head and Neck Squamous Cell Cancer (HNSCC) for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent. ( 1.4 ) in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC. ( 1.4 ) as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test. ( 1.4 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. ( 1.4 ) Classical Hodgkin Lymphoma (cHL) for the treatment of adult patients with relapsed or refractory cHL. ( 1.5 ) for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy. ( 1.5 ) Primary Mediastinal Large B-Cell Lymphoma (PMBCL) for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therapy. ( 1.6 ) Limitations of Use : KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy. Urothelial Cancer in combination with enfortumab vedotin, for the treatment of adult patients with locally advanced or metastatic urothelial cancer. ( 1.7 ) as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: are not eligible for any platinum-containing chemotherapy, or who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. ( 1.7 ) as a single agent for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. ( 1.7 ) Microsatellite Instability-High or Mismatch Repair Deficient Cancer for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. ( 1.8 , 2.1 ) Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC) for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-approved test. ( 1.9 , 2.1 ) Gastric Cancer in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) Esophageal Cancer for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either: in combination with platinum- and fluoropyrimidine-based chemotherapy for patients whose tumors express PD-L1 (CPS ≥1), or as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-approved test. ( 1.11 , 2.1 ) Cervical Cancer in combination with chemoradiotherapy, for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, with or without extension to pelvic sidewall, or hydronephrosis/non-functioning kidney, or spread to adjacent pelvic organs (FIGO 2014 Stage III-IVA). ( 1.12 ) in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) Hepatocellular Carcinoma (HCC) for the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen. ( 1.13 ) Biliary Tract Cancer (BTC) in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. ( 1.14 ) Merkel Cell Carcinoma (MCC) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma. ( 1.15 ) Renal Cell Carcinoma (RCC) in combination with axitinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. ( 1.16 ) Endometrial Carcinoma in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. ( 1.17 ) in combination with lenvatinib, for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) as a single agent, for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) Tumor Mutational Burden-High (TMB-H) Cancer for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. 1 ( 1.18 , 2.1 ) Limitations of Use : The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established. Cutaneous Squamous Cell Carcinoma (cSCC) for the treatment of patients with recurrent or metastatic cSCC or locally advanced cSCC that is not curable by surgery or radiation. ( 1.19 ) Triple-Negative Breast Cancer (TNBC) for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.20 ) in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA approved test. ( 1.20 , 2.1 ) Adult Classical Hodgkin Lymphoma and Adult Primary Mediastinal Large B-Cell Lymphoma: Additional Dosing Regimen of 400 mg Every 6 Weeks for use at an additional recommended dosage of 400 mg every 6 weeks for Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma in adults. 2 ( 1.21 , 2.2 ) 1 This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. 2 This indication is approved under accelerated approval based on pharmacokinetic data, the relationship of exposure to efficacy, and the relationship of exposure to safety. Continued approval for this dosing may be contingent upon verification and description of clinical benefit in the confirmatory trials. uuid:b2ddd7ff-c67e-4f86-ad24-4ed0da361e99 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DPT0O3T46P biolink:treats MONDO:0020323 PMID:41385096 "[{""id"":""uuid:50e86251-390a-4186-90e2-5c53009b1c81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e521ec17-988d-4458-b7cc-e6931f726130"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated: Melanoma for the treatment of patients with unresectable or metastatic melanoma. ( 1.1 ) for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection. ( 1.1 ) Non-Small Cell Lung Cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC. ( 1.2 ) as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic. ( 1.2 , 2.1 ) as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. ( 1.2 , 2.1 ) for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.2 ) as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC. ( 1.2 ) Malignant Pleural Mesothelioma (MPM) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic MPM. ( 1.3 ) Head and Neck Squamous Cell Cancer (HNSCC) for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent. ( 1.4 ) in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC. ( 1.4 ) as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test. ( 1.4 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. ( 1.4 ) Classical Hodgkin Lymphoma (cHL) for the treatment of adult patients with relapsed or refractory cHL. ( 1.5 ) for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy. ( 1.5 ) Primary Mediastinal Large B-Cell Lymphoma (PMBCL) for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therapy. ( 1.6 ) Limitations of Use : KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy. Urothelial Cancer in combination with enfortumab vedotin, for the treatment of adult patients with locally advanced or metastatic urothelial cancer. ( 1.7 ) as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: are not eligible for any platinum-containing chemotherapy, or who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. ( 1.7 ) as a single agent for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. ( 1.7 ) Microsatellite Instability-High or Mismatch Repair Deficient Cancer for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. ( 1.8 , 2.1 ) Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC) for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-approved test. ( 1.9 , 2.1 ) Gastric Cancer in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) Esophageal Cancer for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either: in combination with platinum- and fluoropyrimidine-based chemotherapy for patients whose tumors express PD-L1 (CPS ≥1), or as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-approved test. ( 1.11 , 2.1 ) Cervical Cancer in combination with chemoradiotherapy, for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, with or without extension to pelvic sidewall, or hydronephrosis/non-functioning kidney, or spread to adjacent pelvic organs (FIGO 2014 Stage III-IVA). ( 1.12 ) in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) Hepatocellular Carcinoma (HCC) for the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen. ( 1.13 ) Biliary Tract Cancer (BTC) in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. ( 1.14 ) Merkel Cell Carcinoma (MCC) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma. ( 1.15 ) Renal Cell Carcinoma (RCC) in combination with axitinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. ( 1.16 ) Endometrial Carcinoma in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. ( 1.17 ) in combination with lenvatinib, for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) as a single agent, for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) Tumor Mutational Burden-High (TMB-H) Cancer for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. 1 ( 1.18 , 2.1 ) Limitations of Use : The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established. Cutaneous Squamous Cell Carcinoma (cSCC) for the treatment of patients with recurrent or metastatic cSCC or locally advanced cSCC that is not curable by surgery or radiation. ( 1.19 ) Triple-Negative Breast Cancer (TNBC) for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.20 ) in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA approved test. ( 1.20 , 2.1 ) Adult Classical Hodgkin Lymphoma and Adult Primary Mediastinal Large B-Cell Lymphoma: Additional Dosing Regimen of 400 mg Every 6 Weeks for use at an additional recommended dosage of 400 mg every 6 weeks for Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma in adults. 2 ( 1.21 , 2.2 ) 1 This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. 2 This indication is approved under accelerated approval based on pharmacokinetic data, the relationship of exposure to efficacy, and the relationship of exposure to safety. Continued approval for this dosing may be contingent upon verification and description of clinical benefit in the confirmatory trials. uuid:1ea79278-1214-4e8d-a92d-0b04573b11ef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DPT0O3T46P biolink:treats UMLS:C4049507 PMID:41385096 "[{""id"":""uuid:1ce1909d-d725-4dab-b002-f5c9ff45bb92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e4d4a86c-8c91-4ddc-b9cd-6db85788be1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated: Melanoma for the treatment of patients with unresectable or metastatic melanoma. ( 1.1 ) for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection. ( 1.1 ) Non-Small Cell Lung Cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC. ( 1.2 ) as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic. ( 1.2 , 2.1 ) as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. ( 1.2 , 2.1 ) for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.2 ) as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC. ( 1.2 ) Malignant Pleural Mesothelioma (MPM) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic MPM. ( 1.3 ) Head and Neck Squamous Cell Cancer (HNSCC) for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent. ( 1.4 ) in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC. ( 1.4 ) as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test. ( 1.4 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. ( 1.4 ) Classical Hodgkin Lymphoma (cHL) for the treatment of adult patients with relapsed or refractory cHL. ( 1.5 ) for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy. ( 1.5 ) Primary Mediastinal Large B-Cell Lymphoma (PMBCL) for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therapy. ( 1.6 ) Limitations of Use : KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy. Urothelial Cancer in combination with enfortumab vedotin, for the treatment of adult patients with locally advanced or metastatic urothelial cancer. ( 1.7 ) as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: are not eligible for any platinum-containing chemotherapy, or who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. ( 1.7 ) as a single agent for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. ( 1.7 ) Microsatellite Instability-High or Mismatch Repair Deficient Cancer for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. ( 1.8 , 2.1 ) Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC) for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-approved test. ( 1.9 , 2.1 ) Gastric Cancer in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) Esophageal Cancer for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either: in combination with platinum- and fluoropyrimidine-based chemotherapy for patients whose tumors express PD-L1 (CPS ≥1), or as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-approved test. ( 1.11 , 2.1 ) Cervical Cancer in combination with chemoradiotherapy, for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, with or without extension to pelvic sidewall, or hydronephrosis/non-functioning kidney, or spread to adjacent pelvic organs (FIGO 2014 Stage III-IVA). ( 1.12 ) in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) Hepatocellular Carcinoma (HCC) for the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen. ( 1.13 ) Biliary Tract Cancer (BTC) in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. ( 1.14 ) Merkel Cell Carcinoma (MCC) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma. ( 1.15 ) Renal Cell Carcinoma (RCC) in combination with axitinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. ( 1.16 ) Endometrial Carcinoma in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. ( 1.17 ) in combination with lenvatinib, for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) as a single agent, for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) Tumor Mutational Burden-High (TMB-H) Cancer for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. 1 ( 1.18 , 2.1 ) Limitations of Use : The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established. Cutaneous Squamous Cell Carcinoma (cSCC) for the treatment of patients with recurrent or metastatic cSCC or locally advanced cSCC that is not curable by surgery or radiation. ( 1.19 ) Triple-Negative Breast Cancer (TNBC) for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.20 ) in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA approved test. ( 1.20 , 2.1 ) Adult Classical Hodgkin Lymphoma and Adult Primary Mediastinal Large B-Cell Lymphoma: Additional Dosing Regimen of 400 mg Every 6 Weeks for use at an additional recommended dosage of 400 mg every 6 weeks for Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma in adults. 2 ( 1.21 , 2.2 ) 1 This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. 2 This indication is approved under accelerated approval based on pharmacokinetic data, the relationship of exposure to efficacy, and the relationship of exposure to safety. Continued approval for this dosing may be contingent upon verification and description of clinical benefit in the confirmatory trials. uuid:4f2450f1-8848-4e32-99a9-8ee343c2e64a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DPT0O3T46P biolink:treats MONDO:0004703 PMID:41385096 "[{""id"":""uuid:c535b7bd-4613-4e71-96ee-1e75e9bd6681"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:77c63b46-45dc-4e96-ae51-3fdef75c8f4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated: Melanoma for the treatment of patients with unresectable or metastatic melanoma. ( 1.1 ) for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection. ( 1.1 ) Non-Small Cell Lung Cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC. ( 1.2 ) as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic. ( 1.2 , 2.1 ) as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. ( 1.2 , 2.1 ) for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.2 ) as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC. ( 1.2 ) Malignant Pleural Mesothelioma (MPM) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic MPM. ( 1.3 ) Head and Neck Squamous Cell Cancer (HNSCC) for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent. ( 1.4 ) in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC. ( 1.4 ) as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test. ( 1.4 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. ( 1.4 ) Classical Hodgkin Lymphoma (cHL) for the treatment of adult patients with relapsed or refractory cHL. ( 1.5 ) for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy. ( 1.5 ) Primary Mediastinal Large B-Cell Lymphoma (PMBCL) for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therapy. ( 1.6 ) Limitations of Use : KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy. Urothelial Cancer in combination with enfortumab vedotin, for the treatment of adult patients with locally advanced or metastatic urothelial cancer. ( 1.7 ) as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: are not eligible for any platinum-containing chemotherapy, or who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. ( 1.7 ) as a single agent for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. ( 1.7 ) Microsatellite Instability-High or Mismatch Repair Deficient Cancer for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. ( 1.8 , 2.1 ) Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC) for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-approved test. ( 1.9 , 2.1 ) Gastric Cancer in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) Esophageal Cancer for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either: in combination with platinum- and fluoropyrimidine-based chemotherapy for patients whose tumors express PD-L1 (CPS ≥1), or as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-approved test. ( 1.11 , 2.1 ) Cervical Cancer in combination with chemoradiotherapy, for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, with or without extension to pelvic sidewall, or hydronephrosis/non-functioning kidney, or spread to adjacent pelvic organs (FIGO 2014 Stage III-IVA). ( 1.12 ) in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) Hepatocellular Carcinoma (HCC) for the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen. ( 1.13 ) Biliary Tract Cancer (BTC) in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. ( 1.14 ) Merkel Cell Carcinoma (MCC) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma. ( 1.15 ) Renal Cell Carcinoma (RCC) in combination with axitinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. ( 1.16 ) Endometrial Carcinoma in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. ( 1.17 ) in combination with lenvatinib, for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) as a single agent, for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) Tumor Mutational Burden-High (TMB-H) Cancer for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. 1 ( 1.18 , 2.1 ) Limitations of Use : The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established. Cutaneous Squamous Cell Carcinoma (cSCC) for the treatment of patients with recurrent or metastatic cSCC or locally advanced cSCC that is not curable by surgery or radiation. ( 1.19 ) Triple-Negative Breast Cancer (TNBC) for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.20 ) in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA approved test. ( 1.20 , 2.1 ) Adult Classical Hodgkin Lymphoma and Adult Primary Mediastinal Large B-Cell Lymphoma: Additional Dosing Regimen of 400 mg Every 6 Weeks for use at an additional recommended dosage of 400 mg every 6 weeks for Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma in adults. 2 ( 1.21 , 2.2 ) 1 This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. 2 This indication is approved under accelerated approval based on pharmacokinetic data, the relationship of exposure to efficacy, and the relationship of exposure to safety. Continued approval for this dosing may be contingent upon verification and description of clinical benefit in the confirmatory trials. uuid:52eecbaf-c557-484d-b00a-ae074e2fd96d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DPT0O3T46P biolink:treats MONDO:0030840 PMID:41385096 "[{""id"":""uuid:21dc9ea3-9eb3-48b8-9575-026f5b7865e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9b74d581-9b20-4ee2-91b4-b23a914ce61f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated: Melanoma for the treatment of patients with unresectable or metastatic melanoma. ( 1.1 ) for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection. ( 1.1 ) Non-Small Cell Lung Cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC. ( 1.2 ) as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic. ( 1.2 , 2.1 ) as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. ( 1.2 , 2.1 ) for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.2 ) as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC. ( 1.2 ) Malignant Pleural Mesothelioma (MPM) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic MPM. ( 1.3 ) Head and Neck Squamous Cell Cancer (HNSCC) for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent. ( 1.4 ) in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC. ( 1.4 ) as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test. ( 1.4 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. ( 1.4 ) Classical Hodgkin Lymphoma (cHL) for the treatment of adult patients with relapsed or refractory cHL. ( 1.5 ) for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy. ( 1.5 ) Primary Mediastinal Large B-Cell Lymphoma (PMBCL) for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therapy. ( 1.6 ) Limitations of Use : KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy. Urothelial Cancer in combination with enfortumab vedotin, for the treatment of adult patients with locally advanced or metastatic urothelial cancer. ( 1.7 ) as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: are not eligible for any platinum-containing chemotherapy, or who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. ( 1.7 ) as a single agent for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. ( 1.7 ) Microsatellite Instability-High or Mismatch Repair Deficient Cancer for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. ( 1.8 , 2.1 ) Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC) for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-approved test. ( 1.9 , 2.1 ) Gastric Cancer in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) Esophageal Cancer for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either: in combination with platinum- and fluoropyrimidine-based chemotherapy for patients whose tumors express PD-L1 (CPS ≥1), or as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-approved test. ( 1.11 , 2.1 ) Cervical Cancer in combination with chemoradiotherapy, for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, with or without extension to pelvic sidewall, or hydronephrosis/non-functioning kidney, or spread to adjacent pelvic organs (FIGO 2014 Stage III-IVA). ( 1.12 ) in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) Hepatocellular Carcinoma (HCC) for the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen. ( 1.13 ) Biliary Tract Cancer (BTC) in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. ( 1.14 ) Merkel Cell Carcinoma (MCC) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma. ( 1.15 ) Renal Cell Carcinoma (RCC) in combination with axitinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. ( 1.16 ) Endometrial Carcinoma in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. ( 1.17 ) in combination with lenvatinib, for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) as a single agent, for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) Tumor Mutational Burden-High (TMB-H) Cancer for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. 1 ( 1.18 , 2.1 ) Limitations of Use : The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established. Cutaneous Squamous Cell Carcinoma (cSCC) for the treatment of patients with recurrent or metastatic cSCC or locally advanced cSCC that is not curable by surgery or radiation. ( 1.19 ) Triple-Negative Breast Cancer (TNBC) for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.20 ) in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA approved test. ( 1.20 , 2.1 ) Adult Classical Hodgkin Lymphoma and Adult Primary Mediastinal Large B-Cell Lymphoma: Additional Dosing Regimen of 400 mg Every 6 Weeks for use at an additional recommended dosage of 400 mg every 6 weeks for Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma in adults. 2 ( 1.21 , 2.2 ) 1 This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. 2 This indication is approved under accelerated approval based on pharmacokinetic data, the relationship of exposure to efficacy, and the relationship of exposure to safety. Continued approval for this dosing may be contingent upon verification and description of clinical benefit in the confirmatory trials. uuid:16a5c729-fdfc-4097-bcfd-4c44dd7be4a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DPT0O3T46P biolink:treats UMLS:C4544822 PMID:41385096 "[{""id"":""uuid:76302a56-398d-4238-82a8-f0bc87071d7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0d3ecebd-da6d-44b7-bb4e-ccf565a0ba36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated: Melanoma for the treatment of patients with unresectable or metastatic melanoma. ( 1.1 ) for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection. ( 1.1 ) Non-Small Cell Lung Cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC. ( 1.2 ) as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic. ( 1.2 , 2.1 ) as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. ( 1.2 , 2.1 ) for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.2 ) as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC. ( 1.2 ) Malignant Pleural Mesothelioma (MPM) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic MPM. ( 1.3 ) Head and Neck Squamous Cell Cancer (HNSCC) for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent. ( 1.4 ) in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC. ( 1.4 ) as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test. ( 1.4 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. ( 1.4 ) Classical Hodgkin Lymphoma (cHL) for the treatment of adult patients with relapsed or refractory cHL. ( 1.5 ) for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy. ( 1.5 ) Primary Mediastinal Large B-Cell Lymphoma (PMBCL) for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therapy. ( 1.6 ) Limitations of Use : KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy. Urothelial Cancer in combination with enfortumab vedotin, for the treatment of adult patients with locally advanced or metastatic urothelial cancer. ( 1.7 ) as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: are not eligible for any platinum-containing chemotherapy, or who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. ( 1.7 ) as a single agent for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. ( 1.7 ) Microsatellite Instability-High or Mismatch Repair Deficient Cancer for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. ( 1.8 , 2.1 ) Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC) for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-approved test. ( 1.9 , 2.1 ) Gastric Cancer in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) Esophageal Cancer for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either: in combination with platinum- and fluoropyrimidine-based chemotherapy for patients whose tumors express PD-L1 (CPS ≥1), or as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-approved test. ( 1.11 , 2.1 ) Cervical Cancer in combination with chemoradiotherapy, for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, with or without extension to pelvic sidewall, or hydronephrosis/non-functioning kidney, or spread to adjacent pelvic organs (FIGO 2014 Stage III-IVA). ( 1.12 ) in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) Hepatocellular Carcinoma (HCC) for the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen. ( 1.13 ) Biliary Tract Cancer (BTC) in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. ( 1.14 ) Merkel Cell Carcinoma (MCC) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma. ( 1.15 ) Renal Cell Carcinoma (RCC) in combination with axitinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. ( 1.16 ) Endometrial Carcinoma in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. ( 1.17 ) in combination with lenvatinib, for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) as a single agent, for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) Tumor Mutational Burden-High (TMB-H) Cancer for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. 1 ( 1.18 , 2.1 ) Limitations of Use : The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established. Cutaneous Squamous Cell Carcinoma (cSCC) for the treatment of patients with recurrent or metastatic cSCC or locally advanced cSCC that is not curable by surgery or radiation. ( 1.19 ) Triple-Negative Breast Cancer (TNBC) for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.20 ) in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA approved test. ( 1.20 , 2.1 ) Adult Classical Hodgkin Lymphoma and Adult Primary Mediastinal Large B-Cell Lymphoma: Additional Dosing Regimen of 400 mg Every 6 Weeks for use at an additional recommended dosage of 400 mg every 6 weeks for Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma in adults. 2 ( 1.21 , 2.2 ) 1 This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. 2 This indication is approved under accelerated approval based on pharmacokinetic data, the relationship of exposure to efficacy, and the relationship of exposure to safety. Continued approval for this dosing may be contingent upon verification and description of clinical benefit in the confirmatory trials. uuid:7f141293-a844-4402-9ac7-81abf27b1f02 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DPT0O3T46P biolink:treats MONDO:0001056 PMID:41385096 "[{""id"":""uuid:9d4e0a2b-9794-4025-b82c-06629cb5469c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:849e813f-f075-4cea-98fd-643b3ec2c916"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated: Melanoma for the treatment of patients with unresectable or metastatic melanoma. ( 1.1 ) for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection. ( 1.1 ) Non-Small Cell Lung Cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC. ( 1.2 ) as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic. ( 1.2 , 2.1 ) as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. ( 1.2 , 2.1 ) for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.2 ) as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC. ( 1.2 ) Malignant Pleural Mesothelioma (MPM) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic MPM. ( 1.3 ) Head and Neck Squamous Cell Cancer (HNSCC) for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent. ( 1.4 ) in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC. ( 1.4 ) as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test. ( 1.4 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. ( 1.4 ) Classical Hodgkin Lymphoma (cHL) for the treatment of adult patients with relapsed or refractory cHL. ( 1.5 ) for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy. ( 1.5 ) Primary Mediastinal Large B-Cell Lymphoma (PMBCL) for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therapy. ( 1.6 ) Limitations of Use : KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy. Urothelial Cancer in combination with enfortumab vedotin, for the treatment of adult patients with locally advanced or metastatic urothelial cancer. ( 1.7 ) as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: are not eligible for any platinum-containing chemotherapy, or who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. ( 1.7 ) as a single agent for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. ( 1.7 ) Microsatellite Instability-High or Mismatch Repair Deficient Cancer for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. ( 1.8 , 2.1 ) Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC) for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-approved test. ( 1.9 , 2.1 ) Gastric Cancer in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) Esophageal Cancer for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either: in combination with platinum- and fluoropyrimidine-based chemotherapy for patients whose tumors express PD-L1 (CPS ≥1), or as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-approved test. ( 1.11 , 2.1 ) Cervical Cancer in combination with chemoradiotherapy, for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, with or without extension to pelvic sidewall, or hydronephrosis/non-functioning kidney, or spread to adjacent pelvic organs (FIGO 2014 Stage III-IVA). ( 1.12 ) in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) Hepatocellular Carcinoma (HCC) for the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen. ( 1.13 ) Biliary Tract Cancer (BTC) in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. ( 1.14 ) Merkel Cell Carcinoma (MCC) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma. ( 1.15 ) Renal Cell Carcinoma (RCC) in combination with axitinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. ( 1.16 ) Endometrial Carcinoma in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. ( 1.17 ) in combination with lenvatinib, for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) as a single agent, for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) Tumor Mutational Burden-High (TMB-H) Cancer for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. 1 ( 1.18 , 2.1 ) Limitations of Use : The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established. Cutaneous Squamous Cell Carcinoma (cSCC) for the treatment of patients with recurrent or metastatic cSCC or locally advanced cSCC that is not curable by surgery or radiation. ( 1.19 ) Triple-Negative Breast Cancer (TNBC) for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.20 ) in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA approved test. ( 1.20 , 2.1 ) Adult Classical Hodgkin Lymphoma and Adult Primary Mediastinal Large B-Cell Lymphoma: Additional Dosing Regimen of 400 mg Every 6 Weeks for use at an additional recommended dosage of 400 mg every 6 weeks for Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma in adults. 2 ( 1.21 , 2.2 ) 1 This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. 2 This indication is approved under accelerated approval based on pharmacokinetic data, the relationship of exposure to efficacy, and the relationship of exposure to safety. Continued approval for this dosing may be contingent upon verification and description of clinical benefit in the confirmatory trials. uuid:823dc4fc-f010-41ca-8afb-0cff0946eebf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DPT0O3T46P biolink:treats MONDO:0007576 PMID:41385096 "[{""id"":""uuid:ed805d90-13d9-4695-8165-e13cadee64d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2b7b35eb-feb0-4984-9235-c33ac2afcaff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a1d22b22-aa57-41ed-a0db-c3729b6a7dc6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated: Melanoma for the treatment of patients with unresectable or metastatic melanoma. ( 1.1 ) for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection. ( 1.1 ) Non-Small Cell Lung Cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC. ( 1.2 ) as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic. ( 1.2 , 2.1 ) as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. ( 1.2 , 2.1 ) for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.2 ) as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC. ( 1.2 ) Malignant Pleural Mesothelioma (MPM) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic MPM. ( 1.3 ) Head and Neck Squamous Cell Cancer (HNSCC) for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent. ( 1.4 ) in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC. ( 1.4 ) as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test. ( 1.4 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. ( 1.4 ) Classical Hodgkin Lymphoma (cHL) for the treatment of adult patients with relapsed or refractory cHL. ( 1.5 ) for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy. ( 1.5 ) Primary Mediastinal Large B-Cell Lymphoma (PMBCL) for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therapy. ( 1.6 ) Limitations of Use : KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy. Urothelial Cancer in combination with enfortumab vedotin, for the treatment of adult patients with locally advanced or metastatic urothelial cancer. ( 1.7 ) as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: are not eligible for any platinum-containing chemotherapy, or who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. ( 1.7 ) as a single agent for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. ( 1.7 ) Microsatellite Instability-High or Mismatch Repair Deficient Cancer for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. ( 1.8 , 2.1 ) Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC) for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-approved test. ( 1.9 , 2.1 ) Gastric Cancer in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) Esophageal Cancer for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either: in combination with platinum- and fluoropyrimidine-based chemotherapy for patients whose tumors express PD-L1 (CPS ≥1), or as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-approved test. ( 1.11 , 2.1 ) Cervical Cancer in combination with chemoradiotherapy, for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, with or without extension to pelvic sidewall, or hydronephrosis/non-functioning kidney, or spread to adjacent pelvic organs (FIGO 2014 Stage III-IVA). ( 1.12 ) in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) Hepatocellular Carcinoma (HCC) for the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen. ( 1.13 ) Biliary Tract Cancer (BTC) in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. ( 1.14 ) Merkel Cell Carcinoma (MCC) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma. ( 1.15 ) Renal Cell Carcinoma (RCC) in combination with axitinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. ( 1.16 ) Endometrial Carcinoma in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. ( 1.17 ) in combination with lenvatinib, for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) as a single agent, for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) Tumor Mutational Burden-High (TMB-H) Cancer for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. 1 ( 1.18 , 2.1 ) Limitations of Use : The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established. Cutaneous Squamous Cell Carcinoma (cSCC) for the treatment of patients with recurrent or metastatic cSCC or locally advanced cSCC that is not curable by surgery or radiation. ( 1.19 ) Triple-Negative Breast Cancer (TNBC) for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.20 ) in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA approved test. ( 1.20 , 2.1 ) Adult Classical Hodgkin Lymphoma and Adult Primary Mediastinal Large B-Cell Lymphoma: Additional Dosing Regimen of 400 mg Every 6 Weeks for use at an additional recommended dosage of 400 mg every 6 weeks for Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma in adults. 2 ( 1.21 , 2.2 ) 1 This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. 2 This indication is approved under accelerated approval based on pharmacokinetic data, the relationship of exposure to efficacy, and the relationship of exposure to safety. Continued approval for this dosing may be contingent upon verification and description of clinical benefit in the confirmatory trials.|[PMDA] A drug with a new indication and a new dosage for the treatment of unresectable advanced or recurrent esophageal cancer. uuid:3f340e71-724d-4e13-9545-2981cecfa577 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DPT0O3T46P biolink:treats MONDO:0002974 PMID:41385096 "[{""id"":""uuid:68d0f232-96a9-4626-8c8e-92853ac786b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4d8a179d-0e5e-47cf-aec5-de83713f9596"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:1262f77d-6a6b-4fb4-834c-74a94a39ad42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated: Melanoma for the treatment of patients with unresectable or metastatic melanoma. ( 1.1 ) for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection. ( 1.1 ) Non-Small Cell Lung Cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC. ( 1.2 ) as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic. ( 1.2 , 2.1 ) as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. ( 1.2 , 2.1 ) for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.2 ) as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC. ( 1.2 ) Malignant Pleural Mesothelioma (MPM) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic MPM. ( 1.3 ) Head and Neck Squamous Cell Cancer (HNSCC) for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent. ( 1.4 ) in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC. ( 1.4 ) as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test. ( 1.4 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. ( 1.4 ) Classical Hodgkin Lymphoma (cHL) for the treatment of adult patients with relapsed or refractory cHL. ( 1.5 ) for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy. ( 1.5 ) Primary Mediastinal Large B-Cell Lymphoma (PMBCL) for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therapy. ( 1.6 ) Limitations of Use : KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy. Urothelial Cancer in combination with enfortumab vedotin, for the treatment of adult patients with locally advanced or metastatic urothelial cancer. ( 1.7 ) as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: are not eligible for any platinum-containing chemotherapy, or who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. ( 1.7 ) as a single agent for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. ( 1.7 ) Microsatellite Instability-High or Mismatch Repair Deficient Cancer for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. ( 1.8 , 2.1 ) Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC) for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-approved test. ( 1.9 , 2.1 ) Gastric Cancer in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) Esophageal Cancer for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either: in combination with platinum- and fluoropyrimidine-based chemotherapy for patients whose tumors express PD-L1 (CPS ≥1), or as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-approved test. ( 1.11 , 2.1 ) Cervical Cancer in combination with chemoradiotherapy, for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, with or without extension to pelvic sidewall, or hydronephrosis/non-functioning kidney, or spread to adjacent pelvic organs (FIGO 2014 Stage III-IVA). ( 1.12 ) in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) Hepatocellular Carcinoma (HCC) for the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen. ( 1.13 ) Biliary Tract Cancer (BTC) in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. ( 1.14 ) Merkel Cell Carcinoma (MCC) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma. ( 1.15 ) Renal Cell Carcinoma (RCC) in combination with axitinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. ( 1.16 ) Endometrial Carcinoma in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. ( 1.17 ) in combination with lenvatinib, for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) as a single agent, for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) Tumor Mutational Burden-High (TMB-H) Cancer for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. 1 ( 1.18 , 2.1 ) Limitations of Use : The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established. Cutaneous Squamous Cell Carcinoma (cSCC) for the treatment of patients with recurrent or metastatic cSCC or locally advanced cSCC that is not curable by surgery or radiation. ( 1.19 ) Triple-Negative Breast Cancer (TNBC) for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.20 ) in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA approved test. ( 1.20 , 2.1 ) Adult Classical Hodgkin Lymphoma and Adult Primary Mediastinal Large B-Cell Lymphoma: Additional Dosing Regimen of 400 mg Every 6 Weeks for use at an additional recommended dosage of 400 mg every 6 weeks for Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma in adults. 2 ( 1.21 , 2.2 ) 1 This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. 2 This indication is approved under accelerated approval based on pharmacokinetic data, the relationship of exposure to efficacy, and the relationship of exposure to safety. Continued approval for this dosing may be contingent upon verification and description of clinical benefit in the confirmatory trials.|[PMDA] A drug with a new indication for the treatment of advanced or recurrent cervical cancer. A drug with a new indication and a new dosage for the preoperative and postoperative adjuvant treatment of hormone receptor (HR)-negative and human epidermal growth factor receptor 2 (HER2)-negative breast cancer with a high risk of recurrence. uuid:fd92b939-f865-40a8-8188-c35543750dc6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DPT0O3T46P biolink:treats MONDO:0007256 PMID:41385096 "[{""id"":""uuid:a7cf062a-bf83-4ddc-a6ff-2995d3499d46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:3d560631-c9f1-4c62-a7f0-758524cc9cdc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated: Melanoma for the treatment of patients with unresectable or metastatic melanoma. ( 1.1 ) for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection. ( 1.1 ) Non-Small Cell Lung Cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC. ( 1.2 ) as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic. ( 1.2 , 2.1 ) as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. ( 1.2 , 2.1 ) for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.2 ) as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC. ( 1.2 ) Malignant Pleural Mesothelioma (MPM) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic MPM. ( 1.3 ) Head and Neck Squamous Cell Cancer (HNSCC) for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent. ( 1.4 ) in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC. ( 1.4 ) as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test. ( 1.4 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. ( 1.4 ) Classical Hodgkin Lymphoma (cHL) for the treatment of adult patients with relapsed or refractory cHL. ( 1.5 ) for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy. ( 1.5 ) Primary Mediastinal Large B-Cell Lymphoma (PMBCL) for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therapy. ( 1.6 ) Limitations of Use : KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy. Urothelial Cancer in combination with enfortumab vedotin, for the treatment of adult patients with locally advanced or metastatic urothelial cancer. ( 1.7 ) as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: are not eligible for any platinum-containing chemotherapy, or who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. ( 1.7 ) as a single agent for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. ( 1.7 ) Microsatellite Instability-High or Mismatch Repair Deficient Cancer for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. ( 1.8 , 2.1 ) Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC) for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-approved test. ( 1.9 , 2.1 ) Gastric Cancer in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) Esophageal Cancer for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either: in combination with platinum- and fluoropyrimidine-based chemotherapy for patients whose tumors express PD-L1 (CPS ≥1), or as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-approved test. ( 1.11 , 2.1 ) Cervical Cancer in combination with chemoradiotherapy, for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, with or without extension to pelvic sidewall, or hydronephrosis/non-functioning kidney, or spread to adjacent pelvic organs (FIGO 2014 Stage III-IVA). ( 1.12 ) in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) Hepatocellular Carcinoma (HCC) for the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen. ( 1.13 ) Biliary Tract Cancer (BTC) in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. ( 1.14 ) Merkel Cell Carcinoma (MCC) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma. ( 1.15 ) Renal Cell Carcinoma (RCC) in combination with axitinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. ( 1.16 ) Endometrial Carcinoma in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. ( 1.17 ) in combination with lenvatinib, for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) as a single agent, for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) Tumor Mutational Burden-High (TMB-H) Cancer for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. 1 ( 1.18 , 2.1 ) Limitations of Use : The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established. Cutaneous Squamous Cell Carcinoma (cSCC) for the treatment of patients with recurrent or metastatic cSCC or locally advanced cSCC that is not curable by surgery or radiation. ( 1.19 ) Triple-Negative Breast Cancer (TNBC) for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.20 ) in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA approved test. ( 1.20 , 2.1 ) Adult Classical Hodgkin Lymphoma and Adult Primary Mediastinal Large B-Cell Lymphoma: Additional Dosing Regimen of 400 mg Every 6 Weeks for use at an additional recommended dosage of 400 mg every 6 weeks for Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma in adults. 2 ( 1.21 , 2.2 ) 1 This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. 2 This indication is approved under accelerated approval based on pharmacokinetic data, the relationship of exposure to efficacy, and the relationship of exposure to safety. Continued approval for this dosing may be contingent upon verification and description of clinical benefit in the confirmatory trials. uuid:f66db0da-c3a4-449d-8bae-c176ed21f15e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DPT0O3T46P biolink:treats MONDO:0003060 PMID:41385096 "[{""id"":""uuid:9e04cbf2-e80e-4eb7-99f3-1444abd1363a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b0ea3c0b-9acb-4533-957a-ea9e9d771f6d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated: Melanoma for the treatment of patients with unresectable or metastatic melanoma. ( 1.1 ) for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection. ( 1.1 ) Non-Small Cell Lung Cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC. ( 1.2 ) as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic. ( 1.2 , 2.1 ) as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. ( 1.2 , 2.1 ) for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.2 ) as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC. ( 1.2 ) Malignant Pleural Mesothelioma (MPM) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic MPM. ( 1.3 ) Head and Neck Squamous Cell Cancer (HNSCC) for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent. ( 1.4 ) in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC. ( 1.4 ) as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test. ( 1.4 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. ( 1.4 ) Classical Hodgkin Lymphoma (cHL) for the treatment of adult patients with relapsed or refractory cHL. ( 1.5 ) for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy. ( 1.5 ) Primary Mediastinal Large B-Cell Lymphoma (PMBCL) for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therapy. ( 1.6 ) Limitations of Use : KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy. Urothelial Cancer in combination with enfortumab vedotin, for the treatment of adult patients with locally advanced or metastatic urothelial cancer. ( 1.7 ) as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: are not eligible for any platinum-containing chemotherapy, or who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. ( 1.7 ) as a single agent for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. ( 1.7 ) Microsatellite Instability-High or Mismatch Repair Deficient Cancer for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. ( 1.8 , 2.1 ) Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC) for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-approved test. ( 1.9 , 2.1 ) Gastric Cancer in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) Esophageal Cancer for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either: in combination with platinum- and fluoropyrimidine-based chemotherapy for patients whose tumors express PD-L1 (CPS ≥1), or as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-approved test. ( 1.11 , 2.1 ) Cervical Cancer in combination with chemoradiotherapy, for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, with or without extension to pelvic sidewall, or hydronephrosis/non-functioning kidney, or spread to adjacent pelvic organs (FIGO 2014 Stage III-IVA). ( 1.12 ) in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) Hepatocellular Carcinoma (HCC) for the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen. ( 1.13 ) Biliary Tract Cancer (BTC) in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. ( 1.14 ) Merkel Cell Carcinoma (MCC) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma. ( 1.15 ) Renal Cell Carcinoma (RCC) in combination with axitinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. ( 1.16 ) Endometrial Carcinoma in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. ( 1.17 ) in combination with lenvatinib, for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) as a single agent, for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) Tumor Mutational Burden-High (TMB-H) Cancer for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. 1 ( 1.18 , 2.1 ) Limitations of Use : The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established. Cutaneous Squamous Cell Carcinoma (cSCC) for the treatment of patients with recurrent or metastatic cSCC or locally advanced cSCC that is not curable by surgery or radiation. ( 1.19 ) Triple-Negative Breast Cancer (TNBC) for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.20 ) in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA approved test. ( 1.20 , 2.1 ) Adult Classical Hodgkin Lymphoma and Adult Primary Mediastinal Large B-Cell Lymphoma: Additional Dosing Regimen of 400 mg Every 6 Weeks for use at an additional recommended dosage of 400 mg every 6 weeks for Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma in adults. 2 ( 1.21 , 2.2 ) 1 This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. 2 This indication is approved under accelerated approval based on pharmacokinetic data, the relationship of exposure to efficacy, and the relationship of exposure to safety. Continued approval for this dosing may be contingent upon verification and description of clinical benefit in the confirmatory trials. uuid:88b6138a-6221-4e1d-ab0d-6d9b9dd98aac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DPT0O3T46P biolink:treats MONDO:0019210 PMID:41385096 "[{""id"":""uuid:be0d2c7e-6676-4b2f-b45d-6be53b0e4604"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:70fabde7-371c-477c-97d1-99ccbab7b2f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated: Melanoma for the treatment of patients with unresectable or metastatic melanoma. ( 1.1 ) for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection. ( 1.1 ) Non-Small Cell Lung Cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC. ( 1.2 ) as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic. ( 1.2 , 2.1 ) as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. ( 1.2 , 2.1 ) for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.2 ) as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC. ( 1.2 ) Malignant Pleural Mesothelioma (MPM) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic MPM. ( 1.3 ) Head and Neck Squamous Cell Cancer (HNSCC) for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent. ( 1.4 ) in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC. ( 1.4 ) as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test. ( 1.4 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. ( 1.4 ) Classical Hodgkin Lymphoma (cHL) for the treatment of adult patients with relapsed or refractory cHL. ( 1.5 ) for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy. ( 1.5 ) Primary Mediastinal Large B-Cell Lymphoma (PMBCL) for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therapy. ( 1.6 ) Limitations of Use : KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy. Urothelial Cancer in combination with enfortumab vedotin, for the treatment of adult patients with locally advanced or metastatic urothelial cancer. ( 1.7 ) as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: are not eligible for any platinum-containing chemotherapy, or who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. ( 1.7 ) as a single agent for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. ( 1.7 ) Microsatellite Instability-High or Mismatch Repair Deficient Cancer for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. ( 1.8 , 2.1 ) Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC) for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-approved test. ( 1.9 , 2.1 ) Gastric Cancer in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) Esophageal Cancer for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either: in combination with platinum- and fluoropyrimidine-based chemotherapy for patients whose tumors express PD-L1 (CPS ≥1), or as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-approved test. ( 1.11 , 2.1 ) Cervical Cancer in combination with chemoradiotherapy, for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, with or without extension to pelvic sidewall, or hydronephrosis/non-functioning kidney, or spread to adjacent pelvic organs (FIGO 2014 Stage III-IVA). ( 1.12 ) in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) Hepatocellular Carcinoma (HCC) for the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen. ( 1.13 ) Biliary Tract Cancer (BTC) in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. ( 1.14 ) Merkel Cell Carcinoma (MCC) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma. ( 1.15 ) Renal Cell Carcinoma (RCC) in combination with axitinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. ( 1.16 ) Endometrial Carcinoma in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. ( 1.17 ) in combination with lenvatinib, for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) as a single agent, for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) Tumor Mutational Burden-High (TMB-H) Cancer for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. 1 ( 1.18 , 2.1 ) Limitations of Use : The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established. Cutaneous Squamous Cell Carcinoma (cSCC) for the treatment of patients with recurrent or metastatic cSCC or locally advanced cSCC that is not curable by surgery or radiation. ( 1.19 ) Triple-Negative Breast Cancer (TNBC) for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.20 ) in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA approved test. ( 1.20 , 2.1 ) Adult Classical Hodgkin Lymphoma and Adult Primary Mediastinal Large B-Cell Lymphoma: Additional Dosing Regimen of 400 mg Every 6 Weeks for use at an additional recommended dosage of 400 mg every 6 weeks for Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma in adults. 2 ( 1.21 , 2.2 ) 1 This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. 2 This indication is approved under accelerated approval based on pharmacokinetic data, the relationship of exposure to efficacy, and the relationship of exposure to safety. Continued approval for this dosing may be contingent upon verification and description of clinical benefit in the confirmatory trials. uuid:35ea7a0e-b27d-441a-8617-76167db6700b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DPT0O3T46P biolink:treats MONDO:0005086 PMID:41385096 "[{""id"":""uuid:7a18cf8b-35ed-4944-9c22-707612047b3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1cf637ae-cee1-4d46-b611-76aae168ec22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:4d6deb7c-46c2-4776-a35b-f99c18da553f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated: Melanoma for the treatment of patients with unresectable or metastatic melanoma. ( 1.1 ) for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection. ( 1.1 ) Non-Small Cell Lung Cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC. ( 1.2 ) as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic. ( 1.2 , 2.1 ) as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. ( 1.2 , 2.1 ) for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.2 ) as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC. ( 1.2 ) Malignant Pleural Mesothelioma (MPM) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic MPM. ( 1.3 ) Head and Neck Squamous Cell Cancer (HNSCC) for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent. ( 1.4 ) in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC. ( 1.4 ) as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test. ( 1.4 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. ( 1.4 ) Classical Hodgkin Lymphoma (cHL) for the treatment of adult patients with relapsed or refractory cHL. ( 1.5 ) for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy. ( 1.5 ) Primary Mediastinal Large B-Cell Lymphoma (PMBCL) for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therapy. ( 1.6 ) Limitations of Use : KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy. Urothelial Cancer in combination with enfortumab vedotin, for the treatment of adult patients with locally advanced or metastatic urothelial cancer. ( 1.7 ) as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: are not eligible for any platinum-containing chemotherapy, or who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. ( 1.7 ) as a single agent for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. ( 1.7 ) Microsatellite Instability-High or Mismatch Repair Deficient Cancer for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. ( 1.8 , 2.1 ) Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC) for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-approved test. ( 1.9 , 2.1 ) Gastric Cancer in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) Esophageal Cancer for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either: in combination with platinum- and fluoropyrimidine-based chemotherapy for patients whose tumors express PD-L1 (CPS ≥1), or as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-approved test. ( 1.11 , 2.1 ) Cervical Cancer in combination with chemoradiotherapy, for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, with or without extension to pelvic sidewall, or hydronephrosis/non-functioning kidney, or spread to adjacent pelvic organs (FIGO 2014 Stage III-IVA). ( 1.12 ) in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) Hepatocellular Carcinoma (HCC) for the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen. ( 1.13 ) Biliary Tract Cancer (BTC) in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. ( 1.14 ) Merkel Cell Carcinoma (MCC) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma. ( 1.15 ) Renal Cell Carcinoma (RCC) in combination with axitinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. ( 1.16 ) Endometrial Carcinoma in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. ( 1.17 ) in combination with lenvatinib, for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) as a single agent, for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) Tumor Mutational Burden-High (TMB-H) Cancer for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. 1 ( 1.18 , 2.1 ) Limitations of Use : The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established. Cutaneous Squamous Cell Carcinoma (cSCC) for the treatment of patients with recurrent or metastatic cSCC or locally advanced cSCC that is not curable by surgery or radiation. ( 1.19 ) Triple-Negative Breast Cancer (TNBC) for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.20 ) in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA approved test. ( 1.20 , 2.1 ) Adult Classical Hodgkin Lymphoma and Adult Primary Mediastinal Large B-Cell Lymphoma: Additional Dosing Regimen of 400 mg Every 6 Weeks for use at an additional recommended dosage of 400 mg every 6 weeks for Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma in adults. 2 ( 1.21 , 2.2 ) 1 This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. 2 This indication is approved under accelerated approval based on pharmacokinetic data, the relationship of exposure to efficacy, and the relationship of exposure to safety. Continued approval for this dosing may be contingent upon verification and description of clinical benefit in the confirmatory trials.|[PMDA] A drug with a new indication and a new dosage for postoperative adjuvant treatment for renal cell carcinoma. uuid:25cd6d44-0837-4431-9d65-7d5a7d5bf74c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DPT0O3T46P biolink:treats MONDO:0002447 PMID:41385096 "[{""id"":""uuid:912d890c-8b94-4163-9b06-1cad56385814"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:b48d9f0a-31e6-4809-a82e-c04b47478596"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated: Melanoma for the treatment of patients with unresectable or metastatic melanoma. ( 1.1 ) for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection. ( 1.1 ) Non-Small Cell Lung Cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC. ( 1.2 ) as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic. ( 1.2 , 2.1 ) as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. ( 1.2 , 2.1 ) for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.2 ) as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC. ( 1.2 ) Malignant Pleural Mesothelioma (MPM) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic MPM. ( 1.3 ) Head and Neck Squamous Cell Cancer (HNSCC) for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent. ( 1.4 ) in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC. ( 1.4 ) as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test. ( 1.4 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. ( 1.4 ) Classical Hodgkin Lymphoma (cHL) for the treatment of adult patients with relapsed or refractory cHL. ( 1.5 ) for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy. ( 1.5 ) Primary Mediastinal Large B-Cell Lymphoma (PMBCL) for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therapy. ( 1.6 ) Limitations of Use : KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy. Urothelial Cancer in combination with enfortumab vedotin, for the treatment of adult patients with locally advanced or metastatic urothelial cancer. ( 1.7 ) as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: are not eligible for any platinum-containing chemotherapy, or who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. ( 1.7 ) as a single agent for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. ( 1.7 ) Microsatellite Instability-High or Mismatch Repair Deficient Cancer for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. ( 1.8 , 2.1 ) Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC) for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-approved test. ( 1.9 , 2.1 ) Gastric Cancer in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) Esophageal Cancer for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either: in combination with platinum- and fluoropyrimidine-based chemotherapy for patients whose tumors express PD-L1 (CPS ≥1), or as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-approved test. ( 1.11 , 2.1 ) Cervical Cancer in combination with chemoradiotherapy, for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, with or without extension to pelvic sidewall, or hydronephrosis/non-functioning kidney, or spread to adjacent pelvic organs (FIGO 2014 Stage III-IVA). ( 1.12 ) in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) Hepatocellular Carcinoma (HCC) for the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen. ( 1.13 ) Biliary Tract Cancer (BTC) in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. ( 1.14 ) Merkel Cell Carcinoma (MCC) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma. ( 1.15 ) Renal Cell Carcinoma (RCC) in combination with axitinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. ( 1.16 ) Endometrial Carcinoma in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. ( 1.17 ) in combination with lenvatinib, for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) as a single agent, for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) Tumor Mutational Burden-High (TMB-H) Cancer for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. 1 ( 1.18 , 2.1 ) Limitations of Use : The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established. Cutaneous Squamous Cell Carcinoma (cSCC) for the treatment of patients with recurrent or metastatic cSCC or locally advanced cSCC that is not curable by surgery or radiation. ( 1.19 ) Triple-Negative Breast Cancer (TNBC) for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.20 ) in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA approved test. ( 1.20 , 2.1 ) Adult Classical Hodgkin Lymphoma and Adult Primary Mediastinal Large B-Cell Lymphoma: Additional Dosing Regimen of 400 mg Every 6 Weeks for use at an additional recommended dosage of 400 mg every 6 weeks for Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma in adults. 2 ( 1.21 , 2.2 ) 1 This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. 2 This indication is approved under accelerated approval based on pharmacokinetic data, the relationship of exposure to efficacy, and the relationship of exposure to safety. Continued approval for this dosing may be contingent upon verification and description of clinical benefit in the confirmatory trials. uuid:f47f6ada-a268-43e6-942b-c6d6fee3c8ad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DPT0O3T46P biolink:treats UMLS:C5442339 PMID:41385096 "[{""id"":""uuid:8bfd7dc4-b918-4261-a70b-21c22c44db35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a3fce140-179a-4960-a9c3-6cff3bec9e2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated: Melanoma for the treatment of patients with unresectable or metastatic melanoma. ( 1.1 ) for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection. ( 1.1 ) Non-Small Cell Lung Cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC. ( 1.2 ) as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic. ( 1.2 , 2.1 ) as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. ( 1.2 , 2.1 ) for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.2 ) as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC. ( 1.2 ) Malignant Pleural Mesothelioma (MPM) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic MPM. ( 1.3 ) Head and Neck Squamous Cell Cancer (HNSCC) for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent. ( 1.4 ) in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC. ( 1.4 ) as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test. ( 1.4 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. ( 1.4 ) Classical Hodgkin Lymphoma (cHL) for the treatment of adult patients with relapsed or refractory cHL. ( 1.5 ) for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy. ( 1.5 ) Primary Mediastinal Large B-Cell Lymphoma (PMBCL) for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therapy. ( 1.6 ) Limitations of Use : KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy. Urothelial Cancer in combination with enfortumab vedotin, for the treatment of adult patients with locally advanced or metastatic urothelial cancer. ( 1.7 ) as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: are not eligible for any platinum-containing chemotherapy, or who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. ( 1.7 ) as a single agent for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. ( 1.7 ) Microsatellite Instability-High or Mismatch Repair Deficient Cancer for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. ( 1.8 , 2.1 ) Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC) for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-approved test. ( 1.9 , 2.1 ) Gastric Cancer in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) Esophageal Cancer for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either: in combination with platinum- and fluoropyrimidine-based chemotherapy for patients whose tumors express PD-L1 (CPS ≥1), or as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-approved test. ( 1.11 , 2.1 ) Cervical Cancer in combination with chemoradiotherapy, for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, with or without extension to pelvic sidewall, or hydronephrosis/non-functioning kidney, or spread to adjacent pelvic organs (FIGO 2014 Stage III-IVA). ( 1.12 ) in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) Hepatocellular Carcinoma (HCC) for the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen. ( 1.13 ) Biliary Tract Cancer (BTC) in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. ( 1.14 ) Merkel Cell Carcinoma (MCC) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma. ( 1.15 ) Renal Cell Carcinoma (RCC) in combination with axitinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. ( 1.16 ) Endometrial Carcinoma in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. ( 1.17 ) in combination with lenvatinib, for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) as a single agent, for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) Tumor Mutational Burden-High (TMB-H) Cancer for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. 1 ( 1.18 , 2.1 ) Limitations of Use : The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established. Cutaneous Squamous Cell Carcinoma (cSCC) for the treatment of patients with recurrent or metastatic cSCC or locally advanced cSCC that is not curable by surgery or radiation. ( 1.19 ) Triple-Negative Breast Cancer (TNBC) for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.20 ) in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA approved test. ( 1.20 , 2.1 ) Adult Classical Hodgkin Lymphoma and Adult Primary Mediastinal Large B-Cell Lymphoma: Additional Dosing Regimen of 400 mg Every 6 Weeks for use at an additional recommended dosage of 400 mg every 6 weeks for Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma in adults. 2 ( 1.21 , 2.2 ) 1 This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. 2 This indication is approved under accelerated approval based on pharmacokinetic data, the relationship of exposure to efficacy, and the relationship of exposure to safety. Continued approval for this dosing may be contingent upon verification and description of clinical benefit in the confirmatory trials. uuid:9e1b7c22-3d35-470d-83cf-7958084983ac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DPT0O3T46P biolink:treats MONDO:0002529 PMID:41385096 "[{""id"":""uuid:285fec0f-2a12-4e89-a809-39bb4d2c5796"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:54b2b6e7-3a07-402a-a062-26bc7049e22d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated: Melanoma for the treatment of patients with unresectable or metastatic melanoma. ( 1.1 ) for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection. ( 1.1 ) Non-Small Cell Lung Cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC. ( 1.2 ) as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic. ( 1.2 , 2.1 ) as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. ( 1.2 , 2.1 ) for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.2 ) as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC. ( 1.2 ) Malignant Pleural Mesothelioma (MPM) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic MPM. ( 1.3 ) Head and Neck Squamous Cell Cancer (HNSCC) for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent. ( 1.4 ) in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC. ( 1.4 ) as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test. ( 1.4 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. ( 1.4 ) Classical Hodgkin Lymphoma (cHL) for the treatment of adult patients with relapsed or refractory cHL. ( 1.5 ) for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy. ( 1.5 ) Primary Mediastinal Large B-Cell Lymphoma (PMBCL) for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therapy. ( 1.6 ) Limitations of Use : KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy. Urothelial Cancer in combination with enfortumab vedotin, for the treatment of adult patients with locally advanced or metastatic urothelial cancer. ( 1.7 ) as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: are not eligible for any platinum-containing chemotherapy, or who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. ( 1.7 ) as a single agent for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. ( 1.7 ) Microsatellite Instability-High or Mismatch Repair Deficient Cancer for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. ( 1.8 , 2.1 ) Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC) for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-approved test. ( 1.9 , 2.1 ) Gastric Cancer in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) Esophageal Cancer for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either: in combination with platinum- and fluoropyrimidine-based chemotherapy for patients whose tumors express PD-L1 (CPS ≥1), or as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-approved test. ( 1.11 , 2.1 ) Cervical Cancer in combination with chemoradiotherapy, for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, with or without extension to pelvic sidewall, or hydronephrosis/non-functioning kidney, or spread to adjacent pelvic organs (FIGO 2014 Stage III-IVA). ( 1.12 ) in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) Hepatocellular Carcinoma (HCC) for the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen. ( 1.13 ) Biliary Tract Cancer (BTC) in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. ( 1.14 ) Merkel Cell Carcinoma (MCC) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma. ( 1.15 ) Renal Cell Carcinoma (RCC) in combination with axitinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. ( 1.16 ) Endometrial Carcinoma in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. ( 1.17 ) in combination with lenvatinib, for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) as a single agent, for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) Tumor Mutational Burden-High (TMB-H) Cancer for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. 1 ( 1.18 , 2.1 ) Limitations of Use : The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established. Cutaneous Squamous Cell Carcinoma (cSCC) for the treatment of patients with recurrent or metastatic cSCC or locally advanced cSCC that is not curable by surgery or radiation. ( 1.19 ) Triple-Negative Breast Cancer (TNBC) for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.20 ) in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA approved test. ( 1.20 , 2.1 ) Adult Classical Hodgkin Lymphoma and Adult Primary Mediastinal Large B-Cell Lymphoma: Additional Dosing Regimen of 400 mg Every 6 Weeks for use at an additional recommended dosage of 400 mg every 6 weeks for Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma in adults. 2 ( 1.21 , 2.2 ) 1 This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. 2 This indication is approved under accelerated approval based on pharmacokinetic data, the relationship of exposure to efficacy, and the relationship of exposure to safety. Continued approval for this dosing may be contingent upon verification and description of clinical benefit in the confirmatory trials. uuid:b7e9d297-879a-4339-80b8-f82f5df60e09 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DPT0O3T46P biolink:treats MONDO:0005494 PMID:41385096 "[{""id"":""uuid:bdde68d2-7a24-4255-8b89-6badbe38ce55"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8186ca44-c91c-4c1e-8685-4f33e708683a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:81b5e9b3-ab80-43e5-8ffc-469043089f2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated: Melanoma for the treatment of patients with unresectable or metastatic melanoma. ( 1.1 ) for the adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection. ( 1.1 ) Non-Small Cell Lung Cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor aberrations. ( 1.2 ) in combination with carboplatin and either paclitaxel or paclitaxel protein-bound, as first-line treatment of patients with metastatic squamous NSCLC. ( 1.2 ) as a single agent for the first-line treatment of patients with NSCLC expressing PD-L1 [Tumor Proportion Score (TPS) ≥1%] as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations, and is: Stage III where patients are not candidates for surgical resection or definitive chemoradiation, or metastatic. ( 1.2 , 2.1 ) as a single agent for the treatment of patients with metastatic NSCLC whose tumors express PD-L1 (TPS ≥1%) as determined by an FDA-approved test, with disease progression on or after platinum-containing chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving KEYTRUDA. ( 1.2 , 2.1 ) for the treatment of patients with resectable (tumors ≥4 cm or node positive) NSCLC in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.2 ) as a single agent, for adjuvant treatment following resection and platinum-based chemotherapy for adult patients with Stage IB (T2a ≥4 cm), II, or IIIA NSCLC. ( 1.2 ) Malignant Pleural Mesothelioma (MPM) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of adult patients with unresectable advanced or metastatic MPM. ( 1.3 ) Head and Neck Squamous Cell Cancer (HNSCC) for the treatment of adult patients with resectable locally advanced HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test, as a single agent as neoadjuvant treatment, continued as adjuvant treatment in combination with radiotherapy (RT) with or without cisplatin and then as a single agent. ( 1.4 ) in combination with platinum and FU for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC. ( 1.4 ) as a single agent for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 [Combined Positive Score (CPS) ≥1] as determined by an FDA-approved test. ( 1.4 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic HNSCC with disease progression on or after platinum-containing chemotherapy. ( 1.4 ) Classical Hodgkin Lymphoma (cHL) for the treatment of adult patients with relapsed or refractory cHL. ( 1.5 ) for the treatment of pediatric patients with refractory cHL, or cHL that has relapsed after 2 or more lines of therapy. ( 1.5 ) Primary Mediastinal Large B-Cell Lymphoma (PMBCL) for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therapy. ( 1.6 ) Limitations of Use : KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy. Urothelial Cancer in combination with enfortumab vedotin, for the treatment of adult patients with locally advanced or metastatic urothelial cancer. ( 1.7 ) as a single agent for the treatment of patients with locally advanced or metastatic urothelial carcinoma who: are not eligible for any platinum-containing chemotherapy, or who have disease progression during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. ( 1.7 ) as a single agent for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy. ( 1.7 ) Microsatellite Instability-High or Mismatch Repair Deficient Cancer for the treatment of adult and pediatric patients with unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. ( 1.8 , 2.1 ) Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC) for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-approved test. ( 1.9 , 2.1 ) Gastric Cancer in combination with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) in combination with fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.10 ) Esophageal Cancer for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation either: in combination with platinum- and fluoropyrimidine-based chemotherapy for patients whose tumors express PD-L1 (CPS ≥1), or as a single agent after one or more prior lines of systemic therapy for patients with tumors of squamous cell histology that express PD-L1 (CPS ≥10) as determined by an FDA-approved test. ( 1.11 , 2.1 ) Cervical Cancer in combination with chemoradiotherapy, for the treatment of patients with locally advanced cervical cancer involving the lower third of the vagina, with or without extension to pelvic sidewall, or hydronephrosis/non-functioning kidney, or spread to adjacent pelvic organs (FIGO 2014 Stage III-IVA). ( 1.12 ) in combination with chemotherapy, with or without bevacizumab, for the treatment of patients with persistent, recurrent, or metastatic cervical cancer whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) as a single agent for the treatment of patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy whose tumors express PD-L1 (CPS ≥1) as determined by an FDA-approved test. ( 1.12 , 2.1 ) Hepatocellular Carcinoma (HCC) for the treatment of patients with HCC secondary to hepatitis B who have received prior systemic therapy other than a PD-1/PD-L1-containing regimen. ( 1.13 ) Biliary Tract Cancer (BTC) in combination with gemcitabine and cisplatin, for the treatment of patients with locally advanced unresectable or metastatic biliary tract cancer. ( 1.14 ) Merkel Cell Carcinoma (MCC) for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma. ( 1.15 ) Renal Cell Carcinoma (RCC) in combination with axitinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) in combination with lenvatinib, for the first-line treatment of adult patients with advanced RCC. ( 1.16 ) for the adjuvant treatment of patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions. ( 1.16 ) Endometrial Carcinoma in combination with carboplatin and paclitaxel, followed by KEYTRUDA as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial carcinoma. ( 1.17 ) in combination with lenvatinib, for the treatment of adult patients with advanced endometrial carcinoma that is mismatch repair proficient (pMMR) or not MSI-H as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) as a single agent, for the treatment of adult patients with advanced endometrial carcinoma that is MSI-H or dMMR, as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiation. ( 1.17 , 2.1 ) Tumor Mutational Burden-High (TMB-H) Cancer for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that have progressed following prior treatment and who have no satisfactory alternative treatment options. 1 ( 1.18 , 2.1 ) Limitations of Use : The safety and effectiveness of KEYTRUDA in pediatric patients with TMB-H central nervous system cancers have not been established. Cutaneous Squamous Cell Carcinoma (cSCC) for the treatment of patients with recurrent or metastatic cSCC or locally advanced cSCC that is not curable by surgery or radiation. ( 1.19 ) Triple-Negative Breast Cancer (TNBC) for the treatment of patients with high-risk early-stage TNBC in combination with chemotherapy as neoadjuvant treatment, and then continued as a single agent as adjuvant treatment after surgery. ( 1.20 ) in combination with chemotherapy, for the treatment of patients with locally recurrent unresectable or metastatic TNBC whose tumors express PD-L1 (CPS ≥10) as determined by an FDA approved test. ( 1.20 , 2.1 ) Adult Classical Hodgkin Lymphoma and Adult Primary Mediastinal Large B-Cell Lymphoma: Additional Dosing Regimen of 400 mg Every 6 Weeks for use at an additional recommended dosage of 400 mg every 6 weeks for Classical Hodgkin Lymphoma and Primary Mediastinal Large B-Cell Lymphoma in adults. 2 ( 1.21 , 2.2 ) 1 This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials. 2 This indication is approved under accelerated approval based on pharmacokinetic data, the relationship of exposure to efficacy, and the relationship of exposure to safety. Continued approval for this dosing may be contingent upon verification and description of clinical benefit in the confirmatory trials.|[PMDA] A drug with a new indication for the treatment of unresectable advanced or recurrent microsatellite instability-high (MSI-High) colorectal cancer. A drug with a new indication and a new dosage for the treatment of PD-L1-positive, hormone receptor-negative and HER2-negative inoperable or recurrent breast cancer. uuid:0c7c426e-4cd1-4168-9465-1acb7e00d0e7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134700 biolink:treats MONDO:0006964 PMID:41385096 "[{""id"":""uuid:f4020cf6-767e-45ae-be40-afcea3f297f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:dd51f509-d6d8-4bb8-9b17-bef72ac2623a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:acf4a95a-d1d2-4a69-8ea4-cbce97b66dce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:dfe2b948-1a30-4401-8aa8-83f19db79c1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PARSABIV is indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.|[EMA] Parsabiv is indicated for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) on haemodialysis therapy.|[PMDA] Drugs with a new active ingredient indicated for the treatment of secondary hyperparathyroidism in patients on hemodialysis. uuid:a69b989f-7023-420b-8cef-1f38d4e60b06 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134700 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:d90ebff9-9638-4187-9303-88e603b25979"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9a3e42ad-6bc9-4ad2-88ad-815220fd964f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a38e51d5-7f1a-42c1-b89c-c5baf6bfba67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] PARSABIV is indicated for the treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on hemodialysis.|[EMA] Parsabiv is indicated for the treatment of secondary hyperparathyroidism (SHPT) in adult patients with chronic kidney disease (CKD) on haemodialysis therapy. uuid:d47ca655-f1fe-47e8-87b1-9a5ba20c8475 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6A901E312A biolink:treats EFO:1001480 PMID:41385096 "[{""id"":""uuid:66b0de7e-d146-4b07-853f-0075f7be20c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:d38722ba-ad03-42b7-b4fa-d95cf0c5b727"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Vectibix is an epidermal growth factor receptor (EGFR) antagonist indicated for the treatment of: Adult patients with wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test) Metastatic Colorectal Cancer (mCRC)*: In combination with FOLFOX for first-line treatment. ( 1 , 14.2 ) As monotherapy following disease progression after prior treatment with fluoropyrimidine, oxaliplatin, and irinotecan-containing chemotherapy. ( 1 , 14.1 ) KRAS G12C-mutated Metastatic Colorectal Cancer (mCRC)* In combination with sotorasib, for the treatment of adult patients with KRAS G12C- mutated mCRC, as determined by an FDA-approved test, who have received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. ( 1 ) *Limitations of Use: Vectibix is not indicated for the treatment of patients with RAS -mutant mCRC unless used in combination with sotorasib in KRAS G12C-mutated mCRC. Vectibix is not indicated for the treatment of patients with mCRC for whom RAS mutation status is unknown ( 1 , 2.1 , 5.2 , 12.1 , 14.3 ). uuid:1cb42fcf-57f3-49e2-957f-9087dd59bf3d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85973 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:af4766db-79ec-4e79-994f-f7a31e0cdaf9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:42c1a4b2-341b-4168-a648-6602513b5fbb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d15e5725-db83-4b2a-bc1a-1a971dc9ab01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SAVAYSA is a factor Xa inhibitor indicated: To reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) ( 1.1 ) Limitation of Use for NVAF SAVAYSA should not be used in patients with creatinine clearance (CrCL) > 95 mL/min because of increased risk of ischemic stroke compared to warfarin at the highest dose studied (60 mg) ( 1.1 ) SAVAYSA is indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5 to 10 days of initial therapy with a parenteral anticoagulant ( 1.2 )|[EMA] Prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack (TIA).Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. uuid:94845ecb-d509-4678-aa43-bbf9144b729a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85973 biolink:treats UMLS:C5400523 PMID:41385096 "[{""id"":""uuid:d838c109-766d-4456-bd96-8eca63940ce6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bc6e2a46-bc78-42f6-a2c2-2c6a69cdafcd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:05fc8918-d39b-4910-80a5-91ee48f90653"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SAVAYSA is a factor Xa inhibitor indicated: To reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) ( 1.1 ) Limitation of Use for NVAF SAVAYSA should not be used in patients with creatinine clearance (CrCL) > 95 mL/min because of increased risk of ischemic stroke compared to warfarin at the highest dose studied (60 mg) ( 1.1 ) SAVAYSA is indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5 to 10 days of initial therapy with a parenteral anticoagulant ( 1.2 )|[PMDA] Drugs with a new dosage indicated for the prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation. uuid:4ceaa9c1-4ad0-40f8-a775-ab53d9525825 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85973 biolink:treats MONDO:0004981 PMID:41385096 "[{""id"":""uuid:025503d4-23a3-4594-9f38-bf721b9cfbb5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:af2d6218-a17d-4ecb-93d4-59ad87a0e9fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SAVAYSA is a factor Xa inhibitor indicated: To reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) ( 1.1 ) Limitation of Use for NVAF SAVAYSA should not be used in patients with creatinine clearance (CrCL) > 95 mL/min because of increased risk of ischemic stroke compared to warfarin at the highest dose studied (60 mg) ( 1.1 ) SAVAYSA is indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5 to 10 days of initial therapy with a parenteral anticoagulant ( 1.2 ) uuid:3040bd43-69da-4159-8d71-e190fdcd1592 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85973 biolink:treats HP:0002625 PMID:41385096 "[{""id"":""uuid:acdfec54-7c53-4d37-94a3-f19c09635c2d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:18cc5dd7-dafb-450d-b8b0-3d3674a8a058"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:dc6f52c5-39d0-4d85-8a0d-3ffe4bb36bd9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a7dc5a82-39a4-4070-9589-9e6797f829c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SAVAYSA is a factor Xa inhibitor indicated: To reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) ( 1.1 ) Limitation of Use for NVAF SAVAYSA should not be used in patients with creatinine clearance (CrCL) > 95 mL/min because of increased risk of ischemic stroke compared to warfarin at the highest dose studied (60 mg) ( 1.1 ) SAVAYSA is indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5 to 10 days of initial therapy with a parenteral anticoagulant ( 1.2 )|[EMA] Prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack (TIA).Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.|[PMDA] Drugs with new additional indications and new dosages, and a drug with a newly-added dosage form indicated for prevention of ischemic stroke and systemic embolism in patients with non- valvular atrial fibrillation, or for the treatment and prevention of the recurrence of venous thromboembolism (deep vein thrombosis and pulmonary thromboembolism). uuid:32cdbd48-48ba-46ff-a6c4-d025b6cc2ce0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85973 biolink:treats MONDO:0005279 PMID:41385096 "[{""id"":""uuid:a362f3a7-1146-4885-b7fb-250fa0e513d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:584823de-72df-4f3e-ae66-d4a607e0f062"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:7fc721cd-7ef4-4987-8c19-7b33f5257d62"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SAVAYSA is a factor Xa inhibitor indicated: To reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) ( 1.1 ) Limitation of Use for NVAF SAVAYSA should not be used in patients with creatinine clearance (CrCL) > 95 mL/min because of increased risk of ischemic stroke compared to warfarin at the highest dose studied (60 mg) ( 1.1 ) SAVAYSA is indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5 to 10 days of initial therapy with a parenteral anticoagulant ( 1.2 )|[EMA] Prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack (TIA).Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. uuid:de94be33-fcf7-4930-a8b7-8dcc03cb2b42 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:420K487FSG biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:e36c4e76-fd21-4b08-84e5-981cd33a5cac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:01d6721a-113b-498a-9824-63b8e0ebb5af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d6e82dcc-8257-4502-969c-3dbce8c8fed3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/dupixent""]},{""id"":""uuid:cbcf9513-5d5f-4a8f-afc3-9181c3688f0f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DUPIXENT is an interleukin-4 receptor alpha antagonist indicated: Atopic Dermatitis for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids. ( 1.1 ) Asthma as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma. ( 1.2 ) Limitations of Use: Not for the relief of acute bronchospasm or status asthmaticus. ( 1.2 ) Chronic Rhinosinusitis with Nasal Polyps as an add-on maintenance treatment in adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP). ( 1.3 ) Eosinophilic Esophagitis for the treatment of adult and pediatric patients aged 1 year and older, weighing at least 15 kg, with eosinophilic esophagitis (EoE). ( 1.4 ) Prurigo Nodularis for the treatment of adult patients with prurigo nodularis (PN). ( 1.5 ) Chronic Obstructive Pulmonary Disease as an add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. ( 1.6 ) Limitations of Use: Not for the relief of acute bronchospasm. ( 1.6 ) Chronic Spontaneous Urticaria for the treatment of adult and pediatric patients aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment. ( 1.7 ) Limitations of Use: Not indicated for other forms of urticaria. ( 1.7 ) Bullous Pemphigoid for the treatment of adult patients with bullous pemphigoid (BP). ( 1.8 )|[EMA] Atopic dermatitisAdults and adolescentsDupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.Children 6 months to 11 years of ageDupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy.AsthmaAdults and adolescentsDupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO), see section 5.1, who are inadequately controlled with high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment.Children 6 to 11 years of ageDupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO), who are inadequately controlled with medium to high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment.Chronic rhinosinusitis with nasal polyposis (CRSwNP)Dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control.Prurigo Nodularis (PN)Dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (PN) who are candidates for systemic therapy.Eosinophilic esophagitis (EoE)Dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.|[PMDA] A drug with a new active ingredient indicated for the treatment of atopic dermatitis in patients who have not responded sufficiently to conventional treatments. uuid:1510811a-d616-4881-accf-0afa54384c10 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:420K487FSG biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:dc07a017-ff89-4f38-ab82-e8199a55b2a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:70acb2ab-f14b-4f17-a9c4-2b73bfaffc43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:ab986432-4489-4c80-be49-8b4c59803daa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/dupixent""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] DUPIXENT is an interleukin-4 receptor alpha antagonist indicated: Atopic Dermatitis for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids. ( 1.1 ) Asthma as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma. ( 1.2 ) Limitations of Use: Not for the relief of acute bronchospasm or status asthmaticus. ( 1.2 ) Chronic Rhinosinusitis with Nasal Polyps as an add-on maintenance treatment in adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP). ( 1.3 ) Eosinophilic Esophagitis for the treatment of adult and pediatric patients aged 1 year and older, weighing at least 15 kg, with eosinophilic esophagitis (EoE). ( 1.4 ) Prurigo Nodularis for the treatment of adult patients with prurigo nodularis (PN). ( 1.5 ) Chronic Obstructive Pulmonary Disease as an add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. ( 1.6 ) Limitations of Use: Not for the relief of acute bronchospasm. ( 1.6 ) Chronic Spontaneous Urticaria for the treatment of adult and pediatric patients aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment. ( 1.7 ) Limitations of Use: Not indicated for other forms of urticaria. ( 1.7 ) Bullous Pemphigoid for the treatment of adult patients with bullous pemphigoid (BP). ( 1.8 )|[EMA] Atopic dermatitisAdults and adolescentsDupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.Children 6 months to 11 years of ageDupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy.AsthmaAdults and adolescentsDupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO), see section 5.1, who are inadequately controlled with high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment.Children 6 to 11 years of ageDupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO), who are inadequately controlled with medium to high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment.Chronic rhinosinusitis with nasal polyposis (CRSwNP)Dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control.Prurigo Nodularis (PN)Dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (PN) who are candidates for systemic therapy.Eosinophilic esophagitis (EoE)Dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy. uuid:78491d91-8dd6-44c2-8931-ad9553be0b01 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:420K487FSG biolink:treats EFO:1002029 PMID:41385096 "[{""id"":""uuid:aa6792ef-2993-4f84-b953-e33ca4ddf27c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0fb76dd5-2be4-40a9-90bc-828f46e1d110"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b87fb611-aabb-4fe8-acd4-770ada56176a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DUPIXENT is an interleukin-4 receptor alpha antagonist indicated: Atopic Dermatitis for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids. ( 1.1 ) Asthma as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma. ( 1.2 ) Limitations of Use: Not for the relief of acute bronchospasm or status asthmaticus. ( 1.2 ) Chronic Rhinosinusitis with Nasal Polyps as an add-on maintenance treatment in adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP). ( 1.3 ) Eosinophilic Esophagitis for the treatment of adult and pediatric patients aged 1 year and older, weighing at least 15 kg, with eosinophilic esophagitis (EoE). ( 1.4 ) Prurigo Nodularis for the treatment of adult patients with prurigo nodularis (PN). ( 1.5 ) Chronic Obstructive Pulmonary Disease as an add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. ( 1.6 ) Limitations of Use: Not for the relief of acute bronchospasm. ( 1.6 ) Chronic Spontaneous Urticaria for the treatment of adult and pediatric patients aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment. ( 1.7 ) Limitations of Use: Not indicated for other forms of urticaria. ( 1.7 ) Bullous Pemphigoid for the treatment of adult patients with bullous pemphigoid (BP). ( 1.8 )|[PMDA] A drug with a new additional indication and a new dosage for the treatment of chronic rhinosinusitis with nasal polyps (for use only in patients who have not responded sufficiently to conventional treatments). uuid:d8506891-906d-4af4-b720-4b10c080efeb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:420K487FSG biolink:treats MONDO:0005361 PMID:41385096 "[{""id"":""uuid:d2dfd7a4-743f-4c33-a4fa-bb3e4a65b099"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c803b349-7483-491f-877c-326a09630977"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:895f97ea-f5b4-4476-95b9-da7ffb3559a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/dupixent""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] DUPIXENT is an interleukin-4 receptor alpha antagonist indicated: Atopic Dermatitis for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids. ( 1.1 ) Asthma as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma. ( 1.2 ) Limitations of Use: Not for the relief of acute bronchospasm or status asthmaticus. ( 1.2 ) Chronic Rhinosinusitis with Nasal Polyps as an add-on maintenance treatment in adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP). ( 1.3 ) Eosinophilic Esophagitis for the treatment of adult and pediatric patients aged 1 year and older, weighing at least 15 kg, with eosinophilic esophagitis (EoE). ( 1.4 ) Prurigo Nodularis for the treatment of adult patients with prurigo nodularis (PN). ( 1.5 ) Chronic Obstructive Pulmonary Disease as an add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. ( 1.6 ) Limitations of Use: Not for the relief of acute bronchospasm. ( 1.6 ) Chronic Spontaneous Urticaria for the treatment of adult and pediatric patients aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment. ( 1.7 ) Limitations of Use: Not indicated for other forms of urticaria. ( 1.7 ) Bullous Pemphigoid for the treatment of adult patients with bullous pemphigoid (BP). ( 1.8 )|[EMA] Atopic dermatitisAdults and adolescentsDupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.Children 6 months to 11 years of ageDupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy.AsthmaAdults and adolescentsDupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO), see section 5.1, who are inadequately controlled with high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment.Children 6 to 11 years of ageDupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO), who are inadequately controlled with medium to high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment.Chronic rhinosinusitis with nasal polyposis (CRSwNP)Dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control.Prurigo Nodularis (PN)Dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (PN) who are candidates for systemic therapy.Eosinophilic esophagitis (EoE)Dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy. uuid:d55c4f13-11e2-4ebf-acca-61d0ed335433 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:420K487FSG biolink:treats MONDO:0026045 PMID:41385096 "[{""id"":""uuid:f8710813-524f-4f2c-85e2-3b4a6dd452e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cd84961d-015e-47e7-afc4-a8d04292c238"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:67e57313-39e0-4735-82a4-06d449dac5ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/dupixent""]},{""id"":""uuid:979dc57b-f810-4257-9d6d-3dc7c07b8817"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DUPIXENT is an interleukin-4 receptor alpha antagonist indicated: Atopic Dermatitis for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids. ( 1.1 ) Asthma as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma. ( 1.2 ) Limitations of Use: Not for the relief of acute bronchospasm or status asthmaticus. ( 1.2 ) Chronic Rhinosinusitis with Nasal Polyps as an add-on maintenance treatment in adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP). ( 1.3 ) Eosinophilic Esophagitis for the treatment of adult and pediatric patients aged 1 year and older, weighing at least 15 kg, with eosinophilic esophagitis (EoE). ( 1.4 ) Prurigo Nodularis for the treatment of adult patients with prurigo nodularis (PN). ( 1.5 ) Chronic Obstructive Pulmonary Disease as an add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. ( 1.6 ) Limitations of Use: Not for the relief of acute bronchospasm. ( 1.6 ) Chronic Spontaneous Urticaria for the treatment of adult and pediatric patients aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment. ( 1.7 ) Limitations of Use: Not indicated for other forms of urticaria. ( 1.7 ) Bullous Pemphigoid for the treatment of adult patients with bullous pemphigoid (BP). ( 1.8 )|[EMA] Atopic dermatitisAdults and adolescentsDupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.Children 6 months to 11 years of ageDupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy.AsthmaAdults and adolescentsDupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO), see section 5.1, who are inadequately controlled with high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment.Children 6 to 11 years of ageDupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO), who are inadequately controlled with medium to high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment.Chronic rhinosinusitis with nasal polyposis (CRSwNP)Dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control.Prurigo Nodularis (PN)Dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (PN) who are candidates for systemic therapy.Eosinophilic esophagitis (EoE)Dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy.|[PMDA] Drugs with a new indication and a new dosage for the treatment of prurigo nodularis in patients who have not responded sufficiently to conventional treatments. uuid:4115649e-e24b-4a51-a10c-fbd151daaf9c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:420K487FSG biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:33e35321-06b6-48a0-a77f-0b668ccb93d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:8d04afdc-cc7d-4507-91e4-2c081b403955"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DUPIXENT is an interleukin-4 receptor alpha antagonist indicated: Atopic Dermatitis for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids. ( 1.1 ) Asthma as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma. ( 1.2 ) Limitations of Use: Not for the relief of acute bronchospasm or status asthmaticus. ( 1.2 ) Chronic Rhinosinusitis with Nasal Polyps as an add-on maintenance treatment in adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP). ( 1.3 ) Eosinophilic Esophagitis for the treatment of adult and pediatric patients aged 1 year and older, weighing at least 15 kg, with eosinophilic esophagitis (EoE). ( 1.4 ) Prurigo Nodularis for the treatment of adult patients with prurigo nodularis (PN). ( 1.5 ) Chronic Obstructive Pulmonary Disease as an add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. ( 1.6 ) Limitations of Use: Not for the relief of acute bronchospasm. ( 1.6 ) Chronic Spontaneous Urticaria for the treatment of adult and pediatric patients aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment. ( 1.7 ) Limitations of Use: Not indicated for other forms of urticaria. ( 1.7 ) Bullous Pemphigoid for the treatment of adult patients with bullous pemphigoid (BP). ( 1.8 ) uuid:c3d683f3-55f5-489a-b70d-1c0e37ffcfdf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:420K487FSG biolink:treats MONDO:0044212 PMID:41385096 "[{""id"":""uuid:82110c06-570e-4f0d-9951-de4e4d51e466"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5e7ba4b1-70f3-4754-afb5-54d3728fe162"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:76939755-0ba2-43fc-9ddc-9befa66d9816"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DUPIXENT is an interleukin-4 receptor alpha antagonist indicated: Atopic Dermatitis for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids. ( 1.1 ) Asthma as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma. ( 1.2 ) Limitations of Use: Not for the relief of acute bronchospasm or status asthmaticus. ( 1.2 ) Chronic Rhinosinusitis with Nasal Polyps as an add-on maintenance treatment in adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP). ( 1.3 ) Eosinophilic Esophagitis for the treatment of adult and pediatric patients aged 1 year and older, weighing at least 15 kg, with eosinophilic esophagitis (EoE). ( 1.4 ) Prurigo Nodularis for the treatment of adult patients with prurigo nodularis (PN). ( 1.5 ) Chronic Obstructive Pulmonary Disease as an add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. ( 1.6 ) Limitations of Use: Not for the relief of acute bronchospasm. ( 1.6 ) Chronic Spontaneous Urticaria for the treatment of adult and pediatric patients aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment. ( 1.7 ) Limitations of Use: Not indicated for other forms of urticaria. ( 1.7 ) Bullous Pemphigoid for the treatment of adult patients with bullous pemphigoid (BP). ( 1.8 )|[PMDA] Drugs with a new indication and a new dosage for the treatment of chronic spontaneous urticaria in patients who have not responded sufficiently to conventional treatments. uuid:927c90ec-1efb-41fb-9f10-8bf8d3e7a3de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:420K487FSG biolink:treats MONDO:0019082 PMID:41385096 "[{""id"":""uuid:eda82935-bf6b-4272-89b3-a6a97d7dbf43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f01325cd-2608-45ca-928f-430dc4e4d76c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DUPIXENT is an interleukin-4 receptor alpha antagonist indicated: Atopic Dermatitis for the treatment of adult and pediatric patients aged 6 months and older with moderate-to-severe AD whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. DUPIXENT can be used with or without topical corticosteroids. ( 1.1 ) Asthma as an add-on maintenance treatment of adult and pediatric patients aged 6 years and older with moderate-to-severe asthma characterized by an eosinophilic phenotype or with oral corticosteroid dependent asthma. ( 1.2 ) Limitations of Use: Not for the relief of acute bronchospasm or status asthmaticus. ( 1.2 ) Chronic Rhinosinusitis with Nasal Polyps as an add-on maintenance treatment in adult and pediatric patients aged 12 years and older with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP). ( 1.3 ) Eosinophilic Esophagitis for the treatment of adult and pediatric patients aged 1 year and older, weighing at least 15 kg, with eosinophilic esophagitis (EoE). ( 1.4 ) Prurigo Nodularis for the treatment of adult patients with prurigo nodularis (PN). ( 1.5 ) Chronic Obstructive Pulmonary Disease as an add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. ( 1.6 ) Limitations of Use: Not for the relief of acute bronchospasm. ( 1.6 ) Chronic Spontaneous Urticaria for the treatment of adult and pediatric patients aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite H1 antihistamine treatment. ( 1.7 ) Limitations of Use: Not indicated for other forms of urticaria. ( 1.7 ) Bullous Pemphigoid for the treatment of adult patients with bullous pemphigoid (BP). ( 1.8 ) uuid:c5d4bb51-d9b9-4d84-9607-1c0221435b11 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:R30772KCU0 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:dcc9b321-7f51-42cd-bf34-b350dea16ce7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:546fe064-575c-48e3-9c0e-085f1403c958"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d866a78b-724f-4f73-91cc-b243dfec999b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/sarclisa""]},{""id"":""uuid:1a5fab76-f502-45e7-baf6-545a0b9d8954"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SARCLISA is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy. in combination with bortezomib, lenalidomide, and dexamethasone, for the treatment of adult patients with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant (ASCT).|[EMA] Sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (MM) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (PI) and have demonstrated disease progression on the last therapy.in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.1).|[PMDA] Drugs with a new active ingredient indicated for the treatment of relapsed or refractory multiple myeloma. uuid:d3cb0c89-c4a9-4462-b85e-206aabf671b2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2637 biolink:treats MONDO:0005230 PMID:41385096 "[{""id"":""uuid:6daa085e-270a-4c6b-983e-ba5c46d2dfbb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:dfed9bf8-df2e-4101-88ec-dbb7bcd88e4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Amikacin Sulfate Injection USP is indicated in the short-term treatment of serious infections due to susceptible strains of Gram-negative bacteria, including Pseudomonas species, Escherichia coli , species of indole-positive and indole-negative Proteus , Providencia species, Klebsiella-Enterobacter-Serratia species, and Acinetobacter ( Mima-Herellea ) species. Clinical studies have shown Amikacin Sulfate Injection USP to be effective in bacterial septicemia (including neonatal sepsis); in serious infections of the respiratory tract, bones and joints, central nervous system (including meningitis) and skin and soft tissue; intra-abdominal infections (including peritonitis); and in burns and post-operative infections (including post-vascular surgery). Clinical studies have shown amikacin also to be effective in serious complicated and recurrent urinary tract infections due to these organisms. Aminoglycosides, including Amikacin Sulfate Injection USP are not indicated in uncomplicated initial episodes of urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Bacteriologic studies should be performed to identify causative organisms and their susceptibilities to amikacin. Amikacin may be considered as initial therapy in suspected Gram-negative infections and therapy may be instituted before obtaining the results of susceptibility testing. Clinical trials demonstrated that amikacin was effective in infections caused by gentamicin and/or tobramycin-resistant strains of Gram-negative organisms, particularly Proteus rettgeri , Providencia stuartii , Serratia marcescens , and Pseudomonas aeruginosa . The decision to continue therapy with the drug should be based on results of the susceptibility tests, the severity of the infection, the response of the patient and the important additional considerations contained in the WARNINGS box above. Amikacin has also been shown to be effective in staphylococcal infections and may be considered as initial therapy under certain conditions in the treatment of known or suspected staphylococcal disease such as, severe infections where the causative organism may be either a Gram-negative bacterium or a staphylococcus, infections due to susceptible strains of staphylococci in patients allergic to other antibiotics, and in mixed staphylococci/Gram-negative infections. In certain severe infections such as neonatal sepsis, concomitant therapy with a penicillin-type drug may be indicated because of the possibility of infections due to Gram-positive organisms such as streptococci or pneumococci. To reduce the development of drug-resistant bacteria and maintain the effectiveness of amikacin and other antibacterial drugs, amikacin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. uuid:a4126dac-24ad-463c-8ca2-7c20d4e0ab2a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2055806 biolink:treats MONDO:0004951 PMID:41385096 "[{""id"":""uuid:fb007886-d3ee-46f6-bdfb-aa9ca86dc804"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:700d2d74-3ce0-4a7e-b98d-15cf5eb0ab25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DELSTRIGO ® is indicated as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 35 kg: with no prior antiretroviral treatment history, OR to replace the current antiretroviral regimen in those who are virologically-suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of DELSTRIGO [see Clinical Studies (14) ] . uuid:1db5d03f-295c-4065-9c0b-e35743b13378 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:81579 biolink:treats MONDO:0020725 PMID:41385096 "[{""id"":""uuid:abfe2b59-187d-4ee8-bb80-18994aa0e781"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:2daa2eeb-3333-4eb0-b87b-7b2a0fa1fcbb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] RETACRIT is an erythropoiesis-stimulating agent (ESA) indicated for: • Treatment of anemia due to o Chronic Kidney Disease (CKD) in patients on dialysis and not on dialysis ( 1.1 ). o Zidovudine in patients with Human Immunodeficiency Virus (HIV) infection ( 1.2 ). o The effects of concomitant myelosuppressive chemotherapy, and upon initiation, there is a minimum of two additional months of planned chemotherapy ( 1.3 ). • Reduction of allogeneic red blood cell (RBC) transfusions in patients undergoing elective, noncardiac, nonvascular surgery ( 1.4 ). Limitations of Use RETACRIT has not been shown to improve quality of life, fatigue, or patient well-being ( 1.5 ). RETACRIT is not indicated for use: • In patients with cancer receiving hormonal agents, biologic products, or radiotherapy, unless also receiving concomitant myelosuppressive chemotherapy ( 1.5 ). • In patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure ( 1.5 ). • In patients with cancer receiving myelosuppressive chemotherapy in whom the anemia can be managed by transfusion ( 1.5 ). • In patients scheduled for surgery who are willing to donate autologous blood ( 1.5 ). • In patients undergoing cardiac or vascular surgery ( 1.5 ). • As a substitute for RBC transfusions in patients who require immediate correction of anemia ( 1.5 ). uuid:23cceee6-9068-4119-9f2b-a1edc60317e4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:90ZX3Q3FR7 biolink:treats UMLS:C0406317 PMID:41385096 "[{""id"":""uuid:93f0e778-ec56-448c-8b80-901f4a457692"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:27e1a4b7-dc09-41e0-ad59-644f125f14f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f39f1bd3-a706-4a06-bf6a-904f77cab5aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SKYRIZI is an interleukin-23 antagonist indicated for the treatment of: moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. ( 1.1 ) active psoriatic arthritis in adults. ( 1.2 ) moderately to severely active Crohn's disease in adults. ( 1.3 ) moderately to severely active ulcerative colitis in adults. ( 1.4 )|[PMDA] A drug with a new active ingredient indicated for the treatment of plaque psoriasis, psoriatic arthritis, pustular psoriasis and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies. uuid:88ec3b92-5710-44fe-b916-9a579f050dad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:90ZX3Q3FR7 biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:8322eb49-9c7b-4567-9d09-c2f0c1081446"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b0661467-0a1a-4f44-8d57-9e555b3417f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:3a1e73aa-19f8-4187-bcd2-33ae57f394f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/skyrizi""]},{""id"":""uuid:51820c2f-8cd7-4353-807d-c5859f9ea60d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SKYRIZI is an interleukin-23 antagonist indicated for the treatment of: moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. ( 1.1 ) active psoriatic arthritis in adults. ( 1.2 ) moderately to severely active Crohn's disease in adults. ( 1.3 ) moderately to severely active ulcerative colitis in adults. ( 1.4 )|[EMA] Plaque PsoriasisSkyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.Psoriatic ArthritisSkyrizi, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).Crohn's diseaseSkyrizi is indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy.|[PMDA] A drug with a new active ingredient indicated for the treatment of plaque psoriasis, psoriatic arthritis, pustular psoriasis and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies. uuid:e320d576-ecfd-417e-8079-a973720ce681 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:90ZX3Q3FR7 biolink:treats MONDO:0005011 PMID:41385096 "[{""id"":""uuid:ff8c86fd-a53d-4417-85a2-53730946763e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6b01c63e-f50b-46ee-9cb5-664df863df28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:b963a8a4-e176-4a9b-b92f-38249e2373f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/skyrizi""]}]" infores:medic knowledge_assertion text_mining_agent [FDA] SKYRIZI is an interleukin-23 antagonist indicated for the treatment of: moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. ( 1.1 ) active psoriatic arthritis in adults. ( 1.2 ) moderately to severely active Crohn's disease in adults. ( 1.3 ) moderately to severely active ulcerative colitis in adults. ( 1.4 )|[EMA] Plaque PsoriasisSkyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.Psoriatic ArthritisSkyrizi, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).Crohn's diseaseSkyrizi is indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy. uuid:a49bdd72-de09-436e-992d-07307a7f132d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:90ZX3Q3FR7 biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:8a0aa7c5-d31f-41b8-80dc-9f1d8e28f57a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:af06d876-f7f5-4109-8804-d4fe1a61a64b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] SKYRIZI is an interleukin-23 antagonist indicated for the treatment of: moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. ( 1.1 ) active psoriatic arthritis in adults. ( 1.2 ) moderately to severely active Crohn's disease in adults. ( 1.3 ) moderately to severely active ulcerative colitis in adults. ( 1.4 ) uuid:bbb2a75c-83e4-4984-b483-89f0c581d098 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135351 biolink:treats MONDO:0005180 PMID:41385096 "[{""id"":""uuid:da83579f-fe97-4ed3-908f-fa8334dacdef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:35a96a4f-3230-43df-8e23-5d7fea440b7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f99f3586-5efc-4c76-aa56-d3e3c13bfec7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/leganto""]},{""id"":""uuid:5fbe5977-f2ca-4c79-a46e-4419eb3771f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NEUPRO is a dopamine agonist indicated for the treatment of: Parkinson's disease ( 1.1 ) Moderate-to-severe primary Restless Legs Syndrome ( 1.2 )|[EMA] Parkinson's disease: Neupro is indicated for the treatment of the signs and symptoms of early-stage idiopathic Parkinson's disease as monotherapy (i.e. without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or 'on-off' fluctuations).Restless-legs syndrome: Neupro is indicated for the symptomatic treatment of moderate to severe idiopathic restless-legs syndrome in adults.|[PMDA] [2] Drugs with a new active ingredient indicated for the treatment of Parkinson's disease and moderate to severe idiopathic restless legs syndrome. [3] [4] Drugs with a new active ingredient indicated for the treatment of Parkinson's disease. uuid:313636ef-a9dd-4c85-b751-899e2983c771 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135351 biolink:treats MONDO:0005391 PMID:41385096 "[{""id"":""uuid:2eacffd8-6b07-43f3-b914-5d2be543f904"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:579f966d-3e60-47a3-aca5-3796c72949d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e59a8722-c0d0-4963-bdb4-b2055dc620a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/leganto""]},{""id"":""uuid:b8d4aa63-11d3-4107-9d9d-d4387c709900"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NEUPRO is a dopamine agonist indicated for the treatment of: Parkinson's disease ( 1.1 ) Moderate-to-severe primary Restless Legs Syndrome ( 1.2 )|[EMA] Parkinson's disease: Neupro is indicated for the treatment of the signs and symptoms of early-stage idiopathic Parkinson's disease as monotherapy (i.e. without levodopa) or in combination with levodopa, i.e. over the course of the disease, through to late stages when the effect of levodopa wears off or becomes inconsistent and fluctuations of the therapeutic effect occur (end of dose or 'on-off' fluctuations).Restless-legs syndrome: Neupro is indicated for the symptomatic treatment of moderate to severe idiopathic restless-legs syndrome in adults.|[PMDA] [2] Drugs with a new active ingredient indicated for the treatment of Parkinson's disease and moderate to severe idiopathic restless legs syndrome. [3] [4] Drugs with a new active ingredient indicated for the treatment of Parkinson's disease. uuid:a0d5315c-2298-41b4-9cad-c461a69bc9fc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:25187 biolink:treats MONDO:0005984 PMID:41385096 "[{""id"":""uuid:93b877e7-4288-4617-876f-951fbef8de22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:0f8d308c-847e-4570-919a-d215eee16b00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clotrimazole and Betamethasone Dipropionate Cream is a combination of an azole antifungal and corticosteroid and is indicated for the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris, and tinea corporis due to Epidermophyton floccosum , Trichophyton mentagrophytes , and Trichophyton rubrum in patients 17 years and older. uuid:13d649d6-3869-4d14-9115-e2aacb8d540f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:25187 biolink:treats MONDO:0001405 PMID:41385096 "[{""id"":""uuid:a138db45-002d-46de-af9f-9ca749d21652"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:52df29df-8d57-4b56-8a99-00d828c45952"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clotrimazole and Betamethasone Dipropionate Cream is a combination of an azole antifungal and corticosteroid and is indicated for the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris, and tinea corporis due to Epidermophyton floccosum , Trichophyton mentagrophytes , and Trichophyton rubrum in patients 17 years and older. uuid:13bb66ae-7f69-4477-ba25-932b7ba1c3a1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:25187 biolink:treats MONDO:0001461 PMID:41385096 "[{""id"":""uuid:9b5b0129-512c-42b8-9de1-43760e637bf3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:ddf78f93-7d23-4285-81a1-feb9e6b34ee6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Clotrimazole and Betamethasone Dipropionate Cream is a combination of an azole antifungal and corticosteroid and is indicated for the topical treatment of symptomatic inflammatory tinea pedis, tinea cruris, and tinea corporis due to Epidermophyton floccosum , Trichophyton mentagrophytes , and Trichophyton rubrum in patients 17 years and older. uuid:edfa4039-be2f-4274-8d97-5d2946a636d0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:0CA0VSF91Y biolink:treats MONDO:0005340 PMID:41385096 "[{""id"":""uuid:8d8702d0-69e8-42a4-a6cd-06746230ac8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:90405977-5d0f-4c20-a4c7-e7bbc06de148"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] LEQSELVI™ is indicated for the treatment of adult patients with severe alopecia areata. Limitations of Use LEQSELVI is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine, or other potent immunosuppressants. uuid:9167e4e0-183f-4202-b47f-83e4ff2600b1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6741 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:9c4b5d96-e52b-4d8f-9af8-4ab4e3eb77da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:6e4b31bc-43c3-4e91-a134-e74d6bcaac17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] XIFYRM is indicated for use in adults for the management of moderate-to-severe pain, alone or in combination with non-NSAID analgesics. Limitation of Use Because of delayed onset of analgesia, XIFYRM alone is not recommended for use when rapid onset of analgesia is required. uuid:6bd8c3e3-7547-4730-9f93-aea03608913a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5670521 biolink:treats MONDO:0001577 PMID:41385096 "[{""id"":""uuid:33468a53-2dca-4867-9382-d9914cf32807"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:436b5686-e69b-4339-b633-4cbbcbfecf22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ENFLONSIA is indicated for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates and infants who are born during or entering their first RSV season. DRUGBANK:DB18877 uuid:cfebb2c8-004e-44b3-a699-19bc56eb7411 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:65347 biolink:treats UMLS:C5577628 PMID:41385096 "[{""id"":""uuid:79959a5b-cf91-4d99-9ecb-3f6a5c843591"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:74366534-d6c4-452d-b187-cd6380bef990"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Kyprolis is a proteasome inhibitor that is indicated: for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with Lenalidomide and dexamethasone; or Dexamethasone; or Daratumumab and dexamethasone; or Daratumumab and hyaluronidase-fihj and dexamethasone; or Isatuximab and dexamethasone. ( 1 , 14 ) as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy. ( 1 , 14 ) uuid:e567830f-5ac4-4ec4-a659-aeeabbaf43f6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:65347 biolink:treats UMLS:C4551538 PMID:41385096 "[{""id"":""uuid:e247b8d3-d464-439a-b666-73c347412616"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:a7c9b9b5-5986-45be-b21c-8717bd38633a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Kyprolis is a proteasome inhibitor that is indicated: for the treatment of adult patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy in combination with Lenalidomide and dexamethasone; or Dexamethasone; or Daratumumab and dexamethasone; or Daratumumab and hyaluronidase-fihj and dexamethasone; or Isatuximab and dexamethasone. ( 1 , 14 ) as a single agent for the treatment of patients with relapsed or refractory multiple myeloma who have received one or more lines of therapy. ( 1 , 14 ) uuid:7554ce2f-05e6-42c3-a1ee-b0615224c7ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2682677 biolink:treats MONDO:0004200 PMID:41385096 "[{""id"":""uuid:a6b9e2cb-5662-41c1-a92b-0ea3bdbc36d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:e0585d66-de68-4e1d-836f-2a38be313cad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ANKTIVA in combination with Bacillus Calmette-Guérin (BCG) is indicated for the treatment of adult patients with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. uuid:82d43330-cda5-4f44-a7b6-6f596e1f4c70 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2682677 biolink:treats MONDO:0004641 PMID:41385096 "[{""id"":""uuid:4876cbce-e459-4f42-be57-88cf659aaa40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:083d6178-d970-4232-bab0-470c5f0ce94e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] ANKTIVA in combination with Bacillus Calmette-Guérin (BCG) is indicated for the treatment of adult patients with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. uuid:73de361c-118c-46df-b363-85d2274c17b7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:90Z2UF0E52 biolink:treats UMLS:C0581126 PMID:41385096 "[{""id"":""uuid:fb2e6d31-a575-451e-8859-d2ee62a0ea95"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7a6746b1-73f4-4f17-8e63-b9a17733d887"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NUCALA is an interleukin-5 (IL-5) antagonist monoclonal antibody (IgG1 kappa) indicated for: • Add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma and with an eosinophilic phenotype. ( 1.1 ) • Add-on maintenance treatment of adult patients aged 18 years and older with chronic rhinosinusitis with nasal polyps (CRSwNP). ( 1.2 ) • Add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. ( 1.3 ) • The treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). ( 1.4 ) • The treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for greater than or equal to 6 months without an identifiable non-hematologic secondary cause. ( 1.5 ) Limitations of use: Not for relief of acute bronchospasm or status asthmaticus. ( 1.1 , 1.3 ) uuid:3e25fec9-4c09-4d3e-ac1d-e5d4a089ab30 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:90Z2UF0E52 biolink:treats EFO:1002029 PMID:41385096 "[{""id"":""uuid:da6d38a6-dff5-4a5a-8c5c-1ec977d88bbb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:45caa14a-0b6b-4da7-aa20-d30f5999d9a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NUCALA is an interleukin-5 (IL-5) antagonist monoclonal antibody (IgG1 kappa) indicated for: • Add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma and with an eosinophilic phenotype. ( 1.1 ) • Add-on maintenance treatment of adult patients aged 18 years and older with chronic rhinosinusitis with nasal polyps (CRSwNP). ( 1.2 ) • Add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. ( 1.3 ) • The treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). ( 1.4 ) • The treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for greater than or equal to 6 months without an identifiable non-hematologic secondary cause. ( 1.5 ) Limitations of use: Not for relief of acute bronchospasm or status asthmaticus. ( 1.1 , 1.3 ) uuid:a38fedcd-4746-4f79-86bd-0c8123403e81 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:90Z2UF0E52 biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:882c35b8-6191-484e-84ce-9e008d06cb5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:1b7bf8d1-5b4c-4ff0-af8a-b78b69445cf7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NUCALA is an interleukin-5 (IL-5) antagonist monoclonal antibody (IgG1 kappa) indicated for: • Add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma and with an eosinophilic phenotype. ( 1.1 ) • Add-on maintenance treatment of adult patients aged 18 years and older with chronic rhinosinusitis with nasal polyps (CRSwNP). ( 1.2 ) • Add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. ( 1.3 ) • The treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). ( 1.4 ) • The treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for greater than or equal to 6 months without an identifiable non-hematologic secondary cause. ( 1.5 ) Limitations of use: Not for relief of acute bronchospasm or status asthmaticus. ( 1.1 , 1.3 ) uuid:006d546e-a02f-4fd7-a2ad-dfd2bb9e689b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:90Z2UF0E52 biolink:treats MONDO:0015943 PMID:41385096 "[{""id"":""uuid:94d3a85e-8d9b-484a-bcb3-2ed33e3e109a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed"",""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d6b14fef-a87a-49f9-b884-a64c648b7462"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:49f9a816-0d9f-44c0-8c42-a784c87a315b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/nucala""]},{""id"":""uuid:011fd30f-e7d3-4c10-9183-94ac399e4a13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NUCALA is an interleukin-5 (IL-5) antagonist monoclonal antibody (IgG1 kappa) indicated for: • Add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma and with an eosinophilic phenotype. ( 1.1 ) • Add-on maintenance treatment of adult patients aged 18 years and older with chronic rhinosinusitis with nasal polyps (CRSwNP). ( 1.2 ) • Add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. ( 1.3 ) • The treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). ( 1.4 ) • The treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for greater than or equal to 6 months without an identifiable non-hematologic secondary cause. ( 1.5 ) Limitations of use: Not for relief of acute bronchospasm or status asthmaticus. ( 1.1 , 1.3 )|[EMA] Severe eosinophilic asthmaNucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older .Chronic rhinosinusitis with nasal polyps (CRSwNP)Nucala is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate control.Eosinophilic granulomatosis with polyangiitis (EGPA)Nucala is indicated as an add-on treatment for patients aged 6 years and older with relapsing-remitting or refractory eosinophilic granulomatosis with polyangiitis (EGPA).Hypereosinophilic syndrome (HES)Nucala is indicated as an add-on treatment for adult patients with inadequately controlled hypereosinophilic syndrome without an identifiable non-haematologic secondary cause.|[PMDA] A drug with a new additional indication and a new dosage for the treatment of eosinophilic granulomatosis with polyangiitis in patients who have not responded sufficiently to conventional treatments. [Orphan drug] uuid:fc92f7c4-3c1b-47a6-be2b-4a0bd4e9e41e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:90Z2UF0E52 biolink:treats MONDO:0011895 PMID:41385096 "[{""id"":""uuid:7146f6be-08d0-4589-a2c6-b1e5e1a1bbdf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:4e69740d-b6b7-4fc8-aa75-ebe243bf1c4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] NUCALA is an interleukin-5 (IL-5) antagonist monoclonal antibody (IgG1 kappa) indicated for: • Add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma and with an eosinophilic phenotype. ( 1.1 ) • Add-on maintenance treatment of adult patients aged 18 years and older with chronic rhinosinusitis with nasal polyps (CRSwNP). ( 1.2 ) • Add-on maintenance treatment of adult patients with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype. ( 1.3 ) • The treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA). ( 1.4 ) • The treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for greater than or equal to 6 months without an identifiable non-hematologic secondary cause. ( 1.5 ) Limitations of use: Not for relief of acute bronchospasm or status asthmaticus. ( 1.1 , 1.3 ) uuid:8618c488-0518-4cca-8ef6-9964c1e2cab0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB16410 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:bfd95b76-6188-4d01-ab92-289ba24fd5b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:95968aa1-bb0b-41f2-8957-a68d6ea9ccb4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DATROWAY is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of: adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy. ( 1.1 ) This indication is approved under accelerated approval based on objective response rate and duration of response [see Clinical Studies (14.1) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. adult patients with unresectable or metastatic, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. ( 1.2 ) uuid:1507423c-a5fd-4fbd-8426-1f9d353ace81 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB16410 biolink:treats MONDO:0700079 PMID:41385096 "[{""id"":""uuid:91da744c-49dd-4727-9302-b1a3883cc871"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:f137e788-06ad-4944-b07f-a6b12158782b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] DATROWAY is a Trop-2-directed antibody and topoisomerase inhibitor conjugate indicated for the treatment of: adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) who have received prior EGFR-directed therapy and platinum-based chemotherapy. ( 1.1 ) This indication is approved under accelerated approval based on objective response rate and duration of response [see Clinical Studies (14.1) ] . Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial. adult patients with unresectable or metastatic, hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who have received prior endocrine-based therapy and chemotherapy for unresectable or metastatic disease. ( 1.2 ) uuid:5f6b5298-53f7-4db9-ac4a-132cdeec742f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4875 biolink:treats MONDO:0019436 PMID:41385096 "[{""id"":""uuid:7a262a66-5c63-43e3-a29d-c878a473ce37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:9e4cafdc-6064-4ea9-89c3-a8d49bbb14fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Enbrel is a tumor necrosis factor (TNF) blocker indicated for the treatment of: Adult patients with: Rheumatoid Arthritis (RA) ( 1.1 ) Psoriatic Arthritis (PsA) ( 1.3 ) Ankylosing Spondylitis (AS) ( 1.4 ) Plaque Psoriasis (PsO) ( 1.5 ) Pediatric patients with: Polyarticular Juvenile Idiopathic Arthritis (pJIA), 2 years of age or older ( 1.2 ) Juvenile Psoriatic Arthritis, 2 years of age or older (JPsA) ( 1.6 ) Plaque Psoriasis, 4 years of age or older ( 1.5 ) uuid:53934872-06c9-4f29-9a7e-8ec5701747b4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:122173976 biolink:treats MONDO:0002076 PMID:41385096 "[{""id"":""uuid:fc7e3918-a64f-43c0-89a2-cf8eec62e33e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:7630bba2-5fb9-489f-816a-38f4c78f3bf4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] 1.INDICATIONS AND USAGE 1.1 Malignant Pleural Effusion STERITALC is indicated to decrease the recurrence of malignant pleural effusions in symptomatic patients following maximal drainage of the pleural effusion. 1.2 Pneumothorax STERITALC is indicated in adults to decrease the recurrence of pneumothorax. uuid:f4f2ebc3-e2b6-40ae-94ba-986dc51d8b42 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:18050 biolink:treats MONDO:0005632 PMID:41385096 "[{""id"":""uuid:f5e89514-3c43-4bba-b19e-e62dda0a484d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:dailymed""],""source_record_urls"":null},{""id"":""uuid:409a6e90-c87e-4e8e-b5b8-957a13b2b6d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:dailymed"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [FDA] Endari is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older. uuid:6e6ab49f-f1ab-4562-b98f-388921e09583 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2556801 biolink:treats MONDO:0007886 PMID:41385096 "[{""id"":""uuid:4ca904ae-acf3-485f-98c6-1c58e453564d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:41840b5b-4e1d-4888-b1fa-b2d05401c10e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ryeqo""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ryeqo is indicated in adult women of reproductive age for:- treatment of moderate to severe symptoms of uterine fibroids,- symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis. uuid:3b445282-a4aa-483b-b000-bc24f1ed6d47 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2556801 biolink:treats MONDO:0005133 PMID:41385096 "[{""id"":""uuid:f1c61edd-70cf-4c73-9fa4-81b48d6df8f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b2165fa6-9e92-45ea-9f3b-73ee90ee4ee8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ryeqo""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ryeqo is indicated in adult women of reproductive age for:- treatment of moderate to severe symptoms of uterine fibroids,- symptomatic treatment of endometriosis in women with a history of previous medical or surgical treatment for their endometriosis. uuid:988ddc82-7714-4a28-8cfb-e69d25a0fbff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:15C2VL427D biolink:treats MONDO:0006951 PMID:41385096 "[{""id"":""uuid:ad60686d-09d5-4b34-b7eb-7bc847be3b8e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:592443af-6b95-423e-be5f-fafb7f137144"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/yesafili""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Yesafili is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (AMD) (see section 5.1),visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) (see section 5.1),visual impairment due to diabetic macular oedema (DME) (see section 5.1),visual impairment due to myopic choroidal neovascularisation (myopic CNV) (see section 5.1). uuid:d09e0d42-ce44-483c-ac44-df007d11b46c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:15C2VL427D biolink:treats MONDO:0810000 PMID:41385096 "[{""id"":""uuid:90f6359a-94d4-43da-adeb-38ae9a3006ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0f4e3834-08c8-4847-b570-9612e09535dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/yesafili""]},{""id"":""uuid:b2d5c68f-2310-47d1-aba7-118069f3c174"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Yesafili is indicated for adults for the treatment ofneovascular (wet) age-related macular degeneration (AMD) (see section 5.1),visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO) (see section 5.1),visual impairment due to diabetic macular oedema (DME) (see section 5.1),visual impairment due to myopic choroidal neovascularisation (myopic CNV) (see section 5.1).|[PMDA] Drugs with a new additional indication for the treatment of choroidal neovascularization in patients with pathologic myopia. uuid:c4245246-f452-48e0-aa24-dc90ed623c03 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PVI5M0M1GW biolink:treats MONDO:0011996 PMID:41385096 "[{""id"":""uuid:8f1deb7c-1e50-41fe-838a-65da996e0bbe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4281e430-d2b9-43d4-9cea-9a935ea95ccc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/filgrastim-hexal""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone-marrow transplantation considered to be at increased risk of prolonged severe neutropenia.The safety and efficacy of filgrastim are similar in adults and children receiving cytotoxic chemotherapy.Mobilisation of peripheral blood progenitor cells (PBPCs).In children and adults with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of of ≤ 0.5 x 109/l, and a history of severe or recurrent infections, long-term administration of filgrastim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.Treatment of persistent neutropenia (ANC ≤ 0.5 x 109/l), and a history of severe or recurrent infections, long-term administration of filgrastim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other therapeutic options are inappropriate. uuid:c4053b3f-6908-42ca-8add-b5201d4f919e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PVI5M0M1GW biolink:treats MONDO:0018881 PMID:41385096 "[{""id"":""uuid:c4f4a14c-1805-4831-969f-b29283e6a47e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9ba525b4-ba89-49dd-acda-94b9ecd11b7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/filgrastim-hexal""]},{""id"":""uuid:05a89b8a-53e5-472e-983e-01f84d921ba6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone-marrow transplantation considered to be at increased risk of prolonged severe neutropenia.The safety and efficacy of filgrastim are similar in adults and children receiving cytotoxic chemotherapy.Mobilisation of peripheral blood progenitor cells (PBPCs).In children and adults with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of of ≤ 0.5 x 109/l, and a history of severe or recurrent infections, long-term administration of filgrastim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.Treatment of persistent neutropenia (ANC ≤ 0.5 x 109/l), and a history of severe or recurrent infections, long-term administration of filgrastim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other therapeutic options are inappropriate.|[PMDA] Follow-on biologics indicated for mobilization of hematopoietic stem cell to peripheral blood, promotion of increase in neutrophil count at the time of hematopoietic stem cell transplantation, and the treatment of neutropenia caused by cancer chemotherapy, neutropenia which affects the treatment of human immunodeficiency virus (HIV) infection, neutropenia associated with myelodysplastic syndrome, neutropenia associated with aplastic anemia and congenital/idiopathic neutropenia. uuid:99701f01-c0d6-46ad-8eb2-0445420944b0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PVI5M0M1GW biolink:treats MONDO:0011922 PMID:41385096 "[{""id"":""uuid:f8c0e41b-dd58-4ade-93b5-81eafc54398e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:60d4179a-dba8-4541-a265-894cbf69ee4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/filgrastim-hexal""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone-marrow transplantation considered to be at increased risk of prolonged severe neutropenia.The safety and efficacy of filgrastim are similar in adults and children receiving cytotoxic chemotherapy.Mobilisation of peripheral blood progenitor cells (PBPCs).In children and adults with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of of ≤ 0.5 x 109/l, and a history of severe or recurrent infections, long-term administration of filgrastim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.Treatment of persistent neutropenia (ANC ≤ 0.5 x 109/l), and a history of severe or recurrent infections, long-term administration of filgrastim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other therapeutic options are inappropriate. uuid:633c1474-575c-4c92-9a4a-e4711c60ce47 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PVI5M0M1GW biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:88e32c55-c99a-46f6-9de0-dc6fbf3bd441"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e2d54594-b16d-4d39-b01e-2b10123dea16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/filgrastim-hexal""]},{""id"":""uuid:6cf2f893-e1ae-4b4a-b027-f5ca25b18a09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone-marrow transplantation considered to be at increased risk of prolonged severe neutropenia.The safety and efficacy of filgrastim are similar in adults and children receiving cytotoxic chemotherapy.Mobilisation of peripheral blood progenitor cells (PBPCs).In children and adults with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of of ≤ 0.5 x 109/l, and a history of severe or recurrent infections, long-term administration of filgrastim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.Treatment of persistent neutropenia (ANC ≤ 0.5 x 109/l), and a history of severe or recurrent infections, long-term administration of filgrastim is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other therapeutic options are inappropriate.|[PMDA] Follow-on biologics indicated for mobilization of hematopoietic stem cell to peripheral blood, promotion of increase in neutrophil count at the time of hematopoietic stem cell transplantation, and the treatment of neutropenia caused by cancer chemotherapy, neutropenia which affects the treatment of human immunodeficiency virus (HIV) infection, neutropenia associated with myelodysplastic syndrome, neutropenia associated with aplastic anemia and congenital/idiopathic neutropenia. uuid:bcf72879-e2f7-4938-abce-2e8f958410ea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:66917 biolink:treats MONDO:0008661 PMID:41385096 "[{""id"":""uuid:021301f9-760c-42be-95bb-12d130e2ba4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:63a961ee-588d-4351-bfef-c9f80788a0cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Opzelura is indicated for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. uuid:f651651e-b1ea-480c-aaaa-f877f8a24aa2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3A58010674 biolink:treats MONDO:0001475 PMID:41385096 "[{""id"":""uuid:c256138e-2e30-42de-af4e-1b83b507d499"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d8368bb3-1737-4e18-9111-3c72bfbb5960"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ziextenzo""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Reduction in the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes). uuid:a9dca423-6597-4d15-a6f4-f64538bce76a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3374 biolink:treats MONDO:0021667 PMID:41385096 "[{""id"":""uuid:af9c321f-a52f-4f77-98d2-0617bfa018cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:72318af2-2ecd-4039-969b-6c345e44212d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/qutenza""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Qutenza is indicated for the treatment of peripheral neuropathic pain in adults either alone or in combination with other medicinal products for pain. uuid:a7075518-f5fa-4f29-8135-191341c65bc5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3759 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:881e8c9a-e59d-4853-b116-e8bfd95dba14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:1c4d134d-7a05-4a5a-af38-f7bd42e9c310"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Clopidogrel is indicated in adults for the prevention of atherothrombotic events in:Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. uuid:b6bc38c8-a14c-416f-8ce8-2054cdc45fcf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3759 biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:3a2d414b-32b0-4da4-935b-92e4bb49b11f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:abcdd5ec-cd9e-42c1-a7c7-f517bf0542af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Clopidogrel is indicated in adults for the prevention of atherothrombotic events in:Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. uuid:7f0b04be-7ec9-4741-8948-db93f5868f62 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3759 biolink:treats MONDO:0005386 PMID:41385096 "[{""id"":""uuid:3ffd8d9f-da75-4ccf-88f5-0b182ce58552"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5f82ca87-152b-44a9-8c43-e588bba9bc35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Clopidogrel is indicated in adults for the prevention of atherothrombotic events in:Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. uuid:014b2816-0a50-4867-aec8-df7598aafa67 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:16213489 biolink:treats MONDO:0006781 PMID:41385096 "[{""id"":""uuid:c29e0c4c-53bd-48ad-85df-cbeefb559e73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:81934a05-d7ff-4b37-b66b-e7fc49c4fbce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] This medicinal product is for diagnostic use only.For in vivo diagnosis of gastroduodenal Helicobacter pylori (H. pylori) infection. uuid:6eeda63e-705f-49f0-b031-8f86cb2a18b0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:XZA0KB1BDQ biolink:treats MONDO:0019623 PMID:41385096 "[{""id"":""uuid:ab97ffab-b279-49ce-b64e-26c8bd32e1a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:8f98846b-00c4-4de8-aa7a-9be3d132a75d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Orladeyo is indicated for routine prevention of recurrent attacks of hereditary angioedema (HAE) in adult and adolescent patients aged 12 years and older. uuid:ab56b481-05e0-4fae-952f-1580ad7a683b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:5384HK7574 biolink:treats MONDO:0001056 PMID:41385096 "[{""id"":""uuid:26e4f319-fd81-40cc-be77-590f4aa5cdc9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1f827fc0-cf72-4e01-87a0-ec21a04c00a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ogivri""]},{""id"":""uuid:30099004-281f-48f8-9211-889c8000acc9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Breast cancerMetastatic breast cancerOgivri is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC):as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. Prior chemotherapy must have included at least an anthracycline and a taxane unless patients are unsuitable for these treatments. Hormone receptor positive patients must also have failed hormonal therapy, unless patients are unsuitable for these treatmentsin combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitablein combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic diseasein combination with an aromatase inhibitor for the treatment of postmenopausal patients with hormone-receptor positive MBC, not previously treated with trastuzumab.Early breast cancer Ogivri is indicated for the treatment of adult patients with HER2 positive early breast cancer (EBC):following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable)following adjuvant chemotherapy with doxorubicin and cyclophosphamide, in combination with paclitaxel or docetaxelin combination with adjuvant chemotherapy consisting of docetaxel and carboplatin.in combination with neoadjuvant chemotherapy followed by adjuvant Ogivri therapy, for locally advanced (including inflammatory) disease or tumours > 2 cm in diameter.Ogivri should only be used in patients with metastatic or EBC whose tumours have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.Metastatic gastric cancerOgivri in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of adult patients with HER2 positive metastatic adenocarcinoma of the stomach or gastroesophageal junction who have not received prior anti-cancer treatment for their metastatic disease.Ogivri should only be used in patients with metastatic gastric cancer (MGC) whose tumours have HER2 overexpression as defined by IHC2+ and a confirmatory SISH or FISH result, or by an IHC 3+ result. Accurate and validated assay methods should be used.|[PMDA] A drug with a new indication and a new dosage for the treatment of unresectable advanced or recurrent HER2- positive gastric cancer that has progressed after cancer chemotherapy. [SAKIGAKE designation] uuid:6939a36f-980b-47d6-8fe4-2b9935064f74 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7XL5ISS668 biolink:treats MONDO:0004952 PMID:41385096 "[{""id"":""uuid:8123e3a7-a0e3-4563-8423-fd31f2df63e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f6b7c190-e3cd-4651-910d-1dbc987205af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/adcetris""]},{""id"":""uuid:7f2159e6-2a4f-4f34-92b2-6796a0aa1487"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Hodgkin lymphomaAdcetris is indicated for adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine and dacarbazine (AVD).Adcetris is indicated for the treatment of adult patients with CD30+ HL at increased risk of relapse or progression following autologous stem cell transplant (ASCT).Adcetris is indicated for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL):following ASCT, orfollowing at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option.Systemic anaplastic large cell lymphomaAdcetris in combination with cyclophosphamide, doxorubicin and prednisone (CHP) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL).Adcetris is indicated for the treatment of adult patients with relapsed or refractory sALCL.Cutaneous T cell lymphomaAdcetris is indicated for the treatment of adult patients with CD30+ cutaneous T cell lymphoma (CTCL) after at least 1 prior systemic therapy.|[PMDA] A drug with a new additional pediatric dosage indicated for the treatment of CD30-positive Hodgkin's lymphoma. [Orphan drug] uuid:915e2e04-91e5-4dca-87b9-771ba051e3d1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7XL5ISS668 biolink:treats MONDO:0020325 PMID:41385096 "[{""id"":""uuid:9ee708e2-d335-42d0-9bf4-81e9a4480ce5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c049aa67-b08f-4c02-91ed-a3afb1d49da5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/adcetris""]},{""id"":""uuid:0a1559b2-235b-4546-8a14-9557a208c875"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Hodgkin lymphomaAdcetris is indicated for adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine and dacarbazine (AVD).Adcetris is indicated for the treatment of adult patients with CD30+ HL at increased risk of relapse or progression following autologous stem cell transplant (ASCT).Adcetris is indicated for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL):following ASCT, orfollowing at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option.Systemic anaplastic large cell lymphomaAdcetris in combination with cyclophosphamide, doxorubicin and prednisone (CHP) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL).Adcetris is indicated for the treatment of adult patients with relapsed or refractory sALCL.Cutaneous T cell lymphomaAdcetris is indicated for the treatment of adult patients with CD30+ cutaneous T cell lymphoma (CTCL) after at least 1 prior systemic therapy.|[PMDA] A drug with a new active ingredient indicated for the treatment of relapsed or refractory CD30- positive Hodgkin’s lymphoma and anaplastic large- cell lymphoma. [Orphan drug] uuid:91ec0f16-4e6e-4408-b6b3-c05526763699 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7XL5ISS668 biolink:treats MONDO:0015758 PMID:41385096 "[{""id"":""uuid:509a7ee1-9e9d-4294-96b9-f79253fc38f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:8c122167-d32b-4723-8881-fbeff1d5e2c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/adcetris""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Hodgkin lymphomaAdcetris is indicated for adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma (HL) in combination with doxorubicin, vinblastine and dacarbazine (AVD).Adcetris is indicated for the treatment of adult patients with CD30+ HL at increased risk of relapse or progression following autologous stem cell transplant (ASCT).Adcetris is indicated for the treatment of adult patients with relapsed or refractory CD30+ Hodgkin lymphoma (HL):following ASCT, orfollowing at least two prior therapies when ASCT or multi-agent chemotherapy is not a treatment option.Systemic anaplastic large cell lymphomaAdcetris in combination with cyclophosphamide, doxorubicin and prednisone (CHP) is indicated for adult patients with previously untreated systemic anaplastic large cell lymphoma (sALCL).Adcetris is indicated for the treatment of adult patients with relapsed or refractory sALCL.Cutaneous T cell lymphomaAdcetris is indicated for the treatment of adult patients with CD30+ cutaneous T cell lymphoma (CTCL) after at least 1 prior systemic therapy. uuid:260ff95d-bce3-4cc2-8be1-bbe8ba0b68b5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:78540 biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:a9800daa-8c83-4b62-8783-ac37f0916d29"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:efb2c2ba-1f50-4a88-a8b5-3ce28443d129"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/otezla""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Psoriatic arthritisOtezla, alone or in combination with Disease Modifying Antirheumatic Drugs (DMARDs), is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior DMARD therapy.PsoriasisOtezla is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or psoralen and ultraviolet-A light (PUVA). uuid:14bb7f66-6777-48f2-82b4-0f6c88d515bc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3759 biolink:treats MONDO:0006805 PMID:41385096 "[{""id"":""uuid:fd2db511-0962-4650-adfb-4a33a8b21d6a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a1e7035d-6b8c-4c82-a9b8-7fac28fd1b63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Secondary prevention of atherothrombotic eventsClopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from seven days until less than six months) or established peripheral arterial disease;adult patients suffering from acute coronary syndrome:non-ST-segment-elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA);ST-segment-elevation acute myocardial infarction, in combination with ASA in patients undergoing percutaneous coronary intervention (including patients undergoing a stent replacement) or medically treated patients eligible for thrombolytic/fibrinolytic therapy.In patients with moderate to high-risk Transient Ischemic Attack (TIA) or minor Ischemic Stroke (IS)Clopidogrel in combination with ASA is indicated in:Adult patients with moderate to high-risk TIA (ABCD2 score ≥4) or minor IS (NIHSS ≤3) within 24 hours of either the TIA or IS event.Prevention of atherothrombotic and thromboembolic events in atrial fibrillationIn adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin-K antagonists and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke. uuid:6977d864-9280-477a-bd21-b9c724f382f4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3759 biolink:treats MONDO:0003674 PMID:41385096 "[{""id"":""uuid:f73da913-338f-4223-a803-a51020af0bcb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:3f86720c-3afd-4fe3-9cca-0dfab4fb321e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Secondary prevention of atherothrombotic eventsClopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from seven days until less than six months) or established peripheral arterial disease;adult patients suffering from acute coronary syndrome:non-ST-segment-elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA);ST-segment-elevation acute myocardial infarction, in combination with ASA in patients undergoing percutaneous coronary intervention (including patients undergoing a stent replacement) or medically treated patients eligible for thrombolytic/fibrinolytic therapy.In patients with moderate to high-risk Transient Ischemic Attack (TIA) or minor Ischemic Stroke (IS)Clopidogrel in combination with ASA is indicated in:Adult patients with moderate to high-risk TIA (ABCD2 score ≥4) or minor IS (NIHSS ≤3) within 24 hours of either the TIA or IS event.Prevention of atherothrombotic and thromboembolic events in atrial fibrillationIn adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin-K antagonists and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke. uuid:16fe8c10-b44c-4a57-b2f1-20026a988967 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3759 biolink:treats MONDO:0041656 PMID:41385096 "[{""id"":""uuid:e9e7844a-aab8-4e23-b33a-a7da6a7a4060"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:3fa0b4fa-6242-4afc-a72d-d9881200ce83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Secondary prevention of atherothrombotic eventsClopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from seven days until less than six months) or established peripheral arterial disease;adult patients suffering from acute coronary syndrome:non-ST-segment-elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA);ST-segment-elevation acute myocardial infarction, in combination with ASA in patients undergoing percutaneous coronary intervention (including patients undergoing a stent replacement) or medically treated patients eligible for thrombolytic/fibrinolytic therapy.In patients with moderate to high-risk Transient Ischemic Attack (TIA) or minor Ischemic Stroke (IS)Clopidogrel in combination with ASA is indicated in:Adult patients with moderate to high-risk TIA (ABCD2 score ≥4) or minor IS (NIHSS ≤3) within 24 hours of either the TIA or IS event.Prevention of atherothrombotic and thromboembolic events in atrial fibrillationIn adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin-K antagonists and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke. uuid:15969859-d2c4-443a-8772-5af9fabfe1d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3759 biolink:treats MONDO:0005264 PMID:41385096 "[{""id"":""uuid:85b44acc-07f3-46d9-88f0-60795d602d2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:dfc97114-6048-4e53-b655-aeae9bfe6c46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Secondary prevention of atherothrombotic eventsClopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from seven days until less than six months) or established peripheral arterial disease;adult patients suffering from acute coronary syndrome:non-ST-segment-elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA);ST-segment-elevation acute myocardial infarction, in combination with ASA in patients undergoing percutaneous coronary intervention (including patients undergoing a stent replacement) or medically treated patients eligible for thrombolytic/fibrinolytic therapy.In patients with moderate to high-risk Transient Ischemic Attack (TIA) or minor Ischemic Stroke (IS)Clopidogrel in combination with ASA is indicated in:Adult patients with moderate to high-risk TIA (ABCD2 score ≥4) or minor IS (NIHSS ≤3) within 24 hours of either the TIA or IS event.Prevention of atherothrombotic and thromboembolic events in atrial fibrillationIn adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin-K antagonists and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke. uuid:dad02263-3e8f-4663-9271-ceafc3dfbb94 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3759 biolink:treats HP:0002140 PMID:41385096 "[{""id"":""uuid:23995cfe-ac8a-4c53-955b-bbadefe65a1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:617fc2c6-dd9f-4df5-8b7a-ef3e9ae7c419"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Secondary prevention of atherothrombotic eventsClopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from seven days until less than six months) or established peripheral arterial disease;adult patients suffering from acute coronary syndrome:non-ST-segment-elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA);ST-segment-elevation acute myocardial infarction, in combination with ASA in patients undergoing percutaneous coronary intervention (including patients undergoing a stent replacement) or medically treated patients eligible for thrombolytic/fibrinolytic therapy.In patients with moderate to high-risk Transient Ischemic Attack (TIA) or minor Ischemic Stroke (IS)Clopidogrel in combination with ASA is indicated in:Adult patients with moderate to high-risk TIA (ABCD2 score ≥4) or minor IS (NIHSS ≤3) within 24 hours of either the TIA or IS event.Prevention of atherothrombotic and thromboembolic events in atrial fibrillationIn adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin-K antagonists and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke. uuid:63775c26-6af3-4508-b463-953089a346fc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3759 biolink:treats MONDO:0004981 PMID:41385096 "[{""id"":""uuid:8f558e7d-a424-40a7-9bb5-1ac74192867c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:124a03cd-f906-4b65-8044-e3c51ff9f13b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Secondary prevention of atherothrombotic eventsClopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from seven days until less than six months) or established peripheral arterial disease;adult patients suffering from acute coronary syndrome:non-ST-segment-elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA);ST-segment-elevation acute myocardial infarction, in combination with ASA in patients undergoing percutaneous coronary intervention (including patients undergoing a stent replacement) or medically treated patients eligible for thrombolytic/fibrinolytic therapy.In patients with moderate to high-risk Transient Ischemic Attack (TIA) or minor Ischemic Stroke (IS)Clopidogrel in combination with ASA is indicated in:Adult patients with moderate to high-risk TIA (ABCD2 score ≥4) or minor IS (NIHSS ≤3) within 24 hours of either the TIA or IS event.Prevention of atherothrombotic and thromboembolic events in atrial fibrillationIn adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin-K antagonists and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke. uuid:29b218a1-6034-4197-8549-178ec73a037c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134709 biolink:treats MONDO:0007147 PMID:41385096 "[{""id"":""uuid:30029a8c-6ba7-47af-813c-d934e89af964"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:67f5ebd3-b902-4390-b3ef-614d70d59e1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ozawade""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ozawade is indicated to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with obstructive sleep apnoea (OSA) uuid:411a8a7f-787d-4bf0-9ef2-8e041d1497fe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134709 biolink:treats MONDO:0005466 PMID:41385096 "[{""id"":""uuid:9eb1d855-0bee-4e12-bf74-497baa1e5a7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e966a5a9-1915-431c-8a20-97d4c018c763"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ozawade""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ozawade is indicated to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with obstructive sleep apnoea (OSA) uuid:68e3bf93-4705-44c0-91da-bf3776df80b7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PP0SHH6V16 biolink:treats MONDO:0021661 PMID:41385096 "[{""id"":""uuid:1b818c4b-5708-491c-9c7e-ee2bf2816413"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:72bc9941-8e30-4d99-846b-12cd51e44acd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/praluent""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Primary hypercholesterolaemia and mixed dyslipidaemiaPraluent is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin or statin with other lipid lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin or,alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.Established atherosclerotic cardiovascular disease Praluent is indicated in adults with established atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering LDL-C levels, as an adjunct to correction of other risk factors:in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies or,alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.For study results with respect to effects on LDL-C, cardiovascular events and populations studied see section 5.1. uuid:19e9defd-141c-4f60-9137-c204e6c364a9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C000723076 biolink:treats MONDO:0018874 PMID:41385096 "[{""id"":""uuid:f1507745-afb7-40da-ba14-1400dc76cac9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:7260bff3-aa3f-4bf1-abd6-89cd69ac47e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Inaqovi is indicated as monotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for standard induction chemotherapy. uuid:086a5084-82d1-4b8d-91f5-269df9aadb22 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:FYS6T7F842 biolink:treats MONDO:0019437 PMID:41385096 "[{""id"":""uuid:36b59fdc-106b-4838-9374-c300b3b0fd7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:180f46df-588e-4ef3-b37b-112b46bc86eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/hulio""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rheumatoid arthritisYuflyma in combination with methotrexate, is indicated for:- the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate.- the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.Yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.Adalimumab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate.Juvenile idiopathic arthritisPolyarticular juvenile idiopathic arthritisYuflyma in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5.1). Adalimumab has not been studied in patients aged less than 2 years.Enthesitis-related arthritisYuflyma is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5.1).Axial spondyloarthritisAnkylosing spondylitis (AS)Yuflyma is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.Axial spondyloarthritis without radiographic evidence of ASYuflyma is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated CRP and/or MRI, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs).Psoriatic arthritisYuflyma is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate.Adalimumab has been shown to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease (see section 5.1) and to improve physical function.PsoriasisYuflyma is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy.Paediatric plaque psoriasisYuflyma is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies.Hidradenitis suppurativa (HS)Yuflyma is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic HS therapy (see sections 5.1 and 5.2).Crohn’s diseaseYuflyma is indicated for treatment of moderately to severely active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.Paediatric Crohn's diseaseYuflyma is indicated for the treatment of moderately to severely active Crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies.Ulcerative colitisYuflyma is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.Paediatric ulcerative colitisYuflyma is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.UveitisYuflyma is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid- sparing, or in whom corticosteroid treatment is inappropriate.Paediatric uveitisYuflyma is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate. uuid:c8f40ecc-4bc9-415b-a993-89c3e29f61b5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:FYS6T7F842 biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:52a52c6c-0195-4c17-9f4f-01f03de5a788"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0cf3872d-2361-4e1d-a9fa-43080c962144"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/hulio""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rheumatoid arthritisYuflyma in combination with methotrexate, is indicated for:- the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate.- the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.Yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.Adalimumab has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function, when given in combination with methotrexate.Juvenile idiopathic arthritisPolyarticular juvenile idiopathic arthritisYuflyma in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Yuflyma can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5.1). Adalimumab has not been studied in patients aged less than 2 years.Enthesitis-related arthritisYuflyma is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5.1).Axial spondyloarthritisAnkylosing spondylitis (AS)Yuflyma is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy.Axial spondyloarthritis without radiographic evidence of ASYuflyma is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated CRP and/or MRI, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs).Psoriatic arthritisYuflyma is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate.Adalimumab has been shown to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease (see section 5.1) and to improve physical function.PsoriasisYuflyma is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy.Paediatric plaque psoriasisYuflyma is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies.Hidradenitis suppurativa (HS)Yuflyma is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic HS therapy (see sections 5.1 and 5.2).Crohn’s diseaseYuflyma is indicated for treatment of moderately to severely active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.Paediatric Crohn's diseaseYuflyma is indicated for the treatment of moderately to severely active Crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies.Ulcerative colitisYuflyma is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.Paediatric ulcerative colitisYuflyma is indicated for the treatment of moderately to severely active ulcerative colitis in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including corticosteroids and/or 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.UveitisYuflyma is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid- sparing, or in whom corticosteroid treatment is inappropriate.Paediatric uveitisYuflyma is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate. uuid:32a56126-2bd6-462a-87a4-9386ece9fdfb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63916 biolink:treats MONDO:0001999 PMID:41385096 "[{""id"":""uuid:c3c79de0-388e-4730-b204-ee7cac308f13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:3924c0d7-d962-4d22-a426-26a426cda36f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ventavis""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of patients with primary pulmonary hypertension, classified as New York Heart Association functional class III, to improve exercise capacity and symptoms. uuid:f3679ee8-aa76-4de3-9960-184ed85e3659 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2S9ZZM9Q9V biolink:treats MONDO:0041447 PMID:41385096 "[{""id"":""uuid:27caf708-458f-4b78-b787-509e73ed931c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:adeaa952-2ec6-41b4-bdd7-d973ed9c1e13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/abevmy""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Abevmy in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum.Abevmy in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 (HER2) status, please refer to section 5.1.Abevmy in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. Patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with Abevmy in combination with capecitabine. For further information as to HER2 status, please refer to section 5.1.Abevmy, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology.Abevmy, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations (see section 5.1).Abevmy in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer.Abevmy, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics [FIGO] stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5.1).Abevmy, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents.Abevmy in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents (see section 5.1).Abevmy, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.1). uuid:b65eaf8f-fe63-416d-b9ac-6b11d15fbbcb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2S9ZZM9Q9V biolink:treats MONDO:0005086 PMID:41385096 "[{""id"":""uuid:5bb0b290-e6a5-429c-99a9-b34fa6d305b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f46a55ab-75a6-48c4-adb5-9f6eb25e2b1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/abevmy""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Abevmy in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum.Abevmy in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 (HER2) status, please refer to section 5.1.Abevmy in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. Patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with Abevmy in combination with capecitabine. For further information as to HER2 status, please refer to section 5.1.Abevmy, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology.Abevmy, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations (see section 5.1).Abevmy in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer.Abevmy, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics [FIGO] stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5.1).Abevmy, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents.Abevmy in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents (see section 5.1).Abevmy, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.1). uuid:34a05095-ad7a-463d-aa14-0850d83dd85f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2S9ZZM9Q9V biolink:treats MONDO:0005131 PMID:41385096 "[{""id"":""uuid:baf5c8b9-90ce-4c3b-b412-02b7cd68e1f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:64ba171b-7473-4030-b280-987279d43d10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/abevmy""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Abevmy in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum.Abevmy in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 (HER2) status, please refer to section 5.1.Abevmy in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. Patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with Abevmy in combination with capecitabine. For further information as to HER2 status, please refer to section 5.1.Abevmy, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology.Abevmy, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations (see section 5.1).Abevmy in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer.Abevmy, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics [FIGO] stages III B, III C and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5.1).Abevmy, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents.Abevmy in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor–targeted agents (see section 5.1).Abevmy, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.1). uuid:ca0323d6-fdab-49db-b904-f627a356b0b7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:1KUR4BN70F biolink:treats MONDO:0100096 PMID:41385096 "[{""id"":""uuid:35a02590-e4f7-4744-ac92-79116bac1a6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:024c28bb-0f5f-4ef1-b01c-d389c1cca607"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/evusheld""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Prevention of COVID-19. uuid:98cc20a5-2ad2-4fe2-be23-c0c40d7de367 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2P471X1Z11 biolink:treats MONDO:0004784 PMID:41385096 "[{""id"":""uuid:ad00cd57-1678-4d5e-8609-2d89d70fa528"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a1b68dde-edc0-45bd-9eca-ec703f8c0f7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/xolair""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Allergic asthmaXolair is indicated in adults, adolescents and children (6 to uuid:95ba1394-3bf3-4811-9f13-10f78c969601 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:F70C5K4786 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:1242cef7-8a65-47fd-922b-4d8782ad7a11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:93d8be9f-0ee6-4920-b5a7-8b2c53d78adf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Pepaxti is indicated, in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation (see section 4.4). uuid:76df42fb-dffe-4338-8143-f64cbe83f6a8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:284904 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:f86f2e88-92f9-4b42-bcff-04e751980f15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0383d715-45d5-4c06-a515-645fc1021dbb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Trizivir is indicated for the treatment of human-immunodeficiency-virus (HIV) infection in adults.This fixed combination replaces the three components (abacavir, lamivudine and zidovudine) used separately in similar dosages. It is recommended that treatment is started with abacavir, lamivudine,and zidovudine separately for the first six to eight weeks. The choice of this fixed combination should be based not only on potential adherence criteria, but mainly on expected efficacy and risk related to the three nucleoside analogues.The demonstration of the benefit of Trizivir is mainly based on results of studies performed in treatment naive patients or moderately antiretroviral experienced patients with non-advanced disease.In patients with high viral load (>100,000 copies/ml) choice of therapy needs special consideration.Overall, the virologic suppression with this triple nucleoside regimen could be inferior to that obtained with other multitherapies notably including boosted protease inhibitors or non-nucleoside reverse-transcriptase inhibitors, therefore the use of Trizivir should only be considered under special circumstances (e.g. co-infection with tuberculosis).Before initiating treatment with abacavir, screening for carriage of the HLA-B*5701 allele should be performed in any HIV-infected patient, irrespective of racial origin. Screening is also recommended prior to re-initiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir (see 'management after an interruption of Trizivir therapy'). Abacavir should not be used in patients known to carry the HLA-B*5701 allele, unless no other therapeutic option is available in these patients, based on the treatment history and resistance testing. uuid:02e2a03b-943c-4dcf-81a9-d7bdd66ae7d0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:284904 biolink:treats MONDO:0018076 PMID:41385096 "[{""id"":""uuid:ab512bae-887b-4ef8-ad4e-d5205978193c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a427bced-e1ff-4f1f-aff8-a0bce8967bc8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Trizivir is indicated for the treatment of human-immunodeficiency-virus (HIV) infection in adults.This fixed combination replaces the three components (abacavir, lamivudine and zidovudine) used separately in similar dosages. It is recommended that treatment is started with abacavir, lamivudine,and zidovudine separately for the first six to eight weeks. The choice of this fixed combination should be based not only on potential adherence criteria, but mainly on expected efficacy and risk related to the three nucleoside analogues.The demonstration of the benefit of Trizivir is mainly based on results of studies performed in treatment naive patients or moderately antiretroviral experienced patients with non-advanced disease.In patients with high viral load (>100,000 copies/ml) choice of therapy needs special consideration.Overall, the virologic suppression with this triple nucleoside regimen could be inferior to that obtained with other multitherapies notably including boosted protease inhibitors or non-nucleoside reverse-transcriptase inhibitors, therefore the use of Trizivir should only be considered under special circumstances (e.g. co-infection with tuberculosis).Before initiating treatment with abacavir, screening for carriage of the HLA-B*5701 allele should be performed in any HIV-infected patient, irrespective of racial origin. Screening is also recommended prior to re-initiation of abacavir in patients of unknown HLA-B*5701 status who have previously tolerated abacavir (see 'management after an interruption of Trizivir therapy'). Abacavir should not be used in patients known to carry the HLA-B*5701 allele, unless no other therapeutic option is available in these patients, based on the treatment history and resistance testing. uuid:747b1363-bd58-4592-85d3-a3678683395f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16796 biolink:treats MONDO:0013600 PMID:41385096 "[{""id"":""uuid:ee89049a-8f61-4bfa-88c7-ae9440aca202"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d861b478-df2e-4a7a-b66c-dc69d75466cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/slenyto""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Slenyto is indicated for the treatment of insomnia in children and adolescents aged 2-18 with Autism Spectrum Disorder (ASD) and / or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient. uuid:c57bd096-c02f-4d64-bedf-0d75885719ae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16796 biolink:treats MONDO:0005258 PMID:41385096 "[{""id"":""uuid:beba2f89-eefc-4011-b7cc-59f7ebe0bf28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:15ee4078-f8aa-4574-88f3-94bbec82c896"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/slenyto""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Slenyto is indicated for the treatment of insomnia in children and adolescents aged 2-18 with Autism Spectrum Disorder (ASD) and / or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient. uuid:3f05570c-8b2b-4d11-ae47-3b97409740af biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:B72HH48FLU biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:b6190a7f-e458-4f0a-a8a6-c982cc99b53f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:da6e8863-d104-4600-92c1-69c5c0c9fbab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zessly""]},{""id"":""uuid:e86db75a-58ab-4af6-aeef-5bb4f80e5440"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis.|[PMDA] Follow-on biologics indicated for the treatment of rheumatoid arthritis, psoriasis, Crohn’s disease, and ulcerative colitis. uuid:aa77db5a-71f6-47fe-a5e2-fe98010fd080 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:D99YVK4L0X biolink:treats MONDO:0001056 PMID:41385096 "[{""id"":""uuid:9406016a-7baa-47fb-a412-e59875da2c89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:afed92d2-8040-4a71-8c50-d926447a11ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cyramza""]},{""id"":""uuid:06be741b-e9aa-4cd2-a9ed-840dc4f15329"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Gastric cancerCyramza in combination with paclitaxel is indicated for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy.Cyramza monotherapy is indicated for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy, for whom treatment in combination with paclitaxel is not appropriate.Colorectal cancerCyramza, in combination with FOLFIRI (irinotecan, folinic acid, and 5‑fluorouracil), is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin and a fluoropyrimidine.Non-small cell lung cancerCyramza in combination with docetaxel is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with disease progression after platinum-based chemotherapy.Hepatocellular carcinomaCyramza monotherapy is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have a serum alpha fetoprotein (AFP) of ≥ 400 ng/ml and who have been previously treated with sorafenib.|[PMDA] Drugs with a new active ingredient indicated for the treatment of unresectable advanced or recurrent gastric cancer. [Priority review] uuid:4e612fea-d131-406f-ac26-7ce4d3195b1c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:D99YVK4L0X biolink:treats MONDO:0005575 PMID:41385096 "[{""id"":""uuid:8decc28e-ab40-4f29-8f21-d0a740a4b204"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f9eb6c41-b5a6-48c9-8d47-369d895c9bd0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cyramza""]},{""id"":""uuid:5f821686-db85-4dd3-b4a6-02a89d5b8a39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Gastric cancerCyramza in combination with paclitaxel is indicated for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy.Cyramza monotherapy is indicated for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy, for whom treatment in combination with paclitaxel is not appropriate.Colorectal cancerCyramza, in combination with FOLFIRI (irinotecan, folinic acid, and 5‑fluorouracil), is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin and a fluoropyrimidine.Non-small cell lung cancerCyramza in combination with docetaxel is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with disease progression after platinum-based chemotherapy.Hepatocellular carcinomaCyramza monotherapy is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have a serum alpha fetoprotein (AFP) of ≥ 400 ng/ml and who have been previously treated with sorafenib.|[PMDA] Drugs with a new additional indication and a new dosage for the treatment of unresectable advanced or recurrent colorectal cancer. uuid:eb93ad44-dc9e-4aec-9bf4-9cb392be6b4f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:D99YVK4L0X biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:7dc1a53f-faa6-49e6-adac-a1a1f81a80fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cfe75114-691b-4456-88f4-1aeb116df28f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cyramza""]},{""id"":""uuid:09f3bf2e-86b8-490d-b5e9-558605aab099"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Gastric cancerCyramza in combination with paclitaxel is indicated for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy.Cyramza monotherapy is indicated for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy, for whom treatment in combination with paclitaxel is not appropriate.Colorectal cancerCyramza, in combination with FOLFIRI (irinotecan, folinic acid, and 5‑fluorouracil), is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin and a fluoropyrimidine.Non-small cell lung cancerCyramza in combination with docetaxel is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with disease progression after platinum-based chemotherapy.Hepatocellular carcinomaCyramza monotherapy is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have a serum alpha fetoprotein (AFP) of ≥ 400 ng/ml and who have been previously treated with sorafenib.|[PMDA] Drugs with a new dosage indicated for the treatment of unresectable advanced or recurrent non-small cell lung cancer. Drugs with a new dosage indicated for the treatment of unresectable advanced or recurrent gastric cancer, unresectable advanced or recurrent colon or rectal cancer, unresectable advanced or recurrent non-small cell lung cancer, and unresectable hepatocellular carcinoma whose serum AFP level is greater than 400 ng/mL and conditions have progressed after cancer chemotherapy. uuid:dc74589f-406a-4b8b-a0d6-7377840699e6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB15699 biolink:treats MONDO:0018876 PMID:41385096 "[{""id"":""uuid:fd9d1cc9-61f3-4e78-975f-3c29b794bc47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:410cfe90-8d9f-4259-aa1a-a5f3efaac4b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Mantle cell lymphomaTecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after two or more lines of systemic therapy including a Bruton’s tyrosine kinase (BTK) inhibitor.Acute lymphoblastic leukaemiaTecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL). uuid:cfd2e058-b53d-4ebc-a2bf-d9b9fe4f2c99 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB15699 biolink:treats MONDO:0004967 PMID:41385096 "[{""id"":""uuid:f66e7646-a5de-4bdf-9c77-2c18455794f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:97a5c457-59d2-4663-9326-4cb2237b4ad8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Mantle cell lymphomaTecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after two or more lines of systemic therapy including a Bruton’s tyrosine kinase (BTK) inhibitor.Acute lymphoblastic leukaemiaTecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL). uuid:e1fe9266-4ce1-4131-a1b6-31a7fd48ef57 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229213 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:f5b5f316-4677-4613-9445-c99d0d7879cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:cd11914b-16af-4199-aae1-1edd345fc7e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/orserdu""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (ER) positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation who have disease progression following at least one line of endocrine therapy including a CDK 4/6 inhibitor. uuid:51e81128-d664-442b-81bd-4170889d786e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1546884 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:057255b9-d165-4766-8e32-c6d3aee3cb94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:18182787-a684-4159-9c70-f50d20d3f7a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:d52675b4-54b8-4714-8b23-06c41d183c5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Triumeq is indicated for the treatment of Human Immunodeficiency Virus (HIV) infected adults, adolescents and children weighing at least 25 kg who are antiretroviral treatment-naïve or are infected with HIV without documented or clinically suspected resistance to any of the three antiretroviral agents in Triumeq.|[PMDA] A new combination drug indicated for the treatment of HIV infection. [Orphan drug] uuid:7b65da7e-24c6-48b9-8ba7-48d71df4b10e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:G6UF363ECX biolink:treats MONDO:0008315 PMID:41385096 "[{""id"":""uuid:636cb9df-2ce2-4d03-bc0f-51d400df008d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4cbb57d5-fedc-48c0-a447-72e01856ee2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Pluvicto in combination with androgen deprivation therapy (ADT) with or without androgen receptor (AR) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC) who have been treated with AR pathway inhibition and taxane based chemotherapy. uuid:eb7984a5-e28d-4fb8-89a6-80125c0299dc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:901639 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:e5e517d9-59e1-4831-a235-64e97d7d9faf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2e312f0b-d29e-49f4-87b5-360444a87436"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Active immunisation for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae in infants, children and adolescents from 6 weeks to 17 years of age.Active immunisation for the prevention of invasive disease caused by Streptococcus pneumoniae in adults ≥18 years of age and the elderly.See sections 4.4 and 5.1 for information on protection against specific pneumococcal serotypes.The use of Prevenar 13 should be determined on the basis of official recommendations taking into consideration the risk of invasive disease in different age groups, underlying comorbidities as well as the variability of serotype epidemiology in different geographical areas. uuid:f65d9c20-cd57-4c00-959f-37d6bb7fdb49 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:901639 biolink:treats MONDO:0001031 PMID:41385096 "[{""id"":""uuid:ddd8ae39-b7df-4897-9df3-7308ad573aa7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c9abe26f-8c1c-44c9-bb6f-eada875171cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Active immunisation for the prevention of invasive disease, pneumonia and acute otitis media caused by Streptococcus pneumoniae in infants, children and adolescents from 6 weeks to 17 years of age.Active immunisation for the prevention of invasive disease caused by Streptococcus pneumoniae in adults ≥18 years of age and the elderly.See sections 4.4 and 5.1 for information on protection against specific pneumococcal serotypes.The use of Prevenar 13 should be determined on the basis of official recommendations taking into consideration the risk of invasive disease in different age groups, underlying comorbidities as well as the variability of serotype epidemiology in different geographical areas. uuid:adc3e1ac-23b2-4f9a-b7aa-a326b1544d4a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5938 biolink:treats MONDO:0005314 PMID:41385096 "[{""id"":""uuid:57afb0ab-d1ba-4266-b92c-1ad2cd730833"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b7715bdb-27e4-4567-a428-a840cc67a6d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/betaferon""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Betaferon is indicated for the treatment ofpatients with a single demyelinating event with an active inflammatory process, if it is severe enough to warrant treatment with intravenous corticosteroids, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis;patients with relapsing-remitting multiple sclerosis and two or more relapses within the last two years;patients with secondary progressive multiple sclerosis with active disease, evidenced by relapses. uuid:8a17d77f-ed4d-4dc3-a862-c4a3e5f9c14c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:70746 biolink:treats MONDO:0005399 PMID:41385096 "[{""id"":""uuid:f95a2690-b182-4e58-b85c-d5727fbfe1d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:53c4040f-610c-4dc9-9b96-6c188b99399e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Pradaxa 75 mgPrimary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.Pradaxa 110 mgPrimary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischemic attack (TIA); age ≥ 75 years; heart failure (NYHA Class ≥ II); diabetes mellitus; hypertension.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.Pradaxa 150 mgPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischemic attack (TIA); age ≥ 75 years; heart failure (NYHA Class ≥ II); diabetes mellitus; hypertension.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. uuid:54af0f61-4e5e-45a9-aa22-94edbdd4ec99 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4FR53SIF3A biolink:treats HP:0004848 PMID:41385096 "[{""id"":""uuid:ff2af07c-5fd3-43ef-9377-acc2bf476a65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:42634e0c-71e9-48a1-86a1-41a6d08b3d53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/blincyto""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Blincyto is indicated as monotherapy for the treatment of adults with CD19 positive relapsed or refractory B precursor acute lymphoblastic leukaemia (ALL). Patients with Philadelphia chromosome positive B-precursor ALL should have failed treatment with at least 2 tyrosine kinase inhibitors (TKIs) and have no alternative treatment options., , Blincyto is indicated as monotherapy for the treatment of adults with Philadelphia chromosome negative CD19 positive B-precursor ALL in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%., , Blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with Philadelphia chromosome negative CD19 positive B precursor ALL which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation., , Blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed Philadelphia chromosome negative CD19 positive B-precursor ALL as part of the consolidation therapy (see section 4.2)., uuid:8a582c87-f6a1-4b37-ae6c-dd0177cd11e1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4FR53SIF3A biolink:treats UMLS:C4075283 PMID:41385096 "[{""id"":""uuid:79c00124-f257-4e00-a1f8-aec4d3279f7c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:636fbf42-66cb-4d4d-a759-e9deb854f065"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/blincyto""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Blincyto is indicated as monotherapy for the treatment of adults with CD19 positive relapsed or refractory B precursor acute lymphoblastic leukaemia (ALL). Patients with Philadelphia chromosome positive B-precursor ALL should have failed treatment with at least 2 tyrosine kinase inhibitors (TKIs) and have no alternative treatment options., , Blincyto is indicated as monotherapy for the treatment of adults with Philadelphia chromosome negative CD19 positive B-precursor ALL in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%., , Blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with Philadelphia chromosome negative CD19 positive B precursor ALL which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation., , Blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed Philadelphia chromosome negative CD19 positive B-precursor ALL as part of the consolidation therapy (see section 4.2)., uuid:54fa30a9-6ac6-4eae-98ef-f60fe8830e30 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3423 biolink:treats MONDO:0002911 PMID:41385096 "[{""id"":""uuid:f2de7d74-c17e-4bbb-9d19-848ed4497b60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9aedbd4a-2ba7-45ae-8420-3c01463899bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/carmustine-medac-previously-carmustine-obvius""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Carmustine is indicated n adults in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery):, , , Brain tumours (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases, Secondary therapy in non-Hodgkin’s lymphoma and Hodgkin’s disease, as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (HPCT) in malignant haematological diseases (Hodgkin’s disease / Non-hodgkin’s lymphoma)., , uuid:0bd529bd-1e6c-4119-a270-6192950b9090 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3423 biolink:treats MONDO:0018908 PMID:41385096 "[{""id"":""uuid:ec5b1b1f-7200-4576-9440-8cb1b130f9f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:871fed7a-e14b-4b5e-906a-bad5b91d3568"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/carmustine-medac-previously-carmustine-obvius""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Carmustine is indicated n adults in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery):, , , Brain tumours (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases, Secondary therapy in non-Hodgkin’s lymphoma and Hodgkin’s disease, as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (HPCT) in malignant haematological diseases (Hodgkin’s disease / Non-hodgkin’s lymphoma)., , uuid:6c4f0f00-c3d5-4e2c-a2ff-c3be9c468d42 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3423 biolink:treats MONDO:0004952 PMID:41385096 "[{""id"":""uuid:b17ed25d-146a-4bbb-a89d-08be2cf546ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:19b0eaf0-0e78-4147-bc4a-9f4d99075abf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/carmustine-medac-previously-carmustine-obvius""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Carmustine is indicated n adults in the following malignant neoplasms as a single agent or in combination with other antineoplastic agents and/or other therapeutic measures (radiotherapy, surgery):, , , Brain tumours (glioblastoma, brain-stem gliomas, medulloblastoma, astrocytoma and ependymoma), brain metastases, Secondary therapy in non-Hodgkin’s lymphoma and Hodgkin’s disease, as conditioning treatment prior to autologous haematopoietic progenitor cell transplantation (HPCT) in malignant haematological diseases (Hodgkin’s disease / Non-hodgkin’s lymphoma)., , uuid:8d0a66b9-c142-401d-aa58-ced136de408c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64356 biolink:treats MONDO:0021667 PMID:41385096 "[{""id"":""uuid:948c4a66-a314-4897-8bb6-9666a8d75381"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:470c3384-edef-4f8c-9188-bce92885b566"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/pregabalin-sandoz""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Neuropathic painPregabalin Sandoz is indicated for the treatment of peripheral and central neuropathic pain in adults.EpilepsyPregabalin Sandoz is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.Generalised Anxiety DisorderPregabalin Sandoz is indicated for the treatment of Generalised Anxiety Disorder (GAD) in adults. uuid:2f96b61c-1017-4391-848c-092f3e213a0b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64356 biolink:treats MONDO:0005027 PMID:41385096 "[{""id"":""uuid:dc1e31bb-6f97-4b8a-b683-ddf57e6fb094"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:898b58f0-caef-40c8-bd67-27a5bb10e848"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/pregabalin-sandoz""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Neuropathic painPregabalin Sandoz is indicated for the treatment of peripheral and central neuropathic pain in adults.EpilepsyPregabalin Sandoz is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.Generalised Anxiety DisorderPregabalin Sandoz is indicated for the treatment of Generalised Anxiety Disorder (GAD) in adults. uuid:c070ae4f-b728-4385-95fd-36b4f6d3c58e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64356 biolink:treats MONDO:0001942 PMID:41385096 "[{""id"":""uuid:22009d18-14f2-4156-834e-bd158b4a8ac8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:22e701d6-689c-469e-9020-4f65aae598e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/pregabalin-sandoz""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Neuropathic painPregabalin Sandoz is indicated for the treatment of peripheral and central neuropathic pain in adults.EpilepsyPregabalin Sandoz is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.Generalised Anxiety DisorderPregabalin Sandoz is indicated for the treatment of Generalised Anxiety Disorder (GAD) in adults. uuid:1801c804-02a2-4184-80f9-a90f24b97f4e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:EPK39PL4R4 biolink:treats MONDO:0100096 PMID:41385096 "[{""id"":""uuid:cc597f7e-d828-4d99-90a7-19af3620b701"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b74e279e-846a-4ce1-86fa-0deecc77baeb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:44500511-33e7-483d-acc9-6e75249fba56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Spikevax is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older.Spikevax bivalent Original/Omicron BA.1 is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against COVID-19.Spikevax bivalent Original/Omicron BA.4-5 is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. Spikevax XBB.1.5 is indicated for active immunisation to prevent COVID 19 caused by SARS-CoV-2 in individuals 6 months of age and older.The use of this vaccine should be in accordance with official recommendations.|[PMDA] A drug with a new additional pediatric dosage indicated for the prevention of disease caused by SARS-CoV-2 infection (COVID-19). [Drug pertaining to Special Approval for Emergency] uuid:0ffe86c5-f761-4e03-8e18-e1455d264067 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:92043599 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:ad225eb8-9fa1-4e67-9f4d-776dc7bf90c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f00f64d7-c0fe-44b8-a569-7db2a0b2e8a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/epoetin-alfa-hexal""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult and paediatric patients:, , , treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis;, Treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis., , , Treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre-existing anaemia at the start of chemotherapy)., uuid:8dd23cce-ba76-4536-b636-06eb9a215527 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:92043599 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:f8c0b6f1-e254-4535-aa0a-37403e5a09fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5adaa599-d3ec-475c-af8d-1e0546bddee0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/epoetin-alfa-hexal""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult and paediatric patients:, , , treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis;, Treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis., , , Treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre-existing anaemia at the start of chemotherapy)., uuid:3e184ad9-5b65-42f7-888a-70feedae3abd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:92043599 biolink:treats MONDO:0005062 PMID:41385096 "[{""id"":""uuid:387d71ce-c1d0-457f-b280-395aacf7f014"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:59ff358f-abd5-4403-95fb-ee661f4d931d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/epoetin-alfa-hexal""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult and paediatric patients:, , , treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis;, Treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis., , , Treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre-existing anaemia at the start of chemotherapy)., uuid:142e8634-fcf4-4f01-8d77-642f4f3b4d40 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB00058 biolink:treats MONDO:0004849 PMID:41385096 "[{""id"":""uuid:85a12672-6c58-4181-b635-2197e9b59cb6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ae89c4ec-2610-49fc-862d-50d3f2c8305a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Respreeza is indicated for maintenance treatment, to slow the progression of emphysema in adults with documented severe alpha1-proteinase inhibitor deficiency (e.g. genotypes PiZZ, PiZ(null), Pi(null,null), PiSZ). Patients are to be under optimal pharmacologic and non-pharmacologic treatment and show evidence of progressive lung disease (e.g. lower forced expiratory volume per second (FEV1) predicted, impaired walking capacity or increased number of exacerbations) as evaluated by a healthcare professional experienced in the treatment of alpha1-proteinase inhibitor deficiency. uuid:6b634860-905b-4e2a-9a91-2830f582752e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB00058 biolink:treats MONDO:0013282 PMID:41385096 "[{""id"":""uuid:a3a7052f-7b86-47d9-9c43-5df2b8fcd35e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ca1d40c8-26e6-4bb5-b44b-c9e4eb55a8e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:06759605-481b-46a6-a2d1-8d8382391074"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Respreeza is indicated for maintenance treatment, to slow the progression of emphysema in adults with documented severe alpha1-proteinase inhibitor deficiency (e.g. genotypes PiZZ, PiZ(null), Pi(null,null), PiSZ). Patients are to be under optimal pharmacologic and non-pharmacologic treatment and show evidence of progressive lung disease (e.g. lower forced expiratory volume per second (FEV1) predicted, impaired walking capacity or increased number of exacerbations) as evaluated by a healthcare professional experienced in the treatment of alpha1-proteinase inhibitor deficiency.|[PMDA] A drug with a new active ingredient indicated for the augmentation and maintenance therapy of severe alpha 1-antitrypsin deficiency. [Orphan drug] uuid:3664cd63-3efa-479c-b62d-7c2ed189d21f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:95341 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:ed454e3b-4e71-4b7d-9ccb-b74f9a17999e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c7734b42-e694-4417-81e6-8ae805db8037"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/olumiant""]},{""id"":""uuid:1ef13c22-5c7d-4599-8192-fdcec0b52238"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rheumatoid arthritisBaricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (DMARDs). Olumiant may be used as monotherapy or in combination with methotrexate.Atopic DermatitisOlumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy.Alopecia areataBaricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5.1).Juvenile idiopathic arthritisBaricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic DMARDs:- Polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [RF+] or negative [RF-], extended oligoarticular),- Enthesitis related arthritis, and- Juvenile psoriatic arthritis.Baricitinib may be used as monotherapy or in combination with methotrexate.|[PMDA] Drugs with a new indication for the treatment of atopic dermatitis in patients who have not responded sufficiently to conventional treatments. uuid:6f06f906-58e9-45aa-ad32-c16539d66bef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:95341 biolink:treats MONDO:0011429 PMID:41385096 "[{""id"":""uuid:36c08157-ed28-439d-8272-ea5dfaafdc48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6ca62601-320c-4b7a-aa1b-f20b385b49ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/olumiant""]},{""id"":""uuid:86dd9860-987b-4651-8f2c-de56f93f3e18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rheumatoid arthritisBaricitinib is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (DMARDs). Olumiant may be used as monotherapy or in combination with methotrexate.Atopic DermatitisOlumiant is indicated for the treatment of moderate to severe atopic dermatitis in adult and paediatric patients 2 years of age and older who are candidates for systemic therapy.Alopecia areataBaricitinib is indicated for the treatment of severe alopecia areata in adult patients (see section 5.1).Juvenile idiopathic arthritisBaricitinib is indicated for the treatment of active juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response or intolerance to one or more prior conventional synthetic or biologic DMARDs:- Polyarticular juvenile idiopathic arthritis (polyarticular rheumatoid factor positive [RF+] or negative [RF-], extended oligoarticular),- Enthesitis related arthritis, and- Juvenile psoriatic arthritis.Baricitinib may be used as monotherapy or in combination with methotrexate.|[PMDA] (1), (2) Drugs with a new indication and a new dosage and (3) a drug with a new indication and a new dosage in an additional dosage form, for the treatment of polyarticular-course juvenile idiopathic arthritis in patients who have not responded sufficiently to conventional treatments. uuid:0fa545f7-a14b-47ba-b82a-cccfc91b944a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1600704 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:4030fb1c-8ac1-4caf-a435-41659a08e01a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:63220332-f120-436e-bf2f-2e3c06393cbf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/rezolsta""]},{""id"":""uuid:0f598d13-3990-4154-b056-4c71ce17a7f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rezolsta, is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus 1 (HIV 1) infection in adults aged 18 years or older.Genotypic testing should guide the use of Rezolsta.|[PMDA] A new combination drug with a new active ingredient indicated for the treatment of HIV infection. [Orphan drug] uuid:c6ed807a-1480-4c8b-bd79-b260700e4ae1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90939 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:f8a66000-591f-4d43-8ee1-aebfde1d0aff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4ef1c69d-ad12-4d85-929a-3dd29ec2450c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ninlaro in combination with lenalidomide and dexamethasone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. uuid:115c45f2-7d07-4fc3-b14b-ef5119ca2f5a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49005 biolink:treats MONDO:0016486 PMID:41385096 "[{""id"":""uuid:3823a082-1bad-45d9-8d57-3fd3d9560af0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c68ba90c-001f-432e-8bf1-51424c2cc0d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/exjade""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Exjade is indicated for the treatment of chronic iron overload due to frequent blood transfusions (≥ 7 ml/kg/month of packed red blood cells) in patients with beta thalassaemia major aged six years and older.Exjade is also indicated for the treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:in patients with beta thalassaemia major with iron overload due to frequent blood transfusions (≥ 7 ml/kg/month of packed red blood cells) aged two to five years;in patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (< 7 ml/kg/month of packed red blood cells) aged two years and older;in patients with other anaemias aged two years and older.Exjade is also indicated for the treatment of chronic iron overload requiring chelation therapy when deferoxamine therapy is contraindicated or inadequate in patients with non-transfusion-dependent thalassaemia syndromes aged 10 years and older. uuid:a40f3445-ce0d-418d-b486-f81336512d56 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49005 biolink:treats MONDO:0000984 PMID:41385096 "[{""id"":""uuid:8481dbde-a280-4757-bdbe-b7f30dd62790"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:cbe58002-b80e-406a-8804-29a57dcc61dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/exjade""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Exjade is indicated for the treatment of chronic iron overload due to frequent blood transfusions (≥ 7 ml/kg/month of packed red blood cells) in patients with beta thalassaemia major aged six years and older.Exjade is also indicated for the treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in the following patient groups:in patients with beta thalassaemia major with iron overload due to frequent blood transfusions (≥ 7 ml/kg/month of packed red blood cells) aged two to five years;in patients with beta thalassaemia major with iron overload due to infrequent blood transfusions (< 7 ml/kg/month of packed red blood cells) aged two years and older;in patients with other anaemias aged two years and older.Exjade is also indicated for the treatment of chronic iron overload requiring chelation therapy when deferoxamine therapy is contraindicated or inadequate in patients with non-transfusion-dependent thalassaemia syndromes aged 10 years and older. uuid:bad6a60b-5fe7-4915-af34-797e139a660b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9Y9727LS4D biolink:treats MONDO:0010602 PMID:41385096 "[{""id"":""uuid:244f6ee1-6c21-4583-8eb6-6d69ae18d7a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7c407c98-568f-4977-81d1-b83e216dd206"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/esperoct""]},{""id"":""uuid:1f2c8c30-75e9-4cae-a401-b00ca1c806ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment and prophylaxis of bleeding in patients 12 years and above with haemophilia A (congenital factor VIII deficiency).|[PMDA] Drugs with a new active ingredient indicated for the control of bleeding tendency in patients with blood coagulation factor VIII deficiency. uuid:f3e56718-9a3e-41b2-9a24-dbd709d5aa6a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:VY5YX2TQ1F biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:3508182b-4a33-4805-b0ac-74ed73f53d36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:1a817310-3a3a-4fd2-8a4a-0010b2b0862e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Tepmetko as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy. uuid:33e77480-0005-49e3-bdeb-b1fcd0325f06 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:VY5YX2TQ1F biolink:treats UMLS:C4330599 PMID:41385096 "[{""id"":""uuid:add589f2-4391-4ecd-9624-66fe4820a93d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e720f4f5-e361-4ce4-a78a-24dfa01195a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Tepmetko as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum-based chemotherapy. uuid:44e6158a-560d-4f97-8f97-620948ed45e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:230905 biolink:treats MONDO:0000618 PMID:41385096 "[{""id"":""uuid:fe1402a7-f3a7-429f-8a46-43091e81051e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f38c632b-7cb5-4b37-a5d7-8572b21a91c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Kisqali is indicated for the treatment of women with hormone receptor (HR)‑positive, human epidermal growth factor receptor 2 (HER2)‑negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.In pre‑ or perimenopausal women, the endocrine therapy should be combined with a luteinising hormone‑releasing hormone (LHRH) agonist. uuid:50447c50-b2dc-4970-b681-ba919f45ff8d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32660 biolink:treats MONDO:0004969 PMID:41385096 "[{""id"":""uuid:b42c9c7e-0ead-4c3e-8402-993e4187f5ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5e67d187-34a8-4f5a-a6ee-46f0aaf86fdb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/spectrila""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Spectrila is indicated as a component of antineoplastic combination therapy for the treatment of acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years and adults. uuid:69203eb5-8260-4a30-8753-067815400901 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3JB47N2Q2P biolink:treats MONDO:0005314 PMID:41385096 "[{""id"":""uuid:0a8ef9be-2152-461c-9ac9-7b54f0078f10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:868f04b5-5563-4d9d-bca2-24de1c4550f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tysabri""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Tysabri is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis for the following patient groups:, , , Patients with highly active disease activity despite a full and adequate course of treatment with at least one disease modifying therapy (DMT) (for exceptions and information about washout periods see sections 4.4 and 5.1), , or, Patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more Gadolinium enhancing lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI., , uuid:31af1df3-aca4-4423-ac76-01c5d8995ad2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44185 biolink:treats MONDO:0011429 PMID:41385096 "[{""id"":""uuid:f363eebb-f4d0-49be-b718-9f2dbfcac27e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:533a14ee-b08a-410c-9c05-99809df9a5a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/nordimet""]},{""id"":""uuid:a961f254-3fa3-48ee-9595-6d53cf7d6af4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Nordimet is indicated for the treatment of:active rheumatoid arthritis in adult patients,polyarthritic forms of severe, active juvenile idiopathic arthritis (JIA), when the response to nonsteroidal anti-inflammatory drugs (NSAIDs) has been inadequate,moderate to severe plaque psoriasis in adults who are candidates for systemic therapy, and severe psoriatic arthritis in adult patients, induction of remission in moderate steroid-dependent Crohn's disease in adult patients, in combination with corticosteroids and for maintenance of remission, as monotherapy, in patients who have responded to methotrexate.|[PMDA] Drugs with a new indication and a new dosage for the treatment of juvenile idiopathic arthritis accompanied by articular symptoms. [Expedited review] uuid:3d01be49-cb19-4d87-9ed1-dfe37f558c4d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44185 biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:55906db8-b3a3-4c4c-9f1c-f01b324f5ffa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:21b377ff-ac32-4b2d-958b-bb7662d98fc8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/nordimet""]},{""id"":""uuid:eed45005-ad6a-4e37-9d1d-c9b07984d84d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Nordimet is indicated for the treatment of:active rheumatoid arthritis in adult patients,polyarthritic forms of severe, active juvenile idiopathic arthritis (JIA), when the response to nonsteroidal anti-inflammatory drugs (NSAIDs) has been inadequate,moderate to severe plaque psoriasis in adults who are candidates for systemic therapy, and severe psoriatic arthritis in adult patients, induction of remission in moderate steroid-dependent Crohn's disease in adult patients, in combination with corticosteroids and for maintenance of remission, as monotherapy, in patients who have responded to methotrexate.|[PMDA] A drug with new additional indications and a new dosage for the treatment of plaque psoriasis in patients who have not responded sufficiently to topical therapy, or psoriatic arthritis, pustular psoriasis and erythrodermic psoriasis . [Public knowledge-based application after PAFSC's preliminary assessment] uuid:74ecd59a-f2ff-4efa-9a61-1669f4db5cab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44185 biolink:treats MONDO:0005011 PMID:41385096 "[{""id"":""uuid:b5da796b-65dc-41bd-ab94-1a57a28c8f94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:32cbdbd5-4aab-43f3-8a39-f34d5915f617"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/nordimet""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Nordimet is indicated for the treatment of:active rheumatoid arthritis in adult patients,polyarthritic forms of severe, active juvenile idiopathic arthritis (JIA), when the response to nonsteroidal anti-inflammatory drugs (NSAIDs) has been inadequate,moderate to severe plaque psoriasis in adults who are candidates for systemic therapy, and severe psoriatic arthritis in adult patients, induction of remission in moderate steroid-dependent Crohn's disease in adult patients, in combination with corticosteroids and for maintenance of remission, as monotherapy, in patients who have responded to methotrexate. uuid:09e41816-5113-438f-b857-d64a174bf7a7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1161287 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:71df7955-6a9f-4e44-86d6-c04e5dccbdc0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:09c42414-91b7-4315-933c-05dd03d46bde"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/efavirenz-emtricitabine-tenofovir-disoproxil-mylan""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan is a fixed-dose combination of efavirenz, emtricitabine and tenofovir disoproxil. It is indicated for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years and over with virologic suppression to HIV-1 RNA levels of < 50 copies/ml on their current combination antiretroviral therapy for more than three months. Patients must not have experienced virological failure on any prior antiretroviral therapy and must be known not to have harboured virus strains with mutations conferring significant resistance to any of the three components contained in Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan prior to initiation of their first antiretroviral treatment regimen.The demonstration of the benefit of efavirenz/emtricitabine/tenofovir disoproxil is primarily based on 48-week data from a clinical study in which patients with stable virologic suppression on a combination antiretroviral therapy changed to efavirenz/emtricitabine/tenofovir disoproxil (see section 5.1). No data are currently available from clinical studies with efavirenz/emtricitabine/tenofovir disoproxil in treatment-naïve or in heavily pretreated patients.No data are available to support the combination of efavirenz/emtricitabine/tenofovir disoproxil and other antiretroviral agents. uuid:2644a357-85ca-4d20-a692-67714b04b0cd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90943 biolink:treats NCIT:C150124 PMID:41385096 "[{""id"":""uuid:e920d766-5910-4e7d-8e41-ea0a72039868"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6c34660a-0a53-4cea-b490-5ec10aab9baf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] TAGRISSO as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations- the first-line treatment of adult patients NSCLC with activating EGFR mutations.- the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC.TAGRISSO as monotherapy is indicated for:- the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.- the first-line treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR mutations.- the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC. uuid:0a10aaaa-c2a3-406e-9d2b-d7ab9622f024 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4Z63YK6E0E biolink:treats MONDO:0019438 PMID:41385096 "[{""id"":""uuid:1928ed39-9d78-4fa7-a1d2-e241e697d4ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:acf68284-cc20-41f4-ae22-a754266b6a1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/darzalex""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Multiple MyelomaDarzalex is indicated: in combination with lenalidomide and dexamethasone or with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.in combination with bortezomib, thalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.in combination with pomalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received one prior therapy containing a proteasome inhibitor and lenalidomide and were lenalidomide refractory, or who have received at least two prior therapies that included lenalidomide and a proteasome inhibitor and have demonstrated disease progression on or after the last therapy (see section 5.1).as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.AL AmyloidosisDARZALEX is indicated in combination with cyclophosphamide, bortezomib and dexamethasone for the treatment of adult patients with newly diagnosed systemic light chain (AL) amyloidosis. uuid:f69c459a-1cba-4336-9651-a075dc557e64 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63112 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:b65f373e-559d-4ba8-aaeb-a136abe5ce3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:777c973f-f4f9-494b-be23-d49a15c97f06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following groups of adult and paediatric patients aged 10 years and older:, , Patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (for exceptions and information about washout periods see sections 4.4 and 5.1), , or, , Patients with rapidly evolving severe relapsing remitting multiple sclerosis defined by 2 or more disabling relapses in one year, and with 1 or more Gadolinium enhancing lesions on brain MRI or a significant increase in T2 lesion load as compared to a previous recent MRI., uuid:a0c00da9-a05c-4eac-95fc-b20483e3c910 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9139 biolink:treats MONDO:0001999 PMID:41385096 "[{""id"":""uuid:9a61863d-73c4-49f8-885a-48f7f1de6eac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6777244f-4731-4828-baab-89576f8a6ca6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/revatio""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of adult patients with pulmonary arterial hypertension classified as World Health Organization (WHO) functional class II and III, to improve exercise capacity. Efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease.Paediatric populationTreatment of paediatric patients aged one year to 17 years old with pulmonary arterial hypertension. Efficacy in terms of improvement of exercise capacity or pulmonary haemodynamics has been shown in primary pulmonary hypertension and pulmonary hypertension associated with congenital heart disease.Revatio solution for injection is for the treatment of adult patients with pulmonary arterial hypertension who are currently prescribed oral Revatio and who are temporarily unable to take oral therapy, but are otherwise clinically and haemodynamically stable.Revatio (oral) is indicated for treatment of adult patients with pulmonary arterial hypertension classified as WHO functional class II and III, to improve exercise capacity. Efficacy has been shown in primary pulmonary hypertension and pulmonary hypertension associated with connective tissue disease. uuid:594987b2-4d3e-4820-98ac-5e68c3d4ea4e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229212 biolink:treats MONDO:0018876 PMID:41385096 "[{""id"":""uuid:8c9462b5-40d9-4939-8889-8969e679ab7d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:36bcdae1-f529-45ff-bdb6-49aaa38d24d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/jaypirca""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of mantle cell lymphoma (MCL) uuid:0206955d-a35b-4103-8a1b-4d25199de0a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64355 biolink:treats MONDO:0016426 PMID:41385096 "[{""id"":""uuid:b7bbcf1b-2175-48a9-b551-9b58f35af6a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d0c611dd-82f5-42c7-871d-9232248a2a68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/posaconazole-ahcl""]},{""id"":""uuid:89927752-aa94-49b2-8e3b-da35b23a9347"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Posaconazole AHCL oral suspension is indicated for use in the treatment of the following fungal infections in adults:Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.Oropharyngeal candidiasis: as first-line therapy in patients who have severe disease or are immunocompromised, in whom response to topical therapy is expected to be poor.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Posaconazole AHCL oral suspension is also indicated for prophylaxis of invasive fungal infections in the following patients:Patients receiving remission-induction chemotherapy for acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.|[PMDA] Drugs with a new active ingredient indicated for the prophylaxis of deep mycosis in hematopoietic stem cell transplantation recipients or patients with hematologic malignancy who are predicated to decrease neutrophil. treatment of the following mycoses: Fusariosis, mucormycosis, coccidioidomycosis, chromoblastomycosis, and mycetoma. uuid:757d2d28-28f7-499e-83c1-8f6599d6a9fe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64355 biolink:treats MONDO:0015908 PMID:41385096 "[{""id"":""uuid:8fc51f9e-7afe-41dc-9c02-d46703a182d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0d9365a8-01ab-490f-bd2f-071881395e84"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/posaconazole-ahcl""]},{""id"":""uuid:7a65b2a8-e60e-4def-a75f-80c27639a6e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Posaconazole AHCL oral suspension is indicated for use in the treatment of the following fungal infections in adults:Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.Oropharyngeal candidiasis: as first-line therapy in patients who have severe disease or are immunocompromised, in whom response to topical therapy is expected to be poor.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Posaconazole AHCL oral suspension is also indicated for prophylaxis of invasive fungal infections in the following patients:Patients receiving remission-induction chemotherapy for acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.|[PMDA] Drugs with a new active ingredient indicated for the prophylaxis of deep mycosis in hematopoietic stem cell transplantation recipients or patients with hematologic malignancy who are predicated to decrease neutrophil. treatment of the following mycoses: Fusariosis, mucormycosis, coccidioidomycosis, chromoblastomycosis, and mycetoma. uuid:07da72c7-27b3-403b-852a-b7086bceab52 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64355 biolink:treats MONDO:0016823 PMID:41385096 "[{""id"":""uuid:31b43387-87ae-468c-9915-e677ede82208"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fc034ac4-76c8-4a9b-b622-01fbe9765d5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/posaconazole-ahcl""]},{""id"":""uuid:c148935a-a403-4e04-a6c3-800220602655"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Posaconazole AHCL oral suspension is indicated for use in the treatment of the following fungal infections in adults:Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.Oropharyngeal candidiasis: as first-line therapy in patients who have severe disease or are immunocompromised, in whom response to topical therapy is expected to be poor.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Posaconazole AHCL oral suspension is also indicated for prophylaxis of invasive fungal infections in the following patients:Patients receiving remission-induction chemotherapy for acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.|[PMDA] Drugs with a new active ingredient indicated for the prophylaxis of deep mycosis in hematopoietic stem cell transplantation recipients or patients with hematologic malignancy who are predicated to decrease neutrophil. treatment of the following mycoses: Fusariosis, mucormycosis, coccidioidomycosis, chromoblastomycosis, and mycetoma. uuid:eca7cc5d-a39f-4f42-ab3f-6ea2677c2289 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64355 biolink:treats MONDO:0005706 PMID:41385096 "[{""id"":""uuid:2734872a-3bc6-4a44-833a-13a345b55a41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:db769d23-24ca-491a-b404-dd370215779a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/posaconazole-ahcl""]},{""id"":""uuid:6df3e4d8-2c2b-49d5-aac4-013bcafd0dee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Posaconazole AHCL oral suspension is indicated for use in the treatment of the following fungal infections in adults:Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.Oropharyngeal candidiasis: as first-line therapy in patients who have severe disease or are immunocompromised, in whom response to topical therapy is expected to be poor.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Posaconazole AHCL oral suspension is also indicated for prophylaxis of invasive fungal infections in the following patients:Patients receiving remission-induction chemotherapy for acute myelogenous leukemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.|[PMDA] Drugs with a new active ingredient indicated for the prophylaxis of deep mycosis in hematopoietic stem cell transplantation recipients or patients with hematologic malignancy who are predicated to decrease neutrophil. treatment of the following mycoses: Fusariosis, mucormycosis, coccidioidomycosis, chromoblastomycosis, and mycetoma. uuid:460f7e39-2c7d-4e00-942b-9feeac0b724b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8GZG754X6M biolink:treats MONDO:0018874 PMID:41385096 "[{""id"":""uuid:ec157c82-66f4-443d-90bd-7036d39b851c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e13acbaf-9339-4c4b-920e-13f448bf3ade"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/mylotarg-0""]},{""id"":""uuid:a38b559d-ed36-463d-8790-24799f758657"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Mylotarg is indicated for combination therapy with daunorubicin (DNR) and cytarabine (AraC) for the treatment of patients age 15 years and above with previously untreated, de novo CD33-positive acute myeloid leukaemia (AML), except acute promyelocytic leukaemia (APL).|[PMDA] A drug containing a new active ingredient indicated for the treatment of relapsing or intractable CD33 positive acute myeloid [Orphan drug] uuid:671531f8-e8a2-48f6-869f-9c835468f105 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8GZG754X6M biolink:treats MONDO:0012883 PMID:41385096 "[{""id"":""uuid:0083ddbb-fdee-4f02-82c1-d2346cb8e8b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:82d03ada-2aca-4409-914b-aab6fac2f624"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/mylotarg-0""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Mylotarg is indicated for combination therapy with daunorubicin (DNR) and cytarabine (AraC) for the treatment of patients age 15 years and above with previously untreated, de novo CD33-positive acute myeloid leukaemia (AML), except acute promyelocytic leukaemia (APL). uuid:24c87bda-2141-47bd-8fc5-ab2705e39ad2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4875 biolink:treats MONDO:0011429 PMID:41385096 "[{""id"":""uuid:bf869d83-625a-4aa7-ba7c-275cd53d9352"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f367cdcb-7f16-45af-b68e-d65a1b04a960"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/enbrel""]},{""id"":""uuid:bb12a73e-ecf5-4adb-8ba7-25c90ba39ab3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rheumatoid arthritis, , Enbrel in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults when the response to disease-modifying antirheumatic drugs, including methotrexate (unless contraindicated), has been inadequate., , Enbrel can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate., , Enbrel is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate., , Enbrel, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function., , Juvenile idiopathic arthritis, , Treatment of polyarthritis (rheumatoid-factor-positive or -negative) and extended oligoarthritis in children and adolescents from the age of two years who have had an inadequate response to, or who have proved intolerant of, methotrexate., , Treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate., , Treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy., , Enbrel has not been studied in children aged less than two years., , Psoriatic arthritis, , Treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. Enbrel has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease., , Axial spondyloarthritis, , Ankylosing spondylitis (AS), , Treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy., , Non-radiographic axial spondyloarthritis, , Treatment of adults with severe non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to nonsteroidal anti-inflammatory drugs (NSAIDs). , , Plaque psoriasis , , Treatment of adults with moderate to severe plaque psoriasis who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy, including ciclosporin, methotrexate or psoralen and ultraviolet-A light (PUVA)., , Paediatric plaque psoriasis , , Treatment of chronic severe plaque psoriasis in children and adolescents from the age of six years who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.,|[PMDA] Follow-on biologics indicated for the treatment of rheumatoid arthritis (including the prevention of structural joint damage) and polyarticular-course juvenile idiopathic arthritis in patients who have not responded sufficiently to conventional therapies. uuid:6f16435c-ba82-4c69-8a17-bedfe3ba12f7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4875 biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:1867504e-d67f-44b0-a2f1-ae3d71490b28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0a301dca-4f7d-4bfb-b59b-6c1c3e2160d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/enbrel""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rheumatoid arthritis, , Enbrel in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis in adults when the response to disease-modifying antirheumatic drugs, including methotrexate (unless contraindicated), has been inadequate., , Enbrel can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate., , Enbrel is also indicated in the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate., , Enbrel, alone or in combination with methotrexate, has been shown to reduce the rate of progression of joint damage as measured by X-ray and to improve physical function., , Juvenile idiopathic arthritis, , Treatment of polyarthritis (rheumatoid-factor-positive or -negative) and extended oligoarthritis in children and adolescents from the age of two years who have had an inadequate response to, or who have proved intolerant of, methotrexate., , Treatment of psoriatic arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, methotrexate., , Treatment of enthesitis-related arthritis in adolescents from the age of 12 years who have had an inadequate response to, or who have proved intolerant of, conventional therapy., , Enbrel has not been studied in children aged less than two years., , Psoriatic arthritis, , Treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying antirheumatic drug therapy has been inadequate. Enbrel has been shown to improve physical function in patients with psoriatic arthritis, and to reduce the rate of progression of peripheral joint damage as measured by X-ray in patients with polyarticular symmetrical subtypes of the disease., , Axial spondyloarthritis, , Ankylosing spondylitis (AS), , Treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy., , Non-radiographic axial spondyloarthritis, , Treatment of adults with severe non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to nonsteroidal anti-inflammatory drugs (NSAIDs). , , Plaque psoriasis , , Treatment of adults with moderate to severe plaque psoriasis who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy, including ciclosporin, methotrexate or psoralen and ultraviolet-A light (PUVA)., , Paediatric plaque psoriasis , , Treatment of chronic severe plaque psoriasis in children and adolescents from the age of six years who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies., uuid:b437e6b8-bc8f-4772-8183-d172cdf6c5d0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:178199 biolink:treats UMLS:C2747837 PMID:41385096 "[{""id"":""uuid:7379065a-88fb-4426-870b-f33ba7119fac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a0082b04-5653-42a9-b477-7a69f37b553e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lumykras""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Lumykras as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and who have progressed after at least one prior line of systemic therapy. uuid:f3eddc48-dcd4-466e-b988-7f2ed8d6c423 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45783 biolink:treats MONDO:0004967 PMID:41385096 "[{""id"":""uuid:be8a9ede-3c11-489d-b947-a5e87d669de1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0027b34e-e6ba-4f7b-a5f0-c0f209875766"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/glivec""]},{""id"":""uuid:979a613a-c10b-4d56-a43b-616cc56fa672"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Glivec is indicated for the treatment of, , , adult and paediatric patients with newly diagnosed Philadelphia-chromosome (bcr-abl)-positive (Ph+) chronic myeloid leukaemia (CML) for whom bone-marrow transplantation is not considered as the first line of treatment;, adult and paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult and paediatric patients with newly diagnosed Philadelphia-chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy;, adult patients with relapsed or refractory Ph+ ALL as monotherapy;, adult patients with myelodysplastic / myeloproliferative diseases (MDS / MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (HES) and / or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFRa rearrangement., , , The effect of Glivec on the outcome of bone-marrow transplantation has not been determined., , Glivec is indicated for:, , , the treatment of adult patients with Kit (CD 117)-positive unresectable and / or metastatic malignant gastrointestinal stromal tumours (GIST);, the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST. Patients who have a low or very low risk of recurrence should not receive adjuvant treatment;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and / or metastatic DFSP who are not eligible for surgery., , , In adult and paediatric patients, the effectiveness of Glivec is based on overall haematological and cytogenetic response rates and progression-free survival in CML, on haematological and cytogenetic response rates in Ph+ ALL, MDS / MPD, on haematological response rates in HES / CEL and on objective response rates in adult patients with unresectable and / or metastatic GIST and DFSP and on recurrence-free survival in adjuvant GIST. The experience with Glivec in patients with MDS / MPD associated with PDGFR gene re-arrangements is very limited (see section 5.1). Except in newly diagnosed chronic phase CML, there are no controlled trials demonstrating a clinical benefit or increased survival for these diseases.,|[PMDA] Drug with a new indication and dosage for treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. [Orphan Drug] uuid:da491164-396e-4b4e-8a9e-c78eabf3803c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45783 biolink:treats MONDO:0015691 PMID:41385096 "[{""id"":""uuid:9037f062-fdaf-4e0f-9de6-5aee1cd72a2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ff218228-2a3a-48ef-8057-8e77296098fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/glivec""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Glivec is indicated for the treatment of, , , adult and paediatric patients with newly diagnosed Philadelphia-chromosome (bcr-abl)-positive (Ph+) chronic myeloid leukaemia (CML) for whom bone-marrow transplantation is not considered as the first line of treatment;, adult and paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult and paediatric patients with newly diagnosed Philadelphia-chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy;, adult patients with relapsed or refractory Ph+ ALL as monotherapy;, adult patients with myelodysplastic / myeloproliferative diseases (MDS / MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (HES) and / or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFRa rearrangement., , , The effect of Glivec on the outcome of bone-marrow transplantation has not been determined., , Glivec is indicated for:, , , the treatment of adult patients with Kit (CD 117)-positive unresectable and / or metastatic malignant gastrointestinal stromal tumours (GIST);, the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST. Patients who have a low or very low risk of recurrence should not receive adjuvant treatment;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and / or metastatic DFSP who are not eligible for surgery., , , In adult and paediatric patients, the effectiveness of Glivec is based on overall haematological and cytogenetic response rates and progression-free survival in CML, on haematological and cytogenetic response rates in Ph+ ALL, MDS / MPD, on haematological response rates in HES / CEL and on objective response rates in adult patients with unresectable and / or metastatic GIST and DFSP and on recurrence-free survival in adjuvant GIST. The experience with Glivec in patients with MDS / MPD associated with PDGFR gene re-arrangements is very limited (see section 5.1). Except in newly diagnosed chronic phase CML, there are no controlled trials demonstrating a clinical benefit or increased survival for these diseases., uuid:c1ad5d6e-da54-41b2-817b-c25f85dd0e01 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45783 biolink:treats MONDO:0011719 PMID:41385096 "[{""id"":""uuid:eea2797f-56a6-42a4-83db-abad44de6585"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:24c46c7c-a24f-450a-8de8-c229f861aa61"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/glivec""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Glivec is indicated for the treatment of, , , adult and paediatric patients with newly diagnosed Philadelphia-chromosome (bcr-abl)-positive (Ph+) chronic myeloid leukaemia (CML) for whom bone-marrow transplantation is not considered as the first line of treatment;, adult and paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult and paediatric patients with newly diagnosed Philadelphia-chromosome-positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy;, adult patients with relapsed or refractory Ph+ ALL as monotherapy;, adult patients with myelodysplastic / myeloproliferative diseases (MDS / MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (HES) and / or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFRa rearrangement., , , The effect of Glivec on the outcome of bone-marrow transplantation has not been determined., , Glivec is indicated for:, , , the treatment of adult patients with Kit (CD 117)-positive unresectable and / or metastatic malignant gastrointestinal stromal tumours (GIST);, the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST. Patients who have a low or very low risk of recurrence should not receive adjuvant treatment;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (DFSP) and adult patients with recurrent and / or metastatic DFSP who are not eligible for surgery., , , In adult and paediatric patients, the effectiveness of Glivec is based on overall haematological and cytogenetic response rates and progression-free survival in CML, on haematological and cytogenetic response rates in Ph+ ALL, MDS / MPD, on haematological response rates in HES / CEL and on objective response rates in adult patients with unresectable and / or metastatic GIST and DFSP and on recurrence-free survival in adjuvant GIST. The experience with Glivec in patients with MDS / MPD associated with PDGFR gene re-arrangements is very limited (see section 5.1). Except in newly diagnosed chronic phase CML, there are no controlled trials demonstrating a clinical benefit or increased survival for these diseases., uuid:f95ddc06-4b0f-42fc-974d-8a07043b199b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133013 biolink:treats HP:0007359 PMID:41385096 "[{""id"":""uuid:ad939537-0d1b-4d2c-b47e-f78f40c9cbac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:36b4a611-c591-43f1-bb65-ef4a25e100f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/briviact-italy-nubriveo""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Briviact is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy. uuid:b9f0fe2a-f917-4144-80d3-3cfe69de569c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133013 biolink:treats HP:0011188 PMID:41385096 "[{""id"":""uuid:a7574e84-c537-4a79-8a10-138db2ddc3aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:fc3b3e42-ff09-4e0b-8f0d-6491f4cea5c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/briviact-italy-nubriveo""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Briviact is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy. uuid:d0c56628-0e7d-422c-b376-199999d53b2f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:133013 biolink:treats MONDO:0005027 PMID:41385096 "[{""id"":""uuid:1ede00c9-e9d8-4af1-9e7a-ee8ffdfc615b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:cadc1c09-52cc-4288-990a-dd86fe22d65d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/briviact-italy-nubriveo""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Briviact is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy. uuid:f944abbe-8bd1-4dbc-8be2-f68151e9e769 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:52CMI0WC3Y biolink:treats MONDO:0040679 PMID:41385096 "[{""id"":""uuid:0b66375c-27f0-41e7-8912-e45c03248a7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:133e5bac-b13d-47bd-b290-efaa508991b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tecentriq""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Urothelial carcinomaTecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression ≥ 5% (see section 5.1).Non-small cell lung cancer Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (NSCLC). In patients with EGFR mutant or ALK-positive NSCLC, Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5.1).Tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous NSCLC who do not have EGFR mutant or ALK positive NSCLC (see section 5.1).Tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PD-L1 expression ≥ 50% tumour cells (TC) or ≥ 10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC (see section 5.1).Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR mutant or ALK positive NSCLC should also have received targeted therapies before receiving Tecentriq (see section 5.1).Small cell lung cancerTecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) (see section 5.1).Hepatocellular carcinomaTecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy (see section 5.1).Urothelial carcinomaTecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression ≥ 5% (see section 5.1).Non-small cell lung cancerTecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PD-L1 expression ≥ 50% tumour cells (TC) or ≥ 10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC (see section 5.1).Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR mutant or ALK positive NSCLC should also have received targeted therapies before receiving Tecentriq (see section 5.1).Triple-negative breast cancerTecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease. uuid:e8f898fc-cd0f-437b-87cb-309b5cdd151d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:52CMI0WC3Y biolink:treats MONDO:0005494 PMID:41385096 "[{""id"":""uuid:9dbe48a1-0f21-420e-ac8b-e74dbf5e256e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:33df56d4-2506-4646-b988-55846b6d38a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tecentriq""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Urothelial carcinomaTecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression ≥ 5% (see section 5.1).Non-small cell lung cancer Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (NSCLC). In patients with EGFR mutant or ALK-positive NSCLC, Tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5.1).Tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous NSCLC who do not have EGFR mutant or ALK positive NSCLC (see section 5.1).Tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PD-L1 expression ≥ 50% tumour cells (TC) or ≥ 10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC (see section 5.1).Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR mutant or ALK positive NSCLC should also have received targeted therapies before receiving Tecentriq (see section 5.1).Small cell lung cancerTecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) (see section 5.1).Hepatocellular carcinomaTecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy (see section 5.1).Urothelial carcinomaTecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a PD-L1 expression ≥ 5% (see section 5.1).Non-small cell lung cancerTecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a PD-L1 expression ≥ 50% tumour cells (TC) or ≥ 10% tumour-infiltrating immune cells (IC) and who do not have EGFR mutant or ALK-positive NSCLC (see section 5.1).Tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic NSCLC after prior chemotherapy. Patients with EGFR mutant or ALK positive NSCLC should also have received targeted therapies before receiving Tecentriq (see section 5.1).Triple-negative breast cancerTecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD-L1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease. uuid:1422e3f1-b2dd-4081-b427-dfd3eed1fc30 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63918 biolink:treats MONDO:0005625 PMID:41385096 "[{""id"":""uuid:ad6e23a7-9b1e-40f9-8e20-47a38e6d70ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9e90cf24-596b-4227-8352-7db3ae0dd41a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/artesunate-amivas""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Artesunate Amivas is indicated for the initial treatment of severe malaria in adults and children.Consideration should be given to official guidance on the appropriate use of antimalarial agents. uuid:7a6bbd8c-d9aa-4116-9a6b-f64fc5b3a4e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85164 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:f7b4a086-7309-4943-8e2a-53ef6269de4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:02bde5a6-fd22-4699-a546-0b035989e366"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vargatef""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Vargatef is indicated in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first line chemotherapy. uuid:dc5b941d-3750-47a3-af6b-aa309724da42 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85164 biolink:treats MONDO:0004970 PMID:41385096 "[{""id"":""uuid:54e2f229-ea11-4178-a19e-4946a8914723"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:481728c0-54ce-4f5f-a4fd-0139e787e6ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vargatef""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Vargatef is indicated in combination with docetaxel for the treatment of adult patients with locally advanced, metastatic or locally recurrent non-small cell lung cancer (NSCLC) of adenocarcinoma tumour histology after first line chemotherapy. uuid:c0d25b8a-e09d-4e40-9be8-ab5809265800 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:09495UIM6V biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:2a3c0eee-d796-487b-a9d4-06f1dd43aad4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:27abad27-eb13-4345-9838-f4b641fc57a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/bimzelx""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Plaque psoriasisBimzelx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.Psoriatic arthritisBimzelx, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).Axial spondyloarthritisNon-radiographic axial spondyloarthritis (nr-axSpA)Bimzelx is indicated for the treatment of adults with active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) who have responded inadequately or are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs).Ankylosing spondylitis (AS, radiographic axial spondyloarthritis)Bimzelx is indicated for the treatment of adults with active ankylosing spondylitis who have responded inadequately or are intolerant to conventional therapy. uuid:da38b74d-3ec5-4011-bc98-49d8f2412b22 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71197 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:815392c6-40e3-4193-9676-305d8e9a03f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:728c3a56-f756-4e0b-9926-2f50040fe9f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/xeljanz""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rheumatoid arthritisTofacitinib in combination with methotrexate (MTX) is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (DMARDs) (see section 5.1). Tofacitinib can be given as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate (see sections 4.4 and 4.5).Psoriatic arthritisTofacitinib in combination with MTX is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (DMARD) therapy (see section 5.1).Ulcerative colitisTofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5.1).Tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [RF+] or negative [RF-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (PsA) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (DMARDs).Tofacitinib can be given in combination with methotrexate (MTX) or as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.Ankylosing spondylitisTofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy. uuid:a5533d34-1e18-47d7-a461-ab7790f5be50 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71197 biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:47b5f126-b168-49aa-819e-7b14a4522555"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:367dde90-4add-45a5-8cce-8255b90ebe09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/xeljanz""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rheumatoid arthritisTofacitinib in combination with methotrexate (MTX) is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (DMARDs) (see section 5.1). Tofacitinib can be given as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate (see sections 4.4 and 4.5).Psoriatic arthritisTofacitinib in combination with MTX is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (DMARD) therapy (see section 5.1).Ulcerative colitisTofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5.1).Tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [RF+] or negative [RF-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (PsA) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (DMARDs).Tofacitinib can be given in combination with methotrexate (MTX) or as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.Ankylosing spondylitisTofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy. uuid:11fbf18f-62a1-4a13-8422-af9e3122f44f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71197 biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:f0911c4d-e8ec-4c6a-bf5e-c53e14bfd4bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9a4728e8-19c4-4db1-acde-31ed932fd7ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/xeljanz""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rheumatoid arthritisTofacitinib in combination with methotrexate (MTX) is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (DMARDs) (see section 5.1). Tofacitinib can be given as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate (see sections 4.4 and 4.5).Psoriatic arthritisTofacitinib in combination with MTX is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (DMARD) therapy (see section 5.1).Ulcerative colitisTofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5.1).Tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [RF+] or negative [RF-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (PsA) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (DMARDs).Tofacitinib can be given in combination with methotrexate (MTX) or as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.Ankylosing spondylitisTofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy. uuid:c6b44a95-e335-441d-a54d-032266149ac0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71197 biolink:treats MONDO:0018456 PMID:41385096 "[{""id"":""uuid:462a3298-9ec1-4223-88c6-70b37a3e32b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:89d50c1f-c127-4dcc-acde-1bb5c78fa7ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/xeljanz""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rheumatoid arthritisTofacitinib in combination with methotrexate (MTX) is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (DMARDs) (see section 5.1). Tofacitinib can be given as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate (see sections 4.4 and 4.5).Psoriatic arthritisTofacitinib in combination with MTX is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (DMARD) therapy (see section 5.1).Ulcerative colitisTofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5.1).Tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [RF+] or negative [RF-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (PsA) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (DMARDs).Tofacitinib can be given in combination with methotrexate (MTX) or as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.Ankylosing spondylitisTofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy. uuid:e9fca0ad-cd4a-49d3-8095-48a4f283b275 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71197 biolink:treats MONDO:0019436 PMID:41385096 "[{""id"":""uuid:cb55bba6-95e6-4556-82a6-42ca8a74f4e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4cbc4001-f80c-42af-9d47-fd4659ecd1fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/xeljanz""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rheumatoid arthritisTofacitinib in combination with methotrexate (MTX) is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (DMARDs) (see section 5.1). Tofacitinib can be given as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate (see sections 4.4 and 4.5).Psoriatic arthritisTofacitinib in combination with MTX is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (DMARD) therapy (see section 5.1).Ulcerative colitisTofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5.1).Tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [RF+] or negative [RF-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (PsA) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (DMARDs).Tofacitinib can be given in combination with methotrexate (MTX) or as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.Ankylosing spondylitisTofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy. uuid:5cd7a7d6-8211-4536-b781-a90abf493b39 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71197 biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:271d77bd-083a-4c9f-909e-95fbe1c5a5cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ddca02a5-0ea3-43d1-abad-744f7717acf0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/xeljanz""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rheumatoid arthritisTofacitinib in combination with methotrexate (MTX) is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (DMARDs) (see section 5.1). Tofacitinib can be given as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate (see sections 4.4 and 4.5).Psoriatic arthritisTofacitinib in combination with MTX is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (DMARD) therapy (see section 5.1).Ulcerative colitisTofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5.1).Tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [RF+] or negative [RF-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (PsA) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (DMARDs).Tofacitinib can be given in combination with methotrexate (MTX) or as monotherapy in case of intolerance to MTX or where continued treatment with MTX is inappropriate.Ankylosing spondylitisTofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (AS) who have responded inadequately to conventional therapy. uuid:6530b628-5345-40d0-8be7-6bc0700bd453 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:A10SJL62JY biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:e7205a62-3e67-4613-a6e0-0cd8cb8e15e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:48516410-c966-46f5-bfe5-8d6051b1e488"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ocrevus""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.Treatment of adult patients with early primary progressive multiple sclerosis (PPMS) in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity. uuid:2b0c1266-f703-422f-af4e-445efab9d656 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9RV78Q2002 biolink:treats MONDO:0005312 PMID:41385096 "[{""id"":""uuid:8293c087-c403-474e-90cf-87ababf6a91a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d3d62b95-c24c-4130-9705-b74d1aa54a97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/entyvio""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ulcerative colitisEntyvio is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor alpha (TNFα) antagonist.Crohn’s diseaseEntyvio is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor alpha (TNFα) antagonist.PouchitisEntyvio is indicated for the treatment of adult patients with moderately to severely active chronic pouchitis, who have undergone proctocolectomy and ileal pouch anal anastomosis for ulcerative colitis, and have had an inadequate response with or lost response to antibiotic therapy. uuid:b70b57ca-9877-4837-be38-615d09f62e4f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:LDJ89SS0YG biolink:treats MONDO:0018906 PMID:41385096 "[{""id"":""uuid:5c9d25d2-cf9c-4f11-84a3-b2174c922805"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e6e93ecf-d3bf-4003-965f-7e2c4af36fe7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lunsumio""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior systemic therapies. uuid:d89c4b88-3124-4e76-a354-93f234931bcf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:90ZX3Q3FR7 biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:aae333d7-f7a4-4fa7-9a2e-f288a6659924"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:32a22a6f-430b-4c60-9cda-1f3bda0b7b02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/skyrizi""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Plaque PsoriasisSkyrizi is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.Psoriatic ArthritisSkyrizi, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adults who have had an inadequate response or who have been intolerant to one or more disease-modifying antirheumatic drugs (DMARDs).Crohn's diseaseSkyrizi is indicated for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response to, lost response to, or were intolerant to conventional therapy or a biologic therapy. uuid:26e367a6-b362-430f-a419-bb5ddc187a82 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4AWF0N6QV3 biolink:treats MONDO:0001475 PMID:41385096 "[{""id"":""uuid:274ea98d-aa0a-45d6-a4ec-a928cf8f5bbf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:740b983e-f865-4586-977c-0520ba3a202c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lonquex""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Lonquex is indicated in adults and in children 2 years of age and older for reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes). uuid:cf9b8b73-2bdf-45d9-9dc4-8eaf0d3d0535 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4AWF0N6QV3 biolink:treats MONDO:0004992 PMID:41385096 "[{""id"":""uuid:69f0d983-227a-4d8e-83cb-fc88c08f0485"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4297b44c-b7de-4589-a3c1-96ee5a175319"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lonquex""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Lonquex is indicated in adults and in children 2 years of age and older for reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes). uuid:59b07dd1-521f-4928-a9d8-1cc0876a7067 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:757603 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:be45806c-cf8f-46cb-924f-5c3ec548e6e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:756cf40d-9044-4609-a338-e02aeade3981"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/velmetia""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] For patients with type-2 diabetes mellitus:Velmetia is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin.Velmetia is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea.Velmetia is indicated as triple combination therapy with a PPAR agonist (i.e. a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a PPAR agonist.Velmetia is also indicated as add on to insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dosage of insulin and metformin alone do not provide adequate glycaemic control. uuid:f3e75d27-f070-4b16-a1dc-fb8e320fd9e6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10023 biolink:treats MONDO:0044067 PMID:41385096 "[{""id"":""uuid:1f278340-d7a6-4ea9-9bfc-832126294835"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ee4a22f0-c089-4590-82ec-f0d427ef2d79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vfend""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Voriconazole, is a broad spectrum, triazole antifungal agent and is indicated in adults and children aged 2 years and above as follows:treatment of invasive aspergillosis;treatment of in candidaemianon-neutropenic patients;treatment of fluconazole-resistant serious invasive Candida infections (including C. krusei);Treatment of serious fungal infections caused by Scedosporium spp. and Fusarium spp.Vfend should be administered primarily to patients with progressive, possibly life-threatening infections.Prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (HSCT) recipients. uuid:b1e4e13a-11f3-45df-ba59-fbc76efef990 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10023 biolink:treats MONDO:0002041 PMID:41385096 "[{""id"":""uuid:f2ee4b7c-cd6f-4095-ae16-20a692499aed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5fdf13ff-0c19-41a6-9fb9-11c583b2285c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vfend""]},{""id"":""uuid:83e8645b-c668-4dc5-acfd-fcafb9d06984"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Voriconazole, is a broad spectrum, triazole antifungal agent and is indicated in adults and children aged 2 years and above as follows:treatment of invasive aspergillosis;treatment of in candidaemianon-neutropenic patients;treatment of fluconazole-resistant serious invasive Candida infections (including C. krusei);Treatment of serious fungal infections caused by Scedosporium spp. and Fusarium spp.Vfend should be administered primarily to patients with progressive, possibly life-threatening infections.Prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (HSCT) recipients.|[PMDA] Drugs with new additional pediatric dosages, and a drug with a new additional pediatric dosage in an additional dosage form of dry syrup indicated for the treatment of severe or refractory fungus infection. uuid:f0d5db7c-991c-4d6f-8b6e-625721aa9246 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:71308244 biolink:treats MONDO:0100187 PMID:41385096 "[{""id"":""uuid:be85b36d-69ba-4143-b85b-2e6d67d216d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d5567e8f-3f98-4ec2-8f4d-850787c75730"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:6ea9a91b-d412-42f6-8acc-f49b18b28c29"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rizmoic is indicated for the treatment of opioid-induced constipation (OIC) in adult patients who have previously been treated with a laxative.|[PMDA] A drug with a new active ingredient indicated for the treatment of opioid-induced constipation. uuid:7f2e84f6-dc7f-4aa0-b607-ae061af261ac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135939 biolink:treats HP:0007359 PMID:41385096 "[{""id"":""uuid:ee1c66d0-6c77-4249-bccd-e75df2146e91"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:72e49fbf-ed5f-472a-9906-4c6b0aed8cee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vimpat""]},{""id"":""uuid:e172a3a6-1f48-45d1-b3b5-cc5d2ec6a1fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Vimpat is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.|[PMDA] Drugs with a new active ingredient indicated for the use as an adjunctive therapy with other antiepileptic drugs to treat partial seizures (including secondary generalized seizures) in patients with epilepsy who have not responded sufficiently to other antiepileptic drugs. uuid:940c8903-773d-4b89-bc80-1aec5535935e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135939 biolink:treats MONDO:0005027 PMID:41385096 "[{""id"":""uuid:2d6f42f7-e4d4-4e99-8df7-ac850bcf8485"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3d2e5f33-0527-4491-8797-44619e72c804"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vimpat""]},{""id"":""uuid:5a9b049b-e565-4f7d-8452-7434e69accdd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Vimpat is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.|[PMDA] Drugs with a new active ingredient indicated for the use as an adjunctive therapy with other antiepileptic drugs to treat partial seizures (including secondary generalized seizures) in patients with epilepsy who have not responded sufficiently to other antiepileptic drugs. uuid:1d8bc244-fc64-4b9d-8e5d-d3684cf2a07f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:176844 biolink:treats MONDO:0008170 PMID:41385096 "[{""id"":""uuid:4d5832f6-6f8e-41f7-be5b-d30c76f56852"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:82d186b8-2e73-4d24-87d4-f53e1af28942"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:18d64003-843a-4c1e-9cdb-5decbe1ff8cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Zejula is indicated:, , , as monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy., as monotherapy for the maintenance treatment of adult patients with platinum sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy., ,|[PMDA] A drug with a new active ingredient indicated for the maintenance treatment of ovarian cancer in patients who have received first chemotherapy, the maintenance treatment of recurrent ovarian cancer in patients who are in a complete or partial response to platinum-based chemotherapy, and the treatment of homologous recombination deficiency (HRD)-positive recurrent ovarian cancer in patients who are in a complete or partial response to platinum-based chemotherapy. uuid:f939b359-dd6b-4c65-9581-551ff527e29f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76607 biolink:treats MONDO:0017147 PMID:41385096 "[{""id"":""uuid:2be4fc97-4139-43c7-a589-1fda06e1bfda"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:65c113e7-1a99-4854-a480-f7e39a57382b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/opsumit""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Opsumit, as monotherapy or in combination, is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III.Efficacy has been shown in a PAH population including idiopathic and heritable PAH, PAH associated with connective tissue disorders, and PAH associated with corrected simple congenital heart disease. uuid:0644fbdc-38a7-41d3-aaf9-7d02da8d850f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76607 biolink:treats MONDO:0017148 PMID:41385096 "[{""id"":""uuid:a26f8d22-10c8-463e-aaf0-7ad00cdffabd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9e267d01-86a6-446a-9072-b164f9e99ba2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/opsumit""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Opsumit, as monotherapy or in combination, is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients of WHO Functional Class (FC) II to III.Efficacy has been shown in a PAH population including idiopathic and heritable PAH, PAH associated with connective tissue disorders, and PAH associated with corrected simple congenital heart disease. uuid:c2dc8280-b632-463c-8ef0-fb7d448048d3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:27Y83O992Q biolink:treats MONDO:0010604 PMID:41385096 "[{""id"":""uuid:16f03dca-55bd-4e42-a643-e4f2cf2b2ef9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c2cc991f-f0b6-4f26-8f54-83d8b0c27691"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/refixia""]},{""id"":""uuid:27229815-f8a8-406f-bcd8-342c876adf58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency)., Refixia can be used for all age groups.,|[PMDA] Drugs with a new active ingredient indicated for the control of bleeding tendency in patients with coagulation factor IX deficiency. uuid:3d1d35ba-0282-44b2-9769-924a46639f9c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72297 biolink:treats MONDO:0018328 PMID:41385096 "[{""id"":""uuid:6e0d18b0-2ebb-4f3b-b745-6ca7916960d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b822891f-0488-42b6-ad75-ff73afadcec1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lojuxta""]},{""id"":""uuid:2fdd2f4b-8f34-4584-bdc9-7d651d8cec40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Lojuxta is indicated as an adjunct to a low‑fat diet and other lipid‑lowering medicinal products with or without low-density-lipoprotein (LDL) apheresis in adult patients with homozygous familial hypercholesterolaemia (HoFH)., , Genetic confirmation of HoFH should be obtained whenever possible. Other forms of primary hyperlipoproteinaemia and secondary causes of hypercholesterolaemia (e.g. nephrotic syndrome, hypothyroidism) must be excluded.,|[PMDA] Drugs with a new active ingredient indicated for the treatment of homozygous familial hypercholesterolemia. [Orphan drug] uuid:b7c2fd52-87f0-4e15-9ca0-c491a5ddf5d9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72297 biolink:treats MONDO:0005377 PMID:41385096 "[{""id"":""uuid:894b1858-5221-4b94-bed3-5b50cc635362"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5a5cfef4-b022-41dc-88b3-42d5798b5881"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lojuxta""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Lojuxta is indicated as an adjunct to a low‑fat diet and other lipid‑lowering medicinal products with or without low-density-lipoprotein (LDL) apheresis in adult patients with homozygous familial hypercholesterolaemia (HoFH)., , Genetic confirmation of HoFH should be obtained whenever possible. Other forms of primary hyperlipoproteinaemia and secondary causes of hypercholesterolaemia (e.g. nephrotic syndrome, hypothyroidism) must be excluded., uuid:917e14f3-0986-4cc0-8b7e-c0857682f0da biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72297 biolink:treats MONDO:0005420 PMID:41385096 "[{""id"":""uuid:b5688086-44a0-4f00-8b45-77839137e574"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d1dc7131-8bc0-457d-953b-ac1687d4bda3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lojuxta""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Lojuxta is indicated as an adjunct to a low‑fat diet and other lipid‑lowering medicinal products with or without low-density-lipoprotein (LDL) apheresis in adult patients with homozygous familial hypercholesterolaemia (HoFH)., , Genetic confirmation of HoFH should be obtained whenever possible. Other forms of primary hyperlipoproteinaemia and secondary causes of hypercholesterolaemia (e.g. nephrotic syndrome, hypothyroidism) must be excluded., uuid:a6e221e6-d2dc-438e-95ef-8297cd773879 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB00028 biolink:treats MONDO:0021094 PMID:41385096 "[{""id"":""uuid:d3a3f4d0-54d6-4845-9bae-f83256e47e6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:de729734-3ddb-41b8-954f-972bab816596"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/flebogamma-dif""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Replacement therapy in adults, children and adolescents (0-18 years) in:, , , primary immunodeficiency syndromes with impaired antibody production;, hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic luekaemia, in whom prophylactic antibiotics have failed;, hypogammaglobulinaemia and recurrent bacterial infections in plateau-phase-multiple-myeloma patients who failed to respond to pneumococcal immunisation;, hypogammaglobulinaemia in patients after allogenic haematopoietic-stem-cell transplantation (HSCT);, congenital AIDS with recurrent bacterial infections., , , Immunomodulation in adults, children and adolescents (0-18 years) in:, , , primary immune thrombocytopenia (ITP), in patients at high risk of bleeding or prior to surgery to correct the platelet count;, Guillain Barré syndrome;, Kawasaki disease., , uuid:08f5eb72-c11b-4629-b1c5-55e1cf58a698 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB00028 biolink:treats MONDO:0003864 PMID:41385096 "[{""id"":""uuid:4fd83900-91d7-4bdd-9d18-f229bb5724fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:272a8dd1-8b10-4f65-a77f-69af153d07c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/flebogamma-dif""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Replacement therapy in adults, children and adolescents (0-18 years) in:, , , primary immunodeficiency syndromes with impaired antibody production;, hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic luekaemia, in whom prophylactic antibiotics have failed;, hypogammaglobulinaemia and recurrent bacterial infections in plateau-phase-multiple-myeloma patients who failed to respond to pneumococcal immunisation;, hypogammaglobulinaemia in patients after allogenic haematopoietic-stem-cell transplantation (HSCT);, congenital AIDS with recurrent bacterial infections., , , Immunomodulation in adults, children and adolescents (0-18 years) in:, , , primary immune thrombocytopenia (ITP), in patients at high risk of bleeding or prior to surgery to correct the platelet count;, Guillain Barré syndrome;, Kawasaki disease., , uuid:b2918af9-1639-4900-859d-debf9fdf712b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB00028 biolink:treats MONDO:0012268 PMID:41385096 "[{""id"":""uuid:0824319a-776a-4b6c-b30d-edce5fb47bf2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:db0d1fa2-cb14-4781-8edc-9d533b4122da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/flebogamma-dif""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Replacement therapy in adults, children and adolescents (0-18 years) in:, , , primary immunodeficiency syndromes with impaired antibody production;, hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic luekaemia, in whom prophylactic antibiotics have failed;, hypogammaglobulinaemia and recurrent bacterial infections in plateau-phase-multiple-myeloma patients who failed to respond to pneumococcal immunisation;, hypogammaglobulinaemia in patients after allogenic haematopoietic-stem-cell transplantation (HSCT);, congenital AIDS with recurrent bacterial infections., , , Immunomodulation in adults, children and adolescents (0-18 years) in:, , , primary immune thrombocytopenia (ITP), in patients at high risk of bleeding or prior to surgery to correct the platelet count;, Guillain Barré syndrome;, Kawasaki disease., , uuid:82d204be-9cd6-4504-9c96-e25f9ea4ff87 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB00028 biolink:treats MONDO:0008558 PMID:41385096 "[{""id"":""uuid:05f22bd7-5587-431c-9f05-e1a696db3b82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:af8a1f4a-d92f-4adb-9e63-26d277ab334d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/flebogamma-dif""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Replacement therapy in adults, children and adolescents (0-18 years) in:, , , primary immunodeficiency syndromes with impaired antibody production;, hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic luekaemia, in whom prophylactic antibiotics have failed;, hypogammaglobulinaemia and recurrent bacterial infections in plateau-phase-multiple-myeloma patients who failed to respond to pneumococcal immunisation;, hypogammaglobulinaemia in patients after allogenic haematopoietic-stem-cell transplantation (HSCT);, congenital AIDS with recurrent bacterial infections., , , Immunomodulation in adults, children and adolescents (0-18 years) in:, , , primary immune thrombocytopenia (ITP), in patients at high risk of bleeding or prior to surgery to correct the platelet count;, Guillain Barré syndrome;, Kawasaki disease., , uuid:b901d22b-a281-40fa-b9a4-c7dea1beed98 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB00028 biolink:treats MONDO:0016218 PMID:41385096 "[{""id"":""uuid:b9174bf2-8519-4ede-9adc-f0143690bbb6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ee72de96-8e8a-46e2-891a-bbd6d1fc3b16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/flebogamma-dif""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Replacement therapy in adults, children and adolescents (0-18 years) in:, , , primary immunodeficiency syndromes with impaired antibody production;, hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic luekaemia, in whom prophylactic antibiotics have failed;, hypogammaglobulinaemia and recurrent bacterial infections in plateau-phase-multiple-myeloma patients who failed to respond to pneumococcal immunisation;, hypogammaglobulinaemia in patients after allogenic haematopoietic-stem-cell transplantation (HSCT);, congenital AIDS with recurrent bacterial infections., , , Immunomodulation in adults, children and adolescents (0-18 years) in:, , , primary immune thrombocytopenia (ITP), in patients at high risk of bleeding or prior to surgery to correct the platelet count;, Guillain Barré syndrome;, Kawasaki disease., , uuid:4b104ea7-d419-48a6-967c-0c4e7dc1b5f2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB00028 biolink:treats MONDO:0012727 PMID:41385096 "[{""id"":""uuid:d16c6880-d966-48d9-a26b-83bb1e58c063"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:add06778-d557-4baa-b497-4c3eaf7baf3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/flebogamma-dif""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Replacement therapy in adults, children and adolescents (0-18 years) in:, , , primary immunodeficiency syndromes with impaired antibody production;, hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic luekaemia, in whom prophylactic antibiotics have failed;, hypogammaglobulinaemia and recurrent bacterial infections in plateau-phase-multiple-myeloma patients who failed to respond to pneumococcal immunisation;, hypogammaglobulinaemia in patients after allogenic haematopoietic-stem-cell transplantation (HSCT);, congenital AIDS with recurrent bacterial infections., , , Immunomodulation in adults, children and adolescents (0-18 years) in:, , , primary immune thrombocytopenia (ITP), in patients at high risk of bleeding or prior to surgery to correct the platelet count;, Guillain Barré syndrome;, Kawasaki disease., , uuid:b5853fce-93c7-404e-aca7-aa80a0fc16a1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:OP35X9610Y biolink:treats NCIT:C118469 PMID:41385096 "[{""id"":""uuid:1a5474dc-1f52-4501-8c0c-e65972ab5b56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:922ab557-5e12-4879-955c-7a5f0fb23de5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/skytrofa-previously-lonapegsomatropin-ascendis-pharma""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Growth failure in children and adolescents aged from 3 years up to 18 years due to insufficient endogenous growth hormone secretion (growth hormone deficiency [GHD]), uuid:1262ecc3-3fd9-4813-bd8f-f3a4e2424483 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:125354 biolink:treats MONDO:0005062 PMID:41385096 "[{""id"":""uuid:509bbbb3-9624-4044-ab4c-34eba4c9cb06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:423607f5-1127-4a09-911b-bd56256ae764"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/mozobil""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Mozobil is indicated in combination with granulocyte-colony-stimulating factor to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with lymphoma and multiple myeloma whose cells mobilise poorly., uuid:74d4bb40-bc85-4e35-9eee-78d0f2543eeb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:261454 biolink:treats MONDO:0001134 PMID:41385096 "[{""id"":""uuid:83e05cd3-57e7-415f-8bec-76e5b13a0079"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c8329629-a14a-44f1-bb25-3e74152aee4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/coaprovel""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of essential hypertension. This fixed dose combination is indicated in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone. uuid:49570e32-6446-45ba-8639-f924f5e9a281 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:84500 biolink:treats UMLS:C2586081 PMID:41385096 "[{""id"":""uuid:e8adc65b-d269-446d-8f7c-2bfc205021a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:109fe07c-e492-4e75-b676-698931549860"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/champix""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Champix is indicated for smoking cessation in adults. uuid:e978b1cb-78ca-4e20-baf8-e21f2fde8b97 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:JSV288Q5CV biolink:treats MONDO:0100096 PMID:41385096 "[{""id"":""uuid:fcb5fea5-58b4-4617-ac42-54ecdb804003"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:60732906-944e-415f-936f-b032f1121d04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:aa2fde75-dc80-4cb4-9d58-e7678c100c03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 12 years of age and older. Comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 12 years of age and older. Comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in children aged 5 to 11 years. Comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in infants and children aged 6 months to 4 years. Comirnaty Original/Omicron BA.1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against COVID-19.Comirnaty Original/Omicron BA.4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 12 years of age and older.Comirnaty Original/Omicron BA.4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in children aged 5 to 11 years.Comirnaty Original/Omicron BA.4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in children aged 5 to 11 years. Comirnaty Original/Omicron BA.4-5 (1.5/1.5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in infants and children aged 6 months to 4 years. Comirnaty Omicron XBB.1.5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in individuals 12 years of age and older.Comirnaty Omicron XBB.1.5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in children aged 5 to 11 years.Comirnaty Omicron XBB.1.5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in children aged 5 to 11 years.Comirnaty Omicron XBB.1.5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2, in infants and children aged 6 months to 4 years.The use of this vaccine should be in accordance with official recommendations.|[PMDA] A drug with a new additional pediatric dosage in an additional dosage form indicated for the prevention of disease caused by SARS-CoV-2 infection (COVID-19). [Drug pertaining to Special Approval for Emergency] uuid:757f0bbd-f9d6-4416-a882-3e2bb6e2b778 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71013 biolink:treats HP:0007359 PMID:41385096 "[{""id"":""uuid:913c8fc4-f5ac-4569-a92c-36c1a850a8ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6a763926-3124-4044-9876-7f9511406f36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/fycompa""]},{""id"":""uuid:3298dfbd-2fde-4010-ad09-b4b7ebcb8437"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Fycompa is indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in adult and adolescent patients from 12 years of age with epilepsy.Fycompa is indicated for the adjunctive treatment of primary generalised tonic-clonic seizures in adult and adolescent patients from 12 years of age with idiopathic generalised epilepsy.|[PMDA] A drug with a new route of administration indicated for the following treatment: partial seizures (including secondary generalized seizures) in patients with epilepsy and an adjunctive therapy with other antiepileptic drugs to treat tonic-clonic seizure in patients with epilepsy who have not responded sufficiently to other antiepileptic drugs. It is used as an alternative therapy for perampanel oral formulation in patients who are temporarily unable to be administered orally. uuid:b0eaecb8-febe-48a6-bc66-f14ab95c37a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71013 biolink:treats UMLS:C0270838 PMID:41385096 "[{""id"":""uuid:3fdfebe2-12c8-409d-83d3-e2cce24aa429"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:687c4637-7609-4c14-bbd8-93254b683609"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/fycompa""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Fycompa is indicated for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in adult and adolescent patients from 12 years of age with epilepsy.Fycompa is indicated for the adjunctive treatment of primary generalised tonic-clonic seizures in adult and adolescent patients from 12 years of age with idiopathic generalised epilepsy. uuid:b4a5440d-e80b-4a80-87fa-ea3d9ba09d0b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:73B0K5S26A biolink:treats MONDO:0007915 PMID:41385096 "[{""id"":""uuid:39c89915-6ebc-450e-8aab-2c9384f2563d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cd881916-5701-43e1-a2fe-9bd1557ab6f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/benlysta""]},{""id"":""uuid:7059a47a-7db3-4107-8642-a4139d5253e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Benlysta is indicated as add-on therapy in patients aged 5 years and older with active, autoantibody positive systemic lupus erythematosus (SLE) with a high degree of disease activity (e.g., positive anti dsDNA and low complement) despite standard therapy.Benlysta is indicated in combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis.|[PMDA] Drugs with a new active ingredient indicated for the treatment of systemic lupus erythematosus in patients who have not responded sufficiently to conventional treatments. uuid:6b63528d-7657-4904-b26a-bc4d600823d3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB13915 biolink:treats MONDO:0018905 PMID:41385096 "[{""id"":""uuid:c22aef2e-6e0a-4fd5-a155-83a3041661e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:942f59eb-601d-4b1a-8929-fa4c1b0562b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/yescarta""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Yescarta is indicated for the treatment of adult patients with diffuse large B cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy.Yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) DLBCL and primary mediastinal large B cell lymphoma (PMBCL), after two or more lines of systemic therapy.Yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (FL) after three or more lines of systemic therapy. uuid:7d4a27e8-bc65-41dc-b069-6229aa951a6a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB13915 biolink:treats MONDO:0020323 PMID:41385096 "[{""id"":""uuid:b3fa80c2-3f9f-4a9b-98b1-072ba3708754"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6b56f18d-9f7b-47f5-abe0-dd8e4df10f73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/yescarta""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Yescarta is indicated for the treatment of adult patients with diffuse large B cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy.Yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) DLBCL and primary mediastinal large B cell lymphoma (PMBCL), after two or more lines of systemic therapy.Yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (FL) after three or more lines of systemic therapy. uuid:c6977961-de3c-431b-8c8e-c5c47d27f313 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB13915 biolink:treats MONDO:0018906 PMID:41385096 "[{""id"":""uuid:167ddab6-daa4-4c09-ac01-6606782bd00f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4598ed63-cea3-4323-a29e-b0db872d47c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/yescarta""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Yescarta is indicated for the treatment of adult patients with diffuse large B cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy.Yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) DLBCL and primary mediastinal large B cell lymphoma (PMBCL), after two or more lines of systemic therapy.Yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (FL) after three or more lines of systemic therapy. uuid:4a087155-3e42-4271-b98b-214117038b51 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49375 biolink:treats MONDO:0006115 PMID:41385096 "[{""id"":""uuid:17b8f00d-9eec-4b6f-b45b-4cc11ca1b442"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a8192635-0e37-4b12-b98e-c3ef0d35ab39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Sprycel is indicated for the treatment of paediatric patients with:newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukaemia in chronic phase (Ph+ CML CP) or Ph+ CML CP resistant or intolerant to prior therapy including imatinib.newly diagnosed Ph+ acute lymphoblastic leukaemia (ALL) in combination with chemotherapy.Sprycel is indicated for the treatment of adult patients with:newly diagnosed Philadelphia-chromosome-positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase;chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib mesilate;Ph+ acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy.Sprycel is indicated for the treatment of paediatric patients with:newly diagnosed Ph+ CML in chronic phase (Ph+ CML-CP) or Ph+ CML-CP resistant or intolerant to prior therapy including imatinib. uuid:812b9c30-31bc-4872-a3f1-47a357cfdc6a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9H414A99MD biolink:treats MONDO:0043731 PMID:41385096 "[{""id"":""uuid:dd99c6a2-76b1-4798-a8e4-ce9ab89dfb33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:dddb14d1-caf9-4d1e-82df-3a0be4c1b921"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Xofigo is indicated for the treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases. uuid:02d950e2-b081-407a-8a80-9b15034e5093 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:54534MX6Z9 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:c20a69c3-0a11-49ab-9988-a90df7ed5192"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d250382d-b7c8-4261-a57a-a399ce4fdb85"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tecvayli""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] TECVAYLI is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy. uuid:819b6443-8056-44ec-abb2-da1ea802d9a5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31687 biolink:treats MONDO:0010788 PMID:41385096 "[{""id"":""uuid:8f1874ea-e93e-4c95-926e-ac5c91396399"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:423e760d-29ba-4482-9627-456e796d40c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/raxone""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Raxone is indicated for the treatment of visual impairment in adolescent and adult patients with Leber’s Hereditary Optic Neuropathy (LHON). uuid:d63c2b98-31b7-4e1c-8a9a-20c6519bb447 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3A189DH42V biolink:treats MONDO:0005314 PMID:41385096 "[{""id"":""uuid:df3edb9d-d01d-4b3b-a3b3-f20fc07b5ee6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d20d9787-18f0-4a51-9d3f-c15039f000a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lemtrada""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Lemtrada is indicated for adult patients with relapsing-remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features. uuid:28a889c6-3873-40ac-a9da-1d9c2fa9a00c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:391960 biolink:treats UMLS:C0150045 PMID:41385096 "[{""id"":""uuid:a328a69a-1711-46d1-9a18-3f1dd3834234"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:76603d6e-2004-4b4a-a343-f6055bc13a9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/emselex""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in adult patients with overactive bladder syndrome. uuid:79195f51-7958-4d3e-bb4a-527635aa5020 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:391960 biolink:treats MONDO:0006624 PMID:41385096 "[{""id"":""uuid:39d3c449-fc0e-482c-a3c4-a7c8a240cb89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a238df3c-5520-46d3-b024-a001624ff2aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/emselex""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in adult patients with overactive bladder syndrome. uuid:aa60054c-6386-48a1-9451-304b0a2ba98e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:93752 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:85ae5054-e423-4ecc-b650-9e896ed28827"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:1b496999-85de-43f5-8f9c-99688dd602df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/piqray""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Piqray is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as monotherapy (see section 5.1). uuid:e63c51d1-8ecb-4c35-8291-c7574ab9eaac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:93752 biolink:treats MONDO:0700079 PMID:41385096 "[{""id"":""uuid:a65df528-be02-4d7f-975c-50c1ed64190e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:37457f6d-32f4-4f07-93a8-9b05a92bdd37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/piqray""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Piqray is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as monotherapy (see section 5.1). uuid:c09829e2-51ca-49cc-93b6-1d725a3024e7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:93752 biolink:treats MONDO:0000618 PMID:41385096 "[{""id"":""uuid:652cb30c-b2ac-469a-a1d8-485b64423349"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d1385122-82fb-4630-86e2-78e020c31b5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/piqray""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Piqray is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as monotherapy (see section 5.1). uuid:aa6b1ce2-3ac5-4862-8814-72365183aad3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:93752 biolink:treats MONDO:0004379 PMID:41385096 "[{""id"":""uuid:2b792b0d-506b-4a59-b261-08694a609b74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:3eff67d3-4601-4f7a-84a5-2c55a6dd0dde"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/piqray""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Piqray is indicated in combination with fulvestrant for the treatment of postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with a PIK3CA mutation after disease progression following endocrine therapy as monotherapy (see section 5.1). uuid:58a08957-a750-414f-a7bc-1d971a1cb5e5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:129762253 biolink:treats EFO:0006951 PMID:41385096 "[{""id"":""uuid:24d3f8e3-4fba-4f84-a7be-4b4f0ea43879"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ba718f23-92c0-498c-a670-e36cd2d6267c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/pedmarqsi""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Pedmarqsi is indicated for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to < 18 years of age with localised, non-metastatic, solid tumours. uuid:565052ad-e4dd-4d3b-9a65-f840bf3e1f1c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:129762253 biolink:treats MONDO:0004992 PMID:41385096 "[{""id"":""uuid:ed51765e-d8bb-408d-bd33-4c23611565e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:1c0e23a0-9876-47b7-aa9e-42cfbee41a74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/pedmarqsi""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Pedmarqsi is indicated for the prevention of ototoxicity induced by cisplatin chemotherapy in patients 1 month to < 18 years of age with localised, non-metastatic, solid tumours. uuid:973feae8-0e31-45bc-a372-3a0be11dab85 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DB1041CXDG biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:9a6d31e3-32d0-480c-b8b6-5c86cbe29134"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:8c012175-8e94-427d-bd97-09f4e3d41560"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/blenrep""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Blenrep is indicated as monotherapy for the treatment of multiple myeloma in adult patients, who have received at least four prior therapies and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy. uuid:5fea2f16-e77b-4086-93aa-23c81065e6b8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:216293 biolink:treats MONDO:0001134 PMID:41385096 "[{""id"":""uuid:8dcd0de2-afc0-4650-890e-f5867403d382"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b55ccc73-88dd-4342-b633-41902e1d3338"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/actelsar-hct""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of essential hypertension.Actelsar HCT fixed-dose combination (40 mg telmisartan / 12.5 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on telmisartan alone.Actelsar HCT fixed-dose combination (80 mg telmisartan / 12.5 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on telmisartan alone.Actelsar HCT fixed-dose combination (80 mg telmisartan / 25 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on Actelsar HCT 80 mg / 12.5 mg (80 mg telmisartan / 12.5 mg hydrochlorothiazide) or adults who have been previously stabilised on telmisartan and hydrochlorothiazide given separately. uuid:3153c2bc-db0d-420c-8582-ec6d572236b7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9434 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:856d8c46-a58a-43f1-8c08-3d2222531f0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:809d43de-c136-405c-97f9-e74e4b087101"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/telmisartan-actavis""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] HypertensionTreatment of essential hypertension in adults.Cardiovascular preventionReduction of cardiovascular morbidity in patients with:manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or;type 2 diabetes mellitus with documented target organ damage. uuid:ffbdceba-3a57-4c2c-a439-77ea34ca49d3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9434 biolink:treats MONDO:0005386 PMID:41385096 "[{""id"":""uuid:e4e5e31e-2163-408a-b761-9988977c4f5d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2c8de944-1c24-4c2a-8f4d-d90b2f32f255"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/telmisartan-actavis""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] HypertensionTreatment of essential hypertension in adults.Cardiovascular preventionReduction of cardiovascular morbidity in patients with:manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or;type 2 diabetes mellitus with documented target organ damage. uuid:f0251a9d-8108-4a8b-a24d-f7641bafee1d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9434 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:5a094588-4efd-45fb-baa9-b7e2c2bd6c86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0c24a7a2-e776-4fe1-acfa-498442d718b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/telmisartan-actavis""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] HypertensionTreatment of essential hypertension in adults.Cardiovascular preventionReduction of cardiovascular morbidity in patients with:manifest atherothrombotic cardiovascular disease (history of coronary heart disease, stroke, or peripheral arterial disease) or;type 2 diabetes mellitus with documented target organ damage. uuid:0291d890-7caa-4c27-81e6-4964b22d3e7e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4EQZ6YO2HI biolink:treats HP:0020110 PMID:41385096 "[{""id"":""uuid:1fc6a50f-2c58-4d76-8185-5f0bc7ff41da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:12549e18-593b-411c-8275-46c9b4bcf58d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/prolia""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. In postmenopausal women Prolia significantly reduces the risk of vertebral, non vertebral and hip fractures.Treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures. In men with prostate cancer receiving hormone ablation, Prolia significantly reduces the risk of vertebral fractures. uuid:9e99cd02-6f42-49aa-a2ad-61f44bf7df87 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4EQZ6YO2HI biolink:treats MONDO:0000837 PMID:41385096 "[{""id"":""uuid:afcbf116-0ff3-440e-bdea-613f0c7fe51c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:7523fd7b-c85e-41a6-9e44-9f361345334f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/prolia""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures. In postmenopausal women Prolia significantly reduces the risk of vertebral, non vertebral and hip fractures.Treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures. In men with prostate cancer receiving hormone ablation, Prolia significantly reduces the risk of vertebral fractures. uuid:af251167-219f-4b73-b39d-f9d8bc02a831 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76015 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:1dbd5075-4595-4f4f-a6e5-c8758c4a81ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:45cbc69f-417f-4e82-ae95-ece45c7a39c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/brintellix""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of major depressive episodes in adults. uuid:11a8ef90-d6ee-4d93-bd72-efd1c60f37bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63587 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:42c1125e-a42e-41fa-a29e-5ec53e9afd1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f1271c6f-4879-4062-b773-17f6b7b5a97c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/halaven""]},{""id"":""uuid:262b5526-b687-4a8c-bbd5-313f7feb98dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Halaven monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimens for advanced disease (see section 5.1). Prior therapy should have included an anthracycline and a taxane unless patients were not suitable for these treatments.Halaven is indicated for the treatment of adult patients with unresectable liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease (see section 5.1).|[PMDA] A drug with a new active ingredient indicated for the treatment of inoperable or recurrent breast cancer. [Priority review] uuid:2a8c5cb8-0534-47cc-89bd-3d28644de7d9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63587 biolink:treats MONDO:0005060 PMID:41385096 "[{""id"":""uuid:1e77e8c2-dc06-4b27-a77a-7060774b0fa7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:914b8f9e-778d-44e7-aeb3-bc55dd675588"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/halaven""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Halaven monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimens for advanced disease (see section 5.1). Prior therapy should have included an anthracycline and a taxane unless patients were not suitable for these treatments.Halaven is indicated for the treatment of adult patients with unresectable liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease (see section 5.1). uuid:c372a38a-7e56-4dfa-8429-ba3c809876ee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9570 biolink:treats MONDO:0005570 PMID:41385096 "[{""id"":""uuid:376792a6-eee9-4d55-989a-fcbbc21ed5a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a6058498-b96f-4733-9f53-c275a5717116"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/thiotepa-riemser""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Thiotepa Riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with HPCT support is appropriate for the treatment of solid tumours in adult and paediatric patients.Thiotepa Riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (TBI), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with HPCT support is appropriate for the treatment of solid tumours in adult and paediatric patients uuid:15451cc1-c132-4671-8474-e274cc55bf37 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:142406 biolink:treats MONDO:0024317 PMID:41385096 "[{""id"":""uuid:119d1d9f-67ad-4c02-976f-f5f6cb12c2f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5f938d35-116c-49b0-8c78-308b3d10a480"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/prialt""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ziconotide is indicated for the treatment of severe, chronic pain in patients who require intrathecal (IT) analgesia. uuid:1b30dad1-98c4-43bd-a507-08f966cf5dee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:94686 biolink:treats EFO:0005935 PMID:41385096 "[{""id"":""uuid:b62f16d7-1ed3-4aca-bb8c-7d893c9e57e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:51ee29d8-e3a9-4ed4-8694-7577fd7da8b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/alli""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Alli is indicated for weight loss in adults who are overweight (body mass index, BMI, ≥ 28 kg/m2) and should be taken in conjunction with a mildly hypocaloric, lower-fat diet. uuid:88a442e4-4b97-4a85-8654-c6e2c9258a29 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63791 biolink:treats MONDO:0018881 PMID:41385096 "[{""id"":""uuid:fbc8b8d9-1210-42f2-8056-68950895a3ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fd77f96b-b694-4f8d-9b86-7563b6ac2bfb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/revlimid""]},{""id"":""uuid:69761b0f-b420-455d-ab83-e1bdaaf67078"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Multiple myelomaRevlimid as monotherapy is indicated for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.Revlimid as combination therapy with dexamethasone, or bortezomib and dexamethasone, or melphalan and prednisone (see section 4.2) is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.Revlimid in combination with dexamethasone is indicated for the treatment of multiple myeloma in adult patients who have received at least one prior therapy.Myelodysplastic syndromesRevlimid as monotherapy is indicated for the treatment of adult patients with transfusion-dependent anemia due to low- or intermediate-1-risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient or inadequate.Mantle cell lymphomaRevlimid as monotherapy is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.Follicular lymphomaRevlimid in combination with rituximab (anti-CD20 antibody) is indicated for the treatment of adult patients with previously treated follicular lymphoma (Grade 1 – 3a).|[PMDA] A drug with a new additional indication and a new dosage for the treatment of myelodysplastic syndrome associated with a deletion 5q cytogenetic abnormality. [Orphan drug] uuid:7e976b5a-ffd6-4b62-801e-6c9fdf17628a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:567361 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:3faf200d-dc89-4895-a160-be6782f303ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:bfa7f9a0-dae0-4080-9c7b-4cbb883c09f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/mavenclad""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of adult patients with highly active relapsing multiple sclerosis (MS) as defined by clinical or imaging features. uuid:122f910e-271d-4e66-bd63-a39465827d41 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:939U7C91AI biolink:treats MONDO:0020066 PMID:41385096 "[{""id"":""uuid:fbe86627-b455-4ad0-8440-349a25f15ed5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:792ff528-516a-4572-a7ea-43dd265741ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Sunosi is indicated to improve wakefulness and reduce excessive daytime sleepiness in adult patients with narcolepsy (with or without cataplexy).Sunosi is indicated to improve wakefulness and reduce excessive daytime sleepiness (EDS) in adult patients with obstructive sleep apnoea (OSA) whose EDS has not been satisfactorily treated by primary OSA therapy, such as continuous positive airway pressure (CPAP). uuid:853527dd-f3c7-4b17-a13a-090c066b810a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31602 biolink:treats HP:0032149 PMID:41385096 "[{""id"":""uuid:c20a3048-5f46-4ded-a4f8-c17e62f84adf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:90df6367-6d7b-4ebd-921e-8c5068216041"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Instanyl is indicated for the management of breakthrough pain in adults already receiving maintenance opioid therapy for chronic cancer pain. Breakthrough pain is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain. Patients receiving maintenance opioid therapy are those who are taking at least 60 mg of oral morphine daily, at least 25 micrograms of transdermal fentanyl per hour, at least 30 mg oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer. uuid:a4f90024-5b96-4664-808b-5cf0d2f3e072 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31602 biolink:treats NCIT:C9467 PMID:41385096 "[{""id"":""uuid:4fd39ee9-463b-4c2e-aa5d-1ac4dc537d3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e996b2c5-1c84-4189-92c6-844db583cdc2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Instanyl is indicated for the management of breakthrough pain in adults already receiving maintenance opioid therapy for chronic cancer pain. Breakthrough pain is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain. Patients receiving maintenance opioid therapy are those who are taking at least 60 mg of oral morphine daily, at least 25 micrograms of transdermal fentanyl per hour, at least 30 mg oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer. uuid:1974420b-8cdb-4dac-ac1c-809cf35ac5a8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:284756 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:8017b383-a150-49fd-b254-746aa0c5a266"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c798f554-ba37-4bdd-b72f-071070ef1cc9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kaletra""]},{""id"":""uuid:4bd80307-fc3f-4a6d-8a8d-f2e28b46ec9a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Kaletra is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infected adults, adolescents and children aged from 14 days and older.The choice of Kaletra to treat protease inhibitor experienced HIV-1 infected patients should be based on individual viral resistance testing and treatment history of patients.|[PMDA] Drug with a new dosage indicated for treatment of HIV infection. [Orphan Drug] uuid:71f3fc2b-1174-4323-93d3-2466c0acd572 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59900 biolink:treats MONDO:0044067 PMID:41385096 "[{""id"":""uuid:3e3b474a-52d4-483d-926b-61309d186934"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:16c48747-89ca-499b-8ef0-7357b8e9ce76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of invasive candidiasis in adult or paediatric patients;treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin B, lipid formulations of amphotericin B and / or itraconazole. Refractoriness is defined as progression of infection or failure to improve after a minimum of seven days of prior therapeutic doses of effective antifungal therapy;empirical therapy for presumed fungal infections (such as Candida or Aspergillus) in febrile, neutropaenic adult or paediatric patients. uuid:75496686-b3bf-4c7a-bc47-1e4fe3d5c1d3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59900 biolink:treats MONDO:0000240 PMID:41385096 "[{""id"":""uuid:92ebba62-b44e-4fe5-ba06-52944201fbb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f7da90d1-845d-467e-9663-1835ae34f7ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of invasive candidiasis in adult or paediatric patients;treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin B, lipid formulations of amphotericin B and / or itraconazole. Refractoriness is defined as progression of infection or failure to improve after a minimum of seven days of prior therapeutic doses of effective antifungal therapy;empirical therapy for presumed fungal infections (such as Candida or Aspergillus) in febrile, neutropaenic adult or paediatric patients. uuid:1ec6e00b-1deb-48d2-9f0f-23d36832c1ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59900 biolink:treats MONDO:0002041 PMID:41385096 "[{""id"":""uuid:4071c8ce-574d-461f-aa28-39fb988d79cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:846ad469-ac86-46f9-bd04-d6f28599d440"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of invasive candidiasis in adult or paediatric patients;treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin B, lipid formulations of amphotericin B and / or itraconazole. Refractoriness is defined as progression of infection or failure to improve after a minimum of seven days of prior therapeutic doses of effective antifungal therapy;empirical therapy for presumed fungal infections (such as Candida or Aspergillus) in febrile, neutropaenic adult or paediatric patients. uuid:7639c74e-bc20-4b6d-b251-dc6dca2d70fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59900 biolink:treats MONDO:0002026 PMID:41385096 "[{""id"":""uuid:8773c579-5541-4283-aafe-3c1a6562f6fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2e4c75cd-91dc-42a2-90da-c69d64f1b7de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of invasive candidiasis in adult or paediatric patients;treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin B, lipid formulations of amphotericin B and / or itraconazole. Refractoriness is defined as progression of infection or failure to improve after a minimum of seven days of prior therapeutic doses of effective antifungal therapy;empirical therapy for presumed fungal infections (such as Candida or Aspergillus) in febrile, neutropaenic adult or paediatric patients. uuid:3e83c4d3-5d67-4c53-9fff-f6f9a8e57e08 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59900 biolink:treats MONDO:0005657 PMID:41385096 "[{""id"":""uuid:c46782be-0e3f-4ac1-b2df-6a6a339befaa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b85d26f0-192b-4aa3-b54c-527c3f406a56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of invasive candidiasis in adult or paediatric patients;treatment of invasive aspergillosis in adult or paediatric patients who are refractory to or intolerant of amphotericin B, lipid formulations of amphotericin B and / or itraconazole. Refractoriness is defined as progression of infection or failure to improve after a minimum of seven days of prior therapeutic doses of effective antifungal therapy;empirical therapy for presumed fungal infections (such as Candida or Aspergillus) in febrile, neutropaenic adult or paediatric patients. uuid:ff212d08-8cfc-4399-95ac-12a068688934 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4B93MGE4AL biolink:treats MONDO:0019087 PMID:41385096 "[{""id"":""uuid:651ad528-0229-458b-8b22-6dd72d700fde"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:7908b886-dea2-41a8-b7ce-7d64cdb281d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lytgobi""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Lytgobi monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy. uuid:9aa56322-b2fe-4186-9d6d-2a1288257207 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8680B21W73 biolink:treats MONDO:0000050 PMID:41385096 "[{""id"":""uuid:2cba28f4-9513-4654-8819-75434fb3ecf1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:50f9ba62-2ace-47cd-b9ff-9fff99600e5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] This medicinal product is for diagnostic use only. GHRYVELIN is indicated for the diagnosis of growth hormone deficiency (GHD) in adults. uuid:dab81c3b-9070-4f8a-96dd-aa768d381090 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:U59UGK3IPC biolink:treats MONDO:0005314 PMID:41385096 "[{""id"":""uuid:16923ed4-f9c4-4180-a748-df3934eb1c5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c7172adf-4bbf-4b96-9fb0-4f160d3069a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/briumvi""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Briumvi is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features. uuid:9b9663be-fceb-4b7f-9ffe-ce96a49f3c0c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:MLU3LU3EVV biolink:treats MONDO:0001516 PMID:41385096 "[{""id"":""uuid:9b89a377-5b93-457c-8437-52eeacaa8391"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9df52b5f-752c-40d9-b21f-f5c770a98ed1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zolgensma""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Zolgensma is indicated for the treatment of:patients with 5q spinal muscular atrophy (SMA) with a bi-allelic mutation in the SMN1 gene and a clinical diagnosis of SMA Type 1, orpatients with 5q SMA with a bi-allelic mutation in the SMN1 gene and up to 3 copies of the SMN2 gene. uuid:5ca4cf93-409f-498f-bf22-bdaca27d3933 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:MLU3LU3EVV biolink:treats MONDO:0009669 PMID:41385096 "[{""id"":""uuid:71a56ccb-eed8-40b9-b8b0-c4929edf2410"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:781f1aca-33b5-4315-afdd-d25f0673b11d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zolgensma""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Zolgensma is indicated for the treatment of:patients with 5q spinal muscular atrophy (SMA) with a bi-allelic mutation in the SMN1 gene and a clinical diagnosis of SMA Type 1, orpatients with 5q SMA with a bi-allelic mutation in the SMN1 gene and up to 3 copies of the SMN2 gene. uuid:3e026967-4270-4ea9-b769-aa4cb4ee9b8f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:TL60C27RLH biolink:treats MONDO:0006573 PMID:41385096 "[{""id"":""uuid:5e0dee3b-f2c5-47c8-8030-b8755beb5d58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2e9a6ebb-872c-4a05-a1a8-beced590b3be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/myalepta""]},{""id"":""uuid:dd0756d2-8bee-4112-bdff-2481310a72d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Myalepta is indicated as an adjunct to diet as a replacement therapy to treat the complications of leptin deficiency in lipodystrophy (LD) patients:with confirmed congenital generalised LD (Berardinelli-Seip syndrome) or acquired generalised LD (Lawrence syndrome) in adults and children 2 years of age and abovewith confirmed familial partial LD or acquired partial LD (Barraquer-Simons syndrome), in adults and children 12 years of age and above for whom standard treatments have failed to achieve adequate metabolic control.|[PMDA] A drug with a new active ingredient for the treatment of lipodystrophy. [Orphan drug] uuid:7af755a2-bc80-4f01-849e-7be97ac49ead biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:TL60C27RLH biolink:treats MONDO:0006536 PMID:41385096 "[{""id"":""uuid:912bbb0c-f88c-4ebb-923c-2dfbd1204a5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2bea6d5f-8c51-4c6b-b5ca-f470c4589448"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/myalepta""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Myalepta is indicated as an adjunct to diet as a replacement therapy to treat the complications of leptin deficiency in lipodystrophy (LD) patients:with confirmed congenital generalised LD (Berardinelli-Seip syndrome) or acquired generalised LD (Lawrence syndrome) in adults and children 2 years of age and abovewith confirmed familial partial LD or acquired partial LD (Barraquer-Simons syndrome), in adults and children 12 years of age and above for whom standard treatments have failed to achieve adequate metabolic control. uuid:092f5194-6d49-4349-b0ce-453de2bed848 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:TL60C27RLH biolink:treats MONDO:0020088 PMID:41385096 "[{""id"":""uuid:ce63c5df-44a2-4688-9775-348b19f219ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:8afc2691-6e22-4b57-9996-efd9d10d1d4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/myalepta""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Myalepta is indicated as an adjunct to diet as a replacement therapy to treat the complications of leptin deficiency in lipodystrophy (LD) patients:with confirmed congenital generalised LD (Berardinelli-Seip syndrome) or acquired generalised LD (Lawrence syndrome) in adults and children 2 years of age and abovewith confirmed familial partial LD or acquired partial LD (Barraquer-Simons syndrome), in adults and children 12 years of age and above for whom standard treatments have failed to achieve adequate metabolic control. uuid:51497847-fbce-4151-b846-a74b4efc5805 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB16536 biolink:treats MONDO:0006543 PMID:41385096 "[{""id"":""uuid:a12895d5-8816-4cbe-83bb-7291c4803199"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d192514c-010e-43a3-a836-b946f92c56fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in patients 6 months and older. uuid:1a59e435-610e-4265-8d89-714cf1afc254 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB16536 biolink:treats MONDO:0017612 PMID:41385096 "[{""id"":""uuid:0c53ec3c-822a-4b85-80d8-b925d11ab38b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ed5f687f-1e31-4243-b927-a467f30156e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of partial thickness wounds associated with dystrophic and junctional epidermolysis bullosa (EB) in patients 6 months and older. uuid:f5113673-6ce2-4770-9f5f-92e2a8c222d8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:11564052 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:97ebd105-eb95-475e-9a6f-c119f173de5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d768cf8f-efbd-473d-9847-7c42b639de0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Maintenance treatment of asthma in adults whose disease is not adequately controlled. uuid:960e745c-41fb-4168-a4d4-1e50ede70b0f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:25099114 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:73b24251-b8a5-4a29-a99c-720d15aafe07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:72f335c6-be8a-408d-aad1-13d8bba6f0cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/atectura-breezhaler""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Atectura Breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists. uuid:d8a2b185-b77c-449d-89c0-d3547ffae0ae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:ZL1R02VT79 biolink:treats MONDO:0001660 PMID:41385096 "[{""id"":""uuid:9c5cb9ae-f461-4574-8035-2fc3423ab756"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:3e569483-d524-44f9-92d0-e858c5dff26b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ranivisio""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ranivisio is indicated in adults for:• The treatment of neovascular (wet) age-related macular degeneration (AMD)• The treatment of visual impairment due to diabetic macular oedema (DME)• The treatment of proliferative diabetic retinopathy (PDR)• The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)• The treatment of visual impairment due to choroidal neovascularisation (CNV) uuid:c4272acf-b459-4dfd-81d0-331f4c810553 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:ZL1R02VT79 biolink:treats MONDO:0041093 PMID:41385096 "[{""id"":""uuid:dde4ae32-229e-4f34-b380-82b29ed5722e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a3e6d801-001d-41ea-a381-225a9c7271af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ranivisio""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ranivisio is indicated in adults for:• The treatment of neovascular (wet) age-related macular degeneration (AMD)• The treatment of visual impairment due to diabetic macular oedema (DME)• The treatment of proliferative diabetic retinopathy (PDR)• The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)• The treatment of visual impairment due to choroidal neovascularisation (CNV) uuid:70d828fd-c47f-4e86-a14b-64f46dc53a6f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:ZL1R02VT79 biolink:treats MONDO:0810000 PMID:41385096 "[{""id"":""uuid:fccc9e93-a75a-4d87-b581-9fac79dab1f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b886a0dd-2e56-4c52-9f18-0118cbe0e3a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ranivisio""]},{""id"":""uuid:514f57f4-b183-4050-9845-0002b700d6b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ranivisio is indicated in adults for:• The treatment of neovascular (wet) age-related macular degeneration (AMD)• The treatment of visual impairment due to diabetic macular oedema (DME)• The treatment of proliferative diabetic retinopathy (PDR)• The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)• The treatment of visual impairment due to choroidal neovascularisation (CNV)|[PMDA] A drug containing a new active ingredient indicated for treatment of age-related macular degeneration with concurrent choroidal neovascularization. [Orphan drug] uuid:0870bf10-7c85-4d0a-be2f-78d2c697a96b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:1MTK0BPN8V biolink:treats MONDO:0100096 PMID:41385096 "[{""id"":""uuid:e8d22ae9-6288-4ebc-a9ba-d5d5af5c13c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ccf8a7d1-48b0-4f3c-9079-887bb4fce1d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/xevudy""]},{""id"":""uuid:825178e8-f90a-40fa-b77a-621c7565f899"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Xevudy is indicated for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with coronavirus disease 2019 (COVID-19) who do not require oxygen supplementation and who are at increased risk of progressing to severe COVID-19.|[PMDA] A drug with a new active ingredient indicated for the treatment of disease caused by SARS-CoV-2 infection (COVID-19). [Drug pertaining to Special Approval for Emergency] uuid:84c9021d-c46b-4610-b96d-795b66e21e27 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68602 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:8d7a5df9-07d2-4180-ba0c-e0a04a30d680"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0ebb7b9f-ceb0-44aa-b5b4-f76fd9be744e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/rekambys""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rekambys is indicated, in combination with cabotegravir injection, for the treatment of human immunodeficiency virus type 1 (HIV 1) infection in adults who are virologically suppressed (HIV-1 RNA < 50 copies/mL) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with, agents of the NNRTI and INI class. uuid:b16f8892-7af9-468e-929c-1f8ca1d8de28 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68579 biolink:treats MONDO:0004634 PMID:41385096 "[{""id"":""uuid:89e5c104-9dcd-4d90-9790-86ec84a9e275"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:15fe3a36-0d38-496c-9e96-b5cef2605800"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/rivaroxaban-accord""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients).AdultsPrevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.)Paediatric populationTreatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment.Rivaroxaban Accord, co administered with acetylsalicylic acid (ASA) alone or with ASA plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers (see sections 4.3, 4.4 and 5.1).Rivaroxaban Accord, co administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events.AdultsPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. (See section 4.4 for haemodynamically unstable PE patients.)Paediatric populationTreatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment. uuid:1166e896-daea-43df-a87f-f129f518dff3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB16582 biolink:treats MONDO:0018905 PMID:41385096 "[{""id"":""uuid:23e55f7f-9d36-4147-bffc-de8d10854740"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9c3f9eb5-2aca-4c82-aa4a-636ba258f818"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Breyanzi is indicated for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy. uuid:7a2b0211-454e-4db8-8524-750e725630b6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB16582 biolink:treats MONDO:0044889 PMID:41385096 "[{""id"":""uuid:8dbd2e2e-2995-493a-b9c7-3e4ec4d66566"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:bc6dd75c-2493-4f1c-a1b5-0a3db3cd3cb4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Breyanzi is indicated for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy. uuid:e55e489c-e3cb-4a8b-8e3f-b5363b3f8ad0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB16582 biolink:treats MONDO:0020323 PMID:41385096 "[{""id"":""uuid:5bf9752f-e960-420f-816e-2a1098f408a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b032ef91-25e0-4f0d-8311-d17bb7487bc8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Breyanzi is indicated for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL) and follicular lymphoma grade 3B (FL3B), who relapsed within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy. uuid:0500cbb1-5f80-4631-9716-fffe2f45ce2b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEMBL.COMPOUND:CHEMBL4298180 biolink:treats MONDO:0005011 PMID:41385096 "[{""id"":""uuid:86374219-fa59-41ee-9d13-20c025daadb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:dc7bc9f2-0091-4b9e-9822-43829de10ff0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/alofisel""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Alofisel is indicated for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn’s disease, when fistulas have shown an inadequate response to at least one conventional or biologic therapy. Alofisel should be used after conditioning of fistula. uuid:098a0982-903d-49be-b34b-1b56a33ee481 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEMBL.COMPOUND:CHEMBL4298180 biolink:treats HP:0005218 PMID:41385096 "[{""id"":""uuid:9e674b3d-3f91-4fe3-9a9a-66237a241c0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f80e33d2-43cb-44fa-be0b-6b90994ed67c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/alofisel""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Alofisel is indicated for the treatment of complex perianal fistulas in adult patients with non-active/mildly active luminal Crohn’s disease, when fistulas have shown an inadequate response to at least one conventional or biologic therapy. Alofisel should be used after conditioning of fistula. uuid:232f71fb-626e-4f67-94b7-ec1b125d583b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DQ448MW7KS biolink:treats MONDO:0001577 PMID:41385096 "[{""id"":""uuid:cb9c2c6c-0b18-4356-91eb-df4637a4c361"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:00618e90-8671-44a2-be44-393bfa8771fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/synagis""]},{""id"":""uuid:c7df2f50-280d-404d-9c23-3ceffd8711ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Synagis is indicated for the prevention of serious lower-respiratory-tract disease requiring hospitalisation caused by respiratory syncytial virus (RSV) in children at high risk for RSV disease:children born at 35 weeks of gestation or less and less than six months of age at the onset of the RSV season;children less than two years of age and requiring treatment for bronchopulmonary dysplasia within the last six months;children less than two years of age and with haemodynamically significant congenital heart disease.|[PMDA] Drugs with a new indication for the prevention of serious lower respiratory tract disease caused by respiratory syncytial (RS) virus infection in neonates, infants, and children aged 24 months and younger with pulmonary hypoplasia, airway stenosis, congenital esophageal atresia, congenital metabolic disorder, or neuromuscular disease at the early stage of the RS virus season. [Priority review] uuid:91239873-3d6f-4df0-a049-6e868174895a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:D000090984 biolink:treats MONDO:0100096 PMID:41385096 "[{""id"":""uuid:62395188-32ad-4191-890a-15d7454c6b31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6e8becc8-53e6-4e13-9691-fae85eb8b451"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Jcovden is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 years of age and older.The use of this vaccine should be in accordance with official recommendations. uuid:447319b9-6469-4bc9-88e9-eeb23177c7f5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72317 biolink:treats MONDO:0005086 PMID:41385096 "[{""id"":""uuid:7aad2aaf-2d74-4650-9fd5-ce1fb5b32211"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f420d847-4d92-4061-8c79-9877c1de4004"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cometriq""]},{""id"":""uuid:bf900c75-b67b-4514-96ec-21c706654228"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Renal Cell Carcinoma (RCC)Cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (RCC):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy.Cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults.Hepatocellular Carcinoma (HCC)Cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib.|[PMDA] Drugs with a new active ingredient indicated for the treatment of unresectable or metastatic renal cell carcinoma. uuid:adfdd68b-e961-4275-88d7-f87d3c0664e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72317 biolink:treats MONDO:0007256 PMID:41385096 "[{""id"":""uuid:8f395182-7b9a-41a8-bb98-572b76985b69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:78beeca7-4670-4c92-ad2f-6de94885a161"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cometriq""]},{""id"":""uuid:4c4f2b06-67c5-49cc-922b-fcb970f73184"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Renal Cell Carcinoma (RCC)Cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (RCC):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy.Cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults.Hepatocellular Carcinoma (HCC)Cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (HCC) in adults who have previously been treated with sorafenib.|[PMDA] Drugs with a new indication for the treatment of unresectable hepatocellular carcinoma that has progressed after cancer chemotherapy. uuid:b5908c1f-3d3c-4280-91e6-ebed61ab2555 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:38RL9AE51Q biolink:treats MONDO:0007915 PMID:41385096 "[{""id"":""uuid:50b3a773-f667-422c-b83a-502611e34ba8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c295d8a6-ddb2-4ebd-ae1e-ba1398d3ffd1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/saphnelo""]},{""id"":""uuid:3a7e80f3-afc6-4f6e-93b2-3990ea1be521"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Saphnelo is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (SLE), despite standard therapy.,|[PMDA] A drug with a new active ingredient indicated for the treatment of systemic lupus erythematosus in patients who have not responded sufficiently to conventional treatments. uuid:db956ba7-a19e-4c26-b7bd-8132c0d2a1d9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:420K487FSG biolink:treats MONDO:0006031 PMID:41385096 "[{""id"":""uuid:0aebaaff-03d5-4964-848e-67852f2186cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:7f0e45de-1778-49e8-9ce1-11cd3e2522f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/dupixent""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Atopic dermatitisAdults and adolescentsDupixent is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy.Children 6 months to 11 years of ageDupixent is indicated for the treatment of severe atopic dermatitis in children 6 months to 11 years old who are candidates for systemic therapy.AsthmaAdults and adolescentsDupixent is indicated in adults and adolescents 12 years and older as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO), see section 5.1, who are inadequately controlled with high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment.Children 6 to 11 years of ageDupixent is indicated in children 6 to 11 years old as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by raised blood eosinophils and/or raised fraction of exhaled nitric oxide (FeNO), who are inadequately controlled with medium to high dose inhaled corticosteroids (ICS) plus another medicinal product for maintenance treatment.Chronic rhinosinusitis with nasal polyposis (CRSwNP)Dupixent is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adults with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control.Prurigo Nodularis (PN)Dupixent is indicated for the treatment of adults with moderate-to-severe prurigo nodularis (PN) who are candidates for systemic therapy.Eosinophilic esophagitis (EoE)Dupixent is indicated for the treatment of eosinophilic esophagitis in adults and adolescents 12 years and older, weighing at least 40 kg, who are inadequately controlled by, are intolerant to, or who are not candidates for conventional medicinal therapy. uuid:7952d0e9-e85b-4e0b-9d2c-13f8f5674b7d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:AQK7UBA1LS biolink:treats MONDO:0019402 PMID:41385096 "[{""id"":""uuid:ee0ec4ae-cd19-4cdf-bc9e-06206ff7e890"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:49ad9ad5-2f43-41c2-94ff-9238ae4c92d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/reblozyl""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Reblozyl is indicated for the treatment of adult patients with transfusion-dependent anaemia due to very low, low and intermediate-risk myelodysplastic syndromes (MDS) with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based therapy (see section 5.1).Reblozyl is indicated in adults for the treatment of anaemia associated with transfusion dependent and non transfusion dependent beta thalassaemia (see section 5.1). uuid:ed480172-654e-490e-acac-417f2928fdde biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:81569 biolink:treats MONDO:0002775 PMID:41385096 "[{""id"":""uuid:af48a677-d967-4b10-b044-ec5e49b9e7fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c1516331-a59d-4708-a902-cbaafc1aae7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/gonal-f""]},{""id"":""uuid:3faf14d4-21fb-447d-82e4-3d628ead00c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Anovulation (including polycystic ovarian disease, PCOD) in women who have been unresponsive to treatment with clomiphene citrate.Stimulation of multifollicular development in patients undergoing superovulation for assisted reproductive technologies (ART) such as in-vitro fertilisation (IVF), gamete intra-fallopian transfer (GIFT) and zygote intra-fallopian transfer (ZIFT).GONAL-f in association with a luteinising hormone (LH) preparation is recommended for the stimulation of follicular development in women with severe LH and FSH deficiency. In clinical trials these patients were defined by an endogenous serum LH level|[PMDA] A drug with a new additional indication and a new dosage for induction of ovulation in patients with anovulation and infrequent ovulation associated with hypothalamic-pituitary dysfunction or polycystic ovarian syndrome. uuid:22ccec02-9822-47fd-a07e-397b8b3e0d1d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:81569 biolink:treats MONDO:0008487 PMID:41385096 "[{""id"":""uuid:141d9fd8-847f-48d8-8784-8eb7fbbadf29"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:82965af2-42dd-4a44-a6db-631ea2aa0d9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/gonal-f""]},{""id"":""uuid:49fd821a-f133-4ebc-a248-440b7387cd3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Anovulation (including polycystic ovarian disease, PCOD) in women who have been unresponsive to treatment with clomiphene citrate.Stimulation of multifollicular development in patients undergoing superovulation for assisted reproductive technologies (ART) such as in-vitro fertilisation (IVF), gamete intra-fallopian transfer (GIFT) and zygote intra-fallopian transfer (ZIFT).GONAL-f in association with a luteinising hormone (LH) preparation is recommended for the stimulation of follicular development in women with severe LH and FSH deficiency. In clinical trials these patients were defined by an endogenous serum LH level|[PMDA] A drug with a new additional indication and a new dosage for induction of ovulation in patients with anovulation and infrequent ovulation associated with hypothalamic-pituitary dysfunction or polycystic ovarian syndrome. uuid:bb1a45f8-e539-4c3f-b2ca-d8ed0ad4ebc2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:81569 biolink:treats MONDO:0009239 PMID:41385096 "[{""id"":""uuid:c10bf193-b87f-4a6f-8edc-66fce855a14f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c1dc94b2-4e66-4e35-851b-a90530aab59d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/gonal-f""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Anovulation (including polycystic ovarian disease, PCOD) in women who have been unresponsive to treatment with clomiphene citrate.Stimulation of multifollicular development in patients undergoing superovulation for assisted reproductive technologies (ART) such as in-vitro fertilisation (IVF), gamete intra-fallopian transfer (GIFT) and zygote intra-fallopian transfer (ZIFT).GONAL-f in association with a luteinising hormone (LH) preparation is recommended for the stimulation of follicular development in women with severe LH and FSH deficiency. In clinical trials these patients were defined by an endogenous serum LH level uuid:9d863804-0c03-4ee4-b6fe-1be83e7d8442 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB14443 biolink:treats MONDO:0015766 PMID:41385096 "[{""id"":""uuid:7be78f60-7227-426d-8771-52cfeb47ecfe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:bca847ce-f298-44e2-a0ce-9fd195070526"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Vaxchora is indicated for active immunisation against disease caused by Vibrio cholerae serogroup O1 in adults and children aged 2 years and older.This vaccine should be used in accordance with official recommendations. uuid:1c6c06ff-c26e-4907-9446-aa873f66c4b8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:WP58SVM6R4 biolink:treats MONDO:0001586 PMID:41385096 "[{""id"":""uuid:1a82e622-833a-44bc-afad-3fbc2db84e4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:47ddee03-b5d2-44ec-8b1c-eb08599c49e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/aldurazyme""]},{""id"":""uuid:2868d48b-06cd-48c8-b99a-4713568b8766"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Aldurazyme is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of mucopolysaccharidosis I (MPS I; alpha-L-iduronidase deficiency) to treat the nonneurological manifestations of the disease.|[PMDA] Drug containing a new active ingredient indicated for treatment of mucopolysaccharidosis I. [Orphan Drug] uuid:06f32a78-5a45-4edc-91f1-8d34bc9e2be3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2038 biolink:treats MONDO:0015041 PMID:41385096 "[{""id"":""uuid:cf331fa2-83ec-4c30-a136-295a673d5059"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d08e103a-bbc7-4948-a0d3-fb44e8696371"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/azacitidine-mylan""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Azacitidine Mylan is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with:intermediate 2 and high risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS),chronic myelomonocytic leukaemia (CMML) with 10 29% marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (AML) with 20 30% blasts and multi lineage dysplasia, according to World Health Organisation (WHO) classification,AML with > 30% marrow blasts according to the WHO classification. uuid:63e683ab-41fd-46df-ace8-eab9969471ca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71193 biolink:treats MONDO:0007147 PMID:41385096 "[{""id"":""uuid:99908a36-320a-4726-bf47-2bbd37103682"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b89b06b9-f05e-4567-b66e-684a0276f548"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/saxenda""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Saxenda is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index (BMI) of• ≥ 30 kg/m² (obese), or• ≥ 27 kg/m² to < 30 kg/m² (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea.Treatment with Saxenda should be discontinued after 12 weeks on the 3.0 mg/day dose if patients have not lost at least 5% of their initial body weight. uuid:ec4dbb85-fe61-4fa4-bd94-63156009f814 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:34650 biolink:treats MONDO:0009061 PMID:41385096 "[{""id"":""uuid:e80d5f3f-9e1d-4ea8-bddf-08465b720f84"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d6e450f7-4f82-48be-8c43-9275cd2a65ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/colobreathe""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Colobreathe is indicated for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis (CF) aged six years and older.Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:e55bc0c5-9182-40e3-84a7-59574f414025 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:34650 biolink:treats MONDO:0040732 PMID:41385096 "[{""id"":""uuid:3a5c001e-bc40-4903-b1b1-bbb773533eee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:427170e0-862b-4d56-bfa9-7daf1b0d4893"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/colobreathe""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Colobreathe is indicated for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis (CF) aged six years and older.Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:b70031cc-98f1-4f26-9d03-1239f3ce700f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1367006 biolink:treats MONDO:0008159 PMID:41385096 "[{""id"":""uuid:9ff18c9d-acc3-47cf-95cc-5efc30c8fcf6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:8bb5a0ab-5216-4b8a-ac12-46494f22a6d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vantavo""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of postmenopausal osteoporosis in patients at risk of vitamin-D insufficiency.Vantavo reduces the risk of vertebral and hip fractures.Treatment of postmenopausal osteoporosis in patients who are not receiving vitamin-D supplementation and are at risk of vitamin-D insufficiency.Vantavo reduces the risk of vertebral and hip fractures. uuid:916f33b8-5302-460c-84d2-62070a1f1714 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1367006 biolink:treats MONDO:0005298 PMID:41385096 "[{""id"":""uuid:159b2c3f-fb9f-479c-bd31-1e9d7ea2e788"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c0ba24bf-a320-4112-aa8d-5a8c503feaa2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vantavo""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of postmenopausal osteoporosis in patients at risk of vitamin-D insufficiency.Fosavance reduces the risk of vertebral and hip fractures. uuid:594c0acf-a904-464a-8651-4a2bac65645b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8764 biolink:treats UMLS:C0400968 PMID:41385096 "[{""id"":""uuid:d2df9aa4-822a-4ab1-b687-8dad93aa9366"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:7c0ac4c3-7bbb-4d91-9998-070345b2b12b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cellcept""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] CellCept is indicated in combination with ciclosporin and corticosteroids for the prophylaxis of acute transplant rejection in patients receiving allogeneic renal, cardiac or hepatic transplants. uuid:2949b880-9168-4d59-ad7f-892203803278 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85973 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:145a68c7-c214-4bad-a2d6-e78c18658075"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b433b688-f31e-4b5b-b407-ec35d6b0eae0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack (TIA).Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. uuid:cb23da58-b370-4d97-b0e2-f28636ffef55 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85973 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:426be4e5-dc0e-4758-9656-e7b52618a7fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:99329017-17d4-4ec1-82be-8be2dfd80b48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack (TIA).Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. uuid:1a09b0d0-fdf3-4f30-9766-d5835ec7b4ae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85973 biolink:treats MONDO:0005264 PMID:41385096 "[{""id"":""uuid:625c2ddf-f572-4d1a-a174-fd1471fff850"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:89ea39ff-c93e-4a27-8988-45a904ee8a46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack (TIA).Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. uuid:d2d277de-3579-4ad2-89fe-d2faf9177e8a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:5X3GF74R79 biolink:treats MONDO:0010602 PMID:41385096 "[{""id"":""uuid:57c371b2-5d14-48f5-b907-e90025f747e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:05357c69-3cdd-472e-9a6a-70a016a3c800"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/adynovi""]},{""id"":""uuid:5bc41a77-9188-45ef-a215-190165588f0c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment and prophylaxis of bleeding in patients 12 years and above with haemophilia A (congenital factor VIII deficiency).|[PMDA] Drugs with a new active ingredient indicated for the control of bleeding tendency in patients with blood coagulation factor VIII deficiency. uuid:df6ba7f6-31df-4bd3-8dfe-c9d168b65ede biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:ZJ0EKR6M10 biolink:treats MONDO:0850353 PMID:41385096 "[{""id"":""uuid:c95d4464-71c7-4064-bc99-a8e5c1377241"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6bb37286-8e70-4d68-b7b5-2f430845b9c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/locametz""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] This medicinal product is for diagnostic use only. Locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (PSMA) positive lesions with positron emission tomography (PET) in adults with prostate cancer (PCa) in the following clinical settings:Primary staging of patients with high risk PCa prior to primary curative therapy,Suspected PCa recurrence in patients with increasing levels of serum prostate specific antigen (PSA) after primary curative therapy,Identification of patients with PSMA positive progressive metastatic castration resistant prostate cancer (mCRPC) for whom PSMA targeted therapy is indicated (see section 4.4). uuid:c9039d70-dd32-4843-a741-a25523f0aacc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4672 biolink:treats MONDO:0008315 PMID:41385096 "[{""id"":""uuid:78aa3060-f807-47dc-85c3-e766ed91844d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:966212d9-52bc-446d-8f44-a0519841db5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/docetaxel-kabi""]},{""id"":""uuid:aa3f1239-36e6-4674-b7fd-887626041448"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Breast cancerDocetaxel Kabi in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.For patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.Docetaxel Kabi in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.Docetaxel Kabi monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.Docetaxel Kabi in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease.Docetaxel Kabi in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.Non-small-cell lung cancerDocetaxel Kabi is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of prior chemotherapy.Docetaxel Kabi in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small-cell lung cancer, in patients who have not previously received chemotherapy for this condition.Prostate cancerDocetaxel Kabi in combination with prednisone or prednisolone is indicated for the treatment of patients with castration-resistant metastatic prostate cancer.Docetaxel Kabi in combination with androgen-deprivation therapy (ADT), with or without prednisone or prednisolone, is indicated for the treatment of patients with metastatic hormone-sensitive prostate cancer.Gastric adenocarcinomaDocetaxel Kabi in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.Head and neck cancerDocetaxel Kabi in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.|[PMDA] A drug with a new indication and a new dosage for the treatment of prostate cancer. [Priority review] uuid:2965090e-780c-4f63-8ed8-7937f17c9e80 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4672 biolink:treats MONDO:0005627 PMID:41385096 "[{""id"":""uuid:d5287cc5-62a9-4d42-9c57-85f6e541453a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7b5e6550-36cb-46a4-bbf9-42ec3e75ca93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/docetaxel-kabi""]},{""id"":""uuid:05abbb4a-db4c-4f94-be1d-f6f1c1711c85"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Breast cancerDocetaxel Kabi in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.For patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.Docetaxel Kabi in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.Docetaxel Kabi monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.Docetaxel Kabi in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease.Docetaxel Kabi in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.Non-small-cell lung cancerDocetaxel Kabi is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of prior chemotherapy.Docetaxel Kabi in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small-cell lung cancer, in patients who have not previously received chemotherapy for this condition.Prostate cancerDocetaxel Kabi in combination with prednisone or prednisolone is indicated for the treatment of patients with castration-resistant metastatic prostate cancer.Docetaxel Kabi in combination with androgen-deprivation therapy (ADT), with or without prednisone or prednisolone, is indicated for the treatment of patients with metastatic hormone-sensitive prostate cancer.Gastric adenocarcinomaDocetaxel Kabi in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.Head and neck cancerDocetaxel Kabi in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.|[PMDA] Drugs with new dosages for the treatment of breast cancer, non-small cell lung cancer, gastric cancer, head and neck cancer and ovarian cancer. uuid:ba7327fd-ffb7-4a61-955a-d75d8819e024 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:848145 biolink:treats MONDO:0001134 PMID:41385096 "[{""id"":""uuid:a2751300-b3f8-48b3-9a08-3d898c100a6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f339791d-d66d-47d4-b71f-5a4267711aa4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/exforge-hct""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of amlodipine, valsartan and hydrochlorothiazide (HCT), taken either as three single-component formulations or as a dual-component and a single-component formulation. uuid:eefdee8a-eabc-4c1a-8c3f-3023720086d7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:U194AS08HZ biolink:treats MONDO:0024503 PMID:41385096 "[{""id"":""uuid:859246af-2383-4f79-94d1-cf43afe5ab34"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6fd9f48c-56f8-477d-91d0-31226f0d735d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/somakit-toc""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] This medicinal product is for diagnostic use only.After radiolabelling with gallium (68Ga) chloride solution, the solution of gallium (68Ga) edotreotide obtained is indicated for Positron Emission Tomography (PET) imaging of somatostatin receptor overexpression in adult patients with confirmed or suspected well-differentiated gastro-enteropancreatic neuroendocrine tumours (GEP-NET) for localizing primary tumours and their metastases. uuid:2864bb51-43ba-4ace-b88e-c3c939e4073d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:U194AS08HZ biolink:treats MONDO:0000386 PMID:41385096 "[{""id"":""uuid:6034023d-af23-490c-a93a-61109d5e1c69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5db018d8-a62c-49da-bca1-77e3fc252e05"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/somakit-toc""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] This medicinal product is for diagnostic use only.After radiolabelling with gallium (68Ga) chloride solution, the solution of gallium (68Ga) edotreotide obtained is indicated for Positron Emission Tomography (PET) imaging of somatostatin receptor overexpression in adult patients with confirmed or suspected well-differentiated gastro-enteropancreatic neuroendocrine tumours (GEP-NET) for localizing primary tumours and their metastases. uuid:dec3491c-c3fb-4a05-8c20-cc31439357f7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:WKM56H3TLB biolink:treats MONDO:0005789 PMID:41385096 "[{""id"":""uuid:2ed43e19-352c-4a3a-a6ee-60f505266f7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a1f31eb9-c4ac-42ab-a6bb-fe1caf1dba23"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Hepcludex is indicated for the treatment of chronic hepatitis delta virus (HDV) infection in plasma (or serum) HDV-RNA positive adult patients with compensated liver disease. uuid:b8206ad0-6b0c-4586-8f96-c7a1a3656eb6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1603837 biolink:treats UMLS:C0949083 PMID:41385096 "[{""id"":""uuid:c55cfe85-c42d-4183-802c-b656fff15642"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:24944f7e-5930-4af0-9614-54cd1e5095f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zavicefta""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Zavicefta is indicated in adults and paediatric patients aged 3 months and older for the treatment of the following infections:Complicated intra-abdominal infection (cIAI)Complicated urinary tract infection (cUTI), including pyelonephritisHospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP)Treatment of patients with bacteraemia that occurs in association with, or is suspected to be associated with, any of the infections listed above.Zavicefta is also indicated for the treatment of infections due to aerobic Gram-negative organisms in adults and paediatric patients aged 3 months and older with limited treatment options.Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:8d8f4c8d-3c59-4eaf-b3cb-4184d3424deb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4T36H88UA7 biolink:treats MONDO:0850353 PMID:41385096 "[{""id"":""uuid:54515b33-eabc-4ce8-802b-e29549119cce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:50636047-9a49-4702-97cc-9ffdcb4f99c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/erleada""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Erleada is indicated:in adult men for the treatment of non metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.in adult men for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT). uuid:4b0816cd-470f-4597-94df-97114d1a7f69 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEMBL.COMPOUND:CHEMBL2108290 biolink:treats MONDO:0020725 PMID:41385096 "[{""id"":""uuid:a7f22248-4794-4adc-ab93-0f3dd1e10922"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6a882dd8-51be-40be-aa65-3a5a07a1f1ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/eporatio""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of symptomatic anaemia associated with chronic renal failure in adult patients.Treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy. uuid:7a37b251-a8fb-4280-89f3-f02ceed9592d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEMBL.COMPOUND:CHEMBL2108290 biolink:treats MONDO:0002280 PMID:41385096 "[{""id"":""uuid:869493f2-1b1e-457c-b227-61e5bd96155a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a891c518-0381-49eb-8771-fac3598fcad1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/eporatio""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of symptomatic anaemia associated with chronic renal failure in adult patients.Treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy. uuid:eb14c208-4092-461e-8f4b-b5188b30be7c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:216653 biolink:treats MONDO:0001134 PMID:41385096 "[{""id"":""uuid:9a7da261-249a-43fd-a6a4-926a0eeae705"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:96a0196d-492f-4e7f-8316-39c674f8f8c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/copalia-hct""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of amlodipine, valsartan and hydrochlorothiazide (HCT), taken either as three single-component formulations or as a dual-component and a single-component formulation. uuid:bbf0de16-055e-4b9a-8708-2c8478a7f47e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50861 biolink:treats MONDO:0013024 PMID:41385096 "[{""id"":""uuid:a31d3bfd-faef-4fbe-ad33-914e19103693"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:89a45ec2-e996-4003-a572-fe66539388bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of adult patients with WHO Functional Class (FC) III or IV and:inoperable chronic thromboembolic pulmonary hypertension (CTEPH), orpersistent or recurrent CTEPH after surgical treatmentto improve exercise capacity. uuid:511c6d4c-d903-4951-9401-eb6c95e1d19a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85083 biolink:treats MONDO:0005231 PMID:41385096 "[{""id"":""uuid:d26d566f-1ce9-45be-a949-4003af97e211"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:75042c1a-2137-49c5-a2ba-bbcb1545ac6c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/sovaldi""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Sovaldi is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adult and paediatric patients aged 3 years and above (see sections 4.2, 4.4 and 5.1).For hepatitis C virus (HCV) genotype specific activity, see sections 4.4 and 5.1.Sovaldi is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults and paediatric patients aged 3 years and above (see sections 4.2, 4.4 and 5.1).For hepatitis C virus (HCV) genotype specific activity, see sections 4.4 and 5.1. uuid:edee4a9f-8244-411f-b942-6f0429541ae7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:129011857 biolink:treats MONDO:0005354 PMID:41385096 "[{""id"":""uuid:b9cc7158-bcd6-4d96-a7f3-9b0c58b959fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:020bc667-9b0a-4be9-ae9f-7b9f2057e526"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vosevi""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Vosevi is indicated for the treatment of chronic hepatitis C virus (HCV) infection in patients aged 12 years and older and weighing at least 30 kg. (see sections 4.2, 4.4 and 5.1). uuid:159bee58-86aa-44ff-850d-914e755e8398 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:72734365 biolink:treats MONDO:0005354 PMID:41385096 "[{""id"":""uuid:a9979f42-d888-463d-b6e9-03260b3e3bc0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9ee94fa1-4014-423b-9148-9b23af407d77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/harvoni""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Harvoni is indicated for the treatment of chronic hepatitis C (CHC) in adult and paediatric patients aged 3 years and above (see sections 4.2, 4.4 and 5.1).For hepatitis C virus (HCV) genotype-specific activity see sections 4.4 and 5.1. uuid:3d0c496a-c2ad-4f43-8d67-f08b5d12d8a2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:72734365 biolink:treats MONDO:0005231 PMID:41385096 "[{""id"":""uuid:adc27bf0-8f45-46c8-b0e7-404ad57f8c8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c5e37d21-dfb5-4346-9f40-fad624dd8fc9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/harvoni""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Harvoni is indicated for the treatment of chronic hepatitis C (CHC) in adult and paediatric patients aged 3 years and above (see sections 4.2, 4.4 and 5.1).For hepatitis C virus (HCV) genotype-specific activity see sections 4.4 and 5.1. uuid:2c2c2882-bca9-4cc2-be65-b76d175be267 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2642142 biolink:treats MONDO:0001577 PMID:41385096 "[{""id"":""uuid:b1b739eb-275f-4a04-907a-89c0cf66171a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c69f938f-a740-4c6b-813e-26428125a597"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:bd04c933-a421-4e94-8606-b0bd74a3ce39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Abrysvo is indicated for:Passive protection against lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age following maternal immunisation during pregnancy. See sections 4.2 and 5.1.Active immunisation of individuals 60 years of age and older for the prevention of lower respiratory tract disease caused by RSV.The use of this vaccine should be in accordance with official recommendations.|[PMDA] A drug with a new active ingredient indicated for active immunization of pregnant individuals for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in neonates and infants. uuid:ec753fed-22b4-44c3-822c-dc2db61605a9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68639 biolink:treats MONDO:0008315 PMID:41385096 "[{""id"":""uuid:37dc0876-0556-43f4-ba76-b4d320dfbe1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ed8311ff-544d-4c5d-b4b9-3558b0760274"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Abiraterone Accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT)the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen. uuid:a1d7da6a-2f29-4b3b-9a87-87a4c4fe36e2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68639 biolink:treats MONDO:0004956 PMID:41385096 "[{""id"":""uuid:52c1fd27-89cd-4dc9-9ea2-623eebe4e45b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:206e046c-4b0f-4c87-a13e-04f24a35c9ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Abiraterone Accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT)the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen. uuid:61db4783-8626-4c81-8571-4749d0994521 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68639 biolink:treats MONDO:0850353 PMID:41385096 "[{""id"":""uuid:2469a4ea-6b27-49bf-950e-dca0d2f65dc8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9034d91a-c2ae-47ea-be05-a69ce1dfd81f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Abiraterone Accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mHSPC) in adult men in combination with androgen deprivation therapy (ADT)the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mCRPC in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen. uuid:2dcc90ee-da39-433c-855a-e9b552860ffe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9168 biolink:treats HP:0010615 PMID:41385096 "[{""id"":""uuid:86d26be7-f01d-4818-920a-d51a07be440d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d4f66377-9a2f-4bb9-8eeb-d12e4416b2a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/hyftor""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Hyftor is indicated for the treatment of facial angiofibroma associated with tuberous sclerosis complex in adults and paediatric patients aged 6 years and older. uuid:3f7b765d-582f-4c9c-9a90-9aaba20e4127 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7735 biolink:treats MONDO:0004985 PMID:41385096 "[{""id"":""uuid:ed2458ab-1273-4ca0-9e8f-105de7fc6bd4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a155b76e-a8b6-4a15-9daa-13365b4e9429"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/olanzapine-teva""]},{""id"":""uuid:ffd4448c-9ef0-4458-bb44-ef5cc6ac542a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] AdultsOlanzapine is indicated for the treatment of schizophrenia.Olanzapine is effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response.Olanzapine is indicated for the treatment of moderate to severe manic episode.In patients whose manic episode has responded to olanzapine treatment, olanzapine is indicated for the prevention of recurrence in patients with bipolar disorder.|[PMDA] Drugs with a new additional indication and a new dosage for the improvement of depressive symptoms in patients with bipolar disorder. uuid:a48da1ae-1713-4da8-9a5c-67eda15a2315 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5441 biolink:treats MONDO:0016391 PMID:41385096 "[{""id"":""uuid:d1c0fffe-cfb9-40c9-8b75-18c507902738"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a4265151-4792-4495-9d2b-a9e334348b0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/amglidia""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Amglidia is indicated for the treatment of neonatal diabetes mellitus, for use in newborns, infants and children.Sulphonylureas like Amglidia have been shown to be effective in patients with mutations in the genes coding for the β-cell ATP-sensitive potassium channel and chromosome 6q24-related transient neonatal diabetes mellitus. uuid:d4b7b47f-6ad2-46da-9970-7d356c6cae3b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5441 biolink:treats MONDO:0020525 PMID:41385096 "[{""id"":""uuid:e53cb7ed-f617-45ac-ab2e-edfaf6ff2a8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6e09175a-79ed-455d-990d-3e16ef88150a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/amglidia""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Amglidia is indicated for the treatment of neonatal diabetes mellitus, for use in newborns, infants and children.Sulphonylureas like Amglidia have been shown to be effective in patients with mutations in the genes coding for the β-cell ATP-sensitive potassium channel and chromosome 6q24-related transient neonatal diabetes mellitus. uuid:50862e6f-5146-45a3-a9c1-63740a93fe5a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76612 biolink:treats MONDO:0018876 PMID:41385096 "[{""id"":""uuid:21e71164-8565-4392-82a7-c3f20f6c5155"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8c31a48d-78d1-41dc-8e21-6620a2cf3860"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/imbruvica""]},{""id"":""uuid:d9bcbe90-d4f4-4e35-b960-1a03b2fa90aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] IMBRUVICA as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).IMBRUVICA as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (CLL) (see section 5.1).IMBRUVICA as a single agent or in combination with bendamustine and rituximab (BR) is indicated for the treatment of adult patients with CLL who have received at least one prior therapy.IMBRUVICA as a single agent is indicated for the treatment of adult patients with Waldenström’s macroglobulinaemia (WM) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. IMBRUVICA in combination with rituximab is indicated for the treatment of adult patients with WM.|[PMDA] A drug with a new indication and a new dosage for the treatment of mantle cell lymphoma. [Orphan drug] uuid:aa0c904b-4d33-4c1d-875d-c036162645e6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:76RS4S2ET1 biolink:treats MONDO:0009669 PMID:41385096 "[{""id"":""uuid:bd676d0c-a126-4a25-80bd-16bab76a1b86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d562efb0-98b8-49b8-9552-1a1e15d4a070"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/evrysdi""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Evrysdi is indicated for the treatment of 5q spinal muscular atrophy (SMA) in patients with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies. uuid:7831f054-9778-4dbf-928c-2a16492dfc11 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:76RS4S2ET1 biolink:treats MONDO:0009673 PMID:41385096 "[{""id"":""uuid:f791420b-ad5a-4930-93b7-7e69b91478a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:cd775c06-fdeb-4354-b850-89488260f947"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/evrysdi""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Evrysdi is indicated for the treatment of 5q spinal muscular atrophy (SMA) in patients with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies. uuid:243fd3db-63ca-47d3-a581-39d65b28ccff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:76RS4S2ET1 biolink:treats MONDO:0009672 PMID:41385096 "[{""id"":""uuid:d705c188-5971-4556-b6b2-6439bb7dd31f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6ecef7db-9fe4-47e4-ab63-420f2d186c35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/evrysdi""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Evrysdi is indicated for the treatment of 5q spinal muscular atrophy (SMA) in patients with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies. uuid:bfabe9b2-93da-4176-8661-3c990db40e5f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:78538 biolink:treats MONDO:0018634 PMID:41385096 "[{""id"":""uuid:dfac2fde-732c-46b5-a5aa-d8638929567f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:da04c977-6a37-4b85-8c77-e518cd4cd005"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vyndaqel""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Vyndaqel is indicated for the treatment of transthyretin amyloidosis in adult patients with stage-1 symptomatic polyneuropathy to delay peripheral neurologic impairment. uuid:e1a5094d-0818-47df-a45f-b6528436be21 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:78538 biolink:treats MONDO:0001824 PMID:41385096 "[{""id"":""uuid:643d5079-5dac-439c-b0f9-01989a3726d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b4f62db4-9d63-45fe-9a4a-c4df17d4f347"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vyndaqel""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Vyndaqel is indicated for the treatment of transthyretin amyloidosis in adult patients with stage-1 symptomatic polyneuropathy to delay peripheral neurologic impairment. uuid:c8fd0e85-de2b-4539-98ed-181c21bc279d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:QEN1X95CIX biolink:treats MONDO:0007256 PMID:41385096 "[{""id"":""uuid:efc9335c-6326-4fc7-b9a5-c59968aa333b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2185a9b3-ea4b-46b4-8561-aa24ed5aad58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/imjudo""]},{""id"":""uuid:c17f6813-a0f8-4591-97bd-fea014d43d74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC).Imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) with no sensitising EGFR mutations or ALK positive mutations.|[PMDA] Drugs with a new active ingredient indicated for the treatment of unresectable advanced or recurrent non- small-cell lung cancer and unresectable hepatocellular carcinoma. uuid:2c7e5fe1-5c09-4d3d-9ba2-96a744d3b257 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:QEN1X95CIX biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:5071c6e6-c522-4614-9b05-49588f2879f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:35bd18d7-2d3d-4788-bde5-47ff2aac35ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/imjudo""]},{""id"":""uuid:d6270e15-1bb9-4c02-8c65-cdd362a791ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Imjudo in combination with durvalumab is indicated for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma (HCC).Imjudo in combination with durvalumab and platinum-based chemotherapy is indicated for the first-line treatment of adults with metastatic non-small cell lung cancer (NSCLC) with no sensitising EGFR mutations or ALK positive mutations.|[PMDA] Drugs with a new active ingredient indicated for the treatment of unresectable advanced or recurrent non- small-cell lung cancer and unresectable hepatocellular carcinoma. uuid:b7d8e3cb-aa1b-44b7-9334-e260ef77da6c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:131952892 biolink:treats MONDO:0000386 PMID:41385096 "[{""id"":""uuid:2e164dcd-2fdb-4574-ace6-72c2dfbc3e52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:bb8997b0-2f92-4620-ad41-1245b2be1ee4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Lutathera is indicated for the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (GEP‑NETs) in adults. uuid:c8d4e3f6-daa6-48e9-9468-ed3bea1c3156 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PF9462I9HX biolink:treats MONDO:0024883 PMID:41385096 "[{""id"":""uuid:bdb64c81-d1ee-45ee-a190-3be7b1f14017"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:43c88e55-0b8a-427f-8acc-8e19a1f626b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Vitrakvi as monotherapy is indicated for the treatment of adult and paediatric patients with solid tumours that display a Neurotrophic Tyrosine Receptor Kinase (NTRK) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have no satisfactory treatment options. uuid:d8c4a35f-629a-4941-8d6b-448db635bdd0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82699 biolink:treats UMLS:C4552483 PMID:41385096 "[{""id"":""uuid:221214fd-3b12-40a6-8f18-1b987ffd3faa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:813c411b-39f8-422d-afb7-7ae6f6b3c124"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Tenkasi is indicated for the treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults and paediatric patients aged 3 months and older (see sections 4.2, 4.4 and 5.1).Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:fda682ff-70fb-4f1c-9eda-010beb6c8d87 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:83766 biolink:treats MONDO:0006047 PMID:41385096 "[{""id"":""uuid:717a1c51-bc7c-4ee6-9a79-8955c827b36b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4a390d6e-9ef6-4f1c-b29b-8147ae69a440"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ovarian cancerLynparza is indicated as monotherapy for the:maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy.Lynparza in combination with bevacizumab is indicated for the:maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability (see section 5.1).Breast cancerLynparza is indicated as:monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2-mutations who have HER2-negative, high risk early breast cancer previously treated with neoadjuvant or adjuvant chemotherapy (see sections 4.2 and 5.1).monotherapy for the treatment of adult patients with germline BRCA1/2-mutations, who have HER2 negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments (see section 5.1). Patients with hormone receptor (HR)-positive breast cancer should also have progressed on or after prior endocrine therapy, or be considered unsuitable for endocrine therapy.Adenocarcinoma of the pancreasLynparza is indicated as:monotherapy for the maintenance treatment of adult patients with germline BRCA1/2-mutations who have metastatic adenocarcinoma of the pancreas and have not progressed after a minimum of 16 weeks of platinum treatment within a first-line chemotherapy regimen.Prostate cancerLynparza is indicated as:monotherapy for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) and BRCA1/2-mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent.in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with mCRPC in whom chemotherapy is not clinically indicated (see section 5.1). uuid:80e6a8d6-6a0b-462c-941a-a154c363fa1d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C541234 biolink:treats MONDO:0005504 PMID:41385096 "[{""id"":""uuid:45d3d563-e45a-4499-9833-9236ecfc9edf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9126cbf7-6d77-491f-a95b-730944ba55c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Infanrix Hexa is indicated for primary and booster vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and disease caused by Haemophilus influenzae type-b. uuid:4151d395-4261-47fc-8042-78d4edad1922 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C541234 biolink:treats MONDO:0005526 PMID:41385096 "[{""id"":""uuid:869f44c9-5287-4084-b4af-4042eb4971a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9bba05c0-ef78-4915-97ad-a1277ff03b07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Infanrix Hexa is indicated for primary and booster vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and disease caused by Haemophilus influenzae type-b. uuid:05e5826b-af11-4d3a-9c5e-79cbb93e4da7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C541234 biolink:treats MONDO:0005077 PMID:41385096 "[{""id"":""uuid:0caedcb3-0851-4c80-a4f2-69e8ddf6d397"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:72d6d0e9-69af-47a6-83f3-75c1ee82c783"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Infanrix Hexa is indicated for primary and booster vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and disease caused by Haemophilus influenzae type-b. uuid:d1b339f4-86e4-4029-89d1-6b3a27b9a25c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C541234 biolink:treats MONDO:0005344 PMID:41385096 "[{""id"":""uuid:2757650f-efdd-43bf-b148-1019074633cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:8c2f9e3a-0e33-41b7-a5e7-f65c8de8c3f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Infanrix Hexa is indicated for primary and booster vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and disease caused by Haemophilus influenzae type-b. uuid:eb342b29-9cf9-42da-847d-40959b398bac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C541234 biolink:treats MONDO:0017373 PMID:41385096 "[{""id"":""uuid:56edd616-6184-4259-97cd-7be1e6bbb12f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:76766c30-a18c-4680-9514-b076b01deab1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Infanrix Hexa is indicated for primary and booster vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and disease caused by Haemophilus influenzae type-b. uuid:11988d35-a65c-4b5a-abb4-60de84149ae5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C541234 biolink:treats MONDO:0006926 PMID:41385096 "[{""id"":""uuid:a467acc8-ee3b-441c-8318-c66a2b2c95a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:28c01b63-1956-4566-b932-c00268ede0d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Infanrix Hexa is indicated for primary and booster vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and disease caused by Haemophilus influenzae type-b. uuid:7fcc7fb9-22e0-44df-8071-34f772e8981e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB15656 biolink:treats MONDO:0100096 PMID:41385096 "[{""id"":""uuid:3b87ae5c-6923-4181-968f-8cf9e34b5cf9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b2039247-fde3-4a6b-bafb-64cc260bf525"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:743f0d94-7845-4fc8-8d3e-a0292f9bb36a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Vaxzevria is indicated for active immunisation to prevent COVID 19 caused by SARS CoV 2, in individuals 18 years of age and older.The use of this vaccine should be in accordance with official recommendations.|[PMDA] A drug with a new active ingredient indicated for the prevention of disease caused by SARS-CoV-2 infection (COVID-19). [Priority review] uuid:c9b31e5f-c9b3-4eb1-9214-b33e68070ec5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76611 biolink:treats MONDO:0002039 PMID:41385096 "[{""id"":""uuid:8c5bed5e-b6a9-4ccd-b0d3-863cc2c8872f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:36588bbd-d655-404d-82c6-bf003be27082"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] This medicinal product is for diagnostic use only.Vizamyl is a radiopharmaceutical medicinal product indicated for Positron Emission Tomography (PET) imaging of β amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive impairment. Vizamyl should be used in conjunction with a clinical evaluation.A negative scan indicates sparse or no plaques, which is not consistent with a diagnosis of AD. uuid:78bc041d-b68f-4f1c-ac91-56351672bf7a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76004 biolink:treats MONDO:0005314 PMID:41385096 "[{""id"":""uuid:8b83bbea-b06a-40f4-abc7-86a292eff998"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:811a854d-b1e5-4197-87e1-b089a7bec1a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tecfidera""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Tecfidera is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (RRMS). uuid:a45dd74d-7081-4a3a-953a-7aaa923f6b41 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB17593 biolink:treats MONDO:0007064 PMID:41385096 "[{""id"":""uuid:6cf97b9b-29e8-46fe-a9e5-726dc1ad466d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:3bc24c7c-4e0b-458c-bd3d-e4e8b8595170"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Strimvelis is indicated for the treatment of patients with severe combined immunodeficiency due to adenosine deaminase deficiency (ADA-SCID), for whom no suitable human leukocyte antigen (HLA)-matched related stem cell donor is available (see section 4.2 and section 4.4). uuid:6f501864-c36e-41de-9fb1-8ee95bab313e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:5PKM8P0G5I biolink:treats MONDO:0024574 PMID:41385096 "[{""id"":""uuid:5b6e91af-5f87-483c-8e77-5028b8d4c5f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:dfd6e674-316b-4b53-8c21-23d55de90bb2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/veyvondi""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Veyvondi is indicated in adults (age 18 and older) with von Willebrand Disease (VWD), when desmopressin (DDAVP) treatment alone is ineffective or not indicated for the- Treatment of haemorrhage and surgical bleeding- Prevention of surgical bleeding.Veyvondi should not be used in the treatment of Haemophilia A. uuid:209f22d1-12d7-4325-90a1-7f53d2cf8972 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:5PKM8P0G5I biolink:treats NCIT:C26791 PMID:41385096 "[{""id"":""uuid:f34a3db6-af29-4508-b776-73f72fddb33c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:8f5a6000-2eaa-4872-bb36-ad20db3b1c6c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/veyvondi""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Veyvondi is indicated in adults (age 18 and older) with von Willebrand Disease (VWD), when desmopressin (DDAVP) treatment alone is ineffective or not indicated for the- Treatment of haemorrhage and surgical bleeding- Prevention of surgical bleeding.Veyvondi should not be used in the treatment of Haemophilia A. uuid:d1073a89-d945-4176-aa2b-dfb36fa7744d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:5PKM8P0G5I biolink:treats NCIT:C35135 PMID:41385096 "[{""id"":""uuid:b425bb94-3664-4e85-a1db-5613d5e02a5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ad013fa8-72b9-4c17-a031-3e3a7cd6c42a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/veyvondi""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Veyvondi is indicated in adults (age 18 and older) with von Willebrand Disease (VWD), when desmopressin (DDAVP) treatment alone is ineffective or not indicated for the- Treatment of haemorrhage and surgical bleeding- Prevention of surgical bleeding.Veyvondi should not be used in the treatment of Haemophilia A. uuid:c19d942a-b212-4553-b95d-f8abd8a7254a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45863 biolink:treats MONDO:0018364 PMID:41385096 "[{""id"":""uuid:d3baf6be-cef2-4590-8e00-54f1b2d5088b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:41a88c72-c8a9-4e24-86db-b7c1c4454d2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/apealea""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Apealea in combination with carboplatin is indicated for the treatment of adult patients with first relapse of platinum‑sensitive epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer. uuid:b907fbbd-37c6-4c17-a948-32de0a143a9d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45863 biolink:treats MONDO:0015686 PMID:41385096 "[{""id"":""uuid:75ca0548-7c32-4a24-80db-36effc1a0170"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9e957c78-a916-4775-95c0-b88826db55b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/apealea""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Apealea in combination with carboplatin is indicated for the treatment of adult patients with first relapse of platinum‑sensitive epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer. uuid:df1af415-425b-4185-91f9-3935cd7fca9b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45863 biolink:treats MONDO:0002158 PMID:41385096 "[{""id"":""uuid:b2c9dd03-fafd-4665-af57-b1faacdf42d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:716b17aa-f184-4fa2-96dc-eb526ba5c602"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/apealea""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Apealea in combination with carboplatin is indicated for the treatment of adult patients with first relapse of platinum‑sensitive epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer. uuid:0f7343fe-73bc-47a3-886a-87856d5ad252 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231425 biolink:treats HP:0012623 PMID:41385096 "[{""id"":""uuid:81ad5836-fa1d-4677-8f67-9d3f262997e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c5aec6b1-9d2a-44c1-9caa-f21924a13568"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/jinarc""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Jinarc is indicated to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with CKD stage 1 to 3 at initiation of treatment with evidence of rapidly progressing disease. uuid:2dd8899a-b2f6-4b4e-baa7-8ba9f65c9ce4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231425 biolink:treats HP:0012624 PMID:41385096 "[{""id"":""uuid:af49caa0-e4ec-4e39-bc09-48adc6133ff3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:82bede7f-542f-462d-99e1-de2929859849"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/jinarc""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Jinarc is indicated to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with CKD stage 1 to 3 at initiation of treatment with evidence of rapidly progressing disease. uuid:0fa79611-7346-4a19-95a8-6175ff137122 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231425 biolink:treats HP:0012625 PMID:41385096 "[{""id"":""uuid:c1fb6656-e7bf-4c41-864f-c79b7681688d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:658f971a-d7af-463c-a4e7-71f6f9492dd2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/jinarc""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Jinarc is indicated to slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with CKD stage 1 to 3 at initiation of treatment with evidence of rapidly progressing disease. uuid:b9f6e07d-6a73-43ff-b4a7-2ecf1354e817 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:A57KX1VL5P biolink:treats MONDO:0010604 PMID:41385096 "[{""id"":""uuid:1c3e81d5-98ec-4426-9892-58ddaa94b68d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:404cd38a-aaf6-4343-8869-ee7f33629241"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/idelvion""]},{""id"":""uuid:56e6793b-5143-4851-8632-e114bbc228ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency).|[PMDA] Drugs with a new active ingredient indicated for the control of bleeding tendency in patients with coagulation factor IX deficiency. uuid:20de4ffd-b0e9-486b-8d0c-50f016ca30fb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:15C2VL427D biolink:treats MONDO:0003005 PMID:41385096 "[{""id"":""uuid:fe3b6735-6ed5-45fd-81c7-49dc77dbbe6d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:8c79aab4-d0f1-4199-878d-cf82d75484d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/yesafili""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Eylea is indicated for adults for the treatment of:neovascular (wet) age-related macular degeneration (AMD);visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO);visual impairment due to diabetic macular oedema (DME);visual impairment due to myopic choroidal neovascularisation (myopic CNV). uuid:8c63b425-658d-4512-9ad0-d2cb637fc93f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1656336 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:5272029c-8cfa-429b-ae91-bf9e81161ba8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c1ce2606-ea48-4522-bd54-4eca5143775b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/neparvis""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Paediatric heart failureNeparvis is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction (see section 5.1).Adult heart failureNeparvis is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction (see section 5.1). uuid:7038a897-f860-4cb4-b310-a0dda1dc61c5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1656336 biolink:treats HP:0025169 PMID:41385096 "[{""id"":""uuid:c5dcb80f-3cd8-4969-9915-5286fab86c8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2a57c769-67dd-4c0b-a9ac-ce2134cbb745"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/neparvis""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Paediatric heart failureNeparvis is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction (see section 5.1).Adult heart failureNeparvis is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction (see section 5.1). uuid:5d02a62e-4032-46f4-8389-23a8eac7bf18 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1656336 biolink:treats HP:0012664 PMID:41385096 "[{""id"":""uuid:e0fda4f6-1eec-4144-bf9e-2826f0a1ea93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:413d06c6-18a9-4302-b599-5d0b3265188f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/neparvis""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Paediatric heart failureNeparvis is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction (see section 5.1).Adult heart failureNeparvis is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction (see section 5.1). uuid:b0f6749e-1719-4cd8-945d-0ac8b589ec06 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:XSZ53G39H5 biolink:treats MONDO:0005417 PMID:41385096 "[{""id"":""uuid:91be76ba-dbeb-4f1b-961b-75b405c76dd6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:67207d2e-b2fe-4981-bc16-0f3e2c350bf3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/beovu""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Beovu is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (AMD). uuid:2bd12862-8982-4f66-93c4-acd472c10b1c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:Y6BX7BL23K biolink:treats MONDO:0019087 PMID:41385096 "[{""id"":""uuid:e5d23d63-5a31-46bf-8689-9caeae4103a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:21727810-a8a1-43a0-aea6-7af6bf3264b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/pemazyre""]},{""id"":""uuid:5037f90d-7729-42d2-9a84-d213d8316001"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Pemazyre monotherapy is indicated for the treatment of adults with locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.|[PMDA] A drug with a new active ingredient indicated for the treatment of unresectable FGFR2 fusion gene-positive biliary tract cancer that has progressed after cancer chemotherapy. [Orphan drug] uuid:e455dce9-2193-40da-afc5-9235f48a6dc8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9829639 biolink:treats MONDO:0005575 PMID:41385096 "[{""id"":""uuid:e2e96b75-2135-4042-9527-d3c4e0ab2e18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2ec307cb-b625-4877-ba5a-06e9f182d534"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lonsurf""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Colorectal cancerLonsurf is indicated in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (CRC) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and/or anti-EGFR agents.Lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti EGFR agentsGastric cancerLonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease. uuid:b8ce0b58-0e1f-4c87-b413-431d293655b2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9829639 biolink:treats MONDO:0001056 PMID:41385096 "[{""id"":""uuid:8fb49c81-8b23-483d-86c7-f0d639a1c91e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:22350d3d-e835-4901-8b3b-65ae600c5285"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lonsurf""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Colorectal cancerLonsurf is indicated in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (CRC) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and/or anti-EGFR agents.Lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF agents, and anti EGFR agentsGastric cancerLonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease. uuid:5d0b3a9a-7621-44ae-82d9-cded6ec99a4e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:78759283 biolink:treats HP:0002018 PMID:41385096 "[{""id"":""uuid:4538660e-ee03-4493-ada0-dd06a86ee050"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:75812b0e-c6e6-4fdd-87a9-c8326fdc87f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/akynzeo""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Akynzeo is indicated in adults for the:Prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin based cancer chemotherapy.Prevention of acute and delayed nausea and vomiting associated with moderately emetogenic cancer chemotherapy. uuid:3b06a9af-032a-463f-8c8b-9240fc0aec89 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:78759283 biolink:treats HP:0002013 PMID:41385096 "[{""id"":""uuid:6cc4172e-93e7-4567-b56a-b96f054474c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ca58400f-e75c-4854-9f78-d413a195bd1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/akynzeo""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Akynzeo is indicated in adults for the:Prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin based cancer chemotherapy.Prevention of acute and delayed nausea and vomiting associated with moderately emetogenic cancer chemotherapy. uuid:d6932946-2371-4956-a441-f5fd88c95c24 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5959 biolink:treats MONDO:0001134 PMID:41385096 "[{""id"":""uuid:52034fc4-3ecc-45dd-8f53-22bf634ad39e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f79f880f-75d4-4815-9664-cb5b8e8d7b21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/irbesartan-teva""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of essential hypertension.Treatment of renal disease in patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive medicinal product regimen. uuid:a413aa6e-d65b-4f7a-bcb5-be29222830fe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5959 biolink:treats MONDO:0005240 PMID:41385096 "[{""id"":""uuid:83646952-8587-4f11-b513-f019bf1750e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:08b74a00-ac8a-48ff-a161-fc5a57e7785b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/irbesartan-teva""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of essential hypertension.Treatment of renal disease in patients with hypertension and type 2 diabetes mellitus as part of an antihypertensive medicinal product regimen. uuid:fcb65469-f458-4662-977b-ac90a002b9c7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:K0N0Z40J3W biolink:treats MONDO:0005314 PMID:41385096 "[{""id"":""uuid:57b79ff5-1c8e-47af-8efd-cda933bb3a97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:eec539b4-6f44-4f87-a504-8f8716311c2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Vumerity is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (see Section 5.1 for important information on the populations for which efficacy has been established). uuid:085d26f8-b16c-4e05-9e48-d9fea7e7e00f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85010 biolink:treats MONDO:0008558 PMID:41385096 "[{""id"":""uuid:66f43387-88c4-4b6c-a016-1fd4897843df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:27bce714-6a80-4818-a0fb-e3f7d99032c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/revolade""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Revolade is indicated for the treatment of adult patients with primary immune thrombocytopenia (ITP) who are refractory to other treatments (e.g. corticosteroids, immunoglobulins) (see sections 4.2 and 5.1).Revolade is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (ITP) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e.g. corticosteroids, immunoglobulins) (see sections 4.2 and 5.1).Revolade is indicated in adult patients with chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy (see sections 4.4 and 5.1).Revolade is indicated in adult patients with acquired severe aplastic anaemia (SAA) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation (see section 5.1). uuid:69508267-79e2-4f9f-863d-fed8cd173150 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85010 biolink:treats MONDO:0015610 PMID:41385096 "[{""id"":""uuid:e8f123b3-99c2-4f15-aeb8-5b8950363c73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c27fa1b6-cc4b-4de6-a658-5f550b8ba7db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/revolade""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Revolade is indicated for the treatment of adult patients with primary immune thrombocytopenia (ITP) who are refractory to other treatments (e.g. corticosteroids, immunoglobulins) (see sections 4.2 and 5.1).Revolade is indicated for the treatment of paediatric patients aged 1 year and above with primary immune thrombocytopenia (ITP) lasting 6 months or longer from diagnosis and who are refractory to other treatments (e.g. corticosteroids, immunoglobulins) (see sections 4.2 and 5.1).Revolade is indicated in adult patients with chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy (see sections 4.4 and 5.1).Revolade is indicated in adult patients with acquired severe aplastic anaemia (SAA) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation (see section 5.1). uuid:91fea9e7-f3be-4842-8f11-8ad6a456e4e7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75045 biolink:treats MONDO:0005105 PMID:41385096 "[{""id"":""uuid:cb444d16-7c01-47c5-92c4-860bc706faab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:34d02ec2-6c31-4720-9cc8-0de61b920031"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] MelanomaDabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation (see sections 4.4 and 5.1).Adjuvant treatment of melanomaDabrafenib in combination with trametinib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection.Non-small cell lung cancer (NSCLC)Dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation. uuid:2552d5d3-fefb-450e-964c-c66c2a2191ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75045 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:451ddde3-9fb1-4b9c-95e5-061d5741735a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bb164e18-34cc-4b00-a782-7e10e94dd6fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:dba00efe-6cf7-4968-bbcf-086e714ee8f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] MelanomaDabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation (see sections 4.4 and 5.1).Adjuvant treatment of melanomaDabrafenib in combination with trametinib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection.Non-small cell lung cancer (NSCLC)Dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation.|[PMDA] Drugs with a new additional indication and a new dosage indicated for the treatment of unresectable advanced or recurrent BRAF mutation-positive non-small-cell lung cancer. [Orphan drug] uuid:5516bfcd-4ce3-43ef-8e91-1aab84dcbf04 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9XW757O13D biolink:treats MONDO:0011719 PMID:41385096 "[{""id"":""uuid:1169addb-0332-4509-b09d-0d40fc3a768e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:8659b053-cbce-46a8-9a91-cd41ef23eed1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/qinlock""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib. uuid:282ef09a-124c-461d-a161-071eeb665d81 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DLG4EML025 biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:4f534a79-aee7-44b6-a1dc-ec9ba8da2395"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c7606430-9cd5-4366-b3c4-228191987920"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Plaque psoriasisCosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults and children from the age of 6 years old who are candidates for systemic therapy.Hidradenitis suppurativa (HS)Cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic HS therapy.Psoriatic arthritisCosentyx, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous disease modifying anti rheumatic drug (DMARD) therapy has been inadequate.Axial spondyloarthritis (axSpA)Ankylosing spondylitis (AS, radiographic axial spondyloarthritis)Cosentyx is indicated for the treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.Non-radiographic axial spondyloarthritis (nr-axSpA)Cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence in adults who have responded inadequately to non steroidal anti inflammatory drugs (NSAIDs).Juvenile idiopathic arthritis (JIA)Enthesitis-related arthritis (ERA)Cosentyx, alone or in combination with methotrexate (MTX), is indicated for the treatment of active enthesitis-related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.Juvenile psoriatic arthritis (JPsA)Cosentyx, alone or in combination with methotrexate (MTX), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. uuid:dd2a4209-f034-419c-b9ab-044dad6c46e2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DLG4EML025 biolink:treats MONDO:0006559 PMID:41385096 "[{""id"":""uuid:481e6783-1709-4c73-ad65-eb44a67b6ae5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:27cd429d-9885-4fca-a608-0d15c6efb382"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Plaque psoriasisCosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults and children from the age of 6 years old who are candidates for systemic therapy.Hidradenitis suppurativa (HS)Cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic HS therapy.Psoriatic arthritisCosentyx, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous disease modifying anti rheumatic drug (DMARD) therapy has been inadequate.Axial spondyloarthritis (axSpA)Ankylosing spondylitis (AS, radiographic axial spondyloarthritis)Cosentyx is indicated for the treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.Non-radiographic axial spondyloarthritis (nr-axSpA)Cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence in adults who have responded inadequately to non steroidal anti inflammatory drugs (NSAIDs).Juvenile idiopathic arthritis (JIA)Enthesitis-related arthritis (ERA)Cosentyx, alone or in combination with methotrexate (MTX), is indicated for the treatment of active enthesitis-related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.Juvenile psoriatic arthritis (JPsA)Cosentyx, alone or in combination with methotrexate (MTX), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. uuid:ef1b11d8-1eaf-4d38-ba55-a70cce1bb3be biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DLG4EML025 biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:c0ffa0b4-61ee-41cc-93ec-f236b0520b68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e13930bc-b4f3-4e87-b0de-5002f082bb55"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx""]},{""id"":""uuid:ca83332b-6818-49e9-a389-7c927f5d23d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Plaque psoriasisCosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults and children from the age of 6 years old who are candidates for systemic therapy.Hidradenitis suppurativa (HS)Cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic HS therapy.Psoriatic arthritisCosentyx, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous disease modifying anti rheumatic drug (DMARD) therapy has been inadequate.Axial spondyloarthritis (axSpA)Ankylosing spondylitis (AS, radiographic axial spondyloarthritis)Cosentyx is indicated for the treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.Non-radiographic axial spondyloarthritis (nr-axSpA)Cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence in adults who have responded inadequately to non steroidal anti inflammatory drugs (NSAIDs).Juvenile idiopathic arthritis (JIA)Enthesitis-related arthritis (ERA)Cosentyx, alone or in combination with methotrexate (MTX), is indicated for the treatment of active enthesitis-related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.Juvenile psoriatic arthritis (JPsA)Cosentyx, alone or in combination with methotrexate (MTX), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.|[PMDA] Drugs with a new active ingredient indicated for the treatment of plaque psoriasis and psoriatic arthritis in patients who have not responded sufficiently to conventional therapies. uuid:ec7dcc1c-8f9f-4313-a8c2-a089c9f9d414 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DLG4EML025 biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:46c2932a-9afb-4614-be39-ffab18108d90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e85f6089-dbd1-47c2-b249-5e90146cafbe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx""]},{""id"":""uuid:2fa16bc8-f600-405a-8ad2-227d840c5a75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Plaque psoriasisCosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults and children from the age of 6 years old who are candidates for systemic therapy.Hidradenitis suppurativa (HS)Cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic HS therapy.Psoriatic arthritisCosentyx, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous disease modifying anti rheumatic drug (DMARD) therapy has been inadequate.Axial spondyloarthritis (axSpA)Ankylosing spondylitis (AS, radiographic axial spondyloarthritis)Cosentyx is indicated for the treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.Non-radiographic axial spondyloarthritis (nr-axSpA)Cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence in adults who have responded inadequately to non steroidal anti inflammatory drugs (NSAIDs).Juvenile idiopathic arthritis (JIA)Enthesitis-related arthritis (ERA)Cosentyx, alone or in combination with methotrexate (MTX), is indicated for the treatment of active enthesitis-related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.Juvenile psoriatic arthritis (JPsA)Cosentyx, alone or in combination with methotrexate (MTX), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.|[PMDA] Drugs with a new additional indication and a new dosage for the treatment of ankylosing spondylitis in patients who have not responded sufficiently to conventional treatments. uuid:c438029b-2914-4473-8ea6-0c97ee7cab05 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DLG4EML025 biolink:treats MONDO:0019437 PMID:41385096 "[{""id"":""uuid:7cf206d4-0eef-4c90-b223-2c69cc9b71e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:85d2db92-fd97-46b3-a9d1-e98088a63a46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Plaque psoriasisCosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults and children from the age of 6 years old who are candidates for systemic therapy.Hidradenitis suppurativa (HS)Cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic HS therapy.Psoriatic arthritisCosentyx, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous disease modifying anti rheumatic drug (DMARD) therapy has been inadequate.Axial spondyloarthritis (axSpA)Ankylosing spondylitis (AS, radiographic axial spondyloarthritis)Cosentyx is indicated for the treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.Non-radiographic axial spondyloarthritis (nr-axSpA)Cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence in adults who have responded inadequately to non steroidal anti inflammatory drugs (NSAIDs).Juvenile idiopathic arthritis (JIA)Enthesitis-related arthritis (ERA)Cosentyx, alone or in combination with methotrexate (MTX), is indicated for the treatment of active enthesitis-related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.Juvenile psoriatic arthritis (JPsA)Cosentyx, alone or in combination with methotrexate (MTX), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. uuid:da5cdb39-9151-49f2-8965-c284925adff3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DLG4EML025 biolink:treats MONDO:0019436 PMID:41385096 "[{""id"":""uuid:5c8a3eae-2cc7-4ef8-bc89-300368f88aba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:fc5304a5-3f65-4bab-8f50-8d0f2fe4b8be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Plaque psoriasisCosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults and children from the age of 6 years old who are candidates for systemic therapy.Hidradenitis suppurativa (HS)Cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic HS therapy.Psoriatic arthritisCosentyx, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous disease modifying anti rheumatic drug (DMARD) therapy has been inadequate.Axial spondyloarthritis (axSpA)Ankylosing spondylitis (AS, radiographic axial spondyloarthritis)Cosentyx is indicated for the treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy.Non-radiographic axial spondyloarthritis (nr-axSpA)Cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence in adults who have responded inadequately to non steroidal anti inflammatory drugs (NSAIDs).Juvenile idiopathic arthritis (JIA)Enthesitis-related arthritis (ERA)Cosentyx, alone or in combination with methotrexate (MTX), is indicated for the treatment of active enthesitis-related arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.Juvenile psoriatic arthritis (JPsA)Cosentyx, alone or in combination with methotrexate (MTX), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. uuid:c9989ace-7444-4255-93a2-3606e61c1c7e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:K16AIQ8CTM biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:396fbb44-2def-4617-ae1f-99fa601b5839"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:dc893ed2-9613-42eb-91a6-548f74d8d219"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/perjeta""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Metastatic Breast Cancer:Perjeta is indicated for use in combination with trastuzumab and docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.Neoadjuvant Treatment of Breast Cancer:Perjeta is indicated for use in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence. uuid:339aedcb-a087-472e-a88a-f4456e972fcc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:K16AIQ8CTM biolink:treats MONDO:0004989 PMID:41385096 "[{""id"":""uuid:eda604cf-37c2-4af1-bff5-5782f6cd3663"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a948ee3d-c810-49cd-8152-472053e6b78a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/perjeta""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Metastatic Breast Cancer:Perjeta is indicated for use in combination with trastuzumab and docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.Neoadjuvant Treatment of Breast Cancer:Perjeta is indicated for use in combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence. uuid:fc590e15-ac34-473a-9378-aa8bc6544231 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135957 biolink:treats HP:0033730 PMID:41385096 "[{""id"":""uuid:e18b576b-fd5e-45e1-82ab-2cd45a4429e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:01761329-be23-48d8-a3fe-14251664e353"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lupkynis""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Lupkynis is indicated in combination with mycophenolate mofetil for the treatment of adult patients with active class III, IV or V (including mixed class III/V and IV/V) lupus nephritis (LN). uuid:a1252723-4a7a-476a-9415-8197f553ca25 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:GNWE7KJ995 biolink:treats MONDO:0003664 PMID:41385096 "[{""id"":""uuid:3b57b552-a456-4c74-965a-166484fb8aeb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0ffcb751-d7f5-4f2a-af9a-7d08a3d31486"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/enjaymo""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Enjaymo is indicated for the treatment of haemolytic anaemia in adult patients with cold agglutinin disease (CAD). uuid:588e5f1c-6549-48eb-bea6-82f22041dd12 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:37CQ2C7X93 biolink:treats MONDO:0011776 PMID:41385096 "[{""id"":""uuid:c39250e7-4626-473c-90cd-18a5d088a3d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:bf505364-ae2d-49dc-a371-2be717baf106"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ilaris""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Periodic fever syndromesIlaris is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older:Cryopyrin-associated periodic syndromesIlaris is indicated for the treatment of cryopyrin-associated periodic syndromes (CAPS) including:Muckle-Wells syndrome (MWS),Neonatal-onset multisystem inflammatory disease (NOMID) / chronic infantile neurological, cutaneous, articular syndrome (CINCA),Severe forms of familial cold autoinflammatory syndrome (FCAS) / familial cold urticaria (FCU) presenting with signs and symptoms beyond cold-induced urticarial skin rash.Tumour necrosis factor receptor associated periodic syndrome (TRAPS)Ilaris is indicated for the treatment of tumour necrosis factor (TNF) receptor associated periodic syndrome (TRAPS).Hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD)Ilaris is indicated for the treatment of hyperimmunoglobulin D syndrome (HIDS)/mevalonate kinase deficiency (MKD).Familial Mediterranean fever (FMF)Ilaris is indicated for the treatment of Familial Mediterranean Fever (FMF). Ilaris should be given in combination with colchicine, if appropriate.Ilaris is also indicated for the treatment of:Still’s diseaseIlaris is indicated for the treatment of active Still’s disease including adult-onset Still’s disease (AOSD) and systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids. Ilaris can be given as monotherapy or in combination with methotrexate.Gouty arthritisIlaris is indicated for the symptomatic treatment of adult patients with frequent gouty arthritis attacks (at least 3 attacks in the previous 12 months) in whom non-steroidal anti-inflammatory drugs (NSAIDs) and colchicine are contraindicated, are not tolerated, or do not provide an adequate response, and in whom repeated courses of corticosteroids are not appropriate. uuid:d182351d-e5dc-4510-ab80-9f4bd3830e3d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1860167 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:3315501f-1122-42aa-ae45-0c0853c9ec07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:05c1ee5a-b2a4-4305-aa9f-50718eba6a9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/xultophy""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Xultophy is indicated for the treatment of adults with type-2 diabetes mellitus to improve glycaemic control in combination with oral glucose-lowering medicinal products when these alone or combined with a GLP-1 receptor agonist or basal insulin do not provide adequate glycaemic control. uuid:3966e242-7719-47d6-a703-851c83769340 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6402 biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:61e28ea5-0bfc-4042-a709-f8cb8a428634"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2e487303-63f4-4f08-a7bc-aefbb9a9a555"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/leflunomide-medac""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Leflunomide is indicated for the treatment of adult patients with:active rheumatoid arthritis as a 'disease-modifying antirheumatic drug' (DMARD);active psoriatic arthritis.Recent or concurrent treatment with hepatotoxic or haematotoxic DMARDs (e.g. methotrexate) may result in an increased risk of serious adverse reactions; therefore, the initiation of leflunomide treatment has to be carefully considered regarding these benefit / risk aspects.Moreover, switching from leflunomide to another DMARD without following the washout procedure may also increase the risk of serious adverse reactions even for a long time after the switching. uuid:e3702b15-78dc-4bbc-84f5-fbfaf927530d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:36795 biolink:treats MONDO:0006626 PMID:41385096 "[{""id"":""uuid:dc3af974-2aed-4bec-8ba3-2e235529ab08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7a21687e-9e8b-44e2-8bbf-6ac7f7a01424"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/duloxetine-mylan""]},{""id"":""uuid:0e94e30f-98a0-428b-8441-e1b4a5c33aa5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of major depressive disorder;Treatment of diabetic peripheral neuropathic pain;Treatment of generalised anxiety disorder;Duloxetine Mylan is indicated in adults.|[PMDA] Drugs with a new additional indication for the treatment of pain associated with diabetic neuropathy. uuid:72e4b751-fd75-4536-b126-1862e1375e3d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31348 biolink:treats MONDO:0002032 PMID:41385096 "[{""id"":""uuid:cc6f66c9-3a48-40c0-9050-dd367a050394"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f267eb34-9cd4-429a-9099-22cac2ce5268"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ecansya""]},{""id"":""uuid:f6589751-22e1-49b8-9b33-17edcf7bbb4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ecansya is indicated for the adjuvant treatment of patients following surgery of stage-III (Dukes’ stage-C) colon cancer.Ecansya is indicated for the treatment of metastatic colorectal cancer.Ecansya is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen.Ecansya in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline. Ecansya is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.|[PMDA] A drug with a new indication and dosage for use as a postoperative adjuvant chemotherapy of colon cancer. A drug with a new dosage for the treatment of inoperable or relapsed breast cancer. uuid:f031e21d-501a-4ec1-87c3-c909ea1c22f1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31348 biolink:treats MONDO:0004379 PMID:41385096 "[{""id"":""uuid:af35b64d-b581-4a64-8544-761c703b7335"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:465e3223-b874-482f-b0b3-d019b5efa6e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ecansya""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ecansya is indicated for the adjuvant treatment of patients following surgery of stage-III (Dukes’ stage-C) colon cancer.Ecansya is indicated for the treatment of metastatic colorectal cancer.Ecansya is indicated for first-line treatment of advanced gastric cancer in combination with a platinum-based regimen.Ecansya in combination with docetaxel is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline. Ecansya is also indicated as monotherapy for the treatment of patients with locally advanced or metastatic breast cancer after failure of taxanes and an anthracycline containing chemotherapy regimen or for whom further anthracycline therapy is not indicated. uuid:af63646a-7b6b-4bd7-8117-cd48660dec61 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:I0BGE6P6I6 biolink:treats MONDO:0100096 PMID:41385096 "[{""id"":""uuid:56e06bd2-e276-4427-a780-bc645babd223"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9421a213-585f-44ed-9d7f-b5822f1e6634"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/regkirona""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Regdanvimab is indicated for the treatment of adults with coronavirus disease 2019 (COVID-19) who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19. uuid:81e5e734-076b-46bb-8df9-26fedf847e0b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:216293 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:e539ecdc-e561-4e83-8941-824c66f8a74b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:8cc9aee1-ae1a-4cd0-adae-9621929ea06c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/actelsar-hct""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Tolucombi fixed-dose combination (80 mg telmisartan/25 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on Tolucombi 80 mg/12.5 mg (80 mg telmisartan/12.5 mg hydrochlorothiazide) or adults who have been previously stabilised on telmisartan and hydrochlorothiazide given separately. uuid:fc6b486d-9c67-478e-bddc-43591fdf5962 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB14764 biolink:treats MONDO:0005502 PMID:41385096 "[{""id"":""uuid:b38daea5-bd5a-4ca4-b587-2a4d7d5647ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:fcf2919a-4964-4c73-802c-c6786328561c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Dengvaxia is indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4 in individuals 6 to 45 years of age with test-confirmed previous dengue infection (see sections 4.2, 4.4 and 4.8).The use of Dengvaxia should be in accordance with official recommendations. uuid:5a4626c0-006c-42a2-8ef1-dc6886ca94ef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB15595 biolink:treats MONDO:0005737 PMID:41385096 "[{""id"":""uuid:486f9837-40d7-4d71-9e91-51d1f385e73a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:926c7108-16ee-4d66-8dea-cf1e84c0cef7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ervebo is indicated for active immunization of individuals 1 year of age or older to protect against Ebola Virus Disease (EVD) caused by Zaire Ebola virus.The use of Ervebo should be in accordance with official recommendations. uuid:5e259612-b766-449f-80fd-f37f14b5174b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:SB96YO2BR8 biolink:treats MONDO:0004651 PMID:41385096 "[{""id"":""uuid:4bfebbec-2161-4271-8ac0-6fd5d0b06fd6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:be3b2702-a726-40d6-85d3-14d61b09b6e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Tecovirimat SIGA is indicated for the treatment of the following viral infections in adults and children with body weight at least 13 kg:- Smallpox- Monkeypox- CowpoxTecovirimat SIGA is also indicated to treat complications due to replication of vaccinia virus following vaccination against smallpox in adults and children with body weight at least 13 kg (see sections 4.4 and 5.1).Tecovirimat SIGA should be used in accordance with official recommendations. uuid:0063172f-71ea-40c6-877d-bb4736852529 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:SB96YO2BR8 biolink:treats MONDO:0002594 PMID:41385096 "[{""id"":""uuid:871f1742-bca0-4497-9b36-2d0a1203726e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:005d12ea-867d-4d00-b704-c854f189ac51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Tecovirimat SIGA is indicated for the treatment of the following viral infections in adults and children with body weight at least 13 kg:- Smallpox- Monkeypox- CowpoxTecovirimat SIGA is also indicated to treat complications due to replication of vaccinia virus following vaccination against smallpox in adults and children with body weight at least 13 kg (see sections 4.4 and 5.1).Tecovirimat SIGA should be used in accordance with official recommendations. uuid:70810d63-a3c3-4108-8b78-1cd486acb7cd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:SB96YO2BR8 biolink:treats MONDO:0005720 PMID:41385096 "[{""id"":""uuid:c1d12c85-1413-49d7-892f-367ba0b925d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5e09ffc8-a9e7-400b-82ec-dba628e15f7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Tecovirimat SIGA is indicated for the treatment of the following viral infections in adults and children with body weight at least 13 kg:- Smallpox- Monkeypox- CowpoxTecovirimat SIGA is also indicated to treat complications due to replication of vaccinia virus following vaccination against smallpox in adults and children with body weight at least 13 kg (see sections 4.4 and 5.1).Tecovirimat SIGA should be used in accordance with official recommendations. uuid:b718cf62-7c63-4805-9513-580435bd0de5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:234248D0HH biolink:treats MONDO:0004989 PMID:41385096 "[{""id"":""uuid:f8cb6993-c5fd-4a41-b995-3251757cbc17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:011234ab-62a0-42d8-99c8-5d171cece343"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tukysa""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Tukysa is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with HER2‑positive locally advanced or metastatic breast cancer who have received at least 2 prior anti‑HER2 treatment regimens. uuid:bc3fe792-d4cc-47e0-b56b-c83d3d173bb3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:81569 biolink:treats MONDO:0015770 PMID:41385096 "[{""id"":""uuid:f91c63f5-bd25-46c3-9a38-5ca9d07d5e11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:557c6f42-1a1c-4abc-8131-a3888f68b2d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/gonal-f""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] In adult womenAnovulation (including polycystic ovarian syndrome) in women who have been unresponsive to treatment with clomifene citrate;Stimulation of multifollicular development in women undergoing superovulation for assisted reproductive technologies (ART) such as in vitro fertilisation (IVF), gamete intra-fallopian transfer and zygote intra-fallopian transfer;Ovaleap in association with a luteinising hormone (LH) preparation is recommended for the stimulation of follicular development in women with severe LH and FSH deficiency. In clinical trials these patients were defined by an endogenous serum LH level < 1.2 IU/L.In adult menOvaleap is indicated for the stimulation of spermatogenesis in men who have congenital or acquired hypogonadotropic hypogonadism with concomitant human chorionic gonadotropin (hCG) therapy. uuid:46e53c70-6843-455f-8d76-35f3e51e975b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:81569 biolink:treats MONDO:0018555 PMID:41385096 "[{""id"":""uuid:2925b1cb-24a0-40cb-b5f1-6f33b2653fa0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:8b634d3c-da45-4faf-8a5b-592013d1f196"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/gonal-f""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] In adult womenAnovulation (including polycystic ovarian syndrome) in women who have been unresponsive to treatment with clomifene citrate;Stimulation of multifollicular development in women undergoing superovulation for assisted reproductive technologies (ART) such as in vitro fertilisation (IVF), gamete intra-fallopian transfer and zygote intra-fallopian transfer;Ovaleap in association with a luteinising hormone (LH) preparation is recommended for the stimulation of follicular development in women with severe LH and FSH deficiency. In clinical trials these patients were defined by an endogenous serum LH level < 1.2 IU/L.In adult menOvaleap is indicated for the stimulation of spermatogenesis in men who have congenital or acquired hypogonadotropic hypogonadism with concomitant human chorionic gonadotropin (hCG) therapy. uuid:ec2055af-d08b-4df8-89ec-fbee7acf0e93 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135285 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:7677afbd-0d66-4b6c-8d81-747b6e7cb923"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:300b907d-e8c5-4a8a-8cab-94e06b5b2098"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/jalra""]},{""id"":""uuid:4ca2c923-fcdc-410f-8954-7596cccb59c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance.in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4.4, 4.5 and 5.1 for available data on different combinations).|[PMDA] A drug with a new active ingredient indicated for the treatment of type 2 diabetes mellitus (for use only in patients who have not responded sufficiently to either [1] diet and exercise therapies alone or [2] sulfonylurea along with diet and exercise therapies). uuid:2a36f0be-2e7c-4a23-b4d3-a9c7daac7e9a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:722125 biolink:treats MONDO:0001134 PMID:41385096 "[{""id"":""uuid:e0e9894a-92fd-49bb-8815-7c0ab9128362"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:05a7e75b-3556-4104-9589-0e3511347d79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/amlodipine-valsartan-mylan""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of essential hypertension.Amlodipine/Valsartan Mylan is indicated in adults whose blood pressure is not adequately controlled on amlodipine or valsartan monotherapy. uuid:eb5ce565-c67d-42c0-9cb5-c7588b9b2025 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134742 biolink:treats MONDO:0005861 PMID:41385096 "[{""id"":""uuid:863e5e64-6c28-44ac-9e09-9afab7d1eb8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:82db820d-209e-4e10-b3b4-27208211ca1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/deltyba""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Deltyba is indicated for use as part of an appropriate combination regimen for pulmonary multi-drug resistant tuberculosis (MDR-TB) in adults, adolescents, children and infants with a body weight of at least 10 kg when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability (see sections 4.2, 4.4 and 5.1).Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:e47e1708-7dc1-4203-997c-b19dd9c76c20 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:UMD7G2653W biolink:treats MONDO:0005298 PMID:41385096 "[{""id"":""uuid:ddfe0e26-3d5e-4c25-9086-a1be5fe6804b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1def7a3e-867c-4fb4-b287-295ce208001e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/bonviva""]},{""id"":""uuid:20ada9f2-d3fd-415e-b637-fad898cdadf0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of osteoporosis in postmenopausal women at increased risk of fracture (see section 5.1). A reduction in the risk of vertebral fractures has been demonstrated, efficacy on femoral neck fractures has not been established.|[PMDA] A drug with a new route of administration indicated for the treatment of osteoporosis. uuid:424dc64f-19d6-48f0-bd80-d173f702e845 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:156963654 biolink:treats MONDO:0005494 PMID:41385096 "[{""id"":""uuid:dfc0adaf-ade4-42ed-b0d3-f7fb21271132"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:63c166ab-c2ff-495c-9f07-06c368eb9329"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/trodelvy""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Trodelvy as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, including at least one of them for advanced disease. HMDB:HMDB0257437 uuid:7f0d05ac-10b6-4698-a349-b9ecc7d37655 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DEW6X41BEK biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:d8679948-be7c-44af-9027-5bee1dafcf4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:db679207-4323-41b4-b53a-c51ed3d7bf2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ilumetri""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ilumetri is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy. uuid:c87f68e4-b3ae-422b-84ff-bb9405a15b27 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82557 biolink:treats MONDO:0004992 PMID:41385096 "[{""id"":""uuid:c7d73d40-03be-47e2-99b7-514ee40972d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ec45cb26-7667-4cef-a7cb-9178785c526c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/trecondi""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treosulfan in combination with fludarabine is indicated as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (alloHSCT) in adult patients and in paediatric patients older than one month with malignant and non-malignant diseases. uuid:580b1385-cf21-4ff6-912d-8dc978b810a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:23HYE36B0I biolink:treats MONDO:0018150 PMID:41385096 "[{""id"":""uuid:ebe0b2a9-4443-440e-bf5e-8e819879b263"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4046d554-9e74-462a-8f04-863387de941e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vpriv""]},{""id"":""uuid:01c2a5b3-5112-4fa0-9558-c72be77e07e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Vpriv is indicated for long-term enzyme-replacement therapy (ERT) in patients with type-1 Gaucher disease.|[PMDA] A drug with a new active ingredient indicated for the improvement of various symptoms of Gaucher disease (anemia, thrombocytopenia, hepatosplenomegaly, and bone disease). [Orphan drug] uuid:32481cca-c84b-4779-9d00-0f1d4aa758bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:125354 biolink:treats MONDO:0004992 PMID:41385096 "[{""id"":""uuid:7515f43b-89a7-4e82-85a1-bf729367d1f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:69fdaf29-4edb-45c3-a2bd-e0018433e4a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/mozobil""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Adult patientsPlerixafor Accord is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma or multiple myeloma whose cells mobilise poorly (see section 4.2).Paediatric patients (1 to less than 18 years)Plerixafor Accord is indicated in combination with G-CSF to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children with lymphoma or solid malignant tumours, either:- pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with G-CSF (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield, or- who previously failed to collect sufficient haematopoietic stem cells (see section 4.2). uuid:4f18f792-113b-4ff1-a08f-c7b56322da43 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1664472 biolink:treats MONDO:0005812 PMID:41385096 "[{""id"":""uuid:16f0ccde-e554-4ec1-b709-830eff948dbc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2342fb71-4f70-4b59-a413-d1ab8b8d1d60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Prophylaxis of influenza in children and adolescents from 24 months to less than 18 years of age. The use of Fluenz Tetra should be based on official recommendations. uuid:69398e65-2e41-47f0-96fe-772c21f6a0b5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C4723522 biolink:treats MONDO:0005812 PMID:41385096 "[{""id"":""uuid:f2911dc9-2200-43a9-b0fb-188f0fe1bd0f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:37a436e0-b29a-4eda-8806-8efade207518"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Prophylaxis of influenza in adults and children from 2 years of age.Flucelvax Tetra should be used in accordance with official recommendations. DRUGBANK:DB15507 uuid:7992d7cb-4ec6-42eb-82e6-3335fc8fd4ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32127 biolink:treats MONDO:0000328 PMID:41385096 "[{""id"":""uuid:ad225f12-f131-4974-8e62-e1b8f0dbb498"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:05407dcd-6929-45de-bcc5-36d43fc8a16a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/renagel""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Renagel is indicated for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis.Renagel should be used within the context of a multiple therapeutic approach, which could include calcium supplements, 1,25 - dihydroxy Vitamin D3 or one of its analogues to control the development of renal bone disease. uuid:4ab1ca56-01fa-414a-9bbe-365bc8d9dcd9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32127 biolink:treats MONDO:0006946 PMID:41385096 "[{""id"":""uuid:dca0d592-4d8f-4772-8cac-c2602dcf45ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:aab696ba-6c2d-401b-91e7-de1ed3c5b612"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/renagel""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Renagel is indicated for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis.Renagel should be used within the context of a multiple therapeutic approach, which could include calcium supplements, 1,25 - dihydroxy Vitamin D3 or one of its analogues to control the development of renal bone disease. uuid:2779ee9b-c9ef-487f-adfc-21f3eb88f0f9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:5QS67N4551 biolink:treats MONDO:0010481 PMID:41385096 "[{""id"":""uuid:2d80f420-52e5-4dad-892b-b5e6e9e0379c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:209fefea-2ecb-4c60-a604-4acf6c224c79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ruconest is indicated for treatment of acute angioedema attacks in adults with hereditary angioedema (HAE) due to C1-esterase-inhibitor deficiency. uuid:f3ad2259-7f76-4017-885b-d6a280c59a75 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2637 biolink:treats MONDO:0018469 PMID:41385096 "[{""id"":""uuid:55cc28dc-5469-45a6-83ed-b8cd599c9c57"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0135c90b-195b-4962-8f8e-c0f8230dc9e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f7bd3639-6726-4739-9cce-f0c79bfeffe1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Arikayce liposomal is indicated for the treatment of non-tuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium Complex (MAC) in adults with limited treatment options who do not have cystic fibrosis.|[PMDA] A drug with a new route of administration indicated for the treatment of nontuberculous mycobacterial pulmonary disease caused by amikacin-sensitive Mycobacterium avium complex (MAC). uuid:096b9f30-8e10-41e9-92a5-93bedcb31dd4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:913P6LK81M biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:5389e8d9-f031-4a2b-a94a-1d80db1d14b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:17433305-112c-4ce3-b234-c1ae7840957c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/pifeltro""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Pifeltro is indicated, in combination with other antiretroviral medicinal products, for the treatment of adults, and adolescents aged 12 years and older weighing at least 35 kg infected with HIV 1 without past or present evidence of resistance to the NNRTI class. uuid:383ee46d-a883-415e-b934-c464d6d0ebb2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1592713 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:3974a194-0f53-41db-97ef-78f662e47ff1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:97a8d5d2-b9d8-446e-a285-cf66eba278d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ebymect""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Type 2 diabetes mellitusFor the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise.as monotherapy when metformin is considered inappropriate due to intolerance.in addition to other medicinal products for the treatment of type 2 diabetes.For study results with respect to combination of therapies, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.Type 1 diabetes mellitusEdistride is indicated in adults for the treatment of insufficiently controlled type 1 diabetes mellitus as an adjunct to insulin in patients with BMI ≥ 27 kg/m2, when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy. uuid:060b5b4c-86d6-4a99-8395-d25b130aa954 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1592713 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:63ec76dc-d05b-4046-981f-7652456b1ace"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:470ee234-565d-4e49-b163-6ed4576bfadf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ebymect""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Type 2 diabetes mellitusFor the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise.as monotherapy when metformin is considered inappropriate due to intolerance.in addition to other medicinal products for the treatment of type 2 diabetes.For study results with respect to combination of therapies, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.Type 1 diabetes mellitusEdistride is indicated in adults for the treatment of insufficiently controlled type 1 diabetes mellitus as an adjunct to insulin in patients with BMI ≥ 27 kg/m2, when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy. uuid:32bbeda4-cea5-4e9b-8766-7bf57ab21688 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:291342 biolink:treats MONDO:0011786 PMID:41385096 "[{""id"":""uuid:87fb5f2a-e0a9-40c2-a995-ee5173a5b8bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4d18dbb4-8d8a-4923-a01a-212c17f3db61"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/neoclarityn""]},{""id"":""uuid:ecdd6c27-2e94-4df3-8b04-30c171a26433"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Neoclarityn is indicated for the relief of symptoms associated with:allergic rhinitisurticaria|[PMDA] A drug with a new active ingredient indicated for the treatment of allergic rhinitis, urticaria, and itching associated with skin diseases (eczema/dermatitis, cutaneous pruritus). uuid:9aa94f1d-0cb0-47d1-a417-2170d0b5c34f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:291342 biolink:treats MONDO:0005492 PMID:41385096 "[{""id"":""uuid:4686fa73-1bf4-4904-b40b-0333fc690811"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ee77040e-7d6f-4ce7-b664-d4f322e72460"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/neoclarityn""]},{""id"":""uuid:4715f61c-6e5b-45ba-a303-ba0f49645b61"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Neoclarityn is indicated for the relief of symptoms associated with:allergic rhinitisurticaria|[PMDA] A drug with a new active ingredient indicated for the treatment of allergic rhinitis, urticaria, and itching associated with skin diseases (eczema/dermatitis, cutaneous pruritus). uuid:a8ea9430-627c-45f0-97a1-8093a3e5127a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68579 biolink:treats MONDO:0005542 PMID:41385096 "[{""id"":""uuid:70e38ef4-57d4-4605-b1ff-fc358d854588"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:224f2f30-2c19-4d9d-8487-856814281241"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/rivaroxaban-accord""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Xarelto, co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers.Xarelto, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (CAD) or symptomatic peripheral artery disease (PAD) at high risk of ischaemic events.Prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery.Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults.AdultsPrevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack.Paediatric population Treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment.Paediatric population Treatment of venous thromboembolism (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment. uuid:d5d60196-8896-4180-9460-b4f056b8ecca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44423 biolink:treats MONDO:0005632 PMID:41385096 "[{""id"":""uuid:bd3303c8-7398-483d-a9bd-feff2a3fc102"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:716d6776-c32d-446a-bbd3-a24f5ad128cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/siklos""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Siklos is indicated for the prevention of recurrent painful vaso-occlusive crises including acute chest syndrome in paediatric and adult patients suffering from symptomatic sickle-cell syndrome. uuid:565e679e-26b0-478a-8218-5a8ac35a8ecd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:177658 biolink:treats MONDO:0013056 PMID:41385096 "[{""id"":""uuid:d16e19cf-0d64-4759-8bce-93a665267053"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:8f20681d-8f6d-44ee-8cd2-cad453ac8a94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ztalmy""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ztalmy is indicated for the adjunctive treatment of epileptic seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 to 17 years of age. Ztalmy may be continued in patients 18 years of age and older. uuid:e556b6a2-0c62-4c49-a10b-9cda07f304ad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:66917 biolink:treats MONDO:0044903 PMID:41385096 "[{""id"":""uuid:c66fa4e6-57f2-463d-b18c-2b27727bece1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:bb68fa24-5ff6-47cb-94d5-dacbe303d126"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Myelofibrosis (MF)Jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.Polycythaemia vera (PV)Jakavi is indicated for the treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.Graft versus host disease (GvHD)Jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.1). uuid:e6737e71-1222-48b8-9c70-5dc827108844 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:66917 biolink:treats MONDO:0009891 PMID:41385096 "[{""id"":""uuid:a9d0e976-4216-4853-9b80-9293ac5c49c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:360d2b2b-a368-43fc-82d1-b19097092905"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Myelofibrosis (MF)Jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.Polycythaemia vera (PV)Jakavi is indicated for the treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.Graft versus host disease (GvHD)Jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.1). uuid:c1e0076f-cb4e-4616-97cd-6727f46f3d01 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:66917 biolink:treats MONDO:0013730 PMID:41385096 "[{""id"":""uuid:98b4bc4c-2243-4dd8-965f-265360bd7c62"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:bbfbb9b4-6dd9-4965-a378-8cfd35203cc6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Myelofibrosis (MF)Jakavi is indicated for the treatment of disease related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis.Polycythaemia vera (PV)Jakavi is indicated for the treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.Graft versus host disease (GvHD)Jakavi is indicated for the treatment of patients aged 12 years and older with acute graft versus host disease or chronic graft versus host disease who have inadequate response to corticosteroids or other systemic therapies (see section 5.1). uuid:2932e9d8-0e3e-4712-9c7d-502493191c6d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:493191 biolink:treats MONDO:0005194 PMID:41385096 "[{""id"":""uuid:0cb875d2-5029-42b8-beea-641773aaebd6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:70dcce9c-4c42-458a-bfbd-c61de1d45fb2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rotarix is indicated for the active immunisation of infants aged 6 to 24 weeks for prevention of gastroenteritis due to rotavirus infection.The use of Rotarix should be based on official recommendation. uuid:5c55c416-783d-4680-a368-e9f020540e0c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135983 biolink:treats HP:0020110 PMID:41385096 "[{""id"":""uuid:2411c579-8b79-4284-8aaa-f25ca73b5a10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:048f6eb3-5a28-40c9-ad15-6f68a03ddc65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kauliv""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Terrosa is indicated in adults.Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. In postmenopausal women, a significant reduction in the incidence of vertebral and non vertebral fractures but not hip fractures has been demonstrated.Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture. uuid:6170a150-1e2e-4591-b234-1c5f6e7a29d9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135983 biolink:treats HP:0041166 PMID:41385096 "[{""id"":""uuid:c88d0041-4bf9-4a2a-83d5-680431412128"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f10a75f6-9133-4ec1-b33c-028cf0202699"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kauliv""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Terrosa is indicated in adults.Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. In postmenopausal women, a significant reduction in the incidence of vertebral and non vertebral fractures but not hip fractures has been demonstrated.Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture. uuid:2ad39356-5dfa-4416-918b-56df998115fa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135983 biolink:treats UMLS:C0162385 PMID:41385096 "[{""id"":""uuid:1fb2e176-daf1-4ea0-a7c1-61b382ae3be8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:22d33972-363e-4a40-8898-3a44d1471a41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kauliv""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Terrosa is indicated in adults.Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. In postmenopausal women, a significant reduction in the incidence of vertebral and non vertebral fractures but not hip fractures has been demonstrated.Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture. uuid:fb29f5ec-51a0-434b-8239-0190682a236c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB13932 biolink:treats MONDO:0019118 PMID:41385096 "[{""id"":""uuid:2e80986f-55f9-4ac9-acd5-e7f3a4620044"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4321b7c5-f8ac-4f4a-bfd8-6c365b420788"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/luxturna""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Luxturna is indicated for the treatment of adult and paediatric patients with vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells. uuid:f98c634c-ee5e-40f3-9104-1beaa311970a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB13932 biolink:treats MONDO:0001941 PMID:41385096 "[{""id"":""uuid:5fc59e53-f62e-421b-86cf-45c38b4d6f70"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ebc45738-1169-4744-ab03-842cd82c9852"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/luxturna""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Luxturna is indicated for the treatment of adult and paediatric patients with vision loss due to inherited retinal dystrophy caused by confirmed biallelic RPE65 mutations and who have sufficient viable retinal cells. uuid:7a16a9c7-37bb-455a-b08e-72d6ddf51c44 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:71494926 biolink:treats MONDO:0009061 PMID:41385096 "[{""id"":""uuid:4c69b038-6d55-48fb-9fc4-c4cb08839079"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:050e201e-db68-4e0f-9f89-42a9b8c60833"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/orkambi""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Orkambi tablets are indicated for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who are homozygous for the F508del mutation in the CFTR gene.Orkambi granules are indicated for the treatment of cystic fibrosis (CF) in children aged 1 year and older who are homozygous for the F508del mutation in the CFTR gene. uuid:ff94a442-724c-4805-8180-2026d306fda5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63584 biolink:treats MONDO:0008315 PMID:41385096 "[{""id"":""uuid:80d11753-c90d-47c2-9057-9caaf156f61d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:8541dc47-fa7f-4bbe-b314-519097de32e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cabazitaxel-accord""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen. uuid:b548fbf5-42e3-4221-bc55-e1b162067580 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB16665 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:04df8e7f-a9d9-4fd5-8792-3dc5f2f6b051"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:370bbc7c-60e2-47ec-ac92-601791f03468"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/abecma""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti CD38 antibody and have demonstrated disease progression on the last therapy. uuid:c4f7f59b-746a-4fb1-aec2-9b3d5dfd9806 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8NZ41MIK1O biolink:treats MONDO:0005399 PMID:41385096 "[{""id"":""uuid:796fa2ef-d48c-4600-8fa4-39fc90ba93ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0636a912-64ba-4992-9571-8067caaaa239"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/inhixa""]},{""id"":""uuid:8cd0e433-aad0-436d-8a1c-34df5bf71e16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Inhixa is indicated for adults for:Prophylaxis of venous thromboembolism, particularly in patients undergoing orthopaedic, general or oncological surgery.Prophylaxis of venous thromboembolism in patients bedridden due to acute illnesses including acute heart failure, acute respiratory failure, severe infections, as well as exacerbation of rheumatic diseases causing immobilisation of the patient (applies to strengths of 40 mg/0.4 mL).Treatment of deep vein thrombosis (DVT), complicated or uncomplicated by pulmonary embolism.Treatment of unstable angina and non Q wave myocardial infarction, in combination with acetylsalicylic acid (ASA).Treatment of acute ST segment elevation myocardial infarction (STEMI) including patients who will be treated conservatively or who will later undergo percutaneous coronary angioplasty (applies to strengths of 60 mg/0.6 mL, 80 mg/0.8 mL, and 100 mg/1 mL).Blood clot prevention in the extracorporeal circulation during haemodialysis.|[PMDA] A drug containing a new active ingredient indicated for the prevention of venous thromboembolism in patients who have undergone total hip replacement, total knee replacement and hip fracture surgery. [Priority review] uuid:3c49b50d-8c35-4e98-b32f-29aee7df484f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8NZ41MIK1O biolink:treats MONDO:0003674 PMID:41385096 "[{""id"":""uuid:fa7ed368-0ba1-4e3d-9d9f-f2cc48ef2428"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:44415dba-35ed-401c-b2eb-2c703c676d2d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/inhixa""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Inhixa is indicated for adults for:Prophylaxis of venous thromboembolism, particularly in patients undergoing orthopaedic, general or oncological surgery.Prophylaxis of venous thromboembolism in patients bedridden due to acute illnesses including acute heart failure, acute respiratory failure, severe infections, as well as exacerbation of rheumatic diseases causing immobilisation of the patient (applies to strengths of 40 mg/0.4 mL).Treatment of deep vein thrombosis (DVT), complicated or uncomplicated by pulmonary embolism.Treatment of unstable angina and non Q wave myocardial infarction, in combination with acetylsalicylic acid (ASA).Treatment of acute ST segment elevation myocardial infarction (STEMI) including patients who will be treated conservatively or who will later undergo percutaneous coronary angioplasty (applies to strengths of 60 mg/0.6 mL, 80 mg/0.8 mL, and 100 mg/1 mL).Blood clot prevention in the extracorporeal circulation during haemodialysis. uuid:cc2b0402-c2e6-4eef-9ab3-104d0231f192 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3XVL385Q0M biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:7df01eed-f920-427e-8abf-98a8dc6d6448"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b3d86a31-d218-49bd-8525-c55a9cbaf896"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:67e8d466-a6c7-41fe-b445-a2d711121740"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rheumatoid arthritisJyseleca is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (DMARDs). Jyseleca may be used as monotherapy or in combination with methotrexate (MTX).Ulcerative colitisJyseleca is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.|[PMDA] Drugs with a new active ingredient indicated for the treatment of rheumatoid arthritis (including the prevention of structural joint damage) in patients who have not responded sufficiently to conventional treatments. uuid:c12ea15b-9d52-4852-a03b-7e549e81cd29 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3XVL385Q0M biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:6841d9c5-c6a2-4fd2-88b0-bf7ac268a42a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8f31b7b1-669b-486a-8ac3-9cfcccc272ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:8e4c1c12-c5a2-4bbf-b3bc-32afd784a96a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rheumatoid arthritisJyseleca is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (DMARDs). Jyseleca may be used as monotherapy or in combination with methotrexate (MTX).Ulcerative colitisJyseleca is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.|[PMDA] Drugs with a new indication and a new dosage for the treatment and the maintenance therapy of moderate to severe ulcerative colitis (for use only in patients who have not sufficiently responded to conventional treatments). uuid:128ed512-2504-46e1-a277-6c10ec61b92d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2382436 biolink:treats MONDO:0005812 PMID:41385096 "[{""id"":""uuid:45f5d1f1-031d-495d-9b71-359146ddf2c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4b103dc6-8f98-46e5-8ed3-88fd39e1ab77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Supemtek is indicated for active immunization for the prevention of influenza disease in adults.Supemtek should be used in accordance with official recommendations. uuid:3d8e6a7c-bb39-4f5f-9769-b60fd0706caa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2257008 biolink:treats MONDO:0009061 PMID:41385096 "[{""id"":""uuid:17bd466c-ccf9-45bd-b00a-1e797dde790b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:002748c5-41bb-47ec-941e-29127caa39d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kaftrio""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Kaftrio is indicated in a combination regimen with ivacaftor for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. uuid:5fc62569-3bbf-4590-9f56-4f21237381ea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C1997870 biolink:treats MONDO:0020725 PMID:41385096 "[{""id"":""uuid:9c81fc27-37d1-4f4b-aa44-47c869ff1fd0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:19abe785-4e1d-4755-9a91-db4eeba4d95e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/retacrit""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult and paediatric patients:treatment of anaemia associated with chronic renal failure in adult and paediatric patients on haemodialysis and adult patients on peritoneal dialysis;treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis.Treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre-existing anaemia at the start of chemotherapy).Retacrit can be used to increase the yield of autologous blood from patients in a predonation programme. Its use in this indication must be balanced against the reported risk of thromboembolic events. Treatment should only be given to patients with moderate anaemia (no iron deficiency), if blood-saving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (four or more units of blood for females or five or more units for males).Retacrit can be used to reduce exposure to allogeneic blood transfusions in adult non-iron-deficient patients prior to major elective orthopaedic surgery, having a high perceived risk for transfusion complications. Use should be restricted to patients with moderate anaemia (e.g. Hb 10-13 g/dl) who do not have an autologous predonation programme available and with expected moderate blood loss (900 to 1800 ml). MESH:C530192 uuid:0a104369-7b11-4403-a9e0-7b32871591a3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C1997870 biolink:treats MONDO:0002280 PMID:41385096 "[{""id"":""uuid:dd5b8669-7487-446e-8ed1-e44a09e177c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:bea3c5c7-d1fb-4e4f-bdff-e6f3c45e5573"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/retacrit""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult and paediatric patients:treatment of anaemia associated with chronic renal failure in adult and paediatric patients on haemodialysis and adult patients on peritoneal dialysis;treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis.Treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre-existing anaemia at the start of chemotherapy).Retacrit can be used to increase the yield of autologous blood from patients in a predonation programme. Its use in this indication must be balanced against the reported risk of thromboembolic events. Treatment should only be given to patients with moderate anaemia (no iron deficiency), if blood-saving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (four or more units of blood for females or five or more units for males).Retacrit can be used to reduce exposure to allogeneic blood transfusions in adult non-iron-deficient patients prior to major elective orthopaedic surgery, having a high perceived risk for transfusion complications. Use should be restricted to patients with moderate anaemia (e.g. Hb 10-13 g/dl) who do not have an autologous predonation programme available and with expected moderate blood loss (900 to 1800 ml). MESH:C530192 uuid:bfac4a39-dc91-45a2-afb8-851d6acba960 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C1997870 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:565cc6fc-ef9f-4f8d-bfb7-cc166fc20c13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:99d03e88-6543-4885-8960-f7c75677b0f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/retacrit""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult and paediatric patients:treatment of anaemia associated with chronic renal failure in adult and paediatric patients on haemodialysis and adult patients on peritoneal dialysis;treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis.Treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre-existing anaemia at the start of chemotherapy).Retacrit can be used to increase the yield of autologous blood from patients in a predonation programme. Its use in this indication must be balanced against the reported risk of thromboembolic events. Treatment should only be given to patients with moderate anaemia (no iron deficiency), if blood-saving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (four or more units of blood for females or five or more units for males).Retacrit can be used to reduce exposure to allogeneic blood transfusions in adult non-iron-deficient patients prior to major elective orthopaedic surgery, having a high perceived risk for transfusion complications. Use should be restricted to patients with moderate anaemia (e.g. Hb 10-13 g/dl) who do not have an autologous predonation programme available and with expected moderate blood loss (900 to 1800 ml). MESH:C530192 uuid:9b13a832-32dd-4ebd-947d-fd987d3198da biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C1997870 biolink:treats MONDO:0005062 PMID:41385096 "[{""id"":""uuid:7a071d6c-06ea-4d87-981f-aa353f5746c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6ca199be-2997-4371-a3a1-2a83a8481997"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/retacrit""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult and paediatric patients:treatment of anaemia associated with chronic renal failure in adult and paediatric patients on haemodialysis and adult patients on peritoneal dialysis;treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis.Treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre-existing anaemia at the start of chemotherapy).Retacrit can be used to increase the yield of autologous blood from patients in a predonation programme. Its use in this indication must be balanced against the reported risk of thromboembolic events. Treatment should only be given to patients with moderate anaemia (no iron deficiency), if blood-saving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (four or more units of blood for females or five or more units for males).Retacrit can be used to reduce exposure to allogeneic blood transfusions in adult non-iron-deficient patients prior to major elective orthopaedic surgery, having a high perceived risk for transfusion complications. Use should be restricted to patients with moderate anaemia (e.g. Hb 10-13 g/dl) who do not have an autologous predonation programme available and with expected moderate blood loss (900 to 1800 ml). MESH:C530192 uuid:74787dca-2b7c-43a1-8628-2ae956b3b1fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB16738 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:308d89c1-5e5f-400c-a77c-94abac49e839"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f390e5b4-2210-41da-94cf-056a4d10c713"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/carvykti""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody and have demonstrated disease progression on the last therapy. uuid:72d66f18-013f-46e1-8a61-1ba4f244b4a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50381 biolink:treats MONDO:0018982 PMID:41385096 "[{""id"":""uuid:b880c190-0e9a-453d-bf56-bbe8b25210b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b517327f-b5d1-424a-a4af-d8d9e435f9be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/opfolda""]},{""id"":""uuid:782b7f1e-582b-4bcf-aa16-940131112d07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Miglustat Dipharma is indicated for the oral treatment of adult patients with mild to moderate type 1 Gaucher disease.Miglustat Dipharma may be used only in the treatment of patients for whom enzyme replacement therapy is unsuitable.Miglustat Dipharma is indicated for the treatment of progressive neurological manifestations in adult patients and paediatric patients with Niemann-Pick type C disease.|[PMDA] A drug with a new active ingredient indicated for the treatment of Niemann-Pick disease Type C. [Orphan drug] uuid:2a77201c-8131-43cd-bcd7-2dc1d9dde7b8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1597091 biolink:treats MONDO:0002974 PMID:41385096 "[{""id"":""uuid:79881502-5661-4841-b83e-274acdebf467"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b59286c7-9ba5-45a2-aa6a-f9b7c09452a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:60158cb2-0535-4c66-9a50-8224af3f0938"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Gardasil 9 is indicated for active immunisation of individuals from the age of 9 years against the following HPV diseases:Premalignant lesions and cancers affecting the cervix, vulva, vagina and anus caused by vaccine HPV typesGenital warts (Condyloma acuminata) caused by specific HPV types.See sections 4.4 and 5.1 for important information on the data that support these indications.The use of Gardasil 9 should be in accordance with official recommendations.|[PMDA] A drug with a new active ingredient indicated for the prevention of the following diseases caused by infection with human papillomavirus types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Cervical cancer (squamous cell carcinoma and adenosquamous carcinoma) and its precursor lesions (cervical intraepithelial neoplasia [CIN] 1, 2, and 3, and adenocarcinoma in situ [AIS]) Vulvar intraepithelial neoplasia (VIN) 1, 2, and 3, and vaginal intraepithelial noeplasia (VaIN) 1, 2, and 3 Condyloma acuminatum uuid:243ddac1-c463-4d39-89ed-4023f47a1514 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1597091 biolink:treats MONDO:0001528 PMID:41385096 "[{""id"":""uuid:f40f7f78-9ef1-4a57-9a45-9a907d3ad299"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:964ceab8-db37-461d-9bf5-ee88ed91aae0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Gardasil 9 is indicated for active immunisation of individuals from the age of 9 years against the following HPV diseases:Premalignant lesions and cancers affecting the cervix, vulva, vagina and anus caused by vaccine HPV typesGenital warts (Condyloma acuminata) caused by specific HPV types.See sections 4.4 and 5.1 for important information on the data that support these indications.The use of Gardasil 9 should be in accordance with official recommendations. uuid:5ff0e54e-5b86-4d31-a9f2-93b2fb237a91 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1597091 biolink:treats MONDO:0001402 PMID:41385096 "[{""id"":""uuid:a98d7333-4dea-474d-91f2-6975a358a5e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0e5b5a93-3815-449f-b8fa-76bb33079252"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Gardasil 9 is indicated for active immunisation of individuals from the age of 9 years against the following HPV diseases:Premalignant lesions and cancers affecting the cervix, vulva, vagina and anus caused by vaccine HPV typesGenital warts (Condyloma acuminata) caused by specific HPV types.See sections 4.4 and 5.1 for important information on the data that support these indications.The use of Gardasil 9 should be in accordance with official recommendations. uuid:9ef94167-4c62-4226-8519-398f8f155af3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1597091 biolink:treats MONDO:0003199 PMID:41385096 "[{""id"":""uuid:dacd4132-215d-4a40-9d64-c69836ea6f1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9f1e0538-0064-4082-88ed-8918d9fa5876"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Gardasil 9 is indicated for active immunisation of individuals from the age of 9 years against the following HPV diseases:Premalignant lesions and cancers affecting the cervix, vulva, vagina and anus caused by vaccine HPV typesGenital warts (Condyloma acuminata) caused by specific HPV types.See sections 4.4 and 5.1 for important information on the data that support these indications.The use of Gardasil 9 should be in accordance with official recommendations. uuid:b4b00489-243f-4685-b0ad-eb4ef66f4649 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1597091 biolink:treats MONDO:0005647 PMID:41385096 "[{""id"":""uuid:080a29e4-78d2-4124-bc7b-a130c830fee1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c7ca0309-fbf9-4863-92c9-5d4d074fdb16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Gardasil 9 is indicated for active immunisation of individuals from the age of 9 years against the following HPV diseases:Premalignant lesions and cancers affecting the cervix, vulva, vagina and anus caused by vaccine HPV typesGenital warts (Condyloma acuminata) caused by specific HPV types.See sections 4.4 and 5.1 for important information on the data that support these indications.The use of Gardasil 9 should be in accordance with official recommendations. uuid:501b5341-705f-4c4d-8981-3d6dc45274f1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9241 biolink:treats MONDO:0008829 PMID:41385096 "[{""id"":""uuid:307370b4-20da-4a7a-8c66-a1009f2a331b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:00a3db8a-f843-4871-8709-41b2c32b8bb0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/qaialdo""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] In the management of refractory oedema associated with congestive cardiac failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, diagnosis and treatment of primary aldosteronism, essential hypertension.Neonates, children and adolescents should only be treated under guidance of a paediatric specialist (see sections 5.1 and 5.2). uuid:755c4e8c-a7fb-4d28-9589-de835aed3832 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PVI5M0M1GW biolink:treats MONDO:0001475 PMID:41385096 "[{""id"":""uuid:5ca32c7c-8827-415a-b423-eec814d8dccd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9edbb32b-be66-4592-89c5-b0c7b568c2f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/filgrastim-hexal""]},{""id"":""uuid:ff806709-f972-446b-9f2a-fade4199ce9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Accofil is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia. The safety and efficacy of Accofil are similar in adults and children receiving cytotoxic chemotherapy.Accofil is indicated for the mobilisation of peripheral blood progenitor cells (PBPCs).In patients, children or adults with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of ≤ 0.5 x 109/L, and a history of severe or recurrent infections, long term administration of Accofil is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.Accofil is indicated for the treatment of persistent neutropenia (ANC less than or equal to 1.0 x 109/L) in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate.|[PMDA] Follow-on biologics indicated for mobilization of hematopoietic stem cell to peripheral blood, promotion of increase in neutrophil count at the time of hematopoietic stem cell transplantation, and the treatment of neutropenia caused by cancer chemotherapy, neutropenia which affects the treatment of human immunodeficiency virus (HIV) infection, neutropenia associated with myelodysplastic syndrome, neutropenia associated with aplastic anemia and congenital/idiopathic neutropenia. uuid:8145b45c-8d9b-4794-ac8e-358405540502 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PVI5M0M1GW biolink:treats MONDO:0008089 PMID:41385096 "[{""id"":""uuid:4b3deedd-8b3c-4450-8f2c-504e5bb4fe40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:67713303-7309-4378-87cc-4b1d407959ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/filgrastim-hexal""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Accofil is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia. The safety and efficacy of Accofil are similar in adults and children receiving cytotoxic chemotherapy.Accofil is indicated for the mobilisation of peripheral blood progenitor cells (PBPCs).In patients, children or adults with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of ≤ 0.5 x 109/L, and a history of severe or recurrent infections, long term administration of Accofil is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.Accofil is indicated for the treatment of persistent neutropenia (ANC less than or equal to 1.0 x 109/L) in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate. uuid:14d8c9c6-6910-490a-9078-f9bbefcc284a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PVI5M0M1GW biolink:treats MONDO:0005113 PMID:41385096 "[{""id"":""uuid:d50fd8f9-9b6e-4e03-8499-a13dcba1fecd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a1de2060-46aa-47ff-aa97-9193d2b3086e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/filgrastim-hexal""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Accofil is indicated for the reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with established cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes) and for the reduction in the duration of neutropenia in patients undergoing myeloablative therapy followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia. The safety and efficacy of Accofil are similar in adults and children receiving cytotoxic chemotherapy.Accofil is indicated for the mobilisation of peripheral blood progenitor cells (PBPCs).In patients, children or adults with severe congenital, cyclic, or idiopathic neutropenia with an absolute neutrophil count (ANC) of ≤ 0.5 x 109/L, and a history of severe or recurrent infections, long term administration of Accofil is indicated to increase neutrophil counts and to reduce the incidence and duration of infection-related events.Accofil is indicated for the treatment of persistent neutropenia (ANC less than or equal to 1.0 x 109/L) in patients with advanced HIV infection, in order to reduce the risk of bacterial infections when other options to manage neutropenia are inappropriate. uuid:6e85e10b-0492-4e69-a90e-921ffa9abbcc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1551466 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:aaca3fd1-eb0a-43ff-bea2-fb7c4ac790a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:8f8cfbed-5941-4fa6-94c0-a20e4e17491d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/mysimba""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Mysimba is indicated, as an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients (≥18 years) with an initial Body Mass Index (BMI) of≥ 30 kg/m2 (obese), or≥ 27 kg/m2 to < 30 kg/m2 (overweight) in the presence of one or more weight-related co morbidities (e.g., type 2 diabetes, dyslipidaemia, or controlled hypertension)Treatment with Mysimba should be discontinued after 16 weeks if patients have not lost at least 5% of their initial body weight. uuid:59fd2e8a-876a-4311-bf71-e820cae96069 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1551466 biolink:treats HP:0003119 PMID:41385096 "[{""id"":""uuid:308816c0-0999-4609-ac61-cfadda49d71f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:270d0fba-7092-4586-8ad4-d7647d5b2dbd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/mysimba""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Mysimba is indicated, as an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients (≥18 years) with an initial Body Mass Index (BMI) of≥ 30 kg/m2 (obese), or≥ 27 kg/m2 to < 30 kg/m2 (overweight) in the presence of one or more weight-related co morbidities (e.g., type 2 diabetes, dyslipidaemia, or controlled hypertension)Treatment with Mysimba should be discontinued after 16 weeks if patients have not lost at least 5% of their initial body weight. uuid:4fb9bd5c-6769-4041-9259-cfbe569288e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:NQX9KB6PCL biolink:treats NCIT:C118469 PMID:41385096 "[{""id"":""uuid:21400385-a1c4-40f8-b2ed-b332743d4df4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5a00fb5b-b834-4fa1-94e4-78bc1f4c4160"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/omnitrope""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Long-term treatment of children with growth failure due to inadequate endogenous growth hormone secretion.Long-term treatment of growth failure associated with Turner syndrome.Treatment of prepubertal children with growth failure associated with chronic renal insufficiency up to the time of renal transplantation.Replacement of endogenous growth hormone in adults with growth hormone deficiency of either childhood or adult-onset etiology. Growth hormone deficiency should be confirmed appropriately prior to treatment. uuid:735f05e5-6bbd-4eca-b6d9-7046cadbfe13 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71028 biolink:treats MONDO:0009475 PMID:41385096 "[{""id"":""uuid:72f6fbe9-a3ae-4966-8984-cef4e7cba5d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:87ae50d4-171e-4195-b640-95a612f0e284"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/carbaglu""]},{""id"":""uuid:aa4d4bf5-bf93-47c1-8ef5-e90bdaa857fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Carbaglu is indicated in treatment of:hyperammonaemia due to N-acetylglutamate-synthase primary deficiency;hyperammonaemia due to isovaleric acidaemia;hyperammonaemia due to methymalonic acidaemia;hyperammonaemia due to propionic acidaemia.|[PMDA] A drug with a new active ingredient indicated for the treatment of hyperammonemia due to N- acetylglutamate synthetase deficiency, isovaleric acidemia, methylmalonic acidemia, and propionic acidemia. [Orphan drug] uuid:e0b13079-49b5-4f1f-9dca-55b18ab0e9dc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71028 biolink:treats MONDO:0009615 PMID:41385096 "[{""id"":""uuid:835304fa-18d9-4c1f-81ea-8c55e085a8fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:cb90de1a-8a4a-4bd2-ae6f-98bd515c678f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/carbaglu""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Carbaglu is indicated in treatment of:hyperammonaemia due to N-acetylglutamate-synthase primary deficiency;hyperammonaemia due to isovaleric acidaemia;hyperammonaemia due to methymalonic acidaemia;hyperammonaemia due to propionic acidaemia. uuid:60a83ed6-4398-4373-920b-7e3c90c84d3f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10284 biolink:treats MONDO:0005373 PMID:41385096 "[{""id"":""uuid:d591fc74-9cc2-446f-8a35-022f39b215a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d14cd34d-23e2-4c2c-bafb-366bc746afac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Active immunisation against invasive disease caused by Neisseria meningitidis serogroup-B strains., uuid:7761e9ab-4050-47cb-b286-91b7d5343e07 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:QC4F7FKK7I biolink:treats MONDO:0005417 PMID:41385096 "[{""id"":""uuid:621bb7ea-f15c-4bb6-bc97-dc1ed990b289"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:02973dcb-97f2-49a5-a41c-b2aacbf291d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vabysmo""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Vabysmo is indicated for the treatment of adult patients with:neovascular (wet) age-related macular degeneration (nAMD),visual impairment due to diabetic macular oedema (DME). uuid:11a78812-be60-49fc-9782-7cee79124178 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:QC4F7FKK7I biolink:treats MONDO:0004728 PMID:41385096 "[{""id"":""uuid:2863c568-9a17-4179-9812-fe68d5dc85d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e922dcac-8204-40be-90d0-728eceb5044d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vabysmo""]},{""id"":""uuid:0838ccf7-36d0-487c-8c48-ba7d5206438d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Vabysmo is indicated for the treatment of adult patients with:neovascular (wet) age-related macular degeneration (nAMD),visual impairment due to diabetic macular oedema (DME).|[PMDA] A drug with a new active ingredient indicated for the treatment of age-related macular degeneration associated with subfoveal choroidal neovascularization and diabetic macular edema. uuid:cf8bdc17-2b01-456a-98f3-905f0c7c90a3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3614 biolink:treats MONDO:0000809 PMID:41385096 "[{""id"":""uuid:5cb67ca2-ff93-4232-9940-a1102254a37d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d3641d46-e0d3-47fe-b872-440929a97ac1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ceprotin""]},{""id"":""uuid:8a3c2a67-853d-4fd1-9763-8b60e2501772"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] CEPROTIN is indicated for prophylaxis and treatment of purpura fulminans coumarin-induced skin necrosis and venous thrombotic events in patients with severe congenital protein C deficiency.|[PMDA] A drug with a new active ingredient indicated for the treatment of venous thromboembolism and purpura fulminans and for the control of thrombophilia, in patients with congenital protein C deficiency. uuid:8ecd903b-e069-4553-8ad0-eb4a2de2b578 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3614 biolink:treats MONDO:0005380 PMID:41385096 "[{""id"":""uuid:489a2294-a784-4676-a242-936c5ae8dcb4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:225e6bb2-3a34-4e81-b89e-eef7d8f89ce4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ceprotin""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] CEPROTIN is indicated for prophylaxis and treatment of purpura fulminans coumarin-induced skin necrosis and venous thrombotic events in patients with severe congenital protein C deficiency. uuid:2726a379-142c-43e0-9de9-83dcd2dbc9f9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3614 biolink:treats MONDO:0005399 PMID:41385096 "[{""id"":""uuid:e9c6070d-26b4-4a0f-bfe6-66e772f606cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d5daebbb-7939-4494-8f6e-f800ffe245ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ceprotin""]},{""id"":""uuid:dd8e8d09-591b-405a-8fdd-f2a2829f0f5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] CEPROTIN is indicated for prophylaxis and treatment of purpura fulminans coumarin-induced skin necrosis and venous thrombotic events in patients with severe congenital protein C deficiency.|[PMDA] A drug with a new active ingredient indicated for the treatment of venous thromboembolism and purpura fulminans and for the control of thrombophilia, in patients with congenital protein C deficiency. uuid:e23cf39c-a22f-46df-9797-62c0d5f95208 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6QVL057INT biolink:treats MONDO:0002529 PMID:41385096 "[{""id"":""uuid:48a56849-4bd7-4f5e-bbf8-8a5b406a02b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:74d60c62-0132-47fe-bdc7-5234e1a20ba4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/libtayo""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Cutaneous Squamous Cell CarcinomaLibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mCSCC or laCSCC) who are not candidates for curative surgery or curative radiation.Basal Cell CarcinomaLibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (laBCC or mBCC) who have progressed on or are intolerant to a hedgehog pathway inhibitor (HHI).Non-Small Cell Lung CancerLibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 (in ≥ 50% tumour cells), with no EGFR, ALK or ROS1 aberrations, who have:locally advanced NSCLC who are not candidates for definitive chemoradiation, ormetastatic NSCLC.Libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with NSCLC expressing PD-L1 (in ≥ 1% of tumour cells), with no EGFR, ALK or ROS1 aberrations, who have:locally advanced NSCLC who are not candidates for definitive chemoradiation, ormetastatic NSCLC.Cervical CancerLibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy. uuid:39a42059-6799-427e-a48d-799a2daf8da1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6QVL057INT biolink:treats MONDO:0002974 PMID:41385096 "[{""id"":""uuid:c651f455-5469-4490-af1e-a572840d4cb3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0d9ad217-3dfb-4b2b-882f-a3a2d4f9bc1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/libtayo""]},{""id"":""uuid:c4b69846-8ba0-459f-a391-df5b20d55048"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Cutaneous Squamous Cell CarcinomaLibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mCSCC or laCSCC) who are not candidates for curative surgery or curative radiation.Basal Cell CarcinomaLibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (laBCC or mBCC) who have progressed on or are intolerant to a hedgehog pathway inhibitor (HHI).Non-Small Cell Lung CancerLibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (NSCLC) expressing PD-L1 (in ≥ 50% tumour cells), with no EGFR, ALK or ROS1 aberrations, who have:locally advanced NSCLC who are not candidates for definitive chemoradiation, ormetastatic NSCLC.Libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with NSCLC expressing PD-L1 (in ≥ 1% of tumour cells), with no EGFR, ALK or ROS1 aberrations, who have:locally advanced NSCLC who are not candidates for definitive chemoradiation, ormetastatic NSCLC.Cervical CancerLibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.|[PMDA] A drug with a new active ingredient indicated for the treatment of advanced or recurrent cervical cancer that has progressed after cancer chemotherapy. uuid:32e3e1e1-075f-426c-a451-49fa59f66212 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:195558 biolink:treats MONDO:0958299 PMID:41385096 "[{""id"":""uuid:08f2e474-6a0b-44b7-b076-aead2ee92caf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e403721f-d10c-481e-9aeb-2684ca61ce9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/rozlytrek""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rozlytrek as monotherapy is indicated for the treatment of adult and paediatric patients 12 years of age and older with solid tumours expressing a neurotrophic tyrosine receptor kinase (NTRK) gene fusion,who have a disease that is locally advanced, metastatic or where surgical resection is likely to result in severe morbidity, andwho have not received a prior NTRK inhibitorwho have no satisfactory treatment options.Rozlytrek as monotherapy is indicated for the treatment of adult patients with ROS1 positive, advanced non small cell lung cancer (NSCLC) not previously treated with ROS1 inhibitors. uuid:2555433b-64d7-4127-9ceb-136ba3debbb1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4H5YMK1H2E biolink:treats MONDO:0000705 PMID:41385096 "[{""id"":""uuid:a2e99152-bf89-45e0-9dbd-945fa7736f48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:dec7c24c-dd95-4ec3-9ef3-96063eeacc5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zinplava""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Zinplava is indicated for the prevention of recurrence of Clostridium difficile infection (CDI) in adults at high risk for recurrence of CDI. uuid:1f050370-cff3-470b-8d0e-493605cb403a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4H5YMK1H2E biolink:treats MONDO:0015790 PMID:41385096 "[{""id"":""uuid:36466464-94f4-418c-a720-406835ff016b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d16b34d6-bf01-44ba-924b-9859310beb78"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zinplava""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Zinplava is indicated for the prevention of recurrence of Clostridium difficile infection (CDI) in adults at high risk for recurrence of CDI. uuid:e4ce91b7-3126-4475-b35c-222f21b637cc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85662 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:313d3758-aae1-40fc-b690-f68e7c48bf2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b1d2c489-0c9a-4289-8eca-e50d5e32d5dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lyxumia""]},{""id"":""uuid:0d583815-d568-4649-a583-beab7b26f033"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Lyxumia is indicated for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control in combination with oral glucose lowering medicinal products and/or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control.,|[PMDA] A drug with a new active ingredient indicated for the treatment of type 2 diabetes mellitus (for use only in patients who have not responded sufficiently to either treatment (1) or (2): (1) Use of sulfonylureas (including combination with biguanides) in addition to diet and exercise therapies; (2) Use of long-acting soluble insulin or intermediate-acting insulin preparations (including combination with sulfonylureas) in addition to diet and exercise therapies. uuid:67e803fc-9859-4075-8066-2de2a7615f5f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:FU77B4U5Z0 biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:5eaaecd4-e7b4-447f-bf58-ffc563a950a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9b02e46d-fd09-4966-9947-413e635f8837"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/stelara""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Crohn’s DiseaseStelara is indicated for the treatment of adult patients with moderately to severely active Crohn’s disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a TNFα antagonist or have medical contraindications to such therapies.Ulcerative colitisSTELARA is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies.Plaque psoriasisStelara is indicated for the treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and psoralen ultraviolet A.Paediatric plaque psoriasisStelara is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescent patients from the age of 6 years and older, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.Psoriatic arthritisStelara, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous non-biological disease-modifying antirheumatic drug (DMARD) therapy has been inadequate. uuid:266afec1-0fb5-4e5d-aa54-7826537f2d0f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB00028 biolink:treats MONDO:0004948 PMID:41385096 "[{""id"":""uuid:7b103c8b-3db5-482a-8405-71ba18783e1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d6bee74a-1985-4a8f-b468-5ad7e4aff624"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/flebogamma-dif""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Replacement therapy in adults, children and adolescents (0-18 years) in:Primary immunodeficiency syndromes with impaired antibody production.Hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic leukaemia (CLL), in whom prophylactic antibiotics have failed or are contra‑indicated.Hypogammaglobulinaemia and recurrent bacterial infections in multiple myeloma (MM) patients.Hypogammaglobulinaemia in patients pre‑ and post‑allogeneic hematopoietic stem cell transplantation (HSCT). uuid:8ef79e1a-4eaf-4aac-a71e-5b4ac0329458 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB00028 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:debce7e5-2b62-4e83-8594-3f269aa79350"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f90463f2-c8eb-4642-984e-d9c4a590d56c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/flebogamma-dif""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Replacement therapy in adults, children and adolescents (0-18 years) in:Primary immunodeficiency syndromes with impaired antibody production.Hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic leukaemia (CLL), in whom prophylactic antibiotics have failed or are contra‑indicated.Hypogammaglobulinaemia and recurrent bacterial infections in multiple myeloma (MM) patients.Hypogammaglobulinaemia in patients pre‑ and post‑allogeneic hematopoietic stem cell transplantation (HSCT). uuid:d7067099-270b-49c4-bc17-15847b8fae21 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10061 biolink:treats MONDO:0005373 PMID:41385096 "[{""id"":""uuid:33c7f4fa-d108-4d99-a304-d77c461a1075"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:95e25091-fc7d-42e6-825a-67717c515dd7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Nimenrix is indicated for active immunisation of individuals from the age of 6 weeks against invasive meningococcal diseases caused by Neisseria meningitidis group A, C, W-135, and Y. uuid:eaf70295-6a8b-4d58-8751-4be9219008b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:I8309403R0 biolink:treats MONDO:0005314 PMID:41385096 "[{""id"":""uuid:e54ca3cf-782e-48a7-aa37-74d32a1fec67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a8f2db4d-03a9-4762-b48b-79944ace2ce7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/plegridy""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of relapsing remitting multiple sclerosis in adult patients. uuid:24ba39ce-83d6-452e-a37b-d0e0acf25bb1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9013DUQ28K biolink:treats MONDO:0100096 PMID:41385096 "[{""id"":""uuid:7b962ed8-70d1-4143-b4c8-89745b42378c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b2137f57-0074-440b-b0ef-ba6a6466d6b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kineret""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rheumatoid Arthritis (RA)Kineret is indicated in adults for the treatment of the signs and symptoms of RA in combination with methotrexate, with an inadequate response to methotrexate alone.COVID-19Kineret is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adult patients with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) who are at risk of progressing to severe respiratory failure determined by plasma concentration of soluble urokinase plasminogen activator receptor (suPAR) ≥ 6 ng/ml.Periodic fever syndromesKineret is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above:Cryopyrin-Associated Periodic Syndromes (CAPS)Kineret is indicated for the treatment of CAPS, including:Neonatal-Onset Multisystem Inflammatory Disease (NOMID) / Chronic Infantile Neurological, Cutaneous, Articular Syndrome (CINCA)Muckle-Wells Syndrome (MWS)Familial Cold Autoinflammatory Syndrome (FCAS)Familial Mediterranean Fever (FMF)Kineret is indicated for the treatment of Familial Mediterranean Fever (FMF). Kineret should be given in combination with colchicine, if appropriate.Still’s DiseaseKineret is indicated in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above for the treatment of Still’s disease, including Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still’s Disease (AOSD), with active systemic features of moderate to high disease activity, or in patients with continued disease activity after treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or glucocorticoids.Kineret can be given as monotherapy or in combination with other anti-inflammatory drugs and disease-modifying antirheumatic drugs (DMARDs). uuid:be25692c-83d2-414a-bd11-04bed0371f8a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9013DUQ28K biolink:treats MONDO:0016168 PMID:41385096 "[{""id"":""uuid:cf115b7f-a457-48ec-bec2-edbc197bb8d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:8fcb5be6-7cad-419b-8601-616ac6caefe7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kineret""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rheumatoid Arthritis (RA)Kineret is indicated in adults for the treatment of the signs and symptoms of RA in combination with methotrexate, with an inadequate response to methotrexate alone.COVID-19Kineret is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adult patients with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) who are at risk of progressing to severe respiratory failure determined by plasma concentration of soluble urokinase plasminogen activator receptor (suPAR) ≥ 6 ng/ml.Periodic fever syndromesKineret is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above:Cryopyrin-Associated Periodic Syndromes (CAPS)Kineret is indicated for the treatment of CAPS, including:Neonatal-Onset Multisystem Inflammatory Disease (NOMID) / Chronic Infantile Neurological, Cutaneous, Articular Syndrome (CINCA)Muckle-Wells Syndrome (MWS)Familial Cold Autoinflammatory Syndrome (FCAS)Familial Mediterranean Fever (FMF)Kineret is indicated for the treatment of Familial Mediterranean Fever (FMF). Kineret should be given in combination with colchicine, if appropriate.Still’s DiseaseKineret is indicated in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above for the treatment of Still’s disease, including Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still’s Disease (AOSD), with active systemic features of moderate to high disease activity, or in patients with continued disease activity after treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or glucocorticoids.Kineret can be given as monotherapy or in combination with other anti-inflammatory drugs and disease-modifying antirheumatic drugs (DMARDs). uuid:9b5231af-db01-473a-8214-a02f5fdae486 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9013DUQ28K biolink:treats MONDO:0018768 PMID:41385096 "[{""id"":""uuid:80cecd6c-def9-4241-8375-29afda108edb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9b61ed23-7822-4566-b786-0f58cec88195"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kineret""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rheumatoid Arthritis (RA)Kineret is indicated in adults for the treatment of the signs and symptoms of RA in combination with methotrexate, with an inadequate response to methotrexate alone.COVID-19Kineret is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adult patients with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) who are at risk of progressing to severe respiratory failure determined by plasma concentration of soluble urokinase plasminogen activator receptor (suPAR) ≥ 6 ng/ml.Periodic fever syndromesKineret is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above:Cryopyrin-Associated Periodic Syndromes (CAPS)Kineret is indicated for the treatment of CAPS, including:Neonatal-Onset Multisystem Inflammatory Disease (NOMID) / Chronic Infantile Neurological, Cutaneous, Articular Syndrome (CINCA)Muckle-Wells Syndrome (MWS)Familial Cold Autoinflammatory Syndrome (FCAS)Familial Mediterranean Fever (FMF)Kineret is indicated for the treatment of Familial Mediterranean Fever (FMF). Kineret should be given in combination with colchicine, if appropriate.Still’s DiseaseKineret is indicated in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above for the treatment of Still’s disease, including Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still’s Disease (AOSD), with active systemic features of moderate to high disease activity, or in patients with continued disease activity after treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or glucocorticoids.Kineret can be given as monotherapy or in combination with other anti-inflammatory drugs and disease-modifying antirheumatic drugs (DMARDs). uuid:277d346a-112d-42a0-b67b-b1ff5068a65d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9013DUQ28K biolink:treats MONDO:0018088 PMID:41385096 "[{""id"":""uuid:77fc7699-d776-4190-a23e-1ca3f95a0567"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:fa49c9c1-49ba-4c2f-883b-145cfab1417e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kineret""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rheumatoid Arthritis (RA)Kineret is indicated in adults for the treatment of the signs and symptoms of RA in combination with methotrexate, with an inadequate response to methotrexate alone.COVID-19Kineret is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adult patients with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) who are at risk of progressing to severe respiratory failure determined by plasma concentration of soluble urokinase plasminogen activator receptor (suPAR) ≥ 6 ng/ml.Periodic fever syndromesKineret is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above:Cryopyrin-Associated Periodic Syndromes (CAPS)Kineret is indicated for the treatment of CAPS, including:Neonatal-Onset Multisystem Inflammatory Disease (NOMID) / Chronic Infantile Neurological, Cutaneous, Articular Syndrome (CINCA)Muckle-Wells Syndrome (MWS)Familial Cold Autoinflammatory Syndrome (FCAS)Familial Mediterranean Fever (FMF)Kineret is indicated for the treatment of Familial Mediterranean Fever (FMF). Kineret should be given in combination with colchicine, if appropriate.Still’s DiseaseKineret is indicated in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above for the treatment of Still’s disease, including Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still’s Disease (AOSD), with active systemic features of moderate to high disease activity, or in patients with continued disease activity after treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or glucocorticoids.Kineret can be given as monotherapy or in combination with other anti-inflammatory drugs and disease-modifying antirheumatic drugs (DMARDs). uuid:2bbc78a7-8616-4729-98c4-c659c90da918 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9013DUQ28K biolink:treats MONDO:0019355 PMID:41385096 "[{""id"":""uuid:dc3a1b8b-bf3a-47ce-bfc8-2ee41f79fb38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c99cb3ba-009c-4b95-bb75-58901f585c0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kineret""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rheumatoid Arthritis (RA)Kineret is indicated in adults for the treatment of the signs and symptoms of RA in combination with methotrexate, with an inadequate response to methotrexate alone.COVID-19Kineret is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adult patients with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) who are at risk of progressing to severe respiratory failure determined by plasma concentration of soluble urokinase plasminogen activator receptor (suPAR) ≥ 6 ng/ml.Periodic fever syndromesKineret is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above:Cryopyrin-Associated Periodic Syndromes (CAPS)Kineret is indicated for the treatment of CAPS, including:Neonatal-Onset Multisystem Inflammatory Disease (NOMID) / Chronic Infantile Neurological, Cutaneous, Articular Syndrome (CINCA)Muckle-Wells Syndrome (MWS)Familial Cold Autoinflammatory Syndrome (FCAS)Familial Mediterranean Fever (FMF)Kineret is indicated for the treatment of Familial Mediterranean Fever (FMF). Kineret should be given in combination with colchicine, if appropriate.Still’s DiseaseKineret is indicated in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above for the treatment of Still’s disease, including Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still’s Disease (AOSD), with active systemic features of moderate to high disease activity, or in patients with continued disease activity after treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or glucocorticoids.Kineret can be given as monotherapy or in combination with other anti-inflammatory drugs and disease-modifying antirheumatic drugs (DMARDs). uuid:8949218a-8f6a-42d6-8feb-4d45308965db biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9013DUQ28K biolink:treats MONDO:0019434 PMID:41385096 "[{""id"":""uuid:bfa91d96-c239-4db2-9b9d-b61cecabf5a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b2e47a64-19ce-4675-85fa-9eb1cbb15308"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kineret""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rheumatoid Arthritis (RA)Kineret is indicated in adults for the treatment of the signs and symptoms of RA in combination with methotrexate, with an inadequate response to methotrexate alone.COVID-19Kineret is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adult patients with pneumonia requiring supplemental oxygen (low- or high-flow oxygen) who are at risk of progressing to severe respiratory failure determined by plasma concentration of soluble urokinase plasminogen activator receptor (suPAR) ≥ 6 ng/ml.Periodic fever syndromesKineret is indicated for the treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above:Cryopyrin-Associated Periodic Syndromes (CAPS)Kineret is indicated for the treatment of CAPS, including:Neonatal-Onset Multisystem Inflammatory Disease (NOMID) / Chronic Infantile Neurological, Cutaneous, Articular Syndrome (CINCA)Muckle-Wells Syndrome (MWS)Familial Cold Autoinflammatory Syndrome (FCAS)Familial Mediterranean Fever (FMF)Kineret is indicated for the treatment of Familial Mediterranean Fever (FMF). Kineret should be given in combination with colchicine, if appropriate.Still’s DiseaseKineret is indicated in adults, adolescents, children and infants aged 8 months and older with a body weight of 10 kg or above for the treatment of Still’s disease, including Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still’s Disease (AOSD), with active systemic features of moderate to high disease activity, or in patients with continued disease activity after treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or glucocorticoids.Kineret can be given as monotherapy or in combination with other anti-inflammatory drugs and disease-modifying antirheumatic drugs (DMARDs). uuid:616786dc-4711-4657-bc4b-4a4394944989 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4EQZ6YO2HI biolink:treats HP:0002756 PMID:41385096 "[{""id"":""uuid:b92bc765-5fdd-4f6e-a699-65e6bd859ad1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:53f3232c-eec7-4917-ad49-68e53b78874b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/prolia""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone (see section 5.1).Treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity. uuid:1f190933-6b5e-4281-8dac-6d57c0634675 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4EQZ6YO2HI biolink:treats MONDO:0043735 PMID:41385096 "[{""id"":""uuid:9766ae94-fb26-435f-af19-d91e9c4e0670"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6152af25-a08d-4cb2-a69b-89caf1d39d9d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/prolia""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone (see section 5.1).Treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity. uuid:2fe954d4-b017-4029-bbe1-9da8140274f7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4EQZ6YO2HI biolink:treats MONDO:0002545 PMID:41385096 "[{""id"":""uuid:84a4b3c9-f0e6-4c8d-86ad-05ec11cadf68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:44fba10e-d0a8-413b-b25e-721542955b44"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/prolia""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with advanced malignancies involving bone (see section 5.1).Treatment of adults and skeletally mature adolescents with giant cell tumour of bone that is unresectable or where surgical resection is likely to result in severe morbidity. uuid:c8d8266e-875f-4ec3-95ac-45bc94ca1207 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9635 biolink:treats MONDO:0005628 PMID:41385096 "[{""id"":""uuid:9289f76a-8ca7-44e0-a711-d0e9babfa809"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ba1bc2a0-02e9-431e-a8d0-901af7607595"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/fareston""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] First line hormone treatment of hormone-dependent metastatic breast cancer in postmenopausal patients.Fareston is not recommended for patients with estrogen receptor negative tumours. uuid:63544057-2ac3-46a5-a852-119e661d4692 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:UMD7G2653W biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:db1399ab-45b2-4eab-8864-afac53811704"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d5539a3a-84ad-4adc-a3a5-04907a84e480"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/bonviva""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Bondronat is indicated for:prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases;treatment of tumour-induced hypercalcaemia with or without metastases. uuid:1dc7381d-5b19-451d-9588-22b437c8a1c3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:UMD7G2653W biolink:treats MONDO:0043731 PMID:41385096 "[{""id"":""uuid:352424fc-565d-4c56-ab98-23e01f7e79ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:88fa0314-182e-421b-be8e-2de6667c432a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/bonviva""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Bondronat is indicated for:prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases;treatment of tumour-induced hypercalcaemia with or without metastases. uuid:7539b707-126f-470c-a3ad-fea82288a4ac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:UMD7G2653W biolink:treats MONDO:0043455 PMID:41385096 "[{""id"":""uuid:4db36c4a-0402-4029-99a9-da0cb6009aae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f42b659c-8261-42a7-a0aa-1c675c83d965"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/bonviva""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Bondronat is indicated for:prevention of skeletal events (pathological fractures, bone complications requiring radiotherapy or surgery) in patients with breast cancer and bone metastases;treatment of tumour-induced hypercalcaemia with or without metastases. uuid:081ad659-27e2-4490-9a46-ed8a04a76007 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135906 biolink:treats MONDO:0009807 PMID:41385096 "[{""id"":""uuid:cf18e6d3-b308-441e-b0ec-edb1c8d44285"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:3cc058c4-b9c0-488a-8f98-6b2f3ec34452"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/mepact""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Mepact is indicated in children, adolescents and young adults for the treatment of high-grade resectable non-metastatic osteosarcoma after macroscopically complete surgical resection. It is used in combination with postoperative multi-agent chemotherapy. Safety and efficacy have been assessed in studies of patients two to 30 years of age at initial diagnosis. uuid:b01af89d-cdc9-4de2-94b6-d048f406d5c4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:61033 biolink:treats MONDO:0006805 PMID:41385096 "[{""id"":""uuid:ba80e25c-9e2f-4a64-8b78-6a533d9e245f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d3271426-45ec-416c-9c83-6b89a5744e23"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/arixtra""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] 1.5-mg/0.3-ml and 2.5-mg/0.5-ml solution for injectionPrevention of venous thromboembolic events (VTE) in adults undergoing major orthopaedic surgery of the lower limbs such as hip fracture, major knee surgery or hip-replacement surgery.Prevention of VTE in adults undergoing abdominal surgery who are judged to be at high risk of thromboembolic complications, such as patients undergoing abdominal cancer surgery.Prevention of VTE in adult medical patients who are judged to be at high risk for VTE and who are immobilised due to acute illness such as cardiac insufficiency and / or acute respiratory disorders, and / or acute infectious or inflammatory disease.Treatment of adults with acute symptomatic spontaneous superficial-vein thrombosis of the lower limbs without concomitant deep-vein thrombosis.2.5-mg/0.5-ml solution for injectionTreatment of unstable angina or non-ST-segment-elevation myocardial infarction (UA/NSTEMI) in adult patients for whom urgent (< 120 mins) invasive management (PCI) is not indicated.infarction (STEMI) in adult patients who are managed with thrombolytics or who initially are to receive no other form of reperfusion therapy.5-mg/0.4-ml, 7.5-mg/0.6-ml and 10-mg/0.8-ml solution for injectionTreatment of adults with acute deep-vein thrombosis (DVT) and treatment of acute pulmonary embolism (PE), except in haemodynamically unstable patients or patients who require thrombolysis or pulmonary embolectomy. uuid:c6a75545-548a-429f-8e22-36ec265af61e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:61033 biolink:treats MONDO:0000990 PMID:41385096 "[{""id"":""uuid:c71ca4a0-060a-4019-86a0-1dc277d6acef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:910d3a75-34d0-4cc2-83ac-7ad7efae1c9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/arixtra""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] 1.5-mg/0.3-ml and 2.5-mg/0.5-ml solution for injectionPrevention of venous thromboembolic events (VTE) in adults undergoing major orthopaedic surgery of the lower limbs such as hip fracture, major knee surgery or hip-replacement surgery.Prevention of VTE in adults undergoing abdominal surgery who are judged to be at high risk of thromboembolic complications, such as patients undergoing abdominal cancer surgery.Prevention of VTE in adult medical patients who are judged to be at high risk for VTE and who are immobilised due to acute illness such as cardiac insufficiency and / or acute respiratory disorders, and / or acute infectious or inflammatory disease.Treatment of adults with acute symptomatic spontaneous superficial-vein thrombosis of the lower limbs without concomitant deep-vein thrombosis.2.5-mg/0.5-ml solution for injectionTreatment of unstable angina or non-ST-segment-elevation myocardial infarction (UA/NSTEMI) in adult patients for whom urgent (< 120 mins) invasive management (PCI) is not indicated.infarction (STEMI) in adult patients who are managed with thrombolytics or who initially are to receive no other form of reperfusion therapy.5-mg/0.4-ml, 7.5-mg/0.6-ml and 10-mg/0.8-ml solution for injectionTreatment of adults with acute deep-vein thrombosis (DVT) and treatment of acute pulmonary embolism (PE), except in haemodynamically unstable patients or patients who require thrombolysis or pulmonary embolectomy. uuid:35796732-e078-4c7c-b27d-dbc56847fbc3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:61033 biolink:treats MONDO:0041656 PMID:41385096 "[{""id"":""uuid:d7c46c66-b313-4ee0-9cd0-fe9f851c6bd3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4e0e95a4-e48f-4045-97c1-35f54644451e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/arixtra""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] 1.5-mg/0.3-ml and 2.5-mg/0.5-ml solution for injectionPrevention of venous thromboembolic events (VTE) in adults undergoing major orthopaedic surgery of the lower limbs such as hip fracture, major knee surgery or hip-replacement surgery.Prevention of VTE in adults undergoing abdominal surgery who are judged to be at high risk of thromboembolic complications, such as patients undergoing abdominal cancer surgery.Prevention of VTE in adult medical patients who are judged to be at high risk for VTE and who are immobilised due to acute illness such as cardiac insufficiency and / or acute respiratory disorders, and / or acute infectious or inflammatory disease.Treatment of adults with acute symptomatic spontaneous superficial-vein thrombosis of the lower limbs without concomitant deep-vein thrombosis.2.5-mg/0.5-ml solution for injectionTreatment of unstable angina or non-ST-segment-elevation myocardial infarction (UA/NSTEMI) in adult patients for whom urgent (< 120 mins) invasive management (PCI) is not indicated.infarction (STEMI) in adult patients who are managed with thrombolytics or who initially are to receive no other form of reperfusion therapy.5-mg/0.4-ml, 7.5-mg/0.6-ml and 10-mg/0.8-ml solution for injectionTreatment of adults with acute deep-vein thrombosis (DVT) and treatment of acute pulmonary embolism (PE), except in haemodynamically unstable patients or patients who require thrombolysis or pulmonary embolectomy. uuid:13d861c8-1aaa-4c70-aca9-43d070d3fc43 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:61033 biolink:treats MONDO:0005279 PMID:41385096 "[{""id"":""uuid:3613e12f-a6ed-4192-bcda-001bf9a19b5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e7976c41-55d2-4c9f-bc93-323e34334bb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/arixtra""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] 1.5-mg/0.3-ml and 2.5-mg/0.5-ml solution for injectionPrevention of venous thromboembolic events (VTE) in adults undergoing major orthopaedic surgery of the lower limbs such as hip fracture, major knee surgery or hip-replacement surgery.Prevention of VTE in adults undergoing abdominal surgery who are judged to be at high risk of thromboembolic complications, such as patients undergoing abdominal cancer surgery.Prevention of VTE in adult medical patients who are judged to be at high risk for VTE and who are immobilised due to acute illness such as cardiac insufficiency and / or acute respiratory disorders, and / or acute infectious or inflammatory disease.Treatment of adults with acute symptomatic spontaneous superficial-vein thrombosis of the lower limbs without concomitant deep-vein thrombosis.2.5-mg/0.5-ml solution for injectionTreatment of unstable angina or non-ST-segment-elevation myocardial infarction (UA/NSTEMI) in adult patients for whom urgent (< 120 mins) invasive management (PCI) is not indicated.infarction (STEMI) in adult patients who are managed with thrombolytics or who initially are to receive no other form of reperfusion therapy.5-mg/0.4-ml, 7.5-mg/0.6-ml and 10-mg/0.8-ml solution for injectionTreatment of adults with acute deep-vein thrombosis (DVT) and treatment of acute pulmonary embolism (PE), except in haemodynamically unstable patients or patients who require thrombolysis or pulmonary embolectomy. uuid:08fd6266-659d-4164-b572-e21e92983e08 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:233412 biolink:treats MONDO:0005314 PMID:41385096 "[{""id"":""uuid:70967b33-fa86-43fd-9343-606bbff36055"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d4d66fc0-8e6c-4aea-9126-f8ed12cfe9b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ponvory""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ponvory is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features. PUBCHEM.COMPOUND:11363176 uuid:c828bbbe-c5d0-4bc4-8921-23cd19953c82 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:233412 biolink:treats NCIT:C202263 PMID:41385096 "[{""id"":""uuid:fe9339a1-bed3-4eaa-b102-d609680b66f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2f4488cd-dd35-4b11-9e9a-c9a6dbdfa5f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ponvory""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ponvory is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features. PUBCHEM.COMPOUND:11363176 uuid:b4670229-39e2-44e4-b8ac-5a40f80cdabd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:233362 biolink:treats MONDO:0004956 PMID:41385096 "[{""id"":""uuid:1c7f4b56-5707-4857-b535-3fefda577cf0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:be9602ee-e8cb-4f39-af38-42367bec8ead"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/verzenios""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Early Breast CancerVerzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative, node positive early breast cancer at high risk of recurrence (see section 5.1).In pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.Advanced or Metastatic Breast CancerVerzenios is indicated for the treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.In pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist. UNII:60UAB198HK uuid:1f960e23-131a-4f53-95b2-64775c460db0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5931 biolink:treats HP:0001993 PMID:41385096 "[{""id"":""uuid:4b5105fe-d9cf-479d-a5fa-5e2b564590be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9189f677-c126-41ef-ac26-cc42bda984f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/insuman""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Diabetes mellitus where treatment with insulin is required. Insuman Rapid is also suitable for the treatment of hyperglycaemic coma and ketoacidosis, as well as for achieving pre-, intra- and postoperative stabilisation in patients with diabetes mellitus. uuid:bdcc74fa-05e5-4615-9153-d1567cbbb5b0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:72734364 biolink:treats MONDO:0001134 PMID:41385096 "[{""id"":""uuid:15d2c966-a559-4bed-9197-9d3026c4d9fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:09f1b77e-58e5-44bf-85fb-66bfe3b8a5db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/twynsta""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of essential hypertension in adults:Add-on therapyTwynsta is indicated in adults whose blood pressure is not adequately controlled on amlodipine.Replacement therapyAdult patients receiving telmisartan and amlodipine from separate tablets can instead receive tablets of Twynsta containing the same component doses. uuid:c2bb661d-d98c-47dd-a161-aab68944b5d2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:66563540 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:9eaad459-b546-4c5d-9e46-69a6dce521bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:11829116-5b27-4abf-8a9e-3c16c93f92a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vipdomet""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Vipdomet is indicated in the treatment of adult patients aged 18 years and older with type-2 diabetes mellitus:as an adjunct to diet and exercise to improve glycaemic control in adult patients, inadequately controlled on their maximal tolerated dose of metformin alone, or those already being treated with the combination of alogliptin and metformin;in combination with pioglitazone (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled on their maximal tolerated dose of metformin and pioglitazone;in combination with insulin (i.e. triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when insulin at a stable dose and metformin alone do not provide adequate glycaemic control. uuid:d31baffd-f6d4-4507-8b68-c31edf1c14cf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2556915 biolink:treats MONDO:0100096 PMID:41385096 "[{""id"":""uuid:337370aa-01e1-4d1d-8e5f-54231baa9689"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:539aa309-5c6e-4d73-b26e-2fa38b64e686"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ronapreve""]},{""id"":""uuid:f7d6fcac-2095-4f3e-9e9e-d8b85b6b0c61"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ronapreve is indicated for:Treatment of COVID-19 in adults and adolescents aged 12 years and older weighing at least 40 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19 (see section 4.2).Prevention of COVID-19 in adults and adolescents aged 12 years and older weighing at least 40 kg (see section 4.2).The use of Ronapreve should take into account information on the activity of Ronapreve against viral variants of concern. See sections 4.4 and 5.1.|[PMDA] Drugs with new active ingredients indicated for the treatment of disease caused by SARS-CoV-2 infection (COVID-19). [Drug pertaining to Special Approval for Emergency] uuid:110fdfbb-7637-42dd-bf98-a1fc4f932c7b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:261542 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:9d331d9e-4e3c-4e52-b7e7-29b754048a2d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d193b7d5-ba73-435f-9b55-c4d14414a545"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] For the treatment of adults and children with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. Insulin lispro Sanofi is also indicated for the initial stabilisation of diabetes mellitus. uuid:d4bb4bd9-404d-4484-8bce-686c205c4123 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6437 biolink:treats HP:0011188 PMID:41385096 "[{""id"":""uuid:adc11302-cc42-43f7-ae05-99cfad609122"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:3b28d0bd-dae8-4a90-b042-c4b291cc9c1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/levetiracetam-sun""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Levetiracetam Hospira is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in adults and adolescents from 16 years of age with newly diagnosed epilepsy.Levetiracetam Hospira is indicated as adjunctive therapyin the treatment of partial onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.in the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.Levetiracetam Hospira concentrate is an alternative for patients when oral administration is temporarily not feasible. uuid:11dd7e2f-82d9-4890-9c98-e890143177ff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:149836 biolink:treats MONDO:0018602 PMID:41385096 "[{""id"":""uuid:65253442-0962-4dd2-8b70-867823a8b1f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b20c656f-b84f-46d3-8dee-49d25f7fbaeb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tigecycline-accord""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Tygecycline Accord is indicated in adults and in children from the age of eight years for the treatment of the following infections (see sections 4.4 and 5.1):Complicated skin and soft tissue infections (cSSTI), excluding diabetic foot infections (see section 4.4)Complicated intra-abdominal infections (cIAI)Tygecycline Accord should be used only in situations where other alternative antibiotics are not suitable (see sections 4.4, 4.8 and 5.1).Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:98eb8f76-2987-457d-9ba5-d1009f63f4a1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:149836 biolink:treats MONDO:0043424 PMID:41385096 "[{""id"":""uuid:eab2e738-7c95-4573-9146-fdd558696320"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:3f60ba4f-9bbd-4441-b247-5a4e89844748"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tigecycline-accord""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Tygecycline Accord is indicated in adults and in children from the age of eight years for the treatment of the following infections (see sections 4.4 and 5.1):Complicated skin and soft tissue infections (cSSTI), excluding diabetic foot infections (see section 4.4)Complicated intra-abdominal infections (cIAI)Tygecycline Accord should be used only in situations where other alternative antibiotics are not suitable (see sections 4.4, 4.8 and 5.1).Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:e7867747-b7e3-40b8-ac5c-5d55808fcf41 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50924 biolink:treats MONDO:0007256 PMID:41385096 "[{""id"":""uuid:7aa7b4c0-a790-4bb4-9940-d87f3da20d0c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:065073b5-bb92-47de-ae4b-c9bb44616e96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/nexavar""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Hepatocellular carcinomaNexavar is indicated for the treatment of hepatocellular carcinoma.Renal cell carcinomaNexavar is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.Differentiated thyroid carcinomaNexavar is indicated for the treatment of patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma, refractory to radioactive iodine. uuid:a61ad7ec-d895-45b1-adf7-339e092a8453 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50924 biolink:treats MONDO:0005086 PMID:41385096 "[{""id"":""uuid:4fd35756-8ade-4e57-8c44-705388a45458"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b0de27c0-b310-4c42-a114-8c9177c19375"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/nexavar""]},{""id"":""uuid:ab84a31a-1df1-4db1-920d-7f6634ea72c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Hepatocellular carcinomaNexavar is indicated for the treatment of hepatocellular carcinoma.Renal cell carcinomaNexavar is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.Differentiated thyroid carcinomaNexavar is indicated for the treatment of patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma, refractory to radioactive iodine.|[PMDA] A drug containing a new active ingredient indicated for the treatment of unresectable or metastatic renal cell carcinoma. [Priority review] uuid:6cfcc763-08c4-4b64-b7d0-5026870e0e99 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:G9WJT6RD29 biolink:treats MONDO:0010619 PMID:41385096 "[{""id"":""uuid:7ca0ccce-b65c-4a01-95c2-353836ecd69d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:18707bef-8573-4ea3-863d-de9f151ddc82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/crysvita""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Crysvita is indicated for the treatment of X-linked hypophosphataemia, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults.Crysvita is indicated for the treatment of FGF23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults. uuid:9ed67c17-069c-4e8b-aff9-86401d5dff1b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2670556 biolink:treats MONDO:0021108 PMID:41385096 "[{""id"":""uuid:77c15b45-9559-420a-b833-7cab77ac47fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f5e885b8-865a-4c0d-a229-c95654df5b98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/menveo""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] VialsMenveo is indicated for active immunisation of children (from two years of age), adolescents and adults at risk of exposure to Neisseria meningitidis groups A, C, W135 and Y, to prevent invasive disease.The use of this vaccine should be in accordance with official recommendations. uuid:470103da-6f28-4fe0-af5f-7b69639a93c7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:30830 biolink:treats MONDO:0016158 PMID:41385096 "[{""id"":""uuid:19ab3f3c-67ad-40bb-911e-eb2b388d6d57"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a2c3cb50-8283-4102-86ea-20a8c83c5643"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/xyrem""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of narcolepsy with cataplexy in adult patients. uuid:c7021174-81f0-49fa-93ae-018c28a9c99b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:BI009E452R biolink:treats MONDO:0002243 PMID:41385096 "[{""id"":""uuid:57fcd19c-abfd-4ad0-8e28-a7544f3c07c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:dd27cf02-35e2-4563-81bd-60af3909dec8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ondexxya""]},{""id"":""uuid:4dde5381-b126-498e-b8b6-1b0baee578d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] For adult patients treated with a direct factor Xa (FXa) inhibitor (apixaban or rivaroxaban) when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.|[PMDA] A drug with a new active ingredient indicated for the reversal of anticoagulant effect in life- threatening or uncontrolled bleeding in patients treated with a direct-acting factor Xa inhibitor (apixaban, rivaroxaban, or edoxaban tosilate hydrate). [Orphan drug] uuid:5adbfb2a-0b9a-4a1e-bcbb-c2a9ecc1136d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63717 biolink:treats MONDO:0005344 PMID:41385096 "[{""id"":""uuid:87cc4524-c00b-42ea-a09e-a579e7c326b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a2bdb491-1cca-4e8a-9358-1229254778d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] HIV‑1 infectionTenofovir disoproxil Zentiva is indicated in combination with other antiretroviral medicinal products for the treatment of HIV‑1 infected adults.In adults, the demonstration of the benefit of tenofovir disoproxil in HIV‑1 infection is based on results of one study in treatment‑naïve patients, including patients with a high viral load (> 100,000 copies/ml) and studies in which tenofovir disoproxil was added to stable background therapy (mainly tritherapy) in antiretroviral pre‑treated patients experiencing early virological failure (< 10,000 copies/ml, with the majority of patients having < 5,000 copies/ml).Tenofovir disoproxil Zentiva is also indicated for the treatment of HIV‑1 infected adolescents, with NRTI (nucleotide reverse transcriptase inhibitor) resistance or toxicities precluding the use of first line agents, aged 12 to < 18 years.The choice of Tenofovir disoproxil Zentiva to treat antiretroviral‑experienced patients with HIV‑1 infection should be based on individual viral resistance testing and/or treatment history of patients.Hepatitis B infectionTenofovir disoproxil Zentiva is indicated for the treatment of chronic hepatitis B in adults with:compensated liver disease, with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis (see section 5.1);evidence of lamivudine-resistant hepatitis B virus (see sections 4.8 and 5.1);decompensated liver disease (see sections 4.4, 4.8 and 5.1).Tenofovir disoproxil Zentiva is indicated for the treatment of chronic hepatitis B in adolescents 12 to < 18 years of age with:compensated liver disease and evidence of immune active disease, i.e. active viral replication, persistently elevated serum ALT levels and histological evidence of active inflammation and/or fibrosis (see sections 4.4, 4.8 and 5.1). uuid:c69e29df-80a3-46c7-93c1-305122840dbd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:69478 biolink:treats MONDO:0016532 PMID:41385096 "[{""id"":""uuid:5aa6742c-72c7-45b1-9d6e-ed8430b17410"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0102bf89-f773-45cb-95ec-815211c33677"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/epidyolex""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Epidyolex is indicated for use as adjunctive therapy of seizures associated with Lennox Gastaut syndrome (LGS) or Dravet syndrome (DS), in conjunction with clobazam, for patients 2 years of age and older. uuid:db19d214-dccc-486c-834b-61f06e82ddad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90227 biolink:treats MONDO:0018975 PMID:41385096 "[{""id"":""uuid:6b87a0f0-70e0-4eb7-a251-ee1fa6a83f4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d35f84b2-036b-4593-b409-7a67dad18822"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:92856cda-9fdb-4a79-b105-385b3cdacf9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Koselugo as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in paediatric patients with neurofibromatosis type 1 (NF1) aged 3 years and above|[PMDA] Drugs with a new active ingredient indicated for the treatment of plexiform neurofibroma in patients with neurofibromatosis type 1. [Orphan drug] DOID:0111253 uuid:1d480b0f-4f13-4b80-9d26-05435d12c7e2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64733 biolink:treats MONDO:0015827 PMID:41385096 "[{""id"":""uuid:7f9b3499-4a07-4bcf-9265-51e1d3f721a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:48f08249-1cf7-4c54-a2df-897274cd848e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/sibnayal""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Sibnayal is indicated for the treatment of distal renal tubular acidosis (dRTA) in adults, adolescents and children aged one year and older. uuid:10cd5a54-fe35-44b7-9ad3-233c8ac30d48 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:513P80B4YJ biolink:treats MONDO:0011719 PMID:41385096 "[{""id"":""uuid:3eabff5c-3fd1-45ae-a929-135230abd843"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:99853f1b-cb33-4789-9a4a-0f1e5b83f9c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ayvakyt""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ayvakyt is indicated as monotherapy for the treatment of adult patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) harbouring the platelet-derived growth factor receptor alpha (PDGFRA) D842V mutation. uuid:4bf22ed4-9761-4311-9cf7-54b8bfbbe904 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:P85X70RZWS biolink:treats HP:0007359 PMID:41385096 "[{""id"":""uuid:8fb82e23-4f25-43e9-b497-ba29e7ebbd2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f0978608-b719-4a94-a4b6-23e1f5f3115a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ontozry""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Adjunctive treatment of focal-onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least 2 anti-epileptic medicinal products. uuid:ee4b8e10-c20e-4955-bed7-c42ddb126513 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:P85X70RZWS biolink:treats MONDO:0005027 PMID:41385096 "[{""id"":""uuid:fa0a7829-20af-4605-9062-96883ab7e0ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ee6770a7-0c81-4c90-961d-661667f47361"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ontozry""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Adjunctive treatment of focal-onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least 2 anti-epileptic medicinal products. uuid:d1fd79ec-68d0-46e9-96c7-f7977e5a376a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50659 biolink:treats MONDO:0005252 PMID:41385096 "[{""id"":""uuid:cc0bf604-7176-44e3-92e8-4f100828172e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a0f10b3b-5fca-4f3c-870d-afa3355323b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/multaq-0""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Multaq is indicated for the maintenance of sinus rhythm after successful cardioversion in adult clinically stable patients with paroxysmal or persistent atrial fibrillation (AF). Due to its safety profile, Multaq should only be prescribed after alternative treatment options have been considered.Multaq should not be given to patients with left ventricular systolic dysfunction or to patients with current or previous episodes of heart failure. uuid:f7acc0bb-5251-40f2-9dbf-48dfa3081808 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:08GY9K1EUO biolink:treats MONDO:0002492 PMID:41385096 "[{""id"":""uuid:8f1ec5eb-12a1-42fa-a672-f841aa734948"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9710a5bc-f2cf-4996-a043-5f160851ad64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/fasturtec""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment and prophylaxis of acute hyperuricaemia, in order to prevent acute renal failure, in adults, children and adolescents (aged 0 to 17 years) with haematological malignancy with a high tumour burden and at risk of a rapid tumour lysis or shrinkage at initiation of chemotherapy. uuid:319f3715-6867-43bd-ba3e-147f01dd9e79 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:55346 biolink:treats MONDO:0044067 PMID:41385096 "[{""id"":""uuid:8a7e364c-8219-44ee-a0bc-47083cdd5f36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c2f47b28-cdf1-4141-a580-fefac9d509f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ecalta""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of invasive candidiasis in adults and paediatric patients aged 1 month to < 18 years. uuid:f534b2f1-de8d-4693-8f2e-50eb1837dd1f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:BDT58WJ9WE biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:05b75d90-bb86-498d-902d-42a08cc551d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b1d9b9f3-0253-4536-b2db-b8b1b6eda5e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Sunlenca injection, in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant HIV 1 infection for whom it is otherwise not possible to construct a suppressive anti viral regimen (see sections 4.2 and 5.1).Sunlenca tablet, in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant HIV 1 infection for whom it is otherwise not possible to construct a suppressive anti viral regimen, for oral loading prior to administration of long-acting lenacapavir injection (see sections 4.2 and 5.1). uuid:7f7b9b9f-b440-48b5-b7e8-8f07fb819a05 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2109612 biolink:treats MONDO:0005504 PMID:41385096 "[{""id"":""uuid:b9aab2d6-d56d-435b-be23-237202744435"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4e8849b2-6f32-45da-852b-9a7eb559ef33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Hexyon (DTaP-IPV-HB-Hib) is indicated for primary and booster vaccination of infants and toddlers from six weeks of age against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive diseases caused by Haemophilus influenzae type b (Hib).The use of this vaccine should be in accordance with official recommendations. uuid:dc2bd8ab-5930-4eff-83d2-9691741d7c64 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2109612 biolink:treats MONDO:0005526 PMID:41385096 "[{""id"":""uuid:7a7b7ef0-74ea-48ae-b8ce-4cc5d77ea271"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b525eb09-8dfd-4847-9a8e-b5c5d536f67d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Hexyon (DTaP-IPV-HB-Hib) is indicated for primary and booster vaccination of infants and toddlers from six weeks of age against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive diseases caused by Haemophilus influenzae type b (Hib).The use of this vaccine should be in accordance with official recommendations. uuid:1e8c23d5-acdf-45cb-a139-de7b9da7fb0f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2109612 biolink:treats MONDO:0005077 PMID:41385096 "[{""id"":""uuid:c0ca4a06-ed1e-4f0b-8dbb-594ec2ff4372"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e083744a-286c-4180-a0e1-7040272b815d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Hexyon (DTaP-IPV-HB-Hib) is indicated for primary and booster vaccination of infants and toddlers from six weeks of age against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive diseases caused by Haemophilus influenzae type b (Hib).The use of this vaccine should be in accordance with official recommendations. uuid:f947dd9d-7e09-4cd6-bc60-2158cf778c51 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2109612 biolink:treats MONDO:0005344 PMID:41385096 "[{""id"":""uuid:44d225e9-695c-406e-aeb8-43aed4a6cac5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e7ab9565-c1ef-4a5e-b4ef-bf88fc603bbc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Hexyon (DTaP-IPV-HB-Hib) is indicated for primary and booster vaccination of infants and toddlers from six weeks of age against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive diseases caused by Haemophilus influenzae type b (Hib).The use of this vaccine should be in accordance with official recommendations. uuid:32d2b360-5ee5-4bdc-bf71-38f6980de08f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2109612 biolink:treats MONDO:0017373 PMID:41385096 "[{""id"":""uuid:8deb48a6-971b-4cd1-870d-af07a39bc094"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d58c1936-a6d7-4fe9-8040-27218dfd2d39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Hexyon (DTaP-IPV-HB-Hib) is indicated for primary and booster vaccination of infants and toddlers from six weeks of age against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive diseases caused by Haemophilus influenzae type b (Hib).The use of this vaccine should be in accordance with official recommendations. uuid:a5ec36f0-ae9c-4329-8fb7-8d877d0aaae2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2109612 biolink:treats MONDO:0006926 PMID:41385096 "[{""id"":""uuid:d1a0361f-28a5-4610-954c-a3adc32e3fd8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:21226d26-723d-4be1-8aea-09ef1cecc42b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Hexyon (DTaP-IPV-HB-Hib) is indicated for primary and booster vaccination of infants and toddlers from six weeks of age against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive diseases caused by Haemophilus influenzae type b (Hib).The use of this vaccine should be in accordance with official recommendations. uuid:decb0689-4157-492f-9012-a8c780e27893 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82701 biolink:treats MONDO:0018906 PMID:41385096 "[{""id"":""uuid:7bf2c2fa-a51d-4f9f-9948-f6aa32535166"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:7cc9b31f-f12e-42d5-a371-b0578ee28033"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zydelig""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Zydelig is indicated in combination with an anti‑CD20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (CLL):who have received at least one prior therapy, oras first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies.Zydelig is indicated as monotherapy for the treatment of adult patients with follicular lymphoma (FL) that is refractory to two prior lines of treatment. uuid:44327f54-8be2-4565-b662-7f7064932170 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72296 biolink:treats MONDO:0004634 PMID:41385096 "[{""id"":""uuid:91ba0f77-3709-49fe-a804-dc3e135aba56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:062a2b85-1b7b-4f62-8de6-449b304cfd15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/eliquis""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] For Eliquis 2.5 mg film-coated tablets:Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery.Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II).Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients).For Eliquis 5 mg film-coated tablets:Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II).Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients). uuid:f84425da-b759-47f5-a95c-bcdd3b0d6880 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:07896928ZC biolink:treats MONDO:0043424 PMID:41385096 "[{""id"":""uuid:248d76b2-ae44-442f-bd3a-0c33936d549b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d419862e-9f06-4068-9086-08efe7dde10f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/xerava""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Xerava is indicated for the treatment of complicated intra-abdominal infections (cIAI) in adults.Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:1b21ddd2-faa9-4d07-afa8-2a8a96f00abd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:61390 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:eb7da916-f996-4110-ae45-379018098b40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9b6c5c84-b856-42ac-bd30-607f2b26b15c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/giotrif""]},{""id"":""uuid:8e454611-0900-4f8f-8c72-80caaa71e686"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Giotrif as monotherapy is indicated for the treatment ofEpidermal Growth Factor Receptor (EGFR) TKI-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s);locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy.|[PMDA] Drugs with a new active ingredient indicated for the treatment of unresectable advanced or recurrent non-small cell lung cancer with EGFR gene mutation. uuid:cae97b21-edd6-4ddc-ad63-802a5035f363 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:61390 biolink:treats MONDO:0005097 PMID:41385096 "[{""id"":""uuid:7234b585-abad-46ab-8648-16711b3bf66d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:738095a4-b34e-48ba-80c2-8e623a2f5190"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/giotrif""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Giotrif as monotherapy is indicated for the treatment ofEpidermal Growth Factor Receptor (EGFR) TKI-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s);locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy. uuid:8ff9b843-16f5-4c53-9fce-facfe5da5f55 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64355 biolink:treats MONDO:0018874 PMID:41385096 "[{""id"":""uuid:b560d58d-8e79-4ccd-a5c2-8db717530009"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9b82e692-7d0c-4217-9c50-7c10f1115013"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/posaconazole-ahcl""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Noxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in adults (see sections 4.2 and 5.1):- Invasive aspergillosisNoxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections 4.2 and 5.1):- Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;- Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;- Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Noxafil gastro-resistant tablets are also indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections 4.2 and 5.1):- Patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.Please refer to the Summary of Product Characteristics of Noxafil oral suspension for use in oropharyngeal candidiasis. Noxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adults (see sections 4.2 and 5.1):- Invasive aspergillosisNoxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adult and paediatric patients from 2 years of age (see sections 4.2 and 5.1):- Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;- Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;- Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Noxafil concentrate for solution for infusion is also indicated for prophylaxis of invasive fungal infections in the following adult and paediatric patients from 2 years of age (see sections 4.2 and 5.1):- Patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease (GVHD) and who are at high risk of developing invasive fungal infections.Please refer to the Summary of Product Characteristics of Noxafil oral suspension for use in oropharyngeal candidiasis. Noxafil gastro resistant powder and solvent for oral suspension is indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age (see sections 4.2 and 5.1):- Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;- Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;- Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Noxafil gastro-resistant powder and solvent for oral suspension is indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2 years of age:- Patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- Haematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.Please refer to the Summary of Product Characteristics of Noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis.Please refer to the Summary of Product Characteristics of Noxafil oral suspension for use in oropharyngeal candidiasis. Noxafil oral suspension is indicated for use in the treatment of the following fungal infections in adults (see section 5.1):- Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;- Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;- Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products;- Oropharyngeal candidiasis: as first-line therapy in patients who have severe disease or are immunocompromised, in whom response to topical therapy is expected to be poor.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Noxafil oral suspension is also indicated for prophylaxis of invasive fungal infections in the following patients:- Patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.Please refer to the Summary of Product Characteristics of Noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis. uuid:91cae856-3ce1-42af-86f6-ca1268e96fc9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64355 biolink:treats MONDO:0018881 PMID:41385096 "[{""id"":""uuid:dd645f6c-f491-46a3-9472-085a6c9d2b89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:3151093c-c3fd-424a-9bd6-4666898f036a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/posaconazole-ahcl""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Noxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in adults (see sections 4.2 and 5.1):- Invasive aspergillosisNoxafil gastro-resistant tablets are indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections 4.2 and 5.1):- Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;- Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;- Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Noxafil gastro-resistant tablets are also indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2 years of age weighing more than 40 kg and adults (see sections 4.2 and 5.1):- Patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.Please refer to the Summary of Product Characteristics of Noxafil oral suspension for use in oropharyngeal candidiasis. Noxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adults (see sections 4.2 and 5.1):- Invasive aspergillosisNoxafil concentrate for solution for infusion is indicated for use in the treatment of the following fungal infections in adult and paediatric patients from 2 years of age (see sections 4.2 and 5.1):- Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;- Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;- Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Noxafil concentrate for solution for infusion is also indicated for prophylaxis of invasive fungal infections in the following adult and paediatric patients from 2 years of age (see sections 4.2 and 5.1):- Patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease (GVHD) and who are at high risk of developing invasive fungal infections.Please refer to the Summary of Product Characteristics of Noxafil oral suspension for use in oropharyngeal candidiasis. Noxafil gastro resistant powder and solvent for oral suspension is indicated for use in the treatment of the following fungal infections in paediatric patients from 2 years of age (see sections 4.2 and 5.1):- Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;- Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;- Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Noxafil gastro-resistant powder and solvent for oral suspension is indicated for prophylaxis of invasive fungal infections in the following paediatric patients from 2 years of age:- Patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- Haematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.Please refer to the Summary of Product Characteristics of Noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis.Please refer to the Summary of Product Characteristics of Noxafil oral suspension for use in oropharyngeal candidiasis. Noxafil oral suspension is indicated for use in the treatment of the following fungal infections in adults (see section 5.1):- Invasive aspergillosis in patients with disease that is refractory to amphotericin B or itraconazole or in patients who are intolerant of these medicinal products;- Fusariosis in patients with disease that is refractory to amphotericin B or in patients who are intolerant of amphotericin B;- Chromoblastomycosis and mycetoma in patients with disease that is refractory to itraconazole or in patients who are intolerant of itraconazole;- Coccidioidomycosis in patients with disease that is refractory to amphotericin B, itraconazole or fluconazole or in patients who are intolerant of these medicinal products;- Oropharyngeal candidiasis: as first-line therapy in patients who have severe disease or are immunocompromised, in whom response to topical therapy is expected to be poor.Refractoriness is defined as progression of infection or failure to improve after a minimum of 7 days of prior therapeutic doses of effective antifungal therapy.Noxafil oral suspension is also indicated for prophylaxis of invasive fungal infections in the following patients:- Patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (AML) or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are at high risk of developing invasive fungal infections;- Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high-dose immunosuppressive therapy for graft versus host disease and who are at high risk of developing invasive fungal infections.Please refer to the Summary of Product Characteristics of Noxafil concentrate for solution for infusion and the gastro-resistant tablets for use in primary treatment of invasive aspergillosis. uuid:713794c3-7441-4219-9365-4d11c4feb4d4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72564 biolink:treats MONDO:0100342 PMID:41385096 "[{""id"":""uuid:58dd8696-a003-4827-8dc0-dcbd09207b3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:022a0dfa-7a92-40f6-a96c-2442665c9e37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/temozolomide-accord""]},{""id"":""uuid:bec3ca0d-96c4-4e1f-845d-22b364bf150a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Temodal hard capsules is indicated for the treatment of:adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and subsequently as monotherapy treatment;children from the age of three years, adolescents and adult patients with malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.|[PMDA] A drug with a new route of administration indicated for the treatment of malignant glioma. uuid:f986c787-7829-4ccf-a80c-e55feb901c6a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:1H09Y5WO1F biolink:treats MONDO:0005132 PMID:41385096 "[{""id"":""uuid:c050dde4-22c2-48af-abd3-25a8d0578a47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:59801d90-f437-4dcb-a1c5-da2f557fba8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/prevymis""]},{""id"":""uuid:bd406d91-d216-4ad4-957e-a5c25ffe24c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Prevymis is indicated for prophylaxis of cytomegalovirus (CMV) reactivation and disease in adult CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transplant (HSCT).Consideration should be given to official guidance on the appropriate use of antiviral agents.|[PMDA] Drugs with a new active ingredient indicated for the prophylaxis of cytomegalovirus disease in allogeneic hematopoietic stem cell transplant recipients. [Orphan drug] uuid:0849605d-4fd1-43c1-997c-041b58691176 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:ZL1R02VT79 biolink:treats MONDO:0005150 PMID:41385096 "[{""id"":""uuid:8b7483e8-1284-4751-bb9a-17e2425c6f5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2a3e2fa0-4a14-48a3-961f-ff52ea3f05ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ranivisio""]},{""id"":""uuid:ae47f3b1-6f8c-4606-998c-1fa474e0a541"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ximluci is indicated in adults for:The treatment of neovascular (wet) age-related macular degeneration (AMD)The treatment of visual impairment due to diabetic macular oedema (DME)The treatment of proliferative diabetic retinopathy (PDR)The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)The treatment of visual impairment due to choroidal neovascularisation (CNV)|[PMDA] Follow-on biologics indicated for the treatment of age-related macular degeneration associated with subfoveal choroidal neovascularization or choroidal neovascularization in patients with pathologic myopia. uuid:f75a47cf-ff5e-4c14-ab97-c2291fbc82c1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:ZL1R02VT79 biolink:treats MONDO:0006951 PMID:41385096 "[{""id"":""uuid:efe9ca42-a960-4181-8e84-149c8878dbb7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ddec0be6-2bbf-4183-b53d-126f5df4a26c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ranivisio""]},{""id"":""uuid:8f2fc4ef-db26-4e3a-aeb2-2e616eb27e04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ximluci is indicated in adults for:The treatment of neovascular (wet) age-related macular degeneration (AMD)The treatment of visual impairment due to diabetic macular oedema (DME)The treatment of proliferative diabetic retinopathy (PDR)The treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch RVO or central RVO)The treatment of visual impairment due to choroidal neovascularisation (CNV)|[PMDA] A drug with new additional indications and a new dosage for the treatment of macular edema following retinal vein occlusion and choroidal neovascularisasion in pathologic myopia. uuid:9c0b4088-3bf1-45e3-ab47-d89a760cb9b7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90972 biolink:treats HP:0002307 PMID:41385096 "[{""id"":""uuid:26ab1f82-c1ae-429f-bd67-da276b8e5922"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e3dac2a9-ec18-41a2-bfc0-bf4fbe7fc058"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders. uuid:d84baa0b-21c6-444b-9556-14c3e046fea4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90972 biolink:treats MONDO:0005071 PMID:41385096 "[{""id"":""uuid:8640168c-fc93-42ff-9e0a-e2c1edac81d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ecac106b-caab-4184-a23b-68161ff738c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders. uuid:16dbefcb-bbf8-45fd-9f1f-0a2e92d7b81d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:61397 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:cb0b90ce-aafa-47e3-b6f7-9d677480440d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:51ec7a41-ffb6-4ce0-9e1e-0ab89844ae0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/nerlynx""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Nerlynx is indicated for the extended adjuvant treatment of adult patients with early stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who are less than one year from the completion of prior adjuvant trastuzumab based therapy. uuid:5e053069-b63b-4bc8-94ce-563392bec033 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB00028 biolink:treats MONDO:0006702 PMID:41385096 "[{""id"":""uuid:4ef8b338-1179-48e0-8e48-7fa211cf3b66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:781a4d03-efe9-4982-8dae-5b2fc8fe7db6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/privigen""]},{""id"":""uuid:0c293cb4-1bbd-4afd-813d-ee384d3c19b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Replacement therapy in adults, and children and adolescents (0-18 years) in:primary immunodeficiency (PID) syndromes with impaired antibody production;hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic leukaemia, in whom prophylactic antibiotics have failed;hypogammaglobulinaemia and recurrent bacterial infections in plateau-phase-multiple-myeloma patients who have failed to respond to pneumococcal immunisation;hypogammaglobulinaemia in patients after allogeneic haematopoietic-stem-cell transplantation (HSCT);congenital AIDS with recurrent bacterial infections.Immunomodulation in adults, and children and adolescents (0-18 years) in:primary immune thrombocytopenia (ITP), in patients at high risk of bleeding or prior to surgery to correct the platelet count;Guillain-Barré syndrome;Kawasaki disease;chronic inflammatory demyelinating polyneuropathy (CIDP). Only limited experience is available of use of intravenous immunoglobulins in children with CIDP.|[PMDA] Drugs with a new active ingredient indicated for the improvement of muscle weakness in chronic inflammatory demyelinating polyneuropathy and for inhibiting progression of motor disability due to chronic inflammatory demyelinating polyneuropathy (in the cases where patients show an improvement in their acute phase treatment). uuid:3409b95c-da9c-477e-8e80-fe702903e95c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3759 biolink:treats MONDO:0005542 PMID:41385096 "[{""id"":""uuid:9b0c3f10-0877-4344-b4a7-551edec0063f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a480f8d0-77ec-46ea-8431-983f79192f57"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Prevention of atherothrombotic eventsClopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from seven days until less than six months) or established peripheral arterial disease;adult patients suffering from acute coronary syndrome:non-ST-segment-elevation acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA);ST-segment-elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapy.Prevention of atherothrombotic and thromboembolic events in atrial fibrillationIn adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin-K antagonists and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke. uuid:8cf0f4e0-23a1-4457-9230-5babddc1ee96 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1940699 biolink:treats MONDO:0005354 PMID:41385096 "[{""id"":""uuid:1519a375-a893-4c71-bb57-755a09f05b68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a6105ff9-bc0d-451f-b6b5-61c2b2784756"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/maviret""]},{""id"":""uuid:24e50ab2-7cf5-4e9f-9c07-0a4f599e2180"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Maviret is indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults and children aged 3 years and older.Maviret coated granules is indicated for the treatment of chronic hepatitis C virus (HCV) infection in children 3 years and older.|[PMDA] A new combination drug with a new active ingredient indicated for the improvement of viremia in patients with chronic hepatitis C or compensated cirrhosis type C. [Priority review] uuid:62c7f482-0247-41d9-8dcc-336fbc43550d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:132774 biolink:treats MONDO:0002280 PMID:41385096 "[{""id"":""uuid:faba92f7-7880-4122-9b0d-8ec429a5818c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d138f491-062c-4ea9-acf8-33099470f751"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/evrenzo""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Evrenzo is indicated for treatment of adult patients with symptomatic anaemia associated with chronic kidney disease (CKD). uuid:4dd6052a-e936-4fb4-a24e-f27c8a6092de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:132774 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:24158785-43bb-40f6-ba1a-4ce2f31335c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:dee5fe0c-23ca-41e4-94ea-1320090941e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/evrenzo""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Evrenzo is indicated for treatment of adult patients with symptomatic anaemia associated with chronic kidney disease (CKD). uuid:2baf053d-d416-4d27-9aa2-decf3333b0d8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10127 biolink:treats HP:0011188 PMID:41385096 "[{""id"":""uuid:2d3649d0-5264-4d31-853e-6779f5d56e19"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:3d5fcdec-5af4-4c09-ab06-87ba374c6a13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zonisamide-mylan""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Monotherapy in the treatment of partial seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy;adjunctive therapy in the treatment of partial seizures, with or without secondary generalisation, in adults, adolescents, and children aged 6 years and above. uuid:ef5edf93-a1a6-466a-aae1-bebcea6098b7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1243017 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:389d44bf-f060-4ef0-a293-83f6b941ae92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:72b8d546-8025-4341-ba64-aad1e3e9846e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/jentadueto""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of adult patients with type-2 diabetes mellitus:Jentadueto is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients inadequately controlled on their maximal tolerated dose of metformin alone, or those already being treated with the combination of linagliptin and metformin.Jentadueto is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled on their maximal tolerated dose of metformin and a sulphonylurea. uuid:a750cbfb-217b-4d13-83d8-6e0f065e72c2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:30496 biolink:treats MONDO:0004995 PMID:41385096 "[{""id"":""uuid:96c3570c-d6ba-4ba5-8ef5-ffcd4c2dcb27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:220e4d0b-21dc-4c48-92ef-11650e924713"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/sonovue""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] This medicinal product is for diagnostic use only.SonoVue is for use with ultrasound imaging to enhance the echogenicity of the blood, or of fluids in the urinary tract which results in an improved signal to noise ratio.SonoVue should only be used in patients where study without contrast enhancement is inconclusive.EchocardiographySonoVue is a transpulmonary echocardiographic contrast agent for use in adult patients with suspected or established cardiovascular disease to provide opacification of cardiac chambers and enhance left ventricular endocardial border delineation.Doppler of macrovasculatureSonoVue increases the accuracy in detection or exclusion of abnormalities in cerebral arteries and extracranial carotid or peripheral arteries in adult patients by improving the Doppler signal to noise ratio.SonoVue increases the quality of the Doppler flow image and the duration of clinically useful signal enhancement in portal vein assessment in adult patients.Doppler of microvasculatureSonoVue improves display of the vascularity of liver and breast lesions during Doppler sonography in adult patients leading to more specific lesion characterisation.Ultrasonography of excretory urinary tractSonoVue is indicated for use in ultrasonography of the excretory tract in paediatric patients from newborn to 18 years to detect vesicoureteral reflux. For the limitation in the interpretation of a negative urosonography. uuid:55fa1702-1b1b-414e-8003-d8297c500fc4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:30496 biolink:treats MONDO:0005269 PMID:41385096 "[{""id"":""uuid:8f9f8119-0938-458d-b3f1-b4f69ba6fe1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ec683b42-d752-4f78-a5eb-835e4273e6be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/sonovue""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] This medicinal product is for diagnostic use only.SonoVue is for use with ultrasound imaging to enhance the echogenicity of the blood, or of fluids in the urinary tract which results in an improved signal to noise ratio.SonoVue should only be used in patients where study without contrast enhancement is inconclusive.EchocardiographySonoVue is a transpulmonary echocardiographic contrast agent for use in adult patients with suspected or established cardiovascular disease to provide opacification of cardiac chambers and enhance left ventricular endocardial border delineation.Doppler of macrovasculatureSonoVue increases the accuracy in detection or exclusion of abnormalities in cerebral arteries and extracranial carotid or peripheral arteries in adult patients by improving the Doppler signal to noise ratio.SonoVue increases the quality of the Doppler flow image and the duration of clinically useful signal enhancement in portal vein assessment in adult patients.Doppler of microvasculatureSonoVue improves display of the vascularity of liver and breast lesions during Doppler sonography in adult patients leading to more specific lesion characterisation.Ultrasonography of excretory urinary tractSonoVue is indicated for use in ultrasonography of the excretory tract in paediatric patients from newborn to 18 years to detect vesicoureteral reflux. For the limitation in the interpretation of a negative urosonography. uuid:7e582c5a-a9bc-47d7-8b70-dc6cd9b64969 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:30496 biolink:treats MONDO:0005386 PMID:41385096 "[{""id"":""uuid:98a72d6a-202a-472f-b489-130d3ff33354"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b3f210cc-db96-43c2-b8f3-7cc5366073f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/sonovue""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] This medicinal product is for diagnostic use only.SonoVue is for use with ultrasound imaging to enhance the echogenicity of the blood, or of fluids in the urinary tract which results in an improved signal to noise ratio.SonoVue should only be used in patients where study without contrast enhancement is inconclusive.EchocardiographySonoVue is a transpulmonary echocardiographic contrast agent for use in adult patients with suspected or established cardiovascular disease to provide opacification of cardiac chambers and enhance left ventricular endocardial border delineation.Doppler of macrovasculatureSonoVue increases the accuracy in detection or exclusion of abnormalities in cerebral arteries and extracranial carotid or peripheral arteries in adult patients by improving the Doppler signal to noise ratio.SonoVue increases the quality of the Doppler flow image and the duration of clinically useful signal enhancement in portal vein assessment in adult patients.Doppler of microvasculatureSonoVue improves display of the vascularity of liver and breast lesions during Doppler sonography in adult patients leading to more specific lesion characterisation.Ultrasonography of excretory urinary tractSonoVue is indicated for use in ultrasonography of the excretory tract in paediatric patients from newborn to 18 years to detect vesicoureteral reflux. For the limitation in the interpretation of a negative urosonography. uuid:b2030f4e-bc0e-4079-b132-a20dd5374df3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:30496 biolink:treats MONDO:0043693 PMID:41385096 "[{""id"":""uuid:dc0fdb6f-8993-484a-9bbe-0c4e26b21304"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a8037451-f364-446f-be83-746057ac2ea6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/sonovue""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] This medicinal product is for diagnostic use only.SonoVue is for use with ultrasound imaging to enhance the echogenicity of the blood, or of fluids in the urinary tract which results in an improved signal to noise ratio.SonoVue should only be used in patients where study without contrast enhancement is inconclusive.EchocardiographySonoVue is a transpulmonary echocardiographic contrast agent for use in adult patients with suspected or established cardiovascular disease to provide opacification of cardiac chambers and enhance left ventricular endocardial border delineation.Doppler of macrovasculatureSonoVue increases the accuracy in detection or exclusion of abnormalities in cerebral arteries and extracranial carotid or peripheral arteries in adult patients by improving the Doppler signal to noise ratio.SonoVue increases the quality of the Doppler flow image and the duration of clinically useful signal enhancement in portal vein assessment in adult patients.Doppler of microvasculatureSonoVue improves display of the vascularity of liver and breast lesions during Doppler sonography in adult patients leading to more specific lesion characterisation.Ultrasonography of excretory urinary tractSonoVue is indicated for use in ultrasonography of the excretory tract in paediatric patients from newborn to 18 years to detect vesicoureteral reflux. For the limitation in the interpretation of a negative urosonography. uuid:a0d93af5-de1a-41d9-b64b-1ad6cbbc3041 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:30496 biolink:treats NCIT:C159594 PMID:41385096 "[{""id"":""uuid:ef440c38-28de-4aef-a351-14e05d7bd17b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a35368c1-7504-4222-a6aa-fe9ced24debf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/sonovue""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] This medicinal product is for diagnostic use only.SonoVue is for use with ultrasound imaging to enhance the echogenicity of the blood, or of fluids in the urinary tract which results in an improved signal to noise ratio.SonoVue should only be used in patients where study without contrast enhancement is inconclusive.EchocardiographySonoVue is a transpulmonary echocardiographic contrast agent for use in adult patients with suspected or established cardiovascular disease to provide opacification of cardiac chambers and enhance left ventricular endocardial border delineation.Doppler of macrovasculatureSonoVue increases the accuracy in detection or exclusion of abnormalities in cerebral arteries and extracranial carotid or peripheral arteries in adult patients by improving the Doppler signal to noise ratio.SonoVue increases the quality of the Doppler flow image and the duration of clinically useful signal enhancement in portal vein assessment in adult patients.Doppler of microvasculatureSonoVue improves display of the vascularity of liver and breast lesions during Doppler sonography in adult patients leading to more specific lesion characterisation.Ultrasonography of excretory urinary tractSonoVue is indicated for use in ultrasonography of the excretory tract in paediatric patients from newborn to 18 years to detect vesicoureteral reflux. For the limitation in the interpretation of a negative urosonography. uuid:0f6fa489-e093-41e2-a56a-882781e7b552 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:30496 biolink:treats MONDO:0006007 PMID:41385096 "[{""id"":""uuid:868eb53e-3e3e-41bd-ae35-e52f78ffe2cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:8a7747ca-92bc-42d1-9e73-8db22a0c0adf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/sonovue""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] This medicinal product is for diagnostic use only.SonoVue is for use with ultrasound imaging to enhance the echogenicity of the blood, or of fluids in the urinary tract which results in an improved signal to noise ratio.SonoVue should only be used in patients where study without contrast enhancement is inconclusive.EchocardiographySonoVue is a transpulmonary echocardiographic contrast agent for use in adult patients with suspected or established cardiovascular disease to provide opacification of cardiac chambers and enhance left ventricular endocardial border delineation.Doppler of macrovasculatureSonoVue increases the accuracy in detection or exclusion of abnormalities in cerebral arteries and extracranial carotid or peripheral arteries in adult patients by improving the Doppler signal to noise ratio.SonoVue increases the quality of the Doppler flow image and the duration of clinically useful signal enhancement in portal vein assessment in adult patients.Doppler of microvasculatureSonoVue improves display of the vascularity of liver and breast lesions during Doppler sonography in adult patients leading to more specific lesion characterisation.Ultrasonography of excretory urinary tractSonoVue is indicated for use in ultrasonography of the excretory tract in paediatric patients from newborn to 18 years to detect vesicoureteral reflux. For the limitation in the interpretation of a negative urosonography. uuid:9173fe72-9639-4fda-8acc-38078fbc16a5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:997WVV895X biolink:treats MONDO:0005277 PMID:41385096 "[{""id"":""uuid:e4d4305e-3218-4091-92ce-88339c7ce5fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d9c4cb03-65bd-43e8-bd5b-6d68b38a181e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vydura""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Vydura is indicated for theAcute treatment of migraine with or without aura in adults;Preventative treatment of episodic migraine in adults who have at least 4 migraine attacks per month. uuid:956ca299-99a6-4aa4-89be-ef3b1d829938 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:997WVV895X biolink:treats MONDO:0005475 PMID:41385096 "[{""id"":""uuid:c38112c9-055d-4cae-a9d6-9504cd7b9942"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:38b6ebec-61e4-461c-aec1-5b252310b17d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vydura""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Vydura is indicated for theAcute treatment of migraine with or without aura in adults;Preventative treatment of episodic migraine in adults who have at least 4 migraine attacks per month. uuid:01240236-a046-429f-97b1-373d1307d0d7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50378 biolink:treats MONDO:0010161 PMID:41385096 "[{""id"":""uuid:20085518-0968-4c77-8d90-67d047f57ad8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a452bb1a-e77f-451e-8c17-fb739abe787e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/nitisinone-mdk""]},{""id"":""uuid:1d50b085-0f6b-4a35-91cd-d7d3b488caee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of adult and paediatric patients with confirmed diagnosis of hereditary tyrosinemia type 1 (HT-1) in combination with dietary restriction of tyrosine and phenylalanine.|[PMDA] Drugs with a new active ingredient indicated for the treatment of type I hypertyrosinemia. uuid:0674de9c-adc9-4a6c-ad33-982647489f03 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:50FKX8CB2Y biolink:treats MONDO:0001824 PMID:41385096 "[{""id"":""uuid:5bef7982-fe48-4315-98cd-2c008ff83da3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:79d2a77e-167c-4612-a40b-da4d965852ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Onpattro is indicated for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy. uuid:3fe2c385-86b2-4bd0-8912-51428d87b015 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46557 biolink:treats HP:0002756 PMID:41385096 "[{""id"":""uuid:2ed3164a-49f2-4106-a8fe-a10cb7654b37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:8a7a47a2-78e2-4692-ba61-31c42c87be15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Prevention of skeletal-related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone.Treatment of adult patients with tumour-induced hypercalcaemia. uuid:7e801ee3-6339-4845-9f02-fb8d862d56bb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46557 biolink:treats HP:0002176 PMID:41385096 "[{""id"":""uuid:31f56549-9a84-47d9-883f-59e588af6e7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0758f38a-7863-4f26-9ab7-53ee2d1da2ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Prevention of skeletal-related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone.Treatment of adult patients with tumour-induced hypercalcaemia. uuid:0acd9dae-4efb-4bc3-8317-c91082630409 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:144551 biolink:treats UMLS:C0150045 PMID:41385096 "[{""id"":""uuid:aa34a2ff-3bf8-411d-9604-3d630660b5f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a13be550-8897-41a5-aa68-de0850a9ab03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kentera-previously-oxybutynin-nicobrand""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in adult patients with unstable bladder. uuid:55c3f660-715a-4fda-8cd3-8e9503151169 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:144551 biolink:treats MONDO:0006624 PMID:41385096 "[{""id"":""uuid:aadfd383-027f-4545-9808-1e12b6de1d49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c3b7e0ff-6eb4-4e63-a1a3-b70cd6569c98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kentera-previously-oxybutynin-nicobrand""]},{""id"":""uuid:d7b9bd36-3cd2-4591-a343-a24c494349c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in adult patients with unstable bladder.|[PMDA] A drug with a new route of administration and new indications for the treatment of urinary urgency, urinary frequency, and urge urinary incontinence associated with overactive bladder. uuid:0ad46336-792f-4275-a4d6-0df4fe37ccfe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:144551 biolink:treats NCIT:C143907 PMID:41385096 "[{""id"":""uuid:7893e186-9362-4a96-aaad-4865d34048b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:dc304340-ad30-43b4-9b14-71259a8ead45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kentera-previously-oxybutynin-nicobrand""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in adult patients with unstable bladder. uuid:f0919e75-f024-4993-a0ca-fcad37523b99 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DQA630RIE9 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:dcabed93-50ed-44fa-839d-436dbae8f59d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:55b6cdc0-fade-49ae-b651-c2d3432c66ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/rapilysin""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rapilysin is indicated for the thrombolytic treatment of suspected myocardial infarction with persistent ST elevation or recent left bundle branch block within 12 hours after the onset of acute-myocardial-infarction (AMI) symptoms. uuid:d2dd27e2-2c48-476e-9838-11e97a07c557 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63632 biolink:treats MONDO:0005131 PMID:41385096 "[{""id"":""uuid:a6386880-5e65-447b-80fc-e658e3367688"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4dfd08ce-3d0c-4180-b2a0-43aea57d2b15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/hycamtin""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Topotecan monotherapy is indicated for the treatment of:- patients with metastatic carcinoma of the ovary after failure of first-line or subsequent therapy- patients with relapsed small cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate (see section 5.1).Topotecan in combination with cisplatin is indicated for patients with carcinoma of the cervix recurrent after radiotherapy and for patients with Stage IVB disease. Patients with prior exposure to cisplatin require a sustained treatment free interval to justify treatment with the combination (see section 5.1). uuid:660cd2e9-95d9-46f0-a27d-904e879e4532 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90923 biolink:treats MONDO:0005366 PMID:41385096 "[{""id"":""uuid:afa174b3-8c2f-49fc-8f89-f65e7e8aa491"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4b2164b1-b336-4aaf-a0cb-76714d08f0a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Vemlidy is indicated for the treatment of chronic hepatitis B (CHB) in adults and paediatric patients 6 years of age and older weighing at least 25 kg (see section 5.1). uuid:7ccecdba-470a-4ca9-b094-82f8f068ed40 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:I60W9520VV biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:1409b92d-8fed-4c82-8373-432e6e049db1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e2ce032f-c21e-4a96-9715-a7fde724cb40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vafseo""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Vafseo is indicated for the treatment of symptomatic anaemia associated with chronic kidney disease (CKD) in adults on chronic maintenance dialysis. uuid:22d8ad79-aa77-4381-9c94-b3ad959a6a91 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C075654 biolink:treats MONDO:0100244 PMID:41385096 "[{""id"":""uuid:0550f29a-5737-49fc-b443-7ef1a842f6eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:dd9cd7a0-8dac-49d4-afaf-9391bfc49af9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Epysqli is indicated in adults and children for the treatment of Paroxysmal nocturnal haemoglobinuria (PNH).Evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history. uuid:d3c0f402-0d90-4f94-854f-0147261bceaf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5815513 biolink:treats MONDO:0019209 PMID:41385096 "[{""id"":""uuid:b32656d9-280c-4adb-8eec-47f92bba6aec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:02c48aee-84cb-43b4-a726-d279708169dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ixiaro is indicated for active immunisation against Japanese encephalitis in adults, adolescents, children and infants aged two months and older.Ixiaro should be considered for use in individuals at risk of exposure through travel or in the course of their occupation. DRUGBANK:DB17795 uuid:f2efa970-ea2e-4f76-972f-a22f50072ecc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7915 biolink:treats MONDO:0007186 PMID:41385096 "[{""id"":""uuid:b2796d9a-7d55-4879-a64b-bc522b25f228"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:abced2e0-5c44-45b0-a8bc-e538630d5a44"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/pantozol-control""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Short-term treatment of reflux symptoms (e.g. heartburn, acid regurgitation) in adults. uuid:212cc341-675d-4626-8051-a023b9052e97 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:S7V92P67HO biolink:treats MONDO:0012883 PMID:41385096 "[{""id"":""uuid:5e8ee0cb-4bca-41f4-99fc-4bbf80871c80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bdb509c6-76ff-4025-aa54-1b840e7a37b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/trisenox""]},{""id"":""uuid:6919519b-0ebf-4382-b890-e092c599bdb0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Trisenox is indicated for induction of remission, and consolidation in adult patients with:Newly diagnosed low-to-intermediate risk acute promyelocytic leukaemia (APL) (white blood cell count, ≤ 10 x 103/µl) in combination with all‑trans‑retinoic acid (ATRA)Relapsed/refractory acute promyelocytic leukaemia (APL) (previous treatment should have included a retinoid and chemotherapy)characterised by the presence of the t(15;17) translocation and/or the presence of the Pro-Myelocytic Leukaemia/Retinoic-Acid-Receptor-alpha (PML/RAR-alpha) gene.The response rate of other acute myelogenous leukaemia subtypes to arsenic trioxide has not been examined.|[PMDA] A drug with a new administration route with indications for relapsed or refractory acute promyelocytic leukemia. uuid:e030d1f4-403e-43d2-b93d-d8c5fff7f710 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:681569 biolink:treats MONDO:0004969 PMID:41385096 "[{""id"":""uuid:ec2a7bb3-07aa-4e5a-b053-79185e5bea84"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:1b750806-eeeb-4efc-ae43-9f7dd67b97ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/evoltra""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of acute lymphoblastic leukaemia (ALL) in paediatric patients who have relapsed or are refractory after receiving at least two prior regimens and where there is no other treatment option anticipated to result in a durable response. Safety and efficacy have been assessed in studies of patients ≤ 21 years old at initial diagnosis. uuid:34c20a28-8dfe-422a-92ca-8b831d5d7ee0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:803369 biolink:treats MONDO:0005790 PMID:41385096 "[{""id"":""uuid:a75eb8aa-1c02-4397-9f04-715a7fa08d30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:dd3037cb-a3ba-4f3d-a5f5-397f9321e484"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Twinrix Adult is indicated for use in non immune adults and adolescents 16 years of age and above who are at risk of both hepatitis A and hepatitis B infection. uuid:43b2a835-c607-4c39-b067-98929aa8abd7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:803369 biolink:treats MONDO:0005344 PMID:41385096 "[{""id"":""uuid:7fc21070-557b-4764-952e-96e1dabb0d60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:16a2c57e-bf44-4e1b-b6eb-aa0483ff42c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Twinrix Adult is indicated for use in non immune adults and adolescents 16 years of age and above who are at risk of both hepatitis A and hepatitis B infection. uuid:c349a32e-0d77-46ed-8a06-1fde0bc79ee6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C4541385 biolink:treats MONDO:0005344 PMID:41385096 "[{""id"":""uuid:61be1485-8469-42e2-8989-15c43d9598c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:fbfc37a2-40d1-4d0f-8506-c59ce915b0ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Fendrix is indicated in adolescents and adults from the age of 15 years onwards for active immunisation against hepatitis B virus infection (HBV) caused by all known subtypes for patients with renal insufficiency (including pre-haemodialysis and haemodialysis patients). MESH:C000726347 uuid:df806b98-2982-4791-92cf-c79d7191ae9f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C4541385 biolink:treats MONDO:0001106 PMID:41385096 "[{""id"":""uuid:ddb7f77b-898e-457b-96d4-7d4eb29a5fab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:1d649194-de3b-428e-b986-3620f866abbe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Fendrix is indicated in adolescents and adults from the age of 15 years onwards for active immunisation against hepatitis B virus infection (HBV) caused by all known subtypes for patients with renal insufficiency (including pre-haemodialysis and haemodialysis patients). MESH:C000726347 uuid:2b30e733-937c-42ff-a4cb-a90ea4e98fb0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:867485 biolink:treats MONDO:0002974 PMID:41385096 "[{""id"":""uuid:0f5ebd6f-b0d5-4c9b-9b34-38e4043e0b0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:eed50dba-866b-4a28-8e66-2914b226e6ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Cervarix is a vaccine for use from the age of 9 years for the prevention of premalignant ano-genital lesions (cervical, vulvar, vaginal and anal) and cervical and anal cancers causally related to certain oncogenic Human Papillomavirus (HPV) types. See sections 4.4 and 5.1 for important information on the data that support this indication.The use of Cervarix should be in accordance with official recommendations. uuid:96d0169e-d4cc-4f56-a819-039752847fe7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:867485 biolink:treats MONDO:0003199 PMID:41385096 "[{""id"":""uuid:20e6ef07-8ee0-4862-ba7d-4c7a98e7190d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a199f5e5-e689-4e2e-aa5e-b4619738eba3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Cervarix is a vaccine for use from the age of 9 years for the prevention of premalignant ano-genital lesions (cervical, vulvar, vaginal and anal) and cervical and anal cancers causally related to certain oncogenic Human Papillomavirus (HPV) types. See sections 4.4 and 5.1 for important information on the data that support this indication.The use of Cervarix should be in accordance with official recommendations. uuid:3ce921b7-2c00-47da-8af4-c395f451f556 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:867485 biolink:treats MONDO:0021074 PMID:41385096 "[{""id"":""uuid:823c76ad-07eb-4971-a6ec-e6cfb4e328ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:1cbe7e0a-d00b-4622-a5ff-da87574e43a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Cervarix is a vaccine for use from the age of 9 years for the prevention of premalignant ano-genital lesions (cervical, vulvar, vaginal and anal) and cervical and anal cancers causally related to certain oncogenic Human Papillomavirus (HPV) types. See sections 4.4 and 5.1 for important information on the data that support this indication.The use of Cervarix should be in accordance with official recommendations. uuid:00db1ee5-c7f8-4a90-983b-fe86908a2c6e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:867485 biolink:treats MONDO:0001528 PMID:41385096 "[{""id"":""uuid:87494222-9ffb-4d6f-878a-9edf1226b417"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6c2230a9-5048-4d5e-9596-b30dceb3e695"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Cervarix is a vaccine for use from the age of 9 years for the prevention of premalignant ano-genital lesions (cervical, vulvar, vaginal and anal) and cervical and anal cancers causally related to certain oncogenic Human Papillomavirus (HPV) types. See sections 4.4 and 5.1 for important information on the data that support this indication.The use of Cervarix should be in accordance with official recommendations. uuid:ce1cb4a9-3027-42b1-a733-365fc58e3012 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:867485 biolink:treats MONDO:0001402 PMID:41385096 "[{""id"":""uuid:4008ab5d-5b16-4178-a8b2-41d900163c4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c93192e0-949a-4f4f-94ec-be7512c5d3da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Cervarix is a vaccine for use from the age of 9 years for the prevention of premalignant ano-genital lesions (cervical, vulvar, vaginal and anal) and cervical and anal cancers causally related to certain oncogenic Human Papillomavirus (HPV) types. See sections 4.4 and 5.1 for important information on the data that support this indication.The use of Cervarix should be in accordance with official recommendations. uuid:c44c7f01-5d97-45f7-9da4-2c34cf5dadd6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7NL2E3F6K3 biolink:treats MONDO:0015793 PMID:41385096 "[{""id"":""uuid:7577fe99-12a1-4c5d-a99d-663347f0f388"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d05f6661-05dc-47d2-b5e2-034974dc8fd0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/hemlibra""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Hemlibra is indicated for routine prophylaxis of bleeding episodes in patients with haemophilia A (congenital factor VIII deficiency):with factor VIII inhibitorswithout factor VIII inhibitors who have:severe disease (FVIII < 1%)moderate disease (FVIII ≥ 1% and ≤ 5%) with severe bleeding phenotype.Hemlibra can be used in all age groups. uuid:1ddef742-c4de-4154-a341-cc5f2b477703 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45409 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:2b991ad2-d4d7-4ac0-b819-52d0c3879e8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a90dbc56-35e8-4de1-ab1f-bf22e4ca891f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/norvir""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ritonavir is indicated in combination with other antiretroviral agents for the treatment of HIV 1 infected patients (adults and children of 2 years of age and older). uuid:aa782013-4d82-4d27-bea5-358dd3752122 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31596 biolink:treats MONDO:0043875 PMID:41385096 "[{""id"":""uuid:f56c5afb-f939-4a0e-b98d-4dc5716627d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:3b2385e8-2413-4fa4-8da0-9b3b33cc3498"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/febuxostat-mylan""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Febuxostat Mylan is indicated for the prevention and treatment of hyperuricaemia in adult patients undergoing chemotherapy for haematologic malignancies at intermediate to high risk of Tumor Lysis Syndrome (TLS).Febuxostat Mylan is indicated for the treatment of chronic hyperuricaemia in conditions where urate deposition has already occurred (including a history, or presence of, tophus and/or gouty arthritis).Febuxostat Mylan is indicated in adults. uuid:6bc48a53-d926-40db-9781-5f213a62e2cb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:114785 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:1d306060-4c5f-459e-83e2-14e083161c4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4553bed5-17e8-4b83-8f25-8e09e66e33a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tarceva""]},{""id"":""uuid:78566537-729b-4f03-9772-b93266a87b73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Non-small cell lung cancer (NSCLC)Tarceva is also indicated for switch maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer with EGFR activating mutations and stable disease after first-line chemotherapy.Tarceva is also indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.In patients with tumours without EGFR activating mutations, Tarceva is indicated when other treatment options are not considered suitable.When prescribing Tarceva, factors associated with prolonged survival should be taken into account.No survival benefit or other clinically relevant effects of the treatment have been demonstrated in patients with Epidermal Growth Factor Receptor (EGFR)-IHC - negative tumours.Pancreatic cancerTarceva in combination with gemcitabine is indicated for the treatment of patients with metastatic pancreatic cancer.When prescribing Tarceva, factors associated with prolonged survival should be taken into account.|[PMDA] Drugs containing a new active ingredient indicated for the treatment of unresectable, relapsed/advanced non-small cell lung cancer exacerbated after cancer chemotherapy. [Priority review] uuid:09ba1d5e-9f29-4c96-9860-18697d495b94 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72292 biolink:treats MONDO:0005861 PMID:41385096 "[{""id"":""uuid:bb5dccc0-d746-4868-906b-333334465817"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:3d9f6744-1dd8-4a27-88a4-0d8f85fd0348"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Sirturo is indicated for use as part of an appropriate combination regimen for pulmonary multidrug resistant tuberculosis (MDR TB) in adults and adolescent patients (12 years to less than 18 years of age and weighing at least 30 kg) when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability. Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:c1fc2867-151c-4603-ae5e-abb2b3a4c01a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841116 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:ee5d7c6e-9c6d-4893-bb04-1f7837e968b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:152a5786-63b0-44a6-ab11-845d424e2b33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/biresp-spiromax""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Asthma BiResp Spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists.orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists.COPDBiResp Spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with COPD with forced expiratory volume in 1 second (FEV₁) uuid:c05d1b95-a2f3-42a1-8cf1-437ea60bd39e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841116 biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:7092c0bb-b5e8-4d1f-825d-09ce90c00785"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2d97c6a3-028d-440d-af71-87c2de5cb84c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/biresp-spiromax""]},{""id"":""uuid:8300bda5-24a5-4658-86cb-d1825a91d18d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Asthma BiResp Spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists.orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists.COPDBiResp Spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with COPD with forced expiratory volume in 1 second (FEV₁)|[PMDA] New combination drugs with a new active ingredient indicated for the relief of symptoms in patients with chronic obstructive pulmonary disease (chronic bronchitis, emphysema) (who require a combination therapy with an inhaled corticosteroid, a long-acting inhaled anticholinergic agent and a long-acting beta-2 agonist). uuid:58cda7e8-2d00-44ff-95c4-b038956f9b0e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1001585 biolink:treats MONDO:0043327 PMID:41385096 "[{""id"":""uuid:52c93091-faf2-4d51-afbd-b1ff860d8f93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:7e69c2da-4bbb-4bdb-9ca5-719415810479"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tachosil""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] TachoSil is indicated in adults and children from 1 month of age for supportive treatment in surgery for improvement of haemostasis, to promote tissue sealing and for suture support in vascular surgery where standard techniques are insufficient. TachoSil is indicated in adults for supportive sealing of the dura mater to prevent postoperative cerebrospinal leakage following neurological surgery (see section 5.1). uuid:ee11cfd6-65c1-497a-8366-633acd623335 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1001585 biolink:treats MONDO:0001531 PMID:41385096 "[{""id"":""uuid:6d5c3540-309a-47d0-931e-08efdca35c46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:24a46f74-6f32-43cd-886b-6c8950c16046"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tachosil""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] TachoSil is indicated in adults and children from 1 month of age for supportive treatment in surgery for improvement of haemostasis, to promote tissue sealing and for suture support in vascular surgery where standard techniques are insufficient. TachoSil is indicated in adults for supportive sealing of the dura mater to prevent postoperative cerebrospinal leakage following neurological surgery (see section 5.1). uuid:f20c7932-7111-4c29-9802-5237286a5305 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:441410 biolink:treats MONDO:0008315 PMID:41385096 "[{""id"":""uuid:0d208dff-3f7c-4574-b70c-fe49029305e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e695777a-08b1-4b9c-9c60-043ceea197fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:a207b5e1-c516-49b9-a508-9c89890f4669"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Camcevi is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.|[PMDA] A drug in a new dosage form indicated for the treatment of prostate cancer and premenopausal breast cancer. uuid:30e58d0e-d107-4666-be9f-a80acb1c8af9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:55345 biolink:treats MONDO:0005029 PMID:41385096 "[{""id"":""uuid:ab598663-9d68-48f4-b3e8-4ce2fc11eec5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:572bd72e-acf8-493e-a494-a0505b35bcab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Anagrelide is indicated for the reduction of elevated platelet counts in at risk essential thrombocythaemia (ET) patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy.An at-risk patientAn at-risk essential thrombocythaemia patient is defined by one or more of the following features:>60 years of age ora platelet count >1,000 x 10⁹/l ora history of thrombo-haemorrhagic events. uuid:34d752db-282e-40b3-9990-5bfc93ec00fb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:55345 biolink:treats UMLS:C1868936 PMID:41385096 "[{""id"":""uuid:7d696d84-06b4-48a2-a532-c469dce5d113"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6d048a65-4712-4981-997b-0f56ebd0dd7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Anagrelide is indicated for the reduction of elevated platelet counts in at risk essential thrombocythaemia (ET) patients who are intolerant to their current therapy or whose elevated platelet counts are not reduced to an acceptable level by their current therapy.An at-risk patientAn at-risk essential thrombocythaemia patient is defined by one or more of the following features:>60 years of age ora platelet count >1,000 x 10⁹/l ora history of thrombo-haemorrhagic events. uuid:c5a201ad-59bb-4fb7-acc8-7d7b87b84879 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49603 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:56ec13d0-9826-4fe0-b90c-0c4a6e2f04ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3e9ef442-0038-4982-8463-9e652b8112c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tyverb""]},{""id"":""uuid:12fc4227-45ca-4f6e-a31b-090360b4b370"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Tyverb is indicated for the treatment of patients with breast cancer, whose tumours overexpress HER2 (ErbB2):in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting;in combination with trastuzumab for patients with hormone-receptor-negative metastatic disease that has progressed on prior trastuzumab therapy or therapies in combination with chemotherapy;in combination with an aromatase inhibitor for post-menopausal women with hormone-receptor-positive metastatic disease, not currently intended for chemotherapy. The patients in the registration study had not previously been treated with trastuzumab or an aromatase inhibitor. No data are available on the efficacy of this combination relative to trastuzumab in combination with an aromatase inhibitor in this patient population.|[PMDA] A drug with a new active ingredient indicated for the treatment of inoperable or recurrent breast cancer with HER2 overexpression. [Priority review] uuid:d9945faf-399e-4d2d-a67f-7090d2e6b440 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49603 biolink:treats MONDO:0005494 PMID:41385096 "[{""id"":""uuid:7280fc77-4474-495b-a1ba-6f8458b165fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:564a9984-c0fc-4326-8eef-b00b9536f17f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tyverb""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Tyverb is indicated for the treatment of patients with breast cancer, whose tumours overexpress HER2 (ErbB2):in combination with capecitabine for patients with advanced or metastatic disease with progression following prior therapy, which must have included anthracyclines and taxanes and therapy with trastuzumab in the metastatic setting;in combination with trastuzumab for patients with hormone-receptor-negative metastatic disease that has progressed on prior trastuzumab therapy or therapies in combination with chemotherapy;in combination with an aromatase inhibitor for post-menopausal women with hormone-receptor-positive metastatic disease, not currently intended for chemotherapy. The patients in the registration study had not previously been treated with trastuzumab or an aromatase inhibitor. No data are available on the efficacy of this combination relative to trastuzumab in combination with an aromatase inhibitor in this patient population. uuid:b2a400ab-6a8f-420e-a448-6412ebe0876c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB13881 biolink:treats MONDO:0004947 PMID:41385096 "[{""id"":""uuid:73267ae1-7750-48a4-a2e4-12a1614e56a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5e804101-39c1-40ae-910a-5f541ca6f32b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kymriah""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Kymriah is indicated for the treatment of:• Paediatric and young adult patients up to and including 25 years of age with B cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post transplant or in second or later relapse.• Adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) after two or more lines of systemic therapy.• Adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. uuid:d2c8e07d-c324-4d6d-9584-13231dea9302 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB13881 biolink:treats MONDO:0018905 PMID:41385096 "[{""id"":""uuid:126be743-5f9c-4f8f-b7d1-d99db482a50c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2ebb9b90-d558-4eda-a021-b6c2306a35da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kymriah""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Kymriah is indicated for the treatment of:• Paediatric and young adult patients up to and including 25 years of age with B cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post transplant or in second or later relapse.• Adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) after two or more lines of systemic therapy.• Adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. uuid:8f9aa2f3-434c-4b2c-a15a-7e9bfae86176 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB13881 biolink:treats MONDO:0018906 PMID:41385096 "[{""id"":""uuid:94f6af74-68cb-4f0a-b09f-955b731c8537"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5dbbd8de-4a5a-4aef-bf2f-ac697412dd12"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kymriah""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Kymriah is indicated for the treatment of:• Paediatric and young adult patients up to and including 25 years of age with B cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post transplant or in second or later relapse.• Adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) after two or more lines of systemic therapy.• Adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. uuid:f6947197-d9c2-42cf-bef0-58a70f430e5b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6D5766Q4OP biolink:treats MONDO:0011871 PMID:41385096 "[{""id"":""uuid:bbf15190-e58a-4663-ac86-7e21d5b7302c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a0e3c25d-84cb-4098-a57b-36efd2e4a738"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/xenpozyme""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Xenpozyme is indicated as an enzyme replacement therapy for the treatment of non-Central Nervous System (CNS) manifestations of Acid Sphingomyelinase Deficiency (ASMD) in paediatric and adult patients with type A/B or type B. uuid:e010c794-1fb0-49b5-b36b-64afeff4d761 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:0IEO0F56LV biolink:treats MONDO:0001824 PMID:41385096 "[{""id"":""uuid:f8c9608b-af73-4492-996c-dee377693237"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:86c0bb65-c996-4e9c-ad1f-3fb05e10b181"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of stage 1 or Stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR). uuid:6fdbcbad-8531-4f07-9bdf-8dff82ea78ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7K5O7P6QIU biolink:treats MONDO:0018905 PMID:41385096 "[{""id"":""uuid:0672b7a3-746f-4c79-9d30-6249e4559ebb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:34b0c1b4-5dcf-4e88-a8bd-9d754b92760e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zynlonta""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Zynlonta as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy. uuid:7ea69caf-4fff-474e-b385-b7d5bf464dd8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7K5O7P6QIU biolink:treats MONDO:0044889 PMID:41385096 "[{""id"":""uuid:53b6064b-a42f-4e08-85ca-eb0ad1a19d26"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f0e55bc9-c0e0-49d1-a5f1-7aa1bcecc394"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zynlonta""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Zynlonta as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy. uuid:158f4e0d-fde4-415c-83c9-448727da1948 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:VHS6SC660Q biolink:treats MONDO:0007886 PMID:41385096 "[{""id"":""uuid:669b6435-1cc9-4fce-bca3-49018331b286"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:15512ce5-1dac-46db-b865-077fd996fbaa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/yselty""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Yselty is indicated for the treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. uuid:2d747271-7e82-41d2-bb3a-a841221de23f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17549 biolink:treats MONDO:0100342 PMID:41385096 "[{""id"":""uuid:dc13ee47-8e17-401c-81c3-bc8ccaac29a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e9d2da1e-01e7-4fb3-9b56-7b1cb9532691"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/gliolan""]},{""id"":""uuid:37a417ed-e9a5-4b27-b129-c343410389d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Gliolan is indicated in adult patients for visualisation of malignant tissue during surgery for malignant glioma (World Health Organization grade III and IV).|[PMDA] Drugs with a new active ingredient indicated for the visualization of tumor tissues during tumorectomy for malignant glioma. [Orphan drug] uuid:6c3d5f64-92b7-4169-89c4-2eb63b94a581 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1999664 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:e1ea1b5f-f521-4cb2-bd31-02f01d00a070"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:1a0158df-6ee7-494a-8643-2e98ad0234a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/biktarvy""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Biktarvy is indicated for the treatment of human immunodeficiency virus 1 (HIV 1) infection in adults and paediatric patients at least 2 years of age and weighing at least 14 kg i without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir.(see section 5.1) uuid:63b3f310-40c0-4642-b04e-0adabadc69e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:499361 biolink:treats UMLS:C0520909 PMID:41385096 "[{""id"":""uuid:4dd6ba25-493a-463c-9cb2-08425c9ea3de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:67c5244f-d6d6-4df5-90fa-c6910e87b414"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/emend""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Emend 40 mg hard capsules is indicated for the prevention of postoperative nausea and vomiting (PONV) in adults.Emend is also available as 80 mg and 125 mg hard capsules for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and adolescents from the age of 12 (see separate Summary of Product Characteristics).Emend is also available as 165 mg hard capsules for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin based cancer chemotherapy in adults and the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy in adults.Emend is also available as powder for oral suspension for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in children, toddlers and infants from the age of 6 months to less than 12 years.Emend 80 mg, 125 mg, 165 mg hard capsules and Emend powder for oral suspension are given as part of combination therapy. uuid:3c8a813a-5304-49a8-bbbb-87219a09d776 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:UMD07X179E biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:c1b3162b-b810-4e07-87db-27251c3957d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a6c90be0-8d09-41e4-b1de-f9965163aeb0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cimzia""]},{""id"":""uuid:c2916af5-8691-48cc-8849-9ac0bb8758de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rheumatoid arthritisCimzia, in combination with methotrexate (MTX), is indicated for:the treatment of moderate to severe, active rheumatoid arthritis (RA) in adult patients when the response to disease-modifying antirheumatic drugs (DMARDs) including MTX, has been inadequate. Cimzia can be given as monotherapy in case of intolerance to MTX or when continued treatment with MTX is inappropriatethe treatment of severe, active and progressive RA in adults not previously treated with MTX or other DMARDs.Cimzia has been shown to reduce the rate of progression of joint damage as measured by X ray and to improve physical function, when given in combination with MTX.Axial spondyloarthritis Cimzia is indicated for the treatment of adult patients with severe active axial spondyloarthritis, comprising:Ankylosing spondylitis (AS)Adults with severe active ankylosing spondylitis who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).Axial spondyloarthritis without radiographic evidence of ASAdults with severe active axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated C reactive protein (CRP) and /or magnetic resonance imaging (MRI), who have had an inadequate response to, or are intolerant to NSAIDs.Psoriatic arthritis Cimzia, in combination with MTX, is indicated for the treatment of active psoriatic arthritis in adults when the response to previous DMARD therapy has been inadequate.Cimzia can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.|[PMDA] A drug with a new active ingredient indicated for the treatment of rheumatoid arthritis (including prevention of structural joint damage) in patients who have not sufficiently responded to conventional treatments. uuid:6ac26c38-3e5d-4056-881e-efbd97e58d36 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:UMD07X179E biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:51d94bc2-51ef-4f1c-8eea-b06dafd3b131"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4a05b82b-dcfc-470d-95f7-4cb871d270db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cimzia""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rheumatoid arthritisCimzia, in combination with methotrexate (MTX), is indicated for:the treatment of moderate to severe, active rheumatoid arthritis (RA) in adult patients when the response to disease-modifying antirheumatic drugs (DMARDs) including MTX, has been inadequate. Cimzia can be given as monotherapy in case of intolerance to MTX or when continued treatment with MTX is inappropriatethe treatment of severe, active and progressive RA in adults not previously treated with MTX or other DMARDs.Cimzia has been shown to reduce the rate of progression of joint damage as measured by X ray and to improve physical function, when given in combination with MTX.Axial spondyloarthritis Cimzia is indicated for the treatment of adult patients with severe active axial spondyloarthritis, comprising:Ankylosing spondylitis (AS)Adults with severe active ankylosing spondylitis who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).Axial spondyloarthritis without radiographic evidence of ASAdults with severe active axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated C reactive protein (CRP) and /or magnetic resonance imaging (MRI), who have had an inadequate response to, or are intolerant to NSAIDs.Psoriatic arthritis Cimzia, in combination with MTX, is indicated for the treatment of active psoriatic arthritis in adults when the response to previous DMARD therapy has been inadequate.Cimzia can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. uuid:089a5ee8-bb72-41c6-a6a8-1cdc7aa95063 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:UMD07X179E biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:b0205f37-f72b-41c4-8dce-752c1c69815c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:55337816-21de-4a30-ab0a-94fea4d172bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cimzia""]},{""id"":""uuid:d0b97070-3082-4587-83f5-ee70e83afde3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rheumatoid arthritisCimzia, in combination with methotrexate (MTX), is indicated for:the treatment of moderate to severe, active rheumatoid arthritis (RA) in adult patients when the response to disease-modifying antirheumatic drugs (DMARDs) including MTX, has been inadequate. Cimzia can be given as monotherapy in case of intolerance to MTX or when continued treatment with MTX is inappropriatethe treatment of severe, active and progressive RA in adults not previously treated with MTX or other DMARDs.Cimzia has been shown to reduce the rate of progression of joint damage as measured by X ray and to improve physical function, when given in combination with MTX.Axial spondyloarthritis Cimzia is indicated for the treatment of adult patients with severe active axial spondyloarthritis, comprising:Ankylosing spondylitis (AS)Adults with severe active ankylosing spondylitis who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).Axial spondyloarthritis without radiographic evidence of ASAdults with severe active axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated C reactive protein (CRP) and /or magnetic resonance imaging (MRI), who have had an inadequate response to, or are intolerant to NSAIDs.Psoriatic arthritis Cimzia, in combination with MTX, is indicated for the treatment of active psoriatic arthritis in adults when the response to previous DMARD therapy has been inadequate.Cimzia can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.|[PMDA] Drugs with new additional indications and a new dosage for the treatment of plaque psoriasis, psoriatic arthritis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies. uuid:c5461f76-4069-410a-ade1-7008270d76fb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:LKC0U3A8NJ biolink:treats HP:0003124 PMID:41385096 "[{""id"":""uuid:75347050-babf-49a1-b75a-1f09078cb8d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ffefd83e-8f49-44e5-80d6-85060592512f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/repatha""]},{""id"":""uuid:50cf140e-a6cb-4d0d-9823-3d33bc90fb59"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Hypercholesterolaemia and mixed dyslipidaemiaRepatha is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin or statin with other lipid lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin or,alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.Homozygous familial hypercholesterolaemiaRepatha is indicated in adults and adolescents aged 12 years and over with homozygous familial hypercholesterolaemia in combination with other lipid-lowering therapies.Established atherosclerotic cardiovascular diseaseRepatha is indicated in adults with established atherosclerotic cardiovascular disease (myocardial infarction, stroke or peripheral arterial disease) to reduce cardiovascular risk by lowering LDL-C levels, as an adjunct to correction of other risk factors:in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies or,alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.For study results with respect to effects on LDL-C, cardiovascular events and populations studied see section 5.1.|[PMDA] Drugs with a new active ingredient indicated for the treatment of familial hypercholesterolemia and hypercholesterolemia (for use only in patients who are at higher risk of developing cardiovascular event and have not responded sufficiently to HMG- CoA reductase inhibitors). uuid:aca2848d-1640-40f8-a3f3-5dc172ec3623 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:LKC0U3A8NJ biolink:treats MONDO:0021661 PMID:41385096 "[{""id"":""uuid:7883bddb-65ba-4f80-932a-e6b6681c8334"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ee6bc3a6-0daa-44ad-a3bb-24f1af04f5cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/repatha""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Hypercholesterolaemia and mixed dyslipidaemiaRepatha is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin or statin with other lipid lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin or,alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.Homozygous familial hypercholesterolaemiaRepatha is indicated in adults and adolescents aged 12 years and over with homozygous familial hypercholesterolaemia in combination with other lipid-lowering therapies.Established atherosclerotic cardiovascular diseaseRepatha is indicated in adults with established atherosclerotic cardiovascular disease (myocardial infarction, stroke or peripheral arterial disease) to reduce cardiovascular risk by lowering LDL-C levels, as an adjunct to correction of other risk factors:in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies or,alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.For study results with respect to effects on LDL-C, cardiovascular events and populations studied see section 5.1. uuid:4c12c341-8c54-441f-b5c0-e0820ae30cf5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:LKC0U3A8NJ biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:6bb1cd76-c884-4e1e-9395-c8a02d592b7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:071df1a6-8902-45c1-8aba-a12558010c7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/repatha""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Hypercholesterolaemia and mixed dyslipidaemiaRepatha is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin or statin with other lipid lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin or,alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.Homozygous familial hypercholesterolaemiaRepatha is indicated in adults and adolescents aged 12 years and over with homozygous familial hypercholesterolaemia in combination with other lipid-lowering therapies.Established atherosclerotic cardiovascular diseaseRepatha is indicated in adults with established atherosclerotic cardiovascular disease (myocardial infarction, stroke or peripheral arterial disease) to reduce cardiovascular risk by lowering LDL-C levels, as an adjunct to correction of other risk factors:in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies or,alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.For study results with respect to effects on LDL-C, cardiovascular events and populations studied see section 5.1. uuid:eb51d7b3-5a5c-425e-a7a2-49ba5ac2ac12 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:LKC0U3A8NJ biolink:treats MONDO:0005098 PMID:41385096 "[{""id"":""uuid:933ca509-2445-4d21-a395-16fd5acbbacf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:1ae053c4-5e2f-4c06-8c82-1017c7d2ef48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/repatha""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Hypercholesterolaemia and mixed dyslipidaemiaRepatha is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin or statin with other lipid lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin or,alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.Homozygous familial hypercholesterolaemiaRepatha is indicated in adults and adolescents aged 12 years and over with homozygous familial hypercholesterolaemia in combination with other lipid-lowering therapies.Established atherosclerotic cardiovascular diseaseRepatha is indicated in adults with established atherosclerotic cardiovascular disease (myocardial infarction, stroke or peripheral arterial disease) to reduce cardiovascular risk by lowering LDL-C levels, as an adjunct to correction of other risk factors:in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies or,alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.For study results with respect to effects on LDL-C, cardiovascular events and populations studied see section 5.1. uuid:ce26d51b-772a-4766-b80c-b475af9518b6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:LKC0U3A8NJ biolink:treats MONDO:0005386 PMID:41385096 "[{""id"":""uuid:56f5a9a4-1de3-4a13-bf3d-150bf76e143f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ec1479a7-e29d-4ee1-926f-5dba64ad6e2b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/repatha""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Hypercholesterolaemia and mixed dyslipidaemiaRepatha is indicated in adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:in combination with a statin or statin with other lipid lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin or,alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.Homozygous familial hypercholesterolaemiaRepatha is indicated in adults and adolescents aged 12 years and over with homozygous familial hypercholesterolaemia in combination with other lipid-lowering therapies.Established atherosclerotic cardiovascular diseaseRepatha is indicated in adults with established atherosclerotic cardiovascular disease (myocardial infarction, stroke or peripheral arterial disease) to reduce cardiovascular risk by lowering LDL-C levels, as an adjunct to correction of other risk factors:in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies or,alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.For study results with respect to effects on LDL-C, cardiovascular events and populations studied see section 5.1. uuid:2b8a5a9c-fc64-4a6d-85be-5d6d11a8db10 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27565 biolink:treats MONDO:0005861 PMID:41385096 "[{""id"":""uuid:41bd138e-38db-4c45-a4f8-a0dc217be142"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0c2425e9-1275-4ca0-b662-71ba62945e12"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/granupas-previously-para-aminosalicylic-acid-lucane""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Granupas is indicated for use as part of an appropriate combination regimen for multi-drug resistant tuberculosis in adults and paediatric patients from 28 days of age and older when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability (see section 4.4).Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:cae700df-2089-400e-80cb-fd5ffa12f149 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:D652ZWF066 biolink:treats HP:0002153 PMID:41385096 "[{""id"":""uuid:d6199136-dea9-4583-8a71-7a2dfa014fbb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4209de45-59fa-436a-956a-d03db301eeed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lokelma""]},{""id"":""uuid:beaa7158-1753-4b5f-bf36-cb6949054691"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Lokelma is indicated for the treatment of hyperkalaemia in adult patients.|[PMDA] Drugs with a new active ingredient indicated for the treatment of hyperkalaemia. uuid:cfd9b5ba-2bf2-47da-94cf-a4cf5a34e7b8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134745 biolink:treats MONDO:0004739 PMID:41385096 "[{""id"":""uuid:172d2f53-ad6d-464a-a13a-924d3f63f8c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4b7a5772-e2e4-40ad-9a8c-d6aba014ab5d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ravicti""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ravicti is indicated for use as adjunctive therapy for chronic management of patients with urea cycle disorders (UCDs) including deficiencies of carbamoyl phosphate-synthase-I (CPS), ornithine carbamoyltransferase (OTC), argininosuccinate synthetase (ASS), argininosuccinate lyase (ASL), arginase I (ARG) and ornithine translocase deficiency hyperornithinaemia-hyperammonaemia homocitrullinuria syndrome (HHH) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.Ravicti must be used with dietary protein restriction and, in some cases, dietary supplements (e.g., essential amino acids, arginine, citrulline, protein-free calorie supplements). uuid:42fd7c1e-b493-47e6-8d5f-cedd8f43d80c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134745 biolink:treats MONDO:0009376 PMID:41385096 "[{""id"":""uuid:358131e4-867b-4511-9a08-9d0406a15ad8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c4212dbd-a9d0-4c24-a62f-89bda84dda52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ravicti""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ravicti is indicated for use as adjunctive therapy for chronic management of patients with urea cycle disorders (UCDs) including deficiencies of carbamoyl phosphate-synthase-I (CPS), ornithine carbamoyltransferase (OTC), argininosuccinate synthetase (ASS), argininosuccinate lyase (ASL), arginase I (ARG) and ornithine translocase deficiency hyperornithinaemia-hyperammonaemia homocitrullinuria syndrome (HHH) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.Ravicti must be used with dietary protein restriction and, in some cases, dietary supplements (e.g., essential amino acids, arginine, citrulline, protein-free calorie supplements). uuid:65e427e0-5172-4e39-be2d-38f7cdfd721d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134745 biolink:treats MONDO:0010703 PMID:41385096 "[{""id"":""uuid:125e4ebf-bbc4-49f7-9a02-8892bef17de4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:06bccad6-dd92-4074-8a60-19e06db47cc1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ravicti""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ravicti is indicated for use as adjunctive therapy for chronic management of patients with urea cycle disorders (UCDs) including deficiencies of carbamoyl phosphate-synthase-I (CPS), ornithine carbamoyltransferase (OTC), argininosuccinate synthetase (ASS), argininosuccinate lyase (ASL), arginase I (ARG) and ornithine translocase deficiency hyperornithinaemia-hyperammonaemia homocitrullinuria syndrome (HHH) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.Ravicti must be used with dietary protein restriction and, in some cases, dietary supplements (e.g., essential amino acids, arginine, citrulline, protein-free calorie supplements). uuid:1137d0cf-abeb-4c4e-a932-449ab25da572 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134745 biolink:treats MONDO:0008815 PMID:41385096 "[{""id"":""uuid:aab23c0e-0762-4eab-bfa7-49b2866d02f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b6bfa85a-8f68-4493-903c-69ac79e1770b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ravicti""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ravicti is indicated for use as adjunctive therapy for chronic management of patients with urea cycle disorders (UCDs) including deficiencies of carbamoyl phosphate-synthase-I (CPS), ornithine carbamoyltransferase (OTC), argininosuccinate synthetase (ASS), argininosuccinate lyase (ASL), arginase I (ARG) and ornithine translocase deficiency hyperornithinaemia-hyperammonaemia homocitrullinuria syndrome (HHH) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.Ravicti must be used with dietary protein restriction and, in some cases, dietary supplements (e.g., essential amino acids, arginine, citrulline, protein-free calorie supplements). uuid:46e2f2e6-987b-494c-8a74-baaa25b7de96 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134745 biolink:treats MONDO:0008814 PMID:41385096 "[{""id"":""uuid:38f136f3-a77d-45c3-b18a-68b6feba9e29"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:8d0341c4-8ec9-4de3-bbcd-7fd08414dd6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ravicti""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ravicti is indicated for use as adjunctive therapy for chronic management of patients with urea cycle disorders (UCDs) including deficiencies of carbamoyl phosphate-synthase-I (CPS), ornithine carbamoyltransferase (OTC), argininosuccinate synthetase (ASS), argininosuccinate lyase (ASL), arginase I (ARG) and ornithine translocase deficiency hyperornithinaemia-hyperammonaemia homocitrullinuria syndrome (HHH) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.Ravicti must be used with dietary protein restriction and, in some cases, dietary supplements (e.g., essential amino acids, arginine, citrulline, protein-free calorie supplements). uuid:6a4a0a88-a7b0-472e-8122-fca36d9bccbf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134745 biolink:treats MONDO:0009393 PMID:41385096 "[{""id"":""uuid:d2495547-76ac-45af-8181-b0f597935502"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e1fee857-1788-47ec-ae58-da104a1eff36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ravicti""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ravicti is indicated for use as adjunctive therapy for chronic management of patients with urea cycle disorders (UCDs) including deficiencies of carbamoyl phosphate-synthase-I (CPS), ornithine carbamoyltransferase (OTC), argininosuccinate synthetase (ASS), argininosuccinate lyase (ASL), arginase I (ARG) and ornithine translocase deficiency hyperornithinaemia-hyperammonaemia homocitrullinuria syndrome (HHH) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.Ravicti must be used with dietary protein restriction and, in some cases, dietary supplements (e.g., essential amino acids, arginine, citrulline, protein-free calorie supplements). uuid:330ad7d6-951b-4902-b397-c1f80cd0d91a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0006217 biolink:treats UMLS:C0701836 PMID:41385096 "[{""id"":""uuid:f6988465-58e9-4085-87b8-d20299720905"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:534966f0-dc88-4d12-bcfc-5ae4e054e2dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] NexoBrid is indicated for removal of eschar in adults with deep partial- and full-thickness thermal burns. DRUGBANK:DB13281 uuid:e817f119-a34b-43e5-9ac6-e7c47c2bd522 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:94805 biolink:treats MONDO:0010679 PMID:41385096 "[{""id"":""uuid:2da1cbbe-c416-4dc6-9c8f-9f51ce190795"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:cdd2075d-f3c5-445a-a04c-fc864b89e2ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/translarna""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Translarna is indicated for the treatment of Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 2 years and older. Efficacy has not been demonstrated in non-ambulatory patients.The presence of a nonsense mutation in the dystrophin gene should be determined by genetic testing. uuid:5e03ccae-81bd-4f70-b7a9-e3ef14ff45a8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71271 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:1945b523-c584-4de0-9747-766171b75cc0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e2a13f11-6600-4408-a998-091af63d5219"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/onglyza""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Add-on combination therapyOnglyza is indicated in adult patients aged 18 years and older with type-2 diabetes mellitus to improve glycaemic control:as monotherapy:in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to contraindications or intolerance;as dual oral therapy:in combination with metformin, when metformin alone, with diet and exercise, does not provide adequate glycaemic control;in combination with a sulphonylurea, when the sulphonylurea alone, with diet and exercise, does not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate;in combination with a thiazolidinedione, when the thiazolidinedione alone with diet and exercise, does not provide adequate glycaemic control in patients for whom use of a thiazolidinedione is considered appropriate;as triple oral therapy:in combination with metformin plus a sulphonylurea when this regimen alone, with diet and exercise, does not provide adequate glycaemic control;as combination therapy with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control. uuid:45043e35-6a47-4996-8ab8-4bd66b7efe28 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:291902 biolink:treats MONDO:0006805 PMID:41385096 "[{""id"":""uuid:c404dd5b-2e1f-4770-ae33-d94bf961fa79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b53bf69e-73f8-4dcf-832c-1b74d8a22ee9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/eptifibatide-accord""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Eptifibatide Accord is intended for use with acetylsalicylic acid and unfractionated heparin.Eptifibatide Accord is indicated for the prevention of early myocardial infarction in adults presenting with unstable angina or non-Q-wave myocardial infarction, with the last episode of chest pain occurring within 24 hours and with electrocardiogram (ECG) changes and/or elevated cardiac enzymes.Patients most likely to benefit from Eptifibatide Accord treatment are those at high risk of developing myocardial infarction within the first 3-4 days after onset of acute angina symptoms including for instance those that are likely to undergo an early PTCA (Percutaneous Transluminal Coronary Angioplasty). uuid:87293373-2e48-4cd8-90aa-c70f2d145c10 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:291902 biolink:treats MONDO:0003674 PMID:41385096 "[{""id"":""uuid:11bce30f-8316-4c35-a992-244736d54f8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:dfd9f427-d1cc-4587-a005-5ccfc59ef0f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/eptifibatide-accord""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Eptifibatide Accord is intended for use with acetylsalicylic acid and unfractionated heparin.Eptifibatide Accord is indicated for the prevention of early myocardial infarction in adults presenting with unstable angina or non-Q-wave myocardial infarction, with the last episode of chest pain occurring within 24 hours and with electrocardiogram (ECG) changes and/or elevated cardiac enzymes.Patients most likely to benefit from Eptifibatide Accord treatment are those at high risk of developing myocardial infarction within the first 3-4 days after onset of acute angina symptoms including for instance those that are likely to undergo an early PTCA (Percutaneous Transluminal Coronary Angioplasty). uuid:0662ac19-2520-4b14-b74f-b5f5b487dfd6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:291902 biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:bc9b5b85-09b8-4c11-82c5-cdd5aaa01c3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c37abdf0-4893-4857-b235-55a909bf270c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/eptifibatide-accord""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Eptifibatide Accord is intended for use with acetylsalicylic acid and unfractionated heparin.Eptifibatide Accord is indicated for the prevention of early myocardial infarction in adults presenting with unstable angina or non-Q-wave myocardial infarction, with the last episode of chest pain occurring within 24 hours and with electrocardiogram (ECG) changes and/or elevated cardiac enzymes.Patients most likely to benefit from Eptifibatide Accord treatment are those at high risk of developing myocardial infarction within the first 3-4 days after onset of acute angina symptoms including for instance those that are likely to undergo an early PTCA (Percutaneous Transluminal Coronary Angioplasty). uuid:a872947f-ffe7-4ce6-adc8-34582cc53b6d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3POA0Q644U biolink:treats MONDO:0018874 PMID:41385096 "[{""id"":""uuid:5519718d-47f7-48ac-9a02-9f5773edba99"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:78d90bb1-96fa-4aca-a895-d1d9ae477d92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ceplene""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ceplene maintenance therapy is indicated for adult patients with acute myeloid leukaemia in first remission concomitantly treated with interleukin-2 (IL-2). The efficacy of Ceplene has not been fully demonstrated in patients older than age 60. uuid:dbcf668d-e6f7-46be-94e2-f877be535035 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:143117 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:c8c8c4fe-0196-46c4-a30d-eeae4fa094dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0ddba3e3-279b-418e-b69c-47af99317d0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lorviqua""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Lorviqua as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)‑positive advanced non‑small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.Lorviqua as monotherapy is indicated for the treatment of adult patients with ALK‑positive advanced NSCLC whose disease has progressed after:alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy; orcrizotinib and at least one other ALK TKI. uuid:d4c82227-0513-4b88-a75a-2934c616d24d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:131701323 biolink:treats MONDO:0003529 PMID:41385096 "[{""id"":""uuid:f724b364-0fd6-4de9-9d8c-166494753fef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:23944805-b8a6-49c1-889b-60d8cf94915c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zerbaxa""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Zerbaxa is indicated for the treatment of the following infections in adults:Complicated intra abdominal infections;Acute pyelonephritis;Complicated urinary tract infections;Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP).Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:b131d5e7-6806-4899-99f1-946804f78f75 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:131701323 biolink:treats MONDO:0100338 PMID:41385096 "[{""id"":""uuid:bb36df19-d5cc-4710-88c1-3c5b0a0e729e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c14e83b3-5b04-4f97-9e76-7599f5a917c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zerbaxa""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Zerbaxa is indicated for the treatment of the following infections in adults:Complicated intra abdominal infections;Acute pyelonephritis;Complicated urinary tract infections;Hospital-acquired pneumonia (HAP), including ventilator associated pneumonia (VAP).Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:283ef482-ff91-4b50-ba15-c8164a3ff713 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50378 biolink:treats MONDO:0008753 PMID:41385096 "[{""id"":""uuid:3f4bf0ef-6108-4efc-947a-c53615e1b7d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:3f05cf69-41bb-4d0b-8b70-bc020bafc21d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/nitisinone-mdk""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Hereditary tyrosinemia type 1 (HT 1)Orfadin is indicated for the treatment of adult and paediatric (in any age range) patients with confirmed diagnosis of hereditary tyrosinemia type 1 (HT 1) in combination with dietary restriction of tyrosine and phenylalanine.Alkaptonuria (AKU)Orfadin is indicated for the treatment of adult patients with alkaptonuria (AKU). uuid:ca4a4e74-f3c0-48b5-b202-85dfd955cee9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:25110515 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:1d83c11d-bfc0-4e4d-bfa5-21b004628de7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:148fb7ed-f52e-4cd6-b682-b50873982904"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Multiple sclerosisZeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease as defined by clinical or imaging features.Ulcerative colitisZeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent. uuid:2d3c2edd-1413-4350-802f-dcc9b5b95190 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:25110515 biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:4bedb34a-da5e-4f38-85e4-810fa833a96a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b50db2ae-c45d-43fa-ad0a-266e199ccf8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Multiple sclerosisZeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease as defined by clinical or imaging features.Ulcerative colitisZeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent. uuid:9b52f1dd-b02a-4a8b-8050-f5996b05f92f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85182 biolink:treats MONDO:0005354 PMID:41385096 "[{""id"":""uuid:4c0e7ef1-54c9-481b-b886-cb4f9185a3a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:82a7d86c-c8b8-4a96-8dc5-1e189861c0e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Exviera is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults.For hepatitis C virus (HCV) genotype specific activity. uuid:19dd396c-a627-46aa-b4c7-1fc69e974951 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85182 biolink:treats MONDO:0005231 PMID:41385096 "[{""id"":""uuid:5ce466cc-6756-402b-8f0e-7b4d8da5fcd1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b264fc55-e670-4f6d-aeb3-fc42070b58a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Exviera is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults.For hepatitis C virus (HCV) genotype specific activity. uuid:8b51fed5-0343-4de6-b297-3d66fe45968f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1597376 biolink:treats MONDO:0005354 PMID:41385096 "[{""id"":""uuid:9c98433a-d61d-42a5-bd51-1922bff9150c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9ec03044-0804-4080-90fe-a5e2a0db86cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/viekirax""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Viekirax is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults.For hepatitis C virus (HCV) genotype specific activity. uuid:eab652ad-38cc-47ae-b0ef-75778e2b54a3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1597376 biolink:treats MONDO:0005231 PMID:41385096 "[{""id"":""uuid:427b58f1-df8e-426b-8589-7a0aa7bbc884"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b24033d3-4229-44a6-a629-de297cdae438"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/viekirax""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Viekirax is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults.For hepatitis C virus (HCV) genotype specific activity. uuid:17a3ad48-9299-403c-b8f0-bf88265c9ad5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:T7K20Y2GWY biolink:treats MONDO:0018555 PMID:41385096 "[{""id"":""uuid:ab952ae4-30ac-4783-9de7-3940ee13a171"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:068d77a6-578e-4f90-9ad8-fc24696a3329"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/elonva""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Controlled Ovarian Stimulation (COS) in combination with a GnRH antagonist for the development of multiple follicles in women participating in an Assisted Reproductive Technology (ART) program.Elonva is indicated for the treatment of adolescent males (14 to less than 18 years and older) with hypogonadotropic hypogonadism, in combination with human Chorionic Gonadotropin (hCG). uuid:e41ee404-0782-4442-b3ac-886fb7ed4659 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:81567 biolink:treats MONDO:0002108 PMID:41385096 "[{""id"":""uuid:bb0e9dd7-b6ce-41d9-a610-996754e72e62"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:fa65a3dc-bb0a-48b6-8458-9d42be6ac601"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Thyrogen is indicated for use with serum thyroglobulin (Tg) testing with or without radioiodine imaging for the detection of thyroid remnants and well-differentiated thyroid cancer in post thyroidectomy patients maintained on hormone suppression therapy (THST).Low risk patients with well-differentiated thyroid carcinoma who have undetectable serum Tg levels on THST and no rh (recombinant human) TSH-stimulated increase of Tg levels may be followed-up by assaying rh TSH-stimulated Tg levels.Thyrogen is indicated for pre-therapeutic stimulation in combination with a range of 30 mCi (1.1 GBq) to 100 mCi (3.7 GBq) radioiodine for ablation of thyroid tissue remnants in patients who have undergone a near-total or total thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of distant metastatic thyroid cancer (see section 4.4). uuid:ba58bc93-8f6a-452b-ab71-5acd466c52ed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:Q6U6J48BWY biolink:treats MONDO:0018150 PMID:41385096 "[{""id"":""uuid:10c1c9db-ef37-44ac-9e3d-3abfdc5b8919"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:460fec56-743b-4812-9bc0-29c128e417f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cerezyme""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Cerezyme (imiglucerase) is indicated for use as longterm enzyme replacement therapy in patients with a confirmed diagnosis of non-neuronopathic (Type 1) or chronic neuronopathic (Type 3) Gaucher disease who exhibit clinically significant nonneurological manifestations of the disease. The non-neurological manifestations of Gaucher disease include one or more of the following conditions:anaemia after exclusion of other causes, such as iron deficiencyThrombocytopeniaBone disease after exclusion of other causes such as Vitamin D deficiencyhepatomegaly or splenomegaly uuid:ff4c5aa3-754a-48e7-8c4c-12d1c79bfbf6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:Q6U6J48BWY biolink:treats MONDO:0037251 PMID:41385096 "[{""id"":""uuid:c3a78a3e-e277-4003-9b46-cedb99b6468c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d294716e-18c9-4476-a3b0-fc3b3f086777"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cerezyme""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Cerezyme (imiglucerase) is indicated for use as longterm enzyme replacement therapy in patients with a confirmed diagnosis of non-neuronopathic (Type 1) or chronic neuronopathic (Type 3) Gaucher disease who exhibit clinically significant nonneurological manifestations of the disease. The non-neurological manifestations of Gaucher disease include one or more of the following conditions:anaemia after exclusion of other causes, such as iron deficiencyThrombocytopeniaBone disease after exclusion of other causes such as Vitamin D deficiencyhepatomegaly or splenomegaly uuid:e33788dc-87c5-4797-83b8-f0e298c4b372 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:N0A21N6RAU biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:16faf6fb-f63f-47c8-9437-085044c7ee2b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e5bcd602-057f-4faa-afb6-8c14dc6a34b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/sotyktu""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of moderate-to-severe plaque psoriasis in adults. uuid:f13f5e94-7231-42f3-9f9e-df255dd46b6a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2539033 biolink:treats MONDO:0005399 PMID:41385096 "[{""id"":""uuid:a8bffdff-14ca-447b-8921-2aa217fc15de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9b98cb2b-423b-45d9-a07d-d3e0aed44fd4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lydisilka""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Oral contraception.The decision to prescribe Lydisilka should take into consideration the individual woman’s current risk factors, particularly those for venous thromboembolism (VTE), and how the risk of VTE with Lydisilka compares with other combined hormonal contraceptives (CHCs) (see sections 4.3 and 4.4). uuid:6fc4db6c-d65d-4f26-9157-5b321f51a969 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:600520 biolink:treats MONDO:0044067 PMID:41385096 "[{""id"":""uuid:2aeca1be-4f5e-4f7b-aa3a-7a9ae862b4f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b0bb2a77-caac-4d71-94fd-2c4d732e8cd8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/mycamine""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Mycamine is indicated for:Adults, adolescents ≥ 16 years of age and elderlytreatment of invasive candidiasis;treatment of oesophageal candidiasis in patients for whom intravenous therapy is appropriate;prophylaxis of Candida infection in patients undergoing allogeneic haematopoietic stem-cell transplantation or patients who are expected to have neutropenia (absolute neutrophil count < 500 cells/µl) for 10 or more days.Children (including neonates) and adolescents < 16 years of agetreatment of invasive candidiasis.prophylaxis of Candida infection in patients undergoing allogeneic haematopoietic stem-cell transplantation or patients who are expected to have neutropenia (absolute neutrophil count < 500 cells/µl) for 10 or more days.The decision to use Mycamine should take into account a potential risk for the development of liver tumours. Mycamine should therefore only be used if other antifungals are not appropriate. uuid:b2708d1e-e1fb-43ef-a56b-184102c9fba4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28887 biolink:treats MONDO:0005314 PMID:41385096 "[{""id"":""uuid:19a96699-c233-4d66-9eea-47d9501b36a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:84db4bef-11eb-49b8-864b-23af9e836112"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kesimpta""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Kesimpta is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features (see section 5.1). uuid:2c3fa0fa-8e15-436b-bd4e-6ce008951a05 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB15483 biolink:treats MONDO:0004651 PMID:41385096 "[{""id"":""uuid:db0f18ee-4e1b-4e93-9fd2-871e29cae122"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:04918771-8337-4929-94db-e30d2d4e32ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Active immunisation against smallpox, monkeypox and disease caused by vaccinia virus in adults (see sections 4.4 and 5.1).The use of this vaccine should be in accordance with official recommendations. uuid:b65bdc96-bf47-4089-8666-576aed981e1d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB15483 biolink:treats MONDO:0002594 PMID:41385096 "[{""id"":""uuid:a11f192a-c6d2-41d2-ae14-bd8f631ff8de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f0560e04-7416-4779-a20d-b993f1b6e322"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Active immunisation against smallpox, monkeypox and disease caused by vaccinia virus in adults (see sections 4.4 and 5.1).The use of this vaccine should be in accordance with official recommendations. uuid:211f958c-b032-427b-ad41-8daa79a4ea7b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB15483 biolink:treats MONDO:0005108 PMID:41385096 "[{""id"":""uuid:f2c8167a-405b-4362-8bf2-0856e4017eeb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b0f453b1-165e-4676-b69e-3c9d065b9e2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Active immunisation against smallpox, monkeypox and disease caused by vaccinia virus in adults (see sections 4.4 and 5.1).The use of this vaccine should be in accordance with official recommendations. uuid:c26e3e87-a788-49d3-954d-85b814356898 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:81569 biolink:treats MONDO:0021124 PMID:41385096 "[{""id"":""uuid:ea3973db-4b26-48bb-aa2a-10eb4203f496"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:185c7cbb-81cc-4982-b23e-f01342be8711"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/puregon""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] In the female:Puregon is indicated for the treatment of female infertility in the following clinical situations:anovulation (including polycystic ovarian syndrome, PCOS) in women who have been unresponsive to treatment with clomifene citrate;controlled ovarian hyperstimulation to induce the development of multiple follicles in medically assisted reproduction programs (e.g. in-vitro fertilisation / embryo transfer (IVF/ET), gamete intrafallopian transfer (GIFT) and intracytoplasmic sperm injection (ICSI)).In the male:Deficient spermatogenesis due to hypogonadotrophic hypogonadism. uuid:ac851970-e85f-4c7d-a2c9-45fa949aa361 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:N7T15V1FUY biolink:treats MONDO:0015229 PMID:41385096 "[{""id"":""uuid:4095bf1c-0a45-4c21-9009-e79cd6abd358"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f89e514e-9b1f-4951-b7df-baa535cf7ae9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/imcivree""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Imcivree is indicated for the treatment of obesity and the control of hunger associated with genetically confirmed Bardet Biedl syndrome (BBS), loss-of-function biallelic pro-opiomelanocortin (POMC), including PCSK1, deficiency or biallelic leptin receptor (LEPR) deficiency in adults and children 6 years of age and above. uuid:304aca30-d1d6-4be9-96fa-f5c4075f1956 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C075654 biolink:treats MONDO:0001134 PMID:41385096 "[{""id"":""uuid:15b9b48e-8faf-4211-9ac8-e932689529ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:8013da7d-7820-4af8-bd4e-2def29cf561a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of essential hypertension.MicardisPlus fixed-dose combination (40 mg telmisartan / 12.5 mg hydrochlorothiazide, 80 mg telmisartan / 12.5 mg hydrochlorothiazide) is indicated in patients whose blood pressure is not adequately controlled on telmisartan alone.MicardisPlus fixed-dose combination (80 mg telmisartan / 25 mg hydrochlorothiazide) is indicated in patients whose blood pressure is not adequately controlled on MicardisPlus (80 mg telmisartan / 12.5 mg hydrochlorothiazide) or patients who have been previously stabilised on telmisartan and hydrochlorothiazide given separately. uuid:a564aa69-bd69-4424-b7c2-8811ae1e4185 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7PCM518YLR biolink:treats MONDO:0010602 PMID:41385096 "[{""id"":""uuid:c45b03f8-daa1-4f43-9669-69af54659c3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:94372641-9543-455a-9d6a-15907d8429f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/elocta""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).Elocta can be used for all age groups. uuid:3fca2973-3711-4c9c-a79d-08b071c03484 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:91408 biolink:treats MONDO:0044903 PMID:41385096 "[{""id"":""uuid:4022178a-cb39-401c-9c72-17d968f6ac60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:feefed13-8781-46a8-afba-3fa673dbd1a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are Janus Associated Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib. uuid:13eec470-1a01-4737-a48f-c396d600562e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:66903 biolink:treats MONDO:0020804 PMID:41385096 "[{""id"":""uuid:aa89dc32-2dad-40ce-90e5-4208ae929e47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a772bdec-c938-47de-b76d-de9e67bd42b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/erivedge""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Erivedge is indicated for the treatment of adult patients with:- symptomatic metastatic basal cell carcinoma- locally advanced basal cell carcinoma inappropriate for surgery or radiotherapy uuid:23910aa0-b322-410f-8335-681d095ca5c7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:X05U0N2RCO biolink:treats MONDO:0850353 PMID:41385096 "[{""id"":""uuid:a333adc5-962a-4c7c-b71b-44f07a532eda"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:be7b3dcd-bc23-4e65-95a6-1c5dcd8829be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/nubeqa""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] NUBEQA is indicated for the treatment of adult men with- non metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease (see section 5.1).- metastatic hormone sensitive prostate cancer (mHSPC) in combination with docetaxel and androgen deprivation therapy (see section 5.1). uuid:a3bea7d3-0c74-49f0-a88b-bb06b99e35f6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0357131 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:79430b87-0f7d-427d-a5e3-f28f16531082"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e0f8fa4e-446c-4f2d-8215-401c6c90f955"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/neorecormon""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult and paediatric patients;treatment of symptomatic anaemia in adult patients with non-myeloid malignancies receiving chemotherapy;increasing the yield of autologous blood from patients in a pre-donation programme. Its use in this indication must be balanced against the reported increased risk of thromboembolic events. Treatment should only be given to patients with moderate anaemia (Hb 10 - 13 g/dl [6.21 - 8.07 mmol/l], no iron deficiency) if blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). DRUGBANK:DB19434 uuid:7ffb0541-3e8e-4cf7-abdf-7c0a1539c0e4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0357131 biolink:treats MONDO:0004992 PMID:41385096 "[{""id"":""uuid:1c9af77a-2fa8-4676-9b66-670510b7f277"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b5019fdd-bf61-4964-be0e-2d3eb8da2cd9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/neorecormon""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult and paediatric patients;treatment of symptomatic anaemia in adult patients with non-myeloid malignancies receiving chemotherapy;increasing the yield of autologous blood from patients in a pre-donation programme. Its use in this indication must be balanced against the reported increased risk of thromboembolic events. Treatment should only be given to patients with moderate anaemia (Hb 10 - 13 g/dl [6.21 - 8.07 mmol/l], no iron deficiency) if blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males). DRUGBANK:DB19434 uuid:b44686df-859e-4f4c-a3a3-ffe636882ee4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0357131 biolink:treats MONDO:0002280 PMID:41385096 "[{""id"":""uuid:94832ecb-c38e-4365-a192-2958a70a5dc0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e1878e46-415e-40f3-b0d1-9e6850193106"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/neorecormon""]},{""id"":""uuid:4b1977bd-8f0f-4459-91e7-a59af4d28651"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult and paediatric patients;treatment of symptomatic anaemia in adult patients with non-myeloid malignancies receiving chemotherapy;increasing the yield of autologous blood from patients in a pre-donation programme. Its use in this indication must be balanced against the reported increased risk of thromboembolic events. Treatment should only be given to patients with moderate anaemia (Hb 10 - 13 g/dl [6.21 - 8.07 mmol/l], no iron deficiency) if blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males).|[PMDA] Addition of a new indication for anemia in premature infants. DRUGBANK:DB19434 uuid:be31be8e-dce3-4c0a-b679-5f7ee6b0a0b5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEMBL.COMPOUND:CHEMBL3990008 biolink:treats MONDO:0019088 PMID:41385096 "[{""id"":""uuid:a514da43-a3c3-4577-97dc-d402b54bb4c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:18f8b0f4-5f05-4cf5-889c-6f7629777eb4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ebvallo""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ebvallo is indicated as monotherapy for treatment of adult and paediatric patients 2 years of age and older with relapsed or refractory Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) who have received at least one prior therapy. For solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate. uuid:5b2a9302-7c3a-45d7-9b0d-e1759c36b212 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68647 biolink:treats MONDO:0024883 PMID:41385096 "[{""id"":""uuid:1fac23fd-7443-404c-ba3e-964f2075dc64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:49508069-faf5-4eab-89c5-728ffd88ca33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/stivarga""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Stivarga is indicated as monotherapy for the treatment of adult patients with:metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies - these include fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and an anti-EGFR therapy;unresectable or metastatic gastrointestinal stromal tumors (GIST) who progressed on or are intolerant to prior treatment with imatinib and sunitinib;hepatocellular carcinoma (HCC) who have been previously treated with sorafenib. uuid:32bf0a5e-4c31-4fae-b9f2-f6b18de61558 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:73275 biolink:treats NCIT:C154264 PMID:41385096 "[{""id"":""uuid:209762f9-167b-4c32-9d2f-e86c4c7a5efa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e7ad0770-f534-4f48-926a-3d142b8e776f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/senshio""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Senshio is indicated for the treatment of moderate to severe symptomatic vulvar and vaginal atrophy (VVA) in post-menopausal women. uuid:174e792c-a694-4396-9f45-a63e4b13fa6d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:94511 biolink:treats MONDO:0009061 PMID:41385096 "[{""id"":""uuid:059e99ac-07c7-42b5-8998-8b3f90b5566e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:8ed5854e-518f-4538-b26b-4c9e475de109"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Cayston is indicated for the suppressive therapy of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis (CF) aged 6 years and older.Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:46afad9b-61b8-4c24-80c2-4a702eaba16d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:94511 biolink:treats MONDO:0040732 PMID:41385096 "[{""id"":""uuid:17bb0f8c-965d-44fa-8472-b19bb258c2ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:15616573-9a31-4f4d-897a-d13176556bde"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Cayston is indicated for the suppressive therapy of chronic pulmonary infections due to Pseudomonas aeruginosa in patients with cystic fibrosis (CF) aged 6 years and older.Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:c9bfbf8f-f9c7-443d-a050-73b391c49f25 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2670556 biolink:treats MONDO:0005373 PMID:41385096 "[{""id"":""uuid:dc948fb6-7ac3-42ea-ba2e-de9336139ba9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e4bcf99d-88bb-4a0b-bcec-c97ccc1f7eef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/menveo""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] MenQuadfi is indicated for active immunisation of individuals from the age of 12 months and older against invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W, and Y.The use of this vaccine should be in accordance with available official recommendations. uuid:bcdeb426-eb29-4efa-8bd5-0412d4bdbad9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68554 biolink:treats MONDO:0016486 PMID:41385096 "[{""id"":""uuid:da9facdd-a135-4405-9e9e-6f4e652aa9da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ac7ac9de-7adc-4e0f-ae32-04cc4c0ff4d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ferriprox""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ferriprox monotherapy is indicated for the treatment of iron overload in patients with thalassaemia major when current chelation therapy is contraindicated or inadequate.Ferriprox in combination with another chelator is indicated in patients with thalassaemia major when monotherapy with any iron chelator is ineffective, or when prevention or treatment of life-threatening consequences of iron overload (mainly cardiac overload) justifies rapid or intensive correction. uuid:8c93c6c6-b78f-4ad3-b957-b496a7664e0e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68554 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:687be92b-2c01-4acf-9ae2-3410c355fa57"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:3720f5cb-76b8-4c70-bedb-7840e6ae8320"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ferriprox""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ferriprox monotherapy is indicated for the treatment of iron overload in patients with thalassaemia major when current chelation therapy is contraindicated or inadequate.Ferriprox in combination with another chelator is indicated in patients with thalassaemia major when monotherapy with any iron chelator is ineffective, or when prevention or treatment of life-threatening consequences of iron overload (mainly cardiac overload) justifies rapid or intensive correction. uuid:0753e1ed-e3b8-4995-b67e-4e956ae25201 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4031 biolink:treats MONDO:0003085 PMID:41385096 "[{""id"":""uuid:342f158b-5ff4-44f8-850d-01018c16302b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c367026c-0c87-4ca9-bf31-f46e67024e98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/verkazia""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of severe keratitis in adult patients with dry eye disease, which has not improved despite treatment with tear substitutes. uuid:d064e77b-722a-4178-99ec-18d571baf151 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEMBL.COMPOUND:CHEMBL2108334 biolink:treats MONDO:0018660 PMID:41385096 "[{""id"":""uuid:ff7e0bc0-2946-4449-aad4-a9ec0236b0d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4170b036-15c9-4d0f-bf5b-708a07343165"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/novoseven""]},{""id"":""uuid:8af28fd3-bb62-4239-ac2d-f7a1eb751d27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] NovoSeven is indicated for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups:in patients with congenital haemophilia with inhibitors to coagulation factors VIII or IX > 5 Bethesda units (BU);in patients with congenital haemophilia who are expected to have a high anamnestic response to factor-VIII or factor-IX administration;in patients with acquired haemophilia;in patients with congenital factor-VII deficiency;in patients with Glanzmann's thrombasthenia with antibodies to platelet glycoprotein (GP) IIb-IIIa and / or human leucocyte antigens (HLA), and with past or present refractoriness to platelet transfusions.in patients with Glanzmann’s thrombasthenia with past or present refractoriness to platelet transfusions, or where platelets are not readily available.|[PMDA] Drugs with a new dosage to add single-dose administration for the prevention of bleeding in patients with congenital hemophilia who have inhibitors against blood coagulation factor VIII or IX. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:938b2cb9-2a25-4819-b0d9-6c61fc826823 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEMBL.COMPOUND:CHEMBL2108334 biolink:treats MONDO:0019139 PMID:41385096 "[{""id"":""uuid:f9afac31-0ab1-40ec-8c2e-a709a958cfd4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:dc5cacd4-bbff-4bd5-8336-26ab66b9c444"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/novoseven""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] NovoSeven is indicated for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups:in patients with congenital haemophilia with inhibitors to coagulation factors VIII or IX > 5 Bethesda units (BU);in patients with congenital haemophilia who are expected to have a high anamnestic response to factor-VIII or factor-IX administration;in patients with acquired haemophilia;in patients with congenital factor-VII deficiency;in patients with Glanzmann's thrombasthenia with antibodies to platelet glycoprotein (GP) IIb-IIIa and / or human leucocyte antigens (HLA), and with past or present refractoriness to platelet transfusions.in patients with Glanzmann’s thrombasthenia with past or present refractoriness to platelet transfusions, or where platelets are not readily available. uuid:329c4ded-c401-48fc-9624-d360f36e8f14 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEMBL.COMPOUND:CHEMBL2108334 biolink:treats MONDO:0100326 PMID:41385096 "[{""id"":""uuid:328993e1-060d-47d6-a083-2b7508f6f9bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f8faf37e-9aed-47c5-82fe-d2f87eb1e3ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/novoseven""]},{""id"":""uuid:00435392-8633-4923-a439-b52e810aec33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] NovoSeven is indicated for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups:in patients with congenital haemophilia with inhibitors to coagulation factors VIII or IX > 5 Bethesda units (BU);in patients with congenital haemophilia who are expected to have a high anamnestic response to factor-VIII or factor-IX administration;in patients with acquired haemophilia;in patients with congenital factor-VII deficiency;in patients with Glanzmann's thrombasthenia with antibodies to platelet glycoprotein (GP) IIb-IIIa and / or human leucocyte antigens (HLA), and with past or present refractoriness to platelet transfusions.in patients with Glanzmann’s thrombasthenia with past or present refractoriness to platelet transfusions, or where platelets are not readily available.|[PMDA] Drugs with a new additional indication and a new dosage for inhibition of bleeding tendency in patients with Glanzmann thrombasthenia with alloantibodies against platelet, and with past or present refractoriness to platelet transfusions. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:320641d6-d05e-4e11-8f49-ef99648d1586 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7459 biolink:treats HP:0002791 PMID:41385096 "[{""id"":""uuid:d20a9e60-2416-4f00-aa47-d773f9ae5636"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e4ec1e78-b340-4d7e-9737-e21473db12ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Nyxoid is intended for immediate administration as emergency therapy for known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression in both non-medical and healthcare settings.Nyxoid is indicated in adults and adolescents aged 14 years and over.Nyxoid is not a substitute for emergency medical care. uuid:11c22f60-a624-47f1-be76-48eab690a558 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85157 biolink:treats MONDO:0004992 PMID:41385096 "[{""id"":""uuid:56aa41f4-0547-4b97-8502-a8022c422b35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e2b7a58a-c095-4191-b701-6177f7341bc0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Aloxi is indicated in adults for:the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy,the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy.Aloxi is indicated in paediatric patients 1 month of age and older for:the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy. uuid:90aa48c8-ecfb-48fc-a474-2458d65e9c19 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1720952 biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:9bb8909e-bc8e-437e-927d-bad5eea33c3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:10d9ef69-3dc5-4891-a1a7-f7c870f1f11c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ulunar-breezhaler""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ulunar Breezhaler is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). uuid:cb1b0ac9-362b-430c-9001-7f0978885e47 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31638 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:40b94af6-a681-46df-af7a-736ef1817c31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7588d391-299c-4790-a138-2d67fa66b082"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/fulvestrant-mylan""]},{""id"":""uuid:bddaca11-bcf1-44da-8237-dadc0446d3ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Fulvestrant is indicated for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women:not previously treated with endocrine therapy, orwith disease relapse on or after adjuvant anti-estrogen therapy, or disease progression on antiestrogen therapy.|[PMDA] A drug with a new active ingredient indicated for the treatment of postmenopausal breast cancer. uuid:c8721f32-3141-4d46-855f-6916666e1278 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:601027 biolink:treats MONDO:0001134 PMID:41385096 "[{""id"":""uuid:7b7f92f0-7d1e-409d-abc1-b291d14d100b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c3c12c18-a144-455e-94b2-5094ab63acc4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/rasilez""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of essential hypertension. uuid:c602887e-8bb5-4d53-a0b0-b93564ec03ff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134966 biolink:treats MONDO:0016532 PMID:41385096 "[{""id"":""uuid:c30b6190-d7af-4fa0-92a8-54eaae141728"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f21c4797-6769-471e-95d8-d4aac6d7d791"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/inovelon""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Inovelon is indicated as adjunctive therapy in the treatment of seizures associated with Lennox Gastaut syndrome in patients 4 years of age and older. uuid:a738a4e4-73c0-4c4b-bb57-b74d33451644 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:BTY153760O biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:7d442573-287b-4e45-867e-24b15d957599"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:51d8656d-f2b3-4fb2-bdd2-11611d2928ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/taltz""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Plaque psoriasisTaltz is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.Psoriatic arthritisTaltz, alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drug (DMARD) therapies. uuid:c7516ccb-4e45-494d-94c4-ab89b3d29a66 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6916 biolink:treats MONDO:0054869 PMID:41385096 "[{""id"":""uuid:68dcc064-77fd-426f-9aab-edf43ee9e799"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a6e96b88-2b4f-4953-a56a-76393cce1aae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Namuscla is indicated for the symptomatic treatment of myotonia in adult patients with non-dystrophic myotonic disorders. uuid:e230a6d4-d87a-4864-81f6-bd8be94ea3f9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32120 biolink:treats MONDO:0016543 PMID:41385096 "[{""id"":""uuid:ec35ea94-ef8e-4cfa-9368-fbca8b0972a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a108fd9a-581d-4252-8e0e-9aeb0d0668ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Sapropterin Dipharma is indicated for the treatment of hyperphenylalaninaemia (HPA) in adults and paediatric patients of all ages with phenylketonuria (PKU) who have been shown to be responsive to such treatment.Sapropterin Dipharma is also indicated for the treatment of hyperphenylalaninaemia (HPA) in adults and paediatric patients of all ages with tetrahydrobiopterin (BH4) deficiency who have been shown to be responsive to such treatment. uuid:192d8513-18af-40f7-bb49-9c42caf65010 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32120 biolink:treats MONDO:0009861 PMID:41385096 "[{""id"":""uuid:179bf812-c046-43fc-aae0-1f9407d1251b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:22f485c5-57b2-4654-bcd6-20ed74ebff25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Sapropterin Dipharma is indicated for the treatment of hyperphenylalaninaemia (HPA) in adults and paediatric patients of all ages with phenylketonuria (PKU) who have been shown to be responsive to such treatment.Sapropterin Dipharma is also indicated for the treatment of hyperphenylalaninaemia (HPA) in adults and paediatric patients of all ages with tetrahydrobiopterin (BH4) deficiency who have been shown to be responsive to such treatment. uuid:afa3f1b9-f588-4214-b3d4-08da8d491703 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1741730 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:1b0e9217-d480-4b96-a629-40ef681d4dd0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6ba10e77-171a-47ed-a799-2400994bff85"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/odefsey""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus 1 (HIV 1) without known mutations associated with resistance to the non nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine and with a viral load ≤ 100,000 HIV 1 RNA copies/mL., uuid:f611aa07-4280-431c-a0b0-2fd38119facf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51450 biolink:treats MONDO:0019340 PMID:41385096 "[{""id"":""uuid:fab42cb3-87c8-4159-bad4-1b9e4691e3a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:dc8d9f73-59e8-459f-b4f7-255825ad0694"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity and symptoms in patients with WHO functional class III.Efficacy has been shown in:, , , Primary (idiopathic and familial) PAH;, PAH secondary to scleroderma without significant interstitial pulmonary disease;, PAH associated with congenital systemic-to-pulmonary shunts and Eisenmenger's physiology., , , Some improvements have also been shown in patients with PAH WHO functional class II., , Tracleer is also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease., uuid:b165d0cf-e9bc-4e5f-9ba6-7a980d438af5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51450 biolink:treats MONDO:0005100 PMID:41385096 "[{""id"":""uuid:d33a32cc-3750-44d8-a6e9-e3ad36d16cdd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:92fd9ea2-d2a9-4f4a-8737-a53a66236939"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:e9b3d804-838c-4c8c-8aa7-cf9ca03d78fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity and symptoms in patients with WHO functional class III.Efficacy has been shown in:, , , Primary (idiopathic and familial) PAH;, PAH secondary to scleroderma without significant interstitial pulmonary disease;, PAH associated with congenital systemic-to-pulmonary shunts and Eisenmenger's physiology., , , Some improvements have also been shown in patients with PAH WHO functional class II., , Tracleer is also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease.,|[PMDA] A drug with a new additional indication for inhibiting development of digital ulcer in patients with systemic scleroderma (only for patients who currently have digital ulcers or have a history of digital ulcer.) [Orphan drug] uuid:7ac926d3-68d1-4cb1-85ac-ed079acb3edf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51450 biolink:treats MONDO:0019944 PMID:41385096 "[{""id"":""uuid:cbd0e700-d16d-46b5-9b39-e6a9e311717d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a429a775-030b-4943-bfe4-ca16c1cc8d6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity and symptoms in patients with WHO functional class III.Efficacy has been shown in:, , , Primary (idiopathic and familial) PAH;, PAH secondary to scleroderma without significant interstitial pulmonary disease;, PAH associated with congenital systemic-to-pulmonary shunts and Eisenmenger's physiology., , , Some improvements have also been shown in patients with PAH WHO functional class II., , Tracleer is also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease., uuid:bceabe13-be00-4e1e-ace5-7b030fa4c0a8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C1529800 biolink:treats MONDO:0015924 PMID:41385096 "[{""id"":""uuid:24fd5236-611b-4484-b9e8-6a4d5ed135ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ae478f73-03d0-40fc-9a0b-3668b655cc86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity and symptoms in patients with World Health Organization (WHO) functional class III. Efficacy has been shown in:primary (idiopathic and familial) PAH;PAH secondary to scleroderma without significant interstitial pulmonary disease;PAH associated with congenital systemic-to-pulmonary shunts and Eisenmenger’s physiology.Some improvements have also been shown in patients with PAH WHO functional class II.Stayveer is also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital-ulcer disease. uuid:1127e9ad-8ffc-4821-8cb1-b434a263e14c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C1529800 biolink:treats MONDO:0019340 PMID:41385096 "[{""id"":""uuid:8e167b23-0b81-43af-b2db-8b2afe9e84e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b3749524-002c-4864-b2bd-b7e27ef8e3e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity and symptoms in patients with World Health Organization (WHO) functional class III. Efficacy has been shown in:primary (idiopathic and familial) PAH;PAH secondary to scleroderma without significant interstitial pulmonary disease;PAH associated with congenital systemic-to-pulmonary shunts and Eisenmenger’s physiology.Some improvements have also been shown in patients with PAH WHO functional class II.Stayveer is also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital-ulcer disease. uuid:cc058bb3-6c6d-42b1-8d92-8f25d02c0ea4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C1529800 biolink:treats MONDO:0005100 PMID:41385096 "[{""id"":""uuid:6681c11e-5646-4d71-98e7-a09e703dac07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c1080939-d3b9-42e7-89f1-0ed8a6d6000f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity and symptoms in patients with World Health Organization (WHO) functional class III. Efficacy has been shown in:primary (idiopathic and familial) PAH;PAH secondary to scleroderma without significant interstitial pulmonary disease;PAH associated with congenital systemic-to-pulmonary shunts and Eisenmenger’s physiology.Some improvements have also been shown in patients with PAH WHO functional class II.Stayveer is also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital-ulcer disease. uuid:751fdbdd-fb6c-40af-99c0-15557ac2b51e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats MONDO:0016223 PMID:41385096 "[{""id"":""uuid:e6a4cebd-51a5-47b0-b9b7-0ee14aedb11a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0311a2b6-092b-4656-a2e2-044244457e3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Hemangiol is indicated in the treatment of proliferating infantile haemangioma requiring systemic therapy:, , , Life- or function-threatening haemangioma,, Ulcerated haemangioma with pain and/or lack of response to simple wound care measures,, Haemangioma with a risk of permanent scars or disfigurement., , , It is to be initiated in infants aged 5 weeks to 5 months., uuid:3abd31b2-49b3-4de1-9b5a-55b9438cf32b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats MONDO:0006500 PMID:41385096 "[{""id"":""uuid:8b8549a4-06c3-4eb6-b9d1-28191e356633"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:bdea13f2-7b69-4997-9c72-2f2d10effed3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Hemangiol is indicated in the treatment of proliferating infantile haemangioma requiring systemic therapy:, , , Life- or function-threatening haemangioma,, Ulcerated haemangioma with pain and/or lack of response to simple wound care measures,, Haemangioma with a risk of permanent scars or disfigurement., , , It is to be initiated in infants aged 5 weeks to 5 months., uuid:e021ba0c-0c6a-4ace-8cf7-2ad2a04ec946 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:44232548 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:cd09e7c1-e0ac-4654-9124-fab53665e5e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5937127a-a99b-4e4c-84e7-1fd8a769a55b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/stribild""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of human immunodeficiency virus 1 (HIV 1) infection in adults aged 18 years and over who are antiretroviral treatment-naïve or are infected with HIV 1 without known mutations associated with resistance to any of the three antiretroviral agents in Stribild. uuid:98063daf-9d43-4518-8da0-c5276aa7f5c4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:16213489 biolink:treats MONDO:0004247 PMID:41385096 "[{""id"":""uuid:d8cdf655-1b19-4502-a54d-b6afac05e9f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:fdbd55f2-2f22-4d28-b90f-159f56afb944"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Helicobacter Test INFAI may be used for in vivo diagnosis of gastroduodenal Helicobacter pylori infection in:adults;adolescents, who are likely to have peptic ulcer disease.Helicobacter Test INFAI for children aged three to 11 years may be used for in vivo diagnosis of gastrduodenal Helicobacter pylori infection:for the evaluation of the success of eradication treatment, or;when invasive tests cannot be performed, or;when there are discordant results arising from invasive tests.This medicinal product is for diagnostic use only. uuid:8f921a71-e677-4746-9af2-21d88e261ed3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231693 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:c0de2fbe-3780-475a-a9ae-01bc2bd9dc8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a42502ee-8d18-408f-90c4-5e14715dc5d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Tabrecta as monotherapy is indicated for the treatment of adult patients with advanced non small cell lung cancer (NSCLC) harbouring alterations leading to mesenchymal epithelial transition factor gene exon 14 (METex14) skipping, who require systemic therapy following prior treatment with immunotherapy and/or platinum based chemotherapy. UNII:TY34L4F9OZ uuid:ca6005cd-69df-4dae-91b8-0dba2b5343c1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:981TME683S biolink:treats MONDO:0009891 PMID:41385096 "[{""id"":""uuid:5d323a65-c8b1-440a-9825-b4736ee11ff8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ec06336f-2a09-4125-abba-2163e397a61f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/besremi""]},{""id"":""uuid:a6b5ce68-66f7-49a6-afec-72feb993b55b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Besremi is indicated as monotherapy in adults for the treatment of polycythaemia vera without symptomatic splenomegaly.|[PMDA] Drugs with a new active ingredient indicated for the treatment of polycythaemia vera (use only when conventional therapies are not sufficiently effective or inappropriate). uuid:3f1aa9ec-9482-4ec3-a70c-ffa27a392a25 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7D96IR0PPM biolink:treats MONDO:0004969 PMID:41385096 "[{""id"":""uuid:4b4c4e42-6ce7-43c4-99e8-2c20cad7167d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:bf264cd8-d885-4bbc-939d-bbcd6bee1b56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/oncaspar""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Oncaspar is indicated as a component of antineoplastic combination therapy in acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years, and adult patients. uuid:d254ab9b-f984-4cd2-a1ee-0df80082d35f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:WGD229O42W biolink:treats MONDO:0005068 PMID:41385096 "[{""id"":""uuid:24d5f994-263a-46ee-bfe9-d8851d3cae72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5d6f724f-3228-4238-964d-73216a8a4333"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/metalyse""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Metalyse is indicated for the thrombolytic treatment of suspected myocardial infarction with persistent ST elevation or recent left-bundle-branch block within six hours after the onset of acute-myocardial-infarction symptoms., uuid:72eb7a57-8c0f-4b12-9333-092e98363b79 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:FYS6T7F842 biolink:treats MONDO:0018456 PMID:41385096 "[{""id"":""uuid:4b70c9a4-c843-49fe-a36f-fdb489e3ebeb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8c88f737-3176-4e43-bcfd-4f5f0ffea27d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/hulio""]},{""id"":""uuid:1e426ce9-2b3b-4f7a-ba80-fad6f7f1190a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rheumatoid arthritis , , Amgevita in combination with methotrexate, is indicated for:, , , the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate., the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate., , , Amgevita can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate., , Amgevita reduces the rate of progression of joint damage as measured by x-ray and improves physical function, when given in combination with methotrexate., , Juvenile idiopathic arthritis, , Polyarticular juvenile idiopathic arthritis, , Amgevita in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Amgevita can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate (for the efficacy in monotherapy see section 5.1). Adalimumab has not been studied in patients aged less than 2 years., , Enthesitis-related arthritis, , Amgevita is indicated for the treatment of active enthesitis-related arthritis in patients, 6 years of age and older, who have had an inadequate response to, or who are intolerant of, conventional therapy (see section 5.1)., , Axial spondyloarthritis, , Ankylosing spondylitis (AS), , Amgevita is indicated for the treatment of adults with severe active ankylosing spondylitis who have had an inadequate response to conventional therapy., , Axial spondyloarthritis without radiographic evidence of AS, , Amgevita is indicated for the treatment of adults with severe axial spondyloarthritis without radiographic evidence of AS but with objective signs of inflammation by elevated CRP and/or MRI, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs., , Psoriatic arthritis, , Amgevita is indicated for the treatment of active and progressive psoriatic arthritis in adults when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate. Amgevita reduces the rate of progression of peripheral joint damage as measured by x-ray in patients with polyarticular symmetrical subtypes of the disease (see section 5.1) and improves physical function., , Psoriasis, , Amgevita is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy., , Paediatric plaque psoriasis, , Amgevita is indicated for the treatment of severe chronic plaque psoriasis in children and adolescents from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapies., , Hidradenitis suppurativa (HS), , Amgevita is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults and adolescents from 12 years of age with an inadequate response to conventional systemic HS therapy (see sections 5.1 and 5.2)., , Crohn’s disease, , Amgevita is indicated for treatment of moderately to severely active Crohn’s disease, in adult patients who have not responded despite a full and adequate course of therapy with a corticosteroid and/or an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies., , Paediatric Crohn's disease, , Amgevita is indicated for the treatment of moderately to severely active Crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies., , Ulcerative colitis, , Amgevita is indicated for treatment of moderately to severely active ulcerative colitis in adult patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies., , Uveitis, , Amgevita is indicated for the treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate., , Paediatric uveitis, , Amgevita is indicated for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.,|[PMDA] Follow-on biologics indicated for the treatment of rheumatoid arthritis (including the prevention of structural joint damage), and the treatment of the following diseases in patients who have not responded sufficiently to conventional treatments; polyarticular- course juvenile idiopathic arthritis, plaque psoriasis, psoriatic arthritis, pustular psoriasis, ankylosing spondylitis and intestinal Behcet’s disease; and the remission induction therapy and maintenance therapy for moderate to severe active Crohn's disease (for use only in patients who have not sufficiently responded to conventional therapies). uuid:0aaef129-4a8f-46bb-a4d4-e5d7e4001273 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6954 biolink:treats MONDO:0006639 PMID:41385096 "[{""id"":""uuid:4c1b6426-7618-406f-8500-db121ac86249"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:7eac6346-162f-4964-953c-46e1b7d163b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lysodren""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Symptomatic treatment of advanced (unresectable, metastatic or relapsed) adrenal cortical carcinoma. The effect of Lysodren on non-functional adrenal cortical carcinoma is not established. uuid:4d5ed097-179b-4eb9-aa62-84797d9cce50 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90841 biolink:treats MONDO:0005010 PMID:41385096 "[{""id"":""uuid:fb1ec00b-400a-4484-b943-ce0369b7149e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:97d9d5aa-43e0-403a-8035-8fb09f56a1a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kengrexal""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Kengrexal, co-administered with acetylsalicylic acid (ASA), is indicated for the reduction of thrombotic cardiovascular events in adult patients with coronary artery disease undergoing percutaneous coronary intervention (PCI) who have not received an oral P2Y12 inhibitor prior to the PCI procedure and in whom oral therapy with P2Y12 inhibitors is not feasible or desirable. uuid:85b3a7d2-9d38-4f77-9f4e-70b077baea8c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63612 biolink:treats MONDO:0004963 PMID:41385096 "[{""id"":""uuid:c1ce09ae-986c-45f5-8dd4-d4017bef6469"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:dc18a4c9-2755-4988-ab28-562495653bb2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/atriance""]},{""id"":""uuid:4fd9d1f2-fd02-42e7-9f57-22c1fa8cbdd7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Nelarabine is indicated for the treatment of patients with T-cell acute lymphoblastic leukaemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens., , Due to the small patient populations in these disease settings, the information to support these indications is based on limited data.,|[PMDA] A drug containing a new active ingredient indicated for the treatment of relapsed or refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. [Orphan drug] uuid:ab8406d4-76d1-417b-a636-17a68c925b1c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5938 biolink:treats MONDO:0002562 PMID:41385096 "[{""id"":""uuid:f95a8b82-ad9a-492c-8303-c4fb7ec65ae3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:fa3def37-aa64-4084-ba2f-c6a96ff543b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/betaferon""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Extavia is indicated for the treatment of:patients with a single demyelinating event with an active inflammatory process, if it is severe enough to warrant treatment with intravenous corticosteroids, if alternative diagnoses have been excluded, and if they are determined to be at high risk of developing clinically definite multiple sclerosis;patients with relapsing-remitting multiple sclerosis and two or more relapses within the last two years;patients with secondary progressive multiple sclerosis with active disease, evidenced by relapses. uuid:7017b1d3-8cfa-4345-8bd9-703f360fc254 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:172944 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:5aefd648-deb1-466f-a002-789f9acd98d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:3d92e897-d80d-459a-992e-28f94234409a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/apretude""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Vocabria tablets are indicated in combination with rilpivirine tablets for the short-term treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA uuid:11b74bdc-efb6-44f2-adfa-e6bbd9a274ad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135920 biolink:treats UMLS:C0150045 PMID:41385096 "[{""id"":""uuid:def77a31-7c4c-4762-852e-6ceb19a0583a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6f4a7c05-a7d8-48cb-898d-45454f8c7cef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of the symptoms (increased urinary frequency and / or urgency and / or urgency incontinence) that may occur in patients with overactive-bladder syndrome. uuid:ab028065-bff6-44c1-9703-4af580be89ea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6ZA31Y954Z biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:1b91c9e9-51d4-4d9c-9fc4-cfc1fd5c967b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:8e972fc8-1147-44da-b861-644eef6d893a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kyntheum""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Kyntheum is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy. uuid:83411a63-6e6d-4aec-983a-679c236f075f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:GB4I2JI8UI biolink:treats MONDO:0001824 PMID:41385096 "[{""id"":""uuid:0efa88dc-81c9-4d32-91ee-f55776e47f26"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:1f661708-3204-4579-92f3-c1d79cb81384"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy. uuid:0e7eceec-2ac4-4506-900f-28ff1a9cb29a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2S9ZZM9Q9V biolink:treats MONDO:0018364 PMID:41385096 "[{""id"":""uuid:d1f03b66-f3fb-4b87-978f-a75d9df0062a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:66ad525f-4933-471c-9270-c6cbeaf11a12"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/abevmy""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Mvasi in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum.Mvasi in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 (HER2) status, please refer to section 5.1.Mvasi, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology.Mvasi in combination with interferon alfa-2a is indicated for first-line treatment of adult patients with advanced and/or metastatic renal cell cancer.Mvasi, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO) stages IIIB, IIIC and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer.Mvasi, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents.Mvasi in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents.Mvasi, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix. uuid:281e34df-2675-4cc2-b29d-67c885fa320c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2S9ZZM9Q9V biolink:treats MONDO:0006206 PMID:41385096 "[{""id"":""uuid:724b0aa9-71f2-4bd2-9042-1b0ea06df761"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f2e799d7-2f23-4c23-b517-506071fa556d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/abevmy""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Mvasi in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum.Mvasi in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. For further information as to human epidermal growth factor receptor 2 (HER2) status, please refer to section 5.1.Mvasi, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology.Mvasi in combination with interferon alfa-2a is indicated for first-line treatment of adult patients with advanced and/or metastatic renal cell cancer.Mvasi, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (International Federation of Gynecology and Obstetrics (FIGO) stages IIIB, IIIC and IV) epithelial ovarian, fallopian tube, or primary peritoneal cancer.Mvasi, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents.Mvasi in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents.Mvasi, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix. uuid:76c5e263-3009-43dc-a854-3470a809b26c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63717 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:123fd172-8cab-4b91-a777-3f8c7f24a77d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:7b00292b-4cc6-40d0-81fa-a68c1faecf34"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] HIV 1 infectionViread 123 mg film coated tablets are indicated in combination with other antiretroviral medicinal products for the treatment of HIV 1 infected paediatric patients, with NRTI resistance or toxicities precluding the use of first line agents, aged 6 to < 12 years who weigh from 17 kg to less than 22 kg.The choice of Viread to treat antiretroviral experienced patients with HIV 1 infection should be based on individual viral resistance testing and/or treatment history of patients.Hepatitis B infectionViread 123 mg film coated tablets are indicated for the treatment of chronic hepatitis B in paediatric patients aged 6 to < 12 years who weigh from 17 kg to less than 22 kg, withcompensated liver disease and evidence of immune active disease, i.e. active viral replication and persistently elevated serum ALT levels, or histological evidence of moderate to severe inflammation and/or fibrosis. With respect to the decision to initiate treatment in paediatric patients, see sections 4.2, 4.4, 4.8 and 5.1.HIV 1 infectionViread 163 mg film coated tablets are indicated in combination with other antiretroviral medicinal products for the treatment of HIV 1 infected paediatric patients, with NRTI resistance or toxicities precluding the use of first line agents, aged 6 to < 12 years who weigh from 22 kg to less than 28 kg.The choice of Viread to treat antiretroviral experienced patients with HIV 1 infection should be based on individual viral resistance testing and/or treatment history of patients.Hepatitis B infectionViread 163 mg film coated tablets are indicated for the treatment of chronic hepatitis B in paediatric patients aged 6 to < 12 years who weigh from 22 kg to less than 28 kg, with:compensated liver disease and evidence of immune active disease, i.e. active viral replication and persistently elevated serum ALT levels, or histological evidence of moderate to severe inflammation and/or fibrosis. With respect to the decision to initiate treatment in paediatric patients, see sections 4.2, 4.4, 4.8 and 5.1.HIV 1 infectionViread 204 mg film coated tablets are indicated in combination with other antiretroviral medicinal products for the treatment of HIV 1 infected paediatric patients, with NRTI resistance or toxicities precluding the use of first line agents, aged 6 to < 12 years who weigh from 28 kg to less than 35 kg.The choice of Viread to treat antiretroviral experienced patients with HIV 1 infection should be based on individual viral resistance testing and/or treatment history of patients.Hepatitis B infectionViread 204 mg film coated tablets are indicated for the treatment of chronic hepatitis B in paediatric patients aged 6 to < 12 years who weigh from 28 kg to less than 35 kg, with:compensated liver disease and evidence of immune active disease, i.e. active viral replication and persistently elevated serum ALT levels or histological evidence of moderate to severe inflammation and/or fibrosis. With respect to the decision to initiate treatment in paediatric patients, see sections 4.2, 4.4, 4.8 and 5.1.HIV 1 infectionViread 245 mg film coated tablets are indicated in combination with other antiretroviral medicinal products for the treatment of HIV 1 infected adults.In adults, the demonstration of the benefit of Viread in HIV 1 infection is based on results of one study in treatment naïve patients, including patients with a high viral load (> 100,000 copies/ml) and studies in which Viread was added to stable background therapy (mainly tritherapy) in antiretroviral pre-treated patients experiencing early virological failure (< 10,000 copies/ml, with the majority of patients having < 5,000 copies/ml).Viread 245 mg film coated tablets are also indicated for the treatment of HIV 1 infected adolescents, with NRTI resistance or toxicities precluding the use of first line agents, aged 12 to < 18 years.The choice of Viread to treat antiretroviral experienced patients with HIV 1 infection should be based on individual viral resistance testing and/or treatment history of patients.Hepatitis B infectionViread 245 mg film coated tablets are indicated for the treatment of chronic hepatitis B in adults with:compensated liver disease, with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis (see section 5.1).evidence of lamivudine resistant hepatitis B virus (see sections 4.8 and 5.1).decompensated liver disease (see sections 4.4, 4.8 and 5.1).Viread 245 mg film coated tablets are indicated for the treatment of chronic hepatitis B in adolescents 12 to < 18 years of age with:compensated liver disease and evidence of immune active disease, i.e. active viral replication and persistently elevated serum ALT levels, or histological evidence of moderate to severe inflammation and/or fibrosis. With respect to the decision to initiate treatment in paediatric patients, see sections 4.2, 4.4, 4.8 and 5.1.HIV 1 infectionViread 33 mg/g granules are indicated in combination with other antiretroviral medicinal products for the treatment of HIV 1 infected paediatric patients, with NRTI resistance or toxicities precluding the use of first line agents, from 2 to < 6 years of age, and above 6 years of age for whom a solid dosage form is not appropriate.Viread 33 mg/g granules are also indicated in combination with other antiretroviral medicinal products for the treatment of HIV 1 infected adults for whom a solid dosage form is not appropriate.In adults, the demonstration of the benefit of Viread in HIV 1 infection is based on results of one study in treatment naïve patients, including patients with a high viral load (> 100,000 copies/ml) and studies in which Viread was added to stable background therapy (mainly tritherapy) in antiretroviral pre-treated patients experiencing early virological failure (< 10,000 copies/ml, with the majority of patients having < 5,000 copies/ml).The choice of Viread to treat antiretroviral experienced patients with HIV 1 infection should be based on individual viral resistance testing and/or treatment history of patients.Hepatitis B infectionViread 33 mg/g granules are indicated for the treatment of chronic hepatitis B in adults for whom a solid dosage form is not appropriate with:compensated liver disease, with evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis (see section 5.1).evidence of lamivudine resistant hepatitis B virus (see sections 4.8 and 5.1).decompensated liver disease (see sections 4.4, 4.8 and 5.1).Viread 33 mg/g granules are also indicated for the treatment of chronic hepatitis B in paediatric patients2 to < 18 years of age for whom a solid dosage form is not appropriate with:compensated liver disease and evidence of immune active disease, i.e. active viral replication, and persistently elevated serum ALT levels, or histological evidence of moderate to severe inflammation and/or fibrosis. With respect to the decision to initiate treatment in paediatric patients, see sections 4.2, 4.4, 4.8 and 5.1. uuid:cfeaf8d3-9bfc-4d5c-89e2-20d02e6f9c23 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0009061 PMID:41385096 "[{""id"":""uuid:c26be789-3ebb-4c4c-b663-c60410cffc4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:227e0b49-5dec-4df7-b801-08026a172bda"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/quinsair""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Quinsair is indicated for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:9b846b51-808f-4cc0-a030-41912b217947 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68590 biolink:treats MONDO:0000705 PMID:41385096 "[{""id"":""uuid:50eebc97-ebf3-4665-9b82-548d85b04677"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e4036d01-b401-4453-aa76-842b755683c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/dificlir""]},{""id"":""uuid:914b2d87-e36a-4e1a-b6ca-c77011d0e0c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Dificlir film-coated tablets is indicated for the treatment of Clostridioides difficile infections (CDI) also known as C. difficile-associated diarrhoea (CDAD) in adult and paediatric patients with a body weight of at least 12.5 kg.Consideration should be given to official guidelines on the appropriate use of antibacterial agents.Dificlir granules for oral suspension is indicated for the treatment of Clostridioides difficile infections (CDI) also known as C. difficile-associated diarrhoea (CDAD) in adults and paediatric patients from birth to < 18 years of age.Consideration should be given to official guidelines on the appropriate use of antibacterial agents.|[PMDA] A drug with a new active ingredient indicated for the treatment of infectious enteritis (including pseudomembranous colitis) caused by C. difficile . uuid:054dbfa6-797c-4415-9122-064a7b0c2813 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68590 biolink:treats UMLS:C0235952 PMID:41385096 "[{""id"":""uuid:87eba066-fa57-43f8-a356-ba639a21f4da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ffca1bca-bdd8-4922-81d0-26683b86d824"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/dificlir""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Dificlir film-coated tablets is indicated for the treatment of Clostridioides difficile infections (CDI) also known as C. difficile-associated diarrhoea (CDAD) in adult and paediatric patients with a body weight of at least 12.5 kg.Consideration should be given to official guidelines on the appropriate use of antibacterial agents.Dificlir granules for oral suspension is indicated for the treatment of Clostridioides difficile infections (CDI) also known as C. difficile-associated diarrhoea (CDAD) in adults and paediatric patients from birth to < 18 years of age.Consideration should be given to official guidelines on the appropriate use of antibacterial agents. uuid:28c17150-c22d-438c-bf1d-bff144ff094a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:15C2VL427D biolink:treats MONDO:0005575 PMID:41385096 "[{""id"":""uuid:2c996dfc-b2de-4779-bed3-d26b4385af0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a43ac011-dc3f-4f95-a5e0-b88e82e90dd8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/yesafili""]},{""id"":""uuid:b79d48f5-d3a7-49fd-b412-7081ff08f22a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of metastatic colorectal cancer (MCRC).|[PMDA] Drugs with a new active ingredient indicated for the treatment of unresectable advanced or recurrent colorectal cancer. uuid:3b299d6c-3ff6-46fd-8e39-f67a35ba0647 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1421448 biolink:treats MONDO:0005338 PMID:41385096 "[{""id"":""uuid:9e5e1909-094d-4d9d-bae7-7b0b6928c6c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:7d53fb59-86a4-42cf-8593-ed8d4ad23747"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/simbrinza""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Decrease of elevated intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction. uuid:9bae242f-8649-4541-981f-55d7a5c84c83 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1421448 biolink:treats MONDO:0006875 PMID:41385096 "[{""id"":""uuid:fdde8d16-0dea-4645-865c-bea84eb63a2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:26fff5c1-0cce-4626-a5a5-3cd82753260b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/simbrinza""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Decrease of elevated intraocular pressure (IOP) in adult patients with open-angle glaucoma or ocular hypertension for whom monotherapy provides insufficient IOP reduction. uuid:e9a43d62-b3d8-40a7-a70e-be299d4b55de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134703 biolink:treats MONDO:0008315 PMID:41385096 "[{""id"":""uuid:2d92a78a-81d1-48f4-a2b5-632f005a0c21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d1fc0448-610b-4d29-b91c-ec24261e444e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] This medicinal product is for diagnostic use only.Axumin is indicated for Positron Emission Tomography (PET) imaging to detect recurrence of prostate cancer in adult men with a suspected recurrence based on elevated blood prostate specific antigen (PSA) levels after primary curative treatment. uuid:104e9872-d8c4-488a-8aa9-55c66086d4a1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB13924 biolink:treats MONDO:0005609 PMID:41385096 "[{""id"":""uuid:5dc7dc19-45a5-496f-bb4e-01b78a31ac3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f0971898-c5ae-4341-87a2-a276068209ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Shingrix is indicated for prevention of herpes zoster (HZ) and post-herpetic neuralgia (PHN), in:adults 50 years of age or older;adults 18 years of age or older at increased risk of HZ.The use of Shingrix should be in accordance with official recommendations. uuid:284a9c09-2bb0-48b7-86c8-219c402e8f68 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB13924 biolink:treats MONDO:0041052 PMID:41385096 "[{""id"":""uuid:e299b444-3597-4b37-a1b3-17d8e9db6530"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b2be2eca-eede-48b2-844a-59cbd5547427"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Shingrix is indicated for prevention of herpes zoster (HZ) and post-herpetic neuralgia (PHN), in:adults 50 years of age or older;adults 18 years of age or older at increased risk of HZ.The use of Shingrix should be in accordance with official recommendations. uuid:0b97333e-de4e-4811-89fc-fbce02e355c5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41500 biolink:treats MONDO:0004739 PMID:41385096 "[{""id"":""uuid:48ead6b1-2fa3-493f-adde-970a0b1e4d9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8496f41b-da64-4b83-b956-fbce166e22b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ammonaps""]},{""id"":""uuid:2ceac050-fab8-421d-a8b1-f558fa8f237f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ammonaps is indicated as adjunctive therapy in the chronic management of urea cycle disorders, involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase orargininosuccinate synthetase.It is indicated in all patients with neonatal-onset presentation (complete enzyme deficiencies, presenting within the first 28 days of life). It is also indicated in patients with late-onset disease(partial enzyme deficiencies, presenting after the first month of life) who have a history of hyperammonaemic encephalopathy.|[PMDA] Drugs with a new active ingredient indicated for the treatment of urea cycle disorder. [Orphan drug] uuid:b3566985-bf73-412c-9577-7c2414d9fda7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41500 biolink:treats MONDO:0009376 PMID:41385096 "[{""id"":""uuid:ec268679-58b0-4b40-8a10-2b821c01a048"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:53815064-b1da-4e5a-a8bd-79d25bcaaa30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ammonaps""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ammonaps is indicated as adjunctive therapy in the chronic management of urea cycle disorders, involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase orargininosuccinate synthetase.It is indicated in all patients with neonatal-onset presentation (complete enzyme deficiencies, presenting within the first 28 days of life). It is also indicated in patients with late-onset disease(partial enzyme deficiencies, presenting after the first month of life) who have a history of hyperammonaemic encephalopathy. uuid:1b68a82e-d83b-4430-86e0-a615548bea58 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41500 biolink:treats MONDO:0010703 PMID:41385096 "[{""id"":""uuid:ca877699-9016-4780-b215-6aef818f853a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:cdbc724e-2ca0-4d2e-abbe-0233258c4d01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ammonaps""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ammonaps is indicated as adjunctive therapy in the chronic management of urea cycle disorders, involving deficiencies of carbamylphosphate synthetase, ornithine transcarbamylase orargininosuccinate synthetase.It is indicated in all patients with neonatal-onset presentation (complete enzyme deficiencies, presenting within the first 28 days of life). It is also indicated in patients with late-onset disease(partial enzyme deficiencies, presenting after the first month of life) who have a history of hyperammonaemic encephalopathy. uuid:6ad9db7b-363b-412b-8553-717269cd3bf7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135552 biolink:treats MONDO:0002203 PMID:41385096 "[{""id"":""uuid:b1b14614-c88d-4a39-94a7-842f29f4b31a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:00e3688c-bb7f-4684-9286-2243c72891be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Resolor is indicated for symptomatic treatment of chronic constipation in adults in whom laxatives fail to provide adequate relief. uuid:caf77366-5375-4750-8425-2cbc41079cb3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:29Z5DNL48C biolink:treats MONDO:0016595 PMID:41385096 "[{""id"":""uuid:88ec4e57-d5be-40be-ba32-25bf243de43a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e05572b3-03ee-44f8-a17f-654f0cb881f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Obiltoxaximab SFL is indicated in combination with appropriate antibacterial drugs in all age groups for treatment of inhalational anthrax due to Bacillus anthracis (see section 5.1).Obiltoxaximab SFL is indicated in all age groups for post-exposure prophylaxis of inhalational anthrax when alternative therapies are not appropriate or are not available (see section 5.1). uuid:377e3ea6-62b7-4d32-8986-046d81d7d902 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:07730V90L6 biolink:treats MONDO:0005191 PMID:41385096 "[{""id"":""uuid:c09b3e7c-2137-4dca-90ce-399cb931b009"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f25b009c-a060-445e-87ca-d4451a1e53be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/imlygic""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Imlygic is indicated for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic (Stage IIIB, IIIC and IVM1a) with no bone, brain, lung or other visceral disease. uuid:567d7898-478e-4bb9-a88c-e38390e1514c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:07730V90L6 biolink:treats MONDO:0005012 PMID:41385096 "[{""id"":""uuid:f76bc1d0-0f56-4d1b-8ffe-0403273e739b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:91e499f9-10e7-4f72-98d2-095738ccdf8e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/imlygic""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Imlygic is indicated for the treatment of adults with unresectable melanoma that is regionally or distantly metastatic (Stage IIIB, IIIC and IVM1a) with no bone, brain, lung or other visceral disease. uuid:ef922f70-4b3f-44cc-baf8-ef302cc87113 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:538316W9ZU biolink:treats MONDO:0005246 PMID:41385096 "[{""id"":""uuid:f33b1a11-6e1d-4d6b-8544-95a489380ce1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f1a9158a-572e-4f47-ad83-03ece22295bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/scintimun""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] This medicinal product is for diagnostic use only and the approved indication is scintigraphic imaging, in conjunction with other appropriate imaging modalities, for determining the location of inflammation/infection in peripheral bone in adults with suspected osteomyelitis. Scintimun should not be used for the diagnosis of diabetic foot infection. uuid:6538cd02-7aa4-42a1-8a55-74765c60db7f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:86278373 biolink:treats MONDO:0006047 PMID:41385096 "[{""id"":""uuid:3fa92aeb-8449-4b06-9f28-bfce0a8f4003"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0a1abe5e-d9a7-4e9e-899d-78102c63809f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of metastatic adenocarcinoma of the pancreas, in combination with 5 fluorouracil (5 FU) and leucovorin (LV), in adult patients who have progressed following gemcitabine based therapy. uuid:3a934106-5914-485e-b741-753632f82bbb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:177736 biolink:treats MONDO:0100347 PMID:41385096 "[{""id"":""uuid:29c496cb-df67-47dd-b50c-c3740a100c3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:342b7ef0-046f-41ab-8f4d-e45628e61286"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Xermelo is indicated for the treatment of carcinoid syndrome diarrhoea in combination with somatostatin analogue (SSA) therapy in adults inadequately controlled by SSA therapy. uuid:b444a0a6-352f-4554-bb78-ae3af276d973 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5818382 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:3dd58504-93ec-47bf-abe8-0aa0e779c6ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4fc6556d-4e5b-4b02-9bfa-372537aa9677"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/velphoro""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Velphoro is indicated for the control of serum phosphorus levels in adult chronic kidney disease (CKD) patients on haemodialysis (HD) or peritoneal dialysis (PD).Velphoro is indicated for the control of serum phosphorus levels in paediatric patients 2 years of age and older with CKD stages 4-5 (defined by a glomerular filtration rate uuid:d69b5f04-0091-4ab8-b406-f595ff1d8542 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1157755 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:78344857-f3e3-4c69-a3e5-4eb55a8ec94c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:54587ffc-040f-4c36-8302-46b9af4d5ff1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/aerinaze""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Symptomatic treatment of seasonal allergic rhinitis when accompanied by nasal congestion. uuid:dd36b44e-a5b6-40bb-9b43-6cf1e4349c59 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71255 biolink:treats MONDO:0001866 PMID:41385096 "[{""id"":""uuid:75039ef9-c192-48ac-ab46-53e2a4ec3594"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e5ee76dd-2470-4fdf-b6d7-6ba90f6b697a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Sycrest is indicated for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults. uuid:aa4de7ee-79a3-4881-93c8-8ce65f643126 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71255 biolink:treats MONDO:0024612 PMID:41385096 "[{""id"":""uuid:9ff1b246-3cb8-4d45-8a19-0359bbd3b779"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:791d122b-55e5-4b04-914f-53bae1c17fa8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Sycrest is indicated for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults. uuid:0ac9d38b-c02c-42c5-8a4a-bc0c75a6ccc2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:EEO29FZT86 biolink:treats MONDO:0005082 PMID:41385096 "[{""id"":""uuid:06f42223-8d46-439c-b4a5-24c65ae79f91"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ac3c5020-e7a9-4bcb-89e9-d896ffc7e0e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Tookad is indicated as monotherapy for adult patients with previously untreated, unilateral, low risk, adenocarcinoma of the prostate with a life expectancy ≥ 10 years and:Clinical stage T1c or T2a;Gleason Score ≤ 6, based on high-resolution biopsy strategies;PSA ≤ 10 ng/mL;3 positive cancer cores with a maximum cancer core length of 5 mm in any one core or 1-2 positive cancer cores with ≥ 50 % cancer involvement in any one core or a PSA density ≥ 0.15 ng/mL/cm³. uuid:fd37237c-fe97-4bc3-bba7-bcc93b59280a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6D848RA61B biolink:treats MONDO:0015514 PMID:41385096 "[{""id"":""uuid:abeff590-21d2-4714-9506-f50050358f64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:1ce1014a-2d28-4237-b442-30c206e0f700"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ngenla""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Indicated for the long-term treatment of paediatric patients with growth disturbance due to insufficient secretion of growth hormone uuid:80f11757-b80b-4176-8f35-3b9ebccdd4e3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68855 biolink:treats MONDO:0003233 PMID:41385096 "[{""id"":""uuid:c7ee90cd-97c1-467e-a1f4-d0001e82d3d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:633ee98b-89ea-44b5-a01b-bf65d85eb51c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] This medicinal product is for diagnostic use only.Striascan is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum:In adult patients with clinically uncertain parkinsonian syndromes, for example those with early symptoms, in order to help differentiate essential tremor from parkinsonian syndromes related to idiopathic Parkinson’s disease, multiple system atrophy and progressive supranuclear palsy. Striascan is unable to discriminate between Parkinson's disease, multiple system atrophy and progressive supranuclear palsy.In adult patients, to help differentiate probable dementia with Lewy bodies from Alzheimer’s disease. Striascan is unable to discriminate between dementia with Lewy bodies and Parkinson’s disease dementia. uuid:4d61761c-8645-47e7-999d-6db4704ab157 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68855 biolink:treats MONDO:0005180 PMID:41385096 "[{""id"":""uuid:89f3eef1-57c6-4825-a2e4-76f903b6e82a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f5482085-c795-478f-92fa-ecb98a11483d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] This medicinal product is for diagnostic use only.Striascan is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum:In adult patients with clinically uncertain parkinsonian syndromes, for example those with early symptoms, in order to help differentiate essential tremor from parkinsonian syndromes related to idiopathic Parkinson’s disease, multiple system atrophy and progressive supranuclear palsy. Striascan is unable to discriminate between Parkinson's disease, multiple system atrophy and progressive supranuclear palsy.In adult patients, to help differentiate probable dementia with Lewy bodies from Alzheimer’s disease. Striascan is unable to discriminate between dementia with Lewy bodies and Parkinson’s disease dementia. uuid:bcf36ad0-e3bc-4e84-9465-402618611d52 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68855 biolink:treats MONDO:0007803 PMID:41385096 "[{""id"":""uuid:06f62977-759e-4431-a313-9f496dcd3070"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:58459409-8192-43b6-be76-5dde6f8bb2e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] This medicinal product is for diagnostic use only.Striascan is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum:In adult patients with clinically uncertain parkinsonian syndromes, for example those with early symptoms, in order to help differentiate essential tremor from parkinsonian syndromes related to idiopathic Parkinson’s disease, multiple system atrophy and progressive supranuclear palsy. Striascan is unable to discriminate between Parkinson's disease, multiple system atrophy and progressive supranuclear palsy.In adult patients, to help differentiate probable dementia with Lewy bodies from Alzheimer’s disease. Striascan is unable to discriminate between dementia with Lewy bodies and Parkinson’s disease dementia. uuid:a4f055c9-2493-40cf-bd8b-94cfacfb8eb9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68855 biolink:treats MONDO:0019037 PMID:41385096 "[{""id"":""uuid:fb4f85c9-023b-40cb-a0c6-47b40c9e317f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:01ef5f37-cf3e-4f34-95c9-96bd6fdaf842"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] This medicinal product is for diagnostic use only.Striascan is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum:In adult patients with clinically uncertain parkinsonian syndromes, for example those with early symptoms, in order to help differentiate essential tremor from parkinsonian syndromes related to idiopathic Parkinson’s disease, multiple system atrophy and progressive supranuclear palsy. Striascan is unable to discriminate between Parkinson's disease, multiple system atrophy and progressive supranuclear palsy.In adult patients, to help differentiate probable dementia with Lewy bodies from Alzheimer’s disease. Striascan is unable to discriminate between dementia with Lewy bodies and Parkinson’s disease dementia. uuid:20a44b4c-d337-41d9-a346-2079a18323bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68855 biolink:treats MONDO:0007488 PMID:41385096 "[{""id"":""uuid:dba55de3-39be-46d9-944e-d345aa63d87f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6f10dcab-9529-480d-83fd-7eeba8af6dce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] This medicinal product is for diagnostic use only.Striascan is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum:In adult patients with clinically uncertain parkinsonian syndromes, for example those with early symptoms, in order to help differentiate essential tremor from parkinsonian syndromes related to idiopathic Parkinson’s disease, multiple system atrophy and progressive supranuclear palsy. Striascan is unable to discriminate between Parkinson's disease, multiple system atrophy and progressive supranuclear palsy.In adult patients, to help differentiate probable dementia with Lewy bodies from Alzheimer’s disease. Striascan is unable to discriminate between dementia with Lewy bodies and Parkinson’s disease dementia. uuid:ee2779a1-4f09-40da-99e6-aac851feb344 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68855 biolink:treats MONDO:0004975 PMID:41385096 "[{""id"":""uuid:d9467ee3-89ac-4342-abeb-d254fbee0026"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:256d5284-e151-4b25-a213-e6563f3daa99"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] This medicinal product is for diagnostic use only.Striascan is indicated for detecting loss of functional dopaminergic neuron terminals in the striatum:In adult patients with clinically uncertain parkinsonian syndromes, for example those with early symptoms, in order to help differentiate essential tremor from parkinsonian syndromes related to idiopathic Parkinson’s disease, multiple system atrophy and progressive supranuclear palsy. Striascan is unable to discriminate between Parkinson's disease, multiple system atrophy and progressive supranuclear palsy.In adult patients, to help differentiate probable dementia with Lewy bodies from Alzheimer’s disease. Striascan is unable to discriminate between dementia with Lewy bodies and Parkinson’s disease dementia. uuid:4160ffea-943b-425d-ae5a-79bd610062f3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64310 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:0afb8597-52bd-4d6d-b75e-af1c89400128"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:93eb14df-11ba-4e86-abff-033aec9cfeb4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/xalkori""]},{""id"":""uuid:e6cd146b-28d6-4f9d-9b6d-07a097a3f1a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] XALKORI as monotherapy is indicated for:The first‑line treatment of adults with anaplastic lymphoma kinase (ALK)‑positive advanced non‑small cell lung cancer (NSCLC)The treatment of adults with previously treated anaplastic lymphoma kinase (ALK)‑positive advanced non‑small cell lung cancer (NSCLC)The treatment of adults with ROS1‑positive advanced non‑small cell lung cancer (NSCLC)The treatment of paediatric patients (age ≥6 to|[PMDA] Drugs with a new active ingredient indicated for the treatment of unresectable advanced/relapsed ALK fusion gene-positive non-small-cell lung cancer. [Orphan drug] uuid:2f9bbbd2-7169-49f3-8c56-3c31bd61ff4f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEMBL.COMPOUND:CHEMBL2108334 biolink:treats MONDO:0002243 PMID:41385096 "[{""id"":""uuid:b1ef3482-abb0-4598-b4f1-af666d8815bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f9ba84c1-75a6-423c-ab22-427d0d6ce82e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] CEVENFACTA is indicated in adults and adolescents (12 years of age and older) for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups:in patients with congenital haemophilia with high-responding inhibitors to coagulation factors VIII or IX (i.e. ≥5 Bethesda Units (BU)); in patients with congenital haemophilia with low titre inhibitors (BU uuid:9bad5154-1fe1-4ea8-8e8d-ea136a328007 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1306289 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:7596cb0f-f55b-4cc3-9f85-3448ca8b5b0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:75a05681-c350-4612-a5ec-2060fbd1db15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/genvoya""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Genvoya is indicated for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus 1 (HIV 1) without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir. uuid:ec435e3e-f37e-4f62-b0e7-ed648a2fd7d9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90241 biolink:treats MONDO:0006474 PMID:41385096 "[{""id"":""uuid:610e9449-b881-4412-9763-9a00929ae6e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:7799e9ca-6778-419a-a103-03daccd96e1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/javlor""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Javlor is indicated in monotherapy for the treatment of adult patients with advanced or metastatic transitional-cell carcinoma of the urothelial tract after failure of a prior platinum-containing regimen.Efficacy and safety of vinflunine have not been studied in patients with performance status ≥ 2. uuid:a7609fb8-5323-431a-a029-3f59dc0ddf4f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90241 biolink:treats MONDO:0040679 PMID:41385096 "[{""id"":""uuid:65fa4fce-8150-491b-a917-678e888e8f1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:35606e3e-6ea5-4602-957b-8c1fb5aaa7c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/javlor""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Javlor is indicated in monotherapy for the treatment of adult patients with advanced or metastatic transitional-cell carcinoma of the urothelial tract after failure of a prior platinum-containing regimen.Efficacy and safety of vinflunine have not been studied in patients with performance status ≥ 2. uuid:e173f595-a87a-476f-bedd-aa7d2e2fb904 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60070 biolink:treats MONDO:0043424 PMID:41385096 "[{""id"":""uuid:3be8d987-473e-40b2-bf41-e473a8cf1481"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a002b212-a36d-46aa-8c81-c4f49a2b4e4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] TreatmentErtapenem SUN is indicated in paediatric patients (3 months to 17 years of age) and in adults for the treatment of the following infections when caused by bacteria known or very likely to be susceptible to ertapenem and when parenteral therapy is required (see sections 4.4 and 5.1):- Intra-abdominal infections- Community acquired pneumonia- Acute gynaecological infections- Diabetic foot infections of the skin and soft tissue (see section 4.4)PreventionErtapenem SUN is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery (see section 4.4).Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:591a0f02-a38c-4a41-a5e3-21452ff9db26 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60070 biolink:treats MONDO:0005230 PMID:41385096 "[{""id"":""uuid:7000e286-2d59-43e6-9d85-8af8b477aa7c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f7cd09d7-f2e3-43bf-8764-c5b333326c02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] TreatmentErtapenem SUN is indicated in paediatric patients (3 months to 17 years of age) and in adults for the treatment of the following infections when caused by bacteria known or very likely to be susceptible to ertapenem and when parenteral therapy is required (see sections 4.4 and 5.1):- Intra-abdominal infections- Community acquired pneumonia- Acute gynaecological infections- Diabetic foot infections of the skin and soft tissue (see section 4.4)PreventionErtapenem SUN is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery (see section 4.4).Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:055f5677-b2de-413f-a64c-b5dab85f1624 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1734632 biolink:treats MONDO:0005231 PMID:41385096 "[{""id"":""uuid:34ed150a-3a7a-4f1b-8f90-44089345fe19"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:3a1a8148-362b-4cac-8a6a-e8d22bee1cb2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zepatier""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] ZEPATIER is indicated for the treatment of chronic hepatitis C (CHC) in adult and paediatric patients 12 years of age and older who weigh at least 30 kg (see sections 4.2, 4.4 and 5.1).For hepatitis C virus (HCV) genotype-specific activity see sections 4.4 and 5.1. uuid:e49f24ab-ddfd-450c-986a-db2a57c0b994 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50841 biolink:treats MONDO:0004985 PMID:41385096 "[{""id"":""uuid:32189e0e-dba4-470d-8cd6-b4d88eb623b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:3a160362-263e-46cd-9ffe-b369331f34eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/adasuve""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Adasuve is indicated for the rapid control of mild-to-moderate agitation in adult patients with schizophrenia or bipolar disorder. Patients should receive regular treatment immediately after control of acute agitation symptoms. uuid:c1a63db7-c4ff-415f-a896-aa3d813a3c37 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3215 biolink:treats NCIT:C34887 PMID:41385096 "[{""id"":""uuid:511c8a65-03ff-48fe-883b-5453fa22cc86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:124b8679-5ab3-4463-83a4-31dec668456c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/exparel-liposomal""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Exparel liposomal is indicated:in adults as a brachial plexus block or femoral nerve block for treatment of post-operative pain.in adults and children aged 6 years or older as a field block for treatment of somatic post-operative pain from small- to medium-sized surgical wounds. uuid:97da7ff8-5c66-4b3d-9703-baed1132f04d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31602 biolink:treats NCIT:C178565 PMID:41385096 "[{""id"":""uuid:c602e9d0-3307-4e11-b572-9c87e6e90734"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:713884a9-b572-433b-a184-fa116bc841ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Effentora is indicated for the treatment of breakthrough pain (BTP) in adults with cancer who are already receiving maintenance opioid therapy for chronic cancer pain., , BTP is a transitory exacerbation of pain that occurs on a background of otherwise controlled persistent pain., , Patients receiving maintenance opioid therapy are those who are taking at least 60 mg of oral morphine daily, at least 25 micrograms of transdermal fentanyl per hour, at least 30 mg of oxycodone daily, at least 8 mg of oral hydromorphone daily or an equianalgesic dose of another opioid for a week or longer. , uuid:b17bb305-f31f-440d-b7a9-2003824ffe8b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2O4BE0K238 biolink:treats MONDO:0018637 PMID:41385096 "[{""id"":""uuid:bf18d920-809c-40bd-870c-277fe6881434"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e95e11c9-f093-40e7-bc4a-48be2d744425"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Waylivra is indicated as an adjunct to diet in adult patients with genetically confirmed familial chylomicronemia syndrome (FCS) and at high risk for pancreatitis, in whom response to diet and triglyceride lowering therapy has been inadequate., uuid:1fff1c3b-7231-43f8-b286-0983795654f2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2O4BE0K238 biolink:treats MONDO:0004982 PMID:41385096 "[{""id"":""uuid:585798af-5564-4839-a095-565c48d82fa8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9ee2acb4-b56f-46eb-a56c-d8f949db581a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Waylivra is indicated as an adjunct to diet in adult patients with genetically confirmed familial chylomicronemia syndrome (FCS) and at high risk for pancreatitis, in whom response to diet and triglyceride lowering therapy has been inadequate., uuid:1c641194-d5e2-44c3-985a-5018a4d22a7f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:659877 biolink:treats MONDO:0002974 PMID:41385096 "[{""id"":""uuid:f4f31a9f-19f4-410d-80ce-54c3ee690296"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:38bb743d-8df7-4292-90c5-0a425e75b01f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:bf9a89be-c086-4fc4-8481-3c29e32bc969"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Gardasil is a vaccine for use from the age of 9 years for the prevention of:premalignant genital lesions (cervical, vulvar and vaginal), premalignant anal lesions, cervical cancers and anal cancers causally related to certain oncogenic Human Papillomavirus (HPV) types;genital warts (condyloma acuminata) causally related to specific HPV types.See sections 4.4 and 5.1 for important information on the data that support this indication.The use of Gardasil should be in accordance with official recommendations.|[PMDA] Drugs with a new active ingredient indicated for the prevention of cervical cancer and its precursor lesions, vulvar intraepithelial neoplasia, vaginal intraepithelial neoplasia, and condyloma acuminatum caused by infection with human papillomavirus types 6, 11, 16 and 18. uuid:8eea6221-91a9-489c-a787-5e630db10a3b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:659877 biolink:treats MONDO:0003199 PMID:41385096 "[{""id"":""uuid:e3eadc49-fc4b-411f-b758-70d08939ab10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0caceafa-7db1-442d-abf2-2224879c2ec9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:c9af3b57-8f71-45b6-b115-69d0e595ec7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Gardasil is a vaccine for use from the age of 9 years for the prevention of:premalignant genital lesions (cervical, vulvar and vaginal), premalignant anal lesions, cervical cancers and anal cancers causally related to certain oncogenic Human Papillomavirus (HPV) types;genital warts (condyloma acuminata) causally related to specific HPV types.See sections 4.4 and 5.1 for important information on the data that support this indication.The use of Gardasil should be in accordance with official recommendations.|[PMDA] A drug with a new indication for the prevention of the following diseases caused by infection with human papillomavirus types 6, 11, 16, and 18: Cervical cancer (squamous cell carcinoma and adenosquamous carcinoma) and its precursor lesions (cervical intraepithelial neoplasia [CIN] 1, 2, and 3, and adenocarcinoma in situ [AIS]) Vulvar intraepithelial neoplasia (VIN) 1, 2, and 3, and vaginal intraepithelial noeplasia (VaIN) 1, 2, and 3 Anal cancer (squamous cell carcinoma) and its precursor lesions (anal intraepithelial neoplasia [AIN] 1, 2, and 3) Condyloma acuminatum uuid:03aaf3de-73ae-45c0-95e4-78d26f2dad1b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:659877 biolink:treats MONDO:0005647 PMID:41385096 "[{""id"":""uuid:ec4f26fa-4cad-49d6-bef4-85ceed9c88fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f8075238-a0f1-45b2-ac94-b04672b405da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Gardasil is a vaccine for use from the age of 9 years for the prevention of:premalignant genital lesions (cervical, vulvar and vaginal), premalignant anal lesions, cervical cancers and anal cancers causally related to certain oncogenic Human Papillomavirus (HPV) types;genital warts (condyloma acuminata) causally related to specific HPV types.See sections 4.4 and 5.1 for important information on the data that support this indication.The use of Gardasil should be in accordance with official recommendations. uuid:7d95f3d3-3363-44ef-8e81-7efe782d38b5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:659877 biolink:treats MONDO:0021074 PMID:41385096 "[{""id"":""uuid:ddefa013-da16-44eb-b4a0-6a8733aa245d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f2bcf028-b165-446a-9d87-d0407d19e840"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Gardasil is a vaccine for use from the age of 9 years for the prevention of:premalignant genital lesions (cervical, vulvar and vaginal), premalignant anal lesions, cervical cancers and anal cancers causally related to certain oncogenic Human Papillomavirus (HPV) types;genital warts (condyloma acuminata) causally related to specific HPV types.See sections 4.4 and 5.1 for important information on the data that support this indication.The use of Gardasil should be in accordance with official recommendations. uuid:e4947db2-50d7-43c6-b965-2a1a21000f08 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:5458180 biolink:treats MONDO:0010200 PMID:41385096 "[{""id"":""uuid:c85469c3-0d2f-410f-982e-8fe40c92eb59"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6aa3d4d9-98ef-437b-ae48-690727318fc2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Cufence is indicated for the treatment of Wilson’s disease in patients intolerant to D-Penicillamine therapy, in adults and children aged 5 years or older. uuid:8a1c1644-91f5-42e6-adcc-616faac14033 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:60070 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:5b75f505-4560-4ace-823e-6df4d8a58ccf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:88b56f2c-d7ba-463a-a634-6d1fd3af5274"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] TreatmentTreatment of the following infections when caused by bacteria known or very likely to be susceptible to ertapenem and when parenteral therapy is required:intra-abdominal infections;community-acquired pneumonia;acute gynaecological infections;diabetic foot infections of the skin and soft tissue.PreventionInvanz is indicated in adults for the prophylaxis of surgical site infection following elective colorectal surgery.Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:c72c564b-1a3a-49dd-ac67-58a37d3c9b3a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1437811 biolink:treats MONDO:0010604 PMID:41385096 "[{""id"":""uuid:47648f5b-d9fd-4f39-a0e4-b81ba406dab0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:572d7019-c69a-4838-aa4c-525594b559bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor-IX deficiency)., uuid:d6fb43b1-49c1-4d0c-abbe-adcdd4a11835 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:91083 biolink:treats MONDO:0008558 PMID:41385096 "[{""id"":""uuid:e9cc302f-36ad-4def-8071-0704cb6c0c3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4d0505b9-c003-4fc5-952e-6f052c6820ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/nplate""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Adults:Nplate is indicated for the treatment of primary immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).Paediatrics:Nplate is indicated for the treatment of chronic primary immune thrombocytopenia (ITP) in paediatric patients one year of age and older who are refractory to other treatments (e.g. corticosteroids, immunoglobulins). uuid:e90bb5d5-62ff-4954-85d1-6084d8954d17 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:N7V53U4U4T biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:1aebb360-6b30-421b-90f6-20a387b5fba1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:22c23a25-9afc-4dfe-ac26-668ec0f0f0fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Quofenix is indicated for the treatment of the following infections in adults:acute bacterial skin and skin structure infections (ABSSSI),community-acquired pneumonia (CAP), when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of these infections (see sections 4.4 and 5.1).Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:9dc3a32d-f79b-4984-8410-2120f84f8664 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:90Z2UF0E52 biolink:treats MONDO:0015691 PMID:41385096 "[{""id"":""uuid:26f70a3f-5c56-4278-b023-64b7f51b56cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:fa8ad011-bd9c-409b-8e47-c60aee5667e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/nucala""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Severe eosinophilic asthmaNucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older .Chronic rhinosinusitis with nasal polyps (CRSwNP)Nucala is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate control.Eosinophilic granulomatosis with polyangiitis (EGPA)Nucala is indicated as an add-on treatment for patients aged 6 years and older with relapsing-remitting or refractory eosinophilic granulomatosis with polyangiitis (EGPA).Hypereosinophilic syndrome (HES)Nucala is indicated as an add-on treatment for adult patients with inadequately controlled hypereosinophilic syndrome without an identifiable non-haematologic secondary cause. uuid:cc55b008-b8d8-47f3-9372-99a42435c68d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:760I9WM792 biolink:treats MONDO:0005277 PMID:41385096 "[{""id"":""uuid:34887e3a-dadb-40d6-b688-a6059d54d9ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:16adfba6-a82d-4fff-9c2a-f21f49d29260"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:451b14b6-638c-4837-a0ed-118033719202"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] RAYVOW is indicated for the acute treatment of the headache phase of migraine attacks, with or without aura in adults.|[PMDA] Drugs with a new active ingredient indicated for the treatment of migraine. uuid:0f0666f6-18c7-4f3f-8312-8872907f97e9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:760I9WM792 biolink:treats MONDO:0021146 PMID:41385096 "[{""id"":""uuid:c788eac8-0d63-46ea-94bb-afd41112b1bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:cc199663-b1a2-44a1-beb2-7e9d315d2fc0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] RAYVOW is indicated for the acute treatment of the headache phase of migraine attacks, with or without aura in adults. uuid:41dba17f-86bf-4f1c-845e-42beb47fd5da biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76004 biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:49623677-4f86-4d69-bad0-279206cc0fae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d3b2b062-e5cc-4383-8668-04ea48f02b6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tecfidera""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Skilarence is indicated for the treatment of moderate to severe plaque psoriasis in adults in need of systemic medicinal therapy. uuid:1dc49d8b-c55a-4dfa-bb48-935731f2176f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4762 biolink:treats HP:0009937 PMID:41385096 "[{""id"":""uuid:d18552de-235a-48b9-8976-b6a36d3f52e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0f770a47-94d5-4256-b960-3bcc89413e87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vaniqa""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of facial hirsutism in women. uuid:5f0bb857-d493-4f9d-88d2-e90055a65837 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2HLC17MX9G biolink:treats MONDO:0010526 PMID:41385096 "[{""id"":""uuid:a66dfa0a-9514-489c-bb18-323037b7288e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e33ca873-bd33-463a-9936-4b34f4bfeb83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/replagal""]},{""id"":""uuid:ad86c270-a685-49df-8c02-b9680c27f70b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Replagal is indicated for long-term enzyme-replacement therapy in patients with a confirmed diagnosis of Fabry disease (α-galactosidase-A deficiency).|[PMDA] Drug with a new active ingredient indicated for treatment of Fabry disease. [Orphan Drug] uuid:b5bdfd5f-42eb-40ef-8c28-4a83b7ad0d37 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3JGY52XJNA biolink:treats MONDO:0009239 PMID:41385096 "[{""id"":""uuid:bc882e51-8868-48e7-9919-ee79ebfcc501"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:156f1377-aa81-4e6d-9825-69a9a5eacee8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/luveris""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Luveris in association with a follicle-stimulating-hormone (FSH) preparation is recommended for the stimulation of follicular development in women with severe luteinising-hormone (LH) and FSH deficiency. In clinical trials, these patients were defined by an endogenous serum LH level uuid:15581225-9c8d-4b6e-824a-4bcb21de2379 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64321 biolink:treats HP:0002018 PMID:41385096 "[{""id"":""uuid:46afc161-4a2f-4969-9eda-ce51cf36efa2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f87d22e8-caca-4c7c-b0a6-77b73ccb4476"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ivemend""]},{""id"":""uuid:2bbbe724-8033-46f1-ad80-add66a74f5a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and paediatric patients aged 6 months and older.Ivemend 150 mg is given as part of a combination therapy.|[PMDA] A drug with a new active ingredient indicated for the treatment of gastrointestinal symptoms (nausea and vomiting) associated with administration of antineoplastic drugs (cisplatin, etc.) (including delayed phase). uuid:61bab907-2b44-4618-9108-1be3a2768edd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64321 biolink:treats HP:0002013 PMID:41385096 "[{""id"":""uuid:844809ed-54bb-4da9-9359-dc439e89b33d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:acd4a554-6185-4cb8-860c-59000ecce427"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ivemend""]},{""id"":""uuid:9fc69262-d08c-4d5c-9a84-404183755829"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults and paediatric patients aged 6 months and older.Ivemend 150 mg is given as part of a combination therapy.|[PMDA] A drug with a new active ingredient indicated for the treatment of gastrointestinal symptoms (nausea and vomiting) associated with administration of antineoplastic drugs (cisplatin, etc.) (including delayed phase). uuid:2862ea22-be5c-4718-9266-8b16883c86cf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47657 biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:131b1464-d1a6-48d2-af2c-753171fcafad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:84f843ad-310a-4e9a-9fa0-ee9d93a6727d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/daxas""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Daxas is indicated for maintenance treatment of severe chronic obstructive pulmonary disease (COPD) (FEV1 post-bronchodilator less than 50% predicted) associated with chronic bronchitis in adult patients with a history of frequent exacerbations as add-on to bronchodilator treatment., uuid:b60c41c6-7bb8-4d9b-b7a6-c3f58fb799e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:73038 biolink:treats NCIT:C34887 PMID:41385096 "[{""id"":""uuid:be42d684-6af3-4eba-b043-a0582390e4be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:28e936e7-29b2-46a9-916b-42e880c37bbb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] For the short-term treatment of postoperative pain in adults., uuid:682f74c6-5c53-48ef-809f-10ec45546fc7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:36795 biolink:treats MONDO:0002050 PMID:41385096 "[{""id"":""uuid:702b731b-fe15-4a23-a364-94550a91f000"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:600ff521-283c-40f3-a0b8-8cbb821a4d04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/duloxetine-mylan""]},{""id"":""uuid:69936c0d-7963-43e1-85c8-ad6edf593a9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment depressive disorder, diabetic neuropathic pain, anxiety disorder., , Duloxetine Zentiva is indicated in adults.,|[PMDA] Drugs with a new active ingredient indicated for the treatment of depression. uuid:579daccf-8795-4e02-9c90-f82ddc2e06d2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:36795 biolink:treats MONDO:0005618 PMID:41385096 "[{""id"":""uuid:01382a20-12b5-49b5-8cfc-96a1587b735f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e99b55af-f78e-4b0e-b40a-4886e9956bbd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/duloxetine-mylan""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment depressive disorder, diabetic neuropathic pain, anxiety disorder., , Duloxetine Zentiva is indicated in adults., uuid:bc9d9839-b198-4453-8f49-d53da090dc23 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C4541385 biolink:treats MONDO:0005789 PMID:41385096 "[{""id"":""uuid:c60cf22e-85eb-4925-b95e-cf94aff8aad3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4f0a60d7-ed14-427c-a0bb-bc45f2cfd408"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] 5 micrograms, , HBVaxPro is indicated for active immunisation against hepatitis-B-virus infection caused by all known subtypes in individuals from birth through 15 years of age considered at risk of exposure to hepatitis-B virus., , The specific at-risk categories to be immunised are to be determined on the basis of the official recommendations., , It can be expected that hepatitis D will also be prevented by immunisation with HBVaxPro as hepatitis D (caused by the delta agent) does not occur in the absence of hepatitis-B infection., , 10 micrograms, , HBVaxPro is indicated for active immunisation against hepatitis-B-virus infection caused by all known subtypes in individuals 16 years of age or more considered at risk of exposure to hepatitis-B virus., , The specific at-risk categories to be immunised are to be determined on the basis of the official recommendations., , It can be expected that hepatitis D will also be prevented by immunisation with HBVaxPro as hepatitis D (caused by the delta agent) does not occur in the absence of hepatitis-B infection., , 40 micrograms, , HBVaxPro is indicated for the active immunisation against hepatitis-B-virus infection caused by all known subtypes in predialysis and dialysis adult patients., , It can be expected that hepatitis D will also be prevented by immunisation with HBVaxPro as hepatitis D (caused by the delta agent) does not occur in the absence of hepatitis B infection., MESH:C000726347 uuid:e25c833d-46a5-4690-acc6-9e76c1d359ae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134990 biolink:treats MONDO:0002009 PMID:41385096 "[{""id"":""uuid:2d7bcf68-4168-4094-9a27-88b31a2e7f3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:bc25faee-997f-4891-b20a-ece17d8daefd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/thymanax""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of major depressive episodes in adults., uuid:f3cec907-5a23-476c-82c4-8a02ef9348e2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:118753636 biolink:treats MONDO:0005338 PMID:41385096 "[{""id"":""uuid:c296d7f9-776c-4960-870f-8fed2ef5a3d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4d09d984-abb9-435d-8556-7c049387df9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/rhokiinsa""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Reduction of elevated intraocular pressure (IOP) in adult patients with primary open-angle glaucoma or ocular hypertension. uuid:77976f51-7df5-469f-8857-214e72c4bc3d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:118753636 biolink:treats MONDO:0006875 PMID:41385096 "[{""id"":""uuid:c943724f-8fa5-42fb-afeb-755fca197493"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:91b5cf31-3788-4f75-ad68-229f6c82e493"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/rhokiinsa""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Reduction of elevated intraocular pressure (IOP) in adult patients with primary open-angle glaucoma or ocular hypertension. uuid:ea53d0fe-0b74-4dfa-8a06-98575382b7e3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:VQ723R7O8R biolink:treats MONDO:0010602 PMID:41385096 "[{""id"":""uuid:1bc8d203-0d30-44b1-9d20-6a0182c5d356"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:eee068d0-0aa0-4b17-beaf-995a97fa7f41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).Afstyla can be used for all age groups. uuid:057c26b3-eb72-4d52-9956-debfd3e857d9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:089658A12D biolink:treats MONDO:0005083 PMID:41385096 "[{""id"":""uuid:559b9acf-dcf0-417f-a589-15bfc619d0ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:93db5009-711b-41b0-94ef-5be045dc4d47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/tremfya""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Plaque psoriasis, , Tremfya is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy., , Psoriatic arthritis, , Tremfya, alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy (see section 5.1)., uuid:2ac9d2ea-02f6-4dbe-b60b-7f38964f6cdc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C050102 biolink:treats MONDO:0004619 PMID:41385096 "[{""id"":""uuid:f17a8abc-e339-47e0-9f85-6ca4ee8814a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:730c57b6-6e94-47ce-b58f-5a1aa77520a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] ProQuad is indicated for simultaneous vaccination against measles, mumps, rubella and varicella in individuals from 12 months of age., , ProQuad can be administered to individuals from 9 months of age under special circumstances (e.g., to conform with national vaccination schedules, outbreak situations, or travel to a region with high prevalence of measles., uuid:42adc0c3-feb9-4b33-902a-90ac4a053135 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C050102 biolink:treats MONDO:0000989 PMID:41385096 "[{""id"":""uuid:4080e9a9-763b-4dfb-b64b-2426c943b24f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:bc3a8c43-ce8c-4bd6-815e-8778eeb53711"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] ProQuad is indicated for simultaneous vaccination against measles, mumps, rubella and varicella in individuals from 12 months of age., , ProQuad can be administered to individuals from 9 months of age under special circumstances (e.g., to conform with national vaccination schedules, outbreak situations, or travel to a region with high prevalence of measles., uuid:d63c4072-a38b-49da-89d0-d4e923c2c12f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C050102 biolink:treats MONDO:0004656 PMID:41385096 "[{""id"":""uuid:9c703d25-142a-4997-96c3-7c549fcb899c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:47774858-345b-470e-b018-dc7c99c78d10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] ProQuad is indicated for simultaneous vaccination against measles, mumps, rubella and varicella in individuals from 12 months of age., , ProQuad can be administered to individuals from 9 months of age under special circumstances (e.g., to conform with national vaccination schedules, outbreak situations, or travel to a region with high prevalence of measles., uuid:018ff776-a10e-423e-8eb6-50642455ec17 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C050102 biolink:treats MONDO:0005700 PMID:41385096 "[{""id"":""uuid:a4fc1d67-5ad3-40d6-bac2-b4190d568253"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a549609c-2f5e-4cdc-80e3-c84ed8fa657a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] ProQuad is indicated for simultaneous vaccination against measles, mumps, rubella and varicella in individuals from 12 months of age., , ProQuad can be administered to individuals from 9 months of age under special circumstances (e.g., to conform with national vaccination schedules, outbreak situations, or travel to a region with high prevalence of measles., uuid:4552d252-1c73-4fd1-850f-bc5baebdfd65 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:72562361 biolink:treats MONDO:0018602 PMID:41385096 "[{""id"":""uuid:3b63ad12-8216-4233-b821-14edb6eb6a7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b534ff83-453b-4086-9e4c-652de60ab847"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zinforo""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Zinforo is indicated for the treatment of the following infections in neonates, infants, children, adolescents and adults:, , , Complicated skin and soft tissue infections (cSSTI), Community-acquired pneumonia (CAP), , , Consideration should be given to official guidance on the appropriate use of antibacterial agents., uuid:1ffa24ec-c88b-4e52-b1ef-1da850f87ecd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:72562361 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:898092a2-142c-4ac9-949b-9780d6661fc4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:35423535-eb08-44d8-810f-466d87ca1f88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zinforo""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Zinforo is indicated for the treatment of the following infections in neonates, infants, children, adolescents and adults:, , , Complicated skin and soft tissue infections (cSSTI), Community-acquired pneumonia (CAP), , , Consideration should be given to official guidance on the appropriate use of antibacterial agents., uuid:e83bdbc2-1530-4c59-8011-17872bdf61f7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:0P70AR5BYB biolink:treats HP:0000989 PMID:41385096 "[{""id"":""uuid:f7ce402b-4bc4-4f13-b3b3-55e6095bdc81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:de9ab544-b4d2-4303-a49b-73ac405515bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kapruvia""]},{""id"":""uuid:369a8c3b-2f7e-4cae-b32f-d4352f90a305"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Kapruvia is indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on haemodialysis (see section 5.1).|[PMDA] Drugs with a new active ingredient indicated for the improvement of pruritus in patients on hemodialysis (for use only in patients who have not sufficiently responded to conventional treatments). uuid:55100567-5a68-4643-870e-eabe46789601 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:184555 biolink:treats NCIT:C60390 PMID:41385096 "[{""id"":""uuid:9007063c-b4e9-463b-bd17-34df1f04fb5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5965570c-0eb6-435d-ab83-095802a42fe2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/elmiron""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Elmiron is indicated for the treatment of bladder pain syndrome characterized by either glomerulations or Hunner’s lesions in adults with moderate to severe pain, urgency and frequency of micturition., uuid:e8db8dc1-b6e5-4b39-afa1-6b22e5ed4053 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0065828 biolink:treats MONDO:0004619 PMID:41385096 "[{""id"":""uuid:ab9f18fd-829c-4b95-beb0-fdb7b7883627"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:38ecec92-7ad7-4687-8455-750c5f75dd59"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] M-M-RVaxPro is indicated for simultaneous vaccination against measles, mumps, and rubella in individuals 12 months or older., , For use in measles outbreaks, or for post-exposure vaccination, or for use in previously unvaccinated children older than 12 months who are in contact with susceptible pregnant women, and persons likely to be susceptible to mumps and rubella., MESH:D022542 uuid:c1f882dc-f07a-42ec-ba0b-e250b940f175 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0065828 biolink:treats MONDO:0000989 PMID:41385096 "[{""id"":""uuid:720ebca3-156d-42f8-9e52-d81ab348446f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:d128aab6-7fbc-4fc1-a2af-4b8f819ea174"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] M-M-RVaxPro is indicated for simultaneous vaccination against measles, mumps, and rubella in individuals 12 months or older., , For use in measles outbreaks, or for post-exposure vaccination, or for use in previously unvaccinated children older than 12 months who are in contact with susceptible pregnant women, and persons likely to be susceptible to mumps and rubella., MESH:D022542 uuid:831dfff1-1e6e-49f7-9a60-eb88c90af660 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0065828 biolink:treats MONDO:0004656 PMID:41385096 "[{""id"":""uuid:c2820e51-0fa4-4e7b-a8f7-fda9728201aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b76882f6-dcf9-427f-b64c-a47029c3f2d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] M-M-RVaxPro is indicated for simultaneous vaccination against measles, mumps, and rubella in individuals 12 months or older., , For use in measles outbreaks, or for post-exposure vaccination, or for use in previously unvaccinated children older than 12 months who are in contact with susceptible pregnant women, and persons likely to be susceptible to mumps and rubella., MESH:D022542 uuid:fc36e38c-dcb5-4a24-ab3f-f87deddb1346 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6A901E312A biolink:treats MONDO:0024883 PMID:41385096 "[{""id"":""uuid:a733e162-213d-41f4-8797-d5e22613c5fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5effd1ab-0e09-490a-92c2-30319a7b8d1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vectibix""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Vectibix is indicated for the treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRC):, , , in first-line in combination with Folfox or Folfiri., in second-line in combination with Folfiri for patients who have received first-line fluoropyrimidine-based chemotherapy (excluding irinotecan)., as monotherapy after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens., , uuid:b908041f-961d-4ec8-81c5-ad32f4441d9c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90844 biolink:treats MONDO:0017147 PMID:41385096 "[{""id"":""uuid:7122c89e-a335-48a1-bbcb-3faf23823171"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e893e30a-11ef-4a83-8660-a6d8fe2029eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/uptravi""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Uptravi is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II–III, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies., , Efficacy has been shown in a PAH population including idiopathic and heritable PAH, PAH associated with connective tissue disorders, and PAH associated with corrected simple congenital heart disease., uuid:b6e381c1-23ac-40be-94d2-187eed3a7099 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90844 biolink:treats MONDO:0017148 PMID:41385096 "[{""id"":""uuid:4da2b25c-16d2-4170-8336-229542457fc9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f9d50ed6-22a3-4d28-9c5d-6408c616ce3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/uptravi""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Uptravi is indicated for the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II–III, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies., , Efficacy has been shown in a PAH population including idiopathic and heritable PAH, PAH associated with connective tissue disorders, and PAH associated with corrected simple congenital heart disease., uuid:88aa2e89-dfdb-4ff8-bf0f-cfc3976e286d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10318 biolink:treats MONDO:0005609 PMID:41385096 "[{""id"":""uuid:c87cda2f-d8db-44dd-97fe-884df833b098"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fec4e1c5-052b-4be2-8313-270824dad7fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:fd6eaf54-1006-4e8d-b493-71d61cca8b03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Zostavax is indicated for prevention of herpes zoster ('zoster' or shingles) and herpes-zoster-related post-herpetic neuralgia., , Zostavax is indicated for immunisation of individuals 50 years of age or older.,|[PMDA] A drug with a new additional indication for the prevention of herpes zoster in individuals 50 years of age and older. uuid:57ee8500-7477-4897-92a2-826a06f4015f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10318 biolink:treats MONDO:0041052 PMID:41385096 "[{""id"":""uuid:d7deb548-2e34-44a4-8147-719b69469715"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:93dfd13e-3757-41ab-b7d4-8a504dbb2750"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Zostavax is indicated for prevention of herpes zoster ('zoster' or shingles) and herpes-zoster-related post-herpetic neuralgia., , Zostavax is indicated for immunisation of individuals 50 years of age or older., uuid:d293fea9-fc84-4790-9d3e-b3177ae03451 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB00028 biolink:treats MONDO:0018979 PMID:41385096 "[{""id"":""uuid:4741b922-3c43-4d05-b2e6-4362319532b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:880eb902-2b65-4629-89d3-0c7e4f4158c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/flebogamma-dif""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Replacement therapy in adults, and children and adolescents (0-18 years) in:primary immunodeficiency syndromes with impaired antibody production;hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic leukaemia, in whom prophylactic antibiotics have failed;hypogammaglobulinaemia and recurrent bacterial infections in plateau-phase-multiple-myeloma patients who have failed to respond to pneumococcal immunisation;hypogammaglobulinaemia in patients after allogeneic haematopoietic-stem-cell transplantation (HSCT);congenital AIDS and recurrent bacterial infections.Immunomodulation in adults, and children and adolescents (0-18 years) in:primary immune thrombocytopenia (ITP), in patients at high risk of bleeding or prior to surgery to correct the platelet count;Guillain Barré syndrome;Kawasaki disease;multifocal motor neuropathy (MMN). uuid:86f5c1aa-b5ff-452c-97f9-1ca58b2bf800 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68478 biolink:treats MONDO:0004555 PMID:41385096 "[{""id"":""uuid:9e9550bd-71f3-45c0-98e0-9c67d9c2f235"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c685bbee-6ac2-4846-9db6-4dc9d4f6b387"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/votubia""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Renal angiomyolipoma associated with tuberous sclerosis complex (TSC)Votubia is indicated for the treatment of adult patients with renal angiomyolipoma associated with tuberous sclerosis complex (TSC) who are at risk of complications (based on factors such as tumour size or presence of aneurysm, or presence of multiple or bilateral tumours) but who do not require immediate surgery.The evidence is based on analysis of change in sum of angiomyolipoma volume.Subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC)Votubia is indicated for the treatment of patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC) who require therapeutic intervention but are not amenable to surgery.The evidence is based on analysis of change in SEGA volume. Further clinical benefit, such as improvement in disease‑related symptoms, has not been demonstrated. uuid:7313d28c-8fdc-4c2b-922a-6ec5a981cfd9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68478 biolink:treats MONDO:0019954 PMID:41385096 "[{""id"":""uuid:720dcb58-dcf3-4025-bb3c-fe11f3b84ce2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d8a1f019-c49b-4f54-821f-70fb15705597"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/votubia""]},{""id"":""uuid:de4f650c-186c-43e9-8036-1cc33f8f777f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Hormone-receptor-positive advanced breast cancerAfinitor is indicated for the treatment of hormone-receptor-positive, HER2/neu-negative advanced breast cancer, in combination with exemestane, in post-menopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.Neuroendocrine tumours of pancreatic originAfinitor is indicated for the treatment of unresectable or metastatic, well or moderately differentiated neuroendocrine tumours of pancreatic origin in adults with progressive disease.Neuroendocrine tumours of gastrointestinal or lung originAfinitor is indicated for the treatment of unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease.Renal-cell carcinomaAfinitor is indicated for the treatment of patients with advanced renal-cell carcinoma, whose disease has progressed on or after treatment with VEGF-targeted therapy.|[PMDA] A drug with a new additional indication and a new dosage for the treatment of pancreatic neuroendocrine tumor. uuid:e8d9ea67-0990-431a-a097-9ebd12599b1a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:79699 biolink:treats MONDO:0018876 PMID:41385096 "[{""id"":""uuid:0c46ef0a-dbfa-46a1-94ad-2d6706dc71a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:cf9532d1-505d-4532-bf9a-3eb8d7841a38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/torisel""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Renal-cell carcinomaTorisel is indicated for the first-line treatment of adult patients with advanced renal-cell carcinoma (RCC) who have at least three of six prognostic risk factors.Mantle-cell lymphomaTorisel is indicated for the treatment of adult patients with relapsed and / or refractory mantle-cell lymphoma (MCL). uuid:aa214195-a6fa-4ad0-a808-ba98f4617aa2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:65347 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:595b0876-e4f3-4753-b041-e6c7a6289507"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:924d00c2-64fa-4803-a256-f0872ff4abf5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kyprolis""]},{""id"":""uuid:151e2078-2b51-4f08-8ea0-3f25ae5fc93f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Kyprolis in combination with daratumumab and dexamethasone, with lenalidomide and dexamethasone, or with dexamethasone alone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.|[PMDA] Drugs with a new active ingredient indicated for the treatment of relapsed or refractory multiple myeloma. [Orphan drug] uuid:ae7b3cb6-24c5-4f01-a886-c59febc8425a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C4306815 biolink:treats MONDO:0005812 PMID:41385096 "[{""id"":""uuid:44b07aa1-2229-45c2-abc1-f5dd1d2d42ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5beeb734-6708-4e6b-a5fa-478853155776"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Prophylaxis of influenza in an officially declared pandemic situation. Pandemic influenza vaccine should be used in accordance with official guidance. uuid:0574e0c5-1655-4125-ae4f-d3acc867280a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7457 biolink:treats MONDO:0007079 PMID:41385096 "[{""id"":""uuid:84992f6d-3daa-4f5a-b293-d11e2f41ba85"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9fb2581c-f1a5-4dee-9fbd-12f269f5c364"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:2c22751a-9dd8-47b4-8393-64c196639bc3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Selincro is indicated for the reduction of alcohol consumption in adult patients with alcohol dependence who have a high drinking-risk level (see section 5.1), without physical withdrawal symptoms and who do not require immediate detoxification.Selincro should only be prescribed in conjunction with continuous psychosocial support focused on treatment adherence and reducing alcohol consumption.Selincro should be initiated only in patients who continue to have a high drinking-risk level two weeks after initial assessment.|[PMDA] A drug with a new active ingredient indicated to reduce alcohol consumption in patients with alcohol dependence. uuid:e059df37-4541-4e32-a82d-620b34983d16 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1660426 biolink:treats MONDO:0024574 PMID:41385096 "[{""id"":""uuid:a7ada93f-fac4-4d7a-84d6-1588a73a23e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:259a6ca1-43e7-4903-99c7-67e3a3ec7cdd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/voncento""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Von Willebrand disease (VWD)Prophylaxis and treatment of haemorrhage or surgical bleeding in patients with VWD, when desmopressin (DDAVP) treatment alone is ineffective or contraindicated.Haemophilia A (congenital factor-VIII deficiency)Prophylaxis and treatment of bleeding in patients with haemophilia A. uuid:cf92b598-3f55-48f8-83ab-c64e248e1d07 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1660426 biolink:treats MONDO:0010602 PMID:41385096 "[{""id"":""uuid:56ad36e2-e4b9-4d16-a67a-9637f5ed6386"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:02ccc7cc-f143-4bb4-89de-002e163b85ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/voncento""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Von Willebrand disease (VWD)Prophylaxis and treatment of haemorrhage or surgical bleeding in patients with VWD, when desmopressin (DDAVP) treatment alone is ineffective or contraindicated.Haemophilia A (congenital factor-VIII deficiency)Prophylaxis and treatment of bleeding in patients with haemophilia A. uuid:a0af7536-8e83-4cb5-9a81-33877446f424 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C4294565 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:f140b92c-5031-4d1b-9f35-214e55fe2abc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a4366658-7928-4550-b1a4-3cc7382f28d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of diabetes mellitus in adults. MESH:C000629636 uuid:0ed0f8cb-9cd0-4c81-a007-fae63b7314f7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31652 biolink:treats MONDO:0001056 PMID:41385096 "[{""id"":""uuid:a8919aad-e64a-4f0c-ab94-331117250a8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:cda6a055-5f57-4a9a-825c-17ee271a5668"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/teysuno""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Teysuno is indicated in adults:- for the treatment of advanced gastric cancer when given in combination with cisplatin (see section 5.1).- as monotherapy or in combination with oxaliplatin or irinotecan, with or without bevacizumab, for the treatment of patients with metastatic colorectal cancer for whom it is not possible to continue treatment with another fluoropyrimidine due to hand-foot syndrome or cardiovascular toxicity that developed in the adjuvant or metastatic setting. uuid:f7d2c79d-280a-4d2b-afd2-7af72c89e408 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5134 biolink:treats MONDO:0011786 PMID:41385096 "[{""id"":""uuid:b86fc3d0-7724-427c-b0e4-ae528d0425a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2ed3ed67-7c30-41e1-8d4f-8fee5f84f7d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/avamys""]},{""id"":""uuid:7e5ac9df-1c94-4857-8425-afbafb42f706"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Adults, adolescents (12 years and over) and children (6-11 years). Avamys is indicated for the treatment of the symptoms of allergic rhinitis.|[PMDA] A drug with a new active ingredient indicated for the treatment of allergic rhinitis. uuid:76829581-ee07-4869-88c9-6866ddc7c0d2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:84050 biolink:treats MONDO:0018078 PMID:41385096 "[{""id"":""uuid:1d901e03-3dbf-4928-ac97-749e7a3a41d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:60b09dbd-87bd-4f25-9e29-35ec012636bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/yondelis""]},{""id"":""uuid:7bebf3bd-2a17-4487-987c-ea94623cb136"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Yondelis is indicated for the treatment of patients with advanced soft-tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. Efficacy data are based mainly on liposarcoma and leiomyosarcoma patients.Yondelis in combination with pegylated liposomal doxorubicin (PLD) is indicated for the treatment of patients with relapsed platinum-sensitive ovarian cancer.|[PMDA] Drugs with a new active ingredient indicated for the treatment of patients with soft tissue sarcoma. [Orphan drug] uuid:6100b4b3-21ae-44a4-997b-a0c6e2e542bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:84050 biolink:treats MONDO:0008170 PMID:41385096 "[{""id"":""uuid:a7e64af8-3647-4b3d-b561-fb4ed2144c10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5daf7bb8-e737-438e-9c23-cea35bd2077d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/yondelis""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Yondelis is indicated for the treatment of patients with advanced soft-tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. Efficacy data are based mainly on liposarcoma and leiomyosarcoma patients.Yondelis in combination with pegylated liposomal doxorubicin (PLD) is indicated for the treatment of patients with relapsed platinum-sensitive ovarian cancer. uuid:5e2ea60d-46e9-41f0-a2d5-769637686d03 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17549 biolink:treats MONDO:0020804 PMID:41385096 "[{""id"":""uuid:25587411-7997-49b1-8a72-e18c3f769c73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f9e63df7-8b15-45e2-b867-baf3ca43fe47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/gliolan""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of actinic keratosis of mild to moderate severity on the face and scalp (Olsen grade 1 to 2; see section 5.1) and of field cancerization in adults.Treatment of superficial and/or nodular basal cell carcinoma unsuitable for surgical treatment due to possible treatment-related morbidity and/or poor cosmetic outcome in adults. uuid:585f275e-042e-4891-aa6e-b0ecf3f9f5d4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:NU23Q531G1 biolink:treats MONDO:0018029 PMID:41385096 "[{""id"":""uuid:ca7f91ca-d31c-452a-a19f-8f73fbf415e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c2fa03a5-721c-4de0-8d58-cc8a49b432c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/novothirteen""]},{""id"":""uuid:e3bf412a-ecd9-42cf-85bd-d16b266c0081"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Long-term prophylactic treatment of bleeding in adult and paediatric patients 6 years and above with congenital factor-XIII-A-subunit deficiency.|[PMDA] A drug with a new active ingredient indicated for the control of bleeding tendency in patients with congenital blood coagulation factor XIII A-subunit deficiency. [Orphan drug] uuid:4da46e98-ff54-4f54-bce5-ed3ddd3fa05b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68845 biolink:treats MONDO:0001134 PMID:41385096 "[{""id"":""uuid:8b74e838-f09a-487e-aff2-8bb862eaf49b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:52eb8440-4cbc-4d53-ad32-6f31c167bc97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/edarbi""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Edarbi is indicated for the treatment of essential hypertension in adults. uuid:4020aef6-ffd5-4b16-8a4c-87296676d285 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C4753601 biolink:treats MONDO:0004947 PMID:41385096 "[{""id"":""uuid:bdf27089-8b9b-4c52-9723-8bf70be37e3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4992a9b6-a645-47da-b279-640134f9c624"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/besponsa""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Besponsa is indicated as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL). Adult patients with Philadelphia chromosome positive (Ph+) relapsed or refractory B cell precursor ALL should have failed treatment with at least 1 tyrosine kinase inhibitor (TKI). uuid:0fb68a5b-23c5-4210-bc3e-78f609cbce8c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:87016 biolink:treats HP:0007359 PMID:41385096 "[{""id"":""uuid:fabb8677-5713-4671-bd4a-7c3916119385"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4dbf1035-cf36-41a6-a581-b65e5f691813"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zebinix""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Zebinix is indicated as adjunctive therapy in adults, adolescents and children aged above 6 years, with partial-onset seizures with or without secondary generalisation. uuid:3b3424bf-d9f9-41f1-87af-671c2e71ca6a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:87016 biolink:treats HP:0011188 PMID:41385096 "[{""id"":""uuid:69cfd0bf-7b47-4fbb-8b8a-512121678dea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:53131204-c72d-46c6-b20b-862cd1fbd814"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/zebinix""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Zebinix is indicated as adjunctive therapy in adults, adolescents and children aged above 6 years, with partial-onset seizures with or without secondary generalisation. uuid:cf215694-cf56-4dda-ad9b-29db92cf123c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2948 biolink:treats MONDO:0016264 PMID:41385096 "[{""id"":""uuid:d1eac8d8-251d-4104-a13c-eabbcc32762d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ad07f238-192b-4522-9569-df0c65bf6a9a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/jayempi""]},{""id"":""uuid:a826a8b6-83b4-47e0-a8f4-f228f8f58bc4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. Azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression).Jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response.Jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – DMARDs)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidBehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm IgG antibodieschronic refractory idiopathic thrombocytopenic purpuraJayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (IBD) (Crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice.It is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3Jayempi is indicated for the treatment of generalised myasthenia gravis. Depending on the severity of the disease, Jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.|[PMDA] Drugs with a new additional indication for the treatment of autoimmune hepatitis. [Public knowledge-based application after preliminary assessment by the Pharmaceutical Affairs and Food Sanitation Council (PAFSC)] uuid:914ded71-7ad9-4d33-96f4-0558befc1660 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2948 biolink:treats MONDO:0007915 PMID:41385096 "[{""id"":""uuid:c4ec51fb-aa38-485c-8e88-056801919f95"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e20ccad4-58ac-4014-b9e0-42f891cddf96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/jayempi""]},{""id"":""uuid:b1fe2163-b55a-4fa3-9703-3aa73a213963"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. Azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression).Jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response.Jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – DMARDs)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidBehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm IgG antibodieschronic refractory idiopathic thrombocytopenic purpuraJayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (IBD) (Crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice.It is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3Jayempi is indicated for the treatment of generalised myasthenia gravis. Depending on the severity of the disease, Jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.|[PMDA] Drugs with new additional indications and a new dosage for the treatment of the following treatment- resistant rheumatic diseases: systemic vasculitis (e.g., microscopic polyangiitis, Wegener granulomatosis, polyarteritis nodosa, Churg-Strauss syndrome, aortitis syndrome), systemic lupus erythematosus (SLE), polymyositis, dermatomyositis, pachyderma, mixed connective tissue disease and refractory rheumatic disease. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:b1a12197-9d8f-47dd-932b-92c6370e2427 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2948 biolink:treats MONDO:0016367 PMID:41385096 "[{""id"":""uuid:1ed7bb3e-c0c6-45cf-aeeb-010aabc97174"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:40e836ba-ac87-4c57-b6f9-73260f26c377"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/jayempi""]},{""id"":""uuid:d6cb6ad2-ee0f-41d2-84bf-2fb5c8dfc4b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. Azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression).Jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response.Jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – DMARDs)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidBehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm IgG antibodieschronic refractory idiopathic thrombocytopenic purpuraJayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (IBD) (Crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice.It is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3Jayempi is indicated for the treatment of generalised myasthenia gravis. Depending on the severity of the disease, Jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.|[PMDA] Drugs with new additional indications and a new dosage for the treatment of the following treatment- resistant rheumatic diseases: systemic vasculitis (e.g., microscopic polyangiitis, Wegener granulomatosis, polyarteritis nodosa, Churg-Strauss syndrome, aortitis syndrome), systemic lupus erythematosus (SLE), polymyositis, dermatomyositis, pachyderma, mixed connective tissue disease and refractory rheumatic disease. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:bd00ba13-6e9a-485f-9380-b3adfa3b6eb9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2948 biolink:treats MONDO:0019170 PMID:41385096 "[{""id"":""uuid:c0511dfb-5b39-4b1d-85aa-2b4a84caaefa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:603653ce-b22c-4189-9bd9-5524627cfa30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/jayempi""]},{""id"":""uuid:4a11dfb6-260c-43d9-badf-563302c901a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. Azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression).Jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response.Jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – DMARDs)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidBehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm IgG antibodieschronic refractory idiopathic thrombocytopenic purpuraJayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (IBD) (Crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice.It is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3Jayempi is indicated for the treatment of generalised myasthenia gravis. Depending on the severity of the disease, Jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.|[PMDA] Drugs with new additional indications and a new dosage for the treatment of the following treatment- resistant rheumatic diseases: systemic vasculitis (e.g., microscopic polyangiitis, Wegener granulomatosis, polyarteritis nodosa, Churg-Strauss syndrome, aortitis syndrome), systemic lupus erythematosus (SLE), polymyositis, dermatomyositis, pachyderma, mixed connective tissue disease and refractory rheumatic disease. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:f9ee3822-b321-4c6a-a32b-d80de8cbf4c4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2948 biolink:treats MONDO:0008219 PMID:41385096 "[{""id"":""uuid:d8ee4f48-7507-4be6-9be1-bb4c0e955cb0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:91f0d871-7300-4f72-9b41-78561d290cf9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/jayempi""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. Azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression).Jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response.Jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – DMARDs)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidBehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm IgG antibodieschronic refractory idiopathic thrombocytopenic purpuraJayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (IBD) (Crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice.It is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3Jayempi is indicated for the treatment of generalised myasthenia gravis. Depending on the severity of the disease, Jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment. uuid:76dc9356-7008-4bd8-9092-251c28aad80b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2948 biolink:treats MONDO:0019082 PMID:41385096 "[{""id"":""uuid:f3ce4d88-ff21-4c20-87f4-8b44581e7484"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6e6c1266-d23d-46eb-a88b-aa3356a79f85"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/jayempi""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. Azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression).Jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response.Jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – DMARDs)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidBehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm IgG antibodieschronic refractory idiopathic thrombocytopenic purpuraJayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (IBD) (Crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice.It is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3Jayempi is indicated for the treatment of generalised myasthenia gravis. Depending on the severity of the disease, Jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment. uuid:90b9d04f-b7ac-45b1-a192-946f879ec69e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2948 biolink:treats MONDO:0020108 PMID:41385096 "[{""id"":""uuid:e9260fb6-68e6-4113-9940-79c357123370"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:228049cb-3af0-4dd5-927b-dff21fc37f1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/jayempi""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. Azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression).Jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response.Jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – DMARDs)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidBehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm IgG antibodieschronic refractory idiopathic thrombocytopenic purpuraJayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (IBD) (Crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice.It is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3Jayempi is indicated for the treatment of generalised myasthenia gravis. Depending on the severity of the disease, Jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment. uuid:095df389-712e-4983-b0d0-e813aa90df67 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2948 biolink:treats MONDO:0008558 PMID:41385096 "[{""id"":""uuid:6eb581f3-256a-4d33-b4c6-e9e8b648267d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ced308fc-f8d5-419b-9781-aa815be36c28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/jayempi""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. Azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression).Jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response.Jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – DMARDs)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidBehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm IgG antibodieschronic refractory idiopathic thrombocytopenic purpuraJayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (IBD) (Crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice.It is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3Jayempi is indicated for the treatment of generalised myasthenia gravis. Depending on the severity of the disease, Jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment. uuid:3c6f337e-65d5-4816-9a4f-cc8ef904d74a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2948 biolink:treats MONDO:0005011 PMID:41385096 "[{""id"":""uuid:1c13874d-ae41-4316-a005-f03eb2b7481b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:bfe98c05-4b63-4341-b664-232fe81e6e1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/jayempi""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. Azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression).Jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response.Jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – DMARDs)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidBehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm IgG antibodieschronic refractory idiopathic thrombocytopenic purpuraJayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (IBD) (Crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice.It is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3Jayempi is indicated for the treatment of generalised myasthenia gravis. Depending on the severity of the disease, Jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment. uuid:2ca3470d-5eee-48fc-9b92-cce3a791d0c8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2948 biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:ebb7f092-8e01-47aa-aac3-88e8c7a0c9e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b816ea68-22ce-4fa6-b0bd-33de7bc454d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/jayempi""]},{""id"":""uuid:d2db8ebd-0f11-4e5c-8c97-c5d84686f776"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. Azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression).Jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response.Jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – DMARDs)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidBehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm IgG antibodieschronic refractory idiopathic thrombocytopenic purpuraJayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (IBD) (Crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice.It is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3Jayempi is indicated for the treatment of generalised myasthenia gravis. Depending on the severity of the disease, Jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.|[PMDA] Drug with a new indication and dosage indicated for induction and maintenance of remission in steroid- dependent Crohn's disease and maintenance of remission in steroid-dependent ulcerative colitis. [Notification of off-label use] uuid:8f529b2b-8938-46ee-b63a-2b22ec52090f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2948 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:c4ce66fb-f743-4d4d-a942-8de879a97f25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:970b9a17-e2dc-4d57-9077-40bd270df035"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/jayempi""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. Azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression).Jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response.Jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – DMARDs)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidBehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm IgG antibodieschronic refractory idiopathic thrombocytopenic purpuraJayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (IBD) (Crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice.It is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3Jayempi is indicated for the treatment of generalised myasthenia gravis. Depending on the severity of the disease, Jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment. uuid:1d0bec0f-2443-4f8e-a00b-b613126a0219 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2948 biolink:treats MONDO:0009688 PMID:41385096 "[{""id"":""uuid:f08cb798-b034-4f98-81c8-54d04a87aa4c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:933ffe4f-ca7c-444c-b134-b995092a2c64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/jayempi""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. Azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression).Jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response.Jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – DMARDs)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidBehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm IgG antibodieschronic refractory idiopathic thrombocytopenic purpuraJayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (IBD) (Crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice.It is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3Jayempi is indicated for the treatment of generalised myasthenia gravis. Depending on the severity of the disease, Jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment. uuid:94acb01c-e1f3-4e56-b663-ee5e13235ffb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7G4J1ZD9UQ biolink:treats MONDO:0004981 PMID:41385096 "[{""id"":""uuid:b82d2d5b-4d0e-4331-8685-f9f7b39c005b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:edbc7268-4b7a-4bf7-b74b-d225d5f8b8f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/brinavess""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults:for non-surgery patients: atrial fibrillation uuid:150433bf-3726-406a-b3da-a15b52fb3583 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2GFP9BJD79 biolink:treats MONDO:0034212 PMID:41385096 "[{""id"":""uuid:4c6167b9-8741-4e03-abca-cbf79fb6089e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:12bcc45b-e702-4d40-a7c7-f0d52c58c690"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/voraxaze-0""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Voraxaze is indicated to reduce toxic plasma methotrexate concentration in adults and children (aged 28 days and older) with delayed methotrexate elimination or at risk of methotrexate toxicity. uuid:ecbfbab4-6577-4405-9fd4-a14be63cd0f0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB00028 biolink:treats MONDO:0017769 PMID:41385096 "[{""id"":""uuid:b857c748-b361-4ae8-8fbf-de58bfe2062a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:939461ea-d889-4050-b114-9262a8007e4c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/hizentra""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Replacement therapy in adults, children and adolescents (0-18 years) in:- Primary immunodeficiency syndromes with impaired antibody production (see section 4.4).- Secondary immunodeficiencies (SID) in patients who suffer from severe or recurrent infections, ineffective antimicrobial treatment and either proven specific antibody failure (PSAF)* or serum IgG level of uuid:34d0fb96-326a-4719-9111-48efbc75c87a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:80343 biolink:treats MONDO:0009877 PMID:41385096 "[{""id"":""uuid:b33f5455-7bc0-4ea6-8674-85650f1d63f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:69d11c89-414d-4905-a342-de183a32cb81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/increlex""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] For the long-term treatment of growth failure in children and adolescents with severe primary insulin-like-growth-factor-1 deficiency (primary IGFD).Severe primary IGFD is defined by:height standard deviation score ≤ -3.0 and;basal insulin-like growth factor-1 (IGF-1) levels below the 2.5th percentile for age and gender and;growth hormone (GH) sufficiency;exclusion of secondary forms of IGF-1 deficiency, such as malnutrition, hypothyroidism, or chronic treatment with pharmacologic doses of anti-inflammatory steroids.Severe primary IGFD includes patients with mutations in the GH receptor (GHR), post-GHR signalling pathway, and IGF-1 gene defects; they are not GH deficient, and therefore, they cannot be expected to respond adequately to exogenous GH treatment. It is recommended to confirm the diagnosis by conducting an IGF-1 generation test. uuid:d6eb4233-f84e-4533-a60b-b24ca83b4a93 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:23CA79S88F biolink:treats MONDO:0018078 PMID:41385096 "[{""id"":""uuid:90223861-6b54-407d-b06e-a8943db5ea93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:cd0bcca3-d930-4c3d-b3b3-3a89ffa815f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/beromun""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Beromun is indicated in adults as an adjunct to surgery for subsequent removal of the tumour so as to prevent or delay amputation, or in the palliative situation, for irresectable soft-tissue sarcoma of the limbs, used in combination with melphalan via mild hyperthermic isolated-limb perfusion (ILP). uuid:9f74c48f-54d9-4c71-8616-84525cc10aac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:36795 biolink:treats MONDO:0004160 PMID:41385096 "[{""id"":""uuid:f883b181-f4f0-4a90-a74d-d399927b9334"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a74b666e-51c1-41a5-8f03-dd63e0c706d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/duloxetine-mylan""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Yentreve is indicated for women for the treatment of moderate to severe stress urinary incontinence (SUI). uuid:29932fc3-16da-4045-8ba3-81f980b1b0ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90973 biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:a72a3f33-f063-4867-b368-624ce4cacf55"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:c94622d3-2e23-4c56-ade8-bd413b93c3b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/seebri-breezhaler""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Seebri Breezhaler is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). uuid:392260c1-3095-4e47-b20e-88bbf0c8b6ad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:38940 biolink:treats MONDO:0011719 PMID:41385096 "[{""id"":""uuid:c6661635-3b98-43b1-8f30-3e6e32cdbbb3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9350940c-354d-428e-b7be-1cba3ec63c45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/sunitinib-accord""]},{""id"":""uuid:e4432a74-05b0-4c69-9351-cd25b139971d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Gastrointestinal stromal tumour (GIST)Sunitinib Accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (GIST) in adults after failure of imatinib treatment due to resistance or intolerance.Metastatic renal cell carcinoma (MRCC)Sunitinib Accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (MRCC) in adults.Pancreatic neuroendocrine tumours (pNET)Sunitinib Accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pNET) with disease progression in adults.|[PMDA] A drug containing a new active ingredient indicated for the treatment of imatinib-resistant gastrointestinal stromal tumors, and unresectable or metastatic renal cell carcinomas. [Priority review] uuid:3e16c51f-6982-46b1-b670-66e79d284f29 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231344 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:051f18d3-35df-4d38-9bbc-817abd9bfe98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5a541934-ef3a-4941-96ae-c947dd41aa0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/talzenna""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Talzenna is indicated as monotherapy for the treatment of adult patients with germline BRCA1/2 mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine-based therapy, or be considered unsuitable for endocrine-based therapy. uuid:05d7558a-b004-4777-8406-580a3b807971 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231344 biolink:treats MONDO:0000618 PMID:41385096 "[{""id"":""uuid:497b4c2e-cb54-4af3-9a4c-78a7cf919f7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a2d8ba3b-a9c6-4169-8efd-19895d16deb6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/talzenna""]},{""id"":""uuid:27d9ea60-3bd9-48f4-9bc9-dd9aafe48bda"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Talzenna is indicated as monotherapy for the treatment of adult patients with germline BRCA1/2 mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine-based therapy, or be considered unsuitable for endocrine-based therapy.|[PMDA] A drug with a new active ingredient indicated for the treatment of BRCA mutation-positive, metastatic castration-resistant prostate cancer. A drug with a new active ingredient indicated for the treatment of BRCA mutation-positive, metastatic castration-resistant prostate cancer and unresectable or recurrent BRCA mutation-positive and HER2-negative breast cancer in patients who have previously been treated with chemotherapy. A drug with a new active ingredient indicated for the treatment of unresectable or recurrent BRCA mutation-positive and HER2-negative breast cancer in patients who have previously been treated with chemotherapy. uuid:5a277f27-266f-4edd-a8df-d309c28f721c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231344 biolink:treats MONDO:0006512 PMID:41385096 "[{""id"":""uuid:845b7c6a-a79d-4ff2-985a-8164747be812"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:25cdefaf-d121-409c-891e-7bae3f6a7a7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/talzenna""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Talzenna is indicated as monotherapy for the treatment of adult patients with germline BRCA1/2 mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have been previously treated with an anthracycline and/or a taxane in the (neo)adjuvant, locally advanced or metastatic setting unless patients were not suitable for these treatments. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine-based therapy, or be considered unsuitable for endocrine-based therapy. uuid:08abfd18-6270-430e-a0cf-554c79a50b53 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135945 biolink:treats MONDO:0017595 PMID:41385096 "[{""id"":""uuid:333fd196-1919-4ae5-8f80-b1e3f033791a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:1d883248-ce69-4fb6-baa8-8e2c3c87288f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/pixuvri""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Pixuvri is indicated as monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas (NHL). The benefit of pixantrone treatment has not been established in patients when used as fifth-line or greater chemotherapy in patients who are refractory to last therapy. uuid:712ecfb9-f86c-462b-9f2f-8741d3bc7ab4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28876 biolink:treats MONDO:0005062 PMID:41385096 "[{""id"":""uuid:f0a065b2-7de7-4dad-a28a-8a1300038159"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:752441f4-5e3e-4678-ad1f-6284eecc323a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] High-dose of Phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (Hodgkin, non-Hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma.Phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (RIC) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-HSCT) in malignant haematological diseases in adults.Phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:Myeloablative conditioning (MAC) treatment in case of malignant haematological diseasesRIC treatment in case of non-malignant haematological diseases. uuid:b7ae9e15-45f4-408e-82b6-66eb010ee444 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28876 biolink:treats MONDO:0004952 PMID:41385096 "[{""id"":""uuid:4a539b00-e57f-4d71-bd69-a26f2b40f780"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:b792e000-fba8-4619-a768-9cdf372d80bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] High-dose of Phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (Hodgkin, non-Hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma.Phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (RIC) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-HSCT) in malignant haematological diseases in adults.Phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:Myeloablative conditioning (MAC) treatment in case of malignant haematological diseasesRIC treatment in case of non-malignant haematological diseases. uuid:f8e42e3b-2ca7-4fbb-9633-d9d00dec1e21 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28876 biolink:treats MONDO:0018908 PMID:41385096 "[{""id"":""uuid:4cbfdbfc-da3e-42c0-8e72-7c047e7885b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:33acfad9-f449-4034-8150-d2ecda6e42d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] High-dose of Phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (Hodgkin, non-Hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma.Phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (RIC) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-HSCT) in malignant haematological diseases in adults.Phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:Myeloablative conditioning (MAC) treatment in case of malignant haematological diseasesRIC treatment in case of non-malignant haematological diseases. uuid:fb3e3780-f4cb-45a6-a28b-599a8d6e32e9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28876 biolink:treats MONDO:0004967 PMID:41385096 "[{""id"":""uuid:d16ba89e-6bdb-4f07-a57b-f47e36070d0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:54717269-4d62-4156-b1fc-3878f5c020fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] High-dose of Phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (Hodgkin, non-Hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma.Phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (RIC) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-HSCT) in malignant haematological diseases in adults.Phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:Myeloablative conditioning (MAC) treatment in case of malignant haematological diseasesRIC treatment in case of non-malignant haematological diseases. uuid:4fde2a0e-f1af-4f9b-93da-3b07577ab9ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28876 biolink:treats MONDO:0005072 PMID:41385096 "[{""id"":""uuid:ba198df5-4c02-404a-ae6a-bd60df2d7925"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4b1974bd-0f3e-45bb-b003-7541146b7e1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] High-dose of Phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (Hodgkin, non-Hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma.Phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (RIC) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-HSCT) in malignant haematological diseases in adults.Phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:Myeloablative conditioning (MAC) treatment in case of malignant haematological diseasesRIC treatment in case of non-malignant haematological diseases. uuid:157b3ffd-1b04-45f4-9dc1-96b5f2ffcd57 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28876 biolink:treats MONDO:0008170 PMID:41385096 "[{""id"":""uuid:30f9a39a-2620-4911-89ed-79a3677ce6ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:632a4733-92b1-461d-9786-d33dc066557f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] High-dose of Phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (Hodgkin, non-Hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma.Phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (RIC) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-HSCT) in malignant haematological diseases in adults.Phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:Myeloablative conditioning (MAC) treatment in case of malignant haematological diseasesRIC treatment in case of non-malignant haematological diseases. uuid:7c68dcb6-a184-45a4-8acb-dbe1ad6da4bb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28876 biolink:treats MONDO:0004988 PMID:41385096 "[{""id"":""uuid:a5329653-4aed-4b47-9a9b-3ebbbfb59dc4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5961e62c-bf09-4a3f-9997-a3825fad8438"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] High-dose of Phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (Hodgkin, non-Hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma.Phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (RIC) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-HSCT) in malignant haematological diseases in adults.Phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:Myeloablative conditioning (MAC) treatment in case of malignant haematological diseasesRIC treatment in case of non-malignant haematological diseases. uuid:755dd07f-d91a-4af2-8174-2e6dd0b3209e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63638 biolink:treats MONDO:0005384 PMID:41385096 "[{""id"":""uuid:e67d86db-0794-4ad2-afe2-c1c37dba1c6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ae602b1c-7db5-4ebb-971e-90041fde7380"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kigabeq""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Kigabeq is indicated in infants and children from 1 month to less than 7 years of age for:Treatment in monotherapy of infantile spasms (West's syndrome).Treatment in combination with other antiepileptic medicinal products for patients with resistant partial epilepsy (focal onset seizures) with or without secondary generalisation, that is where all other appropriate medicinal product combinations have proved inadequate or have not been tolerated. uuid:b13d4083-6aa4-456f-afb1-9619f176793c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63638 biolink:treats HP:0011188 PMID:41385096 "[{""id"":""uuid:79732744-f4a3-4233-9a12-be8fe104c138"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e2bdeb86-3d9e-4a09-aa6d-b6bbff6c3620"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/kigabeq""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Kigabeq is indicated in infants and children from 1 month to less than 7 years of age for:Treatment in monotherapy of infantile spasms (West's syndrome).Treatment in combination with other antiepileptic medicinal products for patients with resistant partial epilepsy (focal onset seizures) with or without secondary generalisation, that is where all other appropriate medicinal product combinations have proved inadequate or have not been tolerated. uuid:428ce3bf-5937-4228-a7c5-46baba193db4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75922 biolink:treats NCIT:C34887 PMID:41385096 "[{""id"":""uuid:1787c2c1-a403-43cf-b25a-f5743d75d2b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:21fd1b7f-90cc-4789-af87-d0cb60e0d5c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/nevanac""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Nevanac is indicated for:, , , prevention and treatment of postoperative pain and inflammation associated with cataract surgery;, reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients., , uuid:5be47e9e-492b-459f-adb8-5370ff339952 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75922 biolink:treats MONDO:0003005 PMID:41385096 "[{""id"":""uuid:0c37b65c-d38e-46f3-ad63-71a505261d9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:8b0cedea-416c-4c85-8f2f-c6d6a2da2552"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/nevanac""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Nevanac is indicated for:, , , prevention and treatment of postoperative pain and inflammation associated with cataract surgery;, reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients., , uuid:d3b29a41-731d-4d48-816d-930d1d12844a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:65349 biolink:treats UMLS:C0150045 PMID:41385096 "[{""id"":""uuid:18fb5399-cd1f-447b-aeed-41710d95bc82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:db1f3cb3-cf41-4e4c-ba07-3f7061a2d072"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/betmiga""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Symptomatic treatment of urgency.Increased micturition frequency and / or urgency incontinence as may occur in adult patients with overactive-bladder syndrome. uuid:1cb3596a-bbe5-45e1-b077-28db62606e2e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17141 biolink:treats MONDO:0001106 PMID:41385096 "[{""id"":""uuid:46d6667e-f7f8-4804-9bd7-0ce0edb44131"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:a42d0591-89fe-4f60-9644-d468737b049c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/cystagon""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Cystagon is indicated for the treatment of proven nephropathic cystinosis. Cysteamine reduces cystine accumulation in some cells (e.g. leukocytes, muscle and liver cells) of nephropathic cystinosis patients and, when treatment is started early, it delays the development of renal failure. uuid:6f0cca7b-42e3-44e0-b149-e67721aa3a05 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:02E00T2QDE biolink:treats MONDO:0010604 PMID:41385096 "[{""id"":""uuid:2d67d751-429a-4307-8e3c-1540c119260e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cd560f0f-1aa8-487d-81ef-0dd023835062"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/alprolix""]},{""id"":""uuid:aa0d9b2f-c991-4b96-b14b-1bd011ed2722"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment and prophylaxis of bleeding in patients with haemophilia B (congenital factor IX deficiency).|[PMDA] Drugs with a new active ingredient indicated for inhibition of bleeding tendency in patients with blood coagulation factor IX deficiency. uuid:5597a311-6152-42fb-aa64-b45e8689a1cb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9434 biolink:treats MONDO:0001134 PMID:41385096 "[{""id"":""uuid:98883b2a-81bf-4f2d-927e-03a9d9a6b30e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:bd25172a-b912-4229-a3c3-8d8d09153ee1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/telmisartan-actavis""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of essential hypertension in adults. uuid:513240ea-5e2a-4566-80f4-eb35a741d264 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:T472P45MG6 biolink:treats MONDO:0011385 PMID:41385096 "[{""id"":""uuid:a56e0854-323a-425b-a57d-564f616ff06d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:18ee0d4b-3f0d-46ae-b735-bf6de8ba18ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/inductos""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Inductos is indicated for single level lumbar interbody spine fusion as a substitute for autogenous bone graft in adults with degenerative disc disease who have had at least 6 months of non operative treatment for this condition.Inductos is indicated for the treatment of acute tibia fractures in adults, as an adjunct to standard care using open fracture reduction and intramedullary unreamed nail fixation. uuid:77f4b65e-9803-470a-b4b8-7836cc5158b2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:T472P45MG6 biolink:treats HP:0041143 PMID:41385096 "[{""id"":""uuid:c41eda57-f4fa-4585-bda8-ac3b7a752103"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:71cfb58f-5360-4dba-85ac-de12ff032207"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/inductos""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Inductos is indicated for single level lumbar interbody spine fusion as a substitute for autogenous bone graft in adults with degenerative disc disease who have had at least 6 months of non operative treatment for this condition.Inductos is indicated for the treatment of acute tibia fractures in adults, as an adjunct to standard care using open fracture reduction and intramedullary unreamed nail fixation. uuid:5253100e-c636-4854-af3a-7c5b75e92d88 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50663 biolink:treats UMLS:C0858004 PMID:41385096 "[{""id"":""uuid:30ac6575-190e-468a-8cfc-0fedf494eb50"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:e10a47e9-136e-4853-b836-dc85473f7e89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/dectova""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Dectova is indicated for the treatment of complicated and potentially life-threatening influenza A or B virus infection in adult and paediatric patients (aged ≥6 months) when:The patient’s influenza virus is known or suspected to be resistant to anti-influenza medicinal products other than zanamivir, and/orOther anti-viral medicinal products for treatment of influenza, including inhaled zanamivir, are not suitable for the individual patient.Dectova should be used in accordance with official guidance. uuid:a64ce687-9f8c-4d5f-9fb0-d9011075b157 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68575 biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:a39d90d9-c985-4745-9a39-68a2ff07df2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ceef4e43-d7d6-4963-99e5-453799e5eca0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Onbrez Breezhaler is indicated for maintenance bronchodilator treatment of airflow obstruction in adult patients with chronic obstructive pulmonary disease. uuid:9827a0a5-484d-4aa7-a9ef-d057d0d37d47 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1994308 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:ef319435-0d76-4bf4-bb95-65669b5eef65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:0c401a7f-54c3-40ef-902c-c33ddbfb82ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ryzodeg""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of diabetes mellitus in adults, adolescents and children from the age of 2 years. uuid:e86f88d9-47cc-4362-904a-e3bc74c847ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68556 biolink:treats MONDO:0007361 PMID:41385096 "[{""id"":""uuid:8589a367-e9e7-4454-9eb4-4ef8fc51b292"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4f7b34d6-c972-435f-9214-f6681f7ac44f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/firazyr""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Icatibant Accord is indicated for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults, adolescents and children aged 2 years and older, with C1 esterase inhibitor deficiency. uuid:a57b7aab-e658-4cdb-a2ec-5abf252c9135 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:132268 biolink:treats UMLS:C3266992 PMID:41385096 "[{""id"":""uuid:3a5273a5-af19-4d7d-b9c0-301b506c51a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c15e879f-a3b8-4e14-844a-b1d78f84cbd8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null},{""id"":""uuid:f3d651e4-192b-4cb4-9abc-13b17962b4d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Vizimpro, as monotherapy, is indicated for the first-line treatment of adult patients with locally advanced or metastatic non small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) activating mutations.|[PMDA] Drugs with a new active ingredient indicated for the treatment of inoperable or recurrent non-small cell lung cancer with EGFR gene mutation. [Priority review] uuid:3f4a4f5a-72bb-430e-a445-1ce6738f652f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50131 biolink:treats MONDO:0018874 PMID:41385096 "[{""id"":""uuid:d79ebcbf-543f-4979-ac70-c36e08b535d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:66c9181f-e7d5-4f41-93e2-ec4888e2a11e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/dacogen""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of adult patients with newly diagnosed de novo or secondary acute myeloid leukaemia (AML), according to the World Health Organization (WHO) classification, who are not candidates for standard induction chemotherapy. uuid:82b2a0d6-b150-4f43-904c-c10f8d928b68 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:21904A5386 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:de621007-385a-4aa7-8662-76085f33892e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:7dcd947f-91e6-4f6a-b113-89d5a724ca13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Xenleta is indicated for the treatment of community-acquired pneumonia (CAP) in adults when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of CAP or when these have failed.Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:fbf8ed7f-c574-46dd-be99-02bfe77d504a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:21904A5386 biolink:treats MONDO:0015753 PMID:41385096 "[{""id"":""uuid:4f8275ce-98d5-4bbd-af43-633ee0a7746a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:78d77b26-3106-424d-8d51-9b595bb0eb93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Xenleta is indicated for the treatment of community-acquired pneumonia (CAP) in adults when it is considered inappropriate to use antibacterial agents that are commonly recommended for the initial treatment of CAP or when these have failed.Consideration should be given to official guidance on the appropriate use of antibacterial agents. uuid:d19d9163-c40c-486e-8360-8ee6112fc4e5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3H8GSZ4SQL biolink:treats MONDO:0002049 PMID:41385096 "[{""id"":""uuid:55882a00-b6e8-48b5-a4a6-d157d3327caf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2a77f7e3-ad98-4dc7-a0cb-c3b9d8535be8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Doptelet is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure.Doptelet is indicated for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins). uuid:19ecc820-8d66-4c65-8b05-1eca235af371 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3H8GSZ4SQL biolink:treats MONDO:0008558 PMID:41385096 "[{""id"":""uuid:0c83388b-0678-43b7-8cea-f7d4c59cb3fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:1b7eab27-c4d2-4064-95e3-678c3865aa1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Doptelet is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease who are scheduled to undergo an invasive procedure.Doptelet is indicated for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments (e.g. corticosteroids, immunoglobulins). uuid:9be2454c-3940-4617-8e7c-10ca56522ae5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47518 biolink:treats MONDO:0018912 PMID:41385096 "[{""id"":""uuid:6c51f931-4889-40e6-bbfc-e4bc70eb0133"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:4f4e1856-75b4-48b7-9b17-2ebb078b501c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ketoconazole-hra""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ketoconazole HRA is indicated for the treatment of endogenous Cushing’s syndrome in adults and adolescents above the age of 12 years. uuid:5ad379fd-c7d3-400f-820d-74e9a619ac10 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59594 biolink:treats MONDO:0005439 PMID:41385096 "[{""id"":""uuid:291ab782-8ba3-4ea0-8537-984ef9688020"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:517f3e3d-6ab0-4830-828d-215ece864c85"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Cholestagel co-administered with a 3-hydroxy-3-methyl-glutaryl-coenzyme-A (HMG-CoA)-reductase inhibitor (statin) is indicated as adjunctive therapy to diet to provide an additive reduction in low-density-lipoprotein-cholesterol (LDL-C) levels in adult patients with primary hypercholesterolaemia who are not adequately controlled with a statin alone.Cholestagel as monotherapy is indicated as adjunctive therapy to diet for reduction of elevated total cholesterol and LDL-C in adult patients with primary hypercholesterolaemia, in whom a statin is considered inappropriate or is not well tolerated.Cholestagel can also be used in combination with ezetimibe, with or without a statin, in adult patients with primary hypercholesterolaemia, including patients with familial hypercholesterolaemia (see section 5.1). uuid:2fc0f07f-358c-4aa7-a9f8-57596b0cc087 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90863 biolink:treats MONDO:0005341 PMID:41385096 "[{""id"":""uuid:8e2233ab-733a-48f1-9ea4-b4e81ef2b8eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:6426bd84-2614-492d-8715-bdb4ae4b72b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Odomzo is indicated for the treatment of adult patients with locally advanced basal cell carcinoma (BCC) who are not amenable to curative surgery or radiation therapy. uuid:85b0e526-0e6c-4ad3-b3a6-b311276803d2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:66880 biolink:treats MONDO:0002039 PMID:41385096 "[{""id"":""uuid:560fdf62-25ce-4ead-b122-e4d36e83ecc3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5ab90b19-2c54-4bdc-a488-c4929c0982ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] This medicinal product is for diagnostic use only.Amyvid is a radiopharmaceutical indicated for Positron Emission Tomography (PET) imaging of β-amyloid neuritic plaque density in the brains of adult patients with cognitive impairment who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive impairment. Amyvid should be used in conjunction with a clinical evaluation.A negative scan indicates sparse or no plaques, which is not consistent with a diagnosis of AD. uuid:4e07ddb8-d398-48c7-b325-e6712876534b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135947 biolink:treats MONDO:0008159 PMID:41385096 "[{""id"":""uuid:9c8e7c02-f117-4bde-830b-16018ed1218b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema"",""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5cc2da56-5bdd-4443-9d2f-5d8ca2007c35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/conbriza""]},{""id"":""uuid:393a4002-4d48-4b3b-9e28-1877230c4902"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Conbriza is indicated for the treatment of postmenopausal osteoporosis in women at increased risk of fracture. A significant reduction in the incidence of vertebral fractures has been demonstrated; efficacy on hip fractures has not been established.When determining the choice of Conbriza or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits.|[PMDA] A drug with a new active ingredient indicated for the treatment of postmenopausal osteoporosis. uuid:a74a8717-3d85-4bb6-9a0e-2f19cc918900 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135947 biolink:treats HP:0041166 PMID:41385096 "[{""id"":""uuid:2800187a-22e9-4b58-9af1-9788b1c036c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:ddbbad70-eb93-456d-b93d-717a91487ff9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/conbriza""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Conbriza is indicated for the treatment of postmenopausal osteoporosis in women at increased risk of fracture. A significant reduction in the incidence of vertebral fractures has been demonstrated; efficacy on hip fractures has not been established.When determining the choice of Conbriza or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits. uuid:038fc723-7c6e-47e2-b66b-179d37e6bc30 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71025 biolink:treats MONDO:0007886 PMID:41385096 "[{""id"":""uuid:eed096f3-9577-4036-a3a7-0ae02ef70786"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:683fab38-c385-4507-80ca-46ca49b48a0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/ellaone""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Ulipristal acetate is indicated for pre-operative treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.Ulipristal acetate is indicated for intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age. uuid:b76b2d17-df57-4039-b701-f9fedeaae09e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7V6HE3DM5A biolink:treats HP:0031151 PMID:41385096 "[{""id"":""uuid:82ac1d68-4194-4092-a132-d695c993f8f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:9aed92bc-d52e-423e-bcee-d622cf8a3256"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/jetrea""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Jetrea is indicated in adults for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns. uuid:db8dbbff-01dd-489f-9e02-6ec185e82b7f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7V6HE3DM5A biolink:treats MONDO:0006843 PMID:41385096 "[{""id"":""uuid:b1b60e5f-635f-489d-9266-700d98aab67f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:2d007c6b-3516-4ecb-aa25-22da437a709e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/jetrea""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Jetrea is indicated in adults for the treatment of vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns. uuid:ee46479b-098c-40ce-8b99-e0fee5561ea7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C1997870 biolink:treats MONDO:0018881 PMID:41385096 "[{""id"":""uuid:2e2f521b-e5e6-49c1-8587-5c6789758bdc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:8277638f-b8ac-4af5-83e6-ebb36cd4e064"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/retacrit""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult and paediatric patientsTreatment of anaemia associated with chronic renal failure in adult and paediatric patients on haemodialysis and adult patients on peritoneal dialysis.Treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis.Treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre‑existing anaemia at the start of chemotherapy).Silapo can be used to increase the yield of autologous blood from patients in a predonation programme. Its use in this indication must be balanced against the reported risk of thromboembolic events. Treatment should only be given to patients with moderate anaemia (no iron deficiency), if blood saving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males).Silapo is indicated for non-iron deficient adults prior to major elective orthopaedic surgery having a high perceived risk for transfusion complications to reduce exposure to allogeneic blood transfusions. Use should be restricted to patients with moderate anaemia (e.g. haemoglobin concentration range between 10 to 13 g/dl) who do not have an autologous predonation programme available and with expected moderate blood loss (900 to 1 800 ml).Silapo can be used to increase haemoglobin concentration in symptomatic anaemia (haemoglobin concentration of ≤10 g/dl) in adults with low- or intermediate-1-risk primary myelodysplastic syndromes (MDS) who have low serum erythropoietin ( MESH:C530192 uuid:9cd57019-1461-4677-995a-2859b251914f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB15373 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:34c4a099-8bf6-4c2e-949a-e2cf05b84141"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:06438b69-6df5-4997-a700-e06d53a4bec7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lymphoseek""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] This medicinal product is for diagnostic use only.Radiolabelled Lymphoseek is indicated for imaging and intraoperative detection of sentinel lymph nodes draining a primary tumour in adult patients with breast cancer, melanoma, or localised squamous cell carcinoma of the oral cavity.External imaging and intraoperative evaluation may be performed using a gamma detection device. uuid:766c5208-2e54-40b6-89b4-3b343e201fea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB15373 biolink:treats MONDO:0005105 PMID:41385096 "[{""id"":""uuid:b051acb9-d61a-41f6-8817-5ec918006470"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:1a4dcdcf-32c5-433f-a00d-f8f079764396"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lymphoseek""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] This medicinal product is for diagnostic use only.Radiolabelled Lymphoseek is indicated for imaging and intraoperative detection of sentinel lymph nodes draining a primary tumour in adult patients with breast cancer, melanoma, or localised squamous cell carcinoma of the oral cavity.External imaging and intraoperative evaluation may be performed using a gamma detection device. uuid:cb4abb27-461e-4f67-bd2f-f2379ab7f18b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB15373 biolink:treats MONDO:0004958 PMID:41385096 "[{""id"":""uuid:07c6c644-d48b-41da-80fb-d8094aff80ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:32e2a987-d831-40b9-bad9-629725a41a26"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/lymphoseek""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] This medicinal product is for diagnostic use only.Radiolabelled Lymphoseek is indicated for imaging and intraoperative detection of sentinel lymph nodes draining a primary tumour in adult patients with breast cancer, melanoma, or localised squamous cell carcinoma of the oral cavity.External imaging and intraoperative evaluation may be performed using a gamma detection device. uuid:eb768d10-3df6-4483-8763-fc1693f705b2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32293 biolink:treats MONDO:0001383 PMID:41385096 "[{""id"":""uuid:8348a21b-65ba-4731-8b2d-6d9e7f9b1c4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:f7a34ae8-4af5-4b37-8a93-2b390078d138"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/visudyne""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Visudyne is indicated for the treatment of:adults with exudative (wet) age-related macular degeneration (AMD) with predominantly classic subfoveal choroidal neovascularisation (CNV) or;adults with subfoveal choroidal neovascularisation secondary to pathological myopia. uuid:b3823b98-a170-4e20-b70b-9a234cd41c14 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9938056 biolink:treats MONDO:0024298 PMID:41385096 "[{""id"":""uuid:7cdadb2d-5293-4421-b7f2-c92fda26ecc8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:94b70bc0-1a54-408a-8bf3-67b47049999d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vedrop""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Vedrop is indicated in vitamin-E deficiency due to digestive malabsorption in paediatric patients suffering from congenital chronic cholestasis or hereditary chronic cholestasis, from birth (in term newborns) to 16 or 18 years of age, depending on the region. uuid:a07e9fe9-1ee4-4c5e-98e0-ed06eed214c1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9938056 biolink:treats MONDO:0001751 PMID:41385096 "[{""id"":""uuid:5e3aaedd-2e34-46fc-b423-0f7909cac184"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:04a7635e-332e-4a33-b344-137ab5274ad4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vedrop""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Vedrop is indicated in vitamin-E deficiency due to digestive malabsorption in paediatric patients suffering from congenital chronic cholestasis or hereditary chronic cholestasis, from birth (in term newborns) to 16 or 18 years of age, depending on the region. uuid:09428826-5c52-458c-88e0-24c4f533bc5b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9938056 biolink:treats MONDO:0015762 PMID:41385096 "[{""id"":""uuid:0d646e0a-94fc-42e0-b9e9-75457b6be3aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:5c3ddeb6-e936-4432-a635-e3f5eba1fb45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/vedrop""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Vedrop is indicated in vitamin-E deficiency due to digestive malabsorption in paediatric patients suffering from congenital chronic cholestasis or hereditary chronic cholestasis, from birth (in term newborns) to 16 or 18 years of age, depending on the region. uuid:340d0451-23a9-439a-9c84-134d0701f4c8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9437 biolink:treats MONDO:0010150 PMID:41385096 "[{""id"":""uuid:d5ee726b-5e76-4303-9f95-c86f8db31c89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:28113bc0-3ee3-4ea2-a16b-2d766571944d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":[""https://www.ema.europa.eu/en/medicines/human/EPAR/foscan""]}]" infores:medic knowledge_assertion text_mining_agent [EMA] Foscan is indicated for the palliative treatment of patients with advanced head and neck squamous cell carcinoma failing prior therapies and unsuitable for radiotherapy, surgery or systemic chemotherapy. uuid:7c2fdce5-d2ad-4b25-aa8b-07b27341e7fe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:745X144DZY biolink:treats HP:0002653 PMID:41385096 "[{""id"":""uuid:b1af7367-1921-4d92-860d-79f4510bf1a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:ema""],""source_record_urls"":null},{""id"":""uuid:58f4a413-13af-4fba-be15-1841a97f1d6c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:ema"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [EMA] Quadramet is indicated for the relief of bone pain in patients with multiple painful osteoblastic skeletal metastases which take up technetium [99mTc]-labelled biphosphonates on bone scan.The presence of osteoblastic metastases which take up technetium [99mTc]-labelled biphosphonates should be confirmed prior to therapy. uuid:1ec389ba-b9d6-48c4-a0cc-9ae2165145bc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:176399 biolink:treats MONDO:0005439 PMID:41385096 "[{""id"":""uuid:cc6dab79-8e47-465f-9b74-6e6ec80978bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4fc5a7fb-a846-4a16-ae3a-cd0a03cb043d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of familial hypercholesterolemia and hypercholesterolemia (for use only in patients who met all of the followings:) High risk of developing cardiovascular events Patients who have not sufficiently responded to an HMG-CoA reductase inhibitor or in whom treatment with HMG-CoA reductase inhibitors is not suitable. uuid:79fc872c-7aa9-4f78-8bb1-a970c3c37e6b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:176399 biolink:treats HP:0003124 PMID:41385096 "[{""id"":""uuid:eed79229-b8e9-4741-b0e1-9fd292ec31eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:33192c95-b500-4788-877d-11983f883cda"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of familial hypercholesterolemia and hypercholesterolemia (for use only in patients who met all of the followings:) High risk of developing cardiovascular events Patients who have not sufficiently responded to an HMG-CoA reductase inhibitor or in whom treatment with HMG-CoA reductase inhibitors is not suitable. uuid:4024d6ad-4615-4289-bb85-79aeac57e12a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71013 biolink:treats HP:0007334 PMID:41385096 "[{""id"":""uuid:623dd268-c7f0-4278-a8c0-16a142d464c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:034837ae-b8f4-4084-9d33-3c1c04bacfe0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the following treatment: partial seizures (including secondary generalized seizures) in patients with epilepsy and an adjunctive therapy with other antiepileptic drugs to treat tonic-clonic seizure in patients with epilepsy who have not responded sufficiently to other antiepileptic drugs. It is used as an alternative therapy for perampanel oral formulation in patients who are temporarily unable to be administered orally. uuid:79659aac-f580-40cc-8436-a98a5a9860ef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71013 biolink:treats HP:0002069 PMID:41385096 "[{""id"":""uuid:32dfc61c-e252-43a2-989f-63e076519fd7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:74bc5a23-d194-4b7e-9af0-618a85ff726e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the following treatment: partial seizures (including secondary generalized seizures) in patients with epilepsy and an adjunctive therapy with other antiepileptic drugs to treat tonic-clonic seizure in patients with epilepsy who have not responded sufficiently to other antiepileptic drugs. It is used as an alternative therapy for perampanel oral formulation in patients who are temporarily unable to be administered orally. uuid:675147e0-ce9e-4854-9149-174850976cd9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2639950 biolink:treats MONDO:0009688 PMID:41385096 "[{""id"":""uuid:f164e0a2-54dd-4193-9b79-a3171b40f826"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9e234258-589e-4f0f-be49-ac53ce852c77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug with a new active ingredient indicated for the treatment of generalized myasthenia gravis (for use only in patients who have not sufficiently responded to steroids or other immunosuppressants). uuid:cb8681c5-350b-42eb-a096-8c0bba4d0a04 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:349962 biolink:treats MONDO:0014945 PMID:41385096 "[{""id"":""uuid:5297c6c3-d9fa-49f4-a311-8a2ee14d3704"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:78367cf2-5837-44cb-8d2c-90b8dfdf9d9a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for delaying the progression of muscle weakness in patients with distal myopathy with rimmed vacuoles. [Orphan drug] uuid:bcdd424a-4e4b-46c4-a9bd-0ede677a669f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:15C2VL427D biolink:treats MONDO:0005150 PMID:41385096 "[{""id"":""uuid:19bb8d4c-c93e-45f3-86df-94f95413ffa3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:84fbe6e2-243a-423f-a9e3-17d66c68c4c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug in a new dosage form indicated for the treatment of age-related macular degeneration associated with subfoveal choroidal neovascularization and diabetic macular edema. uuid:d0fed8f3-7901-455f-a1c1-8ef6016d14ef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:140376 biolink:treats MONDO:0020920 PMID:41385096 "[{""id"":""uuid:b0479d49-6ab1-45ee-8fd5-bc0b5781df4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9de207b9-6bff-4afc-8945-b45638c79c66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of infections caused by Cefiderocol- sensitive Escherichia coli , Citrobacter spp, Klebsiella pneumoniae , Klebsiella spp, Enterobacter spp, Serratia marcescens , Proteus spp, Morganella morganii , Pseudomonas aeruginosa , Burkholderia spp, Stenotrophomonas maltophilia , and Acinetobacter spp (limited to bacterial strains resistant to carbapenem antimicrobial drugs). [Orphan drug] uuid:74075ae6-f6a5-4a52-859a-e8189a497635 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:140376 biolink:treats MONDO:0030602 PMID:41385096 "[{""id"":""uuid:d089e2cf-4f24-4a19-bd61-b69df010685a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:faf85c59-fe75-4ad0-9082-0f4ed75bfdc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of infections caused by Cefiderocol- sensitive Escherichia coli , Citrobacter spp, Klebsiella pneumoniae , Klebsiella spp, Enterobacter spp, Serratia marcescens , Proteus spp, Morganella morganii , Pseudomonas aeruginosa , Burkholderia spp, Stenotrophomonas maltophilia , and Acinetobacter spp (limited to bacterial strains resistant to carbapenem antimicrobial drugs). [Orphan drug] uuid:538b7300-ae3c-4321-8d55-62c4b2dffb0d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:140376 biolink:treats MONDO:0030603 PMID:41385096 "[{""id"":""uuid:f3af001a-edcf-4c3f-8cff-22dec498f7cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8545d966-7cee-42c8-9948-456411052276"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of infections caused by Cefiderocol- sensitive Escherichia coli , Citrobacter spp, Klebsiella pneumoniae , Klebsiella spp, Enterobacter spp, Serratia marcescens , Proteus spp, Morganella morganii , Pseudomonas aeruginosa , Burkholderia spp, Stenotrophomonas maltophilia , and Acinetobacter spp (limited to bacterial strains resistant to carbapenem antimicrobial drugs). [Orphan drug] uuid:c6f39f82-991b-406f-8544-9a3cb75a42c9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:140376 biolink:treats EFO:1001421 PMID:41385096 "[{""id"":""uuid:8176296c-b25e-4318-8ce9-f4e8ff5987d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a6a3c8db-b500-462d-9877-cad5999cca1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of infections caused by Cefiderocol- sensitive Escherichia coli , Citrobacter spp, Klebsiella pneumoniae , Klebsiella spp, Enterobacter spp, Serratia marcescens , Proteus spp, Morganella morganii , Pseudomonas aeruginosa , Burkholderia spp, Stenotrophomonas maltophilia , and Acinetobacter spp (limited to bacterial strains resistant to carbapenem antimicrobial drugs). [Orphan drug] uuid:09f1f54b-08a8-4721-9b4d-cdc70885b836 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:140376 biolink:treats MONDO:0006929 PMID:41385096 "[{""id"":""uuid:4dbc32d2-6927-47bc-a11c-2599d429ad75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:feca43ec-ba0a-4876-9707-12f66931b0f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of infections caused by Cefiderocol- sensitive Escherichia coli , Citrobacter spp, Klebsiella pneumoniae , Klebsiella spp, Enterobacter spp, Serratia marcescens , Proteus spp, Morganella morganii , Pseudomonas aeruginosa , Burkholderia spp, Stenotrophomonas maltophilia , and Acinetobacter spp (limited to bacterial strains resistant to carbapenem antimicrobial drugs). [Orphan drug] uuid:03d68417-6bae-45b8-a621-12ad87cb672b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:140376 biolink:treats UMLS:C0343404 PMID:41385096 "[{""id"":""uuid:4f20b113-a6dd-4e92-ba31-771b908b1dc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:67c2f965-1c65-4ddb-af21-9ebfda8a1d51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of infections caused by Cefiderocol- sensitive Escherichia coli , Citrobacter spp, Klebsiella pneumoniae , Klebsiella spp, Enterobacter spp, Serratia marcescens , Proteus spp, Morganella morganii , Pseudomonas aeruginosa , Burkholderia spp, Stenotrophomonas maltophilia , and Acinetobacter spp (limited to bacterial strains resistant to carbapenem antimicrobial drugs). [Orphan drug] uuid:3b299287-163d-439c-a92e-a49d9f8eff8c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:140376 biolink:treats MONDO:0005141 PMID:41385096 "[{""id"":""uuid:214085ee-fda6-492e-9ee8-bf06eef28742"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f3d2c820-b4d9-463f-b4b9-28c98cfee0ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of infections caused by Cefiderocol- sensitive Escherichia coli , Citrobacter spp, Klebsiella pneumoniae , Klebsiella spp, Enterobacter spp, Serratia marcescens , Proteus spp, Morganella morganii , Pseudomonas aeruginosa , Burkholderia spp, Stenotrophomonas maltophilia , and Acinetobacter spp (limited to bacterial strains resistant to carbapenem antimicrobial drugs). [Orphan drug] uuid:83282064-bf36-47e1-8eef-cec4d98b0974 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:140376 biolink:treats MONDO:0043953 PMID:41385096 "[{""id"":""uuid:ccc063b0-88a1-4044-8271-332a16c5a66d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:47bed042-a1c2-4c1f-914a-83581cffab0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of infections caused by Cefiderocol- sensitive Escherichia coli , Citrobacter spp, Klebsiella pneumoniae , Klebsiella spp, Enterobacter spp, Serratia marcescens , Proteus spp, Morganella morganii , Pseudomonas aeruginosa , Burkholderia spp, Stenotrophomonas maltophilia , and Acinetobacter spp (limited to bacterial strains resistant to carbapenem antimicrobial drugs). [Orphan drug] uuid:36711f30-baca-4ea9-a0a7-269778c9688d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:140376 biolink:treats MONDO:0006635 PMID:41385096 "[{""id"":""uuid:2c2d03f2-73e4-4a33-897f-1b318298d57c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:dffe6ea5-4749-40bb-b090-c98d57ab349c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of infections caused by Cefiderocol- sensitive Escherichia coli , Citrobacter spp, Klebsiella pneumoniae , Klebsiella spp, Enterobacter spp, Serratia marcescens , Proteus spp, Morganella morganii , Pseudomonas aeruginosa , Burkholderia spp, Stenotrophomonas maltophilia , and Acinetobacter spp (limited to bacterial strains resistant to carbapenem antimicrobial drugs). [Orphan drug] uuid:6d85f5e6-7c89-4dd9-9489-dc31813ebf49 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PX665RAA3H biolink:treats MONDO:0100096 PMID:41385096 "[{""id"":""uuid:32b0afc5-066a-481e-b520-13d80f84c8b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:92916918-9dab-47bc-bce1-cda5bb9a6967"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of disease caused by SARS-CoV-2 infection (COVID-19). uuid:480f808f-0ab4-4fbf-8f9c-0a02c257f4eb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:GN465U8B72 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:59d7f2c1-f613-4b1f-af4f-5f47ac2cfeaf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:350848aa-7b52-4f8d-b306-46d5b4911d22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the treatment of prurigo nodularis in patients who have not responded sufficiently to conventional treatments, and a new additional pediatric dosage in an additional dosage form, indicated for the treatment of pruritus associated with atopic dermatitis in patients who have not responded sufficiently to conventional treatments. uuid:aa548260-fc28-4336-9958-a0b3b11c762c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:5TAA004E22 biolink:treats MONDO:0012579 PMID:41385096 "[{""id"":""uuid:d509d451-fd73-462b-a2ce-a49b8d83bfd0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:81bad98d-4bc8-483e-83af-976c033bae23"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of autoimmune pulmonary alveolar proteinosis. [Orphan drug] uuid:30ffbc87-e7f0-48ab-b295-feb2de742ee8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7D96IR0PPM biolink:treats MONDO:0005062 PMID:41385096 "[{""id"":""uuid:6b681da2-e61e-4e91-8209-2364b0f9eeae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3be891fa-e287-46f0-9d74-926cfeeabc01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of acute lymphocytic leukemia and malignant lymphoma. uuid:d2fcedbf-d627-41e3-bab6-36c157e0f2aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4B93MGE4AL biolink:treats MONDO:0003060 PMID:41385096 "[{""id"":""uuid:a4343dca-ece8-4f0f-92d5-6ed66f493e76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1a699595-de10-4a90-8959-d4b5b8ef9a5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of unresectable FGFR2 fusion gene-positive biliary tract cancer that has progressed after cancer chemotherapy. uuid:723d08c8-5569-40be-b17d-4a244289e345 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1942744 biolink:treats MONDO:0018874 PMID:41385096 "[{""id"":""uuid:3e9db5fd-3c5e-4063-a711-3a0930db9608"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8b2be597-d47b-4b2d-bd36-02f7bf6e6d8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug indicated for the treatment of high-risk acute myeloid leukemia. [Orphan drug] uuid:ee778dd8-9547-4ec7-b6d6-e7bde17633b4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:TF5MPQ8WGY biolink:treats MONDO:0001056 PMID:41385096 "[{""id"":""uuid:24b73cf1-a113-41d9-9649-c3073686639f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:634a921b-a0bc-473d-9770-c9def106214b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of CLDN18.2 (Claudin-18 splice variant 2)-positive unresectable advanced or recurrent gastric cancer. uuid:c14a6e2a-368c-4fba-933b-46db2df05896 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:AP7FFK83RM biolink:treats MONDO:0100096 PMID:41385096 "[{""id"":""uuid:72a0fae7-40c4-42bc-84ef-94718d22d52a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3761c42f-5388-4f1f-a922-79c687320eff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the prevention of disease caused by SARS-CoV-2 infection (COVID-19). [Priority review] uuid:59c5fd5a-5177-46f9-b43d-ff4cf4a0a1b6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1153960 biolink:treats MONDO:0005077 PMID:41385096 "[{""id"":""uuid:d93cbae6-cf63-4527-a365-6b6bc770006b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:57d312a4-8fbf-4f24-ba49-a7b6cb7023af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug with a new active ingredient indicated for the prevention of pertussis, diphtheria, tetanus, acute poliomyelitis, and infections caused by Haemophilus influenzae type b . uuid:d84aaa14-d319-4b13-82d0-47123ab0c097 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1153960 biolink:treats MONDO:0005504 PMID:41385096 "[{""id"":""uuid:fc8703e7-d062-49b6-abfb-1137b93d13dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:71faaba6-ddbb-4ce5-8719-7b0c5a4ca42b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug with a new active ingredient indicated for the prevention of pertussis, diphtheria, tetanus, acute poliomyelitis, and infections caused by Haemophilus influenzae type b . uuid:5b3edd0a-c924-4efa-9cfb-c0ea2086aee9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1153960 biolink:treats MONDO:0005526 PMID:41385096 "[{""id"":""uuid:80b7c200-b755-4bf1-94a7-0614c561132e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:590c9db1-706b-4c78-90a6-a110ffcede93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug with a new active ingredient indicated for the prevention of pertussis, diphtheria, tetanus, acute poliomyelitis, and infections caused by Haemophilus influenzae type b . uuid:cf02d72e-4d10-4d07-a9e6-2d88eeaada56 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1153960 biolink:treats MONDO:0017373 PMID:41385096 "[{""id"":""uuid:8f7ac912-ed9b-43ec-ba43-af3ca951eab1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:56cf5298-cad9-422b-bb81-36c673818352"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug with a new active ingredient indicated for the prevention of pertussis, diphtheria, tetanus, acute poliomyelitis, and infections caused by Haemophilus influenzae type b . uuid:05af704b-d774-472c-a409-d0b1f8399bb7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1153960 biolink:treats MONDO:0000889 PMID:41385096 "[{""id"":""uuid:4e8205b0-375a-43d4-b3a9-840d08ac683e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:61b1f1c0-4de9-4849-b19c-130204b7fdf5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug with a new active ingredient indicated for the prevention of pertussis, diphtheria, tetanus, acute poliomyelitis, and infections caused by Haemophilus influenzae type b . uuid:ab1ef28a-33a1-40eb-9426-1c02d7246aeb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB18713 biolink:treats MONDO:0001577 PMID:41385096 "[{""id"":""uuid:6ad6ee8d-8e58-41fa-8879-250987a3d8e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:14878e3b-3c63-4c38-a56e-6bfcf9894917"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the prevention of disease caused by RS virus infection. uuid:a039de37-2ae8-408b-928f-8e2d6f4ce1e2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5787321 biolink:treats MONDO:0100096 PMID:41385096 "[{""id"":""uuid:17ddd4cd-1810-4075-941b-a3e725a027ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9f7dc8e0-9424-4ba3-b705-9712e6e068c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the prevention of disease caused by SARS-CoV-2 infection (COVID-19). [Priority review] uuid:bec4388a-d6ed-4466-9f98-b7bc24a4d8ea biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2642142 biolink:treats MONDO:0000270 PMID:41385096 "[{""id"":""uuid:e8b1d452-ffd7-4c18-84ce-05702da825bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:977bc22c-4868-41c3-bad3-033f0cbc003c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for active immunization of pregnant individuals for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in neonates and infants. uuid:d3b88935-a10e-41bf-a61e-5a21903a3369 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10298 biolink:treats MONDO:0005114 PMID:41385096 "[{""id"":""uuid:0bdf1ed0-5ab6-4907-bd20-4115bacb5346"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9286e071-182a-4d47-85e8-8b3ef5ffe895"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the prophylaxis of invasive pneumococcal disease (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F) in children. uuid:fceffe69-8d99-4f79-88e3-95151dfdc06b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3614 biolink:treats MONDO:0002305 PMID:41385096 "[{""id"":""uuid:52837c66-e560-43bd-8f88-37fd1e356a23"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5a591b62-584d-49b6-9c72-71ac85c095bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of venous thromboembolism and purpura fulminans and for the control of thrombophilia, in patients with congenital protein C deficiency. uuid:28b8309b-af92-426d-9e7f-68a6776f6231 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0293742 biolink:treats UMLS:C0433405 PMID:41385096 "[{""id"":""uuid:143497a8-b5ac-414b-8de1-f01a9ec702c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7a8ca4eb-97ee-4496-9172-3ae6df2ddcd0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the removal of necrotic tissue of deep dermal burn or deep burn. [Orphan drug] DRUGBANK:DB12249 uuid:b51f7923-48e8-43b6-b80e-b36568628c41 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0293742 biolink:treats UMLS:C1283106 PMID:41385096 "[{""id"":""uuid:46f09fa5-db87-4d5d-8f6a-38701af2e795"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f7db6005-a0d7-4704-ba0e-7e22f5e06c6a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the removal of necrotic tissue of deep dermal burn or deep burn. [Orphan drug] DRUGBANK:DB12249 uuid:ac1c679f-b841-49a3-a9a4-7b54196b3a07 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:144551 biolink:treats HP:0000975 PMID:41385096 "[{""id"":""uuid:beea382a-10fd-4135-bfd3-8cb775991cee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fbcf6558-6136-4564-bcb9-1a2506d45798"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication in a new dosage form for the treatment of primary palmar hyperhidrosis. uuid:e69fb468-5481-4471-bcf8-bd9ed12f148b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:62801 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:c6ec640d-27a2-47ae-bffc-b569b34818a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ec708517-64d7-4834-9db1-c30bbaa323c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug in a new dosage form indicated for the treatment of hyperlipidemia. uuid:83087bac-9156-493d-b906-ba901686778e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5000 biolink:treats MONDO:0005027 PMID:41385096 "[{""id"":""uuid:19c6dece-2eca-4322-bbff-bb74f2d810a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0b852144-68af-424e-a926-58ed775414a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for use as an adjunctive therapy with other antiepileptic drugs to treat epileptic seizures in patients with Dravet syndrome who have not responded sufficiently to other antiepileptic drugs. [Orphan drug] uuid:018f479d-b4ee-4798-b73b-432d07789164 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:F0LZ415Z3B biolink:treats MONDO:0100096 PMID:41385096 "[{""id"":""uuid:3507bd87-4a39-4e8e-88f7-3f20d77a95b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d0f92617-5d14-4653-b1fb-8c0ebf30bd1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new active ingredients indicated for the treatment and suppression of development of disease caused by SARS-CoV-2 infection (COVID-19). [Drug pertaining to Special Approval for Emergency] uuid:f552522e-4ad5-43ff-89b8-8c4c6c1504b2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0004795 PMID:41385096 "[{""id"":""uuid:89762087-d968-4f27-afb9-289ca4af1edc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:065d0af3-7e8a-43d1-afbf-eed78074d0ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the treatment of otitis externa and otitis media caused by Comlex-senstive Staphylococcus spp., Streptococcus spp., Streptococcus pneumoniae , Moraxella (Branhamella) catarrhalis , Klebsiella pneumoniae , Enterobacter spp., Serratia spp., Haemophilus influenzae , Pseudomonas aeruginosa , and Acinetobacter spp. uuid:eca111e5-3306-4dae-a2d1-95f4e8dd5306 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0005441 PMID:41385096 "[{""id"":""uuid:d3c0d4d3-ddcb-43fa-8c2e-a18a297b86d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2663ab5f-b1e4-45f2-b4ae-24ad2baba461"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the treatment of otitis externa and otitis media caused by Comlex-senstive Staphylococcus spp., Streptococcus spp., Streptococcus pneumoniae , Moraxella (Branhamella) catarrhalis , Klebsiella pneumoniae , Enterobacter spp., Serratia spp., Haemophilus influenzae , Pseudomonas aeruginosa , and Acinetobacter spp. uuid:a8735d74-5bee-41b2-827c-e94d0af91886 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:05ZCK72TXZ biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:2a2dea61-b655-472d-9823-5c72b836a89e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5e11a41a-997c-46b6-8d35-45d3ef4284f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of rheumatoid arthritis in patients who have not responded sufficiently to conventional treatments. uuid:f18e1b10-687e-4c36-92b8-72e54ba691fe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:5IB2J79MCX biolink:treats MONDO:0022205 PMID:41385096 "[{""id"":""uuid:6c470809-340a-4c4f-ae3c-807845f7f2fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e3e473a0-6ff6-4ba6-be3a-9ee47213d518"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the improvement of acute symptoms in patients with pustular psoriasis. uuid:6c8bc6a5-7097-4503-b671-8a5c3f39fac9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:RJ1IW3B4QX biolink:treats MONDO:0100470 PMID:41385096 "[{""id"":""uuid:71d1013b-201e-4d0e-a00a-616b672d5438"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:df857a1a-b3f0-4824-a22a-e63323ad3f35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of bronchial asthma (for use only in patients with severe or intractable bronchial asthma whose asthmatic responses are uncontrollable with conventional therapies). uuid:56fcba20-c090-427c-99f4-292f3524693c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:N0A21N6RAU biolink:treats MONDO:0022205 PMID:41385096 "[{""id"":""uuid:dd036c39-fe22-4ba4-bb4f-e1649b676327"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e4793720-75b9-45d9-ba96-87471b0d371e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of plaque psoriasis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies. uuid:e69e2403-3b02-48bb-bf1b-db86c17e613f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:N0A21N6RAU biolink:treats UMLS:C0748052 PMID:41385096 "[{""id"":""uuid:997c20ba-1b86-4c0d-addb-8e5144bbdee0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0710c571-7a2f-451c-8b20-3c4712165f7c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of plaque psoriasis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies. uuid:e62ff789-ed4a-400b-a0fa-b61880220aee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:233475 biolink:treats MONDO:0011719 PMID:41385096 "[{""id"":""uuid:fe9ef40e-99dc-4995-b2fe-eea1d6a3d262"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c4d57339-90e0-4b24-996a-792ade2cbefa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of gastrointestinal stromal tumor that has progressed after cancer chemotherapy. UNII:PLO044MUDZ uuid:8dc36d42-65b2-4258-8eb6-a6eb470b3bf6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:233475 biolink:treats MONDO:0004992 PMID:41385096 "[{""id"":""uuid:d1d925f3-9127-444e-be77-f3df663cc128"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b435362a-623f-4abe-805e-d5ed84a5e55f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of gastrointestinal stromal tumor that has progressed after cancer chemotherapy. UNII:PLO044MUDZ uuid:7ee5f3c3-ca58-4421-b3f8-53337819e03c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2360580 biolink:treats UMLS:C3873491 PMID:41385096 "[{""id"":""uuid:7561972a-e4d7-4c14-b35b-79bd21773a6a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1af6ac62-7d47-4a4c-885e-6724d18c95c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the prophylaxis of invasive meningococcal disease caused by Neisseria meningitidis (serogroups A, C, W and Y). uuid:ce572c93-8271-48b7-a57c-4c41b5d8b239 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:801721 biolink:treats MONDO:0005077 PMID:41385096 "[{""id"":""uuid:19d87ac2-c5aa-44a3-bb97-932ff397ea5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4e54699e-5e1b-4153-8224-bcde48bd37ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug with a new active ingredient indicated for the prevention of pertussis, diphtheria, tetanus, acute poliomyelitis, and infections caused by Haemophilus influenzae type b . uuid:03a4541e-dddf-4ec7-8c0e-91485d2a7ec0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:801721 biolink:treats MONDO:0005504 PMID:41385096 "[{""id"":""uuid:9acd0d8b-d7da-4b01-ad73-811704d99be7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1e6d77b8-88c6-4d10-bd73-01032c882076"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug with a new active ingredient indicated for the prevention of pertussis, diphtheria, tetanus, acute poliomyelitis, and infections caused by Haemophilus influenzae type b . uuid:2ba27efb-29d6-4b66-a026-cdf950db03f0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:801721 biolink:treats MONDO:0005526 PMID:41385096 "[{""id"":""uuid:6fe93abf-6227-4418-818f-4c868c4204e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e53e46e5-7bee-400a-bc24-af26c1f8d875"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug with a new active ingredient indicated for the prevention of pertussis, diphtheria, tetanus, acute poliomyelitis, and infections caused by Haemophilus influenzae type b . uuid:d6449b9c-279e-4ebd-8af2-65ee40e1986e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:801721 biolink:treats MONDO:0017373 PMID:41385096 "[{""id"":""uuid:e3d6e1b9-8661-4f1e-9e91-0adc7cebaba1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2e23c040-7861-4b64-9750-af1ca472e536"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug with a new active ingredient indicated for the prevention of pertussis, diphtheria, tetanus, acute poliomyelitis, and infections caused by Haemophilus influenzae type b . uuid:56ea49db-0113-4465-85f2-09c0b97b0c65 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:801721 biolink:treats MONDO:0000889 PMID:41385096 "[{""id"":""uuid:6ceeabce-7232-44ce-9a53-f8d3cdb24d83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2de7077a-8f10-44aa-8695-102d9711d408"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug with a new active ingredient indicated for the prevention of pertussis, diphtheria, tetanus, acute poliomyelitis, and infections caused by Haemophilus influenzae type b . uuid:293b9dd2-6846-40ff-8b18-6a4d77c6f349 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5931 biolink:treats MONDO:0019623 PMID:41385096 "[{""id"":""uuid:eceb9ec9-677f-4a2d-8282-42fdb14bbcba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:01d360de-6387-4c47-b8cb-6ecfea752761"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the prophylaxis of acute attacks of hereditary angioedema. [Orphan drug] uuid:553fd433-b7a8-4dc7-8937-1631bf0cda32 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:ZR36MFA9P8 biolink:treats HP:0002018 PMID:41385096 "[{""id"":""uuid:b236e6a6-d899-478e-abe3-1785cd94ee58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a0467b2a-371e-4537-a279-ce2b82c5cc1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of digestive symptoms (nausea and vomiting, including delayed phase) resulting from the administration of antineoplastic agents (cisplatin, etc.). uuid:a8f4ad83-8977-463a-b45b-5e36f149de79 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:ZR36MFA9P8 biolink:treats HP:0002013 PMID:41385096 "[{""id"":""uuid:5d1a323c-3060-4ea0-91d3-f397951ec2f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ebc0aef8-c5cb-420a-971b-2949ceacc75c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of digestive symptoms (nausea and vomiting, including delayed phase) resulting from the administration of antineoplastic agents (cisplatin, etc.). uuid:f6a6c321-7f7f-4bda-a32c-3749e53e36fc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:Y1HYC6SO3F biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:4a33203c-73f2-4586-a8b9-51ac0bc5ad7c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f834fedd-e464-42a4-b700-5fcbfc625c52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of moderate ulcerative colitis (for use only in patients who have not sufficiently responded to 5-aminosalicylic acid preparation). uuid:52e5b6a7-acbf-4e33-a00f-a9e08e703104 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:UU226QGU97 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:076faace-37ce-4f50-a977-89f0554637fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7faf4427-a0de-422e-8cef-bc896d845303"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of type 2 diabetes mellitus. uuid:1ebbf4cd-a5fe-419e-9ad2-578d0be78984 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:78538 biolink:treats HP:0031327 PMID:41385096 "[{""id"":""uuid:2c75a0e1-3f4e-4fff-ac67-b83e5e715d9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9e7d6daf-1c05-407e-83e1-bae89be8e328"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of transthyretin cardiac amyloidosis (wild-type and hereditary). uuid:c6850e9e-bfe0-437f-8c0e-ee8a571e93db biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:78538 biolink:treats MONDO:0971004 PMID:41385096 "[{""id"":""uuid:27bb99f6-0f69-45f2-ae94-843914803388"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:195b4f54-0090-4321-b839-13af84bbc924"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of transthyretin cardiac amyloidosis (wild-type and hereditary). uuid:10c17719-c8b8-4e2c-858b-8263f84128bb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3DRR0X4728 biolink:treats UMLS:C0265110 PMID:41385096 "[{""id"":""uuid:30b5e335-1ce6-4139-a26c-c9516becfb90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cffeda0b-7880-4f6a-af86-77a9098beaf5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the prevention of cerebrovascular spasm after surgery for subarachnoid hemorrhage caused by cerebral aneurysm, and cerebral infarctions and cerebral ischemic symptoms accompanying the cerebrovascular spasm. uuid:a1fbd8c9-1d0b-4a59-bd86-47099f78a6ef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3DRR0X4728 biolink:treats MONDO:0002679 PMID:41385096 "[{""id"":""uuid:d851477b-6165-49e9-abf7-75a4c3648847"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b0fba1a2-08b2-4160-9b52-2c96fafe29cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the prevention of cerebrovascular spasm after surgery for subarachnoid hemorrhage caused by cerebral aneurysm, and cerebral infarctions and cerebral ischemic symptoms accompanying the cerebrovascular spasm. uuid:f4691157-089a-40f2-8319-2346cfbd30fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3DRR0X4728 biolink:treats MONDO:0005299 PMID:41385096 "[{""id"":""uuid:7a2646c4-69a9-471b-b63c-fc1257650f90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:43b361e1-4c77-42cb-8f31-c167b436f1e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the prevention of cerebrovascular spasm after surgery for subarachnoid hemorrhage caused by cerebral aneurysm, and cerebral infarctions and cerebral ischemic symptoms accompanying the cerebrovascular spasm. uuid:8eb0fadc-0e16-42f1-b96e-9a40ab2241b0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17026 biolink:treats MONDO:0000931 PMID:41385096 "[{""id"":""uuid:f292406c-2289-4774-a8d8-aa280c0ee153"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c20a0276-e05f-4f31-8c27-7ecca771011e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the prevention of endometrial hyperplasia when estrogen preparations were administered for climacteric disturbance or ovarian deficiency symptoms. uuid:622dfb7a-3765-4e0d-905b-cbf38b9b00c5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:170190 biolink:treats MONDO:0024327 PMID:41385096 "[{""id"":""uuid:78951496-433b-4581-b9ea-94db80841669"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0a33f990-3dfb-458d-a526-c8f15d437dc9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A combination prescription drug with similar formulations to be used as perfusion fluids for hemodialysis in patients with chronic renal failure (use in any of the following cases: ○ when bicarbonate dialysate with high bicarbonate concentration may cause excessive alkalosis; ○ when the patient’s blood sugar level is difficult to control with sugarless dialysate; ○ when other bicarbonate dialysate is not sufficiently effective to improve hyperkalemia and hypermagnesemia or may cause hypercalcemia). uuid:f9baba7f-0e74-488d-880d-2253706aa545 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:170190 biolink:treats HP:0002153 PMID:41385096 "[{""id"":""uuid:79e14a33-c796-4d2e-8b14-7062efaba394"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c9855970-39e0-44db-956c-cf841d01dafd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A combination prescription drug with similar formulations to be used as perfusion fluids for hemodialysis in patients with chronic renal failure (use in any of the following cases: ○ when bicarbonate dialysate with high bicarbonate concentration may cause excessive alkalosis; ○ when the patient’s blood sugar level is difficult to control with sugarless dialysate; ○ when other bicarbonate dialysate is not sufficiently effective to improve hyperkalemia and hypermagnesemia or may cause hypercalcemia). uuid:09811ffe-1bf8-49bf-984e-88ed59f53965 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:170190 biolink:treats HP:0002918 PMID:41385096 "[{""id"":""uuid:2d74ea22-d973-450d-9144-64ec5ab5557f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:18d67e63-52fe-4b19-b052-488faaef2d7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A combination prescription drug with similar formulations to be used as perfusion fluids for hemodialysis in patients with chronic renal failure (use in any of the following cases: ○ when bicarbonate dialysate with high bicarbonate concentration may cause excessive alkalosis; ○ when the patient’s blood sugar level is difficult to control with sugarless dialysate; ○ when other bicarbonate dialysate is not sufficiently effective to improve hyperkalemia and hypermagnesemia or may cause hypercalcemia). uuid:fac3b3e7-e6bf-4c06-91f0-ab6a6f71afcd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:170190 biolink:treats MONDO:0001566 PMID:41385096 "[{""id"":""uuid:9ca1c03b-9ca6-4a2c-a96a-9079d884ae3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7f36a079-1416-4586-945d-86ddbc242aec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A combination prescription drug with similar formulations to be used as perfusion fluids for hemodialysis in patients with chronic renal failure (use in any of the following cases: ○ when bicarbonate dialysate with high bicarbonate concentration may cause excessive alkalosis; ○ when the patient’s blood sugar level is difficult to control with sugarless dialysate; ○ when other bicarbonate dialysate is not sufficiently effective to improve hyperkalemia and hypermagnesemia or may cause hypercalcemia). uuid:a6c118af-271f-46b4-ace5-f2504ebcc9bb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24984318 biolink:treats MONDO:0010096 PMID:41385096 "[{""id"":""uuid:3e68593f-866a-4d80-b444-8ca79af9a494"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:404d4e73-98c4-4419-a911-8160deafe025"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of tardive dyskinesia. uuid:bfe19490-d94e-4f43-9b8b-95adc25a4ca5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:QC4F7FKK7I biolink:treats MONDO:0005150 PMID:41385096 "[{""id"":""uuid:48c6ea65-3b42-4d0e-b4ff-9bf99a981ae0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:04f29421-0c32-4801-80d2-2f91526d5ca3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of age-related macular degeneration associated with subfoveal choroidal neovascularization and diabetic macular edema. uuid:32d8f8b6-e1a8-42f2-979e-3873b0223e05 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2184139 biolink:treats MONDO:0020920 PMID:41385096 "[{""id"":""uuid:3bdc3f4b-7346-4185-abcf-cb00c9c6612c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0dfa963d-a72a-42aa-b43f-e12611582330"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug with a new active ingredient indicated for the treatment of infections caused by Recarbrio-sensitive Escherichia coli , Citrobacter spp. , Klebsiella spp. , Enterococcus spp., Serratia spp., Pseudomonas aeruginosa , and Acinetobacter spp. (limited to the bacterial strains resistant to carbapenem antimicrobial drugs) [Orphan drug] uuid:ce4cc373-f7d7-4bef-814b-adcd068b055e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2184139 biolink:treats MONDO:0030603 PMID:41385096 "[{""id"":""uuid:1e034f43-c9d1-4239-be48-1945c53e286f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6d469723-dcdc-4f20-80ee-2bb77dad9109"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug with a new active ingredient indicated for the treatment of infections caused by Recarbrio-sensitive Escherichia coli , Citrobacter spp. , Klebsiella spp. , Enterococcus spp., Serratia spp., Pseudomonas aeruginosa , and Acinetobacter spp. (limited to the bacterial strains resistant to carbapenem antimicrobial drugs) [Orphan drug] uuid:2b70c480-ffae-4ef5-97b3-cd26ef1ed668 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2184139 biolink:treats EFO:1001421 PMID:41385096 "[{""id"":""uuid:af5baeea-8dd9-43b1-bf10-ffa55dd9bccd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e40661bb-5f7f-4691-a04c-7ee85ffd4e04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug with a new active ingredient indicated for the treatment of infections caused by Recarbrio-sensitive Escherichia coli , Citrobacter spp. , Klebsiella spp. , Enterococcus spp., Serratia spp., Pseudomonas aeruginosa , and Acinetobacter spp. (limited to the bacterial strains resistant to carbapenem antimicrobial drugs) [Orphan drug] uuid:ab759d5f-64cb-4011-bf85-97c716191634 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2184139 biolink:treats MONDO:0005141 PMID:41385096 "[{""id"":""uuid:980fc5fd-5231-4f95-9705-a527491e768b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f8229c92-165a-42f6-8cb8-2820cef7005c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug with a new active ingredient indicated for the treatment of infections caused by Recarbrio-sensitive Escherichia coli , Citrobacter spp. , Klebsiella spp. , Enterococcus spp., Serratia spp., Pseudomonas aeruginosa , and Acinetobacter spp. (limited to the bacterial strains resistant to carbapenem antimicrobial drugs) [Orphan drug] uuid:4b999bc4-c110-4a6d-81ac-fcb15cb4dab6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2184139 biolink:treats MONDO:0006635 PMID:41385096 "[{""id"":""uuid:134386a3-d42f-46bb-a629-5af28b3d5f98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cc11381f-c262-40b2-a189-9c5be2ea346f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug with a new active ingredient indicated for the treatment of infections caused by Recarbrio-sensitive Escherichia coli , Citrobacter spp. , Klebsiella spp. , Enterococcus spp., Serratia spp., Pseudomonas aeruginosa , and Acinetobacter spp. (limited to the bacterial strains resistant to carbapenem antimicrobial drugs) [Orphan drug] uuid:5fec0eaa-5ef4-4f8a-91b0-03e4b8f1e6fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:180653 biolink:treats MONDO:0100096 PMID:41385096 "[{""id"":""uuid:629688e5-95a7-440e-8a6c-3904e2abfa27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2bc6bd48-0fa8-4dfa-a5fe-99783a17a620"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of disease caused by SARS-CoV-2 infection (COVID-19). [Drug pertaining to Special Approval for Emergency] uuid:26728614-488a-43f5-80c6-5f24a9bd1ca0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6K6L7E3F1L biolink:treats UMLS:C4552486 PMID:41385096 "[{""id"":""uuid:afd6c5a4-60b2-4ca5-b631-ae907e4cb9ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7582e838-7add-4e5f-834c-6e8b2d2c7a75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of refractory chronic cough. uuid:c166bff9-ab05-4af6-ad77-011ec4341620 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:131952892 biolink:treats MONDO:0019496 PMID:41385096 "[{""id"":""uuid:5fd11e27-ace7-47e2-af61-a55fb44bb90d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2d55f076-4eaf-4de2-b2f1-24b3ae0a7291"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of somatostatin receptor-positive neuroendocrine tumor. uuid:e1f785c2-46be-4d06-a64d-e21b3f236f39 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:92769 biolink:treats MONDO:0008233 PMID:41385096 "[{""id"":""uuid:8bd23763-3749-4b2d-bad4-b78f5e8c9142"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fd007f28-c877-470c-aa32-d0893e7c2d01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of unresectable MIBG-positive pheochromocytoma/paraganglioma. [Orphan drug] uuid:9fedc15b-c40e-463f-96a2-a235758dd017 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:92769 biolink:treats MONDO:0000448 PMID:41385096 "[{""id"":""uuid:470674c1-d47b-4894-90ba-3302fd7e20b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f5afedd5-0daf-4b47-8ae9-0a77d1df5508"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of unresectable MIBG-positive pheochromocytoma/paraganglioma. [Orphan drug] uuid:804c41a8-59a8-44b2-9542-3fa5c55a8037 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:ZL1R02VT79 biolink:treats UMLS:C3537442 PMID:41385096 "[{""id"":""uuid:38579a09-38bc-4891-8a6f-b277c13007fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b0434d40-886a-49ea-9df6-d1dd8896ea18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Follow-on biologics indicated for the treatment of age-related macular degeneration associated with subfoveal choroidal neovascularization or choroidal neovascularization in patients with pathologic myopia. uuid:29f19e5e-de27-4145-87cd-0dc816ebbc0a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:55F75LJQ0V biolink:treats UMLS:C1391732 PMID:41385096 "[{""id"":""uuid:e396d412-8845-4f5e-ac5f-bdb6ec786a2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:464ab583-b92a-466c-ae75-7187bd9b5077"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of cancer cachexia in the following malignancies: non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer. uuid:c0691655-05ab-403a-bf55-914eb632f696 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:55F75LJQ0V biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:aca1cdf7-1638-4178-8344-fd0dc7b1de7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c9c55583-5ef0-4563-9956-1c3a9c991e08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of cancer cachexia in the following malignancies: non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer. uuid:64c79339-c974-45db-a8b7-de17a8235649 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:55F75LJQ0V biolink:treats MONDO:0001056 PMID:41385096 "[{""id"":""uuid:045856cf-f996-4991-8ebc-135ccf030896"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:55e24bff-2ae2-425b-816f-d019de2c07b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of cancer cachexia in the following malignancies: non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer. uuid:1839908d-d3fc-478a-9e09-1d2b64901b92 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:55F75LJQ0V biolink:treats MONDO:0009831 PMID:41385096 "[{""id"":""uuid:6c24a134-d26a-4b35-91f9-f80122d76628"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8f10a02b-3b3f-4652-a11c-f3d1138cb9c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of cancer cachexia in the following malignancies: non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer. uuid:f0b7d866-b365-4f2f-9d68-2021f92c44a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:55F75LJQ0V biolink:treats MONDO:0005575 PMID:41385096 "[{""id"":""uuid:8b2311b8-e2ca-4c23-98a0-03570938a177"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cd453f94-3ec6-4304-9fb7-c985ad354ab8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of cancer cachexia in the following malignancies: non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer. uuid:a8f5e695-d5c6-4a3d-9775-ee0536e9f091 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:TRF8S0U6ON biolink:treats MONDO:0010674 PMID:41385096 "[{""id"":""uuid:d80f3d4f-3580-4dd5-a63f-2cf874524b47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f6a8806a-e521-41de-8095-420a91d0c1bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of mucopolysaccharidosis type II. [SAKIGAKE review, orphan drug] uuid:f97587e6-373a-4862-91d3-6a50a336cf4a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:170190 biolink:treats HP:0003075 PMID:41385096 "[{""id"":""uuid:437ea87f-827f-44cb-8aed-19ef9e515f29"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:86abb0ec-1ef7-432e-a989-6cf9c9a820a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A combination prescription drug with similar formulations indicated for the supplementation of amino acids, electrolytes, calories, fatty acids, water-soluble vitamin, and water in the following conditions. •When patients with insufficient oral intake and mild hypoproteinemia or mild undernutrition. •When patients in the perioperative period uuid:bde10912-4b09-43aa-af46-336fc6f2526a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28262 biolink:treats HP:0100515 PMID:41385096 "[{""id"":""uuid:8f0f2b61-02d7-4fe3-9229-16d714dbbf0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fe69777a-ae4b-482c-9fde-88e79609a5dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the improvement of symptoms (chronic pelvic pain, pressure and discomfort perceived to be related to the urinary bladder; lower urinary tract symptoms such as persistent urge to void and urinary frequency) in patients with interstitial cystitis (Hunner type). [Orphan drug] uuid:32d027a9-e5a8-4c9e-bb9b-ba208bd023c7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134703 biolink:treats MONDO:0100342 PMID:41385096 "[{""id"":""uuid:ac15bc70-4fb7-44fd-a705-4b228ae784ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:107b26ac-cb92-46e5-9bda-b5a503bf4019"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the visualization of tumors in patients with suspected to be newly identified malignant glioma, (for use only in supporting determination of the extent of tumor resection during tumor resection planning using magnetic resonance imaging). uuid:2b82161d-0ac2-41df-baaa-125ee5db4d5d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:55MOB566V7 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:e97b500f-5265-4562-8029-39fc2db45810"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:81e085d1-f68b-4350-ac64-c06c7f00224d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the treatment of pneumonia, lung abscess, and secondary infection of chronic respiratory disease caused by Lasvic-sensitive Staphylococcus spp, Streptococcus spp, Streptococcus pneumoniae , Enterococcus spp, Moraxella (Branhamella ) catarrhalis , Escherichia coli, Klebsiella spp, Enterobacter spp, Haemophilus influenzae , Legionella pneumophila , Peptostreptococcus spp, Veillonella spp, Bacteroides spp, Prevotella spp, Porphyromonas spp, Fusobacterium spp, and Mycoplasma pneumoniae . uuid:2a97777d-19da-49e2-98c1-e7d78455ad93 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:55MOB566V7 biolink:treats MONDO:0000744 PMID:41385096 "[{""id"":""uuid:11923f52-9d89-4380-84d7-62cafb64c6f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f2b48ad4-1cd5-496b-8639-ba92154b3674"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the treatment of pneumonia, lung abscess, and secondary infection of chronic respiratory disease caused by Lasvic-sensitive Staphylococcus spp, Streptococcus spp, Streptococcus pneumoniae , Enterococcus spp, Moraxella (Branhamella ) catarrhalis , Escherichia coli, Klebsiella spp, Enterobacter spp, Haemophilus influenzae , Legionella pneumophila , Peptostreptococcus spp, Veillonella spp, Bacteroides spp, Prevotella spp, Porphyromonas spp, Fusobacterium spp, and Mycoplasma pneumoniae . uuid:1e6915cb-9e9e-4737-bf24-037d2ec45a2f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:55MOB566V7 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:0f789b13-26bb-4109-8ba9-b64029fbc45a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e3a21a17-a733-4ed6-946d-541012d934f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the treatment of pneumonia, lung abscess, and secondary infection of chronic respiratory disease caused by Lasvic-sensitive Staphylococcus spp, Streptococcus spp, Streptococcus pneumoniae , Enterococcus spp, Moraxella (Branhamella ) catarrhalis , Escherichia coli, Klebsiella spp, Enterobacter spp, Haemophilus influenzae , Legionella pneumophila , Peptostreptococcus spp, Veillonella spp, Bacteroides spp, Prevotella spp, Porphyromonas spp, Fusobacterium spp, and Mycoplasma pneumoniae . uuid:4371b600-6aaa-45f8-9ca2-0271d6623331 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:LG1II3835L biolink:treats MONDO:0005416 PMID:41385096 "[{""id"":""uuid:2424d07a-7e65-4ecd-92a6-ba335d9ffa43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8f142589-ddd6-4328-9aca-eadc9f482bc6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of knee and hip osteoarthritis. uuid:fed1330d-38b4-4d2f-be48-f814e83b02dd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:LG1II3835L biolink:treats MONDO:0006629 PMID:41385096 "[{""id"":""uuid:0aff2a28-d0d3-48ed-9bc3-6e1b1484dd68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:84227a11-f404-415f-b17f-d38f7fafa107"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of knee and hip osteoarthritis. uuid:304b5d0f-9b43-4681-b305-8e2ea20bb127 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats EFO:0801084 PMID:41385096 "[{""id"":""uuid:6b8e3890-5359-4966-a382-1a5becf13244"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a4c6295c-38ba-4257-81e8-76548f1146d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication in a new dosage form for analgesia in various types of cancer. uuid:693b5bd1-435e-4f5a-84c2-aa9634e6dc22 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:Y6BX7BL23K biolink:treats MONDO:0004992 PMID:41385096 "[{""id"":""uuid:190f53a4-f8b6-4e3d-b545-b5c2f9078b84"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ce1f2133-f9a9-4d73-98e6-fa35674c35ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of unresectable FGFR2 fusion gene-positive biliary tract cancer that has progressed after cancer chemotherapy. [Orphan drug] uuid:36a3075b-9cfb-49e9-a47b-fdf9ca86fbb7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1597091 biolink:treats UMLS:C1527424 PMID:41385096 "[{""id"":""uuid:6c39b0ff-d369-4a9b-a9ad-9d4485c237ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2128fae3-403e-4d9a-8d87-206e164b10f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the prevention of the following diseases caused by infection with human papillomavirus types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Cervical cancer (squamous cell carcinoma and adenosquamous carcinoma) and its precursor lesions (cervical intraepithelial neoplasia [CIN] 1, 2, and 3, and adenocarcinoma in situ [AIS]) Vulvar intraepithelial neoplasia (VIN) 1, 2, and 3, and vaginal intraepithelial noeplasia (VaIN) 1, 2, and 3 Condyloma acuminatum uuid:f0629a46-d989-49fd-ae61-b30b2ed3414b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1597091 biolink:treats MONDO:0006137 PMID:41385096 "[{""id"":""uuid:4f03d1d8-7dad-4557-aee4-1412de63e551"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5208992d-7803-4226-a7ac-5aab7bbddc74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the prevention of the following diseases caused by infection with human papillomavirus types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Cervical cancer (squamous cell carcinoma and adenosquamous carcinoma) and its precursor lesions (cervical intraepithelial neoplasia [CIN] 1, 2, and 3, and adenocarcinoma in situ [AIS]) Vulvar intraepithelial neoplasia (VIN) 1, 2, and 3, and vaginal intraepithelial noeplasia (VaIN) 1, 2, and 3 Condyloma acuminatum uuid:b9a4f792-de54-4e36-b98f-5ceb86125ef2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1597091 biolink:treats MONDO:0042487 PMID:41385096 "[{""id"":""uuid:a93ac3ef-c8ab-4b3b-8a42-a4a1151224a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:51c329f1-f1d0-459b-9585-6813a500fd58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the prevention of the following diseases caused by infection with human papillomavirus types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Cervical cancer (squamous cell carcinoma and adenosquamous carcinoma) and its precursor lesions (cervical intraepithelial neoplasia [CIN] 1, 2, and 3, and adenocarcinoma in situ [AIS]) Vulvar intraepithelial neoplasia (VIN) 1, 2, and 3, and vaginal intraepithelial noeplasia (VaIN) 1, 2, and 3 Condyloma acuminatum uuid:95d862f9-4b9b-4dc7-8fed-f73d26754cc4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1597091 biolink:treats MONDO:0018585 PMID:41385096 "[{""id"":""uuid:08f9f7ee-279b-4c4f-a13c-84271cabff8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2932e71d-6128-42c3-96b9-ddcf8f81509c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the prevention of the following diseases caused by infection with human papillomavirus types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Cervical cancer (squamous cell carcinoma and adenosquamous carcinoma) and its precursor lesions (cervical intraepithelial neoplasia [CIN] 1, 2, and 3, and adenocarcinoma in situ [AIS]) Vulvar intraepithelial neoplasia (VIN) 1, 2, and 3, and vaginal intraepithelial noeplasia (VaIN) 1, 2, and 3 Condyloma acuminatum uuid:3fd8f7c8-2eec-4f8f-a071-20d43a660257 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1597091 biolink:treats MONDO:0006274 PMID:41385096 "[{""id"":""uuid:7813133b-f5a6-4821-88f1-8c88b7638017"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:55f97673-a735-433f-8f44-37c271fb1205"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the prevention of the following diseases caused by infection with human papillomavirus types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Cervical cancer (squamous cell carcinoma and adenosquamous carcinoma) and its precursor lesions (cervical intraepithelial neoplasia [CIN] 1, 2, and 3, and adenocarcinoma in situ [AIS]) Vulvar intraepithelial neoplasia (VIN) 1, 2, and 3, and vaginal intraepithelial noeplasia (VaIN) 1, 2, and 3 Condyloma acuminatum uuid:a70b7131-f467-4cf8-9492-77b88ac73b68 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1597091 biolink:treats UMLS:C0495107 PMID:41385096 "[{""id"":""uuid:4b1954c0-1443-4a70-92e6-1c276b5032b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:17cf0507-7939-4b8d-bf0d-469da850c629"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the prevention of the following diseases caused by infection with human papillomavirus types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Cervical cancer (squamous cell carcinoma and adenosquamous carcinoma) and its precursor lesions (cervical intraepithelial neoplasia [CIN] 1, 2, and 3, and adenocarcinoma in situ [AIS]) Vulvar intraepithelial neoplasia (VIN) 1, 2, and 3, and vaginal intraepithelial noeplasia (VaIN) 1, 2, and 3 Condyloma acuminatum uuid:fba94848-e420-48b0-9ab5-17cb0956f1d0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1597091 biolink:treats MONDO:0005198 PMID:41385096 "[{""id"":""uuid:8287b17d-a4d3-435e-af49-35521b03fbb0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:af155bd8-7a1a-4802-8a11-c7c2696d11de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the prevention of the following diseases caused by infection with human papillomavirus types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Cervical cancer (squamous cell carcinoma and adenosquamous carcinoma) and its precursor lesions (cervical intraepithelial neoplasia [CIN] 1, 2, and 3, and adenocarcinoma in situ [AIS]) Vulvar intraepithelial neoplasia (VIN) 1, 2, and 3, and vaginal intraepithelial noeplasia (VaIN) 1, 2, and 3 Condyloma acuminatum uuid:7ed2c642-f054-4639-afcf-587197d1d55b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1597091 biolink:treats UMLS:C0349554 PMID:41385096 "[{""id"":""uuid:906b4972-d447-4928-8dec-aaf78024cc11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:91fd883b-fe25-466e-a93e-c3422f3c2a64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the prevention of the following diseases caused by infection with human papillomavirus types 6, 11, 16, 18, 31, 33, 45, 52, and 58: Cervical cancer (squamous cell carcinoma and adenosquamous carcinoma) and its precursor lesions (cervical intraepithelial neoplasia [CIN] 1, 2, and 3, and adenocarcinoma in situ [AIS]) Vulvar intraepithelial neoplasia (VIN) 1, 2, and 3, and vaginal intraepithelial noeplasia (VaIN) 1, 2, and 3 Condyloma acuminatum uuid:f312a444-5cd3-44de-b3b0-689833d87035 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:167600 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:6e321a1b-43b1-4db7-86b1-bf8667169d6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:29989073-4bed-4264-9d2a-100e55add3de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of atopic dermatitis. uuid:66b16297-87de-4bf1-8a65-17c7d567ae93 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:70708 biolink:treats HP:0100607 PMID:41385096 "[{""id"":""uuid:fd143c3a-2762-4391-9488-b0cdbb132fb9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c58fcdff-abd1-46ce-9337-fb121e02eb46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage in an additional dosage form for the treatment of dysmenorrhea. uuid:2207fe82-3a84-44a8-9fd9-69afeb7a931d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:333OX80X87 biolink:treats EFO:0009472 PMID:41385096 "[{""id"":""uuid:7fae6b5d-53f1-4f6e-aef5-531269475e1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:97e37a85-15a5-4a17-ba7b-15ee9404fc0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the treatment of tympanic membrane perforation. uuid:12fade49-9a82-4c6f-bbae-c80f6f972c71 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:861635 biolink:treats MONDO:0005041 PMID:41385096 "[{""id"":""uuid:0639c6fc-bd5a-473c-a5d2-072364053961"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:026aee9f-2934-4714-a13c-875abaabbff1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug indicated for the treatment of glaucoma and ocular hypertension in patients who have not responded sufficiently to other anti- glaucoma drugs. uuid:d3d8de38-f722-45aa-9522-8e06b9653d4b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:861635 biolink:treats HP:0007906 PMID:41385096 "[{""id"":""uuid:28c0bb42-1311-4054-be4f-10c1e448752a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a2e49a62-b38d-413b-9de1-2abd0bedd039"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug indicated for the treatment of glaucoma and ocular hypertension in patients who have not responded sufficiently to other anti- glaucoma drugs. uuid:f11354b0-1289-43d0-aaf7-2789a94f74d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:XSZ53G39H5 biolink:treats MONDO:0005150 PMID:41385096 "[{""id"":""uuid:b2fe5245-897d-440a-b51f-d1b3045b9fbd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7918c146-03d2-49ec-9e6a-ee800955bb0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of age-related macular degeneration associated with subfoveal choroidal neovascularization. uuid:45c3c680-d52a-491d-bf5d-9c0804902173 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:XSZ53G39H5 biolink:treats HP:0031241 PMID:41385096 "[{""id"":""uuid:a5b6d267-a8e4-40ea-aac2-97d38c773be3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:41eabc14-2686-4395-b0fd-f87340af06b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of age-related macular degeneration associated with subfoveal choroidal neovascularization. uuid:cc05254e-185a-4fbb-af84-e568f4d669bc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1421448 biolink:treats MONDO:0005041 PMID:41385096 "[{""id"":""uuid:2798d2f6-3d69-4073-ab67-702739ab9c75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:650fd24b-7b91-4025-ac88-f6ff90897d69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug indicated for the treatment of glaucoma and ocular hypertension in patients who have not responded sufficiently to other anti- glaucoma drugs. uuid:9a1d503b-8fdb-4fec-8612-5463cf016855 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1421448 biolink:treats HP:0007906 PMID:41385096 "[{""id"":""uuid:c4e6677e-ef20-4e3e-aed0-e8b4ac22cd49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8191ef81-1a57-4aa4-8e84-a88142a3e7f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug indicated for the treatment of glaucoma and ocular hypertension in patients who have not responded sufficiently to other anti- glaucoma drugs. uuid:69dcf592-b4a8-4bbc-8220-fece1c23df9f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134741 biolink:treats UMLS:C0858004 PMID:41385096 "[{""id"":""uuid:edb27168-7154-4c27-88eb-cc1382cca039"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1f17d8de-9d61-41f7-8c9b-71a8f85ee730"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug in a new dosage form indicated for the treatment of influenza A or B virus infection. uuid:ff9da4da-dce2-4ad1-93b4-0f1d12fa1027 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134741 biolink:treats UMLS:C0858005 PMID:41385096 "[{""id"":""uuid:70dd9134-b4e9-49cd-b60f-0317d996fba8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:193ee96b-f672-4111-aed0-715f075bb00d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug in a new dosage form indicated for the treatment of influenza A or B virus infection. uuid:cd07e510-7630-4594-9539-7edd95bf87b6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats MONDO:0003799 PMID:41385096 "[{""id"":""uuid:bf51c590-844b-4400-99f7-9c2876df5b79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:942d4a9f-da30-4df3-b756-556e686da45d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the treatment of conjunctivitis, blepharitis, hordeolum and dacryocystitis caused by azithromycin-sensitive Staphylococcus spp., Streptococcus spp., Streptococcus pneumoniae, Corynebacterium spp., Haemophilus influenzae or Propionibacterium acnes. uuid:1d2b7198-7873-4111-aab8-29f088e6d530 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats MONDO:0004785 PMID:41385096 "[{""id"":""uuid:3c54d3f0-a210-40ce-8a4f-bd7b828faf1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9b6acca3-cb8f-4cbd-bef1-a9808d6193ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the treatment of conjunctivitis, blepharitis, hordeolum and dacryocystitis caused by azithromycin-sensitive Staphylococcus spp., Streptococcus spp., Streptococcus pneumoniae, Corynebacterium spp., Haemophilus influenzae or Propionibacterium acnes. uuid:d4f5a76d-522c-4b6c-ae91-0568d85d6e27 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats MONDO:0005800 PMID:41385096 "[{""id"":""uuid:c4101bf3-49c1-4f20-bc82-ca291f20614a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:10f9b107-0c9d-441d-944b-1e3c2078bd13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the treatment of conjunctivitis, blepharitis, hordeolum and dacryocystitis caused by azithromycin-sensitive Staphylococcus spp., Streptococcus spp., Streptococcus pneumoniae, Corynebacterium spp., Haemophilus influenzae or Propionibacterium acnes. uuid:ecb82dea-c5b7-452e-8e11-1a91dc82242f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats MONDO:0004926 PMID:41385096 "[{""id"":""uuid:1976c174-9c1f-4246-b595-81f6edf08b30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:278c8b6b-4519-46b7-b503-b066c704121b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the treatment of conjunctivitis, blepharitis, hordeolum and dacryocystitis caused by azithromycin-sensitive Staphylococcus spp., Streptococcus spp., Streptococcus pneumoniae, Corynebacterium spp., Haemophilus influenzae or Propionibacterium acnes. uuid:d0f56d2a-d74d-4e30-91fe-9692bc4d84bc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:55MOB566V7 biolink:treats MONDO:0001218 PMID:41385096 "[{""id"":""uuid:45b4772d-345c-44e5-a908-4b14aaeec40a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a7c9340b-6de4-4ac4-87e1-6872bebb9dee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, secondary infection of chronic respiratory disease, otitis media, and sinusitis caused by Lasvic-sensitive Staphylococcus spp., Streptococcus spp., Streptococcus pneumoniae , Moraxella (Branhamella) catarrhalis , Klebsiella spp., Enterobacter spp., Haemophilus influenzae , Legionella pneumophila , Prevotella spp., and Mycoplasma pneumoniae . uuid:7ceab0cb-f353-4578-8cdf-a2667438ee9c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:55MOB566V7 biolink:treats MONDO:0001039 PMID:41385096 "[{""id"":""uuid:39a9d3fe-19c1-4e12-9c0c-543986bb65bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4ef5f44f-d4d5-4bca-9bb9-e21c0ef40b1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, secondary infection of chronic respiratory disease, otitis media, and sinusitis caused by Lasvic-sensitive Staphylococcus spp., Streptococcus spp., Streptococcus pneumoniae , Moraxella (Branhamella) catarrhalis , Klebsiella spp., Enterobacter spp., Haemophilus influenzae , Legionella pneumophila , Prevotella spp., and Mycoplasma pneumoniae . uuid:7526fb64-8006-4ffa-b6cf-4ece56e94c8c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:55MOB566V7 biolink:treats UMLS:C0877267 PMID:41385096 "[{""id"":""uuid:311fd8bd-2791-4d5e-b967-f1d74a46140c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2a81fe20-9156-4031-9254-c6ef2375e6d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, secondary infection of chronic respiratory disease, otitis media, and sinusitis caused by Lasvic-sensitive Staphylococcus spp., Streptococcus spp., Streptococcus pneumoniae , Moraxella (Branhamella) catarrhalis , Klebsiella spp., Enterobacter spp., Haemophilus influenzae , Legionella pneumophila , Prevotella spp., and Mycoplasma pneumoniae . uuid:5dbe6f1f-cb56-4426-9eae-5aec25fc598e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:55MOB566V7 biolink:treats MONDO:0005906 PMID:41385096 "[{""id"":""uuid:3e358ec7-d69d-4e5e-892b-5f0ff0ef3f4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e8534583-75ae-49ea-9f33-6e654d6f8b81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, secondary infection of chronic respiratory disease, otitis media, and sinusitis caused by Lasvic-sensitive Staphylococcus spp., Streptococcus spp., Streptococcus pneumoniae , Moraxella (Branhamella) catarrhalis , Klebsiella spp., Enterobacter spp., Haemophilus influenzae , Legionella pneumophila , Prevotella spp., and Mycoplasma pneumoniae . uuid:d7281b5c-1135-44f0-896a-05100b2c8b59 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:55MOB566V7 biolink:treats HP:0012388 PMID:41385096 "[{""id"":""uuid:c2c68881-481f-414d-a33d-aab37f036668"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8d6d9efd-0fcc-4b49-983e-3aaafa1cb1de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, secondary infection of chronic respiratory disease, otitis media, and sinusitis caused by Lasvic-sensitive Staphylococcus spp., Streptococcus spp., Streptococcus pneumoniae , Moraxella (Branhamella) catarrhalis , Klebsiella spp., Enterobacter spp., Haemophilus influenzae , Legionella pneumophila , Prevotella spp., and Mycoplasma pneumoniae . uuid:f3c479ac-0448-4d07-88fa-62cf0d2d6224 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:55MOB566V7 biolink:treats MONDO:0005441 PMID:41385096 "[{""id"":""uuid:048062ee-3b93-494b-83a8-8f4090283308"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:99a6bfa2-27d5-4ef9-8704-97cb78494b72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, secondary infection of chronic respiratory disease, otitis media, and sinusitis caused by Lasvic-sensitive Staphylococcus spp., Streptococcus spp., Streptococcus pneumoniae , Moraxella (Branhamella) catarrhalis , Klebsiella spp., Enterobacter spp., Haemophilus influenzae , Legionella pneumophila , Prevotella spp., and Mycoplasma pneumoniae . uuid:f575b4c4-d4fc-425d-8236-98457dde571d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:55MOB566V7 biolink:treats MONDO:0005961 PMID:41385096 "[{""id"":""uuid:b2615937-b716-4446-9e10-735bd35cbe24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e44b1c98-82f9-431f-bc45-a6fe4b9c56b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, secondary infection of chronic respiratory disease, otitis media, and sinusitis caused by Lasvic-sensitive Staphylococcus spp., Streptococcus spp., Streptococcus pneumoniae , Moraxella (Branhamella) catarrhalis , Klebsiella spp., Enterobacter spp., Haemophilus influenzae , Legionella pneumophila , Prevotella spp., and Mycoplasma pneumoniae . uuid:af6e8395-2172-4001-9c9f-2727b3128334 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2122519 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:ddd6550d-533b-456f-892d-37def7497e38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ab585f68-c644-4672-a2da-14b6a0b4eddc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug indicated for the treatment of HIV infection. [Orphan drug] uuid:506e4eaa-ee80-4dfc-bbe7-bb37edafd563 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2BT4C47RUI biolink:treats MONDO:0005097 PMID:41385096 "[{""id"":""uuid:8846f99e-4f8f-48e8-96e0-c27a39b85e75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ef9df9db-47d2-4e93-a859-b960c7e84d5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of unresectable advanced or recurrent squamous non-small cell lung cancer. uuid:5addd0f3-2fbe-4532-9449-7938e1b440dc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:52CMI0WC3Y biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:49f26a7d-a41a-4bf2-b401-7349891df3f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:02f9d3d0-fb42-46a4-b49a-b2b5fcc72236"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage in an additional dosage form indicated for the treatment of PD-L1-positive, hormone receptor- negative and HER2-negative inoperable or recurrent breast cancer. uuid:dac07e58-d8a6-4743-a634-b9af35919bda biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:23581792 biolink:treats UMLS:C0854776 PMID:41385096 "[{""id"":""uuid:508cc35c-8720-4149-a326-d2564b747eae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e8b0557b-d660-46a0-b8bb-c36eb4b475b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication in a new dosage form for the treatment of unresectable pancreatic cancer that has progressed after cancer chemotherapy. uuid:e8353648-14e5-4cff-ac02-9cbd0b4f670b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:23581792 biolink:treats MONDO:0004992 PMID:41385096 "[{""id"":""uuid:ed018a12-2708-471d-854a-db18b5cdd377"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d832e46c-9e63-4569-98fe-0baa6276bcaf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication in a new dosage form for the treatment of unresectable pancreatic cancer that has progressed after cancer chemotherapy. uuid:2bf5a6d4-da77-4cfe-b75d-be3db1ccbcf9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:232544 biolink:treats MONDO:0002571 PMID:41385096 "[{""id"":""uuid:44c67735-c087-463c-aa4a-a90efe10f20f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ed328e55-ce56-4032-a428-b1c012691296"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of relapsed or refractory primary central nervous system (CNS) lymphoma. [Orphan drug] uuid:f90b21cd-d60a-4c1a-9004-de60e9fdffda biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:UID84303EL biolink:treats MONDO:0005627 PMID:41385096 "[{""id"":""uuid:d1741673-c223-44da-961c-a0baa7c7b942"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:17979f3a-4287-4dbf-a3b4-bcf7a3f859eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of locally unresectable recurrent or unresectable advanced head and neck cancer. [SAKIGAKE designation] uuid:2771974e-7ea2-424c-9406-477e0465759c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:5PKM8P0G5I biolink:treats MONDO:0010191 PMID:41385096 "[{""id"":""uuid:1417f355-a722-4d7c-a4b7-053e89a309dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:26e1153b-1198-4575-8d10-4bbde3b06e0c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the control of bleeding tendency in patients with von Willebrand disease (VWD). [Orphan drug] uuid:7d695b15-bd94-46b2-aa0b-4c06a0230679 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C033608 biolink:treats HP:0012450 PMID:41385096 "[{""id"":""uuid:aca6dd47-9528-4069-a6ee-eb1f0ae7147a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1f2330c8-d518-4f7a-a6e5-3c176c903586"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug indicated for the treatment of chronic constipation (excluding constipation due to organic diseases). uuid:ef9d316a-75e0-4982-ab96-2c31a7f83a37 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6897GXD6OE biolink:treats MONDO:0002280 PMID:41385096 "[{""id"":""uuid:799c0110-9793-4026-bca1-d45b85049013"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b5361b2f-da3c-4800-9f89-cae682da84ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of iron-deficiency anemia. uuid:b9cd81be-8de3-4378-9433-860e94502724 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7510J153OT biolink:treats MONDO:0008233 PMID:41385096 "[{""id"":""uuid:d282953f-896c-470b-9a09-7af21a559fb2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5c2377fa-c85a-4542-b1e5-360c77275b65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the improvement of the status of excessive catecholamine secretion in patients with pheochromocytoma. [Orphan drug] PUBCHEM.COMPOUND:12650 uuid:07a72e38-1c1e-4039-9fee-9b4b54332c49 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:G0G0H52U6K biolink:treats MONDO:0005041 PMID:41385096 "[{""id"":""uuid:f66d6ef6-6d6e-4653-8477-715cf6f0e6a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:008392ec-84fe-43b3-a070-c8f527613494"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of glaucoma and ocular hypertension. uuid:66d4b8fe-ad6f-4fb9-b777-8d8181ab3e0e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:G0G0H52U6K biolink:treats HP:0007906 PMID:41385096 "[{""id"":""uuid:c9be504b-171c-430c-baf5-4bdc685acfb9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a445c6d0-1441-4e6c-9bb2-5f4d00514142"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of glaucoma and ocular hypertension. uuid:94e982ac-079b-4e3b-8872-b4a644f6d419 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68590 biolink:treats UMLS:C0021342 PMID:41385096 "[{""id"":""uuid:f204c723-83b9-4c74-9fda-685389f28c3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4d97e4cf-3eeb-4e11-b727-e12cbcf46ad5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of infectious enteritis (including pseudomembranous colitis) caused by C. difficile . uuid:beb21e97-0234-48b1-b26c-33e56bcb0c5d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:033ECH6IFG biolink:treats MONDO:0005715 PMID:41385096 "[{""id"":""uuid:b0b1c27b-62de-42ef-b088-7db514128279"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2aaf6d04-a09f-40e2-a825-152adae60523"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the prophylaxis of congenital toxoplasmosis. [Orphan drug] uuid:d49a5ae2-bfbe-4c0c-ab2c-9473abb0a96f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1597612 biolink:treats MONDO:0006032 PMID:41385096 "[{""id"":""uuid:6b787f63-d609-43eb-98a1-c02b1b656338"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8d84aafc-8198-45d8-8d95-838221c6e4dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug with new active ingredients indicated for the treatment of cystitis, pyelonephritis, peritonitis, intra-abdominal abscess, cholecystitis, and liver abscess caused by Zerbaxa- sensitive Streptococcus spp., Escherichia coli , Citrobacter spp., Klebsiella spp., Enterobacter spp., Proteus spp., or Pseudomonas aeruginosa . uuid:923d77fc-3b06-470a-b4e3-bc367a5188fa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1597612 biolink:treats MONDO:0004522 PMID:41385096 "[{""id"":""uuid:f0c20330-9884-4555-b90c-fc9be6e053dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0d2d5d2f-b5c1-42ea-8d2d-d5564486ad33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug with new active ingredients indicated for the treatment of cystitis, pyelonephritis, peritonitis, intra-abdominal abscess, cholecystitis, and liver abscess caused by Zerbaxa- sensitive Streptococcus spp., Escherichia coli , Citrobacter spp., Klebsiella spp., Enterobacter spp., Proteus spp., or Pseudomonas aeruginosa . uuid:66f1c997-e1ab-449c-b678-b8ce28ac327e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1597612 biolink:treats MONDO:0002155 PMID:41385096 "[{""id"":""uuid:2576db92-e9e0-4d24-978c-2adbd3c44f0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:89621d4d-1c35-436e-88a6-5fb86fb408f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug with new active ingredients indicated for the treatment of cystitis, pyelonephritis, peritonitis, intra-abdominal abscess, cholecystitis, and liver abscess caused by Zerbaxa- sensitive Streptococcus spp., Escherichia coli , Citrobacter spp., Klebsiella spp., Enterobacter spp., Proteus spp., or Pseudomonas aeruginosa . uuid:8079d93f-91c4-45aa-8d26-bd6119cbd921 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1597612 biolink:treats UMLS:C0023886 PMID:41385096 "[{""id"":""uuid:be52e59d-7c2a-4747-a7ad-d19d63e16aee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bcf2b79e-fe50-480b-b73b-971ac4494e1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug with new active ingredients indicated for the treatment of cystitis, pyelonephritis, peritonitis, intra-abdominal abscess, cholecystitis, and liver abscess caused by Zerbaxa- sensitive Streptococcus spp., Escherichia coli , Citrobacter spp., Klebsiella spp., Enterobacter spp., Proteus spp., or Pseudomonas aeruginosa . uuid:964f8bce-9fa5-42bd-952c-1b0bf50d30b2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1799208 biolink:treats MONDO:0005231 PMID:41385096 "[{""id"":""uuid:c3431afc-8606-4ee5-8767-a535e5fae810"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5d7ab162-f5a8-44cc-8b10-c8056a672ede"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug with a new active ingredient indicated for: Improvement of viremia in patients with chronic hepatitis C or compensated cirrhosis type C who have previously been treated. Improvement of viremia in patients with decompensated cirrhosis type C. [Priority review] uuid:bed87a39-ee92-4dd9-adaa-4fd6a34bca0b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1799208 biolink:treats MONDO:0005448 PMID:41385096 "[{""id"":""uuid:5c3ad120-aa60-441b-b2da-187406341887"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2762417c-2e95-44b2-aedc-6f20b100388b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug with a new active ingredient indicated for: Improvement of viremia in patients with chronic hepatitis C or compensated cirrhosis type C who have previously been treated. Improvement of viremia in patients with decompensated cirrhosis type C. [Priority review] uuid:d679d466-b262-45e7-be0e-841004fcebaf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:142418 biolink:treats MONDO:0006624 PMID:41385096 "[{""id"":""uuid:b5400026-748f-4fae-b266-9e71b97448d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:95509ba3-9bbc-4fff-80c5-93df54b7ad36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of urinary urgency, urinary frequency, and urge urinary incontinence associated with overactive bladder. uuid:45bd8491-915e-41e6-808a-517c18ec7145 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:142418 biolink:treats HP:0100515 PMID:41385096 "[{""id"":""uuid:9b2cc8a6-b2db-4761-87ee-ee77d0700c46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8d2d72e8-e868-4d21-b10c-ad8994488d34"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of urinary urgency, urinary frequency, and urge urinary incontinence associated with overactive bladder. uuid:34ec19bb-1862-417d-9fa5-7cb27a9328c4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:P76B05O5V6 biolink:treats HP:0000132 PMID:41385096 "[{""id"":""uuid:77ae5146-daa3-429b-85e9-d23fc9df2d92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bb765445-d071-4d35-9d26-d2d72e09116a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the alleviation of menorrhagia, lower abdominal pain, backache, and anemia that are associated with uterine fibroids. uuid:7b68c814-4c7f-4720-9d20-fe484beacb2a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:P76B05O5V6 biolink:treats NCIT:C35272 PMID:41385096 "[{""id"":""uuid:2a826f5c-078f-4dee-a8e1-40668f953c87"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:81d2e8d5-e966-421a-8cbb-d4aa681ce9fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the alleviation of menorrhagia, lower abdominal pain, backache, and anemia that are associated with uterine fibroids. uuid:c5f6971f-d466-4d8d-b69c-cdaa801cebbc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:P76B05O5V6 biolink:treats HP:0003418 PMID:41385096 "[{""id"":""uuid:7df37110-c4c3-40ac-a3c9-5fc93ae91ca6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bb026fa6-f874-4ea5-8b6b-997e20fe6a99"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the alleviation of menorrhagia, lower abdominal pain, backache, and anemia that are associated with uterine fibroids. uuid:202af928-27f2-4d6b-9f16-ee8c0c1c69ff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:P76B05O5V6 biolink:treats MONDO:0002280 PMID:41385096 "[{""id"":""uuid:726de5a1-8a8f-4a5e-a7ae-aedc049bd303"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ad5c86ad-93b4-47a8-a463-4f6497ea2712"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the alleviation of menorrhagia, lower abdominal pain, backache, and anemia that are associated with uterine fibroids. uuid:c16f2fb3-6867-4647-b1cc-67b9dcd532bd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:90ZX3Q3FR7 biolink:treats MONDO:0022205 PMID:41385096 "[{""id"":""uuid:d6fb0bc9-8c91-4010-89c6-ce069746f230"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5a8cd34c-6174-4335-b37f-1a17262a22e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of plaque psoriasis, psoriatic arthritis, pustular psoriasis and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies. uuid:e8997e64-1b5f-4154-ba2c-6cb35e94b08c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:90ZX3Q3FR7 biolink:treats UMLS:C0748052 PMID:41385096 "[{""id"":""uuid:bdf5a370-5d84-4471-831f-9aa626dffadd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:eb1bb2b4-6822-4f04-8f84-c3d688c32fcc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of plaque psoriasis, psoriatic arthritis, pustular psoriasis and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies. uuid:b14d2e13-22e1-40ba-a95a-1e9516fdbdce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:31YO63LBSN biolink:treats MONDO:0005627 PMID:41385096 "[{""id"":""uuid:77764e70-55d8-4bd7-9d1f-9144e8fd635d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1ef3cd34-1bc3-488b-b974-0bf2a8fb688b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new indications and a new dosage in an additional dosage form for the treatment of unresectable or recurrent malignant pleural mesothelioma and melanoma that have progressed after chemotherapy. [Orphan drug] A drug with a new dosage in an additional dosage form indicated for the treatment of melanoma, unresectable or recurrent non-small cell lung cancer, unresectable or metastatic renal cell carcinoma, relapsed or refractory classical Hodgkin lymphoma, recurrent or metastatic head and neck cancer, unresectable or recurrent gastric cancer that has progressed after chemotherapy, and (3) unresectable or metastatic renal cell carcinoma. [(3) Priority review] uuid:e419f7f4-943d-4319-8b45-d8bb8e81b7f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9570 biolink:treats UMLS:C0280100 PMID:41385096 "[{""id"":""uuid:a787346a-f10b-48ca-8211-4fdc98e7f6d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6e058154-2915-4593-b086-da513232eeb3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the conditioning treatment of solid tumors in pediatric patients prior to autologous hematopoietic stem-cell transplantation. [Expedited review] uuid:944a7b6e-52a1-49c4-837e-e57b91fcda24 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10283 biolink:treats MONDO:0019173 PMID:41385096 "[{""id"":""uuid:35754dbf-8960-4dbd-840a-6eb5f7007c68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2001c91a-222e-41da-8248-28d10d699b67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the pre-exposure and post-exposure prophylaxis against rabies. uuid:ddfd1950-baa9-4f08-a29e-f92c7fe0531d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:B72HH48FLU biolink:treats UMLS:C0852922 PMID:41385096 "[{""id"":""uuid:9f593e13-4986-4005-8679-2f23e33949d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0226969a-576e-4db2-9446-3f8fcf7964a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Follow-on biologics indicated for the treatment of rheumatoid arthritis, psoriasis, Crohn’s disease, and ulcerative colitis. uuid:c91ffac8-48e5-4e4e-b805-8db03ce182b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:865UEK4EJC biolink:treats HP:0012450 PMID:41385096 "[{""id"":""uuid:75269bbb-e465-4a3c-a4b9-fbaa191a185d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f6926567-0367-45a3-92c6-e65dc371edc0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of chronic constipation (excluding constipation due to organic diseases). uuid:162e66c5-7309-4eb3-8b5b-4162d8343bda biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:228365 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:f0223d82-93fd-4658-b759-7c5ac3f937e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5f9e7e9e-3251-4fe0-ab01-74caff2f612d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of hyperlipidaemia (including familial hyperlipidaemia). uuid:1e45bf7d-e4dd-4e26-aea4-b66d57d631d1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:228365 biolink:treats UMLS:C0694546 PMID:41385096 "[{""id"":""uuid:40602872-eac7-45d2-8270-0499285167e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:80d497e0-1edc-40d8-8a0d-dbe95b58fed2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of hyperlipidaemia (including familial hyperlipidaemia). uuid:3302d794-0b97-45a1-bafc-a0d7a9ce0a8b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:5Z9SP3X666 biolink:treats MONDO:0009669 PMID:41385096 "[{""id"":""uuid:5eccd0fc-c6cd-43dd-830a-3409f267e111"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0aac74c3-09cb-456d-94fa-e4545bebba4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of infantile spinal muscular atrophy. [Orphan drug] uuid:b034b272-501e-433e-8b58-240a1c24a21c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7SI2UZG934 biolink:treats HP:0008441 PMID:41385096 "[{""id"":""uuid:1b76c7be-e741-4151-94d2-5479629da14e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:595453c8-3ef5-4a25-a09f-c4d4396b5f2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of lumbar disc herniation with subligamentous extrusion that has not adequately responded to conservative treatment. uuid:92a039d8-1661-40b1-bc35-75a0b79bc740 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:94X46KW4AE biolink:treats MONDO:0005609 PMID:41385096 "[{""id"":""uuid:bb9e811d-9532-44f8-9587-2b58946b6319"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e23f1aa6-8964-46d8-8fdd-164ace13bb53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of herpes zoster. uuid:d208a73f-5ea2-4fb2-8bc6-d3ea25c6b27b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1940699 biolink:treats MONDO:0005155 PMID:41385096 "[{""id"":""uuid:60ec64e8-630a-4b3b-a9ba-bf1a1b10ce5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4c61ed9c-6cf6-40d6-897e-ad6dafc1fdfa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug with a new active ingredient indicated for the improvement of viremia in patients with chronic hepatitis C or compensated cirrhosis type C. [Priority review] uuid:9cfe4f52-6713-4469-a792-875370dd76ed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:34549 biolink:treats MONDO:0001628 PMID:41385096 "[{""id"":""uuid:01df4214-c0e2-457a-b310-8acca1aad4f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:dd5781c1-c174-4c22-8fb9-dce910101528"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of onychomycosis due to Trichophyton species. uuid:dc34a688-2811-4fda-a695-4654282b82c3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135673 biolink:treats MONDO:0011786 PMID:41385096 "[{""id"":""uuid:bb338eb5-3197-42c3-b6bf-5e0e5e69932f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1a4826d2-df01-4f36-bfea-ab145f088d9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of allergic rhinitis, urticaria, and itching associated with skin diseases (eczema/dermatitis, cutaneous pruritus). uuid:8add638e-148b-4f7d-8ea2-5e04296a4300 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135673 biolink:treats MONDO:0005492 PMID:41385096 "[{""id"":""uuid:892f4ab9-a2b0-4e34-aed2-3fffbfbb2491"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ee2daef9-49ab-4b10-b1eb-617195900512"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of allergic rhinitis, urticaria, and itching associated with skin diseases (eczema/dermatitis, cutaneous pruritus). uuid:c0b320aa-2106-4622-b786-e7d206bc9216 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135673 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:ae568bbd-a45e-4568-a44b-5f521cb449ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:12bb34e0-cb12-4fef-a592-60eb005a941e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of allergic rhinitis, urticaria, and itching associated with skin diseases (eczema/dermatitis, cutaneous pruritus). uuid:7c0affb6-a12c-4aea-aef0-f6e2573f9ff9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135673 biolink:treats MONDO:0002406 PMID:41385096 "[{""id"":""uuid:748bc8d8-6576-4524-a70b-86e2a3781b24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:27ff1636-aaff-451b-8c33-7cda6818f9fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of allergic rhinitis, urticaria, and itching associated with skin diseases (eczema/dermatitis, cutaneous pruritus). uuid:eea856bb-4a77-4068-92c9-69f8430cffc7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:71492GE1FX biolink:treats MONDO:0100470 PMID:41385096 "[{""id"":""uuid:bf187b8e-016d-4d6c-b0d2-2252e342f112"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ee2af46b-da0b-4577-bf21-df8f826302f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of bronchial asthma (for use only in patients with intractable bronchial asthma whose asthmatic responses are uncontrollable with conventional therapies). uuid:a04ac3dc-4856-4fca-a737-fbf10bf8d41e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:089658A12D biolink:treats MONDO:0022205 PMID:41385096 "[{""id"":""uuid:c243a18f-b5f1-486a-8a53-adf7fad78b1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a6f13a40-0434-4cf8-a19c-a2d7bf393a1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of plaque psoriasis, psoriatic arthritis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies. uuid:900d11b0-a072-4edf-ba69-0cbe76556a7e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:089658A12D biolink:treats UMLS:C0748052 PMID:41385096 "[{""id"":""uuid:90e0029e-c94d-4bfb-afa3-2486bae8fd89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2d63eb6e-2745-493a-8dfc-35d1ef52abb4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of plaque psoriasis, psoriatic arthritis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies. uuid:a2ed578b-9374-4658-8d84-ac8331c70e95 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17549 biolink:treats MONDO:0004200 PMID:41385096 "[{""id"":""uuid:df5177ce-8e4b-4f4f-b94b-bbfbeff3e7b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4b611691-cc97-4729-9c77-b39275ead905"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage in an additional dosage form for the visualization of tumor tissues of the non-muscle invasive bladder cancer in transurethral resection of bladder tumor. [Orphan drug] uuid:98e0d228-83b6-4f68-8474-d49df8c66833 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:P93RUU11P7 biolink:treats MONDO:0020511 PMID:41385096 "[{""id"":""uuid:ee1a87d4-ea5b-4300-b251-f33218b3a03e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e56c1c65-8db5-4591-81a8-3007bb6c18d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of relapsed or refractory CD22- positive acute lymphoblastic leukemia. [Orphan drug] uuid:fc859ee4-4977-417b-8566-6bd8ea162510 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3207 biolink:treats UMLS:C0852922 PMID:41385096 "[{""id"":""uuid:06f57071-a4dc-4257-bf28-bd6aeee4dc95"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:81d5a328-463c-4bc6-880f-155512b57f16"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the treatment of mild to moderately active Crohn's disease. uuid:69b45890-99ea-4aaa-bae5-9243eb3726c8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:205919 biolink:treats EFO:1001494 PMID:41385096 "[{""id"":""uuid:11865216-7d96-4384-b8c9-f0a500a669ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fe66a8e4-87b6-4894-a551-0ca9216628ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug in a new dosage form indicated for the treatment of psoriasis vulgaris of the scalp. uuid:47a46b6c-bd19-4143-b2ea-8c1428f908ca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0353697 biolink:treats MONDO:0005180 PMID:41385096 "[{""id"":""uuid:429fb38c-debf-4134-a28b-fcdf36cf4f74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6f59d24c-bd12-40a6-a266-9e62da1ea5bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug indicated for the improvement of wearing-off phenomenon in the symptoms of Parkinson's disease in patients who have not responded sufficiently to conventional levodopa-containing drug therapies. [Orphan drug] uuid:4f756a45-97ea-4d11-b245-96dc3e3179f4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75246 biolink:treats MONDO:0001711 PMID:41385096 "[{""id"":""uuid:bdb03330-6d01-48fb-a50a-f80dfd30cb17"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9531d27f-f962-4194-a4bb-306cfe0b5644"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the improvement of hyperammonemia in patients with hepatic encephalopathy. [Orphan drug] uuid:21d0992d-6134-4d9a-8cb0-64b1538136a5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:132975 biolink:treats MONDO:0005354 PMID:41385096 "[{""id"":""uuid:7a7846e3-764f-492e-9af3-0d28019d8fe9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bded837d-9a8d-4fd9-8830-242a31c0cdc9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the improvement of viremia in patients with chronic hepatitis C or compensated cirrhosis type C in serogroup 1 (genotype 1). [Priority review] uuid:20aa0fd0-8543-4db5-80da-d5846c9f8c09 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:132975 biolink:treats MONDO:0005155 PMID:41385096 "[{""id"":""uuid:c3a0bcc3-2921-44fe-b6a6-65a474b1639e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6a27dd2c-3494-4c45-9270-87d6d7896667"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the improvement of viremia in patients with chronic hepatitis C or compensated cirrhosis type C in serogroup 1 (genotype 1). [Priority review] uuid:78362e88-0a0c-4c25-ad60-1f72c6d3b054 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:132967 biolink:treats MONDO:0005354 PMID:41385096 "[{""id"":""uuid:165f7ea6-b133-468f-93d8-e47caf09531c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:523a3492-405e-424e-a1ce-5c1a1d02a8f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the improvement of viremia in patients with chronic hepatitis C or compensated cirrhosis type C in serogroup 1 (genotype 1). [Priority review] uuid:07a78566-34f3-4ca7-b3c6-083bf01d0401 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:132967 biolink:treats MONDO:0005155 PMID:41385096 "[{""id"":""uuid:11942c5f-6c24-41ec-a0ba-820891237157"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6f58e692-c359-4ca6-b62a-2fef23137456"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the improvement of viremia in patients with chronic hepatitis C or compensated cirrhosis type C in serogroup 1 (genotype 1). [Priority review] uuid:88a123be-d7ae-450f-ac4d-2c6c0cb8bf3f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:718834 biolink:treats MONDO:0005136 PMID:41385096 "[{""id"":""uuid:bab711c8-c416-4f0c-8db9-c6d292cea697"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1206c0e6-fe7f-4afa-8fbd-783c223fa873"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug with new active ingredients indicated for the treatment of malaria. uuid:c07df0bc-5012-41ff-b483-f9d7e3e8562c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90923 biolink:treats MONDO:0005344 PMID:41385096 "[{""id"":""uuid:acc450ec-00f5-4c43-a864-0523507cc17c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ae54a013-8f84-48e7-af59-f7434f42a565"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the suppression of proliferation of hepatitis B virus in patients with chronic liver disease with hepatitis B virus infection in whom abnormal liver function is confirmed along with hepatitis B virus proliferation. [Priority review] uuid:2dc31dd3-243b-484a-b1b3-b36bdf18f074 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90923 biolink:treats UMLS:C0341439 PMID:41385096 "[{""id"":""uuid:33710ac7-57f8-461b-b74e-189394f06f4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f68d4ade-6d8f-4f95-a164-edb8437184d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the suppression of proliferation of hepatitis B virus in patients with chronic liver disease with hepatitis B virus infection in whom abnormal liver function is confirmed along with hepatitis B virus proliferation. [Priority review] uuid:c56197bf-60ea-4dec-b337-6f09094bf948 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9874151 biolink:treats MONDO:0005133 PMID:41385096 "[{""id"":""uuid:99b26efe-7a5f-4b56-a080-6b8d654d0e59"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:001b8f56-15a0-4b42-8c58-00629126b03d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new indications and a new dosage in an additional dosage form indicated for the alleviation of pain associated with endometriosis, and dysmenorrhea. uuid:42f6dd22-a60b-4ba9-848f-608cb5e76d0e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9874151 biolink:treats HP:0100607 PMID:41385096 "[{""id"":""uuid:189affe6-85b7-4407-9fef-b16847f0b549"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:372b2123-37ec-4059-a616-4471433237e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new indications and a new dosage in an additional dosage form indicated for the alleviation of pain associated with endometriosis, and dysmenorrhea. uuid:a00a99ae-caf3-4d0a-b154-b490c201b7e7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6ZA31Y954Z biolink:treats MONDO:0011849 PMID:41385096 "[{""id"":""uuid:95bc18d4-5540-46a8-88fe-01001714d92c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2ee1e53c-f432-423b-bfc9-6cce29b62a46"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of plaque psoriasis, psoriatic arthritis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies. uuid:043a20b5-ef39-41cd-9da4-f6818472e50b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6ZA31Y954Z biolink:treats MONDO:0022205 PMID:41385096 "[{""id"":""uuid:d7226a5c-fe3d-4fb9-bdea-8ef27c891322"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fe88b202-dc84-4c3b-83d2-9b3ade2e68de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of plaque psoriasis, psoriatic arthritis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies. uuid:091430e2-e5ee-476e-aa98-1137f92e7b49 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6ZA31Y954Z biolink:treats UMLS:C0748052 PMID:41385096 "[{""id"":""uuid:5a1d5b2d-40c2-4d44-b491-00334e176a4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4b5acfbc-cd7c-4fc2-9300-187e9ae190ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of plaque psoriasis, psoriatic arthritis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies. uuid:5925d6ed-a446-4b79-abb6-58d7dc5ab4cd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:291342 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:89e24889-5be8-4283-9633-14b4c16c46d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bf82865b-3416-4fc7-8daa-188928f6d311"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of allergic rhinitis, urticaria, and itching associated with skin diseases (eczema/dermatitis, cutaneous pruritus). uuid:a0fcaf95-8f20-4d9f-bd8e-00cd0af3b7c9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:291342 biolink:treats MONDO:0002406 PMID:41385096 "[{""id"":""uuid:8fa9d9fd-6891-4901-9af0-b3942d8a058f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:eb052563-1a9e-41e4-a39e-709e36ffdc76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of allergic rhinitis, urticaria, and itching associated with skin diseases (eczema/dermatitis, cutaneous pruritus). uuid:b0235c56-c2a8-4a26-a415-97508062067f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135954 biolink:treats MONDO:0011786 PMID:41385096 "[{""id"":""uuid:b9dda016-9821-43c8-9e53-66f9d6e37551"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:648b6622-26e2-42cf-abef-48fbf7df1186"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of allergic rhinitis, urticaria, and itching associated with skin diseases (eczema/dermatitis, cutaneous pruritus). uuid:8883a8ec-36c3-4e26-8159-157be0ed125e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135954 biolink:treats MONDO:0005492 PMID:41385096 "[{""id"":""uuid:dac2e8c2-0b27-47f6-9244-d26ef8a9728e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4a6abb1a-771a-49a8-ba7c-a14c5f1a34c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of allergic rhinitis, urticaria, and itching associated with skin diseases (eczema/dermatitis, cutaneous pruritus). uuid:cba6de52-b40e-41ed-9a55-d69728dc5376 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135954 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:24bd18d5-ad8c-42a4-a432-ac249b9174a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b410c0d8-da59-4238-8b3b-72ab55f2134a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of allergic rhinitis, urticaria, and itching associated with skin diseases (eczema/dermatitis, cutaneous pruritus). uuid:0878b9b6-6352-47ff-9b5e-9ec5fbd003db biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135954 biolink:treats MONDO:0002406 PMID:41385096 "[{""id"":""uuid:2c68f118-3f57-4cc8-be42-dfd9fe82d171"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c0d06679-e53f-471e-b301-b3fb81c16f5d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of allergic rhinitis, urticaria, and itching associated with skin diseases (eczema/dermatitis, cutaneous pruritus). uuid:dbfc4164-0a27-4a0a-9030-7e7e2a852e34 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:78543 biolink:treats MONDO:0004967 PMID:41385096 "[{""id"":""uuid:e7e55772-4184-482e-8b92-5c087879e4fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7d9ce314-c6af-4a5a-a383-5415901ed7ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of chronic myelogenous leukemia with resistance or intolerance to prior drug therapies, and recurrent or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. [Orphan drug] uuid:bb2923b4-c20f-4ce7-b035-5cacdd9a66c3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32660 biolink:treats MONDO:0010643 PMID:41385096 "[{""id"":""uuid:278de8af-cd07-4001-b314-e7b31ae9984e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1babf049-83fb-40d1-a3e9-ab79724bb4ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of acute leukemia (including blast crisis of chronic leukemia) and malignant lymphoma (only for patients who experienced hypersensitivity to L-asparaginase preparations). uuid:1acd60b3-d3b2-42dc-a716-4ffb9da5fac1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32660 biolink:treats MONDO:0006115 PMID:41385096 "[{""id"":""uuid:726740d0-8ebe-48f3-88aa-31e56ada2a79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:11a7de05-eb26-4140-aa4a-25d0051b9be3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of acute leukemia (including blast crisis of chronic leukemia) and malignant lymphoma (only for patients who experienced hypersensitivity to L-asparaginase preparations). uuid:372673bc-df1a-4aac-89e6-76bf17bf61d9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32660 biolink:treats MONDO:0005062 PMID:41385096 "[{""id"":""uuid:e0837e12-d489-43d7-b7eb-11cee8003495"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4cad8296-1bfb-4de6-9fc0-fb74da8115eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of acute leukemia (including blast crisis of chronic leukemia) and malignant lymphoma (only for patients who experienced hypersensitivity to L-asparaginase preparations). uuid:1f7e4213-ac0e-452a-8c74-044a998f6909 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9X7O8V25IT biolink:treats MONDO:0007476 PMID:41385096 "[{""id"":""uuid:00f8ad72-e75d-48c6-a4b2-30a1558cfa1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0f21557f-5a05-47e8-bda5-89674ab8788f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of Dupuytren's contracture. uuid:4ffa901d-6f98-48dc-88c4-ac7f362e5f9a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:882520 biolink:treats EFO:1001494 PMID:41385096 "[{""id"":""uuid:61a553a1-fded-42be-a509-8133d9033c2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c3835bc5-8df1-4921-9f00-223248520c76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug indicated for the treatment of psoriasis vulgaris. uuid:11f90bbc-79c2-447d-a5fb-72463e6cf396 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63638 biolink:treats HP:0012469 PMID:41385096 "[{""id"":""uuid:7320fba9-e933-4a94-9938-3380e6444ab9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cdad0b2f-cef1-45d0-97af-2b7647011eea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of infantile spasms. [Orphan drug] uuid:05baa3e5-9208-403e-bbd5-aeac3a3b1f39 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1591939 biolink:treats MONDO:0005155 PMID:41385096 "[{""id"":""uuid:70e00c48-145c-457b-a48a-2ce781538781"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ad83d9e1-ddad-4c17-82c2-592b263fbee4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug with new active ingredients indicated for the improvement of viremia in patients with chronic hepatitis C or compensated cirrhosis type C in serogroup 1 (genotype 1). [Priority review] uuid:9306b7cc-fb71-44a3-ab79-943f9ddd9333 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:136050 biolink:treats MONDO:0021201 PMID:41385096 "[{""id"":""uuid:6393c530-59d8-4161-9a3c-98162086ba1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:543a18dc-94b7-4f26-ab85-e509f8cba488"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of superficial skin infections and acne (accompanied by purulent inflammation). uuid:c608ff78-b4bd-4614-bc81-3f40235b37a5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:136050 biolink:treats MONDO:0011438 PMID:41385096 "[{""id"":""uuid:00973af3-b1be-4b5e-ae05-5daaf41f8aae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7c162c0a-00a4-4c9f-b33b-7638ed66d0be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of superficial skin infections and acne (accompanied by purulent inflammation). uuid:23d4ad21-77c4-4c1d-9678-e94dce08e51c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1597377 biolink:treats MONDO:0005354 PMID:41385096 "[{""id"":""uuid:bcb35164-b0c4-45b3-b312-b08f41fa7a3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cb10924f-0ec9-473b-8a0e-2991dcc8189e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug with new active ingredients indicated for the improvement of viremia in patients with chronic hepatitis C or compensated cirrhosis type C in serogroup 1 (genotype 1). [Priority review] uuid:a85eafae-f45e-443d-b244-7a861c820081 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1597377 biolink:treats MONDO:0005155 PMID:41385096 "[{""id"":""uuid:9065f8dd-9893-476c-98c6-2f8467b85cfe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3f173322-1724-4787-92bb-e7d8ecb1d6d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug with new active ingredients indicated for the improvement of viremia in patients with chronic hepatitis C or compensated cirrhosis type C in serogroup 1 (genotype 1). [Priority review] uuid:8620c0c4-c757-427b-b8e9-0dd21a20df56 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:34825 biolink:treats MONDO:0001628 PMID:41385096 "[{""id"":""uuid:67093d6c-7740-4151-85e4-e7e4375107a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:395926a5-b200-4613-8a15-25fa11aa91eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication in a new dosage form indicated for the treatment of tinea unguium. uuid:3ebc037d-b363-4f9d-a4d8-c9fde048c489 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8405 biolink:treats MONDO:0005136 PMID:41385096 "[{""id"":""uuid:5524aacd-b971-4947-965a-644e1a8c4f23"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7efbb861-9416-4d76-8366-2b3e3342adee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of malaria caused by Plasmodium vivax and Plasmodium oval . uuid:3cd230fd-096b-4314-b458-b59b797fb86b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8405 biolink:treats MONDO:0001601 PMID:41385096 "[{""id"":""uuid:0af3e154-732d-4735-a937-0b033bffd143"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e74535bb-ea4e-4dc2-9d36-cb5c6c65dc1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of malaria caused by Plasmodium vivax and Plasmodium oval . uuid:ae471a3a-358e-4935-a736-35f79ab8b0c9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5801 biolink:treats MONDO:0005282 PMID:41385096 "[{""id"":""uuid:3fa1a8e7-7e5c-431b-aa8f-711ee4b0f8cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9ec81747-8be6-414c-877f-1e1f4b7f529e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of cutaneous lupus erythematosus and systemic lupus erythematosus. uuid:a44d742e-84f1-4f7a-9203-6af09d2d7d2f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5801 biolink:treats MONDO:0007915 PMID:41385096 "[{""id"":""uuid:ce553a96-9800-413a-81b1-45c39b21c031"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9e964b35-5cec-4dbe-ada7-74d98ff1d8cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of cutaneous lupus erythematosus and systemic lupus erythematosus. uuid:77f8e40f-3b18-4a4e-a0fb-99a1591cffeb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42446 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:7828d6ff-dfd2-4b06-88b8-c0036db4cf63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3a56ce41-edf3-4906-85bf-aa98aa4d8a88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug with a new active ingredient indicated for the relief of inflammation and pain associated with osteoarthritis. uuid:c8ccb1d6-571d-4e07-a175-7e47ce46ce9c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:90Z2UF0E52 biolink:treats MONDO:0100470 PMID:41385096 "[{""id"":""uuid:d6970df7-7821-4182-af47-665ff74fd0e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ed19683f-3dec-47a1-a961-1745f1208afe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of bronchial asthma (for use only in patients with intractable bronchial asthma whose asthmatic responses are uncontrollable with conventional therapies). uuid:98851128-85a4-47d7-912f-43213ed18db4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:441410 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:9efa362a-e8ba-4962-93e9-f0ef96ca0d1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bb74828e-5338-4520-a8c3-6877509f73e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug in a new dosage form indicated for the treatment of prostate cancer and premenopausal breast cancer. uuid:b3920d85-83ba-4db6-bf5f-5f50613cd426 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:33325 biolink:treats UMLS:C0153690 PMID:41385096 "[{""id"":""uuid:25157fc4-29c3-4bc7-8b27-c921b99922c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:222cdbb5-be53-4a4d-a55c-523f07d35aa7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of castration-resistant prostate cancer with bone metastases. uuid:f5a63195-097a-4eda-b46a-50035be6f336 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:78432 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:6bc02405-ae9e-4847-afa5-60881e005fa5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f03be766-ba60-4621-bd39-08ccd65f5f86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of unresectable advanced/relapsed anaplastic lymphoma kinase (ALK)-positive non- small-cell lung cancer with resistance or intolerance to crizotinib. uuid:afc941e8-2564-4e25-a9ec-96705429fd4b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:C9R35M8XV6 biolink:treats MONDO:0006926 PMID:41385096 "[{""id"":""uuid:ec8634a8-4a39-4b86-8171-3796347051e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:82c1ccd6-b3e8-4bed-8320-9cdb7a7317b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the prophylaxis of Haemophilus influenzae type b infections. uuid:22cd9eb1-d5a1-43c5-be6e-9274a171a1ac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:9832804 biolink:treats EFO:1001494 PMID:41385096 "[{""id"":""uuid:df6f1fc4-4ec5-4e47-bb48-2288c6c5ab7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:451646ac-f39d-4909-887a-5350ac9b969c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug indicated for the treatment of psoriasis vulgaris. uuid:e512f5f3-4193-492e-b3e6-58747c8bdaaa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:43830 biolink:treats UMLS:C1263992 PMID:41385096 "[{""id"":""uuid:815570cb-88fa-4919-986b-77b07e053e52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8795c864-ba48-4811-b233-2942da71706b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of toxic methemoglobinemia. uuid:e9165021-7db2-4342-b01e-5eae3508d902 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6437 biolink:treats MONDO:0006891 PMID:41385096 "[{""id"":""uuid:00682b59-2994-465b-99b6-10dd2f088265"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:183792a9-4bc9-41f7-b1ea-e80f007c0536"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for use as an adjunctive therapy with other antiepileptic drugs to treat partial seizure (including secondary generalized seizure) in patients with epilepsy who have not responded sufficiently to other antiepileptic drugs. It is used as an alternative therapy for levetiracetam oral formulation in patients who are temporarily unable to be administered orally. uuid:3e8cabe8-3b1c-4e22-8d58-bdd1c1fb0f29 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6437 biolink:treats HP:0007334 PMID:41385096 "[{""id"":""uuid:785a988f-e2c0-4ff3-b2ff-d68986091e92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5fc35df5-eaa0-42bf-8d60-78d00585bcbd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for use as an adjunctive therapy with other antiepileptic drugs to treat partial seizure (including secondary generalized seizure) in patients with epilepsy who have not responded sufficiently to other antiepileptic drugs. It is used as an alternative therapy for levetiracetam oral formulation in patients who are temporarily unable to be administered orally. uuid:2a3d394b-92e0-4c23-8626-1331b0c26247 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:136046 biolink:treats MONDO:0005041 PMID:41385096 "[{""id"":""uuid:8ab7bdb5-4dd5-4cf2-a783-250e902c2583"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a8a2b40d-ae8d-44da-8d69-d06a0ec63519"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of glaucoma or ocular hypertension in patients who have not sufficiently responded to other therapeutic drugs for glaucoma or who are unable to use them. uuid:900a67ff-9ec8-4ef0-b52c-09a10ad4cfe6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:136046 biolink:treats HP:0007906 PMID:41385096 "[{""id"":""uuid:e0c6096d-5a0b-42ef-b3f7-2ec3640fb478"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b91faae0-3b49-4e86-94d5-c0f368b255b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of glaucoma or ocular hypertension in patients who have not sufficiently responded to other therapeutic drugs for glaucoma or who are unable to use them. uuid:9fb419c5-30c4-4050-9e6a-6e32bb032b49 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:136019 biolink:treats HP:0000989 PMID:41385096 "[{""id"":""uuid:a2a4da1c-3196-4000-92e6-a0822c1cbb11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0155206c-3c02-4998-b536-a7a5720a8913"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the improvement of pruritus in patients with chronic liver diseases (for use only when conventional therapies are not sufficiently effective). uuid:210e82ba-2062-4104-b8d7-4a4662f07e68 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:136019 biolink:treats MONDO:0100193 PMID:41385096 "[{""id"":""uuid:02340d19-2971-4c0c-98b1-ca55175829d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5b07f362-2613-42ba-8a2e-8aa3923d16ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the improvement of pruritus in patients with chronic liver diseases (for use only when conventional therapies are not sufficiently effective). uuid:1f32a88a-8fd9-4e2d-bc11-f7458a839ae1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats UMLS:C0021342 PMID:41385096 "[{""id"":""uuid:c8ba7feb-8541-4c1c-bfd9-877c6b99cc97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fae42e75-df53-4b47-8cf9-0e0cdc8c80f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the treatment of different kinds of anaerobic bacterial infections, infectious enteritis, and amebic dysentery. uuid:571ad6dc-a272-4c01-a612-cc3bbd00c4be biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:136047 biolink:treats MONDO:0005354 PMID:41385096 "[{""id"":""uuid:a3225c89-78ec-4208-86d0-d4996ae928e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f7fd76a0-63d1-4fbd-a7fb-6547d20b7990"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the improvement of viremia in the following patients with serogroup 1 (genotype I [1a] or II [1b]) chronic hepatitis C: Patients with high levels of blood HCV RNA who are treatment-naive, or Patients who are non-responders or relapsed to therapy including interferon. [Priority review] uuid:45805283-09a8-4aa4-a3e5-f2a2e4c6b852 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85083 biolink:treats MONDO:0005155 PMID:41385096 "[{""id"":""uuid:9447dea3-8fe2-4f8c-ab3f-71249101cf97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f5ffe0b3-c1d2-4ab9-98f7-0d530a2f76bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the improvement of viremia in patients with chronic hepatitis C or compensated cirrhosis type C in serogroup 2 (genotype 2) . [Priority review] uuid:f95c416b-6724-46f1-a1e9-eac7ca7c1547 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37943 biolink:treats MONDO:0030603 PMID:41385096 "[{""id"":""uuid:ac557508-6b44-4666-b0c0-0e729961575c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:794d2dcb-721f-41ed-9db6-6f4e2a4586b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the treatment of infections caused by colistin- sensitive Escherichia coli, Citrobacter, Klebsiella, Enterobacter, Pseudomonas aeruginosa, and Acinetobacter (limited to the strains resistant to other antimicrobial drugs). [Orphan drug] uuid:b4c88e2d-2f42-4cca-a441-a4d7c300e9b5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37943 biolink:treats MONDO:0006635 PMID:41385096 "[{""id"":""uuid:8c74571f-61d6-47be-818e-4b6e98948e1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2c72b3ca-dcac-43c4-84d3-bbd874474306"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the treatment of infections caused by colistin- sensitive Escherichia coli, Citrobacter, Klebsiella, Enterobacter, Pseudomonas aeruginosa, and Acinetobacter (limited to the strains resistant to other antimicrobial drugs). [Orphan drug] uuid:2e3d24c0-d187-4d0b-bfc9-a24f6b660bf2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:170190 biolink:treats MONDO:0005137 PMID:41385096 "[{""id"":""uuid:72c0d136-69b3-473c-84d1-4984cb1e5033"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5bca5062-751b-4c3d-989a-002f4d344087"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A combination prescription drug with similar formulations indicated for the supplementation of amino acids, electrolyte, hydrosoluble vitamins, and water. It is used in patients with mild hypoproteinemia or in a mild malnutrition state due to insufficient oral intake or used in perioperative patients. uuid:3397c812-20f4-4988-9afd-00be5919bfa6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46195 biolink:treats UMLS:C0409952 PMID:41385096 "[{""id"":""uuid:16dde850-8cdd-4da1-8a1f-4fee02da7601"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:547daade-4f16-4be6-8bcd-a1997f9f6947"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug in an additional dosage form. Note: the product was submitted for an approval application as a drug with a new additional indication for the treatment of osteoarthrosis and with an expanded dosage of acetaminophen in an additional dosage form. The new additional indication and the expanded dosage were approved on January 21, 2011, whereas approval of the additional dosage form had been under review. uuid:ed88dd23-456b-4b66-9b31-d61b1dca6c0c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82752 biolink:treats MONDO:0018150 PMID:41385096 "[{""id"":""uuid:fa98add9-f6c4-40f8-8631-2188e32c04cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3b2f1e9b-7173-4f52-92b2-2efe7280e8a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the improvement of various symptoms of Gaucher disease (anemia, thrombocytopenia, hepatosplenomegaly, and bone disease). [Orphan drug] uuid:c9a10ed2-a17c-40b5-8cdb-4ef99800676d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:66919 biolink:treats MONDO:0044903 PMID:41385096 "[{""id"":""uuid:07d5cf7d-d72f-43a6-9e8b-8bcfc3f0569f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9c73cebe-c7ed-40ff-aff9-46dadc77f149"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of myelofibrosis. [Orphan drug] uuid:63f81af4-64db-4d22-b58f-b7a6d5992bf4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:142290 biolink:treats MONDO:0005029 PMID:41385096 "[{""id"":""uuid:4ad9ed07-cb59-4ac4-89f9-e3ad150f8297"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:289baa9a-332e-4778-9769-bfeb4ef2c339"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of essential thrombocythemia. [Orphan drug] uuid:12dc08c8-fd1d-4560-949d-da9307ac3302 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3A189DH42V biolink:treats MONDO:0003864 PMID:41385096 "[{""id"":""uuid:cf96d887-995f-4772-8eeb-a841ceb9a774"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e4010f60-006b-4c50-9c82-9d3271a07532"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of relapsed or refractory chronic lymphocytic leukemia. [Orphan drug] uuid:b71d5c33-fe9c-4099-8d5b-d53d2a120174 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9288 biolink:treats MONDO:0019954 PMID:41385096 "[{""id"":""uuid:ac50e26e-df26-4df6-951c-fc9192c72782"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c65e7e45-cbba-4142-9d15-28e6b3d7ba14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of neuroendocrine tumors of the pancreas and gastrointestinal tract. [Orphan drug] uuid:a226e4cb-7108-48a2-8acb-7fe2a3a7bc1f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9288 biolink:treats MONDO:0024503 PMID:41385096 "[{""id"":""uuid:9ab8b297-17fd-41f5-accc-72db703a4094"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7c82dced-bea9-4898-b7cc-1cef6a625bcf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of neuroendocrine tumors of the pancreas and gastrointestinal tract. [Orphan drug] uuid:6538474b-aeb0-4930-883d-71a7f471c026 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB09877 biolink:treats UMLS:C3873491 PMID:41385096 "[{""id"":""uuid:c6034317-936f-4471-a293-c84320c5de2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:db82cbdf-b9f0-4049-8353-42eb0799f9b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the prophylaxis of invasive meningococcal disease. (serotypes A, C, Y, and W-135). uuid:f18a9603-20bd-45e5-950e-10463049b767 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1484959 biolink:treats MONDO:0010602 PMID:41385096 "[{""id"":""uuid:3a4f3044-5816-4c9e-ae00-23d9e07631be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a41b67ad-5a08-4cfb-b9f1-0fa277ce6173"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug with a new active ingredient indicated for prevention of bleeding in patients who have inhibitors against blood coagulation factor VIII or IX. [Orphan drug] uuid:262f75bf-3510-4a5b-a54f-5d45dc59f474 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1484959 biolink:treats MONDO:0010604 PMID:41385096 "[{""id"":""uuid:2279ac2c-dc72-4c70-a83a-2b5d38b3caaa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2519812a-dcfe-4c2d-a1e6-075d19b47a7d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug with a new active ingredient indicated for prevention of bleeding in patients who have inhibitors against blood coagulation factor VIII or IX. [Orphan drug] uuid:30c9b5a7-a5c7-46d8-931b-cf4082a40e84 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134721 biolink:treats MONDO:0011122 PMID:41385096 "[{""id"":""uuid:6e546d1e-a348-4907-927e-f8ad183609db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b2376a07-f0af-437e-8ee3-6d8546b9cc28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of obesity (for use only in patients who have both type 2 diabetes mellitus and dyslipidaemia and whose BMI level is 25kg/m2 or more even with diet and exercise therapies). uuid:3837498d-721e-463f-b9e7-b11126d8deb7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134721 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:a93213aa-62c8-42a9-b569-ab79fadc9690"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:86e87763-2a8c-42f2-8be0-694188de103c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of obesity (for use only in patients who have both type 2 diabetes mellitus and dyslipidaemia and whose BMI level is 25kg/m2 or more even with diet and exercise therapies). uuid:99554b71-42e3-4b62-a8d8-71d5009ea48d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134721 biolink:treats MONDO:0015905 PMID:41385096 "[{""id"":""uuid:2545324b-6a32-4b15-9bb3-c39592eb0d7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3d0b574b-33f2-49eb-80fb-03f46cf75151"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of obesity (for use only in patients who have both type 2 diabetes mellitus and dyslipidaemia and whose BMI level is 25kg/m2 or more even with diet and exercise therapies). uuid:9387ac05-b331-4638-acde-1c04a6a0281f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:144421 biolink:treats MONDO:0000328 PMID:41385096 "[{""id"":""uuid:49291185-4012-4226-9ea5-c14ee41fc3ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:192dfad3-c6bc-4366-b716-6e345b52dfb9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the improvement of hyperphosphatemia in patients with chronic kidney disease. uuid:230dff8d-59e2-45ad-8bfb-1b243a8d53c8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:144421 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:43281f11-a54f-4776-af01-e61b966fc5ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:34ff4ec3-0f7f-4f3c-a5c0-0e24a5bfb456"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the improvement of hyperphosphatemia in patients with chronic kidney disease. uuid:8951bdea-8741-46a4-982a-16142ce9dda9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50223 biolink:treats UMLS:C4324343 PMID:41385096 "[{""id"":""uuid:6ffc14f7-cd49-49dd-b5c7-06398d705569"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6c4e8a7e-e522-43d1-8cbd-d8ca17ffeea0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of anthracycline extravasation. uuid:2ff86c28-3daa-462e-b1d4-18bb1337001d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37941 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:9f87bb57-7d73-44f8-af73-98846ac16d27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:753bac06-0422-43dd-9e86-993662b46dba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug indicated for the treatment of ischemic heart diseases (acute coronary syndrome [unstable angina, non-ST-segment elevation myocardial infarction, ST-segment elevation myocardial infarction], stable angina, old myocardial infarction) to which percutaneous coronary intervention (PCI) is applicable. uuid:e7915adf-9bff-4fd4-80ad-fd82ccaed047 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37941 biolink:treats UMLS:C0155668 PMID:41385096 "[{""id"":""uuid:cfe7ad55-b170-4726-869e-47e02b43808e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2a6dffbb-ef16-434e-8897-928a70f4357b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug indicated for the treatment of ischemic heart diseases (acute coronary syndrome [unstable angina, non-ST-segment elevation myocardial infarction, ST-segment elevation myocardial infarction], stable angina, old myocardial infarction) to which percutaneous coronary intervention (PCI) is applicable. uuid:83d631cf-247b-4d48-8ef5-276d2a69a659 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:78538 biolink:treats MONDO:0007100 PMID:41385096 "[{""id"":""uuid:8f5e52b5-5a3e-49aa-ac96-e6273bc8a21d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4e5b4402-52ef-4af4-be83-102e682da5c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for delaying the peripheral neurologic impairment in transthyretin familial amyloid polyneuropathy. [Orphan drug] uuid:2cd0022e-e91e-479e-96ab-fbc14bd6ae8f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63631 biolink:treats HP:0007334 PMID:41385096 "[{""id"":""uuid:65804cee-b9cf-4e5a-87d7-822076080956"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:922c4889-9419-45dc-83fc-aa02ea360100"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional pediatric dosage in an additional dosage form. The drug is indicated for use as an adjunctive therapy with other antiepileptic drugs to treat partial seizures (including secondary generalized seizures) in patients with epilepsy who have not responded sufficiently to other antiepileptic drugs. uuid:4f3b445e-5a6c-49ad-9f6f-6f01a2e5c9b9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:66899 biolink:treats MONDO:0005041 PMID:41385096 "[{""id"":""uuid:cd3374d8-2526-455a-8436-0bd0ca703eee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:591c97bb-9c0f-4124-8bd0-0530b6eac16b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug indicated for the treatment of glaucoma and ocular hypertension. uuid:a4746b4d-e349-4f01-901b-5284d57dee90 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:66899 biolink:treats HP:0007906 PMID:41385096 "[{""id"":""uuid:1db5504a-b543-4bb7-9208-435ada6cc106"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:34f3da6d-553b-4bca-9015-67734d434a25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug indicated for the treatment of glaucoma and ocular hypertension. uuid:7f4a9ed1-c87f-4608-8798-04de08677386 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3176 biolink:treats MONDO:0005041 PMID:41385096 "[{""id"":""uuid:01c6e560-aa1b-495b-b255-dcead5ccb7d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7ab8e825-11b9-422c-9bea-b7254ac906c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug indicated for the treatment of glaucoma and ocular hypertension in patients who have not responded sufficiently to other glaucoma drugs. uuid:728d5e3e-87d3-435a-a0b3-5e6269cf582e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3176 biolink:treats HP:0007906 PMID:41385096 "[{""id"":""uuid:c4122a53-1e07-4262-8441-d4c10e1b1f6d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6ee0ebfb-d8ee-4147-baab-af12b9ccce96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug indicated for the treatment of glaucoma and ocular hypertension in patients who have not responded sufficiently to other glaucoma drugs. uuid:8329a081-fc2c-4d90-b1bf-92644bc3426e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134743 biolink:treats MONDO:0005354 PMID:41385096 "[{""id"":""uuid:826c0c8b-90a0-42c7-afcf-6752c5dcbd63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d4f1d9d4-f68f-4dcd-be6a-f6b3bfceb87e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the improvement of viraemia in following (1) or (2) patient with chronic hepatitis C serogroup 1 (genotype I [1a] or II [1b]): (1) Patient with high level of blood HCV RNA who have untreated or (2) Patients who have not respond to or relapsed with the treatment including interferon. [Priority review] uuid:64f2a905-e5e1-43e4-96f6-21eab4e6a96c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134743 biolink:treats MONDO:0011101 PMID:41385096 "[{""id"":""uuid:a7355206-e9c4-4b67-a350-cd7675499e0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e7ba623c-e2e4-47d9-a886-731682ed4c3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the improvement of viraemia in following (1) or (2) patient with chronic hepatitis C serogroup 1 (genotype I [1a] or II [1b]): (1) Patient with high level of blood HCV RNA who have untreated or (2) Patients who have not respond to or relapsed with the treatment including interferon. [Priority review] uuid:ea56ce0a-6bb9-491a-b0db-22e86828719a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134722 biolink:treats MONDO:0005812 PMID:41385096 "[{""id"":""uuid:db6b747f-6372-4945-94a3-5291b1797477"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2dba4085-e875-40e5-b0e9-226c6fb3587b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for novel or re-emerging influenza virus infections (for use only in patients who have not responded or not responded sufficiently to other anti-influenza virus drugs). [Priority review] uuid:82186d91-78b9-48a0-a71e-4049ff02a158 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:34916 biolink:treats MONDO:0004525 PMID:41385096 "[{""id"":""uuid:bda2a654-6d3f-40a2-a2ca-2be51737e0d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fc3c5740-e441-4f22-a79b-85defc8f543b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the treatment of scabies. [Priority review] uuid:d5b8b012-5e13-4300-8582-ba47d9d1317b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63717 biolink:treats MONDO:0005366 PMID:41385096 "[{""id"":""uuid:da74c6ee-54fa-4e0f-beb7-e4ab5cd3ee22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:eaca051c-0541-4dfd-83c2-6c785709a4ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the growth inhibition of hepatitis B virus in patients with chronic hepatitis B who show liver dysfunction accompanied by proliferation of the virus. [Priority review] uuid:93e750a8-2b79-4a2d-9341-91c3a50d8cf3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63717 biolink:treats HP:0001410 PMID:41385096 "[{""id"":""uuid:2dafcc27-d945-41da-b950-5154e12c30d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7e36a23c-b2cc-4a49-ad2b-a5c50ddab342"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the growth inhibition of hepatitis B virus in patients with chronic hepatitis B who show liver dysfunction accompanied by proliferation of the virus. [Priority review] uuid:76632f13-e9e2-41ab-a61f-4a3462e3b598 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:11564052 biolink:treats MONDO:0005607 PMID:41385096 "[{""id"":""uuid:1cbc15d4-81f4-41fc-92d7-43d869beca6a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3322234f-4019-49e4-9c65-edae4e02102f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug indicated for the relief of symptoms secondary to airway obstructive disorder in chronic obstructive pulmonary disease (chronic bronchitis, emphysema) (when a combination treatment of an inhaled long-acting anticholinergic and a long-acting beta-2 agonist is needed). uuid:151f4a3e-1682-41dc-867b-0deff4b2361a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:11564052 biolink:treats MONDO:0004849 PMID:41385096 "[{""id"":""uuid:4e9d606a-659b-45fe-bbe5-ade1eb845cb7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2b06e025-3195-42d2-acc9-c7bfd4016e3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug indicated for the relief of symptoms secondary to airway obstructive disorder in chronic obstructive pulmonary disease (chronic bronchitis, emphysema) (when a combination treatment of an inhaled long-acting anticholinergic and a long-acting beta-2 agonist is needed). uuid:5c822683-b565-4573-8f2c-e3461ead6dff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5050 biolink:treats MONDO:0011786 PMID:41385096 "[{""id"":""uuid:427ac156-6eab-457b-8a73-93da2bf5f06a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1c0aef0c-d6a0-478b-8066-f8659970e9ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional pediatric (6 months of age and older and less than 7 years of age) dosage in an additional dosage form of dry syrup. This drug is indicated for the treatment of allergic rhinitis, urticaria, and itching associated with skin diseases (eczema/dermatitis, pruritus cutaneous, atopic dermatitis). uuid:3c7c3621-68fb-416f-abe8-b0ecb9a1d516 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5050 biolink:treats MONDO:0005492 PMID:41385096 "[{""id"":""uuid:e2f1009f-ee6e-45b8-88fa-8088510d57c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:928455db-c0e0-4c81-9f1c-60c06f8cc29d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional pediatric (6 months of age and older and less than 7 years of age) dosage in an additional dosage form of dry syrup. This drug is indicated for the treatment of allergic rhinitis, urticaria, and itching associated with skin diseases (eczema/dermatitis, pruritus cutaneous, atopic dermatitis). uuid:5c118391-8ca1-4168-8251-799b0fa029c6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5050 biolink:treats HP:0000989 PMID:41385096 "[{""id"":""uuid:f2af100d-f9ad-48a9-a66e-49347cce5349"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8e63166f-f827-4e7d-9de5-9f6353439384"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional pediatric (6 months of age and older and less than 7 years of age) dosage in an additional dosage form of dry syrup. This drug is indicated for the treatment of allergic rhinitis, urticaria, and itching associated with skin diseases (eczema/dermatitis, pruritus cutaneous, atopic dermatitis). uuid:54decf95-f0d2-485d-825c-ba43105f7945 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5050 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:35a6c41a-e1c0-4f30-a2d3-19cf0326518a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:08404868-4761-41ad-ad48-b46f19812989"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional pediatric (6 months of age and older and less than 7 years of age) dosage in an additional dosage form of dry syrup. This drug is indicated for the treatment of allergic rhinitis, urticaria, and itching associated with skin diseases (eczema/dermatitis, pruritus cutaneous, atopic dermatitis). uuid:049973ff-c5ba-4202-afa5-38e0f3e37395 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:94559 biolink:treats MONDO:0011786 PMID:41385096 "[{""id"":""uuid:34b3b9fb-9ef1-49e3-b0f5-9e388e6be671"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:327405f9-9aa3-4c4b-8273-568fbfb6b964"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional pediatric (6 months of age and older and less than 7 years of age) dosage in an additional dosage form of dry syrup. This drug is indicated for the treatment of allergic rhinitis, urticaria and itching associated with skin disease. (eczema/dermatitis and pruritus cutaneous) uuid:38ba0e8b-8176-4924-a4a1-c345a6101a1b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:94559 biolink:treats MONDO:0005492 PMID:41385096 "[{""id"":""uuid:ca9433d8-1e06-416b-b636-b0b3b626ec53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:92d98214-cc9a-448f-a3cf-5e373c543cdc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional pediatric (6 months of age and older and less than 7 years of age) dosage in an additional dosage form of dry syrup. This drug is indicated for the treatment of allergic rhinitis, urticaria and itching associated with skin disease. (eczema/dermatitis and pruritus cutaneous) uuid:3130baa4-71fa-4723-a5c8-3191917f8ba9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:94559 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:2e4b53d4-17b7-4e08-9ba7-f8dd413dc17e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:458b5014-2796-4fda-9464-853c56069380"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional pediatric (6 months of age and older and less than 7 years of age) dosage in an additional dosage form of dry syrup. This drug is indicated for the treatment of allergic rhinitis, urticaria and itching associated with skin disease. (eczema/dermatitis and pruritus cutaneous) uuid:207ab0ad-a7ce-4a22-9307-378af905973e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:94559 biolink:treats MONDO:0002406 PMID:41385096 "[{""id"":""uuid:1575500c-a408-482f-8d53-010577c0b762"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b5c2f0c3-4f7a-4366-8521-ced642a44fba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional pediatric (6 months of age and older and less than 7 years of age) dosage in an additional dosage form of dry syrup. This drug is indicated for the treatment of allergic rhinitis, urticaria and itching associated with skin disease. (eczema/dermatitis and pruritus cutaneous) uuid:3e964c03-3686-4f1e-b713-c4ac31cff5fa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:94559 biolink:treats HP:0000989 PMID:41385096 "[{""id"":""uuid:1f84ee04-3a4f-41ef-8899-5f0864e2d7fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ef79d85e-38ea-47ce-b899-9620f90c06b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional pediatric (6 months of age and older and less than 7 years of age) dosage in an additional dosage form of dry syrup. This drug is indicated for the treatment of allergic rhinitis, urticaria and itching associated with skin disease. (eczema/dermatitis and pruritus cutaneous) uuid:79892b76-2a6b-41a5-b194-57a233391f26 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:VF232WE742 biolink:treats MONDO:0007488 PMID:41385096 "[{""id"":""uuid:492dd4c3-899c-47c5-a38e-87b9f7e88326"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a18fc489-7a05-4688-a1fd-b55a575ac4d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for dopamine transporter scintigraphy in the diagnoses of Parkinson's syndrome and dementia with Lewy bodies. uuid:dff7ffd4-9ace-459f-8382-dd272318a014 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7662KG2R6K biolink:treats HP:0012450 PMID:41385096 "[{""id"":""uuid:cf997dfb-3ca4-43e5-886e-47949c8a08f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:222a401b-c069-420e-b26e-4a1110cbf398"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of chronic constipation (excluding constipation due to organic diseases). uuid:ebad8016-a132-4760-af5e-fdf62453a775 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:200251 biolink:treats MONDO:0000313 PMID:41385096 "[{""id"":""uuid:afe633ea-46b4-4497-8f9b-2fce40b38b31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a95252b9-2707-403d-8ea7-8b92cdc76dc0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage in an additional dosage form for the treatment of hypophosphatemia. [Orphan drug] uuid:d1786393-6338-4a57-9753-b27cfd96e129 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:34523 biolink:treats UMLS:C0267167 PMID:41385096 "[{""id"":""uuid:30423ffa-f7a1-4d68-bff2-d52ec7f68345"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f8a3a453-4319-45d1-8997-6afd3afb45d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of postprandial fullness, upper abdominal bloating, and early satiation in functional dyspepsia. uuid:414aea0b-3dfd-4958-82c3-b1b58bc8ad6f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:D87YGH4Z0Q biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:cfc58119-f686-4752-9d79-5d3249501d71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f5f2ca34-0a1a-4895-83c3-1ef1e6b23991"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of hyperlipidaemia. uuid:ca6640bd-c7af-4236-ae94-21cbd555de5f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64028 biolink:treats MONDO:0001595 PMID:41385096 "[{""id"":""uuid:7aa6698f-0237-4ee2-99ce-555f0167d3b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1c755ef3-f973-4491-b845-c7daa8fde593"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of chorea associated with Huntington's disease. [Orphan drug] uuid:3f997105-3b79-4301-8be3-9a3aaca39a89 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:149836 biolink:treats MONDO:0002922 PMID:41385096 "[{""id"":""uuid:98977067-127c-4521-baaf-cacddb5ec21e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:28982963-eb4f-4f0d-954f-6fdd4e2c4b92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of deep skin infection, chronic pyoderma, secondary infection of trauma, burn, and surgical wounds, secondary infection of erosion and ulcer, peritonitis, intraperitoneal abscess, and cholecystitis. [Priority review] uuid:bad902f4-a435-4cd7-82ae-d8dade230eb0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:149836 biolink:treats UMLS:C0332803 PMID:41385096 "[{""id"":""uuid:3fad64fd-5c1a-4d10-82c8-c5c42398f4e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:55c0152f-77ae-4de5-b4d0-87958806f804"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of deep skin infection, chronic pyoderma, secondary infection of trauma, burn, and surgical wounds, secondary infection of erosion and ulcer, peritonitis, intraperitoneal abscess, and cholecystitis. [Priority review] uuid:e53aa103-7d42-47eb-8061-ab9938a0df51 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:149836 biolink:treats MONDO:0004247 PMID:41385096 "[{""id"":""uuid:f5dadc39-8efb-4c14-a791-59d8a7b5adaa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b8ced270-e8a6-4a73-b54d-66e2a212be07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of deep skin infection, chronic pyoderma, secondary infection of trauma, burn, and surgical wounds, secondary infection of erosion and ulcer, peritonitis, intraperitoneal abscess, and cholecystitis. [Priority review] uuid:0a422d02-3502-429a-8ed0-e6349550b139 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:149836 biolink:treats MONDO:0004522 PMID:41385096 "[{""id"":""uuid:d131135e-19cf-42f7-a4d7-01b8112ebfe0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bc96a385-687d-429b-baa3-e3c91b02a0a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of deep skin infection, chronic pyoderma, secondary infection of trauma, burn, and surgical wounds, secondary infection of erosion and ulcer, peritonitis, intraperitoneal abscess, and cholecystitis. [Priority review] uuid:3d697258-df4d-47c4-a2e0-3c54785a3a30 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:149836 biolink:treats HP:0100592 PMID:41385096 "[{""id"":""uuid:1cf6c864-5ac8-4754-99d1-e8c0dfbc58d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:df5ed756-d669-4fb0-96c9-b162e7176cc8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of deep skin infection, chronic pyoderma, secondary infection of trauma, burn, and surgical wounds, secondary infection of erosion and ulcer, peritonitis, intraperitoneal abscess, and cholecystitis. [Priority review] uuid:d994e448-aff9-4ef6-87c5-fb01a9989f7a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:149836 biolink:treats MONDO:0002155 PMID:41385096 "[{""id"":""uuid:9fa2ef36-db1e-4d78-a644-d2cd4cedb2e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d7e195e5-1931-4578-b6a7-96a024ac2e61"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of deep skin infection, chronic pyoderma, secondary infection of trauma, burn, and surgical wounds, secondary infection of erosion and ulcer, peritonitis, intraperitoneal abscess, and cholecystitis. [Priority review] uuid:d297eb1a-d261-49e0-97e7-d08e69e55f2e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7934 biolink:treats MONDO:0024275 PMID:41385096 "[{""id"":""uuid:435610b2-1cc3-43b5-8fcb-26bf32e70120"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5adc8c64-954e-4a8c-a7c3-9682cb09dc9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of intestinal amoebiasis. uuid:aee53357-27b7-4b1e-a487-e0cb17730ceb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:64759 biolink:treats MONDO:0015790 PMID:41385096 "[{""id"":""uuid:4da74cec-3b25-4ae3-91b8-637e57c02175"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fbce1a22-e937-43f9-80f9-d0a4373bbb60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage in an additional dosage form for the treatment of central diabetes insipidus. uuid:ef8effc9-941c-45d0-b4e3-a4723a0afc98 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:144551 biolink:treats HP:0100515 PMID:41385096 "[{""id"":""uuid:177bf826-7365-47c5-8cff-5973991677d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bef89cd4-09a8-4604-9a06-76f165e865c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration and new indications for the treatment of urinary urgency, urinary frequency, and urge urinary incontinence associated with overactive bladder. uuid:dcfa09c8-8908-46e2-bdfe-bc9c4e7b4752 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90973 biolink:treats MONDO:0005607 PMID:41385096 "[{""id"":""uuid:ea3966ee-4d3c-477d-b420-06d89849e46e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b82442f5-774b-45dc-acd4-f2aef359bb02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the relief of symptoms secondary to airway obstructive disorder in chronic obstructive pulmonary disease (chronic bronchitis, emphysema). uuid:e6e0e932-5f65-4efa-8479-b35a9a6d10da biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90973 biolink:treats MONDO:0004849 PMID:41385096 "[{""id"":""uuid:e879e3ae-5715-4d3a-9a5b-dca04c3619a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9b8b7ff1-78bd-467b-8ed0-6a6fe2d09cf6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the relief of symptoms secondary to airway obstructive disorder in chronic obstructive pulmonary disease (chronic bronchitis, emphysema). uuid:48fbf992-0879-49bf-b166-6a4809077134 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:215122 biolink:treats MONDO:0011786 PMID:41385096 "[{""id"":""uuid:93ad01c0-a1e8-4fa2-acae-6e00b9eaf342"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:20f0abc1-8cd8-409c-a692-c88a0281ac91"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug indicated for the treatment of allergic rhinitis. uuid:2b179a1b-2580-4cbe-b331-6d24b92668ef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:136042 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:db259f50-17d3-411b-9ad2-912f64dee827"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1330323e-f36c-4a5b-8f51-e29000a3f0b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of type 2 diabetes mellitus. uuid:eded7ff6-5f60-487a-8625-c2abb6d3333a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:152770 biolink:treats HP:0002901 PMID:41385096 "[{""id"":""uuid:578680c5-9450-4b0d-bfe1-c4908a956194"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ce262f48-2a14-4f9b-a33b-f530ce2df841"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A combination prescription drug with a similar formulation indicated for the treatment and prevention of hypocalcemia in association with administration of RANKL inhibitors (e.g. denosumab [genetical recombination]) [Expedited review] uuid:d18a0998-93b6-4ed0-807f-1b897e0834bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68647 biolink:treats MONDO:0005575 PMID:41385096 "[{""id"":""uuid:9d690d0e-2acc-48eb-a656-dd7bf892b208"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7c2b2c3a-461b-467f-aa10-7ab5a75db888"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of unresectable advanced or recurrent colorectal cancer. [Priority review] uuid:d4725180-5962-4196-93c2-4b6c6a5abf28 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10796 biolink:treats MONDO:0017373 PMID:41385096 "[{""id"":""uuid:8669cda2-2101-4f05-b5ed-21d4d8de822c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6c0b1b71-908c-4a4f-a4c8-c9b55c09ccfa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the prevention of acute poliomyelitis. [Expedited review] uuid:2f7322c1-c2dc-46d2-8948-7fcda1a50bd3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB09877 biolink:treats UMLS:C2748361 PMID:41385096 "[{""id"":""uuid:2e4aafa7-f078-4503-96bc-4d9786195420"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e814c54f-ea6d-458e-9f9a-8dd3bc0f3719"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the prevention of pandemic influenza (H5N1). [Orphan drug] uuid:337dd8ab-35ac-4265-b180-2a31683a6d4c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50275 biolink:treats UMLS:C1442968 PMID:41385096 "[{""id"":""uuid:5669b1e8-7af7-4c7d-8aad-d445a71e211b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:da2659c2-bf7d-41f1-b97b-d97388565f74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of gastric ulcer, duodenal ulcer, anastomotic ulcer, reflux esophagitis, non-erosive reflux disease and Zollinger-Ellison syndrome, prevention of recurrence of gastric ulcer or duodenal ulcer in patients treated with nonsteroidal antiinflammatory drugs, and aid to eradication of Helicobacter pylori in patients with gastric ulcer, duodenal ulcer, gastric MALT lymphoma, idiopathic thrombocytopenic purpura, and stomach after endoscopic treatment for early gastric cancer. uuid:e1aee817-cc19-46aa-b08a-cd2a7693528e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50275 biolink:treats MONDO:0006896 PMID:41385096 "[{""id"":""uuid:e611d639-97d5-4e0e-9ebc-f704a1f1db4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:45d9129f-5f05-489b-b6de-5f5f20a91718"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of gastric ulcer, duodenal ulcer, anastomotic ulcer, reflux esophagitis, non-erosive reflux disease and Zollinger-Ellison syndrome, prevention of recurrence of gastric ulcer or duodenal ulcer in patients treated with nonsteroidal antiinflammatory drugs, and aid to eradication of Helicobacter pylori in patients with gastric ulcer, duodenal ulcer, gastric MALT lymphoma, idiopathic thrombocytopenic purpura, and stomach after endoscopic treatment for early gastric cancer. uuid:471a8c37-4d04-430d-a509-aed203abe168 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50275 biolink:treats MONDO:0006226 PMID:41385096 "[{""id"":""uuid:39cbe66e-04d1-4e17-a0d5-9f2009a2273a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fe253c5e-dc7c-4b55-a232-308abc8dd7f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of gastric ulcer, duodenal ulcer, anastomotic ulcer, reflux esophagitis, non-erosive reflux disease and Zollinger-Ellison syndrome, prevention of recurrence of gastric ulcer or duodenal ulcer in patients treated with nonsteroidal antiinflammatory drugs, and aid to eradication of Helicobacter pylori in patients with gastric ulcer, duodenal ulcer, gastric MALT lymphoma, idiopathic thrombocytopenic purpura, and stomach after endoscopic treatment for early gastric cancer. uuid:1b7d5836-339b-4095-aed5-ad675000cf5f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50275 biolink:treats MONDO:0019098 PMID:41385096 "[{""id"":""uuid:9af9690d-7534-49a2-aa55-6bced31083be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e2d964c5-669d-49af-85d0-021e9481a63c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of gastric ulcer, duodenal ulcer, anastomotic ulcer, reflux esophagitis, non-erosive reflux disease and Zollinger-Ellison syndrome, prevention of recurrence of gastric ulcer or duodenal ulcer in patients treated with nonsteroidal antiinflammatory drugs, and aid to eradication of Helicobacter pylori in patients with gastric ulcer, duodenal ulcer, gastric MALT lymphoma, idiopathic thrombocytopenic purpura, and stomach after endoscopic treatment for early gastric cancer. uuid:4d575b39-9277-474e-9ce1-fff071011671 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50275 biolink:treats MONDO:0004716 PMID:41385096 "[{""id"":""uuid:07a93684-dcfe-4df8-bfda-001551e64ea5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:464e70e7-079b-43e3-a6c1-8515baf04bb5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of gastric ulcer, duodenal ulcer, anastomotic ulcer, reflux esophagitis, non-erosive reflux disease and Zollinger-Ellison syndrome, prevention of recurrence of gastric ulcer or duodenal ulcer in patients treated with nonsteroidal antiinflammatory drugs, and aid to eradication of Helicobacter pylori in patients with gastric ulcer, duodenal ulcer, gastric MALT lymphoma, idiopathic thrombocytopenic purpura, and stomach after endoscopic treatment for early gastric cancer. uuid:da2eaeb8-63dd-480e-9f30-242d2f696cdd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50275 biolink:treats MONDO:0019610 PMID:41385096 "[{""id"":""uuid:201960db-1f00-408f-818c-19edd3c89388"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b72bbfc1-8bc3-4812-80f9-3bdbf0667465"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of gastric ulcer, duodenal ulcer, anastomotic ulcer, reflux esophagitis and Zollinger- Ellison syndrome, prevention of recurrence of gastric ulcer or duodenal ulcer in patients treated with nonsteroidal antiinflammatory drugs, and aid to eradication of Helicobacter pylori in patients with gastric ulcer, duodenal ulcer, gastric MALT lymphoma, idiopathic thrombocytopenic purpura, and stomach after endoscopic treatment for early gastric cancer. uuid:3fff5a57-d815-4e2b-be07-18772f76fd6f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3160WY51LV biolink:treats MONDO:0000328 PMID:41385096 "[{""id"":""uuid:709ffca4-4335-4948-ac7f-29733bbbe332"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6f52fbff-4d92-4908-a938-bd93006aa997"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the improvement of hyperphosphatemia in patients with chronic renal failure under dialysis. uuid:6016c0d7-443d-4b6a-87ff-176ad12c3c14 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3160WY51LV biolink:treats MONDO:0024327 PMID:41385096 "[{""id"":""uuid:e50ecaa0-b08d-479b-b8da-9e30bddb57e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:05154c9a-ba4d-479d-a17b-7d2f1ae69390"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the improvement of hyperphosphatemia in patients with chronic renal failure under dialysis. uuid:248a5205-ce5f-4223-a06b-e9b2f2db63f4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:121437280 biolink:treats MONDO:0005180 PMID:41385096 "[{""id"":""uuid:f35fb806-77df-4943-a555-af20bbc4333e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0520521b-9de1-4e4b-a6a9-fad1fd0ee84f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[PMDA] A drug with a new active ingredient indicated for the treatment of ""off"" episodes associated with Parkinson's disease (when levodopa-containing products that are frequently administered and other anti-Parkinson drugs at increased doses are not sufficiently effective). [Orphan drug]" uuid:8f250c15-0fb8-4ced-84d8-883ba82973d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5165 biolink:treats MONDO:0002125 PMID:41385096 "[{""id"":""uuid:cd8e4880-4c59-4ba4-b833-5ef1ae45621a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:330aecf1-abc0-4b81-9c77-04160c647a14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for: treatment of status epilepticus prevention of seizures occurring in connection with neurosurgery, and/or consciousness disorder (head trauma, etc.) temporary substitution of oral phenytoin therapy in epilepsy patients. uuid:b620e85f-0b90-44d2-8865-2a28be7e73e9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5165 biolink:treats MONDO:0005027 PMID:41385096 "[{""id"":""uuid:892476b5-e41a-49e7-b862-f1f12876a9a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:072f9449-8235-4d2d-8214-70619c725fc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for: treatment of status epilepticus prevention of seizures occurring in connection with neurosurgery, and/or consciousness disorder (head trauma, etc.) temporary substitution of oral phenytoin therapy in epilepsy patients. uuid:32b0d1a1-b503-42bd-9da3-b92e3d90f965 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3175 biolink:treats MONDO:0005041 PMID:41385096 "[{""id"":""uuid:c586b9bd-0c5b-447e-b6fa-9a4915b0be35"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0e956bd1-072e-4069-9c45-0bf1717dfa09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of glaucoma and ocular hypertension when other glaucoma drugs are not sufficiently effective or cannot be used. uuid:d3f58562-48ce-4c07-a8af-4005dd46966a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3175 biolink:treats HP:0007906 PMID:41385096 "[{""id"":""uuid:43bfa289-7d92-4f39-ae03-1c41cdb539ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:09cf1927-5cb8-4317-92c7-cf27ea47670a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of glaucoma and ocular hypertension when other glaucoma drugs are not sufficiently effective or cannot be used. uuid:673f245d-57e1-4982-9a0a-d75024ea31bb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:209468 biolink:treats MONDO:0024317 PMID:41385096 "[{""id"":""uuid:c82e3021-76e2-4da1-854c-40126ae3e95f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7dc18ebd-4c9a-4380-92ae-0cd9bd02a4d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug indicated for analgesia of chronic non-cancer pain and pain after tooth extraction which are not managed by treatments with non-opioid analgesics. uuid:c0f3f1dd-72d9-43ca-a86b-8d7b4a4e6ea3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:600103 biolink:treats HP:0100806 PMID:41385096 "[{""id"":""uuid:3f60421f-a42f-421a-8dad-2494b902babc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9fb0b70b-c993-4287-b5f7-cd57a9f71f22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of sepsis, infective endocarditis, deep skin infection, secondary infection of trauma, burn, and surgical wounds, and secondary infection of erosion and ulcer caused by daptomycin-sensitive methicillin-resistant Staphylococcus aureus (MRSA). uuid:1ca4a8af-ed79-4e98-9f77-062c633ba675 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:600103 biolink:treats UMLS:C0332803 PMID:41385096 "[{""id"":""uuid:a2e9daa0-0cd6-4274-8c0a-26a2f2d7b39c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:53990833-db40-43e7-85db-b99359e85050"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of sepsis, infective endocarditis, deep skin infection, secondary infection of trauma, burn, and surgical wounds, and secondary infection of erosion and ulcer caused by daptomycin-sensitive methicillin-resistant Staphylococcus aureus (MRSA). uuid:11f65788-4288-4381-ae6f-b6b40ad3ba26 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:600103 biolink:treats MONDO:0100073 PMID:41385096 "[{""id"":""uuid:cd2d44d8-7a90-411b-a2a1-3f286e17cba0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:86ee903b-f793-4a95-b1dd-6a6fc817ca45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of sepsis, infective endocarditis, deep skin infection, secondary infection of trauma, burn, and surgical wounds, and secondary infection of erosion and ulcer caused by daptomycin-sensitive methicillin-resistant Staphylococcus aureus (MRSA). uuid:63934fb5-a263-41dc-a91f-cdaa48377374 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68595 biolink:treats MONDO:0005354 PMID:41385096 "[{""id"":""uuid:c2b77386-1c02-4f25-b536-31427e04b92c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6b84fa7e-c7f4-4377-b74f-3a8b3a4caf10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the improvement of viremia in serogroup 1 (genotype I [1a] or II [1b]) chronic hepatitis C in: untreated patients with high blood HCV RNA; or patients who did not respond to, or in whom the symptom relapsed with, interferon monotherapy or interferon-ribavirin combination therapy. [Priority review] uuid:b1fcdd82-3269-4c47-a917-f370d520975e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31933 biolink:treats MONDO:0011786 PMID:41385096 "[{""id"":""uuid:bf03d0a6-2db1-4727-b7f8-51ea2e4c645e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:72d93035-9b40-4551-96a0-ba87f8a6bac2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with an additional dosage form of granules and with a new additional pediatric dosage indicated for the treatment of allergic rhinitis, urticaria, and itching associated with skin disease (eczema/dermatitis and pruritus cutaneous). uuid:c22b393b-2d14-4c75-b78d-8be29ea70a76 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31933 biolink:treats MONDO:0005492 PMID:41385096 "[{""id"":""uuid:4a680162-1781-4ab9-ae76-c26704569746"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ce04ea24-40c8-46ce-9d05-b6124b9d2a6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with an additional dosage form of granules and with a new additional pediatric dosage indicated for the treatment of allergic rhinitis, urticaria, and itching associated with skin disease (eczema/dermatitis and pruritus cutaneous). uuid:558f78ad-f2ba-44ee-af71-e8784705f149 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31933 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:7353f5b7-03f9-4608-9522-de2e850bdca9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7c5c54bf-c57a-41c7-834e-cb678f8fee5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with an additional dosage form of granules and with a new additional pediatric dosage indicated for the treatment of allergic rhinitis, urticaria, and itching associated with skin disease (eczema/dermatitis and pruritus cutaneous). uuid:c0a12790-d57e-4fab-8b5b-da9a923cdf77 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31933 biolink:treats MONDO:0002406 PMID:41385096 "[{""id"":""uuid:3252fd6e-4f47-4076-a521-b7a5015f94ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d3396d11-9f42-4964-bb7d-e775ce819c1e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with an additional dosage form of granules and with a new additional pediatric dosage indicated for the treatment of allergic rhinitis, urticaria, and itching associated with skin disease (eczema/dermatitis and pruritus cutaneous). uuid:418876eb-6976-4c6a-b8c3-34e6eada89e1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31933 biolink:treats HP:0000989 PMID:41385096 "[{""id"":""uuid:8da42111-c1df-483a-ac12-3b4459a40263"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d57595ad-6f48-45fb-bf91-dc8609bba578"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with an additional dosage form of granules and with a new additional pediatric dosage indicated for the treatment of allergic rhinitis, urticaria, and itching associated with skin disease (eczema/dermatitis and pruritus cutaneous). uuid:28d920f0-3fad-4d21-85cd-2a094845880b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68575 biolink:treats MONDO:0005607 PMID:41385096 "[{""id"":""uuid:7f4198d5-3b91-4c7a-bfd6-eb478dab37e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6db5534b-56fb-4758-8824-3457fe5516ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the alleviation of various symptoms due to airway obstructive impairment in chronic obstructive pulmonary diseases (chronic bronchitis and emphysema). uuid:fe48d6c2-ad28-4207-8722-98b2c4e29a96 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68575 biolink:treats MONDO:0004849 PMID:41385096 "[{""id"":""uuid:066b9efb-f2c4-42b5-9e81-1c5eeb09b1f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:871fe18b-2c31-4268-9dcf-adb95c0557a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the alleviation of various symptoms due to airway obstructive impairment in chronic obstructive pulmonary diseases (chronic bronchitis and emphysema). uuid:3a503dc7-1498-4be7-b502-48dff4394474 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32090 biolink:treats MONDO:0006733 PMID:41385096 "[{""id"":""uuid:2c55a846-613d-4f27-ab63-9c497b181d9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e6f279f9-3562-4fc5-8f78-4d63a6825e05"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the treatment of dry eye. uuid:0e6c1c83-6162-45e3-b3aa-d641d6bccde3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135349 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:622d9d81-05f7-4fe2-8241-cc98c13fcaf6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3a35fcc9-9a5f-42a3-8fcf-8d02bf9b34f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug indicated for the treatment of type 2 diabetes mellitus (only when a concomitant use of mitiglinide calcium hydrate with voglibose is deemed appropriate). uuid:1e53710b-a458-4d9b-b701-2912477f233a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:YI437801BE biolink:treats UMLS:C0280427 PMID:41385096 "[{""id"":""uuid:f8f0c9cf-3479-482c-89c6-0eca233fab6a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0b94048f-7c72-4a42-b0ba-406656999670"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of recurrent or relapsed CCR4- positive adult T-cell leukemia/lymphoma. [Orphan drug] uuid:8d265a92-a770-4e0b-aacd-efd12e3c1532 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:493191 biolink:treats MONDO:0002269 PMID:41385096 "[{""id"":""uuid:ee2e8d57-8319-429e-b337-b01ccd17d5cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6508ed9c-479b-4f80-84e6-59a79b3844cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the prevention of gastroenteritis due to rotavirus. uuid:4ba5b280-d465-4de6-abf2-3eb5283af5a8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231425 biolink:treats HP:0000969 PMID:41385096 "[{""id"":""uuid:97717e33-b78e-4672-9d05-c64ed972ed0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:728e29c0-db89-4bbf-a28b-6e3f64a37aaf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of fluid retention in heart failure patients who have not responded sufficiently to other diuretics to such as loop diuretics. uuid:6edfc39b-6e7e-42ef-8a5b-67bd3b58e579 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:91083 biolink:treats MONDO:0019098 PMID:41385096 "[{""id"":""uuid:704a5d70-e12d-4ee9-a04c-eae5cdc07fc7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:26225f20-4741-47fd-95e7-86dbb04480e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of chronic idiopathic thrombocytopenic purpura. [Orphan drug] uuid:b3abdb34-b9dc-4f4d-83fc-80e6d2970ca7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:0Y70779M1F biolink:treats MONDO:0000481 PMID:41385096 "[{""id"":""uuid:19166811-9d01-41ba-b1fb-b0f7b0b8f6b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5b7b30f9-b641-4002-9cea-c3a18acfde72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of spasmodic torticollis (cervical dystonia). uuid:204d50ec-3a39-48de-829a-1f37b3207840 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1923432 biolink:treats MONDO:0005041 PMID:41385096 "[{""id"":""uuid:b08b8ade-e1cc-4bd7-8d74-e38467cfa66a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:73d0f3cd-5ac9-4edd-8089-872ea1ba0c21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug indicated for the treatment of glaucoma and ocular hypertension in patients who have not responded sufficiently to other glaucoma drugs. uuid:ae66fca0-431f-4635-8879-959545081633 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1923432 biolink:treats HP:0007906 PMID:41385096 "[{""id"":""uuid:e316b08f-a19f-4f3e-8e00-56179ae697b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:311dd457-cb65-4e1b-8625-8cef2dfd788d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug indicated for the treatment of glaucoma and ocular hypertension in patients who have not responded sufficiently to other glaucoma drugs. uuid:69ab661c-da92-4365-8852-7d057da8d6ac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134741 biolink:treats MONDO:0005812 PMID:41385096 "[{""id"":""uuid:1e9415c0-3279-443a-aa5e-6720dcca722b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5a66bf13-6a72-44fe-b9b9-c2aa7383975f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of influenza A or B virus infections. uuid:4a450a95-2aa1-4ad8-a19f-837d47f87c20 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134741 biolink:treats UMLS:C0276353 PMID:41385096 "[{""id"":""uuid:82c48b34-13ab-4a71-8c85-06144c7f84f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d0f222b5-33bd-4892-9bfb-f60ccda7192a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of influenza A or B virus infections. uuid:a97f7e8f-a421-4f1b-af59-275123499d71 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0004785 PMID:41385096 "[{""id"":""uuid:3e0ab256-a13c-4948-84a6-47f64b6293a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7b88d502-fac5-406c-ba1c-70ac41d17467"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new dosage of the 1.5% formulation for the treatment of blepharitis, dacryocystitis, hordeolum, conjunctivitis, meibomianitis, and keratitis (including corneal ulcer) and sterilization during the ophthalmic perioperative period. uuid:71fa5fcc-6d1a-4b71-83cb-650fb28eb2a1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0004926 PMID:41385096 "[{""id"":""uuid:b7b3c64f-53d0-48a3-8b0d-09e529afe9bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c8dd1b5e-f47f-4b4c-bb04-0709392c43bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new dosage of the 1.5% formulation for the treatment of blepharitis, dacryocystitis, hordeolum, conjunctivitis, meibomianitis, and keratitis (including corneal ulcer) and sterilization during the ophthalmic perioperative period. uuid:f3b991db-f363-4ef7-bd5c-9546e980fc36 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0005800 PMID:41385096 "[{""id"":""uuid:50ce6bd3-68f3-4815-8cf1-0791062900f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d9422812-e771-482f-a47b-20b481245124"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new dosage of the 1.5% formulation for the treatment of blepharitis, dacryocystitis, hordeolum, conjunctivitis, meibomianitis, and keratitis (including corneal ulcer) and sterilization during the ophthalmic perioperative period. uuid:839b14f3-3ef3-4f8c-b556-7f75f3976384 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0003799 PMID:41385096 "[{""id"":""uuid:34ecba9a-a737-4d78-820e-efd53f1bd6cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4d9c7b9a-260e-40bb-9001-7ebf560825ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new dosage of the 1.5% formulation for the treatment of blepharitis, dacryocystitis, hordeolum, conjunctivitis, meibomianitis, and keratitis (including corneal ulcer) and sterilization during the ophthalmic perioperative period. uuid:52268ad5-35c5-4105-9fcd-33eada7058a7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats UMLS:C0549398 PMID:41385096 "[{""id"":""uuid:13084abc-863b-4f43-8970-e8e4f2589732"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d3ee6b05-b58f-4253-962f-f06af39aa379"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new dosage of the 1.5% formulation for the treatment of blepharitis, dacryocystitis, hordeolum, conjunctivitis, meibomianitis, and keratitis (including corneal ulcer) and sterilization during the ophthalmic perioperative period. uuid:99083e47-6c9d-403f-be09-820e15603298 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0003085 PMID:41385096 "[{""id"":""uuid:e962d6a1-5de3-4582-8794-cd2bc046232a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:62f69d4b-1698-4a46-b167-50ed7afd7c0b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new dosage of the 1.5% formulation for the treatment of blepharitis, dacryocystitis, hordeolum, conjunctivitis, meibomianitis, and keratitis (including corneal ulcer) and sterilization during the ophthalmic perioperative period. uuid:2cd928f9-3923-4e8c-b153-b7af62dbd69d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16336 biolink:treats MONDO:0005416 PMID:41385096 "[{""id"":""uuid:1766ea95-4ced-4223-abf4-f431cceb3930"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:139af735-4699-4f0b-a6db-d57eac8bd1ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for pain relief in patients with knee osteoarthritis who have not responded sufficiently to conservative non-drug treatment and oral drug treatment. uuid:f8790124-f223-4587-803c-1f89b623db3d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135515 biolink:treats MONDO:0018876 PMID:41385096 "[{""id"":""uuid:e8f5fa69-1a0c-4ab1-b632-1bb934717960"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cbf406a6-e67d-4309-afae-292cbadd994c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of relapsed or refractory indolent B- cell non-Hodgkin’s lymphoma and mantle cell lymphoma. [Orphan drug] uuid:64664a56-2876-4219-8234-98c2263198b2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2038 biolink:treats MONDO:0018881 PMID:41385096 "[{""id"":""uuid:646bbadc-ba28-45d4-8c7e-688fb52a8918"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1b739fda-2c05-4150-aed6-dbeb92d2d424"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of myelodysplastic syndrome. [Orphan drug] uuid:750b0d76-78d8-417d-a261-6a383144c5ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:493191 biolink:treats MONDO:0004619 PMID:41385096 "[{""id"":""uuid:f45b2495-dd81-4122-a4ea-0f413867c1e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:497ec4f7-a3fb-467d-9b45-fea4bc0ce8a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the prevention of measles and rubella. uuid:c7a944cc-7843-4bc1-8937-851a17afa01c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:493191 biolink:treats MONDO:0004656 PMID:41385096 "[{""id"":""uuid:b7a3a585-bad3-460c-98fe-7c3740a748ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f3527c4c-57a7-4ec3-82ba-e77addbfa5e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the prevention of measles and rubella. uuid:94fe4972-9d75-4387-b8e5-7318443c79e2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10769 biolink:treats MONDO:0019209 PMID:41385096 "[{""id"":""uuid:c550c39c-786f-4e63-9599-6fab0d3a9e2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7112e573-36b8-43a4-90cf-6487f6b5a251"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the prevention of Japanese encephalitis. [Expedited review] uuid:9232d8f3-246a-401b-80f7-b205a385138a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:283316 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:08a424f9-fee6-4188-8434-b5d7dbe6f98a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:811a8db7-3dff-4f44-9394-2c741a0c40db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New combination drugs indicated for the treatment of hypertension. uuid:45862833-7c92-4980-9e84-e161a9df37f6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51230 biolink:treats MONDO:0005041 PMID:41385096 "[{""id"":""uuid:fc1a1e4d-5b47-4c2b-a16d-37986a493609"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:81ad4ded-87b7-48b2-ab4f-8da95028a7ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of glaucoma and ocular hypertension. uuid:4e75e9fe-88be-4ea8-8d28-4ac604d09005 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51230 biolink:treats HP:0007906 PMID:41385096 "[{""id"":""uuid:ea798bb1-4888-4986-beaf-76b71ce18727"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b063254a-7d16-45fb-bc45-5e2b82cc72e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of glaucoma and ocular hypertension. uuid:2f1e09e7-9cf3-4498-bcf8-5b564feb77a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135799 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:75b9fa3f-15e1-49cc-8036-1965781bf5c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6fd902e0-f80c-4ccd-90f7-415874de9802"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of pneumonia, otitis media, and sinusitis. uuid:e0216096-b825-4d77-861d-891bef797495 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135799 biolink:treats MONDO:0005441 PMID:41385096 "[{""id"":""uuid:02435234-693f-46a1-8e77-321f411f0dd3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:deb73542-5607-4ee6-8837-c7b566e0a9b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of pneumonia, otitis media, and sinusitis. uuid:f428ea9a-cab5-4344-9c70-dbadcc07a1f5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135799 biolink:treats MONDO:0005961 PMID:41385096 "[{""id"":""uuid:314f3504-9cf3-4bd0-b16a-a9b23a3c6a97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:04210b49-6662-4b79-84ed-b856fda7fe7d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of pneumonia, otitis media, and sinusitis. uuid:bce42f9f-1c49-47a1-bdf1-896bca5537aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28001 biolink:treats MONDO:0003799 PMID:41385096 "[{""id"":""uuid:f5d0f799-75d2-44e9-b7cb-66a7795af4fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:56a144ee-563c-4739-8ae2-297da44f0f33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the treatment of conjunctivitis, blepharitis, meibomianitis, and dacryocystitis caused by vancomycin-sensitive methicillin- resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE). [Orphan drug] uuid:b2a25424-64fd-4743-aead-2cbc98be4116 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28001 biolink:treats MONDO:0004785 PMID:41385096 "[{""id"":""uuid:bb9391ab-5bf2-413d-b1fa-d4bc8305e675"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:61788ec2-d5d7-4caa-8ecf-99008cd3ab3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the treatment of conjunctivitis, blepharitis, meibomianitis, and dacryocystitis caused by vancomycin-sensitive methicillin- resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE). [Orphan drug] uuid:f6159dfc-7066-43d5-8f94-0e6475048d09 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28001 biolink:treats UMLS:C0549398 PMID:41385096 "[{""id"":""uuid:948bfcb9-6e2f-4d02-9677-cb52c259ed28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:99cf4e82-3843-43ac-a474-a33516187b5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the treatment of conjunctivitis, blepharitis, meibomianitis, and dacryocystitis caused by vancomycin-sensitive methicillin- resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE). [Orphan drug] uuid:4e22a888-df21-40e9-9801-b0204805f27e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28001 biolink:treats MONDO:0004926 PMID:41385096 "[{""id"":""uuid:6d868980-0118-4ca7-a8c4-7ccfda988f54"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1d6fc4cd-25c1-4465-a0ce-220de1247b86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the treatment of conjunctivitis, blepharitis, meibomianitis, and dacryocystitis caused by vancomycin-sensitive methicillin- resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE). [Orphan drug] uuid:cab13038-2910-4e37-9308-3a89bd811971 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77573 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:820dc41b-9fd2-4e4a-ba38-3369aa6a1bc2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9b454b3e-3ddc-4745-ace2-66bd9c7fc346"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new additional indications and a new dosage and in a new dosage form for the treatment of pneumonia, cholera, otitis media, and anthrax in children. uuid:724d052e-ed2a-41ca-8f16-59842ecbe177 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77573 biolink:treats MONDO:0015766 PMID:41385096 "[{""id"":""uuid:40de5704-a8a1-4613-a84a-f69cac7b81e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f7afa454-2710-4bf9-94d4-ea61b1d1c702"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new additional indications and a new dosage and in a new dosage form for the treatment of pneumonia, cholera, otitis media, and anthrax in children. uuid:2265c552-a1b6-497a-a47e-d32864e699b4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77573 biolink:treats MONDO:0005441 PMID:41385096 "[{""id"":""uuid:b5ab0ecf-0bb9-4b01-a68e-e2fd92f1499a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8e463f25-acbd-44e7-83ee-5b1ba59d02e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new additional indications and a new dosage and in a new dosage form for the treatment of pneumonia, cholera, otitis media, and anthrax in children. uuid:0acfcec4-ce0b-4d6f-92c1-e6458f40651f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77573 biolink:treats MONDO:0005119 PMID:41385096 "[{""id"":""uuid:81bff459-72c6-4d79-8949-1cf075310a3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bcd27692-7b01-4010-8604-51cbd151cb9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new additional indications and a new dosage and in a new dosage form for the treatment of pneumonia, cholera, otitis media, and anthrax in children. uuid:ef08f96c-de19-487b-921c-fe404f62eccc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:180554 biolink:treats MONDO:0011786 PMID:41385096 "[{""id"":""uuid:335b2234-a023-46b6-b6fc-ad8f133745af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d34b2e33-4417-465a-8729-d703e4835f03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of allergic rhinitis. uuid:5acd6439-8043-474c-84e6-92bc42374bff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49603 biolink:treats NCIT:C150634 PMID:41385096 "[{""id"":""uuid:bab9fda2-1762-4fb9-86f4-a17f3887ffc9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:beff9181-3cdb-40fb-836c-648d8b3d5761"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of inoperable or recurrent breast cancer with HER2 overexpression. [Priority review] uuid:d8ff706d-174b-4a79-b7a0-49c4dacc8637 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:780F0P8N4I biolink:treats MONDO:0007256 PMID:41385096 "[{""id"":""uuid:a2860910-c3bf-4e9b-be6d-cda72d791b09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9e5b50c1-fb08-4344-8f03-0f91e9d04eaf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for lipiodolization in hepatocellular carcinoma. uuid:3e1778a5-b9bb-4651-a951-9fce281718f0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1597091 biolink:treats MONDO:0005096 PMID:41385096 "[{""id"":""uuid:9e0c0d76-61be-48fe-8e27-23cff1b8cb2f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:38cab2ce-0c80-4774-8007-6085fcba036b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for prevention of cervical cancer (squamous-cell carcinoma and adenocarcinoma) and its precursor lesions (cervical intraepithelial neoplasia [CIN] 2 and 3) associated with human papillomavirus (HPV) types 16 and 18 infection. [Priority review] uuid:98699df1-b30a-4b06-9992-ae66498c15e2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1597091 biolink:treats MONDO:0004970 PMID:41385096 "[{""id"":""uuid:5d144014-dbc9-47ec-a98a-894d868610e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:188d74e0-c418-4f79-971c-b3da687dcc06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for prevention of cervical cancer (squamous-cell carcinoma and adenocarcinoma) and its precursor lesions (cervical intraepithelial neoplasia [CIN] 2 and 3) associated with human papillomavirus (HPV) types 16 and 18 infection. [Priority review] uuid:11a6394a-9d68-4a86-8717-5780bd57abe2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1597091 biolink:treats MONDO:0022394 PMID:41385096 "[{""id"":""uuid:677f8eaf-cc56-4356-b8dc-74cad911d4f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:66fc1508-461a-4dfe-9997-f7dd7af584ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for prevention of cervical cancer (squamous-cell carcinoma and adenocarcinoma) and its precursor lesions (cervical intraepithelial neoplasia [CIN] 2 and 3) associated with human papillomavirus (HPV) types 16 and 18 infection. [Priority review] uuid:276569b7-1406-42d2-b8b2-2320d974d898 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10127 biolink:treats MONDO:0005180 PMID:41385096 "[{""id"":""uuid:95ccfbeb-2c24-4d55-acad-82dbe68ae073"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:68b0e2d1-af83-478f-8a27-6292b90f5429"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the treatment of Parkinson's disease (in patients who have been treated with other anti- Parkinson drugs in combination with a levodopa- containing agent, but sufficient therapeutic effect was not obtained). uuid:303f8eaf-15ff-4d28-a299-74e1c8ae24bc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2H1PA8H1EN biolink:treats MONDO:0005150 PMID:41385096 "[{""id"":""uuid:2ca6378d-2adf-409b-be22-1422d6426162"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:989d0ec1-60ec-49bf-8093-70512f6c242f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for treatment of age-related macular degeneration with concurrent choroidal neovascularization. [Orphan drug] uuid:011458f1-d91a-48e6-9447-0e14632cf1ae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2H1PA8H1EN biolink:treats MONDO:0810000 PMID:41385096 "[{""id"":""uuid:9580a1af-6416-4211-8c4e-a9cf9a09d90c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6e91192e-8b15-4dcc-a546-d0696f8c9973"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for treatment of age-related macular degeneration with concurrent choroidal neovascularization. [Orphan drug] uuid:6723589d-e6d5-4903-a81a-080400dd84da biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:25CC4N0P8J biolink:treats HP:0000989 PMID:41385096 "[{""id"":""uuid:13de3d65-9e05-480c-b605-1f6402a56c5d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ea8f6bf1-681b-4f84-9c76-865f24984e07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of pruritus in hemodialysis patients (for use only when conventional therapies are not sufficiently effective). PUBCHEM.COMPOUND:6918287 uuid:11fea37c-daaa-4430-b78a-1ea0eb97cab0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45367 biolink:treats MONDO:0018076 PMID:41385096 "[{""id"":""uuid:0b84bad0-8257-4207-b171-0818b5fbc318"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b2f81d43-46bb-46c9-a097-3e519d29138f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of 1) tuberculosis, 2) non-tuberculous mycobacteriosis including mycobacterium avium complex (MAC) infections, and 3) prophylaxis of disseminated MAC infections in patients with HIV disease. uuid:51061a9b-a70c-4959-96e4-0673e422dff8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45367 biolink:treats UMLS:C0026919 PMID:41385096 "[{""id"":""uuid:fe51a69f-f7af-41d6-9265-fdbafbec99ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a63680df-4b8a-4ea8-80be-dc16876fb0a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of 1) tuberculosis, 2) non-tuberculous mycobacteriosis including mycobacterium avium complex (MAC) infections, and 3) prophylaxis of disseminated MAC infections in patients with HIV disease. uuid:8dffc6dc-9a20-4ff1-8841-6d570374c93e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats MONDO:0004277 PMID:41385096 "[{""id"":""uuid:87679f39-ae56-426e-a7bd-9e2f2d3b34c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:99357bee-5c96-4af4-9dcf-aec2e230e876"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication for Neisseria gonorrhoeae infections, with a new dosage in a new dosage form. Conversion from an immediate release formulation of azithromycin to a sustained release formulation. uuid:765dd79e-e15f-4e47-b989-4b6bf00aa006 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16469 biolink:treats UMLS:C1306878 PMID:41385096 "[{""id"":""uuid:4b02eb6b-b988-4f5f-bc15-1c63687b27e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cd9f5a7e-23d6-4f2e-b2ec-6449a611a4c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the treatment of vasomotor symptoms (hot flushes and sweating) and vaginal atrophy symptoms associated with climacteric disturbance and ovarian deficiency symptoms. uuid:80d15efd-5440-4754-bf2e-119695e284fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1295555 biolink:treats HP:0031217 PMID:41385096 "[{""id"":""uuid:3570d51e-6289-43d4-a03a-128742a26b5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8e300d1c-c5a3-41fc-b93f-18daecc5033e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug indicated for the treatment of vasomotor symptoms (hot flushes and sweating) associated with climacteric disturbance and ovarian deficiency symptoms. uuid:7b0e5a34-c613-4687-aef6-15051e006115 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1295555 biolink:treats UMLS:C1306878 PMID:41385096 "[{""id"":""uuid:3544464b-ccd4-49b5-b28d-e37ed1b09356"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a9f99b75-30a7-4970-9dfa-7909e065ab12"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug indicated for the treatment of vasomotor symptoms (hot flushes and sweating) associated with climacteric disturbance and ovarian deficiency symptoms. uuid:b1fd3fa5-2b8d-49c9-b9db-7bda7ad268fc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1295555 biolink:treats MONDO:0005387 PMID:41385096 "[{""id"":""uuid:83832b8a-daab-4625-9955-571fc5936227"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:da8de262-1828-4a96-b498-9fbc8644b72c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug indicated for the treatment of vasomotor symptoms (hot flushes and sweating) associated with climacteric disturbance and ovarian deficiency symptoms. uuid:cfd637a3-5546-411d-8923-b55421f5bb98 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2P471X1Z11 biolink:treats MONDO:0100470 PMID:41385096 "[{""id"":""uuid:ce4ac12a-bbc1-48e1-b726-2c93734f0277"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:909ed3f7-a27a-4d84-8d37-c13ddc2788d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of bronchial asthma (for use only in patients with intractable bronchial asthma whose asthmatic responses are uncontrollable with conventional therapies). uuid:58a1995d-c5bd-471d-80f6-5fe24a1764e4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4495 biolink:treats MONDO:0005803 PMID:41385096 "[{""id"":""uuid:9e5fad6d-77c4-4c0c-8db8-bd917dc6dfab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0dbba694-9d64-4674-b9ef-41db43077555"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of hyperinsulinemic hypoglycemia. [Priority review] uuid:45901034-ca58-4570-a4eb-7eb3f373504c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PQX0D8J21J biolink:treats MONDO:0024331 PMID:41385096 "[{""id"":""uuid:f02df37f-b8b7-452f-84e5-14041a8ca250"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:17a2c965-8ef2-4767-b16a-8994465b8891"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of EGFR-expressing, unresectable and advanced/recurrent colorectal carcinomas. [Priority review] uuid:37060db8-99d7-403b-be7b-717faeecc655 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:K37N7BYX3X biolink:treats MONDO:0011996 PMID:41385096 "[{""id"":""uuid:d82a845a-a9f0-4619-81e9-5a44e2c3a58f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:985cf3a3-1012-4740-88c3-13ec513eb75a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of imatinib-resistant, chronic phase and accelerated phase chronic myelogenous leukemia. [Orphan drug] uuid:9c8c30df-5811-4dba-a0bf-37e235f95f67 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:K37N7BYX3X biolink:treats MONDO:0021367 PMID:41385096 "[{""id"":""uuid:0b3d274e-280a-4b39-aed0-e73797f7b124"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:90d4ccef-2570-496a-a601-6767b4e8526e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of imatinib-resistant, chronic phase and accelerated phase chronic myelogenous leukemia. [Orphan drug] uuid:0b9f50be-e472-476f-b55f-9ac730c930c4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:D7RD81HE4W biolink:treats MONDO:0015909 PMID:41385096 "[{""id"":""uuid:9f8d471d-d8d2-4857-973c-f0cd4881f9dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:02f0d6b4-b579-4873-9a45-d098a6ccf6e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of moderate to very severe aplastic anemia, for use as pretreatment prior to hematopoietic stem cell transplantation, and for the treatment of acute graft-versus-host disease after hematopoietic stem cell transplantation. [Orphan drug] uuid:15c60488-09c5-45b5-a35f-ecd8287a1e1e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:D7RD81HE4W biolink:treats MONDO:0020546 PMID:41385096 "[{""id"":""uuid:7f28e654-b35a-4234-a41c-ce35665da4ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:33afc900-ebdd-4cd4-bebc-d1876c6c68c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of moderate to very severe aplastic anemia, for use as pretreatment prior to hematopoietic stem cell transplantation, and for the treatment of acute graft-versus-host disease after hematopoietic stem cell transplantation. [Orphan drug] uuid:8fee7a3f-3cf4-44e2-a768-5aa8e6fd619f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB05777 biolink:treats MONDO:0001243 PMID:41385096 "[{""id"":""uuid:78852f70-080e-41df-87d6-34b4a7634030"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b905b794-067a-4e30-8d5e-a619062f8982"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of disseminated intravascular coagulation (DIC). uuid:8177b66d-0626-44c7-a947-c8931ba2b78d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:131716 biolink:treats MONDO:0001218 PMID:41385096 "[{""id"":""uuid:ad189881-1124-4760-8760-480a55fd3c85"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d7073f07-5541-4bd5-95fe-3945f1a67990"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, infections secondary to chronic respiratory disease, otitis media, and sinusitis. uuid:81ae0714-c369-4d53-ac8e-4ec52baca613 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:131716 biolink:treats MONDO:0001039 PMID:41385096 "[{""id"":""uuid:6da16083-caeb-4527-9df4-3a93ddb39ed6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a86da820-95fa-441c-8eb2-2742e293394c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, infections secondary to chronic respiratory disease, otitis media, and sinusitis. uuid:a116195d-5b27-40b8-a41b-bf043d3aa310 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:131716 biolink:treats UMLS:C0877267 PMID:41385096 "[{""id"":""uuid:2ff36894-72db-4eef-97fd-b0319115410d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2dc1c374-ee96-488d-a51a-9816c0718e7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, infections secondary to chronic respiratory disease, otitis media, and sinusitis. uuid:2f9b2ee9-4bd3-45b7-9170-49080f9674bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:131716 biolink:treats MONDO:0005906 PMID:41385096 "[{""id"":""uuid:457687c6-c0a1-4897-a728-cf64e2cd0c38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6ef298d9-6ec0-4d64-b399-e5c2c546df6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, infections secondary to chronic respiratory disease, otitis media, and sinusitis. uuid:a92d5c84-735f-437c-9554-26d028bf13a7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:131716 biolink:treats HP:0012388 PMID:41385096 "[{""id"":""uuid:b8b31375-87d4-4999-a9a4-b26f1e9772e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7dfefac5-ea82-4f10-8dbb-b052d314900c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, infections secondary to chronic respiratory disease, otitis media, and sinusitis. uuid:590a6db5-cb0b-4200-a4dc-548007a73385 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:131716 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:6be78732-97f6-4041-8348-a60887a3b516"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d038c5ca-082c-4f31-a5d6-b155c027a26b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, infections secondary to chronic respiratory disease, otitis media, and sinusitis. uuid:2b46749f-2552-40fd-a605-cfcbe17f91ce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:131716 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:946a9d62-8681-430f-a264-d85af3f9c937"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fd88232f-f77c-42bc-890a-718d33fee769"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, infections secondary to chronic respiratory disease, otitis media, and sinusitis. uuid:3864f063-9236-4edf-8599-16a2317fbd49 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:131716 biolink:treats MONDO:0005441 PMID:41385096 "[{""id"":""uuid:4c4176cc-658a-4fe0-8033-1a1fb15b63b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d75dc0ae-05f0-448c-85ca-758f3af8623d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, infections secondary to chronic respiratory disease, otitis media, and sinusitis. uuid:38af7fba-949f-4d8d-b12e-334838e6f3db biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:131716 biolink:treats MONDO:0005961 PMID:41385096 "[{""id"":""uuid:ac3b30b9-f61d-4bd5-b29e-cb54e4165b4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6f805212-83bd-4c7e-a5c7-dd20707bfdcf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, infections secondary to chronic respiratory disease, otitis media, and sinusitis. uuid:10465f2b-b8af-4196-b093-1d87849d2b38 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16469 biolink:treats HP:0031217 PMID:41385096 "[{""id"":""uuid:16a6ea77-be54-414b-bef9-e6345e2c32d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a762106d-0e0a-438c-8932-f6bc6cee9805"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug in a new dosage form, or gel, indicated for the treatment of vasomotor symptoms (hot flushes and sweating) associated with menopausal disorders and ovarian deficiency symptoms. uuid:31309b35-ec69-43f1-b8be-50238148d839 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16469 biolink:treats UMLS:C0025319 PMID:41385096 "[{""id"":""uuid:667c0bb3-aeec-4693-afe9-ccf46efe88f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7a7a6207-af65-4c4b-8fa3-71ba1ca3e79d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug in a new dosage form, or gel, indicated for the treatment of vasomotor symptoms (hot flushes and sweating) associated with menopausal disorders and ovarian deficiency symptoms. uuid:cb899f8f-424b-4f43-867a-db13521155f7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:70708 biolink:treats MONDO:0005133 PMID:41385096 "[{""id"":""uuid:42e06893-d95a-47ca-ad0a-205c660b3081"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1d926bd4-9ad5-4df4-8243-9d5b873fbaf4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of endometriosis. uuid:0a2d9810-117f-4a11-8f67-c5dc3d0141dc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:61049 biolink:treats MONDO:0002313 PMID:41385096 "[{""id"":""uuid:b49c5532-9386-42c0-b236-ad86adbc9426"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:18725902-7bce-4c38-870b-c068208db420"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the treatment of vernal conjunctivitis (in the case where anti-allergic drugs are not sufficiently effective). [Orphan drug] uuid:bf3e436e-47a6-4862-a7e7-f5cef7ef65cf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:33324 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:d24b69f6-b9e6-4e8a-a297-29c467128a11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:76480be0-d484-4d43-9eec-8d8ceb09445a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for pain relief in bone scintigraphy- positive metastatic lesions in patients with solid cancers. uuid:f21aa4a9-fc3c-49ad-a207-08660db52bf7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:33324 biolink:treats MONDO:0004992 PMID:41385096 "[{""id"":""uuid:175119db-80b0-44f6-9401-c5421aeb4bd4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:123c4a8e-99e8-4b32-b848-2585a7b32cd7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for pain relief in bone scintigraphy- positive metastatic lesions in patients with solid cancers. uuid:94df5dc0-7c7e-45d1-bd21-58a9c364ae9b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:33324 biolink:treats MONDO:0024883 PMID:41385096 "[{""id"":""uuid:6d84a90f-a13e-4c7f-ace7-64fd42f3b564"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ee1c950e-b2de-4fb7-ba8e-c22f5bdd1ab6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for pain relief in bone scintigraphy- positive metastatic lesions in patients with solid cancers. uuid:e5ffac9a-b1bf-4f2e-97e2-81a2dcb36126 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7852 biolink:treats EFO:0801084 PMID:41385096 "[{""id"":""uuid:a375fdf8-7e26-4110-8ca5-3db0bd686bc9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9a57882a-7e56-4ae5-acaa-405e63cf2563"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drug with a new dosage form used as an analgesic agent for moderate to severe pain associated with various types of cancer. uuid:ba437c7d-4c81-4654-b974-160611ec5d28 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63611 biolink:treats MONDO:0004785 PMID:41385096 "[{""id"":""uuid:01c9f953-fea6-468f-b7e0-90cb31d852a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fa1da388-0739-445c-b7b7-2a62b8e1cefd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drug with a new route of administration, indicated for blepharitis, dacryocystitis, hordeolum, conjunctivitis, meibomianitis, keratitis (including corneal ulcer), and perioperative sterilization in ophthalmological surgery. uuid:97569161-62b4-4a1d-b939-fd70701cccf0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63611 biolink:treats MONDO:0004926 PMID:41385096 "[{""id"":""uuid:c70fc71e-bb1d-4165-b974-3508572559f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8e8e7b2d-d4cb-438e-bc67-967ea8c6efae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drug with a new route of administration, indicated for blepharitis, dacryocystitis, hordeolum, conjunctivitis, meibomianitis, keratitis (including corneal ulcer), and perioperative sterilization in ophthalmological surgery. uuid:80281570-f815-4595-bc57-ed075fc2333b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63611 biolink:treats MONDO:0005800 PMID:41385096 "[{""id"":""uuid:5ce74cbd-8576-465d-bb68-4beaed984c3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3ca4027e-96f1-4340-8f9e-9d8eae222853"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drug with a new route of administration, indicated for blepharitis, dacryocystitis, hordeolum, conjunctivitis, meibomianitis, keratitis (including corneal ulcer), and perioperative sterilization in ophthalmological surgery. uuid:04cf2926-260f-4543-8e59-d641a4d2ff4c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63611 biolink:treats MONDO:0003799 PMID:41385096 "[{""id"":""uuid:10e11045-eec7-43dd-bf85-576da1b90999"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:37170270-2225-46fb-bee1-5840a546491e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drug with a new route of administration, indicated for blepharitis, dacryocystitis, hordeolum, conjunctivitis, meibomianitis, keratitis (including corneal ulcer), and perioperative sterilization in ophthalmological surgery. uuid:3257368f-6590-4ea4-89c7-4c2a3654b4f6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63611 biolink:treats UMLS:C0549398 PMID:41385096 "[{""id"":""uuid:fe3897ea-62c8-4d6f-85bb-6ac8c477f4d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9447f062-4137-4922-99fd-491aba4530b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drug with a new route of administration, indicated for blepharitis, dacryocystitis, hordeolum, conjunctivitis, meibomianitis, keratitis (including corneal ulcer), and perioperative sterilization in ophthalmological surgery. uuid:3a8b3f3b-ddb0-40e3-aa91-4d67cd34af9b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63611 biolink:treats MONDO:0003085 PMID:41385096 "[{""id"":""uuid:3f99c770-0693-46b1-b27c-086bd001351d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9e3daf8b-4657-4c3a-b6b8-6bfcefa99736"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drug with a new route of administration, indicated for blepharitis, dacryocystitis, hordeolum, conjunctivitis, meibomianitis, keratitis (including corneal ulcer), and perioperative sterilization in ophthalmological surgery. uuid:813ba0eb-061e-4801-9691-2ca02008f24d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63611 biolink:treats MONDO:0004577 PMID:41385096 "[{""id"":""uuid:1e7392d4-5847-4614-b51a-c5e82684daa2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3238aa66-012c-4fa6-9abd-d5bffdfec76d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drug with a new route of administration, indicated for blepharitis, dacryocystitis, hordeolum, conjunctivitis, meibomianitis, keratitis (including corneal ulcer), and perioperative sterilization in ophthalmological surgery. uuid:7d42a7c2-1247-4464-ae60-5dae9a8bb40a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6076 biolink:treats UMLS:C0085082 PMID:41385096 "[{""id"":""uuid:8634f62b-375f-440b-9d2c-8e842beea944"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f5a6dbf4-fec1-4aea-8443-1a30a0fd42d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drug with a new route of administration indicated for treatment of fungemia, respiratory mycosis, gastrointestinal mycosis, urinary tract mycosis, fungal meningitis, esophageal candidiasis, blastomycosis, and histoplasmosis, caused by Aspergillus species, Candida species, Cryptococcus species, Blastomyces species or Histoplasma species and febrile neutropenia suspected of having fungal infections. uuid:c2719715-bb34-4665-bae4-f2e856d762b2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6076 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:0dfac91d-5b26-44ea-a59c-8fd6db7446d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:dbdce9f1-1584-4d26-9eb1-0d3ff70b635b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drug with a new route of administration indicated for treatment of fungemia, respiratory mycosis, gastrointestinal mycosis, urinary tract mycosis, fungal meningitis, esophageal candidiasis, blastomycosis, and histoplasmosis, caused by Aspergillus species, Candida species, Cryptococcus species, Blastomyces species or Histoplasma species and febrile neutropenia suspected of having fungal infections. uuid:0399ea64-580e-4f66-9fe4-a7f0d26704f4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6076 biolink:treats MONDO:0000256 PMID:41385096 "[{""id"":""uuid:63ec7ec3-bf31-4584-ac2b-8de0eb3c25e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:83d385ee-7b5a-49b8-ad21-92a7f55ff303"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drug with a new route of administration indicated for treatment of fungemia, respiratory mycosis, gastrointestinal mycosis, urinary tract mycosis, fungal meningitis, esophageal candidiasis, blastomycosis, and histoplasmosis, caused by Aspergillus species, Candida species, Cryptococcus species, Blastomyces species or Histoplasma species and febrile neutropenia suspected of having fungal infections. uuid:bcfe11e4-85ce-4a13-913e-d6993aa40609 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6076 biolink:treats MONDO:0006764 PMID:41385096 "[{""id"":""uuid:77879d40-1427-42c7-aca4-7749d6106293"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b4293f10-23cd-4373-9c2f-546042ebbb64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drug with a new route of administration indicated for treatment of fungemia, respiratory mycosis, gastrointestinal mycosis, urinary tract mycosis, fungal meningitis, esophageal candidiasis, blastomycosis, and histoplasmosis, caused by Aspergillus species, Candida species, Cryptococcus species, Blastomyces species or Histoplasma species and febrile neutropenia suspected of having fungal infections. uuid:bd2ea241-34a7-4c44-8b99-6e9b87d5ef4c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6076 biolink:treats UMLS:C0746883 PMID:41385096 "[{""id"":""uuid:df50d1e0-e6fb-4d99-8ae8-01cd59442cbf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:96ddad1d-8491-4328-b68b-874e7ac42c0c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drug with a new route of administration indicated for treatment of fungemia, respiratory mycosis, gastrointestinal mycosis, urinary tract mycosis, fungal meningitis, esophageal candidiasis, blastomycosis, and histoplasmosis, caused by Aspergillus species, Candida species, Cryptococcus species, Blastomyces species or Histoplasma species and febrile neutropenia suspected of having fungal infections. uuid:17d0e5f1-18d5-4f1f-b3e8-e690f5ff5b2d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63599 biolink:treats MONDO:0018908 PMID:41385096 "[{""id"":""uuid:e47fb395-01fa-43bc-ac38-503e4828f650"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e2e5fa96-1539-4ae5-bcd6-f53b88513f3d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drug with a new route of administration and indications for treatment of low-grade B cell non- Hodgkin lymphoma and mantle-cell lymphoma uuid:612ec792-0fce-48e1-b0ae-98848a8f1a20 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63599 biolink:treats MONDO:0005062 PMID:41385096 "[{""id"":""uuid:9297715d-f3e0-4f36-b684-faa1bb66330d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:df78e608-778b-4425-b0bd-9e148fc4a7e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drug with a new route of administration and indications for treatment of low-grade B cell non- Hodgkin lymphoma and mantle-cell lymphoma uuid:7143564b-d81e-4a57-ae5a-6ee4ef487541 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32599 biolink:treats UMLS:C0022876 PMID:41385096 "[{""id"":""uuid:74534338-81da-4b5a-8e3e-2482c72df18c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:eebec0a6-02e0-4277-98bd-bb399674142d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new indication and new dosage for relaxing the uterus muscles and suppressing preterm labour [Notification of off label] uuid:585807f5-e7b9-4e2e-ad22-f9491ed94c79 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76172 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:32f73117-6d74-4128-a36a-92ec5525f5a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c0aca2cc-93f1-4a49-bdb8-297226469587"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the treatment of osteoarthritis, myalgia, post-traumatic swelling/pain and anti-inflammatory/analgesic effects on these symptoms uuid:de24e70b-48ce-46f8-ad9c-68bf14cd2175 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76172 biolink:treats HP:0003326 PMID:41385096 "[{""id"":""uuid:18854182-44ef-4358-9bb7-6811d5b9ff66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:130ba42a-b2a3-4441-981d-0e746eb5e707"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the treatment of osteoarthritis, myalgia, post-traumatic swelling/pain and anti-inflammatory/analgesic effects on these symptoms uuid:ecb4d472-a7dd-4184-a9f2-af3b782bcf2c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76172 biolink:treats NCIT:C3399 PMID:41385096 "[{""id"":""uuid:967f0a7e-4c51-4d3f-84f8-35614f04bfd2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9527b046-24dc-44ef-ae82-69beed9637f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the treatment of osteoarthritis, myalgia, post-traumatic swelling/pain and anti-inflammatory/analgesic effects on these symptoms uuid:cb9282ad-4432-47bf-ba98-4c43c5a5b5ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76172 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:3e98a096-0233-4fa3-bb81-ddd4e8b1b358"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:52da5ea2-dcd6-4065-b272-634f8a87d0be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the treatment of osteoarthritis, myalgia, post-traumatic swelling/pain and anti-inflammatory/analgesic effects on these symptoms uuid:f8f6752f-42c5-440a-837a-958794e8f256 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8GZG754X6M biolink:treats UMLS:C2349276 PMID:41385096 "[{""id"":""uuid:3dc08fce-5a5d-406a-a4e3-b30751a5b244"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:89d99c97-c69e-4f06-b793-a109560ad527"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of relapsing or intractable CD33 positive acute myeloid [Orphan drug] uuid:072ce82a-2f8d-4e10-9642-6560fae36512 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:RWM8CCW8GP biolink:treats MONDO:0021223 PMID:41385096 "[{""id"":""uuid:c81e0588-5446-4a4f-a9fb-a29e4a78ede1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2f49990d-2a59-46c2-80d1-5812834ced0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New form drug with a new administration route administered once every four weeks and which has the following indications: alleviation of various symptoms associated with gastrointestinal hormone-producing tumors and alleviation of excessive secretions of growth hormone and somatomedin-C and other various symptoms in acromegaly and pituitary gigantism uuid:02b2e074-fb57-447b-91c6-337fcc7ba8dc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:RWM8CCW8GP biolink:treats MONDO:0020479 PMID:41385096 "[{""id"":""uuid:f45a4dbd-b7c1-4118-89be-6f26900a9496"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:697be6fd-3640-42e3-a600-d330292e99a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New form drug with a new administration route administered once every four weeks and which has the following indications: alleviation of various symptoms associated with gastrointestinal hormone-producing tumors and alleviation of excessive secretions of growth hormone and somatomedin-C and other various symptoms in acromegaly and pituitary gigantism uuid:a7d316d9-3010-466c-8305-e33ce598aa00 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:353007 biolink:treats MONDO:0004873 PMID:41385096 "[{""id"":""uuid:ad70e795-d0ba-4dde-831f-2e8ad90eb78a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5c898a75-c98b-4847-b8af-04b2e00f0ac4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new compound agent for local injection with indications for internal hemorrhoids associated with prolapse and is used for internal hemorrhoid sclerotherapy. uuid:f98212b6-a885-4e99-a84e-62e84f1a465c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:G8RGG88B68 biolink:treats MONDO:0005354 PMID:41385096 "[{""id"":""uuid:27984a7d-7ef8-40e2-99f6-fd80fc6180c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8749eccd-8261-48d3-9882-90e90dba9810"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient which enables weekly administration through chemical modification of interferon alfa-2b by polyethylene glycol (PEG) to prolong the drug elimination time in blood and has indications combined with ribavirin to alleviate viremia in patients with chronic hepatitis C with high blood HCV RNA levels for serogroup 1. uuid:4994c17d-fadb-426d-9479-0481460edf46 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5001 biolink:treats MONDO:0001336 PMID:41385096 "[{""id"":""uuid:7bab636f-4864-435c-a27b-5038426bb94e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c3bda00d-4f5f-46b9-a52a-5aac20b1e885"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Pulverization enables a reduction in the dosage to two thirds of the current dosage for hyperlipidemia (including familial hyperlipidemia). uuid:56f2f40e-fe29-4109-a06a-fa378e509b32 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:38545 biolink:treats MONDO:0005439 PMID:41385096 "[{""id"":""uuid:faf6239d-7472-43bf-a4b0-8ad4c3b02ac3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:be0cac05-2e4d-4261-aaa0-0806e9051196"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient with indications for HMG-CoA reductase inhibition for hypercholestelemia and familial hypercholestelemia. uuid:bc3ed0ca-9daa-473f-ad42-3375a1592a1f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32230 biolink:treats MONDO:0005607 PMID:41385096 "[{""id"":""uuid:b315a0df-4957-4b36-a987-5c6af172cdfa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0e58a2b6-109b-47bc-a805-628cf903aa69"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient with indications for anticholinergic bronchodilation to alleviate various symptoms due to airway obstructive impairment in chronic obstructive pulmonary diseases (chronic bronchitis and emphysema). uuid:1eb50025-ce28-4422-8380-f8ce494e6b59 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32230 biolink:treats MONDO:0004849 PMID:41385096 "[{""id"":""uuid:8a5f0362-7cce-43f3-a053-d13e1775e796"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7732931f-69b0-4332-b9da-63a048dc4ee8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient with indications for anticholinergic bronchodilation to alleviate various symptoms due to airway obstructive impairment in chronic obstructive pulmonary diseases (chronic bronchitis and emphysema). uuid:07047fde-0ea7-47d0-bbd5-9ec200e78aa2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51032 biolink:treats MONDO:0011786 PMID:41385096 "[{""id"":""uuid:064fd5c5-fd09-40ee-87a7-50b657522fa0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fc4e7f31-3934-4095-8e1a-f83fb6d15170"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A pediatric preparation with indications for allergic rhinitis, urticaria, skin diseases (eczema, dermatitis, skin pruritus) uuid:0c1b927b-5727-4480-8813-77ad4a2076ab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51032 biolink:treats MONDO:0005492 PMID:41385096 "[{""id"":""uuid:85b57e91-bb4e-4c26-a21e-9df9e5a3156f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d97db31d-4d75-4dce-b3cb-038ee54dbdb4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A pediatric preparation with indications for allergic rhinitis, urticaria, skin diseases (eczema, dermatitis, skin pruritus) uuid:820d4a6d-61b4-40a3-99c2-814cd658bc89 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51032 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:98ea1146-57ec-412d-9a50-bfde051b9465"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:73b06f7a-7d48-4d1b-a4e5-477fcd7d4627"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A pediatric preparation with indications for allergic rhinitis, urticaria, skin diseases (eczema, dermatitis, skin pruritus) uuid:5835c750-39f9-4411-8223-26d7a0ceef17 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51032 biolink:treats MONDO:0002406 PMID:41385096 "[{""id"":""uuid:095a9765-698b-434f-bd4c-2e02d29e1d79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a155bfd1-2a97-474d-a0c9-9da4ea92d092"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A pediatric preparation with indications for allergic rhinitis, urticaria, skin diseases (eczema, dermatitis, skin pruritus) uuid:c5bed809-80dd-4f96-a5b9-1db4ccdd4d5b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51032 biolink:treats HP:0000989 PMID:41385096 "[{""id"":""uuid:fa9a86e7-19ef-4ba8-8ead-e06f25d9c581"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a218e2eb-0757-43bf-ae97-282849147745"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A pediatric preparation with indications for allergic rhinitis, urticaria, skin diseases (eczema, dermatitis, skin pruritus) uuid:4f3de06f-4de9-4d33-a5d1-55b48f5a72c6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5280 biolink:treats MONDO:0004785 PMID:41385096 "[{""id"":""uuid:3b2a1b70-f9d5-45a2-ba6a-a0a302535511"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bc0ee163-1c7b-47be-97e3-971fcb7253b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New quinolone antibacterial agent. An ophthalomic solution with indications for blepharitis, hordeolum, dacryocystitis, conjunctivitis, tarsadenitis, keratitis, aseptic therapy for ophthalmologic perioperative period. uuid:264401e3-a4f9-46cc-865c-28eb7c0cc73f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5280 biolink:treats MONDO:0005800 PMID:41385096 "[{""id"":""uuid:0b885f77-7c9d-4bd0-8fc6-5e44f1aa04eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0123282a-8f56-4282-9c4d-dafc32875d6a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New quinolone antibacterial agent. An ophthalomic solution with indications for blepharitis, hordeolum, dacryocystitis, conjunctivitis, tarsadenitis, keratitis, aseptic therapy for ophthalmologic perioperative period. uuid:1a084f0f-291d-43f4-9fb5-3062b89a6290 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5280 biolink:treats MONDO:0004926 PMID:41385096 "[{""id"":""uuid:6df5ecb9-f66f-45f3-b094-c005addab52b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:72d390a0-2934-4b14-9c6c-df8792634e36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New quinolone antibacterial agent. An ophthalomic solution with indications for blepharitis, hordeolum, dacryocystitis, conjunctivitis, tarsadenitis, keratitis, aseptic therapy for ophthalmologic perioperative period. uuid:ce894e73-97dc-4b8b-ae5d-b8da7364c1b4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5280 biolink:treats MONDO:0003799 PMID:41385096 "[{""id"":""uuid:c8b7b32c-24a9-49ae-97ca-3b7dc22fed7c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1ba9819c-1e55-4abb-b789-177ec7cc6924"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New quinolone antibacterial agent. An ophthalomic solution with indications for blepharitis, hordeolum, dacryocystitis, conjunctivitis, tarsadenitis, keratitis, aseptic therapy for ophthalmologic perioperative period. uuid:a7019c52-8751-4de9-b5b7-67fdeb5b8eb8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5280 biolink:treats MONDO:0003085 PMID:41385096 "[{""id"":""uuid:af0c8719-f723-4933-a2d4-a625e0a84b66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:02ae04ea-341b-4799-9df2-d2fc2dfe9da0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New quinolone antibacterial agent. An ophthalomic solution with indications for blepharitis, hordeolum, dacryocystitis, conjunctivitis, tarsadenitis, keratitis, aseptic therapy for ophthalmologic perioperative period. uuid:1f1ff131-6b50-4ddd-8977-0fa7ff820d73 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7DVX185FLQ biolink:treats MONDO:0005027 PMID:41385096 "[{""id"":""uuid:93a6ffc0-32fc-4503-bc04-62aa76edd81a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e76a5540-3e7e-46e5-bc4d-102cf3a18c7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient with indications for detection of epileptic focus in epilepsy by the central benzodiazepine-receptor scintigraphy. uuid:6f436534-c151-48e4-be77-3fba399add1a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46557 biolink:treats MONDO:0001566 PMID:41385096 "[{""id"":""uuid:fa40b7e0-0b09-4624-b197-5253b290c283"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2b3d52f2-5152-44be-8088-fe4afd23fcbb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient which has a bone-absorption-inhibitory action and has indications for hypercalcemia caused by malignant tumors. uuid:995112d3-0cec-4631-acdd-c10a8da99b34 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46557 biolink:treats MONDO:0004992 PMID:41385096 "[{""id"":""uuid:1d18ac60-07eb-4625-89a2-707d096a8f4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3f096969-6d3d-45b7-ab58-e4ad26e56a72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient which has a bone-absorption-inhibitory action and has indications for hypercalcemia caused by malignant tumors. uuid:5cec9a0c-1894-4666-84ec-241dc3b72b69 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16236 biolink:treats MONDO:0007256 PMID:41385096 "[{""id"":""uuid:a800d58c-15bc-4f46-bb5f-ffec270fb7fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:251c7bfd-8228-4a3f-ad2d-2879e97d7e78"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new administration route with indications for percutaneous ethanol injection therapy in hepatocellular carcinoma. uuid:d256f4b1-d63c-47e6-bcf7-8580bde5d017 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31941 biolink:treats MONDO:0006519 PMID:41385096 "[{""id"":""uuid:a093dfef-97a9-49b2-be27-0221390c8e37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bf307964-e038-4de8-adb5-1e86c60d3f56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient with indications for colonic and rectal cancers. uuid:47ee44bd-b95f-40b9-9669-31639777da71 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63635 biolink:treats MONDO:0002708 PMID:41385096 "[{""id"":""uuid:8b88c021-c290-4b87-81ea-4a9f910b8c81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1bfa9dc6-f8f0-4de6-8009-b51a19164815"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient, L- valine ester of ganciclovir, with indications for treatment of retinitis caused by cytomegalovirus in patients with acquired immune deficiency syndrome (AIDS) and dosage regimen. uuid:72c34489-4233-4244-9b7b-c61bdce98633 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82941 biolink:treats MONDO:0005109 PMID:41385096 "[{""id"":""uuid:0f1a22cb-6216-4a3c-b6e9-40b42d7f9f25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e8506073-7be1-4935-b14d-e0430d89dc18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient with indications for HIV infection. uuid:919cbd40-09a9-43c7-889b-1fc992c5b989 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:57453565 biolink:treats UMLS:C0854521 PMID:41385096 "[{""id"":""uuid:96206220-70d9-4f3c-8cb9-462fc0c1434d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:69c8a022-0baf-4277-bd1b-8805c7780d54"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of hypozincemia. uuid:4208c67e-40fa-4460-b3e9-928e67d1a229 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:WB8FT61183 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:b9482b9f-8ebe-4ae3-932e-28c11b5f02fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a9669624-1d2f-49c5-82c4-338e16f4d334"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new additional pediatric dosage in an additional dosage form for the treatment of chronic heart failure. uuid:cef726f4-b40d-45ad-841b-5482e48cd052 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2382602 biolink:treats MONDO:0002032 PMID:41385096 "[{""id"":""uuid:02b017f9-04d2-4f63-97fc-1ada89b885da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:338f1015-c4be-4549-8c5f-89d172b1917b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New combination drugs with a new active ingredient indicated for the treatment of HER2- positive breast cancer and unresectable advanced or recurrent HER2-positive colon or rectal cancer that has progressed after cancer chemotherapy. uuid:726b0209-a98e-41d5-822a-165efec0afd4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2382602 biolink:treats MONDO:0006519 PMID:41385096 "[{""id"":""uuid:e0aa50a9-623e-4167-8581-b78a017318ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:07bfb227-31a4-47ab-b597-00bf74a81de6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New combination drugs with a new active ingredient indicated for the treatment of HER2- positive breast cancer and unresectable advanced or recurrent HER2-positive colon or rectal cancer that has progressed after cancer chemotherapy. uuid:c7349c1f-2ae6-4b51-9a4e-aa3a68dc5be9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:D6OMY2L0WA biolink:treats MONDO:0020323 PMID:41385096 "[{""id"":""uuid:e94ad0ad-cc79-47f7-94a7-18db3247bf09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:68f4d75d-1eaf-43ba-81a3-58562c60dcda"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of relapsed or refractory large B-cell lymphoma (diffuse large B-cell lymphoma, high- grade B-cell lymphoma, and primary mediastinal large B-cell lymphoma) or relapsed or refractory follicular lymphoma. uuid:10503228-c08e-43c9-9ac1-96cecf5c9e7f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:AQK7UBA1LS biolink:treats MONDO:0018881 PMID:41385096 "[{""id"":""uuid:23904c27-14b1-435f-846e-192c1ffab41c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:037f0450-6e18-45e0-bd1b-ae3eca4cfbf0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of anemia associated with myelodysplastic syndrome. [Orphan drug] uuid:861473e0-eb09-4095-9bb7-359d70b5ba12 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229222 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:b0039211-6334-4257-85e4-d85908eabed5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:614c5606-e3f6-4d8d-8bda-b773fb7a5708"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative inoperable or recurrent breast cancer with PIK3CA, AKT1, or PTEN mutation that has progressed after endocrine therapy. uuid:6953e54f-4e96-4345-85f8-be0e458c91ff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:L0HR9A577V biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:cd3c5cc8-5eba-4066-875f-97aad2f6f4b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0b6756cf-2485-428b-914b-12244a6f7edb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of relapsed or refractory multiple myeloma (for use only if refractory or intolerant to standard therapies). [Orphan drug] uuid:d501863f-8568-4c3d-9baf-9d47d11a8598 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2583638 biolink:treats MONDO:0017572 PMID:41385096 "[{""id"":""uuid:5712efd5-65a6-46d7-be43-c9b0a808a2b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:294bea08-cc6a-4bfa-a27f-767f375041b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the prevention of tick-borne encephalitis. uuid:4ac47b57-41ae-4546-bfb6-36db0495e1f0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:90ZX3Q3FR7 biolink:treats UMLS:C0852922 PMID:41385096 "[{""id"":""uuid:fb491bb8-c75a-460b-896f-c6176dc25e65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:13d958bb-353f-41f3-ab66-38c591682a57"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the remission induction therapy of moderate to severe active Crohn’s disease (for use only in patients who have not sufficiently responded to conventional treatments). A drug with a new indication and a new dosage in an additional dosage form for the maintenance therapy of moderate to severe active Crohn’s disease (for use only in patients who have not sufficiently responded to conventional treatments). uuid:5e085815-ef81-4d96-8b5d-51d5cce63772 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:T3U32GLJ0F biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:e14ca5a6-3a41-4f0b-b6a3-a9755ca6bd3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b8584cd6-67ff-4337-9739-03600f1f53be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of atopic dermatitis. uuid:61d5b54e-0a9d-43e4-85a1-dc1775b55d5b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:AHU547PI9H biolink:treats MONDO:0002280 PMID:41385096 "[{""id"":""uuid:194fed3b-195d-48ff-8cb1-6894040b0027"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:52de0da1-8780-44c9-9bac-dbe169613edc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of iron-deficiency anemia. uuid:e0df3953-3624-4968-9df3-367980526dcf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6D848RA61B biolink:treats MONDO:0000050 PMID:41385096 "[{""id"":""uuid:c99dbb44-a3b9-4e31-9679-dc07da083dc2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:39005520-3f85-4f34-a31f-fc1d58ddce39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of short stature due to growth hormone deficiency prior to epiphyseal closure. uuid:dd729867-74b3-4d4d-a6bd-83706d8f95b8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DE2O63YV8R biolink:treats MONDO:0005016 PMID:41385096 "[{""id"":""uuid:81da5cb0-ab8d-4742-b58f-83c242dfb3cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c341492c-f853-45f4-9d8f-72dbae9a85d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of chronic kidney disease associated with type 2 diabetes mellitus (excluding patients who have end-stage renal failure or are undergoing dialysis). uuid:5fefa68c-110f-4249-9242-c8657a122fc8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:09495UIM6V biolink:treats MONDO:0022205 PMID:41385096 "[{""id"":""uuid:19672313-250f-4dd9-9515-69a74077f971"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:88a85667-0838-4498-b3ba-0f967dc265e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of plaque psoriasis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies. uuid:57803285-0cfd-444b-bf64-3ec5d8e54d80 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:09495UIM6V biolink:treats UMLS:C0748052 PMID:41385096 "[{""id"":""uuid:e9d734bc-b836-4828-9325-63bfc0f5e0d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:69df9c7e-5205-4c24-83b9-fa16cfe19927"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of plaque psoriasis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies. uuid:c2a0b49b-eb99-43fb-a458-27bad2daaa35 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2S9ZZM9Q9V biolink:treats MONDO:0002032 PMID:41385096 "[{""id"":""uuid:bc8df031-2d67-4a26-9edc-b8d8b5c167c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c4b199df-6ddc-4ffc-aa1b-5129332239dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Follow-on biologics indicated for the treatment of unresectable advanced or recurrent colon or rectal cancer and unresectable advanced or recurrent non-squamous non-small cell lung cancer. uuid:9f395651-25e0-47cb-bb46-43996edcee20 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2S9ZZM9Q9V biolink:treats MONDO:0006519 PMID:41385096 "[{""id"":""uuid:88a6b4bf-b6ca-4949-9153-87f9973c811c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:176f911e-432d-49ac-8e38-0bdd4318ef82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Follow-on biologics indicated for the treatment of unresectable advanced or recurrent colon or rectal cancer and unresectable advanced or recurrent non-squamous non-small cell lung cancer. uuid:f29ec7f5-c6be-470c-9266-6f3ce73e91dd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:50899324 biolink:treats UMLS:C1142276 PMID:41385096 "[{""id"":""uuid:2f7f4785-6698-4b24-8078-50693daa8f6c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1dda33b3-4a48-4182-b0bf-d6e005c9b8f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of renal anemia. uuid:51c43f52-ace0-472a-80f6-0690ce2fa3ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8FOJ430U94 biolink:treats UMLS:C1720505 PMID:41385096 "[{""id"":""uuid:d17fef9c-2ce9-4f5d-aee4-6fce3ee41f1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3f5cc146-d05c-4df5-aa1c-6a34e5599687"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of adult growth hormone deficiency (used only for severe cases). uuid:5e21bb9f-fab2-4c34-89b4-d34b88aae722 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:64759 biolink:treats HP:0000017 PMID:41385096 "[{""id"":""uuid:b7e04f3d-0110-4274-90eb-b42c6ae342c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d5a86af9-12cd-4a50-8f9d-40ff6582c611"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage in an additional dosage form indicated for the treatment of nocturia due to nocturnal polyuria in males. uuid:1f106ec3-3f54-4ced-b7a3-3f4203c9ea5f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:64759 biolink:treats UMLS:C0848232 PMID:41385096 "[{""id"":""uuid:569fb9b9-d040-4aa8-9c54-de9f17a8ebc2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:22dac04e-0c69-42d9-8606-bf5cd613b1f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage in an additional dosage form indicated for the treatment of nocturia due to nocturnal polyuria in males. uuid:88226777-0ebe-406e-9356-8b9ecb5750db biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76016 biolink:treats MONDO:0002050 PMID:41385096 "[{""id"":""uuid:161fa40b-23d8-4d86-87fe-6ab5eeb67f47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b2793e80-330b-43c1-869f-4b8c7327ebb3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of depression. uuid:4cb9d10e-a52f-4327-a717-8f17cafa9e55 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64355 biolink:treats MONDO:0019136 PMID:41385096 "[{""id"":""uuid:6060e272-e7a5-408c-ad41-5fa6547f86e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:168c45b1-0660-4a73-ab88-3866bff23ff6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the prophylaxis of deep mycosis in hematopoietic stem cell transplantation recipients or patients with hematologic malignancy who are predicated to decrease neutrophil. treatment of the following mycoses: Fusariosis, mucormycosis, coccidioidomycosis, chromoblastomycosis, and mycetoma. uuid:e2e0d920-084f-4e5f-818e-d679826cdd57 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841116 biolink:treats MONDO:0005607 PMID:41385096 "[{""id"":""uuid:a244273e-848d-4211-83ad-60d78cbc6dd3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a6203e0d-a948-43e9-90e4-79bd161219a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New combination drugs with a new active ingredient indicated for the relief of symptoms in patients with chronic obstructive pulmonary disease (chronic bronchitis, emphysema) (who require a combination therapy with an inhaled corticosteroid, a long-acting inhaled anticholinergic agent and a long-acting beta-2 agonist). uuid:3ed22fe5-779a-478a-b88c-6c2e61dc20ae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:56841116 biolink:treats MONDO:0004849 PMID:41385096 "[{""id"":""uuid:624909ec-862e-47ad-b34f-09efe7e0f1fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:27d2fb7c-429b-476a-8331-d3484db1374f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New combination drugs with a new active ingredient indicated for the relief of symptoms in patients with chronic obstructive pulmonary disease (chronic bronchitis, emphysema) (who require a combination therapy with an inhaled corticosteroid, a long-acting inhaled anticholinergic agent and a long-acting beta-2 agonist). uuid:ad5f6e43-0ba1-459a-8ccd-2c24d6465ece biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1790637 biolink:treats MONDO:0005607 PMID:41385096 "[{""id"":""uuid:e69ad8b1-a028-47bd-8db7-d3e9aebf6011"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b079fbb4-488f-4295-b6f6-f807671721cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New combination drugs with a new active ingredient indicated for the relief of symptoms secondary to airway obstructive disorder in patients with chronic obstructive pulmonary disease (chronic bronchitis, emphysema) (who require a combination therapy with a long-acting inhaled anticholinergic agent and a long-acting beta-2 agonist). uuid:aca00a0c-a2e7-4411-b20e-bb72c2d4696b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1790637 biolink:treats MONDO:0004849 PMID:41385096 "[{""id"":""uuid:cbc77caa-9822-4655-b080-ac1054c6bd84"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:970fcecd-2817-4e4e-b9dc-dd13686800c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New combination drugs with a new active ingredient indicated for the relief of symptoms secondary to airway obstructive disorder in patients with chronic obstructive pulmonary disease (chronic bronchitis, emphysema) (who require a combination therapy with a long-acting inhaled anticholinergic agent and a long-acting beta-2 agonist). uuid:6e62ed9a-4719-4b59-895c-8cedbd6909ce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:195558 biolink:treats NCIT:C183255 PMID:41385096 "[{""id"":""uuid:8ddc2829-5635-4362-ae0d-3d1c5b5c6acd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:87e0be70-1853-40c9-9902-de35876b698e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of NTRK fusion gene positive advanced or recurrent solid tumors. [SAKIGAKE designation, Orphan drug] uuid:54eee5c5-7959-4847-b248-743e64594475 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85993 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:7923bd4a-1f6d-460d-bc8b-af62d92bc422"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2b2e3c64-c67b-4cc6-87ec-3a18435e849d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication in a new dosage form for the treatment of hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative inoperable or recurrent breast cancer. uuid:ac178fd2-4f42-459b-951d-603025952479 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2S9ZZM9Q9V biolink:treats MONDO:0005575 PMID:41385096 "[{""id"":""uuid:b463587a-3f71-43a9-aea7-0c33687a375d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6f9a9523-c06b-470c-b094-ee2faba7e669"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Follow-on biologics indicated for the treatment of unresectable advanced or recurrent colorectal cancer. uuid:9ca4e45e-6dc6-4de3-8f36-0c593edcea9e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2535744 biolink:treats HP:0003124 PMID:41385096 "[{""id"":""uuid:7f3748e4-a44a-4132-99bb-483aba780026"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0471aea4-6c32-435a-8f7e-0ecc4822e4d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New combination drugs indicated for the treatment of hypercholesterolemia and familial hypercholesterolemia. uuid:63964dbd-fd1a-4a7d-8f7d-dbef87023a67 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:2535744 biolink:treats MONDO:0005439 PMID:41385096 "[{""id"":""uuid:ab248c42-106b-4fd6-a63c-81d91dbba5a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bd782d69-a43b-4a2c-a517-d8dc8d735beb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New combination drugs indicated for the treatment of hypercholesterolemia and familial hypercholesterolemia. uuid:df899408-ea36-4705-88b1-d063da7758c7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1945037 biolink:treats MONDO:0005607 PMID:41385096 "[{""id"":""uuid:bc0c1987-1c4b-4d34-b78f-730e61517a65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6e603e20-51aa-4f78-b4e5-3f4cab9e086f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New combination drugs indicated for the relief of symptoms in patients with chronic obstructive pulmonary disease (chronic bronchitis, emphysema) (who require a combination therapy with an inhaled corticosteroid, a long-acting inhaled anticholinergic agent and a long-acting beta-2 agonist). uuid:66cf81b4-ddd9-43e2-b1cd-3509b9cb215b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1945037 biolink:treats MONDO:0004849 PMID:41385096 "[{""id"":""uuid:948e43e4-35ea-46fc-927b-ee82a4468c47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:780364cc-efff-4169-9084-acc0f47e5733"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New combination drugs indicated for the relief of symptoms in patients with chronic obstructive pulmonary disease (chronic bronchitis, emphysema) (who require a combination therapy with an inhaled corticosteroid, a long-acting inhaled anticholinergic agent and a long-acting beta-2 agonist). uuid:a7a99c24-0369-43c0-b643-8e3309998c6f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:57928403 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:2f0fa168-a6b3-4b8e-8124-083b4ba5394c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1ce4365a-7721-4958-a942-d3051fe58ec4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of rheumatoid arthritis (including prevention of structural joint damage) in patients who have not responded sufficiently to conventional treatments. uuid:2746c097-471f-4a70-8b1f-39e62206e040 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:E58MLH082P biolink:treats MONDO:0006964 PMID:41385096 "[{""id"":""uuid:d874d119-2e04-42e2-b09f-c2a4c9a44ec5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bbddc470-9278-4bf7-a36f-18afd0c1efaa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of secondary hyperparathyroidism in patients on maintenance dialysis. uuid:7246d9b4-0544-4fc9-890c-73d0607f0f83 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1422082 biolink:treats MONDO:0005439 PMID:41385096 "[{""id"":""uuid:b897c57d-3889-4b47-9ec3-c11dc4c81d1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9de72b91-7a3d-423b-94c3-699188c9789c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New combination drugs indicated for the treatment of hypercholesterolemia and familial hypercholesterolemia. uuid:53f70d2b-6a19-4243-8d12-56fd2ce7783f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5790 biolink:treats EFO:0801084 PMID:41385096 "[{""id"":""uuid:0d0c2875-a07d-4ef7-a0d3-c89b18f3602d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6787ab54-523b-4a4a-a3ef-5b6bb48cd07a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new route of administration indicated for management of moderate to severe pain in various types of cancer. uuid:380f686c-cfef-4ebe-997e-b415b41b42a0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82717 biolink:treats MONDO:0005113 PMID:41385096 "[{""id"":""uuid:0d97aa75-b6dd-40a2-a39a-cab83b1a0c14"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:aa03d107-030b-49ab-95b6-c5b5fc872f25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of bacterial skin infections mainly involving the dermis and/or subcutaneous tissues, secondary bacterial infections of pre-existing skin ulcers and/or erosion, and secondary bacterial infections of trauma, burn, and surgical wounds. uuid:0493e0a5-3caa-464e-ae10-6dfef454965a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82717 biolink:treats UMLS:C0038941 PMID:41385096 "[{""id"":""uuid:9811c9d8-d68f-413d-807c-9ccf99329477"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c499f5db-522e-435a-8e6e-0fe42ebf1abf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of bacterial skin infections mainly involving the dermis and/or subcutaneous tissues, secondary bacterial infections of pre-existing skin ulcers and/or erosion, and secondary bacterial infections of trauma, burn, and surgical wounds. uuid:6e1bb9f4-8b6b-4a8b-b804-ba457a2daa6c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4779 biolink:treats MONDO:0011786 PMID:41385096 "[{""id"":""uuid:3136585d-134c-475b-be9e-486c0c1f3d2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cb047e1d-871d-41df-9787-6b92f24e8b3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new route of administration indicated for the treatment of allergic rhinitis. uuid:63005453-7b09-4b61-bbe4-d72d5cdfbb96 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:83766 biolink:treats UMLS:C0278689 PMID:41385096 "[{""id"":""uuid:f6ef6391-96ff-49cf-a55f-087f370ece72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:29be4c99-847c-4515-bea5-b39bab99f491"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the maintenance treament of recurrent ovarian cancer in patients who are in a complete or partial response to platinum-based chemotherapy. uuid:42ebdbfc-1dfd-4ba0-bfc4-c31ccb3a4182 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4F4X42SYQ6 biolink:treats MONDO:0016537 PMID:41385096 "[{""id"":""uuid:9ae24356-ddd0-49d3-98d4-43e14a5a1238"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fe3e1caa-8ad2-40c5-b61f-764de8d4e6db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Follow-on biologics indicated for the treatment of CD20-positive B-cell non-Hodgkin's lymphoma, CD20-positive B-cell lymphoproliferative disorder associated with immunosuppression, Wegener's granulomatosis, and microscopic polyangiitis. uuid:0c6cf73c-bd43-414a-af6d-773d2a38fc84 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:333OX80X87 biolink:treats MONDO:0005076 PMID:41385096 "[{""id"":""uuid:453b8918-2fb2-42f9-a281-35a7c51241a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:074f8491-0dad-4d5d-9d62-da1fa20c0c05"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new route of administration indicated for the treatment of alveolar bone loss due to periodontitis. uuid:18d6b4b3-b9be-4123-85fe-076ad16a0469 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68558 biolink:treats UMLS:C0155668 PMID:41385096 "[{""id"":""uuid:77c9696e-6ce7-4036-b384-74b3b70538bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cc557596-9044-402a-8e80-95b70354b378"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of: Old myocardial infarction at especially high risk of developing atherothrombosis with at least one of the following risk factors: age of 65 years or older, with diabetes mellitus requiring drug therapy, history of two or more episodes of myocardial infarction, angiography- confirmed multivessel coronary artery disease, or non-end-stage chronic renal dysfunction. Acute coronary syndrome (unstable angina, non-ST-segment elevation myocardial infarction, and ST-segment elevation myocardial infarction) for which percutaneous coronary intervention (PCI) is indicated. (provided that dual antiplatelet therapy including aspirin is appropriate but the administration of other antiplatelet drugs in combination with aspirin is not suitable for the patient.) uuid:b87ac815-a38c-4cbb-97e4-cd90a32e1cd7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68558 biolink:treats MONDO:0006805 PMID:41385096 "[{""id"":""uuid:c5e39e5a-9a19-49b2-ae6c-4e4b33c4eb3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fd6f9ed2-2435-4212-a01a-58c77c18432e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of: Old myocardial infarction at especially high risk of developing atherothrombosis with at least one of the following risk factors: age of 65 years or older, with diabetes mellitus requiring drug therapy, history of two or more episodes of myocardial infarction, angiography- confirmed multivessel coronary artery disease, or non-end-stage chronic renal dysfunction. Acute coronary syndrome (unstable angina, non-ST-segment elevation myocardial infarction, and ST-segment elevation myocardial infarction) for which percutaneous coronary intervention (PCI) is indicated. (provided that dual antiplatelet therapy including aspirin is appropriate but the administration of other antiplatelet drugs in combination with aspirin is not suitable for the patient.) uuid:110802db-b3b5-4885-bb7f-90a135187a64 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68558 biolink:treats MONDO:0000990 PMID:41385096 "[{""id"":""uuid:0fb6eda2-6c51-4d39-b948-9d3cccce7980"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:537cd729-322c-4609-955c-07c59e8fc0ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of: Old myocardial infarction at especially high risk of developing atherothrombosis with at least one of the following risk factors: age of 65 years or older, with diabetes mellitus requiring drug therapy, history of two or more episodes of myocardial infarction, angiography- confirmed multivessel coronary artery disease, or non-end-stage chronic renal dysfunction. Acute coronary syndrome (unstable angina, non-ST-segment elevation myocardial infarction, and ST-segment elevation myocardial infarction) for which percutaneous coronary intervention (PCI) is indicated. (provided that dual antiplatelet therapy including aspirin is appropriate but the administration of other antiplatelet drugs in combination with aspirin is not suitable for the patient.) uuid:ecebbca3-e96e-4cb3-b606-d34f0fbc1416 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68558 biolink:treats MONDO:0041656 PMID:41385096 "[{""id"":""uuid:67c4a483-7211-401c-aba0-e84b32ae7660"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:63b937d3-ed2f-440a-99d3-d9978d82e5b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of: Old myocardial infarction at especially high risk of developing atherothrombosis with at least one of the following risk factors: age of 65 years or older, with diabetes mellitus requiring drug therapy, history of two or more episodes of myocardial infarction, angiography- confirmed multivessel coronary artery disease, or non-end-stage chronic renal dysfunction. Acute coronary syndrome (unstable angina, non-ST-segment elevation myocardial infarction, and ST-segment elevation myocardial infarction) for which percutaneous coronary intervention (PCI) is indicated. (provided that dual antiplatelet therapy including aspirin is appropriate but the administration of other antiplatelet drugs in combination with aspirin is not suitable for the patient.) uuid:047c5622-3706-413b-8bee-435ad42e210d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135939 biolink:treats HP:0007334 PMID:41385096 "[{""id"":""uuid:78213651-4bea-40b8-a5da-d39c8db25388"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7bf535d6-ce92-4853-9d2b-9285b22249a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the use as an adjunctive therapy with other antiepileptic drugs to treat partial seizures (including secondary generalized seizures) in patients with epilepsy who have not responded sufficiently to other antiepileptic drugs. uuid:56a3a95c-75ec-44e4-82ac-92629b57b4e5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76004 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:c097921e-a789-47d0-8cab-25fa3d759a5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cc73c0fd-1e72-43d6-9878-a521c1ff7b52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the prevention of relapse and for delaying the accumulation of physical disability in multiple sclerosis. [Orphan drug] uuid:87373713-2407-4e31-8295-89f4417a9283 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:BTY153760O biolink:treats MONDO:0022205 PMID:41385096 "[{""id"":""uuid:cc048736-b75e-4ec3-8c0b-a71ec9dd6938"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ec38bb96-57a2-49be-a4bb-2a18024ed91a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of plaque psoriasis, psoriatic arthritis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies. uuid:e219fd1c-112e-4509-955e-8b3044eddf1c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:BTY153760O biolink:treats UMLS:C0748052 PMID:41385096 "[{""id"":""uuid:47223947-2e41-4b54-b7f8-7053fcc5f140"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:42f823a3-1657-45d9-a178-d66789d06bed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of plaque psoriasis, psoriatic arthritis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies. uuid:b685f287-84f6-4609-b8ba-4ec98723e7db biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DPT0O3T46P biolink:treats UMLS:C4725093 PMID:41385096 "[{""id"":""uuid:69000c95-e914-4c99-a6f2-92e43d7c0523"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8488215b-3c36-460d-90ae-da7afd1f0b15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of unresectable melanoma. [Orphan drug] uuid:03bd1492-3087-4c49-9b11-b5f74cee99f3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:192761 biolink:treats MONDO:0000328 PMID:41385096 "[{""id"":""uuid:c3a26a44-f572-4aee-b458-771f6057cf83"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:484d0e56-29c6-4eac-9a89-8e4e9d9f8590"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the improvement of hyperphosphatemia in patients with chronic kidney disease who are receiving dialysis. uuid:06604abd-23e7-4660-9c45-6bff033ffeac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:192761 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:e021d02a-d6aa-4444-8a9f-3dfb12750024"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a6a476c8-b462-4bdf-b007-163fd7e1fcb0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the improvement of hyperphosphatemia in patients with chronic kidney disease who are receiving dialysis. uuid:bfd4778a-1e92-4466-9a6f-b7656a00f605 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:521033 biolink:treats MONDO:0005339 PMID:41385096 "[{""id"":""uuid:7bb04cf8-d75b-42cf-8a46-52e8fa1881fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8b27f7bb-1839-4d9b-8a23-6e95eadf736a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage in an additional dosage form, and a drug with a new indication and a new dosage, indicated for the treatment of the male pattern hair loss (androgenetic alopecia) in men. uuid:41cebd30-f474-444a-8df9-c3246e8c1aaf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:LKC0U3A8NJ biolink:treats MONDO:0005439 PMID:41385096 "[{""id"":""uuid:fbf2bc22-bacf-4d7e-b48c-49a5ea54ed6c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:92fffb68-9b3a-4199-be6e-7ded36264d7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of familial hypercholesterolemia and hypercholesterolemia (for use only in patients who are at higher risk of developing cardiovascular event and have not responded sufficiently to HMG- CoA reductase inhibitors). uuid:53a791af-8c7e-4a59-81ef-fb0ba965cf49 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9943 biolink:treats MONDO:0002050 PMID:41385096 "[{""id"":""uuid:1b221309-0561-4f45-a547-59656d9e18fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:12486eef-2aac-44d7-a8a3-32753550bf29"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of depression. uuid:2a266097-0d13-4573-8679-f2a40054ca89 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1651267 biolink:treats MONDO:0005607 PMID:41385096 "[{""id"":""uuid:9bc9ac7d-4a60-4d11-91b2-197bcf90489e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4953dd3a-d071-43a6-850c-fee279b330c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New combination drugs with a new active ingredient indicated for the relief of symptoms secondary to airway obstructive disorder in chronic obstructive pulmonary disease (chronic bronchitis, emphysema) (when a combination treatment of an inhaled long-acting anticholinergic and a long- acting beta-2 agonist is needed). uuid:c5d92431-22f1-4938-952b-ead712fd7226 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1651267 biolink:treats MONDO:0004849 PMID:41385096 "[{""id"":""uuid:f644bda8-c8b9-4381-a63a-94898ceadb98"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e0cabd5f-480f-42ea-ba39-333e1326fad3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New combination drugs with a new active ingredient indicated for the relief of symptoms secondary to airway obstructive disorder in chronic obstructive pulmonary disease (chronic bronchitis, emphysema) (when a combination treatment of an inhaled long-acting anticholinergic and a long- acting beta-2 agonist is needed). uuid:4d39a819-3876-48f7-8d71-ea1cc306469c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134735 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:d353ac9b-2f61-4cee-bf48-3bb303c4d4e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:57ecc3cb-4963-474a-8f21-c4d454f6bf6f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of type 2 diabetes mellitus. uuid:887d14d2-472c-48fe-8ade-0ff061b21e09 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:136048 biolink:treats MONDO:0001126 PMID:41385096 "[{""id"":""uuid:5ad4e701-fec8-4de1-ac1d-0a49c0d7f3ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a359b53e-f85c-4e01-b361-c20b1a1d5611"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of gastric ulcer, duodenal ulcer, reflux esophagitis, prevention of recurrence of gastric or duodenal ulcer in patients treated with low-dose aspirin, prevention of recurrence of gastric or duodenal ulcer in patients treated with non- steroidal anti-inflammatory drugs (NSAIDs), and aid to eradication of Helicobacter pylori in patients with gastric ulcer, duodenal ulcer, gastric MALT lymphoma, idiopathic thrombocytopenic purpura, Helicobacter pylori gastritis, and stomach after endoscopic treatment for early gastric cancer. uuid:3cfc1277-1a63-4eca-a01d-a49ce0682e26 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:136048 biolink:treats MONDO:0005412 PMID:41385096 "[{""id"":""uuid:012a7bfc-592b-4c6c-b652-1fa09fc4a709"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cad260b9-66df-4160-b971-6b976a37f1fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of gastric ulcer, duodenal ulcer, reflux esophagitis, prevention of recurrence of gastric or duodenal ulcer in patients treated with low-dose aspirin, prevention of recurrence of gastric or duodenal ulcer in patients treated with non- steroidal anti-inflammatory drugs (NSAIDs), and aid to eradication of Helicobacter pylori in patients with gastric ulcer, duodenal ulcer, gastric MALT lymphoma, idiopathic thrombocytopenic purpura, Helicobacter pylori gastritis, and stomach after endoscopic treatment for early gastric cancer. uuid:31f02c44-e0b3-4453-a700-8c4d0ef98262 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:136048 biolink:treats MONDO:0006896 PMID:41385096 "[{""id"":""uuid:20535572-0400-42c4-be05-7286199a4fa2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c5928f30-1d4a-4270-b101-210c7868bab0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of gastric ulcer, duodenal ulcer, reflux esophagitis, prevention of recurrence of gastric or duodenal ulcer in patients treated with low-dose aspirin, prevention of recurrence of gastric or duodenal ulcer in patients treated with non- steroidal anti-inflammatory drugs (NSAIDs), and aid to eradication of Helicobacter pylori in patients with gastric ulcer, duodenal ulcer, gastric MALT lymphoma, idiopathic thrombocytopenic purpura, Helicobacter pylori gastritis, and stomach after endoscopic treatment for early gastric cancer. uuid:ec60b09a-0ae1-44e0-a9fc-1e16a9806b70 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:136048 biolink:treats UMLS:C0343378 PMID:41385096 "[{""id"":""uuid:fd4b2faf-d45d-4335-b8ff-9a7ac04aa272"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2e3a4603-2569-4940-8f82-caffaa5aa57b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of gastric ulcer, duodenal ulcer, reflux esophagitis, prevention of recurrence of gastric or duodenal ulcer in patients treated with low-dose aspirin, prevention of recurrence of gastric or duodenal ulcer in patients treated with non- steroidal anti-inflammatory drugs (NSAIDs), and aid to eradication of Helicobacter pylori in patients with gastric ulcer, duodenal ulcer, gastric MALT lymphoma, idiopathic thrombocytopenic purpura, Helicobacter pylori gastritis, and stomach after endoscopic treatment for early gastric cancer. uuid:9f0136ac-f600-4399-bb84-e92a0a79d6e1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:136048 biolink:treats MONDO:0006226 PMID:41385096 "[{""id"":""uuid:c00deb81-ddb1-4b8c-aefe-0b86393ef6fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:04a7bb08-fabb-4a30-9872-87a554ff4f9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of gastric ulcer, duodenal ulcer, reflux esophagitis, prevention of recurrence of gastric or duodenal ulcer in patients treated with low-dose aspirin, prevention of recurrence of gastric or duodenal ulcer in patients treated with non- steroidal anti-inflammatory drugs (NSAIDs), and aid to eradication of Helicobacter pylori in patients with gastric ulcer, duodenal ulcer, gastric MALT lymphoma, idiopathic thrombocytopenic purpura, Helicobacter pylori gastritis, and stomach after endoscopic treatment for early gastric cancer. uuid:4021b34c-6118-45f5-9136-ea6fdcf5e640 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:136048 biolink:treats MONDO:0019098 PMID:41385096 "[{""id"":""uuid:2476df9c-5ccd-4b0e-a095-a3b0a4fddf4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:80a7ef83-bcc2-4662-8e56-059eb1457c4c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of gastric ulcer, duodenal ulcer, reflux esophagitis, prevention of recurrence of gastric or duodenal ulcer in patients treated with low-dose aspirin, prevention of recurrence of gastric or duodenal ulcer in patients treated with non- steroidal anti-inflammatory drugs (NSAIDs), and aid to eradication of Helicobacter pylori in patients with gastric ulcer, duodenal ulcer, gastric MALT lymphoma, idiopathic thrombocytopenic purpura, Helicobacter pylori gastritis, and stomach after endoscopic treatment for early gastric cancer. uuid:7a3b7d67-88f8-4b37-afdd-da89f9e1cbad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:136048 biolink:treats MONDO:0004716 PMID:41385096 "[{""id"":""uuid:8f7dfa41-8a2f-46e7-950c-46be115e4dd8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9761dc62-92d6-4438-8301-6c1ac24abd91"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of gastric ulcer, duodenal ulcer, reflux esophagitis, prevention of recurrence of gastric or duodenal ulcer in patients treated with low-dose aspirin, prevention of recurrence of gastric or duodenal ulcer in patients treated with non- steroidal anti-inflammatory drugs (NSAIDs), and aid to eradication of Helicobacter pylori in patients with gastric ulcer, duodenal ulcer, gastric MALT lymphoma, idiopathic thrombocytopenic purpura, Helicobacter pylori gastritis, and stomach after endoscopic treatment for early gastric cancer. uuid:106f5241-0d65-4e80-a0bc-c3d4c285e5c7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:83800 biolink:treats MONDO:0005354 PMID:41385096 "[{""id"":""uuid:42fef4e4-f8cf-4dd6-90f6-5ea4f5995eca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:641f9e37-7cc0-41bb-9d67-0937a644f651"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new active ingredients indicated for the improvement of viremia in patients with chronic hepatitis C or compensated cirrhosis type C in serogroup 1 (genotype 1) who are untreated and ineligible for, or are intolerant to therapy including interferon; or who did not respond to therapy including interferon. [Priority review] uuid:ef242ad8-3cc6-41f0-9908-6a7b74359da0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:83800 biolink:treats MONDO:0005155 PMID:41385096 "[{""id"":""uuid:b4041ce6-caf9-47c0-b289-f1ebc59118c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:aee5bbb7-5c9d-49c1-80d8-2cf3a9b67e03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new active ingredients indicated for the improvement of viremia in patients with chronic hepatitis C or compensated cirrhosis type C in serogroup 1 (genotype 1) who are untreated and ineligible for, or are intolerant to therapy including interferon; or who did not respond to therapy including interferon. [Priority review] uuid:2e2e4393-1d34-40c4-b095-f199a25631bd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1487516 biolink:treats MONDO:0005607 PMID:41385096 "[{""id"":""uuid:aff85601-8091-43dd-9398-51e32de4f42a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:99c0a23d-8d6d-497a-a1cc-7f9ed01d7345"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New combination drugs with a new active ingredient indicated for the relief of symptoms secondary to airway obstructive disorder in chronic obstructive pulmonary disease (chronic bronchitis, emphysema) (when a combination treatment of an inhaled long-acting anticholinergic and a long- acting beta-2 agonist is needed). uuid:6c2eb5fd-cd2d-48c8-911f-adf00471f89e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1487516 biolink:treats MONDO:0004849 PMID:41385096 "[{""id"":""uuid:e172ad6b-76d5-4732-99ca-15f86673fc22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3e3c06cc-4ce8-4883-834c-e79770c08b9d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New combination drugs with a new active ingredient indicated for the relief of symptoms secondary to airway obstructive disorder in chronic obstructive pulmonary disease (chronic bronchitis, emphysema) (when a combination treatment of an inhaled long-acting anticholinergic and a long- acting beta-2 agonist is needed). uuid:dd59a5ed-c2dd-453c-9c81-f57d57b23ef4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DLG4EML025 biolink:treats UMLS:C0406317 PMID:41385096 "[{""id"":""uuid:6c3a3c09-2f7e-4ff1-a242-a0eda92132e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d40ce313-bb38-413d-a34c-171ad447d0d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of plaque psoriasis and psoriatic arthritis in patients who have not responded sufficiently to conventional therapies. uuid:3091345e-d954-45e1-9d77-ac850afe71b5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:65346 biolink:treats MONDO:0005607 PMID:41385096 "[{""id"":""uuid:4d9935d6-1455-489c-9648-094f4bbb3764"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:12296437-56e6-4acc-a139-22a4d20556d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the relief of symptoms secondary to airway obstructive disorder in chronic obstructive pulmonary disease (chronic bronchitis, emphysema). uuid:ada8ffba-8879-4af7-a08d-c1d6c5a4a197 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:65346 biolink:treats MONDO:0004849 PMID:41385096 "[{""id"":""uuid:961cb898-26db-41f7-b377-d45307e44a33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:eb358c97-2d8b-44eb-96ba-5bf8363d8786"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the relief of symptoms secondary to airway obstructive disorder in chronic obstructive pulmonary disease (chronic bronchitis, emphysema). uuid:de80fb3e-1f31-4046-b27e-a2132471589f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:GE2T1418SV biolink:treats MONDO:0005607 PMID:41385096 "[{""id"":""uuid:6935fdf8-06cd-49f5-9731-14cc38c5bbde"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:07ccbd54-bd34-4b0c-adba-0466fc220802"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Other drugs with a new dosage indicated for the relief of symptoms secondary to airway obstructive disorder in chronic obstructive pulmonary disease (chronic bronchitis, emphysema). uuid:824d2a68-2c8c-4d3a-84fd-e908296b9b75 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:GE2T1418SV biolink:treats MONDO:0004849 PMID:41385096 "[{""id"":""uuid:15dbd254-994a-45ef-a974-6364ee95e547"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:78018745-0b19-4e95-862f-0b0dc0c54894"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Other drugs with a new dosage indicated for the relief of symptoms secondary to airway obstructive disorder in chronic obstructive pulmonary disease (chronic bronchitis, emphysema). uuid:a1daf393-e4fd-43b5-96a6-ce1f9114970c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4118932Z90 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:20cc6076-df03-4a7d-a94b-0ee6321b5408"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:72dcb6e8-9430-4ee8-94c9-08edea740a48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of type 2 diabetes mellitus. uuid:96e9e2fb-c500-484e-85d7-cf9b0980ff52 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90936 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:f30fa9e4-8258-43da-8e0e-c919a5f546f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ecdcf297-f738-4b9a-be31-f53b8752463b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of unresectable advanced/relapsed ALK fusion gene-positive non-small-cell lung cancer. [Orphan drug] uuid:88fbbe91-a3ab-441f-a9b3-1be3d87cfc8f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85994 biolink:treats MONDO:0002108 PMID:41385096 "[{""id"":""uuid:5d285ba5-75c7-4d6e-8b7f-a96a70438cc0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f67441ac-bf1c-48a7-82fb-94e15d4f9880"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of unresectable thyroid cancer. [Orphan drug] uuid:2ab761ba-2530-4899-aa9c-a38700ad6eee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3127 biolink:treats MONDO:0001134 PMID:41385096 "[{""id"":""uuid:c3e91428-75ca-4c5e-a87f-c495acc068d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2550bf1b-6f3c-41f2-b851-bb3f6e21bc24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of essential hypertension (mild to moderate). uuid:bdc7265e-1804-418f-9e48-9c7020045c55 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:87715 biolink:treats MONDO:0005542 PMID:41385096 "[{""id"":""uuid:f6d090c8-f64f-4b83-aa09-b677ac850a4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2f1557fd-d00b-4595-8ea7-126f06258f65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of the following ischemic heart diseases managed with percutaneous coronary intervention (PCI): acute coronary syndrome (unstable angina, non ST-segment elevation myocardial infarction, ST- segment elevation myocardial infarction), stable angina, old myocardial infarction. uuid:b3400332-0a9e-48d3-89b2-1f5b2c6a62ff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:87715 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:7a4bd0af-3110-4ce2-be6d-a77c0b4c9b7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f28e8cca-3df6-4974-969c-07e2f843b504"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of the following ischemic heart diseases managed with percutaneous coronary intervention (PCI): acute coronary syndrome (unstable angina, non ST-segment elevation myocardial infarction, ST- segment elevation myocardial infarction), stable angina, old myocardial infarction. uuid:9bba1928-072f-4d46-b57c-6b53d8b40de1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:87715 biolink:treats UMLS:C0155668 PMID:41385096 "[{""id"":""uuid:511ee90a-db4b-46a5-af5f-61091d21995c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5d95cc4f-cbc2-41cf-8957-1568ad9482f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of the following ischemic heart diseases managed with percutaneous coronary intervention (PCI): acute coronary syndrome (unstable angina, non ST-segment elevation myocardial infarction, ST- segment elevation myocardial infarction), stable angina, old myocardial infarction. uuid:bf77b0dd-7d4a-4e3f-89cc-61f7053df445 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71940 biolink:treats HP:0100518 PMID:41385096 "[{""id"":""uuid:96543361-c7d8-4557-bc70-f2429057bea1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fc701937-3c1d-4c28-b83e-ae36e7eb2a77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage in a new additional dosage form indicated for the treatment of dysuria associated with benign prostatic hypertrophy. uuid:fb3058e7-578b-44c7-b605-f9000d93ac9a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134724 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:9a8ae75b-0408-4100-8d7c-20aaeeece748"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a1c57469-f2a6-4224-ae8a-6fd31547a139"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of type 2 diabetes mellitus. uuid:1de739b3-ecb1-4342-bd92-8999b6133f76 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134725 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:d61bd0d4-14ef-43f7-94c7-43d13e9a0792"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:aaf11be0-02f8-4b88-a8a0-c36bbb53a15d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of type 2 diabetes mellitus. uuid:fbe48c8c-b4f8-4470-bbcf-5fb3d230debd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:136041 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:71d7756f-ab00-4ce1-8534-b1705dfdf71d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:85a449e2-4dbf-4a3c-b13e-45c788803aba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of type 2 diabetes mellitus. uuid:5582b667-76eb-4640-8cf8-d1d3b3c33c3a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1670307 biolink:treats MONDO:0005575 PMID:41385096 "[{""id"":""uuid:26de8d3c-1ff5-428a-ab40-ffaec19496ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ad5d2024-67b1-4f31-bf5f-214fd118e387"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New combination drugs with a new active ingredient indicated for the treatment of unresectable advanced or recurrent colorectal cancer (for use only if refractory or intolerant to standard therapies). uuid:5cd86951-458d-461b-bf3c-74ece8e9c625 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72296 biolink:treats HP:0002140 PMID:41385096 "[{""id"":""uuid:31c6e3f6-df5a-4988-b2f5-6ad9c8c8a114"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f5d35d7f-4242-4958-9107-6b1b1d064c51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for prevention of ischemic stroke and systemic embolism in patients with nonvalvular atrial fibrillation. uuid:441b06ca-b2cf-4960-849b-a205bbe113de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134966 biolink:treats HP:0032792 PMID:41385096 "[{""id"":""uuid:1286f27e-a288-4557-9736-17b76c394049"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0a7f0988-91fc-48c2-b801-e5c40dd6bd75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for use as a concomitant therapy with other antiepileptic drugs to treat tonic and atonic seizures in patients with Lennox-Gastaut syndrome who have not responded sufficiently to other antiepileptic drugs. [Orphan drug] uuid:a5eb17c5-5e3d-412c-89a5-476d48965f26 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134966 biolink:treats HP:0010819 PMID:41385096 "[{""id"":""uuid:cbe59149-071e-4ea9-a0ee-8d6225495735"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e32c0d89-a911-4223-8a47-8610fd68c816"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for use as a concomitant therapy with other antiepileptic drugs to treat tonic and atonic seizures in patients with Lennox-Gastaut syndrome who have not responded sufficiently to other antiepileptic drugs. [Orphan drug] uuid:665fee28-fa0e-439d-b38f-924d139bd4c2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:15C2VL427D biolink:treats HP:0031241 PMID:41385096 "[{""id"":""uuid:205183a4-6a22-4780-9edb-fc1fb339c5f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b5263172-d06a-483c-b8e7-c7750ef5ca8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of age-related macular degeneration associated with subfoveal choroidal neovascularization. uuid:f9b97abd-78c1-40f2-a297-bf6f2977f5cd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:167309 biolink:treats EFO:0801084 PMID:41385096 "[{""id"":""uuid:5b4f47fe-ac95-4576-a64c-2cbea3cea2b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2e09fb1d-9d79-4cc6-9bb1-974b40b671cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for achieving analgesia of moderate to severe pain associated with various types of cancer which can not be managed by treatment with other strong opioid analgesics. uuid:e809b06f-b78d-4b2f-9acd-959210b3b24b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135920 biolink:treats MONDO:0006624 PMID:41385096 "[{""id"":""uuid:f639f4c5-5e14-4a07-ac35-9ffb564f63e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3f3df37e-8b97-4457-8ecd-fb7474082794"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of urinary urgency, urinary frequency, and urge urinary incontinence associated with overactive bladder. uuid:58d762bb-1a87-49e9-9098-3a16329c3df9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135920 biolink:treats HP:0100515 PMID:41385096 "[{""id"":""uuid:8dc20f7d-9cf3-4a07-881b-4669af1e959d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7cb14e6b-84ac-49a0-b957-69daaf763c59"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of urinary urgency, urinary frequency, and urge urinary incontinence associated with overactive bladder. uuid:9f1b27bc-26ec-4522-9adb-592249668d65 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31689 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:070268df-b6b1-449a-a58a-e22ab37f7c3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1c494f4c-78cc-4ecc-94d8-b462cd79cacc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of rheumatoid arthritis. uuid:2c250501-e6ed-4663-a224-360be8213878 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:136043 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:64a66930-e9e6-410b-9551-8ac442d8738a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8e2dd96c-9e30-4872-89be-9324730c1522"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of type 2 diabetes mellitus. uuid:776b3074-f92e-4ad3-be51-cb4ab746b112 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8868 biolink:treats MONDO:0005298 PMID:41385096 "[{""id"":""uuid:79276f2e-5c24-4a1f-8a7a-29f060e912bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:15e2f6dd-712d-47a3-b2a2-ca0c8de673b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage in a new additional dosage form. These drugs are indicated for the treatment of osteoporosis. uuid:f8a4c9f2-76b1-45ac-9ab2-245daa76a1fa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85973 biolink:treats MONDO:0005399 PMID:41385096 "[{""id"":""uuid:e72e924d-425b-41ac-995d-a3669fe9f964"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:27f3c2ff-9174-4669-a9dc-7869f5b67e4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for prevention of venous thromboembolism in patients undergoing orthopedic surgery of lower limbs including total knee arthroplasty, total hip arthroplasty and hip fracture surgery. uuid:35916e44-54a0-49c1-97db-00cb14f2434d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68579 biolink:treats HP:0002140 PMID:41385096 "[{""id"":""uuid:6838b8ba-79d0-42e4-9a42-63fdb291a1ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:98a8b128-ecd9-4752-825f-be7f3d80ad15"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the prevention of ischemic stroke and systemic embolism in patients with nonvalvular atrial fibrillation. uuid:79241da4-d408-415d-8b6d-e5328db3815f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:474180 biolink:treats MONDO:0044067 PMID:41385096 "[{""id"":""uuid:29333dbe-c175-40c9-bf10-351645f12bc0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:42de4e7a-e29f-435d-9068-1698d05c2360"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of febrile neutropenia suspected of a fungal infection and fungal infections due to Candida or Aspergillus (esophageal candidiasis, invasive candidiasis, aspergillosis). uuid:351d2b32-5811-471f-942a-cfda57136304 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:474180 biolink:treats MONDO:0005657 PMID:41385096 "[{""id"":""uuid:89ea51b9-41b0-4e5b-a322-cbc0912bdb3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5a574e3e-e3ad-471b-ae72-d0be3a431ee5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of febrile neutropenia suspected of a fungal infection and fungal infections due to Candida or Aspergillus (esophageal candidiasis, invasive candidiasis, aspergillosis). uuid:9a7cd62d-a29a-4051-bd79-e46ef9c3be74 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:65349 biolink:treats MONDO:0006624 PMID:41385096 "[{""id"":""uuid:35980f99-fc7b-4886-adf9-bf190a417192"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3fc2a495-491b-4d1f-af00-a6d5442ffe2b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of urinary urgency, urinary frequency, and urge urinary incontinence associated with overactive bladder. uuid:b87acdc1-3d29-4913-af0d-50eacf03034a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:64759 biolink:treats MONDO:0000022 PMID:41385096 "[{""id"":""uuid:23633a06-e51a-4cbf-a078-8e97e14f0baf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7d108a0c-5f32-43c4-af06-9637c5f220d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new route of administration indicated for the treatment of nocturnal enuresis associated with decreased urine osmolality or urinary specific gravity. uuid:af756321-8112-4dfa-96da-37e555db8451 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:40SGR63TGL biolink:treats MONDO:0005298 PMID:41385096 "[{""id"":""uuid:a1ea9970-02a2-4d1f-b8ac-781a67d5e55b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:223a8a24-8c7d-4fcf-930a-7b2d4da4c3a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage and an additional dosage form indicated for the treatment of osteoporosis. uuid:71bf2a5b-0c8c-4372-a924-fd5c0c19840f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:659877 biolink:treats MONDO:0005198 PMID:41385096 "[{""id"":""uuid:11cb0793-438a-458f-a4bd-c87a9a549a81"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f7bdb424-e301-439e-9d15-bf834d053921"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the prevention of cervical cancer and its precursor lesions, vulvar intraepithelial neoplasia, vaginal intraepithelial neoplasia, and condyloma acuminatum caused by infection with human papillomavirus types 6, 11, 16 and 18. uuid:9f6e53d8-67d3-430b-a747-5dc770d32d9f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:659877 biolink:treats UMLS:C0346208 PMID:41385096 "[{""id"":""uuid:a9628a9b-0ed0-48db-826d-7f906be57423"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8dccb3b5-c26d-49d7-9053-9983f48d90c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the prevention of cervical cancer and its precursor lesions, vulvar intraepithelial neoplasia, vaginal intraepithelial neoplasia, and condyloma acuminatum caused by infection with human papillomavirus types 6, 11, 16 and 18. uuid:9c68226e-94e6-455a-8950-2470f4dc86d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:70746 biolink:treats HP:0002140 PMID:41385096 "[{""id"":""uuid:0244f541-ab09-4a2b-9fc0-fddf4fd207b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7d1f6bc9-de2d-4db0-a7b6-69f2864a141a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for prevention of ischemic stroke and systemic embolism in patients with nonvalvular atrial fibrillation. uuid:56dc8937-4a68-44a1-acc9-b87a89037f30 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:61033 biolink:treats UMLS:C3873363 PMID:41385096 "[{""id"":""uuid:75d735cc-e3d6-45f5-b647-a11b098b348d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:01e94652-040f-4e56-9583-d955e8f509e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and new dosages for the treatment of acute pulmonary thromboembolism and acute deep vein thrombosis. uuid:e6905f15-0226-4ce5-b28f-f82bbb3ab495 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75722 biolink:treats EFO:0801084 PMID:41385096 "[{""id"":""uuid:6d987b1f-cc45-4dc1-b95b-21c36e2e64c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bcdf5961-7cbb-45fb-a06f-f7d2d7bccfc8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new route of administration indicated for analgesia in various types of cancer with mild to moderate pain. uuid:94536da7-a917-4be2-ad42-02edd989de5a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0024355 PMID:41385096 "[{""id"":""uuid:6fdc3b46-d775-4b06-b4d5-a2d9e8551387"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:33202697-3812-40d3-bd47-e22e7c815352"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new route of administration indicated for the treatment of pneumonia, secondary infection of chronic respiratory disease, typhoid, paratyphoid, anthrax, brucellosis, plague, tularemia and Q fever. uuid:38ae46b5-31cf-4c5c-ba13-91795d5afe6f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0005619 PMID:41385096 "[{""id"":""uuid:bebd6d5c-e0ff-4c0b-b173-30963970184d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:acd5cd4a-b9dc-4eb0-a644-4115d2060035"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new route of administration indicated for the treatment of pneumonia, secondary infection of chronic respiratory disease, typhoid, paratyphoid, anthrax, brucellosis, plague, tularemia and Q fever. uuid:932aeeeb-5b8c-464f-a1c1-dd8f1724670c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0018626 PMID:41385096 "[{""id"":""uuid:91754757-280d-4f72-bb3b-69f78f69220b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:604751f5-0a6c-43ad-a1c0-47adf49a9d04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new route of administration indicated for the treatment of pneumonia, secondary infection of chronic respiratory disease, typhoid, paratyphoid, anthrax, brucellosis, plague, tularemia and Q fever. uuid:f3acfb89-aa0c-4fd0-8188-70de8953e03d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0005119 PMID:41385096 "[{""id"":""uuid:a70f7dbb-1564-4867-8041-b8e04a0f7624"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:263be9f9-4c89-4dfd-ac02-bf669203d750"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new route of administration indicated for the treatment of pneumonia, secondary infection of chronic respiratory disease, typhoid, paratyphoid, anthrax, brucellosis, plague, tularemia and Q fever. uuid:7f545d73-1d39-4a4c-97f3-a44145571f70 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0005683 PMID:41385096 "[{""id"":""uuid:f977a112-501b-45d3-9e96-26326f2af49a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5832c108-1931-44c1-a6a5-aed383ad76b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new route of administration indicated for the treatment of pneumonia, secondary infection of chronic respiratory disease, typhoid, paratyphoid, anthrax, brucellosis, plague, tularemia and Q fever. uuid:c24931e1-acf2-481f-8b16-5a678ba3f841 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0018077 PMID:41385096 "[{""id"":""uuid:0acc597f-157d-45d8-b220-a0787a42bcda"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:432e9eee-bca3-4a36-a8d4-8a6d13d78904"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new route of administration indicated for the treatment of pneumonia, secondary infection of chronic respiratory disease, typhoid, paratyphoid, anthrax, brucellosis, plague, tularemia and Q fever. uuid:37e3ee4d-26e1-4e7a-8bd2-31986872db46 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0019186 PMID:41385096 "[{""id"":""uuid:072549f8-ac0c-4732-8594-953b140bfec7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:568b709c-8168-4a86-b83c-d5a5b47b9cc9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new route of administration indicated for the treatment of pneumonia, secondary infection of chronic respiratory disease, typhoid, paratyphoid, anthrax, brucellosis, plague, tularemia and Q fever. uuid:2a426003-b100-4557-8c9c-bc1b5cd265c7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:73927 biolink:treats MONDO:0005298 PMID:41385096 "[{""id"":""uuid:df849ee0-fb9b-459d-9170-c31ad114cb5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f67b6fe4-4302-4aaf-b6cc-9cd985ac9014"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of osteoporosis. uuid:c18d2b65-b522-44a6-9807-4ecf28482715 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6A901E312A biolink:treats MONDO:0005575 PMID:41385096 "[{""id"":""uuid:8398ff1b-258f-424b-942f-42fd1443c487"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f2fdc6f9-a213-4e8e-8e0f-41c4dd8d960c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of unresectable, advanced or recurrent colorectal cancer with wild-type KRAS. uuid:ea24bf79-0816-4bad-9711-330f9052ed88 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6950 biolink:treats MONDO:0002050 PMID:41385096 "[{""id"":""uuid:257ab4d0-3c55-4339-94c1-5ce999c325e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:95f935cf-8f52-457a-87d3-2032cf1c9574"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of depression. uuid:82f6fd69-dc84-4db0-8127-9d49e877df30 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85202 biolink:treats MONDO:0005812 PMID:41385096 "[{""id"":""uuid:a056e030-da16-4215-8f69-631c8f59489f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:45fe7fcb-3e0f-45d6-be4e-9f006d136616"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of influenza A or B virus infections. uuid:74597846-69f2-46c4-9d21-b27ccac159c2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:327148 biolink:treats MONDO:0100470 PMID:41385096 "[{""id"":""uuid:e3b7a446-30fc-4e8a-9fe3-607f4080d1b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f05168e2-376f-4b8d-ad63-6849c454be94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New combination drugs indicated for the treatment of bronchial asthma (when a combination treatment of an inhaled steroid and a long-acting beta-2 agonist is needed). uuid:3e2816da-5fd3-4b03-a3f3-875c614f539b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:08GY9K1EUO biolink:treats HP:0002149 PMID:41385096 "[{""id"":""uuid:f2cc273f-9fb3-48c7-8bf3-65d0679cb92b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:11e0e1b4-9555-4989-853d-e7c4b36fbd12"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of hyperuricemia in patients receiving cancer chemotherapy. uuid:c06aac1e-db43-440f-8db0-99e7352401a9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135156 biolink:treats MONDO:0005052 PMID:41385096 "[{""id"":""uuid:17eadb5b-39c7-4043-9965-3c9d4cdcd670"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2034c7c6-f9cf-444b-ae76-2ca1938b575b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and new dosages for the treatment of diarrhea-predominant irritable bowel syndrome in men. uuid:5239742d-e679-4dc0-bcd1-ef6702170225 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:0M78EU4V9H biolink:treats MONDO:0000328 PMID:41385096 "[{""id"":""uuid:26053c36-8ef1-451f-8701-574b192c2ab5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8cadc721-c27e-4e00-b7a5-f9a6948e45b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs containing a new active ingredient indicated for the treatment of hyperphosphatemia in dialysis patients with chronic renal failure. uuid:361ecf66-5041-44bd-adc5-49e651c0ad27 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:0M78EU4V9H biolink:treats MONDO:0024327 PMID:41385096 "[{""id"":""uuid:6631739b-a159-4f91-9ebd-47d5114f0024"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3e0511ec-d6be-463c-aabb-ecc433232876"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs containing a new active ingredient indicated for the treatment of hyperphosphatemia in dialysis patients with chronic renal failure. uuid:c7eaade9-9851-4ec8-9c9a-be83719fccf5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0250480 biolink:treats MONDO:0700217 PMID:41385096 "[{""id"":""uuid:29607bd9-41df-4e86-8c3f-9a63ca0b2a68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6398b3b5-c85b-458e-80ac-25e636815635"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New combination drugs indicated for the treatment of septicemia, pneumonia, pyelonephritis, and complicated cystitis. uuid:9262e608-796b-48ee-8cc7-5829d3a200a1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0250480 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:eaf50a6e-2c4f-4a47-865a-a736afd6fd5e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d0ea4911-7574-4e36-a25a-a2acd647d120"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New combination drugs indicated for the treatment of septicemia, pneumonia, pyelonephritis, and complicated cystitis. uuid:68482d97-620b-492e-9c21-859d04e3f562 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0250480 biolink:treats MONDO:0006939 PMID:41385096 "[{""id"":""uuid:5ca578bc-db6c-4204-9f18-298a2327ca96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b6834d22-5503-4824-aec3-03f15cfc98af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New combination drugs indicated for the treatment of septicemia, pneumonia, pyelonephritis, and complicated cystitis. uuid:2c1db432-4de4-44e0-a779-518624ecc3a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49375 biolink:treats HP:0004848 PMID:41385096 "[{""id"":""uuid:3dfdb3dd-27df-4a51-bdf5-663a60f49069"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0c84306e-eb72-41c2-aa5a-f7125c4dd749"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs containing a new active ingredient indicated for the treatment of 1) imatinib-resistant chronic myelogenous leukemia and 2) recurrent or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia. [Orphan drug] uuid:53cf9b21-077f-46da-afc2-cfe0955a0695 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31270 biolink:treats MONDO:0015924 PMID:41385096 "[{""id"":""uuid:8968a6cc-aafe-43f1-b357-6d12edb622fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a314d545-6aae-4cc1-a304-ebba8e109f7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and dosage and in a new dosage form for the treatment of pulmonary arterial hypertension. [Priority review] uuid:a7a0ee4e-4011-481f-8917-83858340b295 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3437 biolink:treats MONDO:0005041 PMID:41385096 "[{""id"":""uuid:666d3beb-7646-48de-90b3-e527a7b8408f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:06d260df-136b-4bcb-92ce-333550727726"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs in a new dosage form indicated for the treatment of glaucoma and ocular hypertension. uuid:fb25f3e7-8de5-4d88-94c6-bd04a0ded852 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3437 biolink:treats HP:0007906 PMID:41385096 "[{""id"":""uuid:d4ec134e-acf0-4ce5-ad73-6d63f121f57a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e832cf54-ff01-4ee9-9da0-167fec0280fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs in a new dosage form indicated for the treatment of glaucoma and ocular hypertension. uuid:35fa0c8a-0d2d-42bb-ad41-ab55e6f02e8c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4304 biolink:treats MONDO:0001218 PMID:41385096 "[{""id"":""uuid:042342ce-67a1-4b65-96a6-f2a57ecba251"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3226d457-ba7a-4c75-86a3-664e6c6956f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, infections secondary to chronic respiratory disease, cystitis, pyelonephritis, urethritis, cervicitis, otitis media, sinusitis, periodontal inflammation, pericoronitis and jaw inflammation. uuid:7b2afc5b-f002-4a9d-8206-68e38f31cd13 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4304 biolink:treats MONDO:0001039 PMID:41385096 "[{""id"":""uuid:94801968-0740-4dfe-a4ff-3ffb5e3b102f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a2daa5ec-0072-4d84-82a3-30b6475c8d6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, infections secondary to chronic respiratory disease, cystitis, pyelonephritis, urethritis, cervicitis, otitis media, sinusitis, periodontal inflammation, pericoronitis and jaw inflammation. uuid:f995f743-a334-413f-aeb6-203e59c852bd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4304 biolink:treats UMLS:C0877267 PMID:41385096 "[{""id"":""uuid:3ced7c8e-d5e5-4494-b72d-57b1f4c8f199"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ad44b4bb-3ed8-48a6-adef-45d25cfe9a7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, infections secondary to chronic respiratory disease, cystitis, pyelonephritis, urethritis, cervicitis, otitis media, sinusitis, periodontal inflammation, pericoronitis and jaw inflammation. uuid:e399b499-56fc-4bcb-9eac-9ccdacad7ddd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4304 biolink:treats MONDO:0005906 PMID:41385096 "[{""id"":""uuid:652d117a-1dc1-42d4-8417-5a3156c72cd0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d0edb313-cf44-4105-b875-ce9fd9abb951"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, infections secondary to chronic respiratory disease, cystitis, pyelonephritis, urethritis, cervicitis, otitis media, sinusitis, periodontal inflammation, pericoronitis and jaw inflammation. uuid:e735e108-ad52-4d6c-885d-5dfcb07b70ef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4304 biolink:treats HP:0012388 PMID:41385096 "[{""id"":""uuid:998a98d8-8905-4cd4-b54f-32f6c5fb1c58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2045992c-17c0-491e-8d32-fab43001969c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, infections secondary to chronic respiratory disease, cystitis, pyelonephritis, urethritis, cervicitis, otitis media, sinusitis, periodontal inflammation, pericoronitis and jaw inflammation. uuid:240dd554-6f3d-48da-89ce-e5048b1b841b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4304 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:7dfa8c8d-3a53-424c-be41-90cca15aac8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b1109877-61a8-4120-a389-aa954c4294a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, infections secondary to chronic respiratory disease, cystitis, pyelonephritis, urethritis, cervicitis, otitis media, sinusitis, periodontal inflammation, pericoronitis and jaw inflammation. uuid:55b416e0-9821-4e98-8af1-d97a1c55b3f2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4304 biolink:treats MONDO:0006032 PMID:41385096 "[{""id"":""uuid:8540ed0e-e6dc-4e75-a322-441d27e781c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ed23d6e0-5b45-48b6-a32c-0a497b380f8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, infections secondary to chronic respiratory disease, cystitis, pyelonephritis, urethritis, cervicitis, otitis media, sinusitis, periodontal inflammation, pericoronitis and jaw inflammation. uuid:aa9ab220-0cb8-4c0b-b750-3066aa4ea1cd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4304 biolink:treats MONDO:0006939 PMID:41385096 "[{""id"":""uuid:1928f9f8-06db-4ed1-9466-cca806b22fcd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e41c4251-98b4-400a-ba50-d2ad28c6a1aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, infections secondary to chronic respiratory disease, cystitis, pyelonephritis, urethritis, cervicitis, otitis media, sinusitis, periodontal inflammation, pericoronitis and jaw inflammation. uuid:c8abe70f-20db-479e-8b0d-17c7afab3a3b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4304 biolink:treats MONDO:0005297 PMID:41385096 "[{""id"":""uuid:062e0ec0-033c-4ec2-9106-d6454bd5014f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b26e9e4a-db53-47be-8545-608373d8c9f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, infections secondary to chronic respiratory disease, cystitis, pyelonephritis, urethritis, cervicitis, otitis media, sinusitis, periodontal inflammation, pericoronitis and jaw inflammation. uuid:025eec5e-8ec8-4f00-8311-69e24364db7e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4304 biolink:treats MONDO:0002345 PMID:41385096 "[{""id"":""uuid:0653c41c-5b42-43e2-a116-239dc972f917"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b3cdf121-1410-48d7-807f-65c36176f8f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, infections secondary to chronic respiratory disease, cystitis, pyelonephritis, urethritis, cervicitis, otitis media, sinusitis, periodontal inflammation, pericoronitis and jaw inflammation. uuid:0a17128f-a293-4eb4-99f0-a7725a1e7575 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4304 biolink:treats MONDO:0005441 PMID:41385096 "[{""id"":""uuid:3c9560d7-5285-4da5-baee-6955c8d7a7f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:32015b1e-be7d-4637-9375-a79d6b620ccb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, infections secondary to chronic respiratory disease, cystitis, pyelonephritis, urethritis, cervicitis, otitis media, sinusitis, periodontal inflammation, pericoronitis and jaw inflammation. uuid:01dda495-4888-4314-8c14-ccdde7a3cce2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4304 biolink:treats MONDO:0005961 PMID:41385096 "[{""id"":""uuid:a555c844-96bd-4199-8686-8739476191c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:728b188f-3bf4-42ab-a1ab-6c7fce17b796"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, infections secondary to chronic respiratory disease, cystitis, pyelonephritis, urethritis, cervicitis, otitis media, sinusitis, periodontal inflammation, pericoronitis and jaw inflammation. uuid:cc864341-9134-4b88-99be-392466a162a0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4304 biolink:treats UMLS:C3495798 PMID:41385096 "[{""id"":""uuid:784efed9-b10f-4ff6-9ecc-890100f765db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:af5ed064-a577-416e-a29f-ee179ce3ab75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, infections secondary to chronic respiratory disease, cystitis, pyelonephritis, urethritis, cervicitis, otitis media, sinusitis, periodontal inflammation, pericoronitis and jaw inflammation. uuid:5ae948d0-26d6-4a10-a496-a93467bfd716 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4304 biolink:treats MONDO:0006899 PMID:41385096 "[{""id"":""uuid:80671f03-cb82-4b8b-b284-e27c93e00878"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ee01051f-a290-420f-9367-6359f82c57c0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, infections secondary to chronic respiratory disease, cystitis, pyelonephritis, urethritis, cervicitis, otitis media, sinusitis, periodontal inflammation, pericoronitis and jaw inflammation. uuid:fd480dbd-41f8-4b96-b2cd-e530aa84a66e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4304 biolink:treats UMLS:C0854217 PMID:41385096 "[{""id"":""uuid:8c4ca0aa-45a8-4dd7-9168-1fc255b6741d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:615ef0eb-ea84-401d-a770-523263fe12bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug containing a new active ingredient indicated for the treatment of laryngopharyngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, infections secondary to chronic respiratory disease, cystitis, pyelonephritis, urethritis, cervicitis, otitis media, sinusitis, periodontal inflammation, pericoronitis and jaw inflammation. uuid:6b0218b5-0cf6-4e73-9de0-eb04506e1ba2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:62984 biolink:treats MONDO:0010200 PMID:41385096 "[{""id"":""uuid:d93fc131-fc69-4f0e-876f-5cc6c64e48cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:69df1eb7-c07d-423c-850c-b3471e55c45b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs containing a new active ingredient indicated for the treatment of Wilson’s disease (hepatolenticular degeneration). [Orphan drug] uuid:44721a29-f0d0-48de-854f-ec7b10760db2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:92002593 biolink:treats MONDO:0018908 PMID:41385096 "[{""id"":""uuid:48638020-7ae2-423c-9b6a-c886204499b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:52a8796c-f01f-40a6-84d9-f5c0077af9e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] 1: A drug containing a new active ingredient indicated for the treatment of relapsed or refractory, CD20-positive lyphomas of the following: low-grade B-cell non-Hodgkin’s lymphoma and mantle cell lymphoma. 2: A drug containing a new active ingredient indicated for determining the site of ibritumomab tiuxetan accumulation. [Orphan drug] uuid:70358b56-a69d-4944-8384-1bb9035f7713 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:92002593 biolink:treats MONDO:0018876 PMID:41385096 "[{""id"":""uuid:8689560a-4269-4fdd-8935-05543f68834b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1a4f05c5-a5c8-46a4-9707-8ad5fd45edb4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] 1: A drug containing a new active ingredient indicated for the treatment of relapsed or refractory, CD20-positive lyphomas of the following: low-grade B-cell non-Hodgkin’s lymphoma and mantle cell lymphoma. 2: A drug containing a new active ingredient indicated for determining the site of ibritumomab tiuxetan accumulation. [Orphan drug] uuid:8b5ee8c0-aba9-40a6-bce5-7232e5f42a0b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135694 biolink:treats HP:0002902 PMID:41385096 "[{""id"":""uuid:51b8b853-7af6-485a-8563-4552187a3d3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a49cfe1a-afbe-4073-9b87-5ef345eb03de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for improvement of hyponatremia in syndrome of inappropriate secretion of antidiuretic hormone due to paraneoplastic syndrome of inappropriate antidiuretic hormone secretion (used only when conventional therapies are not sufficiently effective). [Orphan Drug] uuid:eafeb98e-f051-46e0-8191-3f5369f779f5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135694 biolink:treats MONDO:0006802 PMID:41385096 "[{""id"":""uuid:85163470-a154-403b-b719-8aa0d9a7a1e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:12149f81-dc7f-45fb-89bc-1e82f21b2dd2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for improvement of hyponatremia in syndrome of inappropriate secretion of antidiuretic hormone due to paraneoplastic syndrome of inappropriate antidiuretic hormone secretion (used only when conventional therapies are not sufficiently effective). [Orphan Drug] uuid:ab9fca95-0908-4d20-8916-3ca6b9a24083 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9622 biolink:treats MONDO:0006624 PMID:41385096 "[{""id"":""uuid:202ac297-dff5-49e5-afcd-544777bf20b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2d578750-e444-45ba-8bab-c12d1101debe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for treatment of urinary urgency, urinary frequency, and urge urinary incontinence associated with overactive bladder. uuid:4e879218-000d-42c5-91f8-7097a1ff1b3e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9622 biolink:treats HP:0100515 PMID:41385096 "[{""id"":""uuid:43350edb-83b7-4407-aaea-748d94eb2a27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4d03af30-0804-453c-a0bd-9fbe5ddcf842"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for treatment of urinary urgency, urinary frequency, and urge urinary incontinence associated with overactive bladder. uuid:7dd52f49-7d36-48b6-8b2a-30a295a00f0e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77573 biolink:treats MONDO:0004785 PMID:41385096 "[{""id"":""uuid:db1f0029-899e-44f4-baa0-df1c6d227300"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:83329035-437e-4255-b4a3-0fba80d2183a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new route of administration (eye drops) indicated for the treatment of blepharitis, dacryoadenitis, hordeolum, conjunctivitis, inflammation of the tarsal glands, inflammation of the cornea (including corneal ulcer), and aseptic treatment during ophthalmic surgery. uuid:8b8bfb57-0281-451e-8cfd-711d2f0b6d1e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77573 biolink:treats MONDO:0004804 PMID:41385096 "[{""id"":""uuid:cfc29cfe-0bfb-4411-abdb-38707e60bb49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a88ac0a6-d50b-4e78-911c-e9fbdb06e7a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new route of administration (eye drops) indicated for the treatment of blepharitis, dacryoadenitis, hordeolum, conjunctivitis, inflammation of the tarsal glands, inflammation of the cornea (including corneal ulcer), and aseptic treatment during ophthalmic surgery. uuid:6d3c07fd-d698-442c-8207-f422f59664dd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77573 biolink:treats MONDO:0005800 PMID:41385096 "[{""id"":""uuid:3b3702b6-cc22-47f1-9025-9ae08795aa77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:57a43ee3-5e84-4df7-8c94-25d8dc46b0a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new route of administration (eye drops) indicated for the treatment of blepharitis, dacryoadenitis, hordeolum, conjunctivitis, inflammation of the tarsal glands, inflammation of the cornea (including corneal ulcer), and aseptic treatment during ophthalmic surgery. uuid:08e5993c-bab8-492e-86c1-b906bada754d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77573 biolink:treats MONDO:0003799 PMID:41385096 "[{""id"":""uuid:ae64d629-dd1b-4e23-a27f-122a39023a8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:204ade56-48e0-4514-9ea7-ec5351e0df8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new route of administration (eye drops) indicated for the treatment of blepharitis, dacryoadenitis, hordeolum, conjunctivitis, inflammation of the tarsal glands, inflammation of the cornea (including corneal ulcer), and aseptic treatment during ophthalmic surgery. uuid:231d8510-3b0e-47e4-bf90-7f342ef0b510 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77573 biolink:treats MONDO:0003085 PMID:41385096 "[{""id"":""uuid:f92ed1fc-8233-4554-ae70-bedffa39429b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1b05e483-4300-44b1-ac30-754436c5254f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new route of administration (eye drops) indicated for the treatment of blepharitis, dacryoadenitis, hordeolum, conjunctivitis, inflammation of the tarsal glands, inflammation of the cornea (including corneal ulcer), and aseptic treatment during ophthalmic surgery. uuid:6bad9e6d-65f1-4090-9f1b-8912e425fbb0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77573 biolink:treats MONDO:0004577 PMID:41385096 "[{""id"":""uuid:5d289383-0a80-40d7-9d24-02f78aa51f95"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:73eceac2-942e-4ea9-bb3c-08d77f76d7b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new route of administration (eye drops) indicated for the treatment of blepharitis, dacryoadenitis, hordeolum, conjunctivitis, inflammation of the tarsal glands, inflammation of the cornea (including corneal ulcer), and aseptic treatment during ophthalmic surgery. uuid:76a98d01-0425-4e77-bfac-2762fe989c25 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49135 biolink:treats MONDO:0004992 PMID:41385096 "[{""id"":""uuid:80ca2438-796c-4d53-8b0e-a7eb913afca8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:af7617f5-3737-4b23-a5b5-442eea6a21fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs containing a new active ingredient used for making a diagnosis of malignant tumors accompanied by accelerated glucose metabolism, ischemic heart diseases or epilepsy uuid:02ae6b2a-3b86-4c35-80a8-22dd6f28bc2c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49135 biolink:treats MONDO:0024644 PMID:41385096 "[{""id"":""uuid:def28d4c-61fd-4064-bc52-5928ede4fc8e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d0df8880-fc39-488d-a8d0-20e66d9b1fa6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs containing a new active ingredient used for making a diagnosis of malignant tumors accompanied by accelerated glucose metabolism, ischemic heart diseases or epilepsy uuid:7fe9b881-509f-48db-9858-ea9ed103bec3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:49135 biolink:treats MONDO:0005027 PMID:41385096 "[{""id"":""uuid:16786cbe-e75b-4604-bd0f-a24de29144ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:953d34f7-e61e-431e-af78-9863dff2b0a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs containing a new active ingredient used for making a diagnosis of malignant tumors accompanied by accelerated glucose metabolism, ischemic heart diseases or epilepsy uuid:3e3e60ee-0ce0-42f2-ba7a-d5425d091aa4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16335 biolink:treats MONDO:0005267 PMID:41385096 "[{""id"":""uuid:7d0775f5-1d0e-4fcc-b615-9ede48c7577d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:16148714-c308-4351-a7a1-d68b6624f7aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs containing a new active ingredient used for load induction to make a diagnosis of heart disease based on myocardial perfusion scintigraphy in patients unable to tolerate sufficient exercise load uuid:a3ead50f-01ae-4678-99e1-3b944ee75eb7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32181 biolink:treats MONDO:0012883 PMID:41385096 "[{""id"":""uuid:a5e9af41-755c-45d6-b4fb-161281e9b064"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:80ccb955-ef5a-4a38-8e1c-861babbca4e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs containing a new active ingredient indicated for the treatment of acute promyelocytic leukemia [Orphan drug] uuid:211c1cb3-ca52-46e6-a37b-b4ee96d6c4b1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:142432 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:bfc6f967-e6b7-4bb1-ae2e-321de7a1abab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0579fa27-ff35-4ca4-93f6-456e2172eaa6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of chronic heart failure (for use only in patients receiving standard treatment of chronic heart failure). uuid:b6daf8da-fff9-4d44-8474-557963ff5185 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16684 biolink:treats HP:0006986 PMID:41385096 "[{""id"":""uuid:9945e6eb-20f7-473b-b017-2397eccab4a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3848b088-6a3c-4886-bd8b-dfdd76763101"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of upper limb spasticity. uuid:e37c621f-ff0c-492a-aa6b-b8c0d64d7663 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1721551 biolink:treats MONDO:0100470 PMID:41385096 "[{""id"":""uuid:eed2f191-cf07-49a5-849e-62ebd9fc1319"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:885d8427-568e-4010-8a6c-0922f3d4af4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New combination drugs with a new active ingredient indicated for the treatment of bronchial asthma (when a combination treatment of an inhaled steroid and a long- acting beta-2 agonist is needed). uuid:aaaf7bcb-6e1c-4c02-a432-da82dbc63861 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:FYS6T7F842 biolink:treats MONDO:0022205 PMID:41385096 "[{""id"":""uuid:1f6f72d9-0f0e-4710-9f5f-9d7711f2e339"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:10f9b9ff-eb02-4aec-91f5-3a895a733a90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Follow-on biologics indicated for the treatment of rheumatoid arthritis (including the prevention of structural joint damage), and the treatment of the following diseases in patients who have not responded sufficiently to conventional treatments; polyarticular- course juvenile idiopathic arthritis, plaque psoriasis, psoriatic arthritis, pustular psoriasis, ankylosing spondylitis and intestinal Behcet’s disease; and the remission induction therapy and maintenance therapy for moderate to severe active Crohn's disease (for use only in patients who have not sufficiently responded to conventional therapies). uuid:acb2656b-f212-4989-8ca7-4defe47f3a81 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:FYS6T7F842 biolink:treats MONDO:0007191 PMID:41385096 "[{""id"":""uuid:3da01e0e-fcdf-4778-b41f-9f55dfe9eaef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:aa0bb7b1-5180-47cc-b549-d523d937afc6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Follow-on biologics indicated for the treatment of rheumatoid arthritis (including the prevention of structural joint damage), and the treatment of the following diseases in patients who have not responded sufficiently to conventional treatments; polyarticular- course juvenile idiopathic arthritis, plaque psoriasis, psoriatic arthritis, pustular psoriasis, ankylosing spondylitis and intestinal Behcet’s disease; and the remission induction therapy and maintenance therapy for moderate to severe active Crohn's disease (for use only in patients who have not sufficiently responded to conventional therapies). uuid:d255638e-5b9c-47d8-a6b5-d059ac059264 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:FYS6T7F842 biolink:treats UMLS:C0852922 PMID:41385096 "[{""id"":""uuid:3c89fef5-004d-45aa-8e73-e549f1932f30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:23e6a1b0-30c1-4c1c-b638-b7690e13768e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Follow-on biologics indicated for the treatment of rheumatoid arthritis (including the prevention of structural joint damage), and the treatment of the following diseases in patients who have not responded sufficiently to conventional treatments; polyarticular- course juvenile idiopathic arthritis, plaque psoriasis, psoriatic arthritis, pustular psoriasis, ankylosing spondylitis and intestinal Behcet’s disease; and the remission induction therapy and maintenance therapy for moderate to severe active Crohn's disease (for use only in patients who have not sufficiently responded to conventional therapies). uuid:94c34f85-af4f-4b24-8396-c90254be58ac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:132774 biolink:treats UMLS:C1142276 PMID:41385096 "[{""id"":""uuid:a74f8f6e-adda-45f4-ada0-5554e039bfed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fb8bf65e-8075-452c-8636-d19bae2f2fee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of renal anaemia in patients who are undergoing dialysis. uuid:8312ac0e-6b6a-4bbf-a9c3-d7856f53a264 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:305EB53128 biolink:treats MONDO:0005393 PMID:41385096 "[{""id"":""uuid:e6e131ee-a29e-4451-bfb2-fc68441358de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f39825b8-a714-4675-b488-aac9b728dac2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of gout and hyperuricemia. uuid:21071f80-52e1-41c2-954d-96d185abbd12 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:305EB53128 biolink:treats HP:0002149 PMID:41385096 "[{""id"":""uuid:a54abe13-db6a-4358-9518-29ba601717fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1afe519b-a10e-4302-9ecb-4eb529432326"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of gout and hyperuricemia. uuid:26567b97-5fe9-41f9-8032-cc53ddaa48fb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31296 biolink:treats MONDO:0005090 PMID:41385096 "[{""id"":""uuid:c3263536-5dfd-42a8-b9ec-bdb9087843be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f100a035-e19c-45fc-b817-98137e956b01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new route of administration indicated for the treatment of schizophrenia. uuid:e4b9194c-4013-46d6-9292-e074271d7d7d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:N62TGJ04A1 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:f1718f72-b0b6-47bb-8aff-8ff1ec20f0f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a710bd13-1cd7-4950-8807-b5a974b68067"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of hypertension. uuid:4d8d9431-197d-4189-b5e7-dd9b4da56cb1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72312 biolink:treats MONDO:0020479 PMID:41385096 "[{""id"":""uuid:2097ca2e-a9d2-4fdc-a00b-6f94fa37da24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6141b48f-7107-40f5-a6ae-e3c23ac3aa85"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the improvement of hypersecretion of growth hormone and IGF-I (somatomedin-C) and related symptoms in acromegaly and pituitary gigantism (when surgical therapies are not sufficiently effective or are difficult to perform). uuid:8383e801-1afb-4e4b-9bcc-17e6ef36bae0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135935 biolink:treats EFO:0801084 PMID:41385096 "[{""id"":""uuid:2066b450-d4b6-4be5-a035-e06b19c1ef50"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6720dbcb-c6cb-46b2-b875-2498d19677e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for management of moderate to severe pain in various types of cancer. uuid:f09b4bf9-38d9-4f65-a8cd-07f683b65b21 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB00028 biolink:treats MONDO:0015977 PMID:41385096 "[{""id"":""uuid:146d80b5-b4b2-43b5-9a51-f9f31a1c7d4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:99c8ea84-8540-4ee4-8c0c-7e109f3f682e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of agammaglobulinemia or hypogammaglobulinemia. uuid:da9f7b76-80e0-4863-8133-7a2d61cae519 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB00028 biolink:treats MONDO:0003827 PMID:41385096 "[{""id"":""uuid:89c562cf-35a8-4e4e-8afd-29717cfb745f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:75a9c2ae-664b-499a-91b5-475b262c1cc0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of agammaglobulinemia or hypogammaglobulinemia. uuid:c15f20f6-288f-40b8-bd13-aee34eb79314 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PVI5M0M1GW biolink:treats MONDO:0015909 PMID:41385096 "[{""id"":""uuid:7ff24637-c99a-46f0-843a-d346f2802def"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:57877835-3d70-4617-8f46-5d34ce393b09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Follow-on biologics indicated for mobilization of hematopoietic stem cell to peripheral blood, promotion of increase in neutrophil count at the time of hematopoietic stem cell transplantation, and the treatment of neutropenia caused by cancer chemotherapy, neutropenia which affects the treatment of human immunodeficiency virus (HIV) infection, neutropenia associated with myelodysplastic syndrome, neutropenia associated with aplastic anemia and congenital/idiopathic neutropenia. uuid:7961934e-0aa9-4ab5-ab77-5c2b06f3534d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PVI5M0M1GW biolink:treats MONDO:0015134 PMID:41385096 "[{""id"":""uuid:a965806c-00e6-4e4a-ac8c-d26c151aeabe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e4902961-fb37-4eeb-91f1-3c9ea31f26b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Follow-on biologics indicated for mobilization of hematopoietic stem cell to peripheral blood, promotion of increase in neutrophil count at the time of hematopoietic stem cell transplantation, and the treatment of neutropenia caused by cancer chemotherapy, neutropenia which affects the treatment of human immunodeficiency virus (HIV) infection, neutropenia associated with myelodysplastic syndrome, neutropenia associated with aplastic anemia and congenital/idiopathic neutropenia. uuid:2ea4907f-9861-4c88-bed6-84a1fe904170 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:94435 biolink:treats MONDO:0005754 PMID:41385096 "[{""id"":""uuid:6168226f-0a06-495c-b264-acebacfb4a7d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:174a6d52-6781-4038-b904-0b5c3f13ea39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for use in conjunction with clobazam and sodium valproate as adjunctive therapy of refractory generalized tonic-clonic and clonic seizures in patients with Dravet’s syndrome whose seizures are not adequately controlled with clobazam and sodium valproate. [Orphan drug] uuid:b7d819d3-2463-4be7-8b92-d8ae209d50b0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:94435 biolink:treats HP:0020221 PMID:41385096 "[{""id"":""uuid:a5d250c4-ebff-4376-a360-b43458ac95d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b8fc30e5-ab84-49e4-9143-a0b3d05f02d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for use in conjunction with clobazam and sodium valproate as adjunctive therapy of refractory generalized tonic-clonic and clonic seizures in patients with Dravet’s syndrome whose seizures are not adequately controlled with clobazam and sodium valproate. [Orphan drug] uuid:eca664f8-b650-4ddd-bb8b-4b441e2a85aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135901 biolink:treats MONDO:0020479 PMID:41385096 "[{""id"":""uuid:0ba15e38-3c59-4f33-812d-8e79f90a105e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3d758972-65a6-4ddb-88b0-b3506338e622"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient for the improvement of hypersecretion of growth hormone and IGF-I (somatomedin-C) and related symptoms in acromegaly and pituitary gigantism (when surgical therapies are not sufficiently effective or are difficult to perform). uuid:15e7b3fd-035d-4d31-80f3-251b9943cfa1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3216 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:452ae7ee-5d52-4cfb-b7d9-fc484217918b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4b9946eb-0258-40ff-b92d-a929f997ee66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for analgesia of chronic pain associated with osteoarthritis and lumbago which cannot be managed by treatments with non-opioid analgesics. uuid:f741effe-6ca5-46a0-9369-1a181095e542 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3216 biolink:treats HP:0003419 PMID:41385096 "[{""id"":""uuid:3677606f-75f2-499e-9450-a6f954ff7d1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c54713fa-f116-442a-865f-5a242714de56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for analgesia of chronic pain associated with osteoarthritis and lumbago which cannot be managed by treatments with non-opioid analgesics. uuid:79d4182d-1673-4983-b3a1-e1a86304bc97 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:61049 biolink:treats MONDO:0013730 PMID:41385096 "[{""id"":""uuid:63592d36-b1c0-445a-8b1a-2fa80fa1c595"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3163b063-acf8-4a90-b28c-5cf9b7ffa76c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs in a new dosage form indicated for suppression of organ rejection in renal, liver, heart, lung, and pancreatic transplantation, as well as for suppression of graft rejection and graft versus host disease (GVHD) in bone marrow transplantation. uuid:a6faeea2-0328-4859-85f1-2eebe0c5896c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134720 biolink:treats NCIT:C143907 PMID:41385096 "[{""id"":""uuid:dba2a40c-0e49-4b14-9511-11cca0b333f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:03913685-24cb-4198-92cb-a7b8bc1c32dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs containing a new active ingredient indicated for the treatment of micturition urgency, pollakiuria, and urge incontinence associated with overactive bladder. uuid:87c37ed3-0ded-4b7c-88a0-4485eed8ad1e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134720 biolink:treats HP:0100515 PMID:41385096 "[{""id"":""uuid:fdfee584-9658-4922-967b-aa0df9b27769"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3b42666e-7074-4332-8871-f9d09660faa9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs containing a new active ingredient indicated for the treatment of micturition urgency, pollakiuria, and urge incontinence associated with overactive bladder. uuid:ea828315-6bd5-49b9-9136-b91d412510e7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134720 biolink:treats EFO:0006865 PMID:41385096 "[{""id"":""uuid:d091b148-afd4-4e72-8777-5d5aece09ac4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5d09bd90-68ce-4ca1-9540-56ffbbef90d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs containing a new active ingredient indicated for the treatment of micturition urgency, pollakiuria, and urge incontinence associated with overactive bladder. uuid:12cd7b6b-9efd-47b8-b668-13dc35b5e9e4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:896228 biolink:treats MONDO:0004979 PMID:41385096 "[{""id"":""uuid:40e0b4a4-b476-4a95-b6c5-447a1dcc9d38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c2a0c33d-31a5-46f7-917b-028088d02dc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new combination drug indicated for the treatment of asthma (in the case where a combination of inhaled corticosteroids and inhaled long-acting β2 agonists is necessary). uuid:deceafce-d1ef-4f97-8a09-951816eec8fc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9123 biolink:treats MONDO:0002050 PMID:41385096 "[{""id"":""uuid:dd80da04-3bcc-4968-b5c4-c78ae1ef7483"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cdba9991-df5e-4c43-ad6b-3069b8a4920c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs containing a new active ingredient, indicated for depression and panic disorder. uuid:131b06e6-0af7-444b-90c7-ea8c20b8854b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32151 biolink:treats MONDO:0006624 PMID:41385096 "[{""id"":""uuid:4db15ecc-c258-45d9-b795-aca802d00ff4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6e4ad98a-75da-4a99-af25-ccea014cce38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for treatment of urinary urgency, urinary frequency, and urge urinary incontinence associated with overactive bladder. uuid:e83d90a0-24b4-4b4e-bb33-deb734a230ff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:5X3GF74R79 biolink:treats MONDO:0002242 PMID:41385096 "[{""id"":""uuid:4019aa2b-c91b-4b09-9957-f6bc9b344ebc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:683b97fa-c2e3-4633-9905-b411a1e39caa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs containing a new active ingredient, indicated for the control of bleeding tendency by supplementing blood coagulation factor VIII in patients with blood coagulation factor VIII deficiency (new product that eliminates the addition of human- and animal-derived components). uuid:7a0b9736-02a6-4aad-89e0-b5498f053e75 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37941 biolink:treats MONDO:0005299 PMID:41385096 "[{""id"":""uuid:a79ab8ef-dd18-4533-a4f3-7b1cf0a98351"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6b7d77e9-2987-4f0d-beaa-1e08563bc65b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs containing a new active ingredient indicated for preventing recurrences of ischemic cerebrovascular diseases (except cardiogenic cerebral infarction) [Prompt review] uuid:c6a33a6f-ad7d-4cb1-98cf-a47ec0aa628e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:34825 biolink:treats MONDO:0002041 PMID:41385096 "[{""id"":""uuid:5da49dfe-d643-4c38-9c57-e9ebb4e06d48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:af47f746-76f1-41a2-a54b-4251890b640a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs containing a new active ingredient, an imidazole anti-fungal agent uuid:4f36dcec-2e73-4f10-9ca4-c100d962bc85 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:50605O2ZNS biolink:treats MONDO:0000328 PMID:41385096 "[{""id"":""uuid:26016191-b019-4031-ac53-5883ab65596f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fee1f0b1-d9c7-4a76-aa25-cbb44a84b1ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the improvement of hyperphosphatemia in patients with chronic kidney disease on dialysis. uuid:fc147212-b70f-4d9f-ac88-502ea0d0b255 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:68603V9EAF biolink:treats MONDO:0018660 PMID:41385096 "[{""id"":""uuid:ac72bf1e-9a5e-4988-83d0-684d1a42cd9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fe0b5b79-af5f-4b30-b3ed-ea50c51e1977"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the control of bleeding tendency in patients with congenital haemophilia who have inhibitors against blood coagulation factor VIII or IX. [Orphan drug] uuid:4fdb01ac-d21d-454c-bc12-e7e06aff8d5b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:229223 biolink:treats UMLS:C1142276 PMID:41385096 "[{""id"":""uuid:c6dd624e-9a4b-4dd3-bf5d-30ef497ff51b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6a4a2a55-3e01-4ce9-99db-f7c626a45631"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of renal anemia. uuid:523655a3-3f70-43d8-a7ee-14d1d9ae9576 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:70735 biolink:treats MONDO:0004985 PMID:41385096 "[{""id"":""uuid:e72361dc-d1b6-41dd-a7ec-147388bc72a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:575a420e-723e-4416-a1b9-568f4cec5ce8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of schizophrenia and the improvement of depressive symptoms in patients with bipolar disorder. uuid:64316936-c417-4a51-8cca-c7adece77526 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:S7LK2KDM5U biolink:treats UMLS:C0458960 PMID:41385096 "[{""id"":""uuid:a1c1fe69-3b74-40d3-9c37-58627d6d73ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2f71deb9-c197-4cb7-86ef-5fc4efd13398"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of peripheral neuropathic pain. uuid:b23a5b15-0211-43db-acee-5a998cb0d912 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0338204 biolink:treats MONDO:0001056 PMID:41385096 "[{""id"":""uuid:83f4eb55-a10e-4310-9acf-b8e254c2ba12"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9aa7f814-2c30-4578-84c3-dd5da683af2e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Follow-on biologics indicated for the treatment of unresectable advanced or recurrent gastric cancer with HER2 overexpression. MESH:C000721628 uuid:248aa432-3a70-43de-a2d0-283bd6f0fd83 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0338204 biolink:treats NCIT:C150634 PMID:41385096 "[{""id"":""uuid:dc6a918a-8f40-4059-9fea-d4b5b8b0e358"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e8e138ae-96ca-4811-a0a5-ceb1128cc706"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Follow-on biologics indicated for the treatment of unresectable advanced or recurrent gastric cancer with HER2 overexpression. MESH:C000721628 uuid:2351d738-01d6-4ea7-bcf1-829191286dc8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5134 biolink:treats MONDO:0100470 PMID:41385096 "[{""id"":""uuid:554caabb-e0d7-48f7-889c-bee917cbbe28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:80d1bb75-a56b-4e90-b0e9-f88a3f68b6ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage and other characteristics indicated for the treatment of bronchial asthma. uuid:c5127189-60d1-4d60-83aa-775c3ddbdf08 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8232 biolink:treats HP:0100806 PMID:41385096 "[{""id"":""uuid:8854bb3e-c0ca-402a-8494-09135aa364ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f80ac24b-7e01-4183-87e2-22b5e48abd11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of sepsis, acute bronchitis, pneumonia, lung abscess, thoracic empyema, secondary infection of chronic respiratory disease, cystitis, pyelonephritis, cholecystitis, choledochitis, bartholinitis, intrauterine infection, uterine adnexitis, parametritis, and purulent meningitis. uuid:8706e8cc-e1ae-4062-a997-76aca5d116c7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8232 biolink:treats HP:0012388 PMID:41385096 "[{""id"":""uuid:775ba66a-c0c0-4773-bfc1-f61911f8d40b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c0b9da06-4b72-48f5-9cf7-4140dbf49817"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of sepsis, acute bronchitis, pneumonia, lung abscess, thoracic empyema, secondary infection of chronic respiratory disease, cystitis, pyelonephritis, cholecystitis, choledochitis, bartholinitis, intrauterine infection, uterine adnexitis, parametritis, and purulent meningitis. uuid:6d569661-eab8-4506-bd29-b15dbe178dd8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8232 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:c9941672-e88e-462a-ba2b-de03c05c7306"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1f68be12-ac5b-45ad-a680-4963ef5db0d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of sepsis, acute bronchitis, pneumonia, lung abscess, thoracic empyema, secondary infection of chronic respiratory disease, cystitis, pyelonephritis, cholecystitis, choledochitis, bartholinitis, intrauterine infection, uterine adnexitis, parametritis, and purulent meningitis. uuid:26505701-ba33-4152-908c-d99445dd4e6d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8232 biolink:treats MONDO:0000744 PMID:41385096 "[{""id"":""uuid:362714e1-c2d6-4ba7-96d6-1df570db9d2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:25b0edfd-7260-46e0-8509-daa0f74adf43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of sepsis, acute bronchitis, pneumonia, lung abscess, thoracic empyema, secondary infection of chronic respiratory disease, cystitis, pyelonephritis, cholecystitis, choledochitis, bartholinitis, intrauterine infection, uterine adnexitis, parametritis, and purulent meningitis. uuid:98ec1259-5b8c-44ff-a6eb-8fc4bdecac83 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8232 biolink:treats MONDO:0018667 PMID:41385096 "[{""id"":""uuid:eecceedc-e19b-461d-8ac1-608d3cd21008"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e4c6960c-74e8-46a8-8806-a70230fc52a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of sepsis, acute bronchitis, pneumonia, lung abscess, thoracic empyema, secondary infection of chronic respiratory disease, cystitis, pyelonephritis, cholecystitis, choledochitis, bartholinitis, intrauterine infection, uterine adnexitis, parametritis, and purulent meningitis. uuid:9092aa17-8bf4-4ff8-9c64-2eec90fead8a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8232 biolink:treats MONDO:0006032 PMID:41385096 "[{""id"":""uuid:e79f71f5-2f36-4bae-9358-f5a89c44fb72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d888cc67-24b4-43a0-8efa-2e0f6009a4ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of sepsis, acute bronchitis, pneumonia, lung abscess, thoracic empyema, secondary infection of chronic respiratory disease, cystitis, pyelonephritis, cholecystitis, choledochitis, bartholinitis, intrauterine infection, uterine adnexitis, parametritis, and purulent meningitis. uuid:96119811-b034-407e-89b7-26a4240aa053 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8232 biolink:treats MONDO:0006939 PMID:41385096 "[{""id"":""uuid:c2ad343c-2468-468f-b27f-a252d0b18f70"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cb6fcad6-9d0f-41ba-bcff-1f74f789dc38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of sepsis, acute bronchitis, pneumonia, lung abscess, thoracic empyema, secondary infection of chronic respiratory disease, cystitis, pyelonephritis, cholecystitis, choledochitis, bartholinitis, intrauterine infection, uterine adnexitis, parametritis, and purulent meningitis. uuid:a898b103-bf24-4676-ba76-d32a9d13b654 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8232 biolink:treats MONDO:0002155 PMID:41385096 "[{""id"":""uuid:2fe2327b-cd03-47c4-b625-eb55785f48a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e2cb5dd7-f7bd-4696-925a-c9c5db93923c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of sepsis, acute bronchitis, pneumonia, lung abscess, thoracic empyema, secondary infection of chronic respiratory disease, cystitis, pyelonephritis, cholecystitis, choledochitis, bartholinitis, intrauterine infection, uterine adnexitis, parametritis, and purulent meningitis. uuid:505b2012-3019-4139-b2bb-d64fec91cf2f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8232 biolink:treats UMLS:C0004769 PMID:41385096 "[{""id"":""uuid:5ea395b9-a7f5-4120-9459-07e3753da992"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f1463c27-382c-4419-854d-854a818ff480"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of sepsis, acute bronchitis, pneumonia, lung abscess, thoracic empyema, secondary infection of chronic respiratory disease, cystitis, pyelonephritis, cholecystitis, choledochitis, bartholinitis, intrauterine infection, uterine adnexitis, parametritis, and purulent meningitis. uuid:4d07f234-67b6-479e-8a5a-9d0d38f558e9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8232 biolink:treats UMLS:C1112157 PMID:41385096 "[{""id"":""uuid:ae7a92be-90bb-432d-92fe-7caf1ddd67e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2ebe8995-297b-4359-91b3-f9a0db392313"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of sepsis, acute bronchitis, pneumonia, lung abscess, thoracic empyema, secondary infection of chronic respiratory disease, cystitis, pyelonephritis, cholecystitis, choledochitis, bartholinitis, intrauterine infection, uterine adnexitis, parametritis, and purulent meningitis. uuid:0d0bf75a-84fe-4ac1-a868-508e7b628fe0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8232 biolink:treats UMLS:C0001577 PMID:41385096 "[{""id"":""uuid:ab017d90-03e0-473e-b530-def3d34c33f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f38845b5-d17e-4ec9-bd3d-fdc6c3d39cf0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of sepsis, acute bronchitis, pneumonia, lung abscess, thoracic empyema, secondary infection of chronic respiratory disease, cystitis, pyelonephritis, cholecystitis, choledochitis, bartholinitis, intrauterine infection, uterine adnexitis, parametritis, and purulent meningitis. uuid:c348aaf2-576d-468d-b13d-a4fbeac7e5b4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8232 biolink:treats UMLS:C0865440 PMID:41385096 "[{""id"":""uuid:b559758e-4f30-44a3-ba93-78fa0120dc36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fd1dff3e-f5d7-4f64-b4f6-aaeed93a9b84"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of sepsis, acute bronchitis, pneumonia, lung abscess, thoracic empyema, secondary infection of chronic respiratory disease, cystitis, pyelonephritis, cholecystitis, choledochitis, bartholinitis, intrauterine infection, uterine adnexitis, parametritis, and purulent meningitis. uuid:e4bbdd76-a095-4dff-8610-2d1ceed76ea4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:73357808 biolink:treats MONDO:0100470 PMID:41385096 "[{""id"":""uuid:46259430-681f-42b8-84ae-0a7f4784b293"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:918c7462-c9a1-4047-aacc-95438c48830e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New combination drugs indicated for the treatment of bronchial asthma (when a combination treatment of an inhaled steroid and a long-acting beta-2 agonist is needed). uuid:64149d43-9fc8-4486-924a-7d52785c0c79 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1648788 biolink:treats MONDO:0100470 PMID:41385096 "[{""id"":""uuid:5bd8b758-2bed-4947-94d4-240dafbb55ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0eba211f-b553-47b8-ab89-069ef6343423"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New combination drugs with a new active ingredient indicated for the treatment of bronchial asthma (when a combination treatment of an inhaled steroid and a long-acting beta-2 agonist is needed). uuid:bc70f5db-f1c6-4d67-b060-64c81f0686c5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:61390 biolink:treats UMLS:C3266992 PMID:41385096 "[{""id"":""uuid:44d5a0ec-e8bd-4088-9e4f-6327f74182bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1e41a771-ab3e-49fb-b77e-3f3147b72fe7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of unresectable advanced or recurrent non-small cell lung cancer with EGFR gene mutation. uuid:d43d7f62-2dbb-4198-8e95-d22bae14c10a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:404914 biolink:treats HP:0001681 PMID:41385096 "[{""id"":""uuid:98afa117-b10c-4fd2-8c33-ae4007f20190"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e4b436a8-b3f5-4b8e-b157-c33a45d3f02e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New combination drugs indicated for the treatment of comorbidity of hypertension or angina pectoris and hypercholesterolemia or familial hypercholesterolemia. uuid:1daf1577-6ea8-4437-8fde-80b9e3201fe8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:404914 biolink:treats MONDO:0005439 PMID:41385096 "[{""id"":""uuid:9c49cbaf-9121-4ec7-bf60-beb1d8ff2948"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:547f38d8-5d57-44b0-b79b-726ca24cb56d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New combination drugs indicated for the treatment of comorbidity of hypertension or angina pectoris and hypercholesterolemia or familial hypercholesterolemia. uuid:2dae0004-9001-4469-9540-6e3560f18bc9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6367 biolink:treats HP:0002197 PMID:41385096 "[{""id"":""uuid:67c6189d-a39b-4331-9244-cc8285fc5135"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:49469af6-6bbc-4da1-b3b0-fa9590b0272a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs containing a new active ingredient indicated for use as adjunctive treatment with other antiepileptic drugs for partial seizures (including secondary generalized seizures), tonic-clonic seizures, and generalized seizures associated with Lennox-Gastaut syndrome in patients with epilepsy for whom other antiepileptic drugs are not sufficiently effective. uuid:dbf3c50a-58c5-40e3-8748-8c01de26261e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:42797 biolink:treats HP:0007334 PMID:41385096 "[{""id"":""uuid:736b82f9-78b9-4dbc-894d-79f4c6435bf4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:27985e83-987a-4fee-81ff-7ca8d6b7f217"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs containing a new active ingredient indicated for use as adjunctive therapy with other antiepileptic drugs to treat partial seizures (including secondarily generalized seizure) in patients with epilepsy, to whom other antiepileptic therapies are not sufficiently effective. uuid:b738c2af-21fd-4f6b-83fd-fb68d38c5cc3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:167574 biolink:treats MONDO:0021187 PMID:41385096 "[{""id"":""uuid:1c08128b-4ff2-49fc-8b26-b70d33ac439d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3abeb8e3-f2a8-42f7-ab82-0ce9952e73d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication, a new dosage and other characteristics for the treatment of obesity. Drugs with a new indication and a new dosage in an additional dosage form for the treatment of obesity. For use only in patients with any of hypertension, hyperlipidemia or type 2 diabetes mellitus who have not responded sufficiently to diet therapy and exercise therapy, and meet the following conditions: BMI of 27 kg/m2 or greater in the presence of at least two obesity-related comorbidities or BMI of 35 kg/m2 or greater uuid:74e5aed0-c94d-48b7-b354-25e589511b41 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9JH486CZ13 biolink:treats UMLS:C1142276 PMID:41385096 "[{""id"":""uuid:e37da5ad-1445-45e1-b00a-41ef2e1493fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:129d8a94-e8d3-4974-8954-8c1704779e61"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of renal anemia. uuid:c55c3c06-fc25-49af-be6c-e50a98f1d653 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:0J877412JV biolink:treats MONDO:0005393 PMID:41385096 "[{""id"":""uuid:6acc7340-7a78-4452-b20b-8fb0c2fbf897"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7eff3f4e-5b8e-41ab-9ca4-8594ac531999"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of gout and hyperuricemia. uuid:620f8f8d-0567-4467-99be-1c3bb74b1f40 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:0J877412JV biolink:treats HP:0002149 PMID:41385096 "[{""id"":""uuid:438efbad-4457-42ca-ad2a-0ae81b05d310"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:383e219f-4802-4152-be17-6efd39537125"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of gout and hyperuricemia. uuid:da6386c2-5e78-4bcf-ba40-89ec86c0b7b3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6149 biolink:treats NCIT:C34887 PMID:41385096 "[{""id"":""uuid:abc47950-6e74-4437-9989-0135c02e6fab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:427cf07f-ff70-4c39-b277-ffa57a21d570"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs containing a new active ingredient. The 0.25% formulation is indicated for postoperative analgesia, and the 0.75% formulation is indicated for epidural anaesthesia. uuid:e29db214-84c1-4048-a387-71d8f2137783 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:53444 biolink:treats MONDO:0006525 PMID:41385096 "[{""id"":""uuid:1585326b-ce03-4f33-a7a1-04a1416b59ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:dda33f16-ff29-4f33-9081-e47278fd386b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs indicated for use in patch tests to identify allergens in patients with allergic dermatitis. uuid:08731a6d-185d-44bc-b5bf-088666f72447 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:138404169 biolink:treats MONDO:0006964 PMID:41385096 "[{""id"":""uuid:ad5f3696-f8cb-4383-9b22-f69c029982aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:33d6f479-8614-4cdd-a655-043f743a07ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of secondary hyperparathyroidism in patients on hemodialysis. uuid:178a5164-f73c-404d-b881-d962ef88a4f2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:U50VWW6XH6 biolink:treats MONDO:0010602 PMID:41385096 "[{""id"":""uuid:b667b03a-7fa7-4a7a-b588-833fb487de6a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b917fa0b-2721-46e1-9e88-df96eb02b13e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the control of bleeding tendency in patients with blood coagulation factor VIII deficiency. uuid:7a97a80b-56d2-47f2-9817-c2f89ecd8f7d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0357131 biolink:treats UMLS:C1142276 PMID:41385096 "[{""id"":""uuid:000def72-23d2-4be9-8235-4e4f918aea11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f02f5802-778d-4870-8c42-04433fecbdee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of renal anemia. DRUGBANK:DB19434 uuid:954038fa-7ace-4122-9d19-f1dbbfca6614 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1945037 biolink:treats MONDO:0100470 PMID:41385096 "[{""id"":""uuid:f07a156f-63cd-42d6-89ce-f32411549a2d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:61001cfb-fb53-468f-a7bb-44b13998b173"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] , (2) New combination drugs indicated for the treatment of bronchial asthma (when a combination treatment of an inhaled steroid, a long-acting inhaled anticholinergic agent and a long-acting beta-2 agonist is needed). (3), (4) Drugs with a new indication and a new dosage for the treatment of bronchial asthma (when a combination treatment of an inhaled steroid, a long- acting inhaled anticholinergic agent and a long-acting beta-2 agonist is needed). uuid:8c6fce9e-4fab-4052-96b0-8343ddd28a7f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31941 biolink:treats MONDO:0001462 PMID:41385096 "[{""id"":""uuid:34d8cbb1-8cca-415a-9074-86770416bc6a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f61e0404-c9e6-427e-a113-85f763f8afee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage in an additional dosage form (Elplat I.V. Infusion Solution 50 mg and Elplat I.V. Infusion Solution 100 mg) for post-operative adjuvant chemotherapy for colon cancer. [Priority review] uuid:06ba1552-6157-4b93-a738-396cedcbd004 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68579 biolink:treats HP:0004831 PMID:41385096 "[{""id"":""uuid:ed76edc4-f9b7-47f8-a4ba-e24f575cca3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9d2ee0b9-68f6-4d1e-a25d-ba7f8606447c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs ([1-8]) with a new indication and a new additional pediatric dosage for the treatment and prevention of recurrent venous thromboembolism. In addition, drugs ([1, 2]) are in an additional dosage form. uuid:afbafb02-8fa8-40fb-aafe-c0a8c2546047 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:G9WJT6RD29 biolink:treats MONDO:0024300 PMID:41385096 "[{""id"":""uuid:ca9f6da1-35a2-4ee0-8431-77d12c9c6752"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:42c225fa-d6d9-48f1-baa0-4cc76e7392ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of FGF23-related hypophosphatemic rickets/osteomalacia. [Orphan drug] uuid:6db3cffa-fd46-4e99-8759-36e8617e8854 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:FU77B4U5Z0 biolink:treats UMLS:C0852922 PMID:41385096 "[{""id"":""uuid:b69c04be-ba39-4a77-a81d-46ad7758a412"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0e48187e-2224-4784-9517-da1ce26cb811"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the induction therapy for moderate to severe active Crohn's disease (for use only in patients who have not sufficiently responded to conventional treatments). A drug with a new indication and a new dosage for the maintenance therapy for moderate to severe active Crohn's disease (for use only in patients who have not sufficiently responded to conventional treatments). uuid:75a3238f-de42-489a-b2cf-23fd3335da8a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8768 biolink:treats MONDO:0001126 PMID:41385096 "[{""id"":""uuid:791b129a-a149-43b9-8338-b9e94f335997"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ebcd0b07-72e7-41fa-95c8-980fe3f232f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage in a newly-added dosage form, and a drug with a new additional indication and a new dosage for the prevention of recurrence of gastric ulcer or duodenal ulcer in patients treated with low-dose aspirin. uuid:5f44c2a5-f977-4ede-8ada-db5c9683c0c5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:I031V2H011 biolink:treats MONDO:0011429 PMID:41385096 "[{""id"":""uuid:e7e660cc-e373-482b-b0c5-68390701e769"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6d33b4bb-3713-4641-b3fd-9c2eb0a55c82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage in a new dosage form for the treatment of rheumatoid arthritis (including prevention of structural damage of joint) that cannot be treated sufficiently with conventional therapies, active juvenile idiopathic arthritis in multiple joints, and systemic juvenile idiopathic arthritis. [Priority review] [Expedited review] uuid:48b339ca-3f6e-4171-a417-15eb9b8b60d9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:22145087 biolink:treats UMLS:C0854521 PMID:41385096 "[{""id"":""uuid:bbe45954-ebb3-4978-abf9-c4e07d8ed470"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d9b34ad3-bbf6-40d4-8e4d-d18aa56a8c7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage and a drug in an additional dosage form for the treatment of hypozincemia. uuid:4e4cf36b-e9ac-4ecb-8289-ada520cb3a83 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3127 biolink:treats MONDO:0004981 PMID:41385096 "[{""id"":""uuid:2007d539-32d6-42e6-973f-5deec02f7d25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6fe02bb4-499f-49a2-8e46-0ae25672ebbf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage in an additional dosage form indicated for the treatment of tachycardiac atrial fibrillation. (2)(3) Drugs with a new additional indication, a new dosage, and other characteristics indicated for the treatment of tachycardiac atrial fibrillation. uuid:0a19cee0-935b-446c-bd9a-92f4d662e675 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:95021 biolink:treats MONDO:0005112 PMID:41385096 "[{""id"":""uuid:7cd2ff60-1360-4167-b7e2-6336d09c98bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:54123d39-453c-46e6-886d-e3e57d2426ea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Combination therapy with a drug containing a new active ingredient and a drug with a new indication and dosage, for use to treat malignant pleural mesothelioma. [Priority Review] [Expedited Review] uuid:7dfd1d74-c3fb-4440-a1f0-7b1aa75a5080 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85978 biolink:treats MONDO:0005657 PMID:41385096 "[{""id"":""uuid:77ee278d-e6bf-46f7-8cee-4bd16b6a7a00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a11f9ea5-32c3-4818-b0a5-414e8b8b18b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of the following mycoses: Aspergillosis (invasive aspergillosis, chronic progressive pulmonary aspergillosis, simple pulmonary aspergilloma) Mucormycosis Cryptococcosis (pulmonary cryptococcosis, disseminated cryptococcosis [including cryptococcal meningitis]) uuid:b7d4c3d3-5957-4600-b380-18605c65ab41 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85978 biolink:treats MONDO:0019136 PMID:41385096 "[{""id"":""uuid:d818a581-996a-4e42-881a-dc762e1be8d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:baeaf4a0-9bf3-4708-bf99-0f681a877530"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of the following mycoses: Aspergillosis (invasive aspergillosis, chronic progressive pulmonary aspergillosis, simple pulmonary aspergilloma) Mucormycosis Cryptococcosis (pulmonary cryptococcosis, disseminated cryptococcosis [including cryptococcal meningitis]) uuid:1b0723ee-16d6-40e2-a34e-f2b20d1493fb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85978 biolink:treats MONDO:0005724 PMID:41385096 "[{""id"":""uuid:3c2681fd-f39b-4204-9bd5-596758f72cf8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1db1636f-7d61-45c4-9610-b7ce4a5ec190"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of the following mycoses: Aspergillosis (invasive aspergillosis, chronic progressive pulmonary aspergillosis, simple pulmonary aspergilloma) Mucormycosis Cryptococcosis (pulmonary cryptococcosis, disseminated cryptococcosis [including cryptococcal meningitis]) uuid:af965392-33ac-4bb5-8a8e-c261c85bd473 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85978 biolink:treats MONDO:0005723 PMID:41385096 "[{""id"":""uuid:ab55dbbb-1032-4518-be57-a45e7153e752"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3c2c1407-4270-4e93-8d23-5c7d992fdc7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of the following mycoses: Aspergillosis (invasive aspergillosis, chronic progressive pulmonary aspergillosis, simple pulmonary aspergilloma) Mucormycosis Cryptococcosis (pulmonary cryptococcosis, disseminated cryptococcosis [including cryptococcal meningitis]) uuid:f802b5c1-b8ff-4fe8-b70b-09e58e6f4e7c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:I60W9520VV biolink:treats UMLS:C1142276 PMID:41385096 "[{""id"":""uuid:6a7550dd-0c59-4069-aeca-f07dcdb16bc4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e89626f8-ba5f-4691-8915-c8d56f65468e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of renal anemia. uuid:0a98a80c-0567-442e-befe-0086cf869bb0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:Z7G02XZ0M6 biolink:treats MONDO:0000450 PMID:41385096 "[{""id"":""uuid:77343029-56b3-45dd-9d8f-f642d1bc01f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ed09ddb2-be5f-448d-b5d8-0db084c1f699"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the prevention of relapse and for delaying the accumulation of physical disability in secondary progressive multiple sclerosis (SPMS). [Orphan drug] uuid:435a1f65-5a97-43e9-bb5f-de4213264055 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:Z7G02XZ0M6 biolink:treats MONDO:0005301 PMID:41385096 "[{""id"":""uuid:bf44b74c-2fc7-4dec-b9ad-b9b2b5c689c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:529dd6c6-8e7b-4f5b-b194-85e456dd5978"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the prevention of relapse and for delaying the accumulation of physical disability in secondary progressive multiple sclerosis (SPMS). [Orphan drug] uuid:347ac395-96e3-4346-acc1-7a531392b9f3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6970 biolink:treats MONDO:0100470 PMID:41385096 "[{""id"":""uuid:4bc061f0-2314-4f84-b07c-1243b621077d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4d93dfbe-f1e2-4a25-b5db-d65962961bd7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new route of administration indicated for the treatment of bronchial asthma. uuid:0ae24f9a-b06c-4bbc-8c9a-9a40d99500be biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:200284 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:470c6adb-59c0-4321-a1e1-dd33ef0d2fb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4fdf00c2-2325-4151-9352-65103dbbc7c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] New combination drugs indicated for the treatment of hypertension. uuid:89a1076e-8b5b-4c18-9611-f15276b8eeb8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:I031V2H011 biolink:treats MONDO:0015564 PMID:41385096 "[{""id"":""uuid:641bdc29-9bb5-4ac1-8c23-f6dcfb83e5cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b536252c-4c49-46f3-a110-ee4df80f4240"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs containing a new active ingredient indicated for improving various symptoms and laboratory findings associated with Castleman’s disease for which lymphadenectomy is not indicated. [Orphan drug] uuid:56ab91d7-7c22-43dc-873a-4e77b585b644 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231344 biolink:treats MONDO:0004956 PMID:41385096 "[{""id"":""uuid:1a456cdc-deaa-48e7-8335-b8efac16ad36"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ffa21f27-c039-4535-b1ae-0fec587f3b09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for the treatment of BRCA mutation-positive, metastatic castration-resistant prostate cancer. A drug with a new active ingredient indicated for the treatment of BRCA mutation-positive, metastatic castration-resistant prostate cancer and unresectable or recurrent BRCA mutation-positive and HER2-negative breast cancer in patients who have previously been treated with chemotherapy. A drug with a new active ingredient indicated for the treatment of unresectable or recurrent BRCA mutation-positive and HER2-negative breast cancer in patients who have previously been treated with chemotherapy. uuid:73df745d-9bb1-42cd-b66c-155d969575cf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7824 biolink:treats HP:0007334 PMID:41385096 "[{""id"":""uuid:03d52717-fdcf-4129-9f97-d2c8d750b976"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fde7711c-4985-4f15-a068-51993d70c86d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the use as an adjunctive therapy with other antiepileptic drugs to treat partial seizures (including secondary generalized seizures) in patients with epilepsy who have not responded sufficiently to other antiepileptic drugs. uuid:8ed51f17-d7a0-446a-9e15-1d9dd9886e09 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PP0SHH6V16 biolink:treats MONDO:0005439 PMID:41385096 "[{""id"":""uuid:88bcb3cf-592d-4569-bdcd-bd6f64e4b28e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bfd87eb3-0098-4b04-a000-8d9806b4bfff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of familial hypercholesteremia and hypercholesterolemia (for use only in patients who are at higher risk of developing cardiovascular event and have not responded sufficiently to HMG- CoA reductase inhibitors). uuid:a0dcdc96-4cf4-44a6-967d-ee42a2f552ca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PP0SHH6V16 biolink:treats HP:0003124 PMID:41385096 "[{""id"":""uuid:a88a9cd7-5937-4057-9e4a-f24694f560fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2ca1aa07-857b-4c9f-afb4-c9f694f61b34"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new active ingredient indicated for the treatment of familial hypercholesteremia and hypercholesterolemia (for use only in patients who are at higher risk of developing cardiovascular event and have not responded sufficiently to HMG- CoA reductase inhibitors). uuid:37f4d733-7366-42ff-b9d7-73a23b967f75 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:FYS6T7F842 biolink:treats MONDO:0006806 PMID:41385096 "[{""id"":""uuid:22d50b1b-aab0-4f66-97e8-753322ef10f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cf9440f6-b1d3-4286-a506-33771afbc886"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Biosimilars indicated for the treatment of rheumatoid arthritis (including the prevention of structural joint damage), and the treatment of the following diseases in patients who have not sufficiently responded to conventional treatments: polyarticular-course juvenile idiopathic arthritis, plaque psoriasis, psoriatic arthritis, pustular psoriasis, ankylosing spondylitis, intestinal Behcet’ s disease, non-infectious intermediate uveitis, posterior uveitis, and panuveitis; the remission induction therapy and maintenance therapy for moderate to severe active Crohn's disease (for use only in patients who have not sufficiently responded to conventional therapies), and the treatment of moderate or severe ulcerative colitis (for use only in patients who have not sufficiently responded to conventional treatments). uuid:6c2445c0-f81a-43a5-af90-bcd8697ccf0f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:FYS6T7F842 biolink:treats MONDO:0006918 PMID:41385096 "[{""id"":""uuid:35203faf-2d16-4f0a-bdf9-e0a6689db93b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0a053649-e93f-45be-953f-a011b87df707"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Biosimilars indicated for the treatment of rheumatoid arthritis (including the prevention of structural joint damage), and the treatment of the following diseases in patients who have not sufficiently responded to conventional treatments: polyarticular-course juvenile idiopathic arthritis, plaque psoriasis, psoriatic arthritis, pustular psoriasis, ankylosing spondylitis, intestinal Behcet’ s disease, non-infectious intermediate uveitis, posterior uveitis, and panuveitis; the remission induction therapy and maintenance therapy for moderate to severe active Crohn's disease (for use only in patients who have not sufficiently responded to conventional therapies), and the treatment of moderate or severe ulcerative colitis (for use only in patients who have not sufficiently responded to conventional treatments). uuid:1448117e-2702-420f-962d-12e3986651e5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:FYS6T7F842 biolink:treats MONDO:0017255 PMID:41385096 "[{""id"":""uuid:3bcfd820-d761-4e7d-824e-491893385498"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3880dfc5-d178-4499-b593-b59e0279a7f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Biosimilars indicated for the treatment of rheumatoid arthritis (including the prevention of structural joint damage), and the treatment of the following diseases in patients who have not sufficiently responded to conventional treatments: polyarticular-course juvenile idiopathic arthritis, plaque psoriasis, psoriatic arthritis, pustular psoriasis, ankylosing spondylitis, intestinal Behcet’ s disease, non-infectious intermediate uveitis, posterior uveitis, and panuveitis; the remission induction therapy and maintenance therapy for moderate to severe active Crohn's disease (for use only in patients who have not sufficiently responded to conventional therapies), and the treatment of moderate or severe ulcerative colitis (for use only in patients who have not sufficiently responded to conventional treatments). uuid:90e796a4-7e45-4b21-999a-1b9d17c056f0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9168 biolink:treats MONDO:0002013 PMID:41385096 "[{""id"":""uuid:5207a90a-80cc-48de-97fb-0b0617854dcd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b9507f55-e7e5-4d42-b950-d66d3a8359a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] (1) A drug with a new indication and a new dosage in an additional dosage form and (2) a drug with a new indication and a new dosage, for the treatment of the following refractory vascular tumors and refractory vascular malformations: lymphangioma (lymphatic malformation), lymphangiomatosis, Gorham disease, lymphangiectasia, hemangioendothelioma, tufted angioma, venous malformation, blue rubber bleb nevus syndrome, mixed vascular malformation and Klippel-Trenaunay-Weber syndrome. [Orphan drug] uuid:acb045ae-a965-484b-9048-173ac3fc20cc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9168 biolink:treats UMLS:C0334102 PMID:41385096 "[{""id"":""uuid:73587d45-aeff-4104-9cc6-13e01cc22c57"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:47880c97-2972-4f55-90fa-a792aea937b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] (1) A drug with a new indication and a new dosage in an additional dosage form and (2) a drug with a new indication and a new dosage, for the treatment of the following refractory vascular tumors and refractory vascular malformations: lymphangioma (lymphatic malformation), lymphangiomatosis, Gorham disease, lymphangiectasia, hemangioendothelioma, tufted angioma, venous malformation, blue rubber bleb nevus syndrome, mixed vascular malformation and Klippel-Trenaunay-Weber syndrome. [Orphan drug] uuid:ef7ca174-118d-4be2-a58d-824edea49f79 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9168 biolink:treats MONDO:0007414 PMID:41385096 "[{""id"":""uuid:4cc84d75-5628-4590-a502-1d18f8773292"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:637fb0dc-4e73-4121-8a38-3c378926be75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] (1) A drug with a new indication and a new dosage in an additional dosage form and (2) a drug with a new indication and a new dosage, for the treatment of the following refractory vascular tumors and refractory vascular malformations: lymphangioma (lymphatic malformation), lymphangiomatosis, Gorham disease, lymphangiectasia, hemangioendothelioma, tufted angioma, venous malformation, blue rubber bleb nevus syndrome, mixed vascular malformation and Klippel-Trenaunay-Weber syndrome. [Orphan drug] uuid:b70361cf-d4eb-4a44-89bd-0bea2499ed7b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9168 biolink:treats MONDO:0006840 PMID:41385096 "[{""id"":""uuid:3afc8e6f-6ae1-467b-8d93-744385053db8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:490c6864-cb49-4666-9995-c1a2b9ccf845"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] (1) A drug with a new indication and a new dosage in an additional dosage form and (2) a drug with a new indication and a new dosage, for the treatment of the following refractory vascular tumors and refractory vascular malformations: lymphangioma (lymphatic malformation), lymphangiomatosis, Gorham disease, lymphangiectasia, hemangioendothelioma, tufted angioma, venous malformation, blue rubber bleb nevus syndrome, mixed vascular malformation and Klippel-Trenaunay-Weber syndrome. [Orphan drug] uuid:31c9910b-5833-49b5-9b45-d6b04baa3c8c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9168 biolink:treats MONDO:0021121 PMID:41385096 "[{""id"":""uuid:90d11ccf-70ef-43f2-b0c2-87675415f408"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3c8a9193-de8d-4d7a-baae-7baedd88f7e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] (1) A drug with a new indication and a new dosage in an additional dosage form and (2) a drug with a new indication and a new dosage, for the treatment of the following refractory vascular tumors and refractory vascular malformations: lymphangioma (lymphatic malformation), lymphangiomatosis, Gorham disease, lymphangiectasia, hemangioendothelioma, tufted angioma, venous malformation, blue rubber bleb nevus syndrome, mixed vascular malformation and Klippel-Trenaunay-Weber syndrome. [Orphan drug] uuid:58ea0db7-6df1-4bb5-be4f-835d9e6aab8c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9168 biolink:treats MONDO:0011927 PMID:41385096 "[{""id"":""uuid:700ed271-624d-4fbf-b13f-30e53f3c82c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2babe082-46f1-417e-a463-44cdd01a31cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] (1) A drug with a new indication and a new dosage in an additional dosage form and (2) a drug with a new indication and a new dosage, for the treatment of the following refractory vascular tumors and refractory vascular malformations: lymphangioma (lymphatic malformation), lymphangiomatosis, Gorham disease, lymphangiectasia, hemangioendothelioma, tufted angioma, venous malformation, blue rubber bleb nevus syndrome, mixed vascular malformation and Klippel-Trenaunay-Weber syndrome. [Orphan drug] uuid:3d59b308-f54c-46cd-8dad-dc3c968d2561 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9168 biolink:treats HP:0012721 PMID:41385096 "[{""id"":""uuid:01a7c000-bc33-46d0-ab4a-d4736c29af0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7bdc9c83-dfea-4f64-bf2a-8fe269441753"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] (1) A drug with a new indication and a new dosage in an additional dosage form and (2) a drug with a new indication and a new dosage, for the treatment of the following refractory vascular tumors and refractory vascular malformations: lymphangioma (lymphatic malformation), lymphangiomatosis, Gorham disease, lymphangiectasia, hemangioendothelioma, tufted angioma, venous malformation, blue rubber bleb nevus syndrome, mixed vascular malformation and Klippel-Trenaunay-Weber syndrome. [Orphan drug] uuid:3aba3da7-ee6e-4459-ab65-5b5db77c743c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9168 biolink:treats MONDO:0007203 PMID:41385096 "[{""id"":""uuid:430f7ce5-40e9-4982-bfc6-e0b075628df2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:22c755d8-58d7-438c-b8d3-91c11da20648"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] (1) A drug with a new indication and a new dosage in an additional dosage form and (2) a drug with a new indication and a new dosage, for the treatment of the following refractory vascular tumors and refractory vascular malformations: lymphangioma (lymphatic malformation), lymphangiomatosis, Gorham disease, lymphangiectasia, hemangioendothelioma, tufted angioma, venous malformation, blue rubber bleb nevus syndrome, mixed vascular malformation and Klippel-Trenaunay-Weber syndrome. [Orphan drug] OMIM:112200 uuid:4280c459-dfa6-4b4d-aae7-5ef645db7da2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9168 biolink:treats UMLS:C0340845 PMID:41385096 "[{""id"":""uuid:0c9515d8-2097-44e5-8584-a65b8f82e615"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4e8d4a93-c7e5-4f58-b30c-3def7ce7520d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] (1) A drug with a new indication and a new dosage in an additional dosage form and (2) a drug with a new indication and a new dosage, for the treatment of the following refractory vascular tumors and refractory vascular malformations: lymphangioma (lymphatic malformation), lymphangiomatosis, Gorham disease, lymphangiectasia, hemangioendothelioma, tufted angioma, venous malformation, blue rubber bleb nevus syndrome, mixed vascular malformation and Klippel-Trenaunay-Weber syndrome. [Orphan drug] uuid:7bde0ed2-b6c2-4053-bb47-e80100b2aa13 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:91083 biolink:treats MONDO:0015909 PMID:41385096 "[{""id"":""uuid:93578479-d23f-498a-b2d3-d326a0d8cbaf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:088b6e31-408a-479f-a2fe-5c63d2cc5455"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the treatment of aplastic anemia. uuid:5a13f708-8ea7-4309-a886-82bc5801b5a8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:961YV2O515 biolink:treats MONDO:0019098 PMID:41385096 "[{""id"":""uuid:6750cf41-6268-491f-9042-b50891ea991f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:927d620b-caa6-4f4e-b387-163d37da535d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the treatment of chronic idiopathic thrombocytopenic purpura. [Orphan drug] uuid:deb39511-236e-483e-8069-fd1ff6e6ccc9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31617 biolink:treats MONDO:0003308 PMID:41385096 "[{""id"":""uuid:a4ca4bf5-5cd3-482a-91f0-d5e94f1dd81e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b3f9f2f8-16e2-4d30-8903-3c4477dc72a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the diagnosis of malignant tumors (pleural mesothelioma, esophageal cancer, gastric cancer, gastrointestinal stromal tumor, hepatic cancer, biliary tract cancer, pancreatic cancer, bladder cancer, renal pelvis/ureter cancer, uterine cancer, ovarian cancer, bone soft tissue tumor, skin cancer [when the diagnosis of disease stage and metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; thymic tumor, renal cancer, testicular tumor, thyroid cancer [when the diagnosis of metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; visualization of bone lesion or extramedullary lesion in patients suspected of multiple myeloma or with multiple myeloma [when the presence of bone lesion or extramedullary lesion is suspected by other tests/imaging diagnosis]); and the visualization of inflammatory sites in patients suspected of cardiac sarcoidosis or with cardiac sarcoidosis. [Public knowledge-based application] uuid:0cb7ed45-9b99-4229-8a9b-b7d79d74d9b0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31617 biolink:treats MONDO:0007576 PMID:41385096 "[{""id"":""uuid:18ca6d38-8090-485a-bc40-ae95ec189d25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:124c75a7-82fd-4c21-9d32-d8ffa133e4e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the diagnosis of malignant tumors (pleural mesothelioma, esophageal cancer, gastric cancer, gastrointestinal stromal tumor, hepatic cancer, biliary tract cancer, pancreatic cancer, bladder cancer, renal pelvis/ureter cancer, uterine cancer, ovarian cancer, bone soft tissue tumor, skin cancer [when the diagnosis of disease stage and metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; thymic tumor, renal cancer, testicular tumor, thyroid cancer [when the diagnosis of metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; visualization of bone lesion or extramedullary lesion in patients suspected of multiple myeloma or with multiple myeloma [when the presence of bone lesion or extramedullary lesion is suspected by other tests/imaging diagnosis]); and the visualization of inflammatory sites in patients suspected of cardiac sarcoidosis or with cardiac sarcoidosis. [Public knowledge-based application] uuid:2a070c9f-68ba-47fd-91c7-ffeca7a089fd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31617 biolink:treats MONDO:0001056 PMID:41385096 "[{""id"":""uuid:19f11b1f-1f38-4ec9-bb28-2f6ad4a1c94c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1bb4e32c-37cb-491f-bfdf-c79259a00fd8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the diagnosis of malignant tumors (pleural mesothelioma, esophageal cancer, gastric cancer, gastrointestinal stromal tumor, hepatic cancer, biliary tract cancer, pancreatic cancer, bladder cancer, renal pelvis/ureter cancer, uterine cancer, ovarian cancer, bone soft tissue tumor, skin cancer [when the diagnosis of disease stage and metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; thymic tumor, renal cancer, testicular tumor, thyroid cancer [when the diagnosis of metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; visualization of bone lesion or extramedullary lesion in patients suspected of multiple myeloma or with multiple myeloma [when the presence of bone lesion or extramedullary lesion is suspected by other tests/imaging diagnosis]); and the visualization of inflammatory sites in patients suspected of cardiac sarcoidosis or with cardiac sarcoidosis. [Public knowledge-based application] uuid:6e264e13-c657-4d72-825f-7bb131e62053 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31617 biolink:treats MONDO:0011719 PMID:41385096 "[{""id"":""uuid:d2fdbe0a-ec7f-48ab-aaa4-04943b17b2a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:301a1b3c-5e64-4503-abfe-4056080aaf72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the diagnosis of malignant tumors (pleural mesothelioma, esophageal cancer, gastric cancer, gastrointestinal stromal tumor, hepatic cancer, biliary tract cancer, pancreatic cancer, bladder cancer, renal pelvis/ureter cancer, uterine cancer, ovarian cancer, bone soft tissue tumor, skin cancer [when the diagnosis of disease stage and metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; thymic tumor, renal cancer, testicular tumor, thyroid cancer [when the diagnosis of metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; visualization of bone lesion or extramedullary lesion in patients suspected of multiple myeloma or with multiple myeloma [when the presence of bone lesion or extramedullary lesion is suspected by other tests/imaging diagnosis]); and the visualization of inflammatory sites in patients suspected of cardiac sarcoidosis or with cardiac sarcoidosis. [Public knowledge-based application] uuid:642d5ef6-5cdf-47e3-a7d3-a350c85ee503 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31617 biolink:treats MONDO:0002691 PMID:41385096 "[{""id"":""uuid:294ea800-35c6-49e3-951a-f7147c6ab37a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:423b58ec-f025-41d2-86a4-da4c5d998f4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the diagnosis of malignant tumors (pleural mesothelioma, esophageal cancer, gastric cancer, gastrointestinal stromal tumor, hepatic cancer, biliary tract cancer, pancreatic cancer, bladder cancer, renal pelvis/ureter cancer, uterine cancer, ovarian cancer, bone soft tissue tumor, skin cancer [when the diagnosis of disease stage and metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; thymic tumor, renal cancer, testicular tumor, thyroid cancer [when the diagnosis of metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; visualization of bone lesion or extramedullary lesion in patients suspected of multiple myeloma or with multiple myeloma [when the presence of bone lesion or extramedullary lesion is suspected by other tests/imaging diagnosis]); and the visualization of inflammatory sites in patients suspected of cardiac sarcoidosis or with cardiac sarcoidosis. [Public knowledge-based application] uuid:62db426b-8cba-4502-b455-3ffc530bc0c9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31617 biolink:treats MONDO:0003060 PMID:41385096 "[{""id"":""uuid:68204d0c-4452-474a-b79a-ef5227b4b2d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9e9b1bbe-5e72-47f4-aa73-8f1486a2fead"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the diagnosis of malignant tumors (pleural mesothelioma, esophageal cancer, gastric cancer, gastrointestinal stromal tumor, hepatic cancer, biliary tract cancer, pancreatic cancer, bladder cancer, renal pelvis/ureter cancer, uterine cancer, ovarian cancer, bone soft tissue tumor, skin cancer [when the diagnosis of disease stage and metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; thymic tumor, renal cancer, testicular tumor, thyroid cancer [when the diagnosis of metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; visualization of bone lesion or extramedullary lesion in patients suspected of multiple myeloma or with multiple myeloma [when the presence of bone lesion or extramedullary lesion is suspected by other tests/imaging diagnosis]); and the visualization of inflammatory sites in patients suspected of cardiac sarcoidosis or with cardiac sarcoidosis. [Public knowledge-based application] uuid:e796b993-0155-442e-ac74-5affe04ee719 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31617 biolink:treats MONDO:0009831 PMID:41385096 "[{""id"":""uuid:5f97a537-ac6b-471f-b213-693ee1c8c017"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9038d9a7-fc22-48e0-887b-31d416929286"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the diagnosis of malignant tumors (pleural mesothelioma, esophageal cancer, gastric cancer, gastrointestinal stromal tumor, hepatic cancer, biliary tract cancer, pancreatic cancer, bladder cancer, renal pelvis/ureter cancer, uterine cancer, ovarian cancer, bone soft tissue tumor, skin cancer [when the diagnosis of disease stage and metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; thymic tumor, renal cancer, testicular tumor, thyroid cancer [when the diagnosis of metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; visualization of bone lesion or extramedullary lesion in patients suspected of multiple myeloma or with multiple myeloma [when the presence of bone lesion or extramedullary lesion is suspected by other tests/imaging diagnosis]); and the visualization of inflammatory sites in patients suspected of cardiac sarcoidosis or with cardiac sarcoidosis. [Public knowledge-based application] uuid:15b9d9cf-aa95-454d-ac7e-29de5967b13a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31617 biolink:treats MONDO:0001187 PMID:41385096 "[{""id"":""uuid:ef1ed806-5af1-42a4-a119-a89b94ba3f58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:18302dd7-8f29-42c0-905f-bfd0fdd07285"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the diagnosis of malignant tumors (pleural mesothelioma, esophageal cancer, gastric cancer, gastrointestinal stromal tumor, hepatic cancer, biliary tract cancer, pancreatic cancer, bladder cancer, renal pelvis/ureter cancer, uterine cancer, ovarian cancer, bone soft tissue tumor, skin cancer [when the diagnosis of disease stage and metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; thymic tumor, renal cancer, testicular tumor, thyroid cancer [when the diagnosis of metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; visualization of bone lesion or extramedullary lesion in patients suspected of multiple myeloma or with multiple myeloma [when the presence of bone lesion or extramedullary lesion is suspected by other tests/imaging diagnosis]); and the visualization of inflammatory sites in patients suspected of cardiac sarcoidosis or with cardiac sarcoidosis. [Public knowledge-based application] uuid:84df7385-b2e7-4e83-b702-b9b3e41ef06c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31617 biolink:treats MONDO:0005221 PMID:41385096 "[{""id"":""uuid:7263801c-a651-49f6-8b71-ee630e776132"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:da9962e3-352d-4946-804d-dd1950d5dad4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the diagnosis of malignant tumors (pleural mesothelioma, esophageal cancer, gastric cancer, gastrointestinal stromal tumor, hepatic cancer, biliary tract cancer, pancreatic cancer, bladder cancer, renal pelvis/ureter cancer, uterine cancer, ovarian cancer, bone soft tissue tumor, skin cancer [when the diagnosis of disease stage and metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; thymic tumor, renal cancer, testicular tumor, thyroid cancer [when the diagnosis of metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; visualization of bone lesion or extramedullary lesion in patients suspected of multiple myeloma or with multiple myeloma [when the presence of bone lesion or extramedullary lesion is suspected by other tests/imaging diagnosis]); and the visualization of inflammatory sites in patients suspected of cardiac sarcoidosis or with cardiac sarcoidosis. [Public knowledge-based application] uuid:f389f9c5-e7cf-4ca0-a062-45967af22e41 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31617 biolink:treats MONDO:0002715 PMID:41385096 "[{""id"":""uuid:cf9c75ac-558c-49e1-ad4a-968dd02f1fb5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c2dcd68d-2da5-45bb-93ab-8b980a10a531"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the diagnosis of malignant tumors (pleural mesothelioma, esophageal cancer, gastric cancer, gastrointestinal stromal tumor, hepatic cancer, biliary tract cancer, pancreatic cancer, bladder cancer, renal pelvis/ureter cancer, uterine cancer, ovarian cancer, bone soft tissue tumor, skin cancer [when the diagnosis of disease stage and metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; thymic tumor, renal cancer, testicular tumor, thyroid cancer [when the diagnosis of metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; visualization of bone lesion or extramedullary lesion in patients suspected of multiple myeloma or with multiple myeloma [when the presence of bone lesion or extramedullary lesion is suspected by other tests/imaging diagnosis]); and the visualization of inflammatory sites in patients suspected of cardiac sarcoidosis or with cardiac sarcoidosis. [Public knowledge-based application] uuid:f3e09990-a7b6-4c2d-acea-d33c31514e90 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31617 biolink:treats MONDO:0008170 PMID:41385096 "[{""id"":""uuid:3a107cec-3aa6-495e-b616-2c866b30e011"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:78b6817d-bc46-4f02-a83a-f049c477c831"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the diagnosis of malignant tumors (pleural mesothelioma, esophageal cancer, gastric cancer, gastrointestinal stromal tumor, hepatic cancer, biliary tract cancer, pancreatic cancer, bladder cancer, renal pelvis/ureter cancer, uterine cancer, ovarian cancer, bone soft tissue tumor, skin cancer [when the diagnosis of disease stage and metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; thymic tumor, renal cancer, testicular tumor, thyroid cancer [when the diagnosis of metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; visualization of bone lesion or extramedullary lesion in patients suspected of multiple myeloma or with multiple myeloma [when the presence of bone lesion or extramedullary lesion is suspected by other tests/imaging diagnosis]); and the visualization of inflammatory sites in patients suspected of cardiac sarcoidosis or with cardiac sarcoidosis. [Public knowledge-based application] uuid:58a52a3b-3a32-4e9e-b705-d53d6cfa1e85 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31617 biolink:treats MONDO:0002898 PMID:41385096 "[{""id"":""uuid:85892ad6-39ca-45d6-af28-5f844c3ac2da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d6b7db96-6caf-4119-abca-251fbc43bf21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the diagnosis of malignant tumors (pleural mesothelioma, esophageal cancer, gastric cancer, gastrointestinal stromal tumor, hepatic cancer, biliary tract cancer, pancreatic cancer, bladder cancer, renal pelvis/ureter cancer, uterine cancer, ovarian cancer, bone soft tissue tumor, skin cancer [when the diagnosis of disease stage and metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; thymic tumor, renal cancer, testicular tumor, thyroid cancer [when the diagnosis of metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; visualization of bone lesion or extramedullary lesion in patients suspected of multiple myeloma or with multiple myeloma [when the presence of bone lesion or extramedullary lesion is suspected by other tests/imaging diagnosis]); and the visualization of inflammatory sites in patients suspected of cardiac sarcoidosis or with cardiac sarcoidosis. [Public knowledge-based application] uuid:305cbc0d-ddcc-4804-bfa9-29babf0e10f7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31617 biolink:treats MONDO:0005197 PMID:41385096 "[{""id"":""uuid:26414ba0-83a0-45a6-8ba2-39e4c4c6f681"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3788e199-19be-4d01-a020-033ae5e884ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the diagnosis of malignant tumors (pleural mesothelioma, esophageal cancer, gastric cancer, gastrointestinal stromal tumor, hepatic cancer, biliary tract cancer, pancreatic cancer, bladder cancer, renal pelvis/ureter cancer, uterine cancer, ovarian cancer, bone soft tissue tumor, skin cancer [when the diagnosis of disease stage and metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; thymic tumor, renal cancer, testicular tumor, thyroid cancer [when the diagnosis of metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; visualization of bone lesion or extramedullary lesion in patients suspected of multiple myeloma or with multiple myeloma [when the presence of bone lesion or extramedullary lesion is suspected by other tests/imaging diagnosis]); and the visualization of inflammatory sites in patients suspected of cardiac sarcoidosis or with cardiac sarcoidosis. [Public knowledge-based application] uuid:d1ee9998-91d1-42c4-9f91-d54df4278e45 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31617 biolink:treats MONDO:0005206 PMID:41385096 "[{""id"":""uuid:198148b9-226a-4d34-90dd-4bf078d8447a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8fce2414-1b10-4c75-9413-029ded1a2dd2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the diagnosis of malignant tumors (pleural mesothelioma, esophageal cancer, gastric cancer, gastrointestinal stromal tumor, hepatic cancer, biliary tract cancer, pancreatic cancer, bladder cancer, renal pelvis/ureter cancer, uterine cancer, ovarian cancer, bone soft tissue tumor, skin cancer [when the diagnosis of disease stage and metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; thymic tumor, renal cancer, testicular tumor, thyroid cancer [when the diagnosis of metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; visualization of bone lesion or extramedullary lesion in patients suspected of multiple myeloma or with multiple myeloma [when the presence of bone lesion or extramedullary lesion is suspected by other tests/imaging diagnosis]); and the visualization of inflammatory sites in patients suspected of cardiac sarcoidosis or with cardiac sarcoidosis. [Public knowledge-based application] uuid:172efc3c-6595-48f3-9e3b-3da2a6f606ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31617 biolink:treats MONDO:0021348 PMID:41385096 "[{""id"":""uuid:d7552c43-39d9-4228-865b-0c31c3370c60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d00a57ec-976f-4660-9ed6-ad8935196f3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the diagnosis of malignant tumors (pleural mesothelioma, esophageal cancer, gastric cancer, gastrointestinal stromal tumor, hepatic cancer, biliary tract cancer, pancreatic cancer, bladder cancer, renal pelvis/ureter cancer, uterine cancer, ovarian cancer, bone soft tissue tumor, skin cancer [when the diagnosis of disease stage and metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; thymic tumor, renal cancer, testicular tumor, thyroid cancer [when the diagnosis of metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; visualization of bone lesion or extramedullary lesion in patients suspected of multiple myeloma or with multiple myeloma [when the presence of bone lesion or extramedullary lesion is suspected by other tests/imaging diagnosis]); and the visualization of inflammatory sites in patients suspected of cardiac sarcoidosis or with cardiac sarcoidosis. [Public knowledge-based application] uuid:74050d37-126b-416d-9613-5697889912f4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31617 biolink:treats MONDO:0002108 PMID:41385096 "[{""id"":""uuid:81953a68-0214-4238-91c4-b4a40096e8a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bfee6454-8259-489d-ad8f-35947b2dd516"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the diagnosis of malignant tumors (pleural mesothelioma, esophageal cancer, gastric cancer, gastrointestinal stromal tumor, hepatic cancer, biliary tract cancer, pancreatic cancer, bladder cancer, renal pelvis/ureter cancer, uterine cancer, ovarian cancer, bone soft tissue tumor, skin cancer [when the diagnosis of disease stage and metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; thymic tumor, renal cancer, testicular tumor, thyroid cancer [when the diagnosis of metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; visualization of bone lesion or extramedullary lesion in patients suspected of multiple myeloma or with multiple myeloma [when the presence of bone lesion or extramedullary lesion is suspected by other tests/imaging diagnosis]); and the visualization of inflammatory sites in patients suspected of cardiac sarcoidosis or with cardiac sarcoidosis. [Public knowledge-based application] uuid:51ac4e94-fbdc-4c80-8d18-355147b3419a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31617 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:9ec3cbad-18e9-4c41-99e4-487cac8ef32c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ead59ba4-2c31-4a25-9209-a366511009bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the diagnosis of malignant tumors (pleural mesothelioma, esophageal cancer, gastric cancer, gastrointestinal stromal tumor, hepatic cancer, biliary tract cancer, pancreatic cancer, bladder cancer, renal pelvis/ureter cancer, uterine cancer, ovarian cancer, bone soft tissue tumor, skin cancer [when the diagnosis of disease stage and metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; thymic tumor, renal cancer, testicular tumor, thyroid cancer [when the diagnosis of metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; visualization of bone lesion or extramedullary lesion in patients suspected of multiple myeloma or with multiple myeloma [when the presence of bone lesion or extramedullary lesion is suspected by other tests/imaging diagnosis]); and the visualization of inflammatory sites in patients suspected of cardiac sarcoidosis or with cardiac sarcoidosis. [Public knowledge-based application] uuid:8058322c-7cdf-44db-b9c7-6e34ffea004c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31617 biolink:treats MONDO:0001707 PMID:41385096 "[{""id"":""uuid:db92f140-8c4b-418b-9162-c2e9424bc729"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c3891e84-0e62-4832-882f-5d0ae64a7436"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the diagnosis of malignant tumors (pleural mesothelioma, esophageal cancer, gastric cancer, gastrointestinal stromal tumor, hepatic cancer, biliary tract cancer, pancreatic cancer, bladder cancer, renal pelvis/ureter cancer, uterine cancer, ovarian cancer, bone soft tissue tumor, skin cancer [when the diagnosis of disease stage and metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; thymic tumor, renal cancer, testicular tumor, thyroid cancer [when the diagnosis of metastasis/recurrence cannot be confirmed by other tests/imaging diagnosis]; visualization of bone lesion or extramedullary lesion in patients suspected of multiple myeloma or with multiple myeloma [when the presence of bone lesion or extramedullary lesion is suspected by other tests/imaging diagnosis]); and the visualization of inflammatory sites in patients suspected of cardiac sarcoidosis or with cardiac sarcoidosis. [Public knowledge-based application] uuid:56b54204-0228-468e-98bb-b8a54c7401b8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76611 biolink:treats EFO:0007982 PMID:41385096 "[{""id"":""uuid:b804fcfa-b43c-4b9f-9b9f-58f718858487"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c04a1996-916f-4498-9221-3d50683126eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the visualization of beta‑amyloid plaques in the brain of patients suspected of mild cognitive impairment or dementia due to Alzheimer's disease. [Expedited review] uuid:22666d70-2de8-4e92-82e8-754f7922d1dc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:66880 biolink:treats EFO:0007982 PMID:41385096 "[{""id"":""uuid:d3d82836-2a40-4b5d-a371-0db2a43eedf2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2605401e-4927-4f46-8a98-44ebb997de8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the visualization of beta‑amyloid plaques in the brain of patients suspected of mild cognitive impairment or dementia due to Alzheimer's disease. [Expedited review] uuid:9d602526-f1e3-42af-b801-3d61b18d5287 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:92769 biolink:treats MONDO:0005180 PMID:41385096 "[{""id"":""uuid:5d21d1cf-e44e-4831-bbae-5dd537ad15b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:42a5e11a-942e-4012-82b7-00093f42a6b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for cardiac scintigraphy in the diagnoses of Parkinson's disease and dementia with Lewy bodies. uuid:1a6fc659-dfd4-4087-b51d-e5f4c448eaab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:92769 biolink:treats MONDO:0007488 PMID:41385096 "[{""id"":""uuid:f7c58b1a-9ed7-4e5c-b553-4117e5302291"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5e4e6c48-c0f9-49fd-8cda-05da16273829"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for cardiac scintigraphy in the diagnoses of Parkinson's disease and dementia with Lewy bodies. uuid:6d6459bb-0bea-42c6-8ffe-272cc06bb0df biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:QC4F7FKK7I biolink:treats MONDO:0003005 PMID:41385096 "[{""id"":""uuid:9cbbe0b4-1e47-43b0-8184-2fcf7f0d1256"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a80d794d-af79-4cbb-af89-bbf94f81ca20"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the treatment of macular edema following retinal vein occlusion. uuid:aa12bfec-2243-4770-a252-e250d51c02e6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:QC4F7FKK7I biolink:treats MONDO:0006951 PMID:41385096 "[{""id"":""uuid:9ea8fa1c-6afe-4cb0-83de-46639512c167"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e38b6bbb-f2ef-4d63-bc9d-a14638125dc2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the treatment of macular edema following retinal vein occlusion. uuid:3ba7aca7-164f-4dbf-bb91-258db71fd290 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6ZA31Y954Z biolink:treats MONDO:0015597 PMID:41385096 "[{""id"":""uuid:952b9dda-2bef-4102-831d-6607a3144ac6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3030d3dc-b694-4448-b312-7cd29eafae38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the treatment of palmoplantar pustulosis in patients who have not responded sufficiently to conventional therapies. uuid:fbc8f942-0d47-4e53-916e-f3f25679a78e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DPT0O3T46P biolink:treats MONDO:0000901 PMID:41385096 "[{""id"":""uuid:4f8f1e3a-88f8-4164-be0d-0c1fd4f14548"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:59b4ab62-1efc-49a1-9104-9dbe83d05cf5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the treatment of relapsed or refractory primary mediastinal large B- cell lymphoma. [Orphan drug] uuid:c6ca07f7-1072-48c9-aa01-1f91d613c1ab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:73274 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:343fee5f-e485-41df-aaea-9a7a51964b2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:449ec525-25f9-4ee9-8206-f0a5f5c8bcbe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the treatment of chronic kidney disease associated with type 2 diabetes mellitus (excluding patients who have end-stage renal failure or are undergoing dialysis). uuid:60e7a6c2-ebf9-45cd-8cd0-398f4067a6d6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31527 biolink:treats MONDO:0005047 PMID:41385096 "[{""id"":""uuid:92208afc-deb5-49f2-9835-466cb9105885"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:138d2854-3b03-4438-b540-6d5cb73776ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage indicated for luteal support as part of assisted reproductive technology for infertile women. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:358862d5-52f1-460e-801d-bdace84cd700 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3286 biolink:treats MONDO:0011972 PMID:41385096 "[{""id"":""uuid:9b71cd7c-5f55-4823-ba1b-fb4e1ab22ef1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a2cba038-03b5-4d4a-aca2-b01a04937302"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the prevention of ovarian hyperstimulation syndrome associated with assisted reproductive technology. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:8bcde707-d5cf-4258-84ff-b1f7c1f5ffef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6437 biolink:treats MONDO:0002125 PMID:41385096 "[{""id"":""uuid:2f7e9242-fd35-4ba5-abd5-fbbeff7de250"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:362c1320-b7d9-4ccd-ad14-b8bd878844fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the treatment of status epilepticus. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:fe91f688-570c-4db6-9660-1488f82c2a4d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:XSZ53G39H5 biolink:treats MONDO:0004728 PMID:41385096 "[{""id"":""uuid:293b5ed4-69bb-400f-b27d-80dd7ea29e1f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0c270884-6921-49a4-aef9-2dee9c86c869"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the treatment of diabetic macular edema. uuid:eed2b291-8dfd-4df4-975d-75ccef76d4ab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:15C2VL427D biolink:treats MONDO:0006952 PMID:41385096 "[{""id"":""uuid:5877605c-d46f-4940-a6a5-6239edfe409b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:916b7379-d82b-4b75-bab8-8f566953642e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the treatment of retinopathy of prematurity. uuid:3003faf5-091f-4dc3-a956-1430ea3bff79 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1799208 biolink:treats MONDO:0005155 PMID:41385096 "[{""id"":""uuid:e689c2eb-1cda-4958-aa42-7d6bebd0bc5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4913b257-9458-47d0-808f-2c607f421a10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the improvement of viremia in patients with chronic hepatitis C or compensated cirrhosis type C who are naïve or have not previously been treated. uuid:830d8387-f594-4ce6-819e-4cddb0f3fc10 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:94X46KW4AE biolink:treats UMLS:C0276223 PMID:41385096 "[{""id"":""uuid:8cc466ed-6679-4feb-8265-47dbe691ae53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:35dafcb1-d6fe-4aa3-9deb-cafe2bf935a2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the treatment of recurrent herpes simplex. uuid:4969b64a-f951-4fd7-a9b5-c481c376d6bd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63635 biolink:treats MONDO:0017409 PMID:41385096 "[{""id"":""uuid:78cec548-9daa-4b84-a997-9224278ffbf3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c2a50241-51c4-4ae5-ab5b-7518c203de37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the treatment of symptomatic congenital cytomegalovirus infection. [Orphan drug] uuid:061b20c3-7170-46fe-857a-535def9555a2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats HP:0003419 PMID:41385096 "[{""id"":""uuid:dad21a1e-0909-424d-a540-cdf37f7790a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:484dc56c-1e07-4a3b-8c45-0acd60317847"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the analgesia and anti-inflammation in patients with lumbago, periarthritis scapulohumeralis, neck‐shoulder‐ arm syndrome, and tenosynovitis. uuid:fd0be68e-95cb-4ed1-8198-8850de0376c1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats UMLS:C0877557 PMID:41385096 "[{""id"":""uuid:faed95bf-c545-4683-9700-1028af2dbebb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7c86f038-4113-458f-a8ae-e9ecb895901b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the analgesia and anti-inflammation in patients with lumbago, periarthritis scapulohumeralis, neck‐shoulder‐ arm syndrome, and tenosynovitis. uuid:074ab396-92b9-4219-974e-5236b962b24e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats MONDO:0004855 PMID:41385096 "[{""id"":""uuid:49f8c8f2-e8ad-4152-9b5f-59f25e7c7a7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b03a9912-ac18-401a-9df2-960d9eb38da1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the analgesia and anti-inflammation in patients with lumbago, periarthritis scapulohumeralis, neck‐shoulder‐ arm syndrome, and tenosynovitis. uuid:59888410-3b08-459f-ba1d-e20abb496f37 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63599 biolink:treats MONDO:0018874 PMID:41385096 "[{""id"":""uuid:472896e7-251c-42dc-9fa0-d465187c9997"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f89d8a40-1014-4bbb-8b75-f5e491847170"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the treatment of relapsed or refractory acute myeloid leukemia. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:3ab04a9f-5b60-4199-bbf5-982b7972eaef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DPT0O3T46P biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:5fc2faf0-0a09-4866-ad27-d728dca69c5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:962b5db5-b730-4752-a165-a2b779db590b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the treatment of advanced or recurrent cervical cancer. A drug with a new indication and a new dosage for the preoperative and postoperative adjuvant treatment of hormone receptor (HR)-negative and human epidermal growth factor receptor 2 (HER2)-negative breast cancer with a high risk of recurrence. uuid:041e9071-3b26-4bc2-89dc-96e65cbd07e7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PQX0D8J21J biolink:treats MONDO:0002032 PMID:41385096 "[{""id"":""uuid:a257540b-69ff-44df-b958-2aedccfc1488"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:735d4f13-1e1b-48ad-8acb-06fe183da4fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional dosage indicated for the treatment of unresectable, advanced or recurrent colon or rectal cancer with wild-type RAS and head and neck cancer. [Public knowledge-based application] uuid:b3794f9b-13ba-4f71-bf05-17469ce9e805 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PQX0D8J21J biolink:treats MONDO:0006519 PMID:41385096 "[{""id"":""uuid:f15b12c9-72da-4300-be61-e20e568f7e3e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8f4b1c65-4049-4312-9292-b7b512ec05ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional dosage indicated for the treatment of unresectable, advanced or recurrent colon or rectal cancer with wild-type RAS and head and neck cancer. [Public knowledge-based application] uuid:6dd9e0b9-5587-4d36-b85f-307529955e3e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76612 biolink:treats MONDO:0000432 PMID:41385096 "[{""id"":""uuid:6e9f08cc-2ec5-47fa-b2b6-5e85633bcfa2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1b829012-e598-4562-b783-6aa7eff6f682"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new indications for the treatment of Waldenström's macroglobulinemia and lymphoplasmacytic lymphoma. [Orphan drug] uuid:956640cf-ac16-466d-902c-74358cf0a157 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:O43472U9X8 biolink:treats MONDO:0003864 PMID:41385096 "[{""id"":""uuid:1da0ab70-bac2-480c-8dd1-9b34be89fee3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:77e4dca2-1335-4509-a3e9-b3c5d3f6b71c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the treatment of CD20-positive chronic lymphocytic leukemia (including small lymphocytic lymphoma). uuid:cb51fa86-ad46-4b66-b221-e64c2985346e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:Y6BX7BL23K biolink:treats MONDO:0015688 PMID:41385096 "[{""id"":""uuid:b059235c-35dd-4ee9-a11b-aa71df863cf7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:73367bd3-3d36-4716-a43c-16642d9d2043"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the treatment of FGFR1 fusion gene-positive myeloid/lymphoid neoplasms. [Orphan drug] uuid:4438bead-88f3-49f1-b1ba-f0e6085ae284 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:52717 biolink:treats MONDO:0017816 PMID:41385096 "[{""id"":""uuid:cba17d3d-3a37-4866-a35b-b03b06ac4b43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:308d3f84-0884-404e-b9d6-da7f4c38dfa9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the treatment of systemic AL amyloidosis. [Orphan drug] uuid:6b5ace6c-a71f-4969-b3a9-d2e14f9ea950 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:82720 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:1db429e6-b701-46da-a678-454de6e18088"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f476f5e3-9aac-4407-9185-3358b7855b7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the treatment of chronic heart failure (for use only in patients receiving standard treatment of chronic heart failure). uuid:9db348a2-4963-4e24-b56c-ba00d6311f2c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:P76B05O5V6 biolink:treats MONDO:0005133 PMID:41385096 "[{""id"":""uuid:863a7903-e245-4965-a0a4-65fd6a8862a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:02fcf9c7-78ec-4554-b2fc-e61cc221a243"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the alleviation of pain associated with endometriosis. uuid:15dc118a-9316-474c-afd0-fc15a71fe0e0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3752 biolink:treats MONDO:0001913 PMID:41385096 "[{""id"":""uuid:5c8e4ba6-cc82-4cbf-8219-23fda71158a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:40b0ad5a-6bec-4d3c-8189-0f7cc72095af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the induction of spermatogenesis in oligozoospermia. [Public knowledge-based application] uuid:53041ebf-b6fe-44ea-922d-f367a4854285 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75055 biolink:treats MONDO:0005072 PMID:41385096 "[{""id"":""uuid:07bc7075-3a9c-4c2e-8ee2-8458123c5ab7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b952070d-b708-4e88-8f43-182043906eb9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the enhancement of an antitumor effect of dinutuximab for neuroblastoma. [Expedited review] uuid:d1720f30-7532-4325-98db-3484bf4e2460 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DPT0O3T46P biolink:treats MONDO:0005575 PMID:41385096 "[{""id"":""uuid:298bf5ba-f45c-49c2-a469-ad052231d5b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:acf2ddc5-de01-4747-9da6-1a2cd80b6943"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the treatment of unresectable advanced or recurrent microsatellite instability-high (MSI-High) colorectal cancer. A drug with a new indication and a new dosage for the treatment of PD-L1-positive, hormone receptor-negative and HER2-negative inoperable or recurrent breast cancer. uuid:bc368b90-6599-438d-b712-3e80152ca379 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28901 biolink:treats MONDO:0012817 PMID:41385096 "[{""id"":""uuid:ca401aaa-fff9-426a-8ad6-25eebc59baf5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e81c0b14-07f5-4851-a7e5-eb5a3b5261f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new dosage indicated for the conditioning treatments prior to allogeneic hematopoietic stem cell transplantation, and autologous hematopoietic stem-cell transplantation for Ewing's sarcoma family of tumors and neuroblastoma. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:59f5607a-bc7f-4033-a117-6a0e3e318f1b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28901 biolink:treats MONDO:0005072 PMID:41385096 "[{""id"":""uuid:dc601ef0-f790-4d83-a2de-c4207d9f678a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fd274e9f-e19c-44c7-ae6c-188e97f6b6d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new dosage indicated for the conditioning treatments prior to allogeneic hematopoietic stem cell transplantation, and autologous hematopoietic stem-cell transplantation for Ewing's sarcoma family of tumors and neuroblastoma. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:7a19943b-2167-4b4c-839a-83e3954245db biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135515 biolink:treats MONDO:0000901 PMID:41385096 "[{""id"":""uuid:2b628301-2d0b-4504-9e33-a147ac216195"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:39188716-ca47-4ffb-9254-99ff2e602327"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new dosage indicated for the treatment of low-grade B-cell non-Hodgkin’s lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia, and relapsed or refractory diffuse large B-cell lymphoma. uuid:441c944c-c3f4-4e89-b365-00dbb92d17bc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:K16AIQ8CTM biolink:treats MONDO:0002032 PMID:41385096 "[{""id"":""uuid:401ee1f1-3dc5-4bf4-88a6-f0e579d02012"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c83d8e80-04c3-4dee-93f1-bf20ac4c8c32"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the treatment of unresectable advanced or recurrent HER2-positive colon or rectal cancer that has progressed after cancer chemotherapy. uuid:59f124a0-b3a3-4f92-a444-55d17683d721 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:K16AIQ8CTM biolink:treats MONDO:0006519 PMID:41385096 "[{""id"":""uuid:52535286-c5b1-4ff9-a47d-f01df13fc08a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2e861ee4-a651-49ee-9b9c-30efe336f812"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the treatment of unresectable advanced or recurrent HER2-positive colon or rectal cancer that has progressed after cancer chemotherapy. uuid:90fb9f2b-514c-4237-8568-25151f5f3964 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:144421 biolink:treats MONDO:0001356 PMID:41385096 "[{""id"":""uuid:e483eab3-6471-4587-b6cf-b7a4b30eab38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c0f1cf5a-1767-44bb-a7da-6e56509ddfba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the treatment of iron deficiency anemia. uuid:241cd2b7-f56b-4348-aa1e-0ac83a8f7ed2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6ZA31Y954Z biolink:treats MONDO:0005306 PMID:41385096 "[{""id"":""uuid:ddb3388f-e8b3-4d35-acf0-8fe0fc73ea6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:42979c44-03fd-4ff3-bd42-e648bc934c47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new indications for the treatment of ankylosing spondylitis and non-radiographic axial spondyloarthritis in patients who have not responded sufficiently to conventional treatments. uuid:f881c0db-0d40-48d8-88c4-a94b1682ea4b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6ZA31Y954Z biolink:treats UMLS:C3203547 PMID:41385096 "[{""id"":""uuid:d1e45459-ae67-41dd-a5ea-23561384ba82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e813cb7c-9618-44dc-89be-e7dae5a627d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new indications for the treatment of ankylosing spondylitis and non-radiographic axial spondyloarthritis in patients who have not responded sufficiently to conventional treatments. uuid:5d47a75a-e567-4112-97f9-d53b26c5d86f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DPT0O3T46P biolink:treats MONDO:0005580 PMID:41385096 "[{""id"":""uuid:bc306ebe-61e0-43f7-8740-a3e928e35770"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:36f6be45-e3bd-44a0-87d5-43bc253af59c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the treatment of unresectable advanced or recurrent PD-L1- positive esophageal squamous cell carcinoma that has progressed after cancer chemotherapy. uuid:45411999-8072-4792-9d72-617015575964 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:232544 biolink:treats MONDO:0100280 PMID:41385096 "[{""id"":""uuid:c446249f-fe68-4401-8cbd-ac8e21c8d9c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9654e47e-1231-438e-83a7-af7d8a87f4d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new indications for the treatment of Waldenström's macroglobulinemia and lymphoplasmacytic lymphoma. [Orphan drug] uuid:d8574e57-6590-4d10-b241-92354420e7dd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:232544 biolink:treats MONDO:0000432 PMID:41385096 "[{""id"":""uuid:e1e71cf0-6a42-4396-bc37-80ad78f9578d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:863979db-2c17-484b-be2a-6c651037ce9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new indications for the treatment of Waldenström's macroglobulinemia and lymphoplasmacytic lymphoma. [Orphan drug] uuid:4dd3270a-b0fa-4006-95a6-6747bd3e5542 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:52CMI0WC3Y biolink:treats UMLS:C1112459 PMID:41385096 "[{""id"":""uuid:d69f9ef6-bdfd-44ad-beff-4b8ea6175d7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7a704b06-b8c0-449e-87df-0c1b1aa89e56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the treatment of unresectable hepatocellular carcinoma. [Priority review] uuid:82ad9fdb-59eb-421f-a801-5807295d7e1f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:5384HK7574 biolink:treats MONDO:0005036 PMID:41385096 "[{""id"":""uuid:91f37d28-f93d-47ea-b9a9-4dc1441ab3e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e6fd0f98-5fc0-4000-901b-e30070be4ffc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the treatment of unresectable advanced or recurrent HER2- positive gastric cancer that has progressed after cancer chemotherapy. [SAKIGAKE designation] uuid:ca9ca0e0-54e4-40db-9511-4ad2872dd1d3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:145371 biolink:treats MONDO:0005575 PMID:41385096 "[{""id"":""uuid:547385db-12a5-4051-86f8-d2ed4aba5aa2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:82894a68-0c89-492d-ab50-938ec4eb0e7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the treatment of unresectable, advanced or recurrent BRAF mutation-positive colorectal cancer that has progressed after cancer chemotherapy. [Priority review] uuid:1cb6b29b-fba2-467a-915b-126939406afd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41977 biolink:treats MONDO:0010643 PMID:41385096 "[{""id"":""uuid:b9ade9bb-e766-4303-9800-f7bea302d34a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d024d97b-5da1-4ad0-8098-e1567da2c926"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new dosage indicated for the treatment of acute leukemia (including blast crisis of chronic myeloid leukemia). [Public knowledge-based application] uuid:d290f552-96bb-4b71-8d64-1c81128f2e6d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41977 biolink:treats MONDO:0006115 PMID:41385096 "[{""id"":""uuid:f5350935-ed61-4e01-a54d-7fb65422c4d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:543c3fe7-b73a-48f3-81f7-ecbb242d460f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new dosage indicated for the treatment of acute leukemia (including blast crisis of chronic myeloid leukemia). [Public knowledge-based application] uuid:95d6ce8b-b680-4b51-b5bd-92b447939a34 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:659877 biolink:treats UMLS:C1527424 PMID:41385096 "[{""id"":""uuid:b2d1c017-e8ef-49db-9b9b-39aaceef5826"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:659c1428-5d56-46d7-9881-4e2f84427430"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the prevention of the following diseases caused by infection with human papillomavirus types 6, 11, 16, and 18: Cervical cancer (squamous cell carcinoma and adenosquamous carcinoma) and its precursor lesions (cervical intraepithelial neoplasia [CIN] 1, 2, and 3, and adenocarcinoma in situ [AIS]) Vulvar intraepithelial neoplasia (VIN) 1, 2, and 3, and vaginal intraepithelial noeplasia (VaIN) 1, 2, and 3 Anal cancer (squamous cell carcinoma) and its precursor lesions (anal intraepithelial neoplasia [AIN] 1, 2, and 3) Condyloma acuminatum uuid:46d09411-19e7-4c7d-8be6-458fa06479d1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:659877 biolink:treats MONDO:0006137 PMID:41385096 "[{""id"":""uuid:b07ed471-8993-4847-b611-5343841932e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:817ae862-05d4-4941-bf1f-325e545eeb51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the prevention of the following diseases caused by infection with human papillomavirus types 6, 11, 16, and 18: Cervical cancer (squamous cell carcinoma and adenosquamous carcinoma) and its precursor lesions (cervical intraepithelial neoplasia [CIN] 1, 2, and 3, and adenocarcinoma in situ [AIS]) Vulvar intraepithelial neoplasia (VIN) 1, 2, and 3, and vaginal intraepithelial noeplasia (VaIN) 1, 2, and 3 Anal cancer (squamous cell carcinoma) and its precursor lesions (anal intraepithelial neoplasia [AIN] 1, 2, and 3) Condyloma acuminatum uuid:27b23c27-86e9-469f-8e68-5145f2767444 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:659877 biolink:treats MONDO:0042487 PMID:41385096 "[{""id"":""uuid:fd817da1-a498-4583-b9c2-5ed03c38bf27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3c018d6c-99e3-4e80-89a3-5e08a010b70b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the prevention of the following diseases caused by infection with human papillomavirus types 6, 11, 16, and 18: Cervical cancer (squamous cell carcinoma and adenosquamous carcinoma) and its precursor lesions (cervical intraepithelial neoplasia [CIN] 1, 2, and 3, and adenocarcinoma in situ [AIS]) Vulvar intraepithelial neoplasia (VIN) 1, 2, and 3, and vaginal intraepithelial noeplasia (VaIN) 1, 2, and 3 Anal cancer (squamous cell carcinoma) and its precursor lesions (anal intraepithelial neoplasia [AIN] 1, 2, and 3) Condyloma acuminatum uuid:f86f4ad2-75ec-4198-9975-d2b24a88de68 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:659877 biolink:treats MONDO:0018585 PMID:41385096 "[{""id"":""uuid:40e28456-9909-4633-adf6-6b2a814899c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:915b771e-3d2b-467c-84fa-18b0f5036e43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the prevention of the following diseases caused by infection with human papillomavirus types 6, 11, 16, and 18: Cervical cancer (squamous cell carcinoma and adenosquamous carcinoma) and its precursor lesions (cervical intraepithelial neoplasia [CIN] 1, 2, and 3, and adenocarcinoma in situ [AIS]) Vulvar intraepithelial neoplasia (VIN) 1, 2, and 3, and vaginal intraepithelial noeplasia (VaIN) 1, 2, and 3 Anal cancer (squamous cell carcinoma) and its precursor lesions (anal intraepithelial neoplasia [AIN] 1, 2, and 3) Condyloma acuminatum uuid:f45018d6-35d6-42da-91a5-0276346d012d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:659877 biolink:treats MONDO:0006274 PMID:41385096 "[{""id"":""uuid:978aa4fc-4906-4c34-a7dc-e86c0ea6219e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:50beacb8-61ce-4ba5-af1b-44989794d996"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the prevention of the following diseases caused by infection with human papillomavirus types 6, 11, 16, and 18: Cervical cancer (squamous cell carcinoma and adenosquamous carcinoma) and its precursor lesions (cervical intraepithelial neoplasia [CIN] 1, 2, and 3, and adenocarcinoma in situ [AIS]) Vulvar intraepithelial neoplasia (VIN) 1, 2, and 3, and vaginal intraepithelial noeplasia (VaIN) 1, 2, and 3 Anal cancer (squamous cell carcinoma) and its precursor lesions (anal intraepithelial neoplasia [AIN] 1, 2, and 3) Condyloma acuminatum uuid:19229594-b008-4aba-854a-81de09304dba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:659877 biolink:treats UMLS:C0495107 PMID:41385096 "[{""id"":""uuid:0e29b88a-7ee1-4424-be6e-c26e30ab94ee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ef3eede7-4ac5-4322-b349-29ec3cafe0bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the prevention of the following diseases caused by infection with human papillomavirus types 6, 11, 16, and 18: Cervical cancer (squamous cell carcinoma and adenosquamous carcinoma) and its precursor lesions (cervical intraepithelial neoplasia [CIN] 1, 2, and 3, and adenocarcinoma in situ [AIS]) Vulvar intraepithelial neoplasia (VIN) 1, 2, and 3, and vaginal intraepithelial noeplasia (VaIN) 1, 2, and 3 Anal cancer (squamous cell carcinoma) and its precursor lesions (anal intraepithelial neoplasia [AIN] 1, 2, and 3) Condyloma acuminatum uuid:b0f069a2-6457-4da8-9b75-90b3869ad1de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:659877 biolink:treats UMLS:C0349554 PMID:41385096 "[{""id"":""uuid:057c16a7-67d8-4104-bd11-e371f7337a30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7d386b41-e6fa-4835-bb96-d602ddcf8c22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the prevention of the following diseases caused by infection with human papillomavirus types 6, 11, 16, and 18: Cervical cancer (squamous cell carcinoma and adenosquamous carcinoma) and its precursor lesions (cervical intraepithelial neoplasia [CIN] 1, 2, and 3, and adenocarcinoma in situ [AIS]) Vulvar intraepithelial neoplasia (VIN) 1, 2, and 3, and vaginal intraepithelial noeplasia (VaIN) 1, 2, and 3 Anal cancer (squamous cell carcinoma) and its precursor lesions (anal intraepithelial neoplasia [AIN] 1, 2, and 3) Condyloma acuminatum uuid:38fe3991-cf24-4915-a271-20ef6c47a3f1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:659877 biolink:treats MONDO:0859203 PMID:41385096 "[{""id"":""uuid:cfa672b3-dc41-4b80-a93f-92ece42ab50b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ddf34974-0111-47fe-b77f-2dbcc71b09f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the prevention of the following diseases caused by infection with human papillomavirus types 6, 11, 16, and 18: Cervical cancer (squamous cell carcinoma and adenosquamous carcinoma) and its precursor lesions (cervical intraepithelial neoplasia [CIN] 1, 2, and 3, and adenocarcinoma in situ [AIS]) Vulvar intraepithelial neoplasia (VIN) 1, 2, and 3, and vaginal intraepithelial noeplasia (VaIN) 1, 2, and 3 Anal cancer (squamous cell carcinoma) and its precursor lesions (anal intraepithelial neoplasia [AIN] 1, 2, and 3) Condyloma acuminatum uuid:5debd1ed-982c-493a-9284-9dcf8ff8feaf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:659877 biolink:treats UMLS:C1274831 PMID:41385096 "[{""id"":""uuid:00609178-e4af-4a84-83b0-a7c019742227"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f0d37a51-0698-4323-90fc-82622d2fda8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the prevention of the following diseases caused by infection with human papillomavirus types 6, 11, 16, and 18: Cervical cancer (squamous cell carcinoma and adenosquamous carcinoma) and its precursor lesions (cervical intraepithelial neoplasia [CIN] 1, 2, and 3, and adenocarcinoma in situ [AIS]) Vulvar intraepithelial neoplasia (VIN) 1, 2, and 3, and vaginal intraepithelial noeplasia (VaIN) 1, 2, and 3 Anal cancer (squamous cell carcinoma) and its precursor lesions (anal intraepithelial neoplasia [AIN] 1, 2, and 3) Condyloma acuminatum uuid:f4696cba-13b7-41c2-9d99-385db677ec04 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:9RV78Q2002 biolink:treats UMLS:C0852922 PMID:41385096 "[{""id"":""uuid:37df03af-2055-4762-8c2d-95695a8a613b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:773aafa7-8a71-4981-9a90-e4ba3ca238c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication for the treatment and maintenance therapy of moderate to severe active Crohn's disease (for use only in patients who have not sufficiently responded to conventional treatments). uuid:612454e4-859b-4874-a98e-ed1d5a571690 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:A3ULP0F556 biolink:treats MONDO:0019100 PMID:41385096 "[{""id"":""uuid:dd8d0242-9023-4686-b50c-d4dcc2e619dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:43298744-2516-42de-819a-45bb0575c9d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication for the prevention of relapse of neuromyelitis optica spectrum disorder (including neuromyelitis optica). [Orphan drug] uuid:c8a18412-86d7-4d60-a1c2-359d11fc0d87 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31859 biolink:treats MONDO:0018044 PMID:41385096 "[{""id"":""uuid:18b894b4-d564-4163-87ea-d19b20a3d8b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3597adf8-fb76-42d6-b0cf-cb9567a9015a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the treatment of excessive daytime sleepiness associated with idiopathic hypersomnia. [Orphan drug] uuid:25503416-2182-4337-afc0-09688384b7df biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:ZL1R02VT79 biolink:treats MONDO:0006952 PMID:41385096 "[{""id"":""uuid:8827f749-f368-4e83-a495-1dc1316c7ae1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b73f17ed-ec20-42ec-a51b-3d7085d9c91e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for the treatment of retinopathy of prematurity. [Orphan drug] uuid:87c08783-8632-41b0-93b7-a4cb762fe0c8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1597612 biolink:treats HP:0100806 PMID:41385096 "[{""id"":""uuid:aef6a52a-9817-4d1c-8ca5-6e3d6b54c44d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3163790a-3911-428f-b04d-48f4b9fabc31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new additional indications and a new dosage for the treatment of sepsis and pneumonia caused by Serratia and Haemophilus influenzae . uuid:ad2cda3d-259b-4002-a4b7-e2fcb04c4be7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1597612 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:d1837369-977f-4c8e-9682-a684d2b56048"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cce70352-9d4a-4b6c-97dc-b14c5f2a95bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new additional indications and a new dosage for the treatment of sepsis and pneumonia caused by Serratia and Haemophilus influenzae . uuid:a3c492f9-b051-4d6d-b870-0875add79a37 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90936 biolink:treats MONDO:0020325 PMID:41385096 "[{""id"":""uuid:a4571d57-1502-47d4-b3b4-77e4e7c8cadd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:65197ed8-c04a-48ed-a2b2-9e6a0adb6720"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the treatment of relapsed or refractory ALK fusion gene-positive anaplastic large cell lymphoma. [Orphan drug] uuid:406e4e3b-a9e3-4908-bd4a-c3617eab1de8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9570 biolink:treats MONDO:0005062 PMID:41385096 "[{""id"":""uuid:f6bc080f-04cc-4399-ba92-e650f4e1dcf2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5814f74b-9023-4684-8f3b-e6dacaab8ab3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the conditioning treatment of malignant lymphoma in patients prior to autologous hematopoietic stem- cell transplantation. uuid:18f2ba8d-54c9-4114-b3e6-873acf3cb07e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28901 biolink:treats MONDO:0005062 PMID:41385096 "[{""id"":""uuid:409fdcea-37de-44b3-8b16-5e368a82ce3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5da95d05-945f-4ff8-9dcb-a4ea4f1fe225"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the conditioning treatment of malignant lymphoma in patients prior to autologous hematopoietic stem- cell transplantation. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:29698e01-d42b-4551-a70a-d5b88918408e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68551 biolink:treats HP:0012450 PMID:41385096 "[{""id"":""uuid:4608a704-e620-42f9-a3bf-a0a4ed08606b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4489fcf2-4d68-42bf-b449-fd70d95a6758"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication for the treatment of chronic constipation (excluding constipation due to organic diseases). uuid:bf88f221-553f-4d3c-8a22-021c20876613 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15891 biolink:treats MONDO:0010789 PMID:41385096 "[{""id"":""uuid:9fbeb2e8-496c-4258-9dfc-6dfe6f908ebf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c406cfca-f549-41c5-8169-b7cd48bb1861"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for the inhibition of stroke-like episodes in patients with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS). [Orphan drug] uuid:5e0fc2c2-4eeb-4073-b6d7-74cd4ea00a95 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15891 biolink:treats HP:0002401 PMID:41385096 "[{""id"":""uuid:10f78574-c55b-4de9-bc12-182a83141138"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d88f3fc1-a1d7-49b7-9032-8bbbe8c33704"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for the inhibition of stroke-like episodes in patients with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS). [Orphan drug] uuid:9d7c7101-c38b-4324-813f-09d197b3f5be biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63580 biolink:treats MONDO:0005155 PMID:41385096 "[{""id"":""uuid:9096cfb7-fb2d-4ff8-a0a8-5468c7d46c70"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8723e0a7-af9e-4cd1-ab78-4dd6a1fc6c4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage, used in combination with sofosbuvir and velpatasvir, for the improvement of viremia in patients with chronic hepatitis C or compensated cirrhosis type C who have previously been treated. [Expedited review] uuid:204a78ce-11ec-420b-b3cd-fc97028243f4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4974 biolink:treats MONDO:0004609 PMID:41385096 "[{""id"":""uuid:8323a98e-95cb-4451-9b9a-b57231d8e976"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:501426ab-a58c-4c3b-a4b8-bfd075aad4a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new dosage indicated for the treatment of herpes simplex. uuid:0f7b1245-98d9-4098-b8d9-fbb60bfe3f95 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:127780 biolink:treats MONDO:0027029 PMID:41385096 "[{""id"":""uuid:b897eea8-45d6-4cdf-af02-5ca505eb8d03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:71f32d81-5abb-46fa-9f7f-817f9a2a8932"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage indicated for the treatment of human herpesvirus 6 encephalitis after hematopoietic stem cell transplantation. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:f123c6e6-e758-4716-bf66-3b0a5ff33f89 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:089658A12D biolink:treats MONDO:0015597 PMID:41385096 "[{""id"":""uuid:46059fb2-b9e2-41b4-bf70-c00fe5e11cd4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f978ca90-a040-4420-aea2-613c67d4d28e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication for the treatment of palmoplantar pustulosis in patients who have not responded sufficiently to conventional therapies. uuid:4e30a7b4-62e1-4d25-a279-87f38e2697eb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:420K487FSG biolink:treats MONDO:0100470 PMID:41385096 "[{""id"":""uuid:9bc429a2-d3cd-456d-9195-dfe8ab27a8a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3bc0f1fa-bd6d-4169-9970-2b861d30d17f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication, a new dosage and other characteristics for the treatment of bronchial asthma (for use only in patients with severe or intractable bronchial asthma whose asthmatic responses are uncontrollable with conventional therapies). uuid:98a44578-ae6d-487b-808e-4b49c55d14db biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44185 biolink:treats UMLS:C0406317 PMID:41385096 "[{""id"":""uuid:ad8378ef-c3fc-47c5-80b0-3c9f7842e8cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6e83a893-f27e-46d6-ad2e-5fb1a264c609"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new additional indications and a new dosage for the treatment of plaque psoriasis in patients who have not responded sufficiently to topical therapy, or psoriatic arthritis, pustular psoriasis and erythrodermic psoriasis . [Public knowledge-based application after PAFSC's preliminary assessment] uuid:26b3b55f-813b-4239-bf96-58d7b78199cc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44185 biolink:treats MONDO:0022205 PMID:41385096 "[{""id"":""uuid:4f80e5bf-7bff-425e-9a7d-8971b09929d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:55df079e-937f-4e6c-87c4-8b18bcc312a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new additional indications and a new dosage for the treatment of plaque psoriasis in patients who have not responded sufficiently to topical therapy, or psoriatic arthritis, pustular psoriasis and erythrodermic psoriasis . [Public knowledge-based application after PAFSC's preliminary assessment] uuid:c35a8bc4-a4ac-4302-9d1e-927ae8d71dc5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44185 biolink:treats UMLS:C0748052 PMID:41385096 "[{""id"":""uuid:6426c2a7-9375-498d-9b29-dd6197a9ebf9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d08caf09-8b2c-408f-8334-ea665ee047d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new additional indications and a new dosage for the treatment of plaque psoriasis in patients who have not responded sufficiently to topical therapy, or psoriatic arthritis, pustular psoriasis and erythrodermic psoriasis . [Public knowledge-based application after PAFSC's preliminary assessment] uuid:502b1793-2991-4037-ae2f-4999cc5721a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6T8C155666 biolink:treats UMLS:C4725093 PMID:41385096 "[{""id"":""uuid:86616a8c-5213-497b-8c9d-083d677a4251"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:90fe1cca-5922-4195-a4e6-cb1eed093db7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new dosage indicated for the treatment of unresectable melanoma. [Orphan drug] uuid:c8b421cc-2b15-4ee9-8a3e-c42e7bbe2c45 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:YI437801BE biolink:treats MONDO:0015758 PMID:41385096 "[{""id"":""uuid:477e4bb2-03b5-4be9-8870-ba3633592936"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3f5a772e-e857-4ead-9dcf-0a90bb41e13c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new indications and a new dosage for the treatment of relapsed or refractory cutaneous T-cell lymphoma. [Orphan drug] uuid:702cfc6c-10fd-445f-b707-d15b0dcd9c41 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4F4X42SYQ6 biolink:treats MONDO:0019098 PMID:41385096 "[{""id"":""uuid:07bbd449-ea92-487f-b380-a64180c76e4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2fc98df9-c1a2-4c33-b0b0-4b3c8d624f31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for the treatment of chronic idiopathic thrombocytopenic purpura. [Public knowledge-based application after preliminary assessment by the Pharmaceutical Affairs and Food Sanitation Council (PAFSC)] uuid:917cadaf-46a9-4ea4-98eb-479dae66eb20 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:441410 biolink:treats MONDO:0010735 PMID:41385096 "[{""id"":""uuid:fbd98b17-a246-4587-a6f9-a547be443a7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f9a86adb-1c4e-4761-87a9-76985107d119"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication for inhibiting progression of spinal and bulbar muscular atrophy. [Orphan drug] uuid:0a301379-f39b-4c99-9e4f-2281c725c96d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4EQZ6YO2HI biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:0bfd46a5-3d55-466e-a641-ea7ba3fc3669"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:52a7b52c-702e-418d-9be6-42a8000e29a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage indicated for inhibiting progression of bone erosion associated with rheumatoid arthritis. uuid:d6c8c3fa-1dab-4f65-a7ea-0c3b3ef9ada4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7D0YB67S97 biolink:treats MONDO:0011429 PMID:41385096 "[{""id"":""uuid:1becdbbc-d24e-4d72-90ae-9db48dfeb95a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:61a9b3f6-45bc-4cc3-b679-332e473e407b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage indicated for the treatment of polyarticular- course juvenile idiopathic arthritis in patients who have not responded sufficiently to conventional therapies. uuid:7675eb27-269f-4404-8149-68a5d35afacc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15355 biolink:treats MONDO:0005356 PMID:41385096 "[{""id"":""uuid:1bce8b26-0fbd-4c38-9d1c-cf248a2b75e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:10ac3083-d27b-4157-a0a2-6e799278fbe1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for the induction of coronary spasm in a drug- induced coronary spasm provocation test during coronary angiography. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:6b729997-55cb-475f-a41d-e5abb3badba0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135901 biolink:treats MONDO:0019954 PMID:41385096 "[{""id"":""uuid:4978abbb-e5a6-4e77-8861-bad8b438f897"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1dd88ba9-bcd1-46c8-a455-6e068467aed0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage indicated for the treatment of neuroendocrine tumors of the pancreas and gastrointestinal tract. uuid:8d83dda2-d8b4-49e4-893e-4b3f2b3ab549 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45863 biolink:treats MONDO:0001056 PMID:41385096 "[{""id"":""uuid:a74ba9bc-2ae0-499f-a340-1f6a66cec19a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d20ea9b4-c2c9-44d6-9961-87656ab23b6c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new dosage indicated for the treatment of gastric cancer. uuid:557c38c9-4b4d-4243-a12d-9dcf5aa27c51 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68642 biolink:treats MONDO:0008315 PMID:41385096 "[{""id"":""uuid:58721913-92ac-4e9a-ab2c-b279f9c6fb03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b67427ec-b830-4aa6-a581-18fedce2f704"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication for the treatment of prostate cancer in patients with high- risk prognostic factors who have not received previous endocrine therapy. [Priority review] uuid:54f2bc2c-cdf9-4ee9-8f6e-d86f9b6a91bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:52717 biolink:treats MONDO:0100280 PMID:41385096 "[{""id"":""uuid:55f8bca0-5a73-4fe3-86c6-c03f96cba6fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b7a41b19-ac80-4e57-b97a-56f34a8ae314"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage indicated for the treatment of Waldenströ m's macroglobulinemia and lymphoplasmacytic lymphoma. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:75dd4f93-d271-4bbd-8caa-e845b00f0e02 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:52717 biolink:treats MONDO:0000432 PMID:41385096 "[{""id"":""uuid:57c9e13d-e500-4c23-a013-e7a93fe42a79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b7c09e84-cf0a-4af8-b6c7-8379ae4e9569"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage indicated for the treatment of Waldenströ m's macroglobulinemia and lymphoplasmacytic lymphoma. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:3c38db9a-35cf-4b46-8fec-ddb01d863d08 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0004728 PMID:41385096 "[{""id"":""uuid:bfa7964a-80de-43db-8da2-f5e2f78e3d43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:848bed97-dd74-4f28-b1e2-b314facdb0a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for alleviation of diabetic macular edema and macular edema associated with retinal vein occlusion or non-infectious uveitis. uuid:8537de6d-da8a-4487-b9a3-0801052354bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0041093 PMID:41385096 "[{""id"":""uuid:d69105fb-a997-463c-aba2-196f90dc2289"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:16f7ce4c-562f-4405-a15c-868a8ae40955"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for alleviation of diabetic macular edema and macular edema associated with retinal vein occlusion or non-infectious uveitis. uuid:db284455-82e2-4641-a420-3ad11678d70d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9667 biolink:treats MONDO:0003005 PMID:41385096 "[{""id"":""uuid:0c97ae71-39b3-4e34-be55-02017366a9da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:05e7083a-7964-4c72-bf93-6ad0caa806ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration indicated for alleviation of diabetic macular edema and macular edema associated with retinal vein occlusion or non-infectious uveitis. uuid:afb88df3-0180-4e4a-9728-bf0f304d30b1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:48814 biolink:treats UMLS:C4049395 PMID:41385096 "[{""id"":""uuid:bcc34b6d-e1ae-4804-bc59-99b3626cf5cb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e52eacd5-adc8-43a1-968f-2511fd9bece5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for the improvement of viremia in patients with chronic hepatitis C in serogroup 2 (genotype 2). uuid:6559e00c-671b-46b7-a0a5-81fcce8d6a1f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63580 biolink:treats UMLS:C4049395 PMID:41385096 "[{""id"":""uuid:8c4be3e4-1216-4422-8cf9-b88c96002fd9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1adfb9db-a42f-4baa-b3bd-7c7895d1171b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for the improvement of viremia in patients with chronic hepatitis C in serogroup 2 (genotype 2), for a combination use of ombitasvir hydrate, paritaprevir hydrate, and ritonavir. uuid:f190ad32-c6b3-43a4-b30d-b73464070bbf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77573 biolink:treats MONDO:0005867 PMID:41385096 "[{""id"":""uuid:cbcf2e3f-068c-458d-a6b5-963f1a407534"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b1b891df-b64f-4400-bea2-87f2f9b91276"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication for the treatment of mycoplasma pneumonia caused by Mycoplasma pneumoniae . uuid:ec047fa2-003d-4d1a-9062-73143d4b3596 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7798 biolink:treats UMLS:C0858004 PMID:41385096 "[{""id"":""uuid:6bea4f61-40b6-4f72-a4ba-afa892a54832"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:49bdef3f-340a-400d-a3de-dce8c22827a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional dosage for newborns and infants for the treatment of influenza A or B virus infection. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:d1306986-ff42-4a36-9b57-57a54f0dd53b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7798 biolink:treats UMLS:C0858005 PMID:41385096 "[{""id"":""uuid:f4baabc2-4ec2-4fc2-ad51-ad0c487a2e08"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ae340c5f-4501-4fb2-bfbc-a927eec9bf2c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional dosage for newborns and infants for the treatment of influenza A or B virus infection. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:3fd9545d-4ab9-430c-9064-6e973ad76562 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:B72HH48FLU biolink:treats MONDO:0022205 PMID:41385096 "[{""id"":""uuid:cace5dcd-449d-4e33-8890-7cdb3321e52b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:82db111c-ae26-46ba-ae8f-6988a0fea3d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new dosage indicated for plaque psoriasis, psoriatic arthritis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional treatments. uuid:8ef7445b-cad6-4b09-8231-d7e587ae8bed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:B72HH48FLU biolink:treats UMLS:C0748052 PMID:41385096 "[{""id"":""uuid:7b2f5b6a-88a5-4601-af5b-623b46bad486"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b81bbd80-d190-4e0b-9442-7f991439da92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new dosage indicated for plaque psoriasis, psoriatic arthritis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional treatments. uuid:59e29372-208e-4a1a-ad9f-2caac3a8e6a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:3160WY51LV biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:96fc0bad-e300-4f7f-95e5-90151178a8ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f610b2cb-c437-4316-b787-167d949a1ef3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new expanded indication for the improvement of hyperphosphatemia in patients with chronic kidney disease. uuid:5d2cb86c-c302-4903-9660-789b7b4f09d3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:51450 biolink:treats HP:0031917 PMID:41385096 "[{""id"":""uuid:6b8515e5-0e27-4456-a0ad-938332b6a2e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f11178f6-76f5-4ac2-8d5c-b9755e241377"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication for inhibiting development of digital ulcer in patients with systemic scleroderma (only for patients who currently have digital ulcers or have a history of digital ulcer.) [Orphan drug] uuid:995d1848-ab89-4b10-9946-f216e53e74e9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:36791 biolink:treats MONDO:0001247 PMID:41385096 "[{""id"":""uuid:878f2482-d45b-4eb5-842c-437cb9d1dd92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:de6a8567-4483-473a-b030-05a2a139c3c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication for the treatment of social anxiety disorder. uuid:dbaf1510-0bf3-40a6-a08f-ce2a40d6caf1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1314134 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:59cd003c-a0fc-4df3-99ea-dbe563b3409b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:81788320-5235-4eb6-a955-83bec6749d4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for adults indicated for the relief of pain during pricking with injection needles and intravenous indwelling needles, and with a new pediatric dosage indicated for the relief of pain during skin laser radiation therapy and pricking with injection needles and intravenous indwelling needles. uuid:ddf2af87-68ad-4e7e-a79d-20b70a12925a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats HP:0100806 PMID:41385096 "[{""id"":""uuid:efb205eb-68a3-4db3-bf2c-11f808a4b89d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e421c231-0b50-4ab6-ba60-7f7d70c6e656"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new increased dose for adults indicated for the treatment of sepsis, pneumonia, etc., and also with new indications and new dosages for children for both the treatment of complicated cystitis, pyelonephritis and anthrax, and the improvement of symptoms associated with respiratory infection caused by Pseudomonas aeruginosa in cystic fibrosis. uuid:cbab1202-9d25-452a-b159-52b1621fbd90 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats MONDO:0005119 PMID:41385096 "[{""id"":""uuid:95666670-7949-4553-8c1c-6e01d140f085"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e8e855c5-f6b3-4e63-9348-d17c833358ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new increased dose for adults indicated for the treatment of sepsis, pneumonia, etc., and also with new indications and new dosages for children for both the treatment of complicated cystitis, pyelonephritis and anthrax, and the improvement of symptoms associated with respiratory infection caused by Pseudomonas aeruginosa in cystic fibrosis. uuid:a41a3029-f9b0-4b5b-a7ff-23552ce53a1b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats MONDO:0037398 PMID:41385096 "[{""id"":""uuid:f164e4f6-6267-4d1c-ae4f-5745892794c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a77021ae-07df-42e9-9086-d6ccdd11ea55"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new increased dose for adults indicated for the treatment of sepsis, pneumonia, etc., and also with new indications and new dosages for children for both the treatment of complicated cystitis, pyelonephritis and anthrax, and the improvement of symptoms associated with respiratory infection caused by Pseudomonas aeruginosa in cystic fibrosis. uuid:2bb66004-0c94-42ca-9f4c-4230c7605c92 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:66919 biolink:treats MONDO:0009891 PMID:41385096 "[{""id"":""uuid:4c5319d7-1db1-4433-98f6-b1de6e1d8013"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c7967a6d-7c00-4371-9231-c11da85ee84b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for the treatment of polycythemia vera (use only when conventional therapies are not sufficiently effective or inappropriate). uuid:ced2417e-b6d5-4ca2-aef5-769a9019a747 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63587 biolink:treats MONDO:0018078 PMID:41385096 "[{""id"":""uuid:99da5cf8-d505-48a1-a023-daf0819b46ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9f6d25d7-f1d7-4df1-b5ae-ff474c9c6197"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication for the treatment of soft tissue sarcoma. [Orphan drug] uuid:874f1487-b6dd-45a1-b622-dfe2a0de37c5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50924 biolink:treats MONDO:0002108 PMID:41385096 "[{""id"":""uuid:b557d783-f35b-4107-831b-46e947dfe49b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a4dde7f7-ea85-4422-9d5c-ad6dc297eb58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a revised indication for the treatment of unresectable thyroid cancer. [Orphan drug] uuid:f215252b-8089-4b2c-81f8-ad01fbb3f001 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4F4X42SYQ6 biolink:treats MONDO:0044765 PMID:41385096 "[{""id"":""uuid:bca2022a-3611-4aec-9d0c-fc8dc82b0c0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ecb1346b-345e-45db-a44b-52cbfd300447"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for the treatment of refractory nephrotic syndrome (for use in patients with frequent recurrence or steroid-dependent). [Orphan drug] uuid:2cb33d3b-b292-4599-94e5-e9927b95e604 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB00028 biolink:treats UMLS:C0877157 PMID:41385096 "[{""id"":""uuid:1570d9f5-8b86-443d-befd-594d059feea6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e092dc69-0315-49eb-8dcb-7cc4b67a8e75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for the treatment of acute rejection after the liver, heart, lungs, pancreas, or small intestinal transplantation. uuid:00e44993-3a4b-487a-8bdc-9273e6753e4b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28001 biolink:treats HP:0100806 PMID:41385096 "[{""id"":""uuid:056797c3-b5e6-4254-ae24-eec697a38435"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:315401e7-28d8-476b-9509-cd1a7a4cd6bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new additional indications for the treatment of: sepsis, infective endocarditis, secondary infection of trauma, burn or surgical wounds, osteomyelitis, arthritis, peritonitis and purulent meningitis caused by vancomycin-sensitive methicillin-resistant coagulase-negative Staphylococcus (MRCNS); or febrile neutropenia which is suspected of MRSA or MRCNS infection. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:a1142ed5-cdd7-4c1e-8116-9cc725903733 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28001 biolink:treats MONDO:0005578 PMID:41385096 "[{""id"":""uuid:11c45de6-ca6c-4451-b025-b5962406846f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a9b4843c-f57d-4922-a104-b40c1b575a11"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new additional indications for the treatment of: sepsis, infective endocarditis, secondary infection of trauma, burn or surgical wounds, osteomyelitis, arthritis, peritonitis and purulent meningitis caused by vancomycin-sensitive methicillin-resistant coagulase-negative Staphylococcus (MRCNS); or febrile neutropenia which is suspected of MRSA or MRCNS infection. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:6071f5c5-7903-4263-911c-91ee4a7bf83f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28001 biolink:treats MONDO:0004522 PMID:41385096 "[{""id"":""uuid:a27a6f95-9ff7-4e33-b89e-42610720c023"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a641b873-1e29-48e5-a0c5-60463acf9bc3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new additional indications for the treatment of: sepsis, infective endocarditis, secondary infection of trauma, burn or surgical wounds, osteomyelitis, arthritis, peritonitis and purulent meningitis caused by vancomycin-sensitive methicillin-resistant coagulase-negative Staphylococcus (MRCNS); or febrile neutropenia which is suspected of MRSA or MRCNS infection. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:42b32fc9-a960-40db-b175-4fba0674e9ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28001 biolink:treats UMLS:C0865440 PMID:41385096 "[{""id"":""uuid:fae68a60-2ea8-47fc-a526-555ccfcbd166"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:af6fcdc9-1b4a-4a8e-9459-63039542e72d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new additional indications for the treatment of: sepsis, infective endocarditis, secondary infection of trauma, burn or surgical wounds, osteomyelitis, arthritis, peritonitis and purulent meningitis caused by vancomycin-sensitive methicillin-resistant coagulase-negative Staphylococcus (MRCNS); or febrile neutropenia which is suspected of MRSA or MRCNS infection. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:03033b02-8495-4433-817b-d38f3c43bc12 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28001 biolink:treats UMLS:C0746883 PMID:41385096 "[{""id"":""uuid:c425e45d-4280-4237-a1a6-f8d7b787c253"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c95e42ca-1f27-44d6-b9cb-4d7d3645e489"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new additional indications for the treatment of: sepsis, infective endocarditis, secondary infection of trauma, burn or surgical wounds, osteomyelitis, arthritis, peritonitis and purulent meningitis caused by vancomycin-sensitive methicillin-resistant coagulase-negative Staphylococcus (MRCNS); or febrile neutropenia which is suspected of MRSA or MRCNS infection. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:13a85a59-fa9c-47ee-8d4b-b2b0b222d3a8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63580 biolink:treats MONDO:0005231 PMID:41385096 "[{""id"":""uuid:bbfd3164-6933-472c-af84-7332854043a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:837fc27b-48c9-4138-b42a-a28c12f124ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for the improvement of viremia with the concomitant use of sofosbuvir in patients with chronic hepatitis C or compensated cirrhosis type C in serogroup 2 (genotype 2) . [Expedited review] uuid:e8ede204-785d-4b97-8662-90ee282a033d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63580 biolink:treats MONDO:0005448 PMID:41385096 "[{""id"":""uuid:96cf42cd-59e6-473c-80ae-d7731cc6d106"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:02082ce4-d060-4618-a47e-1b929d68eedc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for the improvement of viremia with the concomitant use of sofosbuvir in patients with chronic hepatitis C or compensated cirrhosis type C in serogroup 2 (genotype 2) . [Expedited review] uuid:5c21f57a-0a31-42ca-82b0-50af28e35e49 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6443 biolink:treats HP:0100607 PMID:41385096 "[{""id"":""uuid:1fd15eb4-aa4c-4958-947b-5bcc5d4acf60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f1178c91-db74-4e98-a52d-c6f87c317abd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication for the treatment of dysmenorrhoea. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:d8376afc-d3c4-469f-9456-edf4ff638434 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90959 biolink:treats MONDO:0100470 PMID:41385096 "[{""id"":""uuid:43034305-e414-4ba2-88f8-e6f34113ce86"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:62fafa75-60be-4e08-8afb-ef779ac38cf1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication for the relief of symptoms secondary to airway obstructive disorders in bronchial asthma (for use only in patients with the severe persistent type). uuid:fbea0093-33c5-4312-a9e5-756d68c767d4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:681848 biolink:treats MONDO:0020567 PMID:41385096 "[{""id"":""uuid:2f4ebaee-5205-48b2-a1eb-992360124059"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c3cdbc8d-7005-414e-a39a-519c172e4ea0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for the treatment of primary apnoea (apnea of prematurity) in immature or low birth weight infants who have not responded sufficiently to conventional therapies. uuid:c19d56ea-1cc3-4b34-a374-e9469d23179c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45863 biolink:treats UMLS:C0854776 PMID:41385096 "[{""id"":""uuid:0c16b003-3fa7-47d2-815b-de0dae7c9666"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2e655311-bec6-4430-9a9f-c9418f4a66e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for the treatment of unresectable pancreatic cancer. [Priority review] uuid:c71cfd2b-9e23-4529-a917-19748424f066 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:YI437801BE biolink:treats MONDO:0019471 PMID:41385096 "[{""id"":""uuid:91bfeccd-1dc4-45c1-a641-15bd9b2130e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:62a355a7-fe65-4769-ad66-c23db3942425"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a revised indication and a new dosage for the treatment of CCR4-positive adult T-cell leukemia/lymphoma. [Expedited review] uuid:80984d01-80d1-4fef-a411-41af4d4f42f0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2663 biolink:treats MONDO:0000745 PMID:41385096 "[{""id"":""uuid:51ee2b6f-bc07-4752-850d-077a9090eecd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3f511750-b9cb-4b3e-b81e-024f3b78c36f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage indicated for the treatment of cardiac arrest due to ventricular fibrillation/pulseless ventricular tachycardia, resistant to electrical cardioversion. uuid:e1cc7b43-719f-483c-b2c7-6432a1ebcebf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231425 biolink:treats MONDO:0005155 PMID:41385096 "[{""id"":""uuid:d859b7fa-e354-480e-a680-26eeba0ad740"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f9d25e64-d811-4fd4-a96d-773b7319c97c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for the treatment of fluid retention in patients with hepatic cirrhosis who have not responded sufficiently to other diuretics such as loop diuretics. uuid:d9622414-4dd5-49eb-87d4-9ef8f9651840 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135809 biolink:treats UMLS:C0080203 PMID:41385096 "[{""id"":""uuid:1269faa0-3718-432e-a684-ff36804d1d03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:02a2317e-6de2-4f63-bc2a-5bffd8637180"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for the treatment of tachyarrhythmia including atrial fibrillation/flutter in patients with low cardiac function. uuid:f8732771-77dc-4161-80f7-0f57ce4d2a78 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:ZL1R02VT79 biolink:treats MONDO:0003005 PMID:41385096 "[{""id"":""uuid:fb873753-7708-467c-a5d9-f9027c4127b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a10ac077-bd66-467e-b70c-74aed2030567"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new additional indications and a new dosage for the treatment of macular edema following retinal vein occlusion and choroidal neovascularisasion in pathologic myopia. uuid:caa405cd-9406-4ff4-a4ab-a213be5a440e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17076 biolink:treats UMLS:C5543174 PMID:41385096 "[{""id"":""uuid:d0fdb974-566b-42c9-83e2-7cdf4ffd83f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1aa50042-2129-498a-b3fa-c3d4555e3617"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and new dosage for the treatment of non-tuberculous mycobacterial infection including mycobacterium avium complex (MAC) caused by streptomycin- sensitive mycobacterium as its applicable microorganism. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:6d401edc-b165-445f-a493-36c4417fe115 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17076 biolink:treats MONDO:0005866 PMID:41385096 "[{""id"":""uuid:aa06914e-c65f-44a1-b697-d9b72729fc60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:72116f71-046e-4b30-972c-1a70ec0e66ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and new dosage for the treatment of non-tuberculous mycobacterial infection including mycobacterium avium complex (MAC) caused by streptomycin- sensitive mycobacterium as its applicable microorganism. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:5e5ea02f-b4c7-4cdd-a868-cd32d897388b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16469 biolink:treats MONDO:0010706 PMID:41385096 "[{""id"":""uuid:43e1a51d-bdaf-4179-b357-ac3cba033fa8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:08a93984-b6ea-44c9-811a-72a565e417f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and new dosages for the treatment of hypoestrogenism caused by hypogonadism, gonadectomy or primary ovarian insufficiency. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:5bbfc0a9-7df3-4047-86e4-b2e005709fa7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68647 biolink:treats MONDO:0011719 PMID:41385096 "[{""id"":""uuid:6d68c8e5-a28a-4ab3-a987-14b16433b4b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:65487da2-60f9-4ea0-b178-b02b9d4e1720"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication for the treatment of gastrointestinal stromal tumor which has progressed after cancer chemotherapy. [Priority review] uuid:0edd7e14-a80c-4dc3-afc6-e07f3130f7e3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68647 biolink:treats MONDO:0004992 PMID:41385096 "[{""id"":""uuid:9a9b1dd4-4054-47a2-b825-89b98c8adaeb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9c68439b-45b9-4104-a100-1c7c8ad4d874"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication for the treatment of gastrointestinal stromal tumor which has progressed after cancer chemotherapy. [Priority review] uuid:1ad89020-8f90-48e8-bcd6-9579b1e3e085 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135875 biolink:treats MONDO:0001657 PMID:41385096 "[{""id"":""uuid:6bf6d8f3-19ba-45af-a2aa-d15b06cf8d5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5dce0f59-16fd-474e-a473-2ab8c0e448d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for the treatment of primary malignant brain tumor (only for the case where surgical excision of tumor is performed). [Orphan drug] uuid:def8375a-ac38-4114-8963-e93af697ebe2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5523 biolink:treats UMLS:C0741682 PMID:41385096 "[{""id"":""uuid:3f49bbb2-3af5-4ea7-b435-f58b73f85c8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:96cce56e-dec9-452d-ab77-00143f610fd6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication for the treatment of premenopausal breast cancer. uuid:863b6b53-69f3-4f12-96cb-1c91d7658619 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:NU23Q531G1 biolink:treats MONDO:0021133 PMID:41385096 "[{""id"":""uuid:7495847a-e343-451c-a72f-f054a419a9b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d939dc8a-02f5-4366-85e9-a1da77a16204"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication for the treatment of bleeding tendency caused by acquired blood coagulation factor XIII deficiency. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:1e77870b-0ce5-44fd-ab41-50818b7dfd7d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:NU23Q531G1 biolink:treats HP:0001892 PMID:41385096 "[{""id"":""uuid:e6103ebb-610d-4160-9c46-93af6c705025"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:34f981d1-bdba-4f2d-a039-8066461ce597"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication for the treatment of bleeding tendency caused by acquired blood coagulation factor XIII deficiency. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:d606a2ec-ac13-46b8-ac2c-e00026b56bf5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:K2CJI135MU biolink:treats MONDO:0041996 PMID:41385096 "[{""id"":""uuid:76dcbbc2-09f2-4997-b03c-91e1dc55192f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:69c9dade-e2bc-4a0e-906b-badf69a75bd9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication for the treatment of thallium and thallium compound poisoning. uuid:5781183f-29f0-49d1-afef-3ed2f7a886c3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6456 biolink:treats MONDO:0005855 PMID:41385096 "[{""id"":""uuid:0ccf195e-511d-4ba2-9dbb-03e902cc271f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fbc2eedd-c748-42e0-8226-86393b5d7859"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for pain relief at the resection of molluscum contagiosum. uuid:be0f15a7-04af-457b-92cd-c8c51a462b33 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59343 biolink:treats MONDO:0005441 PMID:41385096 "[{""id"":""uuid:1c8c02f7-a2ee-4907-bb83-7431c92e5e18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:52ff6fc9-1080-4990-b4b1-17409e7af0eb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional dosage for the treatment of pneumonia, otitis media, and sinusitis. uuid:e310276f-4446-4602-a24c-4f69df942786 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59343 biolink:treats MONDO:0005961 PMID:41385096 "[{""id"":""uuid:c76dc714-09ac-4cdc-b572-56d344add4d3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f1ce9707-b273-4afe-9d94-a3a0328c6b1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional dosage for the treatment of pneumonia, otitis media, and sinusitis. uuid:dabdb65e-2e6a-403a-9825-ba326744c3e7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0024389 PMID:41385096 "[{""id"":""uuid:7c455edd-326d-49fb-b924-28f81a835e74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7f12116e-bba9-42d9-bff9-3187dd39a4fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new additional indications and a new dosage for the treatment of anaerobic bacterial infection, infectious enteritis, amoebic dysentery, and Giardia lamblia infection. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:543e8534-4231-49d1-83e3-ae1806edea4f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6909 biolink:treats MONDO:0001103 PMID:41385096 "[{""id"":""uuid:21da08a2-e4a9-4150-a0c1-6c58e8d2112b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c8ddf6e5-6460-49ca-8ad2-24f0d3c10cef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new additional indications and a new dosage for the treatment of anaerobic bacterial infection, infectious enteritis, amoebic dysentery, and Giardia lamblia infection. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:9bd1833b-cf8b-4f12-bc79-8cabce2d29f6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:38940 biolink:treats MONDO:0019954 PMID:41385096 "[{""id"":""uuid:15f7dd24-73a0-4a2e-89b5-f06e6f0f482a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:905f6379-f7d7-4328-86ea-5623721adea7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for pancreatic neuroendocrine tumour. [Orphan drug] uuid:46c0add6-4c7d-435a-8100-05f25dc340a5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:177836 biolink:treats MONDO:0008233 PMID:41385096 "[{""id"":""uuid:1c970b04-5548-428b-9ada-b397874bca8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:993a9b84-4c7a-4ddf-a6f9-543782682dbe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for the treatment of pheochromocytoma. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:1d37895c-1385-4c54-9e93-4153467b1aa6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28445 biolink:treats MONDO:0008233 PMID:41385096 "[{""id"":""uuid:f66f3b74-b44c-46bb-812b-599ddb2ffbef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8dfc23a1-cd18-413f-b85d-99dd74079489"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for the treatment of pheochromocytoma. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:cd249a62-a355-4566-b90b-3cd3b72c1f54 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44423 biolink:treats MONDO:0005029 PMID:41385096 "[{""id"":""uuid:15629ee2-56e9-4520-a564-141b95cb02b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5205709c-7182-4a29-9562-296068c46622"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new additional indications for the treatment of essential thrombocythemia and polycythemia vera. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:52f0caed-67a4-4888-a14b-3baa86292c25 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44423 biolink:treats MONDO:0009891 PMID:41385096 "[{""id"":""uuid:512e729b-072b-4b26-8610-a8064e33761e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:57d5459a-56d9-4cd8-8403-d4135001fe7d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new additional indications for the treatment of essential thrombocythemia and polycythemia vera. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:a2534bd6-c524-4215-bdea-a9b3efea6513 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:203439 biolink:treats MONDO:0005790 PMID:41385096 "[{""id"":""uuid:068f1d21-0e3f-44ed-b03f-d91d9df7b02e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a93c6818-0c0d-4495-94e9-5ceccea66561"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new pediatric dosage. The drug is indicated for the prevention of hepatitis A. uuid:bac26739-216a-4f38-8cb8-b5236341620f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4027 biolink:treats MONDO:0005377 PMID:41385096 "[{""id"":""uuid:8e440a54-6eb0-4ca9-8b5c-1c489775aa40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4580856d-2d3a-4dbc-977d-400c44b7ad9d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for the treatment of nephrotic syndrome (for use only in patients who have not sufficiently responded to adequate treatment with corticosteroids). [Public knowledge-based application after PAFSC's preliminary assessment] uuid:e64f3c88-6b9a-4a17-bd0a-0b4f6a50bdff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77733 biolink:treats UMLS:C0080203 PMID:41385096 "[{""id"":""uuid:052c1afc-9713-4a7b-b628-649edc892cff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9371c3f6-5f91-4713-bfe2-d7fcf74582bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional dosage indicated for the treatment of tachyarrhythmia in pediatric patients (paroxysmal supraventricular tachycardia, paroxysmal atrial fibrillation, paroxysmal atrial flutter). [Public knowledge-based application after PAFSC's preliminary assessment] uuid:21b116b4-4b95-4ad8-86be-ac9e337e57bf biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77733 biolink:treats MONDO:1030011 PMID:41385096 "[{""id"":""uuid:0d81e629-5dc1-4b93-9ca7-87718c91df18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9c769ed1-8831-4cf4-855c-ef6d2e380496"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional dosage indicated for the treatment of tachyarrhythmia in pediatric patients (paroxysmal supraventricular tachycardia, paroxysmal atrial fibrillation, paroxysmal atrial flutter). [Public knowledge-based application after PAFSC's preliminary assessment] uuid:75c42071-6f82-4336-b5b3-90ff151fc8ae biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:77733 biolink:treats UMLS:C0741292 PMID:41385096 "[{""id"":""uuid:e8fc6d5f-3122-4633-ad26-71e7a6e1f04d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a884c72e-fdf7-4d15-9b30-934160696133"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional dosage indicated for the treatment of tachyarrhythmia in pediatric patients (paroxysmal supraventricular tachycardia, paroxysmal atrial fibrillation, paroxysmal atrial flutter). [Public knowledge-based application after PAFSC's preliminary assessment] uuid:f4f1a2fd-5225-4f6f-b3da-61c9e668a518 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31859 biolink:treats HP:0001262 PMID:41385096 "[{""id"":""uuid:dfe0a765-30d0-458d-8348-a73bd6fa6c9a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2888367f-5e96-453d-a0e4-0a56046e2a6e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication for the treatment of excessive daytime sleepiness in patients with obstructive sleep apnea syndrome who receive treatment of airway obstruction with continuous positive airway pressure (CPAP) therapy, etc. uuid:4ba4d1d7-6256-4860-9238-615018166638 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:127780 biolink:treats UMLS:C0877635 PMID:41385096 "[{""id"":""uuid:4f189570-fe9b-438f-899c-161a584b93dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:58786aee-d203-4144-a8c7-67e790500cfb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new additional indications and a new dosage for the treatment of cytomegalovirus viremia and cytomegalovirus infection in patients undergoing hematopoietic stem cell transplantation. uuid:ff49093e-fbe1-4359-8632-12b1d9565c2e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats MONDO:0005823 PMID:41385096 "[{""id"":""uuid:eaaec554-a991-49bc-8d59-408fe45ce187"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:abbeecde-7ec3-40fc-8ca2-95b327439dc8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication for Legionella pneumophila as applicable microorganism. uuid:5778ec5f-2679-46dd-ab82-7df9f2b14511 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6076 biolink:treats MONDO:0002041 PMID:41385096 "[{""id"":""uuid:a5a54142-7003-43db-8720-f5c848f6db56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:13cbb0c1-ffe3-46f0-8a93-7d314e609352"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new indications for (1) the treatment of fungal infection, (2) the treatment of febrile neutropenia with suspected fungal infection, and (3) the prevention of deep mycosis in patients with hematologic malignancy or hematopoietic stem cell transplantation in whom neutropenia is anticipated. uuid:9dd1a394-2820-4658-a2a3-dc2eafe280f6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6076 biolink:treats UMLS:C0948382 PMID:41385096 "[{""id"":""uuid:69bd1b0a-1a72-4dc5-82cf-4a67806293b0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:98e90ac6-c114-48cc-afb9-e13650e9454c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new indications for (1) the treatment of fungal infection, (2) the treatment of febrile neutropenia with suspected fungal infection, and (3) the prevention of deep mycosis in patients with hematologic malignancy or hematopoietic stem cell transplantation in whom neutropenia is anticipated. uuid:60834a9f-76a9-454a-a410-dcfd90ac3bab biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:81569 biolink:treats UMLS:C1699041 PMID:41385096 "[{""id"":""uuid:5e0a7d19-6238-4a60-8601-dbc88d7e1d88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:178a6671-8a37-4275-b47e-c372f971e50a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for induction of ovulation in patients with anovulation and infrequent ovulation associated with hypothalamic-pituitary dysfunction or polycystic ovarian syndrome. uuid:c9b5ffa2-e284-403b-b287-95548770b64d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:81569 biolink:treats MONDO:0043101 PMID:41385096 "[{""id"":""uuid:b3d7d2a9-1ce3-440e-8559-8901334a3bda"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ad1d5100-7e8b-419e-862a-193b3fb70643"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for induction of ovulation in patients with anovulation and infrequent ovulation associated with hypothalamic-pituitary dysfunction or polycystic ovarian syndrome. uuid:2ebadeed-ead2-4b52-a60f-2df7a4038212 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:94810 biolink:treats MONDO:0011786 PMID:41385096 "[{""id"":""uuid:f3473e62-9fbe-464e-af5d-23cdbb6f681d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:892c8bd7-2e85-4059-abe5-046988456e80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication for the treatment of allergic rhinitis in pediatric patients. uuid:fa0bdea3-93e8-482b-b120-03de98fd30e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:44241 biolink:treats MONDO:0018912 PMID:41385096 "[{""id"":""uuid:54fb2929-efb0-410b-a015-05bb0b9d6b18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:70d6b4bd-385b-4c82-99ef-0925fc41db62"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for the treatment of Cushing's syndrome. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:0890d9b8-1a4e-4f48-8bb5-a1c568ea3763 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5864 biolink:treats MONDO:0005062 PMID:41385096 "[{""id"":""uuid:b18fd79e-d60e-405c-9fb5-b0818b43dc4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a6488dcd-badf-4112-9bea-c8a1cdd55035"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for the treatment of malignant lymphoma. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:9df26358-1c7f-4249-a76c-dbe196c557ee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8768 biolink:treats MONDO:0007186 PMID:41385096 "[{""id"":""uuid:bbeb9019-8d1d-4211-9cf3-3916efae5488"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:38d185e1-ca1f-4216-be7d-394b446cf43d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for the treatment of non-erosive reflux disease. uuid:9e212296-3300-450d-9d36-1202f2e5c059 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27375 biolink:treats MONDO:0018310 PMID:41385096 "[{""id"":""uuid:4b1c56a2-64d3-48f3-a502-34f6c8d16e5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:292d3345-da2d-416e-b8cd-9c7759d89907"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for the treatment of Langerhans cell histiocytosis. [Public knowledge-based application after preliminary assessment by the Pharmaceutical Affairs and Food Sanitation Council (PAFSC)] uuid:f1068175-ab7d-429d-a788-9ecec3f3891e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2663 biolink:treats MONDO:0004981 PMID:41385096 "[{""id"":""uuid:2cdf8f98-7b7d-4ff3-a2cc-95ccd35e76ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6f9ccbc1-273f-4ad4-bef5-c1d9c7464365"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication for the treatment of arterial fibrillation with cardiac failure (impaired cardiac function). uuid:7cc416db-55f1-4edf-a2bf-0a6115b82c50 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2663 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:55d1e8c3-7e36-42e3-a49d-b5a65fe875fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:df69ac2a-0548-45ba-994d-5c5e232ebfd0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication for the treatment of arterial fibrillation with cardiac failure (impaired cardiac function). uuid:6970337b-185a-461c-8a87-ac4ff6519787 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB10343 biolink:treats MONDO:0004200 PMID:41385096 "[{""id"":""uuid:36bffb89-4254-41ef-b889-de0c13c25176"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:548d27dd-b991-42b9-8098-5a09898d916e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional dosage indicated for the treatment of superficial bladder cancer and carcinoma in situ of bladder. uuid:509cff9b-4aa7-408f-b5be-0e42f9c9a00a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:XRO4566Q4R biolink:treats MONDO:0005354 PMID:41385096 "[{""id"":""uuid:47bb525a-412d-49e7-968a-e0565fc9b777"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ef8748b0-1df5-4e1d-af56-99334cc98f5d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the improvement of viraemia in chronic hepatitis C on concomitant administration with ribavirin. uuid:74cb80d6-f237-42fd-9f7a-c210cef6f662 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2682 biolink:treats UMLS:C5391333 PMID:41385096 "[{""id"":""uuid:88a5bd7b-75d0-4f37-aabb-c880cbe19621"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9019f800-a290-41b4-a7e9-719e8d678039"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new additional indications and a new dosage for the treatment of fungal infections caused by Mucor species, Absidia species, Rhizopus species, Rhizomucor species, Cladosporium species, Cladophialophora species, Fonsecaea species, Phialophora species, Exophiala species, Coccidioides species, Histoplasma species, and Blastomyces species and visceral leishmaniasis. uuid:da85f0ff-96b5-4ea9-8df7-eb043be357e7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2682 biolink:treats UMLS:C0864807 PMID:41385096 "[{""id"":""uuid:dccf90c8-ef06-4bcb-b153-ce23b6fff0bd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:94f0df0a-2639-455d-a16f-273c9f8a03fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new additional indications and a new dosage for the treatment of fungal infections caused by Mucor species, Absidia species, Rhizopus species, Rhizomucor species, Cladosporium species, Cladophialophora species, Fonsecaea species, Phialophora species, Exophiala species, Coccidioides species, Histoplasma species, and Blastomyces species and visceral leishmaniasis. uuid:051384ff-3e1d-419a-938e-1e1e00e5270e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63599 biolink:treats MONDO:0002280 PMID:41385096 "[{""id"":""uuid:555e814f-28ae-49fa-bdea-7cb011078ea2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5102e594-22bc-46de-a3e1-3570b38a9cc2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication for the treatment of chronic lymphocytic leukemia with anemia or thrombocytopenia. uuid:9b64ed58-a831-4562-b708-849c1e103cd0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63599 biolink:treats MONDO:0002049 PMID:41385096 "[{""id"":""uuid:c38cb761-57d6-49eb-970b-c3bbf59636f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cd168351-c1c9-4b03-8d6e-645723d7c740"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication for the treatment of chronic lymphocytic leukemia with anemia or thrombocytopenia. uuid:3f8c2c74-445b-4fed-b3ce-3352b5c7b7a0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63599 biolink:treats MONDO:0018876 PMID:41385096 "[{""id"":""uuid:c0d6dd52-66e3-477b-8355-d97860654a72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1da970a5-10a9-470d-90e1-769e5abe1d52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new additional indications and a new dosage for the treatment of recurrent or refractory low-grade B-cell non-Hodgkin’s lymphoma and mantle cell lymphoma. uuid:b0bbd38a-1c3d-424c-9b45-b275b0f060f5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90117 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:bed1dce1-7bbc-4196-a444-b306529c5659"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cfce9b5c-d8cb-40c2-8e55-3a0ce1c490f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration, a new indication, and a new dosage for sentinel lymph node mapping in breast cancer and malignant melanoma. [Expedited review] uuid:e89ce5d2-4c8f-49e5-a44b-8e2dcecc92e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90117 biolink:treats MONDO:0005012 PMID:41385096 "[{""id"":""uuid:803338db-73b1-4cfa-9766-77234201f5fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e8e02ecc-dff7-4b40-9436-e411ca766494"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration, a new indication, and a new dosage for sentinel lymph node mapping in breast cancer and malignant melanoma. [Expedited review] uuid:de7fa25f-ecfa-4fdb-837e-9c532a007708 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31696 biolink:treats MONDO:0005012 PMID:41385096 "[{""id"":""uuid:3a863730-f4e9-4e71-b900-ad8789615a1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:40a18399-0e4a-408f-a149-2c25c45c3dc1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration, a new indication, and a new dosage for sentinel lymph node mapping in breast cancer and malignant melanoma. [Expedited review] uuid:5dd868d8-cb57-4d01-9430-8561928f4d93 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:33353 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:0f4201ec-2409-4aed-bda5-5a6e94e65df9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:16d540f9-8fe0-4292-9831-fa45b2bd935c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration and a new indication for sentinel lymph node mapping in breast cancer and malignant melanoma. [Expedited review] uuid:ba321a5c-fbd4-4ae6-a870-22d7c9fff743 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:33353 biolink:treats MONDO:0005012 PMID:41385096 "[{""id"":""uuid:22203367-498e-4a8f-897e-5f5a2808ced2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2d060ad2-0527-4813-bce5-18f8a26526c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new route of administration and a new indication for sentinel lymph node mapping in breast cancer and malignant melanoma. [Expedited review] uuid:1fa51542-d4c6-4753-9d23-4618768399bd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:92769 biolink:treats MONDO:0005072 PMID:41385096 "[{""id"":""uuid:e8cbe44f-7a12-405a-be65-6810af14de89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:34803b55-af7e-4986-9005-b0eb4c576bc1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for diagnosis of neuroblastoma in tumor scintigraphy. uuid:fdff999d-e0a3-463e-ae96-ee64f27c9cd5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:33353 biolink:treats MONDO:0001741 PMID:41385096 "[{""id"":""uuid:4ea8bed4-0636-4f1e-bee1-4ab7d6933a4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a8f75fde-0772-4da7-9fe4-3c4d249a0072"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication for diagnostic localization of hyperparathyroidism in parathyroid scintigraphy. uuid:8b0b1910-73a4-4c63-9888-fd7136513e56 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:N6OU7HJ70P biolink:treats MONDO:0001741 PMID:41385096 "[{""id"":""uuid:51082421-cd8e-4399-a958-b4db39f07410"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7e5d905e-27e6-497a-abbe-fccd8cd51369"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication for diagnostic localization of hyperparathyroidism in parathyroid scintigraphy. uuid:4039a805-121e-401f-8094-07f89334ef83 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:LR3UXN0193 biolink:treats MONDO:0006594 PMID:41385096 "[{""id"":""uuid:f33edbf3-6b4f-4230-9de5-6e8bf30a68c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:db85035d-7869-40d9-be90-b90e92790239"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for the treatment of pemphigus (for use when steroid drugs are not sufficiently effective). uuid:1de4e555-9dd8-4feb-b5c7-5ff2049d71b5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0006050 biolink:treats UMLS:C0014670 PMID:41385096 "[{""id"":""uuid:075341b3-d515-43c8-a320-7d6e7f2fab9b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:15d63e1c-09b3-4d4a-96dc-0221094283c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of equinus deformity associated with lower limb spasticities in juvenile cerebral palsy in patients 2 years or older. DRUGBANK:DB00083 uuid:2c884391-be5e-4af1-96a3-301a0df513e2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0006050 biolink:treats MONDO:0006497 PMID:41385096 "[{""id"":""uuid:64d6d19c-affa-4510-8333-7f0192440e7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:58a73079-e7c8-4d0b-92ea-d55d28d3f514"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of equinus deformity associated with lower limb spasticities in juvenile cerebral palsy in patients 2 years or older. DRUGBANK:DB00083 uuid:fd9d8c61-705a-4d96-9251-f0a29829fe54 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2469 biolink:treats MONDO:0005344 PMID:41385096 "[{""id"":""uuid:6be6cd04-565e-407b-b7c6-09b01f7822ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7f528c03-21d0-4d99-99ed-85e3310cbd04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for inhibition of hepatitis B virus replication in patients with type B chronic liver disease in whom abnormal hepatic function was observed in association with proliferation of hepatitis B virus. uuid:a7e53bf1-352b-42d1-8760-1574bb763687 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2469 biolink:treats UMLS:C0341439 PMID:41385096 "[{""id"":""uuid:f481518b-a8cd-4c25-a717-43e9f86c145a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4fe60d42-b690-4687-9020-3850a060cbee"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for inhibition of hepatitis B virus replication in patients with type B chronic liver disease in whom abnormal hepatic function was observed in association with proliferation of hepatitis B virus. uuid:893ddf3d-0347-4e6b-bac7-5806b2909e74 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:71300723 biolink:treats MONDO:0005002 PMID:41385096 "[{""id"":""uuid:78e20f23-13fb-4f98-97ea-0b07e298b467"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f098201a-b2d4-480a-aae1-58214757c456"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for the alleviation of various symptoms associated with chronic obstructive pulmonary disease (chronic bronchitis and emphysema) (for use when concomitant use of inhaled corticosteroid and long-acting β2-agonist is required). uuid:771a1f9b-916e-40d1-9625-b1d737f8e269 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:71300723 biolink:treats MONDO:0005607 PMID:41385096 "[{""id"":""uuid:68bab942-2832-48ac-8a7c-612e621b191b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1413dc18-5bca-4791-a6a5-7797eb7d536b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for the alleviation of various symptoms associated with chronic obstructive pulmonary disease (chronic bronchitis and emphysema) (for use when concomitant use of inhaled corticosteroid and long-acting β2-agonist is required). uuid:a81e70ba-7392-432f-9850-84a297a547ca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:71300723 biolink:treats MONDO:0004849 PMID:41385096 "[{""id"":""uuid:f51b8639-bb6a-4da2-ba74-b6f00d164595"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a1296eb1-b255-4d03-95cd-096b4cf53bb2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional indication and a new dosage for the alleviation of various symptoms associated with chronic obstructive pulmonary disease (chronic bronchitis and emphysema) (for use when concomitant use of inhaled corticosteroid and long-acting β2-agonist is required). uuid:232209cc-0044-4461-b6ec-43082ba2313e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59560 biolink:treats MONDO:0019335 PMID:41385096 "[{""id"":""uuid:eafa471b-f175-41c4-bbb0-b059ae565dd2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f84b9513-9f1e-44d6-970b-4d831c249212"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for reduction of serum phenylalanine levels in patients with hyperphenylalaninemia (tetrahydrobiopterin-responsive hyperphenylalaninemia) caused by tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. [Orphan drug] uuid:4bedd5ab-e8a1-49ba-826a-36dee5ba9e4d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:59560 biolink:treats MONDO:0017389 PMID:41385096 "[{""id"":""uuid:7da2a132-c372-40af-b990-2b8795473ec0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:487378b1-b0f1-428f-9aaa-db3a45c5839b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for reduction of serum phenylalanine levels in patients with hyperphenylalaninemia (tetrahydrobiopterin-responsive hyperphenylalaninemia) caused by tetrahydrobiopterin-responsive phenylalanine hydroxylase deficiency. [Orphan drug] uuid:74c2294d-b201-493f-9b13-52ad3107a297 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63599 biolink:treats MONDO:0018881 PMID:41385096 "[{""id"":""uuid:41a0134f-7916-4b7e-bccc-08697782db79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:df046d47-f230-44ab-bbf8-f16b24b58ffc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for use as a conditioning prior to allogeneic hematopoietic stem cell transplantation in the following diseases: acute myeloid leukemia, myelodysplastic syndrome, chronic myeloid leukemia, chronic lymphocytic leukemia, malignant lymphoma, and multiple myeloma. uuid:098213d0-b86d-4c97-ac34-8d9797a50042 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63599 biolink:treats MONDO:0011996 PMID:41385096 "[{""id"":""uuid:8e7c625c-e794-482a-9ed3-312065a870f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fccbe05a-6435-4de0-b52f-e0b2c0c2b83a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for use as a conditioning prior to allogeneic hematopoietic stem cell transplantation in the following diseases: acute myeloid leukemia, myelodysplastic syndrome, chronic myeloid leukemia, chronic lymphocytic leukemia, malignant lymphoma, and multiple myeloma. uuid:ff1800b6-a7aa-4b81-abff-2b00a43c7cb9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63599 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:4b9cb223-de57-4cbb-93ae-f9855d987b55"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ba77b6c8-4201-4b33-8584-27cbfd5b441d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and a new dosage for use as a conditioning prior to allogeneic hematopoietic stem cell transplantation in the following diseases: acute myeloid leukemia, myelodysplastic syndrome, chronic myeloid leukemia, chronic lymphocytic leukemia, malignant lymphoma, and multiple myeloma. uuid:d01f098d-9906-4fc0-894e-6963332d7db1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:175901 biolink:treats MONDO:0040679 PMID:41385096 "[{""id"":""uuid:696598aa-e8c2-4839-85a7-adbe4090a4f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9d57f2f8-2ac9-4fac-92a1-0748dbc68d82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication for the treatment of urothelial carcinoma. uuid:83401d3d-a824-4092-8b82-778b3a0b9f44 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:567361 biolink:treats MONDO:0018906 PMID:41385096 "[{""id"":""uuid:cf9be07b-d2b3-47d4-a640-e28c5229524c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:25e0e4fc-7c56-4dea-a9dd-9dd1994383f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional dosage indicated for the treatment of recurrent, relapsing, or refractory indolent B-cell non-Hodgkin's lymphoma including follicular lymphoma, and mantle cell lymphoma. uuid:07416c40-bf13-4d52-8807-e9b34e725fc9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:567361 biolink:treats MONDO:0018876 PMID:41385096 "[{""id"":""uuid:5b8720e0-676c-4356-a68c-5385d3a12551"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:058dedbf-36fa-41f7-92f7-81d6402a5b6a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional dosage indicated for the treatment of recurrent, relapsing, or refractory indolent B-cell non-Hodgkin's lymphoma including follicular lymphoma, and mantle cell lymphoma. uuid:fa17c6f1-f680-47a4-8b4a-00fbaa7174b9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6775 biolink:treats UMLS:C0852922 PMID:41385096 "[{""id"":""uuid:a806bd20-63f0-4f1e-956e-dfdd43139678"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:46d73432-10fc-4790-81c9-5dec53770e0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new dosage for use in pediatric patients for the treatment of ulcerative colitis (excluding severe patients) and Crohn’s disease. uuid:48b70d58-c2cb-4c55-990c-b7721e09a948 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9919 biolink:treats MONDO:0005700 PMID:41385096 "[{""id"":""uuid:dcccf496-26f7-495a-9336-fccad32f229a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1a0ef1f4-4274-4204-868e-cdb7e7e2729c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication and dosage for the treatment of varicella in children. uuid:4f39470a-cd64-4891-8b9d-03433a621139 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151392 biolink:treats MONDO:0005230 PMID:41385096 "[{""id"":""uuid:bd46f315-2b6f-4581-899c-7952671cc368"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:637d12c2-12bd-4b60-a34f-a8c3e106dcd9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the treatment of superficial skin infections, deep skin infections, lymphangitis and lymphadenitis, chronic pyoderma, laryngopharyngitis, tonsillitis, acute bronchitis, cystitis, and pyelonephritis. uuid:de16a97c-bd2d-4d98-ba74-c7f956e6e64a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151392 biolink:treats MONDO:0005832 PMID:41385096 "[{""id"":""uuid:92a72377-3c3b-469e-b953-8b9d8aabb032"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a5b8617d-ac4f-4cd8-9ac1-c1c1dcc69ce2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the treatment of superficial skin infections, deep skin infections, lymphangitis and lymphadenitis, chronic pyoderma, laryngopharyngitis, tonsillitis, acute bronchitis, cystitis, and pyelonephritis. uuid:9ffa90a8-8e6e-4bf3-8f05-272ca33ff181 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151392 biolink:treats MONDO:0002052 PMID:41385096 "[{""id"":""uuid:7a7b7c55-4fe4-489c-b3f3-1d6430a83343"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:07ba4062-6e8c-4791-82a5-cb1b1d0c3fdb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the treatment of superficial skin infections, deep skin infections, lymphangitis and lymphadenitis, chronic pyoderma, laryngopharyngitis, tonsillitis, acute bronchitis, cystitis, and pyelonephritis. uuid:633e9c11-dd09-4b16-b75a-b337205cf8e5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151392 biolink:treats MONDO:0002922 PMID:41385096 "[{""id"":""uuid:67de2a1a-5744-4764-b297-809a3cb34c24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d98560e3-7180-458c-8be8-4731dd3cae2d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the treatment of superficial skin infections, deep skin infections, lymphangitis and lymphadenitis, chronic pyoderma, laryngopharyngitis, tonsillitis, acute bronchitis, cystitis, and pyelonephritis. uuid:a7581871-c93b-47c8-aedc-4bd825aefc12 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151392 biolink:treats MONDO:0001218 PMID:41385096 "[{""id"":""uuid:166c559a-d578-41c1-874f-12358e6eeb2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:641013a1-fb9e-41c9-b6a0-785b3adf7234"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the treatment of superficial skin infections, deep skin infections, lymphangitis and lymphadenitis, chronic pyoderma, laryngopharyngitis, tonsillitis, acute bronchitis, cystitis, and pyelonephritis. uuid:52ee4a85-9a5f-4d74-97a8-98a1b06d6916 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151392 biolink:treats MONDO:0001039 PMID:41385096 "[{""id"":""uuid:b8a195f6-613b-4554-ad1c-a7c5c2951b71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:835edb0b-4b1c-4cff-94fe-e710f8237965"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the treatment of superficial skin infections, deep skin infections, lymphangitis and lymphadenitis, chronic pyoderma, laryngopharyngitis, tonsillitis, acute bronchitis, cystitis, and pyelonephritis. uuid:e0f7bec7-b035-40a5-a83b-288287359b26 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151392 biolink:treats HP:0012388 PMID:41385096 "[{""id"":""uuid:462ec28d-99aa-4a94-ae77-416a3c18ad43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:81f91f20-c1e5-4ad9-b8d3-e432c5d6b81d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the treatment of superficial skin infections, deep skin infections, lymphangitis and lymphadenitis, chronic pyoderma, laryngopharyngitis, tonsillitis, acute bronchitis, cystitis, and pyelonephritis. uuid:731d508d-83af-420e-8aa6-040ff62b438b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151392 biolink:treats MONDO:0006032 PMID:41385096 "[{""id"":""uuid:b849b595-c60e-4d21-95f9-5ddffee84fec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8cefacd2-4c1c-41d3-a8db-25c548711446"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the treatment of superficial skin infections, deep skin infections, lymphangitis and lymphadenitis, chronic pyoderma, laryngopharyngitis, tonsillitis, acute bronchitis, cystitis, and pyelonephritis. uuid:1b720700-8151-4bd2-8cc3-0e7b300a73ac biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:151392 biolink:treats MONDO:0006939 PMID:41385096 "[{""id"":""uuid:68013ab7-1d4f-4dae-99ba-7d395a8bbc30"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:36a0277d-5e57-4045-aaaa-11aea374c775"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new indication for the treatment of superficial skin infections, deep skin infections, lymphangitis and lymphadenitis, chronic pyoderma, laryngopharyngitis, tonsillitis, acute bronchitis, cystitis, and pyelonephritis. uuid:eb40d9e5-13a7-47ca-9427-816f60f18e00 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:71300723 biolink:treats MONDO:0100470 PMID:41385096 "[{""id"":""uuid:0a6073e4-6d65-43a6-b072-d0ddd8c86937"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8d171012-a6ca-46f0-a440-e951132f9458"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new additional pediatric dosage in a new dosage form indicated for the treatment of bronchial asthma (for use when concomitant use of inhaled corticosteroid and long-acting β2- agonist is required). [Expedited review] uuid:8b6eaff4-c952-47be-b2bd-e77151e403dc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4F4X42SYQ6 biolink:treats MONDO:0005556 PMID:41385096 "[{""id"":""uuid:a51c41e6-75c8-4392-aee0-eb46fb566552"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e8209027-44a6-4237-98b1-e02c431e5ab7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of lupus nephritis in patients who have not responded sufficiently to conventional treatments. [Public knowledge-based application after preliminary assessment by the Pharmaceutical Affairs and Food Sanitation Council (PAFSC)] uuid:714b1672-6c19-487d-ac9a-edbedcac1c2f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4F4X42SYQ6 biolink:treats UMLS:C0340530 PMID:41385096 "[{""id"":""uuid:3e83aac9-2021-49e8-9c08-25293987b4c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d846e07b-f3a3-44c3-991d-67e96b15799f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the suppression of antibody-mediated rejection in the following organ transplantations: kidney transplantation, liver transplantation, heart transplantation, lung transplantation, pancreas transplantation, small intestine transplantation, and the treatment of antibody-mediated rejection in the following organ transplantations: kidney transplantation, liver transplantation, heart transplantation, lung transplantation, pancreas transplantation, small intestine transplantation. [Orphan drug] uuid:7422bc0f-0bef-474d-a315-d1055a65f0fe biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85010 biolink:treats MONDO:0015909 PMID:41385096 "[{""id"":""uuid:97af0319-ff45-479c-a8eb-cd52ecedc3f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:492944a1-6fd7-411d-bd8c-662038658931"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional pediatric dosage indicated for the treatment of aplastic anemia. [Orphan drug] uuid:5915155e-0895-49de-b471-92c8a44ef47d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:NQX9KB6PCL biolink:treats HP:0004322 PMID:41385096 "[{""id"":""uuid:01e26a0e-53bc-40d2-a959-434972cd1bac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cbab1ca1-7ba5-4e0f-97cb-825d245d6203"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication for the treatment of short stature in SHOX deficiency prior to epiphyseal closure. uuid:bd883548-55cb-409e-a085-a0b0a05e2f78 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:NQX9KB6PCL biolink:treats UMLS:C3897045 PMID:41385096 "[{""id"":""uuid:9bb811a5-770f-4f88-a5d2-1f6a2b258607"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5bd15b7c-8012-404a-8890-6867542cbf43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication for the treatment of short stature in SHOX deficiency prior to epiphyseal closure. uuid:4ff45d4a-9777-4a81-b11e-13b09d8d5fb1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DQ448MW7KS biolink:treats MONDO:0800133 PMID:41385096 "[{""id"":""uuid:b8aa26e2-5ff3-492a-862b-63c9a1b2fc29"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f21da74d-c4ae-4a09-afb9-7fe51c7e190d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication for the prevention of serious lower respiratory tract disease caused by respiratory syncytial (RS) virus infection in neonates, infants, and children aged 24 months and younger with pulmonary hypoplasia, airway stenosis, congenital esophageal atresia, congenital metabolic disorder, or neuromuscular disease at the early stage of the RS virus season. [Priority review] uuid:10ef7c0a-8405-4b08-8f7c-40355fda026c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DQ448MW7KS biolink:treats MONDO:0001305 PMID:41385096 "[{""id"":""uuid:d3ec4cd8-7f79-40e1-90a7-8cbda914443c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1c90e9a7-2bb9-4f5c-8895-4f23d149ca61"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication for the prevention of serious lower respiratory tract disease caused by respiratory syncytial (RS) virus infection in neonates, infants, and children aged 24 months and younger with pulmonary hypoplasia, airway stenosis, congenital esophageal atresia, congenital metabolic disorder, or neuromuscular disease at the early stage of the RS virus season. [Priority review] uuid:6ee97ef9-7236-4aa8-b766-4daa32eca493 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DQ448MW7KS biolink:treats MONDO:0001044 PMID:41385096 "[{""id"":""uuid:4b7e837d-c0f4-4392-ae4c-4dc271ad4cce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:72a244b2-02da-4786-b0f6-2d276e0a08fa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication for the prevention of serious lower respiratory tract disease caused by respiratory syncytial (RS) virus infection in neonates, infants, and children aged 24 months and younger with pulmonary hypoplasia, airway stenosis, congenital esophageal atresia, congenital metabolic disorder, or neuromuscular disease at the early stage of the RS virus season. [Priority review] uuid:98980fb7-9c6e-4289-9c1f-52de252031f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DQ448MW7KS biolink:treats MONDO:0019052 PMID:41385096 "[{""id"":""uuid:556b427e-0282-4801-a144-d0887fb75e68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:99be91f0-b33f-48d8-a20e-999426d3218d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication for the prevention of serious lower respiratory tract disease caused by respiratory syncytial (RS) virus infection in neonates, infants, and children aged 24 months and younger with pulmonary hypoplasia, airway stenosis, congenital esophageal atresia, congenital metabolic disorder, or neuromuscular disease at the early stage of the RS virus season. [Priority review] uuid:3dc0f96a-2243-4bf0-9ddb-9febc70fd381 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DQ448MW7KS biolink:treats MONDO:0019056 PMID:41385096 "[{""id"":""uuid:5e5806b1-6d4d-442d-a652-12d452ed7d80"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2156e885-900d-4805-a32e-0a2d46db54bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication for the prevention of serious lower respiratory tract disease caused by respiratory syncytial (RS) virus infection in neonates, infants, and children aged 24 months and younger with pulmonary hypoplasia, airway stenosis, congenital esophageal atresia, congenital metabolic disorder, or neuromuscular disease at the early stage of the RS virus season. [Priority review] uuid:c1e9457a-e136-46a4-9000-7137a554dc44 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28680 biolink:treats MONDO:0010643 PMID:41385096 "[{""id"":""uuid:44921778-d188-4b11-b708-13ed2dcd2b73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:864d05be-cf29-47f8-a77d-1891fd1498b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of acute leukemia. [Public knowledge-based application, Expedited review] uuid:625b2c09-782d-4f47-aae4-65fc68b5da05 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75045 biolink:treats MONDO:0018935 PMID:41385096 "[{""id"":""uuid:e6752eb2-3795-4c7c-9f4c-c11b08d0b0ae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:43e29c36-e680-480d-b0c6-7bfd916064cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of advanced or recurrent BRAF mutation-positive solid tumor (excluding colon/rectal cancer) that is refractory or intolerant to standard therapies and relapsed or refractory BRAF mutation-positive hairy cell leukemia. [Orphan drug] uuid:8a1cccc3-3057-41a3-941b-bad37fe59961 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75998 biolink:treats MONDO:0018935 PMID:41385096 "[{""id"":""uuid:d36fd5a9-00d7-4001-8bbc-b81e104be503"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b65b7bf2-eeac-4540-b30e-3ec37ec2a0de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of advanced or recurrent BRAF mutation-positive solid tumor (excluding colon/rectal cancer) that is refractory or intolerant to standard therapies and relapsed or refractory BRAF mutation-positive hairy cell leukemia. [Orphan drug] uuid:c31f55cc-7642-4928-9780-b6799047773b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46345 biolink:treats MONDO:0001056 PMID:41385096 "[{""id"":""uuid:f63a2200-8eaf-4328-a221-a0573e32fea7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3459719c-61d7-4ea9-a8d1-d1d2a9322c0c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of unresectable advanced or recurrent gastric cancer. [Public knowledge-based application] uuid:5502a707-ee7a-4177-bad6-e1e104b3b99c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135920 biolink:treats HP:0000011 PMID:41385096 "[{""id"":""uuid:d0f1da4d-24f7-4995-9aec-5fd1b14618f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:190aa87b-94b0-4027-810f-5dd16f5f5a89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new additional pediatric dosage for the control of urination in patients with neurogenic bladder. uuid:c0077b3d-1823-4960-bebd-7c08e6223410 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4F4X42SYQ6 biolink:treats MONDO:0019100 PMID:41385096 "[{""id"":""uuid:f8c463ec-e6cd-43e3-a2bb-60b461f6a5e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:09740f57-ceda-44c1-8d07-2821f7e4fc44"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the prevention of relapse of neuromyelitis optica spectrum disorder (including neuromyelitis optica). [Orphan drug] uuid:f92dd2a9-5734-48ee-96a8-3e7d4294cd0d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6T8C155666 biolink:treats MONDO:0007576 PMID:41385096 "[{""id"":""uuid:aee4ce39-5bfd-4f6c-a861-00e4e27a07b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d66537c4-a57f-4d21-bf37-84f03956deb4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of unresectable advanced or recurrent esophageal cancer. [Priority review] uuid:2259728f-60dd-4f87-a438-dff417ff9534 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2S9ZZM9Q9V biolink:treats MONDO:0008170 PMID:41385096 "[{""id"":""uuid:9f8e2e75-df88-46c0-aadb-2253efec3655"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5386e11a-1051-40bd-9b4d-c5194991feb8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of ovarian cancer. Public knowledge-based application after PAFSC's preliminary assessment] uuid:1c801ef7-f935-46a3-a0d3-d4cf28ca96ca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45863 biolink:treats MONDO:0002974 PMID:41385096 "[{""id"":""uuid:e56f5654-9612-4c6d-a47d-9678e4131399"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fb6853bc-0986-45f2-a2fe-12bf9c9bca5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for thetreatment of advanced or recurrent cervical cancer. [Public knowledge-based application] uuid:da1d35c8-8c2a-4da0-a21f-66ccbf9cbf20 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22984 biolink:treats MONDO:0001056 PMID:41385096 "[{""id"":""uuid:ef26ea3c-3ef6-4374-a8d4-6977d813a0ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cbc59ef0-4c89-403a-9984-0d115cf671e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of unresectable advanced or recurrent gastric cancer. [Public knowledge-based application after PAESC's preliminary assessment] uuid:d189ed39-a302-4784-a2d9-6688e3d8ac9e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats MONDO:0017816 PMID:41385096 "[{""id"":""uuid:9c5f37b7-a8bd-44f3-9db0-64afd1c4f2bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9e86b0f5-6042-41ab-a3ec-59c79fe16b50"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of systemic AL amyloidosis. [Expedited review] uuid:23893ca6-1408-4b61-90ac-c83094385461 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:90844 biolink:treats MONDO:0013024 PMID:41385096 "[{""id"":""uuid:2cc45e09-fc6a-4a7c-ac6d-1bc5ef933f66"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:da5b2270-65bb-47ba-84e5-e877c8db036c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication for the treatment of persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) after surgical treatment or inoperable CTEPH. [Orphan drug] uuid:0f0002ab-563c-4507-901e-9cb885dd100e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85973 biolink:treats HP:0002140 PMID:41385096 "[{""id"":""uuid:d28caa48-cbc2-441d-937f-b223fe2b75c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:954951c1-ed7d-42e7-93e4-536899d76a8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation. uuid:0a9ec7c2-968e-4dbb-a938-c705c2178ab2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29321 biolink:treats UMLS:C0264714 PMID:41385096 "[{""id"":""uuid:ff655386-d6b3-4506-a72b-0bec9e5177ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8c9803f0-1d2a-4a37-98be-8ed4355f0eda"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of acute heart failure (including chronic heart failure in the exacerbation period) and hypertensive emergencies. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:a1a9626d-8c10-40d8-93da-e870ea2f29f8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29321 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:337b3979-9870-4bf1-a105-4897f51fec43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1d61775c-1701-4faa-9f12-b85c3368d4db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of acute heart failure (including chronic heart failure in the exacerbation period) and hypertensive emergencies. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:1bd68e35-61a2-4a3c-94e4-6221c397a00d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29321 biolink:treats HP:0100735 PMID:41385096 "[{""id"":""uuid:d3490d9c-bc82-4da2-a69c-17c430618ffa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0f1e880e-2f07-4d23-9362-66cb5a0adee8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of acute heart failure (including chronic heart failure in the exacerbation period) and hypertensive emergencies. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:3e6a571a-b45d-456a-8ed9-f334d9436700 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:WB8FT61183 biolink:treats MONDO:0005044 PMID:41385096 "[{""id"":""uuid:e7bc6c3a-9b5a-470e-b7d6-eb41b35edd23"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fab87164-b10d-42e0-bb04-83ff03584ab4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of hypertension. uuid:42198845-fee7-4bac-ba9d-8a5f3daeaee8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:87715 biolink:treats MONDO:0005299 PMID:41385096 "[{""id"":""uuid:1c6a24bb-446f-4ece-bc9e-08cf298ef1b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a395d443-475e-4c9a-aaec-e3f7431521d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the prevention of recurrence after ischemic cerebrovascular disease (associated with large artery atherosclerosis or small vessel occlusion) (for use only in patients having a high risk of cerebral infarction). uuid:0cd2bee1-8bd3-47f8-9045-f70950004ad7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:87715 biolink:treats MONDO:0002679 PMID:41385096 "[{""id"":""uuid:842e1760-55ed-42d9-87f2-d52964646791"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0d06477d-e875-4e5b-9680-3a86eb69c4fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the prevention of recurrence after ischemic cerebrovascular disease (associated with large artery atherosclerosis or small vessel occlusion) (for use only in patients having a high risk of cerebral infarction). uuid:72844816-f56c-471a-b7dc-705036221a2b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4F4X42SYQ6 biolink:treats MONDO:0005100 PMID:41385096 "[{""id"":""uuid:4ddf047a-c91a-442a-a86c-1b57018d3335"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:be77b457-ef26-4f58-bf1d-d9ec3f35d9e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of systemic sclerosis. [Orphan drug] uuid:772a42cf-4eaa-4f79-89a2-25f9a113da79 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4F4X42SYQ6 biolink:treats MONDO:0019324 PMID:41385096 "[{""id"":""uuid:1bd9ebf6-95d2-403f-8709-866a02a02762"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e9eed876-187a-41df-b309-ee76553021f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of refractory pemphigus vulgaris and pemphigus foliaceus. [Orphan drug] uuid:88d65752-f85e-4364-ae89-1f530654dd2c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231601 biolink:treats MONDO:0000521 PMID:41385096 "[{""id"":""uuid:d930290e-a914-47cf-b162-addd26d18361"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:756ff7f9-e4c6-4dda-b743-c4e04472c5d2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of unresectable advanced or recurrent HER2-positive salivary gland tumors. [Orphan drug] uuid:be9cb0f9-4553-42d7-a036-7478adc369ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46345 biolink:treats MONDO:0007576 PMID:41385096 "[{""id"":""uuid:27da641a-ecf9-4196-89c9-67e86901f3c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d0fb9bf0-3799-4ec1-97c3-9d8892a11ee5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of esophageal cancer. [Public knowledge-based application] uuid:1eac0209-fe64-4355-a5df-574562864293 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231601 biolink:treats MONDO:0002032 PMID:41385096 "[{""id"":""uuid:8158b9d7-483d-41cc-8efa-94cf32d42e31"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fe410659-9349-484e-8eb4-ba638c8e4cae"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of unresectable advanced or recurrent HER2-positive colon or rectal cancer that has progressed after cancer chemotherapy. uuid:372e0c14-9941-4e57-bcbe-5262440d0cc8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231601 biolink:treats MONDO:0002169 PMID:41385096 "[{""id"":""uuid:fc8a8e4a-cdb4-4b8c-95a9-b50b89a66ed6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c74573b8-be0c-4be5-8ce1-4e45f3f864f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of unresectable advanced or recurrent HER2-positive colon or rectal cancer that has progressed after cancer chemotherapy. uuid:53d68583-c47a-4aab-9860-ccae0eb86759 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135809 biolink:treats HP:0011703 PMID:41385096 "[{""id"":""uuid:bd07eaf8-4d89-405e-a526-c9f90be1090e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a713dc3e-50ae-49a9-9938-41f5f86a6969"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of the following tachyarrhythmia associated with sepsis: atrial fibrillation, atrial flutter, sinus tachycardia. uuid:b2e70da4-557a-4908-bee1-a8344ea9e9bd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:505CXM6OHG biolink:treats UMLS:C0858004 PMID:41385096 "[{""id"":""uuid:b3681c4f-7305-4f98-8ecc-3ae1c6f633f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6595c71f-b811-460f-a28b-eac1b2479d13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the prophylaxis of influenza A or B virus infection. uuid:521559c7-a1cd-430d-aaa6-5d818baa075e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:505CXM6OHG biolink:treats UMLS:C0858005 PMID:41385096 "[{""id"":""uuid:ab55e53b-f268-495f-aedb-efd4a6d20b99"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:374ecdec-a9c6-47fb-93d9-55f979750473"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the prophylaxis of influenza A or B virus infection. uuid:4228d06f-f46c-45ef-ad7d-65cb75f74687 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DLG4EML025 biolink:treats UMLS:C3203547 PMID:41385096 "[{""id"":""uuid:3ecd2bb7-b120-44a8-b795-091e7b5438dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:28656b89-3666-4be0-9f97-aeaa18ddd1ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of non-radiographic axial spondyloarthritis in patients who have not responded sufficiently to conventional treatments. [Orphan drug] uuid:2c5d7268-b836-4e4a-9680-58cddb119fe9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:D99YVK4L0X biolink:treats MONDO:0002032 PMID:41385096 "[{""id"":""uuid:84789de9-588a-44f7-929e-64dbc7148a0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ad8b320a-cdcb-4276-98ba-957d7430547f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of unresectable advanced or recurrent non-small cell lung cancer. Drugs with a new dosage indicated for the treatment of unresectable advanced or recurrent gastric cancer, unresectable advanced or recurrent colon or rectal cancer, unresectable advanced or recurrent non-small cell lung cancer, and unresectable hepatocellular carcinoma whose serum AFP level is greater than 400 ng/mL and conditions have progressed after cancer chemotherapy. uuid:70c8babb-edbb-4cdd-afac-a5b16603dfdc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:D99YVK4L0X biolink:treats MONDO:0006519 PMID:41385096 "[{""id"":""uuid:ecbc8568-5dd9-4c77-b641-734760f886c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a0b60603-4408-4722-8095-54367ced51a8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of unresectable advanced or recurrent non-small cell lung cancer. Drugs with a new dosage indicated for the treatment of unresectable advanced or recurrent gastric cancer, unresectable advanced or recurrent colon or rectal cancer, unresectable advanced or recurrent non-small cell lung cancer, and unresectable hepatocellular carcinoma whose serum AFP level is greater than 400 ng/mL and conditions have progressed after cancer chemotherapy. uuid:7254637b-4826-493f-94d8-a96bc9692e4b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:83766 biolink:treats MONDO:0009831 PMID:41385096 "[{""id"":""uuid:d28037c9-f4b1-467a-8976-9b2883c5cce0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2e62095b-02cb-4306-b7a7-a94483b4e76a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for maintenance therapy of unresectable BRCA mutation- positive pancreatic cancer after chemotherapy including treatment with platinum-based antineoplastic drugs. [Orphan drug] uuid:9d8d29dd-f4c9-4cc3-a22b-9f959ac50d67 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85994 biolink:treats UMLS:C4724831 PMID:41385096 "[{""id"":""uuid:06e4dfb7-7a2b-449c-912f-f979e91d534f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f4b65285-1775-4f2f-a8c9-b83e027fdb10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication for the treatment of unresectable thymic carcinoma. [Orphan drug] uuid:394d1d1b-e121-4602-8ad6-fbfb11a43c4d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:E58MLH082P biolink:treats MONDO:0001566 PMID:41385096 "[{""id"":""uuid:05df1fba-6218-403d-832d-0f4cdcc9a39c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:53e71732-456d-4225-94e1-b09b6984bb5a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of hypercalcemia in patients with parathyroid carcinoma or patients with primary hyperparathyroidism who are unable to undergo parathyroidectomy or relapse after parathyroidectomy. [Orphan drug] uuid:43465e18-ff51-488b-85de-dd81cbf16dde biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:E58MLH082P biolink:treats MONDO:0012004 PMID:41385096 "[{""id"":""uuid:77efed6e-51a5-44ca-8c8a-01131127aa41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:66d6a49b-2baf-4687-ac89-f850ece3f48d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of hypercalcemia in patients with parathyroid carcinoma or patients with primary hyperparathyroidism who are unable to undergo parathyroidectomy or relapse after parathyroidectomy. [Orphan drug] uuid:78abb9ee-f319-4781-8a0b-a5aafb98bf24 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:E58MLH082P biolink:treats MONDO:0010837 PMID:41385096 "[{""id"":""uuid:2e265159-bf30-41f6-aa06-5749bce52193"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:59dca4e7-76f7-46e9-b622-53e87fcea02e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of hypercalcemia in patients with parathyroid carcinoma or patients with primary hyperparathyroidism who are unable to undergo parathyroidectomy or relapse after parathyroidectomy. [Orphan drug] uuid:89ee4b6b-5bbe-4d6a-aa85-c168f71c1cad biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4F4X42SYQ6 biolink:treats MONDO:0019740 PMID:41385096 "[{""id"":""uuid:8415c8eb-0acd-494d-a761-3bfd63e6c524"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:046f8e68-62e2-4448-81bf-97e981ae8886"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of acquired thrombotic thrombocytopenic purpura. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:ad94a04b-0e7b-424c-b708-94c3c9a43803 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0006050 biolink:treats MONDO:0006624 PMID:41385096 "[{""id"":""uuid:5bdfcd1c-e698-41aa-a59e-30b1e3e0f183"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9f0b0bfa-ccb6-4032-92d9-2ad3142e7f71"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new route of administration indicated for the treatment of urinary urgency, urinary frequency, and urge urinary incontinence associated with overactive bladder or urinary incontinence due to neurogenic bladder, in patients who have not responded sufficiently to conventional therapies or in whom conventional therapies are not suitable. DRUGBANK:DB00083 uuid:8327d479-e28d-47d8-b08a-74359e72e42c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0006050 biolink:treats HP:0000020 PMID:41385096 "[{""id"":""uuid:1dcfba0e-52aa-48ce-8e75-08875c272b76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cb255642-7e75-40be-8836-0b6ddfcb39af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new route of administration indicated for the treatment of urinary urgency, urinary frequency, and urge urinary incontinence associated with overactive bladder or urinary incontinence due to neurogenic bladder, in patients who have not responded sufficiently to conventional therapies or in whom conventional therapies are not suitable. DRUGBANK:DB00083 uuid:86c9c723-316e-450e-ac54-0fadb9b5ee83 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0006050 biolink:treats HP:0000011 PMID:41385096 "[{""id"":""uuid:0cbd99fb-a0bf-46ed-8fb9-acd4819cdf21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bc198308-ea50-431e-84e9-03e69e18ad0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new route of administration indicated for the treatment of urinary urgency, urinary frequency, and urge urinary incontinence associated with overactive bladder or urinary incontinence due to neurogenic bladder, in patients who have not responded sufficiently to conventional therapies or in whom conventional therapies are not suitable. DRUGBANK:DB00083 uuid:5afad90a-6a39-4846-981d-3fcec0930555 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:15C2VL427D biolink:treats MONDO:0019783 PMID:41385096 "[{""id"":""uuid:0063a6a1-996c-4d62-8975-175f8cd68ed0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3f754441-3b82-42fc-a8cd-bc9bde3f1a28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of neovascular glaucoma. [Orphan drug] uuid:8dc2b5ba-71e0-4485-84da-254e1875198b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:UMD07X179E biolink:treats UMLS:C0406317 PMID:41385096 "[{""id"":""uuid:eb9e93e9-da6a-475d-b1fd-59d3d9b97155"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:09f78110-f563-4cf3-a866-969a65ce5d9f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of plaque psoriasis, psoriatic arthritis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies. uuid:33def913-a209-4499-81c5-aa537463f6ed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:UMD07X179E biolink:treats MONDO:0022205 PMID:41385096 "[{""id"":""uuid:ba0efd31-87ee-41b6-9bc3-7e48be699fc3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a20da4a0-acc9-496c-936a-beeb304eb13c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of plaque psoriasis, psoriatic arthritis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies. uuid:cdfc0cfb-d60f-4ef7-b7a6-1bcd2234e8ca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:UMD07X179E biolink:treats UMLS:C0748052 PMID:41385096 "[{""id"":""uuid:4178d1ba-4736-473f-af67-f9bfc52932b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c0e29602-a125-42e4-be28-1fc311e97196"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of plaque psoriasis, psoriatic arthritis, pustular psoriasis, and erythrodermic psoriasis in patients who have not responded sufficiently to conventional therapies. uuid:305757e6-15e3-4b9d-bc97-f1ada470da34 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1670307 biolink:treats MONDO:0001056 PMID:41385096 "[{""id"":""uuid:686d1f92-9901-42b4-8055-056e351c0f88"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ae069d82-63b8-46cd-8c9c-9bc6b88f90c4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication for the treatment of unresectable advanced or recurrent gastric cancer that have progressed after chemotherapy. uuid:5978a2f1-fc65-47a5-8bc9-0c938146c06f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DPT0O3T46P biolink:treats MONDO:0005627 PMID:41385096 "[{""id"":""uuid:552d8ff0-c016-489f-afcc-466b0744ea7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d749f9c5-0732-4c1f-92c1-2f69656c6437"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of unresectable or metastatic renal cell carcinoma. Drugs with a new indication for the treatment of recurrent or metastatic head and neck cancer. uuid:5cc3270d-98c5-4def-a7af-88fc3e99f9e9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10127 biolink:treats MONDO:0021095 PMID:41385096 "[{""id"":""uuid:449bfa0d-5cc9-4734-990d-2dd1ad6d26e3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ce52218c-4eda-4632-a3cb-708f2cd2892b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of parkinsonism in patients with dementia with Lewy bodies (in the cases where parkinsonism persists after using levodopa-containing products). uuid:e8c3b43a-4580-497c-aac4-0e351b25c3f5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10127 biolink:treats MONDO:0007488 PMID:41385096 "[{""id"":""uuid:68b6e5f2-049d-4e39-bc97-62baf814eed1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fe940fae-d11d-43cc-a984-4f8483a96320"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of parkinsonism in patients with dementia with Lewy bodies (in the cases where parkinsonism persists after using levodopa-containing products). uuid:57ac0b8d-0102-4512-a9e0-b147f7de7ff5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135809 biolink:treats MONDO:0000190 PMID:41385096 "[{""id"":""uuid:b1714397-a62f-41fd-b5b6-1963dd8c4282"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ce4e6d35-ebcc-420e-a369-4ab2d22bf84f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the following life-threatening cardiac arrhythmia in refractory and urgent cases: ventricular fibrillation and hemodynamically unstable ventricular tachycardia. [Orphan drug] uuid:78cdaab3-4194-46c0-bdf1-fc7fae636d80 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135809 biolink:treats MONDO:0005477 PMID:41385096 "[{""id"":""uuid:4a136c73-8525-413a-ab76-dae8948f5c48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c9b4b138-6ebe-4027-b63a-532c9914e747"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the following life-threatening cardiac arrhythmia in refractory and urgent cases: ventricular fibrillation and hemodynamically unstable ventricular tachycardia. [Orphan drug] uuid:410ffa92-e431-4ad3-b4ee-af654057cc7d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0006050 biolink:treats MONDO:0000485 PMID:41385096 "[{""id"":""uuid:4e7ca028-c6c9-466a-81d4-3af753b05809"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6db94a23-b126-48bf-b466-e2d94f0bf01e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of spasmodic dysphonia. DRUGBANK:DB00083 uuid:64100e2d-318c-4d8d-8b0f-fd7fa6e9ce53 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134724 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:c597e3a7-65ba-47b6-95c8-ffb2d28f7499"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:31dd1d1b-4890-44be-859f-713aaa3e6535"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of type 1 diabetes mellitus. uuid:b69b6b0d-cf4d-493f-b860-cd403ffb69ff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:31YO63LBSN biolink:treats UMLS:C4725093 PMID:41385096 "[{""id"":""uuid:2f51af1c-e78c-4412-b444-1b3e28f691e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4803f220-e2f5-4937-8601-295c452dfdce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of unresectable melanoma. [Orphan drug] uuid:29a81fd6-66b0-4de0-90e9-6cc52767a949 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:83766 biolink:treats MONDO:0016419 PMID:41385096 "[{""id"":""uuid:d02db404-e839-4427-a864-7e2fb90d521c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:59d77933-bc5e-4272-9de9-2c4053be3a73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication for the treatment of unresectable or recurrent BRCA mutation-positive and HER2-negative breast cancer in patients who have previously been treated with chemotherapy. [Orphan drug] uuid:d54979df-92e1-49bb-b760-3edbac24cd0c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46345 biolink:treats MONDO:0000956 PMID:41385096 "[{""id"":""uuid:b6a1bd43-add2-4ad8-866d-b197035fa40e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bb734029-2054-4dbc-bbaa-1d10db8e08e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of small intestine cancer. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:e3bebf41-bfb8-42ae-812c-7357a4fb2ad6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DPT0O3T46P biolink:treats UMLS:C4543702 PMID:41385096 "[{""id"":""uuid:ce772a5f-43fb-441a-a942-8d1688f34dda"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:72deda54-d551-449f-b426-7670482852af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new indications and a new dosage for the treatment of: advanced or recurrent microsatellite instability- high (MSI-High) solid tumors that have progressed after cancer chemotherapy (for use only if refractory or intolerant to standard therapies), melanoma, and unresectable advanced or recurrent non-small cell lung cancer. [(1) Conditional early approval, (2) Orphan drug, (3) Priority review] uuid:ce0aef38-abe9-4efb-8203-a795dae73ab5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DPT0O3T46P biolink:treats MONDO:0008903 PMID:41385096 "[{""id"":""uuid:f86e5223-d606-40a3-a5a3-b779b75a5a6c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:717dfa9e-05b1-481b-a0df-cda38a02cb44"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new indications and a new dosage for the treatment of: advanced or recurrent microsatellite instability- high (MSI-High) solid tumors that have progressed after cancer chemotherapy (for use only if refractory or intolerant to standard therapies), melanoma, and unresectable advanced or recurrent non-small cell lung cancer. [(1) Conditional early approval, (2) Orphan drug, (3) Priority review] uuid:1227a2c6-9944-4ea6-9db0-054bd7a98b7c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:I031V2H011 biolink:treats MONDO:0017991 PMID:41385096 "[{""id"":""uuid:5dce38ad-362e-447a-8e87-866f77896afd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b2fb67a8-82dc-4e6d-9c88-9480098c9593"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of Takayasu arteritis and giant cell arteritis in patients who have not responded sufficiently to conventional treatments. [Orphan drug] uuid:c1d1f493-83d7-43a9-9ad4-7ef0db19edd8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DPT0O3T46P biolink:treats MONDO:0004992 PMID:41385096 "[{""id"":""uuid:42e68468-59f6-4d62-af93-f7b4ce70d45c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a8db6ec7-980a-4268-912d-d216438cc3ba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication for the treatment of unresectable urothelial cancer which progressed after cancer chemotherapy. [Priority review] uuid:afad0b29-41c1-480a-85cd-48294d66e47f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:70708 biolink:treats MONDO:0010888 PMID:41385096 "[{""id"":""uuid:56e990f7-bb40-4d65-ab82-4e58975c5575"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b631f017-60a8-4ebe-a4a8-784d56c519af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication for the alleviation of pain associated with uterine adenomyosis. uuid:d872276b-0b90-423f-86c1-3617d382f968 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68478 biolink:treats MONDO:0019496 PMID:41385096 "[{""id"":""uuid:08ddbdfb-af78-49bf-bbe2-9bb6af5b0f47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c12586f5-544d-4275-8bdc-80c51579731c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[PMDA] Drugs with a revised indication from ""pancreatic neuroendocrine tumor"" to ""neuroendocrine tumor.""" uuid:e99e572f-f391-4697-9546-a4ac2e02a153 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63791 biolink:treats MONDO:0019471 PMID:41385096 "[{""id"":""uuid:7d4c20fe-bf79-47b5-bc7b-ef0fa939f3a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:80a2a665-f48d-45a0-9147-fffdb27b3801"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of relapsed or refractory adult T-cell leukemia/lymphoma. [Orphan drug] uuid:6442a0e2-800e-4be1-9199-e51845566aec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68579 biolink:treats HP:0034192 PMID:41385096 "[{""id"":""uuid:f62a24ad-f141-4be0-8d30-ec5ca9a88260"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4c838329-bf5d-47d7-8f8a-f30e66c2da6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment and prevention of recurrence of deep vein thrombosis and pulmonary thromboembolism. uuid:6eb69ed0-523f-4fdb-b421-121f5a45ae72 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72296 biolink:treats HP:0034192 PMID:41385096 "[{""id"":""uuid:2bd76a14-a3f8-42cc-b60c-376b7c2e05dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0c1ad91e-ddfe-4864-a900-5a6efcbe43f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment and prevention of the recurrence of venous thromboembolism (deep vein thrombosis and pulmonary thromboembolism). uuid:66c8c115-7710-4e7e-b059-b7cc6e5ed8ce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46081 biolink:treats MONDO:0002234 PMID:41385096 "[{""id"":""uuid:a2dddd42-c979-4cfe-abbc-666688455135"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:dfbdbfdf-dd9c-4b29-82c9-3bf68f8a9f5d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of vaginitis and vulvovaginitis caused by Candida . uuid:85276e89-a888-4d1b-a23a-b630e2735c18 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46081 biolink:treats MONDO:0007019 PMID:41385096 "[{""id"":""uuid:e1d53ea5-77cd-413a-81da-6aa6ea7b66fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a915f2dc-1aa9-4e37-93a6-3196237d2697"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of vaginitis and vulvovaginitis caused by Candida . uuid:4d7c8cb0-6de6-4f95-b17a-11d46d6eea6f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0006032 PMID:41385096 "[{""id"":""uuid:681d44ad-be43-447b-9acf-f3a4c211c93f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2990ae8c-070a-4358-ae81-74bd146ecefd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications for the treatment of cystitis, pyelonephritis, secondary infection of trauma, burns or surgical wounds, and others. uuid:afd5640e-1855-4088-bd8e-b0c463a18e80 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0006939 PMID:41385096 "[{""id"":""uuid:ac85e7a8-5ab5-4acf-8a7d-bd8eb6396563"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:23f6e2b4-e361-40fd-8397-e88c8d634b7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications for the treatment of cystitis, pyelonephritis, secondary infection of trauma, burns or surgical wounds, and others. uuid:fd363277-07a5-4880-abd9-992e2da5a09d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats UMLS:C0332803 PMID:41385096 "[{""id"":""uuid:c155d49c-7d1b-416c-bfa9-ac3e15fe8592"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c891bbf5-98f8-4d2c-85af-1a110e3c63d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications for the treatment of cystitis, pyelonephritis, secondary infection of trauma, burns or surgical wounds, and others. uuid:8adfa886-f391-47cf-a78c-2ea5c4e7441e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DLG4EML025 biolink:treats MONDO:0022205 PMID:41385096 "[{""id"":""uuid:af9c8dfc-3fd1-4951-9eb2-f5ac279af203"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b68f5b9f-6d64-442a-abdb-6ed0ae49e72e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication for the treatment of pustular psoriasis in patients who have not responded sufficiently to conventional therapies. uuid:4c00cd6f-ab52-40c2-b45d-9532f619b069 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats HP:0001705 PMID:41385096 "[{""id"":""uuid:2f443de4-2107-4c67-817b-78698cefee0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:67e4d50d-6678-4ca4-b2a2-9d347ad4bf5b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the prevention of hypoxic attack caused by right ventricular outflow tract obstruction. [Public knowledge-based application after preliminary assessment by the Pharmaceutical Affairs and Food Sanitation Council (PAFSC)] uuid:bb843c77-e4b9-4955-a126-31f5ce7ac8c5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:15C2VL427D biolink:treats UMLS:C3537442 PMID:41385096 "[{""id"":""uuid:d046ea3c-3044-4504-81cb-49f2eef06b7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7d2b3304-1265-4040-9c59-c10ebed764a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication for the treatment of choroidal neovascularization in patients with pathologic myopia. uuid:327127c4-2fef-4a01-a67f-21d0b9f713aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9919 biolink:treats MONDO:0004609 PMID:41385096 "[{""id"":""uuid:47c619e4-c901-4b52-9ff1-1a38190de1d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:04050608-2f92-41b7-ad09-0dbfb88fb43b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and revised indications with a new dosage for prevention of herpes simplex virus infection in adult or pediatric haematopoietic stem cell transplant patients, for treatment of herpes simplex /herpes zoster, and for prevention of recurrent genital herpes in pediatric patients. uuid:33f6c4fa-cbea-4abb-88a3-9bf6554325ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9919 biolink:treats HP:0032157 PMID:41385096 "[{""id"":""uuid:f1e6b9c7-27fa-457f-834b-72a1a46df01e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8c1780f0-9765-478a-beae-145ef3347efd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and revised indications with a new dosage for prevention of herpes simplex virus infection in adult or pediatric haematopoietic stem cell transplant patients, for treatment of herpes simplex /herpes zoster, and for prevention of recurrent genital herpes in pediatric patients. uuid:46319716-f8c9-4d61-931d-f4ef9544b7ee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7903 biolink:treats MONDO:0019019 PMID:41385096 "[{""id"":""uuid:71a7bc52-6a9e-4457-be26-6ad0ce55ec3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:aef7a228-0231-49ac-8754-3f917b95eb1d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of osteogenesis imperfecta. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:df6f2ce5-eed5-42f5-9e11-b026fcbd4d30 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C3500339 biolink:treats MONDO:0009691 PMID:41385096 "[{""id"":""uuid:167b8919-d677-4266-8c25-c962d27c92ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0fb5ead9-13dc-4d36-9156-540b9eaba7dc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of mycosis fungoides and Sézary syndrome. [Orphan drug] uuid:9938d140-71d7-4bab-9139-b2215dd757d7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32089 biolink:treats MONDO:0005062 PMID:41385096 "[{""id"":""uuid:8dd6b76c-225b-4bf1-b528-7ccca9cdb9bc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1f7193c4-e11d-49a6-9cea-adaa469dd9b4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of malignant lymphoma. [Expedited review] uuid:d8bdf4cf-9fa9-43dd-a4e7-b4af6408e278 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:154705018 biolink:treats MONDO:0005575 PMID:41385096 "[{""id"":""uuid:b9b17c12-6cc0-4026-a3eb-a481bb919001"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:af6f7e11-806e-42ad-8895-16d3088cddce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a revised indication for the treatment of unresectable advanced or recurrent colorectal cancer. [Expedited review] uuid:56dc7f7f-77d5-4c14-8fad-94371a4b9285 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28741 biolink:treats MONDO:0005276 PMID:41385096 "[{""id"":""uuid:9024b70a-71de-4960-a5bc-232e31040616"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b4db4362-836e-47b9-a12e-22ce4dae4f7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the prevention of dental caries. uuid:1e2721a9-0192-49dc-8491-0e900114f6da biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47780 biolink:treats MONDO:0021107 PMID:41385096 "[{""id"":""uuid:7f4fba17-005f-46aa-a770-de7b24ab979b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b0b5fce6-9ac0-4d33-965d-1875a8bf4aa8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of cataplexy associated with narcolepsy. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:794609fc-6d0c-4e46-999f-589e993ee39c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3745 biolink:treats MONDO:0005230 PMID:41385096 "[{""id"":""uuid:b6145483-e388-42b7-9ff6-c295b0482fc9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:be9d646e-20c0-44e5-ac92-13a523877c67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication for cellulitis around the jaw bone and jaw inflammation. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:7a0ad05a-1394-4885-a66f-043bcc8b9877 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3745 biolink:treats UMLS:C0854217 PMID:41385096 "[{""id"":""uuid:01e2e952-fd1f-4cb0-b4a5-cac2a724d7ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e414afce-4f53-4932-ab23-0081caf2f2d1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication for cellulitis around the jaw bone and jaw inflammation. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:e019d3d2-fe29-49a3-a725-59fb38c96475 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:61049 biolink:treats MONDO:0019622 PMID:41385096 "[{""id"":""uuid:e6beaaa2-af9f-4351-9c4d-5f06bdff62f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3d6f58e9-7e06-4b00-9bf6-3aa035459714"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and new dosage for the treatment of interstitial pneumonia associated with polymyositis/dermatomyositis. [Orphan drug] uuid:7c60140c-34db-43d6-9898-c18e265f5d7c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2S9ZZM9Q9V biolink:treats MONDO:0100342 PMID:41385096 "[{""id"":""uuid:ce020af8-46ea-4467-9173-484732c38bb2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:aa3e3270-b835-4e18-92fd-2381a596a984"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of malignant glioma. [Orphan drug] uuid:7a1b6e80-7ea5-4eec-908d-b3af8becf320 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231601 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:1e44d9a8-65b1-4851-a42b-2cbcd771c053"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5356ab83-6f20-4ad1-abf6-8e6c721d4071"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage for the treatment of breast cancer with HER2 overexpression. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:b0d5b1d9-621d-456a-b06e-d8a7250b9bf1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231601 biolink:treats NCIT:C150634 PMID:41385096 "[{""id"":""uuid:18d949d6-a453-4173-99b8-62885d8f4a33"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:27a68d6e-8d02-4889-ae5a-b5cd6388deb6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage for the treatment of breast cancer with HER2 overexpression. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:549966dd-f6bf-4f9e-bff1-9a70190e7ed4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3311 biolink:treats UMLS:C0854776 PMID:41385096 "[{""id"":""uuid:cca1da82-7350-456d-aed4-0b9ce683c1ec"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5a747bcc-a49b-4763-9955-36c9637eb2c3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of unresectable pancreatic cancer. [Priority review], [Expedited review] uuid:4750fd39-3d54-4122-abb8-78c042b87999 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46345 biolink:treats UMLS:C0854776 PMID:41385096 "[{""id"":""uuid:efd0967d-00f7-4023-a895-dadc2369bf7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f54d0523-37c9-4b80-a586-2cf65fdffa34"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of unresectable pancreatic cancer. [Priority review], [Expedited review] uuid:286df6f0-c5f9-4306-87a1-daed3fe4ca0e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats UMLS:C0428985 PMID:41385096 "[{""id"":""uuid:dc725d51-e790-4b47-9e85-605e5f1e2e4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:52b4e6be-8141-43db-af32-801fa5e53561"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional pediatric dosages for extrasystole (supraventricular/ventricular), the prevention of paroxysmal tachycardia, atrial fibrillation with rapid ventricular response (bradycardiac effect), sinus tachycardia, atrial fibrillation, and the prevention of paroxysmal atrial fibrillation. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:018f0471-7d12-4aed-ace9-0ccbcda4b473 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats HP:0006688 PMID:41385096 "[{""id"":""uuid:e6b5d30c-9734-43b5-b73c-c5893e020e8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3730fc7b-3df9-4c2f-894a-6b05b31c35e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional pediatric dosages for extrasystole (supraventricular/ventricular), the prevention of paroxysmal tachycardia, atrial fibrillation with rapid ventricular response (bradycardiac effect), sinus tachycardia, atrial fibrillation, and the prevention of paroxysmal atrial fibrillation. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:1fededcf-3334-4fc0-bd35-e00fe13f37aa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8499 biolink:treats MONDO:1030011 PMID:41385096 "[{""id"":""uuid:14eef92d-10c1-484d-b727-f8bf53981799"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a02d88fb-70b4-4ee4-9778-d01ad49546d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional pediatric dosages for extrasystole (supraventricular/ventricular), the prevention of paroxysmal tachycardia, atrial fibrillation with rapid ventricular response (bradycardiac effect), sinus tachycardia, atrial fibrillation, and the prevention of paroxysmal atrial fibrillation. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:4a1ce71c-1f1c-472f-8cdd-dba50eb2a72d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37941 biolink:treats MONDO:0005294 PMID:41385096 "[{""id"":""uuid:ff9b7546-7a8b-4dfe-b4a1-7d4ef34df0e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:aae8a013-1faa-49af-9828-bec22ff24385"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the suppression of embolus/thrombus formation in peripheral arterial diseases. uuid:81b0a8f7-82de-4a03-b797-e27d1b5245f2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0250480 biolink:treats MONDO:0004522 PMID:41385096 "[{""id"":""uuid:9ddcdc6c-0670-4d11-b6b4-1b40e8dbc85a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:626de48c-7b10-4f38-a05f-d9364ff350a3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications for the treatment of peritonitis, intraperitoneal abscess, cholecystitis, and cholangitis. uuid:4498a535-021c-42a5-9908-2184716961ba biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0250480 biolink:treats HP:0100592 PMID:41385096 "[{""id"":""uuid:627903b9-3fc9-4c11-9a6c-a260ec703cf7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ed74ede7-085f-496e-a3e2-5c7882fdeef6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications for the treatment of peritonitis, intraperitoneal abscess, cholecystitis, and cholangitis. uuid:c3bbf31e-5a63-46ef-b07c-d5a72d63c15a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0250480 biolink:treats MONDO:0002155 PMID:41385096 "[{""id"":""uuid:7138bcf0-c2ba-4be6-ae0e-d2336846834f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9cbc7738-4f39-4971-b146-065d9c4dd361"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications for the treatment of peritonitis, intraperitoneal abscess, cholecystitis, and cholangitis. uuid:ce91ac2a-3c46-41a6-8ac2-e5aadaaad47a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0250480 biolink:treats MONDO:0004789 PMID:41385096 "[{""id"":""uuid:991b7205-8143-4c25-85d4-312960842147"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1d2be1fa-589d-4e91-a29b-ac410d927657"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications for the treatment of peritonitis, intraperitoneal abscess, cholecystitis, and cholangitis. uuid:8ab610d2-5686-4fd9-8fd8-991b79c4f34b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63607 biolink:treats HP:0100806 PMID:41385096 "[{""id"":""uuid:f6696f1a-199c-43f4-ba60-dd93b87a32f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e6b3aa11-e322-438b-add1-2f9c12111639"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional pediatric dosage. These drugs are indicated for sepsis, deep skin infection, chronic pyoderma, secondary infection of trauma, burn, and surgical wounds, and pneumonia. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:8abc192f-6200-48ba-bff4-7816cc234e08 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63607 biolink:treats MONDO:0002922 PMID:41385096 "[{""id"":""uuid:c3de2ddc-1150-4851-98bb-c518a39b99a9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ba8b12f5-93db-403e-99ea-a529f85a77a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional pediatric dosage. These drugs are indicated for sepsis, deep skin infection, chronic pyoderma, secondary infection of trauma, burn, and surgical wounds, and pneumonia. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:f5b321f8-1f83-4fe7-84ea-39dcdcc1da2f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63607 biolink:treats UMLS:C0332803 PMID:41385096 "[{""id"":""uuid:c85a164f-ce41-4923-bdf8-fc765b6c5dc4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d1f1d0ee-f83e-43b0-9148-c913008cdc42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional pediatric dosage. These drugs are indicated for sepsis, deep skin infection, chronic pyoderma, secondary infection of trauma, burn, and surgical wounds, and pneumonia. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:f6c3404b-575f-41b4-809c-dad0a3d00e9d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:327148 biolink:treats MONDO:0005607 PMID:41385096 "[{""id"":""uuid:01af482e-17ac-47da-b9cc-161da1d49997"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d912d6cf-d6be-4c0c-a5b4-05ea97a56140"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the relief of symptoms of chronic obstructive pulmonary diseases (chronic bronchitis, emphysema). uuid:c878ea35-0d73-4754-a9a5-4cde8b2108a2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:327148 biolink:treats MONDO:0004849 PMID:41385096 "[{""id"":""uuid:9d84a8d5-f07b-40b1-b8ee-eb9228a986e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c859daf8-2bc7-4eaa-b49d-03bbbedc8d68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the relief of symptoms of chronic obstructive pulmonary diseases (chronic bronchitis, emphysema). uuid:3a398e23-1b3a-42f7-a08c-7b5a99431272 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4027 biolink:treats MONDO:0008233 PMID:41385096 "[{""id"":""uuid:b4613a5d-ab4b-47b8-9f8b-89813ff03a5d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9417f581-0b50-49c2-b2f8-7a90fee2deaa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of pheochromocytoma. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:6c00e19b-d2bc-4b93-820f-7751ea1afe84 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:94385 biolink:treats MONDO:0018048 PMID:41385096 "[{""id"":""uuid:be99232e-e0ad-43fd-881f-b36d5928c747"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:db8cc038-8975-4bb7-9502-a58858c9ebd7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and new dosages for the prevention of perfusion blood coagulation during blood extracorporeal circulation (hemodialysis) in patients with heparin-induced thrombocytopenia (HIT) type II and in addition for the prevention of blood coagulation during percutaneous coronary intervention in HIT type II patients (including the patients who have the risk for HIT). [Orphan drug] uuid:b7404663-a8f9-4737-bcee-162a785e6704 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28077 biolink:treats UMLS:C0026919 PMID:41385096 "[{""id"":""uuid:d5abfb05-ac33-43c4-92f8-e5c658190d53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ee71053f-0a4f-4e0a-a0d2-4f3a9e41707f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of nontuberculous mycobacteriosis including Mycobacterium avium complex (MAC) infection. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:be63c1b3-67fd-469a-b789-8713ef36fc98 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28077 biolink:treats MONDO:0005866 PMID:41385096 "[{""id"":""uuid:1877a0a3-2636-4cfd-b7e5-0fe9ebdcb1b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0408f7d3-7b30-411d-9544-1e7df01bc0fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of nontuberculous mycobacteriosis including Mycobacterium avium complex (MAC) infection. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:8fe74749-6756-4b2d-9daa-f2c29c41cca2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4304 biolink:treats MONDO:0002258 PMID:41385096 "[{""id"":""uuid:c32f8f15-e113-4099-9c45-25ee9e5884d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:17f17c71-c3ef-4589-bbb8-dd93b8649e92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of pharyngitis and laryngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, secondary infection of chronic respiratory disease, cystitis, pyelonephritis, urethritis, cervicitis, otitis media, sinusitis, periodontal inflammation, pericoronitis, and jaw inflammation. uuid:e84872ca-00db-4075-bf56-c71369148dd0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4304 biolink:treats MONDO:0002647 PMID:41385096 "[{""id"":""uuid:2e958111-6d64-40be-b77f-fc5de79743ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7b2a0410-9ce8-4019-b7de-6a18fdb052f6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of pharyngitis and laryngitis, tonsillitis (including peritonsillitis and peritonsillar abscess), acute bronchitis, pneumonia, secondary infection of chronic respiratory disease, cystitis, pyelonephritis, urethritis, cervicitis, otitis media, sinusitis, periodontal inflammation, pericoronitis, and jaw inflammation. uuid:4f63d001-0c68-482d-b627-169f9d8fbb0c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:441410 biolink:treats MONDO:0019165 PMID:41385096 "[{""id"":""uuid:dfcbf83f-cd32-4f02-b101-0132c1e59d58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b8c8ba15-9356-4ef2-9165-1474235bc10c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional dosage indicated for the treatment of central precocious puberty. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:481e63fb-e4c5-4636-9422-6b071df3e175 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2948 biolink:treats UMLS:C0264939 PMID:41385096 "[{""id"":""uuid:15e17b09-36bd-4e18-ba7c-4dd77a9174ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a25db083-8401-49ca-9c1f-5fd447a03bc8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of the following treatment- resistant rheumatic diseases: systemic vasculitis (e.g., microscopic polyangiitis, Wegener granulomatosis, polyarteritis nodosa, Churg-Strauss syndrome, aortitis syndrome), systemic lupus erythematosus (SLE), polymyositis, dermatomyositis, pachyderma, mixed connective tissue disease and refractory rheumatic disease. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:9a6703ba-8556-4f5a-9c3d-2ef83b3c8efa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2948 biolink:treats MONDO:0019124 PMID:41385096 "[{""id"":""uuid:13c9a63a-3d04-4a97-8c8f-00021ceec824"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c1cfcdf6-5572-4c2e-9f78-752198363b47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of the following treatment- resistant rheumatic diseases: systemic vasculitis (e.g., microscopic polyangiitis, Wegener granulomatosis, polyarteritis nodosa, Churg-Strauss syndrome, aortitis syndrome), systemic lupus erythematosus (SLE), polymyositis, dermatomyositis, pachyderma, mixed connective tissue disease and refractory rheumatic disease. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:a442ce61-c455-43a9-9893-de24804f7b68 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2948 biolink:treats MONDO:0012105 PMID:41385096 "[{""id"":""uuid:8b8e2c8d-a808-4e93-ac8f-0b6a68263971"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:affe592c-0952-44d9-9929-b46c2a9fcc44"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of the following treatment- resistant rheumatic diseases: systemic vasculitis (e.g., microscopic polyangiitis, Wegener granulomatosis, polyarteritis nodosa, Churg-Strauss syndrome, aortitis syndrome), systemic lupus erythematosus (SLE), polymyositis, dermatomyositis, pachyderma, mixed connective tissue disease and refractory rheumatic disease. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:7f196827-3d20-4077-9822-e1b9fd0be961 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2948 biolink:treats MONDO:0017991 PMID:41385096 "[{""id"":""uuid:9d949fdc-caa2-4ab2-a5f3-f71e73910b6c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8de467eb-cd2f-49f9-8ef2-a8e58ad26f2b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of the following treatment- resistant rheumatic diseases: systemic vasculitis (e.g., microscopic polyangiitis, Wegener granulomatosis, polyarteritis nodosa, Churg-Strauss syndrome, aortitis syndrome), systemic lupus erythematosus (SLE), polymyositis, dermatomyositis, pachyderma, mixed connective tissue disease and refractory rheumatic disease. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:039d3106-47dc-4243-a33c-1b778a549bf4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2948 biolink:treats MONDO:0019127 PMID:41385096 "[{""id"":""uuid:a229ec50-88ba-4f7d-8a57-ddb086ce5810"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9d8ec27a-e90f-42e3-b609-e311bfbd0483"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of the following treatment- resistant rheumatic diseases: systemic vasculitis (e.g., microscopic polyangiitis, Wegener granulomatosis, polyarteritis nodosa, Churg-Strauss syndrome, aortitis syndrome), systemic lupus erythematosus (SLE), polymyositis, dermatomyositis, pachyderma, mixed connective tissue disease and refractory rheumatic disease. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:1258cf4b-417a-4e4e-8e7e-a92c9a981329 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2948 biolink:treats HP:0001072 PMID:41385096 "[{""id"":""uuid:84db26c3-ab80-48d0-a2e1-0ea7d903630d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:141aef4f-d045-4eac-a72b-0b2247d6b805"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of the following treatment- resistant rheumatic diseases: systemic vasculitis (e.g., microscopic polyangiitis, Wegener granulomatosis, polyarteritis nodosa, Churg-Strauss syndrome, aortitis syndrome), systemic lupus erythematosus (SLE), polymyositis, dermatomyositis, pachyderma, mixed connective tissue disease and refractory rheumatic disease. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:f3c10e9e-88f7-43f4-be1c-0e25be4ff4ef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2948 biolink:treats MONDO:0005854 PMID:41385096 "[{""id"":""uuid:bc774beb-6f88-4226-bb24-fc5ca95ee830"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:54e73eb6-a183-4a86-a674-85f89d1df92a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of the following treatment- resistant rheumatic diseases: systemic vasculitis (e.g., microscopic polyangiitis, Wegener granulomatosis, polyarteritis nodosa, Churg-Strauss syndrome, aortitis syndrome), systemic lupus erythematosus (SLE), polymyositis, dermatomyositis, pachyderma, mixed connective tissue disease and refractory rheumatic disease. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:aeed9472-f31e-4437-b9b2-8fba57e941d4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2948 biolink:treats MONDO:0005554 PMID:41385096 "[{""id"":""uuid:31183218-2b4c-46fe-bc95-1ddc4677d045"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f86a0250-9b17-4af7-ae9d-b958e97af3b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of the following treatment- resistant rheumatic diseases: systemic vasculitis (e.g., microscopic polyangiitis, Wegener granulomatosis, polyarteritis nodosa, Churg-Strauss syndrome, aortitis syndrome), systemic lupus erythematosus (SLE), polymyositis, dermatomyositis, pachyderma, mixed connective tissue disease and refractory rheumatic disease. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:5a2b4577-25ef-4376-8614-bfc304373857 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41423 biolink:treats NCIT:C3137 PMID:41385096 "[{""id"":""uuid:f7d6062e-b799-455a-a1db-8aa259436532"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:00c6eee8-02d3-4f80-9925-6f27e43fc225"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the relief of inflammation and pain after operation, trauma, and tooth extraction. uuid:e270e491-a34c-44c3-9db2-090dee7769ef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41423 biolink:treats HP:0012531 PMID:41385096 "[{""id"":""uuid:49dca5ce-3540-4da2-8aba-3a7ac0fdcb9d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:996a0a73-f335-4b67-a74e-e7f51f7068a0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the relief of inflammation and pain after operation, trauma, and tooth extraction. uuid:fd556acf-446b-4284-9076-2422b3fbc402 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:114785 biolink:treats UMLS:C0854776 PMID:41385096 "[{""id"":""uuid:eb9ce1b7-25bb-4f48-82f0-efe7d640bb23"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:317220ee-792c-47f1-a503-3a8a9a5d2e32"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of unresectable pancreatic cancer. uuid:764fc1cf-178a-4a0b-a361-513666069f4d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231601 biolink:treats MONDO:0006244 PMID:41385096 "[{""id"":""uuid:15ef1125-cd7f-434c-8ba1-d4f0dac52a92"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:296cc007-a851-4ab3-b476-8edeb5a815c6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of breast cancer with HER2 overexpression. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:91687200-bb21-4b5b-9c32-27c03a95d0cd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C5888472 biolink:treats MONDO:0005812 PMID:41385096 "[{""id"":""uuid:331ef91b-399a-4464-8adf-a23d27fce90e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3c109486-ad9f-41e2-978f-be9f685b9c38"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new pediatric dosage indicated for the prevention of influenza. [Expedited review] DRUGBANK:DB18750 uuid:0231c3bb-243c-45a0-bef8-c1efcedc91c6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32107 biolink:treats MONDO:0001126 PMID:41385096 "[{""id"":""uuid:73f2cb29-3190-4523-baf3-c8a343d1ce6a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:621aa280-b94c-44fe-8b85-46faef17302e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional pediatric dosages. These drugs are indicated for gastric ulcer, duodenal ulcer, stomal ulcer, Zollinger-Ellison syndrome, reflux esophagitis, preanesthetic medication and improvement of gastric mucosal lesions (erosion, bleeding, redness, edema) during acute gastritis or acute exacerbation phase of chronic gastritis. uuid:cf8c59e1-c4ae-4cec-919a-070de3d9e2c8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32107 biolink:treats MONDO:0005412 PMID:41385096 "[{""id"":""uuid:917d3a90-82f0-43f8-ae8c-527d5c9a8d4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:479bbe9f-15ca-4e86-916c-c620b81cc7f8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional pediatric dosages. These drugs are indicated for gastric ulcer, duodenal ulcer, stomal ulcer, Zollinger-Ellison syndrome, reflux esophagitis, preanesthetic medication and improvement of gastric mucosal lesions (erosion, bleeding, redness, edema) during acute gastritis or acute exacerbation phase of chronic gastritis. uuid:0ee7cc9b-ceb5-44cd-9556-80b312749fa4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32107 biolink:treats MONDO:0001155 PMID:41385096 "[{""id"":""uuid:284ab207-b6df-40b9-8506-074a5e17aeb4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1dd63393-d0ef-48ef-944a-3457d487f9fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional pediatric dosages. These drugs are indicated for gastric ulcer, duodenal ulcer, stomal ulcer, Zollinger-Ellison syndrome, reflux esophagitis, preanesthetic medication and improvement of gastric mucosal lesions (erosion, bleeding, redness, edema) during acute gastritis or acute exacerbation phase of chronic gastritis. uuid:72263d5e-7a5b-48df-8e69-65857b32a0ff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32107 biolink:treats MONDO:0006896 PMID:41385096 "[{""id"":""uuid:3a7eee61-eb6c-4548-bb6f-d38f9f9fb82b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:817bd07f-6b5b-495c-bce9-8d9323760d0f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional pediatric dosages. These drugs are indicated for gastric ulcer, duodenal ulcer, stomal ulcer, Zollinger-Ellison syndrome, reflux esophagitis, preanesthetic medication and improvement of gastric mucosal lesions (erosion, bleeding, redness, edema) during acute gastritis or acute exacerbation phase of chronic gastritis. uuid:aeb5446b-ae2d-404f-ab53-5e20e2334c12 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32107 biolink:treats UMLS:C0149518 PMID:41385096 "[{""id"":""uuid:0f4c5968-f7b6-42f8-9823-e56c37918ca3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:437cc0ad-0c5e-487d-aa6e-ecf7f20c7513"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional pediatric dosages. These drugs are indicated for gastric ulcer, duodenal ulcer, stomal ulcer, Zollinger-Ellison syndrome, reflux esophagitis, preanesthetic medication and improvement of gastric mucosal lesions (erosion, bleeding, redness, edema) during acute gastritis or acute exacerbation phase of chronic gastritis. uuid:e01fbcfe-91c6-4e17-8cc1-67a9bd267041 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32107 biolink:treats MONDO:0005001 PMID:41385096 "[{""id"":""uuid:3925c642-5a70-4920-9133-4e5dbd6661d0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b849c677-47aa-47ff-88c9-8cb9d2fbd944"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional pediatric dosages. These drugs are indicated for gastric ulcer, duodenal ulcer, stomal ulcer, Zollinger-Ellison syndrome, reflux esophagitis, preanesthetic medication and improvement of gastric mucosal lesions (erosion, bleeding, redness, edema) during acute gastritis or acute exacerbation phase of chronic gastritis. uuid:8acd959c-09de-42af-80ed-43573fe4079d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75984 biolink:treats UMLS:C0080203 PMID:41385096 "[{""id"":""uuid:480f7ed2-b4b4-4696-9977-753eaac586de"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a81a885a-447c-4601-abe6-d324137e81aa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of tachyarrhythmia (paroxysmal atrial fibrillation/flutter, paroxysmal supraventricular tachycardia, ventricular tachycardia) in children. [Expedited review] uuid:08c2c4fd-8454-4605-9d7d-b7b53629baf4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75984 biolink:treats MONDO:0005477 PMID:41385096 "[{""id"":""uuid:1d860a1a-08f3-4f3f-b108-9e3a8b53aca1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3b953446-044e-4f6e-896d-6ed4a73e2686"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of tachyarrhythmia (paroxysmal atrial fibrillation/flutter, paroxysmal supraventricular tachycardia, ventricular tachycardia) in children. [Expedited review] uuid:0e100e6f-d1f4-4961-89bb-7498878c8204 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85202 biolink:treats UMLS:C0858004 PMID:41385096 "[{""id"":""uuid:2cbb3b4a-a3f2-423b-bc5a-1a45857a0d89"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:eace1d96-af32-4113-b55e-626dd2e3249d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional pediatric dosages for influenza A or B virus infection. uuid:f92405b4-c99c-4a3d-9676-6bc941f16feb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85202 biolink:treats UMLS:C0858005 PMID:41385096 "[{""id"":""uuid:f1a9b162-6452-40e5-87c6-3e0e71ef296b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f002b8e5-98c9-45b4-9ff9-6acb8f63952d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional pediatric dosages for influenza A or B virus infection. uuid:ad36d95d-855d-45f8-a1b0-2eebaea622c5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3207 biolink:treats MONDO:0100470 PMID:41385096 "[{""id"":""uuid:0fa7f5cc-3111-4ead-bd60-1f1529f60695"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1171a888-36a9-4e90-8479-557a5361a58e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional adult and pediatric (5 years of age and older) dosages for the treatment of bronchial asthma. uuid:806d7fde-8808-4f05-acf6-5bf0b3568f2b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6128 biolink:treats HP:0003326 PMID:41385096 "[{""id"":""uuid:551b9b6e-be6a-471b-a2c8-b7f6772c5c72"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8ce56662-b82b-4f18-927a-26aa0b2d4a44"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications for the treatment of myalgia and post-traumatic swelling/pain. uuid:a19a306e-5b43-48d0-90a7-641f18b5178e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6128 biolink:treats NCIT:C3399 PMID:41385096 "[{""id"":""uuid:90726232-fc1a-45e6-9e65-0ecbaff945f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f5145b29-48d6-4787-8671-b443ce4d0603"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications for the treatment of myalgia and post-traumatic swelling/pain. uuid:7e6ea75a-b1cf-405f-a428-b1fa28c95383 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4672 biolink:treats MONDO:0001056 PMID:41385096 "[{""id"":""uuid:d350d605-5e1c-4c2d-b502-53de46efeb39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b95d5b0f-6bae-4851-9df8-26630d6a9c4b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new dosages for the treatment of breast cancer, non-small cell lung cancer, gastric cancer, head and neck cancer and ovarian cancer. uuid:59ebeb4c-14f5-42bb-a80b-e2fef07f5456 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4672 biolink:treats MONDO:0008170 PMID:41385096 "[{""id"":""uuid:ee60a4c8-db46-4eee-875c-c13f6258b9ce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:227c36f1-8ad2-45b8-aea3-c84ec4bff6f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new dosages for the treatment of breast cancer, non-small cell lung cancer, gastric cancer, head and neck cancer and ovarian cancer. uuid:02a6fb52-f3ed-4acd-a9c4-16190f0d69a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231601 biolink:treats MONDO:0001056 PMID:41385096 "[{""id"":""uuid:ff181f18-ea58-4405-9975-fd5a225814da"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d32f36ca-f376-41dd-bced-2a7ad7ec7270"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of unresectable advanced or recurrent gastric cancer with HER2 overexpression. [Priority review] uuid:34778da4-72db-49be-9d97-55339bbb9203 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31759 biolink:treats MONDO:0006896 PMID:41385096 "[{""id"":""uuid:bdefe2d8-768f-4b26-a102-add959ee17cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bae19960-86fb-4d5b-886e-689dc4c2f3f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication for the treatment of reflux esophagitis. uuid:f185b161-ae55-4b1b-81c0-087db439f8b0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7798 biolink:treats UMLS:C0276353 PMID:41385096 "[{""id"":""uuid:24238962-55a9-4e7b-96c1-303a8df157b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fa2d4784-2c73-4438-b701-840415235b40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for prophylaxis of influenza A or B virus infections. uuid:83f594ec-ad63-4e1c-81a1-d03318a59993 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3077 biolink:treats MONDO:0700081 PMID:41385096 "[{""id"":""uuid:19e0ff63-f3ad-48d1-8311-26cde8ac3f41"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8eb050af-aebe-4dec-b89d-eaa01e82c7df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for prevention of neonatal respiratory distress syndrome by way of enhancing fetal lung maturation by maternal administration for use in cases where premature birth is expected. uuid:3f9becab-6663-4055-a04c-0357e81e3f11 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134720 biolink:treats MONDO:0006624 PMID:41385096 "[{""id"":""uuid:01e6c425-b8ec-416f-8e26-88195b3d5200"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:95f061cf-11db-468b-9a83-486d8adb63d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of urgency of urination, pollakiuria, and urge urinary incontinence associated with overactive bladder. uuid:39a4d0b9-9b87-4e7b-9e09-72899b09d333 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3561 biolink:treats MONDO:0011786 PMID:41385096 "[{""id"":""uuid:ba4ab39d-b6b0-4e97-8fd4-60b8ff9a3436"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:dfd9d0f7-b319-4dc8-879f-19421541a522"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional pediatric dosage indicated for the treatment of allergic rhinitis, urticaria, and itching associated with skin disease (eczema/dermatitis and pruritus cutaneous). uuid:83a308dc-d0e3-45c2-933e-ec79873d6bcd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3561 biolink:treats MONDO:0005492 PMID:41385096 "[{""id"":""uuid:de5ea942-eb4a-4ad7-aa3c-e31fc084f0c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b0e4ceb6-3d7e-4bf5-bd5b-49e65dd73a4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional pediatric dosage indicated for the treatment of allergic rhinitis, urticaria, and itching associated with skin disease (eczema/dermatitis and pruritus cutaneous). uuid:82985a4b-6f81-4d90-a3d8-42ed23429d72 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3561 biolink:treats HP:0000989 PMID:41385096 "[{""id"":""uuid:3f49c31e-d68f-4b5e-9fae-b615a2138613"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:eb4764d8-eb92-48e5-88aa-d6d9431c7ff0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional pediatric dosage indicated for the treatment of allergic rhinitis, urticaria, and itching associated with skin disease (eczema/dermatitis and pruritus cutaneous). uuid:0249a87a-a3b2-4f42-8db0-3a880e34394c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41423 biolink:treats HP:0003419 PMID:41385096 "[{""id"":""uuid:3038d8d6-161d-4450-80a7-97d6224ac2c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:83b5389f-66f3-46fd-9b8c-739694711710"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications for the treatment of lumbago, scapulohumeral periarthritis, cervico-omo-brachial syndrome, and tendinitis/tenosynovitis. uuid:83008050-86f3-4588-9c5c-e22f8ca971ec biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41423 biolink:treats MONDO:0006898 PMID:41385096 "[{""id"":""uuid:0fb2f418-46b0-4ac8-993d-aefe945cfb47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:522afcba-4468-4edd-b8e9-808c8b233df6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications for the treatment of lumbago, scapulohumeral periarthritis, cervico-omo-brachial syndrome, and tendinitis/tenosynovitis. uuid:c4ffd01f-f08f-4d1a-9e08-06b093946ca9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41423 biolink:treats MONDO:0004857 PMID:41385096 "[{""id"":""uuid:35ca4a87-b089-447f-a61e-4c922934bc67"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7857ada4-3e41-43b8-8970-8a9563784f90"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications for the treatment of lumbago, scapulohumeral periarthritis, cervico-omo-brachial syndrome, and tendinitis/tenosynovitis. uuid:be78d96a-3669-423d-a731-c75189e196b5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41423 biolink:treats MONDO:0004855 PMID:41385096 "[{""id"":""uuid:749c1ebf-7827-44b6-a91f-84ba43244c5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c9b9d9aa-854c-4040-88e3-569c658d1464"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications for the treatment of lumbago, scapulohumeral periarthritis, cervico-omo-brachial syndrome, and tendinitis/tenosynovitis. uuid:a6be8f7b-ea18-497d-b55f-ca5b0efbba52 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32300 biolink:treats MONDO:0005148 PMID:41385096 "[{""id"":""uuid:bf18018d-7674-40d4-b140-5efabb638120"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5882a636-37aa-44db-b6ca-aa2727c4e02b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for prevention of type 2 diabetes mellitus in patients with impaired glucose tolerance (only for whom glycemic control is not sufficient by diet and/or exercise). uuid:b4e8d807-6bb6-4333-aec4-7c686f94da22 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32300 biolink:treats HP:0040270 PMID:41385096 "[{""id"":""uuid:af3656f1-e522-4bdf-b338-9546bce73cca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:313b00cd-ee5b-4af4-889a-b050bd833c24"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for prevention of type 2 diabetes mellitus in patients with impaired glucose tolerance (only for whom glycemic control is not sufficient by diet and/or exercise). uuid:2a83c1df-1f50-4f92-bd74-c6194234e55e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:175901 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:b78b467b-7d5d-480b-8db4-7abcaedbf23b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:eb9242fe-d661-43b5-871f-7f0687ab7208"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of inoperable or recurrent breast cancer. uuid:778ff094-03ce-4f99-8d99-bd3b9643d999 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31801 biolink:treats MONDO:0015597 PMID:41385096 "[{""id"":""uuid:05eb9898-c89b-41a8-bdc6-9b6febb5b32f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7f88ae45-46e6-4617-926a-db11b2480b8f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication for the treatment of palmoplantar pustulosis. uuid:e90a8676-1aa8-418b-a1df-f6a445bc91c9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:94385 biolink:treats MONDO:0000831 PMID:41385096 "[{""id"":""uuid:942d4376-f9c8-4504-90d0-16cda71a3358"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ea0db9dd-12ff-419d-ae04-28f6ef7235c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for prophylaxis of thrombosis in patients with heparin-induced thrombocytopenia (HIT) type II. [Orphan drug] uuid:e8bbc34e-2fe0-4e87-b20f-d3886781bf65 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3061 biolink:treats MONDO:1030009 PMID:41385096 "[{""id"":""uuid:aef39f9d-f854-4991-b91d-816dbfb7cfd6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:eb7cad9c-718a-4b9d-aec5-f52b0eb2949c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication for the treatment of persistent atrial fibrillation in patients in whom other antiarrhythmic drugs are contraindicated or who have not responded to other antiarrhythmic drugs. [Priority review] uuid:486d2ced-a747-43eb-98f0-31ca9a41bcbb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3732 biolink:treats UMLS:C0026919 PMID:41385096 "[{""id"":""uuid:042155d6-9ae2-4933-a845-a1eb78e6dbbf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8f9c9a70-895b-4357-a60f-85c5bea78267"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for non-tuberculous mycobacteriosis including mycobacterium avium complex (MAC) infections. uuid:847abf7e-4694-4ed5-9155-956641587cc8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8868 biolink:treats MONDO:0005382 PMID:41385096 "[{""id"":""uuid:ddad7a59-aa97-45ce-925c-65cfb95f1728"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b56b641f-845e-44f0-addb-232f685da275"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of Paget's disease of bone. [Orphan drug] uuid:e250b380-120e-4af5-95f7-c201a3df812e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:75984 biolink:treats MONDO:0005310 PMID:41385096 "[{""id"":""uuid:e36dd380-2793-41ab-8438-62d08a66d82b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:640c9b80-459a-4c76-8634-e088834e0079"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication for the treatment of tachyarrhythmia (paroxysmal atrial fibrillation and flutter). uuid:44fd50e2-b50b-4d6f-ad1e-bda1268509a0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:637364 biolink:treats MONDO:0003060 PMID:41385096 "[{""id"":""uuid:3360bb37-3338-47d1-a7a9-1f8c00aa146e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:10a47295-f863-41de-ae0f-269da13a9a51"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication for the treatment of biliary cancer in addition to gastric cancer, colorectal cancer, head and neck cancer, non- small cell lung cancer, inoperable or relapsed breast cancer, and pancreatic cancer. uuid:06f208b5-f87b-455e-9abb-35de9dc68cd1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:637364 biolink:treats MONDO:0001056 PMID:41385096 "[{""id"":""uuid:112014f1-4dc4-46ef-b038-fc230d944d94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cc591b15-942c-4e57-a106-84b016f70cf1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication for the treatment of biliary cancer in addition to gastric cancer, colorectal cancer, head and neck cancer, non- small cell lung cancer, inoperable or relapsed breast cancer, and pancreatic cancer. uuid:222fbd6b-2675-4511-8343-c20265033caa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:637364 biolink:treats MONDO:0005575 PMID:41385096 "[{""id"":""uuid:9ad6c16d-04ad-46b5-bcb8-68e5dd5a4972"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ac05becf-93b0-47f8-8deb-67426efed01d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication for the treatment of biliary cancer in addition to gastric cancer, colorectal cancer, head and neck cancer, non- small cell lung cancer, inoperable or relapsed breast cancer, and pancreatic cancer. uuid:d28ef929-bc8b-4cc9-8f65-fae10ad9a97e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:637364 biolink:treats MONDO:0005627 PMID:41385096 "[{""id"":""uuid:001a9022-9cd0-4a76-a77a-8e046ee05e4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:44a363ef-062d-44c5-8c5d-7ce03dc40b03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication for the treatment of biliary cancer in addition to gastric cancer, colorectal cancer, head and neck cancer, non- small cell lung cancer, inoperable or relapsed breast cancer, and pancreatic cancer. uuid:959a805a-edc4-4ff4-8dde-fd502a744015 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:637364 biolink:treats MONDO:0005233 PMID:41385096 "[{""id"":""uuid:14c1c8a9-61ae-48f3-8b82-a5d1bbbc2de4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:816a44be-6a56-4feb-84f0-837fd0bcff2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication for the treatment of biliary cancer in addition to gastric cancer, colorectal cancer, head and neck cancer, non- small cell lung cancer, inoperable or relapsed breast cancer, and pancreatic cancer. uuid:67abc1fe-8127-4595-8c5a-f26288a73127 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:637364 biolink:treats UMLS:C0278493 PMID:41385096 "[{""id"":""uuid:c38662a1-3be4-49e1-97a1-bf49999a6138"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:315f6857-06a3-41a8-8db6-4ee5cddb2e50"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication for the treatment of biliary cancer in addition to gastric cancer, colorectal cancer, head and neck cancer, non- small cell lung cancer, inoperable or relapsed breast cancer, and pancreatic cancer. uuid:b55a89e1-2f03-4e71-afc8-5afa653d2752 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:637364 biolink:treats MONDO:0009831 PMID:41385096 "[{""id"":""uuid:121bb49c-3a98-4475-ab2d-1182284eb370"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7de7b94d-5cd3-4666-a604-d01aeaac32ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication for the treatment of biliary cancer in addition to gastric cancer, colorectal cancer, head and neck cancer, non- small cell lung cancer, inoperable or relapsed breast cancer, and pancreatic cancer. uuid:7fea882a-f209-4256-9ec7-11f2aa7b0b90 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:8FOJ430U94 biolink:treats MONDO:0000050 PMID:41385096 "[{""id"":""uuid:ae88c809-6a3a-453f-80e7-9f3e35f5207f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5bbf4537-b74f-4c53-bba1-dffe7abcfbe9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] (1) Drugs with a new indication, a new dosage, and other characteristics for the treatment of short stature due to growth hormone deficiency prior to epiphyseal closure. (2) A drug with a new indication and a new dosage in an additional dosage form for the treatment of short stature due to growth hormone deficiency prior to epiphyseal closure. uuid:507be086-03fb-477e-9814-adcc77bd1889 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85973 biolink:treats HP:0034192 PMID:41385096 "[{""id"":""uuid:75e8b6c6-ae9e-4a22-a33e-7c25edd701f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a0821c65-27fc-416b-8362-2ee1e337c867"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and new dosages, and a drug with a newly-added dosage form indicated for prevention of ischemic stroke and systemic embolism in patients with non- valvular atrial fibrillation, or for the treatment and prevention of the recurrence of venous thromboembolism (deep vein thrombosis and pulmonary thromboembolism). uuid:45dc8357-4652-4a11-93ef-930407e18fe8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31397 biolink:treats MONDO:0100470 PMID:41385096 "[{""id"":""uuid:ce798cae-d6f5-40ec-b36d-294d82be1134"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e0619cc8-8d10-4f68-aaf8-abdf4bcd3c4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional pediatric dosage indicated for the treatment of bronchial asthma. uuid:32c6eb7b-070c-4467-ac18-f2c8713ca8ed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:C3VX249T6L biolink:treats MONDO:0019100 PMID:41385096 "[{""id"":""uuid:80c189e6-8419-424a-8387-6eb367f358d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e0cf3295-dbf0-4178-9464-583ff0512b84"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication for the prevention of relapse of neuromyelitis optica spectrum disorder (including neuromyelitis optica). uuid:900c866c-3be5-41f6-b838-17c0eb36cda8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:90ZX3Q3FR7 biolink:treats MONDO:0015597 PMID:41385096 "[{""id"":""uuid:1d5180e1-4a7c-4b0a-8fe6-f497193409b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e924f0b4-7948-49ef-a529-e24db0ede057"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of palmoplantar pustulosis in patients who have not responded sufficiently to conventional therapies. uuid:a0612c22-a953-4800-9cb6-3965a455fef6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31355 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:da61c4bd-7461-45e2-9978-003cd4301272"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d59c55b2-5a13-4015-9633-f3edcc3f8bf2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of breast cancer. uuid:9546c16b-527d-49d1-b7d7-c77131ea441d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4027 biolink:treats MONDO:0017816 PMID:41385096 "[{""id"":""uuid:f572e15f-0c1b-4fc7-bc41-6c071f1c853b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:aefd29d2-db10-46bf-9501-8031e6f6dc82"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of systemic AL amyloidosis. [Expedited review] uuid:2ca7f650-689e-435d-9be5-5591ea17924e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:16684 biolink:treats HP:0002061 PMID:41385096 "[{""id"":""uuid:e6f17364-dbb7-42fc-ba8d-71b4725149a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f175fa73-16d2-4677-b96c-98041ad5d7d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of lower limb spasticity. uuid:47975aa9-4cdc-408d-a421-992f28d5f44e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135901 biolink:treats MONDO:0003837 PMID:41385096 "[{""id"":""uuid:cc421e58-f487-4a4d-9476-db1eaa084409"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b7e6b6e6-b9c5-4d61-8b16-e6cd97f35c7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication for the treatment of thyroid- stimulating hormone secreting pituitary tumour. [Orphan drug] uuid:e3131481-3cda-4f8c-a51a-74678d6a44c1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:I031V2H011 biolink:treats MONDO:0019355 PMID:41385096 "[{""id"":""uuid:9a0a9859-56b5-4ef8-b580-8027adcba24b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7f52654f-ad39-4f87-a927-5c7a6381ea02"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of adult Still's disease in patients who have not responded sufficiently to conventional treatments. uuid:33cfa3f8-c2ff-42e8-a21f-1d2c24866b08 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:78540 biolink:treats HP:0000155 PMID:41385096 "[{""id"":""uuid:2aea7123-e4d8-4aa0-9cd7-958bd798a649"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b3919ee8-c1a8-4994-8464-f3d9f370a8e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication for the treatment of oral ulcer associated with Behcet’s disease in patients who have not responded sufficiently to local treatment. uuid:c2e53831-6efe-41e1-82b7-fc8050a2b470 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68478 biolink:treats UMLS:C0400968 PMID:41385096 "[{""id"":""uuid:98554860-456a-48e1-8753-d0ce41166240"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:417be89f-5afb-4e1f-87d6-8852edd3174a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the inhibition of rejection in liver transplantation. uuid:1117eddb-159e-4228-8f49-eb3a1ced9fc2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:74170 biolink:treats MONDO:0005113 PMID:41385096 "[{""id"":""uuid:efd18ada-cced-460f-bae1-76b50121c1d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c0a14f99-6e54-4a49-af9a-167160dd5eab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[PMDA] Drugs with additional indications and new dosages for the treatment of ""bacterial skin infections mainly involving the dermis and/or subcutaneous tissues"" and ""secondary bacterial infections of pre-existing skin ulcers and/or erosion""." uuid:7bc40281-29eb-4a16-8eb8-8c2e8e5099a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:LR3UXN0193 biolink:treats MONDO:0016218 PMID:41385096 "[{""id"":""uuid:5f179b7e-8ad8-47e4-a938-c05ebae1a87f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1fc14e75-e07e-4e36-b8c1-dbaf8ca1b354"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication for the treatment of Guillain-Barré syndrome (severe cases in an acute exacerbation phase with difficulty in walking). uuid:20519018-a8f1-4a59-8390-542187badd76 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:LR3UXN0193 biolink:treats MONDO:0019082 PMID:41385096 "[{""id"":""uuid:e9a8992f-b883-4204-b855-072983a37089"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c0379c22-3bd8-4605-a15a-7a61466843fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication for the treatment of bullous pemphigoid (for use when steroid drugs are not sufficiently effective). uuid:24ab3703-c4e7-4961-9175-e57ffc48c414 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3441 biolink:treats MONDO:0004981 PMID:41385096 "[{""id"":""uuid:b94f3986-cc41-4164-82fc-0703de0160db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:666d28d2-ca1c-4b43-82fe-72d1ddf8835e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of tachycardiac atrial fibrillation. uuid:6503f2d6-ec6a-444b-8f8d-e9b84e8cb2d2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17650 biolink:treats MONDO:0100470 PMID:41385096 "[{""id"":""uuid:de78f7b0-8e14-4a14-a277-470f9946867a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3be82327-1147-4187-88b8-a25704bc9376"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of bronchial asthma. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:0582991e-62b2-41db-aedc-57a73ac50846 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:G8RGG88B68 biolink:treats MONDO:0005105 PMID:41385096 "[{""id"":""uuid:9d06e66a-7940-4705-bf3d-c0f315ca367c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a7f6029b-deba-4efa-81bd-05d9d108c2f5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the adjuvant treatment of melanoma. [Orphan drug] uuid:697d9270-5fa9-4996-a6b4-cc6646e92506 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0005062 PMID:41385096 "[{""id"":""uuid:7124c11f-66e8-4eef-a764-6c748fff4262"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:271e431f-c95c-43a7-9dba-0d4cc40c4492"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with revised indications and a new dosage for the treatment of malignant lymphoma and similar diseases (closely-related diseases). [Expedited review] uuid:81809585-a519-4298-b1fd-fed3f557108b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31941 biolink:treats MONDO:0001056 PMID:41385096 "[{""id"":""uuid:1cd4482b-c007-4a17-a819-e6cfe3d317bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7b384ef0-0efb-43a4-8827-98af24c4774b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of unresectable advanced or recurrent gastric cancer. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:2ba978be-75a5-4b60-afa9-6a890f0f9ab2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats HP:0100806 PMID:41385096 "[{""id"":""uuid:4d16d787-ceb7-43bb-b4db-e71c65f34af3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:deee200a-cf6e-4459-8c4f-15bc0fc6ce03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of sepsis, secondary infection of trauma, burn, and surgical wound, pneumonia, cystitis, pyelonephritis, peritonitis, otitis media caused by following applicable microorganisms: Gentamicin-sensitive Staphylococcus, Escherichia coli, Klebsiella, Enterobacter, Serratia, Proteus, Morganella morganii, Providencia, Pseudomonas aeruginosa uuid:b298944e-fece-4d9d-af21-775306ec5175 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats UMLS:C0332803 PMID:41385096 "[{""id"":""uuid:0973ad40-3d56-4e24-b6df-0c35f28b0554"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d28aced3-4d89-42f4-a237-8198fd92c18b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of sepsis, secondary infection of trauma, burn, and surgical wound, pneumonia, cystitis, pyelonephritis, peritonitis, otitis media caused by following applicable microorganisms: Gentamicin-sensitive Staphylococcus, Escherichia coli, Klebsiella, Enterobacter, Serratia, Proteus, Morganella morganii, Providencia, Pseudomonas aeruginosa uuid:b8e7624c-0615-4edb-a23a-f7c8d20a7802 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:580e4ef1-e613-451a-a5b7-33d80e679a53"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5dfc4bfe-b3d3-4f9c-9dc7-995d023e4872"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of sepsis, secondary infection of trauma, burn, and surgical wound, pneumonia, cystitis, pyelonephritis, peritonitis, otitis media caused by following applicable microorganisms: Gentamicin-sensitive Staphylococcus, Escherichia coli, Klebsiella, Enterobacter, Serratia, Proteus, Morganella morganii, Providencia, Pseudomonas aeruginosa uuid:0c71fe40-77da-458a-b834-03750397b181 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0006032 PMID:41385096 "[{""id"":""uuid:bfbd1cd7-8de8-4ca8-83da-0c42aeabc321"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:89d2f4bf-4f37-4753-a232-d59c25b78886"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of sepsis, secondary infection of trauma, burn, and surgical wound, pneumonia, cystitis, pyelonephritis, peritonitis, otitis media caused by following applicable microorganisms: Gentamicin-sensitive Staphylococcus, Escherichia coli, Klebsiella, Enterobacter, Serratia, Proteus, Morganella morganii, Providencia, Pseudomonas aeruginosa uuid:0530ed9b-3932-4b48-9fcf-795601270e90 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0006939 PMID:41385096 "[{""id"":""uuid:02072c70-8b39-49ed-895d-1cdf0225715d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5289634a-3d50-4a8f-b470-2a7b83c8057a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of sepsis, secondary infection of trauma, burn, and surgical wound, pneumonia, cystitis, pyelonephritis, peritonitis, otitis media caused by following applicable microorganisms: Gentamicin-sensitive Staphylococcus, Escherichia coli, Klebsiella, Enterobacter, Serratia, Proteus, Morganella morganii, Providencia, Pseudomonas aeruginosa uuid:4db27414-805e-4219-8550-834d61aae5b1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:17833 biolink:treats MONDO:0005441 PMID:41385096 "[{""id"":""uuid:c5e875eb-b104-4f88-834c-b08b56f25ee3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e2cbec73-83c7-4bc5-8cb4-33cb5cb6e41f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of sepsis, secondary infection of trauma, burn, and surgical wound, pneumonia, cystitis, pyelonephritis, peritonitis, otitis media caused by following applicable microorganisms: Gentamicin-sensitive Staphylococcus, Escherichia coli, Klebsiella, Enterobacter, Serratia, Proteus, Morganella morganii, Providencia, Pseudomonas aeruginosa uuid:385599bd-ae33-4c8d-8199-47c4b981116a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:43968 biolink:treats UMLS:C0865440 PMID:41385096 "[{""id"":""uuid:5608e6fd-9ec7-423f-a76e-8a4b55ccdc39"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:47439704-d56c-4355-a005-9a233b29ab3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage (the daily dose has been changed) in patients with purulent meningitis. uuid:f43d7582-7983-4436-9b7a-1b502b3f6c43 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:114785 biolink:treats UMLS:C3266992 PMID:41385096 "[{""id"":""uuid:30c444eb-0657-4eb5-b759-1dbb6e56650c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:08867718-d7bf-4c55-b5e1-dc303fbe1829"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of unresectable advanced or recurrent non-small cell lung cancer with EGFR gene mutation in patients who have not been treated with chemotherapy. uuid:f0918591-c597-4391-8023-47bf63631081 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31941 biolink:treats UMLS:C0854776 PMID:41385096 "[{""id"":""uuid:711f3950-ce48-4c5f-b2c4-cc064ae9ffaf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f821177b-3f5f-4290-abe7-a654d07941d6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of unresectable pancreatic cancer. [Priority review], [Expedited review] uuid:66ac2775-e50f-4a7b-a32a-ec95bcfc53ce biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEMBL.COMPOUND:CHEMBL2108334 biolink:treats NCIT:C26791 PMID:41385096 "[{""id"":""uuid:222227ce-a013-49a6-8a77-c33a80b0a8e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e9d09fab-6b26-409d-925c-b69a56293f42"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage to add single-dose administration for the prevention of bleeding in patients with congenital hemophilia who have inhibitors against blood coagulation factor VIII or IX. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:d9f67c86-b6f1-4489-88b7-424723cdd20e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64356 biolink:treats HP:6000040 PMID:41385096 "[{""id"":""uuid:0eeee9e1-3a87-42ff-ad06-d5474d0e74e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e0e3b997-bf2a-409e-9866-58fe50206396"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication for the treatment of neuropathic pain. uuid:a80f746e-7da4-4f6e-97ec-64f85ee0b10a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135928 biolink:treats UMLS:C0865440 PMID:41385096 "[{""id"":""uuid:beed5003-125a-4d91-ad97-ce391afc52af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c26764dd-ca50-4a31-9911-6ef65c429ec2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional pediatric dosage and with a new additional indication for the treatment of purulent meningitis. uuid:1a0c167f-3e65-4d33-a6f4-5d2c76e87e3c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:NQX9KB6PCL biolink:treats MONDO:0005030 PMID:41385096 "[{""id"":""uuid:f2f63361-a4fe-4ff8-8bc1-549c8ad03f97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ce98f30e-5fe5-4bae-954a-8c37016c2623"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of SGA (small-for- gestational age) dwarfism not associated with epiphyseal closure. uuid:61e859af-67ea-4eeb-a92e-528df6ca7c88 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:68478 biolink:treats UMLS:C0238217 PMID:41385096 "[{""id"":""uuid:4ab147d5-72e3-406c-a174-eb0dc0d4b5bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:44e077f9-d295-4780-b227-5c7de247dd19"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the inhibition of rejection in renal transplantation. uuid:55219db7-8ba1-429b-a974-742495dc4697 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3127 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:f81f18f6-d820-4f0a-8f1b-bd27f7a25ec9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f835b2cb-be1f-430c-936f-b21cc4ca385e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and new dosages for the treatment of chronic heart failure secondary to ischemic heart disease or dilated cardiomyopathy in patients receiving basic treatment with angiotensin converting enzyme inhibitors or angiotensin II receptor antagonists, diuretics, digitalis preparations, etc. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:6f2548f9-2753-43f7-bfcf-dffb0f9dfdb0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3127 biolink:treats MONDO:0024644 PMID:41385096 "[{""id"":""uuid:4cb76439-9fc1-4a58-98e2-2f94da73416a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:37a3066c-c9cc-42ee-a1e6-36621d8cf198"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and new dosages for the treatment of chronic heart failure secondary to ischemic heart disease or dilated cardiomyopathy in patients receiving basic treatment with angiotensin converting enzyme inhibitors or angiotensin II receptor antagonists, diuretics, digitalis preparations, etc. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:f9d2dbc8-a308-43d7-8700-9d06f13ec8de biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3127 biolink:treats MONDO:0005021 PMID:41385096 "[{""id"":""uuid:5c0c2c6a-a701-4bc8-8ecf-f429dcc81564"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1e56fcb5-7447-4cc0-a25c-2b73a35ff0f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and new dosages for the treatment of chronic heart failure secondary to ischemic heart disease or dilated cardiomyopathy in patients receiving basic treatment with angiotensin converting enzyme inhibitors or angiotensin II receptor antagonists, diuretics, digitalis preparations, etc. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:97c89537-17ed-4145-86bc-d39b52258359 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:129818801 biolink:treats MONDO:0005277 PMID:41385096 "[{""id"":""uuid:2b358967-4c41-4498-b6cf-9e8891bcd07f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ef2aaadd-6f5e-4578-906b-f97857b2a8fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for prevention of migraine attack. uuid:e9b20733-547a-428b-ad26-f4bdff03af37 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:RWM8CCW8GP biolink:treats MONDO:0000386 PMID:41385096 "[{""id"":""uuid:2a2bb793-0d84-4bd1-b329-e24541df0c22"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:de3cee2a-bad4-4708-9e93-e4507563f9ef"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of gastrointestinal neuroendocrine tumor. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:93e71412-df24-44ab-bd76-f40e5263274d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10033 biolink:treats MONDO:0006809 PMID:41385096 "[{""id"":""uuid:71a5d065-219d-400e-9c7a-ce86c95ef062"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:467f91e3-faa6-463f-8f50-79c003f83205"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional pediatric dosages. These drugs are indicated for the treatment and prophylaxis of thromboembolism (e.g., phlebothrombosis, myocardial infarction, pulmonary embolism, brain embolism, slowly- progressive cerebral thrombosis). [Public knowledge-based application after PAFSC's preliminary assessment] uuid:8760d32d-df0f-4ed9-94f5-fd84ef267e59 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10033 biolink:treats MONDO:0002907 PMID:41385096 "[{""id"":""uuid:72ac5bd0-a786-45e0-b1d9-673e8108990c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3eeefe1a-a592-4b87-b0f4-6d10f2c89fa0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional pediatric dosages. These drugs are indicated for the treatment and prophylaxis of thromboembolism (e.g., phlebothrombosis, myocardial infarction, pulmonary embolism, brain embolism, slowly- progressive cerebral thrombosis). [Public knowledge-based application after PAFSC's preliminary assessment] uuid:5910251e-4410-403c-a230-32af008913c6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:64356 biolink:treats UMLS:C0458960 PMID:41385096 "[{""id"":""uuid:eefa1b7e-ffa5-478b-a058-9744caf1da93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c0633d2e-54d0-4cf1-9d4c-485682d27af7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication for the treatment of peripheral neuropathic pain. uuid:7636daa9-7909-4877-bd78-434742d96b0d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:43968 biolink:treats MONDO:0018542 PMID:41385096 "[{""id"":""uuid:f32ceb76-14af-4c37-85dc-2e9d1438cb3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2ce93019-9ba8-4670-83ae-cd81fe71310e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage (the maximum daily dose has been changed) in patients with general infections that are severe and refractory. uuid:e11d8ad4-b5f2-4707-a7a8-d6f5d1a79028 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4027 biolink:treats MONDO:0005554 PMID:41385096 "[{""id"":""uuid:81b0b42b-a469-4c49-829a-132a49196f07"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:17f44650-7db4-437c-abdf-9841e869c17a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and new dosages for treatment-resistant rheumatic disease in adults and children. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:20f10252-51c7-4432-861d-870960e67483 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:61049 biolink:treats MONDO:0005101 PMID:41385096 "[{""id"":""uuid:6c4f7c9b-10ad-4b35-95f4-91a58ea35838"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:36ed79a9-28c3-4157-9c6b-c86f9dedc930"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of refractory (steroid- resistant/steroid-dependent) active ulcerative colitis (limited to moderate-to-severe cases). uuid:5cea9bbe-ad58-411e-ba81-10f518ca9401 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:43968 biolink:treats UMLS:C0746883 PMID:41385096 "[{""id"":""uuid:310b9a7e-a15f-468b-9fc3-028d08002831"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:aeb66eda-4d5f-400b-90c3-7c3eead0ee93"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of febrile neutropenia. uuid:8c324720-f70e-4b98-9ce0-631eb92cd97b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8493 biolink:treats HP:0100515 PMID:41385096 "[{""id"":""uuid:db3cafc5-5879-48d6-9d88-29edd49e3a6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:53aba7eb-248d-4ce3-b522-4a994cd6a58d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication for the treatment of urgency of urination, pollakiuria, and urge urinary incontinence associated with overactive bladder. uuid:18e888ed-ba87-4ae1-844f-eb02a03fe05b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8493 biolink:treats EFO:0006865 PMID:41385096 "[{""id"":""uuid:68fa2924-c5a5-42ba-a35a-9a96eabdb2a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:51711f86-2a5b-4164-b2b4-09ba2ab3d215"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication for the treatment of urgency of urination, pollakiuria, and urge urinary incontinence associated with overactive bladder. uuid:cc81bf2e-6424-4195-9c98-6dd3fd18f550 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8493 biolink:treats MONDO:0006624 PMID:41385096 "[{""id"":""uuid:b646de29-8372-4abb-9267-c01edf2252e5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7605c74d-2871-4dd7-af2f-6755b76bde97"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication for the treatment of urgency of urination, pollakiuria, and urge urinary incontinence associated with overactive bladder. uuid:fd5cf721-b950-4c95-903d-bae0cbed35e9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:NQX9KB6PCL biolink:treats UMLS:C1720505 PMID:41385096 "[{""id"":""uuid:d7b6485e-5383-44f0-be1c-9bda0064deaa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2830c510-366b-438d-b0ac-8dddd9ec94f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of adult growth hormone deficiency (for use only in severe cases). uuid:c81aade4-8f17-49a4-93ee-c88d24592bd3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6935 biolink:treats MONDO:0005015 PMID:41385096 "[{""id"":""uuid:85cd9e7c-6916-4ab0-9fae-2abc64ed5764"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:47f6fa74-51e8-4a4d-8c99-2592e384a0fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication for improvement of postprandial hyperglycemia in patients with diabetes mellitus (for use only in patients who have not responded sufficiently to treatment with biguanides in conjunction with dietary and exercise regimens). uuid:55141eb6-5c50-4fa5-9289-cadc7b3bba38 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6935 biolink:treats MONDO:0005147 PMID:41385096 "[{""id"":""uuid:abd8a06d-0628-4a41-aafc-7f56101c8ce8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:079bd982-4d60-4ac0-8d9f-d7244e43fe37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication for the treatment of postprandial hyperglycemia in Type 2 diabetes mellitus (for use only in patients who have not benefitted sufficiently from taking insulin preparations in conjunction with dietary and exercise regimens) and the treatment of postprandial hyperglycemia in Type 1 diabetes mellitus (for use only in patients who have not benefited sufficiently from dietary and exercise regimens or from taking sulfonylurea or insulin preparations in conjunction with dietary and exercise regimens). uuid:7f20a6d7-e894-43f3-9a05-8558d6322720 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37922 biolink:treats MONDO:0700217 PMID:41385096 "[{""id"":""uuid:441a1aca-4ddc-4923-87eb-b423c56ea566"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3414cb3e-2b72-4e2c-8490-5924ea8447fb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage and in a new dosage form indicated for the treatment of septicemia and pneumonia caused by arbekacin-sensitive methicillin-resistant staphylococcus aureus (MRSA). uuid:6a5cffb7-32ea-42d0-a375-cdba0d17a92e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:37922 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:e84efba7-833a-4150-a189-117dd71167b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:985e821b-9dfa-4343-a3df-a09ccf0aced0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage and in a new dosage form indicated for the treatment of septicemia and pneumonia caused by arbekacin-sensitive methicillin-resistant staphylococcus aureus (MRSA). uuid:6b3c253c-4197-4e55-b739-66eed4be9be7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:4RA0KN46E0 biolink:treats UMLS:C0852922 PMID:41385096 "[{""id"":""uuid:c191b9fb-1f84-4856-b555-6ccf37d6de56"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f7ec1b92-d677-478d-9003-aaeb2eddcd21"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] (1) (2) (3) Drugs with a new indication and a new dosage for the remission induction therapy and the maintenance therapy of moderate to severe active Crohn’s disease (for use only in patients who have not sufficiently responded to conventional treatments). (4) A drug with a new indication and a new dosage for the remission induction therapy of moderate to severe active Crohn’s disease (for use only in patients who have not sufficiently responded to conventional treatments). uuid:634a3d6d-1938-4286-875b-182a461b8868 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:31YO63LBSN biolink:treats MONDO:0006292 PMID:41385096 "[{""id"":""uuid:e84bc8c9-df87-400f-b122-4f0b5c69e59a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:77e8682d-a1b6-420d-9602-9e7463ffdcdf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of malignant mesothelioma (excluding malignant pleural mesothelioma). [Orphan drug] uuid:cf7cd354-8562-448a-8f68-4268f990a3e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:31YO63LBSN biolink:treats MONDO:0002898 PMID:41385096 "[{""id"":""uuid:bb2e60cd-4176-4440-b993-370ddaa9202f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:31a56bed-a876-4f06-b419-2881c4bdf15c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of unresectable advanced or recurrent epithelial skin malignancies. [Orphan drug] uuid:607c39c3-0e31-4efb-96e4-1036233216a4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:S7LK2KDM5U biolink:treats HP:6000040 PMID:41385096 "[{""id"":""uuid:e6937dbb-e603-4439-8e74-b36028e635e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:08afc05d-59c7-4dd0-8f94-de3b455039b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication for the treatment of neuropathic pain. uuid:4916edbc-7fb7-4399-832a-0895638a8be5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:31YO63LBSN biolink:treats MONDO:0858997 PMID:41385096 "[{""id"":""uuid:f00d08ae-9966-4aaa-8efd-107c0675736c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cb1a275c-7f31-4718-a9ad-29a7615de7e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of carcinoma of unknown primary. [Orphan drug] uuid:e4d26890-cafc-403f-89f9-a9d6a2cb89d3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:RWM8CCW8GP biolink:treats MONDO:0004946 PMID:41385096 "[{""id"":""uuid:2a7d5941-7e8c-4559-8f35-dc2175d1136e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ca203cc7-79e6-4622-9a47-8e316234ac0e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of hypoglycemia associated with congenital hyperinsulinism (for use only in patients who have not sufficiently responded to other pharmaceutical therapies ). [Public knowledge-based application after preliminary assessment by the Pharmaceutical Affairs and Food Sanitation Council (PAFSC)] uuid:fc4d0f70-7cf7-4a50-948a-c19497bdf834 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:RWM8CCW8GP biolink:treats MONDO:0019010 PMID:41385096 "[{""id"":""uuid:177dac35-ebdd-46f5-8383-a17ef0642d1c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e1e3ec31-68a8-4cc2-b33b-265f7fa42594"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of hypoglycemia associated with congenital hyperinsulinism (for use only in patients who have not sufficiently responded to other pharmaceutical therapies ). [Public knowledge-based application after preliminary assessment by the Pharmaceutical Affairs and Food Sanitation Council (PAFSC)] uuid:4d706327-4888-4a30-ba9d-deae20fd4ab1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:FYS6T7F842 biolink:treats MONDO:0018824 PMID:41385096 "[{""id"":""uuid:8c32befd-1e73-48b7-8ca5-8a60173d46ab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:26700116-9a58-40aa-8487-e05aa6f77909"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of pyoderma gangrenosum. [Orphan drug] uuid:84d667d9-a907-443c-9aea-966dc4dc0b9a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:2P471X1Z11 biolink:treats MONDO:0005324 PMID:41385096 "[{""id"":""uuid:4d98d978-5c48-4e0e-81c7-294492cd2e5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3f82b095-f393-4b78-9125-8c882e3cd5e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of seasonal allergic rhinitis (for use only in severe or the most severe patients who have not responded sufficiently to conventional therapies). uuid:0ce7737e-8d8b-4c44-8cd2-92204d542527 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4031 biolink:treats MONDO:0015909 PMID:41385096 "[{""id"":""uuid:a7b65e87-6b7b-4a7f-ac9d-e64293da743f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b303d420-38be-4396-a4f3-4cd73b1016a6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a revised indication and a new dosage for the treatment of aplastic anemia which is not severe. [Expedited review] uuid:d8a26fb2-4ee0-4270-8959-6ab60bb6eec8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:62984 biolink:treats UMLS:C0854521 PMID:41385096 "[{""id"":""uuid:2111e03a-4ccf-477e-b367-8c4f1885f5b5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bdefa0fd-533a-4147-a679-22965fa77a76"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of hypozincemia. uuid:756c7ad4-96bd-477c-bdfe-da9e058a024e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71260 biolink:treats MONDO:0005439 PMID:41385096 "[{""id"":""uuid:42453c8c-3c5e-4258-b4d9-20e99f938b7e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:02bc3514-1625-4696-8c35-c298eb57c73e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional pediatric dosage indicated for the treatment of familial hypercholesterolemia. uuid:ef3e1ecd-290c-44ad-bec3-192f4237da02 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6367 biolink:treats HP:0011147 PMID:41385096 "[{""id"":""uuid:a7cdda40-6c6e-484d-9edb-fb4d944788e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7bf4ecfa-6f3b-4896-95dc-2e9cd963feb5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for use in the monotherapy for the treatment of typical absence seizures in patients with epilepsy. uuid:5a385dcb-6cc8-4a2e-95d0-7c15145a26d0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2666 biolink:treats UMLS:C0458960 PMID:41385096 "[{""id"":""uuid:39dbecd3-7d6e-4e01-a652-1cf8a893f03f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:63d36f61-8be0-44b3-b315-a8103f6f114d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of peripheral neuropathic pain. [Public knowledge-based application after preliminary assessment by the Pharmaceutical Affairs and Food Sanitation Council (PAFSC)] uuid:8fa21d45-cdde-4aab-b09c-3f5a152430ca biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:10023 biolink:treats UMLS:C0948382 PMID:41385096 "[{""id"":""uuid:748e40f0-3acb-472f-8f82-1f56e1e98c8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:545c7d15-d23d-4801-958d-b7eff05aa79b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and new dosages for the prophylaxis of deep mycosis in patients after hematopoietic stem cell transplantation. uuid:4717b42e-fce2-4783-8c91-d72931254a3d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats UMLS:C0264939 PMID:41385096 "[{""id"":""uuid:71bd8da2-187a-42b5-9721-e655f0783bc9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e8a62c52-2087-4b8f-9453-d600b8fb1d73"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of the following treatment- resistant rheumatic diseases: systemic vasculitis (including microscopic polyangiitis, Wegener's granulomatosis, polyarteritis nodosa, Churg- Strauss syndrome, aortitis syndrome), systemic lupus erythematosus, polymyositis, dermatomyositis, scleroderma, mixed connective tissue disease, and refractory rheumatic disease. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:87b8d792-4de5-4388-8205-6ad563c65c73 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0019124 PMID:41385096 "[{""id"":""uuid:4638e2b5-a0ce-45cc-b8e9-c4076cb5fb03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:896f7615-48ce-465c-b9fd-d4094e5555f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of the following treatment- resistant rheumatic diseases: systemic vasculitis (including microscopic polyangiitis, Wegener's granulomatosis, polyarteritis nodosa, Churg- Strauss syndrome, aortitis syndrome), systemic lupus erythematosus, polymyositis, dermatomyositis, scleroderma, mixed connective tissue disease, and refractory rheumatic disease. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:5a609cfd-91d2-4ceb-9f2c-45a60e0aea62 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0012105 PMID:41385096 "[{""id"":""uuid:19741bf5-470a-4f04-adfc-360f7833f7cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8773eebf-b9c0-4d78-9311-c45d4f09c2df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of the following treatment- resistant rheumatic diseases: systemic vasculitis (including microscopic polyangiitis, Wegener's granulomatosis, polyarteritis nodosa, Churg- Strauss syndrome, aortitis syndrome), systemic lupus erythematosus, polymyositis, dermatomyositis, scleroderma, mixed connective tissue disease, and refractory rheumatic disease. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:7351a9da-3962-4de9-9bc6-1efecac9a13d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0019170 PMID:41385096 "[{""id"":""uuid:a5014b9e-718c-4b50-ac89-36ad2698756a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cef3ae24-1a7a-4ca1-bf86-7d6440868581"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of the following treatment- resistant rheumatic diseases: systemic vasculitis (including microscopic polyangiitis, Wegener's granulomatosis, polyarteritis nodosa, Churg- Strauss syndrome, aortitis syndrome), systemic lupus erythematosus, polymyositis, dermatomyositis, scleroderma, mixed connective tissue disease, and refractory rheumatic disease. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:042accb4-d4ff-4911-affa-c886e294d3d0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0015943 PMID:41385096 "[{""id"":""uuid:f15434c4-2cdb-4d83-9cc5-30f011572b75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9635ebaa-77e8-4a05-8957-aa3fe2e1af03"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of the following treatment- resistant rheumatic diseases: systemic vasculitis (including microscopic polyangiitis, Wegener's granulomatosis, polyarteritis nodosa, Churg- Strauss syndrome, aortitis syndrome), systemic lupus erythematosus, polymyositis, dermatomyositis, scleroderma, mixed connective tissue disease, and refractory rheumatic disease. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:714a7b74-896e-42e4-bb7d-730ec800d563 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0017991 PMID:41385096 "[{""id"":""uuid:ee2ca196-ec59-4b23-bf9a-3701b4e44652"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d7efd960-bcc7-4485-9816-265b7c3a9824"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of the following treatment- resistant rheumatic diseases: systemic vasculitis (including microscopic polyangiitis, Wegener's granulomatosis, polyarteritis nodosa, Churg- Strauss syndrome, aortitis syndrome), systemic lupus erythematosus, polymyositis, dermatomyositis, scleroderma, mixed connective tissue disease, and refractory rheumatic disease. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:7630c35c-9969-4c7f-8b60-b3347c9647c3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0007915 PMID:41385096 "[{""id"":""uuid:30c9a101-1310-4bca-8efe-1b799e4ebbca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b3674588-07df-44ee-ba59-1a84e044cb6d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of the following treatment- resistant rheumatic diseases: systemic vasculitis (including microscopic polyangiitis, Wegener's granulomatosis, polyarteritis nodosa, Churg- Strauss syndrome, aortitis syndrome), systemic lupus erythematosus, polymyositis, dermatomyositis, scleroderma, mixed connective tissue disease, and refractory rheumatic disease. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:bee76fc9-d48d-49bb-8fa6-3e3ecbd26a1e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0019340 PMID:41385096 "[{""id"":""uuid:4fdf7e66-0251-4c9e-9e1b-74edcac01b65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:de5922b5-d04a-408a-ae60-2acee10d12e2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of the following treatment- resistant rheumatic diseases: systemic vasculitis (including microscopic polyangiitis, Wegener's granulomatosis, polyarteritis nodosa, Churg- Strauss syndrome, aortitis syndrome), systemic lupus erythematosus, polymyositis, dermatomyositis, scleroderma, mixed connective tissue disease, and refractory rheumatic disease. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:5a901a0a-0643-4974-8502-33fe92873724 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0005854 PMID:41385096 "[{""id"":""uuid:a0db3877-2222-42bb-ab5b-b4ebb357eb2b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cb129cf2-7f36-488e-88b4-a8fb35143fda"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of the following treatment- resistant rheumatic diseases: systemic vasculitis (including microscopic polyangiitis, Wegener's granulomatosis, polyarteritis nodosa, Churg- Strauss syndrome, aortitis syndrome), systemic lupus erythematosus, polymyositis, dermatomyositis, scleroderma, mixed connective tissue disease, and refractory rheumatic disease. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:d93f21d3-1ce0-4abb-8233-50314aaeac50 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0005554 PMID:41385096 "[{""id"":""uuid:db52fb9a-23f6-435e-87ea-a5e3787cef58"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c602ecd2-1182-4fa4-ac50-ca4a552a1bab"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of the following treatment- resistant rheumatic diseases: systemic vasculitis (including microscopic polyangiitis, Wegener's granulomatosis, polyarteritis nodosa, Churg- Strauss syndrome, aortitis syndrome), systemic lupus erythematosus, polymyositis, dermatomyositis, scleroderma, mixed connective tissue disease, and refractory rheumatic disease. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:f7814d95-e0b5-49ff-af0f-81968eb8b14e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:176168 biolink:treats MONDO:0005300 PMID:41385096 "[{""id"":""uuid:fbd28acf-46ca-4ec3-8eba-5cadc94efd63"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:09adf5f6-42f8-4ef3-aa26-232c5ea3589d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication to extend the indication for the improvement of hyperphosphatemia in patients with chronic kidney disease. uuid:38292fca-99d3-4e62-a49a-57dc21cd5c58 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:DQ448MW7KS biolink:treats MONDO:0021094 PMID:41385096 "[{""id"":""uuid:f3131f88-527e-4c60-acde-befbefa3307e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:398093ee-f36e-41b9-b032-0d5ab69d79b8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new indications for the suppression of development of serious lower respiratory tract disease caused by RS viral infection in newborns, infants, and children aged 24 months or less with immunodeficiency and Down syndrome. [Priority review] uuid:911dcf1f-0c52-4329-b94e-b90c1ac80af9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28971 biolink:treats MONDO:0005828 PMID:41385096 "[{""id"":""uuid:e019f4fc-249f-4594-a763-fcc166191959"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9304cf84-0933-4fd9-887e-6a83dc1914a4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication for Listeria monocytogenes as an applicable microorganism and with new additional pediatric and neonate dosages. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:71be15b2-e238-4182-84da-9c8f9b38184d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28741 biolink:treats MONDO:0005114 PMID:41385096 "[{""id"":""uuid:031bd34a-ca27-411c-89c9-bf9f373bf3f2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a64c0d11-479e-41a3-84f4-33701a4e08e6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications for Streptococcus Pneumoniae and Moraxella catarrhalis as applicable microorganisms. A new dosage has been added to enable high-dosage use for severe infections. uuid:3a45c818-ad8a-40d7-9907-0f319d066892 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28741 biolink:treats MONDO:0006878 PMID:41385096 "[{""id"":""uuid:12bf8125-8323-4278-8ffd-1a456e882ece"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:09f59350-4214-4620-b294-5fefd16f1c74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications for Streptococcus Pneumoniae and Moraxella catarrhalis as applicable microorganisms. A new dosage has been added to enable high-dosage use for severe infections. uuid:fce01c53-6715-4e11-a297-087f50d23f71 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4031 biolink:treats MONDO:0020283 PMID:41385096 "[{""id"":""uuid:23c0f042-47a6-49b7-aee9-760e579227f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:38814d10-6442-4f79-a6e0-d0404923c599"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of non-Behcet's, non-infectious uveitis (active non-infectious uveitis in the intermediate or posterior area in patients who have not responded sufficiently to conventional treatments and may involve deterioration of visual acuity). [Public knowledge-based application after PAFSC's preliminary assessment] uuid:395ce305-7c41-499d-b63f-dc85d3559b33 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4877 biolink:treats UMLS:C0026919 PMID:41385096 "[{""id"":""uuid:805f9ef0-6ed4-46cf-8fec-dd81d529cdc9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:853cb044-26cb-421a-87bc-debc13779494"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of nontuberculous mycobacteriosis including Mycobacterium avium complex (MAC) infection. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:6fbfc8f5-4fc2-4ed8-9428-faa7541c10eb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4877 biolink:treats MONDO:0005866 PMID:41385096 "[{""id"":""uuid:664d5c8d-3783-41c5-a322-36472a3b7230"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:777aa70d-aa6b-47d8-98d7-59368071cd40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of nontuberculous mycobacteriosis including Mycobacterium avium complex (MAC) infection. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:6ae1138d-fdc7-416a-90f8-85e99450671c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:204928 biolink:treats UMLS:C0865440 PMID:41385096 "[{""id"":""uuid:64d0b539-f6fe-42f4-9b87-4558927e703a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:121c157f-9ce4-40da-9692-764274077575"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage for the treatment of pediatric purulent meningitis. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:c44a9c04-a7a8-41d8-9094-d62cdc6194dd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4911 biolink:treats MONDO:0008170 PMID:41385096 "[{""id"":""uuid:1410298e-24ad-46a9-96e1-310bf043c990"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ca2a1bd2-44d1-45e3-b1ae-df7fa2432f48"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of ovarian cancer which has progressed after cancer chemotherapy. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:bb6e9a72-b448-4984-af7f-fa4ac9c77047 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:61049 biolink:treats MONDO:0009688 PMID:41385096 "[{""id"":""uuid:a47d437c-b5a1-4372-a79c-a6527132d4ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:bc1dff1d-3156-4c45-bb95-405983c773dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a revised indication for the treatment of myasthenia gravis (limitation of patients to be treated was abolished.) [Orphan drug] uuid:8e54001e-6c77-4f52-a712-799ead7420a9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:43K1W2T1M6 biolink:treats HP:0020071 PMID:41385096 "[{""id"":""uuid:4bb36f83-37c6-4595-bbc5-4e5153ea5bf8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0c5d033d-fa55-4132-91b3-a533d3e64463"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of viremia in patients with compensated cirrhosis type C (excluding patients with high blood levels of serogroup 1 HCV-RNA). uuid:8a855c2b-c6bf-4a0a-8029-75efdd806c09 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:43K1W2T1M6 biolink:treats MONDO:0005448 PMID:41385096 "[{""id"":""uuid:c2b2ac08-f7a5-405e-9f8e-98a9944b39b9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:83ed2a6b-9299-4b9a-81db-c45a72cbb89a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of viremia in patients with compensated cirrhosis type C (excluding patients with high blood levels of serogroup 1 HCV-RNA). uuid:d6cb158d-7798-41ab-8557-f67fe1e07092 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4031 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:ddd07ef3-6cb5-46ec-a21e-9bcb1ce93683"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ca65a450-bfc7-4f58-a496-6108b098bfe6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of atopic dermatitis (in patients in whom conventional therapies are not sufficiently effective). uuid:0b940ff7-9ed6-40b8-94bf-fb72bc40e6fb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UniProtKB:P01233 biolink:treats MONDO:0005047 PMID:41385096 "[{""id"":""uuid:ce7b65b9-fac8-4e7f-9011-7d155ff3b84b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:eedf421e-811b-48fa-97ed-b2e04d1f86b1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] (1) (2) (3) (4) Drugs with a new route of administration indicated for the induction of final follicular maturation and luteinization as part of assisted reproductive technology as well as induction of ovulation and luteinization in general infertility treatment (fertility treatment for in vivo fertilization). [Public knowledge-based application after PAFSC's preliminary assessment] (5) A drug with a new indication and a new dosage for the induction of final follicular maturation and luteinization as part of assisted reproductive technology as well as induction of ovulation and luteinization in general infertility treatment (fertility treatment for in vivo fertilization). [Public knowledge-based application after PAFSC's preliminary assessment] MESH:D018997 uuid:ac25ff58-64b7-413f-beb6-a7bdca6d5803 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UniProtKB:P01233 biolink:treats MONDO:0002775 PMID:41385096 "[{""id"":""uuid:88fa9115-2ef0-4abf-800f-5f5d4e0af2e8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:41e5296c-6117-4ea8-916c-ffc7d9a31247"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] (1) (2) (3) (4) Drugs with a new route of administration indicated for the induction of final follicular maturation and luteinization as part of assisted reproductive technology as well as induction of ovulation and luteinization in general infertility treatment (fertility treatment for in vivo fertilization). [Public knowledge-based application after PAFSC's preliminary assessment] (5) A drug with a new indication and a new dosage for the induction of final follicular maturation and luteinization as part of assisted reproductive technology as well as induction of ovulation and luteinization in general infertility treatment (fertility treatment for in vivo fertilization). [Public knowledge-based application after PAFSC's preliminary assessment] MESH:D018997 uuid:5388f21a-0db3-460c-8121-91022dc6dce8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:7NL2E3F6K3 biolink:treats MONDO:0035735 PMID:41385096 "[{""id"":""uuid:b6e40d83-de19-40e0-a37f-0b20d796c5f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ccb2e60e-a6d7-41ec-952e-d2b7d5fc2e64"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the control of bleeding tendency in patients with acquired hemophilia A. [Orphan drug] uuid:4d82cb5f-ab51-4b0d-877f-ba733837760f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:135939 biolink:treats HP:0002069 PMID:41385096 "[{""id"":""uuid:d9f7a86b-6d18-49cc-9341-a3a34a9bdf0d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:790c0a2d-6406-4934-bf4d-728edbbf4834"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] (1)-(3) Drugs with a new indication for use as an adjunctive therapy with other antiepileptic drugs to treat tonic-clonic seizure in patients with epilepsy who have not responded sufficiently to other antiepileptic drugs. (4), (5) Drugs with a new indication for use as an adjunctive therapy with other antiepileptic drugs to treat tonic-clonic seizure in patients with epilepsy who have not responded sufficiently to other antiepileptic drugs. It is used as an alternative therapy for lacosamide oral formulation in patients who are temporarily unable to be administered orally. uuid:62be5b3f-816b-4733-91dc-1f909acdc42d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28680 biolink:treats MONDO:0859598 PMID:41385096 "[{""id"":""uuid:51c7acdd-2776-4d83-9180-c21cbe18bb19"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:24a54e8a-5127-4b28-ac3e-402f85a6b20c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of acute leukemia (including erythroleukemia and blast crisis of chronic myeloid leukemia). [Public knowledge-based application] uuid:58dd92ea-cfda-4680-b51b-b3059441c776 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:A57KX1VL5P biolink:treats MONDO:0002242 PMID:41385096 "[{""id"":""uuid:e507925b-017d-423b-9046-02eb62c5fabf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:63ef794e-6a53-4d20-9277-8408af9cfa4f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the control of bleeding tendency in patients with blood coagulation factor IX deficiency. uuid:ad9cd181-3b88-4705-b082-4e77e2ab14a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:72564 biolink:treats MONDO:0012817 PMID:41385096 "[{""id"":""uuid:a4b6ea84-d126-4ccb-820c-2fdbbd5c4af2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:678b8927-2382-401d-91fe-f695fc3f29dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of relapsed or refractory Ewing's sarcoma. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:044053f0-dafd-4939-bfce-2aa6f5dce831 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28680 biolink:treats MONDO:0017858 PMID:41385096 "[{""id"":""uuid:52a81b72-e177-4e86-abb1-1b6f16f9574a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6a6097b0-5a6a-4a28-825e-50b59bd5da1a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new route of administration indicated for the treatment of acute leukemia (including acute erythroid leukemia and blast crisis of chronic myelogenous leukemia). [Expedited review] uuid:687d3935-2488-4738-bcda-5e43b40647ee biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46081 biolink:treats UMLS:C0948382 PMID:41385096 "[{""id"":""uuid:3b9954eb-fd60-42ff-bf6f-4c05e3e5e2c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:36ddea8a-ce4c-4e1e-ba9a-e1756d73b355"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional pediatric dosage and a new additional indication for the prevention of deep mycosis in patients with hematopoietic stem cell transplantation. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:5224a6aa-d9f9-4251-bdc4-47f7c9917a7a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:42f012f8-5f4e-40b1-a16e-bdfb46d4cd3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:03d0a340-1dc1-4a86-8a3a-8c791b29ae1b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication for the treatment of multiple myeloma. [Expedited review] uuid:7f52ffab-7b4d-4fe1-805b-be9e9d6d3a11 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:NQX9KB6PCL biolink:treats MONDO:0007037 PMID:41385096 "[{""id"":""uuid:c26a3684-4b89-4a41-827d-272623cbdb28"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8f035528-125f-4683-acec-3387cab9b5df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of dwarfism with no epiphyseal closure in patients born small for gestational age (SGA). uuid:d2fa57b1-23e4-4a72-a3ff-fc9c4ca4b126 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31236 biolink:treats MONDO:0004985 PMID:41385096 "[{""id"":""uuid:2d7e0b42-920c-4c67-a3fe-c1d901657cbd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1310e1f9-2e87-4ae8-b80b-89f2c3053317"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage in new dosage forms for the improvement of manic symptoms in patients with bipolar disorder. uuid:e545fa29-6375-4216-81f2-0db548cd8f3f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6801 biolink:treats MONDO:0008487 PMID:41385096 "[{""id"":""uuid:81863ebe-547f-4c70-8a4d-1da70d0220cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1a21f6e2-8fda-4f50-b483-64a348e3b4cd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new indications and a new dosage for the induction of ovulation in patients with polycystic ovarian syndrome and for controlled ovarian stimulation in assisted reproductive technology in patients with polycystic ovarian syndrome (only for the patients with any of obesity, impaired glucose tolerance or insulin resistance). [Public knowledge-based application after PAFSC's preliminary assessment] uuid:0528ff08-ce56-4322-ba55-61203e3d526f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:PVI5M0M1GW biolink:treats MONDO:0005072 PMID:41385096 "[{""id"":""uuid:737fb6ed-05c8-4af0-a95f-8bbbe4db56ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:303acf9b-19d1-497d-bc5f-90a04fdd2879"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the enhancement of an antitumor effect of dinutuximab for neuroblastoma. [Expedited review] uuid:8b21cc82-c532-49de-a376-687ca129c204 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0006052 PMID:41385096 "[{""id"":""uuid:633e67e6-aaa0-4de2-ab79-82f93a3632e4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d33e9a37-95d3-4cf7-83c8-65fe535f5125"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of pulmonary tuberculosis and other tuberculosis. uuid:b5c2c90e-f359-4e09-a938-1e563600dc11 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0018076 PMID:41385096 "[{""id"":""uuid:7376bf6c-2130-4855-bea9-dda07e3fbfb9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5481986b-1667-49f3-87c5-fd9cbc276b45"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of pulmonary tuberculosis and other tuberculosis. uuid:7a97c039-2eaa-451b-91a5-aa4dd2f24b71 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:1RXS4UE564 biolink:treats MONDO:0005299 PMID:41385096 "[{""id"":""uuid:fdaeea13-afc3-4e33-a9f0-2e05c992ee94"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:70a8a617-dabc-461b-978a-912ee5e45ce5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the improvement of functional impairment in association with acute phase of ischemic cerebrovascular disorder (within 4.5 hours after onset). [Public knowledge-based application after PAFSC's preliminary assessment] uuid:95c69ee3-0b1a-4dd8-9eb3-ebd8fe85bf47 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:231425 biolink:treats UMLS:C0856109 PMID:41385096 "[{""id"":""uuid:4cc6f78c-1fbb-4a13-b97a-db7025c7bdb7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:642782ee-53de-45f7-b0e7-59a8e4c6b5f7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the improvement of hyponatraemia in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH). [Orphan drug] uuid:02b0b23d-e906-4622-acf4-dde77a0d587e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45863 biolink:treats MONDO:0021348 PMID:41385096 "[{""id"":""uuid:e50953ee-6800-4267-a9d4-44050f73fb10"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6ae5fc06-fd24-49ce-9f25-00d6378774cf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of relapsed or refractory germ cell tumors (testicular tumors, ovarian tumors, extragonadal tumors). [Public knowledge-based application after PAFSC's preliminary assessment] uuid:2f5f640a-1f8f-4fe0-97cc-7e1bdbe2688e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45863 biolink:treats MONDO:0021068 PMID:41385096 "[{""id"":""uuid:c61fe562-3fb0-447d-a2e4-0d28bfb46bea"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e1802d1e-37b9-403b-bbc0-f2e83f39cd8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of relapsed or refractory germ cell tumors (testicular tumors, ovarian tumors, extragonadal tumors). [Public knowledge-based application after PAFSC's preliminary assessment] uuid:2e2a36d6-2d22-4a58-a1f6-3d037f89f2e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45863 biolink:treats MONDO:0018201 PMID:41385096 "[{""id"":""uuid:1d00ff66-5488-499f-85e7-4384293ca12f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9551954c-af23-4ed0-b4f8-90d909f052d9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and a new dosage for the treatment of relapsed or refractory germ cell tumors (testicular tumors, ovarian tumors, extragonadal tumors). [Public knowledge-based application after PAFSC's preliminary assessment] uuid:6e45287e-404f-4995-b643-a6a1764cc2c0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C586502 biolink:treats MONDO:0002032 PMID:41385096 "[{""id"":""uuid:900cc58e-4b4c-41eb-a759-0e5d624d8af9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5351db32-a1b0-402d-8433-6df6a227b498"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of gastric cancer, colon or rectal cancer, non-small cell lung cancer, pancreatic cancer, and biliary tract cancer. [Public knowledge-based application] uuid:7b36e35f-f82b-4621-bfcc-149e91e24784 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C586502 biolink:treats MONDO:0006519 PMID:41385096 "[{""id"":""uuid:4a7714d2-b1f5-4821-bb3c-9fe452da39f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b774113d-7e68-433e-88ab-03e7d55e72fd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of gastric cancer, colon or rectal cancer, non-small cell lung cancer, pancreatic cancer, and biliary tract cancer. [Public knowledge-based application] uuid:f09fe602-ce83-4d2c-a307-751fd24f2a96 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation MESH:C586502 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:81e1a2d9-a18d-45f9-af32-985e7363f2b3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:94e96e8f-11c3-46b6-8452-a1b3651910f1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the postoperative adjuvant treatment of hormone receptor(HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer with a high risk of recurrence. uuid:88ba6fe2-665e-4a65-8392-087c2451c9c9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31236 biolink:treats MONDO:0002050 PMID:41385096 "[{""id"":""uuid:ae09c2e3-957f-4ba8-ad4b-687817d3763e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7d73f134-61aa-4ec6-a607-8db12c894008"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of depression (for use only in patients who have an inadequate response to antidepressant therapy). uuid:f7493204-2801-426f-bc15-4cda34e2e480 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45863 biolink:treats MONDO:0005627 PMID:41385096 "[{""id"":""uuid:8d891315-4be2-41e6-947e-7655993cc731"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fbb3df24-9c7d-4648-893c-4c30ca44143c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and new dosages for the treatment of relapsed or metastatic head and neck cancer, relapsed or metastatic esophagus cancer, angiosarcoma, advanced or relapsed cervical cancer. A new dosage for once- weekly administration for ovarian cancer has also been added. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:3ed57a8e-7258-4bf2-8c6b-36fe7fbf9687 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45863 biolink:treats MONDO:0024883 PMID:41385096 "[{""id"":""uuid:80e632a0-3e12-4930-870e-954fd11c3de8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a49cf645-dea8-46ee-8bab-99083dd9b029"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and new dosages for the treatment of relapsed or metastatic head and neck cancer, relapsed or metastatic esophagus cancer, angiosarcoma, advanced or relapsed cervical cancer. A new dosage for once- weekly administration for ovarian cancer has also been added. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:405a64bc-c4c5-43a0-a1ba-762363b2cd94 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45863 biolink:treats MONDO:0016982 PMID:41385096 "[{""id"":""uuid:57eb85ff-19c2-40c1-bb3b-5107203ec6c2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8f9e49ab-ea93-4b95-a6a2-b987b91c48bf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications and new dosages for the treatment of relapsed or metastatic head and neck cancer, relapsed or metastatic esophagus cancer, angiosarcoma, advanced or relapsed cervical cancer. A new dosage for once- weekly administration for ovarian cancer has also been added. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:d60a7cab-bb9b-4857-aeda-78f815e93786 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:91809656 biolink:treats MONDO:0000956 PMID:41385096 "[{""id"":""uuid:5573b56f-0589-40fd-8892-312122fbe904"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5f391869-3795-4c82-8550-cd81d3e2d00c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of small intestine cancer. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:73f04cbd-26f3-457f-99ae-2eeed6d84a01 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:175901 biolink:treats MONDO:0000901 PMID:41385096 "[{""id"":""uuid:68fc2c3e-4453-4e85-a422-a7fbdb62abf3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b3170e24-9b05-4090-8192-a5b25b7628d4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of relapsed or refractory malignant lymphoma. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:98cbed94-58d7-4262-b021-ea0216c2893e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:23581792 biolink:treats MONDO:0006517 PMID:41385096 "[{""id"":""uuid:fe949a83-4793-408c-97cd-d3666f37fc3f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:739f2bc7-3ce3-4ed8-9fba-da6b825e16e1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of pediatric malignant solid tumor. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:a6df01d4-a529-42f6-8ce7-412721285492 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:145499 biolink:treats MONDO:0007488 PMID:41385096 "[{""id"":""uuid:f501f18a-f694-4834-9b70-288a1d1f7e00"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:417ad136-e0c1-46eb-9456-cf5aeb84b678"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for inhibiting progress of dementia symptoms in patients with dementia with Lewy bodies. uuid:96cc8829-3519-47f7-8afc-3f049f0eafa4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24847953 biolink:treats MONDO:0004966 PMID:41385096 "[{""id"":""uuid:40ac43ce-8d8a-453f-9010-0fc99bf0a20e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ba3f51bd-c0bd-4095-a5a9-583f289d84ac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication for the treatment of gastritis induced by Helicbacter pylori infection. uuid:29cacbb5-9be9-467a-945d-d45482b8fa7d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24847953 biolink:treats MONDO:0006781 PMID:41385096 "[{""id"":""uuid:ed36dfcb-aefa-479f-b392-18d8df18e7b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:92bf2dd7-a775-45f2-b076-22f03a39b64b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication for the treatment of gastritis induced by Helicbacter pylori infection. uuid:ba29d79c-9bd1-4f70-8b83-ad0422dbbf97 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:46195 biolink:treats MONDO:0005178 PMID:41385096 "[{""id"":""uuid:3a490de2-97fe-45db-9ee2-6f2797d95fba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:79a35b91-b6c2-4f52-a645-4eeeee528baa"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication for the treatment of osteoarthritis and with an expanded dosage of acetaminophen. uuid:a0d87fb9-b763-4ab4-874e-140e48473d3b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27899 biolink:treats MONDO:0003060 PMID:41385096 "[{""id"":""uuid:998f9d90-9f2e-44f2-b9bc-2770935dbb74"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:0a92dc0f-6614-4a4c-a9c4-4cd84a7bcf6b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of biliary tract cancer. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:48b6f69b-b7f8-4760-84df-0026a83978b5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2676 biolink:treats MONDO:0006226 PMID:41385096 "[{""id"":""uuid:bca11230-a56f-4207-8520-943e796e3010"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3cf5a359-5115-412d-9576-1d75660034db"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication for helicobacter pylori (H. pylori) eradication therapy for gastric MALT lymphoma, for the stomach after endoscopic treatment of early gastric cancer, and for idiopathic thrombocytopenic purpura, in H. pylori infection. uuid:4f6f2252-4cb9-456e-8e1f-ecc430ae9a9e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2676 biolink:treats MONDO:0019098 PMID:41385096 "[{""id"":""uuid:2c4d287e-e14b-4097-9d80-b10000ba8ada"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a68b1d3c-4db6-4710-a028-a05b4eab6dcd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication for helicobacter pylori (H. pylori) eradication therapy for gastric MALT lymphoma, for the stomach after endoscopic treatment of early gastric cancer, and for idiopathic thrombocytopenic purpura, in H. pylori infection. uuid:e9cb4853-8e6f-4861-ad01-69099c26bdb0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:74170 biolink:treats UMLS:C0746883 PMID:41385096 "[{""id"":""uuid:6e699f7a-7a23-4fef-80e6-2776a6998f27"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e121d630-660e-4012-9b5d-f0ba9a509b3b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of febrile neutropenia. uuid:e3e0cfea-913c-4dd6-9113-3f088eadda05 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB00028 biolink:treats MONDO:0018229 PMID:41385096 "[{""id"":""uuid:c953fe65-11a7-4784-945a-a9ec799e06ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:631d84c5-5627-4655-b176-7eddafd5bf3c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications for the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis (for use when steroid drugs are not sufficiently effective). [Orphan drug] uuid:de1477f9-6c17-4296-b9c9-e4143eee913d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation DRUGBANK:DB00028 biolink:treats MONDO:0019810 PMID:41385096 "[{""id"":""uuid:82688d33-19d4-453f-87c2-e486af160b0f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8fd8bc59-f35b-4ebc-853b-c77b41faf93e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications for the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis (for use when steroid drugs are not sufficiently effective). [Orphan drug] uuid:585a92aa-fc6b-4b03-a282-e29907138849 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71260 biolink:treats HP:0003124 PMID:41385096 "[{""id"":""uuid:3e876433-b72b-4518-bbcc-75ce79988c13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:72e94713-27fe-4ecc-b90c-1fe4e48b1eb1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of hypercholesterolemia and familial hypercholesterolemia. uuid:23b705eb-2ca7-4ce5-94f3-0332194b8174 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31941 biolink:treats MONDO:0000956 PMID:41385096 "[{""id"":""uuid:d7c73a40-3bb0-4bbb-834f-78c93bdbfde7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:06f15912-841b-45e4-8623-55e5e099b4b7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of small intestine cancer. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:96eeca08-0215-47a8-a710-e168fc21f055 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71204 biolink:treats MONDO:0011786 PMID:41385096 "[{""id"":""uuid:3ec33646-3f3a-4dfb-ae57-51135382e42a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:628cd253-86c2-4a70-a2df-8ff68f53bb8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional pediatric dosage indicated for the treatment of allergic rhinitis, urticaria, and itching associated with skin diseases (eczema/dermatitis, cutaneous pruritus). uuid:feb4860a-121d-4d7f-a3d9-6ec199fe38d2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71204 biolink:treats MONDO:0005492 PMID:41385096 "[{""id"":""uuid:2cb24235-05b1-42d2-bb47-a4c3ee8619fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:1e6c4dab-7dfe-4f99-9ddd-ae9455fd5ca9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional pediatric dosage indicated for the treatment of allergic rhinitis, urticaria, and itching associated with skin diseases (eczema/dermatitis, cutaneous pruritus). uuid:b4a23ab1-7b15-4c42-b354-06ad4874cccc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71204 biolink:treats MONDO:0004980 PMID:41385096 "[{""id"":""uuid:60469772-75c8-4e81-bac3-9915f3ee78d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f8315ec0-bba8-4b14-81de-eab03ca035df"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional pediatric dosage indicated for the treatment of allergic rhinitis, urticaria, and itching associated with skin diseases (eczema/dermatitis, cutaneous pruritus). uuid:a97272e9-62b2-4f3a-a660-2fb68d10f51a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71204 biolink:treats MONDO:0002406 PMID:41385096 "[{""id"":""uuid:13c8e754-fb3f-4dd0-8521-d847d418fb55"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4736dead-5ffe-4f15-8a33-92d58df6ba91"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional pediatric dosage indicated for the treatment of allergic rhinitis, urticaria, and itching associated with skin diseases (eczema/dermatitis, cutaneous pruritus). uuid:a1fbdedc-0f18-498f-9c78-dde7144dce36 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4027 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:7c7898f0-428c-4466-b4e1-0dacc565d22a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4e9584a6-4b21-4cec-9275-c6acc7630e13"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new dosage indicated for the treatment of breast cancer (preoperative or postoperative chemotherapy in patients with operable breast cancer). [Public knowledge-based application] uuid:59d90968-78bb-447c-8ecf-c875346dfb30 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:85078 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:1a7180b4-3634-43ed-867a-83a42dcc6930"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:651354ef-2540-4326-89f5-884dda560948"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of chronic heart failure (for use only in patients receiving standard treatment of chronic heart failure). uuid:f58ff504-441a-475a-bafd-71f9926a452e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1424887 biolink:treats MONDO:0005607 PMID:41385096 "[{""id"":""uuid:b018fc8c-fc00-45c8-8112-f5ce18796ab0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c7414af9-87a6-4e3c-b51e-c687f28c0873"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the relief of symptoms in patients with chronic obstructive pulmonary disease (chronic bronchitis, emphysema) (who require a combination therapy with an inhaled corticosteroid and a long-acting beta-2 agonist). uuid:e4d10f75-d235-4e5e-9724-425520f1a2ef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:1424887 biolink:treats MONDO:0004849 PMID:41385096 "[{""id"":""uuid:ccaa3067-161a-4f53-baaf-f77970ed26c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:60752e1d-1401-4c84-b9fd-b7e61817b5f9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the relief of symptoms in patients with chronic obstructive pulmonary disease (chronic bronchitis, emphysema) (who require a combination therapy with an inhaled corticosteroid and a long-acting beta-2 agonist). uuid:f0ba3c27-5d3b-4ef3-8454-6eb8b1f45cb1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47898 biolink:treats MONDO:0007256 PMID:41385096 "[{""id"":""uuid:221d055c-e902-452d-943b-f8a6b88b9a47"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4c345947-b30a-4aa7-816a-89f8521ec989"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional dosage indicated for transcatheter arterial chemo-embolization (TACE) in hepatocellular carcinoma. [Public knowledge-based application] uuid:11689a62-baf8-4306-976d-e1d2f7bcde10 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8764 biolink:treats MONDO:0005556 PMID:41385096 "[{""id"":""uuid:8c59ccf9-4b05-45a7-bd2d-e01d8dc010b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:99d36caf-c60e-4bf2-a43c-4e927589271d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of lupus nephritis. [Public knowledge-based application after preliminary assessment by the Pharmaceutical Affairs and Food Sanitation Council (PAFSC)] uuid:079eea7f-9aa0-426d-bd15-1c780bd9cf60 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31964 biolink:treats MONDO:0005114 PMID:41385096 "[{""id"":""uuid:849da89a-9bf9-4b93-924a-9d807e09cd60"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a400108b-ad38-4786-bc58-ca2b47a8856b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications for the treatment of Streptococcus pneumoniae and sepsis and a new dosage in an additional dosage form. uuid:a97160f8-9b0f-4d52-8c5a-cb1e0febda60 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31964 biolink:treats HP:0100806 PMID:41385096 "[{""id"":""uuid:f49b3b5c-af9e-403a-863b-390369cfd542"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c09fc48f-1461-4d12-9e98-ebc1a6291898"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with new additional indications for the treatment of Streptococcus pneumoniae and sepsis and a new dosage in an additional dosage form. uuid:51ec5e37-ed24-41d1-95c0-34f2f4de9b01 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6413 biolink:treats MONDO:0008487 PMID:41385096 "[{""id"":""uuid:a120bbba-4599-42f9-b30d-08acc4a4e385"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:eaa149e9-480f-434f-b929-2efc18280de9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new indications for the induction of ovulation in patients with polycystic ovary syndrome and with unexplained infertility. (3) Drugs with new indications and a new dosage for the induction of ovulation in patients with polycystic ovary syndrome and with unexplained infertility. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:e4a6023a-16a5-4815-95e6-890e393e9e85 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6413 biolink:treats UMLS:C0404585 PMID:41385096 "[{""id"":""uuid:8550e7a5-44c6-483c-a661-100313f2ca49"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2012bfcc-6d11-4c53-a9dc-cfa71ef5ba01"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with new indications for the induction of ovulation in patients with polycystic ovary syndrome and with unexplained infertility. (3) Drugs with new indications and a new dosage for the induction of ovulation in patients with polycystic ovary syndrome and with unexplained infertility. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:276cf6c0-e345-4be5-961f-c5984cfd518d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:6WS4C399GB biolink:treats MONDO:0018874 PMID:41385096 "[{""id"":""uuid:7b619254-fd39-40ff-9bb4-caf45b919e55"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e64acd19-f3b0-4e18-ab9b-f4df3e319b5d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for use as an adjunctive therapy with antineoplastic agents for the treatment of relapsed or refractory acute myeloid leukemia. [Public knowledge-based application after PAFSC's preliminary assessment] uuid:e1cf234b-3b48-48e0-969c-033f048fcee8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31905 biolink:treats UMLS:C0264714 PMID:41385096 "[{""id"":""uuid:94d8977c-9df2-4894-a142-34491c45bea1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:27d4619c-4093-4df5-ac7d-e9a711976e2a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and dosage for the treatment of acute cardiac failure including the acute exacerbation period of chronic cardiac failure. uuid:aa5eb948-777e-4670-8970-4bbb53ae471f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31905 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:666128fa-f27d-456e-9a91-cbd678106f7b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:225f82aa-52d5-4204-8972-8b26eae253be"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and dosage for the treatment of acute cardiac failure including the acute exacerbation period of chronic cardiac failure. uuid:03730364-962c-402a-9768-7fb94b75e7a0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:8378 biolink:treats MONDO:0010679 PMID:41385096 "[{""id"":""uuid:b6222a34-0a2a-4e19-870c-e4d9e7ab95d5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:dad713da-07e9-48ac-a9b5-b53f3bd8068d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage for the treatment of acute-phase Kawasaki's disease (cases where the disease is severe and at risk for coronary artery disorder) ([1] - [6]) and Duchenne muscular dystrophy ([4] - [6]). Duchenne muscular dystrophy: [Public knowledge- based application after PAFSC's preliminary assessment] uuid:87a97a74-2a47-4215-aecb-9c3fc11fc104 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:134716 biolink:treats MONDO:0002050 PMID:41385096 "[{""id"":""uuid:55c75afa-1d50-447e-ae06-62ae25460c25"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8f5b6561-fccf-46e0-abe8-f36eb2d55dd9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and a new dosage for the treatment of depression (for use only in patients who have not sufficiently responded to conventional treatments). uuid:a2f9dbaf-3de0-459e-bdae-d0915c43a65e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7735 biolink:treats HP:0002018 PMID:41385096 "[{""id"":""uuid:8e7ce44d-3f42-41c3-80e4-1a4172ed6815"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:8f9e80e3-b10c-40b7-9c5f-de318cd30dcc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage indicated for the treatment of gastrointestinal symptoms (nausea and vomiting) associated with the administration of antineoplastic drugs (cisplatin, etc.). [Public knowledge-based application after preliminary assessment by the Pharmaceutical Affairs and Food Sanitation Council (PAFSC)] uuid:a73befa6-a17c-4af6-a9d0-d7caaf23e2b7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7735 biolink:treats HP:0002013 PMID:41385096 "[{""id"":""uuid:c8af2139-3dc9-49d6-b254-398f27dfd84b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f3009552-db30-4561-9db7-aeef7b8aebd1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new additional indication and a new dosage indicated for the treatment of gastrointestinal symptoms (nausea and vomiting) associated with the administration of antineoplastic drugs (cisplatin, etc.). [Public knowledge-based application after preliminary assessment by the Pharmaceutical Affairs and Food Sanitation Council (PAFSC)] uuid:daad4986-1e48-486f-a8ae-1e9321d00d5e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C2722689 biolink:treats MONDO:0005812 PMID:41385096 "[{""id"":""uuid:39c004e1-a8a2-45f4-ad91-8b44f4e8bf40"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a81aa369-104d-42f5-b4e9-24d48f81b0e9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for prophylaxis of pandemic (H1N1) influenza. [Emergency approval] DRUGBANK:DB10781 uuid:370eb831-46e6-4c3b-b012-b9cb9bf5eea5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C2722689 biolink:treats MONDO:0005460 PMID:41385096 "[{""id"":""uuid:480fd39a-c22b-4833-a4e9-039b027ae154"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:51739ecf-c469-4e00-bb8d-950613893e61"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A drug with a new active ingredient indicated for prophylaxis of pandemic (H1N1) influenza. [Emergency approval] DRUGBANK:DB10781 uuid:4ee1a6a7-c18c-4097-a171-15e4e7e5f5cd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0015980 biolink:treats HP:0020071 PMID:41385096 "[{""id"":""uuid:af35da1a-015b-422e-be43-c0d54d16de09"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:111232b0-f482-492d-983f-d3613c625916"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drug with a new indication and dosage for treatment of viremia in compensated cirrhosis type C (excluding the patients with a high viral load of HCV serogroup 1). [Priority Review] MESH:D016899 uuid:e47974e0-3ac9-4ff4-bc83-0eb9d948cb45 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UMLS:C0015980 biolink:treats MONDO:0005448 PMID:41385096 "[{""id"":""uuid:a4d8af77-a9ea-4ce0-bd27-0e4fb907a4bb"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6f78c70c-6625-4c4c-bb85-885500629152"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drug with a new indication and dosage for treatment of viremia in compensated cirrhosis type C (excluding the patients with a high viral load of HCV serogroup 1). [Priority Review] MESH:D016899 uuid:2616b2eb-026c-4353-aa42-afe623b9dd3f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2948 biolink:treats UMLS:C0852922 PMID:41385096 "[{""id"":""uuid:e1368210-0443-4074-bea0-15959fa23a5c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b43157de-7cd7-4fdd-8ed8-7cc29ac8fd12"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drug with a new indication and dosage indicated for induction and maintenance of remission in steroid- dependent Crohn's disease and maintenance of remission in steroid-dependent ulcerative colitis. [Notification of off-label use] uuid:cfd2e9aa-ee32-408a-91f7-d3fc546ec9ff biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:32176 biolink:treats EFO:1001494 PMID:41385096 "[{""id"":""uuid:1e878870-3744-4b7e-9471-4642549524dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:045807b5-17fa-48c2-ad96-7bbc3fc68e65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drug with a revised indication that eliminates a limitation to use in intractable cases, and now indicated for treatment of psoriasis vulgaris regardless of the severity. uuid:7922ad8d-ce30-4845-b457-b5723bd7d096 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6078 biolink:treats MONDO:0004525 PMID:41385096 "[{""id"":""uuid:b91cdbf2-8e7d-46bd-a437-c5257daaa28b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:166bb4a3-316b-4f8b-9453-674e9a760df0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition of a new indication and dosage for treatment of scabies. [Notification of off-label use] uuid:83a3b50f-195a-4baa-9267-171846eaf051 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:B72HH48FLU biolink:treats MONDO:0007191 PMID:41385096 "[{""id"":""uuid:57504c7b-2149-440c-8da9-2abe53cf9f9a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:aa03fc41-c9d9-4a43-84c3-10425fcb9541"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition of an indication for refractory uveoretinitis associated with Behcet's disease (used only when conventional therapies are not sufficiently effective). [Orphan Drug] uuid:330ca5ec-9566-41da-a00f-4f85a8acccbb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5931 biolink:treats MONDO:0019145 PMID:41385096 "[{""id"":""uuid:8bcf454d-8296-4c1c-8eaf-bec5701c0381"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2a18672a-47bf-40d6-8911-85d90e3bab06"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition of an indication and dosage for treatment of purpura fulminans caused by congenital protein C deficiency. [Orphan Drug] uuid:cb7b1916-b92f-43d1-98d5-769ca1783377 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63577 biolink:treats HP:0001410 PMID:41385096 "[{""id"":""uuid:0d7e5040-3eb4-49a8-b0d0-6fe2edf99788"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d2961606-212f-46a7-81fa-a0c0219b746f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new indication for “improving viral markers in patients with hepatitis B cirrhosis complicated by proliferation of hepatitis B virus and with abnormal hepatic function to be confirmed” in monotherapy [Priority review] uuid:7b8ca5d6-6724-492f-a528-a6d1ca2873ed biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:50663 biolink:treats MONDO:0005460 PMID:41385096 "[{""id"":""uuid:051f5f06-8a6c-436f-9f26-7d049752af0f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b268ea68-8d8b-4072-a0a9-a68485662940"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new pediatric dosage regimen indicated for the treatment of influenza virus infection uuid:de6fa43f-18b5-4dc0-823d-6946e5c42493 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5280 biolink:treats MONDO:0005823 PMID:41385096 "[{""id"":""uuid:52a7f1b1-4731-4fcd-90e8-bcc8a76f52dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d5ff6643-c740-423d-afc9-e7c82d0962d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new indication for the treatment of genus Legionella infection [Notification of off label use] uuid:963ddb4f-0ef9-47d5-9869-28c459b19ea9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:81573 biolink:treats MONDO:0018555 PMID:41385096 "[{""id"":""uuid:c064cdfd-a157-4f12-8057-18682c5f5b4e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a1daf5b0-a5f4-4318-8961-6b472df2bb26"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new indication and a new route of subcutaneous administration for induction of spermatogenesis in male hypogonadotrophic hypogonadism in combination with follitropin alpha [Prompt review drug] uuid:1ff8185f-a229-4b74-ac01-fca2e111236e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45863 biolink:treats MONDO:0002715 PMID:41385096 "[{""id"":""uuid:d559d594-4a2d-443f-9756-5781d8bcb0c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f275e2e0-5de2-4907-a5d3-7e7aa34f3a9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new indication for the treatment of cancer of the uterus body, in addition to the current indications for ovarian cancer, non-small-cell lung cancer, breast cancer and stomach cancer uuid:e2a081c3-366d-4029-8c12-f2cb2c2a2922 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:45863 biolink:treats MONDO:0004950 PMID:41385096 "[{""id"":""uuid:da9faa91-d292-4d48-85e2-74a0fd4686c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:44232330-f996-4a4d-9c6d-3b3fefdb7011"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new indication for the treatment of cancer of the uterus body, in addition to the current indications for ovarian cancer, non-small-cell lung cancer, breast cancer and stomach cancer uuid:2a91a968-eb57-4740-afbf-a5e5244452d5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4672 biolink:treats MONDO:0006003 PMID:41385096 "[{""id"":""uuid:f25920ce-ff57-49e0-ae85-5fe3ead9537e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4a3afc38-82fd-4c7c-9b2c-5912794ad879"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[PMDA] A new indication for the treatment of ""cancer of the uterus body"", in addition to the current indications for ovarian cancer, non-small-cell lung cancer, breast cancer, stomach cancer, head and neck carcinoma, and esophageal carcinoma" uuid:714eb9a5-8dd0-45b3-877a-cb199c667ddc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4672 biolink:treats MONDO:0004950 PMID:41385096 "[{""id"":""uuid:551ca2fa-c740-4109-be64-307856c58b59"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:60bc3d65-3693-4ac6-84fa-c41f5f789520"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[PMDA] A new indication for the treatment of ""cancer of the uterus body"", in addition to the current indications for ovarian cancer, non-small-cell lung cancer, breast cancer, stomach cancer, head and neck carcinoma, and esophageal carcinoma" uuid:25cff2f4-78fc-42fa-b698-7b6d63f493f3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4672 biolink:treats MONDO:0002038 PMID:41385096 "[{""id"":""uuid:d7fd02b8-97ce-49d7-9dcf-89eb37730bce"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:238b704a-a55b-4d99-ae74-86020447b8a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[PMDA] A new indication for the treatment of ""cancer of the uterus body"", in addition to the current indications for ovarian cancer, non-small-cell lung cancer, breast cancer, stomach cancer, head and neck carcinoma, and esophageal carcinoma" uuid:8e9a94ba-c785-4884-b310-588167e6ef71 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4672 biolink:treats MONDO:0019086 PMID:41385096 "[{""id"":""uuid:4df95470-bba6-462f-b614-111a551c10b6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:17e7c1bb-6c66-44b2-8638-9bf3476ae23c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[PMDA] A new indication for the treatment of ""cancer of the uterus body"", in addition to the current indications for ovarian cancer, non-small-cell lung cancer, breast cancer, stomach cancer, head and neck carcinoma, and esophageal carcinoma" uuid:54b42e6b-7bdd-4a72-b9f1-8e049661af50 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:441410 biolink:treats UMLS:C0741682 PMID:41385096 "[{""id"":""uuid:bd08cff2-3cfb-4126-b7da-fcc7ec32c06e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ac02db20-7ca0-4f06-aa3a-447240594ec4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[PMDA] A new indication for the treatment of ""premenopausal breast cancer"", in addition to the current indication for prostatic cancer" uuid:32364638-fc57-4e75-a891-fe65e78be367 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:441410 biolink:treats MONDO:0004956 PMID:41385096 "[{""id"":""uuid:64c5e23c-e62c-4d81-af23-36b52a9ea423"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fb4dd1ac-a217-4ef2-adf6-8c06f839cc7f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[PMDA] A new indication for the treatment of ""premenopausal breast cancer"", in addition to the current indication for prostatic cancer" uuid:224266e9-1cc8-41a0-aa41-44263d3c76f0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15365 biolink:treats MONDO:0012727 PMID:41385096 "[{""id"":""uuid:cff78839-9fbe-4df6-abfc-5010eadd2e8b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c120e928-b5b3-4670-876b-bc7098a14931"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[PMDA] A new indication for ""Kawasaki disease"" [Notification of off label use]" uuid:de7830bb-84aa-447b-8135-debe73e2abf4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:9907 biolink:treats MONDO:0005354 PMID:41385096 "[{""id"":""uuid:90bd3b93-d6f6-4f1c-a455-b381601fafb9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cb9a8620-965c-4326-bad0-a3bf642fa1e7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and dosage indicated for the improvement of liver enzyme elevations in chronic hepatitis C. uuid:b94c6434-4ff4-488d-b95e-9b5d964dda89 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6541 biolink:treats MONDO:0003634 PMID:41385096 "[{""id"":""uuid:9574a3bd-1704-4f86-abbc-036e02640fba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d42d292b-0bf8-4e8a-af74-09d2256c8baf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition of a new indication for diabetic nephropathy in patients with type2 diabetes, hypertension, and proteinuria. uuid:890bc660-3bdb-4632-814e-23790fe99c1f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63607 biolink:treats MONDO:0100073 PMID:41385096 "[{""id"":""uuid:897a1fd0-f989-4a6d-8da4-04acaded2e18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:75696317-9ffa-49d0-9e5f-ea498d1db9f0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition of a new indication for methicillin-resistant Staphylococcus aureus (MRSA). uuid:b062bf46-02fd-412b-a37b-f5d64f563e1b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:61049 biolink:treats MONDO:0005556 PMID:41385096 "[{""id"":""uuid:fa1ed12e-7a03-44e9-8afa-6aa5d7c63c79"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e7612fd4-a297-4c78-8548-c9264e69c088"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication for lupus nephritis (in cases where steroid therapy is not sufficiently effective or well tolerated due to side effects). [Orphan Drug] uuid:18fa0d04-ed17-43f9-89b6-c3c3fc2af002 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:7936 biolink:treats MONDO:0008114 PMID:41385096 "[{""id"":""uuid:a98b7d11-509f-4eef-ab74-ce95220fa4ca"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:05472385-b5f3-4072-be48-b36bad14ac4a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new indication for the treatment of “obsessive compulsive disorder” uuid:066eb86b-ece1-4197-aa7f-de79425228fa biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:63598 biolink:treats MONDO:0005823 PMID:41385096 "[{""id"":""uuid:4ae70db1-dac0-4b97-a21d-3f9f9f2c6219"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:627f830a-1bce-4ef3-bcc9-e488806da9a7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new indication for the treatment of genus Legionella infection [Notification of off label use] uuid:2be64aca-9c4e-4131-9495-c436eb45acf4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:61049 biolink:treats MONDO:0005554 PMID:41385096 "[{""id"":""uuid:4e1e854b-d68f-4d1f-a6b8-ff42d96da096"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:45bbdc62-eacf-4ccc-96ef-4223dd6e9633"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new indication for the treatment of articular rheumatism (only where conventional treatments are inadequate) uuid:5f13b665-89c2-4840-aaa1-8078cbabd587 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:480999 biolink:treats MONDO:0007254 PMID:41385096 "[{""id"":""uuid:858ba236-9839-4b4b-81ea-8402736f27f4"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:972b7af9-f1eb-4b72-9e50-b80e973afe37"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new indication for the treatment of inoperable or recurrent breast cancer, in addition to the current indication for lung cancer uuid:ce0aaeec-06f5-4bf9-a3b8-edfcb8539505 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:480999 biolink:treats MONDO:0008903 PMID:41385096 "[{""id"":""uuid:07afa81b-e29f-46dd-a1bb-35462be59133"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:dc483cc0-ce50-43e6-b2d5-4a275af69bb2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new indication for the treatment of inoperable or recurrent breast cancer, in addition to the current indication for lung cancer uuid:09407369-81e6-41ca-a061-d1afbe4eb5a8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats HP:0002018 PMID:41385096 "[{""id"":""uuid:48418499-0761-4a72-b777-c9fd0202bbb0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:dfa54061-b72f-45c8-a009-61507f912064"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new indication and a new dosage regimen for the treatment of gastrointestinal (nausea, vomiting) symptoms associated with administration of antitumor agents [Combination chemotherapy with anti-cancer drgs] uuid:84c5d659-8ce0-4ece-9a76-5876aea6186b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:41879 biolink:treats HP:0002013 PMID:41385096 "[{""id"":""uuid:e292e053-c962-4841-ac90-69e184240068"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:54a6b253-7883-4edc-ab82-dbd4cd4aec4d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new indication and a new dosage regimen for the treatment of gastrointestinal (nausea, vomiting) symptoms associated with administration of antitumor agents [Combination chemotherapy with anti-cancer drgs] uuid:22e71f9d-d6c1-4f1d-8abf-4b0b18ea744f biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:0J4C69C6FB biolink:treats MONDO:0005279 PMID:41385096 "[{""id"":""uuid:189b1e03-7f67-4f05-9ffe-cc79bdfceae5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c8a06433-5afe-4787-b37c-b20a37a0ea3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[PMDA] A new indication for ""lysis of pulmonary artery thrombosis caused by acute pulmonary embolism in the presence of hemodynamic instability"" [Orphan drug]" uuid:a326b228-103b-4408-b7d4-3cea442dbfd0 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:0J4C69C6FB biolink:treats UMLS:C0151947 PMID:41385096 "[{""id"":""uuid:6522a653-7c0d-4d96-8076-36f7f15b3999"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2cf74b18-0972-4d5d-91b5-9c863d24e5b2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[PMDA] A new indication for ""lysis of pulmonary artery thrombosis caused by acute pulmonary embolism in the presence of hemodynamic instability"" [Orphan drug]" uuid:14643c7a-99c1-4a74-b356-283f6435f2da biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3347 biolink:treats MONDO:0005009 PMID:41385096 "[{""id"":""uuid:12ec25f2-3db4-403b-8e8c-5fd90ed1fa52"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3704df6a-cc69-432f-aaef-d30756ba007b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new indication for chronic heart failure, extended from use as an angiotensin-converting enzyme inhibitor uuid:dc2725db-104b-4019-a9e8-a7d5dcbe6acb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:23667621 biolink:treats HP:0002018 PMID:41385096 "[{""id"":""uuid:1a919d46-6f85-41d5-8706-cf08d286fdb7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e4dafe7e-7e53-4e6a-bde7-38d602873ec3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new indication and a new dosage regimen for the treatment of gastrointestinal (nausea, vomiting) symptoms associated with administration of antitumor agents [Combination chemotherapy with anti-cancer drgs] uuid:4185db25-30e7-44bb-85ef-358a018d065a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:23667621 biolink:treats HP:0002013 PMID:41385096 "[{""id"":""uuid:e91a02a0-6202-47b0-8ece-dcefef432458"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9ea28c2a-acbe-443c-b768-42f29fba6bba"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new indication and a new dosage regimen for the treatment of gastrointestinal (nausea, vomiting) symptoms associated with administration of antitumor agents [Combination chemotherapy with anti-cancer drgs] uuid:f10a593a-969a-407c-802a-af6ebc01454b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4031 biolink:treats MONDO:0009688 PMID:41385096 "[{""id"":""uuid:47267c56-bfbf-4802-a2e6-caadaeee7973"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:2be1b6e9-8f8d-41e6-9240-0a1209fa7702"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition of a new indication for systemic myasthenia gravis (in cases where post-thymectomy steroid therapy is not sufficiently effective or not well tolerated due to adverse drug reactions). [Notification of off-label use] uuid:e36336c0-26d8-4827-8c8d-cf8a8bf64fef biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5138 biolink:treats MONDO:0001247 PMID:41385096 "[{""id"":""uuid:8e0085b7-8e9a-4e40-9bb8-00ad1d132842"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:28dc2d31-c665-466a-9cc7-dd4b71e50902"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new indication for the treatment of “social anxiety disorder” uuid:e7fb0a02-e4c0-4770-af88-ecbddbd3850a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:100241 biolink:treats MONDO:0005823 PMID:41385096 "[{""id"":""uuid:2c901768-e513-40c1-bf71-95311a53c10f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:37af9bd4-d9ac-46f9-88f5-11feb72bddd6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new indication for the treatment of genus Legionella infection [Notification of off label use] uuid:fdaa82c6-fe5c-45cf-b203-bd47292bdbfb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:47381 biolink:treats EFO:0010072 PMID:41385096 "[{""id"":""uuid:02844821-a3f9-4ba3-9dec-a5ed3642bc65"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f172de0a-11dc-4721-a1aa-9631b7c7dc5d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[PMDA] A new indication for the treatment of “toothache”, the format of the indication for ""rheumatoid arthritis"" was coordinated. [Notification of off label use]" uuid:040031f5-2c66-44d3-a406-0f6b28e2a78b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3732 biolink:treats MONDO:0005823 PMID:41385096 "[{""id"":""uuid:a8731aba-e899-4b72-bba1-565432352bbf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:acf52326-fb84-43d9-b96c-03bc230f3ca0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new indication for the treatment of genus Legionella infection [Notification of off label use] uuid:6fcb8dae-3209-4d68-82c8-f0913dcf3d5c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27899 biolink:treats MONDO:0005062 PMID:41385096 "[{""id"":""uuid:a17dcfcc-9208-44fe-8a41-e9bece281c9e"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5d49eecb-3709-4347-8795-92e3f7ebd44f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new indication and a new dosage regimen in combination with other anti-cancer agents for the treatment of malignant lymphoma [Combination chemotherapy with anti-cancer drgs] uuid:faa0f2ec-ed3c-43c0-babc-6ebbe021581c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:24847953 biolink:treats MONDO:0001126 PMID:41385096 "[{""id"":""uuid:0514551c-443e-4b07-a182-f2fa2fb123af"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:66097725-0d78-4873-8598-5acff4f41820"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition of a new dosage indicated for a combination therapy with sodium rabeprazole, amoxicillin, and clarithromycin to eradicate Helicobacter pylori in patients with gastric or duodenal ulcer. uuid:da4baf20-aed4-41d3-a5fc-2a51cbc10ca7 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:6888 biolink:treats MONDO:0005062 PMID:41385096 "[{""id"":""uuid:beb71fe1-20e4-4797-8df8-23c228904c23"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:e22cb789-157f-4e68-9687-48293385c395"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] A new indication and a new dosage regimen in combination with other anti-cancer agents for the treatment of malignant lymphoma [Combination chemotherapy with anti-cancer drgs] uuid:3878e1b6-c7c3-4c01-a8a7-4b10a22d331e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76172 biolink:treats EFO:0010072 PMID:41385096 "[{""id"":""uuid:ff7f0321-17c5-4e01-a76f-3f369fa42a96"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:288f4888-a884-4383-a01c-16057c457b43"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[PMDA] A new indication for the treatment of “toothache”, the format of the indication for ""rheumatoid arthritis"" was coordinated. [Notification of off label use]" uuid:6e99b4b2-e423-4d7d-91bb-8847bb242245 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:76172 biolink:treats MONDO:0008383 PMID:41385096 "[{""id"":""uuid:f9d4a7c6-ed72-4dda-8d1b-e02edc48c383"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:b8eb8ec3-ff95-4697-a9fa-5fd78605ae0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[PMDA] A new indication for the treatment of “toothache”, the format of the indication for ""rheumatoid arthritis"" was coordinated. [Notification of off label use]" uuid:136b499b-dd2e-4735-9cd9-88dcb0cd0f78 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:175901 biolink:treats MONDO:0003060 PMID:41385096 "[{""id"":""uuid:7dba2e2d-8e91-45a0-9716-99624b5c73fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6ff6a885-9aa3-4bf6-bb90-12641e9142ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition of an indication for biliary tract cancer. uuid:a0ded400-d34d-4591-b85c-f9c2c80745dc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:600520 biolink:treats MONDO:0005657 PMID:41385096 "[{""id"":""uuid:90d429ca-537c-48a9-9966-f114dd6b11fc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:50c2c89c-69d9-4c5c-b787-824a90ef6d18"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Drugs with a new indication and dosage for prophylaxis of aspergillosis and candidiasis in hematopoietic stem cell transplant patients. uuid:abacfbfa-2254-411a-bbbd-2a20d7fa13cb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:15552 biolink:treats MONDO:0005149 PMID:41385096 "[{""id"":""uuid:31c597b2-4237-44a1-8fb1-992bdf1c4764"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:05aee7a6-3f5c-4a9c-a9bc-c656ff256812"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent "[PMDA] Addition to indications of pulmonary hypertension associated with specific diseases and a change of the description from ""primary pulmonary hypertension"" to ""pulmonary arterial hypertension""" uuid:8e1368fa-d3bc-4a68-8d4c-13d6167d4038 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:3001 biolink:treats MONDO:0100470 PMID:41385096 "[{""id"":""uuid:f7e98b24-0dcf-40fd-882e-ec342b17fd0a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:45a1c11c-c5d3-4957-a56b-e23e8844439f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition of a pediatric dosage for bronchial asthma uuid:989cad02-66f2-4f95-8390-ba323172e1e4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:2955 biolink:treats MONDO:0005701 PMID:41385096 "[{""id"":""uuid:1b20d3e3-827d-418c-8165-fdc0c9acb264"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a8db3e13-cfff-4090-b720-caf9ce4c4ac0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition of indications for Chlamydia trachomatis, urethritis and uterine cervicitis and to dosage regimen. uuid:79e5ae54-64e9-45b9-964a-ab88e65a30a5 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29007 biolink:treats UMLS:C0149966 PMID:41385096 "[{""id"":""uuid:0f25840f-d272-4025-80c8-6efdc0095f8c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:66bc470c-c94d-4ea5-be57-f553c0bf9ab6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition of indications for gonococcus and gonococcal pharyngitis, gonococcal urethritis, gonococcal uterine cervicitis, gonococcal pelvic inflammatory diseases, gonococcal epididymitis, gonococcal proctitis, and to dosage regimen. uuid:681f666b-e284-414d-a7a1-286fe6b18346 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29007 biolink:treats MONDO:0020971 PMID:41385096 "[{""id"":""uuid:b53eafdc-8585-4aa4-93c7-7b6023daa1cc"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:7ddfbc7d-5aaa-4f0f-aedf-e49e3e4d1271"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition of indications for gonococcus and gonococcal pharyngitis, gonococcal urethritis, gonococcal uterine cervicitis, gonococcal pelvic inflammatory diseases, gonococcal epididymitis, gonococcal proctitis, and to dosage regimen. uuid:4741c2ce-2707-466e-ba1a-281f98e35729 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29007 biolink:treats MONDO:0021157 PMID:41385096 "[{""id"":""uuid:f2b25061-a238-4628-a045-b9b5691c36dd"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:da95a286-a85f-4d42-a567-e645eb53eef5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition of indications for gonococcus and gonococcal pharyngitis, gonococcal urethritis, gonococcal uterine cervicitis, gonococcal pelvic inflammatory diseases, gonococcal epididymitis, gonococcal proctitis, and to dosage regimen. uuid:300c13d3-53f7-4346-90f4-09565e5d4309 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29007 biolink:treats MONDO:0021159 PMID:41385096 "[{""id"":""uuid:c10f7dfb-fcae-41f5-afd2-898a427cf3a1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fbf27dd5-451e-4c94-8610-0455cd2b4be2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition of indications for gonococcus and gonococcal pharyngitis, gonococcal urethritis, gonococcal uterine cervicitis, gonococcal pelvic inflammatory diseases, gonococcal epididymitis, gonococcal proctitis, and to dosage regimen. uuid:4e02e2aa-ab72-4efa-9f72-7df02958824e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:29007 biolink:treats UMLS:C0341778 PMID:41385096 "[{""id"":""uuid:09d34635-dfd5-403d-adb6-fde9fe963c7a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:82a12b4a-9d61-4f39-a6d2-89360a824f8d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition of indications for gonococcus and gonococcal pharyngitis, gonococcal urethritis, gonococcal uterine cervicitis, gonococcal pelvic inflammatory diseases, gonococcal epididymitis, gonococcal proctitis, and to dosage regimen. uuid:3fd47aa7-d215-473e-a8e8-5b12fd6defdd biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28001 biolink:treats MONDO:0005249 PMID:41385096 "[{""id"":""uuid:86fd1834-e679-4b93-b2bf-b418a9b122d8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:dc369e81-63f3-4849-bea8-f3b249a7316d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Additions of indications for sepsis, pneumonia, and purulent meningitis caused by penicillin- resistant-Streptococcus . uuid:4b02563a-a01a-468c-8909-162abfa028e9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31964 biolink:treats MONDO:0005823 PMID:41385096 "[{""id"":""uuid:6cbe4ae1-cd8b-4343-9261-84dafdf15df9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9194cdf5-4a1a-48b2-a3f7-b4e0339a6033"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition of indications for legionella infection. uuid:913fa9b4-838b-482d-9dc7-ff555efe5bdb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:22907 biolink:treats MONDO:0005040 PMID:41385096 "[{""id"":""uuid:d1329979-dcb0-46ae-b0a1-884d12a45c5f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:be408905-d66c-4fc7-bb06-829596c7c1e0"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition of indications for germ cell tumors and dosage regimen uuid:097f79fb-2863-4562-ab22-41c14a9843a6 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:4911 biolink:treats MONDO:0005040 PMID:41385096 "[{""id"":""uuid:f022ede8-e900-491c-b37d-00b68ad3c6c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:20f65e44-e160-40a6-9f43-7666af70aa9d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition of indications for germ cell tumors and dosage regimen uuid:921da722-4b32-45d2-9e40-e1c7c1467423 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27899 biolink:treats MONDO:0005040 PMID:41385096 "[{""id"":""uuid:37dcc6ef-302c-419c-bf8f-19c22597be77"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:eb0293ee-0a4d-4669-8d90-03c52cd1c479"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition of indications for germ cell tumors and dosage regimen uuid:294c5e0f-1c0b-4ec6-a4a9-997b3a062e23 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation RXCUI:637364 biolink:treats MONDO:0021063 PMID:41385096 "[{""id"":""uuid:4d08b426-c027-4957-ba06-9a53cfa98f5d"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:fad72531-792a-40c2-a7b1-e0cd5b854791"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] An addition to indications of non-small cell lung cancer to current indications of gastric cancer, rectal and colonic cancers and head and neck cancers. uuid:62ba5185-f5f8-4a98-a1ba-ac24039a0625 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5864 biolink:treats MONDO:0021348 PMID:41385096 "[{""id"":""uuid:08877d2a-80e6-4be9-9a71-c5746231ba75"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:845b6cc8-918a-4eac-9184-f0d8ad2923c7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition to indications of relapsed or refractory germ cell tumors (testicular tumor, ovarian tumor, extragonadal tumors) and to dosage regimen. uuid:09a6233d-eaaa-467d-9829-16895018b44d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5864 biolink:treats MONDO:0021068 PMID:41385096 "[{""id"":""uuid:db8edb28-4c7d-416a-815c-276b28c1622f"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6097459e-ec10-40f4-afa9-54281e91e253"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition to indications of relapsed or refractory germ cell tumors (testicular tumor, ovarian tumor, extragonadal tumors) and to dosage regimen. uuid:dfbcb350-080d-491a-8268-02470c7dd2f2 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5864 biolink:treats MONDO:0018201 PMID:41385096 "[{""id"":""uuid:2611f855-88b3-4ed6-9c1f-cf595a362013"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6b591b2a-1377-4d73-8444-8b73462adbac"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition to indications of relapsed or refractory germ cell tumors (testicular tumor, ovarian tumor, extragonadal tumors) and to dosage regimen. uuid:2d1a5772-efae-4bfa-aa5c-b40c8616d57e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27375 biolink:treats MONDO:0021348 PMID:41385096 "[{""id"":""uuid:e3ce157a-bb42-47b1-a469-b5ce767ce681"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a279a36b-6343-4f40-8e68-d870a536e744"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition to indications of relapsed or refractory germ cell tumors (testicular tumor, ovarian tumor, extragonadal tumors) and to dosage regimen. uuid:ad906049-7769-4ab5-a821-80b88a2c6fb9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27375 biolink:treats MONDO:0021068 PMID:41385096 "[{""id"":""uuid:6cad4f3f-0859-4a6e-8305-19e213372dbf"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3d850f19-dd8b-46ad-a607-2c5182f4b132"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition to indications of relapsed or refractory germ cell tumors (testicular tumor, ovarian tumor, extragonadal tumors) and to dosage regimen. uuid:61e5ec22-aa2d-4126-a5ee-794645ec3c76 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27375 biolink:treats MONDO:0018201 PMID:41385096 "[{""id"":""uuid:a2a377ff-c45e-45e1-9bde-3841bf0d1600"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:33a1fdd4-79d5-4eda-8873-36700c9f0439"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition to indications of relapsed or refractory germ cell tumors (testicular tumor, ovarian tumor, extragonadal tumors) and to dosage regimen. uuid:4b3af37a-b97c-44a7-99be-ad3aece4840d biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:C7S8VWP5DH biolink:treats MONDO:0004992 PMID:41385096 "[{""id"":""uuid:955c9ed1-2af1-4772-841d-710cf72d668c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d64eaa99-252d-499b-ad9f-a6011d55d060"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] uuid:1529970e-04cc-4682-a4cd-171c1fb33efc biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats MONDO:0011962 PMID:41385096 "[{""id"":""uuid:cbf59e6c-e8f1-4eed-b84d-47583f1126ed"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:efb0437d-0d35-4f56-83c5-241106a71c3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition to indications of combined therapy with other anticancer agents in postoperative chemotherapy or chemotherapy for metastasis or recurrence of endometrial cancer uuid:8ea2d7f0-ee9d-4231-8479-866b77223f57 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats UMLS:C0027627 PMID:41385096 "[{""id"":""uuid:c1ab8e18-9abd-47dd-9ed0-c950274fb3c5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3faa85d3-f1ae-45e7-ad74-a2e1da1771f3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition to indications of combined therapy with other anticancer agents in postoperative chemotherapy or chemotherapy for metastasis or recurrence of endometrial cancer uuid:754a71d1-10aa-407d-b73c-8bdefd0bfed4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27899 biolink:treats MONDO:0011962 PMID:41385096 "[{""id"":""uuid:eb1283aa-234b-41d9-a59c-ddbc5937be04"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6cb39167-cbbc-4903-8706-0646326476c8"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition to indications of combined therapy with other anticancer agents in postoperative chemotherapy or chemotherapy for metastasis or recurrence of endometrial cancer uuid:8a129cd3-ce0d-4fcc-aedf-bb4b832a16f1 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:27899 biolink:treats UMLS:C0027627 PMID:41385096 "[{""id"":""uuid:d7404d3c-8b36-4dc6-bde0-75da0e4810c1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:cc6bae6e-e913-4685-a241-2a601be2e31a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition to indications of combined therapy with other anticancer agents in postoperative chemotherapy or chemotherapy for metastasis or recurrence of endometrial cancer uuid:4d374c99-4270-4b93-b8b9-e1ef7f431a8a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats MONDO:0002129 PMID:41385096 "[{""id"":""uuid:d8f39eb5-150a-4489-9890-b875c5ec4f9c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:6c16ee73-9a74-4129-a6a8-01c0d4a15bc5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition to indications of combined therapy with other anticancer agents for malignant bone tumors and to dosage regimen. uuid:f46419b9-564b-47db-8615-007e80001788 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5864 biolink:treats MONDO:0002129 PMID:41385096 "[{""id"":""uuid:16f77603-2318-47e3-9449-1b03432abfc2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:d53155fa-2357-4354-b65a-9e3a3f9ceb2b"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition to indications of combined therapy with other anticancer agents for malignant bone and soft tissue tumors and to dosage regimen. uuid:645a5655-f909-4896-8210-f22966fb7aa3 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5864 biolink:treats MONDO:0006424 PMID:41385096 "[{""id"":""uuid:670dbce3-7296-459a-ac3e-21518ddc2c8a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:94f98d6a-1372-4ba3-9d62-f3944d0d00d7"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition to indications of combined therapy with other anticancer agents for malignant bone and soft tissue tumors and to dosage regimen. uuid:07bf9837-b2e3-456b-b9ee-a882784f32c9 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28748 biolink:treats MONDO:0006424 PMID:41385096 "[{""id"":""uuid:90f004c9-b5c4-491d-b119-bfd7264d477a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:3b1882ca-d59e-47ec-afe3-de3984e618ff"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition to indications of combined therapy with other anticancer agents for malignant bone and soft tissue tumors and to dosage regimen. uuid:ea5e397e-7a56-4547-996d-f95cac4ddceb biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31824 biolink:treats MONDO:0005089 PMID:41385096 "[{""id"":""uuid:ad7ca498-7f62-4f70-8113-4b4ebacd9a68"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a8b79b66-28de-4b4e-b26e-433a089a0cf2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] In line with the addition to the indications of ifosfamide for malignant bone and soft tissue tumors, an addition to dosage for inhibiting the development of urological impairment associated with administration of said ifosfamide. uuid:00f1cc9c-d7d4-4229-b81d-e5638c039f3b biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31824 biolink:treats MONDO:0004992 PMID:41385096 "[{""id"":""uuid:2d7dbf47-83cd-4b57-afb3-a2ee2f9e437a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:f63e7b35-8115-4120-8751-609ff90a8952"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] uuid:76f3a586-5bcf-4b8a-82c7-ca6a66e70425 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:31824 biolink:treats MONDO:0002118 PMID:41385096 "[{""id"":""uuid:44065059-94ae-469c-8c82-113723ee4f3a"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:34181bdd-5bf5-49f1-b4be-6ca602075107"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] In line with the addition to the indications of ifofamide for pediatric malignant solid tumors, an addition to dosage for inhibiting the development of urological impairment associated with the administration of said ifosfamide. uuid:f7a9a41e-0d8b-4f8c-a0c4-b03d0cbc53e8 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:125224 biolink:treats MONDO:0004992 PMID:41385096 "[{""id"":""uuid:b309353a-bf44-4358-8a2a-32d1b813a5a5"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:916c5f5b-846c-41df-a7a8-f78156a5ffa6"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] uuid:e07424a0-5423-4b38-8f5d-dd96fb0fff8c biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:28445 biolink:treats MONDO:0009693 PMID:41385096 "[{""id"":""uuid:a45fe9eb-5adf-4eea-b0be-f0b7971a9853"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:c4e36360-c89f-4a9e-8576-efc3f46e785c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition to indications of combined therapy with anticancer agents for multiple myeloma and to dosage regimen. uuid:766defdc-8b94-4ec4-a730-c492e1e42a00 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation PUBCHEM.COMPOUND:125224 biolink:treats MONDO:0005627 PMID:41385096 "[{""id"":""uuid:f075cbb0-f96a-4bf8-8ce5-5ec503493935"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:a304356a-953f-42ac-891d-032f4c56cad1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition to indications of combined therapy with other anticancer agents for head and neck cancers and to dosage regimen. uuid:e3a7d9fb-fd17-430f-8b4b-aeb1f0c4c074 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71417 biolink:treats MONDO:0021042 PMID:41385096 "[{""id"":""uuid:e20c5ca5-e09c-44b9-ad35-ae29d3b7d73c"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:4edb3cfe-89fb-4bb4-b43c-7be617223da2"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition to indications of combined therapy with other anticancer agents for glioma which possesses components of malignant astrocytoma and oligodendroglioma and to dosage regimen. uuid:397eb544-5d4c-4447-a85b-fdac2682fb58 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71417 biolink:treats MONDO:0016684 PMID:41385096 "[{""id"":""uuid:2ddd7ac4-8fd5-4ea6-813b-cb5ba8b50ef1"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:9c77a41c-246a-4181-8e30-9f7a2391b1fe"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition to indications of combined therapy with other anticancer agents for glioma which possesses components of malignant astrocytoma and oligodendroglioma and to dosage regimen. uuid:4edd7d51-91e5-4c5a-9e52-432537d59c7a biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:71417 biolink:treats MONDO:0016695 PMID:41385096 "[{""id"":""uuid:f7c768ce-bb1e-4e63-98af-a9eb03718341"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:5587b608-5c4f-41fa-a953-0bcc00c9deb3"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition to indications of combined therapy with other anticancer agents for glioma which possesses components of malignant astrocytoma and oligodendroglioma and to dosage regimen. uuid:6a0e7679-2a35-4aef-879a-5853dd37f41e biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation UNII:C7S8VWP5DH biolink:treats MONDO:0043731 PMID:41385096 "[{""id"":""uuid:8548e967-1f97-4ad2-8345-0dc02e76a879"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:58ef63c7-8848-4b22-8f40-221ce4183995"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA] Addition to indications of combined use with chemotherapy, endocrine therapy, or radiotherapy for osteolytic bone metastases of uuid:1b94b253-90f3-4fd2-b2d7-c36ab2569fe4 biolink:ChemicalOrDrugOrTreatmentToDiseaseOrPhenotypicFeatureAssociation CHEBI:5864 biolink:treats MONDO:0004992 PMID:41385096 "[{""id"":""uuid:6455461d-de63-4546-a796-7d9476e162c9"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:medic"",""resource_role"":""primary_knowledge_source"",""upstream_resource_ids"":[""infores:pmda""],""source_record_urls"":null},{""id"":""uuid:ec58c1ed-f61c-48e7-8bfe-d9ad80b9b6ad"",""category"":[""biolink:RetrievalSource""],""resource_id"":""infores:pmda"",""resource_role"":""supporting_data_source"",""upstream_resource_ids"":null,""source_record_urls"":null}]" infores:medic knowledge_assertion text_mining_agent [PMDA]